<?xml version="1.0" encoding="UTF-8" standalone="no" ?><xml><records><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chan,C.K.</style></author><author><style face="normal" font="Arial"> Lin,T.C.</style></author><author><style face="normal" font="Arial"> Huang,Y.A.</style></author><author><style face="normal" font="Arial"> Chen,Y.S.</style></author><author><style face="normal" font="Arial"> Wu,C.L.</style></author><author><style face="normal" font="Arial"> Lo,H.Y.</style></author><author><style face="normal" font="Arial"> Kuo,M.L.</style></author><author><style face="normal" font="Arial"> Wu,K.H.</style></author><author><style face="normal" font="Arial"> Huang,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Taoyuan General Hospital, Taoyuan, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">The modulation of Th2 immune pathway in the immunosuppressive effect of human umbilical cord mesenchymal stem cells in a murine asthmatic model</style></title><secondary-title><style face="normal" font="Arial">Inflamm Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflamm Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Umbilical Cord</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="7" Year="2016">2016/7/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a chronic airway inflammatory disease that has a high prevalence nowadays, and seeking the means of relieving asthmatic symptoms is now an issue with increased importance. While mesenchymal stem cells have been demonstrated to display immunomodulatory effects, the effect of fetus-type mesenchymal stem cells (MSCs) on asthmatic symptoms in vivo have not been reported to date. METHODS: Female BALB/c mice at 8 weeks of age were sensitized by ovalbumin, and MSCs derived from Wharton's jelly of human umbilical cord mesenchymal stem cells (hUCMSCs) were injected into the asthmatic mice. Airway hyper-responsiveness, lung eosinophil infiltration, cytokine level in splenocyte cultures and serum immunoglobulin level were measured. Enzyme-linked immunosorbent assay was used to determine cytokine and immunoglobulin levels. RESULTS: This current study demonstrated that hUCMSCs attenuated both lung lymphocyte and eosinophil infiltration, and significantly decreased the concentration of Th2 cytokines interleukin-5 in splenocyte cultures. CONCLUSIONS: Human umbilical cord mesenchymal stem cells have the advantage of being easily harvested non-invasively and are capable of rapid proliferation, therefore an ideal material for stem cell-based immune therapies. The current study showed that fetal-type MSCs were able to suppress asthmatic symptoms efficiently, and its immunomodulatory effect resulted primarily from suppressing the Th2 pathway in the animal model. This study suggested that hUCMSCs could be an ideal candidate for cell-based therapies of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160707IS - 1420-908X (Electronic)IS - 1023-3830 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00011-016-0961-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27384607">PM:27384607</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflamm Res\20160707-ChanCK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflamm Res\20160707-ChanCK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160707, Chan CK</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00011-016-0961-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciaccio,E.J.</style></author><author><style face="normal" font="Arial"> Bhagat,G.</style></author><author><style face="normal" font="Arial"> Lewis,S.K.</style></author><author><style face="normal" font="Arial"> Green,P.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Trends in gluten research and its relationship to autoimmune and allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Inform Med Unlocked</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inform Med Unlocked</style></full-title></periodical><pages end="14" start="7">7-14</pages><volume><style face="normal" font="Arial">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> glutenin</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Minerals</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Running</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2352-9148</style></isbn><abstract><style face="normal" font="Arial">Introduction Gluten is a protein found in certain grains, and causes an autoimmune response in celiac disease patients. Although the subject of considerable research, gluten research foci and future directions are largely unknown. Methods The MEDLINE search tool was used to evaluate research trends. For perspective, yearly publications on gluten and other celiac disease reactive proteins were compared to food allergy proteins research. Then the relationship of gluten publications to affiliated keywords was determined. The affiliated keywords belonged to one of several groups: grains, vitamins and minerals, interaction, autoimmunity, genetics, or enzymes. The yearly number of publications in the peer-reviewed medical literature was determined for each relationship from years 1960</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2013. The relationships were graphed, and linear regression analysis was used to determine the rate of change in publications per year, and the coefficient of determination. Results Among celiac disease reactive proteins (gluten, gliadin, and glutenin) and selected food allergy proteins (ovalbumin, lysozyme, ovomucoid, and Ara h), gluten showed the greatest rate of increase in published medical research (+20.01 studies/year since 1996, r2=0.97). Additionally, there were sharp increases in the rate of gluten research publications per year in association with keywords </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿautoimmunity</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ (+7.69 studies/year since 1997), </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿwheat</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ (+6.08 studies/year since 1999), and </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿtransglutaminase</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ enzyme (+5.05 studies/year since 1995). The longest running moderate trend was research on </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿgluten</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ and </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿantibodies</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ (+2.50 studies/year, r2=0.92 since 1971). Conclusions Research on gluten as a reactive protein is of rapidly growing interest in the medical literature. MEDLINE is helpful to determine foci and future directions</style></abstract><notes><style face="normal" font="Arial">LA - WNGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imu.2016.05.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.imu.2016.05.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inform Med Unlocked\2016-3-7-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">f:\A&amp;H HMW Papers\Inform Med Unlocked\2016-3-7-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160723, Ciaccio ej</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imu.2016.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jin,M.</style></author><author><style face="normal" font="Arial"> Choi,J.K.</style></author><author><style face="normal" font="Arial"> Choi,Y.A.</style></author><author><style face="normal" font="Arial"> Kim,Y.Y.</style></author><author><style face="normal" font="Arial"> Baek,M.C.</style></author><author><style face="normal" font="Arial"> Lee,B.H.</style></author><author><style face="normal" font="Arial"> Jang,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,W.J.</style></author><author><style face="normal" font="Arial"> Lee,S.J.</style></author><author><style face="normal" font="Arial"> Kim,D.W.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author><author><style face="normal" font="Arial"> Park,E.K.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Park,Z.Y.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">1,2,4,5-Tetramethoxybenzene Suppresses House Dust Mite-Induced Allergic Inflammation in BALB/c Mice</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="45" start="35">35-45</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinases</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Kinases</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="30" Month="6" Year="2016">2016/6/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is the most common allergic inflammatory skin disease. The activation of innate immunity by house dust mite (Dermatophagoides farinae extract, DFE) allergen plays an important role in the pathogenesis of AD. We previously showed the inhibitory effect of an extract of Amomum xanthioides on allergic diseases, and isolated 1,2,4,5-tetramethoxybenzene (TMB) as a major active component. In this study, we investigated whether TMB relieves DFE-induced allergic inflammation symptoms. METHODS: We established a DFE-induced allergic inflammation model in BALB/c mice by repeated skin exposure to DFE. To define the underlying mechanisms of action, we used a tumor necrosis factor-alpha and interferon-947;-activated human keratinocytes (HaCaT cell line) and mouse keratinocytes (3PC cell line) cell line model. RESULTS: Oral administration of TMB suppressed allergic inflammation symptoms, such as histopathological analysis and ear thickness, in addition to serum IgE, DFE-specific IgE and IgG2a levels. TMB decreased the serum histamine levels and tissue infiltration of inflammatory cells, including mast cells and eosinophils. TMB also inhibited CD4+IFN-947;+, CD4+IL-4+, and CD4+IL-17A+ lymphocyte expansion in the draining lymph nodes and expression of the Th2 cytokines in the ear tissue. TMB significantly inhibited the expression of cytokines and chemokines by the downregulation of the mitogen-activated protein kinases and nuclear factor of activated cytoplasmic T cells in HaCaT cells. CONCLUSIONS: TMB improved DFE-induced allergic inflammation by suppressing the production of proinflammatory cytokines and chemokines. Our results suggest that TMB might be a potential therapeutic agent for AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160629IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1159/000446510</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27355819">PM:27355819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-35-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-35-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160629, Jin M</style></custom2><misc3><style face="normal" font="Arial">10.1159/000446510</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cantillo,J.F.</style></author><author><style face="normal" font="Arial"> Puerta,L.</style></author><author><style face="normal" font="Arial"> Lafosse-Marin,S.</style></author><author><style face="normal" font="Arial"> Subiza,J.L.</style></author><author><style face="normal" font="Arial"> Caraballo,L.</style></author><author><style face="normal" font="Arial"> Fernandez-Caldas,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Immunological Research, University of Cartagena, Cartagena, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Identification and Characterization of IgE-Binding Tropomyosins in Aedes aegypti</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="56" start="46">46-56</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aedes</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Asc l 3</style></keyword><keyword><style face="normal" font="Arial"> Ascaris</style></keyword><keyword><style face="normal" font="Arial"> Ascaris lumbricoides</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Blo t 10</style></keyword><keyword><style face="normal" font="Arial"> Caribbean</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Der p 10</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Lit v 1</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> tropomyosins</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="6" Year="2016">2016/6/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The mosquito Aedes aegypti is a potential source of important clinically relevant allergens. However, the allergenicity and cross-reactivity of most of these has not been fully described. METHODS: Natural wild-type mosquito tropomyosin was purified by size exclusion and anionic-exchange chromatography from an A. aegypti extract. Further characterization was accomplished by MALDI-TOF/TOF. Two recombinant variants of tropomyosin were obtained by expression in Escherichia coli. Specific IgE measurement by ELISA and skin tests for mosquito extract were performed in 12 patients with asthma or allergy rhinitis residing on the Caribbean island of Martinique. Cross-reactivity between natural A. aegypti tropomyosin and recombinant tropomyosins from A. aegypti, house dust mite, shrimp and Ascaris lumbricoides was analyzed by ELISA competition. RESULTS: Four variants of natural tropomyosin were purified. A band of 32 kDa in SDS-PAGE representing 2 tropomyosin variants (Aed a 10.0101 and Aed a 10.0201) reacted with specific IgE of 4 of the 12 (33%) allergic patients and with rabbit polyclonal anti-shrimp tropomyosin. A high degree of cross-reactivity (60-70%) was detected between natural mosquito tropomyosin and Blo t 10, Der p 10 and Lit v 1, and a lower degree with Asc l 3 from A. lumbricoides (&lt;30%). rAed a 10.0101 inhibited IgE binding to natural A. aegypti tropomyosin; however, rAed a 10.0201 showed a low inhibitory capacity. CONCLUSION: Tropomyosin is a new IgE-binding protein from A. aegypti. Two of the 4 variants identified showed different degree of cross-reactivity with tropomyosins from other arthropods. The potential allergenic role of each variant should be further investigated</style></abstract><notes><style face="normal" font="Arial">DA - 20160629IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Colombia -CO - France -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000447298</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27355916">PM:27355916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-46-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-46-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160629, Cantillo JF</style></custom2><misc3><style face="normal" font="Arial">10.1159/000447298</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawada,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to Inhalant Allergens in Schoolchildren with Special Reference to Passive Smoking</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="68" start="67">67-68</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> passive smoking</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword></keywords><dates><year Day="6" Month="7" Year="2016">2016/7/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000446914</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27380027">PM:27380027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-67-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-67-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Kawada T</style></custom2><misc3><style face="normal" font="Arial">10.1159/000446914</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Campos,D.</style></author><author><style face="normal" font="Arial"> Ravagnani,F.G.</style></author><author><style face="normal" font="Arial"> Gurgueira,S.A.</style></author><author><style face="normal" font="Arial"> Vercesi,A.E.</style></author><author><style face="normal" font="Arial"> Teixeira,S.A.</style></author><author><style face="normal" font="Arial"> Costa,S.K.</style></author><author><style face="normal" font="Arial"> Muscara,M.N.</style></author><author><style face="normal" font="Arial"> Ferreira,H.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Inflammation Research, Sao Leopoldo Mandic Institute and Research Center, Campinas, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Increased glutathione levels contribute to the beneficial effects of hydrogen sulfide and inducible nitric oxide inhibition in allergic lung inflammation</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="62" start="57">57-62</pages><volume><style face="normal" font="Arial">39</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid peroxidation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="7" Year="2016">2016/7/14</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The interaction between nitric oxide (NO) and hydrogen sulfide (H2S) in the airways could have significant implications for the pathogenesis and therapeutic effects of both on lung diseases. In this study we investigated whether the beneficial effects of H2S on asthma could be comparable to that inhibition of inducible NO synthase (iNOS). METHODS: Female BALB/C mice sensitized with ovalbumin (OVA) received either the H2S donor sodium hydrosulfide (NaHS, 14mumol/kg) or the iNOS inhibitor 1400W (1mg/kg), 30min before each OVA challenge during six days. On the first, second and sixth days, the leucocyte infiltration in lung parenchyma and bronchoalveolar lavage was evaluated. The aconitase activity (a sensor of O2 formation) and lipid peroxidation, as well as levels of reduced glutathione (GSH) and oxidized glutathione (GSSG) were determined in the lung tissues. RESULTS: OVA-challenge caused a significant and time-dependent increase in the eosinophil number in the airways, which was accompanied by a significant decrease of aconitase activity and GSH/GSSG ratio along with enhanced lipid peroxidation in the lungs. Treatment with NaHS or 1400W significantly attenuated the airways eosinophilia that was paralleled by an increase in aconitase activity and decrease of lipid peroxidation. NaHS or 1400W treatments also reversed the decreased GSH/GSSG ratio seen after OVA-challenge. CONCLUSIONS: The present study shows for the first time that the increased GSH/GSSG ratio caused by either H2S supplementation or iNOS-inhibition is a potential mechanism protecting airways against oxidative stress and inflammatory lung diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160717IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2016.07.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27424079">PM:27424079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2016-39-57-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2016-39-57-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160717, Campos D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2016.07.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez Salguero,C.A.</style></author><author><style face="normal" font="Arial"> Sanchez Chacon,A.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatrics Allergy and Pneumology Section, School of Medicine, University Hospital Puerto Real, Cádiz, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Immunological Changes in Specific Oral Tolerance Induction for Cow's Milk Allergy</style></title><secondary-title><style face="normal" font="Arial">Int J Allergy Medic</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Allergy Medic</style></full-title></periodical><pages end="" start="018">018-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> cow milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Objective:The aim of this study was to evaluate the safety and efficacy of oral rush desensitization in children with cow milk allergy. Material and methods:Prospective study: We included IgE-mediated cow milk allergy children over 3 years in 3 Spanish hospitals. Increasing doses of cow milk for 5 days from 1cc of 1% to 200 cc of pure milk were administered. Clinical follow-up was conducted and we compared specific IgE levels at onset, 6, 12 and 24 months after desensitization. Results:We included 18 children (13 males) between 3 and 14 years (mean 5.96). A total of 271 doses were administered; there were 55 adverse reactions (84% mild). At the end of the protocol, 100% showed some degree of tolerance (39% total). Full tolerance was achieved in 72% of patients after two years. Two children failed to achieve tolerance. There was a significant decrease in the levels of specific IgE to cow milk and alpha-lactoalbumin at 24 months, and to casein at 6, 12 and 24 months, compared to baseline. Conclusions:Oral rush desensitization is a safe and effective therapeutic option for patients with persistent cow milk allergy to medium term.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://clinmedjournals.org/articles/ijam/international-journal-of-allergy-medications-ijam-2-018.php?jid=ijam</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Allergy Medic\2016-2-018.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Allergy Medic\2016-2-018.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Sanchez Salguero CA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,K.R.</style></author><author><style face="normal" font="Arial"> Kim,M.</style></author><author><style face="normal" font="Arial"> Choe,H.S.</style></author><author><style face="normal" font="Arial"> Han,M.J.</style></author><author><style face="normal" font="Arial"> Lee,H.R.</style></author><author><style face="normal" font="Arial"> Oh,J.W.</style></author><author><style face="normal" font="Arial"> Kim,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Meteorological Sciences, Seogwipo-si, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="Arial">A biology-driven receptor model for daily pollen allergy risk in Korea based on Weibull probability density function</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="272" start="259">259-272</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Atmospheric pollen</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> maturity</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen production</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sanitation</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Pollen is an important cause of respiratory allergic reactions. As individual sanitation has improved, allergy risk has increased, and this trend is expected to continue due to climate change. Atmospheric pollen concentration is highly influenced by weather conditions. Regression analysis and modeling of the relationships between airborne pollen concentrations and weather conditions were performed to analyze and forecast pollen conditions. Traditionally, daily pollen concentration has been estimated using regression models that describe the relationships between observed pollen concentrations and weather conditions. These models were able to forecast daily concentrations at the sites of observation, but lacked broader spatial applicability beyond those sites. To overcome this limitation, an integrated modeling scheme was developed that is designed to represent the underlying processes of pollen production and distribution. A maximum potential for airborne pollen is first determined using the Weibull probability density function. Then, daily pollen concentration is estimated using multiple regression models. Daily risk grade levels are determined based on the risk criteria used in Korea. The mean percentages of agreement between the observed and estimated levels were 81.4-88.2 % and 92.5-98.5 % for oak and Japanese hop pollens, respectively. The new models estimated daily pollen risk more accurately than the original statistical models because of the newly integrated biological response curves. Although they overestimated seasonal mean concentration, they did not simulate all of the peak concentrations. This issue would be resolved by adding more variables that affect the prevalence and internal maturity of pollens</style></abstract><notes><style face="normal" font="Arial">DA - 20160708IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-016-1208-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27387542">PM:27387542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\20160708-KimKR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biometeorol\20160708-KimKR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160708, Kim KR</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-016-1208-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,M.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Liu,H.</style></author><author><style face="normal" font="Arial"> Shen,Y.</style></author><author><style face="normal" font="Arial"> Kong,Q.</style></author><author><style face="normal" font="Arial"> Sang,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Southern medical university, Jinling Hospital, Nanjing, China</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization and cross-reactions of dermatophyte and Candida albicans allergens in patients with chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="1142" start="1138">1138-1142</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candida albicans</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross-reactions</style></keyword><keyword><style face="normal" font="Arial"> crossreactions</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophytes</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onychomycosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Trichophyton</style></keyword><keyword><style face="normal" font="Arial"> Trichophyton rubrum</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="15" Month="7" Year="2016">2016/7/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic fungal infections are known to exacerbate allergic symptoms, including those of asthma and chronic urticaria (CU). We applied four prepared fungal antigens of Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Candida albicans to examine sensitization to each in subjects with CU and onychomycosis and in healthy subjects, and to evaluate the etiologic role of dermatophytic infection in CU and observe any cross-reactions among these four antigens. METHODS: Participants were divided into four groups, including those with CU with onychomycosis (experiment group), those with onychomycosis without allergic diseases (control group 1), those with CU without fungal infections (control group 2), and a healthy group (control group 3). In all subjects, skin prick tests with the four fungal antigens were performed. Subjects in the experiment group and control group 1 were also submitted to mycologic investigations. RESULTS: The experiment group showed significantly higher rates of positivity than the three control groups to T. rubrum, E. floccosum, and T. mentagrophytes antigens. Control group 1 showed rates higher than those in control groups 2 and 3; no significant difference emerged between control groups 2 and 3. Positivity to the C. albicans antigen did not differ among the four groups. In control group 1, rates of positivity to the three dermatophytic antigens did not differ significantly but did for C. albicans. CONCLUSIONS: Fungal infection seems to be an important determinant of trichophyton hypersensitivity. Cross-reactions among T. mentagrophytes, T. rubrum, and E. floccosum antigens were obvious, but none emerged between the antigens of the three dermatophytes and that of C. albicans</style></abstract><notes><style face="normal" font="Arial">DA - 20160715IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.13162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27420771">PM:27420771</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\20160715-ZhangM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\20160715-ZhangM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160715, Zhang M</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.13162</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,G.H.</style></author><author><style face="normal" font="Arial"> Shinn,H.K.</style></author><author><style face="normal" font="Arial"> Kang,J.H.</style></author><author><style face="normal" font="Arial"> Na,W.J.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Park,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Hypoxia-Related Disease Research Center, Inha Research Institute for Medical Sciences, Inha University College of Medicine, Incheon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Anti-interleukin-33 Reduces Ovalbumin-Induced Nephrotoxicity and Expression of Kidney Injury Molecule-1</style></title><secondary-title><style face="normal" font="Arial">Int Neurourol J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Neurourol J</style></full-title></periodical><pages end="121" start="114">114-121</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Kidney Injury</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Urea Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Creatinine</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase-2</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urea</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE: To evaluate the effect of anti-interleukin-33 (anti-IL-33) on a mouse model of ovalbumin (OVA)-induced acute kidney injury (AKI). METHODS: Twenty-four female BALB/c mice were assigned to 4 groups: group A (control, n=6) was administered sterile saline intraperitoneally (i.p.) and intranasally (i.n.); group B (allergic, n=6) was administered i.p./i.n. OVA challenge; group C (null treatment, n=6) was administered control IgG i.p. before OVA challenge; and group D (anti-IL-33, n=6) was pretreated with 3.6 microg of anti-IL-33 i.p. before every OVA challenge. The following were evaluated after sacrifice: serum blood urea nitrogen and creatinine levels, Kidney injury molecule-1 gene (Kim-1) and protein (KIM-1) expression in renal parenchyma, and expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), phosphorylated endothelial NOS (p-eNOS), and phosphorylated AMP kinase (p-AMPK) proteins in renal parenchyma. RESULTS: After OVA injection and intranasal challenge, mice in groups B and C showed significant increases in the expression of Kim-1 at both the mRNA and protein levels. After anti-IL-33 treatment, mice in group D showed significant Kim-1 down-regulation at the mRNA and protein levels. Group D also showed significantly lower COX-2 protein expression, marginally lesser iNOS expression than groups B and C, and p-eNOS and p-AMPK expression at baseline levels. CONCLUSIONS: Kim-1 could be a useful marker for detecting early-stage renal injury in mouse models of OVA-induced AKI. Further, anti-IL-33 might have beneficial effects on these mouse models</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 2093-4777 (Print)IS - 2093-4777 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5213/inj.1632578.289</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27377943">PM:27377943</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Neurourol J\2016-20-114-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Neurourol J\2016-20-114-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Park GH</style></custom2><misc3><style face="normal" font="Arial">10.5213/inj.1632578.289</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tay,T.R.</style></author><author><style face="normal" font="Arial"> Bosco,J.</style></author><author><style face="normal" font="Arial"> Aumann,H.</style></author><author><style face="normal" font="Arial"> O'Hehir,R.</style></author><author><style face="normal" font="Arial"> Hew,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Elevated total serum immunoglobulin E (>1000 IU/mL): implications?</style></title><secondary-title><style face="normal" font="Arial">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Intern Med J</style></full-title></periodical><pages end="849" start="846">846-849</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Atopic eczema, allergic broncho-pulmonary aspergillosis, helminthic infections and rare primary immunodeficiencies are known to elevate total serum immunoglobulin E (IgE) above 1000 IU/mL. However, of 352 patients with IgE >1000 IU/mL seen in our hospital over a 5-year period, less than 50% had these conditions. Markedly elevated IgE levels in the rest of the patients were associated with asthma, allergic rhinitis and food allergy, instances where the test is of limited diagnostic utility</style></abstract><notes><style face="normal" font="Arial">DA - 20160713IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - engPT - Journal ArticleSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/imj.13073</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27405892">PM:27405892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med J\2016-46-846-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med J\2016-46-846-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160713, Tay TR</style></custom2><misc3><style face="normal" font="Arial">10.1111/imj.13073</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simpson,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Thoracic Medicine, The Cairns Hospital, Cairns, Queensland, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Menstrual anaphylactoid reactions and presumed systemic mast cell activation syndrome</style></title><secondary-title><style face="normal" font="Arial">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Intern Med J</style></full-title></periodical><pages end="859" start="858">858-859</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reactions</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160713IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - engPT - LetterSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/imj.13077</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27405897">PM:27405897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med J\2016-46-858-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med J\2016-46-858-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160713, Simpson G</style></custom2><misc3><style face="normal" font="Arial">10.1111/imj.13077</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smith-Norowitz,T.A.</style></author><author><style face="normal" font="Arial"> Carvajal-Raga,S.</style></author><author><style face="normal" font="Arial"> Weedon,J.</style></author><author><style face="normal" font="Arial"> Joks,R.</style></author><author><style face="normal" font="Arial"> Norowitz,K.B.</style></author><author><style face="normal" font="Arial"> Weaver,D.</style></author><author><style face="normal" font="Arial"> Durkin,H.G.</style></author><author><style face="normal" font="Arial"> Hammerschlag,M.R.</style></author><author><style face="normal" font="Arial"> Kohlhoff,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, State University of New York Downstate Medical Center, Box 49, 450 Clarkson Ave., Brooklyn, New York, 11203, USA</style></auth-address><titles><title><style face="normal" font="Arial">Increased seroprevalence of Enterovirus 71 IgE antibodies in asthmatic compared with non-asthmatic children</style></title><secondary-title><style face="normal" font="Arial">Ir J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ir J Med Sci</style></full-title></periodical><pages end="503" start="495">495-503</pages><volume><style face="normal" font="Arial">186</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> enterovirus</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viral infection</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a common pediatric chronic inflammatory airway disease. Respiratory viral infections are frequent infectious triggers for exacerbations of asthma. OBJECTIVE: We sought to determine whether Enterovirus 71 (EV71), a ubiquitous virus that causes systemic inflammatory responses in children but is not a known respiratory pathogen, can also serve as an infectious trigger for asthma. METHODS: Specific EV71 IgE and IgM antibodies (Abs), total serum IgE, and IL-2 and IL-4 cytokine levels in serum of asthmatic and non-asthmatic children (N = 42, ages 5-19; N = 35, ages 1-20, respectively) were measured (ELISA). RESULTS: Asthmatic children had higher EV71 IgE Ab levels than non-asthmatic (P &lt; 0.001). Non-asthmatic children had significantly higher EV71 IgM Ab levels than asthmatic (P &lt; 0.001). Despite low serum IgE levels of non-asthmatic, compared with asthmatic (P &lt; 0.001), the non-asthmatic children produced significantly more IL-2 and IL-4 than asthmatic (P &lt; 0.001; P &lt; 0.001). The ages of the asthmatics, but not the non-asthmatics had a significant effect on the levels of EV 71 IgE Abs (P = 0.02; P = 0.356). A test of difference between these two slopes was significant. However, the ages of the non-asthmatic, but not the asthmatic children had a significant effect on the levels of EV 71 IgM Abs; a test of difference between these two slopes was significant. CONCLUSIONS: Increased specific EV71 IgE Ab responses may indicate that EV71 infection may also be an infectious trigger in asthma. However, the role of specific EV71 IgM Abs, Th2 cytokines, and age in non-asthmatic children should be further studied</style></abstract><notes><style face="normal" font="Arial">DA - 20160721IS - 1863-4362 (Electronic)IS - 0021-1265 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11845-016-1480-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27440276">PM:27440276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ir J Med Sci\20160721-SmithNorowitzTA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ir J Med Sci\20160721-SmithNorowitzTA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160721, Smith-Norowitz TA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11845-016-1480-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aslani,M.R.</style></author><author><style face="normal" font="Arial"> Keyhanmanesh,R.</style></author><author><style face="normal" font="Arial"> Khamaneh,A.M.</style></author><author><style face="normal" font="Arial"> Ebrahimi Saadatlou,M.A.</style></author><author><style face="normal" font="Arial"> Mesgari Abbasi ,.</style></author><author><style face="normal" font="Arial"> Alipour,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Lung Altered Expression of IL-1beta mRNA and Its Signaling Pathway Molecules in Obese-asthmatic Male Wistar Rats</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="197" start="183">183-197</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real time-PCR</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TRAF6</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Epidemiological and clinical studies indicate a close relationship between obesity and asthma. Here, we determined the impact of diet-induced obesity on the expression levels of IL-1beta, IRAK-1 and TRAF-6 mRNA as well as IL-1beta protein level and pathological changes in male Wistar rat's lung after sensitization with ovalbumin (OVA). Twenty male Wistar rats divided into four groups, control with normal diet (C+ND), OVA-sensitized with normal diet (S+ND), control with high-fat diet (C+HFD), and OVA-sensitized with high-fat diet (S+HFD). All rats fed for 12 weeks with standard pellets or high-fat diet while sensitization and challenging with OVA or saline were done for groups in the last month. In the end of intervention, lung was isolated and tested for the expression levels of IL-1beta, IRAK-1 and TRAF-6 mRNA with real time-PCR method, and pathological changes were determined. Diet-induced obesity groups showed increased weight, obesity indexes and lipid profiles The expression levels of IL-1beta mRNA in OVA-sensitization groups (S+ND and S+HFD) showed a significant increase compared with other groups. Also in S+HFD group, expression level of IRAK-1 and TRAF-6 mRNA were markedly higher than other groups (p&lt;0.001). The pathological changes were marked in sensitized groups compared to non-sensitized groups; with marked increase in obese sensitized rat. The results showed that high fat diet caused overexpression of IL-1beta, IRAK-1 and TRAF-6 mRNA as well as IL-1beta protein in an experimental model of asthma. Our results suggest that obese-asthmatic conditions may lead to the local production and activation of pro-inflammatory agents</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleSB - IMCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27424133">PM:27424133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-183-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-183-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Aslani MR</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moghtaderi,M.</style></author><author><style face="normal" font="Arial"> Hejrati,Z.</style></author><author><style face="normal" font="Arial"> Dehghani,Z.</style></author><author><style face="normal" font="Arial"> Dehghani,F.</style></author><author><style face="normal" font="Arial"> Kolahi,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Clinic of Ali-Asghar Hospital, Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran AND Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, IranDepartment of Pediatrics, College of Medicine, Islamic Azad University, Kazerun Branch, Kazerun, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to Food Additives in Patients with Allergy: A Study Based on Skin Test and Open Oral Challenge</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="203" start="198">198-203</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Additives</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">There has been a great increase in the consumption of various food additives in recent years. The purpose of this study was to identify the incidence of sensitization to food additives by using skin prick test in patients with allergy and to determine the concordance rate between positive skin tests and oral challenge in hypersensitivity to additives. This cross-sectional study included 125 (female 71, male 54) patients aged 2-76 years with allergy and 100 healthy individuals. Skin tests were performed in both patient and control groups with 25 fresh food additives. Among patients with allergy, 22.4% showed positive skin test at least to one of the applied materials. Skin test was negative to all tested food additives in control group. Oral food challenge was done in 28 patients with positive skin test, in whom 9 patients showed reaction to culprit (Concordance rate=32.1%). The present study suggested that about one-third of allergic patients with positive reaction to food additives showed positive oral challenge; it may be considered the potential utility of skin test to identify the role of food additives in patients with allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleSB - IMCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27424134">PM:27424134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-198-203.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-198-203.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Moghtaderi M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fuiano,N.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy Service, San Severo, ItalyAllergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Utility of the Atopy Patch Test in the Diagnosis of Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Iran J Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Otorhinolaryngol</style></full-title></periodical><pages end="175" start="169">169-175</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">86</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch test</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal challenge</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The diagnostic work-up of allergic rhinitis (AR) is first and foremost based on the combination of clinical history data and results of skin prick tests (SPT). Other tests, including specific IgE measurement, nasal challenge, and, as a third option, component resolved diagnosis or basophil activation test, may be useful when the diagnosis is difficult because of polysensitization or when negative results of SPT are observed despite a suggestive history for allergy. The atopy patch test (APT) that assesses the type 4 delayed hypersensitivity allergy is currently not sufficiently used. The data obtained in recent studies on the diagnostic utility of the APT in patients with AR was reviewed. DATA SOURCES: Review of the literature. CONCLUSION: The data from available studies show that the APT is frequently positive in patients with AR, especially when there is a positive history for atopic dermatitis. Very often, APT is the only positive test and therefore performing only SPT or in vitro IgE measurement may lead to an erroneous diagnosis of nonallergic rhinitis. Recent data suggest a role for APT not only for diagnosis but also in epidemiological investigation on respiratory allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 2251-7251 (Print)IS - 2251-7251 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27429944">PM:27429944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Otorhinolaryngol\2016-28-169-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Otorhinolaryngol\2016-28-169-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Fuiano N</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kohn,J.B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Does Exposing Infants to Peanut Products Influence the Risk of a Peanut Allergy?</style></title><secondary-title><style face="normal" font="Arial">J Acad Nutr Diet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Acad Nutr Diet</style></full-title></periodical><pages end="" start="1224">1224-</pages><volume><style face="normal" font="Arial">116</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160626IS - 2212-2672 (Print)IS - 2212-2672 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jand.2016.04.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27343973">PM:27343973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Acad Nutr Diet\2016-116-1224.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Acad Nutr Diet\2016-116-1224.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160626, Kohn JB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jand.2016.04.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korte,R.</style></author><author><style face="normal" font="Arial"> Monneuse,J.M.</style></author><author><style face="normal" font="Arial"> Gemrot,E.</style></author><author><style face="normal" font="Arial"> Metton,I.</style></author><author><style face="normal" font="Arial"> Humpf,H.U.</style></author><author><style face="normal" font="Arial"> Brockmeyer,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A new HPLC-MS Method for the Detection of Lobster and Shrimp Allergens in Food Samples via MRM and MRM(3)</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="6227" start="6219">6219-6227</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">31</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Proteotypic peptide</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shellfish allergy</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergen</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="7" Year="2016">2016/7/8</year></dates><abstract><style face="normal" font="Arial">Crustacean shellfish allergy ranks among the most frequent and severe food allergies for adults, demanding rugged and sensitive analytical routine methods. The objective of this study was therefore to develop a mass spectrometric approach for the detection of contamination with shrimp and lobster, two economically important types of crustaceans, in complex food matrices. Following a biomarker approach, we identified proteotypic peptides and developed a multiple reaction monitoring (MRM) method allowing the identification and differentiation of shrimp and lobster in food matrix at concentrations down to 0.1%. To further enhance sensitivity we employed the MRM cubed (MRM(3)) mode which allowed us to detect crustaceans down to concentrations of 25 microg/g (crustacean/food, 0.0025%). We hereby present the first mass spectrometric method for the detection of shrimp and lobster in food matrices</style></abstract><notes><style face="normal" font="Arial">DA - 20160708IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b02620</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27391354">PM:27391354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20160708-KorteR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20160708-KorteR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160708, Korte R</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b02620</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Birdi,G.</style></author><author><style face="normal" font="Arial"> Cooke,R.</style></author><author><style face="normal" font="Arial"> Knibb,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Psychology, School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK</style></auth-address><titles><title><style face="normal" font="Arial">Quality of Life, Stress, and Mental Health in Parents of Children with Parentally Diagnosed Food Allergy Compared to Medically Diagnosed and Healthy Controls</style></title><secondary-title><style face="normal" font="Arial">J Allergy (Cairo)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy (Cairo)</style></full-title></periodical><pages end="" start="1497375">1497375-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> Mental Health</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background. Food allergy is related to poorer quality of life (QoL) and mental health of caregivers. Many parents diagnose food allergy in their child without seeking medical care and there is limited research on this group. This study investigated parental QoL and mental health in parents of children with parent-diagnosed food allergy (PA), medically diagnosed food allergy (MA), and a control group with no allergy (NA). Methods. One hundred and fifty parents from a general population completed validated measures of QoL, anxiety, depression, and stress. Results. Parents of children with food allergy (PA or MA) reported higher stress, anxiety, and depression than the control group (all p &lt; 0.05). Parents of children with MA reported poorer food allergy related QoL compared to parents of children with PA (p &lt; 0.05); parents of children with PA reported poorer general QoL compared to parents of children with MA (p &lt; 0.05). Conclusion. Parents of children with food allergy have significantly poorer mental health compared to healthy controls, irrespective of whether food allergy is medically diagnosed or not. It is important to encourage parents to have their child medically tested for food allergy and to recognise and refer for psychological support where needed</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1687-9783 (Print)IS - 1687-9783 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/1497375</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27429624">PM:27429624</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy (Cairo)\2016-2016-1497375.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy (Cairo)\2016-2016-1497375.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Birdi G</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/1497375</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pagovich,O.E.</style></author><author><style face="normal" font="Arial"> Wang,B.</style></author><author><style face="normal" font="Arial"> Chiuchiolo,M.J.</style></author><author><style face="normal" font="Arial"> Kaminsky,S.M.</style></author><author><style face="normal" font="Arial"> Sondhi,D.</style></author><author><style face="normal" font="Arial"> Jose,C.L.</style></author><author><style face="normal" font="Arial"> Price,C.C.</style></author><author><style face="normal" font="Arial"> Brooks,S.F.</style></author><author><style face="normal" font="Arial"> Mezey,J.G.</style></author><author><style face="normal" font="Arial"> Crystal,R.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Genetic Medicine, Weill Cornell Medical College, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1662" start="1652">1652-1662</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Therapy</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> peanut-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="6" Year="2016">2016/6/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanuts are the most common food to provoke fatal or near-fatal anaphylactic reactions. Treatment with an anti-hIgE mAb is efficacious but requires frequent parenteral administration. OBJECTIVE: Based on the knowledge that peanut allergy is mediated by peanut-specific IgE, we hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector encoding for anti-hIgE would protect against repeated peanut exposure in the host with peanut allergy. METHODS: We developed a novel humanized murine model of peanut allergy that recapitulates the human anaphylactic response to peanuts in NOD-scid IL2Rgammanull mice transferred with blood mononuclear cells from donors with peanut allergy and then sensitized with peanut extract. As therapy, we constructed an adeno-associated rh.10 serotype vector coding for a full-length, high-affinity, anti-hIgE antibody derived from the Fab fragment of the anti-hIgE mAb omalizumab (AAVrh.10anti-hIgE). In the reconstituted mice peanut-specific IgE was induced by peanut sensitization and hypersensitivity, and reactions were provoked by feeding peanuts to mice with symptoms similar to those of human subjects with peanut allergy. RESULTS: A single administration of AAVrh.10anti-hIgE vector expressed persistent levels of anti-hIgE. The anti-hIgE vector, administered either before sensitization or after peanut sensitization and manifestation of the peanut-induced phenotype, blocked IgE-mediated alterations in peanut-induced histamine release, anaphylaxis scores, locomotor activity, and free IgE levels and protected animals from death caused by anaphylaxis. CONCLUSION: If this degree of persistent efficacy translates to human subjects, AAVrh.10anti-hIgE could be an effective 1-time preventative therapy for peanut allergy and possibly other severe, IgE-mediated allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20160703IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.03.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27372563">PM:27372563</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160703-PagovichOE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160703-PagovichOE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160703, Pagovich OE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.03.053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dinakar,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Asthma, and Immunology, Children's Mercy Hospital, Kansas City, Mo. Electronic address: cdinakar@cmh.edu</style></auth-address><titles><title><style face="normal" font="Arial">Updated epinephrine autoinjector labeling</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1021" start="1020">1020-1021</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="9" Month="7" Year="2016">2016/7/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160713IS - 2213-2201 (Electronic)LA - ENGPT - LETTERCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27406970">PM:27406970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-1020-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-1020-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160713, Dinakar C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loprinzi Brauer,C.E.</style></author><author><style face="normal" font="Arial"> Motosue,M.S.</style></author><author><style face="normal" font="Arial"> Li,J.T.</style></author><author><style face="normal" font="Arial"> Hagan,J.B.</style></author><author><style face="normal" font="Arial"> Bellolio,M.F.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Campbell,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="Arial">Prospective Validation of the NIAID/FAAN Criteria for Emergency Department Diagnosis of Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1226" start="1220">1220-1226</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Likelihood ratio</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="7" Year="2016">2016/7/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis diagnostic criteria were proposed at the Second Symposium on the Definition and Management of Anaphylaxis. These criteria were 97% sensitive and 82% specific when retrospectively validated. OBJECTIVE: To prospectively evaluate the diagnostic accuracy of the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria for diagnosis of anaphylaxis in the emergency department (ED). METHODS: We conducted a prospective observational study of patients seen in our institution's ED from April 2010 to March 2013. Patients seeking care for an allergic reaction and possible anaphylaxis were enrolled. Patients and providers completed questionnaires regarding onset, trigger, and signs and symptoms. Records were reviewed independently and blindly by 2 board-certified allergist-immunologists, and their final diagnosis (anaphylaxis vs no anaphylaxis) was used as the reference standard. Two-by-two tables were built, and test characteristics were calculated. RESULTS: Among the 174 enrolled patients, 91 (52%) met the NIAID/FAAN criteria for anaphylaxis. The allergist-immunologists diagnosed 61 cases of anaphylaxis (35%), of which 58 (95%) also satisfied the NIAID/FAAN criteria. The interrater agreement between allergist-immunologists was substantial (kappa = 0.7). Test characteristics (95% CIs) of the NIAID/FAAN criteria were as follows: sensitivity, 95.1% (85.4%-98.7%); specificity, 70.8% (61.4%-78.8%); positive predictive value, 63.7% (52.9%-73.4%); negative predictive value, 96.4% (89.1%-99.1%); positive likelihood ratio, 3.26; and negative likelihood ratio, 0.07. CONCLUSIONS: Prospectively, the NIAID/FAAN criteria continued to be highly sensitive (95%) but had lower specificity (71%) than on retrospective assessment. These criteria are likely to be useful for the diagnosis of anaphylaxis in the ED</style></abstract><notes><style face="normal" font="Arial">DA - 20160713IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27406968">PM:27406968</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-1220-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-1220-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160713, Loprinzi Brauer CE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choy,D.F.</style></author><author><style face="normal" font="Arial"> Jia,G.</style></author><author><style face="normal" font="Arial"> Abbas,A.R.</style></author><author><style face="normal" font="Arial"> Morshead,K.B.</style></author><author><style face="normal" font="Arial"> Lewin-Koh,N.</style></author><author><style face="normal" font="Arial"> Dua,R.</style></author><author><style face="normal" font="Arial"> Rivera,P.</style></author><author><style face="normal" font="Arial"> Moonsamy,P.</style></author><author><style face="normal" font="Arial"> Fontecha,M.</style></author><author><style face="normal" font="Arial"> Balasubramanyam,A.</style></author><author><style face="normal" font="Arial"> Santini,C.</style></author><author><style face="normal" font="Arial"> Bassett,E.</style></author><author><style face="normal" font="Arial"> Ray,J.M.</style></author><author><style face="normal" font="Arial"> Cabanski,C.R.</style></author><author><style face="normal" font="Arial"> Bradley,M.S.</style></author><author><style face="normal" font="Arial"> Maciuca,R.</style></author><author><style face="normal" font="Arial"> Mosesova,S.</style></author><author><style face="normal" font="Arial"> Scheerens,H.</style></author><author><style face="normal" font="Arial"> Arron,J.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Peripheral blood gene expression predicts clinical benefit from anti</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôIL-13 in asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1233" start="1230">1230-1233</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27474124">PM:27474124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-ChoyDF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-ChoyDF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Choy DF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hulse,K.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Separating sensitization and regulatory T-cell functions in patients with food allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="813" start="812">812-813</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.007</style></work-type><urls><web-urls><url ppv-ref="no">PM27464959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-HulseKE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-HulseKE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Hulse KE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kannan,Y.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Coomes,S.M.</style></author><author><style face="normal" font="Arial"> Okoye,I.S.</style></author><author><style face="normal" font="Arial"> Pelly,V.S.</style></author><author><style face="normal" font="Arial"> Sriskantharajah,S.</style></author><author><style face="normal" font="Arial"> Guckel,E.</style></author><author><style face="normal" font="Arial"> Webb,L.</style></author><author><style face="normal" font="Arial"> Czieso,S.</style></author><author><style face="normal" font="Arial"> Nikolov,N.</style></author><author><style face="normal" font="Arial"> MacDonald,A.S.</style></author><author><style face="normal" font="Arial"> Ley,S.C.</style></author><author><style face="normal" font="Arial"> Wilson,M.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">TPL-2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="666" start="655">655-666</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> bone marrow chimeras</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Ccl24</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chimera</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-2</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Map3k8</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô/</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TPL-2</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"></style><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">Background The molecular and cellular pathways driving the pathogenesis of severe asthma are poorly defined. TPL-2 (COT, MAP3K8) kinase activates the MEK1/2-ERK1/2 MAP kinase signaling pathway following TLR, TNFR1 and IL-1R stimulation. Objective TPL-2 has been widely described as a critical regulator of inflammation and we sought to investigate the role of TPL-2 in house dust mite (HDM) mediated allergic airway inflammation. Methods A comparative analysis of wild type and Map3k8</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô/</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô mice was conducted. Mixed bone marrow chimeras, conditional knockout mice and adoptive transfer models were also used. Differential cell counts were performed on the bronchoalveolar lavage fluid (BAL), followed by histological analysis of lung sections. Flow cytometry and quantitative PCR was used to measure type-2 cytokines. Elisa was used to assess the production of IgE, type-2 cytokines and Ccl24. RNA sequencing was used to characterize dendritic cell (DC) transcripts. Results TPL-2 deficiency led to exacerbated HDM-induced airway allergy, with increased airway and tissue eosinophilia, lung inflammation, IL-4, IL-5, IL-13 and IgE production. Increased airway allergic responses in Map3k8</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô/</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô mice was not due to a cell intrinsic role for TPL-2 in T cells, B cells or LysM+ cells but due to a regulatory role for TPL-2 in DCs. TPL-2 inhibited Ccl24 expression in lung DCs and blockade of Ccl24 prevented the exaggerated airway eosinophilia and lung inflammation in mice given HDM-pulsed Map3k8</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô/</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô DCs. Conclusion TPL-2 regulates DC-derived Ccl24 production to prevent severe type-2 airway allergy in mice</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.jaci.2016.05.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27484038">PM:27484038</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-KannanY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-KannanY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Kannan Y</style></custom2><misc3><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.jaci.2016.05.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anderson,H-M.</style></author><author><style face="normal" font="Arial"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="Arial"> Arron,J.R.</style></author><author><style face="normal" font="Arial"> Holweg,C.T.J.</style></author><author><style face="normal" font="Arial"> Rajamanickam,V.</style></author><author><style face="normal" font="Arial"> Gangnon,R.E.</style></author><author><style face="normal" font="Arial"> Gern,J.E.</style></author><author><style face="normal" font="Arial"> Jackson,D.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Relationships Among Aeroallergen Sensitization, Peripheral Blood Eosinophils and Periostin in Pediatric Asthma Development</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="796" start="790">790-796</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> origins of asthma</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood eosinophils</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">Background Biomarkers, preferably non-invasive, that predict asthma inception children are lacking. Objective Little is known about biomarkers of type 2 inflammation in early life in relation to asthma inception. We evaluated aeroallergen sensitization, peripheral blood eosinophils and serum periostin as potential biomarkers of asthma in children. Methods Children enrolled in the Childhood Origins of ASThma (COAST) study were followed prospectively from birth. Blood samples were collected at ages 2, 4, 6, and 11 years, and serum-specific IgE, blood eosionophils and periostin were measured in 244 children. Relationships among these biomarkers, age and asthma were assessed. Results Serum periostin levels were approximately 2-3 fold higher in children than previously-observed adult levels. Levels were highest at 2 years (145 ng/mL), and did not change significantly between 4 and 11 years (128 and 130 ng/mL). Age 2 periostin</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ150 ng/mL predicted asthma at age 6 [Odds Ratio (OR) 2.3 95%CI (1.3-4.4)]. Eosinophil count </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ300 cells/ul and aeroallergen sensitization at age 2 were each associated with increased risk of asthma at age 6 [OR 3.1(1.7-6.0) and 3.3(1.7-6.3)]. Children with any two of the biomarkers had significantly increased risk of developing asthma by school age [</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ2 biomarkers vs. none OR= 6.6 (95%CI 2.7-16.0). Conclusion Serum periostin levels are significantly higher in children than adults, likely due to bone turnover, which impairs clinical utility in children. Early life aeroallergen sensitization and elevated blood eosinophils are robust predictors of asthma development. Children with evidence of activation of multiple pathways of type 2 inflammation in early life are at greatest risk for asthma development</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27484037">PM:27484037</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-AndersonHM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-AndersonHM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Anderson HM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Platt,C.D.</style></author><author><style face="normal" font="Arial"> D'Angelo,L.</style></author><author><style face="normal" font="Arial"> Neufeld,E.J.</style></author><author><style face="normal" font="Arial"> Broyles,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Boston Children's Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="Arial">Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1008" start="1006">1006-1008</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/31/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">blood</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="9" Month="7" Year="2016">2016/7/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160713IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.05.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27406969">PM:27406969</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-1006-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-1006-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160713, Platt CD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.05.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wosny,K.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author><author><style face="normal" font="Arial"> Werner,A.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Altrichter,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Antihistamine updosing reduces disease activity in difficult-to-treat cholinergic urticaria patients</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1485" start="1483">1483-1485</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Difficult-to-treat</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pruritus7 score</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496595">PM:27496595</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-WosnyK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-WosnyK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Wosny K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shi,B.</style></author><author><style face="normal" font="Arial"> Bangayan,N.J.</style></author><author><style face="normal" font="Arial"> Curd,E.</style></author><author><style face="normal" font="Arial"> Taylor,P.A.</style></author><author><style face="normal" font="Arial"> Gallo,R.L.</style></author><author><style face="normal" font="Arial"> Leung,D.Y.M.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The skin microbiome is different in-ápediatric versus adult atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1236" start="1233">1233-1236</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27474122">PM:27474122</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-ShiB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160726-ShiB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Shi B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McGain,F.</style></author><author><style face="normal" font="Arial"> Welton,R.</style></author><author><style face="normal" font="Arial"> Solley,G.O.</style></author><author><style face="normal" font="Arial"> Winkel,K.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Australian Venom Research Unit, Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">First fatalities from tick bite anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="770" start="769">769-770</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2015.12.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27393785">PM:27393785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-769-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-769-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160710, McGain F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2015.12.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simberloff,T.</style></author><author><style face="normal" font="Arial"> Parambi,R.</style></author><author><style face="normal" font="Arial"> Bartnikas,L.M.</style></author><author><style face="normal" font="Arial"> Broyles,A.D.</style></author><author><style face="normal" font="Arial"> Hamel,V.</style></author><author><style face="normal" font="Arial"> Timmons,K.G.</style></author><author><style face="normal" font="Arial"> Miller,D.M.</style></author><author><style face="normal" font="Arial"> Graham,D.A.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> MacGinnitie,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Program for Patient Safety and Quality, Boston Children's Hospital, Boston, MassInstitute for Relevant Clinical Data Analytics (IRCDA), Boston Children's Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="Arial">Implementation of a Standardized Clinical Assessment and Management Plan (SCAMP) for Food Challenges</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="344" start="335">335-344</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patient safety</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Triage</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oral food challenges (OFCs) are routinely used to confirm ongoing food allergy. Serum-specific IgE (sIgE) and skin prick testing (SPT) are imperfect predictors of which patients will pass OFCs. OBJECTIVE: The objective of this study was to describe the design and implementation of a Standardized Clinical Assessment and Management Plan (SCAMP) to study and iteratively improve sIgE and SPT thresholds to determine when and where to conduct OFCs for patients. METHODS: Allergists consulted recommended sIgE and SPT thresholds when ordering challenges although diversions were permitted. Criteria were iteratively improved after periodic analyses of challenge outcome and diversions. RESULTS: Over 3 years, allergists ordered 2368 food challenges for 1580 patients with histories of IgE-mediated reactions to food: 1386 in an outpatient clinic and 945 in a higher resource infusion center. Reactions to challenge were observed in 13% of clinic and 23% of infusion center challenges. Six patients challenged in clinic required treatment with epinephrine compared with 22 in the infusion center. The need for epinephrine was more common in patients with asthma-5% of asthmatic patients required epinephrine compared with 1% of nonasthmatic patients (P &lt; .01). Recommended sIgE and SPT thresholds were incrementally changed and, using the control chart methodology, a significant decrease was noted in the proportion of challenges ordered in the higher resource location. CONCLUSIONS: By setting and continually refining sIgE and SPT recommendations using the SCAMP method, allergists can better determine the risk of severe reaction and triage patients to the appropriate setting for an OFC</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.05.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27373725">PM:27373725</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160704-SimberloffT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160704-SimberloffT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Simberloff T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.05.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santos,A.F.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma, Allergy &amp; Lung Biology, Department of Pediatric Allergy, King's College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Is the Prevalence of Food Allergy Not on the Rise After All?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="722" start="721">721-722</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160710IS - 2213-2201 (Electronic)LA - engPT - EditorialSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.04.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27393781">PM:27393781</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-721-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-721-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160710, Santos AF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.04.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Population Medicine, Center for Healthcare Research in Pediatrics, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="Arial">The Promise of Improving Asthma Control Using Mobile Health</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="739" start="738">738-739</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160710IS - 2213-2201 (Electronic)LA - engPT - EditorialSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.04.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27393782">PM:27393782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-738-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-738-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160710, Wu AC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.04.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Stowe,J.</style></author><author><style face="normal" font="Arial"> Andrews,N.J.</style></author><author><style face="normal" font="Arial"> Miller,E.</style></author><author><style face="normal" font="Arial"> Turner,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport, Isle of Wight, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">No association between atopic outcomes and type of pertussis vaccine given in children born on the Isle of Wight 2001-2002</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1250" start="1248">1248-1250</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pertussis Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="30" Month="6" Year="2016">2016/6/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160703IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27372600">PM:27372600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160703-VenterC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160703-VenterC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160703, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farooqui,N.</style></author><author><style face="normal" font="Arial"> Peden,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Partners of Central Indiana, Indianapolis, Ind.</style></auth-address><titles><title><style face="normal" font="Arial">Occupational Asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="784" start="783">783-784</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="07/31/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2015.12.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27393786">PM:27393786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-783-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-783-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160710, Farooqui N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2015.12.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liccardi,G.</style></author><author><style face="normal" font="Arial"> Salzillo,A.</style></author><author><style face="normal" font="Arial"> Calzetta,L.</style></author><author><style face="normal" font="Arial"> Piccolo,A.</style></author><author><style face="normal" font="Arial"> Rogliani,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Chest Diseases , Division of Pneumology and Allergology, High Specialty "A.Cardarelli" Hospital , Naples Italy</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified?</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> pet exposure</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword></keywords><dates><year Day="23" Month="6" Year="2016">2016/6/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3109/02770903.2016.1174260</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27336848">PM:27336848</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20160711-LiccardiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20160711-LiccardiG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, Liccardi G</style></custom2><misc3><style face="normal" font="Arial">10.3109/02770903.2016.1174260</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moral,A.</style></author><author><style face="normal" font="Arial"> Moreno,V.</style></author><author><style face="normal" font="Arial"> Giron,F.</style></author><author><style face="normal" font="Arial"> El-Qutob,D.</style></author><author><style face="normal" font="Arial"> Moure,J.D.</style></author><author><style face="normal" font="Arial"> Alcantara,M.</style></author><author><style face="normal" font="Arial"> Padial,A.</style></author><author><style face="normal" font="Arial"> Oehling,A.G.</style></author><author><style face="normal" font="Arial"> Millan,C.</style></author><author><style face="normal" font="Arial"> De la Torre,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Service, Hospital Virgen del Valle, Toledo</style></auth-address><titles><title><style face="normal" font="Arial">Adverse reactions and tolerability of high-dose sublingual allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="133" start="129">129-133</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> olive pollen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sublingual allergen immunotherapy is an effective treatment against allergic respiratory disease. Many studies have shown the safety of this type of therapy, although the factors that might affect the tolerability of high-dose sublingual immunotherapy have not been well established. The aim of this study was to determine the factors that affect the tolerability of sublingual allergen immunotherapy. PATIENTS AND METHODS: A total of 183 subjects aged >/=5 years, diagnosed with allergic rhinitis with/without mild to moderate asthma due to sensitization to grass, olive pollen, or mites, were included in this open, retrospective, multicentric, noninterventional study. Sublingual immunotherapy was administered for at least 3 months. RESULTS: The most frequent adverse reaction was oral pruritus (13.7% of the patients). Most of the reactions were local (84.7%) and immediate (93.5%) and occurred during the initiation phase (60.6%). All reactions were mild to moderate in severity. No serious adverse reactions were registered. When comparing factors with potential influence on the occurrence of adverse reactions, the results between the groups of subjects with and without adverse reactions showed no statistically significant differences in sex (P=0.6417), age (P=0.1801), years since the disease was first diagnosed (P=0.3800), treatment composition (P=0.6946), polysensitization (P=0.1730), or clinical diagnosis (P=0.3354). However, it was found that treatment duration had a statistically significant influence (3 months, >3 months: P=0.0442) and the presence of asthma was close to statistical significance (P=0.0847). CONCLUSION: In our study, treatment duration is significantly associated with the occurrence of adverse reactions after the administration of high doses of sublingual allergen immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160715IS - 1178-6965 (Electronic)IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S107830</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27418842">PM:27418842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-129-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-129-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160715, Moral A</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S107830</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zuo,Y.</style></author><author><style face="normal" font="Arial"> Evangelista,F.</style></author><author><style face="normal" font="Arial"> Culton,D.</style></author><author><style face="normal" font="Arial"> Guilabert,A.</style></author><author><style face="normal" font="Arial"> Lin,L.</style></author><author><style face="normal" font="Arial"> Li,N.</style></author><author><style face="normal" font="Arial"> Diaz,L.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid</style></title><secondary-title><style face="normal" font="Arial">J Autoimmun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Autoimmun</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Blister</style></keyword><keyword><style face="normal" font="Arial"> Blistering disease</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> BP180</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG3</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IgG4 blocking antibody</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> NC16A</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2016">2016/7/1</year></dates><abstract><style face="normal" font="Arial">The IgG4 subclass of antibodies exhibits unique characteristics that suggest it may function in an immunoregulatory capacity. The inhibitory function of IgG4 has been well documented in allergic disease by the demonstration of IgG4 blocking antibodies, but similar functions have not been explored in autoimmune disease. Bullous pemphigoid (BP) is a subepidermal autoimmune blistering disease characterized by autoantibodies directed against BP180 and an inflammatory infiltrate including eosinophils and neutrophils. Animal models have revealed that the NC16A region within BP180 harbors the critical epitopes necessary for autoantibody mediated disease induction. BP180 NC16A-specific IgG belong to the IgG1, IgG3, and IgG4 subclasses. The purpose of this study was to determine effector functions of different IgG subclasses of NC16A-specific autoantibodies in BP. We find that IgG4 anti-NC16A autoantibodies inhibit the binding of IgG1 and IgG3 autoantibodies to the NC16A region. Moreover, IgG4 anti-NC16A blocks IgG1 and IgG3 induced complement fixation, neutrophil infiltration, and blister formation clinically and histologically in a dose-dependent manner following passive transfer to humanized BP180-NC16A mice. These findings highlight the inhibitory role of IgG4 in autoimmune disease and have important implications for the treatment of BP as well as other antibody mediated inflammatory and autoimmune diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 1095-9157 (Electronic)IS - 0896-8411 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaut.2016.06.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27377454">PM:27377454</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Autoimmun\20160705-ZuoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Autoimmun\20160705-ZuoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Zuo Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaut.2016.06.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carpena,N.T.</style></author><author><style face="normal" font="Arial"> Abueva,C.D.</style></author><author><style face="normal" font="Arial"> Padalhin,A.R.</style></author><author><style face="normal" font="Arial"> Lee,B.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Regenerative Medicine, College of Medicine, SoonChunHyang University, Cheonan, 330-390, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of egg white ovomucin-based porous scaffold as an implantable biomaterial for tissue engineering</style></title><secondary-title><style face="normal" font="Arial">J Biomed Mater Res B Appl Biomater</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Biomed Mater Res B Appl Biomater</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> biocompatibility</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Foam</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Hydrogels</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Ovomucin</style></keyword><keyword><style face="normal" font="Arial"> Periodicals</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tissue Engineering</style></keyword><keyword><style face="normal" font="Arial"> tissue repair</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="13" Month="7" Year="2016">2016/7/13</year></dates><abstract><style face="normal" font="Arial">Studies have shown the technological and functional properties of ovomucin (OVN) in the food-agricultural industry. But research has yet to explore its potential as an implantable biomaterial for tissue engineering and regenerative medicine. In this study we isolated OVN from egg white by isoelectric precipitation and fabricated scaffolds with tunable porosity by utilizing its foaming property. Gelatin a known biocompatible material was introduced to stabilize the foams, wherein different ratios of OVN and gelatin had a significant effect on the degree of porosity, pore size and stability of the formed hydrogels. The porous scaffolds were crosslinked with EDC resulting in stable scaffolds with prolonged degradation. Improved cell proliferation and adhesion of rat bone marrow-derived mesenchymal stem cells were observed for OVN containing scaffolds. Although, scaffolds with 75% OVN showed decrease in cell proliferation for L929 fibroblast type of cells. Further biocompatibility assessment as implant material was determined by subcutaneous implantation in rats of selected scaffold. H&amp;E staining showed reasonable vascularization over time and little evidence of severe fibrosis at the implant site. Persistent polarization of classically activated macrophage was not observed, potentially reducing inflammatory response, and showed increased expression of alternatively activated macrophage cells that is favorable for tissue repair. Analysis of IgE levels in rat serum after implantation indicated minimal and resolvable allergic response to the OVN implants. The results demonstrate OVN as an acceptable implant scaffold that could provide new opportunities as an alternative natural biocompatible and functional biomaterial in various biomedical applications. (c) 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2016</style></abstract><notes><style face="normal" font="Arial">DA - 20160713IS - 1552-4981 (Electronic)IS - 1552-4973 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1002/jbm.b.33750</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27405539">PM:27405539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biomed Mater Res B Appl Biomater\20160713-CarpenaNT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biomed Mater Res B Appl Biomater\20160713-CarpenaNT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160713, Carpena NT</style></custom2><misc3><style face="normal" font="Arial">10.1002/jbm.b.33750</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maaske,A.</style></author><author><style face="normal" font="Arial"> Devos,F.C.</style></author><author><style face="normal" font="Arial"> Niezold,T.</style></author><author><style face="normal" font="Arial"> Lapuente,D.</style></author><author><style face="normal" font="Arial"> Tannapfel,A.</style></author><author><style face="normal" font="Arial"> Vanoirbeek,J.A.</style></author><author><style face="normal" font="Arial"> Uberla,K.</style></author><author><style face="normal" font="Arial"> Peters,M.</style></author><author><style face="normal" font="Arial"> Tenbusch,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular and Medical Virology, Ruhr-University, Bochum, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Mucosal expression of DEC-205 targeted allergen alleviates an asthmatic phenotype in mice</style></title><secondary-title><style face="normal" font="Arial">J Control Release</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Control Release</style></full-title></periodical><pages end="22" start="14">14-22</pages><volume><style face="normal" font="Arial">237</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenovirus</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Single-Chain Antibodies</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> virology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2016">2016/7/1</year></dates><abstract><style face="normal" font="Arial">Considering the rising incidence of allergic asthma, the symptomatic treatments that are currently applied in most cases are less than ideal. Specific immunotherapy is currently the only treatment that is able to change the course of the disease, but suffers from a long treatment duration. A gene based immunization that elicits the targeting of allergens towards dendritic cells in a steady-state environment might have the potential to amend these difficulties. Here we used a replication deficient adenovirus to induce the mucosal expression of OVA coupled to a single-chain antibody against DEC-205. A single intranasal vaccination was sufficient to mitigate an OVA-dependent asthmatic phenotype in a murine model. Invasive airway measurements demonstrated improved lung function after Ad-Dec-OVA treatment, which was in line with a marked reduction of goblet cell hyperplasia and lung eosinophilia. Furthermore OVA-specific IgE titers and production of type 2 cytokines were significantly reduced. Together, the here presented data demonstrate the feasibility of mucosal expression of DEC-targeted allergens as a treatment of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160709IS - 1873-4995 (Electronic)IS - 0168-3659 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jconrel.2016.06.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27374625">PM:27374625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Control Release\2016-237-14-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Control Release\2016-237-14-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160709, Maaske A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jconrel.2016.06.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kulthanan,K.</style></author><author><style face="normal" font="Arial"> Tuchinda,P.</style></author><author><style face="normal" font="Arial"> Chularojanamontri,L.</style></author><author><style face="normal" font="Arial"> Likitwattananurak,C.</style></author><author><style face="normal" font="Arial"> Ungaksornpairote,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Dermatology, Faculty of Medicine Siriraj Hospital , Mahidol University , Bangkok , Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population</style></title><secondary-title><style face="normal" font="Arial">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin allergy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="7" Year="2016">2016/7/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: There are limited data regarding omalizumab in the treatment of recalcitrant chronic spontaneous urticaria (CSU) in Asian populations. This study evaluated the effectiveness and the proper dosage of omalizumab for Asian CSU patients in a real-life setting. METHODS: We retrospectively reviewed recalcitrant CSU patients seeking treatment at the Skin Allergy Clinic, Siriraj Hospital during the 3-year period. All patients were treated with omalizumab as an add-on therapy. Standard seven-day urticaria activity score (UAS7) and medication score were used to assess omalizumab response. RESULTS: Of 13 patients, 9 patients (70%) responded well to 150 mg omalizumab injection every month, whereas 4 patients requiring updosing to 300 mg. In the 150 mg group, one patient achieved complete symptom control without antihistamine intake. Most of them required antihistamines without prednisolone and ciclosporin. Onset of omalizumab was fast, usually within the first week. Though only two patients in the 300 mg group achieved complete absence of symptoms, ciclosporin and oral corticosteroids could be discontinued. No patients reported adverse effects. CONCLUSIONS: Omalizumab at an initial dosage of 150 mg was effective in the treatment of recalcitrant CSU among Asians. Updosing to 300 mg was required to achieve satisfactory outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20160708IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1080/09546634.2016.1200710</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27388043">PM:27388043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatolog Treat\20160708-KulthananK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatolog Treat\20160708-KulthananK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160708, Kulthanan K</style></custom2><misc3><style face="normal" font="Arial">10.1080/09546634.2016.1200710</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bodoutchian,A.A.</style></author><author><style face="normal" font="Arial"> Jain,H.</style></author><author><style face="normal" font="Arial"> Velez,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Not All Coughs Are Asthma or Allergies: Churg</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôStrauss Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cell Count</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> cardiomyopathy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exertion</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunosuppressive therapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Leg</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Troponin</style></keyword><keyword><style face="normal" font="Arial"> Troponin T</style></keyword><keyword><style face="normal" font="Arial"> troponins</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white blood cell</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0736-4679</style></isbn><abstract><style face="normal" font="Arial">Background Cardiomyopathy in patients with Churg</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôStrauss syndrome (CSS) carries a poor prognosis, with a high 5-year mortality rate, and requires treatment with immunosuppressive therapy. There is no single pathognomonic test or clinical finding for diagnosing CSS; instead, it is based upon meeting four of six criteria. Case Report A 47-year-old woman with a 6-month medical history of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£asthma</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ presented to our hospital with a 1-month history or dyspnea on exertion. She denied any chest pain, cough, fever, orthopnea, or leg swelling. She was afebrile and normotensive, and her physical examination was unremarkable. Her white blood cell count was 23,000/mm3 with 23% eosinophils, and her troponin T level was 1.08 </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇïNg/ml. Extensive work-up revealed CSS. Why Should an Emergency Physician Be Aware of This? Emergency physicians should be aware of unusual cases because not every patient that walks into an emergency department has a simple case of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£asthma</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ or </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£allergies.</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ Our patient had been diagnosed with asthma for 6-ámonths before her symptoms had progressed to a point that prompted her to seek medical attention in a hospital. Emergency physicians are in a unique position to identify patients who present with recurrent complaints of asthma</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çöespecially late-onset asthma, which gradually worsens and is refractory to usual treatment. A complete blood cell count with a differential will prove valuable. Assessments of a patient's C-reactive protein level and erythrocyte sedimentation rate are inexpensive and check for signs of inflammation, although they are nonspecific. A chest radiograph or computed tomography scan of the chest or sinuses in some patients can also prove to be of value. Prompt recognition and treatment with steroids is imperative to ablate vasculitis tissue damage because this can improve the outcome</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jemermed.2016.05.054</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jemermed.2016.05.054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Emerg Med\20160716-BodoutchianAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Emerg Med\20160716-BodoutchianAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Bodoutchian AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jemermed.2016.05.054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mihic,T.</style></author><author><style face="normal" font="Arial"> Rainkie,D.</style></author><author><style face="normal" font="Arial"> Wilby,K.J.</style></author><author><style face="normal" font="Arial"> Pawluk,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The University of British Columbia, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="Arial">The Therapeutic Effects of Camel Milk: A Systematic Review of Animal and Human Trials</style></title><secondary-title><style face="normal" font="Arial">J Evid Based Complementary Altern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Evid Based Complementary Altern Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Autism</style></keyword><keyword><style face="normal" font="Arial"> Bodily Secretions</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Camels</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Heavy metal</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Qatar</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="7" Year="2016">2016/7/18</year></dates><abstract><style face="normal" font="Arial">The clinical effectiveness and value of camel milk as a therapeutic agent is currently unclear. MEDLINE (1946 to March 2016), EMBASE (1974 to March 2016), and Google Scholar were searched using the following terms: milk, bodily secretions, camels, camelus, camelini, camelidae, dromedary, bactrian camel, body fluid, and bodily secretions. Articles identified were reviewed if the study was investigating the use of camel milk for the potential treatment of diseases affecting humans. Of 430 studies, 24 were included after assessment. Identified studies highlighted treatment with camel milk of diseases, including diabetes, autism, cancer, various infections, heavy metal toxicity, colitis, and alcohol-induced toxicity. Although most studies using both the human and animal model do show a clinical benefit with an intervention and camel milk, limitations of these studies must be taken into consideration before widespread use. Based on the evidence, camel milk should not replace standard therapies for any indication in humans</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 2156-5899 (Electronic)IS - 2156-5899 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -CO - Qatar -</style></notes><work-type><style face="normal" font="Arial">10.1177/2156587216658846</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27432772">PM:27432772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Evid Based Complementary Altern Med\20160719-MihicT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Evid Based Complementary Altern Med\20160719-MihicT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Mihic T</style></custom2><misc3><style face="normal" font="Arial">10.1177/2156587216658846</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moronta,J.</style></author><author><style face="normal" font="Arial"> Smaldini,P.L.</style></author><author><style face="normal" font="Arial"> Fossati,C.A.</style></author><author><style face="normal" font="Arial"> Anon,M.C.</style></author><author><style face="normal" font="Arial"> Docena,G.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The anti-inflammatory SSEDIKE peptide from Amaranth seeds modulates IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="Arial">J Funct Foods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Funct Foods</style></full-title></periodical><pages end="587" start="579">579-587</pages><volume><style face="normal" font="Arial">25</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amaranth</style></keyword><keyword><style face="normal" font="Arial"> Amaranthus</style></keyword><keyword><style face="normal" font="Arial"> Amaranthus hypochondriacus</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Jejunum</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergens</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> NF-+¦B</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><isbn><style face="normal" font="Arial">1756-4646</style></isbn><abstract><style face="normal" font="Arial">The in vivo immunomodulatory effect of a bioactive peptide from Amaranthus hypochondriacus grains in an IgE-mediated food allergy mouse model was examined. The synthetic SSEDIKE peptide was orally administered to prevent food allergy. Upon oral challenge with milk allergens we observed an alleviation of hypersensitivity symptoms with negativization of skin test, a significant inhibition of specific IgE and IgG1 secretion, a substantial reduction in the secretion of IL-5 and IL-13 by antigen-stimulated spleen cells and mucosal reduction of transcripts coding for ccl20, gata-3 and nf-kb. In addition tgf-+¦ and foxp3 mRNA levels were up-regulated in jejunum. The charged SSEDIKE peptide from Amaranth inhibited the allergy reaction in a mouse model of food allergy, with suppression of IgE secretion and control of the intestinal inflammation preventing the activation of NF-+¦B, which might be attributed to the induction of local tolerance</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jff.2016.06.031</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jff.2016.06.031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Funct Foods\2016-25-579-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Funct Foods\2016-25-579-87.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160723, Moronta J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jff.2016.06.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,H.</style></author><author><style face="normal" font="Arial"> Huang,N.</style></author><author><style face="normal" font="Arial"> Li,W.J.</style></author><author><style face="normal" font="Arial"> Dong,X.</style></author><author><style face="normal" font="Arial"> Qi,S.S.</style></author><author><style face="normal" font="Arial"> Wang,Y.N.</style></author><author><style face="normal" font="Arial"> Liu,G.H.</style></author><author><style face="normal" font="Arial"> Zhu,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China</style></auth-address><titles><title><style face="normal" font="Arial">Clinical and laboratory features, and quality of life assessment in wheat dependent exercise-induced anaphylaxis patients from central China</style></title><secondary-title><style face="normal" font="Arial">J Huazhong Univ Sci Technolog Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Huazhong Univ Sci Technolog Med Sci</style></full-title></periodical><pages end="415" start="410">410-415</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Cardiovascular System</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Omega-5-gliadin</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergen</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Wheat dependent exercise-induced anaphylaxis (WDEIA) is a rare but potentially severe food allergy caused by the combination of wheat ingestion and physical exercise. The impact of WDEIA on quality of life (QOL) is unclear. This study characterized the clinical and laboratory features and investigated the QOL in WDEIA patients from Central China. Twenty-eight WDEIA patients were analyzed, and QOL was measured by validated Chinese version Food Allergy Quality of Life Questionnaire-Adult Form (FAQLQ-AF) and Food Allergy Independent Measure (FAIM) after obtaining the diagnosis. The results showed that half of the patients were females. The median onset age was 37 years old. The symptoms occurred within 1 h after wheat ingestion (26/28). Symptoms of anaphylaxis included cutaneous (26/28), respiratory (11/28), gastro-intestinal (5/28) and cardiovascular manifestations (27/28). Skin prick tests were positive to salt soluble (89.3%) and salt insoluble wheat allergen extracts (100%). Positive rate to wheat, gluten and omega-5 gliadin specific IgE was 64.3%, 92.9% and 92.9% respectively. Specific IgE to omega-5 gliadin with a cut-off value 0.83 KU/L offered highly efficient diagnostic criterion for WDEIA (sensitivity: 89.3%; and specificity: 88.9%). The mean scores of FAQLQ-AF and FAIM were 4.70 and 4.98 respectively and level of anti-omega-5 gliadin IgE had positive correlations with FAQLQ scores. Thereby, WDEIA is commonly found in mid-age adults. In most cases, multi-organs especially skin and cardiovascular systems are involved. Salt insoluble wheat allergen skin test and serum specific IgE to gluten and omega-5 gliadin help to diagnose WDEIA. QOL in WDEIA patients is severely impaired</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 1672-0733 (Print)IS - 1672-0733 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11596-016-1601-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27376813">PM:27376813</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Huazhong Univ Sci Technolog Med Sci\2016-36-410-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Huazhong Univ Sci Technolog Med Sci\2016-36-410-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Chen H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11596-016-1601-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Drake,L.Y.</style></author><author><style face="normal" font="Arial"> Iijima,K.</style></author><author><style face="normal" font="Arial"> Bartemes,K.</style></author><author><style face="normal" font="Arial"> Kita,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55905</style></auth-address><titles><title><style face="normal" font="Arial">Group 2 Innate Lymphoid Cells Promote an Early Antibody Response to a Respiratory Antigen in Mice</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> humoral immunity</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> soluble factors</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="15" Month="7" Year="2016">2016/7/15</year></dates><abstract><style face="normal" font="Arial">Innate lymphoid cells (ILCs) are a new family of immune cells that play important roles in innate immunity in mucosal tissues, and in the maintenance of tissue and metabolic homeostasis. Recently, group 2 ILCs (ILC2s) were found to promote the development and effector functions of Th2-type CD4+ T cells by interacting directly with T cells or by activating dendritic cells, suggesting a role for ILC2s in regulating adaptive immunity. However, our current knowledge on the role of ILCs in humoral immunity is limited. In this study, we found that ILC2s isolated from the lungs of naive BALB/c mice enhanced the proliferation of B1- as well as B2-type B cells and promoted the production of IgM, IgG1, IgA, and IgE by these cells in vitro. Soluble factors secreted by ILC2s were sufficient to enhance B cell Ig production. By using blocking Abs and ILC2s isolated from IL-5-deficient mice, we found that ILC2-derived IL-5 is critically involved in the enhanced production of IgM. Furthermore, when adoptively transferred to Il7r-/- mice, which lack ILC2s and mature T cells, lung ILC2s promoted the production of IgM Abs to a polysaccharide Ag, 4-hydroxy-3-nitrophenylacetyl Ficoll, within 7 d of airway exposure in vivo. These findings add to the growing body of literature regarding the regulatory functions of ILCs in adaptive immunity, and suggest that lung ILC2s promote B cell production of early Abs to a respiratory Ag even in the absence of T cells</style></abstract><notes><style face="normal" font="Arial">DA - 20160716IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1502669</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27421480">PM:27421480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20160716-DrakeLY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20160716-DrakeLY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Drake LY</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1502669</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zou,L.</style></author><author><style face="normal" font="Arial"> Buchner,A.</style></author><author><style face="normal" font="Arial"> Roberge,M.</style></author><author><style face="normal" font="Arial"> Liu,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Global Bioassays and Technology, Teva Pharmaceuticals, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy</style></title><secondary-title><style face="normal" font="Arial">J Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Res</style></full-title></periodical><pages end="" start="9248061">9248061-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bioassay</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast cancer</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocyte Colony-Stimulating Factor</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Neutropenia</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Lipegfilgrastim is a long-acting, once-per-cycle, glycopegylated recombinant granulocyte colony-stimulating factor (G-CSF) used to prevent neutropenia in patients receiving myelosuppressive chemotherapy. This integrated analysis examined the immunogenicity of lipegfilgrastim and its potential clinical impact in two double-blind randomized studies (phases II and III) of patients with breast cancer receiving chemotherapy. Serum samples were analyzed using sequential assays for screening, confirmation, antibody titer, and characterization of antidrug antibodies (ADA). Neutropenia-related efficacy measures were reviewed for each ADA-positive patient. Among 255 patients receiving lipegfilgrastim (154 in phase II, 101 in phase III) and 155 patients receiving pegfilgrastim (54 in phase II, 101 in phase III), the incidence of treatment-emergent ADA was low and similar between the lipegfilgrastim (phase II: 1.3%; phase III: 1.0%) and pegfilgrastim (phase II: 1.9%; phase III: 1.0%) arms. None of the treatment-emergent ADA-positive samples exhibited neutralizing activity against lipegfilgrastim, pegfilgrastim, or glycosylated G-CSF in a cell-based neutralizing antibody assay. No changes were observed in neutropenia-related efficacy measures among ADA-positive patients, and no treatment-related hypersensitivity or anaphylaxis occurred. These results indicate that there is no apparent impact of ADA on lipegfilgrastim efficacy and safety</style></abstract><notes><style face="normal" font="Arial">DA - 20160715IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/9248061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27419145">PM:27419145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Res\2016-2016-9248061.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Res\2016-2016-9248061.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160715, Zou L</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/9248061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hansen,J.S.</style></author><author><style face="normal" font="Arial"> Norgaard,A.W.</style></author><author><style face="normal" font="Arial"> Koponen,I.K.</style></author><author><style face="normal" font="Arial"> Sorli,J.B.</style></author><author><style face="normal" font="Arial"> Paidi,M.D.</style></author><author><style face="normal" font="Arial"> Hansen,S.W.</style></author><author><style face="normal" font="Arial"> Clausen,P.A.</style></author><author><style face="normal" font="Arial"> Nielsen,G.D.</style></author><author><style face="normal" font="Arial"> Wolkoff,P.</style></author><author><style face="normal" font="Arial"> Larsen,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a The National Research Centre for the Working Environment , Copenhagen , Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Limonene and its ozone-initiated reaction products attenuate allergic lung inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">J Immunotoxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunotoxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Balb/cJ</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fragrance</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor air pollutants</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> neurogenic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> surfactant protein D</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> vagal</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> working environment</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">Inhalation of indoor air pollutants may cause airway irritation and inflammation and is suspected to worsen allergic reactions. Inflammation may be due to mucosal damage, upper (sensory) and lower (pulmonary) airway irritation due to activation of the trigeminal and vagal nerves, respectively, and to neurogenic inflammation. The terpene, d-limonene, is used as a fragrance in numerous consumer products. When limonene reacts with the pulmonary irritant ozone, a complex mixture of gas and particle phase products is formed, which causes sensory irritation. This study investigated whether limonene, ozone or the reaction mixture can exacerbate allergic lung inflammation and whether airway irritation is enhanced in allergic BALB/cJ mice. Naive and allergic (ovalbumin sensitized) mice were exposed via inhalation for three consecutive days to clean air, ozone, limonene or an ozone-limonene reaction mixture. Sensory and pulmonary irritation was investigated in addition to ovalbumin-specific antibodies, inflammatory cells, total protein and surfactant protein D in bronchoalveolar lavage fluid and hemeoxygenase-1 and cytokines in lung tissue. Overall, airway allergy was not exacerbated by any of the exposures. In contrast, it was found that limonene and the ozone-limonene reaction mixture reduced allergic inflammation possibly due to antioxidant properties. Ozone induced sensory irritation in both naive and allergic mice. However, allergic but not naive mice were protected from pulmonary irritation induced by ozone. This study showed that irritation responses might be modulated by airway allergy. However, aggravation of allergic symptoms was observed by neither exposure to ozone nor exposure to ozone-initiated limonene reaction products. In contrast, anti-inflammatory properties of the tested limonene-containing pollutants might attenuate airway allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1547-6901 (Electronic)IS - 1547-691X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1080/1547691X.2016.1195462</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27434663">PM:27434663</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunotoxicol\20160719-HansenJS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunotoxicol\20160719-HansenJS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Hansen JS</style></custom2><misc3><style face="normal" font="Arial">10.1080/1547691X.2016.1195462</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakatsuji,T.</style></author><author><style face="normal" font="Arial"> Chen,T.H.</style></author><author><style face="normal" font="Arial"> Two,A.M.</style></author><author><style face="normal" font="Arial"> Chun,K.A.</style></author><author><style face="normal" font="Arial"> Narala,S.</style></author><author><style face="normal" font="Arial"> Geha,R.S.</style></author><author><style face="normal" font="Arial"> Hata,T.R.</style></author><author><style face="normal" font="Arial"> Gallo,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of California, San Diego, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger cytokine expression</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="2200" start="2192">2192-2200</pages><volume><style face="normal" font="Arial">136</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> cathelicidin</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> Epidermal barrier defect</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penetration</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="7" Year="2016">2016/7/2</year></dates><abstract><style face="normal" font="Arial">Patients with atopic dermatitis (AD) have an abnormal skin barrier and are frequently colonized by S. aureus. In this study we investigated if S. aureus penetrates the epidermal barrier of subjects with AD and sought to understand the mechanism and functional significance of this entry. S. aureus was observed to be more abundant in the dermis of lesional skin from AD patients. Bacterial entry past the epidermis was observed in cultured human skin equivalents and in mice, but found to be increased in the skin of cathelicidin knockout (Camp-/-) and ovalbumin-sensitized filaggrin mutant (FLGft/ft) mice. S. aureus penetration through the epidermis was dependent on bacterial viability and protease activity as killed bacteria or a protease-null mutant strain of S. aureus was unable to penetrate. Entry of S. aureus directly correlated with increased expression of IL4, IL13, IL22, TSLP and other cytokines associated with AD, and with decreased expression of cathelicidin. These data illustrate how abnormalities of the epidermal barrier in AD can alter the balance of S. aureus entry into the dermis and provides an explanation for how such dermal dysbiosis results in increased inflammatory cytokines and exacerbation of disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160706IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2016.05.127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27381887">PM:27381887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2016-136-2192-200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2016-136-2192-200.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160706, Nakatsuji T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2016.05.127</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ali,A.</style></author><author><style face="normal" font="Arial"> Suhail,M.</style></author><author><style face="normal" font="Arial"> Mathew,S.</style></author><author><style face="normal" font="Arial"> Shah,M.A.</style></author><author><style face="normal" font="Arial"> Harakeh,S.M.</style></author><author><style face="normal" font="Arial"> Ahmad,S.</style></author><author><style face="normal" font="Arial"> Kazmi,Z.</style></author><author><style face="normal" font="Arial"> Alhamdan,M.A.</style></author><author><style face="normal" font="Arial"> Chaudhary,A.</style></author><author><style face="normal" font="Arial"> Damanhouri,G.A.</style></author><author><style face="normal" font="Arial"> Qadri,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Nanomaterial Induced Immune Responses and Cytotoxicity</style></title><secondary-title><style face="normal" font="Arial">J Nanosci Nanotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Nanosci Nanotechnol</style></full-title></periodical><pages end="57" start="40">40-57</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Asbestos</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cobalt</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effect on human health</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronics</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Nanotubes</style></keyword><keyword><style face="normal" font="Arial"> Nickel</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword></keywords><dates><year Day="0" Month="1" Year="2016">2016/1</year></dates><abstract><style face="normal" font="Arial">Nanomaterials are utilized in a wide array of end user products such as pharmaceuticals, electronics, clothes and cosmetic products. Due to its size (&lt; 100 nm), nanoparticles have the propensity to enter through the airway and skin, making its path perilous with the potential to cause damages of varying severity. Once within the body, these particles have unconstrained access to different tissues and organs including the brain, liver, and kidney. As a result, nanomaterials may cause the perturbation of the immune system eliciting an inflammatory response and cytotoxicity. This potential role is dependent on many factors such as the characteristics of the nanomaterials, presence or absence of diseases, and genetic predisposition. Cobalt and nickel nanoparticles, for example, were shown to have inflammogenic properties, while silver nanoparticles were shown to reduce allergic inflammation. Just as asbestos fibers, carbon nanotubes were shown to cause lungs damage. Some nanomaterials were shown, based on animal studies, to result in cell damage, leading to the formation of pre-cancerous lesions. This review highlights the impact of nanomaterials on immune system and its effect on human health with toxicity consideration. It recommends the development of suitable animal models to study the toxicity and bio-clearance of nanomaterials and propose safety guidelines</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 1533-4880 (Print)IS - 1533-4880 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tSB - IMCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1166/jnn.2016.10885</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27398432">PM:27398432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Nanosci Nanotechnol\2016-16-40-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Nanosci Nanotechnol\2016-16-40-57.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, Ali A</style></custom2><misc3><style face="normal" font="Arial">10.1166/jnn.2016.10885</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Antonio,E.</style></author><author><style face="normal" font="Arial"> Khalil,N.M.</style></author><author><style face="normal" font="Arial"> Mainardes,R.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Bovine Serum Albumin Nanoparticles Containing Quercetin: Characterization and Antioxidant Activity</style></title><secondary-title><style face="normal" font="Arial">J Nanosci Nanotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Nanosci Nanotechnol</style></full-title></periodical><pages end="1353" start="1346">1346-1353</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="09/17/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Diffusion</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Glutaraldehyde</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Nanotechnology</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> Quercetin</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="2" Year="2016">2016/2</year></dates><abstract><style face="normal" font="Arial">Quercetin is a flavonoid reported as anti-allergic, anti-inflammatory, antiplatelet, anti-microbial, antioxidant, antineurodegenerative and antitumoral. However, due to its low water solubility, its efficacy is restricted. Nanotechnology can be an importante tool to improve the quercetin properties and increase its bioavailability. In this study, bovine serum albumin (BSA) nanoparticles containing quercetin were developed by desolvation technique, characterized the mean particle size, polydispersity, zeta potential, encapsulation efficiency, physical state of drug in nanoparticles and drug release profile as well as their antioxidant activity was evaluated. The influence of glutaraldehyde percentage in nanoparticles properties was evaluated and did not influence the nanoparticles parameters. Nanoparticles presented a mean size around 130 nm and encapsulation efficiency around 85%. Results from X-ray diffractometry showed that the crystal of the drug was converted to an amorphous state in polymeric matrix. Quercetin release profile demonstrated a biphasic pattern and after 96 h approximately 18% of drug was released. Kinetic models demonstrated that the quercetin release followed a second-order model and the release was governed by Fickian diffusion. After 96 h, quercetin-loaded nanoparticles were more effective than free quercetin for scanvenger of radical ABTS + and hypochlorous acid. BSA nanoparticles represents potential carriers for improve quercetin properties</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1533-4880 (Print)IS - 1533-4880 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tSB - IMCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1166/jnn.2016.11672</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27433585">PM:27433585</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160719, Antonio E</style></custom2><misc3><style face="normal" font="Arial">10.1166/jnn.2016.11672</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rohman,P.J.</style></author><author><style face="normal" font="Arial"> Scott,E.</style></author><author><style face="normal" font="Arial"> Richfield,L.</style></author><author><style face="normal" font="Arial"> Ramaswami,U.</style></author><author><style face="normal" font="Arial"> Hughes,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Lysosomal Storage Disorders Unit, Department of Haematology, Royal Free London NHS Foundation Trust, University College London, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease)</style></title><secondary-title><style face="normal" font="Arial">J Obstet Gynaecol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Obstet Gynaecol Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> cardiomyopathy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fetus</style></keyword><keyword><style face="normal" font="Arial"> Glycogen Storage Disease Type II</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscles</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy Outcome</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="7" Month="7" Year="2016">2016/7/7</year></dates><abstract><style face="normal" font="Arial">AIM: Glycogen storage disease type II (GSD II or Pompe disease; OMIM; 232 300) is a rare autosomal recessive lysosomal storage disorder resulting from deficiency of alpha-glucosidase and accumulation of glycogen in muscle. Clinical symptoms include weakness of skeletal and respiratory muscles and, in infants, cardiomyopathy. Patients with GSD II receive infusions of recombinant alpha-glucosidase (enzyme replacement therapy; ERT), which slow the progression of the disease. ERT is given to male and female patients of all ages but as yet little is documented on the effects of continuing ERT during pregnancy. The aim of this case series was therefore to ascertain the pregnancy outcomes of women with GSD II on ERT and to describe adverse events associated with pregnancy, delivery and therapy. METHODS: The medical records of eight women attending the Royal Free Hospital Lysosomal Storage Disorders Unit were reviewed. Four of the eight women had seven pregnancies over a period of 8 years. RESULTS: In this series GSD II was associated with interventional deliveries but normal neonates. Cessation of ERT in early pregnancy resulted in deterioration of maternal symptoms and emergence of allergic reactions on restarting ERT. CONCLUSION: Individualized care plans are required to ensure the best neonatal and maternal outcomes. Consideration should be given to the potential benefits to mother and fetus of continuing ERT during pregnancy</style></abstract><notes><style face="normal" font="Arial">DA - 20160707IS - 1447-0756 (Electronic)IS - 1341-8076 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/jog.13055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27384519">PM:27384519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Obstet Gynaecol Res\20160707-RohmanPJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Obstet Gynaecol Res\20160707-RohmanPJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160707, Rohman PJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/jog.13055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Koletzko,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dr. v. Hauner Children's Hospital, University Munich Medical Center, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Probiotics and Prebiotics for Prevention of Food Allergy: Indications and Recommendations by Societies and Institutions</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="S10" start="S9">S9-S10</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">1S Suppl 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health benefit</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Probiotics are defined as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host". Unfortunately, misuse of the term probiotic is very common. According to the regulation of the European food safety authority (EFSA) health claims on pre- and probiotics are not judged as favorable. Scientific societies should give guidance to the consumers and health care professionals on the use of probiotics and prebiotics for prevention and disease management. There is currently no positive recommendation from international scientific medical societies to use prebiotics or probiotics for treatment of food allergy or other allergic manifestations and for prevention of food allergy, allergic rhinitis, and asthma. Discrepant recommendations exist for probiotics for prevention of eczema in high risk infants</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001220</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27380601">PM:27380601</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\2016-63S1-9-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\2016-63S1-9-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Koletzko S</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001220</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Pecora,V.</style></author><author><style face="normal" font="Arial"> Dahdah,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, The Bambino Gesu Children's Research Hospital, Rome Italy</style></auth-address><titles><title><style face="normal" font="Arial">Probiotics, Prebiotics &amp; Food allergy Prevention: Clinical Data in Children</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="S17" start="S14">S14-S17</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">1S Suppl 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: there are accruing evidences on the role of the intestinal microbiota in the development of allergic diseases among infants. Elaborating on this theoretical basis, studies did assess the possibilities to prevent allergic diseases in infancy through manipulation of the intestinal microbiota. We review here such studies. RECENT FINDINGS: interventional studies led to conflicting conclusions on the possible role of probiotics and prebiotics in allergy prevention. Two metanalyses published in 2015 did reconcile all data. Guidelines have been predicated on such studies using the GRADE methodology. SUMMARY: the guidelines for allergy prevention suggest for the first time the use of probiotics and prebiotics. The existing evidences stand for a use of such supplementation in particular for the prevention of eczema. As there is no evidence so far of superiority of one probiotic strand over the others, they should be considered as class and not as individual products</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001220</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27380592">PM:27380592</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\2016-63S1-14-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\2016-63S1-14-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Fiocchi A</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001220</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Di Costanzo,M.</style></author><author><style face="normal" font="Arial"> Amoroso,A.</style></author><author><style face="normal" font="Arial"> Canani,R.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Department of Translational Medical Science-Pediatric Section daggerEuropean Laboratory for the Investigation of Food Induced Diseases double daggerCEINGE Advanced Biotechnologies, University of Naples "Federico II", Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Gut Microbiota as a Target for Food Allergy</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="S13" start="S11">S11-S13</pages><volume><style face="normal" font="Arial">63 Suppl 1</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary Fiber</style></keyword><keyword><style face="normal" font="Arial"> dietary fibers</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The purpose of this review is to present an overview on the potential role of gut microbiota as target of intervention against food allergy. RECENT FINDINGS: Many studies suggest a key pathogenetic role for gut microbiota modifications (dysbiosis) in food allergy development. Several factors responsible for dysbiosis have been associated with the occurrence of food allergy, such as caesarean delivery, lack of breast milk, drugs use (mainly antibiotics and gastric acidity inhibitors), antiseptic agents use, and low fibers/hight fat diet. No specific bacterial taxa have been consistently associated with food allergy, but evidence suggests that gut dysbiosis occurs even before food allergy signs and symptoms presentation. Data from animal and human studies highlight the ability of particular bacterial taxa to ferment dietary fibers for the production of short chain fatty acids that affect host immunity and help to explain their health-promoting role. SUMMARY: Modulation of gut microbiota composition and/or function represents a promising strategy for treatment and prevention of food allergy in childhood</style></abstract><notes><style face="normal" font="Arial">DA - 20160706IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001220</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27380591">PM:27380591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\2016-63S1-11-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\2016-63S1-11-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160706, Di Costanzo M</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001220</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Natali,K.M.</style></author><author><style face="normal" font="Arial"> Goldman,J.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Insulin Allergy: A Case Report and Review of Literature</style></title><secondary-title><style face="normal" font="Arial">J Pharm Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pharm Technol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> generalized reaction</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Insulin allergy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Type 2 diabetes</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="6" Year="2016">2016/6/23</year></dates><abstract><style face="normal" font="Arial">Objective: A case of insulin allergy to insulin aspart, insulin aspart protamine/insulin aspart 70/30, insulin lispro, and insulin lispro protamine/insulin lispro 75/25 in a patient with type 2 diabetes mellitus is reported. Case Summary: A 76-year-old Caucasian male weighing 81 kg presented with complaints of burning, lumps, and a rash where his insulin aspart protamine/insulin aspart 70/30 was injected 2 months after initiation. Because poor injection technique can mimic insulin allergy, the patient was counseled again on proper injection technique. The patient presented 2 weeks later with the same complaints. Insulin aspart protamine/insulin aspart 70/30 was discontinued and insulin lispro protamine/insulin lispro 75/25 was initiated. The patient presented 3 months later with a localized reaction. Insulin lispro protamine/insulin lispro 75/25 was discontinued and insulin U100 glargine and insulin lispro were initiated. One week later, the patient still had complaints of a localized reaction and was referred to an allergist for testing. Skin prick tests revealed insulin allergy to insulin aspart and insulin lispro but not to insulin U100 glargine or insulin glulisine. The patient</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs regimen was changed to insulin U100 glargine and insulin glulisine, and he has not experienced any reaction since. Discussion: Allergic reactions to human insulin preparations are rare and may present as a localized reaction or a generalized reaction. Different types of allergic reactions to human insulin have been reported, including type I, type III, and type IV hypersensitivity reactions. If insulin allergy is suspected, the following steps should be taken to confirm such allergy: evaluation of injection technique, switching to a different insulin preparation, and referral to an allergist for allergy testing if necessary. Conclusion: A patient with type 2 diabetes mellitus experienced a type I hypersensitivity reaction to insulin aspart, insulin aspart protamine/insulin aspart 70/30, insulin lispro, and insulin lispro protamine/insulin lispro 75/25</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/8755122516655544</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1177/8755122516655544</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharm Technol\20160725-NataliKM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharm Technol\20160725-NataliKM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160725, Natali KM</style></custom2><misc3><style face="normal" font="Arial">10.1177/8755122516655544</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smith,G.J.</style></author><author><style face="normal" font="Arial"> Thrall,R.S.</style></author><author><style face="normal" font="Arial"> Cloutier,M.M.</style></author><author><style face="normal" font="Arial"> Manautou,J.E.</style></author><author><style face="normal" font="Arial"> Morris,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Connecticut</style></auth-address><titles><title><style face="normal" font="Arial">Acetaminophen Attenuates House Dust Mite Induced Allergic Airway Disease in Mice</style></title><secondary-title><style face="normal" font="Arial">J Pharmacol Exp Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pharmacol Exp Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetaminophen</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Connecticut</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytochrome P450</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2016">2016/7/11</year></dates><abstract><style face="normal" font="Arial">Epidemiological evidence suggests that APAP may play a role in the pathogenesis of asthma, likely through pro-oxidant mechanisms. However, no studies have investigated the direct effects of APAP on the development of allergic inflammation. To determine the likelihood of a causal relationship between APAP and asthma pathogenesis, we explored the effects of APAP on inflammatory responses in a murine house dust mite (HDM) model of allergic airway disease. We hypothesized that APAP would enhance the development of HDM induced allergic inflammation. The HDM model consisted of once daily intranasal instillations for up to two weeks with APAP or vehicle administration 1 hour prior to HDM during either week 1 or 2. Primary assessment of inflammation included bronchoalveolar lavage (BAL), cytokine expression in lung tissue, and histopathology. Contrary to our hypothesis, the effects of HDM treatment were substantially diminished in APAP treated groups compared to controls. APAP treated groups had markedly reduced airway inflammation: including decreased inflammatory cells in the BAL fluid, lower cytokine expression in lung tissue, and less perivascular and peribronchiolar immune cell infiltration. The anti-inflammatory effect of APAP was not abrogated by an inhibitor of cytochrome P450 metabolism, suggesting that the effect was due to the parent compound or a non-CYP450 generated metabolite. Taken together, our studies do not support the biological plausibility of the "APAP hypothesis" that APAP use may contribute to the causation of asthma. Importantly, they suggest the mechanism by which APAP modulates airway inflammation may provide novel therapeutic targets for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160712IS - 1521-0103 (Electronic)IS - 0022-3565 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1124/jpet.116.233684</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27402277">PM:27402277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharmacol Exp Ther\20160712-SmithGJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharmacol Exp Ther\20160712-SmithGJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160712, Smith GJ</style></custom2><misc3><style face="normal" font="Arial">10.1124/jpet.116.233684</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sessa,M.</style></author><author><style face="normal" font="Arial"> Sullo,M.G.</style></author><author><style face="normal" font="Arial"> Mascolo,A.</style></author><author><style face="normal" font="Arial"> Cimmaruta,D.</style></author><author><style face="normal" font="Arial"> Romano,F.</style></author><author><style face="normal" font="Arial"> Puca,R.V.</style></author><author><style face="normal" font="Arial"> Capuano,A.</style></author><author><style face="normal" font="Arial"> Rossi,F.</style></author><author><style face="normal" font="Arial"> Schiavo,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Medicine, Pharmacoepidemiology and Pharmacovigilance Centre of the Campania Region, Section of Pharmacology, Second University of Naples, Via Costantinopoli 16, 80138 Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">A case of figurate urticaria by etanercept</style></title><secondary-title><style face="normal" font="Arial">J Pharmacol Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pharmacol Pharmacother</style></full-title></periodical><pages end="108" start="106">106-108</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B virus</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacoepidemiology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Proteinase</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Skin Manifestations</style></keyword><keyword><style face="normal" font="Arial"> Spondylitis</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">Etanercept is a competitive inhibitor of tumor necrosis factor-alpha (TNF-alpha) a polypeptide hormone, involved in the development of the immune system, in host defense and immune surveillance. Even if the etanercept mechanism of action is not completely understood, it is supposed that it negatively modulates biological responses mediated by molecules (cytokines, adhesion molecules, or proteinases) induced or regulated by TNF. For this reason, it is widely used in the treatment of immunologicals diseases, such as rheumatoid and psoriatic arthritis, polyarticular juvenile idiopathic active, ankylosing spondylitis, and plaque psoriasis. Etanercept has a good tolerability profile. Adverse events related to skin are rare, arising usually in about 5% of patients treated with anti-TNF alpha. In this scenario, we describe a case of figurate urticaria arose after the re-administration of etanercept in a patient affected by psoriasis and hepatitis B. A 65-year-old man, affected by psoriasis, was hospitalized in September 2014 to the Regional Center for the treatment of psoriasis and Biological Drugs of Second University of Naples for progressive extension of psoriatic skin lesions. The laboratory analysis detected positivity for hepatitis B virus (HBV) antigens. For this reason, it was administered to him lamivudine 100 mg/die about 30 days before to start etanercept treatment. The etanercept therapy has resulted in a progressive improving of skin manifestations, and the patient decided individually to stop the therapy. Afterwards, for worsening of the psoriatic lesions, he was again hospitalized and treated with the same therapeutic schedule (lamivudine followed by etanercept). Ten days after the start of therapy, the patient showed the onset of urticarial rash. Due to this, the treatment with lamivudine and etanercept was suspended and the patient's clinical conditions improved. It is probably that immunological disorders due to etanercept therapy and HBV infection could explain the onset of figurate urticaria in our patient. In this contest, the post-marketing surveillance confirms its important role in the monitoring of drugs tolerability and effectiveness</style></abstract><notes><style face="normal" font="Arial">DA - 20160721IS - 0976-500X (Print)IS - 0976-500X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4103/0976-500X.184777</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27440958">PM:27440958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharmacol Pharmacother\2016-7-106-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharmacol Pharmacother\2016-7-106-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160721, Sessa M</style></custom2><misc3><style face="normal" font="Arial">10.4103/0976-500X.184777</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jakubas-Zawalska,J.</style></author><author><style face="normal" font="Arial"> Asman,M.</style></author><author><style face="normal" font="Arial"> Klys,M.</style></author><author><style face="normal" font="Arial"> Solarz,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sensitization to Sitophilus granarius in selected suburban population of South Poland</style></title><secondary-title><style face="normal" font="Arial">J Stored Products Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Stored Products Res</style></full-title></periodical><pages end="6" start="1">1-6</pages><volume><style face="normal" font="Arial">69</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Granary weevil</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insect allergens</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein fraction</style></keyword><keyword><style face="normal" font="Arial"> Protein fractions</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Sitophilus granarius</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage insects</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><isbn><style face="normal" font="Arial">0022-474X</style></isbn><abstract><style face="normal" font="Arial">Storage insects may cause occupational allergies in humans. The identification of the prevalence of IgE reactions were measured from protein fractions prepared from multiple life stage of granary weevil Sitophilus granarius [SG] is reported. Sera of 30 patients from a suburban population of Upper Silesia (South Poland) were tested for the presence of IgE antibodies to antigens from larvae, pupae and adults of both sexes of the beetle. To identify protein fractions containing potential allergens, proteins collected from four life stages of granary weevil were fractionated by SDS-PAGE and probed with anti-human, anti-IgE monoclonal antibodies. The proteins were fractionated by SDS PAGE and identified by Western blot. The patients</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ antibodies against particular antigens were identified using anti-human anti-IgE monoclonal antibody. The conducted immunological analysis showed the existence of many protein fractions for each life stage of SG which give positive reactions with IgE antibodies. The largest number of allergenic potential fractions was shown in pupae (60 protein fractions) while the smallest amount was shown in larvae (44 protein fractions). Summarizing, the obtained results suggest the existence of many protein fractions with an allergenic potential multiple life stages of SG. This indicates that all developmental stages of SG may be a serious source of antigens and potential risk factors for the exposed persons</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jspr.2016.05.006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jspr.2016.05.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Stored Products Res\2016-69-1-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Stored Products Res\2016-69-1-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160725, Jakubas-Zawalska J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jspr.2016.05.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hao,L.</style></author><author><style face="normal" font="Arial"> Xie,H.</style></author><author><style face="normal" font="Arial"> Zhang,B.</style></author><author><style face="normal" font="Arial"> Chen,D.</style></author><author><style face="normal" font="Arial"> Wang,S.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> He,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Sect. 5, Renmin Street, Guta District, Jinzhou, 121001, Liaoning, People's Republic of ChinaDepartment of Dentistry, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121001, Liaoning, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells</style></title><secondary-title><style face="normal" font="Arial">J Transl Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Transl Med</style></full-title></periodical><pages end="" start="202">202-</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Increased leucine-rich alpha2-glycoprotein-1 (LRG1) has been observed in plasma of individuals with various diseases. However, the role of LRG1 in allergic airway disease has not been investigated. OBJECTIVE: To explore the involvement of LRG1 in allergy and its cell origins. METHODS: The expression levels of LRG1 and its receptor transforming growth factor-beta receptor II (TGFBR2) in patients with allergic rhinitis (AR) and asthma (AS) were examined by flow cytometry, and enzyme-linked immunosorbent assay (ELISA). RESULTS: LRG1 and soluble TGFBR2 expression in plasma of patients with AR and AS were markedly lower than that of healthy control (HC) subjects. Large proportions of CD123 + HLA-DR-, CD16+, CD4+, CD8+, CD14+, and CD19+ cells expressed LRG1, although the percentages of LRG1+ cells in these cell populations were lower in AR and AS patients. Up to 89.8 and 15.5 % of dispersed mast cells expressed LRG1 and TGFBR2. Moreover, allergen extract exposure significantly reduced LRG1 and TGFBR2 expression in the plasma and leukocytes of patients with AR and AS. CONCLUSIONS: Reduced LRG1 and TGFBR2 levels in patients with allergic airway disorders are likely caused by inhibitory actions of allergens in LRG1 producing cells. Thus, LRG1 may be a key regulatory factor of allergic responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 1479-5876 (Electronic)IS - 1479-5876 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12967-016-0929-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27378305">PM:27378305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Transl Med\2016-14-202.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Transl Med\2016-14-202.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Hao L</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12967-016-0929-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rasmussen,S.G.</style></author><author><style face="normal" font="Arial"> Ogburn,E.L.</style></author><author><style face="normal" font="Arial"> McCormack,M.</style></author><author><style face="normal" font="Arial"> Casey,J.A.</style></author><author><style face="normal" font="Arial"> Bandeen-Roche,K.</style></author><author><style face="normal" font="Arial"> Mercer,D.G.</style></author><author><style face="normal" font="Arial"> Schwartz,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Association Between Unconventional Natural Gas Development in the Marcellus Shale and Asthma Exacerbations</style></title><secondary-title><style face="normal" font="Arial">JAMA Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Intern Med</style></full-title></periodical><pages end="1343" start="1334">1334-1343</pages><volume><style face="normal" font="Arial">176</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Health Records</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Records</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="7" Year="2016">2016/7/18</year></dates><abstract><style face="normal" font="Arial">Importance: Asthma is common and can be exacerbated by air pollution and stress. Unconventional natural gas development (UNGD) has community and environmental impacts. In Pennsylvania, UNGD began in 2005, and by 2012, 6253 wells had been drilled. There are no prior studies of UNGD and objective respiratory outcomes. Objective: To evaluate associations between UNGD and asthma exacerbations. Design: A nested case-control study comparing patients with asthma with and without exacerbations from 2005 through 2012 treated at the Geisinger Clinic, which provides primary care services to over 400000 patients in Pennsylvania. Patients with asthma aged 5 to 90 years (n = 35508) were identified in electronic health records; those with exacerbations were frequency matched on age, sex, and year of event to those without. Exposures: On the day before each patient's index date (cases, date of event or medication order; controls, contact date), we estimated activity metrics for 4 UNGD phases (pad preparation, drilling, stimulation [hydraulic fracturing, or "fracking"], and production) using distance from the patient's home to the well, well characteristics, and the dates and durations of phases. Main Outcomes and Measures: We identified and defined asthma exacerbations as mild (new oral corticosteroid medication order), moderate (emergency department encounter), or severe (hospitalization). Results: We identified 20749 mild, 1870 moderate, and 4782 severe asthma exacerbations, and frequency matched these to 18693, 9350, and 14104 control index dates, respectively. In 3-level adjusted models, there was an association between the highest group of the activity metric for each UNGD phase compared with the lowest group for 11 of 12 UNGD-outcome pairs: odds ratios (ORs) ranged from 1.5 (95% CI, 1.2-1.7) for the association of the pad metric with severe exacerbations to 4.4 (95% CI, 3.8-5.2) for the association of the production metric with mild exacerbations. Six of the 12 UNGD-outcome associations had increasing ORs across quartiles. Our findings were robust to increasing levels of covariate control and in sensitivity analyses that included evaluation of some possible sources of unmeasured confounding. Conclusions and Relevance: Residential UNGD activity metrics were statistically associated with increased risk of mild, moderate, and severe asthma exacerbations. Whether these associations are causal awaits further investigation, including more detailed exposure assessment</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 2168-6114 (Electronic)IS - 2168-6106 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamainternmed.2016.2436</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27428612">PM:27428612</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Intern Med\2016-176-1334-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Intern Med\2016-176-1334-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Rasmussen SG</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamainternmed.2016.2436</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kretschmer,S.</style></author><author><style face="normal" font="Arial"> Pieper,M.</style></author><author><style face="normal" font="Arial"> Huttmann,G.</style></author><author><style face="normal" font="Arial"> Bolke,T.</style></author><author><style face="normal" font="Arial"> Wollenberg,B.</style></author><author><style face="normal" font="Arial"> Marsh,L.M.</style></author><author><style face="normal" font="Arial"> Garn,H.</style></author><author><style face="normal" font="Arial"> Konig,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Structural and Cell Biology in Medicine, Institute of Anatomy, University of Lubeck, Lubeck, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Autofluorescence multiphoton microscopy for visualization of tissue morphology and cellular dynamics in murine and human airways</style></title><secondary-title><style face="normal" font="Arial">Lab Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lab Invest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> autofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Vessels</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular dynamics</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> experimental allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Tissue Culture</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2016">2016/7/11</year></dates><abstract><style face="normal" font="Arial">The basic understanding of inflammatory airway diseases greatly benefits from imaging the cellular dynamics of immune cells. Current imaging approaches focus on labeling specific cells to follow their dynamics but fail to visualize the surrounding tissue. To overcome this problem, we evaluated autofluorescence multiphoton microscopy for following the motion and interaction of cells in the airways in the context of tissue morphology. Freshly isolated murine tracheae from healthy mice and mice with experimental allergic airway inflammation were examined by autofluorescence multiphoton microscopy. In addition, fluorescently labeled ovalbumin and fluorophore-labeled antibodies were applied to visualize antigen uptake and to identify specific cell populations, respectively. The trachea in living mice was imaged to verify that the ex vivo preparation reflects the in vivo situation. Autofluorescence multiphoton microscopy was also tested to examine human tissue from patients in short-term tissue culture. Using autofluorescence, the epithelium, underlying cells, and fibers of the connective tissue, as well as blood vessels, were identified in isolated tracheae. Similar structures were visualized in living mice and in the human airway tissue. In explanted murine airways, mobile cells were localized within the tissue and we could follow their migration, interactions between individual cells, and their phagocytic activity. During allergic airway inflammation, increased number of eosinophil and neutrophil granulocytes were detected that moved within the connective tissue and immediately below the epithelium without damaging the epithelial cells or connective tissues. Contacts between granulocytes were transient lasting 3 min on average. Unexpectedly, prolonged interactions between granulocytes and antigen-uptaking cells were observed lasting for an average of 13 min. Our results indicate that autofluorescence-based imaging can detect previously unknown immune cell interactions in the airways. The method also holds the potential to be used during diagnostic procedures in humans if integrated into a bronchoscope.Laboratory Investigation advance online publication, 11 July 2016; doi:10.1038/labinvest.2016.69</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 1530-0307 (Electronic)IS - 0023-6837 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1038/labinvest.2016.69</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27400364">PM:27400364</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lab Invest\20160711-KretschmerS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lab Invest\20160711-KretschmerS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, Kretschmer S</style></custom2><misc3><style face="normal" font="Arial">10.1038/labinvest.2016.69</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korenblat,P.E.</style></author><author><style face="normal" font="Arial"> Wedner,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Washington University School of Medicine, St Louis, MO 63141, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Evaluating results of outcome studies of biological drugs</style></title><secondary-title><style face="normal" font="Arial">Lancet Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Respir Med</style></full-title></periodical><pages end="665" start="664">664-665</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status date="07/31/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anti-Asthmatic Agents</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Monoclonal</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="9" Year="2015">2015/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20150919IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - CommentPT - Journal ArticleRN - 0 (Anti-Asthmatic Agents)RN - 0 (Antibodies, Monoclonal)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2213-2600(15)00276-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26231287">PM:26231287</url></web-urls><pdf-urls><url ppv-ref="no">pkorenblat@att.net</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20150919, Korenblat PE</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2213-2600(15)00276-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choi,S.Y.</style></author><author><style face="normal" font="Arial"> Oh,C.T.</style></author><author><style face="normal" font="Arial"> Kwon,T.R.</style></author><author><style face="normal" font="Arial"> Kwon,H.J.</style></author><author><style face="normal" font="Arial"> Choi,E.J.</style></author><author><style face="normal" font="Arial"> Jang,Y.J.</style></author><author><style face="normal" font="Arial"> Kim,H.S.</style></author><author><style face="normal" font="Arial"> Chu,H.</style></author><author><style face="normal" font="Arial"> Mun,S.K.</style></author><author><style face="normal" font="Arial"> Kim,M.N.</style></author><author><style face="normal" font="Arial"> Kim,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Gain-switched 311-nm Ti:Sapphire laser might be a potential treatment modality for atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Lasers Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lasers Med Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mouse</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phototherapy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="7" Year="2016">2016/7/9</year></dates><abstract><style face="normal" font="Arial">Phototherapy with 311-nm narrowband-UVB (NBUVB) is an effective adjuvant treatment modality for atopic dermatitis (AD). In this study, we evaluated the therapeutic effect of the newly developed gain-switched 311-nm Ti:Sapphire laser device using a NC/Nga mouse AD model. A total number of 50 mice were used in this study. Atopic dermatitis (AD) was induced in mice by exposure to Dermatophagoides farina. These, NC/Nga mice were then treated with conventional 311-nm NBUVB or the newly developed gain-switched 311-nm Ti:Sapphire laser. The clinical features, dermatitis severity scores, and scratching behavior were assessed. In addition, serologic analyses including inflammatory cytokines and histological analyses were performed. Gain-switched 311-nm Ti:Sapphire laser improved the AD-like skin lesions, severity, and symptoms of AD in the NC/Nga mouse model. This new laser also modulated the immune response found in the AD model, including hyper-IgE, upregulated Th2 cytokines, and the Th2-mediated allergic inflammatory reaction. Gain-switched 311-nm Ti:Sapphire laser shows therapeutic promise via an immune-modulation mechanism in an AD mouse model. These data suggest that gain-switched 311-nm Ti:Sapphire laser may be useful as a targeted phototherapy modality for AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160710IS - 1435-604X (Electronic)IS - 0268-8921 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10103-016-2006-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27394442">PM:27394442</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lasers Med Sci\20160710-ChoiSY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lasers Med Sci\20160710-ChoiSY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160710, Choi SY</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10103-016-2006-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,H.</style></author><author><style face="normal" font="Arial"> Che,S.</style></author><author><style face="normal" font="Arial"> Lin,R.</style></author><author><style face="normal" font="Arial"> Li,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Efficacy of sublingual immunotherapy in children with allergic rhinitis]</style></title><secondary-title><style face="normal" font="Arial">Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="232" start="230">230-232</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2016">2016/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To evaluate the efficacy of sublingual immunotherapy with dermatophagoides farina drops on children with allergic rhinitis. METHOD: This was retrospective study analyzing the efficacy of dermatophaguides farinae drops SLIT in 110 patients (aged 4-14 years old) with house dust mites induced allergic rhinitis (without asthma). All the patients were divided into the SLIT group (n = 60) and drug group (n = 50). Patients in SLIT group received sublingual immunotherapy combined with symptomatic medication, and patients in drug group only received symptomatic medication. We recorded and evaluated the total nasal symptom scores (TNSS), total medication scores (TMS) and visual analogue scale (VAS) of the 2 groups at three time points, before the treatment, and the treatment for 1-year and 2-year. RESULT: After 1-year and 2-year treatment, compared with drug group, TMS, TNSS and VAS in SLIT group decreased significantly (P &lt; 0.01). When compared with baseline, we got the similar result as compared with drug group. Besides, the TMS of drug group increased significantly after treatment (P &lt; 0.01). And no significant difference was observed in TNSS and VAS. In addition, there was significant difference in the Proportion of patients withdrawing symptomatic medication in SLIT group and drug group (68.33%,16.00%, respectively; P &lt; 0.01). There were 4 local adverse reactions occurred during the treatment and no serious adverse events occurred. CONCLUSION: Sublingual immunotherapy with Dermatophagoides farinae drops showed significant clinical efficacy in children with allergic rhinitis comparing with pharmacotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1001-1781 (Print)LA - chiPT - English AbstractPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27373095">PM:27373095</url></web-urls></urls><custom2><style face="normal" font="Arial">20160704, Lin H</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xie,L.</style></author><author><style face="normal" font="Arial"> Jiang,Y.</style></author><author><style face="normal" font="Arial"> Li,Q.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Efficacy of the dust mites drops sublingual immunotherapy in pediatric allergic rhinitis]</style></title><secondary-title><style face="normal" font="Arial">Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="360" start="357">357-360</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2016">2016/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To observe the role of the dust mites drops sublingual immunotherapy(SLIT) in pediatric allergic rhiriitis caused by dust mites and compare its efficacy between monosensitized and polysensitized children. METHOD: A total of 77 pediatric allergic rhinitis patients received Dermatophagoides farina extracts sublingual immunotherapy for 2 years were enrolled as desensitization group and were allocated into monosensitized group (41 cases) and polysensitized group (36 cases) according to the number of coexisting allergens. Meanwhile another 33 allergic rhinitis children treated by pharmacotherapy during the period were collected as control group. The total symptom scores (TNSS), total medication scores (TMS) and visual analogue scale(VAS) were assessed at the beginning, six months, 1 year and 2 years of the treatment. SPSS 13. 0 software was used to analyze the data. RESULT: the score of TNSS and VAS in desensitization was slightly higher than the control after six months treatment, but without difference at l year and 2 years; the score of TMS had significantly improved in desensitization compared with the corresponding points in control. All the parameters in monosensitized group were equivalent with polysensitizend group, except the score of TMS was slightly lower than the polysensitizend group at six months. CONCLUSION: Dust mite drops sublingual immunotherapy is effective for the allergic rhinitis children caused by mites. And it has similar immunotherapy efficacy between monosensitized and polysensitized children</style></abstract><notes><style face="normal" font="Arial">DA - 20160706IS - 1001-1781 (Print)LA - chiPT - English AbstractPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27382674">PM:27382674</url></web-urls></urls><custom2><style face="normal" font="Arial">20160706, Xie L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deng,Y.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Li,S.</style></author><author><style face="normal" font="Arial"> Yan,Y.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Zheng,Y.</style></author><author><style face="normal" font="Arial"> Deng,A.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Tao,Z.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Efficient evaluation of standardized specific immunotherapy in personalized maintenance phase to patients of allergic rhinitis]</style></title><secondary-title><style face="normal" font="Arial">Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="294" start="291">291-294</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2016">2016/2</year></dates><abstract><style face="normal" font="Arial">Objective:To explore the efficacy of individualized subcutaneous immunotherapy (SCIT) in allergic rhinitis(AR) maintain phase. Method:Compare nasal symptom scores (VAS) and special disease scale--nasal conjunctivitis quality of life questionnaire(RQLQ) score after 3 years treatment to evaluate the therapeutic effect of each group and the level of improving patients quality of life. Take patients' blood to detect the serum level of IL-10 by enzyme linked immunosorbent test (enzyme linked immunosorbent assay). Result: After 3 years treatment, there was no difference of VAS between the conventional SCIT group and the individualized SCIT group. ELISA results showed that the level of IL-10 was significantly higher in the drug symptomatic treatment group than that in the healthy group, the levels of IL-10 were significantly lower in the conventional SCIT group and the individualized SCIT group than that in the healthy group, but there was no difference between the conventional SCIT and the individualized SCIT group. Conclusion: After 3 years treatment, there was no difference between conventional and individualized SCIT groups. But the efficacy of the conventional and individualized SCIT groups were significantly better than that in the drug symptomatic treatment group</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1001-1781 (Print)LA - chiPT - English AbstractPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27373036">PM:27373036</url></web-urls></urls><custom2><style face="normal" font="Arial">20160704, Deng Y</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gu,X.</style></author><author><style face="normal" font="Arial"> Li,Q.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Ma,Y.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Sun,C.</style></author><author><style face="normal" font="Arial"> You,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Effect and mechanism of IL-1beta/JNK transduction pathway on the nasal mucosa remodeling in allergic rhinitis rats]</style></title><secondary-title><style face="normal" font="Arial">Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="229" start="226">226-229</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2016">2016/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To study the role of JNK (c-Jun N-terminal kinase) signal transduction pathway on the nasal mucosa remodeling in allergic rhinitis rats, to explore whether IL-1beta participates the nasal mucosa remodeling in allergic rhinitis by JNK signal transduction pathway. METHOD: Totally 60 male Wistar rats (weighing about 200-250 g)were randomly divided into A (AR group) and B group (control group). The rats in A group were sensitized for inducing AR by intraperitoneal injection ovalbumin and Al(OH)(3). Ovalbumin was respectively dropped in each nasal cavity of every rat for 4,8,12 weeks(A4,A8,or A12 group) each had 10 rats. The rats in B group were sensitized by intraperitoneal injection saline. Saline was respectively dropped in each nasal cavity of every rat for 4,8, 12 weeks(B4, B8, or B12 group), and each had 10 rats. The concentration of IL-1beta in serum and nasal lavage fluid were tested by ELASA. The protein expressions of P-JNK and P-c-Jun were detected by immunohistochemical technique. Linear correlation analysis showed the correlation between levels of IL-1beta in serum and P-JNK protein, levels of IL-1beta in nasal lavage fluid and P-JNK protein. RESULT: The concentrations of IL-1beta in serum and nasal lavage fluid of A group were all significantly higher than those of the corresponding B group (all P &lt; 0.01). Compared with A4 group and A8 group, concentrations of IL-1beta in nasal lavage fluid of A12 group were significantly increased (all P &lt; 0.01). However the levels of IL-1beta in serum were not significantly different among them (all P > 0.05). Mean absorbance values of P-JNK and P-c-Jun in A group were significantly higher than those in corresponding B group (all P &lt; 0.01) and compared with A4 group and A8 group, those of A12 group were significantly increased (all P &lt; 0.01). Strong positive correlation were found between P-JNK and concentration of IL-1beta in serum or nasal lavage fluid (r = 0.835 and r = 0.902, all P &lt; 0.01). CONCLUSION: JNK signal transduction pathway plays important role in the nasal mucosa remodeling in allergic rhinitis rats. IL-1beta participates in AR nasal mucosa remodeling possibly partly through activating JNK signal transduction pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1001-1781 (Print)LA - chiPT - English AbstractPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27373094">PM:27373094</url></web-urls></urls><custom2><style face="normal" font="Arial">20160704, Gu X</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suresh,K.</style></author><author><style face="normal" font="Arial"> Belchis,D.</style></author><author><style face="normal" font="Arial"> Askin,F.</style></author><author><style face="normal" font="Arial"> Pearse,D.B.</style></author><author><style face="normal" font="Arial"> Terry,P.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care Medicine, Johns Hopkins Department of Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument St., Suite 500, Baltimore, MD, 21287, USA</style></auth-address><titles><title><style face="normal" font="Arial">Occupational Asthma Due to Inhalation of Aerosolized Lipophilic Coating Materials</style></title><secondary-title><style face="normal" font="Arial">Lung</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lung</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="8" Month="7" Year="2016">2016/7/8</year></dates><abstract><style face="normal" font="Arial">We present a case of onset of severe asthma in a 59-year-old patient who worked in an aerospace plant. He was noted to have wheezing on exam and obstruction on PFTs. Review of his occupational history revealed exposure to lipophilic industrial compounds. We outline the radiographic and histologic findings that were found in the patient, and discuss occupational asthma due to inhalation of lipophilic compounds</style></abstract><notes><style face="normal" font="Arial">DA - 20160709IS - 1432-1750 (Electronic)IS - 0341-2040 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00408-016-9919-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27392782">PM:27392782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lung\20160709-SureshK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lung\20160709-SureshK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160709, Suresh K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00408-016-9919-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,L.</style></author><author><style face="normal" font="Arial"> Sen,S.</style></author><author><style face="normal" font="Arial"> Sun,Y.</style></author><author><style face="normal" font="Arial"> Zhou,J.</style></author><author><style face="normal" font="Arial"> Mo,L.</style></author><author><style face="normal" font="Arial"> He,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China</style></auth-address><titles><title><style face="normal" font="Arial">Ketamine Inhalation Ameliorates Ovalbumin-Induced Murine Asthma by Suppressing the Epithelial-Mesenchymal Transition</style></title><secondary-title><style face="normal" font="Arial">Med Sci Monit</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Sci Monit</style></full-title></periodical><pages end="2483" start="2471">2471-2483</pages><volume><style face="normal" font="Arial">22</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> epithelial-mesenchymal transition</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Relaxation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> Relaxation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Suspensions</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND Asthma accounts for 0.4% of all deaths worldwide, a figure that increases annually. Ketamine induces bronchial smooth muscle relaxation, and increasing evidence suggests that its anti-inflammatory properties might protect against lung injury and ameliorate asthma. However, there is a lack of evidence of the usefulness and mechanism of ketamine in acute asthma exacerbation. This study aimed to analyze the therapeutic effects and mechanism of action of ketamine on acute ovalbumin (OVA)-induced murine asthma. MATERIAL AND METHODS In vivo, BALB/c mice with OVA-induced asthma were treated with or without ketamine (25 or 50 mg/mL). Serum, lung sections, and mononuclear cell suspensions from the lung were collected for histological, morphometric, immunofluorescence, microRNA, quantitative polymerase chain reaction, regulatory T cell identification, cytokine, and Western blotting analyses. In vitro, bronchial epithelial cells were cultured to analyze the effect and mechanism of ketamine on epithelial-mesenchymal transition (EMT) and transforming growth factor-beta (TGF-beta) signaling. RESULTS The inhalation of ketamine 25 or 50 mg/mL markedly suppressed OVA-induced airway hyper-responsiveness and airway inflammation, significantly increased the percentage of CD4+CD25+ T cells, and significantly decreased OVA-induced up-regulation of TGF-beta1 and the EMT. MiR-106a was present at higher amounts in OVA-induced lung samples and was suppressed by ketamine treatment. The in vitro results showed that TGF-beta1-induced EMT was suppressed by ketamine via miR-106a level regulation. CONCLUSIONS Ketamine ameliorates lung fibrosis in OVA-induced asthmatic mice by suppressing EMT and regulating miR-106a level, while ketamine inhalation might be a new therapeutic approach to the treatment of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160715IS - 1643-3750 (Electronic)IS - 1234-1010 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.12659/MSM.899955</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27418244">PM:27418244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Sci Monit\2016-22-2471-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Sci Monit\2016-22-2471-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160715, Song L</style></custom2><misc3><style face="normal" font="Arial">10.12659/MSM.899955</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wei,C.C.</style></author><author><style face="normal" font="Arial"> Lin,C.L.</style></author><author><style face="normal" font="Arial"> Shen,T.C.</style></author><author><style face="normal" font="Arial"> Tsai,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aChina Medical University Children's Hospital bCollege of Medicine, China Medical University cManagement Office for Health Data, China Medical University Hospital dDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine eDepartment of Pediatrics, Chung Shan Medical University Hospital fInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis and association of risk for primary immune thrombocytopenia and autoimmune diseases among children: A nationwide population-based cohort study</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e4226">e4226-</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">29</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Primary immune thrombocytopenia (ITP) is currently defined as an acquired autoimmune disorder with persistent thrombocytopenia. However, the temporal interaction between T helper type 2 cell (Th2)-mediated allergic diseases and T helper type 1 cell (Th1)-mediated ITP remains unknown. Atopic dermatitis (AD) is considered one of the first steps in the atopic march. Herein, we conducted a population-based cohort analysis to investigate the risk of ITP in children with AD in comparison with non-AD controls. We subsequently compared the occurrence of other autoimmune diseases in ITP children in both AD and non-AD cohorts. From 2000 to 2007, 120,704 children with newly diagnosed AD and 241,408 randomly selected non-AD controls were included in the study. By the end of 2008, incidences of ITP in both cohorts and the AD cohort to non-AD cohort hazard ratios (HRs) and confidence intervals (CIs) were measured. Comparison of the occurrence of other autoimmune diseases in ITP between children with and without AD was analyzed. The incidence of ITP during the study period was 1.72-fold greater (95% CI: 1.13-2.62) in the AD cohort than in the non-AD cohort (6.96 vs 4.00 per 100,000 person-years). The risk was greatest among male children, children >2 years, those in densely populated areas, and those with white-collar parents. The HR of ITP in AD children increased significantly with the number of AD-related clinical visits (P &lt; 0.001). The risk of developing ITP in the AD cohort was highest within the first 3 years after the diagnosis of AD (HR: 1.78; CI: 1.14-2.78). The AD cohort with ITP had a higher occurrence rate of other autoimmune diseases than the non-AD cohort with ITP. AD children had a greater risk of developing ITP and other autoimmune diseases. Further research is needed to clarify the role of allergy in the pathogenesis of ITP and autoimmune diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000004226</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27442647">PM:27442647</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-95-e4226.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-95-e4226.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Wei CC</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000004226</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kuo,H.C.</style></author><author><style face="normal" font="Arial"> Yang,Y.L.</style></author><author><style face="normal" font="Arial"> Ho,S.C.</style></author><author><style face="normal" font="Arial"> Guo,M.M.</style></author><author><style face="normal" font="Arial"> Jiang,J.H.</style></author><author><style face="normal" font="Arial"> Huang,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDepartment of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung bKawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan University cDepartment of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung dDepartment of Public Health, College of Health Sciences, Kaohsiung Medical University eDepartment of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">General anesthesia exposure in early life reduces the risk of allergic diseases: A nationwide population-based cohort study</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e4269">e4269-</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">28</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Claims data</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Status Asthmaticus</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">General anesthesia (GA) has been used for second line treatment strategy for status asthmaticus in pediatric patients. The association between GA in children and risk of followed-up allergic diseases is unclear. This study aims to assess the risk of allergic diseases after GA in children.We did a nationwide retrospective cohort study by analyzing data from the National Health Insurance Research Database (NHIRD) in Taiwan. The subsequent risks for allergic diseases, including asthma (ICD-9: 493.X), allergic rhinitis (AR; ICD-9 CM code 477.X), and atopic dermatitis (AD; ICD-9-CM code 691.X), were compared between exposure to GA and none before 1 year of age throughout the follow-up period using the Cox proportional hazards model.Insurance claims data for 32,742 children younger than 1 year old from all insured children in the NHIRD. Of those, 2358 subjects were exposed to GA; 414 and 1944 children exposed to mask and intubation ventilation, respectively, served as the study cohort, whereas the remaining 30,384 children made up the comparison cohort. Children in the GA group were at a lower risk of developing asthma, AR and AD, with adjusted hazard ratios of 0.67 (0.62-0.72, 95%CI), 0.72 (0.68-0.77, 95%CI), 0.60 (0.56-0.64, 95%CI), respectively.Children who were exposed to GA in early life before 1 year of age had reduced risk of subsequently developing allergic diseases such as asthma, AD, and AR, when compared with general population</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000004269</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27428241">PM:27428241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-95-e4269.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-95-e4269.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Kuo HC</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000004269</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bs</style></author></authors></contributors><auth-address><style face="normal" font="Arial">.</style></auth-address><titles><title><style face="normal" font="Arial">[Heart infarct trigger - pollen count]</style></title><secondary-title><style face="normal" font="Arial">MMW Fortschr Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">MMW Fortschr Med</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="Arial">158</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis,Allergic,Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="31" Month="3" Year="2016">2016/3/31</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160416IS - 1438-3276 (Print)IS - 1438-3276 (Linking)LA - gerPT - NewsSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s15006-016-7962-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27084127">PM:27084127</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\MMW Fortschr Med\2016-158-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\MMW Fortschr Med\2016-158-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160416, Bs</style></custom2><misc3><style face="normal" font="Arial">10.1007/s15006-016-7962-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Li,F.</style></author><author><style face="normal" font="Arial"> Ding,J.</style></author><author><style face="normal" font="Arial"> Tian,G.</style></author><author><style face="normal" font="Arial"> Jiang,M.</style></author><author><style face="normal" font="Arial"> Gao,Z.</style></author><author><style face="normal" font="Arial"> Tuyghun,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Xinjiang Key Laboratory of Respiratory Disease Research, TCM Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Investigation of the antiasthmatic activity of Oridonin on a mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> TCM</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="7" Year="2016">2016/7/8</year></dates><abstract><style face="normal" font="Arial">Oridonin is an extract obtained from a traditional Chinese medicinal herb, Xihuangcao. Previous studies have demonstrated that Oridonin exerts various pharmaceutical effects, such as antitumor and immunosuppressive effects, as well as modulating cytokine balance. The present study identified that Oridonin could regulate the Th1/Th2 cytokine balance in mice. However, as the antiasthmatic effect of Oridonin is currently unknown a mouse model of asthma was used in the present study. BALB/c mice were sensitized using ovalbumin (OVA), then the sensitized mice were treated with Oridonin prior to OVA challenge. The in vivo study indicated that Oridonin decreased the OVAinduced airway hyperresponsiveness significantly (P&lt;0.05). In addition, the results indicated that in Oridonintreated mice, the eosinophil number and total inflammatory cell number in bronchoalveolar lavage (BAL) fluid decreased significantly in the Oridonin group when compared with the control group. Further study indicated that Oridonin significantly decreased the level of inflammatory cytokines, which were induced by OVA, in BAL fluid. Histological studies were performed to evaluate the effect of Oridonin on eosinophilia and mucus in the airway, the results indicated that Oridonin significantly inhibited the eosinophilia and mucus production in the lungs. Therefore the present study demonstrated that Oridonin regulates Th1/Th2 balance in mice and exhibited antiasthmatic effects in a mouse model of asthma. These findings indicate that Oridonin may serve as a potential therapeutic compound for the treatment of asthma in future</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2016.5485</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27431862">PM:27431862</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\20160719-WangJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\20160719-WangJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2016.5485</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guillon,B.</style></author><author><style face="normal" font="Arial"> Bernard,H.</style></author><author><style face="normal" font="Arial"> Drumare,M.F.</style></author><author><style face="normal" font="Arial"> Hazebrouck,S.</style></author><author><style face="normal" font="Arial"> Adel-Patient,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">UMR CEA-INRA Service de Pharmacologie et d'Immunoanalyse, Universite Paris-Saclay, F-91991, Gif-sur-Yvette, France</style></auth-address><titles><title><style face="normal" font="Arial">Heat processing of peanut seed enhances the sensitization potential of the major peanut allergen Ara h 6</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> 2S Albumins</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Disulfide bridge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heat denaturation</style></keyword><keyword><style face="normal" font="Arial"> Heat processing</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vitro digestion</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Pharmacologie</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Roasting</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="4" Month="7" Year="2016">2016/7/4</year></dates><abstract><style face="normal" font="Arial">SCOPE: Processing of food has been shown to impact IgE binding and functionality of food allergens. In the present study, we investigated the impact of heat processing on the sensitization capacity of Ara h 6, a major peanut allergen and one of the most potent elicitors of the allergic reaction. METHODS AND RESULTS: Peanut extracts obtained from raw or heat-processed peanut and some fractions thereof were biochemically and immunochemically characterized. These extracts/fractions, purified Ara h 6 or recombinant Ara h 6 including Ara h 6 mutants lacking disulfide bridges were used in in vitro digestion tests and mouse models of experimental sensitization. Peanut roasting led to the formation of complexes of high molecular weight, notably between Ara h 6 and Ara h 1, which supported the induction of IgE specific to native Ara h 6. On the contrary, a fraction containing free monomeric 2S albumins or purified native Ara h 6 displayed no intrinsic allergenicity. In addition to complex formation, heat denaturation and/or partial destabilization enhanced Ara h 6 immunogenicity and increased its sensitivity to digestion. CONCLUSION: These results suggest that sensitization potency and IgE binding capacity can be supported by different structures, modified and/or produced during food processing in interaction with other food constituents. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201500923</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27374416">PM:27374416</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20160704-GuillonB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20160704-GuillonB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Guillon B</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201500923</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gao,Z.S.</style></author><author><style face="normal" font="Arial"> Zhou,X.</style></author><author><style face="normal" font="Arial"> Yang,Z.W.</style></author><author><style face="normal" font="Arial"> Versteeg,S.A.</style></author><author><style face="normal" font="Arial"> Gao,L.</style></author><author><style face="normal" font="Arial"> Fu,W.Y.</style></author><author><style face="normal" font="Arial"> Wang,H.Y.</style></author><author><style face="normal" font="Arial"> Zhou,J.Y.</style></author><author><style face="normal" font="Arial"> Akkerdaas,J.H.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Horticulture, College of Agriculture and Biotechnology, Zhejiang University, Hangzhou, 310058, China</style></auth-address><titles><title><style face="normal" font="Arial">IgE-binding potencies of three peach Pru p 1 isoforms</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pru p 1</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2016">2016/7/4</year></dates><abstract><style face="normal" font="Arial">SCOPE: Pru p 1, the Bet v 1 homologue from peach, has been identified as a clinically relevant allergen. Three isoforms have been described, two in peach fruit (Pru p 1.0101, Pru p 1.0201) and one in pollen (Pru p 1.0301). The present study aimed to compare their IgE binding potencies. METHODS AND RESULTS: Three Pru p 1 isoforms were cloned and expressed as soluble proteins with His-tags in Escherichia coli. Protein identity was confirmed by mass spectrometry, circular dichroism, and RNAse activity. IgE binding capacity by ELISA and ImmunoCAP was compared. Three Pru p 1 isoforms had quite similar IgE-binding potencies for 60% of the sera, but more than two-fold between any two isoforms among 40% of the 47 sera. The mean IgE binding of Pru p 1.0201 was slightly higher than other two isoforms. In a sera pool, homologous ImmunoCAP inhibition was higher than other two heterologous isoforms. Individual serum with diverse IgE values of three isoforms demonstrated the higher IgE inhibition of specific isoform with higher IgE value. CONCLUSION: A similar and variable pattern of IgE recognition was observed among three Pru p 1 isoforms. The two new isoforms can be used as more accurate diagnostic reagents. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201500798</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27374664">PM:27374664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20160704-GaoZS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20160704-GaoZS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Gao ZS</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201500798</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chhabra,S.K.</style></author><author><style face="normal" font="Arial"> Dash,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Delhi. skchhabra@mailcity.com</style></auth-address><titles><title><style face="normal" font="Arial">Concurrent sensitization to Aspergillus Fumigatus in tropical pulmonary eosinophilia</style></title><secondary-title><style face="normal" font="Arial">Monaldi Arch Chest Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Monaldi Arch Chest Dis</style></full-title></periodical><pages end="" start="736">736-</pages><volume><style face="normal" font="Arial">81</style></volume><number><style face="normal" font="Arial">1-2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Tropical pulmonary eosinophilia (TPE) is characterized by lung tissue and peripheral blood eosinophilia. Serum total IgE is also markedly increased in TPE. However, an association with asthma or other hypersensitivity conditions has not been described. During the diagnostic workup of three patients eventually confirmed to have TPE, hypersensitivity to the fungus, Aspergillus Fumigatus was found. However, there was no evidence of diseases of aspergillus hypersensitivity such as severe asthma with fungal sensitization (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). This association however raises the possibility of a future risk of these potentially serious allergic respiratory manifestations.RiassuntoL'eosinofilia polmonare tropicale (TPE) e caratterizzata da tessuto polmonare e eosinofilia nel sangue periferico. Anche il siero IgE totale e notevolmente aumentato in TPE. Tuttavia, un'associazione con asma o altre condizioni di ipersensibilita non e stata descritta. Durante l'iter diagnostico di tre pazienti, che alla fine si sono rivelati presentare TPE, ipersensibilita al fungo, e stato trovato l'Aspergillus fumigatus. Tuttavia, non vi era alcuna evidenza di malattie di Aspergillus ipersensibilita come l'asma grave con sensibilizzazione fungina (SAF) e aspergillosi broncopolmonare allergica (ABPA). Questa associazione pone tuttavia la possibilita di un rischio futuro di queste potenzialmente gravi manifestazioni allergiche respiratorie</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1122-0643 (Print)IS - 1122-0643 (Linking)LA - engPT - Journal ArticleSB - IMCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4081/monaldi.2015.736</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27374215">PM:27374215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Monaldi Arch Chest Dis\2016-81-736.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Monaldi Arch Chest Dis\2016-81-736.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Chhabra SK</style></custom2><misc3><style face="normal" font="Arial">10.4081/monaldi.2015.736</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,I.C.</style></author><author><style face="normal" font="Arial"> Tsai,J.D.</style></author><author><style face="normal" font="Arial"> Shen,T.C.</style></author><author><style face="normal" font="Arial"> Lin,C.L.</style></author><author><style face="normal" font="Arial"> Li,T.C.</style></author><author><style face="normal" font="Arial"> Wei,C.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital of China Medical University Hospital , Taichung , Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Conjunctivitis and the Associated Risk of Migraine Among Children: A Nationwide Population-based Cohort Study</style></title><secondary-title><style face="normal" font="Arial">Ocul Immunol Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ocul Immunol Inflamm</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="7" Year="2016">2016/7/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE: To investigate the risk of migraine in children with allergic conjunctivitis (AC). METHODS: In this population-based cohort study, 309 138 children with AC and 309 138 non-AC controls were included between 2000 and 2007. By 2008 end, the incidences of migraine in both cohorts, and the AC-to-non-AC cohort hazard ratios (HRs) were measured. RESULTS: The incidence of migraine during the study period was 1.92-fold higher in the AC cohort than in the non-AC cohort. The risk was greater for boys with AC and children aged &lt;6 years. The mean time-interval between physician-diagnosed AC to physician-diagnosed migraine was 3.67 years (SD = 2.19).The risk of migraine development in the AC cohort increased with follow-up time and was highest during 4-5 years after AC diagnosis. The children with AC more likely had migraine without than with aura. CONCLUSIONS: Children with AC had a higher incidence and subsequent risk of migraine</style></abstract><notes><style face="normal" font="Arial">DA - 20160707IS - 1744-5078 (Electronic)IS - 0927-3948 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1080/09273948.2016.1178303</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27382919">PM:27382919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ocul Immunol Inflamm\20160707-WangIC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ocul Immunol Inflamm\20160707-WangIC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160707, Wang IC</style></custom2><misc3><style face="normal" font="Arial">10.1080/09273948.2016.1178303</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,J.H.</style></author><author><style face="normal" font="Arial"> Gong,C.H.</style></author><author><style face="normal" font="Arial"> Choi,G.E.</style></author><author><style face="normal" font="Arial"> Kim,S.A.</style></author><author><style face="normal" font="Arial"> Kim,H.S.</style></author><author><style face="normal" font="Arial"> Jang,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Natural Killer Cell Deficits Aggravate Allergic Rhinosinusitis in a Murine Model</style></title><secondary-title><style face="normal" font="Arial">ORL J Otorhinolaryngol Relat Spec</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ORL J Otorhinolaryngol Relat Spec</style></full-title></periodical><pages end="207" start="199">199-207</pages><volume><style face="normal" font="Arial">78</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal challenge</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> natural killer cell</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> NK cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white blood cell</style></keyword></keywords><dates><year Day="7" Month="7" Year="2016">2016/7/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Defective innate immune functions can contribute to chronic rhinosinusitis (RS). Recently, it has been reported that chronic RS patients show impaired function of natural killer (NK) cells. We investigated the role of NK cells in eosinophilic inflammation in an allergic RS mouse model. METHODS: Mice sensitized to ovalbumin (OVA) by intraperitoneal injection received nasal challenges with OVA for 5 weeks. NK cell depletion was achieved by intraperitoneal injections of anti-asialo ganglio-N-tetraosylceramide (ASGM1) antibodies 10 days before OVA sensitization and every 5 days thereafter until sacrifice. Sinonasal complex samples were evaluated histologically, and IL-4, IL-5, IL-13, IFN-947;, MIP-2, and eotaxin levels were measured in the nasal lavage fluid. Differential white blood cell counts were also obtained. RESULTS: Allergic RS mice showed significantly more eosinophilic inflammation in the sinonasal mucosa, elevated levels of IL-4, IL-5, IL-13, and eotaxin in the nasal lavage fluid, and peripheral blood eosinophilia compared to control mice. The depletion of NK cells by anti-ASGM1 treatment induced more prominent eosinophilic inflammation and increased secretion of IL-5 and peripheral blood eosinophilia in allergic RS mice. CONCLUSION: The depletion of NK cells aggravates allergen-induced sinonasal eosinophilic inflammation, suggesting that impaired NK cell activity may be an exacerbating factor in eosinophilic chronic RS</style></abstract><notes><style face="normal" font="Arial">DA - 20160707IS - 1423-0275 (Electronic)IS - 0301-1569 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1159/000445775</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27383429">PM:27383429</url></web-urls></urls><custom2><style face="normal" font="Arial">20160707, Kim JH</style></custom2><misc3><style face="normal" font="Arial">10.1159/000445775</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foong,R.X.</style></author><author><style face="normal" font="Arial"> Brough,H.A.</style></author><author><style face="normal" font="Arial"> Lozinsky,A.C.</style></author><author><style face="normal" font="Arial"> Shah,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The role of the gastroenterologist in non-IgE mediated gastrointestinal food allergy</style></title><secondary-title><style face="normal" font="Arial">Paediatr Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Paediatr Child Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disorders</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> non-IgE mediated allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1751-7222</style></isbn><abstract><style face="normal" font="Arial">The prevalence of food allergy has been on the rise in the UK over the last 30 years. Food allergy can be classified as Immunoglobulin E (IgE)-mediated, non-IgE mediated or mixed IgE and non-IgE mediated food allergy. Whilst the management of IgE-mediated food allergy is relatively well established with regards to investigations and treatment options, non-IgE mediated food allergy management is emerging. The role of the gastroenterologist in food allergy is in the management of non-IgE mediated gastrointestinal food allergy, which is performed closely alongside allergologists. The aim of this review is to discuss the common presentations of non-IgE mediated food allergy (i.e. cow's milk protein allergy, food protein-induced enterocolitis, eosinophilic gastrointestinal disorders) and describe current investigation and treatment options for these conditions. It focuses on the main management options available such as elimination diets, drug therapies, as well as gastroenterology-specific tests such as endoscopy. It also highlights the importance of both allergy and gastroenterology multi-disciplinary team support in order to ensure the best management of these children</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.paed.2016.06.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.paed.2016.06.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Paediatr Child Health\20160723-FoongRX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Paediatr Child Health\20160723-FoongRX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160723, Foong RX</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.paed.2016.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saleh-Langenberg,J.</style></author><author><style face="normal" font="Arial"> Bootsma,G.M.</style></author><author><style face="normal" font="Arial"> van Ginkel,C.D.</style></author><author><style face="normal" font="Arial"> Kollen,B.J.</style></author><author><style face="normal" font="Arial"> Flokstra-de Blok,B.M.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Groningen, University Medical Centre Groningen, Department of Pediatric Pulmonology and Pediatric Allergy, Groningen, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">The prevalence of food allergy and epinephrine auto-injectors in Dutch food-allergic adolescents</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="759" start="755">755-759</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> epinephrine auto-injectors</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long term care</style></keyword><keyword><style face="normal" font="Arial"> Long-Term Care</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="7" Year="2016">2016/7/5</year></dates><abstract><style face="normal" font="Arial">Food-induced anaphylaxis continues to be increasing across all ages, and the risk of fatal food-induced anaphylaxis is disproportionately high in adolescents(1,2). Effective management of food-induced anaphylaxis must include both prompt acute, emergency treatment and long-term care. When a severe food-allergic reaction occurs, prompt administration of epinephrine may be life-saving. Therefore, all food-allergic patients at high-risk of anaphylaxis should carry an epinephrine auto-injector (EAI) at all times. However, a previous study in 2009 showed that there was an alarming underprescription of EAIs to high-risk food-allergic adolescents (11-20 years) in Dutch high schools(3). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - LETTERCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12611</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27378275">PM:27378275</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160705-SalehLangenbergJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160705-SalehLangenbergJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Saleh-Langenberg J</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12611</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kloos,R.Q.</style></author><author><style face="normal" font="Arial"> Pieters,R.</style></author><author><style face="normal" font="Arial"> Escherich,G.</style></author><author><style face="normal" font="Arial"> van der Sluis,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Oncology and Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation</style></title><secondary-title><style face="normal" font="Arial">Pediatr Blood Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Blood Cancer</style></full-title></periodical><pages end="1934" start="1928">1928-1934</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erwinia</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2016">2016/7/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asparaginase is an important component of pediatric acute lymphoblastic leukemia (ALL) therapy. Unfortunately, this treatment is hampered by hypersensitivity reactions. In general, allergies - regardless of severity - cause complete inactivation of the drug. However, we report atypical allergic reactions without inactivation of asparaginase, here called allergic-like reactions. PROCEDURE: Patients with an allergic-like reaction, who were treated according to the Dutch Childhood Oncology Group ALL-11 or the CoALL 08-09 protocol, were described. The reactions were identified by continual measurement of asparaginase activity levels. Characteristics, including timing of occurrence, symptoms, grade, and the presence of antiasparaginase antibodies, were compared to those of real allergies. RESULTS: Fourteen allergic-like reactions occurred in nine patients. Five reactions were to PEGasparaginase and nine to Erwinia asparaginase. Allergic-like reactions occurred relatively late after the start of infusion compared to real allergies. Antibodies were absent in all but one patient with an allergic-like reaction, while they were detected in all patients with a real allergy. Symptoms and grade did not differ between the groups. Asparaginase was continued with the same formulation in six patients of whom four finished treatment with adequate activity levels. CONCLUSIONS: In conclusion, allergic-like reactions occur relatively late after the start of infusion and without antibodies. Despite these clinical differences, allergic-like reactions can only be distinguished from real allergies by continually measuring asparaginase activity levels. If clinically tolerated, formulations should not be switched in case of allergic-like reactions. Moreover, failure to recognize these reactions may lead to a less favorable prognosis if asparaginase therapy is terminated unnecessarily</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1545-5017 (Electronic)IS - 1545-5009 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/pbc.26123</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27376478">PM:27376478</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Blood Cancer\20160704-KloosRQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Blood Cancer\20160704-KloosRQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Kloos RQ</style></custom2><misc3><style face="normal" font="Arial">10.1002/pbc.26123</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pruitt,Z.</style></author><author><style face="normal" font="Arial"> Pruitt,R.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the *College of Public Health, Health Policy and Management, University of South Florida, Tampa; and daggerPremier Care Pediatrics, Lithia, FL</style></auth-address><titles><title><style face="normal" font="Arial">Children Covered by Medicaid/State Children's Health Insurance Program More Likely to Use Emergency Departments for Food Allergies</style></title><secondary-title><style face="normal" font="Arial">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Geography</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Policy</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment guidelines</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="7" Year="2016">2016/7/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergies (FAs) occur in 4% to 8% of children in the United States, and emergency department (ED) visits account for up to 20% of their costs. In 2010, the National Institute of Allergy and Infectious Diseases established diagnostic criteria and management practices for FAs, and recognition and treatment of FAs for pediatric ED practitioners has been described. OBJECTIVE: This study identified trends and factors related to ED visits for pediatric FAs in the United States from 2001 to 2010. It was hypothesized that FAs increased and that differences existed in ED utilization based on age, insurance status, and geography. Low concordance with treatment guidelines for FAs was expected. METHODS: Multivariate logistic regression, using National Hospital Ambulatory Medical Care Survey data, estimated factors associated with ED visits and treatment of FAs and nonspecific allergic reactions. Trends and treatment patters used weighted frequencies to account for the complex 4-stage probability survey design. RESULTS: An estimated 239,303 (95% confidence interval [CI], 180,322-298,284) children visited the ED for FAs, demonstrating a significant rate increase during the period (53.08, P &lt; 0.001). Logistic regression showed that the odds of ED visits for FAs were significantly associated with Medicaid/State Children's Health Insurance Program insurance (OR, 1.65 [95% CI, 1.01-2.69], P = 0.04), adolescents (OR, 1.92 [95% CI, 1.10-3.35], P = 0.02), and boys (OR, 1.55 [95% CI, 1.03-2.35], P = 0.04). Treatment with epinephrine for anaphylaxis diagnoses occurred in 57.4% of visits (95% CI, 42.3%-66.8%). CONCLUSIONS: Medicaid/State Children's Health Insurance Program-insured pediatric patients had higher odds of visiting ED for recognized FAs and nonspecific allergic reactions and higher odds of receiving epinephrine than privately insured children</style></abstract><notes><style face="normal" font="Arial">DA - 20160712IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/PEC.0000000000000794</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27404464">PM:27404464</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Emerg Care\20160712-PruittZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Emerg Care\20160712-PruittZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160712, Pruitt Z</style></custom2><misc3><style face="normal" font="Arial">10.1097/PEC.0000000000000794</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cui,Y.</style></author><author><style face="normal" font="Arial"> Teng,F.</style></author><author><style face="normal" font="Arial"> Yu,L.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Laboratory, Affiliated Yancheng Hospital, School of Medicine, Southeast University, Yancheng, 224001, Jiangsu Province, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Dermatophagoides farinae allergen Der f 9: Cloning, expression, purification, characterization and IgE-binding in children with atopic asthma</style></title><secondary-title><style face="normal" font="Arial">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Pulmonol</style></full-title></periodical><pages end="292" start="282">282-292</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical laboratory</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Der f 9</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Nickel</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Periodicals</style></keyword><keyword><style face="normal" font="Arial"> Plasmid</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The house dust mite species Dermatophagoides farinae releases allergens that cause allergies and asthma worldwide. This study sought to clone and express the full-length cDNA encoding the group 9 allergen of D. farinae (Der f 9). METHODS: The published sequence of Der f 9 was used to design primers for RT-PCR and RACE to obtain the full-length cDNA encoding Der f 9. After removal of signal peptide sequence, Der f 9 was then sub-cloned into plasmid pET-28b (+), and the plasmid was transformed into Escherichia coli BL21 (DE3) cells for expression. The recombinant protein was purified by Nickel affinity chromatography, identified by SDS-PAGE, Western blotting, dot blotting, and MALDI-TOF, and tested by ELISA for IgE reactivity with sera from children with asthma. Bioinformatics analyses were used to identify features of Der f 9. RESULTS: By RT-PCR, 3'-RACE, and 5'-RACE, the full-length sequence of Der f 9 was generated, which was confirmed by nucleotide sequencing. The mature Der f 9 was expressed successfully in E. coli, which was identified by SDS-PAGE. The recombinant allergen was purified by chromatography and confirmed by SDS-PAGE, Western blotting, dot blotting, and MALDI-TOF. Sera from 56.7% (17/30) of mite-allergic patients reacted with the purified recombinant Der f 9. CONCLUSIONS: The successful production of recombinant Der f 9 protein revealed the importance of Der f 9 in mite allergy, and provides a foundation for further study of this allergen in diagnosis and treatment of symptoms. Pediatr Pulmonol. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/ppul.23526</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27434417">PM:27434417</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Pulmonol\20160719-CuiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Pulmonol\20160719-CuiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Cui Y</style></custom2><misc3><style face="normal" font="Arial">10.1002/ppul.23526</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lynch,S.J.</style></author><author><style face="normal" font="Arial"> Sears,M.R.</style></author><author><style face="normal" font="Arial"> Hancox,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; andFirestone Institute for Respiratory Health, Michael de Groote School of Medicine, McMaster University and St Joseph's Healthcare, Hamilton, ON, CanadaDepartment of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; and bob.hancox@otago.ac.nz</style></auth-address><titles><title><style face="normal" font="Arial">Thumb-Sucking, Nail-Biting, and Atopic Sensitization, Asthma, and Hay Fever</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20160443">e20160443-</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Crowding</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> ownership</style></keyword><keyword><style face="normal" font="Arial"> parental atopy</style></keyword><keyword><style face="normal" font="Arial"> parental smoking</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> pet ownership</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2016">2016/7/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The hygiene hypothesis suggests that early-life exposure to microbial organisms reduces the risk of developing allergies. Thumb-sucking and nail-biting are common childhood habits that may increase microbial exposures. We tested the hypothesis that children who suck their thumbs or bite their nails have a lower risk of developing atopy, asthma, and hay fever in a population-based birth cohort followed to adulthood. METHODS: Parents reported children's thumb-sucking and nail-biting habits when their children were ages 5, 7, 9, and 11 years. Atopic sensitization was defined as a positive skin-prick test (>/=2-mm weal) to >/=1 common allergen at 13 and 32 years. Associations between thumb-sucking and nail-biting in childhood, and atopic sensitization, asthma, and hay fever at these ages were assessed by using logistic regression with adjustments for sex and other potential confounding factors: parental atopy, breastfeeding, pet ownership, household crowding, socioeconomic status, and parental smoking. RESULTS: Thirty-one percent of children were frequent thumb-suckers or nail-biters at >/=1 of the ages. These children had a lower risk of atopic sensitization at age 13 years (odds ratio 0.67, 95% confidence interval 0.48-0.92, P = .013) and age 32 years (odds ratio 0.61, 95% confidence interval 0.46-0.81, P = .001). These associations persisted when adjusted for multiple confounding factors. Children who had both habits had a lower risk of atopic sensitization than those who had only 1. No associations were found for nail-biting, thumb-sucking, and asthma or hay fever at either age. CONCLUSIONS: Children who suck their thumbs or bite their nails are less likely to have atopic sensitization in childhood and adulthood</style></abstract><notes><style face="normal" font="Arial">DA - 20160712IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - ENGPT - JOURNAL ARTICLECO - New Zealand -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2016-0443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27401101">PM:27401101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\20160712-LynchSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\20160712-LynchSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160712, Lynch SJ</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2016-0443</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Urbanek,K.</style></author><author><style face="normal" font="Arial"> De Angelis,A.</style></author><author><style face="normal" font="Arial"> Spaziano,G.</style></author><author><style face="normal" font="Arial"> Piegari,E.</style></author><author><style face="normal" font="Arial"> Matteis,M.</style></author><author><style face="normal" font="Arial"> Cappetta,D.</style></author><author><style face="normal" font="Arial"> Esposito,G.</style></author><author><style face="normal" font="Arial"> Russo,R.</style></author><author><style face="normal" font="Arial"> Tartaglione,G.</style></author><author><style face="normal" font="Arial"> De Palma,R.</style></author><author><style face="normal" font="Arial"> Rossi,F.</style></author><author><style face="normal" font="Arial"> D'Agostino,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Intratracheal Administration of Mesenchymal Stem Cells Modulates Tachykinin System, Suppresses Airway Remodeling and Reduces Airway Hyperresponsiveness in an Animal Model</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0158746">e0158746-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> indoleamine 2,3-dioxygenase</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Neuropeptides</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> tachykinin</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tissue remodeling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VIP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The need for new options for chronic lung diseases promotes the research on stem cells for lung repair. Bone marrow-derived mesenchymal stem cells (MSCs) can modulate lung inflammation, but the data on cellular processes involved in early airway remodeling and the potential involvement of neuropeptides are scarce. OBJECTIVES: To elucidate the mechanisms by which local administration of MSCs interferes with pathophysiological features of airway hyperresponsiveness in an animal model. METHODS: GFP-tagged mouse MSCs were intratracheally delivered in the ovalbumin mouse model with subsequent functional tests, the analysis of cytokine levels, neuropeptide expression and histological evaluation of MSCs fate and airway pathology. Additionally, MSCs were exposed to pro-inflammatory factors in vitro. RESULTS: Functional improvement was observed after MSC administration. Although MSCs did not adopt lung cell phenotypes, cell therapy positively affected airway remodeling reducing the hyperplastic phase of the gain in bronchial smooth muscle mass, decreasing the proliferation of epithelium in which mucus metaplasia was also lowered. Decrease of interleukin-4, interleukin-5, interleukin-13 and increase of interleukin-10 in bronchoalveolar lavage was also observed. Exposed to pro-inflammatory cytokines, MSCs upregulated indoleamine 2,3-dioxygenase. Moreover, asthma-related in vivo upregulation of pro-inflammatory neurokinin 1 and neurokinin 2 receptors was counteracted by MSCs that also determined a partial restoration of VIP, a neuropeptide with anti-inflammatory properties. CONCLUSION: Intratracheally administered MSCs positively modulate airway remodeling, reduce inflammation and improve function, demonstrating their ability to promote tissue homeostasis in the course of experimental allergic asthma. Because of a limited tissue retention, the functional impact of MSCs may be attributed to their immunomodulatory response combined with the interference of neuropeptide system activation and tissue remodeling</style></abstract><notes><style face="normal" font="Arial">DA - 20160720IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0158746</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27434719">PM:27434719</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0158746.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0158746.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160720, Urbanek K</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0158746</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mothes,B.</style></author><author><style face="normal" font="Arial"> Bucher,K.</style></author><author><style face="normal" font="Arial"> Ammon-Treiber,S.</style></author><author><style face="normal" font="Arial"> Schwab,M.</style></author><author><style face="normal" font="Arial"> Piekorz,R.P.</style></author><author><style face="normal" font="Arial"> Hirsch,E.</style></author><author><style face="normal" font="Arial"> Nurnberg,B.</style></author><author><style face="normal" font="Arial"> Beer-Hammer,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology and ICePhA, University of Tuebingen, 72074 Tuebingen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">p110gamma/delta Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0159310">e0159310-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The catalytical isoforms p110gamma and p110delta of phosphatidylinositide 3-kinase gamma (PI3Kgamma) and PI3Kdelta play an important role in the pathogenesis of asthma. Two key elements in allergic asthma are increased levels of eosinophils and IgE. Dual pharmacological inhibition of p110gamma and p110delta reduces asthma-associated eosinophilic lung infiltration and ameliorates disease symptoms, whereas the absence of enzymatic activity in p110gammaKOdeltaD910A mice increases IgE and basal eosinophil counts. This suggests that long-term inhibition of p110gamma and p110delta might exacerbate asthma. Here, we analysed mice genetically deficient for both catalytical subunits (p110gamma/delta-/-) and determined basal IgE and eosinophil levels and the immune response to ovalbumin-induced asthma. Serum concentrations of IgE, IL-5 and eosinophil numbers were significantly increased in p110gamma/delta-/- mice compared to single knock-out and wildtype mice. However, p110gamma/delta-/- mice were protected against OVA-induced infiltration of eosinophils, neutrophils, T and B cells into lung tissue and bronchoalveolar space. Moreover, p110gamma/delta-/- mice, but not single knock-out mice, showed a reduced bronchial hyperresponsiveness. We conclude that increased levels of eosinophils and IgE in p110gamma/delta-/- mice do not abolish the protective effect of p110gamma/delta-deficiency against OVA-induced allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - Germany -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0159310</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27442134">PM:27442134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0159310.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0159310.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Mothes B</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0159310</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sun,R.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Ran,X.</style></author><author><style face="normal" font="Arial"> Yang,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Institute of Battle Surgery, Daping Hospital, Third Military Medical University, Chongqing, 400042, China</style></auth-address><titles><title><style face="normal" font="Arial">Calcium Influx of Mast Cells Is Inhibited by Aptamers Targeting the First Extracellular Domain of Orai1</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0158223">e0158223-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Aptamers</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Ca2+ influx</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Oligonucleotides</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Streptavidin</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Using the systematic evolution of ligands by exponential enrichment (SELEX) method, we identified oligonucleotides that bind to the first extracellular domain of the Orai1 protein with high affinities and high specificities. These ligands were isolated from a random single-strand DNA (ssDNA) library with 40 randomized sequence positions, using synthesized peptides with amino acid sequences identical to the first extracellular domain of the Orai1 protein as the targets for SELEX selection. Seven aptamers were obtained after 12 rounds of SELEX. An enzyme-linked oligonucleotide assay (ELONA) was performed to determine the affinities of the aptamers. Aptamer Y1 had the highest affinity (Kd = 1.72x10-8 mol/L) and was selected for functional experiments in mast cells. Using LAD2 cells with the human high-affinity IgE receptor and Ca2+ release activation channel (CRAC), we demonstrated that Aptamer Y1 blocked IgE-mediated beta-hexosaminidase release from cells triggered by biotin-IgE and streptavidin. A specific binding assay showed that Aptamer Y1 not only bound the Orai1 peptide specifically but also that the Orai1 peptide did not bind significantly to other random oligonucleotide molecules. Furthermore, Aptamer Y1 regulation of intracellular Ca2+ mobilization was investigated by probing intracellular Ca2+ with a Fluo-4-AM fluorescent probe. We found that Aptamer Y1 inhibits Ca2+ influx into antigen-activated mast cells. These results indicate that the target of Aptamer Y1 in the degranulation pathway is upstream of Ca2+ influx. Therefore, these oligonucleotide agents represent a novel class of CRAC inhibitors that may be useful in the fight against allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160708IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0158223</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27390850">PM:27390850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0158223.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0158223.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160708, Sun R</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0158223</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tacquard,C.</style></author><author><style face="normal" font="Arial"> Laroche,D.</style></author><author><style face="normal" font="Arial"> Stenger,R.</style></author><author><style face="normal" font="Arial"> Mariotte,D.</style></author><author><style face="normal" font="Arial"> Uring-Lambert,B.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Malinovsky,J.M.</style></author><author><style face="normal" font="Arial"> Mertes,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hopitaux universitaires de Strasbourg, departement d'anesthesie-reanimation, 67000 Strasbourg, France.</style></auth-address><titles><title><style face="normal" font="Arial">Diagnostic procedure after an immediate hypersensitivity reaction in the operating room</style></title><secondary-title><style face="normal" font="Arial">Presse Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Presse Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Basal tryptase</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE assays</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assay</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assays</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword></keywords><dates><year Day="30" Month="6" Year="2016">2016/6/30</year></dates><abstract><style face="normal" font="Arial">The diagnosis of a perioperative allergic reaction is based on clinical features associated with a suggestive timeline, the exclusion of other diagnoses, elevated concentrations of degranulation markers (histamine, tryptase), and positive allergy assessments (skin tests, specific IgE). After initiating appropriate treatment, the anesthesiologist should take blood samples to measure histamine and tryptase concentrations just after the reaction and repeat them 1-2hours later to validate the diagnosis of immediate hypersensitivity. A delayed measurement of basal tryptase is useful to rule out mastocytosis and to interpret moderate tryptase levels. The anesthesiologist must inform the patient of the reaction to obtain adhesion and consent to subsequent investigations and must record the timing of the reaction and of the blood sampling, the possible causal agents, and the treatment administered. These data must be shared with the laboratory and the allergist. An adverse drug reaction report must be filed. The gold standard for allergy assessment is skin testing. These tests should be done in an appropriate facility, with experienced staff and in compliance with current guidelines. Specific IgE assays and cellular assays can help when clinical features and skin tests are discordant. Provocation tests are sometimes required. After allergy assessment, the safest protocol for subsequent anesthesia is determined in collaboration with the anesthesiologist. The patient must be informed and carry an allergy alert card</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 0755-4982 (Electronic)IS - 0755-4982 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.lpm.2016.05.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27374263">PM:27374263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Presse Med\20160704-TacquardC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Presse Med\20160704-TacquardC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Tacquard C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.lpm.2016.05.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feng,S.</style></author><author><style face="normal" font="Arial"> Zhang,Y.Y.</style></author><author><style face="normal" font="Arial"> Gao,W.J.</style></author><author><style face="normal" font="Arial"> Bian,X.H.</style></author><author><style face="normal" font="Arial"> Shi,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Role of transient receptor potential vanilloid 1 in airway inflammation in asthmatic mice]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="878" start="874">874-878</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Capsaicin</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-8</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To study the effects of the change in transient receptor potential vanilloid 1 (TRPV1) channel activity on the degree of airway inflammation in asthmatic mice. METHODS: BALB/c mice were randomly divided into control, asthma, capsaicin (TRPV1 agonist), capsazepine (TRPV1 antagonist), and dexamethasone groups. The asthmatic mouse model was established by intraperitoneal injection of mixed ovalbumin-aluminium hydroxide solution and ultrasonic atomization with OVA for sensitization and challenge. The capsaicin, capsazepine, and dexamethasone groups were given intraperitoneal injection of capsaicin (30 mug/kg), capsazepine (10 mumol/kg), and dexamethasone (2 mg/kg) respectively, at 30 minutes before challenge. Hematoxylin and eosin staining was used to observe the degree of pulmonary inflammation. ELISA was used to measure the content of interleukin-8 (IL-8) and interleukin-13 (IL-13) in bronchoalveolar lavage fluid (BALF). Real-Time PCR was used to measure the relative content of TRPV1 mRNA in lung tissue. RESULTS: Compared with the asthma group, the capsazepine and dexamethasone groups showed reduced pulmonary inflammation, while the capsaicin group showed aggravated pulmonary inflammation. Compared with the control group, the asthma and capsaicin groups showed increases in the content of IL-13 and IL-8 in BALF and the mRNA expression of TRPV1 in lung tissue (P&lt;0.05). Compared with the asthma group, the capsazepine and dexamethasone groups showed reductions in the content of IL-13 and IL-8 in BALF and the mRNA expression of TRPV1 in lung tissue (P&lt;0.05). The capsaicin group showed increases in the content of IL-13 and IL-8 in BALF (P&lt;0.05). CONCLUSIONS: TRPV1 channel agonist and antagonist can influence the degree of airway inflammation in asthmatic mice. Dexamethasone may reduce airway inflammation through regulating TRPV1 level</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - CHIPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27655547">PM:27655547</url></web-urls></urls><custom2><style face="normal" font="Arial">20160922, Feng S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">North,C.M.</style></author><author><style face="normal" font="Arial"> Ezendam,J.</style></author><author><style face="normal" font="Arial"> Hotchkiss,J.A.</style></author><author><style face="normal" font="Arial"> Maier,C.</style></author><author><style face="normal" font="Arial"> Aoyama,K.</style></author><author><style face="normal" font="Arial"> Enoch,S.</style></author><author><style face="normal" font="Arial"> Goetz,A.</style></author><author><style face="normal" font="Arial"> Graham,C.</style></author><author><style face="normal" font="Arial"> Kimber,I.</style></author><author><style face="normal" font="Arial"> Karjalainen,A.</style></author><author><style face="normal" font="Arial"> Pauluhn,J.</style></author><author><style face="normal" font="Arial"> Roggen,E.L.</style></author><author><style face="normal" font="Arial"> Selgrade,M.</style></author><author><style face="normal" font="Arial"> Tarlo,S.M.</style></author><author><style face="normal" font="Arial"> Chen,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ExxonMobil Biomedical Sciences, Inc., Annandale, NJ, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Developing a framework for assessing respiratory sensitization: A workshop report</style></title><secondary-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory sensitization</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin sensitization</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="7" Year="2016">2016/7/7</year></dates><abstract><style face="normal" font="Arial">Respiratory tract sensitization can have significant acute and chronic health implications. While induction of respiratory sensitization is widely recognized for some chemicals, validated standard methods or frameworks for identifying and characterizing the hazard are not available. A workshop on assessment of respiratory sensitization was held to discuss the current state of science for identification and characterization of respiratory sensitizer hazard, identify information facilitating development of validated standard methods and frameworks, and consider the regulatory and practical risk management needs. Participants agreed on a predominant Th2 immunological mechanism and several steps in respiratory sensitization. Some overlapping cellular events in respiratory and skin sensitization are well understood, but full mechanism(s) remain unavailable. Progress on non-animal approaches to skin sensitization testing, ranging from in vitro systems, -omics, in silico profiling, and structural profiling were acknowledged. Addressing both induction and elicitation phases remains challenging. Participants identified lack of a unifying dose metric as increasing the difficulty of interpreting dosimetry across exposures. A number of research needs were identified, including an agreed list of respiratory sensitizers and other asthmagens, distinguishing between adverse effects from immune-mediated versus non-immunological mechanisms. A number of themes emerged from the discussion regarding future testing strategies, particularly the need for a tiered framework respiratory sensitizer assessment. These workshop present a basis for moving towards a weight-of-evidence assessment</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Netherlands -CO - United Kingdom -CO - Denmark -CO - Japan -CO - Finland -CO - Germany -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.yrtph.2016.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27396307">PM:27396307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20160711-NorthCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20160711-NorthCM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, North CM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.yrtph.2016.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Beaudouin,E.</style></author><author><style face="normal" font="Arial"> Birnbaum,J.</style></author><author><style face="normal" font="Arial"> Neukirch,C.</style></author><author><style face="normal" font="Arial"> Meininger,C.</style></author><author><style face="normal" font="Arial"> Leroy,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Who should have an epinephrine autoinjector? Position statement of the French Allergology Society's Anaphylaxis, Food Allergy and Stinging insects working groups</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="486" start="477">477-486</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxie</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Recommandations</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Stinging insects</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Intramuscular epinephrine is the first-line treatment for anaphylaxis. For certain allergic patients, an epinephrine autoinjector (EAI) should be prescribed and educational training should be provided. In 2014, the European Academy of Allergy and Clinical Immunology (EAACI) Taskforce on Anaphylaxis provided evidence-based guidelines for the diagnosis, risk factor assessment and management of anaphylaxis. Our aim here is to provide up-to-date guidelines for the prescription of an EAI for use in children and in adults as well, a prescription for a second EAI to be carried in the same sack in case the initial injection is not successful. This position statement, prepared by the Anaphylaxis, Food Allergy and Stinging insects working groups of the French Allergology Society, is based on the EAACI anaphylaxis guidelines and it provides a critical review of their recommendations</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.06.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.06.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20160719-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20160719-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Pouessel G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Isoda,A.</style></author><author><style face="normal" font="Arial"> Ishikawa,T.</style></author><author><style face="normal" font="Arial"> Sato,N.</style></author><author><style face="normal" font="Arial"> Miyazawa,Y.</style></author><author><style face="normal" font="Arial"> Matsumoto,M.</style></author><author><style face="normal" font="Arial"> Sawamura,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Hematology, National Hospital Organization Nishigunma Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Repeated rituximab-induced serum sickness with anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Rinsho Ketsueki</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rinsho Ketsueki</style></full-title></periodical><pages end="773" start="771">771-773</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arthralgia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Sickness</style></keyword><keyword><style face="normal" font="Arial"> Serum-sickness</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sjogren's Syndrome</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">We describe a patient who developed repeated rituximab-induced serum sickness (RISS) followed by anaphylaxis soon after the third administration of rituximab at relapse. A 65-year-old woman with Sjogren's syndrome and relapsed mucosal associated lymphoma tissue (MALT) lymphoma of the lung underwent rituximab monotherapy (375 mg/m2/week). Several days after the second exposure to rituximab, she developed a rash, fever, and arthralgia. These symptoms showed relief, but a severe anaphylactic reaction occurred when she was treated with rituximab for the third time. Although a rare complication in patients with lymphoma, clinicians should be aware of RISS symptoms and avoid repeatedly administering rituximab to such patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160707IS - 0485-1439 (Print)IS - 0485-1439 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.11406/rinketsu.57.771</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27384859">PM:27384859</url></web-urls></urls><custom2><style face="normal" font="Arial">20160707, Isoda A</style></custom2><misc3><style face="normal" font="Arial">10.11406/rinketsu.57.771</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Apostolovic,D.</style></author><author><style face="normal" font="Arial"> Stanic-Vucinic,D.</style></author><author><style face="normal" font="Arial"> de Jongh,H.H.</style></author><author><style face="normal" font="Arial"> de Jong,G.A.</style></author><author><style face="normal" font="Arial"> Mihailovic,J.</style></author><author><style face="normal" font="Arial"> Radosavljevic,J.</style></author><author><style face="normal" font="Arial"> Radibratovic,M.</style></author><author><style face="normal" font="Arial"> Nordlee,J.A.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Milcic,M.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author><author><style face="normal" font="Arial"> Garrido,C.N.</style></author><author><style face="normal" font="Arial"> Cirkovic,V.T.</style></author><author><style face="normal" font="Arial"> Koppelman,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center of Excellence for Molecular Food Sciences, University of Belgrade - Faculty of Chemistry, Studentski trg 16, 11000 Belgrade, Serbia</style></auth-address><titles><title><style face="normal" font="Arial">Conformational stability of digestion-resistant peptides of peanut conglutins reveals the molecular basis of their allergenicity</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="29249">29249-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Conglutin</style></keyword><keyword><style face="normal" font="Arial"> Conglutins</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal digestion</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> intestinal immune system</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics Simulation</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Conglutins represent the major peanut allergens and are renowned for their resistance to gastro-intestinal digestion. Our aim was to characterize the digestion-resistant peptides (DRPs) of conglutins by biochemical and biophysical methods followed by a molecular dynamics simulation in order to better understand the molecular basis of food protein allergenicity. We have mapped proteolysis sites at the N- and C-termini and at a limited internal segment, while other potential proteolysis sites remained unaffected. Molecular dynamics simulation showed that proteolysis only occurred in the vibrant regions of the proteins. DRPs appeared to be conformationally stable as intact conglutins. Also, the overall secondary structure and IgE-binding potency of DRPs was comparable to that of intact conglutins. The stability of conglutins toward gastro-intestinal digestion, combined with the conformational stability of the resulting DRPs provide conditions for optimal exposure to the intestinal immune system, providing an explanation for the extraordinary allergenicity of peanut conglutins</style></abstract><notes><style face="normal" font="Arial">DA - 20160705IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Serbia -CO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep29249</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27377129">PM:27377129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-29249.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-29249.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160705, Apostolovic D</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep29249</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burg,A.R.</style></author><author><style face="normal" font="Arial"> Quigley,L.</style></author><author><style face="normal" font="Arial"> Jones,A.V.</style></author><author><style face="normal" font="Arial"> O'Connor,G.M.</style></author><author><style face="normal" font="Arial"> Boelte,K.</style></author><author><style face="normal" font="Arial"> McVicar,D.W.</style></author><author><style face="normal" font="Arial"> Orr,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cancer and Inflammation Program, National Cancer Institute-Frederick, Frederick, MD 21702 USA</style></auth-address><titles><title><style face="normal" font="Arial">Orally administered beta-glucan attenuates the Th2 response in a model of airway hypersensitivity</style></title><secondary-title><style face="normal" font="Arial">Springerplus</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Springerplus</style></full-title></periodical><pages end="" start="815">815-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> cell walls</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dietary supplement</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">beta-Glucan is a polysaccharide that can be extracted from fungal cell walls. Wellmune WGP((R)), a preparation of beta-1,3/1,6-glucans, is a dietary supplement that has immunomodulating properties. Here we investigated the effect WGP had on a mouse model of asthma. OVA-induced asthma in mice is characterized by infiltration of eosinophils into the lung, production of Th2 cytokines and IgE. Daily oral administration of WGP (400 microg) significantly reduced the influx of eosinophils into the lungs of OVA-challenged mice compared to control mice. In addition, WGP inhibited pulmonary production of Th2 cytokines (IL-4, IL-5, IL-13), however serum IgE levels were unaffected by WGP treatment. These data indicate that WGP could potentially be useful as an oral supplement for some asthma patients, however, it would need to be combined with therapies that target other aspects of the disease such as IgE levels. As such, further studies that examine the potential of WGP in combination with other therapies should be explored</style></abstract><notes><style face="normal" font="Arial">DA - 20160708IS - 2193-1801 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40064-016-2501-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27390655">PM:27390655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Springerplus\2016-5-815.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Springerplus\2016-5-815.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160708, Burg AR</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40064-016-2501-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kamthan,A.</style></author><author><style face="normal" font="Arial"> Chaudhuri,A.</style></author><author><style face="normal" font="Arial"> Kamthan,M.</style></author><author><style face="normal" font="Arial"> Datta,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Plant Genome Research, Aruna Asaf Ali Marg, New Delhi, 110067, India</style></auth-address><titles><title><style face="normal" font="Arial">Genetically modified (GM) crops: milestones and new advances in crop improvement</style></title><secondary-title><style face="normal" font="Arial">Theor Appl Genet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Theor Appl Genet</style></full-title></periodical><pages end="1655" start="1639">1639-1655</pages><volume><style face="normal" font="Arial">129</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abiotic stress</style></keyword><keyword><style face="normal" font="Arial"> acceptance</style></keyword><keyword><style face="normal" font="Arial"> Achievement</style></keyword><keyword><style face="normal" font="Arial"> Biosafety</style></keyword><keyword><style face="normal" font="Arial"> Biotic and abiotic stresses</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Silencing</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Engineering</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> GM Crops</style></keyword><keyword><style face="normal" font="Arial"> GM-crops</style></keyword><keyword><style face="normal" font="Arial"> hybridization</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Nutritional quality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Transformation</style></keyword><keyword><style face="normal" font="Arial"> transgene</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic plants</style></keyword></keywords><dates><year Day="5" Month="7" Year="2016">2016/7/5</year></dates><abstract><style face="normal" font="Arial">KEY MESSAGE: New advances in crop genetic engineering can significantly pace up the development of genetically improved varieties with enhanced yield, nutrition and tolerance to biotic and abiotic stresses. Genetically modified (GM) crops can act as powerful complement to the crops produced by laborious and time consuming conventional breeding methods to meet the worldwide demand for quality foods. GM crops can help fight malnutrition due to enhanced yield, nutritional quality and increased resistance to various biotic and abiotic stresses. However, several biosafety issues and public concerns are associated with cultivation of GM crops developed by transgenesis, i.e., introduction of genes from distantly related organism. To meet these concerns, researchers have developed alternative concepts of cisgenesis and intragenesis which involve transformation of plants with genetic material derived from the species itself or from closely related species capable of sexual hybridization, respectively. Recombinase technology aimed at site-specific integration of transgene can help to overcome limitations of traditional genetic engineering methods based on random integration of multiple copy of transgene into plant genome leading to gene silencing and unpredictable expression pattern. Besides, recently developed technology of genome editing using engineered nucleases, permit the modification or mutation of genes of interest without involving foreign DNA, and as a result, plants developed with this technology might be considered as non-transgenic genetically altered plants. This would open the doors for the development and commercialization of transgenic plants with superior phenotypes even in countries where GM crops are poorly accepted. This review is an attempt to summarize various past achievements of GM technology in crop improvement, recent progress and new advances in the field to develop improved varieties aimed for better consumer acceptance</style></abstract><notes><style face="normal" font="Arial">DA - 20160706IS - 1432-2242 (Electronic)IS - 0040-5752 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00122-016-2747-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27381849">PM:27381849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Theor Appl Genet\20160706-KamthanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Theor Appl Genet\20160706-KamthanA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160706, Kamthan A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00122-016-2747-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liccardi,G.</style></author><author><style face="normal" font="Arial"> Salzillo,A.</style></author><author><style face="normal" font="Arial"> Piccolo,A.</style></author><author><style face="normal" font="Arial"> Calzetta,L.</style></author><author><style face="normal" font="Arial"> Rogliani,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chest Diseases, Division of Pneumology and Allergology , High Speciality 'A. Cardarelli' Hospital , Naples Italy</style></auth-address><titles><title><style face="normal" font="Arial">Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens</style></title><secondary-title><style face="normal" font="Arial">Ups J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ups J Med Sci</style></full-title></periodical><pages end="197" start="196">196-197</pages><volume><style face="normal" font="Arial">121</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal allergen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> small airways</style></keyword></keywords><dates><year Day="11" Month="7" Year="2016">2016/7/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 2000-1967 (Electronic)IS - 0300-9734 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3109/03009734.2016.1173745</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27399169">PM:27399169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ups J Med Sci\20160711-LiccardiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ups J Med Sci\20160711-LiccardiG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, Liccardi G</style></custom2><misc3><style face="normal" font="Arial">10.3109/03009734.2016.1173745</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lo,K.L.</style></author><author><style face="normal" font="Arial"> Rosenkrantz,W.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Animal Dermatology Clinic, 2965 Edinger Avenue, Tustin, CA, 92780, USAAnimal Dermatology Clinic, 2965 Edinger Avenue, Tustin, CA, 92780, USA</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of cytology collection techniques and prevalence of Malassezia yeast and bacteria in claw folds of normal and allergic dogs</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="e67" start="279">279-e67</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> corneocytes</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Canine bacterial and Malassezia paronychia are common secondary complications of atopic dermatitis and adverse food reactions. HYPOTHESIS/OBJECTIVES: The aim of this study was to compare three different sampling methods for claw fold cytology and to evaluate the numbers of bacteria, Malassezia yeast and inflammatory cells. ANIMALS: Sixty client-owned dogs were classified into three groups: (A) normal dogs; (B) allergic dogs with no clinical evidence of claw disease (brown staining, erythema, swelling, crusts or exudates); and (C) allergic dogs with clinical paronychia. METHODS: A prospective, blinded, split-plot study design was used. Claw folds from each dog were sampled using either a toothpick, tape preparation or direct impression smear. Slides were evaluated by two investigators for inflammatory cells, nuclear streaming, debris, corneocytes, yeast, intracellular (IC) cocci, extracellular (EC) cocci, IC rods and EC rods. For each parameter, data were compared between groups and between methods. Inter-reader agreements were calculated. RESULTS: Group C had significantly higher values of EC cocci and corneocytes than Groups A or B. Although Malassezia organisms were more prevalent in allergic dogs than normal dogs, the counts were not significantly different. There were significantly higher numbers of Malassezia organisms (P = 0.0016) and EC cocci (P = 0.0106) retrieved from samples collected with a toothpick compared to other methods. Tape preparations were associated with significantly more debris and corneocytes (both P &lt; 0.0001) and impression smears with significantly more nuclear streaming (P = 0.0468). CONCLUSIONS AND CLINICAL IMPORTANCE: Sample collection using a toothpick optimizes the value of cytological results when sampling allergic dogs with clinical paronychia</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27374469">PM:27374469</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\2016-27-279-e67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\2016-27-279-e67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Lo KL</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12297</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vilson,A.</style></author><author><style face="normal" font="Arial"> Hedhammar,A.</style></author><author><style face="normal" font="Arial"> Reynolds,A.</style></author><author><style face="normal" font="Arial"> Spears,J.</style></author><author><style face="normal" font="Arial"> Satyaraj,E.</style></author><author><style face="normal" font="Arial"> Pelker,R.</style></author><author><style face="normal" font="Arial"> Rottman,C.</style></author><author><style face="normal" font="Arial"> Bjorksten,B.</style></author><author><style face="normal" font="Arial"> Hansson-Hamlin,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immunoglobulins in dogs: correspondence and maturation in 15 litters of German shepherd dogs and their dams</style></title><secondary-title><style face="normal" font="Arial">Vet Rec Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Rec Open</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2016">2016/7/1</year></dates><abstract><style face="normal" font="Arial">Some dog breeds, including the German shepherd dog (GSD), are predisposed to immune-related disorders. The authors prospectively described development of serum and faecal IgA and serum IgE in GSD from puppies until adulthood and the relationship between mothers and their offspring. Further, the authors tested whether dogs with lower serum IgA also have low faecal IgA and/or serum IgE. To reveal whether any of the parameters could be proven to influence the immune response, the authors also measured serum IgG against canine distemper virus (CDV). To test their hypothesis, the authors used linear mixed models to investigate the relationship of serum IgA, serum IgE and faecal IgA levels in litters and their mothers. Fifteen GSD bitches beginning at 42</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çàdays of pregnancy and subsequently all of their offspring (n=83 puppies), reared under well-controlled conditions, were included. All dogs came from the kennel of the Swedish Armed Forces.Serum IgE, serum IgA and faecal IgA levels were lower in seven-week-old puppies than at one year of age. There was no relationship in Ig concentrations between bitches and their puppies at seven weeks of age. Dogs with higher faecal IgA had higher IgG titres against CDV, indicating a favourable systemic immune status</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1136/vetreco-2016-000173</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1136/vetreco-2016-000173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Rec Open\20160723-VilsonA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Rec Open\20160723-VilsonA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160723, Vilson A</style></custom2><misc3><style face="normal" font="Arial">10.1136/vetreco-2016-000173</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shrivastava,P.</style></author><author><style face="normal" font="Arial"> Sarkar,I.</style></author><author><style face="normal" font="Arial"> Atanley,E.</style></author><author><style face="normal" font="Arial"> Gomis,S.</style></author><author><style face="normal" font="Arial"> van Drunen Littel-van den Hurk</style></author></authors></contributors><auth-address><style face="normal" font="Arial">VIDO-InterVac, University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan, Canada</style></auth-address><titles><title><style face="normal" font="Arial">IL-12p40 gene-deficient BALB/c mice exhibit lower weight loss, reduced lung pathology and decreased sensitization to allergen in response to infection with pneumonia virus of mice</style></title><secondary-title><style face="normal" font="Arial">Virology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Virology</style></full-title></periodical><pages end="10" start="1">1-10</pages><volume><style face="normal" font="Arial">497</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchiolitis</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> Saskatchewan</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Loss</style></keyword></keywords><dates><year Day="8" Month="7" Year="2016">2016/7/8</year></dates><abstract><style face="normal" font="Arial">Respiratory syncytial virus (RSV) is a major cause of bronchiolitis and pneumonia in infants and pneumonia virus of mice (PVM) causes similar disease. BALB/c mice are highly susceptible, while C57BL/6 mice are more resistant to PVM. IL-12 was significantly more up-regulated in response to PVM infection in BALB/c than in C57BL/6 mice. IL-12p40-deficient neonatal and adult BALB/c mice showed significantly less weight loss than wild-type mice after PVM challenge. The percentage of regulatory T cells, as well as IFN-beta and IL-18 expression, was higher in the lungs of both neonatal and adult IL-12p40-/- mice. Adult IL-12p40-/- mice also showed enhanced TGF-beta and IL-10 expression and reduced inflammatory responses. Furthermore, IL-12p40-/- mice showed decreased sensitization to inhaled cockroach antigen after PVM infection when compared to wild-type mice. In conclusion, these data suggest that a depressed regulatory capacity in BALB/c mice to PVM infection results in enhanced immunopathology and sensitization to allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 1096-0341 (Electronic)IS - 0042-6822 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.virol.2016.06.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27400340">PM:27400340</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Virology\2016-497-1-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Virology\2016-497-1-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, Shrivastava P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.virol.2016.06.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caraballo,L.</style></author><author><style face="normal" font="Arial"> Zakzuk,J.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Acevedo,N.</style></author><author><style face="normal" font="Arial"> Soh,J.Y.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Hossny,E.</style></author><author><style face="normal" font="Arial"> Garcia,E.</style></author><author><style face="normal" font="Arial"> Rosario,N.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.</style></author><author><style face="normal" font="Arial"> Puerta,L.</style></author><author><style face="normal" font="Arial"> Sanchez,J.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Immunological Research, University of Cartagena, Cra. 5 # 7-77, Cartagena, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Particularities of allergy in the Tropics</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Stinging insects</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergic diseases are distributed worldwide and their risk factors and triggers vary according to geographical and socioeconomic conditions. Allergies are frequent in the Tropics but aspects of their prevalence, natural history, risk factors, sensitizers and triggers are not well defined and some are expected to be different from those in temperate zone countries. The aim of this review is to investigate if allergic diseases in the Tropics have particularities that deserve special attention for research and clinical practice. Such information will help to form a better understanding of the pathogenesis, diagnosis and management of allergic diseases in the Tropics. As expected, we found particularities in the Tropics that merit further study because they strongly affect the natural history of common allergic diseases; most of them related to climate conditions that favor permanent exposure to mite allergens, helminth infections and stinging insects. In addition, we detected several unmet needs in important areas which should be investigated and solved by collaborative efforts led by the emergent research groups on allergy from tropical countries</style></abstract><notes><style face="normal" font="Arial">DA - 20160707IS - 1939-4551 (Electronic)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Colombia -CO - Singapore -CO - Sweden -CO - Venezuela -CO - Egypt -CO - Brazil -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0110-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27386040">PM:27386040</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160707, Caraballo L</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0110-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Piao,Y.</style></author><author><style face="normal" font="Arial"> Yu,W.</style></author><author><style face="normal" font="Arial"> He,C.</style></author><author><style face="normal" font="Arial"> Yue,C.</style></author><author><style face="normal" font="Arial"> Liu,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Beijing Tongren Hospital, Capital Medical University; the Key Laboratory of Head and Neck Molecular Pathological Diagnosis, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">[IgG4-related sialodacryoadenitis and chronic rhinosinusitis: a clinicopathologic analysis of 13 cases]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Bing Li Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Bing Li Xue Za Zhi</style></full-title></periodical><pages end="185" start="180">180-185</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lacrimal Apparatus</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Salivary Glands</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sialadenitis</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> systemic disease</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2016">2016/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To study the clinicopathologic characteristics of IgG4-related sialodacryoadenitis and chronic rhinosinusitis (CRS). METHODS: A total of 13 patients (patient group) were evaluated clinically and biopsy specimens from the lacrimal/salivary glands (n=12) and nasal mucosa (n=8) were reviewed and immunohistochemistry was performed to assess IgG-and IgG4-positive cells. Similarly, nine patients with IgG4-related sialodacryoadenitis without CRS and 10 patients with common CRS were included as controls. RESULTS: There were 8 male patients and 5 female patients. The age of patients ranged from 32 to 71 years (mean 50.2 years). The patient group had higher serum IgG4 concentration than that of the control group (P&lt;0.05). Lymphoplasmacytic infiltration, lymphoid follicle formation and sclerosis were prominent in lacrimal/salivary glands in both groups; however the magnitude of IgG4-positive plasmacytic infiltration in the patient group was significantly higher than that of the control group (P&lt;0.05). Similarly, evaluation of nasal mucosa revealed greater lymphocytic and plasmacytic infiltration, and lymphoid follicle formation, together with significantly higher amount of IgG4-positive plasma cell infiltration in the patient group compared to the common CRS group (P&lt;0.05). CONCLUSIONS: IgG4-related disease (IgG4-RD) simultaneously involving lacrimal/salivary glands and nasal cavity/paranasal sinuses is rare and characterized by a combination of IgG4-positive plasma cell infiltration involving lacrimal/salivary glands and nasal mucosa along with an increased serum level of IgG4. As a systemic disease, early and accurate diagnosis is therefore of great importance, and unnecessary surgery should be avoided</style></abstract><notes><style face="normal" font="Arial">DA - 20160309IS - 0529-5807 (Print)IS - 0529-5807 (Linking)LA - chiPT - English AbstractPT - Journal ArticleRN - 0 (Immunoglobulin G)SB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.0529-5807.2016.03.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26956963">PM:26956963</url></web-urls></urls><custom2><style face="normal" font="Arial">20160309, Piao Y</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.0529-5807.2016.03.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doriya,K.</style></author><author><style face="normal" font="Arial"> Jose,N.</style></author><author><style face="normal" font="Arial"> Gowda,M.</style></author><author><style face="normal" font="Arial"> Kumar,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Indian Institute of Technology, Hyderabad, Telangana, India</style></auth-address><titles><title><style face="normal" font="Arial">Solid-State Fermentation vs Submerged Fermentation for the Production of l-Asparaginase</style></title><secondary-title><style face="normal" font="Arial">Adv Food Nutr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Food Nutr Res</style></full-title></periodical><pages end="135" start="115">115-135</pages><volume><style face="normal" font="Arial">78</style></volume><reprint-status date="07/31/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asparagine</style></keyword><keyword><style face="normal" font="Arial"> Aspartic Acid</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Industrial Waste</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> L-asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> moisture</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Solid-state fermentation</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">l-Asparaginase, an enzyme that catalyzes l-asparagine into aspartic acid and ammonia, has relevant applications in the pharmaceutical and food industry. So, this enzyme is used in the treatment of acute lymphoblastic leukemia, a malignant disorder in children. This enzyme is also able to reduce the amount of acrylamide found in carbohydrate-rich fried and baked foods which is carcinogenic to humans. The concentration of acrylamide in food can be reduced by deamination of asparagine using l-Asparaginase. l-Asparaginase is present in plants, animals, and microbes. Various microorganisms such as bacteria, yeast, and fungi are generally used for the production of l-Asparaginase as it is difficult to obtain the same from plants and animals. l-Asparaginase from bacteria causes anaphylaxis and other abnormal sensitive reactions. To overcome this, eukaryotic organisms such as fungi can be used for the production of l-Asparaginase. l-Asparaginase can be produced either by solid-state fermentation (SSF) or by submerged fermentation (SmF). SSF is preferred over SmF as it is cost effective, eco-friendly and it delivers high yield of enzyme. SSF process utilizes agricultural and industrial wastes as solid substrate. The contamination level is substantially reduced in SSF through low moisture content. Current chapter will discuss in detail the chemistry and applications of l-Asparaginase enzyme and various methods available for the production of the enzyme, especially focusing on the advantages and limitations of SSF and SmF processes</style></abstract><notes><style face="normal" font="Arial">DA - 20160725IS - 1043-4526 (Print)IS - 1043-4526 (Linking)LA - engPT - Journal ArticleSB - IMCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/bs.afnr.2016.05.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27452168">PM:27452168</url></web-urls><pdf-urls><url ppv-ref="no">devarai@iith.ac.in researchgate</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20160725, Doriya K</style></custom2><misc3><style face="normal" font="Arial">10.1016/bs.afnr.2016.05.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loftus,P.A.</style></author><author><style face="normal" font="Arial"> Wise,S.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic Fungal Rhinosinusitis: The Latest in Diagnosis and Management</style></title><secondary-title><style face="normal" font="Arial">Adv Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Otorhinolaryngol</style></full-title></periodical><pages end="20" start="13">13-20</pages><volume><style face="normal" font="Arial">79</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> African American</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> humoral immunity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergic fungal rhinosinusitis (AFRS) is the most common form of fungal sinusitis in the United States. Its pathophysiological basis is associated with a predisposed person's type I IgE-mediated allergic response to inhaled mold spores that are ubiquitous in the environment. AFRS is a well-recognized type of chronic, recurrent, and non-invasive hypertrophic sinus disease that affects immunocompetent hosts, most commonly young African American males. There are 5 main criteria used for the diagnosis of AFRS, one being the presence of nasal polyposis. A review of the current literature was performed in order to provide the most up-to-date knowledge regarding the background, diagnosis, management, recent research, and controversies surrounding AFRS. Although much is known about the pathophysiology and etiology of this disease, controversy exists regarding the importance of type I hypersensitivity in AFRS, as humoral immunity and immunoglobulin-independent pathways may also contribute. The potential role of local sinonasal IgE production in the pathophysiology of AFRS is an area of discussion, as is the role of preoperative antifungal medication in improving postoperative patient outcomes. Recent advancements in the diagnosis of AFRS include identification of genes and proteins unique to or over-expressed in AFRS patients. Although AFRS is a well-known and well-described cause of nasal polyposis, controversy still exists regarding this diagnosis. Advances in research may eventually resolve any diagnostic controversies in AFRS</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1662-2847 (Electronic)IS - 0065-3071 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000444958</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27466842">PM:27466842</url></web-urls></urls><custom2><style face="normal" font="Arial">20160729, Loftus PA</style></custom2><misc3><style face="normal" font="Arial">10.1159/000444958</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">London,N.R.,Jr.</style></author><author><style face="normal" font="Arial"> Tharakan,A.</style></author><author><style face="normal" font="Arial"> Ramanathan,M.,Jr.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Role of Innate Immunity and Aeroallergens in Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Adv Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Otorhinolaryngol</style></full-title></periodical><pages end="77" start="69">69-77</pages><volume><style face="normal" font="Arial">79</style></volume><reprint-status date="09/17/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobials</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Cigarette smoke</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endocytosis</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> Penetration</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> PRR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sinonasal epithelial</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergy has been inferred to contribute to the pathophysiology of chronic rhinosinusitis (CRS) although this role is controversial and the mechanism is debated. Furthermore, the role of aeroallergens in CRS is poorly defined and has been postulated to contribute to CRS through direct penetration in the sinuses or downstream systemic consequences. Common aeroallergens implicated in chronic rhinosinusitis include air pollution/second hand smoke, dust mite and pollen [&lt;citeref rid="ref1">1&lt;/citeref>,&lt;citeref rid="ref2">2&lt;/citeref>,&lt;citeref rid="ref3">3&lt;/citeref>]. One emerging potential mechanism whereby aeroallergens contribute to CRS is through sinonasal epithelial barrier disruption (fig. &lt;figref rid="fig01">1&lt;/figref>). Characterization of cytokine disruption of sinonasal epithelial cell barrier has been described including interleukin (IL)-4 and IL-13, as well as aeroallergens such as house dust mite and cigarette smoke. Recent results have demonstrated severe barrier disruption in response to direct application of either particulate matter (PM) or house dust mite (HDM) to sinonasal epithelial cells. Sinonasal epithelial barrier disruption may contribute to CRS by enabling the perpetual and chronic exposure of inflammatory allergens and stimuli. The sinonasal epithelial barrier plays a significant role in innate immune host defense. Mechanisms of innate immune defense include pattern recognition receptors (PRRs), secreted endogenous antimicrobials and inflammatory cytokines that aid in repair mechanisms including IL-33. Here we discuss recent evidence implicating aeroallergens and dysregulated host innate immune responses in the development of CRS. &lt;figure id="fig01">&lt;no>1&lt;/no>&lt;figcap>Fig. 1. Aeroallergens and inflammatory stimuli disrupt sinonasal epithelial barrier function. These agents act to destabilize the barrier through stimulating endocytosis and destruction of cell junction proteins via oxidative stress and MyD88-dependent mechanisms. Furthermore, aeroallergens and inflammatory stimuli induce secretion of IL-25, IL-33, and TSLP from sinonasal epithelial cells.&lt;/figcap>&lt;figbody filename="F01" filetype="JPG">F01&lt;/figbody>&lt;/figure></style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1662-2847 (Electronic)IS - 0065-3071 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000445132</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27466848">PM:27466848</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160729, London NR Jr</style></custom2><misc3><style face="normal" font="Arial">10.1159/000445132</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nolin,J.D.</style></author><author><style face="normal" font="Arial"> Ogden,H.L.</style></author><author><style face="normal" font="Arial"> Lai,Y.</style></author><author><style face="normal" font="Arial"> Altemeier,W.A.</style></author><author><style face="normal" font="Arial"> Frevert,C.W.</style></author><author><style face="normal" font="Arial"> Bollinger,J.G.</style></author><author><style face="normal" font="Arial"> Naika,G.S.</style></author><author><style face="normal" font="Arial"> Kicic,A.</style></author><author><style face="normal" font="Arial"> Stick,S.M.</style></author><author><style face="normal" font="Arial"> Lambeau,G.</style></author><author><style face="normal" font="Arial"> Henderson,W.R.,Jr.</style></author><author><style face="normal" font="Arial"> Gelb,M.H.</style></author><author><style face="normal" font="Arial"> Hallstrand,T.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Washington, Medicine, Seattle, Washington, United States</style></auth-address><titles><title><style face="normal" font="Arial">Identification of Epithelial Phospholipase A2 Receptor 1 (PLA2R1) as a Potential Target in Asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="836" start="825">825-836</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antigen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> C-type lectin receptor</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> trafficking</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="22" Month="7" Year="2016">2016/7/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Secreted phospholipase A2 (sPLA2)s regulate eicosanoid formation and have been implicated in asthma. Although sPLA2s function as enzymes, some of the sPLA2s bind with high affinity to a C-type lectin receptor called PLA2R1 that has functions in both cellular signaling and clearance of sPLA2s. OBJECTIVES: To examine the expression of PLA2R1 in the airway epithelium of human subjects with asthma, and the function of the murine Pla2r1 gene in a model of asthma. METHODS: Expression of PLA2R1 in epithelial brushings was assessed in two distinct cohorts of children with asthma by microarray and quantitative PCR, and immunostaining for PLA2R1 was conducted on endobronchial tissue and epithelial brushings from adults with asthma. C57BL/129 mice deficient in Pla2r1 (Pla2r1-/-) were characterized in an ovalbumin (OVA) model of allergic asthma. RESULTS: PLA2R1 was differentially overexpressed in epithelial brushings of children with atopic asthma in both cohorts. Immunostaining for PLA2R1 in endobronchial tissue localized to submucosal glandular epithelium and columnar epithelial cells. Following OVA sensitization and challenge, Pla2r1-/- mice had increased airway hyperresponsiveness (AHR), as well as an increase in cellular trafficking of eosinophils to the peribronchial space and bronchoalveolar lavage (BAL) fluid, and an increase in airway permeability. Additionally, Pla2r1-/- mice had more dendritic cells (DC) in the lung, higher levels of OVA-specific IgG, and increased production of both type-1 and type-2 cytokines by lung leukocytes. CONCLUSIONS: PLA2R1 is increased in the airway epithelium in asthma, and serves as a regulator of AHR, airway permeability, antigen sensitization, and airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2015-0150OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27448109">PM:27448109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Cell Mol Biol\2016-55-825-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Cell Mol Biol\2016-55-825-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Nolin JD</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2015-0150OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moawad,F.J.</style></author><author><style face="normal" font="Arial"> Cheng,E.</style></author><author><style face="normal" font="Arial"> Schoepfer,A.</style></author><author><style face="normal" font="Arial"> Al-Haddad,S.</style></author><author><style face="normal" font="Arial"> Bellizzi,A.M.</style></author><author><style face="normal" font="Arial"> Dawson,H.</style></author><author><style face="normal" font="Arial"> El-Zimaity,H.</style></author><author><style face="normal" font="Arial"> Guindi,M.</style></author><author><style face="normal" font="Arial"> Penagini,R.</style></author><author><style face="normal" font="Arial"> Safrooneva,E.</style></author><author><style face="normal" font="Arial"> Chehade,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Gastroenterology Service, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic esophagitis: current perspectives from diagnosis to management</style></title><secondary-title><style face="normal" font="Arial">Ann N Y Acad Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann N Y Acad Sci</style></full-title></periodical><pages end="217" start="204">204-217</pages><volume><style face="normal" font="Arial">1380</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dilation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Reed</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="28" Month="7" Year="2016">2016/7/28</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is a chronic antigen-mediated immune disease of the esophagus characterized by symptoms related to esophageal dysfunction, as well as significant esophageal eosinophilia. Although dense eosinophilia is the hallmark of EoE, other characteristic histologic features have been described that may help distinguish EoE from other competing diagnoses, although none are specific to EoE. One or more foods and, at times, environmental allergens trigger EoE. Left untreated, esophageal inflammation in EoE may lead to esophageal remodeling and stricture formation. Symptoms in EoE vary with age, as they relate to the progression of the disease from an inflammatory to a fibrostenotic phenotype over time. There are currently no U.S. Food and Drug Administration-approved therapies for EoE. Current options include various dietary-restriction therapies, topical corticosteroids, and esophageal dilations. Several emerging therapies aiming at restoring the esophageal barrier function or targeting various inflammatory cells or their mediators are under investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 1749-6632 (Electronic)IS - 0077-8923 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Switzerland -CO - Canada -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/nyas.13164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27467185">PM:27467185</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann N Y Acad Sci\20160728-MoawadFJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann N Y Acad Sci\20160728-MoawadFJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, Moawad FJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/nyas.13164</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Basinas,I.</style></author><author><style face="normal" font="Arial"> Sigsgaard,T.</style></author><author><style face="normal" font="Arial"> Bonlokke,J.H.</style></author><author><style face="normal" font="Arial"> Andersen,N.T.</style></author><author><style face="normal" font="Arial"> Omland,O.</style></author><author><style face="normal" font="Arial"> Kromhout,H.</style></author><author><style face="normal" font="Arial"> Schlunssen,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1.Department of Public Health, Section for Environment, Occupation and Health, Danish Ramazzini Center, Aarhus University, Bartholins Alle 2, bg 1260, 8000 Aarhus C, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Feedback on Measured Dust Concentrations Reduces Exposure Levels Among Farmers</style></title><secondary-title><style face="normal" font="Arial">Ann Occup Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Occup Hyg</style></full-title></periodical><pages end="824" start="812">812-824</pages><volume><style face="normal" font="Arial">60</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alle</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cattle</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> exposure reduction</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intervention Studies</style></keyword><keyword><style face="normal" font="Arial"> Livestock</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> organic dust</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The high burden of exposure to organic dust among livestock farmers warrants the establishment of effective preventive and exposure control strategies for these workers. The number of intervention studies exploring the effectiveness of exposure reduction strategies through the use of objective measurements has been limited. OBJECTIVE: To examine whether dust exposure can be reduced by providing feedback to the farmers concerning measurements of the exposure to dust in their farm. METHODS: The personal dust levels of farmers in 54 pig and 26 dairy cattle farms were evaluated in two measurement series performed approximately 6 months apart. Detailed information on work tasks and farm characteristics during the measurements were registered. Participating farms were randomized a priori to a control (n = 40) and an intervention group (n = 40). Shortly after the first visit, owners of intervention farms only received a letter with information on the measured dust concentrations in the farm together with some general advises on exposure reduction strategies (e.g. use of respirators during certain tasks). Relationships between measured dust concentrations and intervention status were quantified by means of linear mixed effect analysis with farm and worker id as random effects. Season, type of farming, and work tasks were treated as fixed effects. Changes in exposure over time were explored primarily at a farm level in models combined, as well as separate for pig and cattle farmers. RESULTS: After adjustment for fixed effects, an overall reduction of 23% in personal dust exposures was estimated as a result of the intervention (P = 0.02). Exposure reductions attributable to the intervention were similar across pig and cattle farmers, but statistically significant only for pig farmers. Intervention effects among pig farmers did not depend on the individuals' information status; but among cattle farmers a significant 48% reduction in exposure was found only among individuals that reported to have been informed. No systematic differences in changes over time considering the use of respiratory protection between the intervention and control groups were observed. CONCLUSION: The results of the present study suggest reductions between 20 and 30% in personal exposure to inhalable dust to be feasible through simple information provided to the farm owners regarding actual levels of exposure together with instructions on basic measures of prevention. The exact reasons for these effects are unclear, but likely they involve changes in behavior and working practices among intervention farmers</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1475-3162 (Electronic)IS - 0003-4878 (Linking)LA - engPT - Journal ArticleSB - IMCO - Denmark -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1093/annhyg/mew032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27245773">PM:27245773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Occup Hyg\2016-60-812-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Occup Hyg\2016-60-812-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Basinas I</style></custom2><misc3><style face="normal" font="Arial">10.1093/annhyg/mew032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,C.</style></author><author><style face="normal" font="Arial"> Dong,H.</style></author><author><style face="normal" font="Arial"> Zou,M.</style></author><author><style face="normal" font="Arial"> Luo,L.</style></author><author><style face="normal" font="Arial"> Hu,Y.</style></author><author><style face="normal" font="Arial"> Xie,Z.</style></author><author><style face="normal" font="Arial"> Le,Y.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Zou,F.</style></author><author><style face="normal" font="Arial"> Cai,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China</style></auth-address><titles><title><style face="normal" font="Arial">Bevacizumab reduced auto-phosphorylation of VEGFR2 to protect HDM-induced asthma mice</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="186" start="181">181-186</pages><volume><style face="normal" font="Arial">478</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Embryonic Development</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> Wound Healing</style></keyword></keywords><dates><year Day="22" Month="7" Year="2016">2016/7/22</year></dates><abstract><style face="normal" font="Arial">Vascular endothelial growth factor (VEFG) is a major angiogenic factor involved in both normal physiological processes, such as embryonic development and wound healing, and in diseases, like cancer. Recent studies have revealed the functions of VEGF in inflammation and immunoregulation. Asthma is a chronic inflammation of the airways characterized by airway epithelial barrier dysfunction and imbalance in T-helper (Th) 1/Th2 during immunoregulation. We hypothesized that VEGF plays an important role in asthma. Utilizing a house dust mite extract (HDM)-induced murine model of asthma, we investigated whether bevacizumab, a humanized anti-VEGF monoclonal antibody, could protect the epithelial barrier in murine airways. We found that bevacizumab reduced airway hyper-responsiveness (AHR) and airway inflammation induced by HDM. In addition, HDM exposure promoted expression of VEGF, and caused AHR, disruptions of the epithelial barrier, and airway inflammation. Bevacizumab ameliorated AHR and the release of Th2 cytokines, thereby protecting the epithelial barrier. Our data suggest that bevacizumab may be a new therapeutic strategy for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2016.07.072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27453339">PM:27453339</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20160730-HuangC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20160730-HuangC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Huang C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2016.07.072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bissonnette,R.</style></author><author><style face="normal" font="Arial"> Papp,K.A.</style></author><author><style face="normal" font="Arial"> Poulin,Y.</style></author><author><style face="normal" font="Arial"> Gooderham,M.</style></author><author><style face="normal" font="Arial"> Raman,M.</style></author><author><style face="normal" font="Arial"> Mallbris,L.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Purohit,V.</style></author><author><style face="normal" font="Arial"> Mamolo,C.</style></author><author><style face="normal" font="Arial"> Papacharalambous,J.</style></author><author><style face="normal" font="Arial"> Ports,W.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Innovaderm Research, Montreal, QC, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Topical tofacitinib for atopic dermatitis: A Phase 2a randomised trial</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="911" start="902">902-911</pages><volume><style face="normal" font="Arial">175</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Body Surface Area</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Janus kinase</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> topical therapy</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="7" Year="2016">2016/7/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown. OBJECTIVES: Tofacitinib, a small molecule JAK inhibitor, was investigated for the topical treatment of AD. METHODS: In this 4-week, Phase 2a, randomised, double-blind, vehicle-controlled study (NCT02001181), 69 adults with mild-to-moderate AD were randomised 1:1 to 2% tofacitinib or vehicle ointment twice daily. Percent change from baseline (CFB) in Eczema Area and Severity Index (EASI) score at Week 4 was the primary endpoint. Secondary efficacy endpoints included: percent CFB in Body Surface Area (BSA), CFB in EASI Clinical Signs Severity Sum Score, proportion of patients with Physician's Global Assessment (PGA) response; and CFB in patient-reported pruritus. Safety, local tolerability and pharmacokinetics were monitored. RESULTS: Mean percent CFB at Week 4 in EASI score was significantly greater (p&lt;0.001) for tofacitinib (-81.7%) vs vehicle (-29.9%). Tofacitinib-treated patients showed significant (p&lt;0.001) improvements vs vehicle across all pre-specified efficacy endpoints and pruritus at Week 4. Significant improvements in EASI, PGA and BSA were observed by Week 1 and pruritus by Day 2. Safety/local tolerability were generally similar between treatments, although more adverse events (AEs) were observed for vehicle vs tofacitinib. CONCLUSIONS: Tofacitinib ointment showed significantly greater efficacy vs vehicle across endpoints, with early onset of effect, and comparable safety/local tolerability to vehicle. JAK inhibition through topical delivery is potentially a promising therapeutic target for AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160716IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.14871</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27423107">PM:27423107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20160716-BissonnetteR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20160716-BissonnetteR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Bissonnette R</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.14871</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Poza,G.P.</style></author><author><style face="normal" font="Arial"> Sanchez Machin,I</style></author><author><style face="normal" font="Arial"> Matheu,V.</style></author><author><style face="normal" font="Arial"> Iraola,V.</style></author><author><style face="normal" font="Arial"> Gonzalez,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital del Torax, HUNS La Candelaria, 38320 Santa Cruz de Tenerife, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Role of Predatory Mites in Persistent Nonoccupational Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Can Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Can Respir J</style></full-title></periodical><pages end="" start="5782317">5782317-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Pyroglyphidae</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Mites can sensitize and induce atopic disease in predisposed individuals and are an important deteriorating factor in patients with allergic rhinitis, asthma, and atopic dermatitis. Although Pyroglyphidae mites have been extensively studied, very scarce reports are available on Cheyletidae spp. especially regarding human respiratory pathology. The main objective of the present study is to investigate the clinical role of this predator mite (Cheyletus eruditus) as a respiratory antigen in a selected sensitized human population. Fifty-two adult patients were recruited from the outpatient allergy clinic to assess their eligibility for the study. The thirty-seven subjects with persistent allergic rhinitis (PAR) who fulfilled the ARIA criteria had a positive IgE response confirmed by skin prick test (SPT) to C. eruditus. Only those individuals (37/47) with a positive SPT to C. eruditus showed a positive nasal provocation test (NPT), while 10 patients with nonallergic mild-to-moderate persistent rhinitis, control group, had a negative NPT with C. eruditus. The present paper describes a new role for the predator mite Cheyletus eruditus as a respiratory allergen in a selected subset of patients in a subtropical environment afflicted with persistent nonoccupational allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1916-7245 (Electronic)IS - 1198-2241 (Linking)LA - engPT - Journal ArticleSB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/5782317</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27445552">PM:27445552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Can Respir J\20160722-PozaGP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Can Respir J\20160722-PozaGP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Poza GP</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/5782317</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liao,H.C.</style></author><author><style face="normal" font="Arial"> Wu,S.Y.</style></author><author><style face="normal" font="Arial"> Ou,C.Y.</style></author><author><style face="normal" font="Arial"> Hsiao,J.R.</style></author><author><style face="normal" font="Arial"> Huang,J.S.</style></author><author><style face="normal" font="Arial"> Tsai,S.T.</style></author><author><style face="normal" font="Arial"> Huang,C.C.</style></author><author><style face="normal" font="Arial"> Wong,T.Y.</style></author><author><style face="normal" font="Arial"> Lee,W.T.</style></author><author><style face="normal" font="Arial"> Chen,K.C.</style></author><author><style face="normal" font="Arial"> Fang,S.Y.</style></author><author><style face="normal" font="Arial"> Wu,J.L.</style></author><author><style face="normal" font="Arial"> Huang,T.T.</style></author><author><style face="normal" font="Arial"> Wu,Y.H.</style></author><author><style face="normal" font="Arial"> Hsueh,W.T.</style></author><author><style face="normal" font="Arial"> Yen,C.J.</style></author><author><style face="normal" font="Arial"> Yang,M.W.</style></author><author><style face="normal" font="Arial"> Lin,F.C.</style></author><author><style face="normal" font="Arial"> Lai,Y.H.</style></author><author><style face="normal" font="Arial"> Chang,J.Y.</style></author><author><style face="normal" font="Arial"> Lin,C.L.</style></author><author><style face="normal" font="Arial"> Wang,Y.H.</style></author><author><style face="normal" font="Arial"> Weng,Y.L.</style></author><author><style face="normal" font="Arial"> Yang,H.C.</style></author><author><style face="normal" font="Arial"> Chen,Y.S.</style></author><author><style face="normal" font="Arial"> Chang,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, Tainan, 70456, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Allergy symptoms, serum total immunoglobulin E, and risk of head and neck cancer</style></title><secondary-title><style face="normal" font="Arial">Cancer Causes Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cancer Causes Control</style></full-title></periodical><pages end="1115" start="1105">1105-1115</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Carcinogens</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Cigarette smoke</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> effect modification</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Head and neck cancer</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2016">2016/7/21</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Allergy symptoms have been associated with a reduced head and neck cancer (HNC) risk, while elevated blood immunoglobulin E (IgE) levels have been associated with an increased HNC risk. According to the "prophylaxis hypothesis," allergic reaction is the body's way of expelling carcinogens. IgE level may be increased by exposure to environmental carcinogens, including alcohol and cigarette smoke. We hypothesized that individuals with elevated serum IgE without allergy symptoms (i.e., asymptomatic atopic) would have the highest HNC risk. METHODS: A case-control study of HNC (576 cases and 740 controls) was conducted to evaluate the association between allergy symptoms or serum total IgE and HNC risk and the effect modification of allergy symptoms on the association between serum total IgE and HNC risk. RESULTS: Elevated serum total IgE was associated with a significantly increased HNC risk [odds ratio (OR) 1.71, 95 % confidence interval (CI) 1.21-2.42]. Having allergy symptoms was associated with a significantly reduced HNC risk (OR 0.56, 95 % CI 0.43-0.73). Compared to subjects with normal serum total IgE and no allergy symptoms, asymptomatic atopic individuals had a significantly increased HNC risk (OR 2.12, 95 % CI 1.33-3.35). CONCLUSIONS: Our results provided further evidence to support the "prophylaxis hypothesis." Further investigations regarding the immune profiles of asymptomatic atopic individuals may provide additional clues for the biological mechanisms underlying the association between allergy symptoms, IgE, and HNC risk</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1573-7225 (Electronic)IS - 0957-5243 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10552-016-0788-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27443169">PM:27443169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cancer Causes Control\20160722-LiaoHC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cancer Causes Control\20160722-LiaoHC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Liao HC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10552-016-0788-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soler,Z.M.</style></author><author><style face="normal" font="Arial"> Kohli,P.</style></author><author><style face="normal" font="Arial"> Storck,K.A.</style></author><author><style face="normal" font="Arial"> Schlosser,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, 135 Rutledge Avenue, MSC 550, Charleston, SC 29425, USA</style></auth-address><titles><title><style face="normal" font="Arial">Olfactory Impairment in Chronic Rhinosinusitis Using Threshold, Discrimination, and Identification Scores</style></title><secondary-title><style face="normal" font="Arial">Chem Senses</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chem Senses</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> olfaction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2016">2016/7/28</year></dates><abstract><style face="normal" font="Arial">Differences in testing modalities and cut-points used to define olfactory dysfunction contribute to the wide variability in estimating the prevalence of olfactory dysfunction in chronic rhinosinusitis (CRS). The aim of this study is to report the prevalence of olfactory impairment using each component of the Sniffin' Sticks test (threshold, discrimination, identification, and total score) with age-adjusted and ideal cut-points from normative populations. Patients meeting diagnostic criteria for CRS were enrolled from rhinology clinics at a tertiary academic center. Olfaction was assessed using the Sniffin' Sticks test. The study population consisted of 110 patients. The prevalence of normosmia, hyposmia, and anosmia using total Sniffin' Sticks score was 41.8%, 20.0%, and 38.2% using age-appropriate cut-points and 20.9%, 40.9%, and 38.2% using ideal cut-points. Olfactory impairment estimates for each dimension mirrored these findings, with threshold yielding the highest values. Threshold, discrimination, and identification were also found to be significantly correlated to each other (P &lt; 0.001). In addition, computed tomography scores, asthma, allergy, and diabetes were found to be associated with olfactory dysfunction. In conclusion, the prevalence of olfactory dysfunction is dependent upon olfactory dimension and if age-adjusted cut-points are used. The method of olfactory testing should be chosen based upon specific clinical and research goals</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1464-3553 (Electronic)IS - 0379-864X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/chemse/bjw080</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27469973">PM:27469973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chem Senses\20160729-SolerZM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chem Senses\20160729-SolerZM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Soler ZM</style></custom2><misc3><style face="normal" font="Arial">10.1093/chemse/bjw080</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Svirshchevskaya,E.</style></author><author><style face="normal" font="Arial"> Fattakhova,G.</style></author><author><style face="normal" font="Arial"> Khlgatian,S.</style></author><author><style face="normal" font="Arial"> Chudakov,D.</style></author><author><style face="normal" font="Arial"> Kashirina,E.</style></author><author><style face="normal" font="Arial"> Ryazantsev,D.</style></author><author><style face="normal" font="Arial"> Kotsareva,O.</style></author><author><style face="normal" font="Arial"> Zavriev,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 16/10, Miklukho-Maklaya St., GSP-7, 117997 Moscow, Russian Federation.</style></auth-address><titles><title><style face="normal" font="Arial">Direct versus sequential immunoglobulin switch in allergy and antiviral responses</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="38" start="31">31-38</pages><volume><style face="normal" font="Arial">170</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE synthesis</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="25" Month="7" Year="2016">2016/7/25</year></dates><abstract><style face="normal" font="Arial">Allergy is characterized by IgE production to innocuous antigens. The question whether the switch to IgE synthesis occurs via direct or sequential pathways is still unresolved. The aim of this work was to analyze the distribution of immunoglobulins (Ig) to house dust mite D. farinae and A. alternata fungus in allergic children with primarily established diagnosis and compare it to Epstein-Barr antiviral (EBV) response in the same patients. In allergy patients the only significant difference was found in allergen specific IgE, likely mediated by a direct isotype switch, while antiviral response was dominated by EBV specific IgG and low level of concordant IgA and IgG4 production consistent with a minor sequential Ig switches. Taken collectively, we concluded that sequential isotype switch is likely to be a much rarer event than a direct one</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2016.07.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27471213">PM:27471213</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20160729-SvirshchevskayaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\20160729-SvirshchevskayaE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Svirshchevskaya E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2016.07.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paton,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Auckland, Auckland, New Zealand.</style></auth-address><titles><title><style face="normal" font="Arial">Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids</style></title><secondary-title><style face="normal" font="Arial">Drugs Today (Barc)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs Today (Barc)</style></full-title></periodical><pages end="329" start="323">323-329</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bioactive compounds</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">The starting point for this drug was the growing realization that eosinophils appeared to be associated with a severe form of asthma in which patients were subject to exacerbations of their condition that could not be adequately managed using inhaled and/or oral corticosteroids. Studies of the pathophysiology of eosinophils revealed that they produce many bioactive compounds that contribute to the pathophysiology of a number of diseases including asthma. Interleukin-5 (IL-5) in particular is an important factor in some forms of severe asthma. A rat antibody to IL-5 (39D10) was humanized producing the product now know as reslizumab. However, initial studies of this antibody in patients with asthma were unsuccessful. It was only when the importance of the eosinophilic asthma endotype was recognized that reslizumab was found to indeed reduce the severity and exacerbations of asthma in patients who were inadequately treated by inhaled and/ or oral corticosteroids. These studies have determined that reslizumab is a valuable drug for the management of such patients provided that they have an eosinophil count of > 400 cells/mcL. Because a very small percentage of patients receiving reslizumab may experience anaphylaxis, reslizumab must be only given in a facility with adequate facilities and by a health professional trained in the management of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1699-3993 (Print)IS - 1699-3993 (Linking)LA - engPT - Journal ArticleSB - IMCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1358/dot.2016.52.6.2510261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27458609">PM:27458609</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs Today (Barc)\2016-52-323-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs Today (Barc)\2016-52-323-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Paton DM</style></custom2><misc3><style face="normal" font="Arial">10.1358/dot.2016.52.6.2510261</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zuiker,R.G.</style></author><author><style face="normal" font="Arial"> Tribouley,C.</style></author><author><style face="normal" font="Arial"> Diamant,Z.</style></author><author><style face="normal" font="Arial"> Boot,J.D.</style></author><author><style face="normal" font="Arial"> Cohen,A.F.</style></author><author><style face="normal" font="Arial"> van Dyck,K.</style></author><author><style face="normal" font="Arial"> De Lepeleire,I.</style></author><author><style face="normal" font="Arial"> Rivas,V.M.</style></author><author><style face="normal" font="Arial"> Malkov,V.A.</style></author><author><style face="normal" font="Arial"> Burggraaf,J.</style></author><author><style face="normal" font="Arial"> Ruddy,M.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Human Drug Research, Leiden, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Sputum RNA signature in allergic asthmatics following allergen bronchoprovocation test</style></title><secondary-title><style face="normal" font="Arial">Eur Clin Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Clin Respir J</style></full-title></periodical><pages end="" start="31324">31324-</pages><volume><style face="normal" font="Arial">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug effects</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> RNA extraction</style></keyword><keyword><style face="normal" font="Arial"> single-blind</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Inhaled allergen challenge is a validated disease model of allergic asthma offering useful pharmacodynamic assessment of pharmacotherapeutic effects in a limited number of subjects. OBJECTIVES: To evaluate whether an RNA signature can be identified from induced sputum following an inhaled allergen challenge, whether a RNA signature could be modulated by limited doses of inhaled fluticasone, and whether these gene expression profiles would correlate with the clinical endpoints measured in this study. METHODS: Thirteen non-smoking, allergic subjects with mild-to-moderate asthma participated in a randomised, placebo-controlled, 2-period cross-over study following a single-blind placebo run-in period. Each period consisted of three consecutive days, separated by a wash-out period of at least 3 weeks. Subjects randomly received inhaled fluticasone ((FP) MDI; 500 mcg BIDx5 doses in total) or placebo. On day 2, house dust mite extract was inhaled and airway response was measured by FEV1 at predefined time points until 7 h post-allergen. Sputum was induced by NaCl 4.5%, processed and analysed at 24 h pre-allergen and 7 and 24 h post-allergen. RNA was isolated from eligible sputum cell pellets (&lt;80% squamous of 500 cells), amplified according to NuGEN technology, and profiled on Affymetrix arrays. Gene expression changes from baseline and fluticasone treatment effects were evaluated using a mixed effects ANCOVA model at 7 and at 24 h post-allergen challenge. RESULTS: Inhaled allergen-induced statistically significant gene expression changes in sputum, which were effectively blunted by fluticasone (adjusted p&lt;0.025). Forty-seven RNA signatures were selected from these responses for correlation analyses and further validation. This included Th2 mRNA levels for cytokines, chemokines, high-affinity IgE receptor FCER1A, histamine receptor HRH4, and enzymes and receptors in the arachidonic pathway. Individual messengers from the 47 RNA signatures correlated significantly with lung function and sputum eosinophil counts. CONCLUSION: Our RNA extraction and profiling protocols allowed reproducible assessments of inflammatory signatures in sputum including quantification of drug effects on this response in allergic asthmatics. This approach offers novel possibilities for the development of pharmacodynamic (PD) biomarkers in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160716IS - 2001-8525 (Electronic)IS - 2001-8525 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3402/ecrj.v3.31324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27421833">PM:27421833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Clin Respir J\2016-3-31324.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Clin Respir J\2016-3-31324.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Zuiker RG</style></custom2><misc3><style face="normal" font="Arial">10.3402/ecrj.v3.31324</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nader,M.A.</style></author><author><style face="normal" font="Arial"> Gameil,N.</style></author><author><style face="normal" font="Arial"> Abdelaziz,R.R.</style></author><author><style face="normal" font="Arial"> Zalata,K.R.</style></author><author><style face="normal" font="Arial"> Osman,A.</style></author><author><style face="normal" font="Arial"> Zedan,M.M.</style></author><author><style face="normal" font="Arial"> Abo-Elkheir,N.</style></author><author><style face="normal" font="Arial"> Elsiddig,A.A.</style></author><author><style face="normal" font="Arial"> Zedan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pharmacology &amp; Toxicology , College of Pharmacy, Taibah University , El-Madinah El-Munawarah , Saudi Arabia</style></auth-address><titles><title><style face="normal" font="Arial">Effect of tranilast in comparison with beclomethasone in chronic murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Lung Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Lung Res</style></full-title></periodical><pages end="306" start="296">296-306</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Beclomethasone</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Collagen content</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Transforming growth factor beta-1</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta1</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="22" Month="7" Year="2016">2016/7/22</year></dates><abstract><style face="normal" font="Arial">AIM OF THE STUDY: The current investigation was taken to scrutinize the action of tranilast on the airway remodeling in chronic asthma in mice. MATERIALS AND METHODS: Intraperitoneal injection of ovalbumin was applied to mice for sensitization and subsequent inhalation of 1% ovalbumin three times week for 10 weeks for challenge. Beclomethasone or tranilast were given daily for the 10 week challenge period. At the end of the study, lung weight index, total collagen content, bronchoalveolar lavage level of total and differential cell counts, interleukin-13, in addition to lung tissue nitrate/nitrite and transforming growth beta-1 were measured. Also, histological analysis was done. RESULTS: Asthmatic mice demonstrated apparent fibrotic changes. Significant airway fibrosis was demonstrated by hyperplasia of goblet cells and thickening of airway epithelium, increased content of lung collagen, lung and bronchoalveolar lavage of transforming growth factor beta-1 and interleukin-13 mutually accompanied by reduction in nitrate/nitrite generation. CONCLUSIONS: Beclomethasone influence on airway remodeling was mediated mainly via suppression of eosinophilic recruitment into the airways and reduction of interleukin-13 cytokine levels. Whereas, tranilast effects on airway remodeling was found to be mainly mediated via its inhibitory effect on transforming growth beta-1. Both beclomethasone and tranilast influence airway remodeling by different degrees and mechanisms</style></abstract><notes><style face="normal" font="Arial">DA - 20160724IS - 1521-0499 (Electronic)IS - 0190-2148 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Saudi Arabia -CO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1080/01902148.2016.1207727</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27450020">PM:27450020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Lung Res\20160724-NaderMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Lung Res\20160724-NaderMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160724, Nader MA</style></custom2><misc3><style face="normal" font="Arial">10.1080/01902148.2016.1207727</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deng,Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Geng,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Anti-allergic effect of Artemisia extract in rats</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="1134" start="1130">1130-1134</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Artemisinin</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular permeability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Artemisia apiacea (also known as Artemisia annua L) is a herb commonly used in traditional Chinese medicine. In the early 1970s, artemisinin was isolated and identified as the active antimalarial ingredient, and thereafter, A. apiacea and artemisinin have been studied extensively, such as anti-inflammation and antipyresis, antibacteria, antiparasitic and immunosuppression effects of A. apiacea extract. The present study investigated the extracts anti-allergic effect obtained from the dried flowering tips of A. apiacea in rats. A systemic anaphylactic reaction model was induced in rats using compound 48/80. Artemisia extract was administered 1 h prior to the injection of compound 48/80. Artemisia was extracted from dried flowering tips of A. deserti using 80% ethanol. Subsequently, the systemic anaphylactic shock, histamine release, scratching behavior and vascular permeability induced by compound 48/80 were evaluated. The administration of Artemisia extract at 200 and 400 mg/kg doses suppressed the systemic anaphylactic shock induced by compound 48/80 in a dose-dependent manner. Overall, the Artemisia extract was able to effectively decrease systemic anaphylactic shock, histamine release, scratching behavior and vascular permeability induced by compound 48/80 in a dose-dependent manner</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2016.3361</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27446332">PM:27446332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2016-12-1130-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2016-12-1130-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Deng Y</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2016.3361</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Walsh,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a School of Medicine &amp; Dentistry , University of Aberdeen , Scotland , UK</style></auth-address><titles><title><style face="normal" font="Arial">Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="149" start="143">143-149</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> refractory asthma</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Scotland</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The development of monoclonal antibody-based biologics targeted at inhibition of the Th2 cytokines IL-4, IL-5 and IL-13 represent potentially effective treatments for patients with the glucocorticoid refractory eosinophilic asthma phenotype. Areas covers: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level, requiring specifically targeted treatments to block the key pathways of the disease. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of reproducible and straightforward discriminatory biomarkers may aid identification of those patients most likely to benefit from treatment with these expensive interventions. This narrative review is based on English-language original articles in PubMed or Med-Line that reported significant clinical findings published in the last two years on the evidence demonstrating the effectiveness or otherwise of the targeting of IL-4, IL-5, or IL-13 in carefully selected patients with severe refractory asthma. Expert commentary: The use of a baseline peripheral blood eosinophilia as a simple reproducible biomarker to identify patients with particular sub-phenotypes of asthma to guide the effective use of biologic therapy represents a significant step forward</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2016.1216316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27459348">PM:27459348</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160726, Walsh GM</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2016.1216316</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khuda,S.E.</style></author><author><style face="normal" font="Arial"> Sharma,G.M.</style></author><author><style face="normal" font="Arial"> Gaines,D.</style></author><author><style face="normal" font="Arial"> Do,A.B.</style></author><author><style face="normal" font="Arial"> Pereira,M.</style></author><author><style face="normal" font="Arial"> Chang,M.</style></author><author><style face="normal" font="Arial"> Ferguson,M.</style></author><author><style face="normal" font="Arial"> Williams,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Center for Food Safety and Applied Nutrition , United States Food and Drug Administration (USFDA) , Laurel , MD , USA</style></auth-address><titles><title><style face="normal" font="Arial">Survey of undeclared soy allergen levels in the most frequently recalled food categories with or without precautionary labelling</style></title><secondary-title><style face="normal" font="Arial">Food Addit Contam Part A Chem Anal Control Expo Risk Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Addit Contam Part A Chem Anal Control Expo Risk Assess</style></full-title></periodical><pages end="1282" start="1274">1274-1282</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Bakery</style></keyword><keyword><style face="normal" font="Arial"> Bakery products</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eliciting dose</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> precautionary labelling</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> United States Food and Drug Administration</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="7" Year="2016">2016/7/29</year></dates><abstract><style face="normal" font="Arial">A comprehensive study was designed to determine the frequency and levels of soy allergen in packaged bakery and snack food products. A representative sample of products with no soy allergen disclosed on the label was analysed using two widely used enzyme-linked immunosorbent assay (ELISA) methods. Samples were chosen that either had no soy identified on the product label or which had a soy precautionary statement. Among 558 bakery and snack products, soy protein was detected in 17% of the products using the Neogen (NE) kit and 11% of the products using the Elisa Systems (ES) kit. The disagreement rates between kits were 8.8% for bakery products and 3.3% for snack products. Overall soy protein was detected at higher frequency in bakery products than in snack foods. Among 284 bakery samples, soy protein was detected in 25% of the samples with no precautionary statement and 19% of the samples which had a precautionary statement. Among 274 snack samples, soy protein was detected in 11% of the samples with no precautionary statement and 9% of the samples which had a precautionary statement. The sample repeatability was at an acceptable level (&lt; 9%) for each method and food commodity. The reproducibility between kits was 23% for bakery foods and 36% for snack foods. None of the bakery (21) and snack (6) products without precautionary labelling (measured level > 5 ppm) had a higher level of soy protein per serving compared with the eliciting dose10 (ED10) of 10.6 mg for soy allergic patients. But the level of soy protein per serving may be clinically relevant to a subpopulation of soy allergic patients if a more stringent eliciting dose is applied. These findings emphasise that suitable detection methodologies and references doses are crucial for labelling accuracy and the safety of soy allergic consumers</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1944-0057 (Electronic)IS - 1944-0057 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/19440049.2016.1207809</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470934">PM:27470934</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Addit Contam Part A Chem Anal Control Expo Risk Assess\20160729-KhudaSE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Addit Contam Part A Chem Anal Control Expo Risk Assess\20160729-KhudaSE.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Addit Contam Part A Chem Anal Control Expo Risk Assess\20160729-KhudaSE.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Addit Contam Part A Chem Anal Control Expo Risk Assess\20160729-KhudaSE.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20160729, Khuda SE</style></custom2><misc3><style face="normal" font="Arial">10.1080/19440049.2016.1207809</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klein,B.</style></author><author><style face="normal" font="Arial"> Mrowetz,H.</style></author><author><style face="normal" font="Arial"> Thalhamer,J.</style></author><author><style face="normal" font="Arial"> Scheiblhofer,S.</style></author><author><style face="normal" font="Arial"> Weiss,R.</style></author><author><style face="normal" font="Arial"> Aigner,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Molecular Regenerative Medicine, Paracelsus Medical UniversitySalzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Allergy Enhances Neurogenesis and Modulates Microglial Activation in the Hippocampus</style></title><secondary-title><style face="normal" font="Arial">Front Cell Neurosci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Front Cell Neurosci</style></abbr-1></periodical><pages end="" start="169">169-</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Bromodeoxyuridine</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Central Nervous System</style></keyword><keyword><style face="normal" font="Arial"> CNS</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> Phl p 5</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergies and their characteristic TH2-polarized inflammatory reactions affect a substantial part of the population. Since there is increasing evidence that the immune system modulates plasticity and function of the central nervous system (CNS), we investigated the effects of allergic lung inflammation on the hippocampus-a region of cellular plasticity in the adult brain. The focus of the present study was on microglia, the resident immune cells of the CNS, and on hippocampal neurogenesis, i.e., the generation of new neurons. C57BL/6 mice were sensitized with a clinically relevant allergen derived from timothy grass pollen (Phl p 5). As expected, allergic sensitization induced high serum levels of allergen-specific immunoglobulins (IgG1 and IgE) and of TH2 cytokines (IL-5 and IL-13). Surprisingly, fewer Iba1(+) microglia were found in the granular layer (GL) and subgranular zone (SGZ) of the hippocampal dentate gyrus and also the number of Iba1(+)MHCII(+) cells was lower, indicating a reduced microglial surveillance and activation in the hippocampus of allergic mice. Neurogenesis was analyzed by labeling of proliferating cells with bromodeoxyuridine (BrdU) and determining their fate 4 weeks later, and by quantitative analysis of young immature neurons, i.e., cells expressing doublecortin (DCX). The number of DCX(+) cells was clearly increased in the allergy animals. Moreover, there were more BrdU(+) cells present in the hippocampus of allergic mice, and these newly born cells had differentiated into neurons as indicated by a higher number of BrdU(+)NeuN(+) cells. In summary, allergy led to a reduced microglia presence and activity and to an elevated level of neurogenesis in the hippocampus. This effect was apparently specific to the hippocampus, as we did not observe these alterations in the subventricular zone (SVZ)/olfactory bulb (OB) system, also a region of high cellular plasticity and adult neurogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1662-5102 (Electronic)IS - 1662-5102 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3389/fncel.2016.00169</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27445696">PM:27445696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Cell Neurosci\2016-10-169.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Cell Neurosci\2016-10-169.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Klein B</style></custom2><misc3><style face="normal" font="Arial">10.3389/fncel.2016.00169</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khan,A.H.</style></author><author><style face="normal" font="Arial"> Sadroddiny,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Licensed monoclonal antibodies and associated challenges</style></title><secondary-title><style face="normal" font="Arial">Hum Antibodies</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Antibodies</style></full-title></periodical><pages end="72" start="63">63-72</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="23" Month="12" Year="2015">2015/12/23</year></dates><abstract><style face="normal" font="Arial">Monoclonal antibodies (mAbs) are the leading class of targeted therapeutics and remarkably effective in addressing autoimmune diseases, inflammations, infections, and various types of cancer. Several mAbs approved by US food and drug administration (FDA), are available on the market and a number are pending for approval. Luckily, FDA approved mAbs have played a pivotal role in the treatment and prevention of lethal diseases. However, claiming that licensed mAbs are 100% safe is still debatable, because infections, malignancies, anaphylactoid, and anaphylactic reactions are the more frequently associated adverse events. To evaluate benefit to risk ratio of mAbs, it is important for the clinical research staff or physicians to monitor and follow-up the patients who are receiving mAbs dozes. It is recommended that patients, physicians, biopharmaceutical companies, and researchers should keep in touch to highlight and resolve antibody-based adverse events. In this review we underscore the associated challenges of mAbs, approved by FDA from 2007-2014</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1875-869X (Electronic)IS - 1093-2607 (Linking)LA - engPT - Journal ArticleSB - IMCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.3233/HAB-150286</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27472864">PM:27472864</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Antibodies\2015-23-63-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Antibodies\2015-23-63-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Khan AH</style></custom2><misc3><style face="normal" font="Arial">10.3233/HAB-150286</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Neiser,S.</style></author><author><style face="normal" font="Arial"> Koskenkorva,T.S.</style></author><author><style face="normal" font="Arial"> Schwarz,K.</style></author><author><style face="normal" font="Arial"> Wilhelm,M.</style></author><author><style face="normal" font="Arial"> Burckhardt,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chemical and Preclinical Research and Development, Vifor International Ltd., 9014 St. Gallen, Switzerland.</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA)</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="1185">1185-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dextran</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Ferumoxytol</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> Immunodiffusion</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Sucrose</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Intravenous iron preparations are typically classified as non-dextran-based or dextran/dextran-based complexes. The carbohydrate shell for each of these preparations is unique and is key in determining the various physicochemical properties, the metabolic pathway, and the immunogenicity of the iron-carbohydrate complex. As intravenous dextran can cause severe, antibody-mediated dextran-induced anaphylactic reactions (DIAR), the purpose of this study was to explore the potential of various intravenous iron preparations, non-dextran-based or dextran/dextran-based, to induce these reactions. An IgG-isotype mouse monoclonal anti-dextran antibody (5E7H3) and an enzyme-linked immunosorbent assay (ELISA) were developed to investigate the dextran antigenicity of low molecular weight iron dextran, ferumoxytol, iron isomaltoside 1000, ferric gluconate, iron sucrose and ferric carboxymaltose, as well as isomaltoside 1000, the isolated carbohydrate component of iron isomaltoside 1000. Low molecular weight iron dextran, as well as dextran-based ferumoxytol and iron isomaltoside 1000, reacted with 5E7H3, whereas ferric carboxymaltose, iron sucrose, sodium ferric gluconate, and isolated isomaltoside 1000 did not. Consistent results were obtained with reverse single radial immunodiffusion assay. The results strongly support the hypothesis that, while the carbohydrate alone (isomaltoside 1000) does not form immune complexes with anti-dextran antibodies, iron isomaltoside 1000 complex reacts with anti-dextran antibodies by forming multivalent immune complexes. Moreover, non-dextran based preparations, such as iron sucrose and ferric carboxymaltose, do not react with anti-dextran antibodies. This assay allows to assess the theoretical possibility of a substance to induce antibody-mediated DIARs. Nevertheless, as this is only one possible mechanism that may cause a hypersensitivity reaction, a broader set of assays will be required to get an understanding of the mechanisms that may lead to intravenous iron-induced hypersensitivity reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleSB - IMCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms17071185</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27455240">PM:27455240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2016-17-1185.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2016-17-1185.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Neiser S</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms17071185</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masek,J.</style></author><author><style face="normal" font="Arial"> Lubasova,D.</style></author><author><style face="normal" font="Arial"> Lukac,R.</style></author><author><style face="normal" font="Arial"> Turanek-Knotigova,P.</style></author><author><style face="normal" font="Arial"> Kulich,P.</style></author><author><style face="normal" font="Arial"> Plockova,J.</style></author><author><style face="normal" font="Arial"> Maskova,E.</style></author><author><style face="normal" font="Arial"> Prochazka,L.</style></author><author><style face="normal" font="Arial"> Koudelka,S.</style></author><author><style face="normal" font="Arial"> Sasithorn,N.</style></author><author><style face="normal" font="Arial"> Gombos,J.</style></author><author><style face="normal" font="Arial"> Bartheldyova,E.</style></author><author><style face="normal" font="Arial"> Hubatka,F.</style></author><author><style face="normal" font="Arial"> Raska,M.</style></author><author><style face="normal" font="Arial"> Miller,A.D.</style></author><author><style face="normal" font="Arial"> Turanek,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.</style></auth-address><titles><title><style face="normal" font="Arial">Multi-layered nanofibrous mucoadhesive films for buccal and sublingual administration of drug-delivery and vaccination nanoparticles - important step towards effective mucosal vaccines</style></title><secondary-title><style face="normal" font="Arial">J Control Release</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Control Release</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adsorption</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dendrimers</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug delivery</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> liposome</style></keyword><keyword><style face="normal" font="Arial"> Liposomes</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal vaccines</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral mucosa</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual administration</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> virus-like particle</style></keyword><keyword><style face="normal" font="Arial"> Virus-like particles</style></keyword><keyword><style face="normal" font="Arial"> viruslike particles</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="7" Year="2016">2016/7/25</year></dates><abstract><style face="normal" font="Arial">Nanofibre-based mucoadhesive films were invented for oromucosal administration of nanocarriers used for delivery of drugs and vaccines. The mucoadhesive film consists of an electrospun nanofibrous reservoir layer, a mucoadhesive film layer and a protective backing layer. The mucoadhesive layer is responsible for tight adhesion of the whole system to the oral mucosa after application. The electrospun nanofibrous reservoir layer is intended to act as a reservoir for polymeric and lipid-based nanoparticles, liposomes, virosomes, virus-like particles, dendrimers and the like, plus macromolecular drugs, antigens and/or allergens. The extremely large surface area of nanofibrous reservoir layers allows high levels of nanoparticle loading. Nanoparticles can either be reversibly adsorbed to the surface of nanofibres or they can be deposited in the pores between the nanofibres. After mucosal application, nanofibrous reservoir layers are intended to promote prolonged release of nanoparticles into the submucosal tissue. Reversible adsorption of model nanoparticles as well as sufficient mucoadhesive properties were demonstrated. This novel system appears appropriate for the use in oral mucosa, especially for sublingual and buccal tissues. To prove this concept, trans-/intramucosal and lymph-node delivery of PLGA-PEG nanoparticles was demonstrated in a porcine model. This system can mainly be used for sublingual immunization and the development of "printed vaccine technology"</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1873-4995 (Electronic)IS - 0168-3659 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Czech Republic -CO - Switzerland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jconrel.2016.07.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27469472">PM:27469472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Control Release\20160729-MasekJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Control Release\20160729-MasekJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Masek J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jconrel.2016.07.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gandini,S.</style></author><author><style face="normal" font="Arial"> Stanganelli,I.</style></author><author><style face="normal" font="Arial"> Palli,D.</style></author><author><style face="normal" font="Arial"> De Giorgi,V.</style></author><author><style face="normal" font="Arial"> Masala,G.</style></author><author><style face="normal" font="Arial"> Caini,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis, naevi count and skin cancer risk: A meta-analysis</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Melanoma</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Sunlight</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="7" Year="2016">2016/7/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The risk of skin malignancy among atopic dermatitis (AD) patients is not well established. OBJECTIVE: We reviewed the epidemiological evidence on the association between AD, naevi count, and the risk of cutaneous melanoma and keratinocyte skin cancer (KSC). METHODS: We included all studies that compared the naevi count and the risk of skin cancer (melanoma and/or KSC) between AD patients and unaffected individuals. We calculated summary relative risks (SRRs) and 95% confidence intervals (CI) through random effects models; explored correlates of between-studies heterogeneity using sub-group and sensitivity analysis; and assessed publication bias using a funnel-plot-based approach. RESULTS: The number of common naevi larger >/=2mm on the whole body was consistently lower among AD patients vs. unaffected individuals when measured by trained health professionals. The risk of melanoma was not increased among AD patients (SRR=0.77, 95%CI 0.44-1.35, I2=85%). We found a significantly increased risk of basal cell cancer (BCC) (SRR=1.34, 95%CI 1.03-1.75, I2=24.0%) but not for squamous cell cancer (SRR=1.91, 95% CI 0.74-4.91, I2=0.0%); however, only a few papers adjusted for phenotypic characteristics and/or sunlight exposure. We found no evidence of publication bias. CONCLUSIONS: AD patients may be at increased BCC risk; however, methodological limitations prevented from drawing definitive conclusions. Despite the lack of strong scientific evidence, AD patients should avoid excessive sun exposure, regularly perform skin self examination, and consult a doctor in case of a suspicious skin lesion</style></abstract><notes><style face="normal" font="Arial">DA - 20160727IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2016.07.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27461758">PM:27461758</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20160727-GandiniS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20160727-GandiniS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160727, Gandini S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2016.07.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jain,S.V.</style></author><author><style face="normal" font="Arial"> Mullins,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Cold urticaria: a 20-year follow-up study</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Age of Onset</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Australian Capital Territory</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> cold urticaria</style></keyword><keyword><style face="normal" font="Arial"> community-based</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Initial assessment</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="7" Year="2016">2016/7/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic cold urticaria results in significant morbidity, yet information on its natural history is limited. OBJECTIVE: We examined the natural history of chronic cold urticaria and its impact on quality of life. METHODS: We analysed the characteristics of patients diagnosed with cold urticaria at a community-based specialist allergy practice in the Australian Capital Territory (ACT) between 1995 and 2015. Follow-up data were obtained using a mailed questionnaire. Possible predictive factors of disease severity and symptom duration were evaluated. RESULTS: A total of 99 patients were assessed with a median age of 42 (range 5-81 years); 63% were female and the median age of onset of symptoms was 22 years. Of 41 questionnaire responders (14 +/- 10.9 years follow-up; median 12 years), 5- and 10-year resolution rates were 17.9% +/- 6.2% and 24.5% +/- 7.2%, respectively. Whereas 22% reported resolution and 23% described improvement, the remaining 55% reported stable or worsening disease. Most individuals relied on lifestyle modification to ameliorate symptoms rather than medication. Risk factors for persistent disease were intercurrent atopic disease (P = 0.025) and those with longer duration of symptoms at the time of initial assessment (P &lt; 0.001). Secondary causes of cold urticaria were identified in only two patients, both with B-cell malignancy. CONCLUSION: In a subset of patients, cold urticaria has low rates of spontaneous resolution and results in lifestyle changes and impaired quality of life</style></abstract><notes><style face="normal" font="Arial">DA - 20160716IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.13841</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27422852">PM:27422852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160716-JainSV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160716-JainSV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Jain SV</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.13841</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>80998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ather,J.L.</style></author><author><style face="normal" font="Arial"> Burgess,E.J.</style></author><author><style face="normal" font="Arial"> Hoyt,L.R.</style></author><author><style face="normal" font="Arial"> Randall,M.J.</style></author><author><style face="normal" font="Arial"> Mandal,M.K.</style></author><author><style face="normal" font="Arial"> Matthews,D.E.</style></author><author><style face="normal" font="Arial"> Boyson,J.E.</style></author><author><style face="normal" font="Arial"> Poynter,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Vermont Lung Center, Division of Pulmonary Disease and Critical Care, Department of Medicine, University of Vermont, Burlington, VT 05405</style></auth-address><titles><title><style face="normal" font="Arial">Uricase Inhibits Nitrogen Dioxide-Promoted Allergic Sensitization to Inhaled Ovalbumin Independent of Uric Acid Catabolism</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="1732" start="1720">1720-1732</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allopurinol</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> Human serum albumin</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deviation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Uric Acid</style></keyword><keyword><style face="normal" font="Arial"> Vermont</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">Nitrogen dioxide (NO2) is an environmental air pollutant and endogenously generated oxidant that contributes to the exacerbation of respiratory disease and can function as an adjuvant to allergically sensitize to an innocuous inhaled Ag. Because uric acid has been implicated as a mediator of adjuvant activity, we sought to determine whether uric acid was elevated and participated in a mouse model of NO2-promoted allergic sensitization. We found that uric acid was increased in the airways of mice exposed to NO2 and that administration of uricase inhibited the development of OVA-driven allergic airway disease subsequent to OVA challenge, as well as the generation of OVA-specific Abs. However, uricase was itself immunogenic, inducing a uricase-specific adaptive immune response that occurred even when the enzymatic activity of uricase had been inactivated. Inhibition of the OVA-specific response was not due to the capacity of uricase to inhibit the early steps of OVA uptake or processing and presentation by dendritic cells, but occurred at a later step that blocked OVA-specific CD4+ T cell proliferation and cytokine production. Although blocking uric acid formation by allopurinol did not affect outcomes, administration of ultra-clean human serum albumin at protein concentrations equivalent to that of uricase inhibited NO2-promoted allergic airway disease. These results indicate that, although uric acid levels are elevated in the airways of NO2-exposed mice, the powerful inhibitory effect of uricase administration on allergic sensitization is mediated more through Ag-specific immune deviation than via suppression of allergic sensitization, a mechanism to be considered in the interpretation of results from other experimental systems</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1600336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27465529">PM:27465529</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20160728-AtherJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20160728-AtherJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, Ather JL</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1600336</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kanchan,T.</style></author><author><style face="normal" font="Arial"> Atreya,A.</style></author><author><style face="normal" font="Arial"> Shekhawat,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Jodhpur, India</style></auth-address><titles><title><style face="normal" font="Arial">Fatal anaphylaxis from hymenoptera stings</style></title><secondary-title><style face="normal" font="Arial">Med Leg J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Med Leg J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Forensic Medicine</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Nepal</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword></keywords><dates><year Day="26" Month="7" Year="2016">2016/7/26</year></dates><abstract><style face="normal" font="Arial">Venomous insect stings are a cause of morbidity and mortality worldwide. The sting reactions are unpredictable and vary among individuals. A case of fatal insect sting in an elderly female is presented to discuss the associated challenges during necropsy</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 2042-1834 (Electronic)IS - 0025-8172 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Nepal -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1177/0025817216661092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27465313">PM:27465313</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Leg J\20160728-KanchanT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Leg J\20160728-KanchanT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, Kanchan T</style></custom2><misc3><style face="normal" font="Arial">10.1177/0025817216661092</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bae,M.J.</style></author><author><style face="normal" font="Arial"> See,H.J.</style></author><author><style face="normal" font="Arial"> Choi,G.</style></author><author><style face="normal" font="Arial"> Kang,C.Y.</style></author><author><style face="normal" font="Arial"> Shon,D.H.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institutes of Entrepreneurial BioConvergence, Seoul National University, Seoul 151-742, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Regulatory T Cell Induced by Poria cocos Bark Exert Therapeutic Effects in Murine Models of Atopic Dermatitis and Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mediators Inflamm</style></full-title></periodical><pages end="" start="3472608">3472608-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cocos</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> herbal medicines</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The prevalence of allergic disorders including atopic dermatitis (AD) and food allergy (FA) has increased dramatically in pediatric populations, but there is no effective drug available for their management. Therefore, trials are required for the development of safe therapeutic agents such as herbal medicines. We determined whether orally administered Poria cocos bark (PCB) extract could exert immunosuppressive effects on allergic and inflammatory symptoms of AD and FA. For both AD, which was induced using house dust mite extract, and FA, which was induced by exposure to ovalbumin, model mice were orally treated with PCB extract for 62 days and 18 days, respectively. We also investigated the inductive effect of PCB extract on the generation and maintenance of Foxp3(+)CD4(+) regulatory T cells (Tregs). The symptoms of AD and FA were ameliorated by the administration of PCB extract. Furthermore, PCB extract inhibited the Th2-related cytokines and increased the population of Foxp3(+)CD4(+) Tregs in both AD and FA models. In ex vivo experiments, PCB extract promoted the functional differentiation of Foxp3(+)CD4(+) Tregs, which is dependent on aryl hydrocarbon receptor activation. Thus, PCB extract has potential as an oral immune suppressor for the treatment of AD and FA through the generation of Tregs</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/3472608</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27445434">PM:27445434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mediators Inflamm\2016-2016-3472608.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mediators Inflamm\2016-2016-3472608.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Bae MJ</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/3472608</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Landgraf-Rauf,K.</style></author><author><style face="normal" font="Arial"> Anselm,B.</style></author><author><style face="normal" font="Arial"> Schaub,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary and Allergy, Dr. von Hauner Children's Hospital, LMU, Lindwurmstrasse 4, 80337, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">The puzzle of immune phenotypes of childhood asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Cell Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Mol Cell Pediatr</style></abbr-1></periodical><pages end="" start="27">27-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic and non-allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental influence</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> new biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Asthma represents the most common chronic childhood disease worldwide. Whereas preschool children present with wheezing triggered by different factors (multitrigger and viral wheeze), clinical asthma manifestation in school children has previously been classified as allergic and non-allergic asthma. For both, the underlying immunological mechanisms are not yet understood in depth in children. Treatment is still prescribed regardless of underlying mechanisms, and children are not always treated successfully. This review summarizes recent key findings on the complex mechanisms of the development and manifestation of childhood asthma. Whereas traditional classification of childhood asthma is primarily based on clinical symptoms like wheezing and atopy, novel approaches to specify asthma phenotypes are under way and face challenges such as including the stability of phenotypes over time and transition into adulthood. Epidemiological studies enclose more information on the patient's disease history and environmental influences. Latest studies define endotypes based on molecular and cellular mechanisms, for example defining risk and protective single nucleotide polymorphisms (SNPs) and new immune phenotypes, showing promising results. Also, regulatory T cells and recently discovered T helper cell subtypes such as Th9 and Th17 cells were shown to be important for the development of asthma. Innate lymphoid cells (ILC) could play a critical role in asthma patients as they produce different cytokines associated with asthma. Epigenetic findings showed different acetylation and methylation patterns for children with allergic and non-allergic asthma. On a posttranscriptional level, miRNAs are regulating factors identified to differ between asthma patients and healthy controls and also indicate differences within asthma phenotypes. Metabolomics is another exciting chapter important for endotyping asthmatic children. Despite the development of new biomarkers and the discovery of new immunological molecules, the complex puzzle of childhood asthma is still far from being completed. Addressing the current challenges of distinct clinical asthma and wheeze phenotypes, including their stability and underlying endotypes, involves addressing the interplay of innate and adaptive immune regulatory mechanisms in large, interdisciplinary cohorts</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 2194-7791 (Electronic)IS - 2194-7791 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40348-016-0057-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27468754">PM:27468754</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Cell Pediatr\2016-3-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Cell Pediatr\2016-3-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Landgraf-Rauf K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40348-016-0057-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ravida,A.</style></author><author><style face="normal" font="Arial"> Cwiklinski,K.</style></author><author><style face="normal" font="Arial"> Aldridge,A.M.</style></author><author><style face="normal" font="Arial"> Clarke,P.</style></author><author><style face="normal" font="Arial"> Thompson,R.</style></author><author><style face="normal" font="Arial"> Gerlach,J.Q.</style></author><author><style face="normal" font="Arial"> Kilcoyne,M.</style></author><author><style face="normal" font="Arial"> Hokke,C.H.</style></author><author><style face="normal" font="Arial"> Dalton,J.P.</style></author><author><style face="normal" font="Arial"> O'Neill,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dublin City University, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Fasciola hepatica surface tegument: glycoproteins at the interface of parasite and host</style></title><secondary-title><style face="normal" font="Arial">Mol Cell Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Cell Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enolase</style></keyword><keyword><style face="normal" font="Arial"> Fasciola</style></keyword><keyword><style face="normal" font="Arial"> Fasciola hepatica</style></keyword><keyword><style face="normal" font="Arial"> Glycoconjugates</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Host-Parasite Interactions</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectin microarray</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Motifs</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> oligomannose</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Paramyosin</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Ruminants</style></keyword><keyword><style face="normal" font="Arial"> Spine</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> trematode</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">Fasciola hepatica, commonly known as liver fluke, is a trematode which causes Fasciolosis in ruminants and humans. The outer tegumental coat of F. hepatica (FhTeg) is a complex metabolically active biological matrix that is continually exposed to the host immune system and therefore makes a good vaccine target. F. hepatica tegumental coat is highly glycosylated and helminth-derived immunogenic oligosaccharide motifs and glycoproteins are currently being investigated as novel vaccine candidates. This report presents the first systematic characterisation of FhTeg glycosylation using lectin microarrays to characterise carbohydrates motifs present, and lectin histochemistry to localize these on the F. hepatica tegument. We discovered that FhTeg glycoproteins are predominantly oligomannose oligosaccharides that are expressed on the spines, suckers and tegumental coat of F. hepatica and lectin blot analysis confirmed the abundance of N- glycosylated proteins. While some oligosaccharides are widely distributed on the fluke surface other subsets are restricted to distinct anatomical regions. We selectively enriched for FhTeg mannosylated glycoprotein subsets using lectin affinity chromatography and identified 369 proteins by mass spectrometric analysis. Among these proteins are a number of potential vaccine candidates with known immune modulatory properties including proteases, protease inhibitors, paramyosin, Venom Allergen-like II, Enolase and two proteins, nardilysin and TRIL, that have not been previously associated with F. hepatica Furthermore, we provide a comprehensive insight regarding the putative glycosylation of FhTeg components which could highlight the importance of further studies examining glycoconjugates in host-parasite interactions in the context of F. hepatica infection and the development of an effective vaccine</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 1535-9484 (Electronic)IS - 1535-9476 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Ireland -CO - United Kingdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1074/mcp.M116.059774</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27466253">PM:27466253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Cell Proteomics\20160728-RavidaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Cell Proteomics\20160728-RavidaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, Ravida A</style></custom2><misc3><style face="normal" font="Arial">10.1074/mcp.M116.059774</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="" start="398">398-</pages><volume><style face="normal" font="Arial">375</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> peanut consumption</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2016">2016/7/28</year></dates><abstract><style face="normal" font="Arial">Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy Original Article, N Engl J Med 2015;372:803-813. In the legend for Figure 3 (page 810), the final sentence should have begun, "The log10 of the ratio of peanut-specific IgG4:IgE was calculated after the peanut-specific IgG4 levels were converted from micrograms per liter," rather than ". . . from milligrams per liter," and should have ended, "with the use of the formula IgG4 / (IgE x 2.4)," rather than "with the use of the formula (IgG4 x 1000) / (IgE x 2.4)." In the bottom graph in Figure 3B, the values on the y axis were incorrect. The article is correct at NEJM.org</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMx150044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27464222">PM:27464222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2016-375-398.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2016-375-398.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMx150044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wulaningsih,W.</style></author><author><style face="normal" font="Arial"> Holmberg,L.</style></author><author><style face="normal" font="Arial"> Garmo,H.</style></author><author><style face="normal" font="Arial"> Karagiannis,S.N.</style></author><author><style face="normal" font="Arial"> Ahlstedt,S.</style></author><author><style face="normal" font="Arial"> Malmstrom,H.</style></author><author><style face="normal" font="Arial"> Lambe,M.</style></author><author><style face="normal" font="Arial"> Hammar,N.</style></author><author><style face="normal" font="Arial"> Walldius,G.</style></author><author><style face="normal" font="Arial"> Jungner,I.</style></author><author><style face="normal" font="Arial"> Ng,T.</style></author><author><style face="normal" font="Arial"> Van Hemelrijck,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cancer Epidemiology Group, Division of Cancer Studies, King's College London, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival</style></title><secondary-title><style face="normal" font="Arial">Oncoimmunology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncoimmunology</style></full-title></periodical><pages end="" start="e1154250">e1154250-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Melanoma</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Prior findings linking allergy and cancer have been inconsistent, which may be driven by diverse assessment methods. We used serum specific immunoglobulin E (IgE) against common inhalant allergens that was assessed prior to cancer diagnosis in studying this association. We selected 8,727 Swedish men and women who had measurements of serum allergen-specific IgE and total IgE between 1992 and 1996. Multivariable Cox regression using age as a timescale was performed to assess the associations of IgE sensitization, defined by any levels of serum specific IgE >/=35 kU/L, with risk of overall and specific cancers. A test for trend was performed by assigning scores derived from allergen-specific IgE levels at baseline as an ordinal scale. Kaplan-Meier curves and log-rank test were used to assess cancer survival by IgE sensitization status. During a mean follow-up of 16 year, 689 persons were diagnosed with cancer. We found an inverse association between IgE sensitization and cancer risk, with a hazard ratio (HR) of 0.83 and 95% confidence intervals (CI) of 0.70-0.99. A similar trend was seen with specific IgE scores overall (Ptrend = 0.007) and in women (Ptrend = 0.01). Although IgE sensitization was not associated with risk of common site-specific cancers, serum specific IgE scores were inversely associated with melanoma risk in men and women combined, and with risk of female breast and gynecological cancers combined. No association with survival was observed. The association between circulating IgE levels and incident cancer may point toward a role of T-helper 2 (TH2)-biased response in development of some cancers</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 2162-4011 (Print)IS - 2162-4011 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1080/2162402X.2016.1154250</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27471625">PM:27471625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncoimmunology\2016-5-e1154250.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncoimmunology\2016-5-e1154250.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Wulaningsih W</style></custom2><misc3><style face="normal" font="Arial">10.1080/2162402X.2016.1154250</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carballeda-Sangiao,N.</style></author><author><style face="normal" font="Arial"> Rodriguez-Mahillo,A.I.</style></author><author><style face="normal" font="Arial"> Careche,M.</style></author><author><style face="normal" font="Arial"> Navas,A.</style></author><author><style face="normal" font="Arial"> Moneo,I.</style></author><author><style face="normal" font="Arial"> Gonzalez-Munoz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, University Hospital La Paz Institute for Health Research, (IdiPaz), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Changes over Time in IgE Sensitization to Allergens of the Fish Parasite Anisakis spp</style></title><secondary-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></full-title></periodical><pages end="" start="e0004864">e0004864-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Aquaculture</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fisheries</style></keyword><keyword><style face="normal" font="Arial"> Fishery products</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sensitization to Anisakis spp. can produce allergic reactions after eating raw or undercooked parasitized fish. Specific IgE is detected long after the onset of symptoms, but the changes in specific IgE levels over a long follow-up period are unknown; furthermore, the influence of Anisakis spp. allergen exposure through consumption of fishery products is also unknown. OBJECTIVE: To analyse the changes in IgE sensitization to Anisakis spp. allergens over several years of follow-up and the influence of the consumption of fishery products in IgE sensitization. METHODS: Total IgE, Anisakis spp.-specific IgE, anti-Ani s 1 and anti-Ani s 4 IgE were repeatedly measured over a median follow-up duration of 49 months in 17 sensitized patients. RESULTS: Anisakis spp.-specific IgE was detected in 16/17 patients throughout the follow-up period. The comparison between baseline and last visit measurements showed significant decreases in both total IgE and specific IgE. The specific IgE values had an exponential or polynomial decay trend in 13/17 patients. In 4/17 patients, an increase in specific IgE level with the introduction of fish to the diet was observed. Three patients reported symptoms after eating aquaculture or previously frozen fish, and in two of those patients, symptom presentation was coincident with an increase in specific IgE level. CONCLUSIONS: IgE sensitization to Anisakis spp. allergens lasts for many years since specific IgE was detectable in some patients after more than 8 years from the allergic episode. Specific IgE monitoring showed that specific IgE titres increase in some allergic patients and that allergen contamination of fishery products can account for the observed increase in Anisakis spp.-specific IgE level. CLINICAL RELEVANCE: Following sensitization to Anisakis spp. allergens, the absence of additional exposure to those allergens does not result in the loss of IgE sensitization. Exposure to Anisakis spp. allergens in fishery products can increase the specific IgE level in some sensitized patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160724IS - 1935-2735 (Electronic)IS - 1935-2727 (Linking)LA - engPT - Journal ArticleSB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pntd.0004864</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27448190">PM:27448190</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2016-10-e0004864.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2016-10-e0004864.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160724, Carballeda-Sangiao N</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pntd.0004864</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baird,F.J.</style></author><author><style face="normal" font="Arial"> Su,X.</style></author><author><style face="normal" font="Arial"> Aibinu,I.</style></author><author><style face="normal" font="Arial"> Nolan,M.J.</style></author><author><style face="normal" font="Arial"> Sugiyama,H.</style></author><author><style face="normal" font="Arial"> Otranto,D.</style></author><author><style face="normal" font="Arial"> Lopata,A.L.</style></author><author><style face="normal" font="Arial"> Cantacessi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Biodiscovery &amp; Molecular Development of Therapeutics, James Cook University, Townsville, Australia</style></auth-address><titles><title><style face="normal" font="Arial">The Anisakis Transcriptome Provides a Resource for Fundamental and Applied Studies on Allergy-Causing Parasites</style></title><secondary-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></full-title></periodical><pages end="" start="e0004845">e0004845-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> cDNA library</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Cyclophilin</style></keyword><keyword><style face="normal" font="Arial"> Cyclophilins</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Immunogenic properties</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Motifs</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> ontology</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food-borne nematodes of the genus Anisakis are responsible for a wide range of illnesses (= anisakiasis), from self-limiting gastrointestinal forms to severe systemic allergic reactions, which are often misdiagnosed and under-reported. In order to enhance and refine current diagnostic tools for anisakiasis, knowledge of the whole spectrum of parasite molecules transcribed and expressed by this parasite, including those acting as potential allergens, is necessary. METHODOLOGY/PRINCIPAL FINDINGS: In this study, we employ high-throughput (Illumina) sequencing and bioinformatics to characterise the transcriptomes of two Anisakis species, A. simplex and A. pegreffii, and utilize this resource to compile lists of potential allergens from these parasites. A total of ~65,000,000 reads were generated from cDNA libraries for each species, and assembled into ~34,000 transcripts (= Unigenes); ~18,000 peptides were predicted from each cDNA library and classified based on homology searches, protein motifs and gene ontology and biological pathway mapping. Using comparative analyses with sequence data available in public databases, 36 (A. simplex) and 29 (A. pegreffii) putative allergens were identified, including sequences encoding 'novel' Anisakis allergenic proteins (i.e. cyclophilins and ABA-1 domain containing proteins). CONCLUSIONS/SIGNIFICANCE: This study represents a first step towards providing the research community with a curated dataset to use as a molecular resource for future investigations of the biology of Anisakis, including molecules putatively acting as allergens, using functional genomics, proteomics and immunological tools. Ultimately, an improved knowledge of the biological functions of these molecules in the parasite, as well as of their immunogenic properties, will assist the development of comprehensive, reliable and robust diagnostic tools</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1935-2735 (Electronic)IS - 1935-2727 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -CO - United Kingdom -CO - Japan -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pntd.0004845</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27472517">PM:27472517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2016-10-e0004845.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2016-10-e0004845.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2016-10-e0004845.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2016-10-e0004845.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20160729, Baird FJ</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pntd.0004845</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doenhoff,M.J.</style></author><author><style face="normal" font="Arial"> El-Faham,M.</style></author><author><style face="normal" font="Arial"> Liddell,S.</style></author><author><style face="normal" font="Arial"> Fuller,H.R.</style></author><author><style face="normal" font="Arial"> Stanley,R.G.</style></author><author><style face="normal" font="Arial"> Schramm,G.</style></author><author><style face="normal" font="Arial"> Igetei,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Life Sciences, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Cross-Reactivity between Schistosoma mansoni Antigens and the Latex Allergen Hev b 7: Putative Implication of Cross-Reactive Carbohydrate Determinants (CCDs)</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0159542">e0159542-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid Binding protein</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hev b 7</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex-fruit syndrome</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Nigeria</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma mansoni</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">IgG antibodies produced by rabbits immunized against S. mansoni antigens cross-reacted with aqueous soluble constituents of a variety of allergens. The antibody cross-reactivity was largely sensitive to degradation by treatment of the target antigens with sodium meta-periodate, suggesting the cross-reactivity was due to carbohydrate determinants that were common to both the schistosome and the allergens (CCDs). The reaction between the rabbit antibodies and a 43 kDa molecule in a rubber latex extract was analysed further: tandem mass spectrometry identified the latex molecule as allergen Hev b 7. Rabbit anti-schistosome IgG antibodies purified by acid-elution from solid-phase latex Hev b 7 reacted with the S. mansoni egg antigens IPSE/alpha-1 and kappa-5 and cercarial antigens SPO-1 and a fatty acid-binding protein. Moreover, purified anti-S. mansoni egg, latex cross-reactive antibodies reacted with antigenic constituents of some fruits, a result of potential relevance to the latex-fruit syndrome of allergic reactions. We propose that IgG anti-schistosome antibodies that cross-react with allergens may be able to block IgE-induced allergic reactions and thus provide a possible explanation for the hygiene hypothesis</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - United KIngdom -CO - Egypt -CO - Nigeria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0159542</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27467385">PM:27467385</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0159542.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0159542.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Doenhoff MJ</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0159542</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">You,H.</style></author><author><style face="normal" font="Arial"> Li,R.</style></author><author><style face="normal" font="Arial"> Wei,C.</style></author><author><style face="normal" font="Arial"> Chen,S.</style></author><author><style face="normal" font="Arial"> Mao,L.</style></author><author><style face="normal" font="Arial"> Zhang,Z.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Environmental Biomedicine, School of Life Sciences, Central China Normal University, Wuhan, China</style></auth-address><titles><title><style face="normal" font="Arial">Thymic Stromal Lymphopoietin Neutralization Inhibits the Immune Adjuvant Effect of Di-(2-Ethylhexyl) Phthalate in Balb/c Mouse Asthma Model</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0159479">e0159479-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Di-(2-ethylhexyl) phthalate (DEHP), a commonly used plasticizer, has an adjuvant effect in combination with ovalbumin (OVA). The adjuvant effect of DEHP has already been verified in our previous studies. In this study, to further investigate whether thymic stromal lymphopoietin (TSLP) was involved in the DEHP-adjuvant effect, DEHP was administered through a daily gavage exposure route. Mice were sensitized with ovalbumin (OVA) to trigger allergic responses, and an anti-TSLP monoclonal antibody was used to neutralize the effect of TSLP. Biomarkers including cytokines in bronchoalveolar lavage fluid (BALF), serum total IgE and TSLP content in the lung were detected. In addition, airway hyperreactivity and lung sections were examined. Collectively, these data indicated a salient Th2 response which was characterized by the upregulation of Th2-type cytokines, such as interleukin 4 (IL-4), IL-5 and IL-13. Moreover, the eosinophil number in BALF and the eosinophil cationic protein (ECP) in the lung were seen to have increased significantly. However, neutralization of TSLP with an anti-TSLP mAb reversed the adjuvant effect of DEHP on airway inflammation, structural alterations in the airway wall and increased airway hyperresponsiveness (AHR) to methacholine induced by the OVA allergen, suggesting that TSLP was an effective target site for suppressing the adjuvant effect of DEHP co-exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0159479</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27467143">PM:27467143</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0159479.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0159479.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, You H</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0159479</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marinho,F.V.</style></author><author><style face="normal" font="Arial"> Alves,C.C.</style></author><author><style face="normal" font="Arial"> de Souza,S.C.</style></author><author><style face="normal" font="Arial"> da Silva,C.M.</style></author><author><style face="normal" font="Arial"> Cassali,G.D.</style></author><author><style face="normal" font="Arial"> Oliveira,S.C.</style></author><author><style face="normal" font="Arial"> Pacifico,L.G.</style></author><author><style face="normal" font="Arial"> Fonseca,C.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Imunologia de Doencas Infecciosas, Departamento de Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte-MG, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Schistosoma mansoni Tegument (Smteg) Induces IL-10 and Modulates Experimental Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0160118">e0160118-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Evasion</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma mansoni</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous studies have demonstrated that S. mansoni infection and inoculation of the parasite eggs and antigens are able to modulate airways inflammation induced by OVA in mice. This modulation was associated to an enhanced production of interleukin-10 and to an increased number of regulatory T cells. The S. mansoni schistosomulum is the first stage to come into contact with the host immune system and its tegument represents the host-parasite interface. The schistosomula tegument (Smteg) has never been studied in the context of modulation of inflammatory disorders, although immune evasion mechanisms take place in this phase of infection to guarantee the persistence of the parasite in the host. METHODOLOGY AND PRINCIPAL FINDINGS: The aim of this study was to evaluate the Smteg ability to modulate inflammation in an experimental airway inflammation model induced by OVA and to characterize the immune factors involved in this modulation. To achieve the objective, BALB/c mice were sensitized with ovalbumin (OVA) and then challenged with OVA aerosol after Smteg intraperitoneal inoculation. Protein extravasation and inflammatory cells were assessed in bronchoalveolar lavage and IgE levels were measured in serum. Additionally, lungs were excised for histopathological analyses, cytokine measurement and characterization of the cell populations. Inoculation with Smteg led to a reduction in the protein levels in bronchoalveolar lavage (BAL) and eosinophils in both BAL and lung tissue. In the lung tissue there was a reduction in inflammatory cells and collagen deposition as well as in IL-5, IL-13, IL-25 and CCL11 levels. Additionally, a decrease in specific anti-OVA IgE levels was observed. The reduction observed in these inflammatory parameters was associated with increased levels of IL-10 in lung tissues. Furthermore, Smteg/asthma mice showed high percentage of CD11b+F4/80+IL-10+ and CD11c+CD11b+IL-10+ cells in lungs. CONCLUSION: Taken together, these findings demonstrate that S. mansoni schistosomula tegument can modulates experimental airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0160118</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27454771">PM:27454771</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0160118.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0160118.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Marinho FV</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0160118</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aoki-Yoshida,A.</style></author><author><style face="normal" font="Arial"> Yamada,K.</style></author><author><style face="normal" font="Arial"> Hachimura,S.</style></author><author><style face="normal" font="Arial"> Sashihara,T.</style></author><author><style face="normal" font="Arial"> Ikegami,S.</style></author><author><style face="normal" font="Arial"> Shimizu,M.</style></author><author><style face="normal" font="Arial"> Totsuka,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Applied Biological Chemistry, The University of Tokyo, Yayoi, Bunkyo-ku, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Enhancement of Oral Tolerance Induction in DO11.10 Mice by Lactobacillus gasseri OLL2809 via Increase of Effector Regulatory T Cells</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0158643">e0158643-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Food allergy is a serious problem for infants and young children. Induction of antigen-specific oral tolerance is one therapeutic strategy. Enhancement of oral tolerance induction by diet is a promising strategy to prevent food allergy in infants. Thus, in this study, we evaluate the effect of probiotic Lactobacillus gasseri OLL2809 (LG2809) on oral tolerance induction in a mouse model. The degree of oral tolerance induction was evaluated by measuring the proliferation and level of IL-2 production of splenic CD4+ T cells from DO11.10 mice fed ovalbumin (OVA) alone or OVA with LG2809. Oral administration of LG2809 significantly decreased the rate of proliferation and IL-2 production by CD4+ T cells from OVA-fed mice. LG2809 increased a ratio of CD4+ T-cell population, producing high levels of IL-10 and having strong suppressive activity. Moreover, LG2809 increased a ratio of plasmacytoid dendritic cells (pDCs) among the lamina propria (LP) in small intestine. When used as antigen presenting cells to naive CD4+ T cells from DO11.10 mice, LP cells from BALB/c mice fed LG2809 induced higher IL-10 production and stronger suppressive activity than those from non-treated mice. These results suggest that oral administration of LG2809 increases the population of pDCs in the LP, resulting in the enhancement of oral tolerance induction by increasing the ratio of effector regulatory T cells. LG2809 could, therefore, act as a potent immunomodulator to prevent food allergies by promoting oral tolerance</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0158643</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27472281">PM:27472281</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0158643.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0158643.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Aoki-Yoshida A</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0158643</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mizukawa,Y.</style></author><author><style face="normal" font="Arial"> Doi,T.</style></author><author><style face="normal" font="Arial"> Yamazaki,Y.</style></author><author><style face="normal" font="Arial"> Kudo,A.</style></author><author><style face="normal" font="Arial"> Shiohara,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Epidermal Neuromedin U Attenuates IgE-Mediated Allergic Skin Inflammation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0160122">e0160122-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic skin inflammation</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> hapten</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Although keratinocyte-derived neuropeptide neuromedin U (NMU) mediates the proinflammatory effects of innate-type mast cell activation, no information is available on the physiological roles. Here, to investigate the effects of NMU on IgE-mediated allergic skin inflammation, we determined whether IgE-mediated inflammation associated with severe scratching was induced in Nmu-/- mice administered repeated hapten applications to the ear or footpad. Dry skin was induced by targeted deletion of Nmu. Mice administered repeated hapten application developed IgE-mediated allergic inflammation characterized by severe scratching and increased serum IgE levels only when the ear, and not the footpad, was subjected to scratching, indicating that depletion of NMU from the epidermis alone does not drive such allergic inflammation. Thus, the susceptibility of Nmu-/- mice to allergic inflammation depends primarily on scratching dry skin. Further, allergic skin inflammation mediated by FcepsilonRI cross-linking in Nmu-/-mice was inhibited by prior injection of NMU. These results indicate that NMU plays an important physiological role as a negative regulator during the late stage of IgE-mediated allergic skin inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0160122</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27463114">PM:27463114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0160122.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0160122.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, Mizukawa Y</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0160122</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Margineanu,I.</style></author><author><style face="normal" font="Arial"> Crisan,R.</style></author><author><style face="normal" font="Arial"> Mihaescu,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Asthma-like symptoms in a patient with rheumatoid arthritis and Adalimumab treatment</style></title><secondary-title><style face="normal" font="Arial">Pneumologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pneumologia</style></full-title></periodical><pages end="30" start="28">28-30</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Biological Markers</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Methotrexate</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> reversibility</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="10" Year="2015">2015/10</year></dates><abstract><style face="normal" font="Arial">After the introduction of anti-TNFalpha medication for treatment of autoimmune conditions, clinicians have investigated not only other possible uses for the drugs, but also less common side-effects and interactions with other pathologies. Despite some succes registered with Adalimumab as an antiinflammatory agent in severe asthma, there have been case reports of patients developing asthma or asthma-like symptoms following anti-TNFalpha therapy. The case presents a patient without previous family or personal history of respiratory or atopic conditions that developed bronchospasm immediately after the initiation of Adalimumab and Methotrexate treatment for rheumatoid arthritis. Despite the patient presenting asthma characteristics (expiratory wheezing, dry cough, partial reversibility at post bronchodilator test) and asthma medication alleviating simtomathology, biological markers (eosenophil granulocytes in sputum, serum IgE) for asthma are absent. The relationship between bronchospasm and medication and other possible causes for her respiratory symptoms are discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20160725IS - 2067-2993 (Print)IS - 2067-2993 (Linking)LA - engPT - Journal ArticleSB - IMCO - Romania -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27451592">PM:27451592</url></web-urls></urls><custom2><style face="normal" font="Arial">20160725, Margineanu I</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ge,X.N.</style></author><author><style face="normal" font="Arial"> Ha,S.G.</style></author><author><style face="normal" font="Arial"> Greenberg,Y.G.</style></author><author><style face="normal" font="Arial"> Rao,A.</style></author><author><style face="normal" font="Arial"> Bastan,I.</style></author><author><style face="normal" font="Arial"> Blidner,A.G.</style></author><author><style face="normal" font="Arial"> Rao,S.P.</style></author><author><style face="normal" font="Arial"> Rabinovich,G.A.</style></author><author><style face="normal" font="Arial"> Sriramarao,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108</style></auth-address><titles><title><style face="normal" font="Arial">Regulation of eosinophilia and allergic airway inflammation by the glycan-binding protein galectin-1</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></full-title></periodical><pages end="(33):E4837-46" start="E4837">E4837-(33):E4837-46</pages><volume><style face="normal" font="Arial">113</style></volume><number><style face="normal" font="Arial">33</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> CD11b</style></keyword><keyword><style face="normal" font="Arial"> CD18</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion</style></keyword><keyword><style face="normal" font="Arial"> cell migration</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cytoskeleton</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Space</style></keyword><keyword><style face="normal" font="Arial"> Galectin 1</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> L-Selectin</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vascular Cell Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="7" Year="2016">2016/7/25</year></dates><abstract><style face="normal" font="Arial">Galectin-1 (Gal-1), a glycan-binding protein with broad antiinflammatory activities, functions as a proresolving mediator in autoimmune and chronic inflammatory disorders. However, its role in allergic airway inflammation has not yet been elucidated. We evaluated the effects of Gal-1 on eosinophil function and its role in a mouse model of allergic asthma. Allergen exposure resulted in airway recruitment of Gal-1-expressing inflammatory cells, including eosinophils, as well as increased Gal-1 in extracellular spaces in the lungs. In vitro, extracellular Gal-1 exerted divergent effects on eosinophils that were N-glycan- and dose-dependent. At concentrations &lt;/=0.25 microM, Gal-1 increased eosinophil adhesion to vascular cell adhesion molecule-1, caused redistribution of integrin CD49d to the periphery and cell clustering, but inhibited ERK(1/2) activation and eotaxin-1-induced migration. Exposure to concentrations >/=1 microM resulted in ERK(1/2)-dependent apoptosis and disruption of the F-actin cytoskeleton. At lower concentrations, Gal-1 did not alter expression of adhesion molecules (CD49d, CD18, CD11a, CD11b, L-selectin) or of the chemokine receptor CCR3, but decreased CD49d and CCR3 was observed in eosinophils treated with higher concentrations of this lectin. In vivo, allergen-challenged Gal-1-deficient mice exhibited increased recruitment of eosinophils and CD3+ T lymphocytes in the airways as well as elevated peripheral blood and bone marrow eosinophils relative to corresponding WT mice. Further, these mice had an increased propensity to develop airway hyperresponsiveness and displayed significantly elevated levels of TNF-alpha in lung tissue. This study suggests that Gal-1 can limit eosinophil recruitment to allergic airways and suppresses airway inflammation by inhibiting cell migration and promoting eosinophil apoptosis</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1073/pnas.1601958113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27457925">PM:27457925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\20160726-GeXN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\20160726-GeXN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Ge XN</style></custom2><misc3><style face="normal" font="Arial">10.1073/pnas.1601958113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,J.</style></author><author><style face="normal" font="Arial"> Deng,L.</style></author><author><style face="normal" font="Arial"> Dreymuller,D.</style></author><author><style face="normal" font="Arial"> Jiang,X.</style></author><author><style face="normal" font="Arial"> Long,J.</style></author><author><style face="normal" font="Arial"> Duan,Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Luo,M.</style></author><author><style face="normal" font="Arial"> Lin,F.</style></author><author><style face="normal" font="Arial"> Mao,L.</style></author><author><style face="normal" font="Arial"> Muller,B.</style></author><author><style face="normal" font="Arial"> Koller,G.</style></author><author><style face="normal" font="Arial"> Bartsch,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Changzhou Key Laboratory of Respiratory Medical Engineering, Institute of Biomedical Engineering and Health Sciences, Changzhou University, Changzhou, Jiangsu, China</style></auth-address><titles><title><style face="normal" font="Arial">A novel peptide ADAM8 inhibitor attenuates bronchial hyperresponsiveness and Th2 cytokine mediated inflammation of murine asthmatic models</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="30451">30451-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ADAM8</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Engineering</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tissue remodeling</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">A disintegrin and metalloproteinase 8 (ADAM8) has been identified as a signature gene associated with moderate and severe asthma. Studies in mice have demonstrated that the severity of asthma can be reduced by either transgenic knock-out or by antibodies blocking ADAM8 function, highlighting ADAM8 as potential drug target for asthma therapy. Here, we examined the therapeutic effect of an ADAM8 inhibitor peptide (BK-1361) that specifically blocks cellular ADAM8 activity in ovalbumin-sensitized and challenged Balb/c mice. We found that BK-1361 (25 mug/g body weight) attenuated airway responsiveness to methacholine stimulation by up to 42%, concomitantly reduced tissue remodeling by 50%, and decreased inflammatory cells (e.g. eosinophils down by 54%)/inflammatory factors (e.g. sCD23 down by 50%)/TH2 cytokines (e.g. IL-5 down by 70%)/ADAM8-positive eosinophils (down by 60%) in the lung. We further verified that BK-1361 specifically targets ADAM8 in vivo as the peptide caused significantly reduced levels of soluble CD23 in wild-type but not in ADAM8-deficient mice. These findings suggest that BK-1361 blocks ADAM8-dependent asthma effects in vivo by inhibiting infiltration of eosinophils and TH2 lymphocytes, thus leading to reduction of TH2-mediated inflammation, tissue remodeling and bronchial hyperresponsiveness. Taken together, pharmacological ADAM8 inhibition appears as promising novel therapeutic strategy for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -CO - Germany -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep30451</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27458083">PM:27458083</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-30451.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-30451.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Chen J</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep30451</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abdullah,S.U.</style></author><author><style face="normal" font="Arial"> Alexeev,Y.</style></author><author><style face="normal" font="Arial"> Johnson,P.E.</style></author><author><style face="normal" font="Arial"> Rigby,N.M.</style></author><author><style face="normal" font="Arial"> Mackie,A.R.</style></author><author><style face="normal" font="Arial"> Dhaliwal,B.</style></author><author><style face="normal" font="Arial"> Mills,E.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Food Research, Norwich Research Park, Colney, NR4 7UA, UK</style></auth-address><titles><title><style face="normal" font="Arial">Ligand binding to an Allergenic Lipid Transfer Protein Enhances Conformational Flexibility resulting in an Increase in Susceptibility to Gastroduodenal Proteolysis</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="30279">30279-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> GMO</style></keyword><keyword><style face="normal" font="Arial"> GMOs</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Non-specific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Non-specific lipid transfer proteins (LTPs) are a family of lipid-binding molecules that are widely distributed across flowering plant species, many of which have been identified as allergens. They are highly resistant to simulated gastroduodenal proteolysis, a property that may play a role in determining their allergenicity and it has been suggested that lipid binding may further increase stability to proteolysis. It is demonstrated that LTPs from wheat and peach bind a range of lipids in a variety of conditions, including those found in the gastroduodenal tract. Both LTPs are initially cleaved during gastroduodenal proteolysis at three major sites between residues 39-40, 56-57 and 79-80, with wheat LTP being more resistant to cleavage than its peach ortholog. The susceptibility of wheat LTP to proteolyic cleavage increases significantly upon lipid binding. This enhanced digestibility is likely to be due to the displacement of Tyr79 and surrounding residues from the internal hydrophobic cavity upon ligand binding to the solvent exposed exterior of the LTP, facilitating proteolysis. Such knowledge contributes to our understanding as to how resistance to digestion can be used in allergenicity risk assessment of novel food proteins, including GMOs</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep30279</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27458082">PM:27458082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-30279.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-30279.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Abdullah SU</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep30279</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghiani,A.</style></author><author><style face="normal" font="Arial"> Ciappetta,S.</style></author><author><style face="normal" font="Arial"> Gentili,R.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author><author><style face="normal" font="Arial"> Citterio,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Science Ambientali, Universita di Milano-Bicocca, Piazza della Scienza 1, 20126 Milano, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Is ragweed pollen allergenicity governed by environmental conditions during plant growth and flowering?</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="30438">30438-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Amb a 1</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant growth</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Pollen allergenicity is one of the main factors influencing the prevalence and/or severity of allergic diseases. However, how genotype and environment contribute to ragweed pollen allergenicity has still to be established. To throw some light on the factors governing allergenicity, in this work 180 ragweed plants from three Regions (Canada, France, Italy) were grown in both controlled (constant) and standard environmental conditions (seasonal changes in temperature, relative humidity and light). Pollen from single plants was characterized for its allergenic potency and for the underlying regulation mechanisms by studying the qualitative and quantitative variations of the main isoforms of the major ragweed allergen Amb a 1. Results showed a statistically higher variability in allergenicity of pollen from standard conditions than from controlled conditions growing plants. This variability was due to differences among single plants, regardless of their origin, and was not ascribed to differences in the expression and IgE reactivity of individual Amb a 1 isoforms but rather to quantitative differences involving all the studied isoforms. It suggests that the allergenic potency of ragweed pollen and thus the severity of ragweed pollinosis mainly depends on environmental conditions during plant growth and flowering, which regulate the total Amb a 1 content</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep30438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27457754">PM:27457754</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-30438.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-30438.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Ghiani A</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep30438</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maya-Manzano,J.M.</style></author><author><style face="normal" font="Arial"> Fernandez-Rodriguez,S.</style></author><author><style face="normal" font="Arial"> Smith,M.</style></author><author><style face="normal" font="Arial"> Tormo-Molina,R.</style></author><author><style face="normal" font="Arial"> Reynolds,A.M.</style></author><author><style face="normal" font="Arial"> Silva-Palacios,I.</style></author><author><style face="normal" font="Arial"> Gonzalo-Garijo,A.</style></author><author><style face="normal" font="Arial"> Sadys,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Extremadura, Department of Plant Biology, Ecology and Earth Sciences, Faculty of Science, Avda Elvas s/n, 06006 Badajoz, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Airborne Quercus pollen in SW Spain: Identifying favourable conditions for atmospheric transport and potential source areas</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="1047" start="1037">1037-1047</pages><volume><style face="normal" font="Arial">571</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Badajoz</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Distribution map</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">The pollen grains of Quercus spp. (oak trees) are allergenic. This study investigates airborne Quercus pollen in SW Spain with the aim identifying favourable conditions for atmospheric transport and potential sources areas. Two types of Quercus distribution maps were produced. Airborne Quercus pollen concentrations were measured at three sites located in the Extremadura region (SW Spain) for 3 consecutive years. The seasonal occurrence of Quercus pollen in the air was investigated, as well as days with pollen concentrations >/=80Pm-3. The distance that Quercus pollen can be transported in appreciable numbers was calculated using clusters of back trajectories representing the air mass movement above the source areas (oak woodlands), and by using a state-of-the-art dispersion model. The two main potential sources of Quercus airborne pollen captured in SW Spain are Q. ilex subsp. ballota and Q. suber. The minimum distances between aerobiological stations and Quercus woodlands have been estimated as: 40km (Plasencia), 66km (Don Benito), 62km (Zafra) from the context of this study. Daily mean Quercus pollen concentration can exceed 1,700Pm-3, levels reached not less than 24 days in a single year. High Quercus pollen concentration were mostly associated with moderate wind speed events (6-10ms-1), whereas that a high wind speed (16-20ms-1) seems to be associated with low concentrations</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2016.07.094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27443456">PM:27443456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\20160722-MayaManzanoJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\20160722-MayaManzanoJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Maya-Manzano JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2016.07.094</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tamakuwala,M.</style></author><author><style face="normal" font="Arial"> Ratna,W.</style></author><author><style face="normal" font="Arial"> Joshi,A.</style></author><author><style face="normal" font="Arial"> Stagni,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pharmaceutical Sciences, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Fingolimod hydrochloride gel shows promising therapeutic effects in a mouse model of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Pharm Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pharm Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cellulose</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gels</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TEWL</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transepidermal water loss</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white blood cell</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To assess the efficacy of topically applied 2% hydroxypropyl cellulose gels containing 0.5% fingolimod hydrochloride (FNGL) with or without 6% colloidal oatmeal in an in vivo model of atopic dermatitis (AD). METHODS: AD-like lesions were induced in SKH1/Hr hairless mice and were treated with FNGL gels, non-medicated base gels and Elidel(R) cream for 6 weeks. The severity/improvement of the lesions was assessed regularly using the Eczema Area and Severity Index (EASI), pH of the skin, transepidermal water loss, g/m2 /h (TEWL), humidity and temperature. At the end of the experiments, the plasma levels of cytokines, FNGL and white blood cells were determined. KEY FINDINGS: The EASI score was almost unchanged for the vehicle-only groups compared to before the treatments, whereas the medicated groups showed a significant decrease in the overall EASI score (P &lt; 0.01), although there was non-significant differences among them (P > 0.081). Both the FNGL groups also showed a significant (P &lt; 0.05) reduction in blood WBC. CONCLUSION: This study shows that the gels containing 0.50% FNGL and FNGL 0.50% plus 6% colloidal oatmeal have potential for the treatment of AD. The presence of colloidal oatmeal may provide additional benefits</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 2042-7158 (Electronic)IS - 0022-3573 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/jphp.12588</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27465785">PM:27465785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharm Pharmacol\20160728-TamakuwalaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharm Pharmacol\20160728-TamakuwalaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, Tamakuwala M</style></custom2><misc3><style face="normal" font="Arial">10.1111/jphp.12588</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lighaam,L.C.</style></author><author><style face="normal" font="Arial"> Rispens,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sanquin Research, Department of Immunopathology, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">The Immunobiology of Immunoglobulin G4</style></title><secondary-title><style face="normal" font="Arial">Semin Liver Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Semin Liver Dis</style></abbr-1></periodical><pages end="215" start="200">200-215</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="07/31/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody Formation</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biologicals</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Cross-link</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Equilibrium</style></keyword><keyword><style face="normal" font="Arial"> Fc receptors</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> humoral immunity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-21</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G4</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T helper 2 cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Human immunoglobulin G4 (IgG4) antibodies are in many ways unusual. In this review, an overview is given of the structural and functional aspects of IgG4 antibodies, the consequences of IgG4 antibody formation in various disease settings, and the factors involved in the regulation of IgG4 responses. Unlike most IgG antibodies, IgG4 antibodies exist in a dynamic equilibrium with other IgG4 antibodies, continuously exchanging half-molecules resulting in effectively monovalent antibodies that cannot cross-link. Together with the low affinities to C1q and most Fc receptors, and a generally high affinity for antigen, IgG4 antibodies appear to be nature's way of producing "blocking antibodies." On the one hand, IgG4 may contribute to tolerance to allergens, presumably via competition with IgE. Also, IgG4 immune responses to filarial parasites might prevent excessive immune reactions during such infections. On the other hand, IgG4 autoantibodies may be pathogenic, simply because they inhibit the function of their target molecules. Furthermore, IgG4 antibodies to biologicals may result in secondary loss of response. In addition, IgG4 has been implicated to impair humoral immunity to tumors. The role of high IgG4 serum levels in IgG4-related disease has not yet been established. Regulation of IgG4 responses is most likely a multifactorial process, which in vivo requires prolonged or repeated challenge with antigen, and is associated with regulatory T cells, T helper 2 cells, interleukin- (IL-) 4, and IL-10. In vitro, cytokines like IL-4, IL-13, IL-10, and IL-21 have been shown to differentially influence IgG4 production. The properties of IgG4 B cells have now started to be elucidated, and may provide additional clues to explain the unusual dynamics of IgG4-antibody responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1098-8971 (Electronic)IS - 0272-8087 (Linking)LA - engPT - Journal ArticleSB - IMCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1055/s-0036-1584322</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27466791">PM:27466791</url></web-urls><pdf-urls><url ppv-ref="no">t.rispens@sanquin.nl researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160729, Lighaam LC</style></custom2><misc3><style face="normal" font="Arial">10.1055/s-0036-1584322</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hendrickson,J.E.</style></author><author><style face="normal" font="Arial"> Roubinian,N.H.</style></author><author><style face="normal" font="Arial"> Chowdhury,D.</style></author><author><style face="normal" font="Arial"> Brambilla,D.</style></author><author><style face="normal" font="Arial"> Murphy,E.L.</style></author><author><style face="normal" font="Arial"> Wu,Y.</style></author><author><style face="normal" font="Arial"> Ness,P.M.</style></author><author><style face="normal" font="Arial"> Gehrie,E.A.</style></author><author><style face="normal" font="Arial"> Snyder,E.L.</style></author><author><style face="normal" font="Arial"> George Hauser,R.</style></author><author><style face="normal" font="Arial"> Gottschall,J.L.</style></author><author><style face="normal" font="Arial"> Kleinman,S.</style></author><author><style face="normal" font="Arial"> Kakaiya,R.</style></author><author><style face="normal" font="Arial"> Strauss,R.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT</style></auth-address><titles><title><style face="normal" font="Arial">Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication</style></title><secondary-title><style face="normal" font="Arial">Transfusion</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfusion</style></full-title></periodical><pages end="2596" start="2587">2587-2596</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2016">2016/7/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Prevalence estimates of the serious hazards of transfusion vary widely. We hypothesized that the current reporting infrastructure in the United States fails to capture many transfusion reactions and undertook a multicenter study using active surveillance, data review, and adjudication to test this hypothesis. STUDY DESIGN AND METHODS: A retrospective record review was completed for a random sample of 17% of all inpatient transfusion episodes over 6 months at four academic tertiary care hospitals, with an episode defined as all blood products released to a patient in 6 hours. Data were recorded by trained clinical research nurses, and serious reactions were adjudicated by a panel of transfusion medicine experts. RESULTS: Of 4857 transfusion episodes investigated, 1.1% were associated with a serious reaction. Transfusion-associated circulatory overload was the most frequent serious reaction noted, being identified in 1% of transfusion episodes. Despite clinical notes describing a potential transfusion association in 59% of these cases, only 5.1% were reported to the transfusion service. Suspected transfusion-related acute lung injury/possible transfusion-related acute lung injury, anaphylactic, and hypotensive reactions were noted in 0.08, 0.02, and 0.02% of transfusion episodes, respectively. Minor reactions, including febrile nonhemolytic and allergic, were noted in 0.62 and 0.29% of transfusion episodes, respectively, with 30 and 50% reported to the transfusion service. CONCLUSION: Underreporting of cardiopulmonary transfusion reactions is striking among academic, tertiary care hospitals. Complete and accurate reporting is essential to identify, define, establish pathogenesis, and mitigate/treat transfusion reactions. A better understanding of the failure to report may improve the accuracy of passive reporting systems</style></abstract><notes><style face="normal" font="Arial">DA - 20160727IS - 1537-2995 (Electronic)IS - 0041-1132 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/trf.13730</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27460200">PM:27460200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfusion\20160727-HendricksonJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfusion\20160727-HendricksonJE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160727, Hendrickson JE</style></custom2><misc3><style face="normal" font="Arial">10.1111/trf.13730</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Manning,B.M.</style></author><author><style face="normal" font="Arial"> Gruba,S.M.</style></author><author><style face="normal" font="Arial"> Meyer,A.F.</style></author><author><style face="normal" font="Arial"> Haynes,C.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Analysis of Neuropeptide-Induced Mast Cell Degranulation and Characterization of Signaling Modulation in Response To IgE Conditioning</style></title><secondary-title><style face="normal" font="Arial">ACS Chem Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ACS Chem Biol</style></full-title></periodical><pages end="3083" start="3077">3077-3083</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Calcitonin</style></keyword><keyword><style face="normal" font="Arial"> Calcitonin Gene-Related Peptide</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> neurogenic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> Neuropeptides</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peripheral Nervous System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">As tissue-resident immune cells, mast cells are frequently found in close proximity to afferent neurons and are subjected to immunoactive mediators secreted by these neurons, including substance P (SP) and calcitonin gene-related peptide (CGRP). Neurogenic inflammation is thought to play an important role in the pathophysiology of many diseases. Unraveling the cellular mechanisms at the interface between the immune response and the peripheral nervous system is important for understanding how these diseases arise and progress. In this work, mast cell degranulation following direct exposure to CGRP and SP was studied both at the bulk and single-cell levels to characterize the mouse peritoneal mast cell response to neuropeptides and compare this response to well-studied mast cell activation pathways. Results show that mast cells secrete fewer chemical messenger-filled granules with increased IgE pre-incubation concentrations. The biophysical characteristics of mast cell degranulation in response to SP and CGRP is in many ways similar to calcium ionophore-induced mast cell degranulation; however, neuropeptide-stimulated mast cells secrete reduced chemical messenger content per secretion event, resulting in an overall relative decrease in secreted chemical messengers</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1554-8937 (Electronic)IS - 1554-8929 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acschembio.6b00616</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27580075">PM:27580075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\ACS Chem Biol\20160831-ManningBM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\ACS Chem Biol\20160831-ManningBM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Manning BM</style></custom2><misc3><style face="normal" font="Arial">10.1021/acschembio.6b00616</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chan,W.C.</style></author><author><style face="normal" font="Arial"> Udugama,B.</style></author><author><style face="normal" font="Arial"> Kadhiresan,P.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Mubareka,S.</style></author><author><style face="normal" font="Arial"> Weiss,P.S.</style></author><author><style face="normal" font="Arial"> Parak,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biomaterials and Biomedical Engineering, Donnelly Center for Biomolecular Research, Department of Chemistry, Department of Chemical Engineering, Department of Materials Science and Engineering, University of Toronto , 164 College St., Toronto, Ontario M5T 2R5, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Patients, Here Comes More Nanotechnology</style></title><secondary-title><style face="normal" font="Arial">ACS Nano</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ACS Nano</style></full-title></periodical><pages end="8142" start="8139">8139-8142</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomaterials</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Engineering</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Nanotechnology</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Silicon</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">We describe the current difference in reporting the performance of nanotechnology diagnostic devices between technologists and clinicians. This perspective specifies the "metrics" used to evaluate these devices and describes strategies to bridge the gap between these two communities in order to accelerate the translation from academic bench to the clinic. We use two recently published ACS Nano articles to highlight the evaluation of silicon nanowire and surface-enhanced Raman spectroscopy-breath diagnostic tests for patients afflicted with cancer and asthma. These studies represent some of the earliest studies of emerging nanotechnology devices utilizing clinical parameters to assess performance</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1936-086X (Electronic)IS - 1936-0851 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -CO - Germany -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1021/acsnano.6b05610</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27575458">PM:27575458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\ACS Nano\20160830-ChanWC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\ACS Nano\20160830-ChanWC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Chan WC</style></custom2><misc3><style face="normal" font="Arial">10.1021/acsnano.6b05610</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Egeberg,A.</style></author><author><style face="normal" font="Arial"> Kofoed,K.</style></author><author><style face="normal" font="Arial"> Gislason,G.H.</style></author><author><style face="normal" font="Arial"> Vestergaard,C.</style></author><author><style face="normal" font="Arial"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermato-Allergology, Herlev and Gentofte Hospital, DK-2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Cardiovascular Risk is not Increased in Patients with Chronic Urticaria: A Retrospective Population-based Cohort Study</style></title><secondary-title><style face="normal" font="Arial">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Derm Venereol</style></full-title></periodical><pages end="262" start="261">261-262</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.2340/00015555-2516</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27535552">PM:27535552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Derm Venereol\20160818-EgebergA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Derm Venereol\20160818-EgebergA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Egeberg A</style></custom2><misc3><style face="normal" font="Arial">10.2340/00015555-2516</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rozalski,M.</style></author><author><style face="normal" font="Arial"> Rudnicka,L.</style></author><author><style face="normal" font="Arial"> Samochocki,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zbigniew Samochocki, MD, PhD, Department of Dermatology, Medical University of Warsaw, Koszykowa 82a, 02-008 Warsaw, Poland ; samochocki@gmail.com</style></auth-address><titles><title><style face="normal" font="Arial">Atopic and Non-atopic Eczema</style></title><secondary-title><style face="normal" font="Arial">Acta Dermatovenerol Croat</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Dermatovenerol Croat</style></full-title></periodical><pages end="115" start="110">110-115</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> nonatopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis is a common term used in the medical literature, but according to The Nomenclature Review Committee Of The World Allergy Organization the name which should be used is eczema. Eczema is divided into two subtypes: atopic and non-atopic. These subtypes differ in the level of total immunoglobulin E (IgE) in serum, response to allergens in skin prick tests, and detection of specific IgE antibodies. Non-atopic eczema is characterized by a low level of total IgE, negative skin prick tests, and undetectable specific IgE antibodies. It is estimated that 10-45% cases of eczema are non-atopic ones. In recent studies, other features differentiating these two subtypes have been identified, such as female predominance in non-atopic eczema. A more severe course, damage of the epidermal barrier, predominance of Th2 (T helper cells 2) response, and a lower positive reaction to metal patch tests are the characteristics of the atopic subtype. In our opinion, new diagnostic criteria taking into account the non-atopic subtype of eczema need to be established</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1847-6538 (Electronic)IS - 1330-027X (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Poland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27477170">PM:27477170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2016-24-110-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2016-24-110-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Rozalski M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salmivesi,S.</style></author><author><style face="normal" font="Arial"> Paassilta,M.</style></author><author><style face="normal" font="Arial"> Huhtala,H.</style></author><author><style face="normal" font="Arial"> Nieminen,R.</style></author><author><style face="normal" font="Arial"> Moilanen,E.</style></author><author><style face="normal" font="Arial"> Korppi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Center, Tampere University Hospital, Tampere, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Changes in biomarkers during a six-month oral immunotherapy intervention for cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Paediatr</style></abbr-1></periodical><pages end="1354" start="1349">1349-1354</pages><volume><style face="normal" font="Arial">105</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adipokines</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Leptin</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> resistin</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">AIM: Oral immunotherapy (OIT) is a promising but still experimental method to treat children with cow's milk (CM) allergy (CMA). We evaluated changes in allergic, immunological and inflammatory parameters, which happened during the six-month OIT for CMA. METHODS: We treated 28 school-aged children with CMA using OIT with a double-blind placebo-controlled design. After the controlled study finished, the placebo group was treated with the same but open-label OIT protocol. Sixteen immune variables were tested before and after the six-month OIT. RESULTS: Before OIT, the median serum CM-specific immunoglobulin (Ig) E was 18.0kIU/L in the intervention group and 9.4kIU/L in the placebo group (p=0.46). At six months, interleukin (IL)-6 and IL-10 were significantly higher in the intervention group. When the changes during the blinded and open OIT were analyzed together for both groups, blood eosinophils and serum total IgE decreased and milk-specific IgG and IgG4, serum IL-4 and IL-6, and serum leptin and resistin increased significantly. CONCLUSION: Preliminary evidence was found that markers of allergy like blood eosinophils and serum IgE decreased and milk-specific IgG and IgG4 increased during OIT. Adipokines leptin and resistin, which functionally are cytokines linked to Th1-type response, increased during OIT. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/apa.13550</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27537244">PM:27537244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Paediatr\20160818-SalmivesiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Paediatr\20160818-SalmivesiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Salmivesi S</style></custom2><misc3><style face="normal" font="Arial">10.1111/apa.13550</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Utebayev,M.</style></author><author><style face="normal" font="Arial"> Dashkevich,S.</style></author><author><style face="normal" font="Arial"> Babkenov,A.</style></author><author><style face="normal" font="Arial"> Shtefan,G.</style></author><author><style face="normal" font="Arial"> Fahrudenova,I.</style></author><author><style face="normal" font="Arial"> Bayahmetova,S.</style></author><author><style face="normal" font="Arial"> Sharipova,B.</style></author><author><style face="normal" font="Arial"> Kaskarbayev,Z.</style></author><author><style face="normal" font="Arial"> Shavrukov,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Application of gliadin polymorphism for pedigree analysis in common wheat (Triticum aestivum L.) from Northern Kazakhstan</style></title><secondary-title><style face="normal" font="Arial">Acta Physiol Plant</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Physiol Plant</style></full-title></periodical><pages end="14" start="1">1-14</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alleles</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Germplasm</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Molecular marker</style></keyword><keyword><style face="normal" font="Arial"> Molecular markers</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pedigree</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Triticum</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1861-1664</style></isbn><abstract><style face="normal" font="Arial">Gliadins, seed storage proteins, are popular markers effectively employed for the analysis of common wheat. Gliadin electrophoretic patterns are genotype-specific, reproducible, not dependent on growing conditions and are suitable for germplasm identification complementary to molecular markers. Gliadins have been identified and used in wheat from various countries, but prior to this study little was known about gliadin polymorphism in wheat from Kazakhstan. In this study, 48 alleles of six gliadin-coding loci were identified in 43 cultivars of spring wheat from Northern Kazakhstan. The alleles Gli-A1 f , Gli-B1 e , Gli-D1 a , Gli-A2 p , Gli-B2 d and Gli-D2 e had maximal frequencies in each of the six loci. Identified Gli alleles in the loci formed </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÿGliadin Genetic Formula</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ unique for each studied variety, and these were compared to the published data from previously analyzed wheat varieties. Pedigree analysis of 43 varieties studied for gliadin polymorphisms indicated that some Gli alleles were conserved and inherited from the progenitor cultivar Akmolinka 1. In contrast, other Gli alleles were replaced by those from modern germplasms. It is assumed that a higher frequency of gliadin alleles can be associated with the selection of genotypes with improved traits for yield and seed quality in the studied wheat cultivars from Northern Kazakhstan</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Kazakhstan - CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11738-016-2209-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s11738-016-2209-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Physiol Plant\2016-38-1-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Physiol Plant\2016-38-1-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Utebayev M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11738-016-2209-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kahriman,G.</style></author><author><style face="normal" font="Arial"> Ozcan,N.</style></author><author><style face="normal" font="Arial"> Dogan,S.</style></author><author><style face="normal" font="Arial"> Karaborklu,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Radiology, University of Erciyes, School of Medicine, Gevher Nesibe Hospital, Kayseri, Turkey h</style></auth-address><titles><title><style face="normal" font="Arial">Percutaneous treatment of liver hydatid cysts in 190 patients: a retrospective study</style></title><secondary-title><style face="normal" font="Arial">Acta Radiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Radiol</style></full-title></periodical><pages end="684" start="676">676-684</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Cystic echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Cysts</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hemorrhage</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hydatid liver disease (HLD) is a significant health problem, especially in endemic areas worldwide. Percutaneous treatment is an effective alternative therapeutic option. PURPOSE: To present the clinical and radiological results of percutaneous treatment of HLD in 190 patients. MATERIAL AND METHODS: Percutaneous treatment of HLD between April 2005 and March 2015 was analyzed retrospectively. The demographic data, numbers and types of cysts, initial and final volumes of the cysts, types of percutaneous treatment, and procedure-related complications were determined. RESULTS: A total of 190 patients (95 male patients and 95 female patients; age range, 5-82 years) with 283 liver hydatid cysts who underwent percutaneous treatment were included in the study. Of the 283 cysts, 234 (83%) were cystic echinococcosis CE1, 31 (11%) were CE3a, and 18 (6%) were CE2 cysts, according to the World Health Organization (WHO) classification. The percutaneous procedure was successful in all patients. A total of 12 (6.3%) major complications, including anaphylaxis, allergic skin reaction, perihepatic hemorrhage, and cavity infection, were seen. No mortality was noted. Recurrence in one patient and an additional cyst in one patient were seen. All patients were asymptomatic during the follow-up period. Mean volume reduction was 77.5%, with a mean follow-up period of 18 months. CONCLUSION: Percutaneous treatment is an effective and safe method for the treatment of HLD. It should be regarded as a first-line treatment method for uncomplicated hydatid cysts</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1600-0455 (Electronic)IS - 0284-1851 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1177/0284185116664226</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27565632">PM:27565632</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Radiol\20160827-KahrimanG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Radiol\20160827-KahrimanG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Kahriman G</style></custom2><misc3><style face="normal" font="Arial">10.1177/0284185116664226</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gong,X.</style></author><author><style face="normal" font="Arial"> Wang,Q.</style></author><author><style face="normal" font="Arial"> Lu,S.</style></author><author><style face="normal" font="Arial"> Suzuki,M.</style></author><author><style face="normal" font="Arial"> Nakajima,D.</style></author><author><style face="normal" font="Arial"> Sekiguchi,K.</style></author><author><style face="normal" font="Arial"> Miwa,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Size distribution of allergenic Cry j 2 released from airborne Cryptomeria japonica pollen grains during the pollen scattering seasons</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="69" start="59">59-69</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cry j 1</style></keyword><keyword><style face="normal" font="Arial"> Cry j 2</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria japonica</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Size distribution</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> SPR</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Japanese cedar (Cryptomeria japonica) pollinosis is one of seasonal allergic rhinitis that mainly occurs in Japan. The pollinosis is caused by two main kinds of allergenic proteins called Cry j 1 and Cry j 2 which exist in Cryptomeria japonica pollen. In our previous study, we reported that the size-segregated of airborne fine allergenic Cry j 1 and morphological change of Cry j 1 due to the contact with rainfall. However, the study on airborne allergenic Cry j 2 in different particle sizes has not been identified until now. Therefore, the main aim of this study is to investigate the size distribution and scattering behavior of allergenic Cry j 2. The Cry j 2 particles were collected and determined in different particle sizes at the urban sampling points during the most severe pollination season of 2012 in Saitama, Japan. After the size-segregated Cry j 2 allergenic particles were collected using an Andersen high-volume (AHV) atmospheric sample, the airborne Cry j 2 concentrations were determined with a surface plasmon resonance (SPR) method. At the same time, the airborne Cryptomeria japonica pollens were also counted by the Durham pollen sampler. The higher concentrations of the allergenic Cry j 2 were detected even in particle sizes equal to or less than 1.1-á++m (PM1.1) than other particle sizes. The airborne particles ranges from 0.06 to 11-á++m were also collected by a low-pressure impactor (LPI) atmospheric sampler. After that, the concentrations of Cry j 2 allergenic particles in fine particle sizes were measured by the SPR method either. With the help of this study, we have confirmed the existence of fine daughter allergenic particles, which clearly differ from the parent pollen grains in size, especially after the rainy days. It is possible that the daughter allergenic species will be released from the fractions of cell wall and burst pollen grains. We concluded that rainwater was one of the important factors that affects the release of pollen allergenic proteins of both Cry j 1 and Cry j 2 from the parent pollen grains</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9450-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9450-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20160820-GongX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20160820-GongX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Gong X</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9450-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Craine,J.M.</style></author><author><style face="normal" font="Arial"> Barberan,A.</style></author><author><style face="normal" font="Arial"> Lynch,R.C.</style></author><author><style face="normal" font="Arial"> Menninger,H.L.</style></author><author><style face="normal" font="Arial"> Dunn,R.R.</style></author><author><style face="normal" font="Arial"> Fierer,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Molecular analysis of environmental plant DNA in house dust across the United States</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="86" start="71">71-86</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Cedrus</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA sequencing</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant allergen</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Despite the prevalence and costs of allergic diseases caused by pollen, we know little about the distributions of allergenic and non-allergenic pollen inside and outside homes at the continental scale. To better understand patterns in potential pollen diversity across the United States, we used DNA sequencing of a chloroplast marker gene to identify the plant DNA found in settled dust collected on indoor and outdoor surfaces across 459 homes. House location was the best predictor of the relative abundance of plant taxa found in outdoor dust samples. Urban, southern houses in hotter climates that were further from the coast were more likely to have more DNA from grass and moss species, while rural houses in northern, cooler climates closer to the coast were more likely to have higher relative abundances of DNA from Pinus and Cedrus species. In general, those plant taxa that were more abundant outdoors were also more abundant indoors, but indoor dust had uniquely high abundances of DNA from food plants and plants associated with lawns. Approximately 14-á% of the plant DNA sequences found outside were from plant taxa that are known to have allergenic pollen compared to just 8-á% inside. There was little geographic pattern in the total relative abundance of these allergens highlighting the difficulties associated with trying to predict allergen exposures based on geographic location alone. Together, this work demonstrates the utility of using environmental DNA sequencing to reconstruct the distributions of plant DNA inside and outside buildings, an approach that could prove useful for better understanding and predicting plant allergen exposures</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9451-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9451-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20160820-CraineJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20160820-CraineJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Craine JM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9451-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ozdemir,B.</style></author><author><style face="normal" font="Arial"> Koksal,B.T.</style></author><author><style face="normal" font="Arial"> Karakas,N.M.</style></author><author><style face="normal" font="Arial"> Ozbek,O.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Baskent University Faculty of Medicine, Ankara, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Serum vitamin D levels decrease in children with acute urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="516" start="512">512-516</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Acute urticaria is an immune-inflammatory disease, characterised by acute immune activation. There has been increasing evidence showing that vitamin D deficiency is associated with increased incidence and severity of immune-inflammatory disorders. OBJECTIVE: The aim of this study was to evaluate serum vitamin D levels in acute urticaria. METHODS: We enrolled 30 children with acute urticaria and 30 control subjects. Concentrations of 25-hydroxyvitamin D [25(OH)D], a biomarker of vitamin D status, were measured in serum of acute urticaria patients and compared with the control group. RESULTS: There were no significant differences in baseline variables (age, gender, weight) between the groups. Vitamin D deficiency (&lt;20ng/ml) was significantly higher in patients with acute urticaria than in control patients. Serum 25(OH)D levels were significantly lower in the study group compared to those in the control group (13.1+/-4.3 vs 28.2+/-7.4ng/mL, p&lt;0.05). Moreover, we found negative correlation between mean duration of acute urticaria and serum vitamin D levels (p&lt;0.01). CONCLUSION: This study revealed a significant association of lower serum 25(OH)D concentrations with acute urticaria and an inverse relationship with disease duration. These findings may open up the possibility of the clinical use of vitamin D as a contributing factor in the pathogenesis of acute urticaria and a predictive marker for disease activity in acute urticaria. A potential role of vitamin D in pathogenesis and additive therapy in acute urticaria needs to be examined</style></abstract><notes><style face="normal" font="Arial">DA - 20160731IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27475773">PM:27475773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160731-OzdemirB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160731-OzdemirB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160731, Ozdemir B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Mancebo,E.</style></author><author><style face="normal" font="Arial"> Dominguez-Ortega,J.</style></author><author><style face="normal" font="Arial"> Blanco-Bermejo,S.</style></author><author><style face="normal" font="Arial"> Gonzalez-Seco,E.</style></author><author><style face="normal" font="Arial"> Trujillo,M.J.</style></author><author><style face="normal" font="Arial"> De la Torre,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Universitario de Fuenlabrada, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of two diagnostic techniques, skin-prick test and component resolved diagnosis in the follow-up of a cohort of paediatric patients with pollinosis. Multicentre pilot study in a highly exposed allergenic area</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="126" start="121">121-126</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Over the last years, different works have been published about the importance of incorporating new diagnosis techniques in allergic patients such as component-resolved diagnosis (CRD). The objective of this study is to compare the evolution of allergic sensitisation profiles by means of CRD and cutaneous tests (SPT) on pollen-allergic patients. METHODS: A total of 123 patients aged between 2 and 14 years were included in an open, prospective, multicentre study. All the children had symptoms suggestive of seasonal respiratory allergic disease, with the diagnosis confirmed by cutaneous tests. Specific-IgE to major pollen-allergens (CRD) and SPT were performed at basal and after three years of follow-up. RESULTS: Out of 123 patients included, a total of 85 were analysed. The mean age was 8+/-3 years. Significant changes in the allergic sensitisation profiles were observed for the most prevalent allergens (Olea and grass) but it is in grass, the most relevant allergen in terms of allergen pressure, where changes in both absolute and relative frequencies between SPT and CRD were more evident. CONCLUSION: CRD seems to be an essential tool to carry out an appropriate follow-up of patients with allergic respiratory disease, as well as to decide on the immunotherapy composition that best matches the allergic sensitisation profile of patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27477032">PM:27477032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160801-GonzalezManceboE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160801-GonzalezManceboE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Gonzalez-Mancebo E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miceli Sopo,S.</style></author><author><style face="normal" font="Arial"> Greco,M.</style></author><author><style face="normal" font="Arial"> Monaco,S.</style></author><author><style face="normal" font="Arial"> Bianchi,A.</style></author><author><style face="normal" font="Arial"> Cuomo,B.</style></author><author><style face="normal" font="Arial"> Liotti,L.</style></author><author><style face="normal" font="Arial"> Iacono,I.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Allergy Unit, Agostino Gemelli Hospital, Sacred Heart Catholic University, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Matrix effect on baked milk tolerance in children with IgE cow milk allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="523" start="517">517-523</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> cow milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> matrix effect</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Prick by prick</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="29" Month="7" Year="2016">2016/7/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Children with IgE-mediated cow's milk allergy (IgE-CMA) often tolerate baked milk within a wheat matrix. In our study we evaluated the impact of wheat matrix and of little standardised cooking procedures on tolerance of baked milk. We also tested tolerance versus parmigiano reggiano (PR) and whey-based partially hydrolysed formula (pHF). METHODS: Forty-eight children with IgE-CMA were enrolled. They underwent prick-by-prick (PbP) and open oral food challenge (OFC) with baked cow's milk (CM), both within a wheat matrix (an Italian cake named ciambellone) and without (in a liquid form), with PR and with pHF. After a passed OFC, children continued to eat the food tolerated. In particular, after passed OFC with ciambellone, children were allowed to eat any food containing CM within a wheat matrix, with the only condition that it was baked at 180 degrees C for at least 30min. Three months after, parents were asked to answer a survey. RESULTS: 81% of children tolerated ciambellone, 56% liquid baked CM, 78% PR and 82% pHF. Negative predictive value of PbP performed with tested foods was 100%. No IgE-mediated adverse reactions were detected at follow-up carried out by the survey. CONCLUSIONS: Wheat matrix effect on tolerance of baked milk was relevant in slightly less than half of cases. If our results are confirmed by larger studies, a negative PbP will allow patients to eat processed CM without undergoing OFC. Moreover, in order to guarantee tolerance towards baked milk, strict standardised cooking procedures do not seem to be necessary</style></abstract><notes><style face="normal" font="Arial">DA - 20160802IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27480790">PM:27480790</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160802-MiceliSopoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160802-MiceliSopoS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160802, Miceli Sopo S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.03.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eser,I.</style></author><author><style face="normal" font="Arial"> Yologlu,N.</style></author><author><style face="normal" font="Arial"> Baydemir,C.</style></author><author><style face="normal" font="Arial"> Aydogan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology, Kocaeli University, 41380 Umuttepe, Kocaeli, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">The predictive factors for remission of chronic spontaneous urticaria in childhood: Outcome from a prospective study</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="541" start="537">537-541</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> prognostic factors</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2016">2016/7/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There are few studies in children on the natural course of chronic spontaneous urticaria (CSU) because of its relative infrequency in childhood. OBJECTIVE: To estimate the rate of remission and evaluate the prognostic factors in children with CSU. METHOD: A total of 52 children with CSU were prospectively followed over a period of three years. RESULTS: The remission rates at 12 months and 36 months were 32.7% and 48.1%. The mean duration of disease at the first visit in the non-remission group was higher than in the remission group at the end of the study (P=0.016). The remission rate of the patients who had been treated by standard dose antihistamine was higher than that of the patients who had been treated with the high-dose antihistamine and combination medications (P=0.004, P&lt;0.001). The treatment steps were independent prognostic factors for remission by logistic regression analysis. CONCLUSION: Our study indicates that urticaria controlled by a standard dose of antihistamine can predict a good prognosis independently from disease duration at first visit</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27477033">PM:27477033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160801-EserI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160801-EserI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Eser I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez-Salguero,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy Unit, Department of Pediatrics, Puerto Real University Hospital, Cadiz, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Hives: The target of itching</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="285" start="283">283-285</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160716IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - EditorialSB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.06.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27422862">PM:27422862</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2016-44-283-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2016-44-283-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Sanchez-Salguero CA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.06.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bedolla-Barajas,M.</style></author><author><style face="normal" font="Arial"> Valdez-Lopez,F.</style></author><author><style face="normal" font="Arial"> Alcala-Padilla,G.</style></author><author><style face="normal" font="Arial"> Bedolla-Pulido,T.I.</style></author><author><style face="normal" font="Arial"> Rivera-Mejia,V.</style></author><author><style face="normal" font="Arial"> Morales-Romero,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergia e Inmunologia Clinica, Nuevo Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Salvador de Quevedo y Zubieta No. 750, Colonia La Perla, Guadalajara, Jalisco, C.P. 44340, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence and factors associated to peanut allergy in Mexican school children</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="76" start="69">69-76</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In our country, the prevalence and the factors associated to peanut allergy are unknown, a health problem that has been emerging worldwide. OBJECTIVE: To establish the prevalence and the factors that are associated to peanut allergy amongst school children. METHODS: This is a population-based cross-sectional study. We included 756 children aged 6-7 years. The children's parents were questioned about their peanut intake habits. A structured questionnaire was applied, it included questions regarding peanut intake; family and personal history of asthma; rhinitis; and atopic dermatitis. Allergic reactions to peanuts were registered as: probable, convincing and systematic. The statistical analyses included logistical regression models to look for associated factors. RESULTS: Males were 356/756 (47.1%). Peanut allergy prevalence: probable reaction: 14/756 (1.8%), convincing reaction: 8/756 (1.1%) and systemic reaction: 3/756 (0.4%). Through multivariate analysis, the presence of symptoms of allergic rhinitis (OR=4.2 95% CI 1.3-13.2) and atopic dermatitis (OR=5.2; 95% CI 1.4-19.5) during the previous year, showed significant association to probable peanut reaction. The former year, the presence of atopic dermatitis was the only variable that was substantially associated to a convincing reaction (OR=7.5; 95% CI 1.4-38.4) and to a systematic reaction (OR=45.1; 95% CI 4.0-510.0), respectively. CONCLUSIONS: The reported prevalence of peanut allergy was consistent with that found in previous studies; symptoms of allergic rhinitis and atopic dermatitis were identified as associated factors to peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160731IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27475774">PM:27475774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160731-BedollaBarajasM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160731-BedollaBarajasM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160731, Bedolla-Barajas M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ontiveros,N.</style></author><author><style face="normal" font="Arial"> Valdez-Meza,E.E.</style></author><author><style face="normal" font="Arial"> Vergara-Jimenez,M.J.</style></author><author><style face="normal" font="Arial"> Canizalez-Roman,A.</style></author><author><style face="normal" font="Arial"> Borzutzky,A.</style></author><author><style face="normal" font="Arial"> Cabrera-Chavez,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Regional Program for PhD in Biotechnology, FCQB, Universidad Autonoma de Sinaloa, Culiacan, Sinaloa 80019, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Parent-reported prevalence of food allergy in Mexican schoolchildren: A population-based study</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="570" start="563">563-570</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Chocolate</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Strawberry</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy (FA) prevalence is well documented in developed countries and appears to be increasing, but remains unknown in most Latin American countries. We aimed to evaluate on a population basis the parent-reported prevalence of FA and its clinical characteristics in Mexican schoolchildren. METHODS: A validated Spanish version of a structured written questionnaire was administered to parents of schoolchildren aged 5-13 years old from Culiacan, Mexico. RESULTS: A total of 1049 parents responded to the survey (response rate, 84%). The estimated prevalence rates (95% CI) were: adverse food reactions 10.0% (8.3-11.9), "perceived FA, ever" 5.5% (4.3-7.0), "physician-diagnosed FA, ever" 4.9% (3.7-6.3), "immediate-type FA, ever" 4.4% (3.3-5.8), "immediate-type FA, current" 3.5% (2.6-4.8), and anaphylaxis 1.2% (0.72-2.1). Immediate hypersensitivity reactions were mainly triggered by the consumption of shrimp (1.3%), other shellfish (0.7%), strawberry (0.6%), chocolate (0.5%), and egg (0.4%). Schoolchildren with "immediate-type FA, current" had more atopic dermatitis and allergic rhinitis (p&lt;0.05), but not asthma or drug allergy (p>0.05) than children without FA. All cases of anaphylaxis sought medical attention, but only one child had physician-diagnosed anaphylaxis and was advised to acquire an epinephrine autoinjector. CONCLUSIONS: The prevalence of "immediate-type FA, current" to any food is 3.5% in Mexican schoolchildren. The poor recognition of anaphylaxis and the low frequency of prescription of epinephrine autoinjectors suggest that acute food-induced allergic reactions are not optimally managed in Mexico</style></abstract><notes><style face="normal" font="Arial">DA - 20160731IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Mexico -CO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27475776">PM:27475776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160731-OntiverosN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160731-OntiverosN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160731, Ontiveros N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.03.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kataoka,Y.</style></author><author><style face="normal" font="Arial"> Tamagawa-Mineoka,R.</style></author><author><style face="normal" font="Arial"> Masuda,K.</style></author><author><style face="normal" font="Arial"> Katoh,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis to Japanese butterbur scapes</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="142" start="141">141-142</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160724IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - LETTERCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27451267">PM:27451267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160724-KataokaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160724-KataokaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160724, Kataoka Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.06.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okubo,K.</style></author><author><style face="normal" font="Arial"> Gotoh,M.</style></author><author><style face="normal" font="Arial"> Asako,M.</style></author><author><style face="normal" font="Arial"> Nomura,Y.</style></author><author><style face="normal" font="Arial"> Togawa,M.</style></author><author><style face="normal" font="Arial"> Saito,A.</style></author><author><style face="normal" font="Arial"> Honda,T.</style></author><author><style face="normal" font="Arial"> Ohashi,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Nippon Medical School, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="105" start="97">97-105</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Bilastine</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fexofenadine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bilastine, a novel non-sedating second-generation H1 antihistamine, has been approved in most European countries since 2010. This study aimed to evaluate the superiority of bilastine over placebo in Japanese patients with perennial allergic rhinitis (PAR). METHODS: This randomized, double-blind, placebo-controlled, parallel-group, phase III study (trial registration number JapicCTI-142600) evaluated the effect of a 2-week treatment period with bilastine (20 mg once daily), fexofenadine (60 mg twice daily), or a matched placebo (double dummy) in patients with PAR. All patients were instructed to record individual nasal and ocular symptoms in diaries daily. The primary endpoint was the mean change in total nasal symptom scores (TNSS) from baseline to Week 2 (Days 10-13). RESULTS: A total of 765 patients were randomly allocated to receive bilastine, fexofenadine, or placebo (256, 254, and 255 patients, respectively). The mean change in TNSS from baseline at Week 2 was significantly decreased by bilastine (-0.98) compared to placebo (-0.63, P = 0.023). Bilastine and fexofenadine showed no significant difference in the primary endpoint. However, the mean change in TNSS from baseline on Day 1 was more significantly decreased by bilastine (-0.99) than by placebo (-0.28, P &lt; 0.001) or fexofenadine (-0.62, P = 0.032). The active drugs also improved instantaneous TNSS 1 h after the first and before the second drug administration on Day 1 (P &lt; 0.05). The study drugs were well tolerated. CONCLUSIONS: After 2-week treatment period, bilastine 20 mg once daily was effective and tolerable in Japanese patients with PAR, and exhibited a rapid onset of action</style></abstract><notes><style face="normal" font="Arial">DA - 20160716IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.05.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27421817">PM:27421817</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160716-OkuboK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160716-OkuboK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Okubo K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.05.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inage,E.</style></author><author><style face="normal" font="Arial"> Matsubara,T.</style></author><author><style face="normal" font="Arial"> Honjo,A.</style></author><author><style face="normal" font="Arial"> Baba,Y.</style></author><author><style face="normal" font="Arial"> Yamazaki,S.</style></author><author><style face="normal" font="Arial"> Mori,M.</style></author><author><style face="normal" font="Arial"> Suzuki,K.</style></author><author><style face="normal" font="Arial"> Hara,S.</style></author><author><style face="normal" font="Arial"> Nakazawa,T.</style></author><author><style face="normal" font="Arial"> Obinata,K.</style></author><author><style face="normal" font="Arial"> Ohtsuka,Y.</style></author><author><style face="normal" font="Arial"> Shimizu,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Juntendo University, Urayasu Hospital, Chiba, Japan; Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Pediatric admissions due to travel-related asthmatic attacks in Japan: A retrospective case series and case-control study</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="145" start="143">143-145</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160731IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - LETTERCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.06.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27475626">PM:27475626</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160731-InageE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160731-InageE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160731, Inage E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.06.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hashiguchi,K.</style></author><author><style face="normal" font="Arial"> Wakabayashi,K.I.</style></author><author><style face="normal" font="Arial"> Togawa,M.</style></author><author><style face="normal" font="Arial"> Saito,A.</style></author><author><style face="normal" font="Arial"> Okubo,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Futaba Clinic, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic effect of bilastine in Japanese cedar pollinosis using an artificial exposure chamber (OHIO Chamber)</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="131" start="123">123-131</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Bilastine</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> environmental exposure chamber</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fexofenadine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Prophylactic treatment</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Environmental exposure chambers have been used to expose subjects to aeroallergens to investigate the efficacy of prophylactic treatment with symptomatic agents in Japan. We first examined the therapeutic effect of bilastine (BIL), a novel non-sedative second-generation H1-antihistamine, in subjects with Japanese cedar pollinosis using an artificial exposure chamber (OHIO Chamber). METHODS: This was a randomized, double-blind, four-way crossover, placebo- and active-controlled phase II study (trial registration number JapicCTI-132213). Subjects were exposed to cedar pollen (8000 grains/m3) for 2 h on Day -1 and 4 h each on Day 1 and 2. BIL 10 or 20 mg, placebo, or fexofenadine hydrochloride (FEX) 60 mg was administered orally 1 h after the start of pollen exposure on Day 1. Placebo or FEX was administered 12 h after the first dosing. The primary efficacy endpoint was the sum of total nasal symptom score (TNSS) from 0 to 3 h after the Day 1 dosing. RESULTS: We enrolled 136 subjects and the sum of TNSS on Day 1 of the three active treatments was significantly lower than that of placebo and was maintained up to 26 h after the first dosing (Day 2). The sum of TNSS or sneezing score on Day 1 after BIL 20 mg was more significantly decreased than after FEX. Moreover, BIL showed a faster onset of action than FEX. CONCLUSIONS: We demonstrated the efficacy, rapid onset, and long duration of action of BIL in subjects with Japanese cedar pollinosis exposed to cedar pollen using the OHIO Chamber</style></abstract><notes><style face="normal" font="Arial">DA - 20160731IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27475625">PM:27475625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160731-HashiguchiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160731-HashiguchiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160731, Hashiguchi K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.06.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rondon,C.</style></author><author><style face="normal" font="Arial"> Bogas,G.</style></author><author><style face="normal" font="Arial"> Barrionuevo,E.</style></author><author><style face="normal" font="Arial"> Blanca,M.</style></author><author><style face="normal" font="Arial"> Torres,M.J.</style></author><author><style face="normal" font="Arial"> Campo,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Non-allergic rhinitis and lower airway disease</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="34" start="24">24-34</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">In the past years several investigators have demonstrated the existence of local nasal responses in some patients with typical allergic rhinitis symptoms but without atopy, and have defined a new phenotype called local allergic rhinitis (LAR) or "entopy". In a percentage of LAR subjects, the upper airway disease is also associated with lower airway symptoms. After the description of this phenotype, the differential diagnosis between LAR and non-allergic rhinitis (NAR) has become a challenge for the clinician. To correctly identify LAR patients is of high importance for treatment and management of these patients, and for an appropriate inclusion of patients in clinical trials and genetics studies. The treatment of LAR patients, in contrast with NAR is oriented to allergen avoidance and specific treatment. Allergen immunotherapy, the aetiological specific treatment for allergic respiratory diseases, has demonstrated to be an effective and safe treatment in LAR, increasing immunological tolerance, and reducing the clinical symptoms and the use of medication. In this article, the important and novel aspects of LAR in terms of mechanisms, diagnosis and treatment will be discussed. Also, the involvement of the lower airway and the potential role of IgE in the bronchial disease will be also reviewed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160720IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12988</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27439024">PM:27439024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160720-RondonC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160720-RondonC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160720, Rondon C</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12988</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cardona,V.</style></author><author><style face="normal" font="Arial"> Luengo,O.</style></author><author><style face="normal" font="Arial"> Labrador,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Vall d\'Hebron, Allergy Section, Department of Internal Medicine, Vall d\'Hebron Institut de Recerca, Allergy research GroupHospital Universitari Vall d'Hebron. U, Allergy Section.Internal Medicine Department, Institut de Recerca Vall d'Hebron, Universitat Autonoma de Barcelona, Allergy Research UnitHospital Universitari Vall d'Hebron. U, Allergy Section.Internal Medicine Department, Institut de Recerca Vall d'Hebron, Universitat Autonoma de Barcelona, Allergy Research Unit</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy in allergic rhinitis and lower airway outcomes</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="42" start="35">35-42</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis and asthma constitute two clinical expressions of a single condition, respiratory allergy. Allergen immunotherapy (AIT) is a form of treatment specifically aimed at modifying the response to sensitizing allergens. The inherent potential benefit of AIT is the simultaneous treatment of all clinical expressions of respiratory allergy. Current data support the effectiveness of subcutaneous and sublingual immunotherapy in rhinitis. Studies also provide proof for a beneficial effect in allergic asthma. Even more, substantial evidence points to the preventive effect on the progression from rhinitis to asthma. Despite the current knowledge on the basic mechanisms underlying the immunological effect of AIT is vast, the specific mechanisms for the preventive effect of primary sensitization or new sensitizations are poorly understood. This review aims to provide a critical overview of the current knowledge on the effectiveness of AIT and its potential role in secondary prevention of respiratory allergy progression. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160720IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12989</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27439141">PM:27439141</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160720-CardonaV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160720-CardonaV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160720, Cardona V</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12989</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hochwallner,H.</style></author><author><style face="normal" font="Arial"> Schulmeister,U.</style></author><author><style face="normal" font="Arial"> Swoboda,I.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> Reininger,R.</style></author><author><style face="normal" font="Arial"> Civaj,V.</style></author><author><style face="normal" font="Arial"> Campana,R.</style></author><author><style face="normal" font="Arial"> Thalhamer,J.</style></author><author><style face="normal" font="Arial"> Scheiblhofer,S.</style></author><author><style face="normal" font="Arial"> Balic,N.</style></author><author><style face="normal" font="Arial"> Horak,F.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author><author><style face="normal" font="Arial"> Szepfalusi,Z.</style></author><author><style face="normal" font="Arial"> Herz,U.</style></author><author><style face="normal" font="Arial"> van Tol,E.A.</style></author><author><style face="normal" font="Arial"> Spitzauer,S.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Infant milk formulas differ regarding their allergenic activity and induction of T cell and cytokine responses</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="424" start="416">416-424</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-lactalbumin</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid formula</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cow's milk formula</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hydrolyzed formula</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant milk formula</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Several hydrolyzed cow's milk (CM) formulas are available for avoidance of allergic reactions in CM allergic children and for prevention of allergy development in high risk infants. Our aim was to compare CM formulas regarding the presence of immunoreactive CM components, IgE reactivity, allergenic activity, ability to induce T cell proliferation and cytokine secretion. METHODS: A blinded analysis of eight cow's milk formulas: one non-hydrolyzed, two partially hydrolyzed, four extensively hydrolyzed and one amino acid formula, using biochemical techniques and specific antibody probes was conducted. IgE reactivity and allergenic activity of the formulas was tested with sera from CM allergic patients (n=26) in RAST-based assays and with rat basophils transfected with the human FcepsilonRI, respectively. The induction of T cell proliferation and the secretion cytokines in PBMC cultures from cow's milk allergic patients and non-allergic individuals were assessed. RESULTS: Immune-reactive alpha-lactalbumin and ss-lactoglobulin were found in the two partially hydrolyzed formulas and casein components in one of the extensively hydrolyzed formulas. One partially hydrolyzed formula and the extensively hydrolyzed formula containing casein components showed remaining IgE reactivity whereas the other hydrolyzed formulas lacked IgE reactivity. Only two extensively hydrolyzed formulas and the amino acid formula did not induce T cell proliferation and pro-inflammatory cytokine release. The remaining formulas varied regarding the induction of Th2, Th1 and pro-inflammatory cytokines. CONCLUSION: Our results show that certain CM formulas without allergenic and low pro-inflammatory properties can be identified and they may also explain different outcomes obtained in clinical studies using CM formulas. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160725IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Austria -CO - Greece -CO - Germany -CO - United Kingdom -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12992</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27455132">PM:27455132</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160725-HochwallnerH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160725-HochwallnerH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160725, Hochwallner H</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12992</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vidal-Quist,J.C.</style></author><author><style face="normal" font="Arial"> Ortego,F.</style></author><author><style face="normal" font="Arial"> Castanera,P.</style></author><author><style face="normal" font="Arial"> Hernandez-Crespo,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Interaccion Planta-Insecto, Departamento de Biologia Medioambiental, Centro de Investigaciones Biologicas - CSIC, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Quality control of house dust mite extracts by broad-spectrum profiling of allergen-related enzymatic activities</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="434" start="425">425-434</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> alpha-Amylase</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Reference Standards</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Standardisation</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Diagnosis and immunotherapy of allergy against mites is based on complex extracts from large-scale cultures. However, the analysis of their composition using specific antibodies is limited. By taking advantage of the prevailing enzymatic nature of mite allergens, we have developed a broad-spectrum biochemical method for the standardisation of native mite products. METHODS: Microplate-based assays have been implemented for thirteen Dermatophagoides pteronyssinus enzymatic activities, associated to Der p 1, 3, 4, 6, 8, 9, 15 and 20 allergens. The dynamics of these activities along culture growth, and their profile in purified fractions (bodies and faeces) and international reference standards (WHO/IUIS, two CBER/FDA) have been characterised. The stability of enzymatic activities and major allergens under stress conditions (40 degrees C) has been assessed in the presence/absence of specific protease inhibitors. RESULTS: The analysis of enzymatic activities revealed distinct profiles along culture growth and between fractions (bodies and faeces). Remarkable differences were found when comparing international reference standards, being consistent with their source material (purified bodies or whole cultures). After 72 hours at 40 degrees C, only trypsin and alpha-amylase maintained high activity. Notably, the prominent role of trypsins in the hydrolytic degradation of major allergens is demonstrated by the use of inhibitors. CONCLUSIONS: Our method offers a robust approach to assess the complexity of mite extracts and highlights the critical importance of source materials for the composition and stability of finished products. The implementation of this approach in industry-based quality control procedures would contribute to the standardisation of allergenic extracts used for diagnosis and immunotherapy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160727IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12994</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27460687">PM:27460687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160727-VidalQuistJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160727-VidalQuistJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160727, Vidal-Quist JC</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12994</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gauvreau,G.M.</style></author><author><style face="normal" font="Arial"> Boulet,L.P.</style></author><author><style face="normal" font="Arial"> Fitzgerald,J.M.</style></author><author><style face="normal" font="Arial"> Cockcroft,D.W.</style></author><author><style face="normal" font="Arial"> Davis,B.E.</style></author><author><style face="normal" font="Arial"> Leigh,R.</style></author><author><style face="normal" font="Arial"> Tanaka,M.</style></author><author><style face="normal" font="Arial"> Fourre,J.A.</style></author><author><style face="normal" font="Arial"> Tanaka,M.</style></author><author><style face="normal" font="Arial"> Nabata,T.</style></author><author><style face="normal" font="Arial"> O'Byrne,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, McMaster University, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">A Dual CysLT1/2 Antagonist Attenuates Allergen-induced Airway Responses in Subjects with Mild Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1727" start="1721">1721-1727</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> CysLT1</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Late asthmatic response</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophils</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="7" Year="2016">2016/7/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The cysteinyl leukotrienes (cysLTs) play a key role in the pathophysiology of asthma. In addition to functioning as potent bronchoconstrictors, cysLTs contribute to airway inflammation through eosinophil and neutrophil chemotaxis, plasma exudation and mucus secretion. We tested the activity of the dual cysLT1/2 antagonist, ONO-6950, against allergen-induced airway responses. METHODS: Subjects with documented allergen-induced early (EAR) and late asthmatic response (LAR) were randomized in a 3-way crossover study to receive ONO-6950 (200 mg) or montelukast (10 mg) or placebo q.d. on Days 1-8 of the 3 treatment periods. Allergen was inhaled on Day 7 two hours post-dose,and forced expiratory volume in 1 second (FEV1 ) was measured for 7 hours following challenge. Sputum eosinophils, and airway hyperresponsiveness were measured before and after allergen challenge. The primary outcome was the effect of ONO-6950 versus placebo on the EAR and LAR. RESULTS: Twenty-five non-smoking subjects with mild allergic asthma were enrolled and 20 subjects completed all 3 treatment periods per protocol. ONO-6950 was well tolerated. Compared to placebo, ONO-6950 significantly attenuated the maximum % fall in FEV1 and area under the %FEV1 /time curve during the EAR and LAR asthmatic responses (p&lt;0.05), and allergen-induced sputum eosinophils. There were no significant differences between ONO-6950 and montelukast. CONCLUSIONS: Attenuation of EAR, LAR, and airway inflammation is consistent with cysLT1 blockade. Whether dual cysLT1/2 antagonism offers additional benefit for treatment of asthma requires further study. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12987</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27444660">PM:27444660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160722-GauvreauGM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160722-GauvreauGM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Gauvreau GM</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12987</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stenberg-Hammar,K.</style></author><author><style face="normal" font="Arial"> Niespodziana,K.</style></author><author><style face="normal" font="Arial"> Soderhall,C.</style></author><author><style face="normal" font="Arial"> James,A.</style></author><author><style face="normal" font="Arial"> Cabauatan,C.</style></author><author><style face="normal" font="Arial"> Konradsen,J.R.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Hedlin,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Rhinovirus-specific antibody responses in preschool children with acute wheeze reflect severity of respiratory symptoms</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1735" start="1728">1728-1735</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="22" Month="7" Year="2016">2016/7/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Some children with rhinovirus (RV) infections wheeze but it is unknown if this is due to more virulent strains of virus or differences in host immune responses. The aim of this study was to investigate the RV species-specific antibody responses measured at a follow-up visit in preschool children in relation to reported time with respiratory symptoms and the presence of different RV species during an acute episode of wheeze. METHOD: Nasopharyngeal swabs and blood samples were taken among 120 preschool children (&lt;4 years of age) at an acute episode of wheeze and at a follow-up visit (median 11 weeks later). Nested PCR was used to detect different RV strains and serum levels of IgG1 against purified recombinant VP1-proteins from representatives of the three RV species (RV-A, RV-B and RV-C) were measured by ELISA. RESULTS: RV was detected in 74% (n=80/108) of the children at the acute visit and RV-C was the most common subtype (n=59/80, 74%). An increase in RV-specific IgG1 was seen in 61% (n=73) of the children at follow-up, most frequently against RV-A (n=61/73, 86%) irrespective of the RV strains detected by PCR. Increases in RV-specific IgG1 against RV-A or against RV-A and RV-C were significantly associated with more respiratory symptoms (p=0.03, p=0.007). CONCLUSION: Antibody response to recombinant RV VP1 proteins was associated with longer time with respiratory symptoms. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160722IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12991</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27444786">PM:27444786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160722-StenbergHammarK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160722-StenbergHammarK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160722, Stenberg-Hammar K</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12991</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okamoto,Y.</style></author><author><style face="normal" font="Arial"> Fujieda,S.</style></author><author><style face="normal" font="Arial"> Okano,M.</style></author><author><style face="normal" font="Arial"> Yoshida,Y.</style></author><author><style face="normal" font="Arial"> Kakudo,S.</style></author><author><style face="normal" font="Arial"> Masuyama,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="Arial">House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="443" start="435">435-443</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual tablet</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: House dust mite (HDM) is the major indoor allergen for allergic diseases such as allergic rhinitis (AR) and asthma. Although sublingual immunotherapy (SLIT) is a curative treatment for HDM-induced AR, data from large-scale studies are limited. We evaluated the efficacy and safety of HDM tablets in adolescent and adult patients (aged 12-64 years) with HDM-induced AR with or without intermittent asthma. METHODS: In a double-blind trial in Japan, 968 subjects were randomized 1:1:1 to 300 index of reactivity (IR), 500 IR, or placebo groups. The primary endpoint was the Average Adjusted Symptom Score (AASS) in the last 8 weeks of the 52-week treatment. Secondary endpoints included individual nasal and ocular symptom scores, rescue medication use, and the Japanese Rhinoconjunctivitis Quality of Life Questionnaire (JRQLQ) scores. RESULTS: The AASS in the last 8 weeks of treatment significantly improved in both the 300 IR and the 500 IR groups compared to that in the placebo group (p &lt; 0.001). In the 300 IR group, the onset of action occurred at week 8-10. All four nasal symptoms significantly improved in both active treatment groups; rescue medication use and JRQLQ outcome improved in the 300 IR group. Most adverse events (AEs) were mild, and 16 serious AEs (SAEs) were reported; however, none of them were drug-related. CONCLUSIONS: One-year treatment with 300 IR and 500 IR HDM tablets was effective without major safety concerns. The recommended therapeutic dose for AR is 300 IR. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12996</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27471838">PM:27471838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160729-OkamotoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160729-OkamotoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Okamoto Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12996</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larenas Linnemann,D.E.</style></author><author><style face="normal" font="Arial"> Singh,J.</style></author><author><style face="normal" font="Arial"> Rosario,N.</style></author><author><style face="normal" font="Arial"> Esch,R.</style></author><author><style face="normal" font="Arial"> Matta,J.J.</style></author><author><style face="normal" font="Arial"> Maspero,J.</style></author><author><style face="normal" font="Arial"> Michels,A.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Medica Sur, Mexico D.F, MexicoUniversity Clinic Koln A. o. R., Cologne, GermanyCenter of investigation and statistics, University clinic, Aachen, GermanyUniversidad Federal do Parana, BrasilGreer Laboratories Inc., Lenoir, USACentro Medico Nacional, Mexico D.F, MexicoFundacion CIDEA, Buenos Aires, ArgentinaUniversity Clinic Koln A. o. R., Cologne, GermanyCenter of investigation and statistics, University clinic, Aachen, GermanyUniversity Clinic Koln A. o. R., Cologne, GermanyCenter of investigation and statistics, University clinic, Aachen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Similar biological activity in skin prick test for Oralair(R) (8.200BAU) and Grazax(R) (6.200BAU) reinforces effective SLIT dosing level</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1786" start="1782">1782-1786</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> dose finding</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> relative potency</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="3" Month="8" Year="2016">2016/8/3</year></dates><abstract><style face="normal" font="Arial">In Europe, allergen extracts are standardized based on skin-prick wheal-size in 20-30 allergic subjects. To understand the biologic activity of clinically effective SLIT, we used this method to determine the biologic activity of solution and tablet Timothy grass pollen (TIM) extracts, compared to an FDA approved extract (Reference) of 10.000BAU/mL. Blinded, quadruplicate SPTs with concentrate and three serial half-log dilutions, allowed construction of a semi-logarithmic regression line per extract. BAU values were obtained from comparison with Reference. Extracts and dilutions showed a neat linear dose-response (all: R2 >0.98) in 33 rhinitis patients. Relative potencies: Staloral(R) 12.000BAU/mL, Soluprick(R) 10.300BAU/mL, Oralair(R) 8.200BAU, Grazax(R) 6.200BAU. Even though all extract concentrates differed in wheal-size (p= 0.01-0.001), Grazax(R) producing a 25% smaller wheal-size than Oralair(R) , the biological activity of these clinically effective TIM tablets led in the same range (6.200-8.200BAU; 0.92-1.23cm2 ). SLIT dose-finding studies for other pollens might start with allergen extracts producing 1.1cm2 wheal surface. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Mexico -CO - Germany -CO - Brazil -CO - United States -CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12998</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27484017">PM:27484017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160803-LarenasLinnemannDE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160803-LarenasLinnemannDE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Larenas Linnemann DE</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12998</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fauquert,J.L.</style></author><author><style face="normal" font="Arial"> Jedrzejczak-Czechowicz,M.</style></author><author><style face="normal" font="Arial"> Rondon,C.</style></author><author><style face="normal" font="Arial"> Calder,V.</style></author><author><style face="normal" font="Arial"> Silva,D.</style></author><author><style face="normal" font="Arial"> Kvenshagen,B.K.</style></author><author><style face="normal" font="Arial"> Caillebaut,I.</style></author><author><style face="normal" font="Arial"> Allegri,P.</style></author><author><style face="normal" font="Arial"> Santos,N.</style></author><author><style face="normal" font="Arial"> Doan,S.</style></author><author><style face="normal" font="Arial"> Perez,F.D.</style></author><author><style face="normal" font="Arial"> Chiambaretta,F.</style></author><author><style face="normal" font="Arial"> Delgado,L.</style></author><author><style face="normal" font="Arial"> Leonardi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CHU Estaing, Unite d'Allergologie de l'enfant, 63003, Clermont-Ferrand Cedex1, FranceDepartment of Immunology, Rheumatology, and Allergy, Medical University of Lodz, PolandAllergy Unit, Regional University Hospital of Malaga, IBIMA, UMA, Malaga, SpainDepartment of Ocular Biology &amp; Therapeutics (ORBIT), UCL Institute of Ophthalmology, London, UKServico de Imunoalergologia, Centro Hospitalar Sao Joao, E.P.E., Porto, PortugalPediatric Department, Oestfold Hospital Trust, Fredrikstad, NorwayClinical Immunology, Department of Microbiology and Immunology, Catholic University of Leuven, BelgiumOcular Inflammatory Diseases Referral Center, Allergic Conjunctivitis Unit, Rapallo Hospital Ophtalmological Dep., Genova, ItalyServico de Imunoalergologia, Centro Hospitalar Sao Joao, E.P.E., Porto, PortugalService d'Ophtalmologie, Hopital Bichat and Fondation A. de Rothschild, Paris, FranceServicio de Oftalmologia, Hospital Universitario de Torrejon, Madrid, SpainCHU Montpied, Service d'Ophtalmologie, 63003, Clermont-Ferrand Cedex1, FranceDepartment of Immunology, Faculty of Medicine, University of Porto, PortugalDepartment of Neuroscience, Ophthalmology Unit, University of Padua, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Conjunctival Allergen Provocation Test in daily practice. Guidelines from the Task Force Report of the EAACI Ocular Allergy Interest Group</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="54" start="43">43-54</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation test</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Informed Consent</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Ocular allergy</style></keyword><keyword><style face="normal" font="Arial"> Ocular surface</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Orbit</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Positive criteria</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> skin prick-test</style></keyword><keyword><style face="normal" font="Arial"> skin prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Conjunctival allergen provocation test (CAPT) reproduces the events occurring by instilling an allergen on the ocular surface. This paper is the compilation of a task force focussed on practical aspects of this technique based on the analysis of 131 papers. Main mechanisms involved are reviewed. Indications are diagnosing the allergen(s) triggering symptoms in IgE-mediated ocular allergy in seasonal, acute or perennial forms of allergic conjunctivitis, especially when the relevance of the allergen is not obvious or in polysensitized patients. Contraindications are limited to ongoing systemic severe pathology, asthma and eye disease. CAPT should be delayed if receiving systemic steroids or antihistamines. Local treatment should be interrupted according to the half-life of each drug. Prerequisites are: obtaining informed consent; evidencing of an allergen by skin prick-tests and/or serum specific IgE dosages; being able to deal with an unlikely event such as acute asthma exacerbation, urticaria or anaphylaxis, or an exacerbation of allergic conjunctivitis. Allergen extracts should be diluted locally prior to administration. Positive criteria are based on itching or quoted according to a composite score. An alternative scoring is based on itching. CAPT remains underused in daily practice, although it is a safe and simple procedure which can provide valuable clinical information. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - Poland -CO - Spain -CO - United Kingdom -CO - Portugal -CO - Norway -CO - Belgium -CO - Italy -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12986</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27430124">PM:27430124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160719-FauquertJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160719-FauquertJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Fauquert JL</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12986</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turner,P.J.</style></author><author><style face="normal" font="Arial"> Wainstein,B.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Paediatrics (Allergy and Infectious Diseases) &amp; MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, UKUniversity of Sydney, New South Wales, AustraliaDepartment of Immunology and Infectious Diseases, Sydney Children's Hospital, NSW, AustraliaSchool of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Crossing the threshold: can outcome data from food challenges be used to predict risk of anaphylaxis in the community?</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="12" start="9">9-12</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic mechanism</style></keyword><keyword><style face="normal" font="Arial"> Allergic mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eliciting dose</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">There is increasing interest in using data from oral food challenges (OFC) performed under medical supervision to assist in allergy risk management, both in industry (allergen risk management) (1) and in the clinical management of the allergic individual (2). Data relating to the minimum eliciting dose (MED) needed to trigger symptoms can inform the need for precautionary allergen labelling (PAL) on food (1). However, given that "zero risk" for food-allergic individuals is not considered to be a realistic proposition (3), it is also important to consider the severity of symptoms which might be experienced: for example, a pragmatic approach, using a level of exposure that causes only minimal, transient oral symptoms in under 1% of the food-allergic population, may be acceptable to guide the use of PAL (4). However, there is often an assumption that individuals with a lower MED (i.e. who react to a lower doses of allergen) are at a greater risk of anaphylaxis (5). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12997</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27472017">PM:27472017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160729-TurnerPJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160729-TurnerPJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Turner PJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12997</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hawro,T.</style></author><author><style face="normal" font="Arial"> Lehmann,S.</style></author><author><style face="normal" font="Arial"> Altrichter,S.</style></author><author><style face="normal" font="Arial"> Fluhr,J.W.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Church,M.K.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Allergie-Centrum Charite, Charite-Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Skin provocation tests may help to diagnose atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1752" start="1745">1745-1752</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="29" Month="7" Year="2016">2016/7/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a common skin disorder. Its diagnosis relies on clinical judgment. Mild and untypical manifestations may cause diagnostic difficulties. Biomarkers for the differential diagnostic work up of AD are needed. OBJECTIVE: To test if the results of skin provocation with cowhage, an established model of histamine-independent pruritus, and histamine are different in AD patients and healthy subjects and if these tests may be used as diagnostic markers of AD. METHODS: Twenty-two AD patients and 18 healthy controls were subjected to topical cowhage provocation and skin prick testing with histamine and assessed for differences in the quality, intensity and persistence of itch, for wheal diameter, volume, and flare size and intensity. RESULTS: Patients with AD, compared with healthy controls, exhibited significantly smaller histamine-induced flares (P &lt; 0.01), and markedly longer itch persistence after provocation with cowhage (P &lt; 0.01). Both parameters showed good diagnostic properties for AD (area under the receiver operating characteristic - ROC curve 0.78 and 0.80 respectively). The persistence of cowhage-induced itch for at least 30 minutes and a histamine-induced flare of less than 2 cm in diameter were reliable thresholds for the diagnosis of AD. If combinations of the results of both tests were used, their sensitivity and specificity of diagnosing AD was up to 91% and 94%, respectively. CONCLUSION: The clinical benefit of cowhage and histamine skin provocation tests should be investigated in further studies. Long persistence of cowhage-induced itch and diminished histamine-induced flare in non-lesional skin may support diagnosis of AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12995</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27472813">PM:27472813</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160729-HawroT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160729-HawroT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Hawro T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12995</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cubero,J.L.</style></author><author><style face="normal" font="Arial"> Isidoro-Garcia,M.</style></author><author><style face="normal" font="Arial"> Segura,N.</style></author><author><style face="normal" font="Arial"> Benito,P.D.</style></author><author><style face="normal" font="Arial"> Sanz,C.</style></author><author><style face="normal" font="Arial"> Lorente,F.</style></author><author><style face="normal" font="Arial"> Davila,I.</style></author><author><style face="normal" font="Arial"> Colas,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, University Hospital Lozano Blesa of Zaragoza, Avda. San Juan Bosco 15. 50.009, Zaragoza, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Filaggrin gene mutations and new SNPs in asthmatic patients: a cross-sectional study in a Spanish population</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic and non-allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> filaggrin gene</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene mutations</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> Ichthyosis</style></keyword><keyword><style face="normal" font="Arial"> ichthyosis vulgaris</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zaragoza</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Several null-mutations in the FLG gene that produce a decrease or absence of filaggrin in the skin and predispose to atopic dermatitis and ichthyosis vulgaris have been described. The relationship with asthma is less clear and may be due to the influence of atopy in patients with associated asthma. METHODS: Four hundred individuals were included, 300 patients diagnosed with asthma divided into two groups according to their phenotype (allergic and non-allergic asthma) and 100 strictly characterized controls. The coding region and flanking regions of the FLG gene were amplified by PCR. We proceeded to the characterization of potential gene variants in that region by RFLP and sequencing and analysed their association with lung function parameters, asthma control and severity, and quality of life. RESULTS: We identified two null-mutations (R501X and 2282del4), seven SNPs previously described in databases and three SNPs that had not been previously described. One of the SNP identified in this study (1741A > T) was more frequently detected in patients with non-allergic asthma, worse FVC, FEV1 and PEF values and a higher treatment step. In addition, lowered spirometric values were observed in the non-allergic group carrying any of the nonsynonymous SNPs. CONCLUSIONS: In the association study of genetic variants of the FLG gene in our population the 1741A > T polymorphism seems to be associated with non-allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160727IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0137-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27462351">PM:27462351</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160727, Cubero JL</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0137-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ling,L.</style></author><author><style face="normal" font="Arial"> Ospina,M.B.</style></author><author><style face="normal" font="Arial"> Sideri,K.</style></author><author><style face="normal" font="Arial"> Vliagoftis,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Alberta, Edmonton, AB T6G 2S2 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Retrospective analysis on the agreement between skin prick test and serum food specific IgE antibody results in adults with suspected food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="30">30-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> codfish</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Salmon</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Triage</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is a common clinical problem in adults. Given logistical barriers to conducting food challenges, the use of skin prick test (SPT) and specific IgE (sIgE) are important in establishing the diagnosis. The purpose of this study is to investigate the agreement of SPT and sIgE results in adults presenting to an allergy clinic with suspected food allergy. METHODS: Retrospective analysis of medical records at the University of Alberta Allergy Clinic between September 2013 and May 2015 was performed. Demographic, medical history as well as SPT and specific IgE results were recorded. Agreement of SPT and sIgE for individual food allergens was analyzed by Kappa statistics. RESULTS: Data from 260 patients was collected. The population was predominantly female, often having other atopic diseases. Very few food challenges were performed; IgE mediated food allergy was diagnosed in a minority (29.6 %) of cases. Kappa values which reached statistical significance were moderate for peanut k = 0.535 (p = 0.0002, CI 0.364-0.707), walnut k = 0.408 (p = 0.001 CI 0.159-0.657), pecan k = 0.530 (p = 0.001 CI 0.211-0.848), and lobster k = 0.543 (p = 0.004 CI 0.197-0.889), substantial for pistachio k = 0.657 (p = 0.023 CI 0.224-1.000), codfish k = 0.770 (p = 0.0002 CI 0.558-0.983), shrimp k = 0.627 (p = 0.0006 CI 0.383-0.871) and egg white k = 0.625 (p = 0.002 CI 0.293-0.957), almost perfect for cashew k = 0.894 (p = 0.0008 CI 0.693-1.000) and salmon k = 0.874 (p = 0.004 CI 0.705-1.000). CONCLUSIONS: The agreement between SPT and sIgE results on adults being evaluated for food allergy is at least moderate or better for peanut, walnut, pecan, pistachio, cashew, lobster, shrimp, codfish, salmon and egg white. This should be reassuring for patients who have contraindications or restricted access to either test as the results for the above allergens will likely agree. These findings may suggest that these tests could possibly be interchangeable in adults being evaluated for suspected food allergy and will aid primary care physicians in the triage of patients requiring allergist care</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0136-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27458480">PM:27458480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Ling L</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0136-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Demoly,P.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Sastre,J.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Information technology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergy immunotherapy (AIT) is acknowledged to produce beneficial mid- and long-term clinical and immunologic effects and increased quality of life in patients with allergic respiratory diseases (such as allergic rhinoconjunctivitis and allergic asthma). However, poor adherence to AIT (due to intentional and/or non-intentional factors) is still a barrier to achieving these benefits. There is an urgent need for patient support programs (PSPs) that encompass communication, educational and motivational components. In the field of AIT, a PSP should be capable of (1) improving adherence, (2) boosting patient engagement, (3) explaining how AIT differs from pharmacological allergy treatments; (4) increasing health literacy about chronic, progressive, immunoglobulin-E-mediated immune diseases, (5) helping the patient to understand and manage local or systemic adverse events, and (6) providing and/or predicting local data on aeroallergen levels. We reviewed the literature in this field and have identified a number of practical issues to be addressed when implementing a PSP for AIT: the measurement of adherence, the choice of technologies, reminders, communication channels and content, the use of "push" messaging and social networks, interactivity, and the involvement of caregivers and patient leaders. A key issue is "hi-tech" (i.e. approaches based mainly on information technology) vs. "hi-touch" (based mainly on interaction with humans, i.e. family members, patient mentors and healthcare professionals). We conclude that multistakeholder PSPs (combining patient-, provider and society-based actions) must now be developed and tested with a view to increasing adherence, efficacy and safety in the field of AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -CO - Italy -CO - Spain -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0140-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27478445">PM:27478445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Demoly P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0140-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghosal,K.</style></author><author><style face="normal" font="Arial"> Saha,B.</style></author><author><style face="normal" font="Arial"> Gupta,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Plant Biology, Bose Institute, Main Campus, 93/1, A.P.C. Road, Kolkata, West Bengal 700009 India</style></auth-address><titles><title><style face="normal" font="Arial">Clinical and immuno-proteomic approach on Lantana camara pollen allergy-a major health hazard</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="33">33-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2D-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Aerobiological sampling</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> histamine release assay</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Kolkata</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen load</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thaumatin-like protein</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The incidence of allergic diseases is increasing gradually and is a global burden affecting the socio-economic quality of life. Identification of allergens is the first step towards paving the way for therapeutic interventions against atopic diseases. Our previous investigation figured out that total pollen load correlated significantly with the rise of respiratory allergy in a subtropical city in India. The most dominant pollen responsible for IgE sensitivity in most patients emerged to be from Lantana camara (LC) an obnoxious weed growing in and around suburban areas of West Bengal. In this study, we identified allergenic components from this shrub using an immunoproteomic approach. METHODS: Determination of dominant pollen species was done using aerobiological sampling during two consecutive years and correlated with hospitalization and skin prick test. Serum was collected from LC positive patients and checked for in vitro allergenicity using ELISA and Histamine assay. Total proteome was profiled in SDS-PAGE, 2D PAGE and immunoblotted to detect IgE binding proteins which were further identified using mass spectrometry. RESULTS: Lantana camara pollen emerged as a significant contributor from the correlation study with hospital admission of the respiratory allergy sufferers and its extract demonstrated an elevated IgE response in ELISA and histamine release assay tests. Five IgE reactive bands/zones were observed in 1D blot which resolved to 12 allergo-reactive spots in the 2D blot. Mass spectrometric analysis identified nine spots that grouped into four diverse proteins. Pathogenesis-related Thaumatin-like protein was found to be one of the major allergens in Lantana camara. CONCLUSIONS: This is to our knowledge the first attempt to identify allergens from Lantana camara using a proteomic approach. The allergens identified thereof can be used to prepare hypoallergenic vaccine candidates and design immunotherapy trials against LC pollen and other aeroallergen carriers which are cross-reactive and harbor similar proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0135-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27471520">PM:27471520</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Ghosal K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0135-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chauhan,B.</style></author><author><style face="normal" font="Arial"> Gupta,M.</style></author><author><style face="normal" font="Arial"> Chauhan,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Role of antioxidants on the clinical outcome of patients with perennial allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> dose-ranging</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2016">2016/7/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Antioxidants have a preventive or therapeutic role in oxygen free radical-mediated cell and tissue damage. The study aimed to investigate the therapeutic effects of antioxidants and intranasal steroid fluticasone furoate (FF) on the clinical outcome of patients with perennial allergic rhinitis. METHODS: Subjects with perennial allergic rhinitis (n = 61) were randomly divided into two groups, group A (n = 30) received FF and group B (n = 31) received FF with antioxidants for 6 weeks. Nasal and ocular symptoms were evaluated weekly by using a four-point categoric scale. The efficacy of the study drug was assessed based on the mean change from baseline of the total daytime nasal symptom scores, total nighttime nasal symptom scores, and the composite symptom scores. RESULTS: The combined therapy (FF with antioxidants) resulted in marked improvements (p less then or equal to 0.05) in the mean total daytime nasal symptom scores, total nighttime nasal symptom scores, and composite symptom scores of subjects compared with ones treated with intranasal steroid (FF) alone, which highlighted the therapeutic effect of antioxidants in allergic rhinitis. CONCLUSION: Significant improvement in clinical outcome was observed in subjects who received antioxidants along with FF. However, because this was an open-label study, the results must be interpreted with caution, and further double-blind, placebo-controlled, dose-ranging trials supplemented with different antioxidants together with intranasal steroids are suggested</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0163</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27466026">PM:27466026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\20160728-ChauhanB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\20160728-ChauhanB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, Chauhan B</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0163</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Breslin,M.E.</style></author><author><style face="normal" font="Arial"> Lin,J.H.</style></author><author><style face="normal" font="Arial"> Roberts,R.</style></author><author><style face="normal" font="Arial"> Lim,K.J.</style></author><author><style face="normal" font="Arial"> Stiehm,E.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Transient hypogammaglobulinemia and severe atopic dermatitis: Open-label treatment with immunoglobulin in a case study</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="73" start="69">69-73</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Hypoalbuminemia</style></keyword><keyword><style face="normal" font="Arial"> Hypogammaglobulinemia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Intravenous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Intravenous immunoglobulin therapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We reported on six infants between 5 and 11 months old, with transient hypogammaglobulinemia of infancy and severe refractory atopic dermatitis, who were treated with open-label immunoglobulin (Ig) after conventional therapy failed. All six infants had an IgG level of 225 mg/dL, elevated eosinophil and IgE levels, and no urine or stool protein losses, but they did exhibit hypoalbuminemia. OBJECTIVE: To evaluate the utility of open-label immunoglobulin in infants with severe atopic dermatitis for whom conventional therapy failed. We reviewed the clinical utility of intravenous immunoglobulin in the treatment of severe atopic dermatitis, the most recent research in the field, and suggested mechanisms for its benefit. METHODS: The six infants were identified from a retrospective chart review at the University of California Los Angeles Allergy and Immunology outpatient pediatric clinic. RESULTS: All six patients were treated with 400 mg/kg/month of intravenous immunoglobulin and had normalization of their IgG and albumin levels, and all but one had clinically improved atopic dermatitis. CONCLUSION: Infants with severe atopic dermatitis who did not respond to conventional therapy avoidance may benefit from intravenous immunoglobulin therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470901">PM:27470901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\20160729-BreslinME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\20160729-BreslinME.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Breslin ME</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0164</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kuan,E.C.</style></author><author><style face="normal" font="Arial"> Tajudeen,B.A.</style></author><author><style face="normal" font="Arial"> Bhuta,S.M.</style></author><author><style face="normal" font="Arial"> Diaz,M.F.</style></author><author><style face="normal" font="Arial"> Kedeshian,P.A.</style></author><author><style face="normal" font="Arial"> Suh,J.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Incidental finding of lymphoma after septoplasty</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="95" start="90">90-95</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell lymphoma</style></keyword><keyword><style face="normal" font="Arial"> Cartilage</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Septoplasty, or surgical correction of the deviated septum, is an elective, routinely performed rhinologic procedure to address nasal airway obstruction. In many cases, resected septal cartilage and bone fragments are sent for pathologic review, although there is no consensus on this practice. We reported two cases of incidentally diagnosed lymphoma after elective septoplasty and discussed clinical presentation, diagnosis, and management. METHODS: Retrospective chart review of two patients who underwent septoplasty at a tertiary academic medical center and found to have incidental lymphoma based on histopathology. RESULTS: Two patients who underwent septoplasty had an incidental diagnosis of lymphoma on pathologic analysis. One patient was noted to have an S-shaped septal deviation that produced bilateral nasal obstruction. She underwent a difficult septoplasty, in which the mucoperichondrial flap was firmly adherent to the underlying septum and bone. Final pathology demonstrated diffuse large B-cell lymphoma. She was treated with chemoradiation and remained free of disease at 59 months. The other patient had a history of nasal trauma, which produced left septal deviation. He underwent an uncomplicated septoplasty, with pathology that demonstrated low-grade B-cell lymphoma. Because there was no evidence of active disease, the decision was made to not treat and to observe the patient clinically. CONCLUSIONS: This is the first reported series of septal lymphoma incidentally diagnosed on routine septoplasty. Although histopathologic review of specimens from routine nasal and sinus surgery is not routinely performed, this report highlighted the importance of this process, on a case-by-case basis, in detecting unexpected malignancies that otherwise were clinically silent</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0153</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470206">PM:27470206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\20160729-KuanEC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\20160729-KuanEC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Kuan EC</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0153</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martin,V.J.</style></author><author><style face="normal" font="Arial"> Shreffler,W.G.</style></author><author><style face="normal" font="Arial"> Yuan,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, Boston, MA, USACenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USADepartment of Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Presumed Allergic Proctocolitis Resolves with Probiotic Monotherapy: A Report of 4 Cases</style></title><secondary-title><style face="normal" font="Arial">Am J Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Case Rep</style></full-title></periodical><pages end="624" start="621">621-624</pages><volume><style face="normal" font="Arial">17</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus rhamnosus</style></keyword><keyword><style face="normal" font="Arial"> LGG</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND The prevalence of allergic diseases has been dramatically rising in the United States and other developed nations over recent decades. Growing evidence suggests a partial role for the microbiome in the development of these allergic diseases. Food protein-induced allergic proctocolitis (AP) (also referred to as cow's milk protein intolerance or allergy) is among the earliest and most common food allergic diseases of infancy, yet its pathophysiology is not well understood. The currently accepted clinical practice is to restrict the diet until 12 months of age. CASE REPORT We present 4 cases of clinically diagnosed AP whose symptoms quickly and completely resolved with probiotic Lactobacillus rhamnosus GG (LGG) monotherapy. All 4 infants avoided any dietary restrictions. The range of time from probiotic initiation to symptom resolution was 7-28 days. CONCLUSIONS These cases suggest an important role for the infant intestinal microbiome in the development of gastrointestinal mucosal food allergies such as AP. Prospective investigation of the intestinal microbiome in infants with AP may further our understanding of this disease's pathogenesis. The potential use of probiotic monotherapy in the treatment of AP also warrants further investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 1941-5923 (Electronic)IS - 1941-5923 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.12659/AJCR.898490</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27568925">PM:27568925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Case Rep\2016-17-621-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Case Rep\2016-17-621-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Martin VJ</style></custom2><misc3><style face="normal" font="Arial">10.12659/AJCR.898490</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stephany,M.P.</style></author><author><style face="normal" font="Arial"> Chung,S.</style></author><author><style face="normal" font="Arial"> Handler,M.Z.</style></author><author><style face="normal" font="Arial"> Handler,N.S.</style></author><author><style face="normal" font="Arial"> Handler,G.A.</style></author><author><style face="normal" font="Arial"> Schwartz,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Nebraska Medical Center, College of Medicine, Omaha, NE, USADermatology Department, Rutgers New Jersey Medical School, Newark, NJ, USADermatology Department, Rutgers New Jersey Medical School, Newark, NJ, USA. zac0@aol.comUniversity of Nebraska Medical Center, College of Medicine, Omaha, NE, USADermatology Department, Rutgers New Jersey Medical School, Newark, NJ, USADermatology Department, Rutgers New Jersey Medical School, Newark, NJ, USA</style></auth-address><titles><title><style face="normal" font="Arial">Shiitake Mushroom Dermatitis: A Review</style></title><secondary-title><style face="normal" font="Arial">Am J Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Clin Dermatol</style></full-title></periodical><pages end="489" start="485">485-489</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lentinan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mushrooms</style></keyword><keyword><style face="normal" font="Arial"> Nebraska</style></keyword><keyword><style face="normal" font="Arial"> New Jersey</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shiitake Mushrooms</style></keyword><keyword><style face="normal" font="Arial"> South America</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="26" Month="8" Year="2016">2016/8/26</year></dates><abstract><style face="normal" font="Arial">Shiitake mushroom dermatitis is a cutaneous reaction caused by the consumption of raw or undercooked shiitake mushrooms. Symptoms include linear erythematous eruptions with papules, papulovesicles or plaques, and severe pruritus. It is likely caused by lentinan, a heat-inactivated beta-glucan polysaccharide. Cases were initially reported in Japan but have now been documented in other Asian countries, North America, South America, and Europe, as this mushroom is now cultivated and consumed worldwide. Shiitake mushroom dermatitis may result from mushroom ingestion or from handling, which can result in an allergic contact dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1179-1888 (Electronic)IS - 1175-0561 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40257-016-0212-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566177">PM:27566177</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Clin Dermatol\20160827-StephanyMP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Clin Dermatol\20160827-StephanyMP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Stephany MP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40257-016-0212-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Finn,W.G.</style></author><author><style face="normal" font="Arial"> Gulbranson,R.</style></author><author><style face="normal" font="Arial"> Fisher,S.</style></author><author><style face="normal" font="Arial"> Rae,S.L.</style></author><author><style face="normal" font="Arial"> Shalhoub,R.</style></author><author><style face="normal" font="Arial"> Hedstrom,D.</style></author><author><style face="normal" font="Arial"> Keren,D.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Warde Medical Laboratory, Ann Arbor, MI Department of Pathology, University of Michigan, Ann Arbor.</style></auth-address><titles><title><style face="normal" font="Arial">Detection of Polyclonal Increases in Immunoglobulin G4 Subclass by Distinct Patterns on Capillary Serum Protein Electrophoresis: Diagnostic Pitfalls and Clinical Observations in a Study of 303 Cases</style></title><secondary-title><style face="normal" font="Arial">Am J Clin Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Clin Pathol</style></full-title></periodical><pages end="311" start="303">303-311</pages><volume><style face="normal" font="Arial">146</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ANN</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Capillaries</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G4</style></keyword><keyword><style face="normal" font="Arial"> Isoelectric Focusing</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pitfalls</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="7" Year="2016">2016/7/31</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Autoimmunity, hypersensitivity, and the recently recognized set of syndromes collectively termed immunoglobulin G4-related disease (IgG4-RD) may be associated with increased serum IgG4 levels. We reviewed our experience detecting increased IgG4 by distinct serum protein electrophoresis (SPEP) patterns. METHODS: We studied 303 capillary SPEP cases with dome-like anodal gamma changes and increased measured serum IgG4. RESULTS: IgG4 ranged from 208 to 6,670 mg/dL (normal, &lt;201 mg/dL). Seventeen of 91 cases evaluated by immunosubtraction appeared monotypic (16 kappa, 1 lambda), but all five cases further analyzed by isoelectric focusing appeared polyclonal. Six cases with markedly increased IgG4 had presumptive evidence of IgG4-RD. Sixteen of 45 assessed patients had autoantibodies. CONCLUSIONS: Increased polyclonal IgG4 has a characteristic SPEP pattern that may mimic monoclonal gammopathy, even on immunosubtraction. kappa Pseudo-restriction might reflect the naturally high kappa/lambda ratio of the IgG4 subclass. Autoantibodies were common, and the greatest IgG4 increases had clinical features of IgG4-RD</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1943-7722 (Electronic)IS - 0002-9173 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/ajcp/aqw113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27477045">PM:27477045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Clin Pathol\2016-146-303-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Clin Pathol\2016-146-303-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Finn WG</style></custom2><misc3><style face="normal" font="Arial">10.1093/ajcp/aqw113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lasoff,D.R.</style></author><author><style face="normal" font="Arial"> Ruha,A.M.</style></author><author><style face="normal" font="Arial"> Curry,S.C.</style></author><author><style face="normal" font="Arial"> Koh,C.</style></author><author><style face="normal" font="Arial"> Clark,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">VA Medical Center, San Diego, CA; UCSD Division of Medical Toxicology, Department of Emergency Medicine, San Diego, CA</style></auth-address><titles><title><style face="normal" font="Arial">A new F(ab')2 antivenom for the treatment of crotaline envenomation in children</style></title><secondary-title><style face="normal" font="Arial">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Emerg Med</style></full-title></periodical><pages end="2006" start="2003">2003-2006</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> fibrinogen</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Platelets</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="8" Year="2016">2016/8/2</year></dates><abstract><style face="normal" font="Arial">STUDY OBJECTIVE: To evaluate the efficacy and safety of a new F(ab')2 antivenom preparation in the treatment of Crotalinae envenomation in children. METHODS: We present a case series of children younger than 16 years who suffered Crotalinae envenomation and were treated with a new F(ab')2 antivenom. Envenomated children treated with the new antivenom were assessed for efficacy of the product, defined as improvement of any hemotoxicity (hypofibrinogenemia, defined as fibrinogen &lt;150 mg/dL, or thrombocytopenia, defined as platelets &lt;150 000/mm3), and the cessation of the advancement of swelling. Safety was also evaluated by monitoring for adverse events. A secondary parameter assessed in these children was recurrent hemotoxicity after initial control of signs and symptoms with follow-up visits and laboratory testing on posttreatment days 5, 8, and 15. RESULTS: Twenty-one children received the F(ab')2 antivenom. Efficacy was achieved in all children receiving the product with initial control of swelling and improvement in those with hemotoxicity. No patients suffered anaphylaxis or any other serious adverse events from the F(ab')2 treatment. There were no cases of recurrent hemotoxicity recorded in the study between time of initial control and postinfusion day 15. CONCLUSIONS: In this series of children, the F(ab')2 antivenom appeared to be both safe and effective in the treatment of hemotoxicity and local tissue toxicity (swelling) from Crotalinae envenomation</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1532-8171 (Electronic)IS - 0735-6757 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ajem.2016.07.061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27567423">PM:27567423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Emerg Med\20160827-LasoffDR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Emerg Med\20160827-LasoffDR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Lasoff DR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ajem.2016.07.061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foong,R.E.</style></author><author><style face="normal" font="Arial"> Bosco,A.</style></author><author><style face="normal" font="Arial"> Troy,N.M.</style></author><author><style face="normal" font="Arial"> Gorman,S.</style></author><author><style face="normal" font="Arial"> Hart,P.H.</style></author><author><style face="normal" font="Arial"> Kicic,A.</style></author><author><style face="normal" font="Arial"> Zosky,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Telethon Kids Institute</style></auth-address><titles><title><style face="normal" font="Arial">Identification of genes differentially regulated by vitamin D deficiency that alter lung pathophysiology and inflammation in allergic airways disease</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L663" start="L653">L653-L663</pages><volume><style face="normal" font="Arial">311</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Expression study</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="8" Year="2016">2016/8/5</year></dates><abstract><style face="normal" font="Arial">Vitamin D deficiency is associated with asthma risk. Vitamin D deficiency may enhance the inflammatory response and we have previously shown that airway remodelling and airway hyperresponsiveness (AHR) is increased in vitamin D-deficient mice. In this study, we hypothesize that vitamin D deficiency would exacerbate house dust mite (HDM)-induced inflammation and alterations in lung structure and function. A BALB/c mouse model of vitamin D deficiency was established by dietary manipulation. Responsiveness to methacholine, airway smooth muscle (ASM) mass, mucus cell metaplasia, lung and airway inflammation and cytokines in bronchoalveolar lavage (BAL) fluid were assessed. Gene expression patterns in mouse lung samples were profiled by RNA-Seq. HDM exposure increased inflammation and inflammatory cytokines in BAL, baseline airway resistance, tissue elastance and ASM mass. Vitamin D deficiency enhanced the HDM-induced influx of lymphocytes into BAL, ameliorated the HDM induced increase in ASM mass and protected against the HDM-induced increase in baseline airway resistance. RNA-Seq identified nine genes that were differentially regulated by vitamin D deficiency in the lungs of HDM-treated mice. Immunohistochemical staining confirmed that protein expression of MID1 and ADM were differentially regulated such that they promoted inflammation, while and HILDPA which is associated with ASM remodelling, was downregulated. Protein expression studies in human bronchial epithelial cells also showed that addition of vitamin D decreased MID1 expression. Differential regulation of these genes by vitamin D deficiency could determine lung inflammation and pathophysiology and suggest that the effect of vitamin D deficiency on HDM-induced allergic airways disease is complex</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00026.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496895">PM:27496895</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20160806-FoongRE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20160806-FoongRE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Foong RE</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00026.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,E.J.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author><author><style face="normal" font="Arial"> Hong,S.C.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author><author><style face="normal" font="Arial"> Kang,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">New allergen sensitization might be associated with increased body mass index in children</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="127" start="124">124-127</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Results of previous studies have shown a relationship between obesity and allergic diseases. However, concrete evidence about the association between obesity and allergies has been lacking. OBJECTIVE: The present study aimed to evaluate the potential association between body mass index (BMI) and the change in sensitization on skin-prick tests in children over a 2-year follow-up period. METHODS: Children in first and second grade from six elementary schools were recruited in 2010. The same participants, now in third and fourth grade, were recruited again in 2012. The enrolled children underwent skin-prick tests and physical examinations in 2010 and again in 2012. RESULTS: Four hundred fourteen children (boys to girls, 208 to 206) were included. Among 414 participants, 73 children showed new sensitization and 24 children showed negative conversion of allergic sensitization after 2 years. One hundred sixty-one children showed positive results on both tests, and 156 children showed negative results on both tests. The mean (standard deviation) change in BMI (1.09 +/- 1.81 kg/m(2)) over a 2-year follow-up in newly sensitized children was significantly greater than that of other groups (p = 0.008). CONCLUSION: Children who became newly sensitized to allergens tended to exhibit significant increases in BMI. Therefore, further evaluation of the relationship between obesity and allergy is needed</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4339</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27456587">PM:27456587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-124-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-124-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Lee EJ</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4339</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cingi,C.</style></author><author><style face="normal" font="Arial"> Wallace,D.</style></author><author><style face="normal" font="Arial"> Bayar Muluk,N.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author><author><style face="normal" font="Arial"> Castells,M.</style></author><author><style face="normal" font="Arial"> Sahin,E.</style></author><author><style face="normal" font="Arial"> Altintoprak,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ear, Nose and Throat (ENT) Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Managing anaphylaxis in the office setting</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="123" start="118">118-123</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although the definition of anaphylaxis for clinical use may vary by professional health care organizations and individuals, the definition consistently includes the concepts of a serious, generalized or systemic, allergic or hypersensitivity reaction that can be life-threatening or even fatal. METHODS: In this review, we presented the important topics in the treatment of anaphylaxis in the office setting. This review will discuss triggers and risk factors, clinical diagnosis, and management of anaphylaxis in the office setting. RESULTS: Anaphylaxis in the office setting is a medical emergency. It, therefore, is important to prepare for it, to have a posted, written anaphylaxis emergency protocol, and to rehearse the plan regularly. In this review, we presented the important steps in managing anaphylaxis in the office. Treatment of anaphylaxis should start with epinephrine administered intramuscularly at the first sign of anaphylaxis. Oxygen and intravenous fluids may be needed for moderate-to-severe anaphylaxis or anaphylaxis that is quickly developing or if the patient is unresponsive to the first injection of epinephrine. Antihistamine therapy is considered adjunctive to epinephrine, which mainly relieves itching and urticaria. Corticosteroids, with an onset of action of 4-6 hours, have no immediate effect on anaphylaxis. CONCLUSION: To prevent near-fatal and fatal reactions from anaphylaxis, the patient, the family, and the physician must remember to follow the necessary steps when treating anaphylaxis. In anaphylaxis, there is no absolute contraindication for epinephrine</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleSB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27456586">PM:27456586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-118-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-118-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Cingi C</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4336</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,J.L.</style></author><author><style face="normal" font="Arial"> Ma,Z.</style></author><author><style face="normal" font="Arial"> Sun,W.W.</style></author><author><style face="normal" font="Arial"> Cao,J.P.</style></author><author><style face="normal" font="Arial"> Wang,Z.H.</style></author><author><style face="normal" font="Arial"> Cui,H.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, General Hospital of Shenyang Military Command, Shenyang, China</style></auth-address><titles><title><style face="normal" font="Arial">Programmed vaccination may increase the prevalence of asthma and allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="117" start="113">113-117</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of asthma and allergic diseases has risen in recent decades. The etiology of asthma and allergic diseases has not been entirely elucidated. OBJECTIVE: In this study, we investigated the possibility that programmed vaccination in China may have a potential role in asthma and allergic diseases. METHODS: In this animal model, newborn BALB/c mice were randomly divided into three groups: vaccine plus ovalbumin (OVA), OVA, and control. The mice of vaccine plus OVA only group were inoculated with vaccines by following the National Vaccines Inoculation Program in China. Mice of vaccine plus OVA and OVA only groups were sensitized and challenged with OVA. Airway hyperresponsiveness was assessed by lung function and serum interleukin (IL) 4 and interferon (IFN) gamma were measured. RESULTS: The results of lung function showed that mice of the vaccine plus OVA group exhibited an increase in enhanced pause (Penh) compared with that in the OVA group at methacholine concentrations of 6.25 and 12.5 mg/mL (p &lt; 0.05). Serum IL-4 in the vaccine plus OVA group was higher than that in the OVA group (p &lt; 0.01). The serum IFN-gamma level in the OVA group was lower than that in the control group (p &lt; 0.01), and also lower than that in the vaccine plus OVA group (p &lt; 0.05). The ratio of IFN-gamma to IL-4 both in the OVA and vaccine plus OVA group was lower than that in the control group (p &lt; 0.01). CONCLUSIONS: Results of our study indicated that programmed vaccination in China may have a potential role in the prevalence of asthma and allergic diseases by inducing T-helper 2 cytokine expression and may be responsible for the increasing prevalence of asthma and allergic diseases in China</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4335</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27456585">PM:27456585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-113-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-113-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Zhang JL</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4335</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paz Lansberg,M.</style></author><author><style face="normal" font="Arial"> deTineo,M.</style></author><author><style face="normal" font="Arial"> Lane,J.</style></author><author><style face="normal" font="Arial"> Pinto,J.M.</style></author><author><style face="normal" font="Arial"> Baroody,F.M.</style></author><author><style face="normal" font="Arial"> Naclerio,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Otolaryngology-Head and Neck Surgery, Department of Surgery, The University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA</style></auth-address><titles><title><style face="normal" font="Arial">A clinical trial of a microcrystalline cellulose topical nasal spray on the acute response to allergen challenge</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="273" start="269">269-273</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Cellulose</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal challenge</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis is a common disorder that leads to a negative impact on quality of life. Multiple options are available for treatment of the symptoms, but preventing the reaction should be an effective strategy. OBJECTIVE: We tested a nasal spray that contained microcrystalline cellulose designed to limit airborne allergens from penetrating the nasal mucosa (nasal blocker) and, therefore, prevent the initiation of the allergic reaction. METHODS: We performed a randomized, double-blind, placebo-controlled, two-way crossover clinical trial with 20 subjects who had a history of seasonal grass and/or ragweed allergy symptoms. Each subject underwent two separate nasal challenges with antigen (provocations) after application of the investigational product or placebo to both nostrils. The allergen was delivered into one nostril at a time and was administered at 2-hour intervals (identified as challenge 1 and challenge 2). We assessed peak nasal inspiratory flow and total nasal symptoms as well as the number of sneezes recorded at both 15-minute and 1-hour intervals after challenge 1 and, later, challenge 2. After a washout period, the subjects returned to undergo the alternate therapy. RESULTS: There was a significant overall decrease in peak nasal inspiratory flow after both treatments (investigational product, p = 0.005; placebo, p = 0.001), but, when the average of the change from baseline in peak nasal inspiratory flow was compared with the baseline, the results showed no significant differences between the groups (p = 0.31). Similar results were obtained for total nasal symptoms. CONCLUSION: The investigational product did not prove to be significantly better than placebo in treating seasonal allergic rhinitis symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27456597">PM:27456597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-269-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-269-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Paz Lansberg M</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4314</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Coskun,Z.O.</style></author><author><style face="normal" font="Arial"> Erdivanli,O.C.</style></author><author><style face="normal" font="Arial"> Kazikdas,K.C.</style></author><author><style face="normal" font="Arial"> Terzi,S.</style></author><author><style face="normal" font="Arial"> Sahin,U.</style></author><author><style face="normal" font="Arial"> Ozgur,A.</style></author><author><style face="normal" font="Arial"> Demirci,M.</style></author><author><style face="normal" font="Arial"> Dursun,E.</style></author><author><style face="normal" font="Arial"> Cingi,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">High sensitization to house-dust mites in patients with allergic rhinitis in the eastern Black Sea region of Turkey: A retrospective study</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="1" Month="7" Year="2016">2016/7/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Identification of the most common aeroallergens to which patients are sensitized in a specific area is important in the diagnosis and treatment of allergic rhinitis (AR). We determined the distribution of aeroallergens, detected by skin-prick tests (SPT), in adult patients with AR in the Eastern Black Sea region of Turkey and compared the results with the other regions of Turkey and in the world. METHODS: The medical records of SPT performed on 1457 patients with symptoms of AR (with regard to the Allergic Rhinitis and its Impact on Asthma 2008 guidelines) between March 2010 and March 2013 were analyzed retrospectively. SPT were carried out with the same panel, which included grass; weeds; trees; mold; epidermal mixtures; and with two house-dust mite (HDM) extracts, Dermatophagoides pteronyssinus and Dermatophagoides farinae. RESULTS: In 1229 of 1457 patients (84.4%), there were positive reactions for at least one aeroallergen on the SPT. The most common aeroallergen was the HDM D. pteronyssinus (84% [n = 1033]) followed by D. farinae (78.2% [n = 962]). Grass pollen sensitivity (70.8% [n = 871]) was higher than tree or weed pollen sensitivity in this region. CONCLUSIONS: The most common aeroallergens in AR are HDMs of D. pteronyssinus and D. farinae in the Eastern Black Sea region in Turkey. Our study may help in developing environmental control strategies for AR</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4353</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27465310">PM:27465310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\20160728-CoskunZO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\20160728-CoskunZO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, Coskun ZO</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4353</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amir,A.</style></author><author><style face="normal" font="Arial"> Ngui,R.</style></author><author><style face="normal" font="Arial"> Ismail,W.H.</style></author><author><style face="normal" font="Arial"> Wong,K.T.</style></author><author><style face="normal" font="Arial"> Ong,J.S.</style></author><author><style face="normal" font="Arial"> Lim,Y.A.</style></author><author><style face="normal" font="Arial"> Lau,Y.L.</style></author><author><style face="normal" font="Arial"> Mahmud,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</style></auth-address><titles><title><style face="normal" font="Arial">Anisakiasis Causing Acute Dysentery in Malaysia</style></title><secondary-title><style face="normal" font="Arial">Am J Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Trop Med Hyg</style></full-title></periodical><pages end="412" start="410">410-412</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> Colonoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Larva</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Penetration</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zoonosis</style></keyword></keywords><dates><year Day="3" Month="8" Year="2016">2016/8/3</year></dates><abstract><style face="normal" font="Arial">Human anisakiasis is a zoonosis acquired by eating raw or undercooked infected seafood. Herein, we report a case of acute dysentery caused by anisakiasis in a 64-year-old man in Malaysia. A colonoscopy was performed and a nematode larva was found penetrating the mucosa of the ascending colon. Bleeding was observed at the site of penetration. Y-shaped lateral epidermal cords were seen from the cross section of the worm, which is a prominent feature of Anisakis larva. Molecular analysis using polymerase chain reaction of cytochrome oxidase 2 (cox2) gene confirmed the specimen to be larva of Anisakis simplex</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 1476-1645 (Electronic)IS - 0002-9637 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.4269/ajtmh.16-0007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27325803">PM:27325803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Trop Med Hyg\2016-95-410-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Trop Med Hyg\2016-95-410-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Amir A</style></custom2><misc3><style face="normal" font="Arial">10.4269/ajtmh.16-0007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santiago,H.C.</style></author><author><style face="normal" font="Arial"> Nutman,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry and Immunology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. heltonsantiago@icb.ufmg.brLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Human Helminths and Allergic Disease: The Hygiene Hypothesis and Beyond</style></title><secondary-title><style face="normal" font="Arial">Am J Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Trop Med Hyg</style></full-title></periodical><pages end="753" start="746">746-753</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="29" Month="8" Year="2016">2016/8/29</year></dates><abstract><style face="normal" font="Arial">There is much debate about the interaction between helminths and allergic disease. The "Hygiene Hypothesis," a very popular concept among scientists and the lay public, states that infections, especially during childhood, can protect against allergic diseases. Indeed, helminth infections are known to induce regulatory responses in the host that can help the control of inflammation (including allergic inflammation). However, these infections also induce type-2-associated immune responses including helminth-specific IgE that can cross-react against environmental allergens and mediate IgE-driven effector responses. Thus, it is the delicate balance between the parasites' anti- and proallergenic effects that define the helminth/allergy interface</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1476-1645 (Electronic)IS - 0002-9637 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Brazil -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4269/ajtmh.16-0348</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27573628">PM:27573628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Trop Med Hyg\20160830-SantiagoHC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Trop Med Hyg\20160830-SantiagoHC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Santiago HC</style></custom2><misc3><style face="normal" font="Arial">10.4269/ajtmh.16-0348</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inaba,I.</style></author><author><style face="normal" font="Arial"> Kuramitz,H.</style></author><author><style face="normal" font="Arial"> Sugawara,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Maebashi Institute of Technology</style></auth-address><titles><title><style face="normal" font="Arial">Electrochemical Sensing of Casein Based on the Interaction between Its Phosphate Groups and a Ruthenium(III) Complex</style></title><secondary-title><style face="normal" font="Arial">Anal Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Sci</style></full-title></periodical><pages end="859" start="853">853-859</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hydrophobicity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">A reaction to casein, along with beta-lactoglobulin, is a main cause of milk allergies, and also is a useful indicator of protein in allergic analyses. In the present study, a simple casein sensor was developed based on the interaction between a phosphate group of casein and electroactive [Ru(NH3)6](3+). We evaluated the voltammetric behavior of a casein-[Ru(NH3)6](3+) complex using a glassy carbon electrode. When the ruthenium(III) complex was combined with the phosphate groups of casein, the structure of the casein was changed. Since the hydrophobicity of casein was increased due to the binding, the casein was adsorbed onto the electrode. Furthermore, we modified an electrode with a ruthenium(III) ions/collagen film. When the sensor was applied to the detection of the casein contained in milk, the values coincided with those indicated by the manufacturer. Accordingly, this electrode could be a powerful sensor for the determination of casein in several foods</style></abstract><notes><style face="normal" font="Arial">DA - 20160810IS - 1348-2246 (Electronic)IS - 0910-6340 (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2116/analsci.32.853</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27506711">PM:27506711</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Sci\2016-32-853-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Sci\2016-32-853-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160810, Inaba I</style></custom2><misc3><style face="normal" font="Arial">10.2116/analsci.32.853</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morales-Cabeza,C.</style></author><author><style face="normal" font="Arial"> Prieto-Garcia,A.</style></author><author><style face="normal" font="Arial"> Acero,S.</style></author><author><style face="normal" font="Arial"> Bartolome-Zavala,B.</style></author><author><style face="normal" font="Arial"> Morgado,J.M.</style></author><author><style face="normal" font="Arial"> Matito,A.</style></author><author><style face="normal" font="Arial"> Sanchez-Munoz,L.</style></author><author><style face="normal" font="Arial"> Alvarez-Twose,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Systemic mastocytosis presenting as occupational IgE-mediated anaphylaxis to pine processionary caterpillar</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="334" start="333">333-334</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27474119">PM:27474119</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160730-MoralesCabezaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160730-MoralesCabezaC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Morales-Cabeza C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zazzali,J.L.</style></author><author><style face="normal" font="Arial"> Kaplan,A.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Raimundo,K.</style></author><author><style face="normal" font="Arial"> Trzaskoma,B.</style></author><author><style face="normal" font="Arial"> Solari,P.G.</style></author><author><style face="normal" font="Arial"> Antonova,E.</style></author><author><style face="normal" font="Arial"> Mendelson,M.</style></author><author><style face="normal" font="Arial"> Rosen,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genentech Inc, South San Francisco, California</style></auth-address><titles><title><style face="normal" font="Arial">Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="377" start="370">370-377</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="7" Year="2016">2016/7/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Angioedema, present in some patients with chronic idiopathic/spontaneous urticaria (CIU/CSU), may have a negative effect on patient quality of life. OBJECTIVE: To describe patient-reported angioedema and its management in the pivotal omalizumab studies (ASTERIA I, ASTERIA II, GLACIAL). METHODS: Enrolled patients with CIU/CSU remained symptomatic despite treatment with histamine1 (H1)-antihistamines at licensed doses (ASTERIA I, ASTERIA II) or H1-antihistamines at up to 4 times the approved dose plus H2-antihistamines and/or a leukotriene receptor antagonist (GLACIAL). All studies administered omalizumab (75, 150, or 300 mg in ASTERIA I and ASTERIA II; 300 mg in GLACIAL) or placebo subcutaneously every 4 weeks for at least 12 weeks. Urticaria Patient Daily Diary entries were completed by patients and summarized. RESULTS: At baseline, angioedema prevalence was higher in GLACIAL (53.1%) than in ASTERIA I (47.5%) or ASTERIA II (40.7%). The mean proportion of angioedema-free days during weeks 4 to 12 was greater for patients treated with 300 mg of omalizumab than placebo in ASTERIA I (96.1% vs 88.2%, P &lt; .001), ASTERIA II (95.5% vs 89.2%, P &lt; .001), and GLACIAL (91.0% vs 88.7%, P = .006). Most patient-reported angioedema was managed by low-intensity interventions (doing nothing or taking medication). CONCLUSION: Treatment with 300 mg of omalizumab was efficacious in reducing patient-reported angioedema. Low-intensity interventions were generally used to manage angioedema episodes. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)</style></abstract><notes><style face="normal" font="Arial">DA - 20160717IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.06.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27424128">PM:27424128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160717-ZazzaliJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160717-ZazzaliJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160717, Zazzali JL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.06.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vitalpur,G.</style></author><author><style face="normal" font="Arial"> Padgett,S.</style></author><author><style face="normal" font="Arial"> Kloepfer,K.M.</style></author><author><style face="normal" font="Arial"> Slaven,J.</style></author><author><style face="normal" font="Arial"> Leickly,F.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.</style></auth-address><titles><title><style face="normal" font="Arial">Variations in pollen counts between Indianapolis, IN, and Dayton, OH, in spring 2013 and 2014</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="329" start="328">328-329</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="25" Month="7" Year="2016">2016/7/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.06.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470219">PM:27470219</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160729-VitalpurG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160729-VitalpurG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Vitalpur G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.06.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,J.M.</style></author><author><style face="normal" font="Arial"> Jo,J.H.</style></author><author><style face="normal" font="Arial"> Jin,H.</style></author><author><style face="normal" font="Arial"> Ko,H.C.</style></author><author><style face="normal" font="Arial"> Kim,M.B.</style></author><author><style face="normal" font="Arial"> Kim,J.M.</style></author><author><style face="normal" font="Arial"> Kim,D.W.</style></author><author><style face="normal" font="Arial"> Jang,H.S.</style></author><author><style face="normal" font="Arial"> Kim,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Pusan National University School of Medicine, Busan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Change in Antimicrobial Susceptibility of Skin-Colonizing Staphylococcus aureus in Korean Patients with Atopic Dermatitis during Ten-Year Period</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="478" start="470">470-478</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MRSA</style></keyword><keyword><style face="normal" font="Arial"> NARES</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A small subset of adolescents atopic dermatitis (AD) tends to persist. This also leads to get more antibiotics exposure with advancing years. Antibiotic resistance has been regarded as a serious problem during Staphylococcus aureus treatment, especially methicillin-resistant S. aureus (MRSA). OBJECTIVE: It was investigated the S. aureus colonization frequency in the skin lesions and anterior nares of adolescent AD patients and evaluated the changes in S. aureus antimicrobial susceptibility for years. METHODS: Patients who visited our clinic from September 2003 to August 2005 were classified into group A, and patients who visited from August 2010 to March 2012 were classified into group B. To investigate the differences with regard to patients' age and disease duration, the patients were subdivided into groups according to age. Lesional and nasal specimens were examined. RESULTS: Among the 295 AD patients, the total S. aureus colonization rate in skin lesions was 66.9% (95/142) for group A and 78.4% (120/153) for group B. No significant changes in the systemic antimicrobial susceptibilities of S. aureus strains isolated from adolescent AD patients were observed during about 10-year period. The increased trend of MRSA isolation in recent adolescent AD outpatients suggest that the community including school could be the source of S. aureus antibiotic resistance and higher fusidic acid resistance rates provides evidence of imprudent topical use. CONCLUSION: Relatively high MRSA isolation and fusidic acid resistance rates in recent AD patients suggest that the community harbors antibiotic-resistant S. aureus</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2016.28.4.470</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489430">PM:27489430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2016-28-470-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2016-28-470-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Park JM</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2016.28.4.470</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Curto,E.</style></author><author><style face="normal" font="Arial"> Munteis-Olivas,E.</style></author><author><style face="normal" font="Arial"> Balcells,E.</style></author><author><style face="normal" font="Arial"> Dominguez-Alvarez,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Hospital del Mar, Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Pulmonary eosinophilia associated to treatment with natalizumab</style></title><secondary-title><style face="normal" font="Arial">Ann Thorac Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Thorac Med</style></full-title></periodical><pages end="226" start="224">224-226</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoscopy</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Insufficiency</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Natalizumab (Tysabri((R))) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who started treatment with natalizumab. She began to show mild asthmatic symptoms until she needed admission to the hospital due to respiratory insufficiency. Blood tests showed peripheral eosinophilia and the thoracic computed tomography scan demonstrated pulmonary infiltrates. The bronchoscopy with the bronchoalveolar lavage resulted in eosinophilic alveolitis. No evidence of bacterial, fungal and parasitic infection, connective tissue disease, or vasculitis were observed. After discontinuation of natalizumab, the patient improved without other treatments. As MS is a prevalent disease and the use of natalizumab is increasing, we consider important to point out that this drug can be associated with pulmonary eosinophilia, especially in patients with allergic rhinoconjunctivitis or asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1817-1737 (Print)IS - 1998-3557 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.4103/1817-1737.185762</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512514">PM:27512514</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Thorac Med\2016-11-224-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Thorac Med\2016-11-224-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Curto E</style></custom2><misc3><style face="normal" font="Arial">10.4103/1817-1737.185762</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bar-Sela,G.</style></author><author><style face="normal" font="Arial"> Avgush,S.</style></author><author><style face="normal" font="Arial"> Kaidar-Person,O.</style></author><author><style face="normal" font="Arial"> Beny,A.</style></author><author><style face="normal" font="Arial"> Semenisty,V.</style></author><author><style face="normal" font="Arial"> Bergman,R.</style></author><author><style face="normal" font="Arial"> Khamaysi,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDivision of Oncology bDepartment of Dermatology, Rambam Health Care Campus cTechnion-Israel Institute of Technology, Faculty of Medicine, Haifa, Israel dDepartment of Radiation Oncology, University of North Carolina, Chapel Hill, Carolina, USA</style></auth-address><titles><title><style face="normal" font="Arial">Acne during adolescence did not predict skin rash reaction to cetuximab</style></title><secondary-title><style face="normal" font="Arial">Anticancer Drugs</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Anticancer Drugs</style></abbr-1></periodical><pages end="1037" start="1033">1033-1037</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acne Vulgaris</style></keyword><keyword><style face="normal" font="Arial"> Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Radiation</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="9" Month="8" Year="2016">2016/8/9</year></dates><abstract><style face="normal" font="Arial">Cetuximab, a monoclonal antibody, is a part of the treatment for metastatic colorectal cancer. The most common side effect of cetuximab is skin rash, which has a similar distribution to acne vulgaris and some overlapping pathophysiological mechanisms. The aim of the current study was to determine whether acne vulgaris in adolescence (AinA) is predictive of a cetuximab-related rash to better understand the pathogenesis of this side effect and explore potential preventive actions. From July 2013 to June 2015, patients with metastatic colorectal cancer planned for treatment with cetuximab were enrolled in the study. Before initiating treatment, patients completed a questionnaire evaluating endocrine disorders, other chronic diseases, smoking, chronic medications, allergies, and dermatologic history of AinA and its severity. Patients were followed for 6 months. Data were collected from 32 participants (16 women, 16 men). Twenty-three (69%) patients experienced a cetuximab-associated skin reaction. Nine (28%) patients had a history of AinA. Of these, seven developed a cetuximab-associated skin reaction. Three of the five (60%) patients who used proton pump inhibitors (PPIs) developed severe (grades 3-4) skin toxicity versus 4/27 (15%) patients who were not on PPIs (P=0.057). The degree of skin toxicity correlated to the median time-to-tumor-progression: 2 months for patients with grades 0-1 compared with 5.5 months for grades 2-4 skin toxicity (P=0.047, 95% confidence interval 1.06-4.95). No significant correlation was found between AinA and cetuximab-associated skin reactions. The correlation between PPI treatment and severe skin toxicity related to cetuximab should be examined further</style></abstract><notes><style face="normal" font="Arial">DA - 20160810IS - 1473-5741 (Electronic)IS - 0959-4973 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1097/CAD.0000000000000419</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27509079">PM:27509079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anticancer Drugs\20160810-BarSelaG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anticancer Drugs\20160810-BarSelaG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160810, Bar-Sela G</style></custom2><misc3><style face="normal" font="Arial">10.1097/CAD.0000000000000419</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Segers,F.J.</style></author><author><style face="normal" font="Arial"> van Laarhoven,K.A.</style></author><author><style face="normal" font="Arial"> Huinink,H.P.</style></author><author><style face="normal" font="Arial"> Adan,O.C.</style></author><author><style face="normal" font="Arial"> Wosten,H.A.</style></author><author><style face="normal" font="Arial"> Dijksterhuis,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CBS-KNAW Fungal Biodiversity Centre, Applied and Industrial Mycology, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">The Indoor Fungus Cladosporium halotolerans Survives Humidity Dynamics Markedly Better than Aspergillus niger and Penicillium rubens despite Less Growth at Lowered Steady-State Water Activity</style></title><secondary-title><style face="normal" font="Arial">Appl Environ Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Environ Microbiol</style></full-title></periodical><pages end="5098" start="5089">5089-5098</pages><volume><style face="normal" font="Arial">82</style></volume><number><style face="normal" font="Arial">17</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus niger</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Conidia</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> cryo-scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Hyphae</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="Arial">Indoor fungi cause damage in houses and are a potential threat to human health. Indoor fungal growth requires water, for which the terms water activity (aw) and relative humidity (RH) are used. The ability of the fungi Aspergillus niger, Cladosporium halotolerans, and Penicillium rubens at different developmental stages to survive changes in aw dynamics was studied. Fungi grown on media with high aw were transferred to a controlled environment with low RH and incubated for 1 week. Growth of all developmental stages was halted during incubation at RHs below 75%, while growth continued at 84% RH. Swollen conidia, germlings, and microcolonies of A. niger and P. rubens could not reinitiate growth when retransferred from an RH below 75% to a medium with high aw All developmental stages of C. halotolerans showed growth after retransfer from 75% RH. Dormant conidia survived retransfer to medium with high aw in all cases. In addition, retransfer from 84% RH to medium with high aw resulted in burst hyphal tips for Aspergillus and Penicillium Cell damage of hyphae of these fungi after incubation at 75% RH was already visible after 2 h, as observed by staining with the fluorescent dye TOTO-1. Thus, C. halotolerans is more resistant to aw dynamics than A. niger and P. rubens, despite its limited growth compared to that of these fungi at a lowered steady-state aw The survival strategy of this phylloplane fungus in response to the dynamics of aw is discussed in relation to its morphology as studied by cryo-scanning electron microscopy (cryo-SEM). IMPORTANCE: Indoor fungi cause structural and cosmetic damage in houses and are a potential threat to human health. Growth depends on water, which is available only at certain periods of the day (e.g., during cooking or showering). Knowing why fungi can or cannot survive indoors is important for finding novel ways of prevention. Until now, the ability of fungi to grow on media with little available water at steady state (unchanging conditions) has been important for evaluating whether a fungus can grow indoors. In the present study, we found that the fungus Cladosporium halotolerans, a common indoor fungus, is more resistant to changes in available water than the fungi Aspergillus niger and Penicillium rubens, despite the fact that the latter fungi can grow on media with low water availability. We concluded that the ability of fungi to deal with changes in humidity is at least as important as the ability to grow on low-water media</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1098-5336 (Electronic)IS - 0099-2240 (Linking)LA - engPT - Journal ArticleSB - IMCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1128/AEM.00510-16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27316968">PM:27316968</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Environ Microbiol\2016-82-5089-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Environ Microbiol\2016-82-5089-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Segers FJ</style></custom2><misc3><style face="normal" font="Arial">10.1128/AEM.00510-16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Delgado,J.</style></author><author><style face="normal" font="Arial"> Owens,R.A.</style></author><author><style face="normal" font="Arial"> Doyle,S.</style></author><author><style face="normal" font="Arial"> Asensio,M.A.</style></author><author><style face="normal" font="Arial"> Nunez,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Hygiene and Safety, Institute of Meat Products, University of Extremadura, Caceres, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Manuscript title: antifungal proteins from moulds: analytical tools and potential application to dry-ripened foods</style></title><secondary-title><style face="normal" font="Arial">Appl Microbiol Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Microbiol Biotechnol</style></full-title></periodical><pages end="7000" start="6991">6991-7000</pages><volume><style face="normal" font="Arial">100</style></volume><number><style face="normal" font="Arial">16</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Cheese</style></keyword><keyword><style face="normal" font="Arial"> Chitin</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Filamentous fungi</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Meat Products</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxins</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sensory quality</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Moulds growing on the surface of dry-ripened foods contribute to their sensory qualities, but some of them are able to produce mycotoxins that pose a hazard to consumers. Small cysteine-rich antifungal proteins (AFPs) from moulds are highly stable to pH and proteolysis and exhibit a broad inhibition spectrum against filamentous fungi, providing new chances to control hazardous moulds in fermented foods. The analytical tools for characterizing the cellular targets and affected pathways are reviewed. Strategies currently employed to study these mechanisms of action include 'omics' approaches that have come to the forefront in recent years, developing in tandem with genome sequencing of relevant organisms. These techniques contribute to a better understanding of the response of moulds against AFPs, allowing the design of complementary strategies to maximize or overcome the limitations of using AFPs on foods. AFPs alter chitin biosynthesis, and some fungi react inducing cell wall integrity (CWI) pathway. However, moulds able to increase chitin content at the cell wall by increasing proteins in either CWI or calmodulin-calcineurin signalling pathways will resist AFPs. Similarly, AFPs increase the intracellular levels of reactive oxygen species (ROS), and moulds increasing G-protein complex beta subunit CpcB and/or enzymes to efficiently produce glutathione may evade apoptosis. Unknown aspects that need to be addressed include the interaction with mycotoxin production by less sensitive toxigenic moulds. However, significant steps have been taken to encourage the use of AFPs in intermediate-moisture foods, particularly for mould-ripened cheese and meat products</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1432-0614 (Electronic)IS - 0175-7598 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Spain -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00253-016-7706-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27394712">PM:27394712</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Microbiol Biotechnol\2016-100-6991-7000.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Microbiol Biotechnol\2016-100-6991-7000.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Delgado J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00253-016-7706-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gore,C.</style></author><author><style face="normal" font="Arial"> Griffin,R.</style></author><author><style face="normal" font="Arial"> Rothenberg,T.</style></author><author><style face="normal" font="Arial"> Tallett,A.</style></author><author><style face="normal" font="Arial"> Hopwood,B.</style></author><author><style face="normal" font="Arial"> Sizmur,S.</style></author><author><style face="normal" font="Arial"> O'Keeffe,C.</style></author><author><style face="normal" font="Arial"> Warner,J.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Academic Paediatric Allergy, Imperial College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">New patient-reported experience measure for children with allergic disease: development, validation and results from integrated care</style></title><secondary-title><style face="normal" font="Arial">Arch Dis Child</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dis Child</style></full-title></periodical><pages end="943" start="935">935-943</pages><volume><style face="normal" font="Arial">101</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Focus Groups</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="8" Year="2016">2016/8/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To develop and validate a new allergy-specific patient-reported experience measure (PREM) for children and their parents, and to collect feedback in an integrated care setting. DESIGN: Two allergy-specific PREMs were produced using focus groups, cognitive testing, two prospective validation studies (collaboration: Royal College of Paediatrics and Child Health, Picker Institute Europe, Imperial College/London): 'Your Allergy Care', for children aged 8-16 years; 'Your Child's Allergy Care', for parents of children aged 0-7 years. SETTING: Community event, primary/secondary/tertiary allergy care settings. MAIN OUTCOME MEASURES: Performance of PREMs in validation study; reported experience of allergy care. PARTICIPANTS: 687 children with allergic conditions and their parents/carers. RESULTS: In total, 687 questionnaires were completed; 503/687 (253 child; 250 parent) for the final survey. In both surveys, demographic variations were not associated with differences in results. Although 71% of patients reported one or more allergic conditions (food allergy/eczema/hay fever/asthma), 62% required multiple visits before receiving final diagnosis. Overall, patient experience was good for communication with patient/parent, competence and confidence in ability, and 73% felt looked after 'very well' and 23% 'quite well'. Areas for improvement included communication with nurseries/schools, more information on side effects, allergic conditions and allergen/irritant avoidance. Allergy care in primary/emergency care settings was associated with higher problem-scores (worse experience) than in specialist clinics. CONCLUSIONS: These new PREMs will allow allergy-specific patient experience reporting for children and parents and help identification of priority areas for improvement and commissioning of care. Efforts towards better allergy care provision must be targeted at primary and emergency care settings and underpinned by improving communication between healthcare providers and the community</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1468-2044 (Electronic)IS - 0003-9888 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/archdischild-2015-309598</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27484970">PM:27484970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dis Child\20160803-GoreC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dis Child\20160803-GoreC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Gore C</style></custom2><misc3><style face="normal" font="Arial">10.1136/archdischild-2015-309598</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grimshaw,K.</style></author><author><style face="normal" font="Arial"> Logan,K.</style></author><author><style face="normal" font="Arial"> O'Donovan,S.</style></author><author><style face="normal" font="Arial"> Kiely,M.</style></author><author><style face="normal" font="Arial"> Patient,K.</style></author><author><style face="normal" font="Arial"> van Bilsen,J.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author><author><style face="normal" font="Arial"> Garcia-Larsen,V.</style></author><author><style face="normal" font="Arial"> Grabenhenrich,L.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author><author><style face="normal" font="Arial"> Mills,C.</style></author><author><style face="normal" font="Arial"> Wal,J.M.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development in Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Modifying the infant's diet to prevent food allergy</style></title><secondary-title><style face="normal" font="Arial">Arch Dis Child</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dis Child</style></full-title></periodical><pages end="186" start="179">179-186</pages><volume><style face="normal" font="Arial">102</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergen management</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Recommendations and guidelines on the prevention of food allergy have changed in recent decades. The aim of this review of the current evidence and ongoing studies is to provide a comprehensive and up to date picture of prevention of food allergy for healthcare professionals. The review was undertaken as part of the European Union funded Integrated Approaches to Food Allergy and Allergen Management (iFAAM) study. This is a wide ranging project bringing together expertise across the breadth of food allergy research. Specifically, the review discusses dietary manipulation in food allergy prevention, and covers the possible preventive strategies of allergen avoidance, early allergen introduction, general nutrition and supplements, as well as other strategies, such as prebiotics and probiotics. The review concludes that despite agreement that allergen avoidance strategies should not be undertaken for allergy prevention, there is currently no consensus regarding what actions should be recommended beyond exclusive breastfeeding for the first 4-6 months of life. Recent and upcoming trial results, which are detailed in this review, should help inform the debate and add clarity to the topic</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 1468-2044 (Electronic)IS - 0003-9888 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United KIngdom -CO - Ireland -CO - France -CO - Netherlands -CO - France -CO - Germany -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1136/archdischild-2015-309770</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27530541">PM:27530541</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dis Child\20160817-GrimShawK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dis Child\20160817-GrimShawK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Grimshaw K</style></custom2><misc3><style face="normal" font="Arial">10.1136/archdischild-2015-309770</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Can early allergen exposure prevent food allergy?</style></title><secondary-title><style face="normal" font="Arial">Arch Dis Child</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dis Child</style></full-title></periodical><pages end="" start="802">802-</pages><volume><style face="normal" font="Arial">101</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="25" Month="7" Year="2016">2016/7/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1468-2044 (Electronic)IS - 0003-9888 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/archdischild-2016-311602</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27457705">PM:27457705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dis Child\20160726-noauthors.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dis Child\20160726-noauthors.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1136/archdischild-2016-311602</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,Y.</style></author><author><style face="normal" font="Arial"> Lee,H.Y.</style></author><author><style face="normal" font="Arial"> Gu,K.M.</style></author><author><style face="normal" font="Arial"> Lee,J.Y.</style></author><author><style face="normal" font="Arial"> Yoon,S.W.</style></author><author><style face="normal" font="Arial"> Park,T.Y.</style></author><author><style face="normal" font="Arial"> Choi,J.C.</style></author><author><style face="normal" font="Arial"> Kim,J.Y.</style></author><author><style face="normal" font="Arial"> Park,I.W.</style></author><author><style face="normal" font="Arial"> Shin,J.W.</style></author><author><style face="normal" font="Arial"> Choi,B.W.</style></author><author><style face="normal" font="Arial"> Jung,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul 06974, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Delayed diagnosis of allergic bronchopulmonary aspergillosis due to absence of asthmatic symptoms</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="191" start="187">187-191</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease with small prevalence. Exposure to aspergillus mold causes immunologic hypersensitivity and may cause ranges of symptoms from minimal to detrimental outcomes. Diagnosing and treating the disease before the development of bronchiectasis may save the patient from poor outcomes. This report presents a case of recurrent ABPA without any symptom of asthma, which impeded the correct diagnosis even after numerous hospitalizations</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.187</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489792">PM:27489792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-187-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-187-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Kim Y</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.187</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fok,J.S.</style></author><author><style face="normal" font="Arial"> Kral,A.C.</style></author><author><style face="normal" font="Arial"> Hayball,J.</style></author><author><style face="normal" font="Arial"> Smith,W.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Marking nut anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="194" start="192">192-194</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anacardium</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> South Australia</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Marking nut Semecarpus anacardium, so-called because it contains a pigment that has been used in the past to mark fabrics, is a known cause of contact hypersensitivity. It may be ingested as an ingredient of some traditional Hindi foods. We describe the first reported case of anaphylaxis to marking nut</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.192</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489793">PM:27489793</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-192-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-192-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Fok JS</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.192</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,M.Y.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Jo,E.J.</style></author><author><style face="normal" font="Arial"> Lee,S.E.</style></author><author><style face="normal" font="Arial"> Kang,M.G.</style></author><author><style face="normal" font="Arial"> Song,W.J.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author><author><style face="normal" font="Arial"> Min,K.U.</style></author><author><style face="normal" font="Arial"> Ahn,K.H.</style></author><author><style face="normal" font="Arial"> Chang,Y.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Inje University College of Medicine, Busan 47392, Korea.; Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul 03080, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Feasibility of a smartphone application based action plan and monitoring in asthma</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="180" start="174">174-180</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma patients may experience acute episodic exacerbation. The guidelines recommend that written action plan should be given to asthma patients. However, no one can predict when and where acute exacerbation will happen. As people carry smart phone almost anytime and anywhere, smartphone application could be a useful tool in asthma care. We evaluated the feasibility of the ubiquitous healthcare system of asthma care using a smartphone application (snuCare) based on the self-management guideline or action plan. METHODS: Forty-four patients including fragile asthmatics were enrolled from Seoul National University Bundang Hospital between December 2011 and February 2012. They were randomly assigned into application user (n = 22) or application nonuser group (n = 22). We evaluated user-satisfaction, and clinical parameters such as asthma control, Quality of Life Questionnaire for Adult Korean Asthmatics, and the adherence of patients. RESULTS: The characteristics were similar at baseline between the 2 groups except those who treated with short-term systemic steroid or increased dose of systemic steroid during previous 8 weeks (user vs. nonuser: 31.8% vs. 4.5%, p = 0.020). Total of 2,226 signals was generated during 8 weeks including 5 risky states. After eight weeks, the users answered that it was very easy to use the application, which was shown in highest scores in terms of satisfaction (mean +/- standard deviation, 4.3 +/- 0.56). Seventy-three percent of patients answered that the application was very useful for asthma care. User group showed improved the adherence scores (p = 0.017). One patient in application user group could avoid Emergency Department visit owing to the application while a patient in nonuser group visited Emergency Department. CONCLUSION: The ubiquitous healthcare system using a smartphone application (snuCare) based on the self-management guideline or action plan could be helpful in the monitoring and the management of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.174</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489790">PM:27489790</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-174-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-174-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Kim MY</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.174</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Calderon,M.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sirio Libanes, Sao Paulo 01308-050, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="156" start="149">149-156</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> ICD</style></keyword><keyword><style face="normal" font="Arial"> ICD-10</style></keyword><keyword><style face="normal" font="Arial"> ICD-11</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The new International Classification of Diseases (ICD)-11 "Allergic and hypersensitivity conditions" section has been constructed as a result of a detailed and careful action plan based on scientific evidences for the necessity of changes and collaboration with the World Health Organization (WHO) ICD-11 revision governance. All the efforts are being acknowledged by the Joint Allergy Academies. OBJECTIVE: Considering the new classification model addressed to the allergic and hypersensitivity conditions and following the ICD WHO agenda, we believe it is the appropriate time to start supporting the validation process in collaboration with the WHO ICD governance. METHODS: We conducted a mapping of ICD-10 allergic and hypersensitivity conditions in the ICD-11 beta phase structure and categorized the conditions as fitting by "precoordination," "postcoordination," "indexed to the ICD-11 Foundation," "no code fit properly" or "no correspondence" in the ICD-11. RESULTS: From overall 125 ICD-10 entities spread in 6 chapters, 57.6% were able to be precoordinated, 4% postcoordinated, 12% indexed to the Foundation, 9.6% had no code fitting properly and 18.6% had no correspondence in the ICD-11 framework. CONCLUSION: We have been able to demonstrate that 83.2% of the ICD-10 allergic and hypersensitivity conditions could be captured by the current ICD-11 beta draft framework. We strongly believe that our findings constitute a key step forward for a softer transition of the ICD-10 allergic and hypersensitivity conditions to the ICD-11, supporting the WHO in this process as well as strengthening the visibility of the Allergy specialty and ensuring quality management of allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - France -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.149</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489786">PM:27489786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-149-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-149-56.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-149-56.xls</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-149-56.xls</url></image-urls></urls><custom2><style face="normal" font="Arial">20160804, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.149</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wong,H.H.</style></author><author><style face="normal" font="Arial"> Lee,J.J.</style></author><author><style face="normal" font="Arial"> Shek,L.P.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Goh,A.</style></author><author><style face="normal" font="Arial"> Teoh,O.H.</style></author><author><style face="normal" font="Arial"> Gluckman,P.D.</style></author><author><style face="normal" font="Arial"> Godfrey,K.M.</style></author><author><style face="normal" font="Arial"> Saw,S.M.</style></author><author><style face="normal" font="Arial"> Kwek,K.</style></author><author><style face="normal" font="Arial"> Chong,Y.S.</style></author><author><style face="normal" font="Arial"> Van Bever,H.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National University Health System, Singapore 119228, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Relationship between all fevers or fever after vaccination, and atopy and atopic disorders at 18 and 36 months</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="163" start="157">157-163</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Studies have reported that early febrile episodes and febrile episodes with infections are associated with a decreased risk of developing atopy. OBJECTIVE: To examine further the association between presence of and number of febrile episodes are with atopy and atopic diseases and if there was a difference between all fevers and fever after vaccination. METHODS: We studied 448 infants in a Singapore mother-offspring cohort study (Growing Up in Singapore Towards Healthy Outcomes) which had complete data for the exposures and outcomes of interest. Fever was defined as more than 38.0 and was self-reported. The presence of and number of febrile episodes were examined for association with outcome measures, namely parental reports of doctor-diagnosed asthma and eczema, and rhinitis, which was evaluated by doctors involved in the study at 18 and 36 months. These outcomes were considered atopic if there were 1 or more positive skin prick tests. RESULTS: The presence of all fevers from 0-6 months of age was associated with reduced odds of having atopy at 36 months of age (unadjusted odds ratio [OR], 0.628; 95% confidence interval [CI], 0.396-0.995). The presence of fever after vaccination from 0-24 months of age was associated with reduced odds of having atopy at 36 months of age (OR, 0.566; 95% CI, 0.350-0.915). The presence of all fevers from 0-6 months of age was associated with reduced odds of having atopic eczema at 36 months (OR, 0.430; 95% CI, 0.191-0.970). Fever was associated with increased odds of having doctor-diagnosed asthma and rhinitis. CONCLUSION: There was an inverse relationship between the presence of all fevers from 0-6 months of age and the development of atopy and eczema at 36 months of age. Fever after vaccination might be considered a subclinical infection that did not show the same effect in early life</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - New Zealand -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.157</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489787">PM:27489787</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-157-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-157-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Wong HH</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.157</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chang,Y.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Advances in technology are changing the future of medicine</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="138" start="137">137-138</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.137</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489784">PM:27489784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-137-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-137-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Chang YS</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.137</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yukselen,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy &amp; Immunology, Department of Pediatrics, Baskent University Istanbul Hospital, Istanbul 34662, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-specific immunotherapy in pediatric allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="148" start="139">139-148</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (AIT) is the only curative way that can change the immunologic response to allergens and thus can modify the natural progression of allergic diseases. There are some important criteria which contributes significantly on efficacy of AIT, such as the allergen extract used for treatment, the dose and protocol, patient selection in addition to the severity and control of asthma. The initiation of AIT in allergic asthma should be considered in intermittent, mild and moderate cases which coexisting with other allergic diseases such as allergic rhinitis, and in case of unacceptable adverse effects of medications. Two important impact of AIT; steroid sparing effect and preventing from progression to asthma should be taken into account in pediatric asthma when making a decision on starting of AIT. Uncontrolled asthma remains a significant risk factor for adverse events and asthma should be controlled both before and during administration of AIT. The evidence concerning the efficacy of subcutaneous (SCIT) and sublingual immunotherapy (SLIT) for treatment of pediatric asthma suggested that SCIT decreases asthma symptoms and medication scores, whereas SLIT can ameliorate asthma symptoms. Although the effectiveness of SCIT has been shown for both seasonal and perennial allergens, the data for SLIT is less convincing for perennial allergies in pediatric asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489785">PM:27489785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-139-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-139-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Yukselen A</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.139</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,L.</style></author><author><style face="normal" font="Arial"> Guan,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Peking Union Medical College Hospital, Beijing 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">Effect on quality of life of the mixed house dust mite/weed pollen extract immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="173" start="168">168-173</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> multiple allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although many patients with allergic rhinitis have symptoms due to sensitization to more than one kind of allergens, and mixed allergen extracts are widely used for immunotherapy, there are few published trials. OBJECTIVE: Our study aimed to evaluate the effect of multiple-allergen immunotherapy on improving the symptoms and quality of life of allergic rhinitis patients. METHODS: We performed a 1-year single-center observation study of subcutaneous immunotherapy using house dust mite extract (n = 12), weed pollen extract (n = 21), or mixed house dust mite/weed pollen extract (n = 11) in 44 allergic rhinitis patients. All the allergens responsible for the symptom of each patient were included in his immunotherapy. Symptom score, medication score, and quality of life of the patients were evaluated before and after 1-year immunotherapy. Quality of life was evaluated with the Rhinoconjunctivitis Quality of Life Questionnaire. RESULTS: In all 3 groups receiving subcutaneous immunotherapy, significant improvement of symptom score, medication score, and quality of life was found vs. baseline at 1 year, irrespective of the allergen used. In the weed pollen season, the changes of quality of life questionnaire score after 1-year treatment were not significantly different between the weed pollen group (1.55 +/- 1.24) and the mixed house dust mite/weed pollen group (1.14 +/- 1.01). The same happened in the nonpollen seasons, during which dust mite immunotherapy (1.23 +/- 1.63) and mixed immunotherapy (0.60 +/- 0.47) did not show significantly different effect on the quality of life. CONCLUSION: The multiple-allergen immunotherapy might be effective in polysensitized allergic rhinitis patients, and could improve their quality of life. Our result did not show significant difference between the effects of multiple-allergen immunotherapy and mono-allergen immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.168</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489789">PM:27489789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-168-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-168-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Li L</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.3.168</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pacharn,P.</style></author><author><style face="normal" font="Arial"> Kumjim,S.</style></author><author><style face="normal" font="Arial"> Tattiyapong,P.</style></author><author><style face="normal" font="Arial"> Jirapongsananuruk,O.</style></author><author><style face="normal" font="Arial"> Piboonpocanun,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Identification of wheat sensitization using an in-house wheat extract in Coca-10% alcohol solution in children with wheat anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="158" start="153">153-158</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Alcohol</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> glutenin</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omega-5-gliadin</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergen</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergens</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Identification of wheat sensitization by a skin prick test (SPT) is essential for children with wheat-induced anaphylaxis, since oral food challenge can cause serious adverse effects. Wheat allergens are both water/salt and alcohol soluble. The preparation of wheat extract for SPT containing both water/salt and alcohol soluble allergen is needed. OBJECTIVE: To determine if a wheat extract using Coca's solution containing 10% alcohol (Coca-10% EtOH), prepared in-house, contians both water/salt and alcohol soluble allergens. METHODS: Serum of children with a history of anaphylaxis after wheat ingestion was used. Wheat flour was extracted in Coca-10% alcohol solution. An SPT with both commercial and in-house wheat extracts was performed as well as specific IgE (sIgE) for wheat and omega-5 gliadin. Direct and IgE inhibition immunoblots were performed to determine serum sIgE levels against water/salt as well as alcohol soluble (gliadins and glutenins) allergens in the extracts. RESULTS: Six children with history of wheat anaphylaxis had positive SPT to both commercial and in-house extracts. They also had different levels of sIgE against wheat and omega-5 gliadin allergens. The results of direct immunoblotting showed all tested sera had sIgE bound to ~35 kDa wheat protein. Further IgE inhibition immunoblotting identified the ~35 kDa wheat protein as gliadin but not gluten allergen. CONCLUSION: The in-house prepared Coca-10% EtOH solution could extract both water/salt and alcohol soluble allergens. The ~35 kDa gliadin appears to be a major wheat allergen among tested individuals</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleSB - IMCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0696.34.2.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27007837">PM:27007837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-153-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-153-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, Pacharn P</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0696.34.2.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruxrungtham,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Faculty of Medicine, Chulalongkorn University, Payathai Road, Pathumwan, Bangkok, Thailand 10330</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Inducible Urticaria (CIndU) versus Chronic Spontaneous Urticaria (CSU): Can new names and new updated information improve our care for patients with urticaria?</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="97" start="95">95-97</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleSB - IMCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27394170">PM:27394170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-95-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-95-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, Ruxrungtham K</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'Auria,E.</style></author><author><style face="normal" font="Arial"> Banderali,G.</style></author><author><style face="normal" font="Arial"> Barberi,S.</style></author><author><style face="normal" font="Arial"> Gualandri,L.</style></author><author><style face="normal" font="Arial"> Pietra,B.</style></author><author><style face="normal" font="Arial"> Riva,E.</style></author><author><style face="normal" font="Arial"> Cerri,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, San Paolo Hospital, Department of Health Sciences, University of Milan,Italy</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis: recent insight on pathogenesis and novel therapeutic target</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="108" start="98">98-108</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Calcineurin</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Moisturizers</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> topical calcineurin inhibitors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. It affects infancy, but it is also highly prevalent in adults and it is one of the disease burdens for the patients and their families. Nowadays, AD is recognized as a heterogenous disease with different subtypes with variable clinical manifestations which is affected by the impairments of the skin barrier. The severity of AD dictates the level of treatment. Current AD treatment focuses on restoration of the barrier function, mainly through the use of moisturizers and corticosteroids to control the inflammation, topical calcineurin inhibitors, and immunosuppresive drugs in the most severe cases. However, targeted disease-modifying therapies are under investigation. The most recent findings on the skin microbial dysbiosis is a promising future direction for the development of new treatments. We need to improve the understanding of the complex microbiome-host interactions, the role of autoimmunity, the comparative effectiveness of therapies and the ways to appropriately implement the educational strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20160711IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0732.34.2.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27007830">PM:27007830</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-98-108.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-98-108.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160711, D'Auria E</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0732.34.2.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camoes,S.</style></author><author><style face="normal" font="Arial"> Sampaio,J.</style></author><author><style face="normal" font="Arial"> Rocha,J.</style></author><author><style face="normal" font="Arial"> Tiago,P.</style></author><author><style face="normal" font="Arial"> Lopes,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Internal Medicine Service, Hospital Pedro Hispano, Matosinhos, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Autoimmune progesterone dermatitis: Case report of an unexpected treatment reaction</style></title><secondary-title><style face="normal" font="Arial">Australas J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Australas J Dermatol</style></full-title></periodical><pages end="e134" start="e132">e132-e134</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune progesterone dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Luteal Phase</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Menstrual Cycle</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Progesterone</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Autoimmune progesterone dermatitis (APD) is a rare skin condition with a varying morphology, which appears on a monthly basis during the luteal phase of the menstrual cycle and resolves spontaneously with the endogenous decrease in progesterone during menses. We present the case of 39-year-old multiparous Caucasian woman with generalised, self-limited urticaria in her perimenstrual period. APD was diagnosed in light of the cyclical nature of the symptoms. An intradermal test with the administration of 0.5 mg/mL of medroxyprogesterone acetate showed a positive result. She started using vaginal hormonal contraceptive that paradoxically exacerbate the symptoms, which ceased after the removal of the device. An oral combined contraceptive was initiated instead, with complete resolution of the symptoms. We share the case because of the rarity of the situation, emphasising the importance of a multidisciplinary team for differential diagnosis and patient follow up</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 1440-0960 (Electronic)IS - 0004-8380 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1111/ajd.12529</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489085">PM:27489085</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Australas J Dermatol\20160804-CamoesS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Australas J Dermatol\20160804-CamoesS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Camoes S</style></custom2><misc3><style face="normal" font="Arial">10.1111/ajd.12529</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomas,C.M.</style></author><author><style face="normal" font="Arial"> Timson,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Biological Sciences, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, U.K.</style></auth-address><titles><title><style face="normal" font="Arial">A mysterious family of calcium-binding proteins from parasitic worms</style></title><secondary-title><style face="normal" font="Arial">Biochem Soc Trans</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Soc Trans</style></full-title></periodical><pages end="1010" start="1005">1005-1010</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Binding Properties</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> calcium binding proteins</style></keyword><keyword><style face="normal" font="Arial"> Calcium-Binding Proteins</style></keyword><keyword><style face="normal" font="Arial"> Calmodulin</style></keyword><keyword><style face="normal" font="Arial"> Cations</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fasciola</style></keyword><keyword><style face="normal" font="Arial"> Fasciola hepatica</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Praziquantel</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma mansoni</style></keyword><keyword><style face="normal" font="Arial"> Schistosomiasis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword></keywords><dates><year Day="15" Month="8" Year="2016">2016/8/15</year></dates><abstract><style face="normal" font="Arial">There is a family of proteins from parasitic worms which combine N-terminal EF-hand domains with C-terminal dynein light chain-like domains. Data are accumulating on the biochemistry and cell biology of these proteins. However, little is known about their functions in vivo Schistosoma mansoni expresses 13 family members (SmTAL1-SmTAL13). Three of these (SmTAL1, SmTAL2 and SmTAL3) have been subjected to biochemical analysis which demonstrated that they have different molecular properties. Although their overall folds are predicted to be similar, small changes in the EF-hand domains result in differences in their ion binding properties. Whereas SmTAL1 and SmTAL2 are able to bind calcium (and some other) ions, SmTAL3 appears to be unable to bind any divalent cations. Similar biochemical diversity has been seen in the CaBP proteins from Fasciola hepatica Four family members are known (FhCaBP1-4). All of these bind to calcium ions. However, FhCaBP4 dimerizes in the presence of calcium ions, FhCaBP3 dimerizes in the absence of calcium ions and FhCaBP2 dimerizes regardless of the prevailing calcium ion concentration. In both the SmTAL and FhCaBP families, the proteins also differ in their ability to bind calmodulin antagonists and related drugs. Interestingly, SmTAL1 interacts with praziquantel (the drug of choice for treating schistosomiasis). The pharmacological significance (if any) of this finding is unknown</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1470-8752 (Electronic)IS - 0300-5127 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1042/BST20150270</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27528745">PM:27528745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Soc Trans\2016-44-1005-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Soc Trans\2016-44-1005-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Thomas CM</style></custom2><misc3><style face="normal" font="Arial">10.1042/BST20150270</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferrari,E.</style></author><author><style face="normal" font="Arial"> Casali,E.</style></author><author><style face="normal" font="Arial"> Burastero,S.E.</style></author><author><style face="normal" font="Arial"> Spisni,A.</style></author><author><style face="normal" font="Arial"> Pertinhez,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Biomedical, Biotechnological and Translational Sciences, Italy</style></auth-address><titles><title><style face="normal" font="Arial">The allergen Mus m 1.0102: Dissecting the relationship between molecular conformation and allergenic potency</style></title><secondary-title><style face="normal" font="Arial">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochim Biophys Acta</style></full-title></periodical><pages end="1557" start="1548">1548-1557</pages><volume><style face="normal" font="Arial">1864</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic variant</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Conformation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> Mus m 1</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> NMR spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteinuria</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> reversibility</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="8" Year="2016">2016/8/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The species Mus musculus experiences an obligate proteinuria: predominant are the Major Urinary Proteins (MUPs), that, collectively known as the major mouse allergen Mus m 1, are among the most important aeroallergens for mouse allergic patients. The production of a soluble and stable hypoallergenic form of Mus m 1 is essential for the development of immunotherapeutic protocols to treat allergic symptoms. METHODS: We introduced the substitution C138S in recombinant Mus m 1.0102, an allergenic isoform of Mus m 1. Solubility, conformation, stability and ability to refold after chemical denaturation were investigated with dynamic light scattering, circular dichroism, fluorescence and NMR spectroscopy. An in vitro degranulation assay was used to evaluate the protein allergenic potential, and compare it with Mus m 1.0102 and with an hypoallergenic variant bearing the substitution Y120A. RESULTS: Mus m 1.0102-C138S retains a native-like fold revealing, however, local conformational alterations that influence some of its physical and allergenic properties: it is monodispersed, thermostable up to 56 degrees C, able to reversibly unfold and it exhibits an enhanced allergenicity. CONCLUSIONS: The unique free thiol group affects the solution structural stability of the native protein. Because the mutant C138S does not aggregate over time it is a good lead protein to develop diagnostic and therapeutic applications. GENERAL SIGNIFICANCE: We elucidated the relationship between unfolding reversibility and sulphydryl reactivity. We ascribed the enhanced allergenicity of the mutant C138S to an increased accessibility of its allergenic determinants, an enticing feature to further investigate the structural elements of the allergen-IgE interface</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbapap.2016.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27519162">PM:27519162</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\2016-1864-1548-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\2016-1864-1548-57.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Ferrari E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbapap.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Y.</style></author><author><style face="normal" font="Arial"> Xue,G.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Gong,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a School of Life Science and Technology, Changchun University of Science and Technology , Changchun , China , 130022</style></auth-address><titles><title><style face="normal" font="Arial">Immunosuppressive effect of extracts from leaves of Fraxinus Mandshurica Rupr</style></title><secondary-title><style face="normal" font="Arial">Bioengineered</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bioengineered</style></full-title></periodical><pages end="216" start="212">212-216</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-2</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Multiple Myeloma</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Plants provide a rich resource of medicinal material for research and development of new medicine. To discover new compounds as Immunosuppressant from plants, we evaluated the immunosuppressive effect of different fractions and particularly one compound (Calceolarioside A) that were extracted from the leaves of Fraxinus Mandshurica Rupr. The fractions and the compound were tested on the ability to reduce Immunoglobulin E (IgE) secretion by human U266 multiple myeloma cells (U266 cells) and to reduce interleukin-2 (IL-2) secretion by mouse spleen cells. Our results showed that both the butanol extract fraction and the compound of Calceolarioside A inhibited the IgE and IL-2 production in U266 cells and mouse spleen cells respectively, and no cytotoxicity was observed within the effective dose range. These results suggest that Calceolarioside A could potentially serve as an immunosuppressant</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 2165-5987 (Electronic)IS - 2165-5979 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/21655979.2016.1221023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27533742">PM:27533742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Bioengineered\20160817-ChenY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Bioengineered\20160817-ChenY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Chen Y</style></custom2><misc3><style face="normal" font="Arial">10.1080/21655979.2016.1221023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakamura,R.</style></author><author><style face="normal" font="Arial"> Takanezawa,Y.</style></author><author><style face="normal" font="Arial"> Sone,Y.</style></author><author><style face="normal" font="Arial"> Uraguchi,S.</style></author><author><style face="normal" font="Arial"> Sakabe,K.</style></author><author><style face="normal" font="Arial"> Kiyono,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health, School of Pharmacy, Kitasato University</style></auth-address><titles><title><style face="normal" font="Arial">Immunotoxic Effect of Low-Dose Methylmercury Is Negligible in Mouse Models of Ovalbumin or Mite-Induced Th2 Allergy</style></title><secondary-title><style face="normal" font="Arial">Biol Pharm Bull</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biol Pharm Bull</style></full-title></periodical><pages end="1358" start="1353">1353-1358</pages><volume><style face="normal" font="Arial">39</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Methylmercury (MeHg) is one of the most toxic environmental pollutants and presents a serious hazard to health worldwide. Although the adverse effects of MeHg, including neurotoxicity, have been studied, its effects on immune function, in particular the immune response, remain unclear. This study examined the effects of low-dose MeHg on immune responses in mice. Mice were orally immunized with ovalbumin (OVA) or subcutaneously injected with mite extract to induce a T-helper 2 (Th2) allergic response. They were then exposed to MeHg (0, 0.02, 1.0, or 5.0 mg.kg(-1).d(-1)). Immunization with oral OVA or subcutaneous mite extract increased serum levels of OVA-specific immunoglobulin (Ig) E (OVA-IgE), OVA-IgG1, interleukin (IL)-4, and IL-13, and total IgE, total IgG, and IL-13 when compared with levels in non-immunized mice. However, no interferon (IFN)-gamma was detected. By contrast, serum levels of OVA-IgE, OVA-IgG1, IL-4, and IL-13, or total IgE, total IgG, and IL-13 in Th2 allergy model mice subsequently treated with MeHg were no higher than those in MeHg-untreated mice. These results suggest that MeHg exposure has no adverse effects on Th2 immune responses in antigen-immunized mice</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1347-5215 (Electronic)IS - 0918-6158 (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1248/bpb.b16-00306</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27476942">PM:27476942</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biol Pharm Bull\2016-39-1353-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biol Pharm Bull\2016-39-1353-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Nakamura R</style></custom2><misc3><style face="normal" font="Arial">10.1248/bpb.b16-00306</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ashley,J.</style></author><author><style face="normal" font="Arial"> Piekarska,M.</style></author><author><style face="normal" font="Arial"> Segers,C.</style></author><author><style face="normal" font="Arial"> Trinh,L.</style></author><author><style face="normal" font="Arial"> Rodgers,T.</style></author><author><style face="normal" font="Arial"> Willey,R.</style></author><author><style face="normal" font="Arial"> Tothill,I.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cranfield University, Advanced Diagnostics and Sensors Group, Cranfield, Bedford, MK43 0AL UK</style></auth-address><titles><title><style face="normal" font="Arial">An SPR based sensor for allergens detection</style></title><secondary-title><style face="normal" font="Arial">Biosens Bioelectron</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biosens Bioelectron</style></abbr-1></periodical><pages end="113" start="109">109-113</pages><volume><style face="normal" font="Arial">88</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Label-free</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> Selectivity</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> SPR</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A simple, sensitive and label-free optical sensor method was developed for allergens analysis using alpha-casein as the biomarker for cow's milk detection, to be used directly in final rinse samples of cleaning in place systems (CIP) of food manufacturers. A Surface Plasmon Resonance (SPR) sensor chip consisting of four sensing arrays enabling the measurement of samples and control binding events simultaneously on the sensor surface was employed in this work. SPR offers several advantages in terms of label free detection, real time measurements and superior sensitivity when compared to ELISA based techniques. The gold sensor chip was used to immobilise alpha-casein-polyclonal antibody using EDC/NHS coupling procedure. The performance of the assay and the sensor was first optimised and characterised in pure buffer conditions giving a detection limit of 58ngmL-1 as a direct binding assay. The assay sensitivity can be further improved by using sandwich assay format and amplified with nanoparticles. However, at this stage this is not required as the detection limit achieved exceeded the required allergens detection levels of 2microgmL-1 for alpha-S1-casein. The sensor demonstrated good selectivity towards the alpha-casein as the target analyte and adequate recoveries from CIP final rinse wash samples. The sensor would be useful tool for monitoring allergen levels after cleaning procedures, providing additional data that may better inform upon wider food allergen risk management decision(s) that are made by food manufacturer. In particular, this sensor could potentially help validate or optimise cleaning practices for a given food manufacturing process</style></abstract><notes><style face="normal" font="Arial">DA - 20160809IS - 1873-4235 (Electronic)IS - 0956-5663 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bios.2016.07.101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27503408">PM:27503408</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biosens Bioelectron\2017-88-109-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biosens Bioelectron\2017-88-109-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160809, Ashley J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bios.2016.07.101</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maranna,S.</style></author><author><style face="normal" font="Arial"> Verma,K.</style></author><author><style face="normal" font="Arial"> Talukdar,A.</style></author><author><style face="normal" font="Arial"> Lal,S.K.</style></author><author><style face="normal" font="Arial"> Kumar,A.</style></author><author><style face="normal" font="Arial"> Mukherjee,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Genetics, ICAR-Indian Agricultural Research Institute, New Delhi, 110012, India</style></auth-address><titles><title><style face="normal" font="Arial">Introgression of null allele of Kunitz trypsin inhibitor through marker-assisted backcross breeding in soybean (Glycine max L. Merr.)</style></title><secondary-title><style face="normal" font="Arial">BMC Genet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Genet</style></full-title></periodical><pages end="" start="106">106-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Germplasm</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> Glycine max</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kunitz trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Presence of Kunitz trypsin inhibitor (KTI) in soybean seeds necessitates pre-heat treatment of the soy-flour for its inactivation before using it in food and feed products. The heat treatment not only enhances processing costs of the soy-based foods and feeds but also affects seed-protein quality and solubility. Genetic elimination of KTI is an important and effective approach. Therefore, molecular marker-assisted backcross breeding (MABB) approach was adopted for genetic elimination of KTI from two popular soybean genotypes, DS9712 and DS9814. PI542044, an exotic germplasm line was used as donor of the kti allele which inhibits functional KTI peptide production. RESULTS: Foreground selection for the kti allele was performed with three closely linked SSR markers while background selection was done with 93 polymorphic SSR markers. Plants in the BC1F1 generation were found to recover 70.4-87.63 % and 60.26-73.78 % of the recurrent parent genome (RPG) of DS9712 and DS9814, respectively. Similarly, selected plants in the BC2F1 generation had 93.01-98.92 % and 83.3-91.67 % recovery of their respective RPGs. Recombinant selection was performed so as to identify plants with minimal linkage drag. Biochemical analysis of the seeds of the selected plants (ktikti) confirmed absence of KTI peptides in the seeds. Phenotypically, the selected plants were comparable to the respective recurrent parent in yield and other traits. CONCLUSIONS: MABB approach helped in speedy development of 6 KTI free breeding lines of soybean. Such lines will be suitable for the farmers and the soybean industries to use in production of soy-based foods and feeds without pre-heat treatment of the soy-flour. It would contribute towards wider acceptability of soy-based foods and feeds</style></abstract><notes><style face="normal" font="Arial">DA - 20160713IS - 1471-2156 (Electronic)IS - 1471-2156 (Linking)LA - engPT - Journal ArticleSB - IMCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12863-016-0413-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27407019">PM:27407019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Genet\2016-17-106.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Genet\2016-17-106.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160713, Maranna S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12863-016-0413-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hill,D.A.</style></author><author><style face="normal" font="Arial"> Grundmeier,R.W.</style></author><author><style face="normal" font="Arial"> Ram,G.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.</style></auth-address><titles><title><style face="normal" font="Arial">The epidemiologic characteristics of healthcare provider-diagnosed eczema, asthma, allergic rhinitis, and food allergy in children: a retrospective cohort study</style></title><secondary-title><style face="normal" font="Arial">BMC Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMC Pediatr</style></abbr-1></periodical><pages end="" start="133">133-</pages><volume><style face="normal" font="Arial">16</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The rates of childhood allergic conditions are changing, prompting the need for continued surveillance. Examination of healthcare provider-based diagnosis data is an important and lacking methodology needed to complement existing studies that rely on participant reporting. METHODS: Utilizing our care network of 1,050,061 urban and sub-urban children, we defined two retrospective cohorts: (1) a closed birth cohort of 29,662 children and (2) a cross-sectional cohort of 333,200 children. These cohorts were utilized to determine the epidemiologic characteristics of the conditions studied. Logistic regression was utilized to determine the extent to which food allergy was associated with respiratory allergy. RESULTS: In our birth cohort, the peak age at diagnosis of eczema, asthma, rhinitis, and food allergy was between 0 and 5 months (7.3 %), 12 and 17 months (8.7 %), 24 and 29 months (2.5 %), and 12 and 17 months (1.9 %), respectively. In our cross-sectional cohort, eczema and rhinitis prevalence rates were 6.7 % and 19.9 %, respectively. Asthma prevalence was 21.8 %, a rate higher than previously reported. Food allergy prevalence was 6.7 %, with the most common allergenic foods being peanut (2.6 %), milk (2.2 %), egg (1.8 %), shellfish (1.5 %), and soy (0.7 %). Food allergy was associated with development of asthma (OR 2.16, 95 % CI 1.94-2.40), and rhinitis (OR 2.72, 95 % CI 2.45-3.03). CONCLUSIONS: Compared with previous reports, we measure lower rates of eczema and higher rates of asthma. The distribution of the major allergenic foods diverged from prior figures, and food allergy was associated with the development of respiratory allergy. The utilization of provider-based diagnosis data contributes an important and lacking methodology that complements existing studies</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 1471-2431 (Electronic)IS - 1471-2431 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12887-016-0673-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27542726">PM:27542726</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pediatr\2016-16-133.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pediatr\2016-16-133.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Hill DA</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12887-016-0673-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hu,J.</style></author><author><style face="normal" font="Arial"> Chen,G.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Qian,Q.</style></author><author><style face="normal" font="Arial"> Ding,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Hybrid Rice, College of Life Sciences, Wuhan University, Wuhan, 430072, China</style></auth-address><titles><title><style face="normal" font="Arial">Comparative transcript profiling of alloplasmic male-sterile lines revealed altered gene expression related to pollen development in rice (Oryza sativa L.)</style></title><secondary-title><style face="normal" font="Arial">BMC Plant Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Plant Biol</style></full-title></periodical><pages end="" start="175">175-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anther</style></keyword><keyword><style face="normal" font="Arial"> Anther development</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Differentially expressed gene</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid Metabolism</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oryza</style></keyword><keyword><style face="normal" font="Arial"> Oryza sativa</style></keyword><keyword><style face="normal" font="Arial"> Oryza sativa L</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Transcript profiling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cytoplasmic male sterility (CMS) is an ideal model for investigating the mitochondrial-nuclear interaction and down-regulated genes in CMS lines which might be the candidate genes for pollen development in rice. In this study, a set of rice alloplasmic sporophytic CMS lines was obtained by successive backcrossing of Meixiang B, with three different cytoplasmic types: D62A (D type), ZS97A (WA type) and XQZ-A (DA type). RESULTS: Using microarray, the anther transcript profiles of the three indica rice CMS lines revealed 622 differentially expressed genes (DEGs) in each of the three CMS lines compared with the maintainer line Meixiang B. GO and MapMan analysis indicated that these DEGs were mainly involved in lipid metabolism and cell wall organization. Compared with the gene expression of sporophytic and gametophytic CMS lines, 303 DEGs were identified and 56 of them were down-regulated in all the CMS lines of rice. These down-regulated DEGs in the CMS lines were found to be involved in tapetum or cell wall formation and their suppressed expression might be related to male sterility. Weighted gene co-expression network analysis (WGCNA) revealed that two modules were significantly associated with male sterility and many hub genes that were differentially expressed in the CMS lines. CONCLUSION: A large set of putative genes involved in anther development was identified in the present study. The results will give some information for the nuclear gene regulation by different cytoplasmic genotypes and provide a rich resource for further functional research on the pollen development in rice</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1471-2229 (Electronic)IS - 1471-2229 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12870-016-0864-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496332">PM:27496332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Plant Biol\2016-16-175.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Plant Biol\2016-16-175.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Hu J</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12870-016-0864-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bono,R.</style></author><author><style face="normal" font="Arial"> Romanazzi,V.</style></author><author><style face="normal" font="Arial"> Bellisario,V.</style></author><author><style face="normal" font="Arial"> Tassinari,R.</style></author><author><style face="normal" font="Arial"> Trucco,G.</style></author><author><style face="normal" font="Arial"> Urbino,A.</style></author><author><style face="normal" font="Arial"> Cassardo,C.</style></author><author><style face="normal" font="Arial"> Siniscalco,C.</style></author><author><style face="normal" font="Arial"> Marchetti,P.</style></author><author><style face="normal" font="Arial"> Marcon,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Pediatrics, University of Turin, via Santena, 5 bis, 10126, Turin, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Air pollution, aeroallergens and admissions to pediatric emergency room for respiratory reasons in Turin, northwestern Italy</style></title><secondary-title><style face="normal" font="Arial">BMC Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Public Health</style></full-title></periodical><pages end="" start="722">722-</pages><volume><style face="normal" font="Arial">16</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Gramineae</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Poisson</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> Urban environment</style></keyword><keyword><style face="normal" font="Arial"> Urticaceae</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Air pollution can cause respiratory symptoms or exacerbate pre-existing respiratory diseases, especially in children. This study looked at the short-term association of air pollution concentrations with Emergency Room (ER) admissions for respiratory reasons in pediatric age (0-18 years). METHODS: Daily number of ER admissions in a children's Hospital, concentrations of urban-background PM2.5, NO2, O3 and total aeroallergens (Corylaceae, Cupressaceae, Gramineae, Urticaceae, Ambrosia, Betula) were collected in Turin, northwestern Italy, for the period 1/08/2008 to 31/12/2010 (883 days). The associations between exposures and ER admissions were estimated, at time lags between 0 and 5 days, using generalized linear Poisson regression models, adjusted for non-meteorological potential confounders. RESULTS: In the study period, 21,793 ER admissions were observed, mainly (81 %) for upper respiratory tract infections. Median air pollution concentrations were 22.0, 42.5, 34.1 mug/m(3) for urban-background PM2.5, NO2, and O3, respectively, and 2.9 grains/m(3) for aeroallergens. We found that ER admissions increased by 1.3 % (95 % CI: 0.3-2.2 %) five days after a 10 mug/m(3) increase in NO2, and by 0.7 % (95 % CI: 0.1-1.2 %) one day after a 10 grains/m(3) increase in aeroallergens, while they were not associated with PM2.5 concentrations. ER admissions were negatively associated with O3 and aeroallergen concentrations at some time lags, but these association shifted to the null when meteorological confounders were adjusted for in the models. CONCLUSIONS: Overall, these findings confirm adverse short-term health effects of air pollution on the risk of ER admission in children and encourage a careful management of the urban environment to health protection</style></abstract><notes><style face="normal" font="Arial">DA - 20160805IS - 1471-2458 (Electronic)IS - 1471-2458 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12889-016-3376-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27492006">PM:27492006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Public Health\2016-16-722.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Public Health\2016-16-722.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160805, Bono R</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12889-016-3376-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Larsen,V.</style></author><author><style face="normal" font="Arial"> Potts,J.F.</style></author><author><style face="normal" font="Arial"> Del Giacco,S.</style></author><author><style face="normal" font="Arial"> Bustos,P.</style></author><author><style face="normal" font="Arial"> Diaz,P.V.</style></author><author><style face="normal" font="Arial"> Amigo,H.</style></author><author><style face="normal" font="Arial"> Oyarzun,M.</style></author><author><style face="normal" font="Arial"> Rona,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Epidemiology, Occupational Medicine, and Public Health Group, National Heart &amp; Lung Institute, Imperial College London, Emmanuel Kaye Building, Manresa Road, London, SW3 6LR, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Changes in symptoms of asthma and rhinitis by sensitization status over ten years in a cohort of young Chilean adults</style></title><secondary-title><style face="normal" font="Arial">BMC Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Pulm Med</style></full-title></periodical><pages end="" start="116">116-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> cat fur</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> ECRHS</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> European Community Respiratory Health Survey</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health survey</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergies</style></keyword><keyword><style face="normal" font="Arial"> Nasal allergy</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We investigated the net changes in prevalence of symptoms of asthma and rhinitis over 10 years in a cohort of young by baseline sensitization status. METHODS: One thousand one hundred ninety three Chilean adults subjects aged 22-28 living in a semi-rural area of central Chile answered a lifestyle and the European Community Respiratory Health Survey (ECRHS) questionnaires. Bronchial hyper-responsiveness (BHR) and skin prick test (SPT) to eight allergens were measured at baseline in 2001. Ten years later, 772 participants completed the questionnaires again. Estimates of adjusted net changes in prevalence of symptoms by sensitization status at baseline and association between sensitization status at baseline and respiratory symptoms ten years later were assessed. RESULTS: A quarter of the participants were sensitized to at least one allergen in 2001. Prevalence of wheeze had a net change per year of -0.37 % (95 % Confidence Interval -0.71 to 0.02 %; p = 0.067). Self-reported nasal allergies in the last 12 months increased by 0.83 % per year (95 % CI 0.49 to 1.17 %; p &lt; 0.001). Those sensitized to either cat fur (OR 1.76; CI 1.01 to 3.05), cockroach, (OR 2.09; 1.13 to 3.86) blend of grass and pollens (1.78; 95 % CI 1.08 to 2.92), or weeds (OR 1.77; 95 % CI 1.01 to 3.12) in 2001 were more likely to have wheeze in the last 12 months 10 years later. CONCLUSION: Symptoms of asthma remained stable or slightly changed over 10 years in adults, whilst rhinitis and nasal allergies greatly increased. Being sensitized to at least one allergen is a risk factor for persistent symptoms of asthma and rhinitis, but not for determining net changes of symptoms over time. The underlying causes for the contrasting trends between asthma and nasal allergy are unknown</style></abstract><notes><style face="normal" font="Arial">DA - 20160809IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleSB - IMCO - United Kingdom -CO - Italy -CO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12890-016-0273-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27503476">PM:27503476</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pulm Med\2016-16-116.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pulm Med\2016-16-116.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160809, Garcia-Larsen V</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12890-016-0273-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caminati,M.</style></author><author><style face="normal" font="Arial"> Senna,G.</style></author><author><style face="normal" font="Arial"> Stefanizzi,G.</style></author><author><style face="normal" font="Arial"> Bellamoli,R.</style></author><author><style face="normal" font="Arial"> Longhi,S.</style></author><author><style face="normal" font="Arial"> Chieco-Bianchi,F.</style></author><author><style face="normal" font="Arial"> Guarnieri,G.</style></author><author><style face="normal" font="Arial"> Tognella,S.</style></author><author><style face="normal" font="Arial"> Olivieri,M.</style></author><author><style face="normal" font="Arial"> Micheletto,C.</style></author><author><style face="normal" font="Arial"> Festi,G.</style></author><author><style face="normal" font="Arial"> Bertocco,E.</style></author><author><style face="normal" font="Arial"> Mazza,M.</style></author><author><style face="normal" font="Arial"> Rossi,A.</style></author><author><style face="normal" font="Arial"> Vianello,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma Center and Allergy Unit, Verona General and University Hospital, Verona, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience</style></title><secondary-title><style face="normal" font="Arial">BMC Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Pulm Med</style></full-title></periodical><pages end="" start="128">128-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Achievement</style></keyword><keyword><style face="normal" font="Arial"> Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In patients with asthma, particularly severe asthma, poor adherence to inhaled drugs negatively affects the achievement of disease control. A better adherence rate is expected in the case of injected drugs, such as omalizumab, as they are administered only in a hospital setting. However, adherence to omalizumab has never been systematically investigated. The aim of this study was to review the omalizumab drop-out rate in randomized controlled trials (RCTs) and real-life studies. A comparative analysis was performed between published data and the Italian North East Omalizumab Network (NEONet) database. RESULTS: In RCTs the drop-out rate ranged from 7.1 to 19.4 %. Although the reasons for withdrawal were only occasionally reported, patient decision and adverse events were the most frequently reported causes. In real-life studies the drop-out rate ranged from 0 to 45.5 %. In most cases lack of efficacy was responsible for treatment discontinuation. According to NEONet data, 32 % of treated patients dropped out, with an increasing number of drop outs observed over time. Patient decision and lack of efficacy accounted for most treatment withdrawals. CONCLUSIONS: Treatment adherence is particularly crucial in patients with severe asthma considering the clinical impact of the disease and the cost of non-adherence. The risk of treatment discontinuation has to be carefully considered both in the experimental and real-life settings. Increased knowledge regarding the main reasons for patient withdrawal is important to improve adherence in clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12890-016-0290-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562427">PM:27562427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pulm Med\2016-16-128.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pulm Med\2016-16-128.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Caminati M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12890-016-0290-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomas,F.C.</style></author><author><style face="normal" font="Arial"> Santana,A.M.</style></author><author><style face="normal" font="Arial"> Waterston,M.</style></author><author><style face="normal" font="Arial"> Haining,H.</style></author><author><style face="normal" font="Arial"> Eckersall,P.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biodiversity Animal Health and Comparative Medicine, University of Glasgow, Bearsden Road, Glasgow, UK</style></auth-address><titles><title><style face="normal" font="Arial">Effect of pre-analytical treatments on bovine milk acute phase proteins</style></title><secondary-title><style face="normal" font="Arial">BMC Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Vet Res</style></full-title></periodical><pages end="" start="151">151-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">A3</style></keyword><keyword><style face="normal" font="Arial"> Amyloid</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk composition</style></keyword><keyword><style face="normal" font="Arial"> Nigeria</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Potassium</style></keyword><keyword><style face="normal" font="Arial"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Transportation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Samples for diagnostic procedures often require some form of pre-analytical preparation for preservation or safe handling during transportation prior to analysis in the laboratory. This is particularly important for milk samples which frequently need preservatives to retain milk composition as close to that found in freshly collected samples as possible. METHODS: Milk samples were treated by heating at 56 degrees C for 30 min or preserved by addition of either potassium dichromate or bronopol respectively. Haptoglobin (Hp), mammary associated serum amyloid A3 (M-SAA3) and C-reactive protein (CRP) were measured in the various treatment groups and in control samples which were not treated, using enzyme linked immunoassays. The concentrations of each APP were compared between treated and non-treated groups using the Wilcoxon signed ranks tests. RESULTS: Heat treatment of samples was found to have a significant lowering effect on milk M-SAA3 and CRP but not Hp. The use of potassium dichromate and bronopol as preservatives in milk had no significant effects on milk Hp and M-SAA3 concentration but lowered milk CRP values compared to controls. CONCLUSIONS: The observed effects of heating and preservative use on milk APP should be taken into consideration when assaying samples which have undergone heat treatment as a result of international transfer regulations involving biological samples or samples needing chemical preservation prior to transport to laboratory</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1746-6148 (Electronic)IS - 1746-6148 (Linking)LA - engPT - Journal ArticleSB - IMCO - United Kingdom -CO - Nigeria -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12917-016-0769-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27457305">PM:27457305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Vet Res\2016-12-151.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Vet Res\2016-12-151.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Thomas FC</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12917-016-0769-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iacobucci,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The BMJ</style></auth-address><titles><title><style face="normal" font="Arial">GSK and Google form partnership to develop bioelectronic medicines</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="i4279">i4279-</pages><volume><style face="normal" font="Arial">354</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.i4279</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27488397">PM:27488397</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2016-354-i4279.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2016-354-i4279.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Iacobucci G</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.i4279</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Niven,R.M.</style></author><author><style face="normal" font="Arial"> Saralaya,D.</style></author><author><style face="normal" font="Arial"> Chaudhuri,R.</style></author><author><style face="normal" font="Arial"> Masoli,M.</style></author><author><style face="normal" font="Arial"> Clifton,I.</style></author><author><style face="normal" font="Arial"> Mansur,A.H.</style></author><author><style face="normal" font="Arial"> Hacking,V.</style></author><author><style face="normal" font="Arial"> Lain-Smith,S.</style></author><author><style face="normal" font="Arial"> Menzies-Gow,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Manchester Academic Health Science Centre, The University of Manchester &amp; University Hospital of South Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)</style></title><secondary-title><style face="normal" font="Arial">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ Open</style></full-title></periodical><pages end="" start="e011857">e011857-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Employment</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisations</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To describe the impact of omalizumab on asthma management in patients treated as part of normal clinical practice in the UK National Health Service (NHS). DESIGN: A non-interventional, mixed methodology study, combining retrospective and prospective data collection for 12 months pre-omalizumab and post-omalizumab initiation, respectively. SETTING: Data were collected in 22 UK NHS centres, including specialist centres and district general hospitals in the UK. PARTICIPANTS: 258 adult patients (aged >/=16 years; 65% women) with severe persistent allergic asthma treated with omalizumab were recruited, of whom 218 (84.5%) completed the study. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome measure was change in mean daily dose of oral corticosteroids (OCS) between the 12-month pre-omalizumab and post-omalizumab initiation periods. A priori secondary outcome measures included response to treatment, changes in OCS dosing, asthma exacerbations, lung function, employment/education, patient-reported outcomes and hospital resource utilisation. RESULTS: The response rate to omalizumab at 16 weeks was 82.4%. Comparing pre-omalizumab and post-omalizumab periods, the mean (95% CIs) daily dose of OCS decreased by 1.61 (-2.41 to -0.80) mg/patient/day (p&lt;0.001) and hospital exacerbations decreased by 0.97 (-1.19 to -0.75) exacerbations/patient (p&lt;0.001). Compared with baseline, lung function, assessed by percentage of forced expiratory volume in 1 s, improved by 4.5 (2.7 to 6.3)% at 16 weeks (p&lt;0.001; maintained at 12 months) and patient quality of life (Asthma Quality of Life Questionnaire) improved by 1.38 (1.18 to 1.58) points at 16 weeks (p&lt;0.001, maintained at 12 months). 21/162 patients with complete employment data gained employment and 6 patients lost employment in the 12-month post-omalizumab period. The mean number of A&amp;E visits, inpatient hospitalisations, outpatient visits (excluding for omalizumab) and number of bed days/patient decreased significantly (p&lt;0.001) in the 12-month post-omalizumab period. CONCLUSIONS: These data support the beneficial effects of omalizumab on asthma-related outcomes, quality of life and resource utilisation in unselected patients treated in 'real-world' clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20160810IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmjopen-2016-011857</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27507234">PM:27507234</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2016-6-e011857.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Open\2016-6-e011857.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160810, Niven RM</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmjopen-2016-011857</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rose,M.A.</style></author><author><style face="normal" font="Arial"> Green,S.L.</style></author><author><style face="normal" font="Arial"> Crilly,H.M.</style></author><author><style face="normal" font="Arial"> Kolawole,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anaesthesia, Royal North Shore Hospital, St Leonards, NSW 2065, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Perioperative anaphylaxis grading system: 'making the grade'</style></title><secondary-title><style face="normal" font="Arial">Br J Anaesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Anaesth</style></abbr-1></periodical><pages end="553" start="551">551-553</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaesthesia</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Perioperative anaphylaxis</style></keyword></keywords><dates><year Day="29" Month="8" Year="2016">2016/8/29</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1471-6771 (Electronic)IS - 0007-0912 (Linking)LA - ENGPT - EDITORIALCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1093/bja/aew251</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27574285">PM:27574285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Anaesth\20160830-RoseMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Anaesth\20160830-RoseMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Rose MA</style></custom2><misc3><style face="normal" font="Arial">10.1093/bja/aew251</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heeringa,J.J.</style></author><author><style face="normal" font="Arial"> van Zelm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands .</style></auth-address><titles><title><style face="normal" font="Arial">Is there a pathogenic role for IgE in psoriasis?</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="17" start="16">16-17</pages><volume><style face="normal" font="Arial">175</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleSB - IMCO - Netherlands -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.14607</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27484269">PM:27484269</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\2016-175-16-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\2016-175-16-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Heeringa JJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.14607</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ellepola,A.N.</style></author><author><style face="normal" font="Arial"> Samaranayake,L.P.</style></author><author><style face="normal" font="Arial"> Khan,Z.U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Dentistry, Health Sciences Center, Kuwait University, Kuwait.</style></auth-address><titles><title><style face="normal" font="Arial">Extracellular phospholipase production of oral Candida albicans isolates from smokers, diabetics, asthmatics, denture wearers and healthy individuals following brief exposure to polyene, echinocandin and azole antimycotics</style></title><secondary-title><style face="normal" font="Arial">Braz J Microbiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Braz J Microbiol</style></abbr-1></periodical><pages end="916" start="911">911-916</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amphotericin B</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal drug</style></keyword><keyword><style face="normal" font="Arial"> antifungals</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Azoles</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candida albicans</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Echinocandins</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fluconazole</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Ketoconazole</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Musculature</style></keyword><keyword><style face="normal" font="Arial"> Nystatin</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Phospholipases</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="4" Month="7" Year="2016">2016/7/4</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Candida albicans is the primary causative agent of oral candidosis, and one of its key virulent attributes is considered to be its ability to produce extracellular phospholipases that facilitate cellular invasion. Oral candidosis can be treated with polyenes, and azoles, and the more recently introduced echinocandins. However, once administered, the intraoral concentration of these drugs tend to be sub-therapeutic and rather transient due to factors such as the diluent effect of saliva and cleansing effect of the oral musculature. Hence, intra-orally, the pathogenic yeasts may undergo a brief exposure to antifungal drugs. We, therefore, evaluated the phospholipase production of oral C. albicans isolates following brief exposure to sub-therapeutic concentrations of the foregoing antifungals. MATERIALS AND METHODS: Fifty C. albicans oral isolates obtained from smokers, diabetics, asthmatics using steroid inhalers, partial denture wearers and healthy individuals were exposed to sub-therapeutic concentrations of nystatin, amphotericin B, caspofungin, ketoconazole and fluconazole for one hour. Thereafter the drugs were removed and the phospholipase production was determined by a plate assay using an egg yolk-agar medium. RESULTS: The phospholipase production of these isolates was significantly suppressed with a percentage reduction of 10.65, 12.14, 11.45 and 6.40% following exposure to nystatin, amphotericin B, caspofungin and ketoconazole, respectively. This suppression was not significant following exposure to fluconazole. CONCLUSIONS: Despite the sub-therapeutic, intra oral, bioavailability of polyenes, echinocandins and ketoconazole, they are likely to produce a persistent antifungal effect by suppressing phospholipase production, which is a key virulent attribute of this common pathogenic yeast</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1678-4405 (Electronic)IS - 1517-8382 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Kuwait -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bjm.2016.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27522928">PM:27522928</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Microbiol\20160815-EllepolaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Microbiol\20160815-EllepolaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Ellepola AN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bjm.2016.06.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rome,Q.</style></author><author><style face="normal" font="Arial"> Dambrine,L.</style></author><author><style face="normal" font="Arial"> Onate,C.</style></author><author><style face="normal" font="Arial"> Muller,F.</style></author><author><style face="normal" font="Arial"> Villemant,C.</style></author><author><style face="normal" font="Arial"> Garcia-Perez,A.L.</style></author><author><style face="normal" font="Arial"> Maia,M.</style></author><author><style face="normal" font="Arial"> Carvalho Esteves,P.</style></author><author><style face="normal" font="Arial"> Bruneau,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Spread of the invasive hornet Vespa velutina Lepeletier, 1836, in Europe in 2012 (Hym., Vespidae)</style></title><secondary-title><style face="normal" font="Arial">Bull Soc Entomol Fr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bull Soc Entomol Fr</style></full-title></periodical><pages end="22" start="21">21-22</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Europe</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword></keywords><dates><year Day="0" Month="0" Year="2013">2013</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.lasef.org/new/new_bsef_118(1).html</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Bull Soc Entomol Fr\2013-118-21-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Bull Soc Entomol Fr\2013-118-21-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160828, Rome Q</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamazumi,Y.</style></author><author><style face="normal" font="Arial"> Sasaki,O.</style></author><author><style face="normal" font="Arial"> Imamura,M.</style></author><author><style face="normal" font="Arial"> Oda,T.</style></author><author><style face="normal" font="Arial"> Ohno,Y.</style></author><author><style face="normal" font="Arial"> Shiozaki-Sato,Y.</style></author><author><style face="normal" font="Arial"> Nagai,S.</style></author><author><style face="normal" font="Arial"> Suyama,S.</style></author><author><style face="normal" font="Arial"> Kamoshida,Y.</style></author><author><style face="normal" font="Arial"> Funato,K.</style></author><author><style face="normal" font="Arial"> Yasui,T.</style></author><author><style face="normal" font="Arial"> Kikutani,H.</style></author><author><style face="normal" font="Arial"> Yamamoto,K.</style></author><author><style face="normal" font="Arial"> Dohi,M.</style></author><author><style face="normal" font="Arial"> Koyasu,S.</style></author><author><style face="normal" font="Arial"> Akiyama,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Molecular and Genetic Information, Institute for Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan</style></auth-address><titles><title><style face="normal" font="Arial">The RNA Binding Protein Mex-3B Is Required for IL-33 Induction in the Development of Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Cell Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Rep</style></full-title></periodical><pages end="2471" start="2456">2456-2471</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Repression</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="17" Month="8" Year="2016">2016/8/17</year></dates><abstract><style face="normal" font="Arial">Allergic airway inflammation is one of the primary features of allergic asthma. Interleukin-33 (IL-33) is recognized as a key pro-inflammatory cytokine that mediates allergic airway inflammation, and its expression is elevated in this condition, but little is known about the regulatory mechanisms underlying IL-33 induction. Here, we show that the RNA binding protein Mex-3B plays a critical role in the induction of IL-33 in the development of allergic airway inflammation. We generated Mex3b-/- mice and found that they develop significantly less airway inflammation than wild-type mice due to reduced induction of IL-33. Furthermore, we show that Mex-3B directly upregulates IL-33 expression by inhibiting miR-487b-3p-mediated repression of IL-33. Moreover, we show that inhalation of an antisense oligonucleotide targeting Mex-3B suppresses allergic airway inflammation. Our data identify a signaling pathway that post-transcriptionally regulates IL-33 expression and suggest that Mex-3B could be a promising molecular target for the treatment of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 2211-1247 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.celrep.2016.07.062</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545879">PM:27545879</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Rep\2016-26-2456-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Rep\2016-26-2456-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Yamazumi Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.celrep.2016.07.062</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shi,X.</style></author><author><style face="normal" font="Arial"> Zhang,T.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Feng,Y.</style></author><author><style face="normal" font="Arial"> Tan,X.</style></author><author><style face="normal" font="Arial"> Jin,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Interaction between tangeretin and ovalbumin to reduce the allergic effects of ovalbumin</style></title><secondary-title><style face="normal" font="Arial">Chem Res Chin Univ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chem Res Chin Univ</style></full-title></periodical><pages end="560" start="556">556-560</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Asparagine</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Leucine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Molecular docking</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Quenching</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2210-3171</style></isbn><abstract><style face="normal" font="Arial">Food allergy has become a worldwide problem. To find an effective way to reduce the allergic effect of allergen is an interesting topic. In this work, the interaction between ovalbumin(OVA) and tangeretin was studied by means of spectroscopy, molecular docking calculation and animal experiment. As the results show, static quenching of fluorescence intensity happened due to the interaction between OVA and tangeretin. Binding constants, binding sites, and thermometric parameters were obtained. The conformation changing of OVA occurred due to the interaction between it and tangeretin. The molecular docking calculation results show that the epitopes Arginine 84(ARG84), Leucine 87(LEU87), Asparagine 88(ASN88), Serine 103(SER103), Arginine 104(ARG104), Leucine 124(LEU124), Arginine 126(ARG126), Glycine 127(GLY127), Glycine 128(GLY128) and Tryptohan 148(TRP148) of OVA were occupied by tangeretin after the docking, which means tangeretin may have some inhibition effects. As the results of animal experiments, the amount of IgE and lung tissue sections of female BALB/c mice in different groups show that tangeretin with different concentrations has better effects than dexamethasone. In conclusion, the tangeretin may have the effects to reduce the allergic effects of OVA via occupying the IgE-binding epitopes of OVA</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40242-016-6016-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40242-016-6016-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chem Res Chin Univ\2016-32-556-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chem Res Chin Univ\2016-32-556-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901. Shi X</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40242-016-6016-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yagi-Nakanishi,S.</style></author><author><style face="normal" font="Arial"> Kondo,S.</style></author><author><style face="normal" font="Arial"> Kaneda,M.</style></author><author><style face="normal" font="Arial"> Ozaki,F.</style></author><author><style face="normal" font="Arial"> Ueno,T.</style></author><author><style face="normal" font="Arial"> Aga,M.</style></author><author><style face="normal" font="Arial"> Yamada,K.</style></author><author><style face="normal" font="Arial"> Kawano,M.</style></author><author><style face="normal" font="Arial"> Yoshizaki,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Otorhinolaryngology, Head and Neck Surgery, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Olfactory Dysfunction in IgG4-Related Disease</style></title><secondary-title><style face="normal" font="Arial">Chem Senses</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chem Senses</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> inferior turbinate</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> olfaction</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> systemic disease</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2016">2016/8/1</year></dates><abstract><style face="normal" font="Arial">IgG4-related disease is a newly recognized systemic disease, and its elucidation is progressing. However, little is known about its sinonasal manifestations. The aim of this study was to assess the olfaction of patients with IgG4-related disease. Twenty-five patients with IgG4-related disease underwent T&amp;T olfactometry to measure olfactory function. We analyzed the clinical features, including serum IgG4 and IgE levels, involved organs, and sinonasal computed tomography scores to explore the etiology of olfactory dysfunction. Thirteen patients with IgG4-related disease were found to have moderate to severe olfactory dysfunction (52%). There were no differences in the clinical features between the olfactory dysfunction group and the normal group. In 7 patients, the inferior turbinate was biopsied to study the correlation between olfaction score and the number of IgG4-positive cells, but no such correlation was found. Six hyposmia patients recovered to a normal state. Five patients recovered after corticosteroid treatment and 1 recovered spontaneously. We found that the prevalence of olfactory dysfunction was high in patients with IgG4-related disease and that it could be reversed. Olfactory dysfunction appears to be a novel important manifestation of IgG4-related disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1464-3553 (Electronic)IS - 0379-864X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1093/chemse/bjw076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27486056">PM:27486056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chem Senses\20160803-YagiNakanishiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chem Senses\20160803-YagiNakanishiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Yagi-Nakanishi S</style></custom2><misc3><style face="normal" font="Arial">10.1093/chemse/bjw076</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guan,K.</style></author><author><style face="normal" font="Arial"> Li,L.S.</style></author><author><style face="normal" font="Arial"> Yin,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">Use of sIgE/T-IgE in Predicting Systemic Reactions: Retrospective Analysis of 54 Honeybee Venom Allergy Cases in North China</style></title><secondary-title><style face="normal" font="Arial">Chin Med J (Engl)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chin Med J (Engl)</style></full-title></periodical><pages end="2095" start="2091">2091-2095</pages><volume><style face="normal" font="Arial">129</style></volume><number><style face="normal" font="Arial">17</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Honeybee venom</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Venom allergy is significantly underestimated in China. Venom-specific IgE may not provide accurate clinical reactions. Our conducted retrospective analysis observes alternative diagnostic considerations in assessing confirmation and severity of honeybee venom allergy. METHODS: Retrospective review of honeybee venom allergy versus nonallergy patients presented with positive honeybee venom (i1) sIgE results. According to clinically observed reactions caused by a honeybee sting, patients were divided into three groups. Patient residence and exposure types were analyzed. The sIgE/T-IgE among allergy and control groups was compared. RESULTS: Gender ratio male:female was 32:22; median age was 39 years (31, 50). 48% (26/54) of patients live in urban areas, 52% (28/54) in rural areas. Based on bee sting reactions, patients were divided into common localized reactions (32/54), large localized reactions (7/54), and systemic reactions (15/54). In the systemic reaction group, patients presented as Type II (6/15), Type III (6/15). There is significant difference (P &lt; 0.001) between the three groups in regards to exposure types. In the systemic reaction group, 8.7% (13/15) of patients are beekeepers. A significant difference (P &lt; 0.001) was observed between allergic and control groups based on sIgE/T-IgE results. As well as significant difference observed between the systemic reaction group to the other two reaction groups in regards to sIgE/T-IgE results. Six systemic reaction patients presented with large localized reactions before onset of system symptoms 1 month to 1 year of being stung. CONCLUSIONS: Occupational exposure is the most common cause in honeybee venom allergy induced systemic reactions. The use of sIgE/T-IgE results is a useful diagnostic parameter in determining honeybee venom allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 0366-6999 (Print)IS - 0366-6999 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.4103/0366-6999.189056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27569237">PM:27569237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin Med J (Engl)\2016-129-2091-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin Med J (Engl)\2016-129-2091-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Guan K</style></custom2><misc3><style face="normal" font="Arial">10.4103/0366-6999.189056</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schmidt-Hieltjes,Y.</style></author><author><style face="normal" font="Arial"> Teodorowicz,M.</style></author><author><style face="normal" font="Arial"> Jansen,A.</style></author><author><style face="normal" font="Arial"> den Hartog,G.</style></author><author><style face="normal" font="Arial"> Elfvering-Berendsen,L.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author><author><style face="normal" font="Arial"> Savelkoul,H.F.</style></author><author><style face="normal" font="Arial"> Ruinemans-Koerts,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">An alternative inhibition method for determining cross-reactive allergens</style></title><secondary-title><style face="normal" font="Arial">Clin Chem Lab Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chem Lab Med</style></full-title></periodical><pages end="253" start="248">248-253</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="09/12/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Ficus</style></keyword><keyword><style face="normal" font="Arial"> Ficus Benjamina</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition ELISA</style></keyword><keyword><style face="normal" font="Arial"> Inhibition tests</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Inhibition assays are an useful tool to identify the allergen of primary sensitization of cross-reactive allergens. Classical ELISA-based inhibition assays are limited by both the availability of commercial standardized allergen extracts and the experience and knowledge needed for making home-made extracts. Moreover the direct comparison of the inhibition ELISAs outcomes between different laboratories is difficult because of different sources of used allergen extracts and a number of methodological variations. Therefore, we propose a novel ImmunoCap (Phadia, Thermofisher Scientific) based immunoinhibition method with the use of commercially available Caps as the allergen source. METHODS: The novel ImmunoCap based immunoinhibition method was developed and tested with sera from patients with a well-known cross-reactive sensitization for fig (Ficus carica) and ficus (Ficus benjamina). Results were compared with a classically applied inhibition method, i.e. addition of homemade allergen extract to patient serum. RESULTS: The amount of allergens (fig and ficus extracts) needed to reach a similar degree of inhibition was comparable for both inhibition methods. CONCLUSIONS: The ImmunoCap based inhibition assay, in addition to classical inhibition methods, is a valuable tool as the ImmunoCap analyzer and commercial allergens (Caps) are more widely available which makes the outcomes of inhibition tests comparable between different laboratories. Furthermore, in the ImmunoCap inhibition method the same protein source is used for both the inhibition of sIgE and sIgE measurement, which might be even more relevant when multiple cross-reactive allergens are tested</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1437-4331 (Electronic)IS - 1434-6621 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1515/cclm-2016-0172</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27474838">PM:27474838</url></web-urls><pdf-urls><url ppv-ref="no">JRuinemans-Koerts@rijnstate.nl</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Schmidt-Hieltjes Y</style></custom2><misc3><style face="normal" font="Arial">10.1515/cclm-2016-0172</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gamundi,G.E.</style></author><author><style face="normal" font="Arial"> Morandeira,R.F.</style></author><author><style face="normal" font="Arial"> Clapes Puig,V.</style></author><author><style face="normal" font="Arial"> Mestre,P.M.</style></author><author><style face="normal" font="Arial"> de la Banda,L.E.</style></author><author><style face="normal" font="Arial"> Sarra,E.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">IgE multiple myeloma: a new case report</style></title><secondary-title><style face="normal" font="Arial">Clin Chem Lab Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chem Lab Med</style></full-title></periodical><pages end="e40" start="e37">e37-e40</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="09/12/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Case Report</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Multiple Myeloma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1437-4331 (Electronic)IS - 1434-6621 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1515/cclm-2016-0354</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27474840">PM:27474840</url></web-urls><pdf-urls><url ppv-ref="no">egamundi@bellvitgehospital.cat</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Gamundi GE</style></custom2><misc3><style face="normal" font="Arial">10.1515/cclm-2016-0354</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Freeman,A.F.</style></author><author><style face="normal" font="Arial"> Olivier,K.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Clinical Infectious Diseases, NIAID, NHLBI, National Institutes of Health, Bethesda, MD, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Hyper-IgE Syndromes and the Lung</style></title><secondary-title><style face="normal" font="Arial">Clin Chest Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chest Med</style></full-title></periodical><pages end="567" start="557">557-567</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> DOCK8</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> NIAID</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Elevated serum IgE has many etiologies including parasitic infection, allergy and asthma, malignancy, and immune dysregulation. The hyper-IgE syndromes caused by mutations in STAT3, DOCK8, and PGM3 are monogenic primary immunodeficiencies associated with high IgE, eczema, and recurrent infections. These primary immunodeficiencies are associated with recurrent pneumonias leading to bronchiectasis; however, each has unique features and genetic diagnosis is essential in guiding therapy, discussing family planning, and defining prognosis. This article discusses the clinical features of these primary immunodeficiencies with a particular focus on the pulmonary manifestations and discussion of the genetics, pathogenesis, and approaches to therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1557-8216 (Electronic)IS - 0272-5231 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ccm.2016.04.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27514600">PM:27514600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Chest Med\2016-37-557-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Chest Med\2016-37-557-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Freeman AF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ccm.2016.04.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paparo,L.</style></author><author><style face="normal" font="Arial"> Nocerino,R.</style></author><author><style face="normal" font="Arial"> Cosenza,L.</style></author><author><style face="normal" font="Arial"> Aitoro,R.</style></author><author><style face="normal" font="Arial"> D'Argenio,V.</style></author><author><style face="normal" font="Arial"> Del Monaco,V.</style></author><author><style face="normal" font="Arial"> Di Scala,C.</style></author><author><style face="normal" font="Arial"> Amoroso,A.</style></author><author><style face="normal" font="Arial"> Di Costanzo,M.</style></author><author><style face="normal" font="Arial"> Salvatore,F.</style></author><author><style face="normal" font="Arial"> Berni,C.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Translational Medical Science, University of Naples "Federico II", Via S. Pansini, 5 80131 Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Epigenetic features of FoxP3 in children with cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Epigenetics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Epigenetics</style></full-title></periodical><pages end="" start="86">86-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic regulation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus rhamnosus</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: DNA methylation of the Th1 and Th2 cytokine genes is altered during cow's milk allergy (CMA). Forkhead box transcription factor 3 (FoxP3) is essential for the development and function of regulatory T cells (Tregs) and is involved in oral tolerance acquisition. We assessed whether tolerance acquisition in children with IgE-mediated CMA is associated with DNA demethylation of the Treg-specific demethylated region (TSDR) of FoxP3. RESULTS: Forty children (aged 3-18 months) were enrolled: 10 children with active IgE-mediated CMA (group 1), 10 children who outgrew CMA after dietary treatment with an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG (group 2), 10 children who outgrew CMA after treatment with other formulas (group 3), and 10 healthy controls (group 4). FoxP3 TSDR demethylation and expression were measured in mononuclear cells purified from peripheral blood of the four groups of children. FoxP3 TSDR demethylation was significantly lower in children with active IgE-mediated CMA than in either children who outgrew CMA or in healthy children. Formula selection influenced the FoxP3 TSDR demethylation profile. The FoxP3 TSDR demethylation rate and expression level were correlated. CONCLUSIONS: Tolerance acquisition in children with IgE-mediated CMA involves epigenetic regulation of the FoxP3 gene. This feature could be a new target for preventive and therapeutic strategies against CMA</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1868-7083 (Electronic)IS - 1868-7075 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13148-016-0252-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525046">PM:27525046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Epigenetics\2016-8-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Epigenetics\2016-8-86.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Paparo L</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13148-016-0252-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UKNIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UKThe David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK</style></auth-address><titles><title><style face="normal" font="Arial">LABAs (again), asthma exacerbations and anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1021" start="1020">1020-1021</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160727IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12777</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27460428">PM:27460428</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1020-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1020-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160727, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12777</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ratemi,E.</style></author><author><style face="normal" font="Arial"> Sultana,S.A.</style></author><author><style face="normal" font="Arial"> Al Faraj,A.</style></author><author><style face="normal" font="Arial"> Halwani,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemical and Process Engineering Technology, Jubail Industrial College, Jubail Industrial City, Saudi ArabiaPrince Naif Center for Immunology Research and Asthma Research Chair, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi ArabiaPrince Naif Health Research Center, King Saud University Medical City, Riyadh, Saudi ArabiaDepartment of Radiological Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi ArabiaPrince Naif Center for Immunology Research and Asthma Research Chair, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="Arial">Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1042" start="1033">1033-1042</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Despite the various treatment options and international guidelines currently available for the appropriate therapeutic management of asthma, a large population of patients with asthma continues to have poorly controlled disease. There is therefore a need for novel approaches to achieve better asthma control, especially for severe asthmatics. This review discusses the use of nanoparticles for the specific targeting of inflammatory pathways as a promising approach for the effective control of severe persistent asthma as well as other chronic inflammatory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160727IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12771</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27404025">PM:27404025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1033-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1033-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Ratemi E</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12771</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eifan,A.O.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology, National Heart and Lung Institute, Faculty of Medicine, Imperial College LondonAllergy and Clinical Immunology, National Heart and Lung Institute, Faculty of Medicine, Imperial College London</style></auth-address><titles><title><style face="normal" font="Arial">Pathogenesis of Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1151" start="1139">1139-1151</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">Rhinitis is a heterogeneous condition that has been associated with inflammatory responses as in allergic rhinitis but can also occur in the absence of inflammation such as in so-called 'idiopathic' (previously 'vasomotor') rhinitis. Allergic rhinitis affects approximately 1 in 4 of the population of westernised countries and is characterized by typical symptoms of nasal itching, sneezing, watery discharge and congestion. The intention of this review is to illustrate key concepts of the pathogenesis of rhinitis. Imbalance in innate and adaptive immunity together with environmental factors is likely to play major roles. In allergic rhinitis, initial allergen exposure and sensitization involves antigen presenting cells, T and B lymphocytes and results in the generation of allergen-specific T cells and allergen specific IgE antibodies. On re-exposure to relevant allergens crosslinking of IgE on mast cells results in the release of mediators of hypersensitivity such as histamine and immediate nasal symptoms. Within hours, there is an infiltration by inflammatory cells, particularly Th2 T lymphocytes, eosinophils and basophils into nasal mucosal tissue that results in the late-phase allergic response. Evidence for nasal priming and whether or not remodelling may be a feature of allergic rhinitis will be reviewed. The occurrence of so-called 'local' allergic rhinitis in the absence of systemic IgE will be discussed. Non-allergic (non-IgE mediated) rhinitis will be considered in the context of inflammatory and non-inflammatory disorders. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12780</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27434218">PM:27434218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1139-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1139-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Eifan AO</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12780</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smith,H.</style></author><author><style face="normal" font="Arial"> Horney,D.</style></author><author><style face="normal" font="Arial"> Jones,C.</style></author><author><style face="normal" font="Arial"> Goubet,S.</style></author><author><style face="normal" font="Arial"> Mukhopadhyay,S.</style></author><author><style face="normal" font="Arial"> Frew,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Pragmatic randomised controlled trial of an allergy intervention for children aged 6 to 16 with asthma and rhinitis in general practice</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1235" start="1227">1227-1235</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy history</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> General practice</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="20" Month="7" Year="2016">2016/7/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It is widely believed that for allergic rhinitis and asthma, avoidance of specific triggers can improve symptom control. Whilst many children with asthma or rhinitis are sensitised to airborne allergens, primary care diagnostic and management decisions are often made without a detailed history of the allergic triggers or allergy testing. Thus, treatment decisions are empirical and allergen avoidance advice is either not given or, if given, not tailored to the child's sensitivities. OBJECTIVE: To ascertain whether allergy assessment and tailored advice in General Practice enhances outcomes of children with asthma and rhinitis. METHOD: Pragmatic RCT of allergy intervention (structured allergy history, skin prick testing and appropriate allergy avoidance advice) versus usual care in children with asthma and/or rhino-conjunctivitis. A blinded observer assessed outcomes at 12 months. Main outcome measures were symptom scores and disease-specific health-related QoL. Secondary outcomes were health care utilisation, days unable to pursue usual activities, and self-rated improvement. RESULTS: 335 participants were randomised to formal allergy assessment or normal care. There were no differences in participants' demographic or clinical characteristics at baseline (all p>.05). At 12 months, participants receiving the allergy intervention had fewer rhinitis symptoms (MD -3.14, 95% CI -6.01, -0.81) and an improvement in QoL (MD -0.50, 95% CI 0.32, 0.68). There were no significant changes in asthma symptoms, health care utilisation or number of days unable to pursue usual activities. CONCLUSION: Amongst children with known asthma and/or rhinitis in primary care, taking a structured allergy history with skin prick testing and tailored advice on allergy avoidance resulted in reduced symptoms of rhinitis and improved QoL This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160720IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12781</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27438431">PM:27438431</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1227-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1227-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160720, Smith H</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12781</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Egner,W.</style></author><author><style face="normal" font="Arial"> Sargur,R.</style></author><author><style face="normal" font="Arial"> Shrimpton,A.</style></author><author><style face="normal" font="Arial"> York,M.</style></author><author><style face="normal" font="Arial"> Green,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Immunology and Allergy Unit and Dept. of Immunology and Protein Reference Unit, Sheffield Teaching Hospitals NHS Trust</style></auth-address><titles><title><style face="normal" font="Arial">A 17 year experience in Perioperative Anaphylaxis 1998-2015: Harmonising optimal detection of Mast Cell mediator release</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1473" start="1465">1465-1473</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality assurance</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Teaching</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Tryptases</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sheffield NARCOS (National Adverse Reactions Advisory Service) investigates suspected perioperative anaesthetic reactions using serial tryptase, urinary methylhistamine and clinical information. Further recommendations for additional allergy clinic assessment are provided. OBJECTIVE: To establish a robustly measurable protocol for identifying mast cell mediator (MMR) release in this cohort. To compare these thresholds with previous suggested thresholds and algorithms. METHOD: A review of 3,455 NARCOS cases referred with a suspected peri-operative allergic reaction. Tryptase, Urinary methylhistamine (UMH) and clinical details were analysed. 1746 cases were graded using the Ring and Messmer scale. Reaction grade, tryptase and UMH changes were compared with statistical and graphical presentations appropriate to non-normally distributed measurements using Analyse-IT software. RESULTS: Sensitive strategies such as 3mug/l or 20% are measurable, translatable and would substantially increase detection of potentially relevant changes in tryptases. Adequate quality assurance for low level measurement is needed. An incremental threshold of 20% would identify potential MMR in an additional 14% of cases with peak tryptase (Tp) between 5 and 14 mug/L and a further 15% with Tp below 5 mug/L. Further work is required to establish the diagnostic performance characteristics of this more sensitive approach. UMH also identified up to 120 further cases of potential MMR in absence of tryptase increments. CONCLUSION AND CLINICAL RELEVANCE: Future studies should establish and compare the predictive performance characteristics of each strategy against clinical phenotypes. A single agreed definition of positive serial tryptases is needed to enable robust evaluation of diagnostic strategies. This could serve as a harmonised standard for comparative studies of case series from different centres. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12785</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27473884">PM:27473884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160730-EgnerW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160730-EgnerW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Egner W</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12785</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Becker,K.L.</style></author><author><style face="normal" font="Arial"> Rosler,B.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Lachmandas,E.</style></author><author><style face="normal" font="Arial"> Kamsteeg,M.</style></author><author><style face="normal" font="Arial"> Jacobs,C.W.</style></author><author><style face="normal" font="Arial"> Joosten,L.A.</style></author><author><style face="normal" font="Arial"> Netea,M.G.</style></author><author><style face="normal" font="Arial"> van de Veerdonk,F.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Radboud University Medical Center, Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Th2 and Th9 responses in patients with Chronic Mucocutaneous Candidiasis and Hyper IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1574" start="1564">1564-1574</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic mucocutaneous candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> STAT1</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> STAT3 mutations</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: STAT1 mutations cause Chronic Mucocutaneous Candidiasis (CMC), while STAT3 mutations cause Hyper IgE syndrome (HIES). CMC and HIES patients have T helper(Th)17 defects suffering from mucosal Candida infections, but only HIES patients show an allergic phenotype with eczema, eosinophilia and high IgE levels. OBJECTIVE: We investigated whether differential Th2 and Th9 responses may explain the clinical differences. METHODS: Peripheral blood mononuclear cells of CMC patients (n=4), HIES patients (n=4), atopic dermatitis patients (n=4) and healthy volunteers (n=13) were stimulated with Candida and Staphylococcus aureus, with and without IL-4. The cytokines IL-5, IL-13, IL-9, IL-17 and TGFbeta and regulatory T cells were measured in cell culture supernatants by ELISA or flowcytometry, respectively. RESULTS: PBMCs of CMC patients showed a significantly impaired production of the Th2 cytokines IL-5 and IL-13, especially in the presence of IL-4. Moreover, IL-9 production was significantly lower in CMC patients compared to healthy controls. In contrast, HIES patients and AD patients showed normal IL-5 and IL-13 production, while IL-9 production was significantly lower in HIES patients compared to healthy controls. Although TGFbeta was involved in the IL-4-induced IL-9 production, TGFbeta levels and the frequency of regulatory T cells did not differ between HIES patients and controls. Flowcytometry analysis demonstrated an IL-9+ IL-17+ CD4+ subset in healthy controls after stimulation with Candida which was less present in HIES patients. CONCLUSION: CMC patients have a general Th defect including Th2 and Th9, while HIES patients have normal Th2 cytokines. These differences are in line with their clinical presentation. Surprisingly, the allergic cytokine IL-9 was deficient in both HIES and CMC, suggesting a Th-17 derived origin. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12787</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27474157">PM:27474157</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160730-BeckerKL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160730-BeckerKL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Becker KL</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12787</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruszczynski,M.</style></author><author><style face="normal" font="Arial"> Horvath,A.</style></author><author><style face="normal" font="Arial"> Dziechciarz,P.</style></author><author><style face="normal" font="Arial"> Szajewska,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, The Medical University of Warsaw</style></auth-address><titles><title><style face="normal" font="Arial">Cow's milk allergy guidelines: A quality Appraisal with the agree II instrument</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1241" start="1236">1236-1241</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The appropriate diagnosis and management of cow's milk allergy (CMA) is challenging. We aimed to systematically review the quality of the existing guidelines on CMA. METHODS: The Cochrane Library, MEDLINE, and EMBASE databases were searched from 2010 to November 2015. The methodological rigor, quality, and transparency of relevant guidelines were assessed with the use of the Appraisal of Guidelines for Research and Evaluation (AGREE II) tool. RESULTS: Of 15 included guidelines, 2, both developed by recognized scientific organizations, achieved the highest score (100%). Eight others were considered to be of high quality (i.e., overall quality scores >60%). The quality scores for each domain varied. Of all domains, clarity and presentation had the highest mean score, and applicability had the lowest mean score. The scores (mean +/- SD) for individual domains were as follows: domain 1 (score and purpose) 62% +/- 36%; domain 2 (stakeholder involvement) 56% +/- 33%; domain 3 (rigor of development) 55% +/- 38%; domain 4 (clarity of presentation) 71% +/- 29%; domain 5 (applicability) 44% +/- 33%; and domain 6 (editorial independence) 60% +/- 36%. One guideline had the maximum possible score of 100% for all AGREE II domains CONCLUSION: A number of guidelines on CMA are available; however, their quality varies. Overall, the guidelines developed by recognized professional/scientific organizations were of the highest quality. These guidelines should be recommended for use. Still, the methodological quality of CMA guidelines may be improved. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12784</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27473791">PM:27473791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1236-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1236-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Ruszczynski M</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12784</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Croston,T.L.</style></author><author><style face="normal" font="Arial"> Nayak,A.P.</style></author><author><style face="normal" font="Arial"> Lemons,A.R.</style></author><author><style face="normal" font="Arial"> Goldsmith,W.T.</style></author><author><style face="normal" font="Arial"> Gu,J.K.</style></author><author><style face="normal" font="Arial"> Germolec,D.R.</style></author><author><style face="normal" font="Arial"> Beezhold,D.H.</style></author><author><style face="normal" font="Arial"> Green,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV 26505</style></auth-address><titles><title><style face="normal" font="Arial">Influence of Aspergillus fumigatus conidia viability on murine pulmonary microRNA and mRNA expression following subchronic inhalation exposure</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1327" start="1315">1315-1327</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosol</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosols</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Centers for Disease Control</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Conidia</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Differentially expressed gene</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation Exposure</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Personal exposure to fungal bioaerosols derived from contaminated building materials or agricultural commodities may induce or exacerbate a variety of adverse health effects. The genomic mechanisms that underlie pulmonary immune responses to fungal bioaerosols have remained unclear. OBJECTIVE: The impact of fungal viability on the pulmonary microRNA and messenger RNA profiles that regulate murine immune responses was evaluated following subchronic inhalation exposure to Aspergillus fumigatus conidia. METHODS: Three groups of naive B6C3F1/N mice were exposed via nose-only inhalation to A. fumigatus viable conidia, heat-inactivated conidia, or HEPA-filtered air twice a week for 13 weeks. Total RNA was isolated from whole lung 24 and 48 hours post final exposure and was further processed for gene expression and microRNA array analysis. The molecular network pathways between viable and heat-inactivated conidia groups were evaluated. RESULTS: Comparison of datasets revealed increased Il4, Il13, and Il33 expression in mice exposed to viable versus heat-inactivated conidia. Of 415 microRNAs detected, approximately 50% were altered in mice exposed to viable versus heat-inactivated conidia 48 hours post exposure. Significantly downregulated (P &lt; 0.05) miR-29a-3p was predicted to regulate TGF-beta3 and Clec7a, genes involved in innate responses to viable A. fumigatus. Also significantly downregulated (P &lt; 0.05), miR-23b-3p regulates genes involved in pulmonary IL-13 and IL-33 responses and SMAD2, downstream of TGF-beta signaling. Using Ingenuity Pathway Analysis, a novel interaction was identified between viable conidia and SMAD2/3. CONCLUSION AND CLINICAL RELEVANCE: Examination of the pulmonary genetic profiles revealed differentially expressed genes and microRNAs following subchronic inhalation exposure to A. fumigatus. MicroRNAs regulating genes involved in the pulmonary immune responses were those with the greatest fold change. Specifically, germinating A. fumigatus conidia were associated with Clec7a and were predicted to interact with Il13 and Il33. Furthermore, altered microRNAs may serve as potential biomarkers to evaluate fungal exposure. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12783</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27473664">PM:27473664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160730-CrostonTL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160730-CrostonTL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Croston TL</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12783</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vultaggio,A.</style></author><author><style face="normal" font="Arial"> Petroni,G.</style></author><author><style face="normal" font="Arial"> Pratesi,S.</style></author><author><style face="normal" font="Arial"> Nencini,F.</style></author><author><style face="normal" font="Arial"> Cammelli,D.</style></author><author><style face="normal" font="Arial"> Milla,M.</style></author><author><style face="normal" font="Arial"> Prignano,F.</style></author><author><style face="normal" font="Arial"> Annese,V.</style></author><author><style face="normal" font="Arial"> Romagnani,S.</style></author><author><style face="normal" font="Arial"> Maggi,E.</style></author><author><style face="normal" font="Arial"> Matucci,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre of Research DENOTHE and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Circulating T cells to infliximab are mainly detectable in treated patients developing anti-drug antibodies and hypersensitivity reactions</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Immunol</style></full-title></periodical><pages end="372" start="364">364-372</pages><volume><style face="normal" font="Arial">186</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-drug antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory T cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="29" Month="8" Year="2016">2016/8/29</year></dates><abstract><style face="normal" font="Arial">Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. The paper was addressed to detect IFX-specific T cells in treated patients with inflammatory diseases developing, or not, anti-drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. Co-culture system of IFX-loaded dendritic cells and purified autologous CD4+ T cells was used to detect memory T cells in 32 ADA+ and 39 ADA- IFX-treated patients and control groups. The cytokine profile of IFX-specific T cells was also studied in culture supernatants. IFX-specific cell proliferation was detected mainly in cells from ADA+ patients, irrespective to their different diseases. HRs patients displayed higher T cell proliferation than non responder and tolerant patients. A mixed (IFN-gamma, IL-13, IL-10) cytokine profile was shown in cells from ADA+ patients, while IL-10 was the most frequently detected cytokine in the supernatants of cultures from ADA- patients. IgE+ADA+ patients with previous HRs exhibited a more pronounced type-2 profile than IgE-ADA+ patients. This work provides evidence that IFX-specific circulating T cells are mainly detectable in ADA+ patients with HRs, regardless of their disease. The IFX-induced cytokine pattern partially correlates with the ADA isotype. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 1365-2249 (Electronic)IS - 0009-9104 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/cei.12858</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27569750">PM:27569750</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Immunol\20160829-VultaggioA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Immunol\20160829-VultaggioA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Vultaggio A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cei.12858</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Molina-Infante,J.</style></author><author><style face="normal" font="Arial"> Carroccio,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Hospital San Pedro de Alcantara, Caceres, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Suspected Non-celiac Gluten Sensitivity Confirmed in few Patients After Gluten Challenge in Double-blind, Placebo-controlled Trials</style></title><secondary-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></full-title></periodical><pages end="348" start="339">339-348</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free diet</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Non celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> Xylose</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A double-blind, placebo-controlled, gluten challenge has been proposed to confirm a diagnosis of non-celiac gluten sensitivity (NCGS) in patients without celiac disease who respond to a gluten-free diet. To determine the accuracy of this approach, we analyzed data from 10 double-blind, placebo-controlled, gluten challenge trials, comprising 1312 adults. The studies varied in the duration of the challenge (ranging from 1 day to 6 weeks), daily doses for the gluten challenge (ranging from 2 g to 52 g; 3 studies administered less than 8 g/day), and composition of the placebo (gluten-free products, xylose, whey protein, rice, or corn starch containing fermentable carbohydrates). Most of the studies found gluten challenge to significantly increase symptom scores compared with placebo. However, only 38/231 of NCGS patients (16%) showed gluten-specific symptoms. Furthermore, 40% of these subjects had a nocebo response (similar or increased symptoms in response to placebo). These findings reveal heterogeneity among and potential methodology flaws in studies of gluten challenge, cast doubt on gluten as the culprit food component in most patients with presumptive NCGS, and highlight the importance of nocebo effect in these types of studies</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1542-7714 (Electronic)IS - 1542-3565 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cgh.2016.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27523634">PM:27523634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Gastroenterol Hepatol\20160815-MolinaInfanteJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Gastroenterol Hepatol\20160815-MolinaInfanteJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Molina-Infante J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cgh.2016.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lugogo,N.</style></author><author><style face="normal" font="Arial"> Domingo,C.</style></author><author><style face="normal" font="Arial"> Chanez,P.</style></author><author><style face="normal" font="Arial"> Leigh,R.</style></author><author><style face="normal" font="Arial"> Gilson,M.J.</style></author><author><style face="normal" font="Arial"> Price,R.G.</style></author><author><style face="normal" font="Arial"> Yancey,S.W.</style></author><author><style face="normal" font="Arial"> Ortega,H.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Duke Asthma, Allergy and Airway Center, Duke Medicine, Durham, North Carolina</style></auth-address><titles><title><style face="normal" font="Arial">Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study</style></title><secondary-title><style face="normal" font="Arial">Clin Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Ther</style></full-title></periodical><pages end="2070" start="2058">2058-2070</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid therapy</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="8" Year="2016">2016/8/20</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Patients with severe eosinophilic asthma often experience recurrent asthma exacerbations despite intensive inhaled corticosteroid therapy. In 2 previous double-blind studies (MENSA [NCT01691521] and SIRIUS [NCT01691508]), treatment with intravenous or subcutaneous mepolizumab was associated with significantly reduced annualized exacerbation rates and oral corticosteroid (OCS) requirements compared with placebo. The purpose of this study was to assess the long-term safety and efficacy of subcutaneous mepolizumab treatment in patients with severe eosinophilic asthma. METHODS: COSMOS was a 52-week, open-label extension study in patients who received mepolizumab or placebo in MENSA or SIRIUS. Patients received subcutaneous mepolizumab regardless of prior treatment allocation and continued to receive appropriate standard-of-care asthma therapy throughout. The primary objective was to assess the long-term safety of mepolizumab; end points included adverse events (AEs) and serious AEs (SAEs). Efficacy assessments included the annualized exacerbation rate and durability of response (defined as the exacerbation rate and OCS dose reduction when combined with MENSA and SIRIUS data, respectively). FINDINGS: In total, 558 (86%; previous mepolizumab: 358; previous placebo: 200) and 94 (14%; previous mepolizumab: 58, previous placebo: 36) patients experienced on-treatment AEs and SAEs, respectively. No fatal AEs were reported. Totals of 13 (2%) and 29 (4%) patients experienced systemic and local site reactions, respectively. There were no reports of mepolizumab-related anaphylaxis. Mepolizumab treatment was shown to exert a durable response, with patients who previously received mepolizumab in MENSA or SIRIUS maintaining reductions in exacerbation rate and OCS dosing throughout COSMOS. Patients who previously received placebo in MENSA or SIRIUS demonstrated improvements in these end points following treatment with mepolizumab in COSMOS. IMPLICATIONS: These data demonstrate a favorable safety profile of mepolizumab and indicate a durable and stable effect over time, supporting long-term treatment in patients with severe eosinophilic asthma. ClinicalTrials.gov identifier: NCT01842607</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1879-114X (Electronic)IS - 0149-2918 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -CO - Spain -CO - United States -CO - Canada -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clinthera.2016.07.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27553751">PM:27553751</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Ther\20160824-LugogoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Ther\20160824-LugogoN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Lugogo N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clinthera.2016.07.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nagy,C.F.</style></author><author><style face="normal" font="Arial"> Leach,T.S.</style></author><author><style face="normal" font="Arial"> Hoffman,J.H.</style></author><author><style face="normal" font="Arial"> Czech,A.</style></author><author><style face="normal" font="Arial"> Carpenter,S.E.</style></author><author><style face="normal" font="Arial"> Guttendorf,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Operations, Elusys Therapeutics, Inc, Pine Brook, New Jersey. Electronic address: cnagy@elusys.comInterimMD, Inc, Groton, MassachusettsHoffman Consulting LLC, Park Ridge, New JerseyDepartment of Clinical Operations, Elusys Therapeutics, Inc, Pine Brook, New JerseyDepartment of Research and Nonclinical Development, Elusys Therapeutics, Inc, Pine Brook, New JerseyAclairo Pharmaceutical Development Group, Inc, Vienna, Virginia</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies</style></title><secondary-title><style face="normal" font="Arial">Clin Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Ther</style></full-title></periodical><pages end="2097" start="2083">2083-2097</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extremities</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> New Jersey</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="24" Month="8" Year="2016">2016/8/24</year></dates><abstract><style face="normal" font="Arial">PURPOSE: This report describes the safety, immunogenicity, and pharmacokinetic results of obiltoxaximab treatment in healthy subjects from 5 clinical trials. METHODS: Healthy men and women were enrolled in randomized, double-blind studies of obiltoxaximab versus placebo (studies 1-3), an open-label, parallel-group study of obiltoxaximab alone versus obiltoxaximab and ciprofloxacin (study 4), or a randomized, double-blind, placebo-controlled study involving administration of a second dose of obiltoxaximab 13 or 119 days after an initial dose (study 5). Obiltoxaximab was administered intravenously in all studies. The safety profile was characterized by physical examinations, including focused examinations of the skin and infusion sites; study drug infusion discontinuations; and assessment of adverse events, vital signs, electrocardiographic findings, laboratory parameters, and immunogenicity. Studies 3 to 5 were the primary safety profile studies. Pharmacokinetic parameters were calculated using noncompartmental methods. FINDINGS: Results of 2 multiple dose studies (studies 1 and 2) revealed that obiltoxaximab exposure increased proportionally. Pharmacokinetic results were consistent across studies. After administration of 16 mg/kg of obiltoxaximab, serum concentrations decreased in a biexponential or multiexponential fashion with a terminal half-life of 17 to 23 days. Mean volume of distribution was approximately 6.3 to 7.5 L, suggesting obiltoxaximab distribution outside the vascular compartment and potentially into tissues. Mean systemic clearance was approximately 0.27 L/d, suggesting that hepatic metabolism and/or renal excretion are not critical to obiltoxaximab elimination. Obiltoxaximab was generally well tolerated. Hypersensitivity reactions were the most common adverse reactions in the safety profile clinical trials, occurring in 34 of 320 subjects (10.6%) receiving obiltoxaximab and 4 of 70 subjects (5.7%) receiving placebo. The most common adverse events were headache, pruritus, upper respiratory tract infection, cough, infusion site swelling, bruising and/or pain, nasal congestion, urticaria, and extremity pain. Of the 320 subjects in the primary safety profile studies who received >/=1 dose of 16 mg/kg of obiltoxaximab, 8 (2.5%) tested positive for a exposure-emergent antiobiltoxaximab response; however, quantitative titers were low (1:20-1:320). IMPLICATIONS: On the basis of consistent results of 5 clinical trials in healthy volunteers, the pharmacokinetic properties of obiltoxaximab after a 16-mg/kg IV infusion can be considered adequately characterized, a criteria of the Animal Rule. Obiltoxaximab appears to be generally well tolerated. ClinicalTrials.gov identifiers: NCT00829582, NCT01453907, NCT01929226, NCT01952444, NCT01932242</style></abstract><notes><style face="normal" font="Arial">DA - 20160828IS - 1879-114X (Electronic)IS - 0149-2918 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clinthera.2016.07.170</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27568215">PM:27568215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Ther\20160828-NagyCF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Ther\20160828-NagyCF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160828, Nagy CF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clinthera.2016.07.170</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meyer,R.</style></author><author><style face="normal" font="Arial"> De Koker,C.</style></author><author><style face="normal" font="Arial"> Dziubak,R.</style></author><author><style face="normal" font="Arial"> Godwin,H.</style></author><author><style face="normal" font="Arial"> Dominguez-Ortega,G.</style></author><author><style face="normal" font="Arial"> Chebar,L.A.</style></author><author><style face="normal" font="Arial"> Skrapac,A.K.</style></author><author><style face="normal" font="Arial"> Gholmie,Y.</style></author><author><style face="normal" font="Arial"> Reeve,K.</style></author><author><style face="normal" font="Arial"> Shah,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Gastroenterology Department, Great Ormond Street Hospital for Children NHS foundation Trust, London, UKDepartment of Nutrition and Dietetics, Chelsea and Westminster Hospital NHS Foundation Trust, London, UKGastroenterology Department, Great Ormond Street Hospital for Children NHS foundation Trust, London, UKGastroenterology Department, Great Ormond Street Hospital for Children NHS foundation Trust, London, UKNino Jesus University Children Hospital, Madrid, SpainPaediatric Gastroenterology, Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, BrazilDepartment of Nutrition and Dietetics, Chelsea and Westminster Hospital NHS Foundation Trust, London, UKDepartment of Nutrition and Food Sciences, Faculty of Agricultural and Food Sciences, American University of Beirut, Beirut, LebanonGastroenterology Department, Great Ormond Street Hospital for Children NHS foundation Trust, London, UKGastroenterology Department, Great Ormond Street Hospital for Children NHS foundation Trust, London, UK ; Institute of Child Health, University College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">The impact of the elimination diet on growth and nutrient intake in children with food protein induced gastrointestinal allergies</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="25">25-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietetics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth and Development</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Non immunoglobulin E (IgE) mediated allergies affecting the gastrointestinal tract require an elimination diet to aid diagnosis. The elimination diet may entail multiple food eliminations that contribute significantly to macro- and micro-nutrient intake which are essential for normal growth and development. Previous studies have indicated growth faltering in children with IgE-mediated allergy, but limited data is available on those with delayed type allergies. We therefore performed a study to establish the impact on growth before and after commencing an elimination diets in children with food protein induced non-IgE mediated gastrointestinal allergies. METHODS: A prospective, observational study was performed at the tertiary gastroenterology department. Children aged 4 weeks-16 years without non-allergic co-morbidities who were required to follow an elimination diet for suspected food protein induced gastrointestinal allergies were included. Growth parameters pre-elimination were taken from clinical notes and post-elimination measurements (weight and height) were taken a minimum of 4 weeks after the elimination diet. A 3-day estimated food diary was recorded a minimum of 4 weeks after initiating the elimination diet, including also any hypoallergenic formulas or over the counter milk alternatives that were consumed. RESULTS: We recruited 130 children: 89 (68.5 %) boys and a median age of 23.3 months [IQR 9.4-69.2]. Almost all children (94.8 %) in this study eliminated CM from their diet and average contribution of energy in the form of protein was 13.8 % (SD 3.9), 51.2 % (SD 7.5) from carbohydrates and 35 % (SD 7.5) from fat. In our cohort 9 and 2.8 % were stunted and wasted respectively. There was a statistically significant improvement in weight-for-age (Wtage) after the 4 week elimination diet. The elimination diet itself did not improve any of the growth parameters, but achieving energy and protein intake improved Wtage and WtHt respectively, vitamin and/or mineral supplements and hypoallergenic formulas were positively associated with WtHt and Wtage. CONCLUSION: With appropriate dietary advice, including optimal energy and protein intake, hypoallergenic formulas and vitamins and mineral supplementation, growth parameters increased from before to after dietary elimination. These factors were positively associated with growth, irrespective of the type of elimination diet and the numbers of foods eliminated</style></abstract><notes><style face="normal" font="Arial">DA - 20160715IS - 2045-7022 (Electronic)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Spain -CO - Brazil -CO - Lebanon -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0115-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27418957">PM:27418957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160715, Meyer R</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0115-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> Farrell,J.</style></author><author><style face="normal" font="Arial"> Crooks,G.</style></author><author><style face="normal" font="Arial"> Hellings,P.</style></author><author><style face="normal" font="Arial"> Bel,E.H.</style></author><author><style face="normal" font="Arial"> Bewick,M.</style></author><author><style face="normal" font="Arial"> Chavannes,N.H.</style></author><author><style face="normal" font="Arial"> de Sousa,J.C.</style></author><author><style face="normal" font="Arial"> Cruz,A.A.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Joos,G.</style></author><author><style face="normal" font="Arial"> Khaltaev,N.</style></author><author><style face="normal" font="Arial"> Malva,J.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Nogues,M.</style></author><author><style face="normal" font="Arial"> Palkonen,S.</style></author><author><style face="normal" font="Arial"> Pedersen,S.</style></author><author><style face="normal" font="Arial"> Robalo-Cordeiro,C.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author><author><style face="normal" font="Arial"> Strandberg,T.</style></author><author><style face="normal" font="Arial"> Valiulis,A.</style></author><author><style face="normal" font="Arial"> Yorgancioglu,A.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Bedbrook,A.</style></author><author><style face="normal" font="Arial"> Aberer,W.</style></author><author><style face="normal" font="Arial"> Adachi,M.</style></author><author><style face="normal" font="Arial"> Agusti,A.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author><author><style face="normal" font="Arial"> Ankri,J.</style></author><author><style face="normal" font="Arial"> Alonso,A.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Arnavielhe,S.</style></author><author><style face="normal" font="Arial"> Arshad,H.</style></author><author><style face="normal" font="Arial"> Bai,C.</style></author><author><style face="normal" font="Arial"> Baiardini,I.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Baigenzhin,A.K.</style></author><author><style face="normal" font="Arial"> Barbara,C.</style></author><author><style face="normal" font="Arial"> Bateman,E.D.</style></author><author><style face="normal" font="Arial"> Beghe,B.</style></author><author><style face="normal" font="Arial"> Kheder,A.B.</style></author><author><style face="normal" font="Arial"> Bennoor,K.S.</style></author><author><style face="normal" font="Arial"> Benson,M.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Bieber,T.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Bjermer,L.</style></author><author><style face="normal" font="Arial"> Blain,H.</style></author><author><style face="normal" font="Arial"> Blasi,F.</style></author><author><style face="normal" font="Arial"> Boner,A.L.</style></author><author><style face="normal" font="Arial"> Bonini,M.</style></author><author><style face="normal" font="Arial"> Bonini,S.</style></author><author><style face="normal" font="Arial"> Bosnic-Anticevitch,S.</style></author><author><style face="normal" font="Arial"> Boulet,L.P.</style></author><author><style face="normal" font="Arial"> Bourret,R.</style></author><author><style face="normal" font="Arial"> Bousquet,P.J.</style></author><author><style face="normal" font="Arial"> Braido,F.</style></author><author><style face="normal" font="Arial"> Briggs,A.H.</style></author><author><style face="normal" font="Arial"> Brightling,C.E.</style></author><author><style face="normal" font="Arial"> Brozek,J.</style></author><author><style face="normal" font="Arial"> Buhl,R.</style></author><author><style face="normal" font="Arial"> Burney,P.G.</style></author><author><style face="normal" font="Arial"> Bush,A.</style></author><author><style face="normal" font="Arial"> Caballero-Fonseca,F.</style></author><author><style face="normal" font="Arial"> Caimmi,D.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Calverley,P.M.</style></author><author><style face="normal" font="Arial"> Camargos,P.A.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Camuzat,T.</style></author><author><style face="normal" font="Arial"> Carlsen,K.H.</style></author><author><style face="normal" font="Arial"> Carr,W.</style></author><author><style face="normal" font="Arial"> Carriazo,A.</style></author><author><style face="normal" font="Arial"> Casale,T.</style></author><author><style face="normal" font="Arial"> Cepeda Sarabia,A.M.</style></author><author><style face="normal" font="Arial"> Chatzi,L.</style></author><author><style face="normal" font="Arial"> Chen,Y.Z.</style></author><author><style face="normal" font="Arial"> Chiron,R.</style></author><author><style face="normal" font="Arial"> Chkhartishvili,E.</style></author><author><style face="normal" font="Arial"> Chuchalin,A.G.</style></author><author><style face="normal" font="Arial"> Chung,K.F.</style></author><author><style face="normal" font="Arial"> Ciprandi,G.</style></author><author><style face="normal" font="Arial"> Cirule,I.</style></author><author><style face="normal" font="Arial"> Cox,L.</style></author><author><style face="normal" font="Arial"> Costa,D.J.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author><author><style face="normal" font="Arial"> Dahl,R.</style></author><author><style face="normal" font="Arial"> Dahlen,S.E.</style></author><author><style face="normal" font="Arial"> Darsow,U.</style></author><author><style face="normal" font="Arial"> De Carlo,G.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Dedeu,T.</style></author><author><style face="normal" font="Arial"> Deleanu,D.</style></author><author><style face="normal" font="Arial"> De Manuel,K.E.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Denburg,J.A.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Didier,A.</style></author><author><style face="normal" font="Arial"> Anh-Xuan,A.T.</style></author><author><style face="normal" font="Arial"> Djukanovic,R.</style></author><author><style face="normal" font="Arial"> Dokic,D.</style></author><author><style face="normal" font="Arial"> Douagui,H.</style></author><author><style face="normal" font="Arial"> Dray,G.</style></author><author><style face="normal" font="Arial"> Dubakiene,R.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Dykewicz,M.S.</style></author><author><style face="normal" font="Arial"> El-Gamal,Y.</style></author><author><style face="normal" font="Arial"> Emuzyte,R.</style></author><author><style face="normal" font="Arial"> Fabbri,L.M.</style></author><author><style face="normal" font="Arial"> Fletcher,M.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Fink,W.A.</style></author><author><style face="normal" font="Arial"> Fonseca,J.</style></author><author><style face="normal" font="Arial"> Fokkens,W.J.</style></author><author><style face="normal" font="Arial"> Forastiere,F.</style></author><author><style face="normal" font="Arial"> Frith,P.</style></author><author><style face="normal" font="Arial"> Gaga,M.</style></author><author><style face="normal" font="Arial"> Gamkrelidze,A.</style></author><author><style face="normal" font="Arial"> Garces,J.</style></author><author><style face="normal" font="Arial"> Garcia-Aymerich,J.</style></author><author><style face="normal" font="Arial"> Gemicioglu,B.</style></author><author><style face="normal" font="Arial"> Gereda,J.E.</style></author><author><style face="normal" font="Arial"> Gonzalez,D.S.</style></author><author><style face="normal" font="Arial"> Gotua,M.</style></author><author><style face="normal" font="Arial"> Grisle,I.</style></author><author><style face="normal" font="Arial"> Grouse,L.</style></author><author><style face="normal" font="Arial"> Gutter,Z.</style></author><author><style face="normal" font="Arial"> Guzman,M.A.</style></author><author><style face="normal" font="Arial"> Heaney,L.G.</style></author><author><style face="normal" font="Arial"> Hellquist-Dahl,B.</style></author><author><style face="normal" font="Arial"> Henderson,D.</style></author><author><style face="normal" font="Arial"> Hendry,A.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Heve,D.</style></author><author><style face="normal" font="Arial"> Horak,F.</style></author><author><style face="normal" font="Arial"> Hourihane,J.O.</style></author><author><style face="normal" font="Arial"> Howarth,P.</style></author><author><style face="normal" font="Arial"> Humbert,M.</style></author><author><style face="normal" font="Arial"> Hyland,M.E.</style></author><author><style face="normal" font="Arial"> Illario,M.</style></author><author><style face="normal" font="Arial"> Ivancevich,J.C.</style></author><author><style face="normal" font="Arial"> Jardim,J.R.</style></author><author><style face="normal" font="Arial"> Jares,E.J.</style></author><author><style face="normal" font="Arial"> Jeandel,C.</style></author><author><style face="normal" font="Arial"> Jenkins,C.</style></author><author><style face="normal" font="Arial"> Johnston,S.L.</style></author><author><style face="normal" font="Arial"> Jonquet,O.</style></author><author><style face="normal" font="Arial"> Julge,K.</style></author><author><style face="normal" font="Arial"> Jung,K.S.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Kaidashev,I.</style></author><author><style face="normal" font="Arial"> Kaitov,M.R.</style></author><author><style face="normal" font="Arial"> Kalayci,O.</style></author><author><style face="normal" font="Arial"> Kalyoncu,A.F.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Keith,P.K.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Koffi N'Goran,B.</style></author><author><style face="normal" font="Arial"> Kolek,V.</style></author><author><style face="normal" font="Arial"> Koppelman,G.H.</style></author><author><style face="normal" font="Arial"> Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Kvedariene,V.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Laune,D.</style></author><author><style face="normal" font="Arial"> Le,L.T.</style></author><author><style face="normal" font="Arial"> Lieberman,P.</style></author><author><style face="normal" font="Arial"> Lipworth,B.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Lodrup,C.K.</style></author><author><style face="normal" font="Arial"> Louis,R.</style></author><author><style face="normal" font="Arial"> MacNee,W.</style></author><author><style face="normal" font="Arial"> Magard,Y.</style></author><author><style face="normal" font="Arial"> Magnan,A.</style></author><author><style face="normal" font="Arial"> Mahboub,B.</style></author><author><style face="normal" font="Arial"> Mair,A.</style></author><author><style face="normal" font="Arial"> Majer,I.</style></author><author><style face="normal" font="Arial"> Makela,M.J.</style></author><author><style face="normal" font="Arial"> Manning,P.</style></author><author><style face="normal" font="Arial"> Mara,S.</style></author><author><style face="normal" font="Arial"> Marshall,G.D.</style></author><author><style face="normal" font="Arial"> Masjedi,M.R.</style></author><author><style face="normal" font="Arial"> Matignon,P.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Mavale-Manuel,S.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Melo-Gomes,E.</style></author><author><style face="normal" font="Arial"> Meltzer,E.O.</style></author><author><style face="normal" font="Arial"> Menzies-Gow,A.</style></author><author><style face="normal" font="Arial"> Merk,H.</style></author><author><style face="normal" font="Arial"> Michel,J.P.</style></author><author><style face="normal" font="Arial"> Miculinic,N.</style></author><author><style face="normal" font="Arial"> Mihaltan,F.</style></author><author><style face="normal" font="Arial"> Milenkovic,B.</style></author><author><style face="normal" font="Arial"> Mohammad,G.M.</style></author><author><style face="normal" font="Arial"> Molimard,M.</style></author><author><style face="normal" font="Arial"> Momas,I.</style></author><author><style face="normal" font="Arial"> Montilla-Santana,A.</style></author><author><style face="normal" font="Arial"> Morais-Almeida,M.</style></author><author><style face="normal" font="Arial"> Morgan,M.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Nafti,S.</style></author><author><style face="normal" font="Arial"> Namazova-Baranova,L.</style></author><author><style face="normal" font="Arial"> Naclerio,R.</style></author><author><style face="normal" font="Arial"> Neou,A.</style></author><author><style face="normal" font="Arial"> Neffen,H.</style></author><author><style face="normal" font="Arial"> Nekam,K.</style></author><author><style face="normal" font="Arial"> Niggemann,B.</style></author><author><style face="normal" font="Arial"> Ninot,G.</style></author><author><style face="normal" font="Arial"> Nyembue,T.D.</style></author><author><style face="normal" font="Arial"> O'hehir,R.E.</style></author><author><style face="normal" font="Arial"> Ohta,K.</style></author><author><style face="normal" font="Arial"> Okamoto,Y.</style></author><author><style face="normal" font="Arial"> Okubo,K.</style></author><author><style face="normal" font="Arial"> Ouedraogo,S.</style></author><author><style face="normal" font="Arial"> Paggiaro,P.</style></author><author><style face="normal" font="Arial"> Pali-Scholl,I.</style></author><author><style face="normal" font="Arial"> Panzner,P.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.</style></author><author><style face="normal" font="Arial"> Papi,A.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Pavord,I.</style></author><author><style face="normal" font="Arial"> Pawankar,R.</style></author><author><style face="normal" font="Arial"> Pengelly,R.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Picard,R.</style></author><author><style face="normal" font="Arial"> Pigearias,B.</style></author><author><style face="normal" font="Arial"> Pin,I.</style></author><author><style face="normal" font="Arial"> Plavec,D.</style></author><author><style face="normal" font="Arial"> Poethig,D.</style></author><author><style face="normal" font="Arial"> Pohl,W.</style></author><author><style face="normal" font="Arial"> Popov,T.A.</style></author><author><style face="normal" font="Arial"> Portejoie,F.</style></author><author><style face="normal" font="Arial"> Potter,P.</style></author><author><style face="normal" font="Arial"> Postma,D.</style></author><author><style face="normal" font="Arial"> Price,D.</style></author><author><style face="normal" font="Arial"> Rabe,K.F.</style></author><author><style face="normal" font="Arial"> Raciborski,F.</style></author><author><style face="normal" font="Arial"> Radier,P.F.</style></author><author><style face="normal" font="Arial"> Repka-Ramirez,S.</style></author><author><style face="normal" font="Arial"> Reitamo,S.</style></author><author><style face="normal" font="Arial"> Rennard,S.</style></author><author><style face="normal" font="Arial"> Rodenas,F.</style></author><author><style face="normal" font="Arial"> Roberts,J.</style></author><author><style face="normal" font="Arial"> Roca,J.</style></author><author><style face="normal" font="Arial"> Rodriguez,M.L.</style></author><author><style face="normal" font="Arial"> Rolland,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CHRU, University Hospital, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France</style></auth-address><titles><title><style face="normal" font="Arial">Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="29">29-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Algeria</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bangladesh</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Care pathways</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Chronic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Congo</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Estonia</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mozambique</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Peru</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Slovakia</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> Ukraine</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 2045-7022 (Electronic)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -CO - Spain -CO - Finland -CO - Austria -CO - Italy -CO - Portugal -CO - Canada -CO - Sweden -CO - Netherlands -CO - Brazil -CO - Germany -CO - Singapore -CO - United Kingdom -CO - Greece -CO - Thailand -CO - Belgium -CO - Kyrgyzstan -CO - Norway -CO - Paraguay -CO - Switzerland -CO - Venezuela -CO - Israel -CO - United States -CO - Colombia -CO - Poland -CO - South Africa -CO - Bulgaria -CO - Croatia -CO - Japan -CO - South Korea -CO - Czech Republic -CO - Burkina Faso -CO - Congo -CO - Argentina -CO - Algeria -CO - Syria -CO - Serbia -CO - Romania -CO - Croatia -CO - Mozambique -CO - Croatia -CO - Slovakia -CO - Ireland -CO - Dubai -CO - China -CO - Vietnam -CO - Mexico -CO - Lithuania -CO - Ukraine -CO - Russia -CO - Estonia -CO - Australia -CO - Argentina -CO - Denmark -CO - Chile -CO - Latvia -CO - Georgia -CO - Peru -CO - Egypt -CO - Macedonia -CO - Bangladesh -CO - Tunisia -CO - Kazakhstan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40242-016-6016-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27478588">PM:27478588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-29.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-29.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40242-016-6016-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simpson,M.R.</style></author><author><style face="normal" font="Arial"> Ro,A.D.</style></author><author><style face="normal" font="Arial"> Grimstad,O.</style></author><author><style face="normal" font="Arial"> Johnsen,R.</style></author><author><style face="normal" font="Arial"> Storro,O.</style></author><author><style face="normal" font="Arial"> Oien,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway ; Det medisinske fakultet, Instiutt for samfunnsmedisin, MTFS, NTNU, Postboks 8905, 7491 Trondheim, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis prevention in children following maternal probiotic supplementation does not appear to be mediated by breast milk TSLP or TGF-beta</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="27">27-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> General practice</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The Probiotics in Prevention of Allergy among Children in Trondheim (ProPACT) study, a randomised, placebo controlled trial, demonstrated that maternal supplementation with probiotic milk reduced the incidence of atopic dermatitis (AD) in infancy. The mechanisms behind this effect are incompletely understood and breast milk cytokines have been postulated as possible mediating factors. In this study we aimed to assess whether breast milk TLSP and TGF-beta are affected by a maternal probiotic supplementation regime, and their contribution to the preventive effect of this regime on AD in the offspring. METHODS: TSLP and TGF-beta isoforms (TGF-beta1, TGF-beta2 and TGF-beta3) were measured using ELISA and multiplex assays, respectively, in breast milk samples collected at 10 days and 3 months postpartum from women participating in the ProPACT trial (n = 259). The natural indirect and direct effects of maternal probiotics on AD, due to changes in breast milk cytokines, were estimated using causal mediation techniques. RESULTS: Probiotic supplementation tend to lead to high levels of breast milk TSLP at 10 days postpartum (p = 0.062), but this change did not contribute to the prevention of AD according to the mediation analysis. Probiotics had no apparent effect on TSLP at 3 months or TGF-betas at either time points. Thus, these are unlikely to be mediators of the effect of maternal probiotics on AD in offspring. CONCLUSIONS: Whilst maternal probiotic supplementation resulted in higher breast milk concentrations of TLSP at 10 days postpartum, this does not appear to be a mechanism for prevention of AD by maternal probiotics. Trial registration The original trial protocol is registered in ClinicalTrials.gov (identifier NCT00159523)</style></abstract><notes><style face="normal" font="Arial">DA - 20160725IS - 2045-7022 (Electronic)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0119-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27453775">PM:27453775</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160725, Simpson MR</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0119-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sayej,W.N.</style></author><author><style face="normal" font="Arial"> Menoret,A.</style></author><author><style face="normal" font="Arial"> Maharjan,A.S.</style></author><author><style face="normal" font="Arial"> Fernandez,M.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author><author><style face="normal" font="Arial"> Balarezo,F.</style></author><author><style face="normal" font="Arial"> Hyams,J.S.</style></author><author><style face="normal" font="Arial"> Sylvester,F.A.</style></author><author><style face="normal" font="Arial"> Vella,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Digestive Diseases, Hepatology &amp; Nutrition, Connecticut Children's Medical Center , Hartford, CT, USA</style></auth-address><titles><title><style face="normal" font="Arial">Characterizing the inflammatory response in esophageal mucosal biopsies in children with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Immunology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Immunology</style></full-title></periodical><pages end="" start="e88">e88-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Connecticut</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Esophageal biopsy</style></keyword><keyword><style face="normal" font="Arial"> esophageal epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is an emerging allergic, IgE- and non-IgE (Th2 cell)-mediated disease. There are major gaps in the understanding of the basic mechanisms that drive the persistence of EoE. We investigated whether esophageal biopsies from children with EoE demonstrate an inflammatory response that is distinct from normal controls. We prospectively enrolled 84 patients, of whom 77 were included in our analysis, aged 4-17 years (12.8+/-3.8 years; 81% males). Five esophageal biopsies were collected from each patient at the time of endoscopy. Intramucosal lymphocytes were isolated, phenotyped and stimulated with phorbol 12-myristate 13-acetate/ionomycin to measure their potential to produce cytokines via flow cytometry. We also performed cytokine arrays on 72-h biopsy culture supernatants. CD8(+) T cells, compared with CD4(+) T cells, synthesized more TNF-alpha and interferon (IFN)-gamma after mitogen stimulation in the EoE-New/Active vs EoE-Remission group (P=0.0098; P=0.02) and controls (P=0.0008; P=0.03). Culture supernatants taken from explant esophageal tissue contained 13 analytes that distinguished EoE-New/Active from EoE-Remission and Controls. Principal component analysis and cluster analysis based on these analytes distinctly separated EoE-New/Active from EoE-Remission and Controls. In summary, we have identified a previously unappreciated role for CD8(+) T lymphocytes with potential to produce TNF-alpha and IFN-gamma in EoE. Our results suggest that CD8(+) T cells have a role in the persistence or progression of EoE. We have also identified a panel of analytes produced by intact esophageal biopsies that differentiates EoE-New/Active from EoE-Remission and controls. Our results suggest that esophageal epithelial cells may have specific immune effector functions in EoE that control the type and amplitude of inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 2050-0068 (Electronic)IS - 2050-0068 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/cti.2016.30</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525061">PM:27525061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Immunology\2016-5-e88.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Immunology\2016-5-e88.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Sayej WN</style></custom2><misc3><style face="normal" font="Arial">10.1038/cti.2016.30</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,R.Y.</style></author><author><style face="normal" font="Arial"> Rae,B.</style></author><author><style face="normal" font="Arial"> Neal,R.</style></author><author><style face="normal" font="Arial"> Donovan,C.</style></author><author><style face="normal" font="Arial"> Pinkerton,J.</style></author><author><style face="normal" font="Arial"> Balachandran,L.</style></author><author><style face="normal" font="Arial"> Starkey,M.R.</style></author><author><style face="normal" font="Arial"> Knight,D.A.</style></author><author><style face="normal" font="Arial"> Horvat,J.C.</style></author><author><style face="normal" font="Arial"> Hansbro,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Priority Research Centre for Healthy Lungs and Hunter Medical Research Institute, University of Newcastle , Newcastle, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Elucidating novel disease mechanisms in severe asthma</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Immunology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Immunology</style></full-title></periodical><pages end="" start="e91">e91-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Bowel Diseases</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Nephrotic Syndrome</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroid-resistant asthma</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Corticosteroids are broadly active and potent anti-inflammatory agents that, despite the introduction of biologics, remain as the mainstay therapy for many chronic inflammatory diseases, including inflammatory bowel diseases, nephrotic syndrome, rheumatoid arthritis, chronic obstructive pulmonary disease and asthma. Significantly, there are cohorts of these patients with poor sensitivity to steroid treatment even with high doses, which can lead to many iatrogenic side effects. The dose-limiting toxicity of corticosteroids, and the lack of effective therapeutic alternatives, leads to substantial excess morbidity and healthcare expenditure. We have developed novel murine models of respiratory infection-induced, severe, steroid-resistant asthma that recapitulate the hallmark features of the human disease. These models can be used to elucidate novel disease mechanisms and identify new therapeutic targets in severe asthma. Hypothesis-driven studies can elucidate the roles of specific factors and pathways. Alternatively, 'Omics approaches can be used to rapidly generate new targets. Similar approaches can be used in other diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 2050-0068 (Electronic)IS - 2050-0068 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1038/cti.2016.37</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525064">PM:27525064</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Immunology\2016-5-e91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Immunology\2016-5-e91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Kim RY</style></custom2><misc3><style face="normal" font="Arial">10.1038/cti.2016.37</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khatami,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Cancer Institute (NCI), the National Institutes of Health (NIH), Bethesda, MD, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Is cancer a severe delayed hypersensitivity reaction and histamine a blueprint?</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Med</style></full-title></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> emphysema</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fetus</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Gastritis</style></keyword><keyword><style face="normal" font="Arial"> Glycolysis</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune suppression</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Longevity</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mitochondria</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Longevity and accumulation of multiple context-dependent signaling pathways of long-standing inflammation (antigen-load or oxidative stress) are the results of decreased/altered regulation of immunity and loss of control switch mechanisms that we defined as Yin and Yang of acute inflammation or immune surveillance. Chronic inflammation is initiated by immune disruptors-induced progressive changes in physiology and function of susceptible host tissues that lead to increased immune suppression and multistep disease processes including carcinogenesis. The interrelated multiple hypotheses that are presented for the first time in this article are extension of author's earlier series of 'accidental' discoveries on the role of inflammation in developmental stages of immune dysfunction toward tumorigenesis and angiogenesis. Detailed analyses of data on chronic diseases suggest that nearly all age-associated illnesses, generally categorized as 'mild' (e.g., increased allergies), 'moderate' (e.g., hypertension, colitis, gastritis, pancreatitis, emphysema) or 'severe' (e.g., accelerated neurodegenerative and autoimmune diseases or site-specific cancers and metastasis) are variations of hypersensitivity responses of tissues that are manifested as different diseases in immune-responsive or immune-privileged tissues. Continuous release/presence of low level histamine (subclinical) in circulation could contribute to sustained oxidative stress and induction of 'mild' or 'moderate' or 'severe' (immune tsunami) immune disorders in susceptible tissues. Site-specific cancers are proposed to be 'severe' (irreversible) forms of cumulative delayed hypersensitivity responses that would induce immunological chaos in favor of tissue growth in target tissues. Shared or special features of growth from fetus development into adulthood and aging processes and carcinogenesis are briefly compared with regard to energy requirements of highly complex function of Yin and Yang. Features of Yang (growth-promoting) arm of acute inflammation during fetus and cancer growth will be compared for consuming low energy from glycolysis (Warburg effect). Growth of fetus and cancer cells under hypoxic conditions and impaired mitochondrial energy requirements of tissues including metabolism of essential branched amino acids (e.g., val, leu, isoleu) will be compared for proposing a working model for future systematic research on cancer biology, prevention and therapy. Presentation of a working model provides insightful clues into bioenergetics that are required for fetus growth (absence of external threat and lack of high energy-demands of Yin events and parasite-like survival in host), normal growth in adulthood (balance in Yin and Yang processes) or disease processes and carcinogenesis (loss of balance in Yin-Yang). Future studies require focusing on dynamics and promotion of natural/inherent balance between Yin (tumoricidal) and Yang (tumorigenic) of effective immunity that develop after birth. Lawless growth of cancerous cells and loss of cell contact inhibition could partially be due to impaired mitochondria (mitophagy) that influence metabolism of branched chain amino acids for biosynthesis of structural proteins. The author invites interested scientists with diverse expertise to provide comments, confirm, dispute and question and/or expand and collaborate on many components of the proposed working model with the goal to better understand cancer biology for future designs of cost-effective research and clinical trials and prevention of cancer. Initial events during oxidative stress-induced damages to DNA/RNA repair mechanisms and inappropriate expression of inflammatory mediators are potentially correctable, preventable or druggable, if future studies were to focus on systematic understanding of early altered immune response dynamics toward multistep chronic diseases and carcinogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20160825IS - 2001-1326 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40169-016-0108-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27558401">PM:27558401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Med\2016-5-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Med\2016-5-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Khatami M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40169-016-0108-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kew,K.M.</style></author><author><style face="normal" font="Arial"> Cates,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, UK, SW17 0RE</style></auth-address><titles><title><style face="normal" font="Arial">Home telemonitoring and remote feedback between clinic visits for asthma</style></title><secondary-title><style face="normal" font="Arial">Cochrane Database Syst Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cochrane Database Syst Rev</style></full-title></periodical><pages end="" start="CD011714">CD011714-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mild to moderate persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="3" Month="8" Year="2016">2016/8/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a chronic disease that causes reversible narrowing of the airways due to bronchoconstriction, inflammation and mucus production. Asthma continues to be associated with significant avoidable morbidity and mortality. Self management facilitated by a healthcare professional is important to keep symptoms controlled and to prevent exacerbations.Telephone and Internet technologies can now be used by patients to measure lung function and asthma symptoms at home. Patients can then share this information electronically with their healthcare provider, who can provide feedback between clinic visits. Technology can be used in this manner to improve health outcomes and prevent the need for emergency treatment for people with asthma and other long-term health conditions. OBJECTIVES: To assess the efficacy and safety of home telemonitoring with healthcare professional feedback between clinic visits, compared with usual care. SEARCH METHODS: We identified trials from the Cochrane Airways Review Group Specialised Register (CAGR) up to May 2016. We also searched www.clinicaltrials.gov, the World Health Organization (WHO) trials portal and reference lists of other reviews, and we contacted trial authors to ask for additional information. SELECTION CRITERIA: We included parallel randomised controlled trials (RCTs) of adults or children with asthma in which any form of technology was used to measure and share asthma monitoring data with a healthcare provider between clinic visits, compared with other monitoring or usual care. We excluded trials in which technologies were used for monitoring with no input from a doctor or nurse. We included studies reported as full-text articles, those published as abstracts only and unpublished data. DATA COLLECTION AND ANALYSIS: Two review authors screened the search and independently extracted risk of bias and numerical data, resolving disagreements by consensus.We analysed dichotomous data as odds ratios (ORs) while using study participants as the unit of analysis, and continuous data as mean differences (MDs) while using random-effects models. We rated evidence for all outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) approach. MAIN RESULTS: We found 18 studies including 2268 participants: 12 in adults, 5 in children and one in individuals from both age groups. Studies generally recruited people with mild to moderate persistent asthma and followed them for between three and 12 months. People in the intervention group were given one of a variety of technologies to record and share their symptoms (text messaging, Web systems or phone calls), compared with a group of people who received usual care or a control intervention.Evidence from these studies did not show clearly whether asthma telemonitoring with feedback from a healthcare professional increases or decreases the odds of exacerbations that require a course of oral steroids (OR 0.93, 95% confidence Interval (CI) 0.60 to 1.44; 466 participants; four studies), a visit to the emergency department (OR 0.75, 95% CI 0.36 to 1.58; 1018 participants; eight studies) or a stay in hospital (OR 0.56, 95% CI 0.21 to 1.49; 1042 participants; 10 studies) compared with usual care. Our confidence was limited by imprecision in all three primary outcomes. Evidence quality ratings ranged from moderate to very low. None of the studies recorded serious or non-serious adverse events separately from asthma exacerbations.Evidence for measures of asthma control was imprecise and inconsistent, revealing possible benefit over usual care for quality of life (MD 0.23, 95% CI 0.01 to 0.45; 796 participants; six studies; I2 = 54%), but the effect was small and study results varied. Telemonitoring interventions may provide additional benefit for two measures of lung function. AUTHORS' CONCLUSIONS: Current evidence does not support the widespread implementation of telemonitoring with healthcare provider feedback between asthma clinic visits. Studies have not yet proven that additional telemonitoring strategies lead to better symptom control or reduced need for oral steroids over usual asthma care, nor have they ruled out unintended harms. Investigators noted small benefits for quality of life, but these are subject to risk of bias, as the studies were unblinded. Similarly, some benefits for lung function are uncertain owing to possible attrition bias.Larger pragmatic studies in children and adults could better determine the real-world benefits of these interventions for preventing exacerbations and avoiding harms; it is difficult to generalise results from this review because benefits may be explained at least in part by the increased attention participants receive by taking part in clinical trials. Qualitative studies could inform future research by focusing on patient and provider preferences, or by identifying subgroups of patients who are more likely to attain benefit from closer monitoring, such as those who have frequent asthma attacks</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1469-493X (Electronic)IS - 1361-6137 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1002/14651858.CD011714.pub2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27486836">PM:27486836</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cochrane Database Syst Rev\2016-8-CD11714.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cochrane Database Syst Rev\2016-8-CD11714.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Kew KM</style></custom2><misc3><style face="normal" font="Arial">10.1002/14651858.CD011714.pub2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lukacs,J.</style></author><author><style face="normal" font="Arial"> Schliemann,S.</style></author><author><style face="normal" font="Arial"> Elsner,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University Hospital Jena, 07743, Jena, GermanyDepartment of Dermatology, University Hospital Jena, 07743, Jena, GermanyDepartment of Dermatology, University Hospital Jena, 07743, Jena, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Occupational contact urticaria caused by food - a systematic clinical review</style></title><secondary-title><style face="normal" font="Arial">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Contact Dermatitis</style></full-title></periodical><pages end="204" start="195">195-204</pages><volume><style face="normal" font="Arial">75</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">baker</style></keyword><keyword><style face="normal" font="Arial"> Bakers</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Occupations</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword></keywords><dates><year Day="18" Month="7" Year="2016">2016/7/18</year></dates><abstract><style face="normal" font="Arial">Food industry workers are at increased risk for occupational contact urticaria (CU). There are many foodstuffs that have been reported to cause occupational CU, including seafood, meat, vegetables, and fruits. The aim of this review is to summarize all reported occupational cases of CU in the food industry. This is a systematic review based on a MEDLINE search of articles in English and German and a manual search, between 1990 and 2014, to summarize the case reports and case series of occupational CU in the food industry. Many different foodstuffs have been implicated in CU. Occupational CU has been reported in many different occupations, mostly in individuals dealing with seafood, meat, vegetables, and fruits, such as chefs, cooks, bakers, butchers, slaughterhouse workers, and fish-factory workers. Foodstuffs that commonly induce occupational protein contact dermatitis include fish, seafood, meats, vegetables, and fruits. Food handlers may acquire CU resulting from occupational exposures. The prognosis varies widely. The diagnosis of immunological CU is based on the clinical history and on a positive prick test with the suspected substance and/or measurement of specific IgE</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cod.12653</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27425004">PM:27425004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\20160718-LukacsJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\20160718-LukacsJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Lukacs J</style></custom2><misc3><style face="normal" font="Arial">10.1111/cod.12653</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Benedetto,D.</style></author><author><style face="normal" font="Arial"> Agostoni,P.</style></author><author><style face="normal" font="Arial"> de Waal,E.</style></author><author><style face="normal" font="Arial"> Stella,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aUniversity Medical Centre Utrecht, Utrecht bDepartment of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands cState University of Milan, Milan, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Kounis syndrome with cardiogenic shock during transfemoral transcatheter aortic valve replacement</style></title><secondary-title><style face="normal" font="Arial">Coron Artery Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Coron Artery Dis</style></abbr-1></periodical><pages end="727" start="726">726-727</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Aged,80 and over</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Aortic Valve</style></keyword><keyword><style face="normal" font="Arial"> Aortic Valve Stenosis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> chemically induced</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Contrast Media</style></keyword><keyword><style face="normal" font="Arial"> Coronary Vasospasm</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Femoral Artery</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Intraoperative Complications</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Shock,Cardiogenic</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Transcatheter Aortic Valve Replacement</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2015">2015/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20151104IS - 1473-5830 (Electronic)IS - 0954-6928 (Linking)LA - engPT - Case ReportsPT - Journal ArticlePT - Video-Audio MediaRN - 0 (Contrast Media)SB - IMCO - Netherlands -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1097/MCA.0000000000000300</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26398150">PM:26398150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Coron Artery Dis\2015-26-726-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Coron Artery Dis\2015-26-726-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151104, Benedetto D</style></custom2><misc3><style face="normal" font="Arial">10.1097/MCA.0000000000000300</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Varzakas,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Technological Educational Institute of Peloponnese , Kalamata , Greece</style></auth-address><titles><title><style face="normal" font="Arial">Quality and Safety Aspects of Cereals (Wheat) and Their Products</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="2510" start="2495">2495-2510</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">15</style></number><reprint-status date="09/12/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Baking</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Dough</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Flours</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxins</style></keyword><keyword><style face="normal" font="Arial"> Pasta</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality and safety</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Sodium Chloride</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Cereals and most specifically wheat are described in this chapter highlighting on their safety and quality aspects. Moreover, wheat quality aspects are adequately addressed since they are used to characterize dough properties and baking quality. Determination of dough properties is also mentioned and pasta quality is also described in this chapter. Chemometrics-multivariate analysis is one of the analysis carried out. Regarding production weighing/mixing of flours, kneading, extruded wheat flours, and sodium chloride are important processing steps/raw materials used in the manufacturing of pastry products. Staling of Cereal-Based Products is also taken into account. Finally, safety aspects of cereal-based products are well documented with special emphasis on mycotoxins, acrylamide, and near infra red (NIR) methodology</style></abstract><notes><style face="normal" font="Arial">DA - 20150401IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2013.866070</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="25830822">PM:25830822</url></web-urls><pdf-urls><url ppv-ref="no">tvarzakas@teikal.gr</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20150401, Varzakas T</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2013.866070</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bruins,S.I.</style></author><author><style face="normal" font="Arial"> van der Fels-Klerx,H.J.</style></author><author><style face="normal" font="Arial"> Bremer,M.G.</style></author><author><style face="normal" font="Arial"> Hamer,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a RIK</style></auth-address><titles><title><style face="normal" font="Arial">Immunochemical Detection Methods for Gluten in Food Products: Where Do We Go from Here?</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="2466" start="2455">2455-2466</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">15</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Consumer</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Detection methods</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Accurate and reliable quantification methods for gluten in food are necessary to ensure proper product labelling and thus safeguard the gluten sensitive consumer against exposure. Immunochemical detection is the method of choice, as it is sensitive, rapid and relatively easy to use. Although a wide range of detection kits are commercially available, there are still many difficulties in gluten detection that have not yet been overcome. This review gives an overview of the currently commercially available immunochemical detection methods, and discusses the problems that still exist in gluten detection in food. The largest problems are encountered in the extraction of gluten from food matrices, the choice of epitopes targeted by the detection method, and the use of a standardized reference material. By comparing the available techniques with the unmet needs in gluten detection, the possible benefit of a new multiplex immunoassay is investigated. This detection method would allow for the detection and quantification of multiple harmful gluten peptides at once and would, therefore, be a logical advancement in gluten detection in food</style></abstract><notes><style face="normal" font="Arial">DA - 20150317IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2013.847817</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="25779856">PM:25779856</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\2016-56-15-2455-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\2016-56-15-2455-66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150317, Bruins SI</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2013.847817</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ozcan,C.</style></author><author><style face="normal" font="Arial"> Ismi,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, School of Medicine, Mersin University, Mersin, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Botulinum Toxin for Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="58">58-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Botulinum Toxin Type A</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> decongestants</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritants</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Nasal Decongestants</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Rhinitis is a common clinical entity. Besides nasal obstruction, itching, and sneezing, one of the most important symptoms of rhinitis is nasal hypersecretion produced by nasal glands and exudate from the nasal vascular bed. Allergic rhinitis is an IgE-mediated inflammatory reaction of nasal mucosa after exposure to environmental allergens. Idiopathic rhinitis describes rhinitis symptoms that occur after non-allergic, noninfectious irritants. Specific allergen avoidance, topical nasal decongestants, nasal corticosteroids, immunotherapy, and sinonasal surgery are the main treatment options. Because the current treatment modalities are not enough for reducing rhinorrhea in some patients, novel treatment options are required to solve this problem. RECENT FINDINGS: Botulinum toxin is an exotoxin generated by Clostridium botulinum. It disturbs the signal transmission at the neuromuscular and neuroglandular junction by inhibiting the acetylcholine release from the presynaptic nerve terminal. It has been widely used in neuromuscular, hypersecretory, and autonomic nerve system disorders. There have been a lot of published articles concerning the effect of this toxin on rhinitis symptoms. Based on the results of these reports, intranasal botulinum toxin A administration appears to be a safe and effective treatment method for decreasing rhinitis symptoms in rhinitis patients with a long-lasting effect. Botulinum toxin type A will be a good treatment option for the chronic rhinitis patients who are resistant to other treatment methods</style></abstract><notes><style face="normal" font="Arial">DA - 20160727IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0636-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27461136">PM:27461136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-58.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160727, Ozcan C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0636-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hoffmann,H.J.</style></author><author><style face="normal" font="Arial"> Knol,E.F.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author><author><style face="normal" font="Arial"> Mayorga,L.</style></author><author><style face="normal" font="Arial"> Sabato,V.</style></author><author><style face="normal" font="Arial"> Santos,A.F.</style></author><author><style face="normal" font="Arial"> Eberlein,B.</style></author><author><style face="normal" font="Arial"> Nopp,A.</style></author><author><style face="normal" font="Arial"> MacGlashan,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.Johns Hopkins, Baltimore, USA</style></auth-address><titles><title><style face="normal" font="Arial">Pros and Cons of Clinical Basophil Testing (BAT)</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="56">56-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: We review basophil testing by flow cytometry with an emphasis on advantages and disadvantages. RECENT FINDINGS: There are many tools available to assess the presence and severity of allergic diseases in patients. For 50 years, peripheral blood basophils have been used as tools to study these diseases. It is a very accessible cell that binds IgE antibody and secretes the classical mediators responsible for the symptoms of allergic reactions. In the last decade, an even more accessible methodology, using flow cytometry, has been developed to enhance the ability to use basophils for both mechanistic and clinical diagnostics. Basophil testing has been included in diagnostics for different forms of allergies as well as to monitor disease status. A variety of studies have begun to establish both precise methods and their clinical relevance for disease diagnosis, but there remain some important questions on how to take optimal advantage of the behaviours of basophils</style></abstract><notes><style face="normal" font="Arial">DA - 20160714IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Denmark -CO - Netherlands -CO - Spain -CO - Belgium -CO - United Kingdom -CO - Germany -CO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0633-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27411319">PM:27411319</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160714, Hoffmann HJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0633-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Levin,M.E.</style></author><author><style face="normal" font="Arial"> Gray,C.L.</style></author><author><style face="normal" font="Arial"> Marrugo,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food Allergy: International and Developing World Perspectives</style></title><secondary-title><style face="normal" font="Arial">Curr Pediatr Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pediatr Rep</style></full-title></periodical><pages end="137" start="129">129-137</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2167-4841</style></isbn><abstract><style face="normal" font="Arial">Epidemiological data on food allergy worldwide suffer from the challenges of variability in methods of diagnosis, sampling, and response rates. There are little data on food allergy in the developing world and populations with food allergy in such settings may suffer from challenges that are different from those experienced by subjects with food allergy in the developed world</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -CO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40124-016-0104-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40124-016-0104-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Pediatr Rep\20160901-LevinME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Pediatr Rep\20160901-LevinME.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Levin ME</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40124-016-0104-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kanagaratham,C.</style></author><author><style face="normal" font="Arial"> Radzioch,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Human Genetics, McGill University Health Centre, McGill University, Montreal, QC Canada. cynkan@gmail.com</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Asthma: A summary from genetic basis, mouse studies, to diagnosis and treatment</style></title><secondary-title><style face="normal" font="Arial">Curr Pharm Des</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pharm Des</style></full-title></periodical><pages end="6272" start="6261">6261-6272</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">41</style></number><reprint-status date="09/11/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> antileukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion Molecules</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene modifier</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment guidelines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="29" Month="8" Year="2016">2016/8/29</year></dates><abstract><style face="normal" font="Arial">Asthma is a disease that currently affects approximately 300 million people worldwide. It is generally viewed as an allergic disease and can manifest itself in a variety of phenotypes. Two of its main phenotypes routinely assessed at the clinic include airway hyperresponsiveness and IgE production. They can be measured in a non-invasive manner and have been used for genetic studies. However, the genetic complexity of asthma and its phenotypes makes it difficult to map their genetic contributors. Though human studies have been successful at mapping candidate genes for asthma phenotypes, they require large sample sizes and proper segregation of the population to control for potential confounding factors. Another approach for studying allergic asthma is through the use of mouse models. Mouse genetics and immunology are highly homologous to humans. Airway hyperresponsiveness and inflammatory phenotypes of allergic asthma can be studied in mouse models. In addition, the variety of mouse strains and allergic asthma induction protocols allows to study different aspects of the disease in a controlled genetic background. Overall, studying the genetic basis of asthma phenotypes, in mice and humans, has helped in gaining a better understanding of the disease mechanism. Candidate genes identified from genetic studies have served as targets for the development of new and specialized treatments. New treatments are high in demand as the symptoms of a large number of asthmatics are not properly controlled with the existing treatment guidelines mainly involving corticosteroids, beta2-adrenoreceptor agonists, and antileukotrienes or leukotriene modifiers. Promising findings have been obtained from studies exploring new treatments targeting specific immune cell mediators, such as IL-5 and IL-13, which were identified as candidates in genetic studies, and cell adhesion molecules, such as ICAM-1 and VCAM-1. In addition to targeting members of the Th1/Th2 inflammatory profile, mediators of the omega-3/omega-6 pathway are also emerging as novel targets of drug intervention for allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1873-4286 (Electronic)IS - 1381-6128 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27573930">PM:27573930</url></web-urls><pdf-urls><url ppv-ref="no">cynkan@gmail.com researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160830, Kanagaratham C</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanders,N.L.</style></author><author><style face="normal" font="Arial"> Mishra,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Section of Pulmonary Diseases, Tulane Eosinophilic Disorders Center, Tulane University School of Medicine, New Orleans, LA 70112, United States of America; Tulane University in Neuroscience and Biological Chemistry, Tulane University, New Orleans, LA, United States of AmericaDepartment of Medicine, Section of Pulmonary Diseases, Tulane Eosinophilic Disorders Center, Tulane University School of Medicine, New Orleans, LA 70112, United States of America. Electronic address: amishra@tulane.edu</style></auth-address><titles><title><style face="normal" font="Arial">Role of interleukin-18 in the pathophysiology of allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Cytokine Growth Factor Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Cytokine Growth Factor Rev</style></abbr-1></periodical><pages end="39" start="31">31-39</pages><volume><style face="normal" font="Arial">32</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immune system</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic disorders</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> IL-1</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-18</style></keyword><keyword><style face="normal" font="Arial"> isotype switching</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="15" Month="7" Year="2016">2016/7/15</year></dates><abstract><style face="normal" font="Arial">Interleukin (IL)-18 is an IL-1 family cytokine expressed by macrophages, dendritic cells, epithelial cells, and keratinocytes and is implicated in various aspects of both the innate and adaptive immune systems. IL-18 signals similar to IL-1beta intracellularly to activate gene transcription. Since its discovery, IL-18 has been demonstrated to play a key role in pathogen defense from helminths and some bacteria. Recently however, evidence has accumulated that IL-18 expression is increased in many presentations of allergic disease. A pathologic role for IL-18 includes stimulating mast cell and basophil degranulation, recruiting granulocytes to sites of inflammation, increasing cytotoxic activity of natural killer (NK) and NK-T cells, inducing Immunoglobulin (Ig)E production and isotype switching, and affecting a broad range of T cells to promote a type II helper T cell (Th2) response. Evidence and importance of these effects are presented, including novel results from our lab implicating IL-18 in the direct expansion of mast cells, basophils, and other myeloid-lineage cells from bone-marrow precursors. The development of urticaria, asthma, dermatitis, rhinitis, and eosinophilic disorders all have demonstrated correlations to increased IL-18 levels either in the tissue or systemically. IL-18 represents a novel site of immune regulation in not only allergic conditions, but also autoimmune diseases and other instances of aberrant immune functioning. Diagrammatic summarized abstract for readers convinance is presented in Fig. 1</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1879-0305 (Electronic)IS - 1359-6101 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cytogfr.2016.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496752">PM:27496752</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytokine Growth Factor Rev\20160806-SandersNL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytokine Growth Factor Rev\20160806-SandersNL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Sanders NL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cytogfr.2016.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Haahtela,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[About animal allergy]</style></title><secondary-title><style face="normal" font="Arial">Duodecim</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Duodecim</style></full-title></periodical><pages end="1258" start="1253">1253-1258</pages><volume><style face="normal" font="Arial">132</style></volume><number><style face="normal" font="Arial">13-14</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Membranes</style></keyword><keyword><style face="normal" font="Arial"> Mucous Membrane</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Although the opinions about animals and animal allergies may be extreme, animals can even be indispensable for the well-being of humans. The immune tolerance of many modern city dwellers is insufficiently developed, predisposing the skin and mucous membranes to allergic inflammation. There is no need in infancy to avoid animals, and animal contacts in early childhood rather protect from the development of allergies. Pet allergens are present in small amounts everywhere, not only in places where they live. General instructions on avoidance do not exist. New forms of desensitization therapy may in the future bring relief for those having strong symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 0012-7183 (Print)IS - 0012-7183 (Linking)LA - finPT - English AbstractPT - Journal ArticleSB - IMCO - Finland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27522834">PM:27522834</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Duodecim\2016-132-1253-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Duodecim\2016-132-1253-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Haahtela T</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asher,W.W.</style></author><author><style face="normal" font="Arial"> Huang,K.Z.</style></author><author><style face="normal" font="Arial"> Durban,R.</style></author><author><style face="normal" font="Arial"> Iqbal,Z.J.</style></author><author><style face="normal" font="Arial"> Robey,B.S.</style></author><author><style face="normal" font="Arial"> Khalid,F.J.</style></author><author><style face="normal" font="Arial"> Dellon,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, UNC-CH, CB #7080, Bioinformatics Building, 130 Mason Farm Rd.,, Chapel Hill, NC, 27599-7080, USA</style></auth-address><titles><title><style face="normal" font="Arial">The Six-Food Elimination Diet for Eosinophilic Esophagitis Increases Grocery Shopping Cost and Complexity</style></title><secondary-title><style face="normal" font="Arial">Dysphagia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dysphagia</style></full-title></periodical><pages end="770" start="765">765-770</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary therapy</style></keyword><keyword><style face="normal" font="Arial"> Dietitian</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophageal Diseases</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="9" Month="8" Year="2016">2016/8/9</year></dates><abstract><style face="normal" font="Arial">The six-food elimination diet (SFED), where dairy, wheat, eggs, soy, nuts, and seafood are avoided, is an effective treatment for eosinophilic esophagitis (EoE). Patient-related costs of this approach, however, are unknown. We aimed to assess the cost of and ease of shopping for an SFED compared to an unrestricted diet. A dietitian with expertise in EoE generated menus meeting dietary requirements for a week's worth of meals for the SFED and an unrestricted diet. We compared prices and the number of missing items for both diets at standard and specialty grocery stores. The average weekly price of the SFED at a standard supermarket was $92.54 compared to $79.84 for an unrestricted diet (p = 0.0001). A patient shopping at a standard grocery store needed a higher proportion of items from a second store compared to an unrestricted diet (32 vs. 3 %, p = 0.0001). The prices of the SFED and unrestricted diet using a specialty supermarket were comparable ($106.47 vs. $105.96, p = 0.81), as was the percentage of items requiring a trip to a second store (6 vs. 2 % items, p = 0.03). Shopping at a specialty grocery store increased weekly grocery costs by $13.93 (p = 0.04) for the SFED and $26.12 (p = 0.03) for the unrestricted diet. In conclusion, for patients shopping at standard grocery stores, the cost of an SFED is higher, and an SFED requires more items from a second store. These differences disappear at specialty grocery stores, but costs were significantly higher. This cost and logistical burden can inform patients when selecting dietary therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160809IS - 1432-0460 (Electronic)IS - 0179-051X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00455-016-9739-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27503565">PM:27503565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dysphagia\20160809-AsherWW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dysphagia\20160809-AsherWW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160809, Asher WW</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00455-016-9739-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cornelius,C.</style></author><author><style face="normal" font="Arial"> Schoneweis,K.</style></author><author><style face="normal" font="Arial"> Georgi,F.</style></author><author><style face="normal" font="Arial"> Weber,M.</style></author><author><style face="normal" font="Arial"> Niederberger,V.</style></author><author><style face="normal" font="Arial"> Zieglmayer,P.</style></author><author><style face="normal" font="Arial"> Niespodziana,K.</style></author><author><style face="normal" font="Arial"> Trauner,M.</style></author><author><style face="normal" font="Arial"> Hofer,H.</style></author><author><style face="normal" font="Arial"> Urban,S.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immunotherapy with The Pres-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection</style></title><secondary-title><style face="normal" font="Arial">EBioMedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EBioMedicine</style></full-title></periodical><pages end="67" start="58">58-67</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell epitope-based allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> fusion proteins</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B</style></keyword><keyword><style face="normal" font="Arial"> hepatitis B surface protein</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B virus</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> preS</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> virus neutralization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2352-3964</style></isbn><abstract><style face="normal" font="Arial">Background We have constructed and clinically evaluated a hypoallergenic vaccine for grass pollen allergy, BM32, which is based on fusion proteins consisting of peptides from the IgE binding sites of the major grass pollen allergens fused to preS (preS1 + preS2), a domain of the hepatitis B virus (HBV) large envelope protein which mediates the viral attachment and entry. Aim of this study was the characterization of the HBV-specific immune response induced by vaccination of allergic patients with BM32 and investigation of the vaccines' potential to protect against infection with HBV. Methods Hepatitis B-specific antibody and T cell responses of patients vaccinated with BM32 were studied using recombinant preS and synthetic overlapping peptides spanning the preS sequence. The specificities of the antibody responses were compared with those of patients with chronic HBV infection. Furthermore, the capacity of BM32-induced antibodies, to inhibit HBV infection was investigated using HepG2-hNTCP cell-based in vitro virus neutralization assays. Findings IgG antibodies from BM32-vaccinated but not of HBV-infected individuals recognized the sequence motif implicated in NTCP (sodium-taurocholate co-transporting polypeptide)-receptor interaction of the hepatitis B virus and inhibited HBV infection. Interpretation Our study demonstrates that the recombinant hypoallergenic grass pollen allergy vaccine BM32 induces hepatitis B-specific immune responses which protect against hepatitis B virus infection in vitro</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ebiom.2016.07.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27568223">PM:27568223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EBioMedicine\20160808-CorneliusC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EBioMedicine\20160808-CorneliusC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Cornelius C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ebiom.2016.07.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gerlich,W.H.</style></author><author><style face="normal" font="Arial"> Glebe,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Medical Virology, National Reference Center for Hepatitis B and D Viruses, German Center for Infection Research (DZIF), Justus Liebig University, Biomedical Research Center Seltersberg, Schubert Str. 81, D35392 Giessen, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Development of an Allergy Immunotherapy Leads to a New Type of Hepatitis B Vaccine</style></title><secondary-title><style face="normal" font="Arial">EBioMedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EBioMedicine</style></full-title></periodical><pages end="6" start="5">5-6</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B vaccine</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> virology</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 2352-3964 (Electronic)IS - 2352-3964 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ebiom.2016.07.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27485030">PM:27485030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EBioMedicine\20160803-GerlichWH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EBioMedicine\20160803-GerlichWH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Gerlich WH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ebiom.2016.07.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Safari,M.</style></author><author><style face="normal" font="Arial"> Sayemiri,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">M.D., Allergist and Clinical Immunologist, Associate Professor, Department of Immunology and Allergy, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, IranM.D., Medical and Health Network Manager of Marivan, Kurdistan University of Medical Sciences, Marivan, Iran</style></auth-address><titles><title><style face="normal" font="Arial">The Results of Autologous Skin Test in Patients with Chronic Urticaria in Hamadan, Iran</style></title><secondary-title><style face="normal" font="Arial">Electron Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Electron Physician</style></full-title></periodical><pages end="2542" start="2539">2539-2542</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune urticaria</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The etiology of chronic urticaria is unknown in many cases. In this study, we demonstrated the presence of autoimmune antibodies in patients with chronic urticaria by using of the Autologous Serum Skin Test (ASST). METHODS: We performed a cross-sectional study to detect the presence of autologous antibodies in the serum of 38 patients (25 females and 13 males) with idiopathic chronic urticaria who were referred to the Hamedan Allergy Clinic in 2014. All of the necessary tests for demonstrating chronic urticaria were performed, including complete blood count (CBC), thyroid and liver functionality tests, and the prick test but they did not confirm the cause of chronic urticaria. We conducted the Autologous Serum Skin Test on the patients and analyzed the results. RESULTS: In 15 patients (39%), the ASST was positive. Of the 15 patients with positive autoimmune chronic urticaria, five patients (33%) were males, and 10 patients (67%) were females. CONCLUSION: We concluded that many patients with chronic urticaria have autoimmune urticaria. It is the reason for the lack of the response to treatment with common medications for urticaria. New ways of treatment must be considered for them</style></abstract><notes><style face="normal" font="Arial">DA - 20160809IS - 2008-5842 (Electronic)IS - 2008-5842 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.19082/2539</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27504169">PM:27504169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Electron Physician\2016-8-2539-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Electron Physician\2016-8-2539-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160809, Safari M</style></custom2><misc3><style face="normal" font="Arial">10.19082/2539</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amoah,B.</style></author><author><style face="normal" font="Arial"> Schilling,M.W.</style></author><author><style face="normal" font="Arial"> Phillips,T.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Entomology, Kansas State University, Manhattan, KS 66506</style></auth-address><titles><title><style face="normal" font="Arial">Monitoring Tyrophagus putrescentiae (Acari: Acaridae) With Traps in Dry-Cured Ham Aging Rooms</style></title><secondary-title><style face="normal" font="Arial">Environ Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Entomol</style></full-title></periodical><pages end="1039" start="1029">1029-1039</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Acari</style></keyword><keyword><style face="normal" font="Arial"> Acaridae</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Entomology</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fumigation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mitigation</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus putrescentiae</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="5" Year="2016">2016/5/30</year></dates><abstract><style face="normal" font="Arial">Methyl bromide is the most effective fumigant for controlling the mold (or ham) mite, Tyrophagus putrescentiae (Schrank) (Acari: Acaridae), the most significant pest of dry-cured ham. However, methyl bromide is being phased out of use. Therefore, integrated pest management (IPM) methods should be developed to help control mites in dry-cured ham plants. The foundation of a successful IPM program is an effective monitoring program that provides information on pest presence and abundance over time. By using food-baited traps fabricated from disposable petri dishes and a dog food-based bait, mite activity over time and space was monitored in five dry-cured ham aging rooms from three commercial processing facilities that differed in their fumigation frequencies. Weekly sampling of the mite was conducted from June 2012 to September 2013. There were significant differences in the average weekly trap captures in all facilities, especially before and after fumigation, with the majority of mites in traps prior to fumigation. Mite numbers had a pattern of sharp decline after fumigation, followed by a steady increase until the next fumigation. Average trap captures varied due to trap location over the study period at all study sites, indicating that traps could be used to identify specific locations within an aging room where mite infestation of hams was more likely to occur. These findings can inform facility managers of mite population changes that can be used as one factor toward making pest management decisions and assessing the impact of fumigation or other pest mitigation actions</style></abstract><notes><style face="normal" font="Arial">DA - 20160601IS - 1938-2936 (Electronic)IS - 0046-225X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/ee/nvw059</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27247306">PM:27247306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Entomol\2016-45-1029-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Entomol\2016-45-1029-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160601, Amoah B</style></custom2><misc3><style face="normal" font="Arial">10.1093/ee/nvw059</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,C.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author><author><style face="normal" font="Arial"> Cai,J.</style></author><author><style face="normal" font="Arial"> Shen,L.</style></author><author><style face="normal" font="Arial"> Zou,Z.</style></author><author><style face="normal" font="Arial"> Lu,R.</style></author><author><style face="normal" font="Arial"> Chang,J.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Sun,C.</style></author><author><style face="normal" font="Arial"> Zhao,Z.</style></author><author><style face="normal" font="Arial"> Sun,Y.</style></author><author><style face="normal" font="Arial"> Sundell,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Environment and Architecture, University of Shanghai for Science and Technology, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Household indoor air quality and its associations with childhood asthma in Shanghai, China: On-site inspected methods and preliminary results</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="167" start="154">154-167</pages><volume><style face="normal" font="Arial">151</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bedrooms</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Formaldehyde</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Home environment</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor air quality</style></keyword><keyword><style face="normal" font="Arial"> inspection</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> PM10</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="29" Month="7" Year="2016">2016/7/29</year></dates><abstract><style face="normal" font="Arial">Few studies were conducted for associations of home environment with childhood health by on-site inspection in China. During 2013-2014, we conducted a case-control study with home inspection among 454 children (186 asthma children and 268 non-asthma children) in Shanghai, China. In this paper, we detailedly described the inspected methods and analyzed the preliminarily collected data. Except in winter, most residences meet the national standard for indoor temperature and relative humidity. Most living rooms had &lt;/=1000ppm CO2, whereas over half of the child's bedrooms had slightly >1000ppm CO2 during night. Most residences had notably lower than 2500cfu/m3 airborne culturable fungi and &lt;/=100mug/m3 formaldehyde. More than 70% of the child's bedrooms had &lt;/=75mug/m3 PM2.5 and &lt;/=150mug/m3 PM10. Indoor and outdoor concentrations of particulate matters had strong linear correlations (r=0.891-0.922; p-value &lt;0.001). Most differences between cases and controls were not significant with respect to CO2, culturable fungi, formaldehyde, and particulate matters. Before and after adjusted for potential confounders, indoor averaged concentration of CO2 and particulate matters generally had negative associations with childhood history of doctor-diagnosed asthma in spring, summer, and autumn. Only in winter, indoor CO2 concentration was significantly associated with the increased odds of childhood asthma. Our results indicated that air quality among most residences in Shanghai could meet the national standard for indoor air quality in warm seasons; but household air quality and ventilation status in winter should be greatly improved. We suspected that those "unexpected" negative associations could exist due to changes in lifestyle behaviors regarding indoor air quality after the child being diagnosed asthma by a doctor</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2016.07.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27479712">PM:27479712</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2016-151-154-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2016-151-154-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Huang C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2016.07.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lopez,S.</style></author><author><style face="normal" font="Arial"> Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Goldarazena,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Vespa velutina Lepeletier, 1836 (Hymenoptera: Vespidae): first records in Iberian Peninsula</style></title><secondary-title><style face="normal" font="Arial">EPPO Bulletin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EPPO Bulletin</style></full-title></periodical><pages end="441" start="439">439-441</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--Allergeni Nativi</style></keyword><keyword><style face="normal" font="Arial"> 1--Concentrazione</style></keyword><keyword><style face="normal" font="Arial"> 1--Imenotteri</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Iberian Peninsula</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="1" Month="12" Year="2011">2011/12/1</year></dates><publisher><style face="normal" font="Arial">Blackwell Publishing Ltd</style></publisher><isbn><style face="normal" font="Arial">1365-2338</style></isbn><abstract><style face="normal" font="Arial">Vespa velutina Lepeletier, 1836 (Hymenoptera: Vespidae) is reported for the first time from the Iberian Peninsula based on catches made during 2010 in Guipuzcoa and Navarra provinces (northern Spain). Notes about its current geographical distribution, biology, and economic and medical importance are also provided</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/j.1365-2338.2011.02513.x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1111/j.1365-2338.2011.02513.x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EPPO Bulletin\2011-41-439-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EPPO Bulletin\2011-41-439-41.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">2A</style></custom1><custom2><style face="normal" font="Arial">20110110, Lopez S</style></custom2><misc3><style face="normal" font="Arial">10.1111/j.1365-2338.2011.02513.x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kinoshita,Y.</style></author><author><style face="normal" font="Arial"> Ishimura,N.</style></author><author><style face="normal" font="Arial"> Mishiro,T.</style></author><author><style face="normal" font="Arial"> Ishihara,S.i</style></author><author><style face="normal" font="Arial"> Adachi,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Diagnosis and treatment of eosinophilic esophagitis in Japan</style></title><secondary-title><style face="normal" font="Arial">Esophagus</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Esophagus</style></abbr-1></periodical><pages end="75" start="66">66-75</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1612-9067</style></isbn><abstract><style face="normal" font="Arial">Patients in Japan affected by eosinophilic esophagitis (EoE), considered to be a dietary allergen related chronic esophageal disease, are slowly increasing. For diagnosis, careful assessments of atopic diathesis and symptoms, an endoscopic examination focusing on EoE characteristic findings, and histopathological examination of appropriate biopsy samples are important. When clinicopathological examination results suggest EoE, proton pump inhibitor (PPI) administration should be attempted to determine the response (PPI-responsive esophageal eosinophilia, PPI-REE). For PPI-refractory cases, oral topical glucocorticoid administration is the first therapeutic option, followed by systemic glucocorticoids as necessary. Evidence-based guidelines are currently under development in Japan for standardizing diagnosis and treatment</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10388-016-0550-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10388-016-0550-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Esophagus\20160830-KinoshitaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Esophagus\20160830-KinoshitaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Kinoshita Y</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10388-016-0550-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liccardi,G.</style></author><author><style face="normal" font="Arial"> Baldi,G.</style></author><author><style face="normal" font="Arial"> Berra,A.</style></author><author><style face="normal" font="Arial"> Ciccarelli,A.</style></author><author><style face="normal" font="Arial"> Cutajar,M.</style></author><author><style face="normal" font="Arial"> D'Amato,M.</style></author><author><style face="normal" font="Arial"> D'Angelo,R.</style></author><author><style face="normal" font="Arial"> Gargano,D.</style></author><author><style face="normal" font="Arial"> Giannattasio,D.</style></author><author><style face="normal" font="Arial"> Leone,G.</style></author><author><style face="normal" font="Arial"> Lo Schiavo,M.</style></author><author><style face="normal" font="Arial"> Madonna,F.</style></author><author><style face="normal" font="Arial"> Montera,C.</style></author><author><style face="normal" font="Arial"> Monti,R.</style></author><author><style face="normal" font="Arial"> Parente,R.</style></author><author><style face="normal" font="Arial"> Pedicini,A.</style></author><author><style face="normal" font="Arial"> Pio,A.</style></author><author><style face="normal" font="Arial"> Russo,M.</style></author><author><style face="normal" font="Arial"> Salzillo,A.</style></author><author><style face="normal" font="Arial"> Stanziola,A.</style></author><author><style face="normal" font="Arial"> Vatrella,A.</style></author><author><style face="normal" font="Arial"> Manzi,F.</style></author><author><style face="normal" font="Arial"> Bilo,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Haematology and Oncology, Division of Pulmonology and Allergology, High Speciality "A. Cardarelli" Hospital, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Allergy in urban elderly population living in Campania region (Southern Italy). A multicenter study</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="160" start="156">156-160</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Age of Onset</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly patients</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Given the increasing life expectancy observed in Western countries, there is a marked interest to know more about how aging could influence respiratory health. The aim of our study was to assess the prevalence, clinical characteristics and age of onset of allergic sensitization and clinical symptoms in a sample of atopic elders living in Campania region area (Southern Italy). Fourteen Allergy units or Centres examined a total of 462 patients. In this context 215 (46.53%) had positive skin prick tests (SPTs) to at least one allergen and were diagnosed with respiratory allergy. Parietaria represents the most common sensitizing agent in elders living in Campania region, followed by dust mites, grass pollen and Olea europaea. A relatively high percentage of atopic subjects suffered from respiratory symptoms at a fairly advanced age, namely 8.3% at 60-64 years, 10.2% at 65-70 and 5.7% at > 70 years. In conclusion, the prevalence and clinical significance of airway allergic sensitization in the elderly living in Campania region is more significant than expected in latter stages of life. Physicians should not neglect the role of atopy as a risk factor for the onset of allergic respiratory symptoms even in elderly patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - LetterSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27425174">PM:27425174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-156-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-156-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Liccardi G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eke,G.H.</style></author><author><style face="normal" font="Arial"> Uytun,S.</style></author><author><style face="normal" font="Arial"> Murat,S.U.</style></author><author><style face="normal" font="Arial"> Altuner,T.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Pediatric Allergy and Immunology Unit, Kayseri Education and Research Hospital, 38010 Erkilet, Kayseri, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">An unexpected cause of anaphylaxis: potato</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="152" start="149">149-152</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> potato allergy</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Immediate reactions against contact to raw potato has been reported in adults with generally being in the form of an oral contact dermatitis or contact urticaria, but it may also manifest as rhinitis symptoms, wheezing or even anaphylaxis. Cooked or raw potato allergy has been rarely reported in children as some is being immediate and others being late reactions, and it usually results from ingestion. Herein, we report two cases with a background of allergic diseases developed anaphylaxis one with cooked potato and the other one with raw potato</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleSB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27425172">PM:27425172</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-149-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-149-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Eke GH</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cuervo-Pardo,L.</style></author><author><style face="normal" font="Arial"> Barcena-Blanch,M.</style></author><author><style face="normal" font="Arial"> Radojicic,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medicine Institute, Cleveland Clinic, OH, USA</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab use during pregnancy for CIU: a tertiary care experience</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="146" start="145">145-146</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> CIU</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressants</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Teratogenicity</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">The treatment of antihistamine and steroid resistant Chronic Idiopathic Urticaria (CIU) during pregnancy poses a challenge due to teratogenicity of immunosuppressants. Omalizumab is a recently FDA approved therapy for CIU and is classified as pregnancy category B. We present an initial series of subjects treated at a tertiary care center for antihistamine and steroid resistant CIU with omalizumab who became pregnant during therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27425170">PM:27425170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-145-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-145-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Cuervo-Pardo L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martin-Munoz,M.F.</style></author><author><style face="normal" font="Arial"> Pineda,F.</style></author><author><style face="normal" font="Arial"> Garcia Parrado,G.</style></author><author><style face="normal" font="Arial"> Guillen,D.</style></author><author><style face="normal" font="Arial"> Rivero,D.</style></author><author><style face="normal" font="Arial"> Belver,T.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Hospital La Paz Health Research Institute (IdiPAZ), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy in breastfeeding babies. Hidden allergens in human milk</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="128" start="123">123-128</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hidden allergens</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGORUND: Food allergy is a rare disorder among breastfeeding babies. OBJECTIVE: Our aim was to identify responsible allergens in human milk. METHODS: We studied babies developing allergic symptoms at the time they were breastfeeding. Skin prick tests (SPT) were performed with breast milk and food allergens. Specific IgE was assessed and IgE Immunoblotting experiments with breast milk were carried out to identify food allergens. Clinical evolution was evaluated after a maternal free diet. RESULTS: Five babies had confirmed breast milk allergy. Peanut, white egg and/or cow's milk were demonstrated as the hidden responsible allergens. No baby returned to develop symptoms once mother started a free diet. Three of these babies showed tolerance to other food allergens identified in human milk. CONCLUSION: A maternal free diet should be recommended only if food allergy is confirmed in breastfed babies</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleSB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27425167">PM:27425167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-123-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-123-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Martin-Munoz MF</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alcantara-Montiel,J.C.</style></author><author><style face="normal" font="Arial"> Staines-Boone,T.</style></author><author><style face="normal" font="Arial"> Lopez-Herrera,G.</style></author><author><style face="normal" font="Arial"> Ruiz,L.B.</style></author><author><style face="normal" font="Arial"> Borrego-Montoya,C.R.</style></author><author><style face="normal" font="Arial"> Santos-Argumedo,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Somatic mosaicism in B cells of a patient with autosomal dominant hyper IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="2443" start="2438">2438-2443</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Abscess</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Counseling</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Counseling</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mexico City</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Scoliosis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> STAT-3</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="8" Year="2016">2016/8/4</year></dates><abstract><style face="normal" font="Arial">Hyper IgE syndrome (HIES) is characterized by recurrent skin abscesses, eczema, pneumonia, and high levels of serum IgE. Non-immunologic manifestations of HIES include a characteristic face, pathologic dentition, scoliosis, bone alterations, hyperextensible joints, and vascular abnormalities. Somatic mosaicism is defined by the presence of two or more populations of cells with different genotypes in one individual. In this report we describe one patient with classical HIES and another patient with a mild phenotype, both harboring the same genetic mutation. The patient with a mild phenotype did not present the characteristic face, had normal production of IL-17A by T CD4+ cells, but had low phosphorylation of STAT-3 in B cells. Interestingly, the mutation found in B cells was absent in other cell types analyzed, in agreement with the presence of a somatic mosaic genotype. The clinical and functional differences observed between these patients justify the use of complementary tools for a better definition of the cases. These approaches allow for a better understanding of complex phenotypes associated with somatic mosaicisms, and present the possibility to analyze the role of B lymphocytes in the pathophysiology of this disease. This knowledge has an impact on not only the treatment but also the provision of appropriate genetic counseling. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201546275</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27488252">PM:27488252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20160804-AlcantaraMontielJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\20160804-AlcantaraMontielJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Alcantara-Montiel JC</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201546275</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sehra,S.</style></author><author><style face="normal" font="Arial"> Krishnamurthy,P.</style></author><author><style face="normal" font="Arial"> Koh,B.</style></author><author><style face="normal" font="Arial"> Zhou,H.M.</style></author><author><style face="normal" font="Arial"> Seymour,L.</style></author><author><style face="normal" font="Arial"> Akhtar,N.</style></author><author><style face="normal" font="Arial"> Travers,J.B.</style></author><author><style face="normal" font="Arial"> Turner,M.J.</style></author><author><style face="normal" font="Arial"> Kaplan,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics and Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA</style></auth-address><titles><title><style face="normal" font="Arial">Increased Th2 activity and diminished skin barrier function cooperate in allergic skin inflammation</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="2613" start="2609">2609-2613</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic skin inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier function</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="11" Month="8" Year="2016">2016/8/11</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic inflammatory skin disease induced by a complex interaction between susceptibility genes encoding skin barrier components and environmental allergen exposure that results in type 2 cytokine production. Although genetic lesions in either component can be risk factors for disease in patients, whether these pathways interact in the development of AD is not clear. To test this, we mated mice with T-cell specific expression of constitutively active Stat6 (Stat6VT) that spontaneously develop allergic skin inflammation with Flaky tail (Ft) mice that have mutations in Flg and Tmem79 genes that each affect skin barrier function. Our results demonstrate that over 90% of the Stat6VT transgenic mice carrying the Ft alleles (Stat6VTxFt-/- ) develop severe atopic dermatitis lesions by 3-5 months of age, compared with only 40% of Stat6VT mice that develop disease by 6-7 months of age. Further, histopathological analysis of skin tissues from Stat6VTxFt-/- mice revealed extensive thickening of the dermis with increased inflammatory infiltrates as compared with Stat6VT mice. Our study suggests that skin barrier defects and altered Th2 responses independently cooperate in the pathogenesis of allergic skin inflammation, similar to effects observed in patients with AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201646421</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27510401">PM:27510401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20160811-SehraS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\20160811-SehraS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Sehra S</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201646421</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Damm,A.</style></author><author><style face="normal" font="Arial"> Giebeler,N.</style></author><author><style face="normal" font="Arial"> Zamek,J.</style></author><author><style face="normal" font="Arial"> Zigrino,P.</style></author><author><style face="normal" font="Arial"> Kufer,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Epidermal NLRP10 contributes to contact hypersensitivity responses in mice</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="1969" start="1959">1959-1969</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> contact hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> ICD</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">The nucleotide binding and oligomerization domain-like receptor (NLR) protein NLRP10 is highly expressed in the epidermis and contributes to cell-autonomous responses against invasive bacteria. To investigate the role of NLRP10 in inflammatory responses of the skin we analyzed the effect of full-body and keratinocyte-specific depletion of NLRP10 in croton oil-induced irritant contact dermatitis (ICD) and 1-fluoro-2,4-dinitrobenzene (DNFB)-induced contact hypersensitivity (CHS) in mice. Nlrp10(-/-) mice were phenotypically normal and skin repair after wounding was not affected by lack of NLRP10. Similarly, we did not detect a contribution of NLRP10 to the ICD response induced by croton oil. In contrast, Nlrp10(-/-) mice showed significantly reduced inflammation in the DNFB-induced CHS response as compared to control animals. Microscopic analysis revealed significantly reduced numbers of CD4(+) and CD8(+) T cells in the infiltrates of animals lacking NLRP10 expression after CHS challenge. Epidermis-specific deletion of Nlrp10 by keratin-14 promotor driven Cre-recombinase was sufficient to account for this phenotype, although lymphocyte recruitment seemed to be unaltered in animals lacking NLRP10 expression in keratinocytes. Taken together, we provide evidence that NLRP10 contributes to T-cell-mediated inflammatory responses in the skin and highlight a physiological role of NLRP10 in epidermal keratinocytes</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - engPT - Journal ArticleSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201646401</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27221772">PM:27221772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\2016-46-1959-69.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\2016-46-1959-69.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Damm A</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201646401</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Janss,T.</style></author><author><style face="normal" font="Arial"> Mesnil,C.</style></author><author><style face="normal" font="Arial"> Pirottin,D.</style></author><author><style face="normal" font="Arial"> Lemaitre,P.</style></author><author><style face="normal" font="Arial"> Marichal,T.</style></author><author><style face="normal" font="Arial"> Bureau,F.</style></author><author><style face="normal" font="Arial"> Desmet,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Cellular and Molecular Immunology, GIGA-I3, GIGA-Research Center and Faculty of Veterinary Medicine, University of Liege, Liege, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Interferon response factor-3 promotes the pro-Th2 activity of mouse lung CD11b+ conventional dendritic cells in response to house dust mite allergens</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="2628" start="2614">2614-2628</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> costimulation</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="8" Year="2016">2016/8/22</year></dates><abstract><style face="normal" font="Arial">Very few transcription factors have been identified that are required by antigen-presenting cells (APCs) to induce T helper type 2 (Th2) responses. Because lung CD11b+ conventional dendritic cells (CD11b+ cDCs) are responsible for priming Th2 responses in house-dust mite (HDM)-induced airway allergy, we used them as a model to identify transcriptional events regulating the pro-Th2 activity of cDCs. Transcriptomic profiling of lung CD11b+ cDCs exposed to HDM in vivo revealed first that HDM triggers an antiviral defence-like response, and second that the majority of HDM-induced transcriptional changes depend on the transcription factor Interferon Response Factor-3 (Irf3). Validating the functional relevance of these observations, Irf3-deficient CD11b+ cDCs displayed reduced pro-allergic activity. Indeed, Irf3-deficient CD11b+ cDCs induced less Th2, more regulatory T-cell, and similar Th1 differentiation in naive CD4+ T cells compared to their wild-type counterparts. The altered APC activity of Irf3 CD11b+ cDCs was associated with reduced expression of CD86 and was phenocopied by blocking CD86 activity in wild-type CD11b+ cDCs. Altogether, these results establish Irf3, known mostly for its role in antiviral responses, as a transcription factor involved in the induction of Th2 responses through the promotion of pro-Th2 costimulation in CD11b+ DCs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201646513</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27546168">PM:27546168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20160822-JanssT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\20160822-JanssT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Janss T</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201646513</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agoro,R.</style></author><author><style face="normal" font="Arial"> Piotet-Morin,J.</style></author><author><style face="normal" font="Arial"> Palomo,J.</style></author><author><style face="normal" font="Arial"> Michaudel,C.</style></author><author><style face="normal" font="Arial"> Vigne,S.</style></author><author><style face="normal" font="Arial"> Maillet,I.</style></author><author><style face="normal" font="Arial"> Chenuet,P.</style></author><author><style face="normal" font="Arial"> Guillou,N.</style></author><author><style face="normal" font="Arial"> Berichel,J.L.</style></author><author><style face="normal" font="Arial"> Kisielow,M.</style></author><author><style face="normal" font="Arial"> Flodby,U.P.</style></author><author><style face="normal" font="Arial"> Bert,M.L.</style></author><author><style face="normal" font="Arial"> Quesniaux,V.</style></author><author><style face="normal" font="Arial"> Muller,M.</style></author><author><style face="normal" font="Arial"> Padova,F.D.</style></author><author><style face="normal" font="Arial"> Ryffel,B.</style></author><author><style face="normal" font="Arial"> Gabay,C.</style></author><author><style face="normal" font="Arial"> Couturier-Maillard,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Orleans and CNRS, UMR7355, Experimental and Molecular Immunology and Neurogenetics, Orleans, France</style></auth-address><titles><title><style face="normal" font="Arial">IL-1R1-MyD88 axis elicits papain-induced lung inflammation</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="2541" start="2531">2531-2541</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Papain</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> ST2</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="8" Year="2016">2016/8/28</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is characterized by a strong Th2 response with inflammatory cell recruitment and structural changes in the lung. Papain is a protease allergen disrupting the airway epithelium triggering a rapid inflammation with eosinophilia mediated by innate lymphoid cell activation (ILC2) and leading to a Th2 immune response. In this study, we focused on inflammatory responses to a single exposure to papain and showed that intranasal administration of papain results in the recruitment of inflammatory cells, including neutrophils and eosinophils with a rapid production of IL-1alpha, IL-1beta, and IL-33. The inflammatory response is abrogated in the absence of IL-1R1 and MyD88. To decipher the cell type(s) involved in MyD88 dependent IL-1R1/MyD88 signaling, we used new cell-specific MyD88 deficient mice and found that the deletion of MyD88 signaling in single cell types such as T cells, epithelial cells, CD11c-positive or myeloid cells leads to only a partial inhibition compared to complete absence of MyD88, suggesting that several cell types contribute to the response. Importantly, the inflammatory response is largely ST2 and IL-36R independent. In conclusion, IL-1R1 signaling via MyD88 is critical for the first step of inflammatory response to papain. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - Switzerland -CO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201646366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27569535">PM:27569535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20160829-AgoroR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\20160829-AgoroR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Agoro R</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201646366</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harata,G.</style></author><author><style face="normal" font="Arial"> Kumar,H.</style></author><author><style face="normal" font="Arial"> He,F.</style></author><author><style face="normal" font="Arial"> Miyazawa,K.</style></author><author><style face="normal" font="Arial"> Yoda,K.</style></author><author><style face="normal" font="Arial"> Kawase,M.</style></author><author><style face="normal" font="Arial"> Kubota,A.</style></author><author><style face="normal" font="Arial"> Hiramatsu,M.</style></author><author><style face="normal" font="Arial"> Rautava,S.</style></author><author><style face="normal" font="Arial"> Salminen,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Technical Research Laboratory, Takanashi Milk Products Co., Ltd., Yokohama, 241-0023, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Probiotics modulate gut microbiota and health status in Japanese cedar pollinosis patients during the pollen season</style></title><secondary-title><style face="normal" font="Arial">Eur J Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Bacteroidetes</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Firmicutes</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="7" Year="2016">2016/7/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Japanese cedar pollinosis (JCP) is a challenging public health problem in Japan. Altered gut microbiota is associated with several diseases, including allergic diseases. However, only a few studies have focused on JCP and the underlying mechanisms for probiotic effects remain unclear. In addition, this study is the first observation of the correlation between the gut microbiota and blood lipid in JCP. METHODS: Faecal samples from JCP subjects were collected before and after treatment with (n = 14) and without (n = 11) LGG-TMC0356-fermented milk for 10 weeks. Gut microbiota composition was characterized from faecal DNA using sequencing of 16S rRNA genes. RESULTS: 16S rRNA-based operational taxonomic unit clustering of the microbiota revealed that LGG-TMC0356-fermented milk significantly altered gut microbiota after 10 weeks of milk consumption, and eight dominant genera of microbes were detected. During the JCP season, the Bacteroidetes/Firmicutes ratio, when compared to baseline, was significantly decreased in subjects at end of the study. Bacteroidetes showed positive correlation with LDL- and HDL-cholesterol levels, whereas Firmicutes showed negative correlation with total cholesterol, LDL- and HDL- cholesterol. CONCLUSIONS: The altered gut microbiota through supplementation of fermented milk containing the study probiotics may be a prospective target for protection against JCP, with beneficial effects on blood lipid levels</style></abstract><notes><style face="normal" font="Arial">DA - 20160714IS - 1436-6215 (Electronic)IS - 1436-6207 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00394-016-1264-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27412706">PM:27412706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Nutr\20160714-HarataG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Nutr\20160714-HarataG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160714, Harata G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00394-016-1264-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,X.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Wu,L.</style></author><author><style face="normal" font="Arial"> Zhu,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory Animals Center, Nantong University, 19 Qixiu Road, Nantong, JS 226001, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Potent ameliorating effect of Hypoxia-inducible factor 1alpha (HIF-1alpha) antagonist YC-1 on combined allergic rhinitis and asthma syndrome (CARAS) in Rats</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="350" start="343">343-350</pages><volume><style face="normal" font="Arial">788</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> Laboratory animals</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> mucosal inflammation</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> PCR analysis</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="8" Year="2016">2016/8/4</year></dates><abstract><style face="normal" font="Arial">Recent studies have implicated that Hypoxia-inducible factor 1alpha (HIF-1alpha) plays an integral role in the pathogenesis of allergic rhinitis and asthma. In the present study, we showed that HIF-1alpha antagonist YC-1, 3-(5-hydroxymethyl-2-furyl)-1-benzylindazole, elicited a potent allergy-ameliorating effect in a rat model of ovalbumin (OVA)-sensitized combined allergic rhinitis and asthma syndrome (CARAS). We revealed that YC-1 administration markedly impaired the total number and percentage of eosinophil in bronchoalveolar lavage fluid (BAL Fluid) of the rats, suggesting that YC-1 might attenuate lung and nasal mucosal inflammation in OVA-sensitized rats. Moreover, histological examination found that OVA-induced pathological alterations were evidently attenuated following YC-1 administration. In addition, immunohistochemistrial analysis indicated that YC-1 treatment decreased the expression of HIF-1alpha in rat lungs and nasal mucosa. Notably, Nuclear factor kappa B (NF-kappaB) p65 and Peroxisome proliferator-activated receptor alpha (PPARalpha), two important regulators of inflammatory responses, were also significantly down-regulated following YC-1 administration. Real-time PCR analysis confirmed that YC-1 impaired the expression of HIF-1alpha, NF-kappaB and PPARalpha in CARAS model. These findings together indicated that YC-1 exerted remarkable anti-allergic effects through the modulation of inflammatory pathways, implying that YC-1 may potentially serve as a novel anti-CARAS medicine in clinical patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2016.07.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27498367">PM:27498367</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\2016-788-343-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\2016-788-343-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, Wang X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2016.07.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ungar,B.</style></author><author><style face="normal" font="Arial"> Correa da Rosa,J.</style></author><author><style face="normal" font="Arial"> Shemer,A.</style></author><author><style face="normal" font="Arial"> Czarnowicki,T.</style></author><author><style face="normal" font="Arial"> Estrada,Y.D.</style></author><author><style face="normal" font="Arial"> Fuentes-Duculan,J.</style></author><author><style face="normal" font="Arial"> Xu,H.</style></author><author><style face="normal" font="Arial"> Zheng,X.</style></author><author><style face="normal" font="Arial"> Peng,X.</style></author><author><style face="normal" font="Arial"> Suarez-Farinas,M.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Krueger,J.G.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, NY</style></auth-address><titles><title><style face="normal" font="Arial">Patch testing of food allergens promotes Th17 and Th2 responses with increased IL-33: A pilot study</style></title><secondary-title><style face="normal" font="Arial">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Dermatol</style></full-title></periodical><pages end="275" start="272">272-275</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/exd.13148</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27488305">PM:27488305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Dermatol\20160804-UngarB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Dermatol\20160804-UngarB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Ungar B</style></custom2><misc3><style face="normal" font="Arial">10.1111/exd.13148</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,H.T.</style></author><author><style face="normal" font="Arial"> Chen,Z.G.</style></author><author><style face="normal" font="Arial"> Liu,H.</style></author><author><style face="normal" font="Arial"> Ye,J.</style></author><author><style face="normal" font="Arial"> Zou,X.L.</style></author><author><style face="normal" font="Arial"> Wang,Y.H.</style></author><author><style face="normal" font="Arial"> Yang,H.L.</style></author><author><style face="normal" font="Arial"> Meng,P.</style></author><author><style face="normal" font="Arial"> Zhang,T.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Diseases , Institute of Respiratory Diseases of Sun Yat-sen University, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou , China</style></auth-address><titles><title><style face="normal" font="Arial">Treatment of allergic rhinitis with CpG oligodeoxynucleotides alleviates the lower airway outcomes of combined allergic rhinitis and asthma syndrome via a mechanism that possibly involves in TSLP</style></title><secondary-title><style face="normal" font="Arial">Exp Lung Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Lung Res</style></full-title></periodical><pages end="333" start="322">322-333</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> CpG motifs</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Motifs</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Thymic stromal lymphopoietin (TSLP) is a critical regulator of immune responses associated with Th2 cytokine-mediated inflammation. Intranasal administration of oligodeoxynucleotides with CpG motifs (CpG-ODNs) might improve lower airway outcomes of combined allergic rhinitis and asthma syndrome (CARAS), but the inherent mechanisms of CpG-ODNs are not well defined. This study investigated whether CpG-ODNs treated to upper airway could reduce lower airway TSLP expression as well as whether this reduction could contribute to the alleviation of lower allergic inflammation and airway hyper-reactivity (AHR) in CARAS mice. MATERIALS AND METHODS: Ovalbumin (OVA)-sensitized BALB/c mice were intranasal OVA exposure three times a week for 3 weeks. CpG-ODNs or an anti-TSLP mAb was administered to a subset of these mice 1 hour after intranasal OVA challenge, followed by 5 days of OVA aerosol challenge. The resulting immunological variables, nasal symptoms, and nasal mucosa and lung tissues pathology were evaluated. TSLP production in the lung tissues and bronchoalveolar lavage fluid (BALF) were determined by RT-PCR, western blotting or enzyme-linked immunosorbent assay. RESULTS: The CARAS mice exhibited overexpression of TSLP in the lung tissues and BALF, and also demonstrated significant increases in BALF and splenocyte Th2-associated cytokine production, serum OVA-specific IgE, nose and lung pathologies, and AHR. Intranasal administration of CpG-ODNs restored TSLP in the lower airway, and it significantly reduced the following parameters: Th2-type cytokine production levels; the percentage of eosinophils in the BALF; IL-4 and IL-5 concentrations in the supernatants of cultured splenic lymphocytes; serum OVA-specific IgE; peribronchial inflammation score in the lungs; and nose pathology and nasal symptoms. Similar results were obtained when the CARAS mice were treated with an anti-TSLP mAb to block intranasal TSLP activity. CONCLUSIONS: Treatment with intranasal CpG-ODNs improves lower airway immunological variable outcomes in the CARAS model via a mechanism that possibly involves in suppressing pulmonary TSLP-triggered allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 1521-0499 (Electronic)IS - 0190-2148 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/01902148.2016.1215571</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27541375">PM:27541375</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Lung Res\2016-42-322-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Lung Res\2016-42-322-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Li HT</style></custom2><misc3><style face="normal" font="Arial">10.1080/01902148.2016.1215571</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hermanson,T.</style></author><author><style face="normal" font="Arial"> Bennett,C.L.</style></author><author><style face="normal" font="Arial"> Macdougall,I.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Comprehensive Cancer Center , Helsinki University Central Hospital , Helsinki , Finland</style></auth-address><titles><title><style face="normal" font="Arial">Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Drug Saf</style></full-title></periodical><pages end="1426" start="1421">1421-1426</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Anemia</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dialysis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erythropoietin</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Manufacture</style></keyword><keyword><style face="normal" font="Arial"> Marketing</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant DNA</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="8" Year="2016">2016/8/23</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The introduction of recombinant human erythropoietin revolutionized the management of anemia in patients with chronic kidney disease (CKD). In order to circumvent costly recombinant DNA technology, synthetic chemistry techniques were used to manufacture peginesatide, a synthetic peptide that bore no resemblance to previous erythropoiesis-stimulating agents (ESAs), and yet was capable of stimulating erythropoiesis. Compared with other ESAs, peginesatide was deemed to have advantages related to immunogenicity, administration schedule, and cost. Marketing approval was restricted to CKD patients on dialysis because cardiovascular events were more common with peginesatide than with darbepoetin in non-dialysis CKD patients. Unfortunately, unexplained serious adverse drug reactions (sADR) led to quick withdrawal of peginesatide from the market. AREAS COVERED: This review describes the efficacy and safety of peginesatide in pre-approval clinical trials, sADRs after marketing approval, and lessons learned during its short life-span. EXPERT OPINION: The case of peginesatide illustrates the difficulties in detecting rare sADRs in trials with limited patient populations and the need for improved pharmacovigilance after marketing approval. However, the need for simpler drug production methods as a result of non-dependence on recombinant DNA techniques and mammalian cell lines remains. Lessons learned during the scientific development of peginesatide can be used in developing other drugs</style></abstract><notes><style face="normal" font="Arial">DA - 20160823IS - 1744-764X (Electronic)IS - 1474-0338 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Finland -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/14740338.2016.1218467</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27551882">PM:27551882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Opin Drug Saf\20160823-HermansonT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Opin Drug Saf\20160823-HermansonT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160823, Hermanson T</style></custom2><misc3><style face="normal" font="Arial">10.1080/14740338.2016.1218467</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Antoniu,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Lecturer, Department of Surgery II-Palliative Care Nursing , University of Medicine and Pharmacy Gr.T.Popa Iasi , 16 Universitatii Str 700115 , Iasi , Romania</style></auth-address><titles><title><style face="normal" font="Arial">Lebrikizumab for the treatment of asthma</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Investig Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Investig Drugs</style></full-title></periodical><pages end="1249" start="1239">1239-1249</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status date="09/11/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="24" Month="8" Year="2016">2016/8/24</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: In asthma, most commonly, "conventional" anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain inflammation pathways and lebrikizumab an anti IL-13 molecule might represent a relevant example as a potential asthma therapy. AREAS COVERED: Discussion of the rationale for the use of lebrikizumab in asthma. Analysis of the related preclinical and clinical data on lebrikizumab in asthma. EXPERT OPINION: Lebrikizumab demonstrated efficacy in an asthma subset characterized by high serum periostin levels and by heavy eosinophilic inflammation. Phase III data are necessary in order to better position this therapy in asthma including as a potential personalized approach</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1744-7658 (Electronic)IS - 1354-3784 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Romania -</style></notes><work-type><style face="normal" font="Arial">10.1080/13543784.2016.1227319</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27554950">PM:27554950</url></web-urls><pdf-urls><url ppv-ref="no">sabina.antoniu@umfiasi.ro</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160824, Antoniu SA</style></custom2><misc3><style face="normal" font="Arial">10.1080/13543784.2016.1227319</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ouzir,M.</style></author><author><style face="normal" font="Arial"> El Bairi,K.</style></author><author><style face="normal" font="Arial"> Amzazi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Biochemistry and Immunology, Faculty of Sciences, University Mohammed V in Rabat, Morocco.</style></auth-address><titles><title><style face="normal" font="Arial">Toxicological properties of fenugreek (Trigonella foenum graecum)</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="154" start="145">145-154</pages><volume><style face="normal" font="Arial">96</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Chickpea</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> congenital malformations</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Damage</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fenugreek</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> Nutraceutical</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="4" Month="8" Year="2016">2016/8/4</year></dates><abstract><style face="normal" font="Arial">Fenugreek (Trigonella foenum graecum), used as traditional medicine and natural additive food, has been shown to exert significant antiatherogenic, antidiabetic, antianorexic, antioxidant, anticarcinogenic, antihyperlipidemic, galactogogue and anti-inflammatory effects in several human and animal models. Besides, several medicinal pharmaceutical and nutraceutical properties, fenugreek have toxic effects as well. The aim of this review is discuss the cumulative evidence, which suggests that consumption of fenugreek induced some serious toxicological side effects. In this review, many teratogenic effects of fenugreek, from congenital malformations to death, were reported in human, rodent, rabbit, and chick. Moreover, results obtained in rats, mice and rabbits show a testicular toxicity and anti-fertility effects in male associated with oxidative stress and DNA damage, as well as anti-fertility, antiimplantation and abortifacient activity in females related to saponin compound of fenugreek which suggest that fenugreek is not recommended for use during pregnancy. Indeed, the consumption of fenugreek should be avoided for persons having peanut and chickpeas allergy because of possible cross-reactivity as well as chronic asthma. Accumulating evidence suggest also that fenugreek may have neurodevelopmental, neurobehavioral and neuropathological side effects. It is suggested that future studies would be conducted to identify molecular and cellular mechanisms underlying the fenugreek toxicological properties</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Morocco -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2016.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27498339">PM:27498339</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2016-96-145-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2016-96-145-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Ouzir M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dzwolak,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Assessment of food allergen management in small food facilities</style></title><secondary-title><style face="normal" font="Arial">Food Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Control</style></full-title></periodical><pages end="331" start="323">323-331</pages><volume><style face="normal" font="Arial">73</style></volume><number><style face="normal" font="Arial">Part B</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen control</style></keyword><keyword><style face="normal" font="Arial"> Allergen management</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control measures</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food allergen management</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Food safety management</style></keyword><keyword><style face="normal" font="Arial"> HACCP</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Safety Management</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0956-7135</style></isbn><abstract><style face="normal" font="Arial">In terms of public health, food allergen management (FAM) is one of the major areas of food safety management, required by standardised food safety management systems (FSMSs). This study involved performing an evaluation of the scope of application of FAM and identification of non-conformity areas in 24 small food production facilities where FSMSs are implemented. Conformity with the 41 criteria was evaluated by the semi-structured interview method with direct on-site observation. The percentile Conformance Index (CI) and the relative Conformance Index (CIREL) were established, calculated by the relativisation methods (i.e. evaluation and metrisation), applied in quality engineering. The highest level of non-conformities in the 7 groups of criteria established in the form of a questionnaire was found in Cleaning (CI 29.6</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô47.2%, CIREL 0.03</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.32), Transport &amp;amp; Storage (CI 30.6</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô54.2%, CIREL 0.05</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.69) and Hazard Awareness (CI 27.8</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô59.3%, CIREL 0</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.52). Factors which make it difficult to implement FAM included access to the validated methods of assessment of cleaning effectiveness in removing specific allergens, as well as good practices in separation of allergenic and non-allergenic materials during transport and storage, and personnel training in allergen control. These findings show clearly that implementation and certification of standardised FSMSs is a guarantee of implementation of FAM on a higher level of conformity with the evaluation criteria compared to those facilities which apply only the Codex HACCP principles. The conformity indexes CI and CIREL proposed in this paper can be applied not only to determine the areas of non-conformity for FAM, but they can also be used to characterise and monitor FAM-related elements of FSMSs as part of self-evaluation and continuous improvement</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodcont.2016.08.019</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodcont.2016.08.019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Control\20160730-DzwolakW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Control\20160730-DzwolakW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Dzwolak W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodcont.2016.08.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jonsson,K.</style></author><author><style face="normal" font="Arial"> Green,M.</style></author><author><style face="normal" font="Arial"> Barman,M.</style></author><author><style face="normal" font="Arial"> Sjoberg,A.</style></author><author><style face="normal" font="Arial"> Brekke,H.K.</style></author><author><style face="normal" font="Arial"> Wold,A.E.</style></author><author><style face="normal" font="Arial"> Sandberg,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Food and Nutrition Science, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Diet in 1-year-old farm and control children and allergy development: results from the FARMFLORA birth cohort</style></title><secondary-title><style face="normal" font="Arial">Food Nutr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Nutr Res</style></full-title></periodical><pages end="" start="32721">32721-</pages><volume><style face="normal" font="Arial">60</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Butter</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> farm milk</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> farming environment</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Iodine</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Margarine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Oils</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A farming environment confers strong protection against allergy development. We have previously shown that farming mothers consume more full-fat dairy than control mothers, who instead consume more low-fat dairy, margarine, and oils; margarine and oil intake was associated with increased risk of allergy development in their children. OBJECTIVES: The aims of this study were to investigate the differences in diet between children in farming and control families at 1 year of age, to investigate the relation between the diets of the mothers and their children, and to relate the children's diet to allergy development. DESIGN: The diet of 1-year-old children from dairy farming families (n=28) and from control families in the same rural area (n=37) was assessed by 24-h dietary recalls, followed by 24-h food diaries. Allergy was diagnosed by pediatricians at 3 years of age using strict predefined criteria. RESULTS: Farm children had a higher intake of farm milk, whole cream, cholesterol, saturated fat, and fat in total and tended to eat more butter, while controls consumed more carbohydrates and poultry and tended to eat more margarine. Farm children also had higher intakes of homemade porridge/gruel, oily fish, and iodine. The intake of butter and whole milk in children and mothers correlated significantly in farm families but not in controls. A weak negative association was found between seafood intake and allergy development, while allergy was positively associated with the intake of pork as well as zinc in the control group; these intakes also correlated with each other. CONCLUSIONS: Consistent with mothers in farming families, the children consumed more full-fat dairy and saturated fat than did controls, but this could not be linked to the low risk of allergy in the farming group. Seafood intake might protect against allergy development, in accordance with earlier findings</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1654-661X (Electronic)IS - 1654-661X (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.3402/fnr.v60.32721</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27534847">PM:27534847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Nutr Res\2016-60-32721.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Nutr Res\2016-60-32721.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Jonsson K</style></custom2><misc3><style face="normal" font="Arial">10.3402/fnr.v60.32721</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Buchmann,K.</style></author><author><style face="normal" font="Arial"> Mehrdana,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of anisakid nematodes Anisakis simplex (s.l.), Pseudoterranova decipiens (s.l.) and Contracaecum osculatum (s.l.) on fish and consumer health</style></title><secondary-title><style face="normal" font="Arial">Food Waterborne Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Waterborne Parasitol</style></full-title></periodical><pages end="22" start="13">13-22</pages><volume><style face="normal" font="Arial">4</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Anisakid</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> body-cavity</style></keyword><keyword><style face="normal" font="Arial"> Cetaceans</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Contracaecum osculatum</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control measures</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish Products</style></keyword><keyword><style face="normal" font="Arial"> Fish species</style></keyword><keyword><style face="normal" font="Arial"> Freezing</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Invertebrates</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Mesentery</style></keyword><keyword><style face="normal" font="Arial"> Musculature</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Pinnipeds</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Pseudoterranova</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seawater</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> Whales</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword><keyword><style face="normal" font="Arial"> Zoonosis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2405-6766</style></isbn><abstract><style face="normal" font="Arial">The anisakid nematodes Anisakis simplex (Rudolphi, 1809), Pseudoterranova decipiens (Krabbe, 1878) and Contracaecum osculatum (Rudolphi, 1802) occur as third-stage larvae in marine fish products and may infect consumers ingesting raw or under-cooked fish products. Clinical symptoms associated with the infection, termed anisakidosis, vary from irritation of the oesophagus and stomach, via nausea, vomiting and diarrhoea to severe epigastric and abdominal pain. Third-stage larvae of A. simplex are found in the body cavity, musculature and various organs, P. decipiens occur mainly in the fish musculature (fillet) and C. osculatum larvae reside predominantly in the liver, body cavity, mesenteries and pyloric caeca. Preventive measures, including mechanical removal of worms, heat treatment or freezing to kill worms, are needed in order to reduce the risk of human infections. The anisakid life cycle involves several hosts. A. simplex nematodes use cetaceans (whales) as final hosts whereas P. decipiens and C. osculatum have their adult stage in pinnipeds (seals). Eggs released by worms in these hosts pass with feces to seawater where free-living third-stage larvae hatch from the eggs. Various invertebrates </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô including euphausiids, copepods and amphipods </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô feed on these larvae, become infected and serve as intermediate hosts. A range of fish species may serve as transport hosts following ingestion of infected invertebrates and the final stage develops after two additional moults in the stomach of marine mammals which consumed infected fish. Control measures may be implemented to reduce infections of fish stocks and thereby risk of human infections</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fawpar.2016.07.003</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.fawpar.2016.07.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Waterborne Parasitol\20160730-BuchmannK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Waterborne Parasitol\20160730-BuchmannK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Buchmann K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fawpar.2016.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Davidson,R.K.</style></author><author><style face="normal" font="Arial"> Lavikainen,A.</style></author><author><style face="normal" font="Arial"> Konyaev,S.</style></author><author><style face="normal" font="Arial"> Schurer,J.</style></author><author><style face="normal" font="Arial"> Miller,A.L.</style></author><author><style face="normal" font="Arial"> Oksanen,A.</style></author><author><style face="normal" font="Arial"> Skirnisson,K.</style></author><author><style face="normal" font="Arial"> Jenkins,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Echinococcus across the north: Current knowledge, future challenges</style></title><secondary-title><style face="normal" font="Arial">Food Waterborne Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Waterborne Parasitol</style></full-title></periodical><pages end="53" start="39">39-53</pages><volume><style face="normal" font="Arial">4</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alaska</style></keyword><keyword><style face="normal" font="Arial"> Alveolar echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Arctic</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Circumpolar</style></keyword><keyword><style face="normal" font="Arial"> Cystic echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Echinococcus</style></keyword><keyword><style face="normal" font="Arial"> Echinococcus multilocularis</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Knowledge gaps</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> Livestock</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Social Change</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2405-6766</style></isbn><abstract><style face="normal" font="Arial">Zoonotic Echinococcus spp. cestodes are present in almost all circumpolar nations, and have historically posed a risk to health of indigenous as well as other northern residents. However, surveillance data on both alveolar (AE) and cystic (CE) echinococcosis remains incomplete throughout the circumpolar region: Russia, Fennoscandia, Iceland, Greenland, Canada and Alaska (USA). Prevalence of Echinococcus spp. varies considerably in definitive canid hosts, animal intermediate hosts and accidental hosts like humans. Yet despite the high prevalence reported in canids in some geographic locations, human AE and CE are much less common than in endemic Asian and central European countries. This paper explores knowledge gaps and future challenges posed by Echinococcus spp. in eight circumpolar countries, a region where rapid environmental and social change are rewriting the boundaries, transmission, and impact of many pathogens, including zoonotic Echinococcus spp. Genotypes G6, G8 and G10 of Echinococcus canadensis are causative agents of human CE and have been identified in sylvatic (wild animal) and synanthropic (ecological association with humans) cervid-canine life cycles in the following northern regions: Alaska and northern Canada - G8 and G10; northern Russia - G6, G8, G10; and Fennoscandia - G10 in Finland - with no recent reports from Norway or Sweden. Echinococcus multilocularis, which causes AE, has been identified in a sylvatic arvicoline rodent-canine lifecycle in Alaska, Canada, Russia, Sweden and Svalbard (Norway). Asian, Mongolian, European and North American strains of E. multilocularis are found in Russia, with the North American N1 strain predominating in the north. The N1 strain is also found in Alaska, as well as Svalbard, whilst Asian strains have been identified in western Alaska. Central North American (N2) strain and European-type strains of E. multilocularis are present in Canada. Typing of the strain in Sweden is still pending. Individual human cases of AE with N2 and European-type strains are reported in North America, as well as multiple cases with Asian strains in Russia and historically on St Lawrence Island, Alaska (although genotyping of human cases was not available at the time). Echinococcus spp. have not been detected in Greenland and have been eliminated from Iceland. The predominance of E. multilocularis N1 strain and E. canadensis genotypes, in regions with high prevalence in definitive hosts yet low incidence of human AE and CE, suggests that these genotypes have lower zoonotic potential and pathogenicity than European and Asian strains of E. multilocularis and livestock genotypes of E granulosus sensu stricto. The continued monitoring of the emergence of Echinococcus genotypes within definitive and intermediate hosts, as well as people, is needed to assess the impact on public health risk, since the introduction of other genotypes could have serious repercussions. Lastly, determining risk factors and source attribution for human cases, including the possibility of food and waterborne transmission and the likelihood of autochthonous transmission, remain challenges</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Norway -CO - Finland -CO - Russia -CO - Canada -CO - Sweden -CO - Iceland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fawpar.2016.08.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.fawpar.2016.08.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Waterborne Parasitol\20160730-DavidsonRK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Waterborne Parasitol\20160730-DavidsonRK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Davidson RK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fawpar.2016.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Byard,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, The University of Adelaide, Frome Road, Level 3 Medical School North Building, Adelaide, 5005, SA, Australia. roger.byard@sa.gov.au</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis at autopsy</style></title><secondary-title><style face="normal" font="Arial">Forensic Sci Med Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Forensic Sci Med Pathol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Autopsy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="29" Month="8" Year="2016">2016/8/29</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1556-2891 (Electronic)IS - 1547-769X (Linking)LA - ENGPT - EDITORIALCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12024-016-9799-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27572893">PM:27572893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Forensic Sci Med Pathol\20160830-ByardRW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Forensic Sci Med Pathol\20160830-ByardRW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Byard RW</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12024-016-9799-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,Y.</style></author><author><style face="normal" font="Arial"> Garnaud,C.</style></author><author><style face="normal" font="Arial"> Brenier-Pinchart,M.P.</style></author><author><style face="normal" font="Arial"> Thiebaut-Bertrand,A.</style></author><author><style face="normal" font="Arial"> Saint-Raymond,C.</style></author><author><style face="normal" font="Arial"> Camara,B.</style></author><author><style face="normal" font="Arial"> Hamidfar,R.</style></author><author><style face="normal" font="Arial"> Cognet,O.</style></author><author><style face="normal" font="Arial"> Maubon,D.</style></author><author><style face="normal" font="Arial"> Cornet,M.</style></author><author><style face="normal" font="Arial"> Perlin,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">New Jersey Medical School, Public Health Research Institute, Rutgers Biomedical and Health Sciences Newark, NJ, USA</style></auth-address><titles><title><style face="normal" font="Arial">Direct Molecular Diagnosis of Aspergillosis and CYP51A Profiling from Respiratory Samples of French Patients</style></title><secondary-title><style face="normal" font="Arial">Front Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Microbiol</style></full-title></periodical><pages end="" start="1164">1164-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> New Jersey</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory samples</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Microbiological diagnosis of aspergillosis and triazole resistance is limited by poor culture yield. To better estimate this shortcoming, we compared culture and molecular detection of A. fumigatus in respiratory samples from French patients at risk for aspergillosis. METHODS: A total of 97 respiratory samples including bronchoalveolar lavages (BAL), bronchial aspirates (BA), tracheal aspirates, sputa, pleural fluids, and lung biopsy were collected from 33 patients having invasive aspergillosis (n = 12), chronic pulmonary aspergillosis (n = 3), allergic bronchopulmonary aspergillosis (n = 7), or colonization (n = 11) and 28 controls. Each specimen was evaluated by culture, pan-Aspergillus qPCR, and CYP51A PCR and sequencing. RESULTS: One A. flavus and 19 A. fumigatus with one multiazole resistant strain (5.3%) were cultured from 20 samples. Culture positivity was 62.5, 75, 42.9, and 15.8% in ABPA, CPA, IA, and colonized patients, respectively. Aspergillus detection rate was significantly higher by pan-Aspergillus qPCR than by culture in IA (90.5 vs. 42.9%; P &lt; 0.05) and colonization group (73.7 vs. 15.8%; P &lt; 0.05). The CYP51A PCR found one TR34/L98H along with 5 novel cyp51A mutations (4 non-synonymous and 1 promoter mutations), yet no association can be established currently between these novel mutations and azole resistance. The analysis of 11 matched pairs of BA and BAL samples found that 9/11 BA carried greater fungal load than BAL and CYP51A detection was more sensitive in BA than in BAL. CONCLUSION: Direct molecular detection of Aspergillus spp. and azole resistance markers are useful adjunct tools for comprehensive aspergillosis diagnosis. The observed superior diagnostic value of BAs to BAL fluids warrants more in-depth study</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1664-302X (Electronic)IS - 1664-302X (Linking)LA - engPT - Journal ArticleCO - United States -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.3389/fmicb.2016.01164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27524978">PM:27524978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Microbiol\2016-7-1164.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Microbiol\2016-7-1164.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Zhao Y</style></custom2><misc3><style face="normal" font="Arial">10.3389/fmicb.2016.01164</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,F.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author><author><style face="normal" font="Arial"> Chen,P.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Medicine, The Second Affiliated Hospital of Jilin University, Changchun, Jilin, China</style></auth-address><titles><title><style face="normal" font="Arial">Expression of M3 acetylcholine receptor in asthmatic mice and bronchial airway remodeling prediction</style></title><secondary-title><style face="normal" font="Arial">Genet Mol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Genet Mol Res</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Ipratropium</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">This study aimed to investigate the role of M3 acetylcholine receptor (M3-AChR) expression in airway remodeling. Additionally, we aimed to evaluate the effects of ipratropium bromide solution inhaled in an early phase of asthma on airway remodeling in ovalbumin (OVA)-sensitized and challenged mice. Thirty BALB/c mice were divided into three groups, namely, control group (saline sensitized/challenged mice), asthma group (OVA sensitized/challenged mice), and treatment group (OVA sensitized/challenged mice treated by ipratropium bromide). Pathological changes were detected by histological staining in the bronchopulmonary tissue of mice. WAt/Pbm (the airway wall area /basement membrane perimeter) ratio of the asthma group (25.37 +/- 4.25) increased significantly (P &lt; 0.05) when compared with that of the control (12.89 +/- 1.71) and treatment group (15.82 +/- 2.91). WAm/Pbm (smooth muscle wall area / basement membrane perimeter) ratio of the asthma group (7.58 +/- 2.16) increased significantly (P &lt; 0.05) when compared with that of the control (2.55 +/- 0.72) and treatment group (3.36 +/- 1.69). M3-AChR concentration increased in the treatment group (29.24 +/- 3.59) and was significantly different (P &lt; 0.05) from that of the control group (25.50 +/- 1.83). During asthma treatment, SAMA can alleviate airway remodeling in murine model by lessening the thickness of bronchial walls and inhibiting the proliferation of smooth muscle cells. There were no obvious changes in M3-AChR density in the murine model of asthma characterized by airway remodeling. However, ipratropium bromide may up-regulate the expression of M3-AChR in bronchial walls of asthmatic murine model</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1676-5680 (Electronic)IS - 1676-5680 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.4238/gmr.15038805</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525852">PM:27525852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Genet Mol Res\20160816-ZhaoF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Genet Mol Res\20160816-ZhaoF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Zhao F</style></custom2><misc3><style face="normal" font="Arial">10.4238/gmr.15038805</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wildenberg,M.E.</style></author><author><style face="normal" font="Arial"> van den Brink,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, The NetherlandsDepartment of Gastroenterology, Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">House dust mite: a new player in intestinal inflammation?</style></title><secondary-title><style face="normal" font="Arial">Gut</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Gut</style></full-title></periodical><pages end="728" start="727">727-728</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Pyroglyphidae</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160409IS - 1468-3288 (Electronic)IS - 0017-5749 (Linking)LA - engPT - CommentPT - Journal ArticleSB - AIMSB - IMCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1136/gutjnl-2015-311042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26762194">PM:26762194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Gut\2016-65-727-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Gut\2016-65-727-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160409, Wildenberg ME</style></custom2><misc3><style face="normal" font="Arial">10.1136/gutjnl-2015-311042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Damm,K.</style></author><author><style face="normal" font="Arial"> Volk,J.</style></author><author><style face="normal" font="Arial"> Horn,A.</style></author><author><style face="normal" font="Arial"> Allam,J.P.</style></author><author><style face="normal" font="Arial"> Troensegaard-Petersen,N.</style></author><author><style face="normal" font="Arial"> Serup-Hansen,N.</style></author><author><style face="normal" font="Arial"> Winkler,T.</style></author><author><style face="normal" font="Arial"> Thiessen,I.</style></author><author><style face="normal" font="Arial"> Borchert,K.</style></author><author><style face="normal" font="Arial"> Wustenberg,E.G.</style></author><author><style face="normal" font="Arial"> Mittendorf,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Health Economics Research Hannover (CHERH), Leibniz University Hannover, Hannover, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Patient preferences in allergy immunotherapy (AIT) in Germany - a discrete-choice-experiment</style></title><secondary-title><style face="normal" font="Arial">Health Econ Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Health Econ Rev</style></abbr-1></periodical><pages end="" start="32">32-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="12" Year="2015">2015/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic Rhinitis (AR) is a common disorder in Europe with Allergic Asthma (AA) as a frequent comorbidity. Allergy immunotherapy (AIT) is the only causal therapy of AR and AA, and can be administered as subcutaneous injections at the physician or as sublingual drops or tablets at home. The usual treatment duration is 3 years. OBJECTIVE: This study aimed to elicit patient preferences to identify the AIT administration mode preferred by patients. METHODS: A discrete-choice-experiment (DCE) was developed to determine how people weight different treatment options using a paper-based questionnaire from June to September 2014, including 16 study centres. Main inclusion criteria: >18 years, grass, birch and/or house dust mite AR with moderate to severe symptoms, AIT-naive and AIT-indicated. DCE-attributes were: Administration form, number and duration of physician visits, frequency of life-threatening anaphylactic shocks, local side-effects and co-payments. RESULTS: Two-hundred thirty-nine subjects participated, resulting in analysable 1842 choices. All attributes were significant predictors for the treatment-choice. Ranked by importance, the following first three attributes are most preferred by patients: 1(st) Number and duration of physician visits: Fewer visits with shorter duration preferred (0.658*) 2(nd) Frequency of life-threatening anaphylactic shocks: Lower risk of shocks preferred (0.285*) 3(rd) Local side-effects: Preference for rash/swelling on upper arm over itching/swelling under the tongue (0.210*) (*coefficient-size represents relative importance of the attributes) CONCLUSION: The most important attribute is the number and duration of visits to a physician. A lower risk of life-threatening anaphylactic shocks was ranked as the second whereas co-payments and administration form play a limited role</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 2191-1991 (Electronic)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13561-016-0110-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27485437">PM:27485437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Health Econ Rev\2015-6-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Health Econ Rev\2015-6-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Damm K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13561-016-0110-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Contini,P.</style></author><author><style face="normal" font="Arial"> Puppo,F.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Murdaca,G.</style></author><author><style face="normal" font="Arial"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Immunology, Department of Internal Medicine, University of Genoa &amp; IRCCS-Azienda Ospedaliera Universitaria San Martino, 16132 Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients</style></title><secondary-title><style face="normal" font="Arial">Hum Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Immunol</style></full-title></periodical><pages end="1178" start="1172">1172-1178</pages><volume><style face="normal" font="Arial">77</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> membrane-expression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="12" Month="8" Year="2016">2016/8/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It has been reported that soluble HLA-G serum levels are increased in patients with pollen-induced allergic rhinitis and decrease after immunotherapy. However, no functional study has been conducted so far. The aim of this study was to evaluate the membrane expression and secretion of HLA-G molecules in peripheral blood mononuclear cells from allergic rhinitis patients after in vitro incubation with the causal allergen. METHODS AND RESULTS: Twenty-two allergic rhinitis patients and ten healthy subjects were enrolled. Membrane HLA-G expression was determined by flow cytometry and soluble HLA-G in culture supernatant was determined by immunoenzymatic assay. HLA-G expression was detected in CD4+ (T-helper-2) cells and monocytes after in vitro stimulation with the causal allergen but not with non specific stimuli and non causal allergens. Accordingly, the release of soluble HLA-G in culture supernatant occurred only after the stimulation with the causal allergen. Collectively, these results were confirmed by Western blot analysis. CONCLUSIONS: The present study provides the first in vitro evidence that in allergic patients HLA-G expression and secretion is specifically induced by the causal allergen. These data may add new insights into the pathogenetic mechanisms underlying allergic inflammation and allergen specific immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1879-1166 (Electronic)IS - 0198-8859 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.humimm.2016.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27527921">PM:27527921</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Immunol\20160816-ContiniP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Immunol\20160816-ContiniP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Contini P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.humimm.2016.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, KAIST, Daejeon 34141, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Regulation of IgE-Mediated Food Allergy by IL-9 Producing Mucosal Mast Cells and Type 2 Innate Lymphoid Cells</style></title><secondary-title><style face="normal" font="Arial">Immune Netw</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immune Netw</style></full-title></periodical><pages end="218" start="211">211-218</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immune system</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Due to the increasing prevalence and number of life-threatening cases, food allergy has emerged as a major health concern. The classic immune response seen during food allergy is allergen-specific IgE sensitization and hypersensitivity reactions to foods occur in the effector phase with often severe and deleterious outcomes. Recent research has advanced understanding of the immunological mechanisms occurring during the effector phase of allergic reactions to ingested food. Therefore, this review will not only cover the mucosal immune system of the gastrointestinal tract and the immunological mechanisms underlying IgE-mediated food allergy, but will also introduce cells recently identified to have a role in the hypersensitivity reaction to food allergens. These include IL-9 producing mucosal mast cells (MMC9s) and type 2 innate lymphoid cells (ILC2s). The involvement of these cell types in potentiating the type 2 immune response and developing the anaphylactic response to food allergens will be discussed. In addition, it has become apparent that there is a collaboration between these cells that contributes to an individual's susceptibility to IgE-mediated food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1598-2629 (Print)IS - 1598-2629 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4110/in.2016.16.4.211</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27574500">PM:27574500</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immune Netw\2016-16-211-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immune Netw\2016-16-211-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Lee JB</style></custom2><misc3><style face="normal" font="Arial">10.4110/in.2016.16.4.211</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krishnamurthy,P.</style></author><author><style face="normal" font="Arial"> Kaplan,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Wells Center for Pediatric Research, Indianapolis, IN 46202, USA.; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USADepartment of Pediatrics, Wells Center for Pediatric Research, Indianapolis, IN 46202, USA.; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA</style></auth-address><titles><title><style face="normal" font="Arial">STAT6 and PARP Family Members in the Development of T Cell-dependent Allergic Inflammation</style></title><secondary-title><style face="normal" font="Arial">Immune Netw</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immune Netw</style></full-title></periodical><pages end="210" start="201">201-210</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> esophageal epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Allergic inflammation requires the orchestration of altered gene expression in the target tissue and in the infiltrating immune cells. The transcription factor STAT6 is critical in activating cytokine gene expression and cytokine signaling both in the immune cells and in target tissue cells including airway epithelia, keratinocytes and esophageal epithelial cells. STAT6 is activated by the cytokines IL-4 and IL-13 to mediate the pathogenesis of allergic disorders such as asthma, atopic dermatitis, food allergy and eosinophilic esophagitis (EoE). In this review, we summarize the role of STAT6 in allergic diseases, its interaction with the co-factor PARP14 and the molecular mechanisms by which STAT6 and PARP14 regulate gene transcription</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1598-2629 (Print)IS - 1598-2629 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4110/in.2016.16.4.201</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27574499">PM:27574499</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immune Netw\2016-16-201-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immune Netw\2016-16-201-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Krishnamurthy P</style></custom2><misc3><style face="normal" font="Arial">10.4110/in.2016.16.4.201</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Amici,M.</style></author><author><style face="normal" font="Arial"> Perotti,F.</style></author><author><style face="normal" font="Arial"> Marseglia,G.L.</style></author><author><style face="normal" font="Arial"> Ierullo,A.M.</style></author><author><style face="normal" font="Arial"> Bollani,L.</style></author><author><style face="normal" font="Arial"> Decembrino,L.</style></author><author><style face="normal" font="Arial"> Licari,A.</style></author><author><style face="normal" font="Arial"> Quaglini,S.</style></author><author><style face="normal" font="Arial"> Stronati,M.</style></author><author><style face="normal" font="Arial"> Spinillo,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Cord and blood levels of newborn IgE: Correlation, role and influence of maternal IgE</style></title><secondary-title><style face="normal" font="Arial">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunobiology</style></full-title></periodical><pages end="453" start="450">450-453</pages><volume><style face="normal" font="Arial">222</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The role of cord blood immunoglobulin E (IgE) levels in predicting the development of atopy has been widely investigated. The aim of the study was to evaluate the correlation between serum and cord blood total IgE in newborns and the possible influence of the atopic status of the mother on them. It was also investigated the possible role of gestational age on neonatal total IgE levels. We considered 763 deliveries, 724>/=37 weeks of gestation and 39&lt;37 weeks of gestation. 14% of mothers (13.7% at term, 15.4% preterm) showed high total IgE levels. The results showed a significant correlation between serum and cord IgE levels both in preterm and term newborns. The data revealed also that mother's total IgE levels affect both neonatal serum and cord total IgE levels. For the latters we also found child gender as an additional independent predictor. On the contrary total IgE levels are not affected by gestational age. Clinical limitations of total IgE is known but their determination can be useful to define atopy and to suggest follow-up of the children</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1878-3279 (Electronic)IS - 0171-2985 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imbio.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562898">PM:27562898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunobiology\20160826-DeAmiciM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunobiology\20160826-DeAmiciM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, De Amici M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imbio.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonura,A.</style></author><author><style face="normal" font="Arial"> Vlah,S.</style></author><author><style face="normal" font="Arial"> Longo,A.</style></author><author><style face="normal" font="Arial"> Bulati,M.</style></author><author><style face="normal" font="Arial"> Melis,M.R.</style></author><author><style face="normal" font="Arial"> Cibella,F.</style></author><author><style face="normal" font="Arial"> Colombo,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Istituto di Biomedicina e di Immunologia Molecolare del Consiglio Nazionale delle Ricerche, Via Ugo La Malfa 153, 90146 Palermo, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Hydroxytyrosol modulates Par j 1-induced IL-10 production by PBMCs in healthy subjects</style></title><secondary-title><style face="normal" font="Arial">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunobiology</style></full-title></periodical><pages end="1377" start="1374">1374-1377</pages><volume><style face="normal" font="Arial">221</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> costimulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Par j 1</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="25" Month="7" Year="2016">2016/7/25</year></dates><abstract><style face="normal" font="Arial">Several papers have demonstrated the importance of substances from natural sources which can exert powerful anti-inflammatory effects. In this respect, hydroxytyrosol, one of the major elements of the phenolic components of olive oil, has been extensively studied for its anti-inflammatory activities and safety profile. In this report, we demonstrate that the co-stimulation of human PBMCs from healthy subjects with the Par j 1 allergen and hydroxytyrosol induced a statistically significant increase in the amount of Par j 1-induced IL-10, demonstrating that hydroxytyrosol can modulate an allergen-specific immune response potentiating a suppressive immune response towards an allergen. Our work opens the way to further studies to elaborate the possibility of using hydroxytyrosol as a nutrient for allergy prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20160731IS - 1878-3279 (Electronic)IS - 0171-2985 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imbio.2016.07.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27475990">PM:27475990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunobiology\20160731-BonuraA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunobiology\20160731-BonuraA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160731, Bonura A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imbio.2016.07.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farhan,R.K.</style></author><author><style face="normal" font="Arial"> Vickers,M.A.</style></author><author><style face="normal" font="Arial"> Ghaemmaghami,A.M.</style></author><author><style face="normal" font="Arial"> Hall,A.M.</style></author><author><style face="normal" font="Arial"> Barker,R.N.</style></author><author><style face="normal" font="Arial"> Walsh,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunity, Infection and Inflammation Programme, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK</style></auth-address><titles><title><style face="normal" font="Arial">Effective Antigen Presentation to Helper T Cells by Human Eosinophils</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="422" start="413">413-422</pages><volume><style face="normal" font="Arial">149</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD40</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> MHC class II</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Mycobacteria</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood eosinophils</style></keyword><keyword><style face="normal" font="Arial"> PPD</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> timothy grass extract</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="8" Year="2016">2016/8/9</year></dates><abstract><style face="normal" font="Arial">Although eosinophils are inflammatory cells, there is increasing attention on their immunomodulatory roles. For example, murine eosinophils can present antigen to CD4+ T helper (Th) cells, but it remains unclear whether human eosinophils also have this ability. This study determined whether human eosinophils present a range of antigens, including allergens, to activate Th cells, and characterized their expression of MHC class II and co-stimulatory molecules required for effective presentation. Human peripheral blood eosinophils purified from non-allergic donors were pulsed with the antigens house dust mite extract (HDM), Timothy Grass extract (TG), or Mycobacterium tuberculosis purified protein derivative (PPD), before co-culture with autologous CD4+ Th cells. Proliferative and cytokine responses were measured, with eosinophil expression of HLA-DR/DP/DQ and the co-stimulatory molecules CD40, CD80 and CD86 determined by flow cytometry. Eosinophils pulsed with HDM, TG or PPD drove Th proliferation, with the response strength dependent on antigen concentration. The cytokine responses varied with donor and antigen, and were not biased towards any particular Th subset, often including combinations of pro- and anti-inflammatory cytokines. Eosinophils upregulated surface expression of HLA-DR/DP/DQ, CD80, CD86 and CD40 in culture, increases that were sustained over 5 days when incubated with antigens, including HDM, or the major allergens it contains, Der p 1 or Der p 2. Human eosinophils can, therefore, act as effective APC to stimulate varied Th cell responses against a panel of antigens including HDM, TG or PPD, an ability that may help to determine the development of allergic disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160809IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12658</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27502559">PM:27502559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20160809-FarhanRK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20160809-FarhanRK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160809, Farhan RK</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12658</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jha,O.K.</style></author><author><style face="normal" font="Arial"> Khanna,A.</style></author><author><style face="normal" font="Arial"> Dabral,C.</style></author><author><style face="normal" font="Arial"> Talwar,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Metro Center for Respiratory Diseases, Metro Multispeciality Hospital, Noida, Uttar Pradesh, India</style></auth-address><titles><title><style face="normal" font="Arial">Tombs of Aspergillus: A missed cause of recurrent respiratory infections in allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Indian J Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Crit Care Med</style></full-title></periodical><pages end="424" start="421">421-424</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchoscopy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hemoptysis</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> respiratory failure</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Broncholithiasis is an often overlooked condition and has been associated with symptoms such as cough, hemoptysis, and recurrent respiratory infections. The most common mechanism of a broncholith formation is the enlargement and subsequent erosion of a lymph node into an adjacent airway. Here, we describe this entity in a patient with advanced allergic bronchopulmonary aspergillosis, with chronic hypercapnic respiratory failure, and with frequent infective exacerbations. These frequent exacerbations were initially attributed to the poor lung function of the patient and the inability to cough out the secretions. The diagnosis of broncholithiasis was eventually established on bronchoscopy, when the patient was intubated and mechanically ventilated. In this patient, the mixed broncholiths were not associated with mediastinal lymphadenopathy and with biopsy showing Aspergillus with no lymph node tissue indicating its bronchial origin. A high index of suspicion should be kept in patients with recurrent infective exacerbations of pulmonary diseases, especially when computed tomography images show calcifications in the vicinity of airways even in the absence of lymphadenopathy, as most of these can be treated with routine bronchoscopic interventions</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 0972-5229 (Print)IS - 0972-5229 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-5229.186228</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27555698">PM:27555698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Crit Care Med\2016-20-421-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Crit Care Med\2016-20-421-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Jha OK</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-5229.186228</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Subramaniyan,R.</style></author><author><style face="normal" font="Arial"> Chopra,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Command Hospital Air Force, Bengaluru, Karnataka, IndiaDepartment of Dermatology, Command Hospital Air Force, Bengaluru, Karnataka, India</style></auth-address><titles><title><style face="normal" font="Arial">Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases</style></title><secondary-title><style face="normal" font="Arial">Indian J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Dermatol</style></full-title></periodical><pages end="" start="467">467-</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fexofenadine</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic spontaneous urticaria (CSU) has a detrimental effect on patients' emotional and physical quality of life. Omalizumab, an anti-immunoglobulin E humanized monoclonal antibody, has been shown to be very effective in the treatment of refractory chronic urticaria patients but may not be an economically viable option for all CSU patients. However, we present a case series where a single dose of omalizumab gave sustained relief of symptoms in patients with CSU, which may be an economical option. AIMS: The aim of this study is to assess the efficacy of a single dose of omalizumab in the treatment of CSU. MATERIALS AND METHODS: Four patients of CSU whose disease was not controlled with four times the licensed dose of tablet fexofenadine 180 mg were exhibited one subcutaneous injection of omalizumab and were followed up at 4 weekly intervals for 24 weeks for Weekly Urticaria Activity Score 7 (UAS7) and Dermatology Life Quality Index (DLQI). RESULTS: A sharp decline in UAS7 and DLQI was documented in 7-10 days. The decline was maintained up to 16 weeks in one case and 20 weeks in the other three cases. Both the scores at the end of the follow-up period of 24 weeks were better than the pre-omalizumab scores. CONCLUSION: The results of this case series indicate the efficacy of a single-dose omalizumab in treating moderate to severe refractory CSU. Further studies are required to identify the minimum frequency of administering omalizumab to effectively control CSU. This would greatly reduce the cost of this novel therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1998-3611 (Electronic)IS - 0019-5154 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0019-5154.185745</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512204">PM:27512204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Dermatol\2016-61-467.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Dermatol\2016-61-467.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Subramaniyan R</style></custom2><misc3><style face="normal" font="Arial">10.4103/0019-5154.185745</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ren,Y.</style></author><author><style face="normal" font="Arial"> Su,X.</style></author><author><style face="normal" font="Arial"> Kong,L.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Zhao,X.</style></author><author><style face="normal" font="Arial"> Yu,N.</style></author><author><style face="normal" font="Arial"> Kang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Institute of Respiratory Diseases, The First Affiliated Hospital of China Medical University, 155 North Nanjing Street, Shenyang, 110001, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic effects of histone deacetylase inhibitors in a murine asthma model</style></title><secondary-title><style face="normal" font="Arial">Inflamm Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflamm Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Cytoplasm</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Histone deacetylase</style></keyword><keyword><style face="normal" font="Arial"> Histone Deacetylase Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="8" Year="2016">2016/8/26</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE AND DESIGN: To investigate the therapeutic effects of various HDAC inhibitors on the development of chronic allergic airway disease in mice with airway inflammation, airway remodeling, and airway hyperresponsiveness. SUBJECTS: Wild-type BALB/C mice (N = 72). TREATMENT: Tubastatin A HCl [TSA, a selective histone deacetylase 6 (HDAC6) inhibitor], PCI-34051 (a selective HDAC8 inhibitor), and givinostat (a broad-spectrum HDAC inhibitor that inhibits class I and class II HDACs and several pro-inflammatory cytokines). METHODS: Mice were divided into six groups: control, asthma, dexamethasone (positive control), TSA, PCI-34051, and givinostat (n = 12 per group). Twenty-four hours after OVA nebulization, airway hyperresponsiveness, inflammation, and remodeling were assessed. RESULTS: The chronic asthma mouse model produced typical airway inflammation, airway remodeling, and airway hyperresponsiveness. Administration of PCI-34051 and dexamethasone reduced the eosinophilic inflammation and airway hyperresponsiveness in asthma to reduce the airway remodeling. Treatment with Tubastatin A HCl reduced airway inflammation and was associated with decreased IL-4, IL-5 and total inflammatory cell count, as well as goblet cell metaplasia and subepithelial fibrosis; however, this outcome was not as effective as that with dexamethasone. TGF-beta1 expression in the cytoplasm of airway epithelium of mice in the Tubastatin A HCl group was reduced and expression of alpha-SMA in the airway smooth muscle was also decreased. CONCLUSIONS: The results suggested that treatment with HDAC inhibitors can reduce airway inflammation, airway remodeling, and airway hyperresponsiveness in chronic allergic airway disease in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1420-908X (Electronic)IS - 1023-3830 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00011-016-0984-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27565183">PM:27565183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflamm Res\20160827-RenY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflamm Res\20160827-RenY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Ren Y</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00011-016-0984-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cui,W.</style></author><author><style face="normal" font="Arial"> Zhang,P.</style></author><author><style face="normal" font="Arial"> Gu,J.</style></author><author><style face="normal" font="Arial"> Tian,Y.</style></author><author><style face="normal" font="Arial"> Gao,X.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Jin,Z.</style></author><author><style face="normal" font="Arial"> Yan,D.</style></author><author><style face="normal" font="Arial"> Zhu,X.</style></author><author><style face="normal" font="Arial"> Li,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Nutrition and Food Hygiene, School of Public Health, Jilin University, Changchun, 130021, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin A Deficiency Promotes Inflammation by Induction of Type 2 Cytokines in Experimental Ovalbumin-Induced Asthma Murine Model</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin A</style></keyword></keywords><dates><year Day="15" Month="8" Year="2016">2016/8/15</year></dates><abstract><style face="normal" font="Arial">Vitamin A (VA) deficiency is one of the most common malnutrition conditions. Recent reports showed that VA plays an important role in the immune balance; lack of VA could result in enhanced type 2 immune response characterized by increased type 2 cytokine production and type 2 innate lymphoid cell infiltration and activation. Type 2 immune response plays protective role in anti-infection but plays pathological role in asthmatic disease. In order to investigate the role of VA in the asthmatic disease, we used ovalbumin-induced asthma murine model and observed the pathological changes between mouse-received VA-deficient and VA-sufficient diets. We also measured the type 2 cytokine expressions to reveal the potential mechanism. Our results showed that VA deficiency exacerbates ovalbumin-induced lung inflammation and type 2 cytokine productions. Thus, VA deficiency, or malnutrition in further extent, may contribute to the increasing prevalence of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-016-0415-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525423">PM:27525423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20160815-CuiW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20160815-CuiW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Cui W</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-016-0415-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chauveau,A.</style></author><author><style face="normal" font="Arial"> Dalphin,M.L.</style></author><author><style face="normal" font="Arial"> Kaulek,V.</style></author><author><style face="normal" font="Arial"> Roduit,C.</style></author><author><style face="normal" font="Arial"> Pugin,A.</style></author><author><style face="normal" font="Arial"> von Mutius,E.</style></author><author><style face="normal" font="Arial"> Vuitton,D.A.</style></author><author><style face="normal" font="Arial"> Dalphin,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatrics Department, University Hospital of Besanx00E7;on, Besanx00E7;on, France</style></auth-address><titles><title><style face="normal" font="Arial">Disagreement between Skin Prick Tests and Specific IgE in Early Childhood</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="74" start="69">69-74</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Rural environment</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2016">2016/7/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Accurate diagnosis of allergic sensitization is essential in clinical practice and allergy research, and the choice of assessment method may have an important impact. The PASTURE study (Protection against Allergy: Study of Rural Environment) examines the influence of exposure to a dairy farm environment on the occurrence of allergy in a cohort of rural European children from birth to 10 years. The aim of our study was to analyze agreement between skin prick tests (SPTs), to aeroallergens and food allergens, and specific IgE and to evaluate the association of SPT with atopic dermatitis in the 204 French children of the PASTURE study. METHODS: SPT, atopic dermatitis assessment, and specific IgE measurements were performed at 1, 4.5, and 6 years. RESULTS: A total of 137 children attended all three visits. The agreement between SPTs and specific IgE was poor except for perennial aeroallergens at 6 years and for an IgE cutoff greater than 0.7 IU/ml (x03BA; = 0.69, 0.5</style></abstract><notes><style face="normal" font="Arial">DA - 20160725IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000446776</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27454436">PM:27454436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-69-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-69-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160725, Chauveau A</style></custom2><misc3><style face="normal" font="Arial">10.1159/000446776</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ilves,T.</style></author><author><style face="normal" font="Arial"> Virolainen,A.</style></author><author><style face="normal" font="Arial"> Harvima,I.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of Eastern Finland, Kuopio, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Immediate Wheal Reactivity to Autologous Sweat in Atopic Dermatitis Is Associated with Clinical Severity, Serum Total and Specific IgE and Sweat Tryptase Activity</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="91" start="84">84-91</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chymase</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> intracutaneous test</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAR-2</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> Sweating</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="22" Month="7" Year="2016">2016/7/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sweating can worsen atopic dermatitis (AD). The purpose of this work was to study the associations between reactivity to autologous sweat and the clinical severity of AD as well as investigate the possible wheal-inducing factors of sweat. METHODS: Intracutaneous skin tests with autologous sweat were performed on 50 AD patients and 24 control subjects. In skin biopsies, tryptase and PAR-2 were enzyme and immunohistochemically stained. The associations between skin test reactivity and sweat histamine concentration, tryptase or chymase activity levels, tryptase or PAR-2 expression and AD clinical severity or IgE levels were investigated. RESULTS: The wheal reactions in the intracutaneous tests with autologous sweat were positive, weakly positive and negative in 38, 34 and 28% of the AD patients, respectively, and in 4, 46 and 50% of the healthy controls, respectively (p = 0.008). In AD, the wheal reaction was associated significantly with clinical severity, serum total and specific IgE levels and sweat tryptase activity, but not with sweat histamine and chymase. In nonlesional AD skin, the percentage of PAR-2+ mast cells (MCs) or the number of tryptase+ MCs did not differ significantly between the intracutaneous test reactivity groups. CONCLUSION: Reactivity to autologous sweat correlates with the clinical severity of AD, and tryptase may be one of the factors involved in the sweat-induced wheal</style></abstract><notes><style face="normal" font="Arial">DA - 20160721IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1159/000447638</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27442010">PM:27442010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-84-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-84-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160721, Ilves T</style></custom2><misc3><style face="normal" font="Arial">10.1159/000447638</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hassidim,A.</style></author><author><style face="normal" font="Arial"> Merdler,I.</style></author><author><style face="normal" font="Arial"> Chorin,O.</style></author><author><style face="normal" font="Arial"> Merdler-Rabinowicz,R.</style></author><author><style face="normal" font="Arial"> Dallal,I.</style></author><author><style face="normal" font="Arial"> Perlman,M.</style></author><author><style face="normal" font="Arial"> Chorin,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Plastic and Reconstructive Surgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Atopic Predilection among Kawasaki Disease Patients: A Cross-Sectional Study of 1,187,757 Teenagers</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="96" start="92">92-96</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Severity of the disease</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> teenagers</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2016">2016/7/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Kawasaki disease (KD) is an acute, systemic vasculitis in children, with an etiology that is not completely understood. It is assumed that the development of KD is mediated by an immunologic response. Several reports from East Asia have found a higher prevalence of atopic diseases among patients with KD, but a large-scale study of a non-Asian population regarding this correlation is still lacking. The purpose of this article was to achieve this goal. METHODS: We conducted a cross-sectional, large-scale study to estimate the correlation of KD with allergic diseases. The medical history of 1,187,757 Israeli teenagers (aged 16-20 years during the years 1998-2013) was retrieved. The study population was divided into 3 groups according to a past history of noncomplicated and complicated KD and a control group. The prevalence of allergic diseases among these groups was further investigated. RESULTS: The prevalence of atopic diseases in the 3 study groups was presented (asthma in 11.4, 8.1 and 3.5%, respectively; angioedema/urticaria in 7.1, 0 and 0.46%, respectively; allergic rhinitis in 20, 12.1 and 6.7%, respectively). In noncomplicated KD, a statistically significant link to asthma [odds ratio (OR) 2.4; p = 0.048] and a borderline significant link to allergic rhinitis (OR 1.9; p = 0.06) were found. In KD complicated with cardiac disease, statistically significant links were found for all the allergic conditions, asthma (OR 3.5; p = 0.003), allergic rhinitis (OR 3.5; p &lt; 0.001) and angioedema/urticaria (OR 16.48; p &lt; 0.001). CONCLUSION: KD is associated with allergic diseases. This association increases with the severity of the disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160720IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1159/000447639</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27437950">PM:27437950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-92-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-92-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160720, Hassidim A</style></custom2><misc3><style face="normal" font="Arial">10.1159/000447639</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Specjalski,K.</style></author><author><style face="normal" font="Arial"> Maciejewska,A.</style></author><author><style face="normal" font="Arial"> Pawlowski,R.</style></author><author><style face="normal" font="Arial"> Chelminska,M.</style></author><author><style face="normal" font="Arial"> Jassem,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, Medical University of Gdansk, Gdansk, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Changes in the Expression of MicroRNA in the Buildup Phase of Wasp Venom Immunotherapy: A Pilot Study</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="100" start="97">97-100</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="22" Month="7" Year="2016">2016/7/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific immunotherapy is the most effective method of treatment in allergy to wasp venom. However, its mechanism of action is still not fully understood. The aim of this study is to describe changes in microRNA (miRNA) expression in patients undergoing the buildup phase of venom immunotherapy. METHODS: The study group comprised 7 adult patients with a history of severe systemic reactions after stinging by a wasp. In all patients, sensitization to wasp venom had been confirmed by skin tests and serum IgE. The buildup phase of wasp venom immunotherapy (VIT) was conducted according to an ultrarush protocol. In blood samples collected before and 24 h after completing the VIT buildup phase, 740 miRNAs were assessed. RESULTS: Of the 740 miRNAs, 440 were detected in the study group, and in 5 expression was significantly changed after the buildup phase of VIT: miR-370, miR-539, miR-502-3p, miR-299, and miR-29c. Another 62 miRNAs changed 2-fold in some patients (nonsignificant), including increases in miR-143 (stimulating FOXp3 expression) and let-7d (reducing expression of IL-13, IL-6, and TLR4), and decreases in proinflammatory miR-301, miR-146b, miR-106, and miR-485. CONCLUSIONS: Several changes in miRNA expression have been found as a result of the buildup phase of wasp VIT, with lower expression of some miRNAs involved in allergic inflammation and higher expression of those possibly involved in tolerance induction. However, the role of the most significant changes is uncertain</style></abstract><notes><style face="normal" font="Arial">DA - 20160721IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1159/000447637</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27441833">PM:27441833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-97-100.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-97-100.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160721, Specjalski K</style></custom2><misc3><style face="normal" font="Arial">10.1159/000447637</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Duman,H.</style></author><author><style face="normal" font="Arial"> Bostanci,I.</style></author><author><style face="normal" font="Arial"> Ozmen,S.</style></author><author><style face="normal" font="Arial"> Dogru,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Immunology and Allergy, Sami Ulus Maternity and Children Research and Training Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">The Relevance of Nasal Provocation Testing in Children with Nonallergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="121" start="115">115-121</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> nasal resistance</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function test</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinomanometry</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It is important to understand that allergic rhinitis, whether seasonal or perennial, may be difficult to distinguish clinically from the nonallergic forms of rhinitis. OBJECTIVE: This study aimed to investigate the presence of local allergic rhinitis (LAR) in children who have allergic rhinitis symptoms in the absence of skin test positivity and specific IgE by performing a nasal provocation test (NPT). METHODS: Our study followed a case-controlled, prospective design. Twenty-eight patients and 30 healthy children were included in the study in a pollen-free season. The NPTs with a grass mix, Dermatophagoides pteronyssinus (DP) and D. farinae (DF) allergens were performed with an interval of 1 week. The total symptom score and visual analog scale, nasal eosinophilia and pulmonary function tests were evaluated before and after each NPT. The change to nasal flow and resistance was recorded by anterior rhinomanometry. RESULTS: The symptom frequencies before the NPTs were as follows: nasal congestion 100%; itching 82.1%; rhinorrhea 75% and sneezing 71.4%. The NPT was positive in 7 (25%) patients. In the NPT-positive group there was a statistically significant decrease in nasal flow at the concentrations of 10 and 100 IR/ml for DF (p = 0.026, p = 0.031, respectively). In the NPT-positive group total nasal resistance for DP was increased at the concentrations of 0.1 and 10 IR/ml, and for DF at 10 and 100 IR/ml (p = 0.049, p = 0.041, p = 0.022, p = 0.035, respectively). CONCLUSIONS: We emphasize that the diagnosis of LAR should be taken into consideration by pediatricians and pediatric allergy specialists</style></abstract><notes><style face="normal" font="Arial">DA - 20160731IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1159/000447635</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27475650">PM:27475650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-115-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-115-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160731, Duman H</style></custom2><misc3><style face="normal" font="Arial">10.1159/000447635</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'Anza,B.</style></author><author><style face="normal" font="Arial"> Stokken,J.</style></author><author><style face="normal" font="Arial"> Greene,J.S.</style></author><author><style face="normal" font="Arial"> Kennedy,T.</style></author><author><style face="normal" font="Arial"> Woodard,T.D.</style></author><author><style face="normal" font="Arial"> Sindwani,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Head and Neck Institute, Cleveland Clinic Foundation, Cleveland, OH</style></auth-address><titles><title><style face="normal" font="Arial">Chronic invasive fungal sinusitis: characterization and shift in management of a rare disease</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="1300" start="1294">1294-1300</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Antifungal</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Debridement</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopic surgery</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Granuloma</style></keyword><keyword><style face="normal" font="Arial"> granulomas</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Orbit</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Skull</style></keyword><keyword><style face="normal" font="Arial"> Skull Base</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> voriconazole</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic invasive fungal sinusitis (CIFS) is a rare subtype of mycotic diseases involving the paranasal sinuses. It is characterized by a slow onset and invasive organisms with non-granulomatous inflammation seen on histopathology. Historically, treatment has involved radical surgical resection. The purpose of this study was to describe the presentation, comorbidities, and role of more conservative treatment options. METHODS: This is a multi-institutional retrospective case series of 6 patients with CIFS over 15 years. Patients' medical comorbidities, imaging results, operative procedures, pathological findings including organisms identified, antimicrobial medications used, and outcomes were reviewed. RESULTS: The mean time from onset of symptoms to diagnosis was 6 months. Cultures and fungal PCR identified Aspergillus species in every case. All 6 patients were found to have systemic comorbidities, with many being diabetic. Imaging findings ranged from thickening of sinus mucosa to invasion of the orbit and skull base. Treatment included long-term antifungal therapy and conservative endoscopic surgery in all but 1 patient, who had an open approach. Every patient was free of invasive fungal disease at last follow-up, with a range of 1 to 27 months. CONCLUSION: CIFS is an insidious disease often with months between symptom onset and diagnosis. It is differentiated from chronic granulomatous invasive fungal sinusitis (CGIFS) by a lack of granulomas on histopathology and an association with diabetes mellitus. Endoscopic debridement combined with long-term oral voriconazole was an effective treatment strategy in this series</style></abstract><notes><style face="normal" font="Arial">DA - 20160727IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21828</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27463614">PM:27463614</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20160727-DAnzaB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20160727-DAnzaB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160727, DAnza B</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21828</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">El-Sherbeeny,N.A.</style></author><author><style face="normal" font="Arial"> Hassan,Z.A.</style></author><author><style face="normal" font="Arial"> Ateyya,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Pharmacology, Faculty of Medicine, Suez canal University, Egypt.</style></auth-address><titles><title><style face="normal" font="Arial">Tiron ameliorates oxidative stress and inflammation in a murine model of airway remodeling</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="180" start="172">172-180</pages><volume><style face="normal" font="Arial">39</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Biological Markers</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> DEXA</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> NF-kappa B</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">Airway remodeling includes lung structural changes that have a role in the irreversibility of pulmonary dysfunction shown in chronic bronchial asthmatics. The current experiment investigated the effect of the mitochondrial antioxidant, tiron in comparison with dexamethasone (DEXA) on airway remodeling in chronic asthma. Sensitized BALB/c mice were challenged with ovalbumin (OVA) aerosol for 8weeks, OVA sensitized-challenged mice were treated with either DEXA or tiron, respectively. After that, lung tissue and bronchoaveolar lavage fluid (BALF) were used for measurement of different biological markers. Lungs were examined for histopathological changes and immunohistochemistry. Upon comparing with vehicle treated animals, trion or DEXA treatment significantly reduced eosinophils, lymphocytes, neutrophils and macrophages count in the BALF. Both drugs significantly alleviated chronic OVA-induced oxidative stress as illustrated by decreased pulmonary malondialdenhyde (MDA) and increased glutathione (GSH) and superoxide dismutase (SOD) levels. Asthmatic mice exhibited elevated levels of NOx, IL-13 and TGF-beta1 that were reduced by DEXA and tiron. Histopathological changes and increased immunoreactivity of nuclear factor-Kappa B (NF-kappa B) in OVA-challenged mice were minimized by tiron and DEXA treatment. In conclusion, in this model of chronic asthma DEXA and tiron ameliorated airway remodeling and inflammation in experimental chronic asthma with no difference between the effect of tiron and DEXA. Tiron has a potential role as adjuvant treatment in chronic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2016.07.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27485290">PM:27485290</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2016-39-172-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2016-39-172-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, El-Sherbeeny NA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2016.07.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Scherer,E.</style></author><author><style face="normal" font="Arial"> Valot,B.</style></author><author><style face="normal" font="Arial"> Vacheyrou,M.</style></author><author><style face="normal" font="Arial"> Naegele,A.</style></author><author><style face="normal" font="Arial"> Knapp,J.</style></author><author><style face="normal" font="Arial"> Rocchi,S.</style></author><author><style face="normal" font="Arial"> Roussel,S.</style></author><author><style face="normal" font="Arial"> Millon,L.</style></author><author><style face="normal" font="Arial"> Reboux,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Chrono-Environnement, UMR/CNRS 6249 , University of Bourgogne-Franche-Comte , Besancon , France</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of pets (cats and dogs) in homes using electrostatic dust collectors and QPCR: new tools to evaluate exposure and risk of allergies</style></title><secondary-title><style face="normal" font="Arial">Int J Environ Health Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Environ Health Res</style></full-title></periodical><pages end="599" start="589">589-599</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5-6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> pet exposure</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="8" Year="2016">2016/8/25</year></dates><abstract><style face="normal" font="Arial">Contradictory results are found in the literature concerning fungi, bacteria, and pet exposure and the risk of developing asthma. All these allergens have been thoroughly studied separately in cohort studies, and a variety of sampling and analytical methods are used. It is already possible to characterize fungi, mites, and bacteria by QPCR. The aim of our study is to evaluate QPCR systems to quantify the presence of cats and dogs in homes. Twenty-four houses were sampled with an Electrostatic Dust Collector which was analyzed by QPCR. Questionnaires on the presence of pets in homes were completed. The results from QPCR were correlated for real presence of cats and dogs, and highlighted indirect exposure. This study provides a useful screening tool that will be used in future large cohort studies, such as the ELFE cohort study</style></abstract><notes><style face="normal" font="Arial">DA - 20160825IS - 1369-1619 (Electronic)IS - 0960-3123 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1080/09603123.2016.1217316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27557849">PM:27557849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Environ Health Res\20160825-SchererE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Environ Health Res\20160825-SchererE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Scherer E</style></custom2><misc3><style face="normal" font="Arial">10.1080/09603123.2016.1217316</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qiu,Q.</style></author><author><style face="normal" font="Arial"> Xu,M.</style></author><author><style face="normal" font="Arial"> Lu,C.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Chen,S.</style></author><author><style face="normal" font="Arial"> Kong,W.</style></author><author><style face="normal" font="Arial"> Han,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology Head &amp; Neck Surgery, Guangdong General Hospital, Guangdong Academy of Medical Science, Southern Medical University, Guangzhou, Guangdong, China</style></auth-address><titles><title><style face="normal" font="Arial">Safety and efficacy of rush allergen-specific immunotherapy in Chinese allergic rhinitis patients</style></title><secondary-title><style face="normal" font="Arial">Int J Immunopathol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Immunopathol Pharmacol</style></full-title></periodical><pages end="725" start="720">720-725</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rush immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="8" Year="2016">2016/8/10</year></dates><abstract><style face="normal" font="Arial">The purpose of this prospective, open-IV clinical trial was to assess the safety and efficacy differences between Rush immunotherapy (RIT) and conventional immunotherapy in Chinese allergic rhinitis (AR) patients. The trial involved 174 patients with AR. They were divided into two groups according to their preference of therapy: RIT or conventional immunotherapy. A total of 162 patients completed a 1-year treatment course. For safety and effectiveness evaluation, the local and systemic adverse reactions were recorded throughout the initial phase of both groups. Weeks 0, 2, 5, and 17 were set as observation time points for immunoglobulin G (IgG) and IgG4. Besides that, another observation time point (Week 11) was added in for a visual analog scale (VAS) and a weekly drug dosage scale. In the RIT group, systemic adverse events of AR were similar to those of the conventional therapy group. LTB4 was descended. The VAS of the RIT group did not show a downward trend clearly, instead Week 5 was higher compared with Week 0. The weekly drug dosage scale did not indicate a significant decline, but there was a clear rise in IgG4 in the RIT group. The safety and efficacy of RIT for AR is positive, but further study is needed for improvement</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 2058-7384 (Electronic)IS - 0394-6320 (Linking)LA - ENGPT - LETTERCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1177/0394632016659301</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27510816">PM:27510816</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Immunopathol Pharmacol\20160811-QiuQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Immunopathol Pharmacol\20160811-QiuQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Qiu Q</style></custom2><misc3><style face="normal" font="Arial">10.1177/0394632016659301</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liccardi,G.</style></author><author><style face="normal" font="Arial"> Calzetta,L.</style></author><author><style face="normal" font="Arial"> Sapio,C.</style></author><author><style face="normal" font="Arial"> Rogliani,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">High Speciality "A. Cardarelli" Hospital, Naples, Italy (Department of Chest Diseases Division of Pneumology and Allergology).</style></auth-address><titles><title><style face="normal" font="Arial">Occupational allergy to horse allergens: More than exposure to horses!</style></title><secondary-title><style face="normal" font="Arial">Int J Occup Med Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Occup Med Environ Health</style></full-title></periodical><pages end="723" start="721">721-723</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1896-494X (Electronic)IS - 1232-1087 (Linking)LA - engPT - EditorialSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.13075/ijomeh.1896.00770</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27518882">PM:27518882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Occup Med Environ Health\2016-29-721-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Occup Med Environ Health\2016-29-721-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Liccardi G</style></custom2><misc3><style face="normal" font="Arial">10.13075/ijomeh.1896.00770</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Katotomichelakis,M.</style></author><author><style face="normal" font="Arial"> Danielides,G.</style></author><author><style face="normal" font="Arial"> Iliou,T.</style></author><author><style face="normal" font="Arial"> Anastassopoulos,G.</style></author><author><style face="normal" font="Arial"> Nikolaidis,C.</style></author><author><style face="normal" font="Arial"> Kirodymos,E.</style></author><author><style face="normal" font="Arial"> Giotakis,E.</style></author><author><style face="normal" font="Arial"> Constantinidis,T.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic sensitization prevalence in a children and adolescent population of northeastern Greece region</style></title><secondary-title><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="37" start="33">33-37</pages><volume><style face="normal" font="Arial">89</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Co-sensitivities</style></keyword><keyword><style face="normal" font="Arial"> Co-sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><isbn><style face="normal" font="Arial">0165-5876</style></isbn><abstract><style face="normal" font="Arial">Objectives To evaluate the prevalence of allergic sensitization in a childhood and adolescent population, to explore age- and gender-specific variations and finally to discover co-sensitivities among allergens. Methods A two-stage cross-sectional survey among school-aged children. The two stages of the study involved enrollment of schools and then skin prick testing (SPT) within schools. A total of 675 school children were included in the study. Of those, 231 were diagnosed with allergic rhinitis (AR), according to the medical history as provided by parental-completed questionnaires and positive SPT results. The antigen panel consisted of common allergens and more specifically house dust mites-HDM (Dermatophagoides farinae and Dermatophagoides pteronyssinus), grass mix, trees (olive, cypress and pine), weeds (Parietaria spp.), cat and dog epithelium and moulds (Alternaria spp., Cladosporium spp.). The SPT sensitivity was graded according to SPT-USA Standards. Results The overall prevalence rate of AR was 34.22%. In total, 93 school children (40.3%) were mono- and 138 (59.7%) were poly-sensitized. Overall, the most prevalent sensitizations in decreasing order were to HDM (59.74%), to grasses (48.9%), to Alternaria (34.6%) and to olive (14.71%). There were no age- and sex-specific differences, except for Alternaria mould that showed a significant prevalence among primary school-aged children and predominance in the female gender, by contrast to grass pollen allergy that was predominant to males. A 32% of SPT-positive individuals were not aware of their allergy, with no statistically significant differences between ages. Co-sensitivities were detected for grass pollens and pine and olive trees, for Alternaria and Cladosporium moulds, for cypress and pine trees, and finally for dog and cat danders. Conclusions Given data among school-aged children should be a baseline from which to monitor disease trends and is considered important for the optimal management of AR patients</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Greece -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijporl.2016.07.027</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.ijporl.2016.07.027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2016-89-33-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2016-89-33-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Katotomichelakis M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijporl.2016.07.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Atan,S.O.</style></author><author><style face="normal" font="Arial"> Kececioglu,N.</style></author><author><style face="normal" font="Arial"> Serdar,M.</style></author><author><style face="normal" font="Arial"> Ozpinar,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Acibadem University School of Medicine, Department of Pediatrics, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">The association of residential mold exposure and adenotonsillar hypertrophy in children living in damp environments</style></title><secondary-title><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="238" start="233">233-238</pages><volume><style face="normal" font="Arial">88</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenoids</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental triggers</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypertrophy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> lower respiratory tract infections</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Recurrent respiratory tract infections</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There are many consequences of mold exposure related to respiratory system health of children This retrospective cohort study aims to find the association between adenoid hypertrophy and mold exposure in children living in damp environments. METHODS: Children with history of recurrent respiratory tract infections were enrolled in the study between June 2012 and June 2013 and were followed up for adenoid hypertrophy from June 2013 to June 2016. One hundred and forty two children were residents of moldy houses and 242 were living in normal houses. Skin prick test results for 60 common allergens, vitamin D levels, IgE levels, age, presence of comorbidities such as urticaria, atopic dermatitis, allergic conjunctivitis, allergic rhinitis, asthma, frequency of upper respiratory tract infections and lower respiratory tract infections, were evaluated in both groups. RESULTS: A total of 384 children (mean age +/- standard deviation = 53.37 +/- 36 months; 198 males and 186 females) were included. The children were classified into 2 groups (1)Children living normal houses (n = 242) (2); Children living in damp houses (n = 142) according to mold exposure. Children with adenoid hypertrophy (p &lt; 0,001) and higher IgE levels (p &lt; 0,001) were more common in mold exposed group. Lower respiratory tract infections were more common in children with mold exposure (p &lt; 0,05). Bivariate correlation analysis showed no significant association between IgE levels and adenoid hypertrophy. Multiple linear regression analysis was performed to evaluate IgE levels, vitamin D levels, and presence of adenoid as independent variables; age as dependent variable among two groups and was found statistically significant (p &lt; 0,001). Dermatophagoid sensitive group living in damp houses had a significant increase in adenoid hypertrophy (p = 0,01). Housedustmite sensitive children with recurrent lower respiratory tract infection and upper respiratory tract infection were mainly residents of damp houses (p &lt; 0,001). Allergic comorbidities were significantly more in damp environment group (p &lt; 0,001), but there was no significant increase in any of the subgroups. CONCLUSIONS: Children with mold exposure had significantly increased adenoid hypertrophy regardless of their atopic nature, however, they may have become more sensitized due to other environmental triggers and genetic factors. In damp environments, sensitization to dermatophagoids, was significantly increased in children with adenoid hypertrophy. During the period of infancy, when children were mostly vitamin D supplemented, they were not sensitized and had normal adenoids. As children with recurrent respiratory tract infections grow, they tend to have lower vitamin D levels, become more atopic and tend to have adenoid hypertrophy</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 1872-8464 (Electronic)IS - 0165-5876 (Linking)LA - engPT - Journal ArticleSB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijporl.2016.07.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27497421">PM:27497421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2016-88-233-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2016-88-233-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, Atan SO</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijporl.2016.07.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caffarelli,C.</style></author><author><style face="normal" font="Arial"> Santamaria,F.</style></author><author><style face="normal" font="Arial"> Di Mauro,D.</style></author><author><style face="normal" font="Arial"> Mastrorilli,C.</style></author><author><style face="normal" font="Arial"> Mirra,V.</style></author><author><style face="normal" font="Arial"> Bernasconi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinica Pediatrica, Department of Clinical and Experimental Medicine, Azienda Ospedaliera-Universitaria, University of Parma, Parma, Italy. carlo.caffarelli@unipr.it</style></auth-address><titles><title><style face="normal" font="Arial">Progress in pediatrics in 2015: choices in allergy, endocrinology, gastroenterology, genetics, haematology, infectious diseases, neonatology, nephrology, neurology, nutrition, oncology and pulmonology</style></title><secondary-title><style face="normal" font="Arial">Ital J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ital J Pediatr</style></full-title></periodical><pages end="" start="75">75-</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anemia</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Bronchiolitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Cerebral Palsy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Down Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Endocrinology</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Hashimoto's thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Insulin Resistance</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Jaundice</style></keyword><keyword><style face="normal" font="Arial"> Low birth weight</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> Nephrotic Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Non celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Otitis</style></keyword><keyword><style face="normal" font="Arial"> Otitis Media</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus pyogenes</style></keyword><keyword><style face="normal" font="Arial"> Stroke</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> Weaning</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Gain</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> X Chromosome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">This review focuses key advances in different pediatric fields that were published in Italian Journal of Pediatrics and in international journals in 2015. Weaning studies continue to show promise for preventing food allergy. New diagnostic tools are available for identifying the allergic origin of allergic-like symptoms. Advances have been reported in obesity, short stature and autoimmune endocrine disorders. New molecules are offered to reduce weight gain and insulin-resistance in obese children. Regional investigations may provide suggestions for preventing short stature. Epidemiological studies have evidenced the high incidence of Graves' disease and Hashimoto's thyroiditis in patients with Down syndrome. Documentation of novel risk factors for celiac disease are of use to develop strategies for prevention in the population at-risk. Diagnostic criteria for non-celiac gluten sensitivity have been reported. Negative effect on nervous system development of the supernumerary X chromosome in Klinefelter syndrome has emerged. Improvements have been made in understanding rare diseases such as Rubinstein-Taybi syndrome. Eltrombopag is an effective therapy for immune trombocytopenia. Children with sickle-cell anemia are at risk for nocturnal enuresis. Invasive diseases caused by Streptococcus pyogenes are still common despite of vaccination. No difference in frequency of antibiotic prescriptions for acute otitis media between before the publication of the national guideline and after has been found. The importance of timing of iron administration in low birth weight infants, the effect of probiotics for preventing necrotising enterocolitis and perspectives for managing jaundice and cholestasis in neonates have been highlighted. New strategies have been developed to reduce the risk for relapse in nephrotic syndrome including prednisolone during upper respiratory infection. Insights into the pathophysiology of cerebral palsy, arterial ischemic stroke and acute encephalitis may drive advances in treatment. Recommendations on breastfeeding and complementary feeding have been updated. Novel treatments for rhabdomyosarcoma should be considered for paediatric patients. Control of risk factors for bronchiolitis and administration of pavilizumab for preventing respiratory syncytial virus infection may reduce hospitalization. Identification of risk factors for hospitalization in children with wheezing can improve the management of this disease. Deletions or mutations in genes encoding proteins for surfactant function may cause diffuse lung disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1824-7288 (Electronic)IS - 1720-8424 (Linking)LA - engPT - EditorialSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13052-016-0288-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566421">PM:27566421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Pediatr\2016-42-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Pediatr\2016-42-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Caffarelli C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13052-016-0288-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pepper,A.N.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine and James A. Haley Veterans' Affairs Hospital, Tampa, Fla</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual Immunotherapy for the Polyallergic Patient</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="45" start="41">41-45</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Polyallergies</style></keyword><keyword><style face="normal" font="Arial"> Polyallergy</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE testing</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy is the only disease-modifying treatment for allergic diseases. Sublingual immunotherapy (SLIT) in liquid and tablet form has been used by clinicians in Europe for years, but has only recently gained popularity and approval in the United States. In 2014, the US Food and Drug Administration approved 3 SLIT tablets for the treatment of allergic rhinitis, with or without allergic conjunctivitis. Immunotherapy treatment strategies for the polysensitized patient vary between the United States and Europe. This variation hinges upon whether the polysensitized patient is truly polyallergic. Polysensitization is the positive response to 2 or more allergens on skin prick testing or in vitro specific-IgE testing. Polyallergy is the symptomatic clinical response to 2 or more allergens. In this review, we discuss the use of SLIT in the United States with a focus on treating the polyallergic patient with SLIT</style></abstract><notes><style face="normal" font="Arial">DA - 20160725IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United KIngdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27452888">PM:27452888</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160725-PepperAN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160725-PepperAN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160725, Pepper AN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bakshi,S.S.</style></author><author><style face="normal" font="Arial"> Bhattacharjee,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of ENT and Head &amp; Neck Surgery, Mahatma Gandhi Medical College and Research Institute, Pillaiyarkuppam, Pondicherry, India.</style></auth-address><titles><title><style face="normal" font="Arial">Geographic Tongue</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="176">176-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160720IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27436616">PM:27436616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-176.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-176.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160720, Bakshi SS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Taylor,S.L.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Boudreau-Romano,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Research &amp; Resource Program (FARRP), University of Nebraska, Lincoln, Neb.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic reaction from fingerprint kit attributable to unlabeled gluten, probable wheat flour</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="481" start="479">479-481</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Nebraska</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="21" Month="7" Year="2016">2016/7/21</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160725IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27452885">PM:27452885</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-479-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-479-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160725, Taylor SL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,Q.L.</style></author><author><style face="normal" font="Arial"> Li,F.</style></author><author><style face="normal" font="Arial"> Wang,J.L.</style></author><author><style face="normal" font="Arial"> Ma,J.Q.</style></author><author><style face="normal" font="Arial"> Sheng,X.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Child and Adolescent Healthcare, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine/Shanghai Key Laboratory of Children's Environmental Health, Shanghai 200092, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Establishment of a rat model of oral food allergy]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="761" start="757">757-761</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> BN rat</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To establish a food allergy model in Brown Norway (BN) rats by gavage of ovalbumin (OVA) without any adjuvant, and to evaluate this model. METHODS: A total of 20 male BN rats aged 3 weeks were randomly divided into allergy group and control group (n=10 each). BN rats in the allergy group were given OVA 1 mg per day by gavage, and all the rats were treated for 41 days continuously. On day 42, the rats in the allergy group were given OVA 100 mg by gavage for challenge. The rats in the control group were given normal saline of the same volume by gavage. Differences in body length, body weight, and food intake were compared between the two groups on days 7, 14, 21, 28, 35, and 42. ELISA was used to measure the serum OVA-IgE level and plasma histamine level after challenge on day 42, and the changes in rats' appearance and fecal properties were observed. The model of food allergy was considered successful when the serum OVA-IgE level in the allergy group was no less than the mean serum OVA-IgE level + 3 standard deviation in the control group. RESULTS: There were no significant differences in body length, body weight or food intake between the allergy and control groups at all time points (P>0.05). On day 21, the control group had a significantly higher food intake than the allergy group (P&lt;0.05). On day 42 after challenge, the allergy group showed significantly higher serum OVA-IgE and plasma histamine levels than the control group (P&lt;0.05). The sensitization rate (rate of successful modeling) was 90%. The fecal properties showed no significant differences between the two groups. CONCLUSIONS: OVA by gavage without any adjuvant can successfully establish the model of food allergy in BN rats and has a high success rate. Food allergy induced by OVA may reduce food intake within a short period of time, but no influence on rats' body length or body weight has been observed</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - English AbstractPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27530796">PM:27530796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2016-18-757-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2016-18-757-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Zhu QL</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Durham,S.R.</style></author><author><style face="normal" font="Arial"> Creticos,P.S.</style></author><author><style face="normal" font="Arial"> Nelson,H.S.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Kaur,A.</style></author><author><style face="normal" font="Arial"> Meltzer,E.O.</style></author><author><style face="normal" font="Arial"> Nolte,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Royal Brompton and Harefield Hospitals National Health Service Trust and Imperial College, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1088" start="1081">1081-1088</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desloratadine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="7" Year="2016">2016/7/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Data comparing the treatment effect of allergy immunotherapy and pharmacotherapy are lacking. OBJECTIVE: We sought to indirectly compare the treatment effect of sublingual immunotherapy (SLIT)-tablets with pharmacotherapy for seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). METHODS: Pooled data from randomized, double-blind, placebo-controlled trials for the clinical development programs of selected allergic rhinitis treatments were evaluated. Total nasal symptom scores (TNSSs) relative to placebo were compared. Subjects scored symptoms daily during entire pollen seasons in 6 timothy grass SLIT-tablet trials (n = 3094) and 2 ragweed SLIT-tablet trials (n = 658) and during the last 8 weeks of treatment in 2 house dust mite (HDM) SLIT-tablet trials (n = 1768). Subjects scored symptoms daily in 7 montelukast (10 mg, n = 6799), 9 desloratadine (5 mg, n = 4455), and 8 mometasone furoate nasal spray (MFNS; 200 mug daily, n = 2140) SAR or PAR trials. SLIT-tablet trials allowed rescue medication use, whereas most pharmacotherapy trials did not. A fixed-effect meta-analysis method estimated differences in on-treatment average TNSSs. RESULTS: In grass and ragweed SLIT-tablet trials, overall improvement in TNSSs relative to placebo was 16.3% and 17.1%, respectively. In HDM SLIT-tablet trials, TNSS overall improvement relative to placebo was 16.1%. In the montelukast, desloratadine, and MFNS trials, TNSS overall improvement relative to placebo was 5.4%, 8.5%, and 22.2%, respectively, for SAR trials, and 3.7%, 4.8%, and 11.2%, respectively, for PAR trials. CONCLUSIONS: Although comparisons were limited by study design heterogeneity and use of rescue medications in SLIT-tablet trials, effects on nasal symptoms with timothy grass and ragweed SLIT-tablets were nearly as great as with MFNS and numerically greater than with montelukast and desloratadine for SAR. HDM SLIT-tablet effects were numerically greater than all pharmacotherapies for PAR. SLIT-tablets offer the additional benefit of long-term efficacy</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United KIngdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27527264">PM:27527264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160816-DurhamSR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160816-DurhamSR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Durham SR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smith,P.K.</style></author><author><style face="normal" font="Arial"> Masilamani,M.</style></author><author><style face="normal" font="Arial"> Li,X.M.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, Griffith University, Southport, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">The false alarm hypothesis: Food allergy is associated with high dietary advanced glycation end-products and proglycating dietary sugars that mimic alarmins</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="437" start="429">429-437</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> alarmins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cheese</style></keyword><keyword><style face="normal" font="Arial"> Danger signal</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Oils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> receptor for advanced glycation end products</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> sugars</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The incidence of food allergy has increased dramatically in the last few decades in westernized developed countries. We propose that the Western lifestyle and diet promote innate danger signals and immune responses through production of "alarmins." Alarmins are endogenous molecules secreted from cells undergoing nonprogrammed cell death that signal tissue and cell damage. High molecular group S (HMGB1) is a major alarmin that binds to the receptor for advanced glycation end-products (RAGE). Advanced glycation end-products (AGEs) are also present in foods. We propose the "false alarm" hypothesis, in which AGEs that are present in or formed from the food in our diet are predisposing to food allergy. The Western diet is high in AGEs, which are derived from cooked meat, oils, and cheese. AGEs are also formed in the presence of a high concentration of sugars. We propose that a diet high in AGEs and AGE-forming sugars results in misinterpretation of a threat from dietary allergens, promoting the development of food allergy. AGEs and other alarmins inadvertently prime innate signaling through multiple mechanisms, resulting in the development of allergic phenotypes. Current hypotheses and models of food allergy do not adequately explain the dramatic increase in food allergy in Western countries. Dietary AGEs and AGE-forming sugars might be the missing link, a hypothesis supported by a number of convincing epidemiologic and experimental observations, as discussed in this article</style></abstract><notes><style face="normal" font="Arial">DA - 20160821IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27544741">PM:27544741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160821-SmithPK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160821-SmithPK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160821, Smith PK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Drucker,A.M.</style></author><author><style face="normal" font="Arial"> Li,W.Q.</style></author><author><style face="normal" font="Arial"> Cho,E.</style></author><author><style face="normal" font="Arial"> Li,T.</style></author><author><style face="normal" font="Arial"> Flint,A.J.</style></author><author><style face="normal" font="Arial"> Camargo,C.A.,Jr.</style></author><author><style face="normal" font="Arial"> Qureshi,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Warren Alpert Medical School, Providence, RI; Department of Dermatology, Rhode Island Hospital, Providence</style></auth-address><titles><title><style face="normal" font="Arial">Atopic conditions are associated with food addiction in US women</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1247" start="1246">1246-1247</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Rhode Island</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="12" Month="7" Year="2016">2016/7/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160716IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27421898">PM:27421898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-1246-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-1246-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Drucker AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gupta,R.S.</style></author><author><style face="normal" font="Arial"> Walkner,M.M.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Lau,C.H.</style></author><author><style face="normal" font="Arial"> Caruso,D.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Pongracic,J.A.</style></author><author><style face="normal" font="Arial"> Smith,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Smith Child Health Research Program, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy Sensitization and Presentation in Siblings of Food Allergic Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="962" start="956">956-962</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2016">2016/5/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Many parents of food allergic children have concerns about the development of food allergies in their other children. OBJECTIVE: We sought to determine prevalence of food sensitization and clinical food allergy among siblings of food allergic children. METHODS: Two thousand eight hundred and thirty-four children were enrolled in the Chicago Family Cohort Food Allergy study. One thousand one hundred and twenty children (ages 0-21 years) with a food allergy (defined by a reported reaction history and evidence of food-specific IgE or skin prick test) and at least 1 biological sibling were included in this study. RESULTS: Among siblings of children with food allergy, 33.4% had no sensitization and no clinical symptoms to food. Fifty-three percent had a positive food serum-specific IgE or skin prick test, but no reported symptoms of food allergy. Only 13.6% of siblings were both sensitized and clinically reactive to the same food. Milk allergy was the most common allergy among siblings (5.9%), followed by egg allergy (4.4%) and peanut allergy (3.7%). CONCLUSIONS: In a large cohort of food allergic families, only a small proportion of siblings were both sensitized and clinically reactive to a food. Sensitization without reactivity was common among siblings. Testing for food allergy in siblings without a history of clinical reactivity appears to be unjustified. Screening may lead to negative consequences related to potential misdiagnosis and unnecessary avoidance of a food. More data are needed to determine the absolute risk of food allergy development in siblings of food allergic children</style></abstract><notes><style face="normal" font="Arial">DA - 20160716IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.04.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27421900">PM:27421900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-956-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2016-4-956-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160716, Gupta RS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.04.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gao,S.S.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences, Shandong Academy of Occupational Health and Occupational Medicine, Jinan 250062, China</style></auth-address><titles><title><style face="normal" font="Arial">[Occupational asthma: an analysis of two cases]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi</style></full-title></periodical><pages end="292" start="291">291-292</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial provocation</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Detergents</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dilation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spices</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> working environment</style></keyword></keywords><dates><year Day="20" Month="4" Year="2016">2016/4/20</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the incidence of occupational asthma induced by occupational exposure to detergents and spices. METHODS: The occupational history, case data, and results of auxiliary examinations were collected from patients with asthma induced by occupational exposure to detergents and spices and submitted to the expert group for diagnosis of occupational diseases to obtain the diagnostic results. RESULTS: Both patients with asthma were exposed to asthmogenic substances in the working environment and developed the symptoms of asthma after a certain latency period. In case 1, the patient had positive results from bronchial dilation test and peak expiratory flow test; in case 2, the patient had positive results from allergen skin prick test for spices and essence and allergen bronchial provocation test. Therefore, the possibility of asthma induced by occupational factors could not be excluded. CONCLUSION: Occupational exposure to detergents and spices can induce occupational asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1001-9391 (Print)IS - 1001-9391 (Linking)LA - chiPT - English AbstractPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1001-9391.2016.04.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27514265">PM:27514265</url></web-urls></urls><custom2><style face="normal" font="Arial">20160812, Gao SS</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1001-9391.2016.04.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Honjo,A.</style></author><author><style face="normal" font="Arial"> Nakano,N.</style></author><author><style face="normal" font="Arial"> Yamazaki,S.</style></author><author><style face="normal" font="Arial"> Hara,M.</style></author><author><style face="normal" font="Arial"> Uchida,K.</style></author><author><style face="normal" font="Arial"> Kitaura,J.</style></author><author><style face="normal" font="Arial"> Nishiyama,C.</style></author><author><style face="normal" font="Arial"> Yagita,H.</style></author><author><style face="normal" font="Arial"> Ohtsuka,Y.</style></author><author><style face="normal" font="Arial"> Ogawa,H.</style></author><author><style face="normal" font="Arial"> Okumura,K.</style></author><author><style face="normal" font="Arial"> Shimizu,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacologic inhibition of Notch signaling suppresses food antigen-induced mucosal mast cell hyperplasia</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="996" start="987">987-996</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-3</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mucosal mast cells (MMCs) play a central role in the development of symptoms associated with IgE-mediated food allergy. Recently, Notch2-mediated signaling was shown to be involved in proper MMC distribution in the intestinal tract. OBJECTIVE: This study aimed to clarify the mechanism by which Notch signaling regulates MMC distribution in the intestinal mucosa. Furthermore, pharmacologic inhibition of Notch signaling was evaluated as a treatment for symptoms associated with experimental food allergy. METHODS: Bone marrow-derived mast cells generated from mice were cultured with Notch ligands, and then expression of genes associated with MMCs was measured in the cells. In addition, the effect of an inhibitor of Notch signaling on food antigen-induced allergic reactions was examined in a mouse model of food allergy. RESULTS: Notch signaling induced MMC differentiation through upregulation of expression of genes characteristic of MMCs in the presence of IL-3. Some lamina propria cells isolated from the mouse small intestine expressed Notch ligands and were able to upregulate MMC markers in bone marrow-derived mast cells through Notch signaling. In a mouse model of food allergy, administration of a Notch signaling inhibitor led to suppression of food antigen-induced hyperplasia of intestinal MMCs, resulting in alleviation of allergic diarrhea and systemic anaphylaxis. CONCLUSION: Notch signaling contributes to differentiation and accumulation of MMCs in the intestinal mucosa. Thus inhibition of Notch signaling alleviates symptoms associated with experimental food allergy. These results raise the possibility that Notch signaling in mast cells is a novel target for therapy in patients with food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27555456">PM:27555456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-HonjoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-HonjoA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Honjo A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ege,M.J.</style></author><author><style face="normal" font="Arial"> Pfaffl,M.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dr von Hauner Children's Hospital, LMU Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers to: Milk: An epigenetic inducer of FoxP3 expression)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="939" start="938">938-939</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword></keywords><dates><year Day="12" Month="7" Year="2016">2016/7/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160715IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - LETTERCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27417021">PM:27417021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-938-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-938-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160715, Ege MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caubet,J.C.</style></author><author><style face="normal" font="Arial"> Bencharitiwong,R.</style></author><author><style face="normal" font="Arial"> Ross,A.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Berin,M.C.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy, University Hospital of Geneva, Geneva, Switzerland; Jaffe Food Allergy Institute, Department of Pediatrics, Division of Allergy and Immunology, Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Humoral and cellular responses to casein in patients with food protein-induced enterocolitis to cow's milk</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="583" start="572">572-583</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> Lethargy</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Positive oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy manifesting within 1 to 4 hours of food ingestion with repetitive emesis and lethargy. OBJECTIVE: We sought to characterize immune responses to casein in children with FPIES caused by cow's milk (CM). METHODS: Total IgE and IgM, CM-specific IgG, and casein-specific IgE, IgG, IgG4, and IgM levels, as well as immunoglobulin free light chains, were measured in both patients with active and those with resolved CM-FPIES. Proliferating casein/T-effector cell counts were measured in children with CM-FPIES, children with IgE-mediated CM allergy, and those tolerating CM. Cytokine concentrations in the supernatants were quantified. Serum cytokine and tryptase levels were measured before and after a positive oral food challenge (OFC) result and compared with levels in those with a negative OFC result. RESULTS: We found low levels of CM and casein-specific IgG and casein-specific IgG4 in patients with CM-FPIES versus those tolerating CM (P &lt; .05). Although we found both a high CD4+ T cell-proliferative response and TH2 cytokines production after casein stimulation in children with CM-FPIES, results were similar to those in control subjects. Significantly lower secretion of IL-10 and higher secretion of IL-9 by casein-stimulated T cells were found in patients with CM-FPIES versus those with IgE-mediated CM allergy. Lower baseline serum levels of IL-10 and higher tryptase levels were found in active CM-FPIES versus resolved CM-FPIES. We found a significant increase in serum IL-10 and IL-8 levels after a positive OFC result. CONCLUSIONS: We confirm the paucity of humoral response in patients with CM-FPIES. IL-10 might play a key role in acquisition of tolerance in patients with CM-FPIES. Increased serum IL-8 levels in patients with active FPIES suggest neutrophil involvement. Elevated baseline serum tryptase levels in patients with active FPIES suggest low-grade intestinal mast cell activation or increased mast cell load</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.02.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545065">PM:27545065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160822-CaubetJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160822-CaubetJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Caubet JC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.02.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Balbino,B.</style></author><author><style face="normal" font="Arial"> Sibilano,R.</style></author><author><style face="normal" font="Arial"> Starkl,P.</style></author><author><style face="normal" font="Arial"> Marichal,T.</style></author><author><style face="normal" font="Arial"> Gaudenzio,N.</style></author><author><style face="normal" font="Arial"> Karasuyama,H.</style></author><author><style face="normal" font="Arial"> Bruhns,P.</style></author><author><style face="normal" font="Arial"> Tsai,M.</style></author><author><style face="normal" font="Arial"> Reber,L.L.</style></author><author><style face="normal" font="Arial"> Galli,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France; Universite Pierre et Marie Curie, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Pathways of immediate hypothermia and leukocyte infiltration in an adjuvant-free mouse model of anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="596" start="584">584-596</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody isotypes</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fc receptors</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> liposome</style></keyword><keyword><style face="normal" font="Arial"> Liposomes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> platelet-activating factor</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Conflicting results have been obtained regarding the roles of Fc receptors and effector cells in models of active systemic anaphylaxis (ASA). In part, this might reflect the choice of adjuvant used during sensitization because various adjuvants might differentially influence the production of particular antibody isotypes. OBJECTIVE: We developed an "adjuvant-free" mouse model of ASA and assessed the contributions of components of the "classical" and "alternative" pathways in this model. METHODS: Mice were sensitized intraperitoneally with ovalbumin at weekly intervals for 6 weeks and challenged intraperitoneally with ovalbumin 2 weeks later. RESULTS: Wild-type animals had immediate hypothermia and late-phase intraperitoneal inflammation in this model. These features were reduced in mice lacking the IgE receptor FcepsilonRI, the IgG receptor FcgammaRIII or the common gamma-chain FcRgamma. FcgammaRIV blockade resulted in a partial reduction of inflammation without any effect on hypothermia. Depletion of monocytes/macrophages with clodronate liposomes significantly reduced the hypothermia response. By contrast, depletion of neutrophils or basophils had no significant effects in this ASA model. Both the hypothermia and inflammation were dependent on platelet-activating factor and histamine and were reduced in 2 types of mast cell (MC)-deficient mice. Finally, engraftment of MC-deficient mice with bone marrow-derived cultured MCs significantly exacerbated the hypothermia response and restored inflammation to levels similar to those observed in wild-type mice. CONCLUSION: Components of the classical and alternative pathways contribute to anaphylaxis in this adjuvant-free model, with key roles for MCs and monocytes/macrophages</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - United States -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27555460">PM:27555460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-BalbinoB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-BalbinoB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Balbino B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Annesi-Maesano,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sorbonne Universites, UPMC Univ Paris 06, INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP UMRS 1136), Epidemiology of Allergic and Respiratory Diseases Department (EPAR), Saint-Antoine Medical School, Paris, France.</style></auth-address><titles><title><style face="normal" font="Arial">United Nations Climate Change Conferences: COP21 a lost opportunity for asthma and allergies and preparing for COP22</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="58" start="57">57-58</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United Nations</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialSB - AIMSB - IMCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.02.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27373326">PM:27373326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-57-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-57-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Annesi-Maesano I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.02.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garn,H.</style></author><author><style face="normal" font="Arial"> Bahn,S.</style></author><author><style face="normal" font="Arial"> Baune,B.T.</style></author><author><style face="normal" font="Arial"> Binder,E.B.</style></author><author><style face="normal" font="Arial"> Bisgaard,H.</style></author><author><style face="normal" font="Arial"> Chatila,T.A.</style></author><author><style face="normal" font="Arial"> Chavakis,T.</style></author><author><style face="normal" font="Arial"> Culmsee,C.</style></author><author><style face="normal" font="Arial"> Dannlowski,U.</style></author><author><style face="normal" font="Arial"> Gay,S.</style></author><author><style face="normal" font="Arial"> Gern,J.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Kircher,T.</style></author><author><style face="normal" font="Arial"> Muller-Ladner,U.</style></author><author><style face="normal" font="Arial"> Neurath,M.F.</style></author><author><style face="normal" font="Arial"> Preissner,K.T.</style></author><author><style face="normal" font="Arial"> Reinhardt,C.</style></author><author><style face="normal" font="Arial"> Rook,G.</style></author><author><style face="normal" font="Arial"> Russell,S.</style></author><author><style face="normal" font="Arial"> Schmeck,B.</style></author><author><style face="normal" font="Arial"> Stappenbeck,T.</style></author><author><style face="normal" font="Arial"> Steinhoff,U.</style></author><author><style face="normal" font="Arial"> van Os,J.</style></author><author><style face="normal" font="Arial"> Weiss,S.</style></author><author><style face="normal" font="Arial"> Zemlin,M.</style></author><author><style face="normal" font="Arial"> Renz,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, University of Marburg, Marburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Current concepts in chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and inflammation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="56" start="47">47-56</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urbanization</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Recent research indicates that chronic inflammatory diseases, including allergies and autoimmune and neuropsychiatric diseases, share common pathways of cellular and molecular dysregulation. It was the aim of the International von-Behring-Rontgen Symposium (October 16-18, 2014, in Marburg, Germany) to discuss recent developments in this field. These include a concept of biodiversity; the contribution of urbanization, lifestyle factors, and nutrition (eg, vitamin D); and new mechanisms of metabolic and immune dysregulation, such as extracellular and intracellular RNAs and cellular and mitochondrial stress. Epigenetic mechanisms contribute further to altered gene expression and therefore to the development of chronic inflammation. These novel findings provide the foundation for further development of preventive and therapeutic strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - Germany -CO - Denmark -CO - United Kingdom -CO - Australia -CO - United States -CO - Switzerland -CO - Finland -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.02.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27373325">PM:27373325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-47-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-47-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Garn H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.02.046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamanaka,K.</style></author><author><style face="normal" font="Arial"> Nakanishi,T.</style></author><author><style face="normal" font="Arial"> Isono,K.</style></author><author><style face="normal" font="Arial"> Hasegawa,C.</style></author><author><style face="normal" font="Arial"> Inada,H.</style></author><author><style face="normal" font="Arial"> Mizutani,K.</style></author><author><style face="normal" font="Arial"> Matsushima,Y.</style></author><author><style face="normal" font="Arial"> Okada,K.</style></author><author><style face="normal" font="Arial"> Mabuchi,T.</style></author><author><style face="normal" font="Arial"> Kondo,M.</style></author><author><style face="normal" font="Arial"> Yamagiwa,A.</style></author><author><style face="normal" font="Arial"> Kakeda,M.</style></author><author><style face="normal" font="Arial"> Habe,K.</style></author><author><style face="normal" font="Arial"> Nosaka,T.</style></author><author><style face="normal" font="Arial"> Gabazza,E.C.</style></author><author><style face="normal" font="Arial"> Yamazaki,H.</style></author><author><style face="normal" font="Arial"> Mizutani,H.</style></author><author><style face="normal" font="Arial"> Kawano,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Mie University, Graduate School of Medicine, Tsu, Mie, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Restrictive IL-10 induction by an innocuous parainfluenza virus vector ameliorates nasal allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="686" start="682">682-686</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergies</style></keyword><keyword><style face="normal" font="Arial"> Nasal allergy</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27555458">PM:27555458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-YamanakaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-YamanakaK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Yamanaka K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Namazy,J.A.</style></author><author><style face="normal" font="Arial"> Schatz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Scripps Clinic, La Jolla, Calif</style></auth-address><titles><title><style face="normal" font="Arial">The safety of intranasal steroids during pregnancy: A good start</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="106" start="105">105-106</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27373328">PM:27373328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-105-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-105-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Namazy JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Duan,S.</style></author><author><style face="normal" font="Arial"> Wanke,K.</style></author><author><style face="normal" font="Arial"> Wawrzyniak,P.</style></author><author><style face="normal" font="Arial"> Meng,Y.</style></author><author><style face="normal" font="Arial"> Kast,J.I.</style></author><author><style face="normal" font="Arial"> Ruckert,B.</style></author><author><style face="normal" font="Arial"> Rebane,A.</style></author><author><style face="normal" font="Arial"> Xian,M.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Broesby,S.</style></author><author><style face="normal" font="Arial"> Raab,U.</style></author><author><style face="normal" font="Arial"> Werfel,T.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Platelet-activating factor decreases skin keratinocyte tight junction barrier integrity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1728" start="1725">1725-1728</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Estonia</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> platelet-activating factor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="7" Year="2016">2016/7/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Switzerland -CO - China -CO - Estonia -CO - Denmark -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27527261">PM:27527261</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160816-DuanS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160816-DuanS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Duan S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maizels,R.M.</style></author><author><style face="normal" font="Arial"> McSorley,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UKCentre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK</style></auth-address><titles><title><style face="normal" font="Arial">Regulation of the host immune system by helminth parasites</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="675" start="666">666-675</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> co-infection</style></keyword><keyword><style face="normal" font="Arial"> Coinfection</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunosurveillance</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasite infection</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="28" Month="7" Year="2016">2016/7/28</year></dates><abstract><style face="normal" font="Arial">Helminth parasite infections are associated with a battery of immunomodulatory mechanisms, which impact all facets of the host immune response to ensure their persistence within the host. This broad-spectrum modulation of host immunity has intended and unintended consequences, both advantageous and disadvantageous. Thus the host may benefit from suppression of collateral damage during parasite infection, and from reduced allergic, autoimmune and inflammatory reactions. However, helminth infection can also be detrimental in reducing vaccine responses, increasing susceptibility to co-infection, and potentially reducing tumor immunosurveillance. In this review we will summarize the panoply of immunomodulatory mechanisms used by helminths, their potential utility in human disease, and prospective areas of future research</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27476889">PM:27476889</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-666-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-666-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Maizels RM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Levin,A.S.</style></author><author><style face="normal" font="Arial"> Otani,I.M.</style></author><author><style face="normal" font="Arial"> Lax,T.</style></author><author><style face="normal" font="Arial"> Hochberg,E.</style></author><author><style face="normal" font="Arial"> Banerji,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="Arial">Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="113" start="107">107-113</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decision Making</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Reactions to rituximab occur frequently, with up to 77% of patients developing a reaction during initial exposure. The safety of rechallenging patients after a reaction is not clear and standard guidelines are lacking. OBJECTIVE: To better understand clinical decision making surrounding rituximab reactions and subsequent rechallenge. METHODS: We performed a 5-year retrospective review of all rituximab reactions at a large academic outpatient infusion center. Patients' demographic characteristics, clinical symptoms, and management of reactions were reviewed. Reaction severity was classified using standard criteria. RESULTS: Between June 2006 and January 2011, 67 patients (mean age, 58 +/- 13 years, 54% men) with at least 1 rituximab reaction were identified. Most reactions occurred during the first exposure to rituximab (63%). Most reactions (n = 59 [88%]) were grade 1 or 2. Fifty-one patients (n = 51 [88%]) were rechallenged with rituximab on the same day as the initial reaction. Most patients with a grade 1 reaction tolerated rechallenge. Conversely, all 4 patients with a grade 3 reaction had a reaction during rechallenge. The outcome of same-day rechallenge after an initial grade 2 reaction was varied; most patients (26 of 31 [84%]) tolerated same-day challenge, but 5 patients had a reaction (all grade 1-2 severity). CONCLUSIONS: Consistent with previous data, our observations suggest that patients who experience grade 1 reactions to rituximab can be safely rechallenged the same day. A grade 3 or 4 reaction should prompt referral to an allergy specialist for risk assessment before additional rituximab administration. Further research is needed to understand the optimal management of patients with grade 2 reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27497683">PM:27497683</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-107-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-107-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, Levin AS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asare,A.L.</style></author><author><style face="normal" font="Arial"> Carey,V.J.</style></author><author><style face="normal" font="Arial"> Rotrosen,D.</style></author><author><style face="normal" font="Arial"> Nepom,G.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immune Tolerance Network, Bethesda, Md</style></auth-address><titles><title><style face="normal" font="Arial">Clinical trial data access: Opening doors with TrialShare</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="726" start="724">724-726</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="12" Month="7" Year="2016">2016/7/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160730IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - EDITORIALCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27474121">PM:27474121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-724-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-724-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160730, Asare AL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Melnik,B.C.</style></author><author><style face="normal" font="Arial"> John,S.M.</style></author><author><style face="normal" font="Arial"> Schmitz,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Environmental Medicine and Health Theory, University of Osnabruck, Osnabruck, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Milk: An epigenetic inducer of FoxP3 expression</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="938" start="937">937-938</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="12" Month="7" Year="2016">2016/7/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160715IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - LETTERCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27417024">PM:27417024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160715-MelnikBC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160715-MelnikBC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160715, Melnik BC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Povsic,T.J.</style></author><author><style face="normal" font="Arial"> Lawrence,M.G.</style></author><author><style face="normal" font="Arial"> Lincoff,A.M.</style></author><author><style face="normal" font="Arial"> Mehran,R.</style></author><author><style face="normal" font="Arial"> Rusconi,C.P.</style></author><author><style face="normal" font="Arial"> Zelenkofske,S.L.</style></author><author><style face="normal" font="Arial"> Huang,Z.</style></author><author><style face="normal" font="Arial"> Sailstad,J.</style></author><author><style face="normal" font="Arial"> Armstrong,P.W.</style></author><author><style face="normal" font="Arial"> Steg,P.G.</style></author><author><style face="normal" font="Arial"> Bode,C.</style></author><author><style face="normal" font="Arial"> Becker,R.C.</style></author><author><style face="normal" font="Arial"> Alexander,J.H.</style></author><author><style face="normal" font="Arial"> Adkinson,N.F.</style></author><author><style face="normal" font="Arial"> Levinson,A.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Duke Clinical Research Institute, Duke Medicine, Durham, NC.</style></auth-address><titles><title><style face="normal" font="Arial">Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1715" start="1712">1712-1715</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="14" Month="7" Year="2016">2016/7/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160814IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - France -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27522158">PM:27522158</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160814-PovsicTJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160814-PovsicTJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160814, Povsic TJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.058</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Malhotra,N.</style></author><author><style face="normal" font="Arial"> Yoon,J.</style></author><author><style face="normal" font="Arial"> Leyva-Castillo,J.M.</style></author><author><style face="normal" font="Arial"> Galand,C.</style></author><author><style face="normal" font="Arial"> Archer,N.</style></author><author><style face="normal" font="Arial"> Miller,L.S.</style></author><author><style face="normal" font="Arial"> Geha,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="Arial">IL-22 derived from gammadelta T cells restricts Staphylococcus aureus infection of mechanically injured skin</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1107" start="1098">1098-1107</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial peptides</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plasminogen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="7" Year="2016">2016/7/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Staphylococcus aureus is an opportunistic pathogen that colonizes the skin of patients with atopic dermatitis (AD) and aggravates their disease. Neutrophils and the cytokines IL-17A and IL-17F, which drive the expression of the neutrophil-attracting chemokines, are important for the clearance of S aureus infection. The cytokine IL-22 is often coproduced by IL-17-secreting cells. The levels of IL-22 are elevated in AD skin lesions. OBJECTIVE: We sought to determine the role of IL-22 in the clearance of S aureus infection of mouse skin subjected to tape stripping, a surrogate for scratching, a cardinal feature of AD. METHODS: S aureus was applied to the tape-stripped skin of wild-type and Il22-/- mice. Bacterial burden was evaluated by enumerating colony-forming units. Quantitative PCR and ELISA were performed to quantify Il22 mRNA and IL-22 protein in mouse and human skin. Flow cytometry was used to enumerate neutrophils in the skin. RESULTS: Scratching the skin of healthy adults and tape stripping of mouse skin induced local expression of Il22 mRNA and IL-22 protein. Induction of Il22 expression by tape stripping was dependent on IL-23 and gammadelta T cells. Clearance of S aureus from tape-stripped skin was significantly impaired in Il22-/- mice. Neutrophil infiltration and upregulation of expression of genes encoding the antimicrobial peptides antigen-6/urokinase-type plasminogen activator receptor related protein-1 and beta-DEFENSIN 14 and the chemokine (C-X-C motif) ligand following tape stripping were significantly impaired in Il22-/- mice. CONCLUSIONS: These findings show that IL-22 is important for limiting the growth of S aureus on mechanically injured skin and caution that IL-23 and IL-22 blockade in patients with AD may enhance susceptibility to staphylococcal skin infection</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27543072">PM:27543072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160820-MalhotraN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160820-MalhotraN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Malhotra N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,H.H.</style></author><author><style face="normal" font="Arial"> Li,Y.C.</style></author><author><style face="normal" font="Arial"> Huang,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1722" start="1719">1719-1722</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="7" Year="2016">2016/7/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27543070">PM:27543070</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160820-WangHH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160820-WangHH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Wang HH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Faber,M.A.</style></author><author><style face="normal" font="Arial"> Van Gasse,A.L.</style></author><author><style face="normal" font="Arial"> Decuyper,I.I.</style></author><author><style face="normal" font="Arial"> Uyttebroek,A.</style></author><author><style face="normal" font="Arial"> Sabato,V.</style></author><author><style face="normal" font="Arial"> Hagendorens,M.M.</style></author><author><style face="normal" font="Arial"> Bridts,C.H.</style></author><author><style face="normal" font="Arial"> De Clerck,L.S.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Pascal,M.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Ebo,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Allergology, and Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">IgE-reactivity profiles to nonspecific lipid transfer proteins in a northwestern European country</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="682" start="679">679-682</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160814IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Belgium -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27522157">PM:27522157</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160814-FaberMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160814-FaberMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160814, Faber MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hansen,C.S.</style></author><author><style face="normal" font="Arial"> Dufva,M.</style></author><author><style face="normal" font="Arial"> Bogh,K.L.</style></author><author><style face="normal" font="Arial"> Sullivan,E.</style></author><author><style face="normal" font="Arial"> Patel,J.</style></author><author><style face="normal" font="Arial"> Eiwegger,T.</style></author><author><style face="normal" font="Arial"> Szepfalusi,Z.</style></author><author><style face="normal" font="Arial"> Nielsen,M.</style></author><author><style face="normal" font="Arial"> Christiansen,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Biological Sequence Analysis, Technical University of Denmark, Kgs Lyngby, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Linear epitope mapping of peanut allergens demonstrates individualized and persistent antibody-binding patterns</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1730" start="1728">1728-1730</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitope Mapping</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="7" Year="2016">2016/7/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -CO - United States -CO - Canada -CO - Austria -CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27523433">PM:27523433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160815-HansenCS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160815-HansenCS.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160815-HansenCS.xslx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160815-HansenCS.xslx</url></image-urls></urls><custom2><style face="normal" font="Arial">20160815, Hansen CS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lawrence,M.G.</style></author><author><style face="normal" font="Arial"> Woodfolk,J.A.</style></author><author><style face="normal" font="Arial"> Schuyler,A.J.</style></author><author><style face="normal" font="Arial"> Stillman,L.C.</style></author><author><style face="normal" font="Arial"> Chapman,M.D.</style></author><author><style face="normal" font="Arial"> Platts-Mills,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Virginia Asthma and Allergic Diseases Center, Charlottesville, Va</style></auth-address><titles><title><style face="normal" font="Arial">Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="428" start="422">422-428</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypogammaglobulinemia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We present results from clinical studies on plasma infusion done in the late 1970s in patients with hypogammaglobulinemia in which we documented the short half-life of both total and allergen-specific IgE in serum. The development of specific allergic sensitization in the skin of those patients followed by the gradual decrease in sensitization over 50 days was also documented. The data are included here along with a discussion of the existing literature about the half-life of IgE in both the circulation and skin. This rostrum reinterprets the earlier clinical studies in light of new insights and mechanisms that could explain the rapid removal of IgE from the circulation. These mechanisms have clinical implications that relate to the increasing use of anti-IgE mAbs for the treatment of allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496596">PM:27496596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160806-LawrenceMG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160806-LawrenceMG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Lawrence MG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.056</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Millon,L.</style></author><author><style face="normal" font="Arial"> Rognon,B.</style></author><author><style face="normal" font="Arial"> Valot,B.</style></author><author><style face="normal" font="Arial"> Barrera,C.</style></author><author><style face="normal" font="Arial"> Bellanger,A.P.</style></author><author><style face="normal" font="Arial"> Roussel,S.</style></author><author><style face="normal" font="Arial"> Dalphin,J.D.</style></author><author><style face="normal" font="Arial"> Monod,M.</style></author><author><style face="normal" font="Arial"> Reboux,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CNRS, University of Bourgogne-Franche-Comte, UMR 6249 Chrono-Environnement, France; University Hospital of Besancon, Department of Parasitology-Mycology, France.</style></auth-address><titles><title><style face="normal" font="Arial">Common peptide epitopes induce cross-reactivity in hypersensitivity pneumonitis serodiagnosis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1741" start="1738">1738-1741</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity pneumonitis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="8" Year="2016">2016/8/3</year></dates><abstract><style face="normal" font="Arial">The identification of common epitopes in orthologous immunogenic proteins from two microorganisms belonging to very different phylogenetic families, each involved in a specific form of HP, could help in developing new diagnostic and therapeutic strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27498359">PM:27498359</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160807-MillonL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160807-MillonL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, Millon L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Werfel,T.</style></author><author><style face="normal" font="Arial"> Allam,J.P.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author><author><style face="normal" font="Arial"> Eyerich,K.</style></author><author><style face="normal" font="Arial"> Gilles,S.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author><author><style face="normal" font="Arial"> Hoetzenecker,W.</style></author><author><style face="normal" font="Arial"> Knol,E.</style></author><author><style face="normal" font="Arial"> Simon,H.U.</style></author><author><style face="normal" font="Arial"> Wollenberg,A.</style></author><author><style face="normal" font="Arial"> Bieber,T.</style></author><author><style face="normal" font="Arial"> Lauener,R.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Traidl-Hoffmann,C.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Cellular and molecular immunologic mechanisms in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="349" start="336">336-349</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immune deviation</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a complex skin disease frequently associated with other diseases of the atopic diathesis. Recent evidence supports the concept that AD can also recognize other comorbidities, such as chronic inflammatory bowel or cardiovascular diseases. These comorbidities might result from chronic cutaneous inflammation or from a common, yet-to-be-defined immunologic background leading to immune deviations. The activation of immune cells and their migration to the skin play an essential role in the pathogenesis of AD. In patients with AD, an underlying immune deviation might result in higher susceptibility of the skin to environmental factors. There is a high unmet medical need to define immunologic endotypes of AD because it has significant implications on upcoming stratification of the phenotype of AD and the resulting targeted therapies in the development of precision medicine. This review article emphasizes studies on environmental factors affecting AD development and novel biological agents used in the treatment of AD. Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor alpha-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players. These targeted molecules can be expressed on or drive the cellular players infiltrating the skin (eg, T lymphocytes, dendritic cells, or eosinophils). Such approaches can have immunomodulatory and thereby beneficial clinical effects on the overall skin condition, as well as on the underlying immune deviation that might play a role in comorbidities. An effect of these immunologic treatments on pruritus and the disturbed microbiome in patients with AD has other potential consequences for treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - AIMSB - IMCO - Germany -CO - Switzerland -CO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27497276">PM:27497276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-336-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-336-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, Werfel T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mukai,K.</style></author><author><style face="normal" font="Arial"> Gaudenzio,N.</style></author><author><style face="normal" font="Arial"> Gupta,S.</style></author><author><style face="normal" font="Arial"> Vivanco,N.</style></author><author><style face="normal" font="Arial"> Bendall,S.C.</style></author><author><style face="normal" font="Arial"> Maecker,H.T.</style></author><author><style face="normal" font="Arial"> Chinthrajah,R.S.</style></author><author><style face="normal" font="Arial"> Tsai,M.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author><author><style face="normal" font="Arial"> Galli,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Stanford University School of Medicine, Stanford, Calif; Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, Calif</style></auth-address><titles><title><style face="normal" font="Arial">Assessing basophil activation by using flow cytometry and mass cytometry in blood stored 24 hours before analysis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="899" start="889">889-899</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Bats</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD203c</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Heparin</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IL-3</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Basophil activation tests (BATs) have promise for research and for clinical monitoring of patients with allergies. However, BAT protocols vary in blood anticoagulant used and temperature and time of storage before testing, complicating comparisons of results from various studies. OBJECTIVE: We attempted to establish a BAT protocol that would permit analysis of blood within 24 hours of obtaining the sample. METHODS: Blood from 46 healthy donors and 120 patients with peanut allergy was collected into EDTA or heparin tubes, and samples were stored at 4 degrees C or room temperature for 4 or 24 hours before performing BATs. RESULTS: Stimulation with anti-IgE or IL-3 resulted in strong upregulation of basophil CD203c in samples collected in EDTA or heparin, stored at 4 degrees C, and analyzed 24 hours after sample collection. However, a CD63hi population of basophils was not observed in any conditions in EDTA-treated samples unless exogenous calcium/magnesium was added at the time of anti-IgE stimulation. By contrast, blood samples collected in heparin tubes were adequate for quantification of upregulation of basophil CD203c and identification of a population of CD63hi basophils, irrespective of whether the specimens were analyzed by means of conventional flow cytometry or cytometry by time-of-flight mass spectrometry, and such tests could be performed after blood was stored for 24 hours at 4 degrees C. CONCLUSION: BATs to measure upregulation of basophil CD203c and induction of a CD63hi basophil population can be conducted with blood obtained in heparin tubes and stored at 4 degrees C for 24 hours</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.060</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27527263">PM:27527263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160816-MukaiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160816-MukaiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Mukai K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.060</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stein,K.</style></author><author><style face="normal" font="Arial"> Brand,S.</style></author><author><style face="normal" font="Arial"> Jenckel,A.</style></author><author><style face="normal" font="Arial"> Sigmund,A.</style></author><author><style face="normal" font="Arial"> Chen,Z.J.</style></author><author><style face="normal" font="Arial"> Kirschning,C.J.</style></author><author><style face="normal" font="Arial"> Kauth,M.</style></author><author><style face="normal" font="Arial"> Heine,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Innate Immunity, Research Center Borstel, Airway Research Center North, German Center for Lung Research (DZL), Germany</style></auth-address><titles><title><style face="normal" font="Arial">Endosomal recognition of Lactococcus lactis G121 and its RNA by dendritic cells is key to its allergy-protective effects</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="678" start="667">667-678</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy protection</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> cowshed</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactococcus</style></keyword><keyword><style face="normal" font="Arial"> Lactococcus lactis</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> Phagocytosis</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell activation</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bacterial cowshed isolates are allergy protective in mice; however, the underlying mechanisms are largely unknown. We examined the ability of Lactococcus lactis G121 to prevent allergic inflammatory reactions. OBJECTIVE: We sought to identify the ligands and pattern recognition receptors through which L lactis G121 confers allergy protection. METHODS: L lactis G121-induced cytokine release and surface expression of costimulatory molecules by untreated or inhibitor-treated (bafilomycin and cytochalasin D) human monocyte-derived dendritic cells (moDCs), bone marrow-derived mouse dendritic cells (BMDCs), and moDC/naive CD4+ T-cell cocultures were analyzed by using ELISA and flow cytometry. The pathology of ovalbumin-induced acute allergic airway inflammation after adoptive transfer of BMDCs was examined by means of microscopy. RESULTS: L lactis G121-treated murine BMDCs and human moDCs released TH1-polarizing cytokines and induced TH1 T cells. Inhibiting phagocytosis and endosomal acidification in BMDCs or moDCs impaired the release of TH1-polarizing cytokines, costimulatory molecule expression, and T-cell activation on L lactis G121 challenge. In vivo allergy protection mediated by L lactis G121 was dependent on endosomal acidification in dendritic cells (DCs). Toll-like receptor (Tlr) 13-/- BMDCs showed a weak response to L lactis G121 and were unresponsive to its RNA. The TH1-polarizing activity of L lactis G121-treated human DCs was blocked by TLR8-specific inhibitors, mediated by L lactis G121 RNA, and synergistically enhanced by activation of nucleotide-binding oligomerization domain-containing protein (NOD) 2. CONCLUSION: Bacterial RNA is the main driver of L lactis G121-mediated protection against experimentally induced allergy and requires both bacterial uptake by DCs and endosomal acidification. In mice L lactis G121 RNA signals through TLR13; however, the most likely intracellular receptor in human subjects is TLR8</style></abstract><notes><style face="normal" font="Arial">DA - 20160821IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27544739">PM:27544739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160821-SteinK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160821-SteinK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160821, Stein K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Johansson,K.</style></author><author><style face="normal" font="Arial"> Malmhall,C.</style></author><author><style face="normal" font="Arial"> Ramos-Ramirez,P.</style></author><author><style face="normal" font="Arial"> Radinger,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">MicroRNA-155 is a critical regulator of type 2 innate lymphoid cells and IL-33 signaling in experimental models of allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1016" start="1007">1007-1016</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic airway inflammation is triggered by allergen exposure through several steps including release of interleukin (IL)-33 which promotes cytokine (IL-5, IL-13) production by type 2 innate lymphoid cells (ILC2s). MicroRNA (miR)-155 has recently been described to regulate adaptive responses in allergic inflammation. However, the role of miR-155 in the regulation of ILC2s remains unexplored. OBJECTIVE: We sought to elucidate the contribution of miR-155 in ILC2 expansion using experimental murine models of allergic airway inflammation. METHOD: To determine the role of miR-155 in the regulation of ILC2s in allergic airway inflammation miR-155 deficient (miR-155-/-) and wild type (WT) mice were subjected to acute or chronic allergen induced inflammation or treated with recombinant IL-33. RESULTS: miR-155 was 10-fold upregulated in WT derived ILC2s in response to IL-33. Furthermore demonstrated miR-155-/- mice impaired lung IL-33 levels in response to allergen challenge and the number of ILC2s was significantly reduced in allergen challenged miR-155-/- mice compared to WT mice. Exogenous IL-33 treatment revealed that miR-155 is needed for IL-33 induced ILC2 expansion and eosinophilic airway inflammation. Indeed, ILC2s from IL-33 challenged miR-155-/- lungs exhibited impaired proliferation, GATA-3 expression, and IL-13 production as compared with IL-33 challenged WT ILC2s. CONCLUSION: Our findings for the first time demonstrate that ILC2s and IL-33 signaling are regulated by miR-155 in allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160805IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27492144">PM:27492144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160805-JohanssonK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160805-JohanssonK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160805, Johansson K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burastero,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biotechnology, San Raffaele Scientific Institute, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">T-cell receptor-mediated cross-reactivity to different allergens is driven by recognition of homologous, phylogenetically conserved epitopes</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="1237">1237-</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - LETTERCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27484036">PM:27484036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160803-BurasteroSE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160803-BurasteroSE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Burastero SE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Westernberg,L.</style></author><author><style face="normal" font="Arial"> Schulten,V.</style></author><author><style face="normal" font="Arial"> Sette,A.</style></author><author><style face="normal" font="Arial"> Peters,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">La Jolla Institute for Allergy and Immunology, La Jolla, Calif</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers To:  T-cell receptor-mediated cross-reactivity to different allergens is driven by recognition of homologous, phylogenetically conserved epitopes)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1238" start="1237">1237-1238</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - LETTERCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27484034">PM:27484034</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160803-WesternbergL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160803-WesternbergL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Westernberg L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">LeBovidge,J.S.</style></author><author><style face="normal" font="Arial"> Elverson,W.</style></author><author><style face="normal" font="Arial"> Timmons,K.G.</style></author><author><style face="normal" font="Arial"> Hawryluk,E.B.</style></author><author><style face="normal" font="Arial"> Rea,C.</style></author><author><style face="normal" font="Arial"> Lee,M.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Program, Division of Immunology, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="Arial">Multidisciplinary interventions in the management of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="334" start="325">325-334</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is the most common pediatric skin disease. AD has a significant effect on patient and family quality of life caused by intense pruritus, sleep disruption, dietary and nutritional concerns, and psychological stress associated with the disease and its management. Multidisciplinary approaches to AD care have been developed in appreciation of the complex interplay among biological, psychological, behavioral, and dietary factors that affect disease control and the wide range of knowledge, skills, and support that patients and families require to effectively manage and cope with this condition. Common components of multidisciplinary treatment approaches include medical evaluation and management by an AD specialist, education and nursing care, psychological and behavioral support, and nutritional assessment and guidance. Models of care include both clinical programs and structured educational groups provided as adjuncts to standard clinical care. Available evidence suggests beneficial effects of multidisciplinary interventions in improving disease severity and quality of life, particularly for patients with moderate-to-severe disease. Additional research is needed to identify the best candidates for the various multidisciplinary approaches and evaluate the cost-effectiveness of these programs</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27497275">PM:27497275</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-325-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-325-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, LeBovidge JS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,J.P.</style></author><author><style face="normal" font="Arial"> Chao,L.X.</style></author><author><style face="normal" font="Arial"> Simpson,E.L.</style></author><author><style face="normal" font="Arial"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="Arial">Persistence of atopic dermatitis (AD): A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="17" Month="8" Year="2016">2016/8/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous studies found conflicting results about whether childhood atopic dermatitis (AD) persists into adulthood. OBJECTIVE: We sought to determine persistence rates and clinical factors associated with prolonged AD. METHODS: A systematic review was performed in MEDLINE, EMBASE, Scopus, GREAT, LILACS, Web of Science, Academic Search Complete, and Cochrane Library. Meta-analysis was performed using Kaplan-Meier plots and random-effects proportional hazards regression. RESULTS: In total, 45 studies including 110,651 subjects spanning 434,992 patient-years from 15 countries were included. In pooled analysis, 80% of childhood AD did not persist by 8 years and less than 5% persisted by 20 years after diagnosis (mean +/- SE: 6.1 +/- 0.02 years). Children with AD that persisted already for more than 10 years (8.3 +/- 0.08 years) had longer persistence than those with 3 (3.2 +/- 0.02 years) or 5 (6.8 +/- 0.06 years) years of persistence. Children who developed AD by age 2 years had less persistent disease (P &lt; .0001). Persistence was greater in studies using patient-/caregiver-assessed versus physician-assessed outcomes, female versus male patients (P &lt;/= .0006), but not in those with sensitivity to allergens (P = .90). Three studies found prolonged persistence with more severe AD. LIMITATIONS: Some studies did not capture recurrences later in life. CONCLUSIONS: Most childhood AD remitted by adulthood. However, children with already persistent disease, later onset, and/or more severe disease have increased persistence</style></abstract><notes><style face="normal" font="Arial">DA - 20160821IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2016.05.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27544489">PM:27544489</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20160821-KimJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20160821-KimJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160821, Kim JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2016.05.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zheng,H.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Castillo,E.F.</style></author><author><style face="normal" font="Arial"> Luo,Y.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author><author><style face="normal" font="Arial"> Yang,X.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of New Mexico, United States</style></auth-address><titles><title><style face="normal" font="Arial">Leptin Enhances TH2 and ILC2 Responses in Allergic Airway Disease</style></title><secondary-title><style face="normal" font="Arial">J Biol Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Biol Chem</style></abbr-1></periodical><pages end="22052" start="22043">22043-22052</pages><volume><style face="normal" font="Arial">291</style></volume><number><style face="normal" font="Arial">42</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> experimental allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Leptin</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> New Mexico</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="8" Year="2016">2016/8/26</year></dates><abstract><style face="normal" font="Arial">Allergic asthma and obesity are the leading health problems in the world. Many studies have shown that obesity is a risk factor of development of asthma. However, the underlying mechanism has not been well established. In this study, we demonstrate that leptin, an adipokine elevated in obese individuals, promoted proliferation and survival of pro-allergic type 2 helper T cells and group 2 innate lymphoid cells and production of type 2 cytokines, which together contribute to allergic responses. Leptin activates mTORC1, MAPK and STAT3 pathways in TH2 cells. The effects of leptin on TH2 cell proliferation, survival and cytokine production are dependent on the mTORC1 and MAPK pathways as revealed by specific inhibitors. In vivo, leptin-deficiency led to attenuated experimental allergic airway inflammation. Our results thus support that obesity associated elevation of leptin may increase the susceptibility of asthma via modulation of pro-allergic lymphocyte responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1083-351X (Electronic)IS - 0021-9258 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1074/jbc.M116.743187</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566543">PM:27566543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biol Chem\20160827-ZhengH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biol Chem\20160827-ZhengH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Zheng H</style></custom2><misc3><style face="normal" font="Arial">10.1074/jbc.M116.743187</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">ElRamlawy,K.G.</style></author><author><style face="normal" font="Arial"> Fujimura,T.</style></author><author><style face="normal" font="Arial"> Baba,K.</style></author><author><style face="normal" font="Arial"> Kim,J.W.</style></author><author><style face="normal" font="Arial"> Kawamoto,C.</style></author><author><style face="normal" font="Arial"> Isobe,T.</style></author><author><style face="normal" font="Arial"> Abe,T.</style></author><author><style face="normal" font="Arial"> Hodge-Hanson,K.</style></author><author><style face="normal" font="Arial"> Downs,D.M.</style></author><author><style face="normal" font="Arial"> Refaat,I.H.</style></author><author><style face="normal" font="Arial"> Al-Azhary,D.B.</style></author><author><style face="normal" font="Arial"> Aki,T.</style></author><author><style face="normal" font="Arial"> Asaoku,Y.</style></author><author><style face="normal" font="Arial"> Hayashi,T.</style></author><author><style face="normal" font="Arial"> Katsutani,T.</style></author><author><style face="normal" font="Arial"> Tsuboi,S.</style></author><author><style face="normal" font="Arial"> Ono,K.</style></author><author><style face="normal" font="Arial"> Kawamoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hiroshima University, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Der f 34, a Novel Major House Dust Mite Allergen Belonging to a Highly Conserved Rid/YjgF/YER057c/UK114 Family of Imine Deaminases</style></title><secondary-title><style face="normal" font="Arial">J Biol Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Biol Chem</style></abbr-1></periodical><pages end="21615" start="21607">21607-21615</pages><volume><style face="normal" font="Arial">291</style></volume><number><style face="normal" font="Arial">41</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Der f 2</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Leucine</style></keyword><keyword><style face="normal" font="Arial"> Methionine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pan-allergen</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> two-dimensional immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">(HDM) allergy is a growing health problem worldwide, and the characterization of clinically important HDM allergens is a prerequisite for the development of diagnostic and therapeutic strategies. Here, we report a novel HDM allergen that belongs structurally to the highly conserved Rid/YjgF/YER057c/UK114 family (Rid family) with imine deaminase activity. Isolated HDM cDNA, named der f 34, encodes 128 amino acids homologous to Rid-like proteins. This new protein belongs to the Rid family and has seven conserved residues involved in enamine/imine deaminase activity. Indeed, we demonstrated that purified Der f 34 had imine deaminase activity that preferentially acted on leucine and methionine. Native Der f 34 showed a high IgE-binding frequency as revealed by two-dimensional immunoblotting (62.5%) or ELISA (68%), which was comparable to those of a major HDM allergen Der f 2 (77.5% and 79%, respectively). We also found that Der f 34 showed cross-reactivity with another prominent indoor allergen source, Aspergillus fumigatus. This is the first report showing that the Rid family imine deaminase represents an additional important pan-allergen that is conserved across organisms</style></abstract><notes><style face="normal" font="Arial">DA - 20160819IS - 1083-351X (Electronic)IS - 0021-9258 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Egypt -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1074/jbc.M116.728006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27539850">PM:27539850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biol Chem\20160819-ElRamlawyKG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biol Chem\20160819-ElRamlawyKG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160819, ElRamlawy KG</style></custom2><misc3><style face="normal" font="Arial">10.1074/jbc.M116.728006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Planque,M.</style></author><author><style face="normal" font="Arial"> Arnould,T.</style></author><author><style face="normal" font="Arial"> Dieu,M.</style></author><author><style face="normal" font="Arial"> Delahaut,P.</style></author><author><style face="normal" font="Arial"> Renard,P.</style></author><author><style face="normal" font="Arial"> Gillard,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CER Groupe, Health department, rue du Point du Jour, 8 6900 Marloie Belgium; Laboratory of Biochemistry and Cell Biology (URBC)-Namur Research Institute for Life Sciences (NARILIS), University of Namur, 61, rue de Bruxelles, 5000 Namur, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Advances in ultra-high performance liquid chromatography coupled to tandem mass spectrometry for sensitive detection of several food allergens in complex and processed foodstuffs</style></title><secondary-title><style face="normal" font="Arial">J Chromatogr A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Chromatogr A</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Caseins</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chocolate</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Cookies</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Ice</style></keyword><keyword><style face="normal" font="Arial"> Ice Cream</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy Proteins</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> tomato</style></keyword><keyword><style face="normal" font="Arial"> tomato sauce</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">Sensitive detection of food allergens is affected by food processing and foodstuff complexity. It is therefore a challenge to detect cross-contamination in food production that could endanger an allergic customer's life. Here we used ultra-high performance liquid chromatography coupled to tandem mass spectrometry for simultaneous detection of traces of milk (casein, whey protein), egg (yolk, white), soybean, and peanut allergens in different complex and/or heat-processed foodstuffs. The method is based on a single protocol (extraction, trypsin digestion, and purification) applicable to the different tested foodstuffs: chocolate, ice cream, tomato sauce, and processed cookies. The determined limits of quantitation, expressed in total milk, egg, peanut, or soy proteins (and not soluble proteins) per kilogram of food, are: 0.5mg/kg for milk (detection of caseins), 5mg/kg for milk (detection of whey), 2.5mg/kg for peanut, 5mg/kg for soy, 3.4mg/kg for egg (detection of egg white), and 30.8mg/kg for egg (detection of egg yolk). The main advantage is the ability of the method to detect four major food allergens simultaneously in processed and complex matrices with very high sensitivity and specificity</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1873-3778 (Electronic)IS - 0021-9673 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.chroma.2016.08.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27554027">PM:27554027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Chromatogr A\20160824-PlanqueM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Chromatogr A\20160824-PlanqueM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Planque M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.chroma.2016.08.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanino,Y.</style></author><author><style face="normal" font="Arial"> Hashimoto,T.</style></author><author><style face="normal" font="Arial"> Ojima,T.</style></author><author><style face="normal" font="Arial"> Mizuno,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada-ku, Kobe 657-8501, Japan</style></auth-address><titles><title><style face="normal" font="Arial">F-fucoidan from Saccharina japonica is a novel inducer of galectin-9 and exhibits anti-allergic activity</style></title><secondary-title><style face="normal" font="Arial">J Clin Biochem Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Biochem Nutr</style></full-title></periodical><pages end="30" start="25">25-30</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Algae</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergy</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> galectin-9</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Passive cutaneous anaphylaxis reaction</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Fucoidan is a sulfated polysaccharide from brown sea algae. In the present study, it was demonstrated that oral administration of F-fucoidan from Saccharina japonica possessed anti-allergic effects using the passive cutaneous anaphylaxis reaction, but not by intraperitoneal administration. The inhibitory mechanism was dependent on galectin-9, which belongs to a soluble lectin family that recognizes beta-galactoside and prevents IgE binding to mast cells. The anti-allergy properties of F-fucoidan were cancelled by an intravenous dose of anti-galectin-9 antibody or lactose, which bind competitively with galectin-9 before the passive cutaneous anaphylaxis reaction. F-fucoidan increased the expression level of galectin-9 mRNA in intestinal epithelial cells and serum galectin-9 levels. Oral treatment with F-fucoidan suppressed allergic symptoms through the induction of galectin-9. This is the first report that F-fucoidan can induce the secretion of galectin-9</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 0912-0009 (Print)IS - 0912-0009 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3164/jcbn.15-144</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499575">PM:27499575</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Biochem Nutr\2016-59-25-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Biochem Nutr\2016-59-25-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Tanino Y</style></custom2><misc3><style face="normal" font="Arial">10.3164/jcbn.15-144</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mesnil,C.</style></author><author><style face="normal" font="Arial"> Raulier,S.</style></author><author><style face="normal" font="Arial"> Paulissen,G.</style></author><author><style face="normal" font="Arial"> Xiao,X.</style></author><author><style face="normal" font="Arial"> Birrell,M.A.</style></author><author><style face="normal" font="Arial"> Pirottin,D.</style></author><author><style face="normal" font="Arial"> Janss,T.</style></author><author><style face="normal" font="Arial"> Starkl,P.</style></author><author><style face="normal" font="Arial"> Ramery,E.</style></author><author><style face="normal" font="Arial"> Henket,M.</style></author><author><style face="normal" font="Arial"> Schleich,F.N.</style></author><author><style face="normal" font="Arial"> Radermecker,M.</style></author><author><style face="normal" font="Arial"> Thielemans,K.</style></author><author><style face="normal" font="Arial"> Gillet,L.</style></author><author><style face="normal" font="Arial"> Thiry,M.</style></author><author><style face="normal" font="Arial"> Belvisi,M.G.</style></author><author><style face="normal" font="Arial"> Louis,R.</style></author><author><style face="normal" font="Arial"> Desmet,C.</style></author><author><style face="normal" font="Arial"> Marichal,T.</style></author><author><style face="normal" font="Arial"> Bureau,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lung-resident eosinophils represent a distinct regulatory eosinophil subset</style></title><secondary-title><style face="normal" font="Arial">J Clin Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Invest</style></full-title></periodical><pages end="3295" start="3279">3279-3295</pages><volume><style face="normal" font="Arial">126</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="8" Year="2016">2016/8/22</year></dates><abstract><style face="normal" font="Arial">Increases in eosinophil numbers are associated with infection and allergic diseases, including asthma, but there is also evidence that eosinophils contribute to homeostatic immune processes. In mice, the normal lung contains resident eosinophils (rEos), but their function has not been characterized. Here, we have reported that steady-state pulmonary rEos are IL-5-independent parenchymal Siglec-FintCD62L+CD101lo cells with a ring-shaped nucleus. During house dust mite-induced airway allergy, rEos features remained unchanged, and rEos were accompanied by recruited inflammatory eosinophils (iEos), which were defined as IL-5-dependent peribronchial Siglec-FhiCD62L-CD101hi cells with a segmented nucleus. Gene expression analyses revealed a more regulatory profile for rEos than for iEos, and correspondingly, mice lacking lung rEos showed an increase in Th2 cell responses to inhaled allergens. Such elevation of Th2 responses was linked to the ability of rEos, but not iEos, to inhibit the maturation, and therefore the pro-Th2 function, of allergen-loaded DCs. Finally, we determined that the parenchymal rEos found in nonasthmatic human lungs (Siglec-8+CD62L+IL-3Rlo cells) were phenotypically distinct from the iEos isolated from the sputa of eosinophilic asthmatic patients (Siglec-8+CD62LloIL-3Rhi cells), suggesting that our findings in mice are relevant to humans. In conclusion, our data define lung rEos as a distinct eosinophil subset with key homeostatic functions</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-8238 (Electronic)IS - 0021-9738 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/JCI85664</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27548519">PM:27548519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Invest\2016-126-3279-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Invest\2016-126-3279-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Mesnil C</style></custom2><misc3><style face="normal" font="Arial">10.1172/JCI85664</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rothenberg,M.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A hidden residential cell in the lung</style></title><secondary-title><style face="normal" font="Arial">J Clin Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Invest</style></full-title></periodical><pages end="3187" start="3185">3185-3187</pages><volume><style face="normal" font="Arial">126</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="22" Month="8" Year="2016">2016/8/22</year></dates><abstract><style face="normal" font="Arial">Eosinophils are classically known as proinflammatory cells, as they are equipped with a variety of preformed cytotoxic mediators and have been shown to definitively contribute to asthma. The connection between eosinophils and asthma development has led to a new class of asthma therapeutics based on blocking eosinophils with humanized antibodies that neutralize IL-5, a potent eosinophil growth, activation, and survival factor. Yet, recent studies have led to an increasing appreciation that eosinophils have a variety of homeostatic functions, including immunomodulation. In this issue of the JCI, Mesnil et al. identify a notable population of lung-resident eosinophils and demonstrate that, compared with traditional eosinophils, these cells have distinct characteristics, including nuclear structure, surface markers, IL-5 independence, and immunoregulatory function that is capable of polarizing adaptive immune responses, at least in vitro. Thus, these results reinforce a key homeostatic role for this enigmatic cell population, particularly in residing and regulating immunity in the lung</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-8238 (Electronic)IS - 0021-9738 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/JCI89768</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27548525">PM:27548525</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Invest\2016-126-3185-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Invest\2016-126-3185-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Rothenberg ME</style></custom2><misc3><style face="normal" font="Arial">10.1172/JCI89768</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shoda,T.</style></author><author><style face="normal" font="Arial"> Futamura,M.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Yamamoto-Hanada,K.</style></author><author><style face="normal" font="Arial"> Narita,M.</style></author><author><style face="normal" font="Arial"> Saito,H.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Timing of eczema onset and risk of food allergy at 3 years of age: a hospital-based prospective birth cohort study</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="148" start="144">144-148</pages><volume><style face="normal" font="Arial">84</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective birth cohort study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0923-1811</style></isbn><abstract><style face="normal" font="Arial">Background Although recent studies suggest that eczema in early childhood is important in the development of food allergy, the importance of the timing of eczema onset has not been fully clarified. Objective This study aim to identify an association between the timing of eczema onset and development of food allergy in a prospective birth cohort study. Methods Data were obtained from the Tokyo Children</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs Health, Illness and Development (T-CHILD) study, which is a hospital-based birth cohort study currently in progress in Japan. A total of 1550 children were born to the recruited women. Outcome data for children were collected from questionnaires completed at 6 months, 1 and 3 years of age. Association between the timing of eczema onset and development of food allergy was estimated by logistic regression analyses. All analysis were performed using SPSS software with a two-sided 5% significance level. Results Eczema in the first year of life was a significant risk factor in multivariate analysis (aOR 3.90, 95% CI 2.34-6.52, p &amp;lt; 0.001). In each age (by month) stratum, infants with onset of eczema within the first 1-2 months after birth had the highest risk of food allergy at 3 years of age (aOR 6.61, 95% CI 3.27-13.34, p&amp;lt;0.001). Conclusion Infants with early eczema onset (especially within the first 1-4 months after birth) were found to have an increased risk of developing food allergy at 3 years of age. Our findings may contribute to a better understanding of the timing of eczema onset as a potentially modifiable risk factor and to defining those who may need to be on guard for food allergy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2016.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27523805">PM:27523805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20160824-ShodaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20160824-ShodaT.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20160824-ShodaT.xslx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20160824-ShodaT.xslx</url></image-urls></urls><custom2><style face="normal" font="Arial">20160824, Shoda T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.</style></author><author><style face="normal" font="Arial"> Luo,Y.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Chen,M.</style></author><author><style face="normal" font="Arial"> Gu,H.</style></author><author><style face="normal" font="Arial"> Wang,B.</style></author><author><style face="normal" font="Arial"> Yao,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, PR China</style></auth-address><titles><title><style face="normal" font="Arial">DC-SIGN promotes allergen uptake and activation of dendritic cells in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen uptake</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> DC-SIGN</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH22</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="9" Month="8" Year="2016">2016/8/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease, concomitant with allergic reactions to allergens. However, the exact mechanisms of allergen-induced immune responses in AD are not clear. The aim of this study is to explore the role of DC-SIGN in capturing and processing glycan-containing allergens and in the subsequent DC activation and T helper cell polarization in AD patients. METHODS: DC-SIGN expression on DCs from AD patients was analysed by confocal microscopy and flow cytometry. DC-SIGN binding to common allergens was determined by ELISA. Activation of monocyte-derived dendritic cells (Mo-DCs) by allergens was analysed by evaluation of pro-inflammatory cytokines production, and their impact on T-cell responses was investigated by a DC-T cell coculture. RESULTS: DC-SIGN expression was higher on DCs in the lesional skin of AD patients compared with that of healthy controls and was correlated with disease severity. DC-SIGN could bind to many common allergens including house dust mite allergen (Der p2) and egg white allergen (Gal d2). Mo-DCs showed measurable expression of DC-SIGN and a concentration-dependent uptake of Der p2 and Gal d2, which was inhibited by mannan and anti-DC-SIGN Abs. Der p2 and Gal d2 induced the production of pro-inflammatory cytokines, including TNF-alpha and IL-6, by DCs from AD patients and facilitated Th2 and Th22 cell polarization. CONCLUSIONS: Binding of common allergens by DC-SIGN on DCs may initiate allergen sensitization of AD or provoke the relapse of AD. Regulating the allergen-DC-SIGN interaction might be a promising strategy to prevent or intervene in the progress of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2016.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27554335">PM:27554335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20160824-ZhangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20160824-ZhangY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Zhang Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2016.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mendelson,M.H.</style></author><author><style face="normal" font="Arial"> Bernstein,J.A.</style></author><author><style face="normal" font="Arial"> Gabriel,S.</style></author><author><style face="normal" font="Arial"> Balp,M.M.</style></author><author><style face="normal" font="Arial"> Tian,H.</style></author><author><style face="normal" font="Arial"> Vietri,J.</style></author><author><style face="normal" font="Arial"> Lebwohl,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Novartis Pharmaceutical Corporation , East Hanover , NJ , USA</style></auth-address><titles><title><style face="normal" font="Arial">Patient-reported impact of chronic urticaria compared with psoriasis in the United States</style></title><secondary-title><style face="normal" font="Arial">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> CIU</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Data are lacking on the burden of chronic idiopathic urticaria (CIU) versus other dermatologic conditions. This analysis compared the burden of chronic urticaria (CU, proxy for CIU) with psoriasis. METHODS: Data from CU (N = 747) and psoriasis patients (N = 5,107) came from 2010-2012 US National Health and Wellness Surveys. Outcomes included SF-12v2/SF-36v2 mental and physical component summary scores (MCS and PCS, respectively) and other health/activity-related measures. RESULTS: MCS score was 44.7 for CU, and 48.2, 44.7, and 44.3 for mild/moderate/severe psoriasis, respectively (US norm = 50). PCS score was 43.8 for CU, and 46.5, 44.1, and 40.3 for mild/moderate/severe psoriasis. Health utility score was 0.67 for CU, and 0.72, 0.67, and 0.65 for mild/moderate/severe psoriasis. More CU patients reported depression (39%), anxiety (42%), and sleep difficulties (50%) than psoriasis patients (any severity). Overall work impairment was 29% for CU, and 19%, 26%, and 31% for mild/moderate/severe psoriasis. Activities impairment was 39% for CU, and 28%, 37%, and 43% for mild/moderate/severe psoriasis. CU and psoriasis patients had frequent healthcare visits. CONCLUSIONS: Patients with CU had impaired mental/physical health and work/non-work activities, similar to moderate-to-severe psoriasis patients. Results suggest better disease management of CU is needed. This analysis should also reflect the significant burden of CIU</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/09546634.2016.1227421</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27577257">PM:27577257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatolog Treat\20160831-MendelsonMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatolog Treat\20160831-MendelsonMH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Mendelson MH</style></custom2><misc3><style face="normal" font="Arial">10.1080/09546634.2016.1227421</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakamura,M.</style></author><author><style face="normal" font="Arial"> Lee,K.</style></author><author><style face="normal" font="Arial"> Singh,R.</style></author><author><style face="normal" font="Arial"> Zhu,T.H.</style></author><author><style face="normal" font="Arial"> Farahnik,B.</style></author><author><style face="normal" font="Arial"> Abrouk,M.</style></author><author><style face="normal" font="Arial"> Koo,J.</style></author><author><style face="normal" font="Arial"> Bhutani,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a University of California San Francisco, Department of Dermatology , San Francisco , CA</style></auth-address><titles><title><style face="normal" font="Arial">Eczema as an Adverse Effect of Anti-TNFalpha Therapy in Psoriasis and Other Th1-Mediated Diseases: a Review</style></title><secondary-title><style face="normal" font="Arial">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="8" Year="2016">2016/8/29</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: There have been rare reports of eczema occurring as an adverse effect of anti-tumor necrosis factor-alpha (TNFalpha) therapy. METHODS: A literature search was conducted on PubMed for articles describing new onset or worsening of pre-existing eczema during anti-TNFalpha therapy for the treatment of various inflammatory diseases. RESULTS: Eczema as an adverse effect of anti-TNFalpha therapy may occur in approximately 5-20% of patients with various Th1-mediated inflammatory diseases such as psoriasis, inflammatory arthritis, and inflammatory bowel disease. Personal history of atopy appears to increase this risk. Out of the anti-TNFalpha agents indicated for the treatment of moderate to severe psoriasis, infliximab may be more strongly associated with development or exacerbation of pre-existing eczema. DISCUSSION: Inhibitors of key mediators in the Th1 pathway such as TNFalpha are successful therapeutic targets for the treatment of various inflammatory conditions such as psoriasis, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel disease. Blocking the Th1 pathway may create an imbalance favoring increased activity of the opposing Th2 pathway implicated in inflammatory conditions such as eczema. Further research is needed to better understand the role of the Th1/Th2 balance in various inflammatory diseases and how the immunologic environment is affected by immunotherapies</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/09546634.2016.1230173</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27571340">PM:27571340</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatolog Treat\20160829-NakamuraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatolog Treat\20160829-NakamuraM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Nakamura M</style></custom2><misc3><style face="normal" font="Arial">10.1080/09546634.2016.1230173</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsunaga,M.C.</style></author><author><style face="normal" font="Arial"> Yamauchi,P.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">IL-4 and IL-13 Inhibition in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Drugs Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Drugs Dermatol</style></full-title></periodical><pages end="929" start="925">925-929</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Azathioprine</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Methotrexate</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> topical therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="1" Month="8" Year="2016">2016/8/1</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic, prevalent, multi-factorial condition that affects infants, children, and adults. Beyond topical therapy, a variety of systemic agents such as steroids, methotrexate, cyclosporine, azathioprine, mycophenoloic acid, and other agents are utilized to treat moderate to severe AD. However, these agents are associated with potential long term adverse events and organ toxicity. There is an unmet need for a safer, long-term systemic agent to adequately control moderate to severe AD. The role of the Th2 cytokines, IL-4 and IL-13, in AD has led to the development of biologic agents to treat AD. The aim of this article is to review the role of IL-4 and IL-13 in the pathogenesis of AD and discuss some of the clinical trial data that target and inhibit IL-4 and IL-13 in positively altering the course and outcome of AD.&lt;BR />&lt;BR /> &lt;EM>J Drugs Dermatol&lt;/EM>. 2016;15(8):925-929</style></abstract><notes><style face="normal" font="Arial">DA - 20160819IS - 1545-9616 (Print)IS - 1545-9616 (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27537991">PM:27537991</url></web-urls></urls><custom2><style face="normal" font="Arial">20160819, Matsunaga MC</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matos,Y.K.</style></author><author><style face="normal" font="Arial"> Schal,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Entomology and W. M. Keck Center for Behavioral Biology, North Carolina State University, Campus Box 7613, Raleigh, NC 27695-7613</style></auth-address><titles><title><style face="normal" font="Arial">Laboratory and Field Evaluation of Zyrox Fly Granular Bait Against Asian and German Cockroaches (Dictyoptera: Blattellidae)</style></title><secondary-title><style face="normal" font="Arial">J Econ Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Econ Entomol</style></full-title></periodical><pages end="1812" start="1807">1807-1812</pages><volume><style face="normal" font="Arial">109</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Blattella germanica</style></keyword><keyword><style face="normal" font="Arial"> Blattellidae</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Entomology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> German cockroach</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Population Density</style></keyword><keyword><style face="normal" font="Arial"> Southeastern United States</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2016">2016/4/27</year></dates><abstract><style face="normal" font="Arial">The Asian cockroach (Blattella asahinai Mizukubo) was introduced to Florida in 1986 and has since spread throughout the Southeastern United States. Blattella asahinai is a peridomestic pest and high population densities in residential areas can become a nuisance, especially when adults fly into homes. Few studies to date have been conducted on Asian cockroach control, and we evaluated the efficacy of Zyrox Fly Granular Bait and Maxforce Complete Granular Insect Bait against this species in the laboratory compared with the closely related German cockroach (Blattella germanica (L.)). In no-choice and two-choice assays with both species, Zyrox bait and Maxforce bait achieved nearly 100% mortality within two and five days, respectively. We also tested Zyrox bait against B. asahinai in an invasive field population in North Carolina at the label rate (2 g/m2) and at approximately three times the label rate (6.9 g/m2), and found that broadcast applications at both rates reduced populations by an average of 64 and 92%, respectively, for 35 d after the initial application. Zyrox Fly Bait appears to be effective against the Asian and German cockroaches, and could be another tool in an integrated pest management program, if its label could be extended or the active ingredient (cyantraniliprole) formulated into a cockroach bait</style></abstract><notes><style face="normal" font="Arial">DA - 20160428IS - 0022-0493 (Print)IS - 0022-0493 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/jee/tow092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27122494">PM:27122494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Econ Entomol\2016-109-1807-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Econ Entomol\2016-109-1807-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160428, Matos YK</style></custom2><misc3><style face="normal" font="Arial">10.1093/jee/tow092</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mirijello,A.</style></author><author><style face="normal" font="Arial"> Pepe,G.</style></author><author><style face="normal" font="Arial"> Zampiello,P.</style></author><author><style face="normal" font="Arial"> Criconia,G.M.</style></author><author><style face="normal" font="Arial"> Mendola,A.</style></author><author><style face="normal" font="Arial"> Manfrini,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">A Male Patient with Syncope, Anaphylaxis, and ST-Elevation: Hepatic and Cardiac Echinococcosis Presenting with Kounis Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic angina</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anaphylaxis treatment</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Ischemia</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Laryngeal Edema</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Ischemia</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syncope</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Approximately 1% of emergency department (ED) visits are due to anaphylaxis. Symptoms can include skin rash, facial and laryngeal edema, dyspnea, vomiting, hypotension, and shock. A transient loss of consciousness can also be a manifestation of anaphylaxis. A variety of electrocardiographic changes due to anaphylaxis have been described for Kounis syndrome, also known as allergic angina. CASE REPORT: Here we describe the case of a male patient presenting at an ED with syncope, anaphylactic shock, and ST-segment elevation on electrocardiogram (ECG). The diagnostic workup led to the diagnosis of ruptured hepatic echinococcal cyst complicated by anaphylactic shock and syncope. ECG alterations were a manifestation of anaphylaxis, as defined by the type I Kounis syndrome. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Kounis syndrome represents an underestimated disease. Its prompt diagnosis in an ED has important clinical and therapeutic implications, such as modifications in the anaphylaxis treatment protocol, that is, adrenaline should be avoided because it could worsen vasospasm and myocardial ischemia</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 0736-4679 (Electronic)IS - 0736-4679 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jemermed.2016.06.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27516403">PM:27516403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Emerg Med\20160812-MirijelloA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Emerg Med\20160812-MirijelloA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Mirijello A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jemermed.2016.06.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kulhari,A.</style></author><author><style face="normal" font="Arial"> Rogers,A.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Kumaraswamy,V.M.</style></author><author><style face="normal" font="Arial"> Xiong,W.</style></author><author><style face="normal" font="Arial"> DeGeorgia,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurology, University Hospitals Case Medical Center, Cleveland, Ohio</style></auth-address><titles><title><style face="normal" font="Arial">Ischemic Stroke After Wasp Sting</style></title><secondary-title><style face="normal" font="Arial">J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Atorvastatin</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Carotid Arteries</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Echocardiography</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Leg</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> MRI</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Plasminogen</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Stroke</style></keyword><keyword><style face="normal" font="Arial"> Telemetry</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tissue Plasminogen Activator</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Despite the common occurrence of hymenopteran stings worldwide, primary neurologic manifestations including stroke are rare. We report a case of a healthy male who developed a right middle cerebral artery (MCA) territory ischemic stroke after getting stung by a wasp. CASE REPORT: A 44-year-old man with hypertension presented to the hospital with sudden-onset left hemiparesis, left facial weakness, and dysarthria after being stung by a wasp. Magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) scans of the brain revealed a right MCA territory infarct and a lack of flow in the distal right internal carotid artery and MCA. He was treated with intravenous tissue plasminogen activator. A computed tomography angiography scan of the brain performed 24 hours later revealed multiple regions of vasoconstriction in the territory of the bilateral MCA. Evaluations for causes of stroke, including echocardiography and telemetry, were not revealing. Immunologic testing showed significantly elevated levels of serum wasp immunoglobulin E. Therapy with aspirin and atorvastatin was started. At discharge, the patient had a mild left facial droop but normal strength in his left arm and leg. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Emergency physicians encounter large numbers of hymenopteran sting cases each year. These patients typically present with local reactions, such as itching, pain, and erythema. Systemic manifestations, such as anaphylaxis causing severe hypotension and bronchospasm, are less common but deadly. Neurologic complications, such as ischemic stroke, are extremely rare. This manuscript highlights the pathophysiology and management of stroke after a hymenopteran sting. There are no guidelines for the management of stroke after a hymenopteran sting, and therefore we intend to provide some guidance to physicians for treating stroke after a hymenopteran sting</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 0736-4679 (Electronic)IS - 0736-4679 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jemermed.2016.06.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545856">PM:27545856</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Emerg Med\20160822-KulhariA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Emerg Med\20160822-KulhariA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Kulhari A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jemermed.2016.06.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Telloli,C.</style></author><author><style face="normal" font="Arial"> Chicca,M.</style></author><author><style face="normal" font="Arial"> Leis,M.</style></author><author><style face="normal" font="Arial"> Vaccaro,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), Technical Unit for Environmental Assessment Models, Methods and Technologies (UTVALAMB), Air Quality Laboratory (AIR), 40129 Bologna, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Fungal spores and pollen in particulate matter collected during agricultural activities in the Po Valley (Italy)</style></title><secondary-title><style face="normal" font="Arial">J Environ Sci (China)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Environ Sci (China)</style></abbr-1></periodical><pages end="240" start="229">229-240</pages><volume><style face="normal" font="Arial">46</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Airborne particulate matter (PM) containing fungal spores and pollen grains was sampled within a monitoring campaign of wheat threshing, plowing and sowing agricultural operations. Fungal spores and pollen grains were detected and identified on morphological basis. No studies were previously available about fungal spore and pollen content in agricultural PM in the Po Valley. Sampling was conducted in a Po Valley farmland in Mezzano (Ferrara, Italy). The organic particles collected were examined by scanning electron microscopy with energy dispersive X-ray spectrometer. Fungal spores and pollen grains were identified when possible at the level of species. The most frequent components of the organic particles sampled were spores of Aspergillus sp., which could represent a risk of developing allergies and aspergillosis for crop farmers</style></abstract><notes><style face="normal" font="Arial">DA - 20160814IS - 1001-0742 (Print)IS - 1001-0742 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jes.2016.02.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27521955">PM:27521955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Environ Sci (China)\2016-46-229-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Environ Sci (China)\2016-46-229-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160814, Telloli C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jes.2016.02.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arora,P.</style></author><author><style face="normal" font="Arial"> Ansari,S.H.</style></author><author><style face="normal" font="Arial"> Anjum,V.</style></author><author><style face="normal" font="Arial"> Mathur,R.</style></author><author><style face="normal" font="Arial"> Ahmad,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacognosy &amp; Phytochemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110062, India</style></auth-address><titles><title><style face="normal" font="Arial">Investigation of anti-asthmatic potential of Kanakasava in ovalbumin-induced bronchial asthma and airway inflammation in rats</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> aluminium hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Grape</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukins</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mesentery</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Nitrites</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="8" Year="2016">2016/8/5</year></dates><abstract><style face="normal" font="Arial">ETHNO-PHARMACOLOGICAL RELEVANCE: Kanakasava is an Indian traditional Ayurvedic formulation containing Datura (Datura metel), Vasaca (Adhatoda vasica), Dhataki (Woodfordia fruiticosa) and Grape (Vitis vinifera) extracts as major constituents and used to treat pulmonary diseases including coughing, breathing difficulty and asthma. The present study was designed to assess the safety and therapeutic efficacy of Kanakasava against ovalbumin-induced bronchial asthma and related airway inflammation in rats due to lack of evidence based therapeutic efficacy data. MATERIAL AND METHODS: Male wistar rats were sensitized with allergen (ovalbumin, 40 mg/rat + aluminium hydroxide, 2.0 mg/rat) and treated orally with standard dexamethasone (2.5 mg/kg, b.w.) or Kanakasava (1.23 and 2.46 ml/kg, b.w.) from day 1 to day 28. Inflammatory markers, including cell counts and cytokines such as interleukins (IL-4, IL-5, IL-1beta), tumor necrosis factor (TNF-alpha), leukotriene (LTD-4), immunoglobulin (IgE), nitric oxide and nitrite levels in both blood and broncheo alveolar lavaged fluid (BALF) were analyzed. Abdominal mesentery was studied histologically for mast cell degranulation, whereas lung functions were investigated by spirometer. Method was also developed to quantify gallic acid and ethyl gallate content in Kanakasava by HPTLC for its quality control. RESULTS: None of the rats exhibited mortality and Kanakasava was found to be safe at the tested doses. Treatment with Kanakasava significantly (P&lt;0.01) reversed elevated levels of IgE, cytokines, nitrites and influx of eosinophils and neutrophils in blood and BALF. These findings were further supported by the significant improvement in lung functions (P&lt;0.01) and suppression (P&lt;0.01) of degranulation of mast cells. The content of gallic acid and ethyl gallate in Kanakasava was found to be 1.94 and 0.98%, respectively. CONCLUSION: These findings demonstrated the preventive effect of Kanakasava in allergen induced model of asthma providing scientific basis for its traditional use in Ayurveda, since long time</style></abstract><notes><style face="normal" font="Arial">DA - 20160809IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2016.07.082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27502540">PM:27502540</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20160809-AroraP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20160809-AroraP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160809, Arora P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2016.07.082</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bae,M.J.</style></author><author><style face="normal" font="Arial"> Lim,S.</style></author><author><style face="normal" font="Arial"> Lee,D.S.</style></author><author><style face="normal" font="Arial"> Ko,K.R.</style></author><author><style face="normal" font="Arial"> Lee,W.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institutes of Entrepreneurial BioConvergence, Seoul National University, Seoul 151-742, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Water soluble extracts from Actinidia arguta, PG102, attenuates house dust mite-induced murine atopic dermatitis by inhibiting the mTOR pathway with Treg generation</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Actinidia</style></keyword><keyword><style face="normal" font="Arial"> Actinidia arguta</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="2" Month="8" Year="2016">2016/8/2</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Actinidia arguta is widespread in northeastern Asia, being found in Siberia, Korea, Japan, and northern China. These fruits have been documented to regulate the uncontrolled heat of body resulting in various allergic diseases in the Korean traditional medicine. PG102, a water-soluble extract from an edible fruit, A. arguta, has been previously shown to control various factors involved in allergic pathogenesis. AIM OF THE STUDY: In this study, we investigated whether PG102 prevents chronic allergic reactions via the generation of Tregs, which play a preventive role in the pathogenesis of allergic disease. METHODS AND RESULTS: In dust mite extract-induced chronic atopic dermatitis, orally administered PG102 inhibited symptoms of dermatitis, including ear swelling and erythema, and decreased lymphocyte infiltration into the inflamed region. Moreover, PG102 reduced inflammatory T cell responses and increased the expression levels of Foxp3 and other Treg-related genes. PG102 treatment enhanced the induction of CD4+Foxp3+ Tregs from naive CD4+CD62L+ T cells, probably via the inhibition of mTOR activation and the phosphorylation of STAT5 rather than using the TGF-beta signaling pathway. CONCLUSION: PG102 may have potential as an orally active immunosuppressor for preventing chronic inflammatory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496579">PM:27496579</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20160806-BaeMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20160806-BaeMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Bae MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cao,T.</style></author><author><style face="normal" font="Arial"> Tan,W.D.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Tey,H.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Skin Centre, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of A Topical Proteinase-Activated Receptor-2 Inhibitor on Cowhage-induced Pruritus: a randomized placebo-controlled double-blind study</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> MMP</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> PAR-2</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">In many chronic pruritic conditions, such as atopic dermatitis, histamine is not the main pruritic mediator.1 The protease-activated receptor-2 (PAR-2) pathway likely plays a more important role.2 Cowhage spicules-induced itch has previously been demonstrated to be an experimental model for studying histamine-independent PAR-2 mediated itch.3 Methylbenzylmethylbenzimidazolepiperidinylmethanone (MMP) is a heterocyclic compound with selective PAR-2 inhibitory effect.4 In this study, we aim to investigate the effects of a MMP-containing cream on cowhage-induced itch in healthy volunteers. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.13919</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27538258">PM:27538258</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160818-CaoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160818-CaoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Cao T</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.13919</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Combalia,A.</style></author><author><style face="normal" font="Arial"> Fusta,X.</style></author><author><style face="normal" font="Arial"> Guilabert,A.</style></author><author><style face="normal" font="Arial"> Mascaro,J.M.,Jr.</style></author><author><style face="normal" font="Arial"> Estrach,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology department, Hospital Clinic, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Yellow urticaria: report of two cases and review of the literature</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">Urticaria is a common skin disease characterized by transient appearance of itchy smooth and slightly elevated erythematous papules or plaques (wheals). It results from transient extravasation of plasma into the dermis that leads to dermal edema. By definition, individual lesions resolve without scarring in less than 24 hours. The diagnosis is based on detailed patient history and physical examination and skin biopsy is rarely required to confirm the diagnosis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.13958</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27579904">PM:27579904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160831-CombaliaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160831-CombaliaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Combalia A</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.13958</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Q.</style></author><author><style face="normal" font="Arial"> Zhai,Z.</style></author><author><style face="normal" font="Arial"> Xu,J.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Chen,S.</style></author><author><style face="normal" font="Arial"> Zhong,H.</style></author><author><style face="normal" font="Arial"> Huang,X.</style></author><author><style face="normal" font="Arial"> Hao,F.</style></author><author><style face="normal" font="Arial"> Song,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, China</style></auth-address><titles><title><style face="normal" font="Arial">Basophil CD63 Expression in Chronic Spontaneous Urticaria: Correlation with Allergic Sensitization, Serum Autoreactivity and Basophil Reactivity</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Cell Membrane</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermographism</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="8" Year="2016">2016/8/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The underlying causes and factors contributing to the disease severity of chronic spontaneous urticaria (CSU) are unknown. OBJECTIVE: Given the important role of basophils in the pathogenesis of urticaria and that CD63 serves as a useful marker for basophil activation and detecting CD63 expression of basophils is a reliable tools for diagnosing allergy and hypersensitivity reactions to different allergens, the objective of this study was to investigate whether the level of basophil CD63 expression is correlated with allergen sensitization, serum autoreactivity, and basophil reactivity in patients with CSU. METHODS: Basophil-enriched leukocytes were separated from the blood of 64 patients with chronic urticaria (54 CSU patients and 10 symptomatic dermographism patients), 18 healthy control subjects, and 7 atopic donors without urticaria. Flow cytometry was then used to detect CD63 expression on the cell membrane of basophils from all samples. Analysis was also preformed on basophils incubated with sera from CSU patients with positive or negative autologous serum skin test (ASST). RESULTS: CD63 expression was significantly higher in the basophils from patients with CSU than in those from patients with symptomatic dermographism and the healthy control group. The levels of CD63 expression in CSU patients with ASST+ and/or allergen sensitization were higher than those with</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.13912</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27518369">PM:27518369</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160812-ChenQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160812-ChenQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Chen Q</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.13912</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Honda,Y.</style></author><author><style face="normal" font="Arial"> Nakamizo,S.</style></author><author><style face="normal" font="Arial"> Dainichi,T.</style></author><author><style face="normal" font="Arial"> Sasai,R.</style></author><author><style face="normal" font="Arial"> Mimori,T.</style></author><author><style face="normal" font="Arial"> Hirata,M.</style></author><author><style face="normal" font="Arial"> Kataoka,T.R.</style></author><author><style face="normal" font="Arial"> Murata,Y.</style></author><author><style face="normal" font="Arial"> Otsuka,A.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Adult-onset asthma and periocular xanthogranuloma associated with IgG4-related disease with infiltration of regulatory T cells</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="8" Year="2016">2016/8/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - ENGPT - LETTERCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.13873</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27519554">PM:27519554</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160813-HondaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160813-HondaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Honda Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.13873</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shaw,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Summer allergies</style></title><secondary-title><style face="normal" font="Arial">J Fam Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Fam Health</style></abbr-1></periodical><pages end="39" start="38">38-39</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 2058-7554 (Print)IS - 2058-7554 (Linking)LA - engPT - Journal ArticleSB - NCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27498524">PM:27498524</url></web-urls></urls><custom2><style face="normal" font="Arial">20160808, Shaw H</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,A.J.</style></author><author><style face="normal" font="Arial"> Ro,M.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Leukotriene B4 Receptor 2 Is Critical for the Synthesis of Vascular Endothelial Growth Factor in Allergen-Stimulated Mast Cells</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="2078" start="2069">2069-2078</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene B4</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="8" Year="2016">2016/8/3</year></dates><abstract><style face="normal" font="Arial">Mast cells are among the principal effector cells in the pathogenesis of allergic asthma. In allergic reactions, allergen (Ag)-induced cross-linking of IgE bound to FcepsilonRI on mast cells results in the production of vascular endothelial growth factor (VEGF), which is essential for the initiation and development of the allergic response. Despite the central role of VEGF in allergic asthma, the signaling events responsible for the production of VEGF remain unclear, particularly in Ag-stimulated mast cells. In the present study, we observed that blocking leukotriene B4 receptor 2 (BLT2) completely abrogated the production of VEGF in Ag-stimulated bone marrow-derived mast cells (BMMCs). The synthesis of BLT2 ligands (leukotriene B4 and 12(S)-hydroxyeicosatetraenoic acid) was also required for VEGF production, suggesting a mediating role of an autocrine BLT2 ligands-BLT2 axis in the production of VEGF in mast cells. The NADPH oxidase 1-reactive oxygen species-NF-kappaB cascade is downstream of BLT2 during Ag signaling to VEGF synthesis in mast cells. Furthermore, the level of VEGF synthesis in genetically mast cell-deficient Kit(W/Wv) mice was significantly lower than that in wild-type mice in the OVA-induced asthma model, suggesting that mast cells play a critical role in the synthesis of VEGF in OVA-induced allergic asthma. Importantly, VEGF production was restored to the levels observed in wild-type mice after adoptive transfer of normal BMMCs into Kit(W/Wv) mice but was not restored in BLT2-/- BMMC-reconstituted Kit(W/Wv) mice in the OVA-induced asthma model. Taken together, our results suggest that BLT2 expression in mast cells is essential for the production of VEGF in OVA-induced allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1502565</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489284">PM:27489284</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-2069-78.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-2069-78.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Lee AJ</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1502565</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gazzinelli-Guimaraes,P.H.</style></author><author><style face="normal" font="Arial"> Bonne-Annee,S.</style></author><author><style face="normal" font="Arial"> Fujiwara,R.T.</style></author><author><style face="normal" font="Arial"> Santiago,H.C.</style></author><author><style face="normal" font="Arial"> Nutman,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Sensitization Underlies Hyperreactive Antigen-Specific CD4+ T Cell Responses in Coincident Filarial Infection</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="2779" start="2772">2772-2779</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil-Derived Neurotoxin</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="26" Month="8" Year="2016">2016/8/26</year></dates><abstract><style face="normal" font="Arial">Among the various hypotheses put forward to explain the modulatory influence of helminth infection on allergic effector responses in humans, the IL-10-induced suppression of Th2-associated responses has been the leading candidate. To explore this helminth/allergy interaction more fully, parasite- and allergen-specific CD4+ T cell responses in 12 subjects with filarial infections, and coincident allergic sensitization (filarial [Fil]+allergy [A]+) were compared with the responses to three appropriate control groups (Fil-A- [n = 13], Fil-A+ [n = 12], Fil+A- [n = 11]). The most important findings revealed that Fil+A+ had marked (p &lt; 0.0001 for all cytokines) increases in parasite Ag-driven Th2 (IL-4, IL-5, IL-13), Th9 (IL-9), and the regulatory (IL-10) cytokines when compared with Fil+A- Moreover, using multiparameter flow cytometry, filarial parasite Ag induced a marked increase in not only the frequency of CD4+ T cells producing IL-4, IL-5, IL-2, and TNF-alpha in Fil+A+ when compared with Fil+A- patients, but also in the frequencies of polyfunctional Th2-like (CD4+IL-4+IL-5+ and CD4+IL-2+IL-4+IL-5+TNF-alpha+) cells. The Th2-associated responses seen in the Fil+A+ group were correlated with serum IgE levels (p &lt; 0.01, r = 0.5165 for IL-4; p &lt; 0.001, r = 0.5544 for IL-5; and p &lt; 0.001, r = 0.4901 for IL-13) and levels of circulating eosinophils (p &lt; 0.0116, r = 0.5656) and their degranulation/activation products (major basic protein [p &lt; 0.001, r = 0.7353] and eosinophil-derived neurotoxin [p &lt; 0.01, r = 0.7059]). CD4+ responses to allergen were not different (to a large extent) among the groups. Taken together, our data suggest that allergic sensitization coincident with filarial infection drives parasite Ag-specific T cell hyperresponsiveness, which is characterized largely by an augmented Th2-dominated immune response</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.4049/?jimmunol.1600829</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566825">PM:27566825</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20160827-GazzinelliGuimaraesPH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20160827-GazzinelliGuimaraesPH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Gazzinelli-Guimaraes PH</style></custom2><misc3><style face="normal" font="Arial">10.4049/?jimmunol.1600829</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nigro,E.A.</style></author><author><style face="normal" font="Arial"> Brini,A.T.</style></author><author><style face="normal" font="Arial"> Yenagi,V.A.</style></author><author><style face="normal" font="Arial"> Ferreira,L.M.</style></author><author><style face="normal" font="Arial"> Achatz-Straussberger,G.</style></author><author><style face="normal" font="Arial"> Ambrosi,A.</style></author><author><style face="normal" font="Arial"> Sanvito,F.</style></author><author><style face="normal" font="Arial"> Soprana,E.</style></author><author><style face="normal" font="Arial"> van Anken,E.</style></author><author><style face="normal" font="Arial"> Achatz,G.</style></author><author><style face="normal" font="Arial"> Siccardi,A.G.</style></author><author><style face="normal" font="Arial"> Vangelista,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, 20132 Milan, Italy</style></auth-address><titles><title><style face="normal" font="Arial">IgE Plays an Active Role in Tumor Immunosurveillance in Mice</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="2588" start="2583">2583-2588</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunosurveillance</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="8" Year="2016">2016/8/26</year></dates><abstract><style face="normal" font="Arial">Exogenous IgE acts as an adjuvant in tumor vaccination in mice, and therefore a direct role of endogenous IgE in tumor immunosurveillance was investigated. By using genetically engineered mice, we found that IgE ablation rendered mice more susceptible to the growth of transplantable tumors. Conversely, a strengthened IgE response provided mice with partial or complete resistance to tumor growth, depending on the tumor type. By genetic crosses, we showed that IgE-mediated tumor protection was mostly lost in mice lacking FcepsilonRI. Tumor protection was also lost after depletion of CD8+ T cells, highlighting a cross-talk between IgE and T cell-mediated tumor immunosurveillance. Our findings provide the rationale for clinical observations that relate atopy with a lower risk for developing cancer and open new avenues for the design of immunotherapeutics relevant for clinical oncology</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -CO - Austria -CO - Kazakhstan -</style></notes><work-type><style face="normal" font="Arial">10.4049/?jimmunol.1601026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566822">PM:27566822</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20160827-NigroEA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20160827-NigroEA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Nigro EA</style></custom2><misc3><style face="normal" font="Arial">10.4049/?jimmunol.1601026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Noges,L.E.</style></author><author><style face="normal" font="Arial"> White,J.</style></author><author><style face="normal" font="Arial"> Cambier,J.C.</style></author><author><style face="normal" font="Arial"> Kappler,J.W.</style></author><author><style face="normal" font="Arial"> Marrack,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Research, National Jewish Health, Denver</style></auth-address><titles><title><style face="normal" font="Arial">Contamination of DNase Preparations Confounds Analysis of the Role of DNA in Alum-Adjuvanted Vaccines</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="1230" start="1221">1221-1230</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="8" Year="2016">2016/8/15</year></dates><abstract><style face="normal" font="Arial">Aluminum salt (alum) adjuvants have been used for many years as adjuvants for human vaccines because they are safe and effective. Despite its widespread use, the means by which alum acts as an adjuvant remains poorly understood. Recently, it was shown that injected alum is rapidly coated with host chromatin within mice. Experiments suggested that the host DNA in the coating chromatin contributed to alum's adjuvant activity. Some of the experiments used commercially purchased DNase and showed that coinjection of these DNase preparations with alum and Ag reduced the host's immune response to the vaccine. In this study, we report that some commercial DNase preparations are contaminated with proteases. These proteases are responsible for most of the ability of DNase preparations to inhibit alum's adjuvant activity. Nevertheless, DNase somewhat reduces responses to some Ags with alum. The effect of DNase is independent of its ability to cleave DNA, suggesting that alum improves CD4 responses to Ag via a pathway other than host DNA sensing</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1501565</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27357147">PM:27357147</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-1221-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-1221-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Noges LE20</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1501565</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schutze,N.</style></author><author><style face="normal" font="Arial"> Trojandt,S.</style></author><author><style face="normal" font="Arial"> Kuhn,S.</style></author><author><style face="normal" font="Arial"> Tomm,J.M.</style></author><author><style face="normal" font="Arial"> von Bergen,M.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author><author><style face="normal" font="Arial"> Polte,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Leipzig Research Center for Civilization Diseases, Junior Research Group on Pathogenesis of New Allergies, Leipzig University Medical Center, 04103 Leipzig, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-Induced IL-6 Regulates IL-9/IL-17A Balance in CD4+ T Cells in Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="2664" start="2653">2653-2664</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine milieu</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="29" Month="8" Year="2016">2016/8/29</year></dates><abstract><style face="normal" font="Arial">IL-9-secreting Th9 cells have been considered to play a pivotal role in the pathogenesis of atopic diseases. To what extent IL-9-producing cells are induced or regulated by sensitization with naturally occurring allergens is not yet clear. Naturally occurring allergens are capable of inducing IL-6 production in dendritic cells (DCs). Whether allergen-induced IL-6 supports a Th9 subtype by increasing IL-9 production, as observed in in vitro studies, or rather favors Th17 differentiation is not finally resolved. Therefore, in the present study we have investigated the impact of IL-6 on the Th9/Th17 balance depending on the predominant cytokine milieu and, additionally, in vivo using a DC-driven murine asthma model. In vitro, IL-6 increases Th9 cells under strong IL-4 and TGF-beta activation, whereas under moderate IL-4 and TGF-beta activation the presence of IL-6 shifts naive CD4+ cells to Th17 cells. To induce allergic airway inflammation, OVA-pulsed DCs from IL-6-deficient or wild-type donors were adoptively transferred into BALB/c mice. Recipients receiving IL-6-producing wild-type DCs showed a significant decrease of Th9- and IL-4-producing Th2 cells but an increase of Th17 cells in lung tissue in comparison with recipients sensitized with IL-6-deficient DCs. Our data suggest that the IL-6-mediated reduction of Th2-related IL-4 leads to a decline of the Th9 immune response and allows Th17 differentiation</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.4049/?jimmunol.1501599</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27574298">PM:27574298</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20160830-SchutzeN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20160830-SchutzeN.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20160830-SchutzeN.xls</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20160830-SchutzeN.xls</url></image-urls></urls><custom2><style face="normal" font="Arial">20160830, Schutze N</style></custom2><misc3><style face="normal" font="Arial">10.4049/?jimmunol.1501599</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,W.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Goleniewska,K.</style></author><author><style face="normal" font="Arial"> Dulek,D.E.</style></author><author><style face="normal" font="Arial"> Toki,S.</style></author><author><style face="normal" font="Arial"> Newcomb,D.C.</style></author><author><style face="normal" font="Arial"> Cephus,J.Y.</style></author><author><style face="normal" font="Arial"> Collins,R.D.</style></author><author><style face="normal" font="Arial"> Wu,P.</style></author><author><style face="normal" font="Arial"> Boothby,M.R.</style></author><author><style face="normal" font="Arial"> Peebles,R.S.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville</style></auth-address><titles><title><style face="normal" font="Arial">Prostaglandin I2 Suppresses Proinflammatory Chemokine Expression, CD4 T Cell Activation, and STAT6-Independent Allergic Lung Inflammation</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="1586" start="1577">1577-1586</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> CXCL12</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Iloprost</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Indomethacin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="Arial">Allergic airway diseases are immune disorders associated with heightened type 2 immune responses and IL-5 and IL-13 production at the site of inflammation. We have previously reported that cyclooxygenase (COX) inhibition by indomethacin augmented allergic airway inflammation in a STAT6-independent manner. However, the key COX product(s) responsible for restraining indomethacin-mediated STAT6-independent allergic inflammation is unknown. In this study, using the mouse model of OVA-induced allergic airway inflammation, we identified that PGI2 receptor (IP) signaling was critical for indomethacin-induced, STAT6-independent proallergic effects. We demonstrated that IP deficiency increased inflammatory cell infiltration, eosinophilia, and IL-5 and IL-13 expression in the lung in a STAT6-independent manner. The augmented STAT6-independent allergic inflammation correlated with enhanced primary immune responses to allergic sensitization and elevated production of multiple inflammatory chemokines (CCL11, CCL17, CCL22, and CXCL12) in the lung after allergen challenge. We also showed that the PGI2 analogue cicaprost inhibited CD4 T cell proliferation and IL-5 and IL-13 expression in vitro, and IP deficiency diminished the stimulatory effect of indomethacin on STAT6-independent IL-5 and IL-13 responses in vivo. The inhibitory effects of PGI2 and the IP signaling pathway on CD4 T cell activation, inflammatory chemokine production, and allergic sensitization and airway inflammation suggest that PGI2 and its analogue iloprost, both Food and Drug Administration-approved drugs, may be useful in treating allergic diseases and asthma. In addition, inhibiting PGI2 signaling by drugs that either block PGI2 production or restrain IP signaling may augment STAT6-independent pathways of allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/?jimmunol.1501063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27456482">PM:27456482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-1577-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-1577-86.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Zhou W</style></custom2><misc3><style face="normal" font="Arial">10.4049/?jimmunol.1501063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chini,L.</style></author><author><style face="normal" font="Arial"> Pacciani,V.</style></author><author><style face="normal" font="Arial"> Corrente,S.</style></author><author><style face="normal" font="Arial"> Monteferrario,E.</style></author><author><style face="normal" font="Arial"> Romiti,M.L.</style></author><author><style face="normal" font="Arial"> Moschese,V.</style></author><author><style face="normal" font="Arial"> Angelini,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatrics, Allergy and Immunology Unit, University Hospital of Tor Vergata, University of Rome Tor Vergata, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Kinetics of in Vitro Response to beta-Lactoglobulin in Children Allergic to and Tolerant of Cow's Milk Protein</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="277" start="275">275-277</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0074</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470650">PM:27470650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-263-77.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-263-77.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Chini L</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0074</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carolino,F.</style></author><author><style face="normal" font="Arial"> Ferreira,A.</style></author><author><style face="normal" font="Arial"> Martinez,J.</style></author><author><style face="normal" font="Arial"> Cernadas,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servico de Imunoalergologia, Centro Hospitalar Sao Joao, E.P.E., Porto, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Identification of Putative Kunitz-Type Proteinase Inhibitor as an Allergenic Protein in Potato</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="264" start="263">263-264</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteinase</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleSB - IMCO - Portugal -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470644">PM:27470644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-263-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-263-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Carolino F</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author><author><style face="normal" font="Arial"> Comite,P.</style></author><author><style face="normal" font="Arial"> Mussap,M.</style></author><author><style face="normal" font="Arial"> De Amici,M.</style></author><author><style face="normal" font="Arial"> Quaglini,S.</style></author><author><style face="normal" font="Arial"> Barocci,F.</style></author><author><style face="normal" font="Arial"> Marseglia,G.L.</style></author><author><style face="normal" font="Arial"> Scala,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, IRCCS-AOU San Martino-IST, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Profiles of Birch Sensitization (Bet v 1, Bet v 2, and Bet v 4) and Oral Allergy Syndrome Across Italy</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="248" start="244">244-248</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 2</style></keyword><keyword><style face="normal" font="Arial"> Bet v 4</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Birch allergy (BA) is a common pollinosis caused by the allergens Bet v 1, Bet v 2, and Bet v 4. Oral allergy syndrome (OAS) is frequently associated with BA. A gradient of sensitization to birch allergen across Europe has been reported. Therefore, this study aimed to investigate the birch sensitization profile, including OAS, across Italy. METHODS: We performed a retrospective study of 854 patients (391 males, mean age 35.9 years, range 18-93 years): 196 patients were recruited in Genoa, 188 in northern Italy, 359 in central Italy, and 111 in southern Italy. Serum IgE to Bet v 1, Bet v 2, and Bet v 4 was assessed, and OAS was analyzed. RESULTS: With respect to the geographical path Genoa-North-Center-South, the frequency of sensitization to Bet v 1 decreased significantly (P&lt;.0001) from Genoa (95.41%) to southern Italy (58.56%). The frequency of sensitization to Bet v 2 increased significantly (P&lt;.0001) from Genoa (6.12%) to southern Italy (52.25%). The frequency of Bet v 4 also increased significantly (P=.0002) from Genoa (6.12%) to southern Italy (14.41%). The distribution of patients with OAS differed significantly across the areas (P&lt;.0001), the most marked difference ranging between 33.5% in Genoa and 76.9% in northern Italy. The frequency of birch allergens correlated with OAS in central Italy only. CONCLUSIONS: The present study demonstrated a significant difference between sensitization to birch and its clinical expression across Italy</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470643">PM:27470643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-244-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-244-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bourrain,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergologie, Hopital Arnaud de Villeneuve</style></auth-address><titles><title><style face="normal" font="Arial">Hevea brasiliensis Rather Than Latex</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="0" start="278">278-0</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergologie</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hevea</style></keyword><keyword><style face="normal" font="Arial"> Hevea brasiliensis</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleSB - IMCO - France -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0067</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470651">PM:27470651</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-278.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-278.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Bourrain JL</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0067</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cardona,R.</style></author><author><style face="normal" font="Arial"> Sanchez,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Reply to "Hevea brasiliensis Rather Than Latex"</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="0" start="278">278-0</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Colombia</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160729IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleSB - IMCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470652">PM:27470652</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-278.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-278.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160729, Cardona R</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0071</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,S.R.</style></author><author><style face="normal" font="Arial"> Park,H.J.</style></author><author><style face="normal" font="Arial"> Park,K.H.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">IgE Sensitization Patterns to Commonly Consumed Foods Determined by Skin Prick Test in Korean Adults</style></title><secondary-title><style face="normal" font="Arial">J Korean Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Korean Med Sci</style></full-title></periodical><pages end="1201" start="1197">1197-1201</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Maize</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Octopus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Squid</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Offending food allergens can vary with regional preferences in food consumption. In this study, we analysed sensitization rates to commonly consumed foods in Korean adults suspected of having food allergy. One hundred and thirty four subjects underwent a skin prick test (SPT) with 55 food allergens, of which 13 were made by our laboratory and the rest were commercially purchased. Of the 134 patients, 73 (54.5%) were sensitized to one or more food allergens. Sensitization to chrysalis was detected most frequently, at a rate of 25.4%. Sensitization rates to other food allergens were as follows: maize grain (13.4%), shrimp (11.9%), almond (11.1%), wheat flour (8.2%), lobster (8.2%), buckwheat (8.2%), mackerel (5.2%), pollack (5.2%), halibut (4.5%), peanut (4.5%), anchovy (4.4%), squid (3.7%), saury (3.0%), common eel (3.0%), yellow corvina (3.0%), hairtail (2.2%), octopus (2.2%), and others. In addition to well-known food allergens, sensitivity to mackerel, chrysalis, pollack, and halibut, which are popular foods in Korea, was observed at high rates in Korean adults. We suggest that the SPT panel for food allergy in Korea should include these allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1598-6357 (Electronic)IS - 1011-8934 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3346/jkms.2016.31.8.1197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27478328">PM:27478328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Korean Med Sci\2016-31-1197-201.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Korean Med Sci\2016-31-1197-201.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Kim SR</style></custom2><misc3><style face="normal" font="Arial">10.3346/jkms.2016.31.8.1197</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jeong,K.Y.</style></author><author><style face="normal" font="Arial"> Son,M.</style></author><author><style face="normal" font="Arial"> Park,J.H.</style></author><author><style face="normal" font="Arial"> Park,K.H.</style></author><author><style face="normal" font="Arial"> Park,H.J.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Hong,C.S.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Cross-Reactivity between Oak and Birch Pollens in Korean Tree Pollinosis</style></title><secondary-title><style face="normal" font="Arial">J Korean Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Korean Med Sci</style></full-title></periodical><pages end="1207" start="1202">1202-1207</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Oak and birch trees belong to Fagales order. Specific IgE to pollen allergens of both trees are frequently found in Korea pollinosis patients. Oak trees which comprise 40% of forest area are common in Korea. However, birch trees are sparse. We compared the allergenicity of pollen extracts of white oak, sawtooth and Mongolian oaks which are prevalent species in Korea, with the pollen extract of birch. The cross-reactivity of four pollen extracts was examined with pooled sera of 12 patients by ELISA, immunoblotting and CAP inhibitions. A protein of 17 kDa, putatively homologous to a major birch allergen Bet v 1, displayed strong IgE reactivity from white oak and sawtooth oak pollen extract but not from Mongolian oak pollen. Notably, a 23-kDa protein from sawtooth and white oaks showed strong IgE reactivity and inhibited by Bet v 1. IgE binding to white oak was inhibited a maximum of 94.6% by white oak, 93.4% by sawtooth oak, 83.2% by Mongolian oak, and 68.8% by birch. Furthermore, sawtooth oak, white oak, and Mongolian oak extracts were able to inhibit up to 78.5%, 76.6% and 67.3% of IgE binding to birch extract, while birch extract itself inhibited up to 94.3%. Specific IgE to Bet v 1 was inhibited a maximum of 79.1% by sawtooth oak, 77.4% by white oak, and 72.7% by Mongolian oak, while 81.5% inhibition was shown by birch. Bet v 1 was able to partially inhibit its homologous molecules from sawtooth oak and white oak in immunoblotting. Birch pollen extract was found to be cross-reactive primarily with Bet v 1-homologous allergen from oak pollens in Korea pollinosis patients. Considering the sparseness of birch tree in Korea, oak, especially sawtooth oak may be the main cause of tree pollinosis in Korea, rather than birch</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1598-6357 (Electronic)IS - 1011-8934 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3346/jkms.2016.31.8.1202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27478329">PM:27478329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Korean Med Sci\2016-31-1202-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Korean Med Sci\2016-31-1202-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Jeong KY</style></custom2><misc3><style face="normal" font="Arial">10.3346/jkms.2016.31.8.1202</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Percopo,C.M.</style></author><author><style face="normal" font="Arial"> Brenner,T.A.</style></author><author><style face="normal" font="Arial"> Ma,M.</style></author><author><style face="normal" font="Arial"> Kraemer,L.S.</style></author><author><style face="normal" font="Arial"> Hakeem,R.M.</style></author><author><style face="normal" font="Arial"> Lee,J.J.</style></author><author><style face="normal" font="Arial"> Rosenberg,H.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inflammation Immunobiology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA</style></auth-address><titles><title><style face="normal" font="Arial">SiglecF+Gr1hi eosinophils are a distinct subpopulation within the lungs of allergen-challenged mice</style></title><secondary-title><style face="normal" font="Arial">J Leukoc Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Leukoc Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Differential expression</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="8" Year="2016">2016/8/16</year></dates><abstract><style face="normal" font="Arial">Although eosinophils as a group are readily identified by their unique morphology and staining properties, flow cytometry provides an important means for identification of subgroups based on differential expression of distinct surface Ags. Here, we characterize an eosinophil subpopulation defined by high levels of expression of the neutrophil Ag Gr1 (CD45+CD11c-SiglecF+Gr1hi). SiglecF+Gr1hi eosinophils, distinct from the canonical SiglecF+Gr1- eosinophil population, were detected in allergen-challenged wild-type and granule protein-deficient (EPX-/- and MBP-1-/-) mice, but not in the eosinophil-deficient DeltadblGATA strain. In contrast to Gr1+ neutrophils, which express both cross-reacting Ags Ly6C and Ly6G, SiglecF+Gr1hi eosinophils from allergen-challenged lung tissue are uniquely Ly6G+ Although indistinguishable from the more-numerous SiglecF+Gr1- eosinophils under light microscopy, FACS-isolated populations revealed prominent differences in cytokine contents. The lymphocyte-targeting cytokines CXCL13 and IL-27 were identified only in the SiglecF+Gr1hi eosinophil population (at 3.9 and 4.8 pg/106 cells, respectively), as was the prominent proinflammatory mediator IL-13 (72 pg/106 cells). Interestingly, bone marrow-derived (SiglecF+), cultured eosinophils include a more substantial Gr1+ subpopulation ( approximately 50%); Gr1+ bmEos includes primarily a single Ly6C+ and a smaller, double-positive (Ly6C+Ly6G+) population. Taken together, our findings characterize a distinct SiglecF+Gr1hi eosinophil subset in lungs of allergen-challenged, wild-type and granule protein-deficient mice. SiglecF+Gr1hi eosinophils from wild-type mice maintain a distinct subset of cytokines, including those active on B and T lymphocytes. These cytokines may facilitate eosinophil-mediated immunomodulatory responses in the allergen-challenged lung as well as in other distinct microenvironments</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 1938-3673 (Electronic)IS - 0741-5400 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1189/jlb.3A0416-166R</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27531929">PM:27531929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Leukoc Biol\20160817-PercopoCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Leukoc Biol\20160817-PercopoCM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Percopo CM</style></custom2><misc3><style face="normal" font="Arial">10.1189/jlb.3A0416-166R</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,C.H.</style></author><author><style face="normal" font="Arial"> Bui,T.T.</style></author><author><style face="normal" font="Arial"> Piao,C.H.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author><author><style face="normal" font="Arial"> Shon,D.H.</style></author><author><style face="normal" font="Arial"> Han,E.H.</style></author><author><style face="normal" font="Arial"> Kim,H.T.</style></author><author><style face="normal" font="Arial"> Chai,O.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Anatomy, Chonbuk National University Medical School , Jeonju, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Rosae Multiflorae Fructus Hot Water Extract Inhibits a Murine Allergic Asthma Via the Suppression of Th2 Cytokine Production and Histamine Release from Mast Cells</style></title><secondary-title><style face="normal" font="Arial">J Med Food</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Food</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">Mast cell-mediated anaphylactic reactions are involved in many allergic diseases, including asthma and allergic rhinitis. In Korea, where it has been used as a traditional medicine, Rosae Multiflorae fructus (RMF) is known to have potent antioxidative, analgesic, and anti-inflammatory activities and to have no obvious acute toxicity. However, its specific effect on asthma is still unknown. In this study, we evaluated whether or not RMF hot water extracts (RMFW) could inhibit ovalbumin (OVA)-induced allergic asthma and evaluated compound 48/80-induced mast cell activation to elucidate the mechanisms of asthma inhibition by RMFW. Oral administration of RMFW decreased the number of eosinophils and lymphocytes in the lungs of mice challenged by OVA and downregulated histological changes such as eosinophil infiltration, mucus accumulation, goblet cell hyperplasia, and collagen fiber deposits. In addition, RMFW significantly reduced T helper 2 cytokines, TNF-alpha, IL-4, and IL-6 levels in the BAL fluid of mice challenged by OVA. Moreover, RMFW suppressed compound 48/80-induced rat peritoneal mast cell degranulation and inhibited histamine release from mast cells induced by compound 48/80 in a dose-dependent manner. These results suggest that RMFW may act as an antiallergic agent by inhibitingTh2 cytokine production from Th2 cells and histamine release from mast cells, and could be used as a therapy for patients with Th2-mediated or mast cell-mediated allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1557-7600 (Electronic)IS - 1096-620X (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1089/jmf.2016.3736</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27574849">PM:27574849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Food\20160830-SongCH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Food\20160830-SongCH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Song CH</style></custom2><misc3><style face="normal" font="Arial">10.1089/jmf.2016.3736</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kirkeleit,J.</style></author><author><style face="normal" font="Arial"> Hollund,B.E.</style></author><author><style face="normal" font="Arial"> Riise,T.</style></author><author><style face="normal" font="Arial"> Eduard,W.</style></author><author><style face="normal" font="Arial"> Bratveit,M.</style></author><author><style face="normal" font="Arial"> Storaas,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Occupational Medicine , Haukeland University Hospital , Bergen , Norway</style></auth-address><titles><title><style face="normal" font="Arial">Bakers' Exposure To Flour Dust</style></title><secondary-title><style face="normal" font="Arial">J Occup Environ Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Occup Environ Hyg</style></full-title></periodical><pages end="91" start="81">81-91</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> baker</style></keyword><keyword><style face="normal" font="Arial"> Bakers</style></keyword><keyword><style face="normal" font="Arial"> Bakery</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dough</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Occupational rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: We aimed to characterize bakers' personal exposure to airborne flour dust in respect to the health-related aerosol fractions inhalable, extrathoracic and thoracic dust, and to examine possible production-related determinants of dust exposure. METHODS: Sixty-eight bakers from 7 bakeries in Bergen, Norway (2009-2012) participated in the exposure assessment, comprising full-shift personal samples of inhalable dust (n = 107) and thoracic dust (n = 61). The relation between possible determinants and exposure was estimated using mixed effects models, while associations between the various aerosol fractions across task groups and type of bakeries were described by Pearson's correlation coefficients. RESULTS: Bakers overall geometric mean personal exposure to inhalable, extrathoracic and thoracic dust were 2.6 mg/m3 (95% CI: 2.0, 3.2), 2.2 mg/m3 (95% CI: 1.9, 2.7) and 0.33 mg/m3 (95% CI 0.3, 0.4), respectively. A total of 29% of the measurements of inhalable dust were above the Norwegian Occupational Exposure Limit of 3 mg/m3. The exposure variability of inhalable dust could not be explained by any of the examined production-related determinants, while the daily production volume explained 18% of the variance in thoracic dust. Overall, the thoracic dust represented 15% of the inhalable dust, being rather stable across the production-related determinants. The overall correlation between inhalable and thoracic dust was nevertheless moderate (r = 0.52, p&lt;0.001), with the highest correlation for craft bakers (r = 0.62) and no correlation during dough forming (r = 0.01). CONCLUSION: Bakers are exposed to flour dust at a level that most likely represents an excess risk of developing chronic diseases of the respiratory system, and a decrease of present exposure level is imperative. Extrathoracic dust - likely the most relevant sub-fraction in respect to flour-induced sensitization and occupational rhinitis - represented the main proportion of the measured inhalable dust. The variation in correlation coefficients between the dust fractions across bakery types and task groups underlines the need of more knowledge about how these aerosol fractions are distributed across the production process and bakery types</style></abstract><notes><style face="normal" font="Arial">DA - 20160819IS - 1545-9632 (Electronic)IS - 1545-9624 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.1080/15459624.2016.1225156</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27540715">PM:27540715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Occup Environ Hyg\20160819-KirkeleitJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Occup Environ Hyg\20160819-KirkeleitJ.pdf</url></text-urls><image-urls><url ppv-ref="no">pdfpdf era presto - 18 mesi</url></image-urls></urls><custom2><style face="normal" font="Arial">20160819, Kirkeleit J</style></custom2><misc3><style face="normal" font="Arial">10.1080/15459624.2016.1225156</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zheng,X.</style></author><author><style face="normal" font="Arial"> Yao,J.</style></author><author><style face="normal" font="Arial"> Li,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Corneal Diseases, Shanxi Eye Hospital, Fu Dong Street No. 100, Xinghualing District, Taiyuan City, Shanxi Province, ChinaDepartment of Corneal Diseases, Shanxi Eye Hospital, Fu Dong Street No. 100, Xinghualing District, Taiyuan City, Shanxi Province, ChinaDepartment of Corneal Diseases, Shanxi Eye Hospital, Fu Dong Street No. 100, Xinghualing District, Taiyuan City, Shanxi Province, China</style></auth-address><titles><title><style face="normal" font="Arial">Expression of TSLP and Downstream Molecules IL-4, IL-5, and IL-13 on the Eye Surface of Patients with Various Types of Allergic Conjunctivitis</style></title><secondary-title><style face="normal" font="Arial">J Ophthalmol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ophthalmol</style></abbr-1></periodical><pages end="" start="5072781">5072781-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Corneal Diseases</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> RNA extraction</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> tear</style></keyword><keyword><style face="normal" font="Arial"> Tears</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background. The pathogenesis of allergic conjunctivitis has not been clearly established. Moreover, previous studies fail to consider human models of allergic conjunctivitis. This study investigated the expression of thymic stromal lymphopoiet in TSLP and its downstream molecules in conjunctival scrappings and tear. Methods. This cross-sectional study compares patients with vernal keratoconjunctivitis (VKC), seasonal allergic conjunctivitis (SAC), and perennial allergic conjunctivitis (PAC) with normal controls. There are 80 people recorded in Shanxi Eye Hospital. Increasingly, 20 are with VKC, 20 are with SAC, 20 are with PAC, and the remaining 20 are normal controls. Conjunctiva were harvested for total RNA extraction and gene expression by real-time polymerase chain reaction. Epithelial cells were collected to make pathological sections for immunohistochemical staining. Human tears were evaluated by Luminex microbead assay. A P value less than 0.05 from Dunnett's post hoc test in SPSS means a statistical significant distinction. Results. Positive expression in conjunctival cells of patients with allergic conjunctivitis. The expression of TSLP and IL-4, IL-5, and IL-13 mRNA shows a statistically significant difference (P &lt; 0.05). TSLP and IL-4, IL-5, and IL-13 concentrations show a statistically significant difference (P &lt; 0.01). Conclusions. This study suggests that TSLP and downstream molecules are expressed in patients with various types of allergic conjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160809IS - 2090-004X (Print)IS - 2090-004X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/5072781</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27504196">PM:27504196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ophthalmol\2016-2016-5072781.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ophthalmol\2016-2016-5072781.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160809, Zheng X</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/5072781</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khoo,P.</style></author><author><style face="normal" font="Arial"> Boyce,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Royal Children's Hospital, Melbourne.</style></auth-address><titles><title><style face="normal" font="Arial">Does early introduction of allergenic foods decrease the risk of food allergies?</style></title><secondary-title><style face="normal" font="Arial">J Paediatr Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Paediatr Child Health</style></full-title></periodical><pages end="" start="850">850-</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1440-1754 (Electronic)IS - 1034-4810 (Linking)LA - engPT - Journal ArticleSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/jpc.13279</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27535887">PM:27535887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Paediatr Child Health\2016-52-850.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Paediatr Child Health\2016-52-850.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Khoo P</style></custom2><misc3><style face="normal" font="Arial">10.1111/jpc.13279</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marsili,M.</style></author><author><style face="normal" font="Arial"> Di Battista,C.</style></author><author><style face="normal" font="Arial"> Chiarelli,F.</style></author><author><style face="normal" font="Arial"> Breda,L.</style></author><author><style face="normal" font="Arial"> Ceccherini,I.</style></author><author><style face="normal" font="Arial"> Gattorno,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics University of Chieti Chieti, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Neonatal-Onset Urticaria and Fever</style></title><secondary-title><style face="normal" font="Arial">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jpeds.2016.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27514240">PM:27514240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr\20160812-MarsiliM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr\20160812-MarsiliM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Marsili M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jpeds.2016.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vanderhoof,J.</style></author><author><style face="normal" font="Arial"> Moore,N.</style></author><author><style face="normal" font="Arial"> de Boissieu,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Boston Children's Hospital, Boston MA daggerMead Johnson Nutrition, Evansville, IN 47712 USA double daggerPrivate Practice, 104 Avenue Victor Hugo, Boulogne, France</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of An Amino Acid-Based Formula in Infants Not Responding to Extensively Hydrolyzed Protein Formula</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Gain</style></keyword><keyword><style face="normal" font="Arial"> Weight Loss</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="12" Month="8" Year="2016">2016/8/12</year></dates><abstract><style face="normal" font="Arial">Nearly 2-3% of infants and children under the age of 3 have confirmed cow's milk protein allergy (CMPA) with multiple clinical presentations including atopic dermatitis (AD), diarrhea, and vomiting/spitting up. Although most infants with CMPA experience clinical improvement with the use of an extensively hydrolyzed (EH) formula, highly sensitive infants may require an amino acid based formula. In this observational, prospective study, 30 infants (1-12 months of age) with a history of weight loss and persistent allergic manifestations while on an EH formula were provided an amino acid based formula for 12 weeks. Mean weight gain (z-score change) improved +0.43 +/- 0.28 (mean +/- Standard Deviation) following the 12 week feeding period. Improvement was observed for many allergic symptoms including significant decreases in AD severity (p = 0.02). These results indicate the new amino acid based infant formula supported healthy weight gain and improvement in allergic manifestations in infants not responding to EH formulas.This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001374</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27526059">PM:27526059</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20160815-VanderhoofJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20160815-VanderhoofJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Vanderhoof J</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001374</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Monceau,K.</style></author><author><style face="normal" font="Arial"> Bonnard,O.</style></author><author><style face="normal" font="Arial"> Thiery,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Vespa velutina: a new invasive predator of honeybees in Europe</style></title><secondary-title><style face="normal" font="Arial">J Pest Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pest Sci</style></full-title></periodical><pages end="16" start="1">1-16</pages><volume><style face="normal" font="Arial">87</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--Allergeni Nativi</style></keyword><keyword><style face="normal" font="Arial"> 1--Imenotteri</style></keyword><keyword><style face="normal" font="Arial"> Alien species</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> beekeeping</style></keyword><keyword><style face="normal" font="Arial"> Biological invasion</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Ecosystem</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> invasions</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reproduction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword></keywords><dates><year Day="0" Month="0" Year="2014">2014</year></dates><isbn><style face="normal" font="Arial">1612-4766</style></isbn><abstract><style face="normal" font="Arial">The yellow-legged hornet (Vespa velutina) is the first invasive Vespidae predator of honeybees to be accidentally introduced into Europe from Asia. In the current pollinator decline, V. velutina is an additional stressor for honeybees and other pollinators. Although V. velutina contributes to the loss of honeybee colonies, little is known about its biology and behaviour both in the native and in the invaded area. Here, we review the current knowledge of this species and describe its life cycle and life history traits (reproduction, overwintering, foraging and dispersal) in the light of the biology of other Vespidae. We also review the impact of this species on ecosystems, on the economics of beekeeping, and on human health (this species being potentially deadly for allergic people). Based on this information and on previous worldwide experiences with Vespidae invasions, we propose key research topics for the development of effective management plans. We identify methods to limit the impact and proliferation of V. velutina in Europe that are based on nest destruction, trapping, population genetics, and biological control. In our opinion, research effort on the means to detect and destroy V. velutina nests at an early stage is required in order to short-circuit the colony cycle and thus limit both its impact on honeybees and its expansion through Europe. Finally, we discuss the impact of this biological invasion on the development of methods that should be used to manage alien species in the future</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10340-013-0537-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10340-013-0537-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pest Sci\2014-87-1-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pest Sci\2014-87-1-16.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">2AR</style></custom1><custom2><style face="normal" font="Arial">20140501, Monceau K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10340-013-0537-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,J.O.</style></author><author><style face="normal" font="Arial"> Sung,D.</style></author><author><style face="normal" font="Arial"> Park,S.H.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Shon,D.H.</style></author><author><style face="normal" font="Arial"> Ahn,K.</style></author><author><style face="normal" font="Arial"> Han,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, KoreaDepartment of Food Science and Technology, College of Engineering, Ewha Womans University, Seoul, KoreaEnvironmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, KoreaEnvironmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, KoreaEnvironmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, KoreaKorea Food Research Institute, Gyeonggi, KoreaEnvironmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, KoreaDepartment of Medical Science, Sungkyunkwan University School of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effect of acid treatment on allergenicity of peanut and egg</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetic Acid</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Many food experts have studied various treatments or processing techniques in order to develop hypoallergenic foods. In a previous study, acid treatment dramatically mitigated the allergenicity of peanut, especially Ara h 2. RESULTS: Gel electrophoresis showed that most protein bands of acid treated peanut were not detected, but protein bands of egg white became weaker and broader by acid treatment. In immunolabeling using a rabbit antibody, the antigenicity against ovalbumin or ovomucoid in acid treated egg white was decreased but the antigenicity against Ara h 1 or Ara h 2 in peanut treated with pH 2 acetic acid was completely undetected. The allergenicity of ovalbumin and peanut fell significantly to 1/1022 and 1/5380, respectively, when measured as IC50 in the sample treated with pH 2.0 acetic acid. CONCLUSION: This study showed that acid treatment was more effective in peanut and barely effective in ovomucoid. This may contribute to the development of hypoallergenic food and clinical management of food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27571929">PM:27571929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20160830-LeeJO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20160830-LeeJO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Lee JO</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rok,T.</style></author><author><style face="normal" font="Arial"> Rokita,E.</style></author><author><style face="normal" font="Arial"> Taton,G.</style></author><author><style face="normal" font="Arial"> Guzik,T.</style></author><author><style face="normal" font="Arial"> Sliwa,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Thermographic imaging as alternative method in allergy diagnosis</style></title><secondary-title><style face="normal" font="Arial">J Therm Anal Calorim</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Therm Anal Calorim</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Forearm</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1588-2926</style></isbn><abstract><style face="normal" font="Arial">Allergen sensitization is being diagnosed by commonly available methods in clinical practice</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çöskin prick tests (SPTs) and specific immunoglobulin E test (sIgE). Recently, a new thermographic (TH) method for the assessment of SPT was developed, and it was demonstrated that the TH measurements of forearm temperature distribution during SPT, supported by a mathematical model, offer a new quantification method of allergen-induced skin reactions. The aim of this study is a comprehensive comparison of the TH method with SPT and sIgE techniques. The studies were performed for a group of 51 patients. The SPT and sIgE examinations were done in a routine way. For TH analyses, set of thermograms of both forearms were acquired after prick and analyzed with the use of developed software. All results were converted into categorized scale for comparison. The collected results indicate high correlation coefficients between methods equal to 0.76</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.99. Sensitivity and accuracy of TH assessment in respect of both SPT and sIgE methods is at good level (0.72</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.93). Acceptable level of specificity 0.60</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.88 was also achieved for most allergic responses. Excellent agreement between SPT and sIgE methods was observed which makes the TH assessment competitive. Due to higher precision and sensitivity of digital infrared technology, possibility of making error in diagnosis is significantly reduced. Additional advantage of the TH method relies on an estimation of the skin reactivity which allows highlighting the hypersensitivity patients and automatic correction of the diagnosis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10973-016-5676-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10973-016-5676-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Therm Anal Calorim\20160823-RokT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Therm Anal Calorim\20160823-RokT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160823, Rok T</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10973-016-5676-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kebbe,J.</style></author><author><style face="normal" font="Arial"> Mador,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University at Buffalo, The State University of New York, Buffalo, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Exophiala pisciphila: a novel cause of allergic bronchopulmonary mycosis</style></title><secondary-title><style face="normal" font="Arial">J Thorac Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Thorac Dis</style></full-title></periodical><pages end="E541" start="E538">E538-E541</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Buffalo</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Plague</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary mycosis (ABPM) is a hypersensitivity reaction to fungal antigens, which may particularly plague uncontrolled asthmatics. Non-aspergillus fungal organisms may be implicated and may elicit a more severe immunologic response. Exophiala pisciphila, a marine organism, has not been reported as a culprit yet. However, this report indicates it may be implicated in unrelenting symptoms in a severe asthmatic patient who had become dependent on corticosteroids. Proper identification and adequate therapy of this organism led to complete resolution of respiratory symptoms, with adequate subsequent control of the asthma. ABPM may complicate asthma and lead to a lack of its control. Proper awareness, testing and treatment of non-aspergillus pulmonary mycosis is essential to proper asthma care and beneficial for its control</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 2072-1439 (Print)IS - 2072-1439 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.21037/jtd.2016.05.77</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499992">PM:27499992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Thorac Dis\2016-8-E538-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Thorac Dis\2016-8-E538-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Kebbe J</style></custom2><misc3><style face="normal" font="Arial">10.21037/jtd.2016.05.77</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boylan,B.</style></author><author><style face="normal" font="Arial"> Rice,A.S.</style></author><author><style face="normal" font="Arial"> Neff,A.T.</style></author><author><style face="normal" font="Arial"> Manco-Johnson,M.J.</style></author><author><style face="normal" font="Arial"> Kempton,C.L.</style></author><author><style face="normal" font="Arial"> Miller,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia</style></auth-address><titles><title><style face="normal" font="Arial">Survey of the Anti-Factor IX Immunoglobulin Profiles in Patients With Hemophilia B Using a Fluorescence-Based Immunoassay</style></title><secondary-title><style face="normal" font="Arial">J Thromb Haemost</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Thromb Haemost</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth defects</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Centers for Disease Control</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Factor IX</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Hemophilia A</style></keyword><keyword><style face="normal" font="Arial"> Hemophilia B</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hemophilia B (HB) is an inherited bleeding disorder caused by the absence or dysfunction of coagulation factor IX (FIX). A subset of patients who have HB develop neutralizing alloantibodies (inhibitors) against FIX following infusion therapy. HB prevalence and the proportion of patients who develop inhibitors are much lower than that of hemophilia A (HA), which makes studies of inhibitors in patients with HB challenging due to the limited availability of samples. As a result, there is a knowledge gap regarding HB inhibitors. OBJECTIVE: Evaluate the largest group of inhibitor positive HB patients studied to date to assess the relationship between anti-FIX antibody profiles and inhibitor formation METHODS: A fluorescence immunoassay (FLI) was used to detect anti-FIX antibodies in plasma samples from 37 patients with HB RESULTS: Assessments of antibody profiles showed that anti-FIX IgG1-4 , IgA, and IgE were detected significantly more often in patients with a positive Nijmegen-Bethesda Assay (NBA). All NBA-positive samples were positive for IgG4 . Anti-FIX IgG4 demonstrated a strong correlation with the NBA, while correlations were significant, yet more moderate, for anti-FIX IgG1-2 and IgA CONCLUSIONS: The anti-FIX antibody profile in HB patients who develop inhibitors is diverse and correlates well with the NBA across immunoglobulin (sub)class, and anti-FIX IgG4 is particularly relevant to functional inhibition. The anti-FIX FLI may serve as a useful tool to confirm the presence of antibodies in patients who have low positive NBA results and to more clearly define, predict, and treat alloantibody formation against FIX. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1538-7836 (Electronic)IS - 1538-7836 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/jth.13438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27501440">PM:27501440</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Thromb Haemost\20160808-BoylanB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Thromb Haemost\20160808-BoylanB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Boylan B</style></custom2><misc3><style face="normal" font="Arial">10.1111/jth.13438</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Acar,M.</style></author><author><style face="normal" font="Arial"> Sutcu,M.</style></author><author><style face="normal" font="Arial"> Umur,O.</style></author><author><style face="normal" font="Arial"> Akturk,H.</style></author><author><style face="normal" font="Arial"> Torun,S.H.</style></author><author><style face="normal" font="Arial"> Tamay,Z.</style></author><author><style face="normal" font="Arial"> Salman,N.</style></author><author><style face="normal" font="Arial"> Somer,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Infectious Diseases and Clinical Immunology, Istanbul University Faculty of Medicine, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Acquired Immune Deficiency Syndrome in Differential Diagnosis of Hyper-IgE-Immunoglobulinemia: Pediatric Case Report</style></title><secondary-title><style face="normal" font="Arial">J Trop Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Trop Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Hiv</style></keyword><keyword><style face="normal" font="Arial"> HIV infection</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> Hypergammaglobulinemia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymphopenia</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Loss</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="10" Month="8" Year="2016">2016/8/10</year></dates><abstract><style face="normal" font="Arial">Acquired immune deficiency syndrome can be encountered with hypereosinophilia and hyperimmunoglobulin E (hyper-IgE) values, though these levels are rarely so high to be compared with hyperimmunoglobulin E syndrome. A 9-year-old boy presented with the complaint of fatigue, weakness, weight loss and generalized pruritic rash lasting for a year. He had frequent respiratory tract infections, wheezing episodes and urticarial skin lesions before that. On admission, he was cachectic and he had generalized lymphadenopathy, hepatosplenomegaly, oral moniliasis and pruritic rash all over his body. Laboratory evaluation revealed marked lymphopenia and hypergammaglobulinemia with extremely high IgE values (IgE: 59 300 kU/l). He was diagnosed with stage 4 human immunodeficiency virus (HIV) infection and started on antiretroviral treatment. In conclusion, HIV infection can be presented with increased IgE values</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1465-3664 (Electronic)IS - 0142-6338 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1093/tropej/fmw053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27516418">PM:27516418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Trop Pediatr\20160812-AcarM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Trop Pediatr\20160812-AcarM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Acar M</style></custom2><misc3><style face="normal" font="Arial">10.1093/tropej/fmw053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Myles,I.A.</style></author><author><style face="normal" font="Arial"> Williams,K.W.</style></author><author><style face="normal" font="Arial"> Reckhow,J.D.</style></author><author><style face="normal" font="Arial"> Jammeh,M.L.</style></author><author><style face="normal" font="Arial"> Pincus,N.B.</style></author><author><style face="normal" font="Arial"> Sastalla,I.</style></author><author><style face="normal" font="Arial"> Saleem,D.</style></author><author><style face="normal" font="Arial"> Stone,K.D.</style></author><author><style face="normal" font="Arial"> Datta,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bacterial Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Maryland, USA</style></auth-address><titles><title><style face="normal" font="Arial">Transplantation of human skin microbiota in models of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Baths</style></keyword><keyword><style face="normal" font="Arial"> Bleach</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Gram-Negative Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune activation</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="7" Month="7" Year="2016">2016/7/7</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is characterized by reduced barrier function, reduced innate immune activation, and susceptibility to Staphylococcus aureus. Host susceptibility factors are suggested by monogenic disorders associated with AD-like phenotypes and can be medically modulated. S. aureus contributes to AD pathogenesis and can be mitigated by antibiotics and bleach baths. Recent work has revealed that the skin microbiome differs significantly between healthy controls and patients with AD, including decreased Gram-negative bacteria in AD. However, little is known about the potential therapeutic benefit of microbiome modulation. To evaluate whether parameters of AD pathogenesis are altered after exposure to different culturable Gram-negative bacteria (CGN) collected from human skin, CGN were collected from healthy controls and patients with AD. Then, effects on cellular and culture-based models of immune, epithelial, and bacterial function were evaluated. Representative strains were evaluated in the MC903 mouse model of AD. We found that CGN taken from healthy volunteers but not from patients with AD were associated with enhanced barrier function, innate immunity activation, and control of S. aureus. Treatment with CGN from healthy controls improved outcomes in a mouse model of AD. These findings suggest that a live-biotherapeutic approach may hold promise for treatment of patients with AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 2379-3708 (Print)IS - 2379-3708 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.86955</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27478874">PM:27478874</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\20160801-MylesIA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\20160801-MylesIA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Myles IA</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.86955</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Karimian,Z.</style></author><author><style face="normal" font="Arial"> Whitley,C.B.</style></author><author><style face="normal" font="Arial"> Rudser,K.D.</style></author><author><style face="normal" font="Arial"> Utz,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Delayed Infusion Reactions to Enzyme Replacement Therapies</style></title><secondary-title><style face="normal" font="Arial">JIMD Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JIMD Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reactions</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="8" Year="2016">2016/8/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There are currently ten intravenous enzyme replacement therapy (ERT) products available for the treatment of eight different lysosomal diseases (LD) in the USA. Additional ERT products are in clinical trials. The most common ERT adverse events are infusion reactions (IR). While IR are often defined as hypersensitivity or anaphylactoid reactions occurring concurrently with (i.e., during) infusion administration (CIR), there exists the potential for delayed infusion reactions (DIR), which present after completion of infusion administration. HYPOTHESIS: Concurrent infusion reactions (CIR) are not the only infusion reactions associated with enzyme therapy. METHODS: This study evaluated the occurrence of infusion reactions in 46 patients with LD who had received ERT for a minimum of 2 years. Infusion reactions were evaluated according to symptoms, time of onset, and duration of reactions. The frequency of infusion reactions with each ERT product was compared to that reported in the FDA-approved product package insert. RESULTS AND CONCLUSIONS: In this study, DIR were observed and occurred as often as CIR in the study population, despite not being characterized or reported in most ERT product package inserts. Effective methods for managing DIR and CIR differed, thus emphasizing the importance of monitoring for both types of infusion reactions in order to optimize outcomes for patients using ERT</style></abstract><notes><style face="normal" font="Arial">DA - 20160825IS - 2192-8304 (Print)IS - 2192-8304 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/8904_2016_8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27557812">PM:27557812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JIMD Rep\20160825-KarimianZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JIMD Rep\20160825-KarimianZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Karimian Z</style></custom2><misc3><style face="normal" font="Arial">10.1007/8904_2016_8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawarai,S.</style></author><author><style face="normal" font="Arial"> Fujimoto,A.</style></author><author><style face="normal" font="Arial"> Nozawa,G.</style></author><author><style face="normal" font="Arial"> Kanemaki,N.</style></author><author><style face="normal" font="Arial"> Madarame,H.</style></author><author><style face="normal" font="Arial"> Shida,T.</style></author><author><style face="normal" font="Arial"> Kiuchi,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of weekly bathing in allergic dogs with methicillin-resistant Staphylococcal colonization</style></title><secondary-title><style face="normal" font="Arial">Jpn J Vet Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Jpn J Vet Res</style></abbr-1></periodical><pages end="158" start="153">153-158</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">We evaluated the efficacy of weekly bathing in reducing methicillin-resistant Staphylococcus (MRS) colonization in canine allergic dermatitis in a pilot clinical trial. Six dogs with allergic dermatitis controlled by prescription medications were treated with weekly bathing for 1 month. The Canine Atopic Dermatitis Extent and Severity Index version 3 (CADESI-03) and pruritus scores and frequency of mecA-positive Staphylococcus spp. isolated from three body sites between weeks 0 and 4 were compared. There was no significant difference in CADESI-03 scores with bathing, whereas the pruritus scores were significantly reduced (p &lt; 0.05). Furthermore, MRS frequency was decreased in four of the six dogs (p &lt; 0.05). In conclusion, weekly bathing should be considered for reducing MRS colonization in canine allergic dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160810IS - 0047-1917 (Print)IS - 0047-1917 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27506090">PM:27506090</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Jpn J Vet Res\2016-64-153-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Jpn J Vet Res\2016-64-153-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160810, Kawarai S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">von Weikersthal,G.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[New chances in allergy risk: prevention by breastfeeding, HA food and care from the beginning]</style></title><secondary-title><style face="normal" font="Arial">Kinderkrankenschwester</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Kinderkrankenschwester</style></full-title></periodical><pages end="168" start="165">165-168</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> Double-Blind Method</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> Infant,Newborn</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 0723-2276 (Print)IS - 0723-2276 (Linking)LA - gerPT - Journal ArticlePT - Randomized Controlled TrialRN - 0 (Protein Hydrolysates)SB - NCO - Germany -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27430051">PM:27430051</url></web-urls></urls><custom2><style face="normal" font="Arial">20160719, von Weikersthal GF</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,H.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Seo,J.H.</style></author><author><style face="normal" font="Arial"> Oh,K.H.</style></author><author><style face="normal" font="Arial"> Cho,Y.H.</style></author><author><style face="normal" font="Arial"> Yoo,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Konyang University, Daejeon 35365, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Induction of Oral Tolerance by Gamma-Irradiated Ovalbumin Administration</style></title><secondary-title><style face="normal" font="Arial">Korean J Food Sci Anim Resour</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Korean J Food Sci Anim Resour</style></full-title></periodical><pages end="18" start="14">14-18</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Induction of oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> irradiated</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Peripheral Tolerance</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Oral administration of soluble antigen can induce peripheral tolerance to the antigen. This study was conducted to evaluate whether gamma-irradiated ovalbumin (OVA) can induce oral tolerance. To investigate this, we administrated intact or irradiated OVA to mice, induced allergic response using intact OVA and alum, then compared humoral and cellular immune responses. Mice treated with gammairradiated OVA had less OVA-specific IgE compared with those who were administered intact OVA. There was no difference in levels of OVA-specific IgG+A+M, IgG1, and IgG2a. Splenocytes of mice administered irradiated OVA showed similar OVA-specific T cell proliferation and secretion of IFN-gamma and IL-4. However, there was an increase in IL-2 and a decrease of IL-6 secretion in mice treated with irradiated OVA. These results indicate that gamma-irradiated OVA have similar effects to intact OVA on antigen tolerance</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1225-8563 (Print)IS - 1225-8563 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5851/kosfa.2016.36.1.14</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499658">PM:27499658</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Food Sci Anim Resour\2016-36-14-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Food Sci Anim Resour\2016-36-14-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Yang H</style></custom2><misc3><style face="normal" font="Arial">10.5851/kosfa.2016.36.1.14</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gulen,T.</style></author><author><style face="normal" font="Arial"> Bjorkander,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Karolinska Universitetssjukhuset, Huddinge - Lung- och Allergikliniken, Stockholm, Sweden Karolinska Universitetssjukhuset, Huddinge - Lung- och Allergikliniken, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">[Insektsgiftallergi - diagnostiken kan vara svår men bra behandling finns]</style></title><secondary-title><style face="normal" font="Arial">Lakartidningen</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lakartidningen</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">113</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic testing</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Bee and wasp stings can cause allergic reactions. Although the local reactions are more frequent, anaphylaxis due to insect stings can be potentially fatal. Rapid recognition of anaphylaxis is therefore critical and reactions should immediately be treated with i.m. adrenaline. Patients having experienced anaphylaxis should be referred to an allergist for diagnostic evaluation and possible venom-immunotherapy (VIT). The clinical history is essential in diagnosis of venom allergy as the test results are not always reliable. Diagnostic testing with venom components might be beneficial in appropriate patients. The analysis of serum tryptase from the acute episode can be crucial. Mastocytosis is associated in about 8 percent of patients with severe anaphylaxis from insect stings and should be considered in the differential diagnosis. VIT is indicated for patients with a history of anaphylaxis and is effective in preventing future anaphylaxis from Hymenoptera stings</style></abstract><notes><style face="normal" font="Arial">DA - 20160810IS - 1652-7518 (Electronic)IS - 0023-7205 (Linking)LA - swePT - English AbstractPT - Journal ArticleSB - IMCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27505851">PM:27505851</url></web-urls></urls><custom2><style face="normal" font="Arial">20160810, Gulen T</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Younis,R.T.</style></author><author><style face="normal" font="Arial"> Ahmed,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Otolaryngology, Department of Otolaryngology-Head &amp; Neck Surgery, University of Miami, Miami, Florida, U.S.ADepartment of Otolaryngology-Head &amp; Neck Surgery, Jackson Memorial Hospital-University of Miami, Miami, Florida, U.S.A</style></auth-address><titles><title><style face="normal" font="Arial">Predicting revision sinus surgery in allergic fungal and eosinophilic mucin chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Laryngoscope</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Laryngoscope</style></full-title></periodical><pages end="63" start="59">59-63</pages><volume><style face="normal" font="Arial">127</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/11/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic mucin</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic rhinosinusitis consists of several disease processes. Eosinophilic mucin is found in the subtypes of allergic fungal sinusitis (AFS) and eosinophilic mucin chronic rhinosinusitis (EMCRS). These entities frequently require surgical intervention and have high recurrence rates. OBJECTIVE: We aimed to determine factors in patients with AFS and EMCRS that may be associated with a higher rate of revision surgeries. Our hypothesis is that patients who have polyps, high Lund-Mackay score (LMS), and fungus may have higher revision rates. STUDY DESIGN: Retrospective cohort study. METHODS: This is a retrospective analysis of 117 patients identified over a 5-year period (2005-2009) with the diagnosis of AFS or EMCRS. Contingency tables were created to obtain the odds ratios estimates, and 95% confidence intervals were used to access the association between the outcome (having revision surgery or not) and other clinical binary predictors. RESULTS: Twenty-six of 117 (22%) of the study patients underwent revision surgery. Within the 2-year follow-up period, an additional five of 26 (19%) required another revision surgery. Average LMS was slightly higher in those who underwent revision surgery (16 vs. 13) on a scale of 0 to 24, with an overall mean score of 18 and standard deviation of 6.82 for the whole sample (117). Other factors evaluated were the presence of fungus, polyps, eosinophilic mucin, and the eosinophilic count and medical therapy received. CONCLUSION: The presence of eosinophilic mucin was significantly associated a higher rate of revision surgery. LEVEL OF EVIDENCE: 4. Laryngoscope, 2016</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1531-4995 (Electronic)IS - 0023-852X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/lary.26248</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27577717">PM:27577717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Laryngoscope\2017-127-59-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Laryngoscope\2017-127-59-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Younis RT</style></custom2><misc3><style face="normal" font="Arial">10.1002/lary.26248</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huschek,G.</style></author><author><style face="normal" font="Arial"> Bonick,J.</style></author><author><style face="normal" font="Arial"> Lowenstein,Y.</style></author><author><style face="normal" font="Arial"> Sievers,S.</style></author><author><style face="normal" font="Arial"> Rawel,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Quantification of allergenic plant traces in baked products by targeted proteomics using isotope marked peptides</style></title><secondary-title><style face="normal" font="Arial">LWT - Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">LWT - Food Sci Technol</style></full-title></periodical><pages end="293" start="286">286-293</pages><volume><style face="normal" font="Arial">74</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plant</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bakery</style></keyword><keyword><style face="normal" font="Arial"> Bakery products</style></keyword><keyword><style face="normal" font="Arial"> Baking</style></keyword><keyword><style face="normal" font="Arial"> BLAST</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> LC/MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Lupine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant allergen</style></keyword><keyword><style face="normal" font="Arial"> Plant allergen (soy,sesame,lupine)</style></keyword><keyword><style face="normal" font="Arial"> plant protein</style></keyword><keyword><style face="normal" font="Arial"> Plant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantification of allergenic plant traces</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white lupine</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><isbn><style face="normal" font="Arial">0023-6438</style></isbn><abstract><style face="normal" font="Arial">The right choice of analytical methods for plant allergen quantification is a deciding factor for the correct assessment and labeling of allergens in processed food in view of consumer protection. The aim of the present study was to develop a validated target peptide multi-method by LC/MS/MS providing high specificity and sensitivity for plant allergen protein detection, plant identification in vegan or vegetarian products using peptide markers for quantification. The methodical concept considers the selection of target peptides of thermostable allergenic plant proteins (Gly m6 soy, Ses i6 sesame and +¦-conglutin from white lupine) by data base research, BLAST and in silico digestion using Skyline software. Different allergenic concentration levels of these proteins were integrated into our own reference bakery products and quantified with synthesized isotopically labeled peptides after in-solution digestion using LC/MS/MS. Recovery rates within the range of 70</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô113% and LOQ of 10-áppm</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô50-áppm (mg allergenic food/kg) could be determined. The results are independent of thermal processing applied during baking and of epitope binding site for the tested allergens</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.lwt.2016.07.057</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.lwt.2016.07.057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\LWT - Food Sci Technol\2016-74-286-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\LWT - Food Sci Technol\2016-74-286-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Huschek G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.lwt.2016.07.057</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ducatti,R.</style></author><author><style face="normal" font="Arial"> de Almeida Nogueira Pinto,J.P.</style></author><author><style face="normal" font="Arial"> Sartori,M.M.</style></author><author><style face="normal" font="Arial"> Ducatti,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary Hygiene and Public Health, School of Veterinary Medicine and Animal Science, Univ. Estadual Paulista - UNESP, Distrito de Rubiao Junior, s/n, Botucatu, SP Postal Code 18.618-970, Brazil. Electronic address: rhaniducatti13@hotmail.comDepartment of Veterinary Hygiene and Public Health, School of Veterinary Medicine and Animal Science, Univ. Estadual Paulista - UNESP, Distrito de Rubiao Junior, s/n, Botucatu, SP Postal Code 18.618-970, BrazilDepartment of Production and Plant Breeding, School of Agronomic Science, Univ. Estadual Paulista - UNESP, Fazenda Lageado, Portaria I: Rua Jose Barbosa de Barros, No. 1780, Botucatu, SP Postal Code 18.610-307, BrazilCenter of Stable Isotopes, Institute of Biosciences, Univ. Estadual Paulista - UNESP, Distrito de Rubiao Junior, s/n, Botucatu, SP Postal Code 18.618-970, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Quantification of soy protein using the isotope method (delta13C and delta15N) for commercial brands of beef hamburger</style></title><secondary-title><style face="normal" font="Arial">Meat Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Meat Sci</style></full-title></periodical><pages end="100" start="97">97-100</pages><volume><style face="normal" font="Arial">122</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Isotopes</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="7" Year="2016">2016/7/22</year></dates><abstract><style face="normal" font="Arial">Hamburgers (beef patties) may be adulterated through the overuse of protein extenders. Among vegetables, soy protein is the best substitute for animal protein. These ingredients help to reduce the cost of producing a final product, and they maximize profits for fraudulent industries. Moreover, the ingestion of soy or other non-meat proteins by allergic individuals may present a health risk. In addition, monitoring by supervisory bodies is hampered by a lack of appropriate analytical methodologies. Within this context, the aim of this study was to determine and quantify the levels of added soy protein by determination of 15N and 13C stable isotopes. A total of 100 beef hamburger samples from 10 commercial brands were analyzed. Only three samples of the G brand were within the standards set the Brazilian legislation. The remaining 97 samples from 10 commercial brands contained >4% soy protein; therefore, they are adulterated and not in compliance with the current legislation</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1873-4138 (Electronic)IS - 0309-1740 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.meatsci.2016.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27501234">PM:27501234</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Meat Sci\2016-122-97-100.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Meat Sci\2016-122-97-100.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Ducatti R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.meatsci.2016.07.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Honnavar,P.</style></author><author><style face="normal" font="Arial"> Chakrabarti,A.</style></author><author><style face="normal" font="Arial"> Prasad,G.S.</style></author><author><style face="normal" font="Arial"> Singh,P.</style></author><author><style face="normal" font="Arial"> Dogra,S.</style></author><author><style face="normal" font="Arial"> Rudramurthy,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mycology Division, Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India</style></auth-address><titles><title><style face="normal" font="Arial">beta-Endorphin enhances the phospholipase activity of the dandruff causing fungi Malassezia globosa and Malassezia restricta</style></title><secondary-title><style face="normal" font="Arial">Med Mycol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Mycol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Colorimetry</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Malassezia globosa</style></keyword><keyword><style face="normal" font="Arial"> Malassezia pachydermatis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="8" Year="2016">2016/8/5</year></dates><abstract><style face="normal" font="Arial">beta-Endorphin is known to stimulate phospholipase production by Malassezia pachydermatis during canine dermatoses. The role of beta-endorphin in Malassezia infection in humans is not well studied. The present study compares the influence of beta-endorphin on Malassezia globosa and Malassezia restricta isolated from patients with seborrhoeic dermatitis/dandruff (SD/D) and healthy controls. Malassezia isolates (five each of the two species from patients and healthy controls) were grown on modified Dixon's agar with or without 100 nmol/L beta-endorphin. Phospholipase activity was quantified based on its ability to hydrolyze L-alpha-phosphatidylcholine dimyristoyl (phospholipid substrate). Free fatty acid was measured by a colorimetry method. In isolates from patients, the phospholipase activity significantly increased after exposure to beta-endorphin (M. globosa, P = .04; M. restricta, P = .001), which did not occur in isolates from healthy controls. Moreover, after beta-endorphin exposure the patient isolates had significantly higher (P = .0004) phospholipase activity compared to the healthy control isolates. The results suggest that isolates of M. globosa and M. restricta from patients may differ from those of healthy humans</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1460-2709 (Electronic)IS - 1369-3786 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1093/mmy/myw058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27497434">PM:27497434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Mycol\20160806-HonnavarP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Mycol\20160806-HonnavarP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Honnavar P</style></custom2><misc3><style face="normal" font="Arial">10.1093/mmy/myw058</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ibba,S.V.</style></author><author><style face="normal" font="Arial"> Ghonim,M.A.</style></author><author><style face="normal" font="Arial"> Pyakurel,K.</style></author><author><style face="normal" font="Arial"> Lammi,M.R.</style></author><author><style face="normal" font="Arial"> Mishra,A.</style></author><author><style face="normal" font="Arial"> Boulares,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Stanley Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA</style></auth-address><titles><title><style face="normal" font="Arial">Potential of Inducible Nitric Oxide Synthase as a Therapeutic Target for Allergen-Induced Airway Hyperresponsiveness: A Critical Connection to Nitric Oxide Levels and PARP Activity</style></title><secondary-title><style face="normal" font="Arial">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mediators Inflamm</style></full-title></periodical><pages end="" start="1984703">1984703-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Louisiana</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein nitration</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Although expression of inducible NO synthase (iNOS) in the lungs of asthmatics and associated nitrosative damage are established, iNOS failed as a therapeutic target for blocking airway hyperresponsiveness (AHR) and inflammation in asthmatics. This dichotomy calls for better strategies with which the enzyme is adequately targeted. Here, we confirm iNOS expression in the asthmatic lung with concomitant protein nitration and poly(ADP-ribose) polymerase (PARP) activation. We show, for the first time, that iNOS is highly expressed in peripheral blood mononuclear cells (PBMCs) of asthmatics with uncontrolled disease, which did not correspond to protein nitration. Selective iNOS inhibition with L-NIL protected against AHR upon acute, but not chronic, exposure to ovalbumin or house dust mite (HDM) in mice. Supplementation of NO by nitrite administration significantly blocked AHR in chronically HDM-exposed mice that were treated with L-NIL. Protection against chronic HDM exposure-induced AHR by olaparib-mediated PARP inhibition may be associated with the partial but not the complete blockade of iNOS expression. Indeed, L-NIL administration prevented olaparib-mediated protection against AHR in chronically HDM-exposed mice. Our study suggests that the amount of iNOS and NO are critical determinants in the modulation of AHR by selective iNOS inhibitors and renews the potential of iNOS as a therapeutic target for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -CO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/1984703</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27524861">PM:27524861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mediators Inflamm\2016-2016-1984703.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mediators Inflamm\2016-2016-1984703.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Ibba SV</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/1984703</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,C.C.</style></author><author><style face="normal" font="Arial"> Wang,C.H.</style></author><author><style face="normal" font="Arial"> Fu,C.H.</style></author><author><style face="normal" font="Arial"> Huang,C.C.</style></author><author><style face="normal" font="Arial"> Chang,P.H.</style></author><author><style face="normal" font="Arial"> Chen,I.W.</style></author><author><style face="normal" font="Arial"> Lee,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDivision of Rhinology, Department of Otolaryngology, Chang Gung Memorial Hospital bGraduate Institute of Clinical Medical Sciences, College of Medicine cDepartment of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">The link between chronic rhinosinusitis and asthma: A questionnaire-based study</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e4294">e4294-</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">31</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Treatments for chronic rhinosinusitis (CRS) and asthma can affect both conditions, based on the united airway concept. This study aimed to evaluate the link between CRS and asthma, based on disease-specific quality of life measures.We performed a prospective cohort study to investigate the correlations between results from CRS- and asthma-specific questionnaires. Thirty-two patients with asthma and CRS were evaluated before and after undergoing nasal surgery at a tertiary medical center.There were significant correlations between the results from the Asthma Control Test (ACT) and the Sino-Nasal Outcome Test-22, as well as between the results of the ACT and Rhinoconjunctivitis Quality of Life Questionnaire, at both the preoperative and 3-month postoperative evaluations (P &lt; 0.01). Moreover, nasal surgery improved the sinonasal symptoms, asthma control, and pulmonary function (P &lt; 0.01).Increasingly severe sinonasal symptoms of CRS were associated with poor asthma control. Therefore, CRS and asthma should be considered and treated as common airway diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleSB - AIMSB - IMCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000004294</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27495032">PM:27495032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-2016-e4294.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-2016-e4294.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Huang CC</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000004294</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kostyleva,E.V.</style></author><author><style face="normal" font="Arial"> Sereda,A.S.</style></author><author><style face="normal" font="Arial"> Velikoretskaya,I.A.</style></author><author><style face="normal" font="Arial"> Nefedova,L.I.</style></author><author><style face="normal" font="Arial"> Sharikov,A.Y.</style></author><author><style face="normal" font="Arial"> Tsurikova,N.V.</style></author><author><style face="normal" font="Arial"> Lobanov,N.S.</style></author><author><style face="normal" font="Arial"> Semenova,M.V.</style></author><author><style face="normal" font="Arial"> Sinitsyn,A.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A new Bacillus licheniformis mutant strain producing serine protease efficient for hydrolysis of soy meal proteins</style></title><secondary-title><style face="normal" font="Arial">Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Microbiology</style></full-title></periodical><pages end="470" start="462">462-470</pages><volume><style face="normal" font="Arial">85</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-nutritional</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> Mutagenesis</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein composition</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy Proteins</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean meal</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Subtilisin</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1608-3237</style></isbn><abstract><style face="normal" font="Arial">Induced mutagenesis with +¦-irradiation of the industrial strain Bacillus licheniformis-60 VKM B-2366 D was used to obtain a new highly active producer of an extracellular serine protease, Bacillus licheniformis-145. Samples of dry concentrated preparations of serine protease produced by the original and mutant strains were obtained, and identity of their protein composition was established. Alkaline serine protease subtilisin DY was the main component of the preparations. The biochemical and physicochemical properties of the Protolicheterm-145 enzyme preparation obtained from the mutant strain were studied. It exhibited proteolytic activity (1.5 times higher than the preparation from the initial strain) within broad ranges of pH (5</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô11) and temperature (30</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô70-¦C). Efficient hydrolysis of extruded soybean meal protein at high concentrations (20 to 50%) in the reaction mixture was the main advantage of the Protolicheterm-145 preparation. Compared to the preparation obtained using the initial strain, the new preparation with increased proteolytic activity provided for more complete hydrolysis of the main non-nutritious anti-nutritional soy proteins (glycinin and +¦-conglycinin) with the yield of soluble protein increased by 19</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô28%, which decreased the cost of bioconversion of the proteinaceous material and indicated promise of the new preparation in resource-saving technologies for processing soybean meals and cakes</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1134/S0026261716040123</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1134/S0026261716040123</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microbiology\2016-85-462-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microbiology\2016-85-462-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Kostyleva EV</style></custom2><misc3><style face="normal" font="Arial">10.1134/S0026261716040123</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,D.</style></author><author><style face="normal" font="Arial"> Xie,G.</style></author><author><style face="normal" font="Arial"> Cao,X.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Colorimetric determination of staphylococcal enterotoxin B via DNAzyme-guided growth of gold nanoparticles</style></title><secondary-title><style face="normal" font="Arial">Microchim Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Microchim Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Aptamers</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> H2O2</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen Peroxide</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Nucleic Acids</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal enterotoxin B</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1436-5073</style></isbn><abstract><style face="normal" font="Arial">The authors describe a colorimetric method for the determination of the staphylococcal enterotoxin B (SEB) that also allows for visual readout. The assay is based on the growth of gold nanoparticles (AuNPs) mediated by a hemin/G-quadruplex DNAzyme which generates a color change from red to blue in the presence of SEB. The method is enzyme-free and does not require a label. The kinetics of the formation of the AuNPs is controlled by the hemin/G-quadruplex DNAzyme and this is key to the signal generation mechanism. In the presence of SEB, the reactions between aptamer and target modulated the amount of single probe G strands that form DNAzyme capable of consuming hydrogen peroxide. The growth process of AuNPs is influenced by the resulting concentration of H2O2 and leads to the color change. Under optimal conditions, a linear relationship exists between absorbance and SEB concentration in the range from 0.1 to 500-ápg-ÀmL</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¥1 which covers the clinically relevant range. In case of visual detection, the lower limit of detection is 1-ápg-ÀmL</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1. The assay described here is sensitive, comparably inexpensive and can detect SEB rapidly without the need for sophisticated equipment. In our perception, the method has a wide scope in that it may be adapted to various nucleic acids, proteins and other biomolecules if respective aptamers are available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00604-016-1919-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00604-016-1919-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microchim Acta\20160820-ZhouD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microchim Acta\20160820-ZhouD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Zhou D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00604-016-1919-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sun,Y.</style></author><author><style face="normal" font="Arial"> Cheng,L.</style></author><author><style face="normal" font="Arial"> Gu,Y.</style></author><author><style face="normal" font="Arial"> Xin,A.</style></author><author><style face="normal" font="Arial"> Wu,B.</style></author><author><style face="normal" font="Arial"> Zhou,S.</style></author><author><style face="normal" font="Arial"> Guo,S.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Diao,H.</style></author><author><style face="normal" font="Arial"> Shi,H.</style></author><author><style face="normal" font="Arial"> Wang,G.</style></author><author><style face="normal" font="Arial"> Tao,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China</style></auth-address><titles><title><style face="normal" font="Arial">A Human Lectin Microarray for Sperm Surface Glycosylation Analysis</style></title><secondary-title><style face="normal" font="Arial">Mol Cell Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Cell Proteomics</style></full-title></periodical><pages end="2851" start="2839">2839-2851</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--Beads ABA Lectins</style></keyword><keyword><style face="normal" font="Arial"> 1--IgE Isoforme</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Galectin 1</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heat shock protein</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectin microarray</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Lectins</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Glycosylation is one of the most abundant and functionally important protein post-translational modifications. As such, technology for efficient glycosylation analysis is in high demand. Lectin microarrays are a powerful tool for such investigations and have been successfully applied for a variety of glycobiological studies. However, most of the current lectin microarrays are primarily constructed from plant lectins, which are not well suited for studies of human glycosylation because of the extreme complexity of human glycans. Herein, we constructed a human lectin microarray with 60 human lectin and lectin-like proteins. All of the lectins and lectin-like proteins were purified from yeast, and most showed binding to human glycans. To demonstrate the applicability of the human lectin microarray, human sperm were probed on the microarray and strong bindings were observed for several lectins, including galectin-1, 7, 8, GalNAc-T6, and ERGIC-53 (LMAN1). These bindings were validated by flow cytometry and fluorescence immunostaining. Further, mass spectrometry analysis showed that galectin-1 binds several membrane-associated proteins including heat shock protein 90. Finally, functional assays showed that binding of galectin-8 could significantly enhance the acrosome reaction within human sperms. To our knowledge, this is the first construction of a human lectin microarray, and we anticipate it will find wide use for a range of human or mammalian studies, alone or in combination with plant lectin microarrays</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1535-9484 (Electronic)IS - 1535-9476 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1074/mcp.M116.059311</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27364157">PM:27364157</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Cell Proteomics\2016-15-2839-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Cell Proteomics\2016-15-2839-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Sun Y</style></custom2><misc3><style face="normal" font="Arial">10.1074/mcp.M116.059311</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gazza,L.</style></author><author><style face="normal" font="Arial"> Gazzelloni,G.</style></author><author><style face="normal" font="Arial"> Taddei,F.</style></author><author><style face="normal" font="Arial"> Latini,A.</style></author><author><style face="normal" font="Arial"> Muccilli,V.</style></author><author><style face="normal" font="Arial"> Alfieri,M.</style></author><author><style face="normal" font="Arial"> Conti,S.</style></author><author><style face="normal" font="Arial"> Redaelli,R.</style></author><author><style face="normal" font="Arial"> Pogna,N.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Consiglio per la ricerca in agricoltura e l'analisi dell'economia agraria (CREA-QCE), Via Manziana 30, 00189, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">The starch-bound alpha-amylase/trypsin-inhibitors in Avena</style></title><secondary-title><style face="normal" font="Arial">Mol Genet Genomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Genet Genomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S Proteins</style></keyword><keyword><style face="normal" font="Arial"> alpha-Amylase</style></keyword><keyword><style face="normal" font="Arial"> alpha-amylase/trypsin inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid composition</style></keyword><keyword><style face="normal" font="Arial"> Avena sativa</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fractionation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Isoelectric Point</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Non celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> oat</style></keyword><keyword><style face="normal" font="Arial"> Oats</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Texture</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="5" Month="8" Year="2016">2016/8/5</year></dates><abstract><style face="normal" font="Arial">Oat kernels exhibit an extra-soft texture, a trait recently demonstrated to be largely modulated by starch-bound tryptophan-rich 2S proteins, the vromindolines. In this study, fractionation by two-dimensional electrophoresis of starch-bound proteins in 25 oat (Avena sativa) cultivars and 11 diploid or tetraploid Avena species revealed novel 2S proteins called Avena alpha-amylase/trypsin-inhibitors (AATI) because of their sequence similarity with wheat alpha-amylase/trypsin inhibitors. Thirty-seven AATI polypeptides, about 14 kDa in size, were split into three families named AATI-1, AATI-2, and AATI-3 with different primary structures and isoelectric points. AATI-1 and AATI-2 proteins showed 55.5-60.0 % sequence similarity with wheat alpha-amylase inhibitors CM1, CM2, and CM16, which have been found to cause innate immunity responses in celiac disease and non-celiac gluten sensitivity. Diploid A-genome and tetraploid AC-genome oat species possess three and five genes encoding for the AATI proteins, respectively, whereas hexaploid A. sativa exhibits 12 genes dispersed over the A-, C-, and D-genomes. Some AATI proteins expressed in hexaploid oats were assigned to the A-genome based on similarity to their counterparts in diploid species, contributing to further clarify the genetic origin of hexaploid oats. Moreover, AATI may interact with starch-bound vromindolines in determining the extra-soft texture of oat kernels and, due to their balanced amino acid compositions, may contribute to the biological value of oat proteins in a positive manner</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1617-4623 (Electronic)IS - 1617-4623 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00438-016-1238-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27495179">PM:27495179</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Genet Genomics\20160806-GazzaL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Genet Genomics\20160806-GazzaL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Gazza L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00438-016-1238-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pratesi,S.</style></author><author><style face="normal" font="Arial"> Nencini,F.</style></author><author><style face="normal" font="Arial"> Fili,L.</style></author><author><style face="normal" font="Arial"> Occhiato,E.G.</style></author><author><style face="normal" font="Arial"> Romagnani,S.</style></author><author><style face="normal" font="Arial"> Parronchi,P.</style></author><author><style face="normal" font="Arial"> Maggi,E.</style></author><author><style face="normal" font="Arial"> Vultaggio,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Experimental and Clinical Medicine, Research Center DENOTHE of University of Florence, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Dermatophagoides pteronyssinus group 2 allergen bound to 8-OH modified adenine reduces the Th2-mediated airway inflammation without inducing a Th17 response and autoimmunity</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="70" start="60">60-70</pages><volume><style face="normal" font="Arial">77</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2016">2016/7/28</year></dates><abstract><style face="normal" font="Arial">8-OH modified adenine bound to Dermatophagoides pteronyssinus group 2 (nDer p2-Conj), a novel allergen-TLR7 agonist conjugate, improves murine airway inflammation in priming and therapeutic settings, however no data are known on the activity of this construct on Th17 cells. The aim of the study was to evaluate if nDer p2-Conj elicited in vivo Th17 cells and Th17-driven autoimmune responses, by using both short- and long-term priming and therapeutic protocols in a nDer p2-driven model of murine airway inflammation. The conjugate induced the in vitro production of cytokines favouring the Th17 polarization by bone marrow-derived dendritic cells. In short-term protocols, the priming or treatment with the conjugate ameliorated the airway inflammation by shifting Th2 allergen-specific cells into T cells producing IFN-gamma, IL-10, but not IL-17A. Similar results were found in long-term protocol where the conjugate down-regulated airway inflammation without any evidence of autoimmune response and B cell compartment expansion. nDer p2-Conj also failed to shorten the spontaneous onset of diabetes on conjugates-primed NOD/LtJ mice. We found that neutrophils in BALF, ROR-gammat and IL-17A expression in lungs were increased in conjugate-treated IL-10KO mice. These data emphasize the role of conjugate-driven IL-10 production, which can regulate the activity of memory Th17 cells and prevent the onset of autoimmune response</style></abstract><notes><style face="normal" font="Arial">DA - 20160731IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2016.07.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27475304">PM:27475304</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2016-77-60-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2016-77-60-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160731, Pratesi S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2016.07.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Z.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Sun,X.</style></author><author><style face="normal" font="Arial"> Ren,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Internal Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">The protective role of vitamin D3 in a murine model of asthma via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamin D3</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">Asthma is a common worldwide health burden, the prevalence of which is increasing. Recently, the biologically active form of vitamin D3, 1,25-dihydroxyvitamin D3, has been reported to have a protective role in murine asthma; however, the molecular mechanisms by which vitamin D3 attenuates asthmaassociated airway injury remain elusive. In the present study, BALB/c mice were sensitized to ovalbumin (OVA) and were administered 100 ng 1,25-dihydroxyvitamin D3 (intraperitoneal injection) 30 min prior to each airway challenge. The inflammatory responses were measured by ELISA, airway damage was analyzed by hematoxylin and eosin staining, airway remodeling was analyzed by Masson staining and periodic acidSchiff staining, markers of oxidative stress were measured by commercial kits, and the expression levels of alphasmooth muscle actin (alpha-SMA) and the activity of the NFE2related factor 2 (Nrf2)/heme oxygenase1 (HO1) and the transforming growth factorbeta (TGFbeta)/Smad signaling pathways were measured by immunohistochemistry and western blotting. The results demonstrated that OVAinduced airway inflammation and immunoglobulin E overexpression were significantly reduced by vitamin D3 treatment. In addition, treatment with vitamin D3 decreased alphaSMA expression, collagen deposition and goblet cell hyperplasia, and inhibited TGFbeta/Smad signaling in the asthmatic airway. The upregulated levels of malondialdehyde, and the reduced activities of superoxide dismutase and glutathione in OVAchallenged mice were also markedly restored following vitamin D3 treatment. Furthermore, treatment with vitamin D3 enhanced activation of the Nrf2/HO1 pathway in the airways of asthmatic mice. In conclusion, these findings suggest that vitamin D3 may protect airways from asthmatic damage via the suppression of TGFbeta/Smad signaling and activation of the Nrf2/HO1 pathway; however, these protective effects were shown to be accompanied by hypercalcemia</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2016.5563</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27484042">PM:27484042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\20160803-WangZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\20160803-WangZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Wang Z</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2016.5563</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agarwal,R.</style></author><author><style face="normal" font="Arial"> Dua,D.</style></author><author><style face="normal" font="Arial"> Choudhary,H.</style></author><author><style face="normal" font="Arial"> Aggarwal,A.N.</style></author><author><style face="normal" font="Arial"> Sehgal,I.S.</style></author><author><style face="normal" font="Arial"> Dhooria,S.</style></author><author><style face="normal" font="Arial"> Garg,M.</style></author><author><style face="normal" font="Arial"> Behera,D.</style></author><author><style face="normal" font="Arial"> Chakrabarti,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India</style></auth-address><titles><title><style face="normal" font="Arial">Role of Aspergillus fumigatus-specific IgG in diagnosis and monitoring treatment response in allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Mycoses</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycoses</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Precipitins</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="8" Year="2016">2016/8/15</year></dates><abstract><style face="normal" font="Arial">Few studies have evaluated the utility of Aspergillus fumigatus-specific IgG in allergic bronchopulmonary aspergillosis (ABPA). Herein, we evaluate the role of specific IgG in diagnosis and monitoring treatment response in ABPA. Forty-eight control subjects with A. fumigatus-associated asthma underwent A. fumigatus-specific IgG measurements at baseline, while specific IgG was assayed in 102 treatment-naive subjects of ABPA at baseline, after eight weeks of glucocorticoid therapy, and during exacerbations. For determining the cut-off of A. fumigatus-specific IgG, we randomly classified two-thirds of the study subjects (cases and controls) as the derivation cohort, while the remaining one-thirds were labelled as the validation cohort. The best cut-off value of A. fumigatus-specific IgG in the derivation cohort was 26.9 mgA /L (sensitivity: 88%; specificity: 100%). Using this limit, the sensitivity and specificity of A. fumigatus-specific IgG in diagnosis of ABPA was 89% and 100%, respectively, in the validation cohort. In contrast, the sensitivity of Aspergillus precipitins was only 27.4%. Following treatment, the A. fumigatus-specific IgG increased in 38 (37.2%) subjects, while it decreased in three (23.1%) of the 13 subjects experiencing an exacerbation. The A. fumigatus-specific IgG was found to be an extremely useful test in the diagnosis and differential diagnosis of ABPA but is unreliable in monitoring treatment response in this disorder</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1439-0507 (Electronic)IS - 0933-7407 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1111/myc.12541</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27523578">PM:27523578</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycoses\20160815-AgarwalR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycoses\20160815-AgarwalR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Agarwal R</style></custom2><misc3><style face="normal" font="Arial">10.1111/myc.12541</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chatila,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Division of Immunology, Boston Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston</style></auth-address><titles><title><style face="normal" font="Arial">Innate Immunity in Asthma</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="479" start="477">477-479</pages><volume><style face="normal" font="Arial">375</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunity,Innate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="4" Month="8" Year="2016">2016/8/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - CommentPT - EditorialSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMe1607438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27518667">PM:27518667</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2016-375-477-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2016-375-477-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Chatila TA</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMe1607438</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stein,M.M.</style></author><author><style face="normal" font="Arial"> Hrusch,C.L.</style></author><author><style face="normal" font="Arial"> Gozdz,J.</style></author><author><style face="normal" font="Arial"> Igartua,C.</style></author><author><style face="normal" font="Arial"> Pivniouk,V.</style></author><author><style face="normal" font="Arial"> Murray,S.E.</style></author><author><style face="normal" font="Arial"> Ledford,J.G.</style></author><author><style face="normal" font="Arial"> Marques dos Santos,M.</style></author><author><style face="normal" font="Arial"> Anderson,R.L.</style></author><author><style face="normal" font="Arial"> Metwali,N.</style></author><author><style face="normal" font="Arial"> Neilson,J.W.</style></author><author><style face="normal" font="Arial"> Maier,R.M.</style></author><author><style face="normal" font="Arial"> Gilbert,J.A.</style></author><author><style face="normal" font="Arial"> Holbreich,M.</style></author><author><style face="normal" font="Arial"> Thorne,P.S.</style></author><author><style face="normal" font="Arial"> Martinez,F.D.</style></author><author><style face="normal" font="Arial"> von Mutius,E.</style></author><author><style face="normal" font="Arial"> Vercelli,D.</style></author><author><style face="normal" font="Arial"> Ober,C.</style></author><author><style face="normal" font="Arial"> Sperling,A.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Human Genetics</style></auth-address><titles><title><style face="normal" font="Arial">Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="421" start="411">411-421</pages><volume><style face="normal" font="Arial">375</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adaptor Proteins,Vesicular Transport</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Christianity</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease Models,Animal</style></keyword><keyword><style face="normal" font="Arial"> disparities</style></keyword><keyword><style face="normal" font="Arial"> disparity</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunity,Innate</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocyte Count</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice,Inbred BALB C</style></keyword><keyword><style face="normal" font="Arial"> Mice,Inbred C57BL</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Models,Animal</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Differentiation Factor 88</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="4" Month="8" Year="2016">2016/8/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The Amish and Hutterites are U.S. agricultural populations whose lifestyles are remarkably similar in many respects but whose farming practices, in particular, are distinct; the former follow traditional farming practices whereas the latter use industrialized farming practices. The populations also show striking disparities in the prevalence of asthma, and little is known about the immune responses underlying these disparities. METHODS: We studied environmental exposures, genetic ancestry, and immune profiles among 60 Amish and Hutterite children, measuring levels of allergens and endotoxins and assessing the microbiome composition of indoor dust samples. Whole blood was collected to measure serum IgE levels, cytokine responses, and gene expression, and peripheral-blood leukocytes were phenotyped with flow cytometry. The effects of dust extracts obtained from Amish and Hutterite homes on immune and airway responses were assessed in a murine model of experimental allergic asthma. RESULTS: Despite the similar genetic ancestries and lifestyles of Amish and Hutterite children, the prevalence of asthma and allergic sensitization was 4 and 6 times as low in the Amish, whereas median endotoxin levels in Amish house dust was 6.8 times as high. Differences in microbial composition were also observed in dust samples from Amish and Hutterite homes. Profound differences in the proportions, phenotypes, and functions of innate immune cells were also found between the two groups of children. In a mouse model of experimental allergic asthma, the intranasal instillation of dust extracts from Amish but not Hutterite homes significantly inhibited airway hyperreactivity and eosinophilia. These protective effects were abrogated in mice that were deficient in MyD88 and Trif, molecules that are critical in innate immune signaling. CONCLUSIONS: The results of our studies in humans and mice indicate that the Amish environment provides protection against asthma by engaging and shaping the innate immune response. (Funded by the National Institutes of Health and others.)</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tRN - 0 (Adaptor Proteins, Vesicular Transport)RN - 0 (Cytokines)RN - 0 (Dust)RN - 0 (Myd88 protein, mouse)RN - 0 (Myeloid Differentiation Factor 88)RN - 0 (TICAM-1 protein, mouse)RN - 37341-29-0 (Immunoglobulin E)SB - AIMSB - IMCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa1508749</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27518660">PM:27518660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2016-375-411-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2016-375-411-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Stein MM</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa1508749</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fine,J.H.</style></author><author><style face="normal" font="Arial"> Bondy,G.S.</style></author><author><style face="normal" font="Arial"> Coady,L.</style></author><author><style face="normal" font="Arial"> Pearce,B.</style></author><author><style face="normal" font="Arial"> Ross,N.</style></author><author><style face="normal" font="Arial"> Tayabali,A.F.</style></author><author><style face="normal" font="Arial"> Halappanavar,S.</style></author><author><style face="normal" font="Arial"> Caldwell,D.</style></author><author><style face="normal" font="Arial"> Curran,I.</style></author><author><style face="normal" font="Arial"> Lefebvre,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Regulatory Toxicology Research Division , Bureau of Chemical Safety, Food Directorate, HPFB, Health Canada , Ottawa , ON , Canada</style></auth-address><titles><title><style face="normal" font="Arial">Immunomodulation by Gastrointestinal Carbon Black Nanoparticle Exposure in Ovalbumin T Cell Receptor Transgenic Mice</style></title><secondary-title><style face="normal" font="Arial">Nanotoxicology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nanotoxicology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunophenotyping</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptome analysis</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">Humans could become exposed to carbon black nanoparticles (CBNPs) in consumer products or an occupational setting. In rodent models, acute respiratory, subcutaneous, and direct immune cell exposure to CBNPs has been shown to enhance allergic sensitization to co-administered ovalbumin (OVA) protein from chicken egg. However, little is known about the effects of ingested CBNPs on immunological responses and oral tolerance to food antigens. We hypothesized that ingestion of CBNPs would enhance the development of food allergy to OVA. Allergy prone DO11.10 mice were orally exposed to CBNPs every second day for 2 weeks (total dose 10.8 (LO) or 108 mug (HI)), with and without (+/-) co-administered OVA. Systemic immune parameters were measured at necropsy. Exposure to OVA resulted in significant increases in serum anti-OVA IgG1, anti-OVA IgM and anti-OVA IgA antibodies relative to vehicle control. Immunophenotyping revealed a reduction in the number of OVA specific CD4+ T helper cells upon OVA+/-CBNPHI treatment in the spleen. Yet, secretion of the allergy associated Th2 cytokines IL-4, IL-9 and IL-13 was greater in OVA323-339 peptide pulsed splenocytes from OVA+CBNPHI treated mice compared to control. Transcriptome analysis at necropsy of splenocytes from OVA+CBNPHI dose mice compared to OVA mice revealed increases in the allergy associated genes Il4 and Stat6 and decreases in Csf3r and Retnlg. Although oral exposure of high dose CBNPs did not impact OVA-specific antibody production relative to OVA, we did observe increased expression of genes and cytokines associated with allergy in peripheral splenocytes. This work suggests that CBNP gastrointestinal exposure may potentiate allergy pathways</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1743-5404 (Electronic)IS - 1743-5390 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1080/17435390.2016.1225131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27534448">PM:27534448</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nanotoxicology\20160818-FineJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nanotoxicology\20160818-FineJH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Fine JH</style></custom2><misc3><style face="normal" font="Arial">10.1080/17435390.2016.1225131</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Massoud,A.H.</style></author><author><style face="normal" font="Arial"> Charbonnier,L.M.</style></author><author><style face="normal" font="Arial"> Lopez,D.</style></author><author><style face="normal" font="Arial"> Pellegrini,M.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author><author><style face="normal" font="Arial"> Chatila,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells</style></title><secondary-title><style face="normal" font="Arial">Nat Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> iTreg</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> RORC</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="1" Month="8" Year="2016">2016/8/1</year></dates><abstract><style face="normal" font="Arial">Mechanisms by which regulatory T (Treg) cells fail to control inflammation in asthma remain poorly understood. We show that a severe asthma-associated polymorphism in the gene encoding the interleukin (IL)-4 receptor alpha chain (Il4raR576) promotes conversion of induced Treg (iTreg) cells toward a T helper 17 (TH17) cell fate. This skewing is mediated by the recruitment by IL-4RalphaR576 of the growth-factor-receptor-bound protein 2 (GRB2) adaptor protein, which drives IL-17 expression by activating a pathway that involves extracellular-signal-regulated kinase, IL-6 and the transcription factor STAT3. Treg cell-specific deletion of genes that regulate TH17 cell differentiation, including Il6ra and RAR-related orphan receptor gamma (Rorc), but not of Il4 or Il13, prevented exacerbated airway inflammation in mice expressing Il4raR576 (hereafter referred to as Il4raR576 mice). Furthermore, treatment of Il4raR576 mice with a neutralizing IL-6-specific antibody prevented iTreg cell reprogramming into TH17-like cells and protected against severe airway inflammation. These findings identify a previously unknown mechanism for the development of mixed TH2-TH17 cell inflammation in genetically prone individuals and point to interventions that stabilize iTreg cells as potentially effective therapeutic strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1546-170X (Electronic)IS - 1078-8956 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/nm.4147</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27479084">PM:27479084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Med\20160801-MassoudAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Med\20160801-MassoudAH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Massoud AH</style></custom2><misc3><style face="normal" font="Arial">10.1038/nm.4147</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chng,K.R.</style></author><author><style face="normal" font="Arial"> Tay,A.S.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Ng,A.H.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Suri,B.K.</style></author><author><style face="normal" font="Arial"> Matta,S.A.</style></author><author><style face="normal" font="Arial"> McGovern,N.</style></author><author><style face="normal" font="Arial"> Janela,B.</style></author><author><style face="normal" font="Arial"> Wong,X.F.</style></author><author><style face="normal" font="Arial"> Sio,Y.Y.</style></author><author><style face="normal" font="Arial"> Au,B.V.</style></author><author><style face="normal" font="Arial"> Wilm,A.</style></author><author><style face="normal" font="Arial"> De Sessions,P.F.</style></author><author><style face="normal" font="Arial"> Lim,T.C.</style></author><author><style face="normal" font="Arial"> Tang,M.B.</style></author><author><style face="normal" font="Arial"> Ginhoux,F.</style></author><author><style face="normal" font="Arial"> Connolly,J.E.</style></author><author><style face="normal" font="Arial"> Lane,E.B.</style></author><author><style face="normal" font="Arial"> Chew,F.T.</style></author><author><style face="normal" font="Arial"> Common,J.E.</style></author><author><style face="normal" font="Arial"> Nagarajan,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genome Institute of Singapore, Singapore 138672, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare</style></title><secondary-title><style face="normal" font="Arial">Nat Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Microbiol</style></full-title></periodical><pages end="" start="16106">16106-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Metagenome</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus epidermidis</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Whole metagenome analysis has the potential to reveal functional triggers of skin diseases, but issues of cost, robustness and sampling efficacy have limited its application. Here, we have established an alternative, clinically practical and robust metagenomic analysis protocol and applied it to 80 skin microbiome samples epidemiologically stratified for atopic dermatitis (AD). We have identified distinct non-flare, baseline skin microbiome signatures enriched for Streptococcus and Gemella but depleted for Dermacoccus in AD-prone versus normal healthy skin. Bacterial challenge assays using keratinocytes and monocyte-derived dendritic cells established distinct IL-1-mediated, innate and Th1-mediated adaptive immune responses with Staphylococcus aureus and Staphylococcus epidermidis. Bacterial differences were complemented by perturbations in the eukaryotic community and functional shifts in the microbiome-wide gene repertoire, which could exacerbate a dry and alkaline phenotype primed for pathogen growth and inflammation in AD-susceptible skin. These findings provide insights into how the skin microbial community, skin surface microenvironment and immune system cross-modulate each other, escalating the destructive feedback cycle between them that leads to AD flare</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 2058-5276 (Electronic)IS - 2058-5276 (Linking)LA - engPT - Journal ArticleSB - IMCO - Singapore -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/nmicrobiol.2016.106</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562258">PM:27562258</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Microbiol\2016-1-16106.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Microbiol\2016-1-16106.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Chng KR</style></custom2><misc3><style face="normal" font="Arial">10.1038/nmicrobiol.2016.106</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leavy,O.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Asthma and allergy: Old McDonald had a farm (but no asthma)!</style></title><secondary-title><style face="normal" font="Arial">Nat Rev Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nat Rev Immunol</style></abbr-1></periodical><pages end="" start="535">535-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="25" Month="8" Year="2016">2016/8/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160825IS - 1474-1741 (Electronic)IS - 1474-1733 (Linking)LA - engPT - Journal ArticleSB - IMCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/nri.2016.97</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27558411">PM:27558411</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Rev Immunol\2016-16-935.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Rev Immunol\2016-16-935.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Leavy O</style></custom2><misc3><style face="normal" font="Arial">10.1038/nri.2016.97</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mendonca,A.</style></author><author><style face="normal" font="Arial"> Paula,M.C.</style></author><author><style face="normal" font="Arial"> Fernandes,W.D.</style></author><author><style face="normal" font="Arial"> Andrade,L.H.</style></author><author><style face="normal" font="Arial"> Lima,S.M.</style></author><author><style face="normal" font="Arial"> Antonialli-Junior,W.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Univ Federal da Grande Dourados, Dourados, MS, Brasil.</style></auth-address><titles><title><style face="normal" font="Arial">Variation in Venoms of Polybia Paulista Von Ihering and Polybia Occidentalis Olivier (Hymenoptera: Vespidae), Assessed by the FTIR-PAS Technique</style></title><secondary-title><style face="normal" font="Arial">Neotrop Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Neotrop Entomol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Gas chromatography</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Wasps</style></keyword></keywords><dates><year Day="25" Month="7" Year="2016">2016/7/25</year></dates><abstract><style face="normal" font="Arial">Wasps are able to synthesize toxic compounds known as venoms, which form a part of a mechanism to overcome prey and also to defend their colonies. Study of the compounds that constitute these substances is essential in order to understand how this defense mechanism evolved, since there is evidence that the venoms can vary both intra- and interspecifically. Some studies have used liquid and gas chromatography as a reliable technique to analyze these compounds. However, the use of Fourier transform infrared photoacoustic spectroscopy (FTIR-PAS) to analyze the variations in venom's chemical profile has been proposed recently. This study evaluated whether the FTIR-PAS technique is effective for assessing the role of environmental factors on intra- and interspecific differences in the venom of the wasps Polybia paulista Von Ihering and Polybia occidentalis Olivier by FTIR-PAS. The colonies were collected in three municipalities of Mato Grosso do Sul, Brazil, in different types of environments. The results showed that the venoms of P. paulista and P. occidentalis differed significantly in profile. In addition, the intraspecific differences in the venom's chemical profile of P. paulista are related to the type of environment where they nested, regardless of the geographical distance between the nests. The FTIR-PAS technique proved to be reliable and effective to evaluate the variations in the venom's chemical profile in social wasps</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1678-8052 (Electronic)IS - 1519-566X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13744-016-0426-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27457373">PM:27457373</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Neotrop Entomol\20160726-MendoncaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Neotrop Entomol\20160726-MendoncaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Mendonca A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13744-016-0426-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Lato">ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing</style></title><secondary-title><style face="normal" font="Arial">NICE</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">NICE</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ISAC 112</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.nice.org.uk/guidance/dg24</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\NICE\2016-DG24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\NICE\2016-DG24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, no authors</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,S.E.</style></author><author><style face="normal" font="Arial"> Kwon,Y.S.</style></author><author><style face="normal" font="Arial"> Paik,J.K.</style></author><author><style face="normal" font="Arial"> Kwak,T.K.</style></author><author><style face="normal" font="Arial"> Hong,W.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Foodservice Management and Nutrition, Sangmyung University, 20 Hongjimun 2-gil, Jongno-gu, Seoul 03016, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Perception and practice regarding allergen labeling: focus on food-related employees</style></title><secondary-title><style face="normal" font="Arial">Nutr Res Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutr Res Pract</style></full-title></periodical><pages end="432" start="424">424-432</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Foodservice</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/OBJECTIVES: Most consumers are able to recognize allergenic foods. However, the frequency of checking such foods is reportedly low, resulting in higher prevalence of food-related allergic reactions in Korea compared to other countries. Thus, this study was performed to investigate the overall perception of allergenic food labeling and its practice level in food manufacturing company employees. SUBJECTS/METHODS: The survey was administered to food safety employees and food development teams at food companies located in metropolitan areas. A total of 399 (93.8%) valid samples were used in the final analysis. Statistical analyses, including Frequency Analysis, t-test, Anova, PCA (Principal Component Analysis), and Pearson Correlation Analysis using SPSS ver. 21.0, were performed. RESULTS: The correct answer rate in the analysis of allergy-related knowledge level ranged from 15.0% to 89.7%. Analysis of differences in allergy-related perception by knowledge level showed significant differences in introduction of a food recall system, strengthening of relevant laws and regulations, content labeling, description of substitutional food, and differentiated package by age. CONCLUSIONS: It can be concluded that labeling of allergenic foods should be made easier and more convenient for checking by employees, developers, and consumers, and it is necessary to provide contents through the development of publicity, guidelines, or APP along with labeling</style></abstract><notes><style face="normal" font="Arial">DA - 20160801IS - 1976-1457 (Print)IS - 1976-1457 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4162/nrp.2016.10.4.424</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27478550">PM:27478550</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutr Res Pract\2016-10-424-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutr Res Pract\2016-10-424-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160801, Park SE</style></custom2><misc3><style face="normal" font="Arial">10.4162/nrp.2016.10.4.424</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suojalehto,H.</style></author><author><style face="normal" font="Arial"> Karvala,K.</style></author><author><style face="normal" font="Arial"> Haramo,J.</style></author><author><style face="normal" font="Arial"> Korhonen,M.</style></author><author><style face="normal" font="Arial"> Saarinen,M.</style></author><author><style face="normal" font="Arial"> Lindstrom,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Occupational Medicine, Finnish Institute of Occupational Health, 00251 Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Medical surveillance for occupational asthma-how are cases detected?</style></title><secondary-title><style face="normal" font="Arial">Occup Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Occup Med (Lond)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> Work related rhinitis</style></keyword></keywords><dates><year Day="4" Month="8" Year="2016">2016/8/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In Finland, medical surveillance, including spirometry, is periodically performed for workers who are exposed to agents capable of causing occupational asthma (OA). Although it has been shown that surveillance can detect OA at an early stage, few studies have assessed its benefits or the role of surveillance spirometry. AIMS: To assess the role of surveillance and spirometry in detecting OA and to evaluate the quality of spirometry. METHODS: We retrospectively reviewed the medical files of patients in health surveillance programmes who were diagnosed with sensitizer-induced OA at the Finnish Institute of Occupational Health in 201214. We collected information on work exposure, respiratory symptoms, healthcare visits that initiated the diagnostic process, first spirometry and other diagnostic tests. RESULTS: Sixty files were reviewed. Medical surveillance detected 11 cases (18%) and 49 cases (82%) were detected at doctors' appointments that were not related to surveillance. The median delay from the onset of asthma symptoms to diagnosis was 2.2 years. Delay did not differ between these groups. No cases were detected on the basis of abnormal spirometry without respiratory symptoms. However, five patients (8%) initially reported solely work-related rhinitis symptoms. Spirometry was normal in half of the cases and quality criteria were fulfilled in 86% of the tests. CONCLUSIONS: Fewer than one in five OA cases were detected through medical surveillance. Investigations were initiated by respiratory symptoms. No asymptomatic worker was referred because of abnormal spirometry. Our results highlight the importance of work-related nasal symptoms in detecting OA</style></abstract><notes><style face="normal" font="Arial">DA - 20160805IS - 1471-8405 (Electronic)IS - 0962-7480 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1093/occmed/kqw101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27492471">PM:27492471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Occup Med (Lond)\20160805-SuojalehtoH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Occup Med (Lond)\20160805-SuojalehtoH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160805, Suojalehto H</style></custom2><misc3><style face="normal" font="Arial">10.1093/occmed/kqw101</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,L.Z.</style></author><author><style face="normal" font="Arial"> Yang,L.T.</style></author><author><style face="normal" font="Arial"> Qiu,S.Q.</style></author><author><style face="normal" font="Arial"> Yang,G.</style></author><author><style face="normal" font="Arial"> Luo,X.Q.</style></author><author><style face="normal" font="Arial"> Miao,B.P.</style></author><author><style face="normal" font="Arial"> Geng,X.R.</style></author><author><style face="normal" font="Arial"> Liu,Z.Q.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Wen,Z.</style></author><author><style face="normal" font="Arial"> Wang,S.</style></author><author><style face="normal" font="Arial"> Zhang,H.P.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Li,H.B.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ENT Institute of The Research Center of Allergy &amp; Immunology, Shenzhen University School of Medicine, Shenzhen, China</style></auth-address><titles><title><style face="normal" font="Arial">Combination of specific allergen and probiotics induces specific regulatory B cells and enhances specific immunotherapy effect on allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="7" Year="2016">2016/7/29</year></dates><abstract><style face="normal" font="Arial">The therapeutic efficacy of allergen specific immunotherapy (SIT) on allergic diseases is to be improved. Probiotics can regulate immune response. This study aims to promote the effect of SIT on allergic rhinitis (AR) by co-administration with Clostridium butyricum (Cb). In this study, patients with AR sensitized to mite allergens were enrolled to this study, and treated with SIT or/and Cb. The therapeutic efficacy was evaluated by the total nasal symptom scores (NSS), medication scores, serum specific IgE levels and T helper (Th)2 cytokine levels. The improvement of immune regulation in the AR patients was assessed by immunologic approaches. The results showed that treating AR patients with SIT alone markedly reduced NSS and medication scores; but did not alter the serum specific IgE, Th2 cytokines and skin prick test (SPT) index. The clinical symptoms on AR in SIT group relapsed one month after stopping SIT. Co-administration of Cb significantly enhanced the efficacy of SIT on AR as shown by suppression of NSS, medication scores, serum specific IgE, Th2 cytokines and SPT index; the regulatory B cell frequency was also markedly increased. Such an effect on AR was maintained throughout the observation period even after stopping the treatment. Butyrate blocked the activation of histone deacetylase-1, the downstream activities of epsilon chain promoter activation, and the IgE production in the antigen specific B cells. On the other hand, butyrate induced the IL-10 expression in B cells with a premise of the B cell receptor activation by specific antigens. In conclusion, administration with Cb can markedly enhance the efficacy of SIT on AR</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.10946</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27486985">PM:27486985</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20160803-XuLZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20160803-XuLZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Xu LZ</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.10946</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Payne,S.J.</style></author><author><style face="normal" font="Arial"> Mitzner,R.</style></author><author><style face="normal" font="Arial"> Kunchala,S.</style></author><author><style face="normal" font="Arial"> Roland,L.</style></author><author><style face="normal" font="Arial"> McGinn,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, The Pennsylvania State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA</style></auth-address><titles><title><style face="normal" font="Arial">Acute Invasive Fungal Rhinosinusitis: A 15-Year Experience with 41 Patients</style></title><secondary-title><style face="normal" font="Arial">Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Otolaryngol Head Neck Surg</style></full-title></periodical><pages end="764" start="759">759-764</pages><volume><style face="normal" font="Arial">154</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Acute Disease</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Consultations</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunocompromised Host</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> surgical treatment</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To describe a 15-year single-institution experience of 41 cases of acute invasive fungal sinusitis (AIFRS), identify clinical indicators predictive of AIFRS, and discuss our approach to these high-acuity patients. STUDY DESIGN: Case series with chart review. SETTING: Tertiary referral center; The Pennsylvania State University Hershey Medical Center. SUBJECTS AND METHODS: A retrospective review was performed for AIFRS consultations between September 1999 and March 2014. Variables reviewed included underlying condition, presenting symptoms, absolute neutrophil count, disease extent on examination, radiographic findings, medical treatment, biopsy results, surgical treatment, and outcomes. Univariate analysis was performed to determine variables significantly associated with AIFRS. Outcome measures were assessed and patient assessment algorithm developed. RESULTS: Of 131 patients evaluated, 41 were diagnosed with AIFRS; 92.7% had an underlying hematologic malignancy. Disease predictive variables included absolute neutrophil count &lt;500/muL (P &lt; .0001; sensitivity = 78%), mucosal abnormalities of middle turbinate (P &lt; .0001; specificity = 88%) and septum (P &lt; .0001; specificity = 97%), and specifically, necrosis of the middle turbinate (P &lt; .0001; specificity = 97%). Twenty-five AIFRS patients (61%) survived until discharge; 25% (n = 10) expired secondary to AIFRS infection explicitly. CONCLUSION: This series represents one of the largest single-institution experiences of AIFRS published to date. Timely diagnosis is necessary to improve patient outcomes and limit morbidity. Maintaining a high index of suspicion in at-risk patient populations, followed by prompt evaluation and management, is crucial in suspected AIFRS. The presence or absence of certain findings appear to correlate with biopsy results and may aid in appropriately gauging clinical suspicion for the presence of AIFRS</style></abstract><notes><style face="normal" font="Arial">DA - 20160405IS - 1097-6817 (Electronic)IS - 0194-5998 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/0194599815627786</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26884367">PM:26884367</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Otolaryngol Head Neck Surg\2016-154-759-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Otolaryngol Head Neck Surg\2016-154-759-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160405, Payne SJ</style></custom2><misc3><style face="normal" font="Arial">10.1177/0194599815627786</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Araujo,E.S.</style></author><author><style face="normal" font="Arial"> de Jesus Pereira,C.A.</style></author><author><style face="normal" font="Arial"> de Moura Pereira,A.T.</style></author><author><style face="normal" font="Arial"> Moreira,J.M.</style></author><author><style face="normal" font="Arial"> de Rezende,M.C.</style></author><author><style face="normal" font="Arial"> Rodrigues,J.L.</style></author><author><style face="normal" font="Arial"> Teixeira,M.M.</style></author><author><style face="normal" font="Arial"> Negrao-Correa,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Parasitologia Bloco Q3-sala 242, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Avenida Antonio Carlos 6627, Campus Pampulha, Belo Horizonte, MG, Brazil denegrao@icb.ufmg.br</style></auth-address><titles><title><style face="normal" font="Arial">The role of IL-33/ST2, IL-4, and eosinophils on the airway hyperresponsiveness induced by Strongyloides venezuelensis in BALB/c mice</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="3117" start="3107">3107-3117</pages><volume><style face="normal" font="Arial">115</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Larva</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides</style></keyword><keyword><style face="normal" font="Arial"> Strongyloidiasis</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Strongyloidiasis is a neglected chronic nematode infection, in which the control of autoinfection rate and severity of disease is dependent on type 2 immune responses. Strongyloides also causes Th2 responses in the lung of infected animals and changes in airway function, including airway hyperresponsiveness (AHR). Mechanisms of AHR during Strongyloides venezuelensis infection are not entirely known, and we investigate here the role of IL-4, eosinophils, and IL-33/ST2. AHR was evaluated in infected mice by determining changes in lung function after increasing doses of methacholine. Balb/C, but no C57Bl/6, mice developed AHR, tissue eosinophilia, and increased local IL-4 and IL-5 production. Functional changes peaked at day 4 and 7, after the larva had left the lungs. AHR was clearly dependent on IL-4 but not on eosinophils, as evaluated by experiments in IL-4 and Gata-1-deficient mice. Experiments in ST2-deficient mice showed that this pathway was not needed for induction of AHR but was necessary for the maintenance of AHR and for Th2 responses in the lung. These studies clearly show a crucial role for IL-4 in the induction of AHR following S. venezuelensis infection and for IL-33/ST2 in maintaining AHR and lung Th2 responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160724IS - 1432-1955 (Electronic)IS - 0932-0113 (Linking)LA - engPT - Journal ArticleSB - IMCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-016-5066-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27102638">PM:27102638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\2016-115-3107-117.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\2016-115-3107-117.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160724, Araujo ES</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-016-5066-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Peters,R.L.</style></author><author><style face="normal" font="Arial"> Dang,T.D.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre of Food and Allergy Research, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Australia, 3052Institute of Inflammation and Repair, University of Manchester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Specific Oral Tolerance Induction in Childhood</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="794" start="784">784-794</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> desensitisation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food tolerance</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> specific oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="8" Year="2016">2016/8/6</year></dates><abstract><style face="normal" font="Arial">Food allergy continues to be a significant public health concern for which there are no approved treatments and management strategies primarily include allergen avoidance and pharmacological measures for accidental exposures. Food allergy is thought to result from either a failure to establish oral tolerance or the breakdown of existing oral tolerance, therefore, experimental preventative and treatment strategies are now aimed at inducing specific oral tolerance. This may occur in infancy prior to the development of food allergy through the optimal timing of dietary exposure (primary oral tolerance induction) or as a treatment for established food allergy through oral immunotherapy (secondary oral tolerance induction). Trials examining the effectiveness of early dietary allergen exposure to prevent food allergy have yielded promising results for peanut allergy but not so for other allergens, although the results of several trials are yet to be published. Although infant feeding guidelines no longer advise to avoid allergenic foods and exposure to food allergens orally is an important step in inducing food tolerance by the immune system, evidence regarding the optimal timing, dose and form of these foods into the infant's diet is lacking. Likewise, oral immunotherapy trials appear promising for inducing desensitisation however the long term efficacy in achieving sustained desensitisation and optimal protocols to achieve this are unknown. More research is needed in this emerging field. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Australia -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12620</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496561">PM:27496561</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160806-PetersRL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160806-PetersRL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Peters RL</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12620</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Castilla-Hernandez,E.</style></author><author><style face="normal" font="Arial"> Garriga-Baraut,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Priapism as a new symptom of anaphylaxis in a prepubescent child</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="872" start="871">871-872</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="6" Month="8" Year="2016">2016/8/6</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a severe, potentially life-threatening systemic hypersensitivity reaction. It is rapid in onset (minutes to a few hours) and typically involves multiple body systems1,2 . The prevalence in children is unknown, although there has been a prevalence of between 0.05 to 2% in the general population3,4 . There are several mechanisms involved: IgE-dependent immune-mediated, non-IgE-dependent immune-mediated, non-immune and idiopathic. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - LETTERCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12618</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496320">PM:27496320</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160806-CastillaHernandezE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160806-CastillaHernandezE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Castilla-Hernandez E</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12618</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,H.</style></author><author><style face="normal" font="Arial"> Radabaugh,T.</style></author><author><style face="normal" font="Arial"> Lu,Z.</style></author><author><style face="normal" font="Arial"> Galligan,M.</style></author><author><style face="normal" font="Arial"> Billheimer,D.</style></author><author><style face="normal" font="Arial"> Vercelli,D.</style></author><author><style face="normal" font="Arial"> Wright,A.L.</style></author><author><style face="normal" font="Arial"> Monks,T.J.</style></author><author><style face="normal" font="Arial"> Halonen,M.</style></author><author><style face="normal" font="Arial"> Lau,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, AZ, USA</style></auth-address><titles><title><style face="normal" font="Arial">Exploration of Early-Life Candidate Biomarkers for Childhood Asthma Using Antibody Arrays</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="701" start="696">696-701</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody arrays</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-3</style></keyword><keyword><style face="normal" font="Arial"> EPO</style></keyword><keyword><style face="normal" font="Arial"> Erythropoietin</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Proteomic approaches identifying biomarkers have been applied to asthma to only a very limited extent. METHODS: With an antibody array (RayBiotech, Norcross, GA) the relative intensity and rank differences of 444 proteins were compared in 24 plasma samples obtained at age 3, 11 from children with and 12 without asthma diagnoses at ages 5 and 9. Protein candidates identified by antibody array were quantitated by ELISA in an enlarged sample. Proteins found to differentiate children with and without asthma were also examined for association with known Year 1 asthma risk factors, eczema and wheeze. RESULTS: In the antibody array, four proteins had rank differences between asthma and non-asthma groups (FDR &lt;0.1). By ELISA, mean log (+/-SEM) erythropoietin (EPO) level (IU/L) was lower (0.750+/-0.048 vs. 0.898+/-0.035; p=0.006) and mean (+/-SEM) soluble GP130 (sGP130) level (ng/mL) was higher in the asthma vs. the non-asthma group (302+/-13 vs. 270+/-8; p=0.041). The other 2 array proteins (galactin-3, eotaxin-3) did not differ by ELISA by asthma. EPO related to the asthma risk factor, first year eczema, whereas sGP130 related to first year wheeze. CONCLUSIONS: Through two independent assessments, age 3 plasma levels of EPO and sGP130 were found related to childhood asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12613</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27434124">PM:27434124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160719-XuH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160719-XuH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Xu H</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12613</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gabet,S.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Couderc,R.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Seta,N.</style></author><author><style face="normal" font="Arial"> Momas,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">EA 4064 Laboratoire Sante Publique et Environnement, Universite Paris Descartes, Sorbonne Paris Cite,, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Early polysensitisation is associated to allergic multimorbidity in PARIS birth cohort infants</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="837" start="831">831-837</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Early sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environnement</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Polysensitisation</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword><keyword><style face="normal" font="Arial"> Sante publique</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Profiles of allergic sensitisation are poorly documented in infancy. Relations between early sensitisation and allergic morbidity need to be clarified. METHODS: This study dealt with children involved in the Pollution and Asthma Risk: an Infant Study (PARIS), a population-based prospective birth cohort. Allergic sensitisation to 12 food and 4 inhalant allergens was assessed at 18 months and defined by a specific IgE level >/= 0.35 kUA /L. Health data were collected by standardised questionnaires at 2 and 6 years. Early allergic profiles were identified by an unsupervised cluster analysis based on health data at 2 years and IgE measurements. Profiles were compared with regard to allergic morbidity and multimorbidity at 6 years. RESULTS: Sensitisation to any allergen concerned 13.6% of infants. By cluster analysis, 1525 infants were grouped in 3 profiles: 89.2% not or rarely sensitised (only 3.7% of sensitised), 9.2% mainly sensitised to one or few allergens (45.2% of monosensitised and 45.9% of paucisensitised), and 1.6% all polysensitised. The prevalence of doctor-diagnosed asthma, rhinitis, eczema, food allergy, and multimorbidity at 2 years increased from profile 1 to profile 3 (p-trend &lt; 0.001). At 6 years, symptoms of current asthma, rhinitis, eczema, and multimorbidity were significantly more frequent in the last two profiles. CONCLUSIONS: This study highlights, as early as 18 months of age, 3 profiles of increasing severity with regard to allergic sensitisation and diseases. These profiles also differ in terms of allergic morbidity at 6 years. Early sensitisation can predict allergic multimorbidity in childhood, and in the case of early polysensitisation, multimorbidity is more frequent as soon as infancy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12622</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27501330">PM:27501330</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160808-GabetS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160808-GabetS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Gabet S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12622</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van der Valk,J.P</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Flokstra-de Blok,B.M.</style></author><author><style face="normal" font="Arial"> van der Velde,J.L.</style></author><author><style face="normal" font="Arial"> de Groot,H.</style></author><author><style face="normal" font="Arial"> Wichers,H.J.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department Of Internal Medicine, Allergology, Erasmus MC, Rotterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">No difference in health-related quality of life, after a food challenge with cashew nut in children participating in a clinical trial</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="817" start="812">812-817</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental exposure</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Delta</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> teenagers</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="8" Year="2016">2016/8/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous studies showed that Health-Related Quality of Life (HRQL) significantly improved after the food challenge, with greater improvements in HRQL after a negative outcome than a positive outcome. It is currently unknown whether this also occurs in patients undergoing DBPCFCs with cashew nut in the context of a clinical trial. METHODS: Quality of life was studied in children enrolled in a cashew nut study using food allergy quality of life questionnaires (FAQLQs). Children, teenagers and parents of the children completed the questionnaires before the challenge test and 6 months after the DBPCFC with cashew nut. The difference in the change in HRQL between the children with a positive and negative DBPCFC outcome was studied by Mann-Whitney U test. RESULTS: In total 112 children (67 boys, median age 9 yrs.) were included. The children, teenagers and parents of the children completed in total 143 sets of questionnaires. There were no significant differences in baseline total and domain scores compared to the follow-up scores in the FAQLQ-CF, -TF and -PF. In children, the delta FAIM score in the negative DBPCFC tested group was significantly better than the delta FAIM score in the positive challenged group (p= 0.026). There were no significant differences in the changes in the scores of the FAQLQ-CF and FAQLQ-PF in the children with a positive challenge outcome, compared to the children with a negative challenge result. However, there was a significant difference in the change in score between the latter groups in the domain 'accidental exposure' of the FAQLQ-TF (p=0.049). CONCLUSION: This study showed no difference in change of HRQL scores after a DBPCFC with cashew nut in children participating in a clinical trial. The utility of HRQL as an outcome for clinical trials in food allergy may be limited if participant baseline HRQL is relatively unimpaired. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12621</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27495003">PM:27495003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160806-vanderValkJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160806-vanderValkJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, van der Valk JP</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12621</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gray,C.L.</style></author><author><style face="normal" font="Arial"> Levin,M.E.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergology, Red Cross War Memorial Children's Hospital, Cape TownDivision of Allergology, Red Cross War Memorial Children's Hospital, Cape TownDepartment of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape TownKing's College London, King's Health Partners, MRM &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, Department of Paediatric Allergy, Guy's and St Thomas' NHS Foundation Trust, London</style></auth-address><titles><title><style face="normal" font="Arial">Egg Sensitisation, Allergy and Component Patterns in African Children with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="715" start="709">709-715</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> African children</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen chip</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic mechanism</style></keyword><keyword><style face="normal" font="Arial"> Allergic mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Gal d 1</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ISAC 103</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Screening test</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> War</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Egg allergy is the most common food allergy in children with atopic dermatitis (AD). This study aimed to determine the prevalence of, component patterns and predictive values of screening tests in egg allergy in South African children with AD. METHODOLOGY: This was a prospective, observational study in a paediatric university hospital in Cape Town. Children with AD, aged 6 months to 10 years, were recruited randomly. They were assessed for sensitisation and allergy to egg by questionnaire, skin prick tests (SPT), Immuno Solid Phase Allergen Chip (ISAC 103) test, ImmunoCAP component tests to egg and ovomucoid (Gal d 1); and incremental food challenges. RESULTS: 100 participants (59 black Africans and 41 of mixed ethnicity) were enrolled, median age 42 months. There was a high rate of egg sensitisation of 54% and prevalence of confirmed egg allergy of 25%. History and screening laboratory tests overestimated egg allergy significantly. SPT to fresh egg white was significantly more sensitive in diagnosing egg allergy than SPT to the commercial egg white extract, and produced the highest area under the receiver operator characteristics (ROC) curve of all the screening tests in predicting true egg allergy. In those participants sensitised to egg, the component ovomucoid was best at differentiating true egg allergy from tolerance. Commonly used 95% Positive Predictive Values (PPV) for SPT to egg and ImmunoCAP egg white produced low PPV of 57% and 74% respectively in this population overall, with generally poorer predictive values amongst the black Africans than the mixed ethnicity participants. A SPT to fresh egg of 17 mm and ImmunoCAP egg white of 13 kU/L produced the best PPV for egg allergy in this population. CONCLUSION: The prevalence of egg allergy is high in African children with AD, but history of egg allergy and sensitisation to egg significantly overestimate the true egg allergy rate. SPT to fresh egg white was more sensitive than that to commercial egg white extract, hence fresh egg white should be recommended in an egg allergy screening panel. The component ovomucoid was useful for differentiating allergy from tolerance in egg-sensitised participants. Population specific 95% PPV for egg allergy tests may need to be established in developing world populations. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Africa -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12615</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27434263">PM:27434263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160719-GrayCL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160719-GrayCL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Gray CL</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12615</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Maslin,K.</style></author><author><style face="normal" font="Arial"> Patil,V.</style></author><author><style face="normal" font="Arial"> Kurukulaaratchy,R.</style></author><author><style face="normal" font="Arial"> Grundy,J.</style></author><author><style face="normal" font="Arial"> Glasbey,G.</style></author><author><style face="normal" font="Arial"> Twiselton,R.</style></author><author><style face="normal" font="Arial"> Dean,T.</style></author><author><style face="normal" font="Arial"> Arshad,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, Newport, Isle of Wight, PO30 5TG, UK</style></auth-address><titles><title><style face="normal" font="Arial">The prevalence, natural history and time trends of peanut allergy over the first 10 years of life in two cohorts born in the same geographical location 12 years apart</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="811" start="804">804-811</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time trends</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The aim of this study was to explore the natural history of peanut allergy in childhood in two birth cohorts from the same geographical region in the South of England. METHODS: The FAIR birth cohort was established on the Isle of Wight (UK) between 2001-2002 (n = 969). Children were followed up prospectively, skin prick tested (SPT) to peanut allergens at 1, 2, 3 and 10 years and food challenges performed. The Isle of Wight (IOW) Birth cohort was established in 1989 (n = 1456). SPTs were performed at 1, 2, 4 and 10 years. Peanut allergy was based on positive SPT and a good clinical history. RESULTS: In the FAIR cohort, the prevalence of sensitization to peanut was 0.4%, 2.0%, 2.0% and 2.4% at 1,2,3 and 10 years respectively. At 10 years of age, 12/828 (1.5%) children were diagnosed with peanut allergy. One child (8%) outgrew her peanut allergy between 3 and 10 years and two children (15%) presented with new onset peanut allergy. Over the first ten years of life, 13/934 (1.4%) children were diagnosed with peanut allergy. In the IOW cohort, 6/1034 (0.58%) were diagnosed with peanut allergy at 10 years. We found no significant differences between the FAIR and the IOW birth cohort for any of the time points studied. CONCLUSION: Peanut allergy appears to be stable over the first ten years of life in our cohorts. There was no significant difference in peanut sensitization or clinical peanut allergy between 1989 and 2001. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12616</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27434312">PM:27434312</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160719-VenterC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160719-VenterC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12616</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khoo,S.K.</style></author><author><style face="normal" font="Arial"> Makela,M.</style></author><author><style face="normal" font="Arial"> Chandler,D.</style></author><author><style face="normal" font="Arial"> Schultz,E.N.</style></author><author><style face="normal" font="Arial"> Jamieson,S.E.</style></author><author><style face="normal" font="Arial"> Goldblatt,J.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Lesouef,P.</style></author><author><style face="normal" font="Arial"> Zhang,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Paediatrics and Child Health, The University of Western Australia, Perth, AustraliaSkin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, FinlandAustralian Genome Research Facility Ltd, Perth, AustraliaSchool of Paediatrics and Child Health, The University of Western Australia, Perth, AustraliaTelethon Kids Institute, Centre for Child Health Research, The University of Western Australia, Perth, AustraliaGenetic Services &amp; Familial Cancer Program of Western Australia, King Edward Memorial Hospital for Women, Perth, AustraliaSkin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, FinlandSchool of Paediatrics and Child Health, The University of Western Australia, Perth, AustraliaSchool of Paediatrics and Child Health, The University of Western Australia, Perth, AustraliaTelethon Kids Institute, Centre for Child Health Research, The University of Western Australia, Perth, AustraliaSchool of Public Health, Curtin University, Perth, AustraliaCentre for Genetic Origins of Health and Disease, Curtin University and the University of Western Australia, Perth, Australia</style></auth-address><titles><title><style face="normal" font="Arial">No simple answers for the Finnish and Russian Karelia allergy contrast: Methylation of CD14 gene</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="727" start="721">721-727</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> CD14</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> familial</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Finnish and Russian Karelian children have a highly contrasting occurrence of asthma and allergy. In these two environments, we studied associations between total serum IgE with methylation levels in CD14. METHODS: 500 Finnish and Russian Karelian children were included in four groups: Finnish children with high IgE (n=126) and low IgE (n=124) as well as Russian children with high IgE (n=125) and low IgE (n=125). DNA was extracted from whole blood cells and pyrosequenced. Three CpG sites were selected in the promoter region of CD14. RESULTS: Methylation levels in two of the three CpG sites were higher in the Finnish compared to Russian Karelian children. In the promoter area of CD14, the Finnish compared to Russian children with low IgE had a significant (p&lt;0.0001) increase in methylation levels at the Amp5Site 2. Likewise, the Finnish compared to Russian children with high IgE had a significant (p=0.003) increase in methylation levels at the Amp5Site 3. In Russian children with low vs. high IgE there were significant differences in methylation levels, but this was not the case on the Finnish side. In the regression analysis, adding the methylation variation of CD14 to the model did not explain the higher asthma and allergy risk in the Finnish children. CONCLUSIONS: The methylation levels in the promoter region of CD14 gene were higher in the Finnish compared to Russian Karelian children. However, the methylation variation of this candidate gene did not explain the asthma and allergy contrast between these two areas. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160719IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27434019">PM:27434019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160719-KhooSK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160719-KhooSK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160719, Khoo SK</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12612</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sidhu,N.</style></author><author><style face="normal" font="Arial"> Jones,S.</style></author><author><style face="normal" font="Arial"> Perry,T.</style></author><author><style face="normal" font="Arial"> Thompson,T.</style></author><author><style face="normal" font="Arial"> Storm,E.</style></author><author><style face="normal" font="Arial"> Melguizo Castro,M.S.</style></author><author><style face="normal" font="Arial"> Nick,T.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Departments of *Pediatrics Emergency Medicine daggerPediatric Allergy and Immunology, and double daggerBiostatistics, University of Arkansas for Medical Sciences and Arkansas Children Hospital, Little Rock, AR</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of Anaphylaxis Management in a Pediatric Emergency Department</style></title><secondary-title><style face="normal" font="Arial">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Emerg Care</style></full-title></periodical><pages end="513" start="508">508-513</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> African American</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Arkansas</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> self-injectable</style></keyword><keyword><style face="normal" font="Arial"> self-injectable epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment guidelines</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: In 2006, the National Institute of Allergy and Infectious Disease established evidence-based treatment guidelines for anaphylaxis. The purpose of our study was to evaluate provider adherence to guidelines-based management for anaphylaxis in a tertiary care pediatric emergency department (ED). METHODS: Retrospective chart review was conducted of patients (0-18 years) presenting to the Arkansas Children Hospital ED from 2004 to 2011 for the treatment of anaphylaxis using International Classification of Diseases, Ninth Edition, codes. Multiple characteristics including demographics, clinical features, allergen source, and anaphylaxis management were collected. Fisher exact or chi tests were used to compare proportion of patients treated with intramuscular (IM) epinephrine in the preguideline versus postguideline period. Relative risk (RR) statistics were computed to estimate the ratio of patients who received self-injectable epinephrine prescription and allergy follow-up in the preguideline and postguideline groups. RESULTS: A total of 187 patients (median [range] age, 7 [1-18] years; 67% male; 48% African American) were evaluated. Food (44%) and hymenoptera stings (22%) were commonly described culprit allergens, whereas 29% had no identifiable allergen. Only 47% (n = 87) received epinephrine in the ED and 31% (n = 27) via the preferred IM route. Comparing postguideline (n = 126) versus preguideline (n = 61) periods demonstrated increase in the usage of the IM route (46% postguideline vs 6% preguideline; risk ratio (RR), 7.64; 95% confidence interval [CI], 2.04-46.0; P &lt; 0.001). Overall, 61% (n = 115) of the patients received self-injectable epinephrine upon discharge, and there were no significant differences between the groups (64% postguideline vs 56% preguideline, P = 0.30). Postguideline patients were more likely to receive a prescription compared with preguideline patients (64% postguideline vs 56% preguideline; RR, 1.15; 95% CI, 0.89-1.55; P = 0.30). Only 45% (n = 85) received an allergy referral. Postguideline patients were more likely to receive an allergy referral than preguideline patients (48% postguideline vs 41% preguideline; RR, 1.16; 95% CI, 0.81-1.73; P = 0.40). CONCLUSIONS: Provider use of IM epinephrine has improved since anaphylaxis guidelines were published. However, more provider education is needed to improve overall adherence of guidelines in a tertiary care pediatric ED</style></abstract><notes><style face="normal" font="Arial">DA - 20160805IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/PEC.0000000000000864</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27490724">PM:27490724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Emerg Care\2016-32-508-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Emerg Care\2016-32-508-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160805, Sidhu N</style></custom2><misc3><style face="normal" font="Arial">10.1097/PEC.0000000000000864</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marrs,T.</style></author><author><style face="normal" font="Arial"> Flohr,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Paediatric Allergy, Division of Asthma, Allergy and Lung Biology, King's College London. 2 Children's Allergies Department, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Westminster Bridge Road, Lambeth, SE1 7EH 3 Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London and Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">How Do Microbiota Influence the Development and Natural History of Eczema and Food Allergy?</style></title><secondary-title><style face="normal" font="Arial">Pediatr Infect Dis J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Infect Dis J</style></full-title></periodical><pages end="1261" start="1258">1258-1261</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="10" Month="8" Year="2016">2016/8/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1532-0987 (Electronic)IS - 0891-3668 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1097/INF.0000000000001314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27518828">PM:27518828</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Infect Dis J\20160812-MarrsT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Infect Dis J\20160812-MarrsT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Marrs T</style></custom2><misc3><style face="normal" font="Arial">10.1097/INF.0000000000001314</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">CaJacob,N.J.</style></author><author><style face="normal" font="Arial"> Cohen,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatric Gastroenterology, Hepatology, and Nutrition and Pediatrics, University of Alabama at Birmingham, Birmingham, AL</style></auth-address><titles><title><style face="normal" font="Arial">Update on Diarrhea</style></title><secondary-title><style face="normal" font="Arial">Pediatr Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Rev</style></full-title></periodical><pages end="322" start="313">313-322</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Alabama</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160802IS - 1526-3347 (Electronic)IS - 0191-9601 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1542/pir.2015-0099</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27482061">PM:27482061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Rev\2016-37-313-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Rev\2016-37-313-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160802, CaJacob NJ</style></custom2><misc3><style face="normal" font="Arial">10.1542/pir.2015-0099</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vargas,M.H.</style></author><author><style face="normal" font="Arial"> Campos,N.E.</style></author><author><style face="normal" font="Arial"> de Souza,R.G.</style></author><author><style face="normal" font="Arial"> da Cunha,A.A.</style></author><author><style face="normal" font="Arial"> Nunez,N.K.</style></author><author><style face="normal" font="Arial"> Pitrez,P.M.</style></author><author><style face="normal" font="Arial"> Donadio,M.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research (IPB), Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Protective effect of early prenatal stress on the induction of asthma in adult mice: Sex-specific differences</style></title><secondary-title><style face="normal" font="Arial">Physiol Behav</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Physiol Behav</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="8" Year="2016">2016/8/24</year></dates><abstract><style face="normal" font="Arial">Adversities faced during the prenatal period can be related to the onset of diseases in adulthood. However, little is known about the effects on the respiratory system. This study aimed to evaluate the effects of prenatal stress in two different time-points during pregnancy on pulmonary function and on the inflammatory profile of mice exposed to an asthma model. Male and female BALB/c mice were divided into 3 groups: control (CON), prenatal stress from the second week of pregnancy (PNS1) and prenatal stress on the last week of pregnancy (PNS2). Both PNS1 and PNS2 pregnant females were submitted to restraint stress. As adults, fear/anxiety behaviors were assessed, and animals were subjected to an asthma model induced by ovalbumin. Pulmonary function, inflammatory parameters in bronchoalveolar lavage (BAL) and histology were evaluated. There was a significant decrease in the number of entries and time spent in the central quadrant on the open field test for the PNS1 animals. Females (PNS1) showed improved pulmonary function (airway resistance, tissue damping and pulmonary elastance), significant increase in the percentage of neutrophils and lymphocytes and a decrease in eosinophils when compared to controls. There was a significant decrease in inflammatory cytokines in BAL of both males (IL-5 and IL-13) and females (IL-4, IL-5 and IL-13) from PNS1 and PNS2 when compared to the CON group. Prenatal stress starting from the beginning of pregnancy reduces the impact of asthma development in adult female mice, showing an improved pulmonary function and a lower inflammatory response in the lungs</style></abstract><notes><style face="normal" font="Arial">DA - 20160828IS - 1873-507X (Electronic)IS - 0031-9384 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.physbeh.2016.08.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27568231">PM:27568231</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Physiol Behav\20160828-VargasMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Physiol Behav\20160828-VargasMH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160828, Vargas MH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.physbeh.2016.08.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Samitas,K.</style></author><author><style face="normal" font="Arial"> Malmhall,C.</style></author><author><style face="normal" font="Arial"> Radinger,M.</style></author><author><style face="normal" font="Arial"> Ramos-Ramirez,P.</style></author><author><style face="normal" font="Arial"> Lu,Y.</style></author><author><style face="normal" font="Arial"> Deak,T.</style></author><author><style face="normal" font="Arial"> Semitekolou,M.</style></author><author><style face="normal" font="Arial"> Gaga,M.</style></author><author><style face="normal" font="Arial"> Sjostrand,M.</style></author><author><style face="normal" font="Arial"> Lotvall,J.</style></author><author><style face="normal" font="Arial"> Bossios,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Precursor B Cells Increase in the Lung during Airway Allergic Inflammation: A Role for B Cell-Activating Factor</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0161161">e0161161-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> BAFF</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> CD40</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> costimulation</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> TACI</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: B cells, key cells in allergic inflammation, differentiate in the bone marrow and their precursors include pro-B, pre-B and immature B cells. Eosinophil progenitor cells increase in the lung after allergen exposure. However, the existence and possible role of B cell precursors in the lung during allergic inflammation remains elusive. METHODS: A BALB/c mouse model of allergic airway inflammation was utilized to perform phenotypic and quantification analyses of pro-B and pre-B cells in the lung by flow cytometry. B cell maturation factors IL-7 and B cell-activating factor (BAFF) and their receptors (CD127 and BAFFR, BCMA, TACI, respectively) were also evaluated in the lung and serum. The effect of anti-BAFF treatment was investigated both in vivo (i.p. administration of BAFF-R-Ig fusion protein) and in vitro (colony forming cell assay). Finally, BAFF levels were examined in the bronchoalveolar lavage (BAL) of asthmatic patients and healthy controls. RESULTS: Precursor pro and pre-B cells increase in the lung after allergen exposure, proliferate in the lung tissue in vivo, express markers of chemotaxis (CCR10 and CXCR4) and co-stimulation (CD40, CD86) and are resistant to apoptosis (Bax). Precursor B cells express receptors for BAFF at baseline, while after allergen challenge both their ligand BAFF and the BCMA receptor expression increases in B cell precursors. Blocking BAFFR in the lung in vivo decreases eosinophils and proliferating precursor B cells. Blocking BAFFR in bone marrow cultures in vitro reduces pre-B colony formation units. BAFF is increased in the BAL of severe asthmatics. CONCLUSION: Our data support the concept of a BAFF-mediated role for B cell precursors in allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - Sweden -CO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0161161</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27513955">PM:27513955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0161161.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0161161.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Samitas K</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0161161</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elhaik,G.S.</style></author><author><style face="normal" font="Arial"> Moshkovits,I.</style></author><author><style face="normal" font="Arial"> Shemesh,A.</style></author><author><style face="normal" font="Arial"> Filiba,A.</style></author><author><style face="normal" font="Arial"> Tsirulsky,Y.</style></author><author><style face="normal" font="Arial"> Vronov,E.</style></author><author><style face="normal" font="Arial"> Shagan,M.</style></author><author><style face="normal" font="Arial"> Apte,R.N.</style></author><author><style face="normal" font="Arial"> Benharroch,D.A.</style></author><author><style face="normal" font="Arial"> Karo-Atar,D.</style></author><author><style face="normal" font="Arial"> Dagan,R.</style></author><author><style face="normal" font="Arial"> Munitz,A.</style></author><author><style face="normal" font="Arial"> Mizrachi,N.Y.</style></author><author><style face="normal" font="Arial"> Porgador,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben Gurion University of the Negev, Beer Sheva 84105, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Natural Killer Receptor 1 Dampens the Development of Allergic Eosinophilic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0160779">e0160779-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Beer</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Ccl24</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> NK cells</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The function of NCR1 was studied in a model of experimental asthma, classified as a type 1 hypersensitivity reaction, in mice. IgE levels were significantly increased in the serum of OVA immunized NCR1 deficient (NCR1gfp/gfp) mice in comparison to OVA immunized wild type (NCR1+/+) and adjuvant immunized mice. Histological analysis of OVA immunized NCR1gfp/gfp mice revealed no preservation of the lung structure and overwhelming peribronchial and perivascular granulocytes together with mononuclear cells infiltration. OVA immunized NCR+/+ mice demonstrated preserved lung structure and peribronchial and perivascular immune cell infiltration to a lower extent than that in NCR1gfp/gfp mice. Adjuvant immunized mice demonstrated lung structure preservation and no immune cell infiltration. OVA immunization caused an increase in PAS production independently of NCR1 presence. Bronchoalveolar lavage (BAL) revealed NCR1 dependent decreased percentages of eosinophils and increased percentages of lymphocytes and macrophages following OVA immunization. In the OVA immunized NCR1gfp/gfp mice the protein levels of eosinophils' (CCL24) and Th2 CD4+ T-cells' chemoattractants (CCL17, and CCL24) in the BAL are increased in comparison with OVA immunized NCR+/+ mice. In the presence of NCR1, OVA immunization caused an increase in NK cells numbers and decreased NCR1 ligand expression on CD11c+GR1+ cells and decreased NCR1 mRNA expression in the BAL. OVA immunization resulted in significantly increased IL-13, IL-4 and CCL17 mRNA expression in NCR1+/+ and NCR1gfp/gfp mice. IL-17 and TNFalpha expression increased only in OVA-immunized NCR1+/+mice. IL-6 mRNA increased only in OVA immunized NCR1gfp/gfp mice. Collectively, it is demonstrated that NCR1 dampens allergic eosinophilic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0160779</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27580126">PM:27580126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0160779.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0160779.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Elhaik GS</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0160779</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,B.</style></author><author><style face="normal" font="Arial"> An,L.</style></author><author><style face="normal" font="Arial"> Han,Y.</style></author><author><style face="normal" font="Arial"> Gao,H.</style></author><author><style face="normal" font="Arial"> Ren,H.</style></author><author><style face="normal" font="Arial"> Zhao,X.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Krishnan,H.B.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Soybean Biology in Chinese Ministry of Education (Key Laboratory of Soybean Biology and Breeding/Genetics of Chinese Agriculture Ministry), Northeast Agricultural University, Harbin 150030, China</style></auth-address><titles><title><style face="normal" font="Arial">Transcriptome Profile of Near-Isogenic Soybean Lines for beta-Conglycinin alpha-Subunit Deficiency during Seed Maturation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0159723">e0159723-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen genes</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cupin</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Differentially expressed gene</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> Glycine max</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Proline</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein quality</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Crossing, backcrossing, and molecular marker-assisted background selection produced a soybean (Glycine max) near-isogenic line (cgy-2-NIL) containing the cgy-2 allele, which is responsible for the absence of the allergenic alpha-subunit of beta-conglycinin. To identify alpha-null-related transcriptional changes, the gene expressions of cgy-2-NIL and its recurrent parent DN47 were compared using Illumina high-throughput RNA-sequencing of samples at 25, 35, 50, and 55 days after flowering (DAF). Seeds at 18 DAF served as the control. Comparison of the transcript profiles identified 3,543 differentially expressed genes (DEGs) between the two genotypes, with 2,193 genes downregulated and 1,350 genes upregulated. The largest numbers of DEGs were identified at 55 DAF. The DEGs identified at 25 DAF represented a unique pattern of GO category distributions. KEGG pathway analyses identified 541 altered metabolic pathways in cgy-2-NIL. At 18DAF, 12 DEGs were involved in arginine and proline metabolism. The cgy-2 allele in the homozygous form modified the expression of several Cupin allergen genes. The cgy-2 allele is an alteration of a functional allele that is closely related to soybean protein amino acid quality, and is useful for hypoallergenic soybean breeding programs that aim to improve seed protein quality</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0159723</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27532666">PM:27532666</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0159723.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0159723.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Song B</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0159723</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Toljamo,A.</style></author><author><style face="normal" font="Arial"> Blande,D.</style></author><author><style face="normal" font="Arial"> Karenlampi,S.</style></author><author><style face="normal" font="Arial"> Kokko,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental and Biological Sciences, University of Eastern Finland, Kuopio, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Reprogramming of Strawberry (Fragaria vesca) Root Transcriptome in Response to Phytophthora cactorum</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0161078">e0161078-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Ethylene</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Fragaria</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Hawaii</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Jasmonic acid</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Phytophthora</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Roots</style></keyword><keyword><style face="normal" font="Arial"> Salicylic Acid</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Strawberry</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Crown rot (Phytophthora cactorum) causes significant economic losses in strawberry production. The best control strategy would be to use resistant cultivars, but polygenically inherited resistance makes the breeding of the garden strawberry (Fragaria x ananassa) challenging. The diploid wild strawberry Fragaria vesca Hawaii 4 genotype was shown previously to have resistance against crown rot. To explore the resistance mechanisms, we inoculated the roots of Hawaii 4 with P. cactorum in a novel in vitro hydroponic system to minimize interference caused by other microbes. Major reprogramming of the root transcriptome occurred, involving 30% of the genes. The surveillance system of the plant shifted from the development mode to the defense mode. Furthermore, the immune responses as well as many genes involved in the biosynthesis of the defense hormones jasmonic acid, ethylene and salicylic acid were up-regulated. Several major allergen-like genes encoding PR-10 proteins were highly expressed in the inoculated plants, suggesting that they also have a crucial role in the defense responses against P. cactorum. Additionally, flavonoids and terpenoids may be of vital importance, as several genes involved in their biosynthesis were up-regulated. The cell wall biosynthesis and developmental processes were down-regulated, possibly as a result of the down-regulation of the key genes involved in the biosynthesis of growth-promoting hormones brassinosteroids and auxin. Of particular interest was the expression of potential resistance genes in the recently identified P. cactorum resistance locus RPc-1. These new findings help to target the breeding efforts aiming at more resistant strawberry cultivars</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0161078</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27518577">PM:27518577</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0161078.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0161078.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Toljamo A</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0161078</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,C.</style></author><author><style face="normal" font="Arial"> Jiang,X.</style></author><author><style face="normal" font="Arial"> Luo,M.</style></author><author><style face="normal" font="Arial"> Feng,G.</style></author><author><style face="normal" font="Arial"> Sun,Q.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Guangxi Medical College, Nanning, Guangxi, China</style></auth-address><titles><title><style face="normal" font="Arial">Mycobacterium vaccae Nebulization Can Protect against Asthma in Balb/c Mice by Regulating Th9 Expression</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0161164">e0161164-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mycobacteria</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Asthma is a heterogeneous disease characterized by chronic airway inflammation. CD4(+) T-helper 9 (Th9) cells are closely linked to asthma, helping to regulate inflammation and immunity. Epidemiological studies showed that mycobacteria infections are negatively associated with asthma. Our previous research showed that inactivated Mycobacterium phlei nebulization alleviated the airway hyperresponsiveness and inflammation of asthma. However, the relationship between Th9 cells and mycobacteria remains unknown. Here, we evaluated the relationship between Mycobacterium vaccae nebulization and Th9 cells in asthmatic mice. Eighteen Balb/c mice were randomized into 3 groups of 6 mice each (normal control group, asthma control group, and nebulization asthma group [Neb. group]). The Neb. group was nebulized with M. vaccae one month before establishment of the asthmatic model with ovalbumin (OVA) sensitization, and the normal and asthma control groups were nebulized with phosphate-buffered saline. The hyperresponsiveness of the mouse airways was assessed using a non-invasive lung function machine. Lung airway inflammation was evaluated by hematoxylin and eosin and periodic acid-Schiff staining. Cytokine interlukin-9 (IL-9) concentration and OVA-specific IgE in the bronchoalveolar lavage fluid were measured by enzyme-linked immunosorbent assays. The percentages of gammadeltaTCR+ CD3+, IL-9+CD3+, IL-10+CD3+ lymphocytes, and IL9+gammadeltaT and IL-10+gammadeltaT cells were detected by flow cytometry. The airway inflammation and concentration of IL-9 and OVA-specific IgE were significantly reduced in the Neb. group compared to the asthma control group. The Neb. group had lower airway hyperresponsiveness, percentages of gammadeltaTCR+CD3+ and IL-9+CD3+ lymphocytes, and IL9+gammadeltaT cells, and higher percentages of IL-10+CD3+ lymphocytes and IL-10+gammadeltaT cells compared to the asthma control group. Thus, mouse bronchial asthma could be prevented by M. vaccae nebulization. The mechanism could involve M. vaccae-mediated effects on induction of IL-9 secretion and suppression of IL-10 secretion from gammadeltaT cells. gammadeltaT cells showed prominent IL-10 expression, indicating that they possibly belong to the Th9 family</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0161164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27518187">PM:27518187</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0161164.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0161164.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Li C</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0161164</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Resch,Y.</style></author><author><style face="normal" font="Arial"> Blatt,K.</style></author><author><style face="normal" font="Arial"> Malkus,U.</style></author><author><style face="normal" font="Arial"> Fercher,C.</style></author><author><style face="normal" font="Arial"> Swoboda,I.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> Chen,K.W.</style></author><author><style face="normal" font="Arial"> Seiberler,S.</style></author><author><style face="normal" font="Arial"> Mittermann,I.</style></author><author><style face="normal" font="Arial"> Lupinek,C.</style></author><author><style face="normal" font="Arial"> Rodriguez-Dominguez,A.</style></author><author><style face="normal" font="Arial"> Zieglmayer,P.</style></author><author><style face="normal" font="Arial"> Zieglmayer,R.</style></author><author><style face="normal" font="Arial"> Keller,W.</style></author><author><style face="normal" font="Arial"> Krzyzanek,V.</style></author><author><style face="normal" font="Arial"> Valent,P.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0160641">e0160641-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chitinase</style></keyword><keyword><style face="normal" font="Arial"> chitinases</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Crustacea</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Der p 18</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mollusca</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The house dust mite (HDM) allergen Der p 18 belongs to the glycoside hydrolase family 18 chitinases. The relevance of Der p 18 for house dust mite allergic patients has only been partly investigated. OBJECTIVE: To perform a detailed characterization of Der p 18 on a molecular, structural and immunological level. METHODS: Der p 18 was expressed in E. coli, purified to homogeneity, tested for chitin-binding activity and its secondary structure was analyzed by circular dichroism. Der p 18-specific IgG antibodies were produced in rabbits to localize the allergen in mites using immunogold electron microscopy and to search for cross-reactive allergens in other allergen sources (i.e. mites, crustacea, mollusca and insects). IgE reactivity of rDer p 18 was tested with sera from clinically well characterized HDM-allergic patients (n = 98) and its allergenic activity was analyzed in basophil activation experiments. RESULTS: Recombinant Der p 18 was expressed and purified as a folded, biologically active protein. It shows weak chitin-binding activity and partial cross-reactivity with Der f 18 from D. farinae but not with proteins from the other tested allergen sources. The allergen was mainly localized in the peritrophic matrix of the HDM gut and to a lower extent in fecal pellets. Der p 18 reacted with IgE from 10% of mite allergic patients from Austria and showed allergenic activity when tested for basophil activation in Der p 18-sensitized patients. CONCLUSION: Der p 18 is a rather genus-specific minor allergen with weak chitin-binding activity but exhibits allergenic activity and therefore should be included in diagnostic test panels for HDM allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160823IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - Austria -CO - Germany -CO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0160641</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27548813">PM:27548813</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0160641.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0160641.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160823, Resch Y</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0160641</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lesniak,M.</style></author><author><style face="normal" font="Arial"> Dyga,W.</style></author><author><style face="normal" font="Arial"> Rusinek,B.</style></author><author><style face="normal" font="Arial"> Mazur,M.</style></author><author><style face="normal" font="Arial"> Czarnobilska,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison of the basophil activation test versus the nasal provocation test in establishing eligibility for specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Pol Arch Med Wewn</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol Arch Med Wewn</style></full-title></periodical><pages end="529" start="521">521-529</pages><volume><style face="normal" font="Arial">126</style></volume><number><style face="normal" font="Arial">7-8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="8" Year="2016">2016/8/25</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION Allergic rhinitis (AR) is the most common atopic disease. Specific immunotherapy (SIT) is the only effective treatment method for AR. In uncertain diagnostic cases, before establishing eligibility for SIT, nasal provocation tests (NPTs) should be performed. However, there are numerous contraindications to performing NPTs, and there is ongoing search for an alternative in vitro method. OBJECTIVES The aim of the study was to determine whether a specific in vitro provocation, that is, the basophil activation test (BAT), may replace a specific in vivo provocation, that is, the NPT, in establishing patient's eligibility for SIT. PATIENTS AND METHODS The study included 30 patients with AR caused by allergy to house dust mite or birch pollen, referred for SIT. The assessment of basophil activation by measuring CD63 antigen expression was performed using the Flow2 CAST test. Basophils were stimulated with allergen preparation (concentrations of 5000, 500, and 50 standardized biological units) used in NPTs. BAT results were expressed as stimulation index (SI) and basophil reactivity (BR). RESULTS Allergen concentrations of 500 and 50 SBU proved to be appropriate for basophil stimulation. Median SI and BR were higher for positive NPT results than for negative NPT results (P &lt;0.001). Sensitivity for SI and BR was in the range from 83% to 100%; specificity, from 78% to 89%; positive predictive value, from 75% to 87%; and negative predictive value, from 89% to 100%. We observed a high correlation of the analyzed parameters for the allergen concentrations of 500 and 50 SBU (range, 0.58-0.74; P &lt;0.05). CONCLUSIONS If there are contraindications to performing the NPT, BAT may be regarded as an alternative in establishing patients' eligibility for SIT. The optimal concentrations of allergen preparations are 500 and 50 SBU. Both SI and BR are good indicators of basophil activation</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1897-9483 (Electronic)IS - 0032-3772 (Linking)LA - engPT - Journal ArticleSB - IMCO - POland -</style></notes><work-type><style face="normal" font="Arial">10.20452/pamw.3525</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27578221">PM:27578221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol Arch Med Wewn\2016-126-521-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol Arch Med Wewn\2016-126-521-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Lesniak M</style></custom2><misc3><style face="normal" font="Arial">10.20452/pamw.3525</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosenberg,H.F.</style></author><author><style face="normal" font="Arial"> Druey,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inflammation Immunobiology Section, Laboratory of Allergic Diseases, National Institutes of Health, Bethesda, MD 20892</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophils, galectins, and a reason to breathe</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></full-title></periodical><pages end="9141" start="9139">9139-9141</pages><volume><style face="normal" font="Arial">113</style></volume><number><style face="normal" font="Arial">33</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Galectins</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="5" Month="8" Year="2016">2016/8/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1073/pnas.1610644113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496328">PM:27496328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2016-113-9139-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2016-113-9139-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Rosenberg HF</style></custom2><misc3><style face="normal" font="Arial">10.1073/pnas.1610644113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deliu,M.</style></author><author><style face="normal" font="Arial"> Sperrin,M.</style></author><author><style face="normal" font="Arial"> Belgrave,D.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Health Informatics, Institute of Population Health, University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Identification of Asthma Subtypes Using Clustering Methodologies</style></title><secondary-title><style face="normal" font="Arial">Pulm Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Pulm Ther</style></abbr-1></periodical><pages end="41" start="19">19-41</pages><volume><style face="normal" font="Arial">2</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Age of Onset</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Asthma is a heterogeneous disease comprising a number of subtypes which may be caused by different pathophysiologic mechanisms (sometimes referred to as endotypes) but may share similar observed characteristics (phenotypes). The use of unsupervised clustering in adult and paediatric populations has identified subtypes of asthma based on observable characteristics such as symptoms, lung function, atopy, eosinophilia, obesity, and age of onset. Here we describe different clustering methods and demonstrate their contributions to our understanding of the spectrum of asthma syndrome. Precise identification of asthma subtypes and their pathophysiological mechanisms may lead to stratification of patients, thus enabling more precise therapeutic and prevention approaches</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 2364-1754 (Print)IS - 2364-1754 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s41030-016-0017-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512723">PM:27512723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Ther\2016-2-19-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Ther\2016-2-19-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Deliu M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s41030-016-0017-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ben Ghezala,H.</style></author><author><style face="normal" font="Arial"> Kouraichi,N.</style></author><author><style face="normal" font="Arial"> Brahmi,N.</style></author><author><style face="normal" font="Arial"> Bouguerba,A.</style></author><author><style face="normal" font="Arial"> Thabet,H.</style></author><author><style face="normal" font="Arial"> Amamou,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis in a medical intensive care unit: Experience of a Tunisian reference center</style></title><secondary-title><style face="normal" font="Arial">Reanimation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Reanimation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1951-6959</style></isbn><abstract><style face="normal" font="Arial">Anaphylaxis is the most severe immediate hypersensitivity reaction. However, it is underreported in Tunisia. We decided to perform this study in order to describe the clinical and epidemiological features of anaphylactic reactions recorded in a Tunisian reference center</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Tunisia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13546-016-1221-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13546-016-1221-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Reanimation\20160824-BenGhezalaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Reanimation\20160824-BenGhezalaH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Ben Ghezala H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13546-016-1221-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Coenraads,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">European Commission, Directorate General for Health and Food Safety, 11, rue E. Ruppert, L-2920 Luxembourg, Luxembourg.</style></auth-address><titles><title><style face="normal" font="Arial">Revision of the opinion on hydrolysed wheat proteins - Sensitisation only</style></title><secondary-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="668">668-</pages><volume><style face="normal" font="Arial">73</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Cosmetics</style></keyword><keyword><style face="normal" font="Arial"> drug effects</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant protein</style></keyword><keyword><style face="normal" font="Arial"> Plant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Triticum</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="0" Month="11" Year="2015">2015/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20151102IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Cosmetics)RN - 0 (Plant Proteins)SB - IMCO - Luxembourg -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.yrtph.2015.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26279001">PM:26279001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\2015-73-668.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\2015-73-668.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151102, Coenraads PJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.yrtph.2015.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schafer,B.W.</style></author><author><style face="normal" font="Arial"> Embrey,S.K.</style></author><author><style face="normal" font="Arial"> Herman,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dow AgroSciences LLC, Indianapolis, IN, 46268, USA</style></auth-address><titles><title><style face="normal" font="Arial">Rapid simulated gastric fluid digestion of in-seed/grain proteins expressed in genetically engineered crops</style></title><secondary-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> Cotton</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Double mutant</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> gastric digestion</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> SGF</style></keyword><keyword><style face="normal" font="Arial"> simulated gastric fluid</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="8" Year="2016">2016/8/4</year></dates><abstract><style face="normal" font="Arial">The speed of simulated gastric digestion of proteins expressed in genetically engineered (GE) crops is commonly used to inform the allergenicity risk assessment. However, persistence of purified proteins in simulated gastric fluid (SGF) is poorly correlated with the allergenic status of proteins. It has been proposed that the plant or food matrix may affect the digestion of proteins and should be considered in interpreting digestion results. Here the SGF digestion of several GE proteins both as purified preparations and in soybean, corn, and cotton seed/grain extracts (in-matrix) are compared. Cry1F, Cry1Ac, phosphinothricin acetyltransferase (PAT), aryloxyalkanoate dioxygenase-1 (AAD-1), aryloxyalkanoate dioxygenase-12 (AAD-12), and double mutant 5-enol pyruvylshikimate-3-phosphate synthase (2mEPSPS) were all found to rapidly digest both as purified protein preparations and in seed/grain extracts from GE crops expressing these proteins. Based on these results, purified protein from microbial sources is a suitable surrogate for proteins in-matrix when conducting SGF digestion studies</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.yrtph.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27497625">PM:27497625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20160807-SchaferBW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20160807-SchaferBW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, Schafer BW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.yrtph.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kianifar,H.R.</style></author><author><style face="normal" font="Arial"> Pourreza,A.</style></author><author><style face="normal" font="Arial"> Jabbari,Azad F.</style></author><author><style face="normal" font="Arial"> Yousefzadeh,H.</style></author><author><style face="normal" font="Arial"> Masomi,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Sensitivity Comparison of the Skin Prick Test and Serum and Fecal Radio Allergosorbent Test (RAST) in Diagnosis of Food Allergy in Children</style></title><secondary-title><style face="normal" font="Arial">Rep Biochem Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rep Biochem Mol Biol</style></full-title></periodical><pages end="103" start="98">98-103</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Radioallergosorbent Test</style></keyword><keyword><style face="normal" font="Arial"> rast</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Diagnosis of food allergy is difficult in children. Food allergies are diagnosed using several methods that include medical histories, clinical examinations, skin prick and serum-specific immunoglobulin E (IgE) tests, radio-allergosorbent test (RAST), food challenge, and supervised elimination diets. In this study we evaluated allergies to cow's milk, egg, peanut, and fish in children with suspected food allergies with skin prick tests and serum and feces RAST. METHODS: Forty-one children with clinical symptoms of food allergies were enrolled in the study. Skin prick tests and serum and fecal RAST were performed and compared with challenge tests. RESULTS: The most common sites of food allergy symptoms were gastrointestinal (82.9%) and skin (48.8%). 100% of the patients responded to the challenge tests with cow's milk, egg, peanut, and fish. 65% of the patients tested positive with the skin prick test, 12.1% tested positive with serum RAST, and 29.2% tested positive with fecal RAST. CONCLUSION: The skin prick test was more sensitive than serum or fecal RAST, and fecal RAST was more than twice as sensitive as serum RAST</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 2322-3480 (Electronic)IS - 2322-3480 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27536703">PM:27536703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rep Biochem Mol Biol\2016-4-98-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rep Biochem Mol Biol\2016-4-98-103.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Kianifar HR</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matulonga,B.</style></author><author><style face="normal" font="Arial"> Rava,M.</style></author><author><style face="normal" font="Arial"> Siroux,V.</style></author><author><style face="normal" font="Arial"> Bernard,A.</style></author><author><style face="normal" font="Arial"> Dumas,O.</style></author><author><style face="normal" font="Arial"> Pin,I.</style></author><author><style face="normal" font="Arial"> Zock,J.P.</style></author><author><style face="normal" font="Arial"> Nadif,R.</style></author><author><style face="normal" font="Arial"> Leynaert,B.</style></author><author><style face="normal" font="Arial"> Le Moual,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inserm, UMR 1152, Pathophysiology and Epidemiology of Respiratory Diseases, Epidemiology Team, F-75890, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Women using bleach for home cleaning are at increased risk of non-allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med</style></full-title></periodical><pages end="271" start="264">264-271</pages><volume><style face="normal" font="Arial">117</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bleach</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic cough</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> EGEA</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> skin prick-test</style></keyword><keyword><style face="normal" font="Arial"> skin prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white blood cell</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bleach is widely used for household cleaning. Although it is recognized that occupational use of bleach may have adverse respiratory health effects, it is unknown whether common domestic use of bleach may be a risk factor for asthma. AIM: To assess whether the domestic use of bleach for home cleaning is associated with asthma and other respiratory outcomes. METHODS: Questionnaire-based information on respiratory symptoms and cleaning habits and data from skin prick-tests, bronchial responsiveness challenge and white blood cells were analyzed in 607 women participating in the follow-up of the Epidemiological Study on the Genetics and Environment of Asthma (EGEA). Bleach use was evaluated in 3 categories (&lt;1 day/week; 1-3 days/week; 4-7 days/week "frequent"). RESULTS: Overall, 37% of the women reported using bleach weekly. Women using bleach frequently (11%) were more likely to have current asthma as compared to non-users (adjusted Odds-Ratio (aOR) = 1.7; 95% Confidence Interval (95%CI) 1.0-3.0). Among women with asthma, frequent use of bleach was significantly associated with higher blood neutrophil cell counts. Bleach use was significantly associated with non-allergic asthma (aOR 3.3; 95%CI 1.5-7.1), and more particularly with non-allergic adult-onset asthma (aOR 4.9; 95%CI 2.0-11.6). Consistently, among women without allergic sensitization, significant positive associations were found between use of bleach and bronchial hyperresponsiveness, asthma like-symptoms and chronic cough. No association was observed for allergic asthma. CONCLUSIONS: Frequent use of bleach for home-cleaning is associated with non-allergic adult-onset asthma, elevated neutrophil counts and lower-airway symptoms in women</style></abstract><notes><style face="normal" font="Arial">DA - 20160805IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleSB - IMCO - France -CO - Spain -CO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmed.2016.06.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27492540">PM:27492540</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2016-117-264-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2016-117-264-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160805, Matulonga B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmed.2016.06.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kobayashi,H.</style></author><author><style face="normal" font="Arial"> Taira,T.</style></author><author><style face="normal" font="Arial"> Wakuda,K.</style></author><author><style face="normal" font="Arial"> Takahashi,T.</style></author><author><style face="normal" font="Arial"> Endo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A favorable clinical effect of an expectorant in allergic bronchopulmonary mycosis caused by Schizophyllum commune</style></title><secondary-title><style face="normal" font="Arial">Respir Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med Case Rep</style></full-title></periodical><pages end="57" start="54">54-57</pages><volume><style face="normal" font="Arial">19</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Bromhexine</style></keyword><keyword><style face="normal" font="Arial"> Bronchoscopy</style></keyword><keyword><style face="normal" font="Arial"> bronchus</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Schizophyllum</style></keyword><keyword><style face="normal" font="Arial"> Schizophyllum commune</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">An 80-year-old Japanese woman with wet cough and dyspnea was diagnosed with pneumonia at a clinic. Antibiotics did not improve her symptoms; therefore, she was referred to our hospital one month after symptom onset. Chest radiograph findings revealed complete collapse of the left lung. Bronchoscopy showed white mucus plug in the left main bronchus, which could not be removed. She was initially treated with bromhexine. Subsequently, culture results of the mucus plug specimen obtained during bronchoscopy yielded Schizophyllum commune. After three weeks, improvement of the collapsed lung was observed on chest radiograph</style></abstract><notes><style face="normal" font="Arial">DA - 20160804IS - 2213-0071 (Electronic)IS - 2213-0071 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmcr.2016.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27489762">PM:27489762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med Case Rep\2016-19-54-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med Case Rep\2016-19-54-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160804, Kobayashi H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmcr.2016.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,P.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Lv,Z.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Yao,X.</style></author><author><style face="normal" font="Arial"> Corrigan,C.J.</style></author><author><style face="normal" font="Arial"> Huang,K.</style></author><author><style face="normal" font="Arial"> Wang,W.</style></author><author><style face="normal" font="Arial"> Ying,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling by the PI3K inhibitor LY294002</style></title><secondary-title><style face="normal" font="Arial">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respirology</style></full-title></periodical><pages end="85" start="78">78-85</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Hypertrophy</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> phosphoinositide 3-kinase</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Existing in vitro and in vivo studies suggest that both IL-25 and phosphoinositide 3-kinases (PI3Ks) exhibit broad effects on the functions of immune cells implicated in the pathogenesis of asthma. Whether the blockade of PI3K signalling directly inhibits the asthma relevant pathogenetic changes induced by IL-25 in an in vivo condition is still unclear. Using an established IL-25-induced murine model of asthma, we undertook a comprehensive evaluation of the effects of co-administered LY294002, a pharmacological pan-inhibitor of PI3K on IL-25-induced changes on this model, with particular regard to airway remodelling. METHODS: BALB/c mice were serially intranasally challenged with IL-25 according to an established protocol to induce airway inflammation, hyperresponsiveness (AHR) and remodelling. In an additional subgroup LY294002 was administered intranasally. Lung function and airway cytokine and chemokine concentrations and cellular infiltration and remodelling changes assessed by histology and immunohistochemistry were measured at specific time points. RESULTS: Intranasal administration of LY294002 significantly inhibited IL-25-induced AHR and recruitment of inflammatory cells into bronchoalveolar lavage fluid. LY294002 also attenuated IL-25-induced increased concentrations of cytokines and chemokines in lung tissue. Histological and immunohistochemical analysis showed that LY294002 also significantly inhibited IL-25-induced lung tissue eosinophilia, mucus production, collagen deposition, smooth muscle hypertrophy and angiogenesis. CONCLUSION: The PI3K pan-inhibitor LY294002 attenuated not only IL-25-induced asthma-like AHR and airway inflammation but also remodelling in this model, suggesting that PI3K is a major downstream messenger for IL-25 and that targeting this pathway might reduce asthma symptoms in the short term and airway remodelling in the longer term</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/resp.12880</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27556731">PM:27556731</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respirology\20160824-HuangP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respirology\20160824-HuangP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Huang P</style></custom2><misc3><style face="normal" font="Arial">10.1111/resp.12880</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gan,S.K.</style></author><author><style face="normal" font="Arial"> Poon,J.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The world of biomedical apps: their uses, limitations, and potential</style></title><secondary-title><style face="normal" font="Arial">Sci Phone Apps Mobile Dev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Phone Apps Mobile Dev</style></full-title></periodical><pages end="7" start="1">1-7</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--IT</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2364-4958</style></isbn><abstract><style face="normal" font="Arial">Many significant biomedical discoveries of old were made in the private property of famous scientists e.g. Leeuwenhoek and Archimedes. Today, discoveries are made in brightly-lit, hi-tech, ergonomic buildings that house research institutes. While such development is advantageous in many aspects, the spatial restriction of research into well-organized structures may delay and limit the spontaneity necessary for discoveries. The smartphone and peripheral mobile devices have the potential to not only increase the productivity and mobility of biomedical research, but also restore some freedom from spatial constraints. One possible way this can occur is the development of a mobile biomedical lab that allows researchers to carry out core research processes </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿon-the-go</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ without being spatially restrained within a building or availability of equipment. For this exciting prospect, we surveyed the Google and Apple app stores, discussing the limitations and the potential of this area. Based on the developments, it appears to be just a matter of time before the majority of biomedical labs processes and equipment become mobile, centred on the smartphone and peripheral devices</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1186/s41070-016-0009-2</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s41070-016-0009-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Phone Apps Mobile Dev\2016-2-1-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Phone Apps Mobile Dev\2016-2-1-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Gan SK</style></custom2><misc3><style face="normal" font="Arial">10.1186/s41070-016-0009-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosskopf,S.</style></author><author><style face="normal" font="Arial"> Jutz,S.</style></author><author><style face="normal" font="Arial"> Neunkirchner,A.</style></author><author><style face="normal" font="Arial"> Candia,M.R.</style></author><author><style face="normal" font="Arial"> Jahn-Schmid,B.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Pickl,W.F.</style></author><author><style face="normal" font="Arial"> Steinberger,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="31580">31580-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic peptides</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> immunodominant peptide</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> K562 Cells</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> MHC class II</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> mugwort pollen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">We have generated engineered APC to present immunodominant peptides derived from the major aero-allergens of birch and mugwort pollen, Bet v 1142-153 and Art v 125-36, respectively. Jurkat-based T cell reporter lines expressing the cognate allergen-specific T cell receptors were used to read out the presentation of allergenic peptides on the engineered APC. Different modalities of peptide loading and presentation on MHC class II molecules were compared. Upon exogenous loading with allergenic peptides, the engineered APC elicited a dose-dependent response in the reporter T cells and the presence of chemical loading enhancers strongly increased reporter activation. Invariant chain-based MHC class II targeting strategies of endogenously expressed peptides resulted in stronger activation of the reporters than exogenous loading. Moreover, we used Bet v 1 as model allergen to study the ability of K562 cells to present antigenic peptides derived from whole proteins either taken up or endogenously expressed as LAMP-1 fusion protein. In both cases the ability of these cells to process and present peptides derived from whole proteins critically depended on the expression of HLA-DM. We have identified strategies to achieve efficient presentation of allergenic peptides on engineered APC and demonstrate their use to stimulate T cells from allergic individuals</style></abstract><notes><style face="normal" font="Arial">DA - 20160819IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep31580</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27539532">PM:27539532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-31580.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-31580.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160819, Rosskopf S</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep31580</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bae,M.J.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author><author><style face="normal" font="Arial"> See,H.J.</style></author><author><style face="normal" font="Arial"> Jung,S.Y.</style></author><author><style face="normal" font="Arial"> Kwon,D.A.</style></author><author><style face="normal" font="Arial"> Shon,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Korea Food Research Institute, 1201-62, Anyangpangyo-ro, Bundang-gu, Seongnam-si, Kyeonggi-do 463-746, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Baicalein induces CD4(+)Foxp3(+) T cells and enhances intestinal barrier function in a mouse model of food allergy</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="32225">32225-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Baicalein</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Tight Junctions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The incidence of food allergy, which is triggered by allergen permeation of the gastrointestinal tract followed by a T-helper (Th) 2-mediated immune response, has been increasing annually worldwide. We examined the effects of baicalein (5,6,7-trihydroxyflavone), a flavonoid from Scutellaria baicalensis used in oriental herbal medicine, on regulatory T (Treg) cell induction and intestinal barrier function through the regulation of tight junctions in a mouse model of food allergy. An allergic response was induced by oral challenge with ovalbumin, and the incidence of allergic symptoms and T cell-related activity in the mesenteric lymph nodes were analyzed with and without the presence of baicalein. Our results demonstrated that the administration of baicalein ameliorated the symptoms of food allergy and attenuated serum IgE and effector T cells. However, Treg-related factors were up-regulated by baicalein. Furthermore, baicalein was shown to enhance intestinal barrier function through the regulation of tight junctions. We also found that baicalein treatment induced the differentiation of Treg cells via aryl hydrocarbon receptors (AhRs). Thus, the action of baicalein as an agonist of AhR can induce Treg differentiation and enhance barrier function, suggesting that baicalein might serve as an effective immune regulator derived from foods for the treatment of food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep32225</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27561877">PM:27561877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-32225.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-32225.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Bae MJ</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep32225</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Friedlander,S.F.</style></author><author><style face="normal" font="Arial"> Simpson,E.L.</style></author><author><style face="normal" font="Arial"> Irvine,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Professor of Dermatology and Pediatrics Chief, Pediatric and Adolescent Dermatology University of California San Diego School of Medicine Rady Children's Hospital San Diego, California</style></auth-address><titles><title><style face="normal" font="Arial">Assessing the New and Emerging Treatments for Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Semin Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Cutan Med Surg</style></full-title></periodical><pages end="S96" start="S92">S92-S96</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">5S</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/ IL-13 receptor alpha chain. Semin Cutan Med Surg 35(supp5):S92-S96</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.12788/j.sder.2016.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525671">PM:27525671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Cutan Med Surg\2016-35-S92-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Cutan Med Surg\2016-35-S92-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Eichenfield LF</style></custom2><misc3><style face="normal" font="Arial">10.12788/j.sder.2016.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Irvine,A.D.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Friedlander,S.F.</style></author><author><style face="normal" font="Arial"> Simpson,E.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Professor of Dermatology Trinity College Dublin Attending Dermatologist Our Lady's Children's Hospital Crumlin St. James's Hospital Dublin, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Review of Critical Issues in the Pathogenesis of Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Semin Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Cutan Med Surg</style></full-title></periodical><pages end="S91" start="S89">S89-S91</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">5S</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Ichthyosis</style></keyword><keyword><style face="normal" font="Arial"> ichthyosis vulgaris</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">About a decade age, loss-of-function mutations in the filaggrin molecule were first implicated in the pathogenesis of ichthyosis vulgaris and, subsequently, of atopic dermatitis and other atopic diseases. Since then, intensive study of the role of filaggrin null mutations have led to other milestones in understanding the pathologic pathways in these diseases, including the initiation, maintenance, and promotion of the disease processes. The result has been new and emerging clinical and pharmacologic strategies for early identification of and intervention in atopic diseases. Semin Cutan Med Surg 35(supp5):S89-S91</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Ireland -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.12788/j.sder.2016.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525507">PM:27525507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Cutan Med Surg\2016-35-S89-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Cutan Med Surg\2016-35-S89-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Irvine AD</style></custom2><misc3><style face="normal" font="Arial">10.12788/j.sder.2016.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simpson,E.L.</style></author><author><style face="normal" font="Arial"> Irvine,A.D.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Friedlander,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Professor of Dermatology Director of Clinical Studies Oregon Health and Science University Department of Dermatology Portland, Oregon</style></auth-address><titles><title><style face="normal" font="Arial">Update on Epidemiology, Diagnosis, and Disease Course of Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Semin Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Cutan Med Surg</style></full-title></periodical><pages end="S88" start="S84">S84-S88</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">5S</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental risk factors</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Oregon</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TEWL</style></keyword><keyword><style face="normal" font="Arial"> transepidermal water loss</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Studies of the prevalence of atopic dermatitis (AD) have provided insights into associated environmental risk factors, demonstrating the complex interactions between the presence of filaggrin (FLG) gene defects and environment. Among other important findings is that elevated transepidermal water loss (TEWL) in newborns is a strong predictor of AD, regardless of FLG status. Recently recognized predictors of disease course and severity include onset of AD signs and symptoms before 12 months of age and the presence of an FLG mutation and concomitant immunoglobulin E sensitization early in life. Semin Cutan Med Surg 35(supp5):S84-S88</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.12788/j.sder.2016.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525380">PM:27525380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Cutan Med Surg\2016-35-S84-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Cutan Med Surg\2016-35-S84-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Simpson EL</style></custom2><misc3><style face="normal" font="Arial">10.12788/j.sder.2016.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Friedlander,S.F.</style></author><author><style face="normal" font="Arial"> Simpson,E.L.</style></author><author><style face="normal" font="Arial"> Irvine,A.D.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Professor of Dermatology and Pediatrics University of California San Diego School of Medicine Fellowship Program Director Pediatric and Adolescent Dermatology Rady Children's Hospital San Diego, California</style></auth-address><titles><title><style face="normal" font="Arial">The Changing Paradigm of Atopic Dermatitis Therapy</style></title><secondary-title><style face="normal" font="Arial">Semin Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Cutan Med Surg</style></full-title></periodical><pages end="S99" start="S97">S97-S99</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">5S</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">The pathophysiology of atopic dermatitis (AD) is complex, and future treatment options will likely be incorporated in a multimodal approach to management. The new, directed therapies that have been developed will likely be used in conjunction with concomitant continuous or intermittent use of standard therapies; the goal is to optimize therapeutic outcomes while minimizing adverse impacts on safety and cost. Current data regarding disease course and expression throughout life suggest that treatment strategies also will need to be adjusted as a patient grows. Research also indicates that interventions begun in infancy-such as the use of emollients-may mitigate or prevent AD signs and symptoms in children at high risk for the disease. Semin Cutan Med Surg 35(supp5):S97-S99</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.12788/j.sder.2016.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27526330">PM:27526330</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Cutan Med Surg\2016-35-S97-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Cutan Med Surg\2016-35-S97-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Friedlander SF</style></custom2><misc3><style face="normal" font="Arial">10.12788/j.sder.2016.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumar,R.</style></author><author><style face="normal" font="Arial"> Bonicelli,A.</style></author><author><style face="normal" font="Arial"> Sekula-Neuner,S.</style></author><author><style face="normal" font="Arial"> Cato,A.C.</style></author><author><style face="normal" font="Arial"> Hirtz,M.</style></author><author><style face="normal" font="Arial"> Fuchs,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Nanotechnology (INT) &amp; Karlsruhe Nano Micro Facility (KNMF), Karlsruhe Institute of Technology (KIT), 76201, Karlsruhe, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Click-Chemistry Based Allergen Arrays Generated by Polymer Pen Lithography for Mast Cell Activation Studies</style></title><secondary-title><style face="normal" font="Arial">Small</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Small</style></full-title></periodical><pages end="5338" start="5330">5330-5338</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">38</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hapten</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Nanotechnology</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="11" Month="8" Year="2016">2016/8/11</year></dates><abstract><style face="normal" font="Arial">The profiling of allergic responses is a powerful tool in biomedical research and in judging therapeutic outcome in patients suffering from allergy. Novel insights into the signaling cascades and easier readouts can be achieved by shifting activation studies of bulk immune cells to the single cell level on patterned surfaces. The functionality of dinitrophenol (DNP) as a hapten in the induction of allergic reactions has allowed the activation process of single mast cells seeded on patterned surfaces to be studied following treatment with allergen specific Immunoglobulin E antibodies. Here, a click-chemistry approach is applied in combination with polymer pen lithography (PPL) to pattern DNP-azide on alkyne-terminated surfaces to generate arrays of allergen. The large area functionalization offered by PPL allows an easy incorporation of such arrays into microfluidic chips. In such a setup, easy handling of cell suspension, incubation process, and read-out by fluorescence microscopy will allow immune cell activation screening to be easily adapted for diagnostics and biomedical research</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1613-6829 (Electronic)IS - 1613-6810 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/smll.201601623</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27511293">PM:27511293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Small\20160811-KumarR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Small\20160811-KumarR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Kumar R</style></custom2><misc3><style face="normal" font="Arial">10.1002/smll.201601623</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Banas,A.</style></author><author><style face="normal" font="Arial"> Banas,K.</style></author><author><style face="normal" font="Arial"> Kalaiselvi,S.M.</style></author><author><style face="normal" font="Arial"> Pawlicki,B.</style></author><author><style face="normal" font="Arial"> Kwiatek,W.M.</style></author><author><style face="normal" font="Arial"> Breese,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Singapore Synchrotron Light Source, 5 Research Link, 117603 Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="Arial">Is it possible to find presence of lactose in pharmaceuticals? - Preliminary studies by ATR-FTIR spectroscopy and chemometrics</style></title><secondary-title><style face="normal" font="Arial">Spectrochim Acta A Mol Biomol Spectrosc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Spectrochim Acta A Mol Biomol Spectrosc</style></full-title></periodical><pages end="286" start="280">280-286</pages><volume><style face="normal" font="Arial">171</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Compressibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> FTIR</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lactose Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="4" Month="8" Year="2016">2016/8/4</year></dates><abstract><style face="normal" font="Arial">Lactose and saccharose have the same molecular formula; however, the arrangement of their atoms is different. A major difference between lactose and saccharose with regard to digestion and processing is that it is not uncommon for individuals to be lactose intolerant (around two thirds of the population has a limited ability to digest lactose after infancy), but it is rather unlikely to be saccharose intolerant. The pharmaceutical industry uses lactose and saccharose as inactive ingredients of drugs to help form tablets because of their excellent compressibility properties. Some patients with severe lactose intolerance may experience symptoms of many allergic reactions after taking medicine that contains this substance. People who are specifically "allergic" to lactose (not just lactose intolerant) should not use tablets containing this ingredient. Fourier Transform Infrared (FTIR) spectroscopy has a unique chemical fingerprinting capability and plays a significant important role in the identification and characterization of analyzed samples and hence has been widely used in pharmaceutical science. However, a typical FTIR spectrum collected from tablets contains a myriad of valuable information hidden in a family of tiny peaks. Powerful multivariate spectral data processing can transform FTIR spectroscopy into an ideal tool for high volume, rapid screening and characterization of even minor tablet components. In this paper a method for distinction between FTIR spectra collected for tablets with or without lactose is presented. The results seem to indicate that the success of identifying one component in FTIR spectra collected for pharmaceutical composition (that is tablet) is largely dependent on the choice of the chemometric technique applied</style></abstract><notes><style face="normal" font="Arial">DA - 20160819IS - 1873-3557 (Electronic)IS - 1386-1425 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Singapore -CO - POland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.saa.2016.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27541800">PM:27541800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Spectrochim Acta A Mol Biomol Spectrosc\2016-171-280-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Spectrochim Acta A Mol Biomol Spectrosc\2016-171-280-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160819, Banas A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.saa.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Solmazgul,E.</style></author><author><style face="normal" font="Arial"> Kutlu,A.</style></author><author><style face="normal" font="Arial"> Dogru,S.</style></author><author><style face="normal" font="Arial"> Ozalper,V.</style></author><author><style face="normal" font="Arial"> Cetindagli,I.</style></author><author><style face="normal" font="Arial"> Sezer,O.</style></author><author><style face="normal" font="Arial"> Salmanoglu,M.</style></author><author><style face="normal" font="Arial"> Kilic,E.</style></author><author><style face="normal" font="Arial"> Karabacak,E.</style></author><author><style face="normal" font="Arial"> Ozturk,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, GATA Haydarpasa Training Hospital, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylactic reactions presenting with hypertension</style></title><secondary-title><style face="normal" font="Arial">Springerplus</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Springerplus</style></full-title></periodical><pages end="" start="1223">1223-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although a few case reports about hypertensive anaphylaxis (HA) are available in the present literature, there is no study about the prevalence of HA. In this study, we review our cases with anaphylaxis presenting with hypertension and ascertain its prevalence. The documents of the patients who had anaphylactic reactions after the procedures performed for the diagnosis and treatment of allergic diseases in GATA Haydarpasa Clinic of Allergy and Immunology between January 2010 and December 2014 were retrospectively reviewed. Within the study period, 324 patients had undergone 4332 procedures in which 62 of them had developed anaphylaxis. RESULTS: During the procedures, the rate of anaphylaxis was found to be 1.43 %. The rate of HA among the anaphylaxis patients was 12.9 % (8 of 62 patients). During treatments, 2 patients received adrenaline injections without any adverse reaction. CONCLUSIONS: HA may be seen at a considerable rate during an anaphylactic reaction. Anaphylaxis and hypertension can be recovered by adrenaline injection when required. According to the best of our knowledge, this study is the first original study about the prevalence of HA in English-language medical literature</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 2193-1801 (Electronic)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40064-016-2913-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27536507">PM:27536507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Springerplus\2016-5-1223.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Springerplus\2016-5-1223.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Solmazgul E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40064-016-2913-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inam,M.</style></author><author><style face="normal" font="Arial"> Shafique,R.H.</style></author><author><style face="normal" font="Arial"> Roohi,N.</style></author><author><style face="normal" font="Arial"> Irfan,M.</style></author><author><style face="normal" font="Arial"> Abbas,S.</style></author><author><style face="normal" font="Arial"> Ismail,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Physiology/Endocrinology Lab, Department of Zoology, University of the Punjab, Quaid-i-Azam Campus, Lahore, 54590 Pakistan</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of sensitization to food allergens and challenge proven food allergy in patients visiting allergy centers in Rawalpindi and Islamabad, Pakistan</style></title><secondary-title><style face="normal" font="Arial">Springerplus</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Springerplus</style></full-title></periodical><pages end="" start="1330">1330-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Banana</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> lentil</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Self-reported food allergy</style></keyword><keyword><style face="normal" font="Arial"> self-reported history</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">In this study, we estimated the prevalence of food allergy in the adult allergic patients of Rawalpindi and Islamabad , Pakistan, based on self-report, skin prick test (SPT) and oral food challenge test (OFC). SPT was used for the estimation of sensitization to wheat, egg, milk, beef, chicken, mutton, fish, corn, lentils, rice, soya, peanut and banana. Among 689 patients, 39.19 % showed sensitivity to one or more foods, where, sensitization to wheat (156; 22.6 %) was highest, followed by egg (148; 21.48 %) and milk (138; 20.03 %). Sensitization to various proteins ranged between 15.53-15.97 %, while lentils, corn, rice, soya and peanut sensitization was 15.4, 16, 12.5, 12 and 11.5 % respectively. Only 7.1 % patients were SPT positive for banana allergen. SPT was performed in patients with self-reported food allergy (341/689) and also with no self-reported history of food allergy (348/689). SPT results were positive in 69.8 % of the self-report group, whereas, in the patients with no self-reported food allergy 9.2 % were found sensitized to one or more tested food allergens. 101 patients were recruited for OFC, 61 % of these were confirmed of food allergy. The prevalence of food allergy in the study population was 9 %. Food specific OFC results show that wheat allergy is affecting 1.6 % (95 % CI 0.9-2.84 %) of the total allergy patients, followed by egg allergy 1.31 % (95 % CI 0.70-2.47 %). Furthermore, corn allergy, rice allergy and peanut allergy were 1.02, 0.87 and 0.73 %, respectively. In conclusion, wheat allergy is the most prevalent, followed by egg, chicken, beef and fish allergy, respectively</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 2193-1801 (Electronic)LA - engPT - Journal ArticleCO - Pakistan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40064-016-2980-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27563525">PM:27563525</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Springerplus\2016-5-1330.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Springerplus\2016-5-1330.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Inam M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40064-016-2980-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanzani,S.M.</style></author><author><style face="normal" font="Arial"> Miazzi,M.M.</style></author><author><style face="normal" font="Arial"> Di Rienzo,V.</style></author><author><style face="normal" font="Arial"> Fanelli,V.</style></author><author><style face="normal" font="Arial"> Gambacorta,G.</style></author><author><style face="normal" font="Arial"> Taurino,M.R.</style></author><author><style face="normal" font="Arial"> Montemurro,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Scienze del Suolo, della Pianta e degli Alimenti, Universita degli Studi di Bari Aldo Moro, Via G. Amendola 165/A, 70126 Bari, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">A Rapid Assay to Detect Toxigenic Penicillium spp. Contamination in Wine and Musts</style></title><secondary-title><style face="normal" font="Arial">Toxins (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxins (Basel)</style></full-title></periodical><pages end="" start="E235">E235-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Grape</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Patulin</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Single-tube nested real-time PCR</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wine</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Wine and fermenting musts are grape products widely consumed worldwide. Since the presence of mycotoxin-producing fungi may greatly compromise their quality characteristics and safety, there is an increasing need for relatively rapid "user friendly" quantitative assays to detect fungal contamination both in grapes delivered to wineries and in final products. Although other fungi are most frequently involved in grape deterioration, secondary infections by Penicillium spp. are quite common, especially in cool areas with high humidity and in wines obtained by partially dried grapes. In this work, a single-tube nested real-time PCR approach-successfully applied to hazelnut and peanut allergen detection-was tested for the first time to trace Penicillium spp. in musts and wines. The method consisted of two sets of primers specifically designed to target the beta-tubulin gene, to be simultaneously applied with the aim of lowering the detection limit of conventional real-time PCR. The assay was able to detect up to 1 fg of Penicillium DNA. As confirmation, patulin content of representative samples was determined. Most of analyzed wines/musts returned contaminated results at >50 ppb and a 76% accordance with molecular assay was observed. Although further large-scale trials are needed, these results encourage the use of the newly developed method in the pre-screening of fresh and processed grapes for the presence of Penicillium DNA before the evaluation of related toxins</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 2072-6651 (Electronic)IS - 2072-6651 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3390/toxins8080235</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27509524">PM:27509524</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxins (Basel)\20160811-SanzaniSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxins (Basel)\20160811-SanzaniSM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Sanzani SM</style></custom2><misc3><style face="normal" font="Arial">10.3390/toxins8080235</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Niedzwiecki,M.</style></author><author><style face="normal" font="Arial"> Yamada,Y.</style></author><author><style face="normal" font="Arial"> Inci,I.</style></author><author><style face="normal" font="Arial"> Weder,W.</style></author><author><style face="normal" font="Arial"> Jungraithmayr,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Decrease of Airway Allergies After Lung Transplantation Is Associated With Reduced Basophils and Eosinophils</style></title><secondary-title><style face="normal" font="Arial">Transplant Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transplant Proc</style></full-title></periodical><pages end="2146" start="2140">2140-2146</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Transplantation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergies are hypersensitive reactions of the immune system on antigen exposure similar to immune reactions after transplantation (Tx). Their activity can change after Tx. The lung as a transplantable organ is challenged two-fold, by antigens from the blood and the air environment. Herein we analyzed if airway allergies change after lung Tx. METHODS: We systematically reviewed patients' airway allergies before and after lung Tx between 1992 and 2014. The course of lymphocytes, thrombocytes, and leukocytes, among them neutrophils, eosinophils, and basophils, was analyzed in patients in whom airway allergies have changed and in whom they did not change. RESULTS: From 362 lung transplanted patients, 44 patients had suffered from allergies before Tx (12.2%). In 20 of these patients (45.5%), airway allergies disappeared completely within 1 year after lung Tx and were persistently absent thereafter. In these patients, basophils and eosinophils decreased significantly (P &lt; .0012); in contrast, cells did not decrease in patients whose allergies did not disappear. Leukocytes overall, and in particular, neutrophils, decreased significantly in patients whose allergy disappeared (P &lt; .014, P &lt; .012, respectively). CONCLUSIONS: Airway allergies disappeared in almost half of cases after lung Tx. Along with this reduction, basophils and eosinophils decreased as potentially responsible cells for this phenomenon. These findings may stimulate intensified research on basophils and eosinophils as major drivers of airway allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 1873-2623 (Electronic)IS - 0041-1345 (Linking)LA - engPT - Journal ArticleSB - IMCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.transproceed.2016.02.084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27569960">PM:27569960</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transplant Proc\2016-48-2140-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transplant Proc\2016-48-2140-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Niedzwiecki M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.transproceed.2016.02.084</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Parlak,M.</style></author><author><style face="normal" font="Arial"> Cikman,A.</style></author><author><style face="normal" font="Arial"> Bayram,Y.</style></author><author><style face="normal" font="Arial"> Ceylan,N.</style></author><author><style face="normal" font="Arial"> Calisir,U.</style></author><author><style face="normal" font="Arial"> Berktas,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Microbiology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to food and inhalant allergens in healthy children in Van, East Turkey</style></title><secondary-title><style face="normal" font="Arial">Turk J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Turk J Med Sci</style></full-title></periodical><pages end="282" start="278">278-282</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> codfish</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Trout</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/AIM: The purpose of this study was to determine the most frequent food and inhalant allergens leading to allergic sensitization in children in Van Province of Turkey. MATERIALS AND METHODS: The study included 1052 serum samples with no diagnosis of allergy. The sera were tested with the Euroline Pediatric IgE test kit (EUROIMMUN, Germany). By using the EUROLineScan digital evaluation system, the intensity of bands was calculated with enzyme allergosorbent test classification. RESULTS: Out of the 1052 tested sera, 143 were found to be cross-reactive carbohydrate determinant-positive and were discarded from the study. Of the remaining 909 sera, 513 (56%) were from males and 296 (44%) were from females. Among the food allergens, specific IgE was most frequently found against codfish, potato, cow's milk, egg yolk, egg white, and rice, and among the inhalant allergens against cats, dogs, grass mix, Dermatophagoides pteronyssinus, and Aspergillus fumigatus, respectively. CONCLUSION: The finding of codfish being the most frequent allergen was related to the high consumption of trout in the region and endemicity of pearl mullet in Lake Van. The results obtained could contribute to determining the etiology of allergic diseases. Additionally, regular analysis of changes in allergen sensitization is important for prevention of allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1300-0144 (Print)IS - 1300-0144 (Linking)LA - engPT - Journal ArticleSB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.3906/sag-1403-77</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27511484">PM:27511484</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Turk J Med Sci\2016-46-278-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Turk J Med Sci\2016-46-278-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Parlak M</style></custom2><misc3><style face="normal" font="Arial">10.3906/sag-1403-77</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fisara,P.</style></author><author><style face="normal" font="Arial"> Shipstone,M.</style></author><author><style face="normal" font="Arial"> von Berky,A.</style></author><author><style face="normal" font="Arial"> von Berky,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MSD Animal Health, 26 Artisan Road, Seven Hills, 2147, NSW, AustraliaDermatology for Animals, 263 Appleby Road, Stafford Heights, 4053, NSW, Australiavon Berky Veterinary Services, 3 Hawthorne street, Woody Point, QLD, 4019, Australiavon Berky Veterinary Services, 3 Hawthorne street, Woody Point, QLD, 4019, Australia</style></auth-address><titles><title><style face="normal" font="Arial">A small-scale open-label study of the treatment of canine flea allergy dermatitis with fluralaner</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="418" start="417">417-418</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acaricide</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Administration,Oral</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dog Diseases</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flea Infestations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Insecticides</style></keyword><keyword><style face="normal" font="Arial"> Isoxazoles</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword></keywords><dates><year Day="0" Month="12" Year="2015">2015/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fluralaner is an isoxazoline systemic insecticide and acaricide that provides persistent flea-killing activity on dogs for 12 weeks. European and US field studies have shown that fluralaner treatment alleviates the signs of flea allergy dermatitis (FAD) in client-owned dogs. HYPOTHESIS/OBJECTIVE: To assess the clinical response in FAD affected dogs over the 12-week period following a single oral fluralaner treatment. ANIMALS: Twenty client-owned dogs were diagnosed with FAD on the basis of compatible clinical signs and a positive response in flea antigen tests, using intradermal and or serological methods. METHODS: An open-label small-scale study with all dogs receiving a single oral fluralaner treatment. All enrolled dogs were diagnosed with FAD and then clinically monitored at 4-week intervals for 12 weeks. Twenty dogs completed the study. RESULTS: All dogs were flea-free at all post-treatment assessments except for one dog that had a single flea at the first post-enrollment assessment at 4 weeks. At the 4-week post-treatment assessment active FAD signs had resolved in all dogs; at 8 weeks post-treatment, two dogs showed mild signs. All clinical signs of FAD had resolved at the final assessment of 12 weeks after treatment. CONCLUSIONS AND CLINICAL IMPORTANCE: A single administration of fluralaner alleviated or resolved signs associated with FAD in all treated dogs over the recommended 12-week treatment period</style></abstract><notes><style face="normal" font="Arial">DA - 20151105IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (A1443 compound)RN - 0 (Insecticides)RN - 0 (Isoxazoles)SB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12249</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26271195">PM:26271195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\2015-26-417-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\2015-26-417-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151105, Fisara P</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12249</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bruet,V.</style></author><author><style face="normal" font="Arial"> Dumon,H.</style></author><author><style face="normal" font="Arial"> Bourdeau,P.</style></author><author><style face="normal" font="Arial"> Desfontis,J.C.</style></author><author><style face="normal" font="Arial"> Martin,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology, Parasitology CE, Mycology Unit, LUNAM, Oniris, Atlanpole, CS 40706, Nantes, F-44307, France</style></auth-address><titles><title><style face="normal" font="Arial">Prospective pilot study to detect dogs with non food-induced canine atopic dermatitis using Fourier transform infrared spectroscopy</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="356">356-</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> FTIR</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Infrared spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The diagnosis of canine atopic dermatitis (CAD) remains challenging due to the lack of a simple biomarker or metabolic profile. In human medicine, Fourier transform infrared spectroscopy (FTIR) is an analytical technique used for several diseases. It requires a small amount of sample and allows the identification of structural moieties of biomolecules on the basis of their infrared absorption, with limited sample pretreatment. HYPOTHESIS/OBJECTIVES: The aim of the study was to evaluate the diagnostic value of FTIR. ANIMALS: Three groups were tested: 21 dogs with non food-induced CAD (NFICAD), 16 dogs with inflammatory conditions of various origins but without allergic dermatoses (OD) and 10 healthy dogs (H). METHODS: Peripheral blood was collected and spectra were acquired with a FTIR spectrophotometer. A principal component analysis (PCA) was performed on the full wavenumber spectra (4000-600/cm), followed by a Fisher discriminant analysis (DA) to assess the differences between the three groups. RESULTS: The PCA followed by the DA of whole spectra showed significant differences between the three groups. These results suggest that by using the FTIR method, dogs with NFICAD can be differentiated from healthy dogs and dogs with nonallergic inflammation. There was no overlap between the spectral data of the three groups indicating that NFICAD dogs were correctly segregated from the H and OD groups. CONCLUSIONS: A study on a larger cohort including common pruritic skin diseases is necessary to confirm these initial results and the relevance of this diagnostic technique</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12365</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27500559">PM:27500559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20160808-BruetV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20160808-BruetV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Bruet V</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12365</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pierezan,F.</style></author><author><style face="normal" font="Arial"> Olivry,T.</style></author><author><style face="normal" font="Arial"> Paps,J.S.</style></author><author><style face="normal" font="Arial"> Lawhon,S.D.</style></author><author><style face="normal" font="Arial"> Wu,J.</style></author><author><style face="normal" font="Arial"> Steiner,J.M.</style></author><author><style face="normal" font="Arial"> Suchodolski,J.S.</style></author><author><style face="normal" font="Arial"> Rodrigues,Hoffmann A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Texas A&amp;M University, College of Veterinary Medicine and Biomedical Sciences, College Station, TX, 77843, USA</style></auth-address><titles><title><style face="normal" font="Arial">The skin microbiome in allergen-induced canine atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="332">332-</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> Abundance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="8" Year="2016">2016/8/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Studies focusing on next-generation sequencing of the bacterial 16S rRNA gene have allowed detailed surveys of skin bacterial populations (microbiota) of the skin. HYPOTHESIS/OBJECTIVES: This study evaluated temporal changes in the skin microbiota in a canine model of atopic dermatitis. ANIMALS: Eight atopic dogs previously sensitized with house dust mites (HDM). METHODS: The dogs were topically challenged on the right groin with HDM allergens. Swabs were collected from the challenged and the contralateral nonchallenged sites prior to provocation (pre-challenge; baseline sample) and on days 1, 7, 14, 21 and 28 after allergen challenge. The 16S rRNA gene was amplified, sequenced and analysed. Staphylococcus spp. and Staphylococcus pseudintermedius were quantified with quantitative PCR (RT-qPCR). RESULTS: Skin lesions developed in all dogs on the challenged sites. Differences in bacterial groups were observed on the challenged site over time. Relatively lower abundances of Fusobacteriaceae on Day 7, and, based on LEfSe, increased abundances of Corynebacteriaceae on Day 1, and Staphylococcaceae on days 7, 14 and 21, were observed on the challenged site, compared to the contralateral site. Results of RT-qPCR correlated with those of next-generation sequencing, with significantly increased numbers of Staphylococcus spp. and S. pseudintermedius on Day 21, and days 7 and 21 on the challenged site compared to the contralateral site, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE: This study demonstrates that an allergen challenge in sensitized dogs leads to bacterial dysbiosis with increased abundance of S. pseudintermedius at the site of lesion induction</style></abstract><notes><style face="normal" font="Arial">DA - 20160803IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27485242">PM:27485242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20160803-PierezanF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20160803-PierezanF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160803, Pierezan F</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12366</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Savchenko,V.M.</style></author><author><style face="normal" font="Arial"> Belyaeva,S.N.</style></author><author><style face="normal" font="Arial"> Govorun,M.I.</style></author><author><style face="normal" font="Arial"> Pirogova,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">S.I. Georgievsky Medical Academy of V.I. Vernadsky Crimean Federal University</style></auth-address><titles><title><style face="normal" font="Arial">[Analysis of the effectiveness of the spa and health resort-based treatment of the patients presenting with broncho-pulmonary pathology at the southern coast of the Crimea depending on the period of flowering of Mediterranean Cypress (Cupressus sempervirens)]</style></title><secondary-title><style face="normal" font="Arial">Vopr Kurortol Fizioter Lech Fiz Kult</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Vopr Kurortol Fizioter Lech Fiz Kult</style></abbr-1></periodical><pages end="35" start="31">31-35</pages><volume><style face="normal" font="Arial">93</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Cupressus</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Cypress pollen</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocyte Count</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">AIM: The objective of the present study was to evaluate the influence of pollen of Mediterranean Cypress (Cupressus sempervirens) on the effectiveness of the spa and health resort-based treatment (SHRT) of the patients with broncho-pulmonary pathology at the southern coast of the Crimea (SCC). MATERIAL AND METHODS: This article presents the results of the analysis of the data on 122 patients presenting with broncho-pulmonary pathology who received SHRT under the conditions of the Southern Coast of the Crimea. Fifty one (41.8%) of these patients suffered from chronic obstructive pulmonary disease and 71 (58.2%) ones had bronchial asthma. The whole group was comprised of 44 men (36.1%) and 78 women (63.9%). The average (median) age of the patients was 55.8 years. All the participants of the study underwent the comprehensive examination including the general medical and physical examination, complete blood count, the study of sputum cytology and immunological properties of blood including the standard characteristics, IgE and lysozyme levels), evaluation of the respiratory and locomotor (physical) functions with the use of the 6-minute walking test. RESULTS: The aeropollenological study of the aerial environment of the southern coast of the Crimea in the region of Yalta showed that the &lt;&lt;bloom>> of the Mediterranean Cypress occurs during the period from February till April inclusive. The highest concentrations of cypress pollen are observed in March and early April. The overall effectiveness of SHRT for the patients with broncho-pulmonary pathology arriving for the treatment at the southern coast of the Crimea from other Crimean localities does not depend on the period of &lt;&lt;flowering>> (the presence of pollen in the air) of the Mediterranean Cypress. In these patients, the termination of the spa and health resort-based treatment during the &lt;&lt;flowering>> of the Mediterranean Cypress resulted in nothing more than a strained adaptive response manifested as the altered blood leukocyte count. Such reaction is considered to be a natural consequence of intake of antigenic substances into the human body</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 0042-8787 (Print)IS - 0042-8787 (Linking)LA - RUSPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - Russia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27500676">PM:27500676</url></web-urls></urls><custom2><style face="normal" font="Arial">20160808, Savchenko VM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mudde,A.C.</style></author><author><style face="normal" font="Arial"> Lexmond,W.S.</style></author><author><style face="normal" font="Arial"> Blumberg,R.S.</style></author><author><style face="normal" font="Arial"> Nurko,S.</style></author><author><style face="normal" font="Arial"> Fiebiger,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Harvard Medical School, and Division of Gastroenterology and Nutrition, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115 USA</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic esophagitis: published evidences for disease subtypes, indications for patient subpopulations, and how to translate patient observations to murine experimental models</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="23">23-</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Individual variation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus and commonly classified as a Th2-type allergy. Major advances in our understanding of the EoE pathophysiology have recently been made, but clinicians struggle with highly unpredictable therapy responses indicative of phenotypic diversity within the patient population. Here, we summarize evidences for the existence of EoE subpopulations based on diverse inflammatory characteristics of the esophageal tissue in EoE. Additionally, clinical characteristics of EoE patients support the concept of disease subtypes. We conclude that clinical and experimental evidences indicate that EoE is an umbrella term for conditions that are unified by esophageal eosinophilia but that several disease subgroups with various inflammatory esophageal patterns and/or different clinical features exist. We further discuss strategies to study the pathophysiologic differences as observed in EoE patients in murine experimental EoE. Going forward, models of EoE that faithfully mimic EoE subentities as defined in humans will be essential because mechanistic studies on triggers which regulate the onset of diverse EoE subpopulations are not feasible in patients. Understanding how and why different EoE phenotypes develop will be a first and fundamental step to establish strategies that integrate individual variations of the EoE pathology into personalized therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160726IS - 1939-4551 (Electronic)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0114-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27458501">PM:27458501</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160726, Mudde AC</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0114-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iwanczak,B.M.</style></author><author><style face="normal" font="Arial"> Ryzko,J.</style></author><author><style face="normal" font="Arial"> Jankowski,P.</style></author><author><style face="normal" font="Arial"> Sladek,M.</style></author><author><style face="normal" font="Arial"> Wasilewska,A.</style></author><author><style face="normal" font="Arial"> Szczepanik,M.</style></author><author><style face="normal" font="Arial"> Sienkiewicz,E.</style></author><author><style face="normal" font="Arial"> Szaflarska-Poplawska,A.</style></author><author><style face="normal" font="Arial"> Wiecek,S.</style></author><author><style face="normal" font="Arial"> Kwiecien,J.</style></author><author><style face="normal" font="Arial"> Korczowski,B.</style></author><author><style face="normal" font="Arial"> Maslana,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">2nd Department and Clinic of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Induction and Maintenance Infliximab Therapy for the Treatment of Crohn's Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study</style></title><secondary-title><style face="normal" font="Arial">Adv Clin Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Clin Exp Med</style></full-title></periodical><pages end="530" start="523">523-530</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Fistula</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Infliximab is a biological drug used for the treatment of Crohn's disease in children. OBJECTIVES: The aim of this retrospective study was the estimation of effectiveness and safety of infliximab in the treatment of Crohn's disease with perianal fistulas in children. MATERIAL AND METHODS: Analysis comprised 50 children with Crohn's disease with perianal fistulas aged 9 to 18 years (16 girls and 34 boys) who failed to respond to conventional therapy. The children were divided into two groups: the first group contained 23 children with simple fistulas and the second - 27 children with complex fistulas. All children were treated with infliximab, administered in the dose of 5 mg per kilogram of the body mass. In the induction phase infliximab was administered at weeks 0, 2 and 6 and after clinical response in maintenance phase the drug was administered every 8 weeks; together for 12 months. RESULTS: In 76% of children after induction therapy with infliximab and in 71.87% after maintenance therapy the complete closure of fistula occurred. During the first year after the treatment a recurrence of a fistula was observed in 30.43% of the children. In two children anaphylactic shock was observed during injection of infliximab. The remaining children tolerated the drug well. CONCLUSIONS: The treatment with infliximab was effective in the majority of fistulazing Crohn's disease and caused the closure of perianal fistula which improved quality of life</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1899-5276 (Print)IS - 1899-5276 (Linking)LA - engPT - Journal ArticleSB - IMCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.17219/acem/36417</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27629741">PM:27629741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Clin Exp Med\2016-25-523-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Clin Exp Med\2016-25-523-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Iwanczak BM</style></custom2><misc3><style face="normal" font="Arial">10.17219/acem/36417</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gharbi,D.</style></author><author><style face="normal" font="Arial"> Brighetti,M.A.</style></author><author><style face="normal" font="Arial"> Travaglini,A.</style></author><author><style face="normal" font="Arial"> Trigo,M.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison between the counting methods used by two aerobiology networks in southern Europe (Spain and Italy)</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="92" start="87">87-92</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Biological particles</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Aerobiology studies the biological particles suspended in the atmosphere in order to know what types are present in the air and how their concentrations vary spatially or seasonally. The measurement of airborne pollen concentration requires a standardized methodology. Normally, the analysis of the slides obtained after samplings is carried out according to national network procedures. Different networks use different slide counting methods (longitudinal sweeps, transverse sweeps or random fields), and a different number of lines/fields are routinely read. In this study, we compared two slide counting methods adopted by two monitoring centres belonging to different aerobiology networks that operate in southern Europe, the University of Malaga (Spanish Aerobiology Network, the REA) and the University of Roma Tor Vergata (Rete Italiana di Monitoraggio in Aerobiologia, the RIMA). For that, the same samples were counted following the two methodologies consisting on the reading of four (REA) and six (RIMA), respectively, longitudinal sweeps at a magnification of 400X (REA). Statistical analysis was performed in order to search the degree of association between the two series of data obtained, as well as whether or not there were significant differences between them. The results showed highly significant correlation and regression coefficients. On the other hand, Wilcoxon tests, in general, did not showed significant differences between the series for the total pollen as well as for the major pollen types. This confirms that the two methods can be used indistinctly although it would be convenient for the different networks to standardize and unify methodologies in order to follow the same operating procedures</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9452-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9452-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20160912-GharbiD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20160912-GharbiD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Gharbi D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9452-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bedolla-Barajas,M.</style></author><author><style face="normal" font="Arial"> Kestler-Gramajo,A.</style></author><author><style face="normal" font="Arial"> Alcala-Padilla,G.</style></author><author><style face="normal" font="Arial"> Morales-Romero,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergia e Inmunologia Clinica, Nuevo Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Salvador de Quevedo y Zubieta No. 750, Colonia La Perla, Guadalajara, Jalisco, C. P. 44340, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of oral allergy syndrome in children with allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="133" start="127">127-133</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick by prick</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The oral allergy syndrome (OAS) is a particular type of food allergy rarely explored in the paediatric population that is already considered an adult problem. OBJECTIVE: Identify the prevalence of OAS, symptoms and pollen species associated with its presence in children affected by allergic diseases. METHODS: A cross-sectional study was conducted. Consecutive sampling included children from 6 to 14 years who needed allergy treatment for the first time. A structured questionnaire was carried out to collect demographic and clinical data and history of OAS. Besides sensitisation to various allergens, the skin prick-by-prick test was performed to corroborate sensitisation to food related to OAS. Prevalence of OAS and its association with pollens was established following the covariate adjusted logistic regression. RESULTS: 267 subjects were included. Overall prevalence of OAS was 8.9% (95%CI 6.1-13.1%). Prevalence of OAS for allergic rhinitis and asthma were 8.8% and 9.1%, respectively. In patients sensitised to pollen, the prevalence ranged from 9.6% to 12.2% depending on the type of pollen. 62.5% of children with OAS were sensitive to pineapple. After adjusting for gender and family history of atopic disease, trees from the Quercus species showed an association with OAS (OR=2.7, 95%CI 1.2-6.2). CONCLUSIONS: OAS is not uncommon in our environment. Pineapple, a typical fruit from the region, was the main food related. Quercus sp., but not birch nor olive, was the pollen associated with this syndrome</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27567321">PM:27567321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160827-BedollaBarajasM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160827-BedollaBarajasM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Bedolla-Barajas M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goncalves,L.C.</style></author><author><style face="normal" font="Arial"> Guimaraes,T.C.</style></author><author><style face="normal" font="Arial"> Silva,R.M.</style></author><author><style face="normal" font="Arial"> Cheik,M.F.</style></author><author><style face="normal" font="Arial"> de Ramos Napolis,A.C.</style></author><author><style face="normal" font="Arial"> Barbosa e Silva,G.</style></author><author><style face="normal" font="Arial"> Segundo,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Research Group, Pediatric Departments, Universidade Federal de Uberlandia, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of food allergy in infants and pre-schoolers in Brazil</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="503" start="497">497-503</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth and Development</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="8" Year="2016">2016/8/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is an increasing problem in public health, especially in childhood. Its incidence has increased in the last decade. Despite this, estimates of the actual incidence and prevalence are uncertain. The aim of this study was to estimate the prevalence of food allergy in infants and pre-schoolers. METHODS: The parents of 3897 children completed questionnaires on the occurrence of any reaction to food. Children with parentally reported reactions were selected for further examination including a clinical interview, physical examination, allergic tests, and if necessary, oral food challenge to conclude the diagnosis of FA. RESULTS: The estimated prevalence of allergy in children aged 4-59 months was 0.61%, being, 1.9% in infants and 0.4% in pre-schoolers. Among the 604 patients physicians evaluated with parent-reported FA, 24 (4%) had a confirmed diagnosis of food allergy, and 580 (96%) were excluded in the remaining. Of these, approximately half (51/52.6%) of 97 infants and (128/48%) of 487 pre-schoolers already performed the diet exclusion suspected food for a period of time. CONCLUSION: This study shows that high overall prevalence of parental belief of current food allergy however the same was not observed in the in physician-diagnosed food allergy. The prevalence of food allergy was lower than that observed in the literature. This study alerts health professionals to the risk entailed by overestimation of cases of food allergy and unnecessary dietary exclusion, which may result in impairment in growth and development of children, especially in their first years of life</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496782">PM:27496782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160806-GoncalvesLC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20160806-GoncalvesLC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Goncalves LC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Comberiati,P.</style></author><author><style face="normal" font="Arial"> Landi,M.</style></author><author><style face="normal" font="Arial"> Martelli,A.</style></author><author><style face="normal" font="Arial"> Piacentini,G.L.</style></author><author><style face="normal" font="Arial"> Capristo,C.</style></author><author><style face="normal" font="Arial"> Paiola,G.</style></author><author><style face="normal" font="Arial"> Peroni,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Clinic, Department of Life and Reproduction Sciences, University of Verona, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Awareness of allergic enterocolitis among primary-care paediatricians: A web-based pilot survey</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="466" start="461">461-466</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colic</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cow's milk formula</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic guidelines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Reproduction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="8" Year="2016">2016/8/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic enterocolitis, also known as food protein-induced enterocolitis syndrome (FPIES), is an increasingly reported and potentially severe non-IgE mediated food allergy of the first years of life, which is often misdiagnosed due to its non-specific presenting symptoms and lack of diagnostic guidelines. OBJECTIVE: We sought to determine the knowledge of clinical, diagnostic and therapeutic features of FPIES among Italian primary-care paediatricians. METHODS: A 16-question anonymous web-based survey was sent via email to randomly selected primary care paediatricians working in the north of Italy. RESULTS: There were 194 completed surveys (48.5% response rate). Among respondents, 12.4% declared full understanding of FPIES, 49% limited knowledge, 31.4% had simply heard about FPIES and 7.2% had never heard about it. When presented with clinical anecdotes, 54.1% recognised acute FPIES and 12.9% recognised all chronic FPIES, whereas 10.3% misdiagnosed FPIES as allergic proctocolitis or infantile colic. To diagnose FPIES 55.7% declared to need negative skin prick test or specific-IgE to the trigger food, whereas 56.7% considered necessary a confirmatory oral challenge. Epinephrine was considered the mainstay in treating acute FPIES by 25.8% of respondents. Only 59.8% referred out to an allergist for the long-term reintroduction of the culprit food. Overall, 20.1% reported to care children with FPIES in their practice, with cow's milk formula and fish being the most common triggers; the diagnosis was self-made by the participant in 38.5% of these cases and by an allergist in 48.7%. CONCLUSION: There is a need for promoting awareness of FPIES to minimise delay in diagnosis and unnecessary diagnostic and therapeutic interventions</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27498217">PM:27498217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2016-44-461-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2016-44-461-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, Comberiati P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.03.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Samorano,L.P.</style></author><author><style face="normal" font="Arial"> Fernandez,V.V.</style></author><author><style face="normal" font="Arial"> Valente,N.Y.</style></author><author><style face="normal" font="Arial"> Arnone,M.</style></author><author><style face="normal" font="Arial"> Nico,M.M.</style></author><author><style face="normal" font="Arial"> Rivitti-Machado,M.C.</style></author><author><style face="normal" font="Arial"> Oliveira,Z.N.</style></author><author><style face="normal" font="Arial"> Criado,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital das Clinicas of the University of Sao Paulo Medical School, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Urticaria multiforme: Two cases with histopathological findings</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="155" start="154">154-155</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Brazil</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - LETTERCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27526975">PM:27526975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160816-SamoranoLP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160816-SamoranoLP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Samorano LP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sato,S.</style></author><author><style face="normal" font="Arial"> Ogura,K.</style></author><author><style face="normal" font="Arial"> Takahashi,K.</style></author><author><style face="normal" font="Arial"> Sato,Y.</style></author><author><style face="normal" font="Arial"> Yanagida,N.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Clinical Research Center for Allergology and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Usefulness of antigen-specific IgE probability curves derived from the 3gAllergy assay in diagnosing egg, cow's milk, and wheat allergies</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="301" start="296">296-301</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food challenge outcome</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Specific IgE (sIgE) antibody detection using the Siemens IMMULITE(R) 3gAllergy (3gAllergy) assay have not been sufficiently examined for the diagnosis of food allergy. The aim of this study was to evaluate the utility of measuring sIgE levels using the 3gAllergy assay to diagnose allergic reactions to egg, milk, and wheat. METHODS: This retrospective study was conducted on patients with diagnosed or suspected allergies to egg, milk and wheat. Patients were divided into two groups according to their clinical reactivity to these allergens based on oral food challenge outcomes and/or convincing histories of immediate reaction to causative food(s). The sIgE levels were measured using 3gAllergy and ImmunoCAP. Predicted probability curves were estimated using logistic regression analysis. RESULTS: We analyzed 1561 patients, ages 0-19 y (egg = 436, milk = 499, wheat = 626). The sIgE levels determined using 3gAllergy correlated with those of ImmunoCAP, classifying 355 patients as symptomatic: egg = 149, milk = 123, wheat = 83. 3gAllergy sIgE levels were significantly higher in symptomatic than in asymptomatic patients (P &lt; 0.0001). Predictive probability for positive food allergy was significantly increased and correlated with increased sIgE levels. The cut-offs for allergic reaction with 95% predictive probability as determined by the 3gAllergy probability curves were different from those of ImmunoCAP. CONCLUSIONS: Measurements of sIgE against egg, milk, and wheat as determined by 3gAllergy may be used as a tool to facilitate the diagnosis of food allergy in subjects with suspected food allergies. However, these probability curves should not be applied interchangeably between different assays</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.06.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27523600">PM:27523600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160815-SatoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160815-SatoS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Sato S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.06.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Borres,M.P.</style></author><author><style face="normal" font="Arial"> Maruyama,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Maternal and Child Health, Uppsala University, Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Recent advances in component resolved diagnosis in food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="387" start="378">378-387</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="16" Month="8" Year="2016">2016/8/16</year></dates><abstract><style face="normal" font="Arial">Due to the high prevalence of food allergic diseases globally there are increasing demands in clinical practice for managing IgE-mediated conditions. During the last decade, component resolved diagnostics has been introduced into the field of clinical allergology, providing information that cannot be obtained from extract-based tests. Component resolved data facilitate more precise diagnosis of allergic diseases and identify sensitizations attributable to cross-reactivity. Furthermore it assists risk assessment in clinical practice as sensitization to some allergenic molecules is related to persistence of clinical symptoms and systemic rather than local reactions. The information may also aid the clinician in prescription of oral immunotherapy (OIT) in patients with severe symptoms, and in giving advice on food allergen avoidance or on the need to perform food challenges. The use of allergen components is rapidly evolving and increases our possibility to treat food allergic patients with a more individual approach. Using molecular allergology, we can already now better diagnose, prognose and grade the food allergy. In summary, daily routine molecular allergy diagnostics offers a number of benefits that give us a higher diagnostic precision and allow for better management of the patient</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Sweden -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27543004">PM:27543004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160820-BorresMP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160820-BorresMP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Borres MP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.07.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tamai,K.</style></author><author><style face="normal" font="Arial"> Yoshimatsu,H.</style></author><author><style face="normal" font="Arial"> Saito,T.</style></author><author><style face="normal" font="Arial"> Matsuoka,H.</style></author><author><style face="normal" font="Arial"> Okada,N.</style></author><author><style face="normal" font="Arial"> Koma,Y.</style></author><author><style face="normal" font="Arial"> Otsuka,A.</style></author><author><style face="normal" font="Arial"> Oda,N.</style></author><author><style face="normal" font="Arial"> Inoue,S.</style></author><author><style face="normal" font="Arial"> Kume,S.</style></author><author><style face="normal" font="Arial"> Suzuki,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Shinko Hospital, Kobe, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Autoantibody profiles and their association with blood eosinophils in asthma and COPD</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="337" start="332">332-337</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antinuclear antibodies</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Proteinase</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rheumatoid Factor</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Autoimmune involvement in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD) has been proposed, and autoantibodies are a hallmark of autoimmunity. This study aimed to compare the autoantibody profiles of asthma and COPD, and the relationship between autoantibodies and features of these diseases. METHODS: We recruited 110 asthma patients and 92 COPD patients for a prospective study. Six autoantibody types were evaluated: antinuclear antibody, anti-cytoplasmic antibodies, rheumatoid factor, anti-cyclic citrullinated peptide antibody, myeloperoxidase-anti-neutrophil cytoplasmic autoantibody (MPO-ANCA) and proteinase 3-ANCA. Other clinical data were also recorded concurrently. RESULTS: An antinuclear antibody titre of >/=1:160 presented only in asthma but not in COPD (10% vs. 0%, p = 0.0002). Eosinophil counts in blood were negative predictors of antinuclear antibody in asthma. Conversely, eosinophil counts in blood and immunoglobulin-E levels of >/=100 IU/mL were positively associated with rheumatoid factor in asthma but not in COPD. There was no relationship between antinuclear antibody or rheumatoid factor and disease severity. CONCLUSIONS: It is possible that asthma tends to involve autoimmunity associated with antinuclear antibody more frequently than COPD because asthma is the more robust factor for antinuclear antibody positivity. Antinuclear antibody and rheumatoid factor are associated with eosinophilic responses, but they do not work as biomarkers for disease severity</style></abstract><notes><style face="normal" font="Arial">DA - 20160904IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27592398">PM:27592398</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160904-TamaiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160904-TamaiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160904, Tamai K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mizuno,Y.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author><author><style face="normal" font="Arial"> Nagao,M.</style></author><author><style face="normal" font="Arial"> DunnGalvin,A.</style></author><author><style face="normal" font="Arial"> Fujisawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Clinical Research, Mie National Hospital, Mie, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Validation and reliability of the Japanese version of the Food Allergy Quality of Life Questionnaire-Parent Form</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="295" start="290">290-295</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy (FA) is a heavy burden for patients and their families and can significantly reduce the quality of life (QoL) of both. To provide adequate support, qualitative and quantitative evaluation of the parents' QoL may be helpful. The objective of this study is to develop and validate a Japanese version of the Food Allergy QoL Questionnaire-Parent Form (FAQLQ-PF-J), an internationally validated disease-specific QoL measurement of the parental burden of having a child with FA. METHODS: The FAQLQ-PF and the Food Allergy Independent Measure (FAIM), an instrument to test the construct validity of the FAQLQ-PF-J, were translated into Japanese. After language validation, the questionnaires were administered to parents of FA children aged 0-12 years and those of age-matched healthy (without FA) children. Internal consistency (by Cronbach's alpha) and test-retest reliability were evaluated. Construct validity and discriminant validity were also examined. RESULTS: One hundred twenty-seven parents of children with FA and 48 parents of healthy children filled out the questionnaire. The FAQLQ-PF-J showed excellent internal consistency (Cronbach's alpha > 0.77) and test-retest reliability. Good construct validity was demonstrated by significant correlations between the FAQLQ-PF-J and FAIM-J scores. It discriminated parents of children with FA from those without. The scores were significantly higher (lower QoL) for parents of FA children with a history of anaphylaxis than those without, for those with >6 FA-related symptoms experienced than those with less FA-related symptoms. CONCLUSIONS: The FAQLQ-PF-J is a reliable and valid measure of the parental burden of FA in children</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27599914">PM:27599914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160907-MizunoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160907-MizunoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Mizuno Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.06.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fujimoto,W.</style></author><author><style face="normal" font="Arial"> Fukuda,M.</style></author><author><style face="normal" font="Arial"> Yokooji,T.</style></author><author><style face="normal" font="Arial"> Yamamoto,T.</style></author><author><style face="normal" font="Arial"> Tanaka,A.</style></author><author><style face="normal" font="Arial"> Matsuo,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Kawasaki Medical School, Okayama, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis provoked by ingestion of hydrolyzed fish collagen probably induced by epicutaneous sensitization</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="476" start="474">474-476</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword></keywords><dates><year Day="25" Month="8" Year="2016">2016/8/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - LETTERCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.03.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27569115">PM:27569115</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160829-FujimotoW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160829-FujimotoW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Fujimoto W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.03.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hide,M.</style></author><author><style face="normal" font="Arial"> Yagami,A.</style></author><author><style face="normal" font="Arial"> Togawa,M.</style></author><author><style face="normal" font="Arial"> Saito,A.</style></author><author><style face="normal" font="Arial"> Furue,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="325" start="317">317-325</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Bilastine</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bilastine, a novel non-sedating second-generation H1-antihistamine, has been widely used in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once daily in most European countries since 2010. We evaluated its efficacy and safety in Japanese patients with chronic spontaneous urticaria (CSU). METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled phase II/III study (trial registration No. JapicCTI-142574). Patients (age, 18-74 years) were randomly assigned to receive bilastine 20 mg, 10 mg or placebo once daily for 2 weeks. The primary efficacy endpoint was the change from baseline (Day -3 to 0) in total symptom score (TSS) at 2 weeks (Day 8-14), consisting of the itch and rash scores. RESULTS: A total of 304 patients were randomly allocated to bilastine 20 mg (101 patients), bilastine 10 mg (100 patients), and placebo (103 patients). The changes in TSS at 2 weeks were significantly decreased by bilastine 20 mg than did placebo (p &lt; 0.001), demonstrating the superiority of bilastine 20 mg. Bilastine 10 mg also showed a significant difference from placebo (p &lt; 0.001). The TSS changes for the bilastine showed significant improvement from Day 1, and were maintained during the treatment period. The Dermatology Life Quality Index scores were also improved in bilastine than in placebo. The bilastine treatments were safe and well tolerated. CONCLUSIONS: Two-week treatment with bilastine (20 or 10 mg) once daily was effective and tolerable in Japanese patients with CSU, demonstrating an early onset of action</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27599913">PM:27599913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160907-HideM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160907-HideM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Hide M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy: Past, present and future</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="369" start="363">363-369</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="9" Year="2016">2016/9/6</year></dates><abstract><style face="normal" font="Arial">Hippocrates is often credited with first recognizing that food could be responsible for adverse symptoms and even death in some individuals, but it was not until the seminal observations by Prausnitz that the investigation of food allergy was viewed on a more scientific basis. In the first half of the 20th century, there were periodic reports in the medical literature describing various food allergic reactions. In the mid- to late- 1970's, the studies of Charles May and colleagues began to penetrate the medical world's skepticism about the relevance of food allergy and how to diagnose it, since standard skin testing was known to correlate poorly with clinical symptoms. With May's introduction of the double-blind placebo-controlled oral food challenge, the study of food allergy became evidence-based and exponential strides have been made over the past four decades in the study of basic immunopathogenic mechanisms and natural history, and the diagnosis and management of food allergies. Today IgE- and non-IgE-mediated food allergic disorders are well characterized and efforts to treat these allergies by various immunotherapeutic strategies are well under way</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613366">PM:27613366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160910-SampsonHA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160910-SampsonHA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Sampson HA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Du Toit,G.</style></author><author><style face="normal" font="Arial"> Foong,R.M.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Allergy, King's College London and Guy's and St. Thomas' NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Prevention of food allergy - Early dietary interventions</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="377" start="370">370-377</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="8" Month="9" Year="2016">2016/9/8</year></dates><abstract><style face="normal" font="Arial">The prevalence of food allergy has increased over the last 30 years and remains a disease, which significantly impacts on the quality of life of children and their families. Several hypotheses have been formulated to explain the increasing prevalence; this review will focus on the hypothesis that dietary factors may influence the development of food allergy. Historically, the prevention of food allergy has focused on allergen avoidance. However, recent findings from interventional studies have prompted a shift in the mind set from avoidance to early introduction of potentially allergenic foods. This review aims to facilitate a better understanding of contemporary research studies that make use of early introduction of common allergenic foods into infant diets as a preventative strategy against the development of food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27617655">PM:27617655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160912-DuToitG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160912-DuToitG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Du Toit G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kimura,M.</style></author><author><style face="normal" font="Arial"> Shimomura,M.</style></author><author><style face="normal" font="Arial"> Morishita,H.</style></author><author><style face="normal" font="Arial"> Meguro,T.</style></author><author><style face="normal" font="Arial"> Seto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Shizuoka Children's Hospital, Shizuoka, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilia in infants with food protein-induced enterocolitis syndrome in Japan</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="316" start="310">310-316</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood eosinophils</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Many Japanese infants with food protein-induced enterocolitis syndrome (FPIES) show eosinophilia, which has been thought to be a characteristic of food protein-induced proctocolitis (FPIP). METHODS: To elucidate the characteristics of eosinophilia in Japanese FPIES patients, 113 infants with non-IgE-mediated gastrointestinal food allergy due to cow's milk were enrolled and classified into FPIES (n = 94) and FPIP (n = 19). RESULTS: The percentage of peripheral blood eosinophils (Eo) was increased in most FPIES patients (median, 7.5%), which was comparable with that in FPIP patients (9.0%). Among FPIES patients, Eo was the highest in patients who had vomiting, bloody stool, and diarrhea simultaneously (12.9%) and lowest in patients with diarrhea alone (3.2%). Eo showed a significant positive correlation with the incidence of vomiting (Cramer's V = 0.31, p &lt; 0.005) and bloody stool (Cramer's V = 0.34, p &lt; 0.0005). A significant difference was found in Eo between early- (&lt;/=10 days, n = 56) and late-onset (>10 days, n = 38) FPIES (median, 9.8% vs. 5.4%; p &lt; 0.005). IL-5 production by peripheral blood T cells stimulated with cow's milk protein in early-onset FPIES was significantly higher than that in late-onset FPIES (67.7 pg/mL vs. 12.5 pg/mL, p &lt; 0.01), and showed a significant positive correlation with Eo (rs = 0.60, p &lt; 0.01). CONCLUSIONS: This study demonstrated two types of eosinophilia in Japanese FPIES infants: conspicuous and mild eosinophilia in early- and late-onset FPIES patients, respectively. Conspicuous eosinophilia in early-onset FPIES is suggested to be caused by abnormally high IL-5 production</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27624222">PM:27624222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160914-KimuraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160914-KimuraM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Kimura M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ota,Y.</style></author><author><style face="normal" font="Arial"> Ikemiyagi,Y.</style></author><author><style face="normal" font="Arial"> Sato,T.</style></author><author><style face="normal" font="Arial"> Funakoshi,T.</style></author><author><style face="normal" font="Arial"> Hiruta,N.</style></author><author><style face="normal" font="Arial"> Kitamura,M.</style></author><author><style face="normal" font="Arial"> Bujo,H.</style></author><author><style face="normal" font="Arial"> Suzuki,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Toho University Sakura Medical Center, Chiba, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Measuring local immunoglobulin E in the inferior turbinate nasal mucosa in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="399" start="396">396-399</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> inferior turbinate</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Local IgE</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen-specific</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Studies show that immunoglobulin E (IgE) is produced in the local nasal mucosa in allergic rhinitis patients. However, no study involved the measurement of IgE levels in the local nasal mucosal tissue in allergic rhinitis patients. This study aimed to measure the local IgE levels in the nasal mucosal tissue and to compare the levels of total IgE and specific IgEs in the serum and the inferior turbinate nasal mucosa in allergic rhinitis patients using the AlaSTAT 3gAllergy assay (Siemens Healthcare Diagnostics AG, Erlangen, Germany). METHODS: Total IgE antibodies and allergen-specific IgE antibodies in each sample of nasal mucosal tissue from 11 allergic rhinitis patients were measured with the AlaSTAT 3gAllergy assay. We compared the levels of total IgE and IgEs specific for house dust (HD), mites, and cedar pollen in the serum and the inferior turbinate. RESULTS: The total IgE levels and the cedar pollen-specific IgE levels in the inferior turbinate mucosal tissue correlated significantly with their respective levels in serum. The HD- and mite-specific IgE levels in the inferior turbinate mucosal tissue did not correlate significantly with their respective levels in the serum. CONCLUSIONS: Our results evaluating the correlations between nasal mucosal and serum levels of antigen-specific IgE indicate that IgE produced in the nasal mucosa affects the IgE levels in the serum, especially the cedar pollen-specific IgE</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.03.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27516133">PM:27516133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160812-OtaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160812-OtaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Ota Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.03.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hirata,H.</style></author><author><style face="normal" font="Arial"> Tatewaki,M.</style></author><author><style face="normal" font="Arial"> Shiromori,S.</style></author><author><style face="normal" font="Arial"> Ikeno,Y.</style></author><author><style face="normal" font="Arial"> Akutsu,I.</style></author><author><style face="normal" font="Arial"> Sugiyama,K.</style></author><author><style face="normal" font="Arial"> Arima,M.</style></author><author><style face="normal" font="Arial"> Kurasawa,K.</style></author><author><style face="normal" font="Arial"> Fukuda,T.</style></author><author><style face="normal" font="Arial"> Shima,D.</style></author><author><style face="normal" font="Arial"> Fukushima,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Specific IgE sensitization to honey bee venom and auto-injector adrenaline prescriptions for Japanese beekeepers</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="151" start="149">149-151</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Honey</style></keyword><keyword><style face="normal" font="Arial"> honey bee</style></keyword><keyword><style face="normal" font="Arial"> honey bee venom</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160812IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - LETTERCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27516131">PM:27516131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160812-HirataH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160812-HirataH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160812, Hirata H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cui,Y.</style></author><author><style face="normal" font="Arial"> Yu,L.</style></author><author><style face="normal" font="Arial"> Teng,F.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author><author><style face="normal" font="Arial"> Wang,N.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Central Laboratory, The Third People's Hospital of Yancheng, Affiliated Yancheng Hospital, School of Medicine, Southeast University, Yancheng, Jiangsu Province, China</style></auth-address><titles><title><style face="normal" font="Arial">Transcriptomic/proteomic identification of allergens in the mite Tyrophagus putrescentiae</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1639" start="1635">1635-1639</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shotgun proteomics</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage mite</style></keyword><keyword><style face="normal" font="Arial"> storage mites</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus putrescentiae</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="8" Year="2016">2016/8/6</year></dates><abstract><style face="normal" font="Arial">While a number of allergens from house dust mites have been described, much remains to be discovered about allergens from storage mites. Here, next-generation sequencing was combined with MS/MS shotgun proteomics to identify proteins, especially potential allergens from Tyrophagus putrescentiae, commonly found in stored food products, especially flour. cDNAs of suspected allergens were cloned and expressed from bacterial cells, and recombinant allergens were tested for binding to IgE in sera from T. putrescentiae-sensitive patients. These analyses identified three previously uncharacterized allergens, Tyr p 28, Tyr p 35, and Tyr p 36, which have been officially assigned by the WHO/IUIS Allergen Nomenclature Sub-committee. Recombinant proteins rTyr p 28, rTyr p 35, and rTyr p 36 bound with 47.1%, 82.4%, and 70.6% of T. putrescentiae-sensitive sera. We provide here a new method to identify allergens by the combination of transcriptomic and proteomic approaches</style></abstract><notes><style face="normal" font="Arial">DA - 20160825IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12999</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27496383">PM:27496383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160825-CuiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160825-CuiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Cui Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12999</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bachmann,M.F.</style></author><author><style face="normal" font="Arial"> Kundig,T.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology, RIA, University Hospital Bern, Sahlihaus 2, CH-3010, Bern, SwitzerlandThe Jenner Institute, University of Oxford, Oxford, UKDepartment of Dermatology University Hospital Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Allergen specific immunotherapy: is it vaccination against toxins after all?</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="23" start="13">13-23</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">IgE-mediated allergies, in particular allergic rhino-conjunctivitis and asthma, have reached epidemic proportions, affecting about one third of the population in developed countries. The most effective treatment for allergies is specific immunotherapy (SIT), which involves the injection of increasing doses of an allergen extract to allergic individuals. The current form of SIT was first introduced 1911 and recently celebrated its 100th birthday for the treatment of hay fever. The concept of this therapy at the time was straight-forward, since it was believed that pollen contained toxins against which the patient could be vaccinated. However, the understanding became blurred with the discovery that IgE antibodies were the effector molecules of the allergic response. Subsequent research focused on the idea that SIT should induce tolerance keeping the IgE antibodies at bay. In this review, we will discuss the various hypotheses for the mechanism of SIT and we will put forward the concept that allergens may be viewed as "protoxins" which need to be activated by IgE antibodies. Within this framework, protoxin-neutralizing antibodies are the key effector molecules while a shift to Th1 or Treg cells mainly contributes to the efficacy of SIT by helping B cells to produce neutralizing IgG antibodies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160825IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Switzerland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12890</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27558586">PM:27558586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160825-BachmannMF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160825-BachmannMF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Bachmann MF</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12890</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wolbing,F.</style></author><author><style face="normal" font="Arial"> Kunz,J.</style></author><author><style face="normal" font="Arial"> Kempf,W.E.</style></author><author><style face="normal" font="Arial"> Grimmel,C.</style></author><author><style face="normal" font="Arial"> Fischer,J.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Technical University of Munich, Biedersteiner Strasse 29, 80802, Munich</style></auth-address><titles><title><style face="normal" font="Arial">The clinical relevance of birch pollen profilin cross reactivity in sensitized patients</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="569" start="562">562-569</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 2</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phl p 12</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Overlapping seasons and cross reactivity, especially to grass pollen profilin, can hamper the diagnosis of birch pollen allergy. To identify the primary sensitizing allergen and the clinical relevance of cross sensitization, we correlated sensitization profiles with in vitro and in vivo tests, symptom scores and pollen counts. METHODS: 433 patients with positive skin prick test (SPT) to birch pollen were analyzed regarding IgE to major birch and grass pollen allergens Bet v 1 and Phl p 1/p 5 and the profilins Bet v 2 and Phl p 12. Subgroups were analyzed by basophil activation test (BAT) and CAP-FEIA based cross- and self-inhibition tests. RESULTS: 349 patients were sensitized to Bet v 1, 44 to both Bet v 1 and Bet v 2 and 15 patients to Bet v 2 only. From Bet v 2 sensitized patients 40 were also sensitized to Phl p 12. Ex vivo, Bet v 2 and Phl p 12 induced dose dependent activation in basophils of these patients. Cross- and self-inhibition tests with both allergens confirmed cross reactivity. However, semi-quantitative analysis of SPTs demonstrated markedly increased reactivity to grass compared to birch pollen extract in Bet v 2 only sensitized patients. Accordingly, in most of those patients clinical symptoms precisely correlated with grass pollen counts. CONCLUSION: Identification of the clinically relevant and sensitizing allergen needs correlation of actual pollen counts with clinical symptoms and sensitization status to major allergens. Semi-quantitative analysis of SPT or BAT and determining profilin-specific IgE can contribute to making the diagnosis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27588729">PM:27588729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160902-WolbingF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160902-WolbingF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Wolbing F</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garbani,M.</style></author><author><style face="normal" font="Arial"> Xia,W.</style></author><author><style face="normal" font="Arial"> Rhyner,C.</style></author><author><style face="normal" font="Arial"> Prati,M.</style></author><author><style face="normal" font="Arial"> Scheynius,A.</style></author><author><style face="normal" font="Arial"> Malissen,B.</style></author><author><style face="normal" font="Arial"> Engqvist,H.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Crameri,R.</style></author><author><style face="normal" font="Arial"> Terhorst,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Platz, SwitzerlandBerlin Institute of Health (BIH), Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific immunotherapy in mice</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="578" start="570">570-578</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T-cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Immunomodulatory interventions play a key role in the treatment of infections and cancer as well as allergic diseases. Adjuvants such as micro- and nanoparticles are often added to immunomodulatory therapies to enhance the triggered immune response. Here, we report the immunological assessment of novel and economically manufactured microparticle adjuvants, namely strontium-doped hydroxyapatite porous spheres (SHAS), which we suggest for the use as adjuvant and carrier in allergen-specific immunotherapy (ASIT). METHODS AND RESULTS: Scanning electron microscopy revealed that the synthesis procedure developed for the production of SHAS results in a highly homogeneous population of spheres. SHAS bound and released proteins such as ovalbumin (OVA) or the major cat allergen Fel d 1. SHAS-OVA were taken up by human monocyte-derived dendritic cells (mdDCs) and murine DCs and did not have any necrotic or apoptotic effects even at high densities. In a murine model of ASIT for allergic asthmatic inflammation we found that OVA released from subcutaneously injected SHAS-OVA led to a sustained stimulation of both CD4+ and CD8+ T-cells. ASIT with SHAS-OVA as compared to soluble OVA resulted in similar humoral responses but in a higher efficacy as assessed by symptom scoring. CONCLUSION: We conclude that SHAS may constitute a suitable carrier and adjuvant for ASIT with great potential due to its unique protein-binding properties. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Switzerland -CO - Sweden -CO - France -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590538">PM:27590538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160903-GarbaniM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160903-GarbaniM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Garbani M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Decuyper,I.I.</style></author><author><style face="normal" font="Arial"> Van Gasse,A.L.</style></author><author><style face="normal" font="Arial"> Cop,N.</style></author><author><style face="normal" font="Arial"> Sabato,V.</style></author><author><style face="normal" font="Arial"> Faber,M.</style></author><author><style face="normal" font="Arial"> Mertens,C.</style></author><author><style face="normal" font="Arial"> Bridts,C.H.</style></author><author><style face="normal" font="Arial"> Hagendorens,M.M.</style></author><author><style face="normal" font="Arial"> De Clerck,L.</style></author><author><style face="normal" font="Arial"> Rihs,H.P.</style></author><author><style face="normal" font="Arial"> Ebo,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine and Health Sciences, Department of Immunology - Allergology - Rheumatology, University of Antwerp, Antwerp University Hospital, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Cannabis sativa allergy: looking through the fog</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="206" start="201">201-206</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Alcoholic Beverages</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Beverages</style></keyword><keyword><style face="normal" font="Arial"> Cannabis</style></keyword><keyword><style face="normal" font="Arial"> Cannabis sativa</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-allergy</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Non-specific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Nsltp</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thaumatin-like protein</style></keyword><keyword><style face="normal" font="Arial"> Thaumatin-like Proteins</style></keyword><keyword><style face="normal" font="Arial"> TLP</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">IgE-mediated Cannabis (C. sativa, marihuana) allergy seems to be on the rise. Both active and passive exposure to cannabis allergens may trigger a C. sativa sensitization and/or allergy. The clinical presentation of a C. sativa allergy varies from mild to life-threatening reactions and often seems to depend on the route of exposure. In addition, sensitization to cannabis allergens can result in various cross-allergies, mostly for plant foods. This clinical entity, designated as the "cannabis-fruit/vegetable syndrome" might also imply cross-reactivity with tobacco, natural latex and plant-food derived alcoholic beverages. Hitherto, these cross-allergies are predominantly reported in Europe and appear mainly to rely upon cross-reactivity between non-specific lipid transfer proteins (ns-LTPs) or thaumatin-like proteins (TLPs) present in C. sativa and their homologues, ubiquitously distributed throughout plant kingdom. At present, diagnosis of cannabis-related allergies predominantly rests upon a thorough history completed with skin testing using native extracts from crushed buds and leaves. However, quantification of specific IgE (sIgE) antibodies and basophil activation tests (BAT) can also be helpful to establish correct diagnosis. In the absence of a cure, treatment comprises absolute avoidance measures. Whether avoidance of further use will halt the extension of related cross-allergies remains uncertain. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590896">PM:27590896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160903-DecuyperII.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160903-DecuyperII.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Decuyper II</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gusdorf,L.</style></author><author><style face="normal" font="Arial"> Asli,B.</style></author><author><style face="normal" font="Arial"> Barbarot,S.</style></author><author><style face="normal" font="Arial"> Neel,A.</style></author><author><style face="normal" font="Arial"> Masseau,A.</style></author><author><style face="normal" font="Arial"> Puechal,X.</style></author><author><style face="normal" font="Arial"> Gottenberg,J.E.</style></author><author><style face="normal" font="Arial"> Grateau,G.</style></author><author><style face="normal" font="Arial"> Blanchard-Delaunay,C.</style></author><author><style face="normal" font="Arial"> Rizzi,R.</style></author><author><style face="normal" font="Arial"> Lifermann,F.</style></author><author><style face="normal" font="Arial"> Kyndt,X.</style></author><author><style face="normal" font="Arial"> Aubin,F.</style></author><author><style face="normal" font="Arial"> Bessis,D.</style></author><author><style face="normal" font="Arial"> Boye,T.</style></author><author><style face="normal" font="Arial"> Gayet,S.</style></author><author><style face="normal" font="Arial"> Rongioletti,F.</style></author><author><style face="normal" font="Arial"> Sauleau,E.</style></author><author><style face="normal" font="Arial"> Fermand,J.P.</style></author><author><style face="normal" font="Arial"> Lipsker,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinique Dermatologique, Hopitaux Universitaires de Strasbourg, Strasbourg, France</style></auth-address><titles><title><style face="normal" font="Arial">Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="182" start="177">177-182</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinique</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Schnitzler Syndrome</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Schnitzler syndrome is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and biological signs of neutrophil-mediated inflammation. The aim of this study was to assess the applicability and validity of the existing diagnostic criteria in real-life patients. METHODS: This multicentric study was conducted between 2009 and 2014 in 14 hospitals in which patients with Schnitzler syndrome or controls with related disorders were followed up. We compared the sensitivities and specificities and calculated the positive and negative predictive values of the Lipsker and of the Strasbourg criteria for the patients with Schnitzler syndrome and for the controls. We included 42 patients with Schnitzler syndrome, 12 with adult-onset Still's disease, 7 with cryopyrin-associated periodic disease, 9 with Waldenstrom disease, and 10 with chronic spontaneous urticaria. RESULTS: All patients with Schnitzler syndrome met the Lipsker criteria. According to the Strasbourg criteria, 34 patients had definite Schnitzler syndrome, five had probable Schnitzler syndrome, and three did not meet the criteria. One control met the Lipsker criteria and had probable Schnitzler syndrome according to the Strasbourg criteria. Sensitivity and specificity of the Lipsker criteria were 100% and 97%, respectively. For the Strasbourg criteria, sensitivity for definite and probable diagnosis was 81% and 93%, respectively, with a corresponding specificity of 100% and 97%. CONCLUSION: Diagnostic criteria currently in use to diagnose Schnitzler syndrome are reliable. More investigations must be done to attest their efficiency in patients with recent-onset manifestations</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27564982">PM:27564982</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160912-GusdorfL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160912-GusdorfL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Giusdorf L</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cabauatan,C.R.</style></author><author><style face="normal" font="Arial"> Campana,R.</style></author><author><style face="normal" font="Arial"> Niespodziana,K.</style></author><author><style face="normal" font="Arial"> Reinisch,C.</style></author><author><style face="normal" font="Arial"> Lundberg,U.</style></author><author><style face="normal" font="Arial"> Meinke,A.</style></author><author><style face="normal" font="Arial"> Henning,R.</style></author><author><style face="normal" font="Arial"> Neubauer,A.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="168" start="164">164-168</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blocking IgG</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Epicutaneous allergen-specific immunotherapy (EPIT) is proposed as an alternative route for allergen-specific immunotherapy (AIT). The induction of allergen-specific blocking IgG antibodies represents an important mechanism underlying AIT, but has not been investigated for EPIT. Here, we compared the induction of allergen-specific blocking IgG in outbred guinea pigs which had been immunized with recombinant birch pollen allergen Bet v 1 using patch delivery system (PDS) with or without heat-labile toxin (LT) from Escherichia coli or subcutaneously with Aluminum hydroxide (Alum)-adsorbed rBet v 1. Only subcutaneous immunization with Alum-adsorbed rBet v 1 and epicutaneous administration of rBet v 1 with PDS in combination with LT from E. coli induced allergen-specific IgG antibodies blocking allergic patients' IgE, but not immunization with rBet v 1 via PDS alone. Our results suggest that patch vaccination with rBet v 1 in combination with LT may be a promising strategy for allergen-specific immunotherapy against birch pollen allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27568860">PM:27568860</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160829-CabauatanCR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160829-CabauatanCR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Cabauatan CR</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Offermann,N.</style></author><author><style face="normal" font="Arial"> Plum,M.</style></author><author><style face="normal" font="Arial"> Hubner,U.</style></author><author><style face="normal" font="Arial"> Rathloff,K.</style></author><author><style face="normal" font="Arial"> Fooke,M.</style></author><author><style face="normal" font="Arial"> Spillner,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dr. Fooke Laboratories, Neuss, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Human serum substitution by artificial sera of scalable allergen reactivity based on polyclonal antibodies and chimeras of human FcgammaRI and IgE domains</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1799" start="1794">1794-1799</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> CD64</style></keyword><keyword><style face="normal" font="Arial"> Chimera</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbit IgG</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> rast</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">Human sera are the first choice as controls for diagnostic applications like immunoassays, but are limited regarding availability, varying quality and high costs. In this study we aimed to circumvent these limitations by the use of a chimeric adaptor molecule comprising the extracellular domains of the human FcgammaRI (CD64) fused to human IgE Fc domains (CD64-IgE Fc). Allergen-specific antibodies were produced in rabbits using 8 different allergens, extracts and allergen mixtures including mites, pollen, drugs, food and others. Pre-incubation of polyclonal IgG with CD64-IgE Fc established allergen-specific artificial sera that showed comparable results for more than 20 allergens and allergen extracts in three diagnostic systems for determination of specific IgE. The agreement for these artificial sera is within +/- 1 RAST class. Hence, rabbit IgG complexed with the IgG-specific CD64-IgE Fc adaptor molecule could provide a substitute for human reference sera with specificity for virtually any protein of interest. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27588368">PM:27588368</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160902-OffermannN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160902-OffermannN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Offermann N</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Crameri,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="Arial">Artificial human sera: a breakthrough?</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1651" start="1649">1649-1651</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="3" Month="9" Year="2016">2016/9/3</year></dates><abstract><style face="normal" font="Arial">It is not common that a Brief Communication is chosen for an Editorial; however, the work presented by Offermann et al. (1) deserves to be commented. Obviously the in vitro diagnosis of allergic sensitisation is based on the determination of soluble allergen-specific IgE in serum (2). Although the correlation between sIgE and allergic sensitization might be disturbed by the presence of clinically irrelevant cross-reactive carbohydrate determinants (3), in most cases allergen-specific IgE in serum can be correlated with the symptomatic (4). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - EDITORIALCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27591103">PM:27591103</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160903-CrameriR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160903-CrameriR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Crameri R</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Percival,E.</style></author><author><style face="normal" font="Arial"> Bhatia,R.</style></author><author><style face="normal" font="Arial"> Preece,K.</style></author><author><style face="normal" font="Arial"> McElduff,P.</style></author><author><style face="normal" font="Arial"> McEvoy,M.</style></author><author><style face="normal" font="Arial"> Collison,A.</style></author><author><style face="normal" font="Arial"> Mattes,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Experimental &amp; Translational Respiratory Medicine Group, Hunter Medical Research Institute, University of Newcastle, Lookout Road, New Lambton, Newcastle, NSW 2305 Australia</style></auth-address><titles><title><style face="normal" font="Arial">Reproducibility of serum IgE, Ara h2 skin prick testing and fraction of exhaled nitric oxide for predicting clinical peanut allergy in children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h2</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ara h2 sIgE serum levels improve the diagnostic accuracy for predicting peanut allergy, but the use of Ara h2 purified protein as a skin prick test (SPT), has not been substantially evaluated. The fraction of exhaled nitric oxide (FeNO) shows promise as a novel biomarker of peanut allergy. Reproducibility of these measures has not been determined. The aim was to assess the accuracy and reproducibility (over a time-period of at least 12 months) of SPT to Ara h2 in comparison with four predictors of clinical peanut allergy (Peanut SPT, Ara h2 specific Immunoglobulin E (sIgE), Peanut sIgE and FeNO). METHODS: Twenty-seven children were recruited in a follow-up of a prospective cohort of fifty-six children at least 12 months after an open-labelled peanut food challenge. Their repeat assessment involved a questionnaire, SPT to peanut and Ara h2 purified protein, FeNO and sIgE to peanut and Ara h2 measurements. RESULTS: Ara h2 SPT was no worse in accuracy when compared with peanut SPT, FeNO, Ara h2 sIgE and peanut sIgE (AUC 0.908 compared with 0.887, 0.889, 0.935 and 0.804 respectively) for predicting allergic reaction at previous food challenge. SPT for peanut and Ara h2 demonstrated limited reproducibility (ICC = 0.51 and 0.44); while FeNO demonstrated good reproducibility (ICC = 0.73) and sIgE for peanut and Ara h2 were highly reproducible (ICC = 0.81 and 0.85). CONCLUSIONS: In this population, Ara h2 SPT was no worse in accuracy when compared with current testing for the evaluation of clinical peanut allergy, but had-like peanut SPT-poor reproducibility. FeNO, peanut sIgE and Ara h2 sIgE were consistently reproducible despite an interval of at least 12 months between the repeated measurements</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0143-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499764">PM:27499764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Percival E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0143-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lozoya-Ibanez,C.</style></author><author><style face="normal" font="Arial"> Morgado-Nunes,S.</style></author><author><style face="normal" font="Arial"> Rodrigues,A.</style></author><author><style face="normal" font="Arial"> Lobo,C.</style></author><author><style face="normal" font="Arial"> Taborda-Barata,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Castelo Branco Local Health Unit, Allergy Department, Castelo Branco, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence and clinical features of adverse food reactions in Portuguese adults</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="36">36-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Probable food allergy</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Self-reported food allergy</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Only one previous study, via telephone call, on the prevalence of self-reported food allergies has been performed in Portugal, in a small sample of adults. The objective of this study was to determine the prevalence of self-reported and probable food allergy, analyze the clinical features and involved foods in Portuguese adults. METHODS: Population-based, cross-sectional study performed in various healthcare centres from central Portugal. All 1436 randomly selected individuals (median age: 45 years, 50.6 % female) replied to a validated food allergy questionnaire by phone. Those who reported an adverse food reaction were invited to come to the hospital, where clinical history was taken, skin prick (SPT) and prick-prick skin (SPPT) tests were performed and food allergen-specific IgE levels (sIgE) were determined. An open oral challenge was performed in selected cases. Cases of positive clinical history of immediate (up to 2 h after ingestion) reaction in association with positive food sIgE levels and/or skin prick tests were classified as IgE-associated probable food allergy. Cases of positive clinical history of delayed (more than 2 h after ingestion) and negative food sIgE levels independently of positive SPT or SPPT results were classified as non-IgE associated probable food allergy. RESULTS: The prevalence of probable food allergy in our sample was 1 %, with shellfish and fish as the most frequently implicated foods. IgE-mediated probable food allergy occurred in 0.71 % of cases, with shellfish, peanut and nuts mainly involved. Cutaneous symptoms were most frequently reported. Prevalence values and food types were discrepant between self-reported and probable food allergies. CONCLUSIONS: The prevalence of probable food allergies in Portuguese adults is low, is mostly related to shellfish, peanut and nuts and most frequently involves cutaneous symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0139-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499765">PM:27499765</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Lozoya-Ibanez C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0139-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Love,B.L.</style></author><author><style face="normal" font="Arial"> Mann,J.R.</style></author><author><style face="normal" font="Arial"> Hardin,J.W.</style></author><author><style face="normal" font="Arial"> Lu,Z.K.</style></author><author><style face="normal" font="Arial"> Cox,C.</style></author><author><style face="normal" font="Arial"> Amrol,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, The University of South Carolina, 715 Sumter St., CLS 314D, Columbia, SC 29208 USA</style></auth-address><titles><title><style face="normal" font="Arial">Antibiotic prescription and food allergy in young children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="41">41-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administrative data</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> cephalosporin</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicaid</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: To assess the relationship between any systemic antibiotic prescription within the first year of life and the presence of an ICD-9-CM diagnosis code for food allergy (FA). METHODS: This was a matched case-control study conducted using South Carolina Medicaid administrative data. FA cases born between 2007 and 2009 were matched to controls without FA on birth month/year, sex, race/ethnicity. Conditional logistic regression was used to model the adjusted odds ratio (aOR) of FA diagnosis. All models were adjusted for presence of asthma, wheeze, or atopic dermatitis. RESULTS: A total of 1504 cases and 5995 controls were identified. Receipt of an antibiotic prescription within the initial 12 months of life was associated with FA diagnosis in unadjusted and adjusted models (aOR 1.21; 95 % CI 1.06-1.39). Compared to children with no antibiotic prescriptions, a linear increase in the aOR was seen with increasing antibiotic prescriptions. Children receiving five or more (aOR 1.64; 95 % CI 1.31-2.05) antibiotic prescriptions were significantly associated with FA diagnosis. The strongest association was noted among recipients of cephalosporin and sulfonamide antibiotics in both unadjusted and adjusted models. CONCLUSIONS: Receipt of antibiotic prescription in the first year of life is associated with FA diagnosis code in young children after controlling for common covariates. Multiple antibiotic prescriptions are more strongly associated with increases in the odds of FA diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0148-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27536320">PM:27536320</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Love BL</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0148-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arora,P.</style></author><author><style face="normal" font="Arial"> Ansari,S.H.</style></author><author><style face="normal" font="Arial"> Najmi,A.K.</style></author><author><style face="normal" font="Arial"> Anjum,V.</style></author><author><style face="normal" font="Arial"> Ahmad,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, 110062 India</style></auth-address><titles><title><style face="normal" font="Arial">Investigation of anti-asthmatic potential of dried fruits of Vitis vinifera L. in animal model of bronchial asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="42">42-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Grape</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine content</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nitrites</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Tidal Volume</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> Vitis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fruits of Vitis vinifera L., commonly known as grapes, are largely consumed worldwide because of their high nutritional and medicinal benefits. CONTEXT AND PURPOSE: The present study investigated effects of V. vinifera fruits in ovalbumin-induced animal model of bronchial asthma. METHODS: Male wistar rats (except group 1) were sensitized with allergen (ovalbumin, 40 mg/rat + aluminum hydroxide, 2 mg/rat). Groups of sensitized animals were treated orally with either vehicle (0.4 mL/kg), standard dexamethasone (2.5 mg/kg) or alcoholic extract of V. vinifera dried fruits (31 and 42.5 mg/kg) from day 1 to 28 (n = 6 for all groups). Inflammatory markers including cell counts, cytokines such as interleukin (IL)-4, IL-5, IL-1beta, tumor necrosis factor, immunoglobulin E (IgE), leukotrienes and nitrite levels in both blood/serum and bronchoalveolar fluid were analysed. Breathing rate and tidal volume as lung function parameters were examined by spirometer. Lung tissues were studied for histamine content and histopathology. RESULTS: Treatment of sensitized animals with dexamethasone or two doses of V. vinifera fruits extract inhibited recruitment of inflammatory cytokines, IgE, nitrites and circulating cells particularly eosinophils in blood/serum and bronchoalveolar fluid (p &lt; 0.001, p &lt; 0.01 and p &lt; 0.05). Dexamethasone and V. vinifera fruits extract treatment also normalized lung functions and histamine levels compared to ovalbumin-sensitized controls (p &lt; 0.05 and p &lt; 0.01). Moreover, both drugs exhibited protection against airway inflammation in lung histology. CONCLUSION: Results of study demonstrate the effectiveness of V. vinifera fruits in allergic asthma possibly related to its ability to inhibit cellular response and subsequent production of inflammatory cytokines</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0145-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27536321">PM:27536321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Arora P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0145-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rubin,T.</style></author><author><style face="normal" font="Arial"> Clayton,J.</style></author><author><style face="normal" font="Arial"> Adams,D.</style></author><author><style face="normal" font="Arial"> Persad,R.</style></author><author><style face="normal" font="Arial"> Vohra,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Alberta, 11405-87 Avenue, 3rd Floor, Edmonton Clinic Health Academy, Edmonton, AB T6G 1C9 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Systematic review of outcome measures in pediatric eosinophilic esophagitis treatment trials</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="45">45-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alberta</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decision Making</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Heterogeneity has been noted in the selection and reporting of disease-specific, pediatric outcomes in randomized controlled trials (RCTs). The consequence is invalid results or difficulty comparing results across trials. The primary objective of this systematic review was to assess primary outcome and outcome measure selection and reporting, in pediatric eosinophilic esophagitis (EoE) treatment trials. As secondary objectives, we compared trial disease definition to established concensus guidelines, and the efficacy of current EoE treatments. METHODS: We searched MEDLINE, EMBASE, The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL), and CINAHL since 2001. We also searched clinical trial registries (portal.nihr.ac.uk; clinicaltrials.gov; isrctn.com; and anzctr.org.au) and references of included studies. We included RCTs of EoE treatment in patients 0-18 years. Two authors independently assessed articles. RESULTS: Eleven studies met inclusion criteria. All identified primary outcomes, however, of 9 unique primary outcomes, only 2 were used in more than one study. In total, 25 unique primary and secondary outcome measures were employed for pediatric EoE treatment trials. Measurement properties and rationale for their selection was rarely provided. Uptake of consensus-based diagnostic criteria was 25 % in trials initiated after 2011. Due to the small number and heterogeneity of studies obtained, no meta-analysis of treatment efficacy could be undertaken. This SR was limited to exclusively pediatric RCTs. CONCLUSIONS: The results of this study confirm the need for a standardized set of core outcomes that are universally reported in pediatric EoE trials. Consistent disease definition and standardized outcome reporting will facilitate meta-analyses across similar trials and inform future clinical decision-making. Systematic review registration number CRD42013003798</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0144-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27582776">PM:27582776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Rubin T</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0144-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lefrancois,P.</style></author><author><style face="normal" font="Arial"> Chapdelaine,H.</style></author><author><style face="normal" font="Arial"> Cote,B.</style></author><author><style face="normal" font="Arial"> Desrosiers,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculte de Medecine, Universite de Montreal, Montreal, QC Canada</style></auth-address><titles><title><style face="normal" font="Arial">A role for auto-immunity in chronic rhinosinusitis? Lessons learned from sub-epidermal bullous disorders of the skin</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Auto-immunity</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Chronic rhinosinusitis (CRS) is a frequent chronic condition, which has origins in complex interactions between genetic, immunological and microbial factors. The role of auto-immunity in CRS remains unclear, although recent studies have started to emerge in CRS patient refractory to maximal medical management. We discuss the possible auto-immunity link between CRS and other skin diseases, in particular acquired bullous dermatoses, and review the current evidence. We raise additional considerations for auto-immunity from both research and clinical standpoints</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0141-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499767">PM:27499767</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Lefrancois P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0141-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cai,M.</style></author><author><style face="normal" font="Arial"> Zeng,L.</style></author><author><style face="normal" font="Arial"> Li,L.J.</style></author><author><style face="normal" font="Arial"> Mo,L.H.</style></author><author><style face="normal" font="Arial"> Xie,R.D.</style></author><author><style face="normal" font="Arial"> Feng,B.S.</style></author><author><style face="normal" font="Arial"> Zheng,P.Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Liu,Z.J.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Specific immunotherapy ameliorates ulcerative colitis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="37">37-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Capsules</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Ulcerative Colitis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hypersensitivity reaction to certain allergens plays a role in the pathogenesis of inflammatory bowel disease (IBD). This study aims to observe the effect of specific immunotherapy in a group of IBD patients. METHODS: Patients with both ulcerative colitis (UC) and food allergy were recruited into this study. Food allergy was diagnosed by skin prick test and serum specific IgE. The patients were treated with specific immunotherapy (SIT) and Clostridium butyricum (CB) capsules. RESULTS: After treating with SIT and CB, the clinical symptoms of UC were markedly suppressed as shown by reduced truncated Mayo scores and medication scores. The serum levels of specific IgE, interleukin (IL)-4 and tumor necrosis factor (TNF)-alpha were also suppressed. Treating with SIT alone or CB alone did not show appreciable improvement of the clinical symptoms of UC. CONCLUSIONS: UC with food allergy can be ameliorated by administration with SIT and butyrate-production probiotics</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0142-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499766">PM:27499766</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-37.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Cai M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0142-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takahashi,M.</style></author><author><style face="normal" font="Arial"> Taniuchi,S.</style></author><author><style face="normal" font="Arial"> Soejima,K.</style></author><author><style face="normal" font="Arial"> Hatano,Y.</style></author><author><style face="normal" font="Arial"> Yamanouchi,S.</style></author><author><style face="normal" font="Arial"> Kaneko,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Kansai Medical University, 2-5-1 Shin-machi, Hirakata, Osaka Japan</style></auth-address><titles><title><style face="normal" font="Arial">Two-weeks-sustained unresponsiveness by oral immunotherapy using microwave heated cow's milk for children with cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="44">44-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microwave</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Several studies have reported that oral immunotherapy (OIT) is effective for children with cow's milk (CM) allergy. These studies reported the efficacy of OIT in terms of desensitization, but did not describe sustained unresponsiveness to CM. The aim of this study was to evaluate the efficacy of the OIT protocol using microwave heated cow's milk (MH-CM) in terms of 2-weeks-sustained unresponsiveness (2-weeks-SU) and safety. METHODS: Forty-eight children were enrolled in this study. Thirty-one children agreed to receive rush OIT using MH-CM (the OIT group) and another 17 children who did not want to receive rush OIT formed the untreated group. Rates of desensitization and 2-weeks-sustained unresponsiveness were compared between the two groups at 1 year after the start of OIT. We followed up these rates and safety data for another year and for longer in the OIT group. RESULTS: No children in the untreated group did not pass an open food challenge to CM. Of the 31 children in the OIT group, 14 (P = 0.002) achieved desensitization, and 8 (P = 0.036) achieved 2-weeks-SU to CM at 1 year from the start of OIT. Two years after the start of OIT, both the rate of desensitization and the rate of 2-weeks-SU in the OIT group significantly increased compared with the rates at 1 year (P = 0.025 and P = 0.008 respectively). CONCLUSIONS: The rush OIT protocol using MH-CM was effective at inducing 2-weeks-SU s to CM and had a good safety profile in children with CM allergy. Trial registration Approval number: 324, Registered 3 February 2009</style></abstract><notes><style face="normal" font="Arial">DA - 20160829IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0150-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27570533">PM:27570533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160829, Takahashi M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0150-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kozlowska,R.</style></author><author><style face="normal" font="Arial"> Bozek,A.</style></author><author><style face="normal" font="Arial"> Jarzab,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Association between cancer and allergies</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of allergies and the incidence of cancer are both increasing worldwide. It has been hypothesized that atopy may affect the risk of some cancers. METHODS: In this study, 1525 patients (754 women and 771 men with a mean age of 52.7 +/- 11.9 years) with different types of cancer were examined for the presence of allergies. Allergies were confirmed based on retrospective analysis of allergy diagnostic procedures in patients previously diagnosed with cancer. All patients were also analyzed for bronchial asthma and allergic rhinitis according to relevant guidelines. A control group of patients without cancer diagnoses was used for comparison. RESULTS: Patients with cancer had significantly fewer IgE-mediated allergic diseases than the control population. For the oncological group compared to the non-cancer patients, the odds ratios (ORs) for allergic rhinitis, atopic dermatitis, and bronchial asthma were 0.67 (95 % CI 0.52-0.81), 0.89 (95 % CI 0.78-0.99), and 1.03 (95 % CI 0.91-1.13), respectively. The mean serum concentrations of total IgE were significantly lower in the study population of patients with cancer than in the patients in the control group (45.98 +/- 14.9 vs. 83.2 +/- 40.1 IU/l; p &lt; 0.05). There were no significant correlations between the type of cancer diagnosed and the form of allergy. CONCLUSION: Our results indicate that the overall incidence of allergies, particularly allergic rhinitis, was lower in patients with some types of cancer. Further studies are needed to confirm our findings</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0147-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525013">PM:27525013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Kozlowska R</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0147-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roger,A.</style></author><author><style face="normal" font="Arial"> Arcala Campillo,E.</style></author><author><style face="normal" font="Arial"> Torres,M.C.</style></author><author><style face="normal" font="Arial"> Millan,C.</style></author><author><style face="normal" font="Arial"> Jauregui,I.</style></author><author><style face="normal" font="Arial"> Mohedano,E.</style></author><author><style face="normal" font="Arial"> Linan,S.</style></author><author><style face="normal" font="Arial"> Verdu,P.</style></author><author><style face="normal" font="Arial"> Rubira,N.</style></author><author><style face="normal" font="Arial"> Santaolalla,M.</style></author><author><style face="normal" font="Arial"> Gonzalez,P.</style></author><author><style face="normal" font="Arial"> Orovitg,A.</style></author><author><style face="normal" font="Arial"> Villarrubia,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Germans Trias i Pujol Hospital, Badalona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Reduced work/academic performance and quality of life in patients with allergic rhinitis and impact of allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="40">40-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) is characterised by burdensome nasal and/or ocular symptoms. This inflammatory disease can be debilitating and thus result in considerable health-related and economic consequences. METHODS: In a cross-sectional study, adult subjects with AR (N = 683) completed three allergy-specific questionnaires that assessed the impact of AR on the work/academic performance, daily activities, health-related quality of life (HRQOL), and satisfaction with allergen immunotherapy (AIT). Regression analyses were used to examine the associations between several clinical variables and the patient-reported outcomes. RESULTS: Total loss of productivity was 21.0 and 21.2 % for employed and student patients, respectively, whereas the impairment of daily activities was 22.0 %. The mean overall HRQOL score was 1.94 +/- 1.29 (on the scale of 0-6 points). Global score for satisfaction with AIT was 65.5 +/- 24.8 (on a 0-100 scale). Simple regression analysis found statistically significant associations between loss of work and academic productivity, impairment of daily activities and the type and severity of AR. AIT was a protective factor. The persistent and more severe types of AR and lack of AIT contributed to the worsening of HRQOL. CONCLUSIONS: AR (the persistent and more severe form of the disease) has an impact on functional characteristics of adult patients in Spain. AIT might reduce the effect of this disease on the work/academic performance and HRQOL. Trial registration Retrospectively registered</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0146-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27525014">PM:27525014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Roger A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0146-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dilek,F.</style></author><author><style face="normal" font="Arial"> Ozceker,D.</style></author><author><style face="normal" font="Arial"> Ozkaya,E.</style></author><author><style face="normal" font="Arial"> Tamay,Z.</style></author><author><style face="normal" font="Arial"> Yazici,M.</style></author><author><style face="normal" font="Arial"> Kesgin,S.</style></author><author><style face="normal" font="Arial"> Kocyigit,A.</style></author><author><style face="normal" font="Arial"> Guler,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Allergy and Immunology, Bezmialem Vakif University Medical Faculty, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Plasma Levels of Matrix Metalloproteinase-9 in Children With Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="526" start="522">522-526</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Chronic spontaneous urticaria (CSU) is a disease that is primarily seen in adults and is comparatively rare in children. Consequently, only a few studies have focused on the pathogenesis of the disease in children. This study investigated the possible role of metalloproteinase-9 (MMP-9) in the pathogenesis of CSU in children. METHODS: The study group was composed of 54 children with CSU; 34 healthy children comprised the control group. The demographic and clinical features of the study group were extensively evaluated, and laboratory assessments were also performed. An enzyme-linked immunosorbent assay was used to evaluate levels of plasma MMP-9. Disease activity was quantified using the urticaria activity score (UAS). RESULTS: The median value of plasma MMP-9 was 108.9 ng/mL (interquartile range, 93.3-124.1) in the CSU group and 87.8 ng/mL (69.4-103.0) in the control group. The difference between the 2 groups was statistically significant (P&lt;0.001). Also, MMP-9 levels showed a significant positive correlation with UAS (rho=0.57, P&lt;0.001). Twenty-six percent of patients had positive autologous serum skin test (ASST) results. Neither UAS nor plasma MMP-9 levels were significantly different between ASST-positive and -negative patients (P>0.05). CONCLUSIONS: Plasma MMP-9 levels were elevated in children with CSU and were positively correlated with disease activity. MMP-9 may be both a good biomarker of disease activity and a potential therapeutic target in CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2016.8.6.522</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27582403">PM:27582403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2016-8-522-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2016-8-522-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Dilek F</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2016.8.6.522</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Ahn,K.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Jang,G.C.</style></author><author><style face="normal" font="Arial"> Min,T.K.</style></author><author><style face="normal" font="Arial"> Yang,H.J.</style></author><author><style face="normal" font="Arial"> Pyun,B.Y.</style></author><author><style face="normal" font="Arial"> Kwon,J.W.</style></author><author><style face="normal" font="Arial"> Sohn,M.H.</style></author><author><style face="normal" font="Arial"> Kim,K.W.</style></author><author><style face="normal" font="Arial"> Kim,K.E.</style></author><author><style face="normal" font="Arial"> Yu,J.</style></author><author><style face="normal" font="Arial"> Hong,S.J.</style></author><author><style face="normal" font="Arial"> Kwon,J.H.</style></author><author><style face="normal" font="Arial"> Kim,S.W.</style></author><author><style face="normal" font="Arial"> Song,T.W.</style></author><author><style face="normal" font="Arial"> Kim,W.K.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Jeon,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,Y.J.</style></author><author><style face="normal" font="Arial"> Lee,H.R.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Ahn,Y.</style></author><author><style face="normal" font="Arial"> Yum,H.Y.</style></author><author><style face="normal" font="Arial"> Suh,D.I.</style></author><author><style face="normal" font="Arial"> Kim,H.H.</style></author><author><style face="normal" font="Arial"> Kim,J.T.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Park,Y.M.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Hallym University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">A Multicenter Retrospective Case Study of Anaphylaxis Triggers by Age in Korean Children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="540" start="535">535-540</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Korean children</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Radiocontrast media</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Although anaphylaxis is recognized as an important, life-threatening condition, data are limited regarding its triggers in different age groups. We aimed to identify anaphylaxis triggers by age in Korean children. METHODS: We performed a retrospective review of medical records for children diagnosed with anaphylaxis between 2009 and 2013 in 23 secondary or tertiary hospitals in South Korea. RESULTS: A total of 991 cases (mean age=5.89+/-5.24) were reported, with 63.9% involving patients younger than 6 years of age and 66% involving male children. Food was the most common anaphylaxis trigger (74.7%), followed by drugs and radiocontrast media (10.7%), idiopathic factors (9.2%), and exercise (3.6%). The most common food allergen was milk (28.4%), followed by egg white (13.6%), walnut (8.0%), wheat (7.2%), buckwheat (6.5%), and peanut (6.2%). Milk and seafood were the most common anaphylaxis triggers in young and older children, respectively. Drug-triggered anaphylaxis was observed more frequently with increasing age, with antibiotics (34.9%) and nonsteroidal anti-inflammatory drugs (17.9%) being the most common causes. CONCLUSIONS: The most common anaphylaxis trigger in Korean children was food. Data on these triggers show that their relative frequency may vary by age</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2016.8.6.535</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27582405">PM:27582405</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2016-8-535-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2016-8-535-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Lee SY</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2016.8.6.535</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,K.H.</style></author><author><style face="normal" font="Arial"> Son,Y.W.</style></author><author><style face="normal" font="Arial"> Lee,S.C.</style></author><author><style face="normal" font="Arial"> Jeong,K.</style></author><author><style face="normal" font="Arial"> Sim,da W.</style></author><author><style face="normal" font="Arial"> Park,H.J.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Significance of Component Allergens in Fagales Pollen-Sensitized Peanut Allergy in Korea</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="511" start="505">505-511</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 3</style></keyword><keyword><style face="normal" font="Arial"> Ara h 8</style></keyword><keyword><style face="normal" font="Arial"> Ara h 9</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 2</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Fagales pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> peanut consumption</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Tree pollens</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Clinical features of peanut allergy can range from localized to systemic reactions. Because peanut and birch pollen have cross-reactivity, peanut can lead to localized allergic reaction in Fagales pollen-sensitized oral allergy syndrome (OAS) patients without peanut sensitization per se. The purpose of this study was to discriminate true peanut food allergy from cross-reactive hypersensitivity in birch-sensitized peanut allergy. METHODS: Birch-sensitized (n=81) and peanut anaphylaxis patients (n=12) were enrolled. Peanut-related allergic reactions and sensitization profiles were examined. Specific IgE to Fagales tree pollens (birch, oak), peanut, and their component allergens (Bet v 1, Bet v 2, Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9) were evaluated. Based on these specific IgEs and clinical features, the patients were classified into 4 groups: group 1 (Fagales pollen allergy without OAS), group 2 (Fagales pollen allergy with OAS), group 3 (OAS with peanut anaphylaxis), and group 4 (peanut anaphylaxis). RESULTS: After peanut consumption, one-third of OAS patients experienced oral symptoms not associated with peanut sensitization. Ara h 1 or Ara h 2 was positive in peanut anaphylaxis patients, whereas Ara h 8 was positive in OAS patients. There were 4 patients with both peanut anaphylaxis and OAS (group 3). Both Ara h 2 and Ara h 8 were positive in these patients. Foods associated with OAS in Korea showed unique patterns compared to Westernized countries. CONCLUSIONS: Ara h 2 and Ara h 8 may be important component allergens for discriminating peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2016.8.6.505</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27582401">PM:27582401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2016-8-505-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2016-8-505-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Park KH</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2016.8.6.505</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Oliveira,I.</style></author><author><style face="normal" font="Arial"> Crosara,P.F.</style></author><author><style face="normal" font="Arial"> Cassali,G.D.</style></author><author><style face="normal" font="Arial"> Reis,D.C.</style></author><author><style face="normal" font="Arial"> Rodrigues,D.S.</style></author><author><style face="normal" font="Arial"> Nunes,F.B.</style></author><author><style face="normal" font="Arial"> Guimaraes,R.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Azithromycin for the treatment of eosinophilic nasal polyposis: Clinical and histologic analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="e61" start="e55">e55-e61</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Aspirin intolerance</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunomodulators</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> macrolide</style></keyword><keyword><style face="normal" font="Arial"> Macrolides</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2016">2016/7/26</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Macrolides used as immunomodulators are a promising tool for chronic inflammatory airway diseases. Eosinophilic nasal polyposis (ENP) is still considered a disease that is difficult to control with the currently standardized treatments. OBJECTIVES: To evaluate prolonged treatment with low-dose azithromycin for ENP based on clinical and histopathologic variables. METHODS: The present investigation was a self-paired case study of 33 patients with ENP. A comparison was performed between patients before and after treatment with azithromycin for 8 weeks. The patients were subjected to clinical examinations, staging (three-dimensional imaging by endoscopy), application of the questionnaire, and biopsy of nasal polyps at the beginning and at the end of the treatment. RESULTS: The treatment yielded a clinical improvement regarding the two variables studied: polyposis staging (69.7%) and questionnaire (57.6%). We did not find significant differences in the inflammatory pattern and in the percentage or absolute number of eosinophils per field between samples obtained before and after the treatment (p > 0.05). There was no difference between the answers obtained from groups with and without asthma and/or aspirin intolerance (p > 0.3). The patients with advanced initial staging exhibited lower subjective improvement index and staging reduction (p = 0.031 and p = 0.012, respectively). CONCLUSION: Based on this study, azithromycin may be considered as another therapeutic option for ENP. However, further studies are necessary to define the real mechanism of action involved</style></abstract><notes><style face="normal" font="Arial">DA - 20160728IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27465667">PM:27465667</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-e55-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-e55-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160728, de Oliveira I</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0160</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uzun,R.</style></author><author><style face="normal" font="Arial"> Yalcin,A.D.</style></author><author><style face="normal" font="Arial"> Celik,B.</style></author><author><style face="normal" font="Arial"> Bulut,T.</style></author><author><style face="normal" font="Arial"> Yalcin,A.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Antalya Education and Research Hospital, Antalya, TurkeyDepartment of Internal Medicine, Allergy and Clinical Immunology, Academia Sinica, Genomics Research Center, Taipei, TaiwanDepartment of Pathology, Antalya Education and Research Hospital, Antalya, TurkeyDepartment of Pathology, Antalya Education and Research Hospital, Antalya, TurkeyDepartment of Infectious Diseases, Akdeniz University, Faculty of Medicine, Antalya, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone</style></title><secondary-title><style face="normal" font="Arial">Am J Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Case Rep</style></full-title></periodical><pages end="671" start="666">666-671</pages><volume><style face="normal" font="Arial">17</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antalya</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Blister</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Extremities</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> graft-versus-host disease</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis C</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG2</style></keyword><keyword><style face="normal" font="Arial"> IgG3</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Levofloxacin</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Pulse</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND Toxic epidermal necrolysis (TEN) is characterized by widespread erythematous and bullous lesions on the skin. Nowadays, considerable progress has been made in the understanding of its pathogenesis. Immunologically it is similar to graft-versus-host disease. Therefore, we may propose that TEN is a disorder of cell-mediated immunity. CASE REPORT Our patient was a 74-year-old white female who had pneumonia and was positive for hepatitis C virus (HCV), and who had been on levofloxacin therapy. After the first levofloxacin dose, erythematous dusky red macules occurred on her extremities and trunk, and on the following day, confluent purpuric lesions tended to run together over 85% of her body. Her biopsy results indicated TEN. Laboratory testing for serum ECP (eosinophil cationic peptide) and serum immunoglobulin (Ig) levels were performed, and blister fluid was investigated. The patient responded positively to omalizumab treatment and after treatment laboratory tests revealed decreased high sensitive CRP, ECP, IgG1, IgG2, IgG3, IgG4, IgA, and IgM levels. CONCLUSIONS To the best of our knowledge, this is the first case of a patient with HCV who developed cutaneous adverse drug reaction on levofloxacin medication and recovered with omalizumab treatment. This is the first documentation of omalizumab treatment of a TEN patient</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1941-5923 (Electronic)IS - 1941-5923 (Linking)LA - engPT - Journal ArticleSB - IMCO - Turkey -CO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.12659/AJCR.898594</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27634312">PM:27634312</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Case Rep\2016-17-666-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Case Rep\2016-17-666-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Uzun R</style></custom2><misc3><style face="normal" font="Arial">10.12659/AJCR.898594</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Danyal,K.</style></author><author><style face="normal" font="Arial"> de Jong,W.</style></author><author><style face="normal" font="Arial"> O'Brien,E.</style></author><author><style face="normal" font="Arial"> Bauer,R.A.</style></author><author><style face="normal" font="Arial"> Heppner,D.E.</style></author><author><style face="normal" font="Arial"> Little,A.</style></author><author><style face="normal" font="Arial"> Hristova,M.</style></author><author><style face="normal" font="Arial"> Habibovic,A.</style></author><author><style face="normal" font="Arial"> van der Vliet,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Vermont College of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Acrolein and thiol-reactive electrophiles suppress allergen-induced innate airway epithelial responses by inhibition of DUOX1 and EGFR</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L923" start="L913">L913-L923</pages><volume><style face="normal" font="Arial">311</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acrolein</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Alkylation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cigarette smoke</style></keyword><keyword><style face="normal" font="Arial"> Cinnamaldehyde</style></keyword><keyword><style face="normal" font="Arial"> Curcumin</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> EGFR</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Src</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sulforaphane</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vermont</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">Acrolein is a major thiol-reactive component of cigarette smoke (CS) that is thought to contribute to increased asthma incidence associated with smoking. Here, we explored the effects of acute acrolein exposure on innate airway responses to two common airborne allergens, house dust mite and Alternaria alternata, and observed that acrolein exposure of C57BL/6 mice (5 ppm, 4 hrs) dramatically inhibited innate airway responses to subsequent allergen challenge, demonstrated by attenuated release of the epithelial-derived cytokines IL-33, IL-25, and IL-1alpha. Acrolein and other anti-inflammatory thiol-reactive electrophiles, cinnamaldehyde, curcumin, and sulforaphane, similarly inhibited allergen-induced production of these cytokines from human or murine airway epithelial cells in vitro. Based on our previous observations indicating the importance of Ca2+-dependent signaling, activation of the NADPH oxidase DUOX1, and Src/EGFR-dependent signaling in allergen-induced epithelial secretion of these cytokines, we explored the impact of acrolein on these pathways. Acrolein and other thiol-reactive electrophiles were found to dramatically prevent allergen-induced activation of DUOX1 as well as EGFR, and acrolein was capable of inhibiting EGFR tyrosine kinase activity via modification of C797. Biotin-labeling strategies indicated increased cysteine modification and carbonylation of Src, EGFR, as well as DUOX1, in response to acrolein exposure in vitro and in vivo, suggesting that direct alkylation of these proteins on accessible cysteine residues may be responsible for their inhibition. Collectively, our findings indicate a novel anti-inflammatory mechanism of CS-derived acrolein and other thiol-reactive electrophiles, by directly inhibiting D</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00276.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27612966">PM:27612966</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20160910-DanyalK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20160910-DanyalK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Danyal K</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00276.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gebe,J.A.</style></author><author><style face="normal" font="Arial"> Yadava,K.</style></author><author><style face="normal" font="Arial"> Ruppert,S.M.</style></author><author><style face="normal" font="Arial"> Marshall,P.</style></author><author><style face="normal" font="Arial"> Hill,P.</style></author><author><style face="normal" font="Arial"> Falk,B.A.</style></author><author><style face="normal" font="Arial"> Sweere,J.M.</style></author><author><style face="normal" font="Arial"> Han,H.</style></author><author><style face="normal" font="Arial"> Kaber,G.</style></author><author><style face="normal" font="Arial"> Medina,C.</style></author><author><style face="normal" font="Arial"> Mikecz,K.</style></author><author><style face="normal" font="Arial"> Ziegler,S.F.</style></author><author><style face="normal" font="Arial"> Balaji,S.</style></author><author><style face="normal" font="Arial"> Keswani,S.G.</style></author><author><style face="normal" font="Arial"> de Jesus Perez,V.</style></author><author><style face="normal" font="Arial"> Butte,M.J.</style></author><author><style face="normal" font="Arial"> Nadeau,K.</style></author><author><style face="normal" font="Arial"> Altemeier,W.A.</style></author><author><style face="normal" font="Arial"> Fanger,N.</style></author><author><style face="normal" font="Arial"> Bollyky,P.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Benaroya Research Institute at Virginia Mason, 128776, Seattle, Washington, United States</style></auth-address><titles><title><style face="normal" font="Arial">Modified High Molecular Weight Hyaluronan Promotes Allergen-Specific Immune Tolerance</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="120" start="109">109-120</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> costimulation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> hyaluronan</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The extracellular matrix in asthmatic lungs contains abundant low-molecular-weight hyaluronan (LMW-HA) and this is known to promote antigen presentation and allergic responses. Conversely, high-molecular-weight hyaluronan, typical of un-inflamed tissues, is known to suppress inflammation. OBJECTIVE: We asked whether HMW-HA can be adapted to adapted to promote tolerance to airway allergens. METHODS: HMW-HA was thiolated to prevent its catabolism and tethered it to allergens via thiol linkages. This platform, which we call "XHA", delivers antigenic payloads in the context of anti-inflammatory co-stimulation. Allergen/XHA was administered intra-nasally to mice that were previously sensitized to those allergens. RESULTS: XHA prevents allergic airway inflammation (AAI) in mice previously sensitized to either ovalbumin or cockroach proteins. Allergen/XHA treatment reduced inflammatory cell counts, airway hyper-responsiveness, allergen-specific IgE, and Th2 cytokine production in comparison to animals challenged with allergen alone. These effects were allergen specific and were durable for weeks after the last challenge, providing a substantial advantage over current desensitization protocols. Mechanistically, XHA promoted CD44-dependent inhibition of NFkappaB signaling in monocyte-derived dendritic cells and diminished dendritic cell maturation and the induction of allergen specific CD4 T-helper responses. CONCLUSIONS: XHA and potentially other strategies that target CD44 are promising alternatives for the treatment of asthma and allergic sinusitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2016-0111OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27598620">PM:27598620</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Cell Mol Biol\2017-56-109-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Cell Mol Biol\2017-56-109-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Gebe JA</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2016-0111OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stokholm,J.</style></author><author><style face="normal" font="Arial"> Sevelsted,A.</style></author><author><style face="normal" font="Arial"> Anderson,U.D.</style></author><author><style face="normal" font="Arial"> Bisgaard,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Preeclampsia Associates with Asthma, Allergy and Eczema in Childhood</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="621" start="614">614-621</pages><volume><style face="normal" font="Arial">195</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> In utero</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Introduction Preeclampsia reflects an unusual increase in systemic inflammation during pregnancy. We studied associations between preeclampsia and asthma, allergy and eczema in Copenhagen Prospective Studies on Asthma in Childhood2000 (COPSAC2000) and in national registries. Methods COPSAC2000 is a high-risk birth cohort of 411 Danish children. Asthma, allergy and eczema were diagnosed prospectively, and lung function measured at age 1mo and 7yrs. Sensitization was evaluated at age 6mo, 18mo, 4yrs and 6yrs by skin prick tests and IgE measurements. The register-based cohort included 1.7 million children from Danish national registries. Children born to mothers with preeclampsia were analyzed regarding risk of asthma, allergy and eczema in the 35-year-period 1977-2012. Results COPSAC2000: 5.6% (23) was diagnosed with preeclampsia. Preeclampsia was associated with increased risk of treatment with inhaled corticosteroids at age 7yrs; adjusted Odds Ratio (aOR) 4.01 (1.11 to 14.43), p=0.0337, increased bronchial responsiveness to methacholine; adjusted beta-Coefficient log-micromol -0.80 (-1.55 to -0.06), p=0.0348, and allergic rhinitis; aOR 4.83 (1.58 to 14.78), p=0.0057 in the 7-year-old children. Furthermore, the children had an increased risk of sensitization to both aero- and food-allergens, and increased amount of total-IgE during childhood. Registry-based cohort: 3.7% (62,728) were born to mothers with preeclampsia. Preeclampsia was associated with increased risk of asthma, eczema, and aeroallergen and food allergy, especially pronounced after a duration of preeclampsia of >14 days. Maternal asthma increased the risk of preeclampsia. Conclusions Preeclampsia is a shared prenatal risk factor for asthma, eczema and allergy in childhood pointing towards in-utero immune programming of the child</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201604-0806OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27626972">PM:27626972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20160914-StokholmJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20160914-StokholmJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Stokholm J</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201604-0806OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gallina,S.</style></author><author><style face="normal" font="Arial"> Saletti,R.</style></author><author><style face="normal" font="Arial"> Cunsolo,V.</style></author><author><style face="normal" font="Arial"> Muccilli,V.</style></author><author><style face="normal" font="Arial"> Foti,S.</style></author><author><style face="normal" font="Arial"> Roepstorff,P.</style></author><author><style face="normal" font="Arial"> Rasmussen,M.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Organic Mass Spectrometry Laboratory, Department of Chemical Sciences, University of Catania, Viale A. Doria 6, 95125, Catania, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Site-specific glycosylation of donkey milk lactoferrin investigated by high-resolution mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">Amino Acids</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Amino Acids</style></full-title></periodical><pages end="2808" start="2799">2799-2808</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asparagine</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Donkey</style></keyword><keyword><style face="normal" font="Arial"> Donkey milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Goat milk</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Ion Exchange</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mannose</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="8" Year="2016">2016/8/22</year></dates><abstract><style face="normal" font="Arial">A comprehensive monosaccharide composition of the N-glycans of donkey milk lactoferrin, isolated by ion exchange chromatography from an individual milk sample, was obtained by means of chymotryptic digestion, TiO2 and HILIC enrichment, reversed-phase high-performance liquid chromatography, electrospray mass spectrometry, and high collision dissociation fragmentation. The results obtained allowed identifying 26 different glycan structures, including high mannose, complex and hybrid N-glycans, linked to the protein backbone via an amide bond to asparagine residues located at the positions 137, 281 and 476. Altogether, the N-glycan structures determined revealed that most of the N-glycans identified in donkey milk lactoferrin are neutral complex/hybrid. Indeed, 10 neutral non-fucosylated complex/hybrid N-glycans and 4 neutral fucosylated complex/hybrid N-glycans were found. In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found. A comparison of the monosaccharide composition of the N-glycans of donkey milk lactoferrin with respect to that of human, bovine and goat milk lactoferrin is reported. Data are available via ProteomeXchange with identifier PXD004289</style></abstract><notes><style face="normal" font="Arial">DA - 20160823IS - 1438-2199 (Electronic)IS - 0939-4451 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00726-016-2315-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27550041">PM:27550041</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Amino Acids\2016-17-666-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Amino Acids\2016-17-666-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160823, Gallina S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00726-016-2315-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korte,R.</style></author><author><style face="normal" font="Arial"> Brockmeyer,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Food Chemistry, Westfalische Wilhelms-Universitat Munster, Corrensstrasse 45, 48149, Munster, Germany</style></auth-address><titles><title><style face="normal" font="Arial">MRM3-based LC-MS multi-method for the detection and quantification of nut allergens</style></title><secondary-title><style face="normal" font="Arial">Anal Bioanal Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Bioanal Chem</style></full-title></periodical><pages end="7855" start="7845">7845-7855</pages><volume><style face="normal" font="Arial">408</style></volume><number><style face="normal" font="Arial">27</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food allergen detection</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food contaminants</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> LC-MS</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Proteotypic peptide</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">Food allergies have become a global challenge to food safety in industrialized countries in recent years. With governmental monitoring and legislation moving towards the establishment of threshold allergen doses, there is a need for sensitive and quantitative analytical methods for the determination of allergenic food contaminants. Targeted proteomics employing liquid chromatography-mass spectrometry (LC-MS) has emerged as a promising technique that offers increased specificity and reproducibility compared to antibody and DNA-based technologies. As the detection of trace levels of allergenic food contaminants also demands excellent sensitivity, we aimed to significantly increase the analytical performance of LC-MS by utilizing multiple reaction monitoring cubed (MRM3) technology. Following a bottom-up proteomics approach, including a straightforward sample preparation process, 38 MRM3 experiments specific to 18 proteotypic peptides were developed and optimized. This permitted the highly specific identification of peanut, almond, cashew, hazelnut, pistachio, and walnut. The analytical performance of the method was assessed for three relevant food matrices with different chemical compositions. Limits of detection were around 1 mug/g or below in fortified matrix samples, not accounting for the effects of food processing. Compared to an MRM-based approach, the MRM3-based method showed an increase in sensitivity of up to 30-fold. Regression analysis demonstrated high linearity of the MRM3 signal in spiked matrix samples together with robust intersample reproducibility, confirming that the method is highly applicable for quantitative purposes. To the best of our knowledge, we describe here the most sensitive LC-MS multi-method for food allergen detection thus far. In addition, this is the first study that systematically compares MRM3 with MRM for the analysis of complex foods. Graphical abstract Allergen detection by MRM3</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1618-2650 (Electronic)IS - 1618-2642 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00216-016-9888-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590318">PM:27590318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Bioanal Chem\20160903-KorteR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Bioanal Chem\20160903-KorteR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Korte R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00216-016-9888-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soliman,M.</style></author><author><style face="normal" font="Arial"> Steacy,L.</style></author><author><style face="normal" font="Arial"> Thiele,J.</style></author><author><style face="normal" font="Arial"> Adams,D.</style></author><author><style face="normal" font="Arial"> Neighbour,H.</style></author><author><style face="normal" font="Arial"> Ellis,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Administering multiple cumulative allergen challenges: An alternative nasal allergen challenge protocol for the Allergic Rhinitis-Clinical Investigator Collaborative</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="328" start="326">326-328</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.06.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613467">PM:27613467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-326-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-326-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Soliman M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.06.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nolte,H.</style></author><author><style face="normal" font="Arial"> Plunkett,G.</style></author><author><style face="normal" font="Arial"> Grosch,K.</style></author><author><style face="normal" font="Arial"> Larsen,J.N.</style></author><author><style face="normal" font="Arial"> Lund,K.</style></author><author><style face="normal" font="Arial"> Bollen,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Merck &amp; Co Inc, Kenilworth, New Jersey.</style></auth-address><titles><title><style face="normal" font="Arial">Major allergen content consistency of SQ house dust mite sublingual immunotherapy tablets and relevance across geographic regions</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="303" start="298">298-303</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen composition</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 10</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> New Jersey</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Consistency in composition and potency, particularly regarding major allergens, is crucial for the quality of extracts for allergen immunotherapy. OBJECTIVE: To characterize the major allergen composition of house dust mite (HDM) extracts commercially available in the United States and the SQ HDM sublingual immunotherapy (SLIT) tablet, and to relate the composition to patient sensitization patterns. METHODS: Der 1/Der 2 ratios were determined in 10,000- and 30,000-AU/mL HDM extracts from 5 US companies and the SQ HDM SLIT-tablet. Allergen content was analyzed by enzyme-linked immunosorbent assay and compared with an in-house reference. Sensitivity toward Der p 1, Der p 2, and Der p 10 was determined in serum from randomly selected subgroups of 220 individuals from North American and European SQ HDM SLIT-tablet trials. RESULTS: Mean Der 1/Der 2 ratios in US HDM extracts ranged from 0.4 to 20.5. For the SQ HDM SLIT-tablet (20 batches), variability did not exceed 12% regarding content of Der f 1 (SD, 11.9%; 95% confidence interval [CI], 0.94-1.06), Der p 1 (SD, 6.1%; 95% CI, 0.97-1.03), and combined Der 2 allergen (SD, 6.4%; 95% CI, 0.97-1.03), indicating a consistent Der 1/Der 2 ratio. High allergen sensitivity frequencies toward Der p 1 and Der p 2 were observed regardless of geographic region. Efficacy of the SQ HDM SLIT-tablet has been demonstrated in 5 clinical trials. CONCLUSION: The SQ HDM SLIT-tablet has efficacy potential for a broad range of patients because it includes a consistent 1:1 ratio of the 2 major HDM allergens to which individuals were most frequently sensitized across geographic regions. Efficacy has been demonstrated</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613464">PM:27613464</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-298-303.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-298-303.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Nolte H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Forbush,J.T.</style></author><author><style face="normal" font="Arial"> Banks,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Capital Consortium Pediatrics Residency, Walter Reed National Military Medical Center, Bethesda, Maryland.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="337" start="335">335-337</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reed</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613470">PM:27613470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-335-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-335-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Forbush JT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ramsey,N.B.</style></author><author><style face="normal" font="Arial"> Tuano,K.T.</style></author><author><style face="normal" font="Arial"> Davis,C.M.</style></author><author><style face="normal" font="Arial"> Dillard,K.</style></author><author><style face="normal" font="Arial"> Hanson,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Baylor College of Medicine, Houston, Texas</style></auth-address><titles><title><style face="normal" font="Arial">Annatto seed hypersensitivity in a pediatric patient</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="333" start="331">331-333</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613468">PM:27613468</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-331-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-331-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Ramsey NB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weinberger,T.</style></author><author><style face="normal" font="Arial"> Feuille,E.</style></author><author><style face="normal" font="Arial"> Thompson,C.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="Arial">Chronic food protein-induced enterocolitis syndrome: Characterization of clinical phenotype and literature review</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="233" start="227">227-233</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Characterization</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613454">PM:27613454</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-227-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-227-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Weinberger T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.03.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Steinke,J.W.</style></author><author><style face="normal" font="Arial"> Borish,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Beirne Carter Center for Immunology, Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, Virginia.</style></auth-address><titles><title><style face="normal" font="Arial">Chronic rhinosinusitis phenotypes</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="240" start="234">234-240</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To review the current knowledge surrounding different chronic rhinosinusitis (CRS) presentations and the relative roles of nasal polyps, eosinophilia, and allergies in discerning phenotypes. DATA SOURCES: PubMed literature review. STUDY SELECTIONS: Articles discussing the various phenotypes of CRS with emphasis on pathologic and immune mechanistic studies that distinguish disease. RESULTS: Current guidelines primarily separate CRS based on the presence or absence of nasal polyps. This is largely driven by the tendency of eosinophilic disease to present with nasal polyps (NPs) in contrast to noneosinophilic presentations, which less often lead to the development NPs. Further separations have been proposed based on expression of aeroallergen sensitization. CONCLUSION: The presence of NPs may only poorly predict the presence of an underlying eosinophilic process and as such may have poor utility in forming the basis for recommending eosinophil-target therapies. Similarly, there is little evidence to support a significant role for aeroallergen exposure in contributing to the presence, severity, or natural history of CRS. Appropriate separation of CRS into specific phenotypes will allow therapeutic approaches to be individualized to each distinct presentation</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613455">PM:27613455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-234-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-234-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Steinke JW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bender,B.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Jewish Health, Denver, Colorado.</style></auth-address><titles><title><style face="normal" font="Arial">A bootstrap approach to implementation science</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="216" start="213">213-216</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Colorado</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613451">PM:27613451</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-213-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-213-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Bender BG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shah,K.</style></author><author><style face="normal" font="Arial"> Guarderas,J.</style></author><author><style face="normal" font="Arial"> Krishnaswamy,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine and Division of Allergy and Clinical Immunology, Nova Southeastern University/Larkin Hospital, Miami, Florida</style></auth-address><titles><title><style face="normal" font="Arial">Empty nose syndrome and atrophic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="220" start="217">217-220</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - Florida -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613452">PM:27613452</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-217-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-217-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Shah K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moonesinghe,H.</style></author><author><style face="normal" font="Arial"> Mackenzie,H.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Kilburn,S.</style></author><author><style face="normal" font="Arial"> Turner,P.</style></author><author><style face="normal" font="Arial"> Weir,K.</style></author><author><style face="normal" font="Arial"> Dean,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Portsmouth, Portsmouth, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of fish and shellfish allergy: A systematic review</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="272" start="264">264-272</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> geographic variation</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shellfish allergy</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Accurate information on the prevalence of food allergy facilitates a more evidence-based approach to planning of allergy services and can identify important geographic variations. OBJECTIVE: To conduct a systematic review to assess the age-specific prevalence of fish and shellfish allergy worldwide. METHODS: Searches were conducted using Web of Science and PubMed. Population-based cross-sectional studies and cohort studies that examined the prevalence of fish and shellfish allergy (IgE mediated and non-IgE mediated) at an identifiable point in time were eligible for inclusion in the study. Reviewers extracted general study information and study design, type of food allergy considered, food(s) assessed, method of diagnosis, sampling strategy, and sample characteristics. Raw data were extracted and percentage prevalence and 95% confidence intervals calculated. RESULTS: A total of 7,333 articles were identified of which 61 studies met the inclusion criteria and were included in this review. The prevalence of fish allergy ranged from 0% to 7% and the prevalence of shellfish allergy from 0% to 10.3%, depending on the method of diagnosis. Where food challenges were used, the prevalence for fish allergy was found to be 0% to 0.3% and for shellfish allergy was 0% to 0.9%. CONCLUSION: Few studies have established the prevalence of fish or shellfish allergy using the gold standard double-blind, placebo-controlled challenge criteria, with most instead relying on self-reported questionnaire-based methods. The limited data available suggest that fish allergy prevalence is similar worldwide; however, shellfish allergy prevalence may be higher in the Southeast Asia region</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613460">PM:27613460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-264-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-264-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Moonesinghe H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hong,G.U.</style></author><author><style face="normal" font="Arial"> Ro,J.Y.</style></author><author><style face="normal" font="Arial"> Bae,Y.</style></author><author><style face="normal" font="Arial"> Kwon,I.H.</style></author><author><style face="normal" font="Arial"> Park,G.H.</style></author><author><style face="normal" font="Arial"> Choi,Y.H.</style></author><author><style face="normal" font="Arial"> Choi,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology and SBRI, Sungkyunkwan University School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association of TG2 from mast cells and chronic spontaneous urticaria pathogenesis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="297" start="290">290-297</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> c-kit</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukins</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene C4</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mast cells and their mediators play important roles in chronic spontaneous urticaria (CSU) pathogenesis. Transglutaminase 2 (TG2) is expressed in activated mast cells and contributes to airway inflammation in allergic asthma. OBJECTIVE: To investigate the role of TG2 in CSU. METHODS: Patients with CSU (n = 72) and healthy controls (n = 51) were evaluated. Skin biopsy specimens were obtained from 5 patients with CSU and 2 healthy controls. Cord blood-derived human mast cells and peripheral blood-derived human mast cells were activated with IgE. TG2 activity and inflammatory mediators, such as histamine, leukotriene C4, and cytokines, were measured in serum or supernatant from cultured mast cells by enzyme-linked immunosorbent assay. Colocalization of mast cells and TG2 was determined in skin tissues by immunofluorescence. RESULTS: TG2 activity was significantly higher in serum samples from patients with CSU than in serum samples from healthy controls (P &lt; .001). Colocalization of mast cell surface marker c-kit and TG2 was significantly increased in the lesional skin of patients with CSU compared with that in healthy controls. The levels of histamine, leukotriene C4, tumor necrosis factor alpha, transforming growth factor beta, and interleukins 4, 5, and 6 were significantly higher in patients with CSU than in healthy controls (P &lt; .001). Serum TG2 levels had positive correlations with each inflammatory mediator (P &lt; .001). TG2 activity was increased in cord blood-derived human mast cells (CBMCs) and peripheral blood-derived human mast cells activated with IgE compared with those without activation (P &lt; .05). CONCLUSION: Our findings suggest that TG2 expressed in and released from mast cells plays an important role in CSU pathogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.06.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613463">PM:27613463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-290-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-290-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Hong GU</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.06.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Portnoy,J.M.</style></author><author><style face="normal" font="Arial"> Waller,M.</style></author><author><style face="normal" font="Arial"> De Lurgio,S.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Mercy Hospital, Kansas City, Missouri.</style></auth-address><titles><title><style face="normal" font="Arial">Telemedicine is as effective as in-person visits for patients with asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="245" start="241">241-245</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> asthma education</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Telemedicine</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Access to asthma specialists is a problem, particularly in rural areas, thus presenting an opportunity for management using telemedicine. OBJECTIVE: To compare asthma outcomes during 6 months in children managed by telemedicine vs in-person visits. METHODS: Children with asthma residing in 2 remote locations were offered the choice of an in-person visit or a telemedicine session at a local clinic. The telemedicine process involved real-time use of a Remote Presence Solution (RPS) equipped with a digital stethoscope, otoscope, and high-resolution camera. A telefacilitator operated the RPS and performed diagnostic and educational procedures, such as spirometry and asthma education. Children in both groups were assessed initially, after 30 days, and at 6 months. Asthma outcome measures included asthma control using validated tools (Asthma Control Test, Childhood Asthma Control Test, and Test for Respiratory and Asthma Control in Kids) and patient satisfaction (telemedicine group only). Noninferiority analysis of asthma control was performed using the minimally important difference of an adjusted asthma control test that combined the 3 age groups. RESULTS: Of 169 children, 100 were seen in-person and 69 via telemedicine. A total of 34 in-person and 40 telemedicine patients completed all 3 visits. All had a small, although statistically insignificant, improvement in asthma control over time. Telemedicine was noninferior to in-person visits. Most of the telemedicine group subjects were satisfied with their experience. CONCLUSION: Children with asthma seen by telemedicine or in-person visits can achieve comparable degrees of asthma control. Telemedicine can be a viable alternative to traditional in-person physician-based care for the treatment and management of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613456">PM:27613456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-241-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-241-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Portnoy JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ditzler,N.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Michigan, Ann Arbor, Michigan</style></auth-address><titles><title><style face="normal" font="Arial">Influence of health literacy and trust in online information on food allergy quality of life and self-efficacy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="263" start="258">258-263</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Health literacy among caregivers of food allergic individuals (FAIs) is poorly described, as are the information sources sought regarding food allergy. OBJECTIVE: To assess the association among health literacy, trust in online sources of information, and food allergy quality of life (QoL) and self-efficacy. METHODS: An online survey was administered to caregivers of FAIs assessing health literacy (Newest Vital Sign [NVS] and the eHeals Internet health literacy index), trust in online information (Hargittai Internet credibility index and Annenberg National Health Communication Survey [ANHCS]), QoL (Food Allergy Quality of Life Parental Burden), and self-efficacy (Food Allergy Self-Efficacy Questionnaire [FASEQ]). RESULTS: Among 1562 respondents, 94.6% (NVS) and 61.1% (eHeals) had good health literacy, and 58% had high levels of trust in online information (both indexes). The NVS correlated poorly with the eHeals and Hargittai indexes. Hargittai and eHeals scores were moderately correlated (r = 0.37, P &lt; .001). A high NVS score was significantly associated with reported anaphylaxis and high eHeals and Hargittai scores with advocacy group membership. In unadjusted analyses, FAQL-PB scores were worse with high Hargiatti scores (P = .05) and ANHCS scores (P &lt; .001). The FASEQ scores were better with high ANHCS scores (P = .02) and eHeals scores (P &lt; .001). In an adjusted regression, high trust in online information (both indexes), worsening FASEQ score, blog readership, advocacy group membership, caring for multiple FAIs, and having milk or egg allergy were associated with worse FAQL-PB scores. CONCLUSION: In this sample, health literacy and trust in online information sources were high, with high trust in online information sources negatively associated with QoL. Advocacy group membership had an independent negative association with QoL</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613459">PM:27613459</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-258-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-258-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Ditzler N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burbank,A.J.</style></author><author><style face="normal" font="Arial"> Grabich,S.C.</style></author><author><style face="normal" font="Arial"> Todorich,K.</style></author><author><style face="normal" font="Arial"> Frye,M.</style></author><author><style face="normal" font="Arial"> Loughlin,C.</style></author><author><style face="normal" font="Arial"> Duncan,K.</style></author><author><style face="normal" font="Arial"> Robinette,C.</style></author><author><style face="normal" font="Arial"> Mills,K.</style></author><author><style face="normal" font="Arial"> Peden,D.B.</style></author><author><style face="normal" font="Arial"> Diaz-Sanchez,D.</style></author><author><style face="normal" font="Arial"> Hernandez,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of aeroallergen sensitization on asthma control in African American teens with persistent asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="444" start="442">442-444</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> African American</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="8" Year="2016">2016/8/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566861">PM:27566861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160827-BurbankAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160827-BurbankAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Burbank AJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Y.</style></author><author><style face="normal" font="Arial"> Zhou,W.</style></author><author><style face="normal" font="Arial"> Chen,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of sublingual immunotherapy for cedar pollinosis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="353" start="348">348-353</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="8" Year="2016">2016/8/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The efficacy of immunotherapy for cedar pollinosis using a single cedar antigen extract via the sublingual route is uncertain. OBJECTIVE: To assess the efficacy of sublingual immunotherapy (SLIT) for patients with cedar pollinosis by performing a systematic review and meta-analysis. METHODS: Randomized clinical trials (RCTs) that compared SLIT with a placebo for patients with cedar pollinosis were searched in the MEDLINE, EMBASE, and Cochrane databases. The primary outcome was the symptom medication score, and secondary outcomes were adverse events, quality of life, and serum IgE and IgG4 levels. RESULTS: We analyzed 4 RCTs with a total of 762 patients. Meta-analysis revealed that SLIT significantly decreased symptom medication scores compared with placebo groups (standardized mean difference [SMD], -0.94; 95% confidence interval [CI], -1.75 to -0.14; P = .02; I2 = 93%), and subgroup analysis revealed that SLIT had a significant positive effect on cedar pollinosis when pollen concentration was less (SMD, -2.29; 95% CI, -3.64 to -2.16; P &lt; .001) or more (SMD, -0.36; 95% CI, -0.51 to -0.21; P &lt; .001; I2 = 0%) than 1,200/cm2, and treatment duration was longer than 1 year (SMD, -0.43; 95% CI, -0.59 to -0.26; P &lt; .001; I2 = 0%). Adverse events were reported in 237 of 405 patients (58.5%) receiving SLIT vs 192 of 357 patients (53.8%) receiving the placebo. CONCLUSION: This study revealed a statistically significant benefit of SLIT in patients with cedar pollinosis. However, these findings were based on analysis of a small number of RCTs. Additional large-sample and high-quality RCTs are necessary for further study</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566862">PM:27566862</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160827-YangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160827-YangY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Yang Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Polk,B.I.</style></author><author><style face="normal" font="Arial"> Dinakarpandian,D.</style></author><author><style face="normal" font="Arial"> Nanda,M.</style></author><author><style face="normal" font="Arial"> Barnes,C.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Allergy/Immunology, Children's Mercy Kansas City, Kansas City, Missouri.</style></auth-address><titles><title><style face="normal" font="Arial">Association of tree nut and coconut sensitization</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="416" start="412">412-416</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> brazil nut</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Chestnut</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Coconut</style></keyword><keyword><style face="normal" font="Arial"> Cocos</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> hierarchical clustering</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Macadamia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Spearman correlation</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="8" Year="2016">2016/8/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Coconut (Cocos nucifera), despite being a drupe, was added to the US Food and Drug Administration list of tree nuts in 2006, causing potential confusion regarding the prevalence of coconut allergy among tree nut allergic patients. OBJECTIVE: To determine whether sensitization to tree nuts is associated with increased odds of coconut sensitization. METHODS: A single-center retrospective analysis of serum specific IgE levels to coconut, tree nuts (almond, Brazil nut, cashew, chestnut, hazelnut, macadamia, pecan, pistachio, and walnut), and controls (milk and peanut) was performed using deidentified data from January 2000 to August 2012. Spearman correlation (rho) between coconut and each tree nut was determined, followed by hierarchical clustering. Sensitization was defined as a nut specific IgE level of 0.35 kU/L or higher. Unadjusted and adjusted associations between coconut and tree nut sensitization were tested by logistic regression. RESULTS: Of 298 coconut IgE values, 90 (30%) were considered positive results, with a mean (SD) of 1.70 (8.28) kU/L. Macadamia had the strongest correlation (rho = 0.77), whereas most other tree nuts had significant (P &lt; .05) but low correlation (rho &lt; 0.5) with coconut. The adjusted odds ratio between coconut and macadamia was 7.39 (95% confidence interval, 2.60-21.02; P &lt; .001) and 5.32 (95% confidence interval, 2.18-12.95; P &lt; .001) between coconut and almond, with other nuts not being statistically significant. CONCLUSION: Our findings suggest that although sensitization to most tree nuts appears to correlate with coconut, this is largely explained by sensitization to almond and macadamia. This finding has not previously been reported in the literature. Further study correlating these results with clinical symptoms is planned</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566863">PM:27566863</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160827-PolkBI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160827-PolkBI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Polk BI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanaka,A.</style></author><author><style face="normal" font="Arial"> Fujiwara,A.</style></author><author><style face="normal" font="Arial"> Uchida,Y.</style></author><author><style face="normal" font="Arial"> Yamaguchi,M.</style></author><author><style face="normal" font="Arial"> Ohta,S.</style></author><author><style face="normal" font="Arial"> Homma,T.</style></author><author><style face="normal" font="Arial"> Watanabe,Y.</style></author><author><style face="normal" font="Arial"> Yamamoto,M.</style></author><author><style face="normal" font="Arial"> Suzuki,S.</style></author><author><style face="normal" font="Arial"> Yokoe,T.</style></author><author><style face="normal" font="Arial"> Sagara,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University, School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of the association between sensitization to common inhalant fungi and poor asthma control</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="168" start="163">163-168</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adult asthma</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> enzyme immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> forced vital capacity</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Trichophyton</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fungi are well-known airborne allergens that are predisposing environmental factors to asthma. Few comparative studies have evaluated sensitization to common inhalant fungi in relation to poor asthma control in patients with asthma. OBJECTIVE: To evaluate the association between sensitization to individual fungi and asthma control and elucidate the characteristics of patients with poorly controlled asthma sensitized to fungi. METHODS: This cross-sectional study was performed at Showa University Hospital between September 2014 and December 2014. The specific IgE levels for several major aeroallergens, including house dust mites, Japanese cedar, various types of pollen, furry animals, or insects, were measured with a fluorescent enzyme immunoassay in 160 patients with adult asthma. RESULTS: Fungal sensitization was predominant in men with asthma, and it was associated with poor asthma control. Sensitization to house dust mites, Japanese cedar, pollen, furry animals, or insects was not associated with poor asthma control. Logistic regression analyses revealed that patients sensitized to Aspergillus and Penicillium had a significantly increased risk of poor asthma control. More Penicillium IgE-positive patients were men and pet owners compared with Penicillium IgE-negative patients; in addition, Penicillium IgE-positive patients had higher total IgE levels. The Asthma Control Test level was significantly higher in Penicillium IgE-positive patients than in Penicillium IgE-negative patients. However, there were no differences in fractional exhaled nitric oxide, forced vital capacity, and forced expiratory volume in 1 second. Finally, sensitization to Aspergillus, Cladosporium, and Trichophyton were positively correlated with sensitization to Penicillium. CONCLUSION: Sensitization to fungi is predominant in men, and it is associated with poor asthma control. In particular, sensitization to Penicillium and Aspergillus is a risk factor for asthma severity. These results have potential relevance in asthma management</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499543">PM:27499543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-163-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-163-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Tanaka A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dinakar,C.</style></author><author><style face="normal" font="Arial"> Shroba,J.</style></author><author><style face="normal" font="Arial"> Portnoy,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy/Immunology, Children's Mercy Hospitals, Kansas City, Missouri.</style></auth-address><titles><title><style face="normal" font="Arial">The transforming power of proximity food challenges</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="137" start="135">135-137</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.06.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499540">PM:27499540</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-135-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-135-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Dinakar C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.06.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lawrence,M.G.</style></author><author><style face="normal" font="Arial"> Steinke,J.W.</style></author><author><style face="normal" font="Arial"> Borish,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, Virginia</style></auth-address><titles><title><style face="normal" font="Arial">Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="142" start="138">138-142</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine milieu</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To discuss the general immunologic changes that occur during immunotherapy, focusing on the differences between subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). DATA SOURCES: PubMed literature review. STUDY SELECTIONS: Articles pertaining to SCIT and SLIT, with specific emphasis on those that included immune mechanistic studies. RESULTS: Both SCIT and SLIT are characterized by the induction of regulatory B and T cells, decreased allergen-specific T-cell proliferation, a shift from a TH2 to TH1 cytokine milieu and from an IgE to an IgG4/IgA antibody response. These changes are accompanied by clinical improvement in symptoms. CONCLUSION: Immunotherapy using allergen extracts administered via both subcutaneous and sublingual approaches have demonstrated efficacy in the treatment of allergic rhinoconjunctivitis and other allergic conditions. There are subtle differences between the approaches, and understanding these differences may help clinicians select a preferred route of therapy for particular patients or allergens, depending on the immune response that is being targeted</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.06.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499541">PM:27499541</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-138-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-138-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Lawrence MG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.06.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cook,V.E.</style></author><author><style face="normal" font="Arial"> Ellis,A.K.</style></author><author><style face="normal" font="Arial"> Hildebrand,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy &amp; Immunology, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Mobile health applications in clinical practice: pearls, pitfalls, and key considerations</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="149" start="143">143-149</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pitfalls</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.01.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499542">PM:27499542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-143-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-143-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Cook VE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.01.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rampur,L.</style></author><author><style face="normal" font="Arial"> Jariwala,S.P.</style></author><author><style face="normal" font="Arial"> Hudes,G.</style></author><author><style face="normal" font="Arial"> Rosenstreich,D.L.</style></author><author><style face="normal" font="Arial"> de Vos,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of ivermectin on allergy-type manifestations in occult strongyloidiasis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="428" start="423">423-428</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Ivermectin</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Serologic Tests</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides stercoralis</style></keyword><keyword><style face="normal" font="Arial"> Strongyloidiasis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="8" Year="2016">2016/8/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The immunomodulatory effects of helminths have been well described. However, there is a relative lack of literature regarding the link between parasites and allergic diseases. A number of patients with allergic symptoms have positive serologic test results for Strongyloides stercoralis. OBJECTIVE: To identify patients with allergy-type symptoms and coexisting Strongyloides infection and to analyze the effect of Strongyloides eradication therapy with ivermectin on these symptoms. METHODS: The medical records of our allergy clinic sites were reviewed for Strongyloides test results between January 2011 and October 2014. Each allergy-type symptom was assessed separately with regard to improvement after ivermectin therapy. RESULTS: Among the 1,446 patients who had Strongyloides serologic tests ordered, 127 (8.8%) had positive test results. Eighty-four patients had follow-up data regarding allergy-type symptoms after ivermectin treatment. Among these, 52 patients (61.9%) reported skin-related problems (pruritus, urticaria, angioedema, and/or rash). Forty-nine patients (58.3%) had asthma, and 73.8% had allergic rhinoconjunctivitis. Although respiratory symptoms typically did not respond to ivermectin treatment, 24 of 48 patients (50%) with skin symptoms reported a significant subjective improvement of symptoms after ivermectin treatment. Peripheral eosinophil counts significantly decreased after ivermectin treatment from 450 to 200/muL (P &lt; .001). CONCLUSION: Serologic testing for strongyloides may be indicated for patients with allergy-type symptoms and a suggestive exposure history. Patients with strongyloidiasis and primarily cutaneous symptoms experienced significant symptomatic improvement after ivermectin therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566864">PM:27566864</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160827-RampurL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160827-RampurL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Rampur L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martinez-Saguer,I.</style></author><author><style face="normal" font="Arial"> Escuriola Ettingshausen,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">HZRM Hemophilia Center Rhine Main, Morfelden-Walldorf, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Delayed diagnosis of hereditary angioedema: Thirty-nine years of inadequate treatment</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="556" start="554">554-556</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">angioedema</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hereditary angioedema</style></keyword><keyword><style face="normal" font="Arial"> RHINE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160905IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27593101">PM:27593101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160905-MartinezSaguerI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160905-MartinezSaguerI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160905, Martinez-Saguer I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martina,C.</style></author><author><style face="normal" font="Arial"> Looney,R.J.</style></author><author><style face="normal" font="Arial"> Marcus,C.</style></author><author><style face="normal" font="Arial"> Allen,M.</style></author><author><style face="normal" font="Arial"> Stahlhut,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health Science and Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of allergic disease in Old Order Mennonites in New York</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="563" start="562">562-563</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="9" Year="2016">2016/9/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27612936">PM:27612936</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160910-MartinaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160910-MartinaC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Martina C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goddard,A.G.</style></author><author><style face="normal" font="Arial"> Azar,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Iowa Hospitals and Clinics, Iowa City, Iowa.</style></auth-address><titles><title><style face="normal" font="Arial">Work-related asthma secondary to IgE-mediated reactions to rodents successfully treated with immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="558" start="556">556-558</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Iowa</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Rodents</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> work-related asthma</style></keyword></keywords><dates><year Day="7" Month="9" Year="2016">2016/9/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27614679">PM:27614679</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160911-GoddardAC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160911-GoddardAC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160911, Goddard AG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wagner,A.</style></author><author><style face="normal" font="Arial"> Szwed,A.</style></author><author><style face="normal" font="Arial"> Buczylko,K.</style></author><author><style face="normal" font="Arial"> Wagner,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergology and Respiratory Rehabilitation Department, Medical University, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Allergy to apple cultivars among patients with birch pollinosis and oral allergy syndrome</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="404" start="399">399-404</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apple allergen</style></keyword><keyword><style face="normal" font="Arial"> apple cultivars</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Birch pollinosis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cross-reacting allergens</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Mal d 1</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> pulp</style></keyword><keyword><style face="normal" font="Arial"> Radioallergosorbent Test</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oral allergy syndrome (OAS) is caused by cross-reacting allergens found in pollen, raw fruits, vegetables, and some tree nuts. The major apple allergen, Mal d 1, is a cause of food allergic reactions in birch pollen sensitized patients. OBJECTIVE: To explore the allergenicity of the most popular and commonly consumed apple cultivars in Poland in patients with birch pollen allergy with or without OAS. METHODS: Data were obtained from 46 adults with clinical symptoms of birch allergy and allergic rhinitis or rhinoconjunctivitis. Patients were divided into 2 groups according to the occurrence of OAS to apple. Skin prick tests (SPTs) were performed with pulp from the 11 most popular apple cultivars in Poland. Specific IgE (sIgE) to Bet v 1 was measured by radioallergosorbent test. RESULTS: Patients with OAS had more positive responses to apple SPT vs patients without OAS (odds ratios, 4.8-11.96). Patients with OAS had distinctive responses to apple cultivars. Szara Reneta and Cortland induced positive responses in 50% and 83% of patients, respectively. Patients with OAS vs patients without OAS who were allergic to apples vs nonallergic had 2-fold (P = .008) and 7-fold (P = .03) higher blood concentrations of sIgE Bet v 1, respectively. There were different profiles of correlations of sIgE Bet v 1 with wheal diameter for low and high allergenic cultivars in patients without and with OAS. CONCLUSION: We noted a substantial role for Bet v 1 sensitization in the allergic response based on evaluation of the allergenicity of 11 apple cultivars. The sIgE Bet v 1 and SPT results of patients with and without OAS allowed differentiation between low and high allergenic cultivars</style></abstract><notes><style face="normal" font="Arial">DA - 20160905IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27593099">PM:27593099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160905-WagnerA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160905-WagnerA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160905, Wagner A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">White,J.L.</style></author><author><style face="normal" font="Arial"> Kahoud,R.J.</style></author><author><style face="normal" font="Arial"> Li,J.T.</style></author><author><style face="normal" font="Arial"> Campbell,R.L.</style></author><author><style face="normal" font="Arial"> Ackerman,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota.</style></auth-address><titles><title><style face="normal" font="Arial">Long QT syndrome and life-threatening anaphylaxis: Is epinephrine safe?</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="446" start="444">444-446</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Long QT Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590635">PM:27590635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160903-WhiteJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160903-WhiteJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, White JL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olson,A.A.</style></author><author><style face="normal" font="Arial"> Evans,M.D.</style></author><author><style face="normal" font="Arial"> Johansson,M.W.</style></author><author><style face="normal" font="Arial"> Kim,C.H.</style></author><author><style face="normal" font="Arial"> Manthei,D.M.</style></author><author><style face="normal" font="Arial"> Gaumnitz,E.A.</style></author><author><style face="normal" font="Arial"> Mathur,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin</style></auth-address><titles><title><style face="normal" font="Arial">Role of food and aeroallergen sensitization in eosinophilic esophagitis in adults</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="393" start="387">387-393</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> strictures</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Evaluation of IgE-mediated food sensitivity is frequently performed for patients with eosinophilic esophagitis (EoE). However, the clinical relevance of identifying IgE-mediated sensitivity to foods in adults is unclear. OBJECTIVE: To determine whether EoE associated with food or aeroallergen sensitivity represents a phenotype of EoE with distinct clinical or biological features. METHODS: A medical record review identified 257 patients with a diagnosis of EoE evaluated in the adult allergy clinic at the University of Wisconsin Hospital and Clinics from 2008 to 2013. Patient records were reviewed to capture measures of disease severity, endoscopy results, pathology reports, allergy testing, medical management and patient-reported outcomes. RESULTS: Evaluation of food sensitization with skin prick testing and/or serum IgE was performed for 93% of patients. Sensitization to at least 1 food was identified in 54% of patients who were more likely to report concomitant asthma, allergic rhinitis, eczema, and/or food allergy compared with nonfood sensitive patients. Aeroallergen sensitivity was identified in 87% of patients tested. Clinical characteristics, including EoE symptoms, disease severity, endoscopic findings, peripheral eosinophilia, and patient-reported outcomes, did not differ between food sensitive and non-food sensitive patients. However, on endoscopy, aeroallergen sensitive patients were more likely to have strictures and less likely to exhibit felinization compared with non-aeroallergen sensitized patients. CONCLUSION: Adults with EoE and IgE-mediated food sensitivity are not phenotypically different than non-food sensitive patients. There is no clear clinical utility in identifying food sensitivity in adults with EoE. Further studies are needed to determine whether aeroallergen sensitivity represents a distinct phenotype of EoE</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590636">PM:27590636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160906-OlsonAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160906-OlsonAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, OLson AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.</style></auth-address><titles><title><style face="normal" font="Arial">Diets for diagnosis and management of food allergy: The role of the dietitian in eosinophilic esophagitis in adults and children</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="471" start="468">468-471</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietitian</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160904IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27592143">PM:27592143</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160904-VenterC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160904-VenterC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160904, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Finkelstein,J.</style></author><author><style face="normal" font="Arial"> Jeong,I.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Informatics, Columbia University, New York, New York.</style></auth-address><titles><title><style face="normal" font="Arial">Machine learning approaches to personalize early prediction of asthma exacerbations</style></title><secondary-title><style face="normal" font="Arial">Ann N Y Acad Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann N Y Acad Sci</style></full-title></periodical><pages end="165" start="153">153-165</pages><volume><style face="normal" font="Arial">1387</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--Large cohort</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adult asthma</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Classifiers</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> Machine Learning</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Patient telemonitoring results in an aggregation of significant amounts of information about patient disease trajectory. However, the potential use of this information for early prediction of exacerbations in adult asthma patients has not been systematically evaluated. The aim of this study was to explore the utility of telemonitoring data for building machine learning algorithms that predict asthma exacerbations before they occur. The study dataset comprised daily self-monitoring reports consisting of 7001 records submitted by adult asthma patients during home telemonitoring. Predictive modeling included preparation of stratified training datasets, predictive feature selection, and evaluation of resulting classifiers. Using a 7-day window, a naive Bayesian classifier, adaptive Bayesian network, and support vector machines were able to predict asthma exacerbation occurring on day 8, with sensitivity of 0.80, 1.00, and 0.84; specificity of 0.77, 1.00, and 0.80; and accuracy of 0.77, 1.00, and 0.80, respectively. Our study demonstrated that machine learning techniques have significant potential in developing personalized decision support for chronic disease telemonitoring systems. Future studies may benefit from a comprehensive predictive framework that combines telemonitoring data with other factors affecting the likelihood of developing acute exacerbation. Approaches implemented for advanced asthma exacerbation prediction may be extended to prediction of exacerbations in patients with other chronic health conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1749-6632 (Electronic)IS - 0077-8923 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/nyas.13218</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27627195">PM:27627195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann N Y Acad Sci\20160914-FinkelsteinJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann N Y Acad Sci\20160914-FinkelsteinJ.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20160914, Finkelstein J</style></custom2><misc3><style face="normal" font="Arial">10.1111/nyas.13218</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wan,J.J.</style></author><author><style face="normal" font="Arial"> Shen,M.F.</style></author><author><style face="normal" font="Arial"> Tang,J.Q.</style></author><author><style face="normal" font="Arial"> Lin,H.</style></author><author><style face="normal" font="Arial"> Yan,W.H.</style></author><author><style face="normal" font="Arial"> Li,J.J.</style></author><author><style face="normal" font="Arial"> Zhu,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of soybean meal processing treatments on growth performance, nutrient digestibility, nitrogen and phosphorus excretion in red swamp crayfish, Procambarus clarkii</style></title><secondary-title><style face="normal" font="Arial">Aquaculture Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Aquaculture Int</style></full-title></periodical><pages end="554" start="543">543-554</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">China</style></keyword><keyword><style face="normal" font="Arial"> Crayfish</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth rate</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Phosphorus</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Processing treatment</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean meal</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-143X</style></isbn><abstract><style face="normal" font="Arial">In this study, growth performance, apparent digestibility coefficients, phosphorus and nitrogen excretion were determined in red swamp crayfish (Procambarus clarkii) (5.39-á-¦-á0.12-ág) for four soybean products: soybean meal (SBM), soybean meal diets supplemented with 1000-áIU/kg phytase (SBM-á+-áP), extruded soybean meal (ESBM) and fermented soybean meal (FSBM). The results showed that compared with the SBM diet, the crayfish fed the SBM-á+-áP and FSBM diets showed significantly higher specific growth rate (SGR) and lower feed conversion ratio (FCR) (P-á&lt;-á0.05). The highest and lowest dry matter (DM) digestibilities were observed in SBM-á+-áP and ESBM diets, respectively (P-á&lt;-á0.05). Differences in crude protein (CP) and gross energy (GE) followed differences in DM digestibility. SBM-á+-áP had the highest phosphorus digestibility, and ESBM had the lowest. The highest crude lipid (CL) digestibility coefficient was observed in FSBM, followed by SBM-á+-áP, and the lowest in ESBM (P-á&lt;-á0.05), which was similar to SBM. And the ESBM group had the highest phosphorus content in sediments (P-á&lt;-á0.05); while the highest nitrogen content was observed in SBM group, which was significantly higher than SBM-á+-áP group (P-á&lt;-á0.05). The water phosphorus contents in SBM and ESBM groups were significant higher than SBM-á+-áP group at 48-áh (P-á&lt;-á0.05), but there were no significant differences among the water nitrogen content of all groups (P-á>-á0.05)</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10499-016-0052-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10499-016-0052-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aquaculture Int\20160912-WanJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aquaculture Int\20160912-WanJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Wan JJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10499-016-0052-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Labrosse,R.</style></author><author><style face="normal" font="Arial"> Graham,F.</style></author><author><style face="normal" font="Arial"> Des Roches,A.</style></author><author><style face="normal" font="Arial"> Begin,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy and Clinical Immunology, CHU Sainte-Justine, University of Montreal, Montreal, QC, Canada</style></auth-address><titles><title><style face="normal" font="Arial">The Use of Omalizumab in Food Oral Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Arch Immunol Ther Exp (Warsz)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Immunol Ther Exp (Warsz)</style></full-title></periodical><pages end="199" start="189">189-199</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Multiple foods</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergy is an important health issue that affects up to 8 % of the population. The management of allergic patients involves allergen avoidance and prompts the treatment of accidental reactions, as no curative treatment is available so far in routine practice. Oral immunotherapy (OIT) is a promising therapeutic alternative, but it is associated with frequent allergic reactions and cost-effectiveness issues. In hopes of reducing such reactions, a number of trials have used omalizumab, an anti-IgE monoclonal humanized antibody, as adjunctive therapy in OIT. The allergens studied in these omalizumab-enabled OIT trials include peanuts, milk, eggs, or mixes of multiple foods. In this article, we review the major findings from these studies and discuss potential benefits and issues related to omalizumab-enabled OIT. Results from the previous trials suggest that the use of omalizumab could potentially lead to safer and more efficient OIT protocols, by reducing the number and severity of reactions, and increasing allergen tolerance threshold. While more evidence is needed with regard to the maintenance of the long-term tolerance after OIT, omalizumab's potential immunomodulatory role could be of benefit. More studies are needed to further document this new indication for omalizumab</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1661-4917 (Electronic)IS - 0004-069X (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00005-016-0420-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27628022">PM:27628022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Immunol Ther Exp (Warsz)\20160917-LabrosseR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Immunol Ther Exp (Warsz)\20160917-LabrosseR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Labrosse R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00005-016-0420-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Panaszek,B.</style></author><author><style face="normal" font="Arial"> Pawlowicz,R.</style></author><author><style face="normal" font="Arial"> Grzegrzolka,J.</style></author><author><style face="normal" font="Arial"> Obojski,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine and Allergy, Wroclaw Medical University, Curie-Sklodowskiej 66, 50-367, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Autoreactive IgE in Chronic Spontaneous/Idiopathic Urticaria and Basophil/Mastocyte Priming Phenomenon, as a Feature of Autoimmune Nature of the Syndrome</style></title><secondary-title><style face="normal" font="Arial">Arch Immunol Ther Exp (Warsz)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Immunol Ther Exp (Warsz)</style></full-title></periodical><pages end="143" start="137">137-143</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> autoantigen</style></keyword><keyword><style face="normal" font="Arial"> Autoantigens</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mast cells/basophils</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> self-antigens</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Recent years of research have shed a new light on the role of IgE in immune reactions. It seems to be more than just a contribution to immediate type of allergic response. It appears that monomeric IgE may enhance mast cell activity without cross-linking of FcepsilonRI by IgE specific allergen or autoreactive IgG anti-IgE antibodies. Monomeric IgE molecules are heterogeneous concerning their ability to induce survival and activation of mast cells only by binding the IgE to FcepsilonRI, but not affecting degranulation of cells. It also turned out that IgE may react to autoantigens occurring in the blood not only in chronic spontaneous urticaria (CSU) but also in other autoimmune diseases. The aforementioned phenomena may promote the activity of mast cells/basophils in CSU that easily degranulate when influenced by various inner (autoreactive IgG against IgE and FcepsilonRI, autoreactive IgE for self-antigens) and outer factors (cold, heat, pressure) or allergens. These findings forced the new approach to the role of autoimmunity, self-antigens and IgE autoantibodies in the pathology of CSU. CSU put in the scheme of autoreactive IgG and autoreactive IgE seems to be either a kind of an autoimmune disease or a clinical manifestation of some other defined autoimmune diseases or both</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1661-4917 (Electronic)IS - 0004-069X (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00005-016-0417-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27582030">PM:27582030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Immunol Ther Exp (Warsz)\20160901-PanaszekB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Immunol Ther Exp (Warsz)\20160901-PanaszekB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Panaszek B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00005-016-0417-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okubo,K.</style></author><author><style face="normal" font="Arial"> Gotoh,M.</style></author><author><style face="normal" font="Arial"> Togawa,M.</style></author><author><style face="normal" font="Arial"> Saito,A.</style></author><author><style face="normal" font="Arial"> Ohashi,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Nippon Medical School, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial</style></title><secondary-title><style face="normal" font="Arial">Auris Nasus Larynx</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Auris Nasus Larynx</style></full-title></periodical><pages end="301" start="294">294-301</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Bilastine</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Bilastine is a novel second-generation antihistamine. This open-label, single-arm, phase III study evaluated the safety and efficacy of long-term treatment with bilastine in Japanese patients with seasonal (SAR) or perennial allergic rhinitis (PAR). METHODS: Patients with SAR or PAR who met the registration criteria and did not violate the exclusion criteria received bilastine (20mg, once daily) for 12 weeks (treatment period). Patients with PAR who met the transition criteria could elect to continue the bilastine treatment for an additional 40 weeks (continuous treatment period: a total of 52 weeks). Safety and tolerability were the primary outcomes, and the main secondary endpoint was to evaluate changes in efficacy variables from baseline measurements. RESULTS: Fifty-eight patients with SAR and 64 patients with PAR received bilastine (20mg/day) for 12 weeks. Fifty-five patients with PAR transitioned to the continuous treatment period. Adverse events (AEs) were reported by 17.2% of patients with SAR and by 31.3% of patients with PAR, and adverse drug reactions (ADRs) were reported by 6.3% of patients with PAR but by no patients with SAR during the 12-week treatment period. All of the ADRs were mild in severity. During the 52-week treatment period, AEs and ADRs were reported by 73.4% and 6.3% of patients with PAR, respectively. All of the ADRs occurred during the 12-week treatment period, and none during the continuous treatment period. The AEs were categorized using the System Organ Class of nervous system disorders; 4.7% of patients reported headache, but none reported somnolence. One serious AE was reported, but it was considered to be unrelated to the bilastine treatment. There were no deaths, and no patients withdrew from the study because of AEs. In patients with SAR, bilastine significantly decreased the total nasal symptom score (TNSS), total ocular symptom score (TOSS), and total symptom score (TSS) relative to baseline. Prolonged treatment with bilastine resulted in the maintenance of a significant reduction in TNSS, TOSS, and TSS from the baseline in patients with PAR. Improvement of quality of life was also observed in patients with SAR and PAR. CONCLUSION: Bilastine was safe, well tolerated, and effective for patients with SAR and PAR. The observed improvement was maintained for the duration of the study, with no loss of drug efficacy (registration number JapicCTI-142622)</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1879-1476 (Electronic)IS - 0385-8146 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anl.2016.07.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27561709">PM:27561709</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Auris Nasus Larynx\20160826-OkuboK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Auris Nasus Larynx\20160826-OkuboK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Okubo K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anl.2016.07.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morton,A.</style></author><author><style face="normal" font="Arial"> Laurie,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">FRACP, is Senior Staff Specialist, Endocrinology and Obstetric Medicine, Mater Hospital, Brisbane, Queensland</style></auth-address><titles><title><style face="normal" font="Arial">Allergic reactions to insulin detemir in women with gestational diabetes mellitus</style></title><secondary-title><style face="normal" font="Arial">Aust Fam Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Aust Fam Physician</style></full-title></periodical><pages end="486" start="485">485-486</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Endocrinology</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> senior</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 0300-8495 (Print)IS - 0300-8495 (Linking)LA - engPT - Journal ArticleSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27610430">PM:27610430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aust Fam Physician\2016-45-485-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aust Fam Physician\2016-45-485-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Morton A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hrdy,J.</style></author><author><style face="normal" font="Arial"> Kocourkova,I.</style></author><author><style face="normal" font="Arial"> Lodinova-Zadnikova,R.</style></author><author><style face="normal" font="Arial"> Kolarova,L.</style></author><author><style face="normal" font="Arial"> Prokesova,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Institute of immunology and microbiology, First faculty of medicine, Charles University in Prague, Studnickova 7, 128 00 Prague, Czech Republic</style></auth-address><titles><title><style face="normal" font="Arial">The effect of a probiotic Escherichia coli strain on regulatory T-cells in six year-old children</style></title><secondary-title><style face="normal" font="Arial">Benef Microbes</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Benef Microbes</style></full-title></periodical><pages end="648" start="639">639-648</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="9" Year="2016">2016/9/16</year></dates><abstract><style face="normal" font="Arial">Probiotics are believed to prevent or reduce allergy development but the mechanism of their beneficial effect is still poorly understood. Immune characteristics of regulatory T cells (Tregs) in peripheral blood of perinatally probiotic-supplemented children of allergic mothers (51 children), non-supplemented children of allergic mothers (42 children), and non-supplemented children of healthy mothers (28 children) were compared at the age of 6-7 years. A first dose of a probiotic Escherichia coli strain (E. coli O83:K24:H31) was administered within 2 days after the birth and then 12 times during the first months of life and children were followed longitudinally. Proportion and functional properties of Tregs were estimated by flow cytometry in relation to the children's allergy status. Proportion of Tregs in the peripheral blood of children suffering from allergy tends to be higher whereas median of fluorescence intensity (MFI) of FoxP3 was significantly decreased in allergic group. Intracellular presence of regulatory cytokine interleukin (IL)-10 was also lower in allergic children. Immune functions of Tregs reflected by both MFI of FoxP3 and IL-10 in the group of probiotic-supplemented children of allergic mothers were nearly comparable with children of healthy mothers while probiotic non-supplemented children of allergic mothers have decreased immune function of Tregs. Supplementation by probiotic E. coli strain decreases allergy incidence in high-risk children. In contrast to our expectation, proportion of Tregs has not been increased in probiotic supplemented children. Beneficial effect of probiotics on newborn immature immune system could be, at least partially, explained by the modulating immune function of Tregs. In summary, we detected increased proportion of Tregs in peripheral blood of allergic children, their functional properties were decreased in comparison with the Tregs of healthy children. A unifying hypothesis for these findings is that Treg numbers in allergic children are increased in order to compensate for decreased function</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1876-2891 (Electronic)IS - 1876-2883 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.3920/BM2016.0030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27633175">PM:27633175</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Benef Microbes\2016-7-639-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Benef Microbes\2016-7-639-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Hrdy J</style></custom2><misc3><style face="normal" font="Arial">10.3920/BM2016.0030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harima-Mizusawa,N.</style></author><author><style face="normal" font="Arial"> Kano,M.</style></author><author><style face="normal" font="Arial"> Nozaki</style></author><author><style face="normal" font="Arial"> Nonaka,C.</style></author><author><style face="normal" font="Arial"> Miyazaki,K.</style></author><author><style face="normal" font="Arial"> Enomoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Yakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Citrus juice fermented with Lactobacillus plantarum YIT 0132 alleviates symptoms of perennial allergic rhinitis in a double-blind, placebo-controlled trial</style></title><secondary-title><style face="normal" font="Arial">Benef Microbes</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Benef Microbes</style></full-title></periodical><pages end="658" start="649">649-658</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Juice</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus plantarum</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="9" Year="2016">2016/9/16</year></dates><abstract><style face="normal" font="Arial">This study aimed to examine whether citrus juice fermented with Lactobacillus plantarum YIT 0132 (LP0132), which was pasteurised after fermentation, could alleviate the symptoms of perennial allergic rhinitis in a double-blind, placebo-controlled, parallel-group trial. Subjects with perennial allergic rhinitis consumed LP0132-fermented juice (n=17) or unfermented citrus juice (placebo; n=16) once a day for 8 weeks. During the pre-intervention and intervention periods, the subjects recorded nasal symptoms (number of sneezing attacks, number of nose-blowing incidents, and stuffy nose score). The primary endpoint, nasal symptoms score (NSS), was scored from 0 to 4 according to the 'Practical Guideline for the Management of Allergic Rhinitis in Japan 2009' using a combination of the three nasal symptom items. Blood samples were collected at pre-intervention and at 8 weeks after commencing the intervention. There were several significant improvements not only in the LP0132 group but also in the placebo group because of potential anti-allergic effects of citrus. Compared with the placebo group, the LP0132 group showed a significant reduction in the NSS and stuffy nose score during the intervention period. Also, the LP0132 group, but not the placebo group, showed significant attenuation of type 2 helper T cells (Th2 cells)/helper T cells, serum total immunoglobulin E (IgE), and eosinophil cationic protein (ECP), and showed significant augmentation of type 1 helper T cells (Th1 cells)/Th2 cells at 8 weeks of intervention compared with baseline. It is suggested that daily intake of fermented citrus juice containing heat-killed LP0132 has beneficial effects on symptoms of perennial allergic rhinitis, and these benefits may be associated with the attenuation of Th2 cells, total IgE, and ECP via the immunomodulating activities of LP0132</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1876-2891 (Electronic)IS - 1876-2883 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3920/BM2016.0003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27633173">PM:27633173</url></web-urls><pdf-urls><url ppv-ref="no">naomi-mizusawa@yakult.co.jp</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160916, Harima-Mizusawa N</style></custom2><misc3><style face="normal" font="Arial">10.3920/BM2016.0003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,Y.X.</style></author><author><style face="normal" font="Arial"> He,J.</style></author><author><style face="normal" font="Arial"> Tan,C.Y.</style></author><author><style face="normal" font="Arial"> Luo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Engineering, Ji Nan University, Guang Zhou, China.</style></auth-address><titles><title><style face="normal" font="Arial">Easy and rapid multi-pass detection of antigen and antibody with micro-lens sensors</style></title><secondary-title><style face="normal" font="Arial">Biosens Bioelectron</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biosens Bioelectron</style></abbr-1></periodical><pages end="1010" start="1003">1003-1010</pages><volume><style face="normal" font="Arial">86</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Engineering</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="30" Month="7" Year="2016">2016/7/30</year></dates><abstract><style face="normal" font="Arial">We introduce a micro-lens imaging method that can perform easy and rapid multi-pass detection of antigen/antibody (Ag/Ab) without the requirement of any labeling, expensive enzymes, pre-immobilization/modification, and post-washing. Our method detects Ag or Ab presenting in solutions in a quantitative or qualitative manner by using micro-lens as the sensor to monitor the refractive index variation of the solutions during the primary stage of Ag-Ab reaction. The detection can be taken rapidly and finished in two minutes, while requires very low sample volume (several micron liters) and its detection limit can be as low as approximately pg/mL. The method is also able to provide kinetic and thermodynamic parameters of Ag-Ab reactions. The detections of ten Ag-Ab systems and two kinds of clinical samples demonstrated that our method is of high sensitivity, accuracy, reliability and permitting on-site analysis</style></abstract><notes><style face="normal" font="Arial">DA - 20160807IS - 1873-4235 (Electronic)IS - 0956-5663 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bios.2016.07.113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27498328">PM:27498328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biosens Bioelectron\2016-86-1003-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biosens Bioelectron\2016-86-1003-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160807, Huang YX</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bios.2016.07.113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Swystun,L.L.</style></author><author><style face="normal" font="Arial"> James,P.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology and Molecular Medicine, Richardson Laboratory, 88 Stuart St, Queen's University, Kingston, ON K7L 3N6, Canada. Electronic address: swystunl@queensu.caDepartment of Medicine, Etherington Hall, 94 Stuart St, Queen's University, Kingston, ON K7L 3N6, Canada. Electronic address: jamesp@queensu.ca</style></auth-address><titles><title><style face="normal" font="Arial">Genetic diagnosis in hemophilia and von Willebrand disease</style></title><secondary-title><style face="normal" font="Arial">Blood Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Blood Rev</style></full-title></periodical><pages end="56" start="47">47-56</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic testing</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic testing</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Phenotypic assays are first-line in terms of diagnostic testing for inherited bleeding disorders. However, since the characterization of the genes that encode coagulation factors in the 1980s, significant progress has been made in translating this knowledge for diagnostic and therapeutic purposes. For the hemophilias, molecular genetic testing can be used to determine carrier status, establish a prenatal diagnosis and predict the likelihood of inhibitor development or anaphylaxis in response to infused coagulation factor concentrates. In contrast, for von Willebrand disease (VWD), significant recent advances in our understanding of the molecular genetic basis of the disease have allowed for the development of rational approaches to genetic diagnostics. Questions remain however, about this complex genetic disorder and how to incorporate emerging knowledge into diagnostic strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1532-1681 (Electronic)IS - 0268-960X (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.blre.2016.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27596108">PM:27596108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Blood Rev\20160906-SwystunLL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Blood Rev\20160906-SwystunLL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Swystun LL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.blre.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Majewska,A.</style></author><author><style face="normal" font="Arial"> Gajewska,M.</style></author><author><style face="normal" font="Arial"> Dembele,K.</style></author><author><style face="normal" font="Arial"> Maciejewski,H.</style></author><author><style face="normal" font="Arial"> Prostek,A.</style></author><author><style face="normal" font="Arial"> Jank,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Lymphocytic, cytokine and transcriptomic profiles in peripheral blood of dogs with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">BMC Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Vet Res</style></full-title></periodical><pages end="" start="174">174-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Differentially expressed gene</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray Analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Canine atopic dermatitis (cAD) is a common chronic and pruritic skin disease in dogs. The development of cAD involves complex interactions between environmental antigens, genetic predisposition and a number of disparate cell types. The aim of the present study was to perform comprehensive analyses of peripheral blood of AD dogs in relation to healthy subjects in order to determine the changes which would be characteristic for cAD. RESULTS: The number of cells in specific subpopulations of lymphocytes was analyzed by flow cytometry, concentration of chosen pro- and anti-inflammatory cytokines (IL-4, IL-10, IL-13, TNF-alpha, TGF-beta1) was determined by ELISA; and microarray analysis was performed on RNA samples isolated from peripheral blood nuclear cells of AD and healthy dogs. The number of Th cells (CD3(+)CD4(+)) in AD and healthy dogs was similar, whereas the percentage of Tc (CD3(+)CD8(+)) and Treg (CD4(+)CD25(+) Foxp3(+)) cells increased significantly in AD dogs. Increased concentrations of IL-13 and TNF-alpha, and decreased levels of IL-10 and TGF-beta1 was observed in AD dogs. The level of IL-4 was similar in both groups of animals. Results of the microarray experiment revealed differentially expressed genes involved in transcriptional regulation (e.g., transcription factors: SMAD2, RORA) or signal transduction pathways (e.g., VEGF, SHB21, PROC) taking part in T lymphocytes lineages differentiation and cytokines synthesis. CONCLUSIONS: Results obtained indicate that CD8(+) T cells, beside CD4(+) T lymphocytes, contribute to the development of the allergic response. Increased IL-13 concentration in AD dogs suggests that this cytokine may play more important role than IL-4 in mediating changes induced by allergic inflammation. Furthermore, observed increase in Treg cells in parallel with high concentrations of TNF-alpha and low levels of IL-10 and TGF-beta1 in the peripheral blood of AD dogs point at the functional insufficiency of Treg cells in patients with AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1746-6148 (Electronic)IS - 1746-6148 (Linking)LA - engPT - Journal ArticleSB - IMCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12917-016-0805-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27553600">PM:27553600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Vet Res\20160824-MajewskaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Vet Res\20160824-MajewskaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Majewska A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12917-016-0805-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khalil,H.</style></author><author><style face="normal" font="Arial"> Joseph,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Great Western Hospitals NHS Foundation Trust, Swindon, UKDepartment of Gastroenterology, Great Western Hospitals NHS Foundation Trust, Swindon, UK</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic ascites: a diagnostic challenge</style></title><secondary-title><style face="normal" font="Arial">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdomen</style></keyword><keyword><style face="normal" font="Arial"> Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Ascites</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Eosinophilic ascites is a rare feature of eosinophilic gastroenteritis. We would like to highlight this increasingly recognised diagnosis in a case of unexplained ascites. We present a challenging case of a woman aged 25 years who presented with nausea, vomiting, diarrhoea, generalised abdominal pain and swelling 8-week following delivery of her first baby. Her symptoms were primarily aggravated by eating, and she had also noticed postprandial itching and self-limiting generalised rash. She had a strong history of atopy. Physical examination revealed abdominal tenderness and distension with shifting dullness. Urticarial skin rash was noted on the face, neck, chest and abdomen. Routine biochemistry was normal apart from peripheral eosinophilia. Imaging confirmed moderate ascites. Diagnostic paracentesis showed exudative ascites with numerous eosinophils. Histology of the upper and lower gastrointestinal tract showed infiltration of the oesophageogastroduodenal and rectosigmoid mucosa with eosinophils. The patient significantly improved following a course of steroids and six-food elimination diet</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bcr-2016-216791</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27600059">PM:27600059</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Case Rep\20160907-KhalilH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Case Rep\20160907-KhalilH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Khalil H</style></custom2><misc3><style face="normal" font="Arial">10.1136/bcr-2016-216791</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weller,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Chariteplatz 1, 10117, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Heat urticaria - easy to diagnose but also to misdiagnose</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="455" start="454">454-455</pages><volume><style face="normal" font="Arial">175</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.14729</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27632958">PM:27632958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\2016-175-454-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\2016-175-454-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Weller K</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.14729</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Denman,S.</style></author><author><style face="normal" font="Arial"> Ford,K.</style></author><author><style face="normal" font="Arial"> Toolan,J.</style></author><author><style face="normal" font="Arial"> Mistry,A.</style></author><author><style face="normal" font="Arial"> Corps,C.</style></author><author><style face="normal" font="Arial"> Wood,P.</style></author><author><style face="normal" font="Arial"> Savic,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, UK</style></auth-address><titles><title><style face="normal" font="Arial">Home Self-Administration of Omalizumab for Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="1407" start="1405">1405-1407</pages><volume><style face="normal" font="Arial">175</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Self Administration</style></keyword><keyword><style face="normal" font="Arial"> self-administration</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="17" Month="9" Year="2016">2016/9/17</year></dates><abstract><style face="normal" font="Arial">Omalizumab is an anti-IgE monoclonal antibody, which is licensed as add-on therapy for chronic spontaneous urticaria (CSU)1 . Although it provides effective symptomatic control, omalizumab does not always induce lasting remission and many patients require repeated courses. Between August 2010 and July 2016 we treated 123 CSU patients with omalizumab. Only 5% (n=6) have stopped omalizumab after achieving remission (1.6% [n=2] after one course only). Of our current cohort, 75% have had >1 treatment course. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - LETTERCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15074</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27639259">PM:27639259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20160917-DenmanS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20160917-DenmanS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Denman S</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15074</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Halling-Overgaard,A.S.</style></author><author><style face="normal" font="Arial"> Kezic,S.</style></author><author><style face="normal" font="Arial"> Jakasa,I.</style></author><author><style face="normal" font="Arial"> Engebretsen,K.A.</style></author><author><style face="normal" font="Arial"> Maibach,H.</style></author><author><style face="normal" font="Arial"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900, Hellerup</style></auth-address><titles><title><style face="normal" font="Arial">Skin absorption through atopic dermatitis skin: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="106" start="84">84-106</pages><volume><style face="normal" font="Arial">177</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact allergy</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emollients</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Medicament</style></keyword><keyword><style face="normal" font="Arial"> Medicaments</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin Absorption</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Patients with atopic dermatitis have skin barrier impairment in both lesional and non-lesional skin. They are typically exposed to emollients daily and topical anti-inflammatory medicaments intermittently, hereby increasing the risk of developing contact allergy and systemic exposed to chemicals ingredients found in these topical preparations. We systematically searched for studies that investigated skin absorption of various penetrants, including medicaments, in atopic dermatitis patients, but also animals with experimentally induced dermatitis. We identified 40 articles, i.e. 11 human studies examining model penetrants, 26 human studies examining atopic dermatitis drugs and 3 animal studies. We conclude that atopic dermatitis patients have nearly two-fold increased skin absorption when compared to healthy controls. There is a need for well-designed epidemiological and dermato-pharmacokinetic studies that examine to what extent atopic dermatitis patients are systemically exposed to chemicals compared to non-atopics. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Denmark -CO - Netherlands -CO - Croatia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15065</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27639188">PM:27639188</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20160917-HallingOvergaardAS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20160917-HallingOvergaardAS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Halling-Overgaard AS</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15065</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schwartzer,J.J.</style></author><author><style face="normal" font="Arial"> Careaga,M.</style></author><author><style face="normal" font="Arial"> Coburn,M.A.</style></author><author><style face="normal" font="Arial"> Rose,D.R.</style></author><author><style face="normal" font="Arial"> Hughes,H.K.</style></author><author><style face="normal" font="Arial"> Ashwood,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Program in Neuroscience and Behavior, Department of Psychology and Education, Mount Holyoke College, 50 College Street, South Hadley, MA 01075.</style></auth-address><titles><title><style face="normal" font="Arial">Behavioral impact of maternal allergic-asthma in two genetically distinct mouse strains</style></title><secondary-title><style face="normal" font="Arial">Brain Behav Immun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Brain Behav Immun</style></full-title></periodical><pages end="107" start="99">99-107</pages><volume><style face="normal" font="Arial">63</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> ASD</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autism</style></keyword><keyword><style face="normal" font="Arial"> Autism spectrum disorder</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic diversity</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Grooming</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> multiplex array</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell polarization</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Recent population-based studies of expecting mothers identified a unique profile of immune markers that are associated with an increased risk of having a child diagnosed with autism spectrum disorder (ASD). This immune profile, including increased levels of maternal and placental interleukin (IL)-4 and IL-5, is consistent with an immune response found in an allergic-asthma phenotype. Allergies and asthma reflect an imbalance in immune responses including polarization towards T-helper type 2 (TH2) responses, with both genetic susceptibility and environmental factors affecting this T-cell polarization. Mouse strains provide a known and controlled source of genetic diversity to explore the role of genetic predisposition on environmental factors. In particular, the FVB background exhibits a skew towards TH2-mediated allergic-asthma response in traditional models of asthma whereas the C57 strain exhibits a more blunted TH2 polarized phenotype resulting in an attenuated allergic-asthma response. C57BL/6J (C57) and the sighted FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant (FVB/Ant) lines were selected based on their characteristic high sociability and differing sensitivity to TH2-mediated stimuli. Based on the distinct allergy-sensitive immune responses of these two strains we hypothesized that unique developmental consequences would occur in offspring following maternal allergy-asthma exposure. Female C57 and FVB/Ant dams were primed/sensitized with an exposure to ovalbumin (OVA) before pregnancy, then exposed to either aerosolized OVA or PBS-vehicle throughout gestation. Sera from pregnant dams were analyzed for changes in cytokine profiles using multiplex-arrays and offspring were assessed for changes in autism-like behavioral responses. Analysis of maternal sera revealed elevated IL-4 and IL-5 in OVA-treated dams of both strains but only C57 mice expressed increased levels of IL-1beta, IL-6, TNFalpha, and IL-17. Behavioral assessments revealed strain-dependent changes in juvenile reciprocal social interaction in offspring of maternal allergic asthma dams. Moreover, mice of both strains showed decreased repetitive grooming and increased marble burying behavior when born to OVA-exposed dams. Together, these findings support the important role genetic predisposition plays in the effects of maternal immune activation and underscore differences in ASD-like behavioral outcomes across mouse strains</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1090-2139 (Electronic)IS - 0889-1591 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbi.2016.09.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27622677">PM:27622677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Brain Behav Immun\20160913-SchwartzerJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Brain Behav Immun\20160913-SchwartzerJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Schwartzer JJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbi.2016.09.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grumetto,L.</style></author><author><style face="normal" font="Arial"> Prete,A.D.</style></author><author><style face="normal" font="Arial"> Ortosecco,G.</style></author><author><style face="normal" font="Arial"> Borrelli,A.</style></author><author><style face="normal" font="Arial"> Prete,S.D.</style></author><author><style face="normal" font="Arial"> Mancini,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report</style></title><secondary-title><style face="normal" font="Arial">Case Rep Ophthalmol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Rep Ophthalmol Med</style></full-title></periodical><pages end="" start="7240209">7240209-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Betamethasone</style></keyword><keyword><style face="normal" font="Arial"> Bilastine</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Ketotifen</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Manganese</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Visual Acuity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background. We report a case of bilateral posterior subcapsular cataracts (PSCs) in a 24-year-old man with an allergic conjunctivitis history caused by a long-term therapy with glucocorticoids. Case Presentation. The patient showed a visual acuity of 9/10 for both eyes. He followed a therapy with ketotifen and bilastine for four years. During the last six months before our evaluation, he was treated with chloramphenicol and betamethasone, interrupted for onset of cataracts and increased intraocular pressure. We treated him with ophthalmic gel preparation containing a new recombinant form of manganese superoxide dismutase (rMnSOD) at a concentration of 12.5 mug/mL, only for the right eye, while left eye was treated with standard protocol of Bendazac-lysine g 0.5. Conclusion. This case report shows the protective effects of rMnSOD versus PSC disease, probably due to the capacity of rMnSOD of countering free radical species</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 2090-6722 (Print)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/7240209</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27610257">PM:27610257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Ophthalmol Med\2016-2016-7240209.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Ophthalmol Med\2016-2016-7240209.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Grumetto L</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/7240209</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pham Van,L.</style></author><author><style face="normal" font="Arial"> Germaud,N.</style></author><author><style face="normal" font="Arial"> Ramadan,A.</style></author><author><style face="normal" font="Arial"> Thieblemont,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universite Paris Descartes, Paris 75015, France; CNRS UMR 8147, Necker Hospital, Paris 75015, France</style></auth-address><titles><title><style face="normal" font="Arial">MyD88 modulates eosinophil and neutrophil recruitment as well as IL-17A production during allergic inflammation</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="122" start="116">116-122</pages><volume><style face="normal" font="Arial">310</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Differentiation Factor 88</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">The contribution of dysregulated innate immune responses to the pathogenesis of allergic disease remains largely unknown. Herein, we addressed the role of Toll-like receptor signaling in airway inflammation by studying mice rendered deficient for the myeloid differentiation factor 88 (MyD88-/-) which results in concurrent deficiencies in TLR and IL-1R1 signaling pathways. We show that the lack of MyD88 offers a partial protection from allergic disease evidenced by reduced airway eosinophilia and production of the Th17-associated effector cytokine IL-17A. By contrast, airway hyperreactivity and Th2 cytokine production, the cardinal features of allergic disease, remained unchanged. We found that the impaired IL-17A production in MyD88-/- mice was associated with defective CD4+ T cells, which failed to respond to IL-23 stimulation. The total number of Th17-associated effectors in lymph nodes was likewise decreased. Taken together, our results demonstrate that MyD88-dependent mechanisms are critical for orchestrating lung inflammatory responses, in terms of IL-17A production, as well as eosinophil and neutrophil recruitment</style></abstract><notes><style face="normal" font="Arial">DA - 20160911IS - 1090-2163 (Electronic)IS - 0008-8749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2016.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27614844">PM:27614844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\2016-310-116-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\2016-310-116-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160911, Pham Van L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2016.08.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ma,C.</style></author><author><style face="normal" font="Arial"> Gao,Q.</style></author><author><style face="normal" font="Arial"> Liang,Y.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Huang,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Shrimp arginine kinase being a binding protein of WSSV envelope protein VP31</style></title><secondary-title><style face="normal" font="Arial">Chin J Oceanol Limnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chin J Oceanol Limnol</style></full-title></periodical><pages end="1296" start="1287">1287-1296</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Arginine kinase</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Hemocyanin</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> White spot syndrome virus</style></keyword><keyword><style face="normal" font="Arial"> WSSV</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1993-5005</style></isbn><abstract><style face="normal" font="Arial">Viral entry into the host is the earliest stage of infection in the viral life cycle in which attachment proteins play a key role. VP31 (WSV340/WSSV396), an envelope protein of white spot syndrome virus (WSSV), contains an Arg-Gly-Asp (RGD) peptide domain known as a cellular attachment site. At present, the process of VP31 interacting with shrimp host cells has not been explored. Therefore, the VP31 gene was cloned into pET30a (+), expressed in Escherichia coli strain BL21 and purified with immobilized metal ion affinity chromatography. Four gill cellular proteins of shrimp (Fenneropenaeus chinensis) were pulled down by an affinity column coupled with recombinant VP31 (rVP31), and the amino acid sequences were identified with MALDI-TOF/TOF mass spectrometry. Hemocyanin, beta-actin, arginine kinase (AK), and an unknown protein were suggested as the putative VP31 receptor proteins. SDS-PAGE showed that AK is the predominant binding protein of VP31. An i n vitro binding activity experiment indicated that recombinant AK</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs (rAK) binding activity with rVP31 is comparable to that with the same amount of WSSV. These results suggested that AK, as a member of the phosphagen kinase family, plays a role in WSSV infection. This is the first evidence showing that AK is a binding protein of VP31. Further studies on this topic will elucidate WSSV infection mechanism in the future</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s00343-016-5198-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00343-016-5198-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin J Oceanol Limnol\2016-34-1287-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin J Oceanol Limnol\2016-34-1287-96.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160921, Ma C</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s00343-016-5198-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beer,L.A.</style></author><author><style face="normal" font="Arial"> Kossenkov,A.V.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Luning,Prak E.</style></author><author><style face="normal" font="Arial"> Domchek,S.</style></author><author><style face="normal" font="Arial"> Speicher,D.W.</style></author><author><style face="normal" font="Arial"> Ky,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Systems and Computational Biology, The Wistar Institute</style></auth-address><titles><title><style face="normal" font="Arial">Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction</style></title><secondary-title><style face="normal" font="Arial">Circ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Circ Res</style></full-title></periodical><pages end="1144" start="1135">1135-1144</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast cancer</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Computational Biology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Doxorubicin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Label-free</style></keyword><keyword><style face="normal" font="Arial"> LC-MS</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> new biomarkers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">RATIONALE: There is a critical need to develop robust, mechanistic strategies to identify patients at increased risk of cancer therapeutics-related cardiac dysfunction (CTRCD). OBJECTIVE: We aimed to discover new biomarkers associated with doxorubicin and trastuzumab-induced CTRCD using high-throughput proteomic profiling. METHODS AND RESULTS: Plasma, echocardiograms, and clinical outcomes were collected at standardized intervals in breast cancer patients undergoing doxorubicin and trastuzumab cancer therapy. Thirty-one longitudinal plasma samples from three cases with CTRCD and four age- and cancer-matched controls without CTRCD were processed and analyzed using label-free liquid chromatography- mass spectrometry (LC-MS). From these analyses, 862 proteins were identified from case/control pairs 1 and 2, and 1,360 proteins from case/control pair 3. Proteins with a greater than 1.5-fold change in cases compared to controls with a p&lt;0.05 either at the time of CTRCD diagnosis or across all timepoints were considered candidate diagnostic or predictive biomarkers, respectively. The protein that demonstrated the largest differences between cases and controls was immunoglobulin E (IgE), with higher levels detected at baseline and across all timepoints in controls without CTRCD as compared to matched CTRCD cases (p&lt;0.05). Similarly, in a validation study of 35 participants treated with doxorubicin and trastuzumab, high baseline IgE levels were associated with a significantly lower risk of CTRCD (p=0.018). CONCLUSIONS: In patients receiving doxorubicin and trastuzumab, high baseline IgE levels are associated with a lower risk of CTRCD. These novel findings suggest a new paradigm in cardio-oncology, implicating the immune system as a potential mediator of doxorubicin and trastuzumab-induced cardiac dysfunction</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1524-4571 (Electronic)IS - 0009-7330 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1161/CIRCRESAHA.116.309004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27582370">PM:27582370</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Circ Res\20160901-BeerLA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Circ Res\20160901-BeerLA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Beer LA</style></custom2><misc3><style face="normal" font="Arial">10.1161/CIRCRESAHA.116.309004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gazit,S.L.</style></author><author><style face="normal" font="Arial"> Mariko,B.</style></author><author><style face="normal" font="Arial"> Therond,P.</style></author><author><style face="normal" font="Arial"> Decouture,B.</style></author><author><style face="normal" font="Arial"> Xiong,Y.</style></author><author><style face="normal" font="Arial"> Couty,L.</style></author><author><style face="normal" font="Arial"> Bonnin,P.</style></author><author><style face="normal" font="Arial"> Baudrie,V.</style></author><author><style face="normal" font="Arial"> Le Gall,S.M.</style></author><author><style face="normal" font="Arial"> Dizier,B.</style></author><author><style face="normal" font="Arial"> Zoghdani,N.</style></author><author><style face="normal" font="Arial"> Ransinan,J.</style></author><author><style face="normal" font="Arial"> Hamilton,J.R.</style></author><author><style face="normal" font="Arial"> Gaussem,P.</style></author><author><style face="normal" font="Arial"> Tharaux,P.L.</style></author><author><style face="normal" font="Arial"> Chun,J.</style></author><author><style face="normal" font="Arial"> Coughlin,S.R.</style></author><author><style face="normal" font="Arial"> Bachelot-Loza,C.</style></author><author><style face="normal" font="Arial"> Hla,T.</style></author><author><style face="normal" font="Arial"> Ho-Tin-Noe,B.</style></author><author><style face="normal" font="Arial"> Camerer,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">INSERM U970</style></auth-address><titles><title><style face="normal" font="Arial">Platelet and Erythrocyte Sources of S1P Are Redundant for Vascular Development and Homeostasis, but both Rendered Essential After Plasma S1P Depletion in Anaphylactic Shock</style></title><secondary-title><style face="normal" font="Arial">Circ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Circ Res</style></full-title></periodical><pages end="e126" start="e110">e110-e126</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Endothelium</style></keyword><keyword><style face="normal" font="Arial"> Erythrocytes</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activation</style></keyword><keyword><style face="normal" font="Arial"> Platelets</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Sphingosine</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vascular Resistance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Sphingosine-1-phosphate (S1P) signaling is essential for vascular development and postnatal vascular homeostasis. The level of redundancy in S1P sources sustaining these processes remains unclear. OBJECTIVE: To address S1P source redundancy in the regulation of vascular development, integrity and tone. METHODS AND RESULTS: S1P production was selectively impaired in mouse platelets, erythrocytes, endothelium, and/or smooth muscle cells by targeted deletion of genes encoding sphingosine kinases (Sphks) 1&amp;2. S1P deficiency blunted aggregation and spreading of washed platelets and profoundly impaired their capacity to promote endothelial barrier function ex vivo. However, and in contrast to recent reports, neither platelets nor any other source of S1P was essential for vascular development, vascular integrity, or hemostasis/thrombosis. Yet rapid and profound depletion of plasma S1P during systemic anaphylaxis rendered both platelet- and erythrocyte-derived S1P essential for survival, with a contribution from blood endothelium observed only in the absence of circulating sources. Recovery was sensitive to aspirin in mice with but not without platelet S1P, suggesting that platelet activation and stimulus-response coupling is needed. S1P2 mediated most of the survival benefit of S1P, while endothelial S1P1 was dispensable for survival despite its importance for maintaining vascular integrity. Accordingly, S1P deficiency aggravated vasoplegia, arguing a vital role for S1P in maintaining vascular resistance during recovery from circulatory shock. CONCLUSIONS: While source redundancy secures essential roles of S1P in vascular development and integrity, profound depletion of plasma S1P during anaphylactic shock renders both erythrocyte and platelet S1P pools necessary for recovery and high basal plasma S1P levels protective</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1524-4571 (Electronic)IS - 0009-7330 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1161/CIRCRESAHA.116.308929</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27582371">PM:27582371</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Circ Res\20160901-GazitSL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Circ Res\20160901-GazitSL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Gazit SL</style></custom2><misc3><style face="normal" font="Arial">10.1161/CIRCRESAHA.116.308929</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Johnson,M.B.</style></author><author><style face="normal" font="Arial"> Flanagan,S.E.</style></author><author><style face="normal" font="Arial"> MARTINS,T.B.</style></author><author><style face="normal" font="Arial"> HILL,H.R.</style></author><author><style face="normal" font="Arial"> Hattersley,A.T.</style></author><author><style face="normal" font="Arial"> McDonald,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biomedical and Clinical ScienceUniversity of Exeter MedicalSchoolExeter, Devon, UK</style></auth-address><titles><title><style face="normal" font="Arial">Low IgE Is a Useful Tool to Identify STAT3 Gain-of-Function Mutations</style></title><secondary-title><style face="normal" font="Arial">Clin Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chem</style></full-title></periodical><pages end="1538" start="1536">1536-1538</pages><volume><style face="normal" font="Arial">62</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="8" Month="9" Year="2016">2016/9/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1530-8561 (Electronic)IS - 0009-9147 (Linking)LA - ENGPT - LETTERCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1373/clinchem.2016.263624</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27608644">PM:27608644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Chem\20160909-JohnsonMB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Chem\20160909-JohnsonMB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Johnson MB</style></custom2><misc3><style face="normal" font="Arial">10.1373/clinchem.2016.263624</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hirsch,A.G.</style></author><author><style face="normal" font="Arial"> Pollak,J.</style></author><author><style face="normal" font="Arial"> Glass,T.A.</style></author><author><style face="normal" font="Arial"> Poulsen,M.N.</style></author><author><style face="normal" font="Arial"> Bailey-Davis,L.</style></author><author><style face="normal" font="Arial"> Mowery,J.</style></author><author><style face="normal" font="Arial"> Schwartz,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Health Research Geisinger Health System, Danville, PA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Early Life Antibiotic Use and Subsequent Diagnosis of Food Allergy and Allergic Diseases</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="244" start="236">236-244</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> cephalosporin</style></keyword><keyword><style face="normal" font="Arial"> Cephalosporins</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> macrolide</style></keyword><keyword><style face="normal" font="Arial"> Macrolides</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> penicillin</style></keyword><keyword><style face="normal" font="Arial"> Penicillins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Antibiotic use in early life has been linked to disruptions in the microbiome. Such changes can disturb immune system development. Differences have been observed in the microbiota of children with and without allergies, but there have been few studies on antibiotic use and allergic disease. OBJECTIVE: We evaluated associations of early-life antibiotic use with subsequent occurrence of food allergy and other allergies in childhood using electronic health record data. METHODS: We used longitudinal data on 30,060 children up to age 7 years from Geisinger Clinic's electronic health record to conduct a sex and age matched case-control study to evaluate the association between antibiotic use and milk allergy, non-milk food allergies, and other allergies. For each outcome, we estimated conditional logistic regression models adjusting for race/ethnicity, history of Medical Assistance, and mode of birth delivery. Models were repeated separately for penicillins, cephalosporins, and macrolides. RESULTS: There were 484 milk allergy cases, 598 non-milk food allergy cases, and 3652 other allergy cases. Children with three or more antibiotic orders had a greater odds of milk allergy (odds ratio; 95% confidence interval) (1.78; 1.28-2.48), non-milk food allergy (1.65; 1.27-2.14), and other allergies (3.07; 2.72-3.46) compared to children with no antibiotic orders. Associations were strongest at younger ages and differed by antibiotic class. CONCLUSIONS AND CLINICAL RELEVANCE: We observed associations between antibiotic orders and allergic diseases, providing evidence of a potentially modifiable clinical practice associated with pediatric allergic disease. Differences by antibiotic class should be further explored, as this knowledge could inform pediatric treatment decisions. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562571">PM:27562571</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-HirschAG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-HirschAG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Hirsch AG</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12807</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Metcalfe,J.R.</style></author><author><style face="normal" font="Arial"> Marsh,J.A.</style></author><author><style face="normal" font="Arial"> D'Vaz,N.</style></author><author><style face="normal" font="Arial"> Geddes,D.T.</style></author><author><style face="normal" font="Arial"> Lai,C.T.</style></author><author><style face="normal" font="Arial"> Prescott,S.L.</style></author><author><style face="normal" font="Arial"> Palmer,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Paediatrics and Child Health, The University of Western Australia, Perth, WA, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Effects of maternal dietary egg intake during early lactation on human milk ovalbumin concentration: a randomized controlled trial</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1613" start="1605">1605-1613</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Potassium</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="26" Month="8" Year="2016">2016/8/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is limited understanding of how maternal diet affects breast milk food allergen concentrations, and whether exposure to allergens through this route influences the development of infant oral tolerance or sensitization. OBJECTIVE: To investigate how maternal dietary egg ingestion during early lactation influences egg protein (ovalbumin) levels detected in human breast milk. METHODS: In a randomized controlled trial, women were allocated to a dietary group for the first six weeks of lactation: high-egg diet (> 4 eggs per week), low-egg diet (1-3 eggs per week) or an egg-free diet. Breast milk samples were collected at two, four and six weeks of lactation for the measurement of ovalbumin. The permeability of the mammary epithelium was assessed by measuring the breast milk sodium: potassium ratio. Egg-specific IgE and IgG4 were measured in infant plasma at six weeks, and prior to the introduction of egg in solids at 16 weeks. RESULTS: Average maternal egg ingestion was associated with breast milk ovalbumin concentration. Specifically, for each additional egg ingested per week there was an average 25% increase in ovalbumin concentration (95% CI 5%-48%, p=0.01). Breast milk ovalbumin concentrations were significantly higher in the 'high-egg' group (> 4 eggs per week) compared with the 'egg-free' group (p=0.04). However one third of women had no breast milk ovalbumin detected. No detectable associations were found between mammary epithelium permeability and breast milk ovalbumin concentrations. Infant plasma egg-specific IgG4 levels were also positively associated with maternal egg ingestion, with an average 22% (95% CI 3%-45%) increase in infant egg-specific IgG4 levels per additional egg consumed per week (P=0.02). CONCLUSIONS &amp; CLINICAL RELEVANCE: Increased maternal egg ingestion is associated with increased breast milk ovalbumin, and markers of immune tolerance in infants. These results highlight the potential for maternal diet to benefit infant oral tolerance development during lactation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12806</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562481">PM:27562481</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-MetcalfeJR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-MetcalfeJR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Metcalfe JR</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12806</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wegienka,G.</style></author><author><style face="normal" font="Arial"> Havstad,S.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Zoratti,E.</style></author><author><style face="normal" font="Arial"> Ownby,D.</style></author><author><style face="normal" font="Arial"> Woodcroft,K.J.</style></author><author><style face="normal" font="Arial"> Johnson,C.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI</style></auth-address><titles><title><style face="normal" font="Arial">Subgroup Differences in the Associations between Dog Exposure during the First Year of Life and Early Life Allergic Outcomes</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="105" start="97">97-105</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The effect of dog exposure on the risk of children developing allergic disease remains controversial. Many analyses have not considered that associations may vary within population subgroups. OBJECTIVE: Examine whether associations between living with a dog in the first year of life and allergic outcomes vary within subgroups selected a priori (race, gender and delivery mode). METHODS: Black (n=496) and White (n=196) children enrolled in the WHEALS birth cohort study had a clinical examination at age 2 years to assess eczema and allergen-specific IgE (sIgE) and perform skin prick testing (SPT). Whether the child lived with an indoor dog in the first year of life was assessed through interview, as was doctor diagnosis of asthma at ages 3-6 years. RESULTS: Living with a dog was associated with decreased odds of having >/=1 positive SPT (OR=0.56, 95%CI 0.34, 0.91) and having eczema (OR=0.34, 95%CI 0.20, 0.60). The association with SPT was stronger in those children born via cesarian-section versus vaginally (OR=0.29, 95%CI 0.12, 0.74 versus OR=0.76, 95%CI 0.43, 1.37, respectively, interaction p=0.087) and in those who were firstborn versus not (OR=0.27, 95%CI 0.11, 0.67 versus OR=0.82, 95%CI 0.45, 1.47, respectively, interaction p=0.044). The association with eczema was stronger in children born vaginally compared with those born via cesarian-section (OR=0.17, 95%CI 0.06, 0.43 versus OR=0.65, 95%CI 0.31, 1.35, respectively, interaction p=0.025) and was stronger in Black versus White children (OR=0.30, 95%CI 0.15, 0.61 versus OR=0.78, 95%CI 0.29, 2.11, respectively, interaction p=0.12). Dog keeping was not significantly inversely associated with having >/=1 elevated sIgE and only approached statistical significance with asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12804</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562398">PM:27562398</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-WegienkaG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-WegienkaG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Wegienka G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12804</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">A call to arms</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1135" start="1134">1134-1135</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Arm</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12789</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27574039">PM:27574039</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1134-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1134-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12789</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Walker,S.M.</style></author><author><style face="normal" font="Arial"> Akdis,C.</style></author><author><style face="normal" font="Arial"> Dahlen,S.E.</style></author><author><style face="normal" font="Arial"> Djukanovic,R.</style></author><author><style face="normal" font="Arial"> Edwards,J.</style></author><author><style face="normal" font="Arial"> Garcia-Marcos,L.</style></author><author><style face="normal" font="Arial"> Johnston,S.</style></author><author><style face="normal" font="Arial"> Kupczyk,M.</style></author><author><style face="normal" font="Arial"> Martin,T.</style></author><author><style face="normal" font="Arial"> Myles,D.</style></author><author><style face="normal" font="Arial"> Palkonen,S.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.</style></author><author><style face="normal" font="Arial"> Powell,P.</style></author><author><style face="normal" font="Arial"> Riley,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research &amp; Policy, European Asthma Research &amp; Innovation Partnership, Asthma UK, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Building the investment case for asthma R&amp;D: the European Asthma Research and Innovation Partnership argument</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1138" start="1136">1136-1138</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialSB - IMCO - United Kingdom -CO - Sweden -CO - Switzerland -CO - United Kingdom -CO - Spain -CO - Poland -CO - United States -CO - Greece -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12779</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27574040">PM:27574040</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1136-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1136-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Walker SM</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12779</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Spaziano,G.</style></author><author><style face="normal" font="Arial"> Sorrentino,R.</style></author><author><style face="normal" font="Arial"> Matteis,M.</style></author><author><style face="normal" font="Arial"> Malgieri,G.</style></author><author><style face="normal" font="Arial"> Sgambato,M.</style></author><author><style face="normal" font="Arial"> Russo,T.P.</style></author><author><style face="normal" font="Arial"> Terlizzi,M.</style></author><author><style face="normal" font="Arial"> Roviezzo,F.</style></author><author><style face="normal" font="Arial"> Rossi,F.</style></author><author><style face="normal" font="Arial"> Pinto,A.</style></author><author><style face="normal" font="Arial"> Fattorusso,R.</style></author><author><style face="normal" font="Arial"> D'Agostino,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Medicine, Section of Pharmacology, Second University of Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Nociceptin reduces the inflammatory immune microenvironment in a conventional murine model of airway hyperresponsiveness</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="216" start="208">208-216</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are involved in airway hyperresponsiveness (AHR) and inflammation. However the role of nociceptin at modulating the inflammatory immune microenvironment in asthma is still unclear. OBJECTIVE: To understand the role of N/OFQ in the regulation of a Th2-like environment we used a conventional murine model of AHR. METHODS: Balb/c and CD1 mice were sensitized to ovalbumin (OVA) and treated with saline solution or N/OFQ, at days 0 and 7. A group of Balb/c mice were sacrificed at 7 and 14 days from the first sensitization for the inflammatory profile evaluation while a group of Balb/c and CD1 mice were aerosol-challenged from day 21 to 23 with OVA and sacrificed 24 hours later for functional evaluations. RESULTS: In OVA-sensitized mice, N/OFQ significantly reduced IL-4+CD4+T cells in lymph nodes (LN) and IL-13 in the lungs, while it induced IFN-gamma increase in the lung. The efflux of dendritic cells (DCs) to the mediastinic LN and into the lung of OVA-sensitized mice were reduced in N/OFQ treated and sensitized mice. N/OFQ reduced the expression of CD80 on DCs, indicating its ability to modulate the activation of DCs. In a less prone Th2-like environment mice strain, such as CD1 mice, N/OFQ didn't modify lung resistances as observed in BALB/c mice. Finally, spectroscopic data showed the N/OFQ was able to interact onto the membrane of DCs obtained from Balb/c rather than CD1 mice, indicating its ability to modulate AHR in a Th2-like environment with a direct activity on DCs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12808</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562660">PM:27562660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-SpazianoG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-SpazianoG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Spaziano G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12808</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Devillier,P.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Salvator,H.</style></author><author><style face="normal" font="Arial"> Naline,E.</style></author><author><style face="normal" font="Arial"> Grassin-Delyle,S.</style></author><author><style face="normal" font="Arial"> de Beaumont,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">UPRES EA 220, Universite de Versailles Saint-Quentin, Suresnes, FranceStallergenes SA, Antony, France</style></auth-address><titles><title><style face="normal" font="Arial">In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1464" start="1456">1456-1464</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Classroom</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> RQLQ</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="26" Month="8" Year="2016">2016/8/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The impact of grass-pollen-induced allergic rhinoconjunctivitis (AR) on classroom/work productivity and activities can be assessed with a specific instrument: the Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Allergy Specific (WPAI-AS). The present study evaluated the relationships between the WPAI-AS and other outcome measures in AR. METHODS: Adolescents (aged 12-17) and adults (aged 18-65) consulting specialists for AR were enrolled in a four-week, multicentre, observational study. The management of AR was left to the physicians' discretion. Participants regularly rated the WPAI-AS, their symptoms (using the Rhinoconjunctivitis Total Symptom Score (RTSS) and a 0-to-100 mm visual analogue scale (VAS)), and quality of life (according to the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)). RESULTS: 247 adolescents and 292 adults showed similar baseline impairments in classroom/work productivity and activities other than work. In both age groups, the WPAI-AS scores were moderately correlated with the RQLQ score and, to a lesser extent, with the VAS score and the RTSS. A multiple regression analysis indicated that the RQLQ score was a weak but statistically significant predictor of both impaired work/classroom productivity and daily activities. A 50 mm VAS cut-off categorized patients in whom AR had the greatest impact on productivity. CONCLUSIONS: Grass-pollen-induced AR impairs work/classroom and daily activity to a similar extent in adults and adolescents. The weak-to-moderate correlations with AR symptom scores and quality of life scores suggest that a specific tool (such as the WPAI-AS) should be used to assess AR's impact on word/classroom productivity and daily activities. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12801</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562177">PM:27562177</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-DevillierP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160826-DevillierP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Devillier P</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12801</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Just,J.</style></author><author><style face="normal" font="Arial"> Elegbede,C.F.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Moneret-Vautrin,D.A.</style></author><author><style face="normal" font="Arial"> Crepet,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergology Department, Centre de l'Asthme et des Allergies. Hopital d'Enfants Armand-Trousseau - 26, Avenue du Dr. Arnold Netter, 75571, PARIS Cedex 12</style></auth-address><titles><title><style face="normal" font="Arial">Three peanut allergic/sensitized phenotypes with gender difference</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1604" start="1596">1596-1604</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy phenotypes</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> patient management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold dose</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="8" Year="2016">2016/8/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergic reactions are heterogeneous ranging from mild symptoms to anaphylaxis. OBJECTIVE: Identify peanut allergic/sensitized phenotypes to personalize patient management. METHODS: A combined factor and cluster analysis was used to study the phenotypes of 696 patients diagnosed with peanut sensitization and enrolled in the MIRABEL survey. The method was first applied to the 247 patients with an Oral Food Challenge (OFC). It was then applied to the 449 patients without OFC to confirm the findings in an independent population. RESULTS: Three independent clusters emerged from the OFC subgroup. Cluster 1, "Severe peanut allergy with little allergic multimorbidity" (123 subjects), had the highest proportion of patients with positive OFC (92%), a medium level of peanut protein inducing a positive OFC (235 mg), lower percentage of allergic multimorbidity (2% asthma plus atopic dermatitis (A+AD), no cases of A+AD + multiple food allergies (MFA)). Cluster 2, "Severe peanut allergy with frequent allergic multimorbidity" (62 subjects), had a high proportion of patients with positive OFC (85%) with the lowest level of peanut protein inducing a positive OFC (112mg), 89% allergic subjects, 100% with allergic multimorbidity (A+AD) and 84% with A+AD+MFA. Cluster 3, "Mild peanut allergic/sensitized phenotype" (62 subjects), had the lowest mean age, the lowest proportion of patients with positive OFC (53%) with a high level of peanut protein inducing a positive OFC (770 mg), a low percentage of allergic multimorbidity (48% A+AD+MFA). The two severe peanut allergy phenotypes were more frequent in girls. The same clusters were found in the subgroup of patients without OFC. CONCLUSION &amp; CLINICAL RELEVANCE: Besides the classic markers associated with lower threshold doses of OFC (such as SPT and rAra h2), allergic multimorbidity and female gender should also be taken into account to better adapt the progressive dosage of provocation tests. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12791</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512923">PM:27512923</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160811-JustJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160811-JustJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Just J</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12791</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van der Valk,J.P.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Vergouwe,Y.</style></author><author><style face="normal" font="Arial"> Steyerberg,E.W.</style></author><author><style face="normal" font="Arial"> Reitsma,M.</style></author><author><style face="normal" font="Arial"> Wichers,H.J.</style></author><author><style face="normal" font="Arial"> Savelkoul,H.F.</style></author><author><style face="normal" font="Arial"> Vlieg-Boerstra,B.</style></author><author><style face="normal" font="Arial"> de Groot,H.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Allergology, Erasmus MC, Rotterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">sIgE Ana o 1, 2 and 3 accurately distinguish tolerant from allergic children sensitised to cashew nuts</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="120" start="113">113-120</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ana o 1</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The double-blind, placebo-controlled food challenge test (DBPCFC) is the gold standard in cashew nut allergy. This test is costly, time-consuming and not without side effects. Analysis of IgE-reactivity to cashew nut components may reduce the need for food challenge tests. METHODS: In a prospective and multicentre study, children with suspected cashew nut allergy underwent a DBPCFC with cashew nut. Specific IgE to cashew nut and to the components Ana o 1, 2 and 3 were determined. A skin prick test (SPT) with cashew nut extract was performed. The association between the outcome of the food challenge test and specific IgE to Ana o 1, 2 and 3 was assessed with logistic regression analyses, unadjusted and adjusted for other diagnostic variables. Discriminative ability was quantified with a concordance index (c). RESULTS: 173 children (103 boys, 60%) with a median age of 9 years were included. 79% had a positive challenge test outcome. A steep rise in the risk of a positive challenge was observed for specific IgE to each individual component Ana o 1, 2 and 3 with estimated risks up to approximately 100%. Median values of Ana o 1, 2, 3 were 6.0 kU/l (range 0-100 kU/l), 13.6 kU/l (range 0-100 kU/l) and 22.2 kU/l (range 0-100 kU/l) respectively and varied significantly (p &lt; 0.001). Specific IgE to Ana o 1, 2 and 3 better distinguished between cashew-allergic and tolerant children (c=0.87, 0.85 and 0.89 respectively), than specific IgE to cashew nut or SPT (c=0.76 and 0.83 respectively). CONCLUSION: The major cashew nut allergens Ana o 1, 2 and 3 are each individually predictive for the outcome of food challenge tests in cashew-allergic children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12794</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27513566">PM:27513566</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160811-vanderValkJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160811-vanderValkJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, van der Valk JP</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12794</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Utsch,L.</style></author><author><style face="normal" font="Arial"> Logiantara,A.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Van Rijt,L.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Depts. of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Experimental food allergy to peanut enhances the immune response to house dust mite in the airways of mice</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="128" start="121">121-128</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Respiratory sensitization</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy has been associated with an increased risk for the development of allergic asthma. Asthma is a risk factor for the development of an anaphylactic response to food allergens. An immunological interplay between sensitization to different allergens in different compartments of the body might be involved. OBJECTIVE: To evaluate the immunological interplay between intragastrical peanut (PE) sensitization and respiratory sensitization to house dust mite (HDM) allergens. METHODS: BALB/c mice were intra-gastrically sensitized to peanut or sham-sensitized and challenged systemically to PE. Between sensitization and challenge, mice were intranasally exposed to HDM extract or PBS, as a control. The response to HDM (eosinophil recruitment, cytokine response, HDM specific immunoglobulins, and airway hyperreactivity) and to PE (cytokine response, mast cells in gut, mMCP-1 in serum, body temperature) was assessed. RESULTS: A preceding PE sensitization increased HDM induced production of IL-4, IL-5, IL-13 and IFNgamma in lung draining lymph nodes and total IgE levels in HDM sensitized mice. However, recruitment of inflammatory cells to the airways or airway hyperreactivity was not aggravated in PE/HDM double-sensitized mice. Alternatively, HDM induced airway inflammation did not significantly affect the immune response or the anaphylactic response to a systemic challenge with peanut. CONCLUSION AND CLINICAL RELEVANCE: Our data show that a preceding peanut sensitization boosted IgE and HDM-specific Th2 response in the airways in mice. It contributes to the understanding of the underlying immunological mechanism of polysensitization which often occurs in allergic individuals over time. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12799</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27533916">PM:27533916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160818-UtschL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160818-UtschL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Utsch L</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12799</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mo,L.H.</style></author><author><style face="normal" font="Arial"> Yang,L.T.</style></author><author><style face="normal" font="Arial"> Zeng,L.</style></author><author><style face="normal" font="Arial"> Xu,L.Z.</style></author><author><style face="normal" font="Arial"> Zhang,H.P.</style></author><author><style face="normal" font="Arial"> Li,L.J.</style></author><author><style face="normal" font="Arial"> Liu,J.Q.</style></author><author><style face="normal" font="Arial"> Xiao,X.J.</style></author><author><style face="normal" font="Arial"> Zheng,P.Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ENT Institute of the Research Center of Allergy &amp; Immunology, Shenzhen University School of Medicine, Shenzhen, 518060, China</style></auth-address><titles><title><style face="normal" font="Arial">Dust mite allergen, glutathione S-transferase, induces T cell immunoglobulin mucin domain-4 in dendritic cells to facilitate initiation of airway allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="270" start="264">264-270</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> glutathione S transferase</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergens from dust mites play a critical role in the pathogenesis of airway allergy. The mechanism by which dust mite allergens induce allergic diseases is not fully understood yet. OBJECTIVE: This study tests a hypothesis that the eighth subtypes of Dermatophagoides farina allergen (Derf8) plays an important role in the induction of airway allergy. METHODS: The protein of Derf8 was synthesized via molecular cloning approach. Dendritic cells (DC) were stimulated with Derf8 in the culture and then the expression of T cell immunoglobulin and mucin domain 4 (TIM4) in dendritic cells (DC) was analyzed. The role of Derf8 in the induction of airway allergy was evaluated with a mouse model. RESULTS: Exposure to Derf8 markedly induced the TIM4 expression in DCs by modulating the chromatin at the TIM4 promoter locus. Derf8 played a critical role in the expansion of the T helper 2 response in the mouse airway via inducing DCs to produce TIM4. Administration with Derf8-depleted dust mite extracts (DME) inhibited the allergic inflammation and induced regulatory T cells in mice with airway allergy. CONCLUSION: Derf8 plays an important role in the initiation of dust mite allergy. Vaccination with Derf8-deficient DME is more efficient to inhibit the dust mite allergic inflammation than using wild DME. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12800</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27532130">PM:27532130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160817-MoLH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160817-MoLH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Mo LH</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12800</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Husslik,F.</style></author><author><style face="normal" font="Arial"> Nurnberg,J.</style></author><author><style face="normal" font="Arial"> Seutter von Loetzen,C.</style></author><author><style face="normal" font="Arial"> Mews,T.</style></author><author><style face="normal" font="Arial"> Ballmer-Weber,B.K.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author><author><style face="normal" font="Arial"> Randow,S.</style></author><author><style face="normal" font="Arial"> Volker,E.</style></author><author><style face="normal" font="Arial"> Reuter,A.</style></author><author><style face="normal" font="Arial"> Rosch,P.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Holzhauser,T.</style></author><author><style face="normal" font="Arial"> Schiller,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">The conformational IgE epitope profile of soybean allergen Gly m 4</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1497" start="1484">1484-1497</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> avidity</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Clinical tolerance</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gly m 4</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> NMR spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation test</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Protein structures</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy allergy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="8" Year="2016">2016/8/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Birch pollen-related soy allergy is mediated by Gly m 4. Conformational IgE epitopes of Gly m 4 are unknown. OBJECTIVE: To identify the IgE epitope profile of Gly m 4 in subjects with birch pollen-related soy allergy utilizing an epitope library presented by Gly m 4-type model proteins. METHODS: Sera from patients with (n = 26) and without (n = 19) allergy to soy as determined by oral provocation tests were studied. Specific IgE (Bet v 1/Gly m 4) was determined by ImmunoCAP. A library of 59 non-allergenic Gly m 4-type model proteins harboring individual and multiple putative epitopes for IgE was tested in IgE binding assays. Primary, secondary, and tertiary protein structures were assessed by mass spectrometry, CD and NMR spectroscopy. RESULTS: All subjects were sensitized to Gly m 4 and Bet v 1. Allergen-specific serum IgE levels ranged from 0.94 to >100 kUA /L. The avidities of serum IgE were 5.06 ng (allergic) and 1.8 ng (tolerant) as determined by EC50 for IgE binding to Gly m 4. 96% (46/48) of the protein variants bound IgE. Model proteins had Gly m 4-type conformation and individual IgE binding clustered in six major surface areas. Gly m 4-specific IgE binding could be inhibited to up to 80% by model proteins harboring individual IgE binding sites in an epitope-wise equimolar fashion. ROC analysis revealed an AUC of up to 0.88 for model proteins and 0.66 for Gly m 4. CONCLUSION: and Clinical Relevance Serum levels and avidity of Gly m 4-specific IgE do not correlate with clinical reactivity to soy. Six IgE binding areas, represented by 23 amino acids, account for more than 80% of total IgE binding capacity of Gly m 4. Model proteins may be used for epitope-resolved diagnosis to differentiate birch-soy allergy from clinical tolerance. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12796</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27533495">PM:27533495</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160817-HusslikF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160817-HusslikF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Husslik F</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12796</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anas,A.A.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author><author><style face="normal" font="Arial"> de Boer,J.D.</style></author><author><style face="normal" font="Arial"> Roelofs,J.J.</style></author><author><style face="normal" font="Arial"> Hou,B.</style></author><author><style face="normal" font="Arial"> de Vos,A.F.</style></author><author><style face="normal" font="Arial"> van der Poll,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Academic Medical Center, University of Amsterdam, Center for Experimental and Molecular Medicine, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">General, but not myeloid or type II lung epithelial cell, myeloid differentiation factor-88 deficiency abrogates house dust mite induced allergic lung inflammation</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Immunol</style></full-title></periodical><pages end="212" start="204">204-212</pages><volume><style face="normal" font="Arial">187</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Differentiation Factor 88</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is a highly prevalent chronic allergic inflammatory disease of the airways affecting people worldwide. House dust mite (HDM) is the most common allergen implicated in human allergic asthma. HDM induced allergic responses are thought to depend on activation of pathways involving Toll-like receptors and their adaptor protein myeloid differentiation factor 88 (MyD88). We here sought to determine the role of MyD88 in myeloid and type II lung epithelial cells in the development of asthma-like allergic disease using a mouse model. Repeated exposure to HDM caused allergic responses in control mice characterized by influx of eosinophils into the bronchoalveolar space and lung tissue, lung pathology and mucus production, and protein leak into bronchoalveolar lavage fluid. All these responses were abrogated in mice with a general deficiency of MyD88 but unaltered in mice with MyD88 deficiency specifically in myeloid or type II lung epithelial cells. We conclude that cells other than myeloid or type II lung epithelial cells are responsible for MyD88 dependent HDM induced allergic airway inflammation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1365-2249 (Electronic)IS - 0009-9104 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/cei.12867</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27625307">PM:27625307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Immunol\20160914-AnasAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Immunol\20160914-AnasAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Anas AA</style></custom2><misc3><style face="normal" font="Arial">10.1111/cei.12867</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foong,R.X.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Fox,A.T.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma, Allergy and Lung Biology, Guy's and St. Thomas' NHS Foundation Trust, London, SE1 7EH UK</style></auth-address><titles><title><style face="normal" font="Arial">Pilot study: assessing the clinical diagnosis of allergy in atopic children using a microarray assay in addition to skin prick testing and serum specific IgE</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray assay</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Children with atopic dermatitis (AD) are at risk of developing allergy. Alongside clinical history, testing modalities include skin prick tests (SPT), specific immunoglobulin-E (sp-IgE) and recently, microarray assays. The aim of this pilot study was to assess current tests and the ISAC sIgE-112 system in the diagnosis of food and aeroallergen allergy. METHODS: Children aged 0-11 years with moderate to severe AD were included. An initial allergy assessment including clinical history, SPT and sp-IgE was performed to determine food and aeroallergen sensitization. A second independent clinical assessment using the same information given to the first assessor and ISAC test results for food and aeroallergen sensitization was also made for each participant. The results from both were compared. RESULTS: 30 children [mean age 3.91 years (SD 3.3)] were included; 53.3 and 46.7 % had moderate and severe AD, respectively. Sp-IgE tests had a higher percentage of positive results compared to SPT and ISAC tests for common allergens. There was a significant difference between the three tests in detecting aeroallergen sensitization (p = 0.038), especially between sp-IgE and ISAC tests, but no significant difference between the tests for food allergen sensitization. There was good agreement between the two assessors; 70 % of the children had a change in diagnosis, with 60 % having at least one diagnosis added and 40 % having at least one diagnosis removed. CONCLUSIONS: There is a role for the use of ISAC testing in diagnosing sensitization and allergy in children with AD as it leads to a change in diagnosis for many patients. Further work is required to assess its clinical and cost effectiveness</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1476-7961 (Electronic)IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-016-0046-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27547124">PM:27547124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Foong RX</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-016-0046-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Petrarca,C.</style></author><author><style face="normal" font="Arial"> Clemente,E.</style></author><author><style face="normal" font="Arial"> Amato,V.</style></author><author><style face="normal" font="Arial"> Gatta,A.</style></author><author><style face="normal" font="Arial"> Cortese,S.</style></author><author><style face="normal" font="Arial"> Lamolinara,A.</style></author><author><style face="normal" font="Arial"> Rossi,C.</style></author><author><style face="normal" font="Arial"> Zanotta,S.</style></author><author><style face="normal" font="Arial"> Mistrello,G.</style></author><author><style face="normal" font="Arial"> Paganelli,R.</style></author><author><style face="normal" font="Arial"> Di Gioacchino,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Allergy and Immunotoxicology, Center of Ageing Science, "Universita G. d'Annunzio" Foundation, Chieti, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="7">7-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deviation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune suppression</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamin D3</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Airborne allergens can induce an immunological chronic disease characterized by airway hyper responsiveness and inflammation, mediated by exaggerated Th2 immune response. Allergen-specific immunotherapy (AIT) is effective for treating this condition because it is able to modify its natural course by opposing the underlying pathogenic mechanisms and determining immune suppression, immune deviation and tolerance. The rational for the present study was to investigate the possibility of improving allergoid-based IT in terms of efficacy and safety. Recently, 1alpha,25-dihydroxyvitamin D3 (VD3), the active metabolite of vitamin D3, was described to be a potent inducer of T regulatory cells and to be a good adjuvant in AIT settings. METHODS: We investigated whether the co-administration of VD3 could potentiate the effect of AIT even when added to a low dose of chemically-modified monomeric allergoid of Der p 2 (d2-OID), in a Derp p 2 (d2)-sensitized BALB/c mice model. Control groups where treated with sham, VD3 alone or d2-OID only. RESULTS: The d2-OID alone was not fully successful, as expected for a low dose. VD3 administration was associated with some valuable, although limited, changes in the immunological parameters in the lung. On the contrary, the VD3 adjuvated allergoid vaccine induced the most prominent reduction of airway eosinophilia and Th2 cytokines and concomitant increase of T regulatory cells and IL-10 in the lung and Der p 2-specific IgG2a in the serum. CONCLUSIONS: The addition of VD3 to a conventional AIT protocol would allow the reduction of allergoid dose needed and therefore, the production costs. Moreover, beneficial immunomodulatory effects have been achieved by the oral administration which might favour the management of the therapy by the patients and their adherence, possibly enhancing the efficacy of the treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1476-7961 (Electronic)IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-016-0044-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499704">PM:27499704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Petrarca C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-016-0044-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mousan,G.</style></author><author><style face="normal" font="Arial"> Kamat,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital of Michigan, Detroit, MI, USA gmousanyazigi@gmail.comChildren's Hospital of Michigan, Detroit, MI, USA</style></auth-address><titles><title><style face="normal" font="Arial">Cow's Milk Protein Allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Pediatr (Phila)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Pediatr (Phila)</style></abbr-1></periodical><pages end="1063" start="1054">1054-1063</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">Cow's milk protein allergy (CMPA) is a common condition encountered in children with incidence estimated as 2% to 7.5% in the first year of life. Formula and breast-fed babies can present with symptoms of CMPA. It is important to accurately diagnose CMPA to avoid the consequences of either under- or overdiagnosis. CMPA is classically categorized into immunoglobulin E (IgE)- or non-IgE-mediated reaction that vary in clinical manifestations, diagnostic evaluation, and prognosis. The most commonly involved systems in patients with CMPA are gastrointestinal, skin, and respiratory. Evaluation of CMPA starts with good data gathering followed by testing if indicated. Treatment is simply by avoidance of cow's milk protein (CMP) in the child's or mother's diet, if exclusively breast-feeding. This article reviews the definition, epidemiology, risk factors, pathogenesis, clinical presentation, evaluation, management, and prognosis of CMPA and provides an overview of different options for formulas and their indication in the treatment of CMPA</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1938-2707 (Electronic)IS - 0009-9228 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/0009922816664512</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27582492">PM:27582492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Pediatr (Phila)\2016-55-1054-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Pediatr (Phila)\2016-55-1054-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Mousan G</style></custom2><misc3><style face="normal" font="Arial">10.1177/0009922816664512</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mendes,C.</style></author><author><style face="normal" font="Arial"> Costa,J.</style></author><author><style face="normal" font="Arial"> Vicente,A.A.</style></author><author><style face="normal" font="Arial"> Oliveira,M.B.</style></author><author><style face="normal" font="Arial"> Mafra,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">REQUIMTE-LAQV, Faculdade de Farmacia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Cashew Nut Allergy: Clinical Relevance and Allergen Characterisation</style></title><secondary-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ana o 1</style></keyword><keyword><style face="normal" font="Arial"> Ana o 2</style></keyword><keyword><style face="normal" font="Arial"> Ana o 3</style></keyword><keyword><style face="normal" font="Arial"> Anacardium</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cupin</style></keyword><keyword><style face="normal" font="Arial"> Cupin superfamily</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food labelling</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Industrial application</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> Prolamin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="Arial">Cashew plant (Anacardium occidentale L.) is the most relevant species of the Anacardium genus. It presents high economic value since it is widely used in human nutrition and in several industrial applications. Cashew nut is a well-appreciated food (belongs to the tree nut group), being widely consumed as snacks and in processed foods by the majority of world's population. However, cashew nut is also classified as a potent allergenic food known to be responsible for triggering severe and systemic immune reactions (e.g. anaphylaxis) in sensitised/allergic individuals that often demand epinephrine treatment and hospitalisation. So far, three groups of allergenic proteins have been identified and characterised in cashew nut: Ana o 1 and Ana o 2 (cupin superfamily) and Ana o 3 (prolamin superfamily), which are all classified as major allergens. The prevalence of cashew nut allergy seems to be rising in industrialised countries with the increasing consumption of this nut. There is still no cure for cashew nut allergy, as well as for other food allergies; thus, the allergic patients are advised to eliminate it from their diets. Accordingly, when carefully choosing processed foods that are commercially available, the allergic consumers have to rely on proper food labelling. In this sense, the control of labelling compliance is much needed, which has prompted the development of proficient analytical methods for allergen analysis. In the recent years, significant research advances in cashew nut allergy have been accomplished, which are highlighted and discussed in this review</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Portugal -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s12016-016-8580-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27585580">PM:27585580</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20160902-MendesC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20160902-MendesC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Mendes C</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s12016-016-8580-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hahn-Pedersen,J.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Green,W.</style></author><author><style face="normal" font="Arial"> Andreasen,J.N.</style></author><author><style face="normal" font="Arial"> Taylor,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ALK, Horsholm, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Cost utility analysis of the SQ((R)) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> disease-modifying effect</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-Adjusted Life Years</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma affects an estimated 300 million people worldwide with the condition associated with significant healthcare utilisation costs and a large impact on patient quality of life. The SQ((R)) HDM SLIT-tablet (ACARIZAX((R)), Horsholm, Denmark) is a sublingually administered allergy immunotherapy tablet for house dust mite allergic asthma and allergic rhinitis and has recently been licensed in Europe. OBJECTIVE: To assess the cost-effectiveness of ACARIZAX plus pharmacotherapy versus placebo plus pharmacotherapy in patients with house dust mite allergic asthma that is uncontrolled by inhaled corticosteroids, in a German setting. Eligible patients should also have symptoms of mild to severe allergic rhinitis. METHODS: A cost utility analysis was undertaken, based on the results of a European phase III randomised controlled trial, in which ACARIZAX was compared with placebo with both treatment groups also receiving pharmacotherapy in the form of inhaled corticosteroids and short-acting beta2-agonists. Cost and quality-adjusted life years from the trial were extrapolated over a nine year time horizon and the incremental cost-effectiveness ratio calculated to compare treatment options. RESULTS: ACARIZAX plus pharmacotherapy was estimated to generate 6.16 quality-adjusted life years per patient at a cost of euro5658, compared with 5.50 quality-adjusted life years (QALYs) at a cost of euro2985 for placebo plus pharmacotherapy. This equated to an incremental cost of euro2673, incremental QALYs of 0.66 and an incremental cost-effectiveness ratio (ICER) of euro4041. The ICER was, therefore, substantially lower than the euro40,000 willingness-to-pay threshold per QALY adopted for the analysis. Deterministic sensitivity analyses indicate the results are most sensitive to the utility score of ACARIZAX patients during years 2 and 3 of treatment. CONCLUSION: This analysis indicates that ACARIZAX plus pharmacotherapy is cost-effective compared with placebo plus pharmacotherapy for house dust mite allergic asthma patients in Germany. If a disease-modifying effect can be proven the results of this analysis may underestimate the true benefits of ACARIZAX</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 2045-7022 (Electronic)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Germany -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0127-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27610217">PM:27610217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Hahn-Pedersen J</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0127-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brown,C.E.</style></author><author><style face="normal" font="Arial"> Jones,C.J.</style></author><author><style face="normal" font="Arial"> Stuttaford,L.</style></author><author><style face="normal" font="Arial"> Robertson,A.</style></author><author><style face="normal" font="Arial"> Rashid,R.S.</style></author><author><style face="normal" font="Arial"> Smith,H.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Primary Care and Public Health Medicine, Brighton and Sussex Medical School, Room 319, Mayfield House, Village Way, Brighton, BN1 9PH UK</style></auth-address><titles><title><style face="normal" font="Arial">A qualitative study of the allergy testing experiences, views and preferences of adult patients</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE testing</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Test method</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients can be tested for IgE sensitivities with in vivo or in vitro testing, but patients' experiences of different allergy test modalities have not been studied. The objective of this study was to investigate adult patients' experiences, views and preferences for allergy testing, exploring skin prick testing and allergen-specific IgE testing. METHODS: A qualitative study of adults attending out-patients for investigation of a suspected allergy. A purposive, convenience sample identified participants and semi-structured interviews were conducted, face to face or by telephone. Interviews were recorded and transcribed verbatim. Thematic content analysis was used to explore patients' experiences. RESULTS: 23 patients were interviewed. The characteristics of skin prick tests particularly valued were the immediacy and visibility of results, which enabled testing and interpretation to be achieved within a single clinic appointment. In vitro testing offered patients simplicity and procedural speed, necessitating only a single puncture site, and was perceived to be a superior test as it was conducted in a laboratory. CONCLUSIONS: The patient preferred method of allergy testing was skin prick testing rather than in vitro allergen specific IgE testing. However, most patients were accepting of either testing modality because their desire to confirm or exclude an allergic trigger overrode any perceived disadvantages of the test method. TRIAL REGISTRATION: Not applicable as study descriptive and qualitative</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 2045-7022 (Electronic)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0125-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27583128">PM:27583128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Brown CE</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0125-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gimenez-Arnau,A.M.</style></author><author><style face="normal" font="Arial"> Spector,S.</style></author><author><style face="normal" font="Arial"> Antonova,E.</style></author><author><style face="normal" font="Arial"> Trzaskoma,B.</style></author><author><style face="normal" font="Arial"> Rosen,K.</style></author><author><style face="normal" font="Arial"> Omachi,T.A.</style></author><author><style face="normal" font="Arial"> Stull,D.</style></author><author><style face="normal" font="Arial"> Balp,M.M.</style></author><author><style face="normal" font="Arial"> Murphy,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital del Mar, Institut Mar d'Investigacions Mediques, Universitat Autonoma Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="32">32-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Arm</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Hive</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep. METHODS: We examined the effect of omalizumab on sleep-related outcomes during 3-6 months omalizumab or placebo treatment and a 16-week follow-up period within three Phase III double-blind randomized placebo-controlled pivotal trials in CIU/CSU: ASTERIA I, ASTERIA II, and GLACIAL. Sleep quality was assessed in all three studies using sleep-related questions included in an electronic diary, the Chronic Urticaria Quality of Life Questionnaire, and the Medical Outcomes Study Sleep Scale. Score changes from baseline in the treatment arms were compared with that in the placebo arm and adjusted for baseline score and weight. We also examined correlations of sleep scores at baseline, week 12, and week 24 and the slopes of change between sleep and itch and hive. RESULTS: Patients treated with omalizumab reported a larger reduction in sleep problems than those in the placebo arm; omalizumab 300 mg demonstrated the greatest improvement on all sleep components among all treatment arms. The largest reduction in sleep problems was reported within the first 4 weeks of therapy. After treatment discontinuation, sleep quality worsened. Sleep scores demonstrated moderate-to-strong correlation between them, and the change in sleep scores was associated with changes in itch and hives. CONCLUSIONS: Improvement in sleep was reported after the first dose of omalizumab. Sleep continued to improve throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatment arms. Trial registration ClinicalTrials.gov, NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)</style></abstract><notes><style face="normal" font="Arial">DA - 20160819IS - 2045-7022 (Electronic)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United States -CO - United Kingdom -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0120-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27540466">PM:27540466</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160819, Gimenez-Arnau AM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0120-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Byberg,K.K.</style></author><author><style face="normal" font="Arial"> Eide,G.E.</style></author><author><style face="normal" font="Arial"> Forman,M.R.</style></author><author><style face="normal" font="Arial"> Juliusson,P.B.</style></author><author><style face="normal" font="Arial"> Oymar,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Stavanger University Hospital, POB 8100, 4068 Stavanger, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Body mass index and physical activity in early childhood are associated with atopic sensitization, atopic dermatitis and asthma in later childhood</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="33">33-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Anthropometry</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The results of studies on the associations of childhood excessive weight/obesity and physical activity with atopic sensitization and atopic diseases are inconsistent. We studied the associations of anthropometry and physical activity in childhood with atopic sensitization and atopic diseases in late childhood. METHODS: In a cohort study including cases exposed to preeclampsia during pregnancy and controls, anthropometry and physical activity were assessed at several ages in 617 children. Associations with atopic sensitization and atopic diseases in late childhood were analysed using multiple logistic regression. RESULTS: Body mass index standard deviation score (BMI SDS) at 1 year and low physical activity at 3-6 years were positively associated with atopic sensitization at 12.8 years [adjusted odds ratio (OR) 1.22; 95 % confidence interval (1.00, 1.49) and OR 2.36; (1.15, 4.81), respectively]. Change in BMI SDS from 1 to 4 years, BMI SDS at 4 years, and high physical activity at 6-10 years were positively associated with atopic dermatitis by 10.8 years [OR 1.46; (1.11, 1.92); OR 1.32; (1.06, 1.65) and OR 1.94; (1.16, 3.24); respectively]. Low physical activity at 3-6 and 6-10 years were positively associated with asthma by 10.8 years [OR 3.61; (1.56, 8.36) and OR 2.52; (1.24, 5.12), respectively]. CONCLUSIONS: BMI and physical activity in early childhood were associated with atopic sensitization, atopic dermatitis and asthma in later childhood. Larger cohorts with repeated measurements of both predictors and outcomes are required to further elucidate this issue. Trial registration Our study was observational without any clinical intervention on the participants. Therefore, no trial registration number is available</style></abstract><notes><style face="normal" font="Arial">DA - 20160825IS - 2045-7022 (Electronic)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Norway -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0124-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27559467">PM:27559467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160825, Byberg KK</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0124-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Edkins,T.J.</style></author><author><style face="normal" font="Arial"> Koller-Eichhorn,R.</style></author><author><style face="normal" font="Arial"> Alhadeff,J.A.</style></author><author><style face="normal" font="Arial"> Mayer,U.</style></author><author><style face="normal" font="Arial"> Faust,H.</style></author><author><style face="normal" font="Arial"> Del Tito,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Edkins Pharma Services, LLC, Wayne, Pennsylvania, USA</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of potential cross-reactivity of human endogenous matrix metalloproteinases with collagenase Clostridium histolyticum antibodies in human sera obtained from patients with Dupuytren's contracture</style></title><secondary-title><style face="normal" font="Arial">Clin Vaccine Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Vaccine Immunol</style></full-title></periodical><pages end="569" start="562">562-569</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Bacterial</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Clo hi Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Dupuytren Contracture</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> Gram-Positive Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinases</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbial Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> MMP</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Homology,Amino Acid</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2012">2012/4</year></dates><abstract><style face="normal" font="Arial">Collagenase Clostridium histolyticum (CCH) contains a fixed ratio of class I (AUX-I) and class II (AUX-II) collagenases and is used as treatment for Dupuytren's contracture. These two Zn-dependent enzymes, produced by the Gram-positive bacterium Clostridium histolyticum, are related functionally to matrix metalloproteinases (MMPs) which, among other functions, degrade the extracellular matrix. Since AUX-I and AUX-II exhibit sequence similarities to human MMPs, we assessed MMP-1 (interstitial collagenase), MMP-2 (gelatinase A), MMP-3 (stromelysin 1), MMP-8 (collagenase 2), and MMP-13 (collagenase 3) for cross-reactivity with anti-AUX-I and anti-AUX-II antibodies in patient serum. Serum samples from 71 subjects enrolled in a long-term clinical study (58 males and 13 females; 63 +/- 10 years old [mean +/- standard error]) were evaluated for cross-reactivity with the five MMPs using the two validated enzyme-linked immunosorbent assays (ELISAs). Inhibition cutoff points for anti-AUX-I and anti-AUX-II antibodies were based on assay inhibition obtained with a nonspecific protein, bovine gamma globulin, which was tested for each clinical sample. No MMP cross-reactivity was found for any of the 71 clinical antibody-positive sera evaluated. Sequence identity assessments indicated minimal, nonmeaningful alignments of the MMPs and AUX-I/AUX-II. Furthermore, clinical adverse event assessments indicated no safety signals related to MMP inhibition. The bioanalytical results, sequence identity, and clinical assessments consistently did not demonstrate cross-reactivity between CCH antidrug antibodies and endogenous human matrix metalloproteinases. The results presented here suggest that treatment of Dupuytren's contracture patients with CCH does not lead to any clinical adverse events associated with MMP inhibition</style></abstract><notes><style face="normal" font="Arial">DA - 20120330IS - 1556-679X (Electronic)IS - 1556-679X (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Antibodies, Bacterial)RN - EC 3.4.24.- (Matrix Metalloproteinases)RN - EC 3.4.24.3 (Microbial Collagenase)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1128/CVI.00018-12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="22357647">PM:22357647</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Vaccine Immunol\2012-19-562-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Vaccine Immunol\2012-19-562-9.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20120330, Edkins TJ</style></custom2><misc3><style face="normal" font="Arial">10.1128/CVI.00018-12</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shao,M.</style></author><author><style face="normal" font="Arial"> Hussain,Z.</style></author><author><style face="normal" font="Arial"> Thu,H.E.</style></author><author><style face="normal" font="Arial"> Khan,S.</style></author><author><style face="normal" font="Arial"> Katas,H.</style></author><author><style face="normal" font="Arial"> Ahmed,T.A.</style></author><author><style face="normal" font="Arial"> Tripathy,M.</style></author><author><style face="normal" font="Arial"> Leng,J.</style></author><author><style face="normal" font="Arial"> Qin,H.L.</style></author><author><style face="normal" font="Arial"> Bukhari,S.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmaceutical Engineering, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 205 Luoshi Road, Wuhan, 430070, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease</style></title><secondary-title><style face="normal" font="Arial">Colloids Surf B Biointerfaces</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Colloids Surf B Biointerfaces</style></full-title></periodical><pages end="491" start="475">475-491</pages><volume><style face="normal" font="Arial">147</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug delivery</style></keyword><keyword><style face="normal" font="Arial"> Drug Delivery Systems</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> liposome</style></keyword><keyword><style face="normal" font="Arial"> Liposomes</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> premature</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Retention time</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Solid lipid nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="8" Year="2016">2016/8/20</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier integrity. Pruritus, intense itching, psychological stress, deprived physical and mental performance and sleep disturbance are the hallmark features of this dermatological complication. Preventive interventions which include educational programs, avoidance of allergens, exclusive care towards skin, and the rational selection of therapeutic regimen play key roles in the treatment of dermatosis. In last two decades, it is evident from a plethora of studies that scientific focus is being driven from conventional therapies to the advanced nanocarrier-based regimen for an effective management of AD. These nanocarriers which include polymeric nanoparticles (NPs), hydrogel NPs, liposomes, ethosomes, solid lipid nanoparticles (SLNs) and nanoemulsion, provide efficient roles for the target specific delivery of the therapeutic payload. The success of these targeted therapies is due to their pharmaceutical versatility, longer retention time at the target site, avoiding off-target effects and preventing premature degradation of the incorporated drugs. The present review was therefore aimed to summarise convincing evidence for the therapeutic superiority of advanced nanocarrier-mediated strategies over the conventional therapies used in the treatment of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160904IS - 1873-4367 (Electronic)IS - 0927-7765 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - China -CO - Malaysia -CO - Pakistan -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.colsurfb.2016.08.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27592075">PM:27592075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Colloids Surf B Biointerfaces\2016-147-475-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Colloids Surf B Biointerfaces\2016-147-475-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160904, Shao M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.colsurfb.2016.08.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Portnoy,J.M.</style></author><author><style face="normal" font="Arial"> Williams,P.B.</style></author><author><style face="normal" font="Arial"> Barnes,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO, 64108, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Innate Immune Responses to Fungal Allergens</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="62">62-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> C-type lectin receptor</style></keyword><keyword><style face="normal" font="Arial"> C-type lectin receptors</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> fungal allergens</style></keyword><keyword><style face="normal" font="Arial"> fungal exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAMP</style></keyword><keyword><style face="normal" font="Arial"> pathogen-associated molecular pattern</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> PRR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TLRs</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: In this review, we describe innate immunity to fungi and the ability of pattern recognition receptors (PRRs) to recognize fungal-associated molecular patterns (FAMPs) and danger-associated molecular patterns (DAMPs). RECENT FINDINGS: Protective responses against fungal antigens can be divided into two parts: innate immunity and adaptive immunity. Detection of foreign substance by the innate immune system is mediated by a variety of genetically encoded receptors known as pattern recognition receptors (PRRs). These PRRs bind to PAMPs (pathogen-associated molecular patterns) and more specifically to fungal-associated molecular patterns or FAMPs on target microorganisms. They also bind to DAMPs (damage-associated molecular patterns) which are substances released due to tissue and cell damage. PRRs can be divided into several families including Toll-like receptors (TLRs), nucleotide-oligomerization domain (NOD)-like receptors (NLRs), and C-type lectin receptors. Fungal PRRs can respond to internal and external components found in fungi. In addition, a number of fungal products, including some fungal allergens, seem to mimic or represent DAMPs. Collectively, activation of these fungal PRRs alerts the innate immune system to the presence of fungal exposure and can promote both innate and adaptive immune responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0643-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27520938">PM:27520938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Portnoy JM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0643-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dominguez-Ortega,J.</style></author><author><style face="normal" font="Arial"> Barranco,P.</style></author><author><style face="normal" font="Arial"> Rodriguez-Perez,R.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, La Paz Institute for Health Research (IdiPAZ), Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Biomarkers in Occupational Asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="63">63-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adult asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene-environment</style></keyword><keyword><style face="normal" font="Arial"> gene-environment interaction</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> work-related asthma</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword><keyword><style face="normal" font="Arial"> Workplace exposure</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Work-related asthma is a common disorder among adult asthma patients, and in the case of occupational asthma, it is induced by workplace exposures. RECENT FINDINGS: Occupational asthma provides an excellent model and benchmark for identifying and testing different allergy or inflammatory biomarkers associated with its inception or progression. Moreover, specific inhalation challenge with the incriminated agent represents an experimental setting to identify and validate potential systemic or local biomarkers. Some biomarkers are mainly blood-borne, while local airway biomarkers are derived from inflammatory or resident cells. Genetic and gene-environment interaction studies also provide an excellent framework to identify relevant profiles associated with the risk of developing these work-related conditions. Despite significant efforts to identify clinically relevant inflammatory and genomic markers for occupational asthma, apart from the documented utility of airway inflammatory biomarkers, it remains elusive to define specific markers or signatures clearly associated with different endpoints or outcomes in occupational asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Madrid -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0644-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27520939">PM:27520939</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Dominguez-Ortega J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0644-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomas,W.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Telethon Kids Institute, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">House Dust Mite Allergens: New Discoveries and Relevance to the Allergic Patient</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="69">69-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Der p 23</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Recent findings on house dust allergens and their contribution to knowledge that will significantly impact on current and future allergy treatments are appraised. RECENT FINDINGS: Quantitation of IgE binding to a spectrum of allergen components in several independent studies in varying locations has largely affirmed the main components as the groups 1 and 2 and possibly 23 allergens with mid-tier contributions from the groups 4, 5, 7, and 21. Prevalent binding to Der p 23 has been recapitulated sometimes with low titers. The IgE of non-asthmatic atopic subjects binds at lower titer and to fewer components than that of asthmatics, and their IgG binding relative to IgE is higher especially for children hospitalized for exacerbation. The higher IgG ratios were associated with increased IL-10 a cytokine more readily induced from T cells of allergic subjects. Peptides representing the groups 1 and 2 allergens can be used to stimulate ex vivo T cells showing responses correlating with IgE binding and providing a valuable tool for ascertaining the contribution of IgE and T cells to disease. Also, the induction of Th2 and follicular helper T cells are shown to make different contributions in mice. Cross-reactivity of IgE binding assays with high-titer cross-reactive antibodies induced by scabies is a problem in the many areas of the world where scabies is highly prevalent and endemic and from recent increases in immigration. In the last few years, allergen research has produced results that warrant rapid translation into diagnostic tools and the formulation of allergen components for immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0649-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27600386">PM:27600386</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-69.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-69.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Thomas WR</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0649-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tan,H.T.</style></author><author><style face="normal" font="Arial"> Sugita,K.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Platz, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Novel Biologicals for the Treatment of Allergic Diseases and Asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="70">70-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> Biologicals</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Natural killer T cell</style></keyword><keyword><style face="normal" font="Arial"> natural killer T cells</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The development of biological therapies has rapidly progressed during the last few years, and major advances were reported for the treatment of allergic diseases, such as atopic dermatitis, allergic rhinitis, urticaria, food allergy, and asthma. Here, we review biologicals targeting the type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, natural killer T cells, mast cells, basophils, and epithelial cells, such as IL-4, IL-5, IL-13, IL-31, tumor necrosis factor alpha (TNF-alpha), and thymic stromal lymphopoietin (TSLP). RECENT FINDINGS: The biologicals that have been currently approved for asthma are omalizumab targeting IgE and reslizumab and mepolizumab targeting interleukin (IL)-5. Many other monoclonal antibodies are currently in various phases of clinical development. The new biological therapies for allergic diseases will eventually be tailored to the endotypes of these diseases and the identification of novel biomarkers. Further development of novel biologicals for the treatment of allergic diseases and asthma will be possible upon improved understanding of mechanisms of allergic diseases. Accordingly, further refinement of endotypes of allergen-specific and non-specific type 2 immune response and related inflammatory mediators is needed for optimal treatment of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Switzerland -CO - Malaysia -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0650-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613653">PM:27613653</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Tan HT</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0650-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Commins,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine &amp; Pediatrics, Thurston Research Center, Division of Rheumatology, Allergy and Immunology, University of North Carolina, 3300 Thurston Building, CB 7280, Chapel Hill, NC, 27599-7280, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Invited Commentary: Alpha-Gal Allergy: Tip of the Iceberg to a Pivotal Immune Response</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="61">61-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Scandinavia</style></keyword><keyword><style face="normal" font="Arial"> South America</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">The syndrome of delayed allergic reactions to the carbohydrate galactose-alpha-1,3-galactose ("alpha-gal") has become increasingly recognized in allergy and immunology clinics regionally throughout the southeastern USA. Due to the increasing awareness of this unique food allergy, cases have been identified in the northeastern and central USA as well as in Central and South America, Europe, Asia, Scandinavia, and Australia. Clinically, alpha-gal allergy is characterized by reactions to non-primate mammalian meat (e.g., beef, pork, lamb) that occur 3-6 h following exposure. The IgE response to alpha-gal is thought to develop after tick bites and can result in the loss of tolerance to foods that have been safely consumed for years. Although the initial description of alpha-gal allergy in 2009 was limited to red meat, this epitope is now identified in an expanded number of products, medications and foods-both labeled and unlabeled. Moreover, we are beginning to recognize that alpha-gal food allergy is the tip of the iceberg for this immune response</style></abstract><notes><style face="normal" font="Arial">DA - 20160813IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0641-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27520937">PM:27520937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160813, Commins SP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0641-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nony,E.</style></author><author><style face="normal" font="Arial"> Le Mignon,M.</style></author><author><style face="normal" font="Arial"> Brier,S.</style></author><author><style face="normal" font="Arial"> Martelet,A.</style></author><author><style face="normal" font="Arial"> Moingeon,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Stallergenes Greer, Research Department, 6 rue Alexis de Tocqueville, 92183, Antony cedex, France.</style></auth-address><titles><title><style face="normal" font="Arial">Proteomics for Allergy: from Proteins to the Patients</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="64">64-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Structural features</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Proteomics encompasses a variety of approaches unraveling both the structural features, post-translational modifications, and abundance of proteins. As of today, proteomic studies have shed light on the primary structure of about 850 allergens, enabling the design of microarrays for improved molecular diagnosis. Proteomic methods including mass spectrometry allow as well to investigate protein-protein interactions, thus yielding precise information on critical epitopes on the surface of allergens. Mass spectrometry is now being applied to the unambiguous identification, characterization, and comprehensive quantification of allergens in a variety of matrices, as diverse as food samples and allergen immunotherapy drug products. As such, it represents a method of choice for quality testing of allergen immunotherapy products</style></abstract><notes><style face="normal" font="Arial">DA - 20160818IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - France -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s11882-016-0642-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27534655">PM:27534655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160818, Nony E</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s11882-016-0642-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McCluskey,J.</style></author><author><style face="normal" font="Arial"> O'hehir,R.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Melbourne, Melbourne, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Editorial overview: Allergy and hypersensitivity</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - ENGPT - EDITORIALCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2016.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27623177">PM:27623177</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\20160913-McCluskeyJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\20160913-McCluskeyJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, McCluskey J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2016.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pali-Scholl,I.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinarplatz 1, 1210 Vienna, Austria. Electronic address: isabella.pali@meduniwien.ac.atComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinarplatz 1, 1210 Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">The concept of allergen-associated molecular patterns (AAMP)</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="118" start="113">113-118</pages><volume><style face="normal" font="Arial">42</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell receptor</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">For proteins to become allergenic, they need to acquire features enabling them to induce B cell activation and isotype switch to IgE production. Crosslinking of the B-cell receptor (BCR) is the most efficient way to productively activate B-cells. The IgE-crosslinking capability of allergens is equally crucial in the effector phase of immediate type allergy. Antigens, which acquire enhanced crosslinking capacity by oligomerization, aggregation, or the expression of repetitive epitopes may therefore gain allergenic potency. The accumulated evidence for repetitive epitope display by allergens suggests the existence of allergen-associated molecular patterns</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27619413">PM:27619413</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\2016-42-113-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\2016-42-113-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Pali-Scholl I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garg,M.K.</style></author><author><style face="normal" font="Arial"> Sharma,M.</style></author><author><style face="normal" font="Arial"> Agarwal,R.</style></author><author><style face="normal" font="Arial"> Aggarwal,A.</style></author><author><style face="normal" font="Arial"> Gupta,P.</style></author><author><style face="normal" font="Arial"> Sodhi,K.S.</style></author><author><style face="normal" font="Arial"> Chakrabarty,A.</style></author><author><style face="normal" font="Arial"> Khandelwal,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">[2:35:10 PM] marium shahab: Department of radiodiagnosis and imaging, PGIMER, Chandigarh, India. gargmandeep@hotmail.com</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Bronchopulmonary Aspergillosis: All A Radiologist Needs To Know</style></title><secondary-title><style face="normal" font="Arial">Curr Pediatr Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pediatr Rev</style></full-title></periodical><pages end="189" start="179">179-189</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis (ABPA) is an immunological lung disorder occurring due to hypersensitivity to fungus Aspergillus fumigatus. Early diagnosis of ABPA is desirable before the disease leads to irreversible damage and end stage lung disease. Diagnosis of ABPA is based upon a set of clinical, serological and radiological criteria. Radiology plays an important role not only in diagnosis but also in prognostication of the disease. However, a radiologist should also be familiar with the clinical spectrum and laboratory findings of the disease. In this article, we have reviewed clinical, serological and radiological aspects of ABPA, with emphasis on the radiological findings</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1875-6336 (Electronic)IS - 1573-3963 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27585455">PM:27585455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Pediatr Rev\2016-12-179-89.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Pediatr Rev\2016-12-179-89.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Garg MK</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81502</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tokura,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan</style></auth-address><titles><title><style face="normal" font="Arial">New Etiology of Cholinergic Urticaria</style></title><secondary-title><style face="normal" font="Arial">Curr Probl Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Probl Dermatol</style></full-title></periodical><pages end="100" start="94">94-100</pages><volume><style face="normal" font="Arial">51</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> Sweating</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Cholinergic urticaria (CholU) is characterized by pinpoint-sized, highly pruritic wheals occurring upon sweating. Both direct and indirect theories in the interaction of acetylcholine (ACh) with mast cells have been put forward in the sweating-associated histamine release from mast cells. In the mechanism of indirect involvement of ACh, patients are hypersensitive to sweat antigen(s) and develop wheals in response to sweat substances leaking from the syringeal ducts to the dermis, possibly by obstruction of the ducts. Some patients with CholU exhibit a positive reaction to intradermal injection of their own diluted sweat, representing 'sweat allergy (hypersensitivity)'. Regarding the direct interaction theory between ACh and mast cells, we found that CholU with anhidrosis and hypohidrosis lacks cholinergic receptor M3 (CHRM3) expression in eccrine sweat gland epithelial cells. The expression of CHRM3 is completely absent in the anhidrotic areas and lowly expressed in the hypohidrotic areas. In the hypohidrotic area, where CholU occurs, it is hypothesized that ACh released from nerves cannot be completely trapped by cholinergic receptors of eccrine glands and overflows to the adjacent mast cells, leading to wheals</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1662-2944 (Electronic)IS - 1421-5721 (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000446787</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27584968">PM:27584968</url></web-urls></urls><custom2><style face="normal" font="Arial">20160902, Tokura Y</style></custom2><misc3><style face="normal" font="Arial">10.1159/000446787</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hiragun,T.</style></author><author><style face="normal" font="Arial"> Hide,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sweat Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Probl Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Probl Dermatol</style></full-title></periodical><pages end="108" start="101">101-108</pages><volume><style face="normal" font="Arial">51</style></volume><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil histamine release</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Malassezia globosa</style></keyword><keyword><style face="normal" font="Arial"> Malassezia species</style></keyword><keyword><style face="normal" font="Arial"> MGL_1304</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> Sweat antigen</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tannic Acid</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">For many years, sweat has been recognized as an exacerbation factor in all age groups of atopic dermatitis (AD) and a trigger of cholinergic urticaria (CholU). Recently, we reported the improvement of AD symptoms by spray with tannic acid, which suppresses basophil histamine release by semipurified sweat antigens in vitro, and showering that removes antigens in sweat from the skin surface. We finally identified MGL_1304 secreted by Malassezia globosa as a major histamine-releasing antigen in human sweat. MGL_1304 is detected as a 17-kDa protein in sweat and exhibits almost the highest histamine-release ability from basophils of patients with AD and CholU among antigens derived from Malassezia species. Moreover, serum levels of anti-MGL_1304 IgE of patients with AD and CholU were significantly higher than those of normal controls. Desensitization therapy using autologous sweat or MGL_1304 purified from culture of M. globosa or its cognates might be beneficial for patients with intractable CholU due to sweat allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1662-2944 (Electronic)IS - 1421-5721 (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000446788</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27584969">PM:27584969</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160902, Hiragun T</style></custom2><misc3><style face="normal" font="Arial">10.1159/000446788</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thong,B.Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Prevention of Anaphylaxis Based on Risk Factors and Cofactors</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="223" start="212">212-223</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Anaphylaxis is most commonly caused by drugs, food, and hymenoptera stings, or in certain instances may be idiopathic. A variety of risk factors, cofactors, and augmenting factors may act together to trigger anaphylaxis. Patients with certain underlying medical conditions may be at increased risk of anaphylaxis of certain etiologies, e.g., monoclonal mast cell activation syndromes and insect venom anaphylaxis, asthma, and fatal food-induced anaphylaxis especially in adolescents. Identification of risk factors, cofactors, and augmenting factors during clinical assessment is key to determining the type of in vitro and in vivo diagnostic tests that would be most appropriate in accurately identifying the putative allergen(s). Provocation tests, despite being the gold standard in allergy diagnosis, should be avoided in anaphylaxis as the risks outweigh the benefits. Accurate diagnosis of the putative allergen and cofactor is key to both prevention of recurrence of anaphylaxis, avoidance measures, and interventions like allergen-specific immunotherapy, which may impact the quality of life of allergy sufferers and their family members</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0095-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0095-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-212-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-212-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Thong BY</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0095-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Current Trends in Prevalence and Mortality of Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="211" start="205">205-211</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">It has not been until the last decade that we have gained insight to the global epidemiology of anaphylaxis, due to the methodological difficulties of such studies. Heterogeneity in definitions, severity grading and study designs have hampered compiling robust data which can be consistently analysed and compared. Also, previous International Classification of Diseases coding for anaphylaxis has been suboptimal further hindering epidemiological studies. Under-diagnosis is still a major pitfall in anaphylaxis, despite the efforts of national and international scientific societies to improve education of all health care professionals and implement clinical practice guidelines. Further collaborative projects are needed to overcome this gap. Currently, it seems that worldwide incidence of anaphylaxis and admission rates are increasing both in children and adults, according to recent studies. This may be partly due to an improvement in recognition, but most likely, due to a rise in allergic diseases in general and of food and drug allergy in particular. On the other hand, fatality rates seem to remain stable or to decrease slightly. We optimistically could hypothesize that this is a result of improved management, both acutely and in the long-term, but published data are still scarce. Prevention strategies are needed in order to halt this scaling trend; ongoing education on recognition and treatment will aid to improve anaphylaxis outcomes</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0094-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0094-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-205-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-205-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Ansotegui IJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0094-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Redmond,M.T.</style></author><author><style face="normal" font="Arial"> Wada,K.J.</style></author><author><style face="normal" font="Arial"> Hauswirth,D.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pediatric Allergic Rhinitis: the Stepwise Treatment Approach</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="267" start="253">253-267</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental controls</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Treatment of allergic rhinitis in children requires a thoughtful, stepwise approach. Before considering medication for rhinitis, possibly chronic medication, you must (1) confirm disease based on symptoms or testing for offending allergens, (2) implement environmental controls when possible, (3) understand how allergy medication will affect children, and (4) recognize the need to use the minimum amount of medicine necessary to treat symptoms. Special attention to the impact of medication on school performance and social interactions is important when treating children. For intermittent symptoms, an oral antihistamine should be tried first. Chronic symptoms will respond best to a topical nasal steroid spray. Spending the time to figure out what most troubles the child will focus therapy (such as an antihistamine eye drop when ocular itching is a primary symptom) and prevent use of unnecessary medication. Moving past medication to immunotherapy is an important next step as we look for ways to change the natural course of atopic disease. There are now multiple approved forms of immunotherapy in the USA; this should allow a tailored approach to treating symptoms that have progressed beyond pharmacologic therapy. These layers of therapy, environmental control, pharmacologic management focused on bothersome symptoms, and immunotherapy, naturally allow for escalation of treatment with increasing symptoms. Working with the parents is imperative to fully understand the impact symptoms are having on the child and to achieve compliance with medications. This combined, stepwise approach will lead to good relief for the child and satisfaction among both parents and treating physician</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0092-2</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0092-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-253-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-253-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Redmond MT</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0092-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jhamnani,R.D.</style></author><author><style face="normal" font="Arial"> Frischmeyer-Guerrerio,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Desensitization for Peanut Allergies in Children</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="291" start="282">282-291</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Immunotherapy for peanut allergy has been an exploding topic of study within the last few years. Sublingual, epicutaneous, and oral immunotherapy are being investigated and show promise in the treatment of peanut allergy. Oral immunotherapy has shown the most clinical benefit; however, sublingual and epicutaneous immunotherapy appear to have the most favorable safety profiles. Most studies to date suggest that only a minority of subjects achieve sustained unresponsiveness to peanut after discontinuation of immunotherapy. Recent efforts have been focused on identifying adjunct therapies, such as omalizumab, that may assist patients in achieving peanut desensitization more quickly and with greater success. Several underlying immunologic mechanisms, including a switch from IgE to IgG4 production and induction of T regulatory cells, have been studied although more research is needed to identify reliable biomarkers. This article will describe the immunotherapy approaches that are being investigated to induce peanut desensitization, and highlight the benefits and risks of these therapies that need to be considered before they are ready for routine clinical practice</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s40521-016-0091-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0091-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-282-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-282-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Jhamnani RD</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s40521-016-0091-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Badellino,H.</style></author><author><style face="normal" font="Arial"> Jares,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Advances in Food-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="234" start="224">224-234</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Anaphylaxis is a potentially life-threatening severe systemic reaction and food allergy is one of its most frequent causes. Diagnosis of food-induced anaphylaxis requires diagnostic criteria for anaphylaxis based on clinical features and a comprehensive history. Adrenaline is a first-line treatment along with support measures. Epinephrine (adrenaline) is the first choice drug in anaphylaxis because it is the only medication that has been proved to reduce hospitalization and death. Long-term treatment based on an accurate identification of the anaphylaxis trigger, a clear education and training of the patients, their family and the community, under the coordination of a trained allergist, is strongly recommended in order to avoid future events</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0093-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0093-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-224-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-224-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Badellino H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0093-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,S.S.</style></author><author><style face="normal" font="Arial"> Ledford,D.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Killer Insects: Who Is at Risk for Anaphylaxis From Insect Stings?</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="242" start="235">235-242</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect allergy</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Patients who have had an anaphylactic reaction to stinging insect should be educated on the potential of fatality from venom allergy. These patients should be referred to an allergist/immunologist, a specialist with training in the diagnosis and management of stinging insect allergy. The three tenets of treatment for stinging insect allergy are insect avoidance measures, proper use of epinephrine, and insect immunotherapy. Avoidance is ideal but not always practical. Intramuscular epinephrine is the only effective therapy for anaphylaxis. Insect immunotherapy is proven to reduce the probability of anaphylaxis with repeat stings from approximately 60-á% to less than 5-á%. This reduction is not only potentially life-saving but also improves quality of life and reduces anxiety. Before starting immunotherapy, clinicians should have a discussion with patients regarding their goals of care, disease-specific anxiety level, comorbid conditions, and possible compliance issues</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0086-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0086-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-235-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-235-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Patel SS</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0086-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaplan,F.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Indiana Hand to Shoulder Center, Indianapolis, USA. tdk@hand.md</style></auth-address><titles><title><style face="normal" font="Arial">Collagenase clostridium histolyticum injection for the treatment of Dupuytren's contracture</style></title><secondary-title><style face="normal" font="Arial">Drugs Today (Barc)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs Today (Barc)</style></full-title></periodical><pages end="667" start="653">653-667</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clo hi Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Clostridium histolyticum</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Interactions</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Dupuytren Contracture</style></keyword><keyword><style face="normal" font="Arial"> enzymology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Injections,Intralesional</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbial Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shoulder</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2011">2011/9</year></dates><abstract><style face="normal" font="Arial">Collagenase clostridium histolyticum is a novel treatment for Dupuytren's contracture, approved by the U.S. Food and Drug Administration in February 2010. Prior to its availability, surgery was the only treatment for contracture related to this disorder. Dupuytren's disease is a benign, progressive fibroproliferative disorder affecting the palms of the hands. It is characterized by the formation of collagen- rich nodules and cords, which gradually shorten by the action of myofibroblasts, resulting in finger contractures. Intralesional use of clostridial collagenase has been evaluated in a total of 1,082 patients receiving 2,630 injections during its clinical development, including 2 large prospective, randomized, double-blind, placebo-controlled trials: Collagenase Option for Reduction of Dupuytren's I (CORD I) and CORD II. Both studies showed a statistically significant reduction in contracture compared to placebo and treatment was well-tolerated with the majority of adverse events self-limited. Serious adverse events related to collagenase activity were rare. Maximal improvement was seen in patients with less severe contractures and with contractures of the metacarpophalangeal joint. This first-in-class biologic, injectable clostridial collagenase histolyticum, provides a safe, effective alternative to surgery for patients with Dupuytren's contracture</style></abstract><notes><style face="normal" font="Arial">DA - 20111005IS - 1699-3993 (Print)IS - 1699-3993 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - ReviewRN - EC 3.4.24.3 (Microbial Collagenase)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1358/dot.2011.47.9.1656502</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="21971540">PM:21971540</url></web-urls><pdf-urls><url ppv-ref="no">tdk@hand.md</url></pdf-urls></urls><custom1><style face="normal" font="Arial">1D</style></custom1><custom2><style face="normal" font="Arial">20111005, Kaplan FT</style></custom2><misc3><style face="normal" font="Arial">10.1358/dot.2011.47.9.1656502</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Radon,K.</style></author><author><style face="normal" font="Arial"> Nowak,D.</style></author><author><style face="normal" font="Arial"> Vogelberg,C.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, AllergieZENTRUM, Klinikum der Universitat Munchen, Comprehensive Pneumology Center, DZL, Deutsches Zentrum fur Lungenforschung, Munchen, Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Department of Dermatology and Allergology, AllergieZENTRUM, Klinikum der Universitat Munchen</style></auth-address><titles><title><style face="normal" font="Arial">Career Advice for Young Allergy Patients</style></title><secondary-title><style face="normal" font="Arial">Dtsch Arztebl Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dtsch Arztebl Int</style></full-title></periodical><pages end="524" start="519">519-524</pages><volume><style face="normal" font="Arial">113</style></volume><number><style face="normal" font="Arial">31-32</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> exposure reduction</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> Laboratory animals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: One-third of all young persons entering the work force have a history of atopic disease. Occupationally induced allergy and asthma generally arise in the first few months on the job, while pre-existing symptoms tend to worsen. Young persons with a history of an atopic disease should receive evidence-based advice before choosing a career. METHODS: We systematically searched PubMed for cohort studies investigating the new onset of asthma, rhinitis, or hand eczema among job trainees from before the start of training and onward into the first few years on the job. The search revealed 514 articles; we read their abstracts and selected 85 full-text articles for further analysis. 24 of these met the inclusion criteria. RESULTS: According to present evidence, atopy and a history of allergic disease (allergic rhinitis, atopic dermatitis) are the main risk factors for occupationally induced disease. The predictive value of a personal history of allergic diseases for the later development of an occupationally induced disease varies from 9% to 64% in the studies we analyzed. It follows that only young people with severe asthma or severe atopic eczema should be advised against choosing a job that is associated with a high risk of allergy, e.g., hairdressing or working with laboratory animals. Young people with a history of other atopic diseases should be counseled about their individual risk profile. CONCLUSION: In view of the relatively poor predictive value of pre-existing atopic disease, secondary prevention is particularly important. This includes frequent medical follow-up of the course of symptoms over the first few years on the job. If sensitization or allergic symptoms arise, it should be carefully considered whether exposure reduction will enable the apprentice to stay on the job</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1866-0452 (Electronic)IS - 1866-0452 (Linking)LA - engPT - Journal ArticleSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3238/arztebl.2016.0519</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27581504">PM:27581504</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dtsch Arztebl Int\2016-113-519-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dtsch Arztebl Int\2016-113-519-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Radon K</style></custom2><misc3><style face="normal" font="Arial">10.3238/arztebl.2016.0519</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gabb,H.A.</style></author><author><style face="normal" font="Arial"> Blake,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate School of Library and Information Science, University of Illinois at Urbana-Champaign, Champaign, Illinois, USA</style></auth-address><titles><title><style face="normal" font="Arial">Response to "Comment on 'An Informatics Approach to Evaluating Combined Chemical Exposures from Consumer Products: A Case Study of Asthma-Associated Chemicals and Potential Endocrine Disruptors'"</style></title><secondary-title><style face="normal" font="Arial">Environ Health Perspect</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Health Perspect</style></full-title></periodical><pages end="" start="A156">A156-</pages><volume><style face="normal" font="Arial">124</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">case study</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Information Science</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1552-9924 (Electronic)IS - 0091-6765 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1289/EHP778</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27581111">PM:27581111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Health Perspect\2016-124-A156.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Health Perspect\2016-124-A156.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Gabb HA</style></custom2><misc3><style face="normal" font="Arial">10.1289/EHP778</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ait,B.Y.</style></author><author><style face="normal" font="Arial"> Araki,A.</style></author><author><style face="normal" font="Arial"> Kawai,T.</style></author><author><style face="normal" font="Arial"> Tsuboi,T.</style></author><author><style face="normal" font="Arial"> Saito,I.</style></author><author><style face="normal" font="Arial"> Yoshioka,E.</style></author><author><style face="normal" font="Arial"> Cong,S.</style></author><author><style face="normal" font="Arial"> Kishi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hokkaido University Center for Environmental and Health Sciences, Kita 12, Nishi 7, Kita-ku, Sapporo 060-0812, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Exposure to phthalates in house dust and associated allergies in children aged 6-12years</style></title><secondary-title><style face="normal" font="Arial">Environ Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Int</style></full-title></periodical><pages end="23" start="16">16-23</pages><volume><style face="normal" font="Arial">96</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Household Products</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> phthalates</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">Phthalates are widely used as plasticizers in household products. Several studies have reported an association between phthalate exposure and an increased risk of allergies. The present study estimated phthalate exposure in children aged 6-12years and assessed potential correlations with allergies. House dust samples were collected from floors and multi-surface objects >35cm above the floor. Urine samples were collected from the first morning void of the day. Daily phthalate intake (DIdust and DI) was estimated using both house dust and urinary metabolite concentrations. Exposure to di-2-ethylhexyl phthalate (DEHP) in floor dust was associated with parental-reported rhino-conjunctivitis. After stratification by gender, this trend was found to only occur in boys. Furthermore, urinary mono-isobutyl phthalate was inversely associated with parental-reported wheeze in boys. DIdust of benzyl butyl phthalate (BBzP) and DEHP were significantly correlated with DI_BBzP and DI_DEHP, respectively. These correlations were stronger with floor than with multi-surface dust. Our results suggest that, among Japanese children, house dust from low surfaces, such as living room floors, might play a meaningful role in the indoor environmental exposure pathway for BBzP and DEHP</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1873-6750 (Electronic)IS - 0160-4120 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envint.2016.08.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27588698">PM:27588698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Int\2016-96-16-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Int\2016-96-16-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Ait BY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envint.2016.08.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Depciuch,J.</style></author><author><style face="normal" font="Arial"> Kasprzyk,I.</style></author><author><style face="normal" font="Arial"> Roga,E.</style></author><author><style face="normal" font="Arial"> Parlinska-Wojtan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Nuclear Physics Polish Academy of Sciences, 31342, Krakow, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of morphological and molecular composition changes in allergenic Artemisia vulgaris L. pollen under traffic pollution using SEM and FTIR spectroscopy</style></title><secondary-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></full-title></periodical><pages end="23214" start="23203">23203-23214</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">22</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plant</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Artemisia vulgaris</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> FTIR</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infrared spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> mugwort pollen</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> traffic</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2016">2016/9/7</year></dates><abstract><style face="normal" font="Arial">Nowadays, pollen allergy becomes an increasing problem for human population. Common mugwort (Artemisia vulgaris L.) is one of the major allergenic plants in Europe. In this study, the influence of air pollution caused by traffic on the structure and chemical composition of common mugwort pollen was investigated. Scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), and curve-fitting analysis of amide I profile was applied to assess the morphological and structural changes of mugwort pollen grains collected from sites with different vehicle pollution levels. Microscopic observations support the conclusion, that the higher the car traffic, the smaller the pollen grains. The obtained results clearly show that air pollution had an impact on different maximum absorbance values of individual functional groups composing the chemical structure of pollen. Moreover, air pollution induced structural changes in macromolecules of mugwort pollen. In pollen collected from the unpolluted site, the content of sporopollenin (850 cm-1) was the highest, whereas polysaccharide concentration (1032 cm-1) was the lowest. Significant differences were observed in lipids. Pollen collected from the site with heavy traffic had the lowest content of lipids at 1709, 2071, and 2930 cm-1. The largest differences were observed in the spectra regions corresponding to proteins. In pollen collected from unpolluted site, the highest level of beta-sheet (1600 cm-1) and alpha-helix (1650 cm-1) was detected. The structural changes in proteins, observed in the second derivative of the FTIR spectrum and in the curve-fitting analysis of amide I profile, could be caused inter alia by air pollutants. Alterations in protein structure and in their content in the pollen may increase the sensitization and subsequent risk of allergy in predisposed people. The obtained results suggest that the changes in chemical composition of pollen may be a good indicator of air quality and that FTIR may be successfully applied in biomonitoring</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 1614-7499 (Electronic)IS - 0944-1344 (Linking)LA - ENGPT - JOURNAL ARTICLECO - POland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11356-016-7554-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27604125">PM:27604125</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20160908-DepciuchJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20160908-DepciuchJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Depciuch J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11356-016-7554-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez Mosquera,M.</style></author><author><style face="normal" font="Arial"> Sola Martinez,F.J.</style></author><author><style face="normal" font="Arial"> Montoro de Francisco,A.</style></author><author><style face="normal" font="Arial"> Chivato,P.T.</style></author><author><style face="normal" font="Arial"> Sanchez Moreno,V.</style></author><author><style face="normal" font="Arial"> Rodriguez-Marco,A.</style></author><author><style face="normal" font="Arial"> Hernandez-Pena,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Universitario Puerta de Hierro Majadahonda, Servicio de Alergia, Majadahonda, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Satisfaction and perceived effectiveness in patients on subcutaneous immunotherapy with a high-dose hypoallergenic pollen extract</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="193" start="188">188-193</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">This study was designed to determine the level of satisfaction, tolerance and perceived effectiveness by patients in the first pollen season after starting treatment with Alergovit((R)). For this purpose, a nationwide, retrospective, multicentre and cross-sectional observational study was carried on 256 patients. Perceived effectiveness by the patients was measured using a visual analogue scale and was clinically significant in 92.4% of the patients. The satisfaction level was evaluated with a specific questionnaire. 32.5% of the patients were totally satisfied with Allergovit((R)) and 48.8% reported a high degree of satisfaction. The treatment was well tolerated by 99.2% of the patients. Our results demonstrate that subcutaneous immunotherapy with Allergovit((R)) is effective and well-tolerated in routine clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleSB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27608475">PM:27608475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-188-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-188-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Rodriguez Mosquera M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vassilopoulou,E.</style></author><author><style face="normal" font="Arial"> Efthymiou,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Diet and Nutrition, Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.</style></auth-address><titles><title><style face="normal" font="Arial">Milk hypersensitivities: where is the grey line regarding their dietary management?</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="173" start="164">164-173</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cyprus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">The proportion of people suffering or reporting to have a hypersensitivity caused by cow's milk consumption is increasing, and even health professionals often face difficulties into elaborating properly with a milk reaction due to misdiagnosis. The scope of this review is to present literature data that lead into putting the border line between cow's milk allergy and cow's milk intolerance, mainly focusing on how the different pathophysiology leads to their different dietary diagnosis and management</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Cyprus -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27608472">PM:27608472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-164-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-164-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Vassilopoulou E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Konstantinou,G.N.</style></author><author><style face="normal" font="Arial"> Chioti,A.G.</style></author><author><style face="normal" font="Arial"> Daniilidis,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.</style></auth-address><titles><title><style face="normal" font="Arial">Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="207" start="205">205-207</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Omalizumab has been recently approved for treating patients with refractory to H1- antihistamines chronic spontaneous urticaria (CSU). Although hair loss is listed among omalizumab side effects, there are no available data to estimate its frequency. We describe for the first time hair loss as a side effect associated with omalizumab administration in three women, 38, 62 and 70 years old, suffering from refractory to H1-antihistamines CSU. This information was retrieved from their Chronic Urticaria Quality of Life Questionnaires. Despite this side effect, all patients agreed to continue omalizumab regular administration. Hair loss appeared to be transient, lasting up to four months. All cases finally benefited from omalizumab continuation</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleSB - IMCO - Greece -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27608479">PM:27608479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-205-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-205-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Konstantinou GN</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sunzini,F.</style></author><author><style face="normal" font="Arial"> Barbato,C.</style></author><author><style face="normal" font="Arial"> Canofari,C.</style></author><author><style face="normal" font="Arial"> Lugari,L.</style></author><author><style face="normal" font="Arial"> Perricone,R.</style></author><author><style face="normal" font="Arial"> Bergamini,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Clinical and radiological signs of ABPA associated with airways infection with Aspergillus in the absence of specific IgE</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="204" start="202">202-204</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus infection</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to Aspergillus that mainly affects patients with asthma. For diagnosis, elevated serum IgE level are needed according to Greenberger and Patterson criteria. We report a case of 43 years-old woman who developed ABPA with productive cough, fever and radiological findings of multiple confluent areas of consolidation in both upper lobes. Laboratory tests showed elevated peripheral eosinophil counts (9.3 x 10(3)/ml). In bronchial washing A. galactomannans and A. Fumigatus were isolated, although we found normal levels of serum IgE, and the absence of serum IgG and IgE antibodies to Aspergillus and A. galactomannans. In conclusion, clinical and radiological signs of ABPA can be associated with Aspergillus infection also in the absence of a specific serum antibody reaction</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27608478">PM:27608478</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-202-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-202-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Sunzini F</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Padua,I.</style></author><author><style face="normal" font="Arial"> Moreira,A.</style></author><author><style face="normal" font="Arial"> Moreira,P.</style></author><author><style face="normal" font="Arial"> Barros,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Nutrition and Food Sciences, University of Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy: practical approach on education and accidental exposure prevention</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="181" start="174">174-181</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental exposure</style></keyword><keyword><style face="normal" font="Arial"> Airplanes</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Cross-contact</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food label</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> restaurant</style></keyword><keyword><style face="normal" font="Arial"> Restaurants</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Food allergies are a growing problem and currently the primary treatment of food allergy is avoidance of culprit foods. However, given the lack of information and education and also the ubiquitous nature of allergens, accidental exposures to food allergens are not uncommon. The fear of potential fatal reactions and the need of a proper avoidance leads in most of the cases to the limitation of leisure and social activities. This review aims to be a practical approach on education and accidental exposure prevention regarding activities like shopping, eating out, and travelling. The recommendations are focused especially on proper reading of food labels and the management of the disease, namely in restaurants and airplanes, concerning cross-contact and communication with other stakeholders. The implementation of effective tools is essential to manage food allergy outside home, avoid serious allergic reactions and minimize the disease's impact on individuals' quality of life</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27608473">PM:27608473</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-174-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-174-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Padua I</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nettis,E.</style></author><author><style face="normal" font="Arial"> Di Leo,E.</style></author><author><style face="normal" font="Arial"> Pastore,A.</style></author><author><style face="normal" font="Arial"> Distaso,M.</style></author><author><style face="normal" font="Arial"> Zaza,I.</style></author><author><style face="normal" font="Arial"> Vacca,M.</style></author><author><style face="normal" font="Arial"> Macchia,L.</style></author><author><style face="normal" font="Arial"> Vacca,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, University of Bari Policlinico, Piazza Giulio Cesare 11, 70124 Bari, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Probiotics and refractory chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="187" start="182">182-187</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium breve</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Background. In chronic spontaneous urticaria (CSU) first-line therapy with an antihistamine-based regimen may not achieve satisfactory control in patients. Thus, a continuing need exists for effective and safe treatments for refractory CSU. Aim. To evaluate the clinical efficacy and safety of an intake of a combination of 2 probiotics (Lactobacillus salivarius LS01 and Bifidobacterium breve BR03) in patients with CSU who remain symptomatic despite concomitant H1-antihistamine therapy. Methods. This report analyzes the effects of therapy with two probiotic strains on the clinical progress of 52 unselected patients with difficulty to treat CSU underwent to medical examination in two Italian specialist urticaria Clinics between September 2013 and September 2014. A mixture of Lactobacillus LS01 and Bifidobacterium BR03 were administered in each patient twice daily for 8 weeks. To evaluate patients' improvement with probiotics, urticaria activity score over 7 days (UAS7) was used at baseline and at week 8 in addition to a 5-question urticaria quality of life questionnaire. Results. Fifty-two patients with CSU were included in this study (10 male and 42 female, age range 19-72 years). Mean disease duration was 1.5 years. Fourteen patients discontinued treatment, so evaluable population consisted of 38 patients. Nine of the 38 patients experienced mild clinical improvement during probiotic treatment (23.7%); one patient reported significant clinical improvement (2.6%) and one patient had complete remission of urticaria (2.6%). Twenty-seven patients did not have improvement in symptoms (71.1%). No side effects during the course of therapy were reported. Conclusions. A combination of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03 administered twice daily for 8 weeks might reduce the symptoms scores and improve quality of life scores in a part of patients with CSU who remained symptomatic despite treatment with H1 antihistamine mostly in subjects with allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27608474">PM:27608474</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-182-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-182-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Nettis E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thompson,T.</style></author><author><style face="normal" font="Arial"> Lyons,T.B.</style></author><author><style face="normal" font="Arial"> Jones,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Gluten Free Watchdog, Manchester, MA, USADepartment of Clinical Nutrition, MetroHealth Medical Center, Cleveland, OH, USAMary Rutan Hospital Nutrition, Bellefontaine, OH, USA</style></auth-address><titles><title><style face="normal" font="Arial">Allergen advisory statements for wheat: do they help US consumers with celiac disease make safe food choices?</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Nutr</style></full-title></periodical><pages end="1347" start="1341">1341-1347</pages><volume><style face="normal" font="Arial">70</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="14" Month="9" Year="2016">2016/9/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1476-5640 (Electronic)IS - 0954-3007 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/ejcn.2016.155</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27623978">PM:27623978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Nutr\20160914-ThompsonT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Nutr\20160914-ThompsonT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Thompson T</style></custom2><misc3><style face="normal" font="Arial">10.1038/ejcn.2016.155</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fuchs,S.</style></author><author><style face="normal" font="Arial"> Kaiser-Labusch,P.</style></author><author><style face="normal" font="Arial"> Bank,J.</style></author><author><style face="normal" font="Arial"> Ammann,S.</style></author><author><style face="normal" font="Arial"> Kolb-Kokocinski,A.</style></author><author><style face="normal" font="Arial"> Edelbusch,C.</style></author><author><style face="normal" font="Arial"> Omran,H.</style></author><author><style face="normal" font="Arial"> Ehl,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Tyrosine kinase 2 is not limiting human antiviral type III interferon responses</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="2649" start="2639">2639-2649</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abscess</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine receptor</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-10 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferons</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> TYK2</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword></keywords><dates><year Day="12" Month="9" Year="2016">2016/9/12</year></dates><abstract><style face="normal" font="Arial">Tyrosine kinase 2 (TYK2) associates with interferon (IFN) alpha receptor, IL-10 receptor (IL-10R) beta and other cytokine receptor subunits for signal transduction, in response to various cytokines including type I and type III interferons, IL-6, IL-10, IL-12 and IL-23. Data on TYK2 dependence on cytokine responses and in vivo consequences of TYK2 deficiency are inconsistent. We investigated a TYK2 deficient patient, presenting with eczema, skin abscesses, respiratory infections and IgE levels >1000 U/ml, without viral or mycobacterial infections and a corresponding cellular model to analyze the role of TYK2 in type III IFN mediated responses and NK-cell function. We established a novel simple diagnostic monocyte assay to show that the mutation completely abolishes the IFN-alpha mediated antiviral response. It also partly reduces IL-10 but not IL-6 mediated signaling associated with reduced IL-10Rbeta expression. However, we found almost normal type III IFN signaling associated with minimal impairment of virus control in a TYK2 deficient human cell line. Contrary to observations in TYK2 deficient mice, NK-cell phenotype and function, including IL-12/IL-18 mediated responses, were normal in the patient. Thus, preserved type III IFN responses and normal NK-cell function may contribute to antiviral protection in TYK2 deficiency leading to a surprisingly mild human phenotype. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201646519</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27615517">PM:27615517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20160912-FuchsS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\20160912-FuchsS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Fuchs S</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201646519</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gur,L.</style></author><author><style face="normal" font="Arial"> Reuveni,M.</style></author><author><style face="normal" font="Arial"> Cohen,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Occurrence and etiology of Alternaria leaf blotch and fruit spot of apple caused by Alternaria alternata f. sp. mali on cv. Pink lady in Israel</style></title><secondary-title><style face="normal" font="Arial">Eur J Plant Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Plant Pathol</style></full-title></periodical><pages end="708" start="695">695-708</pages><volume><style face="normal" font="Arial">147</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> apple cultivars</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Suspensions</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-8469</style></isbn><abstract><style face="normal" font="Arial">Severe outbreaks of Alternaria leaf blotch and fruit spot were recently observed in cv. Pink Lady apples in northern Israel, especially on fruit. Such severe outbreaks have not been reported from other countries. Symptoms involved cracks and rot around the calyx and external rot of the fruit body. Up to 80-á% of the fruit in some orchards were affected by the disease. Microscopic examinations, fulfillment of Koch</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs postulates and molecular (genetic) analyses confirmed the causal agent as Alternaria alternata f. sp. mali. The incidence of Alternaria increased as the degree of calyx cracking increased, or if fruit were both cracked and rotted. Injecting spore suspensions into the fruit produced typical rot symptoms. Injection assays of detached fruit of eight apple cultivars showed that cvs. Pink Lady and Golden Delicious were susceptible whereas cv. Jonathan was resistant. Pink Lady and Golden Delicious produced more fruit rot as the inoculum concentration increased. Rot in all three cultivars was moderate close to the skin but more severe close to the seed locule. Aqueous extracts taken from Jonathan fruit peel inhibited germ tube elongation of A. alternata f. sp. mali in vitro. This is the first report on heavy infection of Pink Lady fruit in Israel caused by A. alternata f. sp. mali</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10658-016-1037-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10658-016-1037-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Plant Pathol\20160912-GurL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Plant Pathol\20160912-GurL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Gur L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10658-016-1037-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,S.</style></author><author><style face="normal" font="Arial"> Chung,H.S.</style></author><author><style face="normal" font="Arial"> Shin,D.</style></author><author><style face="normal" font="Arial"> Jung,K.H.</style></author><author><style face="normal" font="Arial"> Lee,H.</style></author><author><style face="normal" font="Arial"> Moon,J.</style></author><author><style face="normal" font="Arial"> Bae,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Science in Korean Medicine, Kyung Hee University, Dongdaemoon-gu, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Adenovirus-mediated Foxp3 expression in lung epithelial cells reduces airway inflammation in ovalbumin and cockroach-induced asthma model</style></title><secondary-title><style face="normal" font="Arial">Exp Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Exp Mol Med</style></abbr-1></periodical><pages end="" start="e259">e259-</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenovirus</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Diphtheria</style></keyword><keyword><style face="normal" font="Arial"> Diphtheria Toxin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Hypertrophy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Foxp3 is a master regulator of CD4(+)CD25(+) regulatory T-cell (Treg) function and is also a suppressor of SKP2 and HER2/ErbB2. There are an increasing number of reports describing the functions of Foxp3 in cell types other than Tregs. In this context, we evaluated the functions of Foxp3 in ovalbumin- and cockroach-induced asthma models. Foxp3-EGFP-expressing adenovirus or EGFP control adenovirus was administered intratracheally (i.t.), followed by challenge with ovalbumin (OVA) or cockroach extract to induce asthma. Th2 cytokine and immune cell profiles of bronchoalveolar lavage fluid (BALF), as well as serum IgE levels, were analyzed. Histological analyses were also conducted to demonstrate the effects of Foxp3 expression on airway remodeling, goblet cell hyperplasia and inflammatory responses in the lung. Adenoviral Foxp3 was expressed only in lung epithelial cells, and not in CD4(+) or CD8(+) cells. BALF from Foxp3 gene-delivered mice showed significantly reduced numbers of total immune cells, eosinophils, neutrophils, macrophages and lymphocytes in response to cockroach allergen or OVA. In addition, Foxp3 expression in the lung reduced the levels of Th2 cytokines and IgE in BALF and serum, respectively. Moreover, histopathological analysis also showed that Foxp3 expression substantially inhibited eosinophil infiltration into the airways, goblet cell hyperplasia and smooth muscle cell hypertrophy. Furthermore, when Tregs were depleted by diphtheria toxin in Foxp3(DTR) mice, the anti-asthmatic functions of Foxp3 were not altered in OVA-challenged asthma models. In this study, our results suggest that Foxp3 expression in lung epithelial cells, and not in Tregs, inhibited OVA- and cockroach extract-induced asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 2092-6413 (Electronic)IS - 1226-3613 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1038/emm.2016.83</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27633092">PM:27633092</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Mol Med\2016-48-e259.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Mol Med\2016-48-e259.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Park S</style></custom2><misc3><style face="normal" font="Arial">10.1038/emm.2016.83</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Avila,G.</style></author><author><style face="normal" font="Arial"> Bazan-Perkins,B.</style></author><author><style face="normal" font="Arial"> Sandoval,C.</style></author><author><style face="normal" font="Arial"> Sommer,B.</style></author><author><style face="normal" font="Arial"> Vadillo-Gonzalez,S.</style></author><author><style face="normal" font="Arial"> Ramos,C.</style></author><author><style face="normal" font="Arial"> Aquino-Galvez,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biomedical Oncology Laboratory, Department of Chronic-Degenerative Diseases, National Institute of Respiratory Diseases 'Ismael Cosio Villegas', CP 14080 Mexico City, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Interstitial collagen turnover during airway remodeling in acute and chronic experimental asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="1427" start="1419">1419-1427</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Collagen content</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mexico City</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Asthma airway remodeling is characterized by the thickening of the basement membrane (BM) due to an increase in extracellular matrix (ECM) deposition, which contributes to the irreversibility of airflow obstruction. Interstitial collagens are the primary ECM components to be increased during the fibrotic process. The aim of the present study was to examine the interstitial collagen turnover during the course of acute and chronic asthma, and 1 month after the last exposure to the allergen. Guinea pigs sensitized to ovalbumin (OVA) and exposed to 3 further OVA challenges (acute model) or 12 OVA challenges (chronic model) were used as asthma experimental models. A group of animals from either model was sacrificed 1 h or 1 month after the last OVA challenge. Collagen distribution, collagen content, interstitial collagenase activity and matrix metalloproteinase (MMP)-1, MMP-13 and tissue inhibitor of metalloproteinase (TIMP)-1 protein expression levels were measured in the lung tissue samples from both experimental models. The results revealed that collagen deposit in bronchiole BM, adventitial and airway smooth muscle layers was increased in both experimental models as well as lung tissue collagen concentration. These structural changes persisted 1 month after the last OVA challenge. In the acute model, a decrease in collagenase activity and in MMP-1 concentration was observed. Collagenase activity returned to basal levels, and an increase in MMP-1 and MMP-13 expression levels along with a decrease in TIMP-1 expression levels were observed in animals sacrificed 1 month after the last OVA challenge. In the chronic model, there were no changes in collagenase activity or in MMP-13 concentration, although MMP-1 expression levels increased. One month later, an increase in collagenase activity was observed, although MMP-1 and TIMP-1 levels were not altered. The results of the present study suggest that even when the allergen challenges were discontinued, and collagenase activity and MMP-1 expression increased, fibrosis remained, contributing to the irreversibility of bronchoconstriction</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2016.3509</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27602069">PM:27602069</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2016-12-1419-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2016-12-1419-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Gonzalez-Avila G</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2016.3509</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruan,G.</style></author><author><style face="normal" font="Arial"> Tao,B.</style></author><author><style face="normal" font="Arial"> Wang,D.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Wu,J.</style></author><author><style face="normal" font="Arial"> Yin,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Taizhou Municipal Hospital, Medical College of Taizhou University, Taizhou, Zhejiang 318000, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Chinese herbal medicine formula Gu-Ben-Fang-Xiao-Tang attenuates airway inflammation by modulating Th17/Treg balance in an ovalbumin-induced murine asthma model</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="1434" start="1428">1428-1434</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Gu-Ben-Fang-Xiao-Tang (GBFXT) is a traditional Chinese medicine formula consisting of 11 medicinal plants, which has been used in the treatment of asthma. The present study aimed to determine the protective effects and the underlying mechanisms of GBFXT on ovalbumin (OVA)-induced allergic inflammation in a mouse model of allergic asthma. A total of 50 mice were randomly assigned to the following five experimental groups: Normal, model, montelukast (2.6 mg/kg), 12 g/kg GBFXT and 36 g/kg GBFXT groups. Airway responsiveness was measured using the forced oscillation technique, while differential cell count in the bronchoalveolar lavage fluid (BALF) was measured by Wright-Giemsa staining. Histological assessment was performed by hematoxylin and eosin staining, while BALF levels of Th17/Treg cytokines were measured by enzyme-linked immunosorbent assay, and the proportions of Th17 and Treg cells were evaluated by flow cytometry. The results showed that GBFXT suppressed airway hyperresponsiveness during methacholine-induced constriction, reduced the percentage of leukocytes and eosinophils, and resulted in decreased absolute neutrophil infiltration in lung tissue. In addition, GBFXT treatment significantly decreased the IL-17A cytokine level and increased the IL-10 cytokine level in the BALF. Furthermore, GBFXT significantly suppressed Th17 cells and increased Treg cells in asthmatic mice. In conclusion, the current results demonstrated that GBFXT may effectively inhibit the progression of airway inflammation in allergic asthma, partially by modulating the Th17/Treg cell balance</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2016.3507</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27588063">PM:27588063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2016-12-1428-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2016-12-1428-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Ruan G</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2016.3507</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Desai,S.S.</style></author><author><style face="normal" font="Arial"> Hentz,V.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Stanford University Hospitals and Clinics, Robert A. Chase Hand &amp; Upper Limb Center, 770 Welch Road, Suite #400, Palo Alto, CA 94304, USA</style></auth-address><titles><title><style face="normal" font="Arial">Collagenase clostridium histolyticum for Dupuytren's contracture</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></full-title></periodical><pages end="1404" start="1395">1395-1404</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status date="12/26/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Clo hi Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Clostridium histolyticum</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Dupuytren Contracture</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enzymology</style></keyword><keyword><style face="normal" font="Arial"> Ethnic Groups</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbial Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="9" Year="2010">2010/9</year></dates><abstract><style face="normal" font="Arial">IMPORTANCE OF THE FIELD: Dupuytren's disease is a non-malignant, progressive disorder of the hands that can severely limit hand function and diminish overall quality of life. With global life expectancy increasing, the prevalence of this disease appears to be increasing amongst all ethnic groups. Treatment has traditionally remained surgical with few effective, nonsurgical options. However, with the introduction of collagenase clostridium histolyticum to treat Dupuytren's contractures, physicians and surgeons may be provided with a new, office-based, non-surgical option to treat this disease. AREAS COVERED IN THIS REVIEW: The literature behind the use of collagenase to treat Dupuytren's disease; including its mechanism of action, safety, efficacy and clinical evidence behind its recent FDA approval. WHAT THE READER WILL GAIN: The latest information available on collagenase through a comprehensive review of PubMed and the websites of licensing organizations for medicinal products. TAKE HOME MESSAGE: Phase III, clinical trials on collagenase for treatment of Dupuytren's contractures have recently been completed. Meeting primary and secondary objectives, collagenase has obtained FDA approval for clinical use. Collagenase now provides a non-operative option for Dupuytren's disease. Although short-term results show that collagenase is safe and efficacious, long-term effects of repeat injections and contracture recurrence rates have yet to be examined</style></abstract><notes><style face="normal" font="Arial">DA - 20100810IS - 1744-7682 (Electronic)IS - 1471-2598 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - EC 3.4.24.3 (Microbial Collagenase)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1517/14712598.2010.510509</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="20666587">PM:20666587</url></web-urls></urls><custom1><style face="normal" font="Arial">1D</style></custom1><custom2><style face="normal" font="Arial">20100810, Desai SS</style></custom2><misc3><style face="normal" font="Arial">10.1517/14712598.2010.510509</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferrando,M.</style></author><author><style face="normal" font="Arial"> Bagnasco,D.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Varricchi,G.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Allergy &amp; Respiratory Diseases, DIMI Dept of Internal Medicine , University of Genoa, IRCCS AOU San Martino-IST , Genoa , Italy</style></auth-address><titles><title><style face="normal" font="Arial">MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></full-title></periodical><pages end="1441" start="1435">1435-1441</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> sublingual tablet</style></keyword><keyword><style face="normal" font="Arial"> Sublingual tablets</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Since its introduction in clinical practice one century ago for the treatment of respiratory allergic diseases, allergen-specific immunotherapy (AIT) has exhibited a relevant clinical efficacy that was subsequently confirmed in controlled trials. Thus, AIT has been accepted worldwide, as testified by guidelines and international documents. AIT is considered pivotal in the management of allergic rhinitis with or without conjunctivitis and with or without asthma. These conditions, in addition to hymenoptera venom allergy, currently are the accepted indications. The use of AIT in house-dust mite allergy still remains debated, especially due to the methodological problems in assessing this form of respiratory allergy. The more recent experimental data on MK-8237 sublingual tablets provided evidence that AIT, in the sublingual form, is effective in dust mite allergy. AREAS COVERED: At present, the evidence of the efficacy of AIT in conditions other than respiratory allergy are not conclusive, but encouraging results have been obtained in food allergy and atopic dermatitis. Herein, the authors discuss the data for these indications. EXPERT OPINION: Not all patients respond to AIT in the same way. Accordingly, AIT represents a promising path to precision medicine and hopefully will be able to reduce this burden of non-responding patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1744-7682 (Electronic)IS - 1471-2598 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/14712598.2016.1234601</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27620194">PM:27620194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Opin Biol Ther\2016-16-1435-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Opin Biol Ther\2016-16-1435-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Ferrando M</style></custom2><misc3><style face="normal" font="Arial">10.1080/14712598.2016.1234601</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Knutsen,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Division of Allergy &amp; Immunology, Department of Pediatrics , Saint Louis University , St. Louis , MO</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Bronchopulmonary Aspergillosis in Asthma</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="14" start="11">11-14</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1232620</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27599560">PM:27599560</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-11-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-11-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Knutsen AP</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1232620</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marquez-Escobar,V.A.</style></author><author><style face="normal" font="Arial"> Rosales-Mendoza,S.</style></author><author><style face="normal" font="Arial"> Beltran-Lopez,J.I.</style></author><author><style face="normal" font="Arial"> Gonzalez-Ortega,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Universidad Autonoma de San Luis Potosi , Facultad de Ciencias Quimicas , San Luis Potosi , San Luis Potosi 78000 , MX</style></auth-address><titles><title><style face="normal" font="Arial">Plant-based vaccines against respiratory diseases: current status and future prospects</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Vaccines</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Vaccines</style></full-title></periodical><pages end="149" start="137">137-149</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Respiratory infections have an enormous, worldwide epidemiologic impact on humans and animals. Among the prophylactic measures, vaccination has the potential to neutralize this impact. New technologies for vaccine production and delivery are of importance in this field since they offer the potential to develop new immunization approaches overriding the current limitations that comprise high cost, safety issues, and limited efficacy. AREAS COVERED: In the present review, the state of the art in developing plant-based vaccines against respiratory diseases is presented. The review was based on the analysis of current biomedical literature. Expert Commentary: Preclinical and clinical evaluations of several vaccine candidates against influenza, tuberculosis, respiratory syncytial virus, pneumonia, anthrax and asthma are discussed and placed in perspective</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1744-8395 (Electronic)IS - 1476-0584 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1080/14760584.2017.1232167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27599605">PM:27599605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Vaccines\20160907-Marquez-EscobarVA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Vaccines\20160907-Marquez-EscobarVA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Marquez-Escobar VA</style></custom2><misc3><style face="normal" font="Arial">10.1080/14760584.2017.1232167</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomaa,A.I.</style></author><author><style face="normal" font="Arial"> Nsonzi,F.</style></author><author><style face="normal" font="Arial"> Sedman,J.</style></author><author><style face="normal" font="Arial"> Ismail,A.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Enhanced Unfolding of Bovine +¦-Lactoglobulin Structure Using Microwave Treatment: a Multi-Spectroscopic Study</style></title><secondary-title><style face="normal" font="Arial">Food Biophysics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Biophysics</style></full-title></periodical><pages end="379" start="370">370-379</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> fluorescence spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Microwave</style></keyword><keyword><style face="normal" font="Arial"> microwave heating</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> MW</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> NMR spectra</style></keyword><keyword><style face="normal" font="Arial"> Non-thermal</style></keyword><keyword><style face="normal" font="Arial"> Nuclear Magnetic Resonance</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> sequential epitope</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptophan</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1557-1866</style></isbn><abstract><style face="normal" font="Arial">Commercial whey protein hydrolysates containing bovine +¦-lactoglobulin (+¦-Lg) may have residual allergenicity due to the inaccessibility of some sequential epitopes to proteases. Microwave may enhance unfolding pathways in protein structure due to its non-thermal effects. This research compared the effects of microwave heating (MW) and conventional heating (CH) on the unfolding in the secondary and tertiary structures of +¦-Lg over a temperature range of 40-90-á-¦C using circular dichroism (CD), fluorescence spectroscopy, and two dimensional (2D) 1H nuclear magnetic resonance (NMR) spectroscopy. Above 50-á-¦C, +¦-sheet and +¦-helical secondary structures decreased during MW and CH, with a higher decrease being observed during MW. The near-UV spectra of MW +¦-Lg showed lower intensity suggesting higher tertiary structure loss than in CH +¦-Lg at all temperatures. The fluorescence spectra of MW +¦-Lg showed increased exposure of tryptophan residues to solvent as compared to CH +¦-Lg and suggested greater unfolding in tertiary structure in MW +¦-Lg at 60-á-¦C than in CH +¦-Lg at 70-á-¦C. 2D 1H NMR spectra confirmed more extensive H-D exchange in MW +¦-Lg explained by the exposure of +¦-sheets (C, G, and H) at 50-á-¦C under microwave treatment, which are thermally resistant to H-D exchange up to 75-á-¦C during conventional heating. These results revealed a substantial enhancing effect of microwave treatment on the thermal unfolding and exposure of buried amide groups in +¦-Lg compared to conventional heating. Microwave processing could be a promising alternative to produce hydrolysates with lower allergenicity and improved bioactivity through structure modification</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -CO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11483-016-9451-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s11483-016-9451-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Biophysics\20160915-GomaaAI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Biophysics\20160915-GomaaAI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160915, Gomaa AI</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11483-016-9451-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kang,H.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author><author><style face="normal" font="Arial"> Kim,J.R.</style></author><author><style face="normal" font="Arial"> Kwon,J.Y.</style></author><author><style face="normal" font="Arial"> Son,M.J.</style></author><author><style face="normal" font="Arial"> Kim,J.E.</style></author><author><style face="normal" font="Arial"> Lee,K.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Major in Biomodulation, Department of Agricultural Biotechnology and Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151-742, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Theobroma cacao extract attenuates the development of Dermatophagoides farinae-induced atopic dermatitis-like symptoms in NC/Nga mice</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="26" start="19">19-26</pages><volume><style face="normal" font="Arial">216</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">agricultural biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cacao</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> thymus and activation-regulated chemokine</style></keyword><keyword><style face="normal" font="Arial"> transepidermal water loss</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">Cacao beans from Theobroma cacao are an abundant source of polyphenols, particularly flavonoids. Previous studies demonstrated that cacao flavanols decrease pro-inflammatory cytokines resulting in the alleviation of allergic symptoms. We sought to investigate the effects of cacao extract (CE) on Dermatophagoides farinae extract (DFE)-induced atopic dermatitis (AD)-like symptoms. CE attenuated DFE-induced AD-like symptoms as assessed by skin lesion analyses, dermatitis score, and skin thickness. Histopathological analysis revealed that CE suppressed DFE-induced immune cell infiltration into the skin. These observations occurred concomitantly with the downregulation of inflammatory markers including serum immunoglobulin (Ig) E, chemokine; thymus and activation-regulated chemokine and macrophage-derived chemokine as well as the skin-derived cytokines interleukin (IL)-4, IL-5, and interferon-gamma. CE also significantly alleviated transepidermal water loss and increased skin hydration. These results suggest that CE, a natural phytochemical-rich food, has potential therapeutic efficacy for the treatment of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.07.141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27596387">PM:27596387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2016-216-19-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2016-216-19-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Kang H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.07.141</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tran,L.</style></author><author><style face="normal" font="Arial"> Astengo,B.</style></author><author><style face="normal" font="Arial"> Palmiere,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Center of Legal Medicine, CURML, Lausanne, Geneva, SwitzerlandS.C. Medicina Legale, Via Camozzini 15, Genova Voltri, 16158 Genova, ItalyUniversity Center of Legal Medicine, CURML, Lausanne, Geneva, Switzerland. Electronic address: cristian.palmiere@chuv.ch</style></auth-address><titles><title><style face="normal" font="Arial">Determination of specific IgE in pericardial and cerebrospinal fluids in forensic casework</style></title><secondary-title><style face="normal" font="Arial">Forensic Sci Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Forensic Sci Int</style></full-title></periodical><pages end="209" start="204">204-209</pages><volume><style face="normal" font="Arial">267</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cerebrospinal fluid</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="Arial">The aim of this study was to characterize total and specific IgE distribution in postmortem serum as well as pericardial and cerebrospinal fluid samples and evaluate the diagnostic usefulness of total and specific IgE determination in pericardial and cerebrospinal fluids in the forensic setting. Three groups were investigated (non-allergic deaths in non-atopic individuals, fatal allergic anaphylaxis deaths and non-allergic deaths in individuals without medical records). In the first group (non-allergic deaths in non-atopic individuals), total IgE concentrations in postmortem serum from femoral blood, pericardial and cerebrospinal fluids were lower than 40, 32 and 11kU/l, respectively. No specific IgE were identified in any of the sampled fluids. In the second group (fatal allergic anaphylaxis deaths), total IgE concentrations in postmortem serum from femoral blood ranged from 139kU/l to 818kU/l, in pericardial fluid from 89kU/l to 622kU/l and in cerebrospinal fluid from 4kU/l to 11kU/l. A positive Phadiatop(R) test and specific IgE antibodies >0.35kU/l were found exclusively in postmortem serum from femoral blood and pericardial fluid. In the third group (non-allergic deaths in individuals without medical records, possibly including atopic individuals), total IgE concentrations ranged from 42kU/l to 516kU/l in postmortem serum from femoral blood, from 34kU/l to 417kU/l in pericardial fluid and from 3kU/l to 12kU/l in cerebrospinal fluid. A positive Phadiatop(R) test and specific IgE antibodies >0.35kU/l were found exclusively in postmortem serum from femoral blood and pericardial fluid. These results seem to suggest that total and specific IgE may be measured in postmortem serum from femoral blood and pericardial fluid to estimate total and specific IgE titers at the time of death. Conversely, cerebrospinal fluid total and specific IgE measurement in suspected IgE mediated fatal anaphylaxis cases is of no value for diagnostic purposes</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1872-6283 (Electronic)IS - 0379-0738 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Switzerland -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.forsciint.2016.08.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27618809">PM:27618809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Forensic Sci Int\2016-267-204-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Forensic Sci Int\2016-267-204-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Tran L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.forsciint.2016.08.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Holzer,L.A.</style></author><author><style face="normal" font="Arial"> Holzer,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Deutsch-Ordens-Spital Friesach, Abteilung fur Chirurgie, St. Veiter Strasse 12, Friesach, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Collagenase Clostridum histolyticum in the management of Dupuytren's contracture</style></title><secondary-title><style face="normal" font="Arial">Handchir Mikrochir Plast Chir</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Handchir Mikrochir Plast Chir</style></full-title></periodical><pages end="274" start="269">269-274</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chirurgie</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials,Phase III as Topic</style></keyword><keyword><style face="normal" font="Arial"> Clo hi Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Clostridium histolyticum</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Dupuytren Contracture</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> enzymology</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Metabolic Clearance Rate</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbial Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Penile Induration</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Retreatment</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surgical treatment</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2011">2011/10</year></dates><abstract><style face="normal" font="Arial">Dupuytren's contracture is a fibroproliferate disease of the palmar aponeurosis with a formation of nodules and cords. Surgical treatment is the gold standard for Dupuytren's contracture at the moment. A short while ago Collagenase clostridium histolyticum was licensed as a non-surgical method to treat Dupuytren's contracture. Collagenase clostridium histolyticum is injected directly into the Dupuytren's cord and after 24 h the contracture is distended by manual rupturing. Collagenase clostridium histolyticum causes a depletion of collagen, however neurovascular structures are spared. 2 clinical phase III studies showed that contractures could be effectively reduced when using Collagenase clostridium histolyticum. However, there are no long-term results regarding effectiveness and side effects, or comparative studies using surgical methods. This paper presents a review of Collagenase clostridium histolyticum and its role in the management of Dupuytren's contracture. Indication, technical procedure, treatment results and complications are described</style></abstract><notes><style face="normal" font="Arial">DA - 20110921IS - 1439-3980 (Electronic)IS - 0722-1819 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewRN - EC 3.4.24.3 (Microbial Collagenase)SB - IMCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1055/s-0031-1286314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="21935843">PM:21935843</url></web-urls><pdf-urls><url ppv-ref="no">lukasholzer@gmail.com</url></pdf-urls></urls><custom1><style face="normal" font="Arial">1D</style></custom1><custom2><style face="normal" font="Arial">20110921, Holzer LA</style></custom2><misc3><style face="normal" font="Arial">10.1055/s-0031-1286314</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schwarz,I.</style></author><author><style face="normal" font="Arial"> Bokanovic,D.</style></author><author><style face="normal" font="Arial"> Aberer,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Univ. Klinik fur Dermatologie, LKH Graz, Auenbruggerplatz 8, 8036, Graz, Osterreich.</style></auth-address><titles><title><style face="normal" font="Arial">[Mucosal diseases from an allergological perspective]</style></title><secondary-title><style face="normal" font="Arial">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hautarzt</style></full-title></periodical><pages end="785" start="780">780-785</pages><volume><style face="normal" font="Arial">67</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cheilitis</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dental Materials</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> hemorrhagic</style></keyword><keyword><style face="normal" font="Arial"> herpes</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immediate type reactions</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Lip</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Membranes</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Mucous Membrane</style></keyword><keyword><style face="normal" font="Arial"> Ointments</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> oral mucosa</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Semen</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> Stomatitis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">The oral allergy syndrome is one of the most common form of food allergy and manifests as contact urticaria of the oral mucosa after consumption of cross reacting foods. Whereas allergic contact stomatitis often occurs due to dental materials, allergic contact cheilitis is usually a reaction due to topical therapeutics like herpes ointments or lip care products. As late type reactions are more frequent than immediate type reactions in the anogenital mucosa, contact dermatitis in this area should be identified via epicutaneous testing. In case of contact urticaria at the genital mucosa, a semen allergy or a latex allergy should be given due consideration as a possible cause. Angioedemas, which are mostly common histamine mediated, usually prefer skin areas with loose connective tissue such as the oral or genital mucosa. Fixed drug eruption also occurs preferentially in these areas. Bullous drug-induced skin reactions (e.g., SJS and TEN) are characterized by severe hemorrhagic, erosive affections of mucous membranes</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - GERPT - REVIEWPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - Austria -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s00105-016-3866-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27580724">PM:27580724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hautarzt\20160901-SchwarzI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hautarzt\20160901-SchwarzI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Schwarz I</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s00105-016-3866-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Westwood,M.</style></author><author><style face="normal" font="Arial"> Ramaekers,B.</style></author><author><style face="normal" font="Arial"> Lang,S.</style></author><author><style face="normal" font="Arial"> Armstrong,N.</style></author><author><style face="normal" font="Arial"> Noake,C.</style></author><author><style face="normal" font="Arial"> de Kock,S.</style></author><author><style face="normal" font="Arial"> Joore,M.</style></author><author><style face="normal" font="Arial"> Severens,J.</style></author><author><style face="normal" font="Arial"> Kleijnen,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Kleijnen Systematic Reviews Ltd, York, UK</style></auth-address><titles><title><style face="normal" font="Arial">ImmunoCAP(R) ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis</style></title><secondary-title><style face="normal" font="Arial">Health Technol Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Health Technol Assess</style></full-title></periodical><pages end="178" start="1">1-178</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">67</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute exacerbations</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> admissions</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen chip</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Caribbean</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resource use</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> SCI</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy is a form of immune-mediated exaggerated sensitivity (hypersensitivity) to a substance that is either inhaled, swallowed, injected or comes into contact with the skin. Foreign substances that provoke allergies are called allergens. It has been claimed that multiplex allergen testing may help in diagnosing the cause of symptoms in patients with an unclear cause of allergy or who are allergic to more than one substance. OBJECTIVES: To evaluate multiplex allergen testing [devices that can measure the presence of multiple immunoglobulin E (IgE) antibodies in a patient's blood at the same time], by assessing (1) clinical effectiveness (allergy symptoms, incidence of acute exacerbations, mortality, adverse events of testing and treatment, health-care presentations or admissions, health-related quality of life); (2) effects on treatment (diet, immunotherapy medications, other potential testing); (3) any additional diagnostic information provided by multiplex allergen testing; and (4) cost-effectiveness (cost of different assessment strategies). METHODS: Fifteen databases were searched from 2005 to April 2015, including MEDLINE (via OvidSp), MEDLINE In-Process Citations, MEDLINE Daily Update, PubMed (National Library of Medicine), EMBASE, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA) database, Science Citation Index (SCI), Conference Proceedings Citation Index-Science (CPCI-S), BIOSIS Previews, Latin American and Caribbean Health Sciences Literature (LILACS), National Institute for Health Research (NIHR) HTA programme, and the US Food and Drug Administration (FDA); supplementary searches of conference proceedings and trials registries were performed. Review methods followed published guidance from the Cochrane Collaboration and the Centre for Reviews and Dissemination, University of York, UK. The methodological quality of included studies was assessed using appropriate published tools or a review-specific tool designed by the project team. Studies were summarised in a narrative synthesis. Owing to a lack of data on the clinical effectiveness of multiplex allergen testing, no long-term cost-effectiveness model was developed. A conceptual model structure was developed and cost analyses were performed to examine the short-term costs of various possible diagnostic pathways. RESULTS: Fifteen studies were included in the review. The very limited available data indicated that the addition of multiplex allergen testing [ImmunoCAP((R)) Immuno Solid-phase Allergen Chip (ISAC), Thermo Fisher Scientific/Phadia AB, Uppsala, Sweden] to standard diagnostic work-up can change the clinicians' views on the diagnosis, management and treatment of patients. There was some indication that the use of ImmunoCAP ISAC testing may be useful to guide decisions on the discontinuation of restrictive diets, the content of allergen-specific immunotherapy (SIT) prescriptions, and whether or not patients should receive SIT. However, none of the studies that we identified reported any information on clinical outcomes subsequent to changes in treatment or management. There was some evidence that ImmunoCAP ISAC may be useful for discriminating allergens that are structurally similar and are recognised by the same IgE antibody (cross-immunoreactive). No data were available for Microtest (Microtest Matrices Ltd, London, UK). Detailed cost analyses suggested that multiplex allergen testing would have to result in a substantial reduction of the proportions of patients receiving single IgE testing and oral food challenge tests in order to be cost-saving in the short term. CONCLUSIONS: No recommendations for service provision can be made based on the analyses included in this report. It is suggested that a consensus-based protocol for the use of multiplex allergen testing be developed. The clinical effectiveness and cost-effectiveness of the proposed protocol should then be assessed by comparing long-term clinical and quality of life outcomes and resource use in patients managed using the protocol with those managed using a standard diagnostic pathway. STUDY REGISTRATION: This study is registered as PROSPERO CRD42015019739. FUNDING: This project was a Diagnostic Assessment Report commissioned by the NIHR HTA programme on behalf of the National Institute for Health and Care Excellence</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 2046-4924 (Electronic)IS - 1366-5278 (Linking)LA - engPT - Meta-AnalysisSB - IMCO - United Kingdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3310/hta20670</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27623692">PM:27623692</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Health Technol Assess\2016-20-1-178.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Health Technol Assess\2016-20-1-178.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Westwood M</style></custom2><misc3><style face="normal" font="Arial">10.3310/hta20670</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hon,K.L.</style></author><author><style face="normal" font="Arial"> Leung,T.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong</style></auth-address><titles><title><style face="normal" font="Arial">Food avoidance does not improve childhood eczema</style></title><secondary-title><style face="normal" font="Arial">Hong Kong Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hong Kong Med J</style></full-title></periodical><pages end="575" start="574">574-575</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood eczema</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> diet therapy</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> Food Habits</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="0" Month="12" Year="2015">2015/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20151204IS - 1024-2708 (Print)IS - 1024-2708 (Linking)LA - engPT - Journal ArticleSB - IMCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.12809/hkmj154618</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26634376">PM:26634376</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hong Kong Med J\2015-21-574-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hong Kong Med J\2015-21-574-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151204, Hon KL</style></custom2><misc3><style face="normal" font="Arial">10.12809/hkmj154618</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goncalves,R.</style></author><author><style face="normal" font="Arial"> Valente,C.</style></author><author><style face="normal" font="Arial"> Ferreira,E.</style></author><author><style face="normal" font="Arial"> Serra,J.E.</style></author><author><style face="normal" font="Arial"> da Cunha,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Infectious Diseases Unit - Centro Hospitalar e Universitario de Coimbra (Coimbras Hospital Centre and University), Coimbra, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Cytomegalic hepatitis in a patient receiving omalizumab</style></title><secondary-title><style face="normal" font="Arial">IDCases</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">IDCases</style></full-title></periodical><pages end="84" start="83">83-84</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Body Fluids</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cytomegalovirus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> refractory asthma</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Cytomegalovirus is a double stranded DNA virus that can be present in nearly all organs and body fluids. The primary infection is usually asymptomatic in the immunocompetent host and it is common among adolescents and young adults. The symptomatic form appears, in the majority of cases, as a mononucleosis syndrome with full recovery without specific treatment. We report a case of a 25 years old woman who presented with hepatitis due to CMV infection and history of omalizumab administration one month earlier. This recombinant monoclonal antibody is used to control refractory asthma and chronic spontaneous urticarial as it inhibits human IgE. Despite that, the long course of the disease lead us to initiate treatment with valganciclovir. The improvement after that was rapid and complete</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 2214-2509 (Electronic)IS - 2214-2509 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.idcr.2016.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27583207">PM:27583207</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\IDCases\2016-5-83-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\IDCases\2016-5-83-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Goncalves R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.idcr.2016.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smet,M.</style></author><author><style face="normal" font="Arial"> Van Hoecke,L.</style></author><author><style face="normal" font="Arial"> De Beuckelaer,A.</style></author><author><style face="normal" font="Arial"> Vander Beken,S.</style></author><author><style face="normal" font="Arial"> Naessens,T.</style></author><author><style face="normal" font="Arial"> Vergote,K.</style></author><author><style face="normal" font="Arial"> Willart,M.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Gustafsson,J.A.</style></author><author><style face="normal" font="Arial"> Steffensen,K.R.</style></author><author><style face="normal" font="Arial"> Grooten,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Molecular Biology Ghent University Ghent Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Cholesterol-sensing liver X receptors stimulate Th2-driven allergic eosinophilic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="361" start="350">350-361</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Liver X receptors (LXRs) are nuclear receptors that function as cholesterol sensors and regulate cholesterol homeostasis. High cholesterol has been recognized as a risk factor in asthma; however, the mechanism of this linkage is not known. METHODS: To explore the importance of cholesterol homeostasis for asthma, we investigated the contribution of LXR activity in an ovalbumin- and a house dust mite-driven eosinophilic asthma mouse model. RESULTS: In both models, airway inflammation, airway hyper-reactivity, and goblet cell hyperplasia were reduced in mice deficient for both LXRalpha and LXRbeta isoforms (LXRalpha(-/-)beta(-/-)) as compared to wild-type mice. Inversely, treatment with the LXR agonist GW3965 showed increased eosinophilic airway inflammation. LXR activity contributed to airway inflammation through promotion of type 2 cytokine production as LXRalpha(-/-)beta(-/-) mice showed strongly reduced protein levels of IL-5 and IL-13 in the lungs as well as reduced expression of these cytokines by CD4(+) lung cells and lung-draining lymph node cells. In line herewith, LXR activation resulted in increased type 2 cytokine production by the lung-draining lymph node cells. CONCLUSIONS: In conclusion, our study demonstrates that the cholesterol regulator LXR acts as a positive regulator of eosinophilic asthma in mice, contributing to airway inflammation through regulation of type 2 cytokine production</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.118</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27621817">PM:27621817</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-350-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-350-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Smet M</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.118</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Edukulla,R.</style></author><author><style face="normal" font="Arial"> Rehn,K.L.</style></author><author><style face="normal" font="Arial"> Liu,B.</style></author><author><style face="normal" font="Arial"> McAlees,J.W.</style></author><author><style face="normal" font="Arial"> Hershey,G.K.</style></author><author><style face="normal" font="Arial"> Wang,Y.H.</style></author><author><style face="normal" font="Arial"> Lewkowich,I.</style></author><author><style face="normal" font="Arial"> Lindsley,A.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA</style></auth-address><titles><title><style face="normal" font="Arial">Intratracheal myriocin enhances allergen-induced Th2 inflammation and airway hyper-responsiveness</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="262" start="248">248-262</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chemotactic Factors</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic association</style></keyword><keyword><style face="normal" font="Arial"> Genetic Association Studies</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene B4</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Ceramide is the central substrate of sphingolipid metabolism and plays a key role in cellular signal transduction pathways, regulating apoptosis, differentiation, and chemotaxis. Alterations in airway ceramide levels are observed in multiple pulmonary diseases and recent human genetic association studies have linked dysregulation of sphingolipid regulatory genes with asthma pathogenesis. METHODS: Utilizing myriocin, a potent inhibitor of sphingolipid synthesis, we evaluated the immune regulatory role of de novo ceramide generation in vitro and in vivo. Intratracheal myriocin was administered alone or during house dust mite sensitization (HDM) of BALB/C mice and airway hyper-responsiveness (AHR) was evaluated by invasive plethysmography followed by bronchial lavage (BAL) cytology and cytokine quantification. RESULTS: Myriocin inhibits and HDM exposure activates de novo ceramide synthesis in bone marrow-derived dendritic cells. Mice receiving intratracheal myriocin developed a mild airway neutrophilic infiltrate without inducing a significant increase in AHR. CXCL1 was elevated in the BAL fluid of myriocin-treated mice while the neutrophilic chemotactic factors anaphylatoxin C5a, leukotriene B4, and IL-17 were unaffected. HDM treatment combined with myriocin led to a dramatic enhancement of AHR (63% increase over HDM alone, p &lt; 0.001) and increased granulocyte pulmonary infiltrates versus HDM or myriocin alone. Elevated Th2 T cell counts and Th2 cytokines/chemokines (IL5, IL13, CCL17) were observed in mice treated with combined HDM/myriocin compared to HDM alone. Myriocin-treated pulmonary CD11c+ cells stimulated with HDM secreted significantly more CXCL1 than cells stimulated with HDM alone while HDM stimulated airway epithelial cells showed no change in CXCL1 secretion following myriocin treatment. CONCLUSIONS: Intratracheal myriocin, likely acting via ceramide synthesis inhibition, enhances allergen-induced airway inflammation, granulocyte and Th2 lymphocyte recruitment, and allergen-induced AHR. Sphingolipid pathways may represent novel targets for possible future anti-inflammatory asthma medications</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.110</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27621809">PM:27621809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-248-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-248-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Edukulla R</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.110</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cassard,L.</style></author><author><style face="normal" font="Arial"> Lalanne,A.I.</style></author><author><style face="normal" font="Arial"> Garault,P.</style></author><author><style face="normal" font="Arial"> Cotillard,A.</style></author><author><style face="normal" font="Arial"> Chervaux,C.</style></author><author><style face="normal" font="Arial"> Wels,M.</style></author><author><style face="normal" font="Arial"> Smokvina,T.</style></author><author><style face="normal" font="Arial"> Daeron,M.</style></author><author><style face="normal" font="Arial"> Bourdet-Sicard,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unite d'Allergologie Moleculaire &amp; Cellulaire Institut Pasteur Paris France</style></auth-address><titles><title><style face="normal" font="Arial">Individual strains of Lactobacillus paracasei differentially inhibit human basophil and mouse mast cell activation</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="299" start="289">289-299</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human basophils</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> Lactobacilli</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus paracasei</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The microbiota controls a variety of biological functions, including immunity, and alterations of the microbiota in early life are associated with a higher risk of developing allergies later in life. Several probiotic bacteria, and particularly lactic acid bacteria, were described to reduce both the induction of allergic responses and allergic manifestations. Although specific probiotic strains were used in these studies, their protective effects on allergic responses also might be common for all lactobacilli. METHODS: To determine whether allergic effector cells inhibition is a common feature of lactobacilli or whether it varies among lactobacilli strains, we compared the ability of 40 strains of the same Lactobacillus paracasei species to inhibit IgE-dependent mouse mast cell and human basophil activation. RESULTS: We uncovered a marked heterogeneity in the inhibitory properties of the 40 Lactobacillus strains tested. These segregated into three to four clusters depending on the intensity of inhibition. Some strains inhibited both mouse mast cell and human basophil activation, others strains inhibited only one cell type and another group induced no inhibition of activation for either cell type. CONCLUSIONS: Individual Lactobacillus strains of the same species differentially inhibit IgE-dependent activation of mouse mast cells and human basophils, two cell types that are critical in the onset of allergic manifestations. Although we failed to identify specific bacterial genes associated with inhibition by gene-trait matching analysis, our findings demonstrate the complexity of the interactions between the microbiota and the host. These results suggest that some L. paracasei strains might be more beneficial in allergies than others strains and provide the bases for a rational screening of lactic acid bacteria strains as next-generation probiotics in the field of allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - France -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27621812">PM:27621812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-3288-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-3288-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Cassard L</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Manti,S.</style></author><author><style face="normal" font="Arial"> Lougaris,V.</style></author><author><style face="normal" font="Arial"> Cuppari,C.</style></author><author><style face="normal" font="Arial"> Tardino,L.</style></author><author><style face="normal" font="Arial"> Dipasquale,V.</style></author><author><style face="normal" font="Arial"> Arrigo,T.</style></author><author><style face="normal" font="Arial"> Salpietro,C.</style></author><author><style face="normal" font="Arial"> Leonardi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Sciences, University of Messina, Messina, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Breastfeeding and IL-10 levels in children affected by cow's milk protein allergy: A restrospective study</style></title><secondary-title><style face="normal" font="Arial">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunobiology</style></full-title></periodical><pages end="362" start="358">358-362</pages><volume><style face="normal" font="Arial">222</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> hyposensitization</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> inverse correlation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">AIM: To assess the protective role of breast-feeding in infants with CMPA-related AEDS as well as IL-10 utility as marker of disease evolution. METHODS: 64 breast-feeding children with CMPA-related AEDS (31 males and 33 females; mean age 5.56+/-2.41months; 21 mild AEDS; 25 moderate AEDS; 18 severe AEDS) and 60 artificial feeding babies (33 males and 27 females; mean age 6.01+/-2.08months; 26 mild AEDS; 19 moderate AEDS; 15 severe AEDS) were evaluated. In all patients serum IL-10 levels were detected. RESULTS: Significant Score Atopic Dermatitis (SCORAD) index point differences between breastfed and not breastfed children (p&lt;0.001) have been detected. The serum IL-10 levels were lower in children with CMPA-related AEDS as compared to the healthy control group (p&lt;0.001). Moreover, a significant inverse correlation between serum IL-10 levels and SCORAD in both enrolled groups has been also noted. In particular, IL-10 levels, in both groups, were significantly lower in children with severe symptoms. Conversely, serum IL-10 levels were significantly increased in children with mild-severe symptoms in both groups. Furthermore, breastfed children, with lower severe symptoms, had higher serum IL-10 levels. Finally, serum total IgE levels were negatively correlated with serum IL-10 levels in both breastfed and non-breastfed children with CMPA-related AEDS (p&lt;0.001). CONCLUSIONS: We reported that exclusive breast-feeding induces hyposensitization in children with CMPA-related AEDS and it is associated with minor disease severity and higher serum IL-10 levels, resulting as useful disease-monitor marker</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1878-3279 (Electronic)IS - 0171-2985 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imbio.2016.09.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27622938">PM:27622938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunobiology\20160913-MantiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunobiology\20160913-MantiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Manti S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imbio.2016.09.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jain,S.</style></author><author><style face="normal" font="Arial"> Singh,A.</style></author><author><style face="normal" font="Arial"> Joshi,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Complex aspergilloma presenting as chronic dry cough: An unusual finding</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="34" start="32">32-34</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal culture</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hemoptysis</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">The most common symptom of aspergilloma is hemoptysis. Dry cough is a rare symptom of aspergilloma. It is estimated that 10-20% of tubercular-healed cavities are colonized by fungus. The case report discusses persistent dry cough in a 30-year-old male. Radiograph of the chest revealed left upper zone infiltrates while contrast-enhanced computed tomography of the chest revealed classical Monad sign suggestive of aspergilloma. Diagnosis was confirmed by anti-&lt;i>Aspergillus&lt;/i> antibodies (100 IU/ml) and growth of &lt;i>Aspergillus fumigatus&lt;/i> in sputum fungal culture</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.187566</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.187566</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-32-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-32-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Jain S</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.187566</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chaudhary,A.</style></author><author><style face="normal" font="Arial"> Utpat,K.</style></author><author><style face="normal" font="Arial"> Desai,U.</style></author><author><style face="normal" font="Arial"> Joshi,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis masquerading as malignancy in a nonasthmatic: A rare case report</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="37" start="35">35-37</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease caused by hypersensitivity reaction to antigens of &lt;i>Aspergillus&lt;/i> species of which &lt;i>Aspergillus&lt;/i> &lt;i>fumigatus&lt;/i> is the most common culprit. ABPA is most commonly diagnosed in patients with a history of uncontrolled bronchial asthma despite optimum treatment. ABPA is rarely diagnosed in nonasthmatics. Diverse radiological appearances are known in ABPA patients; however, whole lung collapse has been rarely reported. We report a case of ABPA in a 62-year-old female with no background history of asthma, initially suspected to have bronchogenic carcinoma of the right lung. After ruling out malignancy, the diagnosis of ABPA was established based on Rosenberg-Patterson criteria. Treatment with oral steroids for 6 months in tapering doses lead to clinical and radiological improvement and decrease in IgE levels. This case is unique as ABPA masquerading as malignancy causing a lung collapse in a nonasthmatic is a very rare presentation</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.187567</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.187567</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-35-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-35-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Chaudhary A</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.187567</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Phadtare,J.</style></author><author><style face="normal" font="Arial"> Ramraje,N.</style></author><author><style face="normal" font="Arial"> Mehta,J.</style></author><author><style face="normal" font="Arial"> Hegde,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Bronchial challenge testing in mild to moderate asthmatics</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="16" start="12">12-16</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway reactivity</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge testing</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PC20</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">Bronchial challenge is almost confirmatory test for airway reactivity, a significant test for confirming asthma. &lt;b>Methodology:&lt;/b> Already established methodology for the test was used by the direct method using graded concentrations of histamine and using FEV1 as parameter. &lt;b>Results:&lt;/b> Fifty mild to moderate asthmatic patients were assessed for airway hyper-responsiveness The youngest was 18 years, the oldest 51 years, the mean age was 34 years. Forty-four percent were males and 56% were females. Bronchial challenge tests were positive in 90% of mild to moderate asthmatic patients. &lt;b>Conclusion:&lt;/b> There was a significant linear correlation of PC20 levels with forced expiratory volume in the first second. There was no significant correlation of PC20 levels with serum IgE levels</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.187560</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.187560</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-12-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-12-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Phadtare J</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.187560</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meena,C.</style></author><author><style face="normal" font="Arial"> Poddar,M.</style></author><author><style face="normal" font="Arial"> Sharma,B.</style></author><author><style face="normal" font="Arial"> Devpura,K.</style></author><author><style face="normal" font="Arial"> Meena,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Estimation of serum immunoglobulin E levels as suggestive indicator of atopy in children having allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="21" start="17">17-21</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">Atopy is the major factor predisposing for the development of allergic airway diseases. Immunoglobulin E (IgE) levels of children having atopy are elevated as compared with nonatopic children. Serum total IgE levels can be utilized as a surrogate marker for the presence of atopy. &lt;b>Objective:&lt;/b> To study the presence of atopy by estimation of serum IgE levels in children having allergic rhinitis and to determine the proportion of concomitant allergic conditions in these children. &lt;b>Methods:&lt;/b> From May 2012 to April 2013, 134 children aged 6-14 years having allergic rhinitis as diagnosed on the basis of their response to the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire were included in the study. Children were screened for concomitant atopic disorders, viz., asthma, atopic eczema, and conjunctivitis on the basis of their response to ISAAC questionnaire. Total serum IgE levels were determined for all subjects. &lt;b>Results:&lt;/b> Total IgE levels of study subjects were found to be increased in 114 (85.07%) out of 134 children (cut-off value = 100 IU/mL). Mean serum IgE of the study subjects was 312.18 (95% confidence interval, 253.1-385.1) IU/mL. Children having persistent allergic rhinitis had higher mean IgE levels of 392.18 IU/mL as compared to 199.08 IU/mL (&lt;i>P&lt;/i> &amp;lt; 0.01) for children having intermittent allergic rhinitis. One hundred and twenty-two (91.0%) children had concomitant asthma. Persistent allergic rhinitis was found to be significantly associated with family history of smoking (&lt;i>P&lt;/i> &amp;lt; 0.01) and family history of atopy (&lt;i>P&lt;/i> = 0.02). &lt;b>Conclusion:&lt;/b> Significant number of children having allergic rhinitis had increased levels of serum IgE. Hence, total serum IgE can be considered as a supportive and suggestive indicator of atopy in children presenting with allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.187562</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.187562</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-17-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-17-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Meena C</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.187562</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vaggu,A.</style></author><author><style face="normal" font="Arial"> Srivastava,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Rash before shock: A case of cholinergic urticaria associated with syncope</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="44" start="42">42-44</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Smell</style></keyword><keyword><style face="normal" font="Arial"> Sunlight</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syncope</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">We report a case of cholinergic urticaria (CU) associated with systemic manifestations, in the form of syncope. A 21-year-old female patient, suffering for 14 years, triggers being strong emotional reactions, foul smell, and sunlight. She was diagnosed after a thorough history and extensive literature search as systemic symptoms are not usually suspected in the spectrum of CU. She was effectively managed with nonsedating antihistamines</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.187569</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.187569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-42-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-42-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Vaggu A</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.187569</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kale,S.</style></author><author><style face="normal" font="Arial"> Arora,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Safety assessment of genetically modified crops</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="3" start="1">1-3</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">assessment</style></keyword><keyword><style face="normal" font="Arial"> genetically modified crops</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.187543</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.187543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-1-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-1-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Kale S</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.187543</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahmadi,M.</style></author><author><style face="normal" font="Arial"> Rahbarghazi,R.</style></author><author><style face="normal" font="Arial"> Soltani,S.</style></author><author><style face="normal" font="Arial"> Aslani,M.R.</style></author><author><style face="normal" font="Arial"> Keyhanmanesh,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Contributory Anti-Inflammatory Effects of Mesenchymal Stem Cells, Not Conditioned Media, On Ovalbumin-Induced Asthmatic Changes in Male Rats</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">Our aim in selecting an appropriate cell fraction and conditioned media (CM) was to achieve the suitable candidate for ameliorating long-term chronic asthmatic changes of respiratory tract. Thirty-six rats were classified into healthy and sensitized groups, which were further divided into three subgroups; rats received systemically 50 mul volume of PBS, CM, or 2 x 106 rat bone marrow-derived mesenchymal stem cells (rBMMSCs). Tracheal responsiveness (TR), immunologic responses, and recruitment of rBMMSCs into the lungs were evaluated. A high degree of TR and total WBC and percentages of eosinophils and neutrophils was significantly recorded in all sensitized groups rather than of controls (p &lt; 0.001 to p &lt; 0.05). Concurrently, a significant improvement of TR and eosinophil and neutrophil return toward normal levels was evident in sensitized rats receiving cells as compared to parallel asthmatic animals. Flow cytometric monitoring of lymphocyte subpopulation revealed a decrease in the number of CD3+CD4+ and concurrent increase in CD3+CD8+ in all sensitized rats as compared to control (p &lt; 0.001 to p &lt; 0.05). Noticeably, no significant modulatory effects of either cell or CM administration were achieved on the CD3+CD4+ and CD3+CD8+ populations in non-asthmatic rats. Corroborating our results, the number of CD3+CD4+ tended to increase (p &lt; 0.05) which coincided with a decreased manner of CD3+CD8+ populations as compared to other asthmatic groups (p &lt; 0.01 to p &lt; 0.05). Moreover, stem cells could efficiently transmigrate to the lung parenchyma, albeit the dynamic of asthmatic changes stimulated the rate of recruited cells. Our study shed light on superior effects of mesenchymal stem cells, but not CM, in attenuating chronic asthmatic changes in the model of rat</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-016-0431-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590236">PM:27590236</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20160903-AhmadiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20160903-AhmadiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Ahmadi M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-016-0431-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wei,D.Z.</style></author><author><style face="normal" font="Arial"> Guo,X.Y.</style></author><author><style face="normal" font="Arial"> Lin,L.N.</style></author><author><style face="normal" font="Arial"> Lin,M.X.</style></author><author><style face="normal" font="Arial"> Gong,Y.Q.</style></author><author><style face="normal" font="Arial"> Ying,B.Y.</style></author><author><style face="normal" font="Arial"> Huang,M.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Angelicin on Ovalbumin (OVA)-Induced Airway Inflammation in a Mouse Model of Asthma</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">Angelicin, a furocoumarin found in Psoralea corylifolia L. fruit, has been reported to have anti-inflammatory activity. The purpose of this study was to determine the protective effects of angelicin on allergic asthma induced by ovalbumin (OVA) in mice. Mice were sensitized to OVA (on days 0 and 14) and challenged with OVA three times (on days 21 to 23). Angelicin (2.5, 5, 10 mg/kg) was given intraperitoneally 1 h before OVA treatment after the initial OVA sensitization. The production of IL-4, IL-5, and IL-13 in BALF and IgE in the serum were measured by ELISA. Lung histological changes were detected by using hematoxylin and eosin (H&amp;E) stain. The results showed that angelicin significantly inhibited inflammatory cells infiltration into the lungs. Histological studies showed that angelicin significantly attenuated OVA-induced lung injury. Meanwhile, treatment of angelicin dose-dependently inhibited OVA-induced the production of IL-4, IL-5, and IL-13 in BALF and IgE in the serum. Furthermore, angelicin was found to inhibit airway hyperresponsiveness and NF-kB activation. In conclusion, our results suggested that angelicin inhibited allergic airway inflammation and hyperresponsiveness by inhibiting NF-kB activation</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-016-0423-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27581277">PM:27581277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20160901-WeiDZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20160901-WeiDZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Wei DZ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-016-0423-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wada,T.</style></author><author><style face="normal" font="Arial"> Matsuda,Y.</style></author><author><style face="normal" font="Arial"> Toma,T.</style></author><author><style face="normal" font="Arial"> Koizumi,E.</style></author><author><style face="normal" font="Arial"> Okamoto,H.</style></author><author><style face="normal" font="Arial"> Yachie,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Increased CD69 Expression on Peripheral Eosinophils from Patients with Food Protein-Induced Enterocolitis Syndrome</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="205" start="201">201-205</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil-Derived Neurotoxin</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="9" Year="2016">2016/9/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food protein-induced enterocolitis syndrome (FPIES) is an uncommon, non-IgE-mediated food allergy. We recently described a significant increase in fecal eosinophil-derived neurotoxin (EDN) after ingestion of the causative food. However, little is known about the activation status of circulating eosinophils in patients with an acute FPIES reaction. METHODS: Surface CD69 expression was assessed by flow cytometry on peripheral eosinophils from 5 patients with FPIES before and after ingestion of the causative food. Fecal EDN was measured by enzyme-linked immunosorbent assay. RESULTS: No eosinophil activation was observed before ingestion; however, a significant increase in CD69 expression on eosinophils after an acute FIPES reaction was demonstrated in all of the patients. There was no significant change in absolute eosinophil counts in the peripheral blood. The levels of fecal EDN increased on the day after ingestion of the causative food in all patients. CONCLUSION: These results suggest that circulating eosinophils as well as eosinophils in the intestinal mucosal tissue are activated in acute FPIES reactions and might be associated with systemic immune events in FPIES</style></abstract><notes><style face="normal" font="Arial">DA - 20160905IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000448755</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27595267">PM:27595267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-201-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-201-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160905, Wada T</style></custom2><misc3><style face="normal" font="Arial">10.1159/000448755</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mosbech,H.</style></author><author><style face="normal" font="Arial"> Tang,L.</style></author><author><style face="normal" font="Arial"> Linneberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Clinic, Copenhagen University Hospital Gentofte, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Insect Sting Reactions and Specific IgE to Venom and Major Allergens in a General Population</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="200" start="194">194-200</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="3" Month="9" Year="2016">2016/9/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Insect sting reactions are frequently reported, but population studies documenting the frequency and the relation to IgE-sensitization and serum tryptase are scarce. METHODS: Questionnaire data and results from measurements of specific IgE against venom, major allergens and cross-reacting carbohydrate determinants (CCDs) were collected from 2,090 adult participants in a cross-sectional survey. RESULTS: 13% of the population reported symptoms of sting reactions and about half were systemic in nature. In all, 15% were sensitized to venom but only 31% of these had reacted to stings and only 38% of those with reactions had IgE to venom. In addition, 12% with IgE to venom were double-sensitized (DS), i.e. to both bee and wasp venom. Among DS IgE to major venom allergens, rApi m 1, rVes v 1 and rVes v 5 were negative and of no help in 31%, but 59% could be identified as likely sensitized to bee or wasp. IgE to CCDs occurred in only 0.7%, but 80% of these were DS. Finally, 36% with IgE to CCDs had had symptoms, mostly local. Serum tryptase was not associated with a history of sting reactions. CONCLUSIONS: In a temperate climate, self-reported insect sting reactions and sensitization to venom are frequent, but in most cases, these are not seen in the same individual. In DS individuals, measurements of IgE to major allergens can be helpful in some but not all cases and additional analyses are needed. IgE to CCDs may have some clinical relevance</style></abstract><notes><style face="normal" font="Arial">DA - 20160904IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1159/000448399</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27591992">PM:27591992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-194-200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-194-200.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160904, Mosbech H</style></custom2><misc3><style face="normal" font="Arial">10.1159/000448399</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Becker,S.</style></author><author><style face="normal" font="Arial"> Schlederer,T.</style></author><author><style face="normal" font="Arial"> Kramer,M.F.</style></author><author><style face="normal" font="Arial"> Haack,M.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author><author><style face="normal" font="Arial"> Resch,Y.</style></author><author><style face="normal" font="Arial"> Lupinek,C.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Groger,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center, Johannes Gutenberg University, Mainz, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Real-Life Study for the Diagnosis of House Dust Mite Allergy - The Value of Recombinant Allergen-Based IgE Serology</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="137" start="132">132-137</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biochip</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 10</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Der p 23</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> enzyme immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> MeDALL</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dermatophagoides pteronyssinus is one of the most important perennial allergen sources worldwide. Molecular diagnostics using the commercially available major allergens (Der p 1 and Der p 2) in combination with Der p 10 do not detect house dust mite (HDM) sensitization in a number of cases when used alone. The objective was to evaluate the IgE reactivity profiles of these patients using an experimental immunoassay biochip. METHODS: Sera of HDM-allergic patients (positive skin prick test, CAP class >/=1 for allergen extract, and positive intranasal provocation) were tested for IgE antibodies against Der p 1, Der p 2, and Der p 10 by ImmunoCAP fluorescence enzyme immunoassay. Negatively tested sera were examined by an experimental chip containing 13 microarrayed HDM allergens. RESULTS: Of 97 patients tested, 16 showed negative results to Der p 1, Der p 2, and Der p 10. MeDALL chip evaluation revealed 5 patients monosensitized to Der p 23, and 11 patients were negative for all HDM MeDALL chip components. Seven sera were available for further testing, and 3 of them showed IgE reactivity to dot-blotted nDer p 1, and 2 reacted with high-molecular weight components (>100 kDa) in nitrocellulose-blotted HDM extract when tested with 125I-labeled anti-IgE in a RAST-based assay. The HDM extract-specific IgE levels of the 11 patients were &lt;3.9 kU/l. CONCLUSIONS: Recombinant allergen-based IgE serology is of great value when conventional IgE diagnostics fails. Der p 23 is an important HDM allergen, especially when major allergens are negative. Therefore, it would be desirable to have Der p 23 commercially available. Further research concerning the prevalence and clinical significance of different HDM allergens is needed</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleSB - IMCO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000447694</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27505432">PM:27505432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-132-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-132-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Becker S</style></custom2><misc3><style face="normal" font="Arial">10.1159/000447694</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,X.</style></author><author><style face="normal" font="Arial"> Yu,D.</style></author><author><style face="normal" font="Arial"> Wang,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Otolaryngology, Head and Neck Surgery, 2nd Hospital Affiliated to Jilin University, Changchun, China</style></auth-address><titles><title><style face="normal" font="Arial">Sappanone A Attenuates Allergic Airway Inflammation in Ovalbumin-Induced Asthma</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="186" start="180">180-186</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sappanone A (SA) is isolated from the heartwood of Caesalpinia sappan and exerts a wide range of pharmacological activities. In the present study, we investigated the protective effects of SA on allergic asthma in a murine model of ovalbumin (OVA)-induced asthma. METHODS: BALB/c mice were sensitized and challenged. Then, the mice were intraperitoneally injected with SA (12.5, 25 and 50 mg/kg) 1 h before OVA challenge; 24 h after the last challenge, the mice were sacrificed, and data were collected by different experimental methods. RESULTS: The results showed that SA dose-dependently reduced inflammatory cell counts, levels of cytokines IL-4, IL-5 and IL-13, and OVA-specific IgE in bronchoalveolar lavage fluid. The level of IFN-gamma decreased by OVA was upregulated by the treatment with SA. Furthermore, SA was found to attenuate the airway inflammation and mucus hypersecretion induced by the OVA challenge. In addition, SA dose-dependently upregulated the expression of Nrf2 and HO-1. SA inhibited OVA-induced asthma by activating the Nrf2 signaling pathway. CONCLUSIONS: These data suggest that SA may have a potential use as a therapeutic agent for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1159/000448331</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27576536">PM:27576536</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-180-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-180-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Liu X</style></custom2><misc3><style face="normal" font="Arial">10.1159/000448331</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Savilahti,E.M.</style></author><author><style face="normal" font="Arial"> Makitie,O.</style></author><author><style face="normal" font="Arial"> Kukkonen,A.K.</style></author><author><style face="normal" font="Arial"> Andersson,S.</style></author><author><style face="normal" font="Arial"> Viljakainen,H.</style></author><author><style face="normal" font="Arial"> Savilahti,E.</style></author><author><style face="normal" font="Arial"> Kuitunen,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Serum 25-Hydroxyvitamin D in Early Childhood Is Nonlinearly Associated with Allergy</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="148" start="141">141-148</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Umbilical Cord</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Vitamin D has several immunological functions. Data on the relation of vitamin D status and allergy are controversial. METHODS: We investigated the association between serum concentrations of 25-hydroxyvitamin D (25-OHD) and allergy in childhood. The study population (n = 819) was part of a randomized, double-blind, placebo-controlled trial where the mothers of offspring with a high risk for allergy received a mixture of probiotics (or placebo) for the last 4 weeks of pregnancy, and the child received this from birth to 6 months. Study subjects were followed for the emergence of sensitization and allergic symptoms for a period of 5 years, with medical examinations at the ages of 3 and 6 months, 2 and 5 years and also in the event of allergic symptoms. Levels of 25-OHD were measured in umbilical cord blood (UCB) samples (n = 724) and serum samples drawn at the age of 2 years (n = 369); the data were categorized into tertiles (T1-T3) and quartiles (Q1-Q4). The relation between 25-OHD levels and sensitization and allergy was analyzed with multivariable logistic regression analysis. RESULTS: 25-OHD levels in T2 in UCB were associated with a higher risk for sensitization by the age of 2 years and allergic disorders by the age of 5 years. In the serum samples, at the age of 2 years, 25-OHD levels in Q3 were associated with a higher risk of sensitization and IgE-mediated allergies by the age of 5 years. CONCLUSIONS: The 25-OHD levels in early childhood are associated with the emergence of allergy, but the association appears to be nonlinear</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Finland -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1159/000447636</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27533066">PM:27533066</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-141-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-141-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Savilahti EM</style></custom2><misc3><style face="normal" font="Arial">10.1159/000447636</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Peng,Z.</style></author><author><style face="normal" font="Arial"> Caihe,L.</style></author><author><style face="normal" font="Arial"> Beckett,A.N.</style></author><author><style face="normal" font="Arial"> Guan,Q.</style></author><author><style face="normal" font="Arial"> James,A.A.</style></author><author><style face="normal" font="Arial"> Simons,F.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatrics and Child Health, University of Manitoba, Winnipeg, Man., Canada</style></auth-address><titles><title><style face="normal" font="Arial">rAed a 4: A New 67-kDa Aedes aegypti Mosquito Salivary Allergen for the Diagnosis of Mosquito Allergy</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="210" start="206">206-210</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aedes</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="9" Year="2016">2016/9/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Accurate diagnosis of mosquito allergy has been hampered by the laborious task of obtaining mosquito salivary allergens. We have previously studied 3 recombinant (r) Aedes aegypti mosquito salivary allergens: rAed a 1, rAed a 2 and rAed a 3. Here, we report the expression, purification, identification and evaluation of rAed a 4, a 67-kDa alpha-glucosidase. METHODS: rAed a 4 was expressed using a baculovirus/insect cell system, purified by a combination of anion- and cation-exchange chromatography, and identified by immunoblotting. A. aegypti saliva extract was prepared in our laboratory. An indirect enzyme-linked immunosorbent assay (ELISA) was developed to measure rAed a 4-specific immunoglobulin E (IgE) and IgG antibodies in sera from 13 individuals with a positive mosquito-bite test from a laboratory-reared mosquito. Sera from 18 individuals with a negative bite test served as controls. RESULTS: Purified rAed a 4 bound to the IgE in mosquito-allergic sera, as detected by ELISA and immunoblotting. The binding of rAed a 4 to IgE could be inhibited in a dose-dependent manner by the addition of an A. aegypti extract. Mosquito-allergic individuals had significantly higher mean levels of rAed a 4-specific IgE and IgG than controls. Using the mean of the controls +/- 2 SD as a cut-off level, 46% of the 13 allergic individuals had a positive IgE, while none of the controls was positive (p &lt; 0.001). CONCLUSIONS: Aed a 4 is a major allergen in mosquito saliva. Its recombinant form has the hydrolase function and can be used for the diagnosis of mosquito allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1159/000448587</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27603527">PM:27603527</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-206-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-206-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Peng Z</style></custom2><misc3><style face="normal" font="Arial">10.1159/000448587</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamizan,A.W.</style></author><author><style face="normal" font="Arial"> Christensen,J.M.</style></author><author><style face="normal" font="Arial"> Ebenzer,J.</style></author><author><style face="normal" font="Arial"> Oakley,G.</style></author><author><style face="normal" font="Arial"> Tattersall,J.</style></author><author><style face="normal" font="Arial"> Sacks,R.</style></author><author><style face="normal" font="Arial"> Harvey,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Rhinology and Skull Base Research Group, St. Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, NSW, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Middle turbinate edema as a diagnostic marker of inhalant allergy</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="42" start="37">37-42</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergy</style></keyword><keyword><style face="normal" font="Arial"> Likelihood ratio</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> nasal endoscopy</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Skull</style></keyword><keyword><style face="normal" font="Arial"> Skull Base</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Middle turbinate edema could be a characteristic feature of aeroallergen sensitization. In this study we sought to determine the diagnostic characteristics of middle turbinate edema as a marker of inhalant allergy. METHODS: A cross-sectional diagnostic study was performed on patients who had undergone nasal endoscopy and allergy testing. Allergy status was determined by positive serology or epicutaneous testing. Endoscopy was reviewed by blinded assessors for middle turbinate head edema. Appearance was graded as either normal, focal, multifocal, diffuse, or polypoid edema. Receiver-operator (ROC) analysis, likelihood ratio (LR), sensitivity, specificity, and positive predictive value (PPV) were determined. RESULTS: One hundred eighty-seven patients representing 304 nasal cavities were assessed (42% female, age 39.74 +/- 14.7 years, 57% allergic). Diffuse edema (PPV 91.7%/LR = 8) and polypoid edema (PPV 88.9%/LR = 6.2) demonstrated the strongest association with inhalant allergy. Multifocal edema was used as a cut-off to represent inhalant allergy from ROC analysis, which demonstrated 94.7% specificity and 23.4% sensitivity. The PPV for multifocal was 85.1% and LR = 4.4. CONCLUSION: Middle turbinate edema is a useful nasal endoscopic feature to predict presence of inhalant allergy and, although not sensitive, has excellent PPV</style></abstract><notes><style face="normal" font="Arial">DA - 20160817IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Malaysia -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21835</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27530103">PM:27530103</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-37-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-37-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160817, Hamizan AW</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21835</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,W.C.</style></author><author><style face="normal" font="Arial"> Lai,C.L.</style></author><author><style face="normal" font="Arial"> Liang,Y.T.</style></author><author><style face="normal" font="Arial"> Hung,H.C.</style></author><author><style face="normal" font="Arial"> Liu,H.C.</style></author><author><style face="normal" font="Arial"> Liou,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Health Industry Technology and Research Center for Industry of Human Ecology, College of Human Ecology, Chang Gung University of Science and Technology, No.261, Wenhua 1st Rd., Guishan Dist., Taoyuan City 33303, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Phloretin attenuates LPS-induced acute lung injury in mice via modulation of the NF-kappaB and MAPK pathways</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="105" start="98">98-105</pages><volume><style face="normal" font="Arial">40</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heme</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> intercellular adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">Phloretin, which can be isolated from apple trees, has demonstrable anti-inflammatory and anti-oxidant effects in macrophages. We previously reported that phloretin could inhibit the inflammatory response and reduce intercellular adhesion molecule 1 (ICAM-1) expression in interleukin (IL)-1beta-activated human lung epithelial cells. In the present study we now evaluate whether phloretin exposure could ameliorate lipopolysaccharide (LPS)-induced acute lung injury in mice. Intra-peritoneal injections of phloretin were administered to mice for 7 consecutive days, prior to the induction of lung injury by intra-tracheal administration of LPS. Our subsequent analyses demonstrated that phloretin could significantly suppress LPS-induced neutrophil infiltration of lung tissue, and reduce the levels of IL-6 and tumor necrosis factor (TNF)-alpha in serum and bronchoalveolar lavage fluid. We also found that phloretin modulated myeloperoxidase activity and superoxide dismutase activity, with decreased gene expression levels for chemokines, proinflammatory cytokines, and ICAM-1 in inflamed lung tissue. Phloretin also significantly reduced the phosphorylation of nuclear factor kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK), thus limiting the inflammatory response, while promoting expression of heme oxygenase (HO)-1 and nuclear factor erythroid 2-related factor 2, both of which are cytoprotective. Our findings suggest that, mechanistically, phloretin attenuates the inflammatory and oxidative stress pathways that accompany lung injury in mice via blockade of the NF-kappaB and MAPK pathways</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2016.08.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27588909">PM:27588909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2016-40-98-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2016-40-98-105.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Huang WC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2016.08.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81562</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singh,D.K.</style></author><author><style face="normal" font="Arial"> Gulati,K.</style></author><author><style face="normal" font="Arial"> Ray,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110 007, India</style></auth-address><titles><title><style face="normal" font="Arial">Effects of chelidonic acid, a secondary plant metabolite, on mast cell degranulation and adaptive immunity in rats</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="234" start="229">229-234</pages><volume><style face="normal" font="Arial">40</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Foot</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat peritoneal mast cells</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">The present study evaluated the immunomodulatory effects of chelidonic acid, a secondary plant metabolite, with therapeutic potential in allergic disorders, in experimental animals. In mast cell degranulation studies, ovalbumin immunized and challenged rats, chelidonic acid (1, 3 and 10mg/kg, i.p.) dose relatedly prevented ovalbumin challenge induced mast cell degranulation by differing degrees when compared with vehicle treated group, and these effects were comparable with prednisolone (10mg/kg). A reduction in post-challenge mortality was also observed in all treated groups. Further, there were reductions in the blood eosinophil counts and serum IgE levels after chelidonic acid treatment. Chelidonic acid also inhibited histamine release from rat peritoneal mast cells (RPMC) in vitro, in a dose related manner. In tests for adaptive immunity, in rats immunized with sheep RBC, chelidonic acid differentially suppressed the (a) plaque forming cell (PFC) count in rat splenic cells, (b) anti-SRBC antibody titre and serum IgG levels and (c) increases in foot pad thickness in the DTH assay - all of which were comparable with prednisolone. These experimental results are discussed in light of the possible therapeutic potential of chelidonic acid in allergic disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2016.08.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27620504">PM:27620504</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2016-40-229-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2016-40-229-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Singh DK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2016.08.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,L.T.</style></author><author><style face="normal" font="Arial"> Chang,H.W.</style></author><author><style face="normal" font="Arial"> Wu,M.J.</style></author><author><style face="normal" font="Arial"> Lai,Y.T.</style></author><author><style face="normal" font="Arial"> Wu,W.C.</style></author><author><style face="normal" font="Arial"> Yu,W.C.</style></author><author><style face="normal" font="Arial"> Chang,V.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Klf10 deficiency in mice exacerbates pulmonary inflammation by increasing expression of the proinflammatory molecule NPRA</style></title><secondary-title><style face="normal" font="Arial">Int J Biochem Cell Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Biochem Cell Biol</style></abbr-1></periodical><pages end="238" start="231">231-238</pages><volume><style face="normal" font="Arial">79</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> repressor</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">KLF10 is a transforming growth factor (TGF)-beta/Smad downstream regulated gene. KLF10 binds to the promoter of target genes and mimics the effects of TGF-beta as a transcriptional factor. In our laboratory, we noted that Klf10 deficiency in mice is associated with significant inflammation of the lungs. However, the precise mechanism of this association remains unknown. We previously identified NPRA as a target gene potentially regulated by KLF10 through direct binding; NPRA knockout have known that prevented lung inflammation in a mouse model of allergic asthma. Here, we further explored the regulatory association between KLF10 and NPRA on the basis of the aforementioned findings. Our results demonstrated that KLF10 acts as a transcriptional repressor of NPRA and that KLF10 binding reduces NPRA expression in vitro. Compared with wild-type mice, Klf10-deficient mice were more sensitive to lipopolysaccharide or ovalbumin challenge and showed more severe inflammatory histological changes in the lungs. Moreover, Klf10-deficient mice showed pulmonary neutrophil accumulation. These findings collectively reveal the precise site where KLF10 signaling affects pulmonary inflammation by attenuating NPRA expression. They also verify the importance of KLF10 and atrial natriuretic peptide/NPRA in exerting influences on chronic pulmonary disease pathogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1878-5875 (Electronic)IS - 1357-2725 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biocel.2016.08.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27592451">PM:27592451</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biochem Cell Biol\2016-79-231-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biochem Cell Biol\2016-79-231-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Huang LT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biocel.2016.08.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stanciuc,N.</style></author><author><style face="normal" font="Arial"> Banu,I.</style></author><author><style face="normal" font="Arial"> Turturica,M.</style></author><author><style face="normal" font="Arial"> Aprodu,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dunarea de Jos University of Galati, Faculty of Food Science and Engineering, Domneasca Street 111, 800201, Galati, Romania</style></auth-address><titles><title><style face="normal" font="Arial">pH and heat induced structural changes of chicken ovalbumin in relation with antigenic properties</style></title><secondary-title><style face="normal" font="Arial">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biol Macromol</style></full-title></periodical><pages end="581" start="572">572-581</pages><volume><style face="normal" font="Arial">93</style></volume><number><style face="normal" font="Arial">Pt A</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics Simulation</style></keyword><keyword><style face="normal" font="Arial"> Molecular dynamics simulations</style></keyword><keyword><style face="normal" font="Arial"> Molecular model</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">Ovalbumin is the major egg white protein known to induce allergic reactions in humans. A comprehensive evaluation of the structural and antigenicity features of ovalbumin subjected to different pH and heat treatments was performed by combining fluorescence spectroscopic measurements, ELISA and in silico prediction. The intrinsic fluorescence spectra indicated modification of the ovalbumin tertiary structure depending on pH and applied temperature. The heat treatment caused the alteration of ovalbumin structure, which exhibited gradual hydrophobic exposure. The in depths check of ovalbumin molecular model, after performing molecular dynamics simulations, indicated the slight transition toward a typical beta-strand dominant structure with the temperature increase. Moreover the immunoenzymatic test was employed to estimate the effect of the pH and thermal treatment on the stability of ovalbumin epitopes. Only a 5.5% reduction of the residual antigenicity was observed when heat treating the ovalbumin samples at pH 7.0, whereas a significant reduction (over 82%) of the antigenicity was obtained at pH 9.5 and temperatures over 80 degrees C. Both pH and thermal treatment affected the conformation of ovalbumin. The reduced recognition of the modified native ovalbumin by specific antibodies at alkaline pH is most probably a consequence of significant changes in the local conformation of the epitopes</style></abstract><notes><style face="normal" font="Arial">DA - 20160915IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Romania -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijbiomac.2016.09.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27616691">PM:27616691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biol Macromol\2016-93-572-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biol Macromol\2016-93-572-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160915, Stanciuc N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijbiomac.2016.09.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,H.I.</style></author><author><style face="normal" font="Arial"> Cha,K.C.</style></author><author><style face="normal" font="Arial"> Cha,Y.S.</style></author><author><style face="normal" font="Arial"> Kim,O.H.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author><author><style face="normal" font="Arial"> Ahn,M.S.</style></author><author><style face="normal" font="Arial"> Lee,J.W.</style></author><author><style face="normal" font="Arial"> Hwang,S.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, Wonju College of Medicine, Yonsei University, Wonju, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">A subset of type I variant Kounis syndrome: Allergic angina syndrome and persistent presence of coronary spasm</style></title><secondary-title><style face="normal" font="Arial">Int J Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Cardiol</style></full-title></periodical><pages end="961" start="959">959-961</pages><volume><style face="normal" font="Arial">223</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic angina</style></keyword><keyword><style face="normal" font="Arial"> Coronary spasm</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Spasm</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="8" Year="2016">2016/8/24</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1874-1754 (Electronic)IS - 0167-5273 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijcard.2016.08.247</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27589045">PM:27589045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Cardiol\2016-223-959-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Cardiol\2016-223-959-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Kim HI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijcard.2016.08.247</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,B.</style></author><author><style face="normal" font="Arial"> Mo,L.</style></author><author><style face="normal" font="Arial"> Zeng,L.</style></author><author><style face="normal" font="Arial"> Li,X.X.</style></author><author><style face="normal" font="Arial"> Qiu,S.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Research Center of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China</style></auth-address><titles><title><style face="normal" font="Arial">SEB/OVA Facilitated TIM4 Expression in Intestinal Antigen Presenting Cells via Acetylation of Histone H3</style></title><secondary-title><style face="normal" font="Arial">Int J Clin Med Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Clin Med Allergy</style></full-title></periodical><pages end="43" start="38">38-43</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Histones</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal enterotoxin B</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background: Various animal models have been established to dictate the pathogenesis of food allergy and each one has its own limitation. This study aimed to investigate the detailed molecular mechanisms underlying Staphylococcal enterotoxin B (SEB)/ovalbumin (OVA)-induced allergic reaction in mouse intestine.Methods: Using SEB/OVA-sensitized food allergic model, the effect of SEB/OVA on Th1/Th2 cytokine production was determined by ELISA. Mean while, the gene and protein expression of TIM4 in intestinal antigen presenting cells (APCs) was evaluated by PCR and Western blot, respectively. The inducible effect of SEB/OVA-primed APCs on TIM1 expression of CD4+ T cell was also investigated. Finally, the acetylation of histones induced by SEB/OVA was analyzed by Western blot.Results: We demonstrated that SEB/OVA showed dual effect on Th1/Th2 responses. The mRNA and protein expression of TIM4 in intestinal APCs was significantly elevated by SEB/OVA sensitization, which could further induce TIM1 expression on CD4+ T cell. The enhancement of TIM4 was mediated by acetylation of histone H3.Conclusion: The present study demonstrated that the effect of SEB/OVA on Th0 cell differentiation is dependent on its concentration. Furthermore, SEB/OVA induced TIM4 up-regulation may be via acetylation of histone H3.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://scidoc.org/IJCMA-2332-2799-04-101.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Clin Med Allergy\2016-4-38-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Clin Med Allergy\2016-4-38-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Yang B</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81567</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tous Romero,F.</style></author><author><style face="normal" font="Arial"> Delgado-Marquez,A.M.</style></author><author><style face="normal" font="Arial"> Gargallo-Moneva,V.</style></author><author><style face="normal" font="Arial"> Burillo-Martinez,S.</style></author><author><style face="normal" font="Arial"> Martin Diaz,A.</style></author><author><style face="normal" font="Arial"> Zarco-Olivo,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Linear and urticarial rash-like manifestation of acute strongyloidiasis</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="e9" start="e7">e7-e9</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strongyloidiasis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - ENGPT - LETTERCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.13391</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27613704">PM:27613704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\20160910-TousRomeroF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\20160910-TousRomeroF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Tous Romero F</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.13391</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Piontek,M.</style></author><author><style face="normal" font="Arial"> Luszczynska,K.</style></author><author><style face="normal" font="Arial"> Lechow,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Applied Ecology, Faculty of Civil Engineering, Architecture and Environmental Engineering, Institute of Environmental Engineering, University of Zielona Gora, ul. Prof. Z. Szafrana 15, 65-516 Zielona Gora, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Occurrence of the Toxin-Producing Aspergillus versicolor Tiraboschi in Residential Buildings</style></title><secondary-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></full-title></periodical><pages end="" start="862">862-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus versicolor</style></keyword><keyword><style face="normal" font="Arial"> Biomass</style></keyword><keyword><style face="normal" font="Arial"> Biosafety</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">In an area representative of a moderate climate zone (Lubuskie Province in Poland), mycological tests in over 270 flats demonstrated the occurrence of 82 species of moulds. Aspergillus versicolor Tiraboschi was often encountered on building partitions (frequency 4: frequently). The ability to synthesize the carcinogenic sterigmatocystin (ST) means that it poses a risk to humans and animals. Biotoxicological tests of biomasses of A. versicolor were conducted in the Microbiological and Toxicological Laboratory, using the planarians Dugesia tigrina (Girard). The obtained results of the tests covered a broad range of toxicity levels of isolated strains: from weakly toxic (100-1000 mg.L(-3)) to potently toxic (1-10 mg.L(-3)). The high-performance liquid chromatography (HPLC) physicochemical method confirmed the ability of A. versicolor strains to synthesize sterigmatocystin. All of the samples of the air-dry biomasses of the fungi contained ST in the range between 0.03 and 534.38 mg.kg(-1). In the bio-safety level (BSL) classification A. versicolor belongs to category 1. Additionally, A. versicolor is an allergenic mould</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Journal ArticleSB - IMCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijerph13090862</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27589778">PM:27589778</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Environ Res Public Health\2016-13-862.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Environ Res Public Health\2016-13-862.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Piontek M</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijerph13090862</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boga,J.A.</style></author><author><style face="normal" font="Arial"> Rojo,S.</style></author><author><style face="normal" font="Arial"> Fernandez,J.</style></author><author><style face="normal" font="Arial"> Rodriguez,M.</style></author><author><style face="normal" font="Arial"> Iglesias,C.</style></author><author><style face="normal" font="Arial"> Martinez-Camblor,P.</style></author><author><style face="normal" font="Arial"> Vazquez,F.</style></author><author><style face="normal" font="Arial"> Rodriguez-Guardado,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Microbiologia, Hospital Universitario Central de Asturias, Oviedo, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Is the treatment of Enterobius vermicularis co-infection necessary to eradicate Dientamoeba fragilis infection?</style></title><secondary-title><style face="normal" font="Arial">Int J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Infect Dis</style></full-title></periodical><pages end="61" start="59">59-61</pages><volume><style face="normal" font="Arial">49</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> co-infection</style></keyword><keyword><style face="normal" font="Arial"> Coinfection</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterobius</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Mebendazole</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Metronidazole</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Failure</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Dientamoeba fragilis is a pathogenic protozoan of the human gastrointestinal tract with a worldwide distribution, which has emerged as an important and misdiagnosed cause of chronic gastrointestinal illnesses such as diarrhea and 'irritable-bowel-like' gastrointestinal disease. Very little research has been conducted on the use of suitable antimicrobial compounds. Furthermore, higher rates of co-infection with Enterobius vermicularis have been described, suggesting that E. vermicularis could influence the treatment of D. fragilis-infected patients. To study this, the treatment of E. vermicularis and D. fragilis co-infected patients was evaluated. METHODS: Forty-nine patients with a D. fragilis infection, including 25 (51.0%) patients co-infected with E. vermicularis, were studied. All of them were treated with metronidazole. Patients with E. vermicularis co-infection and/or an E. vermicularis-positive case in the family were treated with mebendazole. RESULTS: Metronidazole treatment failure was significantly more frequent in patients with E. vermicularis co-infection and in patients with children in the family. CONCLUSIONS: Co-infection with E. vermicularis may act as a factor favoring D. fragilis infection by preventing eradication measures. This suggests that both parasites should be treated simultaneously</style></abstract><notes><style face="normal" font="Arial">DA - 20160806IS - 1878-3511 (Electronic)IS - 1201-9712 (Linking)LA - engPT - Journal ArticleSB - IMCO - Spain -CO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijid.2016.05.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27263118">PM:27263118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Infect Dis\2016-49-59-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Infect Dis\2016-49-59-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160806, Boga JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijid.2016.05.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,X.L.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Guo,Y.H.</style></author><author><style face="normal" font="Arial"> Sun,P.</style></author><author><style face="normal" font="Arial"> Jia,H.X.</style></author><author><style face="normal" font="Arial"> Fan,W.</style></author><author><style face="normal" font="Arial"> Lu,M.Z.</style></author><author><style face="normal" font="Arial"> Hu,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Tree Genetics and Breeding, Key Laboratory of Tree Breeding and Cultivation of State Forestry Administration, Research Institute of Forestry, Chinese Academy of Forestry, Beijing 100091, China.</style></auth-address><titles><title><style face="normal" font="Arial">Comparative Proteomic Analysis of Mature Pollen in Triploid and Diploid Populus deltoides</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="1475">1475-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2-DE</style></keyword><keyword><style face="normal" font="Arial"> Abundance</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Cell Size</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cytoskeleton</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Fertility</style></keyword><keyword><style face="normal" font="Arial"> Forestry</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant growth</style></keyword><keyword><style face="normal" font="Arial"> Ploidies</style></keyword><keyword><style face="normal" font="Arial"> Ploidy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polyploidy</style></keyword><keyword><style face="normal" font="Arial"> Populus</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Two dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Ploidy affects plant growth vigor and cell size, but the relative effects of pollen fertility and allergenicity between triploid and diploid have not been systematically examined. Here we performed comparative analyses of fertility, proteome, and abundances of putative allergenic proteins of pollen in triploid poplar 'ZhongHuai1' ('ZH1', triploid) and 'ZhongHuai2' ('ZH2', diploid) generated from the same parents. The mature pollen was sterile in triploid poplar 'ZH1'. By applying two-dimensional gel electrophoresis (2-DE), a total of 72 differentially expressed protein spots (DEPs) were detected in triploid poplar pollen. Among them, 24 upregulated and 43 downregulated proteins were identified in triploid poplar pollen using matrix-assisted laser desorption/ionisation coupled with time of-flight tandem mass spectrometer analysis (MALDI-TOF/TOF MS/MS). The main functions of these DEPs were related with "S-adenosylmethionine metabolism", "actin cytoskeleton organization", or "translational elongation". The infertility of triploid poplar pollen might be related to its abnormal cytoskeletal system. In addition, the abundances of previously identified 28 putative allergenic proteins were compared among three poplar varieties ('ZH1', 'ZH2', and '2KEN8'). Most putative allergenic proteins were downregulated in triploid poplar pollen. This work provides an insight into understanding the protein regulation mechanism of pollen infertility and low allergenicity in triploid poplar, and gives a clue to improving poplar polyploidy breeding and decreasing the pollen allergenicity</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms17091475</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27598155">PM:27598155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2016-17-1475.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2016-17-1475.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Zhang XL</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms17091475</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zubchenko,S.O.</style></author><author><style face="normal" font="Arial"> Yuriev,S.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Assessment diagnostic criteria in patients with different clinical and laboratory manifestations of sensitization to house dust mites efficiency and forecasting allergen specific immunotherapy based on allergies component diagnostic</style></title><secondary-title><style face="normal" font="Arial">Int Rev Allergol Clin Immunol Fam Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Rev Allergol Clin Immunol Fam Med</style></full-title></periodical><pages end="160" start="153">153-160</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> poly-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ukraine</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">In recent years, marked increase in the number of allergic diseases. Among the common causes of allergic sensitization pathologies allergens are dust mites.The aim of the study was to evaluate the efficiency forecast of allergen specific immunotherapy in 20 patients with sensitization and clinical manifestations of allergy to house dust mites.Material and methods. Verify the diagnosis carried out on the basis of anamnesis, clinical and general laboratory, instrumental studies, the results of skin prick tests (Diater, Spain) ELISA using test kits "Euroimmun" and allergic component diagnostics using immunofluorescence method ImmunoCAP ("Phadia AB", Sweden).Results. Based on studies in 45.0% of defined - absolute mild eosinophilia ,in 40.0% - the presence of eosinophils in cytology nasal mucosa, in 65.0% - elevated levels of total serum ige, in 30.0% - parasitic invasion. According prick test and ELISA tests showed 35.0% of people with poly sensitization and all patients exhibited a previous diagnosis. After the diagnosis of allergies component in 80.0% of patients proved true allergic sensitization to various ingredients often - rDer p1, rDer p2.Conclusion. Component allergy diagnostics allowed to verify the final diagnosis and decide on the selection of adequate treatment and to determine the forecast of its performance. Component definition of sensitizing profile by Consensus of molecular diagnostics and high sensitivity of this method reveals that the true protein is the primary cause allergies and assign causal allergenspecific allergen immunotherapy is the fact, which revealed sensitization. In the treatment of patients is important to use standardized allergens in activity, which controlled for the major components that achieves the highest possible treatment effect.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Ukraine -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.medpress.com.pl/IRa2015.htm</url></web-urls></urls><custom2><style face="normal" font="Arial">20160908, Zubchenko SO</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kotwica,E.</style></author><author><style face="normal" font="Arial"> Kubaszewska,M.</style></author><author><style face="normal" font="Arial"> Szybinska,M.</style></author><author><style face="normal" font="Arial"> Sokolowski,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Science Student's Group, Department of Internal Medicine, Pneumonology and Allergology, Central Clinical Hospital of the Ministry of National Defence, Military Institute of Medicine in Warsaw; 2Department of Internal Medicine, Pneumonology and Allergology, Central Clinical Hospital of the Ministry of National Defence, Military Institute of Medicine in Warsaw</style></auth-address><titles><title><style face="normal" font="Arial">Occupational respiratory diseases and skin disorders among workers hairdressers</style></title><secondary-title><style face="normal" font="Arial">Int Rev Allergol Clin Immunol Fam Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Rev Allergol Clin Immunol Fam Med</style></full-title></periodical><pages end="" start="049">049-</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> hairdressers</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Paint</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Potassium</style></keyword><keyword><style face="normal" font="Arial"> PPD</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Toxic reaction</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Makeup used in a hair salon may contribute to the development of allergic and toxic reactions, in particular in the respiratory system. Components of varnish and paint for example: persulfates of ammonium and potassium, cause inflammation in the airways. Therefore, bronchial asthma, eosinophilic bronchitis and rhinitis are common disorders in this professional group. Repeated skin contact hands with shampoo and soap, contributes to induce inflammatory skin diseases. This applies to approx. 30% of hairdressers. Parafenylodiamina (PPD) belongs to a group of allergens most often responsible for allergic contact dermatitis. There are no effective prophylaxis, it is important to raise awareness among doctors and hairdressers on risks and methods of prevention of these diseases.</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.medpress.com.pl/IRa2016.htm</url></web-urls></urls><custom2><style face="normal" font="Arial">20160908, Kotwica E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Noguchi,S.</style></author><author><style face="normal" font="Arial"> Yatera,K.</style></author><author><style face="normal" font="Arial"> Jinbo,M.</style></author><author><style face="normal" font="Arial"> Yamada,S.</style></author><author><style face="normal" font="Arial"> Shimabukuro,I.</style></author><author><style face="normal" font="Arial"> Yamasaki,K.</style></author><author><style face="normal" font="Arial"> Kido,T.</style></author><author><style face="normal" font="Arial"> Ishimoto,H.</style></author><author><style face="normal" font="Arial"> Yoshii,C.</style></author><author><style face="normal" font="Arial"> Mukae,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan</style></auth-address><titles><title><style face="normal" font="Arial">IgG4-related Lung Disease Associated with Autoimmune Hemolytic Anemia: A Case Report and a Literature Review</style></title><secondary-title><style face="normal" font="Arial">Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Intern Med</style></abbr-1></periodical><pages end="2474" start="2469">2469-2474</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">17</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anemia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchiolitis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">We herein report a case of IgG4-related lung disease (IgG4-RLD) associated with autoimmune hemolytic anemia (AIHA). A 73-year-old Japanese female visited our hospital for an examination following an abnormal chest X-ray in 1999. She was diagnosed with bronchiolitis and AIHA, and treatment with prednisolone was started. After seven years, she visited our department due to a cough. Chest computed tomography (CT) demonstrated focal consolidation with ground-glass attenuations and thickened bronchial walls in the bilateral lungs. She was clinically diagnosed and treated for bronchial asthma. CT findings had shown no changes, and a lung biopsy was performed using video-assisted thoracic surgery at eleven years from the first diagnosis of AIHA. The pathological findings demonstrated the presence of peribronchovascular lymphoplasmacytic infiltrates with stromal fibrotic changes, admixed with many IgG4-positive plasma cells. Furthermore, the patient's serum IgG4 level was high, and her CT findings did not show any obvious abnormal findings in the any organs other than the lungs. She was diagnosed with IgG4-RLD based on the findings. We believe that this case report of IgG4-RLD associated with AIHA is clinically helpful for a better understanding of these diseases, although there are five reported cases of IgG4-related disease associated with AIHA</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1349-7235 (Electronic)IS - 0918-2918 (Linking)LA - engPT - Journal ArticleSB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2169/internalmedicine.55.6499</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27580552">PM:27580552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med\2016-55-2469-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med\2016-55-2469-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Noguchi S</style></custom2><misc3><style face="normal" font="Arial">10.2169/internalmedicine.55.6499</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Altinel,A,E.</style></author><author><style face="normal" font="Arial"> Akcaboy,M.</style></author><author><style face="normal" font="Arial"> Melek,Oguz M.</style></author><author><style face="normal" font="Arial"> Kilic,M.</style></author><author><style face="normal" font="Arial"> Zorlu,P.</style></author><author><style face="normal" font="Arial"> Senel,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Dr. Sami Ulus Maternity and Children's Health Education and Research Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Hypoalbuminemia and Malnutrition Associated With Cow's Milk Allergy: A Case Report</style></title><secondary-title><style face="normal" font="Arial">Iran Red Crescent Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran Red Crescent Med J</style></full-title></periodical><pages end="" start="e34810">e34810-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-tissue transglutaminase antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Education</style></keyword><keyword><style face="normal" font="Arial"> Hypoalbuminemia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Leg</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Proteinuria</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urea</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Cow's milk allergy is the most common food allergy in children. Symptoms usually involve the skin and the gastrointestinal and respiratory tracts. Gastrointestinal tract manifestations of cow's milk allergy are nonspecific, and are the only type that can be diagnosed in all age groups. Here, we report a rare case of cow's milk allergy in an infant with hypoalbuminemia and malnutrition. CASE PRESENTATION: A nine-month-old girl was admitted to Dr. Sami Ulus maternity and children's health and diseases training and research hospital, Ankara, Turkey, in September 2013, for weakness and swelling of the legs that had endured for two days. She had bilateral pretibial pitting (+2) edema. Laboratory data revealed albumin at 1.7 g/dL; serum Na, K, urea, creatinin, and alanine-aspartate aminotransferase levels were normal. Her urinary analysis did not reveal proteinuria. Stool samples were normal, and stool steatocrite was negative. Anti-gliadin, anti-endomysium, and anti-tissue transglutaminase antibodies were negative. Cow's milk allergy was diagnosed due to cow's milk-specific IgE and skin prick test results. CONCLUSIONS: On rare occasions, cow's milk allergy presents with hypoalbuminemia. When diagnosis is delayed, this allergy may impair the growth and quality of life and may even be life-threatening</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 2074-1804 (Print)IS - 2074-1804 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5812/ircmj.34810</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27621935">PM:27621935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran Red Crescent Med J\2016-18-e34810.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran Red Crescent Med J\2016-18-e34810.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Antinel AE</style></custom2><misc3><style face="normal" font="Arial">10.5812/ircmj.34810</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marseglia,A.</style></author><author><style face="normal" font="Arial"> Artusio,L.</style></author><author><style face="normal" font="Arial"> Bulzomi,P.</style></author><author><style face="normal" font="Arial"> Cairello,F.</style></author><author><style face="normal" font="Arial"> Masa,G.</style></author><author><style face="normal" font="Arial"> Merli,P.</style></author><author><style face="normal" font="Arial"> Labo,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Scienze Pediatriche, Fondazione IRCCS Policlinico San Matteo - Università di Pavia (PV)</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Urticaria and infestation Dientamoeba fragilis</style></title><secondary-title><style face="normal" font="Arial">Ital J Genet Pediatr Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ital J Genet Pediatr Immunol</style></full-title></periodical><pages end="" start="16">16-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--FCE</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2011">2011</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ITACO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.geneticapediatrica.it/archivi/2011/archivio2/page.php?id=16</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Genet Pediatr Immunol\2011-3-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Genet Pediatr Immunol\2011-3-16.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20110404, Marseglia A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Villalta,D.</style></author><author><style face="normal" font="Arial"> TONUTTI,E.</style></author><author><style face="normal" font="Arial"> BIZZARO,N.</style></author><author><style face="normal" font="Arial"> BRUSCA,I.</style></author><author><style face="normal" font="Arial"> Sargentini,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Recommendations for the use of molecular diagnostics in the diagnosis of allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Ital J Lab Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ital J Lab Med</style></full-title></periodical><pages end="215" start="198">198-215</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--Allergome Used</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2039-6821</style></isbn><abstract><style face="normal" font="Arial">The Study Group on Allergology of the Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL) developed recommendations on the diagnosis of allergic diseases based on the use of molecular allergenic components. The purpose of this document is to provide the pathologists and the clinicians with information and algorithms enabling a proper use of this second-level diagnostics. In the face of greater economic commitments, for which its indiscriminate use must be absolutely avoided, molecular diagnostics allows definition of the exact sensitization profile of the allergic patient</style></abstract><notes><style face="normal" font="Arial">LA - ITACO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13631-016-0122-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13631-016-0122-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Lab Med\20160915-VillaltaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Lab Med\20160915-VillaltaD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160915, Villalta D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13631-016-0122-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Klerk,T.A.</style></author><author><style face="normal" font="Arial"> Sharma,V.</style></author><author><style face="normal" font="Arial"> Arkwright,P.D.</style></author><author><style face="normal" font="Arial"> Biswas,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Manchester Royal Eye Hospital, Manchester, United Kingdom.</style></auth-address><titles><title><style face="normal" font="Arial">Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab</style></title><secondary-title><style face="normal" font="Arial">J AAPOS</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J AAPOS</style></full-title></periodical><pages end="306" start="305">305-306</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-Allergic Agents</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic agents</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Anti-Idiotypic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Monoclonal,Humanized</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis,Allergic</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Injections,Subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="6" Year="2013">2013/6</year></dates><abstract><style face="normal" font="Arial">A 12-year-old boy with severe mixed limbal and palpebral vernal keratoconjunctivitis experienced persistent ocular symptoms despite treatment with topical corticosteroids or cyclosporine. Signs and symptoms resolved completely with monthly subcutaneous omalizumab, an immunomodulating biologic agent. To our knowledge, this is the first report of its use as a monotherapy agent to treat vernal keratoconjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20130624IS - 1528-3933 (Electronic)IS - 1091-8531 (Linking)LA - engPT - Case ReportsPT - Journal ArticleRN - 0 (Anti-Allergic Agents)RN - 0 (Antibodies, Anti-Idiotypic)RN - 0 (Antibodies, Monoclonal, Humanized)RN - 2P471X1Z11 (Omalizumab)SB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaapos.2012.12.153</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="23607979">PM:23607979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J AAPOS\2013-17-305-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J AAPOS\2013-17-305-6.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20130624, de Klerk TA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaapos.2012.12.153</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,L.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Qiang,S.</style></author><author><style face="normal" font="Arial"> Zhao,J.</style></author><author><style face="normal" font="Arial"> Song,S.</style></author><author><style face="normal" font="Arial"> Jin,W.</style></author><author><style face="normal" font="Arial"> Wang,B.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Huang,L.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mass Spectrometric Analysis of N-Glycoforms of Soybean Allergenic Glycoproteins Separated by SDS-PAGE</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Glycan moieties</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> oligomannose</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Sodium Dodecyl Sulfate</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> soybean allergens</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein</style></keyword><keyword><style face="normal" font="Arial"> Structural analysis</style></keyword><keyword><style face="normal" font="Arial"> Structural features</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="9" Year="2016">2016/9/12</year></dates><abstract><style face="normal" font="Arial">Glycosylation of many proteins has been revealed to be closely related with food allergy, and screening and structural analysis of related glycoproteins and glycoallergens are essential for studies in this field. Herein, we describe detailed N-glycoform analysis of all glycoprotein fractions of soybean protein isolate (SPI) separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), to disclose structural features of the glycan moieties of more soybean glycoproteins. SPI was fractionated by SDS-PAGE and the generated protein bands were recovered and subjected to in-gel N-glycan release and labeling using a one-pot method newly developed by our group, followed by detailed analysis by electrospray ionization mass spectrometry (ESI-MS) and online hydrophilic interaction liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HILIC-ESI-MS/MS). As a result, we found seven bands mainly contain oligo-mannose type glycans, two mainly contain core alfa1,3-fucosylated glycans, and six have no glycans. This study is the first report that discovers core alfa1,3-fucosylated N-glycans in band 1, band 2 and band 6 and discloses band 3, band 4, band 5 and band 7 as glycoproteins and their N-glycoforms. Therefore, it can expand our knowledge about soybean protein glycosylation and provide significant structural reference for the research of soybean allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b02773</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27616296">PM:27616296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20160912-LiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20160912-LiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Li L</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b02773</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vickery,B.P.</style></author><author><style face="normal" font="Arial"> Berglund,J.P.</style></author><author><style face="normal" font="Arial"> Burk,C.M.</style></author><author><style face="normal" font="Arial"> Fine,J.P.</style></author><author><style face="normal" font="Arial"> Kim,E.H.</style></author><author><style face="normal" font="Arial"> Kim,J.I.</style></author><author><style face="normal" font="Arial"> Keet,C.A.</style></author><author><style face="normal" font="Arial"> Kulis,M.</style></author><author><style face="normal" font="Arial"> Orgel,K.G.</style></author><author><style face="normal" font="Arial"> Guo,R.</style></author><author><style face="normal" font="Arial"> Steele,P.H.</style></author><author><style face="normal" font="Arial"> Virkud,Y.V.</style></author><author><style face="normal" font="Arial"> Ye,P.</style></author><author><style face="normal" font="Arial"> Wright,B.L.</style></author><author><style face="normal" font="Arial"> Wood,R.A.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of North Carolina-Chapel Hill, Chapel Hill, NC</style></auth-address><titles><title><style face="normal" font="Arial">Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="181" start="173">173-181</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> early intervention</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> peanut-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> reversibility</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oral immunotherapy (OIT) is an effective experimental food allergy treatment that is limited by treatment withdrawal and the frequent reversibility of desensitization if interrupted. Newly diagnosed preschool children may have clinical and immunological characteristics more amenable to treatment. OBJECTIVE: We sought to test the safety, effectiveness, and feasibility of early OIT (E-OIT) in the treatment of peanut allergy. METHODS: We enrolled 40 children aged 9 to 36 months with suspected or known peanut allergy. Qualifying subjects reacted to peanut during an entry food challenge and were block-randomized 1:1 to receive E-OIT at goal maintenance doses of 300 or 3000 mg/d in a double-blinded fashion. The primary end point, sustained unresponsiveness at 4 weeks after stopping early intervention oral immunotherapy (4-SU), was assessed by double-blinded, placebo-controlled food challenge either upon achieving 4 prespecified criteria, or after 3 maintenance years. Peanut-specific immune responses were serially analyzed. Outcomes were compared with 154 matched standard-care controls. RESULTS: Of 40 consented subjects, 3 (7.5%) did not qualify. Overall, 29 of 37 (78%) in the intent-to-treat analysis achieved 4-SU (300-mg arm, 17 of 20 [85%]; 3000 mg, 12 of 17 [71%], P = .43) over a median of 29 months. Per-protocol, the overall proportion achieving 4-SU was 29 of 32 (91%). Peanut-specific IgE levels significantly declined in E-OIT-treated children, who were 19 times more likely to successfully consume dietary peanut than matched standard-care controls, in whom peanut-specific IgE levels significantly increased (relative risk, 19.42; 95% CI, 8.7-43.7; P &lt; .001). Allergic side effects during E-OIT were common but all were mild to moderate. CONCLUSIONS: At both doses tested, E-OIT had an acceptable safety profile and was highly successful in rapidly suppressing allergic immune responses and achieving safe dietary reintroduction</style></abstract><notes><style face="normal" font="Arial">DA - 20160814IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27522159">PM:27522159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160814-VickeryBP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160814-VickeryBP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160814, Vickery BP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81580</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nolte,H.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> Nelson,H.S.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Sussman,G.L.</style></author><author><style face="normal" font="Arial"> Seitzberg,D.</style></author><author><style face="normal" font="Arial"> Rehm,D.</style></author><author><style face="normal" font="Arial"> Kaur,A.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Lu,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Merck &amp; Co, Kenilworth, NJ.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1638" start="1631">1631-1638</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Harmonization</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="8" Year="2016">2016/8/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The house dust mite (HDM) sublingual immunotherapy (SLIT) tablet (MK-8237; Merck &amp; Co, Kenilworth, NJ/ALK-Abello, Horsholm, Denmark) has demonstrated beneficial effects on allergic rhinoconjunctivitis and asthma outcomes in European trials. OBJECTIVE: This is the first trial to assess the efficacy/safety of HDM SLIT-tablets in North American subjects with HDM-induced allergic rhinitis with or without conjunctivitis (AR/C). METHODS: In this double-blind, multicenter trial (NCT01700192) 1482 subjects (aged >/=12 years) with HDM-induced AR/C with or without asthma were randomized to a daily SQ HDM SLIT-tablet (12 SQ-HDM dose) or placebo for up to approximately 52 weeks. A rhinitis daily symptom score (DSS; 4 nasal symptoms, maximum score = 12) of 6 or greater, or 5 or greater with 1 symptom being severe, on 5 of 7 consecutive days before randomization was required. The primary end point was the average total combined rhinitis score, which was defined as the rhinitis DSS plus rhinitis daily medication score (DMS), during the last 8 treatment weeks. RESULTS: Treatment with 12 SQ-HDM improved the total combined rhinitis score by 17% (95% CI, 10% to 25%) versus placebo. Improvements versus placebo in the secondary end points of average rhinitis DSS, rhinitis DMS, total combined rhinoconjunctivitis score, and visual analog scale-assessed AR/C symptoms were 16%, 18%, 17%, and 16%, respectively. All nominal P values were less than .001 versus placebo, except rhinitis DMS (P = 0.15). No treatment-related adverse events meeting the International Council on Harmonization definition of a serious adverse event were reported; 1 nonserious treatment-related systemic allergic reaction occurred (assessed as moderate intensity) at first administration under medical supervision and was treated with epinephrine. CONCLUSIONS: In the first North American trial of use of a SLIT-tablet for HDM allergy, 12 SQ-HDM was well tolerated and improved HDM-induced rhinitis symptoms in adults and adolescents</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Germany -CO - Canada -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27521719">PM:27521719</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160913-NolteH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160913-NolteH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Nolte H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bellach,J.</style></author><author><style face="normal" font="Arial"> Schwarz,V.</style></author><author><style face="normal" font="Arial"> Ahrens,B.</style></author><author><style face="normal" font="Arial"> Trendelenburg,V.</style></author><author><style face="normal" font="Arial"> Aksunger,O.</style></author><author><style face="normal" font="Arial"> Kalb,B.</style></author><author><style face="normal" font="Arial"> Niggemann,B.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Pneumology and Immunology, Charite-Universitatsmedizin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Randomized placebo-controlled trial of hen's egg consumption for primary prevention in infants</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1599" start="1591">1591-1599</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> hen's egg allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weaning</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hen's egg is the most common cause of food allergy in early childhood. OBJECTIVE: We investigated the efficacy and safety of early hen's egg introduction at age 4 to 6 months to prevent hen's egg allergy in the general population. METHODS: This randomized, placebo-controlled trial included 4- to 6-month-old infants who were not sensitized against hen's egg, as determined based on specific serum antibodies (IgE). These infants were randomized to receive either verum (egg white powder) or placebo (rice powder) added to the first weaning food 3 times a week under a concurrent egg-free diet from age 4 to 6 until 12 months. The primary outcome was sensitization to hen's egg (increased specific serum IgE levels) by age 12 months. Hen's egg allergy (secondary outcome) was confirmed by double-blind, placebo-controlled food challenges. RESULTS: Among 406 screened infants, 23 (5.7%) had hen's egg-specific IgE before randomization. Seventeen of 23 underwent subsequent double-blind, placebo-controlled food challenges, and 16 were confirmed as allergic, including 11 with anaphylactic reactions. Of the 383 nonsensitized infants (56.7% male), 184 were randomized to verum and 199 to placebo. At 12 months of age, 5.6% of the children in the verum group were hen's egg sensitized versus 2.6% in the placebo group (primary outcome; relative risk, 2.20; 95% CI, 0.68-7.14; P = .24), and 2.1% were confirmed to have hen's egg allergy versus 0.6% in the placebo group (relative risk, 3.30; 95% CI, 0.35-31.32; P = .35). CONCLUSION: We found no evidence that consumption of hen's egg starting at 4 to 6 months of age prevents hen's egg sensitization or allergy. In contrast, it might result in frequent allergic reactions in the community considering that many 4- to 6-month-old infants were already allergic to hen's egg</style></abstract><notes><style face="normal" font="Arial">DA - 20160911IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27523961">PM:27523961</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160911-BellachJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160911-BellachJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160911, Bellach J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tham,R.</style></author><author><style face="normal" font="Arial"> Vicendese,D.</style></author><author><style face="normal" font="Arial"> Dharmage,S.</style></author><author><style face="normal" font="Arial"> Hyndman,R.J.</style></author><author><style face="normal" font="Arial"> Newbigin,E.</style></author><author><style face="normal" font="Arial"> Lewis,E.</style></author><author><style face="normal" font="Arial"> O'Sullivan,M.</style></author><author><style face="normal" font="Arial"> Lowe,A.J.</style></author><author><style face="normal" font="Arial"> Taylor,P.</style></author><author><style face="normal" font="Arial"> Bardin,P.</style></author><author><style face="normal" font="Arial"> Tang,M.L.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Erbas,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Associations between outdoor fungal spores and childhood and adolescent asthma hospitalisations</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1147" start="1140">1140-1147</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Coprinus</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> fungal allergens</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisations</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> spore count</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Childhood asthma is a significant public health problem and severe exacerbations can result in diminished quality of life and hospitalisation. OBJECTIVE: To examine the contribution of outdoor fungi to childhood and adolescent asthma hospitalisations. METHODS: The Melbourne Air Pollen Children and Adolescent (MAPCAH) study is a case-crossover study of 644 children and adolescents (aged 2-17 years) hospitalised for asthma. MAPCAH collected individual data on human rhinovirus (HRV) infection and sensitisation to Alternaria and Cladosporium; and daily counts of ambient concentrations of fungal spores, pollen and air pollutants. Conditional logistic regression models were used to assess associations with increases in spore counts while controlling for potential confounding and testing interactions. RESULTS: Exposure to Alternaria (aOR=1.07, 95%CI 1.03-1.11), Leptosphaeria (aOR=1.05, 95%CI 1.02-1.07), Coprinus (aOR=1.04, 95%CI 1.01-1.07), Drechslera (aOR=1.03, 95%CI1.00-1.05) and total spores (aOR=1.05, 95%CI 1.01-1.09) were significantly associated with child asthma hospitalisations independent of HRV infection. There were significant lagged effects up to 3-days with Alternaria, Leptosphaeria, Cladosporium, Sporormiella, Coprinus, and Drechslera. Some of these associations were significantly greater in participants with Cladosporium sensitisation. CONCLUSION: Exposures to several outdoor fungal spore taxa, including some not reported in previous research, are associated with the risk of child and adolescent asthma hospitalisation, particularly in individuals sensitised to Cladosporium. We need further studies to examine cross-reactivity causing asthma exacerbations. Identifying sensitisation to multiple fungal allergens in asthmatic children could support the design and implementation of more effective strategies to prevent asthma exacerbations</style></abstract><notes><style face="normal" font="Arial">DA - 20160815IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27523960">PM:27523960</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160915-ThamR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160915-ThamR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160815, Tham R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Noval Rivas,M.</style></author><author><style face="normal" font="Arial"> Chatila,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Infectious Diseases and Immunology, Department of Pediatric, Infectious and Immunologic Diseases Research Center, Cedars-Sinai Medical Center, Los Angeles, CalifDivision of Immunology, Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass. Electronic address: talal.chatila@childrens.harvard.edu</style></auth-address><titles><title><style face="normal" font="Arial">Regulatory T cells in allergic diseases</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="652" start="639">639-652</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">The pathogenesis of allergic diseases entails an ineffective tolerogenic immune response to allergens. Regulatory T (Treg) cells play a key role in sustaining immune tolerance to allergens, yet mechanisms by which Treg cells fail to maintain tolerance in patients with allergic diseases are not well understood. We review current concepts and established mechanisms regarding how Treg cells regulate different components of allergen-triggered immune responses to promote and maintain tolerance. We will also discuss more recent advances that emphasize the "dual" functionality of Treg cells in patients with allergic diseases: how Treg cells are essential in promoting tolerance to allergens but also how a proallergic inflammatory environment can skew Treg cells toward a pathogenic phenotype that aggravates and perpetuates disease. These advances highlight opportunities for novel therapeutic strategies that aim to re-establish tolerance in patients with chronic allergic diseases by promoting Treg cell stability and function</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27596705">PM:27596705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160906-NovalRivasM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160906-NovalRivasM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Noval Rivas M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Levin,M.</style></author><author><style face="normal" font="Arial"> Levander,F.</style></author><author><style face="normal" font="Arial"> Palmason,R.</style></author><author><style face="normal" font="Arial"> Greiff,L.</style></author><author><style face="normal" font="Arial"> Ohlin,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunotechnology, Lund University, Lund, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Antibody-encoding repertoires of bone marrow and peripheral blood-a focus on IgE</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1030" start="1026">1026-1030</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160911IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27521279">PM:27521279</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160911-LevinM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160911-LevinM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160911, Levin M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Van De Veen,W.</style></author><author><style face="normal" font="Arial"> Stanic,B.</style></author><author><style face="normal" font="Arial"> Wirz,O.F.</style></author><author><style face="normal" font="Arial"> Jansen,K.</style></author><author><style face="normal" font="Arial"> Globinska,A.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Role of regulatory B cells in immune tolerance to allergens and beyond</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="665" start="654">654-665</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Br1</style></keyword><keyword><style face="normal" font="Arial"> Breg</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> self-antigens</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Immune tolerance to both self-antigens and innocuous non-self-antigens is essential to protect the host against chronic inflammatory diseases and tissue damage. A wide range of cell types and suppressive molecules are involved in induction and maintenance of tolerance. In addition to their key function in the production of immunoglobulins, B cells can regulate immune responses through their surface molecules and secretion of cytokines. Regulatory B (Breg) cells are characterized by their immunosuppressive capacity, which is often mediated through IL-10 secretion. However, IL-35 and TGF-beta have also been associated with B cell-mediated immunosuppression. Several types of murine and human Breg cells have been described, such as mouse CD5(+)CD1d(hi) B10 cells, CD21(hi)CD23(hi)CD24(hi) transitional stage 2-like B cells, and CD138(+) plasma cells and plasmablasts. Human Breg cell types include CD27(+)CD24(high) B10 cells, CD24(hi)CD38(hi) immature transitional B cells, and CD73(-)CD25(+)CD71(+) BR1 cells and a subset of plasma cells. Support for the in vivo existence of allergen-specific human Breg cells comes from direct detection of their increase during the course of allergen-specific immunotherapy, as well as their increased expression in nonallergic but high-dose allergen-exposed beekeepers. Human BR1 cells selectively upregulate IgG4 antibodies on differentiation to plasma cells. This suggests an additional immune regulatory role because of the noninflammatory and blocking antibody function of IgG4. Taken together, Breg cells appear to be involved in mediating allergen tolerance, but many open questions remain to be answered</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - AIMSB - IMCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27596706">PM:27596706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-654-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-654-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, van de Veen W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tordesillas,L.</style></author><author><style face="normal" font="Arial"> Rahman,A.H.</style></author><author><style face="normal" font="Arial"> Hartmann,B.M.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Berin,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY; Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Mass cytometry profiling the response of basophils and the complete peripheral blood compartment to peanut</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1744" start="1741">1741-1744</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="13" Month="8" Year="2016">2016/8/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27531074">PM:27531074</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160912-TordesillasL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160912-TordesillasL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Tordesillas L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">MacGinnitie,A.J.</style></author><author><style face="normal" font="Arial"> Rachid,R.</style></author><author><style face="normal" font="Arial"> Gragg,H.</style></author><author><style face="normal" font="Arial"> Little,S.V.</style></author><author><style face="normal" font="Arial"> Lakin,P.</style></author><author><style face="normal" font="Arial"> Cianferoni,A.</style></author><author><style face="normal" font="Arial"> Heimall,J.</style></author><author><style face="normal" font="Arial"> Makhija,M.</style></author><author><style face="normal" font="Arial"> Robison,R.</style></author><author><style face="normal" font="Arial"> Chinthrajah,R.S.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> LeBovidge,J.</style></author><author><style face="normal" font="Arial"> Dominguez,T.</style></author><author><style face="normal" font="Arial"> Rooney,C.</style></author><author><style face="normal" font="Arial"> Lewis,M.O.</style></author><author><style face="normal" font="Arial"> Koss,J.</style></author><author><style face="normal" font="Arial"> Burke-Roberts,E.</style></author><author><style face="normal" font="Arial"> Chin,K.</style></author><author><style face="normal" font="Arial"> Logvinenko,T.</style></author><author><style face="normal" font="Arial"> Pongracic,J.A.</style></author><author><style face="normal" font="Arial"> Umetsu,D.T.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Boston Children's Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab facilitates rapid oral desensitization for peanut allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="881" start="873">873-881</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Xolair</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut oral immunotherapy (OIT) is a promising approach to peanut allergy but reactions are frequent and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair) may allow more rapid peanut updosing and decrease reactions. OBJECTIVE: To evaluate if omalizumab facilitated rapid peanut desensitization in highly allergic patients. METHODS: Thirty-seven subjects were randomized to omalizumab (n=29) or placebo (n=8). After 12 weeks of treatment subjects underwent a rapid one-day desensitization of up to 250 mg of peanut protein, followed by weekly increases up to 2000 mg. Omalizumab was then discontinued and subjects continued on 2000 mg of peanut protein. They underwent an open challenge to 4000 mg peanut protein twelve weeks after stopping study drug. If tolerated, subjects continued on 4000 mg of peanut protein daily. RESULTS: The median peanut dose tolerated on the initial desensitization day was 250 mg for omalizumab versus 22.5 mg for placebo treated subject. Subsequently 23 of 29 (79%) subjects randomized to omalizumab tolerated 2000 mg peanut protein 6 weeks after stopping omalizumab versus 1 of 8 (12%) receiving placebo (p&lt;0.01). Twenty-three subjects on omalizumab versus 1 on placebo passed the 4000 mg food challenge. Overall reaction rates were not significantly lower in omalizumab versus placebo treated subjects (OR=0.57 p=0.15), although omalizumab treated subjects were exposed to much higher doses of peanut. CONCLUSION: Omalizumab allows subjects with peanut allergy to be rapidly desensitized over as little as 8 weeks of peanut OIT. In the majority of subjects, this desensitization is sustained after omalizumab is discontinued. Additional studies will help clarify which patients would benefit most from this approach</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27609658">PM:27609658</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160909-MacGinnitieAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160909-MacGinnitieAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, MacGinnitie AJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kennedy,E.A.</style></author><author><style face="normal" font="Arial"> Connolly,J.</style></author><author><style face="normal" font="Arial"> O'B Hourihane,J.</style></author><author><style face="normal" font="Arial"> Fallon,P.G.</style></author><author><style face="normal" font="Arial"> McLean,W.I.</style></author><author><style face="normal" font="Arial"> Murray,D.</style></author><author><style face="normal" font="Arial"> Jo,J.H.</style></author><author><style face="normal" font="Arial"> Segre,J.A.</style></author><author><style face="normal" font="Arial"> Kong,H.H.</style></author><author><style face="normal" font="Arial"> Irvine,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Branch, CCR, NCI, NIH</style></auth-address><titles><title><style face="normal" font="Arial">Skin microbiome prior to development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="172" start="166">166-172</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Cheek</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococci</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Disease flares of established atopic dermatitis (AD) are generally associated with a low-diversity skin microbiota and Staphylococcus aureus dominance. The temporal transition of the skin microbiome between early infancy and the dysbiosis of established AD is unknown. METHODS: We randomly selected 50 children from the Cork BASELINE longitudinal birth cohort for microbiome sampling at three times in the first six months of life, at four skin sites relevant to AD: the antecubital and popliteal fossae, nasal tip, and cheek. We identified ten infants who developed AD and compared them with ten randomly selected control infants with no AD. We performed bacterial 16S ribosomal RNA sequencing and analysis directly from clinical samples. RESULTS: Bacterial community structures and diversity shifted over time, suggesting that age strongly affects the skin microbiome in infants. Unlike established AD, these infantile AD patients did not have noticeably dysbiotic communities prior to or with disease and were not colonized by S. aureus. In comparing patients and controls, infants who had affected skin at month 12 had statistically significant differences in bacterial communities on the antecubital fossa at month 2 compared to infants who were unaffected at month 12. In particular, commensal staphylococci were significantly less abundant in infants affected at month 12, suggesting that this genus may protect against the later development of AD. CONCLUSIONS: This study suggests that 12-month-old infants with AD were not colonized with Staphylococcus aureus before developing AD. Additional studies are needed to confirm if colonization with commensal staphylococci modulates skin immunity and attenuates development of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Ireland</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27609659">PM:27609659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160909-KennedyEA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160909-KennedyEA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Kennedy EA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loser,S.</style></author><author><style face="normal" font="Arial"> Gregory,L.G.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Schaefer,K.</style></author><author><style face="normal" font="Arial"> Walker,S.A.</style></author><author><style face="normal" font="Arial"> Buckley,J.</style></author><author><style face="normal" font="Arial"> Denney,L.</style></author><author><style face="normal" font="Arial"> Dean,C.H.</style></author><author><style face="normal" font="Arial"> Cookson,W.O.</style></author><author><style face="normal" font="Arial"> Moffatt,M.F.</style></author><author><style face="normal" font="Arial"> Lloyd,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inflammation, Repair &amp; Development Section, National Heart and Lung Institute, Imperial College London, Exhibition Road, SW7 2AZ, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Pulmonary ORMDL3 is critical for induction of Alternaria induced allergic airways disease</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1507" start="1496">1496-1507</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma susceptibility</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial epithelium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association studies</style></keyword><keyword><style face="normal" font="Arial"> Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> ORMDL3</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Uric Acid</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Genome-wide association studies have identified the ORMDL3 (ORM (yeast)-like protein isoform 3) gene locus on human chromosome 17q to be a highly significant risk factor for childhood-onset asthma. OBJECTIVE: We sought to investigate in vivo the functional role of ORMDL3 in disease inception. METHODS: An Ormdl3 deficient mouse was generated and the role of ORMDL3 in the generation of allergic airways disease to the fungal aeroallergen Alternaria alternata determined. An adeno-associated viral vector was also utilized to reconstitute ORMDL3 expression in airway epithelial cells of Ormdl3 KO mice. RESULTS: Ormdl3 knock-out mice were found to be protected from developing allergic airways disease and showed a marked decrease in pathophysiology, including lung function and airway eosinophilia induced by Alternaria. Alternaria is a potent inducer of cellular stress and the unfolded protein response and ORMDL3 was found to play a critical role in driving the ATF6 mediated arm of this response through Xbp1 and downstream activation of the endoplasmic reticulum-associated degradation pathway. Additionally ORMDL3 mediated uric acid release, another marker of cellular stress. In the knockout mice, reconstitution of Ormdl3 transcript levels specifically in the bronchial epithelium resulted in reinstatement of susceptibility to fungal allergen-induced allergic airways disease. CONCLUSIONS: This study demonstrates that ORMDL3, an asthma susceptibility gene identified by genome-wide association studies, contributes to key pathways that promote changes in airway physiology during allergic immune responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27623174">PM:27623174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160913-LoserS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160913-LoserS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Loser S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Virkud,Y.V.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Steele,P.H.</style></author><author><style face="normal" font="Arial"> Edwards,L.J.</style></author><author><style face="normal" font="Arial"> Berglund,J.P.</style></author><author><style face="normal" font="Arial"> Jones,S.M.</style></author><author><style face="normal" font="Arial"> Scurlock,A.M.</style></author><author><style face="normal" font="Arial"> Perry,T.T.</style></author><author><style face="normal" font="Arial"> Pesek,R.D.</style></author><author><style face="normal" font="Arial"> Vickery,B.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Massachusetts General Hospital, Boston, MA</style></auth-address><titles><title><style face="normal" font="Arial">Novel Baseline Predictors of Allergic Side Effects During Peanut Oral Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="888" start="882">882-888</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Though peanut oral immunotherapy (OIT) is a promising investigational therapy, its potential is limited by substantial adverse events (AEs), which are relatively understudied. OBJECTIVE: To conduct a retrospective analysis pooling three pediatric peanut OIT trials, comprising the largest analysis of peanut OIT safety to date. METHODS: We pooled 104 peanut-allergic children from three peanut OIT studies. We catalogued AEs from parental report, daily symptom diaries, and dose escalations. We included events that were likely related to OIT and identified potential baseline predictors of higher AE rates using generalized linear regression models. RESULTS: Eighty percent of subjects experienced likely-related AEs during OIT (72% during buildup and 47% during maintenance). Of these AEs, over 90% occurred while at home. Approximately 42% of subjects experienced systemic reactions, and 49% experienced gastrointestinal symptoms. Twenty percent of subjects dropped out, with half (10% of overall group) due to persistent gastrointestinal symptoms. Baseline allergic rhinitis (AR), asthma, and peanut skin prick test (SPT) were significant predictors of higher overall AE rates. SPT predicted increased gastrointestinal AEs, and AR predicted increased systemic reactions. Over the course of OIT, 61% of subjects received treatment for likely-related AEs, 59% with antihistamines and 12% with epinephrine. CONCLUSION: Peanut OIT is associated with frequent AEs, with rates declining over time, and most graded mild. However, systemic reactions and intolerable gastrointestinal AEs do occur and are significantly associated with AR and peanut SPT, respectively. Further study is needed of predictive biomarkers and the overall risks and benefits of OIT</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27609653">PM:27609653</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160909-VirkudYV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160909-VirkudYV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Virkud YV</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baiz,N.</style></author><author><style face="normal" font="Arial"> Macchiaverni,P.</style></author><author><style face="normal" font="Arial"> Tulic,M.K.</style></author><author><style face="normal" font="Arial"> Rekima,A.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Verhasselt,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sorbonne Universites, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidemiologie et de Sante Publique (IPLESP UMRS 1136), Epidemiology of Allergic and Respiratory diseases department (EPAR), Medical School Saint-Antoine, F75012 Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Early oral exposure to house dust mite allergen through breast milk: a potential risk factor for allergic sensitization and respiratory allergies in children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="372" start="369">369-372</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword><keyword><style face="normal" font="Arial"> Sante publique</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Elevated levels of House Dust Mite allergens in breastmilk are associated with an increased risk of atopic sensitization and respiratory allergy in children. This observation highlights a yet unexplored factor that may contribute to allergy development and interfere with prevention of allergy by breastfeeding</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - Brazil -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566456">PM:27566456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-BaizN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-BaizN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Baiz N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81593</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Van De Veen,W.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland; Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Role of IgG4 in IgE-mediated allergic responses</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1435" start="1434">1434-1435</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="8" Year="2016">2016/8/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - EDITORIALCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566454">PM:27566454</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-vandeVeenW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-vandeVeenW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, van de Veen W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81594</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blankestijn,M.A.</style></author><author><style face="normal" font="Arial"> Blom,M.</style></author><author><style face="normal" font="Arial"> Otten,H.G.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author><author><style face="normal" font="Arial"> Bruijnzeel-Koomen,C.A.</style></author><author><style face="normal" font="Arial"> Houben,G.F.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author><author><style face="normal" font="Arial"> Klemans,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Specific IgE to Jug r 1 has no additional value compared to extract based testing in diagnosing walnut allergy in adults</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="690" start="688">688-690</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Jug r 1</style></keyword><keyword><style face="normal" font="Arial"> Jug r 2</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> walnut allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Specific IgE to walnut 2S albumin Jug r 1 was superior compared to Jug r 2 and 3 in diagnosing walnut allergy in adults, but did not have additional value compared to sIgE to walnut extract or SPT with commercial walnut extract</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27597723">PM:27597723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160906-BlankestijnMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160906-BlankestijnMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Blankestijn MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gillis,C.M.</style></author><author><style face="normal" font="Arial"> Jonsson,F.</style></author><author><style face="normal" font="Arial"> Mancardi,D.A.</style></author><author><style face="normal" font="Arial"> Tu,N.</style></author><author><style face="normal" font="Arial"> Beutier,H.</style></author><author><style face="normal" font="Arial"> van Rooijen,N.</style></author><author><style face="normal" font="Arial"> Macdonald,L.E.</style></author><author><style face="normal" font="Arial"> Murphy,A.J.</style></author><author><style face="normal" font="Arial"> Bruhns,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1265" start="1253">1253-1265</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunisation</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> IVIg</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> platelet-activating factor</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis can proceed through distinct IgE- or IgG-dependant pathways, which have been investigated in various mouse models. We developed a novel mouse strain in which the human low-affinity IgG receptor locus, comprising both activating (hFcgammaRIIA, hFcgammaRIIIA, hFcgammaRIIIB) and inhibitory (hFcgammaRIIB) hFcgammaR genes, has been inserted into the equivalent murine locus, corresponding to a locus 'swap'. OBJECTIVE: We sought to determine the capabilities of hFcgammaRs to induce systemic anaphylaxis, and identify the cell types and mediators involved. METHODS: hFcgammaR expression on mouse and human cells was compared to validate the model. Passive systemic anaphylaxis was induced by injection of heat-aggregated human IVIG, and active systemic anaphylaxis following immunisation and challenge. Anaphylaxis severity was evaluated by hypothermia and mortality. The contribution of receptors, mediators or cell types was assessed by receptor blockade or depletion. RESULTS: The human to mouse low-affinity FcgammaR locus swap engendered hFcgammaRIIA/IIB/IIIA/IIIB expression in mice comparable to that in humans. Knock-in mice were susceptible to passive and active anaphylaxis, accompanied by downregulation of both activating and inhibitory hFcgammaR expression on specific myeloid cells. The contribution of hFcgammaRIIA was predominant. Depletion of neutrophils protected against hypothermia and mortality. Basophils contributed to a lesser extent. Anaphylaxis was inhibited by Platelet-Activating Factor receptor or Histamine receptor-1 blockade. CONCLUSION: Low-affinity FcgammaR locus-switched mice represent an unprecedented model of cognate hFcgammaR expression. Importantly, IgG-anaphylaxis proceeds within a native context of activating and inhibitory hFcgammaRs; indicating that, despite robust hFcgammaRIIB expression, activating signals can dominate to initiate a severe anaphylactic reaction</style></abstract><notes><style face="normal" font="Arial">DA - 20160828IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27568081">PM:27568081</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160828-GillisCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160828-GillisCM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160828, Gillis CM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.058</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barcik,W.</style></author><author><style face="normal" font="Arial"> Pugin,B.</style></author><author><style face="normal" font="Arial"> Westermann,P.</style></author><author><style face="normal" font="Arial"> Perez,N.R.</style></author><author><style face="normal" font="Arial"> Ferstl,R.</style></author><author><style face="normal" font="Arial"> Wawrzyniak,M.</style></author><author><style face="normal" font="Arial"> Smolinska,S.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Hessel,E.M.</style></author><author><style face="normal" font="Arial"> Michalovich,D.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Frei,R.</style></author><author><style face="normal" font="Arial"> O'Mahony,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Histamine-secreting microbes are increased in the gut of adult asthma patients</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1494" start="1491">1491-1494</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adult asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Switzerland -CO - Poland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.05.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27576125">PM:27576125</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160830-BarcikW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160830-BarcikW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Barcik W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.05.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harris,J.M.</style></author><author><style face="normal" font="Arial"> Cabanski,C.R.</style></author><author><style face="normal" font="Arial"> Scheerens,H.</style></author><author><style face="normal" font="Arial"> Samineni,D.</style></author><author><style face="normal" font="Arial"> Bradley,M.S.</style></author><author><style face="normal" font="Arial"> Cochran,C.</style></author><author><style face="normal" font="Arial"> Staubach,P.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Sussman,G.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genentech, Inc, South San Francisco, Calif. Electronic address: harris.jeffrey@gene.com</style></auth-address><titles><title><style face="normal" font="Arial">A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1732" start="1730">1730-1732</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Quilizumab</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Germany -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27567329">PM:27567329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-HarrisJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-HarrisJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Harris JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Madsen,F.</style></author><author><style face="normal" font="Arial"> Sidenius,K.</style></author><author><style face="normal" font="Arial"> Enevoldsen,H.</style></author><author><style face="normal" font="Arial"> Frolund,L.</style></author><author><style face="normal" font="Arial"> Guul,S.J.</style></author><author><style face="normal" font="Arial"> Soes-Petersen,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Lung Clinic Helsingor, Sct. Olai Gade, Denmark. Electronic address: flem-mad@dadlnet.dk</style></auth-address><titles><title><style face="normal" font="Arial">Safety of allergen immunotherapy: A 10-year prospective study</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1495" start="1494">1494-1495</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword></keywords><dates><year Day="27" Month="7" Year="2016">2016/7/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27577877">PM:27577877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160831-MadsenF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160831-MadsenF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Madsen F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maggi,L.</style></author><author><style face="normal" font="Arial"> Montaini,G.</style></author><author><style face="normal" font="Arial"> Mazzoni,A.</style></author><author><style face="normal" font="Arial"> Rossettini,B.</style></author><author><style face="normal" font="Arial"> Capone,M.</style></author><author><style face="normal" font="Arial"> Rossi,M.C.</style></author><author><style face="normal" font="Arial"> Santarlasci,V.</style></author><author><style face="normal" font="Arial"> Liotta,F.</style></author><author><style face="normal" font="Arial"> Rossi,O.</style></author><author><style face="normal" font="Arial"> Gallo,O.</style></author><author><style face="normal" font="Arial"> De Palma,R.</style></author><author><style face="normal" font="Arial"> Maggi,E.</style></author><author><style face="normal" font="Arial"> Cosmi,L.</style></author><author><style face="normal" font="Arial"> Romagnani,S.</style></author><author><style face="normal" font="Arial"> Annunziato,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental and Clinical Medicine and DENOTHE Center, Florence</style></auth-address><titles><title><style face="normal" font="Arial">Human circulating group 2 innate lymphoid cells can express CD154 and promote IgE production</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="976" start="964">964-976</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Ionomycin</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> RORC</style></keyword><keyword><style face="normal" font="Arial"> TBX21</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Protection against helminths consists of adaptive responses by TH2 cells and innate responses by group 2 innate lymphoid cells (ILC2s), with these latter being well characterized in mice but less so in human subjects. OBJECTIVE: We sought to characterize human circulating ILC2s and compare their functional profile with that of autologous TH2 cells. METHODS: Circulating ILC2s and TH2 cells were isolated by means of fluorescence-activated cell sorting and magnetic cell sorting and expanded in vitro. ILC2s were then stimulated with phorbol 12-myristate 13-acetate plus ionomycin, IL-25 plus IL-33 (IL-25/IL-33), or a mixture of Toll-like receptor ligands to evaluate their ability to produce cytokines, express CD154, and induce IgE production by autologous B cells. Cytokines and transcription factor gene methylation were assessed. RESULTS: ILC2s expressed GATA-3, retinoic acid orphan receptor (RORC) 2, and RORalpha; were able to produce IL-5, IL-13, and IL-4; and, accordingly, were characterized by demethylation of IL4, IL13, IL5, GATA3, and RORC2, whereas the IFNG, IFNG promoter, and TBX21 regions of interest were methylated. ILC2s expressed TLR1, TLR4, and TLR6, and TLR stimulation induced IL-5 and IL-13 production. Moreover, ILC2s expressed CD154 in response to phorbol 12-myristate 13-acetate plus ionomycin, IL-25/IL-33, or a mixture of TLR ligands. Stimulated ILC2s also induced IgM, IgG, IgA, and IgE production by B cells. Finally, circulating ILC2s from atopic patients were not different in numbers and frequency but expressed higher IL-4 levels than those from nonatopic subjects. CONCLUSION: This study provides the first evidence that human ILC2s can express CD154 and stimulate the production of IgE by B lymphocytes through IL-25/IL-33 stimulation or TLR triggering</style></abstract><notes><style face="normal" font="Arial">DA - 20160830IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27576126">PM:27576126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160830-MaggiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160830-MaggiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160830, Maggi L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gau,J.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Rate of food introduction after a negative oral food challenge in the pediatric population</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="476" start="475">475-476</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 2213-2201 (Electronic)LA - ENGCO - United States -PT - JOURNAL ARTICLE</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566905">PM:27566905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-475-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-475-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Gau J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Balhara,J.</style></author><author><style face="normal" font="Arial"> Shan,L.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Muhuri,A.</style></author><author><style face="normal" font="Arial"> Halayko,A.J.</style></author><author><style face="normal" font="Arial"> Almiski,M.S.</style></author><author><style face="normal" font="Arial"> Doeing,D.</style></author><author><style face="normal" font="Arial"> McConville,J.</style></author><author><style face="normal" font="Arial"> Matzuk,M.M.</style></author><author><style face="normal" font="Arial"> Gounni,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Pentraxin 3 deletion aggravates allergic inflammation through a TH17-dominant phenotype and enhanced CD4 T-cell survival</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="963" start="950">950-963</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fertility</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> multifunctional</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pentraxin 3 (PTX3) is a multifunctional molecule that plays a nonredundant role at the crossroads between pathogen clearance, innate immune system, matrix deposition, female fertility, and vascular biology. It is produced at sites of infection and inflammation by both structural and inflammatory cells. However, its role in allergen-induced inflammation remains to be tested. OBJECTIVE: We sought to determine the effect of Ptx3 deletion on ovalbumin (OVA)-induced allergic inflammation in a murine model of asthma. METHODS: Bronchoalveolar lavage fluid was collected from patients with severe asthma and healthy subjects, and the level of PTX3 was determined by using ELISA. Ptx3+/+ and Ptx3-/- mice were sensitized and challenged with OVA and bronchoalveolar lavage fluid, and the lungs were collected for assessing inflammation. Lung tissue inflammation and mucus production were assessed by means of flow cytometry and hematoxylin and eosin and periodic acid-Schiff staining, respectively. flexiVent was used to determine airway resistance to methacholine in these mice. RESULTS: Here we report that mice with severe asthma and OVA-sensitized/challenged mice had increased PTX3 levels in the lungs compared with healthy control mice. Mice lacking PTX3 have exaggerated neutrophilic/eosinophilic lung inflammation, mucus production, and airway hyperresponsiveness in an experimental model of OVA-induced asthma. Furthermore, OVA-exposed lung Ptx3-/- CD4 T cells exhibit an increased production of IL-17A, an effect that is accompanied by an increased signal transducer and activator of transcription 3 phosphorylation, reduced IL-2 production, and enhanced activation and survival. Also, we observed an increase in numbers of IL-6- and IL-23-producing dendritic cells in OVA-exposed Ptx3-/- mice compared with those in wild-type control mice. CONCLUSION: Altogether, PTX3 deficiency results in augmented airway hyperresponsiveness, mucus production, and IL-17A-dominant pulmonary inflammation, suggesting a regulatory role of PTX3 in the development of allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.04.063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27567326">PM:27567326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-BahlaraJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-BahlaraJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Balhara J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.04.063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Respiratory Diseases, IRCCS San Martino -Icahn School of Medicine at Mount Sinai, Jaffe Food Allergy Institute, New York, NYAllergy and Respiratory Diseases, IRCCS San Martino -</style></auth-address><titles><title><style face="normal" font="Arial">Local Side Effects of Sublingual and Oral Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="21" start="13">13-21</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Sublingual immunotherapy (SLIT) is increasingly used worldwide, and several products have been recently registered as drugs for respiratory allergy by the European Medicine Agency and the Food and Drug Administration. Concerning inhalant allergens, the safety of SLIT is overall superior to that of subcutaneous immunotherapy in terms of systemic adverse events. No fatality has been ever reported, and episodes of anaphylaxis were described only exceptionally. Looking at the historical and recent trials, most (>90%) adverse events are "local" and confined to the site of administration. For this reason, a specific grading system has been developed by the World Allergy Organization to classify and describe local adverse events. There is an increasing amount of literature concerning oral desensitization for food allergens, referred to as oral immunotherapy. Also, in this case, local side effects are predominant, although systemic adverse events are more frequent than with inhalant allergens. We review herein the description of local side effects due to SLIT, with a special focus on large trials having a declared sample size calculation. The use of the Medical Dictionary for Regulatory Activities nomenclature for adverse events is mentioned in this context, as recommended by regulatory agencies. It is expected that a uniform classification/grading of local adverse events will improve and harmonize the surveillance and reporting on the safety of SLIT</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - San Marino -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27527548">PM:27527548</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-13-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-13-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Passalacqua G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Calderon,M.</style></author><author><style face="normal" font="Arial"> Sublett,J.L.</style></author><author><style face="normal" font="Arial"> Casale,T.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sirio Libanes, Sao Paulo, Brazil; University Hospital of Montpellier, Montpellier, and Sorbonne Universites, UPMC Paris 06, Paris, France.</style></auth-address><titles><title><style face="normal" font="Arial">Smoothing the transition from International Classification of Diseases, Tenth Revision, Clinical Modification to International Classification of Diseases, Eleventh Revision</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1267" start="1265">1265-1267</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - France -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.06.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27546357">PM:27546357</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160822-TannoLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160822-TannoLK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.06.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hesla,H.M.</style></author><author><style face="normal" font="Arial"> Stenius,F.</style></author><author><style face="normal" font="Arial"> Jarnbert-Pettersson,H.</style></author><author><style face="normal" font="Arial"> Alm,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Karolinska Institutet, Department of Clinical Science and Education, Sodersjukhuset, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Allergy-Related Disease in Relation to Early Life Exposures - The Aladdin Birth Cohort</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="688" start="686">686-688</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> recurrent wheeze</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">An anthroposophic lifestyle is associated with reduced risk of parent-reported food hypersensitivity and recurrent wheeze up to two years of age. Mediating factors for the risk reduction appear to be different for the two outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.057</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27554820">PM:27554820</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-HeslaHM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-HeslaHM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Hesla HM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.057</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Joetham,A.</style></author><author><style face="normal" font="Arial"> Schedel,M.</style></author><author><style face="normal" font="Arial"> O'Connor,B.P.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Takeda,K.</style></author><author><style face="normal" font="Arial"> Abbott,J.</style></author><author><style face="normal" font="Arial"> Gelfand,E.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Cell Biology, Department of Pediatrics, National Jewish Health, 1400 Jackson Street, Denver, CO, 80206, USA</style></auth-address><titles><title><style face="normal" font="Arial">Inducible and Naturally Occurring T Regulatory Cells Enhance Lung Allergic Responses Via Divergent Transcriptional Pathways</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1342" start="1331">1331-1342</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> iTreg</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: T regulatory cells attenuate development of asthma in wild-type (WT) mice with both naturally occurring (nTregs) and inducible T regulatory cells (iTregs) exhibiting suppressive activity. When transferred into CD8-deficient (CD8-/-) recipients, both cell types enhanced development of allergen-induced airway hyperresponsiveness (AHR). OBJECTIVE: To determine if the pathways leading to enhancement of lung allergic responses by transferred nTregs and iTregs differed. METHODS: nTregs (CD4+CD25+) were isolated from WT mice and iTregs were generated from WT CD4+</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27542981">PM:27542981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160820-JoethamA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160820-JoethamA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Joetham A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.051</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmer,D.J.</style></author><author><style face="normal" font="Arial"> Sullivan,T.R.</style></author><author><style face="normal" font="Arial"> Gold,M.S.</style></author><author><style face="normal" font="Arial"> Prescott,S.L.</style></author><author><style face="normal" font="Arial"> Makrides,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Paediatrics and Child Health, The University of Western Australia (M561), 35 Stirling Highway, Crawley, Western Australia, 6009, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Randomized controlled trial of early regular egg intake to prevent egg allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1607" start="1600">1600-1607</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The ideal age to introduce egg into the infant diet has been debated for the past two decades in the context of rising rates of egg allergy. OBJECTIVE: To determine if regular consumption of egg protein from 4-6 months of age reduces the risk of IgE-mediated egg allergy in infants with hereditary risk, but without eczema. METHODS: Infants aged 4 to 6 months were randomly allocated to receive daily pasteurized raw whole egg powder (n=407) or a color-matched rice powder (n=413) to 10 months of age. All infants followed an egg-free diet and cooked egg was introduced to both groups at 10 months. The primary outcome was IgE-mediated egg allergy defined by a positive pasteurized raw egg challenge and egg sensitization at 12 months of age. RESULTS: There was no difference between groups in the percentage of infants with IgE-mediated egg allergy (egg 7.0% vs. control 10.3%; adjusted relative risk 0.75; 95% confidence interval 0.48 to 1.17; P=0.20). A higher proportion of participants in the egg group stopped taking the study powder due to a confirmed allergic reaction (25/407, 6.1% compared to 6/413, 1.5%). Egg-specific IgG4 levels were substantially higher in the egg group at 12 months (median 1.22 mgA/L vs. control 0.07 mgA/L; P&lt;0.0001). CONCLUSION: We found no evidence that regular egg intake from 4-6 months of age substantially alters the risk of egg allergy by 1 year of age, in infants who are at hereditary risk of allergic disease and had no eczema symptoms at study entry</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27554812">PM:27554812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-PalmerDJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-PalmerDJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Palmer DJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.052</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Orgel,K.A.</style></author><author><style face="normal" font="Arial"> Duan,S.</style></author><author><style face="normal" font="Arial"> Wright,B.L.</style></author><author><style face="normal" font="Arial"> Maleki,S.J.</style></author><author><style face="normal" font="Arial"> Wolf,J.C.</style></author><author><style face="normal" font="Arial"> Vickery,B.P.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Paulson,J.C.</style></author><author><style face="normal" font="Arial"> Kulis,M.D.</style></author><author><style face="normal" font="Arial"> Macauley,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of North Carolina School of Medicine; UNC Food Allergy Initiative, Chapel Hill, NC; Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC</style></auth-address><titles><title><style face="normal" font="Arial">Exploiting CD22 on Antigen-Specific B-Cells to Prevent Allergy to the Major Peanut Allergen Ara h 2</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="369" start="366">366-369</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Methods for inducing antigen-specific immune tolerance are needed for the treatment and prevention of food allergies. We demonstrate that mice can be tolerized to the major peanut allergen through engaging CD22, an inhibitory B-cell co-receptor</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27554819">PM:27554819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-OrgelKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160824-OrgelKA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Orgel KA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Groetch,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.</style></auth-address><titles><title><style face="normal" font="Arial">LEAPing ahead with early allergen consumption</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1121" start="1119">1119-1121</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="23" Month="8" Year="2016">2016/8/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - EDITORIALCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27566457">PM:27566457</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-VenterC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160827-VenterC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Erp,F.C.</style></author><author><style face="normal" font="Arial"> Knol,E.F.</style></author><author><style face="normal" font="Arial"> Pontoppidan,B.</style></author><author><style face="normal" font="Arial"> Meijer,Y.</style></author><author><style face="normal" font="Arial"> van der Ent,C.K.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Pulmonology and Allergology, University Medical Centre Utrecht, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">The IgE and basophil responses to Ara h 2 and Ara h 6 are good predictors of peanut allergy in children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="360" start="358">358-360</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160911IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27516216">PM:27516216</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160911-vanErpFC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160911-vanErpFC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160911, van Erp FC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Itoh,E.</style></author><author><style face="normal" font="Arial"> Nakahara,T.</style></author><author><style face="normal" font="Arial"> Murata,M.</style></author><author><style face="normal" font="Arial"> Ito,T.</style></author><author><style face="normal" font="Arial"> Onozuka,D.</style></author><author><style face="normal" font="Arial"> Furumura,M.</style></author><author><style face="normal" font="Arial"> Hagihara,A.</style></author><author><style face="normal" font="Arial"> Furue,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Skin Surface Sensing, Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Chronic spontaneous urticaria: implications of subcutaneous inflammatory cell infiltration in an intractable clinical course</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="366" start="363">363-366</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We investigated the relationship between clinical outcomes and histopathological findings in chronic spontaneous urticaria. Subcutaneous inflammatory infiltration is an integral part of the histopathological features and is potentially predictive of unresponsiveness to standard therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20160819IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27538970">PM:27538970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160819-ItohE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160819-ItohE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160819, Itoh E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dzidic,M.</style></author><author><style face="normal" font="Arial"> Abrahamsson,T.R.</style></author><author><style face="normal" font="Arial"> Artacho,A.</style></author><author><style face="normal" font="Arial"> Bjorksten,B.</style></author><author><style face="normal" font="Arial"> Collado,M.C.</style></author><author><style face="normal" font="Arial"> Mira,A.</style></author><author><style face="normal" font="Arial"> Jenmalm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical and Experimental Medicine, Unit of Autoimmunity and Immune Regulation, Linkoping University, Linkoping, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Aberrant IgA responses to the gut microbiota during infancy precede asthma and allergy development</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1025" start="1017">1017-1025</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">16S rDNA</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bacteroides</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although a reduced gut microbiota diversity and low mucosal total IgA levels in infancy have been associated with allergy development, IgA responses to the gut microbiota have not yet been studied. OBJECTIVE: We sought to determine the proportions of IgA coating together with the characterization of the dominant bacteria, bound to IgA or not, in infant stool samples in relation to allergy development. METHODS: A combination of flow cytometric cell sorting and deep sequencing of the 16S rDNA gene was used to characterize the bacterial recognition patterns by IgA in stool samples collected at 1 and 12 months of age from children staying healthy or having allergic symptoms up to 7 years of age. RESULTS: The children with allergic manifestations, particularly asthma, during childhood had a lower proportion of IgA bound to fecal bacteria at 12 months of age compared with healthy children. These alterations cannot be attributed to differences in IgA levels or bacterial load between the 2 groups. Moreover, the bacterial targets of early IgA responses (including coating of the Bacteroides genus), as well as IgA recognition patterns, differed between healthy children and children with allergic manifestations. Altered IgA recognition patterns in children with allergy were observed already at 1 month of age, when the IgA antibodies are predominantly maternally derived in breast-fed children. CONCLUSION: An aberrant IgA responsiveness to the gut microbiota during infancy precedes asthma and allergy development, possibly indicating an impaired mucosal barrier function in allergic children</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27531072">PM:27531072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160912-DzidicM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160912-DzidicM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Dzidic M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Uribe,V.</style></author><author><style face="normal" font="Arial"> Navarrete-Rodriguez,E.M.</style></author><author><style face="normal" font="Arial"> Sienra-Monge,J.J.</style></author><author><style face="normal" font="Arial"> Del Rio-Navarro,B.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy and Clinical Immunology Department, Hospital Infantil de México Federico Gómez, México City, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Reactions in the Perioperative Period in Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="238">238-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Fluid Therapy</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Neuromuscular blocking agents</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Perioperative Period</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background: There have been reported some reviews and position papers of international societies concerning to perioperative hypersensitivity reactions in adult patients, However the information in the pediatric patient is very limited. Objectives: Updated review on the identification, diagnosis and management of perioperative hypersensitivity reactions in pediatrics. Methods: Search of the literature from 1980 through Medline database. Results: The correct treatment of perioperative hypersensitivity reactions are based on the suspected diagnosis, signs and symptoms, and time of occurrence. Latex, neuromuscular blocking agents (NMBA) and antibiotics are most often associated with immediate hypersensitivity reactions in anesthetic / surgical events. The Ring-Messmer classification can help to categorize perioperative hypersensitivity reactions and provide proper treatment. The adrenaline is the first-line drug in the management of hypersensitivity reactions grade II or higher by Ring-Messmer classification/ or when the patient meets clinical anaphylaxis scenarios; adrenaline administration and aggressive fluid therapy as first-line treatment is responsibility of surgeons and anesthesiologists. Late assessment corresponds to the allergist / clinical immunologist to discern the hypersensitivity mechanism, confirm a diagnosis, and provide prevention setting applicable to each patient. Conclusion: Pediatric perioperative hypersensitivity reactions are rare but with serious consequences. Unlike the adult patient, the latex is the most common agent, therefore, reduction in use becomes a preventive measure.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000238</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000238</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2016-7-238.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2016-7-238.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Gonzalez-Uribe V</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000238</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hill,M.K.</style></author><author><style face="normal" font="Arial"> Kheirandish,P.A.</style></author><author><style face="normal" font="Arial"> Braunberger,T.L.</style></author><author><style face="normal" font="Arial"> Armstrong,A.W.</style></author><author><style face="normal" font="Arial"> Dunnick,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Colorado School of Medicine, Aurora, Colorado</style></auth-address><titles><title><style face="normal" font="Arial">Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="9" Year="2016">2016/9/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A significant number of instruments exist that are aimed at quantifying atopic dermatitis (AD) outcomes. OBJECTIVE: We sought to assess recent trends in the use of disease severity and quality of life (QOL) outcome instruments in randomized controlled trials (RCTs) conducted on patients with AD between July 2010 and July 2015. METHODS: A total of 540 nonduplicate records were identified through searches of Scopus and Ovid MEDLINE. Included studies were RCTs conducted on humans with AD that were published in English between July 2010 and July 2015 and that reported the results of disease severity or QOL outcome measures. RESULTS: All of the 135 included studies assessed disease severity. Only 45 studies assessed QOL. Sixty-two disease severity measures and 28 QOL scales were identified. LIMITATIONS: This study was limited by its timeframe of 5 years and by the exclusion of non-RCTs and gray literature. CONCLUSION: Disease severity and QOL outcome measures are instrumental in evaluating AD treatment efficacy. The number of such tools used in RCTs on patients with AD continues to rise. Standardization of outcomes instruments is essential for comparability among studies and improved quality of evidence</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2016.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27615798">PM:27615798</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20160912-HillMK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20160912-HillMK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Hill MK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2016.07.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Z.</style></author><author><style face="normal" font="Arial"> Zheng,J.</style></author><author><style face="normal" font="Arial"> Zhang,N.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Neonatology , Yidu Central Hospital , Qingzhou, Shandong , China</style></auth-address><titles><title><style face="normal" font="Arial">Berberine improves airway inflammation and inhibits NF-kappaB signaling pathway in an ovalbumin-induced rat model of asthma</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="1005" start="999">999-1005</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Berberine has been reported for its various activities including anti-inflammatory effects and has been used in treating many diseases. However, its effects on airway inflammation in asthma have not been investigated. This study mainly aimed to detect its effects on the airway inflammation and the nuclear factor-kappaB (NF-kappaB) signaling pathway activity in a rat model of asthma. METHODS: Asthma was induced by ovalbumin (OVA) sensitization and challenge. The asthmatic rats were respectively treated with vehicle PBS or berberine (100 mg/kg or 200 mg/kg) for 28 days. The control rats were treated with PBS. Inflammatory cells in bronchoalveolar lavage fluid (BALF) were counted and the lung inflammation was scored. Levels of NF-kappaB p65 (mRNA and protein), phosphorylated NF-kappaB p65 (p-NF-kappaB p65), inhibitory kappaB alpha (IkappaBalpha) (mRNA and protein) and phosphorylated IkappaBalpha (p-IkappaBalpha), as well as NF-kappaB p65 DNA-binding activity, were measured to assess the activity of NF-kappaB signaling pathway. Levels of the downstream inflammatory mediators of NF-kappaB signaling, IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17 in BALF, were measured. Besides, the serum levels of OVA-specific immunoglobulin (Ig)E were measured. RESULTS: Results showed that OVA increased the number of inflammatory cells in BALF, elevated lung inflammation scores, enhanced the NF-kappaB signaling activity and promoted the production of IgE in rats. Berberine dose-dependently reversed the alterations induced by OVA in the asthmatic rats. CONCLUSIONS: The findings suggested a therapeutic potential of berberine on OVA- induced airway inflammation. The ameliorative effects on the OVA-induced airway inflammation might be associated with the inhibition of the NF-kappaB signaling pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1180530</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27175622">PM:27175622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\2016-53-999-1005.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\2016-53-999-1005.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Li Z</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1180530</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tat,T.S.</style></author><author><style face="normal" font="Arial"> Cilli,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Internal Medicine, School of Medicine , Akdeniz University , Antalya , Turkeyb Department of Pulmonary Medicine, School of Medicine , Akdeniz University , Antalya , Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab treatment in asthma-COPD overlap syndrome</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="1050" start="1048">1048-1050</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antalya</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a poorly understood disease with an increasing morbidity and mortality. Currently, the most effective treatment for ACOS is unknown and omalizumab for ACOS has not yet been reported. METHODS: We report our experience with anti-IgE, omalizumab treatment on 3 patients with ACOS as a retrospective case study. RESULTS: After 1 year of omalizumab treatment, patients experienced significantly lower rates of asthma exacerbation and hospitalization and better asthma control test results. CONCLUSION: Our study shows that omalizumab may be an effective and safe therapy for patients with ACOS. However larger randomized trials are needed</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleSB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1178281</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27144514">PM:27144514</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\2016-53-1048-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\2016-53-1048-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Tat TS</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1178281</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xia,Y.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Shen,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Respiratory and Critical Care Medicine , Second Affiliated Hospital of Zhejiang University School of Medicine , Hangzhou, Zhejiang , 310052 , China</style></auth-address><titles><title><style face="normal" font="Arial">Anti-IgE therapy as novel target for asthma-COPD overlap syndrome: more questions before celebration</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="22" Month="8" Year="2016">2016/8/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1201838</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27547882">PM:27547882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20160822-XiaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20160822-XiaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Xia Y</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1201838</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81617</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pacheco-Gonzalez,R.</style></author><author><style face="normal" font="Arial"> Ellwood,E.</style></author><author><style face="normal" font="Arial"> Exeter,D.</style></author><author><style face="normal" font="Arial"> Stewart,A.W.</style></author><author><style face="normal" font="Arial"> Asher,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Paediatric Consultant, Department of Paediatrics , Clinic Hospital Virgen de la Arrixaca , Murcia , Spain</style></auth-address><titles><title><style face="normal" font="Arial">Does urban extent from satellite images relate to symptoms of asthma, rhinoconjunctivitis and eczema in children? A cross-sectional study from ISAAC Phase Three</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="861" start="854">854-861</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="21" Month="5" Year="2016">2016/5/21</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The relationship between urbanisation and the symptom prevalence of asthma, rhinoconjunctivitis and eczema is not clear, and varying definitions of urban extent have been used. Furthermore, a global analysis has not been undertaken. This study aimed to determine whether the symptom prevalence of asthma, rhinoconjunctivitis and eczema in centres involved in the International Study of Asthma and Allergies in Childhood (ISAAC) were higher in urban than rural centres, using a definition of urban extent as land cover from satellite data. METHODS: A global map of urban extent from satellite images (MOD500 map) was used to define the urban extent criterion. Maps from the ISAAC centres were digitised and merged with the MOD500 map to describe the urban percentage of each centre. We investigated the association between the symptom prevalence of asthma, rhinoconjunctivitis and eczema and the percentage of urban extent by centre. RESULTS: A weak negative relationship was found between the percentage of urban extent of each ISAAC centre and current wheeze in the 13-14-year age group. This association was not statistically significant after adjusting for region of the world and gross national income. No other relationship was found between urban extent and symptoms of asthma, rhinoconjunctivitis and eczema. CONCLUSIONS: In this study, the prevalence of symptoms of asthma, rhinoconjunctivitis and eczema in children were not associated with urbanisation, according to the land cover definition of urban extent from satellite data. Comparable standardised definitions of urbanisation need to be developed so that global comparisons can be made</style></abstract><notes><style face="normal" font="Arial">DA - 20160617IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -CO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.3109/02770903.2016.1156693</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27211111">PM:27211111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\2016-53-854-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\2016-53-854-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160617, Pacheco-Gonzalez R</style></custom2><misc3><style face="normal" font="Arial">10.3109/02770903.2016.1156693</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,S.</style></author><author><style face="normal" font="Arial"> Jiang,Y.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Guo,D.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Wang,R.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Institute of Respiratory Disease, Xinqiao Hospital, Third Military Medical University , Chongqing 400037 , China</style></auth-address><titles><title><style face="normal" font="Arial">Lipopolysaccharides promote a shift from Th2-derived airway eosinophilic inflammation to Th17-drived neutrophilic inflammation in an ovalbumin-sensitized murine asthma model</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="0">0-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lipopolysaccharides</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The currently available treatments for severe asthma are insufficient. Infiltration of neutrophils rather than eosinophils into the airways is an important inflammatory characteristic of severe asthma. However, the mechanism of the phenotypic change from eosinophilic to neutrophilic inflammation has not yet been fully elucidated. METHODS: In the current study, we examined the effect of lipopolysaccharides (LPS) on eosinophilic asthmatic mice sensitized with ovalbumin (OVA), as well as the roles of interleukin (IL)-17A/T helper (Th) 17 cells on the change in the airway inflammatory phenotype from eosinophilic to neutrophilic inflammation in asthmatic lungs of IL-17A-deficient mice. RESULTS: Following exposure of OVA-induced asthmatic mice to LPS, neutrophil-predominant airway inflammation rather than eosinophil-predominant inflammation was observed, with increases in airway hyperresponsiveness (AHR), the IL-17A level in bronchoalveolar lavage fluid (BALF) and Th17 cells in the spleen and in the pulmonary hilar lymph nodes. Moreover, the neutrophilic asthmatic mice showed decreased mucus production and Th2 cytokine levels (IL-4 and IL-5). In contrast, IL-17A knockout (KO) mice exhibited eosinophil-predominant lung inflammation, decreased AHR, mucus overproduction and increased Th2 cytokine levels and Th2 cells. CONCLUSION: These findings suggest that the eosinophilic inflammatory phenotype of asthmatic lungs switches to the neutrophilic phenotype following exposure to LPS. The change in the inflammatory phenotype is strongly correlated with the increases in IL-17A and Th17 cells</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1223687</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27589490">PM:27589490</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20160902-ZhaoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20160902-ZhaoS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Zhao S</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1223687</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,C.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author><author><style face="normal" font="Arial"> Cai,J.</style></author><author><style face="normal" font="Arial"> Weschler,L.B.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Hu,Y.</style></author><author><style face="normal" font="Arial"> Zou,Z.</style></author><author><style face="normal" font="Arial"> Shen,L.</style></author><author><style face="normal" font="Arial"> Sundell,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Building Environment and Energy Engineering , School of Environment and Architecture, University of Shanghai for Science and Technology , Shanghai , PR China</style></auth-address><titles><title><style face="normal" font="Arial">Breastfeeding and Timing of First Dietary Introduction in Relation to Childhood Asthma, Allergies, and Airway Diseases: A Cross-sectional Study</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Heredity</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> ownership</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="7" Month="9" Year="2016">2016/9/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: We investigated associations of breastfeeding (BF) durations and patterns and of timing of other dietary introductions with prevalences of asthma, wheeze, hay fever, rhinitis, pneumonia, and eczema among preschool children. METHODS: During April 2011-April 2012, we conducted a cross-sectional study in 72 kindergartens from five districts of Shanghai, China and obtained 13,335 questionnaires of children 4-6 year-old. We used multiple logistic regression models to evaluate the target associations. RESULTS: Compared to children who were never BF, children who were exclusively breastfed for three-six months had the lowest risk of asthma (adjusted odds ratio and 95% confidence interval: 0.81, 0.72-0.91) and wheeze (0.93, 0.87-0.99); and exclusive BF >6 months was significantly associated with a reduced risk of hay fever (0.93, 0.89-0.97), rhinitis (0.97, 0.94-0.99), pneumonia (0.97, 0.94-0.99), and eczema (0.96, 0.93-0.99). No significant associations were found between time when fruits or vegetables were introduced and the studied diseases. Associations were independent of the child's sex and parent's ownership of the current residence. Longer duration BF was only significantly protective when there was no family history of atopy. CONCLUSIONS: This study suggests that heredity, but not sex and socioeconomic status, may negatively impact the effect of BF on childhood airway and allergic diseases. Our findings support China's national recommendation that mothers provide exclusive BF for the first four months, and continue partial BF for more than six months</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1231203</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27603296">PM:27603296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20160907-HuangC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20160907-HuangC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Huang C</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1231203</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maselli,D.J.</style></author><author><style face="normal" font="Arial"> Velez,M.I.</style></author><author><style face="normal" font="Arial"> Rogers,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Pulmonary Diseases and Critical Care, University of Texas Health Science Center at San Antonio, San Antonio, TXDepartment of Medicine, Division of Pulmonary Diseases and Critical Care, University of Texas Health Science Center at San Antonio, San Antonio, TXPulmonary, Critical Care, and Sleep Division, Mount Sinai-National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Reslizumab in the management of poorly controlled asthma: the data so far</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="162" start="155">155-162</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Interleukin-5, an important cytokine in the pathophysiology of asthma, participates in terminal maturation and increases chemotaxis, endothelial adhesion, and activation of eosinophils. Blockade of interleukin-5 activity with monoclonal antibodies have been successful in decreasing eosinophil counts. Reslizumab, a monoclonal antibody that targets interleukin-5, has been studied for the treatment of severe asthma. Several studies have shown that reslizumab can effectively treat severe asthma with an eosinophilic phenotype. Compared to placebo, patients treated with reslizumab had a reduction in the rates of asthma exacerbations and experienced improvement in FEV1 and asthma control questionnaires scores as early as 4 weeks after the therapy was initiated. Reslizumab was not effective in various asthma outcomes in patients without eosinophilia. The adverse events reported were similar in both treatment and placebo groups. Patients should be observed immediately after treatment because anaphylaxis may occur rarely (0.3%) after exposure to reslizumab. Future surveillance studies are still needed to establish the risks of malignancy and safety during pregnancy</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1178-6965 (Electronic)IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S94164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27621657">PM:27621657</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-155-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-155-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Maselli DJ</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S94164</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Balseiro-Gomez,S.</style></author><author><style face="normal" font="Arial"> Flores,J.A.</style></author><author><style face="normal" font="Arial"> Acosta,J.</style></author><author><style face="normal" font="Arial"> Ramirez-Ponce,M.P.</style></author><author><style face="normal" font="Arial"> Ales,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dpto. Fisiologia Medica y Biofisica, Facultad de Medicina, Universidad de Sevilla</style></auth-address><titles><title><style face="normal" font="Arial">Transient fusion ensures granule replenishment to maintain repeated release after IgE-mediated mast cell degranulation</style></title><secondary-title><style face="normal" font="Arial">J Cell Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cell Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Actomyosin</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">To ensure normal immune function, mast cells (MC) employ different pathways to release mediators. Here, we report a thus far unknown capacity of MC to recycle and reuse secretory granules (SG) after an antigen-evoked degranulation process under physiological conditions; this phenomenon involves the existence of a recycling SG pool available for release in a short time-scale. Approximately 60% of the total recycled SG was promoted by rapid endocytic modes, which involved kiss-and-run and cavicapture mechanisms, causing retention of the intragranular matrix. We found the presence of normal-size granules and giant actomyosin- and dynamin-dependent granules, which were characterized by large quantal content. These large structures allowed the recovered MC to release a large amount of 5-HT, compensating for the decrease in the number of exocytosed SG. This work uncovers a new physiological role of the exo-endocytosis cycle in the immunological plasticity of MC and reveals a novel property of their biological secretion</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1477-9137 (Electronic)IS - 0021-9533 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1242/jcs.194340</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27624612">PM:27624612</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cell Sci\20160914-BalseiroGomezS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cell Sci\20160914-BalseiroGomezS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Balseiro-Gomez S</style></custom2><misc3><style face="normal" font="Arial">10.1242/jcs.194340</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bulat,L.S.</style></author><author><style face="normal" font="Arial"> Plavec,D.</style></author><author><style face="normal" font="Arial"> Rikic,P.J.</style></author><author><style face="normal" font="Arial"> Zivkovic,J.</style></author><author><style face="normal" font="Arial"> Nogalo,B.</style></author><author><style face="normal" font="Arial"> Turkalj,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital Srebrnjak, Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-Specific IgE Measurement: Intermethod Comparison of Two Assay Systems in Diagnosing Clinical Allergy</style></title><secondary-title><style face="normal" font="Arial">J Clin Lab Anal</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Lab Anal</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Common ragweed</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immulite</style></keyword><keyword><style face="normal" font="Arial"> Immulite 2000</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="8" Month="9" Year="2016">2016/9/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Our aim was to examine the performance of IMMULITE 2000 assay for specific IgE (sIgE) by comparing it with ImmunoCAP technology in light of a clinical background. METHODS: Measurements of sIgE were done in a selected patient group (N = 569; varied sample size for each allergen) and in a random sample group (N = 100; 8 allergens). sIgE results were correlated with skin-prick test results (selected patients) and medical history (nonselected patients). RESULTS: We have detected fair to excellent correlation and agreement between the results of both assays, despite their methodological differences, both in selected and nonselected patient group (rhoc = 0.431-0.976; rhoc = 0.390-0.972, respectively). Associations of sIgE levels with skin-prick test (SPT) levels and medical history have shown significant correlation for both assays for majority of tested allergens, where applicable (D. pteronyssinus, cat dander, egg white, milk, peanut, orchard grass, Alternaria tenuis, and common ragweed in selected patients; birch, cat dander, common ragweed, D. pteronyssinus, and orchard grass in nonselected; P &lt; 0.05 for all). CONCLUSIONS: Laboratory testing for sIgE can be successfully accomplished by IMMULITE 2000 immunoanalyzer at a diagnostic accuracy relative to SPT, comparable to the results acquired by CAP technology but not fully comparable on the level of an individual patient</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 1098-2825 (Electronic)IS - 0887-8013 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Croatia -</style></notes><work-type><style face="normal" font="Arial">10.1002/jcla.22047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27604174">PM:27604174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Lab Anal\20160908-BulatLS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Lab Anal\20160908-BulatLS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Bulat LS</style></custom2><misc3><style face="normal" font="Arial">10.1002/jcla.22047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia,L.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">LSG &amp; Associates, Santa Monica, California, USA lynnegarcia2@verizon.net</style></auth-address><titles><title><style face="normal" font="Arial">Dientamoeba fragilis, One of the Neglected Intestinal Protozoa</style></title><secondary-title><style face="normal" font="Arial">J Clin Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Microbiol</style></full-title></periodical><pages end="2250" start="2243">2243-2250</pages><volume><style face="normal" font="Arial">54</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Giardiasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protozoa</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Dientamoeba fragilis is a single-celled protozoan, closely related to the trichomonads. Reported worldwide as causing human gastrointestinal symptoms, D. fragilis is very common and is second only to Blastocystis spp. Dientamoebiasis equals or exceeds the incidence of giardiasis. This minireview includes diagnostic options, clinical relevance, therapy, an animal model, the confirmed cyst stage, and sequencing data. The development of a rodent model, fulfilling Koch's postulates, and the confirmation of a cyst stage have clarified transmission routes, including fecal-oral transmission. The prevalence of D. fragilis varies between 0% to over 82%; results depend on the geographic location, group studied, and diagnostic methods used</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1098-660X (Electronic)IS - 0095-1137 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1128/JCM.00400-16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27053676">PM:27053676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Microbiol\2016-54-2243-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Microbiol\2016-54-2243-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Garcia LS</style></custom2><misc3><style face="normal" font="Arial">10.1128/JCM.00400-16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gooderham,M.</style></author><author><style face="normal" font="Arial"> Lynde,C.W.</style></author><author><style face="normal" font="Arial"> Papp,K.</style></author><author><style face="normal" font="Arial"> Bourcier,M.</style></author><author><style face="normal" font="Arial"> Guenther,L.</style></author><author><style face="normal" font="Arial"> Gulliver,W.</style></author><author><style face="normal" font="Arial"> Hong,C.H.</style></author><author><style face="normal" font="Arial"> Poulin,Y.</style></author><author><style face="normal" font="Arial"> Sussman,G.</style></author><author><style face="normal" font="Arial"> Vender,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Queen's University, SKiN Centre for Dermatology, and Probity Medical Research, Peterborough, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Review of Systemic Treatment Options for Adult Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cutan Med Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> systemic treatment</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> topical therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="9" Year="2016">2016/9/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease resulting from defects in skin barrier and aberrant immune responses. AD significantly affects the quality of life. Not all patients respond to topical therapies, and often systemic therapy is required to control the disease. OBJECTIVE: To review the treatment options for adult AD patients including those options for patients who do not respond adequately or have contraindications to oral systemic therapy. METHODS: A working group of clinicians with experience managing AD was convened to review the current literature on treatment options for adult AD patients. This review is based on the best available evidence from a published systematic review and an additional literature search. RESULTS: Current treatments for AD are reviewed, including options for adult AD patients who do not respond or have contraindications to current systemic therapies. A new approach with targeted therapies is reviewed based on best available evidence. CONCLUSION: Many AD patients respond satisfactorily to topical or systemic treatments, but for those patients who do not respond or have contraindications, new biologic agents appear to be promising therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1615-7109 (Electronic)IS - 1203-4754 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">1203475416670364</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27635033">PM:27635033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cutan Med Surg\20160916-GooderhamM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cutan Med Surg\20160916-GooderhamM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Gooderham M</style></custom2><misc3><style face="normal" font="Arial">1203475416670364</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bruning,J.H.</style></author><author><style face="normal" font="Arial"> Ziemer,M.</style></author><author><style face="normal" font="Arial"> Pemler,S.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Venereology, and Allergology, University Hospital Leipzig, Leipzig, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Successful treatment of solar urticaria with omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Dtsch Dermatol Ges</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dtsch Dermatol Ges</style></abbr-1></periodical><pages end="937" start="936">936-937</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1610-0387 (Electronic)IS - 1610-0379 (Linking)LA - engPT - LetterSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/ddg.13017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27607042">PM:27607042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dtsch Dermatol Ges\2016-14-936-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dtsch Dermatol Ges\2016-14-936-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Bruning JH</style></custom2><misc3><style face="normal" font="Arial">10.1111/ddg.13017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Danescu,S.</style></author><author><style face="normal" font="Arial"> Leppert,J.</style></author><author><style face="normal" font="Arial"> Cosgarea,R.</style></author><author><style face="normal" font="Arial"> Zurac,S.</style></author><author><style face="normal" font="Arial"> Pop,S.</style></author><author><style face="normal" font="Arial"> Baican,A.</style></author><author><style face="normal" font="Arial"> Has,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of Medicine and Pharmacy "Iuliu Hatieganu"Cluj-Napoca, Romania</style></auth-address><titles><title><style face="normal" font="Arial">Compound heterozygosity for dominant and recessive DSG1 mutations in a patient with atypical SAM syndrome (severe dermatitis, multiple allergies, metabolic wasting)</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Desmoglein</style></keyword><keyword><style face="normal" font="Arial"> Desmoglein 1</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> DSG1</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hyponatremia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergies</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="9" Year="2016">2016/9/15</year></dates><abstract><style face="normal" font="Arial">SAM syndrome (OMIM 615508), comprising severe dermatitis, multiple allergies and metabolic wasting, was first described by Samuelov et al in 20131 . Cutaneous findings consisted of congenital erythroderma, superficial skin erosions, fine scales and palmoplantar keratoderma and were accompanied by extracutaneous findings including perinatal hyponatremia, food allergies, elevated IgE levels, recurrent infections, metabolic wasting, malabsorbtion, esophageal reflux and eosinophilic esophagitis, cardiac defects, microcephaly and development delay 2,3 . In the initial description, SAM syndrome was caused by biallelic loss-of-function mutations of the desmoglein 1 (DSG1) gene1 and resulted in a severe lethal prognosis in 3 out of 6 cases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160915IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Romania -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.13967</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27632246">PM:27632246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160915-DanescuS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160915-DanescuS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160915, Danescu S</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.13967</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wagner,N.</style></author><author><style face="normal" font="Arial"> Dirk,D.</style></author><author><style face="normal" font="Arial"> Peveling-Oberhag,A.</style></author><author><style face="normal" font="Arial"> Reese,I.</style></author><author><style face="normal" font="Arial"> Rady-Pizarro,U.</style></author><author><style face="normal" font="Arial"> Mitzel,H.</style></author><author><style face="normal" font="Arial"> Staubach,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Clinical Center Darmstadt GmbH, Germany</style></auth-address><titles><title><style face="normal" font="Arial">A Popular myth - low-histamine diet improves chronic spontaneous urticaria - fact or fiction?</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> DAO</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic spontaneous urticaria (CsU) is a frequent dermatological disease that might last for months or years with high impact on quality of life. Known causes are autoreactive phenomena, infections or intolerances, rarely IgE-mediated allergies. One third of CsU patients benefit from a low-pseudoallergen diet. Additionally, it is often discussed, that reducing histamine ingestion alone might improve clinical symptoms and quality of life in CsU-patients despite the uncertain role of the histamine-degrading enzyme diamine oxidase (DAO). OBJECTIVE: Aim of this study is to investigate the impact of low-histamine diet on symptoms and quality of life in patients with CsU. METHODS: Patients suffering from CsU accompanied by gastrointestinal symptoms were included in the study. They underwent low-histamine diet for at least 3 weeks. During the whole study, urticaria activity score (UAS) was recorded daily in a patient's diary. Quality of life was assessed during screening, baseline and post-diet visits by completing questionnaires (DLQI and CuQ(2)oL). Diamine oxidase (DAO)- activity was measured before and after elimination diet. RESULTS: 75 % of the patients had a benefit from the low-histamine diet. 34 of 56 patients (61 %) reached the primary endpoint of the study, an improvement of UAS 4 of >/= 3. Overall a significant reduction from 9.05 to 4.23 points (p=0.004) was achieved; the average reduction in a strongly affected subgroup was 8.59 points (p&lt;0.001). DAO activity remained stable. CONCLUSION: Low-histamine diet is a therapeutically useful, simple and cost-free tool to decrease symptoms and increase quality of life in CsU-patients with gastrointestinal involvement. Further research is needed to understand the role of diamine oxidase. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.13966</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27624921">PM:27624921</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160914-WagnerN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20160914-WagnerN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Wagner N</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.13966</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanjun,C.</style></author><author><style face="normal" font="Arial"> Shengyun,Z.</style></author><author><style face="normal" font="Arial"> Linfeng,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Beijing Key Laboratory of Food Flavor Chemistry &amp; Beijing Higher Inst. Engineering Research Center of Food Additives and Ingredients, Beijing Technology and Business Univ, Haidian District, Beijing, 100048, P. R. China.</style></auth-address><titles><title><style face="normal" font="Arial">Identification of the Critical Amino Acid Residues of Immunoglobulin E and Immunoglobulin G Epitopes in alpha-Lactalbumin by Alanine Scanning Analysis</style></title><secondary-title><style face="normal" font="Arial">J Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> Alanine</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-lactalbumin</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> cow milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Additives</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> Immunodominant Epitopes</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2016">2016/9/7</year></dates><abstract><style face="normal" font="Arial">alpha-Lactalbumin represents one of the major allergens causing cow milk allergy. Few studies have clearly evaluated immunological relationships between immunoglobulin E (IgE) and immunoglobulin G (IgG)-binding epitopes of alpha-lactalbumin. IgE- and IgG-binding epitopes were immunolabeled with individual sera from cow milk-allergic patients. Alanine scanning of immunodominant epitopes was used to identify the critical amino acid (aa). Our initial data revealed Val8 , Phe9 , Arg10 , Tyr103 , Leu105 , and His107 were the critical aa for IgE-binding epitope. The critical aa of IgG-binding epitopes were Phe9 , Leu15 , Pro24 , Trp26 , and His32 . This study will provide necessary information to alter the cDNA to encode a protein capable of activating milk-specific T cells, but with reduced IgE- or IgG-binding capacity</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1750-3841 (Electronic)IS - 0022-1147 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/1750-3841.13425</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27603546">PM:27603546</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci\20160907-YanjunC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci\20160907-YanjunC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Yanjun C</style></custom2><misc3><style face="normal" font="Arial">10.1111/1750-3841.13425</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sethi,S.</style></author><author><style face="normal" font="Arial"> Tyagi,S.K.</style></author><author><style face="normal" font="Arial"> Anurag,R.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Plant-based milk alternatives an emerging segment of functional beverages: a review</style></title><secondary-title><style face="normal" font="Arial">J Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci Technol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Beverages</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> cow milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk</style></keyword><keyword><style face="normal" font="Arial"> Developing Countries</style></keyword><keyword><style face="normal" font="Arial"> developing country</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> emulsion</style></keyword><keyword><style face="normal" font="Arial"> emulsion stability</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> high pressure</style></keyword><keyword><style face="normal" font="Arial"> High-pressure</style></keyword><keyword><style face="normal" font="Arial"> Hypercholesterolemia</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lactose Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Non-thermal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> processing technology</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Shelf life</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"></style><style face="normal" font="Arial"> trend</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0975-8402</style></isbn><abstract><style face="normal" font="Arial">Plant-based or non-dairy milk alternative is the fast growing segment in newer food product development category of functional and specialty beverage across the globe. Nowadays, cow milk allergy, lactose intolerance, calorie concern and prevalence of hypercholesterolemia, more preference to vegan diets has influenced consumers towards choosing cow milk alternatives. Plant-based milk alternatives are a rising trend, which can serve as an inexpensive alternate to poor economic group of developing countries and in places, where cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk supply is insufficient. Though numerous types of innovative food beverages from plant sources are being exploited for cow milk alternative, many of these faces some/any type of technological issues; either related to processing or preservation. Majority of these milk alternatives lack nutritional balance when compared to bovine milk, however they contain functionally active components with health promoting properties which attracts health conscious consumers. In case of legume based milk alternatives, sensory acceptability is a major limiting factor for its wide popularity. New and advanced non-thermal processing technologies such as ultra high temperature treatment, ultra high pressure homogenization, pulsed electric field processing are being researched for tackling the problems related to increase of shelf life, emulsion stability, nutritional completeness and sensory acceptability of the final product. Concerted research efforts are required in coming years in functional beverages segment to prepare tailor-made newer products which are palatable as well as nutritionally adequate</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s13197-016-2328-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13197-016-2328-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci Technol\20160919-SethiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci Technol\20160919-SethiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Sethi S</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s13197-016-2328-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmiere,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CURML, University Center of Legal Medicine, Lausanne University Hospital, chemin de la Vulliette 4, 1000, Lausanne 25, Switzerland.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylactic and anaphylactoid reactions</style></title><secondary-title><style face="normal" font="Arial">J Forensic Leg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Forensic Leg Med</style></full-title></periodical><pages end="36" start="35">35-36</pages><volume><style face="normal" font="Arial">44</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reactions</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="8" Year="2016">2016/8/24</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160904IS - 1878-7487 (Electronic)IS - 1752-928X (Linking)LA - ENGPT - LETTERCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jflm.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27592444">PM:27592444</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Forensic Leg Med\2016-44-35-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Forensic Leg Med\2016-44-35-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160904, Palmiere C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jflm.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gilpin,D.</style></author><author><style face="normal" font="Arial"> Coleman,S.</style></author><author><style face="normal" font="Arial"> Hall,S.</style></author><author><style face="normal" font="Arial"> Houston,A.</style></author><author><style face="normal" font="Arial"> Karrasch,J.</style></author><author><style face="normal" font="Arial"> Jones,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Brisbane Hand and Upper Limb Clinic, Brisbane, Queensland</style></auth-address><titles><title><style face="normal" font="Arial">Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease</style></title><secondary-title><style face="normal" font="Arial">J Hand Surg Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Hand Surg Am</style></full-title></periodical><pages end="2038" start="2027">2027-2038</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Clo hi Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Clostridium histolyticum</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Double-Blind Method</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Dupuytren Contracture</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enzymology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Injections,Intralesional</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbial Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2010">2010/12</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The Collagenase Option for the Reduction of Dupuytren's (CORD) II study investigated the efficacy and safety of injectable Xiaflex (collagenase clostridium histolyticum), in patients with Dupuytren's contracture. METHODS: This was a prospective, randomized, placebo-controlled trial with 90-day double-blind and 9-month open-label phases. We randomized patients with contractures affecting metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints 2 to 1 to collagenase (0.58 mg) or placebo. Cords received a maximum of 3 injections. Cord disruption was attempted the day after injection using a standardized finger extension procedure. Primary end point was reduction in contracture to 0 degrees to 5 degrees of normal 30 days after the last injection. RESULTS: We enrolled 66 patients; 45 cords (20 MCP to 25 PIP joints) received collagenase and 21 cords (11 MCP to 10 PIP joints) received placebo in the double-blind phase. Statistically significantly more cords injected with collagenase than placebo met the primary end point (44.4% vs 4.8%; p &lt;. 001). The mean percentage decrease in degree of joint contracture from baseline to 30 days after last injection was 70.5% +/- 29.2% in the collagenase group and 13.6% +/- 26.1% in the placebo group (p &lt; .001). The mean increase in range of motion was significantly greater in the collagenase (35.4 degrees +/- 17.8 degrees ) than in the placebo (7.6 degrees +/- 14.9 degrees ; p &lt; .001) group. Efficacy after open-label treatment was similar to that after the double-blind phase: 50.7% of all joints achieved 0 degrees to 5 degrees of normal. More patients were satisfied with collagenase (p &lt; .001). No joint had recurrence of contracture. One patient had a flexion pulley rupture and one patient underwent routine fasciectomy to address cord proliferation and sensory abnormality. No tendon ruptures or systemic allergic reactions were reported. Most adverse events were related to the injection or finger extension procedure. CONCLUSIONS: Collagenase clostridium histolyticum is the first Food and Drug Administration-approved, nonsurgical treatment option for adult Dupuytren's contracture patients with a palpable cord that is highly effective and well tolerated. TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic I</style></abstract><notes><style face="normal" font="Arial">DA - 20101207IS - 1531-6564 (Electronic)IS - 0363-5023 (Linking)LA - engPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tRN - EC 3.4.24.3 (Microbial Collagenase)SB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jhsa.2010.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="21134613">PM:21134613</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Hand Surg Am\2010-35-2027-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Hand Surg Am\2010-35-2027-38.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20101207, Gilpin D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jhsa.2010.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Watt,A.J.</style></author><author><style face="normal" font="Arial"> Curtin,C.M.</style></author><author><style face="normal" font="Arial"> Hentz,V.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Surgery, Stanford University Hospitals and Clinics, Palo Alto, CA 94304, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Collagenase injection as nonsurgical treatment of Dupuytren's disease: 8-year follow-up</style></title><secondary-title><style face="normal" font="Arial">J Hand Surg Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Hand Surg Am</style></full-title></periodical><pages end="539" start="534">534-539</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Aged,80 and over</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Clo hi Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Collagenases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Dupuytren Contracture</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2010">2010/4</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Collagenase has been investigated in phase II and phase III clinical trials for the treatment of Dupuytren's disease. The purpose of this study is to report 8-year follow-up results in a subset of patients who had collagenase injection for the treatment of Dupuytren's contracture. METHODS: Twenty-three patients who participated in the phase II clinical trial of injectable collagenase were contacted by letter and phone. Eight patients were enrolled, completed a Dupuytren's disease questionnaire, and had independent examination of joint motion by a single examiner. RESULTS: Eight patients completed the 8-year follow-up study: 6 had been treated for isolated metacarpophalangeal (MCP) joint contracture, and 2 had been treated for isolated proximal interphalangeal (PIP) joint contracture. Average preinjection contracture was 57 degrees in the MCP group. Average contracture was 9 degrees at 1 week, 11 degrees at 1 year, and 23 degrees at 8-year follow-up. Four of 6 patients experienced recurrence, and 2 of 6 had no evidence of disease recurrence at 8-year follow-up. Average preinjection contracture was 45 degrees in the PIP group. Average contracture was 8 degrees at 1 weeks, 15 degrees at 1 year, and 60 degrees at 8-year follow-up. Both patients experienced recurrence at 8-year follow-up. No patients had had further intervention on the treated finger in either the MCP or the PIP group. Patients subjectively rated the overall clinical success at 60%, and 88% of patients stated that they would pursue further injection for the treatment of their recurrent or progressive Dupuytren's disease. CONCLUSIONS: Enzymatic fasciotomy is safe and efficacious, with initial response to injection resulting in reduction of joint contracture to within 0 degrees -5 degrees of normal in 72 out of 80 patients. Initial evaluation of long-term recurrence rates suggests disease recurrence or progression in 4 out of 6 patients with MCP contractures and 2 patients with PIP contractures; however, recurrence was generally less severe than the initial contracture in the MCP group. In addition, patient satisfaction was high</style></abstract><notes><style face="normal" font="Arial">DA - 20100331IS - 1531-6564 (Electronic)IS - 0363-5023 (Linking)LA - engPT - Clinical Trial, Phase IIPT - Journal ArticlePT - Randomized Controlled TrialRN - EC 3.4.24.- (Collagenases)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jhsa.2010.01.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="20353858">PM:20353858</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Hand Surg Am\2010-35-534-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Hand Surg Am\2010-35-534-9.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20100331, Watt AJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jhsa.2010.01.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Srinivasan,R.C.</style></author><author><style face="normal" font="Arial"> Shah,A.S.</style></author><author><style face="normal" font="Arial"> Jebson,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI 48109, USA.</style></auth-address><titles><title><style face="normal" font="Arial">New treatment options for Dupuytren's surgery: collagenase and percutaneous aponeurotomy</style></title><secondary-title><style face="normal" font="Arial">J Hand Surg Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Hand Surg Am</style></full-title></periodical><pages end="1364" start="1362">1362-1364</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">ANN</style></keyword><keyword><style face="normal" font="Arial"> Clo hi Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Clostridium histolyticum</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Dupuytren Contracture</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enzymology</style></keyword><keyword><style face="normal" font="Arial"> Fascia</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbial Collagenase</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2010">2010/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20100805IS - 1531-6564 (Electronic)IS - 0363-5023 (Linking)LA - engPT - Journal ArticleRN - EC 3.4.24.3 (Microbial Collagenase)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jhsa.2010.03.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="20434276">PM:20434276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Hand Surg Am\2010-35-1362-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Hand Surg Am\2010-35-1362-4.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20100805, Srinivasan RC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jhsa.2010.03.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81636</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,P.S.</style></author><author><style face="normal" font="Arial"> King,R.G.</style></author><author><style face="normal" font="Arial"> Kearney,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294</style></auth-address><titles><title><style face="normal" font="Arial">Pulmonary alpha-1,3-Glucan-Specific IgA-Secreting B Cells Suppress the Development of Cockroach Allergy</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Alabama</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterobacter</style></keyword><keyword><style face="normal" font="Arial"> Enterobacter species</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">There is a higher incidence of allergic conditions among children living in industrialized countries than those in developing regions. One explanation for this is reduced neonatal exposure to microbes and the consequent lack of immune stimulation. Sensitivity to cockroach allergen is highly correlated with the development of severe asthma. In this study, we determined that an Ab to microbial alpha-1,3-glucan binds an Enterobacter species and cockroach allergen. Neonatal, but not adult, mice immunized with this alpha-1,3-glucan-bearing Enterobacter (MK7) are protected against cockroach allergy. Following exposure to cockroach allergen, alpha-1,3-glucan-specific IgA-secreting cells are present in the lungs of mice immunized with MK7 as neonates but not in the lungs of those immunized as adults. Mice that are unable to generate anti-alpha-1,3-glucan IgA Abs were immunized with MK7 as neonates and were no longer protected against cockroach allergy. Thus, neonatal, but not adult, exposure to alpha-1,3-glucan results in suppressed development of cockroach allergy via pulmonary alpha-1,3-glucan-specific IgA-secreting cells</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27581173">PM:27581173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20160901-PatelPS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20160901-PatelPS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Patel PS</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Drucker,A.M.</style></author><author><style face="normal" font="Arial"> Wang,A.R.</style></author><author><style face="normal" font="Arial"> Li,W.Q.</style></author><author><style face="normal" font="Arial"> Sevetson,E.</style></author><author><style face="normal" font="Arial"> Block,J.K.</style></author><author><style face="normal" font="Arial"> Qureshi,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island, USA.</style></auth-address><titles><title><style face="normal" font="Arial">The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="30" start="26">26-30</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhode Island</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Tertiary Care Centers</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="8" Month="9" Year="2016">2016/9/8</year></dates><abstract><style face="normal" font="Arial">To assess the patient-level and societal burden of atopic dermatitis, we comprehensively reviewed the literature related to quality of life, social, economic, academic, and occupational impacts. Atopic dermatitis has profound impacts on patient and family quality of life. A conservative estimate of the annual costs of atopic dermatitis in the United States is $5.297 billion (in 2015 USD). People with atopic dermatitis may change their occupation because of their skin disease. Research gaps include quality of life assessments outside of tertiary care centers, impacts on partners and families of adult patients, and updated comprehensive cost estimates</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2016.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27616422">PM:27616422</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2016-137-26-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2016-137-26-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Drucker AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2016.07.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bu,G.</style></author><author><style face="normal" font="Arial"> Zhu,T.</style></author><author><style face="normal" font="Arial"> Chen,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Food Science and Technology, Henan University of Technology, Zhengzhou, 450001, China.</style></auth-address><titles><title><style face="normal" font="Arial">The structural properties and antigenicity of soybean glycinin by glycation with xylose</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Competitive ELISA</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> FTIR</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> Indirect competitive</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reaction Time</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Structural properties</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Xylose</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Soybean glycinin is considered as a major allergenic protein, and glycation is widely used to reduce allergenic potential of present allergens. Glycation of soybean glycinin with xylose at 55 degrees C for different lengths of time was investigated. The extent of Maillard reaction was reflected through the content changing of free amino groups, color analysis and SDS-PAGE. Alteration in the structural properties of glycinin was characterized by Fourier transform infrared spectrum (FTIR), and the antigenicity was evaluated by indirect competitive ELISA. RESULTS: The changes in the color of glycinin-xylose samples and the reduction of free amino group content in proteins indicated the Maillard reaction occurred. The degree of glycation increased in glycated samples with the increase of reaction time. Glycation induced the changes in the secondary structure of glycinin and the ordered structure of proteins increased during the glycation reaction. The antigenicity of glycinin was reduced with the increase of reaction time. After glycation for 12 h, the antigenicity of glycinin declined about 18% compared with native glycinin. CONCLUSION: The application of glycation may be an efficient method to reduce the antigenicity of soybean glycinin</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27620509">PM:27620509</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20160913-BuG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20160913-BuG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Bu G</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cieslak,J.</style></author><author><style face="normal" font="Arial"> Wodas,L.</style></author><author><style face="normal" font="Arial"> Borowska,A.</style></author><author><style face="normal" font="Arial"> Sadoch,J.</style></author><author><style face="normal" font="Arial"> Pawlak,P.</style></author><author><style face="normal" font="Arial"> Puppel,K.</style></author><author><style face="normal" font="Arial"> Kuczynska,B.</style></author><author><style face="normal" font="Arial"> Mackowski,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Horse Breeding, Poznan University of Life Sciences, Wolynska 33, 60-637, Poznan, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Variability of lysozyme and lactoferrin bioactive protein concentrations in equine milk in relation to LYZ and LTF gene polymorphisms and expression</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Bioactive protein</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> equine milk</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Equine milk is considered to be an interesting product for human nutrition, mainly due to its low allergenicity and significant amounts of bioactive proteins, including lysozyme (LYZ) and lactoferrin (LTF). In the present study we assessed the effect of genetic factors on LYZ and LTF concentration variability in mare's milk. RESULTS: Significant effects of horse breed and lactation stage on milk LYZ and LTF contents were observed. The highest level of LTF and the lowest concentration of LYZ were recorded for the Polish Warmblood Horse breed. The highest amounts of both proteins were found for the earliest investigated time point of lactation (5th week). Altogether 13 (9 novel) polymorphisms were found in the 5'-flanking regions of both genes, but they showed no significant relationship with milk LYZ and LTF contents. Several associations were found between selected SNPs and the LYZ gene relative transcript level. CONCLUSION: While the present study indicated the existence of an intra- and interbreed variability of LYZ and LTF contents in mare's milk, this variation is rather unrelated to the 5'-flanking variants of genes encoding both proteins. Our study is a good introduction for broader investigations focused on the genetic background for variability of bioactive protein contents in mare's milk</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27611486">PM:27611486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20160909-CieslakJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20160909-CieslakJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Cieslak J</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bellocchia,M.</style></author><author><style face="normal" font="Arial"> Boita,M.</style></author><author><style face="normal" font="Arial"> Heffler,E.</style></author><author><style face="normal" font="Arial"> Pizzimenti,S.</style></author><author><style face="normal" font="Arial"> Novero,D.</style></author><author><style face="normal" font="Arial"> Solidoro,P.</style></author><author><style face="normal" font="Arial"> Bicca,C.</style></author><author><style face="normal" font="Arial"> Rolla,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Medicine - Department of Medical Sciences - University of Torino &amp; AOU Città della Salute e della Scienza - Torino , Italy</style></auth-address><titles><title><style face="normal" font="Arial">Autoimmune pancreatitis: The Last Puzzle Piece of IgG4-Related Disease</style></title><secondary-title><style face="normal" font="Arial">Jacobs J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Jacobs J Allergy Immunol</style></full-title></periodical><pages end="" start="023">023-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> Bile</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypothyroidism</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Jaundice</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Retroperitoneal Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Submandibular Gland</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin G4-related systemic disorder (IgG4-RD) is an under-diagnosed fibro-inflammatory disorder with unknown etiology and multiorgan involvement. IgG4-RD manifestations consist of lymphadenopathy, extrapancreatic bile duct lesions, lacrimal and salivary gland lesions, hypothyroidism, retroperitoneal fibrosis, and kidney mass. We report the case of a 46-yearold patient, with moderate persistent asthma and chronic hyperplastic rhinosinusitis, who presented at emergency department because of obstructive jaundice due to a mass in the pancreatic head. The pathology of the surgical specimen disclosed lymphoplasmacytic inflammation with fibrosis of intra and inter-lobular septs and ducts ectasia and abundant infiltration of plasmacytes, most of whom being IgG4-positive (> 200/hpf). These findings were consistent with the diagnosis of IgG4-RD. The patient's medical history suggests pancreatitis is the last piece of the jigsaw puzzle that initiated years before with swelling of submandibular glands and and enlarged lacrimal glands.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://allergyandimmunology.jacobspublishers.com/index.php/j-j-aller-immuno-3-1-023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Jacobs J Allergy Immunol\2016-3-023.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Jacobs J Allergy Immunol\2016-3-023.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Bellocchia M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heffler,E.</style></author><author><style face="normal" font="Arial"> Picardi,G.</style></author><author><style face="normal" font="Arial"> Liuzzo,M.T.</style></author><author><style face="normal" font="Arial"> Pistorio,M.P.</style></author><author><style face="normal" font="Arial"> Crimi,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Respiratory Medicine and Allergology, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Policlinico-Vittorio Emanuele Hospital, University of Catania, Catania, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab Treatment of Vernal Keratoconjunctivitis</style></title><secondary-title><style face="normal" font="Arial">JAMA Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Ophthalmol</style></full-title></periodical><pages end="463" start="461">461-463</pages><volume><style face="normal" font="Arial">134</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Monoclonal,Humanized</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis,Allergic</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Administration Schedule</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Injections,Subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Sampling Studies</style></keyword><keyword><style face="normal" font="Arial"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160415IS - 2168-6173 (Electronic)IS - 2168-6165 (Linking)LA - engPT - Journal ArticleRN - 0 (Antibodies, Monoclonal, Humanized)RN - 2P471X1Z11 (Omalizumab)SB - AIMSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamaophthalmol.2015.5679</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26795360">PM:26795360</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Ophthalmol\2016-134-461-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Ophthalmol\2016-134-461-3.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20160415, Heffler E</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamaophthalmol.2015.5679</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferre,E.M.</style></author><author><style face="normal" font="Arial"> Rose,S.R.</style></author><author><style face="normal" font="Arial"> Rosenzweig,S.D.</style></author><author><style face="normal" font="Arial"> Burbelo,P.D.</style></author><author><style face="normal" font="Arial"> Romito,K.R.</style></author><author><style face="normal" font="Arial"> Niemela,J.E.</style></author><author><style face="normal" font="Arial"> Rosen,L.B.</style></author><author><style face="normal" font="Arial"> Break,T.J.</style></author><author><style face="normal" font="Arial"> Gu,W.</style></author><author><style face="normal" font="Arial"> Hunsberger,S.</style></author><author><style face="normal" font="Arial"> Browne,S.K.</style></author><author><style face="normal" font="Arial"> Hsu,A.P.</style></author><author><style face="normal" font="Arial"> Rampertaap,S.</style></author><author><style face="normal" font="Arial"> Swamydas,M.</style></author><author><style face="normal" font="Arial"> Collar,A.L.</style></author><author><style face="normal" font="Arial"> Kong,H.H.</style></author><author><style face="normal" font="Arial"> Lee,C.R.</style></author><author><style face="normal" font="Arial"> Chascsa,D.</style></author><author><style face="normal" font="Arial"> Simcox,T.</style></author><author><style face="normal" font="Arial"> Pham,A.</style></author><author><style face="normal" font="Arial"> Bondici,A.</style></author><author><style face="normal" font="Arial"> Natarajan,M.</style></author><author><style face="normal" font="Arial"> Monsale,J.</style></author><author><style face="normal" font="Arial"> Kleiner,D.E.</style></author><author><style face="normal" font="Arial"> Quezado,M.</style></author><author><style face="normal" font="Arial"> Alevizos,I.</style></author><author><style face="normal" font="Arial"> Moutsopoulos,N.M.</style></author><author><style face="normal" font="Arial"> Yockey,L.</style></author><author><style face="normal" font="Arial"> Frein,C.</style></author><author><style face="normal" font="Arial"> Soldatos,A.</style></author><author><style face="normal" font="Arial"> Calvo,K.R.</style></author><author><style face="normal" font="Arial"> Adjemian,J.</style></author><author><style face="normal" font="Arial"> Similuk,M.N.</style></author><author><style face="normal" font="Arial"> Lang,D.M.</style></author><author><style face="normal" font="Arial"> Stone,K.D.</style></author><author><style face="normal" font="Arial"> Uzel,G.</style></author><author><style face="normal" font="Arial"> Kopp,J.B.</style></author><author><style face="normal" font="Arial"> Bishop,R.J.</style></author><author><style face="normal" font="Arial"> Holland,S.M.</style></author><author><style face="normal" font="Arial"> Olivier,K.N.</style></author><author><style face="normal" font="Arial"> Fleisher,T.A.</style></author><author><style face="normal" font="Arial"> Heller,T.</style></author><author><style face="normal" font="Arial"> Winer,K.K.</style></author><author><style face="normal" font="Arial"> Lionakis,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA</style></auth-address><titles><title><style face="normal" font="Arial">Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="e88782">e88782-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">13</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic mucocutaneous candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Gastritis</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> NIAID</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="8" Year="2016">2016/8/18</year></dates><abstract><style face="normal" font="Arial">Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare primary immunodeficiency disorder typically caused by homozygous AIRE mutations. It classically presents with chronic mucocutaneous candidiasis and autoimmunity that primarily targets endocrine tissues; hypoparathyroidism and adrenal insufficiency are most common. Developing any two of these classic triad manifestations establishes the diagnosis. Although widely recognized in Europe, where nonendocrine autoimmune manifestations are uncommon, APECED is less defined in patients from the Western Hemisphere. We enrolled 35 consecutive American APECED patients (33 from the US) in a prospective observational natural history study and systematically examined their genetic, clinical, autoantibody, and immunological characteristics. Most patients were compound heterozygous; the most common AIRE mutation was c.967_979del13. All but one patient had anti-IFN-omega autoantibodies, including 4 of 5 patients without biallelic AIRE mutations. Urticarial eruption, hepatitis, gastritis, intestinal dysfunction, pneumonitis, and Sjogren's-like syndrome, uncommon entities in European APECED cohorts, affected 40%-80% of American cases. Development of a classic diagnostic dyad was delayed at mean 7.38 years. Eighty percent of patients developed a median of 3 non-triad manifestations before a diagnostic dyad. Only 20% of patients had their first two manifestations among the classic triad. Urticarial eruption, intestinal dysfunction, and enamel hypoplasia were prominent among early manifestations. Patients exhibited expanded peripheral CD4+ T cells and CD21loCD38lo B lymphocytes. In summary, American APECED patients develop a diverse syndrome, with dramatic enrichment in organ-specific nonendocrine manifestations starting early in life, compared with European patients. Incorporation of these new manifestations into American diagnostic criteria would accelerate diagnosis by approximately 4 years and potentially prevent life-threatening endocrine complications</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 2379-3708 (Print)IS - 2379-3708 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.88782</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27588307">PM:27588307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2016-1-e88782.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2016-1-e88782.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Ferre EM</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.88782</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jung,T.H.</style></author><author><style face="normal" font="Arial"> Yun,S.S.</style></author><author><style face="normal" font="Arial"> Lee,W.J.</style></author><author><style face="normal" font="Arial"> Kim,J.W.</style></author><author><style face="normal" font="Arial"> Ha,H.K.</style></author><author><style face="normal" font="Arial"> Yoo,M.</style></author><author><style face="normal" font="Arial"> Hwang,H.J.</style></author><author><style face="normal" font="Arial"> Jeon,W.M.</style></author><author><style face="normal" font="Arial"> Han,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Animal Biotechnology and Resource, Sahmyook University, Seoul 01795, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Hydrolysis by Alcalase Improves Hypoallergenic Properties of Goat Milk Protein</style></title><secondary-title><style face="normal" font="Arial">Korean J Food Sci Anim Resour</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Korean J Food Sci Anim Resour</style></full-title></periodical><pages end="522" start="516">516-522</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alcalase</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> functional foods</style></keyword><keyword><style face="normal" font="Arial"> Goat milk</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> novel foods</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Goat milk is highly nutritious and is consumed in many countries, but the development of functional foods from goat milk has been slow compared to that for other types of milk. The aim of this study was to develop a goat milk protein hydrolysate (GMPH) with enhanced digestibility and better hypoallergenic properties in comparison with other protein sources such as ovalbumin and soy protein. Goat milk protein was digested with four commercial food-grade proteases (separately) under various conditions to achieve the best hydrolysis of alphas -casein and beta-lactoglobulin. It was shown that treatment with alcalase (0.4%, 60 for 30 min) effectively degraded these two proteins, as determined by SDS-PAGE, measurement of nonprotein nitrogen content, and reverse-phase high-performance liquid chromatography. Hydrolysis with alcalase resulted in a significant decrease in beta-lactoglobulin concentration (almost to nil) and a ~40% reduction in the level of alphas-casein. Quantification of histamine and TNF-alpha released from HMC-1 cells (human mast cell line) showed that the GMPH did not induce an allergic response when compared to the control. Hence, the GMPH may be useful for development of novel foods for infants, the elderly, and convalescent patients, to replace cow milk</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1225-8563 (Print)IS - 1225-8563 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5851/kosfa.2016.36.4.516</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27621693">PM:27621693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Food Sci Anim Resour\2016-36-516-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Food Sci Anim Resour\2016-36-516-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Jung TH</style></custom2><misc3><style face="normal" font="Arial">10.5851/kosfa.2016.36.4.516</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,W.J.</style></author><author><style face="normal" font="Arial"> Choi,I.S.</style></author><author><style face="normal" font="Arial"> Kim,C.S.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Kang,H.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Chonnam National University Medical School, Graduate School and Research Institute of Medical Sciences, Gwangju, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Relationship between serum IgA level and allergy/asthma</style></title><secondary-title><style face="normal" font="Arial">Korean J Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Korean J Intern Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin A</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin sensitization</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">Background/Aims: Mucosal immunoglobulin A (IgA) may prevent the entrance of allergens. This study examined the relationship between serum IgA levels (within the normal range) and sensitization to house dust mites (HDM) or airway hyper-responsiveness (AHR). Methods: The clinical records of 1,136 adult patients with suspected asthma, for whom test data for serum IgA level and methacholine-AHR were available, were reviewed retrospectively. The AHR/allergy indices were compared among patient groups with low (&lt;140 mg/dL, group I), intermediate (140 to 280 mg/dL, group II), or high (>/=280 mg/dL, group III) IgA levels in serum. Results: The HDM skin sensitization rate progressively decreased from 30.0% in group I (n = 139) to 26.8% and 18.5% in groups II (n = 684) and III (n = 313), respectively (p = 0.003). Although both the HDM sensitization degree and the IgA level were significantly related to age, the adjusted odds ratio (OR) of association of a high IgA level (>/= 280 mg/dL) with HDM sensitization was significant (0.617; 95% confidence interval [CI], 0.415 to 0.916; p = 0.017). Among younger subjects (&lt;/= 45 years of age) with AHR, the prevalence of moderate/severe AHR progressively decreased (70.6%, 52.3%, and 47.1% in groups I, II, and III [n = 34, 149, and 51]), respectively (p = 0.045). The IgA &lt; 140 mg/dL was a significant risk factor for moderate/severe AHR (OR, 2.306; 95% CI, 1.049 to 5.071; p = 0.038). Conclusions: Sensitization to HDM and methacholine-AHR were significantly associated with serum IgA levels in suspected asthmatics, even when those levels were normal</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 2005-6648 (Electronic)IS - 1226-3303 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3904/kjim.2014.160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27586868">PM:27586868</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Intern Med\20160902-KimWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Intern Med\20160902-KimWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Kim WJ</style></custom2><misc3><style face="normal" font="Arial">10.3904/kjim.2014.160</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fitzgerald,J.M.</style></author><author><style face="normal" font="Arial"> Bleecker,E.R.</style></author><author><style face="normal" font="Arial"> Nair,P.</style></author><author><style face="normal" font="Arial"> Korn,S.</style></author><author><style face="normal" font="Arial"> Ohta,K.</style></author><author><style face="normal" font="Arial"> Lommatzsch,M.</style></author><author><style face="normal" font="Arial"> Ferguson,G.T.</style></author><author><style face="normal" font="Arial"> Busse,W.W.</style></author><author><style face="normal" font="Arial"> Barker,P.</style></author><author><style face="normal" font="Arial"> Sproule,S.</style></author><author><style face="normal" font="Arial"> Gilmartin,G.</style></author><author><style face="normal" font="Arial"> Werkstrom,V.</style></author><author><style face="normal" font="Arial"> Aurivillius,M.</style></author><author><style face="normal" font="Arial"> Goldman,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Lung Centre, Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="9" Year="2016">2016/9/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor alpha monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts. METHODS: In this randomised, double-blind, parallel-group, placebo-controlled, phase 3 study (CALIMA) undertaken at 303 sites in 11 countries, we enrolled patients aged 12-75 years with severe asthma uncontrolled by medium-dosage to high-dosage inhaled corticosteroids plus long-acting beta(2)-agonists (ICS plus LABA) and a history of two or more exacerbations in the previous year. Patients were randomly assigned (1:1:1) to receive 56 weeks of benralizumab 30 mg every 4 weeks (Q4W), benralizumab 30 mg every 8 weeks (Q8W; first three doses 4 weeks apart), or placebo (all subcutaneous injection). Patients were stratified (2:1) by baseline blood eosinophil counts 300 cells per muL or greater and less than 300 cells per muL, respectively. Patients and study centre staff were masked to treatment allocation. The primary endpoint was annual exacerbation rate ratio versus placebo for patients receiving high-dosage ICS plus LABA with baseline blood eosinophils 300 cells per muL or greater (intention-to-treat analysis). Key secondary endpoints were pre-bronchodilator forced expiratory volume in 1 s (FEV1) and total asthma symptom score. This study is registered with ClinicalTrials.gov, number NCT01914757. FINDINGS: Between Aug 21, 2013, and March 16, 2015, 2505 patients were enrolled, of whom 1306 patients were randomised; 425 patients were randomly assigned to and received benralizumab 30 mg Q4W, 441 to benralizumab 30 mg Q8W, and 440 to placebo. 728 patients were included in the primary analysis population. Benralizumab resulted in significantly lower annual exacerbation rates with the Q4W regimen (rate 0.60 [95% CI 0.48-0.74], rate ratio 0.64 [95% CI 0.49-0.85], p=0.0018, n=241) and Q8W regimen (rate 0.66 [95% CI 0.54-0.82], rate ratio 0.72 [95% CI 0.54-0.95], p=0.0188, n=239) compared with placebo (rate 0.93 [95% CI 0.77-1.12], n=248). Benralizumab also significantly improved pre-bronchodilator FEV1 (Q4W and Q8W) and total asthma symptom score (Q8W only) in these patients. The most common adverse events were nasopharyngitis (90 [21%] in the Q4W group, 79 [18%] in the Q8W group, and 92 [21%] in the placebo group) and worsening asthma (61 [14%] in the Q4W group, 47 [11%] in the Q8W group, and 68 [15%] in the group). INTERPRETATION: Benralizumab significantly reduced annual exacerbation rates and was generally well tolerated for patients with severe, uncontrolled asthma with blood eosinophils 300 cells per muL or greater. Our data further refine the patient population likely to receive the greatest benefit from benralizumab treatment. FUNDING: AstraZeneca and Kyowa Hakko Kirin</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -CO - United States -CO - Japan -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(16)31322-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27609406">PM:27609406</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20160910-FitzGeraldJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20160910-FitzGeraldJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, FitzGerald JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(16)31322-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bleecker,E.R.</style></author><author><style face="normal" font="Arial"> Fitzgerald,J.M.</style></author><author><style face="normal" font="Arial"> Chanez,P.</style></author><author><style face="normal" font="Arial"> Papi,A.</style></author><author><style face="normal" font="Arial"> Weinstein,S.F.</style></author><author><style face="normal" font="Arial"> Barker,P.</style></author><author><style face="normal" font="Arial"> Sproule,S.</style></author><author><style face="normal" font="Arial"> Gilmartin,G.</style></author><author><style face="normal" font="Arial"> Aurivillius,M.</style></author><author><style face="normal" font="Arial"> Werkstrom,V.</style></author><author><style face="normal" font="Arial"> Goldman,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Dosing regimens</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilia is associated with worsening asthma severity and decreased lung function, with increased exacerbation frequency. We assessed the safety and efficacy of benralizumab, a monoclonal antibody against interleukin-5 receptor alpha that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patients with severe, uncontrolled asthma with eosinophilia. METHODS: We did a randomised, double-blind, parallel-group, placebo-controlled phase 3 study at 374 sites in 17 countries. We recruited patients (aged 12-75 years) with a physician-based diagnosis of asthma for at least 1 year and at least two exacerbations while on high-dosage inhaled corticosteroids and long-acting beta2-agonists (ICS plus LABA) in the previous year. Patients were randomly assigned (1:1:1) by an interactive web-based voice response system to benralizumab 30 mg either every 4 weeks (Q4W) or every 8 weeks (Q8W; first three doses every 4 weeks) or placebo Q4W for 48 weeks as add on to their standard treatment. Patients were stratified 2:1 according to blood eosinophil counts of at least 300 cells per muL and less than 300 cells per muL. All patients and investigators involved in patient treatment or clinical assessment were masked to treatment allocation. The primary endpoint was annual exacerbation rate ratio versus placebo, and key secondary endpoints were prebronchodilator forced expiratory volume in 1 s (FEV1) and total asthma symptom score at week 48, for patients with blood eosinophil counts of at least 300 cells per muL. Efficacy analyses were by intention to treat (based on the full analysis set); safety analyses included patients according to study drug received. This study is registered with ClinicalTrials.gov, number NCT01928771. FINDINGS: Between Sept 19, 2013, and March 16, 2015, 2681 patients were enrolled, 1205 of whom met the study criteria and were randomly assigned: 407 to placebo, 400 to benralizumab 30 mg Q4W, and 398 to benralizumab 30 mg Q8W. 267 patients in the placebo group, 275 in the benralizumab 30 mg Q4W group, and 267 in the benralizumab 30 mg Q8W group had blood eosinophil counts at least 300 cells per muL and were included in the primary analysis population. Compared with placebo, benralizumab reduced the annual asthma exacerbation rate over 48 weeks when given Q4W (rate ratio 0.55, 95% CI 0.42-0.71; p&lt;0.0001) or Q8W (0.49, 0.37-0.64; p&lt;0.0001). Both benralizumab dosing regimens significantly improved prebronchodilator FEV1 in patients at week 48 compared with placebo (least-squares mean change from baseline: Q4W group 0.106 L, 95% CI 0.016-0.196; Q8W group 0.159 L, 0.068-0.249). Compared with placebo, asthma symptoms were improved by the Q8W regimen (least-squares mean difference -0.25, 95% CI -0.45 to -0.06), but not the Q4W regimen (-0.08, -0.27 to 0.12). The most common adverse events were worsening asthma (105 [13%] of 797 benralizumab-treated patients vs 78 [19%] of 407 placebo-treated patients) and nasopharyngitis (93 [12%] vs 47 [12%]). INTERPRETATION: These results confirm the efficacy and safety of benralizumab for patients with severe asthma and elevated eosinophils, which are uncontrolled by high-dosage ICS plus LABA, and provide support for benralizumab to be an additional option to treat this disease in this patient population. FUNDING: AstraZeneca and Kyowa Hakko Kirin</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Canada -CO - Italy-CO - France -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(16)31324-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27609408">PM:27609408</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20160909-BleeckerER.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20160909-BleeckerER.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Bleecker ER</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(16)31324-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hanania,N.A.</style></author><author><style face="normal" font="Arial"> Korenblat,P.</style></author><author><style face="normal" font="Arial"> Chapman,K.R.</style></author><author><style face="normal" font="Arial"> Bateman,E.D.</style></author><author><style face="normal" font="Arial"> Kopecky,P.</style></author><author><style face="normal" font="Arial"> Paggiaro,P.</style></author><author><style face="normal" font="Arial"> Yokoyama,A.</style></author><author><style face="normal" font="Arial"> Olsson,J.</style></author><author><style face="normal" font="Arial"> Gray,S.</style></author><author><style face="normal" font="Arial"> Holweg,C.T.</style></author><author><style face="normal" font="Arial"> Eisner,M.</style></author><author><style face="normal" font="Arial"> Asare,C.</style></author><author><style face="normal" font="Arial"> Fischer,S.K.</style></author><author><style face="normal" font="Arial"> Peng,K.</style></author><author><style face="normal" font="Arial"> Putnam,W.S.</style></author><author><style face="normal" font="Arial"> Matthews,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials</style></title><secondary-title><style face="normal" font="Arial">Lancet Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Respir Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Poisson</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody, reduced exacerbation rates and improved FEV1 in patients with uncontrolled asthma, particularly in those with high concentrations of type 2 biomarkers (eg, periostin or blood eosinophils). We undertook replicate phase 3 studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma despite inhaled corticosteroids and at least one second controller medication. METHODS: Adult patients with uncontrolled asthma, pre-bronchodilator FEV1 40-80% predicted, and stable background therapy were randomly assigned (1:1:1) with an interactive voice-web-based response system to receive lebrikizumab 37.5 mg or 125 mg, or placebo subcutaneously, once every 4 weeks. Randomisation was stratified by screening serum periostin concentration, history of asthma exacerbations within the last 12 months, baseline asthma medications, and country. The primary efficacy endpoint was the rate of asthma exacerbations over 52 weeks in biomarker-high patients (periostin >/=50 ng/mL or blood eosinophils >/=300 cells per muL), analysed with a Poisson regression model corrected for overdispersion with Pearson chi2 that included terms for treatment group, number of asthma exacerbations within the 12 months before study entry, baseline asthma medications, geographic region, screening periostin concentration, and blood eosinophil counts as covariates. Both trials are registered at ClinicalTrials.gov, LAVOLTA I, number NCT01867125, and LAVOLTA II, number NCT01868061. FINDINGS: 1081 patients were treated in LAVOLTA I and 1067 patients in LAVOLTA II. Over 52 weeks, lebrikizumab reduced exacerbation rates in biomarker-high patients in the 37.5 mg dose group (rate ratio [RR] 0.49 [95% CI 0.34-0.69], p&lt;0.0001) and in the 125 mg dose group (RR 0.70 [0.51-0.95], p=0.0232) versus placebo in LAVOLTA I. Exacerbation rates were also reduced in biomarker-high patients in both dose groups versus placebo in LAVOLTA II (37.5 mg: RR 0.74 [95% CI 0.54-1.01], p=0.0609; 125 mg: RR 0.74 [0.54-1.02], p=0.0626). Pooling both studies, the proportion of patients who experienced treatment-emergent adverse events (79% [1125 of 1432 patients] for both lebrikizumab doses vs 80% [576 of 716 patients] for placebo), serious adverse events (8% [115 patients] for both lebrikizumab doses vs 9% [65 patients] for placebo), and adverse events leading to study drug discontinuation (3% [49 patients] for both lebrikizumab doses vs 4% [31 patients] for placebo) were similar between lebrikizumab and placebo. The following serious adverse events were reported in the placebo-controlled period: one event of aplastic anaemia and five serious adverse events related to raised concentrations of eosinophils in patients treated with lebrikizumab and one event of eosinophilic pneumonia in the placebo group. INTERPRETATION: Lebrikizumab did not consistently show significant reduction in asthma exacerbations in biomarker-high patients. However, it blocked interleukin-13 as evidenced by the effect on interleukin-13-related pharmacodynamic biomarkers, and clinically relevant changes could not be ruled out. FUNDING: F Hoffmann-La Roche</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Canada -CO - Italy -CO - South Africa -CO - Czech Republic -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2213-2600(16)30265-X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27616196">PM:27616196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet Respir Med\20160912-HananiaNA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet Respir Med\20160912-HananiaNA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Hanania NA</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2213-2600(16)30265-X</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cecchi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical, Biotechnological and Translational Medicine, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Electronic address: rossana.cecchi@uniroma1.it</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis of anaphylactic death in forensics: Review and future perspectives</style></title><secondary-title><style face="normal" font="Arial">Leg Med (Tokyo)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Leg Med (Tokyo)</style></full-title></periodical><pages end="81" start="75">75-81</pages><volume><style face="normal" font="Arial">22</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Autopsy</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">The diagnosis of anaphylaxis in a pre- or post-mortal phase involves the formulation of problems not yet solved by the international scientific literature, due to the complexity of pathogenic factors and pathophysiological processes that characterizes it. For forensic autopsies, further problems of differential diagnosis arise and often leave the forensic pathologist unable to express an opinion of certainty, as a result of lack of case history, circumstantial and autoptical-histopathological data. Nevertheless, in routine cases the postmortem diagnosis of anaphylactic death continues to be based on exclusion and circumstantial evidence. The author, after an extensive review of the literature relating to deaths from anaphylaxis of forensic pathological interest, and a discussion of the microscopical and biochemical findings, proposes a diagnostic protocol for forensic purposes and evaluates the diagnostic perspectives enabled by the newly available analytic techniques and markers. Maybe, the application of omics methodologies could help in the future for anaphylaxis diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20160904IS - 1873-4162 (Electronic)IS - 1344-6223 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.legalmed.2016.08.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27591544">PM:27591544</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Leg Med (Tokyo)\2016-22-75-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Leg Med (Tokyo)\2016-22-75-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160904, Cecchi R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.legalmed.2016.08.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stojanovic,S.</style></author><author><style face="normal" font="Arial"> Zubrinich,C.M.</style></author><author><style face="normal" font="Arial"> O'Hehir,R.</style></author><author><style face="normal" font="Arial"> Hew,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Alfred Hospital, Melbourne, VIC</style></auth-address><titles><title><style face="normal" font="Arial">Airline policies for passengers with nut allergies flying from Melbourne Airport</style></title><secondary-title><style face="normal" font="Arial">Med J Aust</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med J Aust</style></full-title></periodical><pages end="" start="270">270-</pages><volume><style face="normal" font="Arial">205</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword></keywords><dates><year Day="19" Month="9" Year="2016">2016/9/19</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1326-5377 (Electronic)IS - 0025-729X (Linking)LA - engPT - Journal ArticleSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.5694/mja16.00384</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27627938">PM:27627938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med J Aust\2016-205-270.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med J Aust\2016-205-270.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Stojanovic S</style></custom2><misc3><style face="normal" font="Arial">10.5694/mja16.00384</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agarwal,R.</style></author><author><style face="normal" font="Arial"> Bansal,S.</style></author><author><style face="normal" font="Arial"> Chakrabarti,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary, Post Graduate Institute of Medical Education and Research, Sector-12, Chandigarh, India</style></auth-address><titles><title><style face="normal" font="Arial">Are allergic fungal rhinosinusitis and allergic bronchopulmonary aspergillosis lifelong conditions?</style></title><secondary-title><style face="normal" font="Arial">Med Mycol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Mycol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> long-term outcome</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="6" Month="9" Year="2016">2016/9/6</year></dates><abstract><style face="normal" font="Arial">Aspergillus fumigatus can cause several allergic disorders including Aspergillus-sensitized asthma, allergic bronchopulmonary aspergillosis (ABPA), and allergic fungal rhinosinusitis (AFRS). ABPA is an immunological pulmonary disorder caused by allergic reactions mounted against antigens of A. fumigatus colonizing the airways of patients with asthma (and cystic fibrosis). Allergic bronchopulmonary mycosis is an allergic fungal airway disease caused by thermotolerant fungi other than A. fumigatus On the other hand, AFRS is a type of chronic rhinosinusitis that is also a result of hypersensitivity reactions to the presence of fungi that become resident in the sinuses. The pathogenesis of ABPA and AFRS share several common features, and in fact, AFRS can be considered as the upper airway counterpart of ABPA. Despite sharing similar immunopathogenetic features, the simultaneous occurrence of the two disorders is uncommon. Due to the lacuna in understanding of the causative mechanisms, and deficiencies in the diagnosis and treatment, these disorders unfortunately are lifelong illnesses. This review provides an overview of the pathogenesis, diagnosis, and long-term outcomes of both these disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1460-2709 (Electronic)IS - 1369-3786 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1093/mmy/myw071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27601608">PM:27601608</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Mycol\20160907-AgarwalR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Mycol\20160907-AgarwalR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Agarwal R</style></custom2><misc3><style face="normal" font="Arial">10.1093/mmy/myw071</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Luo,W.</style></author><author><style face="normal" font="Arial"> Huang,H.</style></author><author><style face="normal" font="Arial"> Zheng,P.</style></author><author><style face="normal" font="Arial"> Wei,N.</style></author><author><style face="normal" font="Arial"> Luo,J.</style></author><author><style face="normal" font="Arial"> Sun,B.</style></author><author><style face="normal" font="Arial"> Zeng,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease, Guangzhou 510120, Guangdong, China; National Clinical Research Center of Respiratory Disease, Guangzhou 510120, Guangdong, China</style></auth-address><titles><title><style face="normal" font="Arial">Major grass pollen allergens and components detected in a southern Chinese cohort of patients with allergic rhinitis and/or asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="112" start="105">105-112</pages><volume><style face="normal" font="Arial">78</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antigen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bermuda</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cyn d 1</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Humulus</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Phl p 4</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2016">2016/9/7</year></dates><abstract><style face="normal" font="Arial">There is so far a paucity of data about allergen component-resolved diagnosis, and the prevalence of grass pollen allergen components in China, in contrast to those from western countries. Even in this country, allergies to grass pollen allergen components in the vast south are inadequately described. This study aimed to determine the major sensitizing grass pollens in Guangzhou, the largest city in Guangdong province of southern China. Included in this study were 258 patients having allergic rhinitis with or without asthma and 88 healthy controls. ImmunoCap100 was used to examine the serum samples for sIgE to Bermuda, Timothy, and Humulus scandens. Subjects who tested positive were further examined for sIgE to Bermuda antigen Cyn d 1, Timothy antigens Phl p 1/4/5/6/7/11/12, and CCD. The relationship of grass pollen allergy to specific antigen sensitization was assessed. As a result, 22.5% of patients with allergic rhinitis and/or asthma were positive for Bermuda-sIgE, 13.6% for Timothy-sIgE, and 7.0% for Humulus scandens-sIgE. These patients were more likely to be sensitized compared with controls (P&lt;0.001). Of the Bermuda-sIgE positive patients, 53.4% were Cyn d 1 positive and 60.3% were Timothy-sIgE positive. Of the Timothy positive patients, 100% were positive for Phl p 4, 17.1% were positive for Phl p 1 and 8.6% tested positive for Phl p 5/6/7/11/12. Patients with high Bermuda-sIgE levels were more likely to be positive for other grasses. In 41.4% of Bermuda grass positive patients, CCD-sIgE was also positive. Sensitization to Phl p 4 was significantly correlated with CCD (rs=0.928).In summary, we found that these southern Chinese patients with allergic rhinitis and/or asthma tested positive for Bermuda, Timothy, and Humulus scandens IgE. A high Bermuda-sIgE level may predict sensitization to other grasses. Correlations between sensitization to CCD and grass pollen allergens suggested a likelihood of cross-reactivity. Further in vitro inhibition assays are required to confirm this relationship</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2016.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27614266">PM:27614266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2016-78-105-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2016-78-105-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Luo W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2016.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Nam,S.Y.</style></author><author><style face="normal" font="Arial"> Hwang,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,H.M.</style></author><author><style face="normal" font="Arial"> Jeong,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Atractylone, an active constituent of KMP6, attenuates allergic inflammation on allergic rhinitis in vitro and in vivo models</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="132" start="121">121-132</pages><volume><style face="normal" font="Arial">78</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Caspase 1</style></keyword><keyword><style face="normal" font="Arial"> caspase-1</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase-2</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Intercellular Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> invasions</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> macrophage inflammatory protein 2</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Kinases</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">KMP6 (Pyeongwee-San) is a Korean Medicine used to treat gastrointestinal disorders. Recently, we reported KMP6 had beneficial effects on allergic inflammatory diseases. The aim of this study was to evaluate the effects of atractylone (Atr), a constituent of KMP6, on allergic rhinitis (AR) and to identify the mechanism responsible for these effects. The anti-allergic inflammatory effects of Atr were evaluated on phorbol 12-myristate 13-acetate and calcium ionophore A23187 (PMACI)-stimulated human mast cell line, HMC-1 cells and in an ovalbumin (OVA)-induced AR animal model using Western blotting, quantitative real-time PCR, ELISA, and immunohistochemistry methods. In HMC-1 cells, Atr and KMP6 attenuated PMACI-caused proinflammatory cytokine production and mRNA expression. We found that PMACI induced caspase-1/nuclear factor (NF)-kappaB/mitogen activated protein kinases (MAPKs) activation. PMACI-caused caspase-1/NF-kappaB/MAPKs activations were attenuated by Atr and KMP6. In AR animal model, Atr and KMP6 reduced AR clinical symptoms and biomarkers including rub scores, total IgE, histamine, prostaglandin D2, thymic stromal lymphopoietin, interleukin (IL)-1beta, IL-4, IL-5, IL-6, IL-13, tumor necrosis factor-alpha, cyclooxygenase-2, intercellular adhesion molecule-1, and macrophage inflammatory protein-2. In addition, Atr and KMP6 attenuated eosinophils and mast cells invasions into nasal mucosa tissues and diminished mast cell-derived caspase-1 activation. These results indicate that Atr is an active constituent of KMP6 and a potential therapeutic agent for AR</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2016.09.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27636508">PM:27636508</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2016-78-121-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2016-78-121-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Kim HY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2016.09.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schluter,O.</style></author><author><style face="normal" font="Arial"> Rumpold,B.</style></author><author><style face="normal" font="Arial"> Holzhauser,T.</style></author><author><style face="normal" font="Arial"> Roth,A.</style></author><author><style face="normal" font="Arial"> Vogel,R.F.</style></author><author><style face="normal" font="Arial"> Quasigroch,W.</style></author><author><style face="normal" font="Arial"> Vogel,S.</style></author><author><style face="normal" font="Arial"> Heinz,V.</style></author><author><style face="normal" font="Arial"> Jager,H.</style></author><author><style face="normal" font="Arial"> Bandick,N.</style></author><author><style face="normal" font="Arial"> Kulling,S.</style></author><author><style face="normal" font="Arial"> Knorr,D.</style></author><author><style face="normal" font="Arial"> Steinberg,P.</style></author><author><style face="normal" font="Arial"> Engel,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Leibniz Institute for Agricultural Engineering Potsdam-Bornim, Max-Eyth-Allee 100, D-14469, Potsdam, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Safety aspects of the production of foods and food ingredients from insects</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Austria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Food ingredients</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fractionation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="14" Month="9" Year="2016">2016/9/14</year></dates><abstract><style face="normal" font="Arial">At present, insects are rarely used by the European food industry, but they are a subject of growing interest as an alternative source of raw materials. The risks associated with the use of insects in the production of foods and food ingredients have not been sufficiently investigated. There is a lack of scientifically based knowledge of insect processing to ensure food safety, especially when these processes are carried out on an industrial scale. This review focuses on the safety aspects that need to be considered regarding the fractionation of insects for the production of foods and food ingredients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201600520</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27623740">PM:27623740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20160914-SchluterO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20160914-SchluterO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Schluter O</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201600520</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hurst,L.C.</style></author><author><style face="normal" font="Arial"> Badalamente,M.A.</style></author><author><style face="normal" font="Arial"> Hentz,V.R.</style></author><author><style face="normal" font="Arial"> Hotchkiss,R.N.</style></author><author><style face="normal" font="Arial"> Kaplan,F.T.</style></author><author><style face="normal" font="Arial"> Meals,R.A.</style></author><author><style face="normal" font="Arial"> Smith,T.M.</style></author><author><style face="normal" font="Arial"> Rodzvilla,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Orthopaedics, SUNY at Stony Brook, Health Science Center, Level 18, Rm. 020, Stony Brook, NY 11794-8181, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Injectable collagenase clostridium histolyticum for Dupuytren's contracture</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="979" start="968">968-979</pages><volume><style face="normal" font="Arial">361</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Clo hi Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Clostridium histolyticum</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Double-Blind Method</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Dupuytren Contracture</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enzymology</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Injections,Intralesional</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbial Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Range of Motion,Articular</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tendon Injuries</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="9" Year="2009">2009/9/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dupuytren's disease limits hand function, diminishes the quality of life, and may ultimately disable the hand. Surgery followed by hand therapy is standard treatment, but it is associated with serious potential complications. Injection of collagenase clostridium histolyticum, an office-based, nonsurgical option, may reduce joint contractures caused by Dupuytren's disease. METHODS: We enrolled 308 patients with joint contractures of 20 degrees or more in this prospective, randomized, double-blind, placebo-controlled, multicenter trial. The primary metacarpophalangeal or proximal interphalangeal joints of these patients were randomly assigned to receive up to three injections of collagenase clostridium histolyticum (at a dose of 0.58 mg per injection) or placebo in the contracted collagen cord at 30-day intervals. One day after injection, the joints were manipulated. The primary end point was a reduction in contracture to 0 to 5 degrees of full extension 30 days after the last injection. Twenty-six secondary end points were evaluated, and data on adverse events were collected. RESULTS: Collagenase treatment significantly improved outcomes. More cords that were injected with collagenase than cords injected with placebo met the primary end point (64.0% vs. 6.8%, P &lt; 0.001), as well as all secondary end points (P &lt; or = 0.002). Overall, the range of motion in the joints was significantly improved after injection with collagenase as compared with placebo (from 43.9 to 80.7 degrees vs. from 45.3 to 49.5 degrees, P &lt; 0.001). The most commonly reported adverse events were localized swelling, pain, bruising, pruritus, and transient regional lymph-node enlargement and tenderness. Three treatment-related serious adverse events were reported: two tendon ruptures and one case of complex regional pain syndrome. No significant changes in flexion or grip strength, no systemic allergic reactions, and no nerve injuries were observed. CONCLUSIONS: Collagenase clostridium histolyticum significantly reduced contractures and improved the range of motion in joints affected by advanced Dupuytren's disease. (ClinicalTrials.gov number, NCT00528606.)</style></abstract><notes><style face="normal" font="Arial">DA - 20090903IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticlePT - Multicenter StudyPT - Randomized Controlled TrialRN - EC 3.4.24.3 (Microbial Collagenase)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa0810866</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="19726771">PM:19726771</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2009-361-968-79.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2009-361-968-79.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20090903, Hurst LC</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa0810866</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maury,S.</style></author><author><style face="normal" font="Arial"> Chevret,S.</style></author><author><style face="normal" font="Arial"> Thomas,X.</style></author><author><style face="normal" font="Arial"> Heim,D.</style></author><author><style face="normal" font="Arial"> Leguay,T.</style></author><author><style face="normal" font="Arial"> Huguet,F.</style></author><author><style face="normal" font="Arial"> Chevallier,P.</style></author><author><style face="normal" font="Arial"> Hunault,M.</style></author><author><style face="normal" font="Arial"> Boissel,N.</style></author><author><style face="normal" font="Arial"> Escoffre-Barbe,M.</style></author><author><style face="normal" font="Arial"> Hess,U.</style></author><author><style face="normal" font="Arial"> Vey,N.</style></author><author><style face="normal" font="Arial"> Pignon,J.M.</style></author><author><style face="normal" font="Arial"> Braun,T.</style></author><author><style face="normal" font="Arial"> Marolleau,J.P.</style></author><author><style face="normal" font="Arial"> Cahn,J.Y.</style></author><author><style face="normal" font="Arial"> Chalandon,Y.</style></author><author><style face="normal" font="Arial"> Lheritier,V.</style></author><author><style face="normal" font="Arial"> Beldjord,K.</style></author><author><style face="normal" font="Arial"> Bene,M.C.</style></author><author><style face="normal" font="Arial"> Ifrah,N.</style></author><author><style face="normal" font="Arial"> Dombret,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Departement d'Hematologie, Hopital Henri Mondor, Assistance Publique-Hopitaux de Paris</style></auth-address><titles><title><style face="normal" font="Arial">Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="1053" start="1044">1044-1053</pages><volume><style face="normal" font="Arial">375</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asparaginase</style></keyword><keyword><style face="normal" font="Arial"> CD20</style></keyword><keyword><style face="normal" font="Arial"> CD20 antigen</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="9" Year="2016">2016/9/15</year></dates><abstract><style face="normal" font="Arial">Background Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial. Methods We randomly assigned adults (18 to 59 years of age) with CD20-positive, Philadelphia chromosome (Ph)-negative ALL to receive chemotherapy with or without rituximab, with event-free survival as the primary end point. Rituximab was given during all treatment phases, for a total of 16 to 18 infusions. Results From May 2006 through April 2014, a total of 209 patients were enrolled: 105 in the rituximab group and 104 in the control group. After a median follow-up of 30 months, event-free survival was longer in the rituximab group than in the control group (hazard ratio, 0.66; 95% confidence interval [CI], 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) and 52% (95% CI, 43 to 63), respectively. Treatment with rituximab remained associated with longer event-free survival in a multivariate analysis. The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to asparaginase were observed in the rituximab group. Conclusions Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL. (Funded by the Regional Clinical Research Office, Paris, and others; ClinicalTrials.gov number, NCT00327678 .)</style></abstract><notes><style face="normal" font="Arial">DA - 20160915IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tSB - AIMSB - IMCO - France -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa1605085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27626518">PM:27626518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2016-375-1044-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2016-375-1044-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160915, Maury S</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa1605085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zaffini,R.</style></author><author><style face="normal" font="Arial"> Di Paola,R.</style></author><author><style face="normal" font="Arial"> Cuzzocrea,S.</style></author><author><style face="normal" font="Arial"> Menegazzi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurosciences, Biomedicine and Movement Sciences, Biochemistry Section, University of Verona, Strada Le Grazie, 8, 37134, Verona, Italy</style></auth-address><titles><title><style face="normal" font="Arial">PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma</style></title><secondary-title><style face="normal" font="Arial">Naunyn Schmiedebergs Arch Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Naunyn Schmiedebergs Arch Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Neurosciences</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> STAT-6</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2016">2016/9/7</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is an immunological disease that occurs as a consequence of aeroallergen exposure. Inhibition of poly(ADP-ribose) polymerases (PARPs) in conventional models of asthma-like reaction has emerged as an effective anti-inflammatory and airway remodeling intervention. In a house dust mite (HDM) exposure mouse model, we investigated the impact of PARP inhibition on allergic airway inflammation, sensitization, and remodeling. Mice were intranasally exposed to a HDM extract for 5 days per week for up to 5 weeks. Mice were administered, or not, by PARP inhibitors 3-aminobenzamide (3-ABA) or 5-aminoisoquinolinone (5-AIQ) during the last 2 weeks of HDM treatment. Mice treated with PARP inhibitors after HDM stimulation showed a significant decrease in the number of total cells and eosinophils detectable in the bronchoalveolar lavage fluid as compared with the HDM-stimulated ones. In vitro HDM-stimulated splenocyte culture produced considerable amounts of the Th2 cytokines that were not affected by treatment with PARP inhibitors. Immunoglobulin levels in the serum were also unchanged. In the lung tissue, collagen deposition was decreased, whereas alpha-smooth muscle actin thickening was not significantly affected. Moreover, in HDM-stimulated PARP inhibitor-treated groups, we found a downregulation in the activation of signal transducer and activator of trascription-6 (STAT-6) and a significant decrease in the mRNA levels of C-C motif chemokine 11 (CCL11). In this mouse model of chronic asthma PARP inhibition treatment, although it does not affect sensitization, it effectively reduces the allergic airway inflammation and affects the remodeling through a mechanism involving STAT6 and CCL11</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 1432-1912 (Electronic)IS - 0028-1298 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00210-016-1294-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27604227">PM:27604227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Naunyn Schmiedebergs Arch Pharmacol\20160908-ZaffiniR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Naunyn Schmiedebergs Arch Pharmacol\20160908-ZaffiniR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Zaffini R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00210-016-1294-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gallay,L.</style></author><author><style face="normal" font="Arial"> Petiot,P.</style></author><author><style face="normal" font="Arial"> Durieu,I.</style></author><author><style face="normal" font="Arial"> Streichenberger,N.</style></author><author><style face="normal" font="Arial"> Berard,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Immunology, Edouard Herriot University Hospital, 5 place d'Arsonvaal, 69437 Lyon Cedex 03, France</style></auth-address><titles><title><style face="normal" font="Arial">SWORD: A simplified desensitization protocol for enzyme replacement therapy in adult Pompe disease</style></title><secondary-title><style face="normal" font="Arial">Neuromuscul Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Neuromuscul Disord</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Weakness</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> respiratory failure</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2016">2016/7/19</year></dates><abstract><style face="normal" font="Arial">Pompe disease is an inherited lysosomal disease in which there is a decrease or absence of acid alpha-glucosidase activity. This enzyme defect induces glycogen storage in different tissues, especially muscle and heart, resulting in muscle weakness, respiratory failure and heart disease. Substitutive enzyme replacement therapy (ERT) dispensed every two weeks is the only treatment that has shown benefits. However, this treatment induces hypersensitivity for half of the treated patients. Reactions range from mild to severe, sometimes requiring ERT suspension and anti-anaphylaxis drug administration. Understandably, high amount of acid alpha-glucosidase infusion seems to be identified by the immune system as a danger associated molecular pattern, and induce an immune reaction, involving sometimes, but not always, immunoglobulin E (IgE) production and activating mast and basophil polynuclear cells. Considering the lack of therapeutic alternatives and the proved benefit of ERT, desensitization finds its place here. We hereby report the case of a patient for whom a simplified desensitization protocol ("SWORD": Start With One Regular Drop) was successfully achieved, allowing ERT to be pursued, resulting eventually in clinical improvement</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1873-2364 (Electronic)IS - 0960-8966 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.nmd.2016.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27637292">PM:27637292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Neuromuscul Disord\20160917-GallayL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Neuromuscul Disord\20160917-GallayL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Gallay L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.nmd.2016.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shi,J.P.</style></author><author><style face="normal" font="Arial"> Wang,S.Y.</style></author><author><style face="normal" font="Arial"> Chen,L.L.</style></author><author><style face="normal" font="Arial"> Zhang,X.Y.</style></author><author><style face="normal" font="Arial"> Zhao,Y.H.</style></author><author><style face="normal" font="Arial"> Du,B.</style></author><author><style face="normal" font="Arial"> Jiang,W.Z.</style></author><author><style face="normal" font="Arial"> Qian,M.</style></author><author><style face="normal" font="Arial"> Ren,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, P.R.China</style></auth-address><titles><title><style face="normal" font="Arial">P2Y6 contributes to ovalbumin-induced allergic asthma by enhancing mast cell function in mice</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Nucleotides</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> purinergic receptor</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">Extracelluar nucleotides have been identified as regulatory factors in asthmatic pathogenesis by activating purinergic receptors. This research aimed to investigate the function of the purinergic receptor P2Y6 in mediating airway inflammation in allergic asthma. Wild-type (WT) and P2Y6-deficient mice were stimulated with ovalbumin (OVA) to construct asthmatic mouse models. Overexpression of P2Y6 and uridine 5'-diphosphate (UDP)-releasing were demonstrated in lung tissues in ovalbumin-induced asthmatic mice. The release of the cytokine IL-4, mast cell invasion, and the airway remodeling phenotypes were more severe following the application of UDP in asthmatic mice. However, P2Y6 deficiency reduced these asthmatic pathogeneticsymptoms markedly in a mouse model. In vitro, we found that P2Y6 in purified mast cells enhanced the functions of mast cells in the inflammatory response in the asthmatic process by triggering their capability for migration, cytokine secretion and granule release. Moreover, P2Y6 stimulated the function of mast cells through activation of the AKT signaling pathway. Our data provides evidence that P2Y6 contributes to allergic airway inflammation and remodeling by enhancing the functions of mast cells in ovalbumin-induced asthmatic mice</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.11758</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590515">PM:27590515</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20160903-ShiJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20160903-ShiJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Shi JP</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.11758</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Campbell,B.</style></author><author><style face="normal" font="Arial"> Cortes,H.</style></author><author><style face="normal" font="Arial"> Annoscia,G.</style></author><author><style face="normal" font="Arial"> Giannelli,A.</style></author><author><style face="normal" font="Arial"> Parisi,A.</style></author><author><style face="normal" font="Arial"> Latrofa,M.S.</style></author><author><style face="normal" font="Arial"> Dantas-Torres,F.</style></author><author><style face="normal" font="Arial"> Cardoso,L.</style></author><author><style face="normal" font="Arial"> Otranto,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Medicina Veterinaria, Universita degli Studi di Bari, Bari, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Paramyosin of canine Onchocerca lupi: usefulness for the diagnosis of a neglected zoonotic disease</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="493">493-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antigenic epitopes</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Blindness</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> Onchocerca</style></keyword><keyword><style face="normal" font="Arial"> Paramyosin</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phylogenetic analysis</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Of increasing importance to the medical and veterinary communities is the zoonotic filarioid nematode Onchocerca lupi. Onchocercosis, thus far found in wolves, dogs, cats and humans, is diagnosed via skin snips to detect microfilariae and surgical removal of adults from the eye of the host. These methods are time-consuming, laborious and invasive, highlighting the need for new tools for the diagnosis of O. lupi in susceptible hosts. Symptoms related to the presence of the adults in the eye can range from none apparent to severe, including blindness. No reliable chemotherapeutic protocols are available, as yet, to eliminate the infection. Paramyosin, an invertebrate-specific protein, has been well-studied as an allergen, diagnostic marker and vaccine candidate. The aim of this study, therefore, was to isolate and characterise paramyosin from O. lupi to assess its suitability for the development of a serological diagnostic assay. METHODS: The adult and microfilarial stages of O. lupi were isolated from the eyes and skin of a 3-year-old male dog. Total RNA was extracted and reverse transcribed into single stranded cDNA. Reverse-transcription PCR was used to isolate a full-length paramyosin cDNA from adult worms and to investigate the temporal expression patterns of this gene. All amplicons were sequenced using dideoxy chain termination sequencing. Bioinformatics was used to predict the amino acid sequence of the gene, to compare the DNA and protein sequences with those available in public databases and to investigate the phylogenetic relationship of all molecules. Antibody binding sites were predicted using bioinformatics and mapped along with published antigenic epitopes against the O. lupi paramyosin protein. The native protein, and three smaller recombinantly expressed peptides, were subjected to western blot using serum from dogs both positive and negative for O. lupi. RESULTS: Paramyosin of O. lupi was herein molecularly characterized, encoded by a transcript of 2,643 bp and producing a protein of 881 amino acids (101.24 kDa). The paramyosin transcript was detected, by reverse transcription PCR, in adults and microfilariae, but not in eggs. Phylogenetic analysis indicates that this molecule clusters with paramyosins from other filarioids to the exclusion of those from other taxa. A total of 621 unique antibody binding epitopes were predicted for this protein and another 28 were conserved in other organisms. This information was used to design three peptides, for recombinant expression, to identify the antibody binding epitope(s) and reduce potential cross-reactivity with serum from dogs infected with other filarioid nematodes. Native paramyosin, purified from microfilariae and adults, was detected by antibodies present in serum from dogs with known O. lupi infections. CONCLUSIONS: Data provided herein may assist in the development of a serological diagnostic test, based on antibodies to O. lupi paramyosin, for the diagnosis of this infection, in order to gain more information on the real distribution of this little known filarioid of zoonotic concern</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -CO - Brazil -CO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-016-1783-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27604904">PM:27604904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2016-9-493.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2016-9-493.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Campbell B</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-016-1783-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gradman,J.</style></author><author><style face="normal" font="Arial"> Mortz,C.G.</style></author><author><style face="normal" font="Arial"> Eller,E.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Center, Odense University Hospital, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Relationship between specific IgE to egg components and natural history of egg allergy in Danish children</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="830" start="825">825-830</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Conalbumin</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="27" Month="8" Year="2016">2016/8/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The majority of egg allergic children develops tolerance over time. However, it may take numerous of consecutive egg challenges to get there as no good indices to predict tolerance exists. OBJECTIVE: To investigate if serial measurements of specific IgE to egg white, ovomucoid, ovalbumin, conalbumin, lysozyme, and egg yolk could improve the specificity of the diagnostic work up and aid in the decision when to re-challenge egg allergic children. METHODS: The outcome of oral food challenges with hen's egg and corresponding specific IgE levels were evaluated in children referred to The Allergy Center within an 8-year period. The egg allergic children were re-challenged and had specific IgE levels measured once a year. RESULTS: During a median follow-up of 26 months, 287 challenges and corresponding 287 serum analyses were performed in 130 children. Of the 130 children, 99 were egg allergic and 82 of these were re-challenged. Based on the initial diagnostic challenges only, AUC estimates of the ability of specific IgE titers to distinguish between egg sensitization and egg allergy were only modest (maximum 0.83) and provided no clinical meaningful decision points. Specific IgE levels at baseline did not differ between tolerant and persistent allergic children. However longitudinally, acquisition of tolerance was associated with a decrease of IgE to egg white and to ovomucoid. In all cases of an increase in IgE to ovomucoid, the re-challenge was positive. CONCLUSION: The decision when to re-challenge egg allergic children should encounter the course of specific IgE. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160827IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12644</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27565949">PM:27565949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160827-GradmanJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160827-GradmanJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160827, Gradman J</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12644</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ismail,I.H.</style></author><author><style face="normal" font="Arial"> Boyle,R.J.</style></author><author><style face="normal" font="Arial"> Licciardi,P.V.</style></author><author><style face="normal" font="Arial"> Oppedisano,F.</style></author><author><style face="normal" font="Arial"> Lahtinen,S.</style></author><author><style face="normal" font="Arial"> Robins-Browne,R.M.</style></author><author><style face="normal" font="Arial"> Tang,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Murdoch Childrens Research Institute, Melbourne, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Early gut colonisation by Bifidobacterium breve and B. catenulatum differentially modulates eczema risk in children at high-risk of developing allergic disease</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="846" start="838">838-846</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium breve</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Household pets</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> terminal restriction fragment length polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="9" Year="2016">2016/9/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An altered compositional signature and reduced diversity of early gut microbiota are linked to development of allergic disease. We investigated the relationship between dominant Bifidobacterium species during early postnatal period and subsequent development of allergic disease in the first year of life. METHODS: Faecal samples were collected at age 1 week, 1 month and 3 months from 117 infants at high risk of allergic disease. Bifidobacterium species were analysed by quantitative PCR and terminal restriction fragment length polymorphism. Infants were examined at 3, 6 and 12 months, and skin prick test performed at 12 months. Eczema was diagnosed according to the UK-Working Party criteria. RESULTS: The presence of B. catenulatum at 3 months was associated with a higher risk of developing eczema (ORadj =4.5; 95% CI 1.56 to 13.05, padj =0.005). Infants colonised with B. breve at 1 week (ORadj =0.29; 95% CI 0.09 to 0.95, padj =0.04) and 3 months (ORadj =0.15; 95% CI 0.05 to 0.44, padj =0.00001) had a reduced risk of developing eczema. Furthermore, the presence of B. breve at 3 months was associated with a lower risk of atopic sensitisation at 12 months (ORadj =0.38; 95% CI 0.15 to 0.98, padj =0.05). B. breve colonisation patterns were influenced by maternal allergic status, household pets and number of siblings. CONCLUSIONS: Temporal variations in Bifidobacterium colonisation patterns early in life are associated with later development of eczema and/or atopic sensitisation in infants at high risk of allergic disease. Modulation of the early microbiota may provide a means to prevent eczema in high risk infants. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12646</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590263">PM:27590263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-IsmailIH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-IsmailIH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Ismail IH</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12646</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Parente,R.</style></author><author><style face="normal" font="Arial"> Pucino,V.</style></author><author><style face="normal" font="Arial"> Magliacane,D.</style></author><author><style face="normal" font="Arial"> Petraroli,A.</style></author><author><style face="normal" font="Arial"> Loffredo,S.</style></author><author><style face="normal" font="Arial"> Marone,G.</style></author><author><style face="normal" font="Arial"> Triggiani,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Medicine, University of Salerno, Salerno, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of vaccination safety in children with mastocytosis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="95" start="93">93-95</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Mastocytosis is a disease characterized by increased mast cell density in various tissues, including the skin, hematopoietic organs and gastrointestinal tract (1). Mastocytosis may appear in both children and adults. Childhood mastocytosis is more frequently limited to the skin and resolves spontaneously in the majority of cases (2) whereas adult mastocytosis is usually systemic and may have an indolent or aggressive course (1). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - LETTERCO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12647</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590431">PM:27590431</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-ParenteR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-ParenteR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Parente R</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12647</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sopo,S.M.</style></author><author><style face="normal" font="Arial"> Bersani,G.</style></author><author><style face="normal" font="Arial"> Cerchiara,G.</style></author><author><style face="normal" font="Arial"> Monaco,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Department of Paediatrics, Agostino Gemelli Hospital, Sacred Heart Catholic University, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Oral food challenge with a mixture of "at risk" foods in children with FPIES</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="876" start="874">874-876</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Multiple foods</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="10" Month="8" Year="2016">2016/8/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food Protein-Induced Enterocolitis Syndrome (FPIES) is a non-IgE-mediated food allergy. In addition to the elimination diet regarding the culprit food, it has been proposed to avoid, for the 1st year of life, certain foods (legumes, cereals, poultry), which are considered at risk. This suggestion may not be appropriate in countries where the prevalence of multiple foods FPIES is low. We evaluated the usefulness of an oral food challenge (OFC) with a mixture of these "at risk" foods. METHODS: Children with acute FPIES younger than one year were enrolled. Skin prick tests (SPT) with commercial extracts and cooked foods were performed with legumes, cereals, poultry. All children performed an OFC with a mixture of these foods. After 3 months, the patients who passed OFC were contacted by telephone to verify the persistence of "at risk" foods tolerance at home. RESULTS: Fourteen children were enrolled, 13 with cow's milk FPIES and 1 with wheat FPIES. The SPT were always negative. All children passed the OFC and continued to eat "at risk" foods at home without adverse reactions. CONCLUSIONS: To perform an OFC with a mixture of "at risk" foods for children with acute FPIES is a convenient and safe practice in countries where the prevalence of multiple foods FPIES is low. This procedure can avoid unnecessary elimination diet. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160810IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - LETTERCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12623</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27507733">PM:27507733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160810-SopoSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160810-SopoSM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160810, Sopo SM</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12623</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caffarelli,C.</style></author><author><style face="normal" font="Arial"> Rico,S.</style></author><author><style face="normal" font="Arial"> Varini,M.</style></author><author><style face="normal" font="Arial"> Povesi-Dascola,C.</style></author><author><style face="normal" font="Arial"> Mastrorilli,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinica Pediatrica Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria, University of Parma, Parma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Skin prick test and development of tolerance in egg allergy</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="884" start="881">881-884</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> egg tolerance</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="10" Month="8" Year="2016">2016/8/10</year></dates><abstract><style face="normal" font="Arial">IgE-mediated egg allergy is one of the most common food allergies in childhood (1). Most children with egg allergy develop tolerance over time (2). Children with egg allergy periodically undergo oral food challenge (OFC) that is the gold standard for determining tolerance acquisition (3) and for preventing unnecessary allergens avoidance. However, OFC is expensive, time-consuming and may cause anxiety and severe reaction. Therefore, interest in simple markers to predict the development of egg tolerance in children is growing. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160810IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - LETTERCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12625</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27506151">PM:27506151</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160810-CaffarelliC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160810-CaffarelliC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160810, Caffarelli C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12625</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ueno,H.M.</style></author><author><style face="normal" font="Arial"> Kato,T.</style></author><author><style face="normal" font="Arial"> Ohnishi,H.</style></author><author><style face="normal" font="Arial"> Kawamoto,N.</style></author><author><style face="normal" font="Arial"> Kato,Z.</style></author><author><style face="normal" font="Arial"> Kaneko,H.</style></author><author><style face="normal" font="Arial"> Kondo,N.</style></author><author><style face="normal" font="Arial"> Nakano,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research and Development Department, Bean Stalk Snow Co., Ltd, Kawagoe, Japan</style></auth-address><titles><title><style face="normal" font="Arial">T cell epitope-containing hypoallergenic beta-lactoglobulin for oral immunotherapy in milk allergy</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="824" start="818">818-824</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Antiserum</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Chymotrypsin</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbit IgG</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="19" Month="8" Year="2016">2016/8/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Optimally hydrolyzed betaLg is a promising milk oral-immunotherapy candidate with respect to showing reduced B-cell reactivity but retaining the T-cell epitope. To demonstrate that an edible hypoallergenic betaLg hydrolysate containing the T-cell epitope is suitable for oral immunotherapy. We tested how chymotrypsin affected the retention of the T-cell epitope of betaLg when preparing betaLg hydrolysates by using food-grade trypsin. METHODS: We investigated the effect of chymotrypsin activity on the formation of the T-cell epitope-containing peptide of betaLg (betaLg102-124 ), and prepared an edible betaLg hydrolysate containing betaLg102-124 by using screened food-grade trypsins. B-cell reactivity was determined using immunoassays in which ELISA was performed with anti-betaLg rabbit IgG and western blotting was performed with a milk-specific IgE antiserum. RESULTS: In betaLg hydrolysis performed by varying the activity of trypsin and chymotrypsin, chymotrypsin activity inhibited the formation of betaLg102-124 with an increase of hydrolysis time in a dose-dependent manner. betaLg102-124 was generated by 2 out of 5 food-grade trypsins used at a ratio of 1:50 (w/w, enzyme/substrate) for 20 h at 40 degrees C. The edible betaLg hydrolysate retained betaLg102-124 and showed a reduction in molecular weight distribution and antigenicity against IgG and IgE. CONCLUSIONS: Chymotrypsin activity inhibited the formation of betaLg102-124 in the trypsin hydrolysate of betaLg. This betaLg trypsin hydrolysate is a novel candidate for peptide-based oral immunotherapy in cow's milk allergy for safely inducing desensitization. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160819IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12642</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27540712">PM:27540712</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160819-UenoHM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160819-UenoHM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160819, Ueno HM</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12642</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Christiansen,E.S.</style></author><author><style face="normal" font="Arial"> Kjaer,H.F.</style></author><author><style face="normal" font="Arial"> Eller,E.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Host,A.</style></author><author><style face="normal" font="Arial"> Mortz,C.G.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Center, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, DK-5000 Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="Arial">The prevalence of atopic diseases and the patterns of sensitization in adolescence</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="853" start="847">847-853</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> astma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="9" Year="2016">2016/9/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic diseases are among the most common chronic diseases in adolescents and it is uncertain whether the prevalence of atopic diseases has reached a plateau or is still increasing. The use of the ISAAC (International Study of Asthma and Allergy in Childhood) questionnaire has provided comparable prevalence rates from many countries; whereas studies including clinical examinations and strict diagnostic criteria are scarce. We aimed to investigate the prevalence of atopic diseases, the pattern of sensitization and comorbidities at 14 years in a prospective birth cohort. METHODS: The children were examined eight times from birth to 14 years. Visits included questionnaire-based interviews, clinical examination, skin prick test and specific IgE. RESULTS: Follow-up rate at 14-years was 66.2%. The 12-month prevalence of any atopic disease was high (40.3%) mostly due to a high prevalence of rhinoconjunctivitis (32.8%) whereas the prevalence of asthma was 12.9% and of atopic dermatitis 8.1%. In children with at least one atopic disease 60% were sensitized while only 16% of those without atopic diseases were sensitized. The frequency of sensitization depended on the phenotype. Among children with rhinoconjunctivitis only, rhinoconjunctivitis with concomitant astma or atopic dermatitis or both 62.5%, 81.5%, 70% and 100% respectively were sensitized, whereas it was 7.7% and 33.3% of children with only asthma or atopic dermatitis. CONCLUSION: The prevalence of rhinoconjunctivitis was high in adolescence. Children with rhinoconjunctivitis with and without comorbidities were frequently sensitized. Children with asthma without concomitant allergic rhinoconjunctivitis were rarely sensitized. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12650</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27591739">PM:27591739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-ChristiansenES.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-ChristiansenES.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Christiansen ES</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12650</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81667</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Langdon,C.</style></author><author><style face="normal" font="Arial"> Guilemany,J.M.</style></author><author><style face="normal" font="Arial"> Valls,M.</style></author><author><style face="normal" font="Arial"> Alobid,I.</style></author><author><style face="normal" font="Arial"> Bartra,J.</style></author><author><style face="normal" font="Arial"> Davila,I.</style></author><author><style face="normal" font="Arial"> del Cuvillo,A.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author><author><style face="normal" font="Arial"> Jauregui,I.</style></author><author><style face="normal" font="Arial"> Montoro,J.</style></author><author><style face="normal" font="Arial"> Sastre,J.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unitat de Rinologia i Clinica de l'Olfacte, Servei d'Otorinolaringologia, Hospital Clinic, IDIBAPS, Barcelona, Catalonia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="870" start="867">867-870</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Smell</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The objective of the OLFAPEDRIAL study was to assess the olfactory dysfunction in allergic paediatric population, which has been scarcely studied. METHODS: Observational, cross-sectional, and multicentre study evaluated the sense of smell in untreated allergic rhinitis (AR) paediatric patients aged 6-12 yrs. RESULTS: Fourty-four percent (551 out of 1260) of children with AR reported smell dysfunction, with both loss of smell frequency (52.1%, p&lt;0.001) and intensity (0.75+/-0.84, p&lt;0.0001) being more frequent in patients with persistent than intermittent AR (38.0% and 0.51+/-0.73, respectively). In addition, both loss of smell frequency and intensity increased according to disease severity (m-ARIA classification) but always being significantly higher in persistent (p&lt;0.0001) than in intermittent AR. CONCLUSIONS: children with allergic rhinitis present a mild-moderate loss of smell which frequency and intensity is clearly related to the disease duration and severity. The loss of smell can be considered, as in adults, a clinical marker of disease severity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12655</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27612327">PM:27612327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160909-LangdonC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160909-LangdonC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Langdon C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12655</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ricci,G.</style></author><author><style face="normal" font="Arial"> Cipriani,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Which advises for primary food allergy prevention in normal or high-risk infant?</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="778" start="774">774-778</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> food tolerance</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> intestinal immune system</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> self-antigens</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">In recent years, the incidence of food allergy increased significantly, especially in developed countries where its prevalence reaches 3-6% in the pediatric population, with serious implications on the quality life of patients and their families and a relevant burden on public health [1]. The mechanism of food tolerance involves many actors; the intestinal immune system must distinguish not only between self- and non self-antigens, but among non self molecules also between those able to elicit a dangerous response (allergens) and innocuous antigens (food). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12652</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27612289">PM:27612289</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160909-RicciG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160909-RicciG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Ricci G</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12652</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,G.Q.</style></author><author><style face="normal" font="Arial"> Liu,B.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Luo,C.Q.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Chen,J.L.</style></author><author><style face="normal" font="Arial"> Sinha,A.</style></author><author><style face="normal" font="Arial"> Li,Z.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Key Laboratory of Pediatrics in Chongqing, Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Chongqing, China</style></auth-address><titles><title><style face="normal" font="Arial">Fish intake during pregnancy or infancy and allergic outcomes in children: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="161" start="152">152-161</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child Development</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> LC-PUFA</style></keyword><keyword><style face="normal" font="Arial"> long-chain polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It has been suggested that n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) have anti-inflammatory properties and may reduce the risk of allergic disease. Fish is a great source of n-3 LC-PUFAs. However, the effect of fish on allergic disease remains controversial. METHODS: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) and prospective cohort studies regarding the effect of fish intake during pregnancy or infancy on allergic outcomes in children. The outcomes of interest were atopy, eczema, allergic rhinitis, wheeze, asthma, and food allergy. RESULTS: One RCT and seventeen publications from thirteen prospective cohort studies were included for maternal fish intake during pregnancy, and eight publications from five prospective cohort studies for fish intake in infancy. Pooled analysis suggested that maternal fish intake during pregnancy was not associated with lower risk of any allergic outcome, both in RCT and observational studies. Consumption of fish during the first year of life reduced the risk of eczema (RR 0.61; 95% CI 0.47, 0.80; P = 0.0003; I2 = 68%) and allergic rhinitis (RR 0.54; 95% CI 0.36, 0.81; P = 0.003; I2 = 74%). CONCLUSIONS: Current evidence indicates that fish intake in infancy could reduce the risk of eczema and allergic rhinitis in children, whereas maternal fish intake during pregnancy does not affect any atopic outcome. The intake of fish per se in infancy, not specially n-3 LC-PUFAs, may have an allergy protective effect. High-quality and adequately powered RCTs are warranted to confirm this. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - China -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12648</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590571">PM:27590571</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-ZhangGQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-ZhangGQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Zhang GQ</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12648</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81670</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Knipping,K.</style></author><author><style face="normal" font="Arial"> Knippels,L.M.</style></author><author><style face="normal" font="Arial"> Dupont,C.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nutricia Research, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Serum biomarkers for allergy in children</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="123" start="114">114-123</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A large number of studies investigating various biomarkers for allergy have been published over the past decades. The aim of this review was to evaluate these biomarkers on their diagnostic and/or predictive value. To this date, no single or specific biomarker for allergy has been identified. Since allergy is not one disease, but a collection of a number of allergic conditions, it is more plausible a combination of clinical history, clinical read-outs and diagnostic markers will be needed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12649</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590735">PM:27590735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-KnippingK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-KnippingK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Knipping K</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12649</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81671</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alduraywish,S.A.</style></author><author><style face="normal" font="Arial"> Standl,M.</style></author><author><style face="normal" font="Arial"> Lodge,C.J.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Erbas,B.</style></author><author><style face="normal" font="Arial"> Berg,V.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Lowe,A.J.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Is there a march from early food sensitization to later childhood allergic airway disease? Results from two prospective birth cohort studies</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="37" start="30">30-37</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective birth cohort study</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The march from early aeroallergen sensitization to subsequent respiratory allergy is well established, but it is unclear if early life food sensitization precedes and further increases risk of allergic airway disease. OBJECTIVE: To assess the association between food sensitization in the first 2 years of life and subsequent asthma and allergic rhinitis by age 10-12 years. METHODS: We used data from two independent cohorts: the high-risk MACS (n=620) and the population-based LISAplus (n= 3094). Food sensitization was assessed at 6, 12 and 24 months in MACS and 24 months in LISAplus. Multiple logistic regressions were used to estimate associations between sensitization to food only, aeroallergen only or both and allergic airway disease. RESULTS: When compared to non-sensitized children, sensitization to food only at 12 months in MACS and 24 months in LISAplus was associated with increased risk of current asthma (aOR=2.2; 95%CI 1.1, 4.6 in MACS and aOR=4.9; 2.4,10.1 in LISAplus). Similar results were seen for allergic rhinitis. Additionally, co-sensitization to food and aeroallergen in both cohorts at any tested point was a stronger predictor of asthma (at 24 months, aOR=8.3; 3.7, 18.8 in MACS and aOR=14.4; 5.0, 41.6 in LISAplus) and allergic rhinitis (at 24 months, aOR=3.9;1.9,8.1 in MACS and aOR=7.6;3.0,19.6 in LISAplus). CONCLUSIONS: In both cohorts, food sensitization (with or without aeroallergen sensitization) in the first two years of life increased the risk of subsequent asthma and allergic rhinitis. These findings support the role of early life food sensitization in the atopic march and suggest trials to prevent early onset have the potential to reduce the development of allergic airways disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160903IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -CO - Saudi Arabia -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12644</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27590890">PM:27590890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-AlduraywishSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160903-AlduraywishSA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160903, Alduraywish SA</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12644</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hoverson,K.</style></author><author><style face="normal" font="Arial"> Wohltmann,W.E.</style></author><author><style face="normal" font="Arial"> Pollack,R.J.</style></author><author><style face="normal" font="Arial"> Schissel,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tripler Army Medical Center, Honolulu, HawaiiDepartments of Pathology and Dermatology, University of Colorado, Denver, Colorado</style></auth-address><titles><title><style face="normal" font="Arial">Dermestid Dermatitis in a 2-Year-Old Girl: Case Report and Review of the Literature</style></title><secondary-title><style face="normal" font="Arial">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Dermatol</style></full-title></periodical><pages end="e233" start="e228">e228-e233</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Bedbugs</style></keyword><keyword><style face="normal" font="Arial"> Beetles</style></keyword><keyword><style face="normal" font="Arial"> carpet</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Hawaii</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressive Agents</style></keyword><keyword><style face="normal" font="Arial"> Larva</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Ointments</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Tacrolimus</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> Triamcinolone</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2015">2015/11</year></dates><abstract><style face="normal" font="Arial">Dermatitis from contact with carpet, larder, and hide beetles (family Dermestidae) is a seemingly uncommon or underrecognized hypersensitivity reaction to the specialized hairs on the larvae of certain dermestid beetles. The erythematous papulovesicular dermatitis that may result from such contact can be mistakenly construed as evidence of bites of bedbugs or other arthropods or infestation with scabies mites or can be the basis for a diagnosis of delusory parasitosis. We present a case of dermestid dermatitis in a 2-year-old girl and provide a review of the current literature</style></abstract><notes><style face="normal" font="Arial">DA - 20151120IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Case ReportsPT - Journal ArticlePT - ReviewRN - 0 (Allergens)RN - 0 (Glucocorticoids)RN - 0 (Immunosuppressive Agents)RN - 0 (Ointments)RN - 1ZK20VI6TY (Triamcinolone)RN - WM0HAQ4WNM (Tacrolimus)SB - IMCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pde.12641</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26250481">PM:26250481</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Dermatol\2015-32-e228-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Dermatol\2015-32-e228-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151120, Hoverson K</style></custom2><misc3><style face="normal" font="Arial">10.1111/pde.12641</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khoo,A.B.</style></author><author><style face="normal" font="Arial"> Ali,F.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology, Norfolk and Norwich University Hospital, Norwich, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Written Action Plans for Atopic Dermatitis in the Era of Mobile Technology</style></title><secondary-title><style face="normal" font="Arial">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Dermatol</style></full-title></periodical><pages end="" start="561">561-</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - LetterSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pde.12906</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27595877">PM:27595877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Dermatol\2016-33-561.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Dermatol\2016-33-561.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Khoo AB</style></custom2><misc3><style face="normal" font="Arial">10.1111/pde.12906</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Top,K.A.</style></author><author><style face="normal" font="Arial"> Billard,M.N.</style></author><author><style face="normal" font="Arial"> Gariepy,M.C.</style></author><author><style face="normal" font="Arial"> Rouleau,I.</style></author><author><style face="normal" font="Arial"> Pernica,J.M.</style></author><author><style face="normal" font="Arial"> Pham-Huy,A.</style></author><author><style face="normal" font="Arial"> Quach,C.</style></author><author><style face="normal" font="Arial"> Tran,D.</style></author><author><style face="normal" font="Arial"> Vaudry,W.</style></author><author><style face="normal" font="Arial"> Dobson,S.</style></author><author><style face="normal" font="Arial"> Boucher,F.D.</style></author><author><style face="normal" font="Arial"> Carignan,A.</style></author><author><style face="normal" font="Arial"> Jadavji,T.</style></author><author><style face="normal" font="Arial"> McConnell,A.</style></author><author><style face="normal" font="Arial"> McNeil,S.A.</style></author><author><style face="normal" font="Arial"> Halperin,S.A.</style></author><author><style face="normal" font="Arial"> De Serres,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, NS 2Centre hospitalier universitaire de Quebec, Universite Laval, Quebec, QC 3Ministere de la Sante et des Services sociaux du Quebec 4McMaster Children's Hospital, McMaster University, Hamilton, ON 5Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON 6Montreal Children's Hospital, McGill University Health Centre, Montreal, QC 7Hospital for Sick Children, University of Toronto, Toronto, ON 8Stollery Children's Hospital, University of Alberta, Edmonton, AB 9Vaccine Evaluation Centre, BC Children's Hospital, University of British Columbia, Vancouver, BC 10Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC 11Alberta Children's Hospital, University of Calgary, Calgary, AB 12Royal University Hospital, University of Saskatchewan, Saskatoon, SK 13Institut national de sante publique du Quebec, Universite Laval, Quebec, QC</style></auth-address><titles><title><style face="normal" font="Arial">Immunizing Patients with Adverse Events Following Immunization and Potential Contraindications to Immunization: A report from the Special Immunization Clinics Network</style></title><secondary-title><style face="normal" font="Arial">Pediatr Infect Dis J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Infect Dis J</style></full-title></periodical><pages end="e391" start="e384">e384-e391</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Causality</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Nova Scotia</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword><keyword><style face="normal" font="Arial"> Sante publique</style></keyword><keyword><style face="normal" font="Arial"> Saskatchewan</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="9" Year="2016">2016/9/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: For patients who have experienced adverse events following immunization (AEFI) or who have specific medical conditions, there is limited evidence regarding the best approach to immunization. The Special Immunization Clinics (SIC) Network was established to standardize patient management and assess outcomes after re-immunization. The study objective was to describe the first two years of the network's implementation. METHODS: Twelve SICs were established across Canada by infectious diseases specialists and allergists. Inclusion criteria were: local reaction >/=10 cm, allergic symptoms &lt;24h post-immunization, neurological symptoms, and other AEFI or medical conditions of concern. Eligible patients underwent a standardized evaluation, causality assessment was performed, immunization recommendations were made by expert physicians, and patients were followed up to capture AEFI. Following individual consent, data were transferred to a central database for analysis. RESULTS: From June 2013 to May 2015, 151 patients were enrolled. Most were referred for prior AEFI (132/151, 87%): 42 (32%) for allergic-like reactions, 31 (23%) for injection-site reactions, 20 (15%) for neurologic symptoms and 39 (30%) for other systemic symptoms. Nineteen patients (13%) were seen for underlying conditions that complicated immunization. Re-immunization was recommended for 109 patients, 60 of whom (55%) were immunized and followed up. Eleven patients (18%) experienced recurrence of their AEFI; none were serious (e.g., resulting in hospitalization, permanent disability or death). CONCLUSIONS: The most frequent reasons for referral to a SIC were allergic-like events and injection site reactions. Re-immunization was safe in most patients. Larger studies are needed to determine outcomes for specific types of AEFI</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1532-0987 (Electronic)IS - 0891-3668 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1097/INF.0000000000001323</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27626920">PM:27626920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Infect Dis J\20160914-TopKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Infect Dis J\20160914-TopKA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Top KA</style></custom2><misc3><style face="normal" font="Arial">10.1097/INF.0000000000001323</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moncourier,M.</style></author><author><style face="normal" font="Arial"> Assikar,S.</style></author><author><style face="normal" font="Arial"> Matei,I.</style></author><author><style face="normal" font="Arial"> Souyri,N.</style></author><author><style face="normal" font="Arial"> Couture,M.</style></author><author><style face="normal" font="Arial"> Rigot,E.</style></author><author><style face="normal" font="Arial"> Delaumenie,S.</style></author><author><style face="normal" font="Arial"> Bedane,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de dermatologie, hopital Dupytren, CHU de Limoges, France.</style></auth-address><titles><title><style face="normal" font="Arial">Visible light induced solar urticaria is improved by omalizumab</style></title><secondary-title><style face="normal" font="Arial">Photodermatol Photoimmunol Photomed</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Photodermatol Photoimmunol Photomed</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> cyclosporin A</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Intravenous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phototherapy</style></keyword><keyword><style face="normal" font="Arial"> physical urticaria</style></keyword><keyword><style face="normal" font="Arial"> Plasmapheresis</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">Solar urticaria (SU) is a rare type of physical urticaria triggered by sun exposure with pathognomonic wheal and flare seen within five to ten minutes of sun exposure. The mechanism of action is a type 1 hypersensibility, Immunoglobulin E mediated, triggered by an unknown photoallergen. Phototesting determines the eliciting action spectrum and the minimal urticaria dose. The first line treatment relay on antihistamines and sun protectors. Other treatment options are phototherapy, plasmapheresis, cyclosporin A, and intravenous immunoglobulin (1). Therefore some SU are resistant to these treatments. The objective of this study was to investigate the variation in phototest results in patients with solar urticaria, triggered mainly by visible light, resistant to antihistamines treatment, receiving two injections of omalizumab, a monoclonal antibody, 150 mg per month for three months. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1600-0781 (Electronic)IS - 0905-4383 (Linking)LA - ENGPT - LETTERCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/phpp.12271</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27622987">PM:27622987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Photodermatol Photoimmunol Photomed\20160913-MoncourierM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Photodermatol Photoimmunol Photomed\20160913-MoncourierM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Moncourier M</style></custom2><misc3><style face="normal" font="Arial">10.1111/phpp.12271</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takeuchi,K.</style></author><author><style face="normal" font="Arial"> Hasegawa,H.</style></author><author><style face="normal" font="Arial"> Gyohda,A.</style></author><author><style face="normal" font="Arial"> Komatsu,S.</style></author><author><style face="normal" font="Arial"> Okamoto,T.</style></author><author><style face="normal" font="Arial"> Okada,K.</style></author><author><style face="normal" font="Arial"> Terakawa,T.</style></author><author><style face="normal" font="Arial"> Koshiba,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Overexpression of RSOsPR10, a root-specific rice PR10 gene, confers tolerance against drought stress in rice and drought and salt stresses in bentgrass</style></title><secondary-title><style face="normal" font="Arial">Plant Cell Tiss Organ Cult</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Cell Tiss Organ Cult</style></full-title></periodical><pages end="46" start="35">35-46</pages><volume><style face="normal" font="Arial">127</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abscisic Acid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth and Development</style></keyword><keyword><style face="normal" font="Arial"> Growth rate</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Jasmonic acid</style></keyword><keyword><style face="normal" font="Arial"> Low temperature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis-related protein</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Salicylic Acid</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic rice</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1573-5044</style></isbn><abstract><style face="normal" font="Arial">RSOsPR10 was originally identified as a rice root-specific pathogenesis-related protein whose production was induced by drought and salinity stresses, but not by low temperature or abscisic acid. Our previous studies revealed that RSOsPR10 expression is up-regulated by jasmonic acid, and strongly inhibited by salicylic acid. Immunohistochemical experiments indicated RSOsPR10 is expressed in the root cortical cells. In the present study, we generated RSOsPR10-overexpressing lines of rice and bentgrass to examine the physiological roles of RSOsPR10 in plants. RSOsPR10-overexpressing rice plants were highly tolerant against drought stress, but not against salinity. In contrast, RSOsPR10-overexpressing bentgrass plants were tolerant against drought and salinity stresses. There was little difference between transgenic and wild-type plants regarding phenotype or above-ground growth rates. However, the root mass of the transgenic rice and bentgrass plants was significantly greater than that of the wild-type plants. Therefore, RSOsPR10 is likely involved in mediating environmental stress tolerance through an increase in root growth and development</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11240-016-1027-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s11240-016-1027-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Cell Tiss Organ Cult\2016-127-35-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Cell Tiss Organ Cult\2016-127-35-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Takeuchi K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11240-016-1027-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salminen,T.A.</style></author><author><style face="normal" font="Arial"> Blomqvist,K.</style></author><author><style face="normal" font="Arial"> Edqvist,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Abo Akademi University, 20520, Turku, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Lipid transfer proteins: classification, nomenclature, structure, and function</style></title><secondary-title><style face="normal" font="Arial">Planta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Planta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Applications</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Non-specific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Polymers</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Waxes</style></keyword></keywords><dates><year Day="25" Month="8" Year="2016">2016/8/25</year></dates><abstract><style face="normal" font="Arial">The non-specific lipid transfer proteins (LTPs) constitute a large protein family found in all land plants. They are small proteins characterized by a tunnel-like hydrophobic cavity, which makes them suitable for binding and transporting various lipids. The LTPs are abundantly expressed in most tissues. In general, they are synthesized with an N-terminal signal peptide that localizes the protein to spaces exterior to the plasma membrane. The in vivo functions of LTPs are still disputed, although evidence has accumulated for a role in the synthesis of lipid barrier polymers, such as cuticular waxes, suberin, and sporopollenin. There are also reports suggesting that LTPs are involved in signaling during pathogen attacks. LTPs are considered as key proteins for the plant's survival and colonization of land. In this review, we aim to present an overview of the current status of LTP research and also to discuss potential future applications of these proteins. We update the knowledge on 3D structures and lipid binding and review the most recent data from functional investigations, such as from knockout or overexpressing experiments. We also propose and argument for a novel system for the classification and naming of the LTPs</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 1432-2048 (Electronic)IS - 0032-0935 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00425-016-2585-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27562524">PM:27562524</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Planta\20160826-SalminenTA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Planta\20160826-SalminenTA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Salminen TA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00425-016-2585-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Briggs,N.</style></author><author><style face="normal" font="Arial"> Weatherhead,J.</style></author><author><style face="normal" font="Arial"> Sastry,K.J.</style></author><author><style face="normal" font="Arial"> Hotez,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">The Hygiene Hypothesis and Its Inconvenient Truths about Helminth Infections</style></title><secondary-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></full-title></periodical><pages end="" start="e0004944">e0004944-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Current iterations of the hygiene hypothesis suggest an adaptive role for helminth parasites in shaping the proper maturation of the immune system. However, aspects of this hypothesis are based on assumptions that may not fully account for realities about human helminth infections. Such realities include evidence of causal associations between helminth infections and asthma or inflammatory bowel disease as well as the fact that helminth infections remain widespread in the United States, especially among populations at greatest risk for inflammatory and autoimmune diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1935-2735 (Electronic)IS - 1935-2727 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pntd.0004944</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27632204">PM:27632204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2016-10-e0004944.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2016-10-e0004944.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Briggs N</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pntd.0004944</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Honda,H.</style></author><author><style face="normal" font="Arial"> Fujimoto,M.</style></author><author><style face="normal" font="Arial"> Miyamoto,S.</style></author><author><style face="normal" font="Arial"> Ishikawa,N.</style></author><author><style face="normal" font="Arial"> Serada,S.</style></author><author><style face="normal" font="Arial"> Hattori,N.</style></author><author><style face="normal" font="Arial"> Nomura,S.</style></author><author><style face="normal" font="Arial"> Kohno,N.</style></author><author><style face="normal" font="Arial"> Yokoyama,A.</style></author><author><style face="normal" font="Arial"> Naka,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immune Signal, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0162672">e0162672-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a chronic inflammatory disease of airways, but an ideal biomarker that accurately reflects ongoing airway inflammation has not yet been established. The aim of this study was to examine the potential of sputum leucine-rich alpha-2 glycoprotein (LRG) as a new biomarker for airway inflammation in asthma. METHODS: We obtained induced sputum samples from patients with asthma (N = 64) and healthy volunteers (N = 22) and measured LRG concentration by sandwich enzyme-linked immunosorbent assay (ELISA). Ovalbumin (OVA)-induced asthma model mice were used to investigate the mechanism of LRG production during airway inflammation. The LRG concentrations in the bronchoalveolar lavage fluid (BALF) obtained from mice were determined by ELISA and mouse lung sections were stained with anti-LRG antibody and periodic acid-Schiff (PAS) reagent. RESULTS: Sputum LRG concentrations were significantly higher in patients with asthma than in healthy volunteers (p = 0.00686). Consistent with patients' data, BALF LRG levels in asthma model mice were significantly higher than in control mice (p = 0.00013). Immunohistochemistry of lung sections from asthma model mice revealed that LRG was intensely expressed in a subpopulation of bronchial epithelial cells, which corresponded with PAS-positive mucus producing cells. CONCLUSION: These findings suggest that sputum LRG is a promising biomarker of local inflammation in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0162672</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27611322">PM:27611322</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0162672.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0162672.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0162672S1_File.XLSXC:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0162672S2_File.XLSXC:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0162672S3_File.XLSXC:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0162672S1_File.XLSX</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0162672S1_File.XLSXF:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0162672S2_File.XLSXF:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0162672S3_File.XLSXF:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0162672S1_File.XLSX</url></image-urls></urls><custom2><style face="normal" font="Arial">20160909, Honda H</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0162672</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,C.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Chen,F.</style></author><author><style face="normal" font="Arial"> Xu,W.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author><author><style face="normal" font="Arial"> Xiao,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China</style></auth-address><titles><title><style face="normal" font="Arial">IL-25 Promotes Th2 Immunity Responses in Asthmatic Mice via Nuocytes Activation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0162393">e0162393-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> ICOS</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Interleukin-25 (IL-25) is a potent activator of type-2 immune responses, and is responsible for airway inflammation in asthma. Previous reports have shown that IL-25 expressed hyper-reactivity in an experimental mouse-model of asthma. In addition, the production of IL-13/IL-5 promoted by nuocytes induced airway inflammation. Thus, it has been questioned whether blocking IL-25 against its receptor IL-17BR could inhibit the expression of IL-13 and IL-5 via nuocytes, and further protect against inflammation in ovalbumin (OVA) induced mouse-model of asthma. METHODS: In this study, in order to investigate the correlation among IL-25, IL-5, IL-13 and nuocyte activities, we used OVA-sensitization and -challenging to induce the mouse model of asthma. The murine asthmatic model was validated by histology. The expressions of IL-5, IL-13 and IL-25 were detected by ELISA, quantitative real-time PCR, and western blotting of the lung tissue. Nuocyte activation was identified by the levels of ICOS (clone C398.4A) and T1/ST2 (cloneDJ8) (acting as nuocytes surface markers) in the bronchoalveolar lavage fluid (BALF). This, in turn, was done by means of flow cytometry. The expressions of IL-25, IL-5 and IL-13 in our murine model were detected in the BALF. RESULTS: The mice sensitized and challenged with OVA showed a high expression of IL-25 in both the mRNA and protein levels in lungs. The expressions of ICOS and T1/ST2 in BALF were increased. A significant correlation between IL-25 mRNA, protein, and other Th2-cell producing cytokines (such as IL-5 and IL-13) moreover were identified. Furthermore, when the asthmatic mice were treated with anti-IL-25, both the inflammatory cells' infiltration and the inflammatory cytokines' secretion were significantly decreased. The present findings indicate that IL-25 might be involved in a series of asthmatic immune responses, playing an important role in the increase of nuocytes, and that its activation is necessary in maintaining Th2 central memory and sustaining asthmatic inflammation. CONCLUSION: This study showed that IL-25 promoted the accumulation of ICOS and T1/ST2 on nuocytes, further induced the pro-inflammatory Th2 cells, and promoted Th2 cytokine responses in OVA-induced airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0162393</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27617447">PM:27617447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0162393.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0162393.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Wang C</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0162393</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,J.S.</style></author><author><style face="normal" font="Arial"> Choi,J.</style></author><author><style face="normal" font="Arial"> Hahn,H.J.</style></author><author><style face="normal" font="Arial"> Lee,Y.B.</style></author><author><style face="normal" font="Arial"> Yu,D.S.</style></author><author><style face="normal" font="Arial"> Kim,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Dermatology, College of Medicine, The Catholic University of Korea, Uijongbu-City, Kyonggi-do, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association of Macrophage Migration Inhibitory Factor Polymorphisms with Total Plasma IgE Levels in Patients with Atopic Dermatitis in Korea</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0162477">e0162477-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> Haplotypes</style></keyword><keyword><style face="normal" font="Arial"> Heterozygote</style></keyword><keyword><style face="normal" font="Arial"> Homozygote</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> macrophage migration inhibitory factor</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR-RFLP</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The macrophage migration inhibitory factor (MIF) gene is located on human chromosome 22q11.2 and is linked to atopic phenotypes. Plasma MIF and log [total IgE] levels are significantly elevated in atopic dermatitis (AD) patients. The aim of this study was to evaluate the relationship between two MIF polymorphisms, -173 G to C and -794 CATT5-8, and total plasma IgE levels in AD patients in Korea. We performed PCR-RFLP analysis in 178 AD patients and 80 control subjects to determine whether MIF SNPs are associated with susceptibility to AD. Plasma total IgE and MIF levels were determined, and then logistic regression analyses were performed to determine the associations between a SNP or haplotype and plasma total IgE or MIF levels. The -173 G/C polymorphism, located in the MIF promoter, was significantly associated with AD; the odds ratios (ORs) for the CC homozygotes and GC heterozygotes were 9.3 and 2.5, respectively. The MIF C/5-CATT and the MIF C/7-CATT haplotypes were significantly associated with AD; the ORs for the MIF C/5-CATT and MIF C/7-CATT haplotypes were 9.7 and 4.5, respectively. Log [total IgE] levels were highly associated with the MIF -794 7-CATT polymorphism. Notably, the MIF C/7-CATT haplotype was associated with a decrease in plasma log [total IgE] levels in a gene dose-dependent manner. Although log [MIF] levels were not associated with the MIF polymorphisms, the frequencies of the MIF C/5-CATT haplotype-containing genotypes decreased in order of MIF levels. Our results demonstrate that MIF promoter polymorphisms in the -173 C allele and the MIF C/5-CATT and C/7-CATT haplotypes were significantly associated with an increased risk for AD. In particular, the -794 7-CATT locus and the MIF C/7-CATT haplotype were significantly associated with decreased total IgE levels in the plasma, suggesting that these polymorphisms might be a marker for intrinsic AD rather than extrinsic AD that shows high total IgE levels and presence of allergen-specific IgE</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0162477</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27598332">PM:27598332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0162477.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0162477.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Kim JS</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0162477</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kruszewski,R.</style></author><author><style face="normal" font="Arial"> Kruszewski,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">50 years of IgE</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="78" start="75">75-78</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopia</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reagin</style></keyword><keyword><style face="normal" font="Arial"> reagins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">The discovery of IgE was a major breakthrough in the development of allergology as a medical discipline. Exactly fifty years ago two independent research teams in USA and Sweden investigated and explained the role of unknown factor called reagin in allergic hypersensitivity. Provided evidence suggested that reagins are immunoglobulins of a new class. Further research of IgE properties significantly improved our understanding of the mechanism of allergic reaction. Current diagnostic and therapy of allergic diseases are largely based on these findings</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.04.004</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.04.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2016-3-75-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2016-3-75-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Kruszewski R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.04.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cichocka-Jarosz,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Does bureaucracy restrict the use of allergen immunotherapy in children?</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="60" start="56">56-60</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatric investigational plan</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">Guidelines (recommendations) created by scientific societies or panels of experts do not have the strength of regulations, but as they rely on current evidence based medicine, they are the source of important medical knowledge in every day practice. Guidelines should be discriminated from standards, which are legal regulations being an area of responsibility of ministry of health. Allergen immunotherapy is one of the fundamental procedures in allergology. Current national and international guidelines critically review and up-date the knowledge addressed to allergen immunotherapy. For different reasons AIT is especially beneficial for children. In the European Union registration of allergen products for both diagnostic and treatment purposes is regulated by certain directives and is subject to supervision of European Medical Agency. For the purpose of performing high quality clinical trials with allergen immunotherapy in children, pediatric investigational plan was introduced. Its high requirements create a high-risk situation which may limit introduction of AIT in pediatric population. It arises concern of medical authorities</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.alergo.2016.04.002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.04.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2016-3-56-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2016-3-56-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Cichocka-Jarosz E</style></custom2><misc3><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.alergo.2016.04.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaczmarski,M.</style></author><author><style face="normal" font="Arial"> Bartuzi,Z.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Epidemiological aspects of food allergy in children and adults</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="55" start="46">46-55</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">Food allergy is a hypersensitive state of the human body in which the food consumed, which is a source of allergens, triggers immune processes (IgE-mediated, IgE-independent, or mixed) resulting in symptoms. The prevalence of food allergy in the human population shows an upward trend in the last 30</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô40 years as documented by epidemiological studies conducted mainly in developed countries. The reasons for this phenomenon have still not been fully explained. An important role in this upward trend is thought to be played by select environmental factors affecting the human genome. This process is called </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£epigenetic influence</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ. Epidemiological studies on the prevalence of food allergies relate to food products frequently consumed by people all over the world (milk, eggs, wheat, soy, fish, seafood, peanuts, nuts, fruits, and vegetables). The results of such studies on the incidence of allergies to these foods, however, are varied and depend on the study center. The lack of comparability between these results is chiefly caused by different methodologies applied which produce varying incidences. In this paper, the authors present a comparative analysis of the prevalence of food allergies in different countries of the world, taking into account differences in research methodology. We compared the results of past research conducted among children, adolescents, and adults, with current ongoing studies utilizing a food provocation test as an objective method confirming an etiopathogenetic allergic response to the studied food. Epidemiological studies on the incidence of food allergy in Poland have also been characterized</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.06.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.06.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2016-3-46-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2016-3-46-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Kaczmarski M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kartal,D.</style></author><author><style face="normal" font="Arial"> Borlu,M.</style></author><author><style face="normal" font="Arial"> Cinar,S.L.</style></author><author><style face="normal" font="Arial"> Kesikoglu,A.</style></author><author><style face="normal" font="Arial"> Utas,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, Faculty of Medicine, Erciyes University, Kayseri, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Thyroid abnormalities in paediatric patients with vitiligo: retrospective study</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="234" start="232">232-234</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid function</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Function Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vitiligo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The association between vitiligo and thyroid disease is not fully investigated especially in paediatric patients. AIM: To determine the incidence of vitiligo and thyroid disorders in children. This is the first report from middle Anatolia and the second report from Turkey. MATERIAL AND METHODS: A retrospective chart review was performed to examine the presence of thyroid abnormalities in paediatric patients who had been admitted to the dermatology department with vitiligo. RESULTS: A total of 155 paediatric patients, including 80 (52%) male and 75 (48%) female patients were included. The mean age was 8.6 years. Non segmental vitiligo was the most common type of the disease in 140 (90%) reviewed patients, while segmental vitiligo appeared only in 15 (10%) patients. The mean onset of vitiligo was 5.6 +/-0.9 years. A family history of vitiligo was found in 14 (9%) children. Thirty-four (22%) patients had thyroid function tests and/or thyroid autoantibody abnormality. All of these patients had non segmental vitiligo. It was statistically significant (p &lt; 0.05) in types of vitiligo and thyroid disease parameters. CONCLUSIONS: Our results show that it may be useful to screen thyroid in children with non segmental vitiligo</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.60617</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512360">PM:27512360</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-232-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-232-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Kartal D</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.60617</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matysiak,J.</style></author><author><style face="normal" font="Arial"> Matysiak,J.</style></author><author><style face="normal" font="Arial"> Breborowicz,A.</style></author><author><style face="normal" font="Arial"> Derezinski,P.</style></author><author><style face="normal" font="Arial"> Kokot,Z.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Poznan, Poland</style></auth-address><titles><title><style face="normal" font="Arial">The correlation between anti phospholipase A2 specific IgE and clinical symptoms after a bee sting in beekeepers</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="210" start="206">206-210</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Analytical chemistry</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Beekeepers are a group of people with high exposure to honeybee stings and with a very high risk of allergy to bee venom. Therefore, they are a proper population to study the correlations between clinical symptoms and results of diagnostic tests. AIM: The primary aim of our study was to assess the correlations between total IgE, venom- and phospholipase A2-specific IgE and clinical symptoms after a bee sting in beekeepers. The secondary aim was to compare the results of diagnostic tests in beekeepers and in individuals with standard exposure to bees. MATERIAL AND METHODS: Fifty-four individuals were divided into two groups: beekeepers and control group. The levels of total IgE (tIgE), venom-specific IgE (venom sIgE), and phospholipase A2-specific IgE (phospholipase A2 sIgE) were analyzed. RESULTS: Our study showed no statistically significant correlation between the clinical symptoms after a sting and tIgE in the entire analyzed group. There was also no correlation between venom sIgE level and clinical symptoms either in beekeepers or in the group with standard exposure to bees. We observed a statistically significant correlation between phospholipase A2 sIgE level and clinical signs after a sting in the group of beekeepers, whereas no such correlation was detected in the control group. Significantly higher venom-specific IgE levels in the beekeepers, as compared to control individuals were shown. CONCLUSIONS: In beekeepers, the severity of clinical symptoms after a bee sting correlated better with phospholipase A2 sIgE than with venom sIgE levels</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.60613</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512356">PM:27512356</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-206-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-206-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Matysiak J</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.60613</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kutlu,A.</style></author><author><style face="normal" font="Arial"> Ucar,R.</style></author><author><style face="normal" font="Arial"> Aydin,E.</style></author><author><style face="normal" font="Arial"> Arslan,S.</style></author><author><style face="normal" font="Arial"> Caliskaner,A.Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, GATA Haydarpasa Training Hospital, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Could aluminum be a new hidden allergen in type 1 hypersensitivity reactions when used as a drug additive?</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="245" start="243">243-245</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.60620</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512363">PM:27512363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-243-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-243-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Kutlu A</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.60620</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gawlik,R.</style></author><author><style face="normal" font="Arial"> Grzanka,A.</style></author><author><style face="normal" font="Arial"> Jawor,B.</style></author><author><style face="normal" font="Arial"> Czecior,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chair and Clinical Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Specific immunotherapy with mugwort pollen allergoid reduce bradykinin release into the nasal fluid</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="275" start="269">269-275</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bradykinin</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> mugwort pollen</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> nasal secretion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: A pathomechanism of allergic rhinitis is complex. A neurogenic mechanism seems to play a significant role in this phenomenon. AIM: The evaluation of influence of specific immunotherapy of mugwort pollen allergic patients on the bradykinin concentration in the nasal lavage fluid. MATERIAL AND METHODS: The study included 22 seasonal allergic rhinitis patients. Thirty persons with monovalent allergy to mugwort pollen, confirmed with skin prick tests and allergen-specific immunoglobulin E, underwent a 3-year-long allergen immunotherapy with the mugwort extract (Allergovit, Allergopharma, Germany). The control group was composed of 9 persons with polyvalent sensitivity to pollen, who were treated with pharmacotherapy. Before the allergen-specific immunotherapy (AIT) and in subsequent years before the pollen seasons, a provocation allergen test with the mugwort extract was performed, together with collection of nasal fluids, where bradykinin concentration was determined according to Proud method. RESULTS: There were similar levels of bradykinin in both groups at baseline prior to therapy (AIT group: 584.0 +/-87.2 vs. controls 606.3 +/-106.5 pg/ml) and changes after allergen challenge 1112.4 +/-334.8 vs. 1013.3 +/-305.9 pg/ml as well. The bradykinin concentration in nasal lavage fluid after mugwort challenge in 1 year was lower in the AIT group (824.1 +/-184.2 pg/ml vs. 1000.4 +/-411.5 pg/l; p &lt; 005) with a further significant decrease after the 2(nd) and 3(rd) year of specific immunotherapy. Significant reduction of symptoms and medications use was observed in hyposensitized patients. CONCLUSIONS: A decreased level of bradykinin as a result of AIT suggests that some of the symptomatic benefits of AIT may be related to the reduced release of bradykinin into nasal secretions. These values correlate with clinical improvement within the course of treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.61602</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27605897">PM:27605897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-269-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-269-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Gawlik R</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.61602</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gocki,J.</style></author><author><style face="normal" font="Arial"> Bartuzi,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, Clinical Immunology and Internal Diseases, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, PolandDepartment of Allergology, Clinical Immunology and Internal Diseases, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Role of immunoglobulin G antibodies in diagnosis of food allergy</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="256" start="253">253-256</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">This paper presents current views on the role of immunoglobulin G (IgG) antibodies in the reactions with food antigens in the digestive tract and their role in the diagnosis of food allergy based on the assays of specific IgG class antibodies, with a special focus on contemporary practice guidelines. In the light of current scientific knowledge, the IgG-specific antibody-mediated reactions are a body's natural and normal defensive reactions to infiltrating food antigens, which are considered as pathogens. On the other hand, specific IgG antibodies against food allergens play a crucial role in the induction and maintaining of immunological tolerance to food antigens. The statements of many scientific societies stress that sIgG are of no significant importance in the diagnosis of food allergy since their presence is associated with a normal immune response to food allergens and attests to a protracted exposure to food antigens</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Poland -</style></notes><work-type><style face="normal" font="Arial"> 10.5114/ada.2016.61600</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27605894">PM:27605894</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-253-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-253-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Gocki J</style></custom2><misc3><style face="normal" font="Arial"> 10.5114/ada.2016.61600</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stoma,M.</style></author><author><style face="normal" font="Arial"> Slaska-Grzywna,B.</style></author><author><style face="normal" font="Arial"> Zukiewicz-Sobczak,W.A.</style></author><author><style face="normal" font="Arial"> Kostecka,M.</style></author><author><style face="normal" font="Arial"> Bojanowska,M.</style></author><author><style face="normal" font="Arial"> Dudziak,A.</style></author><author><style face="normal" font="Arial"> Kuna-Broniowska,A.</style></author><author><style face="normal" font="Arial"> Adamczuk,P.</style></author><author><style face="normal" font="Arial"> Sobczak,P.</style></author><author><style face="normal" font="Arial"> Andrejko,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Power Engineering and Transportation, Subdepartment of Logistics and Business Management, University of Life Sciences, Lublin, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Food allergies in rural areas</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="285" start="281">281-285</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Digestive System</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Transportation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: A food allergy is a group of symptoms occurring in the organism and resulting from consuming some food, where the problems are conditioned by immunological mechanisms. The symptoms may become apparent first in adulthood and they may be an initial manifestation of a latent allergy. Typical symptoms of a food allergy occur in different organs, thus not only in the digestive system, but also in the skin, respiratory system and circulatory system. AIM: To assess the frequency of food allergy onset in rural areas of the Lublin region as well as to determine which factors induce such allergies. MATERIAL AND METHODS: A survey was conducted, involving the participation of 340 inhabitants of rural areas. The study monitored the knowledge and situation of the disease, concerning allergens, allergy symptoms, methods of treatment and opinions regarding such treatment. RESULTS: The analysis focused on 124 people with diagnosed allergies. CONCLUSIONS: Introducing a diet did not result in a statistically significant difference regarding elimination of the symptoms, as compared to the patients who did not follow any diet. On the other hand, pharmacological treatment causes statistically worse results than using other methods or not being treated at all. The patients in whom allergy symptoms disappeared were more convinced about the positive character of their diet than those in whom the symptoms were not eliminated. The age when the allergy becomes evident does not affect its duration, yet it matters as to the time of its later elimination. The more symptoms were experienced by a patient, the longer the duration of the allergy was</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.61604</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27605899">PM:27605899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-281-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-281-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Stoma M</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.61604</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Filanowicz,M.</style></author><author><style face="normal" font="Arial"> Szynkiewicz,E.</style></author><author><style face="normal" font="Arial"> Cegla,B.</style></author><author><style face="normal" font="Arial"> Bartuzi,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Nursing in Internal Diseases, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of the quality of life of patients with asthma and allergic rhinitis after immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="141" start="134">134-141</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> RQLQ</style></keyword><keyword><style face="normal" font="Arial"> Self-administered questionnaire</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">AIM: To assess the quality of life of Polish patients with asthma and/or allergic rhinitis before the implementation and after 30-36 months of immunotherapy. MATERIAL AND METHODS: Two hundred patients have been involved in the study: 101 with allergic asthma and 99 with pollinosis. In order to collect research material, the Polish versions of AQLQ (Asthma Quality of Life) and RQLQ (Rhinoconjunctivitis Quality of Life) questionnaires have been used. The self-administered questionnaires concerned such data as age, sex and the patients' subjective evaluation of their quality of life. RESULTS: The average increase in quality of life of patients with asthma was 0.84 and of patients with allergic rhinitis - 1.50. A hypothesis was made that changes of quality of life in each examined group differed significantly. A test for two fractions showed that for patients with asthma it was 7.74 and for patients with allergic rhinitis - 10.38. A statistical analysis showed no such relation in the group of patients with asthma (coefficient of correlation = 0.08) and a slight correlation in the group of patients with allergic rhinitis (coefficient of correlation = 0.20). Applied tests did not show any significant differences, which means that an average increase in quality of life does not depend on sex and age of both examined groups. CONCLUSIONS: On the basis of the research conducted among patients before and after a 3-year period of immunotherapy, the following conclusions have been drawn: 1) immunotherapy significantly improves the objective quality of life in both groups; 2) a slight correlation has been identified between the objective and subjective dimension of quality of life amongst patients with asthma, what contributes to a better quality of life; 3) in both study groups, no significant relationship between gender or age and improvement in quality of life has been noted; 4) immunotherapy, from the point of view of the improvement of quality of life, is a valuable therapeutic tool in patients with atopic bronchial asthma and allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160609IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/pdia.2015.48061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27279823">PM:27279823</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-134-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-134-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160609, Filanowicz M</style></custom2><misc3><style face="normal" font="Arial">10.5114/pdia.2015.48061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rok,T.</style></author><author><style face="normal" font="Arial"> Rokita,E.</style></author><author><style face="normal" font="Arial"> Taton,G.</style></author><author><style face="normal" font="Arial"> Guzik,T.</style></author><author><style face="normal" font="Arial"> Sliwa,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biophysics, Chair of Physiology, Jagiellonian University, Medical College, Krakow, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Thermographic assessment of skin prick tests in comparison with the routine evaluation methods</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="198" start="193">193-198</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The skin prick test is still the first and basic procedure in the diagnosis of allergic diseases. The possibility of using a sensitive thermographic method supported by the mathematical model for the assessment of skin test results will be highlighted in the studies. AIM: To compare the proposed approach with routine planimetric and thermographic methods. MATERIAL AND METHODS: A mathematical model of allergic reaction was developed. Simplifying assumptions of the IgE-mediated skin reaction is the essence of the model. Investigations were performed in a group of 40 patients. RESULTS: Using the spatio-temporal evolution of temperature distributions, the ratios of the histamine released from mast cells to the control histamine were determined. The obtained values very well correlate with the standard evaluation of skin prick tests (correlation coefficient = 0.98). CONCLUSIONS: The proposed method of skin test evaluation presents several advantages. The continuous acquisition of data provides the monitoring of time course of the allergic response. The transport of mediator and its concentration were distinctly discriminated, which may be diagnostically useful, especially for abnormal cases. The high sensitivity of the method enables studying patients regardless of age and skin sensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.60611</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512354">PM:27512354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-193-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-193-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Rok T</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.60611</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chelminska,M.</style></author><author><style face="normal" font="Arial"> Specjalski,K.</style></author><author><style face="normal" font="Arial"> Rozylo,A.</style></author><author><style face="normal" font="Arial"> Kolakowska,A.</style></author><author><style face="normal" font="Arial"> Jassem,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, Medical University of Gdansk, Gdansk, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Differentiating of cross-reactions in patients with latex allergy with the use of ISAC test</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="127" start="120">120-127</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> cross-reactions</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crossreactions</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex allergens</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Differentiating between cross-reactivity and double sensitization is still a challenging issue in allergology. AIM: To differentiate cross-reactions accompanying latex allergy with the use of the ISAC test. MATERIAL AND METHODS: Thirty-nine patients reporting immediate allergic reactions to latex were enrolled into the study (group A). The control group was comprised of 41 patients with allergic diseases not associated with latex (group B) and 20 healthy individuals (group C). Their history was recorded and skin prick tests were performed with latex, airborne and food allergens. Specific IgE against food allergens, latex (k82) and recombined latex allergens were determined. ImmunoCAP ISAC test was performed with 103 molecules. RESULTS: Sensitization to latex was found by means of skin tests in 16 cases and sIgE against latex was revealed in 12 cases (including 10 positive in both SPT and sIgE). In the ISAC test antibodies against recombined latex allergens were found in 8 patients with rHev b 6 as the most common. All the patients positive for rHev b 1, 5, 6, 8 had allergy or asymptomatic sensitization to food allergens cross-reacting with latex. Some reactions could not have been differentiated due to the lack of allergens in the ISAC test. Others, not related to latex-fruits syndrome were explained by cross-reactivity with other profilins or PR-10 proteins. CONCLUSIONS: ImmunoCAP ISAC test could be useful in differentiating between cross-reactions and double sensitizations. However, in the case of latex its advantages are limited due to a small panel of allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20160609IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - POland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.59154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27279821">PM:27279821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-120-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-120-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160609, Chelminska M</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.59154</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Woicka-Kolejwa,K.</style></author><author><style face="normal" font="Arial"> Zaczeniuk,M.</style></author><author><style face="normal" font="Arial"> Majak,P.</style></author><author><style face="normal" font="Arial"> Pawlowska-Iwanicka,K.</style></author><author><style face="normal" font="Arial"> Kopka,M.</style></author><author><style face="normal" font="Arial"> Stelmach,W.</style></author><author><style face="normal" font="Arial"> Jerzynska,J.</style></author><author><style face="normal" font="Arial"> Stelmach,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, PolandDepartment of Pediatrics and Allergy, Medical University of Lodz, Lodz, PolandDepartment of Pediatrics and Allergy, Medical University of Lodz, Lodz, PolandDepartment of Pediatrics and Allergy, Medical University of Lodz, Lodz, PolandDepartment of Pediatrics and Allergy, Medical University of Lodz, Lodz, PolandDepartment of Social and Preventive Medicine, Medical University of Lodz, Lodz, PolandDepartment of Pediatrics and Allergy, Medical University of Lodz, Lodz, PolandDepartment of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy is associated with recurrent respiratory tract infections during childhood</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="113" start="109">109-113</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> lower respiratory tract infections</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> Recurrent respiratory tract infections</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: To find out whether children with food allergy have an increased risk of recurrent upper and lower respiratory tract infections and of asthma. AIM: To describe the clinical profile of children diagnosed with food allergy referred to the Allergy Clinic. MATERIAL AND METHODS: We conducted a retrospective study to assess the patients' demographic, anthropometric and clinical data. The analysis included data of all children by the age of 10 years (registered with the Allergy Clinic between 2012 and 2013) in whom IgE mediated food allergy had been diagnosed during 18 months of observation. RESULTS: We included 280 children into the analysis. Recurrent respiratory tract infections (rRTI), asthma and gastrointestinal (GI) symptoms were observed in 153 (54.6%), 96 (34.3%), 39 (13.9%), respectively, with a significant increasing trend across age-subgroups. In children from 1 to 2 years old, sensitization to beta-lactoglobulin increased the risk of rRTI (OR = 3.91; 95% CI: 1.03-14.87). In older children sensitization to allergens other than milk or egg decreases the risk of rRTI (OR = 0.25; 95% CI: 0.10-0.62); sensitization to egg decreased the risk of asthma diagnosis (OR = 0.09; 95% CI: 0.01-0.75). We did not identify food allergens which change the risk of GI symptoms in children. This finding was consistent throughout all age-subgroups. CONCLUSIONS: Sensitization to beta-lactoglobulin increased the risk of rRTI in children under 2 years of age nearly four times. The presence of sensitization to food allergens above 3 years of age did not increase the risk of developing clinical presentation of food allergy other than atopic dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160609IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - POland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.59151</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27279819">PM:27279819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-109-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-109-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160609, Woicka-Kolejwa K</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.59151</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nucera,E.</style></author><author><style face="normal" font="Arial"> Di Rienzo,A.</style></author><author><style face="normal" font="Arial"> Ricci,A.G.</style></author><author><style face="normal" font="Arial"> Buonomo,A.</style></author><author><style face="normal" font="Arial"> Mezzacappa,S.</style></author><author><style face="normal" font="Arial"> Schiavino,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Adverse reactions to nonsteroidal anti-inflammatory drugs and hypersensitivity to lipid transfer proteins</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="310" start="309">309-310</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.61608</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27605905">PM:27605905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-309-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-309-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Nucera E</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.61608</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Igielska-Kalwat,J.</style></author><author><style face="normal" font="Arial"> Goscianska,J.</style></author><author><style face="normal" font="Arial"> Witkowska,B.</style></author><author><style face="normal" font="Arial"> Nowak,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Chemistry, Laboratory of Applied Chemistry, Adam Mickiewicz University, Poznan, PolandFaculty of Chemistry, Laboratory of Applied Chemistry, Adam Mickiewicz University, Poznan, PolandFaculty of Chemistry, Laboratory of Applied Chemistry, Adam Mickiewicz University, Poznan, PolandFaculty of Chemistry, Laboratory of Applied Chemistry, Adam Mickiewicz University, Poznan, Poland</style></auth-address><titles><title><style face="normal" font="Arial">In vivo studies of substances used in the cosmetic industry</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="169" start="163">163-169</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chemistry</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Cosmetic producers are obliged to guarantee the safety and stability of their products. The current legal regulations are based on the European Union Directive (1223/2009) of 30 November 2009. The main aim of the directive is to formulate criteria of safety of a cosmetic product and requirements that it must meet to be placed on the market. A new cosmetic product is subjected to thorough investigation prior to its introduction on the market. It should be studied not only with respect to its safety, but also with respect to its effectiveness declared by the producer. The studies are performed in vivo, by the contact or epidermal patch tests on the human skin</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2016.60607</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27512349">PM:27512349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-163-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2016-33-163-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Igielska-Kalwat J</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2016.60607</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kakli,H.A.</style></author><author><style face="normal" font="Arial"> Riley,T.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Penn State Milton S. Hershey Medical Center, Department of Family &amp; Community Medicine, 500 University Drive, Hershey, PA 17033, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Prim Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prim Care</style></full-title></periodical><pages end="475" start="465">465-475</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> community medicine</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Among the atopic disorders, allergic rhinitis is the most prevalent. Patients who suffer from allergic rhinitis sustain significant morbidity and loss of productivity. Cardinal symptoms include nasal congestion, rhinorrhea, sneezing, and nasal itching, although multiple related symptoms may occur. Causes should be ruled out with a thorough history and physical examination, with particular attention to red flag or atypical symptoms. Skin testing or serum sampling can confirm diagnosis and also guide therapy. Therapy is multimodal, tailored to a particular patient's symptom burden and quality of life</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-299X (Electronic)IS - 0095-4543 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pop.2016.04.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545735">PM:27545735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prim Care\2016-43-465-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prim Care\2016-43-465-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Kakli HA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pop.2016.04.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hernandez,L.</style></author><author><style face="normal" font="Arial"> Papalia,S.</style></author><author><style face="normal" font="Arial"> Pujalte,G.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Family Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Prim Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prim Care</style></full-title></periodical><pages end="485" start="477">477-485</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Resuscitation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Syncope</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vasodilation</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is an acute, systemic reaction mediated by immunoglobulin E hypersensitivity. Release of bioactive factors causes vasodilation and bronchiole constriction that can lead to hypotensive shock and asphyxiation. Differential diagnosis includes acute asthma, localized angioedema, syncope, and anxiety/panic attacks. Diagnostic tests lack specificity. Clinical diagnosis is based on demonstration of specific airway or cardiovascular compromise within proximity of allergen exposure. Treatment includes epinephrine, antihistamines, fluid resuscitation, and airway management. Prevention focuses on awareness/avoidance of triggers, implementation of personalized action plans, as well as immune modulation by desensitization in a closely controlled setting where available</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-299X (Electronic)IS - 0095-4543 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pop.2016.04.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545736">PM:27545736</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prim Care\2016-43-477-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prim Care\2016-43-477-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Hernandez L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pop.2016.04.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singh,M.</style></author><author><style face="normal" font="Arial"> Hays,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Family and Community Medicine, Penn State Hershey Medical Group, 1850 East Park Avenue, Suite 207, State College, PA 16803, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Indoor and Outdoor Allergies</style></title><secondary-title><style face="normal" font="Arial">Prim Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prim Care</style></full-title></periodical><pages end="463" start="451">451-463</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal allergen</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> community medicine</style></keyword><keyword><style face="normal" font="Arial"> Contributing factors</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">In last 30 to 40 years there has been a significant increase in the incidence of allergy. This increase cannot be explained by genetic factors alone. Increasing air pollution and its interaction with biological allergens along with changing lifestyles are contributing factors. Dust mites, molds, and animal allergens contribute to most of the sensitization in the indoor setting. Tree and grass pollens are the leading allergens in the outdoor setting. Worsening air pollution and increasing particulate matter worsen allergy symptoms and associated morbidity. Cross-sensitization of allergens is common. Treatment involves avoidance of allergens, modifying lifestyle, medical treatment, and immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-299X (Electronic)IS - 0095-4543 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pop.2016.04.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545734">PM:27545734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prim Care\2016-43-451-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prim Care\2016-43-451-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Singh M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pop.2016.04.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rael,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Box 18885, Stanford, CA 94309, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Allergen Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Prim Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prim Care</style></full-title></periodical><pages end="494" start="487">487-494</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Allergies affect a large proportion of the population. Allergies can adversely affect productivity, sleep, and quality of life and can lead to life-threatening reactions. Allergies can spread to affect multiple organ systems. Allergen immunotherapy is the only therapy that can change the natural history of allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-299X (Electronic)IS - 0095-4543 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pop.2016.04.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545737">PM:27545737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prim Care\2016-43-487-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prim Care\2016-43-487-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Rael E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pop.2016.04.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grief,S.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Family Medicine, University of Illinois at Chicago, 1919 West Taylor Street, Suite 143, Chicago, IL 60612, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergies</style></title><secondary-title><style face="normal" font="Arial">Prim Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prim Care</style></full-title></periodical><pages end="391" start="375">375-391</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> CAMP</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> sport</style></keyword><keyword><style face="normal" font="Arial"> Sports</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Food allergies are common and seem to be increasing in prevalence. Preventive measures have become far more evident in the public arena (schools, camps, sports venues, and so forth). Evaluation and management of food allergies has evolved such that primary care practitioners may choose to provide initial diagnostic and treatment care or refer to allergists for similar care. Food allergies, once considered incurable, are now being diminished in intensity by new strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-299X (Electronic)IS - 0095-4543 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pop.2016.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545729">PM:27545729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prim Care\2016-43-375-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prim Care\2016-43-375-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Grief SN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pop.2016.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,H.</style></author><author><style face="normal" font="Arial"> Halverson,S.</style></author><author><style face="normal" font="Arial"> Mackey,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Family Medicine, Loma Linda University, 25455 Barton Road, Suite 209B, Loma Linda, CA 92354, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Insect Allergy</style></title><secondary-title><style face="normal" font="Arial">Prim Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prim Care</style></full-title></periodical><pages end="431" start="417">417-431</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Bites and Stings</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fleas</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect allergy</style></keyword><keyword><style face="normal" font="Arial"> Insect Bites and Stings</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> large local reaction</style></keyword><keyword><style face="normal" font="Arial"> Large local reactions</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mosquitoes</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Ticks</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Wasps</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Insect bites and stings are common. Risk factors are mostly associated with environmental exposure. Most insect bites and stings result in mild, local, allergic reactions. Large local reactions and systemic reactions like anaphylaxis are possible. Common insects that bite or sting include mosquitoes, ticks, flies, fleas, biting midges, bees, and wasps. The diagnosis is made clinically. Identification of the insect should occur when possible. Management is usually supportive. For anaphylaxis, patients should be given epinephrine and transported to the emergency department for further evaluation. Venom immunotherapy (VIT) has several different protocols. VIT is highly effective in reducing systemic reactions and anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-299X (Electronic)IS - 0095-4543 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pop.2016.04.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545732">PM:27545732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prim Care\2016-43-417-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prim Care\2016-43-417-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Lee H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pop.2016.04.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tourlas,K.</style></author><author><style face="normal" font="Arial"> Burman,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Family Medicine, University of Pittsburgh Medical Center (UPMC) McKeesport Family Medicine Residency, 2347 Fifth Avenue, McKeesport, PA 15132, USA</style></auth-address><titles><title><style face="normal" font="Arial">Allergy Testing</style></title><secondary-title><style face="normal" font="Arial">Prim Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prim Care</style></full-title></periodical><pages end="374" start="363">363-374</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immediate-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> penicillin</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Allergic diseases are common in outpatient primary care. Allergy testing can guide management to determine allergy as a cause of symptoms and target therapeutic interventions. This article provides a review of common methods of allergy testing available so that physicians may counsel and refer patients appropriately. Immediate-type hypersensitivity skin tests can be used for airborne allergens, foods, insect stings, and penicillin. Radioallergosorbent testing can be used to evaluate immediate-type hypersensitivity. Delayed-type hypersensitivity or patch-type skin tests are used in patients with suspected contact dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160822IS - 1558-299X (Electronic)IS - 0095-4543 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pop.2016.04.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27545728">PM:27545728</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prim Care\2016-43-363-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prim Care\2016-43-363-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160822, Tourlas K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pop.2016.04.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sivaraman,G.K.</style></author><author><style face="normal" font="Arial"> Visnuvinayagam,S.</style></author><author><style face="normal" font="Arial"> Jha,A.K.</style></author><author><style face="normal" font="Arial"> Remya,S.</style></author><author><style face="normal" font="Arial"> Renuka,V.</style></author><author><style face="normal" font="Arial"> Ajeesh,K.</style></author><author><style face="normal" font="Arial"> Vanik,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Molecular Divergence and Identification of Aspergillus Species in Dry Fishes of Gujarat, India</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci India Section B Biol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci India Section B Biol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aflatoxin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> BLAST</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Curvularia</style></keyword><keyword><style face="normal" font="Arial"> Curvularia lunata</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fishes</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2250-1746</style></isbn><abstract><style face="normal" font="Arial">The fungal infestations have become significant cause for the quality and economic loss. They often cause infections to the handlers and consumers. Some of the fungal species are potent allergens, mycotoxin producers and can even cause superficial and pulmonary infection. Reports of previous studies are restricted to genus level due to overlapping of morphological characters. So, the present study was carried out to identify the predominant fungal species prevalent in fishes of west coast region by molecular technique. Totally, 24 sundried fishes were collected from the Veraval region of Gujarat and analyzed for the presence of fungal species. Randomly collected fungal strain was initially indentified based on morphological characters and polymerase chain reaction was carried out for the amplification of 18S rDNA gene. The amplicon was sequenced and analyzed using BLAST. The sequence analysis revealed that Aspergillus flavus, A. nidulans, A. oryzae, A. sydowii, A. rugulosa, A. niger, A. foetidus, Lichtheimia ramosa and Curvularia lunata were present in dried fish. The phylogenetic tree was constructed based on DNA sequence dissimilarity and revealed that two clades were formed among the fungal species with one clade belonging to A. nidulans, A. rugulosa and A. sydowii and the other to A. flavus and A. oryzae. Therefore, it is concluded that, in west coast region A. flavus is a dominant species observed in dry fish which is potent aflatoxin producers and highly carcinogenic in nature. So, handlers need stringent hygienic practices with suitable processing and packaging technique to control the fungal contamination</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40011-016-0779-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40011-016-0779-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci India Section B Biol Sci\20160920-SivaramanGK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci India Section B Biol Sci\20160920-SivaramanGK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Sivaraman GK</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40011-016-0779-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gianniou,N.</style></author><author><style face="normal" font="Arial"> Katsaounou,P.</style></author><author><style face="normal" font="Arial"> Dima,E.</style></author><author><style face="normal" font="Arial"> Giannakopoulou,C.E.</style></author><author><style face="normal" font="Arial"> Kardara,M.</style></author><author><style face="normal" font="Arial"> Saltagianni,V.</style></author><author><style face="normal" font="Arial"> Trigidou,R.</style></author><author><style face="normal" font="Arial"> Kokkini,A.</style></author><author><style face="normal" font="Arial"> Bakakos,P.</style></author><author><style face="normal" font="Arial"> Markozannes,E.</style></author><author><style face="normal" font="Arial"> Litsiou,E.</style></author><author><style face="normal" font="Arial"> Tsakatikas,A.</style></author><author><style face="normal" font="Arial"> Papadopoulos,C.</style></author><author><style face="normal" font="Arial"> Roussos,C.</style></author><author><style face="normal" font="Arial"> Koulouris,N.</style></author><author><style face="normal" font="Arial"> Rovina,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary and Critical Care Department, Evangelismos Hospital, National and Kapodistrian University of Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Prolonged occupational exposure leads to allergic airway sensitization and chronic airway and systemic inflammation in professional firefighters</style></title><secondary-title><style face="normal" font="Arial">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med</style></full-title></periodical><pages end="14" start="7">7-14</pages><volume><style face="normal" font="Arial">118</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial biopsies</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVES: Little data exist on short- and long-term effects of occupational exposure on airway and systemic inflammation in professional firefighters. We aimed to characterize airway and systemic inflammation in training firefighters with a maximum occupational exposure of 1 year compared to the long-term exposure of professional firefighters. METHODS: A questionnaire for symptoms and exposure, pulmonary function, atopy, bronchial hyper-responsiveness, and markers of inflammation in induced sputum, serum, bronchoalveolar lavage (BAL) fluid and bronchial biopsies were assessed in a total of 92 firefighters (63 full-time professionals and 29 trainees). RESULTS: Professional firefighters showed allergic bronchial sensitization documented by the presence of atopy, and eosinophilia in induced sputum, BAL and bronchial biopsies. IL-8, ECP, VEGF, and TNF-alpha levels were statistically significantly higher in the sputum supernatants of professional firefighters compared to the trainees (p = 0.04, p = 0.02, p = 0.04, and p = 0.02, respectively). Serum IL-8 and TNF-alpha levels were also statistically significantly higher in the group of professional firefighters (p = 0.04, p = 0.03, respectively). Finally, there was a linear correlation between the duration of the occupation in Service and the degree of airway and systemic inflammation. CONCLUSIONS: These results indicate a "dose-response" effect of chronic exposure to a polluted environment on bronchial and systemic inflammation in professional firefighters</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleSB - IMCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmed.2016.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27578465">PM:27578465</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2016-118-7-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2016-118-7-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Gianniou N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmed.2016.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bergren,D.R.</style></author><author><style face="normal" font="Arial"> Valentine,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Sciences, School of Medicine, Creighton University, Omaha, Nebraska, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Anti-anaphylactic action of nordihydroguaiaretic acid in antigen sensitized guinea pigs</style></title><secondary-title><style face="normal" font="Arial">Respir Physiol Neurobiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Physiol Neurobiol</style></full-title></periodical><pages end="31" start="26">26-31</pages><volume><style face="normal" font="Arial">234</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Herbs</style></keyword><keyword><style face="normal" font="Arial"> Indomethacin</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene C4</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nebraska</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Propranolol</style></keyword><keyword><style face="normal" font="Arial"> Pyrilamine</style></keyword><keyword><style face="normal" font="Arial"> Radioimmunoassay</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sRaw</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">Therapeutic natural products and medicinal herbs has gained popularity. The anti-antigenic action of the plant alkaloid nordihydroguaiaretic acid (NDGA) was studied in ovalbumin (OA)-sensitized guinea pigs. In one series of experiments conscious, non-sedated guinea pigs were challenged with OA aerosol. Specific airway resistance (SRAW) was monitored using a two-chambered whole-body plethysmograph. OA aerosol increased SRAW above that produced by vehicle administration. Prior NDGA administration by a 1min 0.9% aerosol (w/vol) attenuated the increase in SRAW resulting from OA challenge. In the anesthetized guinea pig pretreated with indomethacin, pyrilamine and propranolol, intravenous OA injection increased intra-tracheal pressure above vehicle injection. Intravenous NDGA administration (5mg/kg) reduced the intra-tracheal pressure increases. In a third series of experiments plasma leukotriene C4 was measured by radio-immunoassay in 3 groups challenged with OA aerosol: vehicle-treated OA-sensitized, OA-sensitized receiving NDGA and vehicle treated guinea pigs. NDGA pretreatment reduced plasma LTC4 in response to OA challenge in OA sensitized guinea pigs. This study demonstrates that NDGA is an effective antigenic agent when given by aerosol or intravenous injection in either conscious or anesthetized guinea pigs, respectively. The mechanism of action of NDGA is presumed primarily be due to the blockage of 5-lipoxygenase and therefore the synthesis of leukotrienes</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1878-1519 (Electronic)IS - 1569-9048 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.resp.2016.09.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27595978">PM:27595978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Physiol Neurobiol\20160906-BergrenDR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Physiol Neurobiol\20160906-BergrenDR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Bergren DR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.resp.2016.09.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fernandez,F.</style></author><author><style face="normal" font="Arial"> Campillay,R.</style></author><author><style face="normal" font="Arial"> Palma,V.</style></author><author><style face="normal" font="Arial"> Norambuena,X.</style></author><author><style face="normal" font="Arial"> Quezada,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Programa de Especialistas en Inmunologia, Santiago, Chile</style></auth-address><titles><title><style face="normal" font="Arial">[Specific antibody deficiency: Primary immunodeficiency associated to respiratory allergy]</style></title><secondary-title><style face="normal" font="Arial">Rev Chil Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Chil Pediatr</style></full-title></periodical><pages end="257" start="252">252-257</pages><volume><style face="normal" font="Arial">88</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody deficiency</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumococcal vaccine</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> polysaccharide vaccine</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharides</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Specific antibody deficiency (SAD) with normal immunoglobulin and normal B cells is a primary immunodeficiency characterized by reduced ability to produce antibodies to specific antigens especially polysaccharides. OBJECTIVE: To describe the characteristics of patients diagnosed with SAD emphasizing the association between primary immunodeficiency and allergic diseases. PATIENTS AND METHOD: Descriptive study showing patients with SAD treated at a public hospital between August 2007 and July 2015. Other secondary or primary immunodeficiency was discarded. The diagnosis of SAD was based on recurrent infections and abnormal response to pneumococcal polysaccharide vaccine assessed by specific IgG to 10 pneumococcal serotypes. RESULTS: Twelve patients were included, 4 males, mean age 6 years, recurrent pneumonia predominated (91.7%) as well as other respiratory and invasive infections. All patients with SAD had associated asthma, 11 had allergic rhinitis, and other allergies. Three patients did not respond to any of the 10 serotypes contained in pneumococcal polysaccharide vaccine, and those who responded were with low titers. Treatment with conjugate pneumococcal vaccine was favorable in 11/12 patients. CONCLUSION: In children older than 2 years with recurrent respiratory infections or invasive S. pneumoniae infections with normal immunoglobulin we recommend to investigate SAD, especially if they have a concurrent allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160911IS - 0717-6228 (Electronic)IS - 0370-4106 (Linking)LA - SPAPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rchipe.2016.08.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27614984">PM:27614984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Chil Pediatr\20160911-FernandezF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Chil Pediatr\20160911-FernandezF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160911, Fernandez F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rchipe.2016.08.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Errazuriz,G.</style></author><author><style face="normal" font="Arial"> Lucero,Y.</style></author><author><style face="normal" font="Arial"> Ceresa,S.</style></author><author><style face="normal" font="Arial"> Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Rossel,M.</style></author><author><style face="normal" font="Arial"> Vives,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unidad de Gastroenterologia, Departamento de Pediatria, Clinica Las Condes, Santiago, Chile.</style></auth-address><titles><title><style face="normal" font="Arial">[Clinical characteristics and management of infants less than 1-year-old suspected with allergy to cow's milk protein]</style></title><secondary-title><style face="normal" font="Arial">Rev Chil Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Chil Pediatr</style></full-title></periodical><pages end="454" start="449">449-454</pages><volume><style face="normal" font="Arial">87</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy to cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid formula</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Colic</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> extensively hydrolysed formula</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="9" Year="2016">2016/9/12</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Cow's milk protein allergy (CMPA) is highly prevalent in infants (2-5%). It has a wide clinical spectrum, and confirmation through an oral food challenge (OFC) is relevant for its differential diagnosis. Information on this topic is scarce in Chile. OBJECTIVE: To describe the demographic and clinical features of infants with suspected CMPA. PATIENTS AND METHOD: A retrospective study of patients&lt;1 year-old, treated for suspected CMPA between 2009 and 2011. Demographic data, symptoms of atopy, nutrition at the time of diagnosis, CMPA symptoms, diagnostic studies, and response to treatment were recorded. Diet response at least 4 weeks after milk modification, and clinical behavior when suspected foods were added back to the diet were considered standard diagnostic criteria. Descriptive statistics were performed using Epiinfo software. RESULTS: The study included 106 infants, of whom, 51% male, 80% term newborns, 74% with>/=1 atopic parent, and 34% with >/=1 parent/sibling with food allergy. The median age at onset of symptoms was 1.5 months (range 1.5-2m). Almost half (46%) were breast-feeding>/=6m, with 15% receiving formula milk since the neonatal period, and 49% before the third month. Common symptoms were: vomiting (63%), colic (49%), and bleeding on passing stools (41%). No anaphylaxis was identified, and 61% had>/=2 symptoms at debut. Only 34% were subjected to OFC. The most frequently requested tests were, test patch (43%), prick test (40%), and blood in stools (37%). TREATMENT: 43% breast feeding with exclusion diet, 24% extensively hydrolysed formula, 26% amino acid formula, and 7% others. CONCLUSION: Demographic characteristics and risk factors were similar to those previously described in international literature. Clinical presentation was early in life, and digestive symptoms predominated. OFC was underused for diagnosis, and most of the tests requested did not change management</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 0717-6228 (Electronic)IS - 0370-4106 (Linking)LA - SPAPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rchipe.2016.06.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27634007">PM:27634007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Chil Pediatr\20160916-ErrazurizG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Chil Pediatr\20160916-ErrazurizG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Errazuriz G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rchipe.2016.06.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Therkelsen,S.P.</style></author><author><style face="normal" font="Arial"> Hetland,G.</style></author><author><style face="normal" font="Arial"> Lyberg,T.</style></author><author><style face="normal" font="Arial"> Lygren,I.</style></author><author><style face="normal" font="Arial"> Johnson,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastrointestinal and Pediatric Surgery, Oslo University Hospital, Ulleval, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Cytokine levels after consumption of a Medicinal Agaricus blazei Murill-based Mushroom Extract, AndoSan , in Patients with Crohn's disease and Ulcerative Colitis in a Randomized Single-Blinded Placebo Controlled Study</style></title><secondary-title><style face="normal" font="Arial">Scand J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Scand J Immunol</style></full-title></periodical><pages end="331" start="323">323-331</pages><volume><style face="normal" font="Arial">84</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Ulcerative Colitis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">Ingestion of the Agaricus blazei Murill-based mushroom extract AndoSan has been shown in randomized placebo-controlled studies to improve symptoms in Crohn's disease (CD) and ulcerative colitis (UC) and also fatigue and quality of life in the latter patients. The aim was to examine whether this clinical impact of AndoSan intake could be explained by influence on foremost pro-inflammatory cytokines in the patients. Fifty patients with symptomatic UC and CD were randomized and blinded for oral daily intake of AndoSan or placebo. Blood samples taken before (visit 1) and after 21 days' (visit 3) consumption were analyzed for cytokines IL-1ss, IL-2, IL-4-8, IL-10, IL-12-13, IL-17, G-CSF, GM-CSF, IFN-gamma, MCP-1, MIP-1ss and TNF-alpha. Baseline cytokine levels were similar in CD and UC. In CD cytokine levels at visit 1 versus visit 3 were unaltered within the AndoSan - and the placebo groups. Only IL-2 was significantly reduced at visit 3 in the Andosan - compared with the placebo group. However, when combining IL-1ss, IL-6 and G-CSF in the CD patients, there was a significant reduction in the Andosan group from visit 1 to visit 3. In UC levels of IL-2, IL-5 and MIP-1ss were reduced within the AndoSan group. IL-5 was also reduced at visit 3 compared with placebo. Generally, the effect on reduction in systemic cytokine levels by consumption of AndoSan was limited, and supported only marginally anti-inflammatory effects in these patients. Therefore, other explanations behind the clinical anti-inflammatory effects than the contribution of cytokines seem more pertinent, including anti-allergic and anti-oxidant activities. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 1365-3083 (Electronic)IS - 0300-9475 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.1111/sji.12476</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27588816">PM:27588816</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Scand J Immunol\20160902-TherkelsenSP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Scand J Immunol\20160902-TherkelsenSP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Therkelsen SP</style></custom2><misc3><style face="normal" font="Arial">10.1111/sji.12476</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mares-Mejia,I.</style></author><author><style face="normal" font="Arial"> Martinez-Caballero,S.</style></author><author><style face="normal" font="Arial"> Garay-Canales,C.</style></author><author><style face="normal" font="Arial"> Cano-Sanchez,P.</style></author><author><style face="normal" font="Arial"> Torres-Larios,A.</style></author><author><style face="normal" font="Arial"> Lara-Gonzalez,S.</style></author><author><style face="normal" font="Arial"> Ortega,E.</style></author><author><style face="normal" font="Arial"> Rodriguez-Romero,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Quimica, Universidad Nacional Autonoma de Mexico, Circuito Exterior, Cd. Universitaria, Coyoacan, Ciudad de Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Structural insights into the IgE mediated responses induced by the allergens Hev b 8 and Zea m 12 in their dimeric forms</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="32552">32552-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Cell Membrane</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dimerization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Hev b 8</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Maize</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zea m 12</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Oligomerization of allergens plays an important role in IgE-mediated reactions, as effective crosslinking of IgE- FcepsilonRI complexes on the cell membrane is dependent on the number of exposed B-cell epitopes in a single allergen molecule or on the occurrence of identical epitopes in a symmetrical arrangement. Few studies have attempted to experimentally demonstrate the connection between allergen dimerization and the ability to trigger allergic reactions. Here we studied plant allergenic profilins rHev b 8 (rubber tree) and rZea m 12 (maize) because they represent an important example of cross-reactivity in the latex-pollen-food syndrome. Both allergens in their monomeric and dimeric states were isolated and characterized by exclusion chromatography and mass spectrometry and were used in immunological in vitro experiments. Their crystal structures were solved, and for Hev b 8 a disulfide-linked homodimer was found. Comparing the structures we established that the longest loop is relevant for recognition by IgE antibodies, whereas the conserved regions are important for cross-reactivity. We produced a novel monoclonal murine IgE (mAb 2F5), specific for rHev b 8, which was useful to provide evidence that profilin dimerization considerably increases the IgE-mediated degranulation in rat basophilic leukemia cells</style></abstract><notes><style face="normal" font="Arial">DA - 20160902IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep32552</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27586352">PM:27586352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-32552.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-32552.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160902, Mares-Mejia I</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep32552</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,L.J.</style></author><author><style face="normal" font="Arial"> Zeng,L.</style></author><author><style face="normal" font="Arial"> Li,X.X.</style></author><author><style face="normal" font="Arial"> Mo,L.H.</style></author><author><style face="normal" font="Arial"> Geng,X.R.</style></author><author><style face="normal" font="Arial"> Zheng,P.Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Feng,B.S.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Department of Gastroenterology, the Second Hospital, Zhengzhou University, Zhengzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">Induction of colitis in mice with food allergen-specific immune response</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="32765">32765-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ussing chamber</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The pathogenesis of intestinal chronic inflammation is unclear. Food allergy plays an important role in the induction of intestinal inflammation. This study aims to test a hypothesis that food allergy initiates colitis. In this study, BALB/c mice were sensitized to a common food allergen, ovalbumin (OVA) with cholera toxin (CT) as an adjuvant. The colon epithelial barrier function was assessed with Ussing chamber technique. Expression of T cell immunoglobulin mucin domain molecule-4 (TIM4) in dendritic cells was evaluated by flow cytometry, RT-PCR and Western blotting. The results showed that allergen-related colitis was induced in mice as shown by heavy infiltration of inflammatory cells in the colon mucosa, loss of body weight of mice, increases in myeloperoxidase, tumor necrosis factor-alpha, interleukin-4, OVA-specific IgE in the colon tissue. The colon epithelial barrier function was markedly compromised in colitis group mice, which was mimicked by exposure the colon mucosa to CT in Ussing chamber. High frequency of TIM4(+) dendritic cells was detected in the colon mucosa of colitis mice. Exposure of dendritic cells to CT markedly increased the expression of TIM4. We conclude that IBD-like inflammation can be induced in the mouse colon by the food allergen-related immune response</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep32765</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27604348">PM:27604348</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-32765.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-32765.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Li LJ</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep32765</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garrido-Arandia,M.</style></author><author><style face="normal" font="Arial"> Silva-Navas,J.</style></author><author><style face="normal" font="Arial"> Ramirez-Castillejo,C.</style></author><author><style face="normal" font="Arial"> Cubells-Baeza,N.</style></author><author><style face="normal" font="Arial"> Gomez-Casado,C.</style></author><author><style face="normal" font="Arial"> Barber,D.</style></author><author><style face="normal" font="Arial"> Pozo,J.C.</style></author><author><style face="normal" font="Arial"> Melendi,P.G.</style></author><author><style face="normal" font="Arial"> Pacios,L.F.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Plant Biotechnology and Genomics (UPM-INIA), Pozuelo de Alarcon, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Characterisation of a flavonoid ligand of the fungal protein Alt a 1</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="33468">33468-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Alt a 1</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Spores of pathogenic fungi are virtually ubiquitous and cause human disease and severe losses in crops. The endophytic fungi Alternaria species produce host-selective phytotoxins. Alt a 1 is a strongly allergenic protein found in A. alternata that causes severe asthma. Despite the well-established pathogenicity of Alt a 1, the molecular mechanisms underlying its action and physiological function remain largely unknown. To gain insight into the role played by this protein in the pathogenicity of the fungus, we studied production of Alt a 1 and its activity in spores. We found that Alt a 1 accumulates inside spores and that its release with a ligand is pH-dependent, with optimum production in the 5.0-6.5 interval. The Alt a 1 ligand was identified as a methylated flavonoid that inhibits plant root growth and detoxifies reactive oxygen species. We also found that Alt a 1 changes its oligomerization state depending on the pH of the surrounding medium and that these changes facilitate the release of the ligand. Based on these results, we propose that release of Alt a 1 should be a pathogenic target in approaches used to block plant defenses and consequently to favor fungal entry into the plant</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Spain -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep33468</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27633190">PM:27633190</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-33468.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-33468.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, Garrido-Arandia M</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep33468</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jairaman,A.</style></author><author><style face="normal" font="Arial"> Maguire,C.H.</style></author><author><style face="normal" font="Arial"> Schleimer,R.P.</style></author><author><style face="normal" font="Arial"> Prakriya,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Northwestern University Feinberg School of Medicine, IL 60611, Chicago, USA</style></auth-address><titles><title><style face="normal" font="Arial">Allergens stimulate store-operated calcium entry and cytokine production in airway epithelial cells</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="32311">32311-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect allergen</style></keyword><keyword><style face="normal" font="Arial"> Insect allergens</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> protease activated receptor</style></keyword><keyword><style face="normal" font="Arial"> Protease-activated receptor</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Aberrant immune responses to environmental allergens including insect allergens from house dust mites and cockroaches contribute to allergic inflammatory diseases such as asthma in susceptible individuals. Airway epithelial cells (AECs) play a critical role in this process by sensing the proteolytic activity of allergens via protease-activated receptors (PAR2) to initiate inflammatory and immune responses in the airway. Elevation of cytosolic Ca(2+) is an important signaling event in this process, yet the fundamental mechanism by which allergens induce Ca(2+) elevations in AECs remains poorly understood. Here we find that extracts from dust mite and cockroach induce sustained Ca(2+) elevations in AECs through the activation of Ca(2+) release-activated Ca(2+) (CRAC) channels encoded by Orai1 and STIM1. CRAC channel activation occurs, at least in part, through allergen mediated stimulation of PAR2 receptors. The ensuing Ca(2+) entry then activates NFAT/calcineurin signaling to induce transcriptional production of the proinflammatory cytokines IL-6 and IL-8. These findings highlight a key role for CRAC channels as regulators of allergen induced inflammatory responses in the airway</style></abstract><notes><style face="normal" font="Arial">DA - 20160908IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep32311</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27604412">PM:27604412</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-32311.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-32311.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160908, Jairaman A</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep32311</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez,R.</style></author><author><style face="normal" font="Arial"> Martinez,J.</style></author><author><style face="normal" font="Arial"> Castro,A.</style></author><author><style face="normal" font="Arial"> Pedrosa,M.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author><author><style face="normal" font="Arial"> Rodriguez-Perez,R.</style></author><author><style face="normal" font="Arial"> Gasset,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Quimica Fisica "Rocasolano", Consejo Superior de Investigaciones Cientificas, 28006 Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">The amyloid fold of Gad m 1 epitopes governs IgE binding</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="32801">32801-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amyloid</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gad m 1</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monomer</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease digestion</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Amyloids are polymeric structural states formed from locally or totally unfolded protein chains that permit surface reorganizations, stability enhancements and interaction properties that are absent in the precursor monomers. beta-Parvalbumin, the major allergen in fish allergy, forms amyloids that are recognized by IgE in the patient sera, suggesting a yet unknown pathological role for these assemblies. We used Gad m 1 as the fish beta-parvalbumin model and a combination of approaches, including peptide arrays, recombinant wt and mutant chains, biophysical characterizations, protease digestions, mass spectrometry, dot-blot and ELISA assays to gain insights into the role of amyloids in the IgE interaction. We found that Gad m 1 immunoreactive regions behave as sequence-dependent conformational epitopes that provide a 1000-fold increase in affinity and the structural repetitiveness required for optimal IgE binding and cross-linking upon folding into amyloids. These findings support the amyloid state as a key entity in type I food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep32801</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27597317">PM:27597317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-32801.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-32801.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Sanchez R</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep32801</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shen,M.L.</style></author><author><style face="normal" font="Arial"> Wang,C.H.</style></author><author><style face="normal" font="Arial"> Lin,C.H.</style></author><author><style face="normal" font="Arial"> Zhou,N.</style></author><author><style face="normal" font="Arial"> Kao,S.T.</style></author><author><style face="normal" font="Arial"> Wu,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Chinese Medicine, China Medical University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Luteolin Attenuates Airway Mucus Overproduction via Inhibition of the GABAergic System</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="32756">32756-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Airway mucus overproduction is one of the most common symptoms of asthma that causes severe clinical outcomes in patients. Despite the effectiveness of general asthma therapies, specific treatments that prevent mucus overproduction in asthma patients remain lacking. Recent studies have found that activation of GABAA receptors (GABAAR) is important for promoting mucus oversecretion in lung airway epithelia. Here, we report that luteolin, a natural flavonoid compound, suppresses mucus overproduction by functionally inhibiting the GABAergic system. This hypothesis was investigated by testing the effects of luteolin on goblet cell hyperplasia, excessive mucus secretion, and GABAergic transmission using histological and electrophysiological approaches. Our results showed that 10 mg/kg luteolin significantly decreased the number of goblet cells in the lung tissue and inhibited mucus overproduction in an in vivo asthma model induced by ovalbumin (OVA) in mice. Patch-clamp recordings showed that luteolin inhibited GABAAR-mediated currents in A549 cells. Furthermore, the inhibitory effects of luteolin on OVA-induced goblet cell hyperplasia and mucus overproduction were occluded by the GABAAR antagonist picrotoxin. In conclusion, our observations indicate that luteolin effectively attenuates mucus overproduction at least partially by inhibiting GABAARs, suggesting the potential for therapeutic administration of luteolin in the treatment of mucus overproduction in asthma patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep32756</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27595800">PM:27595800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-32756.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-32756.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Shen ML</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep32756</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Karaca,S.</style></author><author><style face="normal" font="Arial"> Civelek,E.</style></author><author><style face="normal" font="Arial"> Karaca,M.</style></author><author><style face="normal" font="Arial"> Sahiner,U.M.</style></author><author><style face="normal" font="Arial"> Ozgul,R.K.</style></author><author><style face="normal" font="Arial"> Kocabas,C.N.</style></author><author><style face="normal" font="Arial"> Polimanti,R.</style></author><author><style face="normal" font="Arial"> Sekerel,B.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Aksaray University, Faculty of Health Science, Aksaray, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Allergy-specific Phenome-Wide Association Study for Immunogenes in Turkish Children</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="33152">33152-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ADAM33</style></keyword><keyword><style face="normal" font="Arial"> ADRB2</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> CD14</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immunogenetics</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SerpinE1</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">To dissect the role of immunogenetics in allergy and asthma, we performed a phenome-wide association study in 974 Turkish children selected from a cross-sectional study conducted using ISAAC (International Study of Asthma and Allergies in Children) Phase II tools. We investigated 9 loci involved in different immune functions (ADAM33, ADRB2, CD14, IL13, IL4, IL4R, MS4A2, SERPINE1, and TNF) with respect to 116 traits assessed through blood tests, hypertonic saline challenge tests, questionnaires, and skin prick tests. Multiple associations were observed for ADAM33: rs2280090 was associated with reduced MEF240% (i.e., the ratio of Mean Expiratory Flow after 240s of hypertonic saline inhalation with respect to the age- and ancestry-matched reference value) and with an increased risk of allergic bronchitis (p = 1.77*10(-4) and p = 7.94*10(-4), respectively); rs3918396 was associated with wheezing and eczema comorbidity (p = 3.41*10(-4)). IL4 rs2243250 was associated with increased FEV240 (Forced Expiratory Flow Volume after 240s of hypertonic saline inhalation; p = 4.81*10(-4)) and CD14 rs2569190 was associated with asthma diagnosis (p = 1.36*10(-3)). ADAM33 and IL4 appeared to play a role in the processes linked to allergic airway inflammation and lung function. Due to its association with wheezing and eczema comorbidity, ADAM33 may also be involved in the atopic march</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Turkey -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep33152</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27624002">PM:27624002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-33152.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-33152.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Karaca S</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep33152</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pezer,M.</style></author><author><style face="normal" font="Arial"> Stambuk,J.</style></author><author><style face="normal" font="Arial"> Perica,M.</style></author><author><style face="normal" font="Arial"> Razdorov,G.</style></author><author><style face="normal" font="Arial"> Banic,I.</style></author><author><style face="normal" font="Arial"> Vuckovic,F.</style></author><author><style face="normal" font="Arial"> Gospic,A.M.</style></author><author><style face="normal" font="Arial"> Ugrina,I.</style></author><author><style face="normal" font="Arial"> Vecenaj,A.</style></author><author><style face="normal" font="Arial"> Bakovic,M.P.</style></author><author><style face="normal" font="Arial"> Lokas,S.B.</style></author><author><style face="normal" font="Arial"> Zivkovic,J.</style></author><author><style face="normal" font="Arial"> Plavec,D.</style></author><author><style face="normal" font="Arial"> Devereux,G.</style></author><author><style face="normal" font="Arial"> Turkalj,M.</style></author><author><style face="normal" font="Arial"> Lauc,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genos Glycoscience Research Laboratory, Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="Arial">Effects of allergic diseases and age on the composition of serum IgG glycome in children</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="33198">33198-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycopeptides</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">It is speculated that immunoglobulin G (IgG) plays a regulatory role in allergic reactions. The glycans on the Fc region are known to affect IgG effector functions, thereby possibly having a role in IgG modulation of allergic response. This is the first study investigating patients' IgG glycosylation profile in allergic diseases. Subclass specific IgG glycosylation profile was analyzed in two cohorts of allergen sensitized and non-sensitized 3- to 11-year-old children (conducted at University of Aberdeen, UK and Children's Hospital Srebrnjak, Zagreb, Croatia) with 893 subjects in total. IgG was isolated from serum/plasma by affinity chromatography on Protein G. IgG tryptic glycopeptides were analyzed by liquid chromatography electrospray ionization mass spectrometry. In the Zagreb cohort IgG glycome composition changed with age across all IgG subclasses. In both cohorts, IgG glycome composition did not differ in allergen sensitized subjects, nor children sensitized to individual allergens, single allergen mean wheal diameter or positive wheal sum values. In the Zagreb study the results were also replicated for high total serum IgE and in children with self-reported manifest allergic disease. In conclusion, our findings demonstrate no association between serum IgG glycome composition and allergic diseases in children</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleSB - IMCO - Croatia -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep33198</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27616597">PM:27616597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-33198.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-33198.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Pezer M</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep33198</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Menzella,F.</style></author><author><style face="normal" font="Arial"> Lusuardi,M.</style></author><author><style face="normal" font="Arial"> Galeone,C.</style></author><author><style face="normal" font="Arial"> Facciolongo,N.</style></author><author><style face="normal" font="Arial"> Zucchi,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cardio-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, IR</style></auth-address><titles><title><style face="normal" font="Arial">The clinical profile of benralizumab in the management of severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="Arial">Ther Adv Respir Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ther Adv Respir Dis</style></full-title></periodical><pages end="548" start="534">534-548</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">Despite several therapeutic choices, 10-20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of severe asthma management, such as omalizumab, bronchial thermoplasty and other biological drugs, for example, mepolizumab, reslizumab and benralizumab. The availability of these new treatments and the increasing knowledge of the different asthmatic phenotypes and endotypes makes correct patient selection increasingly complex and important. In this article, we discuss the features of benralizumab compared with other anti-interleukin-5 biologics and omalizumab, the identification of appropriate patients, the safety profile and future developments</style></abstract><notes><style face="normal" font="Arial">DA - 20160910IS - 1753-4666 (Electronic)IS - 1753-4658 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1177/1753465816667659</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27612492">PM:27612492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ther Adv Respir Dis\20160910-MenzellaF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ther Adv Respir Dis\20160910-MenzellaF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Menzella F</style></custom2><misc3><style face="normal" font="Arial">10.1177/1753465816667659</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bryce,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy-Immunology, Department of Medicine, Northwestern Feinberg School of Medicine, 240 East Huron, Chicago, IL 60611, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Balancing Tolerance or Allergy to Food Proteins</style></title><secondary-title><style face="normal" font="Arial">Trends Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Trends Immunol</style></full-title></periodical><pages end="667" start="659">659-667</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dietary Proteins</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="3" Month="9" Year="2016">2016/9/3</year></dates><abstract><style face="normal" font="Arial">Dietary proteins usually induce immune tolerance, but may trigger life-threatening immune responses in the case of food allergy. The associated type 2 immunity, linked with specific IgE production and the activation of mast cells and basophils, is well understood but the mechanisms related to preventing food allergy are still being deciphered. Recent insights into the mechanisms that regulate oral tolerance and dietary antigen sampling have revealed unique regulatory events that occur during early life and into adulthood. Drawing from both recent clinical and experimental discoveries, this article focuses on current evidence for how several key stages of life present mechanistic points that might participate in tipping the balance between food protein tolerance and allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1471-4981 (Electronic)IS - 1471-4906 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.it.2016.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27600681">PM:27600681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trends Immunol\20160907-BrycePJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trends Immunol\20160907-BrycePJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Bryce PJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.it.2016.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Smith,H.E.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sirio Libanes, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Dissemination of definitions and concepts of allergic and hypersensitivity conditions</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="24">24-</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> ICD</style></keyword><keyword><style face="normal" font="Arial"> ICD-11</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy and hypersensitivity can affect people of any age and manifest with problems in a range of organ systems. Moreover, they can have a significant impact on the quality of life of patients and their families. Although once rare, there is presently an epidemic of allergic disorders with associated considerable societal consequences. Our understanding of the pathophysiology of these disorders has changed substantially over the last 20 years. In the light of these developments, the Joint Allergy Academies have made concerted efforts to ensure that these are reflected in the current definitions and concepts used in clinical allergy and to ensure these are reflected in the forthcoming International Classification of Diseases-11 (ICD-11). OBJECTIVE: In this review, we seek to provide an update on the current definitions and concepts in relation to allergic disorders. RESULTS: Once the new section has been built in the ICD-11 to address allergic and hypersensitivity conditions, we have been moving actions to try to support awareness by disseminating updated concepts in the field. Aligned with the ICD and the WAO philosophy of being global, this document presents fundamental and broad allergy concepts to strengthen the understanding by different health professionals worldwide, besides to support the formation of in training students. CONCLUSION: This current review intends to be accepted and used universally by all health professionals involved in diseases' classification and coding and, therefore, contribute to improve care and outcomes in this increasing sub-section of the world's population</style></abstract><notes><style face="normal" font="Arial">DA - 20160823IS - 1939-4551 (Electronic)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -CO - France -CO - United Kingdom -CO - Venezuela -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0115-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27551327">PM:27551327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160823, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0115-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">di Mauro,G.</style></author><author><style face="normal" font="Arial"> Bernardini,R.</style></author><author><style face="normal" font="Arial"> Barberi,S.</style></author><author><style face="normal" font="Arial"> Capuano,A.</style></author><author><style face="normal" font="Arial"> Correra,A.</style></author><author><style face="normal" font="Arial"> De' Angelis,G.L.</style></author><author><style face="normal" font="Arial"> Iacono,I.D.</style></author><author><style face="normal" font="Arial"> de Martino,M.</style></author><author><style face="normal" font="Arial"> Ghiglioni,D.</style></author><author><style face="normal" font="Arial"> Di Mauro,D.</style></author><author><style face="normal" font="Arial"> Giovannini,M.</style></author><author><style face="normal" font="Arial"> Landi,M.</style></author><author><style face="normal" font="Arial"> Marseglia,G.L.</style></author><author><style face="normal" font="Arial"> Martelli,A.</style></author><author><style face="normal" font="Arial"> Miniello,V.L.</style></author><author><style face="normal" font="Arial"> Peroni,D.</style></author><author><style face="normal" font="Arial"> Sullo,L.R.</style></author><author><style face="normal" font="Arial"> Terracciano,L.</style></author><author><style face="normal" font="Arial"> Vascone,C.</style></author><author><style face="normal" font="Arial"> Verduci,E.</style></author><author><style face="normal" font="Arial"> Verga,M.C.</style></author><author><style face="normal" font="Arial"> Chiappini,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Sciences for Health Sciences, Anna Meyer Children's University Hospital, University of Florence, Viale Pieraccini, 24, Florence, 50100 Italy</style></auth-address><titles><title><style face="normal" font="Arial">Prevention of food and airway allergy: consensus of the Italian Society of Preventive and Social Paediatrics, the Italian Society of Paediatric Allergy and Immunology, and Italian Society of Pediatrics</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="28">28-</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> complementary foods</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> functional foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hydrolyzed formula</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Minerals</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> tobacco smoke</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic sensitization in children and allergic diseases arising therefrom are increasing for decades. Several interventions, functional foods, pro- and prebiotics, vitamins are proposed for the prevention of allergies and they can't be uncritically adopted. OBJECTIVE: This Consensus document was developed by the Italian Society of Preventive and Social Paediatrics and the Italian Society of Paediatric Allergy and Immunology. The aim is to provide updated recommendations regarding allergy prevention in children. METHODS: The document has been issued by a multidisciplinary expert panel and it is intended to be mainly directed to primary care paediatricians. It includes 19 questions which have been preliminarily considered relevant by the panel. Relatively to each question, a literature search has been performed, according to the Italian National Guideline Program. Methodology, and a brief summary of the available literature data, has been provided. Many topics have been analyzed including the role of mother's diet restriction, use of breast/formula/hydrolyzed milk; timing of introduction of complementary foods, role (if any) of probiotics, prebiotics, vitamins, exposure to dust mites, animals and to tobacco smoke. RESULTS: Some preventive interventions have a strong level of recommendation. (e.g., the dehumidifier to reduce exposure to mite allergens). With regard to other types of intervention, such as the use of partially and extensively hydrolyzed formulas, the document underlines the lack of evidence of effectiveness. No preventive effect of dietary supplementation with polyunsaturated fatty acids, vitamins or minerals has been demonstrated. There is no preventive effect of probiotics on asthma, rhinitis and allergic diseases. It has demonstrated a modest effect, but steady, in the prevention of atopic dermatitis. CONCLUSIONS: The recommendations of the Consensus are based on a careful analysis of the evidence available. The lack of evidence of efficacy does not necessarily imply that some interventions may not be effective, but currently they can't be recommended</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1939-4551 (Electronic)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0111-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27583103">PM:27583103</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, di Mauro G</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0111-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pedulla,M.</style></author><author><style face="normal" font="Arial"> Fierro,V.</style></author><author><style face="normal" font="Arial"> Marzuillo,P.</style></author><author><style face="normal" font="Arial"> Del Tufo,E.</style></author><author><style face="normal" font="Arial"> Grandone,A.</style></author><author><style face="normal" font="Arial"> Perrone,L.</style></author><author><style face="normal" font="Arial"> Miraglia Del Giudice,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Marcella Pedulla, Vincenzo Fierro, Pierluigi Marzuillo, Ester Del Tufo, Anna Grandone, Laura Perrone, Emanuele Miraglia del Giudice, Department of Woman, Child and General and Specialized Surgery, Seconda Universita degli Studi di Napoli, 80138 Napoli, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Subclinical hypothyroidism in atopic South Italian children</style></title><secondary-title><style face="normal" font="Arial">World J Clin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Clin Pediatr</style></full-title></periodical><pages end="310" start="306">306-310</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hypothyroidism</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">AIM: To verify if subclinical hypothyroidism (SCH) could be associated to atopy in children. METHODS: Seven hundred and thirty-two Caucasian children from South Italy presenting symptoms of allergic disease were enrolled and submitted to atopy, obesity, chronic low grade inflammation, and SCH work up. RESULTS: Four hundred and forty-five out of 705 (63.12%) children affected by allergic disease were diagnosed as atopic and 260 (36.88%) as not atopic. The SCH prevalence was 6.3%. Significant higher prevalence of SCH among atopic children with average (group 2) and high (group 3) low grade chronic inflammation compared to atopic children with mild (group 1) low grade chronic inflammation was present. Moreover, group 1 and group 2 presented an OR to show SCH of 2.57 (95%CI: 1.55-6.26) and 2.96 (95%CI: 1.01-8.65), respectively. Both in atopic and not atopic children we found C3 serum levels significantly higher in group 3 respect to group 2 and group 1. Noteworthy, among atopic patients, also total immunoglobulin E (IgE) serum levels, were significantly higher in group 3 compared to group 2 and group 1 children. In atopic children, C3 and total IgE serum values increased in parallel with the increase of C-reactive protein values, while in not atopic children this phenomenon was not evident. CONCLUSION: The possibility exists that an increasing atopic inflammation contributes to SCH occurrence. So far this is the first report in literature showing an association between SCH and atopy but further studies are needed to confirm our data</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 2219-2808 (Electronic)IS - 2219-2808 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.5409/wjcp.v5.i3.306</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27610347">PM:27610347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Clin Pediatr\2016-5-306-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Clin Pediatr\2016-5-306-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Pedulla M</style></custom2><misc3><style face="normal" font="Arial">10.5409/wjcp.v5.i3.306</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pedulla,M.</style></author><author><style face="normal" font="Arial"> Fierro,V.</style></author><author><style face="normal" font="Arial"> Marzuillo,P.</style></author><author><style face="normal" font="Arial"> Capuano,F.</style></author><author><style face="normal" font="Arial"> Miraglia Del Giudice,E.</style></author><author><style face="normal" font="Arial"> Ruocco,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Marcella Pedulla, Vincenzo Fierro, Pierluigi Marzuillo, Francesco Capuano, Emanuele Miraglia del Giudice, Department of Woman, Child and General and Specialized Surgery, Seconda Universita degli Studi di Napoli, 80138 Napoli, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Skin disease and thyroid autoimmunity in atopic South Italian children</style></title><secondary-title><style face="normal" font="Arial">World J Clin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Clin Pediatr</style></full-title></periodical><pages end="292" start="288">288-292</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> Alopecia</style></keyword><keyword><style face="normal" font="Arial"> Alopecia Areata</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TA</style></keyword><keyword><style face="normal" font="Arial"> Thyroglobulin</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="8" Year="2016">2016/8/8</year></dates><abstract><style face="normal" font="Arial">AIM: To verify the prevalence of thyroid autoimmunity (TA) and the possible association between atopy and TA in children affected by skin disease. METHODS: Three hundred and twenty-four children consecutively referred due to skin disease symptoms to our Pediatric Department were enrolled. One hundred and eighty-seven were diagnosed with atopic dermatitis (AD), 95 with acute urticaria, 40 with chronic urticaria (CU), and 2 with alopecia areata (AA). According to the work-up for atopy, the children were divided into two groups: Atopics and non-atopics. TA was diagnosed by serum thyroid peroxidase autoantibodies and/or thyroglobulin autoantibodies levels more than twice normal values over a period of two months by immunoassay. RESULTS: In all children with skin disease, a significant prevalence of TA in atopics compared with non-atopics (13.67% vs 2.67%, P = 0.0016) and a significant association between TA and atopy (OR = 5.76, 95%CI: 1.71-19.35) were observed. These findings were confirmed as significant in children with AD: TA in atopics was 11.5%, while TA in non-atopics was 2.7% (P = 0.03, OR = 4.68, 95%CI: 1.02-21.38). In addition, atopics with CU showed a significantly higher prevalence of TA (26.9%), but none of the non-atopics showed CU (P = 0.0326). On the other hand, atopics with AA showed a 100% (2 out of 2) prevalence of TA, compared with none of the non-atopics. CONCLUSION: In children with skin disease, atopy seems to be associated with an increased risk of TA</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 2219-2808 (Electronic)IS - 2219-2808 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.5409/wjcp.v5.i3.288</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27610344">PM:27610344</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Clin Pediatr\2016-5-288-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Clin Pediatr\2016-5-288-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Pedulla M</style></custom2><misc3><style face="normal" font="Arial">10.5409/wjcp.v5.i3.288</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hong,J.Y.</style></author><author><style face="normal" font="Arial"> Bae,J.H.</style></author><author><style face="normal" font="Arial"> Lee,K.E.</style></author><author><style face="normal" font="Arial"> Kim,M.</style></author><author><style face="normal" font="Arial"> Kim,M.H.</style></author><author><style face="normal" font="Arial"> Kang,H.J.</style></author><author><style face="normal" font="Arial"> Park,E.H.</style></author><author><style face="normal" font="Arial"> Yoo,K.S.</style></author><author><style face="normal" font="Arial"> Jeong,S.K.</style></author><author><style face="normal" font="Arial"> Kim,K.W.</style></author><author><style face="normal" font="Arial"> Kim,K.E.</style></author><author><style face="normal" font="Arial"> Sohn,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics and Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Antibody to FcepsilonRIalpha Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation</style></title><secondary-title><style face="normal" font="Arial">Yonsei Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yonsei Med J</style></full-title></periodical><pages end="1419" start="1412">1412-1419</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic skin inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation Mediators</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: High-affinity receptor I (FcepsilonRI) on mast cells and basophils plays a key role in the immunoglobulin E (IgE)-mediated type I hypersensitivity mediated by allergen cross-linking of the specific IgE-FcepsilonRI complex. Thus, prevention of IgE binding to FcepsilonRI on these cells is an effective therapy for allergic disease. We have developed a strategy to disrupt IgE binding to FcepsilonRI using an antibody targeting FcepsilonRIalpha. MATERIALS AND METHODS: Fab fragment antibodies, which lack the Fc domain, with high affinity and specificity for FcepsilonRIalpha and effective inhibitory activity against IgE-FcepsilonRI binding were screened. IgE-induced histamine, beta-hexosaminidase and Ca(2)(+) release in basophils were determined by ELISA. A B6.Cg-Fcer1a(tm1Knt) Tg(FCER1A)1Bhk/J mouse model of passive cutaneous anaphylaxis (PCA) was used to examine the inhibitory effect of NPB311 on allergic skin inflammation. RESULTS: NPB311 exhibited high affinity to human FcepsilonRIalpha (KD=4 nM) and inhibited histamine, beta-hexosaminidase and Ca(2)(+) release in a concentration-dependent manner in hFcepsilonRI-expressing cells. In hFcepsilonRIalpha-expressing mice, dye leakage was higher in the PCA group than in controls, but decreased after NPB311 treatment. NPB311 could form a complex with FcepsilonRIalpha and inhibit the release of inflammation mediators. CONCLUSION: Our approach for producing anti-FcepsilonRIalpha Fab fragment antibody NPB311 may enable clinical application to a therapeutic pathway in IgE/FcepsilonRI-mediated diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160905IS - 1976-2437 (Electronic)IS - 0513-5796 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3349/ymj.2016.57.6.1412</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27593869">PM:27593869</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yonsei Med J\2016-57-1412-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yonsei Med J\2016-57-1412-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160905, Hong JY</style></custom2><misc3><style face="normal" font="Arial">10.3349/ymj.2016.57.6.1412</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,K.H.</style></author><author><style face="normal" font="Arial"> Lee,S.C.</style></author><author><style face="normal" font="Arial"> Son,Y.W.</style></author><author><style face="normal" font="Arial"> Jeong,K.Y.</style></author><author><style face="normal" font="Arial"> Shin,Y.S.</style></author><author><style face="normal" font="Arial"> Shin,J.U.</style></author><author><style face="normal" font="Arial"> Sim,D.W.</style></author><author><style face="normal" font="Arial"> Park,H.J.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products</style></title><secondary-title><style face="normal" font="Arial">Yonsei Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yonsei Med J</style></full-title></periodical><pages end="1434" start="1427">1427-1434</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Blocking factor</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgG4</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Specific immunoglobulin G4 (sIgG4) and immunoglobulin E (IgE)-blocking factors produced by subcutaneous immunotherapy (SCIT) play a critical role in the induction of allergen tolerance. However, comparative studies of available SCIT reagents on the induction of sIgG4 are limited. We compared increases in sIgG4 for three different house dust mite (HDM) SCIT reagents. MATERIALS AND METHODS: Seventy-two HDM sensitized allergic patients were enrolled and classified into four groups: 1) control (n=27), 2) SCIT with Hollister-Stier(R) (n=19), 3) Tyrosine S(R) (n=16), and 4) Novo-Helisen(R) (n=10). Levels of specific IgE (sIgE), sIgG4, and IgE blocking factor to Dermatophagoides farinae (D. farinae) were measured using ImmunoCAP (sIgE, sIgG4) and enzyme-linked immunosorbent assay (ELISA) (IgE-blocking factors). Levels were measured before and 13.9+/-6.6 months after the SCIT. The allergen specificity and the induction levels of sIgE and sIgG4 were confirmed by immunoblot analysis. RESULTS: After SCIT, sIgG4 levels to D. farinae increased significantly; however, the increases differed significantly among the SCIT groups (p&lt;0.001). Specific IgG4 levels to D. farinae were highest in Hollister-Stier(R) (3.7+/-4.1 mg/L), followed by Novo-Helisen(R) (2.2+/-2.3 mg/L) and Tyrosine S(R) (0.7+/-0.5 mg/L). In addition, patients who were administered using Hollister-Stier(R) showed the most significant decrease in IgE/IgG4 ratio (p&lt;0.001) and increase in blocking factor (p=0.009). Finally, according to IgE immunoblot results, the Hollister-Stier(R) group showed the most significant attenuation of IgE binding patterns among others. CONCLUSION: Currently available SCIT reagents induce different levels of specific IgG4, IgE/IgG4 ratio, and IgE-blocking factor</style></abstract><notes><style face="normal" font="Arial">DA - 20160905IS - 1976-2437 (Electronic)IS - 0513-5796 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3349/ymj.2016.57.6.1427</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27593871">PM:27593871</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yonsei Med J\2016-57-1427-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yonsei Med J\2016-57-1427-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160905, Park KH</style></custom2><misc3><style face="normal" font="Arial">10.3349/ymj.2016.57.6.1427</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nahm,D.H.</style></author><author><style face="normal" font="Arial"> Kim,M.E.</style></author><author><style face="normal" font="Arial"> Kwon,B.</style></author><author><style face="normal" font="Arial"> Cho,S.M.</style></author><author><style face="normal" font="Arial"> Ahn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Yonsei Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yonsei Med J</style></full-title></periodical><pages end="1426" start="1420">1420-1426</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The clinical usefulness of subcutaneous allergen immunotherapy (SCIT) in the treatment of atopic dermatitis (AD) is still controversial. We analyzed the clinical efficacy of SCIT in patients with AD and the clinical characteristics of patients showing a favorable clinical response to the treatment. MATERIALS AND METHODS: Two hundred and fifty one patients with AD sensitized to house dust mite (HDM) were treated by SCIT using HDM extract. The clinical severity of AD was measured using the standardized clinical severity scoring system for AD (SCORAD) at baseline and 12 months. A favorable clinical response to SCIT was defined as a decrease in SCORAD value at 12 months greater than 50% compared to baseline value. Severe AD was defined as a baseline SCORAD value above 50. RESULTS: A favorable clinical response to SCIT was observed in 73.6% of patients. The proportion of patients showing a favorable clinical response to SCIT was significantly higher in patients with severe AD (90.6%) than patients with mild to moderated AD (63.7%) (p&lt;0.001). Patients with severe AD showing a favorable clinical response had a significantly shorter duration of AD (12.3+/-8.5 years; mean+/-SD) than patients with severe AD showing no significant clinical response (20.6+/-10.9 years) (p&lt;0.05) at baseline. CONCLUSION: SCIT could be a clinically useful therapeutic option for patients with severe AD sensitized to HDM. Early initiation of SCIT might provide a favorable clinical outcome in patients with severe AD sensitized to HDM</style></abstract><notes><style face="normal" font="Arial">DA - 20160905IS - 1976-2437 (Electronic)IS - 0513-5796 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3349/ymj.2016.57.6.1420</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27593870">PM:27593870</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yonsei Med J\2016-57-1420-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yonsei Med J\2016-57-1420-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160905, Nahm DH</style></custom2><misc3><style face="normal" font="Arial">10.3349/ymj.2016.57.6.1420</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,R.</style></author><author><style face="normal" font="Arial"> Ma,L.</style></author><author><style face="normal" font="Arial"> Xu,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Otorhinolaryngology Hospital of First Affiliated Hospital of Sun Yetsan University, Guangzhou 510080, China</style></auth-address><titles><title><style face="normal" font="Arial">[Diagnosis and treatment of allergic fungal rhinosinusitis]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="640" start="635">635-640</pages><volume><style face="normal" font="Arial">51</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="8" Year="2016">2016/8/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2016.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27625139">PM:27625139</url></web-urls></urls><custom2><style face="normal" font="Arial">20160914, Xu R</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2016.08.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grajewski,R.S.</style></author><author><style face="normal" font="Arial"> Barahmand,P.N.</style></author><author><style face="normal" font="Arial"> Burian,K.</style></author><author><style face="normal" font="Arial"> Caramoy,A.</style></author><author><style face="normal" font="Arial"> Kirchhof,B.</style></author><author><style face="normal" font="Arial"> Cursiefen,C.</style></author><author><style face="normal" font="Arial"> Heindl,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology, University of Cologne, Cologne, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of the impact of allergy and atopy on new onset of uveitis</style></title><secondary-title><style face="normal" font="Arial">Acta Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Ophthalmol</style></full-title></periodical><pages end="e241" start="e236">e236-e241</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> self-antigens</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Uveitis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The inappropriate immune response to harmless foreign and self-antigens is a common feature of allergy, atopy and autoimmune disease. The influence of environmental factors in the initiation of autoimmunity is not well understood. It is conceivable that immune responses to allergens may also serve as a trigger of bystander immune reactions, including autoimmunity such as uveitis. Therefore, we wanted to investigate the prevalence of allergies and atopy in patients with different types of uveitis in comparison to a control cohort. METHODS: In total, 530 consecutive patients with new-onset anterior, intermediate, posterior and panuveitis were compared to a non-uveitis control cohort consisting of 1.060 consecutive new-referral patients who attended our specialized outpatient clinics for other reasons than uveitis. Allergy and atopy status as well as demographic data (age, gender and ethnicity) were obtained by standardized interviewer-assisted questionnaires. RESULTS: Uveitis case cohort and control cohort did not differ significantly in the allergy status (p = 0.910), such as the history of pollen allergy (p = 0.671), history of drug allergy (p = 0.920), history of food allergy (p = 0.941), history of house dust mite allergy (p = 0.197) or history of other allergens (p = 0.593), nor in the atopy status (p = 0.802), such as the history of atopic dermatitis (p = 0.365), history of asthma (p = 0.430) or history of allergic rhinitis (p = 0.115). CONCLUSIONS: Our results argue against a substantial influence of allergies and atopy on the onset of uveitis</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1755-3768 (Electronic)IS - 1755-375X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/aos.13239</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27682154">PM:27682154</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Ophthalmol\20160929-GrajewskiRS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Ophthalmol\20160929-GrajewskiRS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Grajewski RS</style></custom2><misc3><style face="normal" font="Arial">10.1111/aos.13239</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ohno,K.</style></author><author><style face="normal" font="Arial"> Kimura,Y.</style></author><author><style face="normal" font="Arial"> Matsuda,Y.</style></author><author><style face="normal" font="Arial"> Takahashi,M.</style></author><author><style face="normal" font="Arial"> Honjyou,M.</style></author><author><style face="normal" font="Arial"> Arai,T.</style></author><author><style face="normal" font="Arial"> Tsutsumi,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Otorhinolaryngology , Tokyo Metropolitan Geriatric Hospital , Itabashi-ku , Japan</style></auth-address><titles><title><style face="normal" font="Arial">Increased number of IgG4-positive plasma cells in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Acta Otolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Otolaryngol</style></abbr-1></periodical><pages end="190" start="186">186-190</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> phlebitis</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">CONCLUSION: High levels of IgG4-positive plasma cells were observed in tissue samples from approximately 30% of patients with chronic rhinosinusitis who satisfied the comprehensive diagnostic criteria for IgG4-related disease. Detection of increased numbers of IgG4-positive plasma cells in the nasal cavity or paranasal sinuses might not be sufficient to make a diagnosis of IgG4-related rhinosinusitis, and a comprehensive evaluation is required. OBJECTIVES: This study aimed to clarify the clinicopathological characteristics of IgG4-positive plasma cells in patients with chronic rhinosinusitis. METHOD: This study examined nasal mucosal specimens from 35 patients and assigned them to high-IgG4 and low-IgG4 groups based on infiltration of IgG4-positive plasma cells. It compared the pathological characteristics of the two groups, including the presence of fibrosis, phlebitis, hyperplasia of the nasal glands and infiltration of inflammatory cells. RESULTS: No cases of chronic rhinosinusitis showed storiform fibrosis or obliterative phlebitis. The mean number of IgG4-positive plasma cells in samples from all patients was 29.8 +/- 40.3/high-power field. Eleven of the 35 cases (31.4%) were classified as high-IgG4. Hyperplasia of the nasal glands was observed significantly more frequently in the high-IgG4 group than in the low-IgG4 group (p = .03)</style></abstract><notes><style face="normal" font="Arial">DA - 20160920IS - 1651-2251 (Electronic)IS - 0001-6489 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/00016489.2016.1219050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27644479">PM:27644479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Otolaryngol\20160920-OhnoK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Otolaryngol\20160920-OhnoK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Ohno K</style></custom2><misc3><style face="normal" font="Arial">10.1080/00016489.2016.1219050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hirtz,M.</style></author><author><style face="normal" font="Arial"> Feng,W.</style></author><author><style face="normal" font="Arial"> Fuchs,H.</style></author><author><style face="normal" font="Arial"> Levkin,P.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Click-Chemistry Immobilized 3D-Infused Microarrays in Nanoporous Polymer Substrates</style></title><secondary-title><style face="normal" font="Arial">Adv Mater Interfaces</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Adv Mater Interfaces</style></abbr-1></periodical><pages end="" start="1500469">1500469-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">3D microarrays</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> click-chemistry</style></keyword><keyword><style face="normal" font="Arial"> copper(I)-catalyzed azide-alkyne cycloaddition</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> microspotting</style></keyword><keyword><style face="normal" font="Arial"> Nanoporous</style></keyword><keyword><style face="normal" font="Arial"> polymer films</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword></keywords><dates><year Day="1" Month="3" Year="2016">2016/3/1</year></dates><isbn><style face="normal" font="Arial">2196-7350</style></isbn><abstract><style face="normal" font="Arial">3D microarrays are created in a nanoporous polymer film. The microarrays are stabilized by covalent attachment over a click-chemistry approach and exhibit an enhanced dynamic range for the detection of antibody binding due to a higher amount of binding sites in the nanoporous film compared to flat substrates with conventional 2D surface arrays.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/admi.201500469</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1002/admi.201500469</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Mater Interfaces\2016-3-1500469.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Mater Interfaces\2016-3-1500469.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Hirtz M</style></custom2><misc3><style face="normal" font="Arial">10.1002/admi.201500469</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Szczepanek,K.</style></author><author><style face="normal" font="Arial"> Myszkowska,D.</style></author><author><style face="normal" font="Arial"> Worobiec,E.</style></author><author><style face="normal" font="Arial"> Piotrowicz,K.</style></author><author><style face="normal" font="Arial"> Ziemianin,M.</style></author><author><style face="normal" font="Arial"> Bielec-Bakowska,Z.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The long-range transport of Pinaceae pollen: an example in Krakow (southern Poland)</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="125" start="109">109-125</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Main pollen season</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Picea</style></keyword><keyword><style face="normal" font="Arial"> Pinaceae</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen deposition</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Slovakia</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Ukraine</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">High Pinaceae pollen concentrations in the air and on the surface of puddles before the main pollen season started were observed in Kraków (southern Poland) in May 2013. The paper presents the results of detailed studies of the composition and source of the "yellow rain" in 2013, and as a comparison, the Pinaceae pollen concentrations and samples collected from the ground surface in 2014 were considered. The air samples were collected using the volumetric method (Hirst-type device), while pollen grains sampled from the ground surface were processed using a modified Erdtman acetolysis method. Finally, all samples were studied using a light microscope. In 2013, the period of higher Abies, Picea and Pinus pollen concentrations was observed from the 5 to 12 of May, earlier than the main pollen season occurred. The presence of rainfall on the 12 and 13 of May 2013 caused the pollen deposition on the ground surface, where the prevalence of Pinaceae pollen was found. The synoptic situation and the analysis of the back-trajectories and air mass advection at the beginning of May 2013 indicated that Pinaceae pollen grains could have been transported from Ukraine, Romania, Hungary and Slovakia. In contrast, Pinaceae pollen grains deposited on the ground surface as a "yellow" film in May 2014, originated from local sources.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9454-2</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9454-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161017-SzczepanekK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161017-SzczepanekK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Szczepanek K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9454-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bicakci,A.</style></author><author><style face="normal" font="Arial"> Tosunoglu,A.</style></author><author><style face="normal" font="Arial"> Altunoglu,M.K.</style></author><author><style face="normal" font="Arial"> Saatcioglu,G.</style></author><author><style face="normal" font="Arial"> Keser,A.M.</style></author><author><style face="normal" font="Arial"> Ozgokce,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">An aeropalynological survey in the city of Van, a high altitudinal region, East Anatolia-Turkey</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="108" start="93">93-108</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic taxa</style></keyword><keyword><style face="normal" font="Arial"> Altitude</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Factors</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant growth</style></keyword><keyword><style face="normal" font="Arial"> Plantago</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen spectrum</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Populus</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> Volumetric sampler</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Pollen concentrations in the atmosphere of Van city has been monitored for two consecutive years (2010</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2011). This was the first detailed aeropalynological study for the elevated East Anatolia Region of Turkey. The sampling was performed by Hirst-type volumetric sampler, and pollen grains of 35 taxa were identified. The main pollen producers of the pollen flora were recorded as: Poaceae (20.94-á%), Cupressaceae (10.53-á%), Fraxinus (8.56-á%), Chenopodiaceae/Amaranthaceae (7.77-á%), Populus (7.75-á%), Quercus (6.70-á%), Platanus (6.68-á%), Morus (5.57-á%), Plantago (3.03-á%). The pollen spectrum reflected the floristic diversity of the region, and the highest pollen concentration was recorded in April. There were a great percentage of allergenic taxa found in the city atmosphere, otherwise many of them scored under threshold values for risk of pollinosis. Statistical analyses were performed for correlating daily pollen concentrations of dominated pollen types concurrent with the data of meteorological parameters in MPS periods and number of significant correlations found. In addition, comparing 2-year data in terms of pollen concentrations and meteorological factors in MPS durations, many variables were found explanatory and concordant with the data. MPS starting dates of many plant taxa were found nearly a month later compared with western sites and lower altitudes of the country as well as Mediterranean countries; this case is mostly thought the ecological factors of the study area which directly affects the plant growth about the timing</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9453-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9453-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161017-BicakaciA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161017-BicakaciA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Bicakci A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9453-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Balolong,M.P.</style></author><author><style face="normal" font="Arial"> Dalmacio,L.M.</style></author><author><style face="normal" font="Arial"> Magabo,M.L.</style></author><author><style face="normal" font="Arial"> Sy,D.N.</style></author><author><style face="normal" font="Arial"> Hallare,A.V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Next-generation sequencing revealed dominant fungal populations in collected dust from selected public school classrooms in Metro Manila</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="135" start="127">127-135</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Classroom</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> NGS</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Philippines</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Public school</style></keyword><keyword><style face="normal" font="Arial"> pyrosequencing</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Titanium</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Fungal contaminants inside classrooms may increase the chance of health-related problems for school children and teachers, reducing their learning and productivity. Recent initiatives have utilized next-generation sequencing (NGS) technology in order to understand dust ecology and were used to significantly correlate some genera with health-related conditions. To our knowledge, this paper is the first report, describing the fungal community profile of collected dust using 454 pyrosequencing of the ITS region of the 18S rRNA gene from public school classrooms in Metro Manila, Philippines. Culture-dependent technique was done by gravimetric sampling on Sabouraud Dextrose Agar (SDA) to note the importance of existing viable spores present in the rooms. Composite samples of settled dust from each classroom were collected and pooled to represent one sample per school. The fungal ITS rRNA genes amplified from genomic DNA with barcoded primers were sent for pyrosequencing on a 454 GS FLX titanium platform, and sequences were analyzed using the ITScan pipeline. Fungal sequences from the collected dust samples clustered in 108 operational taxonomic units (OTUs), most of which occur as singleton. The number of OTUs that correspond to fungal species varied from 16 to 29 per sample. Rarefaction curves indicated that sampling coverage was partial and that the remaining fraction of the species diversity remains to be discovered. Genera that were detected by both NGS and by cultivation on SDA include Alternaria, Aspergillus, Cladosporium and Penicillium</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Philippines -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9455-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9455-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161017-BalolongMP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161017-BalolongMP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Balolong MP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9455-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schumacher,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Erdnuss-Immuntherapie mit anhaltender Wirkung</style></title><secondary-title><style face="normal" font="Arial">Allergo J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J</style></full-title></periodical><pages end="10" start="10">10-10</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergie</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2195-6405</style></isbn><abstract><style face="normal" font="Arial">Frühzeitiger mehrjähriger Erdnusskonsum kann bei Hochrisikokindern die Entwicklung einer Allergie gegen die Hülsenfrucht verhindern. Die Schutzwirkung scheint auch eine anschließende „Erdnuss-Pause" zu überdauern.</style></abstract><notes><style face="normal" font="Arial">LA - GERCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s15007-016-1098-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s15007-016-1098-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J\20161019-SchumacherB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J\20161019-SchumacherB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Schumacher B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s15007-016-1098-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bergmann,K.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Weather conditions and climate change have an effect on allergies</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="137" start="131">131-137</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> mugwort pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> thunderstorm</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Climate change particularly affects the health of vulnerable groups, such as children, the elderly, and socially disadvantaged individuals. Asthmatics are also at greater risk from the results of climate change due to their non-specific and allergen-specific bronchial hyperreactivity. Climate change affects the production, release, and number of allergenic pollens throughout Europe. Tree pollen in particular is being seen earlier and in greater numbers, while little effect is seen on grass pollens, and mugwort pollen is showing a downward trend. The ragweed that is spreading throughout Europe is still only of regional relevance in Germany. Thunderstorm periods represent a risk for pollen asthmatics. Although little is known about changes in molds, an increase in mycelium growth and spore formation is anticipated. Warmer winters may result in changes to mite populations</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0119-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0119-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2016-25-131-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2016-25-131-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Bergmann KC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0119-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simonis,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The basophil activation test (BAT) in bakers with obstructive allergic airway disease</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="130" start="124">124-130</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> baker</style></keyword><keyword><style face="normal" font="Arial"> Bakers</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Test method</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Background: The basophil activation test (BAT) represents a sensitive test method that is available for the detection of sensitization to rye and wheat flour in bakers with obstructive allergic airway disease. Since ImmunoCAP-« failes to detect specific immunoglobulin E (IgE) in a part of the investigated bakers with airway disease, BAT should be used as an additional research method</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0117-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0117-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2016-25-124-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2016-25-124-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Simonis B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0117-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kabesch,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Epigenetic determinants of allergy and tolerance</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="159" start="154">154-159</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Not only genetics and environmental factors are responsible for the development of allergies. Epigenetic mechanisms </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çö that are master regulators of gene transcription and thus of the accessibility and use of genome information </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çö have been identified as a third power that is key in determining many features of allergy. So far, three epigenetic mechanisms have been identified in humans: histone modification, DNA methylation, and posttranscriptional modification by microRNA (miRNA) or small interfering</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0127-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0127-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2016-25-154-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2016-25-154-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Kabesch M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0127-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sennekamp,J.</style></author><author><style face="normal" font="Arial"> Juergens,L.J.</style></author><author><style face="normal" font="Arial"> Sturm,M.</style></author><author><style face="normal" font="Arial"> Juergens,U.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Extrinsic allergic alveolitis due to inhaled molds in occupational onion and potato processing: onion- and potato-sorter alveolitis</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="143" start="138">138-143</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic allergic</style></keyword><keyword><style face="normal" font="Arial"> extrinsic allergic alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Fusarium</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Onion</style></keyword><keyword><style face="normal" font="Arial"> Onions</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Potatoes</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Transportation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Only one case of occupational extrinsic allergic alveolitis due to mold inhaled during the sorting and transportation of onions and potatoes has been described in the literature to date. While having been exposed for one year the disease had healed up completely. Penicillium and Fusarium molds could be identified as cause of the extrinsic allergic alveolitis. We observed the second such patient albeit with more pronounced symptoms. We describe the patient</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs severe symptoms as well as his broader range of antibodies</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s40629-016-0125-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0125-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2016-25-138-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2016-25-138-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Sennekamp J</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s40629-016-0125-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tonti,E.</style></author><author><style face="normal" font="Arial"> Larche,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Concepts and perspectives on peptide-based immunotherapy in allergy</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="153" start="144">144-153</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peptide-based immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual administration</style></keyword><keyword><style face="normal" font="Arial"> synthetic peptides</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Allergen-specific T cells play a key role in the pathogenesis of allergic diseases through provision of help for allergen-specific B cells and control of inflammatory responses. Allergen immunotherapy using intact allergen proteins (given either subcutaneously or sublingually) is clinically effective and demonstrates enduring efficacy (i. e., disease modifying). However, the requirement for monthly injections or daily sublingual administration (both for 3 years), combined with a high frequency of local and systemic adverse events, results in poor compliance. Targeting allergen-specific T cells with synthetic peptides representing dominant T cell epitopes markedly decreases treatment times (4</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô8 intradermal injections), reduces adverse events and provides efficacy for at least 2 years. We have developed peptide immunotherapies for allergies triggered by cats, house dust mites, and grass pollen</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0126-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0126-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2016-25-144-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2016-25-144-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Tonti E</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0126-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brockow,K.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author><author><style face="normal" font="Arial"> Fischer,J.</style></author><author><style face="normal" font="Arial"> Gieler,U.</style></author><author><style face="normal" font="Arial"> Giessler-Fichtner,O.</style></author><author><style face="normal" font="Arial"> Gebert,N.</style></author><author><style face="normal" font="Arial"> Jakob,T.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Kugler,C.</style></author><author><style face="normal" font="Arial"> Reese,I.</style></author><author><style face="normal" font="Arial"> Rietschel,E.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author><author><style face="normal" font="Arial"> Schnadt,S.</style></author><author><style face="normal" font="Arial"> Siemens,C.</style></author><author><style face="normal" font="Arial"> Szczepanski,R.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Ring,J.</style></author><author><style face="normal" font="Arial"> Lange,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Supportive care of patients with anaphylaxis </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çö options and shortcomings: an assessment on behalf of the working group on anaphylaxis training and education (AGATE), Germany</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="168" start="160">160-168</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Anaphylaxis is an acute-onset, life-threatening, systemic hypersensitivity reaction. The acute reaction occurs due to a permanently immunologically altered response, which can result in mild to severe reactions and, in isolated cases, to fatal reactions upon allergen contact. The avoidance strategies required lifelong in affected individuals significantly impair quality of life</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0128-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0128-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2016-25-160-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2016-25-160-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Brockw K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0128-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodrigues,A.</style></author><author><style face="normal" font="Arial"> Gualdi,L.P.</style></author><author><style face="normal" font="Arial"> de Souza,R.G.</style></author><author><style face="normal" font="Arial"> Vargas,M.H.</style></author><author><style face="normal" font="Arial"> Nunez,N.K.</style></author><author><style face="normal" font="Arial"> da Cunha,A.A.</style></author><author><style face="normal" font="Arial"> Jones,M.H.</style></author><author><style face="normal" font="Arial"> Pinto,L.A.</style></author><author><style face="normal" font="Arial"> Stein,R.T.</style></author><author><style face="normal" font="Arial"> Pitrez,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research, Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Bacterial extract (OM-85) with human-equivalent doses does not inhibit the development of asthma in a murine model</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="511" start="504">504-511</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bacterial lysate</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="10" Year="2016">2016/10/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: OM-85 is an immunostimulant bacterial lysate, which has been proven effective in reducing the number of lower airways infections. We investigated the efficacy of the bacterial lysate OM-85 in the primary prevention of a murine model of asthma. METHODS: In the first phase of our study the animals received doses of 0.5mug, 5mug and 50mug of OM-85 through gavage for five days (days -10 to -6 of the protocol), 10 days prior to starting the sensitisation with ovalbumin (OVA), in order to evaluate the results of dose-response protocols. A single dose (5mug) was then chosen in order to verify in detail the effect of OM-85 on the pulmonary allergic response. Total/differential cells count and cytokine levels (IL-4, IL-5, IL-13 and IFN-gamma) from bronchoalveolar lavage fluid (BALF), OVA-specific IgE levels from serum, lung function and lung histopathological analysis were evaluated. RESULTS: OM-85 did not reduce pulmonary eosinophilic response, regardless of the dose used. In the phase protocol using 5mug/animal of OM-85, no difference was shown among the groups studied, including total cell and eosinophil counts in BALF, serum OVA-specific IgE, lung histopathologic findings and lung resistance. However, OM-85 decreased IL-5 and IL-13 levels in BALF. CONCLUSIONS: OM-85, administered in early life in mice in human-equivalent doses, does not inhibit the development of allergic pulmonary response in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20161006IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27707587">PM:27707587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161006-RodriguesA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161006-RodriguesA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161006, Rodrigues A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suzuki,M.</style></author><author><style face="normal" font="Arial"> Yokota,M.</style></author><author><style face="normal" font="Arial"> Nakamura,Y.</style></author><author><style face="normal" font="Arial"> Ozaki,S.</style></author><author><style face="normal" font="Arial"> Murakami,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Nagoya City University, Aichi, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Intranasal administration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="356" start="351">351-356</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal challenge</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IL-35 was recently identified as an anti-inflammatory cytokine. We previously reported that recombinant fusion protein of murine IL-35 and human IgG1 Fc fragment (rIL-35) reduced Th2 cytokines (IL-4 and IL-5) in vitro. However, it is unclear whether IL-35 can attenuate nasal allergic responses and symptoms of allergic rhinitis in vivo. METHODS: To investigate the in vivo effect of IL-35 on allergic rhinitis in mice, mice were sensitized with ovalbumin (OVA). Intranasal administration of rIL-35 and intranasal challenge of OVA were then performed. Nasal symptoms were estimated after the last nasal challenge. Nasal tissue and cervical lymph nodes (CLN) were collected. OVA-specific IgE in sera, OVA-specific T cell response, and the production of cytokines (IL-4, IL-5, and IL-10) stimulated by the OVA antigen were measured. The transcription level of Foxp3 and the frequency of CD4+CD25+ regulatory T cells were also measured. RESULTS: rIL-35 significantly inhibited the number of sneezes and nasal rubbing movements. It also reduced the number of eosinophils in the nasal mucosa and significantly decreased the level of OVA-specific IgE, the OVA-specific T cell proliferation, and the production of IL-4 and IL-5. Furthermore, rIL-35 significantly increased the production of IL-10, the transcription level of Foxp3, and the frequency of CD4+CD25+ regulatory T cells. CONCLUSIONS: This study showed for the first time that rIL-35 inhibits nasal allergic responses and symptoms in mice, and that rIL-35 increases IL-10, Foxp3, and CD4+CD25+ regulatory T cells in CLN. This study also suggests that intranasal administration of IL-35 can attenuate allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20161006IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27707583">PM:27707583</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20161006-SuzukiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20161006-SuzukiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161006, Suzuki M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Habukawa,C.</style></author><author><style face="normal" font="Arial"> Murakami,K.</style></author><author><style face="normal" font="Arial"> Sugitani,K.</style></author><author><style face="normal" font="Arial"> Ohtani,T.</style></author><author><style face="normal" font="Arial"> Saputra,G.P.</style></author><author><style face="normal" font="Arial"> Kashiyama,K.</style></author><author><style face="normal" font="Arial"> Nagasaka,Y.</style></author><author><style face="normal" font="Arial"> Wada,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Minami Wakayama Medical Center, Wakayama, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Changes in lung sounds during asthma progression in a guinea pig model</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="431" start="425">425-431</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma progression</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> progression of asthma</style></keyword><keyword><style face="normal" font="Arial"> small airways</style></keyword><keyword><style face="normal" font="Arial"> Sound</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Lung sound analysis is useful for objectively evaluating airways even in children with asymptomatic asthma. However, the relationship between lung sounds and morphological changes in the airways has not been elucidated. We examined the relationship between lung sounds and chronic morphological changes in the airways during the progression of asthma from onset in guinea pigs. METHODS: Eleven male guinea pigs were examined; of these, seven were used as asthma models and four as controls. The asthma models were sensitized and repeatedly challenged by inhaling albumin chicken egg. We measured lung sounds and lung function twice a week for 21 weeks. After the final antigen challenge, the lungs were excised for histological examination. We measured the ratio of airway wall thickness to the total airway area and the ratio of the internal area to the total airway area in the trachea, third bronchi, and terminal bronchioles. RESULTS: Among the lungs sounds, the difference between the two groups was greatest with respect to inspiratory sound intensity. The ratio of airway wall thickness to the total airway area of the terminal bronchioles was greater in the asthma models than in the controls, and it correlated best with the changes in inspiratory sound intensity in the 501-1000-Hz range (r = 0.76, p &lt; 0.003). CONCLUSIONS: Lung sound intensity in the middle frequency range from 501 to 1000 Hz correlated with peripheral airway wall thickness. Inspiratory sound intensity appeared to be an indicator of morphological changes in small airways in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.03.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27499508">PM:27499508</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\2016-65-425-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\2016-65-425-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Habukawa C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.03.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kobernick,A.K.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Active treatment for food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="395" start="388">388-395</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental ingestion</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Food allergy has grown in rapidly in prevalence, currently affecting 5% of adults and 8% of children. Management strategy is currently limited to 1) food avoidance and 2) carrying and using rescue intramuscular epinephrine/adrenaline and oral antihistamines in the case of accidental ingestion; there is no FDA approved treatment. Recently, oral, sublingual and epicutaneous immunotherapy have been developed as active treatment of food allergy, though none have completed phase 3 study. Efficacy and safety studies of immunotherapy have been variable, though there is clearly signal that immunotherapy will be a viable option to desensitize patients. The use of bacterial adjuvants, anti-IgE monoclonal antibodies, and Chinese herbal formulations either alone or in addition to immunotherapy may hold promise as future options for active treatment. Active prevention of food allergy through early introduction of potentially offending foods in high-risk infants will be an important means to slow the rising incidence of sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27638355">PM:27638355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\2016-65-388-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\2016-65-388-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Kobernick AK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ebisawa,M.</style></author><author><style face="normal" font="Arial"> Izuhara,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Clinical Research Center for Allergology and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy: Current perspectives</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="362" start="361">361-362</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - EDITORIALCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27692283">PM:27692283</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\2016-65-361-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\2016-65-361-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Ebisawa M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ronmark,E.</style></author><author><style face="normal" font="Arial"> Warm,K.</style></author><author><style face="normal" font="Arial"> Bjerg,A.</style></author><author><style face="normal" font="Arial"> Backman,H.</style></author><author><style face="normal" font="Arial"> Hedman,L.</style></author><author><style face="normal" font="Arial"> Lundback,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Clinical Medicine, Division of Occupational and Environmental Medicine, the OLIN</style></auth-address><titles><title><style face="normal" font="Arial">High incidence and persistence of airborne allergen sensitization up to age 19 years</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="730" start="723">723-730</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Order</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> OLIN</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Longitudinal population-based studies about the natural history of allergic sensitization are rare. The aim was to study incidence and persistence of airborne allergen sensitization up to young adulthood, and risk factors for early and late onset of sensitization. METHODS: All children aged 7-8 years in two municipalities in Northern Sweden were invited to a parental questionnaire and skin prick tests (SPT) to ten airborne allergens, and 2,148 (88%) participated. The protocol was repeated at age 11-12 and 19 years, and 1,516 participated in all three examinations. RESULTS: Prevalence of any positive SPT increased from 20.6% at age 7-8y to 30.6% at 11-12y, and 42.1% at 19y. Animals were the primary sensitizers at age 7-8y, 16.3%, followed by pollen, 12.4%. Mite and mold sensitization was low. Mean annual incidence of any positive SPT varied between 2.8-3.4/100/year, decreased by age for animal and was stable for pollen. Sensitization before age 7-8y was independently associated with family history of allergy, OR 2.1(95%CI 1.6-2.8), urban living, OR 1.9(95%CI 1.2-2.9), and male sex, OR 1.3(95%CI 1.0-1.7), and negatively associated with birth order, OR 0.8(95%CI 0.7-1.0) and furry animals at home, OR 0.7(95%CI 0.7-0.9). Incidence after age 11-12y was associated only with family history of allergy. Multi-sensitization at age 19y was significantly associated with early age at sensitization. Remission of sensitization was uncommon. CONCLUSION: The increasing prevalence of allergic sensitization by age was explained by high incidence and persistence. After age 11-12y the factors urban living, number of siblings and male sex lost their importance. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27659134">PM:27659134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160923-LonmarkE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160923-LonmarkE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Ronmark E</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dugue,P.A.</style></author><author><style face="normal" font="Arial"> Geurts,Y.M.</style></author><author><style face="normal" font="Arial"> Milne,R.L.</style></author><author><style face="normal" font="Arial"> Lockett,G.A.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Karmaus,W.</style></author><author><style face="normal" font="Arial"> Holloway,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Is there an association between season of birth and blood DNA methylation in adulthood?</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1504" start="1501">1501-1504</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - LetterSB - IMCO - Australia -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12949</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27624707">PM:27624707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\2016-71-1501-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\2016-71-1501-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Dugue PA</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12949</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bieber,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, University Medical Center, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Why we need a harmonized name for atopic dermatitis/atopic eczema/eczema!</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1380" start="1379">1379-1380</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160914IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - EditorialSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12984</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27624706">PM:27624706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\2016-71-1379-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\2016-71-1379-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160914, Bieber T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12984</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grabenhenrich,L.B.</style></author><author><style face="normal" font="Arial"> Reich,A.</style></author><author><style face="normal" font="Arial"> Bellach,J.</style></author><author><style face="normal" font="Arial"> Trendelenburg,V.</style></author><author><style face="normal" font="Arial"> Sprikkelman,A.B.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Grimshaw,K.</style></author><author><style face="normal" font="Arial"> Sigurdardottir,S.</style></author><author><style face="normal" font="Arial"> Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author><author><style face="normal" font="Arial"> Dubakiene,R.</style></author><author><style face="normal" font="Arial"> Niggemann,B.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Ballmer-Weber,B.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Schnadt,S.</style></author><author><style face="normal" font="Arial"> Mills,E.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Social Medicine, Epidemiology and Health Economics, Charite - Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">A new framework for the documentation and interpretation of oral food challenges in population-based and clinical research</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="461" start="453">453-461</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Decision Making</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dietician</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The conduct of oral food challenges as the preferred diagnostic standard for food allergy was harmonized over the last years. However, documentation and interpretation of challenge results, particularly in research settings, are not sufficiently standardized to allow valid comparisons between studies. Our aim was to develop a diagnostic toolbox to capture and report clinical observations in double-blind placebo-controlled food challenges (DBPCFC). METHODS: A group of experienced allergists, paediatricians, dieticians, epidemiologists and data managers developed generic case report forms and standard operating procedures for DBPCFCs, and piloted them in three clinical centres. The follow-up of the EuroPrevall/iFAAM birth cohort and other iFAAM work packages currently apply these methods. RECOMMENDATIONS: A set of newly developed questionnaire or interview items capture the history of food allergy. Together with sensitization status, this forms the basis for the decision to perform a DBPCFC, following a standardized decision algorithm. A generic form including details about severity and timing captures signs and symptoms observed during or after the procedures. In contrast to the commonly used dichotomous outcome food allergy versus no food allergy, the allergy status is interpreted in multiple categories to reflect the complexity of clinical decision making. CONCLUSION: The proposed toolbox sets a standard for improved documentation and harmonized interpretation of DBPCFCs. By a detailed documentation and common terminology for communicating outcomes, these tools hope to reduce the influence of subjective judgment of supervising physicians. All forms are publicly available for further evolution and free use in clinical and research settings. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Netherlands -CO - United Kingdom -CO - Greece -CO - Spain -CO - Iceland -CO - Poland -CO - Switzerland -CO - Lithuania -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27670637">PM:27670637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160927-GrabenhenrichLB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160927-GrabenhenrichLB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Grabenhenrich LB</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Polloni,L.</style></author><author><style face="normal" font="Arial"> Ferruzza,E.</style></author><author><style face="normal" font="Arial"> Ronconi,L.</style></author><author><style face="normal" font="Arial"> Toniolo,A.</style></author><author><style face="normal" font="Arial"> Lazzarotto,F.</style></author><author><style face="normal" font="Arial"> Bonaguro,R.</style></author><author><style face="normal" font="Arial"> Celegato,N.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Referral Centre for Diagnosis and Treatment, Veneto Region, Department of Women and Child Health, Padua University Hospital, Padua, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of children's nutritional attitudes before oral food challenges to identify patients at risk of food reintroduction failure: a prospective study</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="736" start="731">731-736</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food reintroduction</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Inappropriate dietary eliminations may impair quality of life, affect children's growth and unnecessarily impact on healthcare costs. Previous retrospective studies reported that around 25% of children continue a food-avoidance diet despite a negative oral food challenge (OFC). A definite pattern has not been found yet for patients not reintroducing the food. This study aimed to examine the role of child's nutritional attitudes and maternal anxiety in reintroducing food after a negative OFC. METHODS: A prospective study was conducted involving 81 mothers of children with IgE-mediated food allergy. They completed a survey on nutritional behaviour and attitudes and the State-Trait Anxiety Inventory on the day of OFC and 6 months later. RESULTS: In total, 11.1% of children never or rarely ate the food after a negative OFC. Consumption of the reintroduced food is positively correlated to child's interest in tasting new foods before and after OFC and to changes in child's nutritional habits after OFC. It is negatively correlated to monotony of the diet after OFC. No correlations were found with other participants' characteristics or maternal anxiety. State anxiety significantly decreased after the OFC. A correlation was found between trait and state anxiety and the degree of change in nutritional habits after OFC. CONCLUSIONS: Evaluating child's approach towards food before the OFC is a promising approach to identify patients at risk of food reintroduction failure. Furthermore, it underlined the importance of reassessing food consumption in all patients after a negative OFC and supporting patients in the reintroduction of food</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27659406">PM:27659406</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160923-PolloniL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160923-PolloniL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Polloni L</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Onell,A.</style></author><author><style face="normal" font="Arial"> Whiteman,A.</style></author><author><style face="normal" font="Arial"> Nordlund,B.</style></author><author><style face="normal" font="Arial"> Baldracchini,F.</style></author><author><style face="normal" font="Arial"> Mazzoleni,G.</style></author><author><style face="normal" font="Arial"> Hedlin,G.</style></author><author><style face="normal" font="Arial"> Gronlund,H.</style></author><author><style face="normal" font="Arial"> Konradsen,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Microtest Dx, 56 Wood Lane, London, W12 7SB, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergy testing in children with persistent asthma: Comparison of four diagnostic methods</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="597" start="590">590-597</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Respiratory sensitization</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wood</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Multiple allergic sensitizations are common in persistent childhood asthma, and thorough assessment of allergy is crucial for optimal care of these children. Microarray testing offers opportunities for improved sIgE characterization, which has been projected to be useful in the management of multi-sensitized patients. OBJECTIVE: The aim of this study was to investigate the accuracy and information obtained by two microarray platforms applied on a well-characterized pediatric asthma cohort. METHODS: Seventy-one (71) children were recruited from a nationwide Swedish study on severe childhood asthma. Severe (n = 40) and controlled (n = 31) asthmatics were assessed for allergic sensitization by two microarray systems (Microtest and ISAC) and by two standard diagnostic methods (ImmunoCAP and skin prick test). Data on clinical history, physical examination, spirometry, asthma control test and doctor's diagnosis were collected. Results from the four diagnostic methods were analyzed and compared. RESULTS: A high prevalence of allergic sensitization was observed in this cohort. The pairwise concordance between two methods was 90-92% independently of methods compared. The sensitivity of the four methods against doctor's diagnosis was 0.77-0.88, and the specificity was 0.97-0.99. Microarray methods provided new information in 47% of the sensitized children in comparison to results obtained by standard diagnostic methods. CONCLUSION: The high prevalence of food and respiratory sensitization supports the clinical guideline recommendation that allergies should be evaluated in all children with suspected asthma. The microarray platforms studied here demonstrated acceptable accuracy and provided refined IgE characterization in 47% of the patients compared to standard extract-based methods. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27638292">PM:27638292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160917-OnellA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160917-OnellA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Onell A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lange,L.</style></author><author><style face="normal" font="Arial"> Lasota,L.</style></author><author><style face="normal" font="Arial"> Finger,A.</style></author><author><style face="normal" font="Arial"> Vlajnic,D.</style></author><author><style face="normal" font="Arial"> Busing,S.</style></author><author><style face="normal" font="Arial"> Meister,J.</style></author><author><style face="normal" font="Arial"> Brockaert,I.</style></author><author><style face="normal" font="Arial"> Pfannenstiel,C.</style></author><author><style face="normal" font="Arial"> Friedrichs,F.</style></author><author><style face="normal" font="Arial"> Price,M.</style></author><author><style face="normal" font="Arial"> Trendelenburg,V.</style></author><author><style face="normal" font="Arial"> Niggemann,B.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">St. Marien-Hospital, Dept. of Pediatrics, Bonn, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Ana o 3-specific IgE is a good predictor for clinically relevant cashew allergy in children</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="603" start="598">598-603</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ana o 3</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Cashew allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Component resolved diagnostics using specific IgE to 2 S albumins has shown to be a valuable new option in diagnostic procedure. Ana o 3 is a 2 S albumin from cashew. Aim of this study was to investigate the role of Ana o 3 specific serum IgE in the diagnosis of cashew allergy and to identify cut-off levels to replace oral food challenges. Moreover, the value of additional determination of total IgE has been investigated. METHODS: In a multicentre study we analysed specific IgE to cashew extract and Ana o 3 as well as total IgE in children with suspected cashew allergy using the ImunoCAP-FEIA and a standardized diagnostic procedure including oral challenges where indicated. RESULTS: 61 patients were included in the study. 42 were allergic to cashew, 19 were tolerant. In receiver operating curves Ana o 3 discriminates between allergic and tolerant children better than cashew-specific IgE with an area under the curve of 0.94 versus 0.78. The ratio of Ana o 3-specific IgE to total IgE did not further improve the diagnostic. Probability curves for Ana o 3-specific IgE has been calculated and a 95% probability could be estimated at 2.0 kU/l. CONCLUSION: Specific IgE to Ana o 3 is a valuable tool for the diagnosis of cashew allergy. Considering its positive predictive value it might allow to make a considerable number of oral challenges superfluous. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27644013">PM:27644013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20160919-LangeL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20160919-LangeL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Lange L</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wartna,J.B.</style></author><author><style face="normal" font="Arial"> Bohnen,A.M.</style></author><author><style face="normal" font="Arial"> Elshout,G.</style></author><author><style face="normal" font="Arial"> Pijnenburg,M.W.</style></author><author><style face="normal" font="Arial"> Pols,D.H.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.R.</style></author><author><style face="normal" font="Arial"> Bindels,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of General Practice, Erasmus MC, 3000, CA, Rotterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Symptomatic treatment of pollen-related allergic rhinoconjunctivitis in children: randomized controlled trial</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="644" start="636">636-644</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> fluticasone propionate</style></keyword><keyword><style face="normal" font="Arial"> General practice</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: About 12% of children are affected by allergic rhinoconjunctivitis (AR). Although the main symptomatic treatments are intranasal corticosteroids (INCS) (daily or on demand) and oral antihistamines, it remains unclear which treatment provides the best relief of symptoms. Therefore, this study examines whether daily use of INCS is superior to on demand use, or to oral antihistamines on demand. METHODS: A single-blinded randomized controlled trial in children (aged 6-18 years) with pollen-related AR. Patients received either INCS daily (fluticasone propionate), INCS on demand (fluticasone propionate), or oral antihistamine on demand (levocetrizine) for three months during the grass pollen season. A daily online symptom diary on both nose and eye symptoms was completed. The primary outcome was the percentage of symptom-free days. RESULTS: A total of 150 children were randomized. The percentage symptom-free days was in favour of INCS on demand (30%) compared with INCS daily (22%), i.e. 8% difference (95% CI -5 to +21%; not significant). The antihistamine on demand group had 15% symptom-free days; i.e. 7% difference compared to INCS daily (95% CI -6 to +19%;, not significant). Patients in the INCS on demand group used on average 61% less fluticasone than patients in the INCS daily group during the study period (p&lt;0.0001). CONCLUSIONS: This trial with three parallel treatment groups shows that INCS daily was not superior to INCS on demand or to antihistamine on demand regarding the number of symptom-free days. An on-demand INCS strategy has the advantage of a lower overall corticosteroid exposure and less costs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27696447">PM:27696447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161003-WartnaJB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161003-WartnaJB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Wartna JB</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13056</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ravanetti,L.</style></author><author><style face="normal" font="Arial"> Dijkhuis,A.</style></author><author><style face="normal" font="Arial"> Sabogal Pineros,Y.S.</style></author><author><style face="normal" font="Arial"> Bal,S.M.</style></author><author><style face="normal" font="Arial"> Dierdorp,B.S.</style></author><author><style face="normal" font="Arial"> Dekker,T.</style></author><author><style face="normal" font="Arial"> Logiantara,A.</style></author><author><style face="normal" font="Arial"> Adcock,I.M.</style></author><author><style face="normal" font="Arial"> Rao,N.L.</style></author><author><style face="normal" font="Arial"> Boon,L.</style></author><author><style face="normal" font="Arial"> Villetti,G.</style></author><author><style face="normal" font="Arial"> Sterk,P.J.</style></author><author><style face="normal" font="Arial"> Facchinetti,F.</style></author><author><style face="normal" font="Arial"> Lutter,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Immunology, Academic Medical Centre, Amsterdam, 1105AZ, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">An early innate response underlies severe influenza-induced exacerbations of asthma in a novel steroid-insensitive and anti-IL-5 responsive mouse model</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="753" start="737">737-753</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> fluticasone propionate</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza virus</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viruses</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Acute worsening of asthma symptoms (exacerbation) is predominantly triggered by respiratory viruses, with influenza causing the most severe exacerbations. The lack of an adequate animal model hampers mechanistic insight and the development of new therapeutics. AIM: We developed and characterized a robust, consistent and reproducible mouse model of severe exacerbation of chronic allergic asthma. METHODS: Chronic allergic airway inflammation was induced following a house dust mite (HDM)-sensitization protocol. HDM-sensitized mice and controls were infected with influenza virus A/X31 H3N2 and either or not treated with inhaled Fluticasone Propionate (FP), systemic corticosteroids (Pred) or anti-IL5. Mice were sacrificed at different time points after infection: cellular accumulation and cytokines levels in the airways; PenH as a measure of airway hyperresponsiveness (AHR); lung histology and viral replication were assessed. RESULTS: Infection with low dose A/X31 H3N2 led to prolonged deterioration of lung function, aggravated mucus production, peri-vascular, peri-bronchial and allergic inflammation that was unresponsive to inhaled corticosteroids, but responsive to systemic corticosteroids. The exacerbation was preceded at 14h after virus exposure by a marked innate, but no Th2 and Th1 response, subsequently followed by enhanced numbers of eosinophils, neutrophils, dendritic and T cells into the lung lumen, parenchyma and draining lymph nodes in HDM-sensitized mice. Anti-IL-5 treatment attenuated eosinophils and prevented the X31-induced exacerbation. CONCLUSIONS: Together these findings indicate that an early innate response that involves eosinophils underlies the exacerbation. This model recapitulates all major features of severe asthma exacerbations and can serve to discern driving mechanisms and promote development of novel therapeutics. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -CO - United States -CO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13057</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27696462">PM:27696462</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161003-RavanettiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161003-RavanettiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Ravanetti L</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13057</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Muraro,A.</style></author><author><style face="normal" font="Arial"> Steelant,B.</style></author><author><style face="normal" font="Arial"> Pietikainen,S.</style></author><author><style face="normal" font="Arial"> Borrelli,D.</style></author><author><style face="normal" font="Arial"> Childers,N.</style></author><author><style face="normal" font="Arial"> Callebaut,I.</style></author><author><style face="normal" font="Arial"> Kortekaas Krohn,I.</style></author><author><style face="normal" font="Arial"> Martens,K.</style></author><author><style face="normal" font="Arial"> Pugin,B.</style></author><author><style face="normal" font="Arial"> Dan-Popescu,F.</style></author><author><style face="normal" font="Arial"> Vieru,M.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua.</style></auth-address><titles><title><style face="normal" font="Arial">European symposium on the awareness of allergy: report of the promotional campaign in the European Parliament (April 26-28, 2016)</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="176" start="173">173-176</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">From the 26th to the 28th of April 2016, an allergy awareness campaign was organized by the European Academy of Allergy and Clinical Immunology (EAACI) and the European Federation of Allergy and Airway Diseases Patients Associations (EFA) in the European Parliament in Brussels, with support of the European Parliament's Interest group on Allergy and Asthma and was co-hosted by the Members of the European Parliament (MEP) David Borrelli, Sirpa Pietikainen and Nessa Childers. Skin prick tests (SPT) were performed to gain attention for the increasing prevalence of allergic airways diseases in Europe. Since more than 30% of the total European population suffers from airways allergies and asthma, reaching a higher level of awareness and elaboration of an active prevention plan is mandatory. Of the 406 individuals undergoing SPT in the European Parliament, 211 participants (52%) reported to have suffered from an allergy in the past, with allergic symptoms being present in the nose and eyes (40% and 36% respectively), the skin (27%), lower airways (14%) and the gut (8%). Of the 381 SPT with reliable results, cutaneous hypersensitivity was found in 201 (53%) participants. Of those with positive SPT (n=201), 70 participants (35%) were monosensitized while 131 participants (65%) were polysensitized. The positive skin reactions were found mostly for grass pollen (n=108), followed by Dermatophagoides pteronyssinus (n=105), Dermatophagoides farina (n=96) and birch pollen (n=85). Of note, 54 individuals (14% of the total tested population) without reported allergy or allergic symptoms, showed a positive SPT without clinical relevance. This report summarizes the main idea and goals of the symposium: chronic airway diseases are a major and growing health problem in Europe. Therefore a joint preventive action plan needs to be developed for a better health status of European citizens. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -CO - Belgium -CO - Romania -CO - Poland -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27696452">PM:27696452</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161003-MuraroA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161003-MuraroA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Muraro A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13058</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barber,C.</style></author><author><style face="normal" font="Arial"> Kalicinsky,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Section of Clinical Immunology and Allergy, University of Manitoba, Winnipeg, MB Canada</style></auth-address><titles><title><style face="normal" font="Arial">A novel combination of an IgE mediated adult onset food allergy and a suspected mast cell activation syndrome presenting as anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="46">46-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Adult onset food allergy is a rare, but increasingly recognized phenomenon. Mast cell activation syndromes present an ongoing diagnostic and classification challenge. The combination of the two has been rarely described in the literature. CASE PRESENTATION: We present a case of a new onset, IgE mediated food allergy in combination with a mast cell activation syndrome in an elderly patient not known to have a history of atopy. He presented to a hospital with a first presentation of anaphylaxis manifesting profound hypotension following consumption of a stew consisting of fish and shellfish. He had a persistently elevated serum tryptase and demonstrated evidence of high titre serum specific IgE to shellfish. He responded well to histaminergic blockade. CONCLUSIONS: Given that mast cell activation syndromes pose an increased risk for recurrent, severe anaphylaxis and that secondary causes of mast cell activation syndromes are more prevalent with aging, this case highlights the importance of considering this entity when evaluating an elderly patient with a first presentation of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - ENGPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0151-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27660640">PM:27660640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Barber C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0151-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Magen,E.</style></author><author><style face="normal" font="Arial"> Zueva,E.</style></author><author><style face="normal" font="Arial"> Mishal,J.</style></author><author><style face="normal" font="Arial"> Schlesinger,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Leumit Health Services, Ashdod, Israel</style></auth-address><titles><title><style face="normal" font="Arial">The clinical and laboratory characteristics of acute spontaneous urticaria and its progression to chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="399" start="394">394-399</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antinuclear antibodies</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid function</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Function Tests</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The natural history of the progression from acute spontaneous urticaria (ASU) to chronic spontaneous urticaria (CSU), CSU remains poorly understood. OBJECTIVE: To identify clinical and laboratory patient attributes that may be predictive of ASU progression to CSU. METHODS: We prospectively studied consecutive adult patients (age >/= 18 years) with a diagnosis of urticaria of &lt;6 weeks' duration. Healthy age- and sex-matched subjects served as controls. At study entry, autologous serum skin test (ASST), complete blood cell count, erythrocyte sedimentation rate, thyroid function tests, antinuclear antibodies, antithyroglobulin and antiperoxidase antibodies, and immunoglobulin E level were assessed in all the subjects. ASST and urticaria activity score assessment were performed in all the patients at baseline and then at weeks 7, 12, 24, and 48. RESULTS: Of 114 patients with acute urticaria and without identifiable causes, 73 patients (64%) were included in the ASU group, 41 patients in the CSU group (36%), and 44 healthy subjects in the control group. At baseline, 26 patients in the CSU group (63.4%) had a positive ASST result, whereas only 17 patients with a positive ASST result (23.3%) were revealed in the ASU group (p &lt; 0.001). Patients with baseline ASST positive results were characterized by more profound basopenia (mean [standard deviation], 0.05 +/- 0.08 cell/mm(3)) and more anti-thyroid peroxidase antibodies (18 [41.8%]) than those with the negative baseline ASST result (mean [standard deviation], 0.13 +/- 0.09 cell/mm(3), p &lt; 0.001 more profound basopenia; and 13 (18.1%), p = 0.009 more thyroid peroxidase antibodies). We observed the disappearance of ASST positive result in some patients with CSU with baseline positive ASST results, whereas, in some subjects with CSU, baseline negative ASST results came to be positive results throughout the study period. A baseline positive ASST result of patients with ASU was a significant determinant (odds ratio 5.91 [95% confidence interval, 2.57-13.62]; p &lt; 0.001) for a CSU diagnosis at week 7. CONCLUSION: The patients with ASU who progressed toward CSU were characterized by a positive ASST result, thyroid autoimmunity, and profound basopenia at baseline</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3971</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27657523">PM:27657523</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-394-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-394-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Magen E</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3971</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zelig,A.</style></author><author><style face="normal" font="Arial"> Harwayne-Gidansky,I.</style></author><author><style face="normal" font="Arial"> Gault,A.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Montefiore Medical Center, Bronx, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Effect of educational and electronic medical record interventions on food allergy management</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="408" start="404">404-408</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency action plan</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcome measurement</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> self-injectable</style></keyword><keyword><style face="normal" font="Arial"> self-injectable epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The growing prevalence of food allergies indicates a responsibility among primary care providers to ensure that their patients receive accurate diagnosis and management. OBJECTIVE: To improve physician knowledge and management of food allergies by implementing educational and electronic medical record interventions. METHODS: Pre- and posttest scores of pediatric residents and faculty were analyzed to assess the effectiveness of an educational session designed to improve knowledge of food allergy management. One year later, a best practice advisory was implemented in the electronic medical record to alert providers to consider allergy referral whenever a diagnosis code for food allergy or epinephrine autoinjector prescription was entered. A review of charts 6 months before and 6 months after each intervention was completed to determine the impact of both interventions. Outcome measurements included referrals to an allergy clinic, prescription of self-injectable epinephrine, and documentation that written emergency action plans were provided. RESULTS: There was a significant increase in test scores immediately after the educational intervention (mean, 56.2 versus 84.3%; p &lt; 0.001). Posttest scores remained significantly higher than preintervention scores 6 months later (mean score, 68.0 versus 56.2%; p = 0.006). Although knowledge improved, there was no significant difference in the percentage of patients who were provided allergy referral, were prescribed an epinephrine autoinjector, or were given an emergency action plan before and after both interventions. CONCLUSION: Neither intervention resulted in improvements in the management of children with food allergies at our pediatrics clinic. Further studies are needed to identify effective strategies to improve management of food allergies by primary care physicians</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3970</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27657525">PM:27657525</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-404-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-404-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Zelig A</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3970</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pajno,G.B.</style></author><author><style face="normal" font="Arial"> Caminiti,L.</style></author><author><style face="normal" font="Arial"> Chiera,F.</style></author><author><style face="normal" font="Arial"> Crisafulli,G.</style></author><author><style face="normal" font="Arial"> Salzano,G.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy Unit, University of Messina, Messina, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Safety profile of oral immunotherapy with cow's milk and hen egg: A 10-year experience in controlled trials</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="403" start="400">400-403</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oral immunotherapy (OIT) for food allergy is gaining interest due to the favorable clinical results reported with cow's milk, hen egg and peanut. The safety of the procedure remains a critical aspect that can limit the introduction of OIT in clinical practice. OBJECTIVE: We described herein, in detail, the occurrence and characteristics of adverse events (AE) with OIT in children who participated in controlled trials at our unit. METHODS: The clinical records of 68 children who received active treatment (40 for cow's milk and 28 for hen egg) were carefully reviewed. The inclusion and exclusion criteria, and the grading of AEs were the same across the trials. Of the 68 children involved, 6 (9%) had to discontinue the OIT procedure due to severe AEs. Fifty percent of the children underwent the buildup and maintenance phases without AEs. Mild-to-moderate AEs were documented in 28 patients, who could complete the desensitization. The majority of reactions were mild or moderate, occurred during an acute intercurrent illness and required only symptomatic treatment. CONCLUSION: A careful review of the patients who received food OIT in controlled trials confirmed that AEs were not rare but that approximately 90% of children could achieve an effective desensitization. The procedure remains investigational and should be performed only by trained physicians, especially in the pediatric setting</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3980</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27657524">PM:27657524</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-400-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-400-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Pajno GB</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3980</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vandjelovic,N.D.</style></author><author><style face="normal" font="Arial"> Humphreys,I.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1Department of Otolaryngology-Head and Neck Surgery, Michigan State University, Detroit Medical Center, Detroit, Michigan, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin G4-related sclerosing disease of the paranasal sinuses: A case report and literature review</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="89" start="85">85-89</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Epistaxis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G4</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2016">2016/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Immunoglobulin G4 (IgG4) related sclerosing disease (RSD) of the paranasal sinuses is a rare lesion of dense lymphoplasmacytic tissue, with a high proportion of IgG4+ plasma cells. We presented a rare case of IgG4-RSD with isolated involvement of the paranasal sinuses in the absence of multiorgan involvement. METHODS: A case report and comprehensive literature review. RESULTS: To our knowledge, only 11 cases of IgG4-RSD with paranasal sinus involvement have been reported. Patients with IgG4-RSD commonly present with epistaxis and symptoms that mimic chronic rhinosinusitis, e.g., rhinorrhea, nasal obstruction, and facial pressure. On imaging, an expansive and erosive process is described. Surgery provides tissue for immunohistologic evaluation; however, there is a paucity of evidence about the direct extent of surgical resection or medical therapies. Postoperative steroids were typically started, although the regimen was not standardized. CONCLUSION: Few cases of paranasal sinus IgG4-RSD have been reported in the literature. Evidence-based recommendations regarding treatment and surveillance of paranasal sinus IgG4-RSD are lacking; however, most reports describe systemic steroids as the mainstay of treatment. This single subject analysis, with a review of previously reported cases adds to the expanding body of data related to this rare disorder</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27658185">PM:27658185</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-85-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-85-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Vandjelovic ND</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0154</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Otsuka,H.</style></author><author><style face="normal" font="Arial"> Tsukagoshi,H.</style></author><author><style face="normal" font="Arial"> Kimura,H.</style></author><author><style face="normal" font="Arial"> Takanashi,I.</style></author><author><style face="normal" font="Arial"> Okubo,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Otsuka ENT Clinic, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Are respiratory viruses involved in preseasonal symptoms or severity in Japanese cedar pollinosis?</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="68" start="62">62-68</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human metapneumovirus</style></keyword><keyword><style face="normal" font="Arial"> Human rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Preseasonal</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viral infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viruses</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> shedding</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2016">2016/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Respiratory virus infections are involved in asthma exacerbations. However, there are no reports of the relationship between respiratory virus infections and Japanese cedar pollinosis. OBJECTIVE: We studied the relationship between respiratory viral infection and the appearance of preseasonal symptoms and the severity of seasonal symptoms in Japanese cedar pollinosis. METHODS: In 36 patients with asthma and with no symptoms (PreAsyP) and 54 patients with asthma and with symptoms (PreSyP) before the cedar pollen shedding commenced (preseason), and 37 patients with mild-to-moderate severity (InMild/Mod) and 45 patients with severe to extreme severity (InSev/Ext) after cedar shedding commenced (in season), the occurrence of respiratory viruses and nasal smear cytology were examined. RESULTS: In total, seven infections with respiratory viruses were detected among the subjects. Human rhinovirus (HRV) C infection was detected in one subject in each of the PreAsyP and PreSyP groups, and one HRVA infection occurred in the InMild/Mod group. In the InSev/Ext group, one HRVA, one HRVC, one respiratory syncytial virus, and one human metapneumovirus were detected. There was no significant difference in the rate of detection of viral infections between the PreAsyP and the PreSyP groups (p = 0.077), and between the InMild/Mod group and the InSev/Ext group (p = 0.24, Wilcoxon rank sum test). When cells types in nasal smears were identified and their abundance examined, the rate of neutrophilia in the subjects in the PreSyP group was 54%, which was statistically higher (p &lt; 0.01) than the subjects in the PreAsyP group (25%). Interestingly, in the subjects in the InSev/Ext group, the proportion of eosinophils (40%) was larger (p &lt; 0.05) than in the subjects in the InMild/Mod group (19%). CONCLUSION: These results provided no evidence that respiratory virus infections contributed to preseasonal symptoms and severity in season of Japanese cedar pollinosis. Nasal neutrophilia was related to preseasonal symptoms, whereas nasal eosinophilia was related to severity of symptoms during the pollen season</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0157</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27658182">PM:27658182</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-62-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-62-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Otsuka H</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0157</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shah,A.</style></author><author><style face="normal" font="Arial"> Armstrong-James,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 National Heart and Lung Institute Imperial College London London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Opportunist Turns Allergen: Double Life of Pneumocystis jirovecii in Asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="780" start="779">779-780</pages><volume><style face="normal" font="Arial">194</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pneumocystis jirovecii</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="1" Month="10" Year="2016">2016/10/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201603-0641ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27689700">PM:27689700</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2016-194-779-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2016-194-779-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Shah A</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201603-0641ED</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zicari,A.M.</style></author><author><style face="normal" font="Arial"> Occasi,F.</style></author><author><style face="normal" font="Arial"> Di Fraia,M.</style></author><author><style face="normal" font="Arial"> Mainiero,F.</style></author><author><style face="normal" font="Arial"> Porzia,A.</style></author><author><style face="normal" font="Arial"> Galandrini,R.</style></author><author><style face="normal" font="Arial"> Giuffrida,A.</style></author><author><style face="normal" font="Arial"> Bosco,D.</style></author><author><style face="normal" font="Arial"> Bertin,S.</style></author><author><style face="normal" font="Arial"> Duse,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sapienza University of Rome, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Local allergic rhinitis in children: Novel diagnostic features and potential biomarkers</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="334" start="329">329-334</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation test</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Lolium</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen provocation test</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinomanometry</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Local allergic rhinitis (LAR) is a phenotype of rhinitis that has been poorly studied in children. It is characterized by the same symptoms of allergic rhinitis but with the absence of markers of systemic atopy. OBJECTIVE: To identify children affected by LAR and to analyze the pathogenesis of this disease. We chose to focus our attention on interleukin (IL) and thymic stromal lymphopoietin (TSLP). METHODS: We enrolled 20 children affected by nonallergic rhinitis (negative skin-prick test results and serum specific immunoglobulin E [sIgE] values). Each patient underwent a nasal allergen provocation test (NAPT) with dust mite and grass pollen. Before and after NAPT, nasal lavage was performed to detect sIgE, IL-5, and TSLP; anterior active rhinomanometry was used to evaluate changes in nasal obstruction. RESULTS: Two patients were positive to a nonspecific NAPT and, thus, were excluded from the study. Of the remaining 18 children, 12 (66.7%) had positive results to at least one NAPT. Among these 12 patients, nasal sIgE levels for Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Lolium perenne increased significantly after NAPT (D. pteronyssinus, p &lt; 0.005; D. farinae, p &lt; 0.05; L. perenne, p &lt; 0.05). Nasal IL-5 levels showed a significant increase after NAPT (p &lt;/= 0.006), and this increase was significantly higher in children who had positive NAPT results than in those patients with negative NAPT results (p &lt;/= 0.03). Among the 12 children who had a positive NAPT result, nasal TSLP was detected in 4 patients (33.3%) and its levels showed a relevant increase after NAPT, even though the difference did not reach statistical significance (p &lt;/= 0.061). CONCLUSION: Observed results raise the importance of better refining the diagnostic protocol for LAR in children. Nasal TSLP and IL-5 levels offer new insights concerning localized allergic inflammation, although the role of nasal sIgE has still to be clarified</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27657898">PM:27657898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-329-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-329-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Zicari AM</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4352</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,X.Y.</style></author><author><style face="normal" font="Arial"> Zhang,L.X.</style></author><author><style face="normal" font="Arial"> Tian,C.J.</style></author><author><style face="normal" font="Arial"> Tang,X.Y.</style></author><author><style face="normal" font="Arial"> Zhao,L.M.</style></author><author><style face="normal" font="Arial"> Guo,Y.L.</style></author><author><style face="normal" font="Arial"> Cheng,D.J.</style></author><author><style face="normal" font="Arial"> Chen,X.L.</style></author><author><style face="normal" font="Arial"> Ma,L.J.</style></author><author><style face="normal" font="Arial"> Chen,Z.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, People's Hospital Affiliated to Zhengzhou University Zhengzhou 450003, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">LncRNAs BCYRN1 promoted the proliferation and migration of rat airway smooth muscle cells in asthma via upregulating the expression of transient receptor potential 1</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="3418" start="3409">3409-3418</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cell migration</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Immunoprecipitation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> noncoding RNAs</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Long noncoding RNAs (lncRNAs) played important roles in several biological processes through regulating the expression of protein. However, the function of lncRNA BCYRN1 in airway smooth muscle cells (ASMCs) has not been reported. METHODS: Male Sprague-Dawley (SD) rats were divided into control and asthma groups and the ovalbumin (OVA) model was constructed. The expression of BCYRN1 and transient receptor potential 1 (TRPC1) were detected in the ASMCs separated from these rats. Then 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-1) assay, Roche real-time cell analyzer (RTCA) DP assay and Transwell cell migration assay were performed to detect the effect of BCYRN1 on the viability/proliferation and migration of ASMCs. RNA pull-down assays and RNA immunoprecipitation assay were used to identify and verify the binding between BCYRN1 and TRPC1. Inspiratory resistance and expiratory resistance were measured in OVA challenged rats with BCYRN1 knockdown. RESULTS: We foundthe high expression of BCYRN1 and TRPC1 in asthma groups and ASMCs treated with PDGF-BB. Overexpression of BCYRN1 greatly promoted the proliferation and migration of ASMCs. In addition,TRPC1 overexpression reversed the function of si-BCYRN1 indecreasing the viability/proliferation and migration of ASMCs treated with PDGF-BB. BCYRN1 could up-regulate the protein level of TRPC1 through increasing the stability of TRPC1. Finally, we found that BCYRN1 knockdown reduced the inspiratory resistance and expiratory resistance in OVA challenged rats. CONCLUSION: Our study indicated that BCYRN1 promotedthe proliferation and migration of rat ASMCs in asthma via upregulating the expression of TRPC1</style></abstract><notes><style face="normal" font="Arial">DA - 20160920LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27648131">PM:27648131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2016-8-3409-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2016-8-3409-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Zhang XY</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yee,K.F.</style></author><author><style face="normal" font="Arial"> Wasowicz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Health Network, Toronto General Hospital, Canada. marcin.wasowicz@uhn.ca</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis and cardiac surgery for hypertrophic obstructive cardiomyopathy: a case report and review of anaesthetic management</style></title><secondary-title><style face="normal" font="Arial">Anaesthesiol Intensive Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anaesthesiol Intensive Ther</style></full-title></periodical><pages end="256" start="252">252-256</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cardiomyopathy</style></keyword><keyword><style face="normal" font="Arial"> Cardiopulmonary Bypass</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Echocardiography</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hemodynamics</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="9" Year="2016">2016/9/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The aim of this paper is to describe clinical management in a situation where a patient has experienced anaphylaxis while undergoing surgical septal myectomy for hypertrophic obstructive cardiomyopathy (HOCM). CASE REPORT: A 40-yr-old female was scheduled to undergo surgical septal myectomy for the treatment of HOCM. After induction, the patient developed refractory hypotension that did not respond to escalating doses of vasopressors and volume therapy. Although a clinical examination led to the diagnosis of anaphylaxis, epinephrine, which is the usual treatment of choice, failed to improve the patient's hemodynamics. A transesophageal echocardiography revealed a worsening of left ventricular outflow tract obstruction (LVOTO) after it was given. In the end, the rapid institution of a cardiopulmonary bypass was required to save the patient. CONCLUSION: The anaesthetic goals in a patient in HOCM are to maintain preload and afterload and to avoid stimulation of inotropy and chronotropy to leading to left ventricular outflow obstruction. In a patient with anaphylaxis, maintaining these hemodynamic goals becomes much more difficult since the pathophysiology and usual treatment of choice will worsen LVOTO. Special consideration for the need to have extracorporeal life support to treat refractory hypotension in surgical patients with HOCM may be warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1731-2515 (Electronic)IS - 1642-5758 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.5603/AIT.a2016.0042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27689430">PM:27689430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anaesthesiol Intensive Ther\20160930-YeeKF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anaesthesiol Intensive Ther\20160930-YeeKF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Yee KF</style></custom2><misc3><style face="normal" font="Arial">10.5603/AIT.a2016.0042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weiss,D.</style></author><author><style face="normal" font="Arial"> Marsac,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Injury Research and Prevention, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania</style></auth-address><titles><title><style face="normal" font="Arial">Coping and posttraumatic stress symptoms in children with food allergies</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="562" start="561">561-562</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="22" Month="9" Year="2016">2016/9/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27666152">PM:27666152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160926-WeissD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160926-WeissD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Weiss D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shams,M.</style></author><author><style face="normal" font="Arial"> Fineman,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Emory University School of Medicine, Atlanta, Georgia; Children's Healthcare of Atlanta, Atlanta, Georgia</style></auth-address><titles><title><style face="normal" font="Arial">High Chinese elm pollen counts in the fall in Atlanta, Georgia, 2009-2015</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="554" start="553">553-554</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27637427">PM:27637427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160917-ShamsM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160917-ShamsM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Shams M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alvarez-Arango,S.</style></author><author><style face="normal" font="Arial"> Hou,A.</style></author><author><style face="normal" font="Arial"> Lowes,M.A.</style></author><author><style face="normal" font="Arial"> Jerschow,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, New York</style></auth-address><titles><title><style face="normal" font="Arial">Isotretinoin treatment in a patient with known peanut allergy and positive IgE test results for soybean</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="559" start="558">558-559</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="23" Month="9" Year="2016">2016/9/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27670093">PM:27670093</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160927-AlvarezArangoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20160927-AlvarezArangoS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Alvarez-Arango S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nishi,H.</style></author><author><style face="normal" font="Arial"> Pelleg,A.</style></author><author><style face="normal" font="Arial"> Schulman,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, The Jikei University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">IgE Receptor-Mediated Histamine Release in Human Lung Mast Cells: Modulation by Purinergic Receptor Ligands</style></title><secondary-title><style face="normal" font="Arial">Ann Clin Lab Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Clin Lab Sci</style></full-title></periodical><pages end="469" start="463">463-469</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="10/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adenosine</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human lung mast cell</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> purinergic receptor</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mast cells derived from human lungs (HLMCs) express multiple G-protein coupled purinergic receptors (P2YR) and the so-called alpha-ketoglutarate receptor GPR99, which is homologous to P2YR. The role of the P2YR of HLMC is not clear. Thus, the aim of the present study was to determine the effects of purinergic and purine-related compounds on allergic histamine release (HR) in HLMCs. METHODS: FcepsilonRI-mediated HR was quantified in primary culture of HLMC (cHLMC). The effects of the FcepsilonRI-mediated allergic stimulation on the expression of GPR99 were also determined. RESULTS: Adenosine produced a dual effect on HR: enhancement and marked inhibition at low and high concentrations, respectively. Adenosine 5'-monophosphate (AMP) did not affect FcepsilonRI-mediated HR. However, the non-hydrolysable AMP analog, adenosine-5'-O-thiomonophosphate (AMP-S), concentration dependently inhibited the FcepsilonRI-mediated HR without any enhancement. At high concentrations, alpha-ketoglutarate moderately inhibited FcepsilonRI-mediated HR. However, inhibitions by AMP-S and alpha-ketoglutarate of HR were dissimilar in the inhibitory manner (IC50 and Hill slope) on histamine release by allergic stimulation. CONCLUSIONS: cHLMC express functional GPR99 receptor that is up-regulated following allergic stimulation. Responsiveness to AMP-S is the first indication that cHLMC express P2YR, the activation of which can inhibit FcepsilonRI-mediated HR</style></abstract><notes><style face="normal" font="Arial">DA - 20160921IS - 1550-8080 (Electronic)IS - 0091-7370 (Linking)LA - ENGPT - Journal ArticleSB - IMCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27650611">PM:27650611</url></web-urls><pdf-urls><url ppv-ref="no">harrywestjpjp@yahoo.co.jp</url></pdf-urls><related-urls><url ppv-ref="no">presto - 2 anni</url></related-urls></urls><custom2><style face="normal" font="Arial">20160921, Nishi H</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'Ovidio,M.C.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> D'Amato,G.</style></author><author><style face="normal" font="Arial"> Cecchi,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Medicina, Epidemiologia, Igiene del Lavoro e Ambientale, Istituto Nazionale per l'Assicurazione contro gli Infortuni sul Lavoro (INAIL), Monte Porzio Catone (Rome), Italy</style></auth-address><titles><title><style face="normal" font="Arial">Climate change and occupational allergies: an overview on biological pollution, exposure and prevention</style></title><secondary-title><style face="normal" font="Arial">Ann Ist Super Sanita</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Ist Super Sanita</style></full-title></periodical><pages end="414" start="406">406-414</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> epidemiologia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Climate change, air pollution, temperature increase and other environmental variables are modifying air quality, contributing to the increase of prevalence of allergic respiratory diseases. Allergies are complex diseases characterized by multilevel interactions between individual susceptibility, response to immune modulation and environmental exposures to physical, chemical and biological agents. Occupational allergies introduce a further complexity to these relationships by adding occupational exposure to both the indoor and outdoor ones in the living environment. OBJECTIVE: The aim of this paper is to overview climate-related allergy affecting environmental and occupational health, as literature data are scanty in this regard, and to suggest a management model of this risk based on a multidisciplinary approach, taking the case of biological pollution, with details on exposure and prevention. CONCLUSIONS: The management of climate-related occupational allergy should take into account preventive health strategies, environmental, public and occupational interventions, as well as to develop, implement, evaluate, and improve guidelines and standards protecting workers health under changing climatic conditions; new tools and strategies based on local conditions will have to be developed. Experimental studies and acquisition of environmental and personal data have to be matched to derive useful information for the scope of occupational health and safety</style></abstract><notes><style face="normal" font="Arial">DA - 20161004IS - 0021-2571 (Print)IS - 0021-2571 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4415/ANN_16_03_12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27698299">PM:27698299</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Ist Super Sanita\2016-52-406-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Ist Super Sanita\2016-52-406-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161004, D'Ovidio MC</style></custom2><misc3><style face="normal" font="Arial">10.4415/ANN_16_03_12</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Babina,M.</style></author><author><style face="normal" font="Arial"> Guhl,S.</style></author><author><style face="normal" font="Arial"> Artuc,M.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Charite Campus Mitte, Universitatsmedizin Berlin, Chariteplatz 1, 10117, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">IL-4 and human skin mast cells revisited: reinforcement of a pro-allergic phenotype upon prolonged exposure</style></title><secondary-title><style face="normal" font="Arial">Arch Dermatol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dermatol Res</style></full-title></periodical><pages end="670" start="665">665-670</pages><volume><style face="normal" font="Arial">308</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Mast cells (MCs), unique cellular elements of the body, are commonly associated with IgE-mediated reactions and manifestations of Th2-type immunity. A key characteristic of the lineage is its heterogeneity, with subsets displaying significant variation depending on maturation stage, species, tissue, microenvironment and other. Heterogeneity also affects MC responses to extracellular cues. Indeed, IL-4, the signature cytokine of Th2-immunity, can affect MCs in opposing ways ranging from the induction of apoptosis to positive regulation of lineage characteristics. It is unknown, however, whether IL-4 alters the phenotype of terminally differentiated human cutaneous MCs. Using our well-established technique for homogeneous purification of human skin MCs, we now report that prolonged contact with IL-4 not only increases MC expansion, but also phenotypically and functionally re-shapes the cells. FcepsilonRI cell surface expression, FcepsilonRIalpha-specific mRNA and FcepsilonRI-mediated histamine release are all augmented by IL-4, while histamine release elicited by the non-immunological stimulus, substance P, remains unaffected. IL-4's potential to mold MCs is broad and similarly detectable across donors. Intriguingly, IL-4 impacts granule-associated mediators, especially histamine whose synthesis is boosted in the presence of IL-4. To our knowledge, an increase in histamine production by IL-4 has not been described yet for any type of MCs, but may well contribute to its pro-allergic effect given the significance of this biogenic amine to allergic symptoms. Collectively, IL-4 alters human skin MCs after long-term exposure mimicking chronic disorders by strengthening MC numbers and intensifying processes associated with allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160921IS - 1432-069X (Electronic)IS - 0340-3696 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00403-016-1688-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27650274">PM:27650274</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dermatol Res\2016-308-665-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dermatol Res\2016-308-665-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160921, Babina M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00403-016-1688-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dor-Wojnarowska,A.</style></author><author><style face="normal" font="Arial"> Liebhart,J.</style></author><author><style face="normal" font="Arial"> Miecielica,J.</style></author><author><style face="normal" font="Arial"> Rabski,M.</style></author><author><style face="normal" font="Arial"> Fal,A.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author><author><style face="normal" font="Arial"> Nittner-Marszalska,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Diseases and Allergology, Wroclaw Medical University, M. Sklodowskiej-Curie 66, 50-369, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">The Impact of Sex and Age on the Prevalence of Clinically Relevant Sensitization and Asymptomatic Sensitization in the General Population</style></title><secondary-title><style face="normal" font="Arial">Arch Immunol Ther Exp (Warsz)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Immunol Ther Exp (Warsz)</style></full-title></periodical><pages end="261" start="253">253-261</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sex hormones</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The objective of our study was to evaluate the impact of sex and age on the prevalence of sensitization to inhalant allergens. The study was performed as a part of Polish Epidemiology of Allergic Diseases study, and data concerning citizens of Wroclaw were analyzed. The participants were divided into three age groups (6-7, 13-14, and 20-44 years) with a subdivision according to sex. We randomly selected 1409 individuals, 439 people complied; the complete set of tests was performed on 421 of them. We found that 37.7 % of the study population demonstrated sensitization to at least one of the allergens tested. Positive skin tests were found more frequently in males than in females (p = 0.003); among 6-7-year-old children, the sensitization was independent of sex (p = 0.26), while in two other groups, it was higher in males (p = 0.002 and p = 0.03, respectively). Clinically asymptomatic sensitization (AS) was found more often in females than in males (p = 0.04). The higher rate of AS in women was observed only in the two younger age groups, while in the 20-44-year-old group AS did not differ between the sexes (p = 0.72). Female sex hormones may contribute to a later change in the nature of sensitization from clinically asymptomatic to symptomatic. Further studies are needed to confirm the results of our study</style></abstract><notes><style face="normal" font="Arial">DA - 20160921IS - 1661-4917 (Electronic)IS - 0004-069X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s00005-016-0425-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27652380">PM:27652380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Immunol Ther Exp (Warsz)\20160921-DorWojnarowskaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Immunol Ther Exp (Warsz)\20160921-DorWojnarowskaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160921, Dor-Wojnarowska A</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s00005-016-0425-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Banti,T.</style></author><author><style face="normal" font="Arial"> Carsin,A.</style></author><author><style face="normal" font="Arial"> Chabrol,B.</style></author><author><style face="normal" font="Arial"> Reynaud,R.</style></author><author><style face="normal" font="Arial"> Fabre,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unite de pediatrie multidisciplinaire, CHU Timone-Enfants, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France.</style></auth-address><titles><title><style face="normal" font="Arial">[Infant food diversification. Assessment of practices in relation to French recommendations in pediatricians and pediatric residents in southern France]</style></title><secondary-title><style face="normal" font="Arial">Arch Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Pediatr</style></full-title></periodical><pages end="1027" start="1018">1018-1027</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eviction</style></keyword><keyword><style face="normal" font="Arial"> Exotic fruits</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food diversification</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Honey</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Food</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pediatrie</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Infant food diversification has undergone a rapid succession of good practice recommendations in France, but there has been no assessment of pediatrician practices on food diversification. OBJECTIVE: To assess the practices of pediatricians in relation to current recommendations of the French Society of Pediatrics on infant food diversification. METHODS: This was an observational study conducted from 1 November 2014 to 31 March 2015. The study population consisted of 97 pediatricians in the Var department and 84 pediatric residents assigned to the University of Aix-Marseille in France. A questionnaire was sent by email or post to determine physician characteristics, food diversification methods in healthy children and those at atopic risk, and how the pediatric consultation was conducted. The expected answers were based on the most recent recommendations of the French Society of Pediatrics published in 2008, updated from 2003. In summary, breastfeeding is recommended up to 6 months. Food diversification can be started between 4 and 6 months in children with no allergy risk. Gluten, honey, legumes and cow's milk are introduced between 4 and 7 months, after 12 months and after 36 months, respectively. In atopic children, food diversification is delayed until after 6 months and the most allergenic foods (nuts, exotic fruits, peanuts, and shellfish) are introduced after the age of 12 months. RESULTS: Eighty-four responses were obtained (51%): 50 pediatricians and 34 pediatric residents. Sixteen items were classified depending on whether or not an update after 2003 existed. Over 80% of the physicians responded as recommended for the recently updated items for the age of introduction of "solid food in healthy children", "gluten", "cow's milk protein hydrolysates", and "the time until introduction of cow's milk in the atopic child". At best, 65% of physicians responded in accordance with recommendations for items without a recent update, age of introduction of "cow's milk", "milk desserts", "animal proteins", "fats", "vegetables", "use of a hypoallergenic infant formula", and "breastfeeding extension with atopic child". Pediatric residents had the same responses as pediatricians. Seventy-two physicians did not consider the allergenic status of the children to delay the introduction of the most allergenic foods. The lack of complete updating the introduction of solid foods schedule could explain the differences between pediatrician practices and recommendations. Moreover, old recommendations on allergenic food eviction are still available. CONCLUSION: Pediatricians and pediatric residents partially applied the current recommendations on the introduction of solid food</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 1769-664X (Electronic)IS - 0929-693X (Linking)LA - FREPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.arcped.2016.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27642151">PM:27642151</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Pediatr\2016-23-1018-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Pediatr\2016-23-1018-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Banti T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.arcped.2016.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camargo,L.S.</style></author><author><style face="normal" font="Arial"> Silveira,J.A.</style></author><author><style face="normal" font="Arial"> Taddei,J.A.</style></author><author><style face="normal" font="Arial"> Fagundes,U.Neto</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Disciplina de Nutrologia, Departamento de Pediatria, Universidade Federal de Sao Paulo, SP, Brasil</style></auth-address><titles><title><style face="normal" font="Arial">ALLERGIC PROCTOCOLITIS IN INFANTS: analysis of the evolution of the nutritional status</style></title><secondary-title><style face="normal" font="Arial">Arq Gastroenterol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Arq Gastroenterol</style></abbr-1></periodical><pages end="266" start="262">262-266</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Status</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Background: Allergic proctocolitis is a disease that affects infants in the first months. The change in feed is the primary factor for clinical improvement and maintenance of the nutritional status of the infant. Objective: Study the anthropometric evolution of infants with allergic proctocolitis at diagnosis and 1 to 6 months after nutritional intervention. Methods: A retrospective cohort of infants with allergic proctocolitis diagnosis followed at the Pediatric Gastroenterology Institute of Sao Paulo (IGASTROPED), Brazil. The database with clinical, therapeutic and anthropometric data was obtained from medical records of outpatient infants. The therapeutic intervention was characterized by 1) exclusive breastfeeding with maternal exclusion diet of the six allergens (EBF-MED) or 2) no breastfeeding and use of hypoallergenic formulas. Results: Of the 44 infants diagnosed with allergic proctocolitis, 23 were female. The median age of the infants was 3.5 months at the time of admission and 6 months after the intervention. The main clinical complaint was hematochezia with or without other symptoms of allergic proctocolitis. No difference was shown in the infants anthropometric evaluation between the two diets. Conclusion: The duration of the allergic proctocolitis did not induce worsening of the infants nutritional status. Importantly, both nutritional interventions were able to keep the infants within the growth channel and resulted in the total clinical symptoms remission. Considering the fundamental mother-child link promoted by breastfeeding, the present data highlights the beneficial role of EBF-MED on the nutritional status of infants diagnosed with allergic proctocolitis in addition to the lower cost that breastfeeding brings compared the use of hypoallergenic formulas</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1678-4219 (Electronic)IS - 0004-2803 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1590/S0004-28032016000400010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27706457">PM:27706457</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arq Gastroenterol\2016-53-262-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arq Gastroenterol\2016-53-262-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Camargo LS</style></custom2><misc3><style face="normal" font="Arial">10.1590/S0004-28032016000400010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fujimori,A.</style></author><author><style face="normal" font="Arial"> Yamashita,T.</style></author><author><style face="normal" font="Arial"> Kubota,M.</style></author><author><style face="normal" font="Arial"> Saito,H.</style></author><author><style face="normal" font="Arial"> Takamatsu,N.</style></author><author><style face="normal" font="Arial"> Nambu,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Human Life and Environment, Nara Women's University, Nara, Japan. Email: mkubota@cc.nara-wu.ac.jp</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of the prevalence and characteristics of food hypersensitivity among adolescent and older women</style></title><secondary-title><style face="normal" font="Arial">Asia Pac J Clin Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac J Clin Nutr</style></full-title></periodical><pages end="862" start="858">858-862</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVES: Although food hypersensitivity is a public health concern, its documentation among the elderly is limited. The current study aims to compare the prevalence and characteristics of food hypersensitivity among adolescent women between aged 18-24 with among older women >50 years of age. METHODS AND STUDY DESIGN: 660 female university students between the ages of 18 and 24 who volunteered were enrolled as adolescent subjects. 470 women >50 years old who visited the Health Care Centre of Kyoto Katsura Hospital for health check-ups were enrolled as the older subjects. A questionnaire created by ourselves asking the presence of food hypersensitivity, symptoms, causative food, personal or family history of other allergic disorders was distributed. RESULTS: The prevalence of food hypersensitivity was statistically similar between adolescent (8.2%) and older women (8.9%). Among them, only 24.1% of the adolescent women and 26.2% of the older women had been diagnosed by physicians as having food allergy. The main causative foods (fruits, shellfish and fish) and the manifestations relating to food hypersensitivity were almost identical between adolescent and older women. In both adolescent and older women, food hypersensitivity positive group showed significantly higher prevalence of personal or family history of allergic disorders than that in food hypersensitivity negative group. CONCLUSIONS: These data indicate that food hypersensitivity in older women should be given more attention because the prevalence of this condition was as common as that in adolescent women</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 0964-7058 (Print)IS - 0964-7058 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.6133/apjcn.092015.39</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27702729">PM:27702729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac J Clin Nutr\2016-25-858-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac J Clin Nutr\2016-25-858-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Fujimori A</style></custom2><misc3><style face="normal" font="Arial">10.6133/apjcn.092015.39</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Erdem,S.B.</style></author><author><style face="normal" font="Arial"> Karaman,S.</style></author><author><style face="normal" font="Arial"> Nacaroglu,H.T.</style></author><author><style face="normal" font="Arial"> Unsal Karkiner,C.S.</style></author><author><style face="normal" font="Arial"> Kanik,E.T.</style></author><author><style face="normal" font="Arial"> Nalcabasmaz,T.</style></author><author><style face="normal" font="Arial"> Yazici,S.</style></author><author><style face="normal" font="Arial"> Can,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Risk Grup in Anaphylaxis: Infant Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="36" start="31">31-36</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Pressure</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine injector</style></keyword><keyword><style face="normal" font="Arial"> EpiPen</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal System</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin Manifestations</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Objective: The infantile group that is accepted to be at risk of anaphylaxis has a special importance since they are unable to express their complaints and also the signs and symptoms of anaphylaxis can be confused with common symptoms of infants such as drooling, vomiting, diarrhea and itching. However, early detection of the signs and symptoms of anaphylaxis is crucial for effective diagnosis and treatment. The aim of study was to draw attention to infants anaphylaxis. Materials and Methods: All of the patients in the infant group (n=15) among a total of 35 anaphylaxis cases that we followed in the Pediatric Allergy Clinic of Dr. Behçet Uz Children's Hospital between the years 2011-2015 were included in the study. Demographic and clinical features of the patients were evaluated. Results: 9 of 15 (60%) patients involved in the study were male and 6 (40%) were female, and the average age of anaphylaxis was 8.13±6.83 (min 1-max 24) months. In 93% of cases (n=14) the trigger was food and in 7% of cases (n=1) the trigger was not determined. The most frequently responsible foods were respectively cow's milk (67%) and egg (20%). In 7 patients (47%), there were respiratory system and skin manifestations, in 7 patients (47%) 3 system involvement and in 1 patient respiratory and gastrointestinal system involvement has been observed. In only 3 cases (20%) the blood pressure was measured and also epinephrine was administered to only 3 cases (20%) in the hospital. In only 3 of the patients (20%), an epinephrine injector was prescribed after anaphylaxis. Conclusion: It was detected that the most common triggers are cow's milk and egg, the subjective symptoms are frequently overlooked, an atopic nature is a risk factor and physicians' rates of blood pressure measurement, epinephrine administration and EpiPen autoinjector prescription are low.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/58</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-31-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-31-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Erdem SB</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yilmaz,O.</style></author><author><style face="normal" font="Arial"> Atici,S.</style></author><author><style face="normal" font="Arial"> Ertoy Karagol,H.I.</style></author><author><style face="normal" font="Arial"> Topal,E.</style></author><author><style face="normal" font="Arial"> Bakirtas,A.</style></author><author><style face="normal" font="Arial"> Demirsoy,M.S.</style></author><author><style face="normal" font="Arial"> Turktas,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A Case of Anaphylaxis to Legumes During Prick to Prick Test</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="41" start="37">37-41</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Broad bean</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chickpea</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> lentil</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pea</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Peas</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The most common causes of food allergy vary among countries according to the dietary habits and the frequency of consumption of foods. Legumes are important sources of protein that are widely consumed all over the world. The legume family includes lentils, chickpeas, beans, broad beans as well as peanuts and soybeans. Skin prick tests are generally considered safe. However, systemic reactions may develop during skin prick testing, Systemic reactions from skin testing are more frequent with food, drug, latex and venom allergens. Systemic reactions occur more frequently after prick to prick tests that are performed with fresh food than those with standard extracts. This paper reports a case with a history of anaphylaxis to lentils and peas. The patient was found to have type 1 reaction to chick peas, broad beans and green beans although she did not describe a reaction to these legumes in her history. The patient experienced anaphylaxis during skin testing with legumes when multiple tests were performed at the same time. There was no reaction when skin prick tests were performed in more than one session. The patient is noteworthy in this regard and discussed in detail.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/28</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-37-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-37-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Yilmaz O</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ercan,M.</style></author><author><style face="normal" font="Arial"> Kaymak,E.</style></author><author><style face="normal" font="Arial"> Yuksek,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Role of Environmental Control Measures in Asthmatic Children Who are Sensitized to House Dust Mites</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="18" start="11">11-18</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> carpet</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control measures</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental risk factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Code</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paternal</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Objective: Asthma is a disease that occurs in genetically susceptible individuals who are exposed to allergens. It is currently impossible to change our genetic code. Elimination of environmental risk factors that play an important role in the emergence of asthma may help control asthma symptoms. The aim of this study was to investigate the role of environmental control measures in asthmatic children who are sensitized to house dust mites. Materials and Methods: The study included of 64 asthmatic children aged 7-16 years who had applied to Bulent Ecevit University School of Medicine's child allergy and immunology polyclinic. To evaluate the role of environmental control measures on asthma control, we performed home visits to observe the patients' houses and their environment and the patients were given a questionnaire form of 39 questions about environmental conditions where the child lived and an asthma control questionnaire consisting of 7 questions. Results: The asthma was controlled well in 51 children (79.6%) and poorly in 13 (20.3%). Duration of disease, gender, frequency of doctor visits, economic situation and living conditions of the family, presence of pets, cleaning conditions, heating type and instant relative humidity of the house, regular use of medications, cigarette exposure, flu vaccination, and presence of concomitant diseases to asthma in the family were not different between the groups. There was also no difference between two groups in terms of the presence or absence of carpets in the house and in the room of asthmatic children. The maternal education level was statistically significantly different between the two groups (p=0.023), whereas the paternal education level not (p=0.133). Conclusion: Environmental control measures to control asthma in children who are sensitized to house dust mites are a significant issue to consider. Successful control and prevention of asthma needs a comprehensive approach including education, cleaning, housing features and maintaining these practices.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/45</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-11-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-11-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Ercan M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ozdemir,O.</style></author><author><style face="normal" font="Arial"> Aydin,B.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cockroach Allergy and Its Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="10" start="1">1-10</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Blattella germanica</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> controlled clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Controlled Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> German cockroach</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Invertebrates</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Cockroach allergy has been considered as an important cause of respiratory allergic diseases for over three decades. The most common domiciliary cockroach species are Blattella germanica (German cockroach) and Periplaneta americana (American cockroach). Blattella germanica is a small cockroach, approximately 16 mm in length, which commonly infests houses worldwide. Periplaneta americana is a large cockroach, approximately 35-53 mm in length, that infests houses, schools, hospitals, and other large buildings. There are more than 20 different cockroach species in Turkey, and Blattella germanica is known as the most common. In the United States, the prevalence of cockroach allergy ranges from 17 to 41%'in various studies involving both children and adults. European studies on children and adults attending an allergy clinic show a high variability in cockroach sensitisation varying from %4-26. In Turkey, cockroach allergy prevalence rate varies from %2.2-51.4 in different studies consisting of both children and adults. Tropomyosin, designated as Bla g7 and Per a7, has been identified as a major allergen in cockroaches. Tropomyosin is also an important allergen involved in cross-reactivity among insects and invertebrates including mites, crustaceans, mollusks and parasites. Cosensitization to other invertebrate allergens in cockroachsensitized individuals is a common feature. Consequently, parasite infestations could regulate allergic reactivity through cross-reactive antibody responses. A sustained decrease in cockroach allergen levels is difficult to accomplish even after successful extermination of cockroach populations and commercial cockroach extracts used for diagnosis and treatment remain non-standardized. Although some of the studies suggest that cockroach immunotherapy may be effective, further randomized, controlled clinical trials, using wellcharacterized cockroach extracts, and with larger number of patients and longer follow-up are required to establish the efficacy and safety of specific allergen immunotherapy in the treatment of cockroach allergic patients.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/29</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-1-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-1-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Ozdemir O</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vetillard,A.</style></author><author><style face="normal" font="Arial"> Bouzid,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Ants: a chemical library of anticancer molecules]</style></title><secondary-title><style face="normal" font="Arial">Biol Aujourdhui</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biol Aujourdhui</style></full-title></periodical><pages end="125" start="119">119-125</pages><volume><style face="normal" font="Arial">210</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Ants</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropod Venoms</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> Bioactive substances</style></keyword><keyword><style face="normal" font="Arial"> BLAST</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> cDNA library</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxic test</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> EST</style></keyword><keyword><style face="normal" font="Arial"> Expressed sequence tag</style></keyword><keyword><style face="normal" font="Arial"> Expressed Sequence Tags</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Snakes</style></keyword><keyword><style face="normal" font="Arial"> Sol i 3</style></keyword><keyword><style face="normal" font="Arial"> Specialization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spiders</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venom gland</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Animal venoms are complex mixtures containing simple organic molecules, proteins, peptides, and other bioactive elements with extraordinary biological properties associated with their ability to act on a number of molecular receptors in the process of incapacitating their target organisms. In such a context, arthropod venoms are invaluable sources of bioactive substances, with therapeutic interest but the limited availability of some venom such as those from ants, has restricted the potential that these biomolecules could represent. We investigated for the first time transcriptomic expression from the ant species Tetramorium bicarinatum. Four hundred randomly selected clones from cDNA libraries were sequenced and a total of 374 expressed sequence tags (ESTs) were generated. Based on the results of BLAST searches, these sequences were clustered and assembled into 269 contigs. About 72% (269) of these matched BLASTx hits with an interesting diversity and unusual abundance of cellular transcripts (48%) related to gene and protein expression reflecting the specialization of this tissue. In addition, transcripts encoding transposases were relatively highly expressed (14%). It may be that transposable elements are present and that their presence accounts for some of the variation in venom toxins. About twenty per cent of the ESTs were categorized as putative toxins, the major part represented by allergens (48% of the total venom toxins) such as pilosulin 5, sol i 3 and Myp p I and II. Several contigs encoding enzymes, including zinc-metalloproteases (17%) that are likely involved in the processing and activation of venom proteins/peptides, were also identified from the library. In addition, a number of sequences (8%) had no significant similarity to any known sequence which indicates a potential source of for the discovery of new toxins. In order to provide a global insight on the transcripts expressed in the venom gland of the Brazilian ant species Tetramorium bicarinatum and to unveil the potential of their products, high-throughput expressed sequence tags were generated using Illumina paired-end sequencing technology. A total of 212 371 758 pairs of quality-filtered, 100-base-pair Illumina reads were obtained. The de novo assemblies yielded 36 042 contigs for which 27 873 have at least one predicted ORF among which 59.77% produce significant hits in the available databases. The investigation of the read mapping toxin class revealed and confirmed a high diversification with the major part consistent with the classical hymenopteran venom protein signature represented by venom allergen (33.3%) followed by a diverse toxin-expression profile including several distinct isoforms of phospholipase A1 and A2, venom serine protease, hyaluronidase, protease inhibitor and secapin. Moreover, our results revealed for the first time the presence of toxin-like peptides that have been previously identified from unrelated venomous animals such as waprin-like (snakes) and agatoxins (spiders and conus). These studies provide a first insight of the gene expression scenario of the venom gland of T. bicarinatum which might contribute to acquiring a more comprehensive view about the origin and functional diversity of venom proteins of this ant. Based on such results, we conducted cytotoxic tests from the crude venom of T.bicarinatum ant and reported toxic effect on tumoral cells lines from one of the fifth of the most frequently occurring cancers with a 3-year survival rate of only 30%. In such a context, new therapeutic strategies are essential and the discovery of new molecules in ant venom could be one possible avenue. Thus our project aims to characterize, from the crude venom of T.bicarinatum, the molecule(s) which have potential anti-cancerous toxicity as well as their mechanisms of action</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 2105-0686 (Electronic)IS - 2105-0678 (Linking)LA - FREPT - English AbstractPT - Journal ArticleSB - IMCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1051/jbio/2016021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27687602">PM:27687602</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160930, Vetillard A</style></custom2><misc3><style face="normal" font="Arial">10.1051/jbio/2016021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,S.</style></author><author><style face="normal" font="Arial"> Okamoto,H.</style></author><author><style face="normal" font="Arial"> Yamamoto,S.</style></author><author><style face="normal" font="Arial"> Hatayama,T.</style></author><author><style face="normal" font="Arial"> Matsuzaki,H.</style></author><author><style face="normal" font="Arial"> Kumagai-Takei,N.</style></author><author><style face="normal" font="Arial"> Yoshitome,K.</style></author><author><style face="normal" font="Arial"> Nishimura,Y.</style></author><author><style face="normal" font="Arial"> Sato,T.</style></author><author><style face="normal" font="Arial"> Kirita,Y.</style></author><author><style face="normal" font="Arial"> Fujii,Y.</style></author><author><style face="normal" font="Arial"> Otsuki,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biological Sciences, Universidad De Los Andes, Bogota 111711, Co1. Department of Hygiene, Kawasaki Medical School, 577 Mastushima, Kurashiki 701-0192, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Biological Effects of Cloth Containing Specific Ore Powder in Patients with Pollen Allergy</style></title><secondary-title><style face="normal" font="Arial">Biomed Environ Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Environ Sci</style></full-title></periodical><pages end="573" start="563">563-573</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> mood</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The custom-homebuilding company, Cosmic Garden Co. Ltd., located in Okayama City, Japan was established in 1997 and uses specific natural ore powder (SNOP) in wall materials and surveys customers in order to improve allergic symptoms. METHODS: To investigate the biological effects of SNOP, patients with a pollen allergy were recruited to stay in a room surrounded by cloth containing SNOP (CCSNOP), and their symptoms and various biological parameters were compared with those of individuals staying in a room surrounded by control non-woven cloth (NWC). Each stay lasted 60 min. Before and immediately after the stay, a questionnaire regarding allergic symptoms, as well as POMS (Profile of Mood Status) and blood sampling, was performed. Post-stay minus pre-stay values were calculated and compared between CCSNOP and NWC groups. RESULTS: Results indicated that some symptoms, such as nasal obstruction and lacrimation, improved, and POMS evaluation showed that patients were calmer following a stay in CCSNOP. Relative eosinophils, non-specific Ig E, epidermal growth factor, monocyte chemotactic protein-1, and tumor necrosis factor-alpha increased following a stay in CCSNOP. CONCLUSION: This ore powder improved allergic symptoms, and long-term monitoring involving 1 to 2 months may be necessary to fully explore the biological and physical effects of SNOP on allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 0895-3988 (Print)IS - 0895-3988 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -CO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.3967/bes2016.075</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27660220">PM:27660220</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Environ Sci\2016-29-563-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Environ Sci\2016-29-563-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Lee S</style></custom2><misc3><style face="normal" font="Arial">10.3967/bes2016.075</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kong,Y.H.</style></author><author><style face="normal" font="Arial"> Shi,Q.</style></author><author><style face="normal" font="Arial"> Han,N.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Zhang,Y.Y.</style></author><author><style face="normal" font="Arial"> Gao,T.X.</style></author><author><style face="normal" font="Arial"> Chen,C.</style></author><author><style face="normal" font="Arial"> Li,Y.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Beijing University of Chinese Medicine, Beijing 100029, China</style></auth-address><titles><title><style face="normal" font="Arial">Structural Modulation of Gut Microbiota in Rats with Allergic Bronchial Asthma Treated with Recuperating Lung Decoction</style></title><secondary-title><style face="normal" font="Arial">Biomed Environ Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Environ Sci</style></full-title></periodical><pages end="583" start="574">574-583</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Amplification</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> pyrosequencing</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate whether recuperating lung decoction (RLD) can modulate the composition of gut microbiota in rats during asthma treatment. METHODS: Fifteen Sprague-Dawley rats were divided randomly and equally into control group, model group, dexamethasone (DEX) group, RLD medium-dose group, and RLD high-dose group. The asthma model was established in all groups, except for the control group. The rats in the DEX and RLD groups were treated orally with DEX and RLD, respectively. The rats in the control and model groups were treated orally with 0.9% saline. The intestinal bacterial communities were compared among groups using 16S rRNA gene amplification and 454 pyrosequencing. RESULTS: The microbial flora differed between the control and model groups, but the flora in the RLD groups was similar to that in the control group. No significant differences were observed between the RLD high-dose and medium-dose groups. RLD treatment resulted in an increase in the level beneficial bacteria in the gut, such as Lactobacillus and Bifidobacterium spp. CONCLUSION: Oral administration of RLD increased the number of intestinal lactic acid-producing bacteria, such as Lactobacillus and Bifidobacterium, in asthma model rats</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 0895-3988 (Print)IS - 0895-3988 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.3967/bes2016.076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27660221">PM:27660221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Environ Sci\2016-29-574-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Environ Sci\2016-29-574-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Kong YH</style></custom2><misc3><style face="normal" font="Arial">10.3967/bes2016.076</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mayor,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">London</style></auth-address><titles><title><style face="normal" font="Arial">Growing up on a farm may cut risk of allergic conditions in adulthood</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="i5223">i5223-</pages><volume><style face="normal" font="Arial">354</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="26" Month="9" Year="2016">2016/9/26</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160928IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.i5223</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27679420">PM:27679420</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2016-354-i5223.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2016-354-i5223.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160928, Mayor S</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.i5223</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dupont,B.</style></author><author><style face="normal" font="Arial"> Mariotte,D.</style></author><author><style face="normal" font="Arial"> Dugue,A.E.</style></author><author><style face="normal" font="Arial"> Clarisse,B.</style></author><author><style face="normal" font="Arial"> Grellard,J.M.</style></author><author><style face="normal" font="Arial"> Babin,E.</style></author><author><style face="normal" font="Arial"> Chauffert,B.</style></author><author><style face="normal" font="Arial"> Dakpe,S.</style></author><author><style face="normal" font="Arial"> Moldovan,C.</style></author><author><style face="normal" font="Arial"> Bouhier-Leporrier,K.</style></author><author><style face="normal" font="Arial"> Reimund,J.M.</style></author><author><style face="normal" font="Arial"> Di Fiore,F.</style></author><author><style face="normal" font="Arial"> Zanetta,S.</style></author><author><style face="normal" font="Arial"> Mailliez,A.</style></author><author><style face="normal" font="Arial"> Do,P.</style></author><author><style face="normal" font="Arial"> Peytier,A.</style></author><author><style face="normal" font="Arial"> Galais,M.P.</style></author><author><style face="normal" font="Arial"> Florescu,C.</style></author><author><style face="normal" font="Arial"> Schott,R.</style></author><author><style face="normal" font="Arial"> Le Mauff,B.</style></author><author><style face="normal" font="Arial"> Gervais,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Hepato-Gastroenterology and Nutrition, CHU de Caen, Caen, France.</style></auth-address><titles><title><style face="normal" font="Arial">Utility of serum anti-cetuximab ige levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab</style></title><secondary-title><style face="normal" font="Arial">Br J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Br J Clin Pharmacol</style></full-title></periodical><pages end="631" start="623">623-631</pages><volume><style face="normal" font="Arial">83</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Head and neck cancer</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">AIM: Cetuximab is an anti-EGFR antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSR) are associated with cetuximab use. The aim of the study was to evaluate the utility of anti-cetuximab IgE detection in order to identify patients at risk of HSR to cetuximab. METHODS: We included patients ready to receive a first cetuximab infusion in a prospective cohort carried out at 9 French centers. Pre-treatment anti-cetuximab IgE levels were measured. We compared the proportion of severe HSR in the low anti-cetuximab IgE levels (&lt;/=29 IgE Arbitrary Units (EAU)) subgroup with that in a historical cohort of 213 patients extracted from a previous study. RESULTS: Of the 301 assessable patients (mean age: 60.9 +/- 9.3 years, head-and-neck cancer: 77%), 66 patients (22%) had high anti-cetuximab IgE levels, and 247 patients received cetuximab (including 38 with high anti-cetuximab levels). Severe HSR occurred in 8 patients (5 grade 3; 3 grade 4). The proportion of severe HSR was lower in the low anti-cetuximab IgE levels subgroup vs. the historical cohort [3/209 (1.4%) vs. 11/213 (5.2%), OR, 0.27, 95% CI, 0.07 to 0.97], and higher in high vs. low anti-cetuximab IgE levels subgroup [5/38 (13.2%) vs. 3/209 (1.4%); OR, 10.4, 95% CI, 2.4 to 45.6]. Patients with severe HSR had higher anti-cetuximab IgE levels than patients without reaction (median, 45 vs. 2 EAU, P = 0.006). CONCLUSIONS: Detection of pretreatment anti-cetuximab IgE is feasible and helpful to identify patients at risk of severe cetuximab-induced HSR</style></abstract><notes><style face="normal" font="Arial">DA - 20160924IS - 1365-2125 (Electronic)IS - 0306-5251 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/bcp.13140</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27662818">PM:27662818</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Clin Pharmacol\20160924-DupontB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Clin Pharmacol\20160924-DupontB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160924, Dupont B</style></custom2><misc3><style face="normal" font="Arial">10.1111/bcp.13140</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arruda,L.K.</style></author><author><style face="normal" font="Arial"> Melo,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The allergy epidemics: why are allergies increasing in Brazil and worldwide?</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="" start="6">6-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Epidemics</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2318-5015.20150001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2318-5015.20150001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-1-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-1-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Arruda LK</style></custom2><misc3><style face="normal" font="Arial">10.5935/2318-5015.20150001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Geller,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Exercise-induced anaphylaxis: state of the art</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="46" start="40">40-46</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Atmospheric pollen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Celery</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Exertion</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Flours</style></keyword><keyword><style face="normal" font="Arial"> Flushing</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Laryngeal Edema</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> NSAID</style></keyword><keyword><style face="normal" font="Arial"> NSAIDs</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Omega-5-gliadin</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">The prevalence of exercise-induced anaphylaxis is around 2.3-5% of all cases of anaphylaxis. Theclinical symptoms of exercise-induced anaphylaxis include fatigue, flushing, heat sensation, diffuseitching, urticaria, angioedema, bronchospasm, dyspnea, any gastrointestinal manifestations,hypotension, cardiocirculatory colapse and laryngeal edema. The main differential diagnosis iswith cholinergic urticaria that might also present with anaphylaxis. Exercise-induced anaphylaxismight be food-dependent, with or without specific IgE sensitization. The most common food triggersare wheat (omega-5 gliadin epitope), shellfish (specially shrimp), celery, corn, cow's milk, banana,mite contaminated flours and peanut. Interestingly, isolated aerobic exercises and the ingestionof these food allergens without exertion do not cause anaphylaxis. It is required both synergisticfactors to provoke anaphylaxis. Drug-dependence might also occur. Medications and chemicalsinvolved include aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics(cephalosporins) and the so-called anti-catabolic agents such beta-hydroxymethylbutyrate. It isrecommended to avoid the ingestion of the culprit foods and, in temperate areas of the planet, to exercise indoors when the atmospheric pollen counts are very high for the atopic individuals.It is also advisable to avoid exercising in extreme climate conditions, such as when it is too hot,too cold or in very humid environments. Omalizumab (monoclonal anti-IgE antibody) can stabilizethe mast cells by down regulating expression of high affinity receptors for IgE (FcƒÃRI), and thistherapeutic approach has been shown to prevent anaphylaxis. Epinephrine autoinjectors andpatient education extended to family members is essential for patients who present exerciseinducedanaphylaxis, as well education of all persons involved in the practice of exercises andsports, for appropriate diagnosis and prevention, and successful treatment of exercise-inducedanaphylaxis.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-40-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-40-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Geller M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vieira,F.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical practice, component-resolved molecular diagnosis, and pollinosis: what we learn from our patients</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="" start="32">32-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">31</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-31-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-31-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Vieira FM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leone Martins,F.</style></author><author><style face="normal" font="Arial"> Mota Rabelo,S.H.</style></author><author><style face="normal" font="Arial"> Torres Seroa da Mota,A.L.</style></author><author><style face="normal" font="Arial"> Querino de Araujo Caldas,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Regulatory and normative aspects regarding of latex surgical and procedure gloves</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="12" start="7">7-12</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Gloves</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> tear</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">This article shows the importance of quality control in the manufacturing of latex surgical andprocedure gloves, based on the identification of manufacturing defects, holes, and poor resistance,which could cause the gloves to tear. In addition, the fact that latex gloves may cause contactdermatitis and other hypersensitivity reactions in health care professionals and users is addressed.Considering the relevance of preserving human health, the National Institute of Metrology,Quality and Technology (Inmetro), in response to requests from institutions and consumers, hasdecided to subject surgical gloves to a product analysis program, whose status was later changedto a conformity assessment program, in which technical requirements are established by theNational Health Surveillance Agency (ANVISA). The data presented in this paper show that thecompulsory certification of gloves, complying with regulations issued by Inmetro and ANVISA,improves product quality and consequently offers increased safety to the Brazilian population.The authors also warn about possible allergic reactions caused by latex and by allergens withcross-reactivity to latex, including those present in foods.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-7-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-7-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Leone Martins F</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arruda,L.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Life with allergies: from childhood to old age</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="110" start="109">109-110</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-109-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-109-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161018, Arruda LK</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cassiani Camargo,C.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Telemedicine: a matter of habit</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="" start="30">30-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Brazil</style></keyword><keyword><style face="normal" font="Arial"> Telemedicine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=719</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Cassiani Camargo CE</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mello Junior,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidade de Sao Paulo (USP), Faculdade de Medicina, Sao Paulo, SP, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Local allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Braz J Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Braz J Otorhinolaryngol</style></abbr-1></periodical><pages end="622" start="621">621-622</pages><volume><style face="normal" font="Arial">82</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword></keywords><dates><year Day="12" Month="9" Year="2016">2016/9/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 1808-8686 (Electronic)IS - 1808-8686 (Linking)LA - ENGPT - EDITORIALCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bjorl.2016.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27665688">PM:27665688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Otorhinolaryngol\20160926-MelloJuniorJF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Otorhinolaryngol\20160926-MelloJuniorJF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Mello Junior JF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bjorl.2016.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maeda,M.</style></author><author><style face="normal" font="Arial"> Tani,M.</style></author><author><style face="normal" font="Arial"> Yoshiie,T.</style></author><author><style face="normal" font="Arial"> Vavricka,C.J.</style></author><author><style face="normal" font="Arial"> Kimura,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biofunctional Chemistry, Graduate School of Environmental and Life Science, Okayama University, 1-1-1 Tsushima-Naka, Okayama 700-8530, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Structural features of N-glycans linked to glycoproteins expressed in three kinds of water plants: Predominant occurrence of the plant complex type N-glycans bearing Lewis a epitope</style></title><secondary-title><style face="normal" font="Arial">Carbohydr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Carbohydr Res</style></full-title></periodical><pages end="57" start="50">50-57</pages><volume><style face="normal" font="Arial">435</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biological significance</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Structural analysis</style></keyword><keyword><style face="normal" font="Arial"> Structural features</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="17" Month="9" Year="2016">2016/9/17</year></dates><abstract><style face="normal" font="Arial">The Japanese cedar pollen allergen (Cry j1) and the mountain cedar pollen allergen (Jun a1) are glycosylated with plant complex type N-glycans bearing Lewis a epitope(s) (Galbeta1-3[Fucalpha1-4]GlcNAc-). The biological significance of Lewis a type plant N-glycans and their effects on the human immune system remain to be elucidated. Since a substantial amount of such plant specific N-glycans are required to evaluate immunological activity, we have searched for good plant-glycan sources to characterize Lewis a epitope-containing plant N-glycans. In this study, we have found that three water plants, Elodea nuttallii, Egeria densa, and Ceratophyllum demersum, produce glycoproteins bearing Lewis a units. Structural analysis of the N-glycans revealed that almost all glycoproteins expressed in these three water plants predominantly carry plant complex type N-glycans including the Lewis a type, suggesting that these water plants are good sources for preparation of Lewis a type plant N-glycans in substantial amounts</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1873-426X (Electronic)IS - 0008-6215 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.carres.2016.09.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27705835">PM:27705835</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Carbohydr Res\2016-435-50-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Carbohydr Res\2016-435-50-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Maeda M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.carres.2016.09.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zubrinich,C.</style></author><author><style face="normal" font="Arial"> Hew,M.</style></author><author><style face="normal" font="Arial"> O'Hehir,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Alfred Hospital Prahran Victoria Australia</style></auth-address><titles><title><style face="normal" font="Arial">Egg provoked food protein-induced enterocolitis-like syndrome in an adult</style></title><secondary-title><style face="normal" font="Arial">Clin Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Case Rep</style></full-title></periodical><pages end="901" start="899">899-901</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome is a non-IgE-mediated food allergy usually diagnosed in infancy. We report a case of a similar syndrome in an adult, following ingestion of egg. We remind clinicians to consider this diagnosis which may present to emergency physicians and gastroenterologists long before an allergist is consulted</style></abstract><notes><style face="normal" font="Arial">DA - 20160920IS - 2050-0904 (Linking)LA - ENGPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1002/ccr3.665</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27648271">PM:27648271</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Case Rep\2016-4-899-901.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Case Rep\2016-4-899-901.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Zubrinich C</style></custom2><misc3><style face="normal" font="Arial">10.1002/ccr3.665</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oseroff,C.</style></author><author><style face="normal" font="Arial"> Christensen,L.H.</style></author><author><style face="normal" font="Arial"> Westernberg,L.</style></author><author><style face="normal" font="Arial"> Pham,J.</style></author><author><style face="normal" font="Arial"> Lane,J.</style></author><author><style face="normal" font="Arial"> Paul,S.</style></author><author><style face="normal" font="Arial"> Greenbaum,J.</style></author><author><style face="normal" font="Arial"> Stranzl,T.</style></author><author><style face="normal" font="Arial"> Lund,G.</style></author><author><style face="normal" font="Arial"> Hoof,I.</style></author><author><style face="normal" font="Arial"> Holm,J.</style></author><author><style face="normal" font="Arial"> Wurtzen,P.A.</style></author><author><style face="normal" font="Arial"> Meno,K.H.</style></author><author><style face="normal" font="Arial"> Frazier,A.</style></author><author><style face="normal" font="Arial"> Schulten,V.</style></author><author><style face="normal" font="Arial"> Andersen,P.S.</style></author><author><style face="normal" font="Arial"> Peters,B.</style></author><author><style face="normal" font="Arial"> Sette,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunoproteomic analysis of house dust mite antigens reveals distinct classes of dominant T cell antigens according to function and serological reactivity</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="592" start="577">577-592</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> HLA class II</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> ontology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T cell reactivity</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: House dust mite (HDM) allergens are a common cause of allergy and allergic asthma. A comprehensive analysis of proteins targeted by T cells, which are implicated in the development and regulation of allergic disease independent of their antibody reactivity, is still lacking. OBJECTIVE: To comprehensively analyze the HDM-derived protein targets of T cell responses in HDM-allergic individuals, and investigate their correlation with IgE/IgG responses and protein function. METHODS: Proteomic analysis (liquid chromatography tandem mass spectrometry) of HDM extracts identified 90 distinct protein clusters, corresponding to 29 known allergens and 61 novel proteins. Peripheral blood mononuclear cells (PBMC) from 20 HDM-allergic individuals were stimulated with HDM extracts and assayed with a set of ~2500 peptides derived from these 90 protein clusters and predicted to bind the most common HLA class II types. 2D immunoblots were made in parallel to elucidate IgE and IgG reactivity and putative function analyses were performed in silico according to gene ontology (GO) annotations. RESULTS: Analysis of T cell reactivity revealed a large number of T cell epitopes. Overall response magnitude and frequency was comparable for known and novel proteins, with 15 antigens (nine of which were novel) dominating the total T cell response. Most of the known allergens that were dominant at the T cell level were also IgE-reactive, as expected, while few novel dominant T cell antigens were IgE reactive. Among known allergens, hydrolase activity and detectable IgE/IgG reactivity are strongly correlated, while no protein function correlates with immunogenicity of novel proteins. A total of 106 epitopes accounted for half of the total T-cell response, underlining the heterogeneity of T cell responses to HDM allergens. CONCLUSIONS AND CLINICAL RELEVANCE: Herein, we define the T cell targets for both known allergens and novel proteins, which may inform future diagnostics and immunotherapeutics for allergy to HDM. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12829</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27684489">PM:27684489</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160929-OseroffC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160929-OseroffC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Oseroff C</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12829</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carlier,F.M.</style></author><author><style face="normal" font="Arial"> Sibille,Y.</style></author><author><style face="normal" font="Arial"> Pilette,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institut de Recherche Experimentale et Clinique, Pole Pneumologie, ORL et Dermatologie, B-1200, Brussels, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">The epithelial barrier and immunoglobulin A system in Allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1388" start="1372">1372-1388</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinique</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin A</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immunity</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immunology</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> ORL</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="9" Year="2016">2016/9/29</year></dates><abstract><style face="normal" font="Arial">Airway and intestinal epithelial layers represent first line physical barriers, playing a key role in mucosal immunity. Barrier dysfunction, characterized by alterations such as disruption of cell-cell apical junctions and aberrant epithelial responses, probably constitutes early and key events for chronic immune responses to environmental antigens in the skin and in the gut. For instance, barrier dysfunction drives Th2 responses in atopic disorders or eosinophilic esophagitis. Such epithelial impairment is also a salient feature of allergic asthma and growing evidence indicates that barrier alterations probably play a driving role in this disease. IgA has been identified as the most abundant immunoglobulin in mucosa, where it acts as an active barrier through immune exclusion of inhaled or ingested antigens or pathogens. Historically, it has been thought to represent the serum factor underlying reaginic activity before IgE was discovered. Despite several studies about regulation and major functions of IgA at mucosal surfaces, its role in allergy remains largely unclear. This review aims at summarizing findings about epithelial functions and IgA biology that are relevant to allergy, and to integrate the emerging concepts and the recent developments in mucosal immunology, and how these could translate to clinical observations in allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12830</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27684559">PM:27684559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20160929-CarlierFM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20160929-CarlierFM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Carlier FM</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12830</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,H.X.</style></author><author><style face="normal" font="Arial"> Yount,W.J.</style></author><author><style face="normal" font="Arial"> Culton,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Food allergen-mediated exacerbations of oral lichen planus</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="781" start="779">779-781</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Azathioprine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lichen Planus</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> systemic treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Erosive oral lichen planus (OLP) is a chronic autoimmune condition of unknown aetiology, characterized by periods of exacerbation and quiescence. Many patients with OLP report triggers of flares that overlap with triggers of other oral diseases, including oral allergy syndrome (OAS), an IgE-mediated food allergy. We report a case that, to our knowledge, is the first reported case of concurrent OLP and OAS diagnoses, which provides insight into the triggers of OLP and the role of trigger avoidance. A woman in her 60s presented with erosive OLP refractory to prednisone and azathioprine. She reported that certain food exposures triggered flares of her OLP. She was subsequently diagnosed with concurrent OAS, and avoidance of food allergens resulted in a clinically significant improvement in her OLP, eventually allowing her to taper off systemic treatment altogether. Further studies are needed to pinpoint common triggers and examine the role of trigger avoidance as a management strategy for OLP</style></abstract><notes><style face="normal" font="Arial">DA - 20160924IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - ENGPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.12929</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27663157">PM:27663157</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\2016-41-779-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\2016-41-779-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160924, Chen HX</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.12929</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,Z.</style></author><author><style face="normal" font="Arial"> Xie,Y.</style></author><author><style face="normal" font="Arial"> Guan,W.</style></author><author><style face="normal" font="Arial"> Gao,Y.</style></author><author><style face="normal" font="Arial"> Xia,S.</style></author><author><style face="normal" font="Arial"> Huang,R.</style></author><author><style face="normal" font="Arial"> Zhong,N.</style></author><author><style face="normal" font="Arial"> Zheng,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease, China Clinical Research Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of leukotriene D4 and histamine nasal challenge on airway responsiveness and inflammation in persistent allergic rhinitis patients</style></title><secondary-title><style face="normal" font="Arial">Clin Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Respir J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene D4</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal challenge</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="10" Year="2016">2016/10/3</year></dates><abstract><style face="normal" font="Arial">Background Both histamine and leukotrienes are implicated in the pathogenesis of allergic rhinitis (AR), although the pattern and severity of the nasal response to these two potent inflammatory mediators may differ, which has not been adequately studied in patients with persistent AR. Objective We sought to compare the differential effects of nasal challenge with leukotriene D4 (LTD4 ) and histamine on the airway response and inflammation in patients with AR. Methods An open-label, crossover study was performed in 25 persistent AR patients (AR group) and 16 healthy subjects (control group). Participants randomly underwent histamine and LTD4 nasal provocation within a two-week interval. Nasal symptoms according to a visual analogue scale (VAS), fractional exhaled nitric oxide (FENO), nasal lavage, induced sputum, and spirometry were evaluated before and after nasal challenge. Results Nasal airway resistance (NAR) increased significantly after both LTD4 and histamine nasal challenge in AR patients (p&lt;0.05). The potency of LTD4 was 142-fold higher than that of histamine in increasing NAR (p&lt;0.001). The nasal symptom score induced by histamine challenge was significantly higher than that triggered by LTD4 (3.42+/-0.83 vs. 1.16+/-0.94, p&lt;0.05) in the AR group. LTD4 and histamine nasal challenge led to a significant increase in neutrophils in the nasal lavage and induced sputum (p&lt;0.05) in AR patients. There were no significant differences in the changes of eosinophils before and after LTD4 and histamine nasal challenges in nasal lavage and induced sputum. No significant changes in NAR, the induced symptom score, or inflammatory cells in the nasal lavage and sputum were found in the control group. Conclusions LTD4 and histamine nasal challenge caused different patterns and severities of nasal symptoms, which correlated with symptoms (TSS) that affect patient daily life. LTD4 was far more potent than histamine at increasing the NAR, while histamine nasal challenge induced more sneezing and nasal discharge. These results may guide the prescription of anti-histamine or anti-leukotriene agents for treating different AR phenotypes. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1752-699X (Electronic)IS - 1752-6981 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/crj.12564</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27696764">PM:27696764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Respir J\20161003-ZhuZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Respir J\20161003-ZhuZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Zhu Z</style></custom2><misc3><style face="normal" font="Arial">10.1111/crj.12564</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81800</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Royce,S.G.</style></author><author><style face="normal" font="Arial"> Tominaga,A.M.</style></author><author><style face="normal" font="Arial"> Shen,M.</style></author><author><style face="normal" font="Arial"> Patel,K.P.</style></author><author><style face="normal" font="Arial"> Huuskes,B.M.</style></author><author><style face="normal" font="Arial"> Lim,R.</style></author><author><style face="normal" font="Arial"> Ricardo,S.D.</style></author><author><style face="normal" font="Arial"> Samuel,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Building 13E, 9 Ancora Imparo Way, Clayton, 3800, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Serelaxin improves the therapeutic efficacy of RXFP1-expressing human amnion epithelial cells in experimental allergic airways disease</style></title><secondary-title><style face="normal" font="Arial">Clin Sci (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Sci (Lond)</style></full-title></periodical><pages end="12165" start="215">215-12165</pages><volume><style face="normal" font="Arial">130</style></volume><number><style face="normal" font="Arial">23</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Amnion</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="9" Year="2016">2016/9/19</year></dates><abstract><style face="normal" font="Arial">Current asthma therapies primarily target airway inflammation (AI) and suppress episodes of airway hyperresponsiveness (AHR) but fail to treat airway remodelling (AWR), which can develop independently of AI and contribute to irreversible airway obstruction. This study compared the anti-remodelling and therapeutic efficacy of human bone marrow-derived mesenchymal stem cells (MSCs) to that of human amnion epithelial stem cells (AECs) in the setting of chronic allergic airways disease (AAD), in the absence or presence of an anti-fibrotic (serelaxin; RLX). Female Balb/c mice subjected to the 9-week model of ovalbumin (OVA)-induced chronic AAD, were either vehicle-treated (OVA alone) or treated with MSCs or AECs alone (intranasally (i.n)-administered with 1x106 cells once weekly), RLX alone (i.n-administered with 0.8mg/ml daily) or a combination of MSCs or AECs and RLX from weeks 9-11 (n=6/group). Measures of AI, AWR and AHR were then assessed. OVA alone exacerbated AI, epithelial damage/thickness, sub-epithelial extracellular matrix (ECM) and total collagen deposition, markers of collagen turnover and AHR compared to that in saline-treated counterparts (all p&lt;0.01 vs saline-treated controls). RLX or AECs (but not MSCs) alone normalised epithelial thickness and partially diminished the OVA-induced fibrosis and AHR by ~40-50% (all p&lt;0.05 vs OVA alone). Furthermore, the combination treatments normalised epithelial thickness, measures of fibrosis and AHR to that in normal mice, and significantly decreased AI. While AECs alone demonstrated greater protection against the AAD-induced AI, AWR and AHR, compared to that of MSCs alone, combining RLX with MSCs or AECs reversed airway fibrosis and AHR to an even greater extent</style></abstract><notes><style face="normal" font="Arial">DA - 20160920IS - 1470-8736 (Electronic)IS - 0143-5221 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1042/CS20160328</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27647937">PM:27647937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Sci (Lond)\20160920-RoyceSG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Sci (Lond)\20160920-RoyceSG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Royce SG</style></custom2><misc3><style face="normal" font="Arial">10.1042/CS20160328</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81801</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Malling,H.J.</style></author><author><style face="normal" font="Arial"> lesen-Holm,P.</style></author><author><style face="normal" font="Arial"> Karved,L.S.</style></author><author><style face="normal" font="Arial"> Poulsen,L.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Clinic, Copenhagen University Hospital Gentofte, Kildegardsvej 28, 2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Proficiency testing of skin prick testers as part of a quality assurance system</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="36">36-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Proficiency testing</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality assurance</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Skin prick test is an important diagnostic procedure in clinical allergy but documentation of the quality is often missing. METHODS: We describe a proficiency system to evaluate staff members in relation to the international recommended reproducibility in terms of coefficient of variation (CV &lt; 40 %) and the linearity (coefficient of regression >0.85) based on blinded octuplicate histamine testing using histamine 3, 10, 30 and 100 mg/ml. RESULTS: Fourteen trained allergy nurses participated in the proficiency testing. More than 95 % of the nurses, generated coefficient of variation less than 40 %, and for around 35 % of testers the CV were below 20 % based on wheal area. Regarding the linearity (coefficient of regression), only two nurses produced tests with a value below 0.85. On the contrary, 79 % of testers demonstrated a coefficient of regression >0.95. Depending on the gentleness of the prick procedure, the inter-nurse variability in wheal area varied more than twofold corresponding to a 10-doubling of histamine concentration. This would never have been detected without using a proficiency testing system. CONCLUSION: The described histamine testing provides an objective system for the evaluation of basic skin test quality assessment standards especially for documentation in scientific studies</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 2045-7022 (Linking)LA - ENGPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0126-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27688875">PM:27688875</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Malling HJ</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0126-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chaubal,T.V.</style></author><author><style face="normal" font="Arial"> Bapat,R.A.</style></author><author><style face="normal" font="Arial"> Patil,P.G.</style></author><author><style face="normal" font="Arial"> Shetty,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Periodontology and Oral Implantology, DY Patil University School of Dentistry, 400706, Navi Mumbai, India.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic contact dermatitis caused by latex gloves in a dental undergraduate student</style></title><secondary-title><style face="normal" font="Arial">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Contact Dermatitis</style></full-title></periodical><pages end="257" start="256">256-257</pages><volume><style face="normal" font="Arial">75</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Gloves</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - ENGPT - Journal ArticleSB - IMCO - India -CO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cod.12625</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27620128">PM:27620128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2016-75-256-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2016-75-256-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Chaubal TV</style></custom2><misc3><style face="normal" font="Arial">10.1111/cod.12625</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kadlubowska,D.</style></author><author><style face="normal" font="Arial"> Bargman,H.</style></author><author><style face="normal" font="Arial"> Sasseville,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, Montreal General Hospital, McGill University, Montreal, H3G 1A4, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Systemic contact dermatitis caused by inhaled cashew oil smoke</style></title><secondary-title><style face="normal" font="Arial">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Contact Dermatitis</style></full-title></periodical><pages end="250" start="248">248-250</pages><volume><style face="normal" font="Arial">75</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Canada</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Systemic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - ENGPT - Journal ArticleSB - IMCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/cod.12612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27620124">PM:27620124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2016-75-248-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2016-75-248-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Kadlubowska D</style></custom2><misc3><style face="normal" font="Arial">10.1111/cod.12612</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Andersen,F.</style></author><author><style face="normal" font="Arial"> Paulsen,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and the Allergy Centre, Odense University Hospital, 5000, Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic contact dermatitis caused by the Boston fern Nephrolepis exaltata 'Bostoniensis'</style></title><secondary-title><style face="normal" font="Arial">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Contact Dermatitis</style></full-title></periodical><pages end="256" start="255">255-256</pages><volume><style face="normal" font="Arial">75</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fern</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160913IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - ENGPT - Journal ArticleSB - IMCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/cod.12622</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27620127">PM:27620127</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2016-75-255-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2016-75-255-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160913, Andersen F</style></custom2><misc3><style face="normal" font="Arial">10.1111/cod.12622</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sheehan,W.J.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDivision of Allergy and Immunology, Boston Children's Hospital bHarvard Medical School, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">Indoor allergen exposure and asthma outcomes</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pediatr</style></full-title></periodical><pages end="777" start="772">772-777</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Indoor mold</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="20" Month="9" Year="2016">2016/9/20</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The aim of the present review is to discuss updates on research regarding the relationship between indoor allergen exposure and childhood asthma with a focus on clinical effects, locations of exposure, and novel treatments. RECENT FINDINGS: Recent data continue to demonstrate that early life sensitization to indoor allergens is a predictor of asthma development later in life. Furthermore, avoidance of exposure to these allergens continues to be important especially given that the vast majority of children with asthma are sensitized to at least one indoor allergen. New research suggests that mouse allergen, more so than cockroach allergen, may be the most relevant urban allergen. Recent evidence reminds us that children are exposed to clinically important levels of indoor allergens in locations away from their home, such as schools and daycare centers. Exposure to increased levels of indoor mold in childhood has been associated with asthma development and exacerbation of current asthma; however, emerging evidence suggests that early exposure to higher fungal diversity may actually be protective for asthma development. Novel treatments have been developed that target TH2 pathways thus decreasing asthmatic responses to allergens. These therapies show promise for the treatment of severe allergic asthma refractory to avoidance strategies and standard therapies. SUMMARY: Understanding the relationship between indoor allergens and asthma outcomes is a constantly evolving study of timing, location, and amount of exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 1531-698X (Electronic)IS - 1040-8703 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOP.0000000000000421</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27653703">PM:27653703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pediatr\20160922-SheehanWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pediatr\20160922-SheehanWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160922, Sheehan WJ</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOP.0000000000000421</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Winberg,A.</style></author><author><style face="normal" font="Arial"> Nagaeva,O.</style></author><author><style face="normal" font="Arial"> Nagaev,I.</style></author><author><style face="normal" font="Arial"> Lundell,C.</style></author><author><style face="normal" font="Arial"> Arencibia,I.</style></author><author><style face="normal" font="Arial"> Mincheva-Nilsson,L.</style></author><author><style face="normal" font="Arial"> Ronmark,E.</style></author><author><style face="normal" font="Arial"> West,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, Pediatrics, Umea University, Sweden.</style></auth-address><titles><title><style face="normal" font="Arial">Dynamics of cytokine mRNA expression and fecal biomarkers in school-children undergoing a double-blind placebo-controlled food challenge series</style></title><secondary-title><style face="normal" font="Arial">Cytokine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cytokine</style></full-title></periodical><pages end="266" start="259">259-266</pages><volume><style face="normal" font="Arial">88</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> calprotectin</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cod</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine mRNA expression</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Double-blind challenge</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil-Derived Neurotoxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food challenge outcome</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-15</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Labor</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="30" Month="9" Year="2016">2016/9/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is need for prognostic markers for symptomatic food allergy since current diagnostic methods are insufficient and/or time and labor consuming. OBJECTIVE: To estimate the cytokine mRNA profiles in peripheral blood mononuclear cells (PBMC) before and after a double-blind placebo-controlled food challenge series in schoolchildren with suspected allergy to milk, egg or cod and in healthy controls. Analyses of fecal inflammatory biomarkers before and after the challenge were included. METHODS: Twelve-year-old children from a population-based cohort reporting complete avoidance of milk, egg, cod or wheat due to perceived hypersensitivity were clinically examined and those with suspected food allergy were evaluated with a 3-session double-blind placebo-controlled food challenge (n=18). Seven healthy controls participated in a double-blind challenge with egg. Before and after the challenge series, the cytokine mRNA expression was quantified for 13 cytokines discriminating between humoral Th2-, cytotoxic Th1-, regulatory Th3/Tr1- and inflammatory responses. Fecal calprotectin and eosinophil-derived neurotoxin (EDN) were also analyzed in children with suspected food allergy before and after the challenge series. RESULTS: Pre challenge, children with suspected food allergy had higher IL-13andTNF-alpha expression and lower IFN-gamma and IL-15 expression compared to healthy controls (all p&lt;0.05). Children with challenge-proven food allergy had increased IL13andIL-10 expression compared to the levels seen in negative challenges (p&lt;0.05). Post challenge, IL-1beta and IL-6 mRNA levels were elevated in the food allergic children compared to controls (p&lt;0.05). Fecal calprotectin and EDN levels were higher in challenge-proven food allergy compared to a negative challenge although not statistically significantly. CONCLUSION &amp; CLINICAL RELEVANCE: Increased baseline mRNA levels of the Th2-related cytokine IL-13 and the regulatory cytokine IL-10 predicted a positive food challenge outcome. These cytokines in combination with fecal calprotectin and EDN might serve as future prognostic markers for symptomatic, IgE-mediated food allergy but need further validation in a larger patient cohort</style></abstract><notes><style face="normal" font="Arial">DA - 20161004IS - 1096-0023 (Electronic)IS - 1043-4666 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cyto.2016.09.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27697703">PM:27697703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytokine\2016-88-259-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytokine\2016-88-259-66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161004, Winberg A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cyto.2016.09.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silva,M.B.</style></author><author><style face="normal" font="Arial"> Amor,A.L.</style></author><author><style face="normal" font="Arial"> Santos,L.N.</style></author><author><style face="normal" font="Arial"> Galvao,A.A.</style></author><author><style face="normal" font="Arial"> Oviedo,V.AY</style></author><author><style face="normal" font="Arial"> Silva,E.S.</style></author><author><style face="normal" font="Arial"> Barbosa,C.G.</style></author><author><style face="normal" font="Arial"> Cooper,P.J.</style></author><author><style face="normal" font="Arial"> Figueiredo,C.A.</style></author><author><style face="normal" font="Arial"> Ribeiro,R.C.</style></author><author><style face="normal" font="Arial"> Alcantara-Neves,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Ciencias da Saude, Universidade Federal da Bahia, Salvador, Bahia, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Data on prevalence and risk factors associated with Toxocara spp infection, atopy and asthma development in Northeast Brazilian school children</style></title><secondary-title><style face="normal" font="Arial">Data Brief</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Data Brief</style></full-title></periodical><pages end="428" start="425">425-428</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Home environment</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> School-age children</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Toxocara</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">In the present article, we provide shortly, data on risk factors for acquiring Toxocara spp. infection and investigate possible associations between this infection with atopy and asthma in school children of a small town and its semi-rural areas of Northeast Brazil. The data set are composed by demographic, social and home environment variables. The detection of anti-Toxocara spp. IgG and specific IgE to aeroallergens was determined by ELISA and ImmunocAP/Phadiatrope systems, respectively. The data presented in this article are related to the article entitled "Risk factors for Toxocara spp. seroprevalence and its association with atopy and asthma phenotypes in school-age children in a small town and semi-rural areas of Northeast Brazil" (M.B. Silva, A.L. Amor, L.N. Santos, A.A. Galvao, A.V. Oviedo Vera, E.S. Silva et al., 2016) [1]</style></abstract><notes><style face="normal" font="Arial">DA - 20161004IS - 2352-3409 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.dib.2016.08.062</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27699195">PM:27699195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Data Brief\2016-9-425-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Data Brief\2016-9-425-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161004, Silva MB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.dib.2016.08.062</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,Z.</style></author><author><style face="normal" font="Arial"> Han,B.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Wu,Q.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Li,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Neonatology, Provincial Hospital Affiliated to Shandong University , Jinan, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Pycnogenol Ameliorates Asthmatic Airway Inflammation and Inhibits the Function of Goblet Cells</style></title><secondary-title><style face="normal" font="Arial">DNA Cell Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">DNA Cell Biol</style></full-title></periodical><pages end="739" start="730">730-739</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="9" Year="2016">2016/9/19</year></dates><abstract><style face="normal" font="Arial">Pycnogenol(R) (PYC) is utilized in the treatment of various diseases ranging from chronic inflammation to circulatory diseases, but its efficacy and functional mechanism in pediatric asthma continue to remain obscure. Therefore, the purpose of this study was to investigate the effectiveness and molecular mechanism of PYC on regulation of asthmatic airway inflammation. We found that PYC with tail intravenous injection of 50 mg/kg or intragastric administration of 100 mg/kg all reduced ovalbumin (OVA)-induced airway injury. Pharmacokinetics of PYC was evaluated by high-performance liquid chromatography assay, indicating that PYC was quickly absorbed into the blood after intragastric administration, and PYC metabolism was later improved gradually with increase of time after PYC administration. PYC has a higher bioavailability of 71.96%, and it was more easily absorbed by the body. PYC inhibited the number of total inflammatory cells and levels of interleukin (IL)-4, IL-5, IL-9, and IL-13 in bronchoalveolar lavage fluid of OVA-induced mice. PYC inhibited IL-13 secretion from the Th2 cells, thereby causing a reduction in expression of the signaling molecules in JAK/STAT6 pathway in airway epithelial cells. STAT6 silence suppressed IL-13-increased acetylcholine level. STAT6 overexpression promoted expression of goblet cell metaplasia-associated molecules (FOXA3, SPDEF, and Muc5ac). PYC suppressed OVA-induced expression of FOXA3, SPDEF, and Muc5ac in lung. Our findings indicate that PYC has a higher bioavailability and it prevents emergence of OVA-induced airway injury and airway inflammation in mice by inhibiting IL-13/JAK/STAT6 pathway and blocking release of acetylcholine to reduce goblet cell metaplasia</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 1557-7430 (Electronic)IS - 1044-5498 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1089/dna.2016.3264</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27643741">PM:27643741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\DNA Cell Biol\20160919-LiuZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\DNA Cell Biol\20160919-LiuZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Liu Z</style></custom2><misc3><style face="normal" font="Arial">10.1089/dna.2016.3264</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanino,T.</style></author><author><style face="normal" font="Arial"> Komada,A.</style></author><author><style face="normal" font="Arial"> Ueda,K.</style></author><author><style face="normal" font="Arial"> Bando,T.</style></author><author><style face="normal" font="Arial"> Nojiri,Y.</style></author><author><style face="normal" font="Arial"> Ueda,Y.</style></author><author><style face="normal" font="Arial"> Sakurai,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tokushima Bunri University</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacokinetics and Differential Regulation of Cytochrome P450 Enzymes in Type 1 Allergic Mice</style></title><secondary-title><style face="normal" font="Arial">Drug Metab Dispos</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drug Metab Dispos</style></full-title></periodical><pages end="1957" start="1950">1950-1957</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytochrome P450</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="9" Year="2016">2016/9/30</year></dates><abstract><style face="normal" font="Arial">Type 1 allergic diseases are characterized by elevated production of specific immunoglobulin E (IgE) for each antigen and have become a significant health problem worldwide. This study investigated the effect of IgE-mediated allergy on drug pharmacokinetics. To further understand differential suppression of hepatic cytochrome P450 (CYP) activity, we examined the inhibitory effect of nitric oxide (NO), a marker of allergic conditions. Seven days after primary or secondary sensitization (PS7 and SS7, respectively), hepatic CYP1A2, CYP2C, CYP2E1 and CYP3A activities were decreased to 45%-75% of the corresponding control, however, CYP2D activity was not downregulated. PS7 and SS7 did not change the expression levels of five CYP proteins. Disappearance of CYP1A2 and CYP2D substrates from the plasma was not significantly different between allergic mice and control mice. In contrast, area under the curve of a CYP1A2-mediated metabolite in PS7 and SS7 mice was reduced by 50% of control values. Total clearances of a CYP2E1 substrate in PS7 and SS7 mice were significantly decreased to 70% and 50% of the control without altering plasma protein binding, respectively. Hepatic amounts of CYP1A2 and CYP2E1 substrates were enhanced by allergic induction, being responsible for each downregulated activity. NO scavenger treatment completely improved the downregulated CYP activities. Therefore, our data suggest that the onset of IgE-mediated allergy alters the pharmacokinetics of major CYP-metabolic capacity-limited drugs except for CYP2D drugs. NO is highly expected to participate in regulatory mechanisms of the four CYP isoforms</style></abstract><notes><style face="normal" font="Arial">DA - 20161004IS - 1521-009X (Electronic)IS - 0090-9556 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1124/dmd.116.072462</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27694226">PM:27694226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drug Metab Dispos\20161004-TaninoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drug Metab Dispos\20161004-TaninoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161004, Tanino T</style></custom2><misc3><style face="normal" font="Arial">10.1124/dmd.116.072462</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lyseng-Williamson,KA.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Standardized quality house dust mite sublingual tablets (Acarizax-«): a guide to their use as sublingual allergy immunotherapy in Europe</style></title><secondary-title><style face="normal" font="Arial">Drugs Ther Perspect</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs Ther Perspect</style></full-title></periodical><pages end="509" start="502">502-509</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> precautions</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> sublingual tablet</style></keyword><keyword><style face="normal" font="Arial"> Sublingual tablets</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1179-1977</style></isbn><abstract><style face="normal" font="Arial">Standardized quality (SQ) house dust mite (HDM) allergen extract tablets (Acarizax-«) are a valuable option for sublingual allergy immunotherapy (SLIT) in adults with confirmed HDM-induced allergic rhinitis or allergic asthma. In placebo-controlled natural-field and environmental exposure challenge chamber trials, Acarizax-« reduced the symptoms of allergic rhinitis in adults with HDM-induced allergic rhinitis (-¦-áasthma) and reduced the risk of asthma exacerbations in adults with HDM-induced allergic asthma. A systemic antibody response to HDM allergens has been observed within 4-áweeks of initiating SLIT with Acarizax-«. Precautions should be followed to minimize the risk of systemic and local allergic reactions inherent to SLIT</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40267-016-0349-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40267-016-0349-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs Ther Perspect\20161019-LysengWilliamsonKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs Ther Perspect\20161019-LysengWilliamsonKA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Lyseng-Williamson KA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40267-016-0349-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zieglmayer,P.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> Schmutz,R.</style></author><author><style face="normal" font="Arial"> Lemell,P.</style></author><author><style face="normal" font="Arial"> Zieglmayer,R.</style></author><author><style face="normal" font="Arial"> Weber,M.</style></author><author><style face="normal" font="Arial"> Kiss,R.</style></author><author><style face="normal" font="Arial"> Blatt,K.</style></author><author><style face="normal" font="Arial"> Valent,P.</style></author><author><style face="normal" font="Arial"> Stolz,F.</style></author><author><style face="normal" font="Arial"> Huber,H.</style></author><author><style face="normal" font="Arial"> Neubauer,A.</style></author><author><style face="normal" font="Arial"> Knoll,A.</style></author><author><style face="normal" font="Arial"> Horak,F.</style></author><author><style face="normal" font="Arial"> Henning,R.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Vienna Challenge Chamber, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy</style></title><secondary-title><style face="normal" font="Arial">EBioMedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EBioMedicine</style></full-title></periodical><pages end="57" start="43">43-57</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> fusion proteins</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B</style></keyword><keyword><style face="normal" font="Arial"> hepatitis B surface protein</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> Late phase reaction</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> preS</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Fusion Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We have developed a recombinant B cell epitope-based vaccine (BM32) for allergen-specific immunotherapy (AIT) of grass pollen allergy. The vaccine contains recombinant fusion proteins consisting of allergen-derived peptides and the hepatitis B surface protein domain preS as immunological carrier. METHODS: We conducted a randomized, double-blind, placebo-controlled AIT study to determine safety, clinical efficacy and immunological mechanism of three subcutaneous injections of three BM32 doses adsorbed to aluminum hydroxide versus aluminum hydroxide (placebo) applied monthly to grass pollen allergic patients (n=70). Primary efficacy endpoint was the difference in total nasal symptom score (TNSS) through grass pollen chamber exposure before treatment and 4weeks after the last injection. Secondary clinical endpoints were total ocular symptom score (TOSS) and allergen-specific skin response evaluated by titrated skin prick testing (SPT) at the same time points. Treatment-related side effects were evaluated as safety endpoints. Changes in allergen-specific antibody, cellular and cytokine responses were measured in patients before and after treatment. RESULTS: Sixty-eight patients completed the trial. TNSS significantly decreased with mean changes of -1.41 (BM32/20mug) (P=0.03) and -1.34 (BM32/40mug) (P=0.003) whereas mean changes in the BM32/10mug and placebo group were not significant. TOSS and SPT reactions showed a dose-dependent decrease. No systemic immediate type side effects were observed. Only few grade 1 systemic late phase reactions occurred in BM32 treated patients. The number of local injection site reactions was similar in actively and placebo-treated patients. BM32 induced highly significant allergen-specific IgG responses (P&lt;0.0001) but no allergen-specific IgE. Allergen-induced basophil activation was reduced in BM32 treated patients and addition of therapy-induced IgG significantly suppressed T cell activation (P=0.0063). CONCLUSION: The B cell epitope-based recombinant grass pollen allergy vaccine BM32 is well tolerated and few doses are sufficient to suppress immediate allergic reactions as well as allergen-specific T cell responses via a selective induction of allergen-specific IgG antibodies. (ClinicalTrials.gov number, NCT01445002.)</style></abstract><notes><style face="normal" font="Arial">DA - 20160921IS - 2352-3964 (Electronic)IS - 2352-3964 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ebiom.2016.08.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27650868">PM:27650868</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EBioMedicine\2016-11-43-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EBioMedicine\2016-11-43-57.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160921, Zieglmayer P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ebiom.2016.08.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alvarez-Chavez,C.R.</style></author><author><style face="normal" font="Arial"> Flores-Bernal,J.L.</style></author><author><style face="normal" font="Arial"> Esquer-Peralta,J.</style></author><author><style face="normal" font="Arial"> Munguia-Vega,N.E.</style></author><author><style face="normal" font="Arial"> Corella-Madueno,M.A.</style></author><author><style face="normal" font="Arial"> Rascon-Careaga,A.</style></author><author><style face="normal" font="Arial"> Turcotte,D.</style></author><author><style face="normal" font="Arial"> Velazquez-Contreras,L.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chemical and Biological Sciences Department, University of Sonora, Hermosillo, Sonora, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">Detection of allergen sources in the homes of sensitized children</style></title><secondary-title><style face="normal" font="Arial">Environ Health Prev Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Health Prev Med</style></full-title></periodical><pages end="538" start="531">531-538</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sonora</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United Nations</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="10" Year="2016">2016/10/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To identify the presence of environmental factors linked to the onset of allergies and asthma in the homes of children participating in an early detection program that were identified with sensitivity to common allergens in the region of Sonora, Mexico. METHODS: A walkthrough assessment was carried out in the homes of sensitized children; the research tools were the questionnaire and environmental checklist proposed by the Lowell Healthy Homes Program of the University of Massachusetts-Lowell. RESULTS: The results showed the presence of environmental allergen sources, to which most of the children in the study are sensitized, as well as the environmental conditions and habits that determine the quality of the indoor air of the households, were both related to triggering allergies and asthma in this population. A statistically significant association was found between the visual observation of dust inside homes and the sensitivity of children to dust mites. CONCLUSIONS: Dust found inside the home was the most relevant environmental factor related to positive cases of IgE in children. Early detection of allergies in children in the study and the methodology used in this investigation provided a useful framework for the design of plans and intervention alternatives in these homes to prevent the development of allergies and asthma panorama. These plans should be designed with a multidisciplinary approach to impact social, environmental and economic benefits in the family, improving the living conditions of the study population and contributing to the sustainable development goals of the United Nations for 2030</style></abstract><notes><style face="normal" font="Arial">DA - 20161004IS - 1347-4715 (Electronic)IS - 1342-078X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Mexico -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12199-016-0566-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27699687">PM:27699687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Health Prev Med\20161004-AlvarezChavezCR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Health Prev Med\20161004-AlvarezChavezCR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161004, Alvarez-Chavez CR</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12199-016-0566-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wagner,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin E and allergy</style></title><secondary-title><style face="normal" font="Arial">Equine Vet J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Equine Vet J</style></full-title></periodical><pages end="14" start="13">13-14</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> False Negative Reactions</style></keyword><keyword><style face="normal" font="Arial"> False Positive Reactions</style></keyword><keyword><style face="normal" font="Arial"> Horse Diseases</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serologic Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="0" Month="1" Year="2016">2016/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20151215IS - 2042-3306 (Electronic)IS - 0425-1644 (Linking)LA - ENGPT - CommentPT - EditorialRN - 0 (Allergens)RN - 0 (Immunoglobulin G)RN - 37341-29-0 (Immunoglobulin E)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/evj.12513</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26663407">PM:26663407</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Equine Vet J\2016-48-13-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Equine Vet J\2016-48-13-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151215, Wagner B</style></custom2><misc3><style face="normal" font="Arial">10.1111/evj.12513</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berends,P.</style></author><author><style face="normal" font="Arial"> Merz,M.</style></author><author><style face="normal" font="Arial"> Kochjohann,A.</style></author><author><style face="normal" font="Arial"> Philipps,L.</style></author><author><style face="normal" font="Arial"> Blank,I.</style></author><author><style face="normal" font="Arial"> Stressler,T.</style></author><author><style face="normal" font="Arial"> Fischer,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sensory and antigenic properties of enzymatic wheat gluten hydrolysates produced in an enzyme membrane reactor in comparison with batch</style></title><secondary-title><style face="normal" font="Arial">Eur Food Res Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Food Res Technol</style></full-title></periodical><pages end="816" start="807">807-816</pages><volume><style face="normal" font="Arial">243</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Drying</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Freeze Drying</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Glutaminase</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reactor</style></keyword><keyword><style face="normal" font="Arial"> Sensory evaluation</style></keyword><keyword><style face="normal" font="Arial"> sensory properties</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> Ultrafiltration</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat gluten</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1438-2385</style></isbn><abstract><style face="normal" font="Arial">The aim of this study was to compare the sensory and antigenic properties of enzymatic wheat gluten hydrolysates produced with Flavourzyme and glutaminase in batch and continuous process, respectively. The hydrolysate samples were obtained by a standard batch process with microfiltration (16-á-Ám) and ultrafiltration (10-ákDa) and an optimized continuous enzyme membrane reactor (EMR) process with an ultrafiltration membrane (10-ákDa). Two drying methods were applied: oven and freeze drying. Sensory evaluation showed that the EMR hydrolysates were significantly different and had an improved taste impact for the attributes </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£overall intensity,</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£salty,</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£umami</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ and </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£mushroom.</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ The antigenic potential of the EMR hydrolysates was reduced (222-á-¦-á4-áppm gliadin) compared to batch microfiltered hydrolysate (9030-á-¦-á89-áppm) and batch ultrafiltered hydrolysate (843-á-¦-á49-áppm). The superior quality of wheat gluten hydrolysate from the EMR process compared to batch process was proven since sensory properties of wheat gluten hydrolysate were improved and the antigenic potential was reduced</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00217-016-2794-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00217-016-2794-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Food Res Technol\20161019-BerendsP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Food Res Technol\20161019-BerendsP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Berends P</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00217-016-2794-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,F.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Li,Xin</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Molecular modeling and conformational IgG epitope mapping on bovine +¦-casein</style></title><secondary-title><style face="normal" font="Arial">Eur Food Res Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Food Res Technol</style></full-title></periodical><pages end="1902" start="1893">1893-1902</pages><volume><style face="normal" font="Arial">242</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Alanine</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asparagine</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitope Mapping</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Homology modeling</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Lysine</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Mimotope</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> molecular modeling</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Tryptophan</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1438-2385</style></isbn><abstract><style face="normal" font="Arial">Characterizing conformational B-cell epitopes is a key step for understanding the immunological basis of allergy contributed by +¦-casein. There is no resolved conformational structure of +¦-casein in protein data bank, and most of the previous research on epitope identification of +¦-casein focused on linear epitopes. Hence, the aim of this study is to map conformational epitopes on +¦-casein using molecular modeling and phage display. Phage peptides bound by the rabbit polyclonal antibodies were selected. Ten mimotopes were obtained after three rounds of bio-panning. Analysis on the structural and geometrical properties of the antibody</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôantigen complexes that were compiled from immune epitope database exhibited that the number of the amino acids comprised in epitope ranged from 11 to 25 with a median number of 17. Epitopes spanned an area range from 541.4 to 1131.9-áÃ¦2 with a median value of 782.9-áÃ¦2. Epitopes were enriched with asparagine, tryptophan, tyrosine, glycine and lysine, whereas alanine, cysteine, aspartate, asparagine and serine were prone to separate the epitopes into fragments. These characteristics of epitope were used to select epitope candidates based on mimotopes and conformational structure of +¦-casein that was built by homology modeling. Consequently, four B-cell IgG epitopes were mapped on +¦-casein</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00217-016-2689-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00217-016-2689-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Food Res Technol\2016-242-1893-902.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Food Res Technol\2016-242-1893-902.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Liu F</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00217-016-2689-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Babina,M.</style></author><author><style face="normal" font="Arial"> Guhl,S.</style></author><author><style face="normal" font="Arial"> Artuc,M.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Skin mast cell phenotypes between two highly divergent cohorts - more pronounced variability within than between groups</style></title><secondary-title><style face="normal" font="Arial">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Dermatol</style></full-title></periodical><pages end="449" start="446">446-449</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - ENGPT - LETTERCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/exd.13227</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27677092">PM:27677092</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Dermatol\20160927-BabinaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Dermatol\20160927-BabinaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Babina M</style></custom2><misc3><style face="normal" font="Arial">10.1111/exd.13227</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vickery,B.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pediatrics , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA</style></auth-address><titles><title><style face="normal" font="Arial">Low dose immunotherapy in very young children to treat peanut allergy</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="1253" start="1251">1251-1253</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="12" Month="9" Year="2016">2016/9/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2016.1226131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27599211">PM:27599211</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\20160912-VickeryBP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\20160912-VickeryBP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160912, Vickery BP</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2016.1226131</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nelson,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Medicine , National Jewish Health , Denver , CO , USA</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy (AIT) for the multiple-pollen sensitive patient</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Pharmacol</style></full-title></periodical><pages end="1451" start="1443">1443-1451</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status date="10/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="6" Month="10" Year="2016">2016/10/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The majority of allergic subjects are polysensitized. In Europe, allergy immunotherapy (AIT) in these patients is usually limited to their single clinically most troublesome allergy while in the U.S. the immunotherapy prescription usually includes all allergen extracts to which the patient has evidence of clinical sensitivity. Areas covered: This article will review the evidence supporting the U.S. practice. It will also review the major new development in the management of polysensitized patients, the introduction of component-resolved diagnosis (CRD). Expert commentary: This allows, in many cases, distinguishing in polysensitized patients between sensitization to the major allergens of several unrelated allergen extracts and to panallergens that cause broad patterns of cross-reactivity</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1751-2441 (Electronic)IS - 1751-2433 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/17512433.2016.1237874</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27687128">PM:27687128</url></web-urls><pdf-urls><url ppv-ref="no">nelsonh@njhealyth.org</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Nelson HS</style></custom2><misc3><style face="normal" font="Arial">10.1080/17512433.2016.1237874</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masson,J.D.</style></author><author><style face="normal" font="Arial"> Thibaudon,M.</style></author><author><style face="normal" font="Arial"> Belec,L.</style></author><author><style face="normal" font="Arial"> Crepeaux,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Association E3M (Entraide aux Malades de Myofasciite a Macrophages) , Monprimblanc , France</style></auth-address><titles><title><style face="normal" font="Arial">Calcium phosphate: a substitute for aluminum adjuvants?</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Vaccines</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Vaccines</style></full-title></periodical><pages end="299" start="289">289-299</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> calcium phosphate</style></keyword><keyword><style face="normal" font="Arial"> Diphtheria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Poliomyelitis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Salts</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Tetanus</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Calcium phosphate was used as an adjuvant in France in diphtheria, tetanus, pertussis and poliomyelitis vaccines. It was later completely substituted by alum salts in the late 80's, but it still remains as an approved adjuvant for the World Health Organization for human vaccination. Area covered: Thus, calcium phosphate is now considered as one of the substances that could replace alum salts in vaccines. The aim of this paper is to draw a review of existing data on calcium phosphate as an adjuvant in order to bring out the strengths and weaknesses for its use on a large scale. Expert commentary: Calcium phosphate is a compound naturally present in the organism, safe and already used in human vaccination. Beyond comparisons with the other adjuvants, calcium phosphate represents a good candidate to replace or to complete alum salts as a vaccine adjuvant</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1744-8395 (Electronic)IS - 1476-0584 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1080/14760584.2017.1244484</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27690701">PM:27690701</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Vaccines\20161003-MassonJD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Vaccines\20161003-MassonJD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Masson JD</style></custom2><misc3><style face="normal" font="Arial">10.1080/14760584.2017.1244484</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,H.Y.</style></author><author><style face="normal" font="Arial"> Yoon,T.J.</style></author><author><style face="normal" font="Arial"> Kim,H.H.</style></author><author><style face="normal" font="Arial"> Han,Y.S.</style></author><author><style face="normal" font="Arial"> Choi,H.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Functional Food Research, Korea Food Research Institute, Gyeonggi 463-746, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Changes in the antigenicity and allergenicity of ovalbumin in chicken egg white by N-acetylglucosaminidase</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="345" start="342">342-345</pages><volume><style face="normal" font="Arial">217</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Deglycosylation</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">Ovalbumin (OVA), an (hen) egg allergen, is one of the most abundant glycoprotein allergens associated with IgE-mediated hypersensitivity through the T-helper type 2 immune response. The effect of deglycosylation of the N-terminal glycan in OVA on allergenicity and antigenicity after N-acetylglucosaminidase treatment was studied. N-acetylglucosaminidase-treated OVA (N-OVA) evaluated using an enzyme-linked immunosorbent assay, respectively. N-OVA significantly (p&lt;0.05) OVA-specific IgE and histamine levels. In addition, N-OVA decreased the antigenicity of OVA 1000-fold. These results suggest that the degree of allergenicity and antigenicity reduced with deglycosylation of N-terminal glycan in OVA</style></abstract><notes><style face="normal" font="Arial">DA - 20160925IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.08.112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27664643">PM:27664643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-217-343-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-217-343-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160925, Park HY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.08.112</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rahaman,T.</style></author><author><style face="normal" font="Arial"> Vasiljevic,T.</style></author><author><style face="normal" font="Arial"> Ramchandran,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Advanced Food Systems Research Unit, College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Digestibility and antigenicity of beta-lactoglobulin as affected by heat, pH and applied shear</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="523" start="517">517-523</pages><volume><style face="normal" font="Arial">217</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Pancreatin</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Shear</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">Processing induced conformational changes can modulate digestibility of food allergens and thereby their antigenicity. Effect of different pH (3, 5, 7), temperature (room temperature, 120 degrees C) and shear (0s(-1), 1000s(-1)) on simulated gastrointestinal digestibility of beta-lg and post digestion antigenic characteristics have been studied. At all pH levels unheated beta-lg showed resistance to peptic digestion with high antigenic value while it was fairly susceptible to pancreatin with moderate reduction in antigenicity. Heating at 120 degrees C significantly improved both peptic and pancreatic digestion attributed to structural alterations that resulted in much lower antigenicity; the level of reduction being pH dependant. The lowest antigenicity was recorded at pH 5. Shearing (1000s(-1)) had a minor impact reducing digestibility and thereby enhancing antigenicity of unheated beta-lg at pH 5 and 7 slightly; however in conjunction with heating (120 degrees C) it reduced antigenicity further irrespective of the pH. Overall, treatment at pH 5, 120 degrees C and 1000s(-1) could potentially reduce post digestion antigenicity of beta-lg</style></abstract><notes><style face="normal" font="Arial">DA - 20160925IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticleSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.08.129</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27664667">PM:27664667</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-217-517-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-217-517-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160925, Rahaman T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.08.129</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alves,R.C.</style></author><author><style face="normal" font="Arial"> Pimentel,F.B.</style></author><author><style face="normal" font="Arial"> Nouws,H.P.</style></author><author><style face="normal" font="Arial"> Silva,T.H.</style></author><author><style face="normal" font="Arial"> Oliveira,M.B.</style></author><author><style face="normal" font="Arial"> Delerue-Matos,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Politecnico do Porto, Rua Dr. Antonio Bernardino de Almeida, 4200-072 Porto, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Improving the extraction of Ara h 6 (a peanut allergen) from a chocolate-based matrix for immunosensing detection: Influence of time, temperature and additives</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="248" start="242">242-248</pages><volume><style face="normal" font="Arial">218</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Immunosensor</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk powder</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">The extraction of Ara h 6 (a peanut allergen) from a complex chocolate-based food matrix was optimized by testing different temperatures, extraction times, and the influence of additives (NaCl and skimmed milk powder) in a total of 36 different conditions. Analyses were carried out using an electrochemical immunosensor. Three conditions were selected since they allowed the extraction of the highest levels of Ara h 6. These extractions were performed using 2g of sample and 20ml of Tris-HNO3 (pH=8) containing: a) 0.1M NaCl and 2g of skimmed milk powder at 21 degrees C for 60min; b) 1M NaCl and 1g of skimmed milk powder at 21 degrees C for 60min; and c) 2g of skimmed milk powder at 60 degrees C for 60min. Recoveries were similar or higher than 94.7%. This work highlights the importance to adjust extraction procedures regarding the target analyte and food matrix components</style></abstract><notes><style face="normal" font="Arial">DA - 20161010IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.09.085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27719905">PM:27719905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-218-242-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-218-242-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Alves RC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.09.085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahjoorian,A.</style></author><author><style face="normal" font="Arial"> Mokhtarian,M.</style></author><author><style face="normal" font="Arial"> Fayyaz,N.</style></author><author><style face="normal" font="Arial"> Rahmati,F.</style></author><author><style face="normal" font="Arial"> Sayyadi,S.</style></author><author><style face="normal" font="Arial"> Ariaii,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Modeling of drying kiwi slices and its sensory evaluation</style></title><secondary-title><style face="normal" font="Arial">Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Sci Nutr</style></full-title></periodical><pages end="473" start="466">466-473</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Artificial neural network</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Drying</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> hot-air drying</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kiwi</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> moisture</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sensory evaluation</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2048-7177</style></isbn><abstract><style face="normal" font="Arial">In this study, monolayer drying of kiwi slices was simulated by a laboratory-scale hot-air dryer. The drying process was carried out at three different temperatures of 50, 60, and 70-¦C. After the end of drying process, initially, the experimental drying data were fitted to the 11 well-known drying models. The results indicated that Two-term model gave better performance compared with other models to monitor the moisture ratio (with average R2 value equal .998). Also, this study used artificial neural network (ANN) in order to feasibly predict dried kiwi slices moisture ratio (y), based on the time and temperature drying inputs (x1, x2). In order to do this research, two main activation functions called logsig and tanh, widely used in engineering calculations, were applied. The results revealed that, logsig activation function base on 13 neurons in first and second hidden layers were selected as the best configuration to predict the moisture ratio. This network was able to predict moisture ratio with R2 value .997. Furthermore, kiwi slice favorite is evaluated by sensory evaluation. In this test, sense qualities as color, aroma, flavor, appearance, and chew ability (tissue brittleness) are considered</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1002/fsn3.414</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1002/fsn3.414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Sci Nutr\20161019-MahjoorianA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Sci Nutr\20161019-MahjoorianA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Mahjoorian A</style></custom2><misc3><style face="normal" font="Arial">10.1002/fsn3.414</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xie,Y.H.</style></author><author><style face="normal" font="Arial"> Li,X.P.</style></author><author><style face="normal" font="Arial"> Xu,Z.X.</style></author><author><style face="normal" font="Arial"> Qian,P.</style></author><author><style face="normal" font="Arial"> Li,X.L.</style></author><author><style face="normal" font="Arial"> Wang,Y.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Staff Room of Diagnosis, Basic Medicine College, Shanghai University of Traditional Chinese Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Effect of compound Maqin decoction on TGF-beta1/Smad proteins and IL-10 and IL-17 content in lung tissue of asthmatic rats</style></title><secondary-title><style face="normal" font="Arial">Genet Mol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Genet Mol Res</style></full-title></periodical><pages end="" start="15037539">15037539-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="10/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Smad</style></keyword><keyword><style face="normal" font="Arial"> Smad Proteins</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2016">2016/9/2</year></dates><abstract><style face="normal" font="Arial">In this research, compound Maqin decoction (CMD) has been shown to positively affect in airway inflammation of asthma models. We evaluated the effects of CMD on the expression of transforming growth factor (TGF)-beta1/Smad proteins, interleukin (IL)-17, and IL-10 in lung tissue of asthmatic rats. Asthma was induced in a rat model using ovalbumin. After a 4-week treatment with CMD, rats were killed to evaluate the expression of TGF-beta1 and Smad proteins in lung tissue. IL-10 and IL-17 levels in lung tissue homogenates were determined by ELISA. The expression of TGF-beta1 and Smad3 protein increased, whereas expression of Smad7 protein decreased upon high-dose or low-dose treatment with CMD or by intervention with dexamethasone, compared to the control. There was a significant difference between treatment with a high dose CMD and the control treatment, but no significant difference was found between high-dose CMD treatment and dexamethasone intervention. The expression of TGF-beta1 and Smad7 protein increased, whereas the expression of Smad3 protein decreased in the model group compared to other groups. In the CMD high-dose group, low-dose group, and dexamethasone intervention group, the IL-17 concentrations in lung tissue homogenates were decreased, while IL-10 levels were increased. Again, there was a significant difference between CMD high-dose and control treatment, but not between CMD high-dose treatment and dexamethasone intervention. Thus, positive effects of CMD against asthmatic airway remodeling may be due to its regulatory effect on TGF-beta1, Smad3, and Smad7 protein levels and on cytokines such as IL-10 and IL-17</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1676-5680 (Electronic)IS - 1676-5680 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.4238/gmr.15037539</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27706676">PM:27706676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Genet Mol Res\2016-15-15037539.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Genet Mol Res\2016-15-15037539.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Xie YH</style></custom2><misc3><style face="normal" font="Arial">10.4238/gmr.15037539</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burgel,P.R.</style></author><author><style face="normal" font="Arial"> Paugam,A.</style></author><author><style face="normal" font="Arial"> Hubert,D.</style></author><author><style face="normal" font="Arial"> Martin,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Cochin Hospital, Assistance Publique - Hopitaux de Paris; Universite Paris Descartes, Sorbonne Paris Cite</style></auth-address><titles><title><style face="normal" font="Arial">Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy</style></title><secondary-title><style face="normal" font="Arial">Infect Drug Resist</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Infect Drug Resist</style></full-title></periodical><pages end="238" start="229">229-238</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal drug</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug interaction</style></keyword><keyword><style face="normal" font="Arial"> Drug Interactions</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> lung function decline</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Triazoles</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Aspergillus fumigatus is the main fungus cultured in the airways of patients with cystic fibrosis (CF). Allergic bronchopulmonary aspergillosis occurs in ~10% of CF patients and is clearly associated with airway damage and lung function decline. The effects of A. fumigatus colonization in the absence of allergic bronchopulmonary aspergillosis are less well established. Retrospective clinical studies found associations of A. fumigatus-positive cultures with computed tomography scan abnormalities, greater risk of CF exacerbations and hospitalizations, and/or lung function decline. These findings were somewhat variable among studies and provided only circumstantial evidence for a role of A. fumigatus colonization in CF lung disease progression. The availability of a growing number of oral antifungal triazole drugs, together with the results of nonrandomized case series suggesting positive effects of azole therapies, makes it tempting to treat CF patients with these antifungal drugs. However, the only randomized controlled trial that has used itraconazole in CF patients showed no significant benefit. Because triazoles may have significant adverse effects and drug interactions, and because their prolonged use has been associated with the emergence of azole-resistant A. fumigatus isolates, it remains unclear whether or not CF patients benefit from azole therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1178-6973 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.2147/IDR.S63621</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27703383">PM:27703383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Infect Drug Resist\2016-9-229-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Infect Drug Resist\2016-9-229-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Burgel PR</style></custom2><misc3><style face="normal" font="Arial">10.2147/IDR.S63621</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lan,J.</style></author><author><style face="normal" font="Arial"> Chung,H.S.</style></author><author><style face="normal" font="Arial"> Maltby,K.</style></author><author><style face="normal" font="Arial"> Stewart,C.</style></author><author><style face="normal" font="Arial"> Vickery,J.</style></author><author><style face="normal" font="Arial"> Michael,C.</style></author><author><style face="normal" font="Arial"> Lew,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">High Prevalence of Atopy in Severe Persistent Pediatric Asthmatics in Memphis, Tennessee</style></title><secondary-title><style face="normal" font="Arial">Insights Allergy Asthma Bronchitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Insights Allergy Asthma Bronchitis</style></full-title></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> African American</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> overweight</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Social Change</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Objective: Asthma is a heterogeneous disease that affects millions of adults and children in the United States. The patho-mechanism of asthma is still being elucidated and therapies that control this disease have limitations. It is important to be able to distinguish various asthma phenotypes to allow personalized treatments.Methods: Pediatric asthmatics from one single institution were enrolled for genomic DNA repository study if they fit the WHO guidelines for severe persistent asthmatics. Various personal health information of the first 100 children were reviewed including gender, age, smoke exposure, lung function test, ICU admissions, controller medication, insurance, body mass index, and allergy skin testing results.Results: Review of the cohort showed a younger population with a median age of 9 years old. Most importantly, 97% of the patients were found to be atopic. Other findings include a predominantly African American population (89%), mainly holding public insurance (76%), and a significantly overweight and obese (56%) cohort.Conclusion: The rate of atopy in our cohort of pediatric severe asthmatic children is extremely high, likely due to a warm and humid climate leading to high pollination, mold spores and dust mite content. Early aggressive environmental control and allergen immunotherapy, weight control and social changes are needed.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.21767/2471-304X.100015</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21767/2471-304X.100015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Insights Allergy Asthma Bronchitis\2016-2-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Insights Allergy Asthma Bronchitis\2016-2-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Lan J</style></custom2><misc3><style face="normal" font="Arial">10.21767/2471-304X.100015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tang,W.</style></author><author><style face="normal" font="Arial"> Smith,S.G.</style></author><author><style face="normal" font="Arial"> Salter,B.</style></author><author><style face="normal" font="Arial"> Oliveria,J.P.</style></author><author><style face="normal" font="Arial"> Mitchell,P.</style></author><author><style face="normal" font="Arial"> Nusca,G.M.</style></author><author><style face="normal" font="Arial"> Howie,K.</style></author><author><style face="normal" font="Arial"> Gauvreau,G.M.</style></author><author><style face="normal" font="Arial"> O'Byrne,P.M.</style></author><author><style face="normal" font="Arial"> Sehmi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ont., Canada</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-Induced Increases in Interleukin-25 and Interleukin-25 Receptor Expression in Mature Eosinophils from Atopic Asthmatics</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="242" start="234">234-242</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-25 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Memory cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 memory</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="9" Year="2016">2016/9/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Interleukin (IL)-25 plays a pivotal role in type 2 immune responses. In a baseline cross-sectional study, we previously showed that IL-25 plasma levels and IL-25 receptor (IL-25R: IL-17RA, IL-17RB, and IL-17RA/RB) expression on mature blood eosinophils are increased in atopic asthmatics compared to normal nonatopic controls. This study investigated allergen-induced changes in IL-25 and IL-25R expression in eosinophils from asthmatics. METHODS: Dual responder atopic asthmatics (n = 14) were enrolled in this randomized diluent-controlled crossover allergen challenge study. Blood was collected before and 24 h after the challenge. The surface expression of IL-25R was evaluated by flow cytometry on eosinophils and Th2 memory cells. In addition, plasma levels of IL-25 were measured by ELISA, and functional responses to IL-25 including type 2 cytokine expression, degranulation, and the migrational responsiveness of eosinophils were evaluated in vitro. RESULTS: Following the allergen but not the diluent inhalation challenge, significant increases in the expression of IL-17RB and IL-17RA/B were found on eosinophils but not on Th2 memory cells. IL-25 plasma levels and the number of eosinophils but not of Th2 memory cells expressing intracellular IL-25 increased significantly in response to the allergen but not the diluent challenge. Stimulation with physiologically relevant concentrations of IL-25 in vitro caused (i) degranulation of eosinophils (measured by eosinophil peroxidase release), (ii) enhanced intracellular expression of IL-5 and IL-13, and (iii) priming of eosinophil migration to eotaxin. IL-25 stimulated intracellular cytokine expression, and the migration of eosinophils was blocked in the presence of a neutralizing IL-25 antibody. CONCLUSIONS: Our findings suggest that the IL-25/IL-25R axis may play an important role in promoting the recruitment and proinflammatory function of eosinophils in allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1159/000449248</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27685606">PM:27685606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-234-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-234-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Tang W</style></custom2><misc3><style face="normal" font="Arial">10.1159/000449248</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Candia,M.</style></author><author><style face="normal" font="Arial"> Kratzer,B.</style></author><author><style face="normal" font="Arial"> Pickl,W.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy)</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="233" start="211">211-233</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> altered peptide ligand</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Histocompatibility</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> MHC binding</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="9" Year="2016">2016/9/20</year></dates><abstract><style face="normal" font="Arial">T lymphocytes equipped with clonotypic T cell antigen receptors (TCR) recognize immunogenic peptides only when presented in the context of their own major histocompatibility complex (MHC) molecules. Peptide loading to MHC molecules occurs in intracellular compartments (ER for class I and MIIC for class II molecules) and relies on the interaction of the respective peptides and peptide binding pockets on MHC molecules. Those peptide residues not engaged in MHC binding point towards the TCR screening for possible peptide MHC complex binding partners. Natural or intentional modification of both MHC binding registers and TCR interacting residues of peptides - leading to the formation of altered peptide ligands (APLs) - might alter the way peptides interact with TCRs and hence influence subsequent T cell activation events, and consequently T cell effector functions. This review article summarizes how APLs were detected and first described, current concepts of how APLs modify T cellular signaling, which biological mechanisms might force the generation of APLs in vivo, and how peptides and APLs might be used for the benefit of patients suffering from allergic or autoimmune diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000448756</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27642756">PM:27642756</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-211-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-211-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Candia M</style></custom2><misc3><style face="normal" font="Arial">10.1159/000448756</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sainte-Laudy,J.</style></author><author><style face="normal" font="Arial"> Touraine,F.</style></author><author><style face="normal" font="Arial"> Cluzan,D.</style></author><author><style face="normal" font="Arial"> Belle Moudourou,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Laboratory, Hopital Dupuytren, Limoges, France</style></auth-address><titles><title><style face="normal" font="Arial">Follow-Up of Venom Immunotherapy on Flow Cytometry and Definition of a Protective Index</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="250" start="243">243-250</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Blocking factor</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> intracutaneous test</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="9" Year="2016">2016/9/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A major problem of venom-specific immunotherapy (VIT) is the absence of reliable parameters for deciding treatment discontinuation. AIM OF THE STUDY: Intracutaneous tests (ICTs), the basophil activation test (BAT), specific IgEs (sIgEs) and blocking factor (BF) activity were measured during VIT. We made an evaluation by means of a protective index (PI) including ICT, BAT and BF values. MATERIAL AND METHODS: A population of 45 patients who had experienced a systemic reaction after an insect sting were tested before VIT (T0), at 1 week (T1w), at 10 weeks (T10w) and at 21 weeks (T21w), and, for a subgroup of 17 patients, at 3-5 years (T3-5y). Basophil activation (expressed in % CD63 and in the area under the curve) and BF activity were measured by flow cytometry using the CCR3/CD63 protocol. RESULTS: The first 21 weeks of follow-up showed no significant variation in the ICT, sIgE and BAT measurements, except for BAT, by eliminating weak negative anti-IgE responses. In these conditions, the decrease in basophil activation was significant at T10w (p = 0.009) and T21w (p = 0.009). Increased BF activity was also significant at T10w (p = 0.008) and T21w (p = 0.002). The PI threshold calculated from the mean +/- 3 standard errors (SE) was 64.8 (14.7 +/- 16.7, n = 25) at T0. PI increase was significant at T3-5y (3,430 +/- 6,282; p &lt; 0.001). CONCLUSION: VIT induced a significant decrease in ICT values and basophil activation, along with an increase in serum BF activity, significant after 10 weeks of VIT. Evaluated in a larger population, the PI could represent a new tool for the clinico-biological follow-up of VIT efficacy</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1159/000449162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27685197">PM:27685197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-243-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-243-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Sainte-Laudy J</style></custom2><misc3><style face="normal" font="Arial">10.1159/000449162</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lu,Y.</style></author><author><style face="normal" font="Arial"> Xing,Q.Q.</style></author><author><style face="normal" font="Arial"> Xu,J.Y.</style></author><author><style face="normal" font="Arial"> Ding,D.</style></author><author><style face="normal" font="Arial"> Zhao,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric institution of Nanjing University of Chinese Medicine, Nanjing, 210023, China</style></auth-address><titles><title><style face="normal" font="Arial">Astragalus polysaccharide modulates ER stress response in an OVA-LPS induced murine model of severe asthma</style></title><secondary-title><style face="normal" font="Arial">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biol Macromol</style></full-title></periodical><pages end="1006" start="995">995-1006</pages><volume><style face="normal" font="Arial">93</style></volume><number><style face="normal" font="Arial">Pt A</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoplasmic Reticulum</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Stress response</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Type 2 diabetes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="9" Year="2016">2016/9/16</year></dates><abstract><style face="normal" font="Arial">Endoplasmic reticulum (ER) stress has been recently revealed to play a pivotal role in the pathogenesis of severe asthma. Astragalus polysaccharide (APS), a major bioactive component from Astragalus membranaceus, exerts immunomodulatory and anti-inflammatory effects and has been shown to suppress ER stress in chronic diseases such as type-2 diabetes. However, the pharmaceutical application of APS in the treatment of severe asthma is unknown. The results obtained here indicate that APS significantly attenuates eosinophils and neutrophil-dominant airway inflammation by reducing the mRNA levels of Cxcl5, Il8, and chemokine (C-C motif) ligand 20 (Ccl20) and the protein levels of IL13RA and IL17RA. APS also inhibits the activation of unfolded protein response by decreasing the levels of ER stress markers such as C/EBP homologous protein (CHOP), which was associated with a reduction of PERK phosphorylation. Moreover, APS substantially blocks the nuclear translocation of ATF6 and NF-kappaB p65. Interestingly, we observed that APS markedly suppresses mucus hypersecretion by decreasing the levels of mucin (MUC) 5AC and MUC5B, which might be due to inhibition of goblet cells differentiation by suppressing the expression of IRE1beta-correlated genes. In summary, APS can have potential pharmaceutical application in treatment of severe asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijbiomac.2016.09.058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27645929">PM:27645929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biol Macromol\2016-93-995-1006.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biol Macromol\2016-93-995-1006.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Lu Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijbiomac.2016.09.058</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gabet,S.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Couderc,R.</style></author><author><style face="normal" font="Arial"> Seta,N.</style></author><author><style face="normal" font="Arial"> Momas,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">EA 4064: epidemiologie environnementale, Universite Paris Descartes, Sorbonne Paris Cite, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Allergic sensitisation in early childhood: Patterns and related factors in PARIS birth cohort</style></title><secondary-title><style face="normal" font="Arial">Int J Hyg Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Hyg Environ Health</style></full-title></periodical><pages end="800" start="792">792-800</pages><volume><style face="normal" font="Arial">219</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> Caesarean section</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Day Care</style></keyword><keyword><style face="normal" font="Arial"> Day-care</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologie</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> toddler</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic sensitisation is poorly documented in infants. This study aims to provide new insights into allergic sensitisation patterns and related factors in infancy. METHODS: This study concerns 1860 infants involved in the Pollution and Asthma Risk: an Infant Study (PARIS) population-based birth cohort who had a standardised health examination when 18 months old, from 2004 to 2008. Sensitisation was assessed by measurements of serum specific IgE to 12 food and 4 inhalant allergens and defined by IgE>/=0.35kUA/L. Information regarding lifestyle and environment were obtained from questionnaires prospectively administered. RESULTS: Prevalence of allergic sensitisation to any allergen, to food allergens, and to aeroallergens was 13.8%, 12.3%, and 2.3%, respectively. Multiple sensitisation (to at least two allergens) concerned 6.2% of toddlers. Intrinsic factors such as male gender, family history of allergy, and high birth weight increased the risk of food allergen sensitisation and multiple sensitisation. Caesarean section was also positively associated with multiple sensitisation. Day-care attendance was negatively related to food allergen, aeroallergen, and multiple sensitisation. A cat entering the baby's room in early life was strongly associated with aeroallergen sensitisation (ORa 3.21, 95%CI: 1.29-8.01). An introduction of meat in infant's diet after 6 months of age was negatively related to food allergen sensitisation (ORa 0.46, 95%CI: 0.24-0.91). CONCLUSION: Our results suggest that intrinsic factors and indicators of exposure to microorganisms such as caesarean section and day-care attendance may be associated with inhalant as well as food allergen sensitisation in infancy. For example, male gender, family history of allergy, high birth weight, and caesarean section could be positively related whereas day-care attendance could be negatively related to both aeroallergen and food allergen sensitisation. Conversely, early life exposure to inhalant allergens or food allergens may be specifically linked to either aeroallergen sensitisation or food allergen sensitisation, respectively</style></abstract><notes><style face="normal" font="Arial">DA - 20160921IS - 1618-131X (Electronic)IS - 1438-4639 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijheh.2016.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27649627">PM:27649627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Hyg Environ Health\20160921-GabetS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Hyg Environ Health\20160921-GabetS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160921, Gabet S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijheh.2016.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,J.</style></author><author><style face="normal" font="Arial"> Wei,Y.</style></author><author><style face="normal" font="Arial"> Luo,Q.</style></author><author><style face="normal" font="Arial"> Xu,F.</style></author><author><style face="normal" font="Arial"> Zhao,Z.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Lu,L.</style></author><author><style face="normal" font="Arial"> Sun,J.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Du,X.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Wei,K.</style></author><author><style face="normal" font="Arial"> Dong,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Baicalin attenuates inflammation in mice with OVA-induced asthma by inhibiting NF-kappaB and suppressing CCR7/CCL19/CCL21</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Med</style></full-title></periodical><pages end="1548" start="1541">1541-1548</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="10/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CCL19</style></keyword><keyword><style face="normal" font="Arial"> CCL21</style></keyword><keyword><style face="normal" font="Arial"> CCR7</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> integrative medicine</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="21" Month="9" Year="2016">2016/9/21</year></dates><abstract><style face="normal" font="Arial">Baicalin, extracted and purified from the Chinese medicinal plant, Scutellaria baicalensis Georgi (Huang qin in Chinese), exhibits potent anti-inflammatory activity against asthma. However, it remains unknown whether baicalin inhibits the activity of CC chemokine receptor 7 (CCR7) and its ligands, which are crucial for the initiation of airway inflammation. In the present study, we investigated the effects of baicalin on CCR7 and its ligands, CCL19 and CCL21, as well as on the nuclear factor-kappaB (NF-kappaB) pathway in a mouse model of asthma. A mouse model of acute asthma was established by exposing the mice to ovalbumin (OVA) (by intraperitoneal injection and inhalational challenge). Within 24 h of the final OVA challenge, lung function was detected by direct airway resistance analysis. Lung tissues were examined for pathological changes. Inflammatory cell counts in bronchoalveolar lavage fluid (BALF) were assessed. ELISA was utilized to evaluate the OVA-IgE, CCL19 and CCL21 levels in BALF. The interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha levels in serum were also detected by ELISA. The protein expression levels of CCR7, as well as that of phosphorylated IkappaBalpha (p-IkappaBalpha) and phosphorylated p65 (p-p65) were determined by western blot analysis and RT-qPCR was used to determine the CCR7 mRNA levels. Our data demonstrated that the oral administration of baicalin significantly improved pulmonary function and attenuated inflammatory cell infiltration into the lungs. Baicalin also decreased the levels of OVA-IgE, IL-6, TNF-alpha and CCR7, as well as those of its ligand, CCL19; the levels of NF-kappaB were also markedly suppressed by baicalin. The CCR7 mRNA level was substantially decreased. Our results thus suggest that baicalin exerts an inhibitory effect on airway inflammation, and this effect may be associated with the inhibition of CCR7 and CCL19/CCL21, which may provide new mechanistic insight into the antiinflammatory effects of baicalin</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 1791-244X (Electronic)IS - 1107-3756 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/ijmm.2016.2743</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27666000">PM:27666000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Med\2016-38-1541-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Med\2016-38-1541-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Liu J</style></custom2><misc3><style face="normal" font="Arial">10.3892/ijmm.2016.2743</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lucas,D.</style></author><author><style face="normal" font="Arial"> Lodde,B.</style></author><author><style face="normal" font="Arial"> Jepsen,J.R.</style></author><author><style face="normal" font="Arial"> DeWitte,J.D.</style></author><author><style face="normal" font="Arial"> Jegaden,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Occupational Medical Service of Iroise, Brest, France.</style></auth-address><titles><title><style face="normal" font="Arial">Occupational asthma in maritime environments: an update</style></title><secondary-title><style face="normal" font="Arial">Int Marit Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Marit Health</style></full-title></periodical><pages end="152" start="144">144-152</pages><volume><style face="normal" font="Arial">67</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">In 2006 we published our first review based on the available literature on occupational asthma in maritime environments in the "International Maritime Health" journal. Since then, we have obtained a great deal of new knowledge on asthma in seafood workers and fishermen and on the impact of exposures from sulphites preservatives, container fumigants etc. in maritime workers. This review aims to provide an update of the current knowledge base about occupational asthma in a maritime context and to provide recommendations regarding medical surveillance of workers at risk</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 2081-3252 (Electronic)IS - 1641-9251 (Linking)LA - ENGPT - Journal ArticleSB - IMCO - France -</style></notes><work-type><style face="normal" font="Arial">10.5603/IMH.2016.0027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27681213">PM:27681213</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Marit Health\2016-67-144-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Marit Health\2016-67-144-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Lucas D</style></custom2><misc3><style face="normal" font="Arial">10.5603/IMH.2016.0027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Naderi,M.</style></author><author><style face="normal" font="Arial"> Karimi,M.</style></author><author><style face="normal" font="Arial"> Hosseini,M.S.</style></author><author><style face="normal" font="Arial"> Moradi,E.H.</style></author><author><style face="normal" font="Arial"> Shamsizadeh,M.</style></author><author><style face="normal" font="Arial"> Dorgalaleh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department Of Pediatrics Haematology and Oncology, Ali Ebn-e Abitaleb Hospital Research Center for Children and Adolescents Health [RCCAH], Zahedan University Of Medical Sciences, Zahedan, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P(R)</style></title><secondary-title><style face="normal" font="Arial">Iran J Pharm Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Pharm Res</style></full-title></periodical><pages end="640" start="635">635-640</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hemorrhagic</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis A</style></keyword><keyword><style face="normal" font="Arial"> Hiv</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma (FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P(R)). Our objective was to assess safety and effectiveness of Fibrogammin P(R) in patients with FXIIID. For this purpose we designed this long-term follow up study on a large group of patients with FXIIID. This prospective study was conducted on 213 patients with FXIIID since 2009 to 2013. Administrated dose for Fibrogammin P(R) according to clinical situations of patients ranged from 10 to 26 IU/kg every 4 - 6 weeks. All patients in 6-month intervals were checked for human immunodeficiency virus (HIV), hepatitis A, B and C viruses (HAV, HBV, HCV). Twelve percent of participants had at least one ICH episode until 2008 but after administration of Fibrogammin P(R) did not have any major bleeding or episode of ICH, except in one patient. We also had 7 females with recurrent miscarriage that were managed successfully with a dose of 10 to 26 IU/kg every 4 - 6 weeks. This dose also was quite successful in management of major and minor surgery. None of the participants showed allergic reaction during treatment. A total of 7155450 IU of Fibrogammin P(R) were infused but nobody was positive for HIV, HAV, HBV, and HCV. We found that Fibrogammin P(R) is a safe and effective therapeutic choice in management of FXIIID</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 1735-0328 (Print)IS - 1726-6882 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27642336">PM:27642336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Pharm Res\2016-15-635-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Pharm Res\2016-15-635-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Naderi M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Collins,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Consultant, Marietta, GA</style></auth-address><titles><title><style face="normal" font="Arial">Practice Paper of the Academy of Nutrition and Dietetics: Role of the Registered Dietitian Nutritionist in the Diagnosis and Management of Food Allergies</style></title><secondary-title><style face="normal" font="Arial">J Acad Nutr Diet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Acad Nutr Diet</style></full-title></periodical><pages end="1631" start="1621">1621-1631</pages><volume><style face="normal" font="Arial">116</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Counseling</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dietetics</style></keyword><keyword><style face="normal" font="Arial"> Dietitian</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> false positives</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Incidence of food allergy has increased significantly over the past decade and represents an important health issue for millions of Americans. Diagnosis of immunoglobulin E-mediated food allergies is sometimes difficult because blood and skin tests have high rates of false positives, and oral food challenges are uncommon due to the expense and potential for serious reactions. Accurate diagnosis is crucial to avoid unnecessary dietary restriction, especially in children. Because registered dietitian nutritionists often work independently, receiving referrals for dietary education and guidance for a patient who is followed by one or several other practitioners, navigating the data available and making the appropriate follow-up contact optimizes treatment. The purpose of this paper is to provide guidance to the registered dietitian nutritionists and nutrition and dietetics technician, registered on appropriate and evidence-based nutrition counseling for diagnosis and management of food allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 2212-2672 (Print)IS - 2212-2672 (Linking)LA - ENGPT - Journal ArticleSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jand.2016.07.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27671759">PM:27671759</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Acad Nutr Diet\2016-116-1621-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Acad Nutr Diet\2016-116-1621-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Collins SC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jand.2016.07.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Le Cann,P.</style></author><author><style face="normal" font="Arial"> Paulus,H.</style></author><author><style face="normal" font="Arial"> Glorennec,P.</style></author><author><style face="normal" font="Arial"> Le Bot,B.</style></author><author><style face="normal" font="Arial"> Frain,S.</style></author><author><style face="normal" font="Arial"> Gangneux,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Environmental and Occupational Health Department, EHESP School of Public Health, Rennes, France; Inserm UMR 1085-IRSET, Rennes, France.</style></auth-address><titles><title><style face="normal" font="Arial">Home Environmental Interventions for the Prevention or Control of Allergic and Respiratory Diseases: What Really Works</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="79" start="66">66-79</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental intervention</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evaluation Studies</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health care workers</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Home health care workers interventions have been implemented in western countries to improve health status of patients with respiratory diseases especially asthma and allergic illnesses. Twenty-six controlled studies dealing with prevention and control of these diseases through home environmental interventions were reviewed. After a comprehensive description of the characteristics of these studies, the effectiveness of each intervention was then evaluated in terms of participants' compliance with the intervention program, improvement of quality of the indoor environment, and finally improvement of health outcomes, in detailed tables. Limitations and biases of the studies are also discussed. Overall, this review aims at giving a toolbox for home health care workers to target the most appropriate measures to improve health status of the patient depending on his and/or her environment and disease. Only a case-by-case approach with achievable measures will warrant the efficacy of home interventions. This review will also provide to the research community a tool to better identify targets to focus in future evaluation studies of home health care workers action</style></abstract><notes><style face="normal" font="Arial">DA - 20160925IS - 2213-2201 (Electronic)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.07.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27665387">PM:27665387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160925-LeCannP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20160925-LeCannP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160925, Le Cann P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.07.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sly,P.D.</style></author><author><style face="normal" font="Arial"> Varghese,J.</style></author><author><style face="normal" font="Arial"> Noor,F.</style></author><author><style face="normal" font="Arial"> Tang,M.L.</style></author><author><style face="normal" font="Arial"> Laing,I.</style></author><author><style face="normal" font="Arial"> Oo,S.</style></author><author><style face="normal" font="Arial"> Prastanti,F.</style></author><author><style face="normal" font="Arial"> LeSouef,P.N.</style></author><author><style face="normal" font="Arial"> Holt,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Health Queensland and Child Health Research Centre, University of Queensland, Brisbane, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Severe winter asthma exacerbations may be prevented by omalizumab but no carry over effect</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="705" start="703">703-705</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Our proof-of-concept study shows that omalizumab given during the winter respiratory viral season can prevent severe exacerbations but only while the drug is being taken</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27637383">PM:27637383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160917-SlyPD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160917-SlyPD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Sly PD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gernez,Y.</style></author><author><style face="normal" font="Arial"> Tsuang,A.</style></author><author><style face="normal" font="Arial"> Smith,T.D.</style></author><author><style face="normal" font="Arial"> Shahjehan,K.</style></author><author><style face="normal" font="Arial"> Hui,Y.</style></author><author><style face="normal" font="Arial"> Maglione,P.J.</style></author><author><style face="normal" font="Arial"> Cunningham-Rundles,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Icahn School of Medicine, Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Hemoptysis in a Patient with Elevated Immunoglobulin E</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1058" start="1054">1054-1058</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">aggressive</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chills</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Hemoptysis</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="29" Month="9" Year="2016">2016/9/29</year></dates><abstract><style face="normal" font="Arial">Recurrent pneumonia with cavitation leading to pneumatoceles, secondary fungal infections, and hemoptysis are major causes of mortality and morbidity in patients with hyper-IgE syndrome. Prevention and aggressive treatment of pneumonia in these patients are essential to prevent further lung damage, but treatment may be delayed because the classic signs/symptoms of infection such as fever, chills, or rigors may be lacking. Early imaging to identify infection is essential for diagnosis and treatment. The mainstay of therapy is continuous, full-dose daily trimethoprim-sulfamethoxazole and commonly fungal coverage. Because hyper-IgE syndrome is a progressive disease, patients' condition may worsen despite compliance with prophylactic therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 2213-2201 (Electronic)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27693026">PM:27693026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-4-1054-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-4-1054-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Gernez Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Seppo,A.E.</style></author><author><style face="normal" font="Arial"> Autran,C.A.</style></author><author><style face="normal" font="Arial"> Bode,L.</style></author><author><style face="normal" font="Arial"> Jarvinen,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology and Center for Food Allergy, Department of Pediatrics, University of Rochester School of Medicine and Dentistry and Golisano Children's Hospital, Rochester, NY. Electronic address: antti_seppo@URMC.Rochester.eduDivision of Neonatology and Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Diego, La Jolla, CA</style></auth-address><titles><title><style face="normal" font="Arial">Human milk oligosaccharides and development of cow's milk allergy in infants</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="711" start="708">708-711</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immune system</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Human milk oligosaccharides (HMOs) provide a main substrate to help shape the infant's gut microbiota and affect the maturation of the intestinal mucosal immune system. In our cohort, infants that received human milk with low Lacto-N-fucopentaose (LNFP) III concentrations (&lt; 60muM) were more likely to become affected with cow's milk allergy when compared to high LNFP III-containing milk (odds ratio 6.7, 95% CI 2.0-22)</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27702672">PM:27702672</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161005-SeppoAE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161005-SeppoAE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Seppo AE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ewald,D.A.</style></author><author><style face="normal" font="Arial"> Noda,S.</style></author><author><style face="normal" font="Arial"> Oliva,M.</style></author><author><style face="normal" font="Arial"> Litman,T.</style></author><author><style face="normal" font="Arial"> Nakajima,S.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Xu,H.</style></author><author><style face="normal" font="Arial"> Scheipers,P.</style></author><author><style face="normal" font="Arial"> Svitacheva,N.</style></author><author><style face="normal" font="Arial"> Labuda,T.</style></author><author><style face="normal" font="Arial"> Krueger,J.G.</style></author><author><style face="normal" font="Arial"> Suarez-Farinas,M.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory for Investigative Dermatology, The Rockefeller University, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Major differences between human atopic dermatitis and murine models as determined by global transcriptomic profiling</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="571" start="562">562-571</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is caused by a complex interplay between immune and barrier abnormalities. Murine models of AD are essential for preclinical assessments of new treatments. While many models have been used to simulate AD, their transcriptomic profiles are not fully understood, and a comparison of these models with the human AD transcriptomic fingerprint is lacking. OBJECTIVE: We sought to evaluate the transcriptomic profiles of six common murine models and determine how they relate to human AD skin. METHODS: Transcriptomic profiling was performed using microarrays and qRT-PCR on biopsies from NC/Nga, flaky-tail, Flg-mutated, ovalbumin-challenged, oxazolone-challenged, and IL-23-injected mice. Gene expression data of AD, psoriasis, and contact dermatitis were obtained from previous patient cohorts. Criteria of fold-change/FCH>/=2 and false discovery rate/FDR&lt;/=0.05 were used for gene arrays. RESULTS: IL-23-injected, NC/Nga, and oxazolone-challenged mice show the largest homology with our human meta-analysis derived AD (MADAD) transcriptome (37%, 18%, 17%, respectively). Similar to human AD, robust Th1, Th2, and also Th17 activation are seen in IL-23-injected and NC/Nga mice, with similar, but weaker, inflammation in ovalbumin-challenged mice. Oxazolone-challenged mice show a Th1-centered reaction and flaky-tail mice demonstrate a strong Th17 polarization. Flg-mutated mice display FLG down-regulation without significant inflammation. CONCLUSION: No single murine model fully captures all aspects of the AD profile; instead, each model reflects different immune or barrier disease aspects. Overall, among the six murine models, IL-23-injected mice best simulate human AD; still, the translational focus of the investigation should determine which model is most applicable. CLINICAL IMPLICATIONS: When testing new drugs for atopic dermatitis, murine models might be used to study barrier or immune features, but human trials are needed to determine effects on actual disease profile</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Japan -CO - Denmark -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27702671">PM:27702671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161005-EwaldDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161005-EwaldDA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Ewald DA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Abelson,M.B.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Boelke,G.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Madonini,E.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Sehlinger,T.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">GA(2)LEN Coordinating office; Allergy-Centre-Charite, Charite - Universitatsmedizin Berlin, Luisenstr. 2-5, 10117 Berlin</style></auth-address><titles><title><style face="normal" font="Arial">Validation of the GA2LEN chamber for trials in allergy: Innovation of a mobile allergen exposure chamber</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1166" start="1158">1158-1166</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> environmental exposure chamber</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Field clinical trials of pollen allergy are impacted by the impossibility to predict and to determine individual allergen exposure, due to many factors (e.g., pollen season, atmospheric variations, pollutants, lifestyles). Environmental exposure chambers (EEC), delivering a fixed amount of allergens in a controlled environmental setting, can overcome these limitations. EECs are currently already used in phase 2, 3, and even 4 trials. Unfortunately, few chambers exist in the world, and this makes it difficult to perform large, multicenter clinical trials. The new GA2LEN mobile exposure chamber is a step forward, since the mobility of the chamber makes it convenient for patients to participate in clinical testing. OBJECTIVE: This study was made to validate the reproducibility, sensitivity, and specificity of the results obtained in the new GA2LEN chamber. METHODS: Seventy-two adult patients (19-61 years), with allergic rhinitis with/without asthma due to grass pollen, were included in different clinical validation tests. Total Symptom Scores (TSS) and Total Nasal Symptom Scores (TNSS) were recorded at time zero (0), and every 10 minutes during exposures, along with nasal and respiratory parameters. RESULTS: Exposure tests confirmed the reproducibility between subsequent runs, the sensitivity (p &lt;0.00001 vs. patients exposed to placebo) and the specificity (very low score in nonallergic subjects) in the GA2LEN chamber. No adverse reactions were recorded during the tests. CONCLUSIONS: The mobility of the GA2LEN chamber provides a new, potentially effective, and safe way of generating reliable data in allergy multicenter clinical trials</style></abstract><notes><style face="normal" font="Arial">DA - 20161004IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Austria -CO - Switzerland -CO - France -CO - Italy -CO - Poland -CO - United States -CO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27697498">PM:27697498</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161004-ZuberbierTA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161004-ZuberbierTA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161004, Zuberbier T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsuki,A.</style></author><author><style face="normal" font="Arial"> Takatori,H.</style></author><author><style face="normal" font="Arial"> Makita,S.</style></author><author><style face="normal" font="Arial"> Yokota,M.</style></author><author><style face="normal" font="Arial"> Tamachi,T.</style></author><author><style face="normal" font="Arial"> Suto,A.</style></author><author><style face="normal" font="Arial"> Suzuki,K.</style></author><author><style face="normal" font="Arial"> Hirose,K.</style></author><author><style face="normal" font="Arial"> Nakajima,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="Arial">T-bet inhibits innate lymphoid cell-mediated eosinophilic airway inflammation by suppressing IL-9 production</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1367" start="1355">1355-1367</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> CD25</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> ST2</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptome analysis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Innate lymphoid cells (ILCs) are emerging subsets of immune cells that produce large amounts of cytokines upon cytokine and/or alarmin stimulation. Recent studies have shown that T-bet plays pivotal roles in the development of ILC3s and ILC1s; however, the roles of T-bet in lung ILC2s remain unknown. OBJECTIVE: To determine the role of T-bet in ILC2-mediated airway inflammation. METHODS: The expression of T-bet in lung ILCs (defined as Thy1.2+ Lin- cells) was examined. The roles of T-bet in the development of lung ILC2s and airway inflammation induced by IL-33 administration were examined by using T-bet-deficient (T-bet-/-) mice. Gene expression profiles of T-bet-/- lung ILCs were analyzed by RNA sequencing. RESULTS: T-bet was expressed in lung ILC2s (defined as Thy1.2+ Lin- cells expressing ST2 or CD25) and IFN-gamma enhanced its expression. While the development of lung ILC2s at steady-state conditions was normal in T-bet-/- mice, IL-33-induced accumulation of lung ILC2s and eosinophilic airway inflammation were exacerbated in T-bet-/- mice. The exacerbated accumulation of ILC2s and eosinophilic airway inflammation by the absence of T-bet was evident even in a RAG2-/- background, suggesting that T-bet expressed in non-T/non-B population is involved in the suppression of IL-33-induced eosinophilic airway inflammation. Transcriptome analysis revealed that IL-9 expression in IL-33-stimulated lung ILCs was up-regulated in T-bet-/- mice compared with that in wild-type mice. Importantly, neutralization of IL-9 markedly attenuated IL-33-induced accumulation of lung ILC2s and eosinophilic inflammation in T-bet-/- mice. CONCLUSION: T-bet suppresses IL-9 production from lung ILC2s and thereby inhibits IL-33-induced eosinophilic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27670243">PM:27670243</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-MatsukiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-MatsukiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Matsuki A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krause,K.</style></author><author><style face="normal" font="Arial"> Tsianakas,A.</style></author><author><style face="normal" font="Arial"> Wagner,N.</style></author><author><style face="normal" font="Arial"> Fischer,J.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Church,M.K.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of canakinumab in Schnitzler's syndrome: a multi-center randomized placebo-controlled study</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1320" start="1311">1311-1320</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amyloid</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exanthema</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> SF36</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Schnitzler's syndrome is an adult-onset autoinflammatory disease characterized by urticarial exanthema and monoclonal gammopathy accompanied by systemic symptoms such as fever, bone and muscle pain. Up to now, approved treatment options are not available. OBJECTIVE: We here assessed the effects of the anti-IL-1ss monoclonal antibody canakinumab on the clinical signs and symptoms of Schnitzler's syndrome. METHODS: In this phase II, randomized placebo-controlled multi-center study, 20 patients with active disease enrolled in four German study centers. Patients were randomly assigned to receive single subcutaneous canakinumab 150 mg or placebo injections for 7 days, followed by a 16-week open-label phase with canakinumab injections upon confirmed relapse of symptoms. The primary endpoint was the proportion of patients with complete clinical response evaluated by physician global assessment at day 7. Key secondary endpoints included changes in patient-reported disease activity (Schnitzler activity score), inflammation markers (C-reactive protein [CRP], serum amyloid A [SAA]) and quality of life assessments (DLQI, SF-36). RESULTS: The proportion of patients with complete clinical response at day 7 was significantly higher (P = 0.001) in the canakinumab-treated group (n = 5/7) than the placebo group (n = 0/13). Levels of inflammation markers CRP and SAA and quality of life scores significantly reduced in canakinumab-treated but not in placebo-treated individuals. Positive effects continued up to 16 weeks. Adverse events were manageable and included respiratory tract infections, gastrointestinal symptoms and hypertension. CONCLUSION: In this first placebo-controlled study, canakinumab was effective in patients with Schnitzler's syndrome, and thus canakinumab may be further evaluated as a therapeutic option for this rare disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27658762">PM:27658762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160923-KrauseK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160923-KrauseK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Krause K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anderson,H.M.</style></author><author><style face="normal" font="Arial"> Wood,R.A.</style></author><author><style face="normal" font="Arial"> Busse,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis</style></auth-address><titles><title><style face="normal" font="Arial">Dust Mite-Induced Perennial Allergic Rhinitis in Pediatric Patients and Sublingual Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="51" start="46">46-51</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="10/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> topical therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) is a common illness in children and can impair their quality of life. Furthermore, many children remain symptomatic despite maximizing systemic antihistamine and topical therapies. It is at this clinical juncture that immunotherapy may be considered. The efficacy and safety associated with both subcutaneous (SCIT) and sublingual (SLIT) approaches are reviewed and positioned as treatment options for pediatric patients, with specific focus on current literature as it relates to SLIT in children, including those with perennial allergic rhinitis. Although there is more extensive experience with SLIT treatment in Europe, grass and ragweed tablet forms of SLIT are approved in the US. Approaches to the care of pediatric patients with allergic rhinitis are presented</style></abstract><notes><style face="normal" font="Arial">DA - 20160925IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27665384">PM:27665384</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-46-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-46-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160925, Anderson HM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.07.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Min,J.Y.</style></author><author><style face="normal" font="Arial"> Ocampo,C.J.</style></author><author><style face="normal" font="Arial"> Stevens,W.W.</style></author><author><style face="normal" font="Arial"> Price,C.P.</style></author><author><style face="normal" font="Arial"> Thompson,C.F.</style></author><author><style face="normal" font="Arial"> Homma,T.</style></author><author><style face="normal" font="Arial"> Huang,J.H.</style></author><author><style face="normal" font="Arial"> Norton,J.E.</style></author><author><style face="normal" font="Arial"> Suh,L.A.</style></author><author><style face="normal" font="Arial"> Pothoven,K.L.</style></author><author><style face="normal" font="Arial"> Conley,D.B.</style></author><author><style face="normal" font="Arial"> Welch,K.C.</style></author><author><style face="normal" font="Arial"> Shintani-Smith,S.</style></author><author><style face="normal" font="Arial"> Peters,A.T.</style></author><author><style face="normal" font="Arial"> Grammer,L.C.,III</style></author><author><style face="normal" font="Arial"> Harris,K.E.</style></author><author><style face="normal" font="Arial"> Hulse,K.E.</style></author><author><style face="normal" font="Arial"> Kato,A.</style></author><author><style face="normal" font="Arial"> Modyanov,N.N.</style></author><author><style face="normal" font="Arial"> Kern,R.C.</style></author><author><style face="normal" font="Arial"> Schleimer,R.P.</style></author><author><style face="normal" font="Arial"> Tan,B.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Ill</style></auth-address><titles><title><style face="normal" font="Arial">Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="141" start="130">130-141</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-2</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-3</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human sinonasal epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> K+</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sinonasal epithelial</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutic value</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is often characterized by tissue eosinophilia that is associated with poor prognosis. Recent findings that proton pump inhibitors (PPIs) directly modulate the expression of eotaxin-3, an eosinophil chemoattractant, in patients with eosinophilic diseases suggest therapeutic potential for PPIs in those with CRSwNP. OBJECTIVE: We assessed the effect of type 2 mediators, particularly IL-13 and eotaxin-3, on tissue eosinophilia and disease severity in patients with chronic rhinosinusitis (CRS). Further investigation focused on PPI suppression of eotaxin-3 expression in vivo and in vitro, with exploration of underlying mechanisms. METHODS: Type 2 mediator levels in nasal tissues and secretions were measured by using a multiplex immunoassay. Eotaxin-3 and other chemokines expressed in IL-13-stimulated human sinonasal epithelial cells (HNECs) and BEAS-2B cells with or without PPIs were assessed by using ELISA, Western blotting, real-time PCR, and intracellular pH imaging. RESULTS: Nasal tissues and secretions from patients with CRSwNP had increased IL-13, eotaxin-2, and eotaxin-3 levels, and these were positively correlated with tissue eosinophil cationic protein levels and radiographic scores in patients with CRS (P &lt; .05). IL-13 stimulation of HNECs and BEAS-2B cells dominantly induced eotaxin-3 expression, which was significantly inhibited by PPIs (P &lt; .05). Patients with CRS taking PPIs also showed lower in vivo eotaxin-3 levels compared with those without PPIs (P &lt; .05). Using intracellular pH imaging and altering extracellular K+, we found that IL-13 enhanced H+,K+-exchange, which was blocked by PPIs and the mechanistically unrelated H,K-ATPase inhibitor, SCH-28080. Furthermore, knockdown of ATP12A (gene for the nongastric H,K-ATPase) significantly attenuated IL-13-induced eotaxin-3 expression in HNECs. PPIs also had effects on accelerating IL-13-induced eotaxin-3 mRNA decay. CONCLUSION: Our results demonstrated that PPIs reduce IL-13-induced eotaxin-3 expression by airway epithelial cells. Furthermore, mechanistic studies suggest that the nongastric H,K-ATPase is necessary for IL-13-mediated epithelial responses, and its inhibitors, including PPIs, might be of therapeutic value in patients with CRSwNP by reducing epithelial production of eotaxin-3</style></abstract><notes><style face="normal" font="Arial">DA - 20161008IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27717558">PM:27717558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161008-MinJY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161008-MinJY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161008, Min JY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kepert,I.</style></author><author><style face="normal" font="Arial"> Fonseca,J.</style></author><author><style face="normal" font="Arial"> Muller,C.</style></author><author><style face="normal" font="Arial"> Milger,K.</style></author><author><style face="normal" font="Arial"> Hochwind,K.</style></author><author><style face="normal" font="Arial"> Kostric,M.</style></author><author><style face="normal" font="Arial"> Fedoseeva,M.</style></author><author><style face="normal" font="Arial"> Ohnmacht,C.</style></author><author><style face="normal" font="Arial"> Dehmel,S.</style></author><author><style face="normal" font="Arial"> Nathan,P.</style></author><author><style face="normal" font="Arial"> Bartel,S.</style></author><author><style face="normal" font="Arial"> Eickelberg,O.</style></author><author><style face="normal" font="Arial"> Schloter,M.</style></author><author><style face="normal" font="Arial"> Hartmann,A.</style></author><author><style face="normal" font="Arial"> Schmitt-Kopplin,P.</style></author><author><style face="normal" font="Arial"> Krauss-Etschmann,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Comprehensive Pneumology Center, Ludwig Maximilians University Hospital and Helmholtz Zentrum Munchen, Max-Lebsche Platz 31, 81377 Grosshadern, Germany</style></auth-address><titles><title><style face="normal" font="Arial">D-Tryptophan from probiotic bacteria influences the gut microbiome and allergic airway disease</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1535" start="1525">1525-1535</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> D-amino acids</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Fractionation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Nuclear Magnetic Resonance</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic immune diseases (CIDs), such as asthma, are highly prevalent. Currently available pharmaceuticals improve symptoms, but cannot cure the disease. This prompted demands for alternatives to pharmaceuticals such as probiotics for prevention of allergic disease. However, clinical trials have given inconsistent results. This is at least partly explained by the highly complex crosstalk among probiotic bacteria, the host s microbiota, and immune cells. The identification of a bioactive substance from probiotic bacteria could circumvent this difficulty. OBJECTIVE: To identify and characterize a bioactive, probiotic metabolite for potential prevention of allergic airway disease. METHODS: Probiotic supernatants were screened for their ability to concordantly lower the constitutive CCL17 secretion of a human Hodgkin lymphoma cell line and prevent upregulation of costimulatory molecules of LPS-stimulated human dendritic cells. RESULTS: Supernatants from 13 of 37 tested probiotic strains showed immunoactivity. Bioassay-guided chromatographic fractionation of two supernatants according to polarity, followed by total ion chromatograms and mass spectrometry, yielded C11H12N2O2 as molecular formula of a bioactive substance. Proton nuclear magnetic resonance and enantiomeric separation identified D-Tryptophan. In contrast, L-Tryptophan and eleven other D-amino acids were inactive. Feeding D-Tryptophan to mice prior to experimental asthma induction, increased numbers of lung and gut regulatory T cells, lowered lung Th2 responses, and ameliorated allergic airway inflammation and hyperresponsiveness. Allergic airway inflammation reduced the gut microbial diversity, which was increased by D-Tryptophan. CONCLUSIONS: D-Tryptophan is a newly identified product from probiotic bacteria. Our findings support the concept that defined bacterial products might be exploited in novel preventative strategies for CIDs</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27670239">PM:27670239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-KepertI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-KepertI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Kepert I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Esaki,H.</style></author><author><style face="normal" font="Arial"> Brunner,P.M.</style></author><author><style face="normal" font="Arial"> Renert-Yuval,Y.</style></author><author><style face="normal" font="Arial"> Czarnowicki,T.</style></author><author><style face="normal" font="Arial"> Huynh,T.</style></author><author><style face="normal" font="Arial"> Tran,G.</style></author><author><style face="normal" font="Arial"> Lyon,S.</style></author><author><style face="normal" font="Arial"> Rodriguez,G.</style></author><author><style face="normal" font="Arial"> Immaneni,S.</style></author><author><style face="normal" font="Arial"> Johnson,D.B.</style></author><author><style face="normal" font="Arial"> Bauer,B.</style></author><author><style face="normal" font="Arial"> Fuentes-Duculan,J.</style></author><author><style face="normal" font="Arial"> Zheng,X.</style></author><author><style face="normal" font="Arial"> Peng,X.</style></author><author><style face="normal" font="Arial"> Estrada,Y.D.</style></author><author><style face="normal" font="Arial"> Xu,H.</style></author><author><style face="normal" font="Arial"> de Guzman,S.C.</style></author><author><style face="normal" font="Arial"> Suarez-Farinas,M.</style></author><author><style face="normal" font="Arial"> Krueger,J.G.</style></author><author><style face="normal" font="Arial"> Paller,A.S.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY; Laboratory for Investigative Dermatology, Rockefeller University, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1651" start="1639">1639-1651</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobials</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-19</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Keratin</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Peptidase</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH22</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="9" Year="2016">2016/9/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) affects 15% to 25% of children and 4% to 7% of adults. Paradigm-shifting discoveries about AD have been based on adult biomarkers, reflecting decades of disease activity, although 85% of cases begin by 5 years. Blood phenotyping shows only TH2 skewing in patients with early-onset pediatric AD, but alterations in early pediatric skin lesions are unknown, limiting advancement of targeted therapies. OBJECTIVE: We sought to characterize the early pediatric AD skin phenotype and its differences from pediatric control subjects and adults with AD. METHODS: Using immunohistochemistry and quantitative real-time PCR, we assessed biopsy specimens from 19 children with AD younger than 5 years within 6 months of disease onset in comparison with adults with AD or psoriasis and pediatric and adult control subjects. RESULTS: In lesional skin children showed comparable or greater epidermal hyperplasia (thickness and keratin 16) and cellular infiltration (CD3+, CD11c+, and FcepsilonRI+) than adults with AD. Similar to adults, strong activation of the TH2 (IL-13, IL-31, and CCL17) and TH22 (IL-22 and S100As) axes and some TH1 skewing (IFN-gamma and CXCL10) were present. Children showed significantly higher induction of TH17-related cytokines and antimicrobials (IL-17A, IL-19, CCL20, LL37, and peptidase inhibitor 3/elafin), TH9/IL-9, IL-33, and innate markers (IL-8) than adults (P &lt; .02). Despite the characteristic downregulation in adult patients with AD, filaggrin expression was similar in children with AD and healthy children. Nonlesional skin in pediatric patients with AD showed higher levels of inflammation (particularly IL-17A and the related molecules IL-19 and LL37) and epidermal proliferation (keratin 16 and S100As) markers (P &lt; .001). CONCLUSION: The skin phenotype of new-onset pediatric AD is substantially different from that of adult AD. Although excess TH2 activation characterizes both, TH9 and TH17 are highly activated at disease initiation. Increases in IL-19 levels might link TH2 and TH17 activation</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27671162">PM:27671162</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-EsakiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-EsakiH.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-EsakiH.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-EsakiH.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20160927, Esaki H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,J.B.</style></author><author><style face="normal" font="Arial"> James,L.K.</style></author><author><style face="normal" font="Arial"> Davies,A.M.</style></author><author><style face="normal" font="Arial"> Wu,Y.C.</style></author><author><style face="normal" font="Arial"> Rimmer,J.</style></author><author><style face="normal" font="Arial"> Lund,V.J.</style></author><author><style face="normal" font="Arial"> Chen,J.H.</style></author><author><style face="normal" font="Arial"> McDonnell,J.M.</style></author><author><style face="normal" font="Arial"> Chan,Y.C.</style></author><author><style face="normal" font="Arial"> Hutchins,G.H.</style></author><author><style face="normal" font="Arial"> Chang,T.W.</style></author><author><style face="normal" font="Arial"> Sutton,B.J.</style></author><author><style face="normal" font="Arial"> Kariyawasam,H.H.</style></author><author><style face="normal" font="Arial"> Gould,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Randall Division of Cell and Molecular Biophysics, King's College London, London SE1 1UL, UK</style></auth-address><titles><title><style face="normal" font="Arial">Antibodies and Superantibodies in Chronic Rhinosinusitis with Nasal Polyps</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1204" start="1195">1195-1204</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AERD</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Complementarity Determining Regions</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Enterotoxins</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> FACS</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant antibody</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SPR</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> Superantigens</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with local immunoglobulin hyperproduction and the presence of IgE antibodies against Staphylococcus aureus enterotoxins (SAEs). Aspirin-exacerbated respiratory disease (AERD) is a severe form of CRSwNP in which nearly all patients express anti-SAEs. OBJECTIVES: We aimed to understand antibodies reactive to SAEs and determine whether they recognize SAEs through their complementarity-determining regions (CDRs) or framework regions (FRs). METHODS: Labeled Staphylococcal enterotoxin A (SEA), SED and SEE were used to isolate single SAE-specific B cells from the nasal polyps of three AERD patients by FACS. Recombinant antibodies with "matched" heavy- and light-chains were cloned as IgG1, and those of high-affinity for specific SAEs, assayed by ELISA and surface plasmon resonance (SPR), were re-cloned as IgE and Fab. The activities of the IgEs were tested in basophil degranulation assays. RESULTS: Thirty-seven SAE-specific, IgG or IgA-expressing B cells were isolated and yielded six anti-SAE clones, two each for SEA, SED and SEE. Competition binding assays revealed that the anti-SEE antibodies recognize non-overlapping epitopes in SEE. Unexpectedly, each anti-SEE mediated SEE-induced basophil degranulation and IgG1 or Fab of each anti-SEE enhanced degranulation by the other anti-SEE. CONCLUSIONS: SEE may activate basophils by simultaneously binding as antigens in the conventional manner to CDRs and as superantigens to FRs of anti-SEE IgE in anti-SEE IgE-FcepsilonRI complexes. Anti-SEE IgG1s may enhance the activity of anti-SEE IgEs as conventional antibodies via CDRs or simultaneously as conventional antibodies and as "superantibodies" via CDRs and FRs to SEEs in SEE-anti-SEE IgE-FcepsilonRI complexes (Figure 7)</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -CO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.06.066</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27658758">PM:27658758</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160923-ChenJB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160923-ChenJB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Chen JB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.06.066</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deshpande,D.</style></author><author><style face="normal" font="Arial"> Morgan,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Arizona, Tucson, Ariz.</style></auth-address><titles><title><style face="normal" font="Arial">Wheezing disorders in children: Are girls and boys different?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1570" start="1569">1569-1570</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Arizona</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="13" Month="9" Year="2016">2016/9/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - EDITORIALCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27637384">PM:27637384</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160917-DeshpandeD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160917-DeshpandeD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Deshpande D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahuja,S.K.</style></author><author><style face="normal" font="Arial"> Manoharan,M.S.</style></author><author><style face="normal" font="Arial"> Harper,N.L.</style></author><author><style face="normal" font="Arial"> Jimenez,F.</style></author><author><style face="normal" font="Arial"> Hobson,B.D.</style></author><author><style face="normal" font="Arial"> Martinez,H.</style></author><author><style face="normal" font="Arial"> Ingale,P.</style></author><author><style face="normal" font="Arial"> Liu,Y.G.</style></author><author><style face="normal" font="Arial"> Carrillo,A.</style></author><author><style face="normal" font="Arial"> Lou,Z.</style></author><author><style face="normal" font="Arial"> Kellog,D.L.</style></author><author><style face="normal" font="Arial"> Ahuja,S.S.</style></author><author><style face="normal" font="Arial"> Rather,C.G.</style></author><author><style face="normal" font="Arial"> Esch,R.E.</style></author><author><style face="normal" font="Arial"> Ramirez,D.A.</style></author><author><style face="normal" font="Arial"> Clark,R.A.</style></author><author><style face="normal" font="Arial"> Nadeau,K.</style></author><author><style face="normal" font="Arial"> Andrews,C.P.</style></author><author><style face="normal" font="Arial"> Jacobs,R.L.</style></author><author><style face="normal" font="Arial"> He,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Veterans Administration Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, TX78229</style></auth-address><titles><title><style face="normal" font="Arial">Preservation of epithelial cell barrier function and muted inflammation in resistance to allergic rhinoconjunctivitis from house dust mite challenge</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="854" start="844">844-854</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge chamber</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell activation</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An emerging paradigm holds that resistance to the development of allergic diseases, including allergic rhinoconjunctivitis (AR), relates to an intact epithelial/epidermal barrier during early childhood. Conceivably, the immunologic and genomic footprint of this resistance is preserved in nonatopic, nonallergic adults and is unmasked during exposure to an aeroallergen. OBJECTIVE: To obtain direct support of the epithelial/epidermal barrier model for AR. METHODS: Twenty-three adults allergic to house dust mites (HDM; M+) and 15 nonsensitive, nonallergic (M-) participants completed 3-hour exposures to aerosolized HDM (Dermatophagoides pteronyssinus) powder on 4 consecutive days in an allergen challenge chamber (ACC). We analyzed (1) peripheral blood leukocyte levels and immune responses and (2) RNA-seq-derived expression profiles of nasal cells, before and after HDM exposure. RESULTS: During HDM challenge (1) only M+ persons developed AR symptoms and (2) peripheral blood leukocyte levels/responses and gene expression patterns in nasal cells were largely concordant between M+ and M- participants; gross differences in these parameters were not observed at baseline (pre-exposure). Two key differences were observed. First, peripheral blood CD4+ and CD8+ T-cell activation levels initially decreased in M- vs increased in M+ participants. Second, in M- compared with M+ participants, genes that promoted epidermal/epithelial barrier function (e.g., filaggrin) vs. inflammation (e.g., chemokines) and innate immunity (interferon) were upregulated vs. muted, respectively. CONCLUSION: An imprint of resistance to HDM challenge in nonatopic, nonallergic adults was muted T-cell activation and inflammatory responses in the peripheral blood and nasal compartment, respectively, coupled with upregulation of genes that promote epidermal/epithelial cell barrier function</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27658763">PM:27658763</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160923-AhujaSK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160923-AhujaSK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Ahuja SK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mjosberg,J.</style></author><author><style face="normal" font="Arial"> Spits,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Sweden.</style></auth-address><titles><title><style face="normal" font="Arial">Human Innate Lymphoid Cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1276" start="1265">1265-1276</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell surface receptors</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Ontogeny</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword></keywords><dates><year Day="24" Month="9" Year="2016">2016/9/24</year></dates><abstract><style face="normal" font="Arial">Innate lymphoid cells (ILC) are increasingly acknowledged as important mediators of immune homeostasis and pathology. ILC act as early orchestrators on immunity, responding to epithelial-derived signals by expressing an array of cytokines and cell surface receptors, which shape subsequent immune responses. As such, ILC make up interesting therapeutic targets for several diseases. In allergy and asthma, group 2 ILC (ILC2) produce high amounts of IL-5 and IL-13, thereby contributing to type 2 mediated inflammation. ILC3 are implicated in intestinal homeostasis and psoriasis pathology through abundant IL-22 production, whereas ILC1 are accumulated in chronic inflammation of the gut (IBD) and lung (COPD) where they contribute to IFN-gamma-mediated inflammation. Although the ontogeny of mouse ILC is slowly unraveling, the development of human ILC is far from understood. In addition, the growing complexity of the human ILC family in terms of previously unrecognized functional heterogeneity and plasticity has generated confusion within the field. Here we provide an updated view on the function and plasticity of human ILC in tissue homeostasis and disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160928IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27677386">PM:27677386</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160928-MjosbergJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160928-MjosbergJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160928, Mjosberg J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iribarren,C.</style></author><author><style face="normal" font="Arial"> Rahmaoui,A.</style></author><author><style face="normal" font="Arial"> Long,A.A.</style></author><author><style face="normal" font="Arial"> Szefler,S.J.</style></author><author><style face="normal" font="Arial"> Bradley,M.S.</style></author><author><style face="normal" font="Arial"> Carrigan,G.</style></author><author><style face="normal" font="Arial"> Eisner,M.D.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Omachi,T.A.</style></author><author><style face="normal" font="Arial"> Farkouh,M.E.</style></author><author><style face="normal" font="Arial"> Rothman,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif</style></auth-address><titles><title><style face="normal" font="Arial">Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study of moderate-to-severe asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1495" start="1489">1489-1495</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Stroke</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: EXCELS was a postmarketing commitment to the US Food and Drug Administration to assess long-term safety of omalizumab in an observational setting, focusing predominantly on malignancies. OBJECTIVE: To examine a potential association between omalizumab and cardiovascular (CV)/cerebrovascular (CBV) events in EXCELS. METHODS: Cohort study of patients (>/=12 years of age) with moderate-to-severe allergic asthma followed &lt;/=5 years, treated with omalizumab (n = 5007) or not treated with omalizumab (n = 2829) at baseline. Analyses included overall CV/CBV events, but focused on the subset of arterial thromboembolic events (ATE), comprising CV death, myocardial infarction, ischemic stroke, transient ischemic attack, or unstable angina. A prespecified analysis for the endpoint of ATE was conducted to control for available potential confounders. A blinded independent expert panel adjudicated all events. RESULTS: At baseline, cohorts had similar demographic characteristics, but severe asthma was more common in the omalizumab versus non-omalizumab cohorts (50% vs 23%). Omalizumab-treated patients had a higher rate of CV/CBV serious adverse events (13.4 per 1000 person-years [PY]) than non-omalizumab-treated patients (8.1 per 1000 PY). ATE rate per 1000 PY was 6.66 (101 patients/15,160 PY) for the omalizumab cohort and 4.64 (46 patients/9904 PY) for the non-omalizumab cohort. After controlling for available confounding factors, the hazard ratio was 1.32 (95% CI, 0.91-1.91). CONCLUSION: Results from this observational study demonstrated a higher incidence rate of CV/CBV events in the omalizumab versus non-omalizumab cohorts. Differences in asthma severity between cohorts likely contributed to this imbalance, but some increase in risk cannot be excluded (NCT00252135). CLINICAL IMPLICATIONS: Current asthma management guidelines should not be affected. However, health professionals should be aware of a possible association of omalizumab and serious cardiovascular/cerebrovascular events</style></abstract><notes><style face="normal" font="Arial">DA - 20160918IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27639934">PM:27639934</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160918-IribarrenC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160918-IribarrenC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160918, Iribarren C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Quintero,O.P.</style></author><author><style face="normal" font="Arial"> Arrondo,A.P.</style></author><author><style face="normal" font="Arial"> Veleiro,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, University Hospital of A Coruna, A Coruna, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Rapid response to omalizumab in 3 cases of delayed pressure urticaria</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="180" start="179">179-180</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="10/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed pressure</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160925IS - 2213-2201 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.07.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27665388">PM:27665388</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-179-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-179-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160925, Quintero OP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.07.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ownby,D.R.</style></author><author><style face="normal" font="Arial"> Johnson,C.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Professor of Pediatrics, Medical College of Georgia at Augusta University, Augusta, GA.</style></auth-address><titles><title><style face="normal" font="Arial">Dogs, Cats and Asthma: Will We Ever Really Know the True Risks and Benefits?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1592" start="1591">1591-1592</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="9" Year="2016">2016/9/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - EDITORIALCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27670242">PM:27670242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-OwnbyDR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160927-OwnbyDR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Ownby DR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,J.K.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Baek,M.C.</style></author><author><style face="normal" font="Arial"> Lee,B.H.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author><author><style face="normal" font="Arial"> Kwon,T.K.</style></author><author><style face="normal" font="Arial"> Park,P.H.</style></author><author><style face="normal" font="Arial"> Shin,T.Y.</style></author><author><style face="normal" font="Arial"> Khang,D.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CMRI, Departments of Pharmacology, Kyungpook National University, Daegu, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association between perfluorooctanoic acid exposure and degranulation of mast cells in allergic inflammation</style></title><secondary-title><style face="normal" font="Arial">J Appl Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Appl Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="9" Year="2016">2016/9/29</year></dates><abstract><style face="normal" font="Arial">Perfluorooctanoic acid (PFOA) has wide applications, including as a raw material for converted paper and packaging products. With the widespread use of PFOA, concerns regarding its potential environmental and health impacts have increased. In spite of the known hepatotoxicity and genotoxicity of PFOA, correlation with PFOA and allergic inflammation is not well known. In this study, the effect of PFOA on the degranulation of mast cells and mast cell-mediated allergic inflammation in the presence of FcepsilonRI cross-linking was evaluated. In immunoglobulin (Ig) E-stimulated mast cells, PFOA increased the release of histamine and beta-hexosaminidase by the up-regulation of intracellular calcium levels. PFOA enhanced gene expression of several pro-inflammatory cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and IL-8 by the activation of nuclear factor (NF)-kappaB in IgE-stimulated mast cells. Also, PFOA exacerbated allergic symptoms via hypothermia, and an increase of serum histamine, TNF-alpha, IgE and IgG1 in the ovalbumin-induced systemic anaphylaxis. The present data indicate that PFOA aggravated FcvarepsilonRI-mediated mast cell degranulation and allergic symptoms. Copyright (c) 2016 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1099-1263 (Electronic)IS - 0260-437X (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1002/jat.3389</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27682001">PM:27682001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Appl Toxicol\20160929-LeeJK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Appl Toxicol\20160929-LeeJK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Lee JK</style></custom2><misc3><style face="normal" font="Arial">10.1002/jat.3389</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Costa Carvalho,J.L.</style></author><author><style face="normal" font="Arial"> de Brito,A.A.</style></author><author><style face="normal" font="Arial"> de Oliveira,A.P.</style></author><author><style face="normal" font="Arial"> de Castro Faria Neto,H.C.</style></author><author><style face="normal" font="Arial"> Pereira,T.M.</style></author><author><style face="normal" font="Arial"> de Carvalho,R.A.</style></author><author><style face="normal" font="Arial"> Anatriello,E.</style></author><author><style face="normal" font="Arial"> Aimbire,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Science and Technology, Federal University of Sao Paulo - UNIFESP, Rua Talim</style></auth-address><titles><title><style face="normal" font="Arial">The chemokines secretion and the oxidative stress are targets of low-level laser therapy in allergic lung inflammation</style></title><secondary-title><style face="normal" font="Arial">J Biophotonics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Biophotonics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Rantes</style></keyword><keyword><style face="normal" font="Arial"> Reactive species</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TBARS</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="20" Month="9" Year="2016">2016/9/20</year></dates><abstract><style face="normal" font="Arial">Recent studies show that low-level laser therapy (LLLT) has an important anti-inflammatory action in acute lung inflammation. The present work explored if laser therapy is able to antagonize eosinophils and allergic inflammation induced by oxidative stress in Balb/c mice. Forty-eight hours after challenge, the leukocyte counting, ROS and nitrite/nitrate level, RANTES, CCL3, CCL8 as well as eotaxins were measured in the bronchoalveolar lavage fluid (BALF) of laser-treated mice or not. Into the lung, some chemokines receptors, the iNOS activity and mRNA expression, and the activities of superoxide dismutase (SOD), catalase, gluthatione, NADPH oxidase activities and thiobarbituric acid reactive species (T-Bars) were measured. Laser-treated allergic mice presented reduction of both the ICAM-1 and eosinophil in the lungs. RANTES, CCL8, CCL3 and eotaxins were reduced in BALF of laser-treated allergic mice. In allergic mice lung LLLT decreased the CCR1 and CCR3 and restored the oxidative stress balance as well. Laser decreased the lipidic peroxidation in allergic mice lung as much as increased SOD, GPx and GR. It shows that LLLT on allergic lung inflammation involves leukocyte-attractant chemokines and endogenous antioxidant. Based on results, LLLT may ultimately become a non- invasive option in allergic lung disease treatment. The top figure illustrates the laser decreasing the eosinophils migration into BALF and the bottom figure shows the laser upregulating the expression of heme-oxygenase (anti-oxidant enzyme) in lung tissue anti-oxidant</style></abstract><notes><style face="normal" font="Arial">DA - 20160920IS - 1864-0648 (Electronic)IS - 1864-063X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1002/jbio.201600061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27649282">PM:27649282</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biophotonics\20160920-CostaCarvalhoJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biophotonics\20160920-CostaCarvalhoJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Costa Carvalho JL</style></custom2><misc3><style face="normal" font="Arial">10.1002/jbio.201600061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lu,Y.</style></author><author><style face="normal" font="Arial"> Xu,J.Y.</style></author><author><style face="normal" font="Arial"> Zhang,X.H.</style></author><author><style face="normal" font="Arial"> Zhao,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Institution of Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Key Laboratory of Pediatric Respiratory Disease, Nanjing 210023, China.</style></auth-address><titles><title><style face="normal" font="Arial">Gu-Ben-Fang-Xiao decoction attenuates sustained airway inflammation by suppressing ER stress response in a murine asthma remission model of respiratory syncytial virus infection</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="509" start="496">496-509</pages><volume><style face="normal" font="Arial">192</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> asthma remission</style></keyword><keyword><style face="normal" font="Arial"> asthma susceptibility</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Endoplasmic Reticulum</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation Mediators</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Luminex assay</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> ORMDL3</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> real-time RT-PCR</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Stress response</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="4" Month="11" Year="2016">2016/11/4</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: In recent years, asthma has increased dramatically in prevalence with a considerable economic burden all over the world. Long-term remission should be regarded as the promising and meaningful therapeutic goal in asthma management. However, the precise definition criteria and rational therapies for asthma remission have not been well-established. In academia, there is a consensus that even in those who develop asymptomatic remission of asthma, persistent airway inflammation is ubiquitous. Gubenfangxiao decoction (GBFXD) has been widely used in treating asthma remission stage for decades in the Jiangsu Province Hospital of Chinese Medicine, China. We previously demonstrated that GBFXD could downregulate the asthma susceptibility gene ORMDL3, a trigger of Endoplasmic reticulum (ER) stress and unfolded protein response (UPR). AIM THIS STUDY: To investigate the involvement of ER stress and UPR in the anti-inflammatory effects of GBFXD in Respiratory Syncytial Virus (RSV)-OVA-induced asthma remission mice. MATERIALS AND METHODS: Mice were orally administered GBFXD at three doses for 30 days after an RSV-OVA challenge. The levels of inflammation mediators in serum were measured using a Luminex assay and the amount of IFN-gamma in lung homogenates was detected using ELISA. The splenic CD4+ and CD8+ T lymphocytes were counted using flow cytometric analysis. The mRNA and protein levels of asthma susceptibility gene ORMDL3, ER stress markers (BIP, CHOP), and three canonical UPR branches (PERK-eIF2a-ATF4, IRE1alpha-XBP1/IRE1alpha-JNK-AP1 and ATF6-SERCA2b signal pathways) were detected using real-time RT-PCR and western blot. RESULTS: Histopathological analysis showed that the model group mice still exhibited a sustained airway inflammation even after suspending the OVA-challenge and RSV infections for 30 days. H&amp;E staining results indicated that GBFXD could attenuate sustained airway inflammation. Decreased serum CXCL1 level and increased IFN-gamma level in lung homogenate were observed after GBFXD treatment. Reductions in the number of splenic CD4+/CD8+ T lymphocytes were found after DEX treatment. We further confirmed the previous finding that GBFXD could downregulate the expression of ORMDL3. As a result of suppressed UPR, decreased ER stress markers and inhibited UPR branches (PERK and IRE1alpha signal pathway) were also observed through the significant reduction of signature mRNA and protein expressions after GBFXD treatment. CONCLUSION: GBFXD can significantly attenuate RSV-OVA-induced persistent airway inflammation in murine asthma remission model. These effects may be mediated, at least partially, by inhibiting the activation of ER stress responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2016.09.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27660012">PM:27660012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\2016-192-496-509.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\2016-192-496-509.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Lu Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2016.09.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Q.</style></author><author><style face="normal" font="Arial"> Xiong,Y.</style></author><author><style face="normal" font="Arial"> Li,G.B.</style></author><author><style face="normal" font="Arial"> Tang,Q.</style></author><author><style face="normal" font="Arial"> Cao,M.</style></author><author><style face="normal" font="Arial"> Huang,J.B.</style></author><author><style face="normal" font="Arial"> Xing,M.</style></author><author><style face="normal" font="Arial"> Hu,C.P.</style></author><author><style face="normal" font="Arial"> Gong,Y.</style></author><author><style face="normal" font="Arial"> Wang,Q.H.</style></author><author><style face="normal" font="Arial"> Gao,N.</style></author><author><style face="normal" font="Arial"> Zhang,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacy, Xinqiao Hospital, Third Military Medical University, Chongqing, China</style></auth-address><titles><title><style face="normal" font="Arial">Xinqin exhibits the anti-allergic effect through the JAK2/STAT5 signaling pathway</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Suppressor of cytokine signaling</style></keyword><keyword><style face="normal" font="Arial"> suppressor of cytokine signaling 3</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="22" Month="9" Year="2016">2016/9/22</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Xinqin, a polyherbal medicine, is an important traditional Chinese herbal formula used in traditional oriental medicine for treatment of allergic rhinitis (AR). The formula is based on the Chinese Pharmacopoeia. AIM OF THE STUDY: Previously, Xinqin exhibited potent anti-allergic effect in a guinea pig model of AR. In this study, we explored the molecular mechanism of the anti-allergic effect mediated by Xinqin. MATERIALS AND METHODS: AR was induced in guinea pigs (Hartley) with toluene-2, 4-diisocyanate (TDI) in vivo and in HMC-1 mast cells with A23187/ phorbol 12-myristate-13-acetate (PMA) in vitro. The releases of allergic inflammatory mediators such as histamine, leukotriene (LT) D4, immunoglobulin (Ig) E, TNF-alpha, and IL-6 were analysed for allergy. The mast cell degranulation was displayed in HMC-1 mast cells. The activities of janus protein kinase 2 (JAK2), signal transduction and activator of transcription 5 (STAT5) and suppressor of cytokine signaling 3 (SOCS3) were evaluated by Western blot. RESULTS: Treatment with Xinqin resulted in AR symptoms and decreases in levels of histamine, LTD4, IgE, TNF-alpha, and IL-6 in serum of guinea pig model of AR and in A23187/PMA-stimulated HMC-1 mast cells. Treatment with Xinqin also inhibited cell degranulation in A23187/PMA-stimulated HMC-1 mast cells. The JAK2/STAT5 signaling pathway could play an important role in the anti-allergic activity mediated by Xinqin. CONCLUSIONS: Xinqin exerts the anti-allergic effect by modulating mast cell-mediated allergic responses by down-regulating JAK2/STAT5 signaling pathway. Results from this study provide a mechanistic basis for the application of Xinqin in the treatment of AR</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2016.09.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27666014">PM:27666014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20160926-ZhangQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20160926-ZhangQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Zhang Q</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2016.09.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Panth,N.</style></author><author><style face="normal" font="Arial"> Paudel,K.R.</style></author><author><style face="normal" font="Arial"> Karki,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Muan-gun 58554, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Phytochemical profile and biological activity of Juglans regia</style></title><secondary-title><style face="normal" font="Arial">J Integr Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Integr Med</style></full-title></periodical><pages end="373" start="359">359-373</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animal Diseases</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Ethnic Groups</style></keyword><keyword><style face="normal" font="Arial"> Helminthiasis</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Juglans regia</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peer Review</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Juglans regia Linn. (Juglandaceae), popularly known as English or Persian walnut, is a valuable medicinal plant with a potency to cure various diseases in traditional medicine. Since ancient time, different local ethnic groups have used various part of J. regia for a wide array of ailments including helminthiasis, diarrhea, sinusitis, stomach ache, arthritis, asthma, eczema, scrofula, skin disorders, diabetes mellitus, anorexia, thyroid dysfunction, cancer and infectious diseases. Biological activities of J. regia have been reported in several peer review journals and scientific attention is increasing. The present review attempts to provide comprehensive information on plant description, ethnobotanical use, toxicity, phytochemical profile, pharmacology, clinical studies and current research prospective of the J. regia. Currently, there is an immense interest on isolation/identification of active constituents from walnut and screening those active compounds for pharmacological activities. In addition, researchers are performing clinical trials as well as screening various solvent extracts or fractions of J. regia in several animal diseases models to identify promising therapeutic benefits. In the present work, we review the latest information based on published scientific investigations of J. regia</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 2095-4964 (Print)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2095-4964(16)60274-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27641607">PM:27641607</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Integr Med\2016-14-359-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Integr Med\2016-14-359-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Panth N</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2095-4964(16)60274-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teoh,A.C.</style></author><author><style face="normal" font="Arial"> Ryu,K.H.</style></author><author><style face="normal" font="Arial"> Lee,E.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Korea University of Science and Technology (UST), 217 Gajeong-ro, Yuseong-gu, Daejeon 305-350, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">One-Step Purification of Melittin Derived from Apis mellifera Bee Venom</style></title><secondary-title><style face="normal" font="Arial">J Microbiol Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Microbiol Biotechnol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Apis mellifera</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Honey</style></keyword><keyword><style face="normal" font="Arial"> honey bee</style></keyword><keyword><style face="normal" font="Arial"> honey bee venom</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Melittin</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="23" Month="9" Year="2016">2016/9/23</year></dates><abstract><style face="normal" font="Arial">The concern of the use of melittin in honey bee venom due to its adverse reaction caused by allergens such as phospholipase A2 (PLA(2)) and hyaluronidase (HYA) has been an obstacle towards its usage. We developed a novel single-step method for melittin purification and the removal of PLA(2) and HYA. This study explores the influence of pH, buffer compositions, salt concentration and types of cation-exchange chromatography resins on the recovery of melittin and the removal of both HYA and PLA(2). Melittin can be readily purified with a strong cation-exchange resin at pH 6.0 with sodium phosphate buffer. It resulted in a recovery yield of melittin up to 93% (5.87 mg from a total of 6.32 mg of initial melittin in crude bee venom) which is higher than any previously reported studies on melittin purification. PLA(2) (99%) and HYA (96%) were also successfully removed. Our study generates a single-step purification method for melittin with a high removal rate of PLA(2) and HYA, enabling melittin to be fully utilized for its therapeutic purposes</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 1738-8872 (Electronic)IS - 1017-7825 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4014/jmb.1608.08042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27666985">PM:27666985</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Microbiol Biotechnol\20160926-TeohAC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Microbiol Biotechnol\20160926-TeohAC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Teoh A</style></custom2><misc3><style face="normal" font="Arial">10.4014/jmb.1608.08042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fekete,K.</style></author><author><style face="normal" font="Arial"> Marton,S.</style></author><author><style face="normal" font="Arial"> Csiba,L.</style></author><author><style face="normal" font="Arial"> Fekete,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurology, Faculty of Medicine, University of Debrecen, Hungary.</style></auth-address><titles><title><style face="normal" font="Arial">Outcome of Repeated Thrombolysis in Debrecen Thrombolysis Database</style></title><secondary-title><style face="normal" font="Arial">J Stroke Cerebrovasc Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Stroke Cerebrovasc Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alberta</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> heart failure</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasminogen</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Stroke</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tissue Plasminogen Activator</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="9" Year="2016">2016/9/23</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Recombinant tissue plasminogen activator (rtPA) is an efficient therapy of acute ischemic stroke. The risk of a recurrent ischemic stroke is high. This prospective single center study aimed to assess whether or not the repeated rtPA treatment is beneficial for acute stroke patients. METHODS: All thrombolysed patients' data at the Department of Neurology, University of Debrecen have been recorded in the Debrecen Thrombolysis Database (DTD) since 2004. We identified 21 patients with repeated thrombolysis. Stroke severity by the NIH stroke scale score (NIHSSS) and imaging findings by the Alberta Stroke Programme Early CT Score were evaluated on admission and 1 day later. The modified Rankin Scale score at 3 months and case fatality at 1 year were evaluated. We compared the first and second thrombolyses, and we screened for bleeding and allergic reactions to determine safety. RESULTS: Within the 27-month median time, 18 patients were thrombolysed twice, with complete follow-up. In recurrent stroke patients, diabetes mellitus, congestive heart failure, and anticoagulation were more common. Admission cholesterol levels were decreased. After the first and second treatments, 24-hour NIHSSS were 3 (1;6) and 7 (1;10), respectively. At 3 months, good outcome was significantly higher after the first treatment than those of DTD, with no differences between the 2 attempts. There was little difference in 3-month and 1-year outcomes, regardless of laterality-ipsilateral or contralateral hemisphere-in recurrent strokes. One patient had nonsymptomatic intracranial bleeding after repeated rtPA treatment. DISCUSSION: Recurrent rtPA treatment may be safe and effective in patients who have mild or moderate residual symptoms after the index stroke</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1532-8511 (Electronic)IS - 1052-3057 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jstrokecerebrovasdis.2016.08.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27671096">PM:27671096</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Stroke Cerebrovasc Dis\20160927-FeketeK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Stroke Cerebrovasc Dis\20160927-FeketeK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Fekete K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jstrokecerebrovasdis.2016.08.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Su,X.</style></author><author><style face="normal" font="Arial"> Pan,J.</style></author><author><style face="normal" font="Arial"> Bai,F.</style></author><author><style face="normal" font="Arial"> Yuan,H.</style></author><author><style face="normal" font="Arial"> Dong,N.</style></author><author><style face="normal" font="Arial"> Li,D.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Chen,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Division of Zhongshan Hospital, Shanghai Institute of Respiratory Disease, Fudan University, No.180 Fenglin Road, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">IL-27 attenuates airway inflammation in a mouse asthma model via the STAT1 and GADD45gamma/p38 MAPK pathways</style></title><secondary-title><style face="normal" font="Arial">J Transl Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Transl Med</style></full-title></periodical><pages end="" start="283">283-</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Damage</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> STAT1</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="29" Month="9" Year="2016">2016/9/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is prone to Th2-mediated chronic airway inflammation. Interleukin-27 (IL-27) is a member of the IL-12 family that promotes the differentiation of Th1 cells and inhibits Th2 cells. We use human/mouse CD4+ T cells to see whether IL-27 could inhibit IL-4 production in vitro and then observe whether IL-27 administration could alleviate allergic airway inflammation in vivo by mice asthma model. METHODS: We isolated and cultured CD4+ T cells from healthy humans and mice to test whether IL-27 could inhibit IL-4 production under different conditions. In vivo study, the effect of IL-27 was examined using two types of intra-nasal (i.n.) administration: low-dose-multiple-times prevention or high-dose-limited-times treatment in murine asthma models. The expression levels of signal transducer and activator of transcription-1 (STAT1) and growth arrest and DNA damage 45-gamma (GADD45gamma)/p38 mitogen activated protein kinase (p38 MAPK) in lung tissues were measured using qPCR and Western blotting. RESULTS: In vitro, although IL-27 could inhibit naive CD4+ T cell differentiate into Th2 cells, but it could not redifferentiate already committed Th2 cells. In vivo, preventative administration of IL-27 attenuated allergic inflammation and airway hyperreactivity, whereas treatment group had no significant effect. In the asthma group, the phosphorylation of STAT1 was impaired, while GADD45gamma and p38 MAPK exhibited no obvious changes. Preventative administration of IL-27 could either reverse the impairment of STAT1 or strengthen the expression of GADD45gamma and p38 MAPK, whereas treatment group had no significant effect. CONCLUSIONS: Preventative administration of IL-27 improved the pathological changes in mouse asthma models via both the STAT1 and GADD45gamma/p38 MAPK pathways while therapeutic administration of IL-27 had no significant effect, which may be due to the presence of already differentiated Th2 cells in asthmatic airways that resist IL-27 inhibition</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1479-5876 (Electronic)IS - 1479-5876 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12967-016-1039-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27687913">PM:27687913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Transl Med\2016-14-283.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Transl Med\2016-14-283.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Su X</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12967-016-1039-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ierodiakonou,D.</style></author><author><style face="normal" font="Arial"> Garcia-Larsen,V.</style></author><author><style face="normal" font="Arial"> Logan,A.</style></author><author><style face="normal" font="Arial"> Groome,A.</style></author><author><style face="normal" font="Arial"> Cunha,S.</style></author><author><style face="normal" font="Arial"> Chivinge,J.</style></author><author><style face="normal" font="Arial"> Robinson,Z.</style></author><author><style face="normal" font="Arial"> Geoghegan,N.</style></author><author><style face="normal" font="Arial"> Jarrold,K.</style></author><author><style face="normal" font="Arial"> Reeves,T.</style></author><author><style face="normal" font="Arial"> Tagiyeva-Milne,N.</style></author><author><style face="normal" font="Arial"> Nurmatov,U.</style></author><author><style face="normal" font="Arial"> Trivella,M.</style></author><author><style face="normal" font="Arial"> Leonardi-Bee,J.</style></author><author><style face="normal" font="Arial"> Boyle,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Paediatrics, Imperial College London, London, England</style></auth-address><titles><title><style face="normal" font="Arial">Timing of Allergenic Food Introduction to the Infant Diet and Risk of Allergic or Autoimmune Disease: A Systematic Review and Meta-analysis</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="1192" start="1181">1181-1192</pages><volume><style face="normal" font="Arial">316</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intervention trial</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> type 1 diabetes</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="20" Month="9" Year="2016">2016/9/20</year></dates><abstract><style face="normal" font="Arial">Importance: Timing of introduction of allergenic foods to the infant diet may influence the risk of allergic or autoimmune disease, but the evidence for this has not been comprehensively synthesized. Objective: To systematically review and meta-analyze evidence that timing of allergenic food introduction during infancy influences risk of allergic or autoimmune disease. Data Sources: MEDLINE, EMBASE, Web of Science, CENTRAL, and LILACS databases were searched between January 1946 and March 2016. Study Selection: Intervention trials and observational studies that evaluated timing of allergenic food introduction during the first year of life and reported allergic or autoimmune disease or allergic sensitization were included. Data Extraction and Synthesis: Data were extracted in duplicate and synthesized for meta-analysis using generic inverse variance or Mantel-Haenszel methods with a random-effects model. GRADE was used to assess the certainty of evidence. Main Outcomes and Measures: Wheeze, eczema, allergic rhinitis, food allergy, allergic sensitization, type 1 diabetes mellitus, celiac disease, inflammatory bowel disease, autoimmune thyroid disease, and juvenile rheumatoid arthritis. Results: Of 16289 original titles screened, data were extracted from 204 titles reporting 146 studies. There was moderate-certainty evidence from 5 trials (1915 participants) that early egg introduction at 4 to 6 months was associated with reduced egg allergy (risk ratio [RR], 0.56; 95% CI, 0.36-0.87; I2 = 36%; P = .009). Absolute risk reduction for a population with 5.4% incidence of egg allergy was 24 cases (95% CI, 7-35 cases) per 1000 population. There was moderate-certainty evidence from 2 trials (1550 participants) that early peanut introduction at 4 to 11 months was associated with reduced peanut allergy (RR, 0.29; 95% CI, 0.11-0.74; I2 = 66%; P = .009). Absolute risk reduction for a population with 2.5% incidence of peanut allergy was 18 cases (95% CI, 6-22 cases) per 1000 population. Certainty of evidence was downgraded because of imprecision of effect estimates and indirectness of the populations and interventions studied. Timing of egg or peanut introduction was not associated with risk of allergy to other foods. There was low- to very low-certainty evidence that early fish introduction was associated with reduced allergic sensitization and rhinitis. There was high-certainty evidence that timing of gluten introduction was not associated with celiac disease risk, and timing of allergenic food introduction was not associated with other outcomes. Conclusions and Relevance: In this systematic review, early egg or peanut introduction to the infant diet was associated with lower risk of developing egg or peanut allergy. These findings must be considered in the context of limitations in the primary studies</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2016.12623</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27654604">PM:27654604</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2016-316-1181-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2016-316-1181-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160922, Ierodiakonou D</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2016.12623</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenhawt,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Allergy and Clinical Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora</style></auth-address><titles><title><style face="normal" font="Arial">Early Allergen Introduction for Preventing Development of Food Allergy</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="1159" start="1157">1157-1159</pages><volume><style face="normal" font="Arial">316</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="9" Year="2016">2016/9/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2016.12715</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27654600">PM:27654600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2016-316-1157-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2016-316-1157-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160922, Greenhawt M</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2016.12715</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,T.</style></author><author><style face="normal" font="Arial"> Hazen,M.</style></author><author><style face="normal" font="Arial"> Shang,Y.</style></author><author><style face="normal" font="Arial"> Zhou,M.</style></author><author><style face="normal" font="Arial"> Wu,X.</style></author><author><style face="normal" font="Arial"> Yan,D.</style></author><author><style face="normal" font="Arial"> Lin,Z.</style></author><author><style face="normal" font="Arial"> Solon,M.</style></author><author><style face="normal" font="Arial"> Luis,E.</style></author><author><style face="normal" font="Arial"> Ngu,H.</style></author><author><style face="normal" font="Arial"> Shi,Y.</style></author><author><style face="normal" font="Arial"> Katewa,A.</style></author><author><style face="normal" font="Arial"> Choy,D.F.</style></author><author><style face="normal" font="Arial"> Ramamoorthi,N.</style></author><author><style face="normal" font="Arial"> Castellanos,E.R.</style></author><author><style face="normal" font="Arial"> Balazs,M.</style></author><author><style face="normal" font="Arial"> Xu,M.</style></author><author><style face="normal" font="Arial"> Lee,W.P.</style></author><author><style face="normal" font="Arial"> Matsumoto,M.L.</style></author><author><style face="normal" font="Arial"> Payandeh,J.</style></author><author><style face="normal" font="Arial"> Arron,J.R.</style></author><author><style face="normal" font="Arial"> Hongo,J.A.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Hotzel,I.</style></author><author><style face="normal" font="Arial"> Austin,C.D.</style></author><author><style face="normal" font="Arial"> Reif,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology</style></auth-address><titles><title><style face="normal" font="Arial">Depletion of major pathogenic cells in asthma by targeting CRTh2</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="e86689">e86689-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> disease-modifying effect</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nippostrongylus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2016">2016/5/19</year></dates><abstract><style face="normal" font="Arial">Eosinophilic inflammation and Th2 cytokine production are central to the pathogenesis of asthma. Agents that target either eosinophils or single Th2 cytokines have shown benefits in subsets of biomarker-positive patients. More broadly effective treatment or disease-modifying effects may be achieved by eliminating more than one inflammatory stimulator. Here we present a strategy to concomitantly deplete Th2 T cells, eosinophils, basophils, and type-2 innate lymphoid cells (ILC2s) by generating monoclonal antibodies with enhanced effector function (19A2) that target CRTh2 present on all 4 cell types. Using human CRTh2 (hCRTh2) transgenic mice that mimic the expression pattern of hCRTh2 on innate immune cells but not Th2 cells, we demonstrate that anti-hCRTh2 antibodies specifically eliminate hCRTh2+ basophils, eosinophils, and ILC2s from lung and lymphoid organs in models of asthma and Nippostrongylus brasiliensis infection. Innate cell depletion was accompanied by a decrease of several Th2 cytokines and chemokines. hCRTh2-specific antibodies were also active on human Th2 cells in vivo in a human Th2-PBMC-SCID mouse model. We developed humanized hCRTh2-specific antibodies that potently induce antibody-dependent cell cytotoxicity (ADCC) of primary human eosinophils and basophils and replicated the in vivo depletion capacity of their murine parent. Therefore, depletion of hCRTh2+ basophils, eosinophils, ILC2, and Th2 cells with h19A2 hCRTh2-specific antibodies may be a novel and more efficacious treatment for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161004IS - 2379-3708 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.86689</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27699264">PM:27699264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2016-1-e86689.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2016-1-e86689.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161004, Huang T</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.86689</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,J.H.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,J.S.</style></author><author><style face="normal" font="Arial"> Kim,da R.</style></author><author><style face="normal" font="Arial"> Jung,S.W.</style></author><author><style face="normal" font="Arial"> Jeong,K.H.</style></author><author><style face="normal" font="Arial"> Lee,T.W.</style></author><author><style face="normal" font="Arial"> Lee,Y.H.</style></author><author><style face="normal" font="Arial"> Kim,Y.G.</style></author><author><style face="normal" font="Arial"> Moon,J.Y.</style></author><author><style face="normal" font="Arial"> Lee,S.H.</style></author><author><style face="normal" font="Arial"> Ihm,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Elevated serum immunoglobulin E level as a marker for progression of immunoglobulin A nephropathy</style></title><secondary-title><style face="normal" font="Arial">Kidney Res Clin Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Kidney Res Clin Pract</style></full-title></periodical><pages end="151" start="147">147-151</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Creatinine</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Delta</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Filtration</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="Arial"> Hematuria</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin A</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nephrotic Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Proteinuria</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Immunoglobulin E (IgE) has traditionally been associated with anaphylaxis and atopic disease. Previous studies reported that serum IgE levels are elevated in nephrotic syndrome and suggested IgE levels as a prognostic indicator in glomerular diseases. The aim of this study was to explore the association between serum IgE levels and renal outcome in patients with immunoglobulin A nephropathy (IgAN). METHODS: We included 117 patients with biopsy-proven IgAN. Renal progression was defined if a patient meets one of these criteria: (1) a negative value of delta estimated glomerular filtration rate (mL/min/1.73 m(2)/mo) or (2) a rise in serum creatinine to an absolute level of >/= 1.3 mg/dL (male) or 1.2 mg/dL (female). We defined delta changes in serum creatinine, estimated glomerular filtration rate, and proteinuria as a difference of values during the follow-up period. RESULTS: A total of 117 patients with IgAN were included. The serum IgE level was significantly high in the renal progressive group compared with the nonprogressive group. Sex and history of gross hematuria were significantly different between the high-IgE group and the low-IgE group. Regression analysis showed that a male sex, initial proteinuria, and change of proteinuria were significantly associated with serum IgE levels. CONCLUSION: The serum IgE level is potentially associated with disease progression and pathogenesis of IgAN</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 2211-9132 (Print)IS - 2211-9132 (Linking)LA - ENGPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.krcp.2016.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27668157">PM:27668157</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Kidney Res Clin Pract\2016-35-147-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Kidney Res Clin Pract\2016-35-147-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Lee JH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.krcp.2016.07.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kam,A.W.</style></author><author><style face="normal" font="Arial"> Tong,W.W.</style></author><author><style face="normal" font="Arial"> Christensen,J.M.</style></author><author><style face="normal" font="Arial"> Katelaris,C.H.</style></author><author><style face="normal" font="Arial"> Rimmer,J.</style></author><author><style face="normal" font="Arial"> Harvey,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of New South Wales, Sydney, NSW</style></auth-address><titles><title><style face="normal" font="Arial">Microgeographic factors and patterns of aeroallergen sensitisation</style></title><secondary-title><style face="normal" font="Arial">Med J Aust</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med J Aust</style></full-title></periodical><pages end="315" start="310">310-315</pages><volume><style face="normal" font="Arial">205</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Geography</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcome measurement</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="10" Year="2016">2016/10/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To examine patterns of airborne allergen (aeroallergen) sensitisation in the Greater Sydney area (Sydney), and their relationships with climate, coastal proximity and environment (urban v regional). DESIGN, SETTING, PARTICIPANTS: Retrospective cross-sectional study of patients who underwent aeroallergen skin prick testing at three Sydney allergy clinics, January 2001 - October 2014. MAIN OUTCOME MEASUREMENTS: Proportions of patients sensitised to specific aeroallergen types; relationships between sensitisation patterns and climate and geography. RESULTS: Of 1421 patients who met the selection criteria (mean age, 28.3 years [SD, 21.3]; 53.3% were female), 1092 (76.8%) were sensitised to at least one aeroallergen. Those living less than 15 km from the coast were less commonly sensitised to cockroach (&lt; 15 km, 15.1%; 15-30 km, 40.0%; > 30 km, 39.7%; P &lt; 0.001) and grass aeroallergens (&lt; 15 km, 36.5%; 15-30 km, 52.2%; > 30 km, 58.1%; P &lt; 0.001) than patients further inland; the same applied to mould, weed and tree aeroallergens. Subtropical grass sensitisation was more common in temperate/warm summer climates (about 50%) than in temperate/hot summer (27.1%) or subtropical climates (15%) (P &lt; 0.001), and less common in urban (36.7%) than in regional areas (54%; P = 0.014). 72.4% of grass-sensitised patients were co-sensitised to both temperate and subtropical grasses. A selected ten-aeroallergen skin prick test panel identified 98.5% of atopic patients in this Sydney sample. CONCLUSIONS: Environmental and geographic factors are associated with different patterns of allergic sensitisation in Sydney. Extensive co-sensitisation to subtropical and temperate grasses has implications for immunotherapy in Australia, where most currently available therapies are based on formulations directed at temperate grasses only</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1326-5377 (Electronic)IS - 0025-729X (Linking)LA - ENGPT - Journal ArticleSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.5694/mja16.00264</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27681972">PM:27681972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med J Aust\2016-205-310-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med J Aust\2016-205-310-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Kam AW</style></custom2><misc3><style face="normal" font="Arial">10.5694/mja16.00264</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yan,D.C.</style></author><author><style face="normal" font="Arial"> Chung,F.F.</style></author><author><style face="normal" font="Arial"> Lin,S.J.</style></author><author><style face="normal" font="Arial"> Wan,G.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDivision of Taipei Pediatrics, Department of Pediatrics, Children's Medical Center, Chang Gung Memorial Hospital bDepartment of Respiratory Therapy, Chang Gung Memorial Hospital cCollege of Medicine, Chang Gung University dDepartment of Nursing, College of Nursing, Chang Gung University of Science and Technology eDivision of Asthma, Allergy, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital fDepartment of Respiratory Therapy, College of Medicine, Chang Gung University gDepartment of Neurosurgery, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan, R.O.C</style></auth-address><titles><title><style face="normal" font="Arial">The relationships among Dermatophagoides pteronyssinus exposure, exhaled nitric oxide, and exhaled breath condensate pH levels in atopic asthmatic children</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e4825">e4825-</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">39</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Bla g 1</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Therapy</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">This study examined seasonal changes in indoor Dermatophagoides pteronyssinus 1 (Der p 1)/Blattella germanica 1 (Bla g 1) antigen concentrations in the homes of atopic asthmatic and atopic nonasthmatic children. Possible associations between environmental allergen exposure and levels of exhaled breath indices were also evaluated.A total of 38 atopic children were recruited for this cross-sectional study: 22 were asthmatic and 16 were nonasthmatic. Home visits were conducted for indoor air and dust sampling each season. Exhaled nitric oxide (eNO)/spirometric measurements were taken and exhaled breath condensate (EBC) was collected after sampling of the domestic environment.The highest Der p 1 concentrations were on the top of mattresses in the homes of recruited children. The floors of kitchens and living rooms had the highest Bla g 1 concentrations in the homes of atopic asthmatic children. A positive correlation was found between Der p 1 exposure of mattress, bedroom floor, and living room floor and eNO levels in the atopic asthmatic children. The Der p 1 concentrations on the surfaces of mattress and bedroom floor were positively related to high eNO levels in the atopic asthmatic children after adjusting for season. No association was found between Der p 1 exposure and EBC pH values in the recruited children.A positive correlation was found between Der p 1 exposure and high eNO levels in atopic asthmatic children, especially in Der p 1 exposure of mattress and bedroom floor</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - ENGPT - Journal ArticleSB - AIMSB - IMCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000004825</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27684812">PM:27684812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-95-e4825.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-95-e4825.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Yan DC</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000004825</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tonacci,A.</style></author><author><style face="normal" font="Arial"> Billeci,L.</style></author><author><style face="normal" font="Arial"> Ruta,L.</style></author><author><style face="normal" font="Arial"> Tartarisco,G.</style></author><author><style face="normal" font="Arial"> Pioggia,G.</style></author><author><style face="normal" font="Arial"> Gangemi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Research Council of Italy, Institute of Clinical Physiology, IFC-CNR, Pisa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">A systematic review of the association between allergic asthma and autism</style></title><secondary-title><style face="normal" font="Arial">Minerva Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Minerva Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autism</style></keyword><keyword><style face="normal" font="Arial"> Autism spectrum disorder</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="10" Year="2016">2016/10/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Autism Spectrum Disorder represents a burdensome condition in early childhood, with a number of risk factors proposed to explain its pathogenesis, most of which without a reliable scientific basis. Allergic asthma is likely to be one of the possible comorbilities of autism. EVIDENCE ACQUISITION: In this paper, the relationship between autism and allergic asthma was analyzed through a systematic literature review, conducted according to the PRISMA guidelines. The review was performed on PubMed and Science Direct database and covered the period January 1,</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1827-1715 (Electronic)IS - 0026-4946 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27706122">PM:27706122</url></web-urls></urls><custom2><style face="normal" font="Arial">20161005, Tonacci A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bruhn,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">.</style></auth-address><titles><title><style face="normal" font="Arial">[Allergy diagnosis not trivial]</style></title><secondary-title><style face="normal" font="Arial">MMW Fortschr Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">MMW Fortschr Med</style></full-title></periodical><pages end="" start="67">67-</pages><volume><style face="normal" font="Arial">158</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> General practice</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword></keywords><dates><year Day="23" Month="6" Year="2016">2016/6/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160621IS - 1438-3276 (Print)IS - 1438-3276 (Linking)LA - gerPT - NewsSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s15006-016-8450-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27324012">PM:27324012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\MMW Fortschr Med\2016-158-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\MMW Fortschr Med\2016-158-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160621, Bruhn C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s15006-016-8450-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shelby,S.A.</style></author><author><style face="normal" font="Arial"> Veatch,S.L.</style></author><author><style face="normal" font="Arial"> Holowka,D.A.</style></author><author><style face="normal" font="Arial"> Baird,B.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemistry and Chemical Biology and Field of Biophysics, Cornell University, Ithaca, NY</style></auth-address><titles><title><style face="normal" font="Arial">Functional Nanoscale Coupling of Lyn Kinase with IgE-FcvarepsilonRI is Restricted by the Actin Cytoskeleton in Early Antigen-Stimulated Signaling</style></title><secondary-title><style face="normal" font="Arial">Mol Biol Cell</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Mol Biol Cell</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> actin cytoskeleton</style></keyword><keyword><style face="normal" font="Arial"> Actin polymerization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Cytoskeleton</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Lyn</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Membrane Lipids</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="9" Year="2016">2016/9/28</year></dates><abstract><style face="normal" font="Arial">The allergic response is initiated on the plasma membrane of mast cells by phosphorylation of the receptor for immunoglobulin E (IgE), FcvarepsilonRI, by Lyn kinase after IgE-FcvarepsilonRI complexes are cross-linked by multivalent antigen. Signal transduction requires reorganization of receptors and membrane signaling proteins, but this spatial regulation is not well-defined. We used fluorescence localization microscopy (FLM) and pair-correlation analysis to measure the codistribution of IgE-FcvarepsilonRI and Lyn on the plasma membrane of fixed cells with 20-25 nm resolution. We directly visualized Lyn recruitment to IgE-FcvarepsilonRI within 1 min of antigen stimulation. Parallel FLM experiments captured stimulation-induced FcvarepsilonRI phosphorylation and colocalization of a saturated lipid-anchor probe derived from Lyn's membrane anchorage. We used cytochalasin and latrunculin to investigate participation of the actin cytoskeleton in regulating functional interactions of FcvarepsilonRI. Inhibition of actin polymerization by these agents enhanced colocalization IgE-FcvarepsilonRI with Lyn and its saturated lipid-anchor at early stimulation times, accompanied by augmented phosphorylation within FcvarepsilonRI clusters. Ising model simulations provide a simplified model consistent with our results. These findings extend previous evidence that IgE-FcvarepsilonRI signaling is initiated by colocalization with Lyn in ordered lipid regions and that the actin cytoskeleton regulates this functional interaction by influencing the organization of membrane lipids</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1939-4586 (Electronic)IS - 1059-1524 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1091/mbc.E16-06-0425</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27682583">PM:27682583</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Biol Cell\20160929-ShelbySA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Biol Cell\20160929-ShelbySA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Shelby SA</style></custom2><misc3><style face="normal" font="Arial">10.1091/mbc.E16-06-0425</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Zhu,W.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Lin,Z.</style></author><author><style face="normal" font="Arial"> Ma,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Nanjing Medical University, Affiliated Hangzhou Hospital (Hangzhou First People's Hospital), Hangzhou, Zhejiang 310006, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">CD38 gene-modified dendritic cells inhibit murine asthma development by increasing IL-12 production and promoting Th1 cell differentiation</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="4382" start="4374">4374-4382</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenovirus</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="9" Year="2016">2016/9/21</year></dates><abstract><style face="normal" font="Arial">Predominant T helper (Th)2 and impaired Th1 cell polarization has a crucial role in the development of asthma. Cluster of differentiation (CD)38 is associated with the increased release of interleukin (IL)12 from dendritic cells (DCs) and DCinduced Th1 cell polarization. However, whether CD38 expression affects DC function in asthma development remains unknown. In the current study, adenoviruses were constructed containing the murine CD38 gene. Overexpression of CD38 protein level in DCs induced from bonemarrow derived DCs (BMDCs) by recombinant mouse granulocyte macrophage colonystimulating factor and IL4 was achieved through 24 h adenovirus infection. The results demonstrated that BMDCs with CD38 overexpression exhibited no phenotypic change; however, following stimulation with lipopolysaccharide (LPS), maturation and IL12 secretion were increased. In addition, CD38overexpressing BMDCs stimulated with LPS exhibited more effective Th1 cell differentiation. Mice that were administered CD38overexpressing BMDCs exhibited milder symptoms of asthma. Furthermore, decreased IL4, IL5 and IL13 levels were detected in bronchoalveolar lavage fluid (BALF), reduced immunoglobulin E levels were measured in the sera, and increased interferongamma was detected in BALF from the recipients of CD38overexpressing BMDCs. Increased phosphorylatedp38 expression was also detected in LPS-stimulated CD38-overexpressing BMDCs, whereas pretreatment with a p38specific inhibitor was able to abolish the effects of LPS stimulation and CD38 overexpression on IL12 release and Th1 cell differentiation in BMDCs. These results suggested that CD38 may be involved in the DC function of alleviating asthma via restoration of the Th1/Th2 balance, thus providing a novel strategy for asthma therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2016.5756</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27666020">PM:27666020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2016-14-4374-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2016-14-4374-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2016.5756</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leaker,B.R.</style></author><author><style face="normal" font="Arial"> Malkov,V.A.</style></author><author><style face="normal" font="Arial"> Mogg,R.</style></author><author><style face="normal" font="Arial"> Ruddy,M.K.</style></author><author><style face="normal" font="Arial"> Nicholson,G.C.</style></author><author><style face="normal" font="Arial"> Tan,A.J.</style></author><author><style face="normal" font="Arial"> Tribouley,C.</style></author><author><style face="normal" font="Arial"> Chen,G.</style></author><author><style face="normal" font="Arial"> De Lepeleire,I.</style></author><author><style face="normal" font="Arial"> Calder,N.A.</style></author><author><style face="normal" font="Arial"> Chung,H.</style></author><author><style face="normal" font="Arial"> Lavender,P.</style></author><author><style face="normal" font="Arial"> Carayannopoulos,L.N.</style></author><author><style face="normal" font="Arial"> Hansel,T.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Clinical Trials Ltd, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation (IL-5 and IL-13), the inflammasome (IL-1beta), and complement</style></title><secondary-title><style face="normal" font="Arial">Mucosal Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mucosal Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> C5aR</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> new biomarkers</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcriptomics</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="9" Year="2016">2016/9/28</year></dates><abstract><style face="normal" font="Arial">Non-invasive mucosal sampling (nasosorption and nasal curettage) was used following nasal allergen challenge with grass pollen in subjects with allergic rhinitis, in order to define the molecular basis of the late allergic reaction (LAR). It was found that the nasal LAR to grass pollen involves parallel changes in pathways of type 2 inflammation (IL-4, IL-5 and IL-13), inflammasome-related (IL-1beta), and complement and circadian-associated genes. A grass pollen nasal spray was given to subjects with hay fever followed by serial sampling, in which cytokines and chemokines were measured in absorbed nasal mucosal lining fluid, and global gene expression (transcriptomics) assessed in nasal mucosal curettage samples. Twelve of 19 subjects responded with elevations in interleukin (IL)-5, IL-13, IL-1beta and MIP-1beta/CCL4 protein levels in the late phase. In addition, in these individuals whole-genome expression profiling showed upregulation of type 2 inflammation involving eosinophils and IL-4, IL-5 and IL-13; neutrophil recruitment with IL-1alpha and IL-1beta; the alternative pathway of complement (factor P and C5aR); and prominent effects on circadian-associated transcription regulators. Baseline IL-33 mRNA strongly correlated with these late-phase responses, whereas a single oral dose of prednisone dose-dependently reversed most nasal allergen challenge-induced cytokine and transcript responses. This study shows that the LAR to grass pollen involves a range of inflammatory pathways and suggests potential new biomarkers and therapeutic targets. Furthermore, the marked variation in mucosal inflammatory events between different patients suggests that in the future precision mucosal sampling may enable rational specific therapy.Mucosal Immunology advance online publication, 28 September 2016; doi:10.1038/mi.2016.74</style></abstract><notes><style face="normal" font="Arial">DA - 20160928IS - 1935-3456 (Electronic)IS - 1933-0219 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -CO - United States -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1038/mi.2016.74</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27677865">PM:27677865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mucosal Immunol\20160928-LeakerBR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mucosal Immunol\20160928-LeakerBR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160928, Leaker BR</style></custom2><misc3><style face="normal" font="Arial">10.1038/mi.2016.74</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tiwari,S.</style></author><author><style face="normal" font="Arial"> Thakur,R.</style></author><author><style face="normal" font="Arial"> Goel,G.</style></author><author><style face="normal" font="Arial"> Shankar,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Solan, Himachal Pradesh, 173234, India</style></auth-address><titles><title><style face="normal" font="Arial">Nano-LC-Q-TOF Analysis of Proteome Revealed Germination of Aspergillus flavus Conidia is Accompanied by MAPK Signalling and Cell Wall Modulation</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> Aflatoxin</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Conidia</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Germination</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Information technology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">Aspergillus flavus is the second most leading cause of aspergillosis. The ability of A. flavus to adapt within the host environment is crtical for its colonization. Onset of germination of conidia is one of the crucial events; thus, in order to gain insight into A. flavus molecular adaptation while germination, protein profile of A. flavus was obtained. Approximately 82 % of conidia showed germination at 7 h; thus, samples were collected followed by protein extraction and subjected to nLC-Q-TOF mass spectrometer. Q-TOF data were analysed using Protein Lynx Global Services (PLGS 2.2.5) software. A total of 416 proteins were identified from UniProt Aspergillus species database. Orthologues of A. flavus was observed in A. fumigatus, A. niger, A. terreus, A. oryzae, etc. Proteins were further analysed in NCBI database, which showed that 27 proteins of A. flavus are not reported in UniProt and NCBI database. Functional characterization of proteins resulted majorly to cell wall synthesis and degradation, metabolisms (carbohydrate and amino acid metabolism), protein synthesis and degradation. Proteins/enzymes associated with aflatoxin biosynthesis were observed. We also observed Dicer-like proteins 1, 2 and autophagy-related proteins 2, 9, 18, 13, 11, 22. Expression of protein/enzymes associated with MAPK signalling pathway suggests their role during the germination process. Overall, the data present a catalogue of proteins/enzymes involved in the germination of A. flavus conidia and could also be applied to other Aspergillus species</style></abstract><notes><style face="normal" font="Arial">DA - 20160831IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-016-0056-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27576557">PM:27576557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20160831-TiwariS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20160831-TiwariS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160831, Tiwari S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-016-0056-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simpson,E.L.</style></author><author><style face="normal" font="Arial"> Bieber,T.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Blauvelt,A.</style></author><author><style face="normal" font="Arial"> Cork,M.J.</style></author><author><style face="normal" font="Arial"> Silverberg,J.I.</style></author><author><style face="normal" font="Arial"> Deleuran,M.</style></author><author><style face="normal" font="Arial"> Kataoka,Y.</style></author><author><style face="normal" font="Arial"> Lacour,J.P.</style></author><author><style face="normal" font="Arial"> Kingo,K.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Poulin,Y.</style></author><author><style face="normal" font="Arial"> Wollenberg,A.</style></author><author><style face="normal" font="Arial"> Soo,Y.</style></author><author><style face="normal" font="Arial"> Graham,N.M.</style></author><author><style face="normal" font="Arial"> Pirozzi,G.</style></author><author><style face="normal" font="Arial"> Akinlade,B.</style></author><author><style face="normal" font="Arial"> Staudinger,H.</style></author><author><style face="normal" font="Arial"> Mastey,V.</style></author><author><style face="normal" font="Arial"> Eckert,L.</style></author><author><style face="normal" font="Arial"> Gadkari,A.</style></author><author><style face="normal" font="Arial"> Stahl,N.</style></author><author><style face="normal" font="Arial"> Yancopoulos,G.D.</style></author><author><style face="normal" font="Arial"> Ardeleanu,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Oregon Health and Science University (E.L.S.), and Oregon Medical Research Center</style></auth-address><titles><title><style face="normal" font="Arial">Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Estonia</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oregon</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="9" Year="2016">2016/9/30</year></dates><abstract><style face="normal" font="Arial">Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. Methods In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. Results We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P&lt;0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P&lt;0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P&lt;0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. Conclusions In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .)</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Germany -CO - Japan -CO - Estonia -CO - United Kingdom -CO - Canada -CO - Denmark -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa1610020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27690741">PM:27690741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\20161003-SimpsonEL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\20161003-SimpsonEL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Simpson EL</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa1610020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shukla,A.K.</style></author><author><style face="normal" font="Arial"> Upadhyay,S.K.</style></author><author><style face="normal" font="Arial"> Mishra,M.</style></author><author><style face="normal" font="Arial"> Saurabh,S.</style></author><author><style face="normal" font="Arial"> Singh,R.</style></author><author><style face="normal" font="Arial"> Singh,H.</style></author><author><style face="normal" font="Arial"> Thakur,N.</style></author><author><style face="normal" font="Arial"> Rai,P.</style></author><author><style face="normal" font="Arial"> Pandey,P.</style></author><author><style face="normal" font="Arial"> Hans,A.L.</style></author><author><style face="normal" font="Arial"> Srivastava,S.</style></author><author><style face="normal" font="Arial"> Rajapure,V.</style></author><author><style face="normal" font="Arial"> Yadav,S.K.</style></author><author><style face="normal" font="Arial"> Singh,M.K.</style></author><author><style face="normal" font="Arial"> Kumar,J.</style></author><author><style face="normal" font="Arial"> Chandrashekar,K.</style></author><author><style face="normal" font="Arial"> Verma,P.C.</style></author><author><style face="normal" font="Arial"> Singh,A.P.</style></author><author><style face="normal" font="Arial"> Nair,K.N.</style></author><author><style face="normal" font="Arial"> Bhadauria,S.</style></author><author><style face="normal" font="Arial"> Wahajuddin,M.</style></author><author><style face="normal" font="Arial"> Singh,S.</style></author><author><style face="normal" font="Arial"> Sharma,S.</style></author><author><style face="normal" font="Arial"> Omkar</style></author><author><style face="normal" font="Arial"> Upadhyay,R.S.</style></author><author><style face="normal" font="Arial"> Ranade,S.A.</style></author><author><style face="normal" font="Arial"> Tuli,R.</style></author><author><style face="normal" font="Arial"> Singh,P.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genetics and Plant Molecular Biology, Council of Scientific and Industrial Research (CSIR)-National Botanical Research Institute, Lucknow, India</style></auth-address><titles><title><style face="normal" font="Arial">Expression of an insecticidal fern protein in cotton protects against whitefly</style></title><secondary-title><style face="normal" font="Arial">Nat Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Biotechnol</style></full-title></periodical><pages end="1051" start="1046">1046-1051</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cotton</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Fern</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> GM Crops</style></keyword><keyword><style face="normal" font="Arial"> GM-crops</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="5" Month="9" Year="2016">2016/9/5</year></dates><abstract><style face="normal" font="Arial">Whitefly (Bemisia tabaci) damages field crops by sucking sap and transmitting viral diseases. None of the insecticidal proteins used in genetically modified (GM) crop plants to date are effective against whitefly. We report the identification of a protein (Tma12) from an edible fern, Tectaria macrodonta (Fee) C. Chr., that is insecticidal to whitefly (median lethal concentration = 1.49 mug/ml in in vitro feeding assays) and interferes with its life cycle at sublethal doses. Transgenic cotton lines that express Tma12 at approximately 0.01% of total soluble leaf protein were resistant to whitefly infestation in contained field trials, with no detectable yield penalty. The transgenic cotton lines were also protected from whitefly-borne cotton leaf curl viral disease. Rats fed Tma12 showed no detectable histological or biochemical changes, and this, together with the predicted absence of allergenic domains in Tma12, indicates that Tma12 might be well suited for deployment in GM crops to control whitefly and the viruses it carries</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1546-1696 (Electronic)IS - 1087-0156 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1038/nbt.3665</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27598229">PM:27598229</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Biotechnol\2016-34-1046-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Biotechnol\2016-34-1046-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Shukla AK</style></custom2><misc3><style face="normal" font="Arial">10.1038/nbt.3665</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fujimura,K.E.</style></author><author><style face="normal" font="Arial"> Sitarik,A.R.</style></author><author><style face="normal" font="Arial"> Havstad,S.</style></author><author><style face="normal" font="Arial"> Lin,D.L.</style></author><author><style face="normal" font="Arial"> Levan,S.</style></author><author><style face="normal" font="Arial"> Fadrosh,D.</style></author><author><style face="normal" font="Arial"> Panzer,A.R.</style></author><author><style face="normal" font="Arial"> LaMere,B.</style></author><author><style face="normal" font="Arial"> Rackaityte,E.</style></author><author><style face="normal" font="Arial"> Lukacs,N.W.</style></author><author><style face="normal" font="Arial"> Wegienka,G.</style></author><author><style face="normal" font="Arial"> Boushey,H.A.</style></author><author><style face="normal" font="Arial"> Ownby,D.R.</style></author><author><style face="normal" font="Arial"> Zoratti,E.M.</style></author><author><style face="normal" font="Arial"> Levin,A.M.</style></author><author><style face="normal" font="Arial"> Johnson,C.C.</style></author><author><style face="normal" font="Arial"> Lynch,S.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA</style></auth-address><titles><title><style face="normal" font="Arial">Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation</style></title><secondary-title><style face="normal" font="Arial">Nat Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Med</style></full-title></periodical><pages end="1191" start="1187">1187-1191</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> 16s rRNA sequencing</style></keyword><keyword><style face="normal" font="Arial"> Abundance</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metabolome</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> Rhodotorula</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="12" Month="9" Year="2016">2016/9/12</year></dates><abstract><style face="normal" font="Arial">Gut microbiota bacterial depletions and altered metabolic activity at 3 months are implicated in childhood atopy and asthma. We hypothesized that compositionally distinct human neonatal gut microbiota (NGM) exist, and are differentially related to relative risk (RR) of childhood atopy and asthma. Using stool samples (n = 298; aged 1-11 months) from a US birth cohort and 16S rRNA sequencing, neonates (median age, 35 d) were divisible into three microbiota composition states (NGM1-3). Each incurred a substantially different RR for multisensitized atopy at age 2 years and doctor-diagnosed asthma at age 4 years. The highest risk group, labeled NGM3, showed lower relative abundance of certain bacteria (for example, Bifidobacterium, Akkermansia and Faecalibacterium), higher relative abundance of particular fungi (Candida and Rhodotorula) and a distinct fecal metabolome enriched for pro-inflammatory metabolites. Ex vivo culture of human adult peripheral T cells with sterile fecal water from NGM3 subjects increased the proportion of CD4+ cells producing interleukin (IL)-4 and reduced the relative abundance of CD4+CD25+FOXP3+ cells. 12,13-DiHOME, enriched in NGM3 versus lower-risk NGM states, recapitulated the effect of NGM3 fecal water on relative CD4+CD25+FOXP3+ cell abundance. These findings suggest that neonatal gut microbiome dysbiosis might promote CD4+ T cell dysfunction associated with childhood atopy</style></abstract><notes><style face="normal" font="Arial">DA - 20160912IS - 1546-170X (Electronic)IS - 1078-8956 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/nm.4176</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27618652">PM:27618652</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S2.xlsC:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S3.xlsC:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S4.xlsC:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S5.xlsC:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S6.xlsC:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S7.xlsC:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S8.xls</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S2.xlsF:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S3.xlsF:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S4.xlsF:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S5.xlsF:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S6.xlsF:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S7.xlsF:\A&amp;H HMW Papers\Nat Med\2016-22-1187-91-S8.xls</url></image-urls></urls><custom2><style face="normal" font="Arial">20160912, Fujimura KE</style></custom2><misc3><style face="normal" font="Arial">10.1038/nm.4176</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Budnik,L.T.</style></author><author><style face="normal" font="Arial"> Scheer,E.</style></author><author><style face="normal" font="Arial"> Burge,P.S.</style></author><author><style face="normal" font="Arial"> Baur,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Occupational Toxicology and Immunology Unit, Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf, Hamburg, Germany European Society for Environmental and Occupational Medicine, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Sensitising effects of genetically modified enzymes used in flavour, fragrance, detergence and pharmaceutical production: cross-sectional study</style></title><secondary-title><style face="normal" font="Arial">Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> alpha-Amylase</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> flavour</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Fragrance</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> glucanase</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE assays</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Likelihood ratio</style></keyword><keyword><style face="normal" font="Arial"> Lipase</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Papain</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Savinase</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assay</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assays</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> work-related symptom</style></keyword><keyword><style face="normal" font="Arial"> Xylanase</style></keyword></keywords><dates><year Day="21" Month="9" Year="2016">2016/9/21</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: The use of genetically engineered enzymes in the synthesis of flavourings, fragrances and other applications has increased tremendously. There is, however, a paucity of data on sensitisation and/or allergy to the finished products. We aimed to review the use of genetically modified enzymes and the enormous challenges in human biomonitoring studies with suitable assays of specific IgE to a variety of modified enzyme proteins in occupational settings and measure specific IgE to modified enzymes in exposed workers. METHODS: Specific IgE antibodies against workplace-specific individual enzymes were measured by the specific fluorescence enzyme-labelled immunoassay in 813 exposed workers seen in cross-sectional surveys. RESULTS: Twenty-three per cent of all exposed workers showed type I sensitisation with IgE antibodies directed against respective workplace-specific enzymes. The highest sensitisation frequencies observed were for workers exposed enzymes derived from alpha-amylase (44%), followed by stainzyme (41%), pancreatinin (35%), savinase (31%), papain (31%), ovozyme (28%), phytase (16%), trypsin (15%) and lipase (4%). The highest individual antibody levels (up to 110 kU/L) were detected in workers exposed to phytase, xylanase and glucanase. In a subgroup comprising 134 workers, detailed clinical diagnostics confirmed work-related symptoms. There was a strong correlation (r=0.75, p&lt;0.0001) between the symptoms and antibody levels. Workers with work-related respiratory symptoms showed a higher prevalence for the presence of specific IgE antibodies against workplace-specific enzymes than asymptomatic exposed workers (likelihood ratio 2.32, sensitivity 0.92, specificity 0.6). CONCLUSIONS: Our data confirm the previous findings showing that genetically engineered enzymes are potent allergens eliciting immediate-type sensitisation. Owing to lack of commercial diagnostic tests, few of those exposed receive regular surveillance including biomonitoring with relevant specific IgE assays</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 1470-7926 (Electronic)IS - 1351-0711 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1136/oemed-2015-103442</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27655774">PM:27655774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Occup Environ Med\20160922-BudnikLT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Occup Environ Med\20160922-BudnikLT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160922, Budnik LT</style></custom2><misc3><style face="normal" font="Arial">10.1136/oemed-2015-103442</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Day,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Veterinary Sciences, University of Bristol, Langford, North Somerset, BS40 5DU, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Cats are not small dogs: is there an immunological explanation for why cats are less affected by arthropod-borne disease than dogs?</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="507">507-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disease resistance</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic diversity</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Linkage Disequilibrium</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword></keywords><dates><year Day="20" Month="9" Year="2016">2016/9/20</year></dates><abstract><style face="normal" font="Arial">It is widely recognized that cats appear to be less frequently affected by arthropod-borne infectious diseases than dogs and share fewer zoonotic pathogens with man. This impression is supported by the relative lack of scientific publications related to feline vector-borne infections. This review explores the possible reasons for the difference between the two most common small companion animal species, including the hypothesis that cats might have a genetically-determined immunological resistance to arthropod vectors or the microparasites they transmit. A number of simple possibilities might account for the lower prevalence of these diseases in cats, including factors related to the lifestyle and behaviour of the cat, lesser spend on preventative healthcare for cats and reduced opportunities for research funding for these animals. The dog and cat have substantially similar immune system components, but differences in immune function might in part account for the markedly distinct prevalence and clinicopathological appearance of autoimmune, allergic, idiopathic inflammatory, immunodeficiency, neoplastic and infectious diseases in the two species. Cats have greater genetic diversity than dogs with much lower linkage disequilibrium in feline compared with canine breed groups. Immune function is intrinsically related to the nature of the intestinal microbiome and subtle differences between the canine and feline microbial populations might also impact on immune function and disease resistance. The reasons for the apparent lesser susceptibility of cats to arthropod-borne infectious diseases are likely to be complex, but warrant further investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20160920IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - ENGPT - Journal ArticlePT - ReviewSB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-016-1798-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27646278">PM:27646278</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2016-9-507.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2016-9-507.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Day MJ</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-016-1798-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author><author><style face="normal" font="Arial"> Cao,J.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Gong,H.</style></author><author><style face="normal" font="Arial"> Zhou,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, China</style></auth-address><titles><title><style face="normal" font="Arial">Specific histamine binding activity of a new lipocalin from Hyalomma asiaticum (Ixodidae) and therapeutic effects on allergic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="506">506-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Ixodidae</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> lipocalin</style></keyword><keyword><style face="normal" font="Arial"> Lipocalins</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein purification</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Salivary Glands</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Ticks</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Lipocalin proteins are secreted by tick salivary glands as an important strategy to interfere with the immune response of hosts. A large number of lipocalins are secreted, but the functions of most of these proteins are unclear. Here, we report a new lipocalin protein with particular histamine binding capacity, which was isolated from the salivary glands of the tick Hyalomma asiaticum. METHODS: The full length cDNA of the Ha24 gene was obtained by RACE, and Ha24 gene was expressed in E. coli; after protein purification and mice immunizations, specific Polyclonal antibodies (PcAb) were created in response to the recombinant protein. Reverse transcription PCR (RT-PCR), Quantitative PCR (Q-PCR), indirect immunofluorescence antibody (IFA) assay and western blot were used to detect the existence of native Ha24 in ticks. To confirm the histamine-binding capacity of rHa24, a histamine-binding assay was completed in vitro (ELISA) and in vivo by inhibition of allergic asthma in mice. RESULTS: Ha24 is coded by 681 bases, contains 227 amino acids, and has a molecular weight of 23.3 kDa. Abundant expression in the salivary glands of feeding ticks was confirmed by the identification of native Ha24 in ticks. The results of a histamine binding assay both in vitro and in vivo demonstrated that rHa24 binds specifically with histamine in a dose-dependent manner, and can provide relief from allergic asthma in mice. CONCLUSIONS: Ha24 is a new tick lipocalin with specific histamine binding activity that can provide relief from host inflammation response</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-016-1790-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27639693">PM:27639693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2016-9-506.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2016-9-506.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Wang Y</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-016-1790-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caubet,J.C.</style></author><author><style face="normal" font="Arial"> Szajewska,H.</style></author><author><style face="normal" font="Arial"> Shamir,R.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaffe Food Allergy Institute, Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Non IgE-mediated Gastrointestinal Food Allergies in children</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="17" start="6">6-17</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Colic</style></keyword><keyword><style face="normal" font="Arial"> constipation</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Irritable Bowel Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> nutrient deficiencies</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Non-IgE-mediated gastrointestinal food allergic disorders (non-IgE-GI-FA) including food protein-induced enterocolitis syndrome (FPIES), food protein-induced enteropathy (FPE) and food protein-induced allergic proctocolitis (FPIAP) are relatively uncommon in infants and young children, but are likely under-diagnosed. Non-IgE-GI-FA have a favorable prognosis, with majority resolving by age 3-5 years. Diagnosis relies on the recognition of symptoms pattern in FPIAP and FPIES and biopsy in FPE. Further studies are needed for a better understanding of the pathomechanism, which will lead eventually to the development of diagnostic tests and treatments. Limited evidence supports the role of food allergens in subsets of constipation, gastroesophageal reflux disease, irritable bowel syndrome, and colic. The immunologic pathomechanism is not fully understood and empiric prolonged avoidance of food allergens should be limited to minimize nutrient deficiency and feeding disorders/food aversions in infants. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -CO - Poland -CO - Switzerland -CO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12659</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27637372">PM:27637372</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160917-CaubetJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160917-CaubetJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Caubet JC</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12659</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez del Rio,P.</style></author><author><style face="normal" font="Arial"> Vidal,C.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Tabar,A.I.</style></author><author><style face="normal" font="Arial"> Sanchez-MacHin,I.</style></author><author><style face="normal" font="Arial"> Eberle,P.</style></author><author><style face="normal" font="Arial"> Borja,J.</style></author><author><style face="normal" font="Arial"> Bubel,P.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Section, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a paediatric assessment</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="70" start="60">60-70</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Safety data on "real-life" allergen immunotherapy (AIT) in children and adolescents is usually extrapolated from studies in adults. METHODS: Patients aged 18 or under initiating aeroallergen AIT were evaluated in a prospective European survey. Patient profiles and systemic reactions (SRs) were recorded. Descriptive, univariate and multivariate analyses were used to identify risk factors for SRs. RESULTS: A total of 1,563 patients (mean+/-SD age: 11.7+/-3.9 years; rhinitis: 93.7%; asthma: 61.5%; polysensitization: 62.5%) and 1,578 courses of AIT were assessed. Single-allergen AIT was administered in 89.5% of cases (n=1,412; mites: 49%; grass pollen: 25.8%; tree pollen: 8.7%; Alternaria: 4.6%; dander: 0.8%; weed pollen: 0.6%). Subcutaneous AIT (SCIT) was used in 71.4% (n=1,127) of the treatments, including 574 (50.9%) with natural extracts. Sublingual AIT (SLIT) was used for the remaining 451 treatments (drops: 73.8%; tablets: 26.2%). The mean+/-SD follow-up period was 12.9+/-3.3 months. The estimated total number of doses was 19,669 for SCIT and 131,550 for SLIT. Twenty-four patients (1.53%) experienced 29 SRs. Respiratory (55.7%) and skin symptoms (37.9%) were most frequent. Anaphylaxis was diagnosed in 3 SRs (10.3%), and adrenaline was administered in 2 of these cases. In a univariate analysis, the risk of SRs was lower in mite-sensitized patients and higher in cases of pollen polysensitization (>3), grass pollen extracts and the use of natural extracts (vs. allergoids). CONCLUSIONS: In a real-life paediatric setting, AIT is safe. SRs are infrequent and generally not severe. Pollen polysensitization, grass pollen extracts and natural extracts (vs. allergoids) were risk factors for AIT-associated SRs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -CO - France -CO - Germany -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12660</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27637414">PM:27637414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160917-RodriguezDelRioP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160917-RodriguezDelRioP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Rodriguez Del Rio P</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12660</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kristiansen,M.</style></author><author><style face="normal" font="Arial"> Dhami,S.</style></author><author><style face="normal" font="Arial"> Netuveli,G.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Penagos,M.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author><author><style face="normal" font="Arial"> Pajno,G.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Ryan,D.</style></author><author><style face="normal" font="Arial"> Santos,A.F.</style></author><author><style face="normal" font="Arial"> Timmermanns,F.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="29" start="18">18-29</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is a need to establish the effectiveness, cost-effectiveness and safety of allergen immunotherapy (AIT) for the prevention of allergic disease. METHODS: Two reviewers independently screened nine international biomedical databases. Studies were quantitatively synthesized using random-effects meta-analyses. RESULTS: 32 studies satisfied the inclusion criteria. Overall, meta-analysis found no conclusive evidence that AIT reduced the risk of developing a first allergic disease over the short-term (RR=0.30; 95%CI 0.04 to 2.09) and no randomized controlled evidence was found in relation to its longer-term effects for this outcome. There was however a reduction in the short-term risk of those with allergic rhinitis developing asthma (RR=0.40; 95%CI 0.29 to 0.54), with this finding being robust to a pre-specified sensitivity analysis. We found inconclusive evidence that this benefit was maintained over the longer-term: RR=0.62; 95%CI 0.31 to 1.23. There was evidence that the risk of new sensitization was reduced over the short-term, but this was not confirmed in the sensitivity analysis: RR=0.72; 95%CI 0.24 to 2.18. There was no clear evidence of any longer-term reduction in the risk of sensitization: RR=0.47; 95%CI 0.08 to 2.77. AIT appeared to have an acceptable side-effect profile. CONCLUSIONS: AIT did not result in a statistically significant reduction in the risk of developing a first allergic disease. There was however evidence of a reduced short-term risk of developing asthma in those with allergic rhinitis, but it is unclear whether this benefit was maintained over the longer-term. We are unable to comment on the cost-effectiveness of AIT. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Denmark -CO - Italy -CO - United KIngdom -CO - Germany -CO - Spain -CO - Greece -CO - Mexico -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12661</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27653623">PM:27653623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160930-KristiansenM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160930-KristiansenM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Kristiansen M</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12661</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vivarelli,M.</style></author><author><style face="normal" font="Arial"> Colucci,M.</style></author><author><style face="normal" font="Arial"> Bonanni,A.</style></author><author><style face="normal" font="Arial"> Verzani,M.</style></author><author><style face="normal" font="Arial"> Serafinelli,J.</style></author><author><style face="normal" font="Arial"> Emma,F.</style></author><author><style face="normal" font="Arial"> Ghiggeri,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Nephrology and Dialysis, IRCCS-Bambino Gesu Children's Hospital, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab</style></title><secondary-title><style face="normal" font="Arial">Pediatr Nephrol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Nephrol</style></full-title></periodical><pages end="184" start="181">181-184</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-CD20</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine A</style></keyword><keyword><style face="normal" font="Arial"> Dialysis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Nephrotic Syndrome</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions. CASE-DIAGNOSIS/TREATMENT: Patient 1, a 14-year-old boy with SDNS since the age of 2, was treated with oral prednisone, cyclosporine A (CsA) and mycophenolate mofetil. A first infusion of rituximab at age 12 years was well tolerated, but this was followed by a prolonged relapse unresponsive to oral prednisone, mycophenolate mofetil and CsA. A second rituximab infusion was attempted, but treatment was interrupted due to severe dyspnea. Treatment with a humanized anti-CD20 monoclonal antibody, ofatumumab, was then attempted. The patient experienced a mild allergic reaction and maintained remission despite interruption of all treatment at >12 months of follow-up. Patient 2, a 3-year-old boy who presented at 18 months with nephrotic syndrome initially resistant to treatment with oral prednisone, was given with three intravenous boluses of methylprednisolone followed by CsA and achieved remission. Upon steroid discontinuation, the NS relapsed. Prednisone was restarted and treatment with a single dose of rituximab was never completed due to a severe allergic reaction. Ofatumumab infusion was uneventful, and he maintained remission during the follow-up period (>12 months) despite interruption of prednisone therapy. B cells reappeared at 7 months in both patients. CONCLUSIONS: Ofatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1432-198X (Electronic)IS - 0931-041X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00467-016-3498-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27687621">PM:27687621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Nephrol\20160930-VivarelliM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Nephrol\20160930-VivarelliM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Vivarelli M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00467-016-3498-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Porcaro,F.</style></author><author><style face="normal" font="Arial"> Di Marco,A.</style></author><author><style face="normal" font="Arial"> Cutrera,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Unit, Academic Department of Pediatrics, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria</style></title><secondary-title><style face="normal" font="Arial">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Pulmonol</style></full-title></periodical><pages end="E28" start="E26">E26-E28</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> AERD</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Aspirin hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Periodicals</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Aspirin hypersensitivity associated with chronic rhinosinusitis-with or without nasal polyposis-and asthma resistant to conventional therapy defines the aspirin-exacerbated respiratory disease (AERD). We describe the case of a 15-year-old female patient with adverse reaction to aspirin, chronic rhinosinusitis, and severe asthma. She also experienced chronic idiopathic urticaria worsened by non-steroidal anti-inflammatory drug administration. AERD was diagnosed based on clinical history and symptoms. Given the poor responsiveness to standard therapy for respiratory and cutaneous symptoms, omalizumab was administered for 24 weeks with control of respiratory symptoms and short term improvement of cutaneous symptoms. Pediatr Pulmonol. 2016; 9999:XX-XX. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1002/ppul.23615</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27685608">PM:27685608</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Pulmonol\20160929-PorcaroF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Pulmonol\20160929-PorcaroF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Porcaro F</style></custom2><misc3><style face="normal" font="Arial">10.1002/ppul.23615</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lauren,C.T.</style></author><author><style face="normal" font="Arial"> Belsito,D.V.</style></author><author><style face="normal" font="Arial"> Morel,K.D.</style></author><author><style face="normal" font="Arial"> Larussa,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Dermatology, and Pediatrics, Columbia University Medical Center, New York</style></auth-address><titles><title><style face="normal" font="Arial">Case Report of Subcutaneous Nodules and Sterile Abscesses Due to Delayed Type Hypersensitivity to Aluminum-Containing Vaccines</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20141690">e20141690-</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abscess</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="27" Month="9" Year="2016">2016/9/27</year></dates><abstract><style face="normal" font="Arial">Routine childhood immunizations have resulted in great reductions in vaccine-preventable infectious diseases. Vaccine-related adverse events, albeit rare, can be of significant consequence. Although anaphylaxis, or type I hypersensitivity, is recognized as a potential reaction after vaccination, delayed type hypersensitivity or type IV reactions are less so. We present a case of persistent subcutaneous nodules and sterile abscesses in the setting of delayed type hypersensitivity to aluminum, confirmed by patch testing and recurrence on re-exposure. We review sources of aluminum in common immunizations, principles for treatment, and strategies for management of future vaccinations for this patient</style></abstract><notes><style face="normal" font="Arial">DA - 20160928IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2014-1690</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27677573">PM:27677573</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\2016-138-e20141690.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\2016-138-e20141690.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160928, Lauren CT</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2014-1690</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Willebrand,R.</style></author><author><style face="normal" font="Arial"> Voehringer,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infection Biology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">IL-33-Induced Cytokine Secretion and Survival of Mouse Eosinophils Is Promoted by Autocrine GM-CSF</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0163751">e0163751-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Siglec-F</style></keyword><keyword><style face="normal" font="Arial"> ST2</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Eosinophils are major effector cells during allergic responses and helminth infections. Recent studies further highlight eosinophils as important players in many other biological processes. Therefore it is important to understand how these cells can be modulated in terms of survival and effector function. In the present study we investigated how eosinophils respond to the alarmin IL-33. We show that IL-33 promotes eosinophil survival in a ST2- and MyD88-dependent manner. IL-33-mediated protection from apoptosis was dependent on autocrine GM-CSF release. In addition, GM-CSF increased the IL-33-induced secretion of IL-4 and IL-13 from eosinophils. Unexpectedly, this effect was further enhanced by cross-linking of Siglec-F, a proposed inhibitory and apopotosis-inducing receptor on eosinophils. Co-culture experiments with eosinophils and macrophages revealed that the IL-33-induced release of IL-4 and IL-13 from eosinophils was required for differentiation of alternatively activated macrophages (AAMs). The differentiation of AAMs could be further increased in the presence of GM-CSF. These results indicate that cross-talk between Siglec-F and the receptors for IL-33, LPS and GM-CSF plays an important role for efficient secretion of IL-4 and IL-13. Deciphering the molecular details of this cross-talk could lead to the development of new therapeutic option to treat eosinophil-associated diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0163751</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27690378">PM:27690378</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0163751.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0163751.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Willebrand R</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0163751</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,K.</style></author><author><style face="normal" font="Arial"> Ren,F.</style></author><author><style face="normal" font="Arial"> Han,F.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Wu,G.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Wu,X.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Li,P.</style></author><author><style face="normal" font="Arial"> Shi,W.</style></author><author><style face="normal" font="Arial"> Zhu,H.</style></author><author><style face="normal" font="Arial"> Lv,J.</style></author><author><style face="normal" font="Arial"> Zhao,X.</style></author><author><style face="normal" font="Arial"> Tang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biotechnology Research Institute, Shanghai Academy of Agricultural Sciences, Shanghai, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Edible Safety Assessment of Genetically Modified Rice T1C-1 for Sprague Dawley Rats through Horizontal Gene Transfer, Allergenicity and Intestinal Microbiota</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0163352">e0163352-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> Bacillus thuringiensis</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxicity Tests</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic rice</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">In this study, assessment of the safety of transgenic rice T1C-1 expressing Cry1C was carried out by: (1) studying horizontal gene transfer (HGT) in Sprague Dawley rats fed transgenic rice for 90 d; (2) examining the effect of Cry1C protein in vitro on digestibility and allergenicity; and (3) studying the changes of intestinal microbiota in rats fed with transgenic rice T1C-1 in acute and subchronic toxicity tests. Sprague Dawley rats were fed a diet containing either 60% GM Bacillus thuringiensis (Bt) rice T1C-1 expressing Cry1C protein, the parental rice Minghui 63, or a basic diet for 90 d. The GM Bt rice T1C-1 showed no evidence of HGT between rats and transgenic rice. Sequence searching of the Cry1C protein showed no homology with known allergens or toxins. Cry1C protein was rapidly degraded in vitro with simulated gastric and intestinal fluids. The expressed Cry1C protein did not induce high levels of specific IgG and IgE antibodies in rats. The intestinal microbiota of rats fed T1C-1 was also analyzed in acute and subchronic toxicity tests by DGGE. Cluster analysis of DGGE profiles revealed significant individual differences in the rats' intestinal microbiota</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0163352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27706188">PM:27706188</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0163352.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0163352.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Zhao K</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0163352</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hall,J.A.</style></author><author><style face="normal" font="Arial"> Hartman,J.</style></author><author><style face="normal" font="Arial"> Skinner,M.M.</style></author><author><style face="normal" font="Arial"> Schwindt,A.R.</style></author><author><style face="normal" font="Arial"> Fischer,K.A.</style></author><author><style face="normal" font="Arial"> Vorachek,W.R.</style></author><author><style face="normal" font="Arial"> Bobe,G.</style></author><author><style face="normal" font="Arial"> Valentine,B.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Dietary Enrichment with 20% Fish Oil Decreases Mucus Production and the Inflammatory Response in Mice with Ovalbumin-Induced Allergic Lung Inflammation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0163819">e0163819-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Acids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> Corn Oil</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> fish oil</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Mucins</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oregon</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The prevalence of asthma has increased in recent decades, which may be related to higher dietary intake of (n-6) polyunsaturated fatty acids (PUFA) and lower intake of (n-3) PUFA, e.g., those contained in fish oil. The objective of this study was to determine if dietary PUFA enrichment decreases mucus production or the inflammatory response associated with ovalbumin (OVA)-induced allergic lung inflammation. Mice (n = 10/group) were fed control, 20% fish oil, or 20% corn oil enriched diets for a total of 12 weeks. At 8 and 10 weeks, mice were given an intraperitoneal injection of saline (10 control-fed mice) or OVA (30 remaining mice). Once at 10 weeks and on 3 consecutive days during week 12, mice were challenged by nebulizing with saline or OVA. Mice were euthanized 24 hours after the last challenge and blood was collected for plasma FA analysis. Bronchoalveolar lavage (BAL) fluid was collected to determine cell composition and Th2-type cytokine (IL-4, IL-13) concentrations. Periodic acid-Schiff (PAS) + mucus-producing cells and CD45+ inflammatory cell infiltrates in lung tissue were quantified using morphometric analysis. Relative abundance of mRNA for mucin (Muc4, Muc5ac, and Muc5b) and Th2-type cytokine (IL-4, IL-5, and IL-13) genes were compared with ss-actin by qPCR. Supplementation with either corn oil or fish oil effectively altered plasma FA profiles towards more (n-6) FA or (n-3) FA, respectively (P &lt; 0.0001). Sensitization and challenge with OVA increased the proportion of neutrophils, lymphocytes, and eosinophils, and decreased the proportion of macrophages and concentrations of IL-13 in BAL fluid; increased the percentage of PAS+ mucus-producing cells and CD45+ inflammatory cell infiltrates in lung tissue; and increased gene expression of mucins (Muc4, Muc5ac, and Muc5b) and Th2-type cytokines (IL-5 and IL-13) in lung tissue of control-fed mice. Dietary PUFA reversed the increase in PAS+ mucus-producing cells (P = 0.003). In addition, dietary enrichment with fish oil attenuated the percentage of CD45+ inflammatory cell infiltrates in lung tissue, and increased Muc4 and Muc 5b gene expression compared with OVA-sensitized and challenged control mice. In conclusion, dietary enrichment with either (n-3) or (n-6) PUFA decreased mucus production in lung tissues of OVA-sensitized and challenged mice. More specifically, enrichment with dietary (n-3) PUFA decreased CD45+ inflammatory cell infiltrates, thus inducing potentially beneficial changes in lung tissue of OVA-sensitized and challenged mice</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0163819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27669173">PM:27669173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0163819.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0163819.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Hall JA</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0163819</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krzych-Falta,E.</style></author><author><style face="normal" font="Arial"> Furmanczyk,K.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Najmniejsze przekroje poprzeczne jamy nosa w ocenie donosowej pr+¦by prowokacyjnej z alergenem</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="113" start="108">108-113</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acoustic rhinometry</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Minimal cross-sectional area</style></keyword><keyword><style face="normal" font="Arial"> Mucous Membrane</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> nasal challenge</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year><pub-dates><date Day="0" Month="9" Year="2016">2016/9</date></pub-dates></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">Introduction Acoustic rhinometry as a simple and non-invasive method of evaluation of nasal patency is an important tool in the diagnosis of rhinologic and allergic disorders. The aim of the study was to attempt to evaluate the reaction of the nasal mucous membrane to a topically applied allergen by the measurement of the minimum cross-sectional area of the nose (MCA1 and MCA2). The study group consisted of 60 subjects (30 patients with diagnosed allergic rhinitis and 30 healthy ones). The method that was used in the study was acoustic rhinometry (Rhinometrics, Denmark 2001) assessed in a nasal challenge test. Results In the group with allergic rhinitis, significant changes of the surface of the cross-sectional area have been observed, and were measured from the 10th minute with the most significant changes achieved at the 15th and 20th minute of the test. Definitely, more relative reactivity was observed on the right side of the nasal cavity than on the left side (-13.76 -¦ 33.50 p &amp;lt; 0,05; -14.26 -¦ 28.648 p &amp;lt; 0,05). Conclusion A response to the topically applied allergen was observed mainly in the area of the head of the inferior nasal concha as compared to the area located in the nasal vestibule</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.08.006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.08.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2016-3-108-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2016-3-108-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Krzych-Falta E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.08.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Samolinski,B.</style></author><author><style face="normal" font="Arial"> Namyslowski,A.</style></author><author><style face="normal" font="Arial"> Raciborski,F.</style></author><author><style face="normal" font="Arial"> Zielinski,W.</style></author><author><style face="normal" font="Arial"> Tomaszewska,A.</style></author><author><style face="normal" font="Arial"> Borowicz,J.</style></author><author><style face="normal" font="Arial"> Samel-Kowalik,P.</style></author><author><style face="normal" font="Arial"> Walkiewicz,A.</style></author><author><style face="normal" font="Arial"> Piekarska,B.</style></author><author><style face="normal" font="Arial"> Lipiec,A.</style></author><author><style face="normal" font="Arial"> Bialoszewski,A.</style></author><author><style face="normal" font="Arial"> Krzych-Falta,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The importance of specific IgE in epidemiology of allergic rhinitis and asthma - survey Epidemiology of Allergic Diseases in Poland (ECAP)</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="107" start="102">102-107</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> astma</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> epidemiologia</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> main allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year><pub-dates><date Day="0" Month="9" Year="2016">2016/9</date></pub-dates></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">Introduction The research project was going to be a follow-up to epidemiological studies of allergy and asthma conducted in 9 regions of Poland, known under the acronym as ECAP (Epidemiology of Allergic Disease). Aim The aim of this project was to: a) verify the prevalence of allergies to inhaled allergens; b) determine the role of the most common allergens in allergic rhinitis and asthma. Methods The study was based on sera collected in the project ECAP. Individuals in 3 age groups (6</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô7 years, 13</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô14 years, 20</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô44 years) from 9 locations (8 urban and one rural) were included in the study. Specific IgE antibodies concentration was determined, using the reference method CAP, in sera of 4058 respondents. These are antibodies against main allergens responsible for the IgE-dependent allergic diseases (d1 </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô Dermatophagoides pteronyssinus, g6 </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô Phleum pratense, m6 </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô Alternaria alternata, e1 </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô cat dander). Results 24.9% of sera revealed the presence of IgE antibody levels in at least class 1 (</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ0,35IU/ml) to at least one of the four analyzed allergens (d1, e1, g6, m6). Most frequent were IgE positive test results for house dust mites (d1). The lowest percentage of people with IgE antibodies to at least one of the analyzed allergens was observed in rural area of Zamojszczyzna (20.7%) and in Bialystok (21.3%). The highest percentage of positive IgE test results was achieved in Gdansk (30.7%). In the group of men, 31% have positive IgE test results to at least one of the four analyzed allergens. For women, it was 19.9%. Most frequent IgE antibodies to at least one of the analyzed allergens were observed in the group of 20</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô24 year old (31.9%). Similar results were obtained in the group of 13</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô14 years old (29.2%) and 25</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô29 years old (27.5%). Least frequent IgE antibodies were observed among persons aged 40</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô44 (17.4%). In the case of positive result of skin prick test (</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ9 mm) percentage of subjects with IgE antibodies oscillated from 77.8% to 96.3% depending on the allergen. In the group without asthma, IgE antibody to any analyzed allergen was found in 22.2% of cases. Among those diagnosed with asthma, it was 51.3%. In the group without allergic rhinitis, positive IgE test results for at least one of the tested allergens was obtained in 10.9% of cases. In the group with any form of AR, the percentage was 60.1%. Conclusion In the study group most frequently found positive signs of IgE in the order for house dust mite, grass pollen, cat and mold. The effect of test allergens plays an important role in the pathogenesis of AR and asthma</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.08.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.08.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2016-3-102-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2016-3-102-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Samolinski B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Branicka,O.</style></author><author><style face="normal" font="Arial"> Gluck,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Safety prophylactic vaccination in patients with allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="94" start="90">90-94</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Achievement</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive vaccinations</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year><pub-dates><date Day="0" Month="9" Year="2016">2016/9</date></pub-dates></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">Preventive vaccinations are a great achievement of the medicine. However, as all therapeutic methods, they are not devoid of adverse effects, including hypersensitivity reactions. The administration of vaccines to patients with allergic diseases, especially who are allergic to eggs is a serious concern. In this paper data on hypersensitivity to preventive vaccinations have been presented together with current recommendations for patients with allergic hypersensitivity</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.08.003</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.08.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2016-3-90-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2016-3-90-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Branicka O</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nonotte-Varly,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Why not evaluate the allergenic potential of bee pollen with a skin testing method?</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="122" start="114">114-122</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Bee pollen</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Melissopalynology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin reactivity</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Spectrum Analysis</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year><pub-dates><date Day="0" Month="9" Year="2016">2016/9</date></pub-dates></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">Background: Bee pollen (BP) is a dangerous food for allergics because of allergenic pollens (AP). We present a method to evaluate allergenic potentials of AP in BP by using skin prick testing. Method: First, it is experimentally characterized relationship between mass of one AP (MassAP) content in BP and its allergenic potential measured by skin reactivity testing. MassAP is identified in BP mass after having calculated the proportion of AP using the BP pollinic spectrum based on the European standard. Skin reactivity to AP is assessed by measuring wheal diameters (WAP) from skin prick tests using three serial dilutions of BP on allergic patients to AP, in order to calculate equation of the relationship between MassAP and skin reactivity. Relationship equations are calculated for several AP. Then, for a BP having several AP, allergenic potentials of AP (WAP) are assessed by BP spectrum analysis, AP identifications, MassAP calculations and WAP calculations using equations. Results: Linear functions Log(WAP) = A(Log(MassAP)) + B (R2 = 0.99) were established using BP samples rich in only one genus of AP. For a polyfloral BP with different AP, WAP of each AP is proportional to MassAP included in a stated dose of BP. E.g., for a BP with 0.017 mg of artemisia (A) and 0.367 mg of forage grasses (FG) per mg, WA and WFG are 7.7 mm and 8.9 mm, respectively, for 1 g of BP and 12.5 mm and 13.1 mm for 5 g. Conclusion: This method could help to diagnose of anaphylactic accident after BP ingestion or to prevent anaphylactic risk for allergic consumers</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.08.002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.08.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2016-3-114-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2016-3-114-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Nonotte-Varly C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mertes,P.M.</style></author><author><style face="normal" font="Arial"> Florvaag,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hopitaux universitaires de Strasbourg, Nouvel hopital civil, service d'anesthesie-reanimation chirurgicale, 1, place de l'Hopital, BP 426, 67091 Strasbourg cedex, France.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis in the operating theatre</style></title><secondary-title><style face="normal" font="Arial">Presse Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Presse Med</style></full-title></periodical><pages end="752" start="750">750-752</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 0755-4982 (Print)IS - 0755-4982 (Linking)LA - ENGPT - EditorialSB - IMCO - France -CO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.lpm.2016.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27666588">PM:27666588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Presse Med\2016-45-750-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Presse Med\2016-45-750-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Mertes PM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.lpm.2016.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,X.Y.</style></author><author><style face="normal" font="Arial"> Ma,L.J.</style></author><author><style face="normal" font="Arial"> Guo,Y.L.</style></author><author><style face="normal" font="Arial"> Gao,S.</style></author><author><style face="normal" font="Arial"> Zhao,L.M.</style></author><author><style face="normal" font="Arial"> Li,X.S.</style></author><author><style face="normal" font="Arial"> Tang,X.Y.</style></author><author><style face="normal" font="Arial"> Cheng,D.J.</style></author><author><style face="normal" font="Arial"> Zhang,L.X.</style></author><author><style face="normal" font="Arial"> Chen,Z.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, People's Hospital Affiliated to Zhengzhou University, Zhengzhou 450003, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effect of BCYRN1 on proliferation and migration of airway smooth muscle cells in rat model of asthma]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Yi Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Yi Xue Za Zhi</style></full-title></periodical><pages end="3756" start="3751">3751-3756</pages><volume><style face="normal" font="Arial">96</style></volume><number><style face="normal" font="Arial">46</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> Adenovirus</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> cell migration</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cell viability</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="12" Year="2016">2016/12/13</year></dates><abstract><style face="normal" font="Arial">Objective: To detect the effect of brain cytoplasmic RNA 1 (BCYRN1) on the proliferation and migration of airway smooth muscle cells (ASMCs) in rat model of asthma. Methods: Male SD rats were randomly divided into control group and asthma group (n=10 each). The ovalbumin (OVA) model was constructed in asthma group. Real time-qPCR was performed to detect the level of BCYRN1 in the ASMCs separated from the airway tissue of these rats. Then 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium (WST-1) assay, roche real-time cell analyzer assay and Transwell cell migration assay were performed to detect the viability/proliferation and migration of ASMCs which were transfected with Ad-BCYRN1.Platelet-derived growth factor (PDGF)-BB was used to treat ASMCs to induce proliferation and migration, and the level of BCYRN1 was examined.The viability/proliferation and migration of ASMCs treated with PDGF-BB and transfected with si-BCYRN1 were detected. Inspiratory resistance and expiratory resistance were measured in rats with BCYRN1 knockdown.Briefly, rats were randomly divided into four groups: control (group A), sensitization + Ad-GFP (group B), sensitization + AdSM22alpha-siBCYRN1 (group C), control + Ad-SM22alpha-siBCYRN1 (group D) (n=10 each). The corresponding adenovirus vectors were sent to lung of group B, group C and group D through nasal spray. The OVA model was constructed in group B and group C. The rats in group A and group D were treated with saline.After 24 h of the last treatment with OVA or saline, rats of each group were given tracheal intubation, connected with breathing machine. Rats were injected with methacholine to measure the inspiratory resistance and expiratory resistance. Results: The level of BCYRN1 in ASMCs separated from rats in asthma group and in ASMCs treated with PDGF-BB was 3.60+/-0.45 and 3.53+/-0.35, respectively, significantly higher than those of the corresponding control (both P&lt;0.01). Ad-BCYRN1 significantly increased the expression of BCYRN1 in ASMCs. The cell viability and proliferation rates of ASMCs transfected with Ad-BCYRN1 increased 1.75-and 1.47-fold compared to those of the control group, respectively (P&lt;0.01); mobility increased 2.42-fold compared to that of the control group (all P&lt;0.01). BCYRN1 knockdown reversed the increasing proliferation and migration of ASMCs induced by PDGF-BB. The cell proliferation rate and cell migration number in the PDGF-BB treatment group were (4.87+/-0.21)% and 80.00+/-5.00, respectively, which were significant higher than those in the si-BCYRN1 transfected group ((3.63+/-0.21)% and 25.33+/-2.52, all P&lt;0.01). BCYRN1 knockdown reduced the inspiratory resistance and expiratory resistance in sensitization + Ad-SM22alpha-siBCYRN1 group. When the concentration of acetylcholine reached 1 mg/kg, the inspiratory resistance in the group A, group B, group C, and group D were 8.27+/-0.21, 25.40+/-0.56, 12.07+/-0.67 and 8.40+/-0.46 cmH2O.s.ml-1, and expiratory resistance were 13.30+/-0.56, 38.37+/-1.33, 16.40+/-0.56 and 13.40+/-0.46 cmH2O.s.ml-1, respectively (all P&lt;0.01). Conclusion: Overexpression of BCYRN1 promotes the proliferation and migration of ASMCs in rat model of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 0376-2491 (Print)IS - 0376-2491 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.0376-2491.2016.46.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27998434">PM:27998434</url></web-urls></urls><custom2><style face="normal" font="Arial">20161221, Zhang XY</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.0376-2491.2016.46.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sposato,B.</style></author><author><style face="normal" font="Arial"> Scalese,M.</style></author><author><style face="normal" font="Arial"> Latorre,M.</style></author><author><style face="normal" font="Arial"> Scichilone,N.</style></author><author><style face="normal" font="Arial"> Matucci,A.</style></author><author><style face="normal" font="Arial"> Milanese,M.</style></author><author><style face="normal" font="Arial"> Masieri,S.</style></author><author><style face="normal" font="Arial"> Rolla,G.</style></author><author><style face="normal" font="Arial"> Steinhilber,G.</style></author><author><style face="normal" font="Arial"> Rosati,Y.</style></author><author><style face="normal" font="Arial"> Vultaggio,A.</style></author><author><style face="normal" font="Arial"> Folletti,I.</style></author><author><style face="normal" font="Arial"> Baglioni,S.</style></author><author><style face="normal" font="Arial"> Bargagli,E.</style></author><author><style face="normal" font="Arial"> Di Tomassi,M.</style></author><author><style face="normal" font="Arial"> Pio,R.</style></author><author><style face="normal" font="Arial"> Pio,A.</style></author><author><style face="normal" font="Arial"> Maccari,U.</style></author><author><style face="normal" font="Arial"> Maggiorelli,C.</style></author><author><style face="normal" font="Arial"> Migliorini,M.G.</style></author><author><style face="normal" font="Arial"> Vignale,L.</style></author><author><style face="normal" font="Arial"> Pulera,N.</style></author><author><style face="normal" font="Arial"> Carpagnano,G.E.</style></author><author><style face="normal" font="Arial"> Foschino Barbaro,M.P.</style></author><author><style face="normal" font="Arial"> Perrella,A.</style></author><author><style face="normal" font="Arial"> Paggiaro,P.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pneumologia, Ospedale Misericordia, Grosseto, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Effects of omalizumab in severe asthmatics across ages: A real life Italian experience</style></title><secondary-title><style face="normal" font="Arial">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med</style></full-title></periodical><pages end="149" start="141">141-149</pages><volume><style face="normal" font="Arial">119</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly patients</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: This retrospective study aimed at evaluating long-term effects of Omalizumab in elderly asthmatics in a real-life setting. METHODS: 105 consecutive severe asthmatics (GINA step 4-5; mean FEV1% predicted:66 +/- 15.7) treated with Omalizumab for at least 1 year (treatment mean duration 35.1 +/- 21.7 months) were divided into 3 groups according to their age at Omalizumab treatment onset: 18-39, 40-64 and >/= 65 years. RESULTS: Comorbidities, number of overweight/obese subjects and patients with late-onset asthma were more frequent among older people. A similar reduction of inhaled corticosteroids dosage and SABA on-demand therapy was observed in all groups during Omalizumab treatment; a similar FEV1 increased was also observed. Asthma Control Test (ACT) improved significantly (p &lt; 0.001) in the three groups, increasing from 15 [IQR:12-18] to 24 [IQR:22-25] in younger subjects, from 14 [IQR:10-16] to 21 [IQR:20-23] in the 40-64-year-group and from 15 [IQR:12-16] to 20 [IQR:18-22] in elderly patients where improvement was lower (p = 0.039) compared to younger people. Asthma exacerbations decreased significantly after Omalizumab but the percentage of exacerbation-free patients was higher in younger people (76.9%) compared to middle aged patients (49.2%) and the elderly (29%) (p = 0.049). After Omalizumab treatment, the risk for exacerbations was lower in subjects aged 40-64 (OR = 0.284 [CI95% = 0.098-0.826], p = 0.021) and 18-39 (OR = 0.133 [CI95% = 0.026-0.678], p = 0.015), compared to elderly asthmatics. Also, a significantly reduced ACT improvement (beta = -1.070; p = 0.046) passing from each age class was observed. CONCLUSION: Omalizumab improves all asthma outcomes independently of age, although the magnitude of the effects observed in the elderly seems to be lower than in the other age groups</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmed.2016.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27692136">PM:27692136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2016-119-141-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2016-119-141-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Sposato B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmed.2016.09.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roggenbuck,M.</style></author><author><style face="normal" font="Arial"> Anderson,D.</style></author><author><style face="normal" font="Arial"> Barfod,K.K.</style></author><author><style face="normal" font="Arial"> Feelisch,M.</style></author><author><style face="normal" font="Arial"> Geldenhuys,S.</style></author><author><style face="normal" font="Arial"> Sorensen,S.J.</style></author><author><style face="normal" font="Arial"> Weeden,C.E.</style></author><author><style face="normal" font="Arial"> Hart,P.H.</style></author><author><style face="normal" font="Arial"> Gorman,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Microbiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D and allergic airway disease shape the murine lung microbiome in a sex-specific manner</style></title><secondary-title><style face="normal" font="Arial">Respir Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Res</style></full-title></periodical><pages end="" start="116">116-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> aluminium hydroxide</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="9" Year="2016">2016/9/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Vitamin D is under scrutiny as a potential regulator of the development of respiratory diseases characterised by chronic lung inflammation, including asthma and chronic obstructive pulmonary disease. It has anti-inflammatory effects; however, knowledge around the relationship between dietary vitamin D, inflammation and the microbiome in the lungs is limited. In our previous studies, we observed more inflammatory cells in the bronchoalveolar lavage fluid and increased bacterial load in the lungs of vitamin D-deficient male mice with allergic airway disease, suggesting that vitamin D might modulate the lung microbiome. In the current study, we examined in more depth the effects of vitamin D deficiency initiated early in life, and subsequent supplementation with dietary vitamin D on the composition of the lung microbiome and the extent of respiratory inflammation. METHODS: BALB/c dams were fed a vitamin D-supplemented or -deficient diet throughout gestation and lactation, with offspring continued on this diet post-natally. Some initially deficient offspring were fed a supplemented diet from 8 weeks of age. The lungs of naive adult male and female offspring were compared prior to the induction of allergic airway disease. In further experiments, offspring were sensitised and boosted with the experimental allergen, ovalbumin (OVA), and T helper type 2-skewing adjuvant, aluminium hydroxide, followed by a single respiratory challenge with OVA. RESULTS: In mice fed a vitamin D-containing diet throughout life, a sex difference in the lung microbial community was observed, with increased levels of an Acinetobacter operational taxonomic unit (OTU) in female lungs compared to male lungs. This effect was not observed in vitamin D-deficient mice or initially deficient mice supplemented with vitamin D from early adulthood. In addition, serum 25-hydroxyvitamin D levels inversely correlated with total bacterial OTUs, and Pseudomonas OTUs in the lungs. Increased levels of the antimicrobial murine ss-defensin-2 were detected in the bronchoalveolar lavage fluid of male and female mice fed a vitamin D-containing diet. The induction of OVA-induced allergic airway disease itself had a profound affect on the OTUs identified in the lung microbiome, which was accompanied by substantially more respiratory inflammation than that induced by vitamin D deficiency alone. CONCLUSION: These data support the notion that maintaining sufficient vitamin D is necessary for optimal lung health, and that vitamin D may modulate the lung microbiome in a sex-specific fashion. Furthermore, our data suggest that the magnitude of the pro-inflammatory and microbiome-modifying effects of vitamin D deficiency were substantially less than that of allergic airway disease, and that there is an important interplay between respiratory inflammation and the lung microbiome</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -CO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12931-016-0435-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27655266">PM:27655266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2016-17-116.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2016-17-116.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160922, Roggenbuck M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12931-016-0435-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,N.</style></author><author><style face="normal" font="Arial"> Yan,D.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Gu,X.</style></author><author><style face="normal" font="Arial"> Sun,J.</style></author><author><style face="normal" font="Arial"> Long,F.</style></author><author><style face="normal" font="Arial"> Jiang,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China</style></auth-address><titles><title><style face="normal" font="Arial">A HuR/TGF-beta1 feedback circuit regulates airway remodeling in airway smooth muscle cells</style></title><secondary-title><style face="normal" font="Arial">Respir Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Res</style></full-title></periodical><pages end="" start="117">117-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> actin</style></keyword><keyword><style face="normal" font="Arial"> Actins</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Collagen Type I</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta1</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Untranslated Regions</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="22" Month="9" Year="2016">2016/9/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a worldwide health burden with an alarming prevalence. For years, asthma-associated airway injury remains elusive. Transforming growth factor beta1 (TGF-beta1) is a pleiotropic cytokine that has been shown to be involved in the synthesis of the matrix molecules associated with airway remodeling. Human antigen R (HuR), the member of the Hu RNA-binding protein family, can bind to a subset of short-lived mRNAs in their 3' untranslated regions (UTR). However, the functional roles and relevant signaling pathways of HuR in airway remodeling have not been well illustrated. Thus, we aim to explore the relationship between HuR and TGF-beta1 in platelet derived growth factor(PDGF)-induced airway smooth muscle (ASM) cells and asthmatic animal. METHODS: Cultured human ASM cells were stimulated by PDGF for 0, 6, 12 and 24 h. Western blotting, RT-PCR and immunofluoresence were used to detect the expression of HuR, TGF-beta1, alpha-smooth muscle actins (alpha-SMA) and collagen type I (Col-I). Then knockdown of HuR, flow cytomerty was used to detect the morphological change and western blotting for functionally change of ASM cells. Furthermore, the interference of TGF-beta1 and exogenous TGF-beta1 were implemented to testify the influence on HuR. A murine OVA-driven allergic model based on sensitization and challenge was developed. The inflammatory response was measured by bronchoalveolar lavage fluid (BALF), airway damage was analyzed by hematoxylin and eosin staining, airway remodeling was assessed by sirius red staining and periodic acid-schiff staining, the expression level of HuR, TGF-beta1 and alpha-SMA were measured by RT-PCR, western blotting and immunohistochemistry. RESULTS: Here, we found that PDGF elevated HuR expression both at mRNA and protein level in cultured ASM cells at a time-dependent manner, which was simultaneously accompanied by the enhanced expression of TGF-beta1, alpha-SMA and Col-I. Further study revealed that the knockdown of HuR significantly increased the apoptosis of ASM cells and dampened TGF-beta1, Col-I and alpha-SMA expression. However, interfering TGF-beta1 with siRNA or extra addition of TGF-beta1, HuR could restore its production as well as Col-I. Compared with normal mice stimulating with PBS, OVA-induced mice owned high amount of inflammatory cells, such as eosinophils, lymphocytes and neutrophils except macrophages. HE staining showed accumulation of inflammatory cells surrounding bronchiole and sirius red staining distinguished collagen type I and III deposition around the bronchiole. Higher abundance of HuR, TGF-beta1 and alpha-SMA were verified in OVA-induced mice than PBS-induced mice by RT-PCR, western blotting and immunohistochemistry. CONCLUSIONS: A HuR/TGF-beta1 feedback circuit was established to regulate airway remodeling in vivo and in vitro and targeting this feedback has considerable potential for the intervention of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12931-016-0437-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27658983">PM:27658983</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2016-17-117.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2016-17-117.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Wang N</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12931-016-0437-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meng,S.S.</style></author><author><style face="normal" font="Arial"> Gao,R.</style></author><author><style face="normal" font="Arial"> Yan,B.D.</style></author><author><style face="normal" font="Arial"> Ren,J.</style></author><author><style face="normal" font="Arial"> Wu,F.</style></author><author><style face="normal" font="Arial"> Chen,P.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Wang,L.F.</style></author><author><style face="normal" font="Arial"> Xiao,Y.M.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Maternal allergic disease history affects childhood allergy development through impairment of neonatal regulatory T-cells</style></title><secondary-title><style face="normal" font="Arial">Respir Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Res</style></full-title></periodical><pages end="" start="114">114-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1465-993X</style></isbn><abstract><style face="normal" font="Arial">Maternal allergic disease history and impaired regulatory T-cells (Tregs) are critical risk factors for allergy development in children. However, the mechanisms that underlie these risk factors remain poorly defined. Therefore, the aim of this study was to assess whether maternal allergies affect the Tregs of offspring and lead to allergy development in childhood</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12931-016-0430-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s12931-016-0430-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2016-17-114.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2016-17-114.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Meng SS</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12931-016-0430-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bissinger,I.</style></author><author><style face="normal" font="Arial"> Bareno,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">El Rosario Sede Tesoro, Clinica Conquistadores, Medellin, Antioquia, Colombia.</style></auth-address><titles><title><style face="normal" font="Arial">[Clinical profile of sensitization to fungi in Medellin, Colombia]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="134" start="123">123-134</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candida albicans</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fungi sensitization correlates with patologies like asthma, rhinitis, conjunctivitis and dermatitis. In general it is associated with other sensitizations. In Medellin the multisystemic pattern is associated with fungi sensitization. OBJECTIVE: To determine the clinical pattern of the fungi sensitization in Medellin. MATERIAL AND METHOD: We reviewed the medical records of 897 patients younger than 70 years old with fungi sensitization in the prick test during the period 1 January 2011 to 31 March 2014 in the allergy facility from 2 clinics. We evaluate 16 fungi and the presence of allergic diseases as well as the environmental conditions. RESULTS: Form 897 prick test, 12.8% were positive to fungi, and the most frequent was Candida albicans with 30.4%. Rhinitis were present in 100% of patients, asthma in 46.1%, conjunctivitis in 92.2% and the multisystemic pattern in 9.6%. The multisystemic pattern was associated with younger age with a risk of 9,259, 95% CI: 1.14-74.95 and with Aspergillus fumigatus sensitivity with a risk of 4.381, 95% CI: 1,116-17,204. CONCLUSIONS: The pattern of sensitivity was higher with Candida albicans. Most patients were polysensitized. The multisystemic pattern was associated with been younger and with Aspergillus fumigatus sensitivity. From the findings of this study, allergens like Candida and Aspergillus fumigatus should be tested in Medellin</style></abstract><notes><style face="normal" font="Arial">DA - 20160513IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - SPAPT - English AbstractPT - Journal ArticleSB - IMCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27174755">PM:27174755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-123-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-123-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160513, Bissinger I</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alcala-Padilla,G.</style></author><author><style face="normal" font="Arial"> Bedolla-Barajas,M.</style></author><author><style face="normal" font="Arial"> Kestler-Gramajo,A.</style></author><author><style face="normal" font="Arial"> Valdez-Lopez,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Reproduccion Humana, Centro Universitario en Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">[Prevalence of sensitization to allergens in school children with asthma residents from Guadalajara metropolitan area]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="142" start="135">135-142</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword><keyword><style face="normal" font="Arial"> Zea mays</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic sensitization is dependent on the geographical and climatic conditions in each region; therefore, identify agents most commonly sensitized children with asthma is important for planning prevention measures. OBJECTIVE: To determine the prevalence of the sensitization to allergens in children with asthma. MATERIAL AND METHOD: This cross-sectional and prolective study includes children from ages 6 to 14, who have asthma, attended for the first time in an allergy service. The patients were recruited consecutively between the months of January 1st 2014 to December 31st 2014. The frequency of the allergen sensitization was estimated. RESULTS: This study included 186 children, the median age was 7 years olds, the male group was 104/186 (55.9%) The median of the positive results was 5 and monosensitized were 47/186 (2.2%). The most common category of allergens was the indoor (90.3%), then trees (71.0%), and finally the fungi (9.7%). Individually, the house dust mites were more common in between the interior allergens, followed by the epithelial; in the tree pollen were oaks (31.7%) and ashes (28.0%), in weeds was mugwort (21.5%), in grasses was Zea mays (18.3%) and in the fungi was Cladosporium spp. (6.5%). CONCLUSION: The high prevalence of the sensitization to house dust mites and epithelial in children with asthma, stimulates to implement methods of environmental control for contributing a better control of the disease</style></abstract><notes><style face="normal" font="Arial">DA - 20160513IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - SPAPT - English AbstractPT - Journal ArticleSB - IMCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27174756">PM:27174756</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-135-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-135-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160513, Alcala-Padilla G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Diaz,S.N.</style></author><author><style face="normal" font="Arial"> Arias-Cruz,A.</style></author><author><style face="normal" font="Arial"> Ibarra-Chavez,J.A.</style></author><author><style face="normal" font="Arial"> Elizondo-Villarreal,B.</style></author><author><style face="normal" font="Arial"> Rivero-Arias,D.M.</style></author><author><style face="normal" font="Arial"> Salinas-Diaz,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centro Regional de Alergia e Inmunologia Clinica, Hospital Universitario Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico. aarias45@hotmail.com</style></auth-address><titles><title><style face="normal" font="Arial">[Prevalence of sensitization to fungi in patients with respiratory allergy]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="153" start="143">143-153</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: As part of the etiology of respiratory allergy we have genetics, prenatal factors and sensitivity to various airborne allergens, between these fungi are found. Relationship has been found between sensitization to fungal in skin tests and allergy pathogenesis and aggravation. There is a few literature in Mexico and in the north of the country it is lacking regarding this problem. OBJECTIVE: Assess the prevalence of sensitization to fungi in patients with respiratory allergy in skin tests to airborne allergens; determine the most prevalent fungus and prevalence of sensitization to each species of fungus per year, to assess the prevalence of sensitization to fungi by years. MATERIAL AND METHOD: Cross-sectional, observational and descriptive study conducted from 1 January 2010 to 31 December 2014 in patients treated at the Regional Center of Allergy and Clinical Immunology (Monterrey, Mexico) where we reviewed a database with patients whom performed skin tests, sensitization to 6 species of fungi were evaluated. We performed tables of data capture and statistical analysis. RESULTS: 4880 patients had respiratory allergy, a 17.1% prevalence of sensitization to fungal skin tests was determined. The fungus specie most prevalent was Alternaria alternata with 5.5%. The year range with the highest prevalence of sensitization was 0-10 years with a 6.7. CONCLUSIONS: The prevalence of fungi sensitization was higher than the global prevalence found, but lower than the prevalence found in other researches in Mexico</style></abstract><notes><style face="normal" font="Arial">DA - 20160513IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - SPAPT - English AbstractPT - Journal ArticleSB - IMCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27174757">PM:27174757</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-143-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-143-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160513, Gonzalez-Diaz SN</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Macias-Robles,A.P.</style></author><author><style face="normal" font="Arial"> Moran-Mendoza,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergia e Inmunologia Clinica, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">[Latex sensitization prevalence through prick test in patients with genitourinary malformations and more than 3 surgeries]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="162" start="154">154-162</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> latex sensitization</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Risk groups</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spine</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Latex allergy is a public health issue. It presents elevated prevalence in known risk groups, especially in those patients with spine bifida condition, urinal malformation and for those with orthopedic problems - multiple surgeries. Health Services in Mexico do not have the enough studies about prevalence and risk associated to latex allergy. OBJECTIVE: Determine latex sensitization prevalence through PRICK test in patients with genitourinary malformations and more than 3 surgeries in UMAE pediatric CMNO unit, considering too related factors. MATERIAL AND METHOD: An analytical and descriptive cross-sectional study was performed, which included men and women from 1 to 16 years with genitourinary malformations and more than three surgeries performed. A survey to know the risk factors associated and skin puncture test was performed with latex extract, with positive and negative control. Serum levels of total IgE and eosinophils were measured in peripheral blood. RESULTS: The study exposed prevalence of 30.72%. Related to associated factors as follows: atopy (p=0.047), previous antecedent reaction to latex products (p=0.003) specific for balloons (p=0.000) and gloves (p=0.002). There was not association related to amount of surgeries and surgical interventions on early age, either for high levels of total serum IgE. CONCLUSION: Prevalence to latex sensitization is high in risk groups. Especially in those with atopy thereby is important for health personal to identify these patients in order to implement on time the preventive primary/secondary measures. With these actions potential mortal risks like anaphylaxis will be avoided. This will decrease sanitary costs and mortality</style></abstract><notes><style face="normal" font="Arial">DA - 20160513IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - SPAPT - English AbstractPT - Journal ArticleSB - IMCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27174758">PM:27174758</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-154-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-154-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160513, Dias-Robles AP</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez,J.</style></author><author><style face="normal" font="Arial"> Cardona,R.</style></author><author><style face="normal" font="Arial"> Sanchez,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Grupo de Alergia Clinica y Experimental, IPS Universitaria, Universidad de Antioquia, Medellin, Antioquia, Colombia. jotamsc@yahoo.com</style></auth-address><titles><title><style face="normal" font="Arial">[Impact of allergen immunotherapy after two years of suspension in patients with asthma]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="122" start="113">113-122</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug treatment</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inhaled steroids</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Immunotherapy has proven to be effective in controlling allergic asthma. However, few studies have evaluated whether the control and reduction of drug treatment persist after treatment ends. OBJECTIVE: To evaluate the effect of immunotherapy with mites in asthma patients after two years of its suspension on drug treatment and number of exacerbations. MATERIAL AND METHOD: Observational study ambispective with active group (immunotherapy and pharmacotherapy) and control (only pharmacotherapy) group followed up for 5 years divided into two phases: 3 years of application of immunotherapy and two year of follow-up after its suspension. RESULTS: 122 patients in the active group and 384 in the control group were included. Both groups had fewer exacerbations after the sixth month (p = 0.04). After nine months the active group had a significant reduction in the use of inhaled steroids (p = 0.05) compared to the control group. Two years after finished immunotherapy, patients in the active group received a lower inhaler doses than the control group. Children under 14 years mono-sensitized had the best response in all parameters evaluated. CONCLUSION: The allergen immunotherapy improves asthma control and reduces the required doses of pharmacotherapy. These effects have an important impact on quality of life and perhaps economically for patients with asthma. The beginning at an early age seems to have a major impact</style></abstract><notes><style face="normal" font="Arial">DA - 20160513IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - SPAPT - English AbstractPT - Journal ArticleSB - IMCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27174754">PM:27174754</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-113-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-113-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160513, Sanchez J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fischer,N.</style></author><author><style face="normal" font="Arial"> Rostaher,A.</style></author><author><style face="normal" font="Arial"> Favrot,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Kleintiermedizin, Abteilung fur Dermatologie, Vetsuisse-Fakultat, Universitat Zurich</style></auth-address><titles><title><style face="normal" font="Arial">[Intralymphatic immunotherapy: An effective and safe alternative route for canine atopic dermatitis]</style></title><secondary-title><style face="normal" font="Arial">Schweiz Arch Tierheilkd</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Schweiz Arch Tierheilkd</style></full-title></periodical><pages end="652" start="646">646-652</pages><volume><style face="normal" font="Arial">158</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> ILIT</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> intralymphatic immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Compliance</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Allergen-specific immunotherapy (ASIT) is the only etiologic treatment of atopic dermatitis in dogs. In humans it has been shown that intralymphatic immunotherapy (ILIT) enhanced efficacy and patient compliance and reduced treatment time from 3 years to 8 weeks. As only safety data have been published yet, the aim of this study was to evaluate the clinical efficacy of ILIT in dogs. 20 atopic dogs underwent ILIT with alum-precipitated allergens administered every 4 weeks for 3 to 7 times in the popliteal lymph node. Pruritus (Hill score), CADESI (canine atopic dermatitis severety index), concurrent medications and adverse reactions were recorded initially and every 4 weeks for a total period of 24 weeks. The observed clinical response was good in 12/20 (60%) patients and improvement could be seen in some dogs already after 4 weeks. The median number of injections was 5.6. All dogs tolerated the procedure well and no adverse effects were recognized during or after ILIT. Therefore ILIT should be regarded as a safe alternative to subucaneous ASIT, enabling a faster clinical improvement with the same response rate</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 0036-7281 (Print)IS - 0036-7281 (Linking)LA - GERPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.17236/sat00085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27655164">PM:27655164</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Schweiz Arch Tierheilkd\2016-158-646-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Schweiz Arch Tierheilkd\2016-158-646-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160922, Fiscfher N</style></custom2><misc3><style face="normal" font="Arial">10.17236/sat00085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galan,C.</style></author><author><style face="normal" font="Arial"> Alcazar,P.</style></author><author><style face="normal" font="Arial"> Oteros,J.</style></author><author><style face="normal" font="Arial"> Garcia-Mozo,H.</style></author><author><style face="normal" font="Arial"> Aira,M.J.</style></author><author><style face="normal" font="Arial"> Belmonte,J.</style></author><author><style face="normal" font="Arial"> Diaz de la Guardia,C.</style></author><author><style face="normal" font="Arial"> Fernandez-Gonzalez,D.</style></author><author><style face="normal" font="Arial"> Gutierrez-Bustillo,M.</style></author><author><style face="normal" font="Arial"> Moreno-Grau,S.</style></author><author><style face="normal" font="Arial"> Perez-Badia,R.</style></author><author><style face="normal" font="Arial"> Rodriguez-Rajo,J.</style></author><author><style face="normal" font="Arial"> Ruiz-Valenzuela,L.</style></author><author><style face="normal" font="Arial"> Tormo,R.</style></author><author><style face="normal" font="Arial"> Trigo,M.M.</style></author><author><style face="normal" font="Arial"> Dominguez-Vilches,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Botany, Ecology and Plant Physiology, University of Cordoba, Agrifood Campus of International Excellence (ceiA3), Spain. Department of Botany, University of Santiago de Compostela, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Airborne pollen trends in the Iberian Peninsula</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="59" start="53">53-59</pages><volume><style face="normal" font="Arial">550</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Iberian Peninsula</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean Region</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Physiology</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="15" Month="4" Year="2016">2016/4/15</year></dates><abstract><style face="normal" font="Arial">Airborne pollen monitoring is an effective tool for studying the reproductive phenology of anemophilous plants, an important bioindicator of plant behavior. Recent decades have revealed a trend towards rising airborne pollen concentrations in Europe, attributing these trends to an increase in anthropogenic CO2 emissions and temperature. However, the lack of water availability in southern Europe may prompt a trend towards lower flowering intensity, especially in herbaceous plants. Here we show variations in flowering intensity by analyzing the Annual Pollen Index (API) of 12 anemophilous taxa across 12 locations in the Iberian Peninsula, over the last two decades, and detecting the influence of the North Atlantic Oscillation (NAO). Results revealed differences in the distribution and flowering intensity of anemophilous species. A negative correlation was observed between airborne pollen concentrations and winter averages of the NAO index. This study confirms that changes in rainfall in the Mediterranean region, attributed to climate change, have an important impact on the phenology of plants</style></abstract><notes><style face="normal" font="Arial">DA - 20160229IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - ENGPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Air Pollutants)RN - 0 (Allergens)SB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2016.01.069</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26803684">PM:26803684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2016-550-53-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2016-550-53-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160229, Galan C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2016.01.069</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Astray,G.</style></author><author><style face="normal" font="Arial"> Fernandez-Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Rodriguez-Rajo,F.J.</style></author><author><style face="normal" font="Arial"> Lopez,D.</style></author><author><style face="normal" font="Arial"> Mejuto,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Physical Chemistry Department, Faculty of Science, University of Vigo, 32004 Ourense, Spain; Department of Geological Sciences, College of Arts and Sciences, Ohio University, 45701 Athens, USADepartment of Plant Biology and Soil Sciences, Faculty of Sciences, University of Vigo, 32004 Ourense, SpainDepartment of Plant Biology and Soil Sciences, Faculty of Sciences, University of Vigo, 32004 Ourense, SpainDepartment of Geological Sciences, College of Arts and Sciences, Ohio University, 45701 Athens, USAPhysical Chemistry Department, Faculty of Science, University of Vigo, 32004 Ourense, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Airborne castanea pollen forecasting model for ecological and allergological implementation</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="121" start="110">110-121</pages><volume><style face="normal" font="Arial">548-549</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Artificial neural network</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> beekeeping</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Castanea</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Chestnut</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> Forestry</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Concepts</style></keyword><keyword><style face="normal" font="Arial"> Meteorological variables</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Models,Theoretical</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Neural networks</style></keyword><keyword><style face="normal" font="Arial"> Northwest Spain</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen production</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis,Allergic,Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Soil</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vegetation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2016">2016/4/1</year></dates><abstract><style face="normal" font="Arial">Castanea sativa Miller belongs to the natural vegetation of many European deciduous forests prompting impacts in the forestry, ecology, allergological and chestnut food industry fields. The study of the Castanea flowering represents an important tool for evaluating the ecological conservation of North-Western Spain woodland and the possible changes in the chestnut distribution due to recent climatic change. The Castanea pollen production and dispersal capacity may cause hypersensitivity reactions in the sensitive human population due to the relationship between patients with chestnut pollen allergy and a potential cross reactivity risk with other pollens or plant foods. In addition to Castanea pollen's importance as a pollinosis agent, its study is also essential in North-Western Spain due to the economic impact of the industry around the chestnut tree cultivation and its beekeeping interest. The aim of this research is to develop an Artificial Neural Networks for predict the Castanea pollen concentration in the atmosphere of the North-West Spain area by means a 20years data set. It was detected an increasing trend of the total annual Castanea pollen concentrations in the atmosphere during the study period. The Artificial Neural Networks (ANNs) implemented in this study show a great ability to predict Castanea pollen concentration one, two and three days ahead. The model to predict the Castanea pollen concentration one day ahead shows a high linear correlation coefficient of 0.784 (individual ANN) and 0.738 (multiple ANN). The results obtained improved those obtained by the classical methodology used to predict the airborne pollen concentrations such as time series analysis or other models based on the correlation of pollen levels with meteorological variables</style></abstract><notes><style face="normal" font="Arial">DA - 20160218IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - ENGPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Air Pollutants)RN - 0 (Allergens)SB - IMCO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">1016/j.scitotenv.2016.01.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26802339">PM:26802339</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2016-548_9-110-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2016-548_9-110-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160218, Astray G</style></custom2><misc3><style face="normal" font="Arial">1016/j.scitotenv.2016.01.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Mozo,H.</style></author><author><style face="normal" font="Arial"> Oteros,J.A.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Botany, Ecology and Plant Physiology, University of Cordoba, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Impact of land cover changes and climate on the main airborne pollen types in Southern Spain</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="228" start="221">221-228</pages><volume><style face="normal" font="Arial">548-549</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Physiology</style></keyword><keyword><style face="normal" font="Arial"> Plantago</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollen spectrum</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Rumex</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban planning</style></keyword><keyword><style face="normal" font="Arial"> Urticaceae</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2016">2016/4/1</year></dates><abstract><style face="normal" font="Arial">Airborne pollen concentrations strongly correlate with flowering intensity of wind-pollinated species growing at and around monitoring sites. The pollen spectrum, and the variations in its composition and concentrations, is influenced by climatic features and by available nutritional resources but it is also determined by land use and its changes. The first factor influence is well known on aerobiological researches but the impact of land cover changes has been scarcely studied until now. This paper reports on a study carried out in Southern Spain (Cordoba city) examining airborne pollen trends over a 15-year period and it explores the possible links both to changes in land use and to climate variations. The Seasonal-Trend Decomposition procedure based on Loess (STL) which decomposes long-term data series into smaller seasonal component patterns was applied. Trends were compared with recorded changes in land use at varying distances from the city in order to determine their possible influence on pollen-count variations. The influence of climate-related factors was determined by means of non-parametric correlation analysis. The STL method proved highly effective for extracting trend components from pollen time series, because their features vary widely and can change quickly in a short term. Results revealed mixed trends depending on the taxa and reflecting fluctuations in land cover and/or climate. A significant rising trend in Olea pollen counts was observed, attributable both to the increasing olive-growing area but also to changes in temperature and rainfall. Poaceae pollen concentrations also increased, due largely to an expansion of heterogeneous agricultural areas and to an increase in pollen season length positively influenced by rainfall and temperature. By contrast, the significant declining trend observed for pollen from ruderal taxa, such as Amaranthaceae, Rumex, Plantago and Urticaceae, may be linked to changes in urban planning strategies with a higher building pressure</style></abstract><notes><style face="normal" font="Arial">DA - 20160218IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - ENGPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Air Pollutants)RN - 0 (Allergens)SB - IMCO - Spain -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2016.01.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26802350">PM:26802350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2016-548_9-221-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2016-548_9-221-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160218, Garcia-Mozo H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2016.01.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghiani,A.</style></author><author><style face="normal" font="Arial"> Bruschi,M.</style></author><author><style face="normal" font="Arial"> Citterio,S.</style></author><author><style face="normal" font="Arial"> Bolzacchini,E.</style></author><author><style face="normal" font="Arial"> Ferrero,L.</style></author><author><style face="normal" font="Arial"> Sangiorgi,G.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author><author><style face="normal" font="Arial"> Perrone,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Earth and Environmental Sciences, University of Milano-Bicocca, P.zza della Scienza 1, 20126 Milan, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Nitration of pollen aeroallergens by nitrate ion in conditions simulating the liquid water phase of atmospheric particles</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="1597" start="1589">1589-1597</pages><volume><style face="normal" font="Arial">573</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Aerodynamic diameter</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Atmospheric aerosol</style></keyword><keyword><style face="normal" font="Arial"> Biological particles</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Earth and Environmental Science</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Gaseous pollutants</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> irradiation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Phl p 2</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein nitration</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="14" Month="9" Year="2016">2016/9/14</year></dates><abstract><style face="normal" font="Arial">Pollen aeroallergens are present in atmospheric particulate matter (PM) where they can be found in coarse biological particles such as pollen grains (aerodynamic diameter dae>10mum), as well as fragments in the finest respirable particles (PM2.5; dae&lt;2.5mum). Nitration of tyrosine residues in pollen allergenic proteins can occur in polluted air, and inhalation and deposition of these nitrated proteins in the human respiratory tract may lead to adverse health effects by enhancing the allergic response in population. Previous studies investigated protein nitration by atmospheric gaseous pollutants such as nitrogen dioxide and ozone. In this work we report, for the first time, a study on protein nitration by nitrate ion in aqueous solution, at nitrate concentrations and pH conditions simulating those occurring in the atmospheric aerosol liquid water phase. Experiments have been carried out on the Bovine serum albumin (BSA) protein and the recombinant Phleum pratense allergen (Phl p 2) both in the dark and under UV-A irradiation (range 4-90Wm-2) to take into account thermal and/or photochemical nitration processes. For the latter protein, modifications in the allergic response after treatment with nitrate solutions have been evaluated by immunoblot analyses using sera from grass-allergic patients. Experimental results in bulk solutions showed that protein nitration in the dark occurs only in dilute nitrate solutions and under very acidic conditions (pH&lt;3 for BSA; pH&lt;2.2 for Phl p 2), while nitration is always observed (at pH0.5-5) under UV-A irradiation, both in dilute and concentrated nitrate solutions, being significantly enhanced at the lowest pH values. In some cases, protein nitration resulted in an increase of the allergic response</style></abstract><notes><style face="normal" font="Arial">DA - 20160918IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2016.09.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27639783">PM:27639783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\20160918-GhianiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\20160918-GhianiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160918, Ghiani A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2016.09.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kappen,J.H.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Veen,H.I.</style></author><author><style face="normal" font="Arial"> Shamji,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, STZ centre of excellence for Asthma &amp; COPD, Franciscus Gasthuis &amp; Vlietland, Kleiweg 500, 3045 PM, Rotterdam, The NetherlandsAllergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UKDepartment of Pulmonology, STZ centre of excellence for Asthma &amp; COPD, Franciscus Gasthuis &amp; Vlietland, Kleiweg 500, 3045 PM, Rotterdam, The NetherlandsAllergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, Sir Alexander Fleming Building, South Kensington Campus, London SW7 2AZ, UK m.shamji@imperial.ac.uk</style></auth-address><titles><title><style face="normal" font="Arial">Applications and mechanisms of immunotherapy in allergic rhinitis and asthma</style></title><secondary-title><style face="normal" font="Arial">Ther Adv Respir Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ther Adv Respir Dis</style></full-title></periodical><pages end="86" start="73">73-86</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Breg</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deviation</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such as mast cells, eosinophils and basophils in target organs. Furthermore, AIT down-regulates type 2 innate lymphoid cells and allergen-specific type 2 T-helper (Th2) cells. The immunologic tolerant state following AIT is associated with the induction of distinct phenotypes of regulatory T-cells (T-regs) including interleukin (IL)-10-, IL-35- and transforming growth factor (TGF)-beta- producing T-regs and FoxP3+ T-regs. B-cell responses, including the induction of IL-10+ regulatory B-cells (B-regs) and the production of IgG4-associated blocking antibodies are also induced following successful AIT. These events are associated with the suppression of antigen-specific Th2 responses and delayed immune deviation in favour of Th1 type responses. Insight into the mechanisms of AIT has allowed identification of novel biomarkers with potential to predict the clinical response to AIT and also novel therapeutic strategies for more effective and safer AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20160928IS - 1753-4666 (Electronic)IS - 1753-4658 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1177/1753465816669662</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27678500">PM:27678500</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ther Adv Respir Dis\20160928-KappenJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ther Adv Respir Dis\20160928-KappenJH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160928, Kappen JH</style></custom2><misc3><style face="normal" font="Arial">10.1177/1753465816669662</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Campbell,B.</style></author><author><style face="normal" font="Arial"> Raherison,C.</style></author><author><style face="normal" font="Arial"> Lodge,C.J.</style></author><author><style face="normal" font="Arial"> Lowe,A.J.</style></author><author><style face="normal" font="Arial"> Gislason,T.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Sunyer,J.</style></author><author><style face="normal" font="Arial"> Gomez Real,F.</style></author><author><style face="normal" font="Arial"> Norback,D.</style></author><author><style face="normal" font="Arial"> Matheson,M.C.</style></author><author><style face="normal" font="Arial"> Wjst,M.</style></author><author><style face="normal" font="Arial"> Dratva,J.</style></author><author><style face="normal" font="Arial"> De Marco,R.</style></author><author><style face="normal" font="Arial"> Jarvis,D.</style></author><author><style face="normal" font="Arial"> Schlunssen,V.</style></author><author><style face="normal" font="Arial"> Janson,C.</style></author><author><style face="normal" font="Arial"> Leynaert,B.</style></author><author><style face="normal" font="Arial"> Svanes,C.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy &amp; Lung Health Unit, Centre for Epidemiology &amp; Biostatistics, The University of Melbourne, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">The effects of growing up on a farm on adult lung function and allergic phenotypes: an international population-based study</style></title><secondary-title><style face="normal" font="Arial">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Thorax</style></full-title></periodical><pages end="244" start="236">236-244</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Day Care</style></keyword><keyword><style face="normal" font="Arial"> Day-care</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> European Community Respiratory Health Survey</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> farm exposure</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health survey</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Rural environment</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Evidence has suggested that exposure to environmental or microbial biodiversity in early life may impact subsequent lung function and allergic disease risk. OBJECTIVES: To investigate the influence of childhood living environment and biodiversity indicators on atopy, asthma and lung function in adulthood. METHODS AND MEASUREMENTS: The European Community Respiratory Health Survey II investigated approximately 10 201 participants aged 26-54 years from 14 countries, including participants' place of upbringing (farm, rural environment or inner city) before age 5 years. A 'biodiversity score' was created based on childhood exposure to cats, dogs, day care, bedroom sharing and older siblings. Associations with lung function, bronchial hyper-responsiveness (BHR), allergic sensitisation, asthma and rhinitis were analysed. MAIN RESULTS: As compared with a city upbringing, those with early-life farm exposure had less atopic sensitisation (adjusted OR 0.46, 95% CI 0.37 to 0.58), atopic BHR (0.54 (0.35 to 0.83)), atopic asthma (0.47 (0.28 to 0.81)) and atopic rhinitis (0.43 (0.32 to 0.57)), but not non-atopic outcomes. Less pronounced protective effects were observed for rural environment exposures. Women with a farm upbringing had higher FEV1 (adjusted difference 110 mL (64 to 157)), independent of sensitisation and asthma. In an inner city environment, a higher biodiversity score was related to less allergic sensitisation. CONCLUSIONS: This is the first study to report beneficial effects of growing up on a farm on adult FEV1. Our study confirmed the beneficial effects of early farm life on sensitisation, asthma and rhinitis, and found a similar association for BHR. In persons with an urban upbringing, a higher biodiversity score predicted less allergic sensitisation, but to a lesser magnitude than a childhood farm environment</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -CO - France -CO - Iceland -CO - Germany -CO - Spain -CO - Norway -CO - Sweden -CO - Switzerland -CO - Italy -CO - United Kingdom -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1136/thoraxjnl-2015-208154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27672121">PM:27672121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Thorax\20160927-CampbellB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Thorax\20160927-CampbellB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Campbell B</style></custom2><misc3><style face="normal" font="Arial">10.1136/thoraxjnl-2015-208154</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smit,J.</style></author><author><style face="normal" font="Arial"> Zeeuw-Brouwer,M.L.</style></author><author><style face="normal" font="Arial"> van Roest,M.</style></author><author><style face="normal" font="Arial"> de Jong,G.</style></author><author><style face="normal" font="Arial"> van Bilsen,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Risk Assessment Sciences, University Utrecht, Utrecht, The Netherlands; Utrecht Center for Food Allergy, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of the sensitizing potential of food proteins using two mouse models</style></title><secondary-title><style face="normal" font="Arial">Toxicol Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicol Lett</style></full-title></periodical><pages end="69" start="62">62-69</pages><volume><style face="normal" font="Arial">262</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Lipoxygenase</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> Pan b 1</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Sola t 1</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey protein isolate</style></keyword></keywords><dates><year Day="20" Month="9" Year="2016">2016/9/20</year></dates><abstract><style face="normal" font="Arial">The current methodology to identify allergenic food proteins is effective in identifying those that are likely to cross-react with known allergens. However, most assays show false positive results for low/non-allergens. Therefore, an ex vivo/in vitro DC-T cell assay and an in vivo mouse model were used to distinguish known allergenic food proteins (Ara h 1, beta-Lactoglobulin, Pan b 1, bovine serum albumin, whey protein isolate) from low/non allergenic food proteins (soy lipoxygenase, gelatin, beef tropomyosin, rubisco, Sola t 1). CD4+ T cells from protein/alum-immunized mice were incubated with corresponding protein-pulsed bone marrow-derived DC and analyzed for cytokine release. All known allergens induced Th2 responses in vitro, whereas soy lipoxygenase, gelatin or beef tropomyosin did not. Sola t 1 and rubisco induced a more generalized T cell response due to endotoxin contamination, indicating the endotoxin-sensitivity of the DC-T assay. To analyze responses in vivo, mice were orally sensitized on days 0 and 7. Known allergens induced IgE and mMCP-1 release upon oral challenge at day 16, whereas the low/non-allergens did not. Both the DC-T cell assay and the mouse model were able to distinguish 5 known allergens from 5 low/non-allergens and may be useful to identify novel allergenic food proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20160924IS - 1879-3169 (Electronic)IS - 0378-4274 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.toxlet.2016.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27663974">PM:27663974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol Lett\2016-262-62-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol Lett\2016-262-62-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160924, Smit J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.toxlet.2016.09.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jung,K.H.</style></author><author><style face="normal" font="Arial"> Baek,H.</style></author><author><style face="normal" font="Arial"> Shin,D.</style></author><author><style face="normal" font="Arial"> Lee,G.</style></author><author><style face="normal" font="Arial"> Park,S.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Choi,D.</style></author><author><style face="normal" font="Arial"> Kim,W.</style></author><author><style face="normal" font="Arial"> Bae,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physiology, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemoon-gu, Seoul 130-701, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Protective Effects of Intratracheally-Administered Bee Venom Phospholipase A2 on Ovalbumin-Induced Allergic Asthma in Mice</style></title><secondary-title><style face="normal" font="Arial">Toxins (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxins (Basel)</style></full-title></periodical><pages end="" start="E269">E269-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial inflammation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> PLA2</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="9" Year="2016">2016/9/22</year></dates><abstract><style face="normal" font="Arial">Asthma is a common chronic disease characterized by bronchial inflammation, reversible airway obstruction, and airway hyperresponsiveness (AHR). Current therapeutic options for the management of asthma include inhaled corticosteroids and beta2 agonists, which elicit harmful side effects. In the present study, we examined the capacity of phospholipase A2 (PLA2), one of the major components of bee venom (BV), to reduce airway inflammation and improve lung function in an experimental model of asthma. Allergic asthma was induced in female BALB/c mice by intraperitoneal administration of ovalbumin (OVA) on days 0 and 14, followed by intratracheal challenge with 1% OVA six times between days 22 and 30. The infiltration of immune cells, such as Th2 cytokines in the lungs, and the lung histology, were assessed in the OVA-challenged mice in the presence and absence of an intratracheal administration of bvPLA2. We showed that the intratracheal administration of bvPLA2 markedly suppressed the OVA-induced allergic airway inflammation by reducing AHR, overall area of inflammation, and goblet cell hyperplasia. Furthermore, the suppression was associated with a significant decrease in the production of Th2 cytokines, such as IL-4, IL-5, and IL-13, and a reduction in the number of total cells, including eosinophils, macrophages, and neutrophils in the airway</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 2072-6651 (Electronic)IS - 2072-6651 (Linking)LA - ENGPT - Journal ArticleSB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3390/toxins8100269</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27669297">PM:27669297</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxins (Basel)\20160927-JungKH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxins (Basel)\20160927-JungKH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, Jung KH</style></custom2><misc3><style face="normal" font="Arial">10.3390/toxins8100269</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,F.</style></author><author><style face="normal" font="Arial"> Kang,X.</style></author><author><style face="normal" font="Arial"> Chen,L.</style></author><author><style face="normal" font="Arial"> Chen,C.</style></author><author><style face="normal" font="Arial"> Hu,G.</style></author><author><style face="normal" font="Arial"> Bai,W.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The First Affiliated Hospital of Nanchang University, No. 17, Yongwai Street, Nanchang City, 330006, Jiangxi province, China</style></auth-address><titles><title><style face="normal" font="Arial">Generation of IL10 and TGFB1 coexpressed mice displaying resistance to ovalbumin-induced asthma</style></title><secondary-title><style face="normal" font="Arial">Transgenic Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Transgenic Res</style></abbr-1></periodical><pages end="837" start="829">829-837</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma progression</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="10" Year="2016">2016/10/1</year></dates><abstract><style face="normal" font="Arial">Asthma is a common chronic inflammatory disease in the airways with wide prevalence, and it is thought to be caused by the combinational factors in environment and genetics. A large body of studies has suggested that cell immunity played a vital role in regulating the airway hyperreactivity (AHR) and inflammation. Therefore, we here developed a mouse model of asthma by microinjecting the pronucleus with a vector spontaneously coding human IL10 and TGFB1 gene to explore the possible interaction between these two potent molecules during asthma progression. From the total 35 newborn mice, we successfully obtained 3 founders expressing exogenous genes. In the transgenic mice, we observed profoundly enhanced expression of IL10 and TGFB1. In the condition of ovalbumin challenge, transgenic mice displayed a 1.9-fold higher MCh50 score than wild-type counterparts, indicating reminiscent AHR. Meanwhile, a three-fold decrease of cell counts in bronchoalveolar lavage fluid (BALF) was recorded as well. These results suggested that IL10 and TGFB1 cooperatively protected the respiratory system in response to antigenic stimulus. To interrogate the respective behaviors of the two genes, we quantified the expression of downstream genes in IL10 signaling or TGFB1 signaling. We observed that the examined genes in IL10 signaling were significantly repressed, especially IL5, which showed 5.4-fold decreased expression. Most genes were not altered in TGFB1 signaling, and the production of endogenous TGFB1 was significantly inhibited. These evidences collectively proved that the activation of IL0 and TGFB1 protected the host from antigen-induced asthma, possibly through IL10 signaling. This study shed some light on the modulations of IL10 and TGFB1, and related networks to asthma progression</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1573-9368 (Electronic)IS - 0962-8819 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11248-016-9972-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27696149">PM:27696149</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transgenic Res\20161003-XuF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transgenic Res\20161003-XuF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Xu F</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11248-016-9972-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Waldinger,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA;; Private Practice of Psychiatry and Neurosexology, Amstelveen, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Post orgasmic illness syndrome (POIS)</style></title><secondary-title><style face="normal" font="Arial">Transl Androl Urol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Transl Androl Urol</style></abbr-1></periodical><pages end="606" start="602">602-606</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antigen</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Ejaculation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Masturbation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Private Practice</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Seminal fluid</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Spermatozoa</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vagina</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">Men with post orgasmic illness syndrome (POIS) become ill rather immediately after ejaculation, whether spontaneously at night, during sexual intercourse or masturbation. Two subtypes are distinguished: primary and secondary POIS. It also occurs before or after a man has been sterilized. POIS is an invalidating most probably auto-immune disease leading to much distress in males and their partners. It is characterized by five criteria. Its symptoms are described by seven clusters. However, the manifestation of these symptoms varies from one male to the other but is relatively constant in the person himself. Among men the symptoms vary in intensity, durations and sort of symptoms. POIS is a chronic disorder that manifests itself in POIS "attacks" that occur within a few minutes to a few hours after ejaculation, and disappear spontaneously after 3 to 7 days. POIS is not associated with increased total serum IgE concentrations. On the contrary, there are indications that POIS is triggered by specific cytokines that are released by an auto-immune reaction to the man's seminal fluid. Indirect clinical evidence suggests that the antigen (Ag) triggering the POIS systemic reaction is not bound to spermatozoa but to seminal fluid produced by prostatic tissue. In addition, POIS may also occur-although rarely-in females. In those cases, it is hypothesized that the Ag is associated with female prostatic tissue around the vagina</style></abstract><notes><style face="normal" font="Arial">DA - 20160921IS - 2223-4683 (Linking)LA - ENGPT - Journal ArticlePT - ReviewCO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.21037/tau.2016.07.01</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27652231">PM:27652231</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transl Androl Urol\2016-5-602-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transl Androl Urol\2016-5-602-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160921, Waldinger MD</style></custom2><misc3><style face="normal" font="Arial">10.21037/tau.2016.07.01</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blazquez,A.B.</style></author><author><style face="normal" font="Arial"> Berin,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Microbiome and food allergy</style></title><secondary-title><style face="normal" font="Arial">Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transl Res</style></full-title></periodical><pages end="203" start="199">199-203</pages><volume><style face="normal" font="Arial">179</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> pet exposure</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergy is a common disease affecting approximately 8% of children and 5% of adults. The prevalence has increased over the last two decades, suggesting an important environmental contribution to susceptibility. Studies have identified mode of birth, pet exposure, and having older siblings as being significant risk modifying factors in the development of food allergy. With the discovery that these factors significantly impact the composition of the intestinal microbiome, which is known to play a critical role in shaping the immune system, recent studies have begun to address the role of the intestinal microbiota in the development of food allergy. Studies in human cohorts support a dysbiosis in food allergy, and limited data suggest that this dysbiosis occurs early in life, preceding the onset of sensitization. Studies from animal models have clearly shown that the composition of the intestinal microbiota confers susceptibility to food allergy, and that there are organisms such as Clostridia species that are protective in the development of food allergy. Our understanding of microbial regulation of food allergy is in its nascency, but the state of the field supports an important contribution of intestinal microbes to susceptibility. Challenges going forward are to identify commensal-derived microorganisms that could be used therapeutically to prevent or perhaps treat food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1878-1810 (Electronic)IS - 1878-1810 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.trsl.2016.09.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27686718">PM:27686718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transl Res\20160930-BlazquezAB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transl Res\20160930-BlazquezAB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160930, Blazquez AB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.trsl.2016.09.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Michels,G.M.</style></author><author><style face="normal" font="Arial"> Walsh,K.F.</style></author><author><style face="normal" font="Arial"> Kryda,K.A.</style></author><author><style face="normal" font="Arial"> Mahabir,S.P.</style></author><author><style face="normal" font="Arial"> Walters,R.R.</style></author><author><style face="normal" font="Arial"> Hoevers,J.D.</style></author><author><style face="normal" font="Arial"> Martinon,O.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Global Development and Operations, Zoetis Inc., 333 Portage Street, Kalamazoo, MI, 49007, USA</style></auth-address><titles><title><style face="normal" font="Arial">A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="505">505-</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="19" Month="9" Year="2016">2016/9/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Lokivetmab (ZTS-00103289) is a caninized anti-canine IL-31 monoclonal antibody that has demonstrated efficacy in reducing pruritus associated with atopic dermatitis (AD) in dogs in field trials. HYPOTHESIS/OBJECTIVES: This study evaluated the safety of lokivetmab in a randomized, double blind, placebo-controlled trial in client owned dogs with AD with minimal restrictions on concomitant medications and co-morbidities. ANIMALS: Clinicians at 14 veterinary clinics enrolled client owned dogs (n = 245) with chronic AD. METHODS: Dogs were randomized at a 2:1 ratio to receive either lokivetmab (1.0-3.3 mg/kg) or placebo administered subcutaneously on days 0 and 28. Clinicians examined dogs, and collected blood and urine for assessment of clinical pathology and immunogenicity (days 0, 28 and 42). RESULTS: There were no immediate hypersensitivity reactions (e.g. wheals, vomiting). Discomfort at administration occurred in 5.1% of dogs and was similar in frequency and severity between lokivetmab- and placebo-treated groups. Pruritus was reported as an adverse event during the study less frequently in the lokivetmab-treated group (4.9% and 19.3%, respectively); otherwise, adverse events occurred at a similar frequency between treatment groups. There were no clinically important differences between groups in clinical pathology results. Treatment-induced immunogenicity was found in 2.5% of lokivetmab treated dogs. A wide variety of concomitant medications were used with no clinically apparent adverse interactions. CONCLUSIONS AND CLINICAL IMPORTANCE: Among a diverse population of 162 client owned dogs with a clinical diagnosis of AD, treatment with two monthly doses of lokivetmab was safe, based on observed adverse events and clinical pathology results over a 42 day period</style></abstract><notes><style face="normal" font="Arial">DA - 20160920IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12364</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27647513">PM:27647513</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20160919-MichelsGM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20160919-MichelsGM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Michels GM</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12364</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Michels,G.M.</style></author><author><style face="normal" font="Arial"> Ramsey,D.S.</style></author><author><style face="normal" font="Arial"> Walsh,K.F.</style></author><author><style face="normal" font="Arial"> Martinon,O.M.</style></author><author><style face="normal" font="Arial"> Mahabir,S.P.</style></author><author><style face="normal" font="Arial"> Hoevers,J.D.</style></author><author><style face="normal" font="Arial"> Walters,R.R.</style></author><author><style face="normal" font="Arial"> Dunham,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Global Development and Operations, Zoetis Inc, 333 Portage Street, Kalamazoo, MI, 49007, USA.</style></auth-address><titles><title><style face="normal" font="Arial">A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="478">478-</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="9" Year="2016">2016/9/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Lokivetmab, a caninized anti-canine IL-31 monoclonal antibody, reduced pruritus and associated inflammatory skin lesions in a proof-of-concept study in dogs with AD. HYPOTHESIS/OBJECTIVES: The objective was to describe lokivetmab dose response in a randomized, double blind, placebo-controlled trial. ANIMALS: Clinicians at 15 referral clinics enrolled 211 client owned dogs with a history of chronic AD. METHODS: Dogs were randomized to treatment with lokivetmab (0.125, 0.5 or 2.0 mg/kg) or placebo administered subcutaneously once on Day 0. Dog owners assessed visual analog scale (VAS) scores of pruritus on days 0, 1, 2, 3, 7, 14, 21, 28, 35, 42, 49 and 56. Clinicians assessed Canine AD Extent and Severity Index (CADESI-03) scores on days 0, 7, 14, 28, 42 and 56. RESULTS: Treatment with lokivetmab (2 mg/kg) resulted in a greater percentage reduction from baseline in owner assessed pruritus (days 1-49) and clinician assessed CADESI-03 scores (days 7-56) compared to placebo (P &lt; 0.05); differences were achieved in lower dose groups but at later time points and for shorter duration for both owner assessed pruritus (0.5 mg/kg, days 2-35; 0.125 mg/kg, days 7-21) and clinician assessed CADESI-03 scores (0.5 mg/kg and 0.125 mg/kg, Day 14). CONCLUSIONS AND CLINICAL IMPORTANCE: Lokivetmab (0.5, 2.0 mg/kg) reduced pruritus compared to placebo for at least 1 month. Level and duration of response increased with increasing dose. Further studies are needed to better understand variability in individual responses across a broader population of dogs with AD</style></abstract><notes><style face="normal" font="Arial">DA - 20160920IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12376</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27647569">PM:27647569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20160920-MichelsGM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20160920-MichelsGM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160920, Michels GM</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12376</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moya,R.</style></author><author><style face="normal" font="Arial"> Carnes,J.</style></author><author><style face="normal" font="Arial"> Sinovas,N.</style></author><author><style face="normal" font="Arial"> Ramio,L.</style></author><author><style face="normal" font="Arial"> Brazis,P.</style></author><author><style face="normal" font="Arial"> Puigdemont,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">R&amp;D Department, Laboratorios LETI, S.L. C/del Sol 5, 28760 Tres Cantos, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Immunoproteomic characterization of a Dermatophagoides farinae extract used in the treatment of canine atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Vet Immunol Immunopathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Vet Immunol Immunopathol</style></abbr-1></periodical><pages end="8" start="1">1-8</pages><volume><style face="normal" font="Arial">180</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Densitometry</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Der f 15</style></keyword><keyword><style face="normal" font="Arial"> Der f 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Iberian Peninsula</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG2</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunoblot inhibition</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="1" Month="11" Year="2016">2016/11/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Canine atopic dermatitis is a pruritic allergic skin disease. House dust mites have been identified as the main non-seasonal responsible agent. Unlike in human allergic patients, groups 1 and 2 antigens have been described as minor allergens in dogs, while groups 15 and 18 are considered the major allergens. Despite these differences, allergic dogs have traditionally been treated using extracts intended for human immunotherapy. OBJECTIVES: To investigate the immunological characteristics and the allergen reactivity of dogs with atopic dermatitis using a Dermatophagoides farinae commercial extract. METHODS: Eighteen dogs diagnosed with atopic dermatitis and 3 healthy control dogs from the Iberian Peninsula were included in the study. All the animals were older than 12 months, from both sexes and different breeds and showed positive specific IgE against D. farinae (>2500 ELISA Absorbance Units). The D. farinae allergenic extract used in this study was manufactured and characterized. The allergenic profile of the dogs was investigated by immunoblot and specific IgE, IgG, IgG1 and IgG2 measured by direct ELISA. Allergen identity was confirmed by immunoblot inhibition and mass spectrometry analyses. RESULTS: The results confirmed the relevance of groups 15 and 18 antigens, but also groups 1, 2 and other medium molecular weight allergens in the sensitization of dogs with atopic dermatitis. Immunoblot inhibition and mass spectrometry assays confirmed these results. Relevant allergens were quantified by scanning densitometry (Der f 1: 17mug/mg, Der f 2: 20.3mug/mg, Der f 15: 18.1mug/mg and Der f 18: 9.4mug/mg). Concerning immunoglobulins profile, differences in IgE and IgG1 levels were observed between non-atopic and atopic dogs. CONCLUSIONS: The commercial D. farinae extract characterized in this study contains the major allergens involved in the sensitization of dogs with atopic dermatitis, representing a suitable candidate for its use in the diagnosis and immunotherapy of mite allergic dogs</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 1873-2534 (Electronic)IS - 0165-2427 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.vetimm.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27692089">PM:27692089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Immunol Immunopathol\20161003-MoyaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Immunol Immunopathol\20161003-MoyaR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Maya R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.vetimm.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Widyarani</style></author><author><style face="normal" font="Arial"> Coulen,S.C.W.</style></author><author><style face="normal" font="Arial"> Sanders,J.P.M.</style></author><author><style face="normal" font="Arial"> Bruins,M.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Valorisation of Proteins from Rubber Tree</style></title><secondary-title><style face="normal" font="Arial">Waste Biomass Valorization</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Waste Biomass Valorization</style></full-title></periodical><pages end="1041" start="1027">1027-1041</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animal Feed</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> Indonesia</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> Smallholder farmers</style></keyword><keyword><style face="normal" font="Arial"> Valorisation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-265X</style></isbn><abstract><style face="normal" font="Arial">The objective of this study was to identify the availability, possible applications, and economic potential of proteins that are present in different parts of the rubber tree. Proteins from non-food sources can be used in e.g. animal feed or biochemicals production with no or little competition with food production, rendering them important biobased feedstock. Rubber tree is primarily grown for its latex that is used in rubber production. Indonesia has the largest rubber plantation area that is mostly owned and run by smallholder farmers. Using non-latex fractions from the rubber tree may generate additional income, and increase the economics of rubber plantations in general</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -CO - Indonesia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12649-016-9688-9</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s12649-016-9688-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Waste Biomass Valorization\20161019-Widyarani.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Waste Biomass Valorization\20161019-Widyarani.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Widyarani</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12649-016-9688-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dreskin,S.C.</style></author><author><style face="normal" font="Arial"> Halsey,N.A.</style></author><author><style face="normal" font="Arial"> Kelso,J.M.</style></author><author><style face="normal" font="Arial"> Wood,R.A.</style></author><author><style face="normal" font="Arial"> Hummell,D.S.</style></author><author><style face="normal" font="Arial"> Edwards,K.M.</style></author><author><style face="normal" font="Arial"> Caubet,J.C.</style></author><author><style face="normal" font="Arial"> Engler,R.J.</style></author><author><style face="normal" font="Arial"> Gold,M.S.</style></author><author><style face="normal" font="Arial"> Ponvert,C.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Li,J.T.</style></author><author><style face="normal" font="Arial"> Rottem,M.</style></author><author><style face="normal" font="Arial"> Rosenwasser,L.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Medicine, University of Colorado Denver School of Medicine, Aurora, CO USA</style></auth-address><titles><title><style face="normal" font="Arial">International Consensus (ICON): allergic reactions to vaccines</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="32">32-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Causality</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> International consensus</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Routine immunization, one of the most effective public health interventions, has effectively reduced death and morbidity due to a variety of infectious diseases. However, allergic reactions to vaccines occur very rarely and can be life threatening. Given the large numbers of vaccines administered worldwide, there is a need for an international consensus regarding the evaluation and management of allergic reactions to vaccines. METHODS: Following a review of the literature, and with the active participation of representatives from the World Allergy Organization (WAO), the European Academy of Allergy and Clinical Immunology (EAACI), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Allergy, Asthma, and Immunology (ACAAI), the final committee was formed with the purpose of having members who represented a wide-range of countries, had previously worked on vaccine safety, and included both allergist/immunologists as well as vaccinologists. RESULTS: Consensus was reached on a variety of topics, including: definition of immediate allergic reactions, including anaphylaxis, approaches to distinguish association from causality, approaches to patients with a history of an allergic reaction to a previous vaccine, and approaches to patients with a history of an allergic reaction to components of vaccines. CONCLUSIONS: This document provides comprehensive and internationally accepted guidelines and access to on-line documents to help practitioners around the world identify allergic reactions following immunization. It also provides a framework for the evaluation and further management of patients who present either following an allergic reaction to a vaccine or with a history of allergy to a component of vaccines</style></abstract><notes><style face="normal" font="Arial">DA - 20160928IS - 1939-4551 (Linking)LA - ENGPT - Journal ArticleCO - United States -CO - Switzerland -CO - Australia -CO - France -CO - Venezuela -CO - Italy -CO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0120-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27679682">PM:27679682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160928, Dreskin SC</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0120-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nishikawa,K.</style></author><author><style face="normal" font="Arial"> Fujimura,T.</style></author><author><style face="normal" font="Arial"> Ota,Y.</style></author><author><style face="normal" font="Arial"> Abe,T.</style></author><author><style face="normal" font="Arial"> ElRamlawy,K.G.</style></author><author><style face="normal" font="Arial"> Nakano,M.</style></author><author><style face="normal" font="Arial"> Takado,T.</style></author><author><style face="normal" font="Arial"> Uenishi,A.</style></author><author><style face="normal" font="Arial"> Kawazoe,H.</style></author><author><style face="normal" font="Arial"> Sekoguchi,Y.</style></author><author><style face="normal" font="Arial"> Tanaka,A.</style></author><author><style face="normal" font="Arial"> Ono,K.</style></author><author><style face="normal" font="Arial"> Kawamoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hiroshima Research Center for Healthy Aging (HiHA), Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, Hiroshima 730-8530 Japan</style></auth-address><titles><title><style face="normal" font="Arial">Exposure to positively- and negatively-charged plasma cluster ions impairs IgE-binding capacity of indoor cat and fungal allergens</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="27">27-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aging</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asp f 1</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> fungal allergens</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Environmental control to reduce the amount of allergens in a living place is thought to be important to avoid sensitization to airborne allergens. However, efficacy of environmental control on inactivation of airborne allergens is not fully investigated. We have previously reported that positively- and negatively-charged plasma cluster ions (PC-ions) reduce the IgE-binding capacity of crude allergens from Japanese cedar pollen as important seasonal airborne allergens. Cat (Felis domesticus) and fungus (Aspergillus fumigatus) are also important sources of common airborne allergens in living spaces throughout the year, and early sensitization with those allergens is considered to be a risk factor for future development of allergic rhinitis, pollinosis and asthma. The aim of this study is to examine whether the PC-ions reduce the IgE-binding capacity of a cat major allergen (Fel d 1) and fungal allergens in an experimental condition. METHODS: Fel d 1, crude fungal extract, or a fungal major allergen Asp f 1, was treated with PC-ions for 6 h in an experimental cylindrical apparatus. Sham-treated allergens were prepared in the same experimental apparatus without generation of PC-ions. The degradation of the PC-ions-treated Fel d 1 was analyzed by SDS-PAGE, and the IgE-binding capacity of the PC-ions-treated allergens was analyzed by ELISA inhibition assay. RESULTS: Exposure of Fel d 1, crude fungal extract and Asp f 1 to PC-ions significantly decreased protein content of Fel d 1 or Asp f 1, respectively. SDS-PAGE analysis suggested that the decreased Fel d 1 content upon exposure with PC-ions was attributable to protein degradation. ELISA inhibition indicated that the PC-ions treatment significantly impaired IgE-binding capacities of Fel d 1, crude fungal allergens, and Asp f 1 compared to sham treatment. DISCUSSION: Our data suggest that treatment with PC-ions not only reduce indoor cat and fungal allergens, but also impair their allergenicity. CONCLUSION: These results suggest that environmental control with PC-ions is useful for inactivation of indoor cat and fungal allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1939-4551 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0118-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27660668">PM:27660668</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Nishikawa K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0118-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,L.</style></author><author><style face="normal" font="Arial"> Liu,C.C.</style></author><author><style face="normal" font="Arial"> Shi,X.L.</style></author><author><style face="normal" font="Arial"> Wang,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Asthma, Children's Hospital of Xi'an, Xi'an 710003, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Inhibitory effect of KyoT2 overexpression on proliferation and migration of airway smooth muscle cells in mice with asthma]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="890" start="885">885-890</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plasmid</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the effect of KyoT2 on the proliferation and migration of airway smooth muscle cells (ASMCs) in mice with asthma. METHODS: Ovalbumin (OVA) was used to establish the asthmatic model of airway remodeling in BALB/c mice. ASMCs were isolated and cultured, and primarily cultured ASMCs were used as the control group. The expression of KyoT2 in ASMCs was measured in the control and asthma groups. After the ASMCs from asthmatic mice were transfected with pCMV-Myc (empty vector group) or pCMV-Myc-KyoT2 plasmid with overexpressed KyoT2 (KyoT2 expression group) for 48 hours, RT-PCR and Western blot were used to measure the mRNA and protein expression of KyoT2, the MTT assay and BrdU assay were used to measure the proliferation of ASMCs, and Transwell assay was used to measure the migration of ASMCs. Western blot was used to determine the effect of KyoT2 overexpression on the protein expression of RBP-Jkappa, PTEN, and AKT. RESULTS: Compared with the control group, the asthma group had significantly downregulated expression of KyoT2 in ASMCs, and the KyoT2 expression group had significantly upregulated expression of KyoT2 in ASMCs (P&lt;0.05). Compared with the empty vector group, overexpressed KyoT2 significantly inhibited cell proliferation and migration, downregulated the expression of RBP-Jkappa and AKT, and upregulated the expression of PTEN. CONCLUSIONS: Overexpressed KyoT2 can inhibit the proliferation and migration of ASMCs through the negative regulation of RBP-Jkappa/PTEN/AKT signaling pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - CHIPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27655549">PM:27655549</url></web-urls></urls><custom2><style face="normal" font="Arial">20160922, Zhao L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bangsgaard,N.</style></author><author><style face="normal" font="Arial"> Zachariae,C.</style></author><author><style face="normal" font="Arial"> Skov,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermato-Allergology, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark. nannie.bangsgaard@regionh.dk</style></auth-address><titles><title><style face="normal" font="Arial">Treatment of Refractory Chronic Spontaneous Urticaria with Adalimumab</style></title><secondary-title><style face="normal" font="Arial">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Derm Venereol</style></full-title></periodical><pages end="525" start="524">524-525</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="14" Month="11" Year="2016">2016/11/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.2340/00015555-2573</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27840884">PM:27840884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Derm Venereol\2017-27-524-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Derm Venereol\2017-27-524-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Bangsgaard N</style></custom2><misc3><style face="normal" font="Arial">10.2340/00015555-2573</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nascimento,S.L.</style></author><author><style face="normal" font="Arial"> Carvalho Pacheco,L.G.</style></author><author><style face="normal" font="Arial"> Silva,P.C.</style></author><author><style face="normal" font="Arial"> Alcantara-Neves,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Health Sciences, Federal University of Bahia, Salvador, BA, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Recombinant proteins of helminths with immunoregulatory properties and their possible therapeutic use</style></title><secondary-title><style face="normal" font="Arial">Acta Trop</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Trop</style></full-title></periodical><pages end="211" start="202">202-211</pages><volume><style face="normal" font="Arial">166</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> future immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Helminth Proteins</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Bowel Diseases</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword></keywords><dates><year Day="18" Month="11" Year="2016">2016/11/18</year></dates><abstract><style face="normal" font="Arial">The inverse relationship between helminth infections and the development of immune-mediated diseases is a cornerstone of the hygiene hypothesis and studies were carried out to elucidate the mechanisms by which helminth-derived molecules can suppress immunological disorders. These studies have fostered the idea that parasitic worms may be used as a promising therapeutic alternative for prevention and treatment of immune-mediated diseases. We discuss the current approaches for identification of helminth proteins with potential immunoregulatory properties, including the strategies based on high-throughput technologies. We also explore the methodological approaches and expression systems used for production of the recombinant forms of more than 20 helminth immunomodulatory proteins, besides their performances when evaluated as immunotherapeutic molecules to treat different immune-mediated conditions, including asthma and inflammatory bowel diseases. Finally, we discuss the perspectives of using these parasite-derived recombinant molecules as tools for future immunotherapy and immunoprophylaxis of human inflammatory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1873-6254 (Electronic)IS - 0001-706X (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.actatropica.2016.11.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871775">PM:27871775</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Trop\2016-166-202-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Trop\2016-166-202-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Nascimento SL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.actatropica.2016.11.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chicharro,P.</style></author><author><style face="normal" font="Arial"> Rodriguez,P.</style></author><author><style face="normal" font="Arial"> de Argila,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Dermatologia, Hospital Universitario de La Princesa, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab in the Treatment of Chronic Inducible Urticaria</style></title><secondary-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></full-title></periodical><pages end="431" start="423">423-431</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Omalizumab is a recombinant humanized monoclonal antibody that inhibits immunoglobulin E. It has been approved for the treatment of severe asthma and chronic spontaneous urticaria refractory to other treatments. Its use in the management of chronic inducible urticaria (a type triggered by certain stimuli) is still considered off-label, although this use has been discussed in some consensus papers. This review brings together case reports and case series describing the use of omalizumab to treat chronic inducible urticaria. We analyze the most important aspects of the cases and the outcomes reported. The results seem to position omalizumab as a potentially effective, safe treatment alternative in some cases of chronic inducible urticaria</style></abstract><notes><style face="normal" font="Arial">DA - 20161008IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - ENGLA - SPAPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ad.2016.07.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27717421">PM:27717421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Actas Dermosifiliogr\2017-108-423-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Actas Dermosifiliogr\2017-108-423-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161008, Chicharro P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ad.2016.07.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perez-Ferriols,A.</style></author><author><style face="normal" font="Arial"> Barnadas,M.</style></author><author><style face="normal" font="Arial"> Gardeazabal,J.</style></author><author><style face="normal" font="Arial"> de Argila,D.</style></author><author><style face="normal" font="Arial"> Carrascosa,J.M.</style></author><author><style face="normal" font="Arial"> Aguilera,P.</style></author><author><style face="normal" font="Arial"> Gimenez-Arnau,A.</style></author><author><style face="normal" font="Arial"> Rodriguez-Granados,T.</style></author><author><style face="normal" font="Arial"> de Galvez,M.V.</style></author><author><style face="normal" font="Arial"> Aguilera,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Dermatologia, Hospital General Universitario de Valencia, Valencia, Espana.</style></auth-address><titles><title><style face="normal" font="Arial">Solar urticaria: Epidemiology and clinical phenotypes in a Spanish series of 224 patients</style></title><secondary-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></full-title></periodical><pages end="139" start="132">132-139</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Photobiology</style></keyword><keyword><style face="normal" font="Arial"> Phototherapy</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Solar urticaria is a chronic inducible urticaria also classified as an idiopathic dermatosis. The objective of this paper is to define the phenotypic characteristics of solar urticaria and to evaluate its incidence. MATERIAL AND METHOD: This was a retrospective multicenter study in which data were gathered on the epidemiology and clinical, photobiologic, laboratory, and therapeutic characteristics of solar urticaria. RESULTS: A total of 224 patients (141 women and 83 men) were included from 9 photobiology units. The mean age of the patients was 37.9 years (range, 3-73 years). A history of atopy was detected in 26.7%, and the most common presentation was allergic rhinitis (16.5%). Clinical signs were limited to sun-exposed areas in 75.9% of patients. The light spectrum most commonly implicated was visible light only (31.7%), and in 21% of cases it was only possible to trigger solar urticaria with natural light. The treatments most widely used by photobiology experts were oral antihistamines (65.46%), followed by different forms of phototherapy (34%). Complete resolution was observed most often in patients with solar urticaria triggered exclusively by visible or natural light, with statistically significant differences with respect to other wavelengths (P&lt;.05). No increase in the annual incidence of solar urticaria was observed. CONCLUSIONS: We have presented the largest series of solar urticaria published to date. The epidemiological, clinical, and photobiologic findings confirm previously reported data, although there was a particularly high rate of negative phototests in our series. Reactivity exclusively to visible or natural light was associated with a higher probability of resolution. No increasing trend was observed in the annual incidence</style></abstract><notes><style face="normal" font="Arial">DA - 20161029IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - ENGLA - SPAPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ad.2016.09.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27793344">PM:27793344</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Actas Dermosifiliogr\2017-108-132-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Actas Dermosifiliogr\2017-108-132-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161029, Perez-Ferriols A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ad.2016.09.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adeli,M.</style></author><author><style face="normal" font="Arial"> Hendaus,M.A.</style></author><author><style face="normal" font="Arial"> Abdurrahim,L.I.</style></author><author><style face="normal" font="Arial"> Alhammadi,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Hamad Medical Corporation; Department of Clinical Pediatrics, Weill-Cornell Medical College; Department of Pediatrics, Sidra Medical and Research Center, Doha, Qatar</style></auth-address><titles><title><style face="normal" font="Arial">The importance of educating postgraduate pediatric physicians about food allergy</style></title><secondary-title><style face="normal" font="Arial">Adv Med Educ Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Adv Med Educ Pract</style></abbr-1></periodical><pages end="602" start="597">597-602</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Qatar</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Teaching</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is an increasing public health burden, and is considered among the most common chronic noncommunicable diseases in children. Proper diagnosis and management of food allergy by a health care provider is crucial in keeping affected children safe while simultaneously averting unnecessary avoidance. OBJECTIVE: The rationale of the study was to estimate the knowledge of pediatric residents and academic general pediatric fellows with regard to food allergies in children. METHODS: A cross-sectional and prospective study was carried out at Hamad Medical Corporation, the only tertiary care, academic and teaching hospital in the State of Qatar. The study took place between January 1, 2015 and September 30, 2015. RESULTS: Out of the 68 questionnaires distributed, 68 (100%) were returned by the end of the study. Among the participants, 15 (22%) were in post-graduate year-1 (PGY-1), 16 (23.5%) in PGY-2, 17 (25%) in PGY-3, 12 (16%) in PGY-4, and 8 (12%) were academic general pediatric fellows. Our trainees answered 60.14% of knowledge based questions correctly. In the section of treatment and management of food allergy in childhood, 23 (34%) of respondents' main concern when taking care of a patient with food allergies was making sure the patient is not exposed to food allergen, while 22 (33%) reported no concerns. In the section of treatment and management of food allergy in childhood, 22 (33%) of participants reported no concerns in taking care of a child with food allergy, while 23 (34%) of respondents' main concern was making sure the patient is not exposed to food allergen. In the teaching and training section, 56% of participants stated that they have not received formal education on how to recognize and treat food allergies, while 59% claimed not being trained on how to administer injectable epinephrine. Furthermore, approximately 60% of all participants expressed the need of additional information about recognizing and treating food allergies and recommended certification and regulation of food allergy training for all residents. CONCLUSION: There is an appreciable lack of knowledge in identifying food allergy and managing anaphylaxis reaction in children, among pediatric residents. Robust efforts should be implemented by attending immunologists to improve the lack of knowledge and improve the trainee's confidence when facing such cases</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1179-7258 (Linking)LA - ENGPT - Journal ArticleCO - Qatar -</style></notes><work-type><style face="normal" font="Arial">10.2147/AMEP.S112182</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799840">PM:27799840</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Med Educ Pract\2016-7-597-602.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Med Educ Pract\2016-7-597-602.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Adeli M</style></custom2><misc3><style face="normal" font="Arial">10.2147/AMEP.S112182</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fuentes Perez,J.M.</style></author><author><style face="normal" font="Arial"> Jimenez Polvo,E.N.</style></author><author><style face="normal" font="Arial"> Mendoza Hernandez,D.A.</style></author><author><style face="normal" font="Arial"> Huerta Lopez,J.G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anafilaxia secundaria a ingesta de avellana: reporte de un caso [Anaphylaxis due to hazelnut ingestion - a case report]</style></title><secondary-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="59" start="56">56-59</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bradycardia</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Chocolate</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Keratoconus</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> self-injectable</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Introduction: Hazelnut allergy can range from mild oral symptoms to potentially dangerous anaphylaxis.It is estimated that allergy to nuts, including hazelnut has a prevalence of 1%. Description of thecase: 17 years male, with no history of atopy. History of chronic conjunctivitis, keratoconus in the lefteye with corneal transplantation, allergic rhinitis and bronchial asthma managed with immunotherapy.Actual disease: Twenty minutes after intake of chocolate (with hazelnut) patient presented bilateraleyelid edema, earache, angioedema, sensation of drowning; Physical examination: eyes closed,diffi culty opening bilateral conjunctival erythema, cobblestone papillae, oral cavity edematous uvula, tendency to bradycardia. Adrenaline is handled with good response. ImmunoCAP is requested withsensitization to hazelnut, peanut, almond and walnut. Discussion: Anaphylaxis due to hazelnut in ourcountry is poorly documented. Of the proteins involved, some are related with oral allergy syndromeand the others with cross-reactivity to dried fruit (or both), the latter with increased risk of anaphylaxis.It's important to diagnose by molecular biology and important to have self-injectable adrenaline forprehospital management. Conclusions: We should not consider food allergies nonexistent with hazelnutanaphylaxis. The correct diagnosis and treatment reduces the risk of subsequent events.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/resumen.cgi?IDARTICULO=66627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2016-25-56-69.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2016-25-56-69.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Fuentes Perez JM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goncalves,C.</style></author><author><style face="normal" font="Arial"> Wandalsen,G.</style></author><author><style face="normal" font="Arial"> Lanza,F.</style></author><author><style face="normal" font="Arial"> Goulart,A.L.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author><author><style face="normal" font="Arial"> Dos Santos,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics - Neonatal Division of Medicine, Federal University of Sao Paulo, Sao Paulo, SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Repercussions of preterm birth on symptoms of asthma, allergic diseases and pulmonary function, 6-14 years later</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="496" start="489">489-496</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Bronchodilator response</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary Dysplasia</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="15" Month="10" Year="2016">2016/10/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Prevalence of allergic diseases and impaired pulmonary function may be high in children born prematurely. This study aimed to assess pulmonary function and prevalence of asthma, atopic diseases and allergic sensitisation in these patients. METHODS: A cross-sectional study was conducted with children aged 6-14 years who were born prematurely with birth weight &lt;2000g from January 2008 to May 2011. Exclusion criteria were: major malformations, or acute respiratory disorders. The International Study of Asthma and Allergies in Childhood questionnaire was applied followed by allergic skin prick test and spirometry. RESULTS: The study included 84 children aged 9.3+/-2.3 years born at mean gestational age of 31.8+/-2.4 weeks. The prevalence of current asthma was 25%, more severe asthma was 15.5%; rhinitis was 38.1%; flexural eczema was 8.3%; and a positive skin-prick test was 69.6%. Frequencies of children with values &lt;80% of predicted were: FVC (8.3%), FEV1 (22.6%), and FEV1/FVC ratio (16.7%). Prevalence of children with FEF25-75% &lt;70% of the predicted value was 32.4%, positive bronchodilator response was observed in 20.5% of cases, and altered pulmonary function in 42.9%. Factors associated with altered pulmonary function were oxygen dependency at 28 days of life (OR: 4.213, p=0.021), the presence of wheezing in childhood (OR: 5.979, p=0.014) and infant's height (OR: 0.945, p=0.005). CONCLUSIONS: There was a high prevalence of severe asthma, allergic sensitisation, and altered pulmonary function among children and adolescents born prematurely. Bronchopulmonary dysplasia and a history of wheezing were risk factors for altered pulmonary function</style></abstract><notes><style face="normal" font="Arial">DA - 20161019IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27756492">PM:27756492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161019-GoncalvesC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161019-GoncalvesC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Goncalves C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tortajada-Girbes,M.</style></author><author><style face="normal" font="Arial"> Mesa Del Castillo,M.</style></author><author><style face="normal" font="Arial"> Larramona,H.</style></author><author><style face="normal" font="Arial"> Lucas,J.M.</style></author><author><style face="normal" font="Arial"> Alvaro,M.</style></author><author><style face="normal" font="Arial"> Tabar,A.I.</style></author><author><style face="normal" font="Arial"> Jerez,M.J.</style></author><author><style face="normal" font="Arial"> Martinez-Canavate,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatric Allergology and Pulmonology Unit, Dr. Peset University Hospital, Valencia, Spain; Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Evidence in immunotherapy for paediatric respiratory allergy: Advances and recommendations</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="32" start="1">1-32</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">S1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="21" Month="10" Year="2016">2016/10/21</year></dates><abstract><style face="normal" font="Arial">Allergic respiratory diseases are major health problems in paediatric population due their high level of prevalence and chronicity, and to their relevance in the costs and quality of life. One of the most important risk factors for the development of airway diseases in children and adolescents is atopy. The mainstays for the treatment of these diseases are avoiding allergens, controlling symptoms, and preventing them through sustained desensitization by allergen immunotherapy (AIT). AIT is a treatment option that consists in the administration of increasing amounts of allergens to modify the biological response to them, inducing long-term tolerance even after treatment has ended. This treatment approach has shown to decrease symptoms and improve quality of life, becoming cost effective for a large number of patients. In addition, it is considered the only treatment that can influence the natural course of the disease by targeting the cause of the allergic inflammatory response. The aim of this publication is to reflect the advances of AIT in the diagnosis and treatment of allergic respiratory diseases in children and adolescents reviewing articles published since 2000, establishing evidence categories to support the strength of the recommendations based on evidence. The first part of the article covers the prerequisite issues to understand how AIT is effective, such as the correct etiologic and clinical diagnosis of allergic respiratory diseases. Following this, the article outlines the advancements in understanding the mechanisms by which AIT achieve immune tolerance to allergens. Administration routes, treatment regimens, dose and duration, efficacy, safety, and factors associated with adherence are also reviewed. Finally, the article reviews future advances in the research of AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27776895">PM:27776895</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161025-TortajadaGirbesM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161025-TortajadaGirbesM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Tortajada-Girbes M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arikan-Ayyildiz,Z.</style></author><author><style face="normal" font="Arial"> Karaman,M.</style></author><author><style face="normal" font="Arial"> Ozbal,S.</style></author><author><style face="normal" font="Arial"> Bagriyanik,A.</style></author><author><style face="normal" font="Arial"> Yilmaz,O.</style></author><author><style face="normal" font="Arial"> Karaman,O.</style></author><author><style face="normal" font="Arial"> Uzuner,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Allergy, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of parthenolide on lung histopathology in a murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="68" start="63">63-68</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Feverfew</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Parthenolide is the active constituent of the plant 'Tanacetum parthenium' (Feverfew) which has been used for centuries as a folk remedy for inflammatory conditions. AIM OF THE STUDY: In this study we aimed to investigate the effects of parthenolide in a murine model of chronic asthma. MATERIALS AND METHODS: Thirty-five BALB/c mice were divided into five groups; I (control), II (placebo), III (dexamethasone), IV (parthenolide) and V (dexamethasone and parthenolide combination). Lung histology was evaluated after treatment with the study drugs. Levels of interleukin (IL)-4 and IL-5 were determined by ELISA. RESULTS: Histologic parameters except the number of mast and goblet cells improved in the parthenolide group when compared with placebo. All parameters except basal membrane thickness and number of mast cells were improved significantly better in the group receiving dexamethasone when compared with the parthenolide group. Improvement of most of the histologic parameters was similar in Groups III and V. Interleukin-4 levels were significantly reduced in the parthenolide group when compared to the placebo group. CONCLUSION: We demonstrated that parthenolide administration alleviated some of the pathological changes in asthma. But parthenolide alone is not efficient as dexamethasone therapy and the parthenolide and dexamethasone combination also did not add any beneficial effect to the dexamethasone treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161008IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27717727">PM:27717727</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161018-ArikanAyyildizZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161018-ArikanAyyildizZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161018, Arikan-Ayyildiz Z</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.06.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loghmani,A.</style></author><author><style face="normal" font="Arial"> Raoofi,R.</style></author><author><style face="normal" font="Arial"> Ownagh,A.</style></author><author><style face="normal" font="Arial"> Delirezh,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.</style></auth-address><titles><title><style face="normal" font="Arial">Alternaria alternata acts on human Monocyte-derived Dendritic cells to mediate Th2/Th17 polarisation</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="182" start="175">175-182</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CD14</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> HLA-DR</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Although the mechanism of asthma is not precisely understood in humans, clinical and epidemiological studies have offered a potential relationship between exposure to environmental fungi, such as Alternaria alternata (A. alternata) and the development and exacerbation of asthma. The aim of this project is to investigate the mechanisms of Th2 responses by A. alternata as a clinically relevant model for the environmental exposure. MATERIALS AND METHODS: Plastic adherent monocytes were cultured with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4) to convert these cells into Monocyte-derived Dendritic cells (MoDc) and then matured in the presence of Monocyte-Conditioned Medium (MCM) as the control group and MCM+ A. alternata extract as the inductive groups. RESULTS: The results indicated that the expression of CD14 decreased and CD83 and anti-human leukocyte antigen-DR (HLA-DR) increased in the inductive groups in comparison with the control group. More importantly, A. alternata inhibited IL-12 production by activated dendritic cells (DCs), and the DCs exposed to A. alternata enhanced the Th2 polarisation of CD4+ T cells. The production amount of IL-10 overcame IL-12 as well as Il-23 increased significantly, and hand in T cells the production of cytokines Interferon-gamma (IFN-gamma) decreased. However, both IL-17 and IL-4 increased (p&lt;0.05). Phagocytic activity in the inductive groups decreased significantly compared with the control group. CONCLUSION: The asthma-related environmental fungus A. alternata, with an effect on dendritic cells profile mediates TH2/TH17. Such immunodysregulation properties of causative environmental fungi may explain their strong relationship with human asthma and allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161108IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27823917">PM:27823917</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161108-LoghmaniA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161108-LoghmaniA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161108, Loghmani A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,M.N.</style></author><author><style face="normal" font="Arial"> Lee,K.E.</style></author><author><style face="normal" font="Arial"> Hong,J.Y.</style></author><author><style face="normal" font="Arial"> Kim,K.W.</style></author><author><style face="normal" font="Arial"> Kim,K.E.</style></author><author><style face="normal" font="Arial"> Sohn,M.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Severance Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">IgE cross-reactivity of peanut with walnut and soybean in children with food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="530" start="524">524-530</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergies are common and can be life-threating for sensitised individuals. Peanut allergens share significant amino acid homology with those of other legumes and tree nuts, but their cross-reactivity still remains unclear. OBJECTIVE: We sought to determine the clinical significance of the cross-reactivity of peanut allergens with those of walnut and soybean. METHODS: Pooled sera from eight subjects with both peanut and walnut specific IgE were investigated in an inhibition test. After the sera were incubated with either peanut or walnut protein extracts, the quantity of IgE antibodies against the peanut and walnut was measured using an immunoCAP test. Likewise, pooled sera from 18 subjects with both peanut and soybean specific IgE antibodies were incubated with either peanut or soybean protein extracts and evaluated with a peanut and soybean immunoCAP test. SDS-PAGE and immunoblotting were also performed with peanut, walnut and soybean protein extracts and relevant sera. RESULTS: Peanut specific IgE was inhibited up to 20% and 26% by walnut and soybean protein extracts, respectively. In reverse, walnut and soybean specific IgE were inhibited up to 21% and 23% by peanut protein extracts, respectively. In the immunoblot analysis, pooled serum from the subjects with peanut specific IgE antibodies reacted with walnut protein extracts significantly. CONCLUSION: Although the clinical significance of the cross-reactivity of peanut specific IgE with walnut and soybean protein extracts has not been established, we believe that individuals who are allergic to peanuts need to be cautious about consuming walnuts and soybeans</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.04.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27726958">PM:27726958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161011-KimMN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161011-KimMN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Kim MN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.04.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tosca,M.A.</style></author><author><style face="normal" font="Arial"> Silvestri,M.</style></author><author><style face="normal" font="Arial"> Olcese,R.</style></author><author><style face="normal" font="Arial"> Sacco,O.</style></author><author><style face="normal" font="Arial"> Pistorio,A.</style></author><author><style face="normal" font="Arial"> Rossi,G.A.</style></author><author><style face="normal" font="Arial"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Pulmonology, Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-specific IgE to food molecular components and age: From early childhood to adulthood</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="92" start="87">87-92</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Bos d 8</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gal d 2</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Respiratory allergy is characterised by an IgE-mediated reaction. The immune system functions, including IgE production, progressively decline over time with growing up and ageing. Molecular-based allergy diagnostic defines sensitisation profile. This study aimed to evaluate the impact of age on serum allergen-specific IgE to molecular component levels in a large sample of subjects. METHODS: Serum IgE to: rCor a11, rPru p3, nJug r3, rAra h8, rGly m4, rCor a8, nPen m1, nAct d8, Bos d 8, and nGal d2 were assessed by ISAC method. Sera from 2795 patients, 1234 males (44.1%) and 1561 females (55.9%), median age 23 years (1st and 3rd quartiles: 9.7-43.7 years; age range: 1 month-103 years) were analysed. RESULTS: The number of positive tests (i.e. sensitisation) tended to increase between birth and school-age until young adulthood and then decreased. A similar age-dependent trend was observed considering the levels of each allergen components: the levels of each allergen component tended to increase until early adulthood, but Gal d 2 and Bos d 8 (rapidly diminishing), and then to decrease over time. However, the pattern is significantly dependent on each single tested food. CONCLUSIONS: Allergen-specific IgE production to food molecular components tend to reduce with ageing, but with differences between allergens. This phenomenon should be adequately evaluated managing allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161010IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27720248">PM:27720248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161010-ToscaMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161010-ToscaMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Tosca MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.06.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Echeverria-Zudaire,L.A.</style></author><author><style face="normal" font="Arial"> Fernandez-Fernandez,S.</style></author><author><style face="normal" font="Arial"> Rayo-Fernandez,A.</style></author><author><style face="normal" font="Arial"> Munoz-Archidona,C.</style></author><author><style face="normal" font="Arial"> Checa-Rodriguez,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy Unit, Severo Ochoa Universitary Hospital, Leganes, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Primary eosinophilic gastrointestinal disorders in children who have received food oral immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="536" start="531">531-536</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disorders</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2016">2016/8/31</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food oral immunotherapy (OIT) involves the administration of the food allergen causing the symptoms, in order to induce tolerance. Primary eosinophilic gastrointestinal disorders (PEGDs) are characterised by an eosinophil-rich inflammation affecting different locations of the digestive tract. We present a series of patients with PEGDs in a group of children following OIT with milk and/or egg. MATERIAL AND METHODS: A prospective study during the period 2006-2014 was performed in paediatric patients subjected to OIT with milk and/or egg. When these children present persistent gastrointestinal symptoms, they are referred to the Paediatric Gastroenterology Unit for evaluation. RESULTS: Primary eosinophilic gastrointestinal disorders were diagnosed in eight of the 128 cases of OIT (6.25%). The time to PEGDs development was variable: two cases showed symptoms during OIT, and the rest with a median time of 29 months (15-48 months). Food treatment discontinuation was not required in four of the five cases of eosinophilic oesophagitis, although food removal was necessary in patients with eosinophilic gastroenteritis. CONCLUSIONS: We report the highest prevalence of PEGDs in children subjected to OIT, and the first cases of eosinophilic gastroenteritis following food OIT. The monitoring of new digestive signs and symptoms after OIT is crucial for the diagnosis of these disorders, and prolonged follow-up is required. The management of such patients and the need or not to eliminate the food should be assessed on an individualised basis, according to the severity of the condition, its evolution and response to different treatment alternatives</style></abstract><notes><style face="normal" font="Arial">DA - 20160904IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.05.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27592279">PM:27592279</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2016-44-531-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2016-44-531-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160904, Echeverria-Zudaire LA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.05.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,X.</style></author><author><style face="normal" font="Arial"> Sheng,H.</style></author><author><style face="normal" font="Arial"> Ma,R.</style></author><author><style face="normal" font="Arial"> Gao,Z.</style></author><author><style face="normal" font="Arial"> Han,Z.</style></author><author><style face="normal" font="Arial"> Chi,F.</style></author><author><style face="normal" font="Arial"> Cong,N.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Luo,X.</style></author><author><style face="normal" font="Arial"> Yu,J.</style></author><author><style face="normal" font="Arial"> Ra,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otology and Skull Base Surgery, Eye Ear Nose &amp; Throat Hospital, Fudan University, Shanghai 200031, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergic rhinitis and allergy are risk factors for otitis media with effusion: A meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="32" start="25">25-32</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otitis</style></keyword><keyword><style face="normal" font="Arial"> Otitis Media</style></keyword><keyword><style face="normal" font="Arial"> Otitis Media with Effusion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Skull</style></keyword><keyword><style face="normal" font="Arial"> Skull Base</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE/HYPOTHESIS: We systematically reviewed the associations between allergic rhinitis or allergy and otitis media with effusion, by reference to published data. STUDY DESIGN: A meta-analysis of case-controlled studies. DATA SOURCE: Five databases (Pubmed, Highwire, Medline, Wanfang, and China National Knowledge Infrastructure) were searched for relevant studies in the English language published prior to November 12, 2015. STUDIES CHOSEN: Studies with clearly defined experimental and control groups, in which the experimental groups had otitis media with effusion together with allergic rhinitis or allergy, were selected. METHODS: We performed a meta-analysis on data from the identified cross-sectional and case-controlled studies using fixed- or random-effects models (depending on heterogeneity). We used Reviewer Manager 5.3 software to this end. RESULTS: Seven studies met the inclusion criteria. The prevalence of allergic rhinitis in patients with otitis media with effusion and the control groups differed significantly in three studies (P&lt;0.00001), as did the prevalence of allergy (in six studies; P=0.003). CONCLUSION: Allergic rhinitis and allergy appear to be risk factors for otitis media with effusion</style></abstract><notes><style face="normal" font="Arial">DA - 20161010IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27720440">PM:27720440</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161010-ChenX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161010-ChenX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Cheng X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.03.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mavroudi,A.</style></author><author><style face="normal" font="Arial"> Karagiannidou,A.</style></author><author><style face="normal" font="Arial"> Xinias,I.</style></author><author><style face="normal" font="Arial"> Cassimos,D.</style></author><author><style face="normal" font="Arial"> Karantaglis,N.</style></author><author><style face="normal" font="Arial"> Farmaki,E.</style></author><author><style face="normal" font="Arial"> Imvrios,G.</style></author><author><style face="normal" font="Arial"> Fotoulaki,M.</style></author><author><style face="normal" font="Arial"> Eboriadou,M.</style></author><author><style face="normal" font="Arial"> Tsanakas,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit of the 3rd Pediatric Department, Aristotle University of Thessaloniki, Greece.</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of IgE-mediated food allergies in children with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="81" start="77">77-81</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is an inflammatory disease of the skin, which is characterised by a chronic relapsing course. AIM: The aim of the study was to assign the prevalence of clinically active food allergies among a group of children between 3 months and 7 years of age, with AD. METHODS: Eighty-eight children with AD were screened for specific IgE antibodies to food proteins. All patients with AD and specific IgE antibodies to food proteins were subjected to Oral Food Challenges (OFCs) with the relevant foods. RESULTS: Food-sensitised patients with moderate levels of sIgE had clinically active food allergy to milk (39.28%) and egg (42.34%) on the basis of positive OFCs. High IgE and eosinophilia had a prevalence of almost 80% and 25%, regardless of concomitant food sensitisation and disease severity. CONCLUSIONS: In this study, clinically active food allergies were recognised in 26.13% of children with AD. Nevertheless, no association was confirmed between food sensitisation and AD severity. High IgE and peripheral eosinophilia have not been found more prevalent among children with severe AD nor among children with food sensitisation. Infants and younger children with AD should be screened for an underlying food allergy, regardless of disease severity</style></abstract><notes><style face="normal" font="Arial">DA - 20161008IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27717723">PM:27717723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161008-MavroudiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161008-MavroudiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161008, Mavroudi A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tagawa,Y.</style></author><author><style face="normal" font="Arial"> Namba,K.</style></author><author><style face="normal" font="Arial"> Nakazono,Y.</style></author><author><style face="normal" font="Arial"> Iwata,D.</style></author><author><style face="normal" font="Arial"> Ishida,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="343" start="338">338-343</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmic solution</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> tear</style></keyword><keyword><style face="normal" font="Arial"> Tears</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The efficacy of epinastine 0.05% ophthalmic solution for pollen allergic conjunctivitis has already been shown in a conjunctival allergen challenge (CAC) test using cedar pollen as a challenge. The present study investigated the efficacy of this solution against birch pollen conjunctivitis in a CAC test. METHODS: Ten adult subjects (eight males and two females) with asymptomatic birch pollen conjunctivitis were enrolled in this study. The average age of the subjects was 41.1 years. This study was conducted during a period without birch pollen dispersion. In each subject, the epinastine 0.05% ophthalmic solution was instilled in one eye, and an artificial tear fluid was instilled in the fellow eye in a double-blind manner. Five minutes or 4 h after the drug instillation, both eyes were challenged with an optimal concentration of birch pollen, and ocular itching and conjunctival hyperemia were then graded. Tears were collected before the drug instillation and 20 min after the pollen challenge, and the histamine level was measured. RESULTS: The ocular itching scores and palpebral conjunctival hyperemia scores of the epinastine-treated eyes were significantly lower than those of the contralateral control eyes when the eyes were pretreated with the drug 4 h before the CAC. There was a significant correlation between the tear histamine level and mean ocular itching score of three time points (3, 5 and 10 min) following the CAC in the control eyes but not the epinastine-treated eyes. CONCLUSIONS: Epinastine is effective in suppressing ocular itching and conjunctival hyperemia in birch pollen conjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20161010IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27720602">PM:27720602</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20161010-TagawaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20161010-TagawaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Tagawa Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de la Varga Martinez,R.</style></author><author><style face="normal" font="Arial"> Gutierrez,F.D.</style></author><author><style face="normal" font="Arial"> Foncubierta,F.A.</style></author><author><style face="normal" font="Arial"> Andres Garcia,J.A.</style></author><author><style face="normal" font="Arial"> Medina,V.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unidad de Investigacion, Area de investigacion clinica en Inmunologia y Reumatologia, Hospital Universitario Puerta del Mar, Cadiz, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Rapid subcutaneous desensitization for treatment of hypersensitivity reactions to etanercept in two patients with positive basophil activation test</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="359" start="357">357-359</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161026IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - ENGPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.09.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27780662">PM:27780662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20161026-delaVargaMartinezR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20161026-delaVargaMartinezR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161026, de la Varga Martinez R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.09.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,X.Y.</style></author><author><style face="normal" font="Arial"> Xu,L.Z.</style></author><author><style face="normal" font="Arial"> Luo,X.Q.</style></author><author><style face="normal" font="Arial"> Geng,X.R.</style></author><author><style face="normal" font="Arial"> Liu,Z.Q.</style></author><author><style face="normal" font="Arial"> Yang,L.T.</style></author><author><style face="normal" font="Arial"> Yang,G.</style></author><author><style face="normal" font="Arial"> Chen,S.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Li,H.B.</style></author><author><style face="normal" font="Arial"> Yang,L.T.</style></author><author><style face="normal" font="Arial"> Luan,T.G.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Life Science &amp; College of Oceanography, Sun Yat-sen University, Guangzhou, 510275, China</style></auth-address><titles><title><style face="normal" font="Arial">Forkhead box protein-3 (Foxp3)-producing dendritic cells suppress allergic response</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="917" start="908">908-917</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> chromatin immunoprecipitation</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> forkhead box protein 3</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunoprecipitation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal enterotoxin B</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The generation of the tolerogenic dendritic cells (DC) is not fully understood yet. Forkhead box protein-3 (Foxp3) is an important molecule in the immune tolerance. This study tests a hypothesis that DCs express Foxp3, which can be up regulated by Staphylococcal enterotoxin B (SEB). METHODS: The expression of Foxp3 by DCs was evaluated by real time RT-PCR, Western blotting, flow cytometry and chromatin immunoprecipitation assay. RESULTS: We observed that mice treated with SEB at 0.25-0.5 mug/mouse showed high frequencies of transforming growth factor (TGF)-beta-producing CD4+ T cells and TGF-beta-producing DCs in the intestine, while the IL-4+ CD4+ T cells and TIM4+ DCs were dominated in the intestine in mice treated with SEB at 1-10 mug/mouse. Treating DCs with SEB in the culture induced high levels of Foxp3 at the TGF-beta promoter locus. The function of Foxp3 was blocked by STAT6 (Signal transducer and activator transcription-6); the latter was induced by exposing DCs to SEB in the culture at doses of 100-400 ng/ml. Treating allergic mice with specific immunotherapy (SIT) together with SEB significantly promoted the therapeutic effects on the allergic responses than treating with SIT alone. CONCLUSION: DCs have the capacity to express Foxp3, which can be up regulated by exposure to SEB. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13088</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27861999">PM:27861999</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161118-LiuXY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161118-LiuXY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Liu XY</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13088</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ishibashi,O.</style></author><author><style face="normal" font="Arial"> Sakuragi,K.</style></author><author><style face="normal" font="Arial"> Fukutomi,Y.</style></author><author><style face="normal" font="Arial"> Kawakami,Y.</style></author><author><style face="normal" font="Arial"> Kamata,Y.</style></author><author><style face="normal" font="Arial"> Sakurai,M.</style></author><author><style face="normal" font="Arial"> Nakayama,S.</style></author><author><style face="normal" font="Arial"> Uchiyama,H.</style></author><author><style face="normal" font="Arial"> Kobayashi,H.</style></author><author><style face="normal" font="Arial"> Kojima,H.</style></author><author><style face="normal" font="Arial"> Inui,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Sakai, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Lip b 1 is a novel allergenic protein isolated from the booklouse, Liposcelis bostrychophila</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="926" start="928">928-926</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Books</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> glutathione S transferase</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Isoelectric Point</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lip</style></keyword><keyword><style face="normal" font="Arial"> Lip b 1</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptome analysis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Booklice, belonging to the order Psocoptera, are small household insect pests that are distributed worldwide. Liposcelis bostrychophila (L. bostrychophila), a common home-inhabiting species of booklouse, infests old books, sheets of paper and stored food. Recent entomological and serological studies demonstrated that L. bostrychophila accounted for the majority of detectable insects in house dust and could be a potent inducer of respiratory allergy. Our recent proteomic analysis identified a potent allergenic protein from L. bostrychophila, designated Lip b 1, and determined its partial amino acid sequences. METHODS: Cloning of cDNAs for Lip b 1 was performed by large-scale transcriptome analysis (RNA-seq) and subsequent reverse transcription polymerase chain reaction. The full-length amino acid sequences deduced from Lip b 1 cDNAs were bioinformatically analyzed. The recombinant proteins of glutathione-S-transferase (GST)-fused Lip b 1 were analyzed by Western blot and enzyme-linked immunosorbent assay. RESULTS: Lip b 1 cDNAs encoding two types of 254-amino acid proteins were cloned. The clones shared 87% identity, and the deduced molecular weights and isoelectric points were consistent with those determined in our previous study. The two types of Lip b 1 proteins in the GST-fused form were similarly reactive with sera from allergic patients sensitized with L. bostrychophila. CONCLUSIONS: Lip b 1 is a novel protein possibly causing booklouse allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13091</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27873335">PM:27873335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161122-IshibashiO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161122-IshibashiO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Ishibashi O</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13091</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaplan,A.P.</style></author><author><style face="normal" font="Arial"> Gimenez-Arnau,A.M.</style></author><author><style face="normal" font="Arial"> Saini,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, , Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms of Action That Contribute to Efficacy of Omalizumab in Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="533" start="519">519-533</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> autoantigen</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcepsilonRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcepsilonRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically "abnormal" IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13083</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27861988">PM:27861988</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161118-KaplanAP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161118-KaplanAP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Kaplan AP</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13083</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pfaar,O.</style></author><author><style face="normal" font="Arial"> Bastl,K.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Buters,J.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Clot,B.</style></author><author><style face="normal" font="Arial"> Darsow,U.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author><author><style face="normal" font="Arial"> Gehrig,R.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Jacobsen,L.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Sofiev,M.</style></author><author><style face="normal" font="Arial"> Thibaudon,M.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, Universitatsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI Position Paper</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="722" start="713">713-722</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Clinical efficacy of pollen allergen immunotherapy has been broadly documented in randomized controlled trials. The underlying clinical endpoints are analysed in seasonal time periods pre-defined on the basis of the background pollen concentration. However, any validated or generally accepted definition from academia or regulatory authorities for this relevant pollen-exposure intensity or period of time (season) is currently not available. Therefore, this Task Force initiative of the European Academy of Allergy and Clinical Immunology (EAACI) aimed to propose definitions based on expert-consensus. METHODS: A Task Force of the Immunotherapy and Aerobiology and Pollution Interest Groups of the EAACI reviewed the literature on pollen-exposure in the context of defining relevant time intervals for evaluation of efficacy in allergen immunotherapy trials. Underlying principles in measuring pollen exposure and associated methodological problems and limitations were considered in order to achieve a consensus. RESULTS: The Task Force achieved a comprehensive position in defining pollen exposure times for different pollen types. Definitions are presented for 'pollen season', 'high pollen season' (or 'Peak pollen period') and 'high pollen days'. CONCLUSION: This EAACI position paper provides definitions of pollen exposures for different pollen types for use in Allergen Immunotherapy trials. Their validity as standards remains to be tested in future studies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Austria -CO - United Kingdom -CO - Switzerland -CO - France -CO - Spain -CO - Netherlands -CO - Denmark -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27874202">PM:27874202</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161122-PfaarO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161122-PfaarO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Pfaar O</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13092</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Molinari,N.</style></author><author><style face="normal" font="Arial"> Bruel,S.</style></author><author><style face="normal" font="Arial"> Bourrain,J.L.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Aubas,P.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sirio Libanes, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Field-testing the new anaphylaxis' classification for the who International Classification of Diseases (ICD)-11 revision</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="826" start="820">820-826</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> ICD-10</style></keyword><keyword><style face="normal" font="Arial"> ICD-11</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inpatients</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality assurance</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In order to consolidate the new classification model addressed to the allergic and hypersensitivity conditions according to the International Classification of Diseases (ICD)-11 revision timeline, we here propose real-life application of quality assurance methodology to evaluate sensitivity and accuracy of the "Anaphylaxis" subsection. METHODS: We applied field-testing methodology by analyzing all the consecutive inpatients' files documented as allergies from the University Hospital of Montpellier electronic database for the period of one year. The files clinically validated as being anaphylaxis were manually blind-coded under ICD-10 and current ICD-11 beta draft. The correspondence of coding and the impressions regarding sensibility were evaluated. RESULTS: From all 2,318 files related to allergic or hypersensitivity conditions, 673 had some of the anaphylaxis ICD-10 codes; 309 files (46%) from 209 patients had anaphylaxis and allergic or hypersensitivity comorbidities description. The correspondence between the two coders was perfect for 162 codes from all 309 entities (52.4%) (Cohen-kappa value 0.63) with the ICD-10 and for 221 codes (71.5%) (Cohen-kappa value 0.77) with the ICD-11. There was a high agreement regarding sensibility of the ICD-11 usability (Cohen-kappa value 0.75). CONCLUSION: We here propose the first attempt of real-life application to validate the new ICD-11 "Anaphylaxis" subsection. Clearer was the improvement of accuracy reaching 71.5% of agreement when ICD-11 was used. By allowing all the relevant diagnostic terms for anaphylaxis to be included into the ICD-11 framework, WHO has recognized their importance not only to clinicians but also to epidemiologists, statisticians, health care planners and other stakeholders. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - France -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13093</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27874204">PM:27874204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161122-TannoLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161122-TannoLK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13093</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,H.B.</style></author><author><style face="normal" font="Arial"> Akuthota,P.</style></author><author><style face="normal" font="Arial"> Kanaoka,Y.</style></author><author><style face="normal" font="Arial"> Weller,P.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Inflammation, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Airway Eosinophil Migration into Lymph Nodes in Mice Depends on Leukotriene C4</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="936" start="927">927-936</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> CCL19</style></keyword><keyword><style face="normal" font="Arial"> CCR7</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene C4</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> traffic</style></keyword><keyword><style face="normal" font="Arial"> trafficking</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We previously demonstrated in mice that airway eosinophils traffic from the airway lumen into lung-draining paratracheal lymph nodes. However, mechanisms whereby eosinophils traverse from the lungs and home to paratracheal lymph nodes remain unclear. We investigated roles of cysteinyl leukotrienes in mediating eosinophil trafficking from lungs to paratracheal lymph nodes. METHODS: The expression of CCR7 was determined by flow cytometry. Transwell assays were used to test chemotactic responses of leukotriene C4 synthase-deficient and control airway eosinophils to the chemokine CCL19 ex vivo. Eosinophils from the spleens of IL-5 transgenic mice, fluorescently labeled ex vivo, were intratracheally injected into ovalbumin-sensitized and ovalbumin-aerosol challenged leukotriene C4 synthase-deficient and control mice. Eosinophils were identified by microscopy and flow cytometry in the lungs and paratracheal lymph nodes. RESULTS: Mouse eosinophils expressed CCR7, the receptor for CCL19, and responded chemotactically to CCL19. Leukotriene C4 synthase-deficient eosinophils exhibited impaired chemotaxis to CCL19 that was restored by exogenous leukotriene C4 . The migration of intratracheally-injected eosinophils into paratracheal lymph nodes from distal alveolar lung was diminished in leukotriene C4 synthase-deficient mice compared to wild-type mice, with increased retention of eosinophils in the lungs of leukotriene C4 synthase-deficient mice. Exogenous administration of leukotriene C4 restored trafficking of eosinophils to paratracheal lymph nodes in leukotriene C4 synthase-deficient mice. CONCLUSIONS: Our findings that cysteinyl leukotrienes are involved in regulating airway and lung eosinophil migration into paratracheal lymph nodes identify previously unrecognized roles for the cysteinyl leukotrienes in regulating the pulmonary trafficking of eosinophils in experimental allergic asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27874209">PM:27874209</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161122-WangHB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161122-WangHB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Wang HB</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13094</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bossuyt,X.</style></author><author><style face="normal" font="Arial"> Van Hoeyveld,E.</style></author><author><style face="normal" font="Arial"> Ceuppens,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory Medicine, University Hospitals, KU Leuven, Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">Value-added reporting of specific IgE</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="1644">1644-</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - LETTERCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.12981</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27714881">PM:27714881</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\2016-71-1644.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\2016-71-1644.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Bossuyt X</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.12981</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Vidal,C.</style></author><author><style face="normal" font="Arial"> Rodriguez del Rio,P.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Tabar,A.I.</style></author><author><style face="normal" font="Arial"> Sanchez-MacHin,I.</style></author><author><style face="normal" font="Arial"> Bubel,P.</style></author><author><style face="normal" font="Arial"> Borja,J.</style></author><author><style face="normal" font="Arial"> Eberle,P.</style></author><author><style face="normal" font="Arial"> Reiber,R.</style></author><author><style face="normal" font="Arial"> Bouvier,M.</style></author><author><style face="normal" font="Arial"> Lepelliez,A.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Royal Brompton Hospital, London, UK.</style></auth-address><titles><title><style face="normal" font="Arial">European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a Real-Life Clinical Assessment</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="472" start="462">462-472</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Up-dosing</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Outside clinical trials, data on systemic reactions (SRs) due to allergen immunotherapy (AIT) are scarce. METHODS: A prospective, longitudinal, web-based survey of "real-life" respiratory allergen immunotherapy (AIT) clinical practice was conducted in France, Germany and Spain. SRs were recorded and coded according to the Medical Dictionary for Regulatory Activities (MedDRA) and risk factors associated with SRs were identified. RESULTS: A total of 4,316 patients (corresponding to 4,363 ongoing courses of AIT) were included. 109 SRs were recorded, and 90 patients (2.1%) presented at least one SR. Most of the SRs occurred in subcutaneous allergen immunotherapy (SCIT) (89%, n=97). The most frequently reported symptoms were urticaria, rhinitis, dyspnoea and cough. Respiratory symptoms appeared before skin symptoms. Most SRs occurred during the up-dosing phase (75.8%) and were mild in severity (71.6%). Intramuscular adrenaline was administered in 17 SRs but only 65% of these were subsequently classified as anaphylaxis. Independent risk factors for SRs during SCIT were: the use of natural extracts (odds ratio (OR) [95% confidence interval (CI)]=2.74 [1.61-4.87]; p=0.001), the absence of symptomatic allergy medications (1.707 [1.008-2.892], p=0.047), asthma diagnosis (1.74 [1.05-2.88], p=0.03), sensitization to animal dander (1.93 [1.21-3.09]; p=0.006) or pollen (1.16 [1.03-1.30]; p=0.012), and cluster regimens (vs. rush) (4.18 [1.21-14.37]; p=0.023). A previous episode of anaphylaxis increased the risk for anaphylaxis in SCIT (OR [95%CI]=17.35 [1.91-157.28]; p=0.01). CONCLUSION: AIT for respiratory allergy is safe, with a low number of SRs observed in real-life clinical practice. A personalized analysis of risk factors could be used to minimize SRs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161008IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -CO - France -CO - Spain -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13066</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27718250">PM:27718250</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161008-CalderonMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161008-CalderonMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161008, Calderon MA</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13066</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stemeseder,T.</style></author><author><style face="normal" font="Arial"> Klinglmayr,E.</style></author><author><style face="normal" font="Arial"> Moser,S.</style></author><author><style face="normal" font="Arial"> Lueftenegger,L.</style></author><author><style face="normal" font="Arial"> Lang,R.</style></author><author><style face="normal" font="Arial"> Himly,M.</style></author><author><style face="normal" font="Arial"> Oostingh,G.J.</style></author><author><style face="normal" font="Arial"> Zumbach,J.</style></author><author><style face="normal" font="Arial"> Bathke,A.C.</style></author><author><style face="normal" font="Arial"> Hawranek,T.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Cross-sectional study on allergic sensitization of Austrian adolescents using molecule-based IgE profiling</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="763" start="754">754-763</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Pla l 1</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Pupil</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Type I allergy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen specific IgE antibodies are a hallmark of type I allergy. The aim of this cross-sectional study was to analyze the sensitization profiles of an Austrian adolescent population utilizing molecule-based IgE diagnosis. METHODS: Serum samples of 501 non-selected pupils from Salzburg, Austria, were tested in ImmunoCAP ISAC(R) for IgE reactivity to 112 single allergens. Sensitization profiles were assessed and statistically coordinated with reported allergies. RESULTS: In the population aged 12-21 years, 53.5% showed IgE reactivity to at least one allergen tested. The highest prevalence was found for Phl p 1 from grass pollen (26.5%), group 2 mite allergens (18.2%), Bet v 1 from birch pollen (16.3%) and Fel d 1 from cat (14.4%). The majority of participants showed a complex sensitization profile and reacted on average to 9 allergens. Pollen sensitization was highly prevalent (41.7%) and mainly driven by group I grass and PR-10 allergens of the birch family, while Pla l 1 represented the most relevant weed. Diagnosed and self-reported allergies were noted in 21.8% and 55.5% of participants, respectively and correlated well with in vitro results. Among atopic individuals, 71.4% reported to suffer from at least one allergy; concordance was found for grass and cat sensitization while venom and weed pollen positive individuals were frequently asymptomatic. CONCLUSIONS: More than half of the tested adolescent population had already established an atopic status presenting a complex IgE reactivity profile dominated by pollen sensitization. Detailed molecule-based analysis allows determining relevant biomarkers and monitoring of the atopic status in populations. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161018IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27753449">PM:27753449</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161018-StemesederT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161018-StemesederT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161018, Stemeseder T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13071</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bieber,T.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Broich,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Christine Kuhne-Center for Allergy Research and Education, University Medical Center, Bonn, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">New opportunities and challenges in the assessment of drugs for atopic diseases</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1665" start="1662">1662-1665</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Communicable Diseases</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> paradigm shift</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="Arial">Atopic conditions (atopic dermatitis, rhinitis and asthma) belong to the most common non communicable diseases and are driven by chronic inflammatory reactions. They have a strong impact on the quality of life and represent a substantial and growing socio-economic burden. Interestingly, there is an increasing interest in the development of new therapeutic options with a number of biologics and small molecules targeting potential key mechanisms in atopic conditions. However, besides the safety issue, most of the new active substances are still evaluated according to the traditional efficacy paradigm focusing on the success in treating exacerbations and flares. Instead, the future approaches in drug development and assessment should rather concentrate on the long term control of these diseases and consider their potential as disease modifying strategies in the era of precision medicine. To reach this goal, a number of unsolved issues have to be addressed and consensually accepted by the stakeholders in this field. Thus, a successful and rapid development of new treatments requests a paradigm shift and a new way of thinking in the mind of physicians, pharmaceutical industry, regulators and HTAs. This seems mandatory in order to optimize drug development and to facilitate the accessibility of new therapies to the growing population of patients suffering from atopic conditions on a global level. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27716946">PM:27716946</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161007-BieberT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161007-BieberT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Bieber T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Killingbeck,S.S.</style></author><author><style face="normal" font="Arial"> Ge,M.Q.</style></author><author><style face="normal" font="Arial"> Haczku,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of California, Davis</style></auth-address><titles><title><style face="normal" font="Arial">Patching it together: Epicutaneous vaccination with heat labile Escherichia coli toxin against birch pollen allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="8" start="5">5-8</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blocking IgG</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Immunotherapy has been employed with great success in the form of vaccination to combat viral, bacterial, and parasitic infection. In this issue of Allergy, Cabauatan et al. describe a novel method of allergen specific immunotherapy using epicutaneous patch vaccination with the recombinant birch pollen antigen Bet v 1 in combination with a heat-labile Escherichia coli toxin (LT) as adjuvant. Patch vaccination with rBet v 1 + LT augmented production of IgG instead of IgE antibodies, inhibiting rBet v 1 sensitization in outbred guinea pigs. Sera from these animals blocked allergen binding to IgE derived from allergic patients. This study represents a novel approach to elicit allergen-specific blocking IgG antibodies. Epicutaneous patch vaccination is a safe, standardized, needle-free approach. Further research into this and other strategies is warranted to improve our current vaccine paradigms in order to better protect against allergic disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - EDITORIALCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13064</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27716934">PM:27716934</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161007-KillingbeckSS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161007-KillingbeckSS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Killingbeck SS</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13064</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zellweger,F.</style></author><author><style face="normal" font="Arial"> Eggel,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">IgE-associated allergic disorders: Recent advances in etiology, diagnosis and treatment</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1661" start="1652">1652-1661</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="10" Year="2016">2016/10/6</year></dates><abstract><style face="normal" font="Arial">IgE-associated allergic diseases belong to the most common inflammatory conditions. Their clinical manifestation ranges from mild symptoms to life-threatening episodes. Often patients experience a reduction in physical and psychologic well-being and suffer from a decreased quality-of-life due to disease activity. The continuously rising number of people that are affected by an allergic condition indicates an urgent need for better diagnostics and more efficient treatment options. Recent progress in the understanding of pathophysiologic mechanisms underlying IgE-associated allergic disorders have led to the identification of novel therapeutic targets and the development of drug candidates that are currently under evaluation. In this review, we highlight studies and clinical trials, which have helped to gain further insight in the etiology of IgE-associated allergic conditions as well as advances in the development of diagnostic tools and therapeutic approaches recently published in the European Journal of Allergy and Clinical Immunology. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161006IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13059</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27709638">PM:27709638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161006-ZellwegerF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161006-ZellwegerF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161006, Zellweger F</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13059</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Hamilton,R.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergie- u. Asthma-Zentrum Westend, Spandauer Damm 130, Haus 9, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Cashew Allergy Risks, 2S albumins, and Predictions based on IgE Antibody Levels</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="518" start="515">515-518</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> 2S Albumins</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergie</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Ana o 3</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Cashew allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Positive oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We read with great interest the report of Lange et al (1) that studied cashew allergic children and the potential predictive value of cashew 2S albumin storage protein (Ana o 3)-specific IgE measurements in determining the need for an oral cashew challenge to prove disease. They report that IgE antibody levels >2 kUA /l to Ana o 3 improved their prediction (95% probability) of a positive oral food challenge after cashew consumption in comparison to IgE against the whole cashew extract. In other words, increased analytical specificity of molecular Ana o 3-specific IgE testing (2) reportedly translates into an improved diagnostic efficacy and a superior prediction for a positive oral cashew challenge. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - EditorialCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27859359">PM:27859359</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161118-KleineTebbeJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161118-KleineTebbeJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Kleine-Tebbe J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13084</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahmet,A.</style></author><author><style face="normal" font="Arial"> Benchimol,E.I.</style></author><author><style face="normal" font="Arial"> Goldbloom,E.B.</style></author><author><style face="normal" font="Arial"> Barkey,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Endocrinology, Children's Hospital of Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="49">49-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenocorticotropic Hormone</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Endocrinology</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid therapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Adrenal suppression (AS), a glucocorticoid (GC) side effect associated with significant morbidity, is well described related to inhaled corticosteroid therapy for asthma. Swallowed topical glucocorticoid therapy is the main pharmacotherapy treatment for eosinophilic esophagitis (EoE) and therefore children with EoE are potentially at increased risk of AS. METHODS: In this prospective cohort study, we included children and youth &lt;18 years diagnosed with EoE and treated with swallowed fluticasone or oral viscous budesonide for more than 1 month. First morning cortisol and low dose adrenocorticotropic hormone stimulation test (LDST) were performed 2 weeks following GC discontinuation. AS was defined as an abnormal LDST result (cortisol peak &lt;500 nmol/L). We determined the prevalence and duration of AS related to swallowed topical GC therapy in EoE by LDST, as well as the diagnostic accuracy of first morning cortisol compared to LDST. RESULTS: Of 29 participants enrolled, 26 (89.7 %) received oral viscous budesonide and 3 (10.3 %) received swallowed fluticasone. Nineteen (65.5 %) participants had AS. Median duration of AS was 43 weeks. Five (17.2 %) participants had persistent AS at 12 months. There were no identifiable risk factors for the development of AS. First morning cortisol was highly specific but had poor sensitivity for detection of AS. CONCLUSIONS: The majority of children with EoE had AS after discontinuation of swallowed topical GC therapy. Stress steroids should be considered in children treated with swallowed topical GC therapy for EoE, even after GC discontinuation, to prevent possible adrenal crisis</style></abstract><notes><style face="normal" font="Arial">DA - 20161021IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0154-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27766109">PM:27766109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161021, Ahmet A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0154-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sadakane,K.</style></author><author><style face="normal" font="Arial"> Ichinose,T.</style></author><author><style face="normal" font="Arial"> Nishikawa,M.</style></author><author><style face="normal" font="Arial"> Takano,H.</style></author><author><style face="normal" font="Arial"> Shibamoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Health Sciences, Oita University of Nursing and Health Sciences, Oita, 870-1201 Japan</style></auth-address><titles><title><style face="normal" font="Arial">Co-exposure to zymosan A and heat-inactivated Asian sand dust exacerbates ovalbumin-induced murine lung eosinophilia</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="48">48-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> ASD</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Asian sand dust</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Zymosan</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Epidemiological studies have implicated Asian sand dust (ASD) in the increased prevalence of respiratory disorders, including asthma. It has been observed that fungal elements such as beta-glucan can be adsorbed onto ASD. In the present study, the exacerbating effect of the combined exposure to zymosan A (ZymA) containing yeast beta-glucan and heat-inactivated ASD on ovalbumin (OVA)-induced murine lung eosinophilia was investigated. METHODS: BALB/c mice were repeatedly instilled intratracheally with one of eight immunogenic formulations consisting of various combinations of (1) ZymA, (2) ASD that was briefly heated to remove organic substances (H-ASD), and (3) OVA in normal saline, or each of the above alone. Pathologic changes, cytological alterations in bronchoalveolar lavage fluid (BALF), changes in inflammatory cytokines and chemokines in BALF, and OVA-specific IgE and IgG1 antibodies in serum were investigated. RESULTS: Exposure to ZymA with or without OVA had no effect on most indicators of lung inflammation. Exposure to H-ASD with OVA increased the recruitment of inflammatory cells to the lungs and the serum levels of OVA-specific IgE and IgG1. The combination OVA + ZymA + H-ASD induced a marked recruitment of eosinophils and upregulation of T helper 2 (Th2) cytokines (interleukin [IL]-4 and IL-13), IL-6, eotaxin/CCL11, and monocyte chemotactic protein (MCP)-3/CCL7 in BALF and OVA-specific IgE in serum. This treatment also induced the most severe pathological changes in the lungs of mice. ZymA was found to boost the effects of H-ASD, thereby exacerbating the OVA-induced allergic inflammation, even though ZymA alone did not have such effect. CONCLUSIONS: The results suggest that fungal elements such as beta-1,3-glucan aggravate the allergic inflammation caused by ASD. Our findings may facilitate prophylaxis of some allergic diseases in Asia</style></abstract><notes><style face="normal" font="Arial">DA - 20161021IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0153-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27766108">PM:27766108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161021, Sadakane K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0153-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ellis,A.K.</style></author><author><style face="normal" font="Arial"> Soliman,M.</style></author><author><style face="normal" font="Arial"> Steacy,L.M.</style></author><author><style face="normal" font="Arial"> Adams,D.E.</style></author><author><style face="normal" font="Arial"> Hobsbawn,B.</style></author><author><style face="normal" font="Arial"> Walker,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy &amp; Immunology, Department of Medicine, Queen's University, Kingston, ON Canada</style></auth-address><titles><title><style face="normal" font="Arial">Clinical validation of controlled exposure to birch pollen in the Environmental Exposure Unit (EEU)</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="53">53-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">airflow</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The Environmental Exposure Unit (EEU) in Kingston, Ontario, Canada is a controlled allergen challenge facility (CACF) that has been previously clinically validated for the use of ragweed and grass pollen in clinical studies. In this study we aim to validate the use of birch pollen to challenge allergic participants. METHODS: A total of 59 volunteers were screened and 38 birch allergic participants and ten non-allergics completed the study, outside of tree pollen season. Participants had to have a minimum of 2-year history of allergic rhinoconjunctivitis during the typical tree pollen season and have a positive skin prick test to birch allergen >/=5 mm from the control. Qualified participants were exposed to birch (Betula pendula) pollen for 4 h in the EEU and recorded their symptoms of sneezing, rhinorrhea, nasal congestion, nasal itch which comprised the total nasal symptom score (TNSS), as well as itchy/watery eyes, red/burning eyes and itching of ears/palate/throat which along with the TNSS comprised the total rhinoconjunctival symptom score (TRSS) along with Peak Nasal Inspiratory Flow (PNIF) at baseline and at 30 min intervals for the duration of exposure, then hourly for up to 12 h from the start of exposure. RESULTS: Allergic participants reported a gradual rise in TNSS and TRSS, reaching a mean and standard error of the mean of 7.08 +/- 0.45 and 11.58 +/- 0.93 respectively by 180 min from the start of exposure. Symptoms gradually declined to near baseline values following departing from the unit, reaching 1.9 and 2.7 by 450 min. Allergic participants reported significantly higher TNSS than non-allergics starting from 30 min (p &lt; 0.01, two-way ANOVA with Bonferroni corrections), maintaining maximum significance from 60 to 300 min (p &lt; 0.0001) and losing significance by 420 min. TRSS and PNIF followed similar trends as those seen with TNSS. Participants were phenotyped using previously published definitions using the TNSS into Early Phase Responders (EPR, 57.8 %), protracted EPR (pEPR, 39.5 %), and Dual Phase Responders (DPR, 2.7 %). CONCLUSIONS: The EEU can competently challenge birch allergic participants and achieve statistically significant changes in symptoms and nasal airflow, while such changes are not reported in non-allergic controls. Trial registration NCT02351830 clinicaltrials.gov</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0156-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27777594">PM:27777594</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Ellis AK</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0156-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kwan,A.</style></author><author><style face="normal" font="Arial"> Asper,M.</style></author><author><style face="normal" font="Arial"> Lavi,S.</style></author><author><style face="normal" font="Arial"> Lavine,E.</style></author><author><style face="normal" font="Arial"> Hummel,D.</style></author><author><style face="normal" font="Arial"> Upton,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Toronto, Toronto, ON Canada ; Department of Pediatrics, Division of Immunology and Allergy, The Hospital for Sick Children, Toronto, ON Canada</style></auth-address><titles><title><style face="normal" font="Arial">Prospective evaluation of testing with baked milk to predict safe ingestion of baked milk in unheated milk-allergic children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="54">54-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cow's milk allergy is one of the most common food allergies affecting young children. A subset of milk-allergic individuals can eat baked milk without allergic symptoms which is beneficial in terms of prognostication and liberalization of the diet. A retrospective study suggested that skin prick testing (SPT) with a baked milk (muffin) slurry may provide a sensitive means of predicting the outcome of a medically supervised baked milk oral food challenge. We evaluated the predictive value of SPT with baked milk to identify unheated milk-allergic children who are able to safely eat baked milk. METHODS: Children aged 2-16 years with a prior history of reaction to milk and a milk extract SPT of 8-14 mm were recruited. Investigator-blinded SPT to muffin slurry and powdered milk in triplicate and specific IgE (sIgE) to casein and milk were performed. Graded oral challenge to egg-free baked milk muffins (total 2.6 gm milk protein) was performed in the hospital. Reliability of tests was analyzed for intraclass correlation. Statistical significance for clinical characteristics of population and muffin testing versus baked milk reactivity was calculated with Fisher exact test for dichotomous and t-test for continuous variables. Wilcoxon rank sum test was used to compare immunological characteristics between individuals who tolerated or reacted to baked milk. Fitted predicted probability curves and ROC curves were generated. RESULTS: Thirty-eight children were consented and 30 met study criteria. The muffin SPT and casein sIgE were significantly different in those who passed versus failed baked milk challenge. Negative (&lt;3 mm) baked milk tests were found in 8/30 children (27 %) and were associated with non-reactivity to baked milk (p = 0.01) with a sensitivity of 1 (0.70-1.00). All children with negative SPT for baked milk passed the oral challenge. Specificity was 0.41 (0.19-0.67). The optimal decision point for the muffin SPT was 4 mm and the casein sIgE was 6 kU/L. The powdered milk test was not helpful. CONCLUSIONS: Skin prick testing with a baked milk (muffin) slurry may have a role in clinical practice to identify baked milk tolerance in milk-allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0162-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799957">PM:27799957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Kwan A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0162-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loo,E.X.</style></author><author><style face="normal" font="Arial"> Sim,J.Z.</style></author><author><style face="normal" font="Arial"> Goh,A.</style></author><author><style face="normal" font="Arial"> Teoh,O.H.</style></author><author><style face="normal" font="Arial"> Chan,Y.H.</style></author><author><style face="normal" font="Arial"> Saw,S.M.</style></author><author><style face="normal" font="Arial"> Kwek,K.</style></author><author><style face="normal" font="Arial"> Gluckman,P.D.</style></author><author><style face="normal" font="Arial"> Godfrey,K.M.</style></author><author><style face="normal" font="Arial"> van Bever,H.</style></author><author><style face="normal" font="Arial"> Chong,Y.S.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Kramer,M.S.</style></author><author><style face="normal" font="Arial"> Shek,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Predictors of allergen sensitization in Singapore children from birth to 3 years</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="56">56-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective birth cohort study</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Immune responses in allergic diseases begin with allergen sensitization, which usually occurs in childhood. Allergen sensitization involves a complex interplay of genetic and environmental factors, and sensitization patterns may change with age. OBJECTIVE: To determine the predictors of allergen sensitization in the first 3 years of life in the growing up in Singapore towards healthy outcomes (GUSTO) prospective birth cohort study. METHODS: Interviewers collected information on demographics, family history of allergy, social and lifestyle factors, and the child's health. We analyzed data from 849 children who completed skin prick testing (SPT) to inhalant allergens (house dust mites: Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Blomia tropicalis) and food allergens (egg, peanut and cow's milk) to assess risk factors for allergen sensitization at 18 months. To ensure that clinical phenotypes preceded allergen sensitization, we also analyzed data from 649 children who had a negative skin prick test at 18 months and completed skin prick testing at 36 months. RESULTS: We observed a significant association between eczema reported before 18 months and a positive SPT at 18 months [aOR 4.5 (1.9-10.7)]. Ninety-five (14.6 %) children with negative SPTs at 18 months developed positive tests at 36 months. Onset of eczema before 18 months was associated with an increased risk of new allergen sensitization at 36 months among children non-sensitized at 18 months [aOR 3.4 (1.2-9.3)]. An association was seen between wheeze reported before 18 months and new allergen sensitization at 36 months [aOR 3.2 (1.1-9.1)]. We found no significant association, however, between rhinitis reported before 18 months and new allergen sensitization at 36 months. CONCLUSIONS: Early onset of eczema and wheeze are risk factors for later allergen sensitization, suggesting a possible increased susceptibility to allergen exposure through an impaired skin barrier or defective airway epithelium. Trial registration NCT01174875 Registered 1 July 2010, retrospectively registered</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - New Zealand -CO - United KIngdom -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0161-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799959">PM:27799959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Loo EX</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0161-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schramm,A.</style></author><author><style face="normal" font="Arial"> Jasiewicz-Honkisz,B.</style></author><author><style face="normal" font="Arial"> Osmenda,G.</style></author><author><style face="normal" font="Arial"> Wilk,G.</style></author><author><style face="normal" font="Arial"> Siedlinski,M.</style></author><author><style face="normal" font="Arial"> Sagan,A.</style></author><author><style face="normal" font="Arial"> Matusik,P.T.</style></author><author><style face="normal" font="Arial"> Maciag,J.</style></author><author><style face="normal" font="Arial"> Sliwa,T.</style></author><author><style face="normal" font="Arial"> Czesnikiewicz-Guzik,M.</style></author><author><style face="normal" font="Arial"> Mikolajczyk,T.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Translational Medicine Laboratory, Department of Internal and Agricultural Medicine, School of Medicine, Jagiellonian University, Skarbowa 1, 31-121 Cracow, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Th17 responses are not altered by natural exposure to seasonal allergens in pollen-sensitive patients</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="55">55-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD8</style></keyword><keyword><style face="normal" font="Arial"> CD8 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> effector memory</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Memory cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergens</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis affects 10-30 % of the global population and this number is likely to increase in the forthcoming years. Moreover, it commonly co-exists with allergic asthma as a chronic allergic respiratory syndrome. While the involvement of Th2 cells in allergy is well understood, alterations of pro-inflammatory Th17 responses remain poorly characterized. The aim of our study was to determine whether natural seasonal allergen exposure causes changes in T cell subset characteristics in patients with allergic rhinitis and asthma. METHODS: Sixteen patients with allergic rhinitis/atopic asthma (9M, 7F; age 31.8 +/- 12.1) and 16 healthy controls were recruited into the study (9M, 7F; age 31.2 +/- 5.3). Blood samples were collected from the patients 1-3 months before pollen season (visit 1), within 7 days of the appearance of pollen/initiation of allergic symptoms (visit 2) and 2 weeks after visit 2 following the introduction of symptomatic treatment with antihistamines (visit 3). Flow cytometry was used to assess major T cell subsets (naive, central memory, effector memory and CD45RA+ effector) and key T cell cytokine production (IFNgamma, IL-17A, TNF and IL-4) using intracellular staining. Data were analyzed using repeated measures ANOVA and paired t test. RESULTS: As expected, an increase in the percentage of IL-4+ CD4+ cells was observed during natural pollen exposure in patients with allergic respiratory syndrome. No significant changes were observed in the production of other cytokines, including Th17 cells, which tended to be lower than in the control population but unchanged during pollen exposure. Introduction of antihistamine treatment led to only moderate changes in cytokine production from CD4 and CD8 T cells. Selective changes in CD8+ T cells were observed during natural pollen exposure including a decrease in transient cells (with features of CD45RA+ and CD45RO+ cells) and a decrease in the percentage of central memory cells in the peripheral circulation. Within the CD4 cell group the total percentage of CD45RA positive CD4 cells was increased during pollen exposure. CONCLUSIONS: Th1 and Th17 responses are not altered during pollen season but allergen exposure affects T cell activation and memory cell status in patients with allergic respiratory syndrome</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Poland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0157-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799958">PM:27799958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Schramm A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0157-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,M.A.</style></author><author><style face="normal" font="Arial"> Yoon,M.K.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary, Allergy, and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association of MBL With Work-Related Respiratory Symptoms in Bakery Workers</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="91" start="85">85-91</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baker's asthma</style></keyword><keyword><style face="normal" font="Arial"> Bakery</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> exon 1</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Genetic polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> Haplotypes</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated response</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lipopolysaccharides</style></keyword><keyword><style face="normal" font="Arial"> Mannose-Binding Lectin</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TaqMan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Baker's asthma is the most prevalent occupational asthma, and IgE-mediated response is known as a major pathogenesis. However, recent studies have suggested the involvement of innate immune response because wheat flour contains bacterial endotoxins or lipopolysaccharides. To further understand a role of innate immune response in the development of work-related respiratory symptoms (WRS) in bakery workers, we investigated mannose-binding lectin (MBL), one of the initiating components of the complement cascade in a single cohort of bakery workers. A total of 373 bakery workers completed a questionnaire regarding WRS. The bakery workers were divided into 2 groups according to previous history of allergic rhinitis (AR)/bronchial asthma (BA): those with history of AR/BA (group I) and those without (group II). We measured serum MBL levels by using enzyme-linked immunosorbant assay and genotyped 4 single nucleotide polymorphisms of the MBL2 gene (226G>A in exon 1, -554G>C, -431A>C, and -225G>C in the promoter) by using TaqMan assays. Fifty-nine subjects (15.5%) were previously diagnosed with AR/BA, and 64 subjects (16.8%) complained of WRS. No significant differences were found in serum MBL levels between groups I and II. However, in group II subjects, but not in group I subjects, the serum MBL levels were significantly higher in bakery workers with WRS than in those without. In addition, the serum MBL levels were significantly different according to genetic polymorphisms of the MBL2 gene and its haplotypes. In conclusion, serum MBL, affected by genetic polymorphisms, may be associated with WRS in bakery workers with no previous history of AR/BA</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.1.85</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826966">PM:27826966</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-85-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-85-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Kim MA</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.1.85</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perezabad,L.</style></author><author><style face="normal" font="Arial"> Reche,M.</style></author><author><style face="normal" font="Arial"> Valbuena,T.</style></author><author><style face="normal" font="Arial"> Lopez-Fandino,R.</style></author><author><style face="normal" font="Arial"> Molina,E.</style></author><author><style face="normal" font="Arial"> Lopez-Exposito,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Investigacion en Ciencias de la Alimentacion (CIAL) (CSIC-UAM), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Oral Food Desensitization in Children With IgE-Mediated Cow's Milk Allergy: Immunological Changes Underlying Desensitization</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="42" start="35">35-42</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE: This study aimed to evaluate the safety and efficacy to induce clinical desensitization to cow's milk (CM) of an oral immunotherapy (OIT) protocol in a pediatric population with cow's milk allergy (CMA). In addition, the immune responses against beta-casein, of peripheral blood mononuclear cells (PBMCs) from CMA patients, before and after the protocol were evaluated and compared to a nonallergic population. METHODS: A group of 20 children with IgE-mediated CMA and 15 nonallergic children were recruited. Allergic subjects underwent an OIT protocol based on weekly doses of commercial semi-skimmed ultra-high temperature treated (UHT) CM, followed by a maintenance phase. Immune profiles and changes in all subjects were investigated by measuring Th1, Th2, and Treg cytokines, transcription factors, and specific IgE and IgG4 levels. RESULTS: The CM-OIT protocol enabled to desensitize 70% of the allergic patients. Successful OIT was accompanied by significant increases in casein-specific IgG4 levels, together with a reduction in the concentration of antigen-specific IgE and in IL-5, IL-13, and IL-10 production by beta-casein-stimulated PBMCs. Baseline significant differences observed between allergic and nonallergic children in IL-13 and IL-5 levels were no longer found once the protocol had finished. CONCLUSIONS: The OIT protocol was safe and effective in inducing milk desensitization in 70% of the children with CMA, leading to alterations in their immune profiles toward a nonallergic phenotype</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.1.35</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826960">PM:27826960</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-35-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-35-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Perezabad L</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.1.35</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,H.Y.</style></author><author><style face="normal" font="Arial"> Kim,I.K.</style></author><author><style face="normal" font="Arial"> Yoon,H.K.</style></author><author><style face="normal" font="Arial"> Kwon,S.S.</style></author><author><style face="normal" font="Arial"> Rhee,C.K.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Inhibitory Effects of Resveratrol on Airway Remodeling by Transforming Growth Factor-beta/Smad Signaling Pathway in Chronic Asthma Model</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="34" start="25">25-34</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> epithelial-mesenchymal transition</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Snail</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Asthma is a chronic airway disease characterized by airway remodeling, leading to a progressive decline in lung function. Therapeutic agents that attenuate airway remodeling can complement the limited effects of traditional glucocorticoids. In this study, we investigated the effect of resveratrol on allergic airway inflammation and remodeling in a murine model of chronic bronchial asthma. METHODS: Peribronchial smooth muscle thickening that developed in mice challenged with a 3-month repeated exposure to ovalbumin (OVA) was used to study airway remodeling. Oral resveratrol was administered daily during the OVA challenge. The expression of TGF-beta1/Smad signaling proteins and downstream mesenchymal markers in the presence or absence of resveratrol was examined in bronchial epithelial cells. RESULTS: OVA sensitization and chronic challenge increased airway hyperresponsiveness, inflammation, goblet cell hyperplasia, alpha-smooth muscle actin (SMA), and collagen deposition. Resveratrol effectively suppressed OVA-induced airway inflammation and remodeling. The expression of TGF-beta1/phosphorylated Smad2/3 was increased in the lung tissues of OVA-challenged mice but effectively inhibited by resveratrol. In bronchial epithelial cells, the TGF-beta1-induced expression of the mesenchymal markers snail, slug, vimentin, and alpha-SMA was suppressed by resveratrol treatment. CONCLUSIONS: Resveratrol effectively ameliorated both airway inflammation and airway structural changes in a mouse model of bronchial asthma. These effects were mediated by decreased TGF-beta1 expression, in turn suppressing TGF-beta1/Smad signaling and the epithelial-mesenchymal transition process. Our results demonstrate the potential benefits of resveratrol for the treatment of airway remodeling associated with bronchial asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.1.25</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826959">PM:27826959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-25-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-25-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Lee HY</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.1.25</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferrando,M.</style></author><author><style face="normal" font="Arial"> Bagnasco,D.</style></author><author><style face="normal" font="Arial"> Varricchi,G.</style></author><author><style face="normal" font="Arial"> Bernardi,S.</style></author><author><style face="normal" font="Arial"> Bragantini,A.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy &amp; Respiratory Diseases, DIMI Department of Internal Medicine, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Personalized Medicine in Allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="24" start="15">15-24</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Allergic disease is among the most common pathologies worldwide and its prevalence has constantly increased up to the present days, even if according to the most recent data it seems to be slightly slowing down. Allergic disease has not only a high rate of misdiagnosis and therapeutic inefficacy, but represents an enormous, resource-absorbing black hole in respiratory and general medicine. The aim of this paper is to summarize principal therapeutic innovations in atopic disease management befallen in the recent years in terms of personalized/precision medicine</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.1.15</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826958">PM:27826958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-15-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-15-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Ferrando M</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.1.15</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sokulsky,L.A.</style></author><author><style face="normal" font="Arial"> Collison,A.M.</style></author><author><style face="normal" font="Arial"> Nightingale,S.</style></author><author><style face="normal" font="Arial"> Le Fevre,A.</style></author><author><style face="normal" font="Arial"> Percival,E.</style></author><author><style face="normal" font="Arial"> Starkey,M.R.</style></author><author><style face="normal" font="Arial"> Hansbro,P.M.</style></author><author><style face="normal" font="Arial"> Foster,P.S.</style></author><author><style face="normal" font="Arial"> Mattes,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The University of Newcastle</style></auth-address><titles><title><style face="normal" font="Arial">TRAIL deficiency and PP2A activation with Salmeterol ameliorates egg allergen driven eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Gastrointest Liver Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Gastrointest Liver Physiol</style></full-title></periodical><pages end="G1008" start="G998">G998-G1008</pages><volume><style face="normal" font="Arial">311</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Esophageal biopsy</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> salmeterol</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> TNF-related apoptosis-inducing ligand</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="10" Year="2016">2016/10/13</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Food antigens are common inflammatory triggers in pediatric eosinophilic esophagitis (EoE). TNF-related apoptosis-inducing ligand (TRAIL) promotes eosinophilic inflammation through the upregulation of Midline (MID)-1 and subsequent downregulation of Protein Phosphatase 2A (PP2A) but the role of this pathway in EoE that is experimentally induced by repeated food antigen challenges has not been investigated. METHODS: Esophageal mucosal biopsies were collected from children with EoE and controls and assessed for TRAIL and MID-1 protein and mRNA transcript levels. Wild type and TRAIL deficient (Tnfsf10 -/-) mice were administered subcutaneous ovalbumin (OVA) followed by oral OVA challenges. In separate experiments OVA challenged mice were intraperitoneally administered salmeterol or dexamethasone. RESULTS: Esophageal biopsies from children with EoE revealed increased levels of TRAIL and MID-1 and reduced PP2A activation as compared to controls. Tnfsf10-/- mice with experimental EoE, were largely protected from esophageal fibrosis, eosinophilic inflammation, and the upregulation of TSLP, IL-5, IL-13 and CCL11 when compared with wild type mice. Salmeterol administration to wild type mice with experimental EoE restored PP2A activity and also prevented esophageal eosinophilia, inflammatory cytokine expression and remodeling which was comparable to the treatment effect of dexamethasone. CONCLUSION: TRAIL and PP2A regulate inflammation and fibrosis in experimental EoE, which can be therapeutically modulated by Salmeterol</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1522-1547 (Electronic)IS - 0193-1857 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajpgi.00151.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742702">PM:27742702</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Gastrointest Liver Physiol\20161015-SokulskyLA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Gastrointest Liver Physiol\20161015-SokulskyLA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Sokulsky LA</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajpgi.00151.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,H.S.</style></author><author><style face="normal" font="Arial"> Park,D.E.</style></author><author><style face="normal" font="Arial"> Lee,J.W.</style></author><author><style face="normal" font="Arial"> Chang,Y.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Song,W.J.</style></author><author><style face="normal" font="Arial"> Kang,H.R.</style></author><author><style face="normal" font="Arial"> Park,H.W.</style></author><author><style face="normal" font="Arial"> Chang,Y.S.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology</style></auth-address><titles><title><style face="normal" font="Arial">IL-23 secreted by bronchial epithelial cells contributes allergic sensitization in asthma model</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L21" start="L13">L13-L21</pages><volume><style face="normal" font="Arial">312</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IL-23 has been postulated to be a critical mediator contributing to various inflammatory diseases. Dermatophagoides pteronyssinus (Der p) is one of the most common inhalant allergens. However, the role of IL-23 in Der p-induced mouse asthma model is not well understood, particularly with regard to the development of allergic sensitization in the airways. OBJECTIVE: To evaluate roles of IL-23 in Der p-sensitization and asthma development. METHODS: BALB/c mice were repeatedly administered with Der p intra-nasally to develop Der p-allergic sensitization and asthma. After Der p local administration, changes in IL-23 expression were examined in lung tissues and primary epithelial cells. Anti-IL-23p19 antibody was given during the Der p sensitization period, and its effects were examined. Effects of anti-IL-23p19 antibody at bronchial epithelial levels were also examined in vitro. RESULTS: The expression of IL-23 at bronchial epithelial layers was increased after Der p local administration in mouse. In Der p-induced mouse models, anti-IL-23p19 antibody treatment during allergen sensitization significantly diminished Der p-allergic sensitization and several features of allergic asthma including the production of Th2 cytokines and the population of ILC2 in lungs. The activation of dendritic cells in lung-draining lymph nodes was also reduced by anti-IL-23 treatment. In MLE-12 cells, IL-23 blockade prevented cytokine responses to Der p stimulation, such as IL-1alpha, GM-CSF, IL-33, and also bone marrow-derived DCs activation. CONCLUSION: IL-23 is another important bronchial epithelial cell-driven cytokine which may contribute to the development of house dust mite allergic sensitization and asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00114.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864285">PM:27864285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20161119-LeeHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20161119-LeeHS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Lee HS</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00114.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Girkin,J.L.</style></author><author><style face="normal" font="Arial"> Hatchwell,L.</style></author><author><style face="normal" font="Arial"> Collison,A.M.</style></author><author><style face="normal" font="Arial"> Starkey,M.R.</style></author><author><style face="normal" font="Arial"> Hansbro,P.M.</style></author><author><style face="normal" font="Arial"> Yagita,H.</style></author><author><style face="normal" font="Arial"> Foster,P.S.</style></author><author><style face="normal" font="Arial"> Mattes,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Newcastle and HMRI</style></auth-address><titles><title><style face="normal" font="Arial">TRAIL signaling is pro-inflammatory and pro-viral in a murine model of rhinovirus 1B infection</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L99" start="L89">L89-L99</pages><volume><style face="normal" font="Arial">312</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methacholine challenge</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Quantitative RT-PCR</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tissue Culture</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> Viral Load</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017=1L89</year></dates><abstract><style face="normal" font="Arial">The aim of this study is to elucidate the role of TRAIL during rhinovirus (RV) infection in vivo. Naive wild type and TRAIL-deficient (Tnfsf10-/-) BALB/c mice were infected intranasally with RV1B. In separate experiments, Tnfsf10-/- mice were sensitized and challenged via the airway route with house dust mite (HDM) to induce allergic airways disease and then challenged with RVIB or UV-RVIB. Airways hyperreactivity (AHR) was invasively assessed as total airways resistance in response to increasing methacholine challenge and inflammation assessed in bronchoalveolar lavage fluid (BALF) at multiple time points post infection. Chemokines were quantified by ELISA of whole lung lysates and viral load was determined by quantitative RT-PCR and tissue culture infective dose (TCID50). Human airway epithelial cells (BEAS2B) were infected with RV1B and stimulated with recombinant TRAIL or neutralizing anti-TRAIL antibodies and viral titer assessed by TCID50. HDM challenged Tnfsf10-/- mice were protected against RV-induced AHR and had suppressed cellular infiltration in the airways upon RV infection. Chemokine C-X-C-motif ligand 2 (CXCL2) production was suppressed in naive Tnfsf10-/- mice infected with RV1B, with less RV1B detected 24 hours post-infection. This was associated with reduced apoptotic cell death and a reduction of interferon (IFN)-lambda2/3 but not IFN-alpha or IFN-beta. TRAIL stimulation increased, whereas anti-TRAIL antibodies reduced viral replication in RV1B-infected BEAS2B cells in vitro. In conclusion, TRAIL promotes RV-induced AHR, inflammation and RV1B replication, implicating this molecule and its downstream signaling pathways as a possible target for the amelioration of RV1B-induced allergic and non-allergic lung inflammation and AHR</style></abstract><notes><style face="normal" font="Arial">DA - 20161112IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00200.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27836899">PM:27836899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20161112-GirkinJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20161112-GirkinJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161112, Girkin JL</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00200.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Magalhaes,G.S.</style></author><author><style face="normal" font="Arial"> Rodrigues-Machado,M.D.</style></author><author><style face="normal" font="Arial"> Motta-Santos,D.</style></author><author><style face="normal" font="Arial"> Alenina,N.</style></author><author><style face="normal" font="Arial"> Bader,M.</style></author><author><style face="normal" font="Arial"> Santos,R.A.</style></author><author><style face="normal" font="Arial"> Barcelos,L.S.</style></author><author><style face="normal" font="Arial"> Campagnole-Santos,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Federal University of Minas Gerais</style></auth-address><titles><title><style face="normal" font="Arial">CHRONIC ALLERGIC PULMONARY INFLAMMATION IS AGGRAVATED IN ANGIOTENSIN-(1-7) MAS RECEPTOR KNOCKOUT MICE</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L1148" start="L1141">L1141-L1148</pages><volume><style face="normal" font="Arial">311</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Renin-Angiotensin System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="11" Year="2016">2016/11/4</year></dates><abstract><style face="normal" font="Arial">Angiotensin-(1-7) [Ang-(1-7)]/Mas receptor pathway is currently recognized as a counterbalancing mechanism of the renin-angiotensin system in different pathophysiological conditions. We have previously described that treatment with Ang-(1-7) attenuates lung inflammation and remodeling in an experimental model of asthma. In the present study, we investigated whether lack of Mas receptor could alter the inflammatory response in a model of chronic allergic lung inflammation induced by ovalbumin (OVA). MasWT and MasKO mice were subjected to 4 doses of OVA (20microg/mice, i.p.) with 14 days interval. At the 21st day, nebulization with OVA (1%) was started, 3 times/week until the 46th day. Control groups received saline (0.9%, i.p.) and were nebulized with saline (0.9%). MasWT-OVA developed a modest inflammatory response and minor pulmonary remodeling to OVA challenge. Strikingly, MasKO-OVA presented a significant increase in inflammatory cell infiltrate, extracellular matrix deposition, increase in thickening of the alveolar parenchyma, increase in thickening of the smooth muscle layer of the pulmonary arterioles, increase in pro-inflammatory cytokine and chemokines levels in the lungs, characteristic of chronic asthma. Additionally, MasKO-OVA presented an increase in ERK1/2 phosphorylation in comparison to MasWT-OVA. Furthermore, MasKO-OVA showed a worst performance in a test of maximum physical exercise in comparison to MasWT-OVA. Our study shows that effects triggered by Mas receptor are important to attenuate the inflammatory and remodeling processes in a model of allergic lung inflammation in mice. Our data indicate that impairment of Ang-(1-7)/Mas receptor pathway may lead to worsening of the pathophysiological changes of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161105IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - ENGPT - Journal ArticleCO - Brazil -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00029.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27815255">PM:27815255</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20161105-MagalhaesGS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20161105-MagalhaesGS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161105, Magalhaes GS</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00029.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martins,C.</style></author><author><style face="normal" font="Arial"> Lima,J.</style></author><author><style face="normal" font="Arial"> Nunes,G.</style></author><author><style face="normal" font="Arial"> Borrego,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CEDOC, Chronic Diseases Research Center, Immunology, NOVA Medical School|FCM, Universidade Nova de Lisboa, Lisbon, Portugal. c</style></auth-address><titles><title><style face="normal" font="Arial">Pregnancy alters the circulating B cell compartment in atopic asthmatic women, and transitional B cells are positively associated with the development of allergy manifestations in their progeny</style></title><secondary-title><style face="normal" font="Arial">Am J Reprod Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Reprod Immunol</style></full-title></periodical><pages end="474" start="465">465-474</pages><volume><style face="normal" font="Arial">76</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoption</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Igd</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> maternal atopy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Memory cells</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Reproduction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="25" Month="10" Year="2016">2016/10/25</year></dates><abstract><style face="normal" font="Arial">PROBLEM: Maternal atopy is a risk factor for allergy. B cells are poorly studied in reproduction and atopy. We aimed to assess how pregnancy affects B cells in atopic women and whether B cells relate to allergic manifestations in offspring. METHOD OF STUDY: Women with and without atopic asthma, pregnant and non-pregnant were enrolled for the study, and circulating B cells were evaluated by flow cytometry, using CD19, CD27, CD38, IgD, and IgM. RESULTS: Compared to healthy non-pregnant, atopic asthmatic non-pregnant (ANP) women presented increased B cell counts, enlarged memory subsets, less transitional cells, and plasmablasts. Atopic asthmatic pregnant (AP) and healthy pregnant (HP) women showed similarities: reduced B cell counts and percentages, fewer memory cells, especially switched, and higher plasmablast percentages. Transitional B cell percentages were increased in AP women with allergic manifestations in their progeny. CONCLUSION: Atopic asthmatic non-pregnant women have a distinctive B cell compartment. B cells change in pregnancy, similarly in AP and HP women. The recognition that AP women with allergy in their progeny have a typical immune profile may help, in the future, the adoption of preventive measures to avoid the manifestation of allergic diseases in their newborns</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1600-0897 (Electronic)IS - 1046-7408 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1111/aji.12595</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27778417">PM:27778417</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Reprod Immunol\2016-76-465-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Reprod Immunol\2016-76-465-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Martins C</style></custom2><misc3><style face="normal" font="Arial">10.1111/aji.12595</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thornton,C.A.</style></author><author><style face="normal" font="Arial"> Marsland,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Institute of Life Science Swansea University Medical School Swansea, United Kingdom and2 Faculty of Biology and Medicine University of Lausanne Epalinges, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">A Trajectory toward Allergy: In Utero Uptake of Allergens Can Prime Type 2 Inflammation</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="920" start="919">919-920</pages><volume><style face="normal" font="Arial">194</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> In utero</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="10" Year="2016">2016/10/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161014IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201604-0783ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27739894">PM:27739894</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2016-194-919-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2016-194-919-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161014, Thornton CA</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201604-0783ED</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Freitas,P.D.</style></author><author><style face="normal" font="Arial"> Ferreira,P.G.</style></author><author><style face="normal" font="Arial"> Silva,A.G.</style></author><author><style face="normal" font="Arial"> Stelmach,R.</style></author><author><style face="normal" font="Arial"> Carvalho-Pinto,R.M.</style></author><author><style face="normal" font="Arial"> Fernandes,F.L.</style></author><author><style face="normal" font="Arial"> Mancini,M.C.</style></author><author><style face="normal" font="Arial"> Sato,M.N.</style></author><author><style face="normal" font="Arial"> Martins,M.A.</style></author><author><style face="normal" font="Arial"> Carvalho,C.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, University of Sao Paulo, Department of Physical Therapy, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Exercise in a Weight-loss Program on Clinical Control in Obese Adults with Asthma: a RCT</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="42" start="32">32-42</pages><volume><style face="normal" font="Arial">195</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Bariatric surgery</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Body Composition</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weight Loss</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Clinical control is difficult to achieve in obese patients with asthma. Bariatric surgery has been recommended for weight-loss and to improve asthma control; however, the benefits of nonsurgical interventions have been poorly investigated. OBJECTIVE: To examine the effect of exercise training in a weight-loss program on asthma control, quality of life, inflammatory biomarkers and lung function. METHODS: Fifty-five obese patients with asthma were randomly assigned to either a weight-loss program + exercise (WL+E group, n=28) or a weight-loss program + sham (WL+S group, n=27) group, where the weight-loss program included nutrition (caloric restriction) and psychological therapies. The WL+E group incorporated aerobic and resistance muscle training, whereas the WL+S group incorporated breathing and stretching exercises. MEASUREMENTS: The primary outcome was clinical improvement in asthma control over 3 months. Secondary outcomes included quality of life, lung function, body composition, aerobic capacity, muscle strength and inflammatory/anti-inflammatory biomarkers. MAIN RESULTS: After 3 months, 51 patients were analyzed. Compared with the WL+S group, the WL+E group demonstrated improved clinical control scores (-0.7 [-1.3, -0.3] vs. -0.3 [-0.9, 0.4]; P=0.01) and greater weight-loss (-6.8%+/-3.5 vs. -3.1%+/-2.6; P&lt;0.001) and aerobic capacities (3.0 [2.4, 4.0] vs. 0.9 [-0.3, 1.3] mL O2.kg.min-1; P&lt;0.001). These improvements in the WL+E group were also accompanied by improvements in lung function, anti-inflammatory biomarkers and vitamin D levels, as well as reductions in airway and systemic inflammation. CONCLUSIONS: Adding exercise to a short-term weight-loss program should be considered as a useful strategy to achieving clinical control of asthma in obese patients. Clinical trial registration available at www.clinicaltrials.gov, ID NCT02188940</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201603-0446OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27744739">PM:27744739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-32-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-32-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Freitas PD</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201603-0446OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kouzaki,H.</style></author><author><style face="normal" font="Arial"> Matsumoto,K.</style></author><author><style face="normal" font="Arial"> Kikuoka,H.</style></author><author><style face="normal" font="Arial"> Kato,T.</style></author><author><style face="normal" font="Arial"> Tojima,I.</style></author><author><style face="normal" font="Arial"> Shimizu,S.</style></author><author><style face="normal" font="Arial"> Kita,H.</style></author><author><style face="normal" font="Arial"> Shimizu,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shiga University of Medical Science, Department of Otorhinolaryngology, Otsu, Shiga, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Endogenous Protease Inhibitor in Airway Epithelial Cells Contribute to Eosinophilic Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="747" start="737">737-747</pages><volume><style face="normal" font="Arial">195</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> small interfering RNA</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Cystatin A and SPINK5 are endogenous protease inhibitors (EPIs) that may play key roles in epithelial barrier function. OBJECTIVE: The purpose of this study was to investigate the roles of EPIs in the pathogenesis of chronic rhinosinusitis (CRS). METHODS: We examined the expression of cystatin A and SPINK5 in the nasal epithelial cells of patients with CRS. Additionally, the in vitro effects of recombinant EPIs on the secretion of the epithelial-derived cytokines, interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), in airway epithelial cells, and the in vivo effects of recombinant EPIs in the nasal epithelium of mice exposed to multiple airborne allergens (MAA) were examined. RESULTS: Compared with controls and patients with non-eosinophilic CRS, patients with eosinophilic CRS showed significantly lower protein and mRNA expression of cystatin A and SPINK5 in the nasal epithelium. Allergen-induced production of IL-25, IL-33, and TSLP in normal human bronchial epithelial cells was inhibited by treatment with recombinant cystatin A or SPINK5. Conversely, the production of these cytokines was increased when cystatin A or SPINK5 were knocked down with small interfering RNA. Chronic MAA exposure induced goblet cell metaplasia and epithelial disruption in mouse nasal epithelium and decreased the tissue expression and nasal lavage levels of cystatin A and SPINK5. Intranasal instillations of recombinant EPIs attenuated this MAA-induced pathology. CONCLUSIONS: Cystatin A and SPINK5 play an important role in protecting the airway epithelium from exogenous proteases. The preservation of EPIs may have a therapeutic benefit in intractable airway inflammation such as eosinophilic CRS</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201603-0529OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779422">PM:27779422</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-737-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-737-47.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Kouzaki H</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201603-0529OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,S.</style></author><author><style face="normal" font="Arial"> Wang,G.</style></author><author><style face="normal" font="Arial"> Yang,R.</style></author><author><style face="normal" font="Arial"> Cui,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, Lishui University Lishui 323000, Zhejiang Province, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Anti-inflammatory effects of Boletus edulis polysaccharide on asthma pathology</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="4489" start="4478">4478-4489</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> and ABPA</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Boletus</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cyclophilin</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic airway disease common around the world. The burden of this disease could be reduced with new and effective treatments. Here, the efficacy of a polysaccharide extract from the Boletus edulis (BEP) mushroom, which has demonstrated anti-inflammatory properties, was tested in a mouse model of asthma. Five groups of BaLB/C mice were developed; one group served as a control and did not have asthma induction. The other four groups of mice were sensitized by ovalbumin challenge. FinePointe RC animal airway resistance and pulmonary compliance was used to assess airway function in asthma models. Three of the 4 model groups received treatments: one received pravastatin, one received dexamethasone, and one received BEP. Histopathology of lung tissues was performed using H&amp;E and AB-PAS staining. Levels of cytokines IL-4 and IFN-g were detected using ELISA, qRT-PCR, and Western blotting. Cyclophilin A was measured by Western blot, and flow cytometry was used to determine the proportion of CD4+CD25+FOXP3+ Treg cells. BEP treatment resulted in improvements in lung pathology, IL-4 level (P&lt;0.05), and IFN-gamma level (P&lt;0.05) similar to traditional dexamethasone treatment. Further, the proportion of anti-inflammatory CD4+CD25+FOXP3+ Treg cells significantly increased (P&lt;0.05) compared to untreated asthma models, and expression of cyclophilin A significantly decreased (P&lt;0.05). Thus, Boletus edulis polysaccharide reduces pro-inflammatory responses and increases anti-inflammatory responses in mouse models of asthma, suggesting this may be a novel treatment method</style></abstract><notes><style face="normal" font="Arial">DA - 20161110LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27830033">PM:27830033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2016-8-4478-89.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2016-8-4478-89.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161110, Wu S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yi,D.</style></author><author><style face="normal" font="Arial"> Hou,Y.</style></author><author><style face="normal" font="Arial"> Mei,H.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Hu,C.A.</style></author><author><style face="normal" font="Arial"> Wu,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, China</style></auth-address><titles><title><style face="normal" font="Arial">beta-Conglycinin enhances autophagy in porcine enterocytes</style></title><secondary-title><style face="normal" font="Arial">Amino Acids</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Amino Acids</style></full-title></periodical><pages end="207" start="203">203-207</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animal Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Cell viability</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocytes</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">beta-Conglycinin (beta-CG) is well known for inducing intestinal allergies and dysfunction in neonates and young pigs. However, the underlying mechanisms are largely unknown. In this study, to clarify the role of autophagy in beta-CG-induced cytotoxicity, we investigated the effects of beta-CG on cell viability and autophagy activity in porcine enterocytes (IPEC-1 cells). The results indicated that the cell viability was decreased with the increasing levels of beta-CG. beta-CG treatment enhanced the eGFP-LC3 puncta per cells and LC3-II/LC3-I, and the latter was further increased in IPEC-1 cells cultured with bafilomycin A1. We conclude that beta-CG enhances autophagy activity in enterocytes</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1438-2199 (Electronic)IS - 0939-4451 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00726-016-2352-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27761755">PM:27761755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Amino Acids\20161020-YiD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Amino Acids\20161020-YiD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Yi D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00726-016-2352-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bessa,G.R.</style></author><author><style face="normal" font="Arial"> Quinto,V.P.</style></author><author><style face="normal" font="Arial"> Machado,D.C.</style></author><author><style face="normal" font="Arial"> Lipnharski,C.</style></author><author><style face="normal" font="Arial"> Weber,M.B.</style></author><author><style face="normal" font="Arial"> Bonamigo,R.R.</style></author><author><style face="normal" font="Arial"> d'Azevedo,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidade Federal de Ciencias da Saude de Porto Alegre</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus resistance to topical antimicrobials in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">An Bras Dermatol</style></full-title></periodical><pages end="610" start="604">604-610</pages><volume><style face="normal" font="Arial">91</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobials</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Bacitracin</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Resistance</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Mupirocin</style></keyword><keyword><style face="normal" font="Arial"> Neomycin</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Background:: Topical antimicrobial drugs are indicated for limited superficial pyodermitis treatment, although they are largely used as self-prescribed medication for a variety of inflammatory dermatoses, including atopic dermatitis. Monitoring bacterial susceptibility to these drugs is difficult, given the paucity of laboratory standardization. Objective:: To evaluate the prevalence of Staphylococcus aureus topical antimicrobial drug resistance in atopic dermatitis patients. Methods:: We conducted a cross-sectional study of children and adults diagnosed with atopic dermatitis and S. aureus colonization. We used miscellaneous literature reported breakpoints to define S. aureus resistance to mupirocin, fusidic acid, gentamicin, neomycin and bacitracin. Results:: A total of 91 patients were included and 100 S. aureus isolates were analyzed. All strains were methicillin-susceptible S. aureus. We found a low prevalence of mupirocin and fusidic acid resistance (1.1% and 5.9%, respectively), but high levels of neomycin and bacitracin resistance (42.6% and 100%, respectively). Fusidic acid resistance was associated with more severe atopic dermatitis, demonstrated by higher EASI scores (median 17.8 vs 5.7, p=.009). Our results also corroborate the literature on the absence of cross-resistance between the aminoglycosides neomycin and gentamicin. Conclusions:: Our data, in a southern Brazilian sample of AD patients, revealed a low prevalence of mupirocin and fusidic acid resistance of S. aureus atopic eczema colonizer strains. However, for neomycin and bacitracin, which are commonly used topical antimicrobial drugs in Brazil, high levels of resistance were identified. Further restrictions on the use of these antimicrobials seem necessary to keep resistance as low as possible</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1590/abd1806-4841.20164860</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27828633">PM:27828633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\An Bras Dermatol\2016-91-604-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\An Bras Dermatol\2016-91-604-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Bessa GR</style></custom2><misc3><style face="normal" font="Arial">10.1590/abd1806-4841.20164860</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jauset-Rubio,M.</style></author><author><style face="normal" font="Arial"> Sabate Del Rio,J.</style></author><author><style face="normal" font="Arial"> Mairal,T.</style></author><author><style face="normal" font="Arial"> Svobodova,M.</style></author><author><style face="normal" font="Arial"> El-Shahawi,M.S.</style></author><author><style face="normal" font="Arial"> Bashammakh,A.S.</style></author><author><style face="normal" font="Arial"> Alyoubi,A.O.</style></author><author><style face="normal" font="Arial"> O'Sullivan,C.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nanobiotechnology and Bioanalysis Group, INTERFIBIO Consolidated Group, Department of Chemical Engineering, Universitat Rovira I Virgili, Campus Sescelades, Avinguda dels Paisos Catalans, 26, 43007, Tarragona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Ultrasensitive and rapid detection of beta-conglutin combining aptamers and isothermal recombinase polymerase amplification</style></title><secondary-title><style face="normal" font="Arial">Anal Bioanal Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Bioanal Chem</style></full-title></periodical><pages end="149" start="143">143-149</pages><volume><style face="normal" font="Arial">409</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Aptamers</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> IUIS</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Lup an 1</style></keyword><keyword><style face="normal" font="Arial"> Lupin</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic beads</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Nutraceutical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Lupin is increasingly being used in a variety of food products due to its nutritional, functional and nutraceutical properties. However, several examples of severe and even fatal food-associated anaphylaxis due to lupin inhalation or ingestion have been reported, resulting in the lupin subunit beta-conglutin, being defined as the Lup an 1 allergen by the International Union of Immunological Societies (IUIS) in 2008. Here, we report an innovative method termed aptamer-recombinase polymerase amplification (Apta-RPA) exploiting the affinity and specificity of a DNA aptamer selected against the anaphylactic beta-conglutin allergen termed beta-conglutin binding aptamer II (beta-CBA II), facilitating ultrasensitive detection via isothermal amplification. Combining magnetic beads as the solid phase with Apta-RPA detection, the total assay time was reduced from 210 min to just 25 min, with a limit of detection of 3.5 x 10-11 M, demonstrating a rapid and ultrasensitive generic methodology that can be used with any aptamer. Future work will focus on further simplification of the assay to a lateral flow format. Graphical Abstract Schematic representation of the rapid and novel bead-based Apta-RPA assay</style></abstract><notes><style face="normal" font="Arial">DA - 20161021IS - 1618-2650 (Electronic)IS - 1618-2642 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00216-016-9973-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27766362">PM:27766362</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Bioanal Chem\20161021-JausetRubioM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Bioanal Chem\20161021-JausetRubioM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161021, Jauset-RubioM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00216-016-9973-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moldobaeva,A.</style></author><author><style face="normal" font="Arial"> Jenkins,J.</style></author><author><style face="normal" font="Arial"> Zhong,Q.</style></author><author><style face="normal" font="Arial"> Wagner,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD, 21224, USA</style></auth-address><titles><title><style face="normal" font="Arial">Lymphangiogenesis in rat asthma model</style></title><secondary-title><style face="normal" font="Arial">Angiogenesis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Angiogenesis</style></full-title></periodical><pages end="84" start="73">73-84</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> endothelial cells</style></keyword><keyword><style face="normal" font="Arial"> Endothelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Although bronchial angiogenesis has been well documented in allergic asthma, lymphangiogenesis has not been widely studied. Therefore, we evaluated changes in lung lymphatics in a rat model of allergen-induced asthma using house dust mite (Der p 1; 100 mug/challenge). Additionally, properties of isolated lung lymphatic endothelial cells (CD45-, CD141+, LYVE-1+, Prox-1+) were studied in vitro. Three weeks after the onset of intranasal allergen exposure (twice-weekly), an increase in the number of lung lymphatic vessels was measured (34% increase) by lung morphometry. New lymphatic structures were seen predominantly in the peribronchial and periarterial interstitial space but also surrounding large airways. Isolated lymphatic endothelial cells from sensitized lungs showed enhanced proliferation (% Ki67+), chemotaxis, and tube formation (number and length) compared to lymphatic endothelial cells isolated from naive rat lungs. This hyper-proliferative lymphangiogenic phenotype was preserved through multiple cell passages (2-8). Lymphatic endothelial cells isolated from naive and HDM-sensitized rats produced similar in vitro levels of VEGF-C, VEGF-D, and VEGFR3 protein, each recognized as critical lymphangiogenic factors. Inhibition with anti-VEGFR (axitinib, 0.1 muM) blocked proliferation and chemotaxis. Results suggest that in vivo sensitization causes fundamental changes to lymphatic endothelium, which are retained in vitro, and may relate to VEGFR downstream signaling</style></abstract><notes><style face="normal" font="Arial">DA - 20161027IS - 1573-7209 (Electronic)IS - 0969-6970 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10456-016-9529-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27787629">PM:27787629</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Angiogenesis\20161027-MoldobaevaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Angiogenesis\20161027-MoldobaevaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161027, Moldobaeva A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10456-016-9529-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81977</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Menaya,J.M.</style></author><author><style face="normal" font="Arial"> Chiarella,G.M.</style></author><author><style face="normal" font="Arial"> Cordobes-Duran,C.</style></author><author><style face="normal" font="Arial"> Mahecha,A.C.</style></author><author><style face="normal" font="Arial"> Bobadilla-Gonzalez,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Infanta Cristina University Hospital, Badajoz, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Rye-dependent exercise-induced anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="568" start="566">566-568</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Badajoz</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788890">PM:27788890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-566-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-566-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Garcia-Menaya JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jedryczka,M.</style></author><author><style face="normal" font="Arial"> Sadys,M.</style></author><author><style face="normal" font="Arial"> Gilski,M.</style></author><author><style face="normal" font="Arial"> Grinn-Gofron,A.</style></author><author><style face="normal" font="Arial"> Kaczmarek,J.</style></author><author><style face="normal" font="Arial"> Strzelczak,A.</style></author><author><style face="normal" font="Arial"> Kennedy,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Plant Genetics, Polish Academy of Sciences, Poznan, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Contribution of Leptosphaeria species ascospores to autumn asthma in areas of oilseed rape production</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="501" start="495">495-501</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne fungi</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Oilseed rape</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An increase in the number of hospital admissions from September to November in the northern hemisphere has been frequently reported. At this time, some species of fungal genus Leptosphaeria produce numerous ascospores, which are easily airborne. However, we lack knowledge about whether Leptosphaeria produces allergenic proteins. OBJECTIVE: To evaluate the potential of Leptosphaeria ascospores to contribute to autumn asthma. METHODS: Detailed bioinformatic analysis of proteins produced by Leptosphaeria maculans available in databases was performed and the data compared with allergens found in other airborne fungi. The concentrations of Leptosphaeria ascospores detected at 2 sites were compared to these obtained in other environments worldwide. RESULTS: We found that Leptosphaeria species produce proteins with a high identity to commonly known aeroallergens of several well-characterized molds. The level of amino acid identity significantly exceeded the allergen identity thresholds recommended by the Food and Agricultural Organization/World Health Organization (35%), which indicates allergenic properties of L maculans and ensures the same properties in the other Leptosphaeria species. CONCLUSION: High concentrations of Leptosphaeria species ascospores in the autumn and postulated allergenicity of their proteins strongly suggest that this genus contributes to worldwide reported autumn asthma. The finding opens the question of allergenicity of the other never studied fungal species present in aeroplankton</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Poland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788878">PM:27788878</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-495-501.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-495-501.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Jedryczka M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perez-Rodriguez,E.</style></author><author><style face="normal" font="Arial"> Hernandez-Perez,M.A.</style></author><author><style face="normal" font="Arial"> Martinez-Tadeo,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service of Allergy and Clinical Immunology, Nuestra Senora de la Candelaria University Hospital, Santa Cruz de Tenerife, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Successful desensitization to natalizumab using a 1-solution protocol</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="114" start="113">113-114</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864092">PM:27864092</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161119-PerezRodriguezE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161119-PerezRodriguezE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Perez-Rodriguez E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Walters,K.M.</style></author><author><style face="normal" font="Arial"> White,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Scripps Clinic, San Diego, California.</style></auth-address><titles><title><style face="normal" font="Arial">Tolerance to nonsteroidal anti-inflammatory drugs and alcohol after omalizumab treatment in a patient with chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="561" start="559">559-561</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alcohol</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788887">PM:27788887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-559-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-559-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Walters KM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McGowan,E.C.</style></author><author><style face="normal" font="Arial"> Matsui,E.C.</style></author><author><style face="normal" font="Arial"> Peng,R.</style></author><author><style face="normal" font="Arial"> Salo,P.M.</style></author><author><style face="normal" font="Arial"> Zeldin,D.C.</style></author><author><style face="normal" font="Arial"> Keet,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Racial/ethnic and socioeconomic differences in self-reported food allergy among food-sensitized children in National Health and Nutrition Examination Survey III</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="572" start="570">570-572</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Self-reported food allergy</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788892">PM:27788892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-570-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-570-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160228, McGowan EC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Winslow,A.W.</style></author><author><style face="normal" font="Arial"> Turbyville,J.C.</style></author><author><style face="normal" font="Arial"> Sublett,J.W.</style></author><author><style face="normal" font="Arial"> Sublett,J.L.</style></author><author><style face="normal" font="Arial"> Pollard,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Louisville, Louisville, Kentucky.</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of systemic reactions in rush, cluster, and standard-build aeroallergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="545" start="542">542-545</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Kentucky</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rush immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Given the choice of standard, cluster, and rush build-up for aeroallergen immunotherapy, standard-build immunotherapy has generally been preferred because of a perceived high rate of systemic reactions (SRs) associated with cluster and rush immunotherapy. OBJECTIVE: To characterize the incidence of SRs during standard, cluster, and rush build-up immunotherapy in an allergy practice during a 5-year period. METHODS: A retrospective review was conducted among patients receiving standard-build, 8- to 10-step cluster, or 2-day rush immunotherapy from January 1, 2010, through December 31, 2014, at Family Allergy &amp; Asthma clinics in Louisville, Kentucky. Investigators excluded reactions that occurred during skin prick testing, venom immunotherapy, and not-true SRs, and identified the build-up method, age, sex, date of reaction, vial concentration, and presence of asthma. Per-shot and per-patient incidence of SRs was computed from these data. RESULTS: During our review period, 2,549,643 injections were administered to 11,982 patients. Per-shot incidence of SR was 0.01%, 0.06%, and 0.33% for standard, cluster, and rush immunotherapy, respectively; per-patient incidence of SR was 2.84%, 2.52%, and 11.86% for standard, cluster, and rush immunotherapy, respectively. A total of 42% of SRs were grade 1, 43% were grade 2, 12% were grade 3, and 3% were grade 4. No fatalities were reported. A total of 70% of total SRs, 75% of cluster SR, and 55% of rush SR occurred in females, with an emergent peak in SR from May to October. CONCLUSION: Compared with previously published rates, we observed a decrease in the incidence of SR for standard, cluster, and rush immunotherapy, with peak seasonality from May to October and a female predominance</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788885">PM:27788885</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-542-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-542-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Winslow AW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tat,T.S.</style></author><author><style face="normal" font="Arial"> Cilli,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, School of Medicine, Akdeniz University, Antalya, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="549" start="546">546-549</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antalya</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly patients</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Severe asthma management in elderly patients may be difficult because of increased comorbid conditions, polypharmacy, physiologic changes that occur with aging, incorrect use of inhaler devices, and poor adherence. OBJECTIVE: To evaluate the long-term safety and efficacy of the anti-IgE antibody omalizumab in elderly (aged >/=65 years) patients with uncontrolled allergic asthma. METHODS: The efficiency and adverse effects of omalizumab treatment were evaluated based on data extracted from medical records. Patients were evaluated monthly for efficacy and adverse reactions. Treatment efficacy was evaluated by level of asthma symptom control, using the Global Initiative for Asthma guideline. RESULTS: Nineteen consecutive elderly patients with asthma (female to male ratio, 14:5) formed our cohort. The mean (SD) age, disease duration, and total IgE level were 69.3 (5.8) years, 19.4 (8.6) years, and 299.1 (197.2) IU/mL, respectively. The mean (SD) duration of omalizumab treatment was 35.6 (17.8) months (range, 9-66 months). All the patients had at least 1 perennial inhalant allergen sensitivity and had uncontrolled allergic asthma. Elderly patients experienced no significantly important adverse reaction considered to be related to omalizumab treatment. Only 1 patient had a local adverse reaction and 1 had myalgia that was considered to be drug related. After omalizumab treatment, asthma symptoms were well controlled in 9 patients (47.4%) and partly controlled in 8 patients (42.1%). Two of the patients (10.5%) still had uncontrolled asthma. CONCLUSION: Our study found that omalizumab is a well-tolerated and effective therapy for elderly patients with uncontrolled asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788886">PM:27788886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-546-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-546-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Tat TS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,M.F.</style></author><author><style face="normal" font="Arial"> Chen,Y.H.</style></author><author><style face="normal" font="Arial"> Chiang,C.H.</style></author><author><style face="normal" font="Arial"> Lin,S.J.</style></author><author><style face="normal" font="Arial"> Song,P.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of 10 Environmental Allergen Components of the American Cockroach in Taiwan</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="541" start="535">535-541</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroach allergens</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Per a 1</style></keyword><keyword><style face="normal" font="Arial"> Per a 10</style></keyword><keyword><style face="normal" font="Arial"> Per a 2</style></keyword><keyword><style face="normal" font="Arial"> Per a 4</style></keyword><keyword><style face="normal" font="Arial"> Per a 9</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cockroaches are important sources of indoor airborne allergens. The American cockroach (Periplaneta americana) is the second leading inhalant allergen causing allergic airway diseases in Taiwan. We previously reported a difference in pathogenicity of different allergen components from American cockroaches. OBJECTIVE: To analyze the environmental profile of American cockroach allergen components. METHODS: Polyclonal antibodies were generated to recombinant American cockroach allergens, Per a 1 through Per a 10. The levels of each allergen in (1) whole-body extracts and feces from American cockroaches and in (2) fresh-frozen 6-month-old and 12-month-old dead American cockroaches were evaluated by immunoblotting and quantified. Levels of allergen components from patients' household dust samples were determined by competition enzyme-linked immunosorbent assay. RESULTS: Per a 1, 2, and 10 proteins were present predominantly in roach feces, whereas other allergen components were found predominantly in roach bodies. There was a time-dependent decrease in total levels of some allergen proteins. Although levels of Per a 4, 5, 6, and 9 significantly decreased to less 20% of the basal level, there was no significant change in levels of Per a 2, 7, and 10 after 1-year decomposition. The most abundant allergen components in 20 dust samples from patients' houses were Per a 9, Per a 10, and Per a 2. CONCLUSION: The concentration of 10 American cockroach allergen components differed in the environment. Per a 2 and Per a 10 can be used as markers of long-term environmental cockroach control and Per a 9 as current status of control in patients' houses</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.432</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788884">PM:27788884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-535-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-535-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Lee MF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.432</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klaewsongkram,J.</style></author><author><style face="normal" font="Arial"> Thantiworasit,P.</style></author><author><style face="normal" font="Arial"> Sodsai,P.</style></author><author><style face="normal" font="Arial"> Buranapraditkun,S.</style></author><author><style face="normal" font="Arial"> Mongkolpathumrat,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, and Chulalongkorn Allergy and Clinical Immunology Research Group, Chulalongkorn University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4+CD25+CD134+ lymphocytes</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="519" start="514">514-519</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Exanthema</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> imatinib</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Imatinib is a tyrosine kinase inhibitor indicated for the treatment of gastrointestinal stromal tumors (GISTs) and certain neoplastic diseases; however, nonimmediate adverse reactions are common. OBJECTIVE: To describe the process of imatinib slow desensitization in patients who experienced nonimmediate reactions to imatinib and the dynamic change in drug-specific CD4+CD25+CD134+ T-lymphocyte percentages. METHODS: Five patients diagnosed as having GISTs and with a recent history of imatinib-induced nonimmediate reactions (maculopapular exanthema with eosinophilia, exfoliative dermatitis, palmar-plantar erythrodysesthesia, and drug rash with eosinophilia and systemic symptoms) were desensitized using a slow desensitization protocol. The reintroduced imatinib dosage was stepped up every week starting from 10 mg/d and increasing to 25, 50, 75, 100, 150, 200, and 300 mg/d until the target dose of 400 mg/d was achieved. Prednisolone of up to 30 mg/d was allowed if allergic reactions recurred. The percentages of CD4+CD25+CD134+ T cells present after incubating peripheral blood mononuclear cells with imatinib, at baseline and after successful desensitization, were analyzed using flow cytometric analysis. RESULTS: By using a slow desensitization technique, all patients were able to receive 400 mg/d of imatinib, and prednisolone was gradually tapered off. The percentages of imatinib-induced CD4+CD25+CD134+ T cells decreased from a mean (SD) of 11.3% (6.5%) and 13.4% (7.3%) at baseline to 3.2% (0.7%) and 3.0% (1.1%) after successful desensitization, when stimulating peripheral blood mononuclear cells with 1 and 2 muM of imatinib, respectively. CONCLUSION: Slow desensitization is a helpful procedure in treating patients with imatinib-induced nonimmediate reactions other than simple maculopapular exanthema. The reduced percentages of imatinib-induced CD4+CD25+CD134+ T cells in these patients may be associated with immune tolerance</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788881">PM:27788881</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-514-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-514-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Klaewsongkram J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tiotiu,A.</style></author><author><style face="normal" font="Arial"> Brazdova,A.</style></author><author><style face="normal" font="Arial"> Longe,C.</style></author><author><style face="normal" font="Arial"> Gallet,P.</style></author><author><style face="normal" font="Arial"> Morisset,M.</style></author><author><style face="normal" font="Arial"> Leduc,V.</style></author><author><style face="normal" font="Arial"> Hilger,C.</style></author><author><style face="normal" font="Arial"> BROUSSARD,C.</style></author><author><style face="normal" font="Arial"> Couderc,R.</style></author><author><style face="normal" font="Arial"> Sutra,J.P.</style></author><author><style face="normal" font="Arial"> Senechal,H.</style></author><author><style face="normal" font="Arial"> Poncet,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pneumology-Allergology Department, University Hospital, Nancy, France</style></auth-address><titles><title><style face="normal" font="Arial">Urtica dioica pollen allergy: Clinical, biological, and allergomics analysis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="534" start="527">527-534</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic risk</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> osmotin</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> Parietaria pollen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thaumatin-like protein</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urtica</style></keyword><keyword><style face="normal" font="Arial"> Urticaceae</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The most emblematic members of Urticaceae at allergic risk level are wall pellitories (Parietaria), whereas nettle (Urtica) pollen is considered as poorly allergenic. No allergen from nettle pollen has yet been characterized, whereas 4 are listed for Parietaria pollen by the International Union of Immunological Societies. Clinical and biological profiles of 2 adult men who developed symptoms against nettle pollen and/or leaves were studied. OBJECTIVE: To characterize the allergic reaction and identify the potential nettle pollen sensitizing allergens. METHODS: IgE-mediated reaction to nettle pollen extract was evaluated by skin prick test, immunoassay, nasal provocation, and basophil activation test. To characterize specific nettle pollen allergens, an allergomic (IgE immunoproteomic) analysis was performed combining 1- and 2-dimensional electrophoresis, IgE immunoblots of nettle pollen extract, identification of allergens by mass spectrometry, and database queries. RESULTS: The results of biological and immunochemical analyses revealed that the allergic rhinitis was due to Urtica dioica pollen in both patients. The allergomic analysis of nettle pollen extract allowed the characterization of 4 basic protein allergens: a thaumatin-like protein (osmotin) with a relative molecular mass of 27 to 29 kDa, a pectinesterase (relative molecular mass, 40 kDa), and 2 other basic proteins with relative molecular masses of 14 to 16 kDa and 43 kDa. There is no or only very weak allergen associations between pellitory and nettle pollen. CONCLUSION: Exposure to nettle pollen can be responsible of allergic symptoms, and several allergens were characterized. Unravelling the allergens of this underestimated allergy might help to improve diagnosis and care for patients, to predict cross-reactivities and design adapted specific immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - France -CO - Luxembourg -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.426</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788883">PM:27788883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-527-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-527-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Tiotiu A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.426</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Allenbrand,R.</style></author><author><style face="normal" font="Arial"> Barnes,C.S.</style></author><author><style face="normal" font="Arial"> Mohammed,M.</style></author><author><style face="normal" font="Arial"> Gard,L.</style></author><author><style face="normal" font="Arial"> Pacheco,F.</style></author><author><style face="normal" font="Arial"> Kennedy,K.</style></author><author><style face="normal" font="Arial"> DiDonna,A.</style></author><author><style face="normal" font="Arial"> Portnoy,J.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Children's Mercy Hospital, Kansas City, Missouri</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of allergens collected from furnace filters and vacuum floor dust</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="109" start="108">108-109</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> filter</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vacuum</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27839669">PM:27839669</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161114-Allenbrand.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161114-Allenbrand.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161114, Allenbrand R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moreno-Borque,R.</style></author><author><style face="normal" font="Arial"> Collazo-Lorduy,T.</style></author><author><style face="normal" font="Arial"> Bermudez-Martinez,M.</style></author><author><style face="normal" font="Arial"> Gajate-Fernandez,P.</style></author><author><style face="normal" font="Arial"> Sanchez-Lopez,P.</style></author><author><style face="normal" font="Arial"> Moreno-Geada,M.</style></author><author><style face="normal" font="Arial"> Plaza-Sanchez,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Rey Juan Carlos University Hospital, Mostoles, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis induced by ingested molds</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="113" start="112">112-113</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864089">PM:27864089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161119-MorenoBorqueR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161119-MorenoBorqueR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Moreno-Borque R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Philipp,A.</style></author><author><style face="normal" font="Arial"> Ferdman,R.M.</style></author><author><style face="normal" font="Arial"> Tam,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, California</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of venom allergy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="347" start="344">344-347</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742083">PM:27742083</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-344-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-344-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Philipp A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Crans Yoon,A.M.</style></author><author><style face="normal" font="Arial"> Chiu,V.</style></author><author><style face="normal" font="Arial"> Rana,J.S.</style></author><author><style face="normal" font="Arial"> Sheikh,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Kaiser Permanente Los Angeles, Los Angeles, California</style></auth-address><titles><title><style face="normal" font="Arial">Association of allergic rhinitis, coronary heart disease, cerebrovascular disease, and all-cause mortality</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="364" start="359">359-364</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Inflammation is implicated in atherosclerotic cardiovascular disease. Allergic diseases also involve a systemic inflammatory state, which may potentiate cardiovascular disease. OBJECTIVE: To examine the association of allergic rhinitis, coronary heart disease (CHD), cerebrovascular disease (CVD), and all-cause mortality. METHODS: We conducted a retrospective, population-based, matched cohort study comparing the incidence of CHD, CVD, and all-cause mortality from January 1, 1999, through December 31, 2012, in patients with International Classification of Disease, Ninth Revision, documented allergic rhinitis matched 1:1 by age, sex, and ethnicity to a reference cohort without allergic rhinitis within Kaiser Permanente Southern California. Fully adjusted hazard ratios (HRs) were calculated. Further analyses for those with positive environmental allergen specific IgE (sIgE) test results within the allergic rhinitis cohort were also performed. RESULTS: Patients with physician-diagnosed allergic rhinitis (N = 110, 207 in matched cohort) had significantly lower risk for myocardial infarction (HR, 0.63; 95% confidence interval [CI], 0.59-0.67; P &lt; .001), all CHD (HR, 0.81; 95% CI, 0.78-0.84; P &lt; .001), CVD (HR, 0.67; 95% CI, 0.64-0.70; P &lt; .001), and all-cause mortality (HR, 0.42; 95% CI, 0.40-0.43; P &lt; .001). The results were similar after excluding patients with asthma. Patients with positive sIgE test result also had a decreased risk of all CHD (relative risk [RR], 0.87; 95% CI, 0.79-0.95; P = .003) but no association with cerebrovascular events (RR, 0.89; 95% CI, 0.77-1.02; P = .10) and all-cause mortality (RR, 1.16; 95% CI, 1.00-1.34; P = .06). CONCLUSION: We found that the presence of allergic rhinitis was associated with decreased CHD, CVD, and all-cause mortality. This decreased risk was more pronounced after excluding patients with asthma. Patients with positive sIgE test results also had decreased risk of CHD</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742084">PM:27742084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-359-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-359-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Crans Yoon AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arakali,S.R.</style></author><author><style face="normal" font="Arial"> Green,T.D.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of food allergies in South Asia</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="20" start="16">16-20</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Bangladesh</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sri Lanka</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To evaluate the published medical literature on the prevalence and types of food allergies in South Asia. DATA SOURCES: A PubMed search was performed using the keywords India and food allergy, Asia and food allergy, and South Asia and food allergy for any period. Articles cited in selected studies were reviewed for their appropriateness of inclusion into this review. STUDY SELECTION: Publications were included that were original research and fit the topic of food allergy and South Asia. South Asia is defined as region inclusive of India, Pakistan, Bangladesh, and Sri Lanka. RESULTS: A total of 169 articles were initially identified, and 47 were reviewed in detail for inclusion in this review. The primary focus was placed on 10 studies that consisted of case reports of newly reported or documented food allergy, survey studies that investigated food allergy prevalence in specific demographics, and prospective and cross-sectional studies with case controls, all of which investigated food allergy prevalence by allergy testing in a selected population. CONCLUSION: The medical literature on the prevalence and types of food allergy in South Asia indicates that there is a variety of unusual and unique allergens and an overall low incidence of food allergy. There is also an association of increased food allergy prevalence in individuals who live in metropolitan regions or who migrate to communities that have adopted westernization</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.441</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864090">PM:27864090</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161119-ArakaliSR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161119-ArakaliSR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Arakali SR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.441</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bavishi,A.A.</style></author><author><style face="normal" font="Arial"> Grammer,L.C.</style></author><author><style face="normal" font="Arial"> Pongracic,J.</style></author><author><style face="normal" font="Arial"> Rychlik,K.</style></author><author><style face="normal" font="Arial"> Kumar,R.</style></author><author><style face="normal" font="Arial"> Zee,P.</style></author><author><style face="normal" font="Arial"> Greenberger,P.A.</style></author><author><style face="normal" font="Arial"> Fishbein,A.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology, Department of Allergy, Ann &amp; Robert H. Lurie Children's Hospital, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="Arial">Diurnal variations in subcutaneous allergen immunotherapy reactions</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="107" start="103">103-107</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Circadian Rhythm</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Diurnal variation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Circadian rhythms underlie many immune responses and allergic diseases. Subcutaneous immunotherapy (SCIT) can result in adverse reactions; however, it is unclear whether such reactions have a diurnal pattern. OBJECTIVE: To assess whether the timing of SCIT affects the rate of adverse reactions. METHODS: This study was a retrospective medical record review of adult patients (n = 289) who received SCIT at the Northwestern Medical Faculty Foundation, Chicago, Illinois, during a 10-year period (2004-2014). Injections were given in the outpatient setting. There were a total of 17,457 injections with 574 reactions. Covariates included age, sex, median income, asthma status, vial contents, number of injections, and previous immunotherapy reactions. Logistical regression was used to calculate the odds of having a reaction with time of SCIT administration as the primary determinate. RESULTS: Immunotherapy reactions occurred more frequently after afternoon or evening (pm) injections (328/8721 = 3.8%) vs morning (am) injections (246/8736 = 2.8%), (chi2 = 12.26, P &lt; .01). Systemic reactions, defined as World Allergy Organization grade 1 or higher, did not have diurnal variation (59/8721 = 0.67% for pm vs am 56/8736 = 0.64% for morning; chi2 = 0.08; P = .77). pm injections resulted in higher odds of reaction compared with am injection in a fully adjusted logistic regression model (odds ratio = 1.43; 95% confidence interval, 1.20-1.70; P &lt; .01). When considering time as 4 categories, the highest odds of reaction were noted for the period from 15:01 to 17:30 (odds ratio, 1.55; 95% confidence interval, 1.21-2.00; P &lt; .01). CONCLUSION: pm injections of SCIT are associated with increased cutaneous reaction rates when compared with am injections. In patients experiencing bothersome local reactions, it may be beneficial to administer SCIT in the morning</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864091">PM:27864091</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161119-BavishiAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161119-BavishiAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Bavishi AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Johnson,W.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana.</style></auth-address><titles><title><style face="normal" font="Arial">Angioedema in the omalizumab chronic idiopathic and spontaneous urticarial pivotal studies: Clinical relevance vs statistical significance</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="340" start="339">339-340</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">angioedema</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Louisiana</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - EDITORIALCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742081">PM:27742081</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-339-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-339-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Johnson WD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shah,K.</style></author><author><style face="normal" font="Arial"> Guarderas,J.</style></author><author><style face="normal" font="Arial"> Krishnaswamy,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine and Division of Allergy and Clinical Immunology, Nova Southeastern University/Larkin Hospital, Miami, Florida</style></auth-address><titles><title><style face="normal" font="Arial">Aphthous stomatitis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="343" start="341">341-343</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> aphthous</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Stomatitis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742082">PM:27742082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-341-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-341-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Shah K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bongiorno,M.R.</style></author><author><style face="normal" font="Arial"> Crimi,N.</style></author><author><style face="normal" font="Arial"> Corrao,S.</style></author><author><style face="normal" font="Arial"> Allotta,A.</style></author><author><style face="normal" font="Arial"> Arena,A.</style></author><author><style face="normal" font="Arial"> BRUSCA,I.</style></author><author><style face="normal" font="Arial"> Heffler,E.</style></author><author><style face="normal" font="Arial"> Malara,G.</style></author><author><style face="normal" font="Arial"> Milioto,M.</style></author><author><style face="normal" font="Arial"> Pistone,G.</style></author><author><style face="normal" font="Arial"> Porto,M.</style></author><author><style face="normal" font="Arial"> Raia,E.</style></author><author><style face="normal" font="Arial"> Valenti,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unita Operativa Complessa di Dermatologia e Malattie Sessualmente Trasmesse, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="707" start="703">703-707</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="6" Month="10" Year="2016">2016/10/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161010IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27720581">PM:27720581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161010-BongiornoMR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161010-BongiornoMR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Bongiorno MR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahdavinia,M.</style></author><author><style face="normal" font="Arial"> Bishehsari,F.</style></author><author><style face="normal" font="Arial"> Hayat,W.</style></author><author><style face="normal" font="Arial"> Elhassan,A.</style></author><author><style face="normal" font="Arial"> Tobin,M.C.</style></author><author><style face="normal" font="Arial"> Ditto,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy/Immunology Section, Department of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="Arial">Association of eosinophilic esophagitis and food pollen allergy syndrome</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="117" start="116">116-117</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27856094">PM:27856094</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161118-MahdaviniaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161118-MahdaviniaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Mahdavinia M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van der Valk,J.P.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Nordlee,J.A.</style></author><author><style face="normal" font="Arial"> Vlieg-Boerstra,B.J.</style></author><author><style face="normal" font="Arial"> de Groot,H.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Allergology, Erasmus MC, Rotterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Threshold dose distribution and eliciting dose of cashew nut allergy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="714" start="712">712-714</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eliciting dose</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold dose</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161024IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27773603">PM:27773603</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161024-vanderValkJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161024-vanderValkJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161024, van der Valk JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Makhija,M.M.</style></author><author><style face="normal" font="Arial"> Robison,R.G.</style></author><author><style face="normal" font="Arial"> Caruso,D.</style></author><author><style face="normal" font="Arial"> Cai,M.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Pongracic,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Division of Allergy/Immunology, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="Arial">Patterns of allergen sensitization and self-reported allergic disease in parents of food allergic children</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="386" start="382">382-386</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental allergies</style></keyword><keyword><style face="normal" font="Arial"> environmental allergy</style></keyword><keyword><style face="normal" font="Arial"> Fathers</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Home environment</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Self-reported food allergy</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sensitization in adults has not been extensively studied. OBJECTIVE: To investigate patterns of allergen sensitization in parents of food allergic children and to compare self-report of allergic disease with specific IgE (sIgE) measurements. METHODS: A total of 1,252 mothers and 1,225 fathers of food allergic children answered standardized questionnaires about demographics, home environment, history of atopic diseases, and food allergy. Skin prick testing and sIgE serum tests were performed to 9 foods and 5 aeroallergens. RESULTS: A total of 66.1% of parents were sensitized to either a food or aeroallergen. Mean sIgE levels were low for all foods tested. A total of 14.5% of mothers and 12.7% of fathers reported current food allergy. Only 28.4% had sensitization to their reported allergen. Fathers had significantly higher rates of sensitization to both foods and aeroallergens (P &lt; .01) than mothers. Logistic regression evaluating predictors of self-reported food allergy revealed statistically significant positive associations in fathers with self-reported asthma, environmental allergy, and eczema. For mothers, significant positive associations were found with environmental allergy and having more than 1 food allergic child. CONCLUSION: This cohort of parents of food allergic children found higher rates of sensitization to foods and aeroallergens compared with the general population. However, food sIgE levels were low and correlated poorly with self-reported food allergy. Sex differences in sensitization to foods and aeroallergens were seen</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742085">PM:27742085</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-382-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-382-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Makhija MM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>81999</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gao,J.</style></author><author><style face="normal" font="Arial"> Mansh,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio</style></auth-address><titles><title><style face="normal" font="Arial">Sexual orientation disparities in the prevalence of asthma and allergic rhinitis among US adults</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="437" start="435">435-437</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> disparities</style></keyword><keyword><style face="normal" font="Arial"> disparity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160816IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.07.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27527671">PM:27527671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-435-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-435-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160816, Gao J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.07.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82000</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chung,B.Y.</style></author><author><style face="normal" font="Arial"> Cho,Y.S.</style></author><author><style face="normal" font="Arial"> Kim,H.O.</style></author><author><style face="normal" font="Arial"> Park,C.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy in Korean Patients with Chronic Urticaria</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="568" start="562">562-568</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The etiology of chronic urticaria (CU) remains unknown in most patients. Possible causes in some cases include food, but the role of allergy to food antigens in patients with CU remains controversial. OBJECTIVE: The aim of this study was to evaluate the association between food allergy and CU. METHODS: Korean patients with CU were assessed for a previous history of food allergy that caused symptoms of CU. Blood samples were taken from 350 patients to measure food allergen-specific IgE. Based on history and laboratory results, open oral food challenge (OFC) tests were performed. RESULTS: Of 350 participants, 46 (13.1%) claimed to have experienced previous food hypersensitivity. Pork (n=16) was the main food mentioned, followed by beef (n=7), shrimp (n=6), and mackerel (n=6). We found that 73 participants (20.9%) had elevated levels of food-specific IgE, with pork (n=30), wheat (n=25), and beef (n=23) being the most common. However, when the open OFC tests were conducted in 102 participants with self-reported food hypersensitivity or raised levels of food-specific IgE, only four participants showed a positive reaction to pork (n=3) or crab (n=1). CONCLUSION: Although some participants claimed to have a history of CU related to food intake, when an open OFC test was conducted, few of them had positive results. We therefore conclude that food allergy is an uncommon cause of chronic CU</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2016.28.5.562</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746634">PM:27746634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2016-28-562-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2016-28-562-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Chung BY</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2016.28.5.562</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">You,C.E.</style></author><author><style face="normal" font="Arial"> Moon,S.H.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author><author><style face="normal" font="Arial"> Kim,K.H.</style></author><author><style face="normal" font="Arial"> Park,C.W.</style></author><author><style face="normal" font="Arial"> Seo,S.J.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Emollient Containing Bee Venom on Atopic Dermatitis: A Double-Blinded, Randomized, Base-Controlled, Multicenter Study of 136 Patients</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="599" start="593">593-599</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> transepidermal water loss</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a common, complex disease that follows a chronic relapsing course and significantly affects the quality of life of patients. Skin barrier dysfunction and inflammatory processes induce and aggravate this skin condition. Proper use of an emollient for hydration is a keystone of AD treatment. Bee venom is known to have anti-inflammatory effects and has been widely used in traditional medicine to treat various inflammatory disorders. OBJECTIVE: To find out the beneficial effect of an emollient containing bee venom in the treatment of patients with AD. METHODS: This study included 136 patients with AD who were randomized to receive either an emollient containing bee venom and silk-protein or a vehicle that was identical except for the bee venom for 4 weeks. The patients were instructed to apply the emollient twice daily on their entire body and not to use other medications, including topicals, during the course of the study. The eczema area and severity index (EASI) score, transepidermal water loss, and visual analogue scale (VAS) score of itching were evaluated at the first visit and after 2 and 4 weeks. The investigator global assessment was evaluated at 2 and 4 weeks after the application of emollient containing bee venom or vehicle. RESULTS: Patients applying emollient containing bee venom showed significantly lower EASI score and VAS value compared to patients applying emollient without bee venom. CONCLUSION: Emollient containing bee venom is a safe and effective option for patients with AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2016.28.5.593</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746639">PM:27746639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2016-28-593-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2016-28-593-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, You CE</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2016.28.5.593</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roked,F.</style></author><author><style face="normal" font="Arial"> North,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Birmingham Children's Hospital, Birmingham, UKCity Hospital, SWBH NHS Trust, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="Arial">Thumb-sucking or nail-biting in childhood led to a reduction in atopic sensitisation but not asthma or hay fever</style></title><secondary-title><style face="normal" font="Arial">Arch Dis Child Educ Pract Ed</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dis Child Educ Pract Ed</style></full-title></periodical><pages end="" start="167">167-</pages><volume><style face="normal" font="Arial">102</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161019IS - 1743-0593 (Electronic)IS - 1743-0585 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/archdischild-2016-311819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27756755">PM:27756755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dis Child Educ Pract Ed\20161019-RokedF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dis Child Educ Pract Ed\20161019-RokedF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Roked F</style></custom2><misc3><style face="normal" font="Arial">10.1136/archdischild-2016-311819</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Genere,L.</style></author><author><style face="normal" font="Arial"> Pecciarini,N.</style></author><author><style face="normal" font="Arial"> Peretti,N.</style></author><author><style face="normal" font="Arial"> Villard,F.</style></author><author><style face="normal" font="Arial"> Lachaux,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de gastroenterologie hepatologie et nutrition pediatrique, hospices civils de Lyon, hopital Femme-Mere-Enfant du CHU de Lyon, 59, boulevard Pinel, 69677 Bron cedex, France</style></auth-address><titles><title><style face="normal" font="Arial">[Food protein-induced enterocolitis syndrome: A case report of diarrhea with hypovolemic shock and methemoglobinemia]</style></title><secondary-title><style face="normal" font="Arial">Arch Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Pediatr</style></full-title></periodical><pages end="32" start="28">28-32</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dehydration</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We report on the case of a young infant with chronic diarrhea that worsened and turned into hypovolemic shock with methemoglobinemia. We underline and discuss the main features of food protein-induced enterocolitis syndrome (FPIES). FPIES is a non-IgE-mediated food allergy involving tumor necrosis factor-alpha (TNF-alpha). Many triggering foods exist but cow's milk, as in the case reported herein, is one of the most frequent. It can start early or be delayed and start around the average age of 5 months. Symptoms are nonspecific with diarrhea and vomiting, but in the presence of methemoglobinemia, the diagnosis must be seriously considered. The oral food challenge remains the gold standard to confirm the diagnosis if there is still a doubt. Treatment of FPIES associates emergency treatment of acute dehydration with the prevention of relapses by avoiding the suspected protein</style></abstract><notes><style face="normal" font="Arial">DA - 20161123IS - 1769-664X (Electronic)IS - 0929-693X (Linking)LA - frePT - Journal ArticlePT - English AbstractCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.arcped.2016.10.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27876251">PM:27876251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Pediatr\20161123-GenereL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Pediatr\20161123-GenereL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161123, Genere L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.arcped.2016.10.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de pediatrie, pavillon medicochirurgical de pediatrie, boulevard Lacordaire, 59056 Roubaix, France</style></auth-address><titles><title><style face="normal" font="Arial">[Anaphylaxis in children: What pediatricians should know]</style></title><secondary-title><style face="normal" font="Arial">Arch Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Pediatr</style></full-title></periodical><pages end="1316" start="1307">1307-1316</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic emergencies</style></keyword><keyword><style face="normal" font="Arial"> allergic emergency</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Laryngeal Edema</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Pediatrie</style></keyword><keyword><style face="normal" font="Arial"> Personalized care project</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a severe potentially life-threatening allergic emergency that has been increasing over the last two decades, especially in young children. Anaphylaxis deaths remain rare, in particular in children, and their frequency is stable during this period. Food is the main anaphylaxis trigger in children, notably to cow's milk, peanuts, and tree nuts. In infants, the recognition of anaphylaxis may be difficult. Vomiting, urticaria, and laryngeal edema are more frequent at this age. Cardiovascular involvement is rare, most often encountered in adolescence. A history of asthma or atopy, allergy to particular foods such as peanuts and tree nuts, and adolescence are some risk factors for anaphylaxis and more severe reactions. First-line treatment is intramuscular adrenaline for all patients experiencing anaphylaxis. There are no absolute contra-indications. Guidelines for the prescription of the adrenaline auto-injector and for establishing a personalized care project in allergic children at school have recently been updated. Recognition of anaphylaxis and treatment should also be improved</style></abstract><notes><style face="normal" font="Arial">DA - 20161112IS - 1769-664X (Electronic)IS - 0929-693X (Linking)LA - frePT - Journal ArticlePT - English AbstractCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.arcped.2016.09.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27836164">PM:27836164</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Pediatr\2016-23-1307-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Pediatr\2016-23-1307-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161112, Pouessel G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.arcped.2016.09.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kizhedath,A.</style></author><author><style face="normal" font="Arial"> Wilkinson,S.</style></author><author><style face="normal" font="Arial"> Glassey,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chemical Engineering and Advanced Materials, Newcastle University, Newcastle upon Tyne, NE17RU, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope</style></title><secondary-title><style face="normal" font="Arial">Arch Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Toxicol</style></full-title></periodical><pages end="1612" start="1595">1595-1612</pages><volume><style face="normal" font="Arial">912</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth defects</style></keyword><keyword><style face="normal" font="Arial"> Cardiac arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> in silico tools</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Nephritis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pitfalls</style></keyword><keyword><style face="normal" font="Arial"> predictive model</style></keyword><keyword><style face="normal" font="Arial"> Predictive models</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Biopharmaceuticals, monoclonal antibody (mAb)-based therapeutics in particular, have positively impacted millions of lives. MAbs and related therapeutics are highly desirable from a biopharmaceutical perspective as they are highly target specific and well tolerated within the human system. Nevertheless, several mAbs have been discontinued or withdrawn based either on their inability to demonstrate efficacy and/or due to adverse effects. Approved monoclonal antibodies and derived therapeutics have been associated with adverse effects such as immunogenicity, cytokine release syndrome, progressive multifocal leukoencephalopathy, intravascular haemolysis, cardiac arrhythmias, abnormal liver function, gastrointestinal perforation, bronchospasm, intraocular inflammation, urticaria, nephritis, neuropathy, birth defects, fever and cough to name a few. The advances made in this field are also impeded by a lack of progress in bioprocess development strategies as well as increasing costs owing to attrition, wherein the lack of efficacy and safety accounts for nearly 60 % of all factors contributing to attrition. This reiterates the need for smarter preclinical development using quality by design-based approaches encompassing carefully designed predictive models during early stages of drug development. Different in vitro and in silico methods are extensively used for predicting biological activity as well as toxicity during small molecule drug development; however, their full potential has not been utilized for biological drug development. The scope of in vitro and in silico tools in early developmental stages of monoclonal antibody-based therapeutics production and how it contributes to lower attrition rates leading to faster development of potential drug candidates has been evaluated. The applicability of computational toxicology approaches in this context as well as the pitfalls and promises of extending such techniques to biopharmaceutical development has been highlighted</style></abstract><notes><style face="normal" font="Arial">DA - 20161021IS - 1432-0738 (Electronic)IS - 0340-5761 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00204-016-1876-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27766364">PM:27766364</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Toxicol\20161021-KizhedathA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Toxicol\20161021-KizhedathA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161021, Kizhedath A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00204-016-1876-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arima,T.</style></author><author><style face="normal" font="Arial"> Campos-Alberto,E.</style></author><author><style face="normal" font="Arial"> Funakoshi,H.</style></author><author><style face="normal" font="Arial"> Inoue,Y.</style></author><author><style face="normal" font="Arial"> Tomiita,M.</style></author><author><style face="normal" font="Arial"> Kohno,Y.</style></author><author><style face="normal" font="Arial"> Shimojo,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Immediate systemic allergic reaction in an infant to fish allergen ingested through breast milk</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="259" start="257">257-259</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">This is a rare case report of systemic allergic reaction to fish allergen ingested through breast milk. Mother ate raw fish more than 3 times a week. Her consumption of fish was associated with urticaria and wheeze in an infant via breast-feeding. Fish-specific IgE antibodies were detected by skin prick test but not by in vitro IgE test. This case demonstrates that fish protein ingested by mother can cause an immediate systemic allergic reaction in offspring through breast-feeding. Although fish intake is generally recommended for prevention of allergy, one should be aware that frequent intake of fish by a lactating mother may sensitize the baby and induce an allergic reaction through breast-feeding</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.4.257</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27803887">PM:27803887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-257-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-257-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Arima T</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.4.257</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boonpiyathad,T.</style></author><author><style face="normal" font="Arial"> Sangasapaviliya,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital, Bangkok 10400, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Autologous serum and plasma skin test to predict 2-year outcome in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="235" start="226">226-235</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> long-term outcome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Autologous serum skin test (ASST) and autologous plasma skin test (APST) are simple methods to diagnose autoimmune chronic urticaria. However, the association data of ASST or APST with disease severity and long-term outcome are still unclear. OBJECTIVE: The results of ASST and APST might be used to predict urticaria symptom severity and long-term outcomes among chronic spontaneous urticaria (CSU) patients. METHODS: We evaluated the prevalence of reactive ASST and APST in 128 CSU patients. The patients were characterized by 4 groups: negative, ASST positive, APST positive, and both ASST and APST positive. We observed remission rate among the CSU patients during 2 years. RESULTS: Forty-four of 128 CSU patients (34%) had negative autologous skin test. The CSU patients with positive ASST, positive APST, and both positive ASST and APST were 47 (37%), 6 (5%), and 31 (24%), respectively. No significant difference was found between the groups according to urticaria severity score (USS) and dermatology life quality index (DLQI). Mean wheal diameter of ASST showed positive correlation with DLQI. Also, mean wheal diameter of APST showed positive correlation with USS and DLQI. Both the positive ASST and APST groups had a high proportion of 4-fold dose of H1-antihistamine than the positive ASST (p = 0.03) and negative groups (p = 0.0009). The rate of remission over 2 years in the negative, positive ASST, positive APST, and both positive ASST and APST groups were 81.1%, 62.3%, 60%, and 46.1%, respectively. The urticaria remission rate in patients in the negative group was significantly higher compared with both positive ASST and APST groups (odds ratio, 5.0; 95% confidence interval, 1.61-15.44; p = 0.006). CONCLUSION: ASST and APST results could predict remission rates among patients with CSU. Our results suggested investigating ASST and APST among CSU patients before starting treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.4.226</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27803883">PM:27803883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-226-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-226-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Boonpiyathad T</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.4.226</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sakihara,T.</style></author><author><style face="normal" font="Arial"> Sugiura,S.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Aichi Children's Health and Medical Center, Obu 474-8710, Japan</style></auth-address><titles><title><style face="normal" font="Arial">The ingestion of cow's milk formula in the first 3 months of life prevents the development of cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="212" start="207">207-212</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cow's milk formula</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> hen's egg allergy</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IgE-mediated cow's milk allergy (CMA) is one of the most common food allergies in infants. It is still controversial whether the early introduction of cow's milk formula (CMF) prevents the development of CMA. OBJECTIVE: We aimed to evaluate the duration and frequency of CMF ingestion as compere with exclusive breast-fed for preventing CMA in high-risk infants. METHODS: We enrolled the patients diagnosed with hen's egg allergy by an oral food challenge. A questionnaire was completed by the caregivers of the patients regarding the timing of introduction and discontinuation of CMF, and the frequency of CMF ingestion. Based on the information, we analyzed the relationship between the duration and frequency of CMF ingestion and the development of CMA at 3-24 months of age. RESULTS: Three hundred seventy-four patients were analyzed; 171 were diagnosed with CMA (45.7%). The analyzed patients (n = 374) were categorized into the following subgroups: exclusively breast-fed (breast-fed group, n = 75); discontinued ingestion of CMF before 3 months of age (temporary group, n = 177); continuous ingestion of CMF, but not daily, up to 3 months of age (nondaily group, n = 47); continuous ingestion of CMF at least once daily (daily group, n = 75). The incidence of developing CMA between the breast-fed group and temporary group did not show any statistical difference. Nondaily group and daily group had significantly lower incidence of developing CMA in comparison to the breast-fed group (nondaily group odds ratio 0.43; p = 0.02, daily group odds ratio 0.11; p &lt; 0.001). CONCLUSION: Ingestion of CMF during the first 3 months of life might prevent the development of CMA in high-risk infants</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2016.6.4.207</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27803880">PM:27803880</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-207-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2016-6-207-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Sakihara T</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2016.6.4.207</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yoon,L.</style></author><author><style face="normal" font="Arial"> Kim,B.R.</style></author><author><style face="normal" font="Arial"> Kim,Y.M.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Kim,K.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Research Institute of Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Clinical features of anaphylaxis according to age in a center</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="101" start="96">96-101</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Prevalence of anaphylaxis is increasing steadly but we have little information of anaphylaxis. OBJECTIVE: This study was aimed to identify the prevalence of anaphylaxis and evaluate the cause and features of anaphylaxis according to age. METHODS: This study investigated gender, age, history of allergic diseases, causes and clinical symptoms, treatment and prognosis of anaphylaxis retrospectively in patients diagnosed with anaphylaxis in Pusan National University Hospital from January 2009 to June 2014. RESULTS: A total 161 patients, 30 children and 131 adults were identified. During the period surveyed, the prevalence rate of anaphylaxis in both children and adults has increased. The most common triggers reported were food in children and drug in adults. Especially in less than 5 years, causes of anaphylaxis were mostly food. All the children with episodes of anaphylaxis were presented with cutaneous symptoms and 90% had respiratory symptoms. For adults, cardiovascular symptoms are more common. CONCLUSIONS: In this study, we found increasing prevalence of anaphylaxis annually in both children and adults, especially at a higher rate in children. The causes and symptoms of anaphylaxis may differ depending on ages. Therefore, Clinicians should understand the characteristics of anaphylaxis by age and actively diagnosis and prescribe epinephrine</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0767</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27543733">PM:27543733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\20160820-YoonL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\20160820-YoonL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Yoon L</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0767</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Su,Y.T.</style></author><author><style face="normal" font="Arial"> Yang,Y.N.</style></author><author><style face="normal" font="Arial"> Li,Y.C.</style></author><author><style face="normal" font="Arial"> Tsai,C.C.</style></author><author><style face="normal" font="Arial"> Chen,L.M.</style></author><author><style face="normal" font="Arial"> Lin,Y.C.</style></author><author><style face="normal" font="Arial"> Niu,C.K.</style></author><author><style face="normal" font="Arial"> Tsai,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Pulmonology and Allergy-Immunology, Department of Pediatrics, E-Da Hospital/I-Shou University, Kaohsiung City, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Age-dependent distribution of the atopic phenotype and allergen sensitization among asthmatic children in southern Taiwan</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="211" start="206">206-211</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma guidelines</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is divided into atopic and non-atopic phenotypes. The percentages of atopic asthma and allergen sensitization in patients of different ages have not been well studied. OBJECTIVE: To determine the percentage distribution of atopic and non-atopic phenotypes in different age groups of asthmatic children, and investigate the distribution of specific IgE to different allergens when stratified by age group in southern Taiwan. METHOD: We conducted this hospital-based, retrospective, cross-sectional study in southern Taiwan between 2004 and 2006. Asthmatic children aged 3 to 18 years who were diagnosed according to the Global Initiative for Asthma guidelines were enrolled. The MAST-CLA system was used to detect 36 allergen-specific IgEs. RESULTS: A total of 620 asthmatic children were divided into three groups: preschool (3-6 years old, n=360), school-aged (7-12 years old, n=213), and adolescent (13-18 years old, n=41) children. The atopic and non-atopic phenotypes were observed in 54.8% and 45.2% of the asthmatic children, respectively. The atopic phenotype was observed in 45.6%, 65.7%, and 80.5% of the preschool, school-aged and adolescent groups, respectively. The percentages of the atopic phenotype were significantly different when stratified by age group (p&lt;0.001), and there was a positive trend of percentage distribution. The percentages of sensitization to aeroallergens were significantly different and observed in 44.0%, 65.7%, and 80.5% of the preschool, school-aged and adolescent groups, respectively (p&lt;0.001). There were positive trends between age groups and prevalence rates of sensitization to the main aeroallergen and other aeroallergen groups, but not to each allergen of the seafood or other food allergen group. CONCLUSIONS: A trend of an increasing percentage of the atopic phenotype when stratified by age group was found in asthmatic children in southern Taiwan. Aeroallergens contributed more to pediatric asthma than food allergens. The prevalence of sensitization to aeroallergens increased with increasing age when stratified by age group</style></abstract><notes><style face="normal" font="Arial">DA - 20160521IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0475</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27001656">PM:27001656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-206-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-206-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160521, Su Y</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0475</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kulthanan,K.</style></author><author><style face="normal" font="Arial"> Tuchinda,P.</style></author><author><style face="normal" font="Arial"> Chularojanamontri,L.</style></author><author><style face="normal" font="Arial"> Chanyachailert,P.</style></author><author><style face="normal" font="Arial"> Korkij,W.</style></author><author><style face="normal" font="Arial"> Chunharas,A.</style></author><author><style face="normal" font="Arial"> Wananukul,S.</style></author><author><style face="normal" font="Arial"> Limpongsanurak,W.</style></author><author><style face="normal" font="Arial"> Benjaponpitak,S.</style></author><author><style face="normal" font="Arial"> Wisuthsarewong,W.</style></author><author><style face="normal" font="Arial"> Aunhachoke,K.</style></author><author><style face="normal" font="Arial"> Wessagowit,V.</style></author><author><style face="normal" font="Arial"> Chatchatee,P.</style></author><author><style face="normal" font="Arial"> Wattanakrai,P.</style></author><author><style face="normal" font="Arial"> Jirapongsananuruk,O.</style></author><author><style face="normal" font="Arial"> Klaewsongkram,J.</style></author><author><style face="normal" font="Arial"> Noppakun,N.</style></author><author><style face="normal" font="Arial"> Vichyanond,P.</style></author><author><style face="normal" font="Arial"> Suthipinittharm,P.</style></author><author><style face="normal" font="Arial"> Ruxrungtham,K.</style></author><author><style face="normal" font="Arial"> Singalavanija,S.</style></author><author><style face="normal" font="Arial"> Ngamphaiboon,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Clinical practice guideline for diagnosis and management of urticaria</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="200" start="190">190-200</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Drying</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> NSAID</style></keyword><keyword><style face="normal" font="Arial"> NSAIDs</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Urticaria is a common skin condition that can compromise quality of life and may affect individual performance at work or school. Remission is common in majority of patients with acute spontaneous urticaria (ASU); however, in chronic cases, less than 50% had remission. Angioedema either alone or with urticaria is associated with a much lower remission rate. Proper investigation and treatment is thus required. This guideline, a joint development of the Dermatological Society of Thailand, the Allergy, Asthma, and Immunology Association of Thailand and the Pediatric Dermatological Society of Thailand, is graded and recommended based on published evidence and expert opinion. With simple algorithms, it is aimed to help guiding both adult and pediatric physicians to better managing patients who have urticaria with/without angioedema. Like other recent guideline, urticaria is classified into spontaneous versus inducible types. Patients present with angioedema or angioedema alone, drug association should be excluded, acetyl esterase inhibitors (ACEIs) and non-steroidal anti-inflammatory drugs (NSAIDs) in particular. Routine laboratory investigation is not cost-effective in chronic spontaneous urticaria (CSU), unless patients have clinical suggesting autoimmune diseases. Non-sedating H1-antihistamine is the first-line treatment for 2-4 weeks; if urticaria was not controlled, increasing the dose up to 4 times is recommended. Sedating first-generation antihistamines have not been proven more advantage than non-sedating antihistamines. The only strong evidence-based alternative regimen for CSU is an anti-IgE: omalizumab; due to very high cost it however might not be accessible in low-middle income countries. Non-pharmacotherapeutic means to minimize hyper-responsive skin are also important and recommended, such as prevention skin from drying, avoidance of hot shower, scrubbing, and excessive sun exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20161003IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Thailand -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27690471">PM:27690471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-190-200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-190-200.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161003, Kulthanan K</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tham,E.H.</style></author><author><style face="normal" font="Arial"> Lee,A.J.</style></author><author><style face="normal" font="Arial"> Bever,H.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore and Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Aeroallergen sensitization and allergic disease phenotypes in Asia</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="189" start="181">181-189</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pressing</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Sanitation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urbanization</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Allergic diseases are on the rise in Asia. Aeroallergen exposure is a strong risk factor for sensitization, development and severity of atopic diseases, especially in the Asian paediatric population. Geographical and seasonal variations in aeroallergen sensitization are seen even within Asian countries and changes in aeroallergen sensitization patterns have been observed over time. Some possible reasons include climate change as well as rapid urbanization and improved sanitation which follow socioeconomic development. House dust mite allergy is present in up to 90% of Asian atopic patients, far exceeding that which is seen in Western populations which report prevalences of only 50% to 70%. Pollen and animal dander affect less than 10% of Asian patients as compared to 40-70% of individuals with asthma and allergic rhinitis living in the West, a burden almost equivalent to the dust mite burden in those regions. There is thus a pressing need for preventive measures to reduce dust mite sensitization in Asian children today</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0770</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27543739">PM:27543739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-181-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-181-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Tham EH</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0770</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,K.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Yu,B.</style></author><author><style face="normal" font="Arial"> Duan,Z.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Qi,Q.</style></author><author><style face="normal" font="Arial"> Zhou,R.</style></author><author><style face="normal" font="Arial"> Zhou,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Rehabilitation Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of fastigial nucleus electrostimulation on airway inflammation and remodeling in an experimental rat model of asthma</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="228" start="223">223-228</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a chronic disease involving an immune response, which is characterized by non-specific inflammation and airway remodeling. Glucocorticoids are clinically beneficial in controlling asthma, but further options are needed. In our study, fastigial nucleus electrostimulation (FNS) was applied in a rat asthma model for the first time to investigate the effects of pre-intervention. OBJECTIVE: To observe the effects of FNS on airway inflammation and remodeling in asthmatic rats. METHODS: Forty rats were assigned randomly to the normal control (CON), model (MDL), FNS, or budesonide (BUD) groups. Asthma was induced with chicken egg (OVA). The animals in the CON and MDL groups were treated with normal saline. The animals in the other two groups received FNS or budesonide, respectively. RESULTS: The results indicated that IgE in the serum and airway fiber areas were higher in the MDL group than in other groups. After treatment for 3 weeks, collagen fibers in the bronchial wall in the FNS group were significantly lower compared with the MDL group. CONCLUSION: FNS significantly reduced IL-4, IL-13, TNF-alpha, OVA-IgE and TGF-beta1 in serum and BALF, and increased IFN-gamma. Our results suggest that FNS may ameliorate asthma symptoms and induce changes of cytokines in the serum and lung milieu</style></abstract><notes><style face="normal" font="Arial">DA - 20160521IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0705</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27001654">PM:27001654</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-223-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-223-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160521, Li K</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0705</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pornsuriyasak,P.</style></author><author><style face="normal" font="Arial"> Kawamatawong,T.</style></author><author><style face="normal" font="Arial"> Rattanasiri,S.</style></author><author><style face="normal" font="Arial"> Tantrakul,V.</style></author><author><style face="normal" font="Arial"> Pongmesa,T.</style></author><author><style face="normal" font="Arial"> Birring,S.S.</style></author><author><style face="normal" font="Arial"> Thakkinstian,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University</style></auth-address><titles><title><style face="normal" font="Arial">Validity and reliability of the Thai version of the leicester cough questionnaire in chronic cough</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="216" start="212">212-216</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic cough</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> SF36</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic cough is a common problem potentially disturbing the quality of life (QoL) of coughers. The Leicester Cough Questionnaire (LCQ), previously developed in England, is a validated, self-completed QoL instrument for assessment of chronic cough. This study aimed to develop a Thai version of the LCQ (LCQ-T) and assess its validity and reliability among adult Thai patients with subacute to chronic cough. METHODS: A total of 146 patients with a cough lasting for more than 3 weeks consented to participate in this study and self-administered the LCQ-T, together with the following 3 instruments: Borg Cough Scale (BCS), Short Form-36 (SF-36), and Hospital Anxiety Depression Scale (Thai-HADS). The LCQ-T was developed by applying a forward-backward translation approach. The LCQ-T comprises 19 items divided into 3 domains: physical (8 items), psychological (7 items), and social (4 items). To validate the LCQ-T, concurrent validity, internal consistency reliability, and test-retest reliability were assessed. RESULTS: Participants included 96 women and 50 men with a mean (SD) age of 59.6 (14.4) years. The concurrent validity comparing LCQ-T to BCS yielded statistically significant Pearson correlation coefficients (r= -0.74, P&lt;0.05). The correlation coefficients for SF-36 and Thai-HADS were also significant. The LCQ-T demonstrated very good internal consistency in all domains and the overall scale, with the Cronbach's alpha coefficients ranging from 0.89 to 0.94. The 3-day repeatability of the LCQ-T in 25 clinically stable patients was high with the intra-class correlation coefficients ranging between 0.81 and 0.90. CONCLUSION: LCQ-T is a valid and reliable cough-specific instrument for assessing symptoms and QoL of adult Thai patients with subacute to chronic cough</style></abstract><notes><style face="normal" font="Arial">DA - 20160521IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Thailand -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0685.34.3.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27001649">PM:27001649</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-212-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-212-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160521, Pornsuriyasak P</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0685.34.3.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumjim,S.</style></author><author><style face="normal" font="Arial"> Jirapongsananuruk,O.</style></author><author><style face="normal" font="Arial"> Piboonpocanun,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Molecular Biosciences, Mahidol University, Nakhon pathom, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Cloning and characterization of recombinant tropomyosin of giant freshwater shrimp M. rosenbergii to determine major allergens causing allergic reactions among shrimp-allergic children</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="235" start="229">229-235</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> binding affinity</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Macrobrachium rosenbergii</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Pichia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Seawater</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergen</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergy</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Seawater and freshwater shrimp are some of the most common causes of food allergy among children in Thailand. Tropomyosin has been reported as a major allergen for shrimp allergic populations around the world. Despite a high number of shrimp-allergic Thai children, however, it is unknown whether shrimp tropomyosin is a major cause of allergic reactions. OBJECTIVES: To clone and characterize tropomyosin of giant freshwater shrimp Macrobrachium rosenbergii (Mr) and determine whether this tropomyosin is a major cross-reactive allergen for Thai children with shrimp allergy. METHODS: Recombinant shrimp Mr tropomyosin (Mac r1.0101) was expressed in yeast Pichia pastoris. Secondary structure composition of purified recombinant Mac r1.0101 was determined by Circular Dichroism. IgE reactivity was examined by immunoblot, direct binding ELISA and inhibition of IgE ELISA using serum from shrimp-allergic children. RESULTS AND CONCLUSION: The amino acid sequence of Mac r1.0101 showed 2 polymorphic amino acids (F44 and S45) indicating a variant of tropomyosin. Purified recombinant Mac r1.0101 obtained a nature-like alpha-helix structure which can be bound by serum-specific IgE. The binding affinity of serum-specific IgE to Mac r1.0101 based on the IC50 value was ~1.8 ng/ml. Ten of 13 shrimp-allergic Thai children had serum-specific IgE against Mac r1.0101, but at different levels. Results of the inhibition of specific IgE using Mac r1.0101 showed that 7 of the tested serum samples also had specific IgE against other shrimp allergens in addition to IgE against Mac r1.0101. Tropomyosin therefore appears to be a major cross-reactive allergen for Thai children who are allergic to both seawater and giant freshwater shrimp</style></abstract><notes><style face="normal" font="Arial">DA - 20160521IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0698</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27001653">PM:27001653</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-229-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-229-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160521, Kumjim S</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0698</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uysal,P.</style></author><author><style face="normal" font="Arial"> Demir,F.</style></author><author><style face="normal" font="Arial"> Turan,N.</style></author><author><style face="normal" font="Arial"> Telli,M.</style></author><author><style face="normal" font="Arial"> Ozdemir,N.</style></author><author><style face="normal" font="Arial"> Erge,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Staphylococcus Aureus Colonization and the Factors Affecting Colonization in Children with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="80" start="71">71-80</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Objective: The aims of the study were to evaluate the prevalence of Staphylococcus aureus (S. aureus) colonization and to determine the risk factors related to colonization.Materials and Methods: Nasal swab cultures were obtained from all participants. Lesional skin swabs were taken from atopic children and fingertip skin swabs were taken from healthy controls. The severity of atopic dermatitis was evaluated by using the SCORing Atopic Dermatitis (SCORAD) and Eczema Severity and Scoring Index (EASI) scores at the beginning and also at the end of the study after a year of follow-up. Serum total IgE levels were measured. Atopic status was evaluated by skin prick tests.Results: Nasal S. aureus colonization was higher in children with atopic dermatitis compared to healthy controls (p=0.034). Both nasal and skin S. aureus colonization was associated with disease severity (p=0.047, p=0.04, respectively). Nasal S. aureus colonization was significantly associated with male gender, high serum total IgE levels, extrinsic atopic dermatitis and skin S. aureus colonization (p&lt;0.05). Skin S. aureus colonization was only associated with nasal S. aureus colonization (p=0.012). In logistic regression analysis, female gender [p=0.04, adjusted Odds Ratio (aOR):0.15, 95% Coefficient Interval (CI): 0.28-0.916], and having non-colonized skin with S.aureus (p=0.027, aOR:0.14, 95% CI:0.26-0.807) were associated with lower risk for nasal S. aureus colonization, whereas, high serum total IgE levels were associated with increased risk for nasal S. aureus colonization (p=0.026, aOR:1.04; 95% CI: 1.001-1.008).Conclusion: Nasal S. aureus colonization is high in children with atopic dermatitis. Both nasal and skin S. aureus colonization are associated with disease severity. Male gender, high serum IgE levels and skin S. aureus colonization are associated with nasal S. aureus colonization.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.21911/aai.6005</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.6005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-71-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-71-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Uysal P</style></custom2><misc3><style face="normal" font="Arial">10.21911/aai.6005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Haktanir Abul,M.</style></author><author><style face="normal" font="Arial"> Kaya,A.</style></author><author><style face="normal" font="Arial"> Kilic Topcu,Z.I.</style></author><author><style face="normal" font="Arial"> Irmak,E.</style></author><author><style face="normal" font="Arial"> Orhan,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Parent-Reported Prevalence and Clinical Characteristics of Nut Allergy Among School-Aged Children Living in City Center of Giresun</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="92" start="88">88-92</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Objective: Despite the high rate of consumption in our country, the definite prevalence of any nut allergy is not known. The aim of this study was to evaluate the prevalence and clinical characteristics of hazelnut and other nut allergies in Giresun, a city where hazelnut is cultivated in large amounts.Materials and Methods: This study was a cross-sectional study. The prevalence and clinical characteristics of IgE-mediated nut allergy was investigated with the survey method in 6000 randomly selected children, between the ages of 6 and 17 years, from three kindergarden, nine primary schools and two high schools located in the city center of Giresun.Results: The response rate to questionnaires was 82.0% (4932/6000), and the reported prevalence of nut allergy was 2.7% (134/4932). Among patients who accepted the telephone survey, 49 were thought to have a possible IgE-mediated allergic reaction with nuts. Of them, 25 were female and the mean age was 12.6±3.2 years (between ages 6 and 17 years) and 65.3% of the children had associated atopic disease. Reported prevalence of hazelnut, peanut, pistachio and walnut was 0.4%, 0.3%, 0.2% and 0.1% respectively. The most common symptoms were cutaneous and respiratory. The reactions most commonly occurred at home.Conclusion: The prevalence of nut allergy is low and the clinical symptoms are mild among school-aged children living in Giresun. Children with suspected nut allergy should be referred to allergy clinics for further evaluation as nuts may cause sudden and lifethreatening reactions.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="FrutigerRoman">10.21911/aai.6014</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.6014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-88-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-88-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Haktanir Abul M</style></custom2><misc3><style face="normal" font="FrutigerRoman">10.21911/aai.6014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ginis,T.</style></author><author><style face="normal" font="Arial"> Koc,N.</style></author><author><style face="normal" font="Arial"> Guvenir,H.</style></author><author><style face="normal" font="Arial"> Cetin,C.</style></author><author><style face="normal" font="Arial"> Toyran,M.</style></author><author><style face="normal" font="Arial"> Civelek,E.</style></author><author><style face="normal" font="Arial"> Kocabas,C.N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Level of Knowledge of Dietitians About Dietary Management of Children with Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="87" start="81">81-87</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietetics</style></keyword><keyword><style face="normal" font="Arial"> Dietitian</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Policy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Objective: The aim of this study was to evaluate the knowledge of dietitians and dietetic students about food allergy in order to develop suggestions for educational activities.Materials and Methods: Dietitians and dietetics students were surveyed via a questionnaire aimed to document their knowledge about food allergy management.Results: Of the 150 questionnaires distributed, 122 valid questionnaires were returned. The response rate was 81.3%. Of all the respondents, 51.4% were working in a hospital. About sixty percent of respondents rated themselves 'moderate' for identifying some clinical manifestations of FA, developing elimination diets, providing avoidance education, managing the dietary needs of children with cows' milk allergy (CMA). Only 72.1% of respondents answered the questions about foods that can cause anaphylaxis correctly. About forty percent of respondents did not recognize that food allergens could be transmitted by means of tools used for service such as knives and spoons and thought that smoke of the cooking food does not cause allergy. About sixty percent of respondents also thought that touching the food never causes allergic reactions. Of all the respondents, only about 18.9% suggested amino acid based formulas for children with CMA, 23% suggested fully hydrolized formulas and 39.3% thought that lactose free formulas can be given to patients with CMA.Conclusion: This study revealed that there are some gaps in the knowledge of dietitians about food allergy. Dietitians should be given training on this subject and there should be a re-evaluation of health policies with a wider global perspective.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="FrutigerRoman">10.21911/aai.6006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.6006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-81-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-81-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Ginis T</style></custom2><misc3><style face="normal" font="FrutigerRoman">10.21911/aai.6006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inoue,A.</style></author><author><style face="normal" font="Arial"> Wada,K.</style></author><author><style face="normal" font="Arial"> Matsuura,K.</style></author><author><style face="normal" font="Arial"> Osafune,H.</style></author><author><style face="normal" font="Arial"> Ida,Y.</style></author><author><style face="normal" font="Arial"> Kosakai,A.</style></author><author><style face="normal" font="Arial"> Edamatsu,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Toho University Omori Hospital, Japan</style></auth-address><titles><title><style face="normal" font="Arial">IgG4-related disease in the sinonasal cavity accompanied by intranasal structure loss</style></title><secondary-title><style face="normal" font="Arial">Auris Nasus Larynx</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Auris Nasus Larynx</style></full-title></periodical><pages end="104" start="100">100-104</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic sinusitis</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epistaxis</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Salivary Glands</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Sphenoid Sinus</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2016">2016/2</year></dates><abstract><style face="normal" font="Arial">IgG4-related disease was recently proposed under the classification of systemic chronic inflammatory disease. In the field of otolaryngology, organ-specific diagnostic criteria have been established for the occurrence of this condition in the salivary glands, but not in the sinonasal cavity. Here we report a case involving a 70-year-old man with IgG4-related disease in the sinonasal cavity. The patient, with the chief complaint of nasal bleeding, first visited a physician. However, the patient experienced recurrent bleeding with intranasal structure loss and was subsequently referred to our hospital. His IgG4 level was elevated, and histopathological examination of a tissue sample obtained from the edematous sphenoid sinus showed increased IgG4-positive plasma cells and storiform fibrosclerosis. A definitive diagnosis of IgG4-related rhinosinusitis was made on the basis of comprehensive criteria for IgG4-related disease. The disease showed a progressively destructive course that was clearly different from that of chronic sinusitis and represented a very rare case of IgG4-related rhinosinusitis. IgG4-related disease originating in the sinonasal cavity is rare, and, to the best of our knowledge, this is the first primary case of IgG4-related disease that originated in one side of the sinonasal cavity and showed progressive destruction</style></abstract><notes><style face="normal" font="Arial">DA - 20160206IS - 1879-1476 (Electronic)IS - 0385-8146 (Linking)LA - ENGPT - Case ReportsPT - Journal ArticleRN - 0 (Immunoglobulin G)SB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anl.2015.05.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26104224">PM:26104224</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Auris Nasus Larynx\2016-43-100-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Auris Nasus Larynx\2016-43-100-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160206, Inoue A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anl.2015.05.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shirasaki,H.</style></author><author><style face="normal" font="Arial"> Yamamoto,T.</style></author><author><style face="normal" font="Arial"> Abe,S.</style></author><author><style face="normal" font="Arial"> Kanaizumi,E.</style></author><author><style face="normal" font="Arial"> Kikuchi,M.</style></author><author><style face="normal" font="Arial"> Himi,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Sapporo Medical University, School of Medicine, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Clinical benefit of component-resolved diagnosis in Japanese birch-allergic patients with a convincing history of apple or peach allergy</style></title><secondary-title><style face="normal" font="Arial">Auris Nasus Larynx</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Auris Nasus Larynx</style></full-title></periodical><pages end="446" start="442">442-446</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rosaceae</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: In northern Japan, birch pollen is the major allergen in pollinosis, while oral allergy syndrome (OAS) is caused primarily by apple and peach, and is almost exclusively related to birch pollinosis. To clarify the clinical benefit of allergen-based component-resolved diagnosis (CRD) in Japanese birch-allergic patients with OAS, we present an analysis of IgE profiles in response to crude extracts and recombinant component-resolved allergen to birch pollen and Rosaceae fruits allergens. METHODS: The sera of 30 patients with birch pollen-related OAS to apple or peach were analyzed for specific IgE reactivity to pathogenesis-related class 10 (PR-10) family (birch: rBet v 1, apple: rMal d 1, and peach: rPru p 1), profilin (birch: rBet v 2 and peach: rPru p 4), and lipid transfer protein (LTP) (apple: rMal d 3 and peach: rPru p 3) allergens, as well as to conventional crude, unfractionated extracts (birch: T3, apple: f49, and peach: f95) using the ImmunoCAP System. Allergen-specific IgE values &lt;0.35kUA/L were considered negative. RESULTS: Of the 30 sera CAP-positive for natural birch pollen extract, 28 (93.3%) exhibited specific IgE against Bet v1, and two (6.7%) contained specific IgE against Bet v2. Of the 26 sera of OAS to apple patients, only 17 were positive for specific IgE against f49 extract (65.4%); however, 24 were positive for specific IgE against rMal d 1 (92.3%). Similarly, only 17 of the 23 sera of OAS to peach patients contained specific IgE against the f95 extract (73.9%); however, 22 were positive for specific IgE against rPru p 1 (95.7%). CONCLUSION: Our data suggest that CRD constitutes a reliable tool for the diagnosis of birch pollen-related OAS</style></abstract><notes><style face="normal" font="Arial">DA - 20161106IS - 1879-1476 (Electronic)IS - 0385-8146 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anl.2016.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27816237">PM:27816237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Auris Nasus Larynx\20161106-ShirasakiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Auris Nasus Larynx\20161106-ShirasakiH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161106, Shirasaki H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anl.2016.10.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nikolic,J.</style></author><author><style face="normal" font="Arial"> Nesic,A.</style></author><author><style face="normal" font="Arial"> Cavic,M.</style></author><author><style face="normal" font="Arial"> Dordevic,N.</style></author><author><style face="normal" font="Arial"> Andelkovic,U.</style></author><author><style face="normal" font="Arial"> Atanaskovic-Markovic,M.</style></author><author><style face="normal" font="Arial"> Drakulic,B.</style></author><author><style face="normal" font="Arial"> Gavrovic-Jankulovic,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry, Faculty of Chemistry, University of Belgrade, Belgrade, Serbia</style></auth-address><titles><title><style face="normal" font="Arial">Effect of malondialdehyde on the ovalbumin structure and its interactions with T84 epithelial cells</style></title><secondary-title><style face="normal" font="Arial">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochim Biophys Acta</style></full-title></periodical><pages end="134" start="126">126-134</pages><volume><style face="normal" font="Arial">1861</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid peroxidation</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics Simulation</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein oxidation</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="15" Month="11" Year="2016">2016/11/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Protein oxidation can occur as a consequence of lipid peroxidation during food processing. The aim of this work was to explore the effect of malondialdehyde (MDA) modification of ovalbumin (OVA) on its interaction with T84 intestinal cells. METHODS: Molecular dynamics simulation was employed for the prediction of MDA modification in the OVA, while introduced structural changes were evaluated by measurement of carbonyl group content, fluorescence spectra, MS/MS analysis, and IgE reactivity. Effects of MDA modified OVA on T84 epithelial cells were analyzed by gene expression for pro-inflammatory cytokines and protein secretion. RESULTS: Out of 9 predicted, five modified Lys residues were confirmed by MS/MS analysis: 51TQINKVVR58, 85DILNQITKPNDVYSFSLASR104, 111YPILPEYLQCVKELYR126, 187AFKDEDTQAMPFR199, 277KIKVYLPR284, and 278IKVYLPR284. The introduced MDA modifications influenced profile of IgE reactivity to OVA. Treatment of T84 epithelial cells with OVA and OVA modified with 1mM MDA, induced up-regulation of pro-inflammatory cytokines (IL-1beta, IL-25, IL-33, TSLP and TNFalpha), while OVA modification with 10mM MDA induced down regulation of the cytokine expression profile, except for IL-1beta. OVA and OVA modified with 1mM MDA induced secretion of epithelial cells specific cytokine IL-33. CONCLUSIONS: This finding indicated that OVA and its MDA modified form have the potential to trigger the innate immunity by inducing up-regulation and secretion of pro-allergenic IL-33 in T84 intestinal epithelial cells. GENERAL SIGNIFICANCE: Interactions of ovalbumin and its MDA modified form with intestinal epithelial cells can induce a specific immunological priming necessary for the downstream activation of innate immunity</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticleCO - Serbia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbagen.2016.11.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864150">PM:27864150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\2016-1861-126-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\2016-1861-126-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Nikolic J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbagen.2016.11.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakajima,O.</style></author><author><style face="normal" font="Arial"> Nishimaki-Mogami,T.</style></author><author><style face="normal" font="Arial"> Kondo,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Biochemistry, National Institute of Health Sciences</style></auth-address><titles><title><style face="normal" font="Arial">Cas9 in Genetically Modified Food Is Unlikely to Cause Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Biol Pharm Bull</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biol Pharm Bull</style></full-title></periodical><pages end="1880" start="1876">1876-1880</pages><volume><style face="normal" font="Arial">39</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen database</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetically modified food</style></keyword><keyword><style face="normal" font="Arial"> genetically modified organism</style></keyword><keyword><style face="normal" font="Arial"> genetically modified organisms</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> GMO</style></keyword><keyword><style face="normal" font="Arial"> GMOs</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Open Reading Frames</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> Reading Frames</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> simulated gastric fluid</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Genome editing has undergone rapid development during the last three years. It is anticipated that genetically modified organisms (GMOs) for food purposes will be widely produced using the clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR)/Cas9 system in the near future. However, the Cas9 gene may then enter the genomes of GMOs for food if the breeding process is not strictly managed, which could lead to the Cas9 protein or associated peptides being produced within these organisms. A variety of peptides could theoretically be produced from the Cas9 gene by using open reading frames different from that of Cas9 in the GMOs. In this study, Cas9 and the peptides potentially encoded by Cas9 genes were studied regarding their immunogenicity, in terms of the digestibility of Cas9 and the homology of the peptides to food allergens. First, the digestibility and thermal stability of Cas9 were studied. Digestibility was tested with natural or heat-denatured Cas9 in simulated gastric fluid in vitro. The two types of Cas9 were digested rapidly. Cas9 was also gradually degraded during heat treatment. Second, the peptides potentially encoded by Cas9 genes were examined for their homology to food allergens. Specifically, an 8-mer exact match search and a sliding 80-mer window search were performed using allergen databases. One of the peptides was found to have homology with a food allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 1347-5215 (Electronic)IS - 0918-6158 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1248/bpb.b16-00542</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27803459">PM:27803459</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biol Pharm Bull\2016-39-1876-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biol Pharm Bull\2016-39-1876-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Nakajima O</style></custom2><misc3><style face="normal" font="Arial">10.1248/bpb.b16-00542</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okamoto-Uchida,Y.</style></author><author><style face="normal" font="Arial"> Nakamura,R.</style></author><author><style face="normal" font="Arial"> Matsuzawa,Y.</style></author><author><style face="normal" font="Arial"> Soma,M.</style></author><author><style face="normal" font="Arial"> Kawakami,H.</style></author><author><style face="normal" font="Arial"> Ishii-Watabe,A.</style></author><author><style face="normal" font="Arial"> Nishimaki-Mogami,T.</style></author><author><style face="normal" font="Arial"> Teshima,R.</style></author><author><style face="normal" font="Arial"> Saito,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Medicinal Safety Science, National Institute of Health Sciences</style></auth-address><titles><title><style face="normal" font="Arial">Different Results of IgE Binding- and Crosslinking-Based Allergy Tests Caused by Allergen Immobilization</style></title><secondary-title><style face="normal" font="Arial">Biol Pharm Bull</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biol Pharm Bull</style></full-title></periodical><pages end="1666" start="1662">1662-1666</pages><volume><style face="normal" font="Arial">39</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dimer</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> false positives</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> Immobilization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> monomer</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The physicochemical nature of allergen molecules differ from the liquid phase to the solid phase. However, conventional allergy tests are based on the detection of immunoglobulin (Ig)E binding to immobilized allergens. We recently developed an in vitro allergy testing method using a luciferase-reporting humanized rat mast cell line to detect IgE crosslinking-induced luciferase expression (EXiLE test). The aim of the present study was to evaluate the effects of antigen immobilization on the results of different in vitro allergy tests using two anti-ovalbumin (OVA) antibodies (Abs), E-C1 and E-G5, with different properties in the OVA-induced allergic reaction. Both Abs showed clear binding to OVA with an enzyme-linked immunosorbent assay and by BIAcore analysis. However, only E-C1 potentiated EXiLE response for the liquid-phase OVA. On the other hand, OVA immobilized on solid-phase induced EXiLE responses in both E-C1 Ab- and E-G5 Ab-sensitized mast cells. Western blotting of OVA indicated that E-C1 Ab binds both to OVA monomers and dimers, unlike E-G5 Ab, which probably binds only to the OVA dimer. These results suggest that antigen immobilization enhanced IgE crosslinking ability through multimerization of allergen molecules in the solid phase, resulting in an increase in false positives in IgE binding-based conventional in vitro allergy tests. These findings shed light on the physicochemical nature of antigens as an important factor for the development and evaluation of in vitro allergy tests and suggest that mast cell activation-based allergy testing with liquid-phase allergens is a promising strategy to evaluate the physiological interactions of IgE and allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1347-5215 (Electronic)IS - 0918-6158 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1248/bpb.b16-00389</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27725443">PM:27725443</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biol Pharm Bull\2016-39-1662-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biol Pharm Bull\2016-39-1662-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Okamoto-Uchida Y</style></custom2><misc3><style face="normal" font="Arial">10.1248/bpb.b16-00389</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jang,H.H.</style></author><author><style face="normal" font="Arial"> Cho,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,M.J.</style></author><author><style face="normal" font="Arial"> Kim,J.B.</style></author><author><style face="normal" font="Arial"> Lee,S.H.</style></author><author><style face="normal" font="Arial"> Lee,M.Y.</style></author><author><style face="normal" font="Arial"> Lee,Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Functional Food &amp; Nutrition Division, National Institute of Agricultural Science, Rural Development Administration (RDA), Wanju, 565-851, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Anti-inflammatory effects of Salvia plebeia R. Br extract in vitro and in ovalbumin-induced mouse model</style></title><secondary-title><style face="normal" font="Arial">Biol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biol Res</style></abbr-1></periodical><pages end="" start="41">41-</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin-induced mouse model</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Roots</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Salvia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="10" Year="2016">2016/10/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is an increasing global health problem, and novel strategies to prevent or ameliorate the condition are needed. Here, the effects of 80 % ethanol extracts of Salvia plebeia R. Br. (SE) on an induced inflammatory response were investigated. RESULTS: Salvia plebeia R. Br. inhibited production of pro-inflammatory cytokines, such as TNF-alpha and IL-6, as well as nitric oxide (NO) in LPS-stimulated RAW 264.7 cells. NO and pro-inflammatory cytokine production was suppressed more effectively by SE of the aerial parts (SE-A) than of the roots (SE-R) of S. plebeia. In BEAS-2B cells, both SE-A and SE-R inhibited the increase in production of the inflammatory cytokines IL-6 and IL-8. We also investigated the anti-asthmatic effects of SE in an ovalbumin (OVA)-induced BALB/c mouse model. SE-A treatment significantly reduced the number of airway eosinophils, IL-4 and IL-13 levels, mucus production, and inflammatory infiltration, as compared with the corresponding levels in the untreated, OVA-induced mice, and had similar effects to dexamethasone. CONCLUSIONS: Salvia plebeia ethanol extract ameliorated the induced inflammatory response in RAW 264.7 and BEAS-2B cells, with more effective inhibition noted for SE-A than for SE-R. SE-A treatment was effective in improving the histopathological changes in the lungs of asthma model mice via modulation of eosinophils and Th2 cytokines. These results suggest that SE-A can be considered as a therapeutic agent that can potentially relieve asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 0717-6287 (Electronic)IS - 0716-9760 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40659-016-0102-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27716424">PM:27716424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biol Res\2016-49-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biol Res\2016-49-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Jang HH</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40659-016-0102-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Z.C.</style></author><author><style face="normal" font="Arial"> Yi,M.J.</style></author><author><style face="normal" font="Arial"> Shan,Y.C.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Ran,N.</style></author><author><style face="normal" font="Arial"> Jin,L.Y.</style></author><author><style face="normal" font="Arial"> Fu,P.</style></author><author><style face="normal" font="Arial"> Feng,X.Y.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author><author><style face="normal" font="Arial"> Qu,Z.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Child Health Care, The Affiliated Hospital of Qingdao University, Qingdao 266003, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Targeted inhibition of Six1 attenuates allergic airway inflammation and remodeling in asthmatic mice</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="1825" start="1820">1820-1825</pages><volume><style face="normal" font="Arial">84</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="11" Year="2016">2016/11/12</year></dates><abstract><style face="normal" font="Arial">Asthma is an inflammatory disease of the airways, characterized by lung eosinophilia, mucus hypersecretion by goblet cells and airway hyperresponsiveness to inhaled allergens. The purpose of this study was to evaluate the effects of Six1 on airway inflammation and remodeling and the underlying mechanisms in a murine model of chronic asthma. Female BALB/c mice were randomly divided into four groups: phosphate-buffered saline control, ovalbumin (OVA)-induced asthma group, OVA+siNC and OVA+siSix1. In this mice model, Six1 expression level was significantly elevated in OVA-induced asthma of mice. Additionally, downregulation of Six1 dramatically decreased OVA-challenged inflammation, infiltration, and mucus production. Moreover, silencing of Six1 resulted in decreased levels of immunoglobulin E and inflammatory mediators and reduced inflammatory cell accumulation, as well as inhibiting the expression of important mediators including matrix metalloproteinase MMP-2 and MMP-9, which is related to airway remodeling. Further analysis indicated that silencing of Six1 can significantly inhibit NF-kB pathway activation in the lungs. .In conclusion, these findings indicated that the downregulation of Six1 effectively inhibited airway inflammation and reversed airway remodeling, which suggest that Six1 represents a promising therapeutic strategy for human allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161116IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2016.10.090</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27847210">PM:27847210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\20161116-YangZC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\20161116-YangZC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161116, Yang ZC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2016.10.090</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thakur,R.</style></author><author><style face="normal" font="Arial"> Shankar,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology , Solan-173234 (Himachal Pradesh), India Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology , Solan-173234 (Himachal Pradesh), India</style></auth-address><titles><title><style face="normal" font="Arial">In silico Identification of Potential Peptides or Allergen Shot Candidates Against Aspergillus fumigatus</style></title><secondary-title><style face="normal" font="Arial">Biores Open Access</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biores Open Access</style></abbr-1></periodical><pages end="341" start="330">330-341</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Histocompatibility</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Information technology</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Prioritization</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Aspergillus fumigatus is capable of causing invasive aspergillosis or acute bronchopulmonary aspergillosis, and the current situation is alarming. There are no vaccine or allergen shots available for Aspergillus-induced allergies. Thus, a novel approach in designing of an effective vaccine or allergen shot candidate against A. fumigatus is needed. Using immunoinformatics approaches from the characterized A. fumigatus allergens, we have mapped epitopic regions to predict potential peptides that elicit both Aspergillus-specific T cells and B cell immune response. Experimentally derived immunodominant allergens were retrieved from www.allergen.org. A total of 23 allergenic proteins of A. fumigatus were retrieved. Out of 23 allergenic proteins, 13 of them showed high sequence similarity to both human and mouse counterparts and thus were eliminated from analysis due to possible cross-reactivity. Remaining allergens were subjected to T cell (major histocompatibility complex class I and II alleles) and B cell epitope prediction using immune epitope database analysis resource. Only five allergens have shown a common B and T cell epitopic region between human and mouse. They are Asp f1 {147-156 region (RVIYTYPNKV); Mitogillin}, Asp f2 {5-19 region (LRLAVLLPLAAPLVA); Hypothetical protein}, Asp f5 {305-322 region (LNNYRPSSSSLSFKY); Metalloprotease}, Asp f17 {98-106 region (AANAGGTVY); Hypothetical protein}, and Asp f34 {74-82 region (YIQDGSLYL); PhiA cell wall protein}. The epitopic region from these five allergenic proteins showed potential for development of single peptide- or multipeptide-based vaccine or allergen shots for experimental prioritization</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 2164-7844 (Print)IS - 2164-7844 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1089/biores.2016.0035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27872794">PM:27872794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biores Open Access\2016-5-330-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biores Open Access\2016-5-330-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Thakur R</style></custom2><misc3><style face="normal" font="Arial">10.1089/biores.2016.0035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iki,M.</style></author><author><style face="normal" font="Arial"> Tanaka,K.</style></author><author><style face="normal" font="Arial"> Deki,H.</style></author><author><style face="normal" font="Arial"> Fujimaki,M.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Yoshikawa,S.</style></author><author><style face="normal" font="Arial"> Yamanishi,Y.</style></author><author><style face="normal" font="Arial"> Karasuyama,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immune Regulation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Basophil tryptase mMCP-11 plays a crucial role in IgE-mediated, delayed-onset allergic inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">Blood</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Blood</style></abbr-1></periodical><pages end="2918" start="2909">2909-2918</pages><volume><style face="normal" font="Arial">128</style></volume><number><style face="normal" font="Arial">25</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell protease</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protective immunity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="10" Year="2016">2016/10/27</year></dates><abstract><style face="normal" font="Arial">Recent studies have identified non-redundant roles for basophils in immune responses including allergy and protective immunity. It is well known that activated basophils release granule contents such as histamine and proteases as do mast cells. However, the functional significance of basophil-derived proteases remains poorly understood in contrast to those released from mast cells. Here we generated mice deficient for mouse mast cell protease 11 (mMCP-11) that is preferentially expressed by basophils rather than mast cells. In spite of normal development of basophils, mMCP-11-deficient mice showed ameliorated IgE-mediated chronic allergic inflammation (IgE-CAI) with reduction of cutaneous swelling, microvascular permeability and leukocyte infiltration in the skin lesion, compared to WT mice. Repeated administration of recombinant mMCP-11 in the skin induced infiltration of leukocytes, including basophils, in a tryptase activity-dependent manner. The transwell migration assay in vitro suggested that mMCP-11-mediated proteolytic products of a serum protein(s) promoted migration of basophils, eosinophils and macrophages via a G protein-coupled receptor(s). Thus, basophil tryptase mMCP-11 is a crucial effector molecule for the induction of IgE-CAI-type allergic inflammation. This is the first demonstration that the basophil-derived protease plays a significant role in vivo</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1528-0020 (Electronic)IS - 0006-4971 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1182/blood-2016-07-729392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27789480">PM:27789480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Blood\20161028-IkiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Blood\20161028-IkiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Iki M</style></custom2><misc3><style face="normal" font="Arial">10.1182/blood-2016-07-729392</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kyei,S.</style></author><author><style face="normal" font="Arial"> Tettey,B.</style></author><author><style face="normal" font="Arial"> Asiedu,K.</style></author><author><style face="normal" font="Arial"> Awuah,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Optometry, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape-Coast, Cape-Coast, PMB, Ghana.</style></auth-address><titles><title><style face="normal" font="Arial">Knowledge and awareness of ocular allergy among undergraduate students of public universities in Ghana</style></title><secondary-title><style face="normal" font="Arial">BMC Ophthalmol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMC Ophthalmol</style></abbr-1></periodical><pages end="" start="190">190-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Activities of Daily Living</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Ghana</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Ocular allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="10" Year="2016">2016/10/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ocular allergy is a growing public health problem that greatly impacts the day-to-day life of sufferers and their families. Other aspects of their activities of daily living such as schooling, professional, and social life are affected hence an increased awareness and knowledge of ocular allergies, their detection and treatment is paramount. This study was to assess the level of knowledge and awareness of ocular allergy among undergraduate students of public universities in Ghana. METHODS: A descriptive cross sectional survey was conducted among 1000 students from three selected public universities in Ghana. Each respondent completed a questionnaire that had questions concerning awareness and knowledge of ocular allergy. RESULTS: Out of the 1000 students, 347 (34.7 %) were aware of ocular allergy. Of these 347 students, the level of knowledge of ocular allergy was generally low. Majority of the students had their source of information about ocular allergy from the media and the internet. There was statistical significant association among awareness of ocular allergy, sources of information and programme of study (p &lt; 0.001). CONCLUSION: Level of awareness among university students is generally low. Students' programmes of study influenced their knowledge of ocular allergy. Public health measures are recommended to help educate students on the prevention and control of ocular allergy as well as the complications associated with this condition</style></abstract><notes><style face="normal" font="Arial">DA - 20161029IS - 1471-2415 (Electronic)IS - 1471-2415 (Linking)LA - ENGPT - Journal ArticleCO - Ghana -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12886-016-0366-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27793114">PM:27793114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Ophthalmol\2016-16-190.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Ophthalmol\2016-16-190.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161029, Kyei S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12886-016-0366-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shen,T.C.</style></author><author><style face="normal" font="Arial"> Chen,H.J.</style></author><author><style face="normal" font="Arial"> Wei,C.C.</style></author><author><style face="normal" font="Arial"> Chen,C.H.</style></author><author><style face="normal" font="Arial"> Tu,C.Y.</style></author><author><style face="normal" font="Arial"> Hsia,T.C.</style></author><author><style face="normal" font="Arial"> Shih,C.M.</style></author><author><style face="normal" font="Arial"> Hsu,W.H.</style></author><author><style face="normal" font="Arial"> Sung,F.C.</style></author><author><style face="normal" font="Arial"> Bau,D.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Clinical Medicine Science, College of Medicine, China Medical University, No. 91 Hsueh-Shih Road, Taichung, 404, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Risk of asthma in patients with primary Sjogren's syndrome: a retrospective cohort study</style></title><secondary-title><style face="normal" font="Arial">BMC Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Pulm Med</style></full-title></periodical><pages end="" start="152">152-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Sjogren's Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sjogren's syndrome (SS) has been associated with bronchial hyperresponsiveness and asthma; however, no population-based cohort study has been performed. We evaluated the risk of asthma in patients with primary SS in a nationwide population. METHODS: We conducted a retrospective cohort study using data from the National Health Insurance Research Database in Taiwan. The primary SS group included 4725 adult patients diagnosed between 2000 and 2006. Each patient was frequency-matched with four people without SS by sex, age and year of diagnosis. The occurrence and hazard ratio (HR) of asthma was monitored by the end of 2011. RESULTS: The overall incidence density of asthma was 1.62-fold higher in the primary SS group than in the non-SS group (9.86 vs. 6.10 per 1000 person-years), with a multivariable Cox proportional hazards model measured adjusted HR of 1.38 [95% confidence interval (CI) = 1.21-1.58]. Stratified analyses by sex, age group, and presence of comorbidity revealed that asthma incidences were all higher in the primary SS group than in the non-SS group, and the relative HRs of asthma associated with primary SS were significant in all subgroups. CONCLUSION: Patients with primary SS are associated with an increased risk of developing asthma. We should pay more attention to this group of individuals and provide them with appropriate support</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12890-016-0312-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27852248">PM:27852248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pulm Med\2016-16-152.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pulm Med\2016-16-152.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Shen TC</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12890-016-0312-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Diao,X.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Zhu,H.</style></author><author><style face="normal" font="Arial"> He,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing, 100191, China</style></auth-address><titles><title><style face="normal" font="Arial">Overexpression of programmed cell death 5 in a mouse model of ovalbumin-induced allergic asthma</style></title><secondary-title><style face="normal" font="Arial">BMC Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Pulm Med</style></full-title></periodical><pages end="" start="149">149-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="11" Year="2016">2016/11/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Programmed cell death 5 (PDCD5) was first identified as an apoptosis-promoting protein and involved in some autoimmune diseases and inflammatory processes. Our previous study demonstrated greater expression of serum PDCD5 in asthmatic patients than controls. This study aimed to further explore the significance of PDCD5 in mice with induced allergic asthma. METHODS: We divided 16 female mice into 2 groups: control (n = 8) and allergen (ovalbumin, OVA)-challenged mice (n = 8). The modified ovalbumin inhalation method was used to generate the allergic asthma mouse model, and the impact of OVA was assessed by histology of lung tissue and morphometry. The number of cells in bronchoalveolar lavage fluid (BALF) was detected. Pulmonary function was measured by pressure sensors. PDCD5 and active caspase-3 levels were detected. RESULTS: The expression of PDCD5 was higher with OVA challenge than for controls (p &lt; 0.05). PDCD5 level was correlated with number of inflammatory cells in BALF and lung function. Moreover, active caspase-3 level was increased in the OVA-challenged mice (p &lt; 0.001) and correlated with PDCD5 level (p = 0.000). CONCLUSIONS: These data demonstrate an association between level of PDCD5 and asthma severity and indicate that PDCD5 may play a role in allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161116IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12890-016-0317-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27846830">PM:27846830</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pulm Med\2016-16-149.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pulm Med\2016-16-149.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161116, Diao X</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12890-016-0317-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rimoldi,M.</style></author><author><style face="normal" font="Arial"> Rossi,O.</style></author><author><style face="normal" font="Arial"> Rota,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Stethos Marketing Research Srl, Milan, Italy</style></auth-address><titles><title><style face="normal" font="Arial">State of the art of chronic spontaneous urticaria in Italy: a multicentre survey to evaluate physicians' and patients' perspectives</style></title><secondary-title><style face="normal" font="Arial">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ Open</style></full-title></periodical><pages end="" start="e012378">e012378-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonists</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Marketing</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Up-dosing</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="14" Month="10" Year="2016">2016/10/14</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To assess the clinical status of chronic spontaneous urticaria (CSU) and understand treatment approaches in Italy through specialists who treat CSU (dermatologists and allergy specialists) and CSU patients' experience. DESIGN: Multicentre survey. SETTING: Online structured questionnaires (one for physicians and one for patients). PARTICIPANTS: Physicians and patients with CSU in Italy. INTERVENTIONS: None. PRIMARY/SECONDARY OUTCOMES: Physician and patient attitudes/experiences. RESULTS: Survey results from 160 allergy and 160 dermatology specialists show that specialists see a median of 40 (IQR 20-80) patients with CSU/year. While most specialists (56%) know the CSU guidelines, only 27% use them regularly (36% of allergy specialists vs 18% of dermatologists). This is reflected in treatment choices with differences between physicians who use guidelines regularly and those who do not: 91.6% vs 71.7% choose standard-dose, non-sedating antihistamines as first-line treatment; 85.9% vs 56.0% select up-dosing for second-line treatment and 65.3% vs 37.2% add leukotriene receptor antagonists or H2-antihistamines as third-line treatment. The diaries from 1385 patients highlight that, regardless of treatment regimen, 29.4% of currently treated patients are refractory to therapy. Specialists aim to resolve symptoms and only 7.8% report improving quality of life (QoL) as a priority. Only 16.6% of specialists are familiar with and use the Urticaria Activity Score while 46.9% do not know it. Overall, 537 patients with CSU were surveyed (median age 37 years, IQR 30-46; 44.3% men; median disease duration 5 years, IQR 3-20). Approximately 62% confirm that CSU negatively impacts their QoL. Patients also complain of difficulties in getting information and support: &lt;5% of medical centres provide patient support services. CONCLUSIONS: In Italy, the gap between guideline-based care and QoL-related needs in CSU patients affects treatment satisfaction. This information could be used to improve the management of CSU in Italy</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmjopen-2016-012378</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742625">PM:27742625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2016-6-e012378.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Open\2016-6-e012378.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Rimoldi M</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmjopen-2016-012378</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pascual,J.C.</style></author><author><style face="normal" font="Arial"> Garcia-Martinez,F.J.</style></author><author><style face="normal" font="Arial"> Martorell,A.</style></author><author><style face="normal" font="Arial"> Gonzalez,I.</style></author><author><style face="normal" font="Arial"> Hispan,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University General Hospital of Alicante, Alicante, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Increased total serum IgE levels in moderate-to-severe hidradenitis suppurativa</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="1102" start="1101">1101-1102</pages><volume><style face="normal" font="Arial">175</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hidradenitis Suppurativa</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160811IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.14870</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27425426">PM:27425426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\2016-175-1101-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\2016-175-1101-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160811, Pascual JC</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.14870</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nowrouzian,F.L.</style></author><author><style face="normal" font="Arial"> Lina,G.</style></author><author><style face="normal" font="Arial"> Hodille,E.</style></author><author><style face="normal" font="Arial"> Lindberg,E.</style></author><author><style face="normal" font="Arial"> Hesselmar,B.</style></author><author><style face="normal" font="Arial"> Saalman,R.</style></author><author><style face="normal" font="Arial"> Adlerberth,I.</style></author><author><style face="normal" font="Arial"> Wold,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institution for Biomedicine, Department of Infectious Disease, University of Gothenburg, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="Arial">Superantigens and adhesins of infant gut commensal Staphylococcus aureus strains and association with subsequent development of atopic eczema</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="445" start="439">439-445</pages><volume><style face="normal" font="Arial">176</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Enterotoxins</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> Superantigens</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">According to the hygiene hypothesis, insufficient immune activation by microbes increases the risk of allergy development. Staphylococcus aureus, which is part of the skin and gut microbiota of infants in Western countries, produces a variety of T-cell-activating enterotoxins, called superantigens. We investigated whether early (0-2 months of age) gut colonisation by S. aureus strains that carry specific superantigens and adhesins was related to subsequent development of atopic eczema in a Swedish birth-cohort. S. aureus was isolated from rectal swabs and cultured quantitatively from faecal samples, with individual strains being tested for carriage of genes for superantigens and adhesins. Atopic eczema was diagnosed at onset of symptoms, and at 18 months of age. Although the frequency of early gut colonisation by S. aureus was not related to subsequent eczema development, the S. aureus strains that were found to colonize those infants who developed atopic eczema were less likely to carry the gene encoding the superantigen SElM (p=0.008) and the gene for elastin-binding protein (p=0.03), as compared to strains that were isolated from infants who had not developed atopic eczema by 18 months of age. Thus, gut colonization by S. aureus strains carrying a certain combination of superantigen and adhesin genes was negatively associated with subsequent development of atopic eczema. Such strains may provide stimulation and promote maturation of the infantile immune system. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15138</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27761891">PM:27761891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20161020-NowrouzianFL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20161020-NowrouzianFL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Nowrouzian FL</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15138</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hepburn,L.</style></author><author><style face="normal" font="Arial"> Hijnen,D.J.</style></author><author><style face="normal" font="Arial"> Sellman,B.R.</style></author><author><style face="normal" font="Arial"> Mustelin,T.</style></author><author><style face="normal" font="Arial"> Sleeman,M.A.</style></author><author><style face="normal" font="Arial"> May,R.D.</style></author><author><style face="normal" font="Arial"> Strickland,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MedImmune, Granta Park, Cambridge, CB21 6GH, UK</style></auth-address><titles><title><style face="normal" font="Arial">The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="71" start="63">63-71</pages><volume><style face="normal" font="Arial">177</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a complex, chronic inflammatory skin disorder affecting more than 10% of UK children and is a major cause of occupation-related disability. A subset of patients, particularly those with severe AD, are persistently colonised with Staphylococcus aureus (S. aureus) and exacerbation of disease is commonly associated with this bacterium by virtue of increased inflammation and allergic sensitisation, aggravated by skin barrier defects. Understanding the complex biology of S. aureus is an important factor when developing new drugs to combat infection. S. aureus generates exoproteins that enable invasion and dissemination within the host skin but can also damage the skin and activate the host immune system. Antibiotics are often used by dermatologists to aid clearance of S. aureus; however, these are becoming less effective and chronic usage discouraged with the emergence of multiple antibiotic-resistant strains. New ways to target S. aureus using monoclonal antibodies and vaccines are now being developed. This review will attempt to evaluate the key biology of S. aureus, current treatment of S. aureus infections in atopic dermatitis and recent advances in developing new anti-S. aureus therapies that have potential in severe AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - United Kingdom -CO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779765">PM:27779765</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20161025-HepburnL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20161025-HepburnL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Hepburn L</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15139</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hashimoto,T.</style></author><author><style face="normal" font="Arial"> Ohzono,A.</style></author><author><style face="normal" font="Arial"> Teye,K.</style></author><author><style face="normal" font="Arial"> Numata,S.</style></author><author><style face="normal" font="Arial"> Hiroyasu,S.</style></author><author><style face="normal" font="Arial"> Tsuruta,D.</style></author><author><style face="normal" font="Arial"> Hachiya,T.</style></author><author><style face="normal" font="Arial"> Kuroda,K.</style></author><author><style face="normal" font="Arial"> Hashiguchi,M.</style></author><author><style face="normal" font="Arial"> Kawakami,T.</style></author><author><style face="normal" font="Arial"> Ishii,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Kurume, Fukuoka, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="151" start="141">141-151</pages><volume><style face="normal" font="Arial">177</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adsorption</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> BP180</style></keyword><keyword><style face="normal" font="Arial"> BP230</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IgE autoantibodies are considered to be involved in pathogenesis of bullous pemphigoid (BP), particularly inflammatory and erythematous phenotypes. OBJECTIVE: To develop reliable ELISAs for detection of IgE autoantibodies to both BP180 and BP230 in BP sera, and to compare the ELISA results with clinical features. METHODS: We used commercially available IgG ELISAs to develop IgE ELISAs for both BP180 and BP230. To determine the influence of excess amount of IgG autoantibodies, all normal and BP sera were tested before and after IgG adsorption. The results of IgE ELISAs were statistically compared among various ELISAs, and with various clinical parameters, including our own severity scores and BP phenotypes. RESULTS: IgG adsorption generally showed no changes in sensitivity and specificity of IgE ELISAs, although slight cross-reactivity of anti-IgE secondary antibody to IgG and interference of excess amount of IgG autoantibodies to IgE reactivity were suggested. IgE autoantibodies to BP180 and BP230 were found in 21 and 18 of 36 BP sera, respectively. The results of IgG and IgE ELISAs for both BP180 and BP230 well correlated. IgG and IgE anti-BP180 antibodies, but not IgG and IgE anti-BP230 autoantibodies, correlated with disease activity. IgE anti-BP30 autoantibodies correlated with nodular phenotype but not erythematous phenotype. CONCLUSION: The results in this study indicated that IgE autoantibodies to both BP180 and BP230 are frequently detected in BP sera. IgE anti-BP180 autoantibodies seemed to be pathogenic, while association between IgE autoantibodies and inflammatory BP phenotype was not indicated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15114</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27716903">PM:27716903</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20161007-HashimotoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20161007-HashimotoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Hashimoto T</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15114</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,F.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author><author><style face="normal" font="Arial"> Chen,N.</style></author><author><style face="normal" font="Arial"> Zhou,M.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Yang,Q.</style></author><author><style face="normal" font="Arial"> Xie,Y.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Ma,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy, Histology and Embryology, Institute of Basic Medical Sciences, Neuroscience Center, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Neuronal Fc-epsilon receptor I contributes to antigen-evoked pruritus in a murine model of ocular allergy</style></title><secondary-title><style face="normal" font="Arial">Brain Behav Immun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Brain Behav Immun</style></full-title></periodical><pages end="175" start="165">165-175</pages><volume><style face="normal" font="Arial">61</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> embryology</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Fc receptors</style></keyword><keyword><style face="normal" font="Arial"> Hindlimb</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> Ocular allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Pruritus is the major symptom of ocular allergy but currently available treatments are often ineffective. Previous studies demonstrated that subpopulations of primary sensory neurons express Fc receptors and may contribute to antigen-specific pain. We investigated the role of neuronal Fc-epsilon Receptor I (FcepsilonRI) in allergic ocular pruritus. Ovalbumin (OVA) was used as allergen together with alum adjuvant (OVA+alum) to produce a mouse model of ocular allergy with a significant elevation in the serum levels of both antigen-specific IgE and IgG. Mice sensitized by OVA without alum only induced elevation of serum IgG but not IgE. Scratching behavior toward the eyes with the hindlimb was used as an indicator of ocular itch. Topical OVA challenging to the eye dose-dependently induced scratching toward the eye in the OVA+alum sensitized mice, but not those sensitized by OVA only. The antigen-induced scratching was largely abolished by topical application of the blocking antibody to FcepsilonRIalpha, but was only partially alleviated by pretreatment of mast cell stabilizer or histamine I receptor antagonist. The expression of FcepsilonRI was detected in subpopulations of trigeminal ganglion (TG) neurons including those expressing pruriceptive markers and innervating the conjunctiva in the naive mice. Moreover, FcepsilonRI was found significantly upregulated in small-sized TG neurons in the OVA+alum sensitized mice. In acutely dissociated TG neurons, IgE-immune complex (IC), but not the antibody or antigen alone, induced intracellular calcium increase. The neuronal responses to IgE-IC could be specifically blocked by pre-application of a siRNA for FcepsilonRIalpha. Our results indicate that FcepsilonRI expressed on peripheral nociceptive neurons in the TG may be directly activated by IgE-IC and contribute to allergic ocular pruritus. This study may suggest a novel mechanism for the development of pathological itch in allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161120IS - 1090-2139 (Electronic)IS - 0889-1591 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbi.2016.11.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27865948">PM:27865948</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Brain Behav Immun\20161120-LiuF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Brain Behav Immun\20161120-LiuF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Liu F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbi.2016.11.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Albuquerque,A.A.</style></author><author><style face="normal" font="Arial"> Margarido,E.A.</style></author><author><style face="normal" font="Arial"> Menardi,A.C.</style></author><author><style face="normal" font="Arial"> Scorzoni,A.F.</style></author><author><style face="normal" font="Arial"> Celotto,A.C.</style></author><author><style face="normal" font="Arial"> Rodrigues,A.J.</style></author><author><style face="normal" font="Arial"> Vicente,W.V.</style></author><author><style face="normal" font="Arial"> Evora,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Endothelium and Cardiovascular Function; Department of Surgery and Anatomy, Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo (FMRP-USP), SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Methylene Blue to Treat Protamine-induced Anaphylaxis Reactions. An Experimental Study in Pigs</style></title><secondary-title><style face="normal" font="Arial">Braz J Cardiovasc Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Braz J Cardiovasc Surg</style></abbr-1></periodical><pages end="231" start="226">226-231</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cardiac Output</style></keyword><keyword><style face="normal" font="Arial"> Chemiluminescence</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endothelium</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylene Blue</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Protamine</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vascular Resistance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">Objective:: To examine if methylene blue (MB) can counteract or prevent protamine (P) cardiovascular effects. Methods:: The protocol included five heparinized pig groups: Group Sham -without any drug; Group MB - MB 3 mg/kg infusion; Group P - protamine; Group P/MB - MB after protamine; Group MB/P - MB before protamine. Nitric oxide levels were obtained by the nitric oxide/ozone chemiluminescence method, performed using the Nitric Oxide Analizer 280i (Sievers, Boulder, CO, USA). Malondialdehyde plasma levels were estimated using the thiobarbiturate technique. Results:: 1) Groups Sham and MB presented unchanged parameters; 2) Group P - a) Intravenous protamine infusion caused mean arterial pressure decrease and recovery trend after 25-30 minutes, b) Cardiac output decreased and remained stable until the end of protamine injection, and c) Sustained systemic vascular resistance increased until the end of protamine injection; 3) Methylene blue infusion after protamine (Group P/MB) - a) Marked mean arterial pressure decreased after protamine, but recovery after methylene blue injection, b) Cardiac output decreased after protamine infusion, recovering after methylene blue infusion, and c) Sustained systemic vascular resistance increased after protamine infusion and methylene blue injections; 4) Methylene blue infusion before protamine (Group MB/P) - a) Mean arterial pressure decrease was less severe with rapid recovery, b) After methylene blue, there was a progressive cardiac output increase up to protamine injection, when cardiac output decreased, and c) Sustained systemic vascular resistance decreased after protamine, followed by immediate Sustained systemic vascular resistance increase; 5) Plasma nitrite/nitrate and malondialdehyde values did not differ among the experimental groups. Conclusion:: Reviewing these experimental results and our clinical experience, we suggest methylene blue safely prevents and treats hemodynamic protamine complications, from the endothelium function point of view</style></abstract><notes><style face="normal" font="Arial">DA - 20161013IS - 1678-9741 (Electronic)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/1678-9741.20160054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27737405">PM:27737405</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Cardiovasc Surg\2016-31-226-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Cardiovasc Surg\2016-31-226-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Albuquerque AA</style></custom2><misc3><style face="normal" font="Arial">10.5935/1678-9741.20160054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bacher,P.</style></author><author><style face="normal" font="Arial"> Heinrich,F.</style></author><author><style face="normal" font="Arial"> Stervbo,U.</style></author><author><style face="normal" font="Arial"> Nienen,M.</style></author><author><style face="normal" font="Arial"> Vahldieck,M.</style></author><author><style face="normal" font="Arial"> Iwert,C.</style></author><author><style face="normal" font="Arial"> Vogt,K.</style></author><author><style face="normal" font="Arial"> Kollet,J.</style></author><author><style face="normal" font="Arial"> Babel,N.</style></author><author><style face="normal" font="Arial"> Sawitzki,B.</style></author><author><style face="normal" font="Arial"> Schwarz,C.</style></author><author><style face="normal" font="Arial"> Bereswill,S.</style></author><author><style face="normal" font="Arial"> Heimesaat,M.M.</style></author><author><style face="normal" font="Arial"> Heine,G.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Assenmacher,M.</style></author><author><style face="normal" font="Arial"> Kniemeyer,O.</style></author><author><style face="normal" font="Arial"> Brakhage,A.A.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Wallner,M.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Scheffold,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cellular Immunology, Clinic for Rheumatology and Clinical Immunology, Charite - University Medicine Berlin, 10117 Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans</style></title><secondary-title><style face="normal" font="Arial">Cell</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell</style></full-title></periodical><pages end="1078" start="1067">1067-1078</pages><volume><style face="normal" font="Arial">167</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> self-antigens</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="10" Year="2016">2016/10/18</year></dates><abstract><style face="normal" font="Arial">FOXP3+ regulatory T cells (Tregs) maintain tolerance against self-antigens and innocuous environmental antigens. However, it is still unknown whether Treg-mediated tolerance is antigen specific and how Treg specificity contributes to the selective loss of tolerance, as observed in human immunopathologies such as allergies. Here, we used antigen-reactive T cell enrichment to identify antigen-specific human Tregs. We demonstrate dominant Treg-mediated tolerance against particulate aeroallergens, such as pollen, house dust mites, and fungal spores. Surprisingly, we found no evidence of functional impairment of Treg responses in allergic donors. Rather, major allergenic proteins, known to rapidly dissociate from inhaled allergenic particles, have a generally reduced capability to generate Treg responses. Most strikingly, in individual allergic donors, Th2 cells and Tregs always target disparate proteins. Thus, our data highlight the importance of Treg antigen-specificity for tolerance in humans and identify antigen-specific escape from Treg control as an important mechanism enabling antigen-specific loss of tolerance in human allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161024IS - 1097-4172 (Electronic)IS - 0092-8674 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cell.2016.09.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27773482">PM:27773482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell\2016-167-1067-78.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell\2016-167-1067-78.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161024, Bacher P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cell.2016.09.050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Z.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Han,J.</style></author><author><style face="normal" font="Arial"> Lu,P.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Life Science, Zunyi Normal University, Zunyi 563002, China</style></auth-address><titles><title><style face="normal" font="Arial">[Recombinant adenovirus type 5 does not aggravate asthma symptoms in a mouse model of ovalbumin-induced asthma]</style></title><secondary-title><style face="normal" font="Arial">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</style></full-title></periodical><pages end="1594" start="1590">1590-1594</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenovirus</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> Potassium</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Objective To explore the effect of recombinant adenovirus type 5 (rAd5) on a mouse model of ovalbumin (OVA)-induced asthma. Methods Sixty female C57BL/6 mice (6-8 weeks old and 18-20 g) were randomly divided into 4 groups: healthy control group, rAd5 control group, OVA asthma control group and OVA asthma group with rAd5 immunization. 15 mice in each group. The mice in the OVA asthma control group and the OVA asthma group with rAd5 immunization were sensitized by intraperitoneal injection of 50 mug OVA emulsified in 2 mg of aluminum potassium sulfate on day 0, 7 and 14; subsequently, the mice in the two groups were exposed to OVA aerosol challenge for 3 consecutive days (on day 42, 43 and 44). Meanwhile, mice in the healthy control group and the rAd5 control group were given an equal volume of normal saline. What's more, mice in the OVA asthma group with rAd5 immunization and the rAd5 control group were immunized intramuscularly with 2.5x109 viral particles (VP) of rAd5 vectors on day 21, and were boosted intranasally with the same dose of rAd5 vectors on day 35. All mice were euthanized within 48 hours after the last challenge. The airway hyper-responsiveness (AHR) of mice was measured by single-chamber, whole-body plethysmography. The blood was obtained, the samples of bronchoalveolar lavage fluid (BALF) were collected, and lung tissues were prepared for HE and PAS staining. The levels of interleukin-4 (IL-4), IL-5, IL-13 in BALF and total IgE in serum were detected by ELISA. Results Compared with the healthy control group and the rAd5 control group, the pulmonary inflammation and mucus production significantly increased in the OVA asthma control group and the OVA asthma group with rAd5 immunization. The levels of IL-4, IL-5, IL-13 in BALF, total serum IgE and the AHR were also significantly enhanced in the OVA asthma control group and the OVA asthma group with rAd5 immunization. However, no significant difference was showed between the OVA asthma control group and the OVA asthma group with rAd5 immunization. Conclusion The use of recombinant adenovirus type 5 does not exacerbate asthma symptoms in a mouse model of OVA-induced asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1007-8738 (Print)IS - 1007-8738 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27916086">PM:27916086</url></web-urls></urls><custom2><style face="normal" font="Arial">20161205, Zhang Z</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dittfeld,A.</style></author><author><style face="normal" font="Arial"> Gwizdek,K.</style></author><author><style face="normal" font="Arial"> Michalski,M.</style></author><author><style face="normal" font="Arial"> Wojnicz,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Histology and Embryology, School of Medicine with the Division of Dentistry, Medical University of Silesia, Zabrze, Poland</style></auth-address><titles><title><style face="normal" font="Arial">A possible link between the Epstein-Barr virus infection and autoimmune thyroid disorders</style></title><secondary-title><style face="normal" font="Arial">Cent Eur J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cent Eur J Immunol</style></full-title></periodical><pages end="301" start="297">297-301</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> autoimmune hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> embryology</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious Mononucleosis</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Sjogren's Syndrome</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Diseases</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the Herpesviridae virus family. EBV infection can cause infectious mononucleosis (IM) in the lytic phase of EBV's life cycle. Past EBV infection is associated with lymphomas, and may also result in certain allergic and autoimmune diseases. Although potential mechanisms of autoimmune diseases have not been clearly elucidated, both genetic and environmental factors, such as infectious agents, are considered to be responsible for their development. In addition, EBV modifies the host immune response. The worldwide prevalence of autoimmune diseases shows how common this pathogen is. Normally, the virus stays in the body and remains dormant throughout life. However, this is not always the case, and a serious EBV-related illness may develop later in life. This explains the chronic course of autoimmune diseases that is often accompanied by exacerbations of symptoms. Based on the present studies, EBV infection can cause autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), Sjogren's syndrome, and autoimmune hepatitis. The EBV has also been reported in patients with autoimmune thyroid disorders. Although EBV is not the only agent responsible for the development of autoimmune thyroid diseases, it can be considered a contributory factor</style></abstract><notes><style face="normal" font="Arial">DA - 20161111IS - 1426-3912 (Print)IS - 1426-3912 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ceji.2016.63130</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27833448">PM:27833448</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cent Eur J Immunol\2016-41-297-301.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cent Eur J Immunol\2016-41-297-301.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161111, Dittfeld A</style></custom2><misc3><style face="normal" font="Arial">10.5114/ceji.2016.63130</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,J.H.</style></author><author><style face="normal" font="Arial"> Choi,T.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Centre for Regenerative Medicine, Dankook University, Chonan, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Splenocyte proliferation and anaphylaxis induced by BSA challenge in a D-galactose-induced aging mouse model</style></title><secondary-title><style face="normal" font="Arial">Cent Eur J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cent Eur J Immunol</style></full-title></periodical><pages end="327" start="324">324-327</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immune system</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Fructose</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reducing sugars</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sugars</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">We previously found a cross-reactive autoantibody that bound to bovine serum albumin generated in a D-galactose-induced aging mouse model. Also, we confirmed that other reducing sugars (glucose and fructose) could induce the formation of autoantibody, and only following subcutaneous injection, not oral or intraperitoneal administration. Mice that had never been exposed to bovine serum albumin produced an anti-bovine serum albumin autoantibody following repeated subcutaneous injection of D-galactose (D-gal). In this study, we investigated the involvement of the adaptive immune system in the production of this autoantibody. In particular, we examined bovine serum albumin-induced splenocyte proliferation and bovine serum albumin-induced active cutaneous and systemic anaphylaxis in D-gal-treated mice. We find our results particularly interesting: bovine serum albumin stimulates splenocyte proliferation and induces both active cutaneous and systemic anaphylaxis in D-gal-treated mice. In summary, our results suggest that adaptive immune response participates in the autoantibody formation against bovine serum albumin in D-gal-treated mice</style></abstract><notes><style face="normal" font="Arial">DA - 20161111IS - 1426-3912 (Print)IS - 1426-3912 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5114/ceji.2016.63134</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27833452">PM:27833452</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cent Eur J Immunol\2016-41-324-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cent Eur J Immunol\2016-41-324-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161111, Park JH</style></custom2><misc3><style face="normal" font="Arial">10.5114/ceji.2016.63134</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khosravi,G.R.</style></author><author><style face="normal" font="Arial"> Assarehzadegan,M.A.</style></author><author><style face="normal" font="Arial"> Morakabati,P.</style></author><author><style face="normal" font="Arial"> Akbari,B.</style></author><author><style face="normal" font="Arial"> Dousti,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Cloning and expression of Aca f 1: a new allergen of Acacia farnesiana pollen</style></title><secondary-title><style face="normal" font="Arial">Cent Eur J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cent Eur J Immunol</style></full-title></periodical><pages end="281" start="273">273-281</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acacia</style></keyword><keyword><style face="normal" font="Arial"> Ahvaz</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plant</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunodetection</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nucleotide sequence</style></keyword><keyword><style face="normal" font="Arial"> Ole e</style></keyword><keyword><style face="normal" font="Arial"> Ole e 1</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Homology</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Acacia farnesiana is the main source of allergenic pollen and one of the most important causes of respiratory allergic disease in tropical and subtropical regions of the world. The purpose of this study was to produce a recombinant variety of allergenic Ole e 1-like protein from the pollen of this tree. To predict its allergenic cross-reactivity with other members of the Ole e 1-like protein family of common allergenic plants, the nucleotide sequence homology of the Acacia Ole e 1-like protein was evaluated. Amplification of cDNA strands encoding Acacia Ole e 1-like protein was performed by polymerase chain reaction (PCR) and sequenced. Following expression in Escherichia coli using the pET-21b(+) vector, the recombinant protein was purified using metal-affinity chromatography. IgE-binding competence of purified recombinant Ole e 1- like protein (rAca f 1) was analysed by immunoassay using 25 sera collected from Acacia pollen-sensitised patients. Nucleotide sequencing revealed an open reading frame of 453 bp encoding 150 amino acid residues that belonged to the Ole e 1-like protein family, and 11 patients (44%) had considerable specific IgE levels for the rAca f 1. Immunodetection and inhibition assays indicated that the purified rAca f 1 may be the same as that in the crude extract. Aca f 1, the second allergen from Acacia pollen, was identified as a member of the family of Ole e 1-like protein. A high degree of homology was found among amino acid sequences of Aca f 1 and several allergenic members of Ole e 1-like protein family</style></abstract><notes><style face="normal" font="Arial">DA - 20161111IS - 1426-3912 (Print)IS - 1426-3912 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.5114/ceji.2016.63127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27833445">PM:27833445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cent Eur J Immunol\2016-41-273-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cent Eur J Immunol\2016-41-273-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161111, Khosravi GR</style></custom2><misc3><style face="normal" font="Arial">10.5114/ceji.2016.63127</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maltby,S.</style></author><author><style face="normal" font="Arial"> Gibson,P.G.</style></author><author><style face="normal" font="Arial"> Powell,H.</style></author><author><style face="normal" font="Arial"> McDonald,V.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Health and Medical Research Council Centre of Excellence in Severe Asthma</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab Treatment Response in a Severe Allergic Asthma Population with Overlapping COPD</style></title><secondary-title><style face="normal" font="Arial">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chest</style></full-title></periodical><pages end="89" start="78">78-89</pages><volume><style face="normal" font="Arial">151</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Xolair</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma and chronic obstructive pulmonary disease (COPD) are common airway diseases. Individuals with overlapping asthma and COPD experience increased health impairment and severe disease exacerbations. Efficacious treatment options are required for this population. Omalizumab (anti-IgE) therapy is effective in patients with severe, persistent asthma, but limited data are available on efficacy in populations with overlapping asthma and COPD. METHODS: Data from the Australian Xolair Registry (AXR) was used to compare treatment responses in individuals with asthma-COPD overlap to severe asthma alone. Participants were assessed at baseline and after 6 months of omalizumab treatment. We utilised several different definitions of asthma-COPD overlap. First we compared participants with a previous doctor diagnosis of COPD to participants with no COPD diagnosis. We then made comparisons based on baseline lung function, comparing participants with post-bronchodilator FEV1 &lt;80% predicted to >80% predicted. In the FEV1&lt;80% population, analysis was further stratified based on smoking history. RESULTS: Omalizumab treatment markedly improved asthma control and health related quality of life in all populations assessed, based on ACQ-5 and AQLQ questionnaire scores. Omalizumab treatment did not improve lung function (FEV1, FVC or FEV1/FVC ratio) in populations that were enriched for asthma-COPD overlap (diagnosis of COPD or FEV1&lt;80%/ever smokers). CONCLUSIONS: Our study suggests that omalizumab improves asthma control and health related quality of life in individuals with severe allergic asthma and overlapping COPD. These findings provide real-world efficacy data for this patient population and suggest omalizumab is useful in the management of severe asthma with COPD overlap</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.chest.2016.09.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742181">PM:27742181</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chest\20161015-MaltbyS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chest\20161015-MaltbyS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Maltby S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.chest.2016.09.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amat,F.</style></author><author><style face="normal" font="Arial"> Tallon,P.</style></author><author><style face="normal" font="Arial"> Foray,A.P.</style></author><author><style face="normal" font="Arial"> Michaud,B.</style></author><author><style face="normal" font="Arial"> Lambert,N.</style></author><author><style face="normal" font="Arial"> Saint-Pierre,P.</style></author><author><style face="normal" font="Arial"> Chatenoud,L.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology-Centre de l'Asthme et des Allergies, Hopital d'Enfants Armand Trousseau, Assistance Publique-Hopitaux de Paris, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Control of asthma by omalizumab: the role of CD4+ Foxp3+ regulatory T cells</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1616" start="1614">1614-1616</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword></keywords><dates><year Day="22" Month="10" Year="2016">2016/10/22</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is an inflammatory disease of the airways, resulting from an inappropriate immune response to inhaled allergens, which involves multiple inflammatory cells and mediators that contribute to airway hyper-responsiveness. Omalizumab is a monoclonal antibody, specifically directed to the C-Epsilon3 domain of immunoglobulin E (IgE), indicated as an additional therapy in severe allergic asthma [1]. Impaired function of regulatory T cells (Treg) is incriminated in the aberrant asthma inflammatory response [2]. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161022IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12839</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27770456">PM:27770456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-AmatF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-AmatF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161022, Amat F</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12839</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Groh,N.</style></author><author><style face="normal" font="Arial"> Seutter von Loetzen,C.</style></author><author><style face="normal" font="Arial"> Subbarayal,B.</style></author><author><style face="normal" font="Arial"> Mobs,C.</style></author><author><style face="normal" font="Arial"> Vogel,L.</style></author><author><style face="normal" font="Arial"> Hoffmann,A.</style></author><author><style face="normal" font="Arial"> Fotisch,K.</style></author><author><style face="normal" font="Arial"> Koutsouridou,A.</style></author><author><style face="normal" font="Arial"> Randow,S.</style></author><author><style face="normal" font="Arial"> Volker,E.</style></author><author><style face="normal" font="Arial"> Reuter,A.</style></author><author><style face="normal" font="Arial"> Rosch,P.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Pfutzner,W.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Schiller,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">IgE and allergen-specific immunotherapy-induced IgG4 recognize similar epitopes of Bet v 1, the major allergen of birch pollen</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="703" start="693">693-703</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Nuclear Magnetic Resonance</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific immunotherapy (AIT) with birch pollen generates Bet v 1-specific immunoglobulin (Ig)G4 which blocks IgE-mediated hypersensitivity mechanisms. Whether IgG4 specific for Bet v1a competes with IgE for identical epitopes or whether novel epitope specificities of IgG4 antibodies are developed is under debate. OBJECTIVE: We sought to analyze the epitope specificities of IgE and IgG4 antibodies from sera of patients who received AIT. METHODS: 15 sera of patients (13/15 received AIT) with Bet v 1a-specific IgE and IgG4 were analyzed. The structural arrangements of recombinant (r)Bet v 1a and rBet v 1a_11x , modified in five potential epitopes were analyzed by circular dichroism and nuclear magnetic resonance spectroscopy. IgE binding to Bet v 1 was assessed by ELISA and mediator release assays. Competitive binding of monoclonal antibodies specific for Bet v 1a and serum IgE/IgG4 to rBet v 1a and serum antibody binding to a non-allergenic Bet v 1-type model protein presenting an individual epitope for IgE was analyzed in ELISA and Western blot. RESULTS: rBet v 1a_11x had a Bet v 1a-similar secondary and tertiary structure. Monomeric dispersion of rBet v 1a_11x was concentration and buffer dependent. Up to 1,500-fold increase in the EC50 for IgE-mediated mediator release induced by rBet v 1a_11x was determined. The reduction of IgE and IgG4 binding to rBet v 1a_11x was comparable in 67% (10/15) of sera. Bet v 1a-specific monoclonal antibodies inhibited binding of serum IgE and IgG4 to 66.1% and 64.9%, respectively. Serum IgE and IgG4 bound specifically to an individual epitope presented by our model protein in 33% (5/15) of sera. CONCLUSION AND CLINICAL RELEVANCE PATIENTS RECEIVING: AIT develop Bet v 1a-specific IgG4 which compete with IgE for partly identical or largely overlapping epitopes. The similarities of epitopes for IgE and IgG4 might stimulate the development of epitope-specific diagnostics and therapeutics. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161022IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12835</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27770477">PM:27770477</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-GrohN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-GrohN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161022, Groh N</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12835</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Forsberg,A.</style></author><author><style face="normal" font="Arial"> West,C.E.</style></author><author><style face="normal" font="Arial"> Prescott,S.L.</style></author><author><style face="normal" font="Arial"> Jenmalm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Pre- and probiotics for allergy prevention: time to revisit recommendations?</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1521" start="1505">1505-1521</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune maturation</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="22" Month="10" Year="2016">2016/10/22</year></dates><abstract><style face="normal" font="Arial">Reduced intensity and diversity of microbial exposure is considered a major factor driving abnormal postnatal immune maturation and increasing allergy prevalence, particularly in more affluent regions. Quantitatively the largest important source of early immune-microbial interaction, the gut microbiota is of particular interest in this context, with variations in composition and diversity in the first months of life associated with subsequent allergy development. Attempting to restore the health consequences of the 'dysbiotic drift' in modern society, interventions modulating gut microbiota for allergy prevention have been evaluated in several randomized placebo controlled trials. In this review, we provide an overview of these trials and discuss recommendations from international expert bodies regarding prebiotic, probiotic and synbiotic interventions. Recent guidelines from the World Allergy Organization recommend the use of probiotics for the primary prevention of eczema in pregnant and breastfeeding mothers of infants at high risk for developing allergy and in high risk infants. It is however stressed that these recommendations are conditional, based on very low quality evidence and great heterogeneity between studies, which also impedes specific and practical advice to consumers on the most effective regimens. We discuss how the choice of probiotic strains, timing and duration of administration can critically influence the outcome due to different effects on immune modulation and gut microbiota composition. Furthermore, we propose strategies to potentially improve allergy preventive effects and enable future evidence-based implementation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161022IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12838</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27770467">PM:27770467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-ForsbergA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-ForsbergA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161022, Forsberg A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12838</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vroman,H.</style></author><author><style face="normal" font="Arial"> Bergen,I.M.</style></author><author><style face="normal" font="Arial"> Li,B.W.</style></author><author><style face="normal" font="Arial"> van Hulst,J.A.</style></author><author><style face="normal" font="Arial"> Lukkes,M.</style></author><author><style face="normal" font="Arial"> van Uden,D.</style></author><author><style face="normal" font="Arial"> Hendriks,R.W.</style></author><author><style face="normal" font="Arial"> Kool,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Erasmus MC, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Development of eosinophilic inflammation is independent of B-T cell interaction in a chronic house dust mite-driven asthma model</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="564" start="551">551-564</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental triggers</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germinal Center</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic exposure to environmental triggers, such as house dust mite (HDM), drives T helper 2 (Th2) cell-mediated asthma. Recent evidence has shown that B-T cell interaction, and in particular germinal center reactions and follicular T helper (Tfh) cells are required for the development of eosinophilic airway inflammation in HDM-driven models containing a sensitization and challenge phase. Whether B-T cell interactions are essential for pulmonary eosinophilic inflammation following chronic allergen provocation remains unknown. AIMS: In this study we investigated the importance of B-T cell interaction in the development of eosinophilic airway inflammation and pulmonary remodeling in a chronic HDM-driven asthma model. METHODS: We exposed C57BL/6, Cd40l-/- , and Mb1-/- mice to HDM three times a week for five consecutive weeks. RESULTS: Chronic HDM exposure induced a pronounced eosinophilic allergic airway inflammation in broncho-alveolar lavage fluid (BALf) and lung tissue, associated with the formation of immunologically active inducible bronchus-associated lymphoid tissue (iBALT) in the lungs. The absence of B cells, or lack of CD40L signaling did not hamper eosinophilic inflammation in the airways, although the number of Tfh and Th2 cells was substantially reduced in the lungs. Importantly, type 2 innate lymphoid cells (ILC2) numbers in BALf and lung were not affected by the absence of B cells or B-T cell interaction. Furthermore, eosinophilic airway inflammation is not sufficient to induce pulmonary remodeling and airway hyperresponsiveness. CONCLUSION AND CLINICAL RELEVANCE: From these findings we conclude that B-T cell interaction is required for robust Tfh and Th2 cell induction, but not essential for eosinophilic airway inflammation during a chronic HDM-driven asthma model. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12834</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27743410">PM:27743410</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161015-VromanH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161015-VromanH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Vroman H</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12834</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kozyrskyj,A.</style></author><author><style face="normal" font="Arial"> Letourneau,N.</style></author><author><style face="normal" font="Arial"> Kang,L.</style></author><author><style face="normal" font="Arial"> Salmani,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Associations between postpartum depressive symptoms and childhood asthma diminish with child age</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="330" start="324">324-330</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Low birth weight</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Affecting 19% of women, postpartum depression is a major concern to the immediate health of mothers and infants. In the longterm, it has been linked to the development of early-onset asthma at school entry, but only if the depression persists beyond the postnatal period. No studies have tested whether associations with postpartum depressive symptoms and early-onset asthma phenotypes persist into later school age. OBJECTIVE: To determine associations between maternal postpartum depressive symptoms and childhood asthma between the ages of 5-10 by using a nested longitudinal design. METHODS: Data were drawn from the 1994-2004 administrations of the Canadian National Longitudinal Survey of Children and Youth, which tracks the health of a nationally-representative sample of children in Canada. Child asthma was diagnosed by a health professional, and maternal depressive symptoms were assessed by the Centre for Epidemiological Studies-Depression scale. Analyses were conducted by using a multi-level modeling approach, in which longitudinal assessments of asthma in 1696 children were nested within the exposure of postpartum depression. RESULTS: Postpartum depressive symptoms had a 1.5 fold significant association with childhood asthma between the ages 6-8. This was independent of male sex, maternal asthma, non-immigrant status, low household socioeconomic status, being first-born, low birth weight, low family functioning and urban-rural residence, of which the first 4 covariates elevated the risk of asthma. Statistical significance was lost at age 8 when maternal prenatal smoking replaced urban-rural residence as a covariate. At ages 9-10, an association was no longer evident. CONCLUSIONS AND CLINICAL REVELANCE: Women affected by postpartum depressive symptoms are concerned about long-term health effects of their illness on their infants. Although postpartum depressive symptoms were associated with school-age asthma at ages 6 and 7, this association diminished later. Both home and school-life stress should be considered in future studies on asthma development later in childhood. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161022IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12837</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27770463">PM:27770463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-KozyrskyjA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-KozyrskyjA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161022, Kozyrskyj A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12837</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Schryver,E.</style></author><author><style face="normal" font="Arial"> Derycke,L.</style></author><author><style face="normal" font="Arial"> Campo,P.</style></author><author><style face="normal" font="Arial"> Gabriels,E.</style></author><author><style face="normal" font="Arial"> Joos,G.F.</style></author><author><style face="normal" font="Arial"> Van Zele,T.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author><author><style face="normal" font="Arial"> Gevaert,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Upper Airways Research Laboratory, Department Otorhinolaryngology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Alcohol Hyper-responsiveness In Chronic Rhinosinusitis with Nasal Polyps</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="253" start="245">245-253</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> NSAID</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An important percentage of subjects diagnosed with chronic upper airway disease report alcohol-induced worsening of their symptoms. The prevalence and characteristics of respiratory reactions provoked by alcohol-containing drinks has not been fully investigated yet. OBJECTIVE: The aim of this study was to estimate the prevalence and characteristics of alcohol hyper-responsiveness in patients with chronic airway disease and healthy controls. Furthermore, nasal inflammation was evaluated in nasal polyp patients with and without hyper-responsiveness. METHODS: We evaluated the prevalence and characteristics of alcohol-induced respiratory complaints in 1281 subjects. Nasal polyp (CRSwNP) patients with and without NSAID exacerbated respiratory disease (NERD), chronic rhinosinusitis patients without nasal polyps (CRSsNP), allergic rhinitis (AR) patients and healthy controls were approached by means of a questionnaire. Inflammatory markers (ECP, IL-5, IgE, SAE specific IgE, IL-17, TNFalpha and IFNgamma) in tissue were then compared between alcohol hyper-responsive and non-hyper-responsive CRSwNP patients. RESULTS: The highest prevalence of nasal and bronchial alcohol hyper-responsiveness was observed in patients with NERD, followed by CRSwNP, and less frequent in CRSsNP, AR and healthy controls. Alcohol hyper-responsiveness is significantly more prevalent in CRSwNP patients suffering from recurrent disease and in patients with severe symptomatology. In nasal tissue of the hyper-responsive CRSwNP group we observed significantly higher nasal levels of the eosinophilic biomarker ECP. CONCLUSION &amp; CLINICAL RELEVANCE: Nasal hyper-responsiveness to alcohol is significantly more prevalent in severe eosinophilic upper airway disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161022IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Belgium -CO - Spain -CO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12836</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27770460">PM:27770460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-DeSchryverE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161022-DeSchryverE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161022, De Schryver E</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12836</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author><author><style face="normal" font="Arial"> Boyle,R.</style></author><author><style face="normal" font="Arial"> Bryce,P.J.</style></author><author><style face="normal" font="Arial"> Crane,J.</style></author><author><style face="normal" font="Arial"> Hogan,S.P.</style></author><author><style face="normal" font="Arial"> Saglani,S.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Woodfolk,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. g.c.roberts@soton.ac.ukNIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK. g.c.roberts@soton.ac.ukThe David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Developments in the field of clinical allergy in 2015 through the eyes of Clinical and Experimental Allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1397" start="1389">1389-1397</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">In the second of two papers, we describe developments in the field of clinical allergy as documented by Clinical and Experimental Allergy in 2015. Epidemiology, clinical allergy, asthma and rhinitis are all covered</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United Kingdom -CO - New Zealand -CO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12831</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27748974">PM:27748974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1389-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1389-97.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12831</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vetander,M.</style></author><author><style face="normal" font="Arial"> Protudjer,J.L.</style></author><author><style face="normal" font="Arial"> Lilja,G.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Hedlin,G.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Ostblom,E.</style></author><author><style face="normal" font="Arial"> Bergstrom,A.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sachs' Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis to foods in a population of adolescents: incidence, characteristics and associated risks</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1587" start="1575">1575-1587</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cor a 14</style></keyword><keyword><style face="normal" font="Arial"> Cor a 9</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Information about severe reactions to foods in adolescence is limited. OBJECTIVE: To describe reactions to foods, including anaphylaxis, with regard to incidence, characteristics and associated risks, among 16-year-olds (adolescents) in a large, population-based birth cohort. METHODS: Parent-reported questionnaire data from ages 2-3 months, and 1, 2 and 16 years were used (N = 3153). Anaphylaxis at age 16 years was defined per NIAID/FAAN criteria. Immunoglobulin E (IgE) antibodies to 14 common food and inhalant allergens were analysed at ages 4 (n = 2283) and 16 years (n = 2510). Among adolescents with food-related symptoms (FRS) and for whom blood was available (n = 221), 25 additional food allergen extracts or allergen components were analysed. Associations between reactions to foods, and sensitization and allergic multimorbidity were investigated. RESULTS: In the 12 months prior to the 16-year assessment, 8.5% of adolescents had FRS. This included 0.8% (n = 24) adolescents who were classified as having anaphylaxis, yielding an incidence rate of 761/100 000 person-years. One-third of adolescents accessed health care during anaphylaxis. Allergic multimorbidity in infancy, as well as sensitization to foods and airborne allergens at age 4 years, was associated with an increased risk for FRS in adolescence. Peanuts and tree nuts were the most common culprit foods for anaphylaxis, and fruits and vegetables for non-anaphylactic reactions. Adolescents with anaphylaxis were significantly more likely to be sensitized to storage proteins (Ara h 2, Cor a 9, Cor a 14) and to be polysensitized to foods (P &lt; 0.001 vs. non-anaphylactic reactions). CONCLUSIONS AND CLINICAL RELEVANCE: The incidence of food-induced anaphylaxis during adolescence in our population-based birth cohort is higher than previously reported. Adolescents with anaphylaxis differ from adolescents with non-anaphylactic FRS with regard to culprit foods and sensitization. Adolescents with previous anaphylaxis are likely to be polysensitized to foods, particularly tree nut and peanut storage proteins, and which warrants consideration at follow-up</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12842</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27790764">PM:27790764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1575-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1575-87.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Vetander M</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12842</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. g.c.roberts@soton.ac.ukNIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK. g.c.roberts@soton.ac.ukThe David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK.</style></auth-address><titles><title><style face="normal" font="Arial">A next-generation anti-IgE monoclonal?</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1371" start="1370">1370-1371</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12832</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27790844">PM:27790844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1370-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1370-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12832</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author><author><style face="normal" font="Arial"> Boyle,R.</style></author><author><style face="normal" font="Arial"> Bryce,P.J.</style></author><author><style face="normal" font="Arial"> Crane,J.</style></author><author><style face="normal" font="Arial"> Hogan,S.P.</style></author><author><style face="normal" font="Arial"> Saglani,S.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Woodfolk,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Developments in the field of allergy mechanisms in 2015 through the eyes of Clinical &amp; Experimental Allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1257" start="1248">1248-1257</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">In the first of two papers we described the development in the field of allergy mechanisms as described by Clinical and Experimental Allergy in 2015. Experimental models of allergic disease, basic mechanisms, clinical mechanisms and allergens are all covered. A second paper will cover clinical aspects</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - ENGPT - Journal ArticlePT - ReviewSB - IMCO - United Kingdom -CO - United States -CO - New Zealand -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12823</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27682977">PM:27682977</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1248-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1248-57.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12823</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grouin,J.M.</style></author><author><style face="normal" font="Arial"> Vicaut,E.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">INSERM 1219, University of Rouen, Rouen, France</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of scores associating symptoms and rescue medication use for evaluating the efficacy of allergy immunotherapy in seasonal allergic rhinoconjunctivitis: results from five trials</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="263" start="254">254-263</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> combined score</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Over the past decade, regulatory bodies and scientific societies recommended, as primary efficacy outcome, a score that reflects both symptom severity and use of rescue medication for clinical trials in allergy immunotherapy (AIT). OBJECTIVE: We sought to compare the results obtained with two subject-specific scores, the Combined Score (CS) and the Adjusted Symptom Score (AdSS), for assessment of AIT in seasonal allergic rhinoconjunctivitis due to birch and grass pollen allergens. METHODS: CS and AdSS were evaluated in subjects receiving a 300IR dose of allergen extract daily, by sublingual route, in four clinical trials with the 5-grass pollen tablet (NCT00367640, NCT00409409, NCT00955825 and NCT00418379) and one with the birch pollen solution (NCT01731249). The CS is derived from the Rhinoconjunctivitis Total Symptom Score (RTSS) and the Rescue Medication Score (RMS) giving equal weight to symptoms and medication use. The AdSS is a symptom score adjusting for rescue medication use. Efficacy end-points were analysed using an analysis of covariance linear model. RESULTS: In all trials, despite the different constructs of the two scores, Combined Score or Adjusted Symptom Score were similarly reduced in the 300IR group compared to the placebo group. Treatment effect was consistently demonstrated with both scores, CS and AdSS, used as either daily scores or average of the daily scores over the pollen season. Minor differences with the same statistical conclusions were observed between the results, leading to the same interpretation. CONCLUSIONS AND CLINICAL RELEVANCE: The two scores, combined and adjusted scores, for evaluation of clinical efficacy of AIT have led to similar results, with similar statistical conclusions and similar interpretation</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12845</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27790763">PM:27790763</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161028-GrouinJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161028-GrouinJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Grouin JM</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12845</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Woolnough,K.F.</style></author><author><style face="normal" font="Arial"> Richardson,M.</style></author><author><style face="normal" font="Arial"> Newby,C.</style></author><author><style face="normal" font="Arial"> Craner,M.</style></author><author><style face="normal" font="Arial"> Bourne,M.</style></author><author><style face="normal" font="Arial"> Monteiro,W.</style></author><author><style face="normal" font="Arial"> Siddiqui,S.</style></author><author><style face="normal" font="Arial"> Bradding,P.</style></author><author><style face="normal" font="Arial"> Pashley,C.H.</style></author><author><style face="normal" font="Arial"> Wardlaw,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Lung Health/Department of Infection, Immunity and Inflammation, University of Leicester, Glenfield Hospital, Leicester, UK</style></auth-address><titles><title><style face="normal" font="Arial">The relationship between biomarkers of fungal allergy and lung damage in asthma</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="56" start="48">48-56</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> CT scan</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Filamentous fungi</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergy</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Penicillium chrysogenum</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Immunological biomarkers are the key to the diagnosis of allergic bronchopulmonary aspergillosis (ABPA) and fungal sensitisation, but how these relate to clinically relevant outcomes is unclear. OBJECTIVES: To assess how fungal immunological biomarkers are related to fixed airflow obstruction and radiological abnormalities in moderate to severe asthma. METHODS: Cross-sectional study of 431 asthmatics. Inflammatory biomarkers, lung function and an IgE fungal panel to colonising filamentous fungi, yeasts and fungal aeroallergens were measured. CT scans were scored for the presence of radiological abnormalities. Factor analysis informed the variables used in a k-means cluster analysis. Fixed airflow obstruction and radiological abnormalities were then mapped to these immunological variables in the cluster analysis. RESULTS: 329 (76.3%) subjects were sensitised to >/= 1 fungi. Sensitisation to Aspergillus fumigatus and/or Penicillium chrysogenum was associated with a lower post-bronchodilator FEV1 compared with those not sensitised to fungi ((73.0 (95% CI 70.2-76) vs. 82.8 (95% CI 78.5-87.2)% predicted, P &lt; 0.001), independent of atopic status (P = 0.005)), and an increased frequency of bronchiectasis (54.5%, P &lt; 0.001), tree-in-bud (18.7%, P &lt; 0.001) and collapse/consolidation (37.5%, P = 0.002). Cluster analysis identified three clusters: (i) hypereosinophilic (n = 71, 16.5%), (ii) high immunological biomarker load and high frequency of radiological abnormalities (n = 34, 7.9%) and (iii) low levels of fungal immunological biomarkers (n = 326, 75.6%). CONCLUSIONS AND CLINICAL RELEVANCE: IgE sensitisation to thermotolerant filamentous fungi, in particular A. fumigatus but not total IgE, is associated with fixed airflow obstruction and a number of radiological abnormalities in moderate to severe asthma. All patients with IgE sensitisation to A. fumigatus are at risk of lung damage irrespective of whether they meet the criteria for ABPA</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12848</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27805757">PM:27805757</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161102-WoolnoughKF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161102-WoolnoughKF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Woolnough KF</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12848</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Terrani,I.</style></author><author><style face="normal" font="Arial"> Bircher,A.J.</style></author><author><style face="normal" font="Arial"> Scherer,H.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Unit, University Hospital, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="Arial">Solar urticaria induced by visible light: successful treatment with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="892" start="890">890-892</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intradermal testing</style></keyword><keyword><style face="normal" font="Arial"> irradiated</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">We report the case of a 53-year-old man with solar urticaria (SU) not responding to histamine antagonist therapy. Using intradermal testing with the patient's irradiated serum, we demonstrated that his SU was elicited by visible light only. This type of SU is uncommon, and makes preventive measures such as sun block largely ineffective. However, the patient had an extraordinary response to the treatment with omalizumab. This case report highlights the diagnostic process and the success of omalizumab for the treatment of SU after 16 months of follow-up</style></abstract><notes><style face="normal" font="Arial">DA - 20161021IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.12951</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27766671">PM:27766671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\2016-41-890-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\2016-41-890-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161021, Terrani I</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.12951</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lozano-Masdemont,B.</style></author><author><style face="normal" font="Arial"> Gomez-Recuero-Munoz,L.</style></author><author><style face="normal" font="Arial"> Pulido-Perez,A.</style></author><author><style face="normal" font="Arial"> Molina-Lopez,I.</style></author><author><style face="normal" font="Arial"> Suarez-Fernandez,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital General Universitario Gregorio Maranon, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Urticarial exanthema due to hepatitis B in a pregnant woman, mimicking a polymorphic eruption of pregnancy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="898" start="896">896-898</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exanthema</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B virus</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">Hepatitis B virus (HBV) infection in pregnant women is very rare in western countries, thus, cutaneous manifestation of HBV infection may be confused with a dermatosis specific of pregnancy. We report a 39-year-old woman who presented in her 20th week of pregnancy with a pruritic rash, which consisted of generalized erythematous plaques, some of them with a purple centre. Serology testing showed acute HBV infection, and a biopsy revealed a superficial and interstitial perivascular inflammatory infiltrate of lymphocytes and eosinophils. A diagnosis of exanthema due to acute hepatitis B infection was established. The patient delivered a clinically healthy boy, who was given the first dose of the HBV vaccine and intravenous specific immunoglobulin, followed by the second dose 2 months later, and did not get infected with HBV. To our knowledge, this is the first case describing HBV exanthema in a pregnant woman, which led to early action for the newborn, avoiding vertical transmission and its high prevalence of cirrhosis and hepatocellular carcinoma</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.12936</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27761922">PM:27761922</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\2016-41-896-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\2016-41-896-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Lozano-Masdemont B</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.12936</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ossorio-Garcia,L.</style></author><author><style face="normal" font="Arial"> Jimenez-Gallo,D.</style></author><author><style face="normal" font="Arial"> Albarran-Planelles,C.</style></author><author><style face="normal" font="Arial"> Arjona-Aguilera,C.</style></author><author><style face="normal" font="Arial"> Linares-Barrios,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital Universitario Puerta del Mar, Cadiz, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Chronic spontaneous urticaria in an 8-year-old girl treated with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="930" start="929">929-930</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - ENGPT - LETTERCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.12922</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27761937">PM:27761937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\2016-41-929-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\2016-41-929-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Ossorio-Garcia L</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.12922</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Diesner,S.C.</style></author><author><style face="normal" font="Arial"> Bergmayr,C.</style></author><author><style face="normal" font="Arial"> Pfitzner,B.</style></author><author><style face="normal" font="Arial"> Assmann,V.</style></author><author><style face="normal" font="Arial"> Krishnamurthy,D.</style></author><author><style face="normal" font="Arial"> Starkl,P.</style></author><author><style face="normal" font="Arial"> Endesfelder,D.</style></author><author><style face="normal" font="Arial"> Rothballer,M.</style></author><author><style face="normal" font="Arial"> Welzl,G.</style></author><author><style face="normal" font="Arial"> Rattei,T.</style></author><author><style face="normal" font="Arial"> Eiwegger,T.</style></author><author><style face="normal" font="Arial"> Szepfalusi,Z.</style></author><author><style face="normal" font="Arial"> Fehrenbach,H.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Hartmann,A.</style></author><author><style face="normal" font="Arial"> Pali-Scholl,I.</style></author><author><style face="normal" font="Arial"> Untersmayr,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">A distinct microbiota composition is associated with protection from food allergy in an oral mouse immunization model</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="18" start="10">10-18</pages><volume><style face="normal" font="Arial">173</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="10" Year="2016">2016/10/24</year></dates><abstract><style face="normal" font="Arial">In our mouse model, gastric acid-suppression is associated with antigen-specific IgE and anaphylaxis development. We repeatedly observed non-responder animals protected from food allergy. Here, we aimed to analyse reasons for this protection. Ten out of 64 mice, subjected to oral ovalbumin (OVA) immunizations under gastric acid-suppression, were non-responders without OVA-specific IgE or IgG1 elevation, indicating protection from allergy. In these non-responders, allergen challenges confirmed reduced antigen uptake and lack of anaphylactic symptoms, while in allergic mice high levels of mouse mast-cell protease-1 and a body temperature reduction, indicative for anaphylaxis, were determined. Upon OVA stimulation, significantly lower IL-4, IL-5, IL-10 and IL-13 levels were detected in non-responders, while IL-22 was significantly higher. Comparison of fecal microbiota revealed differences of bacterial communities on single bacterial Operational-Taxonomic-Unit level between the groups, indicating protection from food allergy being associated with a distinct microbiota composition in a non-responding phenotype in this mouse model</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - ENGPT - Journal ArticleCO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2016.10.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27789346">PM:27789346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\2016-173-10-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\2016-173-10-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Diesner SC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2016.10.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berker,M.</style></author><author><style face="normal" font="Arial"> Frank,L.J.</style></author><author><style face="normal" font="Arial"> Gessner,A.L.</style></author><author><style face="normal" font="Arial"> Grassl,N.</style></author><author><style face="normal" font="Arial"> Holtermann,A.V.</style></author><author><style face="normal" font="Arial"> Hoppner,S.</style></author><author><style face="normal" font="Arial"> Kraef,C.</style></author><author><style face="normal" font="Arial"> Leclaire,M.D.</style></author><author><style face="normal" font="Arial"> Maier,P.</style></author><author><style face="normal" font="Arial"> Messerer,D.A.</style></author><author><style face="normal" font="Arial"> Mohrmann,L.</style></author><author><style face="normal" font="Arial"> Nieke,J.P.</style></author><author><style face="normal" font="Arial"> Schoch,D.</style></author><author><style face="normal" font="Arial"> Soll,D.</style></author><author><style face="normal" font="Arial"> Woopen,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">German Academic Scholarship Foundation - Studienstiftung des deutschen Volkes, Bonn, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergies - A T cells perspective in the era beyond the TH1/TH2 paradigm</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="83" start="73">73-83</pages><volume><style face="normal" font="Arial">174</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> TH22</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic diseases have emerged as a major health care burden, especially in the western hemisphere. They are defined by overshooting reactions of an aberrant immune system to harmless exogenous stimuli. The TH1/TH2 paradigm assumes that a dominance of TH2 cell activation and an inadequate TH1 cell response are responsible for the development of allergies. However, the characterization of additional T helper cell subpopulations such as TH9, TH17, TH22, THGM-CSF and their interplay with regulatory T cells suggest further layers of complexity. This review summarizes state-of-the-art knowledge on T cell diversity and their induction, while revisiting the TH1/TH2 paradigm. With respect to these numerous contributors, it offers a new perspective on the pathogenesis of asthma, allergic rhinitis (AR) and atopic dermatitis (AD) incorporating recent discoveries in the field of T cell plasticity</style></abstract><notes><style face="normal" font="Arial">DA - 20161116IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27847316">PM:27847316</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\2017-174-73-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\2017-174-73-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161116, Berker M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Linneberg,A.</style></author><author><style face="normal" font="Arial"> Dam,P.K.</style></author><author><style face="normal" font="Arial"> Hahn-Pedersen,J.</style></author><author><style face="normal" font="Arial"> Hammerby,E.</style></author><author><style face="normal" font="Arial"> Serup-Hansen,N.</style></author><author><style face="normal" font="Arial"> Boxall,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Centre for Prevention and Health, The Capital Region of Denmark, Copenhagen, DenmarkALK, Horsholm, DenmarkALK, Horsholm, DenmarkALK, Horsholm, DenmarkMAPI, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Burden of allergic respiratory disease: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="12">12-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absenteeism</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Mental Health</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> SF36</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">This meta-analysis compared the health-related quality of life (HRQL) of patients with allergic rhinitis (AR) and/or allergic asthma (AA) caused by perennial house dust mite (HDM) versus AR and/or AA caused by seasonal pollen allergy. Following a systematic search, the identified studies used the disease-specific rhinitis quality of life questionnaire or generic instruments (SF-36 and SF-12). Summary estimates obtained by meta-analysis showed that HRQL in patients with perennial HDM allergy was significantly worse than that of patients with seasonal pollen allergy, when measured by both disease-specific and generic HRQL instruments, and was reflected by an impact on both physical and mental health. A systematic review of cost data on AR and AA in selected European countries demonstrated that the majority of the economic burden was indirectly caused by high levels of absenteeism and presenteeism; there was little or no evidence of increasing or decreasing cost trends. Increased awareness of the detrimental effects of AR and/or AA on patients' HRQL and its considerable cost burden might encourage early diagnosis and treatment, in order to minimize the disease burden and ensure beneficial and cost-effective outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20161006IS - 1476-7961 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-016-0049-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27708552">PM:27708552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161006, Linneberg A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-016-0049-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boni,E.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Mauro,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Sant'Anna Hospital, ASST Lariana, Via Napoleona 60, 22100 Como, ItalyAllergy/Cardiac and Pulmonary Rehabilitation ASST G. Pini/CTO, Via Bignami 1, 20126 Milan, ItalyAllergy Unit, Sant'Anna Hospital, ASST Lariana, Via Napoleona 60, 22100 Como, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="14">14-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Systemic reactions (SR) to venom immunotherapy (VIT) are rare but may occur, with a rate significantly higher for honeybee than for vespid VIT. In patients with repeated SRs to VIT it is difficult to reach the maintenance dose of venom and pre-treatment with omalizumab is indicated, as shown by some studies reporting its preventative capacity, when antihistamines and corticosteroids are ineffective. CASE PRESENTATION: We present the case of a 47 years old woman allergic to bee venom who experienced two severe SRs after bee stings and several SRs to VIT with bee venom. Pre-treatment with antihistamines and corticosteroids as well as omalizumab at doses up to 300 mg was unsuccessful, while an omalizumab dose of 450 mg finally achieved in our patient the protection from SRs to VIT with 200 mcg of bee venom. CONCLUSIONS: The search of the dose of omalizumab able to protect a patient with repeated SRs to VIT may be demanding, but this search is warranted by the need to provide to this kind of patient, by an adequate VIT, the protection from potentially life-threatening reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-016-0051-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799850">PM:27799850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Boni E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-016-0051-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsai,Y.L.</style></author><author><style face="normal" font="Arial"> Ko,W.S.</style></author><author><style face="normal" font="Arial"> Hsiao,J.L.</style></author><author><style face="normal" font="Arial"> Pan,H.H.</style></author><author><style face="normal" font="Arial"> Chiou,Y.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan, Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Zinc sulfate improved the unbalanced T cell profiles in Der p-allergic asthma: An ex vivo study</style></title><secondary-title><style face="normal" font="Arial">Clin Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Respir J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="11" Month="10" Year="2016">2016/10/11</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: In the pathogenesis of asthma, an imbalance between helper T (Th) 1/Th2 and Th17/Treg cells is believed to play a key role in asthmatic inflammatory responses. Some studies indicated that zinc deficiency increases inflammatory factor production and worsens asthma. However, the effects of zinc on T cell profiles to reduce inflammatory response remain unclear. OBJECTIVES: We investigated the beneficial effects of zinc on isolated cell populations and cytokine levels from patients with asthma. METHODS: Thirty-six individuals Dermatophagoides pteronyssinus (Der p)-allergic and 31 healthy subjects were enrolled in the study, and peripheral blood mononuclear cells (PBMCs) were collected. Harvested PBMCs were stimulated with recombinant Der p antigen in the presence or absence of zinc sulfate (25 muM or 50 muM) for 48 h. Cell surface markers and intracellular cytokine levels were examined by flow cytometry. The pro-inflammatory factors in plasma and culture supernatants were measured by commercial enzyme-linked immunosorbent assay. RESULTS: Zinc sulfate dramatically reduced the proportions of Th2 and Th17 cells, but increased that of Th1 and Treg cells. Zinc sulfate also markedly reduced the levels of interleukin (IL)-4 and IL-17, but increased the levels of IFN-gamma. CONCLUSIONS: Zinc ameliorates the imbalance in T cell profiles and could be a potential adjuvant therapy for Der p-induced allergic hypersensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1752-699X (Electronic)IS - 1752-6981 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1111/crj.12563</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27727525">PM:27727525</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Respir J\20161011-TsaiYL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Respir J\20161011-TsaiYL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Tsai YL</style></custom2><misc3><style face="normal" font="Arial">10.1111/crj.12563</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yuan,T.</style></author><author><style face="normal" font="Arial"> Zhao,W.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Dong,Y.</style></author><author><style face="normal" font="Arial"> Li,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Endocrinology, Key Laboratory of Endocrinology, The National Health and Family Planning Commission, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Continuous Subcutaneous Insulin Infusion as an Effective Method of Desensitization Therapy for Diabetic Patients with Insulin Allergy: A 4-year Single-Center Experience</style></title><secondary-title><style face="normal" font="Arial">Clin Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Ther</style></full-title></periodical><pages end="2494" start="2489">2489-2494</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Continuous subcutaneous insulin infusion</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endocrinology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Insulin allergy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Rapid desensitization</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="10" Year="2016">2016/10/25</year></dates><abstract><style face="normal" font="Arial">PURPOSE: This article summarizes our experiences in the application of continuous subcutaneous insulin infusion (CSII) as a method of rapid desensitization therapy for diabetic patients with insulin allergy that was subsequently switched to a regimen of multiple-dose injections for long-term insulin therapy. METHODS: The clinical data of 11 diabetic patients with insulin allergy in Peking Union Medical College Hospital from April 1, 2008, through December 31, 2011, were retrospectively analyzed. FINDINGS: All 11 conditions were diagnosed by case history, skin testing, determination of serum specific anti-insulin IgE, and reaction to withdrawal of insulin. Seven patients accepted the traditional injection method of desensitization, and 5 patients accepted CSII with the protocol designed for this study (1 patient accepted CSII after failure by the formal method). Six of the 7 patients who accepted the traditional method and all 5 patients who accepted CSII had successful results. All 5 patients in the CSII group switched to a regimen of multiple dosage injections. In a survey of 28 nurses, both experienced nurses and practical nurses preferred to use CSII as the method of desensitization. IMPLICATIONS: It is feasible and effective for diabetic patients with insulin allergy to use CSII as a method of rapid desensitization with subsequent switching to a regimen of multiple-dose injections for long-term insulin therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161029IS - 1879-114X (Electronic)IS - 0149-2918 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clinthera.2016.09.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27793354">PM:27793354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Ther\20161029-YuanT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Ther\20161029-YuanT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161029, Yuan T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clinthera.2016.09.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Treudler,R.</style></author><author><style face="normal" font="Arial"> Franke,A.</style></author><author><style face="normal" font="Arial"> Schmiedeknecht,A.</style></author><author><style face="normal" font="Arial"> Ballmer-Weber,B.K.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Werfel,T.</style></author><author><style face="normal" font="Arial"> Jappe,U.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author><author><style face="normal" font="Arial"> Schmitt,J.</style></author><author><style face="normal" font="Arial"> Brehler,R.</style></author><author><style face="normal" font="Arial"> Kleinheinz,A.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Bruning,H.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author><author><style face="normal" font="Arial"> Ring,J.</style></author><author><style face="normal" font="Arial"> Saloga,J.</style></author><author><style face="normal" font="Arial"> Schakel,K.</style></author><author><style face="normal" font="Arial"> Holzhauser,T.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Venerology and Allergology, Universitat Leipzig, Leipzig, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Standardization of double blind placebo controlled food challenge with soy within a multicentre trial</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> eliciting dose</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gly m 4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy allergy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> threshold level</style></keyword><keyword><style face="normal" font="Arial"> threshold levels</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Multicentre trials investigating food allergies by double blind placebo controlled food challenges (DBPCFC) need standardized procedures, challenge meals and evaluation criteria. We aimed at developing a standardized approach for identifying patients with birch related soy allergy by means of DBPCFC to soy, including determination of threshold levels, in a multicentre setting. METHODS: Microbiologically stable soy challenge meals were composed of protein isolate with consistent Gly m 4 levels. Patients sensitized to main birch allergen Bet v 1 and concomitant sensitization to its soy homologue Gly m 4 underwent DBPCFC. Outcome was defined according to presence and/or absence of ten objective signs and intensity of eight subjective symptoms as measured by visual analogue scale (VAS). RESULTS: 138 adult subjects (63.8% female, mean age 38 years) underwent DBPCFC. Challenge meals and defined evaluation criteria showed good applicability in all centres involved. 45.7% presented with objective signs and 65.2% with subjective symptoms at soy challenge. Placebo challenge meals elicited non-cardiovascular objective signs in 11.6%. In 82 (59.4%) subjects DBPCFC was judged as positive. 70.7% of DPBCFC+ showed objective signs and 85.4% subjective symptoms at soy challenge. Subjective symptoms to soy challenge meal in DBPCFC+ subjects started at significantly lower dose levels than objective signs (p &lt; 0.001). Median cumulative eliciting doses for first objective signs in DBPCFC+ subjects were 4.7 g [0.7-24.7] and 0.7 g [0.2-4.7] total soy protein for first subjective symptoms (p = 0.01). CONCLUSIONS: We present the hitherto largest group of adults with Bet v 1 and Gly m 4 sensitization being investigated by DBPCFC. In this type of food allergy evaluation of DBPCFC outcome should not only include monitoring of objective signs but also scoring of subjective symptoms. Our data may contribute to standardize DBPCFC in pollen-related food allergy in multicentre settings. TRIAL REGISTRATION: EudraCT: 2009-011737-27</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0129-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826414">PM:27826414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Treudler R</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0129-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Protudjer,J.L.</style></author><author><style face="normal" font="Arial"> Jansson,S.A.</style></author><author><style face="normal" font="Arial"> Middelveld,R.</style></author><author><style face="normal" font="Arial"> Ostblom,E.</style></author><author><style face="normal" font="Arial"> Dahlen,S.E.</style></author><author><style face="normal" font="Arial"> Arnlind,M.H.</style></author><author><style face="normal" font="Arial"> Bengtsson,U.</style></author><author><style face="normal" font="Arial"> Kallstrom-Bengtsson,I.</style></author><author><style face="normal" font="Arial"> Marklund,B.</style></author><author><style face="normal" font="Arial"> Rentzos,G.</style></author><author><style face="normal" font="Arial"> Sundqvist,A.C.</style></author><author><style face="normal" font="Arial"> Akerstrom,J.</style></author><author><style face="normal" font="Arial"> Ahlstedt,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Centre for Allergy Research, Karolinska Institutet, P.O. Box 287, 17177 Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Impaired health-related quality of life in adolescents with allergy to staple foods</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="37">37-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental exposure</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cow's milk, hen's egg and wheat are staple foods in a typical western diet. Despite the ubiquity of these foods, the impact of staple food allergy on health-related quality of life (HRQL) amongst adolescents is incompletely understood. The aims of this study were to make use of the Swedish version of EuroPrevall's disease-specific food allergy quality of life questionnaire-teenager form (FAQLQ-TF) and to investigate the association between objectively-diagnosed staple food allergy and HRQL amongst adolescents. METHODS: In this cross-sectional study, 58 adolescents aged 13-17 years [n = 40 (69 %) boys] with objectively-diagnosed allergy to the staple foods cow's milk, hen's egg and/or wheat and living in Stockholm, Sweden were included. Adolescents completed the FAQLQ-TF, which has a corresponding scale of 1 = best HRQL, and 7 = worst HRQL. Overall HRQL and domain-specific HRQL were established. Adolescents also reported symptoms, adrenaline auto injector (AAI) prescription and presence of other food allergies. A history of anaphylaxis was defined among those reporting difficulty breathing, inability to stand/collapse, and/or loss of consciousness. Clinically different HRQL was set at a mean difference of >/=0.5. RESULTS: Overall mean HRQL was poorer than average [mean: 4.70/7.00 (95 % CI 4.30-5.01)]. The domain risk of accidental exposure was significantly associated with clinically better HRQL than the domain allergen avoidance and dietary restrictions (mean difference = 0.76; p &lt; 0.001). Girls had clinically worse, but not statistically significantly different mean HRQL than boys (mean difference = 0.71; p &lt; 0.07). HRQL tended to be worse amongst those with allergies to more than three foods or an AAI prescription. The number and types of symptoms, including a history of anaphylaxis were not associated with worse HRQL. CONCLUSIONS: As ascertained via a food allergy-specific questionnaire, adolescents with staple food allergy report poorer than average HRQL, specifically in relation to emerging independence and the need for support. Girls have clinically worse HRQL than boys. The number and type of previous symptoms and history of anaphylaxis were not associated with worse HRQL</style></abstract><notes><style face="normal" font="Arial">DA - 20161013IS - 2045-7022 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0128-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27733903">PM:27733903</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-37.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Protudjer JL</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0128-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Konig,J.</style></author><author><style face="normal" font="Arial"> Wells,J.</style></author><author><style face="normal" font="Arial"> Cani,P.D.</style></author><author><style face="normal" font="Arial"> Garcia-Rodenas,C.L.</style></author><author><style face="normal" font="Arial"> MacDonald,T.</style></author><author><style face="normal" font="Arial"> Mercenier,A.</style></author><author><style face="normal" font="Arial"> Whyte,J.</style></author><author><style face="normal" font="Arial"> Troost,F.</style></author><author><style face="normal" font="Arial"> Brummer,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Orebro University, Orebro, SwedenHost-Microbe Interactomics, Animal Sciences, Wageningen University, Wageningen, The NetherlandsMetabolism and Nutrition Research Group, WELBIO-Walloon Excellence in Life Sciences and BIOtechnology, Louvain Drug Research Institute, Universite Catholique de Louvain, Brussels, BelgiumNutrition and Health Research, Nestle Research Center, Lausanne, SwitzerlandInstitute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UKNutrition and Health Research, Nestle Research Center, Lausanne, SwitzerlandEuropean Branch, The International Life Sciences Institute, Brussels, BelgiumDivision of Gastroenterology-Hepatology, Department of Internal Medicine, University Hospital Maastricht, Maastricht University Medical Centre, Maastricht, The NetherlandsNutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Orebro University, Orebro, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Human Intestinal Barrier Function in Health and Disease</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Gastroenterol</style></full-title></periodical><pages end="" start="e196">e196-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electrolytes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> intestinal permeability</style></keyword><keyword><style face="normal" font="Arial"> Irritable Bowel Syndrome</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Non celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">The gastrointestinal tract consists of an enormous surface area that is optimized to efficiently absorb nutrients, water, and electrolytes from food. At the same time, it needs to provide a tight barrier against the ingress of harmful substances, and protect against a reaction to omnipresent harmless compounds. A dysfunctional intestinal barrier is associated with various diseases and disorders. In this review, the role of intestinal permeability in common disorders such as infections with intestinal pathogens, inflammatory bowel disease, irritable bowel syndrome, obesity, celiac disease, non-celiac gluten sensitivity, and food allergies will be discussed. In addition, the effect of the frequently prescribed drugs proton pump inhibitors and non-steroidal anti-inflammatory drugs on intestinal permeability, as well as commonly used methods to assess barrier function will be reviewed</style></abstract><notes><style face="normal" font="Arial">DA - 20161020LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Sweden -CO - Netherlands -CO - Belgium -CO - Switzerland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/ctg.2016.54</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763627">PM:27763627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Gastroenterol\2016-7-e196.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Gastroenterol\2016-7-e196.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Konig J</style></custom2><misc3><style face="normal" font="Arial">10.1038/ctg.2016.54</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guest,J.F.</style></author><author><style face="normal" font="Arial"> Yang,A.C.</style></author><author><style face="normal" font="Arial"> Oba,J.</style></author><author><style face="normal" font="Arial"> Rodrigues,M.</style></author><author><style face="normal" font="Arial"> Caetano,R.</style></author><author><style face="normal" font="Arial"> Polster,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Catalyst Health Economics Consultants, Northwood, Middlesex, UK; Faculty of Life Sciences and Medicine, King's College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Relative cost-effectiveness of using an extensively hydrolyzed casein formula in managing infants with cow's milk allergy in Brazil</style></title><secondary-title><style face="normal" font="Arial">Clinicoecon Outcomes Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clinicoecon Outcomes Res</style></full-title></periodical><pages end="639" start="629">629-639</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid formula</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Consultants</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Nutramigen</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To estimate the cost-effectiveness of three alternative dietetic strategies for cow's milk allergy in Brazil: 1) using an extensively hydrolyzed casein formula (eHCF; Nutramigen) as a first-line formula, but switching to an amino acid formula (AAF) if infants remain symptomatic; 2) using an AAF as a first-line formula and then switching to an eHCF after 4 weeks once infants are symptom-free, but switching back to an AAF if infants become symptomatic; and 3) using an AAF as a first-line formula and keeping all infants on that formula. The analysis was conducted from the perspective of the Brazilian public health care system, Sistema Unico de Saude. METHODS: Decision modeling was used to estimate the probability of immunoglobulin E (IgE)-mediated and non-IgE-mediated allergic infants developing tolerance to cow's milk by 12 months from starting a formula. The models also estimated the Sistema Unico de Saude cost (at 2013/2014 prices) of managing infants over 12 months after starting a formula, as well as the relative cost-effectiveness of each of the dietetic strategies. RESULTS: The probability of developing tolerance to cow's milk by 12 months from starting a formula was higher among infants with either IgE-mediated or non-IgE-mediated allergy who were initially fed with an eHCF, compared with those who were initially fed with an AAF. The total health care cost of initially feeding an eHCF to cow's milk allergic infants was less than that of initially feeding both IgE-mediated and non-IgE-mediated infants with an AAF. CONCLUSION: Within the study's limitations, using an eHCF instead of an AAF for the first-line management of newly-diagnosed infants with cow's milk allergy affords a cost-effective use of publicly funded resources, since it improves the outcome for less cost</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1178-6981 (Linking)LA - ENGPT - Journal ArticleCO - United Kingdom -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.2147/CEOR.S113448</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799804">PM:27799804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clinicoecon Outcomes Res\2016-8-629-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clinicoecon Outcomes Res\2016-8-629-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Guest JF</style></custom2><misc3><style face="normal" font="Arial">10.2147/CEOR.S113448</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shajari,M.</style></author><author><style face="normal" font="Arial"> Eberhardt,E.</style></author><author><style face="normal" font="Arial"> Muller,M.</style></author><author><style face="normal" font="Arial"> Al Khateeb,G.</style></author><author><style face="normal" font="Arial"> Friderich,S.</style></author><author><style face="normal" font="Arial"> Remy,M.</style></author><author><style face="normal" font="Arial"> Kohnen,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology, Goethe-University, Frankfurt am Main, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Atopic Syndrome on Keratoconus</style></title><secondary-title><style face="normal" font="Arial">Cornea</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cornea</style></full-title></periodical><pages end="1420" start="1416">1416-1420</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cornea</style></keyword><keyword><style face="normal" font="Arial"> Densitometry</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Keratoconus</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: To evaluate the effects of atopic syndrome on manifestations of keratoconus. METHODS: In this retrospective study, we reviewed patient files and data generated by Scheimpflug imaging of 670 eyes of 434 keratoconus patients. Patients were divided into a study group consisting of patients suffering from atopic syndrome (110 eyes of 75 patients), namely allergic asthma, atopic dermatitis, and/or allergic rhinitis, and a control group of patients without known atopic syndrome (560 eyes of 359 patients). RESULTS: We found a significant difference with the mean age being 36.1 +/- 11.7 for the control group, 32.8 +/- 9.6 for the atopic group (P = 0.002) with 1 atopic trait, and 30.4 +/- 7.5 for patients with 2 or more atopic traits (P = 0.002). No statistically significant differences were found in the mean corrected distance visual acuity, corneal pachymetry, minimum relative pachymetric progression (RPImin), mean refraction, keratoconus index, anterior chamber depth and volume, Kmax, and location of Kmax in relation to the corneal apex. However, we found a significantly higher corneal density for the anterior 120 mum of the cornea in the atopic group (control: 20.74 +/- 4.68, atopic group: 21.92 +/- 4.65 P = 0.016). CONCLUSIONS: Keratoconus patients suffering from atopic syndrome were significantly younger but showed no topographical changes except in corneal densitometry compared with keratoconus patients without an atopic disease. This suggests atopic syndrome is a factor, which can trigger earlier manifestation of keratoconus</style></abstract><notes><style face="normal" font="Arial">DA - 20160718IS - 1536-4798 (Electronic)IS - 0277-3740 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1097/ICO.0000000000000935</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27429082">PM:27429082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cornea\2016-35-1416-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cornea\2016-35-1416-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160718, Shajari M</style></custom2><misc3><style face="normal" font="Arial">10.1097/ICO.0000000000000935</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kovalenko,P.</style></author><author><style face="normal" font="Arial"> DiCioccio,A.T.</style></author><author><style face="normal" font="Arial"> Davis,J.D.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Ardeleanu,M.</style></author><author><style face="normal" font="Arial"> Graham,N.</style></author><author><style face="normal" font="Arial"> Soltys,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4Ralpha, in Atopic Dermatitis Patients and Normal Volunteers</style></title><secondary-title><style face="normal" font="Arial">CPT Pharmacometrics Syst Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">CPT Pharmacometrics Syst Pharmacol</style></abbr-1></periodical><pages end="624" start="617">617-624</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Subcutaneous route</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="25" Month="10" Year="2016">2016/10/25</year></dates><abstract><style face="normal" font="Arial">An exploratory population pharmacokinetic model for functional dupilumab was developed. Data from healthy volunteers and patients with atopic dermatitis (AD) receiving intravenous or subcutaneous doses were integrated. The data included 197 participants (2,518 measurements of dupilumab in serum) from six phase I and II studies. The data were analyzed using stochastic approximation expectation-maximization and importance sampling methods. The best structural model was a two-compartment model with parallel linear and Michaelis-Menten elimination from the central compartment. Estimated parameters were: central volume 2.74 L, elimination rate 0.0459 d-1 , central-to-peripheral rate 0.0652 d-1 , peripheral-to-central rate 0.129 d-1 , bioavailability 60.7%, maximal target-mediated elimination rate 0.968 mg/L/d, and Michaelis-Menten constant 0.01 mg/L. Body weight was a significant covariate of the central volume. No gender effect was observed when controlling for weight. No differences between healthy volunteers and patients with AD were found. The model adequately described dupilumab pharmacokinetics for intravenous and subcutaneous routes of administration</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 2163-8306 (Electronic)IS - 2163-8306 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/psp4.12136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27778477">PM:27778477</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\CPT Pharmacometrics Syst Pharmacol\20161025-KovalenkoP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\CPT Pharmacometrics Syst Pharmacol\20161025-KovalenkoP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Kovalenko P</style></custom2><misc3><style face="normal" font="Arial">10.1002/psp4.12136</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsuang,A.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box# 1198, New York, NY, 10029, USA</style></auth-address><titles><title><style face="normal" font="Arial">Childcare and School Management Issues in Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="83">83-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> epinephrine auto-injectors</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The goal of this review is to characterize food allergy management and anaphylaxis in schools and assess current policies and level of preparedness of schools to recognize and treat anaphylaxis. RECENT FINDINGS: An increasing number of school-aged children have food allergies, and studies show that a significant number of school children with no known history of allergies will experience their first anaphylactic reaction at school. Stock-unassigned epinephrine auto-injectors are recommended in schools but not mandatory in most states, and therefore, epinephrine is not always available. Non-nursing staff members are sometimes administering epinephrine due to limitations in nurse staffing. Wide variations in staff training and lack of stock epinephrine leave many schools inadequately prepared to manage anaphylactic reactions. Emphasis should be placed not only on ensuring all schools have stock epinephrine but also on training a wider range of school staff members to minimize treatment delay with epinephrine and improve clinical outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0663-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27873193">PM:27873193</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Tsuang A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0663-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mazurek,J.M.</style></author><author><style face="normal" font="Arial"> Weissman,D.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Mailstop HG 900.2, 1095 Willowdale Rd., Morgantown, WV, 26505, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Occupational Respiratory Allergic Diseases in Healthcare Workers</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="77">77-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Centers for Disease Control</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disinfectants</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> healthcare workers</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritants</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Work related rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Healthcare workers (HCWs) are exposed to a range of high and low molecular weight agents that are allergic sensitizers or irritants including cleaners and disinfectants, natural rubber latex, and various medications. Studies have shown that exposed HCWs are at risk for work-related rhinitis and asthma (WRA). Work-related rhinitis may precede development of WRA and should be considered as an early marker of WRA. Avoidance of causative exposures through control strategies such as elimination, substitution, engineering controls, and process modification is the preferred primary prevention strategy for preventing development of work-related allergic diseases. There is limited evidence for the effectiveness of respirators in preventing occupational asthma. If sensitizer-induced WRA is diagnosed, it is important to avoid further exposure to the causative agent, preferably by more rigorous application of exposure control strategies to the workplace. This review focuses on allergic occupational respiratory diseases in HCWs</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0657-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27796792">PM:27796792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-77.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-77.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Mazurek JM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0657-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Giannetti,M.P.</style></author><author><style face="normal" font="Arial"> Cardet,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 75 Francis St. Smith Building, 628, Boston, MA, 02115, USA</style></auth-address><titles><title><style face="normal" font="Arial">Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="80">80-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Asthma is the most common chronic respiratory disease in the USA. A subset of patients with asthma have refractory symptoms, persistent eosinophilic inflammation, and recurrent exacerbations despite maximal medical therapy. The monoclonal antibodies targeting the IL-5 pathway are a new class of medications designed to target severe eosinophilic asthma. There are two medications clinically available: mepolizumab and reslizumab, both of which target IL-5. A third medication, benralizumab, is currently under development and targets the IL-5 receptor. Clinical data suggest these medications can reduce asthma exacerbations and improve lung function in patients with peripheral eosinophilia and poorly controlled asthma despite maximal medical therapy. The anti-IL-5 medications are among the first targeted molecular therapies for asthma and will usher in an exciting new era in the treatment of severe asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0662-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27796795">PM:27796795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Giannetti MP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0662-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Steinke,J.W.</style></author><author><style face="normal" font="Arial"> Borish,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immune Responses in Rhinovirus-Induced Asthma Exacerbations</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="78">78-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Acute asthma exacerbations are responsible for urgent care visits and hospitalizations; they interfere with school and work productivity, thereby driving much of the morbidity and mortality associated with asthma. Approximately 80 to 85 % of asthma exacerbations in children, adolescents, and less frequently adults are associated with viral upper respiratory tract viral infections, and rhinovirus (RV) accounts for approximately 60-70 % of these virus-associated exacerbations. Evidence suggests that it is not the virus itself but the nature of the immune response to RV that drives this untoward response. In particular, evidence supports the concept that RV acts to exacerbate an ongoing allergic inflammatory response to environmental allergens present at the time of the infection. The interaction of the ongoing IgE- and T cell-mediated response to allergen superimposed on the innate and adaptive immune responses to the virus and how this leads to triggering of an asthma exacerbation is discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0661-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27796793">PM:27796793</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-78.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-78.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Steinke JW</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0661-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Platt,M.P.</style></author><author><style face="normal" font="Arial"> Brook,C.D.</style></author><author><style face="normal" font="Arial"> Kuperstock,J.</style></author><author><style face="normal" font="Arial"> Krouse,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology- Head and Neck Surgery, Boston University School of Medicine, 820 Harrison Avenue, Boston, MA, 02118, USA</style></auth-address><titles><title><style face="normal" font="Arial">What Role Does Allergy Play in Chronic Ear Disease and Laryngitis?</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="76">76-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Laryngitis</style></keyword><keyword><style face="normal" font="Arial"> Larynx</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Mucosa</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">IgE-mediated allergy plays a well-established role in both nasal and pulmonary diseases due to the common epithelium and shared mediator responses of the upper and lower airways. This "unified airway" concept has also been described in other sites within the head and neck that contain similar respiratory mucosa: the middle ear and the larynx. This review will highlight the data suggesting a role for IgE-mediated allergic disease in chronic laryngopharyngeal and middle ear disease and the role for allergy testing to aid in diagnosis and treatment of these disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20161026IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0653-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27783318">PM:27783318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161026, Platt MP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0653-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Epp,A.</style></author><author><style face="normal" font="Arial"> Sullivan,K.C.</style></author><author><style face="normal" font="Arial"> Herr,A.B.</style></author><author><style face="normal" font="Arial"> Strait,R.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Systemic Inflammation Research, University of Lubeck, Lubeck, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin Glycosylation Effects in Allergy and Immunity</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="79">79-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fc receptors</style></keyword><keyword><style face="normal" font="Arial"> FcRs</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The aim of this review will be to familiarize the reader with the general area of antibody (Ab) glycosylation and to summarize the known functional roles of glycosylation and how glycan structure can contribute to various disease states with emphasis on allergic disease. RECENT FINDINGS: Both immunoglobulin (Ig) isotype and conserved Fc glycosylation sites often dictate the downstream activity of an Ab where complexity and degree of glycosylation contribute to its ability to bind Fc receptors (FcRs) and activate complement. Most information on the effects of glycosylation center on IgG in cancer therapy and autoimmunity. In cancer therapy, glycosylation modifications that enhance affinity for activating FcRs are utilized to facilitate immune-mediated tumor cell killing. In autoimmunity, disease severity has been linked to alterations in the presence, location, and composition of Fc glycans. Significantly less is understood about the role of glycosylation in the setting of allergy and asthma. However, recent data demonstrate that glycosylation of IgE at the asparagine-394 site of Cepsilon3 is necessary for IgE interaction with the high affinity IgE receptor but, surprisingly, glycosylation has no effect on IgE interaction with its low-affinity lectin receptor, CD23. Variations in the specific glycoform may modulate the interaction of an Ig with its receptors. Significantly more is known about the functional effects of glycosylation of IgG than for other Ig isotypes. Thus, the role of glycosylation is much better understood in the areas of autoimmunity and cancer therapy, where IgG is the dominant isotype, than in the field of allergy, where IgE predominates. Further work is needed to fully understand the role of glycan variation in IgE and other Ig isotypes with regard to the inhibition or mediation of allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0658-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27796794">PM:27796794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-79.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-79.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Epp A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0658-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Graham,M.T.</style></author><author><style face="normal" font="Arial"> Andorf,S.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author><author><style face="normal" font="Arial"> Chatila,T.A.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University, 269 Campus Drive, CCSR Building, Room 3215, Stanford, CA, 94305, USA</style></auth-address><titles><title><style face="normal" font="Arial">Temporal Regulation by Innate Type 2 Cytokines in Food Allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="75">75-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Food allergies (FAs) are a growing epidemic in western countries with poorly defined etiology. Defined as an adverse immune response to common food allergens, FAs present heterogeneously as a single- or multi-organ response that ranges in severity from localized hives and angioedema to systemic anaphylaxis. RECENT FINDINGS: Current research focusing on epithelial-derived cytokines contends that temporal regulation by these factors impact initial sensitization and persistence of FA responses upon repeated food allergen exposure. Mechanistic understanding of FA draws insight from a myriad of atopic conditions studied in humans and modeled in mice. In this review, we will highlight how epithelial-derived cytokines initiate and then potentiate FAs. We will also review existing evidence of the contribution of other atopic diseases to FA pathogenesis and whether FA symptoms overlap with other atopic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0656-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27771884">PM:27771884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Graham MT</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0656-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mennini,M.</style></author><author><style face="normal" font="Arial"> Dahdah,L.</style></author><author><style face="normal" font="Arial"> Mazzina,O.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, University Department of Pediatrics, Pediatric Hospital Bambino Gesu, Vatican City, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Lupin and Other Potentially Cross-Reactive Allergens in Peanut Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="84">84-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> 2S Albumins</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Lupin</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> precautionary labelling</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seed proteins</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The presence of IgE cross-reactivity between peanut allergens and allergens from other legumes and tree nuts has been demonstrated, but the identification of the involved individual allergens is still limited. The aim of this review is to describe new allergenic findings, of potential relevance for cross-reactivity among peanut and lupin. RECENT FINDINGS: Seventeen allergens of peanut have been included in the official allergen nomenclature database to date. Lupin sensitization has been observed in 15-20% of individuals with known peanut allergy, The majority of lupin seed proteins are comprised of alpha-conglutins (legumin-like) and beta-conglutins (vicilin-like), and to a lesser extent gamma-conglutins (vicilin-like) and delta-conglutins (2S albumins). Several molecules may fuel peanut-lupin cross-reactivity. Awareness among physicians and general public could avoid unexpected allergic reactions. However, these do not appear frequent and no data suggest a precautionary labelling of lupin in foods</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0668-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27873194">PM:27873194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Mennini M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0668-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Casset,A.</style></author><author><style face="normal" font="Arial"> Khayath,N.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Pharmacy, Laboratory of Conception and Application of Bioactive Molecules, CNRS, University of Strasbourg, BP 60024, 67401, Illkirch Cedex, France</style></auth-address><titles><title><style face="normal" font="Arial">How In Vitro Assays Contribute to Allergy Diagnosis</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="82">82-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> indoor pollutants</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Diagnosis of allergic disorders is based upon the clinical history of the disease, the immunoglobulin E (IgE) antibody response, and the allergen exposure. During the last decade, many changes have occurred in the in vitro diagnostic tests used in daily practice. The most important one is the use of allergenic molecules, which helps to define severe profile of allergy and/or to better understand cross-reactivity. The correlation between IgE sensitization and bronchial or nasal response in provocation tests is not so clear, which implies that such tests are still helpful in allergy diagnosis. In order to strengthen the link between a real allergen exposure and allergic symptoms, environmental allergen load assessment can be performed. For clinicians, it appears obvious to know the pollen count to treat their patients; however, they rarely measure the allergen load in the indoor environment, while nowadays home-tests (semi-quantitative or quantitative) make the assessment very easy. In the future, assessment of the environmental exposure (preferably with an indoor technician) of an allergic patient should take into account not only the allergens but also the other indoor pollutants, which could enhance respiratory symptoms in allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0659-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864812">PM:27864812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Casset A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0659-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bardella,M.T.</style></author><author><style face="normal" font="Arial"> Elli,L.</style></author><author><style face="normal" font="Arial"> Ferretti,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for the Prevention and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Non Celiac Gluten Sensitivity</style></title><secondary-title><style face="normal" font="Arial">Curr Gastroenterol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Gastroenterol Rep</style></full-title></periodical><pages end="" start="63">63-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amylase</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free diet</style></keyword><keyword><style face="normal" font="Arial"> Gluten-related disorders</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Monosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Non celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: A new syndrome responding to gluten-free diet and defined non-celiac gluten sensitivity entered the spectrum of gluten-related disorders, together with celiac disease and wheat allergy. However, its definition, prevalence, diagnosis, pathogenesis, treatment, and follow up are still controversial. The purpose of the review is to summarize the evidence and problems emerging from the current literature. RECENT FINDINGS: Direct implication of gluten in the onset of symptoms is often unproved as a low fermentable oligo-, di- and mono-saccharides and polyols diet or other components of cereals as wheat amylase trypsin inhibitor could be similarly involved. To date, no specific biomarkers or histological abnormalities confirm diagnosis, and only the self-reported response to gluten-free diet as well as a positive double blind placebo-gluten challenge characterizes these non-celiac, non-wheat allergic patients. Critical revision of published studies can offer practical indications in approaching this clinical topic and useful suggestions to standardize scientific researches</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1534-312X (Electronic)IS - 1522-8037 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11894-016-0536-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27747460">PM:27747460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Gastroenterol Rep\2016-18-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Gastroenterol Rep\2016-18-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Bardella MT</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11894-016-0536-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McGowan,E.C.</style></author><author><style face="normal" font="Arial"> Platts-Mills,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Allergy and Clinical Immunology, University of Virginia School of Medicine, PO Box 801355, Charlottesville, VA, 22903, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Esophagitis From an Allergy Perspective: How to Optimally Pursue Allergy Testing &amp; Dietary Modification in the Adult Population</style></title><secondary-title><style face="normal" font="Arial">Curr Gastroenterol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Gastroenterol Rep</style></full-title></periodical><pages end="" start="58">58-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary therapy</style></keyword><keyword><style face="normal" font="Arial"> Dilation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elemental diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is a clinicopathologic condition characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. In adults, the three most common treatment options are swallowed steroids, elimination diets, and periodic esophageal dilations. Many different elimination diets have been studied in adults, including elemental diets, allergy testing-directed diets, and empiric elimination diets. This article will review the existing data on these dietary therapies and will propose an approach to dietary management in adult EoE</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1534-312X (Electronic)IS - 1522-8037 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11894-016-0531-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27726042">PM:27726042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Gastroenterol Rep\2016-18-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Gastroenterol Rep\2016-18-58.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, McGowan EC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11894-016-0531-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ovchinnikova,T.V.</style></author><author><style face="normal" font="Arial"> Finkina,E.I.</style></author><author><style face="normal" font="Arial"> Melnikova,D.N.</style></author><author><style face="normal" font="Arial"> Bogdanov,I.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shemyakin and Yu.A.Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya str., 16/10, 117997 Moscow, Russia</style></auth-address><titles><title><style face="normal" font="Arial">Plant pathogenesis-related proteins PR-10 and PR-14 as components of innate immunity system and ubiquitous allergens</style></title><secondary-title><style face="normal" font="Arial">Curr Med Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Chem</style></full-title></periodical><pages end="1787" start="1772">1772-1787</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">17</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial activity</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Binding Properties</style></keyword><keyword><style face="normal" font="Arial"> Biotic stress</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Ligand binding properties</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> multifunctional</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis-related protein</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis-related Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> PR protein</style></keyword><keyword><style face="normal" font="Arial"> PR proteins</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR-proteins</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Pathogenesis-related (PR) proteins are components of innate immunity system in plants. They play an important role in plant defense against pathogens. Lipid transfer proteins (LTPs) and Bet v 1 homologues comprise two separate families of PR-proteins. Both LTPs (PR-14) and Bet v 1 homologues (PR-10) are multifunctional small proteins involving in plant response to abiotic and biotic stress conditions. The representatives of these PR-protein families do not show any sequence similarity but have other common biochemical features such as low molecular masses, the presence of hydrophobic cavities, ligand binding properties, and antimicrobial activities. Besides, many members of PR-10 and PR-14 families are ubiquitous plant panallergens which are able to cause sensitization of human immune system and cross-reactive allergic reactions to plant food and pollen. This review is aimed at comparative analysis of structure-functional and allergenic properties of the PR-10 and PR-14 families, as well as prospects for their medicinal application</style></abstract><notes><style face="normal" font="Arial">DA - 20161027IS - 1875-533X (Electronic)IS - 0929-8673 (Linking)LA - ENGPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27784212">PM:27784212</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Med Chem\2017-24-1772-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Med Chem\2017-24-1772-87.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161027, Ovchinnikova TV</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rachid,R.</style></author><author><style face="normal" font="Arial"> Chatila,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDivision of Immunology, Boston Children's Hospital bDepartment of Pediatrics, Harvard Medical School, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="Arial">The role of the gut microbiota in food allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pediatr</style></full-title></periodical><pages end="753" start="748">748-753</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> cesarean</style></keyword><keyword><style face="normal" font="Arial"> Cesarean Section</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="28" Month="9" Year="2016">2016/9/28</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The rise in the prevalence of food allergy over the past decades has focused attention of factors that may impact disease development, most notably the gut microbiota. The gut microbial communities play a crucial role in promoting oral tolerance. Their alteration by such factors as Cesarean section delivery, diet and antibiotics may influence disease development. This review highlights recent progress in our understanding of the role of the gut microbiota in the development of food allergy. RECENT FINDINGS: Food allergy is associated with alterations in the gut microbiota or dysbiosis early in life that may be predictive of disease persistence versus tolerance acquisition. Evidence for the benefits of adjunct therapy with probiotics for the prevention of food allergies and for potentiating oral immunotherapy remains circumstantial, with further studies needed to validate its use. Studies in murine models of food allergy suggest that microbial therapy with protolerogenic bacteria such as certain Clostridial species holds promise in future applications for prevention or therapy of food allergy. SUMMARY: Progress in understanding the role of dysbiosis in food allergy and the factors that promote its development, such as antibiotic therapy, diet, modes of infant delivery, and environmental exposures, offer windows of opportunity for both preventive and therapeutic interventions to stem the rising tide of the food allergy epidemic</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1531-698X (Electronic)IS - 1040-8703 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOP.0000000000000427</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27749359">PM:27749359</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pediatr\2016-28-748-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pediatr\2016-28-748-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Rachid R</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOP.0000000000000427</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sattler,C.</style></author><author><style face="normal" font="Arial"> Garcia,G.</style></author><author><style face="normal" font="Arial"> Humbert,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aUniv Paris-Sud, Faculte de Medecine, Universite Paris-Saclay bAP-HP, Service de Pneumologie, Hopital Bicetre cAPHP, Service de Physiologie, Explorations Fonctionnelles Respiratoires, Hopital Bicetre, Le Kremlin-Bicetre dInserm UMR_S 999, Hopital Marie Lannelongue, Le Plessis-Robinson, France</style></auth-address><titles><title><style face="normal" font="Arial">Novel targets of omalizumab in asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></full-title></periodical><pages end="61" start="56">56-61</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">agonists</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> teenagers</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Omalizumab is a recombinant humanized anti-IgE monoclonal antibody approved in the US for moderate to severe persistent allergic asthma (severe persistent asthma in the European Union), uncontrolled despite treatment with inhaled corticosteroids and long-acting beta2 agonists. It reduces asthma exacerbations, symptoms, oral corticosteroid doses, and improves quality of life. RECENT FINDINGS: Omalizumab may have an antiviral effect when used as a preventive therapy for fall exacerbations in children and teenagers. Two proof-of-concept studies have evaluated omalizumab in nonatopic asthma and showed that it is safe and possibly efficacious in some patients. Omalizumab has been successfully studied as add-on to specific immunotherapy in moderate allergic asthma. Its safety in pregnancy has been assessed in the EXPECT registry. Case series also report positive effects in cases of allergic bronchopulmonary aspergillosis, and in nasal disorders frequently associated with asthma. Last, omalizumab may have corticosteroid-sparing effect in a subset of patients with eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome). SUMMARY: Recent studies argue in favor of positive effects of omalizumab beyond its current indications in asthma. Well-designed studies are needed in order to demonstrate the safety and efficacy of omalizumab in these possible novel indications</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - ENGPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1097/MCP.0000000000000340</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27798419">PM:27798419</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pulm Med\20161031-SattlerC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pulm Med\20161031-SattlerC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Sattler C</style></custom2><misc3><style face="normal" font="Arial">10.1097/MCP.0000000000000340</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Samitas,K.</style></author><author><style face="normal" font="Arial"> Zervas,E.</style></author><author><style face="normal" font="Arial"> Gaga,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">7th Respiratory Medicine Department and Asthma Center, Athens Chest Hospital 'Sotiria', Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">T2-low asthma: current approach to diagnosis and therapy</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></full-title></periodical><pages end="55" start="48">48-55</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune response modifiers</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Asthma is a heterogeneous disease not only on a clinical but also on a mechanistic level. For a long time, the molecular mechanisms of asthma were considered to be driven by type 2 helper T cells (Th2) and eosinophilic airway inflammation; however, extensive research has revealed that T2-low subtypes that differ from the dominant T2 paradigm are also common. RECENT FINDINGS: Research into asthma pathways has led to the recognition that some asthma phenotypes show absence of T2 inflammation or alternate between T2 and non-T2 responses. Moreover, numerous immune response modifiers that block key-molecules such as interleukin (IL)-5, IL-13, and immunoglobulin E (IgE) have been identified. Along the way, these studies pointed that T2-low inflammation may also be responsible for lack of responsiveness to current treatment regimes. SUMMARY: Asthma pathogenesis is characterized by two major endotypes, a T2-high featuring increased eosinophilic airway inflammation, and a T2-low endotype presenting with either neutrophilic or paucigranulocytic airway inflammation and showing greater resistance to steroids. This clearly presents an unmet therapeutic challenge. A precise definition and characterization of the mechanisms that drive this T2-low inflammatory response in each patient phenotype is necessary to help identify novel drug targets and design more effective and targeted treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - ENGPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1097/MCP.0000000000000342</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27798418">PM:27798418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pulm Med\20161031-SamitasK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pulm Med\20161031-SamitasK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Samitas K</style></custom2><misc3><style face="normal" font="Arial">10.1097/MCP.0000000000000342</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonamichi-Santos,R.</style></author><author><style face="normal" font="Arial"> Castells,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Immunology and Allergy; Department of Medicine, Brigham and Women`s Hospital, Harvard Medical School, Boston, MA, USA. mcastells@partners.org</style></auth-address><titles><title><style face="normal" font="Arial">Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies</style></title><secondary-title><style face="normal" font="Arial">Curr Pharm Des</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pharm Des</style></full-title></periodical><pages end="6880" start="6870">6870-6880</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">45</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="25" Month="10" Year="2016">2016/10/25</year></dates><abstract><style face="normal" font="Arial">Chemotherapies drugs and monoclonal antibodies are key components of the treatment of cancer patients and patients with chronic inflammatory conditions to provide increase in life expectancy and quality of life. Their increased use has lead to an increase in drugs hypersensitivity reactions (DHR) worldwide. DHR to those agents prevented their use and promoted the use of second line therapies to protect patients' hypersensitive reactions and anaphylaxis. Second line medications may not fully address the patients' medical condition and it is desirable to keep patients on first line therapy. Drug hypersensitivity symptoms can range from mild cutaneous reactions to life-threatening anaphylaxis. Rapid drug desensitization (RDD) is a novel approach to the management of drug hypersensitivity reactions which are IgE and non-IgE mediated. Through the diferent desensitization protocols patients can receive the full dose of the medications that they have presented a hypersensitive reaction and been protected against anaphylaxis. This review looks at the current literature on hypersensitivity reactions (HSR) to chemotherapy drugs and monoclonal antibodies and the potential use of RDD for their management</style></abstract><notes><style face="normal" font="Arial">DA - 20161027IS - 1873-4286 (Electronic)IS - 1381-6128 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27784245">PM:27784245</url></web-urls><pdf-urls><url ppv-ref="no">mcastells@partners.org</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161027, Bonamichi-Santos R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tuttolomondo,A.</style></author><author><style face="normal" font="Arial"> Simonetta,I.</style></author><author><style face="normal" font="Arial"> Di Raimondo,D.</style></author><author><style face="normal" font="Arial"> Di Chiara,T.</style></author><author><style face="normal" font="Arial"> Conigliaro,R.</style></author><author><style face="normal" font="Arial"> Corpora,F.</style></author><author><style face="normal" font="Arial"> Vassallo,V.</style></author><author><style face="normal" font="Arial"> Pinto,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento Biomedico di Medicina Interna e Specialistica  Facolta di Medicina e Chirurgia, Universita degli Studi di Palermo, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine</style></title><secondary-title><style face="normal" font="Arial">Curr Pharm Des</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pharm Des</style></full-title></periodical><pages end="4685" start="4669">4669-4685</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">30</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Azathioprine</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Hematologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypergammaglobulinemia</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methotrexate</style></keyword><keyword><style face="normal" font="Arial"> Mycophenolate</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pericarditis</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prostatitis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary fibrosis</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Retroperitoneal Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rheumatic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Salivary Glands</style></keyword><keyword><style face="normal" font="Arial"> Sarcoidosis</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> systemic disease</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IgG4-related disease is a rare, clinical and pathologic disease entity of unknown etiology. Its main features are increased serum concentrations of IgG4 > 1,35 g/l, lymphocyte and IgG4+plasma-cell infiltration within tissues, fibrosis or sclerosis. The classical presentation of IgG4-RSD is pancreatitis which is combined with the involvement of biliary ducts in 74 percent of patients. Extrapancreatic manifestations include: abdominal or mediastinal lymphadenopathy; the involvement of salivary glands and lacrimal glands, kidneys, lung, retroperitoneum. Since IgG4-related disease is a multiorgan lymphoproliferative syndrome, it requires a careful differential diagnosis from other distinct disorders (sarcoidosis, immune rheumatic diseases, hematologic diseases, malignancies). Another distinctive feature is a fairly fast response to steroids, that represents the first-choice therapy. Immunosuppressant drugs (azathioprine, mycophenolate mofetil, methotrexate) might be chosen as glucocorticoid-sparing medications or to maintain steroid-induced remission (Fig. 1). METHODS: We report the case of a 70-year-old man and we performed a brief review of loiterature. RESULTS: Our patient has a clinical history including bronchial asthma, aortic aneurysm, histologically confirmed retroperitoneal fibrosis causing hydroureteronephrosis, prostatitis, interstitial pulmonary fibrosis, sclerosing chronic pancreatitis (histologically documented), previous chronic cholecystitis (histologically confirmed), previous pericarditis, xeroftalmia, polyclonal hypergammaglobulinemia, eosinophilia. His serum IgG4 levels were significantly increased (5560 mg/dl). In regard to the above mentioned elements a systemic disease characterized by elevated serum levels of IgG4 and IgG4-positive lymphoplasmacytic infiltrative lesions in several tissues, was suspected. Immune-rheumatic diseases and infectious diseases were excluded. Steroid treatment was started achieving a significant swift response. CONCLUSION: Until now IgG4 related disease has been considered rare in the West and exclusive of Japanese and Korean countries, our case report leads us to reflect on the necessity to take into account this disease in patients with multisystemic involvement</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1873-4286 (Electronic)IS - 1381-6128 (Linking)LA - ENGPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27790959">PM:27790959</url></web-urls><pdf-urls><url ppv-ref="no">bruno.tuttolomondo@unipa.it</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161028, Tuttolomondo A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garvey,L.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Danish Anaesthesia Allergy Centre, Allergy Clinic, Department of Dermatology and Allergy, Gentofte Hospital, University of Copenhagen, Denmark. lene.heise.garvey@regionh.dk</style></auth-address><titles><title><style face="normal" font="Arial">Old, New and Hidden Causes of Perioperative Hypersensitivity</style></title><secondary-title><style face="normal" font="Arial">Curr Pharm Des</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pharm Des</style></full-title></periodical><pages end="6824" start="6814">6814-6824</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">45</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaesthesia</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chlorhexidine</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> Dyes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Excipients</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hidden allergens</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Neuromuscular blocking agents</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pholcodine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="4" Month="10" Year="2016">2016/10/4</year></dates><abstract><style face="normal" font="Arial">Perioperative hypersensitivity reactions are rare, often life-threatening events, and subsequent investigations to identify the culprit are important to avoid re-exposure. All exposures in the perioperative setting may potentially be the cause of a hypersensitivity reaction, but drugs administered intravenously such as neuromuscular blocking agents (NMBA), induction agents and antibiotics have traditionally been reported to be implicated most commonly. It has recently become apparent that there are geographical differences in sensitization patterns related to variation in exposures, referral patterns and performance and interpretation of investigations. Differences in sensitization to NMBAs are partly explained by cross sensitization to pholcodine, an ingredient in cough-medicines available in some countries. While NMBAs are the most common causes of perioperative hypersensitivity in some countries, this may not necessarily be the case in all countries. New and hidden allergens have emerged as causes of perioperative hypersensitivity such as blue dyes, chlorhexidine and excipients. Detailed knowledge of the events at the time of reaction is necessary to identify potential culprits including rare and hidden allergens. Cooperation between allergists and anaesthetists, or other staff present perioperatively, is often needed to identify hidden or even undocumented exposures. The objectives of this review are to provide an overview of the history of investigation of perioperative hypersensitivity, to describe the differences in causes of perioperative hypersensitivity emerging over time and to increase awareness about the "hidden allergens" in the perioperative setting. Some practical advice on how to approach the patient testing negative on all initial investigations is also included</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 1873-4286 (Electronic)IS - 1381-6128 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27712572">PM:27712572</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Pharm Des\20161007-GarveyLH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Pharm Des\20161007-GarveyLH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Garvey LH</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moriyama,M.</style></author><author><style face="normal" font="Arial"> Nakamura,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">OCT Research Center, Faculty of Dental Science, Kyushu University, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Th1/Th2 Immune Balance and Other T Helper Subsets in IgG4-Related Disease</style></title><secondary-title><style face="normal" font="Arial">Curr Top Microbiol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Top Microbiol Immunol</style></full-title></periodical><pages end="83" start="75">75-83</pages><volume><style face="normal" font="Arial">401</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> systemic disease</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">IgG4-related disease (IgG4-RD) is a systemic disease characterized by elevated serum IgG4 levels and a strong infiltration of IgG4-positive plasma cells in various organs. IgG4-RD patients also frequently suffer from allergic diseases, including asthma and atopic dermatitis. It is well known that T helper type 2 (Th2) cells have an important role in the initiation of allergic diseases, and Th2 cytokines such as interleukin (IL)-4 and IL-13 promote class switching to IgG4. Therefore, IgG4-RD is considered to be a Th2-predominant disease. However, other Th subsets, including regulatory T cells and T follicular helper cells, have recently received increasing attention with regard to the pathogenesis of IgG4-RD. Exploring the interconnected network of Th subsets in IgG4-RD is a highly promising field of investigation. In this review, we focus on the localization and functions of individual Th subsets to clarify the involvement of these cells in the pathogenesis of IgG4-RD</style></abstract><notes><style face="normal" font="Arial">DA - 20161016IS - 0070-217X (Print)IS - 0070-217X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/82_2016_40</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27744510">PM:27744510</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Top Microbiol Immunol\20161016-MoriyamaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Top Microbiol Immunol\20161016-MoriyamaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161016, MoriyamaM</style></custom2><misc3><style face="normal" font="Arial">10.1007/82_2016_40</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Demirel,F.</style></author><author><style face="normal" font="Arial"> Kartal,O.</style></author><author><style face="normal" font="Arial"> Gulec,M.</style></author><author><style face="normal" font="Arial"> Yesillik,S.</style></author><author><style face="normal" font="Arial"> Baysan,A.</style></author><author><style face="normal" font="Arial"> Tezel,K.</style></author><author><style face="normal" font="Arial"> Musabak,U.</style></author><author><style face="normal" font="Arial"> Sener,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Gulhane Military Medical Academy and Medical School, Etlik, 06018, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Desensitization to Adalimumab: An Example of Repeated Desensitization to a Biological Agent</style></title><secondary-title><style face="normal" font="Arial">Drug Saf Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Drug Saf Case Rep</style></abbr-1></periodical><pages end="" start="7">7-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spondylitis</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2015">2015/12</year></dates><abstract><style face="normal" font="Arial">Biological agents seem to have been more effective than classic immunosuppressive drugs; however, the adverse events including the hypersensitivity reactions are the main drawbacks of these drugs. We report a 35-year-old man who was treated with adalimumab for ankylosing spondylitis, had a local reaction on the injection site, and generalized itching with rash at the 62nd dose and repeated desensitizations to him with adalimumab. One month after the reaction, skin prick test was performed with a commercial preparation of adalimumab. The skin prick test result was determined positive comparing to positive and negative controls. Because of insufficient responses to other drugs, adalimumab desensitization was performed and the whole process was completed without any reaction. Six months later the patient gave up therapy because of a new reaction which was caused by a possible viral infection. Desensitization was repeated successfully 3 months later. Because there are few cases in the literature about adalimumab desensitization process, there is no standard desensitization protocol for the adalimumab allergy yet. Therefore, we suggest that our case report may contribute to the formation of a standardized desensitization protocol in adalimumab hypersensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 2199-1162 (Print)IS - 2199-1162 (Linking)LA - ENGPT - LETTERCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40800-015-0008-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27747718">PM:27747718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drug Saf Case Rep\2015-2-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drug Saf Case Rep\2015-2-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Demirel F</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40800-015-0008-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elbarbary,N.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Type 1 diabetes mellitus and atopic diseases in children</style></title><secondary-title><style face="normal" font="Arial">Egypt J Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Egypt J Pediatr Allergy Immunol</style></full-title></periodical><pages end="46" start="37">37-46</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> type 1 diabetes</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Egypt -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.jespai.org/ulogs/paperindex.php?paperID=241&amp;topicid=1&amp;issueid=28</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Egypt J Pediatr Allergy Immunol\2016-14-37-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Egypt J Pediatr Allergy Immunol\2016-14-37-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Elbarbary NS</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Devi,S.</style></author><author><style face="normal" font="Arial"> Wu,P.H.</style></author><author><style face="normal" font="Arial"> Chu,P.Y.</style></author><author><style face="normal" font="Arial"> Liu,Y.P.</style></author><author><style face="normal" font="Arial"> Wu,H.L.</style></author><author><style face="normal" font="Arial"> Ho,Y.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemistry, National Dong Hwa University, Hualien, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Studying the effect of microwave heating on the digestion process and identification of proteins</style></title><secondary-title><style face="normal" font="Arial">Electrophoresis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Electrophoresis</style></full-title></periodical><pages end="440" start="429">429-440</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chemistry</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> irradiation</style></keyword><keyword><style face="normal" font="Arial"> LC-MS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Microwave</style></keyword><keyword><style face="normal" font="Arial"> microwave heating</style></keyword><keyword><style face="normal" font="Arial"> Microwave irradiation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The impact of microwave irradiation on the in-solution digestion processes and the detection limit of proteins are systematically studied. Kinetic processes of many peptides produced through the trypsin digestion of various proteins under microwave heating at 50 degrees C were investigated with MALDI-MS. This study also examines the detection limits and digestion completeness of individual proteins under microwave heating at 50 degrees C and at different time intervals (1, 5 and 30 min) using LC-MS. We conclude that, if the peptides without missed cleavage dictate the detection limit, conventional digestion will lead to a better detection limit. The detection limit may not differ between microwave and conventional heating if the peptides with missed cleavage sites and strong intensity are formed at the very early stage (i.e., less than 1 min) and are not further digested throughout the entire digestion process. The digestion of E. coli lysate was compared under conventional and short time (microwave) conditions. The number of proteins identified under conventional heating exceeded that obtained from microwave heating over heating periods less than 5 min. The overall results show that the microwave-assisted digestion is not complete. Although the sequence coverage might be better, the detection limit might be worse than that under conventional heating. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161022IS - 1522-2683 (Electronic)IS - 0173-0835 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1002/elps.201600392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27770443">PM:27770443</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Electrophoresis\20161022-DeviS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Electrophoresis\20161022-DeviS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161022, Devi S</style></custom2><misc3><style face="normal" font="Arial">10.1002/elps.201600392</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shang,S.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author><author><style face="normal" font="Arial"> Xi,Z.</style></author><author><style face="normal" font="Arial"> Lu,Z.</style></author><author><style face="normal" font="Arial"> Li,B.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Li,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Environmental Biomedicine, Hubei Key Laboratory of Genetic Regulation and Integrative Biology, College of Life Science, Central China Normal University, Wuhan, Hubei Province, 430079, Chinaruili@mail.ccnu.edu.cn</style></auth-address><titles><title><style face="normal" font="Arial">Oxidized graphene-aggravated allergic asthma is antagonized by antioxidant vitamin E in Balb/c mice</style></title><secondary-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></full-title></periodical><pages end="1793" start="1784">1784-1793</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin E</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Nanomaterials have been widely used in a number of applications; however, these nanomaterials may potentially be risky for human health, particularly for the respiratory system. In this study, we used a mouse asthma model to study whether graphene oxide (GO), a promising carbonaceous nanomaterial with unique physicochemical properties, aggravates allergic asthma via the oxidative stress pathway. Mice were sensitized with ovalbumin (OVA) to trigger immune reactions, while vitamin E (Ve) was administered as an antioxidant. Our results showed that GO aggravated OVA-induced allergic asthma in mice, as suggested by increased reactive oxygen species (ROS), elevated total immunoglobulin E (IgE), upregulated Th2 response, and the aggravation of allergic asthma symptoms, such as airway remolding, collagen deposition with mucus hypersecretion, and airway hyperresponsiveness (AHR). The administration of Ve dramatically attenuated all of the above effects. In conclusion, Ve showed anti-allergic properties in antagonizing the exacerbation of allergic asthma induced by GO, providing a new possibility for the treatment of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1614-7499 (Electronic)IS - 0944-1344 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11356-016-7903-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27796986">PM:27796986</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20161031-ShangS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20161031-ShangS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Shang S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11356-016-7903-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cordeiro Moreira,A.S.</style></author><author><style face="normal" font="Arial"> Rosmaninho Lopes de Soares E Silva,M.I.</style></author><author><style face="normal" font="Arial"> Pereira Guilherme,M.A.</style></author><author><style face="normal" font="Arial"> da Silva Ferreira,J.A.</style></author><author><style face="normal" font="Arial"> Fonseca Moreira da Silva,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunoallergy Department, Centro Hospitalar Vila Nova Gaia e Espinho, EPE, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">Use of omalizumab in the treatment of chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="246" start="242">242-246</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Omalizumab is indicated to treat chronic spontaneous urticaria (CSU) refractory to antihistamines. We aim to describe the experience of our department in the treatment of CSU with omalizumab. MATERIALS AND METHODS: Retrospective review of the clinical records of patients. RESULTS: Six patients (5 females, median age 33 years) treated with omalizumab for a median of 17.5 months were evaluated. All patients had improvement of symptoms after the first dose. In one case, the treatment was suspended after 7 months, but in 9 weeks there was recurrence of symptoms. The main side effect was headache in the drug administration's day. Currently, all patients maintain therapy with omalizumab and are clinically stable. CONCLUSION: Omalizumab proved to be an effective and safe drug for the treatment of patients with refractory CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27852430">PM:27852430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-242-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-242-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Cordeiro Moreira AS</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yousef,E.</style></author><author><style face="normal" font="Arial"> Haque,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nemours, Children's Specialty Care, Jacksonville, Florida, USA.</style></auth-address><titles><title><style face="normal" font="Arial">A pilot study to assess relationship between total IgE and 95% predictive decision points of food specific IgE concentration</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="236" start="233">233-236</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: False positive test results in children who are tested for food allergies may lead to inappropriate dietary restrictions. OBJECTIVE: The aim of this study was to report our experience with a 3 year-old boy, who presented with "multiple food allergies" and, however, passed the food challenges, and to review our experience regarding management of children with high specific food IgEs with high total IgE. METHODS: Medical records of 16 children with food challenges were reviewed. Median age of subjects was 39 months, with a history of adverse clinical reaction to a food, a specific IgE greater than the decision point, and an elevated total serum IgE level of 500 IU, underwent challenges to the offending food. RESULTS: 13 out of 16 subjects were successfully re-exposed to the suspected foods and continued to tolerate these foods well. CONCLUSION: Our finding suggests a much lower clinical risk with previously defined specific IgE decision points in children with very high levels of total IgE (> 6000 IU/ml)</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27852428">PM:27852428</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-233-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-233-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Yousef E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Manzotti,G.</style></author><author><style face="normal" font="Arial"> Riario-Sforza,G.G.</style></author><author><style face="normal" font="Arial"> Dimatteo,M.</style></author><author><style face="normal" font="Arial"> Scolari,C.</style></author><author><style face="normal" font="Arial"> Makri,E.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Outpatients Service, Treviglio-Caravaggio General Hospital, Treviglio, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="227" start="224">224-227</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy (AIT) in its two forms of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) is an effective treatment of respiratory allergy, but is particularly concerned by the issue of compliance. OBJECTIVE: We aimed a real-life study at evaluating the compliance to SLIT and to SCIT administered by a short-course of four injections during a 3-year period of observation. METHODS: A group of 145 patients (79 males, 66 females, age ranging from 14 to 69 years), suffering from pollen-induced rhino-conjunctivitis with or without asthma, were included in the study. Following adequate education on AIT and according to patient's preference, 72 patients chose to be treated with short-course SCIT and 73 chose to be treated with SLIT. The latter was performed by allergen extracts from different manufacturers according to the suggested schedules. RESULTS: The rate of withdrawal was as follows: after one year, 15.6% for SCIT and 33.4 for SLIT; after two years, 25.6% for SCIT and 44.8% for SLIT; after three years, 26.7 for SCIT and 46% for SLIT. There was no significant difference in the rate of withdrawal between males and females. Regarding the safety, no systemic reaction requiring medical treatment was observed either in SCIT or SLIT group. CONCLUSION: The findings of this study confirm that involving the patient in the choice of the route of administration is associated to a satisfactory compliance to AIT. In particular, more than 70% of patients treated with a short schedule of SCIT completed the three-years course of treatment that is recommended for AIT, while this goal was reached by 54% of SLIT treated patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27852426">PM:27852426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-224-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2016-48-224-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Manzotti G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Papathanassiou,E.</style></author><author><style face="normal" font="Arial"> Loukides,S.</style></author><author><style face="normal" font="Arial"> Bakakos,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">2nd Department of Respiratory Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Severe asthma: anti-IgE or anti-IL-5?</style></title><secondary-title><style face="normal" font="Arial">Eur Clin Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Clin Respir J</style></full-title></periodical><pages end="" start="31813">31813-</pages><volume><style face="normal" font="Arial">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> SEC</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Severe asthma is a discrete clinical entity characterised by recurrent exacerbations, reduced quality of life and poor asthma control as ordinary treatment regimens remain inadequate. Difficulty in managing severe asthma derives partly from the multiple existing phenotypes and our inability to recognise them. Though the exact pathogenetic pathway of severe allergic asthma remains unclear, it is known that numerous inflammatory cells and cytokines are involved, and eosinophils represent a key inflammatory cell mediator. Anti-IgE (omalizumab) and anti-IL-5 (mepolizumab) antibodies are biological agents that interfere in different steps of the Th2 inflammatory cascade and are licensed in severe asthma. Both exhibit a favourable clinical outcome as they reduce exacerbation rate and improve asthma control and quality of life, while mepolizumab also induces an oral steroid sparing effect. Nevertheless, it is still questionable which agent is more suitable in the management of severe allergic asthma since no comparable studies have been conducted. Omalizumab's established effectiveness in clinical practice over a long period is complemented by a beneficial effect on airway remodelling process mediated mainly through its impact on eosinophils and other parameters strongly related to eosinophilic inflammation. However, it is possible that mepolizumab through nearly depleting eosinophils could have a similar effect on airway remodelling. Moreover, to date, markers indicative of the patient population responding to each treatment are unavailable although baseline eosinophils and exacerbation rate in the previous year demonstrate a predictive value regarding anti-IL-5 therapy effectiveness. On the other hand, a better therapeutic response for omalizumab has been observed when low forced expiratory volume in 1 sec, high-dose inhaled corticosteroids and increased IgE concentrations are present. Consequently, conclusions are not yet safe to be drawn based on existing knowledge, and additional research is necessary to unravel the remaining issues for the severe asthmatic population</style></abstract><notes><style face="normal" font="Arial">DA - 20161111IS - 2001-8525 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.3402/ecrj.v3.31813</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27834175">PM:27834175</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Clin Respir J\2016-3-31813.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Clin Respir J\2016-3-31813.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161111, Papathanassiou E</style></custom2><misc3><style face="normal" font="Arial">10.3402/ecrj.v3.31813</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hansen,S.</style></author><author><style face="normal" font="Arial"> Hoffmann-Petersen,B.</style></author><author><style face="normal" font="Arial"> Sverrild,A.</style></author><author><style face="normal" font="Arial"> Brauner,E.V.</style></author><author><style face="normal" font="Arial"> Lykkegaard,J.</style></author><author><style face="normal" font="Arial"> Bodtger,U.</style></author><author><style face="normal" font="Arial"> Agertoft,L.</style></author><author><style face="normal" font="Arial"> Korshoj,L.</style></author><author><style face="normal" font="Arial"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Centre for Prevention and Health, Rigshospitalet Glostrup Hospital, Glostrup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">The Danish National Database for Asthma: establishing clinical quality indicators</style></title><secondary-title><style face="normal" font="Arial">Eur Clin Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Clin Respir J</style></full-title></periodical><pages end="" start="33903">33903-</pages><volume><style face="normal" font="Arial">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absenteeism</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge testing</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Asthma is one of the most common chronic diseases worldwide affecting more than 300 million people. Symptoms are often non-specific and include coughing, wheezing, chest tightness, and shortness of breath. Asthma may be highly variable within the same individual over time. Although asthma results in death only in extreme cases, the disease is associated with significant morbidity, reduced quality of life, increased absenteeism, and large costs for society. Asthma can be diagnosed based on report of characteristic symptoms and/or the use of several different diagnostic tests. However, there is currently no gold standard for making a diagnosis, and some degree of misclassification and inter-observer variation can be expected. This may lead to local and regional differences in the treatment, monitoring, and follow-up of the patients. The Danish National Database for Asthma (DNDA) is slated to be established with the overall aim of collecting data on all patients treated for asthma in Denmark and systematically monitoring the treatment quality and disease management in both primary and secondary care facilities across the country. The DNDA links information from population-based disease registers in Denmark, including the National Patient Register, the National Prescription Registry, and the National Health Insurance Services register, and potentially includes all asthma patients in Denmark. The following quality indicators have been selected to monitor trends: first, conduction of annual asthma control visits, appropriate pharmacological treatment, measurement of lung function, and asthma challenge testing; second, tools used for diagnosis in new cases; and third, annual assessment of smoking status, height, and weight measurements, and the proportion of patients with acute hospital treatment. The DNDA will be launched in 2016 and will initially include patients treated in secondary care facilities in Denmark. In the nearby future, the database aims to include asthma diagnosis codes and clinical data registered by general practitioners and specialised practitioners as well</style></abstract><notes><style face="normal" font="Arial">DA - 20161111IS - 2001-8525 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.3402/ecrj.v3.33903</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27834178">PM:27834178</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Clin Respir J\2016-3-33903.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Clin Respir J\2016-3-33903.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161111, Hansen S</style></custom2><misc3><style face="normal" font="Arial">10.3402/ecrj.v3.33903</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Athari,S.S.</style></author><author><style face="normal" font="Arial"> Pourpak,Z.</style></author><author><style face="normal" font="Arial"> Folkerts,G.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Moin,M.</style></author><author><style face="normal" font="Arial"> Adcock,I.M.</style></author><author><style face="normal" font="Arial"> Movassaghi,M.</style></author><author><style face="normal" font="Arial"> Ardestani,M.S.</style></author><author><style face="normal" font="Arial"> Moazzeni,S.M.</style></author><author><style face="normal" font="Arial"> Mortaz,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IranImmunology, Asthma and Allergy Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="820" start="811">811-820</pages><volume><style face="normal" font="Arial">791</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Beclomethasone</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic degradation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Relaxation</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Relaxation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vasoactive Intestinal Peptide</style></keyword><keyword><style face="normal" font="Arial"> Vasodilation</style></keyword><keyword><style face="normal" font="Arial"> VIP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="10" Year="2016">2016/10/19</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic respiratory disease characterized by airway inflammation, bronchoconstriction, airway hyperresponsiveness and recurring attacks of impaired breathing. Vasoactive intestinal peptide (VIP) has been proposed as a novel anti-asthma drug due to its effects on airway smooth muscle relaxation, bronchodilation and vasodilation along with its immunomodulatory and anti-inflammatory properties. In the current study, we investigated the therapeutic effects of VIP when conjugated with alpha-alumina nanoparticle (alpha-AN) to prevent enzymatic degradation of VIP in the respiratory tract. VIP was conjugated with alpha-AN. Balb/c mice were sensitized and challenges with ovalbumin (OVA) or PBS and were divided in four groups; VIP-treated, alpha-AN-treated, alpha-AN-VIP-treated and beclomethasone-treated as a positive control group. Specific and total IgE level, airway hyperresponsiveness (AHR), bronchial cytokine expression and lung histology were measured. alpha-AN-VIP significantly reduced the number of eosinophils (Eos), serum IgE level, Th2 cytokines and AHR. These effects of alpha-AN-VIP were more pronounced than that seen with beclomethasone or VIP alone (P&lt;0.05). The current data indicate that alpha-AN-VIP can be considered as an effective nano-drug for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Iran -CO - United Kingdom -CO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2016.10.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27771365">PM:27771365</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20161023-AthariSS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20161023-AthariSS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Athari SS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2016.10.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Denning,D.W.</style></author><author><style face="normal" font="Arial"> Cadranel,J.</style></author><author><style face="normal" font="Arial"> Beigelman-Aubry,C.</style></author><author><style face="normal" font="Arial"> Ader,F.</style></author><author><style face="normal" font="Arial"> Chakrabarti,A.</style></author><author><style face="normal" font="Arial"> Blot,S.</style></author><author><style face="normal" font="Arial"> Ullmann,A.J.</style></author><author><style face="normal" font="Arial"> Dimopoulos,G.</style></author><author><style face="normal" font="Arial"> Lange,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The National Aspergillosis Centre, University Hospital of South Manchester, The University of Manchester and the Manchester Academic Health Science Centre, Manchester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management</style></title><secondary-title><style face="normal" font="Arial">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Respir J</style></full-title></periodical><pages end="68" start="45">45-68</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antifibrinolytic Agents</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal Agents</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Antifungal treatment</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis,Allergic Bronchopulmonary</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus infection</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Arteries</style></keyword><keyword><style face="normal" font="Arial"> Bronchoscopy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug interaction</style></keyword><keyword><style face="normal" font="Arial"> Drug Interactions</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Embolization,Therapeutic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> Hemoptysis</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immunocompetence</style></keyword><keyword><style face="normal" font="Arial"> Immunocompromised Host</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Mycetoma</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Precipitins</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> radiography</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Thoracic Surgery,Video-Assisted</style></keyword><keyword><style face="normal" font="Arial"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Tranexamic Acid</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2016">2016/1</year></dates><abstract><style face="normal" font="Arial">Chronic pulmonary aspergillosis (CPA) is an uncommon and problematic pulmonary disease, complicating many other respiratory disorders, thought to affect ~240 000 people in Europe. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA), which untreated may progress to chronic fibrosing pulmonary aspergillosis. Less common manifestations include: Aspergillus nodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (&lt;3 months) usually found in moderately immunocompromised patients, which should be managed as invasive aspergillosis. Few clinical guidelines have been previously proposed for either diagnosis or management of CPA. A group of experts convened to develop clinical, radiological and microbiological guidelines. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp. and exclusion of alternative diagnoses, all present for at least 3 months. Aspergillus antibody (precipitins) is elevated in over 90% of patients. Surgical excision of simple aspergilloma is recommended, if technically possible, and preferably via video-assisted thoracic surgery technique. Long-term oral antifungal therapy is recommended for CCPA to improve overall health status and respiratory symptoms, arrest haemoptysis and prevent progression. Careful monitoring of azole serum concentrations, drug interactions and possible toxicities is recommended. Haemoptysis may be controlled with tranexamic acid and bronchial artery embolisation, rarely surgical resection, and may be a sign of therapeutic failure and/or antifungal resistance. Patients with single Aspergillus nodules only need antifungal therapy if not fully resected, but if multiple they may benefit from antifungal treatment, and require careful follow-up</style></abstract><notes><style face="normal" font="Arial">DA - 20160101IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - ENGPT - Journal ArticlePT - Practice GuidelineRN - 0 (Antifibrinolytic Agents)RN - 0 (Antifungal Agents)RN - 6T84R30KC1 (Tranexamic Acid)SB - IMCO - United Kingdom -CO - France -CO - Switzerland -CO - India -CO - Australia -CO - Germany -CO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1183/13993003.00583-2015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26699723">PM:26699723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Respir J\2016-47-45-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Respir J\2016-47-45-68.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160101, Denning DW</style></custom2><misc3><style face="normal" font="Arial">10.1183/13993003.00583-2015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yin,G.Q.</style></author><author><style face="normal" font="Arial"> Jiang,W.H.</style></author><author><style face="normal" font="Arial"> Wu,P.Q.</style></author><author><style face="normal" font="Arial"> He,C.H.</style></author><author><style face="normal" font="Arial"> Chen,R.S.</style></author><author><style face="normal" font="Arial"> Deng,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong Province, China.</style></auth-address><titles><title><style face="normal" font="Arial">Clinical evaluation of sublingual administration of dust mite drops in the treatment of allergic asthma and allergic rhinitis of children</style></title><secondary-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></full-title></periodical><pages end="4353" start="4348">4348-4353</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual administration</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: This study focuses on evaluating the clinical effects of sublingual dust mite drops for the treatment of allergic asthma in children. PATIENTS AND METHODS: 156 pediatric patients with allergic rhinitis and asthma were randomly divided into control and observation groups (78 cases each). For the control group the standard global initiative for asthma (GINA) asthma control scheme was adopted; meanwhile, the observation group patients received the standard GINA combined with sublingual administration of dust mite drops, once per day, gradually increasing the dose to reach a high maintenance level. After six months the sublingual drops were stopped and then the effects of the treatments on both groups of patients were compared. RESULTS: The symptoms of asthma and rhinitis in the daytime and nighttime for both groups decreased gradually with time. However, the observation group's outcome at the 6th, 12th and 24th month were significantly better than those of the control group (p &lt; 0.05). Moreover, the FVC, FEV1 and PEF values of the two groups increased gradually, but those of the observation group improved more obviously (p &lt; 0.05). The total effective rate of the observation group at the 6th and 24th months was significantly higher than that of the control group (p &lt; 0.05). The contrast of complete and good control at 6 months had no statistical significance (p > 0.05). But at the 24th month, the observation group had significantly higher rates of complete and good control (p &lt; 0.05). During the median time of sublingual administration of 20.3 months (ranging from 6 to 36 months), there were no evident adverse reactions. Finally, after the intervention, there were no significant differences between the IgE levels of the two groups (p > 0.05); however, the levels of IL-2 increased gradually and improved more in the observation group (p &lt; 0.05). CONCLUSIONS: The results of our study support the notion that sublingual administration of dust mite drops to treat allergic rhinitis and asthma can improve clinical symptoms, increase the efficiency rate and increase the serum IL-2 level, and does not cause an increase in adverse reactions or IgE levels in treated children</style></abstract><notes><style face="normal" font="Arial">DA - 20161110IS - 2284-0729 (Electronic)IS - 1128-3602 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27831636">PM:27831636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Rev Med Pharmacol Sci\2016-20-4348-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Rev Med Pharmacol Sci\2016-20-4348-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161110, Yin GQ</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Halwani,R.</style></author><author><style face="normal" font="Arial"> Sultana,S.A.</style></author><author><style face="normal" font="Arial"> Ratemi,E.</style></author><author><style face="normal" font="Arial"> Afzal,S.</style></author><author><style face="normal" font="Arial"> Kenana,R.</style></author><author><style face="normal" font="Arial"> Al-Muhsen,S.</style></author><author><style face="normal" font="Arial"> Al Faraj,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Prince Naif Center for Immunology Research and Asthma Research Chair, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="Arial">A novel anti-IL4Ralpha nanoparticle efficiently controls lung inflammation during asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Exp Mol Med</style></abbr-1></periodical><pages end="" start="e262">e262-</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD8</style></keyword><keyword><style face="normal" font="Arial"> CD8 T cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Resistance</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FACS</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Subcutaneous route</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="Arial">Drug resistance and the harmful side effects accompanying the prolonged corticosteroid treatment of chronic pulmonary diseases prompted the development of more specific anti-inflammatory approaches. Several strategies aiming to block IL4Ralpha, the receptor for a key pro-inflammatory pathway, were investigated. However, their efficiency was limited, mostly due to the systemic or subcutaneous route of administrations. In this paper, we examined the ability of an intranasal treatment with biocompatible nanoparticles targeting IL4Ralpha to control lung inflammation in ovalbumin (OVA)-sensitized mice. OVA-sensitized mice were treated with anti-IL4Ralpha-conjugated nanoparticles. The levels of pro-inflammatory cytokines in the lungs and broncho-alveolar lavage fluid (BALF) were determined using a cytokine array assay. The effects of nanoparticle treatment on the activation of lung inflammatory cells and their ability to proliferate and produce cytokines were determined using fluorescence-activated cell sorting (FACS) analysis. Lung inflammation was also monitored using immunohistochemical staining. Treatment with the anti-IL4Ralpha nanoparticles significantly decreased pro-inflammatory cytokine expression and release in BALF and airway lung tissue in mice. The numbers of lung tissue lymphocytes, neutrophils and eosinophils were also decreased. Interestingly, anti-IL4Ralpha nanoparticles deactivated CD4 and CD8 T cells in lung tissue and inhibited their ability to produce pro-inflammatory cytokines to a significantly lower level than the treatment with free anti-IL4Ralpha. Moreover, they induced a sustained low level of lung inflammation for 1 week following the last instillation compared with the treatment with free anti-IL4Ralpha antibodies. Together, this data suggested that the enhanced tissue penetrability and sustainability of these nanoparticles improved the strength and durability of the immunosuppressive effects of anti-IL4Ralpha</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 2092-6413 (Electronic)IS - 1226-3613 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1038/emm.2016.89</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27713399">PM:27713399</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Mol Med\2016-48-e262.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Mol Med\2016-48-e262.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Halwani R</style></custom2><misc3><style face="normal" font="Arial">10.1038/emm.2016.89</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brotons-Canto,A.</style></author><author><style face="normal" font="Arial"> Martin-Arbella,N.</style></author><author><style face="normal" font="Arial"> Gamazo,C.</style></author><author><style face="normal" font="Arial"> Irache,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pharmacy and Pharmaceutical Technology , University of Navarra , Pamplona , Spain</style></auth-address><titles><title><style face="normal" font="Arial">New pharmaceutical approaches for the treatment of food allergies</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Drug Deliv</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Drug Deliv</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">accidental ingestion</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> self-injectable</style></keyword><keyword><style face="normal" font="Arial"> self-injectable epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Allergic diseases constitute one of the most common causes of chronic illness in developed countries. The main mechanism determining allergy is an imbalance between Th1 and Th2 response towards Th2. Areas covered: This review describes the mechanisms underlying the natural tolerance to food components and the development of an allergic response in sensitized individuals. Furthermore, therapeutic approaches proposed to manage these abnormal immunologic responses food are also presented and discussed. Expert opinion: In the past, management of food allergies has consisted of the education of patients to avoid the ingestion of the culprit food and to initiate the therapy (e.g. self-injectable epinephrine) in case of accidental ingestion. In recent years, sublingual/oral immunotherapies based on the continuous administration of small amounts of the allergen have been developed. However, the long periods of time needed to obtain significant desensitization and the generation of adverse effects, limit their use. In order to solve these drawbacks, strategies to induce tolerance are being studied, such as the use of either adjuvant immunotherapy in order to facilitate the reversion of the Th2 response towards Th1 or the use of monoclonal antibodies to block the main immunogenic elements</style></abstract><notes><style face="normal" font="Arial">DA - 20161012IS - 1744-7593 (Electronic)IS - 1742-5247 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/17425247.2016.1247805</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27732129">PM:27732129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Opin Drug Deliv\20161012-Brotos-CantoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Opin Drug Deliv\20161012-Brotos-CantoA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Brotos-Canto A</style></custom2><misc3><style face="normal" font="Arial">10.1080/17425247.2016.1247805</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Luu,M.</style></author><author><style face="normal" font="Arial"> Bardou,M.</style></author><author><style face="normal" font="Arial"> Bonniaud,P.</style></author><author><style face="normal" font="Arial"> Goirand,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Centre d'Investigations Cliniques 1432, module plurithematique (INSERM 1442) , CHU du Bocage , Dijon , France</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Drug Metab Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Drug Metab Toxicol</style></full-title></periodical><pages end="1511" start="1503">1503-1511</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Clinique</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> pharmacodynamics</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="17" Month="10" Year="2016">2016/10/17</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Omalizumab is a subcutaneously administrated monoclonal anti-IgE antibody indicated in adults, adolescents and children 6 years of age and older with moderate to severe allergic asthma uncontrolled by conventional pharmacological treatments and sensitization to at least one perennial allergen. Area covered: This drug evaluation summarizes published data on pharmacokinetic and pharmacodynamic properties of omalizumab, on clinical efficacy and safety, including real-world evidence, and provides a medico-economic evaluation of the drug. Expert opinion: Omalizumab represents an efficient therapeutic option for the management of patients with uncontrolled moderate/severe allergic asthma. It provides a significant reduction in the asthma exacerbation rate with a steroid-sparing effect, an improvement in quality of life in adults and adolescents, despite a lack of evidence about its efficacy specifically in severe allergic asthma. Clinical trials have demonstrated its efficacy in the pediatric population but further real-life evidence is expected to better characterize long-term effects in this population. There is still some debate about the optimal treatment duration but, to date, it is recommended not to stop the treatment as cessation has resulted in symptom recurrence. Omalizumab is an expensive treatment, but a key therapeutic option when used for uncontrolled severe allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1744-7607 (Electronic)IS - 1742-5255 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1080/17425255.2016.1248403</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27748630">PM:27748630</url></web-urls><pdf-urls><url ppv-ref="no">francoise.goirand@u-bourgogne.fr</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161017, Luu M</style></custom2><misc3><style face="normal" font="Arial">10.1080/17425255.2016.1248403</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Demoly,P.</style></author><author><style face="normal" font="Arial"> Okamoto,Y.</style></author><author><style face="normal" font="Arial"> Yang,W.H.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pulmonology - Division of Allergy , Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier and Sorbonne Universites , UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Paris , France</style></auth-address><titles><title><style face="normal" font="Arial">300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="1151" start="1141">1141-1151</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> pharmacodynamics</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The once-daily 300 index of reactivity (IR) house dust mite (HDM) tablet (Actair(R); Stallergenes Greer, Antony, France/Shionogi &amp; Co. Ltd., Osaka, Japan) is the first sublingual immunotherapy (SLIT) tablet to be approved for the treatment of HDM-induced allergic rhinitis. Areas covered: This drug profile reviews the current body of evidence on the efficacy, safety and tolerability of the 300 IR HDM tablet, its pharmacodynamics, and its role in clinical practice. Expert commentary: Data from its clinical development program demonstrate favorable efficacy and safety in adults and adolescents with HDM-induced allergic rhinitis, irrespective of mono- or polysensitization status, or the presence of comorbid mild asthma. The 300 IR HDM tablet is effective from as early as 2 months after treatment initiation, providing allergic symptom control and a reduction in the need for symptomatic medication, while improving health-related quality of life. Clinical efficacy is maintained for 1 year after treatment is stopped</style></abstract><notes><style face="normal" font="Arial">DA - 20160929IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - Japan -CO - Canada -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2016.1237288</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27632814">PM:27632814</url></web-urls><pdf-urls><url ppv-ref="no">pascal.demoly@inserm.fr</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20160929, Demoly P</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2016.1237288</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Quirce,S.</style></author><author><style face="normal" font="Arial"> Campo,P.</style></author><author><style face="normal" font="Arial"> Dominguez-Ortega,J.</style></author><author><style face="normal" font="Arial"> Fernandez-Nieto,M.</style></author><author><style face="normal" font="Arial"> Gomez-Torrijos,E.</style></author><author><style face="normal" font="Arial"> Martinez-Arcediano,A.</style></author><author><style face="normal" font="Arial"> Mur,P.</style></author><author><style face="normal" font="Arial"> Delgado,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Allergy , Hospital La Paz Institute for Health Research and CIBER of Respiratory Diseases, CIBERES , Madrid , Spain</style></auth-address><titles><title><style face="normal" font="Arial">New developments in work-related asthma</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="281" start="271">271-281</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> irritant-induced asthma</style></keyword><keyword><style face="normal" font="Arial"> Irritants</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> work-exacerbated asthma</style></keyword><keyword><style face="normal" font="Arial"> work-related asthma</style></keyword><keyword><style face="normal" font="Arial"> working environment</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword><keyword><style face="normal" font="Arial"> Workplace exposure</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Work-related asthma includes two subtypes: occupational asthma or asthma caused by specific agents (sensitizers or irritants) in the workplace, and work-exacerbated asthma or pre-existing asthma worsened by workplace exposures. AREAS COVERED: This review provides an update on the definitions and the clinical features of the different work-related asthma subtypes as well as new insights into their etiology and the pathophysiological mechanisms involved. The diagnosis of work-related asthma should be made on objective basis using a constellation of clinical, physiologic and allergologic tests. Specific inhalation challenge with the suspected occupational agent(s) remains as the reference standard for diagnosis. A literature search was performed using the following terms: work-related asthma, occupational asthma, work-exacerbated asthma, irritant-induced asthma and etiological agents. Expert commentary: Studies focusing on the biological effects and mechanisms of environmental exposures in the development of sensitizer-induced or irritant-induced asthma in various workplace settings are of greatest interest. An integrative approach that combines clinical parameters with component-resolved diagnosis as well as inflammatory biomarkers appears to be very promising. Occupational allergy provides a good opportunity to understand the complex relationships between exposure to allergens in the workplace, interaction with genes and the co-exposures to other factors in the working environment</style></abstract><notes><style face="normal" font="Arial">DA - 20160930IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1239529</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27653257">PM:27653257</url></web-urls><pdf-urls><url ppv-ref="no">santiago.quirce@salud.madrid.org</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160930, Quirce S</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1239529</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marodi,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Departments of Dermatology, Venereology and Dermatooncology , Semmelweis University , Budapest , Hungary</style></auth-address><titles><title><style face="normal" font="Arial">Inborn errors of T cell immunity underlying autoimmune diseases</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="99" start="97">97-99</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1256204</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801603">PM:27801603</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-97-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-97-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Marodi L</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1256204</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greiwe,J.</style></author><author><style face="normal" font="Arial"> Bernstein,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Bernstein Allergy Group , Cincinnati , OH , USA</style></auth-address><titles><title><style face="normal" font="Arial">Therapy of antihistamine-resistant chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="318" start="311">311-318</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> physical urticaria</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Chronic urticaria affects up to 1-3% of the general population and contributes to significant direct and indirect medical costs as well as decreased quality of life, which has a significant economic impact on our health care system. Areas covered: Given the prevalence of this condition on a large sector of the population, finding lasting relief for refractory cases is essential and is the focus of this review. Expert commentary: The choice of appropriate therapy in chronic refractory urticaria is not a 'one-size fits all' approach. Treatment should take multiple factors into consideration including the chronicity of hives, presence of physical urticaria, type of cellular infiltrate on skin histopathology, patient age, concomitant comorbid conditions, as well as patient preference and cost</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1249467</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27744711">PM:27744711</url></web-urls><pdf-urls><url ppv-ref="no">jonathan.bernstein@uc.edu</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Greiwe J</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1249467</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agarwal,R.</style></author><author><style face="normal" font="Arial"> Sehgal,I.S.</style></author><author><style face="normal" font="Arial"> Dhooria,S.</style></author><author><style face="normal" font="Arial"> Aggarwal,A.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pulmonary Medicine , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India</style></auth-address><titles><title><style face="normal" font="Arial">Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Respir Med</style></full-title></periodical><pages end="1334" start="1317">1317-1334</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="17" Month="10" Year="2016">2016/10/17</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disorder characterized by recurrent episodes of wheezing, fleeting pulmonary opacities and bronchiectasis. It is the most prevalent of the Aspergillus disorders with an estimated five million cases worldwide. Despite six decades of research, the pathogenesis, diagnosis and treatment of this condition remains controversial. The International Society for Human and Animal Mycology has formed a working group to resolve the controversies around this entity. In the year 2013, this group had proposed new criteria for diagnosis and staging, and suggested a treatment protocol for the management of this disorder. Since then, several pieces of new evidence have been published in the investigation and therapeutics of this condition. Areas covered: A non-systematic review of the available literature was performed. We summarize the current evidence in the evaluation and treatment of this enigmatic disorder. We suggest modifications to the existing criteria and propose a new scoring system for the diagnosis of ABPA. Expert commentary: All patients with asthma and cystic fibrosis should routinely be screened for ABPA using A. fumigatus-specific IgE levels. Glucocorticoids should be used as the first-line of therapy in ABPA, and itraconazole reserved in those with recurrent exacerbations and glucocorticoid-dependent disease</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">10.1080/17476348.2016.1249853</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27744712">PM:27744712</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Respir Med\20161017-AgarwalR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Respir Med\20161017-AgarwalR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Agarwal R</style></custom2><misc3><style face="normal" font="Arial">10.1080/17476348.2016.1249853</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reveneau,E.</style></author><author><style face="normal" font="Arial"> Cottin,P.</style></author><author><style face="normal" font="Arial"> Rasuli,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Sanofi Pasteur , Lyon , France</style></auth-address><titles><title><style face="normal" font="Arial">Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab')2 fragments</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Vaccines</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Vaccines</style></full-title></periodical><pages end="287" start="273">273-287</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Rabies is a worldwide zoonotic viral disease with no specific treatment once symptoms occur; manifest disease is almost always fatal. WHO recommendations for exposed individuals include immediate attention to the wound and use of rabies immunoglobulin and/or vaccine for post-exposure prophylaxis (PEP). Here, we provide an overview of the clinical experience with a highly purified preparation of F(ab')2 fragments from equine rabies immunoglobulin (F(ab')2 pERIG; FavirabTM) in rabies PEP. Areas covered: Our review comprises a retrospective analysis of adverse event reports in the Sanofi Pasteur global pharmacovigilance database for F(ab')2 pERIG, including adverse event reports from eight Sanofi Pasteur-sponsored clinical trials and post-market surveillance data collected between 1995 and 2014. The general safety profile of F(ab')2 pERIG is discussed, as are the occurrence of rare anaphylactic reactions, and suspected intervention failure. Expert commentary: Over 20 years of clinical development and post-licensure experience has established the safety and effectiveness of F(ab')2 pERIG (FavirabTM) in rabies PEP</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 1744-8395 (Electronic)IS - 1476-0584 (Linking)LA - ENGPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1080/14760584.2017.1244009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27809689">PM:27809689</url></web-urls><pdf-urls><url ppv-ref="no">Elisa.Reveneau@sanofipasteur.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Reveneau E</style></custom2><misc3><style face="normal" font="Arial">10.1080/14760584.2017.1244009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45299-3026, USA</style></auth-address><titles><title><style face="normal" font="Arial">Developing food allergy: a potential immunologic pathway linking skin barrier to gut</style></title><secondary-title><style face="normal" font="Arial">F1000Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">F1000Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell progenitors</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> multifunctional</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin E (IgE)-mediated food allergy is an adverse reaction to foods and is driven by uncontrolled type-2 immune responses. Current knowledge cannot explain why only some individuals among those with food allergy are prone to develop life-threatening anaphylaxis. It is increasingly evident that the immunologic mechanisms involved in developing IgE-mediated food allergy are far more complex than allergic sensitization. Clinical observations suggest that patients who develop severe allergic reactions to food are often sensitized through the skin in early infancy. Environmental insults trigger epidermal thymic stromal lymphopoietin and interleukin-33 (IL-33) production, which endows dendritic cells with the ability to induce CD4 +TH2 cell-mediated allergic inflammation. Intestinal IL-25 propagates the allergic immune response by enhancing collaborative interactions between resident type-2 innate lymphoid cells and CD4 +TH2 cells expanded by ingested antigens in the gastrointestinal tract. IL-4 signaling provided by CD4 +TH2 cells induces emigrated mast cell progenitors to become multi-functional IL-9-producing mucosal mast cells, which then expand greatly after repeated food ingestions. Inflammatory cytokine IL-33 promotes the function and maturation of IL-9-producing mucosal mast cells, which amplify intestinal mastocytosis, resulting in increased clinical reactivity to ingested food allergens. These findings provide the plausible view that the combinatorial signals from atopic status, dietary allergen ingestions, and inflammatory cues may govern the perpetuation of allergic reactions from the skin to the gut and promote susceptibility to life-threatening anaphylaxis. Future in-depth studies of the molecular and cellular factors composing these stepwise pathways may facilitate the discovery of biomarkers and therapeutic targets for diagnosing, preventing, and treating food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 2046-1402 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.12688/f1000research.9497.1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27853507">PM:27853507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\F1000Res\20161117-WangYH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\F1000Res\20161117-WangYH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Wang YH</style></custom2><misc3><style face="normal" font="Arial">10.12688/f1000research.9497.1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Celakovska,J.</style></author><author><style face="normal" font="Arial"> Krcmova,I.</style></author><author><style face="normal" font="Arial"> Bukac,J.</style></author><author><style face="normal" font="Arial"> Vaneckova,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sensitivity and specificity of specific IgE, skin prick test and atopy patch test in examination of food allergy</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="247" start="238">238-247</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch test</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch tests</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The aim of this study is the evaluation of the specificity and sensitivity of the skin prick tests (SPTs), specific IgE and atopy patch tests (APTs) in atopic dermatitis patients suffering from food allergy. A total of 301 patients were examined, complete dermatological and allergological examination was performed in all patients. The food allergy was confirmed to peanuts in 62 patients (20%), to egg in 16 patients (5%), to soy in 9 patients (3%), to wheat in 12 patients (4%) and to cow milk in 6 patients (2%). The specificity of SPT, specific IgE and APT is considered as good; the sensitivity of APT is low. The positive results in isolation cannot confirm the food allergy; however, together with other diagnostic methods, such as clinical history and open exposure test, these tests are valuable tool in examination of food allergy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">0.1080/09540105.2016.1258548</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1258548</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-238-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-238-47.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Celakovska J</style></custom2><misc3><style face="normal" font="Arial">0.1080/09540105.2016.1258548</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Celakovska,J.</style></author><author><style face="normal" font="Arial"> Bukac,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Severity of atopic dermatitis in relation to food and inhalant allergy in adults and adolescents</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="133" start="121">121-133</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergy</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Statistical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The aim of this study is the evaluation of the relationship between the severity of atopic dermatitis (AD) and the occurrence of IgE-mediated food allergy, food sensitization, and sensitization to inhalant allergens. The complete dermatological and allergological examinations were performed and the severity of AD was evaluated with the SCORing Atopic Dermatitis index. The statistical evaluation of the relationship between the occurrence of IgE-mediated food allergy, food sensitization, sensitization to inhalant allergens, and the severity of AD was performed. Two hundred and eighty-three patients were examined, 89 men and 194 women, average age 26.2 (s.d. 9.5). The significant relation was recorded between the severity of AD and sensitization to tested inhalant allergens. The significant relation was also found between the severity of AD and IgE-mediated food allergy. It turns out that the higher time to reaction, the higher the severity of AD</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2016.1228838</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1228838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-121-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-121-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Celakovska J</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2016.1228838</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,S.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Liu,B.</style></author><author><style face="normal" font="Arial"> Yu,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Optimization of pine nut (Pinus koraiensis) meal protein peptides on immunocompetence in innate and adaptive immunity response aspects</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="120" start="109">109-120</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunocompetence</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-2</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-6</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phagocytosis</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> pine nut</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">Pine nut (Pinus koraiensis) meal protein peptides (PNMPP), a kind of Korean pine seed oil by-products, were often considered as waste disposal in food industry. In the present study, we found that 3-10 kDa PNMPP could enhance immunity of ICR mice at 100 mg·(kg·d)-1 both in innate and in adaptive immunity. In innate immunity, PNMPP of 3-10 kDa at 100 mg·(kg·d)-1 could enhance the abdominal macrophage phagocytosis of mice at 30.22% and the phagocytosis index of carbon clearance significantly (P?&lt;?.05). In addition, we found out that 3-10 kDa PNMPP at low dose could significantly enhance cytokine interferon-?, interleukin-2, interleukin-4, and interleukin-6 (P?&lt;?.05). Meanwhile, in adaptive immunity, PNMPP could enhance the median hemolytic concentration of mice. These findings suggested that 100 mg·(kg·d)-1, 3-10 kDa PNMPP could increase the function of immunity.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2016.1228835</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1228835</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-109-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-109-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Lin S</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2016.1228835</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,Y.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Pavase,T.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Wang,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of electron beam irradiation to reduce the IgE binding capacity of frozen shrimp tropomyosin</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="201" start="189">189-201</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> irradiation</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergy</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The aim was to determine the effect of electron beam (EB) irradiation on IgE binding capacity of shrimp tropomyosin (TM) at the frozen stage. Following EB irradiation, protein extracts were characterized by sodium dodecyl sulfate?polyacrylamide gel electrophoresis and TM degradation was observed. The degradations were further recognized by IgE from a shrimp-allergic patient by immunoblots. Specific IgE binding results showed that capacity of shrimp extracts and TM initially increased by 10% after irradiation at 3?kGy doses, and then decreased by 20% with irradiation doses increased to 10?kGy. Further inhibition enzyme linked immunosorbent assay results showed that half-maximal inhibitory concentration of shrimp extract treated with 10?kGy doses enhanced to four times as compared with raw shrimp extracts. These results suggest that EB irradiation significantly changes the IgE binding capacity of frozen shrimp at 10?kGy doses by 20% and has the potential to reduce shrimp allergy risk</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2016.1251394</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1251394</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\20161120-LiuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\20161120-LiuY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Liu Y</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2016.1251394</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,J.</style></author><author><style face="normal" font="Arial"> Gu,X.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Luo,Y.</style></author><author><style face="normal" font="Arial"> Wang,M.</style></author><author><style face="normal" font="Arial"> Yang,H.</style></author><author><style face="normal" font="Arial"> Guo,X.</style></author><author><style face="normal" font="Arial"> Zhu,X.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immunomodulatory effects of Glycyrrhiza uralensis polysaccharide in glycinin-induced allergic mouse model</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="188" start="178">178-188</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">This study aimed to investigate the therapeutic effects of Glycyrrhiza uralensis polysaccharide (GUP) on glycinin-induced allergic reactions in mouse model. Female BALB/c mice were pretreated for seven consecutive days with various concentrations of GUP aqueous solution or blank control. The mice were then orally administered with glycinin (10?mg/ml) three times and observed a week later. The survival rate and other indicators of the mice were measured, while IL-4, IL-13, plasma histamine and the lgE and IgG content in the serum were detected by enzyme-linked immunosorbent assay. The percentage of CD4+CD25+FoxP3+T cells was detected by flow cytometry. The results showed that IL-4, IL-13 and plasma histamine levels significantly decreased in the blood of mice treated with low GUP concentrations (20?mg/ml), while the specific glycinin-IgE, glycinin-IgG inhibition ratio and CD4+CD25+FoxP3+ T cells/CD4+ T cells ratio increased. However, the lowest, middle, high and the highest concentrations of GUP did not have significant effects on the immune reactions of glycinin-induced allergic mice. In conclusion, our study suggests that GUP is a promising agent to inhibit glycinin-induced allergy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2016.1251393</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1251393</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-178-88.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-178-88.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Chen J</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2016.1251393</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Slowianek,M.</style></author><author><style face="normal" font="Arial"> Mankowska,D.</style></author><author><style face="normal" font="Arial"> Leszczynska,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Reaction of spice proteins with serum antibodies from celiac patients and rabbit antibodies raised to specific glutamine/proline-containing peptides</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="148" start="134">134-148</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Ginger</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Non celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Spices</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The aim of this study was to determine if extracts from selected spices (caraway, ginger, chili, sweet peppers, anise, sesame, nutmeg and black pepper) might be harmful to people suffering from celiac disease, wheat allergy or non-celiac gluten sensitivity. All of these spice extracts exhibited some reaction to antibodies found in sera from two celiac patients and to sera from rabbits that had been sensitized with the specific peptides, QQQPP, PQQQ and QQQP. These peptides had sequences that might be included in active epitopes for celiac disease and wheat allergy. Methodology followed in this study included ELISA, SDS-PAGE and immunoblotting. The observed reactivities suggest that spice proteins might produce adverse reactions in celiac patients, patients with various wheat allergies or with non-celiac gluten sensitivity. However, further work would be needed to elucidate this possibility</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2016.1230598</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1230598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-134-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-134-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Slowianek M</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2016.1230598</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Celakovska,J.</style></author><author><style face="normal" font="Arial"> Bukac,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food hypersensitivity reactions and peripheral blood eosinophilia in patients suffering from atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="43" start="35">35-43</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Carrot</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The aim of our study is to evaluate the count of eosinophils in peripheral blood in atopic dermatitis (AD) patients over 14 years of age and to compare it with the occurrence of food hypersensitivity (FH) reactions. Complete allergological and dermatological examination was performed in 212 patients included in the study (90 men, 122 women, average age 26.7 years, average SCORAD 32.9). According to our results, in AD patients the difference in count of eosinophils in patients with and without FH reactions is not statistically significant. When evaluating the occurrence of FH reactions to single foods, the count of eosinophils is significantly higher only in patients suffering from reactions to carrot</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2016.1202209</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1202209</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-35-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-35-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Celakovska J</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2016.1202209</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khodaei,H.</style></author><author><style face="normal" font="Arial"> Alizadeh,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Inhibition of IL-4 but not IFN-? production by splenocytes of mice immunized with ovalbumin after oral administration of 5-hydroxymethylfurfural</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="34" start="27">27-34</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">Hydroxymethylfurfural (5-HMF) is one of the most important products of maillard reaction. This study sought to elucidate the immunomodulatory effect of 5-HMF by evaluating IFN-? and IL-4 production in BALB/c mice sensitized with ovalbumin (OVA). Four groups of BALB/c mice (n?=?5 for each group) including control, vehicle and two 5-HMF (188 and 750?mg/kg?bw) treatment groups were studied. Interleukin-4(IL-4) and interferon gamma (IFN-?) levels were measured in culture supernatants of spleen cells using enzyme-linked immunosorbent assay. It was found that the IL-4 level was significantly suppressed in 5-HMF treatment groups compared with the vehicle group (P?&lt;?.05). Moreover, the IFN-?/IL-4 ratio was significantly increased in a dose-independent manner compared with the vehicle group (P?&lt;?.05). Oral administration of 5-HMF inhibited IL-4 but not IFN-? production by splenocytes of mice immunized with OVA. These changes may reflect that 5-HMF could be a novel therapeutic approach for prevention of (Th2) cytokine-dominant disease</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2016.1202208</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1202208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-27-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-27-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Khodaei H</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2016.1202208</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pilolli,R.</style></author><author><style face="normal" font="Arial"> De Angelis,E.</style></author><author><style face="normal" font="Arial"> Monaci,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Streamlining The Analytical Workflow For Multiplex MS/MS Allergen Detection In Processed Foods</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="1753" start="1747">1747-1753</pages><volume><style face="normal" font="Arial">221</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Baking</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Cookies</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> EU legislation</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Multi-allergen analysis</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> On-line SPE</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> SRM</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole egg</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">Allergenic ingredients in pre-packaged foods are regulated by EU legislation mandating their inclusion on labels. In order to protect allergic consumers, sensitive analytical methods are required for detect allergen traces in different food products. As a follow-up to our previous investigations, an optimized, sensitive,label-free LC-MS/MS method for multiplex detection of five allergenic ingredients in a processed food matrix is proposed. A cookie base was chosen as a complex food matrix and home-made cookies incurred with whole egg, skimmed milk, soy flour, ground hazelnut and ground peanut were prepared at laboratory scale. In order to improve the analytical workflow both protein extraction and purification protocols were optimized in order to achieve a sensitive streamlined SRM based analytical method for allergens detection in incurred cookies. The effect of baking on the detection of selected markers was also investigated</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.10.110</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodchem.2016.10.110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\20161104-PilolliR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\20161104-PilolliR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Pilolli R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.10.110</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Walczyk,N.E.</style></author><author><style face="normal" font="Arial"> Smith,M.C.</style></author><author><style face="normal" font="Arial"> Tovey,E.R.</style></author><author><style face="normal" font="Arial"> Roberts,T.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Peanut protein extraction conditions strongly influence yield of allergens Ara h 1 and 2 and sensitivity of immunoassays</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="344" start="335">335-344</pages><volume><style face="normal" font="Arial">221</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Arachis</style></keyword><keyword><style face="normal" font="Arial"> Arachis hypogaea</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Buffers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Defatting</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Immunochemistry</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reducing Agents</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">The clinical importance of peanut (Arachis hypogaea) allergies demands standardized allergen extraction protocols. We determined the effectiveness of common extraction conditions (20 buffers, defatting reagents, extraction time/temperatures, processing, extraction repeats) on crude protein and Ara h 1 and 2 yields. Despite similar 1D-gel profiles, defatting with n-hexane resulted in significantly higher yields of crude protein, Ara h 1, and Ara h 2 than with diethyl ether. The yields were affected by the composition and pH of the extraction buffers and other conditions, but crude protein yield did not always correlate with Ara h 1 and 2 yields. Denaturants, reducing agents, acidic buffers, and thermal processing of peanuts perturbed allergen quantification in ELISAs, probably via exposure of additional epitopes. Allergen detection in 2D-Western blots with PBS resulted in greater sensitivity than with TBS or Tris. We recommend that allergen extraction conditions be selected based on the research question being investigated</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.10.063</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodchem.2016.10.063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\20161031-WalczykNE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\20161031-WalczykNE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Walczyk NE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.10.063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Costa,J.</style></author><author><style face="normal" font="Arial"> Amaral,J.S.</style></author><author><style face="normal" font="Arial"> Grazina,L.</style></author><author><style face="normal" font="Arial"> Oliveira,M.B.</style></author><author><style face="normal" font="Arial"> Mafra,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Matrix-normalised real-time PCR approach to quantify soybean as a potential food allergen as affected by thermal processing</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="1850" start="1843">1843-1850</pages><volume><style face="normal" font="Arial">221</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Cooked ham</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Glycine max L.</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Meat Products</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> pork meat</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> processed meat</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein material</style></keyword><keyword><style face="normal" font="Arial"> Soybean quantification</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatment</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatments</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">The addition of soybean protein materials to meat products is a common practice in the food industry, being a potential hidden allergenic commodity. This study aimed at proposing a novel specific and highly sensitive real-time PCR system for the detection/quantification of soybean as an allergenic ingredient in processed meat products. The method achieved a limit of detection of 9.8 pg of soybean DNA (8.6 copies), with adequate real-time PCR performance parameters, regardless of the soybean material (concentrate or isolate) and after thermal treatments. A normalised approach was also proposed in the range of 0.001</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô10% (w/w) of soybean material in pork meat, which was successfully validated and applied to processed meat products. Soybean was identified in more than 40% of tested samples of cooked ham and mortadella in the range of 0.1</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô4% (w/w), 3 samples not complying with labelling regulations as a result of undeclared soybean</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.10.091</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodchem.2016.10.091</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\20161104-CostaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\20161104-CostaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Costa J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.10.091</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meng,X.</style></author><author><style face="normal" font="Arial"> Bai,Y.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of high hydrostatic pressure on the structure and potential allergenicity of the major allergen bovine +¦-lactoglobulin</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="296" start="290">290-296</pages><volume><style face="normal" font="Arial">219</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> B-lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> fluorescence spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> High hydrostatic pressure</style></keyword><keyword><style face="normal" font="Arial"> Hydrostatic Pressure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Indirect competitive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein Conformation</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ultraviolet</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">Bovine B-lactoglobulin (B-Lg) is recognized as a significant milk allergen in several countries. In this study, B-Lg was isolated and treated with high hydrostatic pressure (HHP) at 100, 200, 300, 400, and 500 MPa. The allergenic properties of the HHP-treated B-Lg were characterized by indirect competitive enzyme-linked immunosorbent assay with anti-B-Lg rabbit antibody and the sera of patients allergic to cows' milk. The conformation of the HHP-treated B-Lg was examined with ultraviolet absorption spectroscopy, endogenous fluorescence spectroscopy, exogenous fluorescence spectroscopy, and circular dichroism spectroscopy analyses. The results indicated that IgG binding increased with treatment pressure, and IgE binding was lowest at 200 MPa and highest at 400 MPa. The tertiary structure of B-Lg changed significantly after HHP, whereas the primary and secondary structures remained stable. Overall, this study suggests that the conformational changes in HHP-treated B-Lg contribute to its altered allergenicity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.09.153</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodchem.2016.09.153</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-219-290-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-219-290-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161026, Meng X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.09.153</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yuan,F.</style></author><author><style face="normal" font="Arial"> Lv,L.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Mi,N.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Lin,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of transglutaminase-catalyzed glycosylation on the allergenicity and conformational structure of shrimp (Metapenaeus ensis) tropomyosin</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="222" start="215">215-222</pages><volume><style face="normal" font="Arial">219</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Glucosamine</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> myofibrillar</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">Tropomyosin (TM), a myofibrillar protein, is a major allergen in shrimp. The aim of this study was to evaluate the effect of transglutaminase (TGase)-catalyzed glycosylation on the potential allergenicity and conformational structure of TM in Metapenaeus ensis. Results showed that glycosylation of TM induced unfolding of the primary protein structure followed by loss of the secondary structure. Cleavage of certain free amino groups was observed during TGase-catalyzed glycosylation. The glycosylation rate correlated with reaction temperature. Western blotting and indirect ELISA with TM-specific polyclonal antibodies from rabbit and sera from patients allergic to shrimp demonstrated that antigenicity and potential allergenicity of TM decreased, which correlated well with the conformational changes in its structure. Considering TGase is widely utilized in the food industry, these results indicate that TGase-catalyzed glycosylation has the potential to serve as a mild method for reducing the allergenicity of shrimp products</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2016.09.139</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodchem.2016.09.139</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-219-215-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-219-215-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161026, Yuan F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2016.09.139</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meng,X.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Characterization of the potential allergenicity of irradiated bovine +¦-lactalbumin in a BALB/c mouse model</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="410" start="402">402-410</pages><volume><style face="normal" font="Arial">97</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fc+ÁRI</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> irradiated</style></keyword><keyword><style face="normal" font="Arial"> irradiation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><isbn><style face="normal" font="Arial">0278-6915</style></isbn><abstract><style face="normal" font="Arial">Bovine +¦-lactalbumin (ALA) is a known food allergen present in milk to induce anaphylaxis. A previous study demonstrated that irradiated ALA (iALA) decreased the IgE-binding properties and weakened the degranulation capacity of basophils in-ávitro. The present study aimed to further assess the potential allergenicity of iALA in-ávivo in a BALB/c mouse model. The mice (n-á=-á10/group) were intragastrically sensitized and orally challenged with either iALA or ALA using cholera toxin as adjuvant. In contrast to the ALA group, the iALA group did not show anaphylactic shock symptoms. A tendency toward decreased serum allergen-specific IgG/IgG1/IgE levels, plasma histamine levels and mast cell protease-1 (mMCP-1) concentrations in the iALA group were also observed, accompanied by a decrease in Th2-related cytokine levels and an increase of IFN-+¦ production in spleen cell cultures. Moreover, the peritoneal mast cell surface expression of Fc+ÁRI and peripheral blood basophil CD200R+ expression were decreased by 64.3% and 35.19%, respectively. Conversely, the percentage of CD4+CD25+Foxp3+ regulatory T cells increased in the iALA group. All of these findings indicated that iALA induces a shift toward the Th1 response, which ultimately reduces its potential allergenicity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2016.10.010</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.fct.2016.10.010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2016-97-402-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2016-97-402-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Meng X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2016.10.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Angelis,E.</style></author><author><style face="normal" font="Arial"> Pilolli,R.</style></author><author><style face="normal" font="Arial"> Monaci,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Coupling SPE on-line pre-enrichment with HPLC and MS/MS for the sensitive detection of multiple allergens in wine</style></title><secondary-title><style face="normal" font="Arial">Food Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Control</style></full-title></periodical><pages end="820" start="814">814-820</pages><volume><style face="normal" font="Arial">73</style></volume><number><style face="normal" font="Arial">Part B</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> egg allergens</style></keyword><keyword><style face="normal" font="Arial"> filter</style></keyword><keyword><style face="normal" font="Arial"> fining</style></keyword><keyword><style face="normal" font="Arial"> Fining agent</style></keyword><keyword><style face="normal" font="Arial"> Fining agents</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergens</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> On-line SPE</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> SRM-MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> White wine</style></keyword><keyword><style face="normal" font="Arial"> Wine</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0956-7135</style></isbn><abstract><style face="normal" font="Arial">Mass spectrometry (MS) represents an essential tool in proteomics studies, in the last years also exploited for monitoring allergens contamination in food products. Milk and egg are renowned allergens often used as fining agents to promote clarification of wines, therefore any residual amount in the end-products could represent a menace for allergic individuals. In view of this, it is of paramount importance to have at disposal sensitive analytical methods able to detect traces of milk and egg allergens in food. In this work we describe the upgrade and the optimization of an analytical workflow based on the use of a pre-enrichment column coupled with HPLC separation and MS/MS detection for the selective and sensitive detection of milk and egg allergens in white wine. Two different sample pre-treatments based on the use of mass cut-off filters or size exclusion cartridges were evaluated and compared, before tryptic digestion and LC-SRM-MS/MS analysis of the resulting peptides mixture. The devised UF based method coupled with peptide on-line pre-enrichment enabled to reach the lowest LODs down at 0.036-á++g/mL and 0.05-á++g/mL for egg and milk allergens respectively, proving to be the most sensitive strategy for monitoring allergens contamination in wine</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodcont.2016.09.031</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodcont.2016.09.031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Control\20161026-DeAngelisE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Control\20161026-DeAngelisE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161026, De Angelis E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodcont.2016.09.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gullon,B.</style></author><author><style face="normal" font="Arial"> Gullon,P.</style></author><author><style face="normal" font="Arial"> Tavaria,F.K.</style></author><author><style face="normal" font="Arial"> Yanez,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemical Engineering, Institute of Technology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of the prebiotic effect of quinoa and amaranth in the human intestinal ecosystem</style></title><secondary-title><style face="normal" font="Arial">Food Funct</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Funct</style></full-title></periodical><pages end="3788" start="3782">3782-3788</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Amaranth</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Ecosystem</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hybridization</style></keyword><keyword><style face="normal" font="Arial"> In Situ Hybridization</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vitro digestion</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Nutritional composition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Pseudocereal</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="14" Month="9" Year="2016">2016/9/14</year></dates><abstract><style face="normal" font="Arial">Quinoa and amaranth belong to the group of the so called "superfoods" and have a nutritional composition that confers multiple benefits. In this work, we explored the possibility of these foods exhibiting a prebiotic effect. These pseudocereals were subjected to an in vitro digestion and used as carbon sources in batch cultures with faecal human inocula. The effects on the microbiota composition and their metabolic products were determined by assessment of variations in pH, short-chain fatty acid (SCFA) production and changes in the dynamic bacterial populations by fluorescence in situ hybridization (FISH). After 48 h of incubation, the total SCFAs were 106.5 mM for quinoa and 108.83 mM for amaranth, in line with the decrease in pH. Considerable differences (p &lt; 0.05) were found in certain microbial groups, including Bifidobacterium spp., Lactobacillus-Enterococcus, Atopobium, Bacteroides-Prevotella, Clostridium coccoides-Eubacterium rectale, Faecalibacterium prausnitzii and Roseburia intestinalis. Our research suggests that these pseudocereals can have the prebiotic potential and that their intake may improve dysbiosis or maintain the gastrointestinal health through a balanced intestinal microbiota, although additional studies are necessary</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 2042-650X (Electronic)IS - 2042-6496 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1039/c6fo00924g</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27713989">PM:27713989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Funct\2016-7-3782-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Funct\2016-7-3782-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Gullon B</style></custom2><misc3><style face="normal" font="Arial">10.1039/c6fo00924g</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shin,J.H.</style></author><author><style face="normal" font="Arial"> Chung,M.J.</style></author><author><style face="normal" font="Arial"> Seo,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">R&amp;D Center, Cell Biotech Co., Ltd., Gyeonggi-do, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">A multistrain probiotic formulation attenuates skin symptoms of atopic dermatitis in a mouse model through the generation of CD4+Foxp3+ T cells</style></title><secondary-title><style face="normal" font="Arial">Food Nutr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Nutr Res</style></full-title></periodical><pages end="" start="32550">32550-</pages><volume><style face="normal" font="Arial">60</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic march</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> the allergic march</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is characterized by chronic inflammation of the skin. AD develops mainly in infants and young children. It induces skin disorders and signals the initiation of the allergic march including allergic asthma and rhinitis. Probiotics modify intestinal microbial populations in a beneficial way for human and animal hosts by reducing inflammatory cytokines. OBJECTIVE: As a result of their immunomodulatory properties, probiotics have been considered a promising therapeutic option for the prevention and treatment of AD. DESIGN: In this study, we examined the effects of GI7, a potential probiotic mixture consisting of seven strains of bifidobacteria and lactic acid bacteria, on AD in a mouse model. RESULTS: Administration of GI7 for 8 weeks reduced AD-like skin lesions and induced changes in the levels of serum markers such as immunoglobulin E and cytokines related to T helper (Th)1 and Th2 cells, and in skin barrier genes. Alleviation of AD seems to be associated with GI7-induced generation of CD4+Foxp3+ regulatory T cells. CONCLUSIONS: The probiotic mixture may have potential to improve symptoms of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 1654-661X (Linking)LA - ENGPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3402/fnr.v60.32550</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27802847">PM:27802847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Nutr Res\2016-60-32550.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Nutr Res\2016-60-32550.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Shin JH</style></custom2><misc3><style face="normal" font="Arial">10.3402/fnr.v60.32550</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sun-Waterhouse,D.</style></author><author><style face="normal" font="Arial"> Waterhouse,G.I.N.</style></author><author><style face="normal" font="Arial"> You,L.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Ma,L.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Dong,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Transforming insect biomass into consumer wellness foods: A review</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="151" start="129">129-151</pages><volume><style face="normal" font="Arial">89</style></volume><number><style face="normal" font="Arial">Pt 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aging</style></keyword><keyword><style face="normal" font="Arial"> Alternative protein sources</style></keyword><keyword><style face="normal" font="Arial"> Bioactives</style></keyword><keyword><style face="normal" font="Arial"> Biomass</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumer perception</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Edible insects</style></keyword><keyword><style face="normal" font="Arial"> Entomophagy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Supply</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Human wellbeing</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Nutrients and bioactives</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">Potential food shortages, human health challenges and environmental concerns, all thematically linked to growing and aging global populations, drive the search for alternative and sustainable food sources. Insects, which have been part of the human diet since antiquity though not currently widely consumed in Western societies, are rich in high quality proteins and nutrients and bioactives. Accordingly, insects could make a significant contribution to the global food supply chain in the future. This review explores the potential of entomophagy in an integrated global food network and focuses on practical approaches for transforming insect biomass into consumer food products. Carefully regulated breeding, rearing, harvesting and processing of insect bioresources are critical for realising the concept of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£edible insects for human well-being</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -CO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2016.10.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodres.2016.10.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\20161026-SunWaterhouseD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\20161026-SunWaterhouseD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161026, Sun-Waterhouse D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2016.10.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lozano-Ojalvo,D.</style></author><author><style face="normal" font="Arial"> Molina,E.</style></author><author><style face="normal" font="Arial"> Lopez-Fandino,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Hypoallergenic hydrolysates of egg white proteins modulate allergen responses induced ex vivo on spleen cells from sensitized mice</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="669" start="661">661-669</pages><volume><style face="normal" font="Arial">89</style></volume><number><style face="normal" font="Arial">Pt 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> egg allergens</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg white proteins</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Hypoallergenic egg white hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory peptides</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide-based immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> Th1 and Th2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> TNF-+¦</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">This study describes the in vivo allergenicity of enzymatic hydrolysates of egg white proteins (ovalbumin, lysozyme and ovomucoid) and explores the possibility that they could modulate T cell cytokine responses to egg allergens ex vivo, using splenocytes from BALB/c mice sensitized to individual egg proteins or to their mixtures in different proportions. The hydrolysate of ovalbumin with pepsin could be regarded as a good candidate for peptide-based immunotherapy on the grounds of its reduced ability to trigger allergic symptoms in a passive cutaneous anaphylaxis assay and its potential to reduce Th2 responses (release of IL-4 and IL-5) induced by egg allergens in the spleen cell cultures, but also to enhance Th1 responses (release of TNF-+¦ and IFN-+¦). While it is possible to obtain chromatographic fractions containing peptides with different Th2-inhibiting or promoting properties, as judged by cytokine production, selective peptide enrichment did not lead to an increase in the immunomodulating efficiency as compared with the whole ovalbumin hydrolysate, possibly due to the presence in the latter of a combination of immunogenic peptides with synergistic or adjuvant actions</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2016.09.021</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodres.2016.09.021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\20161026-LozanoOjalvoD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\20161026-LozanoOjalvoD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161026, Lozano-Ojalvo D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2016.09.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.</style></author><author><style face="normal" font="Arial"> Du,W.X.</style></author><author><style face="normal" font="Arial"> Fan,Y.</style></author><author><style face="normal" font="Arial"> Yi,J.</style></author><author><style face="normal" font="Arial"> Lyu,S.C.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author><author><style face="normal" font="Arial"> McHugh,T.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Identification, characterization, and initial epitope mapping of a pine nut allergen</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="274" start="268">268-274</pages><volume><style face="normal" font="Arial">90</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Copper protein</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitope Mapping</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> pine nut</style></keyword><keyword><style face="normal" font="Arial"> Pine nut allergy</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urea</style></keyword><keyword><style face="normal" font="Arial"> Vicilin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">The aims of this study were to predict, identify and characterize pine nut allergens. Korean pine (Pinus koraiensis) vicilin was predicted to be a pine nut allergen. Recombinant Korean pine vicilin was expressed in E. coli and purified. Natural Korean pine vicilin isolated from pine nuts (which displayed multiple bands in SDS-gels due to posttranslational digestion) and its full length recombinant counterpart were used test whether it is a food allergen. The recognition of the protein (and its fragments) by patient serum IgE was analyzed by Western blot. The study included fourteen patients diagnosed with clinical pine nut allergy. Twenty nine percent of the patient sera recognized both the natural and recombinant pine nut vicilin, indicating that Korean pine vicilin is a bona fide food allergen. The serum recognition patterns of the naturally occurring protein fragments suggested that some of linear IgE epitopes may be mapped to the fragment boundaries. The chemical and thermal stability of the recombinant protein was investigated. It underwent a thermal transition with a Tm = 76.6 -¦C. The transition was accompanied by an increase in the amplitude of the circular dichroism signal at 220 nm. Urea induced unfolding of the recombinant protein had a Cm of 4.6 M</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2016.10.043</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodres.2016.10.043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\20161104-ZhangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\20161104-ZhangY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Zhang Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2016.10.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Y.</style></author><author><style face="normal" font="Arial"> Tu,Z.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Sha,X.</style></author><author><style face="normal" font="Arial"> Pang,J.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Liu,G.</style></author><author><style face="normal" font="Arial"> Yang,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Glycation of +¦-lactoglobulin under dynamic high pressure microfluidization treatment: Effects on IgE-binding capacity and conformation</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="888" start="882">882-888</pages><volume><style face="normal" font="Arial">89</style></volume><number><style face="normal" font="Arial">Pt 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> DHPM</style></keyword><keyword><style face="normal" font="Arial"> Dynamic high-pressure microfluidization</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> fluorescence spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Galactose</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> high pressure</style></keyword><keyword><style face="normal" font="Arial"> High-pressure</style></keyword><keyword><style face="normal" font="Arial"> Hydrophobicity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Unfolding</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">The effects of dynamic high-pressure microfluidization (DHPM) (80, 120, and 160 MPa) treatment and glycation with galactose on the IgE-binding capacity and conformation of +¦-lactoglobulin (+¦-Lg) were investigated. The binding capacity of immunoglobulin E (IgE) from patients' sera with cow's milk allergy on +¦-Lg glycated with galactose decreased after DHPM treatment. +¦-Lg treated after different DHPM methods and pressures yielded a significant discrepancy in IgE-binding capacity. When +¦-Lg was pretreated by DHPM, the IgE-binding capacity of +¦-Lg</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôgalactose conjugates decreased with increasing pressure; however, the conjugates showed higher IgE-binding capacity at 120 MPa than that at 80 and 160 MPa when the +¦-Lg</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôgalactose mixture was treated by DHPM. Results of thermal properties, intrinsic fluorescence spectroscopy, surface hydrophobicity, and circular dichroism (CD) spectra indicated the occurrence of protein unfolding, as well as the tertiary and secondary structural changes of +¦-Lg. The results suggested pretreatment by DHPM and glycation with galactose was a promising approach for eliminating the IgE-binding capacity of +¦-Lg</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2016.10.020</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodres.2016.10.020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\20161031-ChenY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\20161031-ChenY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Chen Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2016.10.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Londono-Renteria,B.</style></author><author><style face="normal" font="Arial"> Cardenas,J.C.</style></author><author><style face="normal" font="Arial"> Troupin,A.</style></author><author><style face="normal" font="Arial"> Colpitts,T.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine , Columbia, SC , USA</style></auth-address><titles><title><style face="normal" font="Arial">Natural Mosquito-Pathogen Hybrid IgG4 Antibodies in Vector-Borne Diseases: A Hypothesis</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="380">380-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> bispecific antibodies</style></keyword><keyword><style face="normal" font="Arial"> bispecific antibody</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Filariasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Malaria</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> Mosquito bites</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Chronic exposure to antigens may favor the production of IgG4 antibodies over other antibody types. Recent studies have shown that up to a 30% of normal human IgG4 is bi-specific and is able to recognize two antigens of different nature. A requirement for this specificity is the presence of both eliciting antigens in the same time and at the same place where the immune response is induced. During transmission of most vector-borne diseases, the pathogen is delivered to the vertebrate host along with the arthropod saliva during blood feeding and previous studies have shown the existence of IgG4 antibodies against mosquito salivary allergens. However, there is very little ongoing research or information available regarding IgG4 bi-specificity with regard to infectious disease, particularly during immune responses to vector-borne diseases, such as malaria, filariasis, or dengue virus infection. Here, we provide background information and present our hypothesis that IgG4 may not only be a useful tool to measure exposure to infected mosquito bites, but that these bi-specific antibodies may also play an important role in modulation of the immune response against malaria and other vector-borne diseases in endemic settings</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1664-3224 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2016.00380</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746778">PM:27746778</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2016-7-380.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2016-7-380.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Londono-Renteria B</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2016.00380</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hinge,V.</style></author><author><style face="normal" font="Arial"> Tidke,J.</style></author><author><style face="normal" font="Arial"> Das,B.</style></author><author><style face="normal" font="Arial"> Bhute,S.</style></author><author><style face="normal" font="Arial"> Parab,P.</style></author><author><style face="normal" font="Arial"> Apte,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Air pollution exacerbates effect of allergenic pollen proteins of Cassia siamea: a preliminary report</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="154" start="147">147-154</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cassia</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte Count</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white blood cell</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">Pollinosis caused by several allergenic proteins in pollen grains has been a major problem of healthcare in most parts of the world. Environmental factors such as air pollution are known to alter the release of allergenic pollen proteins from a variety of the plant species. Cassia siamea is commonly planted along roadsides and in industrialised areas in many parts of India. The present study reports the findings of animal experiments demonstrating the effect of air pollution on the allergenicity of Cassia siamea pollen proteins. Total white blood cell (WBC) count and lymphocyte count were significantly higher in animals that received protein extract of pollen collected from a polluted site compared to those that received protein extract of pollen collected from a non-polluted site. This was concomitant with increased production of IgE antibodies; followed by marked degranulation of mast cell leading to heighten type I hypersensitivity in these animals. These results are important for the development of a consensus linking ever-increasing pollution due to industrialisation and an increase in associated pollinosis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2016.1193221</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2016.1193221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\2017-56-147-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Grana\2017-56-147-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Hinge V</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2016.1193221</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maya Manzano,J.M.</style></author><author><style face="normal" font="Arial"> Fernandez Rodriguez,S.</style></author><author><style face="normal" font="Arial"> Vaquero Del Pino,C.</style></author><author><style face="normal" font="Arial"> Gonzalo Garijo,A.</style></author><author><style face="normal" font="Arial"> Silva Palacios,I.</style></author><author><style face="normal" font="Arial"> Tormo Molina,R.</style></author><author><style face="normal" font="Arial"> Moreno Corchero,A.</style></author><author><style face="normal" font="Arial"> Cosmes Martin,P.M.</style></author><author><style face="normal" font="Arial"> Blanco Perez,R.M.</style></author><author><style face="normal" font="Arial"> Dominguez Noche,C.</style></author><author><style face="normal" font="Arial"> Fernandez Moya,L.</style></author><author><style face="normal" font="Arial"> Alfonso Sanz,J.V.</style></author><author><style face="normal" font="Arial"> Vaquero Perez,P.</style></author><author><style face="normal" font="Arial"> Perez Marin,M.L.</style></author><author><style face="normal" font="Arial"> Rapp,A.</style></author><author><style face="normal" font="Arial"> Rojo,J.</style></author><author><style face="normal" font="Arial"> Perez-Badia,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Variations in airborne pollen in central and south-western Spain in relation to the distribution of potential sources</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="239" start="228">228-239</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Badajoz</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> Volumetric spore trap</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">The present study seeks to compare daily and hourly airborne pollen concentrations at eight different stations in Castilla-La Mancha (central Spain) and Extremadura (south-western Spain) and assess pollen distribution sources. Sampling stations were located 69?440-ákm apart in a straight line in Albacete, Toledo, Talavera de la Reina and Ciudad Real in Castilla-La Mancha, and in Badajoz, Plasencia, Santa Amalia and Zafra in Extremadura. Airborne pollen was collected using Hirst-type volumetric spore traps. Quercus was the most abundant pollen type at all stations except for Ciudad Real, where Olea pollen predominated. Comparisons of daily data between pairs of stations revealed statistically significant positive correlations in all cases for Poaceae and Olea. Comparisons of hourly data between stations indicated greater differences than daily data. Analysis of correlation coefficients and straight-line distances between stations revealed a strong negative correlation. Analysis of total airborne pollen data for the eight sampling stations suggests that airborne pollen concentrations decrease from west to east and from south to north, partly reflecting dominant wind patterns. A clear correlation was observed between airborne pollen concentrations and the surface area covered by olive crops in a 50-ákm radius around the sampling stations</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2016.1208680</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2016.1208680</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\2017-56-228-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\2017-56-228-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Maya Manzano JM</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2016.1208680</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oliveira,D.</style></author><author><style face="normal" font="Arial"> Lopes de Carvalho,C.A.</style></author><author><style face="normal" font="Arial"> Geni da Silva,S.</style></author><author><style face="normal" font="Arial"> Fidelis da Paixao,J.</style></author><author><style face="normal" font="Arial"> Alves de Oliveira,R.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Partitioning of pollen resources by two stingless bee species in the north Bahia, Brazil</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="293" start="285">285-293</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Eucalyptus</style></keyword><keyword><style face="normal" font="Arial"> Fabaceae</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Vegetation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">Analysing the pollen stored by stingless bees allows identification of the diversity of flowering plants visited by these bees while collecting resources during a given period. However, few studies have focused on investigating the sharing of resources between species of native bees that coexist in transitional plant formations, which support conservation efforts and increase colony productivity. This study aims to describe the partitioning of pollen resources among colonies of two species of stingless bees in the state of the Bahia (Brazil) through the analysis of stored pollen. The study was conducted in neighbouring vegetation zones of the relevant species Melipona quadrifasciata anthidioides and Melipona scutellaris by collecting monthly pollen samples stored by three colonies of each species over one-áyear. The collected samples were treated using the acetolysis technique, and the partitioning of pollen resources between the two species was investigated through quali-quantitative analysis of the treated pollen. The results show that among the 16 pollen types belonging to a particular species or group identified in the Melipona quadrifasciata anthidioides samples and the 18 identified in the Melipona scutellaris samples, 13 were shared by both species. The two most common pollen types stored by both species were from Mimosa arenosa (Fabaceae, Mimosoidae) and Eucalyptus sp. (Myrtaceae). These results demonstrate the niche similarity of pollen pasture between these two species and suggest that conservation efforts for these bee species should focus on the plant families most visited by bees</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">doi: 10.1080/00173134.2016.1217040</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2016.1217040</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\2017-56-285-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Grana\2017-56-285-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Oliveira D</style></custom2><misc3><style face="normal" font="Arial">doi: 10.1080/00173134.2016.1217040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Messora,R.</style></author><author><style face="normal" font="Arial"> Florenzano,A.</style></author><author><style face="normal" font="Arial"> Torri,P.</style></author><author><style face="normal" font="Arial"> Mercuri,A.M.</style></author><author><style face="normal" font="Arial"> Muzzalupo,I.</style></author><author><style face="normal" font="Arial"> Arru,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Morphology and discrimination features of pollen from Italian olive cultivars (Olea europaea L.)</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="214" start="204">204-214</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> olive pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> pollen morphology</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">Pollen morphology of 14 cultivars of Olea europaea subsp. europaea var. europaea was analysed in order to discriminate main pollen types. The cultivars were selected from the most spread and early flowering crops grown in Italy. Morphometric parameters were observed on acetolysed pollen by means of light microscopy and scanning electron microscopy. Polar axis (P), equatorial diameter (E), P/E ratio, maximum distance between colpi in mesocolpium, distance between the apices of two colpi, exine thickness, maximum length of lumina in mesocolpium and in apocolpium, and exine reticulum thickness in mesocolpium have been measured. According to P and E, the 14 olive cultivars of this study can be divided into the three groups of small (P: 21.75-á-Ám, E: 22.55-á-Ám; ?Manna? and ?Tonda di Cagliari?), large (P: 25.1-á-Ám, E: 26.1-á-Ám; ?Pescarese? and ?Rotondella di Sanza?) and medium size (P: 23.49-á-Ám, E: 24.54-á-Ám, ?Carolea?, ?Grossa di Cassano?, ?Giarraffa?, ?Nocellara messinese?, ?Nocellara del Belice?, ?Santagatese?, ?Intosso?, ?Maiatica di Ferrandina?, ?Nostrale di Fiano Romano?, ?Santa Caterina?). Maximum length of lumina and exine thickness are useful parameters for further distinction of olive pollen groups, since these parameters are able to provide a specific pollen profile for each cultivar</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2016.1216594</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2016.1216594</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\2017-56-204-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\2017-56-204-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Messora R</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2016.1216594</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Dippold,N.</style></author><author><style face="normal" font="Arial"> Sperl,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zentrum fur Rhinologie und Allergologie, An den Quellen 10, 65183, Wiesbaden, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Insect venom allergies : Update 2016 for otorhinolaryngologists]</style></title><secondary-title><style face="normal" font="Arial">HNO</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">HNO</style></full-title></periodical><pages end="942" start="927">927-942</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergies</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergy</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rapid desensitization</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="27" Month="10" Year="2016">2016/10/27</year></dates><abstract><style face="normal" font="Arial">Due to the increasing incidence of hymenoptera venom allergies and the potentially life-threatening reactions, it is important for otolaryngologists working in allergology to have an understanding of modern diagnostic and treatment standards for this allergic disease. Molecular diagnosis with recombinant single allergens from bee and wasp venom components improves the diagnostics of insect venom allergies, particularly in patients with double-positive extract-based test results. Detection of specific sensitizations to bee or wasp venom enables double sensitizations to be better distinguished from cross-reactivity. Based on patient history and test results, the patient is initially advised on avoidance strategies and prescribed an emergency medication kit. Then, the indication for allergen-specific immunotherapy (AIT) is evaluated. The dose-increase phase can be performed using conventional, cluster, rush, or ultra-rush schedules, whereby rapid desensitization (rush AIT) performed in the clinic seems to be particularly effective as initial treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161027IS - 1433-0458 (Electronic)IS - 0017-6192 (Linking)LA - GERPT - Journal ArticlePT - English AbstractCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00106-016-0274-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27787580">PM:27787580</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\HNO\20161027-KlimekL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\HNO\20161027-KlimekL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161027, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00106-016-0274-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caleffi da Costa Lima Caniatti,M.</style></author><author><style face="normal" font="Arial"> Donizete Borelli,S.</style></author><author><style face="normal" font="Arial"> Lucia Falavigna,G.A.</style></author><author><style face="normal" font="Arial"> Tamie,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Post-Graduate Program in Health Sciences, Universidade Estadual de Maringa (UEM), Maringa - PR, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">ASSOCIATION BETWEEN HLA GENES AND DUST MITE SENSITIVITY IN A BRAZILIAN POPULATION</style></title><secondary-title><style face="normal" font="Arial">Hum Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Immunol</style></full-title></periodical><pages end="94" start="88">88-94</pages><volume><style face="normal" font="Arial">78</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> HLA class II</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Type I hypersensitivity, also known as IgE-mediated allergy, is a complex, multifactorial condition whose onset and severity are influenced by both genetic and environmental factors. Mite allergens stimulate the production of humoral response (IgE), especially in children, which is closely involved in atopic asthma and rhinitis. OBJECTIVE: This study aimed to investigate the association between HLA class I (-A, -B, and -C), and HLA class II (-DRB1) genes in individuals sensitive to dust mites (Dermatophagoides farinae, Dermatophagoides pteronyssinus, or Blomia tropicalis) and mite-insensitive controls. METHODS: 396 participants were grouped as mite-sensitive and mite-insensitive according to immediate hypersensitivity as determined by skin-prick tests, and to HLA genotyping by polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO). RESULTS: After chi-square heterogeneity testing no significant differences were observed in HLA-A, B, and C genes, except for the HLA-DRB1 locus, which, showed a negative association for DRB1 *04, between mite-sensitive and mite-insensitive individuals. In high resolution, DRB1 *04:11 allele was significantly different from all other results (P = 0.0042, OR = 0.26, and 95%CI = 0.09 - 0.70). The analysis stratified by etiologic agent confirmed these associations. CONCLUSION: Our results suggest a possible association between HLA-DRB1 genes and hypersensitivity to dust mites</style></abstract><notes><style face="normal" font="Arial">DA - 20161026IS - 1879-1166 (Electronic)IS - 0198-8859 (Linking)LA - ENGPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.humimm.2016.10.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27780790">PM:27780790</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\20161026-CaleffidaCostaLimaCaniattiMpdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\20161026-CaleffidaCostaLimaCaniattiMpdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161016, Caleffi da Costa Lima Caniatti M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.humimm.2016.10.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harish Babu,B.N.</style></author><author><style face="normal" font="Arial"> Wilfred,A.</style></author><author><style face="normal" font="Arial"> Venkatesh,Y.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Emerging food allergens: Identification of polyphenol oxidase as an important allergen in eggplant (Solanum melongena L.)</style></title><secondary-title><style face="normal" font="Arial">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunobiology</style></full-title></periodical><pages end="163" start="155">155-163</pages><volume><style face="normal" font="Arial">222</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antiserum</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Copper</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> eggplant</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE Binding Ability</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope prediction</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding ability</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> In silico analysis</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol oxidase</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein-bound copper</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0171-2985</style></isbn><abstract><style face="normal" font="Arial">Although many allergens have been detected in eggplant (Solanum melongena L.), their identity have not been elucidated. The aim of this study was to investigate whether polyphenol oxidase (PPO), an important eggplant enzyme, acts as an allergen. The proteins of eggplant peel extract were separated on phenyl-Sepharose (PS), and analyzed by skin prick test (SPT), ELISA and IgE-immunoblotting; the components were analyzed for PPO activity, presence of protein</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôbound copper, and recognition by rabbit polyclonal anti-sweet potato PPO antiserum. LC</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôMS/MS and in silico analysis were employed to identify the separated allergens and prediction of IgE epitopes. Eggplant allergens were separated into 5 components (PS1</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôPS5), of which component PS2 exhibited high specific PPO activity. SPT and ELISA with PPO-rich pool (PS2) were positive in all 6 eggplant-allergic subjects; the 43, 64 and 71 kDa proteins displayed strong IgE-binding ability. The 64 and 71 kDa IgE-binding proteins show PPO activity, presence of copper, and recognition by anti-sweet potato PPO antiserum, clearly identifying them as PPOs; the 43 kDa protein appears to be a degradation product of the 64 or 71 kDa proteins based on enzymic activity and recognition by PPO antiserum. The 64 kDa protein upon further resolution by SDS-PAGE displayed two components (identified as eggplant PPO1 and PPO4 by LC</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôMS/MS). Based on bioinformatics approaches, PPO4 has been identified as an allergen since it harbors an IgE epitope. This study clearly demonstrates that the 64 and 71 kDa allergens in eggplant peel are PPOs based on enzymic activity and recognition by PPO antiserum; the 64 kDa copper-containing protein is identified as one of the several eggplant allergens (Sola m PPO4). This is the first instance of polyphenol oxidase being identified as a new food allergen</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imbio.2016.10.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28164808">PM:28164808</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunobiology\20161031-Harish BabuBN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunobiology\20161031-Harish BabuBN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Harish Babu BN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imbio.2016.10.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Swami,T.</style></author><author><style face="normal" font="Arial"> Pannu,S.</style></author><author><style face="normal" font="Arial"> Kumar,M.</style></author><author><style face="normal" font="Arial"> Gupta,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, S.P. Medical College, Bikaner, Rajasthan, India</style></auth-address><titles><title><style face="normal" font="Arial">Chronic invasive fungal rhinosinusitis by Paecilomyces variotii: A rare case report</style></title><secondary-title><style face="normal" font="Arial">Indian J Med Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Med Microbiol</style></full-title></periodical><pages end="106" start="103">103-106</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Mucor</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Paecilomyces</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Soil</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword></keywords><dates><year Day="0" Month="1" Year="2016">2016/1</year></dates><abstract><style face="normal" font="Arial">Fungal infection of the paranasal sinuses is an increasingly recognised entity, both in normal and immunocompromised individuals. The recent increase in mycotic nasal and paranasal infections is due to both improved diagnostic research and an increase in the conditions that favour fungal infection. Aspergillus, Candida, and Mucor species are the most common causative agents of fungal sinusitis, but infection with lesser known species have been reported across the world infrequently. This article reviews and presents a case report of chronic fungal sinusitis in an immunocompetent adult male infected with Paecilomyces variotii which is opportunistic soil saprophyte, uncommon to humans</style></abstract><notes><style face="normal" font="Arial">DA - 20160118IS - 1998-3646 (Electronic)IS - 0255-0857 (Linking)LA - ENGPT - Case ReportsPT - Journal ArticlePT - ReviewSB - IMCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0255-0857.174126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26776131">PM:26776131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Med Microbiol\2016-34-103-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Med Microbiol\2016-34-103-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160118, Swami T</style></custom2><misc3><style face="normal" font="Arial">10.4103/0255-0857.174126</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yoneda,M.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author><author><style face="normal" font="Arial"> Kajiyama,H.</style></author><author><style face="normal" font="Arial"> Kawabe,S.</style></author><author><style face="normal" font="Arial"> Paiz,J.</style></author><author><style face="normal" font="Arial"> Ward,J.M.</style></author><author><style face="normal" font="Arial"> Kimura,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Md., USA</style></auth-address><titles><title><style face="normal" font="Arial">Secretoglobin Superfamily Protein SCGB3A2 Alleviates House Dust Mite-Induced Allergic Airway Inflammation in Mice</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="44" start="36">36-44</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> CCR4</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Secretoglobin (SCGB) 3A2, a novel, lung-enriched, cytokine-like, secreted protein of small molecular weight, was demonstrated to exhibit various biological functions including anti-inflammatory, antifibrotic and growth-factor activities. Anti-inflammatory activity was uncovered using the ovalbumin-induced allergic airway inflammation model. However, further validation of this activity using knockout mice in a different allergic inflammation model is necessary in order to establish the antiallergic inflammatory role for this protein. METHODS: Scgb3a2-null (Scgb3a2-/-) mice were subjected to nasal inhalation of Dermatophagoides pteronyssinus extract for 5 days/week for 5 consecutive weeks; control mice received nasal inhalation of saline as a comparator. Airway inflammation was assessed by histological analysis, the number of inflammatory cells and various Th2-type cytokine levels in the lungs and bronchoalveolar lavage fluids by qRT-PCR and ELISA, respectively. RESULTS: Exacerbated inflammation was found in the airway of Scgb3a2-/- mice subjected to house dust mite (HDM)-induced allergic airway inflammation compared with saline-treated control groups. All the inflammation end points were increased in the Scgb3a2-/- mice. The Ccr4 and Ccl17 mRNA levels were higher in HDM-treated lungs of Scgb3a2-/- mice than wild-type mice or saline-treated Scgb3a2-/- mice, whereas no changes were observed for Ccr3 and Ccl11 mRNA levels. CONCLUSIONS: These results demonstrate that SCGB3A2 has an anti-inflammatory activity in the HDM-induced allergic airway inflammation model, in which SCGB3A2 may modulate the CCR4-CCL17 pathway. SCGB3A2 may provide a useful tool to treat allergic airway inflammation, and further studies on the levels and function of SCGB3A2 in asthmatic patients are warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000450788</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27820933">PM:27820933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-36-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-36-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Yoneda M</style></custom2><misc3><style face="normal" font="Arial">10.1159/000450788</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Koehler,C.</style></author><author><style face="normal" font="Arial"> Paulus,M.</style></author><author><style face="normal" font="Arial"> Ginzkey,C.</style></author><author><style face="normal" font="Arial"> Hackenberg,S.</style></author><author><style face="normal" font="Arial"> Scherzad,A.</style></author><author><style face="normal" font="Arial"> Ickrath,P.</style></author><author><style face="normal" font="Arial"> Hagen,R.</style></author><author><style face="normal" font="Arial"> Kleinsasser,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Oto-Rhino-Laryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University Hospital of Wurzburg, Wurzburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">The Proinflammatory Potential of Nitrogen Dioxide and Its Influence on the House Dust Mite Allergen Der p 1</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="35" start="27">27-35</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> air-liquid interface</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Asthma and allergies are both major global health problems with an increasing prevalence, and environmental data implicate an influence of air pollutants on their development. The present study focuses on the influence of nitrogen dioxide (NO2) and the major allergen of the house dust mite Der p 1 on human nasal epithelial cells of nonallergic patients in vitro. Nasal epithelial mucosa samples of 11 donors were harvested during nasal air passage surgery and cultured as an air-liquid interface. Exposure to 0.1, 1 and 10 ppm NO2 or synthetic air as a control was performed for 1 h. Subsequently, the cells were exposed to Der p 1 for 24 h. The release of interleukin (IL)-6 and IL-8 was measured by ELISA, and the production of IL-6 mRNA and IL-8 mRNA was measured by RT-PCR. NO2 exposure resulted in a concentration-dependent release of IL-6, but not IL-8 release. The coexposure of 0.1 ppm NO2 and Der p 1, or 1 ppm NO2 and Der p 1 significantly increased both IL-6 and IL-8 release. Exposure to NO2, Der p 1, or their combination, did not significantly influence the production of IL-6 or IL-8 mRNA. In conclusion, NO2 increases the release of inflammatory cytokines in human nasal epithelial cells, especially in coexposure with Der p 1, as a mechanism of allergotoxicology</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000450751</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27820923">PM:27820923</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-27-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-27-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Koehler C</style></custom2><misc3><style face="normal" font="Arial">10.1159/000450751</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,H.K.</style></author><author><style face="normal" font="Arial"> Song,C.H.</style></author><author><style face="normal" font="Arial"> Bae,Y.S.</style></author><author><style face="normal" font="Arial"> Im,S.Y.</style></author><author><style face="normal" font="Arial"> Lee,H.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Chonbuk National University Medical School, Jeonju, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Glutamine Prevents Late-Phase Anaphylaxis via MAPK Phosphatase 1-Dependent Cytosolic Phospholipase A2 Deactivation</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="70" start="61">61-70</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glutamine</style></keyword><keyword><style face="normal" font="Arial"> Hematocrit</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> PAF</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> small interfering RNA</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cytosolic phospholipase A2 (cPLA2) plays a key role in the development of late-phase anaphylaxis. L-Glutamine (Gln), a nonessential amino acid, has anti-inflammatory activity via inhibiting cPLA2. METHODS: We used a penicillin-induced murine model of anaphylaxis, and late-phase anaphylaxis was quantified by measuring the increase in the hematocrit (Ht) value. Various inhibitors, small interfering RNA, and knockout mice were used in inhibition experiments. Phosphorylation and protein expression of cPLA2, ERK, and MAPK phosphatase 1 (MKP-1) were detected by Western blotting. RESULTS: Leukotriene (LT) B4 was found to be another potent inducer of late-phase anaphylaxis besides the known mediator platelet-activating-factor (PAF). Gln efficiently prevented late-phase anaphylaxis when it was administered up to 3 h after challenge injection via inhibiting cPLA2. Inhibition studies indicated that p38 MAPK was the major upstream regulator of cPLA2. Gln dephosphorylated p38 and cPLA2 via up-regulating the negative regulator of p38 MAPK, i.e., MKP-1 protein. MKP-1 blockade abrogated all the effects of Gln. CONCLUSION: Of the cPLA2 metabolites, PAF and LTB4 play a key role in the development of late-phase anaphylaxis, and Gln prevents the reaction via MKP-1-dependent deactivation of cPLA2</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1159/000452103</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838690">PM:27838690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-61-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-61-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Kim HK</style></custom2><misc3><style face="normal" font="Arial">10.1159/000452103</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moutsoglou,D.M.</style></author><author><style face="normal" font="Arial"> Dreskin,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology and Departments of Medicine and Immunology, University of Colorado Denver, Aurora, Colo., USA</style></auth-address><titles><title><style face="normal" font="Arial">Prolonged Treatment of Peanut-Allergic Mice with Bortezomib Significantly Reduces Serum Anti-Peanut IgE but Does Not Affect Allergic Symptoms</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="261" start="257">257-261</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> antibody secreting cell</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="10" Year="2016">2016/10/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anti-peanut immunoglobulin E (anti-Pn IgE) can persist throughout life, suggesting that this condition could be maintained by long-lived antibody-secreting cells (ASCs). To determine the role of long-lived ASCs, peanut-allergic mice underwent prolonged treatment with the proteasome inhibitor, bortezomib (Bz). METHODS: Intravenous Bz was given twice weekly for 21 weeks to peanut-allergic mice. During treatment, serum anti-Pn IgE was measured, and the mice were rechallenged at the end of treatment. Cell populations were measured, and Pn-specific IgG, total IgG, and total IgE ASCs were enumerated in the bone marrow (BM) and spleen (SPL). RESULTS: Prolonged treatment with Bz significantly reduced serum anti-Pn IgE and IgG1 but did not affect symptoms following challenge with Pn, even in mice with undetectable serum anti-Pn IgE. Numbers of CD138+ cells were significantly reduced in the BM but were unaffected in the SPL. Unexpectedly, Bz did not affect numbers of Pn-specific IgG, total IgG, or total IgE ASCs in either the BM or SPL. CONCLUSIONS: Cells that maintain long-lived serum anti-Pn IgE are sensitive to Bz. However, prolonged depletion of serum Pn-specific IgE does not result in a decrease of symptoms following challenge with Pn</style></abstract><notes><style face="normal" font="Arial">DA - 20161005IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000449247</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27705966">PM:27705966</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-257-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-257-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161005, Moutsoglou DM</style></custom2><misc3><style face="normal" font="Arial">10.1159/000449247</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Netchiporouk,E.</style></author><author><style face="normal" font="Arial"> Moreau,L.</style></author><author><style face="normal" font="Arial"> Rahme,E.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Lejtenyi,D.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease Activity</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="88" start="81">81-88</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> physical urticaria</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The basophil activation test (BAT) using CD63 expression is a sensitive and specific tool for the diagnostic workup of autoimmune chronic spontaneous urticaria (CSU). The definition of a positive BAT is directly dependent on the reference range and the cutoff values established in control populations. As of now, the pediatric reference range and cutoff values of the CD63 BAT remain to be established. METHODS: In this study, we analyzed CD63 expression in 80 children (1-17 years old) without chronic urticaria (i.e., controls) and compared the values to those of a pediatric cohort of 105 CSU patients and 23 physical urticaria (PU) patients. RESULTS: Based on the log-normal distribution of CD63 values in control subjects, the reference range and the cutoff for positive CD63 BAT values was established to be 1.2-1.8% (95% CI) and 1.8%, respectively. Children with CSU showed significantly elevated and significantly increased BAT values compared to healthy controls (Wilcoxon rank test p value &lt;0.001). In contrast, no difference was found between BAT results in controls and PU patients. In pediatric CSU patients, a higher disease activity was associated with higher BAT values. CONCLUSIONS: Our study provides, for the first time, reference and cutoff values for the CD63 BAT in children. Our findings show that positive CD63 BAT are common in children with CSU and linked to a high disease activity</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000451084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27846634">PM:27846634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-81-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-81-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Netchiporouk E</style></custom2><misc3><style face="normal" font="Arial">10.1159/000451084</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moreno,A.S.</style></author><author><style face="normal" font="Arial"> McPhee,R.</style></author><author><style face="normal" font="Arial"> Arruda,L.K.</style></author><author><style face="normal" font="Arial"> Howell,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="80" start="71">71-80</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 axis</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects up to 25% of children and 10% of adults. The skin of patients with moderate to severe AD is characterized by significant barrier disruption and T helper 2 (Th2)-driven inflammation, which are thought to play a significant role in the pathogenesis of AD. Current management of AD is aimed at suppressing the inflammatory response and restoring the barrier function of the skin, reducing exacerbations, and preventing secondary skin infections. Combinations of treatment strategies are used to alleviate the symptoms of the disease; however, resolution is often temporary, and long-term usage of some of the medications for AD can be associated with significant side effects. Antibody therapies previously approved for other inflammatory diseases have been evaluated in patients with AD. Unfortunately, they have often failed to result in significant clinical improvement. Monoclonal antibodies and novel small molecules currently in development may provide more consistent benefit to patients with AD by specifically targeting the immune and molecular pathways important for the pathogenesis of AD. Here we review the state-of-the-art therapeutics targeting the Th2 axis in AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1159/000451083</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27846627">PM:27846627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-71-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-71-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Moreno AS</style></custom2><misc3><style face="normal" font="Arial">10.1159/000451083</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Twaroch,T.E.</style></author><author><style face="normal" font="Arial"> Curin,M.</style></author><author><style face="normal" font="Arial"> Sterflinger,K.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> Swoboda,I.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Specific Antibodies for the Detection of Alternaria Allergens and the Identification of Cross-Reactive Antigens in Other Fungi</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="278" start="269">269-278</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alt a 1</style></keyword><keyword><style face="normal" font="Arial"> Alt a 2</style></keyword><keyword><style face="normal" font="Arial"> Alt a 3</style></keyword><keyword><style face="normal" font="Arial"> Alt a 6</style></keyword><keyword><style face="normal" font="Arial"> Alt a 8</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus niger</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Penicillium chrysogenum</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergens</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> synthetic peptides</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The mould Alternaria alternata is an important source of respiratory allergens. A. alternata extracts show great variations regarding allergenic potency. The aim of this study was to generate antibody probes specific for important Alternaria allergens and to use them to study allergen expression, depending on different culture conditions, as well as to search for cross-reactive allergens in other mould species. METHODS: Synthetic peptides from antigenic regions of A. alternata allergens (Alt a 1, Alt a 2, Alt a 3, Alt a 6 and Alt a 8) were used to raise highly specific rabbit antibodies. These antibodies and IgE from allergic patients were used to detect allergens by immunoblotting in extracts of 4 A. alternata strains grown under varying culturing conditions, in commercial skin-prick extracts and in closely (Cladosporium herbarum and Aureobasidium pullulans) or distantly related (Aspergillus niger and Penicillium chrysogenum) mould species. RESULTS: There was a wide variation of expression of the individual A. Alternata allergens, depending on the strain and culture conditions, but the antibody probes allowed us to distinguish strains and culture conditions with low and high allergen expression. In the commercial skin-prick solutions, varying levels of Alt a 1 were found, but no other allergens were detectable. Alt a 1 was identified as species-specific A. Alternata allergen, whereas Alt a 3, 6- and Alt a 8-cross-reactive antigens were found in C.herbarum and/or A. pullulans. CONCLUSIONS AND CLINICAL RELEVANCE: Peptide-specific antibodies are useful to analyze diagnostic and therapeutic mould extracts, to study the presence of A. Alternata allergens in biological samples and to search for cross-reactive allergens in other mould species</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000449415</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27780168">PM:27780168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-269-78.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-170-269-78.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Twaroch TE</style></custom2><misc3><style face="normal" font="Arial">10.1159/000449415</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liang,Z.</style></author><author><style face="normal" font="Arial"> Nie,H.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Peng,J.</style></author><author><style face="normal" font="Arial"> Zeng,Y.</style></author><author><style face="normal" font="Arial"> Wei,Y.</style></author><author><style face="normal" font="Arial"> Wen,X.</style></author><author><style face="normal" font="Arial"> Qiu,J.</style></author><author><style face="normal" font="Arial"> Zhong,W.</style></author><author><style face="normal" font="Arial"> Deng,X.</style></author><author><style face="normal" font="Arial"> He,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Animal Science and Technology, Guangxi University, Nanning, Guangxi 530005, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic effects of rosmarinic acid on airway responses in a murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="97" start="90">90-97</pages><volume><style face="normal" font="Arial">41</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> E-Selectin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> traditional Chinese herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Rosmarinic acid (RA) is an active component of a traditional Chinese herbal medicine. Previously, we reported that RA exerted a strong anti-inflammatory effect in a mouse acute lung injury model. Therefore, we hypothesized that RA might also have potential therapeutic effects in a murine model of asthma. In this study, we aimed to evaluate the anti-asthmatic activity of RA and explored its possible molecular mechanisms of action. Female BALB/c mice that had been sensitized to and challenged with ovalbumin (Ova) were treated with RA (20mg/kg) 1h after challenge. The results showed that RA greatly diminished the number of inflammatory cells and the production of Th2 cytokines in the bronchoalveolar lavage fluid (BALF); significantly reduced the secretion of total IgE, Ova-specific IgE, and eotaxin; and markedly ameliorated airway hyperresponsiveness (AHR) compared with Ova-induced mice. Histological studies further revealed that RA substantially decreased inflammatory cells infiltration and mucus hypersecretion compared with Ova-induced mice. Moreover, our results suggested that the protective effects of RA were mediated by the inhibition of JNK and p38 MAPK phosphorylation and nuclear factor-kappaB (NF-kappaB) activation. Furthermore, RA treatment resulted in a significant reduction in the mRNA expression of AMCase, CCL11, CCR3, Ym2 and E-selectin in lung tissue. These findings suggest that RA may effectively delay the development of airway inflammation and could thus be used as a therapy for allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161108IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2016.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27825045">PM:27825045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2016-41-90-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2016-41-90-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161108, Liang Z</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2016.10.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahmoud,K.H.</style></author><author><style face="normal" font="Arial"> Alzolibani,A.A.</style></author><author><style face="normal" font="Arial"> Rasheed,Z.</style></author><author><style face="normal" font="Arial"> Farouk,Y.</style></author><author><style face="normal" font="Arial"> Saif,G.B.</style></author><author><style face="normal" font="Arial"> Al Robaee,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, College of Medicine, Qassim University, Buraidah, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="Arial">Interleukin-4 and interferon-gamma are possible allergic markers in pediatric patients with beta-lactam hypersensitivity</style></title><secondary-title><style face="normal" font="Arial">Int J Appl Basic Med Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Appl Basic Med Res</style></abbr-1></periodical><pages end="281" start="276">276-281</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="Arial"> betalactam</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Intradermal testing</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: beta-lactam agents are known to elicit T-cell-mediated immune responses that play a central role in the onset of allergic reactions, but the involvement of specific type of cytokines in drug allergy remains largely unexplored in humans. OBJECTIVES: This study was undertaken to investigate the role of cytokines involvement in pediatric patients with beta-lactam hypersensitivity and to determine whether involvement of cytokines in drug-mediated reactions are important for the perspective of allergic patient's management. METHODS: beta-lactam-induced hypersensitivity reactions in eighty pediatric patients were determined by clinical manifestations and skin prick or intradermal testing. Production of T-helper (Th) type-1 cytokine interferon (INF)-gamma, Th-2 cytokine interleukin (IL)-4, regulatory T-cell cytokine IL-10, and other cytokines IL-6 and IL-12 were determined by sandwich ELISAs. RESULTS: Diagnosis of beta-lactam allergy was confirmed in 53 pediatric patients. IL-4 secretion in patients' sera was significantly higher as compared with healthy controls (P &lt; 0.05). However, INF-gamma level in patients' sera was significantly lower as compared with controls (P &lt; 0.05). No significant alterations were found in the protein secretion of IL-10, IL-12, and IL-6 in allergic patients as compared with controls (P > 0.05). CONCLUSION: We conclude that IL-4 is specific marker for the diagnosis of beta-lactam-induced hypersensitivity. Moreover, IL-4 in combination with INF-gamma is more sensitive for the diagnosis of these reactions. This study also concludes that both IL-4 and INF-gamma may play an active role in the onset of allergic reactions against beta-lactam antibiotics</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 2229-516X (Print)IS - 2229-516X (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.4103/2229-516X.192595</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27857897">PM:27857897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Appl Basic Med Res\2016-6-276-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Appl Basic Med Res\2016-6-276-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Mahmoud KH</style></custom2><misc3><style face="normal" font="Arial">10.4103/2229-516X.192595</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stepalska,D.</style></author><author><style face="normal" font="Arial"> Myszkowska,D.</style></author><author><style face="normal" font="Arial"> Katarzyna,L.</style></author><author><style face="normal" font="Arial"> Katarzyna,P.</style></author><author><style face="normal" font="Arial"> Katarzyna,B.</style></author><author><style face="normal" font="Arial"> Kazimiera,C.</style></author><author><style face="normal" font="Arial"> Lukasz,G.</style></author><author><style face="normal" font="Arial"> Idalia,K.</style></author><author><style face="normal" font="Arial"> Barbara,M.W.</style></author><author><style face="normal" font="Arial"> Malgorzata,M.</style></author><author><style face="normal" font="Arial"> Malgorzata,N.</style></author><author><style face="normal" font="Arial"> Krystyna,P.W.</style></author><author><style face="normal" font="Arial"> Malgorzata,P.</style></author><author><style face="normal" font="Arial"> Elzbieta,W.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Botany, Jagiellonian University, Krakow, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Co-occurrence of Artemisia and Ambrosia pollen seasons against the background of the synoptic situations in Poland</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="760" start="747">747-760</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Asteraceae</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The Asteraceae family is one of the largest families, comprising 67 genera and 264 species in Poland. However, only a few genera, including Artemisia and Ambrosia are potential allergenic sources. The aim of the study was to estimate how often and to what degree Artemisia and Ambrosia pollen seasons co-occur intensifying human health risk, and how synoptic situations influence frequency of days with high pollen concentrations of both taxa. Artemisia and Ambrosia pollen data were collected, using the volumetric method, at 8 sites in Poland. Daily concentrations of Artemisia pollen equal to 30 grains or more and Ambrosia pollen equal to 10 grains or more were accepted as high values. Concentrations of more than 10 pollen grains were defined as high in the case of Ambrosia because its allergenicity is considered higher. High concentrations were confronted with synoptic situations. Analysis was performed on the basis of two calendars on circulation types of atmosphere in Poland (Niedzwiedz, 2006, 2015). Co-occurrence of Artemisia and Ambrosia pollen seasons is being found most often, when Ambrosia pollen season starts in the first half of August. If it happens in the last 10 days of August high pollen concentrations of Artemisia and Ambrosia do not occur at the same days. At three sites (Sosnowiec, Rzeszow, Lublin) high Ambrosia pollen concentrations during the Artemisia pollen season appear more often than in other sites under question. The high Artemisia pollen concentrations occur, when continental or polar maritime old air masses inflow into Poland. The impact of air masses on high Ambrosia pollen concentrations depends on site localizations. It is likely, that in the south-eastern part of Poland high Ambrosia pollen concentrations result from the pollen transport from east-south-south-westerly directions and the local sources. Co-occurrence of both taxa pollen seasons depends on the air masses inflow and appears more often in a south-eastern part of Poland</style></abstract><notes><style face="normal" font="Arial">DA - 20161010IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-016-1254-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27722901">PM:27722901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\20161010-StepalskaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biometeorol\20161010-StepalskaD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Stepalska D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-016-1254-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Munetsugu,T.</style></author><author><style face="normal" font="Arial"> Igawa,K.</style></author><author><style face="normal" font="Arial"> Fujimoto,T.</style></author><author><style face="normal" font="Arial"> Shibama,S.</style></author><author><style face="normal" font="Arial"> Nishizawa,A.</style></author><author><style face="normal" font="Arial"> Yokozeki,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Tokyo Medical and Dental University, Graduate School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Cold-induced hyperhidrosis: possible association with hyper-IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="e43" start="e42">e42-e43</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - ENGPT - LETTERCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.13357</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27778332">PM:27778332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\20161025-MunetsuguT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\20161025-MunetsuguT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Munetsugu T</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.13357</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohamed,S.A.</style></author><author><style face="normal" font="Arial"> Elshal,M.F.</style></author><author><style face="normal" font="Arial"> Kumosani,T.A.</style></author><author><style face="normal" font="Arial"> Aldahlawi,A.M.</style></author><author><style face="normal" font="Arial"> Basbrain,T.A.</style></author><author><style face="normal" font="Arial"> Alshehri,F.A.</style></author><author><style face="normal" font="Arial"> Choudhry,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.</style></auth-address><titles><title><style face="normal" font="Arial">L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo</style></title><secondary-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></full-title></periodical><pages end="" start="E1008">E1008-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cell viability</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immunogenic properties</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> L-asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="10" Year="2016">2016/10/14</year></dates><abstract><style face="normal" font="Arial">Escherichia coli-derived L-asparaginases have been used in the treatment of acute lymphoblastic leukemia (ALL), however, clinical hypersensitivity reactions and silent inactivation due to antibodies against E. coli-asparaginase, lead to inactivation of these preparations in most cases.Therefore, this study was aimed to investigate the cytotoxicity and antitumor effects ofa novel L-asparaginaseenzyme, isolated from Phaseolus vulgaris seeds (P-Asp) on the ALL cell line (Jurkat). The immunogenicity of the enzyme was also evaluated in-vivo and results were compared to commercially available enzymes of microbial sources. The data demonstrated that P-Asp has an enhanced anti-proliferative effect on ALL cells as detected by the WST-8 cell viability assay kit. Cells treated with P-Asp also exhibited a higher degree of early apoptosis compared with asparaginase from Escherichia coli (L-Asp) or its pegylated form Pegasparagas (PEG-ASP) that induced higher rates of late apoptosis and necrosis as detected by an Annexin V/Propidium iodide binding assay. In-vivo experiments indicated that mice treated with P-Asp had less distinct allergenic responses than other bacterial enzyme preparations as indicated by lower serum concentrations of IgG, IgE, IgM and mMCP-1 compared with other treated groups. In conclusion, P-Asp can be considered as a promising candidate for use in the treatment of ALL</style></abstract><notes><style face="normal" font="Arial">DA - 20161018IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijerph13101008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27754445">PM:27754445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Environ Res Public Health\2016-13-E1008.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Environ Res Public Health\2016-13-E1008.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161018, Mohamed SA</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijerph13101008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kurai,J.</style></author><author><style face="normal" font="Arial"> Watanabe,M.</style></author><author><style face="normal" font="Arial"> Sano,H.</style></author><author><style face="normal" font="Arial"> Hantan,D.</style></author><author><style face="normal" font="Arial"> Tohda,Y.</style></author><author><style face="normal" font="Arial"> Shimizu,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Asian Dust Particles on the Early-Stage Antigen-Induced Immune Response of Asthma in NC/Nga Mice</style></title><secondary-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></full-title></periodical><pages end="" start="1144">1144-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antigen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocyte Count</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="Arial">Asian dust (AD) can aggravate airway inflammation in asthma, but the association between AD and the development of asthma remains unclear. This study aimed to investigate the effects of AD on the early stage of antigen sensitization using a mouse model of asthma, as well as the role of leukotrienes (LTs) in antigen-induced airway inflammation potentiated by AD particles. NC/Nga mice were co-sensitized by intranasal instillation of AD particles and/or Dermatophagoides farinae (Df) for five consecutive days. Df-sensitized mice were stimulated with an intranasal Df challenge at seven days. Mice were treated with the type 1 cysteinyl LT (CysLT(1)) receptor antagonist orally 4 h before and 1 h after the allergen challenge. At 24 h post-challenge, the differential leukocyte count, inflammatory cytokines, and LTs in bronchoalveolar lavage fluid were assessed, and airway inflammation was evaluated histopathologically. AD augmented neutrophilic and eosinophilic airway inflammation with increased CysLTs and dihydroxy-LT in a mouse model of asthma. The CysLT(1) receptor antagonist was shown to attenuate both neutrophilic and eosinophilic airway inflammation augmented by AD. Therefore, exposure to AD may be associated with the development of asthma and LTs may play important roles in airway inflammation augmented by AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijerph13111144</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27854355">PM:27854355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Environ Res Public Health\2016-13-1144.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Environ Res Public Health\2016-13-1144.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Kurai J</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijerph13111144</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,H.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Jin,M.</style></author><author><style face="normal" font="Arial"> Xie,H.</style></author><author><style face="normal" font="Arial"> He,S.</style></author><author><style face="normal" font="Arial"> Wei,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Molecular cloning, expression, IgE binding activities and in silico epitope prediction of Per a 9 allergens of the American cockroach</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Med</style></full-title></periodical><pages end="1805" start="1795">1795-1805</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> NetMHCII-2.2</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Per a 9</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Per a 9 is a major allergen of the American cockroach (CR), which has been recognized as an important cause of imunoglobulin E-mediated type I hypersensitivity worldwide. However, it is not neasy to obtain a substantial quantity of this allergen for use in functional studies. In the present study, the Per a 9 gene was cloned and expressed in Escherichia coli (E. coli) systems. It was found that 13/16 (81.3%) of the sera from patients with allergies caused by the American CR reacted to Per a 9, as assessed by enzyme-linked immunosorbent assay, confirming that Per a 9 is a major allergen of CR. The induction of the expression of CD63 and CCR3 in passively sensitized basophils (from sera of patients with allergies caused by the American CR) by approximately 4.2-fold indicated that recombinant Per a 9 was functionally active. Three immunoinformatics tools, including the DNAStar Protean system, Bioinformatics Predicted Antigenic Peptides (BPAP) system and the BepiPred 1.0 server were used to predict the potential B cell epitopes, while Net-MHCIIpan-2.0 and NetMHCII-2.2 were used to predict the T cell epitopes of Per a 9. As a result, we predicted 11 peptides (23-28, 39-46, 58-64, 91-118, 131-136, 145-154, 159-165, 176-183, 290-299, 309-320 and 338-344) as potential B cell linear epitopes. In T cell prediction, the Per a 9 allergen was predicted to have 5 potential T cell epitope sequences, 119-127, 194-202, 210-218, 239-250 and 279-290. The findings of our study may prove to be useful in the development of peptide-based vaccines to combat CR-induced allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 1791-244X (Electronic)IS - 1107-3756 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/ijmm.2016.2793</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27840974">PM:27840974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Med\2016-38-1795-805.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Med\2016-38-1795-805.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161114, Yang H</style></custom2><misc3><style face="normal" font="Arial">10.3892/ijmm.2016.2793</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tong,X.</style></author><author><style face="normal" font="Arial"> Guo,M.</style></author><author><style face="normal" font="Arial"> Jin,M.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Wei,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Geriatrics, Beijing Hospital, National Center of Gerontology, Beijing 100730, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">In silico epitope prediction, expression and functional analysis of Per a 10 allergen from the American cockroach</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Med</style></full-title></periodical><pages end="1814" start="1806">1806-1814</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Geriatrics</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> main allergens</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Per a 10</style></keyword><keyword><style face="normal" font="Arial"> Per a 9</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Cockroach (CR) allergies caused by the American cockroach hyave been recognized to be repsonsible for IgE-mediated type I hypersensitivity worldwide. Per a 10 is one of the recognized main allergens of the American CR. In a previous study, we examined another American CR allergen, Per a 9 in patients with CR allergies and examined epitope sequences in this allergen. In the present study, we aimed to examine epitope sequences in the Per a 10 allergen. for this purpose, the Per a 10 gene was cloned and expressed in Escherichia coli (E. coli) systems. Our results revealed that 9 out of 16 (56.3%) sera from patients with American CR allergies reacted to Per a10, as assessed by ELISA, confirming that Per a 10 is a major allergen of the American CR. Our results also revealed that the expression of CD63 and CCR3 on passively sensitized basophils (obtained sera of patients with American CR allergies) was increased by approximately 2.3-fold, indicating that recombinant Per a 10 is functionally active. In addition, 3 immunoinformatics tools, namely the DNAStar Protean system, the Bioinformatics Predicted Antigenic Peptides (BPAP) system and the BepiPred 1.0 server were used to predict the peptides and the results revealed 8 peptides (2-12, 55-67, 98-120, 125-133, 149-160, 170-182, 201-208 and 223-227) as potential B cell epitopes of the Per a 10 allergen. Moreover, Per a 10 was predicted to have 3 T cell epitope sequences, namely 83-92, 139-147 and 162-170. The findings of our study on the CR allergen may prove to be useful in the development of peptide-based vaccine for the prevention and/or treatment of CR allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 1791-244X (Electronic)IS - 1107-3756 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/ijmm.2016.2790</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27840898">PM:27840898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Med\2016-38-1806-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Med\2016-38-1806-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161114, Tong X</style></custom2><misc3><style face="normal" font="Arial">10.3892/ijmm.2016.2790</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Osipowicz,K.</style></author><author><style face="normal" font="Arial"> Kalinska-Bienias,A.</style></author><author><style face="normal" font="Arial"> Kowalewski,C.</style></author><author><style face="normal" font="Arial"> Wozniak,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Development of bullous pemphigoid during the haemodialysis of a young man: case report and literature survey</style></title><secondary-title><style face="normal" font="Arial">Int Wound J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Wound J</style></full-title></periodical><pages end="292" start="288">288-292</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> Biochip</style></keyword><keyword><style face="normal" font="Arial"> Blistering disease</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Clobetasol</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly people</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fistula</style></keyword><keyword><style face="normal" font="Arial"> haemodialysis</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Renal Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Haemodialysis is the most frequent form of renal replacement therapy (RRT) in patients with end-stage renal disorder (ESRD). Patients with ESRD frequently develop skin problems, mainly xerosis, pruritus and hyperpigmentation, as well as bullous diseases, mainly porphyria or pseudoporphyria and, in some cases, bullous pemphigoid (BP). BP is the most common autoimmune sub-epidermal blistering disease, and it predominantly affects elderly people. Clinically, BP is characterised by generalised pruritic, bullous eruptions and urticaria-like lesions. Usually, BP is an idiopathic disorder; however, in some cases, underlying internal disorders are present, like diabetes or neurological disorders. Herein, we present a 33-year-old man with ESRD, maintained on haemodialysis, who developed BP. There are only six cases with BP provoked by the placement of a fistula for haemodialysis. BP in the current patient was confirmed by direct immunofluorescence (DIF) and indirect immunofluorescence using BIOCHIP. The patient responded promptly to tertracycline and 0.05% clobetasol propionate lesionally. However, the relationship between BP and the fistula for haemodialisys still remains unknown. It is highly likely that the skin injury associated with fistula placement was responsible for the alteration of the basement membrane zone (BMZ) and the stimulation of the immune system, leading to BP development. To explain the real role of fistula placement as a provocative factor in BP, other such cases are required for assessment</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1742-481X (Electronic)IS - 1742-4801 (Linking)LA - ENGPT - CASE REPORTSCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1111/iwj.12670</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27748034">PM:27748034</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Wound J\20161017-OsipowiczK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Wound J\20161017-OsipowiczK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Osipowicz K</style></custom2><misc3><style face="normal" font="Arial">10.1111/iwj.12670</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,J.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Improving Allergen Prediction in Main Crops Using a Weighted Integrative Method</style></title><secondary-title><style face="normal" font="Arial">Interdiscip Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Interdiscip Sci</style></abbr-1></periodical><pages end="" start="549">549-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">545</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen prediction</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Maize</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">As a public health problem, food allergy is frequently caused by food allergy proteins, which trigger a type-I hypersensitivity reaction in the immune system of atopic individuals. The food allergens in our daily lives are mainly from crops including rice, wheat, soybean and maize. However, allergens in these main crops are far from fully uncovered. Although some bioinformatics tools or methods predicting the potential allergenicity of proteins have been proposed, each method has their limitation. In this paper, we built a novel algorithm PREALW, which integrated PREAL, FAO/WHO criteria and motif-based method by a weighted average score, to benefit the advantages of different methods. Our results illustrated PREALW has better performance significantly in the crops' allergen prediction. This integrative allergen prediction algorithm could be useful for critical food safety matters. The PREALW could be accessed at http://lilab.life.sjtu.edu.cn:8080/prealw</style></abstract><notes><style face="normal" font="Arial">DA - 20161013IS - 1867-1462 (Electronic)IS - 1867-1462 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12539-016-0192-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27734271">PM:27734271</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Interdiscip Sci\20161013-LiJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Interdiscip Sci\20161013-LiJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Li J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12539-016-0192-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Welton,R.E.</style></author><author><style face="normal" font="Arial"> Williams,D.J.</style></author><author><style face="normal" font="Arial"> Liew,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Fellow, Australian Venom Research Unit, Department of Pharmacology and Therapeutics, University of Melbourne.</style></auth-address><titles><title><style face="normal" font="Arial">Injury trends from envenoming in Australia, 2000-2013</style></title><secondary-title><style face="normal" font="Arial">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Intern Med J</style></full-title></periodical><pages end="176" start="170">170-176</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Geography</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> jellyfish</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Snakes</style></keyword><keyword><style face="normal" font="Arial"> Spiders</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Wasps</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: This study provides the first contemporary epidemiological insight into venomous injuries based on demographics and geography in Australia in the timeframe 2000-2013. METHODS: Analysis of national hospitalisation and mortality data to examine the incidence of injury and death due to envenoming in Australia. Rates were calculated using the intercensal population for all Australian age groups. RESULTS: Over the study period, deaths were due to an anaphylactic event (0.16 per 100 000), snake envenoming (0.13 per 100 000) or box jellyfish envenoming (0.01 per 100 000). Only 44% of cases involving anaphylaxis reached medical care prior to death, compared to 74% of those envenomed by snakes. Over half of all deaths (52%) occurred at home, and 64% of these occurred within a major city or inner regional area, with 48% of anaphylaxis deaths work related. Hospital admission rates of 199 per 100 000 persons over the 11 years were caused by contact with wasps or bees (31%), spiders (30%) and snakes (15%) with a predominate age range of 30-44 years. CONCLUSIONS: The greatest burden of injury due to envenoming was caused by arthropods and snakes. Causes of death led by anaphylaxis subsequent to an arthropod bite or sting, followed by death from snake envenoming. Over half the incidence resulting in death occurred at home, in areas where health care is accessible. Operational data routinely collected is informative, with variations of injury incidence between States and Territories indicating a need for a more localised approach to management of this injury</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/imj.13297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27749012">PM:27749012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med J\20161017-WeltonRE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med J\20161017-WeltonRE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Welton RE</style></custom2><misc3><style face="normal" font="Arial">10.1111/imj.13297</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baris,S.</style></author><author><style face="normal" font="Arial"> Ozen,A.</style></author><author><style face="normal" font="Arial"> Akdeniz,T.</style></author><author><style face="normal" font="Arial"> Karakoc-Aydiner,E.</style></author><author><style face="normal" font="Arial"> Aydin,O.</style></author><author><style face="normal" font="Arial"> Ercan,H.</style></author><author><style face="normal" font="Arial"> Ogulur,I.</style></author><author><style face="normal" font="Arial"> Camcioglu,Y.</style></author><author><style face="normal" font="Arial"> Cengizlier,R.</style></author><author><style face="normal" font="Arial"> Demirkesen,C.</style></author><author><style face="normal" font="Arial"> Yucelten,D.</style></author><author><style face="normal" font="Arial"> Demirel,G.</style></author><author><style face="normal" font="Arial"> Barlan,I.B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">House Dust Mites Confer a Distinct Immunological Feature among Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="274" start="264">264-274</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis,House dust mite,Interferon-gamma,Skin lesion,Th17 Cells</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD8</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a heterogeneous disease with regard to clinical phenotype and natural history. We investigated T cell subtypes and cytokine responses in peripheral blood and skin lesions of AD patients with various sensitivities. Immunological studies were performed in 27 subjects: 9 house dust mite (HDM)-sensitized; 6 subjects with sensitizations other than HDM; 7 non-allergic AD patients and 5 healthy controls. Among those, skin biopsy samples of 13 subjects were evaluated for immunohistochemical analyses, as well. The mean age was 8.93-¦5.17 years. HDM-allergic AD emerged as a distinct immunologic phenotype, with higher production of interleukin (IL)-4, -5, -2 both at rest and when stimulated by Der p1 or SEB along with higher Th17. As for T H 17 cell percentage, it was increased in all AD groups compared to healthy controls, while HDM-allergic group was distinguished with a significantly lower production of IL-17. Patients with sensitizations other than HDM were mostly similar to non-allergic AD, with increased Th17 and CD4 + CD69 + interferon-gamma (IFN-+¦) + T cells percentage. The biopsy of lesional skin showed that HDM-allergic AD had lower IFN-+¦ and IFN-+¦ co-expressing CD8 + T cells compared to patients with other sensitizations ( p =0.03 and p =0.04, respectively). Among the HDM allergic patients, pairwise comparison of lesional versus non-lesional skin revealed higher CD4 + T cells numbers, expression of forkhead box P3 (Foxp3) and T-cell-specific transcription factor (T-bet) ( p =0.018, p =0.018, p =0.018, respectively). HDM-allergic AD is a distinct subtype with a predominant skewing in Th2 and higher Th17 cell percentage along with a blunted Th1 response in the skin, all of which may have therapeutic implications</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-264-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-264-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Baris S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Misnan,R.</style></author><author><style face="normal" font="Arial"> Salahudin Abd Aziz,N.</style></author><author><style face="normal" font="Arial"> Mohamad Yadzir,Z.H.</style></author><author><style face="normal" font="Arial"> Bakhtiar,F.</style></author><author><style face="normal" font="Arial"> Abdullah,N.</style></author><author><style face="normal" font="Arial"> Murad,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Impacts of Thermal Treatments on Major and Minor Allergens of Sea Snail, Cerithidea obtusa (Obtuse Horn Shell)</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="316" start="309">309-316</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen,Cerithidea obtusa,Immunoblotting,SDS-PAGE,Snail,Thermolabile,Thermostable</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding activity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Snail</style></keyword><keyword><style face="normal" font="Arial"> snails</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatment</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatments</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">Snail is one of the worst causes of food allergy. Thus, the aim of this study was to identify the major and minor allergens of the local marine snail ( Cerithidea obtusa ) and subsequently to investigate the impacts of heat treatment on the IgE-binding activity of snail allergens. Proteins from raw and heat-treated snails (boiled, roasted and fried) were extracted and then resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Immunoblotting of all extracts were then performed using sera from patients with snail allergy.-áThe results showed that the raw extract contains numerous protein bands between 12 to&amp;gt;250 kDa. Some thermostable proteins, predominantly the 33 and 42 kDa bands, remained detected in all cooked extracts with decreasing intensities from boiled to roasted to fried extracts, while the majority of thermolabile bands denatured after heating. Boiled snail had more protein bands compared to roasted and fried snails. Immunoblotting of raw extract demostrated 19 IgE-binding bands ranging from 15 to 240 kDa. The thermostable bands of 33 and 42 kDa and a thermolabile of 30 kDa band were identified as the major allergens of this snail. The cooked extracts yielded less allergenic bands. The boiled extract yielded approximately 14 IgE-binding bands with some smeared bands at high molecular weight regions. The roasted extract had lesser IgE-binding bands and the majority appeared as smears, while the IgE-reactivity in the fried extract was less visible and appeared as weak smears. This study indicated that both raw and cooked snails played a crucial role in snail allergenicity, as this species of snail contains both thermostable and thermolabile major allergens. The degree of snail allergenicity was revealed in the order: raw&amp;gt; boiled &amp;gt; roasted&amp;gt; fried. Thus, the results would facilitate in the development of effective diagnosis and management strategies of snail allergy in this country</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-309-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-309-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Misnan R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alyasin,S.</style></author><author><style face="normal" font="Arial"> Nabavizadeh,S.H.</style></author><author><style face="normal" font="Arial"> Houshmand,H.</style></author><author><style face="normal" font="Arial"> Esmaeilzadeh,H.</style></author><author><style face="normal" font="Arial"> Jelodar,S.</style></author><author><style face="normal" font="Arial"> Amin,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Short Time Efficiency of Rhinophototherapy in Management of Patients with Allergic Rhinitis Resistant to Medical Therapy</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="327" start="317">317-327</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinitis,Phototherapy,Quality of life,Treatment</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy skin test</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phototherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> RQLQ</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> single-blind</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis is one of the most common health problems with a major effect on the quality of life. We intended to treat Allergic Rhinitis (AR) in patients who are either unresponsive to antihistamines or their job requires optimal alertness that may be disturbed by antihistamine</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs side effects and those who do not comply with the regular use. We tried short term phototherapy and evaluated its effect on AR. As phototherapy is effective in the treatment of atopic dermatitis (AD) and the same allergens can produce both AD and AR, phototherapy is proposed as a new tool in the AR treatment. In AD, phototherapy causes induction of apoptosis in infiltrating T cells and other immunomodulatory effects. We performed a randomized single-blind study to investigate the effect of low-dose phototherapy in AR patients. Among AR patients who did not respond to local and systemic therapy, we chose 62 allergic patients all above 25 years of age with moderate to severe AR whose disease was verified by allergy skin test or specific IgE to allergens; then, they were randomly divided into 31 patients as treatment group and 31 patients as control group.-áIn treatment groups, we used a mixture of UVA, UVB and visible light. In the control group, we used visible light alone as placebo. Then we evaluated the level of response to treatment in two groups and compared them according to Total Nasal Symptom scores (TNSS) and Global Severity Scores (GSS) and Rhinoconjunctivitis Quality of Life Questionnaires (RQLQ) symptom scores. We found out that phototherapy in the treatment group in comparison with placebo was effective in treatment of AR (p-value &amp;lt;0.001 ). However, we recommend that for substantiation of the claim, further investigations are still required</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-317-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-317-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Alyasin S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abolnezhadian,F.</style></author><author><style face="normal" font="Arial"> Alyasin,S.</style></author><author><style face="normal" font="Arial"> Amin,R.</style></author><author><style face="normal" font="Arial"> Babaei,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Effect of Autologous Serum Therapy on Disease Severity in Patients with Chronic Urticaria</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="333" start="328">328-333</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Angioedema,Antihistamines,Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> single-blind</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2016">2016/8/30</year></dates><abstract><style face="normal" font="Arial">Limited evidence has been obtained concerning the beneficial effects of autologous serum therapy in treatment of skin disorders particularly chronic urticaria. In the present study, we have assessed the effect of this treatment method in patients with chronic urticaria (CU). This randomized single-blind controlled trial was performed on fifty consecutive patients with chronic urticaria. The patients were randomly assigned to receive autologous serum (as the case group, n=35) or normal saline (as the control group, n=15) and treated with monthly autologous serum therapy or normal saline for 6 months. The considered study endpoint was changes in total severity score (TSS) at the 6 months follow-up visit. The TSS score was assessed at baseline as well as at the ninth week and the sixth month of interventions. The mean-¦SD of TSS at the ninth week of intervention was 10.94-¦3.92 in autologous serum therapy group and 11.67-¦2.72 in the normal saline group ( p =0.458). Furthermore, the mean values of TSS at the sixth month of treatment in the study groups were 8.29-¦6.29 and 9.27-¦4.89 respectively ( p =0.593). A downward trend in TSS, from baseline to the end of treatment, was seen in the case and control groups ( p &amp;lt;0.001 for both), however the trend of this decline was insignificant between the two groups ( p =0.592). The change in the trend of TSS after 6 months of treatment was independent from the administration of autologous serum when compared with normal saline administration (beta=-0.962, p =0.630). Multivariate linear regression model with the presence of baseline factors including gender, age, disease duration and history of atopy was performed to assess difference in TSS at six-month follow-up visit compared with the baseline value. Only young age was associated with more reduction of TSS (beta=0.163, p =0.023). We found no difference in the effects of autologous serum therapy and normal saline on the trend of the changes in disease severity in patients with chronic urticaria</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-328-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-328-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Abolnezhadian F</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ragona,G.</style></author><author><style face="normal" font="Arial"> Corrias,F.</style></author><author><style face="normal" font="Arial"> Benedetti,M.</style></author><author><style face="normal" font="Arial"> Paladini,M.</style></author><author><style face="normal" font="Arial"> Salari,F.</style></author><author><style face="normal" font="Arial"> Altomonte,L.</style></author><author><style face="normal" font="Arial"> Martini,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Experimental Veterinary Medicine of Lazio and Tuscany , Scandicci (FI), Italy</style></auth-address><titles><title><style face="normal" font="Arial">Amiata Donkey Milk Chain: Animal Health Evaluation and Milk Quality</style></title><secondary-title><style face="normal" font="Arial">Ital J Food Saf</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ital J Food Saf</style></abbr-1></periodical><pages end="" start="5951">5951-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> Brucella</style></keyword><keyword><style face="normal" font="Arial"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Caseins</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Donkey</style></keyword><keyword><style face="normal" font="Arial"> Donkey milk</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> milk quality</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Rectum</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Salmonella</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="6" Year="2016">2016/6/3</year></dates><abstract><style face="normal" font="Arial">This study presents an investigation of Amiata donkey health and quality of milk for human consumption. Thirty-one lactating dairy jennies were examined. The following samples were collected: faecal samples from the rectum of animals for parasitological examination; cervical swabs for the detection of bacteria causing reproductive disorders; and blood samples for serological diagnosis of main zoonotic (Brucella spp., Leptospira spp.) and donkey abortion agents (Brucella spp., Leptospira spp., Salmonella abortus equi, Equine viral arterithis virus, Equine herpesvirus type 1). In addition, individual milk samples were collected and analysed for mastitis-causing pathogens and milk quality. Regarding animal health, we detected a high prevalence of strongyle parasites in donkeys. It is very important to tackle parasitic diseases correctly. Selective control programmes are preferable in order to reduce anthelmintic drug use. For dairy donkeys, withdrawal periods from anthelmintic drugs need to be carefully managed, in accordance with EU and national regulations. The isolation of Staphylococcus aureus in milk highlights the importance of preventing contamination during milking, by adopting appropriate hygiene and safety practices at a farm level. Lysozyme activity was high compared to cow's milk, contributing to the inhibitory activity against certain bacteria. Donkey milk was characterised by high lactose content, low caseins, low fat, higher levels of unsaturated fatty acids compared to ruminant milks. Unsaturated fatty acids and omega 3 fatty acids in particular have become known for their beneficial health effect, which is favourable for human diet. These characteristics make it suitable for infants and children affected by food intolerance/allergies to bovine milk proteins and multiple food allergies as well as for adults with dyslipidemias. It is also recommended to prevent cardiovascular diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 2239-7132 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4081/ijfs.2016.5951</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27853717">PM:27853717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Food Saf\2016-5-5951.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Food Saf\2016-5-5951.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Ragona G</style></custom2><misc3><style face="normal" font="Arial">10.4081/ijfs.2016.5951</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Piccolo,F.</style></author><author><style face="normal" font="Arial"> Vollano,L.</style></author><author><style face="normal" font="Arial"> Base,G.</style></author><author><style face="normal" font="Arial"> Girasole,M.</style></author><author><style face="normal" font="Arial"> Smaldone,G.</style></author><author><style face="normal" font="Arial"> Cortesi,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary Medicine and Animal Production, University of Naples Federico II , Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Soybean and Lactose in Meat Products and Preparations Sampled at Retail</style></title><secondary-title><style face="normal" font="Arial">Ital J Food Saf</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ital J Food Saf</style></abbr-1></periodical><pages end="" start="5780">5780-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food label</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Meat Products</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="3" Month="6" Year="2016">2016/6/3</year></dates><abstract><style face="normal" font="Arial">Food allergies and intolerances have increased during the last decades and regulatory authorities have taken different measures to prevent and manage consumers' adverse reactions, including correct labelling of foods. Aim of this work was to search for soybean and lactose in meat products and meat preparations taken from retail in some provinces of Campania Region (Southern Italy) and to evaluate the food labels compliance with Regulation (EU) n.1169/2011. Soybean and lactose were searched using commercial kits in n. 58 samples of meat products produced in or distributed by 19 establishments, and in n. 55 samples of meat products and n. 8 of meat preparations produced in 21 plants. All samples were selected on the basis of the absence of any information on the labels about the presence of the two searched allergens, with the exception of n. 5 samples tested for lactose. Traces of soybean were detected in 50 out of the 58 examined samples, at concentrations up to 0.93 mg kg-1. Only two samples contained levels above the detection limit of 0.31 mg kg-1. Lactose levels ranging from 0.11 to 2.95 g/100 g, i.e. above the detection limit, were found in all the tested samples (n. 63). The results of the present research underline the need for careful controls and planning by operators as part of the self-control plans, and deserve attention from the competent authorities considering not only the consumers' health but also the great attention media pay to regulations providing consumers with information on food</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 2239-7132 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4081/ijfs.2016.5780</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27853709">PM:27853709</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Food Saf\2016-5-5780.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Food Saf\2016-5-5780.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Piccolo F</style></custom2><misc3><style face="normal" font="Arial">10.4081/ijfs.2016.5780</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gupta,R.K.</style></author><author><style face="normal" font="Arial"> GUPTA,K.</style></author><author><style face="normal" font="Arial"> Sharma,A.</style></author><author><style face="normal" font="Arial"> Das,M.</style></author><author><style face="normal" font="Arial"> Ansari,I.A.</style></author><author><style face="normal" font="Arial"> Dwivedi,P.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Look Insight: Health Risks and Benefits of Chickpea (Cicer arietinum) Consumption</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amylase</style></keyword><keyword><style face="normal" font="Arial"> anti-nutritional</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Bioactive compounds</style></keyword><keyword><style face="normal" font="Arial"> Carotenoids</style></keyword><keyword><style face="normal" font="Arial"> Chickpea</style></keyword><keyword><style face="normal" font="Arial"> Cicer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary Fiber</style></keyword><keyword><style face="normal" font="Arial"> dietary fibers</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Isoflavones</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> phenolic compounds</style></keyword><keyword><style face="normal" font="Arial"> Phytic Acid</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Saponins</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> Sterols</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword></keywords><dates><year Day="25" Month="10" Year="2016">2016/10/25</year></dates><abstract><style face="normal" font="Arial">Chickpeas (CPs) are one of the most commonly consumed legumes especially in the Mediterranean area as well as in the western world. Being one of the most nutritional elements of the human diet, CP toxicity and allergy have raised health concern. CP may contain various anti-nutritional compounds, including protease inhibitors, phytic acid, lectins, oligosaccharides and some phenolic compounds that may impair the utilization of the nutrients by people. Also, high consumption rate of CPs have enhanced the allergic problems in sensitive individuals as it contains many allergens. On the other hand, beneficial health aspects of CPs consumption have received attention from researchers, recently. Phytic acid, lectins, sterols, saponins, dietary fibers, resistant starch, oligosaccharides, unsaturated fatty acids, amylase inhibitors and certain bioactive compounds such as carotenoids and isoflavones have shown the capability of lowering the clinical complications associated with various human diseases. The aim of this article is to unravel the health risks as well as health promoting aspects of CPs consumption and try to fill the gaps that currently exist. The present review also focuses on the various prevention strategies to avoid health risks of CPs consumption using simple but promising ways</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - ENGPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b02629</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779388">PM:27779388</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20161025-GuptaRK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20161025-GuptaRK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Gupta RK</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b02629</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,J.</style></author><author><style face="normal" font="Arial"> Chen,L.</style></author><author><style face="normal" font="Arial"> Lin,D.</style></author><author><style face="normal" font="Arial"> Ma,Z.</style></author><author><style face="normal" font="Arial"> Deng,X.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development and application of a multiplex real-time PCR assay as an indicator of potential allergenicity in citrus fruits</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="9098" start="9089">9089-9098</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">47</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen genes</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Differential expression</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruit allergy</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene sequence</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Harvest maturity</style></keyword><keyword><style face="normal" font="Arial"> Housekeeping</style></keyword><keyword><style face="normal" font="Arial"> maturity</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulp</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Ripening</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> TaqMan</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="10" Year="2016">2016/10/31</year></dates><abstract><style face="normal" font="Arial">The effects of tissue type, harvest maturity and genetic factors on the expression of genes that related to citrus fruit allergies remain poorly understood. In the present study, a multiplex real-time PCR assay was developed to monitor the expression of citrus allergen genes individually with the advantages of much fewer sample requirements and simultaneously multiple target genes detection. Gene specific primer pairs and Taqman probes of three citrus allergen genes Cit s 1.01, Cit s 2.01, Cit s 3.01 and the house-keeping gene beta-actin were designed based on gene sequence differences. The PCR results showed that differential expression patterns were found during the ripening process. The expression levels of Cit s 3.01 were much higher than those of Cit s 1.01 and Cit s 2.01 in both peel and pulp tissues among ten citrus cultivars. Data suggested that Kao Phuang Pummelo could be safely consumed with a potential low risk in allergenicity. Considering that assessing allergenicity is one of the tests in food safety, this assay might also facilitate the breeding and production of "allergy-friendly" citrus fruits</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - ENGPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b03410</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27794596">PM:27794596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20161031-WuJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20161031-WuJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Wu J</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b03410</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tan,J.W.</style></author><author><style face="normal" font="Arial"> Valerio,C.</style></author><author><style face="normal" font="Arial"> Barnes,E.H.</style></author><author><style face="normal" font="Arial"> Turner,P.J.</style></author><author><style face="normal" font="Arial"> Van Asperen,P.A.</style></author><author><style face="normal" font="Arial"> Kakakios,A.M.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Discipline of Paediatrics and Child Health, University of Sydney, Sydney, New South Wales, Australia; The Department of Allergy and Immunology, Children's Hospital at Westmead, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="Arial">A randomized trial of egg introduction from 4 months of age in infants at risk for egg allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1628" start="1621">1621-1628</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Whole egg</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Epidemiological evidence suggests delayed introduction of egg may not protect against egg allergy in infants at risk of allergic disease. OBJECTIVE: To assess whether dietary introduction of egg between 4-6 months in infants at risk of allergy would reduce sensitization to egg. METHODS: We conducted a randomized controlled trial in infants with at least one first-degree relative with allergic disease. Infants with a skin prick test to egg white (EW-SPT) &lt;2mm were randomized at age 4 months to receive whole-egg powder or placebo (rice powder) until 8-months of age, with all other dietary egg excluded. Diets were liberalized at 8-months in both groups. The primary outcome was EW-SPT >/=3mm at age 12-months. RESULTS: 319 infants were randomized, 165 to egg and 154 to placebo. Fourteen infants reacted to egg within one week of introduction (despite EW-SPT &lt;2mm at entry) and were unsuitable for intervention. 254 infants (83%) were assessed at 12 months of age. Loss to follow up was similar between groups. Sensitization to EW at 12 months was 20% and 11% in infants randomized to placebo and egg, respectively (OR=0.46, 95%CI 0.22-0.95, p=0.03, Chi-Square test). The absolute risk reduction was 9.8% (95%CI: 8.2% to 18.9%) with a number needed to treat of 11 (95%CI: 6 to 122). IgG4 to egg proteins and IgG4/IgE ratios were higher in those randomized to egg (p&lt;0.0001 for each) at 12 months. There was no effect on the proportion of children with probable egg allergy (placebo 13, egg 8). CONCLUSIONS: Introduction of whole-egg powder into the diets of high risk infants reduced sensitization to EW and induced egg-specific IgG4. However 8.5% of infants randomized to egg were not amenable to this primary prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742394">PM:27742394</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161015-TanJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161015-TanJW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Tan JW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marchisotto,M.J.</style></author><author><style face="normal" font="Arial"> Harada,L.</style></author><author><style face="normal" font="Arial"> Kamdar,O.</style></author><author><style face="normal" font="Arial"> Smith,B.M.</style></author><author><style face="normal" font="Arial"> Waserman,S.</style></author><author><style face="normal" font="Arial"> Sicherer,S.</style></author><author><style face="normal" font="Arial"> Allen,K.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Taylor,S.</style></author><author><style face="normal" font="Arial"> Gupta,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Research &amp; Education, Inc, McLean, Va</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergen Labeling and Purchasing Habits in the United States and Canada</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="351.e2" start="345">345-351.e2</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergic consumers</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mandatory labeling of products with top allergens has improved food safety for consumers. Precautionary allergen labeling (PAL), such as "may contain" or "manufactured on shared equipment," are voluntarily placed by the food industry. OBJECTIVE: To establish knowledge of PAL and its impact on purchasing habits by food-allergic consumers in North America. METHODS: Food Allergy Research &amp; Education and Food Allergy Canada surveyed consumers in the United States and Canada on purchasing habits of food products featuring different types of PAL. Associations between respondents' purchasing behaviors and individual characteristics were estimated using multiple logistic regression. RESULTS: Of 6684 participants, 84.3% (n = 5634) were caregivers of a food-allergic child and 22.4% had food allergy themselves. Seventy-one percent reported a history of experiencing a severe allergic reaction. Buying practices varied on the basis of PAL wording; 11% of respondents purchased food with "may contain" labeling, whereas 40% purchased food that used "manufactured in a facility that also processes." Twenty-nine percent of respondents were unaware that the law requires labeling of priority food allergens. Forty-six percent were either unsure or incorrectly believed that PAL is required by law. Thirty-seven percent of respondents thought PAL was based on the amount of allergen present. History of a severe allergic reaction decreased the odds of purchasing foods with PAL. CONCLUSIONS: Almost half of consumers falsely believed that PAL was required by law. Up to 40% surveyed consumers purchased products with PAL. Understanding of PAL is poor, and improved awareness and guidelines are needed to help food-allergic consumers purchase food safely</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -CO - United States -CO - United Kingdom -CO - Italia -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27818137">PM:27818137</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-345-51.e2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-345-51.e2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Marchisotto MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Seth,S.</style></author><author><style face="normal" font="Arial"> Khan,D.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="170.e2" start="165">165-170.e2</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alternative agent</style></keyword><keyword><style face="normal" font="Arial"> Alternative agents</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Dapsone</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> Hydroxychloroquine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Mycophenolate</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sulfasalazine</style></keyword><keyword><style face="normal" font="Arial"> Tacrolimus</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-2198</style></isbn><abstract><style face="normal" font="Arial">Background Patients who have failed traditional treatment of chronic urticaria may require trials of alternative medications. Safety profiles, continuous laboratory monitoring, and physician comfort are often barriers to treatment. Objectives To evaluate the safety of alternative agents used in chronic urticaria. Methods A retrospective chart review of electronic medical records from a single-center allergy and immunology clinic in a major academic hospital was conducted. One hundred twenty-six charts of patients with chronic urticaria treated with alternative agents were reviewed. Results Adverse effects were reported in 39 of 73 (53%) patients on dapsone, 19 of 47 (40%) patients on sulfasalazine, 15 of 36 (42%) patients on tacrolimus, 7 of 45 (16%) patients on hydroxychloroquine, 9 of 27 (33%) patients on mycophenolate, 6 of 8 (75%) patients on cyclosporine, and 3 of 24 (4%) patients on omalizumab. Most of these adverse effects were mild, did not require discontinuation of the medication, and resolved after stopping the medication or decreasing the dose. Conclusions The use of alternative agents for the treatment-áof chronic urticaria angioedema is generally safe when-áproper laboratory and clinical monitoring is observed</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746265">PM:27746265</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-165-70.e2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-165-70.e2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161103, Seth S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ledford,D.</style></author><author><style face="normal" font="Arial"> Busse,W.</style></author><author><style face="normal" font="Arial"> Trzaskoma,B.</style></author><author><style face="normal" font="Arial"> Omachi,T.A.</style></author><author><style face="normal" font="Arial"> Rosen,K.</style></author><author><style face="normal" font="Arial"> Chipps,B.E.</style></author><author><style face="normal" font="Arial"> Luskin,A.T.</style></author><author><style face="normal" font="Arial"> Solari,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Morsani College of Medicine and James A. Haley VA Hospital, University of South Florida, Tampa, FL.</style></auth-address><titles><title><style face="normal" font="Arial">A Randomized, Multicenter Study Evaluating Xolair(R) Persistency Of Response After Long-Term Therapy (XPORT)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="169" start="162">162-169</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACQ</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Few data are available to assist clinicians with decisions regarding long-term use of asthma therapies, including omalizumab. OBJECTIVE: To evaluate the benefit and persistency of response in subjects continuing or withdrawing from long-term omalizumab treatment. METHODS: Evaluating the Xolair(R) Persistency Of Response After Long-Term Therapy (XPORT) was a randomized, double-blind, placebo-controlled withdrawal study that included subjects with moderate-to-severe persistent asthma receiving long-term omalizumab. Subjects were randomized using a hierarchical dynamic randomization scheme, to continue their same dose of omalizumab or withdraw to placebo and were then followed every 4 weeks for 1 year. PRIMARY OUTCOME: any protocol-defined severe asthma exacerbation. Secondary outcome: time to first protocol-defined severe asthma exacerbation. Exploratory outcomes included changes in Asthma Control Questionnaire (ACQ) and Asthma Control Test (ACT) scores. RESULTS: Significantly more subjects in the omalizumab group (67%) had no protocol-defined exacerbation than in the placebo group (47.7%); absolute difference of 19.3% (95% CI: 5.0%, 33.6%) represents a 40.1% relative difference. Time to first protocol-defined exacerbation analysis revealed a significantly different between-group exacerbation pattern that was consistent with the primary analysis. Subjects continuing omalizumab had significantly better asthma control (mean [SD] change from baseline to Week 52: ACT, -1.16 [4.14] vs placebo, -2.88 [5.38]; P = .0188 and ACQ, 0.22 [0.66] vs placebo, 0.63 [1.13]); P = .0039. Discontinuation of omalizumab was associated with an increase in free IgE and an increase in basophil expression of the high-affinity IgE receptor. No safety concerns were noted. CONCLUSION: Continuation of omalizumab following long-term treatment results in continued benefit as evidenced by improved symptom control and reduced exacerbation risk</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826098">PM:27826098</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161109-LedfordD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161109-LedfordD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Ledford D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gericke,J.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Ohanyan,T.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author><author><style face="normal" font="Arial"> Altrichter,S.</style></author><author><style face="normal" font="Arial"> Skov,P.S.</style></author><author><style face="normal" font="Arial"> Falkencrone,S.</style></author><author><style face="normal" font="Arial"> Brand,J.</style></author><author><style face="normal" font="Arial"> Kromminga,A.</style></author><author><style face="normal" font="Arial"> Hawro,T.</style></author><author><style face="normal" font="Arial"> Church,M.K.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charite, Charite - Universitatsmedizin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1061" start="1059">1059-1061</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil histamine release</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A slow response to omalizumab (anti-IgE) in CSU patients is strongly correlated with IgG-anti-FcepsilonRI-mediated serum-induced basophil histamine release suggesting that, in these patients, effects on FcepsilonRI are critical for the mechanism of action of omalizumab</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838346">PM:27838346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161113-GerickeJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161113-GerickeJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Gericke J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsui,E.C.</style></author><author><style face="normal" font="Arial"> Keet,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy/Immunology, Johns Hopkins University School of Medicine, Baltimore, Md</style></auth-address><titles><title><style face="normal" font="Arial">Weighing the evidence: Bias and confounding in epidemiologic studies in allergy/immunology</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="450" start="448">448-450</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Baltimore</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161111IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27833026">PM:27833026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161111-MatsuiEC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161111-MatsuiEC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161111, Matsui EC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yancey,S.W.</style></author><author><style face="normal" font="Arial"> Ortega,H.G.</style></author><author><style face="normal" font="Arial"> Keene,O.N.</style></author><author><style face="normal" font="Arial"> Mayer,B.</style></author><author><style face="normal" font="Arial"> Gunsoy,N.B.</style></author><author><style face="normal" font="Arial"> Brightling,C.E.</style></author><author><style face="normal" font="Arial"> Bleecker,E.R.</style></author><author><style face="normal" font="Arial"> Haldar,P.</style></author><author><style face="normal" font="Arial"> Pavord,I.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Therapeutic Area, GSK, Research Triangle Park, NC.</style></auth-address><titles><title><style face="normal" font="Arial">Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1175" start="1167">1167-1175</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Studies show that mepolizumab can reduce the frequency of clinically significant exacerbations in patients with severe eosinophilic asthma, compared with placebo. However, important events such as hospitalizations and emergency room visits are rare and difficult to characterize in single studies. OBJECTIVE: We sought to compare hospitalization or hospitalization and/or emergency room visit rates in patients with severe eosinophilic asthma treated with mepolizumab or placebo in addition to standard of care for at least 24 weeks. METHODS: This study was conducted and reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. PubMed and the GSK Clinical Study Register were searched for suitable studies. The primary end points were the rate of exacerbations requiring hospitalization and the rate of exacerbations requiring hospitalization/emergency room visit. The proportion of patients with 1 or more event was also assessed. All mepolizumab doses were combined and individual patient-level data were analyzed. RESULTS: Four studies (n = 1388) were eligible for inclusion. Mepolizumab significantly reduced the rate of exacerbations requiring hospitalization (relative rate, 0.49; 95% CI, 0.30-0.80; P = .004) and hospitalization/emergency room visit (relative rate, 0.49; 95% CI, 0.33-0.73; P &lt; .001) versus placebo. Significant reductions of 45% and 38% were also observed for the proportion of patients experiencing 1 or more hospitalization and hospitalization and/or emergency room visit, respectively. CONCLUSIONS: Mepolizumab approximately halved exacerbations requiring hospitalization and/or emergency room visits compared with placebo in patients with severe eosinophilic asthma. This treatment addresses a key outcome in a patient population with a high unmet need (GSK Study 204664)</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27726946">PM:27726946</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161011-YanceySW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161011-YanceySW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Yancey SW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hollams,E.M.</style></author><author><style face="normal" font="Arial"> Teo,S.M.</style></author><author><style face="normal" font="Arial"> Kusel,M.</style></author><author><style face="normal" font="Arial"> Holt,B.J.</style></author><author><style face="normal" font="Arial"> Holt,K.E.</style></author><author><style face="normal" font="Arial"> Inouye,M.</style></author><author><style face="normal" font="Arial"> De Klerk,N.H.</style></author><author><style face="normal" font="Arial"> Zhang,G.</style></author><author><style face="normal" font="Arial"> Sly,P.D.</style></author><author><style face="normal" font="Arial"> Hart,P.H.</style></author><author><style face="normal" font="Arial"> Holt,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Telethon Kids Institute, University of Western Australia, Perth, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D over the first decade and susceptibility to childhood allergy and asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="481" start="472">472-481</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Vitamin D (25(OH)D) deficiency has been implicated as a possible risk factor for asthma development, but studies at selected time points measuring 25(OH)D levels during childhood have yielded conflicting findings. Prospective studies tracking 25(OH)D levels during the initiation phase of asthma in early childhood have not been reported. OBJECTIVE: We sought to elucidate relationships between 25(OH)D levels from birth to age 10 years and susceptibility to allergic sensitization, respiratory tract infections, and asthma. METHODS: Asthma-, allergy-, and respiratory tract infection-associated phenotypes (including pathogen identification) were characterized in a high-risk birth cohort. Plasma 25(OH)D concentrations were quantified at birth and at clinical follow-ups at the ages of 0.5, 1, 2, 3, 4, 5, and 10 years, and relationships with clinical outcomes were examined. RESULTS: Cross-sectional analyses demonstrated inverse associations between 25(OH)D concentrations and the risk for concurrent sensitization at age 0.5, 2, and 3 years, and mixed-effects regression demonstrated inverse longitudinal associations of 25(OH)D levels with both sensitization and eczema. Multivariate regression modeling suggested that the number of 25(OH)D-deficient follow-ups was positively associated with risk for asthma/wheeze, eczema, and sensitization at 10 years; adjustment for sensitization (particularly by 2 years) in the asthma/wheeze models reduced 25(OH)D associations with these latter outcomes. 25(OH)D levels were also inversely associated with early nasopharyngeal colonization with Streptococcus species and age of first febrile lower respiratory illness, both of which are known asthma risk factors. CONCLUSION: 25(OH)D deficiency in early childhood is associated with increased risk for persistent asthma, potentially through modulating susceptibility to early allergic sensitization, upper respiratory tract colonization with bacterial pathogens, or both. These relationships are only evident if 25(OH)D status is monitored prospectively and longitudinally</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27726947">PM:27726947</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161011-HollamsEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161011-HollamsEM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Hollams EM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Segal,L.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author><author><style face="normal" font="Arial"> Alizadehfar,R.</style></author><author><style face="normal" font="Arial"> Primeau,M.N.</style></author><author><style face="normal" font="Arial"> Asai,Y.</style></author><author><style face="normal" font="Arial"> Killorn,K.R.</style></author><author><style face="normal" font="Arial"> Chan,E.</style></author><author><style face="normal" font="Arial"> Cheuk,S.</style></author><author><style face="normal" font="Arial"> Shand,G.</style></author><author><style face="normal" font="Arial"> St-Pierre,Y.</style></author><author><style face="normal" font="Arial"> Harada,L.</style></author><author><style face="normal" font="Arial"> Clarke,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Initial and accidental reactions are managed inadequately in children with sesame allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="485" start="482">482-485</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-2198</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27765458">PM:27765458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-482-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-482-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161103, Segal L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Esquivel,A.</style></author><author><style face="normal" font="Arial"> Busse,W.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis Conundrum: A Trojan Horse Phenomenon</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="329" start="325">325-329</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long term care</style></keyword><keyword><style face="normal" font="Arial"> Long-Term Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Salmon</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-2198</style></isbn><abstract><style face="normal" font="Arial">Anaphylaxis is a serious and potentially life-threatening allergic reaction that may follow the ingestion of foods. Although these reactions usually follow a common clinical pattern and often demonstrate IgE sensitization to the antigen in question, both the clinical presentation and causative allergen may be atypical, surprising, and difficult to identify. Failure to identify the actual cause of the reaction can compromise treatment and complicate long-term care. Here, we present a patient who had symptoms of anaphylaxis after eating salmon, but confirmation of the causative allergen was not readily apparent. This particular case serves as an insightful lesson for patients undergoing evaluation for anaphylaxis and also provides a framework for navigating through a case involving identification of an underlying allergen</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27765461">PM:27765461</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-325-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-325-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161103, Esquivel A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-de-Olano,D.</style></author><author><style face="normal" font="Arial"> Botella-Padilla,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Respiratory allergy buzz on the Internet</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="188" start="187">187-188</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-2198</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.009</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jaip.2016.08.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161103-Gonzalez-de-OlanoD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161103-Gonzalez-de-OlanoD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161103, Gonzalez-de-Olano D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nolte,H.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author><author><style face="normal" font="Arial"> Lockey,R.F.</style></author><author><style face="normal" font="Arial"> Fogh,B.S.</style></author><author><style face="normal" font="Arial"> Kaur,A.</style></author><author><style face="normal" font="Arial"> Lu,S.</style></author><author><style face="normal" font="Arial"> Nelson,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research and Development, Merck &amp; Co., Inc., Kenilworth, NJ.</style></auth-address><titles><title><style face="normal" font="Arial">Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="89.e3" start="84">84-89.e3</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine use</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mouth</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy immunotherapy can result in systemic allergic reactions and even life-threatening anaphylaxis requiring epinephrine administration. OBJECTIVE: The objective of this study was to describe epinephrine use in the clinical trial development programs of 3 rapidly dissolving sublingual immunotherapy tablets (SLIT-tablets; Merck &amp; Co., Inc., Kenilworth, NJ/ALK, Horsholm, Denmark/Torii Pharmaceutical Co., Ltd., Tokyo, Japan). METHODS: Data on epinephrine use were collected from 13 timothy grass SLIT-tablet trials (MK-7243; &lt;/=2800 bioequivalent allergen units/75,000 SQ-T dose, n = 2497; placebo, n = 2139), 5 short ragweed SLIT-tablet trials (MK-3641; &lt;/=12 Amb a 1-U, n = 1725; placebo, n = 770), and 11 house dust mite (HDM) SLIT-tablet trials (MK-8237; &lt;/=12 SQ-HDM; n = 3930; placebo, n = 2246). RESULTS: In grass SLIT-tablet trials, epinephrine was used 13 times (grass SLIT-tablet, n = 10; placebo, n = 3). Eight administrations were for grass SLIT-tablet-related adverse events (AEs): 4 for systemic allergic reactions and 4 for local mouth and/or throat swelling. In ragweed SLIT-tablet trials, epinephrine was used 9 times in 8 subjects (ragweed SLIT-tablet, n = 7; placebo, n = 1 [2 administrations for protracted anaphylaxis]). Four administrations were for ragweed SLIT-tablet-related AEs: 1 for systemic allergic reaction and 3 for local mouth and/or pharynx/throat swelling. In HDM SLIT-tablet trials, epinephrine was administered 13 times (HDM SLIT-tablet, n = 8; placebo, n = 5). Four administrations were for HDM SLIT-tablet-related AEs: 1 for systemic allergic reaction and 3 for local events. Of the 16 epinephrine administrations for events related to SLIT-tablet treatment, 11 occurred within the first week of treatment (7 administrations on day 1) and 5 were subject self-administered. CONCLUSIONS: Epinephrine administrations in response to SLIT-tablet-related reactions in clinical trials are uncommon, typically occur within the first week of treatment, and are rarely self-administered. All SLIT-tablet-related events treated with epinephrine were nonserious</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838323">PM:27838323</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-84-89.e3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-84-89.e3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Nolte H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,E.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author><author><style face="normal" font="Arial"> Barnes,E.H.</style></author><author><style face="normal" font="Arial"> Mehr,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Discipline of Paediatrics and Child Health, University of Sydney, Sydney, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Resolution of acute food protein-induced enterocolitis syndrome in children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="488" start="486">486-488</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838327">PM:27838327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-486-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-486-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Lee E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Upperman,C.R.</style></author><author><style face="normal" font="Arial"> Parker,J.D.</style></author><author><style face="normal" font="Arial"> Akinbami,L.J.</style></author><author><style face="normal" font="Arial"> Jiang,C.</style></author><author><style face="normal" font="Arial"> He,X.</style></author><author><style face="normal" font="Arial"> Murtugudde,R.</style></author><author><style face="normal" font="Arial"> Curriero,F.C.</style></author><author><style face="normal" font="Arial"> Ziska,L.</style></author><author><style face="normal" font="Arial"> Sapkota,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Maryland Institute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, Md</style></auth-address><titles><title><style face="normal" font="Arial">Exposure to Extreme Heat Events Is Associated with Increased Hay Fever Prevalence among Nationally Representative Sample of US Adults: 1997-2013</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="441" start="435">435-441</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> exposure-response relationship</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Poverty</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Warmer temperature can alter seasonality of pollen as well as pollen concentration, and may impact allergic diseases such as hay fever. Recent studies suggest that extreme heat events will likely increase in frequency, intensity, and duration in coming decades in response to changing climate. OBJECTIVE: The overall objective of this study was to investigate if extreme heat events are associated with hay fever. METHODS: We linked National Health Interview Survey (NHIS) data from 1997 to 2013 (n = 505,386 respondents) with extreme heat event data, defined as days when daily maximum temperature (TMAX) exceeded the 95th percentile values of TMAX for a 30-year reference period (1960-1989). We used logistic regression to investigate the associations between exposure to annual and seasonal extreme heat events and adult hay fever prevalence among the NHIS respondents. RESULTS: During 1997-2013, hay fever prevalence among adults 18 years and older was 8.43%. Age, race/ethnicity, poverty status, education, and sex were significantly associated with hay fever status. We observed that adults in the highest quartile of exposure to extreme heat events had a 7% increased odds of hay fever compared with those in the lowest quartile of exposure (odds ratios: 1.07, 95% confidence interval: 1.02-1.11). This relationship was more pronounced for extreme heat events that occurred during spring season, with evidence of an exposure-response relationship (Ptrend &lt; .01). CONCLUSIONS: Our data suggest that exposure to extreme heat events is associated with increased prevalence of hay fever among US adults</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27840238">PM:27840238</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-435-441.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-435-441.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161114, Upperman CR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Epstein,T.G.</style></author><author><style face="normal" font="Arial"> Calabria,C.</style></author><author><style face="normal" font="Arial"> Cox,L.</style></author><author><style face="normal" font="Arial"> Dreborg,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Allergy, and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.</style></auth-address><titles><title><style face="normal" font="Arial">Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United States</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="40.e2" start="34">34-40.e2</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> precautions</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Liquid sublingual allergen immunotherapy (SLIT) has been used off-label for decades, and Food and Drug Administration (FDA)-approved grass and ragweed SLIT tablets have been available in the United States since 2014. Potentially life-threatening events from SLIT do occur, although they appear to be very rare, especially for FDA-approved products. Practice guidelines that incorporate safety precautions regarding the use of SLIT in the United States are needed. This clinical commentary attempts to address unresolved issues including controversy regarding the FDA mandate for the prescription of epinephrine autoinjectors for patients on SLIT; how to approach polysensitized patients; optimal timing and duration of SLIT administration; how to address gaps in therapy; whether antihistamines can prevent local reactions, if certain patient populations (such as persistent asthmatics) should not receive SLIT; and when to instruct patients to self-administer epinephrine. Key points are that physicians should focus on educating patients regarding: (1) when not to administer SLIT; (2) how to recognize a potentially serious allergic reaction to SLIT; and (3) when to administer epinephrine and seek emergency care</style></abstract><notes><style face="normal" font="Arial">DA - 20161105IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27815065">PM:27815065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-34-40.e2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-34-40.e2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161105, Epstein TG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eigenmann,P.A.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author><author><style face="normal" font="Arial"> Mazon,A.</style></author><author><style face="normal" font="Arial"> Nieto,A.</style></author><author><style face="normal" font="Arial"> Haddad,D.</style></author><author><style face="normal" font="Arial"> Brough,H.A.</style></author><author><style face="normal" font="Arial"> Caubet,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy Unit, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland.</style></auth-address><titles><title><style face="normal" font="Arial">Managing Nut Allergy: A Remaining Clinical Challenge</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="300" start="296">296-300</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nut allergy</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Peanut and tree nut allergies have become a public health problem over the last 2 decades. The diagnostic procedure relies on a suggestive history, as well as on evidence of sensitization (skin prick testing and/or specific IgE blood testing), followed in selected cases by a food challenge. Standard IgE tests may be positive to more than 1 nut, due to cross-reactivity (allergens common to several nuts) or cosensitivity (frequently associated positive test results without cross-reactivity). Thus, many patients with a peanut or a tree nut allergy avoid all nuts, relying on positive test results without clinical evidence of reactivity. In addition, coexisting pollen sensitivity may add to diagnostic uncertainty due to potential cross-reactivity between pollens and nuts. In this article, we discuss challenges in diagnosis and clinical management of peanut and tree nut allergy related to cross-reactivity and cosensitization, as well as the avoidance of nuts tested positive to reduce the risk of reactions by cross-contamination. Studies to provide more accurate characterization of genuine clinically relevant cross-reactivity or cosensitivity to multiple nuts are needed</style></abstract><notes><style face="normal" font="Arial">DA - 20161029IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Switzerland -CO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27793601">PM:27793601</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161029-EigenmannPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161029-EigenmannPA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161029, Eigenmann PA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez,J.</style></author><author><style face="normal" font="Arial"> Amaya,E.</style></author><author><style face="normal" font="Arial"> Acevedo,A.</style></author><author><style face="normal" font="Arial"> Celis,A.</style></author><author><style face="normal" font="Arial"> Caraballo,D.</style></author><author><style face="normal" font="Arial"> Cardona,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Group of Experimental and Clinical Allergy, IPS Universitaria, University of Antioquia, Medellin, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of Inducible Urticaria in Patients With Chronic Spontaneous Urticaria: Associated Risk Factors</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="470" start="464">464-470</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> cold urticaria</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermographism</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Information on the prevalence of inducible urticaria (IU) in patients with chronic spontaneous urticaria (CSU) and the factors affecting this prevalence is scarce in the literature. OBJECTIVES: To estimate the frequency of IU in patients with CSU and to explore possible factors associated with CSU. METHODS: Patients older than 12 years diagnosed with CSU and a control group with no history of urticaria were recruited from 2 different cities. All patients were questioned about triggers associated with exacerbation of urticaria, and challenge tests were performed for symptomatic dermographism, pressure, cold, water, and exercise. Atopy to mites and self-reactivity to autologous serum were evaluated using skin tests. RESULTS: The study population comprised 245 patients with CSU and 127 controls. Of the patients with CSU, 186 (75.9%) reported a physical trigger, although only 89 (36.3%) had a positive challenge test result. The challenge tests showed that symptomatic dermographism was the most common type of IU, affecting 24.8% of the CSU group, followed by cold, which affected 13.4%. In the control group, 3.9% of patients were positive for symptomatic dermographism. People living in Medellin city had a higher frequency of symptomatic dermographism 28.5% (odds ratio, 2.1; 95% CI, 1-4.4; P = .03) and cold urticaria 16.5% (odds ratio, 3.3; 95% CI, 1.125-9.8; P = .02) than did people living in Bogota (dermographism 14.4% and cold 5.2%). Atopy and self-reactivity were more frequent in patients with CSU than in the control group. CONCLUSIONS: Physical triggers must be verified by challenge tests to avoid unnecessary lifestyle restrictions. Environmental factors such as geographical characteristics could play a key role in the development of some types of IU, whereas atopy and self-reactivity are major risk factors for CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838325">PM:27838325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161113-SanchezJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161113-SanchezJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Sanchez J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bunne,J.</style></author><author><style face="normal" font="Arial"> Moberg,H.</style></author><author><style face="normal" font="Arial"> Hedman,L.</style></author><author><style face="normal" font="Arial"> Andersson,M.</style></author><author><style face="normal" font="Arial"> Bjerg,A.</style></author><author><style face="normal" font="Arial"> Lundback,B.</style></author><author><style face="normal" font="Arial"> Ronmark,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Clinical Medicine, Division of Occupational and Environmental Medicine, the OLIN Unit, Umea University, Umea, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Increase in Allergic Sensitization in Schoolchildren: Two Cohorts Compared 10 Years Apart</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="463.e1" start="457">457-463.e1</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> OLIN</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time trends</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Time trends of incidence of allergic sensitization are unknown and recent trends of prevalence and risk factors are lacking. OBJECTIVE: To estimate the incidence, prevalence, remission, risk factors, and time trends for allergic sensitization among schoolchildren followed from age 7 to 8 years to age 11 to 12 years. METHODS: In 2006, all children in grades 1 and 2 aged 7 to 8 years in 2 municipalities in northern Sweden were invited to a questionnaire survey and to skin prick testing to 10 common airborne allergens. The cohort was reexamined in 2010, with additional blood sampling for specific IgE. Participation rates were 90% (n = 1700) at age 7 to 8 years and 85% (n = 1657) at age 11 to 12 years. The results were compared with a cohort examined by identical methods 10 years earlier. RESULTS: The prevalence of positive skin prick test result to any allergen increased from 30% at age 7 to 8 years to 41% at age 11 to 12 years (P &lt; .001). The cumulative 4-year incidence was 18%, while remission was low. Sensitization to pollen and furred animals was most common. A family history of allergy was significantly associated with incident sensitization, whereas the presence of furred animals at home was negatively associated. The prevalence at age 7 to 8 years and at age 11 to 12 years and the 4-year incidence were all significantly higher compared with the cohort examined 10 years earlier. CONCLUSIONS: The prevalence of allergic sensitization increased by age as a consequence of a high incidence and a low remission. The trends of increasing incidence and prevalence among schoolchildren imply future increases in the prevalence of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838328">PM:27838328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-457-463.e1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-457-463.e1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Bunne J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bird,J.A.</style></author><author><style face="normal" font="Arial"> Groetch,M.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Bock,S.A.</style></author><author><style face="normal" font="Arial"> Leonard,S.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.H.</style></author><author><style face="normal" font="Arial"> Sicherer,S.</style></author><author><style face="normal" font="Arial"> Clark,A.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Vickery,B.</style></author><author><style face="normal" font="Arial"> Young,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex;</style></auth-address><titles><title><style face="normal" font="Arial">Conducting an Oral Food Challenge to Peanut in an Infant</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="311" start="301">301-311</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Results from the Learning Early About Peanut trial and its follow-up study suggest that early peanut introduction in the diets of high-risk infants may prevent the development of peanut allergy. Allergy organizations around the world released a unified statement, the Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High Risk Infants, in response to results from the Learning Early About Peanut trial, which recommends early introduction of peanut into the diet of those children at greatest risk of development of peanut allergy. As a result, it is expected that practicing allergists will experience an increased demand to perform an oral food challenge (OFC) in infants. Allergists often perform OFCs; however, conducting an OFC in an infant creates unique circumstances that have not been considered in previously published OFC guideline documents. The purpose of this workgroup report is to provide guidance to practitioners regarding the proper approach for conducting a peanut challenge in an infant</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.07.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838326">PM:27838326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161113-BirdJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161113-BirdJA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Bird JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.07.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,B.</style></author><author><style face="normal" font="Arial"> Divekar,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergic Diseases, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="Arial">Urinary N-methyl histamine levels relate to the presence of angioedema and decrease with the duration of chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="203" start="201">201-203</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838330">PM:27838330</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-201-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-201-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Patel B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Erp,F.C.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author><author><style face="normal" font="Arial"> Gorissen,D.M.</style></author><author><style face="normal" font="Arial"> Kok,I.L.</style></author><author><style face="normal" font="Arial"> van der Ent,C.K.</style></author><author><style face="normal" font="Arial"> Meijer,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pulmonology and Allergology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Guided introduction after negative double-blind placebo-controlled peanut challenges in children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="493" start="489">489-493</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27843067">PM:27843067</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161115-vanErpFC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161115-vanErpFC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, van Erp FC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kapoor,M.</style></author><author><style face="normal" font="Arial"> Bird,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Tex</style></auth-address><titles><title><style face="normal" font="Arial">Cow's milk protein is often tolerated by children with oat-induced FPIES</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="497" start="496">496-497</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27843068">PM:27843068</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-496-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-496-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Kapoor M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Madouri,F.</style></author><author><style face="normal" font="Arial"> Chenuet,P.</style></author><author><style face="normal" font="Arial"> Beuraud,C.</style></author><author><style face="normal" font="Arial"> Fauconnier,L.</style></author><author><style face="normal" font="Arial"> Marchiol,T.</style></author><author><style face="normal" font="Arial"> Rouxel,N.</style></author><author><style face="normal" font="Arial"> Ledru,A.</style></author><author><style face="normal" font="Arial"> Gallerand,M.</style></author><author><style face="normal" font="Arial"> Lombardi,V.</style></author><author><style face="normal" font="Arial"> Mascarell,L.</style></author><author><style face="normal" font="Arial"> Marquant,Q.</style></author><author><style face="normal" font="Arial"> Apetoh,L.</style></author><author><style face="normal" font="Arial"> Erard,F.</style></author><author><style face="normal" font="Arial"> LeBert,M.</style></author><author><style face="normal" font="Arial"> Trovero,F.</style></author><author><style face="normal" font="Arial"> Quesniaux,V.F.</style></author><author><style face="normal" font="Arial"> Ryffel,B.</style></author><author><style face="normal" font="Arial"> Togbe,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of experimental and molecular immunology and neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, 3B, rue de la Ferollerie, F-45071 Orleans-Cedex2, France, University of Orleans; Artimmune SAS, 13 Avenue Buffon, 45100-Orleans, France</style></auth-address><titles><title><style face="normal" font="Arial">PKC theta controls ILC2 and Th2 responses to house dust mite allergen</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1666" start="1650">1650-1666</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Protein Kinase C</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Protein Kinase C theta (PKC-theta), a serine/threonine kinase is involved in T helper 2 (Th2) cell activation and proliferation. Innate lymphoid cells 2 (ILC2) resemble Th2 cells; produce the Th2 cytokines IL-5 and IL-13, but lack antigen specific receptors. The mechanism by which PKC-theta drives innate immune cells to instruct Th2 responses in allergic lung inflammation remains unknown. OBJECTIVES: We hypothesized that PKC-theta contributes to ILC2 activation and may be necessary for ILC2 to instruct Th2 response. METHODS: PKC-theta gene expression was assessed in ILC subsets purified from human peripheral blood mononuclear cells (PBMC) and mouse lung ILC2. ILC2 activation and eosinophil recruitment, Th2 related cytokine and chemokine production, lung histopathology, IRF4 mRNA and NFAT1 protein expression, were determined. Adoptive transfer of ILC2 from WT mice was performed in WT and PKC-theta-/- mice. RESULTS: Here we report that PKC-theta is expressed in both human and mouse ILC2. Mice lacking PKC-theta had reduced ILC2, Th2 cell numbers and activation, airway hyperesponsiveness (AHR) as well as the expression of transcription factors IRF4 and NFAT1. Importantly, adoptive transfer of ILC2 restored eosinophil influx, IL-4, IL-5 and IL-13 production in lung tissue as well as Th2 cell activation. The pharmacological PKC-theta inhibitor (compound 20) given during allergen challenge reduced ILC2 numbers and activation as well as airway inflammation, IRF4 and NFAT1 expression. CONCLUSIONS: Therefore, our finding identifies PKC-theta as a critical factor for ILC2 activation and contributes to Th2 cell differentiation which is associated to IRF4 and NFAT1 expression in allergic lung inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746240">PM:27746240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161017-MadouriF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161017-MadouriF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Madouri F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ogburn,R.N.</style></author><author><style face="normal" font="Arial"> Randall,T.A.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Roberts,J.H.</style></author><author><style face="normal" font="Arial"> Mebrahtu,B.</style></author><author><style face="normal" font="Arial"> Karnuta,J.M.</style></author><author><style face="normal" font="Arial"> Rider,S.D.</style></author><author><style face="normal" font="Arial"> Kissling,G.E.</style></author><author><style face="normal" font="Arial"> London,R.E.</style></author><author><style face="normal" font="Arial"> Pomes,A.</style></author><author><style face="normal" font="Arial"> Arlian,L.</style></author><author><style face="normal" font="Arial"> Fitzgerald,M.C.</style></author><author><style face="normal" font="Arial"> Mueller,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chemistry Department, Duke University, Durham, NC</style></auth-address><titles><title><style face="normal" font="Arial">Are dust mite allergens more abundant and/or more stable than other Dermatophagoides pteronyssinus proteins?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1032" start="1030">1030-1032</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27771129">PM:27771129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161023-OgburnRN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161023-OgburnRN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Ogburn RN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Slovick,A.</style></author><author><style face="normal" font="Arial"> Douiri,A.</style></author><author><style face="normal" font="Arial"> Muir,R.</style></author><author><style face="normal" font="Arial"> Guerra,A.</style></author><author><style face="normal" font="Arial"> Tsioulos,K.</style></author><author><style face="normal" font="Arial"> Hay,E.</style></author><author><style face="normal" font="Arial"> Lam,E.P.</style></author><author><style face="normal" font="Arial"> Kelly,J.</style></author><author><style face="normal" font="Arial"> Peacock,J.L.</style></author><author><style face="normal" font="Arial"> Ying,S.</style></author><author><style face="normal" font="Arial"> Shamji,M.H.</style></author><author><style face="normal" font="Arial"> Cousins,D.J.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Till,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma, Allergy and Lung Biology, King's College London, School of Medicine, Guy's Hospital, London SE1 9RT</style></auth-address><titles><title><style face="normal" font="Arial">Intradermal Grass Pollen Allergen Immunotherapy for Seasonal Allergy: A Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1839" start="1830">1830-1839</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Area Under Curve</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phl p 5</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Preseasonal</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergies</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Repeated low dose grass pollen intradermal allergen injection suppresses allergen-induced cutaneous late phase responses, comparable with conventional subcutaneous and sublingual immunotherapy. OBJECTIVE: To evaluate the efficacy and safety of grass pollen intradermal immunotherapy in the treatment of allergic rhinitis. METHODS: We randomly assigned 93 adults with grass pollen allergic rhinitis to receive 7 pre-seasonal intradermal allergen injections (containing 7 nanograms of Phl p 5 major allergen) or histamine control. The primary endpoint was daily combined symptom-medication scores during the 2013 pollen season (area under curve). Analysis was by intention-to-treat. Skin biopsies were collected following intradermal allergen challenges and late phase responses measured four and seven, ten or thirteen months post-treatment. RESULTS: There was no significant difference in primary endpoint between treatment arms (active n=46, control n=47, median difference, 14; 95% CI -172.5-215.1; P=.80). Among secondary endpoints, nasal symptoms were worse in the intradermal treatment group, measured by daily scores (median difference, 35; 95% CI 4.0-67.5; P=.03) and visual-analog scales (median difference, 53; 95% CI -11.6-125.2; P=.05). In a per protocol analysis, intradermal immunotherapy was further associated with worse asthma symptoms and fewer symptom free days. Intradermal immunotherapy increased serum Phl p-specific IgE (P=.001) compared to the control arm. T cells cultured from biopsies of intradermal immunotherapy subjects showed higher expression of Th2 surface marker CRTH2 (P=.04) and lower Th1 marker CXCR (P=.01), respectively. Late phase responses remained inhibited seven months after treatment (P=.03). CONCLUSION: Intradermal allergen immunotherapy suppressed skin late responses but was not clinically effective and resulted in worsening of respiratory allergic symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20161024IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27773851">PM:27773851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161024-SlovickA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161024-SlovickA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161024, Slovick A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dullaers,M.</style></author><author><style face="normal" font="Arial"> Schuijs,M.J.</style></author><author><style face="normal" font="Arial"> Willart,M.</style></author><author><style face="normal" font="Arial"> Fierens,K.</style></author><author><style face="normal" font="Arial"> Van Moorleghem,J.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunoregulation and Mucosal Immunology, VIB Inflammation Research Center, Ghent University, Ghent, 9050 Belgium</style></auth-address><titles><title><style face="normal" font="Arial">House dust mite driven asthma and allergen specific T cells depend on B cells when the amount of inhaled allergen is limiting</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="88" start="76">76-88</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> central memory T cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory T cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immunology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic asthma is a CD4 Th2-lymphocyte driven disease characterized by airway hyper-responsiveness and eosinophilia. B cells can present antigens to CD4 T cells and produce IgE immunoglobulins which arms effector cells, however mouse models are inconclusive whether B cells are necessary for asthma development. OBJECTIVES: To address the role of B cells in a house dust mite (HDM) driven Th2-high asthma mouse model. METHODS: WT and B cell deficient muMT Mice were sensitized and challenged via the airways with HDM extracts. Antigen presenting capacities of B cells were studied using new TCR transgenic 1-DER mice specific for Der p 1 allergen. RESULTS: In vitro, activated B cells from HDM-exposed mice presented antigen to 1-DER T cells and induced a Th2 phenotype. In vivo, B cells were dispensable for activation of naive 1-DER T cells, but necessary for full expansion of primed 1-DER T cells. At high HDM challenge doses, B cells were not required for development of pulmonary asthmatic features, yet contributed to Th2 expansion in the MLN but not in the lungs. When the amount of challenge allergen was lowered, muMT mice had reduced asthma features. Under these limiting conditions, B cells contributed also to expansion of Th2 effector cells in the lungs and central memory T cells in the MLN CONCLUSION: B cells are a major part of the adaptive immune response to inhaled HDM allergen, particularly when the amount of inhaled allergen is low, by expanding allergen specific T cells</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746238">PM:27746238</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161017-DullaersM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161017-DullaersM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Dullaers M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Andersen,Y.M.</style></author><author><style face="normal" font="Arial"> Egeberg,A.</style></author><author><style face="normal" font="Arial"> Gislason,G.H.</style></author><author><style face="normal" font="Arial"> Skov,L.</style></author><author><style face="normal" font="Arial"> Knop,F.K.</style></author><author><style face="normal" font="Arial"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Adult atopic dermatitis and the risk of type 2 diabetes</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1059" start="1057">1057-1059</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Type 2 diabetes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">While AD is not an independent risk factor for T2D in adjusted analysis, age, smoking, alcohol abuse and use of systemic and topical corticosteroids may increase the risk of T2D in adults with AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27771322">PM:27771322</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161023-AndersenYM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161023-AndersenYM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Andersen YM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,D.W.</style></author><author><style face="normal" font="Arial"> Kulka,M.</style></author><author><style face="normal" font="Arial"> Jo,A.</style></author><author><style face="normal" font="Arial"> Eun,K.M.</style></author><author><style face="normal" font="Arial"> Arizmendi,N.</style></author><author><style face="normal" font="Arial"> Tancowny,B.P.</style></author><author><style face="normal" font="Arial"> Hong,S.N.</style></author><author><style face="normal" font="Arial"> Lee,J.P.</style></author><author><style face="normal" font="Arial"> Jin,H.R.</style></author><author><style face="normal" font="Arial"> Lockey,R.F.</style></author><author><style face="normal" font="Arial"> Kim,D.K.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology-Head and Neck Surgery, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Cross-Talk between Human Mast Cells and Epithelial Cells by IgE-mediated Periostin Production in Eosinophilic Nasal Polyps</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1695" start="1692">1692-1695</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Periostin is up-regulated in E-NP and is associated with disease severity and Th2 inflammatory markers. Periostin was produced by IgE-stimulated mast cells. Secreted periostin binds to integrin alphaV on the epithelial cell surface and induces TSLP release from epithelial cells in E-NP</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -CO - United States -CO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27771323">PM:27771323</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161023-KimDW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161023-KimDW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Kim DW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Christensen,M.J.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Successful treatment with omalizumab in challenge confirmed exercise-induced anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="206" start="204">204-206</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27839749">PM:27839749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-204-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-204-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161114, Christensen MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Motosue,M.S.</style></author><author><style face="normal" font="Arial"> Bellolio,M.F.</style></author><author><style face="normal" font="Arial"> Van Houten,H.K.</style></author><author><style face="normal" font="Arial"> Shah,N.D.</style></author><author><style face="normal" font="Arial"> Campbell,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergic Diseases, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="Arial">Increasing Emergency Department Visits for Anaphylaxis, 2005-2014</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="175" start="171">171-175</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis is a potentially life-threatening systemic allergic reaction. Studies suggest that the incidence of anaphylaxis is increasing; however, recent trends in emergency department (ED) visits for anaphylaxis in the United States have not been studied. OBJECTIVE: To examine trends in the incidence and rates of anaphylaxis-related ED visits from 2005 through 2014. METHODS: We retrospectively analyzed data from a national administrative claims database including commercially insured and Medicare Advantage patients. We identified all ED visits for anaphylaxis and calculated rates as number of anaphylaxis-related ED visits per 100,000 enrollees. Rates were compared over time and by age and trigger. RESULTS: During the 10-year time period, 56,212 ED visits for anaphylaxis were identified. The median (interquartile range) age was 36 (17-52 years) years, and 58% were female. Most cases (57%) were due to unspecified triggers, 27% were associated with food, 12% were medication related, and 4% were due to insect venom. The overall rate of anaphylaxis per 100,000 enrollees increased by 101%, from 14.2 in 2005 to 28.6 in 2014 (P &lt; .001). Rates of ED visits for anaphylaxis increased in all age groups, but the greatest increase was in children aged 5 to 17 years (196% increase; P &lt; .001). The rate of food-related anaphylaxis increased by 124% (P &lt; .001), and the rate of medication-related anaphylaxis increased by 212% (P &lt; .001). CONCLUSIONS: ED visits for anaphylaxis increased between 2005 and 2014. Increases in ED visits were greatest among children</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27818135">PM:27818135</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-171-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-171-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Motosue MS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Posa,D.</style></author><author><style face="normal" font="Arial"> Perna,S.</style></author><author><style face="normal" font="Arial"> Resch,Y.</style></author><author><style face="normal" font="Arial"> Lupinek,C.</style></author><author><style face="normal" font="Arial"> Panetta,V.</style></author><author><style face="normal" font="Arial"> Hofmaier,S.</style></author><author><style face="normal" font="Arial"> Rohrbach,A.</style></author><author><style face="normal" font="Arial"> Hatzler,L.</style></author><author><style face="normal" font="Arial"> Grabenhenrich,L.</style></author><author><style face="normal" font="Arial"> Tsilochristou,O.</style></author><author><style face="normal" font="Arial"> Chen,K.W.</style></author><author><style face="normal" font="Arial"> Bauer,C.P.</style></author><author><style face="normal" font="Arial"> Hoffman,U.</style></author><author><style face="normal" font="Arial"> Forster,J.</style></author><author><style face="normal" font="Arial"> Zepp,F.</style></author><author><style face="normal" font="Arial"> Schuster,A.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Pneumology &amp; Immunology, Charite-Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="549" start="541">541-549</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 11</style></keyword><keyword><style face="normal" font="Arial"> Der p 14</style></keyword><keyword><style face="normal" font="Arial"> Der p 15</style></keyword><keyword><style face="normal" font="Arial"> Der p 18</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Der p 21</style></keyword><keyword><style face="normal" font="Arial"> Der p 23</style></keyword><keyword><style face="normal" font="Arial"> Der p 4</style></keyword><keyword><style face="normal" font="Arial"> Der p 5</style></keyword><keyword><style face="normal" font="Arial"> Der p 7</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The evolution of the IgE response to the numerous allergen molecules of Dermatophagoides pteronyssinus is still unknown. OBJECTIVES: We sought to characterize the evolutionary patterns of the IgE response to 12 molecules of D pteronyssinus from birth to adulthood and to investigate their determinants and clinical relevance. METHODS: We investigated the clinical data and sera of 722 participants in the German Multicenter Allergy Study, a birth cohort started in 1990. Diagnoses of current allergic rhinitis (AR) related to mite allergy and asthma were based on yearly interviews at the ages of 1 to 13 years and 20 years. IgE to the extract and 12 molecules of D pteronyssinus were tested by means of ImmunoCAP and microarray technology, respectively, in sera collected at ages 1, 2, 3, 5, 6, 7, 10, 13, and 20 years. Exposure to mites at age 6 and 18 months was assessed by measuring Der p 1 weight/weight concentration in house dust. RESULTS: One hundred ninety-one (26.5%) of 722 participants ever had IgE to D pteronyssinus extract (>/=0.35 kUA/L). At age 20 years, their IgE recognized most frequently Der p 2, Der p 1, and Der p 23 (group A molecules; prevalence, >40%), followed by Der p 5, Der p 7, Der p 4, and Der p 21 (group B molecules; prevalence, 15% to 30%) and Der p 11, Der p 18, clone 16, Der p 14, and Der p 15 (group C molecules; prevalence, &lt;10%). IgE sensitization started almost invariably with group A molecules and expanded sequentially first to group B and finally to group C molecules. Early IgE sensitization onset, parental hay fever, and higher exposure to mites were associated with a broader polymolecular IgE sensitization pattern. Participants reaching the broadest IgE sensitization stage (ie, ABC) had significantly higher risk of mite-related AR and asthma than unsensitized participants. IgE to Der p 1 or Der p 23 at age 5 years or less predicted asthma at school age. CONCLUSIONS: Parental hay fever and early exposure to D pteronyssinus allergens promote IgE polysensitization to several D pteronyssinus molecules, which in turn predicts current mite-related AR and current/future asthma. These results might inspire predictive algorithms and prevention strategies against the progression of IgE sensitization to mites toward AR and asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161029IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - Journal ArticleCO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27793411">PM:27793411</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161029-PosaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161029-PosaD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161029, Posa D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hose,A.J.</style></author><author><style face="normal" font="Arial"> Depner,M.</style></author><author><style face="normal" font="Arial"> Illi,S.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Fuchs,O.</style></author><author><style face="normal" font="Arial"> Pfefferle,P.I.</style></author><author><style face="normal" font="Arial"> Schmausser-Hechfellner,E.</style></author><author><style face="normal" font="Arial"> Genuneit,J.</style></author><author><style face="normal" font="Arial"> Lauener,R.</style></author><author><style face="normal" font="Arial"> Karvonen,A.M.</style></author><author><style face="normal" font="Arial"> Roduit,C.</style></author><author><style face="normal" font="Arial"> Dalphin,J.C.</style></author><author><style face="normal" font="Arial"> Riedler,J.</style></author><author><style face="normal" font="Arial"> Pekkanen,J.</style></author><author><style face="normal" font="Arial"> von Mutius,E.</style></author><author><style face="normal" font="Arial"> Ege,M.J.</style></author><author><style face="normal" font="Arial"> Bauer,C.P.</style></author><author><style face="normal" font="Arial"> Forster,J.</style></author><author><style face="normal" font="Arial"> Zepp,F.</style></author><author><style face="normal" font="Arial"> Wahn,V.</style></author><author><style face="normal" font="Arial"> Schuster,A.</style></author><author><style face="normal" font="Arial"> Bergmann,R.L.</style></author><author><style face="normal" font="Arial"> Bergmann,K.E.</style></author><author><style face="normal" font="Arial"> Reich,A.</style></author><author><style face="normal" font="Arial"> Grabenhenrich,L.</style></author><author><style face="normal" font="Arial"> Schaub,B.</style></author><author><style face="normal" font="Arial"> Loss,G.J.</style></author><author><style face="normal" font="Arial"> Renz,H.</style></author><author><style face="normal" font="Arial"> Kabesch,M.</style></author><author><style face="normal" font="Arial"> Roponen,M.</style></author><author><style face="normal" font="Arial"> Hyvarinen,A.</style></author><author><style face="normal" font="Arial"> Tiittanen,P.</style></author><author><style face="normal" font="Arial"> Remes,S.</style></author><author><style face="normal" font="Arial"> Braun-Fahrlander,C.</style></author><author><style face="normal" font="Arial"> Frei,R.</style></author><author><style face="normal" font="Arial"> Kaulek,V.</style></author><author><style face="normal" font="Arial"> Dalphin,M.L.</style></author><author><style face="normal" font="Arial"> Doekes,G.</style></author><author><style face="normal" font="Arial"> Blumer,N.</style></author><author><style face="normal" font="Arial"> Frey,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, D-80337, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Latent class analysis reveals clinically relevant atopy phenotypes in two birth cohorts</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1945" start="1935">1935-1945</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> latent class analysis</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Phenotypes of childhood-onset asthma are characterized by distinct trajectories and functional features. For atopy, definition of phenotypes during childhood is less clear. OBJECTIVE: To define phenotypes of atopic sensitization over the first 6 years of life by a latent class analysis (LCA) integrating three dimensions of atopy: allergen specificity, time course, and levels of specific IgE. METHODS: Phenotypes were defined by LCA in 680 children of the MAS and 766 of the PASTURE birth cohorts and compared to classical non-disjunctive definitions of seasonal, perennial, and food sensitization with respect to atopic diseases and lung function. Cytokine levels were measured in PASTURE. RESULTS: The LCA classified predominantly by type and multiplicity of sensitization (food versus inhalant), allergen combinations, and sIgE levels. Latent classes were related to atopic disease manifestations with higher sensitivity and specificity than the classical definitions. LCA detected in both cohorts consistently a distinct group of children with severe atopy characterized by high seasonal sIgE and a strong propensity for asthma, hay fever, eczema and impaired lung function even in children without an established asthma diagnosis. Severe atopy was associated with an elevated interleukin-5/interferon-gamma ratio. A path analysis among sensitized children revealed that among all features of severe atopy only excessive sIgE production early in life impacted on asthma risk. CONCLUSIONS: LCA revealed a set of benign, symptomatic, and severe atopy phenotypes. The severe phenotype emerged as a latent condition with signs of a dysbalanced immune response. It determined high asthma risk via excessive sIgE production and directly impacted on impaired lung function</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Switzerland -CO - Netherlands -CO - Finland -CO - France -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27771325">PM:27771325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161023-AndersenYM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161023-AndersenYM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Hose AJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kolkhir,P.</style></author><author><style face="normal" font="Arial"> Church,M.K.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Schmetzer,O.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia</style></auth-address><titles><title><style face="normal" font="Arial">Autoimmune chronic spontaneous urticaria: what we know and what we don't know</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1781" start="1772">1772-1781</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Causality</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Chronic spontaneous urticaria (CSU) is a mast-cell driven skin disease, characterized by the recurrence of transient wheals, angioedema, or both for more than 6 weeks. Autoimmunity is thought to be one of the most frequent causes of CSU. Type I and type II autoimmunity, i.e. IgE to autoallergens and IgG autoantibodies to IgE or its receptor, respectively, have been implicated in the etiology and pathogenesis of CSU. We analyzed the relevant literature and assessed the existing evidence in support of a role for type I and II autoimmunity in CSU with the help of Hill's criteria of causality. For each of these criteria, i.e. strength of association, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment and analogy, we categorized the strength of evidence as "insufficient", "low", "moderate" or "high" and then assigned levels of causality for type I and II autoimmunity in CSU, from level 1 (causal relationship) to level 5 (causality not likely). Based on the evidence in support of Hill's criteria, type I autoimmunity in CSU has level 3 causality (causal relationship suggested) and type II autoimmunity has level 2 causality (causal relationship likely). There are still many aspects of the pathologic mechanisms of CSU that need to be resolved, but it is becoming clear that there are at least two distinct pathways, type I and type II autoimmunity, that contribute to the pathogenesis of this complex disease</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Russia -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27777182">PM:27777182</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161025-KolkhirP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161025-KolkhirP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Kolkhir P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rehman,R.</style></author><author><style face="normal" font="Arial"> Mabalirajan,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Molecular Pathobiology of Respiratory Diseases, Council of Scientific and Industrial Research, Institute of Genomics and Integrative Biology, Delhi, India</style></auth-address><titles><title><style face="normal" font="Arial">Proficient DNA repair in house dust mite-induced asthma?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="714" start="713">713-714</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Repair</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161116IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27847144">PM:27847144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161116-RehmanR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161116-RehmanR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161116, Rehman R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">DeBoer,E.M.</style></author><author><style face="normal" font="Arial"> Spielberg,D.R.</style></author><author><style face="normal" font="Arial"> Brody,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Colorado Anschutz Medical Campus and Breathing Institute Children's Hospital Colorado, 13123 E. 16(th) Avenue B-395, Aurora, CO USA 80045</style></auth-address><titles><title><style face="normal" font="Arial">Journal Allergy &amp; Clinical Immunology Perspective: Clinical potential for imaging in asthma and other lung disorders</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="28" start="21">21-28</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoscopy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> EIT</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> MRI</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> radiography</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The ability of lung imaging to phenotype patients, determine prognosis, and to predict response to treatments is expanding in clinical and translational research. The purpose of this perspective is to describe current imaging modalities that may be useful clinical tools in asthma and other lung disorders and to explore some of the new developments in imaging modalities of the lung. These imaging modalities include chest radiography (CXR), computed tomography (CT), lung magnetic resonance imaging (MRI), electrical impedance tomography (EIT), bronchoscopy, and others</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871877">PM:27871877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161122-DeBoerEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161122-DeBoerEM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, DeBoer EM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fritzsching,B.</style></author><author><style face="normal" font="Arial"> Hagner,M.</style></author><author><style face="normal" font="Arial"> Dai,L.</style></author><author><style face="normal" font="Arial"> Christochowitz,S.</style></author><author><style face="normal" font="Arial"> Agrawal,R.</style></author><author><style face="normal" font="Arial"> van Bodegom,C.</style></author><author><style face="normal" font="Arial"> Schmidt,S.</style></author><author><style face="normal" font="Arial"> Schatterny,J.</style></author><author><style face="normal" font="Arial"> Hirtz,S.</style></author><author><style face="normal" font="Arial"> Brown,R.</style></author><author><style face="normal" font="Arial"> Goritzka,M.</style></author><author><style face="normal" font="Arial"> Duerr,J.</style></author><author><style face="normal" font="Arial"> Zhou-Suckow,Z.</style></author><author><style face="normal" font="Arial"> Mall,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Translational Pulmonology, Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), University of Heidelberg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Impaired mucus clearance exacerbates allergen-induced type 2 airway inflammation in juvenile mice</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="203" start="190">190-203</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Mucociliary Clearance</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Type 2 airway inflammation plays a central role in the pathogenesis of allergen-induced asthma, but the underlying mechanisms remain poorly understood. We recently demonstrated that reduced mucociliary clearance, a characteristic feature of asthma, produces spontaneous type 2 airway inflammation in juvenile Scnn1b-transgenic (Scnn1b-Tg) mice. OBJECTIVE: To determine the role of impaired mucus clearance in the pathogenesis of allergen-induced type 2 airway inflammation and identify cellular sources of the signature cytokine IL-13. METHODS: We challenged juvenile Scnn1b-Tg and wild-type mice with Aspergillus fumigatus and house dust mite allergen and compared effects on airway eosinophilia, type 2 cytokine levels, goblet cell metaplasia and airway hyperresponsiveness. Further, we determined cellular sources of IL-13 and effects of genetic deletion of the key type 2 signal transducing molecule STAT6, and evaluated effects of therapeutic improvement of mucus clearance. RESULTS: Reduced mucociliary allergen clearance exacerbated Stat6-dependent secretion of type 2 cytokines, airway eosinophilia and airway hyperresponsiveness in juvenile Scnn1b-Tg mice. IL-13 was elevated in airway epithelial cells, macrophages, type 2 innate lymphoid cells and Th2 cells along with increased Il33 in the airway epithelium of Scnn1b-Tg mice. Treatment with the epithelial Na+ channel blocker amiloride improving airway surface hydration and mucus clearance reduced allergen-induced inflammation in Scnn1b-Tg. CONCLUSION: Our data support that impaired clearance of inhaled allergen triggering IL-13 production by multiple cell types in the airways plays an important role in the pathogenesis of type 2 airway inflammation and suggest therapeutic improvement of mucociliary clearance as a novel treatment strategy for children with allergen-induced asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161120IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27865862">PM:27865862</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161120-FritzschingB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161120-FritzschingB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Fritzsching B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morita,H.</style></author><author><style face="normal" font="Arial"> Moro,K.</style></author><author><style face="normal" font="Arial"> Koyasu,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Innate lymphoid cells in allergic and nonallergic inflammation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1264" start="1253">1253-1264</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> alarmins</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">In the last decade, the full picture of the role of innate lymphoid cells (ILCs) has been gradually revealed. ILCs are classified into 3 groups based on their transcription factors and cytokine production patterns, which mirror helper T-cell subsets. Unlike T cells and B cells, ILCs do not have antigen receptors. They promptly respond to multiple tissue-derived factors, such as cytokines and alarmins, and produce multiple proinflammatory and immunoregulatory cytokines. It has been reported that ILC-derived cytokines are important for the induction and regulation of inflammation. Accumulating evidence suggests that ILCs play substantial roles in protection against infection and the pathogenesis of inflammatory diseases, such as allergic diseases and autoimmune diseases. Different ILC subsets localize in distinct tissue/organ niches and receive tissue-derived signals on different types of inflammation, which allows them to acquire diverse phenotypes with specialized effector capacities. In this review we highlight the roles of ILCs in a variety of organs, such as the airway, skin, and gastrointestinal tract, in the context of allergic and nonallergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Switzerland -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27817797">PM:27817797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1253-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1253-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Morita H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Robinette,M.L.</style></author><author><style face="normal" font="Arial"> Colonna,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology &amp; Immunology, Washington University School of Medicine, St Louis, Mo</style></auth-address><titles><title><style face="normal" font="Arial">Immune modules shared by innate lymphoid cells and T cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1251" start="1243">1243-1251</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">In recent years, innate lymphoid cells (ILCs) have emerged as innate correlates to T cells. The similarities between ILCs and T cells indicate that lymphocytes of fundamentally distinct lineages can share core "immune modules" that encompass transcriptional circuitry and effector functions while using nonredundant complementary mechanisms of pattern recognition to enact these functions. We review modules currently recognized to be shared between ILCs and T cells</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27817796">PM:27817796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1243-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1243-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Robinette ML</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Freidl,R.</style></author><author><style face="normal" font="Arial"> Gstoettner,A.</style></author><author><style face="normal" font="Arial"> Baranyi,U.</style></author><author><style face="normal" font="Arial"> Swoboda,I.</style></author><author><style face="normal" font="Arial"> Stolz,F.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> Wekerle,T.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Linhart,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1905" start="1897">1897-1905</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiserum</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Carp</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cyp c 1</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic variant</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic variants</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope recognition</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbit IgG</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> RBL</style></keyword><keyword><style face="normal" font="Arial"> RBL assay</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fish is a frequent elicitor of severe IgE-mediated allergic reactions. Beside avoidance, there is currently no allergen-specific therapy available. Hypoallergenic variants of the major fish allergen, parvalbumin, for specific immunotherapy based on mutation of the two calcium-binding sites have been developed. OBJECTIVE: To establish a mouse model of fish allergy resembling human disease and to investigate whether mouse and rabbit IgG antibodies induced by immunization with a hypoallergenic mutant of the major carp allergen, mCyp c 1, protect against allergic symptoms in sensitized mice. METHODS: C3H/HeJ mice were sensitized with rCyp c 1 or carp extract by intragastric gavage. Antibody, cellular immune responses and epitope specificity in sensitized mice were investigated by ELISA, RBL assay, T cell proliferation experiments using rCyp c 1 and overlapping peptides spanning the Cyp c 1 sequence. Anti-mCyp c 1 mouse and rabbit sera were tested for their ability to inhibit IgE recognition of Cyp c 1, Cyp c 1-specific basophil degranulation and Cyp c 1-induced allergic symptoms in the mouse model. RESULTS: A mouse model of fish allergy mimicking human disease regarding IgE epitope recognition and symptoms as close as possible was established. Administration of antisera generated in mice and rabbits by immunization with a hypoallergenic Cyp c 1 mutant inhibited IgE binding to Cyp c 1, Cyp c 1-induced basophil degranulation and allergic symptoms caused by allergen challenge in sensitized mice. CONCLUSION: Antibodies induced by immunization with a hypoallergenic Cyp c 1 mutant protect against allergic reactions in a murine model of fish allergy. CLINICAL IMPLICATIONS: IgG antibodies induced by vaccination with a hypoallergenic Cyp c 1 mutant may protect against fish allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161123IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27876628">PM:27876628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161123-FreidlR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161123-FreidlR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161123, Freidl R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Belgrave,D.</style></author><author><style face="normal" font="Arial"> Henderson,J.</style></author><author><style face="normal" font="Arial"> Simpson,A.</style></author><author><style face="normal" font="Arial"> Buchan,I.</style></author><author><style face="normal" font="Arial"> Bishop,C.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Imperial College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Disaggregating Asthma: Big Investigation vs. Big Data</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="407" start="400">400-407</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Data Mining</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mining</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pressing</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We are facing a major challenge in bridging the gap between identifying subtypes of asthma, to understanding causal mechanisms, and translating this knowledge into personalized prevention and management strategies. In recent years, "big data" has been sold as a panacea for generating hypotheses and driving new frontiers of healthcare; the idea that the data must and will speak for themselves is fast becoming a new dogma. One of the dangers of ready accessibility of healthcare data and computational tools for data analysis is that the process of data mining may become uncoupled from the scientific process of clinical interpretation, understanding the provenance of the data and external validation. Although advances in computational methods can be valuable for using unexpected structure in data to generate hypotheses, there remains a need for testing hypotheses and interpreting results with scientific rigor. We argue for combining data-driven and hypothesis-driven methods in a careful synergy, and the importance of carefully characterized birth and patient cohorts with genetic, phenotypic, biological and molecular data in this process cannot be overemphasized. The main challenge on the road ahead is to harness 'bigger' healthcare data in ways that produce meaningful clinical interpretation and to translate this into better diagnoses and properly personalized prevention and treatment plans. There is a pressing need for cross-disciplinary research with an integrative approach to data science, whereby basic scientists, clinicians, data analysts and epidemiologists work together to understand the heterogeneity of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871876">PM:27871876</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161122-BelgraveD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161122-BelgraveD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Belgrave D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okubo,K.</style></author><author><style face="normal" font="Arial"> Masuyama,K.</style></author><author><style face="normal" font="Arial"> Imai,T.</style></author><author><style face="normal" font="Arial"> Okamiya,K.</style></author><author><style face="normal" font="Arial"> Stage,B.S.</style></author><author><style face="normal" font="Arial"> Seitzberg,D.</style></author><author><style face="normal" font="Arial"> Konno,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and Safety of the SQ House Dust Mite SLIT-tablet in Japanese Adults and Adolescents with House Dust Mite-induced Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1848" start="1840">1840-1848</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The SQ HDM SLIT-tablet has been approved in 11 European countries and Japan for patients suffering from house dust mite (HDM) respiratory allergic disease. OBJECTIVE: This trial was conducted to confirm efficacy and safety in Japanese patients with moderate to severe HDM allergic rhinitis (AR). METHODS: The trial was a randomized, double-blind, placebo-controlled trial including 946 Japanese adults and adolescents (12-64 years). Subjects were randomly assigned to daily treatment with SQ HDM SLIT-tablet at a dose of 10,000 JAU or 20,000 JAU or with placebo (1:1:1). Primary endpoint was the total combined rhinitis score (TCRS) composed of AR symptom and medication scores, during the efficacy evaluation period. Symptom and medication scores of AR and conjunctivitis, rhinitis quality of life, and symptom-free and -severe days were evaluated as secondary endpoints. RESULTS: Analysis of the primary endpoint demonstrated statistically significant reductions of the TCRS of 1.15, 22% (p&lt;.001) in the 10,000 JAU and 0.99, 19% (p&lt;.001) in the 20,000 JAU compared to placebo. The statistically significant treatment effect was evident from 12 weeks of treatment and onwards. All secondary endpoints, except AR medication score, were statistically significant in favor of active treatment compared to placebo. Post hoc analysis of TCRS in adolescents showed the same efficacy as adults (p&lt;.05). The treatment was well-tolerated both adults and adolescents. CONCLUSION: The trial confirmed efficacy and safety profile of the SQ HDM SLIT-tablet in Japanese adult and adolescent patients with moderate to severe HDM AR. These data support the robust efficacy and safety profile of previously reported European data</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864024">PM:27864024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161119-OkuboK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161119-OkuboK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Okubo K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bachert,C.</style></author><author><style face="normal" font="Arial"> Gevaert,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Upper Airways Research Laboratory and ENT-Department, Ghent University Hospital, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Advances in rhinitis and rhinosinusitis in 2015</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1283" start="1277">1277-1283</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> disease-modifying effect</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> Superantigens</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">The last year has seen great progress in the understanding of upper airway disease and in its management. For allergic rhinitis, authors focused on the prediction of and effect on the natural course of disease. New evidence was published for the disease-modifying effect of allergen immunotherapy in terms of avoidance of new sensitizations and prevention of asthma in either randomized or real-life studies. Specifically, for patients with house dust mite allergies, which are often underestimated and difficult to diagnose, the efficacy of SQ house dust mite sublingual immunotherapy tablets has been demonstrated in patients with allergic rhinitis and asthma. For the first time, allergen immunotherapy significantly reduced asthma exacerbations. In patients with chronic rhinosinusitis, a novel endotyping approach purely based on T helper cell biomarkers has been developed and has shown clinical relevance through associations with asthma comorbidity and recurrence after surgery. Severe nasal polyposis with high risk for asthma comorbidity and disease recurrence is characterized by type 2 inflammatory patterns, including IgE antibodies to staphylococcal superantigens; several studies using biologic agents have targeted exactly this spectrum of mediators. This goes in parallel with new knowledge on even more type 2 mediators derived from epithelial cells, which will expand the number of possible candidates for innovative intervention</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27817798">PM:27817798</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1277-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1277-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Bachert C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Levin,M.</style></author><author><style face="normal" font="Arial"> Goga,A.</style></author><author><style face="normal" font="Arial"> Doherty,T.</style></author><author><style face="normal" font="Arial"> Coovadia,H.</style></author><author><style face="normal" font="Arial"> Sanders,D.</style></author><author><style face="normal" font="Arial"> Green,R.J.</style></author><author><style face="normal" font="Arial"> Kling,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Paediatric Allergology, University of Cape Town.</style></auth-address><titles><title><style face="normal" font="Arial">Allergy-and-infant-feeding guidelines in the context of resource-constrained settings</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="458" start="455">455-458</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.jaci.2016.09.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27856332">PM:27856332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161118-LevinM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161118-LevinM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Levin M</style></custom2><misc3><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.jaci.2016.09.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,J.</style></author><author><style face="normal" font="Arial"> Guo,A.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Bin,L.</style></author><author><style face="normal" font="Arial"> He,Y.</style></author><author><style face="normal" font="Arial"> Zhu,W.</style></author><author><style face="normal" font="Arial"> Yan,S.</style></author><author><style face="normal" font="Arial"> Peng,C.</style></author><author><style face="normal" font="Arial"> Chen,M.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Su,J.</style></author><author><style face="normal" font="Arial"> Yi,M.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Zeng,W.</style></author><author><style face="normal" font="Arial"> Leung,D.Y.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China</style></auth-address><titles><title><style face="normal" font="Arial">Association of ORAI1 Gene Polymorphisms with Chronic Spontaneous Urticaria and the Efficacy of the Nonsedating H1-antihistamine Desloratadine</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1388" start="1386">1386-1388</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> desloratadine</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene polymorphism</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Human ORAI1 polymorphisms were associated with susceptibility to CSU, and the South Han Chinese CSU who carry rs3741595C allele have reduced responsiveness to nonsedating H1-antihistamines</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864023">PM:27864023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161119-LiJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161119-LiJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Li J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bush,R.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Pulmonary, Critical Care, and Sleep Medicine, University of Wisconsin, Madison, Wis</style></auth-address><titles><title><style face="normal" font="Arial">Advances in allergen immunotherapy in 2015</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1291" start="1284">1284-1291</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">The year 2015 saw a significant number of advances in allergen immunotherapy (AIT), and several of these are reviewed in this report. Although AIT has been used for more than 100 years, investigations into optimal treatment approaches and mechanisms are ongoing. Among the highlights was a report by an international group of experts who reviewed AIT guidelines from the major specialty societies and addressed potential unmet needs. Herein, advances in the effectiveness, safety, and mechanisms of sublingual and oral immunotherapy are reviewed. Development of hypoallergenic vaccines to enhance safety, newer routes and regimens to improve efficacy, and biomarkers to monitor immunotherapy are also discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27817799">PM:27817799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1284-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1284-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Bush RK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Andersen,Y.M.</style></author><author><style face="normal" font="Arial"> Egeberg,A.</style></author><author><style face="normal" font="Arial"> Gislason,G.H.</style></author><author><style face="normal" font="Arial"> Skov,L.</style></author><author><style face="normal" font="Arial"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.</style></auth-address><titles><title><style face="normal" font="Arial">Autoimmune diseases in adults with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Causality</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="10" Year="2016">2016/10/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An increased susceptibility to autoimmune disease has been shown in patients with atopic dermatitis (AD), but data remain scarce and inconsistent. OBJECTIVE: We examined the co-occurrence of selected autoimmune diseases in adult patients with AD. METHODS: Nationwide health registers were used. Adult patients with a hospital diagnosis of AD in Denmark between 1997 and 2012 were included as cases (n = 8112) and matched with controls (n = 40,560). The occurrence of autoimmune diseases was compared in the 2 groups. Logistic regression was used to estimate odds ratios. RESULTS: AD was significantly associated with 11 of 22 examined autoimmune diseases. In addition, AD was associated with having multiple autoimmune comorbidities. Patients with a history of smoking had a significantly higher occurrence of autoimmune comorbidities compared to nonsmokers. LIMITATIONS: This study was limited to adult patients with AD. No information about AD severity or degree of tobacco consumption was available. Results from a hospital population of AD patients cannot be generalized to the general population. CONCLUSIONS: Our results suggest a susceptibility of autoimmune diseases in adult patients with AD, especially in smokers. While we cannot conclude on causality based on these data, an increased awareness of autoimmune comorbidities in patients with AD may be warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20161015IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2016.08.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27742171">PM:27742171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20161015-AndersenYM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20161015-AndersenYM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161015, Andersen YM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2016.08.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weiss,D.</style></author><author><style face="normal" font="Arial"> Schaschinger,M.</style></author><author><style face="normal" font="Arial"> Ristl,R.</style></author><author><style face="normal" font="Arial"> Gruber,R.</style></author><author><style face="normal" font="Arial"> Kopp,T.</style></author><author><style face="normal" font="Arial"> Stingl,G.</style></author><author><style face="normal" font="Arial"> Bangert,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Division of Immunology, Allergy, and Infectious Diseases, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Ustekinumab treatment in severe atopic dermatitis: Down-regulation of T-helper 2/22 expression</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> p40</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="10" Year="2016">2016/10/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It has recently been suggested that patients with moderate to severe atopic dermatitis (AD) may profit from anti-interleukin (IL)-12/-23 p40 therapy. OBJECTIVE: We sought to assess the immunologic effects of ustekinumab treatment on AD skin and to correlate them with the clinical efficacy of this drug. METHODS: We investigated the course of 3 patients with severe AD who were administered 45 mg of subcutaneous ustekinumab over a period of 16 weeks. Clinical scores and skin biopsy specimens, taken at baseline and at week 8, were used to assess changes in disease severity. RESULTS: All patients showed a gradual improvement of the disease, achieving a 50% reduction in the Eczema Area and Severity Index score by week 16. Immunohistology of skin biopsy specimens revealed a significant decrease in the degree of epidermal hyperplasia/proliferation and the number of infiltrating dermal T cells, dendritic cells, and mast cells after treatment. Using quantitative real-time polymerase chain reaction of lesional skin, we found a clear reduction of T-helper 2-/22-associated molecules after therapy. LIMITATIONS: The small number of patients (n = 3) limits efficacy analysis and warrants prospective placebo-controlled studies in larger patient cohorts. CONCLUSION: Blocking IL-12/-23 p40 could be beneficial for a subgroup of patients with severely infiltrated AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2016.07.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27745907">PM:27745907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20161017-WeissD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20161017-WeissD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Weiss D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2016.07.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tang,H.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Xu,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development of Loop-Mediated Isothermal Amplification (LAMP) Assay for the Rapid Detection of Alternaria alternata</style></title><secondary-title><style face="normal" font="Arial">J AOAC Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J AOAC Int</style></abbr-1></periodical><pages end="103" start="99">99-103</pages><volume><style face="normal" font="Arial">100</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity pneumonitis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Fungi of the Alternaria genus are associated with allergic diseases, with Alternaria alternata being one of the most prevalent species. A. alternata has been frequently reported as the etiologic agent of hypersensitivity pneumonitis, allergic rhinosinusitis, bronchial asthma, and other diseases. In this study, we developed a loop-mediated isothermal amplification (LAMP) assay and a real-time PCR assay to detect low levels of A. alternata in herbal tea samples. The LAMP assay can detect as little as 3 pg/muL of A. alternata genomic DNA with high specificity. In addition, both the LAMP assay and the real-time PCR assay can be used for quantification of A. alternata. Although the newly developed LAMP assay is more rapid and specific in A. alternata identification, the real-time PCR assay is more precise in quantitation analysis</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1060-3271 (Print)IS - 1060-3271 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.5740/jaoacint.16-0196</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27760588">PM:27760588</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20161020, Tang H</style></custom2><misc3><style face="normal" font="Arial">10.5740/jaoacint.16-0196</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Menon,J.C.</style></author><author><style face="normal" font="Arial"> Joseph,J.K.</style></author><author><style face="normal" font="Arial"> Jose,M.P.</style></author><author><style face="normal" font="Arial"> Dhananjaya,B.L.</style></author><author><style face="normal" font="Arial"> Oommen,O.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cardiologist, Amrita Institute of Medical Sciences, Amrita University, Kochi, Kerala</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Profile and Laboratory Parameters in 1051 Victims of Snakebite from a Single Centre in Kerala, South India</style></title><secondary-title><style face="normal" font="Arial">J Assoc Physicians India</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Assoc Physicians India</style></full-title></periodical><pages end="29" start="22">22-29</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> South India</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Snakebite is an occupational hazard causing considerable morbidity and mortality worldwide, particularly so in tropical countries like India. OBJECTIVE: The aim of this study is to (i) review the demographic, clinical and laboratory findings in patients (1051) admitted with venomous snakebite (ii) to correlate mortality, morbidity and duration of hospital stay with clinical signs, symptoms and laboratory parameters. METHODS: A retrospective study of 1051 patients treated for snakebite over 10 years (2</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 0004-5772 (Print)IS - 0004-5772 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27762105">PM:27762105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Assoc Physicians India\2016-64-22-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Assoc Physicians India\2016-64-22-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Menon JC</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pravettoni,V.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Allergy and Immunology Unit, Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, ItalyCardiac/Pulmonary Rehabilitation, ASST Gaetano Pini/CTO, Milan, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis of exercise-induced anaphylaxis: current insights</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="198" start="191">191-198</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Exercise-induced anaphylaxis (EIAn) is defined as the occurrence of anaphylactic symptoms (skin, respiratory, gastrointestinal, and cardiovascular symptoms) after physical activity. In about a third of cases, cofactors, such as food intake, temperature (warm or cold), and drugs (especially nonsteroidal anti-inflammatory drugs) can be identified. When the associated cofactor is food ingestion, the correct diagnosis is food-dependent EIAn (FDEIAn). The literature describes numerous reports of FDEIAn after intake of very different foods, from vegetables and nuts to meats and seafood. One of the best-characterized types of FDEIAn is that due to omega5-gliadin of wheat, though cases of FDEIAn after wheat ingestion by sensitization to wheat lipid transfer protien (LTP) are described. Some pathophysiological mechanisms underlying EIAn have been hypothesized, such as increase/alteration in gastrointestinal permeability, alteration of tissue transglutaminase promoting IgE cross-linking, enhanced expression of cytokines, redistribution of blood during physical exercise leading to altered mast-cell degranulation, and also changes in the acid-base balance. Nevertheless, until now, none of these hypotheses has been validated. The diagnosis of EIAn and FDEIAn is achieved by means of a challenge, with physical exercise alone for EIAn, and with the assumption of the suspected food followed by physical exercise for FDEIAn; in cases of doubtful results, a double-blind placebo-controlled combined food-exercise challenge should be performed. The prevention of this particular kind of anaphylaxis is the avoidance of the specific trigger, ie, physical exercise for EIAn, the assumption of the culprit food before exercise for FDEIAn, and in general the avoidance of the recognized cofactors. Patients must be supplied with an epinephrine autoinjector, as epinephrine has been clearly recognized as the first-line intervention for anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20161108IS - 1178-6965 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S109105</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27822074">PM:27822074</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-191-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-191-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161108, Pravettoni V</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S109105</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suzuki,S.</style></author><author><style face="normal" font="Arial"> Ogawa,M.</style></author><author><style face="normal" font="Arial"> Ohta,S.</style></author><author><style face="normal" font="Arial"> Nunomura,S.</style></author><author><style face="normal" font="Arial"> Nanri,Y.</style></author><author><style face="normal" font="Arial"> Shiraishi,H.</style></author><author><style face="normal" font="Arial"> Mitamura,Y.</style></author><author><style face="normal" font="Arial"> Yoshihara,T.</style></author><author><style face="normal" font="Arial"> Lee,J.J.</style></author><author><style face="normal" font="Arial"> Izuhara,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Saga Medical School, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Induction of airway allergic inflammation by hypothiocyanite via epithelial cells</style></title><secondary-title><style face="normal" font="Arial">J Biol Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Biol Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="18" Month="11" Year="2016">2016/11/18</year></dates><abstract><style face="normal" font="Arial">Hypothiocyanite (OSCN-) serves as a potent innate defense system against microbes in the lungs</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1083-351X (Electronic)IS - 0021-9258 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1074/jbc.M116.746909</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864363">PM:27864363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biol Chem\20161119-SuzukiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biol Chem\20161119-SuzukiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Suzuki S</style></custom2><misc3><style face="normal" font="Arial">10.1074/jbc.M116.746909</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elabras,J.F.</style></author><author><style face="normal" font="Arial"> Mello,F.C.</style></author><author><style face="normal" font="Arial"> Lupi,O.</style></author><author><style face="normal" font="Arial"> Bica,B.E.</style></author><author><style face="normal" font="Arial"> Papi,J.A.</style></author><author><style face="normal" font="Arial"> Franca,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">. Servicos de Imunologia Clinica e Reumatologia, Hospital Universitario Clementino Fraga Filho - HU</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcal superantigen-specific IgE antibodies: degree of sensitization and association with severity of asthma</style></title><secondary-title><style face="normal" font="Arial">J Bras Pneumol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Bras Pneumol</style></full-title></periodical><pages end="361" start="356">356-361</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> SEC</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Toxic shock</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Objective:: To determine the presence of staphylococcal superantigen-specific IgE antibodies and degree of IgE-mediated sensitization, as well as whether or not those are associated with the severity of asthma in adult patients. Methods:: This was a cross-sectional study involving outpatients with asthma under treatment at a tertiary care university hospital in the city of Rio de Janeiro, Brazil. Consecutive patients were divided into two groups according to the severity of asthma based on the Global Initiative for Asthma criteria: mild asthma (MA), comprising patients with mild intermittent or persistent asthma; and moderate or severe asthma (MSA). We determined the serum levels of staphylococcal toxin-specific IgE antibodies, comparing the results and performing a statistical analysis. Results:: The study included 142 patients: 72 in the MA group (median age = 46 years; 59 females) and 70 in the MSA group (median age = 56 years; 60 females). In the sample as a whole, 62 patients (43.7%) presented positive results for staphylococcal toxin-specific IgE antibodies: staphylococcal enterotoxin A (SEA), in 29 (20.4%); SEB, in 35 (24.6%); SEC, in 33 (23.2%); and toxic shock syndrome toxin (TSST), in 45 (31.7%). The mean serum levels of IgE antibodies to SEA, SEB, SEC, and TSST were 0.96 U/L, 1.09 U/L, 1.21 U/L, and 1.18 U/L, respectively. There were no statistically significant differences between the two groups in terms of the qualitative or quantitative results. Conclusions:: Serum IgE antibodies to SEA, SEB, SEC, and TSST were detected in 43.7% of the patients in our sample. However, neither the qualitative nor quantitative results showed a statistically significant association with the clinical severity of asthma. Objetivo:: Determinar a presenca de anticorpos IgE especificos para superantigenos estafilococicos e o grau de sensibilizacao mediada por esses, assim como se esses estao associados a gravidade da asma em pacientes adultos. Metodos:: Estudo transversal incluindo asmaticos adultos em acompanhamento ambulatorial em um hospital universitario terciario no Rio de Janeiro (RJ). Os pacientes foram alocados consecutivamente em dois grupos de gravidade da asma segundo criterios da Global Initiative for Asthma: asma leve (AL), com asmaticos leves intermitentes ou persistentes, e asma moderada ou grave (AMG). Foram determinados os niveis sericos de anticorpos IgE antitoxinas estafilococicas, e os resultados foram comparados por analise estatistica. Resultados:: Foram incluidos 142 pacientes no estudo: 72 no grupo AL (mediana de idade = 46 anos; 59 do sexo feminino) e 70 do grupo AMG (mediana de idade = 56 anos; 60 do sexo feminino). Na amostra geral, 62 pacientes (43,7%) apresentaram resultados positivos para dosagens de anticorpos IgE antitoxinas estafilococicas: enterotoxina (TX) A, em 29 (20,4%); TXB, em 35 (24,6%); TXC, em 33 (23,2%); e toxic shock syndrome toxin (TSST), em 45 (31,7%). As medias das dosagens sericas de anticorpos IgE especificos anti-TXA, TXB, TXC e TSST foram, respectivamente, de 0,96 U/l, 1,09 U/l, 1,21 U/l, e 1,18 U/l. Nao houve diferenca estatisticamente significativa dos resultados qualitativos ou quantitativos entre os grupos. Conclusoes:: A presenca de anticorpos IgE sericos anti-TXA, TXB, TXC e TSST, foi detectada em 43,7% nessa amostra de pacientes, mas nao houve associacao estatisticamente significativa entre seus resultados qualitativos ou quantitativos e gravidade clinica da asma</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 1806-3756 (Electronic)IS - 1806-3713 (Linking)LA - ENGLA - PORPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1590/S1806-37562016000000010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27812635">PM:27812635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Bras Pneumol\2016-42-356-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Bras Pneumol\2016-42-356-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Elabras JF</style></custom2><misc3><style face="normal" font="Arial">10.1590/S1806-37562016000000010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moens,L.</style></author><author><style face="normal" font="Arial"> Schaballie,H.</style></author><author><style face="normal" font="Arial"> Bosch,B.</style></author><author><style face="normal" font="Arial"> Voet,A.</style></author><author><style face="normal" font="Arial"> Bossuyt,X.</style></author><author><style face="normal" font="Arial"> Casanova,J.L.</style></author><author><style face="normal" font="Arial"> Boisson-Dupuis,S.</style></author><author><style face="normal" font="Arial"> Tangye,S.G.</style></author><author><style face="normal" font="Arial"> Meyts,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory Medicine, Experimental Laboratory Immunology, Department of Laboratory Medicine, University Hospitals Leuven and KU Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">AD Hyper-IgE Syndrome Due to a Novel Loss-of-Function Mutation in STAT3: a Diagnostic Pursuit Won by Clinical Acuity</style></title><secondary-title><style face="normal" font="Arial">J Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Australia</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="11" Year="2016">2016/11/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1573-2592 (Electronic)IS - 0271-9142 (Linking)LA - engPT - LetterCO - Belgium -CO - United States -CO - Australia -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10875-016-0351-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27844301">PM:27844301</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Immunol\20161115-MoensL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Immunol\20161115-MoensL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Moens L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10875-016-0351-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Faisant,C.</style></author><author><style face="normal" font="Arial"> Du Thanh,A.</style></author><author><style face="normal" font="Arial"> Mansard,C.</style></author><author><style face="normal" font="Arial"> Deroux,A.</style></author><author><style face="normal" font="Arial"> Boccon-Gibod,I.</style></author><author><style face="normal" font="Arial"> Bouillet,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Internal Medicine Department, Grenoble University Hospital, Grenoble, France.</style></auth-address><titles><title><style face="normal" font="Arial">Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients</style></title><secondary-title><style face="normal" font="Arial">J Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="8" Month="11" Year="2016">2016/11/8</year></dates><abstract><style face="normal" font="Arial">Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease characterized by AE resistant to antihistamines and a chronic course. We report five new cases of InH-AAE (two women and three men) with a rapid and dramatic response to the anti-immunoglobulin-E antibody omalizumab. In our literature review, we found 13 other relevant cases with a good response to this treatment. Overall, in 6 out of 18 patients, the doses of omalizumab required to prevent recurrences of attacks were higher than the licensed dose for chronic urticaria. No significant adverse effects have been reported</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1573-2592 (Electronic)IS - 0271-9142 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10875-016-0345-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826875">PM:27826875</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Immunol\20161109-FaisantC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Immunol\20161109-FaisantC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Faisant C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10875-016-0345-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liang,Y.</style></author><author><style face="normal" font="Arial"> Gudjonsson,J.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">WASP, Tregs, and food allergies - rare disease provides insight into a common problem</style></title><secondary-title><style face="normal" font="Arial">J Clin Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Invest</style></full-title></periodical><pages end="3730" start="3728">3728-3730</pages><volume><style face="normal" font="Arial">126</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dietary antigens</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="3" Month="10" Year="2016">2016/10/3</year></dates><abstract><style face="normal" font="Arial">Dysregulation of the type 2 immune system presents with various manifestations, including allergic inflammation, and has emerged as an alarming public health issue. The pathological mechanisms that underlie T helper type 2 cell-driven (Th2-driven) allergic diseases remain unclear. In particular, it is not completely understood how type 2 immunity is restricted in inflammatory responses. In this issue of the JCI, Lexmond et al. use Wiskott-Aldrich syndrome as a model disease and establish that the Wiskott-Aldrich gene product (WASP) serves an essential role in T regulatory cells to contain Th2 effector cell differentiation and prevent allergic sensitization to dietary antigens</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 1558-8238 (Electronic)IS - 0021-9738 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/JCI90198</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27643436">PM:27643436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Invest\2016-126-3728-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Invest\2016-126-3728-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Liang Y</style></custom2><misc3><style face="normal" font="Arial">10.1172/JCI90198</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lexmond,W.S.</style></author><author><style face="normal" font="Arial"> Goettel,J.A.</style></author><author><style face="normal" font="Arial"> Lyons,J.J.</style></author><author><style face="normal" font="Arial"> Jacobse,J.</style></author><author><style face="normal" font="Arial"> Deken,M.M.</style></author><author><style face="normal" font="Arial"> Lawrence,M.G.</style></author><author><style face="normal" font="Arial"> DiMaggio,T.H.</style></author><author><style face="normal" font="Arial"> Kotlarz,D.</style></author><author><style face="normal" font="Arial"> Garabedian,E.</style></author><author><style face="normal" font="Arial"> Sackstein,P.</style></author><author><style face="normal" font="Arial"> Nelson,C.C.</style></author><author><style face="normal" font="Arial"> Jones,N.</style></author><author><style face="normal" font="Arial"> Stone,K.D.</style></author><author><style face="normal" font="Arial"> Candotti,F.</style></author><author><style face="normal" font="Arial"> Rings,E.H.</style></author><author><style face="normal" font="Arial"> Thrasher,A.J.</style></author><author><style face="normal" font="Arial"> Milner,J.D.</style></author><author><style face="normal" font="Arial"> Snapper,S.B.</style></author><author><style face="normal" font="Arial"> Fiebiger,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">FOXP3+ Tregs require WASP to restrain Th2-mediated food allergy</style></title><secondary-title><style face="normal" font="Arial">J Clin Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Invest</style></full-title></periodical><pages end="4044" start="4030">4030-4044</pages><volume><style face="normal" font="Arial">126</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Dietary antigens</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> effector memory</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="3" Month="10" Year="2016">2016/10/3</year></dates><abstract><style face="normal" font="Arial">In addition to the infectious consequences of immunodeficiency, patients with Wiskott-Aldrich syndrome (WAS) often suffer from poorly understood exaggerated immune responses that result in autoimmunity and elevated levels of serum IgE. Here, we have shown that WAS patients and mice deficient in WAS protein (WASP) frequently develop IgE-mediated reactions to common food allergens. WASP-deficient animals displayed an adjuvant-free IgE-sensitization to chow antigens that was most pronounced for wheat and soy and occurred under specific pathogen-free as well as germ-free housing conditions. Conditional deletion of Was in FOXP3+ Tregs resulted in more severe Th2-type intestinal inflammation than that observed in mice with global WASP deficiency, indicating that allergic responses to food allergens are dependent upon loss of WASP expression in this immune compartment. While WASP-deficient Tregs efficiently contained Th1- and Th17-type effector differentiation in vivo, they failed to restrain Th2 effector responses that drive allergic intestinal inflammation. Loss of WASP was phenotypically associated with increased GATA3 expression in effector memory FOXP3+ Tregs, but not in naive-like FOXP3+ Tregs, an effect that occurred independently of increased IL-4 signaling. Our results reveal a Treg-specific role for WASP that is required for prevention of Th2 effector cell differentiation and allergic sensitization to dietary antigens</style></abstract><notes><style face="normal" font="Arial">DA - 20160919IS - 1558-8238 (Electronic)IS - 0021-9738 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1172/JCI85129</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27643438">PM:27643438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Invest\2016-126-4030-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Invest\2016-126-4030-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160919, Lexmond WS</style></custom2><misc3><style face="normal" font="Arial">10.1172/JCI85129</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ang,W.X.</style></author><author><style face="normal" font="Arial"> Church,A.M.</style></author><author><style face="normal" font="Arial"> Kulis,M.</style></author><author><style face="normal" font="Arial"> Choi,H.W.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Abraham,S.N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mast cell desensitization inhibits calcium flux and aberrantly remodels actin</style></title><secondary-title><style face="normal" font="Arial">J Clin Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Invest</style></full-title></periodical><pages end="4118" start="4103">4103-4118</pages><volume><style face="normal" font="Arial">126</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> actin cytoskeleton</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> calcium flux</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cytoskeleton</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> target cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="9" Year="2016">2016/9/26</year></dates><abstract><style face="normal" font="Arial">Rush desensitization (DS) is a widely used and effective clinical strategy for the rapid inhibition of IgE-mediated anaphylactic responses. However, the cellular targets and underlying mechanisms behind this process remain unclear. Recent studies have implicated mast cells (MCs) as the primary target cells for DS. Here, we developed a murine model of passive anaphylaxis with demonstrated MC involvement and an in vitro assay to evaluate the effect of DS on MCs. In contrast with previous reports, we determined that functional IgE remains on the cell surface of desensitized MCs following DS. Despite notable reductions in MC degranulation following DS, the high-affinity IgE receptor FcepsilonRI was still capable of transducing signals in desensitized MCs. Additionally, we found that displacement of the actin cytoskeleton and its continued association with FcepsilonRI impede the capacity of desensitized MCs to evoke the calcium response that is essential for MC degranulation. Together, these findings suggest that reduced degranulation responses in desensitized MCs arise from aberrant actin remodeling, providing insights that may lead to improvement of DS treatments for anaphylactic responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160926IS - 1558-8238 (Electronic)IS - 0021-9738 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1172/JCI87492</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27669462">PM:27669462</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Invest\2016-126-4103-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Invest\2016-126-4103-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160926, Ang WX</style></custom2><misc3><style face="normal" font="Arial">10.1172/JCI87492</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,S.</style></author><author><style face="normal" font="Arial"> Lee,S.J.</style></author><author><style face="normal" font="Arial"> Park,D.J.</style></author><author><style face="normal" font="Arial"> Oh,S.</style></author><author><style face="normal" font="Arial"> Lim,K.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Science, Cornell University, 411 Tower Road, Ithaca, NY 14853</style></auth-address><titles><title><style face="normal" font="Arial">The anti-allergic activity of Lactobacillus plantarum L67 and its application to yogurt</style></title><secondary-title><style face="normal" font="Arial">J Dairy Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dairy Sci</style></full-title></periodical><pages end="9382" start="9372">9372-9382</pages><volume><style face="normal" font="Arial">99</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> AP1</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bisphenol A</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dietary supplement</style></keyword><keyword><style face="normal" font="Arial"> Dietary Supplements</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus plantarum</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> real-time quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcriptional Activation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword><keyword><style face="normal" font="Arial"> Yogurt</style></keyword></keywords><dates><year Day="13" Month="10" Year="2016">2016/10/13</year></dates><abstract><style face="normal" font="Arial">Recently, interest in the beneficial role of probiotics in the protection and management of allergic diseases caused by immune disorders has been increasing. This study investigated the inhibitory effect of Lactobacillus plantarum L67 on induced allergic inflammatory response in bisphenol A-treated rat basophilic leukemia 2H3 (RBL-2H3) cells and mouse splenocytes. We also evaluated the applicability of L. plantarum L67 as a yogurt starter culture. We measured the ability of Lactobacillus strains to induce the production of IL-12 and IFN- gamma in cultured splenocytes by ELISA. Bisphenol A (50 muM)-treated RBL-2H3 cells were cotreated with a glycoprotein (18 kDa) isolated from L. plantarum L67 (5-100 mug/mL) for 30 min. We measured the expression of mitogen-activated protein kinase (ERK and p38), AP-1 (c-Fos and c-Jun), T-bet, and GATA-binding protein 3 (GATA-3) using Western blotting to examine the differentiation of T helper cells. Furthermore, we evaluated the gene expression of IL-1beta, IL-6, and IL-10 using real-time quantitative PCR. Finally, we evaluated the applicability of L. plantarum L67 as a yogurt starter by measuring pH, enumeration of bacteria, and sensory scores. Our results showed that L67 protein inhibited the phosphorylation of ERK and p38 mitogen-activated protein kinase through the transcriptional activation of AP-1 in bisphenol A-treated RBL-2H3 cells. During differentiation of T helper cells, the expression of transcription factor GATA-3 was significantly suppressed by L67 protein (100 mug/mL) treatment, whereas expression of transcription factor T-bet was increased. In addition, the L67 protein significantly attenuated the expression of T helper 2-linked cytokines IL-1beta, IL-6, and IL-10. These results indicate that L. plantarum L67, made available as yogurt starters and dietary supplements, has the potential to prevent allergy-related immune disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20161016IS - 1525-3198 (Electronic)IS - 0022-0302 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3168/jds.2016-11809</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27743673">PM:27743673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dairy Sci\2016-99-9372-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dairy Sci\2016-99-9372-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161016, Song S</style></custom2><misc3><style face="normal" font="Arial">10.3168/jds.2016-11809</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fotschki,J.</style></author><author><style face="normal" font="Arial"> Szyc,A.M.</style></author><author><style face="normal" font="Arial"> Laparra,J.M.</style></author><author><style face="normal" font="Arial"> Markiewicz,L.H.</style></author><author><style face="normal" font="Arial"> Wroblewska,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology and Food Microbiology, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Tuwima 10, 10-748 Olsztyn, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Immune-modulating properties of horse milk administered to mice sensitized to cow milk</style></title><secondary-title><style face="normal" font="Arial">J Dairy Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dairy Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Microbiology</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Reproduction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="10" Year="2016">2016/10/19</year></dates><abstract><style face="normal" font="Arial">The aim of this study was to examine immune adaptive changes, the expression of innate biomarkers and variations in intestinal microbiota composition after horse-milk administration in BALB/c mice, which were sensitized intraperitoneally using cow beta-lactoglobulin and alpha-casein with aluminum adjuvant. We measured serum antibody IgE levels and the expression of MCP-1, IL-4, and TNF-alpha in duodenal samples. Changes in immune cell populations in peripheral blood were quantified using flow cytometry, and intestinal microbiota composition was assessed using real-time PCR. We found that horse-milk administration decreased serum IgE levels in sensitized mice. The groups that received horse milk showed an increased population of regulatory T cells (CD4+Foxp3+). Horse-milk administration decreased the mRNA levels of IL-4 and resulted in higher transcripts of TLR-4 in all treatment groups; however, the levels of MCP-1, TNF-alpha, and TLR-2 were unaltered. After horse-milk treatment, we observed a positive effect, with increased numbers of intestinal Bifidobacterium spp. We observed immune-modulating properties of horse milk, but future studies should focus on testing horse-milk processing, such as fermentation and destroying most allergenic epitopes to continue research under clinical conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1525-3198 (Electronic)IS - 0022-0302 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3168/jds.2016-11499</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27771084">PM:27771084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dairy Sci\20161023-FotschkiJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dairy Sci\20161023-FotschkiJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Fotschki J</style></custom2><misc3><style face="normal" font="Arial">10.3168/jds.2016-11499</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inoue,T.</style></author><author><style face="normal" font="Arial"> Yagami,A.</style></author><author><style face="normal" font="Arial"> Iwata,Y.</style></author><author><style face="normal" font="Arial"> Ishii,N.</style></author><author><style face="normal" font="Arial"> Hashimoto,T.</style></author><author><style face="normal" font="Arial"> Matsunaga,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Nishichita General Hospital, Tokai, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Mucous membrane pemphigoid reactive only with BP230</style></title><secondary-title><style face="normal" font="Arial">J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dermatol</style></abbr-1></periodical><pages end="1229" start="1228">1228-1229</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">BP230</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mucous Membrane</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161006IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - ENGPT - LETTERCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/1346-8138.13361</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27709732">PM:27709732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol\2016-43-1228-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol\2016-43-1228-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161006, Inoue T</style></custom2><misc3><style face="normal" font="Arial">10.1111/1346-8138.13361</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sharma,V.K.</style></author><author><style face="normal" font="Arial"> Gupta,V.</style></author><author><style face="normal" font="Arial"> Pathak,M.</style></author><author><style face="normal" font="Arial"> Ramam,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Dermatology and Venereology , All India Institute of Medical Sciences , New Delhi , India</style></auth-address><titles><title><style face="normal" font="Arial">An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up-to four times in chronic spontaneous urticaria not controlled with standard dose</style></title><secondary-title><style face="normal" font="Arial">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Levocetirizine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Up-dosing</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="10" Year="2016">2016/10/25</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The EAACI/GA2LEN/EDF/WAO recommendation of increasing antihistamines' dose up-to 4-times in urticaria not adequately controlled with the standard dose is largely based on expert opinion. The objective of this study is to test the current urticaria guidelines of up-dosing antihistamines as second-line treatment. METHODS: This was an open-label study conducted prospectively on 113 patients with chronic spontaneous urticaria. All patients were treated with sequentially increasing doses of levocetrizine (5mg, 10mg, 15mg and 20mg/day) every week till the patients became completely asymptomatic or dose of 20mg/day reached. Urticaria Activity Score (UAS)-7, urticaria-related quality-of-life (CU-Q2oL) and patients' global assessment were used to assess treatment response. RESULTS: Twenty-one (18.58%) patients became asymptomatic with levocetirizine 5mg/day, while fifty required higher doses of levocetirizine for complete control: 29/92 (31.52%), 6/63 (9.52%) and 15/57 (26.31%) with 10mg, 15mg and 20mg/day, respectively. The percentage of patients experiencing >75% improvement increased with increasing doses of levocetirizine: 26.54%, 53.98%, 60.17% and 69.91% with 5mg, 10mg, 15mg and 20mg/day respectively. Sequential up-dosing of levocetirizine produced a progressive improvement in both urticaria control (UAS-7) as well as quality-of-life (CU-Q2oL) without significantly increasing somnolence. CONCLUSIONS: Our results support the current recommendations of increasing antihistamines up-to 4-times the standard dose in patients who fail the first-line treatment. Clinical trial registry number (CTRI/2016/07/007099)</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - ENGPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1080/09546634.2016.1246705</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779432">PM:27779432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatolog Treat\20161025-SharmaVK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatolog Treat\20161025-SharmaVK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Sharma VK</style></custom2><misc3><style face="normal" font="Arial">10.1080/09546634.2016.1246705</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kanzaki,S.</style></author><author><style face="normal" font="Arial"> Hashiguchi,K.</style></author><author><style face="normal" font="Arial"> Wakabayashi,K.I.</style></author><author><style face="normal" font="Arial"> Suematsu,K.</style></author><author><style face="normal" font="Arial"> Okubo,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Keio University School of Medicine , Tokyo , Japan</style></auth-address><titles><title><style face="normal" font="Arial">Histamine antagonist Bepotastine suppresses nasal symptoms caused by Japanese cedar and cypress pollen exposure</style></title><secondary-title><style face="normal" font="Arial">J Drug Assess</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Drug Assess</style></abbr-1></periodical><pages end="23" start="15">15-23</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Cypress pollen</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Objective: To determine the efficacy of the antihistamine bepotastine on treating nasal symptoms in patients with Japanese cedar and cypress pollinosis, based on two previous studies that looked at bepotastine OD's inhibitory effect on symptom onset after exposure. Design and methods: Randomized double-blind placebo controlled, parallel study. Twenty-eight volunteers with Japanese cedar and cypress pollinosis were randomly assigned into two experimental groups: a bepotastine-treated or a placebo control group. Subjects received either 10 mg bepotastine tablets or placebo tablets 1 day before entering an artificial exposure pollen chamber (OHIO Chamber) and also for three or more consecutive days. They were exposed to Japanese cedar and cypress pollen for 3 h per day for 2 days. Nasal and ocular symptoms were self-rated by each patient at regular intervals in addition to being objectively measured. Possible cognitive impairment was assessed by using the digit cancellation test (D-CAT). Results: In Study 1, under controlled conditions, there were no significant differences (p > .05) between subjects exposed to Japanese cedar pollen and those exposed to cypress pollen in terms of total nasal symptom score (TNSS). In Study 2, in the placebo group, the amount of nasal discharge and the number of sneezes did not diminish before cypress pollen exposure on the second day (p &lt; .05). This suggests that an antihistamine can suppress the symptoms of hang over. No deterioration of work performance was observed in the bepotastine group after pollen exposure for 2 days, as measured by D-CAT (p > .05). Conclusion: We conclude that bepotastine can suppress allergy-related symptoms without impairing work performance in subjects with seasonal allergic rhinitis caused by Japanese cedar pollen or cypress pollen</style></abstract><notes><style face="normal" font="Arial">DA - 20161027IS - 2155-6660 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/21556660.2016.1237365</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27785375">PM:27785375</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Drug Assess\2016-5-15-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Drug Assess\2016-5-15-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161027, Kanzaki S</style></custom2><misc3><style face="normal" font="Arial">10.1080/21556660.2016.1237365</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pineau,F.</style></author><author><style face="normal" font="Arial"> Masseguin,T.</style></author><author><style face="normal" font="Arial"> Marianne-Dit-Cassou,P.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">An acute coronary syndrome after crawling insect bites, a new case of syndrome Kounis?</style></title><secondary-title><style face="normal" font="Arial">J Eur Urg Reanim</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Eur Urg Reanim</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Coronary Angiography</style></keyword><keyword><style face="normal" font="Arial"> Foot</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2211-4238</style></isbn><abstract><style face="normal" font="Arial">Kounis syndrome is an acute coronary syndrome (ACS) occurring in a context of allergy. On January 2nd, 2014, on the island of La Reunion, a patient bitten in the foot by a crawling insect, has suffered of an ACS ST+ accompanied with additional arrhythmias and cardiorespiratory arrest. The patient received prehospital thrombolysis. Coronary angiography revealed the presence of a pre-existing coronary lesion. According to current knowledge, it could be a type 2-áKounis syndrome with dormant coronary lesions. This case report details the different types of Kounis syndrome, their pathophysiology and the specifics of their treatment. In front of this little known and difficult-to-diagnose syndrome, we emphasize the importance; in one hand, of a detailed questioning during the treatment of a chest pain in order to detect a possible contact with allergens, and in one another hand to perform a systematic ECG for each patient having an allergic reaction. In order to complete the assessment of this type of syndrome, it would be appropriate to make a quantitative analysis of anaphylaxis various markers</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Reunion -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jeurea.2016.02.009</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jeurea.2016.02.009</url></web-urls><pdf-urls><url ppv-ref="no">pineau.flore@gmail.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161031, Pineau F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jeurea.2016.02.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lechevalier,V.</style></author><author><style face="normal" font="Arial"> Guerin-Dubiard,C.</style></author><author><style face="normal" font="Arial"> Anton,M.</style></author><author><style face="normal" font="Arial"> Beaumal,V.</style></author><author><style face="normal" font="Arial"> David Briand,E.</style></author><author><style face="normal" font="Arial"> Gillard,A.</style></author><author><style face="normal" font="Arial"> Le Gouar,Y.</style></author><author><style face="normal" font="Arial"> Musikaphun,N.</style></author><author><style face="normal" font="Arial"> Tanguy,G.</style></author><author><style face="normal" font="Arial"> Pasco,M.</style></author><author><style face="normal" font="Arial"> Dupont,D.</style></author><author><style face="normal" font="Arial"> Nau,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pasteurisation of liquid whole egg: Optimal heat treatments in relation to its functional, nutritional and allergenic properties</style></title><secondary-title><style face="normal" font="Arial">J Food Eng</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Eng</style></full-title></periodical><pages end="149" start="137">137-149</pages><volume><style face="normal" font="Arial">195</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> emulsion</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> In-ávitro digestion</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Interfacial property</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> ovotransferrin</style></keyword><keyword><style face="normal" font="Arial"> Pasteurisation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Whole egg</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><isbn><style face="normal" font="Arial">0260-8774</style></isbn><abstract><style face="normal" font="Arial">Pasteurised liquid egg products represent around 70% of total egg products. Pasteurisation, necessary for microbiological safety, is a unit operation undergone by the totality of liquid whole egg commercialized. The present work aims to investigate the impact of a wide range of pasteurisation rates (among those classically used in industry) on the interfacial properties, in-ávitro digestibility and antigenicity of whole egg proteins, in order to optimize the unit operation parameters to ensure all whole egg qualities. Pasteurisation from 4 to 10-ámin-áat 60-á-¦C improved protein interfacial properties, in-ávitro digestibility and decreased ovomuco+»d antigenicity but did not significantly change ovotransferrin and lysozyme antigenicity. On the opposite, pasteurisation from 4 to 10-ámin-áat 66-á-¦C decreased protein in-ávitro digestibility and increased drastically ovotransferrin antigenicity. Pasteurisation from 4 to 10-ámin-áat 60-á-¦C enabled to reach all whole egg properties, but for safety reasons, higher pasteurisation rates at 62 or 64-á-¦C are good compromises to ensure microbiological safety without excessively damaging the functional properties</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jfoodeng.2016.10.007</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jfoodeng.2016.10.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Eng\2017-195-137-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Eng\2017-195-137-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161030, Lechevalier V</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jfoodeng.2016.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lechevalier,V.</style></author><author><style face="normal" font="Arial"> Guerin-Dubiard,C.</style></author><author><style face="normal" font="Arial"> Anton,M.</style></author><author><style face="normal" font="Arial"> Beaumal,V.</style></author><author><style face="normal" font="Arial"> David Briand,E.</style></author><author><style face="normal" font="Arial"> Gillard,A.</style></author><author><style face="normal" font="Arial"> Le Gouar,Y.</style></author><author><style face="normal" font="Arial"> Musikaphun,N.</style></author><author><style face="normal" font="Arial"> Pasco,M.</style></author><author><style face="normal" font="Arial"> Dupont,D.</style></author><author><style face="normal" font="Arial"> Nau,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of dry heat treatment of egg white powder on its functional, nutritional and allergenic properties</style></title><secondary-title><style face="normal" font="Arial">J Food Eng</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Eng</style></full-title></periodical><pages end="51" start="40">40-51</pages><volume><style face="normal" font="Arial">195</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Dehydrated egg white</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Dry heating</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white powder</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg white proteins</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> In-vitro digestion</style></keyword><keyword><style face="normal" font="Arial"> In-ávitro digestion</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Interfacial property</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Nutritional quality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Powders</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><isbn><style face="normal" font="Arial">0260-8774</style></isbn><abstract><style face="normal" font="Arial">Egg white is a key ingredient in many food products as it combines high nutritional quality with excellent functional properties. However, it is also one of the leading causes of food allergy in childhood. Dehydrated egg white is a common form of industrial egg white. To increase the functional properties, egg white powders are heated which may change protein antigenicity and susceptibility to digestion. The present work highlighted the effect of a wide range of dry heating rates (from 1 to 10 days between 60 and 90-á-¦C) simultaneously on the interfacial properties, antigenicity and susceptibility to in-ávitro digestion of egg white proteins. Thanks to a powerful statistical methodology, i.e. multiple factor analysis (MFA), that enables to consider all the data in a common space, intermediate dry heating treatments (2</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô5 days at 70-á-¦C or 1</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2 days at 80 or 90-á-¦C) were found to be good compromise to improve egg white functionality without enhancing too much protein resistance to digestion or protein antigenicity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jfoodeng.2016.09.022</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jfoodeng.2016.09.022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Eng\2017-195-40-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Eng\2017-195-40-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Lechevalier V</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jfoodeng.2016.09.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amponsah,A.</style></author><author><style face="normal" font="Arial"> Nayak,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Food and Agriculture. Orono, Univ. of Maine, Maine, 04469, U.S.A</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Microwave and Ultrasound Assisted Extraction on the Recovery of Soy Proteins for Soy Allergen Detection</style></title><secondary-title><style face="normal" font="Arial">J Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci</style></full-title></periodical><pages end="T2885" start="T2876">T2876-T2885</pages><volume><style face="normal" font="Arial">81</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Buffers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> false negative</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> Microwave</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy Milk</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy protein isolate</style></keyword><keyword><style face="normal" font="Arial"> Soy Proteins</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Ultrasound</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urea</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="10" Year="2016">2016/10/14</year></dates><abstract><style face="normal" font="Arial">The extraction of soy proteins for soy allergen detections is conventionally achieved with PBS buffer for at least 2 h at room temperature or 4 degrees C. This method has been reported to be inefficient due to time consumption and inadequate protein extraction resulting in false negative allergen detection and mislabeling of foods containing allergenic proteins. This study investigated the application of microwave (MAE) and ultrasound assisted extraction (UAE) techniques to extract and improve recovery of allergens from various soy matrices. Soy proteins were extracted from raw soy flour, soy protein isolate (SPI) and soy milk using MAE at 60, 70, and 100 degrees C for 5 and 10 min and UAE at 4 and 23 degrees C for extraction times of 1, 5, and 10 min with PBS, Laemmli and urea buffers. Extracts were analyzed for total proteins, protein profile, and antibody-based detection (ELISA) of soy proteins. Conventional extraction with each of the buffers was used as controls. Overall, proteins recovered from MAE and UAE samples were higher than recoveries from the controls in all soy matrices. Under all extraction conditions, Laemmli and urea buffer recovered more proteins than PBS. Electrophoresis analysis of protein showed bands around 75, 50, and 33 kDa indicating the presence of soy allergenic proteins beta-conglycinin and glycinin, in all samples. Using sandwich ELISA, control and UAE extracts resulted in high soy protein detection but this reduced in MAE extracts</style></abstract><notes><style face="normal" font="Arial">DA - 20161014IS - 1750-3841 (Electronic)IS - 0022-1147 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/1750-3841.13534</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27741363">PM:27741363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci\2016-81-T2876-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci\2016-81-T2876-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161014, Amponsah A</style></custom2><misc3><style face="normal" font="Arial">10.1111/1750-3841.13534</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,M.</style></author><author><style face="normal" font="Arial"> Kim,S.Y.</style></author><author><style face="normal" font="Arial"> Randy,A.</style></author><author><style face="normal" font="Arial"> Lim,S.J.</style></author><author><style face="normal" font="Arial"> Dorjsembe,B.</style></author><author><style face="normal" font="Arial"> Nho,C.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Inhibitory effect of the Larix sibirica and its various flavonoids on the IgE-stimulated mast cell activation and anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Funct Foods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Funct Foods</style></full-title></periodical><pages end="644" start="631">631-644</pages><volume><style face="normal" font="Arial">27</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase-2</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fc+ÁRI signalling</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Larix sibirica</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene C4</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinases</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> nuclear factor +¦B</style></keyword><keyword><style face="normal" font="Arial"> Nuclear factor-+¦B</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Kinases</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><isbn><style face="normal" font="Arial">1756-4646</style></isbn><abstract><style face="normal" font="Arial">Larix sibirica (Siberian larch) is a deciduous tree native to Russia, Mongolia, and China and has been reported to possess anti-viral, anti-oxidant, and neuroprotective properties. In this study, we assessed the anti-allergic effects of an L. sibirica extract (LSE) and its various flavonoids using an IgE-sensitized mast cell-like cell line, rat basophilic leukaemia (RBL)-2H3, and a passive anaphylaxis mouse model. In IgE-sensitized RBL-2H3 cells, LSE and several flavonoids reduced release and production of +¦-hexosaminidase, histamine, and inflammatory mediators (prostaglandin D2, leukotriene C4, interleukin-4, and tumour necrosis factor-+¦), reduced expression of cyclooxygenase-2 and 5-lipoxygenase, and suppressed activation of nuclear factor-+¦B. LSE and several flavonoids reduced phosphorylation of downstream signalling molecules, such as Syk, protein kinase C-Á, phospholipase C+¦, and mitogen-activated protein kinases. Oral administration of LSE inhibited mast cell-dependent passive cutaneous anaphylactic reactions. These results suggest that LSE is a beneficial candidate for the prevention and treatment of allergic disorders</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jff.2016.10.009</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jff.2016.10.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Funct Foods\2016-27-631-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Funct Foods\2016-27-631-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161105, Kim M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jff.2016.10.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,P.</style></author><author><style face="normal" font="Arial"> Kearney,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL</style></auth-address><titles><title><style face="normal" font="Arial">Immunological Outcomes of Antibody Binding to Glycans Shared between Microorganisms and Mammals</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="4209" start="4201">4201-4209</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alabama</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Housekeeping</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Polymers</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="Arial">Glycans constitute basic cellular components of living organisms across biological kingdoms, and glycan-binding Abs participate in many cellular interactions during immune defense against pathogenic organisms. Glycan epitopes are expressed as carbohydrate-only entities or as oligomers or polymers on proteins and lipids. Such epitopes on glycoproteins may be formed by posttranslational modifications or neoepitopes resulting from metabolic-catabolic processes and can be altered during inflammation. Pathogenic organisms can display host-like glycans to evade the host immune response. However, Abs to glycans, shared between microorganisms and the host, exist naturally. These Abs are able to not only protect against infectious disease, but also are involved in host housekeeping functions and can suppress allergic disease. Despite the reactivity of these Abs to glycans shared between microorganisms and host, diverse tolerance-inducing mechanisms permit the B cell precursors of these Ab-secreting cells to exist within the normal B cell repertoire</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1600872</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864551">PM:27864551</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-4201-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-4201-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Patel P</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1600872</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vummidi,G.P.</style></author><author><style face="normal" font="Arial"> Bell,S.M.</style></author><author><style face="normal" font="Arial"> Sridharan,A.</style></author><author><style face="normal" font="Arial"> Rajavelu,P.</style></author><author><style face="normal" font="Arial"> Kitzmiller,J.A.</style></author><author><style face="normal" font="Arial"> Na,C.L.</style></author><author><style face="normal" font="Arial"> Kofron,M.</style></author><author><style face="normal" font="Arial"> Brandt,E.B.</style></author><author><style face="normal" font="Arial"> Ericksen,M.</style></author><author><style face="normal" font="Arial"> Naren,A.P.</style></author><author><style face="normal" font="Arial"> Moon,C.</style></author><author><style face="normal" font="Arial"> Khurana Hershey,G.K.</style></author><author><style face="normal" font="Arial"> Whitsett,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Neonatology, Perinatal and Pulmonary Biology, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229</style></auth-address><titles><title><style face="normal" font="Arial">Airway Epithelial KIF3A Regulates Th2 Responses to Aeroallergens</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="4239" start="4228">4228-4239</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Cilia</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Kinesin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mucociliary Clearance</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="28" Month="10" Year="2016">2016/10/28</year></dates><abstract><style face="normal" font="Arial">KIF3A, the gene encoding kinesin family member 3A, is a susceptibility gene locus associated with asthma; however, mechanisms by which KIF3A might influence the pathogenesis of the disorder are unknown. In this study, we deleted the mouse Kif3a gene in airway epithelial cells. Both homozygous and heterozygous Kif3a gene-deleted mice were highly susceptible to aeroallergens from Aspergillus fumigatus and the house dust mite, resulting in an asthma-like pathology characterized by increased goblet cell metaplasia, airway hyperresponsiveness, and Th2-mediated inflammation. Deletion of the Kif3a gene increased the severity of pulmonary eosinophilic inflammation and expression of cytokines (Il-4, Il-13, and Il-17a) and chemokine (Ccl11) RNAs following pulmonary exposure to Aspergillus extract. Inhibition of Kif3a disrupted the structure of motile cilia and impaired mucociliary clearance, barrier function, and epithelial repair, demonstrating additional mechanisms by which deficiency of KIF3A in respiratory epithelial cells contributes to pulmonary pathology. Airway epithelial KIF3A suppresses Th2 pulmonary inflammation and airway hyperresponsiveness following aeroallergen exposure, implicating epithelial microtubular functions in the pathogenesis of Th2-mediated lung pathology</style></abstract><notes><style face="normal" font="Arial">DA - 20161029IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1600926</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27794000">PM:27794000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-4228-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-4228-39.pdf</url></text-urls><related-urls><url ppv-ref="no">video in cartella</url></related-urls></urls><custom2><style face="normal" font="Arial">20161029, Vummidi GP</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1600926</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ito,T.</style></author><author><style face="normal" font="Arial"> Hirose,K.</style></author><author><style face="normal" font="Arial"> Norimoto,A.</style></author><author><style face="normal" font="Arial"> Tamachi,T.</style></author><author><style face="normal" font="Arial"> Yokota,M.</style></author><author><style face="normal" font="Arial"> Saku,A.</style></author><author><style face="normal" font="Arial"> Takatori,H.</style></author><author><style face="normal" font="Arial"> Saijo,S.</style></author><author><style face="normal" font="Arial"> Iwakura,Y.</style></author><author><style face="normal" font="Arial"> Nakajima,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Dectin-1 Plays an Important Role in House Dust Mite-Induced Allergic Airway Inflammation through the Activation of CD11b+ Dendritic Cells</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> C-type lectin receptor</style></keyword><keyword><style face="normal" font="Arial"> CCR7</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid DCs</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptome analysis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="Arial">It is well known that sensitization against fungi is closely associated with severity of asthma. Dectin-1 (gene symbol Clec7a), a C-type lectin receptor, recognizes the fungal cell wall component beta-glucan, as well as some component(s) in house dust mite (HDM) extract. However, the roles of Dectin-1 in HDM-induced allergic airway inflammation remain unclear. In this study, we used Dectin-1-deficient (Clec7a-/-) mice to examine whether Dectin-1 is involved in HDM-induced allergic airway inflammation. We found that HDM-induced eosinophil and neutrophil recruitment into the airways was significantly attenuated in Clec7a-/- mice compared with that in wild-type mice. In addition, HDM-induced IL-5, IL-13, and IL-17 production from mediastinum lymph node cells was reduced in HDM-sensitized Clec7a-/- mice. Dectin-1 was expressed on CD11b+ dendritic cells (DCs), an essential DC subset for the development of allergic inflammation, but not on CD103+ DCs, plasmacytoid DCs, or lung epithelial cells. Transcriptome analysis revealed that the expression of chemokine/chemokine receptors, including CCR7, which is indispensable for DC migration to draining lymph nodes, was decreased in Clec7a-/- DCs. In accordance with these results, the number of HDM-labeled CD11b+ DCs in mediastinum lymph nodes was significantly reduced in Clec7a-/- mice compared with wild-type mice. Taken together, these results suggest that Dectin-1 expressed on CD11b+ DCs senses some molecule(s) in HDM extract and plays a critical role in the induction of HDM-induced allergic airway inflammation by inducing the expression of chemokine/chemokine receptors in DCs</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1502393</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27852745">PM:27852745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20161117-ItoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20161117-ItoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Ito T</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1502393</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawakami,T.</style></author><author><style face="normal" font="Arial"> Blank,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037</style></auth-address><titles><title><style face="normal" font="Arial">From IgE to Omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="4192" start="4187">4187-4192</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE receptors</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="Arial">IgE is the least abundant Ig isotype, yet it plays a critical role in allergic reactions and host protection from helminth infection. Although IgE was discovered 50 years ago, the ultimate evidence for its role in human allergic diseases was obtained by the efficacy of anti-IgE therapy in many clinical trials on asthma and other allergic diseases. Beginning from the discovery of IgE 50 y ago, followed by studies of IgE receptors and activation mechanisms, this review provides a historic perspective of allergy research that has led to the development of anti-IgE therapy and other strategies targeting IgE and its receptors. Current IgE studies toward future precision medicine are also reviewed</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - France -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/?jimmunol.1601476</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864548">PM:27864548</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-4187-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-4187-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Kawakami T</style></custom2><misc3><style face="normal" font="Arial">10.4049/?jimmunol.1601476</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jirmo,A.C.</style></author><author><style face="normal" font="Arial"> Daluege,K.</style></author><author><style face="normal" font="Arial"> Happle,C.</style></author><author><style face="normal" font="Arial"> Albrecht,M.</style></author><author><style face="normal" font="Arial"> Dittrich,A.M.</style></author><author><style face="normal" font="Arial"> Busse,M.</style></author><author><style face="normal" font="Arial"> Habener,A.</style></author><author><style face="normal" font="Arial"> Skuljec,J.</style></author><author><style face="normal" font="Arial"> Hansen,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, 30625 Hannover, Germany</style></auth-address><titles><title><style face="normal" font="Arial">IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod)</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="4227" start="4219">4219-4227</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Peripheral Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> resiquimod</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="Arial">Different models of experimental allergic asthma have shown that the TLR7/8 agonist resiquimod (R848) is a potential inhibitor of type 2 helper cell-driven inflammatory responses. However, the mechanisms mediating its therapeutic effects are not fully understood. Using a model of experimental allergic asthma, we show that induction of IL-27 by R848 is critical for the observed ameliorative effects. R848 significantly inhibited all hallmarks of experimental allergic asthma, including airway hyperreactivity, eosinophilic airway inflammation, mucus hypersecretion, and Ag-specific Ig production. Whereas R848 significantly reduced IL-5, IL-13, and IL-17, it induced IFN-gamma and IL-27. Neutralization of IL-27 completely reversed the therapeutic effect of R848 in the experimental asthma model, demonstrating dependence of R848-mediated suppression on IL-27. In vitro, R848 induced production of IL-27 by murine alveolar macrophages and dendritic cells and enhanced expression of programmed death-ligand 1, whose expression on monocytes and dendritic cells has been shown to regulate peripheral tolerance in both murine and human studies. Moreover, in vitro IL-27 enhanced secretion of IFN-gamma whereas it inhibited IL-5 and IL-13, demonstrating its direct effect on attenuating Th2 responses. Taken together, our study proves that R848-mediated suppression of experimental asthma is dependent on IL-27. These data provide evidence of a central role of IL-27 for the control of Th2-mediated allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799314">PM:27799314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-4219-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-4219-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Jirmo AC</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601094</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chua,Y.L.</style></author><author><style face="normal" font="Arial"> Liong,K.H.</style></author><author><style face="normal" font="Arial"> Huang,C.H.</style></author><author><style face="normal" font="Arial"> Wong,H.S.</style></author><author><style face="normal" font="Arial"> Zhou,Q.</style></author><author><style face="normal" font="Arial"> Ler,S.S.</style></author><author><style face="normal" font="Arial"> Tang,Y.</style></author><author><style face="normal" font="Arial"> Low,C.P.</style></author><author><style face="normal" font="Arial"> Koh,H.Y.</style></author><author><style face="normal" font="Arial"> Kuo,I.C.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Wong,W.S.</style></author><author><style face="normal" font="Arial"> Peh,H.Y.</style></author><author><style face="normal" font="Arial"> Lim,H.Y.</style></author><author><style face="normal" font="Arial"> Ge,M.Q.</style></author><author><style face="normal" font="Arial"> Haczku,A.</style></author><author><style face="normal" font="Arial"> Angeli,V.</style></author><author><style face="normal" font="Arial"> MacAry,P.A.</style></author><author><style face="normal" font="Arial"> Chua,K.Y.</style></author><author><style face="normal" font="Arial"> Kemeny,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Programme, Center for Life Sciences, National University of Singapore, Singapore 117456, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Blomia tropicalis-Specific TCR Transgenic Th2 Cells Induce Inducible BALT and Severe Asthma in Mice by an IL-4/IL-13-Dependent Mechanism</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="3781" start="3771">3771-3781</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Blo t 5</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Compliance</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> Respiratory sensitization</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="Arial">Previous studies have highlighted the importance of lung-draining lymph nodes in the respiratory allergic immune response, whereas the lung parenchymal immune system has been largely neglected. We describe a new in vivo model of respiratory sensitization to Blomia tropicalis, the principal asthma allergen in the tropics, in which the immune response is focused on the lung parenchyma by transfer of Th2 cells from a novel TCR transgenic mouse, specific for the major B. tropicalis allergen Blo t 5, that targets the lung rather than the draining lymph nodes. Transfer of highly polarized transgenic CD4 effector Th2 cells, termed BT-II, followed by repeated inhalation of Blo t 5 expands these cells in the lung >100-fold, and subsequent Blo t 5 challenge induced decreased body temperature, reduction in movement, and a fall in specific lung compliance unseen in conventional mouse asthma models following a physiological allergen challenge. These mice exhibit lung eosinophilia; smooth muscle cell, collagen, and goblet cell hyperplasia; hyper IgE syndrome; mucus plugging; and extensive inducible BALT. In addition, there is a fall in total lung volume and forced expiratory volume at 100 ms. These pathophysiological changes were substantially reduced and, in some cases, completely abolished by administration of neutralizing mAbs specific for IL-4 and IL-13 on weeks 1, 2, and 3. This IL-4/IL-13-dependent inducible BALT model will be useful for investigating the pathophysiological mechanisms that underlie asthma and the development of more effective drugs for treating severe asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161013IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Singapore -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1600926</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27733553">PM:27733553</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-3771-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-3771-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Chua YL</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1600926</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valladao,A.C.</style></author><author><style face="normal" font="Arial"> Frevert,C.W.</style></author><author><style face="normal" font="Arial"> Koch,L.K.</style></author><author><style face="normal" font="Arial"> Campbell,D.J.</style></author><author><style face="normal" font="Arial"> Ziegler,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, University of Washington, Seattle, WA 98101</style></auth-address><titles><title><style face="normal" font="Arial">STAT6 Regulates the Development of Eosinophilic versus Neutrophilic Asthma in Response to Alternaria alternata</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="4551" start="4541">4541-4551</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> CXCL8</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="Arial">Human asthma is a heterogeneous disease characterized by the expression of both Th2 and Th17 cytokines. In vitro and in vivo studies have shown a reciprocal regulation between Th2 and Th17 pathways, suggesting a potential induction of neutrophil-promoting Th17 inflammation in the absence of a Th2 response. Alternaria alternata is a clinically relevant allergen that is associated with severe and fatal asthma exacerbations. Exposure to A. alternata is characterized by a predominant Th2 response, but can also induce the production of factors associated with Th17 responses (e.g., CXCL8) from epithelial cells. Using a mouse model, we found that wild-type mice develop an eosinophilic Th2 airway disease in response to A. alternata exposure, whereas IL-4-, IL-13-, and STAT6-deficient mice exhibit a primarily neutrophilic response. Neutrophilic asthma in STAT6-/- mice was accompanied by elevated lung levels of TNF-alpha, CXCL1, CXCL2, and CXCL5, and was steroid resistant. Neutralization of Th17 signaling only partially reduced neutrophil numbers and total airway inflammation. Airway neutrophilia developed in RAG-deficient and CD4-depleted BALB/c mice, suggesting that the suppression of neutrophil responses is dependent on Th2 cytokine production by T cells and that airway neutrophilia is primarily an innate response to allergen. These results highlight the importance of combination therapies for treatment of asthma and establish a role for factors other than IL-17 as targets for neutrophilic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161105IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1600007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27815425">PM:27815425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2016-197-4541-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2016-197-4541-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161105, Valladao AC</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1600007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">JanssenDuijghuijsen,L.M.</style></author><author><style face="normal" font="Arial"> Wichers,H.J.</style></author><author><style face="normal" font="Arial"> van Norren,K.</style></author><author><style face="normal" font="Arial"> Keijer,J.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> de Jong,G.A.</style></author><author><style face="normal" font="Arial"> Witkamp,R.F.</style></author><author><style face="normal" font="Arial"> Koppelman,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Wageningen Food and Biobased Research, Wageningen University and Research, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Detection of peanut allergen in human blood after consumption of peanuts is skewed by endogenous immunoglobulins</style></title><secondary-title><style face="normal" font="Arial">J Immunol Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Methods</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="11" Year="2016">2016/11/11</year></dates><abstract><style face="normal" font="Arial">Some studies have suggested that allergens may appear in the circulation after ingestion of allergenic food sources. The reported levels of allergen in serum, however, are low, and conclusions between studies differ. Here, we investigated factors that determine the detection of allergens in serum after consumption of peanuts. Ten healthy volunteers ingested 100g of light-roasted peanuts. Serum samples were taken at regular intervals for six hours. A double monoclonal sandwich ELISA was used to analyse the presence and quantity of the major peanut allergen Ara h 6 in serum. In 4 out of 10 subjects, no Ara h 6 could be detected. Purified Ara h 6 that was digested in vitro was still reactive in the ELISA, rejecting the possibility that digestion leads to small peptides that could not be detected. Spiking of purified Ara h 6 in baseline serum showed that the pre-ingestion serum of these four subjects partially prevented Ara h 6 to react in the ELISA, with a reduction of reactivity of up to 3 orders of magnitude or more. Pre-ingestion serum of the other six subjects did not show such an effect. The reduction of reactivity of Ara h 6 coincided with high titres of IgG and IgG4, and removal of IgG from pre-ingestion serum abolished this effect completely, indicating that IgG and IgG4 inhibited the reactivity of Ara h6 in the ELISA. We conclude that some individuals have IgG and IgG4 against food allergens in their blood, which interferes with detection of such food allergens in serum. Because this effect does not occur for each individual, the possibility of such interference should be taken into consideration when interpreting immunochemical studies on the absorption of food allergens in serum</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1872-7905 (Electronic)IS - 0022-1759 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jim.2016.11.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27845035">PM:27845035</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Methods\20161115-JanssenDuijghuijsenLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Methods\20161115-JanssenDuijghuijsenLM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, JanssenDuijghuijsen LM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jim.2016.11.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pegorie,M.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author><author><style face="normal" font="Arial"> Welfare,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Public Health England North West Health Protection Team (Greater Manchester)</style></auth-address><titles><title><style face="normal" font="Arial">Estimating the burden of Invasive and Serious Fungal Disease in the United Kingdom</style></title><secondary-title><style face="normal" font="Arial">J Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Infect</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dialysis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Meningitis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peritonitis</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sarcoidosis</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="24" Month="10" Year="2016">2016/10/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The burden of fungal disease in the UK is unknown. Only limited data are systematically collected. We have estimated the annual burden of invasive and serious fungal disease. METHODS: We used several estimation approaches. We searched and assessed published estimates of incidence, prevalence or burden of specific conditions in various high-risk groups. Studies with adequate internal and external validity allowed extrapolation to estimate current UK burden. For conditions without adequate published estimates, we sought expert advice. RESULTS: The UK population in 2011 was 63,182,000 with 18% aged under 15 and 16% over 65. The following annual burden estimates were calculated: invasive candidiasis 5,142; Candida peritonitis complicating chronic ambulatory peritoneal dialysis 88; Pneumocystis pneumonia 207 to 587 cases, invasive aspergillosis (IA), excluding critical care patients 2,901 to 2,912, and IA in critical care patients 387 to 1,345 patients, , &lt;100 cryptococcal meningitis cases. We estimated 178,000 (50,000-250,000) allergic bronchopulmonary aspergillosis cases in people with asthma, and 873 adults and 278 children with cystic fibrosis. Chronic pulmonary aspergillosis is estimated to affect 3,600 patients, based on burden estimates post tuberculosis and in sarcoidosis. CONCLUSIONS: Uncertainty is intrinsic to most burden estimates due to diagnostic limitations, lack of national surveillance systems, few published studies and methodological limitations. The largest uncertainty surrounds IA in critical care patients. Further research is needed to produce a more robust estimate of total burden</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1532-2742 (Electronic)IS - 0163-4453 (Linking)LA - ENGPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jinf.2016.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27789254">PM:27789254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Infect\20161028-PegorieM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Infect\20161028-PegorieM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Pegorie M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jinf.2016.10.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Badiee,P.</style></author><author><style face="normal" font="Arial"> Moghadami,M.</style></author><author><style face="normal" font="Arial"> Rozbehani,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. badieep@yahoo.com</style></auth-address><titles><title><style face="normal" font="Arial">Comparing immunological and molecular tests with conventional methods in diagnosis of acute invasive fungal rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">J Infect Dev Ctries</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Infect Dev Ctries</style></full-title></periodical><pages end="95" start="90">90-95</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic Tests,Routine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evaluation Studies</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Histocytochemistry</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> maxillary</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Molecular Diagnostic Techniques</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword></keywords><dates><year Day="31" Month="1" Year="2016">2016/1/31</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: This study compared immunological and molecular testswith conventional methods in the diagnosis of acute invasive fungal rhinosinusitis. METHODOLOGY: All tissue samples from maxillary sinuses were cultured and stained using periodic acid-Schiff. Two blood samples were cultured by bedside inoculation into BACTEC medium. Diagnostic tests were used: enzyme-linked immunosorbent assay for detection of galactomannan and mannan in serum samples, real-time PCR assays for Aspergillus spp. and Candida spp., and nested PCR for the Mucoraceae family. RESULTS: Among 31 immunocompromised patients, based on host factors, clinical, radiological and mycological findings, 18 patients were diagnosed with documented infection. By direct smear examination, 9 patients (50%) had positive results for Mucoraceae family, but only 5 samples showed growth in the culture (55.5%). Nested PCR results for species in this family were negative in all serum samples from patients. In addition, 9 patients had positive direct microscopic findings, of which 7 specimens produced positive growth for Aspergillus flavus (77.7%). The galactomannan test was positive in 6/9 (66.6%), and Aspergillus PCR were positive in 6 patients (66.6%). The isolated agent was C. albicans in one patient. The mannan antigen test to detect Candida was negative. None of the blood cultures was positive for fungal infection. CONCLUSIONS: The efficient method to diagnose fungal rhinosinusitis was direct microscopic examination of tissue samples. Immunological and molecular methods, which are available for some important fungi, can help clinicians with the diagnosis and management of infections in patients in critical condition when tissue sampling is not available</style></abstract><notes><style face="normal" font="Arial">DA - 20160202IS - 1972-2680 (Electronic)IS - 1972-2680 (Linking)LA - engPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tSB - IMCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26829542">PM:26829542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Infect Dev Ctries\2016-10-90-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Infect Dev Ctries\2016-10-90-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160202, Badiee P</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brunner,P.M.</style></author><author><style face="normal" font="Arial"> Silverberg,J.I.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author><author><style face="normal" font="Arial"> Paller,A.S.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author><author><style face="normal" font="Arial"> Amagai,M.</style></author><author><style face="normal" font="Arial"> Luger,T.A.</style></author><author><style face="normal" font="Arial"> Deleuran,M.</style></author><author><style face="normal" font="Arial"> Werfel,T.</style></author><author><style face="normal" font="Arial"> Eyerich,K.</style></author><author><style face="normal" font="Arial"> Stingl,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic immune activation. In reviewing atopic dermatitis comorbidities, Councilors of the International Eczema Council found a strong pattern of immune activation in peripheral blood and the propensity to both skin and systemic infections. Associations with cardiovascular, neuropsychiatric, and malignant diseases were increasingly reported, but confirmation of their link with atopic dermatitis requires longitudinal studies. Given the possibility of atopic dermatitis-related systemic immune activation, future investigations of new interventions should concurrently examine the impact on these comorbidities</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Japan -CO - Germany -CO - Denmark -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2016.08.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27771048">PM:27771048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\20161023-BrunnerPM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\20161023-BrunnerPM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Brunner PM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2016.08.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Muinelo,A.</style></author><author><style face="normal" font="Arial"> Perez,O.</style></author><author><style face="normal" font="Arial"> Vila,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy Unit, Hospital Materno-Infantil Teresa Herrera, La Coruna, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Aquagenic Urticaria: Report of a Case in an Adolescent Girl</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="327" start="326">326-327</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763863">PM:27763863</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Muinelo A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0082</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Poza-Guedes,P.</style></author><author><style face="normal" font="Arial"> Barrios,Y.</style></author><author><style face="normal" font="Arial"> Gonzalez,P.R.</style></author><author><style face="normal" font="Arial"> Sanchez-MacHin,I.</style></author><author><style face="normal" font="Arial"> Franco,A.</style></author><author><style face="normal" font="Arial"> Matheu,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Consulta de Alergia Infantil, Unidad de Alergologia-Norte, Hospital del Torax/Ofra, San Cristobal de La Laguna, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Yogurt in the Treatment of beta-Lactoglobulin-Induced Gastrointestinal Cow's Milk Allergy</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="329" start="327">327-329</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Yogurt</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0083</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763864">PM:27763864</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Poza-Guedes P</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0083</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vidal,C.</style></author><author><style face="normal" font="Arial"> Lojo,S.</style></author><author><style face="normal" font="Arial"> Juangorena,M.</style></author><author><style face="normal" font="Arial"> Gonzalez-Quintela,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Association Between Asthma and Sensitization to Allergens of Dermatophagoides pteronyssinus</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="309" start="304">304-309</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Lepidoglyphus</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="10" Year="2016">2016/10/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE:: Little is known about the role of molecular diagnosis in house dust mite (HDM) allergy. In this study, we investigated the association between the sensitization profile of adolescent and adult HDM-allergic patients and asthma in a region with high rates of exposure to HDM. METHODS:: We conducted a cross-sectional study of 384 HDM-allergic patients (38.5%, males; median age, 28 years). A total of 368 patients (95.8%) had rhinitis, and 175 (45.6%) had asthma. Specific IgE (sIgE) to Dermatophagoides pteronyssinus, nDer p 1, rDer p 2, and rPen a 1 was measured in all patients. sIgE to Lepidoglyphus destructor was measured in patients (n=301) with a positive skin test result. RESULTS:: Significantly higher concentrations of sIgE to Der p 1 and sIgE to Der p 2 were observed in patients with asthma than in those without asthma. The proportion of asthmatic patients was higher among individuals who reacted (>/=0.35 kUA/L) to both Der p 1 and Der p 2 (147/291, 50.5%) than among those who reacted to only 1 allergen (either Der p 1 or Der p 2, 18/55, 32.7%) or neither allergen (10/38, 26.3%, P=.002). Reactivity to both allergens was associated with asthma after adjusting for age and sex (OR, 2.87; 95%CI, 1.32-6.20). Higher concentrations of sIgE to L destructor were observed in patients with asthma than in patients without asthma. Tropomyosin sIgE >/=0.35 kUA/L was detected in only 6 individuals (1.6%). CONCLUSIONS:: L destructor may be a relevant allergen in high-exposure areas. Dual sensitization (ie, IgE to both Der p 1 and Der p 2) may help to identify HDM-allergic patients who are at risk of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160704IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27373988">PM:27373988</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-304-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-304-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160704, Vidal C</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Micozzi,S.</style></author><author><style face="normal" font="Arial"> Bartolome,B.</style></author><author><style face="normal" font="Arial"> Sanchis-Merino,M.E.</style></author><author><style face="normal" font="Arial"> Alfaya,T.</style></author><author><style face="normal" font="Arial"> Aldunate,T.</style></author><author><style face="normal" font="Arial"> Diaz,M.</style></author><author><style face="normal" font="Arial"> Pastor-Vargas,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University General Hospital Gregorio Maranon, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Hypersensitivity to Quail Egg Proteins: What About Hen Egg?</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="318" start="316">316-318</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">egg</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quail</style></keyword><keyword><style face="normal" font="Arial"> quail egg</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763859">PM:27763859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Micozzi S</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0076</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lopez-Matas,M.A.</style></author><author><style face="normal" font="Arial"> Moya,R.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author><author><style face="normal" font="Arial"> Gaig,P.</style></author><author><style face="normal" font="Arial"> Malet,A.</style></author><author><style face="normal" font="Arial"> Vinas,M.</style></author><author><style face="normal" font="Arial"> Garcia-Moral,A.</style></author><author><style face="normal" font="Arial"> Labrador,M.</style></author><author><style face="normal" font="Arial"> Alcoceba,E.</style></author><author><style face="normal" font="Arial"> Ibero,M.</style></author><author><style face="normal" font="Arial"> Carnes,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">R&amp;D Department, Laboratorios LETI S.L.U., Tres Cantos, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Relevance of Allergenic Sensitization to Cynodon dactylon and Phragmites communis: Cross-reactivity With Pooideae Grasses</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="303" start="295">295-303</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cyn d 1</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot assay</style></keyword><keyword><style face="normal" font="Arial"> immunoblot inhibition</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Subfamily</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVES: The homologous group of sweet grasses belongs to the Pooideae subfamily, but grass pollen species from other subfamilies can also cause allergy, such as Cynodon dactylon (Chloridoideae) and Phragmites communis (Arundinoideae). C dactylon and P communis have not been included in the sweet grasses homologous group because of their low cross-reactivity with other grasses. The aims of this study were to investigate the profile of sensitization to C dactylon and P communis in patients sensitized to grasses and to analyze cross-reactivity between these 2 species and temperate grasses. METHODS: Patients were skin prick tested with a grass mixture (GM). Specific IgE to GM, C dactylon, P communis, Cyn d 1, and Phl p 1 was measured by ImmunoCAP. A pool of sera was used for the immunoblot assays. Cross-reactivity was studied by ELISA and immunoblot inhibition. RESULTS: Thirty patients had sIgE to GM. Twenty-four (80%) had positive results for C dactylon, 27 (90%) for P communis, 22 (73.3%) for nCyn d 1, and 92.9% for rPhl p 1. Bands were detected in the 3 extracts by immunoblot. Inhibition of GM was not observed with C dactylon or P communis by immunoblot or ELISA inhibition. When C dactylon or P communis were used in the solid phase, GM produced almost complete inhibition. CONCLUSIONS: Eighty percent of patients sensitized to grasses were also sensitized to C dactylon and 90% were sensitized to P communis. Sensitization to these species seems to be induced by allergens different to those in sweet grasses</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763856">PM:27763856</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-295-303.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-295-303.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Lopez-Matas MA</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cugno,M.</style></author><author><style face="normal" font="Arial"> Tedeschi,A.</style></author><author><style face="normal" font="Arial"> Frossi,B.</style></author><author><style face="normal" font="Arial"> Bossi,F.</style></author><author><style face="normal" font="Arial"> Marzano,A.V.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medicina Interna, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, ItalyAmbulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Detection of Low-Molecular-Weight Mast Cell-Activating Factors in Serum From Patients With Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="313" start="310">310-313</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE receptors</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Background y Objective: Functionally active autoantibodies to IgE and to the high-affinity IgE receptor (FcepsilonRI) can be detected in serum in about 40% of patients with chronic spontaneous urticaria (CSU). Recent studies showed that serum from patients with CSU can induce activation of mast cells, irrespective of whether they carry high-affinity IgE receptors. To evaluate mast cell activation induced by factors in the serum of CSU patients with a molecular weight lower than that of autoantibodies. METHODS: Eight CSU patients and 5 healthy controls were evaluated. Whole serum and serum fractionated at 100, 50, and 30 kDa were used to stimulate in vitro LAD2 mast cells. The enzymatic activity of beta-hexosaminidase was evaluated in supernatants and cell pellets as a measure of mast cell degranulation. RESULTS: Mean (SEM) release of mast cell beta-hexosaminidase induced by whole serum from CSU patients was higher than that induced by serum from the healthy controls (14.4 [2.7%] vs 5.1 [2.4%]; P=.027). In addition, serum fractions below 100 kDa and below 50 kDa from CSU patients induced mast cell degranulation that was significantly higher than that induced by the corresponding fractions in sera from healthy controls (10.2% [1.4%] vs 3.8% [1.9%] [P=.024] and 10.1% [1.2%] vs 3.9% [1.7%] [P=.012], respectively). In 4 CSU patients, we evaluated serum fractions &lt;30 kDa, which retained their capacity to activate mast cells (11.0% [0.7%]). CONCLUSIONS: This study shows that sera from CSU patients may contain low-molecular-weight mast cell-activating factors other than autoantibodies. These factors could be an additional mechanism contributing to the pathogenesis of CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763857">PM:27763857</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-310-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-310-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Cugno M</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0051</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khalili,A.</style></author><author><style face="normal" font="Arial"> Khayatzadeh,A.</style></author><author><style face="normal" font="Arial"> Ebrahimi,M.</style></author><author><style face="normal" font="Arial"> Rafiemanesh,H.</style></author><author><style face="normal" font="Arial"> Azizi,G.</style></author><author><style face="normal" font="Arial"> Movahedi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of Tolerance in Patients With Type-1 Hypersensitivity Reaction to Wheat After Oral Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="340" start="339">339-340</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0093</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763870">PM:27763870</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Khalili A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0093</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ebrahimi,M.</style></author><author><style face="normal" font="Arial"> Gharagozlou,M.</style></author><author><style face="normal" font="Arial"> Khalili,A.</style></author><author><style face="normal" font="Arial"> Magaji,H.K.</style></author><author><style face="normal" font="Arial"> Azizi,G.</style></author><author><style face="normal" font="Arial"> Movahedi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Induction of Tolerance by Oral Immunotherapy in Patients With Cow's Milk Allergy</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="343" start="341">341-343</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Induction of tolerance</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763871">PM:27763871</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Ebrahimi M</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0094</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khor,A.H.</style></author><author><style face="normal" font="Arial"> Lim,K.S.</style></author><author><style face="normal" font="Arial"> Tan,C.T.</style></author><author><style face="normal" font="Arial"> Kwan,Z.</style></author><author><style face="normal" font="Arial"> Ng,C.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia</style></auth-address><titles><title><style face="normal" font="Arial">Cross-reactivity in AED-Induced Severe Cutaneous Adverse Reaction: A Case Report</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="331" start="329">329-331</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763865">PM:27763865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Khor AH</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez-Jimenez,B.</style></author><author><style face="normal" font="Arial"> Munoz-Garcia,E.</style></author><author><style face="normal" font="Arial"> Veza Perdomo,S.</style></author><author><style face="normal" font="Arial"> Gonzalez Herrada,C.</style></author><author><style face="normal" font="Arial"> Kindelan-Recarte,C.</style></author><author><style face="normal" font="Arial"> Dominguez-Ortega,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Hospital Universitario de Getafe, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Vitiligo Induced by Specific Immunotherapy With Grass Pollen: The Koebner Phenomenon</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="332" start="331">331-332</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Vitiligo</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0088</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763866">PM:27763866</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-314-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Rodriguez-Jimenez B</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0088</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Acar,M.</style></author><author><style face="normal" font="Arial"> Muluk,N.B.</style></author><author><style face="normal" font="Arial"> Yigitaslan,S.</style></author><author><style face="normal" font="Arial"> Cengiz,B.P.</style></author><author><style face="normal" font="Arial"> Shojaolsadati,P.</style></author><author><style face="normal" font="Arial"> Karimkhani,H.</style></author><author><style face="normal" font="Arial"> Ada,S.</style></author><author><style face="normal" font="Arial"> Berkoz,M.</style></author><author><style face="normal" font="Arial"> Cingi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ENT,Yunus Emre State Hospital,Eskisehir,Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Can curcumin modulate allergic rhinitis in rats?</style></title><secondary-title><style face="normal" font="Arial">J Laryngol Otol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Laryngol Otol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Curcumin</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="10" Year="2016">2016/10/6</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: This study aimed to explore the effects of curcumin on experimental allergic rhinitis in rats. METHODS: Twenty-eight male Wistar albino rats were randomly divided into four groups: a control group; a group in which allergic rhinitis was induced and no treatment given; a group in which allergic rhinitis was induced followed by treatment with azelastine hydrochloride on days 21-28; and a group in which allergic rhinitis was induced followed by treatment with curcumin on days 21-28. Allergy symptoms and histopathological features of the nasal mucosa were examined. RESULTS: The sneezing and nasal congestion scores were higher in the azelastine and curcumin treatment groups than in the control group. Histopathological examination showed focal goblet cell metaplasia on the epithelial surface in the azelastine group. In the curcumin group, there was a decrease in goblet cell metaplasia in the epithelium, decreased inflammatory cell infiltration and vascular proliferation in the lamina propria. CONCLUSION: Curcumin is an effective treatment for experimentally induced allergic rhinitis in rats</style></abstract><notes><style face="normal" font="Arial">DA - 20161006IS - 1748-5460 (Electronic)IS - 0022-2151 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1017/S0022215116008999</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27707425">PM:27707425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Laryngol Otol\20161106-AcarM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Laryngol Otol\20161106-AcarM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161006, Acar M</style></custom2><misc3><style face="normal" font="Arial">10.1017/S0022215116008999</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Maslin,K.</style></author><author><style face="normal" font="Arial"> Dean,T.</style></author><author><style face="normal" font="Arial"> Arshad,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Health Sciences and Social Work, University of Portsmouth, Portsmouth, UK</style></auth-address><titles><title><style face="normal" font="Arial">Does concurrent breastfeeding alongside the introduction of solid food prevent the development of food allergy?</style></title><secondary-title><style face="normal" font="Arial">J Nutr Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Nutr Sci</style></full-title></periodical><pages end="" start="e40">e40-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The timing of introduction of solid food on the subsequent development of food allergy is under debate and the role of concurrent breastfeeding is unclear. The aim of the present study was to investigate the role of solid food introduction whilst concurrently breastfeeding on food allergy outcome, with a specific focus on cows' milk allergy. Prospectively collected infant feeding data from a birth cohort were analysed. Participants with histories suggestive of food allergy underwent diagnostic food challenges. Children with food allergy were matched to control participants for age and sex. Mann-Whitney U tests, chi2, Fisher exact tests and logistic regression calculations were undertaken. A total of thirty-nine food-allergic children and seventy-eight matched controls were identified, including twenty-two cows' milk-allergic children and forty-four matched controls. The control group introduced solid food earlier than the food-allergic group (P &lt; 0.05). There was no effect of concurrent breastfeeding alongside cows' milk introduction or other food allergens on the development of food allergy. Due to small numbers, it was not possible to explore differences for food allergy phenotype. We have therefore found no evidence that introducing solids, or food allergens, whilst breastfeeding has an allergy-preventative effect; however, the results should be interpreted with caution due to sample size. Recommendations regarding infant feeding and food allergy should be carefully considered. Although breastfeeding should be promoted for many health reasons, larger studies looking at the introduction of food allergens on the development of food allergy are needed to make a final conclusion</style></abstract><notes><style face="normal" font="Arial">DA - 20161018IS - 2048-6790 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1017/jns.2016.31</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27752307">PM:27752307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Nutr Sci\2016-5-e40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Nutr Sci\2016-5-e40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161018, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1017/jns.2016.31</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gabrie,J.A.</style></author><author><style face="normal" font="Arial"> Rueda,M.M.</style></author><author><style face="normal" font="Arial"> Rodriguez,C.A.</style></author><author><style face="normal" font="Arial"> Canales,M.</style></author><author><style face="normal" font="Arial"> Sanchez,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Health Sciences, Brock University, St. Catharines, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Immune Profile of Honduran Schoolchildren with Intestinal Parasites: The Skewed Response against Geohelminths</style></title><secondary-title><style face="normal" font="Arial">J Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Parasitol Res</style></full-title></periodical><pages end="" start="1769585">1769585-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anthropometry</style></keyword><keyword><style face="normal" font="Arial"> Ascariasis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> geohelminths</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Status</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitoses</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protozoa</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2-cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Soil-transmitted helminth infections typically induce a type-2 immune response (Th2), but no immunoepidemiological studies have been undertaken in Honduras, an endemic country where the main control strategy is children's annual deworming. We aimed to characterize the immune profile of Honduran schoolchildren harbouring these parasitoses. Demographic and epidemiological data were obtained through a survey; nutritional status was assessed through anthropometry; intestinal parasites were diagnosed by formol-ether and Kato-Katz; and blood samples were collected to determine immunological markers including Th1/Th2 cytokines, IgE, and eosinophil levels. A total of 225 children participated in the study, all of whom had received deworming during the national campaign five months prior to the study. Trichuriasis and ascariasis prevalence were 22.2% and 20.4%, respectively. Stunting was associated with both age and trichuriasis, whereas ascariasis was associated with sex and household conditions. Helminth infections were strongly associated with eosinophilia and hyper-IgE as well as with a Th2-polarized response (increased levels of IL-13, IL-10, and IL4/IFN-gamma ratios and decreased levels of IFN-gamma). Pathogenic protozoa infections were associated with a Th1 response characterized by elevated levels of IFN-gamma and decreased IL10/IFN-gamma ratios. Even at low prevalence levels, STH infections affect children's nutrition and play a polarizing role in their immune system</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 2090-0023 (Print)IS - 2090-0023 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Honduras -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/1769585</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27882241">PM:27882241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Parasitol Res\2016-2016-1769585.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Parasitol Res\2016-2016-1769585.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124. Gabtie JA</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/1769585</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Verga,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Hospital Bambino Gesu Holy See, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Early allergenic-food introduction does not reduce subsequent food allergy development</style></title><secondary-title><style face="normal" font="Arial">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr</style></full-title></periodical><pages end="306" start="305">305-306</pages><volume><style face="normal" font="Arial">178</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - ENGPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jpeds.2016.08.072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788844">PM:27788844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr\2016-178-305-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr\2016-178-305-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Fiocchi A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jpeds.2016.08.072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">O'Keefe,A.</style></author><author><style face="normal" font="Arial"> Clarke,A.</style></author><author><style face="normal" font="Arial"> St,Pierre Y.</style></author><author><style face="normal" font="Arial"> Mill,J.</style></author><author><style face="normal" font="Arial"> Asai,Y.</style></author><author><style face="normal" font="Arial"> Eisman,H.</style></author><author><style face="normal" font="Arial"> La Vieille,S.</style></author><author><style face="normal" font="Arial"> Alizadehfar,R.</style></author><author><style face="normal" font="Arial"> Joseph,L.</style></author><author><style face="normal" font="Arial"> Morris,J.</style></author><author><style face="normal" font="Arial"> Graveli,J.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Discipline of Pediatrics, Faculty of Medicine, Memorial University, St. John's, Newfoundland and Labrador, Canada</style></auth-address><titles><title><style face="normal" font="Arial">The Risk of Recurrent Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To determine the recurrence rate of anaphylaxis in children medically attended in an emergency department (ED), we performed a prospective cohort study to evaluate prehospital and ED management of children with recurrent anaphylaxis and to assess factors associated with recurrent anaphylaxis. STUDY DESIGN: As part of the Cross-Canada Anaphylaxis Registry, parents of children with anaphylaxis identified prospectively in 3 EDs and through an emergency medical response service were contacted annually after presentation and queried on subsequent reactions. Cox regression analysis determined factors associated with recurrence. RESULTS: Among 292 children who were registered as having had medical attended anaphylaxis, 68.5% completed annual follow-up questionnaires. Forty-seven patients experienced 65 episodes of anaphylaxis during 369 patient-years of follow-up. Food was the trigger in 84.6% of cases, and epinephrine was used in 66.2%. In 50.8%, epinephrine was used outside the health care facility, and 81.7% were brought to a health care facility for treatment. Asthma, reaction triggered by food, and use of epinephrine during the index episode increased the odds of recurrent reaction. Patients whose initial reaction was triggered by peanut were less likely to have a recurrent reaction. CONCLUSIONS: We report a yearly anaphylaxis recurrence rate of 17.6% in children. There is substantial underuse of epinephrine in cases of anaphylaxis. Educational programs that promote effective avoidance strategies and prompt use of epinephrine are required</style></abstract><notes><style face="normal" font="Arial">DA - 20161016IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.jpeds.2016.09.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27743592">PM:27743592</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr\20161016-OKeefeA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr\20161016-OKeefeA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161016, O'Keefe A</style></custom2><misc3><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.jpeds.2016.09.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomassen,R.A.</style></author><author><style face="normal" font="Arial"> Kvammen,J.A.</style></author><author><style face="normal" font="Arial"> Eskerud,M.B.</style></author><author><style face="normal" font="Arial"> Juliusson,P.B.</style></author><author><style face="normal" font="Arial"> Henriksen,C.</style></author><author><style face="normal" font="Arial"> Rugtveit,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Department of Paediatric Medicine, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Norway daggerDepartment of Internal Medicine, Clinical Nutrition, Lovisenberg Diaconal Hospital, Oslo, Norway double daggerDepartment of Clinical Science, University of Bergen, Bergen, Norway section signDepartment of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Iodine Status and Growth In 0-2-Year-Old Infants With Cow's Milk Protein Allergy</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Appetite</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food refusal</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Iodine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weaning</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To investigate iodine status and growth in cow's milk protein allergic infants and to identify potential predictors of iodine status and growth. METHODS: Fifty-seven infants under two years of age were included in an observational cross-sectional study. Two spot urine samples were collected and analysed for iodine, together with a three-day food record and a food frequency questionnaire. Urine iodine concentrations were compared to the WHO cut-off values for iodine deficiency. Measurements of weight, length and head circumference at birth and study inclusion were converted to standard deviation scores. Subgroup analyses were performed on different feeding patterns, according to weaning status. RESULTS: Median age was nine months. Median Urinary iodine concentration was 159 ug/L. One third of the children had urine iodine concentrations indicating iodine deficiency. Infants who were mainly breastfed were at highest risk and 58% were classified as deficient. Dietary factors positively associated with iodine excretion were intake of enriched baby cereals and meeting the dietary requirement for iodine. Stunting was present in 5%. Underweight and wasting was frequent at 11% and this was associated with food refusal and poor appetite, but not with iodine status. Growth failure was detected among boys. CONCLUSION: This study suggests that CMPA children have high prevalence of iodine deficiency and poor growth, however the two conditions were not associated. The subgroup of mainly breastfed infants was at higher risk of iodine deficiency compared to weaned infants. Subjects with feeding problems had increased risk of malnutrition</style></abstract><notes><style face="normal" font="Arial">DA - 20161014IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001434</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27741063">PM:27741063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20161014-ThomassenRA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20161014-ThomassenRA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161014, Thomassen RA</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001434</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bordes,B.</style></author><author><style face="normal" font="Arial"> Martin,D.</style></author><author><style face="normal" font="Arial"> Schloss,B.</style></author><author><style face="normal" font="Arial"> Beebe,A.</style></author><author><style face="normal" font="Arial"> Samora,W.</style></author><author><style face="normal" font="Arial"> Klamar,J.</style></author><author><style face="normal" font="Arial"> Stukus,D.</style></author><author><style face="normal" font="Arial"> Tobias,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology &amp; Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio</style></auth-address><titles><title><style face="normal" font="Arial">Intraoperative Anaphylactic Reaction: Is it the Floseal?</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Pharmacol Ther</style></full-title></periodical><pages end="365" start="358">358-365</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> intraoperative anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neuromuscular blocking agents</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patient safety</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Perioperative Care</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spinal Fusion</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Thrombin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">When hemodynamic or respiratory instability occurs intraoperatively, the inciting event must be determined so that a therapeutic plan can be provided to ensure patient safety. Although generally uncommon, one cause of cardiorespiratory instability is anaphylactic reactions. During anesthetic care, these most commonly involve neuromuscular blocking agents, antibiotics, or latex. Floseal is a topical hemostatic agent that is frequently used during orthopedic surgical procedures to augment local coagulation function and limit intraoperative blood loss. As these products are derived from human thrombin, animal collagen, and animal gelatin, allergic phenomenon may occur following their administration. We present 2 pediatric patients undergoing posterior spinal fusion who developed intraoperative hemodynamic and respiratory instability following use of the topical hemostatic agent, Floseal. Previous reports of such reactions are reviewed, and the perioperative care of patients with intraoperative anaphylaxis is discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 1551-6776 (Print)IS - 1551-6776 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.5863/1551-6776-21.4.358</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27713677">PM:27713677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Pharmacol Ther\20161007-BordesB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Pharmacol Ther\20161007-BordesB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Bordes B</style></custom2><misc3><style face="normal" font="Arial">10.5863/1551-6776-21.4.358</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsui,K.</style></author><author><style face="normal" font="Arial"> Tamai,S.</style></author><author><style face="normal" font="Arial"> Ikeda,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Meiji Pharmaceutical University, Department of Microbial Science and Host Defense, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Macrolide Antibiotics on Th1 Cell and Th2 Cell Development Mediated by Langerhans Cells</style></title><secondary-title><style face="normal" font="Arial">J Pharm Pharm Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Pharm Pharm Sci</style></abbr-1></periodical><pages end="366" start="357">357-366</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Cells</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Langerhans Cells</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> macrolide</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">Background: It is well known that Langerhans cells (LCs) work as the primary orchestrators in the polarization of the immune milieu towards a T helper type 1 (Th1) or a Th2 immune response. In this study, we investigated the effects of macrolide antibiotics on Th1 cell and Th2 cell development mediated by LCs. METHODS: LC-like dendritic cells (LDCs) were generated from mouse bone marrow cells and used as substitutes for LCs. Mice were primed with ovalbumin (OVA) peptide-pulsed LDCs, which had been treated with each macrolide antibiotic, via the hind footpad. After 5 days, the cytokine response in the popliteal lymph nodes was investigated by enzyme-linked immunosorbent assay. The expression of cell surface molecules on LDCs was investigated using reverse transcriptase polymerase chain reaction. RESULTS: Injection of OVA peptide-pulsed LDCs, which had been treated with josamycin or spiramycin, inhibited Th2 cell development as represented by down-regulation of interleukin (IL)-4 production as well as Th1 cell development as represented by down-regulation of interferon (IFN)-g production. This inhibition of Th1 cell and Th2 cell development was associated with suppression of CD86 and T-cell immunoglobulin and mucin domain-containing protein (TIM)-4 expression, respectively, in LDCs. Furthermore, Staphylococcus aureus strains isolated from skin lesions of patients with atopic dermatitis (AD) were more susceptible to josamycin than to spiramycin. CONCLUSIONS: These results suggest that topical application of josamycin to AD lesions colonized with S. aureus would be beneficial for control of AD by acting on both superficial S. aureus and epidermal LCs, and inhibiting the development of Th2 cells</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 1482-1826 (Electronic)IS - 1482-1826 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.18433/J3Z32F</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27806249">PM:27806249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharm Pharm Sci\2016-19-357-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharm Pharm Sci\2016-19-357-66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Matsui K</style></custom2><misc3><style face="normal" font="Arial">10.18433/J3Z32F</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cunsolo,V.</style></author><author><style face="normal" font="Arial"> Fasoli,E.</style></author><author><style face="normal" font="Arial"> Di Francesco,A.</style></author><author><style face="normal" font="Arial"> Saletti,R.</style></author><author><style face="normal" font="Arial"> Muccilli,V.</style></author><author><style face="normal" font="Arial"> Gallina,S.</style></author><author><style face="normal" font="Arial"> Righetti,P.G.</style></author><author><style face="normal" font="Arial"> Foti,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemical Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Polyphemus, Odysseus and the ovine milk proteome</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="74" start="58">58-74</pages><volume><style face="normal" font="Arial">152</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein composition</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Sheep milk</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="23" Month="10" Year="2016">2016/10/23</year></dates><abstract><style face="normal" font="Arial">In the last years the amount of ovine milk production, mainly used to formulate a wide range of different and exclusive dairy products often categorized as gourmet food, has been progressively increasing. Taking also into account that sheep milk (SM) also appears to be potentially less allergenic than cow's one, an in-depth information about its protein composition is essential to improve the comprehension of its potential benefits for human consumption. The present work reports the results of an in-depth characterization of SM whey proteome, carried out by coupling the CPLL technology with SDS-PAGE and high resolution UPLC-nESI MS/MS analysis. This approach allowed the identification of 718 different protein components, 644 of which are from unique genes. Particularly, this identification has expanded literature data about sheep whey proteome by 193 novel proteins previously undetected, many of which are involved in the defence/immunity mechanisms or in the nutrient delivery system. A comparative analysis of SM proteome known to date with cow's milk proteome, evidenced that while about 29% of SM proteins are also present in CM, 71% of the identified components appear to be unique of SM proteome and include a heterogeneous group of components which seem to have health-promoting benefits. The data have been deposited to the ProteomeXchange with identifier &lt;PXD004556></style></abstract><notes><style face="normal" font="Arial">DA - 20161027IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - ENGPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2016.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27784645">PM:27784645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\2016-152-58-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\2016-152-58-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161027, Cunsolo V</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2016.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,W.H.</style></author><author><style face="normal" font="Arial"> Tu,Z.C.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Tian,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang, Jiangxi, 330047, China</style></auth-address><titles><title><style face="normal" font="Arial">High intensity ultrasound enhances the IgG and IgE binding of ovalbumin</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> High intensity Ultrasound</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ultrasound</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="16" Month="10" Year="2016">2016/10/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hen's egg is widely used in food industry due to its excellent nutritional and processing properties, and Ovalbumin (OVA) is the major allergen of hen's egg white. Ultrasound has been widely used in food processing industry, but effect of high intensity ultrasound on the immunoglobulin G (IgG) binding, immunoglobulin E (IgE) binding and conformational structure of OVA remains unclear. RESULTS: Ultrasound treatment at</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8095</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27747886">PM:27747886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20161017-YangWH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20161017-YangWH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Yang WH</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8095</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McKay,F.H.</style></author><author><style face="normal" font="Arial"> Cheng,C.</style></author><author><style face="normal" font="Arial"> Wright,A.</style></author><author><style face="normal" font="Arial"> Shill,J.</style></author><author><style face="normal" font="Arial"> Stephens,H.</style></author><author><style face="normal" font="Arial"> Uccellini,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Health and Social Development, Deakin University, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Evaluating mobile phone applications for health behaviour change: A systematic review</style></title><secondary-title><style face="normal" font="Arial">J Telemed Telecare</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Telemed Telecare</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Applications</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mobile phone</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="10" Year="2016">2016/10/18</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Increasing smartphones access has allowed for increasing development and use of smart phone applications (apps). Mobile health interventions have previously relied on voice or text-based short message services (SMS), however, the increasing availability and ease of use of apps has allowed for significant growth of smartphone apps that can be used for health behaviour change. This review considers the current body of knowledge relating to the evaluation of apps for health behaviour change. The aim of this review is to investigate approaches to the evaluation of health apps to identify any current best practice approaches. METHOD: A systematic review was conducted. Data were collected and analysed in September 2016. Thirty-eight articles were identified and have been included in this review. RESULTS: Articles were published between</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1758-1109 (Electronic)IS - 1357-633X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1177/1357633X16673538</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27760883">PM:27760883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Telemed Telecare\20161020-McKayFH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Telemed Telecare\20161020-McKayFH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, McKay FH</style></custom2><misc3><style face="normal" font="Arial">10.1177/1357633X16673538</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rungsa,P.</style></author><author><style face="normal" font="Arial"> Incamnoi,P.</style></author><author><style face="normal" font="Arial"> Sukprasert,S.</style></author><author><style face="normal" font="Arial"> Uawonggul,N.</style></author><author><style face="normal" font="Arial"> Klaynongsruang,S.</style></author><author><style face="normal" font="Arial"> Daduang,J.</style></author><author><style face="normal" font="Arial"> Patramanon,R.</style></author><author><style face="normal" font="Arial"> Roytrakul,S.</style></author><author><style face="normal" font="Arial"> Daduang,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Protein and Proteomics Research Center for Commercial and Industrial Purposes (ProCCI), Department of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, 40002 Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Cloning, structural modelling and characterization of VesT2s, a wasp venom hyaluronidase (HAase) from Vespa tropica</style></title><secondary-title><style face="normal" font="Arial">J Venom Anim Toxins Incl Trop Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Venom Anim Toxins Incl Trop Dis</style></full-title></periodical><pages end="" start="28">28-</pages><volume><style face="normal" font="Arial">22</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiserum</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> cDNA cloning</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Disulfide bridge</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modelling</style></keyword><keyword><style face="normal" font="Arial"> N-glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Structural analysis</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Wasp venom is a complex mixture containing proteins, enzymes and small molecules, including some of the most dangerous allergens. The greater banded wasp (Vespa tropica) is well-known for its lethal venom, whose one of the major components is a hyaluronidase (HAase). It is believed that the high protein proportion and activity of this enzyme is responsible for the venom potency. METHODS: In the present study, cDNA cloning, sequencing and 3D-structure of Vespa tropica venom HAase were described. Anti-native HAase antibody was used for neutralization assay. RESULTS: Two isoforms, VesT2a and VesT2b, were classified as members of the glycosidase hydrolase 56 family with high similarity (42-97 %) to the allergen venom HAase. VesT2a gene contained 1486 nucleotide residues encoding 357 amino acids whereas the VesT2b isoform consisted of 1411 residues encoding 356 amino acids. The mature VesT2a and VesT2b are similar in mass and pI after prediction. They are 39119.73 Da/pI 8.91 and 39571.5 Da/pI 9.38, respectively. Two catalytic residues in VesT2a, Asp107 and Glu109 were substituted in VesT2b by Asn, thus impeding enzymatic activity. The 3D-structure of the VesT2s isoform consisted of a central core (alpha/beta)7 barrel and two disulfide bridges. The five putative glycosylation sites (Asn79, Asn99, Asn127, Asn187 and Asn325) of VesT2a and the three glycosylation sites (Asn1, Asn66 and Asn81) in VesT2b were predicted. An allergenic property significantly depends on the number of putative N-glycosylation sites. The anti-native HAase serum specifically recognized to venom HAase was able to neutralize toxicity of V. tropica venom. The ratio of venom antiserum was 1:12. CONCLUSIONS: The wasp venom allergy is known to cause life-threatening and fatal IgE-mediated anaphylactic reactions in allergic individuals. Structural analysis was a helpful tool for prediction of allergenic properties including their cross reactivity among the vespid HAase</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1678-9180 (Linking)LA - ENGPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40409-016-0084-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27790249">PM:27790249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Venom Anim Toxins Incl Trop Dis\2016-22-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Venom Anim Toxins Incl Trop Dis\2016-22-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Rungsa P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40409-016-0084-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Habibovic,A.</style></author><author><style face="normal" font="Arial"> Hristova,M.</style></author><author><style face="normal" font="Arial"> Heppner,D.E.</style></author><author><style face="normal" font="Arial"> Danyal,K.</style></author><author><style face="normal" font="Arial"> Ather,J.L.</style></author><author><style face="normal" font="Arial"> Janssen-Heininger,Y.M.</style></author><author><style face="normal" font="Arial"> Irvin,C.G.</style></author><author><style face="normal" font="Arial"> Poynter,M.E.</style></author><author><style face="normal" font="Arial"> Lundblad,L.K.</style></author><author><style face="normal" font="Arial"> Dixon,A.E.</style></author><author><style face="normal" font="Arial"> Geiszt,M.</style></author><author><style face="normal" font="Arial"> van der Vliet,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pathology and Laboratory Medicine</style></auth-address><titles><title><style face="normal" font="Arial">DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="e88811">e88811-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">18</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> amphiregulin</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> EGFR</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Src</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="11" Year="2016">2016/11/3</year></dates><abstract><style face="normal" font="Arial">Chronic inflammation with mucous metaplasia and airway remodeling are hallmarks of allergic asthma, and these outcomes have been associated with enhanced expression and activation of EGFR signaling. Here, we demonstrate enhanced expression of EGFR ligands such as amphiregulin as well as constitutive EGFR activation in cultured nasal epithelial cells from asthmatic subjects compared with nonasthmatic controls and in lung tissues of mice during house dust mite-induced (HDM-induced) allergic inflammation. EGFR activation was associated with cysteine oxidation within EGFR and the nonreceptor tyrosine kinase Src, and both amphiregulin production and oxidative EGFR activation were diminished by pharmacologic or genetic inhibition of the epithelial NADPH oxidase dual oxidase 1 (DUOX1). DUOX1 deficiency also attenuated several EGFR-dependent features of HDM-induced allergic airway inflammation, including neutrophilic inflammation, type 2 cytokine production (IL-33, IL-13), mucous metaplasia, subepithelial fibrosis, and central airway resistance. Moreover, targeted inhibition of airway DUOX1 in mice with previously established HDM-induced allergic inflammation, by intratracheal administration of DUOX1-targeted siRNA or pharmacological NADPH oxidase inhibitors, reversed most of these outcomes. Our findings indicate an important function for DUOX1 in allergic inflammation related to persistent EGFR activation and suggest that DUOX1 targeting may represent an attractive strategy in asthma management</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 2379-3708 (Linking)LA - ENGPT - Journal ArticleCO - United States -CO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.88811</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27812543">PM:27812543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2016-1-e88811.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2016-1-e88811.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Habibovic A</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.88811</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rieber,N.</style></author><author><style face="normal" font="Arial"> Gazendam,R.P.</style></author><author><style face="normal" font="Arial"> Freeman,A.F.</style></author><author><style face="normal" font="Arial"> Hsu,A.P.</style></author><author><style face="normal" font="Arial"> Collar,A.L.</style></author><author><style face="normal" font="Arial"> Sugui,J.A.</style></author><author><style face="normal" font="Arial"> Drummond,R.A.</style></author><author><style face="normal" font="Arial"> Rongkavilit,C.</style></author><author><style face="normal" font="Arial"> Hoffman,K.</style></author><author><style face="normal" font="Arial"> Henderson,C.</style></author><author><style face="normal" font="Arial"> Clark,L.</style></author><author><style face="normal" font="Arial"> Mezger,M.</style></author><author><style face="normal" font="Arial"> Swamydas,M.</style></author><author><style face="normal" font="Arial"> Engeholm,M.</style></author><author><style face="normal" font="Arial"> Schule,R.</style></author><author><style face="normal" font="Arial"> Neumayer,B.</style></author><author><style face="normal" font="Arial"> Ebel,F.</style></author><author><style face="normal" font="Arial"> Mikelis,C.M.</style></author><author><style face="normal" font="Arial"> Pittaluga,S.</style></author><author><style face="normal" font="Arial"> Prasad,V.K.</style></author><author><style face="normal" font="Arial"> Singh,A.</style></author><author><style face="normal" font="Arial"> Milner,J.D.</style></author><author><style face="normal" font="Arial"> Williams,K.W.</style></author><author><style face="normal" font="Arial"> Lim,J.K.</style></author><author><style face="normal" font="Arial"> Kwon-Chung,K.J.</style></author><author><style face="normal" font="Arial"> Holland,S.M.</style></author><author><style face="normal" font="Arial"> Hartl,D.</style></author><author><style face="normal" font="Arial"> Kuijpers,T.W.</style></author><author><style face="normal" font="Arial"> Lionakis,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Infectious Diseases and Immunology, Department of Pediatrics I, University of Tubingen, Germany.; Department of Pediatrics, Munich Schwabing Hospital, Munich Technical University, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Extrapulmonary Aspergillus infection in patients with CARD9 deficiency</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="e89890">e89890-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">17</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus infection</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Central Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Neutropenia</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phagocytosis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">Invasive pulmonary aspergillosis is a life-threatening mycosis that only affects patients with immunosuppression, chemotherapy-induced neutropenia, transplantation, or congenital immunodeficiency. We studied the clinical, genetic, histological, and immunological features of 2 unrelated patients without known immunodeficiency who developed extrapulmonary invasive aspergillosis at the ages of 8 and 18. One patient died at age 12 with progressive intra-abdominal aspergillosis. The other patient had presented with intra-abdominal candidiasis at age 9, and developed central nervous system aspergillosis at age 18 and intra-abdominal aspergillosis at age 25. Neither patient developed Aspergillus infection of the lungs. One patient had homozygous M1I CARD9 (caspase recruitment domain family member 9) mutation, while the other had homozygous Q295X CARD9 mutation; both patients lacked CARD9 protein expression. The patients had normal monocyte and Th17 cell numbers in peripheral blood, but their mononuclear cells exhibited impaired production of proinflammatory cytokines upon fungus-specific stimulation. Neutrophil phagocytosis, killing, and oxidative burst against Aspergillus fumigatus were intact, but neither patient accumulated neutrophils in infected tissue despite normal neutrophil numbers in peripheral blood. The neutrophil tissue accumulation defect was not caused by defective neutrophil-intrinsic chemotaxis, indicating that production of neutrophil chemoattractants in extrapulmonary tissue is impaired in CARD9 deficiency. Taken together, our results show that CARD9 deficiency is the first known inherited or acquired condition that predisposes to extrapulmonary Aspergillus infection with sparing of the lungs, associated with impaired neutrophil recruitment to the site of infection</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 2379-3708 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.89890</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27777981">PM:27777981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2016-1-e89890.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2016-1-e89890.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Rieber N</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.89890</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bueno,C.</style></author><author><style face="normal" font="Arial"> Martin-Pedraza,L.</style></author><author><style face="normal" font="Arial"> Cuesta-Herranz,J.</style></author><author><style face="normal" font="Arial"> Villalba,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Is the Cross-Reactivity of Sin a 1, 2S Albumin from Mustard Seeds, Exclusively Restricted to Brassicaceae Members?</style></title><secondary-title><style face="normal" font="Arial">JSM Allergy Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JSM Allergy Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> 2S Albumins</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE Binding Ability</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mustard</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> pine nut</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant protein</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Sin a 1</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Food allergy is an important health problem that is gradually growing worldwide. The most prevalent food allergens are those of vegetal origin, affecting approximately 2-4% of the European adult population and 8% of childhood.2S albumins have been described as relevant food allergens and their availability as purified molecules could constitute important clinical diagnostic advantage for food allergies. Despite the relatively low sequence similarity between members of this plant protein family, especially from distant species, studies focused on a potential role for these allergens in cross-reactivity and unexpected reactions have been approached.In this manuscript, different extracts from Brassicaceae family, tree nuts and other seeds have been isolated. Sin a 1, the 2S albumin from mustard seeds (Sinapis alba) and 2S albumin from pine nuts were purified and identified by mass-spectrometry. These proteins display typical features as their homologues from the 2S albumin family retaining the ability to bind IgE. Immunoblotting assays with a pool of Sin a 1-allergic patients' sera revealed the allergenic capacity of members from the Brassicaceae family across the recognition of Sin a 1 and the IgE binding ability to pine nuts and sesame even though their different phylogenetic family.In conclusion, although cross-reactivity related to Sin a 1 is mainly assigned to Brassicaceae, other seeds, such as pine nut have to be keep in mind in order to unexpected reactions. These characterized allergens could be used as clinical tools elaborating a more accurate diagnosis and therefore a more effective allergy treatment.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.jscimedcentral.com/Allergy/earlyonline.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JSM Allergy Asthma\20161012-BuenoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JSM Allergy Asthma\20161012-BuenoC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Bueno C</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kang,H.S.</style></author><author><style face="normal" font="Arial"> Rhee,C.K.</style></author><author><style face="normal" font="Arial"> Lee,H.Y.</style></author><author><style face="normal" font="Arial"> Yoon,H.K.</style></author><author><style face="normal" font="Arial"> Kwon,S.S.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Different anti-remodeling effect of nilotinib and fluticasone in a chronic asthma model</style></title><secondary-title><style face="normal" font="Arial">Korean J Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Korean J Intern Med</style></full-title></periodical><pages end="1158" start="1150">1150-1158</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> c-kit</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> nilotinib</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Platelet-Derived Growth Factor</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta1</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">Background/Aims: Inhaled corticosteroids are the most effective treatment currently available for asthma, but their beneficial effect against airway remodeling is limited. The tyrosine kinase inhibitor nilotinib has inhibitory activity against c-kit and the platelet-derived growth factor receptor. We compared the effects of fluticasone and nilotinib on airway remodeling in a chronic asthma model. We also examined whether co-treatment with nilotinib and fluticasone had any synergistic effect in preventing airway remodeling. Methods: We developed a mouse model of airway remodeling, including smooth muscle thickening, in which ovalbumin (OVA)-sensitized female BALB/c-mice were repeatedly exposed to intranasal OVA administration twice per week for 3 months. Mice were treated with fluticasone and/or nilotinib intranasally during the OVA challenge. Results: Mice chronically exposed to OVA developed eosinophilic airway inflammation and showed features of airway remodeling, including thickening of the peribronchial smooth muscle layer. Both f luticasone and nilotinib attenuated airway smooth muscle thickening. However, only nilotinib suppressed fibrotic changes, demonstrating inhibition of collagen deposition. Fluticasone reduced pro-inflammatory cells, such as eosinophils, and several cytokines, such as interleukin 4 (IL-4), IL-5, and IL-13, induced by repeated OVA challenges. On the other hand, nilotinib reduced transforming growth factor beta1 levels in bronchoalveolar lavage fluid and inhibited fibroblast proliferation significantly. Conclusions: These results suggest that fluticasone and nilotinib suppressed airway remodeling in this chronic asthma model through anti-inflammatory and anti-fibrotic pathways, respectively</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 2005-6648 (Electronic)IS - 1226-3303 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3904/kjim.2015.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27764539">PM:27764539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Intern Med\2016-31-1150-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Intern Med\2016-31-1150-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Kang HS</style></custom2><misc3><style face="normal" font="Arial">10.3904/kjim.2015.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,K.</style></author><author><style face="normal" font="Arial"> Jeong,K.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Clinical and laboratory findings of childhood buckwheat allergy in a single tertiary hospital</style></title><secondary-title><style face="normal" font="Arial">Korean J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Korean J Pediatr</style></full-title></periodical><pages end="407" start="402">402-407</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat allergy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Korean children</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Buckwheat allergy is one of the most severe types of food allergy in some countries, especially among children. However, few studies have investigated this condition. The aim of this study was to report the clinical and laboratory findings in Korean children with buckwheat allergy. METHODS: Thirty-seven subjects, aged 1 to 14 years, were enrolled by retrospective medical record review from January 2000 through May 2015 at the Department of Pediatrics in Ajou University Hospital. The demographic profile, previous exposure to buckwheat pillows, clinical symptoms, and laboratory findings of each subject were recorded. RESULTS: Twenty-six of the 37 children had immediate-type allergic symptoms to buckwheat, while 11 subjects were tolerant to buckwheat. Seventeen out of 26 buckwheat allergic children (65.4%) had anaphylaxis. The median buckwheat specific IgE level in the buckwheat allergic group (7.71 kUA/L) was significantly higher (P&lt;0.001) than in the buckwheat tolerant group (0.08 kUA/L) with an optimal cutoff value of 1.27 kUA/L (sensitivity 84.6%, specificity 100%). When adjusted for age, the difference between the 2 groups showed no statistical significance (P=0.063). In subjects who had anaphylaxis, buckwheat-specific IgE levels ranged from 0.37 to 100 kUA/L. CONCLUSION: Almost two-thirds of buckwheat-allergic children had anaphylaxis, and a wide-range of buckwheat specific IgE levels were observed in these children. Anaphylaxis occurred in a subject with a remarkably low IgE level (0.37 kUA/L)</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1738-1061 (Print)IS - 1738-1061 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3345/kjp.2016.59.10.402</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826326">PM:27826326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Pediatr\2016-59-402-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Pediatr\2016-59-402-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Park K</style></custom2><misc3><style face="normal" font="Arial">10.3345/kjp.2016.59.10.402</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Access to medicines-the status quo is no longer an option</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="1250">1250-</pages><volume><style face="normal" font="Arial">388</style></volume><number><style face="normal" font="Arial">10051</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Decision Making</style></keyword><keyword><style face="normal" font="Arial"> Health Services Accessibility</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword></keywords><dates><year Day="24" Month="9" Year="2016">2016/9/24</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160928IS - 0140-6736 (Print)IS - 0140-6736 (Linking)LA - ENGPT - EditorialPT - CommentSB - AIMSB - IM</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(16)31706-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27673452">PM:27673452</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\2016-388-1250.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\2016-388-1250.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160928, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(16)31706-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lopez-Rodriguez,J.C.</style></author><author><style face="normal" font="Arial"> Barderas,R.</style></author><author><style face="normal" font="Arial"> Echaide,M.</style></author><author><style face="normal" font="Arial"> Perez-Gil,J.</style></author><author><style face="normal" font="Arial"> Villalba,M.</style></author><author><style face="normal" font="Arial"> Batanero,E.</style></author><author><style face="normal" font="Arial"> Cruz,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Surface activity as a crucial factor of the biological actions of Ole e 1, the main aeroallergen of olive tree (Olea europaea) pollen</style></title><secondary-title><style face="normal" font="Arial">Langmuir</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Langmuir</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> air-liquid interface</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Ole e</style></keyword><keyword><style face="normal" font="Arial"> Ole e 1</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="10" Month="10" Year="2016">2016/10/10</year></dates><abstract><style face="normal" font="Arial">Aeroallergens are airborne substances -mainly proteins- capable of triggering Th2-immune responses in respiratory allergies. They enter into the body through the upper airways, reaching the mucosa afterwards. Mucosae lining at the luminal side consists of an epithelial barrier completely covered by mucus and pulmonary surfactant. Both, pulmonary surfactant and plasma membrane of the epithelial cells represent two physiological phospholipid-based barriers where allergens first impact before triggering their biological effects. The interaction of allergens with lipids at relevant physiological surfaces could promote structural changes on the molecule, resulting on a potential modification of its allergenic properties. In this work, we have firstly described the surface and phospholipid interaction capabilities of the clinically relevant aeroallergen Ole e 1, the main allergen of olive tree pollen. By using epifluorescence microscopy of Langmuir transferred films, we observed that lipid-packed ordered domains may function as a preferential location for allergen to accumulate at the air-liquid interface, an effect that is abolished in the presence of cholestenone. The possible implications of phospholipid-interfacial effects in the modification of allergen structural and functional properties will be discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20161010IS - 1520-5827 (Electronic)IS - 0743-7463 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.langmuir.6b02831</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27723354">PM:27723354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Langmuir\20161010-Lopez-RodriguezJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Langmuir\20161010-Lopez-RodriguezJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Lopez-Rodriguez JC</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.langmuir.6b02831</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rezende,J.P.</style></author><author><style face="normal" font="Arial"> Ferreira,G.M.</style></author><author><style face="normal" font="Arial"> Ferreira,G.M.</style></author><author><style face="normal" font="Arial"> da Silva,L.H.</style></author><author><style face="normal" font="Arial"> do Carmo Hepanhol da Silva,M.</style></author><author><style face="normal" font="Arial"> Pinto,M.S.</style></author><author><style face="normal" font="Arial"> Pires,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Technology, Universidade Federal de Vicosa, Av, PH Rolfs, s/n, Campus Universitario, Vicosa, MG 36570-000, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Polydiacetylene/triblock copolymer nanosensor for the detection of native and free bovine serum albumin</style></title><secondary-title><style face="normal" font="Arial">Mater Sci Eng C Mater Biol Appl</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Mater Sci Eng C Mater Biol Appl</style></abbr-1></periodical><pages end="543" start="535">535-543</pages><volume><style face="normal" font="Arial">70</style></volume><number><style face="normal" font="Arial">Pt 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Technology</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk quality</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">Bovine serum albumin (BSA) has been recognized as a marker of the cow's health, milk quality, an allergenic protein and as a carrier. Its detection is important in the food, pharmaceutical and medical industries. However, traditional techniques used to detect BSA are often time-consuming, expensive, and show limited sensitivity. This paper describes properties of polydiacetylene-triblock copolymer (L64) nanosensors, synthesized to easily detect BSA. Sensor efficiency was studied as a function of nanosensor composition, polydiacetylene chemical structures, BSA conformation and hydrophobic domain availability, using spectroscopic, calorimetric, light scattering, and electrokinetic analyses. Nanosensors were sensitive to detect the average BSA concentration of milk and dairy products and discriminated between native and denatured protein through naked-eye detectable blue-to-red transition. The standard Gibbs free energy (-10.44&lt;DeltaG degrees &lt;-49.52kJM), stoichiometry complex (1&lt;"n"&lt;3), and binding constant (6.7x102&lt;Ka&lt;4.79x108M-1) of BSA-nanosensor complex formation established a direct relationship between nanosensor response and BSA-nanosensor interaction. BSA-nanosensor interaction was entropically (without cholesterol), and enthalpically driven (with cholesterol). Eugenol-BSA complex did not induce colorimetric transition. Polydiacetylene-L64 nanosensors are potential low-cost sensors for rapid detection of BSA, discriminating between native/denatured and free/bound protein</style></abstract><notes><style face="normal" font="Arial">DA - 20161023IS - 1873-0191 (Electronic)IS - 0928-4931 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.msec.2016.09.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27770925">PM:27770925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mater Sci Eng C Mater Biol Appl\2017-70-535-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mater Sci Eng C Mater Biol Appl\2017-70-535-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161023, Rezende JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.msec.2016.09.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tan,M.S.</style></author><author><style face="normal" font="Arial"> Teoh,E.J.</style></author><author><style face="normal" font="Arial"> Hor,C.P.</style></author><author><style face="normal" font="Arial"> Yeoh,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Seberang Jaya Hospital, Department of Paediatrics, Jalan Tun Hussein Onn, 13700 Perai, Pulau Pinang, Malaysia.</style></auth-address><titles><title><style face="normal" font="Arial">Measles-Mumps-Rubella vaccine for children with egg allergy: Is admission for inpatient vaccination necessary?</style></title><secondary-title><style face="normal" font="Arial">Med J Malaysia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med J Malaysia</style></full-title></periodical><pages end="160" start="157">157-160</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immunisation</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inpatients</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> Measles-Mumps-Rubella Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Children who develop any hypersensitivity reaction to eggs are routinely referred to hospital for Measles-Mumps-Rubella (MMR) vaccination as inpatients to prevent anaphylaxis. We aimed to study the association between hypersensitivity reactions after egg exposure and similar reactions after MMR immunisation; and examine the necessity of hospital admission for vaccination. METHODS: A prospective observational study was conducted in Paediatric Department in Bukit Mertajam Hospital, Penang, between March and December 2014. Children referred from local polyclinics for inpatient MMR vaccination because of a history of egg allergy were recruited. The children were observed in the ward for post vaccination allergic reactions. Concurrently, a group of children without egg allergy was recruited from those admitted for other illnesses but had recent MMR vaccination at polyclinics. Parents of these children were interviewed and asked if they had observed any reactions post vaccination. In both groups, sociodemographics, medical history and family history of atopy were collected. RESULTS: Eighty-seven subjects were recruited in this study. Fifty-four infants with egg allergy had previous mild allergic reactions after exposure to eggs or egg-related products. They were associated with a family history of egg hypersensitivity, personal history of acute gastroenteritis and upper respiratory tract infections. Two of them developed cutaneous rashes post vaccination during observation, but none developed anaphylactic or anaphylactoid reactions. Two infants among those without egg allergy had post vaccination fever. There was no association between egg allergy and hypersensitivity reactions to MMR vaccine (p=0.632). CONCLUSIONS: MMR vaccine can be safely administered to children with mild egg allergy, hence admission for vaccination in the hospital is not warranted. Risk stratification is required to ensure only infants with severe reactions will be admitted for vaccination</style></abstract><notes><style face="normal" font="Arial">DA - 20161022IS - 0300-5283 (Print)IS - 0300-5283 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27770112">PM:27770112</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med J Malaysia\2016-71-157-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med J Malaysia\2016-71-157-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161022, Tan MS</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Soyza,A.</style></author><author><style face="normal" font="Arial"> Aliberti,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Cellular Medicine, Newcastle University NE2 4HH; and Adult Bronchiectasis Service, Department of Respiratory Medicine, Freeman Hospital, Heaton Road, Newcastle, NE7 7DN, UK</style></auth-address><titles><title><style face="normal" font="Arial">Bronchiectasis and Aspergillus: How are they linked?</style></title><secondary-title><style face="normal" font="Arial">Med Mycol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Mycol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="10" Year="2016">2016/10/28</year></dates><abstract><style face="normal" font="Arial">Bronchiectasis is a chronic airway infection syndrome, distinct from cystic fibrosis that is rising in prevalence and is associated with significant morbidity and mortality. It can be caused by many etiologies including post-infectious effects or be seen in common lung diseases such as chronic obstructive pulmonary disease (COPD) or severe asthma. Bronchiectasis is associated with many Aspergillus-associated syndromes: allergic bronchopulmonary aspergillosis (ABPA) may complicate asthma, thus leading to bronchiectasis as part of the diagnostic criteria of ABPA or can complicate preexisting bronchiectasis due to another etiology. Aspergilloma can develop in areas of lung damage seen in patients with bronchiectasis, whereas fungal bronchitis may lead to later bronchiectasis. Invasive aspergillosis, perhaps more commonly viewed as a consequence of significant immunosuppression, is also seen in the absence of immunosuppression in those with underlying lung diseases including bronchiectasis. The pathogenesis and treatments of these diverse Aspergillus-associated diseases in bronchiectasis are discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20161030IS - 1460-2709 (Electronic)IS - 1369-3786 (Linking)LA - ENGPT - Journal ArticleCO - United Kingdom -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1093/mmy/myw109</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27794529">PM:27794529</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Mycol\20161030-DeSoyzaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Mycol\20161030-DeSoyzaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161030, De Soyza A</style></custom2><misc3><style face="normal" font="Arial">10.1093/mmy/myw109</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Golinska-Zach,A.</style></author><author><style face="normal" font="Arial"> Krawczyk-Szulc,P.</style></author><author><style face="normal" font="Arial"> Wiszniewska,M.</style></author><author><style face="normal" font="Arial"> Nowakowska-Swirta,E.</style></author><author><style face="normal" font="Arial"> Swierczynska-Machura,D.</style></author><author><style face="normal" font="Arial"> Tymoszuk,D.</style></author><author><style face="normal" font="Arial"> Walusiak-Skorupa,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nofer Institute of Occupational Medicine / Instytut Medycyny Pracy im. prof. J. Nofera, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to occupational allergens in hairdressing apprentices diagnosed already before entering vocational training</style></title><secondary-title><style face="normal" font="Arial">Med Pr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Pr</style></full-title></periodical><pages end="575" start="567">567-575</pages><volume><style face="normal" font="Arial">67</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> hairdressers</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hairdressers are occupationally exposed to many allergenic and irritating substances. Additionally, hairdressing apprentices are exposed to the same allergens as professional hairdressers, due to the fact that vocational training starts in the beginning of the education. This study was undertaken to investigate early occurrence of sensitization to occupational allergens in hairdressing apprentices before the onset of the vocational training. MATERIAL AND METHODS: Three hundred and seven hairdressing apprentices were assessed using a questionnaire and skin prick tests (SPTs) to common and occupational allergens. The level of total and serum specific immunoglobulin E (IgE) to occupational allergens was evaluated and spirometry was performed. RESULTS: At least one skin and/or respiratory and/or conjunctival symptom was reported by 29.9% of subjects. Among subjects with at least one symptom, 28.2% of them were atopic whereas among 43.4% of them total IgE level was elevated. Atopy was found in 20% cases. In the case of one apprentice, positive SPT for paraphenylenediamine was found. Nearly 33% of apprentices had elevated total IgE level and 5 of them had specific IgE for occupational allergens. CONCLUSIONS: The study revealed that hairdressing apprentices might be sensitized to occupational allergens even before the beginning of vocational training, due to prior non-professional exposure to hairdressing agents. Furthermore, many of them report skin, respiratory and conjunctival symptoms, often connected with chronic disease diagnosis. Thus, candidates for hairdressers should be examined thoroughly before the start of the education and tests for allergy to hairdressing substances are indicated. Med Pr 2016;67(5):567-575</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 0465-5893 (Print)IS - 0465-5893 (Linking)LA - ENGPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.13075/mp.5893.00232</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27819696">PM:27819696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Pr\2016-67-567-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Pr\2016-67-567-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Golinska-Zach A</style></custom2><misc3><style face="normal" font="Arial">10.13075/mp.5893.00232</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vidal-Quist,J.C.</style></author><author><style face="normal" font="Arial"> Ortego,F.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Castanera,P.</style></author><author><style face="normal" font="Arial"> Hernandez-Crespo,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Plant-Insect Interaction, Department of Environmental Biology, Centro de Investigaciones Biologicas (CSIC), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Effects of domestic chemical stressors on expression of allergen genes in the European house dust mite</style></title><secondary-title><style face="normal" font="Arial">Med Vet Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Vet Entomol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen genes</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bioassay</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Der p 21</style></keyword><keyword><style face="normal" font="Arial"> Der p 3</style></keyword><keyword><style face="normal" font="Arial"> Der p 8</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Diesel</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust</style></keyword><keyword><style face="normal" font="Arial"> diesel exhaust particle</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust particles</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Pyroglyphidae</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Sound</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="10" Year="2016">2016/10/18</year></dates><abstract><style face="normal" font="Arial">The expression of allergen genes in house dust mites is influenced by temperature and relative humidity, but little is known of the impacts of other environmental factors that may alter the repertoire of allergens released by mites in home microhabitats. Bioassays were conducted in concave microscope slides in combination with real-time quantitative polymerase chain reaction (RT-qPCR) to analyse gene expression of 17 allergens of Dermatophagoides pteronyssinus (Acariformes: Pyroglyphidae) exposed to three chemical stressors that can be present in domestic environments. Short-term exposure (5-12 days) to diesel exhaust particles (DEPs) (1 microg/cm2 ), bacterial lipopolysaccharide endotoxin (0.1 microg/cm2 ) and benzyl benzoate (3.2 microg/cm2 ), at concentrations exceeding those expected in homes, had no significant effect on allergen transcription. A significant increase in the transcription of allergens Der p 3, Der p 8 and Der p 21 was observed only after exposing mites to a higher concentration of DEPs (10 microg/cm2 ) over a whole generation. In combination, the present results suggest that the analysed factors have low impact on allergen production. The methodology described here offers a sound and rapid approach to the broad-spectrum study of factors affecting allergen-related mite physiology, and allows the simultaneous screening of different factors in a relatively short period with consideration of the full spectrum of allergen genes</style></abstract><notes><style face="normal" font="Arial">DA - 20161018IS - 1365-2915 (Electronic)IS - 0269-283X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/mve.12200</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27753116">PM:27753116</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Vet Entomol\20161018-VidalQuistJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Vet Entomol\20161018-VidalQuistJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161018, Vidal-Quist JC</style></custom2><misc3><style face="normal" font="Arial">10.1111/mve.12200</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lopez-Pacheco,C.</style></author><author><style face="normal" font="Arial"> Soldevila,G.</style></author><author><style face="normal" font="Arial"> Du Pont,G.</style></author><author><style face="normal" font="Arial"> Hernandez-Pando,R.</style></author><author><style face="normal" font="Arial"> Garcia-Zepeda,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CBRL, Ciudad de Mexico, Mexico; Departamento de Inmunologia, Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, 04510 Ciudad de Mexico, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">CCR9 Is a Key Regulator of Early Phases of Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mediators Inflamm</style></full-title></periodical><pages end="" start="3635809">3635809-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> Chemokine receptors</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Airway inflammation is the most common hallmark of allergic asthma. Chemokine receptors involved in leukocyte recruitment are closely related to the pathology in asthma. CCR9 has been described as a homeostatic and inflammatory chemokine receptor, but its role and that of its ligand CCL25 during lung inflammation remain unknown. To investigate the role of CCR9 as a modulator of airway inflammation, we established an OVA-induced allergic inflammation model in CCR9-deficient mice. Here, we report the expression of CCR9 and CCL25 as early as 6 hours post-OVA challenge in eosinophils and T-lymphocytes. Moreover, in challenged CCR9-deficient mice, cell recruitment was impaired at peribronchial and perivenular levels. OVA-administration in CCR9-deficient mice leads to a less inflammatory cell recruitment, which modifies the expression of IL-10, CCL11, and CCL25 at 24 hours after OVA challenge. In contrast, the secretion of IL-4 and IL-5 was not affected in CCR9-deficient mice compared to WT mice. These results demonstrate for the first time that CCR9 and CCL25 expressions are induced in the early stages of airway inflammation and they have an important role modulating eosinophils and lymphocytes recruitment at the first stages of inflammatory process, suggesting that they might be a potential target to regulate inflammation in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - ENGPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/3635809</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795621">PM:27795621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mediators Inflamm\2016-2016-3635809.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mediators Inflamm\2016-2016-3635809.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Lopez-Pacheco C</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/3635809</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chang,W.P.</style></author><author><style face="normal" font="Arial"> Kuo,C.N.</style></author><author><style face="normal" font="Arial"> Kuo,L.N.</style></author><author><style face="normal" font="Arial"> Wang,Y.T.</style></author><author><style face="normal" font="Arial"> Perng,W.T.</style></author><author><style face="normal" font="Arial"> Kuo,H.C.</style></author><author><style face="normal" font="Arial"> Wei,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aSchool of Health Care Administration bDepartment of Clinical Pharmacy, School of Pharmacy, Taipei Medical University cDepartment of Pharmacy, Taipei Medical University-Wan Fang Hospital, Taipei dDivision of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung; School of Medicine, Chung Shan Medical University, Taichung eDepartment of Recreation Sport and Health Promotion, National Pingtung University of Science and Technology, Pingtung fDepartment of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital gCollege of Medicine, Chang Gung University, Kaohsiung hDivision of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital; Institute of Medicine, Chung Shan Medical University; Institute of Intergrative Medicine, China Medical University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Increase risk of allergic diseases in patients with ankylosing spondylitis: A 10-year follow-up population-based study in Taiwan</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e5172">e5172-</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">45</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Promotion</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spondylitis</style></keyword><keyword><style face="normal" font="Arial"> sport</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Th2 and Th17 cells are both associated with developing ankylosing spondylitis (AS) and asthma. Th2 cells are also associated with allergic rhinitis and atopic dermatitis (AD). The prevalence of such allergic diseases in AS patients is unknown. In this study, we intended to study the risk of allergic diseases in a 10-year follow-up population of newly diagnosed patients with AS. We used a nationwide 10-year population-based database retrieved from the Longitudinal Health Insurance Database 2005 (LHID2005) in Taiwan. The study cohort comprised 857 patients with AS who had at least 1 claim of inpatient admission or at least 2 claims of ambulatory visit. The comparison cohort consisted of 4285 randomly selected subjects matched with AS group at a ratio of 5:1. We used Cox proportional-hazards regression to determine the 10-year disease-free survival rates after adjusting for potentially confounding factors. The AS patients had a 1.31 times greater risk of developing asthma within 10 years of diagnosis when compared with non-AS age- and sex-matched subjects, after adjusting for other risk factors (95% confidence interval = 1.00-1.75). But the difference was not significantly different. The AS patients also had a 1.46 times and a 1.22 times greater risk of developing allergic rhinitis and AD significantly. AS patients also had a lower allergic disease-free survival rate compared to non-AS group. Our results showed that patients with AS had a higher risk of developing allergic diseases later in life</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000005172</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27828843">PM:27828843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-95-e5172.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2016-95-e5172.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Chang WP</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000005172</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wen,T.</style></author><author><style face="normal" font="Arial"> Rothenberg,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229</style></auth-address><titles><title><style face="normal" font="Arial">The Regulatory Function of Eosinophils</style></title><secondary-title><style face="normal" font="Arial">Microbiol Spectr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Microbiol Spectr</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Eosinophils are a minority circulating granulocyte classically viewed as being involved in host defense against parasites and promoting allergic reactions. However, a series of new regulatory functions for these cells have been identified in the past decade. During homeostasis, eosinophils develop in the bone marrow and migrate from the blood into target tissues following an eotaxin gradient, with interleukin-5 being a key cytokine for eosinophil proliferation, survival, and priming. In multiple target tissues, eosinophils actively regulate a variety of immune functions through their vast arsenal of granule products and cytokines, as well as direct cellular interaction with cells in proximity. The immunologic regulation of eosinophils extends from innate immunity to adaptive immunity and also involves non-immune cells. Herein, we summarize recent findings regarding novel roles of murine and human eosinophils, focusing on interactions with other hematopoietic cells. We also review new experimental tools available and remaining questions to uncover a greater understanding of this enigmatic cell</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 2165-0497 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1128/microbiolspec.MCHD-0020-2015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27780017">PM:27780017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microbiol Spectr\20161025-WenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microbiol Spectr\20161025-WenT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Wen T</style></custom2><misc3><style face="normal" font="Arial">10.1128/microbiolspec.MCHD-0020-2015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harata,G.</style></author><author><style face="normal" font="Arial"> He,F.</style></author><author><style face="normal" font="Arial"> Takahashi,K.</style></author><author><style face="normal" font="Arial"> Hosono,A.</style></author><author><style face="normal" font="Arial"> Miyazawa,K.</style></author><author><style face="normal" font="Arial"> Yoda,K.</style></author><author><style face="normal" font="Arial"> Hiramatsu,M.</style></author><author><style face="normal" font="Arial"> Kaminogawa,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Technical Research Laboratory, Takanashi Milk Products Co., Ltd., Yokohama 241-0023, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Human Lactobacillus Strains from the Intestine can Suppress IgE-Mediated Degranulation of Rat Basophilic Leukaemia (RBL-2H3) Cells</style></title><secondary-title><style face="normal" font="Arial">Microorganisms</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Microorganisms</style></abbr-1></periodical><pages end="" start="40">40-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> intestinal microflora</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> Lactobacilli</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus GG</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> microflora</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword></keywords><dates><year Day="27" Month="10" Year="2016">2016/10/27</year></dates><abstract><style face="normal" font="Arial">Mast cells play a critical role in immunoglobulin E (IgE)-mediated allergic diseases, and the degranulation of mast cells is important in the pathogenesis of these diseases. A disturbance of the intestinal microflora, especially of endogenous lactic acid bacteria, might be a contributing factor for IgE-mediated allergic diseases. Additional knowledge regarding the interaction of human intestinal Lactobacilli with mast cells is still necessary. Twenty-three strains of Lactobacilli, including commercial and reference strains and strains from the human intestine, were tested for their ability to regulate degranulation of cells from rat basophilic leukemia RBL-2H3 cells (RBL-2H3) in vitro based on a beta-hexosaminidase release assay. Each of the tested Lactobacilli characteristically suppressed IgE-mediated degranulation of RBL-2H3 cells, and Lactobacillus GG showed the strongest inhibitory effect on the cells. Furthermore, the bacteria isolated from the human intestine significantly suppressed degranulation of RBL-2H3 cellsin comparison with the reference strains. These results suggest that Lactobacilli, particularly those from the human intestine, can affect the activation of mast cells in a strain-dependent manner. Further study should be conducted to analyse the understanding mechanism</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 2076-2607 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3390/microorganisms4040040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801804">PM:27801804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microorganisms\2016-4-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microorganisms\2016-4-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Harata G</style></custom2><misc3><style face="normal" font="Arial">10.3390/microorganisms4040040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mikals,K.</style></author><author><style face="normal" font="Arial"> Beakes,D.</style></author><author><style face="normal" font="Arial"> Banks,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda MD 20889</style></auth-address><titles><title><style face="normal" font="Arial">Stinging the Conscience: A Case of Severe Hymenoptera Anaphylaxis and the Need for Provider Awareness</style></title><secondary-title><style face="normal" font="Arial">Mil Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mil Med</style></full-title></periodical><pages end="e1403" start="e1400">e1400-e1403</pages><volume><style face="normal" font="Arial">181</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Reed</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Hymenoptera venom allergy accounts for approximately 17% of all cases of anaphylaxis. Insect stings are a common occurrence across the world, with significant impact on active duty personnel. Venom immunotherapy (VIT) provides an effective treatment for those with systemic reactions to insect stings and other similar indications. We present a case of severe reaction to hymenoptera venom requiring an epinephrine drip and provide an overview for primary care providers on who should be referred to allergy or an allergist, carry an epinephrine auto-injector, and be a candidate for VIT. As this case demonstrates, such a framework is critical as even patients with a history of severe reactions may have a delay in referral to specialty care. The preventable morbidity and mortality associated with hymenoptera venom allergy represents a clear imperative to identify those service members at risk for future systemic symptoms and to refer them for assessment and VIT therapy. Allergy evaluation and treatment with VIT affords the opportunity for service members to be retained in the military and remain medically fit and ready for deployment around the world</style></abstract><notes><style face="normal" font="Arial">DA - 20161018IS - 1930-613X (Electronic)IS - 0026-4075 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.7205/MILMED-D-15-00536</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27753590">PM:27753590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mil Med\2016-181-e1400-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mil Med\2016-181-e1400-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161018, Mikals K</style></custom2><misc3><style face="normal" font="Arial">10.7205/MILMED-D-15-00536</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dauner,J.G.</style></author><author><style face="normal" font="Arial"> Pan,Y.</style></author><author><style face="normal" font="Arial"> Hildesheim,A.</style></author><author><style face="normal" font="Arial"> Kemp,T.J.</style></author><author><style face="normal" font="Arial"> Porras,C.</style></author><author><style face="normal" font="Arial"> Pinto,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">HPV Immunology Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD 21702, USA</style></auth-address><titles><title><style face="normal" font="Arial">Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals</style></title><secondary-title><style face="normal" font="Arial">Mol Cell Probes</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Cell Probes</style></full-title></periodical><pages end="80" start="73">73-80</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--IgE Isoforme</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Viral</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody Affinity</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> avidity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Capsid</style></keyword><keyword><style face="normal" font="Arial"> Capsid Proteins</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials,Phase III as Topic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Double-Blind Method</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Guanidine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Oncogene Proteins,Viral</style></keyword><keyword><style face="normal" font="Arial"> Papillomavirus Infections</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> Vaccines,Virus-Like Particle</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus-like particle</style></keyword><keyword><style face="normal" font="Arial"> Virus-like particles</style></keyword><keyword><style face="normal" font="Arial"> viruslike particles</style></keyword><keyword><style face="normal" font="Arial"> VLPs</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2012">2012/4</year></dates><abstract><style face="normal" font="Arial">Antibody responses against infectious agents are an important component in the prevention of disease. The avidity of antibodies for their antigens relates to their functional efficiency, and is a fundamental aspect in the investigation of humoral responses. Modified ELISAs are used to estimate avidity through the use of chaotropic agents and the measurement of the degree to which they disrupt the interaction between antibody and antigen. The theory behind the assay is the higher the avidity of an interaction the less susceptible it is to the effects of the chaotropic agent. The goal of this study was to generate a modified ELISA where a complex, multimeric coating-antigen, human papillomavirus (HPV) virus-like particles (VLP), was used to measure the avidity of anti-HPV antibodies generated following vaccination with HPV VLPs. A series of chaotropic agents were evaluated in the assay for their effectiveness in measuring avidity. Guanidine hydrochloride (GuHCl) was selected as a chaotropic reagent with the ability to disrupt antibody and antigen interactions, while not affecting the integrity of the plate-bound VLP. Two methods of determining the avidity index were assessed and shown to be comparable. This assay was then successfully applied to measure the avidity of anti-HPV VLP serum antibodies in samples from an HPV L1 VLP vaccine clinical trial. Overall, the assay was highly reproducible and captured a wide range of antibody avidities. Therefore, a GuHCl-modified ELISA is an acceptable method that can be used to determine HPV-specific antibody avidity indices within a clinical trial setting</style></abstract><notes><style face="normal" font="Arial">DA - 20120402IS - 1096-1194 (Electronic)IS - 0890-8508 (Linking)LA - ENGPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralRN - 0 (Antibodies, Viral)RN - 0 (Capsid Proteins)RN - 0 (L1 protein, Human papillomavirus type 16)RN - 0 (Oncogene Proteins, Viral)RN - 0 (Vaccines, Virus-Like Particle)RN - JU58VJ6Y3B (Guanidine)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mcp.2012.01.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="22285687">PM:22285687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Cell Probes\2012-26-73-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Cell Probes\2012-26-73-80.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20120402, Dauner JG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mcp.2012.01.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rahmatpour,S.</style></author><author><style face="normal" font="Arial"> Khan,A.H.</style></author><author><style face="normal" font="Arial"> Kalmarzi,R.N.</style></author><author><style face="normal" font="Arial"> Rajabibazl,M.</style></author><author><style face="normal" font="Arial"> Tavoosidana,G.</style></author><author><style face="normal" font="Arial"> Motevaseli,E.</style></author><author><style face="normal" font="Arial"> Zarghami,N.</style></author><author><style face="normal" font="Arial"> Sadroddiny,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Application of immuno-PCR assay for the detection of serum IgE specific to Bermuda allergen</style></title><secondary-title><style face="normal" font="Arial">Mol Cell Probes</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Cell Probes</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bermuda</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immuno-PCR</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nucleotide sequence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="10" Year="2016">2016/10/5</year></dates><abstract><style face="normal" font="Arial">In vivo and in vitro tests are the two major ways of identifying the triggering allergens in sensitized individuals with allergic symptoms. Both methods are equally significant in terms of sensitivity and specificity. However, in certain circumstances, in vitro methods are highly preferred because they circumvent the use of sensitizing drugs in patients. In current study, we described a highly sensitive immuno-PCR (iPCR) assay for serum IgE specific to Bermuda allergens. Using oligonucleotide-labelled antibody, we used iPCR for the sensitive detection of serum IgE. The nucleotide sequence was amplified using conventional PCR and the bands were visualized on 2.5% agarose gel. Results demonstrated a 100-fold enhancement in sensitivity of iPCR over commercially available enzyme-linked immunosorbent assay (ELISA) kit. Our iPCR method was highly sensitive for Bermuda-specific serum IgE and could be beneficial in allergy clinics</style></abstract><notes><style face="normal" font="Arial">DA - 20161010IS - 1096-1194 (Electronic)IS - 0890-8508 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mcp.2016.10.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27720768">PM:27720768</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Cell Probes\20161010-RahmatpourS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Cell Probes\20161010-RahmatpourS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Rahmatpour S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mcp.2016.10.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Govindaraj,D.</style></author><author><style face="normal" font="Arial"> Sharma,S.</style></author><author><style face="normal" font="Arial"> Gaur,S.N.</style></author><author><style face="normal" font="Arial"> Lavasa,S.</style></author><author><style face="normal" font="Arial"> Prasad,N.</style></author><author><style face="normal" font="Arial"> Arora,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CSIR-Institute of Genomics and Integrative Biology, Delhi, India; Academy of Scientific &amp; Innovative Research (AcSIR), CSIR-IGIB, Mall road, Delhi, India</style></auth-address><titles><title><style face="normal" font="Arial">Immunogenic peptides: B &amp; T Cell Epitopes of Per a 10 Allergen of Periplaneta americana</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="32" start="24">24-32</pages><volume><style face="normal" font="Arial">80</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> chum salmon</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> lymphocyte proliferation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modelling</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Per a 10</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Salmon</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="10" Year="2016">2016/10/25</year></dates><abstract><style face="normal" font="Arial">Mapping of B and T cell epitopes of an allergen can be utilised in the development of alternative therapeutic modalities and diagnostics. The present study was aimed to identify B and T cell epitopes of Per a 10, a major cockroach allergen, by computational tools and subsequent validation by in vitro experiments. Per a 10 three-dimensional structure was homology modelled using structure of anionic trypsin from pacific chum salmon as a template. Seven B cell epitopes (B-P1 to B-P7) were predicted by sequence and structure based methods. Three T cell epitopes (T-P8 to T-P10) were predicted by binding score and inhibitory concentration dependent prediction tools. Predicted epitopes were synthesized and biological activity was assessed by ELISA, ELISA inhibition and PBMC proliferation assays. B cell peptides B-P5, B-P6 and B-P7 showed significantly high IgE binding with pooled and individual cockroach hypersensitive patients' sera while the T cell peptides did not show IgE binding. ELISA inhibition was performed to determine the potency of the predicted peptides. Fifty nanogram of peptide B-P7 was required for 50% IgE binding inhibition of surface bound Per a 10 whereas seventy five nanogram and ninety nanogram of B-P5 and B-P6 were required for the same respectively. Upon stimulation with T-P8 and T-P10 peptides, PBMCs from cockroach allergic patients' (n = 15) showed significant lymphocyte proliferation and induced IL-4 and IL-5 cytokine release in the culture supernatant demonstrating Th2 dominant cell mediated response of predicted T cell peptides. In conclusion, Per a 10 3-D structure obtained by homology modelling was used to identify B and T cell epitopes, followed by in vitro validation. The identified peptides can be potentially used in designing diagnostics and therapies for cockroach allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - ENGPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2016.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27792882">PM:27792882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2016-80-24-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2016-80-24-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Govindaraj D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2016.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ming,M.</style></author><author><style face="normal" font="Arial"> Luo,Z.</style></author><author><style face="normal" font="Arial"> Lv,S.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Inhalation of inactivatedMycobacterium phlei prevents asthmamediated airway hyperresponsiveness and airway eosinophilia in mice by reducing IL5 and IL13 levels</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="5349" start="5343">5343-5349</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="05/06/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Fractionation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Fractionation</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methacholine challenge</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Mycobacteria</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="10" Year="2016">2016/10/19</year></dates><abstract><style face="normal" font="Arial">The present study aimed to investigate whether inhalation of inactivatedMycobacterium phlei could prevent airway hyperresponsiveness and airway eosinophilia. A total of 24 male Balb/c mice were randomly divided into three groups: Normal control group (group A), asthma model group (group B) and the intervention group (group C), (8 mice/group). Group A mice were sensitized and with challenged saline and group B with ovalbumin (OVA). Group C mice were administered with aerosol Mycobacterium phlei once daily prior to the allergen challenge. Airway responsiveness in each group was assessed. All the animals were sacrificed and lung tissues, blood samples and bronchoalveolar lavage fluid (BALF) were harvested. Cell fractionation and differential cells were counted in serum and BALF. HE staining and alcian blue/periodic acid Schiff staining were used to measure airway eosinophilic inflammation and mucus production. The levels of the cytokines IL5, IL13 and IgE were measured in lung and BALF as determined by ELISA and reverse transcriptionquantitative polymerase chain reaction assays. The results indicated that inactivatedMycobacterium phlei suppressed the airway hyperresponsiveness and mitigated airway eosinophilia induced by a methacholine challenge, and significantly reduced the levels of cytokines IL5 and IL13 in lung tissue and IgE level in BALF when compared with the OVAsensitized mice. In conclusion, inhalation of inactivatedMycobacterium phlei could reduce OVAinduced airway hyperresponsiveness and may be a potential alternative therapy for allergic airway diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2016.5865</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779664">PM:27779664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2016-14-5343-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2016-14-5343-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Ming M</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2016.5865</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cui,Y.</style></author><author><style face="normal" font="Arial"> Yu,L.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Central Laboratory, The Third People's Hospital of Yancheng City, Affiliated Yancheng Hospital, School of Medicine, Southeast University, Yancheng, Jiangsu 224000, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Mimotope identification of dust mite allergen Der f 5 using phagedisplayed random peptide libraries</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="4822" start="4816">4816-4822</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> Der f 5</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mimotope</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide Library</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> Phage display peptide library</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Mimotope mapping enables the characterization of allergen epitopes for the development of diagnostic and therapeutic approaches. In the present study, a phage display peptide library was used for mimotope mapping based on the binding of antibodies against the recombinant group 5 allergen from the house dust mite Dermatophagoides farinae (Der f 5), an arthropod that causes indoor allergies worldwide. When three monoclonal antiDer f 5 antibodies were used for biopanning, seven mimotopes were identified. Their common subsequence was '[A][T]W[S]H[HSFW][LM][PSKR] [TLV][AST][DP][L]'. When analyzed in combination with predicted discontinous epitopes, amino acids P2, K3, K4, H5, F11, F13, L14, R72, T77, L79, R84, T39, F40, P44, T45 and K46 were identified as key residues in conformational epitopes of Der f 5. Therefore, the seven mimotopes or modification of the key amino acids may facilitate the development of blocking antibodies or epitopespecific immunotherapies for mite allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2016.5848</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27748932">PM:27748932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2016-14-4816-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2016-14-4816-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Cui Y</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2016.5848</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Holzhauser,T.</style></author><author><style face="normal" font="Arial"> Franke,A.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author><author><style face="normal" font="Arial"> Schmiedeknecht,A.</style></author><author><style face="normal" font="Arial"> Randow,S.</style></author><author><style face="normal" font="Arial"> Becker,W.M.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paul-Ehrlich-Institut, Division of Allergology, Langen, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">The BASALIT multicentre trial: Gly m 4 quantification for consistency control of challenge meal batches and towards Gly m 4 threshold data</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gly m 4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Shelf life</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy allergy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy protein isolate</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="10" Year="2016">2016/10/17</year></dates><abstract><style face="normal" font="Arial">SCOPE: The BASALIT clinical trial (EudraCT 2009-011737-27) investigated efficacy of birch allergen immunotherapy on lowest observed adverse effect levels (LOAEL) after soy food challenge in patients with birch-associated and Gly m 4 allergen-mediated soy allergy. Thus, consistently stable Gly m 4 levels were required in standardised challenge meals. METHODS AND RESULTS: Soy meal included soy protein isolate (SPI, 88% total protein). A Gly m 4-specific ELISA was developed and validated. 6 SPI and 24 meal batches were analysed for Gly m 4. (Repeated-measures) analyses of variance were done to identify potential changes between batches/ in time. Gly m 4 was below the ELISA detection limit (2 ng/ml) in placebo batches. With &lt; 20 % mean coefficient of variation, Gly m 4 levels were consistent in 24 soy meal batches and within individual 12 weeks shelf-life. CONCLUSION: The novel Gly m 4-specific ELISA proved consistency of challenge meal batches over a 56 months study period. With an average of 178 mug/g Gly m 4 in SPI, Gly m 4-LOAEL can be calculated once clinical LOAEL data based on SPI are available. Hence, sensitivity of patients can be correlated to the relevant allergen content instead of total protein of the allergenic source. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201600527</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27748994">PM:27748994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20161017-HolzhauserT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20161017-HolzhauserT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Holzhauser T</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201600527</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,F.</style></author><author><style face="normal" font="Arial"> Weng,Z.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Peng,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.</style></auth-address><titles><title><style face="normal" font="Arial">A Reliable Method for the Evaluation of the Anaphylactoid Reaction Caused by Injectable Drugs</style></title><secondary-title><style face="normal" font="Arial">Molecules</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Molecules</style></full-title></periodical><pages end="" start="1352">1352-</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptance</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reactions</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> C3a</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="Arial">Adverse reactions of injectable drugs usually occur at first administration and are closely associated with the dosage and speed of injection. This phenomenon is correlated with the anaphylactoid reaction. However, up to now, study methods based on antigen detection have still not gained wide acceptance and single physiological indicators cannot be utilized to differentiate anaphylactoid reactions from allergic reactions and inflammatory reactions. In this study, a reliable method for the evaluation of anaphylactoid reactions caused by injectable drugs was established by using multiple physiological indicators. We used compound 48/80, ovalbumin and endotoxin as the sensitization agents to induce anaphylactoid, allergic and inflammatory reactions. Different experimental animals (guinea pig and nude rat) and different modes of administration (intramuscular, intravenous and intraperitoneal injection) and different times (15 min, 30 min and 60 min) were evaluated to optimize the study protocol. The results showed that the optimal way to achieve sensitization involved treating guinea pigs with the different agents by intravenous injection for 30 min. Further, seven related humoral factors including 5-HT, SC5b-9, Bb, C4d, IL-6, C3a and histamine were detected by HPLC analysis and ELISA assay to determine their expression level. The results showed that five of them, including 5-HT, SC5b-9, Bb, C4d and IL-6, displayed significant differences between anaphylactoid, allergic and inflammatory reactions, which indicated that their combination could be used to distinguish these three reactions. Then different injectable drugs were used to verify this method and the results showed that the chosen indicators exhibited good correlation with the anaphylactoid reaction which indicated that the established method was both practical and reliable. Our research provides a feasible method for the diagnosis of the serious adverse reactions caused by injectable drugs which could be used in the clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20161018IS - 1420-3049 (Electronic)IS - 1420-3049 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.3390/molecules21101352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27754330">PM:27754330</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Molecules\2016-21-1352.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Molecules\2016-21-1352.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161018, Wang F</style></custom2><misc3><style face="normal" font="Arial">10.3390/molecules21101352</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sheih,A.</style></author><author><style face="normal" font="Arial"> Parks,W.C.</style></author><author><style face="normal" font="Arial"> Ziegler,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA</style></auth-address><titles><title><style face="normal" font="Arial">GM-CSF produced by the airway epithelium is required for sensitization to cockroach allergen</style></title><secondary-title><style face="normal" font="Arial">Mucosal Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mucosal Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophage Colony-Stimulating Factor</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="Arial">Airway epithelial cells are among the first to encounter inhaled allergens and can initiate allergic responses by producing pro-Th2 innate cytokines. In this study, we investigated the role of epithelial-derived cytokines in sensitization to a clinically relevant allergen, cockroach allergen (CRA). Among the epithelial-derived cytokines, granulocyte macrophage colony-stimulating factor (GM-CSF) had a central role in the initiation of Th2 allergic responses to CRA. We show that initial exposure to CRA directly activated airway epithelial cells through a TLR4-MyD88-dependent pathway and MyD88 signaling in epithelial cells induced upregulation of GM-CSF during sensitization. Epithelial-derived GM-CSF was required for allergic sensitization and selectively restored Th2 responses in the absence of MyD88. Thus, we demonstrate that epithelial-derived GM-CSF is a critical early signal during allergic sensitization to CRA.Mucosal Immunology advance online publication 12 October 2016. doi:10.1038/mi.2016.90</style></abstract><notes><style face="normal" font="Arial">DA - 20161012IS - 1935-3456 (Electronic)IS - 1933-0219 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1038/mi.2016.90</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27731325">PM:27731325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mucosal Immunol\20161012-SheihA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mucosal Immunol\20161012-SheihA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Sheih A</style></custom2><misc3><style face="normal" font="Arial">10.1038/mi.2016.90</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bernardi,D.S.</style></author><author><style face="normal" font="Arial"> Bitencourt,C.</style></author><author><style face="normal" font="Arial"> da Silveira,D.S.</style></author><author><style face="normal" font="Arial"> da Cruz,E.L.</style></author><author><style face="normal" font="Arial"> Pereira-da-Silva,M.A.</style></author><author><style face="normal" font="Arial"> Faccioli,L.H.</style></author><author><style face="normal" font="Arial"> Lopez,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Sao Paulo, School of Pharmaceutical Sciences of Ribeirao Preto, Ribeirao Preto, SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Effective transcutaneous immunization using a combination of iontophoresis and nanoparticles</style></title><secondary-title><style face="normal" font="Arial">Nanomedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nanomedicine</style></full-title></periodical><pages end="2448" start="2439">2439-2448</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Iontophoresis</style></keyword><keyword><style face="normal" font="Arial"> liposome</style></keyword><keyword><style face="normal" font="Arial"> Liposomes</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Penetration</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Silver nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Transcutaneous immunization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="16" Month="7" Year="2016">2016/7/16</year></dates><abstract><style face="normal" font="Arial">Needle-free immunization strategies have been sought for years. Transcutaneous immunization using electroporation has been studied, but the high electrical voltage that must be applied may be painful and cause irreversible cell damage. The application of a weak electric field, such as in iontophoresis, has never been attempted. The aim of this work was to verify the potential of employing iontophoresis for transcutaneous immunization using ovalbumin (OVA) as a model antigen. To target the antigen presenting cells that are located in the viable epidermis, a vaccine formulation composed of OVA-loaded liposomes and silver nanoparticles (NPAg) was developed. In vitro cathodal iontophoresis of the OVA-liposomes associated with NPAg increased OVA penetration into the viable epidermis by 92-fold in comparison to passive delivery. In vivo, transcutaneous immunization with a suitable combination of liposome and iontophoresis induced the production of antibodies, differentiation of immune-competent cells and appeared to present an alternative strategy for needle-free vaccination</style></abstract><notes><style face="normal" font="Arial">DA - 20160906IS - 1549-9642 (Electronic)IS - 1549-9634 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.nano.2016.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27431054">PM:27431054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nanomedicine\2016-12-2439-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nanomedicine\2016-12-2439-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160906, Bernardi DS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.nano.2016.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,W.</style></author><author><style face="normal" font="Arial"> Freeland,D.M.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sean N. Parker Center for Allergy and Asthma Research, Stanford University</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy: immune mechanisms, diagnosis and immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Nat Rev Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nat Rev Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Pressing</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="10" Year="2016">2016/10/31</year></dates><abstract><style face="normal" font="Arial">Food allergy is a pathological, potentially deadly, immune reaction triggered by normally innocuous food protein antigens. The prevalence of food allergies is rising and the standard of care is not optimal, consisting of food-allergen avoidance and treatment of allergen-induced systemic reactions with adrenaline. Thus, accurate diagnosis, prevention and treatment are pressing needs, research into which has been catalysed by technological advances that are enabling a mechanistic understanding of food allergy at the cellular and molecular levels. We discuss the diagnosis and treatment of IgE-mediated food allergy in the context of the immune mechanisms associated with healthy tolerance to common foods, the inflammatory response underlying most food allergies, and immunotherapy-induced desensitization. We highlight promising research advances, therapeutic innovations and the challenges that remain</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1474-1741 (Electronic)IS - 1474-1733 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/nri.2016.111</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795547">PM:27795547</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Rev Immunol\20161031-YuW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Rev Immunol\20161031-YuW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Yu W</style></custom2><misc3><style face="normal" font="Arial">10.1038/nri.2016.111</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kwon,J.Y.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author><author><style face="normal" font="Arial"> Joo,C.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Catholic Institute for Visual Science , Seoul St. Mary's Hospital , Seoul , Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model</style></title><secondary-title><style face="normal" font="Arial">Ocul Immunol Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ocul Immunol Inflamm</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Multicolor</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="11" Month="10" Year="2016">2016/10/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: To determine the immunologic functions of TRPA1 or TRPV1 in allergic conjunctivitis (AC). METHODS: Mice were sensitized with ovalbumin (OVA), after which TRPA1 antagonist or TRPV1 antagonist was administered before topical OVA challenge. Expression of TRPV1 or TRPA1 in AC was examined by western blotting and multicolor immunofluorescence. Clinical signs, OVA-specific IgE, infiltration of inflammatory cells into conjunctivae (CJs), and Th2 cytokine in draining lymph nodes (LNs) were evaluated by microscopy, flow cytometry, and ELISA. RESULTS: TRPV1 expression was increased in CJs and LNs from AC mice, but TRPA1 expression was only increased in LNs. TRPV1 antagonist but not TRPA1 antagonist attenuated the clinical signs of AC and OVA-specific IgE in sera. TRPV1 antagonist furthermore inhibited the infiltration of inflammatory cells into CJ and the production of Th2 cytokines in LNs. CONCLUSION: TRPV1 antagonist but not TRPA1 antagonist may ameliorate AC by suppressing the Th2 response in LNs</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1744-5078 (Electronic)IS - 0927-3948 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1080/09273948.2016.1231330</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27726468">PM:27726468</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ocul Immunol Inflamm\20161011-KwonJY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ocul Immunol Inflamm\20161011-KwonJY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Kwon JY</style></custom2><misc3><style face="normal" font="Arial">10.1080/09273948.2016.1231330</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Peng,S.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author><author><style face="normal" font="Arial"> Jiang,C.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Sun,Y.</style></author><author><style face="normal" font="Arial"> Guo,W.</style></author><author><style face="normal" font="Arial"> Xu,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China</style></auth-address><titles><title><style face="normal" font="Arial">Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF-kappaB signaling and NLRP3 inflammasome activation</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="10" Year="2016">2016/10/26</year></dates><abstract><style face="normal" font="Arial">In this study, we attempted to explore the effect and possible mechanism of Andrographolide on OVA-induced asthma. OVA challenge induced significant airway inflammatory cell recruitment and lung histological alterations, which were ameliorated by Andrographolide. The protein levels of cytokines in bron-choalveolar fluid (BALF) and serum were reduced by Andrographolide administration as well as the mRNA levels in lung tissue. Mechanically, Andrographolide markedly hampered the activation of nuclear factor-kappaB (NF-kappaB) and NLRP3 inflammasome both in vivo and vitro thus decreased levels of TNF-alpha and IL-1beta. Finally, we confirmed that ROS scavenging was responsible for Andrographolide's inactivation of NF-kappaB and NLRP3 inflammasome signaling. Our study here revealed the effect and possible mechanism of Andrographolide on asthma, which may represent a new therapeutic approach for treating this disease</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.12918</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27793052">PM:27793052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20161028-PengS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20161028-PengS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Peng S</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.12918</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yeh,K.W.</style></author><author><style face="normal" font="Arial"> Chiu,C.Y.</style></author><author><style face="normal" font="Arial"> Su,K.W.</style></author><author><style face="normal" font="Arial"> Tsai,M.H.</style></author><author><style face="normal" font="Arial"> Hua,M.C.</style></author><author><style face="normal" font="Arial"> Liao,S.L.</style></author><author><style face="normal" font="Arial"> Lai,S.H.</style></author><author><style face="normal" font="Arial"> Chen,L.C.</style></author><author><style face="normal" font="Arial"> Yao,T.C.</style></author><author><style face="normal" font="Arial"> Huang,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">High cord blood CCL22/CXCL10 chemokine ratios precede allergic sensitization in early childhood</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="11" Year="2016">2016/11/15</year></dates><abstract><style face="normal" font="Arial">Atopic diseases are known to be characterized by a T helper (Th) 2-skewed immunity; however, there are few studies addressing the Th1/Th2 immunity at birth related to the development of atopic diseases in early childhood. We investigated 186 children followed up regularly at the clinic for 4 years in a birth cohort study. The Th1-associated CXC chemokine ligand (CXCL)-10, CXCL11, and the Th2-associated CC chemokine ligand (CCL)-17 and CCL22 were quantified in cord blood by multiplex Luminex kits. Specific immunoglobulin E antibodies against food and inhalant allergens were measured at 6 months as well as 1, 1.5, 2, 3, and 4 years of age. Cord blood CCL22 levels were positively associated with IgE sensitization at age 2, whereas cord blood CXCL10 levels were negatively associated with mite sensitization at age 3. Furthermore, a high cord blood CCL22/CXCL10 chemokine ratio was significantly associated with a higher risk of allergic sensitization at age 3 (OR, 1.02; 95% confidence interval [CI], 1.005-1.039; P = 0.012). However, cord blood Th1- and Th2-associated chemokines and their ratios were not associated with atopic diseases at different age. Our study indicates that a Th2-skewed immunity at birth may increase risk of allergic sensitization but not of allergic outcomes later in life</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.13374</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27863395">PM:27863395</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20161118-YehKW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20161118-YehKW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Yeh KW</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.13374</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xiao,L.</style></author><author><style face="normal" font="Arial"> Yang,B.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Luo,Y.</style></author><author><style face="normal" font="Arial"> Ji,Q.</style></author><author><style face="normal" font="Arial"> Wen,Z.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Research Center of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen 518060, China</style></auth-address><titles><title><style face="normal" font="Arial">Kinetic changes of intestinal microbiota in the course of intestinal sensitization</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> Abundance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metagenome</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="10" Year="2016">2016/10/21</year></dates><abstract><style face="normal" font="Arial">Food allergy (FA) is an adverse immune response to certain innocent food. It is estimated about 2% to 6% of the general population suffer from FA. Symptoms of a food allergic reaction may involve the gastrointestinal tract or/and other organs. The gut microbiota plays a critical role in diet-induced health problems. Whether the changes in the composition of the intestinal microbiota regulate allergic responses to food remains poorly understood. Thus, we created an FA animal model, sequenced the V4-V5 regions of 16S rRNA genes to characterize the genera abundance of gut microbiota. The results showed that mice under FA condition showed different gut bacterial structures. Diverse distribution of the bacterial species was identified between FA and control groups. FA altered the components of intestinal Microbiota in mice. The dysbiosis of the gut metagenome correlated with the development of the FA</style></abstract><notes><style face="normal" font="Arial">DA - 20161026IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.12797</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27783988">PM:27783988</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191775-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191776-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191777-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191778-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191779-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191780-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191781-2-SP.xlsx</url></related-urls><image-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191775-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191776-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191777-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191778-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191779-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191780-2-SP.xlsxC:\A&amp;H HMW Papers\Oncotarget\20161026-XiaoL-191781-2-SP.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20161026, Xiao L</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.12797</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zech,A.</style></author><author><style face="normal" font="Arial"> Wiesler,B.</style></author><author><style face="normal" font="Arial"> Ayata,C.K.</style></author><author><style face="normal" font="Arial"> Schlaich,T.</style></author><author><style face="normal" font="Arial"> Durk,T.</style></author><author><style face="normal" font="Arial"> Hossfeld,M.</style></author><author><style face="normal" font="Arial"> Ehrat,N.</style></author><author><style face="normal" font="Arial"> Cicko,S.</style></author><author><style face="normal" font="Arial"> Idzko,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pneumology, University Medical Centre Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">P2rx4 deficiency in mice alleviates allergen-induced airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adenosine</style></keyword><keyword><style face="normal" font="Arial"> Adenosine Triphosphate</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Space</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="Arial"> Nucleotides</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> purinergic receptor</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="11" Year="2016">2016/11/15</year></dates><abstract><style face="normal" font="Arial">Compelling evidences point out a crucial role for extracellular nucleotides such as adenosine triphosphate (ATP) during inflammatory conditions. Once released into the extracellular space, ATP modulates migration, maturation and function of various inflammatory cells via activating of purinergic receptors of the P2Y- and P2X- family. P2RX4 is an ATP-guided ion channel expressed on structural cells such as alveolar epithelial and smooth muscle cells as well as inflammatory cells including macrophages, dendritic cells (DCs) and T cells. P2RX4 has been shown to interact with P2RX7 and promote NLRP3 inflammasome activation. Although P2RX7 has already been implicated in allergic asthma, the role of P2RX4 in airway inflammation has not been elucidated yet. Therefore, we used a selective pharmacological antagonist and genetic ablation to investigate the role of P2RX4 in an ovalbumin (OVA) driven model of allergen-induced airway inflammation (AAI). Both, P2RX4 antagonist 5-BDBD treatment and P2rx4 deficiency resulted in an alleviated broncho alveolar lavage fluid eosinophilia, peribronchial inflammation, Th2 cytokine production and bronchial hyperresponsiveness. Furthermore, P2rx4-deficient bone marrow derived DCs (BMDCs) showed a reduced IL-1ss production in response to ATP accompanied by a decreased P2rx7 expression and attenuated Th2 priming capacity compared to wild type (WT) BMDCs in vitro. Moreover, mice adoptively transferred with P2rx4-deficient BMDCs exhibit a diminished AAI in vivo. In conclusion our data suggests that P2RX4-signaling contributes to AAI pathogenesis by regulating DC mediated Th2 cell priming via modulating IL-1ss secretion and selective P2RX4-antagonists might be a new therapeutic option for allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.13375</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27863396">PM:27863396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20161118-ZechA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20161118-ZechA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Zech A</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.13375</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adachi,N.</style></author><author><style face="normal" font="Arial"> Takayama,E.</style></author><author><style face="normal" font="Arial"> Adachi,M.</style></author><author><style face="normal" font="Arial"> Mizuno-Kamiya,M.</style></author><author><style face="normal" font="Arial"> Kawaki,H.</style></author><author><style face="normal" font="Arial"> Takeuchi,H.</style></author><author><style face="normal" font="Arial"> Kubo,S.</style></author><author><style face="normal" font="Arial"> Ishigami,H.</style></author><author><style face="normal" font="Arial"> Kurachi,M.</style></author><author><style face="normal" font="Arial"> Kondoh,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Oral Biochemistry, Asahi University School of Dentistry, 1851 Hozumi, Mizuho, Gifu, 501-0296, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Promotion of Nickel (Ni) Allergy by Anamnestic Sensitization with a Bacterial Component, Lipopolysaccharide (LPS), in Mice</style></title><secondary-title><style face="normal" font="Arial">Open Dent J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Open Dent J</style></abbr-1></periodical><pages end="537" start="531">531-537</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> CpG DNA</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lipopolysaccharides</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nickel</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/OBJECTIVE: Lipopolysaccharides (LPS) promote allergic responses to nickel (Ni) both in the sensitization and elicitation steps. In this study, we examine the effect of pre-sensitization to LPS on the occurrence of Ni allergy using a mouse model. METHOD: A 100 mg of LPS was injected into C57BL/6J mice intraperitoneally (ip). Three weeks later, the mice were subsequently injected with 0.3 mu moles of nickel dichloride (NiCl2) and 100 mug of CpG-DNA, which acted as an adjuvant. The mice were repeatedly immunized with the 0.3 mug of nickel sulfate (NiSO4), along with 300 mul of the adjuvant, Inject Alum (Pierce, USA). Then we examined the producing capabilities of T helper type 1 (Th1) and 2 (Th2) cytokines (interferon-gamma- (IFN)-gamma and interleukin (IL)-10, respectively) from anti CD3 antibody-stimulated spleen cells. RESULTS: Pre-treatment with LPS, followed by repeated challenges with Ni2+ and adjuvants significantly enhanced the IFN-gamma-producing capability of spleen cells (n=5, p&lt;0.01); however, that could not enhance the capability of spleen cells by a single challenge with Ni2+ and adjuvants (n=5). In contrast, without LPS treatment, single or even repeated challenges by Ni2+ could not enhance the IFN-gamma-producing capability. On the other hand, the IL-10-producing capability of spleen cells was not enhanced even by LPS and repeated challenges with Ni2+ and adjuvants. CONCLUSION: The solitary pre-sensitization to LPS is essential for the onset of Ni allergy by shifting the Th1/Th2 immune balance toward a Th1 dominant</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1874-2106 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2174/1874210601610010531</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27843506">PM:27843506</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Open Dent J\2016-10-531-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Open Dent J\2016-10-531-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Adachi N</style></custom2><misc3><style face="normal" font="Arial">10.2174/1874210601610010531</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mosayebi,M.</style></author><author><style face="normal" font="Arial"> Moini,L.</style></author><author><style face="normal" font="Arial"> Hajihossein,R.</style></author><author><style face="normal" font="Arial"> Didehdar,M.</style></author><author><style face="normal" font="Arial"> Eslamirad,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology and Mycology, Medicine Faculty, Arak University of Medical Sciences, Arak, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Detection of Specific Antibody Reactivity to Toxocara Larval Excretory-secretory Antigens in Asthmatic Patients (5-15 Years)</style></title><secondary-title><style face="normal" font="Arial">Open Microbiol J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Open Microbiol J</style></abbr-1></periodical><pages end="167" start="162">162-167</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Toxocara</style></keyword><keyword><style face="normal" font="Arial"> Toxocara canis</style></keyword><keyword><style face="normal" font="Arial"> Toxocariasis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND &amp; PURPOSE: Humans act as an intermediate host for Toxocara canis and Toxocara cati. Toxocara may be an important risk factor for asthma in humans. The aim of the present study was to evaluate immunoglobulin G (IgG) anti-Toxocara canis antibody, using enzyme-linked immunosorbent assay (ELISA) in asthmatic patients (aged 5-15 years), referring to a clinic of pulmonary diseases in Arak, Iran. MATERIALS &amp; METHODS: In this bi-group cross sectional study, serum samples were collected from 110 children with confirmed asthma and 70 children without asthma within one year. IgG anti-Toxocara antibody was detected viaELISA method. The collected data were analyzed, using SPSS. RESULTS: The seroprevalence of antibodies against Toxocara species was estimated at 1.8% (two males) in asmathic children viaELISA method; however, no antibodies against Toxocara canis were detected in the control group. There was no significant correlation between the frequency of antibodies against Toxocara and variables such as age, gender, or place of residence (P>0.05). Moreover, the frequency of antibodies against Toxocara was not significantly correlated with contact with dogs, consumption of unwashed fruits and vegetables, or use of raw/undercooked sheep liver (P>0.05). CONCLUSION: The present study showed anti-Toxocara antibody in 1.8% of asthmatic children and determined the seroprevalence of toxocariasis in asthmatic children and adolescents in Arak, Iran. Based on the findings, the low rate of infection with Toxocara among asthmatic children may be attributed to acceptable personal hygiene and religious considerations</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1874-2858 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.2174/1874285801610010162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27857820">PM:27857820</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Open Microbiol J\2016-10-162-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Open Microbiol J\2016-10-162-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Mosayebi M</style></custom2><misc3><style face="normal" font="Arial">10.2174/1874285801610010162</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sipka,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">III. Belgyogyaszati Klinika, Klinikai Immunologiai Tanszek, Debreceni Egyetem, Altalanos Orvostudomanyi Kar Debrecen, Moricz Zs. ut 22., 4032</style></auth-address><titles><title><style face="normal" font="Arial">Precision and personalized medicine</style></title><secondary-title><style face="normal" font="Arial">Orv Hetil</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Orv Hetil</style></full-title></periodical><pages end="1741" start="1739">1739-1741</pages><volume><style face="normal" font="Arial">157</style></volume><number><style face="normal" font="Arial">44</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">The author describes the concept of "personalized medicine" and the newly introduced "precision medicine". "Precision medicine" applies the terms of "phenotype", "endotype" and "biomarker" in order to characterize more precisely the various diseases. Using "biomarkers" the homogeneous type of a disease (a "phenotype") can be divided into subgroups called "endotypes" requiring different forms of treatment and financing. The good results of "precision medicine" have become especially apparent in relation with allergic and autoimmune diseases. The application of this new way of thinking is going to be necessary in Hungary, too, in the near future for participants, controllers and financing boards of healthcare. Orv. Hetil., 2016, 157(44), 1739-1741</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 0030-6002 (Print)IS - 0030-6002 (Linking)LA - HUNPT - Journal ArticlePT - English AbstractCO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1556/650.2016.30564</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27796126">PM:27796126</url></web-urls><pdf-urls><url ppv-ref="no">sipka@iiibel.dote.hu</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161031, Sipka S</style></custom2><misc3><style face="normal" font="Arial">10.1556/650.2016.30564</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anagnostou,K.</style></author><author><style face="normal" font="Arial"> Swan,K.E.</style></author><author><style face="normal" font="Arial"> Brough,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The use of antihistamines in children</style></title><secondary-title><style face="normal" font="Arial">Paediatr Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Paediatr Child Health</style></full-title></periodical><pages end="313" start="310">310-313</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><isbn><style face="normal" font="Arial">1751-7222</style></isbn><abstract><style face="normal" font="Arial">Antihistamines are commonly used in paediatric medicine mainly for the treatment of allergic conditions. First generation antihistamines have been in use for many years, despite limited research studies supporting their use. Second generation antihistamines have been investigated for both efficacy and safety in paediatrics. An optimal understanding of their effects and pharmacology are required for optimal use in each patient. In this review we discuss the indications for use, as well as efficacy and safety of both old and newer antihistamines for the paediatric population</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.paed.2016.02.006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.paed.2016.02.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Paediatr Child Health\2016-26-310-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Paediatr Child Health\2016-26-310-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Anagnostou K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.paed.2016.02.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Manuyakorn,W.</style></author><author><style face="normal" font="Arial"> Benjaponpitak,S.</style></author><author><style face="normal" font="Arial"> Siripool,K.</style></author><author><style face="normal" font="Arial"> Prempunpong,C.</style></author><author><style face="normal" font="Arial"> Singvijarn,P.</style></author><author><style face="normal" font="Arial"> Kamchaisatian,W.</style></author><author><style face="normal" font="Arial"> Supapannachart,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology</style></auth-address><titles><title><style face="normal" font="Arial">Cow milk protein allergy presenting as feeding intolerance and eosinophilia: case reports of three preterm neonates</style></title><secondary-title><style face="normal" font="Arial">Paediatr Int Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Paediatr Int Child Health</style></full-title></periodical><pages end="341" start="337">337-341</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cattle</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant,Newborn</style></keyword><keyword><style face="normal" font="Arial"> Infant,Premature</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Sepsis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">Three preterm infants with cow milk protein allergy (CMPA) presented with feeding intolerance, sepsis-like episodes and persistent moderate-to-severe eosinophilia. After eliminating cow milk, the clinical symptoms improved significantly. CMPA can cause common manifestations in sick preterm infants such as feeding intolerance and eosinophilia</style></abstract><notes><style face="normal" font="Arial">DA - 20160108IS - 2046-9055 (Electronic)IS - 2046-9047 (Linking)LA - ENGPT - Case ReportsPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Milk Proteins)SB - IMCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1080/20469047.2015.1109229</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26744160">PM:26744160</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Paediatr Int Child Health\2015-35-337-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Paediatr Int Child Health\2015-35-337-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160108, Manuyakorn W</style></custom2><misc3><style face="normal" font="Arial">10.1080/20469047.2015.1109229</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,M.L.</style></author><author><style face="normal" font="Arial"> Xu,J.</style></author><author><style face="normal" font="Arial"> He,R.</style></author><author><style face="normal" font="Arial"> Shen,N.X.</style></author><author><style face="normal" font="Arial"> Gu,X.B.</style></author><author><style face="normal" font="Arial"> Peng,X.R.</style></author><author><style face="normal" font="Arial"> Yang,G.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China</style></auth-address><titles><title><style face="normal" font="Arial">Preliminary analysis of Psoroptes ovis transcriptome in different developmental stages</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="570">570-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen database</style></keyword><keyword><style face="normal" font="Arial"> Allergen genes</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Infections</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Buffaloes</style></keyword><keyword><style face="normal" font="Arial"> Camels</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Deer</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Differentially expressed gene</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> domestic animals</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Foxes</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mink</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Nymph</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Ticks</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="11" Year="2016">2016/11/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Psoroptic mange is a chronic, refractory, contagious and infectious disease mainly caused by the mange mite Psoroptes ovis, which can infect horses, sheep, buffaloes, rabbits, other domestic animals, deer, wild camels, foxes, minks, lemurs, alpacas, elks and other wild animals. Features of the disease include intense pruritus and dermatitis, depilation and hyperkeratosis, which ultimately result in emaciation or death caused by secondary bacterial infections. The infestation is usually transmitted by close contact between animals. Psoroptic mange is widespread in the world. In this paper, the transcriptome of P. ovis is described following sequencing and analysis of transcripts from samples of larvae (i.e. the Pso_L group) and nymphs and adults (i.e. the Pso_N_A group). The study describes differentially expressed genes (DEGs) and genes encoding allergens, which help understanding the biology of P. ovis and lay foundations for the development of vaccine antigens and drug target screening. METHODS: The transcriptome of P. ovis was assembled and analyzed using bioinformatic tools. The unigenes of P. ovis from each developmental stage and the unigenes differentially between developmental stages were compared with allergen protein sequences contained in the allergen database website to predict potential allergens. RESULTS: We identified 38,836 unigenes, whose mean length was 825 bp. On the basis of sequence similarity with seven databases, a total of 17,366 unigenes were annotated. A total of 1,316 DEGs were identified, including 496 upregulated and 820 downregulated in the Pso_L group compared with the Pso_N_A group. We predicted 205 allergens genes in the two developmental stages similar to genes from other mites and ticks, of these, 14 were among the upregulated DEGs and 26 among the downregulated DEGs. CONCLUSION: This study provides a reference transcriptome of P. ovis in absence of a reference genome. The analysis of DEGs and putative allergen genes may lay the foundation for studies of functional genomics, immunity and gene expression profiles of this parasitic mite species</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-016-1856-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27809902">PM:27809902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2016-9-570.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2016-9-570.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, He ML</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-016-1856-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wright,H.W.</style></author><author><style face="normal" font="Arial"> Bartley,K.</style></author><author><style face="normal" font="Arial"> Huntley,J.F.</style></author><author><style face="normal" font="Arial"> Nisbet,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Moredun Research Institute, Pentlands Science Park, Bush Loan, Edinburgh, Midlothian, EH26 0PZ, Scotland, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Characterisation of tropomyosin and paramyosin as vaccine candidate molecules for the poultry red mite, Dermanyssus gallinae</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="544">544-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acaricide</style></keyword><keyword><style face="normal" font="Arial"> acaricides</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermanyssus gallinae</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Paramyosin</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Scotland</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tissue Distribution</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dermanyssus gallinae is the most economically important haematophagous ectoparasite in commercial egg laying flocks worldwide. It infests the hens during the night where it causes irritation leading to restlessness, pecking and in extreme cases anaemia and increased cannibalism. Due to an increase in the occurrence of acaricide-resistant D. gallinae populations, new control strategies are required and vaccination may offer a sustainable alternative to acaricides. In this study, recombinant forms of D. gallinae tropomyosin (Der g 10) and paramyosin (Der g 11) were produced, characterised and tested as vaccine candidate molecules. METHODS: The D. gallinae paramyosin (Der g 11) coding sequence was characterised and recombinant versions of Der g 11 and D. gallinae tropomyosin (Der g 10) were produced. Hens were immunised with the recombinant proteins and the resulting antibodies were fed to D. gallinae and mite mortality evaluated. Sections of mites were probed with anti- Der g 11 and Der g 10 antibodies to identify the tissue distribution of these protein in D. gallinae. RESULTS: The entire coding sequence of Der g 11 was 2,622 bp encoding 874 amino acid residues. Immunohistochemical staining of mite sections revealed that Der g 10 and Der g 11 were located throughout D. gallinae tissues. In phylogenetic analyses of these proteins both clustered with orthologues from tick species rather than with orthologues from astigmatid mites. Antibodies raised in hens against recombinant forms of these proteins significantly increased D. gallinae mortality, by 19 % for Der g 10 (P &lt; 0.001) and by 23 % for Der g 11 (P = 0.009) when fed to the mites using an in vitro feeding device. CONCLUSIONS: This study has shown that Der g 10 and Der g 11 were located ubiquitously throughout D. gallinae and that antibodies raised against recombinant versions of these proteins can be used to significantly increase D. gallinae mortality in an in vitro feeding assay. When comparing archived data for all recombinant and native proteins assessed as vaccines using this in vitro feeding assay, Der g 10 and Der g 11 ranked highly and performed better than some of the pools of native proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20161013IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial"> 10.1186/s13071-016-1831-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27733192">PM:27733192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2016-9-544.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2016-9-544.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Wright HW</style></custom2><misc3><style face="normal" font="Arial"> 10.1186/s13071-016-1831-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Higashiarakawa,M.</style></author><author><style face="normal" font="Arial"> Hirata,T.</style></author><author><style face="normal" font="Arial"> Tanaka,T.</style></author><author><style face="normal" font="Arial"> Parrott,G.</style></author><author><style face="normal" font="Arial"> Kinjo,T.</style></author><author><style face="normal" font="Arial"> Naka,H.</style></author><author><style face="normal" font="Arial"> Hokama,A.</style></author><author><style face="normal" font="Arial"> Fujita,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious, Respiratory, and Digestive Medicine, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Normal serum IgE levels and eosinophil counts exhibited during Strongyloides stercoralis infection</style></title><secondary-title><style face="normal" font="Arial">Parasitol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Int</style></full-title></periodical><pages end="812" start="807">807-812</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> co-infection</style></keyword><keyword><style face="normal" font="Arial"> Coinfection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Ivermectin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides stercoralis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="Arial">Infections with parasites, such as Strongyloides stercoralis, typically cause elevated levels of serum immunoglobulin E (IgE) and eosinophils; however, co-infection with human T cell lymphotropic virus type 1 (HTLV-1) can cause lower levels of serum IgE during S. stercoralis infection. We conducted this study to determine whether serum IgE levels and eosinophil counts could also be related to other patient characteristics or symptoms. Between 1991 and 2014, we measured and compared the symptoms of 237 patients and evaluated serum IgE levels and eosinophil counts of 199 patients who were infected with S. stercoralis at the Ryukyu University Hospital and the Nishizaki Hospital. Medical records were reviewed and blood samples were taken before treatment with the anthelminthic, ivermectin, 2weeks following the first dosage, and 2weeks following the second dosage. Commonly reported symptoms included abdominal pain, diarrhea, and general fatigue. Serum IgE levels were found to be normal in patients co-infected with HTLV-1. Additionally, females and patients younger than 70years old exhibited normal serum IgE levels when infected with S. stercoralis. No factor included in our analysis was found to affect eosinophil counts. Serum IgE levels can remain within the normal range for some patients infected with S. stercoralis. Therefore, physicians should not eliminate S. stercoralis infection from the differential diagnosis solely according to findings of normal or low IgE levels</style></abstract><notes><style face="normal" font="Arial">DA - 20161016IS - 1873-0329 (Electronic)IS - 1383-5769 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.parint.2016.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27744050">PM:27744050</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Int\2016-66-807-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Int\2016-66-807-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161016, Higashiarakawa M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.parint.2016.10.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marino-Sanchez,F.S.</style></author><author><style face="normal" font="Arial"> Valls-Mateus,M.</style></author><author><style face="normal" font="Arial"> Ruiz-Echevarria,K.</style></author><author><style face="normal" font="Arial"> Alobid,I.</style></author><author><style face="normal" font="Arial"> Cardenas-Escalante,P.</style></author><author><style face="normal" font="Arial"> Jimenez-Feijoo,R.</style></author><author><style face="normal" font="Arial"> Lozano-Blasco,J.</style></author><author><style face="normal" font="Arial"> Giner-Munoz,M.T.</style></author><author><style face="normal" font="Arial"> Rodriguez-Jorge,J.</style></author><author><style face="normal" font="Arial"> Haag,O.</style></author><author><style face="normal" font="Arial"> Plaza-Martin,A.M.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unidad de Rinologia Pediatrica, Servicio de Otorrinolaringologia. Hospital Sant Joan de Deu, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Nasal Obstructive Disorders induce medical treatment failure in Pediatric Persistent Allergic Rhinitis (The NODPAR Study)</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="184" start="176">176-184</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> inferior turbinate</style></keyword><keyword><style face="normal" font="Arial"> International consensus</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Failure</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) is the most common chronic disease among children. To characterize the disease, a modified classification of severity (m-ARIA) has recently been validated in AR children. When medical treatment fails, surgery for nasal obstructive disorders (NOD) may be a therapeutic option. Our objective was to assess the prevalence of NOD and their influence in medical treatment response among children with persistent AR (PER). METHODS: In a prospective, real-life study, 130 pediatric PER patients (13.1+/-2.8 years, females 31.5%, severe rhinitis 49%) referred from Allergy to ENT department were assessed for their response (R, responders; NR, non-responders) to medical treatment (intranasal steroids and antihistamines or antileucotriens) by direct questioning and nasal symptoms VAS, the presence of NOD (septal deformity, turbinate enlargement and adenoidal hyperplasia), comorbidities, nasal symptoms, rhinitis severity (modified-ARIA criterion) and asthma control (International Consensus On Pediatric Asthma criterion). RESULTS: After two months of treatment, the NR group presented a higher prevalence of obstructive septal deformity and severe inferior turbinate enlargement when compared with the R group. Higher septal deformity and turbinate enlargement scores were strongly associated with treatment refractoriness. The prevalence of severe PER was also higher for the NR group. Higher asthma control scores were associated with the probability of treatment-induced improvement. CONCLUSIONS: In pediatric PER patients, medical therapy refractoriness was associated with NOD, mainly septal deformity and turbinate enlargement. In those patients, ENT examination will facilitate an early NOD diagnosis in order to indicate potential corrective surgery. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12679</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801958">PM:27801958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161101-MarinoSanchezFS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161101-MarinoSanchezFS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Marino-Sanchez FS</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12679</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Haktanir,A..</style></author><author><style face="normal" font="Arial"> Dereci,S.</style></author><author><style face="normal" font="Arial"> Hacisalihoglu,S.</style></author><author><style face="normal" font="Arial"> Orhan,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Karadeniz Technical University, School of Medicine, Department of Pediatric Allergy and Immunology, Trabzon, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Is Kiwifruit Allergy a Matter in Kiwifruit-Cultivating Regions? A Population-based Study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="43" start="38">38-43</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Banana</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Hazel</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Kiwi</style></keyword><keyword><style face="normal" font="Arial"> kiwifruit</style></keyword><keyword><style face="normal" font="Arial"> kiwifruit allergy</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Self-administered questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although kiwifruit is known as a common cause of food allergy, population based studies concerning the prevalence of kiwifruit allergy does not exist. We aimed to determine the prevalence and clinical characteristics of IgE-mediated kiwifruit allergy in 6-18 year old urban schoolchildren in a region where kiwifruit is widely cultivated METHODS: This cross-sectional study recruited 20,800 of the randomly selected 6-18-year-old urban schoolchildren from the Rize city in the eastern Black Sea region of Turkey during 2013. Following a self-administered questionnaire completed by the parents and the child, consenting children were invited for skin prick tests (SPTs) and oral food challenges (OFCs). Children with suspected IgE-mediated kiwifruit were skin prick tested with kiwifruit (commercial allergen and prick-to-prick test with fresh kiwifruit) and a predefined panel of allergens (banana, avocado, latex, sesame seed, birch, timothy, hazel, cat, Dermatophagoides pteronyssinus and Dermatophagoides farinae). All children with a positive SPT to kiwifruit were invited for an open OFC. The prevalence of IgE-mediated kiwifruit allergy was established using open OFCs. RESULTS: The response rate to the questionnaire was 75.9% (15783/20800). The estimated prevalence of parental-perceived IgE-mediated kiwifruit allergy was 0.5% (72/15783) (95% CI, 0.39-0.61%). Of the 72 children, 52 (72.2%) were skin tested, and 17 (32.7%) were found to be positive to kiwifruit with both commercial extract and kiwifruit. The most frequently reported symptoms in kiwi SPT-positive children were cutaneous (n = 10, 58.8%) followed by gastrointestinal (n = 6, 35.3%) and bronchial (n = 4, 23.5%). Oral symptoms were reported in six (35.3%) children. All children with kiwifruit positive SPTs were found positive during the oral challenge. The confirmed prevalence of IgE-mediated kiwifruit allergy by means of open OFC in 6-18-year-old urban schoolchildren living in Rize city was 0.10% (95% CI: 0.06-0.16). CONCLUSION: Prevalence of parental-perceived and clinically confirmed kiwifruit allergy is not consistent. In contrast to expectations, kiwifruit allergy prevalence was low in a city where it is cultivated and highly consumed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161012IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12666</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27732749">PM:27732749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161012-HaktanirA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161012-HaktanirA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Haktanir A</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12666</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mueller-Rompa,S.</style></author><author><style face="normal" font="Arial"> Janke,T.</style></author><author><style face="normal" font="Arial"> Schwaiger,K.</style></author><author><style face="normal" font="Arial"> Mayer,M.</style></author><author><style face="normal" font="Arial"> Bauer,J.</style></author><author><style face="normal" font="Arial"> Genuneit,J.</style></author><author><style face="normal" font="Arial"> Braun-Fahrlaender,C.</style></author><author><style face="normal" font="Arial"> Horak,E.</style></author><author><style face="normal" font="Arial"> Boznanski,A.</style></author><author><style face="normal" font="Arial"> von Mutius,E.</style></author><author><style face="normal" font="Arial"> Ege,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dr von Hauner Children's Hospital, Ludwig Maximilian University Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Identification of fungal candidates for asthma protection in a large population based study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="78" start="72">72-78</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bioactive compounds</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Effect size</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Epicoccum</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mattress dust</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Penicillium chrysogenum</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exposure to moulds has been related to asthma risk both positively and negatively, depending on the environmental setting. The pertinent results are based on generic markers or culturing methods though the majority of present fungi cannot be cultured under laboratory conditions. The aim of the present analysis was to assess environmental dust samples for asthma-protective fungal candidates with a comprehensive molecular technique covering also non-cultivable and non-viable fungi. METHODS: Mattress dust samples of 844 children from the GABRIELA study were analysed by polymerase chain reaction - single strand conformation polymorphism (PCR-SSCP) of the fungus-specific internal transcribed spacer (ITS) region. Known asthma candidate species were tested for their associations with asthma, and further gel positions were sought to explain the above. As a second, data-driven, analysis we tested the association of each individual gel position with asthma. RESULTS: In the hypothesis-driven approach Penicillium chrysogenum emerged with an odds ratio of 0.80 (95%-confidence interval 0.66-0.96; p=0.020). The effect size was changed by 39% towards the null when adjusting for the two bands 683 (DNA of Metschnikowia sp., Aureobasidium spp.) and 978 (DNA of Epicoccum spp., Galactomyces spp., uncultured Penicillium). The data-driven approach yielded an additional band (containing DNA of Pseudotaeniolina globosa) with reduced risk of asthma (OR=0.80 [0.66-0.96], p=0.012). CONCLUSIONS: A large population based study revealed several fungal taxa with inverse associations with childhood asthma. Moulds produce a variety of bioactive compounds with detrimental but also beneficial immuno-regulatory capacities, which renders them promising targets for further asthma research. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161006IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -CO - Switzerland -CO - Austria -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12665</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27711990">PM:27711990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161006-MuellerRompaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161006-MuellerRompaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161006, Mueller-Rompa S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12665</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Braig,S.</style></author><author><style face="normal" font="Arial"> Weiss,J.M.</style></author><author><style face="normal" font="Arial"> Stalder,T.</style></author><author><style face="normal" font="Arial"> Kirschbaum,C.</style></author><author><style face="normal" font="Arial"> Rothenbacher,D.</style></author><author><style face="normal" font="Arial"> Genuneit,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Maternal prenatal stress and child atopic dermatitis up to age 2 years: the Ulm SPATZ Health Study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="151" start="144">144-151</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> alternative methods</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biometry</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Evidence linking maternal psychosocial stress during pregnancy to subsequent child atopic dermatitis (AD) is growing but the definition of AD is diverse and results are inconsistent. We aimed to analyze the relationship between stress and AD using alternative methods of measurement of stress and AD. METHODS: In the Ulm SPATZ Health Study, chronic stress and symptoms of anxiety and depression were assessed by standardized self-reported questionnaires in 934 mothers of singletons following delivery in Ulm, Germany, from 04/2012-05/2013. Maternal hair cortisol concentrations (HCC, n=626) at childbirth and the cumulative incidences of parent-reported child AD symptoms, parent-, and pediatrician-reported AD diagnoses were assessed until age 2 years (n=787). Overall, 205 dermatological examinations were performed in 167 children showing AD symptoms. Crude and adjusted risk ratios (RR, aRR) with 95% confidence intervals were estimated. RESULTS: Maternal stress and anxiety were associated with child AD symptoms by trend (RR and aRR: 1.5 (1.0,2.3) for the highest vs. the lowest quarter of chronic stress; aRR: 1.4 (1.0,2.0) for possible anxiety symptoms vs. no symptoms). No relationship was found between stress or related constructs and AD diagnoses nor could we show consistent associations between maternal HCC and child AD. However, a higher RR of child AD was evident in families not yet affected by AD in siblings given maternal depressive symptoms, examined in the crude model. CONCLUSIONS: Stress measurements or related constructs are linked to AD symptoms, but association with AD diagnoses is limited. The reason for this divergence still needs further research. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12680</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801949">PM:27801949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161101-BraigS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161101-BraigS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Braig S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12680</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Brown,K.R.</style></author><author><style face="normal" font="Arial"> Maslin,K.</style></author><author><style face="normal" font="Arial"> Palmer,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA</style></auth-address><titles><title><style face="normal" font="Arial">Maternal dietary intake in pregnancy and lactation and allergic disease outcomes in offspring</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="143" start="135">135-143</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">As the prevalence of allergic disease dramatically rises worldwide, prevention strategies are increasingly being considered. Given the potential modulatory effect of nutritional factors on disease, altering maternal diet during pregnancy and/or lactation has been considered in preventing allergic disease in offspring. Though there are a number of observational studies that have examined possible associations between maternal diet and allergic outcomes in offspring, interventional trials are limited. Furthermore, there is a paucity of studies that have prospectively studied maternal dietary intake as well as measuring maternal and infant biological samples (blood, urine, breast milk) and their relation to allergic outcomes in infants. There is also a particular need to define terminology such as "fruit and vegetables intake", "healthy diet" and "diet diversity" in order to make studies comparable. In this review, we discuss current evidence of maternal dietary factors during pregnancy and/or lactation that may play a role in the offspring developing allergic disease, including factors such as overall dietary intake patterns, specific whole food consumption (fish, fruit and vegetables, and common allergic foods), and individual immunomodulatory nutrient intakes. Additionally, we discuss the limitations of previous studies and propose improvements to study design for future investigation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12682</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864894">PM:27864894</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161119-VenterC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161119-VenterC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12682</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'Amelio,C.</style></author><author><style face="normal" font="Arial"> Gastaminza,G.</style></author><author><style face="normal" font="Arial"> Vega,O.</style></author><author><style face="normal" font="Arial"> Bernad,A.</style></author><author><style face="normal" font="Arial"> Madamba,R.</style></author><author><style face="normal" font="Arial"> Martinez-Aranguren,R.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author><author><style face="normal" font="Arial"> Goikoetxea,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology and Clinical Immunology, Clinica Universidad de Navarra. Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Induction of tolerance to different types of fish through desensitization with hake</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="99" start="96">96-99</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental ingestion</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hake</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Induction of tolerance</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Food</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Steam</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergy is a health concern causing an important impact in patient's quality of life (1) and on that of their families, due to the continuous monitoring required in order to avoid the allergen and the risk of potentially fatal reactions resulting from the accidental ingestion of the allergenic food. Fish is one of the main causes of food allergies in children (2), and, unlike other infant food allergies such as allergies to cow milk or eggs, fish allergy tends to persist over time (3). Even the inhalation of steam generated while cooking the allergenic food can also trigger allergic reactions, hence affecting the quality of life of these patients (4). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20160927IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - LETTERCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12662</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27671208">PM:27671208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160927-DAmelioC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20160927-DAmelioC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160927, D'Amelio C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12662</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Niggemann,B.</style></author><author><style face="normal" font="Arial"> Yurek,S.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Pediatric Pneumology and Immunology, University Children's Hospital Charite, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Severe anaphylaxis requiring intensive care during oral food challenge - it is not always peanuts</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="203" start="201">201-203</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The gold standard in the diagnostics of food allergy is oral food challenges (OFCs) - best performed in a double-blind, placebo-controlled manner (DBPCFC) [1]. Great efforts have been made to standardize oral food challenges [2]. As recommended, in our clinic oral food challenges are performed with semi-log dose increments every 30 minutes [3]. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12676</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779804">PM:27779804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161025-NiggemannB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161025-NiggemannB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Niggemann B</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12676</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barasche,J.</style></author><author><style face="normal" font="Arial"> Stollar,F.</style></author><author><style face="normal" font="Arial"> Bergmann,M.M.</style></author><author><style face="normal" font="Arial"> Caubet,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the *Department of Child and Adolescent, University Hospitals of Geneva and Medical School of The University of Geneva, Geneva, Switzerland; and daggerCentro Pediatrico del Mendrisiotto, Mendrisio, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Severely Altered-Consciousness Status and Profuse Vomiting in Infants: Food Protein-Induced Enterocolitis Syndrome (FPIES) a Challenging Diagnosis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sepsis</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword></keywords><dates><year Day="6" Month="10" Year="2016">2016/10/6</year></dates><abstract><style face="normal" font="Arial">In infants, the causes of acute repetitive vomiting and severely altered-consciousness status include a broad differential diagnosis, that is, primarly sepsis, infectious gastroenteritis, head injury, and intoxication, as well as neurologic, metabolic, and cardiologic condition diseases. In patients developing such symptoms, allergy as an etiological cause is often not considered by primary care physicians. With this case report, we aim to draw the attention of general pediatricians, emergency physicians, and intensivists to the fact that non-immunoglobulin E-mediated food allergic gastrointestinal disorders such as food protein-induced enterocolitis syndrome should be considered in patients with sepsis-like symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20161014IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1097/PEC.0000000000000921</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27741073">PM:27741073</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Emerg Care\20161014-BarascheJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Emerg Care\20161014-BarascheJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161014, Barasche J</style></custom2><misc3><style face="normal" font="Arial">10.1097/PEC.0000000000000921</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nyankovskyy,S.</style></author><author><style face="normal" font="Arial"> Nyankovska,O.</style></author><author><style face="normal" font="Arial"> Dobryanskyy,D.</style></author><author><style face="normal" font="Arial"> Shadrin,O.</style></author><author><style face="normal" font="Arial"> Klimenko,V.</style></author><author><style face="normal" font="Arial"> Iatsula,M.</style></author><author><style face="normal" font="Arial"> Nedelska,S.</style></author><author><style face="normal" font="Arial"> Ashcheulov,O.</style></author><author><style face="normal" font="Arial"> Haiduchyk,H.</style></author><author><style face="normal" font="Arial"> Paholchuk,O.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical effectiveness of amino acid formula in infants with severe atopic dermatitis and cow's-milk protein allergy</style></title><secondary-title><style face="normal" font="Arial">Pediatr Polska</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Polska</style></full-title></periodical><pages end="527" start="521">521-527</pages><volume><style face="normal" font="Arial">91</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid formula</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> constipation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's-milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> diet therapy</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Elemental diet</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Free amino acids</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0031-3939</style></isbn><abstract><style face="normal" font="Arial">Introduction: The incidences of food allergies and related allergic diseases have been increasing in the recent years. Objective: The aim of this study is to evaluate clinical effectiveness of dietary intervention with amino acid-based formula (AAF) containing 100% free amino acids in the management of severe CMP allergy and atopic dermatitis (AD). Material and methods: Thirty infants aged from 29 days to 11 months with severe AD (Eczema Area and Severity Index [EASI] score &amp;gt;18) and confirmed CMP allergy were enrolled into the study. Twenty two patients have completed the study. The evaluation AAF's clinical effectiveness was carried out on the 7th, 14th and 28th day after reaching the full daily feeding volume. Results: In infants with severe AD (EASI score &amp;gt;18) the involvement of several organs and systems into the pathological process was typical: i.e. in 68% of the cases the skin symptoms were combined with the impaired function of the gastrointestinal tract and changes in the frequency of bowel movement (constipation, diarrhea), appearance of pathological admixtures in feces (mucus, blood), vomiting, etc. Feeding with AAF was associated with reliable reduction of severity not only of isolated skin (98%) but of combined skin and gastrointestinal manifestations of food allergy (82% of the cases). The formula was well tolerated by infants with severe AD and may be used for exclusive feeding of babies with severe CMP allergy. Conclusions: The described positive treatment effects were obtained with the diet duration of 4 weeks, the optimal period for the elemental diet administration needs further investigation</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pepo.2016.07.003</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.pepo.2016.07.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Polska\20161012-NyankovskyyS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Polska\20161012-NyankovskyyS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Nyankovskyy S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pepo.2016.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nove-Josserand,R.</style></author><author><style face="normal" font="Arial"> Grard,S.</style></author><author><style face="normal" font="Arial"> Auzou,L.</style></author><author><style face="normal" font="Arial"> Reix,P.</style></author><author><style face="normal" font="Arial"> Murris-Espin,M.</style></author><author><style face="normal" font="Arial"> Bremont,F.</style></author><author><style face="normal" font="Arial"> Mammar,B.</style></author><author><style face="normal" font="Arial"> Mely,L.</style></author><author><style face="normal" font="Arial"> Hubert,D.</style></author><author><style face="normal" font="Arial"> Durieu,I.</style></author><author><style face="normal" font="Arial"> Burgel,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CF Adult Center, University Center Hospital Lyon-Sud, Lyon, France.</style></auth-address><titles><title><style face="normal" font="Arial">Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients</style></title><secondary-title><style face="normal" font="Arial">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Pulmonol</style></full-title></periodical><pages end="197" start="190">190-197</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal drug</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Periodicals</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF). Corticosteroids are used as first-line therapy, but relapse and adverse effects commonly occur. Case reports have suggested the efficacy of the anti-IgE recombinant humanized monoclonal antibody omalizumab. A retrospective multicenter observational French study retrieved 32 CF patients (11 children and 21 adults) who have received omalizumab for more than 3 months in the context of ABPA. Clinical characteristics, concomitant medications (inhaled and oral corticosteroids, antifungal drugs), lung function, body mass index (BMI), and serum IgE were compared at the start and during the first year of omalizumab therapy. Omalizumab-related adverse effects and costs were also evaluated. No significant difference with omalizumab could be demonstrated with regard to lung function, BMI, or the number of patients receiving oral corticosteroids. At the time of initiation of omalizumab, 56% of patients were receiving oral corticosteroids. Five patients were able to discontinue corticosteroids during follow-up and nine patients were able to reduce their daily dose. A total of 78% of the patients had received antifungal therapy at the time of the initiation of omalizumab. Treatment tolerance was good (12.5% of patients experienced side effects). The median cost of omalizumab treatment was euro3,620 per patient per month. Omalizumab may represent a steroid-sparing therapy in CF patients with ABPA. A randomized-controlled trial is urgently required to provide higher level of evidence regarding the efficacy and cost-effectiveness of omalizumab in CF patients with ABPA. Pediatr Pulmonol. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1002/ppul.23612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27717223">PM:27717223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Pulmonol\20161007-NoveJosserandR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Pulmonol\20161007-NoveJosserandR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Nove-Josserand R</style></custom2><misc3><style face="normal" font="Arial">10.1002/ppul.23612</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yan,S.</style></author><author><style face="normal" font="Arial"> Chen,S.A.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Yang,F.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Zhu,Q.</style></author><author><style face="normal" font="Arial"> Zhu,H.</style></author><author><style face="normal" font="Arial"> Sun,X.</style></author><author><style face="normal" font="Arial"> Jiang,M.</style></author><author><style face="normal" font="Arial"> Su,Y.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Xing,Q.</style></author><author><style face="normal" font="Arial"> Luo,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aInstitutes of Biomedical Sciences bDepartment of Dermatology, Huashan Hospital cChildren's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai dDepartment of Pharmacology, School of Medicine, Zhengzhou University, Zhengzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">HLA-A*02 alleles are associated with tetanus antitoxin-induced exanthematous drug eruptions in Chinese patients</style></title><secondary-title><style face="normal" font="Arial">Pharmacogenet Genomics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Pharmacogenet Genomics</style></abbr-1></periodical><pages end="546" start="538">538-546</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Eruptions</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> Histocompatibility</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Linkage Disequilibrium</style></keyword><keyword><style face="normal" font="Arial"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Oligonucleotides</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Tetanus</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Tetanus antitoxin (TAT) is an effective antitetanus medicine, but may sometimes cause adverse drug reactions such as rapid-onset anaphylactic shock and late-onset cutaneous adverse drug reactions, including exanthematous drug eruptions (EDE). Human leukocyte antigen (HLA) class I alleles are strongly associated with different types of cutaneous adverse drug reactions. This study aimed to assess whether there is an association between TAT-induced EDE and HLA-A, HLA-B, and HLA-C alleles in the Chinese Han population. PATIENTS AND METHODS: We carried out an association study in 15 patients with TAT-induced EDE and two groups of general Han Chinese patients. Allele-level genotypes of the HLA-A, HLA-B, and HLA-C genes of each patient were determined using the PCR-sequence-specific oligonucleotides method. RESULTS: The carrier frequency of HLA serotype A2 was significantly higher in the TAT-induced EDE patients than in the general Han Chinese study participants from the human major histocompatibility complex database [n=283, odds ratio (OR)=6.93; P=0.0061]. Particularly, the carrier frequency of three A2 alleles, including HLA-A*02:01, HLA-A*02:06, and HLA-A*02:07, is significantly higher than that of the control group (OR=14.40; P=2.4x10). Furthermore, HLA-B*39:01 was in complete linkage disequilibrium with HLA-A*02:06 in the case patients. Consequently, the distribution of the HLA-A*02:06/-B*39:01 haplotype was also significantly different in the cases and the controls (OR=105.00; P=0.0024). CONCLUSION: The HLA-A*02:06/-B*39:01 haplotype is a potential genetic marker for the TAT-induced EDE. Furthermore, the HLA-A2 serotype, especially three alleles A*02:01, A*02:06, and A*02:07, was identified to be associated with the TAT-induced EDE in the Han Chinese population for the first time</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1744-6880 (Electronic)IS - 1744-6872 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1097/FPC.0000000000000248</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27749688">PM:27749688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharmacogenet Genomics\2016-26-538-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharmacogenet Genomics\2016-26-538-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161017, Yan S</style></custom2><misc3><style face="normal" font="Arial">10.1097/FPC.0000000000000248</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gangwar,R.S.</style></author><author><style face="normal" font="Arial"> Landolina,N.</style></author><author><style face="normal" font="Arial"> Levi-Schaffer,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pharmacology &amp; Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Mast cell and eosinophil surface receptors as targets for anti-allergic therapy</style></title><secondary-title><style face="normal" font="Arial">Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161024IS - 1879-016X (Electronic)IS - 0163-7258 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pharmthera.2016.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27773785">PM:27773785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharmacol Ther\20161024-GangwarRS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharmacol Ther\20161024-GangwarRS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161024, Gangwar RS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pharmthera.2016.10.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ziogas,V.</style></author><author><style face="normal" font="Arial"> Tanou,G.</style></author><author><style face="normal" font="Arial"> Belghazi,M.</style></author><author><style face="normal" font="Arial"> Diamantidis,G.</style></author><author><style face="normal" font="Arial"> Molassiotis,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Agriculture, Aristotle University of Thessaloniki, University Campus, 54124, Thessaloniki, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Characterization of beta-amino- and gamma-amino butyric acid-induced citrus seeds germination under salinity using nanoLC-MS/MS analysis</style></title><secondary-title><style face="normal" font="Arial">Plant Cell Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Cell Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> Citrus seeds</style></keyword><keyword><style face="normal" font="Arial"> Cotyledon</style></keyword><keyword><style face="normal" font="Arial"> Cotyledons</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> GABA</style></keyword><keyword><style face="normal" font="Arial"> Germination</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> glutathione S transferase</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> H2O2</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen Peroxide</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Miraculin</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Pis v 1</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> thaumatin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vicilin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="10" Year="2016">2016/10/19</year></dates><abstract><style face="normal" font="Arial">KEY MESSAGE: BABA or GABA induces salinity acclimation during citrus seeds germination via alternation of specific proteins (e.g., citrin). The impact of four elicitors, namely hydrogen peroxide (H2O2), beta-amino butyric acid (BABA), gamma-amino butyric acid (GABA) and hydrogen sulfide (H2S) donor, sodium hydrosulfide (NaHS), in citrus seed germination under salinity (150 mM NaCl) was tested. The germination potential was adversely affected by NaCl-alone treatment. Pretreatment with H2O2 or the NaHS-H2S donor prior to salinity had no significant effect in germination process, however, BABA and GABA substantially improved seed acclimation to salinity, as evidenced by increased germination percentage and radicle length. Total soluble proteins of radicle and cotyledons were separated by 1DE SDS-PAGE and proteins zones were analyzed by mass spectrometry. In total, 27 and 3 proteins were identified in radicle and cotyledons, respectively. The identified proteins mainly include redox-regulated enzymes (i.e., glutathione S-transferase, dehydroascorbate reductase, Mn-superoxide dismutase, glutathione peroxidase), energy-related proteins (i.e., isocitrate lyase, malate synthase, pyruvate decarboxylase), stress proteins (i.e., stress-related protein, miraculin, thaumatin, disulfide isomerase), storage proteins (i.e., vicilin, Pis v 1 allergen 2S albumin) and transcriptional regulators (i.e., MarR family transcriptional regulator, MADS544 protein). Pretreatments with BABA or GABA altered the accumulation of protein zones exclusively corresponding to citrin, indicating that this protein may serve as a marker for salinity acclimation in citrus seeds</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1432-203X (Electronic)IS - 0721-7714 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Greece -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00299-016-2063-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27761604">PM:27761604</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Cell Rep\20161020-ZiogasV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Cell Rep\20161020-ZiogasV.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Cell Rep\20161020-ZiogasV5_ESM.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Cell Rep\20161020-ZiogasV5_ESM.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20161020, Ziogas V</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00299-016-2063-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kosoy,R.</style></author><author><style face="normal" font="Arial"> Agashe,C.</style></author><author><style face="normal" font="Arial"> Grishin,A.</style></author><author><style face="normal" font="Arial"> Leung,D.Y.</style></author><author><style face="normal" font="Arial"> Wood,R.A.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Jones,S.M.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Davidson,W.F.</style></author><author><style face="normal" font="Arial"> Lindblad,R.W.</style></author><author><style face="normal" font="Arial"> Dawson,P.</style></author><author><style face="normal" font="Arial"> Merad,M.</style></author><author><style face="normal" font="Arial"> Kidd,B.A.</style></author><author><style face="normal" font="Arial"> Dudley,J.T.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Berin,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Transcriptional Profiling of Egg Allergy and Relationship to Disease Phenotype</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0163831">e0163831-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> baked egg</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Differentially expressed gene</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> NK cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Egg allergy is one of the most common food allergies of childhood. There is a lack of information on the immunologic basis of egg allergy beyond the role of IgE. OBJECTIVE: To use transcriptional profiling as a novel approach to uncover immunologic processes associated with different phenotypes of egg allergy. METHODS: Peripheral blood mononuclear cells (PBMCs) were obtained from egg-allergic children who were defined as reactive (BER) or tolerant (BET) to baked egg, and from food allergic controls (AC) who were egg non-allergic. PBMCs were stimulated with egg white protein. Gene transcription was measured by microarray after 24 h, and cytokine secretion by multiplex assay after 5 days. RESULTS: The transcriptional response of PBMCs to egg protein differed between BER and BET versus AC subjects. Compared to the AC group, the BER group displayed increased expression of genes associated with allergic inflammation as well as corresponding increased secretion of IL-5, IL-9 and TNF-alpha. A similar pattern was observed for the BET group. Further similarities in gene expression patterns between BER and BET groups, as well as some important differences, were revealed using a novel Immune Annotation resource developed for this project. This approach identified several novel processes not previously associated with egg allergy, including positive associations with TLR4-stimulated myeloid cells and activated NK cells, and negative associations with an induced Treg signature. Further pathway analysis of differentially expressed genes comparing BER to BET subjects showed significant enrichment of IFN-alpha and IFN-gamma response genes, as well as genes associated with virally-infected DCs. CONCLUSIONS: Transcriptional profiling identified several novel pathways and processes that differed when comparing the response to egg allergen in BET, BER, and AC groups. We conclude that this approach is a useful hypothesis-generating mechanism to identify novel immune processes associated with allergy and tolerance to forms of egg</style></abstract><notes><style face="normal" font="Arial">DA - 20161027IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0163831</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788149">PM:27788149</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0163831.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0163831.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161027, Kosoy R</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0163831</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cho,K.S.</style></author><author><style face="normal" font="Arial"> Park,M.K.</style></author><author><style face="normal" font="Arial"> Mun,S.J.</style></author><author><style face="normal" font="Arial"> Park,H.Y.</style></author><author><style face="normal" font="Arial"> Yu,H.S.</style></author><author><style face="normal" font="Arial"> Roh,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Indoleamine 2,3-Dioxygenase Is Not a Pivotal Regulator Responsible for Suppressing Allergic Airway Inflammation through Adipose-Derived Stem Cells</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0165661">e0165661-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IDO</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune suppression</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> indoleamine 2,3-dioxygenase</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although indoleamine 2,3-dioxygenase (IDO)-mediated immune suppression of mesenchymal stem cells (MSCs) has been revealed in septic and tumor microenvironments, the role of IDO in suppressing allergic airway inflammation by MSCs is not well documented. We evaluated the effects of adipose-derived stem cells (ASCs) on allergic inflammation in IDO-knockout (KO) asthmatic mice or asthmatic mice treated with ASCs derived from IDO-KO mice. METHODS AND FINDINGS: ASCs were injected intravenously in wild-type (WT) and IDO-KO asthmatic mice. Furthermore, asthmatic mice were injected with ASCs derived from IDO-KO mice. We investigated the immunomodulatory effects of ASCs between WT and IDO-KO mice or IDO-KO ASCs in asthmatic mice. In asthmatic mice, ASCs significantly reduced airway hyperresponsiveness, the number of total inflammatory cells and eosinophils in bronchoalveolar lavage fluid (BALF), eosinophilic inflammation, goblet hyperplasia, and serum concentrations of total and allergen-specific IgE and IgG1. ASCs significantly inhibited Th2 cytokines, such as interleukin (IL)-4, IL-5, and IL-13, and enhanced Th1 cytokine (interferon-gamma) and regulatory cytokines (IL-10, TGF-beta) in BALF and lung draining lymph nodes (LLNs). ASCs led to significant increases in regulatory T-cells (Tregs) and IL-10+ T cell populations in LLNs. However, the immunosuppressive effects of ASCs did not significantly differ between WT and IDO-KO mice. Moreover, ASCs derived from IDO-KO mice showed immunosuppressive effects in allergic airway inflammation. CONCLUSIONS: IDO did not play a pivotal role in the suppression of allergic airway inflammation through ASCs, suggesting that it is not the major regulator responsible for suppressing allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0165661</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27812173">PM:27812173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0165661.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0165661.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Cho KS</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0165661</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,F.P.</style></author><author><style face="normal" font="Arial"> Liu,T.</style></author><author><style face="normal" font="Arial"> Lan,Z.</style></author><author><style face="normal" font="Arial"> Li,S.Y.</style></author><author><style face="normal" font="Arial"> Mao,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0166833">e0166833-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PC20</style></keyword><keyword><style face="normal" font="Arial"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recent trials have assessed the efficacy and safety of novel monoclonal antibodies such as reslizumab and benralizumab. However, the overall efficacy and safety anti-interleukin (IL) 5 treatment in asthma have not been thoroughly assessed. METHODS: Randomized controlled trials (RCTs) of anti-IL-5 treatment on patients with asthma published up to October 2016 in PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) that reported pulmonary function, quality of life scores, asthmatic exacerbation rate, blood and sputum eosinophil counts, short-acting beta-agonist (SABA) rescue use, and adverse events were included. The pooled mean difference, and relative risks (RR), and 95% confidence intervals (CIs) were calculated using random-effects models. RESULTS: Twenty studies involving 7100 patients were identified. Pooled analysis revealed significant improvements in FEV1 (first second forced expiratory volume) (MD = 0.09, 95% CI: 0.06-0.12, I2 = 10%), FEV1% (MD = 3.75, 95% CI: 1.66-5.83, I2 = 19%), Asthma Quality of Life Questionnaire (AQLQ) score (MD = 0.22, 95% CI: 0.15-0.30, I2 = 0%), decreased blood, sputum eosinophils and asthmatic exacerbation (RR = 0.66, 95% CI: 0.59-0.73, I2 = 51%); peak expiratory flow (PEF) (MD = 5.45, 95% CI: -2.83-13.72, I2 = 0%), histamine PC20 (MD = -0.62, 95% CI: -1.92-0.68, I2 = 0%) or SABA rescue use (MD = -0.11, 95% CI: -0.3-0.07, I2 = 30%) were unaffected; adverse events were not increased (RR = 0.93, 95% CI: 0.89-0.98, I2 = 46%). No publication bias was observed (Egger's P = 0.78). CONCLUSIONS: Anti-interleukin 5 monoclonal therapies for asthma could be safe for slightly improving FEV1 (or FEV1% of predicted value), quality of life, and reducing exacerbations risk and blood and sputum eosinophils, but have no significant effect on PEF, histamine PC20, and SABA rescue use. Further trials required to establish to clarify the optimal antibody for different patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0166833</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27875559">PM:27875559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0166833.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0166833.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Wang FP</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0166833</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yoo,T.K.</style></author><author><style face="normal" font="Arial"> Kim,S.W.</style></author><author><style face="normal" font="Arial"> Seo,K.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Age-Related Cataract Is Associated with Elevated Serum Immunoglobulin E Levels in the South Korean Population: A Cross-Sectional Study</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0166331">e0166331-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Alcohol</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Pressure</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous research has suggested that immunoglobulin E (IgE)-mediated events lead to several chronic diseases. We investigated the association between allergic conditions and age-related cataracts in the South Korean adult population. METHODS: A cross-sectional study was performed using data obtained from 1,170 participants aged 40 years or older who were enrolled in the Korean National Health and Nutrition Examination Survey 2010. Multivariable logistic regression was used to examine the relationship between age-related cataracts and allergic conditions, including total serum IgE and allergen-specific serum IgE levels, after adjustment for potential confounders (age, sex, alcohol consumption, smoking, sun exposure, blood pressure, plasma glucose and cholesterol levels, as well as histories of asthma, atopic dermatitis, and rheumatoid arthritis). RESULTS: After adjusting for potential confounders, the odds ratio (OR) for age-related cataract was greater in participants with higher total serum IgE levels (OR = 1.37; P = 0.044). In particular, increased IgE levels were significantly associated with nuclear cataract (OR = 1.42; P = 0.032). However, allergen-specific serum IgE levels did not differ significantly between groups. In the trend analysis, no significant relationship was observed between serum IgE and any type of age-related cataract. CONCLUSION: Increased total serum IgE level is independently associated with age-related cataracts after adjustment for confounding factors</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0166331</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27861567">PM:27861567</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0166331.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0166331.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Yoo TK</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0166331</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,Z.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Guo,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Characteristics of Allergic Pulmonary Inflammation in CXCR3Knockout Mice Sensitized and Challenged with House Dust Mite Protein</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0162905">e0162905-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> CXCR3</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte Count</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Chemokine C-X-C motif receptor 3 (CXCR3) is a chemokine receptor that is mainly expressed by activated T lymphocytes. T cells play important roles in allergic pulmonary inflammation, which is a hallmark of asthma and elicits the localized accumulation of activated T cells in the lung. In China, a marked increase in the incidence rate of chronic allergic pulmonary inflammation has made it a major public health threat. In the present study, we investigated the role of CXCR3 and its ligands in airway inflammation induced by house dust mite protein (HDMP) in a CXCR3 knockout (CXCR3KO) asthma mouse model. Pathological manifestations in the lung, cell counts and bronchoalveolar lavage fluid (BALF) classifications were studied using hematoxylin and eosin (H&amp;E) staining. The levels of IL-4 and IFN-gamma in the BALF and splenocyte supernatants were measured using ELISA. CD4+ and CD8+ T cells in the lung and spleen were analyzed by flow cytometry. RT-PCR was applied to measure the mRNA transcript levels of monokines induced by IFN-gamma(CXCL9) and IFN-gamma inducible protein 10(CXCL10). The total cell counts, eosinophil counts, and IL-4 levels in the BALF and cultured splenocyte supernatants were significantly increased, while the levels of IFN-gamma were reduced in the HDMP groups(P&lt;0.01). Changes in the total cell counts, eosinophil counts, and lymphocyte counts, as well as the total protein levels in the BALF, the levels of IL-4 in splenocyte supernatants, and the pathological manifestations in the lung, were all greater in CXCR3KO mice than in C57BL/6 wild-type mice. Furthermore, the expression levels of CXCL9 and CXCL10 mRNA transcripts in the lungs of CXCR3KO mice were lower than those in C57BL/6 wild-type mice (P&lt;0.05). CXCR3 and its ligands (i.e., CXCL9 and CXCL10) may play anti-inflammatory roles in this animal model. Promoting the expression of CXCR3 and its ligands may represent a novel therapeutic approach for preventing and curing asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0162905</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27727269">PM:27727269</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0162905.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0162905.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Liu Z</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0162905</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gulumian,M.</style></author><author><style face="normal" font="Arial"> Verbeek,J.</style></author><author><style face="normal" font="Arial"> Andraos,C.</style></author><author><style face="normal" font="Arial"> Sanabria,N.</style></author><author><style face="normal" font="Arial"> de Jager,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Toxicology and Biochemistry, National Institute for Occupational Health, National Health Laboratory Service, Johannesburg, South Africa</style></auth-address><titles><title><style face="normal" font="Arial">Systematic Review of Screening and Surveillance Programs to Protect Workers from Nanomaterials</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0166071">e0166071-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Health hazards</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword><keyword><style face="normal" font="Arial"> Workplace exposure</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Screening and surveillance approaches for workers exposed to nanomaterials could aid in early detection of health effects, provide data for epidemiological studies and inform action to decrease exposure. The aim of this review is to identify such screening and surveillance approaches, in order to extract available data regarding (i) the studies that have successfully been implemented in present day, (ii) identification of the most common and/or toxic nano-related health hazards for workers and (iii) possible exposure surveillance markers. This review contributes to the current understanding of the risk associated with nanomaterials by determining the knowledge gap and making recommendations based on current findings. METHODS: A systematic review was conducted. PubMed and Embase were searched to identify articles reporting on any surveillance-related study that described both exposure to nanomaterials and the health indicators that were measured. Four reviewers worked in pairs to independently assess the eligibility of studies and risk of bias before extraction of data. Studies were categorised according to the type of study and the medical surveillance performed, which included the type of nanomaterial, any exposure details provided, as well as health indicators and biomarkers tested. RESULTS: Initially 92 studies were identified, from which 84 full texts were assessed for eligibility. Seven studies met all the inclusion criteria, i.e. those performed in Taiwan, Korea, Czech Republic and the US. Of these, six compared health indicators between exposed and unexposed workers and one study described a surveillance program. All studies were at a high risk of bias. Workers were exposed to a mix of nanomaterials in three studies, carbon-based nanomaterials in two studies, nano-silver in one study and nano-titanium oxide in the other study. Two studies did not find a difference in biomarkers between exposed and unexposed workers. In addition, differences in early effects on pulmonary function or neurobehavioral tests were not observed. One study found an increased prevalence of allergic dermatitis and "sneezing" in the exposed group. CONCLUSIONS: This review of recently published data on surveillance studies proves that there is a gap in the current knowledge, where most of the surveillance-related studies reported do not follow a set format that provides the required information on ENM characterisation, the type of exposure and the measured indicators/biomarkers. Hence, there is very low quality evidence that screening and surveillance might detect adverse health effects associated with workplace exposure. This systematic review is relevant because it proves that, although surveillance programs have been initiated and preliminary results are being published, the current studies are actually not answering the important questions or solving the overall problem regarding what the potential health hazards are among workers either handling or potentially exposed to ENMs. The recommendations, thus proposed, are based on an obvious need for (i) exposure registries, where longitudinal follow-up studies should inform surveillance, (ii) known exposure measurements or summary indices for ENMs as a reference (iii) validation of candidate biomarkers and (iv) studies that compare the effects of these surveillance approaches to usual care, e.g. those commonly followed for bulk-size hazardous materials</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Africa -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0166071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27829014">PM:27829014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0166071.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0166071.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Gulumian M</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0166071</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Protudjer,J.L.</style></author><author><style face="normal" font="Arial"> Vetander,M.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Hedlin,G.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Bergstrom,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Environmental Medicine and Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Food-Related Symptoms and Food Allergy in Swedish Children from Early Life to Adolescence</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0166347">e0166347-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parental allergy</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Risk factors for persistence of food-related symptoms (FRS) and food allergy (FA) from early life to adolescence are incompletely understood. The aim of this study was to identify risk factors for FRS and FA in adolescence amongst children with FRS or FA in the first four years of life (early life). METHODS: In children enrolled in a Swedish birth cohort and followed to 16 years (n = 2572), we defined children with early life FRS in the absence of FA, and FA. Corresponding phenotypes were defined at 16 years. Associations between potential risk factors at 4 years and FRS and FA at 16 years were investigated using logistic regression. RESULTS: Early life FRS and FA prevalences were 12.2% and 6.8%, respectively. Amongst children with early life FRS, 35.7% had FRS or FA at 16 years, whereas 74.3% of the children with early life FA had FA at 16 years. For each of the early life phenotypes, parental allergy, early life allergic multimorbidity, early life reactions to peanuts/tree nuts and IgE reactivity at 4 years were statistically significantly associated with FRS or FA at 16 years. In contrast, male sex was associated with an increased risk of FA at 16 years among children with early life FA only. CONCLUSIONS: In early life, food-related symptoms are twice as common as food allergy. Unlike food allergy, food-related symptoms often remit by adolescence. Yet, these phenotypes have many common risk factors for persistence to adolescence</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0166347</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27846286">PM:27846286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0166347.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0166347.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Protudjer JL</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0166347</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ai,C.</style></author><author><style face="normal" font="Arial"> Ma,N.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Wang,G.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Tian,F.</style></author><author><style face="normal" font="Arial"> Chen,P.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Engineering Research Center of Seafood, School of Food Science and Technology, Dalian Polytechnic University, Dalian 116034, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Immunomodulatory Effects of Different Lactic Acid Bacteria on Allergic Response and Its Relationship with In Vitro Properties</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0164697">e0164697-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergy effect</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Some studies reported that probiotic could relieve allergy-induced damage to the host, but how to get a useful probiotic is still a challenge. In this study, the protective effects of three lactic acid bacteria (La, Lp and Lc) were evaluated in a mouse model, and its relationship with the in vitro properties was analyzed. The in vitro results indicated that La with the capacity to inhibit IL-4 production could have a better anti-allergy effect in vivo than two others. However, the animal trials showed that all LAB strains could alleviate allergen-induced airway inflammation. Among them, LAB strain Lp had a better effect in inhibiting allergic response through a modulation of Th1/Th2 balance and an increase of regulatory T cells. This difference could be explained by that different LAB strains have a strain-specific effect on gut microbiota closely associated with host immune responses. Finally, this study did not only obtain an effective anti-allergy probiotic strain via animal study, but also indicate that probiotic-induced effect on intestinal microbiota should be considered as an important screening index, apart from its inherent characteristics</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0164697</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27764153">PM:27764153</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0164697.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0164697.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Ai C</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0164697</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsai,W.C.</style></author><author><style face="normal" font="Arial"> Wu,T.C.</style></author><author><style face="normal" font="Arial"> Chiang,B.L.</style></author><author><style face="normal" font="Arial"> Wen,H.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, 402, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Cloning, expression, and purification of recombinant major mango allergen Man i 1 in Escherichia coli</style></title><secondary-title><style face="normal" font="Arial">Protein Expr Purif</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Protein Expr Purif</style></full-title></periodical><pages end="43" start="35">35-43</pages><volume><style face="normal" font="Arial">130</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruit allergy</style></keyword><keyword><style face="normal" font="Arial"> GAPDH</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mango</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasmid</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="24" Month="6" Year="2016">2016/6/24</year></dates><abstract><style face="normal" font="Arial">In recent years, the number of people around the world who suffer from fruit allergies has increased. Mango can induce anaphylaxis, and two major mango allergens have been identified - Man i 1 and Man i 2. Apart from their molecular weights and pI values, no other information about them is known. This work identifies the DNA and amino acid sequences of Man i 1 and constructs an expression system for recombinant Man i 1 (rMan i 1). Firstly, 3' and 5' RACE assays were used to identify the cDNA fragment of Man i 1. Subsequently, the full length of Man i 1 cDNA was inserted into a pET-21a(+) vector, and the inserted plasmid was transformed to Escherichia coli BL21 (DE3) to express rMan i 1. The conditions for the expression of rMan i 1, including IPTG concentration, induction temperature, and induction time, were optimized. The highest amount of soluble rMan i 1 was obtained after induction with 0.1 mM IPTG at 16 degrees C for 20 h. The His-tagged rMan i 1 was purified using Ni-NTA agarose and its identity was verified using an anti-histidine antibody and the serum of a mango-allergic person. Additionally, rMan i 1 was identified as glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and shared 86.2% identity in amino acid sequence of GAPDH from wheat. Finally, an E. coli expression system of rMan i 1 was established, with the potential to be used in immunotherapy against mango allergy or the development of assays for detecting the residues of mango allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20160628IS - 1096-0279 (Electronic)IS - 1046-5928 (Linking)LA - ENGPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pep.2016.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27350535">PM:27350535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Protein Expr Purif\2016-130-35-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Protein Expr Purif\2016-130-35-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160628, Tsai WC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pep.2016.06.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schaefer,M.</style></author><author><style face="normal" font="Arial"> Harke,R.</style></author><author><style face="normal" font="Arial"> Denke,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical School Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="Arial">Psychoter Psychosom</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Psychoter Psychosom</style></abbr-1></periodical><pages end="374" start="373">373-374</pages><volume><style face="normal" font="Arial">85</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Placebos</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161016IS - 1423-0348 (Electronic)IS - 0033-3190 (Linking)LA - ENGPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000447242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27744433">PM:27744433</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161016, Schaefer M</style></custom2><misc3><style face="normal" font="Arial">10.1159/000447242</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choy,M.S.</style></author><author><style face="normal" font="Arial"> Dixit,D.</style></author><author><style face="normal" font="Arial"> Bridgeman,M.B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mepolizumab (Nucala) For Severe Eosinophilic Asthma</style></title><secondary-title><style face="normal" font="Arial">PT</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PT</style></full-title></periodical><pages end="622" start="619">619-622</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Mepolizumab (Nucala) for severe eosinophilic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161019IS - 1052-1372 (Print)IS - 1052-1372 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27757000">PM:27757000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PT\2016-41-619-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PT\2016-41-619-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161019, Choy MS</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Taille,C.</style></author><author><style face="normal" font="Arial"> Grootenboer-Mignot,S.</style></author><author><style face="normal" font="Arial"> Estellat,C.</style></author><author><style face="normal" font="Arial"> Roy,C.</style></author><author><style face="normal" font="Arial"> Ly Ka,S.S.</style></author><author><style face="normal" font="Arial"> Pretolani,M.</style></author><author><style face="normal" font="Arial"> Aubier,M.</style></author><author><style face="normal" font="Arial"> Crestani,B.</style></author><author><style face="normal" font="Arial"> Chollet-Martin,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Assistance Publique-Hopitaux de Paris, Hopital Bichat, Service de Pneumologie et Centre de Competence des Maladies Pulmonaires Rares, Paris, France.</style></auth-address><titles><title><style face="normal" font="Arial">Perip7lakin is a target for autoimmunity in asthma</style></title><secondary-title><style face="normal" font="Arial">Respir Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Res</style></full-title></periodical><pages end="" start="126">126-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Intracellular signaling</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="Arial">The role of autoimmunity targeting epithelial antigens in asthma has been suggested, in particular in non-atopic and severe asthma. Periplakin, a desmosomal component, is involved in epithelial cohesion and intracellular signaling. We detected anti-periplakin IgG antibodies in 47/260 (18 %) patients with asthma, with no association with severity or atopy. In addition, anti-periplakin IgE antibodies were detected in 12 of 138 tested patients (8.7 %) and were more frequently observed in patients with than without nasal polyposis. This study identifies a new autoimmune epithelial target in asthma. Whether periplakin autoimmunity (both IgG and IgE auto-antibodies) is involved in asthma pathogenesis remains to be studied during the disease course of these patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161008IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - ENGPT - LETTERCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12931-016-0441-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27717390">PM:27717390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2016-17-126.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2016-17-126.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161008, Taille C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12931-016-0441-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gu,W.</style></author><author><style face="normal" font="Arial"> Cui,R.</style></author><author><style face="normal" font="Arial"> Ding,T.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Peng,J.</style></author><author><style face="normal" font="Arial"> Xu,W.</style></author><author><style face="normal" font="Arial"> Han,F.</style></author><author><style face="normal" font="Arial"> Guo,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Simvastatin alleviates airway inflammation and remodelling through up-regulation of autophagy in mouse models of asthma</style></title><secondary-title><style face="normal" font="Arial">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respirology</style></full-title></periodical><pages end="541" start="533">533-541</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> simvastatin</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> statin</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Statins have been widely used in inflammatory diseases including asthma, because of their anti-inflammatory and immunomodulatory properties. It has been shown that simvastatin induces autophagy and cell death in some circumstances. However, the possible cross-talk between simvastatin and autophagic processes in lung disease is largely unknown. Thus, we investigated the impact of simvastatin on airway inflammation and airway remodelling and the possible relationship of these processes to a simvastatin-induced autophagic pathway in mouse models of asthma. METHODS: Ovalbumin (OVA)-sensitized and challenged mice were treated with simvastatin and sacrificed. The autophagy-related proteins Atg5, LC3B and Beclin1 were quantified, as well as the autophagy flux in bronchial smooth muscle cells (BSMCs). The relationship between airway inflammation and the autophagic process was investigated. RESULTS: We show that simvastatin treatment mediates activation of autophagy in BSMCs, which is correlated with airway inflammation and airway remodelling in mouse models of asthma. Simvastatin increases autophagy-related protein Atg5, LC3B and Beclin1 expression and autophagosome formation in lung tissue. Simvastatin-induced autophagy is associated with increased interferon-gamma (IFN-gamma) and decreased IL-4, IL-5 and IL-13 cytokines production in BSMCs, as well as reversed extracellular matrix (ECM) deposition. In contrast, autophagy inhibitor 3-methyladenine (3-MA) eliminates the therapeutic effect of simvastatin. CONCLUSION: These findings demonstrate that simvastatin inhibits airway inflammation and airway remodelling through an activated autophagic process in BSMCs. We propose a crucial function of autophagy in statin-based therapeutic approaches in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161026IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/resp.12926</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27782356">PM:27782356</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respirology\20161026-GuW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respirology\20161026-GuW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161026, Gu W</style></custom2><misc3><style face="normal" font="Arial">10.1111/resp.12926</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mbuila,C.</style></author><author><style face="normal" font="Arial"> Ponvert,C.L.</style></author><author><style face="normal" font="Arial"> Mangyanda,L.K.</style></author><author><style face="normal" font="Arial"> Goulamhoussen,S.</style></author><author><style face="normal" font="Arial"> Nzomvuama,A.</style></author><author><style face="normal" font="Arial"> Kumbi,R.</style></author><author><style face="normal" font="Arial"> Nguyen,T.-L.T.</style></author><author><style face="normal" font="Arial"> Grigorescu,D.</style></author><author><style face="normal" font="Arial"> Loire,M.</style></author><author><style face="normal" font="Arial"> Bentchikou,N.</style></author><author><style face="normal" font="Arial"> Mnif,A.</style></author><author><style face="normal" font="Arial"> Savulescu,G.</style></author><author><style face="normal" font="Arial"> Beydon,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The impact of allergen-specific immunotherapy in a polysensitized child with severe respiratory allergy treated with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="607" start="603">603-607</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">7-8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Congo</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polysensibilisation</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory function</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe allergic disease</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">The avoidance of allergens and allergen-specific immunotherapy (AIT) are the only curative treatments of allergic diseases. This requires identification of the offending allergens based on the clinical history and the results of allergy tests, but also on prior attempts to stabilize the disease with drugs. AIT in polysensitized patients with severe allergic diseases which are difficult to control is a major challenge. We report the case of a 16-year-old girl with rhinitis and severe asthma attributed to mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae), grass pollen and cat dander. The addition of Omaluzimab to the pre-established optimal treatment helped to control the disease and allowed us to initiate sublingual immunotherapy (SLIT). SLIT was well tolerated during Omaluzimab administration and also after the drug was discontinued, and the treatment led to complete control of her allergic disease (symptoms, respiratory function and immunoassays). Several studies have shown that omalizumab increases tolerance to and efficacy of AIT in patients with respiratory and hymenoptera venom allergies. However, in most studies, omalizumab treatment was maintained during AIT. Our results in this young polysensitized girl with severe asthma agree with results reported in other studies which showed that pretreatment with omalizumab could lead to better tolerance and efficacy of AIT. Moreover, it was also reported that AIT can act synergistically with omalizumab and involves only the induction mechanisms of immune-regulation</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -CO - Congo -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.09.002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.09.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20161104-MbuilaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20161104-MbuilaC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Mbuila C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.09.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yazdani,R.</style></author><author><style face="normal" font="Arial"> Azizi,G.</style></author><author><style face="normal" font="Arial"> Abolhassani,H.</style></author><author><style face="normal" font="Arial"> Aghamohammadi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Selective IgA deficiency: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management</style></title><secondary-title><style face="normal" font="Arial">Scand J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Scand J Immunol</style></full-title></periodical><pages end="12" start="3">3-12</pages><volume><style face="normal" font="Arial">85</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody deficiency</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgA Deficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin A</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary antibody deficiency</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Selective immunoglobulin A deficiency (SIgAD) is the most common primary antibody deficiency. Although more patients with SIgAD are asymptomatic, selected patients suffer from different clinical complications such as pulmonary infections, allergies, autoimmune diseases, gastrointestinal disorders and malignancy. Pathogenesis of SIgAD is still unknown, however, a defective terminal differentiation of B-cells and defect in switching to IgA-producing plasma cells are presumed to be responsible. Furthermore, some cytogenic defects and monogenic mutations are associated with SIgAD. There is no specific treatment for patients with symptomatic IgA deficiency; although prophylactic antibiotic therapy along with circumstantial immunoglobulin replacement with justification and supportive care (using a product that contains minimal IgA) could be helpful for patients with a severe phenotype. The epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis, management and treatment in patients with SIgAD have been reviewed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1365-3083 (Electronic)IS - 0300-9475 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Iran -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/sji.12499</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763681">PM:27763681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Scand J Immunol\20161020-YazdaniR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Scand J Immunol\20161020-YazdaniR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Yazdani R</style></custom2><misc3><style face="normal" font="Arial">10.1111/sji.12499</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bazett,M.</style></author><author><style face="normal" font="Arial"> Biala,A.</style></author><author><style face="normal" font="Arial"> Huff,R.D.</style></author><author><style face="normal" font="Arial"> Bosiljcic,M.</style></author><author><style face="normal" font="Arial"> Gunn,H.</style></author><author><style face="normal" font="Arial"> Kalyan,S.</style></author><author><style face="normal" font="Arial"> Hirota,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Qu Biologics Inc., Vancouver, BC, V5T 4T5, Canada</style></auth-address><titles><title><style face="normal" font="Arial">A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="35338">35338-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intervention Studies</style></keyword><keyword><style face="normal" font="Arial"> Klebsiella</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Subcutaneous route</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="10" Year="2016">2016/10/13</year></dates><abstract><style face="normal" font="Arial">There is an unmet need for effective new and innovative treatments for asthma. It is becoming increasingly evident that bacterial stimulation can have beneficial effects at attenuating allergic airway disease through immune modulation. Our aim was to test the ability of a novel inactivated microbe-derived therapeutic based on Klebsiella (KB) in a model of allergic airway disease in mice. BALB/c mice were exposed intranasally to house dust mite (HDM) for two weeks. Mice were treated prophylactically via subcutaneous route with either KB or placebo for one week prior to HDM exposure and throughout the two week exposure period. 24 hours after the last exposure, lungs were analysed for inflammatory cell infiltrate, gene expression, cytokine levels, goblet cell metaplasia, and serum was analysed for allergen-specific serum IgE levels. HDM exposed mice developed goblet cell hyperplasia, elevated allergen-specific serum IgE, airway eosinophilia, and a concomitant increase in TH2 cytokines including IL-4, IL-13 and IL-5. Treatment with KB attenuated HDM-mediated airway eosinophilia, total bronchoalveolar lavage (BAL) cell numbers, BAL TH2 cytokine production, and goblet cell metaplasia. Our prophylactic intervention study illustrates the potential of subcutaneous treatment with bacterial derived biologics as a promising approach for allergic airway disease treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161013IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep35338</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27734946">PM:27734946</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-35338.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-35338.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161013, Bazett M</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep35338</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,J.</style></author><author><style face="normal" font="Arial"> Song,J.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Han,J.</style></author><author><style face="normal" font="Arial"> Luo,H.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Jia,Z.</style></author><author><style face="normal" font="Arial"> Dong,Y.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Jiang,F.</style></author><author><style face="normal" font="Arial"> Wu,C.</style></author><author><style face="normal" font="Arial"> Sun,Z.</style></author><author><style face="normal" font="Arial"> Zhong,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China</style></auth-address><titles><title><style face="normal" font="Arial">Association between allergic conditions and risk of prostate cancer: A Prisma-Compliant Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="35682">35682-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Prostate</style></keyword><keyword><style face="normal" font="Arial"> Prostate cancer</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="10" Year="2016">2016/10/21</year></dates><abstract><style face="normal" font="Arial">Association between allergic conditions and prostate cancer risk has been investigated for many years. However, the results from available evidence for the association are inconsistent. We conducted a meta-analysis to evaluate the relationship between allergic conditions (asthma, atopy, hay fever and "any allergy") and risk of prostate cancer. The PubMed and Embase databases were searched to screen observational studies meeting our meta-analysis criteria. Study selection and data extraction from included studies were independently performed by two authors. Twenty studies were considered eligible involving 5 case-control studies and 15 cohort studies. The summary relative risk (RR) for developing prostate cancer risk was 1.04 (95%CI: 0.92-1.17) for asthma, and 1.25 (95%CI: 0.74-2.10) for atopy, 1.04 (95%CI: 0.99-1.09) for hay fever, 0.96 (95%CI: 0.86-1.06) for any allergy. In the Subgroup and sensitivity analysis, similar results were produced. Little evidence of publication bias was observed. The present meta-analysis of observational studies indicates that no indication of an association between allergic conditions and risk of prostate cancer was found, and the meta-analysis does not support neither the original hypothesis of an overall cancer protective effect of allergic conditions, nor that of an opposite effect in the development of prostate cancer</style></abstract><notes><style face="normal" font="Arial">DA - 20161021IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep35682</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27767045">PM:27767045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-35682.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-35682.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161021, Zhu J</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep35682</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,J.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Chen,D.</style></author><author><style face="normal" font="Arial"> Hua,X.</style></author><author><style face="normal" font="Arial"> Bian,F.</style></author><author><style face="normal" font="Arial"> Deng,R.</style></author><author><style face="normal" font="Arial"> Lu,F.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Pflugfelder,S.C.</style></author><author><style face="normal" font="Arial"> Li,D.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Optometry and Ophthalmology, Wenzhou Medical University, Wenzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">Pollen/TLR4 Innate Immunity Signaling Initiates IL-33/ST2/Th2 Pathways in Allergic Inflammation</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="36150">36150-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial components</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Ocular surface</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="10" Year="2016">2016/10/31</year></dates><abstract><style face="normal" font="Arial">Innate immunity has been extended to respond environmental pathogen other than microbial components. Here we explore a novel pollen/TLR4 innate immunity in allergic inflammation. In experimental allergic conjunctivitis induced by short ragweed (SRW) pollen, typical allergic signs, stimulated IL-33/ST2 signaling and overproduced Th2 cytokine were observed in ocular surface, cervical lymph nodes and isolated CD4+ T cells of BALB/c mice. These clinical, cellular and molecular changes were significantly reduced/eliminated in TLR4 deficient (Tlr4-d) or MyD88 knockout (MyD88-/-) mice. Aqueous SRW extract (SRWe) directly stimulated IL-33 mRNA and protein expression by corneal epithelium and conjunctiva in wild type, but not in Tlr4-d or MyD88-/- mice with topical challenge. Furthermore, SRWe-stimulated IL-33 production was blocked by TLR4 antibody and NF-kB inhibitor in mouse and human corneal epithelial cells. These findings for the first time uncovered a novel mechanism by which SRW pollen initiates TLR4-dependent IL-33/ST2 signaling that triggers Th2-dominant allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - ENGPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep36150</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27796360">PM:27796360</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-36150.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-36150.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Li J</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep36150</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cho,J.L.</style></author><author><style face="normal" font="Arial"> Ling,M.F.</style></author><author><style face="normal" font="Arial"> Adams,D.C.</style></author><author><style face="normal" font="Arial"> Faustino,L.</style></author><author><style face="normal" font="Arial"> Islam,S.A.</style></author><author><style face="normal" font="Arial"> Afshar,R.</style></author><author><style face="normal" font="Arial"> Griffith,J.W.</style></author><author><style face="normal" font="Arial"> Harris,R.S.</style></author><author><style face="normal" font="Arial"> Ng,A.</style></author><author><style face="normal" font="Arial"> Radicioni,G.</style></author><author><style face="normal" font="Arial"> Ford,A.A.</style></author><author><style face="normal" font="Arial"> Han,A.K.</style></author><author><style face="normal" font="Arial"> Xavier,R.</style></author><author><style face="normal" font="Arial"> Kwok,W.W.</style></author><author><style face="normal" font="Arial"> Boucher,R.</style></author><author><style face="normal" font="Arial"> Moon,J.J.</style></author><author><style face="normal" font="Arial"> Hamilos,D.L.</style></author><author><style face="normal" font="Arial"> Kesimer,M.</style></author><author><style face="normal" font="Arial"> Suter,M.J.</style></author><author><style face="normal" font="Arial"> Medoff,B.D.</style></author><author><style face="normal" font="Arial"> Luster,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic asthma is distinguished by sensitivity of allergen-specific CD4+ T cells and airway structural cells to type 2 inflammation</style></title><secondary-title><style face="normal" font="Arial">Sci Transl Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Transl Med</style></full-title></periodical><pages end="" start="359ra132">359ra132-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">359</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> segmental allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="5" Month="10" Year="2016">2016/10/5</year></dates><abstract><style face="normal" font="Arial">Despite systemic sensitization, not all allergic individuals develop asthma symptoms upon airborne allergen exposure. Determination of the factors that lead to the asthma phenotype in allergic individuals could guide treatment and identify novel therapeutic targets. We used segmental allergen challenge of allergic asthmatics (AA) and allergic nonasthmatic controls (AC) to determine whether there are differences in the airway immune response or airway structural cells that could drive the development of asthma. Both groups developed prominent allergic airway inflammation in response to allergen. However, asthmatic subjects had markedly higher levels of innate type 2 receptors on allergen-specific CD4+ T cells recruited into the airway. There were also increased levels of type 2 cytokines, increased total mucin, and increased mucin MUC5AC in response to allergen in the airways of AA subjects. Furthermore, type 2 cytokine levels correlated with the mucin response in AA but not AC subjects, suggesting differences in the airway epithelial response to inflammation. Finally, AA subjects had increased airway smooth muscle mass at baseline measured in vivo using novel orientation-resolved optical coherence tomography. Our data demonstrate that the development of allergic asthma is dependent on the responsiveness of allergen-specific CD4+ T cells to innate type 2 mediators as well as increased sensitivity of airway epithelial cells and smooth muscle to type 2 inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20161006IS - 1946-6242 (Electronic)IS - 1946-6234 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1126/scitranslmed.aag1370</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27708065">PM:27708065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Transl Med\2016-8-359ra132.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Transl Med\2016-8-359ra132.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161006, Cho JL</style></custom2><misc3><style face="normal" font="Arial">10.1126/scitranslmed.aag1370</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Navarro,S.</style></author><author><style face="normal" font="Arial"> Pickering,D.A.</style></author><author><style face="normal" font="Arial"> Ferreira,I.B.</style></author><author><style face="normal" font="Arial"> Jones,L.</style></author><author><style face="normal" font="Arial"> Ryan,S.</style></author><author><style face="normal" font="Arial"> Troy,S.</style></author><author><style face="normal" font="Arial"> Leech,A.</style></author><author><style face="normal" font="Arial"> Hotez,P.J.</style></author><author><style face="normal" font="Arial"> Zhan,B.</style></author><author><style face="normal" font="Arial"> Laha,T.</style></author><author><style face="normal" font="Arial"> Prentice,R.</style></author><author><style face="normal" font="Arial"> Sparwasser,T.</style></author><author><style face="normal" font="Arial"> Croese,J.</style></author><author><style face="normal" font="Arial"> Engwerda,C.R.</style></author><author><style face="normal" font="Arial"> Upham,J.W.</style></author><author><style face="normal" font="Arial"> Julia,V.</style></author><author><style face="normal" font="Arial"> Giacomin,P.R.</style></author><author><style face="normal" font="Arial"> Loukas,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Hookworm recombinant protein promotes regulatory T cell responses that suppress experimental asthma</style></title><secondary-title><style face="normal" font="Arial">Sci Transl Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Transl Med</style></full-title></periodical><pages end="" start="362ra143">362ra143-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">362</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hookworm</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infections</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg induction</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword></keywords><dates><year Day="26" Month="10" Year="2016">2016/10/26</year></dates><abstract><style face="normal" font="Arial">In the developed world, declining prevalence of some parasitic infections correlates with increased incidence of allergic and autoimmune disorders. Moreover, experimental human infection with some parasitic worms confers protection against inflammatory diseases in phase 2 clinical trials. Parasitic worms manipulate the immune system by secreting immunoregulatory molecules that offer promise as a novel therapeutic modality for inflammatory diseases. We identify a protein secreted by hookworms, anti-inflammatory protein-2 (AIP-2), that suppressed airway inflammation in a mouse model of asthma, reduced expression of costimulatory markers on human dendritic cells (DCs), and suppressed proliferation ex vivo of T cells from human subjects with house dust mite allergy. In mice, AIP-2 was primarily captured by mesenteric CD103+ DCs and suppression of airway inflammation was dependent on both DCs and Foxp3+ regulatory T cells (Tregs) that originated in the mesenteric lymph nodes (MLNs) and accumulated in distant mucosal sites. Transplantation of MLNs from AIP-2-treated mice into naive hosts revealed a lymphoid tissue conditioning that promoted Treg induction and long-term maintenance. Our findings indicate that recombinant AIP-2 could serve as a novel curative therapeutic for allergic asthma and potentially other inflammatory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 1946-6242 (Electronic)IS - 1946-6234 (Linking)LA - ENGPT - Journal ArticleCO - Australia -CO - United States -CO - Thailand -CO - Germany -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1126/scitranslmed.aaf8807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27797959">PM:27797959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Transl Med\2016-8-362ra143.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Transl Med\2016-8-362ra143.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Navarro S</style></custom2><misc3><style face="normal" font="Arial">10.1126/scitranslmed.aaf8807</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Buttafuoco,A.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Glatz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Allergiestation, Dermatologische Klinik, Universitat und Universitatsspital Zurich</style></auth-address><titles><title><style face="normal" font="Arial">Atopische Dermatitis und Malassezia spp.</style></title><secondary-title><style face="normal" font="Arial">Ther Umsch</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ther Umsch</style></full-title></periodical><pages end="468" start="463">463-468</pages><volume><style face="normal" font="Arial">73</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161012IS - 0040-5930 (Print)IS - 0040-5930 (Linking)LA - GERPT - JOURNAL ARTICLECO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1024/0040-5930/a000819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27731787">PM:27731787</url></web-urls><pdf-urls><url ppv-ref="no">martin.glatz@usz.ch</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20161012, Buttafuoco A</style></custom2><misc3><style face="normal" font="Arial">10.1024/0040-5930/a000819</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Au,K.Y.</style></author><author><style face="normal" font="Arial"> Shi,W.W.</style></author><author><style face="normal" font="Arial"> Qian,S.</style></author><author><style face="normal" font="Arial"> Zuo,Z.</style></author><author><style face="normal" font="Arial"> Shaw,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Protein Science and Crystallography, School of Life Sciences, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.</style></auth-address><titles><title><style face="normal" font="Arial">Improvement of the Pharmacological Properties of Maize RIP by Cysteine-Specific PEGylation</style></title><secondary-title><style face="normal" font="Arial">Toxins (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxins (Basel)</style></full-title></periodical><pages end="" start="E298">E298-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Crystallography</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Maize</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="17" Month="10" Year="2016">2016/10/17</year></dates><abstract><style face="normal" font="Arial">To improve the pharmacological properties of maize ribosome-inactivating protein (maize RIP) for targeting HIV-infected cells, the previously engineered TAT-fused active form of maize RIP (MOD) was further engineered for cysteine-directed PEGylation. In this work, two potential antigenic sites, namely Lys-78 and Lys-264, were identified. They were mutated to cysteine residue and conjugated with PEG5k or PEG20k. The resultant PEG derivatives of MOD variants were examined for ribosome-inactivating activity, circulating half-life and immunogenicity. Our results showed that MOD-PEG conjugates had two- to five-fold lower biological activity compared to the wild-type. Mutation of the two sites respectively did not decrease the anti-MOD IgG and IgE level in mice, but the conjugation of PEG did dramatically reduce the antigenicity. Furthermore, pharmacokinetics studies demonstrated that attachment of PEG20k prolonged the plasma half-life by five-fold for MOD-K78C and 17-fold for MOD-K264C, respectively. The site-specific mutation together with PEGylation therefore generated MOD derivatives with improved pharmacological properties</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 2072-6651 (Electronic)IS - 2072-6651 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.3390/toxins8100298</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763506">PM:27763506</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxins (Basel)\2016-8-E298.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxins (Basel)\2016-8-E298.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Au KY</style></custom2><misc3><style face="normal" font="Arial">10.3390/toxins8100298</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sbrana,F.</style></author><author><style face="normal" font="Arial"> Cardinali,G.</style></author><author><style face="normal" font="Arial"> Dal Pino,B.</style></author><author><style face="normal" font="Arial"> Bigazzi,F.</style></author><author><style face="normal" font="Arial"> Sabatino,L.</style></author><author><style face="normal" font="Arial"> Pianelli,M.</style></author><author><style face="normal" font="Arial"> Luciani,R.</style></author><author><style face="normal" font="Arial"> Sampietro,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fondazione Toscana Gabriele Monasterio, Pisa, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">A case of 'anaphylactic-like' reaction during LDL apheresis: a pathophysiological hypothesis on white wine containing metabisulphite</style></title><secondary-title><style face="normal" font="Arial">Transfus Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfus Med</style></full-title></periodical><pages end="461" start="460">460-461</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> White wine</style></keyword><keyword><style face="normal" font="Arial"> Wine</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 1365-3148 (Electronic)IS - 0958-7578 (Linking)LA - ENGPT - LETTERCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/tme.12369</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27714882">PM:27714882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfus Med\20161007-SbranaF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfus Med\20161007-SbranaF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161007, Sbrana F</style></custom2><misc3><style face="normal" font="Arial">10.1111/tme.12369</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,S.H.</style></author><author><style face="normal" font="Arial"> Yang,S.Y.</style></author><author><style face="normal" font="Arial"> You,J.</style></author><author><style face="normal" font="Arial"> Lee,S.B.</style></author><author><style face="normal" font="Arial"> You,J.</style></author><author><style face="normal" font="Arial"> Chang,Y.S.</style></author><author><style face="normal" font="Arial"> Kim,H.J.</style></author><author><style face="normal" font="Arial"> Ahn,C.M.</style></author><author><style face="normal" font="Arial"> Byun,M.K.</style></author><author><style face="normal" font="Arial"> Park,H.J.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association of Specific Immunoglobulin E to Staphylococcal Enterotoxin with Airway Hyperresponsiveness in Asthma Patients</style></title><secondary-title><style face="normal" font="Arial">Tuberc Respir Dis (Seoul)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Tuberc Respir Dis (Seoul)</style></full-title></periodical><pages end="301" start="295">295-301</pages><volume><style face="normal" font="Arial">79</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophils</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Specific immunoglobulin E (IgE) sensitization to staphylococcal enterotoxin (SE) has been recently considered to be related to allergic disease, including asthma. Despite studies on specific IgE (sIgE) to SE and its relationship to asthma diagnosis and severity, the association of sIgE to SE with airway hyperresponsiveness (AHR) remains unclear. METHODS: We enrolled 81 asthma patients admitted to the Severance Hospital in Korea from March 1, 2013, to February 28, 2015 and retrospectively reviewed the electronic medical records of the enrolled subjects. The serum levels of sIgE to SE (A/B) of all subjects was measured using the ImmunoCAP 250 (Phadia) system with SE-sIgE positive defined as >0.10 kU/mL. RESULTS: The SE-sIgE level was not significantly correlated with asthma severity (forced expiratory volume in 1 second [FEV1], FEV1/forced vital capacity, sputum eosinophils, and serum eosinophils), whereas the SE-sIgE level in patients with positive AHR (mean+/-standard error of the mean, 0.606+/-0.273 kU/mL) was significantly higher than that in patients with negative AHR (0.062+/-0.015 kU/mL, p=0.034). In regression analysis, SE sensitization (sIgE to SE >/=0.010 kU/mL) was a significant risk factor for AHR, after adjustment for age, sex, FEV1, and sputum eosinophils (odds ratio, 7.090; 95% confidence interval, 1.180-42.600; p=0.032). Prevalence of SE sensitization was higher in patients with allergic rhinitis and non-atopic asthma patients, as compared to patients without allergic rhinitis and atopic asthma patients, respectively, but without statistical significance. CONCLUSION: SE sensitization is significantly associated with AHR</style></abstract><notes><style face="normal" font="Arial">DA - 20161028IS - 1738-3536 (Print)IS - 1738-3536 (Linking)LA - ENGPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4046/trd.2016.79.4.295</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27790282">PM:27790282</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Tuberc Respir Dis (Seoul)\2016-79-295-301.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Tuberc Respir Dis (Seoul)\2016-79-295-301.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161028, Kim SH</style></custom2><misc3><style face="normal" font="Arial">10.4046/trd.2016.79.4.295</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Henriksen,P.</style></author><author><style face="normal" font="Arial"> Borresen,M.L.</style></author><author><style face="normal" font="Arial"> Dahl,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Food protein-induced enterocolitis syndrome in a boy with diarrhoea and severe dehydration]</style></title><secondary-title><style face="normal" font="Arial">Ugeskr Laeger</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ugeskr Laeger</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">178</style></volume><number><style face="normal" font="Arial">41</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Abdomen</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Dehydration</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Sepsis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword></keywords><dates><year Day="10" Month="10" Year="2016">2016/10/10</year></dates><abstract><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome (FPIES) is a rare non-IgE mediated condition. Symptoms of acute FPIES include vomiting, diarrhoea and dehydration. Symptoms are often misread as acute abdomen or sepsis. The condition can be fatal. There are no biomarkers for FPIES, and skin prick test for cow milk is often negative. Treatment is hydrolysed formula milk. This case story describes a one-month-old boy with diarrhoea and an output of up till 2.3 l per day. With this case story we wish to increase the knowledge of FPIES and emphasize the importance of having the diagnosis in mind when confronted with the very ill, dehydrated infant</style></abstract><notes><style face="normal" font="Arial">DA - 20161017IS - 1603-6824 (Electronic)IS - 0041-5782 (Linking)LA - DANPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27745584">PM:27745584</url></web-urls><pdf-urls><url ppv-ref="no">pehen82@gmail.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161017, Henriksen P</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adam,Z.</style></author><author><style face="normal" font="Arial"> Sediva,A.</style></author><author><style face="normal" font="Arial"> Koukalova,R.</style></author><author><style face="normal" font="Arial"> Rehak,Z.</style></author><author><style face="normal" font="Arial"> Petrasova,H.</style></author><author><style face="normal" font="Arial"> Szturz,P.</style></author><author><style face="normal" font="Arial"> Adamova,Z.</style></author><author><style face="normal" font="Arial"> Vetesnikova,E.</style></author><author><style face="normal" font="Arial"> Pour,L.</style></author><author><style face="normal" font="Arial"> Krejci,M.</style></author><author><style face="normal" font="Arial"> Sandecka,V.</style></author><author><style face="normal" font="Arial"> Pourova,E.</style></author><author><style face="normal" font="Arial"> Cermakova,Z.</style></author><author><style face="normal" font="Arial"> Sevcikova,S.</style></author><author><style face="normal" font="Arial"> Kral,Z.</style></author><author><style face="normal" font="Arial"> Mayer,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Schnitzlers SyndromeDifferential diagnostics, an overview of therapeutic options and description of 5 cases treated with anakinra]</style></title><secondary-title><style face="normal" font="Arial">Vnitr Lek</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Vnitr Lek</style></abbr-1></periodical><pages end="727" start="713">713-727</pages><volume><style face="normal" font="Arial">62</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> anakinra</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1</style></keyword><keyword><style face="normal" font="Arial"> Leukocytosis</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Schnitzlers syndrome is an acquired auto-inflammatory disease of still unclear origin. The Strasbourg criteria were adopted (non-infectious fever, chronic urticaria, changes in the bone structure, leukocytosis and higher values of inflammatory markers - CRP and presence of monoclonal immunoglobulin mostly of type IgM, very rarely of IgG) to establish this diagnosis. The first-choice therapy for this disease is the blocking of interleukin-1 effects. In practice, the interleukin-1 receptor antagonist, anakinra, is the most commonly used. Currently reports also appear of the use of other medicines blocking the effect of interleukin-1, namely canakinumab and rilonacept. We have been treating 5 patients with anakinra (108, 72, 33, 32 and 1 months) on a long-term basis. In all the patients, we commenced administration of anakinra in a dose of 100 mg once a day. As a result of 100 mg being administered once a day, all symptoms went away completely in 4 patients, while they receded by about 75 % in 1 patient, without disappearing completely. This patient needs an increased dose of 2 ampoules per day on the days of spontaneously intensified medical ailments. After one year of treatment it turned out for one of the four patients whose symptoms had completely disappeared when administered the 100mg daily dose, that he only needed the respective dose of anakinra at 48-hour intervals. However this patient does not tolerate further extension of the intervals between dose administrations. We have not recorded any adverse effects of anakinra in the course of the treatment, and no decline in the efficiency of anakinra has been observed: it acts as effectively now as it did at the beginning of the treatment. The text discusses the differential diagnostics of the Schnitzler syndrome.Key words: anakinra - auto-inflammatory diseases - canakinumab - fever of unknown origin -</style></abstract><notes><style face="normal" font="Arial">DA - 20161007IS - 0042-773X (Print)IS - 0042-773X (Linking)LA - CZEPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27715073">PM:27715073</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161007, Adam Z</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.</style></author><author><style face="normal" font="Arial"> Aberer,W.</style></author><author><style face="normal" font="Arial"> Al-Ahmad,M.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author><author><style face="normal" font="Arial"> Ballmer-Weber,B.K.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author><author><style face="normal" font="Arial"> Blanca,M.</style></author><author><style face="normal" font="Arial"> Brown,S.</style></author><author><style face="normal" font="Arial"> Bunnag,C.</style></author><author><style face="normal" font="Arial"> Hulett,A.C.</style></author><author><style face="normal" font="Arial"> Castells,M.</style></author><author><style face="normal" font="Arial"> Chng,H.H.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author><author><style face="normal" font="Arial"> Fineman,S.</style></author><author><style face="normal" font="Arial"> Golden,D.B.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Kaliner,M.</style></author><author><style face="normal" font="Arial"> Katelaris,C.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Makowska,J.</style></author><author><style face="normal" font="Arial"> Muller,U.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Oppenheimer,J.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author><author><style face="normal" font="Arial"> Parkerson,J.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Pawankar,R.</style></author><author><style face="normal" font="Arial"> Renz,H.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Sastre,J.</style></author><author><style face="normal" font="Arial"> Scadding,G.</style></author><author><style face="normal" font="Arial"> Sicherer,S.</style></author><author><style face="normal" font="Arial"> Tantilipikorn,P.</style></author><author><style face="normal" font="Arial"> Tracy,J.</style></author><author><style face="normal" font="Arial"> van Kempen,V.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Caraballo,L.</style></author><author><style face="normal" font="Arial"> Gomez,M.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Larche,M.</style></author><author><style face="normal" font="Arial"> Melioli,G.</style></author><author><style face="normal" font="Arial"> Poulsen,L.K.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Rheumatology &amp; Allergy, Medical University of Lodz, 251 Pomorska Str, 92-213 Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="33">33-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity disorders</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">One of the major concerns in the practice of allergy is related to the safety of procedures for the diagnosis and treatment of allergic disease. Management (diagnosis and treatment) of hypersensitivity disorders involves often intentional exposure to potentially allergenic substances (during skin testing), deliberate induction in the office of allergic symptoms to offending compounds (provocation tests) or intentional application of potentially dangerous substances (allergy vaccine) to sensitized patients. These situations may be associated with a significant risk of unwanted, excessive or even dangerous reactions, which in many instances cannot be completely avoided. However, adverse reactions can be minimized or even avoided if a physician is fully aware of potential risk and is prepared to appropriately handle the situation. Information on the risk of diagnostic and therapeutic procedures in allergic diseases has been accumulated in the medical literature for decades; however, except for allergen specific immunotherapy, it has never been presented in a systematic fashion. Up to now no single document addressed the risk of the most commonly used medical procedures in the allergy office nor attempted to present general requirements necessary to assure the safety of these procedures. Following review of available literature a group of allergy experts within the World Allergy Organization (WAO), representing various continents and areas of allergy expertise, presents this report on risk associated with diagnostic and therapeutic procedures in allergology and proposes a consensus on safety requirements for performing procedures in allergy offices. Optimal safety measures including appropriate location, type and required time of supervision, availability of safety equipment, access to specialized emergency services, etc. for various procedures have been recommended. This document should be useful for allergists with already established practices and experience as well as to other specialists taking care of patients with allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1939-4551 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -CO - Spain -CO - Austria -CO - Kuwait -CO - Switzerland -CO - Germany -CO - Australia -CO - Thailand -CO - Venezuela -CO - United States -CO - Singapore -CO - South Korea -CO - Italy -CO - Japan -CO - United Kingdom -CO - Argentina -CO - Canada -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0122-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27777642">PM:27777642</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Kowalski ML</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0122-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Figueiredo,C.A.</style></author><author><style face="normal" font="Arial"> Amorim,L.D.</style></author><author><style face="normal" font="Arial"> Vaca,M.</style></author><author><style face="normal" font="Arial"> Chico,M.E.</style></author><author><style face="normal" font="Arial"> Campos,A.C.</style></author><author><style face="normal" font="Arial"> Barreto,M.L.</style></author><author><style face="normal" font="Arial"> Cooper,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Ciencias da Saude, Universidade Federal da Bahia, Salvador, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Effects of poor hygiene on cytokine phenotypes in children in the tropics</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Order</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> latent class analysis</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">We describe immune phenotypes (innate and adaptive cytokines) according to environmental exposure using latent class analysis. A total of 310 schoolchildren living in Ecuador were assayed for spontaneous cytokine production as well as mitogen (SEB)-stimulated cytokines in whole blood cultures. We collected data on environmental exposures by questionnaire and on intestinal parasites by examination of stool samples. Latent class analysis (LCA) was used to group children according to their innate (IL-6, IL-8, IL-10 and TNF-alpha) and adaptive (IL-5, IL-13, IL-17, IFN-gamma and IL-10) cytokine profile. We also conducted multiple-group LCA and LCA with covariates to evaluate the effect of predictors on profile membership. We identified both hyporesponsive and Th2-modified immune phenotypes produced by peripheral blood leukocytes (PBLs) that were associated with intestinal worms and birth order, providing insights into how poor hygiene mediates immunologic effects on immune-mediated diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Ecuador -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0124-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27843530">PM:27843530</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Figueiredo CA</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0124-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okada,Y.</style></author><author><style face="normal" font="Arial"> Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Sagamihara National Hospital, 18-1, Sakuradai, Minami-ku, Sagamihara, Kanagawa 252-0392 Japan</style></auth-address><titles><title><style face="normal" font="Arial">Heated egg yolk challenge predicts the natural course of hen's egg allergy: a retrospective study</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> egg tolerance</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> heated egg</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> hen's egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Whites</style></keyword><keyword><style face="normal" font="Arial"> Whole egg</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Children do not always outgrow hen's egg allergies in early childhood. Because egg yolks are less allergenic than egg whites, we performed an oral food challenge with heated egg yolk slightly contaminated with egg white (EYSEW OFC) in infants allergic to hen's egg. We hypothesized that the EYSEW OFC results would predict the egg allergy's natural course. METHODS: We retrospectively reviewed participants with hen's egg allergy who underwent their first EYSEW OFC at 12-23 months of age between 2004 and 2010. Participants who passed the first EYSEW OFC were defined as EYSEW-tolerant, and participants who failed the OFC were defined as EYSEW-reactive. Participants who passed the EYSEW OFC underwent an OFC with half of a heated whole egg (WE OFC). Participants who passed a WE OFC were defined to be heated hen's egg-tolerant. Participants who failed the EYSEW OFC or the WE OFC underwent another OFC at least 6 months later. We compared tolerance to heated hen's egg at 36 months after the first EYSEW OFC between EYSEW-tolerant and EYSEW-reactive participants. Univariate and multivariate logistic regression analyses were conducted. RESULTS: Of the 197 included participants (median age: 18.3 months; range: 12.1-23.8 months), 179 (90.9 %) were EYSEW tolerant and 18 (9.1 %) were EYSEW reactive. At 36 months after the first EYSEW OFC, 164 EYSEW-tolerant (91.6 %) and 12 EYSEW-reactive participants (66.7 %) achieved heated hen's egg tolerance. In the univariate logistic regression analyses, EYSEW-reactive participants (crude odds ratio [OR], 5.5 [95 % confidence intervals [CI], 1.8-16.6]; p = 0.003) and those with baseline egg white sIgE levels (crude OR: 3.9 per ten-fold increase [95 % CI, 1.5-10.2]; p = 0.005) had greater odds of persistent allergy to hen's egg at 36 months after the first EYSEW OFC. In a multivariate logistic regression analysis after adjustment for baseline egg white sIgE, EYSEW-reactive participants had greater odds of persistent allergy to hen's egg than EYSEW-tolerant participants (adjusted OR: 4.6 [95 % CI, 1.5-15.0]; p = 0.003). CONCLUSIONS: Classifying infants who are allergic to hen's egg into EYSEW tolerant and EYSEW reactive groups was useful in determining prognosis</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1939-4551 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0121-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27777641">PM:27777641</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Okada Y</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0121-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,S.E.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Human Nutrition, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA</style></auth-address><titles><title><style face="normal" font="Arial">Update on Early Nutrition and Food Allergy in Children</style></title><secondary-title><style face="normal" font="Arial">Yonsei Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yonsei Med J</style></full-title></periodical><pages end="548" start="542">542-548</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Epigenesis,Genetic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic regulation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fetal Development</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Status</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">With growing evidence of an increase in the prevalence, food allergy has been emerged as a new public health problem. As treatment and management of food allergy remain challenging, more attention has been paid to the importance of prevention of food allergy. Although the exact mechanism of recent epidemic is not fully understood, it is suggested that nutritional exposure in early life may play an important role in food allergy development. The underlying hypothesis is that nutritional status or food exposure in the critical period of fetal development can affect the programming of immune system and modify the risk of immunologic reactions to foods in postnatal life. We review accumulating epidemiological studies to examine an association between nutritional exposure during pregnancy or early infancy and food allergy development in children. We also discuss recent advances in the studies of the genetic and epigenetic regulation of food allergy and evaluate the role of early nutrition in food allergy development to provide a new perspective on the prevention of food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20160321IS - 1976-2437 (Electronic)IS - 0513-5796 (Linking)LA - ENGPT - Journal ArticlePT - ReviewRN - 0 (Allergens)SB - IMCO - United States -CO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3349/ymj.2016.57.3.542</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26996550">PM:26996550</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yonsei Med J\2016-57-542-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yonsei Med J\2016-57-542-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160321, Lee SE</style></custom2><misc3><style face="normal" font="Arial">10.3349/ymj.2016.57.3.542</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,L.</style></author><author><style face="normal" font="Arial"> Lou,C.Y.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Zhang,J.B.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, The East Ward of Sichuan Academy of Medical Science &amp; Sichuan Provincial People's Hospital, Chengdu 610110, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Effect of montelukast sodium intervention on airway remodeling and percentage of Th17 cells/CD4+CD25+ regulatory T cells in asthmatic mice]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="1180" start="1174">1174-1180</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To study the dynamic changes in the percentage of Th17 cells/CD4+CD25+ regulatory T cells after intervention with montelukast sodium, a leukotriene receptor antagonist, in asthmatic mice and the association between them. METHODS: Balb/c mice were randomly divided into blank group, asthma group, and montelukast sodium group. The asthmatic mouse model of airway remodeling was established by sensitization with intraperitoneal injection of chicken ovalbumin (OVA) and aluminum hydroxide suspension and aerosol inhalation of OVA. The mice in the blank group were given normal saline, and those in the montelukast sodium group were given montelukast sodium by gavage before aerosol inhalation. Eight mice were randomly sacrificed within 24 hours after 2, 4, and 8 weeks of aerosol inhalation. The pathological sections of lung tissue were used to observe the degree of airway remodeling. Flow cytometry was used to measure the percentages of Th17 cells and CD4+CD25+ regulatory T cells in CD4+ T cells. RESULTS: The asthma group and the montelukast sodium group had significantly higher bronchial wall thickness and smooth muscle thickness at all time points compared with the blank group (P&lt;0.05). At 8 weeks of intervention, the montelukast sodium group had significantly greater improvements in the above changes compared with the asthma group (P&lt;0.05). Compared with the blank group, the asthma group and the montelukast sodium group had significant increases in Th17 cells (positively correlated with airway remodeling) and significant reductions in CD4+CD25+ regulatory T cells (negatively correlated to airway remodeling) at all time points (P&lt;0.05). At 8 weeks of intervention, the montelukast sodium group had a significant reduction in the number of Th17 cells and a significant increase in the number of CD4+CD25+ regulatory T cells compared with the asthma group (P&lt;0.05). CONCLUSIONS: Montelukast sodium intervention can alleviate airway remodeling and achieve better improvements over the time of intervention. The possible mechanism may be related to the improvement of immunologic derangement of CD4+CD25+ regulatory T cells and inhibition of airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - CHIPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2016.11.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27817787">PM:27817787</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2016-18-1174-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2016-18-1174-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Li L</style></custom2><misc3><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2016.11.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xia,T.T.</style></author><author><style face="normal" font="Arial"> Xu,Z.B.</style></author><author><style face="normal" font="Arial"> Liu,X.Z.</style></author><author><style face="normal" font="Arial"> Tong,W.Q.</style></author><author><style face="normal" font="Arial"> Zhang,L.T.</style></author><author><style face="normal" font="Arial"> Chen,F.</style></author><author><style face="normal" font="Arial"> Wang,H.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">First Clinical Medical School,Zhejiang Chinese Medical University,Hangzhou 310053,China</style></auth-address><titles><title><style face="normal" font="Arial">New Advances in the Diagnosis and Treatment of Allergic &lt;br/>Bronchopulmonary Aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Yi Xue Ke Xue Yuan Xue Bao</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Zhongguo Yi Xue Ke Xue Yuan Xue Bao</style></abbr-1></periodical><pages end="616" start="611">611-616</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="10" Month="10" Year="2016">2016/10/10</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis is one of major pulmonary fungal diseases. Although it is not a rare in clinical settings,the misdiagnosis rate is high and the treatment effectiveness remains unstable. This article reviews the recent advances in the diagnosis and treatment of this disease</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1000-503X (Print)IS - 1000-503X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3881/j.issn.1000-503X.2016.05.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27825423">PM:27825423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Zhongguo Yi Xue Ke Xue Yuan Xue Bao\2016-38-611-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Zhongguo Yi Xue Ke Xue Yuan Xue Bao\2016-38-611-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Xia TT</style></custom2><misc3><style face="normal" font="Arial">10.3881/j.issn.1000-503X.2016.05.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tao,J.L.</style></author><author><style face="normal" font="Arial"> Dai,Q.G.</style></author><author><style face="normal" font="Arial"> Lin,L.L.</style></author><author><style face="normal" font="Arial"> Wang,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jiangsu Key Laboratory of Pediatric Respiratory Disease, Nanjing University of Chinese Medicine, Nanjing 210023, China</style></auth-address><titles><title><style face="normal" font="Arial">[Present situation and analysis of murine allergic rhinitis model]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Jing Wai Ke Zha Zhi</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Jing Wai Ke Zha Zhi</style></abbr-1></periodical><pages end="796" start="792">792-796</pages><volume><style face="normal" font="Arial">51</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="Arial">There have been 20 years of history in the study of allergic rhinitis(AR) using a mice model. At present, the AR mice model still exists some problems in the selection of mice strains, allergens and adjuvant types, molding cycle, allergen dose, model judgment, and so on, which affects the authenticity and comparability of the research results. By gradually solving the problems existing in the mice AR model, it is of great significance to realize the standardization of AR model, and the depth of the AR research</style></abstract><notes><style face="normal" font="Arial">DA - 20161021IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - CHIPT - JOURNAL ARTICLEPT - ENGLISH ABSTRACTCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2016.10.019.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27765116">PM:27765116</url></web-urls></urls><custom2><style face="normal" font="Arial">20161021, Tao JL</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2016.10.019.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Raison-Peyron,N.</style></author><author><style face="normal" font="Arial"> Reymann,V.</style></author><author><style face="normal" font="Arial"> Bessis,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Deparment of Dermatology, Hopital Saint-Eloi, CHRU Montpellier, 80 Avenue Augustin Fliche, FR-34295 Montpellier, France. n-raison@chu-montpellier.fr</style></auth-address><titles><title><style face="normal" font="Arial">Follicular Traction Urticaria: A New Form of Chronic Inducible Urticaria?</style></title><secondary-title><style face="normal" font="Arial">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Derm Venereol</style></full-title></periodical><pages end="523" start="522">522-523</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - ENGPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.2340/00015555-2558</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27805718">PM:27805718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Derm Venereol\20161102-Raison-PeyronN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Derm Venereol\20161102-Raison-PeyronN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">201612102, Raison-Peyron N</style></custom2><misc3><style face="normal" font="Arial">10.2340/00015555-2558</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chicharro,P.</style></author><author><style face="normal" font="Arial"> Rodriguez-Jimenez,P.</style></author><author><style face="normal" font="Arial"> de Argila,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Dermatologia, Hospital Universitario de La Princesa, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and Safety of Omalizumab in a Patient With Chronic Spontaneous Urticaria and Active Hepatitis B Virus Infection</style></title><secondary-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></full-title></periodical><pages end="384" start="383">383-384</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B virus</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ad.2016.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914623">PM:27914623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Actas Dermosifiliogr\20161204-ChicharroP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Actas Dermosifiliogr\20161204-ChicharroP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Chicharro P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ad.2016.10.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bardei,F.</style></author><author><style face="normal" font="Arial"> Bouziane,H.</style></author><author><style face="normal" font="Arial"> Trigo,M.</style></author><author><style face="normal" font="Arial"> Ajouray,N.</style></author><author><style face="normal" font="Arial"> El Haskouri,F.</style></author><author><style face="normal" font="Arial"> Kadiri,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Atmospheric concentrations and intradiurnal pattern of Alternaria and Cladosporium conidia in T+®touan (NW of Morocco)</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="228" start="221">221-228</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airborne fungal spore</style></keyword><keyword><style face="normal" font="Arial"> airborne spores</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Conidia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spore concentration</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Fungal spores of Alternaria and Cladosporium are ubiquitous components of both indoor and outdoor air samples and are the main causes of human respiratory allergies. Monitoring these airborne fungal spores during 2009</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2014 was carried out by means of Hirst-type spore trap to investigate their airborne spore concentrations with respect to annual load, seasonality and overall intradiurnal pattern. Alternaria and Cladosporium spores are present throughout the year in the atmosphere of T+®touan, although they show seasonal variations. Despite important differences between years, their highest levels presented a first peak during spring and a higher second peak in summer or autumn depending on the year. The spore concentrations were homogeneously distributed throughout the day with slight increase of 7.6 and 3.7% on average between 12</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô14 and 14</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô16-áh for Alternaria and Cladosporium, respectively. The borderline of 3000-ásp/m3 of Cladosporium linked to the occurrence of allergic diseases was exceeded between 13 and 31-ádays. Airborne spores of Alternaria overcame the threshold value of 100-ásp/m3 up to 95-ádays, suggesting that Cladosporium and Alternaria could be clinically significant aeroallergens for atopic patients</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Morocco -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9465-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9465-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161128-Bardei F.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161128-Bardei F.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Bardei F</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9465-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mentese,S.</style></author><author><style face="normal" font="Arial"> Otkun,M.T.</style></author><author><style face="normal" font="Arial"> Palaz,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison of dichloran rose bengal chloramphenicol and Sabouraud dextrose agar with cycloheximide and chloramphenicol for airborne mold sampling</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="219" start="211">211-219</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Culture Media</style></keyword><keyword><style face="normal" font="Arial"> Culture medium</style></keyword><keyword><style face="normal" font="Arial"> Cycloheximide</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">The more the mold species isolated on a culture medium, the more the sampling environment is represented accurately. According to the sampling purpose, it is crucial to use the best culture medium for mold. However, no study is available regarding the comparison of dichloran rose bengal chloramphenicol (DRBC) and Sabouraud dextrose agar with cycloheximide and chloramphenicol (SDA-CHX-CHL) culture media in terms of their application for airborne sampling, isolation, and identification of fungi. Airborne mold samples were impacted onto both DRBC and SDA-CHX-CHL, simultaneously using single-stage Andersen sampler. The limit of detection (LOD) value for airborne mold count was 7-áCFU-ám</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3 (1 colony growth on the Petri dish). The total mold counts (TMC) ranged between &lt;7 and 504-áCFU-ám</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3 (med 56-áCFU-ám</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3) and &lt;7 and 1218-áCFU-ám</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3 (med 259-áCFU-ám</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3), collected on SDA-CHX-CHL and DRBC, respectively. Significantly higher TMC were observed on DRBC than on SDA regardless of the sampling environment (i.e, indoor or outdoor) (p-á&lt;-á0.05). Among the most predominant mold genera, observation frequencies of Penicillium spp. and Aspergillus spp. on both culture media were found to be more than 70%. Observation frequencies of Cladosporium spp., Alternaria spp., and yeast were found to be higher in samples collected on DRBC than those on SDA-CHX-CHL. Finally, DRBC was found to be superior to SDA in terms of both number of colonies and number of genera isolated from the air</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9462-2</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9462-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161128-MenteseS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161128-MenteseS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Mentese S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9462-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hadj Hamda,S.</style></author><author><style face="normal" font="Arial"> Ben Dhiab,A.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author><author><style face="normal" font="Arial"> Msallem,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pollen spectrum in Northern Tunis, Tunisia</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="251" start="243">243-251</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cupressus</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Main pollen season</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Periodicity</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollen spectrum</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Suction</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> Urticaceae</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">This study has been focused on airborne pollen concentration in Northern Tunis. Pollen has been detected by a volumetric Hirst-type spore trap. This suction sampler was placed for two hydrologic years in the area of Mornag, northeastof Tunisia (36-¦40N; 10-¦17E). Fifty-two taxa were identified with heterogeneous daily pollen concentrations and a dominance of anemophilous plants. The main pollen types detected in the atmosphere were Olea europaea (38.7 and 20.75%), Cupressus (33.57 and 55.4%), Urticaceae (9.22 and 12.24%), Poaceae (3.55 and 3.32%), Mercurialis annua (2.96 and 1.6%) and Amaranthaceae (2.49 and 1.55%). The monthly pollen spectrum indicated a seasonal periodicity of airborne pollen with the main pollen season during spring. Two pollen seasons have been observed during these hydrologic years, due to both Cupressus and Amaranthaceae airborne pollen is represented during winter or spring, and also during autumn and late summer, respectively. Other pollen types represent a long pollen season, i.e., Urticaceae, starting in autumn and following until late spring. Daily pollen concentration showed a different behavior during the flowering season between both years, observing differences related to pollen index. Correlation between daily pollen concentrations of the dominant taxa showed a positive and significant correlation between airborne pollen concentrations of spring-pollinated taxa and mean temperature, but negative with maximum temperature, humidity and rainfall. In the case of minimum temperature, a different response, positive for trees and negative for herbaceous plants, has been observed</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Tunisia -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9464-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9464-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161128-HadjHamdaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161128-HadjHamdaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Hadj Hamda S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9464-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Severova,E.</style></author><author><style face="normal" font="Arial"> Volkova,O.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Variations and trends of Betula pollen seasons in Moscow (Russia) in relation to meteorological parameters</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="264" start="253">253-264</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Betula pollen seasons</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> global warming</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> Volumetric spore trap</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">This study investigates possible links of meteorological data and the start date, end date, duration, date of peak, peak value and Seasonal Pollen Index (SPI) of birch pollen seasons recorded in Moscow, Russia, during 1993</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2015. Pollen data were collected by a volumetric spore trap. Correlation analysis was used to study relationships between various parameters of pollen seasons. Simple linear regression analysis was conducted to investigate trends over time; multiple stepwise regression analysis was used to describe SPI fluctuations as a function of seasonal or monthly climatic parameters. Air temperatures increased significantly during the study period, but no effect on the timing of the birch pollen season was found. Only the severity of the season showed significant changes that can be considered as a consequence of global warming. Rainfall in May and June of the year preceding flowering, total rainfall in the 40-day pre-season period and average temperature during the pollination were shown to be the most important parameters affecting birch pollen concentrations</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9460-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9460-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161128-SeverovaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161128-SeverovaE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Severova E</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9460-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sikoparija,B.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author><author><style face="normal" font="Arial"> Smith,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pollen-monitoring: between analyst proficiency testing</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="199" start="191">191-199</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Asteraceae</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Proficiency testing</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Xanthium</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">This study presents the results of a Europe-wide training and Quality Control (QC) exercise carried out within the framework of the European Aerobiology Society</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs QC Working Group and European COST Action FA1203 entitled </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£sustainable management of Ambrosia artemisiifolia in Europe (SMARTER)</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ with the aim of ensuring that pollen counters in Europe are confident in the identification of Ambrosia pollen grains. A total of 69 analysts from 20 countries examined a test slide by light microscopy, which contained Ambrosia pollen and pollen from other Asteraceae that could be recorded in the atmosphere at the same time of year (i.e. Artemisia, Iva, and Xanthium). Daily average pollen concentrations produced by individual participants were compared with the assigned value and the bias was measured by z-score. Both the assigned value and standard deviation for proficiency testing were calculated following the consensus value principle (ISO13528:2005) from the results reported by all the participants in the test. It took a total of 531-ádays from when the exercise commenced until all 69 analysts reported their results. The most outliers were reported for Artemisia pollen concentrations followed by Xanthium and Iva. The poor results for Artemisia and Xanthium were probably caused by low concentrations on the test slide leading to larger bias due to the unequal distribution of pollen over the microscope slide. Participants performed the best in identifying and quantifying Ambrosia pollen. Performing inter-laboratory ring tests with the same sample is very time consuming and might not be appropriate for large-scale proficiency testing in aerobiology. Pollen with similar morphology should be included in the education process of aerobiologists</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Serbia -CO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9461-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9461-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161129-SikoparijaB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161129-SikoparijaB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Sikoparija B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9461-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sofiev,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">On impact of transport conditions on variability of the seasonal pollen index</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="179" start="167">167-179</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Habitation</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reproduction</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> SILAM</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">This discussion paper reveals the contribution of pollen transport conditions to the inter-annual variability of the seasonal pollen index (SPI). This contribution is quantified as a sensitivity of the pollen model predictions to meteorological variability and is shown to be a noticeable addition to the SPI variability caused by plant reproduction cycles. A specially designed SILAM model re-analysis of pollen seasons 1980</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2014 was performed, resulting in the 35-áyears of the SPI predictions over Europe, which was used to compute the SPI inter-annual variability. The current paper presents the results for birch and grass. Throughout the re-analysis, the source term formulations and habitation maps were kept constant, which allowed attributing the obtained variability exclusively to the pollen release and transport conditions during the flowering seasons. It is shown that the effect is substantial: it amounts to 10</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô20% (grass) and 20</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô40% (birch) of the observed SPI year-to-year changes reported in the literature. The phenomenon has well-pronounced spatial- and species-specific patterns. The findings were compared with observation-based statistical models for the SPI prediction, showing that such models highlight the same processes as the analysis with the SILAM model</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9459-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9459-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161129-SofievM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161129-SofievM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Sofiev M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9459-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sikoparija,B.</style></author><author><style face="normal" font="Arial"> Skjoth,C.A.</style></author><author><style face="normal" font="Arial"> Celenk,S.</style></author><author><style face="normal" font="Arial"> Testoni,C.</style></author><author><style face="normal" font="Arial"> Abramidze,T.</style></author><author><style face="normal" font="Arial"> Alm Kubler,K.</style></author><author><style face="normal" font="Arial"> Belmonte,J.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Bonini,M.</style></author><author><style face="normal" font="Arial"> Charalampopoulos,A.</style></author><author><style face="normal" font="Arial"> Damialis,A.</style></author><author><style face="normal" font="Arial"> Clot,B.</style></author><author><style face="normal" font="Arial"> Dahl,A.</style></author><author><style face="normal" font="Arial"> de Weger,L.A.</style></author><author><style face="normal" font="Arial"> Gehrig,R.</style></author><author><style face="normal" font="Arial"> Hendrickx,M.</style></author><author><style face="normal" font="Arial"> Hoebeke,L.</style></author><author><style face="normal" font="Arial"> Ianovici,N.</style></author><author><style face="normal" font="Arial"> Kofol Seliger,A.</style></author><author><style face="normal" font="Arial"> Magyar,D.</style></author><author><style face="normal" font="Arial"> Manyoki,G.</style></author><author><style face="normal" font="Arial"> Milkovska,S.</style></author><author><style face="normal" font="Arial"> Myszkowska,D.</style></author><author><style face="normal" font="Arial"> Paldy,A.</style></author><author><style face="normal" font="Arial"> Pashley,C.H.</style></author><author><style face="normal" font="Arial"> Rasmussen,K.</style></author><author><style face="normal" font="Arial"> Ritenberga,O.</style></author><author><style face="normal" font="Arial"> Rodinkova,V.</style></author><author><style face="normal" font="Arial"> Rybnicek,O.</style></author><author><style face="normal" font="Arial"> Shalaboda,V.</style></author><author><style face="normal" font="Arial"> Sauliene,I.</style></author><author><style face="normal" font="Arial"> Scevkova,J.</style></author><author><style face="normal" font="Arial"> Stjepanovic,B.</style></author><author><style face="normal" font="Arial"> Thibaudon,M.</style></author><author><style face="normal" font="Arial"> Verstraeten,C.</style></author><author><style face="normal" font="Arial"> Vokou,D.</style></author><author><style face="normal" font="Arial"> Yankova,R.</style></author><author><style face="normal" font="Arial"> Smith,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Spatial and temporal variations in airborne Ambrosia pollen in Europe</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="189" start="181">181-189</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">The European Commission Cooperation in Science and Technology (COST) Action FA1203 </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£SMARTER</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ aims to make recommendations for the sustainable management of Ambrosia across Europe and for monitoring its efficiency and cost-effectiveness. The goal of the present study is to provide a baseline for spatial and temporal variations in airborne Ambrosia pollen in Europe that can be used for the management and evaluation of this noxious plant. The study covers the full range of Ambrosia artemisiifolia L. distribution over Europe (39-¦N</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô60-¦N; 2-¦W</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô45-¦E). Airborne Ambrosia pollen data for the principal flowering period of Ambrosia (August</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôSeptember) recorded during a 10-year period (2004</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2013) were obtained from 242 monitoring sites. The mean sum of daily average airborne Ambrosia pollen and the number of days that Ambrosia pollen was recorded in the air were analysed. The mean and standard deviation (SD) were calculated regardless of the number of years included in the study period, while trends are based on those time series with 8 or more years of data. Trends were considered significant at p-á&lt;-á0.05. There were few significant trends in the magnitude and frequency of atmospheric Ambrosia pollen (only 8% for the mean sum of daily average Ambrosia pollen concentrations and 14% for the mean number of days Ambrosia pollen were recorded in the air). The direction of any trends varied locally and reflected changes in sources of the pollen, either in size or in distance from the monitoring station. Pollen monitoring is important for providing an early warning of the expansion of this invasive and noxious plant</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Serbia -CO - United KIngdom -CO - Turkey -CO - Italy -CO - Georgia -CO - Sweden -CO - Spain -CO - Austria -CO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9463-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9463-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161128-SikoparijaB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161128-SikoparijaB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Sikoparija B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9463-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Isik,S.</style></author><author><style face="normal" font="Arial"> Caglar,A.</style></author><author><style face="normal" font="Arial"> Eroglu-Filibeli,B.</style></author><author><style face="normal" font="Arial"> Caglayan-Sozmen,S.</style></author><author><style face="normal" font="Arial"> Ankan-Ayyildiz,Z.</style></author><author><style face="normal" font="Arial"> Asilsoy,S.</style></author><author><style face="normal" font="Arial"> Uzuner,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dokuz Eylul University, Department of Pediatric Allergy and Immunology.</style></auth-address><titles><title><style face="normal" font="Arial">Knowledge, perspectives and attitudes about allergen-specific immunotherapy for respiratory allergic disease among paediatricians in Turkey</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="197" start="193">193-197</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific immunotherapy (ASI) is the only effective treatment for allergic respiratory diseases which has the potential to change the natural course of the disease. In this present study we aimed to evaluate the paediatricians' knowledge, perspectives and attitudes about ASI for allergic respiratory diseases. MATERIALS AND METHODS: The study was conducted between September 2</style></abstract><notes><style face="normal" font="Arial">DA - 20161127IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27889335">PM:27889335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161127-IsikS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161127-IsikS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161127, Isik S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Polloni,L.</style></author><author><style face="normal" font="Arial"> DunnGalvin,A.</style></author><author><style face="normal" font="Arial"> Ferruzza,E.</style></author><author><style face="normal" font="Arial"> Bonaguro,R.</style></author><author><style face="normal" font="Arial"> Lazzarotto,F.</style></author><author><style face="normal" font="Arial"> Toniolo,A.</style></author><author><style face="normal" font="Arial"> Celegato,N.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Referral Centre for Diagnosis and Treatment, Veneto Region, Department of Women and Child Health, Padua University Hospital, Padua, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Coping strategies, alexithymia and anxiety in young patients with food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1060" start="1054">1054-1060</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emotions</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Subscale</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is major public health concern affecting nearly 15 million Americans and 80 million Europeans. Risk of anaphylaxis and implications for social activities affect patients' quality of life and psychological wellbeing. We previously found that young patients reported higher levels of alexithymia (difficulty in recognizing and expressing emotions) compared to healthy peers, and may influence affect, management style and clinical outcomes. This study aimed to explore links between coping strategies, alexithymia and anxiety among food-allergic adolescents and young adults. METHODS: 92 patients with IgE-mediated food allergy (Mean age 18.6 years) completed Coping Orientation to Problems Experienced Inventory, Toronto Alexithymia Scale and Trait Anxiety subscale of State-Trait Anxiety Inventory. Multivariate Analyses of Variance assessed differences and associations between subgroups on the scales. RESULTS: Significant differences found between alexithymia levels in coping style were explained by Avoidance strategies. "Avoidance" had the highest contribution in explaining alexithymia, followed by trait-anxiety, age, anaphylaxis, and social support. Respondents with higher alexithymia use avoidance as coping strategy over and above other coping strategies such as problem solving and positive thinking, are younger, will have experienced anaphylaxis, and will have lower social support. CONCLUSIONS: Recognizing the specific role of affect regulation in health behaviours may constitute an important step in supporting patients to explore more adaptive strategies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13097</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886387">PM:27886387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161125-PolloniL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161125-PolloniL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Polloni L</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13097</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stensgaard,A.</style></author><author><style face="normal" font="Arial"> DunnGalvin,A.</style></author><author><style face="normal" font="Arial"> Nielsen,D.</style></author><author><style face="normal" font="Arial"> Munch,M.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Odense Research Center for Anaphylaxis (ORCA), Department of Dermatology and Allergy Center, Odense University Hospital, Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Green, Yellow and Red risk perception in everyday life - a communication tool</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1122" start="1114">1114-1122</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> colour</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Fathers</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Adolescents have the highest risk for food allergy-related fatalities. Our main aim was to investigate the level of risk in everyday social situations as perceived by adolescents/young adults with peanut allergy, their families and their friends. METHODS: The web-based 'Colours Of Risks' (COR) questionnaire was completed by 70 patients (aged 12-23 years), 103 mothers and fathers, 31 siblings (aged 12-26 years), and 42 friends (aged 12-24 years). COR deals with six main contexts (home, school/university, work, visiting/social activities, special occasions/parties, and vacations), each with 1-12 items. Response categories are green (I feel safe), yellow (I feel uncertain), or red (I feel everything is risky). RESULTS: There was a high level of agreement between participants in defining situations as safe, uncertain, or risky, but female patients and mothers rated fewer situations as safe compared to male patients and fathers. Being with close friends and family, and attending planned parties without alcohol were perceived as situations of low risk. While 94% of patients took an epinephrine auto-injector (EAI) into risky situations, only 65% took it into safe situations. In contrast to the close family, 31% of the friends did not know the patient had an EAI, and fewer knew how to administer the EAI. CONCLUSION: Young adults with peanut allergy face challenges when moving from the safe home with ready assistance if needed, to independence with unpredictable surroundings and less certain help. Perceived 'safe' situations may in fact be the riskiest, as patients often do not take the EAI with them. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13095</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886390">PM:27886390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161125-StensgaardA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161125-StensgaardA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Stensgaard A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13095</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eder,K.</style></author><author><style face="normal" font="Arial"> Becker,S.</style></author><author><style face="normal" font="Arial"> San,Nicolo M.</style></author><author><style face="normal" font="Arial"> Berghaus,A.</style></author><author><style face="normal" font="Arial"> Groger,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Oto-Rhino-Laryngology, Head &amp; Neck Surgery, Ludwig-Maximilians-University, Marchioninistr. 15, 81377 Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Usefulness of component resolved analysis of cat allergy in routine clinical practice</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="58">58-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> cat allergy</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic testing</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cat allergy is of great importance, and its prevalence is increasing worldwide. Cat allergens and house dust mite allergens represent the major indoor allergens; however, they are ubiquitous. Cat sensitization and allergy are known risk factors for rhinitis, bronchial hyperreactivity and asthma. Thus, the diagnosis of sensitization to cats is important for any allergist. METHODS: 70 patients with positive skin prick tests for cats were retrospectively compared regarding their skin prick test results, as well as their specific immunoglobulin E antibody profiles with regard to their responses to the native cat extract, rFel d 1, nFel d 2 and rFel d 4. 35 patients were allergic to cats, as determined by positive anamnesis and/or nasal provocation with cat allergens, and 35 patients exhibited clinically non-relevant sensitization, as indicated by negative anamnesis and/or a negative nasal allergen challenge. RESULTS: Native cat extract serology testing detected 100% of patients who were allergic to cats but missed eight patients who showed sensitization in the skin prick test and did not have allergic symptoms. The median values of the skin prick test, as well as those of the specific immunoglobulin E antibodies against the native cat extract, were significantly higher for allergic patients than for patients with clinically non-relevant sensitization. Component based diagnostic testing to rFel d 1 was not as reliable. Sensitization to nFel d 2 and rFel d 4 was seen only in individual patients. CONCLUSION: Extract based diagnostic methods for identifying cat allergy and sensitization, such as the skin prick test and native cat extract serology, remain crucial in routine clinical practice. In our study, component based diagnostic testing could not replace these methods with regard to the detection of sensitization to cats and differentiation between allergy and sensitization without clinical relevance. However, component resolved allergy diagnostic tools have individual implications, and future studies may facilitate a better understanding of its use and subsequently may improve the clinical management of allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0163-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27891156">PM:27891156</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-58.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Eder K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0163-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stroo,I.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author><author><style face="normal" font="Arial"> de Boer,J.D.</style></author><author><style face="normal" font="Arial"> Roelofs,J.J.</style></author><author><style face="normal" font="Arial"> van't Veer,C.</style></author><author><style face="normal" font="Arial"> Castellino,F.J.</style></author><author><style face="normal" font="Arial"> Zeerleder,S.</style></author><author><style face="normal" font="Arial"> van der Poll,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">i.stroo@amc.uva.nl i.stroo@amc.uva.nl</style></auth-address><titles><title><style face="normal" font="Arial">Factor XI deficiency enhances the pulmonary allergic response to house dust mite in mice independent of factor XII</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L171" start="L163">L163-L171</pages><volume><style face="normal" font="Arial">312</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> factor XII</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Thrombin</style></keyword><keyword><style face="normal" font="Arial"> Tissue Factor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is associated with activation of coagulation in the airways. The coagulation system can be initiated via the extrinsic tissue factor dependent pathway or via the intrinsic pathway, in which the central player factor XI (FXI) can be either activated via active factor XII (FXIIa) or via thrombin. We aimed to determine the role of the intrinsic coagulation system, and its possible route of activation, in allergic lung inflammation induced by the clinically relevant human allergen house dust mite (HDM). Wild-type (WT), FXI knockout (KO) and FXII KO mice were subjected to repeated exposure to HDM via the airways, and inflammatory responses were compared. FXI KO mice showed increased influx of eosinophils into lung tissue, accompanied by elevated local levels of the main eosinophil chemoattractant eotaxin. While gross lung pathology and airway mucus production did not differ between groups, FXI KO mice displayed an impaired endothelial/epithelial barrier function, as reflected by elevated levels of total protein and IgM in bronchoalveolar lavage fluid. FXI KO mice had a stronger systemic IgE response with an almost completely absent HDM-specific IgG1 response. The phenotype of FXII KO mice was, except for a higher HDM-specific IgG1 response, similar to that of WT mice. In conclusion, FXI attenuates part of the allergic response to repeated administration of HDM in the airways by a mechanism that is independent of activation via FXII</style></abstract><notes><style face="normal" font="Arial">DA - 20161203IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00320.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27913422">PM:27913422</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20161203-StrooI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20161203-StrooI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161203, Stroo I</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00320.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jacobsen,E.A.</style></author><author><style face="normal" font="Arial"> Ochkur,S.I.</style></author><author><style face="normal" font="Arial"> Doyle,A.D.</style></author><author><style face="normal" font="Arial"> Lesuer,W.E.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Protheroe,C.A.</style></author><author><style face="normal" font="Arial"> Colbert,D.</style></author><author><style face="normal" font="Arial"> Zellner,K.R.</style></author><author><style face="normal" font="Arial"> Shen,H.H.</style></author><author><style face="normal" font="Arial"> Irvin,C.G.</style></author><author><style face="normal" font="Arial"> Lee,J.J.</style></author><author><style face="normal" font="Arial"> Lee,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mayo Clinic, Department of Biochemistry and Molecular Biology, Scottsdale, Arizona, United States</style></auth-address><titles><title><style face="normal" font="Arial">Lung Pathologies in a Chronic Inflammation Mouse Model are Independent of Eosinophil Degranulation</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="1332" start="1321">1321-1332</pages><volume><style face="normal" font="Arial">195</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Granule Proteins</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-2</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">RATIONALE: The release of eosinophil granule proteins in the lungs of asthma patients has been dogmatically linked with lung remodeling and airway hyperresponsiveness (AHR). However, the demonstrated inability of established mouse models to display the eosinophil degranulation occurring in human subjects has prevented a definitive in vivo test of this hypothesis. OBJECTIVES: To demonstrate in vivo causative links between induced pulmonary histopathologies/lung dysfunction and eosinophil degranulation. METHODS: A transgenic mouse model of chronic Th2 driven inflammation overexpressing IL-5 from T cells and human eotaxin 2 in the lung (I5/hE2) was used to test the hypothesis that chronic histopathologies and the development of AHR occur as a consequence of extensive eosinophil degranulation in the lung parenchyma. MEASUREMENT AND MAIN RESULTS: Studies targeting specific inflammatory pathways in I5/hE2 mice surprisingly showed that eosinophil-dependent immunoregulative events and not the release of individual secondary granule proteins are the central contributors to Th2-induced pulmonary remodeling and lung dysfunction. Specifically, our studies highlighted a significant role for eosinophil-dependent IL-13 expression. In contrast, extensive degranulation leading to the release of MBP-1 or EPX was not causatively linked to many of the induced pulmonary histopathologies. However, these studies did define a previously unappreciated link between the release of EPX (but not MBP-1) and observed levels of induced airway mucin. CONCLUSIONS: These data suggest that improvements observed in asthma patients responding to therapeutic strategies ablating eosinophils may occur as a consequence of targeting immunoregulatory mechanisms and not by simply eliminating the destructive activities of these purportedly end-stage effector cells</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201603-0446OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27922744">PM:27922744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-1321-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-1321-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Jacobsen EA</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201603-0446OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pourang,D.</style></author><author><style face="normal" font="Arial"> Batech,M.</style></author><author><style face="normal" font="Arial"> Sheikh,J.</style></author><author><style face="normal" font="Arial"> Samant,S.</style></author><author><style face="normal" font="Arial"> Kaplan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis in a health maintenance organization: International Classification of Diseases coding and epinephrine auto-injector prescribing</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="190" start="186">186-190</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Accurate estimates of the incidence of anaphylaxis are limited. Current International Classification of Diseases, Ninth Revision (ICD-9) codes complicate accurate diagnosis of anaphylaxis and assessment of appropriate epinephrine prescribing. OBJECTIVE: To quantify the incidence and demographic character of patients with anaphylaxis-related ICD-9 codes in a large health maintenance organization and analyze epinephrine prescribing and dispensing rates. METHODS: All patients included had at least 12 months of continuous membership over a 4-year period from January 1, 2008 to December 31, 2012 and were selected based on anaphylaxis-related ICD-9 codes (N = 159,172). This algorithm was extrapolated from a previous study that used expanded ICD-9 codes to identify more cases of anaphylaxis. Individual chart reviews found that many expanded ICD-9 codes represented unconfirmed cases of anaphylaxis and therefore were excluded, resulting in analysis of 52,405 patients. RESULTS: Incidence of anaphylaxis over 4 years was 2.07%, with female predominance (56.5%) over male predominance (43.5%). Epinephrine was prescribed in 16.2% of total cases. Highest rates of epinephrine prescription were for traditional ICD-9 codes 995.0 (other anaphylactic shock) and 995.60 to 995.69 (anaphylactic shock caused by food) at 49.3% and 58.6%, respectively. Of the cases in which an epinephrine auto-injector was prescribed, it was dispensed 95.9% of the time, independent of copayment amount. CONCLUSION: Low epinephrine auto-injector prescribing rates in cases of anaphylaxis suggest the continued difficulty in the diagnosis of anaphylaxis and could result in suboptimal treatment of potential future episodes</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - California -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27890557">PM:27890557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161128-PourangD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161128-PourangD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Pourang D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saco,T.V.</style></author><author><style face="normal" font="Arial"> Glaum,M.C.</style></author><author><style face="normal" font="Arial"> Ledford,D.K.</style></author><author><style face="normal" font="Arial"> Lockey,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of South Florida Morsani College of Medicine, James A. Haley Veterans Hospital, Tampa, Florida.</style></auth-address><titles><title><style face="normal" font="Arial">Onset of psoriatic arthritis associated with multiple wasp stings</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="228" start="227">227-228</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Florida -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27881293">PM:27881293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161124-SacoTV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161124-SacoTV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Saco TV</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shakoor,Z.</style></author><author><style face="normal" font="Arial"> AlFaifi,A.</style></author><author><style face="normal" font="Arial"> AlAmro,B.</style></author><author><style face="normal" font="Arial"> AlTawil,L.N.</style></author><author><style face="normal" font="Arial"> AlOhaly,R.Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Prevalence of IgG-mediated food intolerance among patients with allergic symptoms</style></title><secondary-title><style face="normal" font="Arial">Ann Saudi Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Saudi Med</style></full-title></periodical><pages end="390" start="386">386-390</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Barley</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food intolerance</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Kidney bean</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pea</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Red kidney bean</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food intolerance mediated by food specific IgG antibodies has been implicated in a variety of disorders. OBJECTIVES: To assess the prevalence of food specific IgG antibodies among patients clinically presenting with allergic symptoms lacking laboratory evidence of allergy. DESIGN: Descriptive retrospective cross-sectional study. SETTING: King Khalid University Hospital, Riyadh between 2010-2015. PATIENTS AND METHODS: Patients were screened for food specific IgG antibodies. All symptomatic patients lacking laboratory evidence of allergy who underwent food specific IgG testing during the study duration were included. MAIN OUTCOME MEASURE(S): Levels of IgG antibodies in patients with unidentified allergic symptoms. RESULTS: We selected 71 patients with allergic symptoms lacking laboratory evidence of allergy. There were 49 female and 22 male patients mean age 38.8 (16.0) years. The majority (85.7%) had urticaria. The most frequently occurring food specific IgG antibodies were against cola nut in 80.3% of patients followed by yeast in 78.9%, wheat in 77.5%, red kidney bean in 71.8%, pea in 63.4%, corn in 62% and egg white in 62% of the patients. Compared with male patients, females harbored significantly higher food specific IgG antibodies for frequently occurring food materials, particularly against wheat (74% vs 25.5%; P &lt; .0001), corn (77.3% vs 22.7%; P &lt; .0001) and cola nut (71.9% vs 28.1%; P &lt; .001). Patients aged less than 40 years had higher levels of food specific IgG against gliadin (P &lt; .003), egg white (P &lt; .03) and barley (P &lt; .05) compared with older patients. CONCLUSION: The detection of a variety of food specific IgG antibodies among patients with allergic symptoms indicates a possible link to food intolerance allergy. Females are prone to develop food intolerance more than males. LIMITATIONS: Difficulty of comparison of results with previous studies because of lack of data. Follow-up studies could not be performed to assess the effects of elimination from the diet due to limited time allocated for this study</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 0975-4466 (Electronic)IS - 0256-4947 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial"> 10.5144/0256-4947.2016.386</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27920409">PM:27920409</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Saudi Med\2016-36-386-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Saudi Med\2016-36-386-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Shakoor Z</style></custom2><misc3><style face="normal" font="Arial"> 10.5144/0256-4947.2016.386</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mizushima,I.</style></author><author><style face="normal" font="Arial"> Yamamoto,M.</style></author><author><style face="normal" font="Arial"> Inoue,D.</style></author><author><style face="normal" font="Arial"> Nishi,S.</style></author><author><style face="normal" font="Arial"> Taniguchi,Y.</style></author><author><style face="normal" font="Arial"> Ubara,Y.</style></author><author><style face="normal" font="Arial"> Matsui,S.</style></author><author><style face="normal" font="Arial"> Yasuno,T.</style></author><author><style face="normal" font="Arial"> Nakashima,H.</style></author><author><style face="normal" font="Arial"> Takahashi,H.</style></author><author><style face="normal" font="Arial"> Yamada,K.</style></author><author><style face="normal" font="Arial"> Nomura,H.</style></author><author><style face="normal" font="Arial"> Yamagishi,M.</style></author><author><style face="normal" font="Arial"> Saito,T.</style></author><author><style face="normal" font="Arial"> Kawano,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Takara-machi 13-1, Kanazawa, Ishikawa, 920-8640, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study</style></title><secondary-title><style face="normal" font="Arial">Arthritis Res Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arthritis Res Ther</style></full-title></periodical><pages end="" start="273">273-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Atrophy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> EGFR</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Filtration</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="25" Month="11" Year="2016">2016/11/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In immunoglobulin G4-related kidney disease (IgG4-RKD), focal or diffuse renal cortical atrophy is often observed in the clinical course after glucocorticoid therapy. This study aimed to clarify the factors related to renal atrophy after glucocorticoid therapy in IgG4-RKD. METHODS: We retrospectively evaluated clinical features including laboratory data and computed tomography (CT) findings before and after glucocorticoid therapy in 23 patients diagnosed with IgG4-RKD, all of whom were followed up for more than 24 months. RESULTS: Seventeen patients were men, and six were women (average age 62.0 years). Average follow-up period was 54.9 months. The average estimated glomerular filtration rate (eGFR) at diagnosis was 81.7 mL/min/1.73 m2. All patients had had multiple low-density lesions on contrast-enhanced CT before glucocorticoid therapy, and showed disappearance or reduction of these lesions after it. Pre-treatment eGFR and serum IgE level in 11 patients in whom renal cortical atrophy developed 24 months after the start of glucocorticoid therapy were significantly different from those in 12 patients in whom no obvious atrophy was found at that time (68.9 +/- 30.1 vs 93.5 +/- 14.1 mL/min/1.73 m2, P = 0.036, and 587 +/- 254 vs 284 +/- 263 IU/mL, P = 0.008, respectively). Pre-treatment eGFR and serum IgE level were also significant risk factors for renal atrophy development 24 months after the start of therapy with an odds ratio of 0.520 (per 10 mL/min/1.73 m2, 95% confidence interval (CI) 0.273-0.993, P = 0.048) and 1.090 (per 10 IU/mL, 95% CI: 1.013-1.174, P = 0.022), respectively, in age-adjusted, sex-adjusted, serum IgG4 level-adjusted logistic regression analysis. Receiver operating characteristic curve analysis showed that eGFR of less than 71.0 mL/min/1.73 m2 and serum IgE of more than 436.5 IU/mL were the most appropriate cutoffs and yielded sensitivity of 63.6% and specificity of 100%, and sensitivity of 90.9% and specificity of 75.0%, respectively, in predicting renal atrophy development. CONCLUSIONS: This study suggests that pre-treatment renal insufficiency and serum IgE elevation predict renal atrophy development after glucocorticoid therapy in IgG4-RKD</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1478-6362 (Electronic)IS - 1478-6354 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13075-016-1175-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27884179">PM:27884179</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arthritis Res Ther\2016-18-273.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arthritis Res Ther\2016-18-273.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Mizushima I</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13075-016-1175-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lefevre,G.</style></author><author><style face="normal" font="Arial"> Ackermann,F.</style></author><author><style face="normal" font="Arial"> Kahn,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">French Eosinophil Network; CHU Lille, Institut d'Immunologie, Unite d'Immunologie Clinique, F-59000, Lille, France</style></auth-address><titles><title><style face="normal" font="Arial">Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome?</style></title><secondary-title><style face="normal" font="Arial">Autoimmun Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Autoimmun Rev</style></full-title></periodical><pages end="209" start="208">208-209</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinique</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 1873-0183 (Electronic)IS - 1568-9972 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.autrev.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27915050">PM:27915050</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Autoimmun Rev\20161204-LefevreG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Autoimmun Rev\20161204-LefevreG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Lefevre G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.autrev.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahmadi,M.</style></author><author><style face="normal" font="Arial"> Rahbarghazi,R.</style></author><author><style face="normal" font="Arial"> Aslani,M.R.</style></author><author><style face="normal" font="Arial"> Shahbazfar,A.A.</style></author><author><style face="normal" font="Arial"> Kazemi,M.</style></author><author><style face="normal" font="Arial"> Keyhanmanesh,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Bone marrow mesenchymal stem cells and their conditioned media could potentially ameliorate ovalbumin-induced asthmatic changes</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="40" start="28">28-40</pages><volume><style face="normal" font="Arial">85</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> PCR analysis</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white blood cell</style></keyword></keywords><dates><year Day="5" Month="12" Year="2016">2016/12/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The major feature of asthma is governed by chronic airway inflammation. This investigation was proposed to achieve the suitable candidate for ameliorating long-term chronic asthmatic changes of respiratory tract. METHODS: 36 rats were classified into healthy (C) and ovalbumin (OVA)-sensitized animals (S). To sensitize, the rats were exposed to OVA over a course of 32+/-1days. One day after sensitization, equal six different groups were subjected to experimental procedure (n=6); Rats only received intratracheally 50ml PBS (CPT and SPT groups), 50mul conditioned medium (CM) (CST and SST groups) and 50mul PBS containing 2x106 rat bone marrow-derived mesenchymal stem cells (rBMMSCs) (CCT and SCT groups). Two weeks after treatment, tracheal responsiveness, immunologic responses and recruitment of rBMMSCs into the lung as well as pathological changes were evaluated. RESULTS: A high degree of tracheal responsiveness, total white blood cell and percentages of eosinophil and neutrophil was significantly recorded in all sensitized groups rather than of controls (p&lt;0.001 to p&lt;0.05). Of interest, all above-mentioned parameters decreased significantly in SST and notably SCT groups as compared to S group (p&lt;0.001 to p&lt;0.05). The results revealed decrease number of blood CD3+CD4+ and concurrent increase in CD3+CD8+ in all sensitized rats as compared to control (p&lt;0.001 to p&lt;0.05). Noticeably, no significant modulatory effects of either cell or CM administration were achieved on the CD3+CD4+ and CD3+CD8+ populations in non-asthmatic rats. Moreover, the number of CD3+CD4+ in SST and SCT groups tended to increase, which coincided with a decreased manner of CD3+CD8+ populations as compared with S group (p&lt;0.001 to p&lt;0.05). However, the CD3+CD4+ cells in SCT rats were significantly higher than the group SST (p&lt;0.01) whereas CD3+CD8+ cells diminished simultaneously (p&lt;0.001). Real-time PCR analysis further showed that both CM and particularly MSCs changed the expression of interleukin (IL)-4 and IL-10 in the asthmatic groups to the near level of control rats (p&lt;0.001 to p&lt;0.05). Histopathological analysis revealed a profound reduction of lungs injuries in asthmatic rats when received CM and peculiarly mesenchymal stem cells (p&lt;0.01 to p&lt;0.05). CONCLUSION: Our study shed light on the superior effects of rBMMSCs, rather than CM, in attenuating of chronic asthmatic changes in the rat model</style></abstract><notes><style face="normal" font="Arial">DA - 20161208IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2016.11.127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27930984">PM:27930984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2016-85-28-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2016-85-28-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161208, Ahmadi M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2016.11.127</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kersting,C.</style></author><author><style face="normal" font="Arial"> Weltermann,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for General Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. Institute for General Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Electronic reminders to facilitate longitudinal care: a mixed-methods study in general practices</style></title><secondary-title><style face="normal" font="Arial">BMC Med Inform Decis Mak</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Med Inform Decis Mak</style></full-title></periodical><pages end="" start="148">148-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> General practice</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patient-Centered Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> senior</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> traffic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="11" Year="2016">2016/11/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Longitudinal, patient-centered care represents a challenge for general practitioners (GPs), and in this context, reminder systems can offer targeted support. This study aimed to identify details of such reminders: (1) contents of care addressed, (2) their mode of display in the electronic health record (EHR), (3) their visual appearance, (4) personnel responsibilities for editing and applying reminders, and (5) use of reminders for patient recall. METHODS: This mixed-methods study comprised (1) a cross-sectional survey among 185 GP practices from a German university network, and (2) structured observations of reminder utilization in six practices based on a clinical vignette describing a multimorbid senior with 26 care needs. Descriptive statistics were performed for survey data. The practice observations were analyzed by portraying different types of reminders. RESULTS: Seventy-three of 185 practices completed the survey (39.5%): 98.6% reported using reminders in the EHR. Frequent care contents addressed were allergies/adverse drug events (95.8%), preventive measures (93.1%), participation in disease management programs (87.5%), chronic diseases (75.0%), and upcoming vaccinations (68.1%). Practice observations showed a variety of mainly self-configured reminders. In a patients' EHR, information was displayed (1) compiled in a separate field, (2) scattered throughout the EHR, and/or (3) in a pop-up window. The visual appearance of electronic reminders varied: (1) colored fields with short text, (2) EHR entries and/or billing codes in pre-defined colors, (3) abbreviations within the treatment documentation, (4) symbols within the treatment documentation, (5) symbols linked to free text fields, and (6) traffic light schemes. Five practices self-designed reminders 'as needed'; one practice applied an EHR-embedded, pre-defined reminder system. Practices used reminders for a mean of 13.3 of the 26 aspects of care detailed in the clinical vignette (range: 9-21; standard deviation (SD): 4.3). Practices needed 20-35 min (mean: 27.5; SD: 6.1) to retrieve the information requested. CONCLUSIONS: Most GP practices use self-designed, visual reminders for some aspects of care, yet data-based, sophisticated solutions are needed to improve longitudinal care. TRIAL REGISTRATION: German Clinical Trials Register, unique identifying number: DRKS00008777 (date of registration: 06/19/2015)</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1472-6947 (Electronic)IS - 1472-6947 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12911-016-0387-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27881130">PM:27881130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Med Inform Decis Mak\2016-16-148.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Med Inform Decis Mak\2016-16-148.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Kersting C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12911-016-0387-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venkateshaiah,S.U.</style></author><author><style face="normal" font="Arial"> Manohar,M.</style></author><author><style face="normal" font="Arial"> Verma,A.K.</style></author><author><style face="normal" font="Arial"> Blecker,U.</style></author><author><style face="normal" font="Arial"> Mishra,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Tulane Eosinophilic Disorders Center (TEDC), Section of Pulmonary Diseases, New Orleans, LA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Possible Noninvasive Biomarker of Eosinophilic Esophagitis: Clinical and Experimental Evidence</style></title><secondary-title><style face="normal" font="Arial">Case Rep Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Rep Gastroenterol</style></full-title></periodical><pages end="692" start="685">685-692</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic disorders</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) diagnosis and follow-up response to therapy is based on repeated endoscopies and histological examination for eosinophils/HPF. The procedure is invasive and risky in particular for the pediatric population. Presently, there is no highly sensitive and specific noninvasive blood test available to monitor the disease pathogenesis. Reports indicate the expression of PDL1 (CD274) on the eosinophils in allergic patients. Herein, we report that CD274-expressing and -nonexpressing eosinophils were detected in both examined pediatric and adult EoE patients. We show that CD274 expression on blood eosinophils and blood mRNA expression levels increase in the blood of EoE patients and decrease following treatment. These observations are consistent with the esophageal eosinophilia of before and after treatment in both examined patients. These two clinical and experimental analysis reports provide the possibility that the CD274 mRNA and CD274-expressing esinophil levels may be novel possible noninvasive biomarkers for EoE</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 1662-0631 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000452654</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27920662">PM:27920662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Gastroenterol\2016-10-685-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Gastroenterol\2016-10-685-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Venkateshaiah SU</style></custom2><misc3><style face="normal" font="Arial">10.1159/000452654</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,R.</style></author><author><style face="normal" font="Arial"> Dong,H.</style></author><author><style face="normal" font="Arial"> Zhao,H.</style></author><author><style face="normal" font="Arial"> Zhou,L.</style></author><author><style face="normal" font="Arial"> Zou,F.</style></author><author><style face="normal" font="Arial"> Cai,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China</style></auth-address><titles><title><style face="normal" font="Arial">1,25-Dihydroxyvitamin D3 targeting VEGF pathway alleviates house dust mite (HDM)-induced airway epithelial barrier dysfunction</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="24" start="15">15-24</pages><volume><style face="normal" font="Arial">312</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> beta Catenin</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> E-cadherin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> TEER</style></keyword><keyword><style face="normal" font="Arial"> toluene</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In our previous studies, we have indentified that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) can alleviate toluene diisocyanate-induced airway epithelial barrier disruption and we also found that vascular endothelial growth factor (VEGF) derived from airway epithelials cells could disrupt epithelial barrier. OBJECTIVE: The study aimed to investigate whether 1,25(OH)2D3 can inhibit house dust mite (HDM) induced airway epithelial barrier dysfunction by regulating the VEGF pathway. METHOD: The 16HBE and BEAS-2B cells were cultured and treated according to the experiment requirement. Trans Epithelial Electric Resistance (TEER), permeability of epithelial layer, and distribution and expression of junction proteins were used to evaluate the cell layer barrier function, Western Blot was used to evaluate the expression of junction proteins and phosphorylated Akt in the cells, RT-PCR and ELISA were used to evaluate the VEGF gene expression and protein release in the cells. Recombinant VEGF165 was used to determine the role of the VEGF pathway in the epithelial barrier function. RESULTS: HDM resulted in a decline in TEER and increase of cell permeability, following abnormal distribution and expression of junction proteins (E-Cadherin and zona occludens (ZO)-1), accompanied by a significant upregulation of VEGF and phosphorylated Akt, which were all partly recovered by treatment with either 1,25(OH)2D3 or PI3K inhibitor LY294002. VEGF165-induced barrier dysfunction was accompanied by disruption of the epithelial E-cadherin and beta-catenin, pretreatment of 1,25(OH)2D3 and LY294002 markedly attenuated VEGF-induced airway barrier disruption in 16HBE cells. CONCLUSION: 1,25(OH)2D3 can alleviate HDM-induced airway epithelial barrier dysfunction by inhibiting PI3K pathway-dependent VEGF release</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1090-2163 (Electronic)IS - 0008-8749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27884393">PM:27884393</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20161125-ZhangR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20161125-ZhangR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Zhang R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2016.11.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fan,D.C.</style></author><author><style face="normal" font="Arial"> Wang,X.D.</style></author><author><style face="normal" font="Arial"> Wang,C.S.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Cao,F.F.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology Head and Neck Surgery; Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730</style></auth-address><titles><title><style face="normal" font="Arial">Suppression of Immunotherapy on Group 2 Innate Lymphoid Cells in Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Chin Med J (Engl)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chin Med J (Engl)</style></full-title></periodical><pages end="2828" start="2824">2824-2828</pages><volume><style face="normal" font="Arial">129</style></volume><number><style face="normal" font="Arial">23</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin-prick testing</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Group 2 innate lymphoid cells (ILC2s) are regarded as a novel population of lineage-negative cells that induce innate Type 2 responses by producing the critical Th2-type cytokines interleukin (IL)-5 and IL-13. ILC2s as key players in the development of allergic rhinitis (AR) have been proved, however, the effect of subcutaneous immunotherapy (SCIT) with dermatophagoides pteronyssinus extract (Der p-SCIT) on ILC2s in AR patients is not clear. This study aimed to investigate the response of ILC2s of peripheral blood in house dust mites (HDM)-sensitized Chinese patients with AR who received SCIT with Der P extract. METHODS: Seven healthy controls without symptoms of AR who had negative reactions to any of the allergens from skin-prick testing, nine patients diagnosed with persistent AR according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, and 24 AR patients who received Der p-SCIT for 1.0-3.5 years were recruited for the study. ILC2s in the peripheral blood were evaluated using flow cytometry. The severity of their symptoms of all participants was rated based on the Total 5 symptom score. RESULTS: Among 40 participants, 9 AR patients were assigned to the untreated group, 24 AR patients receiving Der p-SCIT were assigned to the immunotherapy group, and 7 healthy controls without symptoms of AR were assigned to healthy control group. The mean Total 5 symptom score of immunotherapy group was significantly lower than that of untreated group (4.3 +/- 1.4 vs. 10.1 +/- 2.5, P&lt; 0.001). Similarly, the levels of ILC2s in the peripheral blood of immunotherapy group were significantly reduced compared with that in untreated group (P &lt; 0.001), but were not significantly different from healthy controls (P = 0.775). Further subgroup analysis based on the duration of SCIT therapy (1.0-2.0 years [SCIT1-2], 2.0-3.0 years [SCIT2-3], and 3.0-3.5 years [SCIT3-3.5]) showed that the percentage of ILC2s was not significantly different between SCIT1-2, SCIT2-3, and SCIT3-3.5groups (SCIT1-2 vs. SCIT2-3: P = 0.268; SCIT1-2vs. SCIT3-3.5: P = 0.635; and SCIT2-3 vs. SCIT3-3.5: P = 0.787). CONCLUSIONS: The present study highlighted the suppression of Der p-SCIT on ILC2s in HDM-AR patients. ILC2s identified in peripheral blood can be used as an effective biomarker for Der p-SCIT</style></abstract><notes><style face="normal" font="Arial">DA - 20161130IS - 0366-6999 (Print)IS - 0366-6999 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.4103/0366-6999.194642</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27900996">PM:27900996</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin Med J (Engl)\2016-129-2824-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin Med J (Engl)\2016-129-2824-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161130, Fan DC</style></custom2><misc3><style face="normal" font="Arial">10.4103/0366-6999.194642</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,L.S.</style></author><author><style face="normal" font="Arial"> Guan,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Peking Union Medical College Hospital, Beijing 100730, ChinaDepartment of Allergy, Peking Union Medical College Hospital, Beijing 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">Occupational Asthma Caused by Inhalable Royal Jelly and Its Cross-reactivity with Honeybee Venom</style></title><secondary-title><style face="normal" font="Arial">Chin Med J (Engl)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chin Med J (Engl)</style></full-title></periodical><pages end="2889" start="2888">2888-2889</pages><volume><style face="normal" font="Arial">129</style></volume><number><style face="normal" font="Arial">23</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Honeybee venom</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> royal jelly</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161130IS - 0366-6999 (Print)IS - 0366-6999 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.4103/0366-6999.194650</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27901009">PM:27901009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin Med J (Engl)\2016-129-2888-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin Med J (Engl)\2016-129-2888-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161130, Li LS</style></custom2><misc3><style face="normal" font="Arial">10.4103/0366-6999.194650</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kasahara,D.I.</style></author><author><style face="normal" font="Arial"> Mathews,J.A.</style></author><author><style face="normal" font="Arial"> Ninin,F.M.</style></author><author><style face="normal" font="Arial"> Wurmbrand,A.P.</style></author><author><style face="normal" font="Arial"> Liao,J.K.</style></author><author><style face="normal" font="Arial"> Shore,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Physiology Program, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, 02115-6021</style></auth-address><titles><title><style face="normal" font="Arial">Role of ROCK2 in CD4+ cells in allergic airways responses in mice</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="235" start="224">224-235</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="Arial"> lymphocyte proliferation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Rho kinases (ROCKs) contribute to allergic airways disease. ROCKs also play a role in lymphocyte proliferation and migration. OBJECTIVE: To determine the role of ROCK2 acting within CD4+ cells in allergic airways responses. METHODS: ROCK2 haploinsufficient (ROCK2+/- ) and wildtype mice were sensitized with ovalbumin (OVA). ROCK2+/- mice then received either CD4+ cells from ROCK2 sufficient OVA TCR transgenic (OT-II) mice or saline i.v. 48 hours before challenge with aerosolized OVA. Wildtype mice received saline before challenge. Allergic airway responses were measured 48 hours after the last challenge. Allergic airways responses were also assessed in mice lacking ROCK2 only in CD4+ cells (ROCK2CD4Cre mice) versus control (CD4-Cre and ROCK2flox/flox ) mice. RESULTS: OVA-induced increases in bronchoalveolar lavage lymphocytes, eosinophils, IL-13, IL-5, and eotaxin were reduced in ROCK2+/- versus wildtype mice, as were airway hyperresponsiveness and mucous hypersecretion. In ROCK2+/- mice, adoptive transfer with CD4+ cells from OT-II mice restored effects of OVA on lymphocytes, eosinophils, IL-13, IL-5, and mucous hypersecretion to wildtype levels, whereas eotaxin and airway hyperrresponsiveness were not affected. ROCK2 inhibitors reduced IL-13-induced release of eotaxin from airway smooth muscle (ASM), similar to effects of these inhibitors on ASM contractility. Despite the ability of adoptive transfer to restore allergic airways inflammation in ROCK2 insufficient mice, allergic inflammation was not different in ROCK2CD4Cre versus control mice. CONCLUSION: ROCK2 contributes to allergic airways responses likely via effects within ASM cells and within non lymphocyte cells involved in lymphocyte activation and migration into the airways. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12866</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886408">PM:27886408</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161125-KasaharaDI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161125-KasaharaDI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Kasahara DI</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12866</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jun,S.H.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Kim,S.I.</style></author><author><style face="normal" font="Arial"> Choi,C.W.</style></author><author><style face="normal" font="Arial"> Park,T.I.</style></author><author><style face="normal" font="Arial"> Jung,H.R.</style></author><author><style face="normal" font="Arial"> Cho,J.W.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Lee,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Kyungpook National University School of Medicine, Daegu, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus-derived membrane vesicles exacerbate skin inflammation in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="96" start="85">85-96</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-8</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> small interfering RNA</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal Protein A</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 2</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Skin colonization or infection with Staphylococcus aureus is known to trigger aggravation of atopic dermatitis (AD). However, the exact mechanisms by which S. aureus can worsen AD are unknown. OBJECTIVE: We investigated whether and how S. aureus-derived membrane vesicles (MVs) contribute to worsening of AD. METHODS: Immunohistochemical and immunoelectron microscopic analyses were performed to detect staphylococcal protein A (SPA) in the epidermis of AD lesions. HaCaT cells were treated with S. aureus MVs and were analysed for the expression of cytokine genes. Immunopathology and cytokine gene profiles were analysed after topical application of S. aureus MVs to AD-like skin lesions in a mouse model. RESULTS: The MV component SPA was detected in the keratinocytes as well as in the intercellular space of the epidermis of AD lesions colonized with S. aureus. Intact MVs from S. aureus delivered their components to keratinocytes and stimulated pro-inflammatory cytokine gene expression in vitro. A knock-down of Toll-like receptor 2 or nucleotide-binding oligomerization domain 2 using small interfering RNAs suppressed interleukin-8 gene expression. Topical application of intact S. aureus MVs to AD-like skin lesions in the mouse model induced massive infiltration of inflammatory cells and the resulting eczematous dermatitis. This inflammatory reaction was associated with a mixed Th1/Th2 immune response and enhanced expression of chemokine genes in AD-like skin lesions. CONCLUSIONS AND CLINICAL RELEVANCE: This study showed the importance of S. aureus MVs as a potent mediator for worsening of AD among many exogenous worsening factors of AD. Thus, S. aureus MVs may be regarded as one of the therapeutic targets for the management of AD aggravation</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12851</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27910159">PM:27910159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161202-JunSH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161202-JunSH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Jun SH</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12851</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brandstrom,J.</style></author><author><style face="normal" font="Arial"> Vetander,M.</style></author><author><style face="normal" font="Arial"> Lilja,G.</style></author><author><style face="normal" font="Arial"> Johansson,S.G.</style></author><author><style face="normal" font="Arial"> Sundqvist,A.C.</style></author><author><style face="normal" font="Arial"> Kalm,F.</style></author><author><style face="normal" font="Arial"> Nilsson,C.</style></author><author><style face="normal" font="Arial"> Nopp,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Individually dosed omalizumab: an effective treatment for severe peanut allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="550" start="540">540-550</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Treatment with omalizumab has shown a positive effect on food allergies, but no dosages are established. Basophil allergen threshold sensitivity (CD-sens) can be used to objectively measure omalizumab treatment efficacy and correlates with the outcome of Double Blind Placebo Controlled Food Challenge to peanut. OBJECTIVE: To evaluate if individualized omalizumab treatment monitored by CD-sens could be an effective intervention for suppression of allergic reactions to peanut. METHODS: Severely peanut allergic adolescents (n=23) were treated with omalizumab for 8 weeks and CD-sens was analysed before and after. Based on whether CD-sens was suppressed after 8 weeks, the patients either were subject to a peanut challenge or received 8 more weeks with increased dose of omalizumab, followed by peanut challenge or another 8-week cycle of omalizumab. IgE and IgE-antibodies to peanut and its components were analysed before treatment. RESULTS: After individualized omalizumab-treatment (8-24 weeks) all patients continued with an open peanut challenge with no (n=18) or mild (n=5) objective allergic symptoms. Patients (n=15) needing an elevated omalizumab-dose (ED) to supress CD-sens, had significantly higher CD-sens values at baseline 1.49 (0.44-20.5) compared to those (n=8) who managed with normal dose (ND) 0.32 (0.24-5.5) (p&lt;0.01). Median ratios for Ara h 2 IgE-ab/IgE were significantly higher in the ED group (17%) compared to the ND group (11%). CONCLUSIONS AND CLINICAL RELEVANCE: Individually dosed omalizumab, monitored by CD-sens, is an effective and safe treatment for severe peanut allergy. The ratio of IgE-ab to storage protein Ara h 2/IgE as well as CD-sens to peanut may predict the need of a higher omalizumab dose. Clinical trials numbers: EudraCT; 2012-005625-78, ClinicalTrials. gov; NCT02402231 This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12862</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27883239">PM:27883239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161124-BrandstromJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161124-BrandstromJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Brandstrom J</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12862</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rekima,A.</style></author><author><style face="normal" font="Arial"> Macchiaverni,P.</style></author><author><style face="normal" font="Arial"> Turfkruyer,M.</style></author><author><style face="normal" font="Arial"> Holvoet,S.</style></author><author><style face="normal" font="Arial"> Dupuis,L.</style></author><author><style face="normal" font="Arial"> Baiz,N.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Mercenier,A.</style></author><author><style face="normal" font="Arial"> Nutten,S.</style></author><author><style face="normal" font="Arial"> Verhasselt,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Nice Sophia Antipolis, TIM, EA 6302, 06200, Nice, France</style></auth-address><titles><title><style face="normal" font="Arial">Long term reduction in food allergy susceptibility in mice by combining breastfeeding-induced tolerance and TGF-beta enriched formula after weaning</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="576" start="565">565-576</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weaning</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oral tolerance induction in early life is a promising approach for food allergy prevention. Its success requires the identification of factors necessary for its persistence. OBJECTIVES: We aimed to assess in mice duration of allergy prevention by breastfeeding-induced oral tolerance and whether oral TGF-beta supplementation after weaning would prolong it. METHODS: We quantified ovalbumin (OVA) and OVA specific immunoglobulins levels by ELISA in milk from the EDEN birth cohort. Since OVA specific Ig were found in all samples, we assessed whether OVA-immunized mice exposed to OVA during lactation could prevent allergic diarrhea in their 6 and 13-week-old progeny. In some experiments, a TGF-beta enriched formula was given after weaning. RESULTS: At 6 weeks, only 13% and 34% of mice breastfed by OVA-exposed mothers exhibited diarrhea after 6 and 7 OVA challenges versus 44% and 72% in mice breastfed by naive mothers (p=0.02 and 0.01). Protection was associated with decreased levels of MMCP1 and OVA specific IgE (p&lt;0.0001). At 13 weeks, although OVA specific IgE remained low (p=0.001), diarrhea occurrence increased to 32% and 46% after 6 and 7 OVA challenges in mice breastfed by OVA-exposed mothers. MMCP1 levels were not significantly inhibited. Supplementation with TGF-beta after weaning induced a strong protection in 13-week-old mice breastfed by OVA-exposed mothers compared to mice breastfed by naive mothers (0%, 13% and 32% of diarrhea at the 5th, 6th and 7th challenges versus 17, 42 and 78%; p=0.05, 0.0043 and 0.0017). MMCP1 levels decreased by half compared to control mice (p=0.02). Prolonged protection was only observed in mice rendered tolerant by breastfeeding and was associated with an improved gut barrier. CONCLUSIONS: In mice, prevention of food allergy by breastfeeding-induced tolerance is of limited duration. Nutritional intervention by TGF-beta supplementation after weaning could prolong beneficial effects of breast milk on food allergy prevention. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - France -CO - Brazil -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12864</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27883236">PM:27883236</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161124-RekimaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161124-RekimaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Rekima A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12864</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cunningham,F.</style></author><author><style face="normal" font="Arial"> Gupta,P.</style></author><author><style face="normal" font="Arial"> Becher,G.</style></author><author><style face="normal" font="Arial"> Magro,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Western Ambulatory Care Hospital, Dalnair Street, Yorkhill, Glasgow, G3 8SJ</style></auth-address><titles><title><style face="normal" font="Arial">Necrotizing eosinophilic folliculitis: a new manifestation of the atopic diathesis?</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="101" start="100">100-101</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Ambulatory Care</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Folliculitis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - LetterCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.12994</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27910130">PM:27910130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20161202-CunninghamF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20161202-CunninghamF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Cunningham F</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.12994</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al Shekaili,L.</style></author><author><style face="normal" font="Arial"> Sheikh,F.</style></author><author><style face="normal" font="Arial"> Al Gazlan,S.</style></author><author><style face="normal" font="Arial"> Al,Dhekri H.</style></author><author><style face="normal" font="Arial"> Al Mousa,H.</style></author><author><style face="normal" font="Arial"> Al Ghonaium,A.</style></author><author><style face="normal" font="Arial"> Al Saud,B.</style></author><author><style face="normal" font="Arial"> Al Mohsen,S.</style></author><author><style face="normal" font="Arial"> Rehan Khaliq,A.M.</style></author><author><style face="normal" font="Arial"> Al Sumayli,S.</style></author><author><style face="normal" font="Arial"> Al Zahrani,M.</style></author><author><style face="normal" font="Arial"> Dababo,A.</style></author><author><style face="normal" font="Arial"> AlKawi,A.</style></author><author><style face="normal" font="Arial"> Hawwari,A.</style></author><author><style face="normal" font="Arial"> Arnaout,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">King Faisal Specialist Hospital and Research Center, Department of Medicine, Allergy and Immunology section, P.O Box 3354, Riyadh 11211, MBC 46, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="Arial">Novel mutation in DOCK8-HIES with severe phenotype and successful transplantation</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="44" start="39">39-44</pages><volume><style face="normal" font="Arial">178</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DOCK8</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fatal Outcome</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> hematopoietic stem cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> reversibility</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Severity of the disease</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> stem cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hyper-IgE syndrome (HIES) due to DOCK8 deficiency is an autosomal recessive (AR) primary combined immunodeficiency which results in significant morbidity and mortality at a young age. Different mutations in the DOCK8 gene can lead to variable severity of the disease. OBJECTIVE: We evaluated the genetic mutations in three related patients with severe clinical manifestations suggestive of AR HIES. We also explored whether treatment with stem cell transplantation could lead to complete disease resolution. METHOD: We examined the clinical manifestations and immunological workup of these patients. Their DNA was also screened for causative mutation. Post transplantation, clinical and immunological data for the transplanted patient was also collected. RESULTS: All patients had a severe course of the disease with rarely reported severe complications in HIES. One patient died with lymphoma while another died with progressive multifocal leukoencephalopathy (PML) due to a slow virus. All our patients had two novel mutations in the DOCK8 gene. One of these mutations was a novel pathogenic mutation and explains the severity of the disease (homozygous splice site mutation at position 5 after the end of exon 45), while the other mutation was mostly non-pathogenic. Hematopoietic stem cell transplantation (HSCT) was performed in the youngest patient with excellent engraftment and full reversibility of the clinical manifestations. CONCLUSION: We report 3 patients from a consanguineous family diagnosed with AR-HIES due to a novel pathogenic mutation in DOCK8 gene leading to fatal outcome in 2 patients and complete resolution of the clinical and immunological features in the third patient by HSCT</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2016.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27890707">PM:27890707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20161128-AlShekailiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20161128-AlShekailiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Al Shekaili L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2016.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Alexander,L.C.</style></author><author><style face="normal" font="Arial"> Leone,F.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Hospital, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Hypothesis: may e-cigarette smoking boost the allergic epidemic?</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="40">40-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 2045-7022 (Linking)LA - engPT - EditorialCO - France -CO - Belgium -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0130-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27891215">PM:27891215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0130-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Casale,T.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Bewick,M.</style></author><author><style face="normal" font="Arial"> Bilo,B.M.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Bonini,S.</style></author><author><style face="normal" font="Arial"> Bush,A.</style></author><author><style face="normal" font="Arial"> Caimmi,D.P.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author><author><style face="normal" font="Arial"> Chiriac,A.M.</style></author><author><style face="normal" font="Arial"> Cox,L.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Didier,A.</style></author><author><style face="normal" font="Arial"> Di Lorenzo,G.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Eng,P.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Fox,A.T.</style></author><author><style face="normal" font="Arial"> Van Wijk,R.G.</style></author><author><style face="normal" font="Arial"> Gomez,R.M.</style></author><author><style face="normal" font="Arial"> Haathela,T.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author><author><style face="normal" font="Arial"> Jacobsen,L.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Knol,E.F.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.E.</style></author><author><style face="normal" font="Arial"> Linneberg,A.</style></author><author><style face="normal" font="Arial"> Matricardi,M.</style></author><author><style face="normal" font="Arial"> Malling,H.J.</style></author><author><style face="normal" font="Arial"> Moesges,R.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Pastorello,E.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Price,D.</style></author><author><style face="normal" font="Arial"> Del Rio,P.R.</style></author><author><style face="normal" font="Arial"> Rueff,R.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author><author><style face="normal" font="Arial"> Scadding,G.K.</style></author><author><style face="normal" font="Arial"> Senti,G.</style></author><author><style face="normal" font="Arial"> Shamji,M.H.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Sisul,J.C.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author><author><style face="normal" font="Arial"> Sturm,G.J.</style></author><author><style face="normal" font="Arial"> Tabar,A.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Ventura,M.T.</style></author><author><style face="normal" font="Arial"> Vidal,C.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Heart and Lung Institute, Royal Brompton Hospital NHS, Imperial College London, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="41">41-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Care pathways</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> life course</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 2045-7022 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United Kingdom -CO - United States -CO - France -CO - Switzerland -CO - Belgium -CO - Italy -CO - Netherlands -CO - Argentina -CO - Finland -CO - Denmark -CO - Netherlands -CO - Germany -CO - Spain -CO - Greece -CO - Singapore -CO - Poland -CO - Paraguay -CO - Brazil -CO - Spain -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0131-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27895895">PM:27895895</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Calderon MA</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0131-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elli,L.</style></author><author><style face="normal" font="Arial"> Villalta,D.</style></author><author><style face="normal" font="Arial"> Roncoroni,L.</style></author><author><style face="normal" font="Arial"> Barisani,D.</style></author><author><style face="normal" font="Arial"> Ferrero,S.</style></author><author><style face="normal" font="Arial"> Pellegrini,N.</style></author><author><style face="normal" font="Arial"> Bardella,M.T.</style></author><author><style face="normal" font="Arial"> Valiante,F.</style></author><author><style face="normal" font="Arial"> Tomba,C.</style></author><author><style face="normal" font="Arial"> Carroccio,A.</style></author><author><style face="normal" font="Arial"> Bellini,M.</style></author><author><style face="normal" font="Arial"> Soncini,M.</style></author><author><style face="normal" font="Arial"> Cannizzaro,R.</style></author><author><style face="normal" font="Arial"> Leandro,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for the Prevention and Diagnosis of Celiac Disease, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Nomenclature and diagnosis of gluten-related disorders: A position statement by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)</style></title><secondary-title><style face="normal" font="Arial">Dig Liver Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dig Liver Dis</style></full-title></periodical><pages end="146" start="138">138-146</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free diet</style></keyword><keyword><style face="normal" font="Arial"> Gluten-related disorders</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Non celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> non-IgE mediated allergy</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: "Gluten-related disorders" is a term that encompasses different diseases induced by the ingestion of gluten-containing food. Because of their incidence the scientific community has been intensively studying them. AIM: To support gastroenterologists with a correct nomenclature and diagnostic approach to gluten-related disorders in adulthood. METHODS: The Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) commissioned a panel of experts to prepare a position statement clarifying the nomenclature and diagnosis of gluten-related disorders, focusing on those of gastroenterological interest. Each member was assigned a task and levels of evidence/recommendation have been proposed. RESULTS: The panel identified celiac disease, wheat allergy and non-celiac gluten sensitivity as the gluten-related disorders of gastroenterological interest. Celiac disease has an autoimmune nature, wheat allergy is IgE-mediated while the pathogenesis of non-celiac gluten sensitivity is still unknown as is the case of non-IgE mediated allergy. Diagnosis should start with the serological screening for celiac disease and wheat allergy. In case of normal values, the response to a gluten-free diet should be evaluated and a confirmatory blind food challenge carried out. CONCLUSIONS: Gluten-related disorders are clinically heterogeneous. Patients should be carefully managed and specific protocols applied for a correct differential diagnosis in gastroenterological setting</style></abstract><notes><style face="normal" font="Arial">DA - 20161126IS - 1878-3562 (Electronic)IS - 1590-8658 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.dld.2016.10.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27887897">PM:27887897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dig Liver Dis\20161126-ElliL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dig Liver Dis\20161126-ElliL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161126, Elli L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.dld.2016.10.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jahan,R.</style></author><author><style face="normal" font="Arial"> Stephen,M.R.</style></author><author><style face="normal" font="Arial"> Forkuo,G.S.</style></author><author><style face="normal" font="Arial"> Kodali,R.</style></author><author><style face="normal" font="Arial"> Guthrie,M.L.</style></author><author><style face="normal" font="Arial"> Nieman,A.N.</style></author><author><style face="normal" font="Arial"> Yuan,N.Y.</style></author><author><style face="normal" font="Arial"> Zahn,N.M.</style></author><author><style face="normal" font="Arial"> Poe,M.M.</style></author><author><style face="normal" font="Arial"> Li,G.</style></author><author><style face="normal" font="Arial"> Yu,O.B.</style></author><author><style face="normal" font="Arial"> Yocum,G.T.</style></author><author><style face="normal" font="Arial"> Emala,C.W.</style></author><author><style face="normal" font="Arial"> Stafford,D.C.</style></author><author><style face="normal" font="Arial"> Cook,J.M.</style></author><author><style face="normal" font="Arial"> Arnold,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53211, United States</style></auth-address><titles><title><style face="normal" font="Arial">Optimization of substituted imidazobenzodiazepines as novel asthma treatments</style></title><secondary-title><style face="normal" font="Arial">Eur J Med Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Med Chem</style></full-title></periodical><pages end="560" start="550">550-560</pages><volume><style face="normal" font="Arial">126</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Discovery</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Relaxation</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Relaxation</style></keyword><keyword><style face="normal" font="Arial"> Screens</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="11" Year="2016">2016/11/24</year></dates><abstract><style face="normal" font="Arial">We describe the synthesis of analogs of XHE-III-74, a selective alpha4beta3gamma2 GABAAR ligand, shown to relax airway smooth muscle ex vivo and reduce airway hyperresponsiveness in a murine asthma model. To improve properties of this compound as an asthma therapeutic, a series of analogs with a deuterated methoxy group in place of methoxy group at C-8 position was evaluated for isotope effects in preclinical assays; including microsomal stability, cytotoxicity, and sensorimotor impairment. The deuterated compounds were equally or more metabolically stable than the corresponding non-deuterated analogs and increased sensorimotor impairment was observed for some deuterated compounds. Thioesters were more cytotoxic in comparison to other carboxylic acid derivatives of this compound series. The most promising compound 16 identified from the in vitro screens also strongly inhibited smooth muscle constriction in ex vivo guinea pig tracheal rings. Smooth muscle relaxation, determined by reduction of airway hyperresponsiveness with a murine ovalbumin sensitized and challenged model, showed that 16 was efficacious at low methacholine concentrations. However, this effect was limited due to suboptimal pharmacokinetics of 16. Based on these findings, further analogs of XHE-III-74 will be investigated to improve in vivo metabolic stability while retaining the efficacy at lung tissues involved in asthma pathology</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 1768-3254 (Electronic)IS - 0223-5234 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejmech.2016.11.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27915170">PM:27915170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Clin Respir J\2016-126-550-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Clin Respir J\2016-126-550-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Jahan R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejmech.2016.11.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hwang,Y.P.</style></author><author><style face="normal" font="Arial"> Jin,S.W.</style></author><author><style face="normal" font="Arial"> Choi,J.H.</style></author><author><style face="normal" font="Arial"> Choi,C.Y.</style></author><author><style face="normal" font="Arial"> Kim,H.G.</style></author><author><style face="normal" font="Arial"> Kim,S.J.</style></author><author><style face="normal" font="Arial"> Kim,Y.</style></author><author><style face="normal" font="Arial"> Lee,K.J.</style></author><author><style face="normal" font="Arial"> Chung,Y.C.</style></author><author><style face="normal" font="Arial"> Jeong,H.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmaceutical Engineering, International University of Korea, Jinju, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Inhibitory effects of L-theanine on airway inflammation in ovalbumin-induced allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="" start="169">169-</pages><volume><style face="normal" font="Arial">99</style></volume><number><style face="normal" font="Arial">162</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Vessels</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocyte Chemoattractant Protein-1</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> trafficking</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">L-theanine, a water-soluble amino acid isolated from green tea (Camellia sinensis), has anti-inflammatory activity, antioxidative properties, and hepatoprotective effects. However, the anti-allergic effect of L-theanine and its underlying molecular mechanisms have not been elucidated. In this study, we investigated the protective effects of L-theanine on asthmatic responses, particularly airway inflammation and oxidative stress modulation in an ovalbumin (OVA)-induced murine model of asthma. Treatment with L-theanine dramatically attenuated the extensive trafficking of inflammatory cells into bronchoalveolar lavage fluid (BALF). Histological studies revealed that L-theanine significantly inhibited OVA-induced mucus production and inflammatory cell infiltration in the respiratory tract and blood vessels. L-theanine administration also significantly decreased the production of IgE, monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-4, IL-5, IL-13, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (INF-gamma) in BALF. The lung weight decreased with L-theanine administration. L-theanine also markedly attenuated the OVA-induced generation of reactive oxygen species and the activation of nuclear factor kappa B (NF-kappaB) and matrix metalloprotease-9 in BALF. Moreover, L-theanine reduced the TNF-alpha-induced NF-kappaB activation in A549 cells. Together, these results suggest that L-theanine alleviates airway inflammation in asthma, which likely occurs via the oxidative stress-responsive NF-kappaB pathway, highlighting its potential as a useful therapeutic agent for asthma management</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2016.11.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27908701">PM:27908701</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\20161202-HwangYP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\20161202-HwangYP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Hwang YP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2016.11.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kianmehr,M.</style></author><author><style face="normal" font="Arial"> Rezaei,A.</style></author><author><style face="normal" font="Arial"> Hosseini,M.</style></author><author><style face="normal" font="Arial"> Khazdair,M.R.</style></author><author><style face="normal" font="Arial"> Rezaee,R.</style></author><author><style face="normal" font="Arial"> Askari,V.R.</style></author><author><style face="normal" font="Arial"> Boskabady,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Immunomodulatory effect of characterized extract of Zataria multiflora on Th1, Th2 and Th17 in normal and Th2 polarization state</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="127" start="119">119-127</pages><volume><style face="normal" font="Arial">99</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Carvacrol</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zataria multiflora</style></keyword></keywords><dates><year Day="21" Month="11" Year="2016">2016/11/21</year></dates><abstract><style face="normal" font="Arial">The effect of the extract of Zataria multiflora (Z. multiflora) on IFN-gamma, FOXP3, IL-4, TGF-beta, and IL-17 gene expression was evaluated in cultured splenocytes obtained from control, nontreated asthma or sensitized mice (group S), Sensetized animals treated with dexamethasone or three concentrations of Z. multiflora extract (200, 400 and 800 mug/ml) (n = 6, for each group). IFN-gamma and FOXP3 gene expressions were significantly decreased (P &lt; 0.001 for both cases) but IL-4 (P &lt; 0.001) and IL-17 (P &lt; 0.05) were increased in group S compared to control group. Z. Multiflora extract 800 mug/ml, significantly upregulated IFN-gamma gene expression (P &lt; 0.01) and its 400 and 800 mug/ml concentrations increased FOXP3 gene expression (P &lt; 0.05 and P &lt; 0.001, respectively) compared to group S. Z. multiflora extract at all concentrations (200, 400 and 800 mug/ml) decreased TGF-beta gene expression and its lowest concentration significantly reduced IL-17 gene expression compared to group S (P &lt; 0.001 for all cases). Only IL-4 and TGF-beta gene expression was significantly decreased following treatment with dexamethasone (P &lt; 0.001 for both cases). The results indicated an increase in IFN-gamma and FOXP3 but decrease in TGF-beta and IL-17 gene expression profile in sensitized splenocytes treated with the extract, which might be partially due to the presence of one of its constituent, carvacrol</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2016.11.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27884791">PM:27884791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2016-99-119-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2016-99-119-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Kianmehr M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2016.11.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galan-Malo,P.</style></author><author><style face="normal" font="Arial"> Lopez,M.</style></author><author><style face="normal" font="Arial"> Ortiz,J.C.</style></author><author><style face="normal" font="Arial"> Perez,M.D.</style></author><author><style face="normal" font="Arial"> Sanchez,L.</style></author><author><style face="normal" font="Arial"> Razquin,P.</style></author><author><style face="normal" font="Arial"> Mata,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Detection of egg and milk residues on working surfaces by ELISA and lateral flow immunoassay tests</style></title><secondary-title><style face="normal" font="Arial">Food Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Control</style></full-title></periodical><pages end="53" start="45">45-53</pages><volume><style face="normal" font="Arial">74</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen management</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Cross contact</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Chain</style></keyword><keyword><style face="normal" font="Arial"> Hidden allergens</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> lateral flow immunoassay</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk powder</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surfaces control</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0956-7135</style></isbn><abstract><style face="normal" font="Arial">In the last few years awareness for allergen management has increased among operators in the food chain. Since a small quantity of allergenic food can trigger an allergic reaction, accurate information in food product labels is essential for people who suffer from food allergy. A key point to reduce the risk of uncontrolled allergen contamination is to implement a strict and validated cleaning process. In this work a sampling method based on swabbing has been optimized with two analytical methods (ELISA and lateral flow tests) for milk and egg analysis on surfaces. Swab material, extraction buffer composition, temperature, time for recovery and the quantity of the allergen residue on the surfaces have been evaluated and a specific procedure was proposed. The new method has demonstrated a good performance to recover egg or milk proteins from two typical working surfaces (stainless steel or Formica). Egg and milk powder were detected by ELISA at a level as low as 0.04 and 0.2-á++g, respectively. However, the detection level with lateral flow tests rose to 0.07-á++g for egg powder and 0.6-á++g for milk, depending on the kind of surface. On average, repeatability of swabbing method ranged from 18 to 32%. Both methods could be applied for validation the cleaning processes and for a routine verification after cleaning</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodcont.2016.11.027</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodcont.2016.11.027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Control\20161201-GalanMaloP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Control\20161201-GalanMaloP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Galan-Malo P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodcont.2016.11.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ji,J.</style></author><author><style face="normal" font="Arial"> Zhu,P.</style></author><author><style face="normal" font="Arial"> Pi,F.</style></author><author><style face="normal" font="Arial"> Sun,C.</style></author><author><style face="normal" font="Arial"> Sun,J.</style></author><author><style face="normal" font="Arial"> Jia,M.</style></author><author><style face="normal" font="Arial"> Ying,C.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Sun,X.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development of a liquid chromatography-tandem mass spectrometry method for simultaneous detection of the main milk allergens</style></title><secondary-title><style face="normal" font="Arial">Food Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Control</style></full-title></periodical><pages end="88" start="79">79-88</pages><volume><style face="normal" font="Arial">74</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absolute quantification</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> LC-MRM/MS</style></keyword><keyword><style face="normal" font="Arial"> marker peptides</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergens</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide fragment</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Simultaneous detection</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0956-7135</style></isbn><abstract><style face="normal" font="Arial">The goal of this study is development and validation of a method to confirm and quantify milk allergens in food products based on liquid chromatography-tandem multiple reactions-monitoring, mass spectrometry (LC-MRM/MS). Here, emphasis was placed on two whey proteins, +¦-lactalbumin (+¦-La) and +¦-lactoglobulin (+¦-Lg), plus a third, +¦s1-casein (+¦s1-CN), known to be the main allergenic components of milk. Five marker peptides (one for +¦-La, two for +¦-Lg and two for +¦s1-CN) and three quantitative marker peptides from the digestion of standard milk proteins were identified using matrix-assisted laser desorption/ionization with tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS). Optimization of enzymatic hydrolysis conditions were defined as 37-á-¦C for 16-áh. The linearity ranges for the three allergenic proteins (+¦-La, +¦-Lg and +¦s1-CN) were 0.97</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô31.25-á++g/mL, 0.48</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô31.25-á++g/mL and 0.48</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô31.25-á++g/mL, respectively. The assays were validated for absolute quantification of three milk proteins with satisfactory results, which indicates that the established mass method is suitable for the expression of levels in daily food</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodcont.2016.11.030</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodcont.2016.11.030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Control\20161201-JiJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Control\20161201-JiJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Ji J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodcont.2016.11.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumari,N.</style></author><author><style face="normal" font="Arial"> Kofi,K.J.</style></author><author><style face="normal" font="Arial"> Grimbs,S.</style></author><author><style face="normal" font="Arial"> D'Souza,R.N.</style></author><author><style face="normal" font="Arial"> Kuhnert,N.</style></author><author><style face="normal" font="Arial"> Vrancken,G.</style></author><author><style face="normal" font="Arial"> Ullrich,M.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Biochemical fate of vicilin storage protein during fermentation and drying of cocoa beans</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="65" start="53">53-65</pages><volume><style face="normal" font="Arial">90</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cocoa</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Drying</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> MALDI-MS</style></keyword><keyword><style face="normal" font="Arial"> Oligopeptides</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Theobroma cacao</style></keyword><keyword><style face="normal" font="Arial"> UHPLC-ESI-MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Vicilin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">Key cocoa-specific aroma precursors are generated during the fermentation of cocoa beans via the proteolysis of the vicilin-like globulin. Previous studies had shown that degradation of this particular 566 amino acid-long storage protein leads to three distinct subunits with different molecular masses. Although oligopeptides generated from the proteolysis of vicilin-like globulin have been studied previously, changes occurring to vicilin at different stages of fermentation have not yet been explored in detail. The aim of this study was to investigate the fate of vicilin protein from the non-fermented stage up to the dried cocoa beans. Our results showed a remarkable shift in the electrophoretic mobility of vicilin towards higher pI during the onset of fermentation. The pI-shifted subunit was found susceptible to further degradation into a lower-molecular-weight vicilin subunit. The observed pI shift correlated with, but did not depend on protein phosphorylation. Glycosylation of some but not all vicilin subunits occurred at different stages of the fermentation process. Peptides generated from vicilin throughout fermentation were analyzed by UHPLC-ESI-MS/MS revealing an initial increase and subsequent decrease in the diversity of peptides with an increasing degree of fermentation. We furthermore describe the rate of degradation of different vicilin subunits. The detected diversity and dynamics of vicilin peptides will help to define biochemical markers of distinct steps of the fermentation process</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2016.10.033</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodres.2016.10.033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\2016-90-53-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\2016-90-53-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Kumari N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2016.10.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Koniari,I.</style></author><author><style face="normal" font="Arial"> Kounis,N.G.</style></author><author><style face="normal" font="Arial"> Soufras,G.</style></author><author><style face="normal" font="Arial"> Koutsogiannis,N.</style></author><author><style face="normal" font="Arial"> Hahalis,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cardiology University of Patras Medical School, Rion, Patras, Achaia,Greece</style></auth-address><titles><title><style face="normal" font="Arial">Specific IgE levels in pericardial and cerebrospinal fluids in forensic casework</style></title><secondary-title><style face="normal" font="Arial">Forensic Sci Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Forensic Sci Int</style></full-title></periodical><pages end="92" start="91">91-92</pages><volume><style face="normal" font="Arial">270</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">cerebrospinal fluid</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="25" Month="11" Year="2016">2016/11/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 1872-6283 (Electronic)IS - 0379-0738 (Linking)LA - engPT - LetterCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.forsciint.2016.11.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27923171">PM:27923171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Forensic Sci Int\2016-270-91-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Forensic Sci Int\2016-270-91-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Koniari I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.forsciint.2016.11.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Scarpelli,M.P.</style></author><author><style face="normal" font="Arial"> Keller,S.</style></author><author><style face="normal" font="Arial"> Tran,L.</style></author><author><style face="normal" font="Arial"> Palmiere,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Sanita Pubblica e Medicina di Comunita, Universita degli Studi di Verona, Policlinico G.B. Rossi, P.le L.A. Scuro 10, 37134 Verona, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Postmortem serum levels of IgE and mast cell tryptase in fatal asthma</style></title><secondary-title><style face="normal" font="Arial">Forensic Sci Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Forensic Sci Int</style></full-title></periodical><pages end="118" start="113">113-118</pages><volume><style face="normal" font="Arial">269</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Autopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cause of Death</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">The aim of this study was to characterize the concentrations of total and specific IgE as well as mast cell-derived tryptase in postmortem serum from femoral blood and evaluate the usefulness of their determination for diagnostic purposes in cases of fatal asthma attacks. 36 autopsy cases were retrospectively selected including cases of witnessed death in asthmatic subjects, deaths in asthmatics and atopic subjects with causes of death unrelated to asthma or allergic anaphylaxis as well as deaths in non-atopic, non-allergic individuals with causes of death unrelated to asthma or allergic anaphylaxis. Initial results indicated increased postmortem serum total IgE in atopic and asthmatic individuals, irrespective of the cause of death. Conversely, increased mast cell tryptase levels were noted exclusively in fatal asthma attacks. This suggests that mast cell tryptase measurement in cases of death potentially caused by severe acute bronchial asthma may be useful for diagnostic purposes</style></abstract><notes><style face="normal" font="Arial">DA - 20161126IS - 1872-6283 (Electronic)IS - 0379-0738 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.forsciint.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888720">PM:27888720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Forensic Sci Int\2016-269-113-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Forensic Sci Int\2016-269-113-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161126, Scarpelli MP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.forsciint.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schuch,A.</style></author><author><style face="normal" font="Arial"> Brockow,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Biederstein, Technische Universitat Munchen, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Mastocytosis and Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="164" start="153">153-164</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Self Medication</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">This article updates current knowledge on epidemiology, risk factors, triggers, and management of anaphylaxis in patients with mastocytosis. Hyperactive mast cells and higher number of effector mast cells are speculated to facilitate anaphylaxis in this condition. In children, increased risk is limited to those with extensive skin involvement and high tryptase. In adults, manifestations of anaphylaxis are severe with high frequency of cardiovascular symptoms. Hymenoptera stings are the most common triggers for these reactions; however, idiopathic anaphylaxis and reactions to food or drugs occur. Patients with mastocytosis should be informed about risk of anaphylaxis and prescribing emergency self-medication and installing emergency preparedness before general anesthesia is considered</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886904">PM:27886904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-153-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-153-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Schuch A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bulkhi,A.</style></author><author><style face="normal" font="Arial"> Cooke,A.J.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Tampa, FL, USA</style></auth-address><titles><title><style face="normal" font="Arial">Biologics in Chronic Urticaria</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="112" start="95">95-112</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune response modifiers</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Intravenous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Chronic urticaria (CU) is defined as wheals, angioedema, or both, that last more than 6 weeks. Second-generation antihistamines are considered the first-line therapy for CU. Unfortunately, many patients will fail antihistamines and require alternative therapy, including immune response modifiers or biologics. Multiple biological agents have been evaluated for use in antihistamine-refractory CU, including omalizumab, rituximab, and intravenous immunoglobulin; omalizumab is the most efficacious. Because of the success of omalizumab, multiple new biologics that are directed at the IgE pathway are under investigation. This review summarizes the relevant data regarding the efficacy of biologics in antihistamine-refractory CU</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886913">PM:27886913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-95-112.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-95-112.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Bulkhi A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tam,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical Immunology and Allergy, Department of Pediatrics, Children's Hospital Los Angeles, 4650 Sunset Boulevard MS#75, Los Angeles, CA 90027, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Cutaneous Manifestation of Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="231" start="217">217-231</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis Herpetiformis</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Hypersensitivity reactions to foods can have diverse and highly variable manifestations. Cutaneous reactions, such as acute urticaria and angioedema, are among the most common manifestations of food allergy. However, cutaneous manifestations of food allergy encompass more than just IgE-mediated processes and include atopic dermatitis, contact dermatitis, and even dermatitis herpetiformis. These cutaneous manifestations provide an opportunity to better understand the diversity of adverse immunologic responses to food and the interconnected pathways that produce them</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886908">PM:27886908</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-217-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-217-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Tam JS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barrett,M.</style></author><author><style face="normal" font="Arial"> Luu,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Keck School of Medicine of USC, 1200 North State Street, Clinic Tower A7D, Los Angeles, CA 90033, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Differential Diagnosis of Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="34" start="11">11-34</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical criteria</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a common inflammatory condition of the skin that is usually seen in childhood, but can onset or persist into adulthood. The characteristic distribution and morphology based on age, chronic relapsing course, and pruritus comprise the clinical criteria used in the diagnosis of AD. However, the numerous morphologies ranging from acute, weeping erythematous papules to chronic lichenified plaques, can be simulated by multiple other conditions, including inflammatory, infectious, neoplastic, and photo-dermatoses. Recognition of the distinguishing features and clinical mimickers of atopic dermatitis is vital for an accurate and timely diagnosis, and initiation of proper treatment regimens</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886900">PM:27886900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-11-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-11-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Barrett M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dreyfus,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Yale School of Medicine, Gesher LLC, Allergy, Asthma and Clinical Immunology, 4 Clifton Avenue, Waterbury CT 06710, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Differential Diagnosis of Chronic Urticaria and Angioedema Based on Molecular Biology, Pharmacology, and Proteomics</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="215" start="201">201-215</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Differential diagnosis of urticaria and angioedema has been based on the phenotype as either acute or chronic depending on the duration of more than 6 to 8 weeks, respectively. Additional subdivisions include poorly defined terms such as idiopathic, spontaneous, or autoimmune. In this article, the author suggests that an increased understanding of the acquired and innate immune system and data from novel proteomic technology have blurred the lines between these categories of diagnosis. Specific molecular pathways and response to specific medications should be incorporated in classification and diagnosis schemes</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886907">PM:27886907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-201-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-201-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Dreyfus DH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gaudinski,M.R.</style></author><author><style face="normal" font="Arial"> Milner,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Allergy and Infectious Diseases, Genetics and Pathogenesis of Allergy Section, 10 Center Drive, Building 10 Room 11N240A, Bethesda, MD 20814, USA</style></auth-address><titles><title><style face="normal" font="Arial">Atopic Dermatitis and Allergic Urticaria: Cutaneous Manifestations of Immunodeficiency</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="10" start="1">1-10</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis and allergic urticaria are common conditions of the skin that can also be the presenting symptoms of uncommon diseases. Defects leading to immunodeficiency may be associated with atopic dermatitis or allergic urticaria. Unusually severe or otherwise atypical presentations of atopic dermatitis or allergic urticaria may lead to clinical suspicion of an underlying immunodeficiency</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886899">PM:27886899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-1-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-1-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Gaudinski MR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Glatz,M.</style></author><author><style face="normal" font="Arial"> Bosshard,P.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, Zurich 8091, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Fungi in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="74" start="63">63-74</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">There is little doubt that Malassezia spp plays a role in atopic dermatitis because it may interact with the local skin immune responses and barrier function, and sensitization against this skin-colonizing yeast can correlate with disease activity. Also, antifungal therapy shows beneficial effects in some patients. However, the pathogenetic mechanism and mutual interaction between Malassezia spp and atopic dermatitis still remain partly unclear and need further investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886911">PM:27886911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-63-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-63-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Glatz M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weller,K.</style></author><author><style face="normal" font="Arial"> Siebenhaar,F.</style></author><author><style face="normal" font="Arial"> Hawro,T.</style></author><author><style face="normal" font="Arial"> Altrichter,S.</style></author><author><style face="normal" font="Arial"> Schoepke,N.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Allergie-Centrum-Charite, Charite - Universitatsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Measures of Chronic Urticaria</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="49" start="35">35-49</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> patient management</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">The use of standardized, valid, and reliable clinical measures is an important element in modern patient management, particularly in diseases that are not objectively assessable and are associated with a high disease burden. Chronic urticaria is such a disorder for which several new and well-developed clinical measures became available. These measures comprise tools to assess disease activity, disease control, and health-related quality-of-life impairment. This review provides an overview of the currently available clinical measures for chronic urticaria. In addition, it provides information on their strengths and limitations and how to best use them and evaluate their results</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886909">PM:27886909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-35-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-35-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Weller K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thijs,J.L.</style></author><author><style face="normal" font="Arial"> De Bruin-Weller,M.S.</style></author><author><style face="normal" font="Arial"> Hijnen,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology &amp; Allergology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Current and Future Biomarkers in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="61" start="51">51-61</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Body Fluids</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a heterogeneous disease and many attempts have been made to define subsets of patients based on clinical characteristics. However, the current characterization of patients with AD might not adequately reflect the pathophysiologic diversity within patients with AD. This article reviews current biomarkers for AD and future perspectives. In the future, patients with AD will be stratified based on biomarker expression levels in body fluids and tissue, genetic variants, or combined biomarker expression patterns. With new targeted therapies for AD currently investigated in clinical trials this will lead to better identification of patients that can benefit from these highly specific, but expensive new treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2016.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886910">PM:27886910</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-51-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-51-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Thijs JL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2016.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhar,S.</style></author><author><style face="normal" font="Arial"> Srinivas,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Dermatology, Institute of Child Health, Kolkata, West Bengal, India</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Indian J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Dermatol</style></full-title></periodical><pages end="648" start="645">645-648</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Kolkata</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Food allergy in atopic dermatitis (AD) is debatable from decades. Role of diet in the cause and treatment of AD is controversial and is not well-defined. Allergists and pediatricians are convinced about the food allergy in AD whereas many dermatologists are contrary for this. However, there are studies in the Indian and western literature supporting the evidence that elimination diet may improve the severe type of AD. There is increasing awareness and lot of misconception among caregivers about food allergy and hence careful understanding about this concept is necessary to counsel parents. Recent evidence-based literature suggests avoidance of proven food allergens in AD could be beneficial in moderate to severe type of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1998-3611 (Electronic)IS - 0019-5154 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0019-5154.193673</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27904183">PM:27904183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Dermatol\2016-61-645-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Dermatol\2016-61-645-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Dhar S</style></custom2><misc3><style face="normal" font="Arial">10.4103/0019-5154.193673</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kuperstock,J.E.</style></author><author><style face="normal" font="Arial"> Brook,D.</style></author><author><style face="normal" font="Arial"> Ryan,M.W.</style></author><author><style face="normal" font="Arial"> Platt,M.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Boston University School of Medicine, Boston, MA</style></auth-address><titles><title><style face="normal" font="Arial">Correlation between the number of allergen sensitizations and immunoglobulin E: monosensitization vs polysensitization</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="388" start="385">385-388</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The purpose of this study was to determine if total serum immunoglobulin E (IgE) could predict monosensitization compared to polysensitization in patients with allergic rhinitis (AR). METHODS: This was a retrospective study of a cohort of 1073 patients who underwent allergy testing. Differences in total IgE level between unsensitized, monosensitized, and polysensitized subjects were calculated. Pearson correlation coefficient was calculated to determine whether there was a relationship between total IgE level and the number of positive allergen sensitizations. In addition, allergen sensitization class was calculated for each allergen sensitization and totaled for each patient. Pearson correlation coefficient was calculated to determine the relationship between total IgE level and weighted allergen sensitization by class. RESULTS: There were 159 patients who were monosensitized compared to 492 patients who were polysensitized. Of the monosensitized patients, almost 50% (74) were sensitized to one or both dust mites. Total IgE was higher in polysensitized patients compared to monosensitized compared to controls (p &lt; 0.001). Pearson correlation coefficient between total IgE and number of positive allergen sensitizations was 0.465 (p &lt;/= 0.001). Pearson correlation coefficient between total IgE and allergen class-weighted sensitizations was 0.529 (p &lt;/= 0.001). CONCLUSION: IgE level can be used to predict monosensitization vs polysensitization. There is a moderate correlation between total IgE sensitization and the number of positive allergen sensitizations, as well as allergen class-weighted sensitizations</style></abstract><notes><style face="normal" font="Arial">DA - 20161126IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21890</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888643">PM:27888643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-385-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-385-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161126, Kuperstock JE</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21890</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Poletti,S.C.</style></author><author><style face="normal" font="Arial"> Sperl,A.</style></author><author><style face="normal" font="Arial"> Spielhaupter,M.</style></author><author><style face="normal" font="Arial"> Bardenhewer,C.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Hormann,K.</style></author><author><style face="normal" font="Arial"> Hummel,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zentrum fur Rhinologie und Allergologie, Wiesbaden, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="292" start="287">287-292</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> olfaction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The purpose of this study was to investigate the effect of MP-AzeFlu on olfaction and the interaction between severity of allergic rhinitis and olfactory improvement after therapy. METHODS: A prospective, multicenter, observational study was performed on 47 patients with persistent allergic rhinitis. Duration and severity of allergic rhinitis was diagnosed and classified using the modified Allergic Rhinitis and its Impact on Asthma (ARIA) criteria and the proof of allergen sensitization from positive skin-prick tests, specific immonoglobulin E (IgE) in serum, and nasal provocation response. Patients were treated with MP-AzeFlu (1 spray/nostril twice daily) over 3 months. Olfactory function was assessed at baseline and at 1 and 3 months of therapy using the "Sniffin' Sticks" test. In addition, a nasal symptom score was recorded on a visual analog scale (VAS) at each given time-point. RESULTS: MP-AzeFlu was found to be associated with a significant improvement in TDI score, from 23.7 at baseline to 34.2 at 1 month (p &lt; 0.001) and 37.1 at 3 months (p &lt; 0.001) of treatment. Furthermore, a highly significant improvement of symptoms over time (p &lt; 0.001; VAS at baseline: 84.3; 1 month: 32.4; 3 months: 26.2) could be demonstrated. Most importantly, there was a highly significant interaction between the severity of allergic rhinitis and olfactory function (p &lt; 0.001) and VAS (p &lt; 0.001). CONCLUSION: MP-AzeFlu is associated with olfactory improvement in persistent allergic rhinitis patients. Further, the modified ARIA severity classification is an indicator of patients' olfactory function. Moreover, assessment of olfaction seems to be a reliable indicator of the clinical success of antiallergic/antiinflammatory therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161126IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21877</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888645">PM:27888645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20161126-KlimekL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20161126-KlimekL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161126, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21877</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,C.H.</style></author><author><style face="normal" font="Arial"> Wang,C.C.</style></author><author><style face="normal" font="Arial"> Lin,Y.C.</style></author><author><style face="normal" font="Arial"> Hori,M.</style></author><author><style face="normal" font="Arial"> Jan,T.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department and Graduate Institute of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Oral administration with diosgenin enhances the induction of intestinal T helper 1-like regulatory T cells in a murine model of food allergy</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="66" start="59">59-66</pages><volume><style face="normal" font="Arial">42</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> CXCR3</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Peyer's Patches</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yam</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="Arial">Although the development of T helper (Th)1-like regulatory T (Treg) cells under Th1 inflammatory conditions has been reported, the role of Th1-like Treg cells in Th2 allergic responses remains mostly unclear. We previously demonstrated that diosgenin, the major sapogenin contained in the Chinese yam, attenuated food allergy and augmented Th1 and Treg immune responses. In this study, we hypothesized that diosgenin may enhance the induction of Th1-like Treg cells in the gut of mice with food allergy. Ovalbumin (OVA)-sensitized BALB/c mice were gavaged daily with diosgenin and received repeatedly intragastric ovalbumin challenges to induce intestinal allergic responses. The induction of Foxp3+ Treg cells co-expressing Th1-type transcription factors, cytokines and chemokines in the intestine was examined, and the mRNA expression of the chemokines corresponding to Th1-like Treg cells was measured. Diosgenin administration increased the number of Foxp3+ Treg cells co-expressing Th1 markers, including CCR5, CXCR3, IFN-gamma and T-bet in the intestine, and enhanced populations of Foxp3+IFN-gamma+ and Foxp3+T-bet+ cells that expressed the regulatory cytokine IL-10 in the Peyer's patches. Diosgenin also augmented the intestinal expression of CXCR3, CCL3, and CXCL10. Concordantly, diosgenin increased the number of CXCR3+Foxp3+IL-10 cells in the Peyer's patches. Our data demonstrated the enhanced induction of Th1-like Treg cells in allergic mice treated with diosgenin, providing evidence to suggest a role for Th1-like Treg cells in diosgenin-mediated anti-allergic effects against Th2-type allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - Taiwan -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2016.11.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886644">PM:27886644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2016-42-59-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2016-42-59-66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Huang CH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2016.11.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahdavinia,M.</style></author><author><style face="normal" font="Arial"> Fox,S.R.</style></author><author><style face="normal" font="Arial"> Smith,B.M.</style></author><author><style face="normal" font="Arial"> James,C.</style></author><author><style face="normal" font="Arial"> Palmisano,E.L.</style></author><author><style face="normal" font="Arial"> Mohamed,A.</style></author><author><style face="normal" font="Arial"> Zahid,Z.</style></author><author><style face="normal" font="Arial"> Assa'ad,A.H.</style></author><author><style face="normal" font="Arial"> Tobin,M.C.</style></author><author><style face="normal" font="Arial"> Gupta,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy/Immunology Section, Department of Immunology and Microbiology, Rush University Medical Center, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="Arial">Racial Differences in Food Allergy Phenotype and Health Care Utilization among US Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="357" start="352">352-357</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">African American</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy to corn</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disparities</style></keyword><keyword><style face="normal" font="Arial"> disparity</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hispanic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicaid</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Tertiary Care Centers</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Whites</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy (FA) is a prevalent condition in the United States, but little is known about its phenotypes in racial minority groups. OBJECTIVE: The objective of this study was to characterize disease phenotypes and disparities in health care utilization among African American (AA), Hispanic, and white children with FA. METHODS: We conducted a large, 2-center, retrospective cohort study of children aged 0-17 years with FA seen in allergy/immunology clinics at 2 urban tertiary care centers in the United States. We used multiple logistic regression analyses adjusted for age, gender, and insurance. RESULTS: The cohort of 817 children was composed of 35% AA, 12% Hispanic, and 53% non-Hispanic white. Compared with non-Hispanic white children, AA children had significantly higher odds of having asthma and eczema (P &lt; .01), and significantly higher odds of allergy to wheat, soy, corn, fish, and shellfish (P &lt; .01). Compared with non-Hispanic white children, Hispanic children had significantly higher odds of allergy to corn, fish, and shellfish (P &lt; .01), and higher odds of eczema (P &lt; .01), but a similar rate of asthma (P = .44). In this cohort, 55%, 18%, and 11% of AA, Hispanic, and white children were covered by Medicaid, respectively (P &lt; .00001). Compared with whites, AA and Hispanic children had a shorter duration of follow-up for FA with an allergy specialist and higher rates of FA-related anaphylaxis and emergency department visits (P &lt; .01). CONCLUSIONS: FA phenotypes and health care utilization differ among children of different racial and/or ethnic backgrounds in the United States that put AA and Hispanic children at higher risks of adverse outcome than white children. These differences include coexistent atopic conditions, less well recognized food allergens, and higher rates of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20161126IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888035">PM:27888035</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161126-MahdaviniaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161126-MahdaviniaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161126, Mahdavinia M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.10.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sundaram,A.</style></author><author><style face="normal" font="Arial"> Chen,C.</style></author><author><style face="normal" font="Arial"> Khalifeh-Soltani,A.</style></author><author><style face="normal" font="Arial"> Atakilit,A.</style></author><author><style face="normal" font="Arial"> Ren,X.</style></author><author><style face="normal" font="Arial"> Qiu,W.</style></author><author><style face="normal" font="Arial"> Jo,H.</style></author><author><style face="normal" font="Arial"> DeGrado,W.</style></author><author><style face="normal" font="Arial"> Huang,X.</style></author><author><style face="normal" font="Arial"> Sheppard,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Targeting integrin alpha5beta1 ameliorates severe airway hyperresponsiveness in experimental asthma</style></title><secondary-title><style face="normal" font="Arial">J Clin Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Invest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chymase</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fibronectin</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> Isoproterenol</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> Myosin light chain</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Relaxation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="12" Year="2016">2016/12/5</year></dates><abstract><style face="normal" font="Arial">Treatment options are limited for severe asthma, and the need for additional therapies remains great. Previously, we demonstrated that integrin alphavbeta6-deficient mice are protected from airway hyperresponsiveness, due in part to increased expression of the murine ortholog of human chymase. Here, we determined that chymase protects against cytokine-enhanced bronchoconstriction by cleaving fibronectin to impair tension transmission in airway smooth muscle (ASM). Additionally, we identified a pathway that can be therapeutically targeted to mitigate the effects of airway hyperresponsiveness. Administration of chymase to human bronchial rings abrogated IL-13-enhanced contraction, and this effect was not due to alterations in calcium homeostasis or myosin light chain phosphorylation. Rather, chymase cleaved fibronectin, inhibited ASM adhesion, and attenuated focal adhesion phosphorylation. Disruption of integrin ligation with an RGD-containing peptide abrogated IL-13-enhanced contraction, with no further effect from chymase. We identified alpha5beta1 as the primary fibronectin-binding integrin in ASM, and alpha5beta1-specific blockade inhibited focal adhesion phosphorylation and IL-13-enhanced contraction, with no additional effect from chymase. Delivery of an alpha5beta1 inhibitor into murine airways abrogated the exaggerated bronchoconstriction induced by allergen sensitization and challenge. Finally, alpha5beta1 blockade enhanced the effect of the bronchodilator isoproterenol on airway relaxation. Our data identify the alpha5beta1 integrin as a potential therapeutic target to mitigate the severity of airway contraction in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1558-8238 (Electronic)IS - 0021-9738 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/JCI88555</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27918306">PM:27918306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Invest\20161205-SundaramA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Invest\20161205-SundaramA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Sundaram A</style></custom2><misc3><style face="normal" font="Arial">10.1172/JCI88555</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simons,B.</style></author><author><style face="normal" font="Arial"> Ferrini,M.E.</style></author><author><style face="normal" font="Arial"> Carvalho,S.</style></author><author><style face="normal" font="Arial"> Bassett,D.J.</style></author><author><style face="normal" font="Arial"> Jaffar,Z.</style></author><author><style face="normal" font="Arial"> Roberts,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Environmental Health Sciences, Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT</style></auth-address><titles><title><style face="normal" font="Arial">PGI2 Controls Pulmonary NK Cells That Prevent Airway Sensitization to House Dust Mite Allergen</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> CCL2</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CX3CL1</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> NK cells</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="11" Year="2016">2016/11/28</year></dates><abstract><style face="normal" font="Arial">In allergic asthma, inhalation of airborne allergens such as the house dust mite (HDM) effectively activates both innate and adaptive immunity in the lung mucosa. To determine the role of the eicosanoid PGI2 and its receptor IP during allergic airway sensitization, HDM responses in mice lacking a functional IP receptor (i.e., PGI2 IP receptor-deficient [IP-/-]) were compared with wild type (WT) mice. Surprisingly, IP-/- mice had increased numbers of pulmonary CD3-NK1.1+Ly49b+ NK cells producing IFN-gamma that was inversely associated with the number of type 2 innate lymphoid cells (ILC2s) expressing IL-33Ralpha and IL-13 compared with WT animals. This phenomenon was associated with elevated CX3CL1 levels in the airways of IP-/- mice and treatment with a neutralizing Ab to CX3CL1 reduced IFN-gamma production by the lung NK cells. Remarkably, IP-/- mice were less responsive to HDM challenge than WT counterparts because intranasal instillation of the allergen induced markedly reduced levels of airway eosinophils, CD4+ lymphocyte infiltration, and mucus production, as well as depressed levels of CCL2 chemokine and Th2 cytokines. NK cells were responsible for such attenuated responses because depletion of NK1.1+ cells in IP-/- mice restored both the HDM-induced lung inflammation and ILC2 numbers, whereas transfer of CD3-NK1.1+ NK cells into the airways of WT hosts suppressed the inflammatory response. Collectively, these data demonstrate a hitherto unknown role for PGI2 in regulating the number and properties of NK cells resident in lung tissue and reveal a role for NK cells in limiting lung tissue ILC2s and preventing allergic inflammatory responses to inhaled HDM allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">    10.4049/jimmunol.1600275</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27895167">PM:27895167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20161129-SimonsB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20161129-SimonsB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Simons B</style></custom2><misc3><style face="normal" font="Arial">    10.4049/jimmunol.1600275</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xue,D.</style></author><author><style face="normal" font="Arial"> Kaufman,G.N.</style></author><author><style face="normal" font="Arial"> Dembele,M.</style></author><author><style face="normal" font="Arial"> Beland,M.</style></author><author><style face="normal" font="Arial"> Massoud,A.H.</style></author><author><style face="normal" font="Arial"> Mindt,B.C.</style></author><author><style face="normal" font="Arial"> Fiter,R.</style></author><author><style face="normal" font="Arial"> Fixman,E.D.</style></author><author><style face="normal" font="Arial"> Martin,J.G.</style></author><author><style face="normal" font="Arial"> Friedel,R.H.</style></author><author><style face="normal" font="Arial"> Divangahi,M.</style></author><author><style face="normal" font="Arial"> Fritz,J.H.</style></author><author><style face="normal" font="Arial"> Mazer,B.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Research Institute of the McGill University Health Centre, Translational Research in Respiratory Diseases Program, Meakins Christie Laboratories, Montreal, Quebec H4A 3J1, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Semaphorin 4C Protects against Allergic Inflammation: Requirement of Regulatory CD138+ Plasma Cells</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CD138+ plasma cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="Arial">The regulatory properties of B cells have been studied in autoimmune diseases; however, their role in allergic diseases is poorly understood. We demonstrate that Semaphorin 4C (Sema4C), an axonal guidance molecule, plays a crucial role in B cell regulatory function. Mice deficient in Sema4C exhibited increased airway inflammation after allergen exposure, with massive eosinophilic lung infiltrates and increased Th2 cytokines. This phenotype was reproduced by mixed bone marrow chimeric mice with Sema4C deficient only in B cells, indicating that B lymphocytes were the key cells affected by the absence of Sema4C expression in allergic inflammation. We determined that Sema4C-deficient CD19+CD138+ cells exhibited decreased IL-10 and increased IL-4 expression in vivo and in vitro. Adoptive transfer of Sema4c-/- CD19+CD138+ cells induced marked pulmonary inflammation, eosinophilia, and increased bronchoalveolar lavage fluid IL-4 and IL-5, whereas adoptive transfer of wild-type CD19+CD138+IL-10+ cells dramatically decreased allergic airway inflammation in wild-type and Sema4c-/- mice. This study identifies a novel pathway by which Th2-mediated immune responses are regulated. It highlights the importance of plasma cells as regulatory cells in allergic inflammation and suggests that CD138+ B cells contribute to cytokine balance and are important for maintenance of immune homeostasis in allergic airways disease. Furthermore, we demonstrate that Sema4C is critical for optimal regulatory cytokine production in CD138+ B cells</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.4049/?jimmunol.1600831</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27881703">PM:27881703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20161124-XueD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20161124-XueD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Xue D</style></custom2><misc3><style face="normal" font="Arial">10.4049/?jimmunol.1600831</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Veres,T.Z.</style></author><author><style face="normal" font="Arial"> Kopcsanyi,T.</style></author><author><style face="normal" font="Arial"> van,Panhuys N.</style></author><author><style face="normal" font="Arial"> Gerner,M.Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Rantakari,P.</style></author><author><style face="normal" font="Arial"> Dunkel,J.</style></author><author><style face="normal" font="Arial"> Miyasaka,M.</style></author><author><style face="normal" font="Arial"> Salmi,M.</style></author><author><style face="normal" font="Arial"> Jalkanen,S.</style></author><author><style face="normal" font="Arial"> Germain,R.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MediCity Research Laboratory, University of Turku, 20520 Turku, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-Induced CD4+ T Cell Cytokine Production within Airway Mucosal Dendritic Cell-T Cell Clusters Drives the Local Recruitment of Myeloid Effector Cells</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> small airways</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="11" Year="2016">2016/11/30</year></dates><abstract><style face="normal" font="Arial">Allergic asthma develops in the mucosal tissue of small bronchi. At these sites, local cytokine production by Th2/Th17 cells is believed to be critical for the development of tissue eosinophilia/neutrophilia. Using the mouse trachea as a relevant model of human small airways, we performed advanced in vivo dynamic and in situ static imaging to visualize individual cytokine-producing T cells in the airway mucosa and to define their immediate cellular environment. Upon allergen sensitization, newly recruited CD4+ T cells formed discrete Ag-driven clusters with dendritic cells (DCs). Within T cell-DC clusters, a small fraction of CD4+ T cells produced IL-13 or IL-17 following prolonged Ag-specific interactions with DCs. As a result of local Th2 cytokine signaling, eosinophils were recruited into these clusters. Neutrophils also infiltrated these clusters in a T cell-dependent manner, but their mucosal distribution was more diffuse. Our findings reveal the focal nature of allergen-driven responses in the airways and define multiple steps with potential for interference with the progression of asthmatic pathology</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601448</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27903737">PM:27903737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20161201-VeresTZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20161201-VeresTZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Veres TZ</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601448</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liao,K.</style></author><author><style face="normal" font="Arial"> Meyer,E.</style></author><author><style face="normal" font="Arial"> Lee,T.N.</style></author><author><style face="normal" font="Arial"> Loercher,A.</style></author><author><style face="normal" font="Arial"> Sikkema,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Immunology, GlaxoSmithKline, King of Prussia, PA 19406, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody</style></title><secondary-title><style face="normal" font="Arial">J Immunol Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Methods</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-drug antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biotin</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> false positives</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="11" Year="2016">2016/11/24</year></dates><abstract><style face="normal" font="Arial">Mepolizumab, a humanized IgG1 monoclonal antibody that blocks native homodimeric interleukin-5 (IL-5) from binding to the IL-5 receptor, has recently been approved for treatment of severe eosinophilic asthma. Our initial immunogenicity assay method for phase I and II studies utilized a bridging electrochemiluminescence format with biotin and ruthenium-labelled mepolizumab linked by anti-drug antibodies (ADA). We discovered that IL-5 significantly increased in dosed subjects from a phase II study and that the increased IL-5 was in the form of a drug-bound complex. We demonstrated that the elevated drug-bound IL-5 produced false-positive response in the in vitro ADA assay, in which drug-bound IL-5 dissociated and then bridged mepolizumab conjugates to yield positive signal. To eliminate the IL-5 interference, we compared two strategies: a solid-phase immunodepletion of IL-5 and an in-solution IL-5 immunocompetition. We identified the best competitive antibody for each purpose. We found both methods demonstrated similar effectiveness in reducing the false positive signal in IL-5 spiked samples; however, the in-solution immunocompetition for IL-5 had fewer false positives in study samples. Additionally, the in-solution immunocompetition method was experimentally simpler to execute. We modified the ADA assay by adding a pre-treatment step with a mepolizumab competitive anti- IL-5 antibody. Using this new method, we retested clinical samples from two phase II studies (MEA112997 and MEA114092). The confirmed ADA positive incidence was reduced from 29% and 61% to 1% and 8% with the modified in-solution immune inhibition method. Target interference is a fairly common problem facing immunogenicity testing, and target-induced false positive cannot be distinguished from true ADA response by the commonly used drug competitive confirmation assay. The approach and method used here for resolving target interference in ADA detection will be useful for differentiating between a true ADA response and target induced false positive as well as similar challenges in other programs</style></abstract><notes><style face="normal" font="Arial">DA - 20161127IS - 1872-7905 (Electronic)IS - 0022-1759 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jim.2016.11.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27889561">PM:27889561</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Methods\20161127-LiaoK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Methods\20161127-LiaoK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161127, Liao K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jim.2016.11.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahmed,S.</style></author><author><style face="normal" font="Arial"> Ernst,P.</style></author><author><style face="normal" font="Arial"> Bartlett,S.J.</style></author><author><style face="normal" font="Arial"> Valois,M.F.</style></author><author><style face="normal" font="Arial"> Zaihra,T.</style></author><author><style face="normal" font="Arial"> Pare,G.</style></author><author><style face="normal" font="Arial"> Grad,R.</style></author><author><style face="normal" font="Arial"> Eilayyan,O.</style></author><author><style face="normal" font="Arial"> Perreault,R.</style></author><author><style face="normal" font="Arial"> Tamblyn,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical Epidemiology, McGill University Health Center, McGill University, Montreal, QC, Canada</style></auth-address><titles><title><style face="normal" font="Arial">The Effectiveness of Web-Based Asthma Self-Management System, My Asthma Portal (MAP): A Pilot Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="Arial">J Med Internet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Internet Res</style></full-title></periodical><pages end="" start="e313">e313-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Case Management</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Behavior</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> medication adherence</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Whether Web-based technologies can improve disease self-management is uncertain. My Asthma Portal (MAP) is a Web-based self-management support system that couples evidence-based behavioral change components (self-monitoring of symptoms, physical activity, and medication adherence) with real-time monitoring, feedback, and support from a nurse case manager. OBJECTIVE: The aim of this study was to compare the impact of access to a Web-based asthma self-management patient portal linked to a case-management system (MAP) over 6 months compared with usual care on asthma control and quality of life. METHODS: A multicenter, parallel, 2-arm, pilot, randomized controlled trial was conducted with 100 adults with confirmed diagnosis of asthma from 2 specialty clinics. Asthma control was measured using an algorithm based on overuse of fast-acting bronchodilators and emergency department visits, and asthma-related quality of life was assessed using the Mini-Asthma Quality of Life Questionnaire (MAQLQ). Secondary mediating outcomes included asthma symptoms, depressive symptoms, self-efficacy, and beliefs about medication. Process evaluations were also included. RESULTS: A total of 49 individuals were randomized to MAP and 51 to usual care. Compared with usual care, participants in the intervention group reported significantly higher asthma quality of life (mean change 0.61, 95% CI 0.03 to 1.19), and the change in asthma quality of life for the intervention group between baseline and 3 months (mean change 0.66, 95% CI 0.35 to 0.98) was not seen in the control group. No significant differences in asthma quality of life were found between the intervention and control groups at 6 (mean change 0.46, 95% CI -0.12 to 1.05) and 9 months (mean change 0.39, 95% CI -0.2 to 0.98). For poor control status, there was no significant effect of group, time, or group by time. For all self-reported measures, the intervention group had a significantly higher proportion of individuals, demonstrating a minimal clinically meaningful improvement compared with the usual care group. CONCLUSIONS: This study supported the use of MAP to enhance asthma quality of life but not asthma control as measured by an administrative database. Implementation of MAP beyond 6 months with tailored protocols for monitoring symptoms and health behaviors as individuals' knowledge and self-management skills improve may result in long-term gains in asthma control. CLINICALTRIAL: International Standard Randomized Controlled Trial Number (ISRCTN): 34326236; http://www.isrctn.com/ISRCTN34326236 (Archived by Webcite at http://www.webcitation.org/6mGxoI1R7)</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1438-8871 (Electronic)IS - 1438-8871 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2196/jmir.5866</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27908846">PM:27908846</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Internet Res\2016-18-e313.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Internet Res\2016-18-e313.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Ahmed S</style></custom2><misc3><style face="normal" font="Arial">10.2196/jmir.5866</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gangneux,J.P.</style></author><author><style face="normal" font="Arial"> Bougnoux,M.E.</style></author><author><style face="normal" font="Arial"> Hennequin,C.</style></author><author><style face="normal" font="Arial"> Godet,C.</style></author><author><style face="normal" font="Arial"> Chandenier,J.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author><author><style face="normal" font="Arial"> Dupont,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre hospitalier universitaire de Rennes, laboratoire de parasitologie-mycologie, 2, rue Henri-le-Guilloux, 35033 Rennes cedex 09, France.</style></auth-address><titles><title><style face="normal" font="Arial">An estimation of burden of serious fungal infections in France</style></title><secondary-title><style face="normal" font="Arial">J Mycol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Mycol Med</style></full-title></periodical><pages end="390" start="385">385-390</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucormycosis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Tinea</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE OF THE STUDY: An estimation of burden of serious fungal diseases in France is essential data to inform public health priorities on the importance of resources and research needed on these infections. In France, precise data are available for invasive fungal diseases but estimates for several other diseases such as chronic and immunoallergic diseases are by contrast less known. MATERIALS AND METHODS: A systematic literature search was conducted using the Web of Science Platform. Published epidemiology papers reporting fungal infection rates from France were identified. Where no data existed, we used specific populations at risk and fungal infection frequencies in those populations to estimate national incidence or prevalence, depending on the condition. RESULTS: The model predicts high prevalences of severe asthma with fungal sensitization episodes (189 cases/100,000 adults per year), of allergic bronchopulmonary aspergillosis (145/100,000) and of chronic pulmonary aspergillosis (5.24/100,000). Besides, estimated incidence for invasive aspergillosis is 1.8/100,000 annually based on classical high risk factors. Estimates for invasive mucormycosis, pneumocystosis and cryptococcosis are 0.12/100,000, 1/100,000 and 0.2/100,000, respectively. Regarding invasive candidiasis, more than 10,000 cases per year are estimated, and a much higher number of recurrent vaginal candidiasis is probable but must be confirmed. Finally, this survey was an opportunity to report a first picture of the frequency of tinea capitis in France. CONCLUSION: Using local and literature data of the incidence or prevalence of fungal infections, approximately 1,000,000 (1.47%) people in France are estimated to suffer from serious fungal infections each year</style></abstract><notes><style face="normal" font="Arial">DA - 20161126IS - 1773-0449 (Electronic)IS - 1156-5233 (Linking)LA - engPT - Journal ArticleCO - France -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mycmed.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27887809">PM:27887809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Mycol Med\2016-26-385-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Mycol Med\2016-26-385-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161126, Gangneux JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mycmed.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shamshuddin,N.S.</style></author><author><style face="normal" font="Arial"> Mohd Zohdi,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Gelam honey attenuates ovalbumin-induced airway inflammation in a mice model of allergic asthma</style></title><secondary-title><style face="normal" font="Arial">J Trad Complement Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Trad Complement Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Honey</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2225-4110</style></isbn><abstract><style face="normal" font="Arial">Allergic asthma is a chronic inflammatory disorder of the pulmonary airways. Gelam honey has been proven to possess anti-inflammatory property with great potential to treat an inflammatory condition. However, the effect of ingestion of Gelam honey on allergic asthma has never been studied. This study aimed to investigate the efficacy of Gelam honey on the histopathological changes in the lungs of a mice model of allergic asthma. Forty-two Balb/c mice were divided into seven groups: control, I, II, III, IV, V and VI group. All groups except the control were sensitized and challenged with ovalbumin. Mice in groups I, II, III, IV, and V were given honey at a dose of 10% (v/v), 40% (v/v) and 80% (v/v), dexamethasone 3-ámg/kg, and phosphate buffered saline (vehicle) respectively, orally once a day for 5 days of the challenged period. Mice were sacrificed 24-áh after the last OVA challenged and the lungs were evaluated for histopathological changes by light microscopy. All histopathological parameters such as epithelium thickness, the number of mast cell and mucus expression in Group III significantly improved when compared to Group VI except for subepithelial smooth muscle thickness (p-á&amp;lt;-á0.05). In comparing Group III and IV, all the improvements in histopathological parameters were similar. Also, Gelam honey showed a significant (p-á&amp;lt;-á0.05) reduction in inflammatory cell infiltration and beta-hexosaminidase level in bronchoalveolar lavage fluid. In conclusion, we demonstrated that administration of high concentration of Gelam honey alleviates the histopathological changes of mice model of allergic asthma</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jtcme.2016.08.009</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jtcme.2016.08.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Trad Complement Med\20161202-ShamshuddinNS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Trad Complement Med\20161202-ShamshuddinNS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Shamshuddin NS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jtcme.2016.08.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oshikata,C.</style></author><author><style face="normal" font="Arial"> Watanabe,M.</style></author><author><style face="normal" font="Arial"> Saito,A.</style></author><author><style face="normal" font="Arial"> Yasueda,H.</style></author><author><style face="normal" font="Arial"> Akiyama,K.</style></author><author><style face="normal" font="Arial"> Kamata,Y.</style></author><author><style face="normal" font="Arial"> Tsurikisawa,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary mycosis caused by Penicillium luteum</style></title><secondary-title><style face="normal" font="Arial">Med Mycol Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Mycol Case Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary mycosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2211-7539</style></isbn><abstract><style face="normal" font="Arial">A 65-year-old Japanese male had severe bronchial asthma had increased mold-containing sputum. Serum total IgE level had increased to 798 IU/mL and antigen-specific precipitating antibodies to P. luteum and P. notatum were present but not those reactive toward any species of Aspergillus. Chest computed tomography revealed central bronchiectasis and bronchial wall thickness. After antigen-specific provocation with 10 mg/mL of P. luteum, the patient developed asthma exacerbation, but not with A. fumigatus. We present a rare case of Penicillium-induced allergic bronchopulmonary mycosis caused by P. luteum</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mmcr.2016.11.007</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.mmcr.2016.11.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Mycol Case Rep\20161202-OshikataC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Mycol Case Rep\20161202-OshikataC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161203, Oshikata C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mmcr.2016.11.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dodd,K.E.</style></author><author><style face="normal" font="Arial"> Mazurek,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Asthma Among Employed Adults, by Industry and Occupation - 21 States, 2013</style></title><secondary-title><style face="normal" font="Arial">MMWR Morb Mortal Wkly Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">MMWR Morb Mortal Wkly Rep</style></full-title></periodical><pages end="1331" start="1325">1325-1331</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">47</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> asthma prevention</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Education program</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> Occupations</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work-related asthma</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword><keyword><style face="normal" font="Arial"> Workplace exposure</style></keyword></keywords><dates><year Day="2" Month="12" Year="2016">2016/12/2</year></dates><abstract><style face="normal" font="Arial">Workers in various industries and occupations are at risk for work-related asthma* (1). Data from the 2006-2007 adult Behavioral Risk Factor Surveillance System (BRFSS) Asthma Call-back Survey (ACBS), an in-depth asthma survey conducted with respondents who report an asthma diagnosis, from 33 states indicated that up to 48% of adult current asthma might be related to work and could therefore potentially be prevented (2). Identification of the industries and occupations with increased prevalence of asthma might inform work-related asthma intervention and prevention efforts. To assess the industry-specific and occupation-specific proportions of adults with current asthma by state, CDC analyzed data from the 2013 BRFSS industry and occupation module, collected from 21 states for participants aged >/=18 years who, at the time of the survey interview, were employed or had been out of work for &lt;12 months. Among these respondents, 7.7% had current asthma; based on the Asthma Call-back Survey results, this finding means as many as 2.7 million U.S. workers might have asthma caused by or exacerbated by workplace conditions. State-specific variations in the prevalence of current asthma by industry and occupation were observed. By state, current asthma prevalence was highest among workers in the information industry (18.0%) in Massachusetts and in health care support occupations (21.5%) in Michigan. Analysis of BRFSS industry and occupation and optional asthma modules can be used to identify industries and occupations to assess for asthma among workers, identify workplace exposures, and guide the design and evaluation of effective work-related asthma prevention and education programs (1)</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1545-861X (Electronic)IS - 0149-2195 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.15585/mmwr.mm6547a1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906909">PM:27906909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\MMWR Morb Mortal Wkly Rep\2016-65-1325-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\MMWR Morb Mortal Wkly Rep\2016-65-1325-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Dodd KE</style></custom2><misc3><style face="normal" font="Arial">10.15585/mmwr.mm6547a1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Davies,A.M.</style></author><author><style face="normal" font="Arial"> Rispens,T.</style></author><author><style face="normal" font="Arial"> Ooijevaar-de Heer,P.</style></author><author><style face="normal" font="Arial"> Aalberse,R.C.</style></author><author><style face="normal" font="Arial"> Sutton,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">King's College London, Randall Division of Cell and Molecular Biophysics, New Hunt's House, London SE1 1UL, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Room temperature structure of human IgG4-Fc from crystals analysed in situ</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="91" start="85">85-91</pages><volume><style face="normal" font="Arial">81</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> packing</style></keyword><keyword><style face="normal" font="Arial"> Phagocytosis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="Arial">The Fc region of IgG antibodies (Cgamma2 and Cgamma3 domains) is responsible for effector functions such as antibody-dependent cell-mediated cytotoxicity and phagocytosis, through engagement with Fcgamma receptors, although the ability to elicit these functions differs between the four human IgG subclasses. A key determinant of Fcgamma receptor interactions is the FG loop in the Cgamma2 domain. High resolution cryogenic IgG4-Fc crystal structures have revealed a unique conformation for this loop, which could contribute to the particular biological properties of this subclass. To further explore the conformation of the IgG4 Cgamma2 FG loop at near-physiological temperature, we solved a 2.7A resolution room temperature structure of recombinant human IgG4-Fc from crystals analysed in situ. The Cgamma2 FG loop in one chain differs from the cryogenic structure, and adopts the conserved conformation found in IgG1-Fc; however, this conformation participates in extensive crystal packing interactions. On the other hand, at room temperature, and free from any crystal packing interactions, the Cgamma2 FG loop in the other chain adopts the conformation previously observed in the cryogenic IgG4-Fc structures, despite both conformations being accessible. The room temperature human IgG4-Fc structure thus provides a more complete and physiologically relevant description of the conformation of this functionally critical Cgamma2 FG loop</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2016.11.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27915153">PM:27915153</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2016-81-85-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2016-81-85-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Davies AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2016.11.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Maaren,M.S.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, Erasmus MC, Rotterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Dutch guideline on food allergy</style></title><secondary-title><style face="normal" font="Arial">Neth J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Neth J Med</style></full-title></periodical><pages end="382" start="376">376-382</pages><volume><style face="normal" font="Arial">74</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Double-blind challenge</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> false negative</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">The diagnosis of food allergy is established in cases where an immediate allergic reaction has occurred in the last year to a clearly identifiable allergenic food combined with sensitisation to this allergenic food. In all other cases, a food challenge test is required to establish or reject the diagnosis of food allergy. Although the double-blind placebo-controlled food challenge (DBPCFC) test is considered the gold standard, false-positive and false-negative outcomes occur. The incidence of false-positive outcomes is unknown because the results of DBPCFC tests cannot be further confirmed by other tests. If possible, it is important to perform double-blind challenges with recipes that have been validated for blinding and to use challenge procedures that have been proven safe in clinical practice, in order to reduce the risk of unwanted false-positive and false-negative outcomes and severe challenge reactions. The national guideline of the Dutch Society of Allergology describes when challenges are indicated and contraindicated, how food challenges are best conducted and how patients could best be managed and followed-up after the challenge tests have been completed</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1872-9061 (Electronic)IS - 0300-2977 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27905314">PM:27905314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Neth J Med\2016-74-376-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Neth J Med\2016-74-376-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, van Maaren MS</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shin,T.H.</style></author><author><style face="normal" font="Arial"> Lee,B.C.</style></author><author><style face="normal" font="Arial"> Choi,S.W.</style></author><author><style face="normal" font="Arial"> Shin,J.H.</style></author><author><style face="normal" font="Arial"> Kang,I.</style></author><author><style face="normal" font="Arial"> Lee,J.Y.</style></author><author><style face="normal" font="Arial"> Kim,J.J.</style></author><author><style face="normal" font="Arial"> Lee,H.K.</style></author><author><style face="normal" font="Arial"> Jung,J.E.</style></author><author><style face="normal" font="Arial"> Choi,Y.W.</style></author><author><style face="normal" font="Arial"> Lee,S.H.</style></author><author><style face="normal" font="Arial"> Yoon,J.S.</style></author><author><style face="normal" font="Arial"> Choi,J.S.</style></author><author><style face="normal" font="Arial"> Lee,C.S.</style></author><author><style face="normal" font="Arial"> Seo,Y.</style></author><author><style face="normal" font="Arial"> Kim,H.S.</style></author><author><style face="normal" font="Arial"> Kang,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 08826, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="11" Year="2016">2016/11/19</year></dates><abstract><style face="normal" font="Arial">Mesenchymal stem cell (MSC) has been applied for the therapy of allergic disorders due to its beneficial immunomodulatory abilities. However, the underlying mechanisms for therapeutic efficacy are reported to be diverse according to the source of cell isolation or the route of administration. We sought to investigate the safety and the efficacy of human adipose tissue-derived MSCs (hAT-MSCs) in mouse atopic dermatitis (AD) model and to determine the distribution of cells after intravenous administration. Murine AD model was established by multiple treatment of Dermatophagoides farinae. AD mice were intravenously infused with hAT-MSCs and monitored for clinical symptoms. The administration of hAT-MSCs reduced the gross and histological signatures of AD, as well as serum IgE level. hAT-MSCs were mostly detected in lung and heart of mice within 3 days after administration and were hardly detectable at 2 weeks. All of mice administered with hAT-MSCs survived until sacrifice and did not demonstrate any adverse events. Co-culture experiments revealed that hAT-MSCs significantly inhibited the proliferation and the maturation of B lymphocytes via cyclooxygenase (COX)-2 signaling. Moreover, mast cell (MC) degranulation was suppressed by hAT-MSC. In conclusion, the intravenous infusion of hAT-MSCs can alleviate AD through the regulation of B cell function</style></abstract><notes><style face="normal" font="Arial">DA - 20161126IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.13473</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888809">PM:27888809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20161126-ShinTH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20161126-ShinTH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161126, Shin TH</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.13473</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tignor,N.</style></author><author><style face="normal" font="Arial"> Wang,P.</style></author><author><style face="normal" font="Arial"> Genes,N.</style></author><author><style face="normal" font="Arial"> Rogers,L.</style></author><author><style face="normal" font="Arial"> Hershman,S.G.</style></author><author><style face="normal" font="Arial"> Scott,E.R.</style></author><author><style face="normal" font="Arial"> Zweig,M.</style></author><author><style face="normal" font="Arial"> Yvonne Chan,Y.F.</style></author><author><style face="normal" font="Arial"> Schadt,E.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">METHODS FOR CLUSTERING TIME SERIES DATA ACQUIRED FROM MOBILE HEALTH APPS</style></title><secondary-title><style face="normal" font="Arial">Pac Symp Biocomput</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Pac Symp Biocomput</style></abbr-1></periodical><pages end="311" start="300">300-311</pages><volume><style face="normal" font="Arial">22</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">In our recent Asthma Mobile Health Study (AMHS), thousands of asthma patients across the country contributed medical data through the iPhone Asthma Health App on a daily basis for an extended period of time. The collected data included daily self-reported asthma symptoms, symptom triggers, and real time geographic location information. The AMHS is just one of many studies occurring in the context of now many thousands of mobile health apps aimed at improving wellness and better managing chronic disease conditions, leveraging the passive and active collection of data from mobile, handheld smart devices. The ability to identify patient groups or patterns of symptoms that might predict adverse outcomes such as asthma exacerbations or hospitalizations from these types of large, prospectively collected data sets, would be of significant general interest. However, conventional clustering methods cannot be applied to these types of longitudinally collected data, especially survey data actively collected from app users, given heterogeneous patterns of missing values due to: 1) varying survey response rates among different users, 2) varying survey response rates over time of each user, and 3) non-overlapping periods of enrollment among different users. To handle such complicated missing data structure, we proposed a probability imputation model to infer missing data. We also employed a consensus clustering strategy in tandem with the multiple imputation procedure. Through simulation studies under a range of scenarios reflecting real data conditions, we identified favorable performance of the proposed method over other strategies that impute the missing value through low-rank matrix completion. When applying the proposed new method to study asthma triggers and symptoms collected as part of the AMHS, we identified several patient groups with distinct phenotype patterns. Further validation of the methods described in this paper might be used to identify clinically important patterns in large data sets with complicated missing data structure, improving the ability to use such data sets to identify at-risk populations for potential intervention</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 2335-6936 (Print)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1142/9789813207813_0029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27896984">PM:27896984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pac Symp Biocomput\2016-22-300-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pac Symp Biocomput\2016-22-300-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Tignor N</style></custom2><misc3><style face="normal" font="Arial">10.1142/9789813207813_0029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Messina,C.M.</style></author><author><style face="normal" font="Arial"> Pizzo,F.</style></author><author><style face="normal" font="Arial"> Santulli,A.</style></author><author><style face="normal" font="Arial"> Buselic,I.</style></author><author><style face="normal" font="Arial"> Boban,M.</style></author><author><style face="normal" font="Arial"> Orhanovic,S.</style></author><author><style face="normal" font="Arial"> Mladineo,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Scienze della Terra e del Mare DiSTeM, Universita degli Studi di Palermo, Laboratorio di Biochimica Marina ed Ecotossicologia, Via G. Barlotta 4, 91100, Trapani, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Anisakis pegreffii (Nematoda: Anisakidae) products modulate oxidative stress and apoptosis-related biomarkers in human cell lines</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="607">607-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis pegreffii</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cell viability</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Damage</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fibroblasts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Mare</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular marker</style></keyword><keyword><style face="normal" font="Arial"> Molecular markers</style></keyword><keyword><style face="normal" font="Arial"> Nematoda</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectrophotometry</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Stress response</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword></keywords><dates><year Day="25" Month="11" Year="2016">2016/11/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In countries with elevated prevalence of zoonotic anisakiasis and high awareness of this parasitosis, a considerable number of cases that associate Anisakis sp. (Nematoda, Anisakidae) and different bowel carcinomas have been described. Although neoplasia and embedded larvae were observed sharing the common site affected by chronic inflammation, no association between the nematode and malignancy were directly proved. Similarly, no data are available about the effect of secretory and excretory products of infecting larvae at the host's cellular level, except in respect to allergenic interaction. METHODS: To test the mechanisms by which human non-immune cells respond to the larvae, we exposed the fibroblast cell line HS-68 to two Anisakis products (ES, excretory/secretory products; and EC, crude extract) and evaluated molecular markers related to stress response, oxidative stress, inflammation and apoptosis, such as p53, HSP70, TNF-alpha, c-jun and c-fos, employing cell viability assay, spectrophotometry, immunoblotting and qPCR. RESULTS: Both Anisakis products led to increased production of reactive oxygen species (ROS), especially in EC-treated cells. While the ES treatment induces activation of kinases suggesting inflammation and cell proliferation (or inhibition of apoptosis), in EC-treated cells, other signaling pathways indicate the inhibition of apoptosis, marked by strong upregulation of Hsp70. Elevated induction of p53 in fibroblasts treated by both Anisakis products, suggests a significantly negative effect on the host DNA. CONCLUSIONS: This study shows that in vitro cell response to Anisakis products can result in at least two different scenarios, which in both cases lead to inflammation and DNA damage. Although these preliminary results are far from proving a relationship between the parasite and cancer, they are the first to support the existence of conditions where such changes are feasible</style></abstract><notes><style face="normal" font="Arial">DA - 20161126IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Croatia -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-016-1895-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27887635">PM:27887635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2016-9-607.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2016-9-607.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161126, Messina CM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-016-1895-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chung,H.J.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Shin,J.S.</style></author><author><style face="normal" font="Arial"> Kim,M.R.</style></author><author><style face="normal" font="Arial"> Koh,W.</style></author><author><style face="normal" font="Arial"> Kim,M.J.</style></author><author><style face="normal" font="Arial"> Lee,J.W.</style></author><author><style face="normal" font="Arial"> Kim,E.J.</style></author><author><style face="normal" font="Arial"> Lee,I.H.</style></author><author><style face="normal" font="Arial"> Kim,W.K.</style></author><author><style face="normal" font="Arial"> Lee,Y.J.</style></author><author><style face="normal" font="Arial"> Lee,S.K.</style></author><author><style face="normal" font="Arial"> Ha,I.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">In Vitro and In Vivo Anti-Allergic and Anti-Inflammatory Effects of eBV, a Newly Developed Derivative of Bee Venom, through Modulation of IRF3 Signaling Pathway in a Carrageenan-Induced Edema Model</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0168120">e0168120-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Alternative Medicine</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apis mellifera</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Complementary and alternative medicine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1beta</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> PGE2</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> PLA2</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin E2</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Spine</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Transducers</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bee venom (BV), a type of toxin extracted from honeybees (Apis mellifera), has been empirically and widely used to treat inflammatory diseases throughout Asia. Essential BV (eBV) was developed by removing phospholipase A2 (PLA2) and histamine to lower occurrence of allergic reaction. This study investigated the anti-allergic and anti-inflammatory activities of eBV in vitro and in vivo and its underlying mechanism of action. METHODS: The anti-inflammatory potential of eBV was assessed in vivo using a carrageenan-induced paw edema model. To further investigate the mechanism by which eBV exerts anti-allergic and anti-inflammatory effects, compound 48/80-stimulated RBL-2H3 cells and lipopolysaccharide (LPS)-stimulated RAW 264.7 murine macrophage cells were studied in vitro. RESULTS: Release of beta-hexosaminidase and histamine was increased by eBV in a dose-dependent manner, but these levels were lower in eBV compared to original BV at the same concentration. In addition, eBV suppressed compound 48/80-induced expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in RBL-2H3 cells. eBV was also shown to suppress nitric oxide (NO) production by down-regulating mRNA expression and subsequent protein expression of inflammatory mediators in LPS-induced RAW 264.7 cells. Phosphorylation of activators and signal transducers of transcription 1/interferon regulatory factor 3 (STAT1/IRF3) was attenuated by eBV treatment. eBV significantly inhibited carrageenan-induced acute edema in vivo. Serum levels of prostaglandin E2 (PGE2), TNF-alpha, and IL-1beta were also down-regulated by eBV. CONCLUSIONS: These results demonstrate that eBV inhibits allergic and inflammatory response by reducing inflammatory mediator production via regulation of the STAT1/IRF3 signaling pathway, suggesting that eBV is a feasible candidate for regulation of allergic-inflammatory response in complementary and alternative medicine</style></abstract><notes><style face="normal" font="Arial">DA - 20161208IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0168120</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27930719">PM:27930719</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0166347.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0166347.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161208, Chung HJ</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0168120</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alsaleh,N.B.</style></author><author><style face="normal" font="Arial"> Persaud,I.</style></author><author><style face="normal" font="Arial"> Brown,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Silver Nanoparticle-Directed Mast Cell Degranulation Is Mediated through Calcium and PI3K Signaling Independent of the High Affinity IgE Receptor</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0167366">e0167366-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial properties</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intracellular signaling</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Silver nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Engineered nanomaterial (ENM)-mediated toxicity often involves triggering immune responses. Mast cells can regulate both innate and adaptive immune responses and are key effectors in allergic diseases and inflammation. Silver nanoparticles (AgNPs) are one of the most prevalent nanomaterials used in consumer products due to their antimicrobial properties. We have previously shown that AgNPs induce mast cell degranulation that was dependent on nanoparticle physicochemical properties. Furthermore, we identified a role for scavenger receptor B1 (SR-B1) in AgNP-mediated mast cell degranulation. However, it is completely unknown how SR-B1 mediates mast cell degranulation and the intracellular signaling pathways involved. In the current study, we hypothesized that SR-B1 interaction with AgNPs directs mast cell degranulation through activation of signal transduction pathways that culminate in an increase in intracellular calcium signal leading to mast cell degranulation. For these studies, we utilized bone marrow-derived mast cells (BMMC) isolated from C57Bl/6 mice and RBL-2H3 cells (rat basophilic leukemia cell line). Our data support our hypothesis and show that AgNP-directed mast cell degranulation involves activation of PI3K, PLCgamma and an increase in intracellular calcium levels. Moreover, we found that influx of extracellular calcium is required for the cells to degranulate in response to AgNP exposure and is mediated at least partially via the CRAC channels. Taken together, our results provide new insights into AgNP-induced mast cell activation that are key for designing novel ENMs that are devoid of immune system activation</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0167366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27907088">PM:27907088</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0167366.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0167366.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Alsaleh NB</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0167366</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ben Ameur,S.</style></author><author><style face="normal" font="Arial"> Kamoun,F.</style></author><author><style face="normal" font="Arial"> Ben Bey,A.</style></author><author><style face="normal" font="Arial"> Feki,H.</style></author><author><style face="normal" font="Arial"> Aloulou,H.</style></author><author><style face="normal" font="Arial"> Damak,J.</style></author><author><style face="normal" font="Arial"> Chabchoub,I.</style></author><author><style face="normal" font="Arial"> Hachicha,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergenic profile and control level in asthmatic children in Sfax</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="514" start="509">509-514</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">7</style><style face="normal" font="Symbol">-</style><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergie</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy skin test</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensibilisation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Sex Ratio</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Traitement</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Aims To describe the allergic profile of asthma in infant, study the asthma control level and the factors that influence it. Methods A prospective study of 120 cases of allergic asthma patients followed in pediatric department in Sfax. Diagnosis of allergy is based on the allergy skin test positivity. Asthma control evaluation at the last consultation was based on GINA 2014 recommendations. Results The average age of our patients was 7 years 8 months. A male predominance was noted (sex ratio = 1.7). Allergic rhinitis was present in 65.8% of cases. The main identified allergens are dust mites (81.7%). Pollens come second (15%) with predominance of olive trees, followed by molds (12.5%), animal dander (10.8%) and cockroaches (10%). The asthma control evaluation showed a controlled asthma in 27.9% of cases, partially controlled (56.7%) and not controlled (15.4%). Younger age (P = 0.01), low socioeconomic level (P = 0.02), presence of allergic rhinitis (P = 0.02), sensitization to molds (P = 0.0009) and bad treatment compliance (P &amp;lt; 0.001) were all significantly associated with a poor control of asthma. Allergen immunotherapy and the use of powder inhaler device were significantly associated with controlled asthma (P = 0.01). Conclusion In the region of Sfax, mites are the predominant allergens followed by pollens. As a result of this study, we point out that the control of asthma is still insufficient</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Tunisia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.10.015</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.10.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\2016-56-509-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\2016-56-509-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Ben Ameur S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.10.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chalmin,J.</style></author><author><style face="normal" font="Arial"> Bourrier,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Oral immunotherapy for peanut allergy. Paediatric experience in Nice</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="17" start="8">8-17</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergie arachide</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral challenge test</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> P+®diatrie</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Traitement</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Oral immunotherapy may offer an alternative to elimination diets in peanut allergy. Of 72-áchildren for whom this treatment was proposed following an oral challenge test (TPO1), 68-áagreed and entered a personalised oral immunotherapy study. There were 10-átreatment failures and 31-ápatients underwent a second oral challenge during treatment (TPO2). Cumulative reactogenic dose and clinical severity score were compared. Skin tests and assay of IgE specific for peanut allergy were first performed prior to TPO1 and again during follow-up. The mean age of these 31-ápatients was 8.1-áyears. The median time between two challenge tests was 1.4-áyears. The mean cumulative reactogenic dose between TPO1 (4207 mg of peanut) and TPO2 (8769 mg of peanut) increased significantly (P &amp;lt; 0.001). Conversely, the clinical severity score was significantly reduced between the two challenge tests (P &amp;lt; 0.001). No serious adverse effects were reported during immunotherapy. This treatment in a paediatric population, administered at the patients</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ homes, confirms the efficacy of the therapy as well as an acceptable benefit/risk ratio consistent with the data. Oral immunotherapy for peanut allergy is part of a personalised therapeutic approach for children with food allergies</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.10.007</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.10.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20161205-ChalminJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20161205-ChalminJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Chalmin J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Molkhou,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Non-coeliac gluten sensitivity (NCGS): The position in 2016</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="561" start="556">556-561</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">7</style><style face="normal" font="Symbol">-</style><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-gliadin antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Coeliac disease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Irritable Bowel Syndrome</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Non-coeliac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Non-coeliac gluten sensitivity (NCGS) is a new entity that has been distinguished from other diseases associated with gluten consumption. In particular, it differs from coeliac disease in terms of absence of mucosal lesions and atrophied villosities. While anti-gliadin antibodies may be numerous, no anti-transglutaminase is observed. NCGS occurs far more frequently in coeliac disease with relatively non-specific gastrointestinal symptoms and in the absence of extra-digestive signs, except for psychiatric diseases, where the association continues to be contested. Diagnosis is based on clinical history, elimination of coeliac disease and gluten elimination-reintroduction challenge tests. There appears to be some overlap with irritable bowel syndrome and NCGS certainly constitutes a framework of expectations with subgroups characterized by different types of pathogenesis, clinical history and course</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.10.006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.10.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\2016-56-556-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\2016-56-556-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Molkhou P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.10.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fontaine,J.F.</style></author><author><style face="normal" font="Arial"> Elias Billon,I.</style></author><author><style face="normal" font="Arial"> Nexon,M.</style></author><author><style face="normal" font="Arial"> Allaert,F.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Frequency, intensity and impact of ocular symptoms in allergic rhinitis: FIRE study</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="521" start="515">515-521</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">7</style><style face="normal" font="Symbol">-</style><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cromone</style></keyword><keyword><style face="normal" font="Arial"> cromones</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Ocular symptoms</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> PAREO</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Signes oculaires</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores fongiques</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TOSS</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSSS</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Background The purpose of the study was to describe the frequency, intensity and impact of ocular symptoms in allergic rhinitis and identify the existence of a specific profile of patients with major ocular symptoms. Methods Cross-sectional observational study conducted in daily practice. Ocular involvement was assessed by the Total Score Subjective Syndrome (TSSS) and the Total Ocular Sign Score (TOSS) and quality of life by Mini-RQLQ. The identification of the profiles was performed by logistic regression analysis and cluster analysis. Results In total, 2719-ápatients aged 38.0 -¦ 14.0 among whom 53.1% of women were analyzed. A total of 22.4% had mild intermittent rhinitis, 15.0% moderate to severe intermittent rhinitis, 13.3% mild persistent rhinitis and 49.2% moderate to severe persistent rhinitis. Their PAREO score was 1.9 -¦ 0.6. Their TOSS score was 41.5 -¦ 22.8 in 100, their TSSS score was 6.4 -¦ 3.3 in 15 and 25.9% of them had a value &amp;gt; 8 corresponding to a major symptomatology. Cluster analysis identified among all patients the existence of a homogeneous group of patients characterized by a more significant ocular involvement (TSSS: 8.5 -¦ vs 4.6 -¦ 2.7, P &amp;lt; 0.0001; TOSS: 60.3 -¦ 16.0 vs 25.8 -¦ 14.1, P &amp;lt; 0.0001) whose rhinitis was more frequently persistent with a moderate to severe intensity (61.4% vs 39.0%, P &amp;lt; 0.0001), and with a greater impairment of the quality of life (3.5 -¦ 1.0 vs 2.5 -¦ 1.0, P &amp;lt; 0.0001). The logistic regression analysis confirmed these data showing also that pollen but also fungal spore allergens are more frequently identified. In these patients the practitioners more frequently associated intranasal corticosteroids (73.9% vs 67.6%, P &amp;lt; 0.001) and cromones (76.0% vs 52.6%, P &amp;lt; 0.0001) with oral H1 antihistamines. Conclusion The association of rhinitis and ocular symptoms could be a frequent and specific entity requiring a specific treatment combining oral H1 antihistamines and cromones</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.10.011</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.10.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\2016-56-515-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\2016-56-515-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Fontaine JF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.10.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Dahda,L.</style></author><author><style face="normal" font="Arial"> Dupont,C.</style></author><author><style face="normal" font="Arial"> Campoy,C.</style></author><author><style face="normal" font="Arial"> Fierro,V.</style></author><author><style face="normal" font="Arial"> Nieto,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, University Department of Pediatrics, Pediatric Hospital Bambino Gesu, Rome, Vatican City Italy</style></auth-address><titles><title><style face="normal" font="Arial">Cow's milk allergy: towards an update of DRACMA guidelines</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> DRACMA</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In 2010, the diagnosis and treatment of IgE-mediated CMA were systematized in a GRADE guideline. OBJECTIVES &amp; METHODS: After 6 years, the state of the knowledge in diagnosis and treatment of CMA has largely evolved. We summarize here the main advances, and exemplify indicating some specific points: studies aimed at better knowledge of the effects of breastfeeding and the production of new special formulae intended for the treatment of CMA. The literature (PubMed/MEDLINE) was searched using the following algorithms: (1) [milk allergy] AND diagnosis; (2) [milk allergy] AND [formul*] OR [breast*], setting the search engine [6-years] time and [human] limits. The authors drew on their collective clinical experience to restrict retrieved studies to those of relevance to a pediatric allergy practice. RESULTS: Several clinical studies did address the possibility to diagnose CMA using new tools in vitro and in vivo, or to diagnose it without any evaluation of sensitization. Some studies also addressed the clinical role of formulae based on milk hydrolysates, soy, or rice hydrolysates in the treatment of CMA. Many studies have elucidated the effects of selective nutrients in breastfed infants on their immunologic and neurologic characteristics. CONCLUSIONS: Evidence-based diagnostic criteria should be identified for non-IgE-mediated CMA. Debate is ongoing about the best substitute for infants with CMA. In particular, Hydrolyzed Rice Formulae have been widely assessed in the last six years. In the substitute choice, clinicians should be aware of recent studies that can modify the interpretation of the current recommendations. New systematic reviews and metanalyses are needed to confirm or modify the current DRACMA recommendations</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1939-4551 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -CO - France -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0125-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27895813">PM:27895813</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Fiocchi A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0125-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Magen,E.</style></author><author><style face="normal" font="Arial"> Chikovani,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Eli Magen, Medicine C Department, Allergy and Clinical Immunology Unit, Barzilai Medical Center, Ben Gurion University of Negev, Ashkelon 78100, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Possible therapeutic role of IgE blockade in irritable bowel syndrome</style></title><secondary-title><style face="normal" font="Arial">World J Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Gastroenterol</style></full-title></periodical><pages end="9456" start="9451">9451-9456</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">43</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Fc receptors</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IBS</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Irritable Bowel Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="21" Month="11" Year="2016">2016/11/21</year></dates><abstract><style face="normal" font="Arial">Omalizumab is a humanized monoclonal antibody that binds to the high-affinity type-I IgE Fc receptors on mast cells (MCs) and basophils, inhibiting the IgE immune pathway. Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder, and dysregulation of the immune system likely contributes to its etiology and/or symptomatology. Colonic biopsies from patients with IBS demonstrate considerable increase in the number of degranulating MCs releasing histamine in proximity to nerves, and this event may underlie the common IBS symptom of abdominal pain. Pharmacologic control of MC activation and mediator release is a current area of active interest in the field of IBS research. Recently, we and Pearson et al described 2 cases of patients with IBS with diarrhea (IBS-D) showing positive clinical response to omalizumab. In both cases, the female patients had severe, long-lasting IBS-D and achieved an almost complete resolution of IBS symptoms. Both patients were also able to discontinue all IBS medications after commencing the anti-IgE therapy. For both patients, the omalizumab treatment showed a relatively rapid onset of action, resembling the efficacy observed in and previously reported for patients with chronic spontaneous urticaria. In this Editorial, we discuss the possible biological mechanisms that may underlie the clinical efficacy of omalizumab in IBS. We suggest that there is a need for a well-designed prospective study to investigate the therapeutic effects of anti-IgE in IBS</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 2219-2840 (Electronic)IS - 1007-9327 (Linking)LA - engPT - EditorialCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.3748/wjg.v22.i43.9451</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27920467">PM:27920467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Gastroenterol\2016-22-9451-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Gastroenterol\2016-22-9451-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Magen E</style></custom2><misc3><style face="normal" font="Arial">10.3748/wjg.v22.i43.9451</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Strinnholm,A.</style></author><author><style face="normal" font="Arial"> Winberg,A.</style></author><author><style face="normal" font="Arial"> Hedman,L.</style></author><author><style face="normal" font="Arial"> Ronmark,E.</style></author><author><style face="normal" font="Arial"> Lindh,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Clinical Medicine, Occupational and Environmental Medicine, The OLIN Unit, Umea University, Umea, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Reintroduction failure is common among adolescents after double-blind placebo-controlled food challenges</style></title><secondary-title><style face="normal" font="Arial">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Paediatr</style></abbr-1></periodical><pages end="287" start="282">282-287</pages><volume><style face="normal" font="Arial">106</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Cod</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> OLIN</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">AIM: There has been a lack of research on adolescents who undergo double-blind placebo-controlled food challenges. The aim of this study was to investigate food allergic adolescents' experiences and consequences of double-blind placebo-controlled food challenges. METHODS: This qualitative, descriptive interview study included 17 adolescents aged 14-15 years with total elimination of cows' milk, hens' eggs or cod due to food allergies. The participants, who were initially identified from a large population-based cohort study, were interviewed 18 months after completing their challenges. RESULTS: The double-blind placebo-controlled food challenge proved to be a complex experience for the adolescents, involving fear of potential reactions and the hope that the food could be reintroduced. Experiences during the challenge were described in three themes: facing fears in a secure environment, being hesitant but curious about unknown tastes and waiting for unknown food reactions. Experiences after the challenge were described in two themes: gaining control and freedom and continuing old habits. A negative challenge was not consistently associated with the reintroduction of the challenged food. CONCLUSION: This study highlighted the importance of considering the adolescents' expectations and experiences of the challenge and the reintroduction process to ensure desirable changes in their dietary habits. Follow-ups should be performed regardless of the outcome of challenges</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/apa.13673</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27859574">PM:27859574</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Paediatr\20161118-StrinnholmA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Paediatr\20161118-StrinnholmA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Strinnholm A</style></custom2><misc3><style face="normal" font="Arial">10.1111/apa.13673</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kukkonen,A.K.</style></author><author><style face="normal" font="Arial"> Uotila,R.</style></author><author><style face="normal" font="Arial"> Malmberg,L.P.</style></author><author><style face="normal" font="Arial"> Pelkonen,A.S.</style></author><author><style face="normal" font="Arial"> Makela,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Helsinki and Helsinki University Hospital; the Skin and Allergy Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Double-blind placebo controlled challenge showed that peanut oral immunotherapy was effective for severe allergies without negative effects on airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Paediatr</style></abbr-1></periodical><pages end="281" start="274">274-281</pages><volume><style face="normal" font="Arial">106</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">AIM: This study examined the efficacy and the safety of peanut oral immunotherapy (OIT). METHODS: We recruited 60 patients aged 6-18 years who had a moderate-to-severe reaction to a double-blind placebo-controlled peanut challenge: 39 received OIT during an eight-month build-up phase and maintenance phase and 21 controls avoided peanuts. We measured specific immunoglobulin E and G4 (IgE and IgG4) to peanuts and to Ara h 1, 2, 3, 8, and 9 and monitored adverse events, bronchial hyperresponsiveness (BHR) to methacholine and fractional concentrations of exhaled nitric oxide (FeNO). The median follow up was 30 months. RESULTS: Most (85%) of the OIT patients passed the build-up phase and 67% tolerated five grams of peanuts during the post-treatment challenge. No controls were desensitised, with a risk ratio of 29 and 95% confidence interval of 1.9-455. During OIT, IgE to peanut, Ara h 1, 2 and 3 decreased and IgG4 increased. Consuming peanuts had no harmful effects on BHR or FeNO. The annual incidence rate of emergency visits during the follow-up period was 11% or 3.0 per 10,000 patient days. CONCLUSION: Peanut OIT was efficacious in severe allergies without negative effects on airway inflammation, but unpredictable long-term reactions might occur. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/apa.13668</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27859599">PM:27859599</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Paediatr\20161118-KukkonenAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Paediatr\20161118-KukkonenAK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Kukkonen AK</style></custom2><misc3><style face="normal" font="Arial">10.1111/apa.13668</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Borres,N.</style></author><author><style face="normal" font="Arial"> Nilsson,N.</style></author><author><style face="normal" font="Arial"> Drake,I.</style></author><author><style face="normal" font="Arial"> Sjolander,S.</style></author><author><style face="normal" font="Arial"> Nilsson,C.</style></author><author><style face="normal" font="Arial"> Hedlin,G.</style></author><author><style face="normal" font="Arial"> Nordlund,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Science, Medical Faculty, University of Lund, MalmoDepartment of Women's and Children's Health, Division for Lung Allergology, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Parents' perceptions are that their child's health-related quality of life is more impaired when they have a wheat rather than a grass allergy</style></title><secondary-title><style face="normal" font="Arial">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Paediatr</style></abbr-1></periodical><pages end="484" start="478">478-484</pages><volume><style face="normal" font="Arial">106</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emotions</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">AIM: It is unknown whether food allergies have greater impact on quality of life than respiratory allergies. This study compared health-related quality of life (HRQoL) in children allergic to wheat or grass. METHODS: We surveyed 63 children with wheat allergies (median age of five) and 72 with grass allergies (median age 12), with their parents. The Child Health Questionnaires for parents (CHQ-PF28) and children (CHQ-CF87) were applied. RESULTS: The parents of children in the wheat group recorded significantly lower CHQ-PF28 scores for the impact of their child's allergy on general behaviour, general health perceptions, parental impact of emotions and time and family activities, than the parents of children with grass allergies (p values &lt;0.001). However, parents in the grass group recorded lower scores for the change in health item than the parents of children with wheat allergies (p=0.020). In the grass group, children and parents reported similar scores for the different questions, but there was poorer correlation between parents and children in the wheat allergy group. CONCLUSION: HRQoL was lower in children with wheat than grass allergies according to parental reports, with more consistent perceptions of HRQoL among parents and children in the grass allergy than wheat allergy group. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/apa.13688</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27925295">PM:27925295</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Paediatr\20161207-BorresN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Paediatr\20161207-BorresN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Borres N</style></custom2><misc3><style face="normal" font="Arial">10.1111/apa.13688</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">von Arnim,U.</style></author><author><style face="normal" font="Arial"> Rohl,F.W.</style></author><author><style face="normal" font="Arial"> Miehlke,S.</style></author><author><style face="normal" font="Arial"> Jechorek,D.</style></author><author><style face="normal" font="Arial"> REINHOLD,D.</style></author><author><style face="normal" font="Arial"> Wex,T.</style></author><author><style face="normal" font="Arial"> Malfertheiner,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, Magdeburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Clinical symptom tool that raises the index of suspicion for eosinophilic oesophagitis in adults and drives earlier biopsy for definitive diagnosis</style></title><secondary-title><style face="normal" font="Arial">Aliment Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Aliment Pharmacol Ther</style></full-title></periodical><pages end="426" start="417">417-426</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gastro-oesophageal reflux</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> GERD</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic oesophagitis (EoE) and gastro-oesophageal reflux disease (GERD) present with overlapping symptomatology and it is challenging to distinguish EoE from GERD clinically before endoscopy. AIM: To investigate the prognostic value of a set of clinical symptoms and laboratory values in patients with EoE and GERD. METHODS: In this prospective, single-centre, observational study, we compared clinical and laboratory data from 202 patients with EoE or GERD (10 relevant characteristics). Those characteristics showing potential significance in a univariate analysis were then included in a multivariate analysis. RESULTS: The set of 10 characteristics (10-marker set) was able to distinguish between EoE and GERD with good reliability (correct assignment, i.e. agreement with subsequent EGD, of 94.4%). Reduction of the set to the six statistically and clinically most relevant markers continued to give good reliability (88.9%), and further stepwise reduction led to four-marker sets comprising history of atopy, history of food impaction, proton pump inhibitor refractory symptoms and either immunoglobulin E or peripheral eosinophilia, with correct assignment rates of 91.3% and 85.1% respectively. CONCLUSIONS: We have developed a simple and easily applicable clinical/laboratory marker set that helps to distinguish EoE from GERD earlier in the treatment course, thus guiding the endoscopist to perform biopsies from the oesophagus to ensure the diagnosis. The application of the scoring system is expected to diagnose EoE earlier and avoiding delay of adequate treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1365-2036 (Electronic)IS - 0269-2813 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/apt.13869</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27896821">PM:27896821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aliment Pharmacol Ther\20161129-vonArnimU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aliment Pharmacol Ther\20161129-vonArnimU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, von Arnim U</style></custom2><misc3><style face="normal" font="Arial">10.1111/apt.13869</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kwiatkowski,L.</style></author><author><style face="normal" font="Arial"> Mitchell,J.</style></author><author><style face="normal" font="Arial"> Langland,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Resolution of Allergic Rhinitis and Reactive Bronchospasm With Supplements and Food-specific Immunoglobulin G Elimination: A Case Report</style></title><secondary-title><style face="normal" font="Arial">Altern Ther Health Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Altern Ther Health Med</style></full-title></periodical><pages end="28" start="24">24-28</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">S3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Albuterol</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Diphenhydramine</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Loratadine</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Perfume</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Context * Allergies are a common affliction, whether they are respiratory, food related, or dermatological. People often resort to continuous use of over-the-counter medications, such as antihistamines, to manage their symptoms. Controversy still remains over testing serum immunoglobulin (Ig) G to diagnose food allergies. Objective * This study intended to examine the benefits of treatment of a pediatric patient with natural supplements and an elimination diet for IgG food allergies. Design * The research team reported a case study. Setting * The study was conducted at Southwest Naturopathic Medical Center (Tempe, AZ, USA). Participant * The participant was a 10-y-old Caucasian female who had diagnoses of allergic rhinitis and reactive bronchospasm, the second of which was exacerbated by allergens such as wheat, perfumes, and seasonal flora. Intervention * Following testing for IgE- and IgG-reactive foods, the patient was treated with natural supplements to reduce her allergic responses and was instructed to make dietary changes to eliminate the IgG-reactive foods. Outcome Measures * The patient's symptom severity was tracked starting 1 mo after her initial visit to Southwest Naturopathic Medical Center. The severity was based on the patient's subjective reports about her congestion to her mother and on her mother's observations of the effect of symptoms on her attention and school performance. The bronchospasm severity was based on the frequency of a sensation of wheezing and chest tightness, the frequency of inhaler use, and the occurrence of any exacerbation of symptoms with acute respiratory illness Results * After 1 mo, in which the patient used the natural supplements, she experienced a 90% improvement in coughing; a 70% improvement in nasal congestion; less chest tightness; and no need for use of loratadine, diphenhydramine, or albuterol. At the 8-mo follow-up visit, her nasal congestion was reported to be entirely gone. Conclusions * The case demonstrates the effectiveness of natural supplements and a diet eliminating IgG-reactive foods in the treatment and management of pediatric allergic rhinitis and reactive bronchospasm</style></abstract><notes><style face="normal" font="Arial">DA - 20161120IS - 1078-6791 (Print)IS - 1078-6791 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27866183">PM:27866183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Altern Ther Health Med\2016-22S3-24-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Altern Ther Health Med\2016-22S3-24-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Kwiatkowski L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Frampton,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.</style></auth-address><titles><title><style face="normal" font="Arial">Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency</style></title><secondary-title><style face="normal" font="Arial">Am J Cardiovasc Drugs</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Am J Cardiovasc Drugs</style></abbr-1></periodical><pages end="468" start="461">461-468</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> hematopoietic stem cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lipase</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Liver Transplantation</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> stem cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Sebelipase alfa (Kanuma(R), Kanuma), the first commercially available recombinant human lysosomal acid lipase (LAL), is approved in various countries worldwide, including those of the EU, the USA and Japan, as a long-term enzyme replacement therapy for patients diagnosed with LAL deficiency (LAL-D), an ultra-rare, autosomal recessive, progressive metabolic liver disease. In an ongoing study in nine infants presenting with early-onset LAL-D (Wolman disease), open-label treatment with sebelipase alfa significantly improved 1-year survival compared with historical controls. A substantial mortality benefit was maintained at 2 years of age, as was a reduction in disease-related activity. In an ongoing study of 66 children and adults with late-onset LAL-D (cholesteryl ester storage disease), 20 weeks' double-blind treatment with sebelipase alfa significantly reduced multiple disease-related hepatic and lipid abnormalities compared with placebo. Sustained improvements in markers of liver damage and dyslipidaemia were seen after 76 weeks' open-label treatment in an extension of this trial and, similarly, after 2 years' open-label treatment in an extension of another study in nine adults with late-onset LAL-D. Sebelipase alfa therapy has thus far been generally well tolerated, with signs and symptoms consistent with anaphylaxis being the most serious adverse reactions experienced by patients receiving the drug in clinical trials. Due to the rarity of the disease, these studies have enrolled a limited number of patients. Nonetheless, the available data indicate that sebelipase alfa is an effective disease-specific therapy for individuals with LAL-D who have historically been managed using supportive therapies (e.g. cholesterol reduction, hematopoietic stem cell transplantation, and liver transplantation)</style></abstract><notes><style face="normal" font="Arial">DA - 20161123IS - 1179-187X (Electronic)IS - 1175-3277 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40256-016-0203-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27878737">PM:27878737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Cardiovasc Drugs\2016-6-461-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Cardiovasc Drugs\2016-6-461-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161123, Frampton JE</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40256-016-0203-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,D.I.</style></author><author><style face="normal" font="Arial"> Park,M.K.</style></author><author><style face="normal" font="Arial"> Kang,S.A.</style></author><author><style face="normal" font="Arial"> Choi,J.H.</style></author><author><style face="normal" font="Arial"> Kang,S.J.</style></author><author><style face="normal" font="Arial"> Lee,J.Y.</style></author><author><style face="normal" font="Arial"> Yu,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, School of Medicine, Pusan National University, Yangsan-si, Gyeongsangnam-do 626-870, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Preventive Intra Oral Treatment of Sea Cucumber Ameliorate OVA-Induced Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Am J Chin Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Chin Med</style></full-title></periodical><pages end="1674" start="1663">1663-1674</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> Antibacterial</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="Arial">Sea cucumber extracts have potent biological effects, including anti-viral, anti-cancer, antibacterial, anti-oxidant, and anti-inflammation effects. To understand their anti-asthma effects, we induced allergic airway inflammation in mice after 7 oral administrations of the extract. The hyper-responsiveness value in mice with ovalbumin (OVA)-alum-induced asthma after oral injection of sea cucumber extracts was significantly lower than that in the OVA-alum-induced asthma group. In addition, the number of eosinophils in the lungs of asthma-induced mice pre-treated with sea cucumber extract was significantly decreased compared to that of PBS pre-treated mice. Additionally, CD4[Formula: see text]CD25[Formula: see text]Foxp3[Formula: see text]T (regulatory T; Treg) cells significantly increased in mesenteric lymph nodes after 7 administrations of the extract. These results suggest that sea cucumber extract can ameliorate allergic airway inflammation via Treg cell activation and recruitment to the lung</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 0192-415X (Print)IS - 0192-415X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1142/S0192415X16500932</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27852121">PM:27852121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Chin Med\2016-44-1663-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Chin Med\2016-44-1663-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Lee DI</style></custom2><misc3><style face="normal" font="Arial">10.1142/S0192415X16500932</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moore,L.E.</style></author><author><style face="normal" font="Arial"> Stewart,P.H.</style></author><author><style face="normal" font="Arial"> deShazo,R.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food Allergy: What We Know Now</style></title><secondary-title><style face="normal" font="Arial">Am J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Med Sci</style></full-title></periodical><pages end="366" start="353">353-366</pages><volume><style face="normal" font="Arial">353</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0002-9629</style></isbn><abstract><style face="normal" font="Arial">Food allergy is an adverse immune reaction that occurs reproducibly on exposure to a given food. Prevalence rates of food allergy continue to increase worldwide, sparking continual research efforts in finding a suitable and safe cure. Food avoidance, the current standard of care, can be difficult to achieve. This review aims to provide a broad overview of IgE mediated food allergy, highlighting its epidemiology, masqueraders, immunopathophysiology, clinical presentation, diagnostic work-up, and available preventative and treatment strategies. This review will also discuss novel, investigative therapies which offer promising therapeutic options, yet require continued research efforts to determine safety effects. Inducing tolerance, whether by immunotherapy or with administration of monoclonal antibodies, allows us to move toward a cure for food allergy, which could vastly change this field of allergic diseases in the coming decades</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.amjms.2016.11.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317623">PM:28317623</url></web-urls><pdf-urls><url ppv-ref="no">phstewart@umc.edu</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161210, Moore LE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.amjms.2016.11.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,X.</style></author><author><style face="normal" font="Arial"> Lin,H.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Huang,Q.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The efficacy and safety of sublingual immunotherapy in children and adult patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Am J Otolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Otolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0196-0709</style></isbn><abstract><style face="normal" font="Arial">Background Clinical research had showed that sublingual immunotherapy (SLIT) is effective and safe in moderate-severe allergic rhinitis (AR) induced by house dust mite (HDM). However, the sample size in many studies is small. Meanwhile, the controversy on the efficacy and safety in the very young children &amp;lt; 4 years old is still existed. Objective The aim of this retrospective study is to evaluate the efficacy and safety of SLIT with Dermatophagoides farinae (Der.f) extracts in children and adult patients with allergic rhinitis, particularly in the very young children. Method A total of 573 subjects aged 3</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô69 with AR were received 3-year course of sublingual immunotherapy with Der.f extracts along with pharmacotherapy. The total nasal symptoms score (TNSS), total medication score (TMS) and visual analogue score (VAS), adverse events (AEs) were evaluated at each visit. Result TNSS, TMS, VAS were significantly improved during the 3-year course of treatment in comparison to the baseline values (P &amp;lt; 0.01). Besides, significant improvement in nasal symptoms and reduction of medication use were also observed in young children aged 3</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô6 years (P &amp;lt; 0.01). No severe systemic adverse events (AEs) were reported. Conclusion SLIT with Der.f drops is clinically effective and safe in children and adult patients with HDM-induced AR, including the very young children &amp;lt; 4 years old</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.amjoto.2016.11.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237130">PM:28237130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Otolaryngol\20161210-LinX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Otolaryngol\20161210-LinX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Lin X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.amjoto.2016.11.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pilolli,R.</style></author><author><style face="normal" font="Arial"> Chaudhari,R.</style></author><author><style face="normal" font="Arial"> Palmisano,F.</style></author><author><style face="normal" font="Arial"> Monaci,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Via G. Amendola 122/O, 70126, Bari, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Development of a mass spectrometry immunoassay for unambiguous detection of egg allergen traces in wines</style></title><secondary-title><style face="normal" font="Arial">Anal Bioanal Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Bioanal Chem</style></full-title></periodical><pages end="1589" start="1581">1581-1589</pages><volume><style face="normal" font="Arial">409</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> egg allergens</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Monolithic</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Simultaneous detection</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A mass spectrometry immunoassay (MSIA) specifically designed for the detection of egg allergens in wines is described. MSIA is based on an immunoaffinity enrichment procedure combined with targeted MS/MS detection of selected egg peptide markers. Polyclonal antibodies raised against native ovalbumin, chosen as the target protein tracing for egg powder, were immobilized onto low backpressure monolithic MSIA customized disposable tips. Ovalbumin-free wine samples were fortified with standard protein at different concentrations in the low microgram-per-milliliter range. A simple protocol was devised consisting of a 1:4 dilution of the wine sample with a basic solution for pH adjustment, followed by a semi-automated purification/enrichment step on MSIA customized disposable tips fitted on a multichannel electronic pipette. Among the main figures of merit, LOD and LOQ values as low as 0.01 and 0.03 mug/mL, respectively, and within-day precision of 18% should be noticed. Noteworthy, the developed assay outperformed current MS-based methods for the detection of allergenic protein in wine matrices, thanks to the immunoaffinity enrichment. In addition, compared to other immunoassays, the present approach boasts the unquestionable advantage of providing an unambiguous identification of the target protein by simultaneous detection of three unique peptide markers each giving three specific MS/MS transitions</style></abstract><notes><style face="normal" font="Arial">DA - 20161208IS - 1618-2650 (Electronic)IS - 1618-2642 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00216-016-0099-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27928610">PM:27928610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Bioanal Chem\20161208-PilolliR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Bioanal Chem\20161208-PilolliR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161208, Pilolli R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00216-016-0099-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lepe,M.</style></author><author><style face="normal" font="Arial"> O'Connell,D.</style></author><author><style face="normal" font="Arial"> Lombardo,K.A.</style></author><author><style face="normal" font="Arial"> Herzlinger,M.</style></author><author><style face="normal" font="Arial"> Mangray,S.</style></author><author><style face="normal" font="Arial"> Resnick,M.B.</style></author><author><style face="normal" font="Arial"> Matoso,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of *Pathology and Laboratory Medicine section signPediatrics, Rhode Island Hospital daggerBrown University Alpert Medical School double daggerDepartment of Biology, Brown University, Providence, RI</style></auth-address><titles><title><style face="normal" font="Arial">The Inflammatory Milieu of Eosinophilic Esophagitis: A Contemporary Review With Emphasis in Putative Immunohistochemistry and Serologic Markers</style></title><secondary-title><style face="normal" font="Arial">Appl Immunohistochem Mol Morphol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Immunohistochem Mol Morphol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Atopy</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Chemotactic Factors</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Esophageal biopsy</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhode Island</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="10" Year="2016">2016/10/31</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis is a chronic disease characterized by esophageal dysfunction, frequent clinical history of atopy, and eosinophilic inflammation of the esophagus. Within the esophageal mucosa, there is a wide variety of immune mediators, chemotactic factors, mediators of transcription, and markers of epithelial differentiation and integrity that are overexpressed or underexpressed in eosinophilic esophagitis, offering many candidates for biomarkers with diagnostic or prognostic potential. In this review, we summarize the results from studies performed so far to evaluate the detection of these markers by immunohistochemistry on esophageal biopsies. In addition, we briefly describe some attempts to identify markers that could be detected in serum to be used to diagnose or monitor the disease without the need of a biopsy</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1533-4058 (Electronic)IS - 1533-4058 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/PAI.0000000000000450</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801733">PM:27801733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Immunohistochem Mol Morphol\20161101-LepeM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Immunohistochem Mol Morphol\20161101-LepeM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Lepe M</style></custom2><misc3><style face="normal" font="Arial">10.1097/PAI.0000000000000450</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Dahdah,L.</style></author><author><style face="normal" font="Arial"> Riccardi,C.</style></author><author><style face="normal" font="Arial"> Mazzina,O.</style></author><author><style face="normal" font="Arial"> Fierro,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Preacutionary labelling of cross-reactive foods: The case of rapeseed</style></title><secondary-title><style face="normal" font="Arial">Asthma Res Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Res Pract</style></full-title></periodical><pages end="" start="13">13-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--Allergome Citation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevention</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy</style></keyword><keyword><style face="normal" font="Arial"> Mustard</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2054-7064</style></isbn><abstract><style face="normal" font="Arial">Food allergic individuals are exposed to unnecessary dietary restrictions due to precautionary food allergy labelling (PFAL). Two forms of PFAL exist: type I identifies the possible presence of allergenic contaminaion in foods (</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿmay content</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çª</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ), type II indicates as potentially dangerous ingredients or contaminants that do no belong to official list of food allergens. PFAL type II is based on the fear of cross-reactivity with foods belonging to that list. PFAL type II is less known, but may be tempting for the legal offices of food companies, for clinicians in a </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿdefensive medicine</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ key, and even for legislators. We identify here a case of PFAL type II, allergy to rapeseed (belonging to the family of Brassicaceae). Increasingly used for their nutritional and nutraceutic value in asthma prevention, rapeseed has been indicated by regulatory authorities in Canada and Europe as potential cross-reactor with mustard. In this review, we provide the elements for a risk assessment of cross-reactivity of rapeseed/mustard allergy in the general population both clinically and from the point of view of the molecular allergy. Three findings emerge:</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40733-016-0028-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s40733-016-0028-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Res Pract\2016-2-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Res Pract\2016-2-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Fiocchi A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40733-016-0028-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Begg,H.E.</style></author><author><style face="normal" font="Arial"> Murphy,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Research Unit for Anxiety and Depression, School of Psychiatry, University of New South Wales, NSW, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Vego, no milk please, I'm allergic ...; a table outlining the (in)appropriateness of common psychiatric medications for special dietary populations</style></title><secondary-title><style face="normal" font="Arial">Aust N Z J Psychiatry</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Aust N Z J Psychiatry</style></abbr-1></periodical><pages end="1127" start="1125">1125-1127</pages><volume><style face="normal" font="Arial">50</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1440-1614 (Electronic)IS - 0004-8674 (Linking)LA - ENGPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1177/0004867416676896</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799416">PM:27799416</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aust N Z J Psychiatry\2016-50-1125-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aust N Z J Psychiatry\2016-50-1125-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Begg HE</style></custom2><misc3><style face="normal" font="Arial">10.1177/0004867416676896</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shevchenko,M.A.</style></author><author><style face="normal" font="Arial"> Troyanova,N.I.</style></author><author><style face="normal" font="Arial"> Servuli,E.A.</style></author><author><style face="normal" font="Arial"> Bolkhovitina,E.L.</style></author><author><style face="normal" font="Arial"> Fedorina,A.S.</style></author><author><style face="normal" font="Arial"> Sapozhnikov,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia.</style></auth-address><titles><title><style face="normal" font="Arial">Study of Immunomodulatory Effects of Extracellular HSP70 in a Mouse Model of Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Biochemistry (Mosc)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochemistry (Mosc)</style></full-title></periodical><pages end="1395" start="1384">1384-1395</pages><volume><style face="normal" font="Arial">81</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heat shock protein</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Immunostimulatory properties of extracellular heat shock proteins 70 kDa (HSP70) became interesting for investigators a long time ago. However, in recent years a series of works showing a significant relation of the immunostimulating effects of recombinant HSP70 to contamination of the protein samples with bacterial endotoxins (lipopolysaccharide, LPS) has been published. The authors showed that intensive elimination of LPS from the protein samples resulted in inversion of immunostimulating effects of HSP70 to immunosuppressive activity of the protein. Nevertheless, at present the conception of immunostimulating, proinflammatory action of extracellular HSP70 is the most common. In this work, we studied immunomodulatory effects of exogenous HSP70 in a mouse model of allergic inflammation of airways. We also analyzed the dynamics of the level of the extracellular pool of HSP70 in the site of inflammation. The results demonstrated a considerable content of extracellular HSP70 in bronchoalveolar lavages with dynamics reflecting the stages of development of the induced inflammation. Oropharyngeal injection of exogenous HSP70 in the acute phase of allergic inflammation of airways resulted in significant suppression of the inflammatory process, which conforms to published data demonstrating an immunosuppressive activity of the extracellular pool of HSP70</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 1608-3040 (Electronic)IS - 0006-2979 (Linking)LA - engPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1134/S0006297916110158</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914463">PM:27914463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochemistry (Mosc)\2016-81-1384-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochemistry (Mosc)\2016-81-1384-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Shevchenko MA</style></custom2><misc3><style face="normal" font="Arial">10.1134/S0006297916110158</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tai,C.S.</style></author><author><style face="normal" font="Arial"> Chen,Y.Y.</style></author><author><style face="normal" font="Arial"> Chen,W.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department and College of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">ß-Lactoglobulin Influences Human Immunity and Promotes Cell ProliferationChun San Tai,1,2 Yi Yun Chen,2 and Wen Liang Chen1</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="7123587">7123587-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Acetylation</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hybridoma</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">ß-Lactoglobulin (LG) is suspected to enhance or modulate human immune responses. Moreover, LG is also hypothesized to increase human cell proliferation. However, these potential functions of LG have not been directly or thoroughly addressed. In this study, we demonstrated that LG is a potent stimulator of cell proliferation using a hybridoma cell (a splenocyte fused with a myeloma cell) model. LG's ability to promote cell proliferation was lost when the protein is denatured. To further investigate the influence of LG's conformation on cell proliferation, we chemically modified LG by either carboxymethylation (CM) or acetylation and observed significantly reduced cell proliferation when the protein structure was altered. Furthermore, we proved that LG enhances cell proliferation via receptor-mediated membrane IgM receptor. These data indicated that nondenatured LG is the major component in milk that modulates cell proliferation. Collectively, our study showed that LG plays a key role in enhancing immune responses by promoting cell proliferation through IgM receptor.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/7123587</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1155/2016/7123587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2016-2016-7123587.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2016-2016-7123587.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Tai CS</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/7123587</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Havenith,H.</style></author><author><style face="normal" font="Arial"> Kern,K.</style></author><author><style face="normal" font="Arial"> Rautenberger,P.</style></author><author><style face="normal" font="Arial"> Spiegel,H.</style></author><author><style face="normal" font="Arial"> Szardenings,M.</style></author><author><style face="normal" font="Arial"> Ueberham,E.</style></author><author><style face="normal" font="Arial"> Lehmann,J.</style></author><author><style face="normal" font="Arial"> Buntru,M.</style></author><author><style face="normal" font="Arial"> Vogel,S.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author><author><style face="normal" font="Arial"> Fischer,R.</style></author><author><style face="normal" font="Arial"> Schillberg,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Combination of two epitope identification techniques enables the rational design of soy allergen Gly m 4 mutants</style></title><secondary-title><style face="normal" font="Arial">Biotechnol J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biotechnol J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gly m 4</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide microarray</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergy</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Detailed IgE-binding epitope analysis is a key requirement for the understanding and development of diagnostic and therapeutic agents to address food allergies. METHODS: We combined an IgE-specific linear peptide microarray with random phage peptide display for the high-resolution mapping of IgE-binding epitopes of the major soybean allergen Gly m 4, which is a homologue to the birch pollen allergen Bet v1. RESULTS: Three epitopes were identified and mapped to a resolution of four key amino acids, allowing the rational design and the production of three Gly m 4 mutants with the aim to abolish or reduce the binding of epitope-specific IgE. In ELISA, the binding of the mutant allergens to polyclonal rabbit-anti Gly m 4 serum as well as IgE purified from Gly m 4-reactive soybean allergy patient sera was reduced by up to 63% compared to the wild-type allergen. Basophil stimulation experiments using RBL-SX38 cells loaded with patient IgE showed a decreased stimulation from 25% for the wild-type Gly m 4 to 13% for one mutant. CONCLUSION: The presented approach demonstrates the feasibility of precise mapping of allergy-related IgE-binding epitopes, allowing the rational design of less allergenic mutants as potential therapeutic agents</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1860-7314 (Electronic)IS - 1860-6768 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/biot.201600441</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906504">PM:27906504</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biotechnol J\20161201-HavenithH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biotechnol J\20161201-HavenithH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Havenith H</style></custom2><misc3><style face="normal" font="Arial">10.1002/biot.201600441</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bocchini,C.E.</style></author><author><style face="normal" font="Arial"> Nahmod,K.</style></author><author><style face="normal" font="Arial"> Katsonis,P.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Kasembeli,M.M.</style></author><author><style face="normal" font="Arial"> Freeman,A.</style></author><author><style face="normal" font="Arial"> Lichtarge,O.</style></author><author><style face="normal" font="Arial"> Makedonas,G.</style></author><author><style face="normal" font="Arial"> Tweardy,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States</style></auth-address><titles><title><style face="normal" font="Arial">Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">Blood</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Blood</style></abbr-1></periodical><pages end="3072" start="3061">3061-3072</pages><volume><style face="normal" font="Arial">128</style></volume><number><style face="normal" font="Arial">26</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Autosomal dominant hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heat shock protein</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Stability</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> STAT3 mutations</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="10" Year="2016">2016/10/31</year></dates><abstract><style face="normal" font="Arial">AD-HIES is caused by dominant negative mutations in STAT3; however, the molecular basis for mutant STAT3 allele dysfunction is unclear and treatment remains supportive. We hypothesized that AD-HIES mutations decrease STAT3 protein stability and that mutant STAT3 activity can be improved by agents that increase chaperone protein activity. We used computer modeling to characterize the effect of STAT3 mutations on protein stability. We measured STAT3 protein half-life (t1/2) and determined levels of STAT3 phosphorylated on tyrosine (Y) 705 (pY-STAT3) and mRNA levels of STAT3 gene targets in EBV-transformed B (EBV) cells, human peripheral blood mononuclear cells (PBMC), and mouse splenocytes incubated without or with chaperone protein modulators-HSF1A, a small-molecule TRiC modulator, or geranylgeranylacetone (GGA), a drug that upregulates heat shock protein (HSP) 70 and HSP90. Computer modeling predicted that 81% of AD-HIES mutations are destabilizing. STAT3 protein t1/2 in EBV cells from AD-HIES patients with destabilizing STAT3 mutations was markedly reduced. Treatment of EBV cells containing destabilizing STAT3 mutations with either HSF1A or GGA normalized STAT3 half-life, increased pY-STAT3 levels, and increased mRNA levels of STAT3 target genes up to 79% of control. In addition, treatment of human PBMC or mouse splenocytes containing destabilizing STAT3 mutations with either HSF1A or GGA increased levels of cytokine-activated pY-STAT3 within human CD4+ and CD8+ T cells and numbers of IL-17-producing CD4+ mouse splenocytes, respectively. Thus, most AD-HIES STAT3 mutations are destabilizing; agents that modulate chaperone protein function improve STAT3 stability and activity in T cells and may provide a specific treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1528-0020 (Electronic)IS - 0006-4971 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1182/blood-2016-02-702373</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799162">PM:27799162</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Blood\20161101-BocchiniCE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Blood\20161101-BocchiniCE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Bocchini CE</style></custom2><misc3><style face="normal" font="Arial">10.1182/blood-2016-02-702373</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mayor,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">London</style></auth-address><titles><title><style face="normal" font="Arial">Biological treatment is approved for severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="i6472">i6472-</pages><volume><style face="normal" font="Arial">355</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="30" Month="11" Year="2016">2016/11/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.i6472</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27908911">PM:27908911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2016-355-i6472.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2016-355-i6472.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Mayor S</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.i6472</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ota,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Chitose City Hospital, Hokkou 2, Chitose, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Allergic lymphangitis</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="i5726">i5726-</pages><volume><style face="normal" font="Arial">355</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword></keywords><dates><year Day="30" Month="11" Year="2016">2016/11/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.i5726</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27903496">PM:27903496</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2016-355-i5726.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2016-355-i5726.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Ota M</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.i5726</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Woodhead,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sydney</style></auth-address><titles><title><style face="normal" font="Arial">Hospitals overwhelmed with patients after "thunderstorm asthma" hits Melbourne</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="i6391">i6391-</pages><volume><style face="normal" font="Arial">355</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword></keywords><dates><year Day="27" Month="11" Year="2016">2016/11/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.i6391</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27895034">PM:27895034</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2016-355-i6391.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2016-355-i6391.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Woodhead M</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.i6391</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Riis,J.L.</style></author><author><style face="normal" font="Arial"> Vestergaard,C.</style></author><author><style face="normal" font="Arial"> Hjuler,K.F.</style></author><author><style face="normal" font="Arial"> Iversen,L.</style></author><author><style face="normal" font="Arial"> Jakobsen,L.</style></author><author><style face="normal" font="Arial"> Deleuran,M.S.</style></author><author><style face="normal" font="Arial"> Olsen,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study</style></title><secondary-title><style face="normal" font="Arial">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ Open</style></full-title></periodical><pages end="" start="e011870">e011870-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Azathioprine</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Methotrexate</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Population Control</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Stroke</style></keyword><keyword><style face="normal" font="Arial"> systemic treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="11" Year="2016">2016/11/11</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Atopic dermatitis (AD) is an inflammatory skin disorder with a childhood prevalence reaching 20%. An estimated 50% of patients have a life-long chronic course. The purpose of this study was to estimate the risk of first-time myocardial infarction (MI) in patients with AD compared with a general population cohort. DESIGN: Cohort study. SETTING: Denmark. PARTICIPANTS: Using population-based medical registries, we identified individuals born in Denmark from 1947 to 1983 with at least two hospital-diagnoses of AD following inpatient admissions or hospital-based outpatient visits at any age from 1977 to 2013. Individuals with AD were matched with general population controls (10:1) for birth-year and gender. Unique personal identifiers permitted unambiguous data linkage. PRIMARY OUTCOME MEASURES: Follow-up began on the date of AD diagnosis (index date for general population controls) and continued until death, emigration, MI or the year 2013. We computed the 15-year-cumulative incidence of MI following a diagnosis of AD. Comparing patients with AD with the general population cohort, we computed HRs of MI presented with 95% CIs and adjusted for history of diabetes mellitus, hypertension, hyperlipidaemia or stroke, educational level, birth-year and sex. RESULTS: We identified 4814 patients diagnosed with AD. The cumulative incidence of MI was 0.6% for patients with AD and 0.4% for their matched controls. The corresponding adjusted HR was 1.74 (1.21 to 2.49). The HR for patients who were not in need of systemic treatment was 1.58 (1.02 to 2.45) and it was 2.40 (1.27 to 4.45) for those who were treated with azathioprine, methotrexate or cyclosporine. CONCLUSIONS: Hospital-diagnosed AD was associated with increased risk of MI compared with the general population</style></abstract><notes><style face="normal" font="Arial">DA - 20161112IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmjopen-2016-011870</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27836869">PM:27836869</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2016-6-e011870.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2016-6-e011870.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161112, Riis JL</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmjopen-2016-011870</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Frederiksen,H.</style></author><author><style face="normal" font="Arial"> Farkas,D.K.</style></author><author><style face="normal" font="Arial"> Horvath-Puho,E.</style></author><author><style face="normal" font="Arial"> Norgaard,J.M.</style></author><author><style face="normal" font="Arial"> Norgaard,M.</style></author><author><style face="normal" font="Arial"> Sorensen,H.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Haematology, Odense University Hospital, Odense, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Asthma and risk of myelodysplastic syndromes: a population-based cohort study</style></title><secondary-title><style face="normal" font="Arial">Br J Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Br J Cancer</style></full-title></periodical><pages end="102" start="100">100-102</pages><volume><style face="normal" font="Arial">116</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug treatment</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incident asthma</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Myelodysplastic Syndromes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Radiation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Risk factors for the development of myelodysplastic syndromes (MDS) include age, exposure to ionising radiation, and cytotoxic drug treatment. Recently, asthma also has been suggested as a risk factor for MDS. METHODS: We undertook this nationwide population-based cohort study on patients with a first-time hospital-based asthma diagnosis during 2002-2013 and followed them for the development of MDS/chronic myelomonocytic leukaemia (CMML). RESULTS: We identified 75 995 patients with incident asthma and no previous MDS/CMML diagnosis. Seventy-eight patients subsequently developed MDS and nine patients developed CMML during 402 892 person-years. The cumulative risks of developing MDS/CMML among asthma patients were 0.02% (95% CI: 0.01-0.04%) and 0.07% (95% CI: 0.05-0.09%) during the first year and the first five years of follow-up, respectively. The standardised incidence ratio of MDS/CMML among asthma patients overall was 1.6 (95% CI: 1.3-2.0) with little variation across subgroups. CONCLUSIONS: Asthma may be a risk factor for the development of MDS/CMML.British Journal of Cancer advance online publication, 29 November 2016; doi:10.1038/bjc.2016.389 www.bjcancer.com</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1532-1827 (Electronic)IS - 0007-0920 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1038/bjc.2016.389</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27898660">PM:27898660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Cancer\20161129-FrederiksenH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Cancer\20161129-FrederiksenH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Frederiksen H</style></custom2><misc3><style face="normal" font="Arial">10.1038/bjc.2016.389</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hajdu,K.</style></author><author><style face="normal" font="Arial"> Irinyi,B.</style></author><author><style face="normal" font="Arial"> Gyimesi,E.</style></author><author><style face="normal" font="Arial"> Kapitany,A.</style></author><author><style face="normal" font="Arial"> Dajnoki,Z.</style></author><author><style face="normal" font="Arial"> Bata-Csorgo,Z.</style></author><author><style face="normal" font="Arial"> Kinyo,A.</style></author><author><style face="normal" font="Arial"> Kiss,F.</style></author><author><style face="normal" font="Arial"> Gaspar,K.</style></author><author><style face="normal" font="Arial"> Szegedi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatological Allergology, University of Debrecen, Debrecen, Hungary</style></auth-address><titles><title><style face="normal" font="Arial">A simple, combined test can improve the diagnosis of autoimmune urticaria</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune urticaria</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The diagnosis of autoimmune chronic urticaria (AIU) is difficult. Autologous serum skin test (ASST) is a screening method to diagnose AIU and was first used by Grattan et al., and was standardized by Sabroe et al. One major limitation of ASST is that positivity can refer not just to the presence of functional autoantibodies against FcepsilonRIalpha or IgE, but other yet unidentified serum factors. Besides the advantages of ASST which are its fast and easy implementation and its cost, since its positivity alone cannot define AIU, other methods are needed to confirm the diagnosis of AIU. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15175</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27858998">PM:27858998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20161118-HajduK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20161118-HajduK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Hajdu K</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15175</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.M.</style></author><author><style face="normal" font="Arial"> Du,L.</style></author><author><style face="normal" font="Arial"> Zhu,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, The Second People's Hospital, Bengbu, Anhui Province, 233000, China</style></auth-address><titles><title><style face="normal" font="Arial">Evidence-based therapies of Chinese medicine for chronic urticaria: Where do we stand and where are we going?</style></title><secondary-title><style face="normal" font="Arial">Chin J Integr Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chin J Integr Med</style></full-title></periodical><pages end="569" start="566">566-569</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptance</style></keyword><keyword><style face="normal" font="Arial"> Acupuncture</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Herbs</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Chronic urticaria (CU) is characterized by repeated occurrence of wheals or itching for more than 6 weeks. When urticaria symptoms repeatedly occur despite taking Western medicines such as antihistamines, Chinese medicine (CM) has been shown to relieve symptoms and prevent recurrence. However, the lack of robust evidence from the evidence-based medicine perspective is hindering acceptance of CM by the Western medicine community. In recent years, more and more evidence-based studies of CU treatment by CM were report in English literatures, including acupuncture, herbs, and food, although some of evidence is still with low quality. These progress in CM treatment of CU will inspire high quality evidences via randomized, controlled trials assessing efficacy and safety of CM treatment of CU</style></abstract><notes><style face="normal" font="Arial">DA - 20161130IS - 1672-0415 (Print)IS - 1672-0415 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11655-016-2533-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27900606">PM:27900606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin J Integr Med\20161130-WangYM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin J Integr Med\20161130-WangYM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161130, Wang YM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11655-016-2533-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsiantoulas,D.</style></author><author><style face="normal" font="Arial"> Bot,I.</style></author><author><style face="normal" font="Arial"> Ozsvar,Kozma M.</style></author><author><style face="normal" font="Arial"> Goederle,L.</style></author><author><style face="normal" font="Arial"> Perkmann,T.</style></author><author><style face="normal" font="Arial"> Hartvigsen,K.</style></author><author><style face="normal" font="Arial"> Conrad,D.H.</style></author><author><style face="normal" font="Arial"> Kuiper,J.</style></author><author><style face="normal" font="Arial"> Mallat,Z.</style></author><author><style face="normal" font="Arial"> Binder,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory Medicine, Medical University of Vienna</style></auth-address><titles><title><style face="normal" font="Arial">Increased Plasma IgE Accelerate Atherosclerosis in Secreted IgM Deficiency</style></title><secondary-title><style face="normal" font="Arial">Circ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Circ Res</style></full-title></periodical><pages end="84" start="78">78-84</pages><volume><style face="normal" font="Arial">120</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atherosclerosis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Deficiency of secreted IgM (sIgM-/-) accelerates atherosclerosis in Ldlr-/- mice. Several atheroprotective effects of increased levels of IgM antibodies have been suggested, including preventing inflammation induced by oxidized LDL and promoting apoptotic cell clearance. However, the mechanisms by which the lack of sIgM promotes lesion formation remain unknown. OBJECTIVE: To identify the mechanisms by which sIgM deficiency accelerates atherosclerosis in mice. METHODS AND RESULTS: We here show that both sIgM-/- and Ldlr-/-sIgM-/- mice develop increased plasma IgE titers due to impaired generation of B cells expressing the low affinity IgE receptor CD23, which mediates the clearance of IgE antibodies. We further report that Ldlr-/-sIgM-/- mice exhibit increased numbers of activated mast cells and neutrophils in the perivascular area of atherosclerotic plaques. Treatment with an anti-IgE neutralizing antibody fully reversed vascular inflammation and accelerated atherosclerotic lesion formation in cholesterol-fed Ldlr-/-sIgM-/- mice. CONCLUSIONS: Thus, our data identify a previously unsuspected mechanism by which sIgM deficiency aggravates atherosclerosis</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1524-4571 (Electronic)IS - 0009-7330 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Netherlands -CO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1161/CIRCRESAHA.116.309606</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27903567">PM:27903567</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Circ Res\20161201-TsiantoulasD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Circ Res\20161201-TsiantoulasD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Tsiantoulas D</style></custom2><misc3><style face="normal" font="Arial">10.1161/CIRCRESAHA.116.309606</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Hage,M.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Skevaki,C.</style></author><author><style face="normal" font="Arial"> Plebani,M.</style></author><author><style face="normal" font="Arial"> Canonica,W.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Nystrand,M.</style></author><author><style face="normal" font="Arial"> Jafari-Mamaghani,M.</style></author><author><style face="normal" font="Arial"> Jakob,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Performance evaluation of ImmunoCAP(R) ISAC 112: a multi-site study</style></title><secondary-title><style face="normal" font="Arial">Clin Chem Lab Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chem Lab Med</style></full-title></periodical><pages end="577" start="571">571-577</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Calibration</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hierarchical clustering</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ISAC 112</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Random forest</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: After the re-introduction of ImmunoCAP(R) ISAC sIgE 112 on the market, we undertook a study to evaluate the performance of this multiplex-based immunoassay for IgE measurements to allergen components. METHODS: The study was carried out at 22 European and one South African site. Microarrays from different batches, eight specific IgE (sIgE) positive, three sIgE negative serum samples and a calibration sample were sent to participating laboratories where assays were performed according to the manufacturer's instructions. RESULTS: For both the negative and positive samples results were consistent between sites, with a very low frequency of false positive results (0.014%). A similar pattern of results for each of the samples was observed across the 23 sites. Homogeneity analysis of all measurements for each sample were well clustered, indicating good reproducibility; unsupervised hierarchical clustering and classification via random forests, showed clustering of identical samples independent of the assay site. Analysis of raw continuous data confirmed the good accuracy across the study sites; averaged standardized, site-specific ISU-E values fell close to the center of the distribution of measurements from all sites. After outlier filtering, variability across the whole study was estimated at 25.5%, with values of 22%, 27.1% and 22.4% for the 'Low', 'Moderate to High' and 'Very High' concentration categories, respectively. CONCLUSIONS: The study shows a robust performance of the ImmunoCAP(R) ISAC 112 immunoassay at different sites. Essentially the same results were obtained irrespective of assay site, laboratory-specific conditions and instruments, operator, or the use of microarrays from different batches</style></abstract><notes><style face="normal" font="Arial">DA - 20161106IS - 1437-4331 (Electronic)IS - 1434-6621 (Linking)LA - ENGPT - Journal ArticleCO - Sweden -CO - Switzerland -CO - Germany -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1515/cclm-2016-0586</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27816950">PM:27816950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Chem Lab Med\20161106-vanHageM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Chem Lab Med\20161106-vanHageM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161106, van Hage M</style></custom2><misc3><style face="normal" font="Arial">10.1515/cclm-2016-0586</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arshad,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Southampton General Hospital, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">An update on allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Clin Med (Lond)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Med (Lond)</style></abbr-1></periodical><pages end="587" start="584">584-587</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect allergy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (AIT) has been used to treat allergic diseases for over a century. It is the only treatment that addresses immune dysfunction underlying allergic responses rather than simply treating symptoms or suppressing inflammation. Its safety and efficacy in allergic rhinitis, asthma and insect allergy has been documented in a number of systematic reviews but its cost effectiveness is less clear. AIT reduces symptoms and requirement for medication, while improving quality of life. Further, the effect continues for years after discontinuation of treatment. However, evidence regarding cost effectiveness is limited. During AIT, allergen extracts are administered through a subcutaneous or sublingual route for 3-5 years. Subcutaneous immunotherapy is more effective in inducing long-term remission but systemic reactions do occur occasionally. Sublingual immunotherapy is safer and more convenient for the patient but evidence regarding its long-term efficacy is patchy. AIT is used widely in western Europe and the USA. In the UK, subcutaneous immunotherapy is often used for bee and wasp allergy, while both subcutaneous and sublingual immunotherapies are used for severe allergic rhinitis and occasionally for house dust mite and pet allergies. In conclusion, AIT is safe and effective and should be considered as a treatment option for those with allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161208IS - 1473-4893 (Electronic)IS - 1470-2118 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.7861/clinmedicine.16-6-584</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27927826">PM:27927826</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Med (Lond)\2016-16-584-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Med (Lond)\2016-16-584-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161208, Arshad SH</style></custom2><misc3><style face="normal" font="Arial">10.7861/clinmedicine.16-6-584</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Min,K.B.</style></author><author><style face="normal" font="Arial"> Min,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Preventive Medicine, Colleague of Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Increased risk for hyperuricemia in adults sensitized to cow milk allergen</style></title><secondary-title><style face="normal" font="Arial">Clin Rheumatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rheumatol</style></full-title></periodical><pages end="1412" start="1407">1407-1412</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> cow milk allergy</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Gout</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Uric Acid</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Several studies indicated the beneficial role of milk or dairy intake in protecting against gout or lowering rate levels. The elimination of milk or other dairy products due to cow milk allergies might increase the risk for gout and hyperuricemia. We investigated the potential risk of hyperuricemia in adults in the USAs according to the presence of milk allergen sensitization. We analyzed the data from the 2005-2006 National Health and Nutrition Examination. A total of 3893 adults with available data from specific IgE tests for milk allergen, serum uric acid levels, and no other missing information on their questionnaires were included in this study. Hyperuricemia was defined as serum uric acid levels >7.0 mg/dL. Overall, 151 (4.0 %) subjects were sensitive to milk allergen. The mean uric acid level in the sensitized subjects was higher than that in their non-sensitized counterparts. A significant difference in the rate of hyperuricemia between the two groups was found. Compared with subjects who were not sensitized to milk allergen (reference), subjects sensitized to milk allergen exhibited a significant increase in uric acid (beta = 0.29; 95 % CI = 0.09-0.48) after adjusting for all potential covariates. In addition, the sensitized subjects, compared with the non-sensitized subjects, showed an increased risk of hyperuricemia (OR = 1.72; 95 % CI = 1.17-2.53). Adults who showed sensitivity to cow milk allergen were at a higher risk of hyperuricemia than those who were not sensitized, suggesting that restricted intake of milk or dairy products may be a possible risk factor for hyperuricemia</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 1434-9949 (Electronic)IS - 0770-3198 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10067-016-3457-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838787">PM:27838787</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rheumatol\20161113-MinKB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rheumatol\20161113-MinKB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Min KB</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10067-016-3457-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loupiac,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">How neutron scattering experiments can target the structure and dynamics of milk proteins?</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Food Sci</style></full-title></periodical><pages end="97" start="93">93-97</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">France</style></keyword><keyword><style face="normal" font="Arial"> Gelation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><isbn><style face="normal" font="Arial">2214-7993</style></isbn><abstract><style face="normal" font="Arial">The powerful of neutron scattering techniques to characterize structure and dynamics of milk proteins is illustrated. Small angle neutron scattering and reflectivity are used to determine the structure and the interactions between milk proteins in solution, during gelation processes, or the protein structure at different interfaces. Experiments performed by inelastic and quasielastic neutron scattering allow one to observe the dynamics of water and proteins showing the major role of hydration on the dynamics of milk proteins</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cofs.2016.10.005</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.cofs.2016.10.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Food Sci\2016-9-93-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Food Sci\2016-9-93-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Loupiac C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cofs.2016.10.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Einarsson,E.</style></author><author><style face="normal" font="Arial"> Ma'ayeh,S.</style></author><author><style face="normal" font="Arial"> Svard,S.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cell and Molecular Biology, BMC, Box 596, Uppsala University, SE-751 24 Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">An up-date on Giardia and giardiasis</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Microbiol</style></full-title></periodical><pages end="52" start="47">47-52</pages><volume><style face="normal" font="Arial">34</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Giardia</style></keyword><keyword><style face="normal" font="Arial"> Giardiasis</style></keyword><keyword><style face="normal" font="Arial"> IBS</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Irritable Bowel Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Failure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="8" Year="2016">2016/8/6</year></dates><abstract><style face="normal" font="Arial">Giardia intestinalis is a non-invasive protozoan parasite infecting the upper small intestine causing acute, watery diarrhea or giardiasis in 280 million people annually. Asymptomatic infections are equally common and recent data have suggested that infections even can be protective against other diarrheal diseases. Most symptomatic infections resolve spontaneously but infections can lead to chronic disease and treatment failures are becoming more common world-wide. Giardia infections can also result in irritable bowel syndrome (IBS) and food allergies after resolution. Until recently not much was known about the mechanism of giardiasis or the cause of post-giardiasis syndromes and treatment failures, but here we will describe the recent progress in these areas</style></abstract><notes><style face="normal" font="Arial">DA - 20160808IS - 1879-0364 (Electronic)IS - 1369-5274 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mib.2016.07.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27501461">PM:27501461</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Microbiol\2016-34-47-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Microbiol\2016-34-47-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160808, Einarsson E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mib.2016.07.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Trivedi,V.</style></author><author><style face="normal" font="Arial"> Apala,D.R.</style></author><author><style face="normal" font="Arial"> Iyer,V.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA</style></auth-address><titles><title><style face="normal" font="Arial">Occupational asthma: diagnostic challenges and management dilemmas</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></full-title></periodical><pages end="183" start="177">177-183</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> false negative</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tertiary prevention</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work-exacerbated asthma</style></keyword><keyword><style face="normal" font="Arial"> work-related asthma</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Work-related asthma encompasses both sensitizer-induced and irritant-induced occupational asthma as well as work-exacerbated asthma. This review summarizes current diagnostic and management strategies for occupational asthma. RECENT FINDINGS: Occupational asthma is the most common occupational lung disease in the industrialized world. Over 400 agents have been described to cause occupational asthma. Specific inhalation challenge is often considered the reference method for diagnosis of occupational asthma but specific inhalation challenge as well as other diagnostic tests all generate false positive or false negative results. Definitive avoidance of the inciting agent is the preferred strategy for sensitizer-induced occupational asthma and reduction of exposure is the next best step. Immunotherapy is not currently well established and can cause systemic reactions. SUMMARY: An accurate diagnosis made in a timely fashion can positively impact the health and socioeconomic burden associated with occupational asthma. Newer diagnostic tools are promising, but much work needs to be done to standardize and validate these testing methods. Primary, secondary, and tertiary prevention strategies are crucial for effective management of sensitizer-induced occupational asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MCP.0000000000000352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27875341">PM:27875341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pulm Med\20161122-TrivediV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pulm Med\20161122-TrivediV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Trivedi V</style></custom2><misc3><style face="normal" font="Arial">10.1097/MCP.0000000000000352</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Parulekar,A.D.</style></author><author><style face="normal" font="Arial"> Diamant,Z.</style></author><author><style face="normal" font="Arial"> Hanania,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aSection of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas, USA</style></auth-address><titles><title><style face="normal" font="Arial">Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></full-title></periodical><pages end="11" start="3">3-11</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Severe asthma is a heterogeneous syndrome that can be classified into distinct phenotypes and endotypes. In the type 2 (T2)-high endotype, multiple cytokines are produced that lead to eosinophilic inflammation. These cytokines and their receptors are targets for biologic therapies in patients with severe asthma who do not respond well to standard therapy with inhaled corticosteroids. RECENT FINDINGS: In the last decade, an increasing number of biologic therapies have been developed targeting T2 inflammation. Clinical trials of therapies targeting immunoglobulin E as well as the T2 cytokines interleukin (IL)-4, IL-5, and IL-13 have demonstrated that these treatments improve asthma-related clinical outcomes and/or have steroid-sparing properties. The use of biomarkers of T2 inflammation can help to identify the subset of patients in whom these therapies may be most efficacious. Multiple biologic agents that are directed at other targets are currently in development, including thymic stromal lymphopoietin (TSLP), prostaglandin (PG)D2 receptor, IL-25, and IL-33. SUMMARY: Biologics are emerging as a key component of severe asthma management. In patients with T2-high severe asthma, the addition of treatments targeting immunoglobulin E and IL-5 to standard therapy may lead to improvement in clinical outcomes. Other biologic therapies have shown promising preliminary results and need to be studied in further clinical trials. These biologic therapies in conjunction with biomarkers will lead to tailored therapy for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - ENGPT - Journal ArticleCO - United States -CO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1097/MCP.0000000000000343</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27820746">PM:27820746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pulm Med\2017-23-3-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pulm Med\2017-23-3-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Parulekar AD</style></custom2><misc3><style face="normal" font="Arial">10.1097/MCP.0000000000000343</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Church,M.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Does Antihistamine Up-dosing Solve Chronic Spontaneous Urticaria?</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="422" start="416">416-422</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine A</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sensory nerves</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Up-dosing</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Urticaria is primarily a disease driven by the actions of mast cell-derived histamine on the dermal vasculature and sensory nerves. Initial treatment with second generation minimally sedating H1-antihistamines is recommended. Start with the standard dose of one tablet daily. Because of the high local levels of histamine in the skin, standard doses of H1-antihistamines are often not able to control the symptoms. Thus, if symptoms persist after 2-áweeks, then double the dosage of H1-antihistamines, usually giving one in the morning and one in the evening. If this is still not effective after 2-áweeks, double the dose to fourfold of the original dose, two tablets given approximately 12-áh apart. For patients still not responsive, then other medication, such as omalizumab or cyclosporine A should be introduced. Omalizumab treatment is highlighted in this review</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0098-9</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0098-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-416-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-416-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Church MK</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0098-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jauregui Presa,I.</style></author><author><style face="normal" font="Arial"> Navajas Rodriguez,B.</style></author><author><style face="normal" font="Arial"> Ramos Bareno,B.</style></author><author><style face="normal" font="Arial"> Gamboa Setien,P.M.</style></author><author><style face="normal" font="Arial"> Urrutia Etxebarria,I.</style></author><author><style face="normal" font="Arial"> Antepara Ercoreca,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Chronic Urticaria in Special Populations: Children, Pregnancy, Lactation and Elderly People</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="438" start="423">423-438</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly people</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Chronic urticaria can occur at any age and in both sexes. Regardless of the different populations affected, a stepwise treatment approach is recommended, beginning with non-sedating antihistamines, from licensed doses to a </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£controlled overdose</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ up to fourfold, followed by a change to a different antihistamine and/or addition of a leukotriene antagonist if symptoms persist; systemic corticosteroids in short courses (3 to 7-ádays) can be used for exacerbations. As a third-line therapy in adults, omalizumab is now considered of choice and only in nonresponsive cases to omalizumab cyclosporin or other options should be used. First-generation H1-antihistamines are no longer recommended, either in adults, in children, in pregnant women, or in the elderly because of their high potential to cause sedation and to impair school/work performance and vehicle driving. Among the second-generation H1-antihistamines, most of them have proven efficacy and safety, but there are important concerns for special populations with nearly every medication used in chronic spontaneous urticaria (CSU) treatment</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0097-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0097-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-423-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-423-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Jauregui Presa I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0097-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adams,K.E.</style></author><author><style face="normal" font="Arial"> Freeman,T.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Venom Immunotherapy: Risk Factors, Predictors, Duration, and Other Unmet Needs</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="494" start="483">483-494</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Venom immunotherapy is the only preventative treatment modality for venom allergic individuals at this time. Given this, decreasing associated risks by improvement of its safety profile is paramount. This article will review new and recent advances in venom immunotherapy for the treatment of hymenoptera venom allergy. Advances include the identification of new risk factors for adverse reactions with immunotherapy, the expanded use of laboratory tests to identify those at highest risk of adverse reactions, the use of novel recombinant allergens for the diagnosis and treatment of venom allergic patients, and an update on known risk factors and predictors of immunotherapy failure. We also review the latest advances on emerging delivery mechanisms and alternate dosing schedules that aim to improve safety, tolerability, and cost of venom immunotherapy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0107-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0107-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-483-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-483-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Adams KE</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0107-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calabria,C.W.</style></author><author><style face="normal" font="Arial"> Smith,D.M.</style></author><author><style face="normal" font="Arial"> Coop,C.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Optimizing Allergen Immunotherapy Safety: What Do We Know and What Are the Unmet Needs</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="482" start="465">465-482</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Subcutaneous immunotherapy (SCIT) is generally safe yet there remains a small risk of fatal and near-fatal injections. Factors that should be considered in the initial risk assessment for systemic reactions to SCIT include poorly controlled asthma, high degree of allergen sensitivity, history of prior systemic reactions, comorbid illness, and building up injections during the height of pollen season. Future studies should evaluate the aforementioned risk factors and also assess protocol modifications including antihistamine pretreatment, lower or higher starting doses (silver [1:10,000-áv/v] vs red [1:1000-áv/v]) and different buildup regimens with different dose increases (0.05 vs 0.1-ámL). Finally, risk management after systemic reactions (SR) needs to be further investigated, including when to discontinue SCIT, how far to decrease the dose after SR, optimal pretreatment regimens, when to increase wait times, and when to prescribe epinephrine autoinjectors. Sublingual immunotherapy (SLIT) is generally felt to be safer, though anaphylaxis has been reported. Local side effects (oral and gastrointestinal) represent the majority of all reported SLIT adverse reactions and affect up to 75-á% of patients. There are a multitude of unanswered questions related to SLIT safety, including the safety of using multiple allergens, using SCIT + SLIT simultaneously, dosage adjustments for missed doses, how long to hold a dose (after infections, dental work, asthma), and identifying SR risk factors</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-016-0108-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-016-0108-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-465-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2016-3-465-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Calabria CW</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-016-0108-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Akbas,A.</style></author><author><style face="normal" font="Arial"> Kilinc,F.</style></author><author><style face="normal" font="Arial"> Sener,S.</style></author><author><style face="normal" font="Arial"> Aktas,A.</style></author><author><style face="normal" font="Arial"> Baran,P.</style></author><author><style face="normal" font="Arial"> Ergin,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a TC Saglik Bakanligi Ankara Ataturk Egitim ve Arastirma Hastanesi , Ankara, 6800 Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Investigation of Thiol-Disulphide Balance in Patients with Acute Urticaria and Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">Cutan Ocul Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cutan Ocul Toxicol</style></full-title></periodical><pages end="210" start="205">205-210</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Thiol-disulphide balance plays a major role in health and diseases. This balance may be disrupted by various diseases. We aimed to determine status of the effect of thiol -disulphide balance in urticaria Objectives: We aimed to investigate the thiol-disulphide balance in patients with acute urticaria and chronic spontaneous urticaria. METHODS: Study included 53 patients with acute urticaria and 47 healthy controls plus 57 patients with chronic spontaneous urticaria and 57 healthy controls. Levels of native thiols, disulphides and total thiols were evaluated in plasma using a new and automated spectrophotometric method. Ratios of disulphides/total thiols, disulphides/native thiols and native thiols/total thiols were calculated. RESULTS: For acute urticaria, there was no statistical difference compared to control group in levels of native thiols, disulphides and total thiols. For chronic spontaneous urticaria, however, there was an increase in levels of native thiols, disulphides and total thiols and the ratio of thiol/disulphide in favour of disulphide. CONCLUSION: Thiol-disulphide balance was not affected by acute urticaria but shifted towards to disulphide in chronic spontaneous urticaria indicating the presence of oxidative stress</style></abstract><notes><style face="normal" font="Arial">DA - 20161208IS - 1556-9535 (Electronic)IS - 1556-9527 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1080/15569527.2016.1240179</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27927024">PM:27927024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cutan Ocul Toxicol\20161208-AkbasA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cutan Ocul Toxicol\20161208-AkbasA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161208, Akbas A</style></custom2><misc3><style face="normal" font="Arial">10.1080/15569527.2016.1240179</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jonsdottir,S.</style></author><author><style face="normal" font="Arial"> Svansson,V.</style></author><author><style face="normal" font="Arial"> Stefansdottir,S.B.</style></author><author><style face="normal" font="Arial"> Mantyla,E.</style></author><author><style face="normal" font="Arial"> Marti,E.</style></author><author><style face="normal" font="Arial"> Torsteinsdottir,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Experimental Pathology, Biomedical Center, University of Iceland, Keldur, Keldnavegur 3, 112, Reykjavik, Iceland</style></auth-address><titles><title><style face="normal" font="Arial">Oral administration of transgenic barley expressing a Culicoides allergen induces specific antibody response</style></title><secondary-title><style face="normal" font="Arial">Equine Vet J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Equine Vet J</style></full-title></periodical><pages end="518" start="512">512-518</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Barley</style></keyword><keyword><style face="normal" font="Arial"> barley flour</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cul n 2</style></keyword><keyword><style face="normal" font="Arial"> Culicoides</style></keyword><keyword><style face="normal" font="Arial"> Culicoides obsoletus</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> Icelandic horses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insect bite hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Insect bite hypersensitivity is an IgE-mediated dermatitis of horses initiated by bites of midges of the genus Culicoides. Culicoides spp. are not indigenous to Iceland and the prevalence of insect bite hypersensitivity is much higher in horses born in Iceland and exported as compared to Icelandic horses born in a Culicoides rich environment. Immunotherapy is therefore needed. OBJECTIVES: The aim of the study was to express an allergen from Culicoides in barley grain and investigate whether an immune response could be obtained in healthy Icelandic horses by oral treatment with transgenic barley expressing the allergen. STUDY DESIGN: In vivo experiment. METHODS: The allergen was expressed in barley grain with the Orfeus technique. A device was developed to orally treat horses with barley flour. Four Icelandic horses were treated with transgenic barley and three with control barley, in total 500 g in seven feedings. Serum and saliva samples were collected for measuring specific antibodies. RESULTS: The allergen Cul n 2, a hyaluronidase originating from the salivary gland of C. nubeculosus, was expressed in barley. Horses treated with the transgenic barley mounted a Cul n 2 specific IgG1 and IgG4/7 response in serum and saliva. The serum response was significantly different between the transgenic and control barley treated horses for both subclasses and the saliva response for IgG1. The induced serum antibodies bound to the corresponding allergen from Culicoides obsoletus, rCul o 2 and were able to partially block binding of Cul n 2 as well as Cul o 2 specific IgE from insect bite hypersensitivity affected horses. MAIN LIMITATIONS: Small number of horses. CONCLUSION: This study shows that specific antibody response can be induced in horses not exposed to Culicoides, using oral treatment with transgenic barley expressing an allergen. Further studies will determine whether this approach is a useful alternative for prevention and treatment of equine insect bite hypersensitivity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 2042-3306 (Electronic)IS - 0425-1644 (Linking)LA - engPT - Journal ArticleCO - Iceland -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/evj.12655</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27859584">PM:27859584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Equine Vet J\20161118-JonsdottirS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Equine Vet J\20161118-JonsdottirS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Jonsdottir S</style></custom2><misc3><style face="normal" font="Arial">10.1111/evj.12655</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bircher,A.J.</style></author><author><style face="normal" font="Arial"> Hofmeier,K.S.</style></author><author><style face="normal" font="Arial"> Link,S.</style></author><author><style face="normal" font="Arial"> Heijnen,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Dermatology Clinic</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy to the carbohydrate galactose-alpha-1,3-galactose (alpha-gal): four case reports and a review</style></title><secondary-title><style face="normal" font="Arial">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Dermatol</style></full-title></periodical><pages end="9" start="3">3-9</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Ixodes</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Until recently, food allergies to mammalian meats have been considered to be very rare. The observation that patients not previously exposed to the monoclonal chimeric antibody cetuximab suffered from severe anaphylaxis upon first exposure, led to the identification of galactose-alpha-1,3-galactose as a new relevant carbohydrate allergen. These patients later often suffered from anaphylactic reactions to red meat. Epidemiological data indicated that bites by the tick Amblyomma americanum in the USA, later also by Ixodes species in other continents, resulted in sensitisation to alpha-gal. On the other hand, in African patients with parasitic disorders, a high prevalence of anti-alpha-gal IgE, without clinical relevance, has been reported. In our four cases, one patient with a late onset of meat allergy had a history of a tick bite. The other three patients had symptoms from childhood or at a juvenile age. This indicates that in some patients, other ways of sensitisation may also take place. However, in patients without atopy, tick bite-induced IgE to alpha-gal may be more relevant. Diagnosis is based on a history of delayed onset of anaphylaxis. Skin tests with commercially available meat test solutions are often equivocal or negative; skin tests with raw meat and particularly pork kidney are more sensitive. Determination of specific IgE to alpha-gal is commercially available. The highest sensitivity is observed with skin and basophil activation tests with cetuximab which is, however, limited by its high costs</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1684/ejd.2016.2908</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27873733">PM:27873733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Dermatol\20161122-BircherAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Dermatol\20161122-BircherAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Bircher AJ</style></custom2><misc3><style face="normal" font="Arial">10.1684/ejd.2016.2908</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vestergaard,C.</style></author><author><style face="normal" font="Arial"> Toubi,E.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Triggiani,M.</style></author><author><style face="normal" font="Arial"> Ballmer-Weber,B.</style></author><author><style face="normal" font="Arial"> Marsland,A.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author><author><style face="normal" font="Arial"> Knulst,A.</style></author><author><style face="normal" font="Arial"> Gimenez-Arnau,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Aarhus University Hospital, Aarhus, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion</style></title><secondary-title><style face="normal" font="Arial">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Dermatol</style></full-title></periodical><pages end="19" start="10">10-19</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Chronic spontaneous urticaria (CSU) is characterized by the sudden, continuous or intermittent appearance of pruritic wheals (hives), angioedema, or both for six weeks or more, with no known specific trigger. The international EAACI/GA2LEN/EDF/WAO urticaria guideline advises standard-dose, second-generation H1-antihistamines as first-line therapy. However, H1-antihistamine treatment leads to absence of symptoms in fewer than 50% of patients. Updosing of second-generation H1-antihistamines (up to fourfold) as recommended by the EAACI/GA2LEN/EDF/WAO urticaria guideline as second-line therapy, can improve response, but many patients remain symptomatic. Definitions of response are often subjective and a consensus is needed regarding appropriate treatment targets. There is also an unmet need for biomarkers to assess CSU severity and activity and to predict treatment response. The EAACI/GA2LEN/EDF/WAO urticaria guideline recommends add-on omalizumab, ciclosporin A (CsA), or montelukast third line in patients with an inadequate response to high-dose H1-antihistamines. Omalizumab is currently the only licensed systemic biologic for use in CSU. Both omalizumab and CsA are effective third-line CSU treatments; montelukast appears to have lower efficacy in this setting. Omalizumab carries a label warning for anaphylaxis, although no cases of anaphylaxis were reported in the phase III trials of omalizumab in CSU and it is generally well tolerated in patients with CSU. Omalizumab arguably has a better safety profile than CsA</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Israel -CO - Germany -CO - Italy -CO - United Kingdom -CO - Spain -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1684/ejd.2016.2905</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27882879">PM:27882879</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Dermatol\2017-27-10-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Dermatol\2017-27-10-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Vestergaard C</style></custom2><misc3><style face="normal" font="Arial">10.1684/ejd.2016.2905</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Knol,E.F.</style></author><author><style face="normal" font="Arial"> Hijnen,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis: A tale of two distinct pathomechanisms that make you itch</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="2515" start="2512">2512-2515</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transgene</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) or eczema is the most common chronic inflammatory skin disease. It is a multifactorial disease with local and systemic immune changes. Current therapies focus on restoring the local skin barrier or inhibiting immune responses. In this issue of the European Journal of Immunology, Sehra et al. [Eur. J. Immunol. 2016. 46:2609-2613] describe a mouse model with T-cell-specific expression of constitutively active Stat6 in Flaky tail mice, which have mutations in the Flg and Tmem79 genes. The authors describe that it is the combination of changes in the skin barrier proteins filaggrin and Tmem79, together with Th2 cytokine signaling in the constitutively active Stat6 transgene, that drives the immune-pathomechanism in AD. These results are consistent with human studies where it is demonstrated that diminished filaggrin expression in skin is a predisposing factor for AD, but is neither required nor sufficient for disease indicating that additional factors are required for disease development. The current mouse model by Sehra et al. could be instrumental in evaluation new therapeutic strategies for AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - ENGPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201646708</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27813070">PM:27813070</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\2016-46-2512-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\2016-46-2512-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Knol EF</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201646708</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garn,H.</style></author><author><style face="normal" font="Arial"> Renz,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg, Medical Faculty, Marburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">GATA-3-specific DNAzyme - A novel approach for stratified asthma therapy</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="30" start="22">22-30</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antisense DNA</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine receptor</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> NFAT</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> STAT-6</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">It is now well established that type-2 immune mechanisms drive the inflammation in about 50% of asthma patients. The major cellular and molecular players regulating this important network have been identified. In terms of therapeutic intervention, cytokine and cytokine-receptor pathways have been given major attention, since these molecules are relatively easily accessible for a blockade through monoclonal antibodies, and a number of positive clinical results support this concept. However, targeting events controlling the type-2 immunity network upstream of selective cytokine pathways would be equally attractive. Type-2 immunity is regulated through a delicate interplay of several transcription factors (including GATA-3, STAT-6, NFAT, IRF4, c-maf), with GATA-3 as master regulator in this regard. Since transcription factors are intracellularly located they cannot be directly targeted by monoclonal antibodies. For intracellular targets, antisense technologies such as antisense DNA and siRNA have been shown to be a promising approach, and have recently made major advances towards clinical application. Here we summarize the development of a GATA-3-specific DNAzyme - a molecule class that combines the superior specificity of antisense molecules with an inherent RNA-cleaving enzymatic activity - for the treatment of type-2-driven asthma from preclinical development towards a proof-of-concept clinical study. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201646450</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27910098">PM:27910098</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20161202-GarnH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\20161202-GarnH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Garn H</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201646450</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gaga,M.</style></author><author><style face="normal" font="Arial"> Zervas,E.</style></author><author><style face="normal" font="Arial"> Humbert,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">7th Respiratory Medicine Dept and Asthma Center, Athens Chest Hospital "Sotiria", Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Targeting immunoglobulin E in non-atopic asthma: crossing the red line?</style></title><secondary-title><style face="normal" font="Arial">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Respir J</style></full-title></periodical><pages end="1540" start="1538">1538-1540</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - EditorialCO - Greece -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1183/13993003.01797-2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27903682">PM:27903682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Respir J\2016-48-1538-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Respir J\2016-48-1538-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Gaga M</style></custom2><misc3><style face="normal" font="Arial">10.1183/13993003.01797-2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pillai,P.</style></author><author><style face="normal" font="Arial"> Chan,Y.C.</style></author><author><style face="normal" font="Arial"> Wu,S.Y.</style></author><author><style face="normal" font="Arial"> Ohm-Laursen,L.</style></author><author><style face="normal" font="Arial"> Thomas,C.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Menzies-Gow,A.</style></author><author><style face="normal" font="Arial"> Rajakulasingam,R.K.</style></author><author><style face="normal" font="Arial"> Ying,S.</style></author><author><style face="normal" font="Arial"> Gould,H.J.</style></author><author><style face="normal" font="Arial"> Corrigan,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept of Respiratory Medicine and Allergy, and Randall Division of Cell and Molecular Biophysics, King's College London, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma</style></title><secondary-title><style face="normal" font="Arial">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Respir J</style></full-title></periodical><pages end="1601" start="1593">1593-1601</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial biopsies</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Omalizumab therapy of non-atopic asthmatics reduces bronchial mucosal IgE and inflammation and preserves/improves lung function when disease is destabilised by staged withdrawal of therapy.18 symptomatic, non-atopic asthmatics were randomised (1:1) to receive omalizumab or identical placebo treatment in addition to existing therapy for 20 weeks. Bronchial biopsies were collected before and after 12-14 weeks of treatment, then the patients destabilised by substantial, supervised reduction of their regular therapy. Primary outcome measures were changes in bronchial mucosal IgE+ cells at 12-14 weeks, prior to regular therapy reduction, and changes in lung function (forced expiratory volume in 1 s) after destabilisation at 20 weeks. Quality of life was also monitored.Omalizumab but not placebo therapy significantly reduced median total bronchial mucosal IgE+ cells (p&lt;0.01) but did not significantly alter median total mast cells, plasma cells, B lymphocytes, eosinophils and plasmablasts, although the latter were difficult to enumerate, being distributed as disperse clusters. By 20 weeks, lung function declined in the placebo-treated patients but improved in the omalizumab treated patients, with significant differences in absolute (p=0.04) and % predicted forced expiratory volume in 1 s (p=0.015).Omalizumab therapy of non-atopic asthmatics reduces bronchial mucosal IgE+ mast cells and improves lung function despite withdrawal of conventional therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161108IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1183/13993003.01501-2015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27824606">PM:27824606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Respir J\2016-48-1593-601.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Respir J\2016-48-1593-601.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161108, Pillai P</style></custom2><misc3><style face="normal" font="Arial">10.1183/13993003.01501-2015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Gritti,B.</style></author><author><style face="normal" font="Arial"> Frati,F.</style></author><author><style face="normal" font="Arial"> Ridolo,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Cardiac/Pulmonary Rehabilitation , ASST G. Pini/CTO , Milan , Italy</style></auth-address><titles><title><style face="normal" font="Arial">The slow progress in achieving an effective treatment for food allergy</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Drug Deliv</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Drug Deliv</style></full-title></periodical><pages end="1651" start="1649">1649-1651</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 1744-7593 (Electronic)IS - 1742-5247 (Linking)LA - ENGPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/17425247.2016.1249465</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27804307">PM:27804307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Opin Drug Deliv\2016-13-1649-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Opin Drug Deliv\2016-13-1649-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Incorvaia C</style></custom2><misc3><style face="normal" font="Arial">10.1080/17425247.2016.1249465</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,H.</style></author><author><style face="normal" font="Arial"> Hu,L.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Cui,C.</style></author><author><style face="normal" font="Arial"> Song,Y.</style></author><author><style face="normal" font="Arial"> Jin,Y.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Veterinary Medicine, Northwest A&amp;F University, Yangling, Shaanxi, China</style></auth-address><titles><title><style face="normal" font="Arial">Generation of beta-lactoglobulin-modified transgenic goats by homologous recombination</style></title><secondary-title><style face="normal" font="Arial">FEBS J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">FEBS J</style></full-title></periodical><pages end="4613" start="4600">4600-4613</pages><volume><style face="normal" font="Arial">283</style></volume><number><style face="normal" font="Arial">24</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Alpha-lactalbumin</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exons</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Goat's milk</style></keyword><keyword><style face="normal" font="Arial"> Goats</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="12" Year="2016">2016/12/5</year></dates><abstract><style face="normal" font="Arial">beta-Lactoglobulin (BLG) is a dominant allergen present in the milk of goats and other ungulates, although it is not found in human breast milk. Thus, the presence of BLG restricts the consumption of goat's milk by humans. In the present study, we examined whether the disruption of the BLG gene in goats by homologous recombination (HR) reduced BLG content in goat's milk and decreased the allergic response to milk. In one approach, exon 2 of the BLG gene was efficiently targeted using HR with a BLG knockout vector. In a second approach to disrupt BLG gene expression and drive exogenous human alpha-lactalbumin (hLA) gene expression, two hLA knock-in constructs were used to target exons 1-4 of the BLG gene via HR, and expression of hLA was then confirmed in goat mammary epithelial cells in vitro. The recombinant clones from both approaches were then used for somatic cell nuclear transfer, generating two transgenic goats possessing a BLG knockout allele or site-specific hLA integration allele. Milk assays demonstrated a reduction in BLG levels in both the BLG knockout and hLA knock-in goats; furthermore, hLA was present in the hLA knock-in goat's milk. Allergenic analysis in mice indicated that the transgenic goat's milk was less allergenic than wild-type goat's milk. These results support the development of gene-targeted animals as an effective tool for reducing allergic reactions to milk and improving nutrition</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1742-4658 (Electronic)IS - 1742-464X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/febs.13950</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27917606">PM:27917606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FEBS J\20161205-ZhuH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FEBS J\20161205-ZhuH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Zhu H</style></custom2><misc3><style face="normal" font="Arial">10.1111/febs.13950</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mainente,F.</style></author><author><style face="normal" font="Arial"> Simonato,B.</style></author><author><style face="normal" font="Arial"> Pasini,G.</style></author><author><style face="normal" font="Arial"> Franchin,C.</style></author><author><style face="normal" font="Arial"> Arrigoni,G.</style></author><author><style face="normal" font="Arial"> Rizzi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Agronomy Food Natural Resources Animals and Environment , University of Padova , Viale dell'Universita 16, 35020 Legnaro (Padova) , Italy</style></auth-address><titles><title><style face="normal" font="Arial">Hen egg white lysozyme is a hidden allergen in Italian commercial ciders</style></title><secondary-title><style face="normal" font="Arial">Food Addit Contam Part A Chem Anal Control Expo Risk Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Addit Contam Part A Chem Anal Control Expo Risk Assess</style></full-title></periodical><pages end="151" start="145">145-151</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gram-Positive Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> hen egg white lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Hen egg white lysozyme (HEWL) is an enzyme used in alcoholic fermentation for its ability to control the growth of Gram-positive bacteria and spoilage bacteria, without inhibiting yeast growth, and it allows a reduction in the use of sulphur dioxide. Nevertheless, considering the potential allergenicity of this protein, the presence of HEWL should be declared on the label of the final product. In this work, we analysed 18 commercial Italian ciders by LC-MS/MS, and found traces of HEWL in 12 samples without label declaration. We used Western blot and Enzyme-linked Immunosorbent Assay (ELISA) to verify the immunological activity of HEWL, and to quantify its content in the ciders. Two out of 18 samples were found to be positive both by Immunoblot and ELISA. Our results indicate the requirement of a more stringent control of the commercial ciders and the need of label declaration for ciders treated with such compounds</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 1944-0057 (Electronic)IS - 1944-0057 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/19440049.2016.1265673</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27892783">PM:27892783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Addit Contam Part A Chem Anal Control Expo Risk Assess\20161128-MainenteF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Addit Contam Part A Chem Anal Control Expo Risk Assess\20161128-MainenteF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Mainente F</style></custom2><misc3><style face="normal" font="Arial">10.1080/19440049.2016.1265673</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yii,A.C.</style></author><author><style face="normal" font="Arial"> Koh,M.S.</style></author><author><style face="normal" font="Arial"> Lapperre,T.S.</style></author><author><style face="normal" font="Arial"> Tan,G.L.</style></author><author><style face="normal" font="Arial"> Chotirmall,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory and Critical Care Medicine, Singapore General Hospital</style></auth-address><titles><title><style face="normal" font="Arial">The emergence of Aspergillus species in chronic respiratory disease</style></title><secondary-title><style face="normal" font="Arial">Front Biosci (Schol Ed)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Biosci (Schol Ed)</style></full-title></periodical><pages end="138" start="127">127-138</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">Chronic lung disease is recognized as an important risk factor for developing pulmonary aspergillosis. The development of specific aspergillus-associated syndromes depends on host immunity and underlying lung disease. In the setting of asthma, hypersensitivity to Aspergillus can lead to allergic bronchopulmonary aspergillosis (ABPA) or severe asthma with fungal sensitization (SAFS). Chronic use of systemic or inhaled corticosteroids coupled with recurrent antibiotic use for exacerbations prevalent in chronic obstructive pulmonary disease (COPD) predisposes to chronic pulmonary aspergillosis (CPA). Prior pulmonary tuberculosis is a risk factor for CPA, a syndrome with a wide range of presentations including a simple aspergilloma, chronic cavities, necrosis or fibrosis. Accumulating evidence suggests that the presence of or colonization by Aspergillus in the setting of chronic lung disease can worsen clinical course and outcomes even in the absence of overt pulmonary aspergillosis. We propose that understanding the complex interplay between host and fungi may provide key insights into the pathogenesis of Aspergillus-associated pulmonary syndromes in the setting of chronic lung disease, and provide novel therapeutic approaches to improve its identification and management</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 1945-0524 (Electronic)IS - 1945-0516 (Linking)LA - ENGPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27814579">PM:27814579</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Biosci (Schol Ed)\2017-9-127-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Biosci (Schol Ed)\2017-9-127-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Yii AC</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lomidze,N.</style></author><author><style face="normal" font="Arial"> Gotua,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center of Allergy and Immunology; Tbilisi State Medical University, Georgia</style></auth-address><titles><title><style face="normal" font="Arial">Patterns of sensitization by food and inhalant components in Georgian patients</style></title><secondary-title><style face="normal" font="Arial">Georgian Med News</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Georgian Med News</style></full-title></periodical><pages end="26" start="23">23-26</pages><number><style face="normal" font="Arial">259</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Amb a 1</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cyn d 1</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Molecular-based allergy (MA) diagnostics is a novel approach used to map the allergen sensitization of a patient at a molecular level, using purified natural or recombinant allergen components instead of allergen extracts. The aim of our study was to: 1) investigate sensitization patterns to food and inhalant allergen components in different age groups of Georgian allergic patients 2) evaluate patient's potential risk of systemic reaction and manage dietary modifications. 3) Study food and inhalant components in different age groups in correlation with clinical manifestations of allergic disease. Allergic patient's sera samples were tested by ImmunoCap ISAC and specific IgE levels against 112 different allergen components were detected. The study population was comprising 81 allergic patients, included 26 adults (mean age 36.2+/-10.9) and 55 children (mean age 6.1+/-4.58). Results revealed that nGal d 1 (11.3%), nGal d 2 (10.1%) and nBos d 8 (10.1%) were more prevalent among food components. Cyn d 1 (35.4%), nCup a 1 (26.5%), n Amb a 1 (21.5%), rAlt a 1 (10.1%), rFel d1 (12.6%), rDer f 2 (26.50%), nDer p 2 (24%) were more prevalent among inhalant components. PR-10 reactivity was detected in 45%, Profilin - 43% and</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1512-0112 (Print)IS - 1512-0112 (Linking)LA - engPT - Journal ArticleCO - Georgia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27845281">PM:27845281</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Georgian Med News\2016-259-23-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Georgian Med News\2016-259-23-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Lomidze N</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mitchell,P.D.</style></author><author><style face="normal" font="Arial"> El-Gammal,A.I.</style></author><author><style face="normal" font="Arial"> O'Byrne,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Firestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Anti-IgE and Biologic Approaches for the Treatment of Asthma</style></title><secondary-title><style face="normal" font="Arial">Handb Exp Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Handb Exp Pharmacol</style></abbr-1></periodical><pages end="152" start="131">131-152</pages><volume><style face="normal" font="Arial">237</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mechanics</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> refractory asthma</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="11" Year="2016">2016/11/19</year></dates><abstract><style face="normal" font="Arial">Current asthma treatments are effective for the majority of patients with mild-to-moderate disease. However, in those with more severe refractory asthma, agents other than inhaled corticosteroids and beta-agonists are needed both to better manage this group of patients and to avoid the side effects of high-dose corticosteroids and the social and personal hardship endured. Several biological pathways have been targeted over the last 20 years, and this research has resulted in pharmacological approaches to attempt to better treat patients with severe refractory asthma. The flagship of the biologics, the anti-IgE monoclonal antibody, omalizumab, has proven efficacious in selected subgroups of asthma patients. Tailoring asthma treatments to suit specific subtypes of asthma patients is in keeping with ideals of personalized medicine. Research in the complex interplay of allergens, epithelial host defenses, cytokines, and innate and adaptive immunity interactions has allowed better understanding of the mechanics of allergy and inflammation in asthma. As a result, new biologic treatments have been developed that target several different phenotypes and endotypes in asthma. As knowledge of the efficacy of these biological agents in asthma emerges, as well as the type of patients in whom they are most beneficial, the movement toward personalized asthma treatment will follow</style></abstract><notes><style face="normal" font="Arial">DA - 20161119IS - 0171-2004 (Print)IS - 0171-2004 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/164_2016_65</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864676">PM:27864676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Handb Exp Pharmacol\20161119-MitchellPD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Handb Exp Pharmacol\20161119-MitchellPD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161119, Mitchell PD</style></custom2><misc3><style face="normal" font="Arial">10.1007/164_2016_65</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krogman,A.</style></author><author><style face="normal" font="Arial"> Tilahun,A.</style></author><author><style face="normal" font="Arial"> David,C.S.</style></author><author><style face="normal" font="Arial"> Chowdhary,V.R.</style></author><author><style face="normal" font="Arial"> Alexander,M.P.</style></author><author><style face="normal" font="Arial"> Rajagopalan,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA</style></auth-address><titles><title><style face="normal" font="Arial">HLA-DR polymorphisms influence in vivo responses to staphylococcal toxic shock syndrome toxin-1 in a transgenic mouse model</style></title><secondary-title><style face="normal" font="Arial">HLA</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">HLA</style></abbr-1></periodical><pages end="28" start="20">20-28</pages><volume><style face="normal" font="Arial">89</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endocarditis</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Histocompatibility</style></keyword><keyword><style face="normal" font="Arial"> HLA class II</style></keyword><keyword><style face="normal" font="Arial"> HLA-DR</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> MHC class II</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> Superantigens</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Toxic shock</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Toxic shock syndrome toxin-1 (TSST-1) is a potent superantigen produced by Staphylococcus aureus. In addition to menstrual and nonmenstrual toxic shock syndromes, TSST-1 is also implicated in the immunopathogenesis of pneumonia, infective endocarditis, neonatal exanthematous disease, and atopic dermatitis among others. Superantigens first bind to major histocompatibility complex (MHC) class II molecules and then activate a large proportion of T cells by cross-linking their T cell receptor. As binding to MHC class II molecules is a critical step in the robust activation of the immune system by TSST-1 and other superantigens, polymorphic variations between different HLA-DR alleles could potentially influence the magnitude of immune activation and immunopathology caused by TSST-1. As TSST-1 is highly toxic to humans and given that multiple variations of alleles of HLA-DR and HLA-DQ are expressed in each individual, it is difficult to determine how HLA-DR polymorphisms quantitatively and qualitatively impact immune activation caused by TSST-1 in humans. However, such investigations can be conducted on transgenic mice lacking all endogenous MHC class II molecules and expressing specific HLA class II alleles. Therefore, transgenic mice expressing different HLA-DRB1 alleles (HLA-DRB1*15:01, HLA-DRB1*15:02, HLA-DRB1*03:01, HLA-DRB1*04:01), and sharing HLA-A1*01:01 chain, were systemically challenged with purified TSST-1 and multiple immune parameters were assessed. Among the HLA-DR alleles, mice expressing HLA-DRB1*15:01 allele elicited a significantly higher serum cytokine/chemokine response; greater splenic T cell expansion and most severe organ pathology. Our study highlights the potential utility of human leukocyte antigen (HLA) transgenic mice in understanding the impact of HLA polymorphisms on the outcomes of diseases caused by TSST-1 and other superantigens</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 2059-2310 (Electronic)IS - 2059-2302 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10 . 1111 / t an.12930</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27863161">PM:27863161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\HLA\20161118-KrogmanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\HLA\20161118-KrogmanA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Krogman A</style></custom2><misc3><style face="normal" font="Arial">10 . 1111 / t an.12930</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chiba,S.</style></author><author><style face="normal" font="Arial"> Yokoyama,H.</style></author><author><style face="normal" font="Arial"> Kumazawa,A.</style></author><author><style face="normal" font="Arial"> Shimmoto,M.</style></author><author><style face="normal" font="Arial"> Naganawa,Y.</style></author><author><style face="normal" font="Arial"> Shinmoto,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Agriculture, Tamagawa University, Machida, Tokyo 194-8610, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Epitope analysis of Japanese cedar pollen allergen Cry j2 with a human IgM class monoclonal antibody 404-117</style></title><secondary-title><style face="normal" font="Arial">Hum Antibodies</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Antibodies</style></full-title></periodical><pages end="21" start="17">17-21</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">1-2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Alanine</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hybridoma</style></keyword><keyword><style face="normal" font="Arial"> Hybridomas</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Japanese cedar pollen allergen Cry j2 is a causal allergen of seasonal pollinosis in Japan. To analyze B cell epitopes of Cry j2, we established two human-mouse hybridomas secreting IgM class human monoclonal antibodies to Cry j2. A pin-peptide enzyme-linked immunosorbent assay with synthesized icosa peptides showed that 404-117 monoclonal antibody bound to peptides #11-13 with cry j2 amino acid sequence of 101F-L140. Detailed analysis with octa peptides and alanine substituted peptides indicated that an amino acid sequence of 118FKVD121 was an essential for antibody binding. When K119 (Asn) was substituted with alanine, 404-117 monoclonal antibody did not bind to the alanine substituted peptide. We concluded that the 118FKVD121 sequence might have a very important role in early recognition by Cry j2-specific B cells, which could act as antigen presenting cells</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1875-869X (Electronic)IS - 1093-2607 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3233/HAB-160301</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27858705">PM:27858705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Antibodies\20161118-ChibaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Antibodies\20161118-ChibaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Chiba S</style></custom2><misc3><style face="normal" font="Arial">10.3233/HAB-160301</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Musa,F.</style></author><author><style face="normal" font="Arial"> Al-Ahmad,M.</style></author><author><style face="normal" font="Arial"> Arifhodzic,N.</style></author><author><style face="normal" font="Arial"> Al-Herz,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Al-Rashid Allergy Center, Ministry of Health, Kuwait City, KUWAIT</style></auth-address><titles><title><style face="normal" font="Arial">Compliance with Allergen Immunotherapy and Factors Affecting Compliance among Patients with Respiratory Allergies</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="517" start="514">514-517</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patient Education</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific immunotherapy (AIT) is safe and effective for the treatment of allergic rhinitis and allergic asthma. However, patient non-compliance is a major barrier to achieving optimal outcomes. OBJECTIVE: To determine the level of compliance among patients using AIT and to identify factors associated with non-compliance. METHODS: A retrospective analysis using questionnaires was conducted to study compliance among 236 patients with allergic rhinitis with or without asthma who began AIT in 2009 or 2010. RESULTS: The compliance rates at 3 years were 58.7% among patients on subcutaneous immunotherapy (SCIT) and 11.6% among those on sublingual immunotherapy (SLIT). The mean durations of treatment with SCIT and SLIT were 31 (+/-18.3) and 15.9 (+/-14.7) months, respectively. The most common causes of non-compliance among patients on SCIT were the frequency of injections (82.2%), the duration of treatment (70.9%), and commuting to the Allergy Center (67.7%). Reasons for non-compliance among patients on SLIT were related to inconvenience (43.4%), improvement without treatment (30.2%) and perception of poor efficacy (25.0%). CONCLUSION: Compliance with AIT is low, but at 3 years, it was higher among patients on SCIT than among patients on SLIT. Reasons for non-compliance include difficulty adjusting to treatment protocols and a perception that the efficacy is low. Patient education regarding the treatment course and the slow effect, as well as the need for close follow up to effectively prevent and treat adverse reactions, are important factors for improving compliance and treatment outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - ENGPT - Journal ArticleCO - Kuwait -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2016.1243632</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27820664">PM:27820664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20161107-MusaF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20161107-MusaF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Musa F</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2016.1243632</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Victor,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Laboratory of Medical Investigation LIM-56, Division of Clinical Dermatology, Medical School, University of Sao Paulo , Sao Paulo , Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-specific IgG as a mediator of allergy inhibition: lessons from mother to child</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="513" start="507">507-513</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergen-specific IgG produced by immune mothers is associated with less predisposition to allergy development in their children. This finding has been described by several groups over the last few decades, but the mechanisms by which maternal IgG can inhibit allergy development are still not fully understood. With the purpose of summarizing past investigations, we review the literature on murine models of maternal immunization with allergens and on immune regulation in humans after passive therapy with purified IgG. Based on our review, a new hypothesis about these mechanisms is presented, which may provide a foundation for the future development of therapies to inhibit allergy development</style></abstract><notes><style face="normal" font="Arial">DA - 20161103IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - ENGPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2016.1244592</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27808600">PM:27808600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20161103-VictorJR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20161103-VictorJR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161103, Victor JR</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2016.1244592</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Toletone,A.</style></author><author><style face="normal" font="Arial"> Voltolini,S.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Dini,G.</style></author><author><style face="normal" font="Arial"> Bignardi,D.</style></author><author><style face="normal" font="Arial"> Minale,P.</style></author><author><style face="normal" font="Arial"> Massa,E.</style></author><author><style face="normal" font="Arial"> Signori,A.</style></author><author><style face="normal" font="Arial"> Troise,C.</style></author><author><style face="normal" font="Arial"> Durando,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Health Sciences , Postgraduate School in Occupational Medicine and Occupational Medicine Unit, IRCCS AOU San Martino-IST, University of Genoa , Italy</style></auth-address><titles><title><style face="normal" font="Arial">Hymenoptera venom allergy in outdoor workers: occupational exposure, clinical features and effects of allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="483" start="477">477-483</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Occupational physician</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To describe (i) the clinical characteristics of workers, exposed to hymenoptera stings, with an ascertained diagnosis of Hymenoptera Venom Allergy (HVA), (ii) the specific role of occupational exposure, (iii) the effect of Venom Immunotherapy (VIT) in reducing the severity of allergic episodes in workers exposed to repeated stings of hymenoptera, and (iv) the management of the occupational consequences caused by allergic reactions due to hymenoptera stings. METHODS: Between 2000 and 2013 an observational study, including patients referred to the regional reference hospital of Liguria, Italy, with an ascertained diagnosis of HVA and treated with VIT, was carried out. A structured questionnaire was administered to all patients to investigate the occupational features of allergic reactions. These were graded according to standard systems in patients at the first episode, and after re-stings, during VIT. RESULTS: One-hundred and eighty-four out of the 202 patients referred had a complete data set. In 32 (17.4%) patients, the allergic reaction occurred during work activities performed outdoor. Of these, 31.2% previously stung by hymenoptera at work, and receiving VIT, were re-stung during occupational activity. The grades of reaction developed under VIT treatment resulted clinically less severe than of those occurred at the first sting (p-value = 0.031). CONCLUSION: Our findings confirmed the clinical relevance of HVA, and described its occupational features in outdoor workers with sensitization, stressing the importance of an early identification and proper management of the professional categories recognized at high risk of hymenoptera stings. The Occupational Physician should be supported by other specialists to recommend appropriate diagnostic procedures and the prescription of VIT, which resulted an effective treatment for the prevention of episodes of severe reactions in workers with a proven HVA</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1264748</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27924689">PM:27924689</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20161207-ToletoneA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20161207-ToletoneA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Toletone A</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1264748</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Z.</style></author><author><style face="normal" font="Arial"> Chen,Z.</style></author><author><style face="normal" font="Arial"> Chen,T.</style></author><author><style face="normal" font="Arial"> Yi,T.</style></author><author><style face="normal" font="Arial"> Zheng,Z.</style></author><author><style face="normal" font="Arial"> Fan,H.</style></author><author><style face="normal" font="Arial"> Chen,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathogen Biology, College of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, 430065, China</style></auth-address><titles><title><style face="normal" font="Arial">Berberine Attenuates Inflammation Associated with Delayed-Type Hypersensitivity via Suppressing Th1 Response and Inhibiting Apoptosis</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Alkaloids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Concanavalin A</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="11" Year="2016">2016/11/10</year></dates><abstract><style face="normal" font="Arial">Berberine, one of the active alkaloids from Rhizoma Coptidis, has been indicated to have anti-inflammatory and immunosuppressive properties. The aim of this study was to determine the role of berberine on ovalbumin (OVA)-induced delayed-type hypersensitivity (DTH) and its potential mechanisms. Berberine treatment significantly reduced footpad swelling, inflammatory cells infiltration, anti-OVA IgG levels, IgE concentration in serum, and the tetramer+CD8+ cells. In homogenized footpad tissue, the production of Th1-mediated cytokines including IFN-gamma, TNF-alpha, and IL-2 were suppressed following the administration of berberine. Detailed studies revealed that berberine prevented differentiation into Th1 cells in the OVA-primed lymphocytes, resulting from suppressing the expression of T-bet and secretion of IFN-gamma but not IL-4. Concanavalin A stimulation assay and MTT assay also indicated inhibiting effect of berberine treatment on IFN-gamma production and decreased cytotoxicity in lymphocytes proliferation, respectively. Additionally, berberine obviously decreased the cell apoptosis and enzymatic activity of caspase-3, which was further confirmed by the facts that berberine clearly lowered Bax/Bcl-2 ratio and expression of cleaved caspase-3 protein. On correlation analysis, the percentage of apoptotic cells showed a significant positive relationship with IFN-gamma/IL-4 ratio of supernatant from footpad tissue in berberine-treated DTH mice. These results demonstrated that berberine attenuated Th1-mediated inflammation in OVA-induced DTH by curbing Th1 response and inhibiting cell apoptosis, suggesting a therapeutic potential for berberine for the treatment of type IV hypersensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20161110IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-016-0472-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27832398">PM:27832398</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20161110-WangZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20161110-WangZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161110, Wang Z</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-016-0472-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chauhan,P.S.</style></author><author><style face="normal" font="Arial"> Dash,D.</style></author><author><style face="normal" font="Arial"> Singh,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Zoology, MMV Unit, Varanasi, India</style></auth-address><titles><title><style face="normal" font="Arial">Intranasal Curcumin Inhibits Pulmonary Fibrosis by Modulating Matrix Metalloproteinase-9 (MMP-9) in Ovalbumin-Induced Chronic Asthma</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Curcumin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary fibrosis</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="11" Year="2016">2016/11/19</year></dates><abstract><style face="normal" font="Arial">Pulmonary fibrosis is associated with irreversible, or partially reversible, airflow obstruction and ultimately unresponsiveness to asthma therapies such as corticosteroids. Intranasal curcumin, an anti-inflammatory molecule, has been found effective in allergic asthma. To study the effect of intranasal curcumin on airway remodeling and fibrosis in murine model of chronic asthma, BALB/c mice were sensitized to ovalbumin (OVA) and exposed to OVA aerosol (2%) from day 21 (after sensitization) for 5 weeks (twice/week). Curcumin (intranasal) was administered during the OVA aerosol challenge. Mice exposed to OVA developed inflammation dominated by eosinophils which lead to fibrosis and airway remodeling. Intranasal administration of curcumin significantly inhibited airway inflammation and pulmonary fibrosis, where MMP-9 activities were decreased along with alpha-smooth muscle actin (alpha-SMA), MMP-9, TIMP-1, and eotaxin expressions. These results suggest that intranasal curcumin regulates airway inflammation and remodeling in chronic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161120IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-016-0475-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27866296">PM:27866296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20161120-ChauhanPS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20161120-ChauhanPS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161120, Chauhan PS</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-016-0475-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohammadi-Shahrokhi,V.</style></author><author><style face="normal" font="Arial"> Rezaei,A.</style></author><author><style face="normal" font="Arial"> Andalib,A.</style></author><author><style face="normal" font="Arial"> Rahnama,A.</style></author><author><style face="normal" font="Arial"> Jafarzadeh,A.</style></author><author><style face="normal" font="Arial"> Eskandari,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Immunomodulatory Effects of Adjuvants CPG, MPLA, and BCG on the Derp2-Induced Acute Asthma at Early Life in an Animal Model of BALB/c Mice</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="11" Year="2016">2016/11/28</year></dates><abstract><style face="normal" font="Arial">The Th1- and Treg cell-related immune responses play key roles in the modulation of Th2 cell-related allergic disorders. The aim was to evaluate the effects of CPG, MPLA, and BCG on the number of Th1-, Th2-, and Treg cell-related parameters in an animal model of asthma. BALB/c mice were divided into five groups and immunized subcutaneously (SC) on days 1, 15, and 22 with allergen Derp2. Three groups of mice were pretreated SC on days 0, 14, and 21 with CPG, CPG + MPLA, or CPG + BCG. All mice were then challenged intranasally with Derp2 on days 28-37. Blood samples were collected from the retro-orbital sinus, on days 0, 23, and 40. The serum levels of IL-4, IFN-gamma, IgE, and IgG2a were measured using ELISA technique. The blood number of Th1 and Treg cells was determined using flow cytometry. At the sensitization phase, the number of Th1 and the serum levels of IFN-gamma and IgG2a were significantly increased in the Derp2-sensitized group pretreated with CPG plus MPLA, and the number of Treg cells was significantly elevated in Derp2-sensitized mice pretreated with CPG or CPG plus MPLA as compared with that in Derp2-sensitized control mice. At the challenge phase, the number of Th1 was significantly elevated in Derp2-sensitized mice pretreated with CPG plus MPLA, CPG plus BCG, or CPG; the count of Treg cells was significantly increased in Derp2-sensitized mice pretreated with CPG plus BCG group; and the levels of IFN-gamma and IgG2a were significantly enhanced in the Derp2-sensitized group pretreated with CPG plus MPLA in comparison with those in Derp2-sensitized control mice. The scores of inflammation and mucus secretion in the lung were significantly decreased in the Derp2-sensitized group pretreated with CPG, BCG, and CPG plus MPLA in comparison with those in the Derp2-sensitized control group. These results showed that BCG, MPLA, and CPG modulate Th1-, Th2-, and Treg-related parameters and ameliorate lung inflammatory parameters in a mouse model of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-016-0476-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27896542">PM:27896542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20161119-MohammadiShahrokhiV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20161119-MohammadiShahrokhiV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Mohammadi-Shahrokhi V</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-016-0476-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Byrne,T.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Acute Throat Swelling in Pregnancy: Review of the Literature and Management</style></title><secondary-title><style face="normal" font="Arial">Insights Allergy Asthma Bronchitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Insights Allergy Asthma Bronchitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://asthma-and-bronchitis.imedpub.com/acute-throat-swelling-in-pregnancy-review-of-the-literature-and-management.php?aid=13671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Insights Allergy Asthma Bronchitis\20161210-ByrneTJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Insights Allergy Asthma Bronchitis\20161210-ByrneTJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Byrne TJ</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomsen,S.F.</style></author><author><style face="normal" font="Arial"> Elmose,C.</style></author><author><style face="normal" font="Arial"> Szecsi,P.B.</style></author><author><style face="normal" font="Arial"> Stender,S.</style></author><author><style face="normal" font="Arial"> Kyvik,K.O.</style></author><author><style face="normal" font="Arial"> Backer,V.</style></author><author><style face="normal" font="Arial"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="Arial">Filaggrin gene loss-of-function mutations explain discordance of atopic dermatitis within dizygotic twin pairs</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="1344" start="1341">1341-1344</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> filaggrin gene</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene mutations</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> twin</style></keyword><keyword><style face="normal" font="Arial"> Twins</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: This study was designed to examine the association between loss-of-function mutations in the filaggrin gene (FLG) and atopic dermatitis (AD) and asthma in adult twins. METHODS: A previously well-characterized cohort of 575 adult twins were genotyped for the loss-of-function mutations in FLG (R501X, 2282del4 and R2447X) most common among northern Europeans. Subjects were examined for symptoms of atopic diseases as well as for lung function, airway responsiveness, and atopy. RESULTS: In the whole population of twins, the risk for AD was significantly increased in individuals with FLG mutations in comparison with wild-type carriers (34.3% vs. 21.8%) after adjustment for possible confounders (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.07-3.41; P = 0.028). A significant association was also observed for persistent AD (OR 2.10, 95% CI 1.02-4.36; P = 0.046). There were no significant differences in risk for asthma by FLG mutation status in individuals with and without AD, respectively (P-value for interaction, 0.595). In 11 dizygotic twin pairs discordant for FLG mutation status, risk for AD was higher in the twin carrying the FLG mutation (five of 11 [45.5%] twins had developed AD) than in the non-carrier co-twin (two of 11 [18.2%] twins had developed AD) (OR 2.50, 95% CI 0.45-13.85; P = 0.293). FLG status did not explain a significant proportion of the variation in AD (P = 0.328) or asthma (P = 0.321). CONCLUSIONS: Filaggrin gene mutations are risk factors for the presence and persistence of AD and explain the discordance of AD within dizygotic twin pairs</style></abstract><notes><style face="normal" font="Arial">DA - 20160922IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - ENGPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.13401</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27653621">PM:27653621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\2016-55-1341-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\2016-55-1341-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160922, Thomsen SF</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.13401</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fathi,S.M.</style></author><author><style face="normal" font="Arial"> Tavakol,M.</style></author><author><style face="normal" font="Arial"> Rezaei,N.</style></author><author><style face="normal" font="Arial"> Movahedi,M.</style></author><author><style face="normal" font="Arial"> Aghamohammadi,A.</style></author><author><style face="normal" font="Arial"> Shariat,M.</style></author><author><style face="normal" font="Arial"> Sadeghi,B.</style></author><author><style face="normal" font="Arial"> Behniafard,N.</style></author><author><style face="normal" font="Arial"> Darabi,B.</style></author><author><style face="normal" font="Arial"> Hajikhani,A.</style></author><author><style face="normal" font="Arial"> Abdollahpour,I.</style></author><author><style face="normal" font="Arial"> Gharagozlou,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children Growth Research Center, Qazvin University of Medical Sciences, Qazvin, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Impact of IgE-mediated Food Allergy on Parental Quality of Life in Iranian Patients</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="380" start="372">372-380</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vigilance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Food allergy is a common disorder especially in the first years of life. Strict avoidance of the responsible food is the most effective therapeutic measure so far. But this continuous vigilance could be stressful for the patient and family and decreases their quality of life (QOL). This survey was designed to evaluate the impact of IgE-mediated food allergy on parental QOL in Iranian patients and to develop a valid Persian version of "Food Allergy Quality Of Life- Parental Burden (FAQL-PB) questionnaire". 90 patients (28 females, 62 males) and their parents who were referred to the clinic of Allergy in Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran were enrolled. The questionnaire was translated with scientific method and its reliability was approved in a pilot study (ICC=0.75, cronbach-alpha=0.90). Among all patients the most common allergens were wheat (60%) and cow's milk (42%). The patient's age (p=0.02), parent's gender (p=0.004), mother's age (p=0.02), duration of the disease (p=0.048), and allergen multiplicity (p=0.004) were found to have the most significant correlation with family and social activity (FSA) domain. The most meaningful associations were achieved between parent's gender (p&lt;0.001) and emotional issues (EM); as well as meal preparation (MP) with patient's age (p=0.02), parent's gender (p&lt;0.0001) and also allergen multiplicity (p= 0.003); likewise nutrition and health concern (NH) domain with parent's gender (p&lt;0.001). Anaphylaxis's history did not place any burden on each domain. It was concluded that presence of food allergic patients in families could considerably affect all domains of QOL</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27917623">PM:27917623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-372-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-372-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Fathi SM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohamadi,M.</style></author><author><style face="normal" font="Arial"> Falak,R.</style></author><author><style face="normal" font="Arial"> Mokhtarian,K.</style></author><author><style face="normal" font="Arial"> Khoramizadeh,M.R.</style></author><author><style face="normal" font="Arial"> Sadroddiny,E.</style></author><author><style face="normal" font="Arial"> Kardar,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran AND Immunology Research center, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Identification and Characterization of Main Allergic Proteins in Cooked Wolf Herring Fish</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="371" start="363">363-371</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> herring</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Sodium Dodecyl Sulfate</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Our aim in this study was to identify and characterize allergic proteins in cooked wolf herring fish. We heated the crude extract alternatively at 50, 60, 70, 80, 90, and 100 degrees C for one hour and results were compared by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Also, proteins were immunoblotted with fish-sensitive patients' sera. The major allergenic proteins were identified via mass spectrometry. These allergenic proteins were then purified by anion exchange chromatography and the IgE-immunoreactivity of the fractions was compared with the crude extracts via disk enzyme-linked immunosorbent assay (ELISA). SDS-PAGE of the crude extract showed more than 15 distinct protein bands. Five of these proteins, with apparent molecular weights of 12, 18, 24, 38, and 51 kDa, were only observed in the 100 degrees C heated extract. Immunoblotting of the heated extract revealed that the 12 and 51 kDa proteins were IgE-immunoreactive with 88 percent of fish-sensitive patient sera while the 24 and 38 kDa proteins reacted with 33.3 and 55.5 percent of fish-sensitive patient sera, respectively. Mass spectrometry of the 12, 38, and 51 kDa proteins revealed that all three were parvalbumin oligomers. Disk ELISA results showed that 20 of 25 and 14 of 25 fish-allergic patients' sera were IgE-reactive with purified oligomeric parvalbumin-coated and crude extract-coated disks, respectively. Parvalbumin and its oligomers are the main allergenic molecules in cooked fish. Therefore, an enriched or purified fraction containing this protein could be a useful source of allergen for applications in ELISA-based immunoassays and could discriminate fish-allergic patients who can tolerate cooked fish from those who cannot</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27917622">PM:27917622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-363-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-363-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Mohamadi M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82498</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'Angelo,G.</style></author><author><style face="normal" font="Arial"> Marseglia,L.</style></author><author><style face="normal" font="Arial"> Manti,S.</style></author><author><style face="normal" font="Arial"> Colavita,L.</style></author><author><style face="normal" font="Arial"> Cuppari,C.</style></author><author><style face="normal" font="Arial"> Impellizzeri,P.</style></author><author><style face="normal" font="Arial"> Arena,S.</style></author><author><style face="normal" font="Arial"> Arrigo,T.</style></author><author><style face="normal" font="Arial"> Salpietro,C.</style></author><author><style face="normal" font="Arial"> Gitto,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Neonatal Intensive Care Unit, Department of Pediatrics, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Atopy and autoimmune thyroid diseases: melatonin can be useful?</style></title><secondary-title><style face="normal" font="Arial">Ital J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ital J Pediatr</style></full-title></periodical><pages end="" start="95">95-</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> melatonin</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Diseases</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="11" Year="2016">2016/11/4</year></dates><abstract><style face="normal" font="Arial">Recently, there has been growing interest in the relationship between allergic and autoimmune diseases. Allergy and autoimmunity can be considered two potential outcomes of dysregulated immunity and analysis of literature data shows a strong positive association between a history of Th2-mediated allergic disorders and Th1-mediated autoimmune disorders.Autoimmune thyroid diseases are the most common of all autoimmune pathological conditions.Currently, the mechanisms explaining an association among atopy, autoimmunity, and thyroid diseases are not fully understood.There are data in literature pointing to the relationship between melatonin and thyroid activity. Several studies have suggested a paracrine role for this molecule in the regulation of thyroid activity, documenting that administration, as an antioxidant, in thyroid tissues under conditions of increased oxidative stress, could be helpful to reduce the oxidative processes involved in autoimmune thyroid diseases.Although thyroid autoimmunity has been regularly associated with atopic conditions in children, the possible protective role of melatonin has not yet been investigated.This review summarizes what is known regarding the connection between atopy and autoimmune thyroid diseases, and analyses the probable beneficial action of melatonin</style></abstract><notes><style face="normal" font="Arial">DA - 20161105IS - 1824-7288 (Electronic)IS - 1720-8424 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13052-016-0305-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27814774">PM:27814774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Pediatr\2016-42-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Pediatr\2016-42-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161105, D'Angelo G</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13052-016-0305-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Siddiqui,M.H.</style></author><author><style face="normal" font="Arial"> Khan,I.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Lahore Teaching Hospital, Defence Road, Lahore, Pakistan</style></auth-address><titles><title><style face="normal" font="Arial">Fascinating Giardia Lamblia and Vexing Chronic Spontaneous Urticaria: An Under-appreciated Association</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="241">241-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Giardia</style></keyword><keyword><style face="normal" font="Arial"> Giardia lamblia</style></keyword><keyword><style face="normal" font="Arial"> Giardiasis</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Teaching</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background: Chronic Spontaneous Urticaria (CSU) has been found to have a negative impact on all aspects of patients' lives - physical, mental, social and emotional. The ubiquitous and fascinating Giardia lamblia is primarily a gastrointestinal pathogen but it may present atypically (with or without gastroenterological manifestations). A link between Giardiasis and CSU was identified in the past. However, the possibility of this combination has been under-appreciated in clinical practice, even in developed world, resulting in inordinate delay in reaching correct diagnosis and instituting targeted pharmacotherapy. Such a situation adds to the miseries of the patients, both mental anguish and physical suffering. Objectives: -To determine the role of Giardia lamblia in the causation of CSU -To ratify the effects of eradication of Giardia lamblia on the course of CSU Methods: The present study was conducted on 63 referred cases of CSU (with insignificant improvement from the treatment already instituted). In view of the possibility of concomitant Giardial infection stool microscopy was advised and three fresh stool specimens, taken on alternate days, were collected from every case and examined for parasites. The two validated instruments employed for comparing Patient Related Outcome Measures (PROMs), before and after treatment, were UAS7 (Urticaria Activity Score of 7days) and CU-Q2oL (Chronic Urticaria Quality of Life Questionnaire). Results: Twenty two percent of those tested were found to have sole infection with Giardia lamblia. Secnidazole Sodium, as a single oral dose, resulted in complete parasitological and clinical cure in 93% of the cases. The results of the PROMs were compared and correlated with the clinical picture. Conclusion: The effects of eradication of Giardia lamblia on the course of the urticaria were excellent. Complete resolution of symptoms was seen in 93% of cases (and no recurrence in the follow up period of 16 weeks) with specific anti-giardial therapy alone proving that the causative agent was Giardia lamblia and that there was no role for any concomitant dermatological pathology. There is a dire need for meaningful cooperation between specialists of Dermatology and Tropical Medicine, in the management of otherwise unexplained urticaria.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Pakistan -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000241</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2016-7-241.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2016-7-241.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Siddiqui MH</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000241</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Munoz,I.</style></author><author><style face="normal" font="Arial"> Danelli,L.</style></author><author><style face="normal" font="Arial"> Claver,J.</style></author><author><style face="normal" font="Arial"> Goudin,N.</style></author><author><style face="normal" font="Arial"> Kurowska,M.</style></author><author><style face="normal" font="Arial"> Madera-Salcedo,I.K.</style></author><author><style face="normal" font="Arial"> Huang,J.D.</style></author><author><style face="normal" font="Arial"> Fischer,A.</style></author><author><style face="normal" font="Arial"> Gonzalez-Espinosa,C.</style></author><author><style face="normal" font="Arial"> de Saint Basile,G.</style></author><author><style face="normal" font="Arial"> Blank,U.</style></author><author><style face="normal" font="Arial"> Menasche,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Normal and Pathological Homeostasis of the Immune System, Institut National de la Sante et de la Recherche Medicale, UMR1163, F-75015 Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Kinesin-1 controls mast cell degranulation and anaphylaxis through PI3K-dependent recruitment to the granular Slp3/Rab27b complex</style></title><secondary-title><style face="normal" font="Arial">J Cell Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cell Biol</style></full-title></periodical><pages end="216" start="203">203-216</pages><volume><style face="normal" font="Arial">215</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE receptors</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Phosphatidylinositol 3-kinase</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="10" Year="2016">2016/10/24</year></dates><abstract><style face="normal" font="Arial">Cross-linking of mast cell (MC) IgE receptors (FcepsilonRI) triggers degranulation of secretory granules (SGs) and the release of many allergic and inflammatory mediators. Although degranulation depends crucially on microtubule dynamics, the molecular machinery that couples SGs to microtubule-dependent transport is poorly understood. In this study, we demonstrate that mice lacking Kif5b (the heavy chain of kinesin-1) in hematopoietic cells are less sensitive to IgE-mediated, passive, systemic anaphylaxis. After IgE-induced stimulation, bone marrow-derived MCs from Kif5b knockout mice exhibited a marked reduction in SG translocation toward the secretion site. In contrast, a lack of Kif5b did not affect cytokine secretion, early FcepsilonRI-initiated signaling pathways, or microtubule reorganization upon FcepsilonRI stimulation. We identified Slp3 as the critical effector linking kinesin-1 to Rab27b-associated SGs. Kinesin-1 recruitment to the Slp3/Rab27b effector complex was independent of microtubule reorganization but occurred only upon stimulation requiring phosphatidylinositol 3-kinase (PI3K) activity. Our findings demonstrate that PI3K-dependent formation of a kinesin-1/Slp3/Rab27b complex is critical for the microtubule-dependent movement of SGs required for MC degranulation</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 1540-8140 (Electronic)IS - 0021-9525 (Linking)LA - engPT - Journal ArticleCO - France -CO - Hong Kong -CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1083/jcb.201605073</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27810912">PM:27810912</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cell Biol\2016-215-203-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cell Biol\2016-215-203-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Munoz I</style></custom2><misc3><style face="normal" font="Arial">10.1083/jcb.201605073</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Washio,K.</style></author><author><style face="normal" font="Arial"> Fukunaga,A.</style></author><author><style face="normal" font="Arial"> Onodera,M.</style></author><author><style face="normal" font="Arial"> Hatakeyama,M.</style></author><author><style face="normal" font="Arial"> Taguchi,K.</style></author><author><style face="normal" font="Arial"> Ogura,K.</style></author><author><style face="normal" font="Arial"> Horikawa,T.</style></author><author><style face="normal" font="Arial"> Nishigori,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Clinical characteristics in cholinergic urticaria with palpebral angioedema: Report of 15 cases</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">angioedema</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="11" Month="11" Year="2016">2016/11/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161123IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27876252">PM:27876252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20161123-WashioK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20161123-WashioK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161123, Washio K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82502</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lucarelli,J.</style></author><author><style face="normal" font="Arial"> Pappas,D.</style></author><author><style face="normal" font="Arial"> Welchons,L.</style></author><author><style face="normal" font="Arial"> Augustyn,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Developmental Medicine Center, Boston Children's Hospital, Harvard Medical School, Boston, MA; daggerThe Kelberman Center, Utica, NY; double daggerDivision of Developmental and Behavioral Pediatrics, Boston Medical, Boston University School of Medicine, Boston, MA</style></auth-address><titles><title><style face="normal" font="Arial">Autism Spectrum Disorder and Avoidant/Restrictive Food Intake Disorder</style></title><secondary-title><style face="normal" font="Arial">J Dev Behav Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dev Behav Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> ASD</style></keyword><keyword><style face="normal" font="Arial"> Autism</style></keyword><keyword><style face="normal" font="Arial"> Autism spectrum disorder</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early intervention</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> folate</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="Arial"> GERD</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> restaurant</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy formula</style></keyword><keyword><style face="normal" font="Arial"> Soy Milk</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="4" Month="11" Year="2016">2016/11/4</year></dates><abstract><style face="normal" font="Arial">CASE: Kendra is a 4-year-old girl with autism spectrum disorder (ASD) who presents for follow-up of feeding problems to her pediatric clinician. She is an only child in a family where both parents are scientists. Feeding concerns date to infancy, when she was diagnosed with Gastroesophageal Reflux Disease (GERD) associated with persistent bottle refusal and the acceptance of few pureed foods. At 13 months, milk and peanut allergies were diagnosed. Following a feeding clinic evaluation at 24 months, she was prescribed a soy milk supplement and an H2 blocker. There was no concern for oral-motor dysfunction. She was also referred to early intervention for feeding therapy. However, her parents terminated participation after 6 months because she became anxious and had tantrum prior to treatment groups.She was seen in another feeding program at 3 years; zinc, folate, thyroid, and a celiac panel were normal, and an endoscopy was negative for eosinophilic esophagitis. She began individual feeding therapy, where concerns for rigidity, difficulty transitioning, and limited peer interactions led to a neuropsychological evaluation. Kendra was diagnosed with an ASD and avoidant/restrictive food intake disorder (ARFID). Her cognitive skills were average, and expressive and receptive language skills were low average.Her diet consisted of French fries, Ritz crackers, pretzels, and 32 ounces of soy formula daily. She had stopped accepting Cheerios and saltines 2 months prior. She controlled other aspects of feeding, insisting on a specific parking spot at a fast food restaurant and drinking from a particular sippy cup. Her parents accepted these demands with concern about her caloric intake, which they tracked daily.Following diagnosis with ARFID, she resumed feeding therapy using a systematic desensitization approach with rewards. At the first session, she kissed and licked 2 new foods without gagging. Her mother appeared receptive to recommendations that included continuing the "food game" at home, replacing 1 ounce of soy formula by offering water each day, limiting between-meal grazing, and refusing specific feeding demands.Currently, her parents plan to discontinue feeding therapy with concerns that the treatment was "too harsh." Her father produces logs of her caloric and micronutrient intake as evidence that she did not replace missed formula with other foods and reports that she subsequently became more difficult to manage behaviorally. Her father now demands to see randomized controlled trials of feeding therapy approaches. Her weight is stable, but she has now limited her pretzel intake to a specific brand. How would you approach her continued care?</style></abstract><notes><style face="normal" font="Arial">DA - 20161108IS - 1536-7312 (Electronic)IS - 0196-206X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/DBP.0000000000000362</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27824638">PM:27824638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dev Behav Pediatr\20161108-LucarelliJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dev Behav Pediatr\20161108-LucarelliJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161108, Lucarelli J</style></custom2><misc3><style face="normal" font="Arial">10.1097/DBP.0000000000000362</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pogorelov,D.</style></author><author><style face="normal" font="Arial"> Olisova,O.</style></author><author><style face="normal" font="Arial"> Nekrasova,T.</style></author><author><style face="normal" font="Arial"> Kolkhir,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, Sechenov First Moscow State Medical University, Moscow, Russia</style></auth-address><titles><title><style face="normal" font="Arial">Chronic spontaneous urticaria associated with primary biliary cirrhosis: a case report and literature review</style></title><secondary-title><style face="normal" font="Arial">J Dtsch Dermatol Ges</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dtsch Dermatol Ges</style></abbr-1></periodical><pages end="1132" start="1130">1130-1132</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Case Report</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161123IS - 1610-0387 (Electronic)IS - 1610-0379 (Linking)LA - engPT - LetterCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1111/ddg.13064</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27879079">PM:27879079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dtsch Dermatol Ges\2016-14-1130-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dtsch Dermatol Ges\2016-14-1130-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161123, Pogorelov D</style></custom2><misc3><style face="normal" font="Arial">10.1111/ddg.13064</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,B.</style></author><author><style face="normal" font="Arial"> Cai,W.</style></author><author><style face="normal" font="Arial"> Zhang,H.H.</style></author><author><style face="normal" font="Arial"> Zhong,Y.S.</style></author><author><style face="normal" font="Arial"> Fang,J.</style></author><author><style face="normal" font="Arial"> Zhang,W.Y.</style></author><author><style face="normal" font="Arial"> Mo,L.</style></author><author><style face="normal" font="Arial"> Wang,L.C.</style></author><author><style face="normal" font="Arial"> Yu,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy, Zhejiang Chinese Medical University, Hangzhou310053, China</style></auth-address><titles><title><style face="normal" font="Arial">Selaginella uncinata flavonoids ameliorated ovalbumin-induced airway inflammation in a rat model of asthma</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> asthmatic reactions</style></keyword><keyword><style face="normal" font="Arial"> Bitter taste</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hek293 Cells</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Selaginella uncinata (Desv.) Spring, known as "Cuiyuncao" is a perennial herb widely distributed in the Southeast Asian countries. In the folk medicine, the local minority commonly use it to treat cough and asthma for centuries. AIM OF THE STUDY: This study was carried out to investigate the protective mechanisms of total flavonoids from S. uncinata (SUF) on airway hyperresponsiveness, cytokine release and bitter taste receptors (T2Rs) signaling with emphasis on inflammatory responses in a rat model of ovalbumin (OVA)-induced asthma. MATERIALS AND METHODS: Rats were sensitized and challenged with OVA to induce typical asthmatic reactions. Pathological changes of lung tissue were examined by HE staining. The serum levels of T cell-associated cytokines (IFN-gamma, IL-4, IL-5 and IL-13), total IgE and OVA-specific IgE were determined by enzyme-linked immunosorbent assay (ELISA). Gene expressions of T2R10, IP3R1 and Orai1 in lung tissue were assayed by fluorescence quantitative real-time polymerase chain reaction (FQ-PCR) while protein expressions of NFAT1 and c-Myc were assayed by western blot analysis. The activation of SUF was investigated on tansgentic T2R10-GFP HEK293 cells. RESULTS: SUF treatment attenuated airway hyperresponsiveness and goblet cell hyperplasia compared with OVA-challenged asthmatic rats. The serum levels of IL-4, IL-5 and IL-13 as well as total and OVA-specific IgE were decreased while serum IFN-gamma was increased in SUF-treated rats. SUF treatment significantly up-regulated T2R10 gene expression, down-regulated IP3R1 and Orai1 gene expression. SUF further suppressed eotaxin, NFAT1 and c-Myc protein expression in lung tissues of OVA-challenged rats. CONCLUSIONS: These results imply that SUF exerts anti-inflammatory function through the T2R10/IP3R1/NFAT1 dependent signaling pathway, and may warrant further evaluation as a possible agent for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2016.11.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27916586">PM:27916586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20161205-YuB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20161205-YuB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Yu B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2016.11.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahn,Y.J.</style></author><author><style face="normal" font="Arial"> Shin,J.S.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Lee,Y.J.</style></author><author><style face="normal" font="Arial"> Kim,M.R.</style></author><author><style face="normal" font="Arial"> Shin,Y.S.</style></author><author><style face="normal" font="Arial"> Park,K.B.</style></author><author><style face="normal" font="Arial"> Kim,E.J.</style></author><author><style face="normal" font="Arial"> Kim,M.J.</style></author><author><style face="normal" font="Arial"> Lee,J.W.</style></author><author><style face="normal" font="Arial"> Lee,H.D.</style></author><author><style face="normal" font="Arial"> Lee,Y.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Chung,H.J.</style></author><author><style face="normal" font="Arial"> Ha,I.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, 858 Eonju-ro, Gangnam-gu, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Safety of essential bee venom pharmacopuncture as assessed in a randomized controlled double-blind trial</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="780" start="774">774-780</pages><volume><style face="normal" font="Arial">194</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Forearm</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> PLA2</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spine</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="10" Month="11" Year="2016">2016/11/10</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: While bee venom (BV) pharmacopuncture use is common in Asia, frequent occurrence of allergic reactions during the treatment process is burdensome for both practitioner and patient. AIM OF THE STUDY: This study compared efficacy and safety in isolated and purified essential BV (eBV) pharmacopuncture filtered for phospholipase A2 (PLA2) and histamine sections, and original BV to the aim of promoting safe BV pharmacopuncture use. MATERIALS AND METHODS: In in vitro, we examined the effect of BV and eBV on nitric oxide (NO) production induced by lipopolysaccharide (LPS) in RAW 264.7 macrophages, and clinically, 20 healthy adults aged 20-40 years were randomly allocated and administered eBV 0.2mL and BV pharmacopuncture 0.2mL on left and right forearm, respectively, and physician, participant, and outcome assessor were blinded to treatment allocation. Local pain, swelling, itching, redness, wheals, and adverse reactions were recorded by timepoint. RESULTS: eBV and BV exhibited similar inhibitory effects on NO production. Also, in comparison between eBV and BV pharmacopuncture administration areas on each forearm, eBV displayed significantly lower local pain at 24hours post-administration (P=0.0062), and less swelling at 30minutes (P=0.0198), 2 (P=0.0028), 24 (P=0.0068), and 48hours post-administration (P=0.0253). eBV also showed significantly less itching at 24 (P=0.0119), 48 (P=0.0082), and 96hours (P=0.0141), while redness was significantly less at 30minutes (P=0.0090), 6 (P=0.0005), and 24hours (P&lt;0.0001). Time-by-treatment interactions were statistically significant for itching and redness (P&lt;0.001, and P&lt;0.001, respectively), and all original BV pharmacopuncture administered regions showed a tendency toward more severe itching and redness in later measurements. CONCLUSIONS: eBV and BV displayed comparable anti-inflammatory effects, and eBV pharmacopuncture presented less local allergic reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2016.11.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27840257">PM:27840257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\2016-194-774-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\2016-194-774-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161114, Ahn YJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2016.11.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nandy,S.</style></author><author><style face="normal" font="Arial"> Shah,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Pediatric Liver Clinic, B J Wadia Hospital for Children, Mumbai, Maharastra, India</style></auth-address><titles><title><style face="normal" font="Arial">Liver abscess in a boy with hyper IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">J Family Med Prim Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Family Med Prim Care</style></full-title></periodical><pages end="492" start="491">491-492</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abscess</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic granulomatous disease</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">Hyper immunoglobulin-E syndrome is a rare primary immunodeficiency disease, characterized by the classical triad of recurrent staphylococcal skin abscesses, pneumonia with pneumatocele formation, and elevated levels of serum IgE, usually over 2000 IU/mL. Chronic granulomatous disease, hyper IgE, and complement deficiencies are immunopathologies known to be associated with liver abscesses. We present a 2 (1/2)-year-old boy with liver abscess and associated hyper IgE</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 2249-4863 (Print)IS - 2249-4863 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/2249-4863.192353</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27843873">PM:27843873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Family Med Prim Care\2016-5-491-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Family Med Prim Care\2016-5-491-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Nandy S</style></custom2><misc3><style face="normal" font="Arial">10.4103/2249-4863.192353</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Junchao,Y.</style></author><author><style face="normal" font="Arial"> Zhen,W.</style></author><author><style face="normal" font="Arial"> Yuan,W.</style></author><author><style face="normal" font="Arial"> Liying,X.</style></author><author><style face="normal" font="Arial"> Libin,J.</style></author><author><style face="normal" font="Arial"> Yuanhong,Z.</style></author><author><style face="normal" font="Arial"> Wei,Z.</style></author><author><style face="normal" font="Arial"> Ruilin,C.</style></author><author><style face="normal" font="Arial"> Lu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiration, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, China</style></auth-address><titles><title><style face="normal" font="Arial">Anti- trachea inflammatory effects of diosgenin from Dioscorea nipponica through interactions with glucocorticoid receptor alpha</style></title><secondary-title><style face="normal" font="Arial">J Int Med Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Int Med Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Dioscorea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiration</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="2" Month="12" Year="2016">2016/12/2</year></dates><abstract><style face="normal" font="Arial">Asthma is a heterogeneous disease characterized by symptoms of chronic inflammation and airway structural and functional changes. It affects about 300 million people worldwide and causes 250 000 deaths annually, but its symptoms can be greatly relieved by regular use of inhaled glucocorticoids (GCs). GCs exert their function through interacting with glucocorticoid receptors (GRs). Diosgenin is a naturally occurring steroidal saponin abundantly present in many medicinal plants, including Dioscorea nipponica, which shares a similar steroidal structure with GC. In this study, ovalbumin (OVA)-induced asthmatic mice and primary tracheal epithelial cells (TECs) were used as research models. ELISAs were applied to measure the secretion of TNF-alpha, IL-1beta, and IL-6, while quantitative PCR and western blotting were applied to evaluate expression of GRs SLPI, TTP, GILZ, MKP-1, and NF-kappaB. Our data demonstrated that diosgenin suppressed the secretion of TNF-alpha, IL-1beta, and IL-6 by enhancing the expression of GRs, SLPI, GILZ, and MKP-1, and inhibiting the expression of HSP70. These data provide some evidence on the molecular mechanism of diosgenin, which might facilitate its clinical applications</style></abstract><notes><style face="normal" font="Arial">DA - 20161203IS - 1473-2300 (Electronic)IS - 0300-0605 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1177/0300060516676724</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27913746">PM:27913746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Int Med Res\20161203-JunchaoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Int Med Res\20161203-JunchaoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161203, Junchao Y</style></custom2><misc3><style face="normal" font="Arial">10.1177/0300060516676724</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,D.</style></author><author><style face="normal" font="Arial"> Lee,N.R.</style></author><author><style face="normal" font="Arial"> Park,S.Y.</style></author><author><style face="normal" font="Arial"> Jun,M.</style></author><author><style face="normal" font="Arial"> Lee,K.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Park,C.S.</style></author><author><style face="normal" font="Arial"> Liu,K.H.</style></author><author><style face="normal" font="Arial"> Choi,E.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea</style></auth-address><titles><title><style face="normal" font="Arial">As in atopic dermatitis, non-lesional skin in allergic contact dermatitis displays abnormalities in barrier function and ceramide content</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="750" start="748">748-750</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - ENGPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2016.10.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826010">PM:27826010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2017-173-748-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2017-173-748-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Kim D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2016.10.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamasaki,R.</style></author><author><style face="normal" font="Arial"> Fujii,T.</style></author><author><style face="normal" font="Arial"> Wang,B.</style></author><author><style face="normal" font="Arial"> Masaki,K.</style></author><author><style face="normal" font="Arial"> Kido,M.A.</style></author><author><style face="normal" font="Arial"> Yoshida,M.</style></author><author><style face="normal" font="Arial"> Matsushita,T.</style></author><author><style face="normal" font="Arial"> Kira,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Neurology and Neurological Therapeutics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Inflammation Leads to Neuropathic Pain via Glial Cell Activation</style></title><secondary-title><style face="normal" font="Arial">J Neurosci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Neurosci</style></abbr-1></periodical><pages end="11945" start="11929">11929-11945</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">47</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autism</style></keyword><keyword><style face="normal" font="Arial"> Autism spectrum disorder</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> CNS</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray Analysis</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Myelitis</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spinal Cord</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="Arial">Allergic and atopic disorders have increased over the past few decades and have been associated with neuropsychiatric conditions, such as autism spectrum disorder and asthmatic amyotrophy. Myelitis presenting with neuropathic pain can occur in patients with atopic disorder; however, the relationship between allergic inflammation and neuropathic pain, and the underlying mechanism, remains to be established. We studied whether allergic inflammation affects the spinal nociceptive system. We found that mice with asthma, atopic dermatitis, or atopic diathesis had widespread and significantly more activated microglia and astroglia in the spinal cord than those without atopy, and displayed tactile allodynia. Microarray analysis of isolated microglia revealed a dysregulated phenotype showing upregulation of M1 macrophage markers and downregulation of M2 markers in atopic mice. Among the cell surface protein genes, endothelin receptor type B (EDNRB) was most upregulated. Immunohistochemical analysis revealed that EDNRB expression was enhanced in microglia and astroglia, whereas endothelin-1, an EDNRB ligand, was increased in serum, lungs, and epidermis of atopic mice. No EDNRA expression was found in the spinal cord. Expression of FBJ murine osteosarcoma viral oncogene homolog B was significantly higher in the dorsal horn neurons of asthma mice than nonatopic mice. The EDNRB antagonist BQ788 abolished glial and neural activation and allodynia. We found increased serum endothelin-1 in atopic patients with myelitis and neuropathic pain, and activation of spinal microglia and astroglia with EDNRB upregulation in an autopsied case. These results suggest that allergic inflammation induces diffuse glial activation, influencing the nociceptive system via the EDNRB pathway. SIGNIFICANCE STATEMENT: The prevalence of allergic disorders has markedly increased over the past few decades. Allergic disorders are associated with neuropsychiatric conditions; however, the relationship between allergic inflammation and CNS complications is unknown. A peculiar myelitis presenting with persistent neuropathic pain has been reported in patients with allergic disorders. We studied how atopy exerts substantial influence on the nociceptive system. We found that mice with allergic disorders had severe allodynia with activated astroglia and microglia, and showed marked upregulation of endothelin-1 (ET-1) receptor type B (EDNRB) in the spinal cord. A selective EDNRB antagonist prevented allodynia and glial activation. Our findings suggest a novel mechanism whereby atopy induces glial activation and neuropathic pain via an ET-1/EDNRB pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1529-2401 (Electronic)IS - 0270-6474 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1523/JNEUROSCI.1981-16.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27881779">PM:27881779</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Neurosci\2016-36-11929-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Neurosci\2016-36-11929-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Yamasaki R</style></custom2><misc3><style face="normal" font="Arial">10.1523/JNEUROSCI.1981-16.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sander,I.</style></author><author><style face="normal" font="Arial"> Neumann,H.D.</style></author><author><style face="normal" font="Arial"> Lotz,A.</style></author><author><style face="normal" font="Arial"> Czibor,C.</style></author><author><style face="normal" font="Arial"> Zahradnik,E.</style></author><author><style face="normal" font="Arial"> Flagge,A.</style></author><author><style face="normal" font="Arial"> Faller,I.</style></author><author><style face="normal" font="Arial"> Buxtrup,M.</style></author><author><style face="normal" font="Arial"> Bruning,T.</style></author><author><style face="normal" font="Arial"> Raulf,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Institut fur Pravention und Arbeitsmedizin der Deutschen Gesetzlichen Unfallversicherung , Institut der Ruhr-Universitat Bochum (IPA) , Bochum , Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergen quantification in surface dust samples from German day care centers</style></title><secondary-title><style face="normal" font="Arial">J Toxicol Environ Health A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Toxicol Environ Health A</style></full-title></periodical><pages end="1105" start="1094">1094-1105</pages><volume><style face="normal" font="Arial">79</style></volume><number><style face="normal" font="Arial">22-23</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bedrooms</style></keyword><keyword><style face="normal" font="Arial"> Can f 1</style></keyword><keyword><style face="normal" font="Arial"> carpet</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Day Care</style></keyword><keyword><style face="normal" font="Arial"> Day-care</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> enzyme immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Home environment</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Linear Models</style></keyword><keyword><style face="normal" font="Arial"> main allergens</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> renovation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Indoor allergens are among the main causes of allergic rhinitis and asthma. Allergen exposure is not limited to private homes. Mite, cat, and dog allergens were measured in day care centers to determine whether these concentrations detected might exert significant influence on human health. In 20 day care centers across North Rhine-Westphalia, Germany, the surfaces of 171 rooms were vacuumed 4 times a year to collect dust (1340 samples in total). In all samples, domestic mite antigens (DM) and the main allergens of cats (Fel d 1) and dogs (Can f 1) were quantified using enzyme immunoassays. Provisional threshold limits (PTL) for increased risks of sensitization and allergic symptoms were estimated according to published values and conversion factors. The influence of room characteristics on allergen concentrations was analyzed in mixed linear models, also considering values below the limit of detection (LOD). Nearly all samples contained allergens (99% DM, 96% Fel d 1, and 96% Can f 1). The concentrations rarely exceeded levels that were previously found to induce symptoms in home environments, but were frequently higher than estimates for enhanced sensitization risk (13% DM, 43% Fel d 1, and 27% Can f 1). Upholstered furnishings had the highest dust and allergen loads, followed by carpets and smooth floors. Allergen concentrations on different surface types that were sampled in the same room at the same time were significantly correlated and analyzed in separate models. The highest DM concentrations were present in bedrooms and in autumn. Further, DM loads on floors decreased significantly in rooms that were renovated within the last 5 years. If there were no records that furnishings were vacuumed, there were then significantly higher Can f 1 loads. Sweeping floors elevated DM and cat allergen concentrations. In addition to mite allergens, cat and dog allergens were detected in nearly all samples from day care centers. Overall, the present results indicate that allergen concentrations may be reduced by renovation and appropriate cleaning procedures</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 1528-7394 (Print)IS - 0098-4108 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1080/15287394.2016.1219597</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27924716">PM:27924716</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Toxicol Environ Health A\2016-79-1094-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Toxicol Environ Health A\2016-79-1094-105.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Sander I</style></custom2><misc3><style face="normal" font="Arial">10.1080/15287394.2016.1219597</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Beek,N.</style></author><author><style face="normal" font="Arial"> Luttmann,N.</style></author><author><style face="normal" font="Arial"> Huebner,F.</style></author><author><style face="normal" font="Arial"> Recke,A.</style></author><author><style face="normal" font="Arial"> Karl,I.</style></author><author><style face="normal" font="Arial"> Schulze,F.S.</style></author><author><style face="normal" font="Arial"> Zillikens,D.</style></author><author><style face="normal" font="Arial"> Schmidt,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of Lubeck, Lubeck, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity</style></title><secondary-title><style face="normal" font="Arial">JAMA Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Dermatol</style></full-title></periodical><pages end="38" start="30">30-38</pages><volume><style face="normal" font="Arial">153</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Blister</style></keyword><keyword><style face="normal" font="Arial"> Blistering disease</style></keyword><keyword><style face="normal" font="Arial"> BP180</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> NC16A</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pemphigus</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Type XVII collagen</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Importance: Bullous pemphigoid (BP) is by far the most frequent autoimmune blistering disease. The presence of IgE autoantibodies against the transmembrane protein BP antigen 2 (BP180, type XVII collagen) has previously been reported in 22% to 100% of BP serum samples, and the pathogenic relevance of anti-BP180 IgE has been suggested in various experimental models and by the successful use of omalizumab in individual patients with BP. Objectives: To determine the rate of anti-BP180-reactive IgE in BP, to evaluate the diagnostic relevance of anti-BP180 IgE in BP, and to correlate anti-BP180 IgE with disease activity and the clinical phenotype of patients with BP. Design, Setting, and Participants: This case-control cohort study examined 3 groups of patients with BP. Sixty-five patients with BP underwent an enzyme-linked immunosorbent assay for IgE antibodies against the 16th noncollagenous domain of BP180 (NC16A); 52 consecutive patients with BP underwent clinical evaluation with the Bullous Pemphigoid Disease Activity Index (BPDAI); and 36 patients with BP without anti-BP180 NC16A IgG reactivity underwent evaluation of the diagnostic importance of serum anti-BP180 IgE. In addition, 49 age-matched control individuals with noninflammatory dermatoses, 127 controls undergoing allergy testing for IgE levels, and 30 controls with pemphigus vulgaris or pemphigus foliaceus were included for comparison. Patients were seen at a university clinic from January 1, 2008, to July 31, 2014. Main Outcomes and Measures: Serum anti-BP180 NC16A IgE and IgG levels and BPDAI scores. Results: Of 117 patients with BP (69 women and 48 men), anti-BP180 NC16A serum IgE was detected in 47 (40.2%) and correlated with disease activity as measured by total BPDAI (r = 0.918; P = .06). An intraindividual correlation of anti-BP180 NC16A serum levels with the total BPDAI was observed during the course of the disease in 10 randomly selected patients with BP (r = 0.983; P = .003). Although no association of circulating BP180 NC16A IgE antibodies with urticarial or erythematous lesions was observed (r = 0.481; P = .31), the presence of IgG anti-BP180 NC16A antibodies was associated with the occurrence of erosions and blisters (r = 0.985; P = .006) but not urticarial and erythematous lesions (r = 0.632; P = .23). Assaying for anti-BP180 IgE increased the diagnostic sensitivity by only 2.2% (1 of 46 serum samples) when combined with the IgG anti-BP180 enzyme-linked immunosorbent assay. Conclusions and Relevance: Although detection of serum anti-BP180 IgE is not of diagnostic importance, it may be relevant for therapeutic decisions (eg, the use of anti-IgE treatment). The correlation of serum anti-BP180 NC16A IgE levels with disease activity in patients with BP supports the notion that anti-BP180 IgE is of pathogenic relevance. Our observation that IgG anti-BP180 antibodies are related to the occurrence of blisters and erosions may encourage further studies on the association of fine autoantibody reactivities with clinical features of BP</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamadermatol.2016.3357</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27829102">PM:27829102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Dermatol\20161109-vanBeekN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Dermatol\20161109-vanBeekN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, van Beek N</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamadermatol.2016.3357</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anvari,S.</style></author><author><style face="normal" font="Arial"> Chokshi,N.Y.</style></author><author><style face="normal" font="Arial"> Kamili,Q.U.</style></author><author><style face="normal" font="Arial"> Davis,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston2Baylor College of Medicine, Houston, Texas</style></auth-address><titles><title><style face="normal" font="Arial">Evolution of Guidelines on Peanut Allergy and Peanut Introduction in Infants: A Review</style></title><secondary-title><style face="normal" font="Arial">JAMA Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="7" Month="11" Year="2016">2016/11/7</year></dates><abstract><style face="normal" font="Arial">Importance: The reported prevalence of peanut allergy among children in the United States has increased more than 3-fold in the last 20 years. Medical guidelines on the introduction of peanut as well as other allergenic foods have evolved with the emerging evidence that an early introduction to these foods is more beneficial than a delayed introduction. This review highlights the studies that have led to the evolving guidelines on peanut introduction in infants. Observations: The prevalence of peanut allergy has increased despite the publication of guidelines from the American Academy of Pediatrics in 2000, which recommended a delayed introduction of peanut. Since the 2000 guidelines, studies have provided evidence to support an earlier rather than delayed introduction. As a result, the American Academy of Pediatrics updated their guidelines in 2008 to promote peanut introduction during infancy. Current evidence continues to support the benefits of an earlier rather than delayed introduction. Conclusions and Relevance: Over the years, guidelines on the introduction of peanut have evolved, and recent literature suggests that an earlier rather than delayed introduction is beneficial to prevent peanut allergies in infants</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 2168-6211 (Electronic)IS - 2168-6203 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamapediatrics.2016.2552</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27820622">PM:27820622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Pediatr\20161107-AnvariS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Pediatr\20161107-AnvariS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Anvari S</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamapediatrics.2016.2552</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sheehan,W.J.</style></author><author><style face="normal" font="Arial"> Permaul,P.</style></author><author><style face="normal" font="Arial"> Petty,C.R.</style></author><author><style face="normal" font="Arial"> Coull,B.A.</style></author><author><style face="normal" font="Arial"> Baxi,S.N.</style></author><author><style face="normal" font="Arial"> Gaffin,J.M.</style></author><author><style face="normal" font="Arial"> Lai,P.S.</style></author><author><style face="normal" font="Arial"> Gold,D.R.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Boston Children's Hospital, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="Arial">Association Between Allergen Exposure in Inner-City Schools and Asthma Morbidity Among Students</style></title><secondary-title><style face="normal" font="Arial">JAMA Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Classroom</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental intervention</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> inner-city asthma</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school-based environmental intervention</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="11" Year="2016">2016/11/21</year></dates><abstract><style face="normal" font="Arial">Importance: Home aeroallergen exposure is associated with increased asthma morbidity in children, yet little is known about the contribution of school aeroallergen exposures to such morbidity. Objective: To evaluate the effect of school-specific aeroallergen exposures on asthma morbidity among students, adjusting for home exposures. Design, Setting, and Participants: The School Inner-City Asthma Study was a prospective cohort study evaluating 284 students aged 4 to 13 years with asthma who were enrolled from 37 inner-city elementary schools in the northeastern United States between March 1, 2008, and August 31, 2013. Enrolled students underwent baseline clinical evaluations before the school year started and were then observed clinically for 1 year. During that same school year, classroom and home dust samples linked to the students were collected and analyzed for common indoor aeroallergens. Associations between school aeroallergen exposure and asthma outcomes during the school year were assessed, adjusting for home exposures. Exposures: Indoor aeroallergens, including rat, mouse, cockroach, cat, dog, and dust mites, measured in dust samples collected from inner-city schools. Main Outcomes and Measures: The primary outcome was maximum days in the past 2 weeks with asthma symptoms. Secondary outcomes included well-established markers of asthma morbidity, including asthma-associated health care use and lung function, measured by forced expiratory volume in 1 second. Results: Among 284 students (median age, 8 years [interquartile range, 6-9 years]; 148 boys and 136 girls), exposure to mouse allergen was detected in 441 (99.5%) of 443 school dust samples, cat allergen in 420 samples (94.8%), and dog allergen in 366 samples (82.6%). Levels of mouse allergen in schools were significantly higher than in students' homes (median settled dust level, 0.90 vs 0.14 microg/g; P &lt; .001). Exposure to higher levels of mouse allergen in school (comparing 75th with 25th percentile) was associated with increased odds of having an asthma symptom day (odds ratio, 1.27; 95% CI, 1.05-1.54; P = .02) and 4.0 percentage points lower predicted forced expiratory volume in 1 second (95% CI, -6.6 to -1.5; P = .002). This effect was independent of allergic sensitization. None of the other indoor aeroallergens were associated with worsening asthma outcomes. Conclusions and Relevance: In this study of inner-city students with asthma, exposure to mouse allergen in schools was associated with increased asthma symptoms and decreased lung function. These findings demonstrate that the school environment is an important contributor to childhood asthma morbidity. Future school-based environmental interventions may be beneficial for this important public health problem</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 2168-6211 (Electronic)IS - 2168-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamapediatrics.2016.2543</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27893060">PM:27893060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Pediatr\20161128-SheehanWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Pediatr\20161128-SheehanWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Sheehan WJ</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamapediatrics.2016.2543</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kubik,M.</style></author><author><style face="normal" font="Arial"> Thottam,P.</style></author><author><style face="normal" font="Arial"> Shaffer,A.</style></author><author><style face="normal" font="Arial"> Choi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, U.S.A</style></auth-address><titles><title><style face="normal" font="Arial">The role of the otolaryngologist in the evaluation and diagnosis of eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Laryngoscope</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Laryngoscope</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic cough</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> croup</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagoscopy</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="11" Year="2016">2016/11/30</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To describe the clinical presentation and role of the otolaryngologist in the evaluation of eosinophilic esophagitis (EoE) at a tertiary pediatric hospital. STUDY DESIGN: Retrospective review. METHODS: Records from pediatric patients with a diagnosis of EoE from 2003 to 2015 were reviewed. Study variables were analyzed to compare patients presenting to different specialties. RESULTS: Two hundred and fifty-one patients with EoE were evaluated. The median age at diagnosis was 9.0 years (range 0.8-19.0); 73% were male. Sixty-seven percent of patients initially presented to gastroenterology and 18% to otolaryngology. Time from initial presentation to diagnosis did not differ between the patients presenting to the two specialties (median 2.3 vs. 2.0 months, P = 0.510). Overall, 26% presented with airway symptoms (stridor, chronic cough, croup, or dysphonia). Patients diagnosed by the otolaryngology service were younger (3.4 vs. 10.4 years, P &lt; 0.0001), had a higher incidence of airway symptoms (68% vs. 15%, P &lt; 0.001), and demonstrated fewer gastrointestinal symptoms (86% vs. 100%, P &lt; 0.001). CONCLUSION: Patients with EoE frequently present to otolaryngology undiagnosed in the first 5 years of life, making esophagoscopy with biopsy an important adjunct to airway endoscopy in children with refractory aerodigestive symptoms. Otolaryngologists are uniquely poised to facilitate early diagnosis and initiation of therapy for these children, potentially reducing long-term sequelae. LEVEL OF EVIDENCE: 4. Laryngoscope, 2016</style></abstract><notes><style face="normal" font="Arial">DA - 20161130IS - 1531-4995 (Electronic)IS - 0023-852X (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1002/lary.26373</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27900765">PM:27900765</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Laryngoscope\20161130-KubikM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Laryngoscope\20161130-KubikM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161130, Kubik M</style></custom2><misc3><style face="normal" font="Arial">10.1002/lary.26373</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larson,K.</style></author><author><style face="normal" font="Arial"> McLaughlin,J.</style></author><author><style face="normal" font="Arial"> Stonehouse,M.</style></author><author><style face="normal" font="Arial"> Young,B.</style></author><author><style face="normal" font="Arial"> Haglund,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Katelin Larson is a Pediatric Nurse Practitioner, Olympia Pediatrics, Olympia, WA.</style></auth-address><titles><title><style face="normal" font="Arial">Introducing Allergenic Food into Infants' Diets: Systematic Review</style></title><secondary-title><style face="normal" font="Arial">MCN Am J Matern Child Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">MCN Am J Matern Child Nurs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complementary foods</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="22" Month="11" Year="2016">2016/11/22</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The purpose of this evidence-based review was to explore the association between timing of introduction of potentially allergenic foods to infants and development of food allergies. METHODS: CINAHL, Medline, PubMed, Science Direct, and Web of Science were searched using the terms solid food, complementary food, or infant feeding combined with allergy or hypersensitivity for articles published in English in 2000 or later. Inclusion criteria were 1) primary research articles with 2) a focus on association between introduction of complementary foods including potentially allergenic foods into diets of infants less than 12 months of age and development of food allergies. Articles were excluded if they were 1) not primary research, 2) about complementary foods only (without specificity of allergenic foods), or 3) on allergic conditions other than food allergy (such as asthma or eczema). RESULTS: The initial literature search yielded 533 articles; 15 articles met inclusion criteria. Level of evidence of each study was determined with the SORT criteria. Results found that delayed introduction of solid foods in general and allergenic foods in particular was not associated with decreased risk for allergic diseases among high and low-risk infants. Later introduction was associated with increased risk for allergy development. CLINICAL IMPLICATIONS: For infants at low risk for development of food allergies, providers should advise caregivers to introduce potentially allergenic foods with other solid foods between 4 and 6 months of age when children show an interest in eating solids. There are several large studies currently in progress. Results will guide recommendations for introduction of all allergenic foods to high-risk infants. Caregivers of infants at high risk for development of food allergies are recommended to introduce peanuts between the ages of 4 and 6 months and work with providers to create an individualized plan for introduction of other allergenic foods</style></abstract><notes><style face="normal" font="Arial">DA - 20161123IS - 1539-0683 (Electronic)IS - 0361-929X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/NMC.0000000000000313</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27879501">PM:27879501</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\MCN Am J Matern Child Nurs\20161123-LarsonK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\MCN Am J Matern Child Nurs\20161123-LarsonK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161123, Larson K</style></custom2><misc3><style face="normal" font="Arial">10.1097/NMC.0000000000000313</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Verma,R.K.</style></author><author><style face="normal" font="Arial"> Patro,S.K.</style></author><author><style face="normal" font="Arial"> Francis,A.A.</style></author><author><style face="normal" font="Arial"> Panda,N.K.</style></author><author><style face="normal" font="Arial"> Chakrabarti,A.</style></author><author><style face="normal" font="Arial"> Singh,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head and Neck surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India</style></auth-address><titles><title><style face="normal" font="Arial">Role of preoperative versus postoperative itraconazole in allergic fungal rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Med Mycol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Mycol</style></full-title></periodical><pages end="623" start="614">614-623</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> antifungals</style></keyword><keyword><style face="normal" font="Arial"> CT scan</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Postoperative Period</style></keyword><keyword><style face="normal" font="Arial"> Preoperative Period</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Antifungals used as adjuvant to surgery in AFRS (Allergic Fungal Rhinosinusitis) have shown varying success in delaying recurrences. Itraconazole has been used both as preoperative and postoperative adjuvant. This study investigates the role of itraconazole in AFRS and compares its role between preoperative and postoperative administration of the drug. Patients were randomly divided into groups as: Group 1 (n = 25), received 4 weeks itraconazole in the preoperative period and operated subsequently, Group 2 (n = 25), received 4 weeks itraconazole in the postoperative period, Group 3 (n = 50), matched patients of AFRS, who didn't receive itraconazole. All the groups received oral steroids in tapering doses staring from 1 mg/kg for 6 weeks in the postoperative period. Symptomatic (SNOT 20), radiologic (Lund Mackay, LM) scores and endoscopic (Kupferberg's NE Grades) were noted. Primary postoperative follow-up was for 24 weeks with routine CT scans and nasal endoscopies, followed by which all the patients were followed with nasal endoscopies only with CT scans when required. Both preoperative and postoperative itraconazole showed significant improvement in the SNOT, LM, and Kupferberg's grades in the follow-up period. Preoperative itraconazole therapy showed significantly better results compared to postoperative itraconazole therapy though the recurrence rates were similar in both groups. Itraconazole is a better preoperative adjunct in AFRS than postoperative</style></abstract><notes><style face="normal" font="Arial">DA - 20161113IS - 1460-2709 (Electronic)IS - 1369-3786 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1093/mmy/myw125</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838640">PM:27838640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Mycol\2017-55-614-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Mycol\2017-55-614-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161113, Verma RK</style></custom2><misc3><style face="normal" font="Arial">10.1093/mmy/myw125</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mueller,G.A.</style></author><author><style face="normal" font="Arial"> Thompson,P.M.</style></author><author><style face="normal" font="Arial"> DeRose,E.F.</style></author><author><style face="normal" font="Arial"> O</style><style face="normal" font="Symbol">'</style><style face="normal" font="Arial">Connell,T.M.</style></author><author><style face="normal" font="Arial"></style><style face="normal" font="Arial"> London,R.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A metabolomic, geographic, and seasonal analysis of the contribution of pollen-derived adenosine to allergic sensitization</style></title><secondary-title><style face="normal" font="Arial">Metabolomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Metabolomics</style></full-title></periodical><pages end="" start="187">187-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenosine</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1573-3890</style></isbn><abstract><style face="normal" font="Arial">Studies on ragweed and birch pollen extracts suggested that the adenosine content is an important factor in allergic sensitization. However, exposure levels from other pollens and considerations of geographic and seasonal factors have not been evaluated</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11306-016-1130-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28798556">PM:28798556</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Metabolomics\2016-12-187.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Metabolomics\2016-12-187.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Mueller GA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11306-016-1130-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Madden,A.A.</style></author><author><style face="normal" font="Arial"> Barberan,A.</style></author><author><style face="normal" font="Arial"> Bertone,M.A.</style></author><author><style face="normal" font="Arial"> Menninger,H.L.</style></author><author><style face="normal" font="Arial"> Dunn,R.R.</style></author><author><style face="normal" font="Arial"> Fierer,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cooperative Institute for Research in Environmental Sciences, University of Colorado, Boulder, CO, 80309, USA</style></auth-address><titles><title><style face="normal" font="Arial">The diversity of arthropods in homes across the United States as determined by environmental DNA analyses</style></title><secondary-title><style face="normal" font="Arial">Mol Ecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Ecol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Geographic distribution</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> home characteristics</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive species</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="1" Month="11" Year="2016">2016/11/1</year></dates><abstract><style face="normal" font="Arial">We spend most of our lives inside homes, surrounded by arthropods that impact our property as pests and our health as disease vectors and producers of sensitizing allergens. Despite their relevance to human health and well-being, we know relatively little about the arthropods that exist in our homes and the factors structuring their diversity. As previous work has been limited in scale by the costs and time associated with collecting arthropods and the subsequent morphological identification, we used a DNA-based method for investigating the arthropod diversity in homes via high-throughput marker gene sequencing of home dust. Settled dust samples were collected by citizen scientists from both inside and outside more than 700 homes across the United States, yielding the first continental-scale estimates of arthropod diversity associated with our residences. We were able to document food webs and previously unknown geographic distributions of diverse arthropods - from allergen producers to invasive species and nuisance pests. Home characteristics, including the presence of basements, home occupants and surrounding land use, were more useful than climate parameters in predicting arthropod diversity in homes. These noninvasive, scalable tools and resultant findings not only provide the first continental-scale maps of household arthropod diversity, but our analyses also provide valuable baseline information on arthropod allergen exposures and the distributions of invasive pests inside homes</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1365-294X (Electronic)IS - 0962-1083 (Linking)LA - ENGPT - Journal ArticleCO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/mec.13900</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801965">PM:27801965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Ecol\20161101-MaddenAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Ecol\20161101-MaddenAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Madden AA</style></custom2><misc3><style face="normal" font="Arial">10.1111/mec.13900</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vincent,M.</style></author><author><style face="normal" font="Arial"> Romano,M.</style></author><author><style face="normal" font="Arial"> Corazza,F.</style></author><author><style face="normal" font="Arial"> Huygen,K.</style></author><author><style face="normal" font="Arial"> Michel,O.</style></author><author><style face="normal" font="Arial"> Denis,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Program Allergology - Scientific Service Immunology, WIV-ISP (site Uccle), 642, Engelandstraat, 1180, Brussels, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">Development of a Dot-Blot Assay for the Detection of Mould-Specific IgE in the Belgian Population</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus versicolor</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="11" Year="2016">2016/11/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Data on mould sensitization in the general population are scarce and mostly on Aspergillus fumigatus, Alternaria alternata and Cladosporium herbarum. OBJECTIVES: To validate a dot-blot assay for the detection of specific IgE and evaluate the prevalence of mould sensitization in a healthy population. METHODS: The dot-blot assay was validated against the CAP test. Sensitization rate to ten common indoor and outdoor mould species in 344 serum samples was calculated. For each serum with more than one reactivity, the "major sensitization" defined as the strongest response against a single mould species was calculated. RESULTS: Intra- and inter-assay variations were both below 20%, and the positivity threshold of the test was of 0.418 kU/L for A. fumigatus. Correlation with CAP results was strong. The overall prevalence of sensitization was 32.8%, and the commonest sensitizations were against A. alternaria, A. flavus and A. niger (around 15%). The most frequent "major reactivities" were against A. niger and A. alternata (20-30%). In 25.1% of the samples, "major reactivities" were directed against a group of moulds commonly found indoor (Penicillium spp., Aspergillus versicolor, Cladosporium sphaerospermum and Cladosporium cladosporioides). CONCLUSIONS: The dot-blot assay was validated for the detection of mould-specific IgE. In the general population, sensitization to indoor species was common and accounted for 25% of overall mould sensitizations</style></abstract><notes><style face="normal" font="Arial">DA - 20161123IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-016-0091-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27878528">PM:27878528</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20161123-VincentM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20161123-VincentM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161123, Vincent M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-016-0091-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wei,Y.</style></author><author><style face="normal" font="Arial"> Dong,M.</style></author><author><style face="normal" font="Arial"> Zhong,L.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Luo,Q.</style></author><author><style face="normal" font="Arial"> Lv,Y.</style></author><author><style face="normal" font="Arial"> Mo,S.</style></author><author><style face="normal" font="Arial"> Sun,J.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Xu,F.</style></author><author><style face="normal" font="Arial"> Yan,C.</style></author><author><style face="normal" font="Arial"> Dong,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Integrative Medicine, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Regulation of hypothalamic-pituitary-adrenal axis activity and immunologic function contributed to the anti-inflammatory effect of acupuncture in the OVA-induced murine asthma model</style></title><secondary-title><style face="normal" font="Arial">Neurosci Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Neurosci Lett</style></full-title></periodical><pages end="183" start="177">177-183</pages><volume><style face="normal" font="Arial">636</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acupuncture</style></keyword><keyword><style face="normal" font="Arial"> Adrenocorticotropic Hormone</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> integrative medicine</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is a complex inflammatory disease of the airways and acupuncture is one of the effective therapies widely used to treat asthma in China. The aim of the study was to evaluate the regulatory role of acupuncture in airway inflammation and the hypothalamic-pituitary-adrenal (HPA) axis activity in OVA-induced murine asthma model. Our results demonstrated that acupuncture was effective in suppression of AHR, inhibition of total leukocyte, neutrophil, lymphocyte and eosinophil counts in BALF, attenuation of airway inflammation and TNF-alpha, IL-1beta, IL-5 and eotaxin secretion. Furthermore, the HPA axis activity was also regulated by acupuncture, which included promotion of adrenocorticotropic hormone and cortisol secretion in the plasma. Our findings revealed that acupuncture could attenuate airway inflammation and regulate HPA axis and immunologic function in the OVA-induced murine asthma model, which may provide support to better understand the contribution of acupuncture to the regulation of airway inflammation and HPA axis activity in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161106IS - 1872-7972 (Electronic)IS - 0304-3940 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.neulet.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27816549">PM:27816549</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Neurosci Lett\2017-636-177-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Neurosci Lett\2017-636-177-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161106, Wei Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.neulet.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cole,S.C.</style></author><author><style face="normal" font="Arial"> Eftekhari,K.</style></author><author><style face="normal" font="Arial"> Anderson,R.L.</style></author><author><style face="normal" font="Arial"> Oberg,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Department of Ophthalmology, Medical College of Georgia at Augusta University, Augusta, Georgia; and daggerAO Surgical Arts, Salt Lake City, Utah, U.S.A</style></auth-address><titles><title><style face="normal" font="Arial">Systemic Allergic Response in the Setting of a Metallic Intraorbital Foreign Body With Intraoperative Magnet-Assisted Retrieval</style></title><secondary-title><style face="normal" font="Arial">Ophthal Plast Reconstr Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ophthal Plast Reconstr Surg</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Foreign bodies</style></keyword><keyword><style face="normal" font="Arial"> Foreign body</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nickel</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Orbit</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Utah</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="11" Year="2016">2016/11/2</year></dates><abstract><style face="normal" font="Arial">A 12-year-old boy with a past medical history of nickel allergy was referred to our service after sustaining an air rifle injury with a retained BB in his left inferior orbit. On examination, he had a palpable orbital mass and systemic urticaria. Plain films demonstrated a spherical metallic foreign body adjacent to the left inferior orbital rim. Given his worsening systemic reaction despite oral antihistamine therapy, decision was made to remove the foreign body. In the operating room, the Allergan Magna Finder-a prepackaged, sterile device normally used for retrieval of a port used in tissue expansion surgery-was placed over the inferior conjunctiva of the lower eyelid. With the magnet holding gentle anterior traction on the foreign body, it was easily dissected and removed. The patient tolerated the procedure well, and had rapid resolution of his systemic allergic response following removal of the BB</style></abstract><notes><style face="normal" font="Arial">DA - 20161104IS - 1537-2677 (Electronic)IS - 0740-9303 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/IOP.0000000000000819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27811635">PM:27811635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ophthal Plast Reconstr Surg\20161104-ColeSC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ophthal Plast Reconstr Surg\20161104-ColeSC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161104, Cole SC</style></custom2><misc3><style face="normal" font="Arial">10.1097/IOP.0000000000000819</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doan,S.</style></author><author><style face="normal" font="Arial"> Amat,F.</style></author><author><style face="normal" font="Arial"> Gabison,E.</style></author><author><style face="normal" font="Arial"> Saf,S.</style></author><author><style face="normal" font="Arial"> Cochereau,I.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ophthalmology Department of Fondation A de Rothschild and Hopital Bichat, Paris, France.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature</style></title><secondary-title><style face="normal" font="Arial">Ophthalmol Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ophthalmol Ther</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eye-drops</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Ocular allergy</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Vernal keratoconjunctivis (VKC) is a severe form of pediatric ocular allergy, characterized by acute and chronic corneoconjunctival inflammation that may lead to visual sequelae. Although topical immunosuppressive drugs such as cyclosporine are usually effective, some severe forms may be refractory and require prolonged steroid therapy. Very few papers report the use of omalizumab in VKC in the literature. In the present study, we describe our clinical experience with omalizumab in severe VKC children. METHODS: We retrospectively reviewed the files of four boys treated with omalizumab because of severe VKC, defined as persistent corneal inflammation despite continuous topical 2% cyclosporine and steroid eye drops. We also performed a literature review. RESULTS: Four boys, aged 7-13 years old, were treated. All children had asthma and one had severe lid eczema. Two patients had required intrapalpebral depot-steroid injections. Omalizumab was administered every 2 weeks by subcutaneous injections, at doses varying from 450 to 600 mg per injection. Three patients out of four responded to the treatment, with a decrease in global symptoms (median symptom rating decreasing from 89 to 29 on a 100-mm visual analog scale), frequency and in duration of the inflammatory flares, and also a decreased need for topical steroid. Their median clinical grade decreased from 4 to 3 (Bonini grading). However, the response was incomplete and they still had inflammatory corneoconjunctival flares despite continuous topical cyclosporine. On the other hand, asthma and lid eczema were completely controlled in these three patients. The fourth child did not respond to omalizumab and needed oral steroids for his VKC and his asthma. Noticeably, this latter patient did not have detectable sensitization to any allergen, contrary to the other cases. The treatment was stopped in this refractory case, but is still ongoing in all other cases, with a median duration of 33 months (range 16-42 months). In the literature (four cases), omalizumab may have a more complete efficacy in some cases, but the results are still variable. CONCLUSION: Omalizumab is an interesting treatment in severe refractory forms of VKC, but its efficacy is incomplete in these very severe cases</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 2193-8245 (Print)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40123-016-0074-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27909980">PM:27909980</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ophthalmol Ther\20161202-DoanS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ophthalmol Ther\20161202-DoanS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Doan S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40123-016-0074-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shu,D.Y.</style></author><author><style face="normal" font="Arial"> Ong,K.</style></author><author><style face="normal" font="Arial"> Lovicu,F.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*BOptom(Hons), BSc daggerMBBS, FRANZCO double daggerPhD Discipline of Anatomy and Histology, Bosch Institute, University of Sydney, Sydney, New South Wales, Australia (DYS, FJL); Save Sight Institute, Sydney, New South Wales, Australia (DYS, KO, FJL); and Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia (KO)</style></auth-address><titles><title><style face="normal" font="Arial">Histopathology of Subcapsular Cataract in a Patient with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Optom Vis Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Optom Vis Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> epithelial-mesenchymal transition</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="10" Year="2016">2016/10/31</year></dates><abstract><style face="normal" font="Arial">PURPOSE: To report the histopathological features of anterior subcapsular cataract associated with atopic dermatitis. CASE REPORT: A 29-year-old man with atopic dermatitis presented with bilateral anterior subcapsular cataract. After routine cataract surgery, the anterior subcapsular cataractous tissue was obtained as an anterior capsulorhexis flap and prepared as a wholemount for histological analysis. The wholemount consisted of a well-demarcated central grayish-white plaque surrounded by transparent capsule, corroborating the slit-lamp biomicroscopic appearance. Higher magnification of the plaque revealed a fibrous and amorphous mass, most likely extracellular matrix owing to the presence of irregularly arranged bundled strands of fibrils, typical of collagen. Lens epithelial cells at the plaque were densely packed and myofibroblast-like and immunoreactive for alpha-smooth muscle actin. In contrast, lens epithelial cells more distant from the plaque retained their regular cuboidal arrangement and regular spacing, and were not labeled for alpha-smooth muscle actin, similar to lens epithelial cells obtained from a non-cataractous case. CONCLUSIONS: The presence of alpha-smooth muscle actin-reactive elongated cells at the plaque suggests that the cuboidal lens epithelial cells making up the anterior subcapsular cataract have transdifferentiated into spindle-shaped myofibroblastic cells that produce and deposit aberrant extracellular matrix. This transdifferentiation process, more commonly known as an epithelial-mesenchymal transition, contributes to a fibrotic response leading to the development of human anterior subcapsular cataract</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1538-9235 (Electronic)IS - 1040-5488 (Linking)LA - ENGPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1097/OPX.0000000000001011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801692">PM:27801692</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Optom Vis Sci\20161101-ShuDY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Optom Vis Sci\20161101-ShuDY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Shu DY</style></custom2><misc3><style face="normal" font="Arial">10.1097/OPX.0000000000001011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,S.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author><author><style face="normal" font="Arial"> Su,L.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Liu,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of General Surgery, Baogang Hospital, Baotou, Inner Mongolia, China</style></auth-address><titles><title><style face="normal" font="Arial">In vivo evaluation of the efficacy of combined albedazole-IFN-alpha treatment for cystic echinococcosis in mice</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Albendazole</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cystic echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Cysts</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Echinococcus</style></keyword><keyword><style face="normal" font="Arial"> Echinococcus granulosus</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Zoonosis</style></keyword></keywords><dates><year Day="7" Month="12" Year="2016">2016/12/7</year></dates><abstract><style face="normal" font="Arial">Cystic echinococcosis (CE) is a serious helminthic zoonosis caused by Echinococcus granulosus metacestode worldwide. The current chemotherapy of CE is mainly based on albendazole (ABZ). However, more than 20% CE cases failed to such chemotherapy. Thus, novel and more efficient treatment options are urgently needed. This study was to evaluate the in vivo efficacy of combined ABZ-interferon (IFN)-alpha treatment for CE in mice. After 5 months of secondary infection with protoscoleces, mice were randomly allocated into four groups: ABZ-treated group, IFN-alpha-treated group, ABZ+IFN-alpha group, and untreated control group. Drugs in diverse treated groups were respectively administered for 2 months. Mice were then euthanized and associated indications were investigated to evaluate the therapeutic efficacy. ABZ+IFN-alpha induced a significant reduction of the number, size, as well as weight of cysts, compared with that in the ABZ (p &lt; 0.05) or untreated group (p &lt; 0.01), respectively. This effect was associated with ultrastructural modification of the cyst in the ABZ+IFN-alpha group. Interestingly, significant decrease of IL (interleukin)-10 in serum and in vitro production by spleen cells with ABZ+IFN-alpha treatment was observed in comparison with untreated control (p &lt; 0.01). Serum IgE, IgG, and subsets were respectively decreased in ABZ+IFN-alpha treatment, compared with that in the control group (p &lt; 0.01). In conclusion, our findings demonstrated that combination of ABZ with IFN-alpha may contribute to an efficient therapeutic regimen of human and animal CE</style></abstract><notes><style face="normal" font="Arial">DA - 20161208IS - 1432-1955 (Electronic)IS - 0932-0113 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-016-5339-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27928681">PM:27928681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20161208-ZhangS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20161208-ZhangS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161208, Zhang S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-016-5339-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82525</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cushing,A.</style></author><author><style face="normal" font="Arial"> Manice,M.P.</style></author><author><style face="normal" font="Arial"> Ting,A.</style></author><author><style face="normal" font="Arial"> Parides,M.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute; CoheroHealth, LLC</style></auth-address><titles><title><style face="normal" font="Arial">Feasibility of a novel mHealth management system to capture and improve medication adherence among adolescents with asthma</style></title><secondary-title><style face="normal" font="Arial">Patient Prefer Adherence</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Patient Prefer Adherence</style></full-title></periodical><pages end="2275" start="2271">2271-2275</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Focus Groups</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> medication adherence</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mobile phone</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Currently, 7.1 million children in the United States have asthma. Nonadherence to daily controller asthma medication is common, leading to more severe symptoms, overuse of rescue medication, and increased hospitalizations. The purpose of this study was to develop and evaluate the feasibility and acceptability of a novel mHealth management system composed of a sensored device, which is connected to mobile phone app that is designed to monitor and improve asthma medication adherence. PATIENTS AND METHODS: The asthma management system was designed using well-established behavioral theory. Seven adolescents aged 11-18 years were enrolled and given an adherence sensor, and four of those also received a mobile phone app with game features and reminders. Five patients completed the study, and one was lost to follow-up in each group. Mobile app users and their parents participated in focus groups to assess patient preferences. Feasibility was assessed by the ability of sensors to capture real-time medication data. Acceptability was assessed by patient questionnaire and focus group analysis. RESULTS: Successful upload of real-time data from six of seven inhaler sensors to the HIPAA-compliant server demonstrates the feasibility of at-home patient monitoring using the sensor device. All three mobile app users who completed the study reported interest in continued use of the management system and would recommend the app to friends. Unstructured interviews and focus groups revealed that patients felt that the intervention helped their sense of asthma control. CONCLUSION: This study demonstrates the feasibility of using the sensor device to remotely monitor real-time medication usage, and user feedback demonstrates the acceptability of the intervention for patient use. The findings provide guidance for the improvement of study design and technology development. Further research is needed to assess the efficacy of the intervention</style></abstract><notes><style face="normal" font="Arial">DA - 20161117IS - 1177-889X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2147/PPA.S115713</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27853357">PM:27853357</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Patient Prefer Adherence\2016-10-2271-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Patient Prefer Adherence\2016-10-2271-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161117, Cushing A</style></custom2><misc3><style face="normal" font="Arial">10.2147/PPA.S115713</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smallwood,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Urticaria: "You're Probably Just Allergic to Something"</style></title><secondary-title><style face="normal" font="Arial">Pediatr Ann</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Ann</style></full-title></periodical><pages end="e402" start="e399">e399-e402</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="1" Month="11" Year="2016">2016/11/1</year></dates><abstract><style face="normal" font="Arial">Urticaria is a common symptom seen in pediatric patients, and it has multiple allergic and nonallergic causes. Unfortunately, it is far too common that when children present acutely for urticaria, they are told that it is an "allergy." This statement often leads to increased anxiety while the patient waits to be evaluated by an allergist/immunologist. This article discusses the frequency that allergic reactions are involved in urticaria and provides examples of potential nonallergic causes. Additionally, the article discusses approaches to treatment that may be appropriate to initiate in the pediatrician's office or acute setting. This article is intended to provide a broader understanding of urticaria and its management in the outpatient or emergency setting so that we are able to tell our patients more than"you're probably just allergic to something." [Pediatr Ann. 2016;45(11):e399-e402.]</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 1938-2359 (Electronic)IS - 0090-4481 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3928/19382359-20161014-02</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27841923">PM:27841923</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Ann\2016-45-e399-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Ann\2016-45-e399-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161114, Smallwood J</style></custom2><misc3><style face="normal" font="Arial">10.3928/19382359-20161014-02</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Youssef,M.J.</style></author><author><style face="normal" font="Arial"> Chiu,Y.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA</style></auth-address><titles><title><style face="normal" font="Arial">Eczema and Urticaria as Manifestations of Undiagnosed and Rare Diseases</style></title><secondary-title><style face="normal" font="Arial">Pediatr Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Clin North Am</style></full-title></periodical><pages end="56" start="39">39-56</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">autoinflammatory syndrome</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Failure to Thrive</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Mycosis Fungoides</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> Nutritional deficiency</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Eczema and urticaria are common disorders encountered in pediatric patients, but they may occasionally be the presenting complaint in a child with an underlying rare disease. Immunodeficiency syndromes should be suspected when eczema is associated with neonatal onset, recurrent infections, chronic lymphadenopathy, or failure to thrive. Nutritional deficiencies and mycosis fungoides are in the differential diagnosis for a child with a recalcitrant eczematous eruption. Autoinflammatory syndromes should be suspected in a child with chronic urticaria, fever, and other systemic signs of inflammation. Although these disorders are rare, early recognition allows for appropriate treatment and decreased morbidity for the child</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1557-8240 (Electronic)IS - 0031-3955 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pcl.2016.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27894451">PM:27894451</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Clin North Am\2017-64-39-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Clin North Am\2017-64-39-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Youssef MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pcl.2016.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82528</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rencher,L.</style></author><author><style face="normal" font="Arial"> Schwartz,J.</style></author><author><style face="normal" font="Arial"> Wilson,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the *Dell Children's Medical Center, Department of Pediatric Emergency Medicine; and daggerDell Children's Medical Center, Department of Pediatric Critical Care</style></auth-address><titles><title><style face="normal" font="Arial">An Anaphylactoid Reaction to Rattlesnake Envenomation in a Pediatric Patient</style></title><secondary-title><style face="normal" font="Arial">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extremities</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Snakes</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="29" Month="11" Year="2016">2016/11/29</year></dates><abstract><style face="normal" font="Arial">Rattlesnake envenomation causes a spectrum of symptoms and signs, many of which closely resemble an anaphylactic reaction. Development of airway compromise after a snake bite to an extremity is unusual, but has been previously reported. The majority of such reports detail a history of probable sensitization from previous contact with snakes or snake venom. Few reports exist without such previous contact; no reports are of pediatric cases. Here we present a 14-year-old boy with no history of prior snake exposure who presents with an anaphylactoid reaction after a rattlesnake bite</style></abstract><notes><style face="normal" font="Arial">DA - 20161130IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/PEC.0000000000000977</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27902669">PM:27902669</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Emerg Care\20161130-RencherL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Emerg Care\20161130-RencherL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161130, Rencher L</style></custom2><misc3><style face="normal" font="Arial">10.1097/PEC.0000000000000977</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Akashi,M.</style></author><author><style face="normal" font="Arial"> Yasudo,H.</style></author><author><style face="normal" font="Arial"> Narita,M.</style></author><author><style face="normal" font="Arial"> Nomura,I.</style></author><author><style face="normal" font="Arial"> Akasawa,A.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author><author><style face="normal" font="Arial"> Takahashi,T.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Saitama City Hospital, Saitama, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Randomized Controlled Trial of Oral Immunotherapy for Egg Allergy in Japanese patients</style></title><secondary-title><style face="normal" font="Arial">Pediatr Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Int</style></full-title></periodical><pages end="539" start="534">534-539</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold dose</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Egg allergy is one of the most common food allergies in young child. While oral immunotherapy (OIT) is not routinely recommended in current guidelines, it has been considered as a potential alternative treatment strategy. Studies on OIT for food allergies have been explored; however, no studies with control group have been reported in Japan. METHODS: The first oral food challenge test (OFC) was performed on participants before treatment to ensure the diagnosis and evaluate the threshold dose for egg by the way of double-blind, placebo-controlled food challenge (DBPCFC). Participants were randomly assigned by computerized algorithm to receive OIT with egg (OIT group) or to eliminate egg (EE group). A second OFC was performed in both groups approximately 6 months after therapy. Blood samples were collected and egg white -specific IgE and IgG4 were measured before and after the treatment period. RESULTS: Eight of the 14 (57%) patients in the OIT group passed 4 g of dry egg powder whereas none of the 16 patients in the EE group did. All 14 patients in the OIT group showed increased threshold for egg powder in the second OFC compared to the baseline. There was no significant change in egg white-specific IgE levels during therapy. After therapy, egg white-specific IgG4 levels increased significantly in the OIT group, but not in the EE group. CONCLUSION: OIT is effective in increasing the threshold for allergens and inducing desensitization also among Japanese egg allergy patients similar to North American and European patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161203IS - 1442-200X (Electronic)IS - 1328-8067 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/ped.13210</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914210">PM:27914210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Int\20161203-AkashiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Int\20161203-AkashiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161203, Akashi M</style></custom2><misc3><style face="normal" font="Arial">10.1111/ped.13210</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rekowska,M.</style></author><author><style face="normal" font="Arial"> Czerwionka-Szaflarska,M.</style></author><author><style face="normal" font="Arial"> Adamska,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Hypersensitivity to food in infants exclusively breastfed - an analysis of the allergy tests' results and the most common food allergens</style></title><secondary-title><style face="normal" font="Arial">Pediatr Polska</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Polska</style></full-title></periodical><pages end="49" start="44">44-49</pages><volume><style face="normal" font="Arial">92</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="12/20/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy to cow's milk</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> bariera jelitowa</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intestinal barrier</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein fraction</style></keyword><keyword><style face="normal" font="Arial"> Protein fractions</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0031-3939</style></isbn><abstract><style face="normal" font="Arial">Introduction The incidence of adverse reactions induced by food proteins in infants exclusively breastfed is poorly understood. The predominant view is that in the pathogenesis of hypersensitivity to food, IgE-mediated mechanisms prevail; the most common food allergen is cow's milk protein. Aim The aim of the study was to determine the prevalence of hypersensitivity to food in infants exclusively breastfed with symptoms suggestive of hypersensitivity to food and to identify the most common food allergens responsible for hypersensitivity in IgE-mediated and non-IgE-mediated mechanisms. Patients and Methods The study involved 106 infants exclusively breastfed up to 6 months of age, in whom allergy tests were performed due to atopic eczema and/or symptoms from gastrointestinal tract. All patients underwent testing for IgE-mediated and non-IgE-mediated allergy. Results Non-IgE-mediated reactions dominated in breastfed infants with positive allergy tests results. Only positive results of APT were found in 68.9% (n = 73) of patients. IgE-mediated sensitization was found in 3.8% of children (n = 4), mixed type of hypersensitivity affected 6.6% (n = 7) of infants. It has been found that in the group of children with positive sIgE panel (n = 11), allergy to cow's milk protein fractions (n = 9) was most frequent. The most common allergens responsible for non-IgE-mediated hypersensitivity in the study infants were egg yolk (55.7% children; n = 59), then egg white (51.9%, n = 55), cow's milk (33.0%; n = 35), wheat flour (27.4%, n = 29) and soybeans (26.0%, n = 28). Conclusion On the basis of own research results, it can be assumed that non-IgE-mediated hypersensitivity to food dominates in infants exclusively breastfed, and the most common food allergen responsible for the clinical response is hen's egg, then cow's milk and wheat</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pepo.2016.11.002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.pepo.2016.11.002</url></web-urls><pdf-urls><url ppv-ref="no">klped@cm.umk.pl</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161210, Rekowska M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pepo.2016.11.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nixon,J.</style></author><author><style face="normal" font="Arial"> Newbold,P.</style></author><author><style face="normal" font="Arial"> Mustelin,T.</style></author><author><style face="normal" font="Arial"> Anderson,G.P.</style></author><author><style face="normal" font="Arial"> Kolbeck,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MedImmune Ltd., Cambridge, UK</style></auth-address><titles><title><style face="normal" font="Arial">Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation</style></title><secondary-title><style face="normal" font="Arial">Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> lung function decline</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="Arial">Eosinophils have been linked with asthma for more than a century, but their role has been unclear. This review discusses the roles of eosinophils in asthma and chronic obstructive pulmonary disease (COPD) and describes therapeutic antibodies that affect eosinophilia. The aims of pharmacologic treatments for pulmonary conditions are to reduce symptoms, slow decline or improve lung function, and reduce the frequency and severity of exacerbations. Inhaled corticosteroids (ICS) are important in managing symptoms and exacerbations in asthma and COPD. However, control with these agents is often suboptimal, especially for patients with severe disease. Recently, new biologics that target eosinophilic inflammation, used as adjunctive therapy to corticosteroids, have proven beneficial and support a pivotal role for eosinophils in the pathology of asthma. Nucala(R) (mepolizumab; anti-interleukin [IL]-5) and Cinquair(R) (reslizumab; anti-IL-5), the second and third biologics approved, respectively, for the treatment of asthma, exemplifies these new treatment options. Emerging evidence suggests that eosinophils may contribute to exacerbations and possibly to lung function decline for a subset of patients with COPD. Here we describe the pharmacology of therapeutic antibodies inhibiting IL-5 or targeting the IL-5 receptor, as well as other cytokines contributing to eosinophilic inflammation. We discuss their roles as adjuncts to conventional therapeutic approaches, especially ICS therapy, when disease is suboptimally controlled. These agents have achieved a place in the therapeutic armamentarium for asthma and COPD and will deepen our understanding of the pathogenic role of eosinophils</style></abstract><notes><style face="normal" font="Arial">DA - 20161024IS - 1879-016X (Electronic)IS - 0163-7258 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - United Kingdom -CO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pharmthera.2016.10.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27773786">PM:27773786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharmacol Ther\20161024-NixonJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharmacol Ther\20161024-NixonJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161024, Nixon J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pharmthera.2016.10.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Van Esch,B.</style></author><author><style face="normal" font="Arial"> Kostadinova,A.I.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Willemsen,L.</style></author><author><style face="normal" font="Arial"> Knippels,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A dietary intervention with non-digestible oligosaccharides and partial hydrolysed whey protein prevents the onset of food allergic symptoms in mice</style></title><secondary-title><style face="normal" font="Arial">PharmaNutrition</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PharmaNutrition</style></abbr-1></periodical><pages end="7" start="1">1-7</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> acute allergic skin response</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> CD103+ dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foxp3 regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> galectin-9</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Non-digestible oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Partial hydrolyzed whey protein</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"></style><style face="normal" font="Arial"> Whey protein</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><isbn><style face="normal" font="Arial">2213-4344</style></isbn><abstract><style face="normal" font="Arial">Strategies to prevent food allergy to common food such as cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk are important because there is no causal treatment available yet. Oral tolerance induction is of great importance for allergy prevention which is strongly dependent on allergen exposure and proper immune environment. Improving the efficacy of oral tolerance with adjuvants is a promising new strategy. In the current study, we investigated non-digestible oligosaccharides (NDO) on their capacity to enhance oral tolerance induced by partial hydrolyzed whey protein (pWH). Mice were treated orally with PBS, pWH, NDO or pWH + NDO for 6 days and subsequently fed a control diet while sensitized to whey protein. Acute allergic skin responses and mast cell activation were measured after whey challenge. pWH + NDO prevented acute allergic skin responses, mast cell activation and induced lower whey-specific IgE compared to NDO fed mice. In mice supplemented with either pWH or NDO, respectively Foxp3+ regulatory T-cells or galectin-9 were enhanced. Increased CD103+ dendritic cells percentages were measured in the mesenteric lymph nodes of mice treated with pWH + NDO. These data show the capacity of NDO, if combined with a pWH, to prevent the onset of allergic symptoms. NDO could act as adjuvant in preventing allergic responses to harmless food proteins</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.phanu.2016.11.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.phanu.2016.11.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PharmaNutrition\2017-5-1-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PharmaNutrition\2017-5-1-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, van Esch B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.phanu.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Im,J.</style></author><author><style face="normal" font="Arial"> Kim,K.</style></author><author><style face="normal" font="Arial"> Yhee,J.Y.</style></author><author><style face="normal" font="Arial"> O'Grady,S.M.</style></author><author><style face="normal" font="Arial"> Nho,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Minnesota, Minneapolis, Minnesota</style></auth-address><titles><title><style face="normal" font="Arial">Desensitization of idiopathic pulmonary fibrosis fibroblasts to Alternaria alternata extract-mediated necrotic cell death</style></title><secondary-title><style face="normal" font="Arial">Physiol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Physiol Rep</style></full-title></periodical><pages end="" start="e13020">e13020-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">21</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cell viability</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fibroblasts</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Alternaria alternata is an allergenic fungus and known to cause an upper respiratory tract infection and asthma in humans with compromised immunity. Although A. alternata's effect on airway epithelial cells has previously been examined, the potential role of A. alternata on lung fibroblast viability is not understood. Since lung fibroblasts derived from patients with idiopathic pulmonary fibrosis (IPF) display a distinct phenotype that is resistant to stress and cell death inducing conditions, the investigation of the role of Alternaria on pathological IPF fibroblasts provides a better understanding of the fibrotic process induced by an allergenic fungus. Therefore, we examined cell viability of control and IPF fibroblasts (n = 8 each) in response to A. alternata extract. Control fibroblast cell death was increased while IPF fibroblasts were resistant when exposed to 50-100 mug/mL of A. alternata extract. However, there was no significant difference in kinetics or magnitude of Ca2+ responses from control lung and IPF fibroblasts. In contrast, unlike control fibroblasts, intracellular reactive oxygen species (ROS) levels remained low when IPF cells were treated with A. alternata extracts as a function of time. Caspase 3/7 and TUNEL assay revealed that enhanced cell death caused by A. alternata extract was likely due to necrosis, and 7-AAD assay and the use of sodium pyruvate for ATP generation further supported our findings that IPF fibroblasts become resistant to A. alternata extract-induced necrotic cell death. Our results suggest that exposure to A. alternata potentially worsens the fibrotic process by promoting normal lung fibroblast cell death in patients with IPF</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 2051-817X (Electronic)IS - 2051-817X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.14814/phy2.13020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27905295">PM:27905295</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Physiol Rep\2016-4-e13020.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Physiol Rep\2016-4-e13020.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Im J</style></custom2><misc3><style face="normal" font="Arial">10.14814/phy2.13020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fear,V.S.</style></author><author><style face="normal" font="Arial"> Lai,S.P.</style></author><author><style face="normal" font="Arial"> Zosky,G.R.</style></author><author><style face="normal" font="Arial"> Perks,K.L.</style></author><author><style face="normal" font="Arial"> Gorman,S.</style></author><author><style face="normal" font="Arial"> Blank,F.</style></author><author><style face="normal" font="Arial"> von Garnier,C.</style></author><author><style face="normal" font="Arial"> Stumbles,P.A.</style></author><author><style face="normal" font="Arial"> Strickland,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Telethon Kids Institute, Perth, Australia</style></auth-address><titles><title><style face="normal" font="Arial">A pathogenic role for the integrin CD103 in experimental allergic airways disease</style></title><secondary-title><style face="normal" font="Arial">Physiol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Physiol Rep</style></full-title></periodical><pages end="" start="e13021">e13021-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">21</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Airways hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell activation</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">The integrin CD103 is the alphaE chain of integrin alphaEbeta7 that is important in the maintenance of intraepithelial lymphocytes and recruitment of T cells and dendritic cells (DC) to mucosal surfaces. The role of CD103 in intestinal immune homeostasis has been well described, however, its role in allergic airway inflammation is less well understood. In this study, we used an ovalbumin (OVA)-induced, CD103-knockout (KO) BALB/c mouse model of experimental allergic airways disease (EAAD) to investigate the role of CD103 in disease expression, CD4+ T-cell activation and DC activation and function in airways and lymph nodes. We found reduced airways hyper-responsiveness and eosinophil recruitment to airways after aerosol challenge of CD103 KO compared to wild-type (WT) mice, although CD103 KO mice showed enhanced serum OVA-specific IgE levels. Following aerosol challenge, total numbers of effector and regulatory CD4+ T-cell subsets were significantly increased in the airways of WT but not CD103 KO mice, as well as a lack of DC recruitment into the airways in the absence of CD103. While total airway DC numbers, and their in vivo allergen capture activity, were essentially normal in steady-state CD103 KO mice, migration of allergen-laden airway DC to draining lymph nodes was disrupted in the absence of CD103 at 24 h after aerosol challenge. These data support a role for CD103 in the pathogenesis of EAAD in BALB/c mice through local control of CD4+ T cell and DC subset recruitment to, and migration from, the airway mucosa during induction of allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 2051-817X (Electronic)IS - 2051-817X (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.14814/phy2.13021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27905296">PM:27905296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Physiol Rep\2016-4-e13021.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Physiol Rep\2016-4-e13021.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Fear VS</style></custom2><misc3><style face="normal" font="Arial">10.14814/phy2.13021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mercuri,A.M.</style></author><author><style face="normal" font="Arial"> Torri,P.</style></author><author><style face="normal" font="Arial"> Fornaciari,R.</style></author><author><style face="normal" font="Arial"> Florenzano,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio di Palinologia e Paleobotanica, Dipartimento di Scienze della Vita, Universita degli Studi di Modena e Reggio Emilia, Viale Caduti in Guerra, 127, 41121 Modena, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Plant Responses to Climate Change: The Case Study of Betulaceae and Poaceae Pollen Seasons (Northern Italy, Vignola, Emilia-Romagna)</style></title><secondary-title><style face="normal" font="Arial">Plants (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Plants (Basel)</style></abbr-1></periodical><pages end="" start="42">42-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Alder</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Alnus</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Betulaceae</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Corylus</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> global warming</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Meteorological variables</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen production</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="6" Month="12" Year="2016">2016/12/6</year></dates><abstract><style face="normal" font="Arial">Aerobiological data have especially demonstrated that there is correlation between climate warming and the pollination season of plants. This paper focuses on airborne pollen monitoring of Betulaceae and Poaceae, two of the main plant groups with anemophilous pollen and allergenic proprieties in Northern Italy. The aim is to investigate plant responses to temperature variations by considering long-term pollen series. The 15-year aerobiological analysis is reported from the monitoring station of Vignola (located near Modena, in the Emilia-Romagna region) that had operated in the years 1990-2004 with a Hirst spore trap. The Yearly Pollen Index calculated for these two botanical families has shown contrasting trends in pollen production and release. These trends were well identifiable but fairly variable, depending on both meteorological variables and anthropogenic causes. Based on recent reference literature, we considered that some oscillations in pollen concentration could have been a main effect of temperature variability reflecting global warming. The duration of pollen seasons of Betulaceae and Poaceae, depending on the different species included in each family, has not unequivocally been determined. Phenological responses were particularly evident in Alnus and especially in Corylus as a general moving up of the end of pollination. The study shows that these trees can be affected by global warming more than other, more tolerant, plants. The research can be a contribution to the understanding of phenological plant responses to climate change and suggests that alder and hazelnut trees have to be taken into high consideration as sensible markers of plant responses to climate change</style></abstract><notes><style face="normal" font="Arial">DA - 20161208IS - 2223-7747 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3390/plants5040042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27929423">PM:27929423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plants (Basel)\2016-5-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plants (Basel)\2016-5-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161208, Mercuri AM</style></custom2><misc3><style face="normal" font="Arial">10.3390/plants5040042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wiesmuller,G.A.</style></author><author><style face="normal" font="Arial"> Heinzow,B.</style></author><author><style face="normal" font="Arial"> Aurbach,U.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Bufe,A.</style></author><author><style face="normal" font="Arial"> Buzina,W.</style></author><author><style face="normal" font="Arial"> Cornely,O.A.</style></author><author><style face="normal" font="Arial"> Engelhart,S.</style></author><author><style face="normal" font="Arial"> Fischer,G.</style></author><author><style face="normal" font="Arial"> Gabrio,T.</style></author><author><style face="normal" font="Arial"> Heinz,W.</style></author><author><style face="normal" font="Arial"> Herr,C.E.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Koberle,M.</style></author><author><style face="normal" font="Arial"> Lichtnecker,H.</style></author><author><style face="normal" font="Arial"> Lob-Corzilius,T.</style></author><author><style face="normal" font="Arial"> Merget,R.</style></author><author><style face="normal" font="Arial"> Mulleneisen,N.</style></author><author><style face="normal" font="Arial"> Nowak,D.</style></author><author><style face="normal" font="Arial"> Rabe,U.</style></author><author><style face="normal" font="Arial"> Raulf,M.</style></author><author><style face="normal" font="Arial"> Seidl,H.P.</style></author><author><style face="normal" font="Arial"> Steiss,J.O.</style></author><author><style face="normal" font="Arial"> Szewszyk,R.</style></author><author><style face="normal" font="Arial"> Thomas,P.</style></author><author><style face="normal" font="Arial"> Valtanen,K.</style></author><author><style face="normal" font="Arial"> Hurrass,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institut fur Hygiene und Umweltmedizin, Uniklinik RWTH Aachen</style></auth-address><titles><title><style face="normal" font="Arial">[Medical Diagnostics for Mold Exposure Indoors]</style></title><secondary-title><style face="normal" font="Arial">Pneumologie</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pneumologie</style></full-title></periodical><pages end="741" start="699">699-741</pages><volume><style face="normal" font="Arial">70</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergie</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1438-8790 (Electronic)IS - 0934-8387 (Linking)LA - gerPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1055/s-0042-116251</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27829254">PM:27829254</url></web-urls></urls><custom2><style face="normal" font="Arial">20161109, Wiesmuller GA</style></custom2><misc3><style face="normal" font="Arial">10.1055/s-0042-116251</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">DAS,S.</style></author><author><style face="normal" font="Arial"> Miller,M.</style></author><author><style face="normal" font="Arial"> Beppu,A.K.</style></author><author><style face="normal" font="Arial"> Mueller,J.</style></author><author><style face="normal" font="Arial"> McGeough,M.D.</style></author><author><style face="normal" font="Arial"> Vuong,C.</style></author><author><style face="normal" font="Arial"> Karta,M.R.</style></author><author><style face="normal" font="Arial"> Rosenthal,P.</style></author><author><style face="normal" font="Arial"> Chouiali,F.</style></author><author><style face="normal" font="Arial"> Doherty,T.A.</style></author><author><style face="normal" font="Arial"> Kurten,R.C.</style></author><author><style face="normal" font="Arial"> Hamid,Q.</style></author><author><style face="normal" font="Arial"> Hoffman,H.M.</style></author><author><style face="normal" font="Arial"> Broide,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of California, San Diego, La Jolla, CA 92093</style></auth-address><titles><title><style face="normal" font="Arial">GSDMB induces an asthma phenotype characterized by increased airway responsiveness and remodeling without lung inflammation</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></full-title></periodical><pages end="13137" start="13132">13132-13137</pages><volume><style face="normal" font="Arial">113</style></volume><number><style face="normal" font="Arial">46</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial epithelium</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Linkage</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> transgene</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="11" Year="2016">2016/11/15</year></dates><abstract><style face="normal" font="Arial">Gasdermin B (GSDMB) on chromosome 17q21 demonstrates a strong genetic linkage to asthma, but its function in asthma is unknown. Here we identified that GSDMB is highly expressed in lung bronchial epithelium in human asthma. Overexpression of GSDMB in primary human bronchial epithelium increased expression of genes important to both airway remodeling [TGF-beta1, 5-lipoxygenase (5-LO)] and airway-hyperresponsiveness (AHR) (5-LO). Interestingly, hGSDMBZp3-Cre mice expressing increased levels of the human GSDMB transgene showed a significant spontaneous increase in AHR and a significant spontaneous increase in airway remodeling, with increased smooth muscle mass and increased fibrosis in the absence of airway inflammation. In addition, hGSDMBZp3-Cre mice showed increases in the same remodeling and AHR mediators (TGF-beta1, 5-LO) observed in vitro in GSDMB-overexpressing epithelial cells. GSDMB induces TGF-beta1 expression via induction of 5-LO, because knockdown of 5-LO in epithelial cells overexpressing GSDMB inhibited TGF-beta1 expression. These studies demonstrate that GSDMB, a gene highly linked to asthma but whose function in asthma is previously unknown, regulates AHR and airway remodeling without airway inflammation through a previously unrecognized pathway in which GSDMB induces 5-LO to induce TGF-beta1 in bronchial epithelium</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1073/pnas.1610433113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799535">PM:27799535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2016-113-13132-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2016-113-13132-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Das S</style></custom2><misc3><style face="normal" font="Arial">10.1073/pnas.1610433113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cruse,G.</style></author><author><style face="normal" font="Arial"> Yin,Y.</style></author><author><style face="normal" font="Arial"> Fukuyama,T.</style></author><author><style face="normal" font="Arial"> Desai,A.</style></author><author><style face="normal" font="Arial"> Arthur,G.K.</style></author><author><style face="normal" font="Arial"> Baumer,W.</style></author><author><style face="normal" font="Arial"> Beaven,M.A.</style></author><author><style face="normal" font="Arial"> Metcalfe,D.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607</style></auth-address><titles><title><style face="normal" font="Arial">Exon skipping of FcepsilonRIbeta eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></full-title></periodical><pages end="14120" start="14115">14115-14120</pages><volume><style face="normal" font="Arial">113</style></volume><number><style face="normal" font="Arial">49</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic disease</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="21" Month="11" Year="2016">2016/11/21</year></dates><abstract><style face="normal" font="Arial">Allergic diseases are driven by activation of mast cells and release of mediators in response to IgE-directed antigens. However, there are no drugs currently available that can specifically down-regulate mast cell function in vivo when chronically administered. Here, we describe an innovative approach for targeting mast cells in vitro and in vivo using antisense oligonucleotide-mediated exon skipping of the beta-subunit of the high-affinity IgE receptor (FcepsilonRIbeta) to eliminate surface high-affinity IgE receptor (FcepsilonRI) expression and function, rendering mast cells unresponsive to IgE-mediated activation. As FcepsilonRIbeta expression is restricted to mast cells and basophils, this approach would selectively target these cell types. Given the success of exon skipping in clinical trials to treat genetic diseases such as Duchenne muscular dystrophy, we propose that exon skipping of FcepsilonRIbeta is a potential approach for mast cell-specific treatment of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161122IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1073/pnas.1608520113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27872312">PM:27872312</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2016-113-14115-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2016-113-14115-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161122, Cruse G</style></custom2><misc3><style face="normal" font="Arial">10.1073/pnas.1608520113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teplyakov,A.</style></author><author><style face="normal" font="Arial"> Malia,T.J.</style></author><author><style face="normal" font="Arial"> Obmolova,G.</style></author><author><style face="normal" font="Arial"> Jacobs,S.A.</style></author><author><style face="normal" font="Arial"> O'Neil,K.T.</style></author><author><style face="normal" font="Arial"> Gilliland,G.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Janssen Research &amp; Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA</style></auth-address><titles><title><style face="normal" font="Arial">Conformational flexibility of an anti-IL-13 DARPindagger</style></title><secondary-title><style face="normal" font="Arial">Protein Eng Des Sel</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Protein Eng Des Sel</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics Simulation</style></keyword><keyword><style face="normal" font="Arial"> Molecular dynamics simulations</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="Arial">Designed ankyrin repeat proteins (DARPin(R)) are artificial non-immunoglobulin binding proteins with potential applications as therapeutic molecules. DARPin 6G9 binds interleukin-13 with high affinity and blocks the signaling pathway and as such is promising for the treatment of asthma and other atopic diseases. The crystal structures of DARPin 6G9 in the unbound form and in complex with IL-13 were determined at high resolution. The DARPin competes for the same epitope as the IL-13 receptor chain 13Ralpha1 but does not interfere with the binding of the other receptor chain, IL-4Ralpha. Analysis of multiple copies of the DARPin molecule in the crystal indicates the conformational instability in the N-terminal cap that was predicted from molecular dynamics simulations. Comparison of the DARPin structures in the free state and in complex with IL-13 reveals a concerted movement of the ankyrin repeats upon binding resulted in the opening of the binding site. The induced-fit mode of binding employed by DARPin 6G9 is very unusual for DARPins since they were designed as particularly stable and rigid molecules. This finding shows that DARPins can operate by various binding mechanisms and suggests that some flexibility in the scaffold may be an advantage</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1741-0134 (Electronic)IS - 1741-0126 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/protein/gzw059</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27881684">PM:27881684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Protein Eng Des Sel\20161124-TeplyakovA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Protein Eng Des Sel\20161124-TeplyakovA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Teplyakov A</style></custom2><misc3><style face="normal" font="Arial">10.1093/protein/gzw059</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fotovat,R.</style></author><author><style face="normal" font="Arial"> Alikhani,M.</style></author><author><style face="normal" font="Arial"> Valizadeh,M.</style></author><author><style face="normal" font="Arial"> Mirzaei,M.</style></author><author><style face="normal" font="Arial"> Salekdeh,G.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Systems Biology, Agricultural Biotechnology Research Institute of Iran, Karaj, Iran</style></auth-address><titles><title><style face="normal" font="Arial">`A proteomics approach to discover drought tolerance proteins in wheat pollen grain at meiosis stage</style></title><secondary-title><style face="normal" font="Arial">Protein Pept Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Protein Pept Lett</style></full-title></periodical><pages end="36" start="26">26-36</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> adaptation</style></keyword><keyword><style face="normal" font="Arial"> agricultural biotechnology</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anther</style></keyword><keyword><style face="normal" font="Arial"> Anthers</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Glutathione Transferase</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heat shock protein</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Meiosis</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Ribosomal Proteins</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Stress response</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Systems Biology</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Plants reproductive phase, when grain yield and consequently farmers' investment is most in jeopardy, is considered as the most sensitive stage to drought stress. In this study, we aimed to explore the proteomic response of wheat anther at meiosis stage in a drought tolerant, Darab, and susceptible, Shiraz, wheat genotypes. Wheat plants were exposed to drought stress at meiosis stage for four days under controlled environmental conditions. Then, anthers from both genotypes were sampled, and their proteomes were examined via quantitative proteomics analysis. Our results demonstrated that short-term stress at meiosis stage reduced plant seed-setting compared to well-watered plants. This reduction was more pronounced in the susceptible genotype, Shiraz, by 51%, compared to the drought tolerant Darab by 14.3%. Proteome analysis revealed that 60 protein spots were drought responsive, out of which 44 were identified using a mass spectrometer. We observed a dramatic up-regulation of several heat shock proteins, as well as induction of Bet v I allergen family proteins, peroxiredoxin-5, and glutathione transferase with similar abundance in both genotypes. However, the abundance of proteins such as several stress response related proteins, including glutaredoxin, proteasome subunit alpha type 5, and ribosomal proteins showed a different response to drought stress in two genotypes. The differential abundance of proteins in two genotypes may suggest mechanisms by which tolerant genotype cope with drought stress. To the best of our knowledge, this is the first proteome analysis of plant reproductive tissue response to drought stress in wheat and could broaden our insight into plant adaptation to drought stress</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1875-5305 (Electronic)IS - 0929-8665 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27908260">PM:27908260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Protein Pept Lett\2017-24-26-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Protein Pept Lett\2017-24-26-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Fotovat R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yousefi,R.</style></author><author><style face="normal" font="Arial"> Ferdowsi,L.</style></author><author><style face="normal" font="Arial"> Tavaf,Z.</style></author><author><style face="normal" font="Arial"> Sadeghian,T.</style></author><author><style face="normal" font="Arial"> Tamaddon,A.M.</style></author><author><style face="normal" font="Arial"> Moghtaderi,M.</style></author><author><style face="normal" font="Arial"> Pourpak,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Protein Chemistry Laboratory (PCL), Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of structure, chaperone activity and allergenicity of reduced glycated adduct of bovine beta-casein</style></title><secondary-title><style face="normal" font="Arial">Protein Pept Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Protein Pept Lett</style></full-title></periodical><pages end="55" start="46">46-55</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> Hyperglycemia</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Ultraviolet</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Milk has a potent reducing environment with an important quantity of sugar levels. In the current study beta-casein was glycated in the presence of D-glucose and sodium cyanoborohydride as a reducing agent. Then, the reduced glucitol adduct of beta-casein was used for the structural and functional analyses using different spectroscopic techniques. The results of fluorescence and far ultraviolet circular dichroism assessments suggest important structural alteration upon non-enzymatic glycation of beta-casein. In addition, the chaperone activity, micellization properties and antioxidant activity of this protein were altered upon glucose modification. Also, as a result of reduced glycation, the allergenicity profile of this protein remained largely unchanged. Additional to its energetic and nutritional values, beta-casein has important functional properties. The native structure of this protein is important to perform accurately its biological functions. Non-enzymatic glycation under reducing state was capable to alter both structural and functional aspects of beta-casein. Due to effective reducing environment and significant quantity of reducing sugar of human milk, similar structural and functional alterations are most likely to occur upon reducing glycation of beta-casein in vivo. Also, these changes might be even intensified during chronic hyperglycemia in diabetic mothers</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1875-5305 (Electronic)IS - 0929-8665 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27903233">PM:27903233</url></web-urls></urls><custom2><style face="normal" font="Arial">20161201, Yousefi R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baldissera,L.,Jr.</style></author><author><style face="normal" font="Arial"> Squebola-Cola,D.M.</style></author><author><style face="normal" font="Arial"> Calixto,M.C.</style></author><author><style face="normal" font="Arial"> Lima-Barbosa,A.P.</style></author><author><style face="normal" font="Arial"> Renno,A.L.</style></author><author><style face="normal" font="Arial"> Anhe,G.F.</style></author><author><style face="normal" font="Arial"> Condino-Neto,A.</style></author><author><style face="normal" font="Arial"> De Nucci,G.</style></author><author><style face="normal" font="Arial"> Antunes,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Faculty of Medical Science, State University of Campinas (UNICAMP), Campinas, 13084-971, SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis</style></title><secondary-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></full-title></periodical><pages end="95" start="86">86-95</pages><volume><style face="normal" font="Arial">41</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Cyclic GMP</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Activators of soluble guanylyl cyclase (sGC) act preferentially in conditions of enzyme oxidation or haem group removal. This study was designed to investigate the effects of the sGC activator BAY 60-2770 in murine airways inflammation and human eosinophil chemotaxis. METHODS: C57Bl/6 mice treated or not with BAY 60-2770 (1 mg/kg/day, 14 days) were intranasally challenged with ovalbumin (OVA). At 48 h, bronchoalveolar lavage fluid (BALF) was performed, and circulating blood, bone marrow and lungs were obtained. Human eosinophils purified from peripheral blood were used to evaluate the cell chemotaxis. RESULTS: OVA-challenge promoted marked increases in eosinophil number in BAL, lung tissue, circulating blood and bone marrow, all of which were significantly reduced by BAY 60-2770. The IL-4 and IL-5 levels in BALF were significantly reduced by BAY 60-2770. Increased protein expression of iNOS, along with decreases of expression of sGC (alpha1 and beta1 subunits) and cGMP levels were detected in lung tissue of OVA-challenged mice. BAY 60-2770 fully restored to baseline the iNOS and sGC subunit expressions, and cGMP levels. In human isolated eosinophils, BAY 60-2770 (1-5 muM) had no effects on the cGMP levels and eotaxin-induced chemotaxis; however, prior incubation with ODQ (10 muM) markedly elevated the BAY 60-2770-induced cyclic GMP production, further inhibiting the eosinophil chemotaxis. CONCLUSIONS: BAY 60-2770 reduces airway eosinophilic inflammation and rescue the sGC levels. In human eosinophils under oxidized conditions, BAY 60-2770 elevates the cGMP levels causing cell chemotaxis inhibition. BAY 60-2770 may reveal a novel therapeutic target for asthma treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161106IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - ENGPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pupt.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27816773">PM:27816773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Pharmacol Ther\2016-41-86-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Pharmacol Ther\2016-41-86-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161106, Baldissera L Jr</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pupt.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krombach,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Diagnostische und Interventionelle Radiologie, Justus-Liebig-Universitat Giessen, Klinikstrasse 33, 35392, Giessen, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Diseases of connective tissue in IgG4-associated autoimmune diseases]</style></title><secondary-title><style face="normal" font="Arial">Radiologe</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Radiologe</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic algorithm</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Intestines</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="Arial"> Mesentery</style></keyword><keyword><style face="normal" font="Arial"> MRI</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Orbit</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="Arial">The IgG4-associated diseases of connective tissue are caused by allergen-mediated autoimmune processes. The retroperitoneum, mesentery and mediastinum as well as other less common localizations, such as the neck, orbit and periarticular connective tissue can be affected. Inflammatory fibrosis is initially dominated by a lymphocytic and plasma cell-rich infiltrate and later by cell-poor storiform fibrosis. Stenosis and occlusion of vessels, ureters and intestines can cause severe complications. Computed tomography (CT) and magnetic resonance imaging (MRI) can be implemented in the diagnostic algorithm to narrow the differential diagnosis, delineate the distribution of fibrosis and reveal complications</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1432-2102 (Electronic)IS - 0033-832X (Linking)LA - gerPT - Journal ArticlePT - English AbstractCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00117-016-0183-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27882402">PM:27882402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Radiologe\20161124-KrombachGA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Radiologe\20161124-KrombachGA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Krombach GA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00117-016-0183-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ben,I.O.</style></author><author><style face="normal" font="Arial"> Woode,E.</style></author><author><style face="normal" font="Arial"> Koffuor,G.A.</style></author><author><style face="normal" font="Arial"> Asiamah,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology and Toxicology, Faculty of Pharmacy, Madonna University, Elele Campus, Rivers State, Nigeria</style></auth-address><titles><title><style face="normal" font="Arial">Anti-anaphylactic effects of Trichilia monadelpha (Thonn.) J. J. De Wilde extracts on rodent models of anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Res Pharm Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Res Pharm Sci</style></abbr-1></periodical><pages end="404" start="397">397-404</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Ghana</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-6</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nigeria</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Petroleum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Effects of petroleum ether and ethanolic extracts of Trichilia monadelpha stem bark (PEE and EAE) on compound 48/80-induced systemic and passive anaphylaxis were determined. Survival rate, extravasation, degranulation of mast cells, and secretion of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were measured after pre-treatment with extracts (10-100 mg/kg) and disodium chromoglycate (2.5-250 mug/kg) and induction of anaphylaxis in C57BL/6 mice or Sprague-Dawley rats with compound 48/80. Histopathological assessments were made from skin biopsies of rats. Data was analyzed by Kaplan-Meier Survival Log-Rank Analysis, or One-way ANOVA and Holm-Sidak's post hoc test. PEE and EAE inhibited (P &lt;/= 0.0001) tremors in systemic anaphylaxis passive cutaneous anaphylactic reactions and extravasation, stabilized or prevented (P &lt;/= 0.001-0.0001) mast cell degranulation, and inhibited (P &lt;/= 0.001-0.0001) TNF-alpha and IL-6 secretion. Per the findings, PEE and EAE of T. monadelpha have exhibited substantial anti-anaphylactic and anti-inflammatory property (with PEE performing better) which substantiates its use traditionally in management of allergies and other inflammatory disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 1735-5362 (Print)IS - 1735-5362 (Linking)LA - engPT - Journal ArticleCO - Nigeria -CO - Ghana -</style></notes><work-type><style face="normal" font="Arial">10.4103/1735-5362.192491</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27920822">PM:27920822</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Res Pharm Sci\2016-11-397-404.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Res Pharm Sci\2016-11-397-404.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Ben IO</style></custom2><misc3><style face="normal" font="Arial">10.4103/1735-5362.192491</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,J.X.</style></author><author><style face="normal" font="Arial"> Fan,L.C.</style></author><author><style face="normal" font="Arial"> Li,M.H.</style></author><author><style face="normal" font="Arial"> Cao,W.J.</style></author><author><style face="normal" font="Arial"> Xu,J.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature</style></title><secondary-title><style face="normal" font="Arial">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med</style></full-title></periodical><pages end="42" start="33">33-42</pages><volume><style face="normal" font="Arial">122</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergy bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigates</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Prednisone dosage</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><isbn><style face="normal" font="Arial">0954-6111</style></isbn><abstract><style face="normal" font="Arial">Omalizumab, a humanized mAb that binds to IgE, has been an effective therapy for patients with severe allergic asthma; however, there are few clinical trials examining the efficacy of Omalizumab in patients with allergic bronchopulmonary aspergillosis (ABPA) except some case reports. To assess the clinical and immunological effects of Omalizumab in ABPA patients, we made a synthesis review of 102 cases from 30 published literature, analyzed the effects of Omalizumab therapy in ABPA and conducted subgroup analyses to determine factors that influenced the therapy endpoints. We found that Omalizumab treatment not only provided a clinically important reduction in serum IgE, exacerbation rates and steroid requirement, but also showed attenuated asthma symptoms and improved pulmonary function parameters in patients with ABPA. Moreover, further discussion was made when interpretating the results. Double-blind, randomized, placebo-controlled trials are necessary to establish the efficacy and safety of this novel therapeutic intervention for ABPA patients</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmed.2016.11.019</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.rmed.2016.11.019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2017-122-33-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2017-122-33-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Li JX</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmed.2016.11.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kansu,A.</style></author><author><style face="normal" font="Arial"> Yuce,A.</style></author><author><style face="normal" font="Arial"> Dalgic,B.</style></author><author><style face="normal" font="Arial"> Sekerel,B.E.</style></author><author><style face="normal" font="Arial"> Cullu-Cokugras,F.</style></author><author><style face="normal" font="Arial"> Cokugras,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Gastroenterology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Consensus statement on diagnosis, treatment and follow-up of cow's milk protein allergy among infants and children in Turkey</style></title><secondary-title><style face="normal" font="Arial">Turk J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Turk J Pediatr</style></full-title></periodical><pages end="11" start="1">1-11</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> eHF</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> hydrolyzed formula</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> Nutritional deficiency</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The present paper aims to provide experts' consensus on diagnosis and management of cow's milk protein allergy (CMPA) among infants and children in Turkey, based on review of available evidence-based guidelines, publications and experts' clinical experience. The experts agreed that CMPA diagnosis should be based on symptomatic evaluation and diagnostic elimination diet as followed by implementation of an open challenge test after disappearance of symptoms and confirmation of CMPA diagnosis in re-appearance of symptoms. For breastfed infants, differential diagnosis involves withdrawal of cow's milk-containing products from the mother's diet, while calcium supplements and appropriate dietary advice are given to mothers to prevent nutritional deficiency. For infants not breastfed exclusively, cow's milk-based formula and any complementary food containing cow's milk protein (CMP) should be avoided. The first line treatment should be extensively hydrolyzed formula (eHF) with use of amino acid-based formula (AAF) in severe cases such as anaphylaxis, enteropathy, eosinophilic esophagitis and food protein induced enterocolitis along with cases of multiple system involvement, multiple food allergies and intolerance to eHF. Introduction of supplementary foods should not be delayed in CMPA, while should be made one by one in small amounts and only after the infant is at least 17 weeks of age. Infants who are at-risk can be identified by family history of atopic disease. Exclusive breastfeeding for 4-6 months (17-27 weeks) is recommended as the best method of infant allergy prevention. There is no evidence that modifying the mother's diet during pregnancy and/or breast-feeding and delaying solid or even potentially allergic foods beyond 4-6 months in infants may be protective against allergy among at-risk infants. When exclusive breastfeeding is not possible, at-risk infants should get a partially or extensively hydrolyzed formula (pHF or eHF) to prevent allergy until risk evaluation by a health professional. In conclusion, the present consensus statement provides recommendations regarding diagnosis, prevention and management of CMPA in infants and children in Turkey, and thus expected to guide physicians to optimize their approach to CMPA and decrease burden of the disease on infants and their caregivers</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 0041-4301 (Print)IS - 0041-4301 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27922230">PM:27922230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Turk J Pediatr\2016-58-1-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Turk J Pediatr\2016-58-1-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Kansu A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goncalves,S.M.</style></author><author><style face="normal" font="Arial"> Lagrou,K.</style></author><author><style face="normal" font="Arial"> Duarte-Oliveira,C.</style></author><author><style face="normal" font="Arial"> Maertens,J.A.</style></author><author><style face="normal" font="Arial"> Cunha,C.</style></author><author><style face="normal" font="Arial"> Carvalho,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho , Braga , Portugal</style></auth-address><titles><title><style face="normal" font="Arial">The microbiome-metabolome crosstalk in the pathogenesis of respiratory fungal diseases</style></title><secondary-title><style face="normal" font="Arial">Virulence</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Virulence</style></full-title></periodical><pages end="684" start="673">673-684</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Filamentous fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Filamentous fungi of the genus Aspergillus are responsible for several superficial and invasive infections and allergic syndromes. The risk of infection and its clinical outcome vary significantly even among patients with similar predisposing clinical factors and pathogen exposure. There is increasing evidence that the individual microbiome supervises the outcome of the host-fungus interaction by influencing mechanisms of immune regulation, inflammation, metabolism, and other physiological processes. Microbiome-mediated mechanisms of resistance allow therefore the control of fungal colonization, preventing the onset of overt disease, particularly in patients with underlying immune dysfunction. Here, we review this emerging area of research and discuss the contribution of the microbiota (and its dysbiosis), including its immunoregulatory properties and relationship with the metabolic activity of commensals, to respiratory fungal diseases. Finally, we highlight possible strategies aimed at decoding the microbiome-metabolome dialog and at its exploitation toward personalized medical interventions in patients at high risk of infection</style></abstract><notes><style face="normal" font="Arial">DA - 20161107IS - 2150-5608 (Electronic)IS - 2150-5594 (Linking)LA - engPT - Journal ArticleCO - Portugal -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1080/21505594.2016.1257458</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27820674">PM:27820674</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Virulence\20161107-GoncalvesSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Virulence\20161107-GoncalvesSM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161107, Goncalves SM</style></custom2><misc3><style face="normal" font="Arial">10.1080/21505594.2016.1257458</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miniero,R.</style></author><author><style face="normal" font="Arial"> Mazza,G.A.</style></author><author><style face="normal" font="Arial"> Mohamed Mahdi,A.</style></author><author><style face="normal" font="Arial"> Dolceamore,T.R.</style></author><author><style face="normal" font="Arial"> Zurlo,F.</style></author><author><style face="normal" font="Arial"> Monti,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Camel's milk: nutritional characters and perspective therapeutic use</style></title><secondary-title><style face="normal" font="Arial">Riv Immunol Allergol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Riv Immunol Allergol Pediatr</style></full-title></periodical><pages end="50" start="46">46-50</pages><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Alle</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> immunoglobuline E</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> Proteine</style></keyword><keyword><style face="normal" font="Arial"> Camel's milk</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Il Latte di Cammella (LC) è utilizzato in molti paesi del mondo, soprattutto in Africa nordorientale,Somalia, Somaliland, Emirati Arabi, Arabia Saudita, Pakistan, India e Cina, comesostituto del Latte Materno (LM). Negli ultimi anni diversi ricercatori, soprattutto arabi, israelianie pakistani, hanno pubblicato, seppure su casistiche limitate, interessanti studi che dimostrerebberocome il LC possa essere impiegato con successo in varie patologie umane qualil'Allergia alle Proteine del Latte Vaccino (APLV), il Diabete Mellito (DM) tipo 1 e 2, l'Autismo,la Steatosi epatica, il morbo di Crohn e la diarrea acuta. Dal punto di vista nutrizionale,seppur con ampie variazioni stagionali, il LC contiene all'incirca il 3,1% di proteine, il 3,5%di grassi, quasi tutti polinsaturi e il 4,4% di lattosio. Per la sua composizione, il LC può fornireal bambino una buona parte del fabbisogno minimo giornaliero necessario di macro emicronutrienti secondo la Recommended Dietary Allowance (RDA). Inoltre, analogamente alLM, il LC contiene una buona concentrazione di fattori antimicrobici ad azione battericida efungicida quali immunoglobuline e lattoferrina, ma soprattutto non contiene â-lattoglobulina.Grazie alle recenti autorizzazioni per l'importazione e/o vendita del LC in Europa e negliUSA si potranno verificare, su più ampie casistiche, le sue presunte potenzialità terapeuticheche, se confermate, ne permetterebbero l'utilizzo nella pratica clinica.</style></abstract><notes><style face="normal" font="Arial">LA - ITACO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Riv Immunol Allergol Pediatr\2016-3-46-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Riv Immunol Allergol Pediatr\2016-3-46-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Miniero R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dullin,C.</style></author><author><style face="normal" font="Arial"> Markus,M.A.</style></author><author><style face="normal" font="Arial"> Larsson,E.</style></author><author><style face="normal" font="Arial"> Tromba,G.</style></author><author><style face="normal" font="Arial"> Hulsmann,S.</style></author><author><style face="normal" font="Arial"> Alves,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Diagnostic and Interventional Radiology, University Medical Center Goettingen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">X-Ray based Lung Function measurement-a sensitive technique to quantify lung function in allergic airway inflammation mouse models</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="36297">36297-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> experimental allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="2" Month="11" Year="2016">2016/11/2</year></dates><abstract><style face="normal" font="Arial">In mice, along with the assessment of eosinophils, lung function measurements, most commonly carried out by plethysmography, are essential to monitor the course of allergic airway inflammation, to examine therapy efficacy and to correlate animal with patient data. To date, plethysmography techniques either use intubation and/or restraining of the mice and are thus invasive, or are limited in their sensitivity. We present a novel unrestrained lung function method based on low-dose planar cinematic x-ray imaging (X-Ray Lung Function, XLF) and demonstrate its performance in monitoring OVA induced experimental allergic airway inflammation in mice and an improved assessment of the efficacy of the common treatment dexamethasone. We further show that XLF is more sensitive than unrestrained whole body plethysmography (UWBP) and that conventional broncho-alveolar lavage and histology provide only limited information of the efficacy of a treatment when compared to XLF. Our results highlight the fact that a multi-parametric imaging approach as delivered by XLF is needed to address the combined cellular, anatomical and functional effects that occur during the course of asthma and in response to therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - ENGPT - Journal ArticleCO - Germany -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep36297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27805632">PM:27805632</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-36297.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-36297.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Dullin C</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep36297</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khwarahm,N.R.</style></author><author><style face="normal" font="Arial"> Dash,J.</style></author><author><style face="normal" font="Arial"> Skjoth,C.A.</style></author><author><style face="normal" font="Arial"> Newnham,R.M.</style></author><author><style face="normal" font="Arial"> Adams-Groom,B.</style></author><author><style face="normal" font="Arial"> Head,K.</style></author><author><style face="normal" font="Arial"> Caulton,E.</style></author><author><style face="normal" font="Arial"> Atkinson,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, College of Education, University of Sulaimani, City Campus, Iraqi Kurdistan Region, Iraq</style></auth-address><titles><title><style face="normal" font="Arial">Mapping the birch and grass pollen seasons in the UK using satellite sensor time-series</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="600" start="586">586-600</pages><volume><style face="normal" font="Arial">578</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chlorophyll</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Iraq</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Meteorology</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vegetation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="11" Year="2016">2016/11/14</year></dates><abstract><style face="normal" font="Arial">Grass and birch pollen are two major causes of seasonal allergic rhinitis (hay fever) in the UK and parts of Europe affecting around 15-20% of the population. Current prediction of these allergens in the UK is based on (i) measurements of pollen concentrations at a limited number of monitoring stations across the country and (ii) general information about the phenological status of the vegetation. Thus, the current prediction methodology provides information at a coarse spatial resolution only. Most station-based approaches take into account only local observations of flowering, while only a small number of approaches take into account remote observations of land surface phenology. The systematic gathering of detailed information about vegetation status nationwide would therefore be of great potential utility. In particular, there exists an opportunity to use remote sensing to estimate phenological variables that are related to the flowering phenophase and, thus, pollen release. In turn, these estimates can be used to predict pollen release at a fine spatial resolution. In this study, time-series of MERIS Terrestrial Chlorophyll Index (MTCI) data were used to predict two key phenological variables: the start of season and peak of season. A technique was then developed to estimate the flowering phenophase of birch and grass from the MTCI time-series. For birch, the timing of flowering was defined as the time after the start of the growing season when the MTCI value reached 25% of the maximum. Similarly, for grass this was defined as the time when the MTCI value reached 75% of the maximum. The predicted pollen release dates were validated with data from nine pollen monitoring stations in the UK. For both birch and grass, we obtained large positive correlations between the MTCI-derived start of pollen season and the start of the pollen season defined using station data, with a slightly larger correlation observed for birch than for grass. The technique was applied to produce detailed maps for the flowering of birch and grass across the UK for each of the years from 2003 to 2010. The results demonstrate that the remote sensing-based maps of onset flowering of birch and grass for the UK together with the pollen forecast from the Meteorology Office and National Pollen and Aerobiology Research Unit (NPARU) can potentially provide more accurate information to pollen allergy sufferers in the UK</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Iraq -CO - United KIngdom -CO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27856057">PM:27856057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\20161118-KhwarahmNR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\20161118-KhwarahmNR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Khwarahm NR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2016.11.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shik,D.</style></author><author><style face="normal" font="Arial"> Tomar,S.</style></author><author><style face="normal" font="Arial"> Lee,J.B.</style></author><author><style face="normal" font="Arial"> Chen,C.Y.</style></author><author><style face="normal" font="Arial"> Smith,A.</style></author><author><style face="normal" font="Arial"> Wang,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Burnet Avenue, Cincinnati, OH, 45229, USA</style></auth-address><titles><title><style face="normal" font="Arial">IL-9-producing cells in the development of IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="Arial">Semin Immunopathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunopathol</style></full-title></periodical><pages end="77" start="69">69-77</pages><volume><style face="normal" font="Arial">39</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell progenitors</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> multifunctional</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergy is a harmful immune reaction driven by uncontrolled type 2 immune responses. Considerable evidence demonstrates the key roles of mast cells, IgE, and TH2 cytokines in mediating food allergy. However, this evidence provides limited insight into why only some, rather than all, food allergic individuals are prone to develop life-threatening anaphylaxis. Clinical observations suggest that patients sensitized to food through the skin early in life may later develop severe food allergies. Aberrant epidermal thymic stromal lymphopoietin and interleukin (IL) 33 production and genetic predisposition can initiate an allergic immune response mediated by dendritic cells and CD4+TH2 cells in inflamed skin. After allergic sensitization, intestinal IL-25 and food ingestion enhance concerted interactions between type 2 innate lymphoid cells (ILC2s) and CD4+TH2 cells, which perpetuate allergic reactions from the skin to the gut. IL-4 and cross-linking of antigen/IgE/FcepsilonR complexes induce emigrated mast cell progenitors to develop into the multi-functional IL-9-producing mucosal mast cells, which produce prodigious amounts of IL-9 and mast cell mediators to drive intestinal mastocytosis in an autocrine loop. ILC2s and TH9 cells may also serve as alternative cellular sources of IL-9 to augment the amplification of intestinal mastocytosis, which is the key cellular checkpoint in developing systemic anaphylaxis. These findings provide a plausible view of how food allergy develops and progresses in a stepwise manner and that atopic signals, dietary allergen ingestion, and inflammatory cues are fundamental in promoting life-threatening anaphylaxis. This information will aid in improving diagnosis and developing more effective therapies for food allergy-triggered anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1863-2300 (Electronic)IS - 1863-2297 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00281-016-0605-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27909880">PM:27909880</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunopathol\20161202-ShikD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunopathol\20161202-ShikD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Shik D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00281-016-0605-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vasilescu,A.</style></author><author><style face="normal" font="Arial"> Nunes,G.</style></author><author><style face="normal" font="Arial"> Hayat,A.</style></author><author><style face="normal" font="Arial"> Latif,U.</style></author><author><style face="normal" font="Arial"> Marty,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">International Centre of Biodynamics, 1B Intrarea Portocalelor, sector 6, 060101 Bucharest, Romania.</style></auth-address><titles><title><style face="normal" font="Arial">Electrochemical Affinity Biosensors Based on Disposable Screen-Printed Electrodes for Detection of Food Allergens</style></title><secondary-title><style face="normal" font="Arial">Sensors (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sensors (Basel)</style></full-title></periodical><pages end="" start="1863">1863-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Aptamers</style></keyword><keyword><style face="normal" font="Arial"> Biosensor</style></keyword><keyword><style face="normal" font="Arial"> biosensors</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electrodes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> fining</style></keyword><keyword><style face="normal" font="Arial"> Fining agent</style></keyword><keyword><style face="normal" font="Arial"> Fining agents</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> functional foods</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immobilization</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wine</style></keyword></keywords><dates><year Day="5" Month="11" Year="2016">2016/11/5</year></dates><abstract><style face="normal" font="Arial">Food allergens are proteins from nuts and tree nuts, fish, shellfish, wheat, soy, eggs or milk which trigger severe adverse reactions in the human body, involving IgE-type antibodies. Sensitive detection of allergens in a large variety of food matrices has become increasingly important considering the emergence of functional foods and new food manufacturing technologies. For example, proteins such as casein from milk or lysozyme and ovalbumin from eggs are sometimes used as fining agents in the wine industry. Nonetheless, allergen detection in processed foods is a challenging endeavor, as allergen proteins are degraded during food processing steps involving heating or fermentation. Detection of food allergens was primarily achieved via Enzyme-Linked Immuno Assay (ELISA) or by chromatographic methods. With the advent of biosensors, electrochemical affinity-based biosensors such as those incorporating antibodies and aptamers as biorecognition elements were also reported in the literature. In this review paper, we highlight the success achieved in the design of electrochemical affinity biosensors based on disposable screen-printed electrodes towards detection of protein allergens. We will discuss the analytical figures of merit for various disposable screen-printed affinity sensors in relation to methodologies employed for immobilization of bioreceptors on transducer surface</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1424-8220 (Electronic)IS - 1424-8220 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Romania -CO - Brazil -CO - Pakistan -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.3390/s16111863</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27827963">PM:27827963</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sensors (Basel)\2016-16-1863.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sensors (Basel)\2016-16-1863.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Vasilescu A</style></custom2><misc3><style face="normal" font="Arial">10.3390/s16111863</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vilaseca,I.</style></author><author><style face="normal" font="Arial"> Lehrer-Coriat,E.</style></author><author><style face="normal" font="Arial"> Torres,M.</style></author><author><style face="normal" font="Arial"> Aguilar,F.</style></author><author><style face="normal" font="Arial"> Almendros,I.</style></author><author><style face="normal" font="Arial"> Martinez-Vidal,B.M.</style></author><author><style face="normal" font="Arial"> Farre,R.</style></author><author><style face="normal" font="Arial"> Montserrat,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Early effects of continuous positive airway pressure in a rodent model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Sleep Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sleep Med</style></full-title></periodical><pages end="27" start="25">25-27</pages><volume><style face="normal" font="Arial">27</style><style face="normal" font="Symbol">-</style><style face="normal" font="Arial">28</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CPAP</style></keyword><keyword><style face="normal" font="Arial"> CPAP-induced rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal inflammation</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Sleep apnea</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year><pub-dates><date Day="0" Month="12" Year="2016">2016/12</date></pub-dates></dates><isbn><style face="normal" font="Arial">1389-9457</style></isbn><abstract><style face="normal" font="Arial">Background Continuous positive airway pressure (CPAP) is the most commonly used treatment in obstructive sleep apnea. In a previous rat model study, we demonstrated that nasal CPAP induces early rhinitis expressed by nasal neutrophil extravasation. Here we hypothesized that nasal CPAP would worsen nasal inflammation on a previously inflamed mucosa. The objective of this study was to evaluate the early nasal CPAP effects of allergic rhinitis (AR) in a rodent model. Methods Twenty Sprague-Dawley rats were sensitized with intraperitoneal ovalbumin (OVA). Nasal inflammation was induced by the administration of intranasal OVA during consecutive days. The same procedure was performed in 20 control rats treated with saline solution. The allergic (AR) and non-allergic (NAR) rats were then randomized to nasal CPAP at 10-ácm H2O for five hours or to sham CPAP. The degree of nasal inflammation was assessed by evaluating the percentage of neutrophils, eosinophils, basophils, and lymphocytes in the nasal mucosa. An unpaired Mann</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆWhitney test was used to analyze differences between groups. Results The greatest inflammation was observed in the group of AR without CPAP (1.24%-á-¦-á0.94%), followed by NAR with CPAP (0.64%-á-¦-á0.30%), AR with CPAP (0.64%-á-¦-á0.40%), and NAR without CPAP (0.21%-á-¦-á0.29%). Conclusions Administration of nasal CPAP or allergy sensitization can produce, individually, neutrophil extravasation on the nasal mucosa of a rat model. The application of both stimuli is not responsible for increased inflammation. Therefore, this study suggests that rhinitis is not a major limitation for CPAP administration</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.sleep.2016.09.016</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.sleep.2016.09.016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sleep Med\2016-28_28-25-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sleep Med\2016-28_28-25-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Vilaseca I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.sleep.2016.09.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Menzella,F.</style></author><author><style face="normal" font="Arial"> Lusuardi,M.</style></author><author><style face="normal" font="Arial"> Galeone,C.</style></author><author><style face="normal" font="Arial"> Taddei,S.</style></author><author><style face="normal" font="Arial"> Facciolongo,N.</style></author><author><style face="normal" font="Arial"> Zucchi,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cardio-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, IR</style></auth-address><titles><title><style face="normal" font="Arial">Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential</style></title><secondary-title><style face="normal" font="Arial">Ther Adv Chronic Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ther Adv Chronic Dis</style></full-title></periodical><pages end="277" start="260">260-277</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> refractory asthma</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Severe asthma is characterized by major impairment of quality of life, poor symptom control and frequent exacerbations. Inflammatory, clinical and causative factors identify different phenotypes and endotypes of asthma. In the last few years, new treatment options have allowed for targeted treatments according to the different phenotypes of the disease. To accurately select a specific treatment for each asthmatic variant, the identification of appropriate biomarkers is required. Eosinophilic asthma is a distinct phenotype characterized by thickening of the basement membrane and corticosteroid responsiveness. This review reports the latest evidence on an anti-IL-5 monoclonal antibody, mepolizumab, a new and promising biological agent recently approved by the FDA specifically for the treatment of severe eosinophilic refractory asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161102IS - 2040-6223 (Print)IS - 2040-6223 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1177/2040622316659863</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27803792">PM:27803792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ther Adv Chronic Dis\2016-7-269-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ther Adv Chronic Dis\2016-7-269-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161102, Menzella F</style></custom2><misc3><style face="normal" font="Arial">10.1177/2040622316659863</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morton,R.W.</style></author><author><style face="normal" font="Arial"> Elphick,H.E.</style></author><author><style face="normal" font="Arial"> Rigby,A.S.</style></author><author><style face="normal" font="Arial"> Daw,W.J.</style></author><author><style face="normal" font="Arial"> King,D.A.</style></author><author><style face="normal" font="Arial"> Smith,L.J.</style></author><author><style face="normal" font="Arial"> Everard,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Academic Unit of Child Health, University of Sheffield, Sheffield, South Yorkshire, UK</style></auth-address><titles><title><style face="normal" font="Arial">STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma</style></title><secondary-title><style face="normal" font="Arial">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Thorax</style></full-title></periodical><pages end="354" start="347">347-354</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACQ</style></keyword><keyword><style face="normal" font="Arial"> Adherence</style></keyword><keyword><style face="normal" font="Arial"> admissions</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled steroids</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Suboptimal adherence to inhaled steroids is common in children with asthma and is associated with poor disease control, reduced quality of life and even death. Previous studies using feedback of electronically monitored adherence data have demonstrated improved adherence, but have not demonstrated a significant impact on clinical outcomes. The aim of this study was to determine whether introduction of this approach into routine practice would result in improved clinical outcomes. METHODS: Children with asthma aged 6-16 years were randomised to the active intervention consisting of electronic adherence monitoring with daily reminder alarms together with feedback in the clinic regarding their inhaled corticosteroid (ICS) use or to the usual care arm with adherence monitoring alone. All children had poorly controlled asthma at baseline, taking ICS and long-acting beta-agonists. Subjects were seen in routine clinics every 3 months for 1 year. The primary outcome was the Asthma Control Questionnaire (ACQ) score. Secondary outcomes included adherence and markers of asthma morbidity. RESULTS: 77 of 90 children completed the study (39 interventions, 38 controls). Adherence in the intervention group was 70% vs 49% in the control group (p&lt;/=0.001). There was no significant difference in the change in ACQ, but children in the intervention group required significantly fewer courses of oral steroids (p=0.008) and fewer hospital admissions (p&lt;/=0.001). CONCLUSIONS: The results indicate that electronic adherence monitoring with feedback is likely to be of significant benefit in the routine management of poorly controlled asthmatic subjects. TRIAL REGISTRATION NUMBER: NCT02451709; pre-result</style></abstract><notes><style face="normal" font="Arial">DA - 20161105IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - ENGPT - Journal ArticleCO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1136/thoraxjnl-2015-208171</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27815524">PM:27815524</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Thorax\20161105-MortonRW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Thorax\20161105-MortonRW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161105, Morton RW</style></custom2><misc3><style face="normal" font="Arial">10.1136/thoraxjnl-2015-208171</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kazemi-Lomedasht,F.</style></author><author><style face="normal" font="Arial"> Khalaj,V.</style></author><author><style face="normal" font="Arial"> Bagheri,K.P.</style></author><author><style face="normal" font="Arial"> Behdani,M.</style></author><author><style face="normal" font="Arial"> Shahbazzadeh,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Venom &amp; Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">The first report on transcriptome analysis of the venom gland of Iranian scorpion, Hemiscorpius lepturus</style></title><secondary-title><style face="normal" font="Arial">Toxicon</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicon</style></full-title></periodical><pages end="130" start="123">123-130</pages><volume><style face="normal" font="Arial">125</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial peptides</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Biotherapeutics</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene sequence</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Iraq</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Metalloproteases</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phospholipases</style></keyword><keyword><style face="normal" font="Arial"> Potassium</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Scorpions</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptome analysis</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venom gland</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Hemiscorpius lepturus scorpion is one of the most venomous members of the Hemiscorpiidae family. H. lepturus is distributed in Iran, Iraq and Yemen. The prevalence and severity of scorpionism is high and health services are not able to control it. Scorpionism in Iran especially in the southern regions (Khuzestan, Sistan and Baluchestan, Hormozgan, Ilam) is one of the main health challenges. Due to the medical and health importance of scorpionism, the focus of various studies has been on the identification of H. lepturus venom components. Nevertheless, until now, only a few percent of H. lepturus venom components have been identified and there is no complete information about the venom components of H. lepturus. The current study reports transcriptome analysis of the venom gland of H. lepturus scorpion. Illumina Next Generation Sequencing results identified venom components of H. lepturus. When compared with other scorpion's venom, the venom of H. lepturus consists of mixtures of peptides, proteins and enzymes such as; phospholipases, metalloproteases, hyaluronidases, potassium channel toxins, calcium channel toxins, antimicrobial peptides (AMPs), venom proteins, venom toxins, allergens, La1-like peptides, proteases and scorpine-like peptides. Comparison of identified components of H. lepturus venom was carried out with venom components of reported scorpions and various identities and similarities between them were observed. With transcriptome analysis of H. lepturus venom unique sequences, coding venom components were investigated. Moreover, our study confirmed transcript expression of previously reported peptides; Hemitoxin, Hemicalcin and Hemilipin. The gene sequences of venom components were investigated employing transcriptome analysis of venom gland of H. lepturus. In summary, new bioactive molecules identified in this study, provide basis for venomics studies of scorpions of Hemiscorpiidae family and promises development of novel biotherapeutics</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 1879-3150 (Electronic)IS - 0041-0101 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.toxicon.2016.11.261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914888">PM:27914888</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicon\20161204-KazemiLomedashtF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicon\20161204-KazemiLomedashtF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Kazemi-Lomedasht F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.toxicon.2016.11.261</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jahdasani,R.</style></author><author><style face="normal" font="Arial"> Jamnani,F.R.</style></author><author><style face="normal" font="Arial"> Behdani,M.</style></author><author><style face="normal" font="Arial"> Habibi-Anbouhi,M.</style></author><author><style face="normal" font="Arial"> Yardehnavi,N.</style></author><author><style face="normal" font="Arial"> Shahbazzadeh,D.</style></author><author><style face="normal" font="Arial"> Kazemi-Lomedasht,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Venom &amp; Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Identification of the immunogenic epitopes of the whole venom component of the Hemiscorpius lepturus scorpion using the phage display peptide library</style></title><secondary-title><style face="normal" font="Arial">Toxicon</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicon</style></full-title></periodical><pages end="93" start="83">83-93</pages><volume><style face="normal" font="Arial">124</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiserum</style></keyword><keyword><style face="normal" font="Arial"> Bioactive compounds</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Biotherapeutics</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mimotope</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide Library</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> Phage display peptide library</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="Arial">The venom of the Hemiscorpius lepturus scorpion contains mixtures of bioactive compounds that disturb biochemical and physiological functions of the victims. Hemiscorpius lepturus envenomation is recognized as a serious health concern in tropical regions. So far, there is no preventive procedure, and the main focus is on treatment of victims with an antiserum purified from hyper-immunized horses. Although antisera can neutralize the venom, they, in some cases, lead to anaphylactic shock and even death. Selection of peptides mimicking antigenic and immunogenic epitopes of toxins from random peptide libraries is a novel approach for the development of recombinant toxins and poly-epitopic vaccine. To achieve this aim, a phage display peptide library and three rounds of biopanning were performed on immobilized antibodies (IgGs) purified from the sera of hyper-immunized horses. The results show that the highest binding of the phage to immobilized horse antibodies occurred in the third round of biopanning. Over 125 individual clones carrying mimotopes of Hemiscorpius lepturus toxins were selected and subjected for sequencing. The sequencing results identified unique peptides mimicking the antigenic and immunogenic epitopes of Hemiscorpius lepturus toxins. The results of this study provide a basis for further studies and the development of a putative epitopic vaccine and a recombinant toxin</style></abstract><notes><style face="normal" font="Arial">DA - 20161115IS - 1879-3150 (Electronic)IS - 0041-0101 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.toxicon.2016.11.247</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27845058">PM:27845058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicon\2016-124-83-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicon\2016-124-83-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161115, Jahdasani R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.toxicon.2016.11.247</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perez-Riverol,A.</style></author><author><style face="normal" font="Arial"> Campos Pereira,F.D.</style></author><author><style face="normal" font="Arial"> Musacchio,L.A.</style></author><author><style face="normal" font="Arial"> Romani Fernandes,L.G.</style></author><author><style face="normal" font="Arial"> Santos-Pinto,J.R.</style></author><author><style face="normal" font="Arial"> Justo-Jacomini,D.L.</style></author><author><style face="normal" font="Arial"> Oliveira de Azevedo,G.</style></author><author><style face="normal" font="Arial"> Bazon,M.L.</style></author><author><style face="normal" font="Arial"> Palma,M.S.</style></author><author><style face="normal" font="Arial"> Zollner,R.L.</style></author><author><style face="normal" font="Arial"> Brochetto-Braga,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Biologia Molecular de Artropodes-LBMA-IBRC-UNESP (Univ Estadual Paulista), Av. 24-A, n masculine 1515, CEP 13506-900, Bela Vista, Rio Claro, SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Molecular cloning, expression and IgE-immunoreactivity of phospholipase A1, a major allergen from Polybia paulista (Hymenoptera: Vespidae) venom</style></title><secondary-title><style face="normal" font="Arial">Toxicon</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicon</style></full-title></periodical><pages end="52" start="44">44-52</pages><volume><style face="normal" font="Arial">124</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Accidents</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunodetection</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inclusion Bodies</style></keyword><keyword><style face="normal" font="Arial"> Inclusion body</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poly p 1</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Venom gland</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="Arial">Polybia paulista (Hymenoptera: Vespidae) is a clinically relevant social wasp that frequently causes stinging accidents in southeast Brazil. To date, diagnosis and specific immunotherapy (SIT) of allergy are based on the use of crude venom extracts. Production of recombinant forms of major allergens from P. paulista venom will improve diagnosis and SIT of allergic patients by reducing the incidence of cross-reactivity and non-specific sensitization. Here, we describe the molecular cloning, heterologous expression, purification and IgE-mediated immunodetection of phospholipase A1 (Poly p 1), a major allergen from P. paulista venom. The cDNA of Poly p 1 was extracted from venom glands and then cloned, and further expression of the recombinant allergen (rPoly p 1) was achieved in Escherichia coli BL21 (DE3) cells. Purification of rPoly p 1 was performed using immobilized Ni2+ metal affinity chromatography. Also, a single-step chromatographic method allowed the purification of native Poly p 1 (nPoly p 1) from the wasp's venom glands. We used western blotting to evaluate IgE-reactivity of the sera from 10 P. paulista venom-allergic patients to rPoly p 1 and nPoly p 1. High levels of insoluble rPoly p 1 were obtained during heterologous expression. After solubilization of inclusion bodies and purification of the recombinant protein, a unique band of approximately 34 kDa was detected in SDS-PAGE analysis. Allergen-specific IgE (sIgE) from allergic patients' sera recognized rPoly p 1, nPoly p 1 and crude venom extract to a similar extent. Our results showed that rPoly p 1 could be used for development of component-resolved diagnosis (CRD) and molecular-defined SIT of P. paulista venom allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161109IS - 1879-3150 (Electronic)IS - 0041-0101 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.toxicon.2016.11.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826019">PM:27826019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicon\2016-124-44-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicon\2016-124-44-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161109, Perez-Riverol A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.toxicon.2016.11.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kramer,M.M.</style></author><author><style face="normal" font="Arial"> Hirota,J.A.</style></author><author><style face="normal" font="Arial"> Sood,A.</style></author><author><style face="normal" font="Arial"> Teschke,K.</style></author><author><style face="normal" font="Arial"> Carlsten,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Airway and serum adipokines after allergen and diesel exposure in a controlled human crossover study of atopic adults</style></title><secondary-title><style face="normal" font="Arial">Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transl Res</style></full-title></periodical><pages end="60" start="49">49-60</pages><volume><style face="normal" font="Arial">182</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adipokines</style></keyword><keyword><style face="normal" font="Arial"> adiponectin</style></keyword><keyword><style face="normal" font="Arial"> Adipose tissue</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Diesel</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Leptin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> resistin</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Adipokines are mediators released from adipose tissue. These proteins are regarded as active elements of systemic and pulmonary inflammation, whose dysregulation can alter an individual's risk of developing allergic lung diseases. Despite this knowledge, adipokine responses to inhaled stimuli are poorly understood. We sought to measure serum and lung adiponectin, leptin, and resistin in an atopic adult study population following exposure to allergen and diesel exhaust (DE). Two types of lung samples including bronchoalveolar lavage (BAL) and bronchial wash (BW), and a time course of serum samples, were collected from the 18 subjects who participated in the randomized, double-blinded controlled human study. The two crossover exposure triads in this study were inhaled DE and filtered air each followed by instilled allergen or saline. Serum and lung adipokine responses to these exposures were quantified using enzyme-linked immunosorbent assay. Allergen significantly increased adiponectin and leptin in BAL, and adiponectin in the BW 48 hours after exposure. Serum leptin and resistin responses were not differentially affected by exposure, but varied over time. Coexposure with DE and allergen revealed significant correlations between the adiponectin/leptin ratio and FEV1 changes and airway responsiveness measures. Changes in lung and serum adipokines in response to allergen exposure were identified in the context of a controlled exposure study. Coexposure identified a potentially protective role of adiponectin in the lung. This response was not observed in those with baseline airway hyper-responsiveness, or after allergen exposure alone. The clinical relevance of this potentially adaptive adipokine pattern warrants further study</style></abstract><notes><style face="normal" font="Arial">DA - 20161125IS - 1878-1810 (Electronic)IS - 1878-1810 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.trsl.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27886976">PM:27886976</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transl Res\20161125-KramerMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transl Res\20161125-KramerMM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161125, Kramer MM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.trsl.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ivanovic,J.</style></author><author><style face="normal" font="Arial"> Baltic,M.Z.</style></author><author><style face="normal" font="Arial"> Boskovic,M.</style></author><author><style face="normal" font="Arial"> Kilibarda,N.</style></author><author><style face="normal" font="Arial"> Dokmanovic,M.</style></author><author><style face="normal" font="Arial"> Markovic,R.</style></author><author><style face="normal" font="Arial"> Janjic,J.</style></author><author><style face="normal" font="Arial"> Baltic,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anisakis allergy in human</style></title><secondary-title><style face="normal" font="Arial">Trends Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Trends Food Sci Technol</style></full-title></periodical><pages end="29" start="25">25-29</pages><volume><style face="normal" font="Arial">59</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis allergy</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish-borne</style></keyword><keyword><style face="normal" font="Arial"> Fisheries</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food-borne parasite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Parasitic zoonoses</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Zoonoses</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><isbn><style face="normal" font="Arial">0924-2244</style></isbn><abstract><style face="normal" font="Arial">Several case reports show allergy and anaphylactic reactions to the fish parasite Anisakis in the domestic and occupational setting. Compared with other well-studied parasitic diseases, fish-borne parasitic zoonoses do not get enough attention, especially because these zoonoses have been limited for the most part to populations living in middle-income countries. Human fishery product-borne parasitic diseases caused by nematodes result in infection following ingestion of viable parasites, or as allergic reactions against parasite antigens. With the globalization of the seafood industry, the risk of humans acquiring anisakiasis in developed countries appears to be underestimated. The risk of infection with Anisakis simplex and related parasites of fish has been recognized for some time, but it is now emerging that indigestion of material from dead parasites in food also present a danger. The resulting allergic reactions range from rapid onset and potentially lethal anaphylactic reaction to chronic, debilitating conditions. This review discusses the importance of infection with Anisakis simplex and potential of allergy in human</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Serbia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tifs.2016.11.006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.tifs.2016.11.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trends Food Sci Technol\2017-59-25-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trends Food Sci Technol\2017-59-25-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161210, Ivanovic J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tifs.2016.11.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawano,T.</style></author><author><style face="normal" font="Arial"> Scheuermeyer,F.X.</style></author><author><style face="normal" font="Arial"> Gibo,K.</style></author><author><style face="normal" font="Arial"> Stenstrom,R.</style></author><author><style face="normal" font="Arial"> Rowe,B.</style></author><author><style face="normal" font="Arial"> Grafstein,E.</style></author><author><style face="normal" font="Arial"> Grunau,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Department of Emergency Medicine, St. Paul's Hospital, Vancouver, BC, Canada</style></auth-address><titles><title><style face="normal" font="Arial">H1-antihistamines reduce progression to anaphylaxis among emergency department patients with allergic reactions</style></title><secondary-title><style face="normal" font="Arial">Acad Emerg Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acad Emerg Med</style></abbr-1></periodical><pages end="741" start="733">733-741</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency medical service</style></keyword><keyword><style face="normal" font="Arial"> Emergency Medical Services</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Propensity score</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: H1-antihistamines (H1a) can be used to treat ED patients with allergic reactions; however, this is inconsistently done, likely as there is no evidence that this therapy has an impact on serious outcomes. Among emergency department (ED) patients initially presenting with allergic reactions, we investigated whether H1a were associated with lower rates of progression to anaphylaxis. METHODS: This was a retrospective cohort study conducted at two urban Canadian EDs from April 1, 2007 to March 31, 2012. We included consecutive adult patients with allergic reactions while excluding those presenting with anaphylaxis, according to pre-specified criteria. The primary outcome was the proportion of patients who subsequently developed anaphylaxis during medical care, either by emergency medical services (EMS) or in the ED. A pre-specified subgroup analysis excluded patients who received H1a prior to EMS or ED contact. We compared those who received H1a and those who did not, and used multivariable regression and propensity score adjustment techniques to compare outcomes. RESULTS: Of 2,376 overall patients included, 1,880 (79.1%) were managed with H1a. Of the latter group, 36 / 1,880 (1.9%) developed anaphylaxis, compared to 17 / 496 (3.4%) in the non-H1a-treated group (adjusted odds ratio [AOR] 0.34, 95% CI 0.17 to 0.70; number needed to treat [NNT] to benefit 44.74, 95% CI 35.36 to 99.67). In the subgroup analysis of 1,717 patients who did not receive H1a prior to EMS or ED contact, a similar association was observed (AOR 0.26, 95% CI 0.10 to 0.50; NNT to benefit 38.20, 95% CI 32.58 to 55.24). CONCLUSIONS: Among ED patient with allergic reactions, H1a administration was associated with a lower likelihood of progression to anaphylaxis. These data indicate that early H1a treatment in the ED or prehospital setting may decrease progression to anaphylaxis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1553-2712 (Electronic)IS - 1069-6563 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/acem.13147</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27976492">PM:27976492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acad Emerg Med\20161215-KawanoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acad Emerg Med\20161215-KawanoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Kawano T</style></custom2><misc3><style face="normal" font="Arial">10.1111/acem.13147</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82562</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Gennaro,L.</style></author><author><style face="normal" font="Arial"> Brunetti,N.D.</style></author><author><style face="normal" font="Arial"> Locuratolo,N.</style></author><author><style face="normal" font="Arial"> Ruggiero,M.</style></author><author><style face="normal" font="Arial"> Resta,M.</style></author><author><style face="normal" font="Arial"> Diaferia,G.</style></author><author><style face="normal" font="Arial"> Rana,M.</style></author><author><style face="normal" font="Arial"> Caldarola,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Cardiology Department , Ospedale S. Paolo , Bari , Italy</style></auth-address><titles><title><style face="normal" font="Arial">Kounis syndrome following canned tuna fish ingestion</style></title><secondary-title><style face="normal" font="Arial">Acta Clin Belg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Clin Belg</style></full-title></periodical><pages end="145" start="142">142-145</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Atherosclerosis</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Coronary spasm</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Poisoning</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histidine</style></keyword><keyword><style face="normal" font="Arial"> Histidine Decarboxylase</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> poisoning</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Scombroid food poisoning</style></keyword><keyword><style face="normal" font="Arial"> Scombroid poisoning</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Spasm</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tuna</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Kounis syndrome (KS) is a complex of cardiovascular symptoms and signs following either allergy or hypersensitivity and anaphylactic or anaphylactoid insults. We report the case of 57-year-old man, with hypertension and history of allergy, referred for facial rash and palpitations appeared after consumption of canned tuna fish. Suddenly, the patient collapsed: electrocardiogram showed ST-elevation in inferior leads. The patient was transferred from the spoke emergency room for coronary angio, which did not show any sign of coronary atherosclerosis. A transient coronary spasm was therefore hypothesized and the final diagnosis was KS. To the best of our knowledge, this is one of the first cases of KS following the ingestion of tuna fish. KS secondary to food allergy has also been reported, and shellfish ingestion has been considered as one of the most active KS inducer foods. Canned tuna fish too is well known as an allergy inducer. Tuna fish allergy should be considered, however, within the context of scombroid food poisoning, also called histamine fish poisoning. Fish with high levels of free histidine, the enzyme substrate converted to histamine by bacterial histidine decarboxylase, are those most often implicated in scombroid poisoning. Inflammatory mediators such as histamine constitute the pathophysiologic basis of Kounis hypersensitivity-associated acute coronary syndrome. Patients with coronary risk factors, allergic reaction after food ingestion, and suspected scombroid poisoning should be therefore carefully monitored for a prompt diagnosis of possible coronary complications</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 2295-3337 (Electronic)IS - 1784-3286 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/17843286.2016.1265756</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27997286">PM:27997286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Clin Belg\20161220-DeGennaroL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Clin Belg\20161220-DeGennaroL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, De Gennaro L</style></custom2><misc3><style face="normal" font="Arial">10.1080/17843286.2016.1265756</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oteros,J.</style></author><author><style face="normal" font="Arial"> Buters,J.</style></author><author><style face="normal" font="Arial"> Laven,G.</style></author><author><style face="normal" font="Arial"> Roseler,S.</style></author><author><style face="normal" font="Arial"> Wachter,R.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.</style></author><author><style face="normal" font="Arial"> Hofmann,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Errors in determining the flow rate of Hirst-type pollen traps</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="210" start="201">201-210</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Calibration</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Data quality</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen trap</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Standardisation</style></keyword><keyword><style face="normal" font="Arial"> Suction</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Standardisation of methods of pollen monitoring networks is vital for data quality. In pollen monitoring networks in Europe, the Hirst-type trap is standard. Hirst traps are calibrated with handheld rotameters. We detected a systematic error in the flow rate calibrated by these standard handheld rotameters. We measured the flow rate of 19 Hirst traps from three commercial brands during calibration but also during monitoring. We used three different rotameters supplied by the manufacturers of the traps, respectively. The actual air flow rate was measured using an electronic heat anemometer with negligible air flow resistance. After calibration to 10-ál/min, the rotameter was removed, which led to a significant increase in the flow rate in the range of 10.5</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô17.2-ál/min, a systematic error between 5 and 72%. No significant difference was found between the different commercial trap brands. The analysis revealed that the error depended on the type of the rotameter and the individual trap. The error may be explained by the additional air flow resistance of each rotameter. The total resistance of the system</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çötrap plus rotameter</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çöis higher during calibration when the rotameter is held on the inlet compared to the routine monitoring without the rotameter. Depending on the characteristic curve of the suction pump in the trap (fan), the air flow rate increases to values considerably higher than 10-ál/min. Thus, monitoring is done under a higher flow rate than that was calibrated. In order to obtain comparable data within a monitoring network, a solution for correction of this systematic error seems advisable, preferably in cooperation with the manufacturers</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9467-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9467-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161220-OterosJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161220-OterosJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Oteros J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9467-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camacho,I.C.</style></author><author><style face="normal" font="Arial"> Caeiro,E.</style></author><author><style face="normal" font="Arial"> Ferro,R.</style></author><author><style face="normal" font="Arial"> Camacho,R.</style></author><author><style face="normal" font="Arial"> Camara,R.</style></author><author><style face="normal" font="Arial"> Grinn-Gofron,A.</style></author><author><style face="normal" font="Arial"> Smith,M.</style></author><author><style face="normal" font="Arial"> Strzelczak,A.</style></author><author><style face="normal" font="Arial"> Nunes,C.</style></author><author><style face="normal" font="Arial"> Morais-Almeida,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Spatial and temporal variations in the Annual Pollen Index recorded by sites belonging to the Portuguese Aerobiology Network</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="279" start="265">265-279</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Multivariate regression tree</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen spectrum</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Urticaceae</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> Volumetric spore trap</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">This study presents the findings of a 10-year survey carried out by the Portuguese Aerobiology Network (RPA) at seven pollen-monitoring stations: five mainland stations (Oporto, Coimbra, Lisbon, +ëvora and Portim+úo) and two insular stations [Funchal (Madeira archipelago) and Ponta Delgada (Azores archipelago)]. The main aim of the study was to examine spatial and temporal variations in the Annual Pollen Index (API) with particular focus on the most frequently recorded pollen types. Pollen monitoring (2003</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2012) was carried out using Hirst-type volumetric spore traps, following the minimum recommendations proposed by the European Aerobiology Society Working Group on Quality Control. Daily pollen data were examined for similarities using the Kruskal</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôWallis nonparametric test and multivariate regression trees. Simple linear regression analysis was used to describe trends in API. The airborne pollen spectrum at RPA stations is dominated by important allergenic pollen types such as Poaceae, Olea and Urticaceae. Statistically significant differences were witnessed in the API recorded at the seven stations. Mean API is higher in the southern mainland cities, e.g. +ëvora, Lisbon and Portim+úo, and lower in insular and littoral cities. There were also a number of significant trends in API during the 10-year study. This report identifies spatial and temporal variations in the amount of airborne pollen recorded annually in the Portuguese territory. There were also a number of significant changes in API, but no general increases in the amount of airborne pollen</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Portugal -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9468-9</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9468-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20161220-CamachoIC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20161220-CamachoIC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Camacho IC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9468-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pawlowski,M.</style></author><author><style face="normal" font="Arial"> Jerzynska,J.</style></author><author><style face="normal" font="Arial"> Podlecka,D.</style></author><author><style face="normal" font="Arial"> Stelmach,W.</style></author><author><style face="normal" font="Arial"> Majak,P.</style></author><author><style face="normal" font="Arial"> Stelmach,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology and Internal Medicine in Children, Copernicus Hospital, al. Pilsudskiego 71, 90-329 Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Effectiveness of immunotherapy in children depends on place of living - A pilot study</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="275" start="272">272-275</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It is considered that farm areas protect young patients from allergy and asthma due to high exposure to endotoxins. Allergen immunotherapy (AIT) is the only treatment of allergy modifying the immune response with the potential to change the natural history of allergic diseases. It seems that studies evaluating the efficacy of immunotherapy in large cohorts of allergic patients living in farm areas are needed to understand the influence of environment on immune response during AIT. AIM: To compare the clinical effectiveness of immunotherapy between children living in farm versus urban areas. MATERIALS AND METHODS: This was a retrospective analysis of 87 children living in farm area (n=42) and city area (n=45), aged 8-16, who completed three years of subcutaneous immunotherapy due to allergic rhinitis/asthma. An AIT efficacy questionnaire has been designed to be filled in by the allergy specialist during a regular immunotherapy visit before and after AIT. RESULTS: We observed significantly higher improvement in total score among children from farm area compared to children from city area (p&lt;0.001). Between-group differences in symptoms and drug scores did not reached the level of significance. Multivariate logistic regression analysis (adjustment for the effect of gender and type of allergy) showed that living in farm areas was independently associated with significant improvement in total score after immunotherapy (OR: 10.9; 95%CI: 3.7-32.2). CONCLUSION: The current analysis of the better AIT effectiveness in the farm population has shown the protective influence of environmental exposures on asthma and allergic rhinitis in our children</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.08.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27908569">PM:27908569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161202-PawlowskiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161202-PawlowskiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Pawlowski M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.08.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Navarrete-Rodriguez,E.M.</style></author><author><style face="normal" font="Arial"> Fernandez-Soto,J.R.</style></author><author><style face="normal" font="Arial"> Del Rio-Navarro,B.E.</style></author><author><style face="normal" font="Arial"> Saucedo-Ramirez,O.J.</style></author><author><style face="normal" font="Arial"> Sienra-Monge,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergia e Inmunologia Clinica Pediatrica, Hospital Infantil de Mexico Federico Gomez, Mexico, DF, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Dermatophagoides pteronyssinus: Changes in sensitisation in the past 11 years and comparison with other centres in Mexico</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="17" start="11">11-17</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> descriptive analysis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Habitat</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mexico City</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: House dust mites are a ubiquitous air allergen in the human habitat. It has been shown that exposure to them is a fundamental factor in sensitisation and development of atopic disease. The objective of the study was to analyse changes in sensitisation to Dermatophagoides pteronyssinus (Der p.) in children treated in a tertiary level care hospital in Mexico City for a period of 11 years and compare with other studies carried out in Mexico. METHODS: A retrospective study was performed at the Hospital Infantil de Mexico Federico Gomez (HIMFG). Information was gathered from skin tests for Der p. performed in the Allergy Laboratory from January 2004 to April 2015. Patients 2-18 years old who presented for examination of some type of allergic condition and who had immediate hypersensitivity tests to Der p. were included in the study. Results were compared with prior reports from other institutions. Descriptive analysis and chi2 statistics were used. RESULTS: A total of 8794 patients were included in the study; 49.3% of the tests (95% CI 48-50) were positive for Der p. The percentage of monosensitised to mites was 2.7% for Der p. (95% CI 2-3). A significant difference was found between the results of older patients and those &lt;6 years old. The frequency of sensitisation had a tendency to decrease during the 11 years analysed in all age groups. CONCLUSIONS AND CLINICAL RELEVANCE: The frequency of sensitisation to Der p. increased with age until reaching adolescence. In the last 11 years a decrease in sensitisation to this air allergen was observed</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.09.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914830">PM:27914830</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161204-NavarreteRodriguezEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161204-NavarreteRodriguezEM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Navarrete-Rodriguez EM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.09.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82567</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guzman-Fulgencio,M.</style></author><author><style face="normal" font="Arial"> Caballero,R.</style></author><author><style face="normal" font="Arial"> Lara,B.</style></author><author><style face="normal" font="Arial"> Mena,M.</style></author><author><style face="normal" font="Arial"> Tejera,M.</style></author><author><style face="normal" font="Arial"> Sastre,A.</style></author><author><style face="normal" font="Arial"> Subiza,J.L.</style></author><author><style face="normal" font="Arial"> Fernandez-Caldas,E.</style></author><author><style face="normal" font="Arial"> Casanovas,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inmunotek S.L., Parque Tecnologico de Alcala de Henares, Calle Punto Mobi, 5, 28805 Alcala de Henares, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Safety of immunotherapy with glutaraldehyde modified allergen extracts in children and adults</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="207" start="198">198-207</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen vaccine</style></keyword><keyword><style face="normal" font="Arial"> allergen vaccines</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> aluminium hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glutaraldehyde</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modified allergen vaccines</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Glutaraldehyde-modified natural allergen extracts show significant reduction in the IgE-binding capacity and proteolytic activity. This allows the administration of higher doses in a shorter period of time, and to mix different allergen extracts. OBJECTIVE: Evaluate the safety of different concentrations and mixtures of glutaraldehyde-modified allergen extracts in a large group of paediatric and adult patients undergoing specific immunotherapy treatment. MATERIALS AND METHODS: 1855 patients (1156 adults and 699 children), suffering from rhinoconjunctivitis and/or asthma, participated in an observational multicentre cohort study, to evaluate the safety of immunotherapy using vaccines containing modified allergen extracts. Patients were monosensitised, or polysensitised, and received a therapeutic vaccine containing polymerised allergen extracts adsorbed onto aluminium hydroxide. Safety was assessed by recording all side reactions related to immunotherapy. RESULTS: The clinically relevant local reactions totalled 120, (90 immediate and 30 delayed) (1.02% of injections). Of them, 31 (0.26% of injections) occurred in children (26 immediate and 5 delayed) and 89 (0.76% of injections) in adults (64 immediate and 25 delayed). There were 38 systemic reactions. Eleven reactions were immediate (9 of grade 1 and 2 of grade 2) and 27 delayed (22 of grade 1 and 5 of grade 2). There were seven grade 2 systemic reactions (0.06% of the injections). No differences (P>0.05) in the number of reactions were observed between adults and children and between treatments were found in systemic reactions. All systemic reactions were mild and resolved spontaneously without the need of medication. CONCLUSION: Specific immunotherapy using natural modified allergen vaccines is safe to treat allergic patients, even at higher doses and in mixtures of unrelated allergen extracts. The percentage of adverse reactions detected is lower than those reported in the literature with native unmodified allergen extracts</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27939406">PM:27939406</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161212-GuzmanFulgencioM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161212-GuzmanFulgencioM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Guzman-Fulgencio M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hemmer,W.</style></author><author><style face="normal" font="Arial"> Sesztak-Greinecker,G.</style></author><author><style face="normal" font="Arial"> Wohrl,S.</style></author><author><style face="normal" font="Arial"> Wantke,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Floridsdorf Allergy Center (FAZ), Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy to millet and cross-reactivity with rice, corn and other cereals</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="492" start="490">490-492</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Millet</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.11.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27939330">PM:27939330</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20161212-HemmerW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20161212-HemmerW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Hemmer W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.11.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tabeling,C.</style></author><author><style face="normal" font="Arial"> Herbert,J.</style></author><author><style face="normal" font="Arial"> Hocke,A.C.</style></author><author><style face="normal" font="Arial"> Lamb,D.</style></author><author><style face="normal" font="Arial"> Wollin,L.</style></author><author><style face="normal" font="Arial"> Erb,K.</style></author><author><style face="normal" font="Arial"> Boiarina,E.</style></author><author><style face="normal" font="Arial"> Movassagh,H.</style></author><author><style face="normal" font="Arial"> Scheffel,J.</style></author><author><style face="normal" font="Arial"> Doehn,J.M.</style></author><author><style face="normal" font="Arial"> Hippenstiel,S.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Gounni,A.S.</style></author><author><style face="normal" font="Arial"> Kuebler,W.M.</style></author><author><style face="normal" font="Arial"> Suttorp,N.</style></author><author><style face="normal" font="Arial"> Witzenrath,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious Diseases and Pulmonary Medicine, Charite - Universitatsmedizin Berlin</style></auth-address><titles><title><style face="normal" font="Arial">Syk inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling in mice</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1072" start="1061">1061-1072</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> spleen tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Spleen tyrosine kinase (Syk) is an intracellular non-receptor tyrosine kinase, which has been implicated as central immune modulator promoting allergic airway inflammation. Syk inhibition has been proposed as a new therapeutic approach in asthma. However, the direct effects of Syk inhibition on airway constriction independent of allergen sensitization remain elusive. METHODS: Spectral confocal microscopy of human and murine lung tissue was performed to localize Syk expression. The effects of prophylactic or therapeutic Syk inhibition on allergic airway inflammation, hyperresponsiveness and airway remodeling were analyzed in allergen-sensitized and airway-challenged mice. The effects of Syk inhibitors BAY 61-3606 or BI 1002494 on airway function were investigated in isolated lungs of wild-type, PKCalpha-deficient, mast cell-deficient or eNOS-deficient mice. RESULTS: Syk expression was found in human and murine airway smooth muscle cells. Syk inhibition reduced allergic airway inflammation, airway hyperresponsiveness and pulmonary collagen deposition. In naive mice, Syk inhibition diminished airway responsiveness independently of mast cells, or PKCalpha or eNOS expression and rapidly reversed established bronchoconstriction independently of NO. Simultaneous inhibition of Syk and PKC revealed additive dilatory effects, whereas combined inhibition of Syk and rho kinase or Syk and p38 MAPK did not cause additive bronchodilation. CONCLUSIONS: Syk inhibition directly attenuates airway smooth muscle cell contraction independent of its protective immunomodulatory effects on allergic airway inflammation, hyperresponsiveness and airway remodeling. Syk mediates bronchoconstriction in a NO-independent manner, presumably via rho kinase and p38 MAPK, and Syk inhibition might present a promising therapeutic approach in chronic asthma as well as acute asthma attacks. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906453">PM:27906453</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161201-TabelingC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161201-TabelingC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Tabeling C</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13101</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Fleischer,D.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Stukus,D.</style></author><author><style face="normal" font="Arial"> Gupta,R.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Allergy, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO</style></auth-address><titles><title><style face="normal" font="Arial">LEAPing Through the Looking Glass: Secondary Analysis of the Effect of Skin Test Size and Age of Introduction on Peanut Tolerance after Early Peanut Introduction</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1260" start="1254">1254-1260</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Glass</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In the Learning Early About Peanut Allergy (LEAP) study, early peanut introduction in high-risk 4-11 month olds was associated with a significantly decreased risk of developing peanut allergy. However, the influences of key baseline high-risk factors on peanut tolerance are poorly understood. METHODS: Secondary analysis was conducted on the publically available LEAP dataset, exploring relationships between peanut tolerance, baseline peanut/egg sensitization, eczema severity/duration, age of introduction, gender, and race. RESULTS: A multiple logistic regression model predicting odds of successful oral food challenge (OFC) at 60 months noted higher odds with early introduction (OR 9.2, P&lt;0.001, 95%CI 4.2-20.3), white race (OR 2.1, p=0.04, 95%CI 1.1-3.9), and advancing age (OR 4.8, P=0.04, 95%CI 1.1-20.8). Odds of peanut tolerance were lower with increasing peanut wheal size (OR 0.58, P&lt;0.001, 95%CI 0.46-0.74), increased baseline SCORAD score (OR 0.98, p=0.04, 95%CI 0.97-1), and increased kUA /L of egg serum IgE (sIgE) (OR 0.99, p=0.04, 95%CI 0.98-1). The probability of peanut tolerance in the early introduction group was 83% vs. 43% in the avoidance group with SPT wheal of less than 4mm. The probability of a successful OFC was significantly higher with peanut introduction between 6-11 months than at 4-6 months. Increasing eczema severity had limited impact on the probability of peanut tolerance in the early introduction arm. CONCLUSION: Increasing peanut wheal size predicted peanut tolerance only in the avoidance arm. Peanut introduction between 6-11 months of age was associated with the highest rates of peanut tolerance, questioning the "urgency" of introduction before 6 months. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13100</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27896827">PM:27896827</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161129-GreenhawtM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161129-GreenhawtM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Greenhawt M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13100</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jeong,K.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Ahn,K.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Lee,H.R.</style></author><author><style face="normal" font="Arial"> Suh,D.I.</style></author><author><style face="normal" font="Arial"> Pyun,B.Y.</style></author><author><style face="normal" font="Arial"> Min,T.K.</style></author><author><style face="normal" font="Arial"> Kwon,J.W.</style></author><author><style face="normal" font="Arial"> Kim,K.E.</style></author><author><style face="normal" font="Arial"> Kim,K.W.</style></author><author><style face="normal" font="Arial"> Sohn,M.H.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Song,T.W.</style></author><author><style face="normal" font="Arial"> Kwon,J.H.</style></author><author><style face="normal" font="Arial"> Jeon,Y.H.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Ahn,Y.M.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Ajou University School of Medicine, Suwon</style></auth-address><titles><title><style face="normal" font="Arial">A Multi-Center Study on Anaphylaxis caused by Peanut, Tree Nuts and Seeds in Children and Adolescents</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="513" start="507">507-513</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Korean children</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> pine nut</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Peanut (PN) and tree nuts (TNs) are common causes of anaphylaxis in Western countries but no information is available in Korea. To feature clinical characteristics of anaphylaxis caused by PN, TNs, and seeds, a retrospective medical record review was performed in 14 university hospitals in Korea (2009-2013).One hundred and twenty-six cases were identified, with the mean age of 4.9 years. PN, walnut (WN), and pine nut accounted for 32.5%, 41.3%, and 7.1%, respectively. The median values of specific IgE (sIgE) to PN, WN and pine nut were 10.50 kUA/L, 8.74 kUA/Land 4.61 kUA/L, respectively. Among 50 cases managed in the emergency department, 52.0% were treated with epinephrine, 66.0% with steroid, 94.0% with antihistamines, 36.0% with oxygen, and 48.0% with bronchodilator. In conclusion, WN, PN and pine nut were the 3 most common triggers of anaphylaxis in Korean children and anaphylaxis could occur at remarkably low levels of sIgE. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13096</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27892597">PM:27892597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161128-JeongK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161128-JeongK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Jeong K</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13096</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McNamee,E.N.</style></author><author><style face="normal" font="Arial"> Biette,K.A.</style></author><author><style face="normal" font="Arial"> Hammer,J.</style></author><author><style face="normal" font="Arial"> Harris,R.</style></author><author><style face="normal" font="Arial"> Miyazawa,H.</style></author><author><style face="normal" font="Arial"> Lee,J.J.</style></author><author><style face="normal" font="Arial"> Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Masterson,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Gastrointestinal Eosinophilic Diseases Program, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine, Aurora, CO, USA</style></auth-address><titles><title><style face="normal" font="Arial">Targeting GM-CSF in epithelial and vascular remodeling in experimental Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1242" start="1232">1232-1242</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> tissue remodeling</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> vascular remodeling</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic antigen-mediated clinicopathologic disease of the esophagus characterized by an eosinophil-predominant inflammatory infiltrate. A clinical hallmark is extensive tissue remodeling including basal zone hyperplasia, fibrosis and angiogenesis. However, the cellular mechanisms responsible for these processes are not fully defined. We hypothesized that targeting GM-CSF (an agonist cytokine linked with eosinophil survival and activation) would be protective in a pre-clinical model of EoE. METHODS: EoE-like esophageal inflammation was induced in the L2-IL5OXA EoE mouse model and GM-CSF production was assessed by mRNA and protein analyses. GM-CSF-receptor-alpha expression patterns were examined by flow cytometric and immunofluorescence analysis. L2-IL5OXA EoE mice were treated with anti-GM-CSF neutralizing antibody or isotype control and assessed for histopathological indices of eosinophilia, epithelial hyperplasia and angiogenesis by immunohistochemistry and RT-PCR. RESULTS: Significantly increased levels of esophageal GM-CSF expression was detected in the L2-IL5OXA mouse EoE model during active inflammation. GM-CSF-receptor-alpha was predominantly expressed on esophageal eosinophils during EoE, in addition to select cells within the lamina propria. Anti-GM-CSF neutralization in L2-IL5OXA EoE mice resulted in a significant diminution of epithelial eosinophilia in addition to basal cell hyperplasia and vascular remodeling. This treatment response was independent of effects on esophageal eosinophil maturation or activation. CONCLUSION: GM-CSF is a potential therapeutic target to reduce esophageal eosinophilia and remodeling. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13105</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27926989">PM:27926989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161207-McNameeEN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161207-McNameeEN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, McNamee EN</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13105</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Di Bona,D.</style></author><author><style face="normal" font="Arial"> Plaia,A.</style></author><author><style face="normal" font="Arial"> Leto-Barone,M.S.</style></author><author><style face="normal" font="Arial"> La Piana,S.</style></author><author><style face="normal" font="Arial"> Macchia,L.</style></author><author><style face="normal" font="Arial"> Di Lorenzo,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Scuola e Cattedra di Allergologia e Immunologia Clinica, Dipartimento dell'Emergenza e dei Trapianti d'Organo (D.E.T.O.), Universita di Bari "Aldo Moro", Italy</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="704" start="691">691-704</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Guidelines and position papers indicate that allergen immunotherapy (AIT) is the only disease-modifying treatment, including prevention of the onset of new allergen sensitizations. However, this preventive effect was shown by only a few observational studies. Our aim was to systematically review the efficacy of AIT in preventing the onset of new allergen sensitizations. METHODS: Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (through June 2015) were supplemented with manual searches of reference lists. Observational studies or randomized controlled trials with a long-term observation period were included. Paired reviewers extracted data about study characteristics and assessed biases. The end-point was the risk difference in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. The strength of the evidence was graded based on the risk of bias, consistency, and magnitude of effect, according to the GRADE Working Group's guide. RESULTS: Eighteen studies (1,049 children, 10,057 adults) met the inclusion criteria. The risk of bias was high in all but one study. Low evidence supports the position that AIT prevents the onset of new allergen sensitizations, with 10 out of 18 studies reporting a reduction of the onset of new sensitizations in patients treated with AIT vs. placebo. Small studies and studies with a shorter follow-up showed the highest benefit of AIT. CONCLUSIONS: The overall evidence provides a low-grade level of the evidence supporting the efficacy of AIT in preventing the onset of new allergen sensitizations, but high-quality studies could change this estimate. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13104</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27926981">PM:27926981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161207-DiBona.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161207-DiBona.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Di Bona D</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13104</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thacher,J.D.</style></author><author><style face="normal" font="Arial"> Gruzieva,O.</style></author><author><style face="normal" font="Arial"> Pershagen,G.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Lorentzen,J.C.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Bergstrom,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Mold and dampness exposure and allergic outcomes from birth to adolescence: data from the BAMSE cohort</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="974" start="967">967-974</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BAMSE</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> dampness</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> Indoor environments</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exposure to moldy or damp indoor environments is associated with allergic disease in young children, but it is unclear if the effects persist to adolescence. Our objective was to assess if exposure to mold or dampness during infancy increases the risk of asthma, rhinitis, or IgE sensitization in children followed from birth to 16 years of age. METHODS: We collected questionnaire derived reports of mold or dampness indicators and allergic outcomes from 3798 children in a Swedish birth cohort (BAMSE). Sensitization was assessed from blood samples in 3293 children. Longitudinal associations between prevalent asthma, rhinitis, and IgE sensitization and mold or dampness indicators were assessed using generalized estimating equations. RESULTS: Exposure to any mold or dampness indicator was associated with asthma up to age 16 years (OR 1.31; 95%CI 1.08-1.59), while exposure to mold odor (OR 1.29; 95%CI 1.03-1.62) and visible mold (OR 1.28; 95%CI 1.04-1.58) were associated with rhinitis. Increased risks were observed for non-allergic asthma (OR 1.80; 95%CI 1.27-2.55) and rhinitis (OR 1.41; 95%CI 1.03-1.93). No association was observed between mold or dampness indicators and IgE sensitization. Exposure to any mold or dampness indicator was associated with persistent asthma (OR 1.73; 95%CI 1.20-2.50), but not with early-transient, or late-onset asthma. CONCLUSION: Exposure to mold or dampness during infancy increased the risk of asthma and rhinitis to age 16 years, particularly for non-allergic disease. Early exposure to mold or dampness appeared particularly associated with persistent asthma through adolescence. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13102</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27925656">PM:27925656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161207-ThacherJD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161207-ThacherJD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Thacher JD</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13102</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wylon,K.</style></author><author><style face="normal" font="Arial"> Dolle,S.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Dermatologie, Venerologie und Allergologie, Charite Universitatsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Polyethylene glycol as a cause of anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="67">67-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cosmetics</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glycols</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Macrogol</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene glycol</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene Glycols</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Polyethylene glycols (PEGs) or macrogols are polyether compounds and are widely used as additives in pharmaceuticals, cosmetics, and food. CASE REPORT: We report on a Caucasian patient experiencing recurrent severe allergic reactions to several drugs. An extensive diagnostic workup including skin prick tests, intradermal tests (IDT) and a double-blind oral challenge was performed to identify the trigger of anaphylaxis. In the present case hypersensitivity to the additive polyethylene glycol was confirmed by an IDT suggesting an Immunoglobulin E-dependent mechanism as a cause of the reaction. CONCLUSION: Potential life-threatening hypersensitivity reactions to hidden molecules like macrogol may be underdiagnosed. Cases of immediate-type PEG hypersensitivity were reported with increasing frequency. The awareness regarding the allergenic potential of PEG should be raised and a proper product labelling is crucial to prevent PEG mediated hypersensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0172-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27999603">PM:27999603</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Wylon K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0172-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Voisin,M.R.</style></author><author><style face="normal" font="Arial"> Borici-Mazi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, ON K7L 3N6 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis to supplemental oral lactase enzyme</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="66">66-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus niger</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cetirizine</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diphenhydramine</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Lactase</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lactose Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylactic reactions involving IgE mediated hypersensitivity have been frequently reported for a number of uncommon foods. However, cases of anaphylaxis to over the counter vitamins and oral supplements have been rarely published. Lactose intolerance affects approximately 20% of Canadians and roughly 70% of the world's population of any age. Lactose intolerance develops primarily due to the absence of the enzyme lactase and treatment involves avoidance of lactose-containing foods or ingestion of commercially available lactase enzyme preparations prior to their consumption. This case report represents the first documented evidence of anaphylaxis after exposure to supplemental lactase enzyme preparation. CASE PRESENTATION: A 38 years old Caucasian female presented with a history of self-diagnosed adult-onset lactose intolerance and a suspected allergy to lactase containing tablets. She reported an episode of bilateral orbital swelling, shortness of breath, and throat constriction after oral ingestion of a supplemental lactase enzyme tablet. Her symptoms slowly resolved with the administration of inhaled salbutamol and oral diphenhydramine. She handled lactase tablets for years to her children who were lactose intolerant, but had never ingested the tablets herself prior to the reported episode. In clinic, physical examination was benign, and skin prick testing to a slurry of the lactase tablet revealed a strongly positive reaction wheal size of 10 mm and flare of 60 mm with normal controls. The patient reported throat tightness and constriction after skin prick testing and required cetirizine treatment and observation in clinic. Subsequent skin testing was performed with individual ingredients of the lactase tablet provided by the manufacturer and Aspergillus niger, a common bacteria used in lactase preparations. Only concentrated lactase enzyme elicited a positive response. The patient was diagnosed with lactase tablet induced anaphylaxis due to synthetic lactase enzyme IgE mediated allergy, and was advised to avoid all products containing lactase enzymes as an ingredient and to carry an epinephrine auto-injector. CONCLUSION: This is the first documented case report of an anaphylactic reaction to supplemental lactase enzyme. This case report reinforces the importance of thorough allergy assessment, education on avoidance of triggers, in particular with uncommon allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0172-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27999602">PM:27999602</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Voisin MR</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0172-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dogra,V.</style></author><author><style face="normal" font="Arial"> Sinha,A.K.</style></author><author><style face="normal" font="Arial"> Saxena,R.</style></author><author><style face="normal" font="Arial"> Talwar,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Rajiv Gandhi Superspeciality Hospital, Tahirpur, Delhi, 110093 India</style></auth-address><titles><title><style face="normal" font="Arial">Aspergillus march: from ABPA to aspergilloma to subacute invasive aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="64">64-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Vessels</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Hemoptysis</style></keyword><keyword><style face="normal" font="Arial"> Hyphae</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Thorax</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Aspergillus is a ubiquitous fungus responsible for allergic as well as saprophytic and invasive manifestations depending on host's immune status. The following case report demonstrates progression of allergic manifestations of Aspergillus to its invasive form in an individual with decreasing immunity. This can lead to uncertainties in diagnosis and management. CASE PRESENTATION: A 28-year-old male, non smoker, known case of ABPA (allergic bronchopulmonary aspergillosis) was admitted with complaints of cough for 1 month, associated with recurrent episodes of hemoptysis for last 5 days. CT Thorax revealed homogenous dense round opacity in right upper lobe which replaced previous fibrocalcific bronchiectatic lesion with cavity and aspergilloma, bulging across the major fissure with fibrotic strands extending to periphery in all directions. Post-pneumonectomy microscopic examination revealed Aspergillus hyphae invading blood vessels. CONCLUSION: There is a need for close clinical and radiologic follow up of patients with Aspergillus and our patient demonstrated overlap of complete spectrum of Aspergillus disease with march from one end to the other end</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0170-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27980539">PM:27980539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Dogra V</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0170-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ukleja-Sokolowska,N.</style></author><author><style face="normal" font="Arial"> Gawronska-Ukleja,E.</style></author><author><style face="normal" font="Arial"> Zbikowska-Gotz,M.</style></author><author><style face="normal" font="Arial"> Socha,E.</style></author><author><style face="normal" font="Arial"> Lis,K.</style></author><author><style face="normal" font="Arial"> Sokolowski,L.</style></author><author><style face="normal" font="Arial"> Kuzminski,A.</style></author><author><style face="normal" font="Arial"> Bartuzi,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, Ludwik Rydygier Collegium Medicum in Bydgoszcz, NCU, ul. Ujejskiego 75, 85-168 Bydgoszcz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of feline and canine allergen components in patients sensitized to pets</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="61">61-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> allergen diagnosis</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Can f 1</style></keyword><keyword><style face="normal" font="Arial"> Can f 2</style></keyword><keyword><style face="normal" font="Arial"> Can f 3</style></keyword><keyword><style face="normal" font="Arial"> Can f 5</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Fel d 2</style></keyword><keyword><style face="normal" font="Arial"> Fel d 4</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Component resolved allergen diagnosis allows for a precise evaluation of the sensitization profiles of patients sensitized to felines and canines. An accurate interpretation of these results allows better insight into the evolution of a given patients sensitizations, and allows for a more precise evaluation of their prognoses. METHODS: 70 patients (42 women and 28 men, aged 18-65, with the average of 35.5) with a positive feline or canine allergy diagnosis were included in the research group. 30 patients with a negative allergy diagnosis were included in the control group. The total IgE levels of all patients with allergies as well as their allergen-specific IgE to feline and canine allergens were measured. Specific IgE levels to canine (Can f 1, Can f 2, Can f 3, Can f 5) and feline (Fel d 1, Fel d 2, Fel d 4) allergen components were also measured with the use of the ImmunoCap method. RESULTS: Monosensitization for only one canine or feline component was found in 30% of patients. As predicted, the main feline allergen was Fel d 1, which sensitized as many as 93.9% of patients sensitized to felines. Among 65 patients sensitized to at least one feline component, for 30 patients (46.2%) the only sensitizing feline component was Fel d 1. Only 19 patients in that group (63.3%) were not simultaneously sensitized to dogs and 11 (36.7%), the isolated sensitization to feline Fel d 1 notwithstanding, displayed concurrent sensitizations to one of the canine allergen components. Fel d 4 sensitized 49.2% of the research group.64.3% of patients sensitized to canine components had heightened levels of specific IgE to Can f 1. Monosensitization in that group occurred for 32.1% of the patients. Sensitization to Can f 5 was observed among 52.4% of the patients. CONCLUSIONS: Concurrent sensitizations to a few allergic components, not only cross-reactive but also originating in different protein families, are a significant problem for patients sensitized to animals</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0167-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27956908">PM:27956908</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2016-12-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Ukleja-Sokolowska N</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0167-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,W.J.</style></author><author><style face="normal" font="Arial"> Kim,D.H.</style></author><author><style face="normal" font="Arial"> Woo,S.H.</style></author><author><style face="normal" font="Arial"> Seol,S.H.</style></author><author><style face="normal" font="Arial"> Choi,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="Arial">Targeted temperature management after cardiac arrest with anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Emerg Med</style></full-title></periodical><pages end="" start="807">807-</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cardiopulmonary Resuscitation</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Pupil</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Resuscitation</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Fatal anaphylaxis is uncommon but not rare. Extrapolated mortality rates are 0.52% of total anaphylaxis patients Bock et al. (Jan. 2001) [1]. Nevertheless, compared with the incidence of the other cardiac arrest events, the incidence of cardiac arrest due to anaphylaxis is relatively small. As a result, the effect using targeted temperature management after anaphylaxis is not clearly understood. We report the case of a 63-year-old man who developed cardiac arrest after ingestion of two pieces of peach. He was resuscitated and his circulation returned spontaneously after approximately 11min of cardiopulmonary resuscitation, but he was unresponsive and had fixed dilated pupils. We initiated therapeutic hypothermia on the basis of protocol for 24h. The patient was gradually and successfully cooled and rewarmed. The patient opened his eyes spontaneously on day 5, obeyed commands on day 6, and was discharged on day 18. At the time of discharge, he had no neurologic deficiencies or other complications</style></abstract><notes><style face="normal" font="Arial">DA - 20161218IS - 1532-8171 (Electronic)IS - 0735-6757 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ajem.2016.12.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27988254">PM:27988254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Emerg Med\20161218-LeeWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Emerg Med\20161218-LeeWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161218, Lee WJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ajem.2016.12.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kantor,D.B.</style></author><author><style face="normal" font="Arial"> McDonald,M.C.</style></author><author><style face="normal" font="Arial"> Stenquist,N.</style></author><author><style face="normal" font="Arial"> Schultz,B.J.</style></author><author><style face="normal" font="Arial"> Smallwood,C.D.</style></author><author><style face="normal" font="Arial"> Nelson,K.A.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author><author><style face="normal" font="Arial"> Hirschhorn,J.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Boston Children's Hospital Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="1555" start="1552">1552-1555</pages><volume><style face="normal" font="Arial">194</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201606-1145LE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27976938">PM:27976938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2016-194-1552-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2016-194-1552-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Kantor DB</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201606-1145LE</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hrabovsky,M.</style></author><author><style face="normal" font="Arial"> Scevkova,J.</style></author><author><style face="normal" font="Arial"> Micieta,K.</style></author><author><style face="normal" font="Arial"> Laffersova,J.</style></author><author><style face="normal" font="Arial"> Dusicka,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Botany, Faculty of Natural Sciences, Comenius University, Bratislava, SlovakiaDepartment of Botany, Faculty of Natural Sciences, Comenius University, Bratislava, SlovakiaDepartment of Botany, Faculty of Natural Sciences, Comenius University, Bratislava, SlovakiaDepartment of Environmental Biology, Public Health Office, Banska Bystrica, SlovakiaDepartment of Botany, Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia</style></auth-address><titles><title><style face="normal" font="Arial">Expansion and aerobiology of Ambrosia artemisiifolia L. in Slovakia</style></title><secondary-title><style face="normal" font="Arial">Ann Agric Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Agric Environ Med</style></full-title></periodical><pages end="70" start="64">64-70</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiological sampling</style></keyword><keyword><style face="normal" font="Arial"> Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen count</style></keyword><keyword><style face="normal" font="Arial"> Alien species</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antigens,Plant</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Introduced Species</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive Alien Species</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Dispersal</style></keyword><keyword><style face="normal" font="Arial"> Plant Extracts</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Slovakia</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION AND OBJECTIVE: The invasive alien species Ambrosia artemisiifolia cause environmental, agronomical and medical problems in many regions of the world, including Slovakia. The purpose of this study was to survey the spread and distribution of this species in Slovakia and to analyse its airborne pollen pattern. MATERIALS AND METHODS: To evaluate the spatiotemporal dynamics of Ambrosia invasion in the territory of Slovakia, herbarium specimens, published databases and field investigations were considered. Aerobiological sampling was based on the analysis of pollen records at five aerobiological stations in Slovakia. For Bratislava and Banska Bystrica Monitoring stations, trends in Ambrosia pollen seasons were determined using Mann-Kendall test and Sen's slope estimator. RESULTS: Since the first record of A. artemisiifolia in Slovakia, the number of its colonies and its spread rate has increased considerably, and the colonisation of this species has been successful mainly in the south-western part of the country. Highest airborne pollen counts were recorded in Nitra, Trnava and Bratislava Monitoring Stations situated in the areas most infested by A. artemisiifolia in Slovakia. However, high pollen counts were also noted in Banska Bystrica and Kosice Monitoring Stations situated in areas where the source species was less abundant. During the study period, the number of days on which the pollen concentration exceeded the threshold of sensitivity increased significantly (+1.33 days/year) in Banska Bystrica, whereas the peak value decreased significantly (-13.37 pollen/year) in Bratislava. CONCLUSION: The number of the populations of A. artemisiifolia has increased considerably in recent years. Besides the most infested areas, high airborne pollen counts were also recorded in territories where the plant species was less abundant. During the study period, the intensity of Ambrosia pollen seasons decreased in Bratislava, probably due to changes in land-use practices, while the increasing trend in the pollen seasons intensity in Banska Bystrica mainly reflects the situation in the ragweed-infested remote areas due to long-range pollen transport</style></abstract><notes><style face="normal" font="Arial">DA - 20160324IS - 1898-2263 (Electronic)IS - 1232-1966 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Allergens)RN - 0 (Antigens, Plant)RN - 0 (Plant Extracts)RN - 0 (ragweed pollen)SB - IMCO - Slovakia -</style></notes><work-type><style face="normal" font="Arial">10.5604/12321966.1196854</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27007519">PM:27007519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Agric Environ Med\2016-23-64-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Agric Environ Med\2016-23-64-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160324, Hrabovsky M</style></custom2><misc3><style face="normal" font="Arial">10.5604/12321966.1196854</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harvey,A.</style></author><author><style face="normal" font="Arial"> Kaufman,K.</style></author><author><style face="normal" font="Arial"> Daily,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Naval Medical Center San Diego, San Diego, California.</style></auth-address><titles><title><style face="normal" font="Arial">Chronic autoimmune urticaria as the presenting manifestation of primary hyperparathyroidism</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="725" start="724">724-725</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune urticaria</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.436</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27979029">PM:27979029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-724-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-724-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Harvey A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.436</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82584</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,S.</style></author><author><style face="normal" font="Arial"> Bashore,C.</style></author><author><style face="normal" font="Arial"> Lohse,C.M.</style></author><author><style face="normal" font="Arial"> Bellolio,M.F.</style></author><author><style face="normal" font="Arial"> Chamberlain,A.</style></author><author><style face="normal" font="Arial"> Yuki,K.</style></author><author><style face="normal" font="Arial"> Hess,E.P.</style></author><author><style face="normal" font="Arial"> Campbell,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota</style></auth-address><titles><title><style face="normal" font="Arial">Rate of recurrent anaphylaxis and associated risk factors among Olmsted County, Minnesota, residents: A population-based study</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="660" start="655">655-660</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Rochester Epidemiology Project</style></keyword><keyword><style face="normal" font="Arial"> self-injectable</style></keyword><keyword><style face="normal" font="Arial"> self-injectable epinephrine</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The rate and risk factors for recurrence of anaphylaxis are not well known. OBJECTIVE: To measure the rate and risk factors for recurrent anaphylaxis in a population-based cohort in Olmsted County, Minnesota. METHODS: We conducted a population-based cohort study using the Rochester Epidemiology Project, a comprehensive medical records linkage system, to obtain records of patients who presented to medical centers within the Olmsted County area with anaphylaxis from January 1, 2001, through December 31, 2010. We evaluated the rate and associations of risk factors with anaphylaxis recurrence. RESULTS: Among the 611 patients with anaphylaxis, 50 (8%) experienced a total of 60 recurrences within the 10-year period, resulting in a recurrence rate of 2.6 per 100 person-years. A history of atopic dermatitis (hazard ratio [HR], 5.6; 95% confidence interval [CI], 2.0-16.1; P = .001), presenting symptoms of cough (HR, 4.7; 95% CI, 2.1-10.7; P &lt; .001) oral pruritus (HR, 9.9; 95% CI, 4.3-23.2; P &lt; .001), and receiving corticosteroids (HR, 5.2; 95% CI, 2.3-11.7; P &lt; .001) were associated with an increased risk of recurrence. The cardiovascular symptom of chest pain (HR, 0.24; 95% CI, 0.07-0.79; P = .02) was associated with a decreased risk of recurrence. CONCLUSION: In this epidemiologic study, the rate of recurrence was 8% during the 10-year study period (recurrence rate of 2.6 per 100 person-years). Those with atopic dermatitis and mucocutaneous or respiratory symptoms were more likely to have a recurrent anaphylactic event. Our findings underscore the importance of early patient access to self-injectable epinephrine and referral to an allergist/immunologist for additional testing and education</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.444</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27979023">PM:27979023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-655-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-655-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Lee S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.444</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zieglmayer,P.</style></author><author><style face="normal" font="Arial"> Nolte,H.</style></author><author><style face="normal" font="Arial"> Nelson,H.S.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> Kaur,A.</style></author><author><style face="normal" font="Arial"> Jacobi,H.</style></author><author><style face="normal" font="Arial"> Lemell,P.</style></author><author><style face="normal" font="Arial"> Schmutz,R.</style></author><author><style face="normal" font="Arial"> Zieglmayer,R.</style></author><author><style face="normal" font="Arial"> Horak,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Vienna Challenge Chamber, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="696" start="690">690-696</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> environmental exposure chamber</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ocular symptoms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Treatment with SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is effective for HDM respiratory allergic disease, but data on long-term effects are lacking. OBJECTIVE: Post hoc analyses were conducted to determine the long-term effect of SQ HDM SLIT-tablet on nasal, ocular, and cough symptoms 1 year after discontinuation of treatment. METHODS: Study participants underwent environmental exposure chamber (EEC) challenges at baseline and week 24 in a randomized, placebo-controlled, double-blind trial (NCT01644617) during which participants received daily 12 SQ-HDM, 6 SQ-HDM, or placebo for 24 weeks. Asthma had to be stable, well controlled, and nonsevere. The mean total asthma symptom score (TASS; sum of 3 symptoms: cough, wheeze, and dyspnea) during baseline and week 24 EEC challenge was analyzed in all participants who completed the trial (n = 106). Approximately 1 year after trial completion, another EEC challenge was conducted in a subset of participants (n = 51). Total nasal symptom score (sum of 4 symptoms), total ocular symptom score (sum of 2 symptoms), and cough were assessed. RESULTS: Compared with baseline and end-of-treatment values, sustained improvement of all symptoms assessed at the 1-year follow-up EEC challenge was evident in participants treated with 12 SQ-HDM. Results with 6 SQ-HDM were less notable. After 24 weeks of 12 SQ-HDM, TASS during EEC challenge was improved 65% vs baseline; at 1-year follow-up, cough was improved 57% vs baseline. CONCLUSION: Persistent improvement of nasal and ocular symptoms was observed up to 1 year after completing 24 weeks of 12 SQ-HDM treatment. Beneficial effects on cough were also observed. TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT01644617</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27979028">PM:27979028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-690-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-690-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Zieglmayer P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Visitsunthorn,N.</style></author><author><style face="normal" font="Arial"> Chatpornvorarux,S.</style></author><author><style face="normal" font="Arial"> Pacharn,P.</style></author><author><style face="normal" font="Arial"> Jirapongsananuruk,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Faculty of Medicine, Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="Arial">Atopy patch test in children with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="673" start="668">668-673</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch test</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch tests</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Informed Consent</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis is frequently associated with food and/or aeroallergen allergy. OBJECTIVE: To evaluate atopy patch tests (APTs) and skin prick tests (SPTs) in children with atopic dermatitis, using allergen extracts from locally lyophilized foods (cow's milk, egg white, egg yolk, wheat, soy, and shrimp), Dermatophagoides pteronyssinus, Dermatophagoides farinae, and American cockroach. METHODS: This study was a prospective, self-controlled study in children with atopic dermatitis. APTs, SPTs, and oral food challenge tests were performed in the cases with written informed consent. RESULTS: Fifty-six children with atopic dermatitis were enrolled. According to the Severity Scoring of Atopic Dermatitis Index, moderate atopic dermatitis was the most common severity (49.1%) followed by mild (20%) and severe atopic dermatitis (13.2%). APT results were positive for food allergens in 49% of participants; SPT results were positive in 54.7%. The sensitivity, specificity, positive predictive value, and negative predictive value of APTs for foods were 40%, 90.2%, 65.2%, and 76.6%, respectively. For SPTs, those values were 40%, 93.9%, 75%, and 77.3%, respectively. APT results for D farinae, D pteronyssinus, and American cockroach were positive in 33.9%, 35.8%, and 21.8% of participants, respectively. SPT results for these allergens were positive in 28.3%, 24.5%, and 9.4% of participants, respectively. No serious complications occurred. CONCLUSION: APTs with locally prepared lyophilized allergen extracts were safe and had high specificity, median positive predictive value, and low sensitivity for evaluation of suspected food allergy in children with atopic dermatitis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01164293</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.446</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27979025">PM:27979025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-668-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-668-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Visitsunthorn N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.446</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oseroff,C.</style></author><author><style face="normal" font="Arial"> Pham,J.</style></author><author><style face="normal" font="Arial"> Frazier,A.</style></author><author><style face="normal" font="Arial"> Hinz,D.</style></author><author><style face="normal" font="Arial"> Sidney,J.</style></author><author><style face="normal" font="Arial"> Paul,S.</style></author><author><style face="normal" font="Arial"> Greenbaum,J.A.</style></author><author><style face="normal" font="Arial"> Vita,R.</style></author><author><style face="normal" font="Arial"> Peters,B.</style></author><author><style face="normal" font="Arial"> Schulten,V.</style></author><author><style face="normal" font="Arial"> Sette,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">La Jolla Institute for Allergy and Immunology, La Jolla, California</style></auth-address><titles><title><style face="normal" font="Arial">Immunodominance in allergic T-cell reactivity to Japanese cedar in different geographic cohorts</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="689" start="680">680-689</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cry j 1</style></keyword><keyword><style face="normal" font="Arial"> Cry j 2</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISpot</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollen-specific</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T cell reactivity</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Japanese cedar (JC) pollen is a common trigger for allergic rhinitis in Japan. Pollen proteins targeted by IgE, including Cry j 1 and Cry j 2, and isoflavone reductase (IFR) have been identified. OBJECTIVE: To compare antigen-specific IgE titers and T-cell responses to JC pollen-derived extract and peptides in cohorts with high and low pollen exposure. METHODS: Peripheral blood mononuclear cells from JC pollen allergic or nonallergic patients who have lived in Japan for at least 1 year and JC pollen allergic patients who have never been to Japan were tested for T-cell responses against JC pollen extract and peptide pools derived from Cry j 1, Cry j 2, or IFR. T-cell reactivity was assessed by interleukin 5 and interferon gamma production by ELISPOT. RESULTS: JC pollen-specific T-cell reactivity and IgE titers were significantly higher in the allergic compared with the nonallergic Japanese cohort, which was also associated with different patterns of polysensitization. Interestingly, a significant overlap was observed in the hierarchy of the T-cell epitopes in the allergic Japanese cohort compared with the allergic non-Japanese cohort. In all 3 cohorts, T-cell reactivity was dominantly directed against peptides from the major allergens Cry j 1 and 2, with few T-cell responses detected against IFR. CONCLUSION: Our studies identify common denominators of T-cell reactivity in patient populations with different sensitization patterns, suggesting that generally applicable immunotherapeutic approaches might be developed irrespective of exposure modality</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.014.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27979027">PM:27979027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-680-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-680-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Oseroff C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.014.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gunel,C.</style></author><author><style face="normal" font="Arial"> Demirci,B.</style></author><author><style face="normal" font="Arial"> Eryilmaz,A.</style></author><author><style face="normal" font="Arial"> Yilmaz,M.</style></author><author><style face="normal" font="Arial"> Meteoglu,I.</style></author><author><style face="normal" font="Arial"> Omurlu,I.K.</style></author><author><style face="normal" font="Arial"> Basal,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology Head and Neck Surgery, Adnan Menderes University School of Medicine, Aydin, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Inhibitory Effect of Pycnogenol(R) on Airway Inflammation in Ovalbumin-Induced Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Balkan Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Balkan Med J</style></full-title></periodical><pages end="626" start="620">620-626</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The supplement Pycnogenol(R) (PYC) has been used for the treatment of several chronic diseases including allergic rhinitis (AR). However, the in vivo effects on allergic inflammation have not been identified to date. AIMS: To investigate the treatment results of PYC on allergic inflammation in a rat model of allergic rhinitis. STUDY DESIGN: Animal experimentation. METHODS: Allergic rhinitis was stimulated in 42 rats by intraperitoneal sensitization and intranasal challenge with Ovalbumin. The animals were divided into six subgroups: healthy controls, AR group, AR group treated with corticosteroid (dexamethasone 1 mg/kg; CS+AR), healthy rats group that were given only PYC of 10 mg/kg (PYC10), AR group treated with PYC of 3mg/kg (PYC3+AR), and AR group treated with PYC of 10 mg/kg (PYC10+AR). Interferon-gamma (IFN-gamma), interleukin-4 (IL-4), interleukin-10 (IL-10), and OVA-specific immunoglobulin E (Ig-E) levels of serum were measured. Histopathological changes in nasal mucosa and expression of tumor necrosis factor-alpha (TNF-alpha) and IL-1beta were evaluated. RESULTS: The levels of the IL-4 were significantly decreased in the PYC3+AR, PYC10+AR and CS+AR groups compared with the AR group (p=0.002, p&lt;0.001, p=0.006). The production of the IFN-gamma was significantly decreased in the PYC3+AR and PYC10+AR groups compared with the AR group (p=0.013, p=0.001). The administration of PYC to allergic rats suppressed the elevated IL-10 production, especially in the PYC3+AR group (p=0.006). Mucosal edema was significantly decreased respectively after treatment at dose 3 mg/kg and 10 mg/kg PYC (both, p&lt;0.001). The mucosal expression of TNF-alpha has significantly decreased in the PYC3+AR and PYC10+AR groups (p=0.005, p&lt;0.001), while the IL-1beta expression significantly decreased in the CS+AR, PYC3+AR, and PYC10+AR groups (p&lt;0.001, p=0.003, p=0.001). CONCLUSION: PYC has multiple suppressive effects on allergic response. Thus, PYC may be used as a supplementary agent in allergic response</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 2146-3131 (Electronic)IS - 2146-3123 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5152/balkanmedj.2016.150057</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27994914">PM:27994914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Balkan Med J\2016-33-620-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Balkan Med J\2016-33-620-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Gunel C</style></custom2><misc3><style face="normal" font="Arial">10.5152/balkanmedj.2016.150057</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakamura,T.</style></author><author><style face="normal" font="Arial"> Fukaya,T.</style></author><author><style face="normal" font="Arial"> Uto,T.</style></author><author><style face="normal" font="Arial"> Takagi,H.</style></author><author><style face="normal" font="Arial"> Arimura,K.</style></author><author><style face="normal" font="Arial"> Tono,T.</style></author><author><style face="normal" font="Arial"> Sato,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Selective depletion of basophils ameliorates immunoglobulin E-mediated anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Rep</style></full-title></periodical><pages end="35" start="29">29-35</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fc+ÁRI</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Passive anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Protective immunity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Type I hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><isbn><style face="normal" font="Arial">2405-5808</style></isbn><abstract><style face="normal" font="Arial">Basophils, which are the rarest granulocytes, play crucial roles in protective immunity against parasites and development of allergic disorders. Although immunoglobulin (Ig)E-dependent responses via receptor for IgE (Fc+ÁRI) in basophils have been extensively studied, little is known about cell surface molecules that are selectively expressed on this cell subset to utilize the elimination in vivo through treatment with monoclonal antibody (mAb). Since CD200 receptor 3 (CD200R3) was exclusively expressed on basophils and mast cells (MCs) using a microarray screening, we have generated anti-CD200R3 mAb recognizing CD200R3A. In this study we examined the expression pattern of CD200R3A on leukocytes, and the influence of the elimination of basophils by anti-CD200R3A mAb on allergic responses. Flow cytometric analysis showed that CD200R3A was primarily expressed on basophils and MCs, but not on other leukocytes. Administration with anti-CD200R3A mAb led to the prominent specific depletion of tissue-resident and circulating basophils, but not MCs. Furthermore, in vivo depletion of basophils ameliorated IgE-mediated systemic and local anaphylaxis. Taken together, these findings suggest that CD200R3A is reliable cell surface marker for basophils in vivo, and targeting this unique molecule with mAb for the elimination of basophils may serve as a novel therapeutic strategy in ameliorating the allergic diseases</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrep.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28955985">PM:28955985</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Rep\2017-9-29-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Rep\2017-9-29-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Nakamura T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrep.2016.11.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kamei,R.</style></author><author><style face="normal" font="Arial"> Fujimura,T.</style></author><author><style face="normal" font="Arial"> Matsuda,M.</style></author><author><style face="normal" font="Arial"> Kakihara,K.</style></author><author><style face="normal" font="Arial"> Hirakawa,N.</style></author><author><style face="normal" font="Arial"> Baba,K.</style></author><author><style face="normal" font="Arial"> Ono,K.</style></author><author><style face="normal" font="Arial"> Arakawa,K.</style></author><author><style face="normal" font="Arial"> Kawamoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hiroshima Research Center for Healthy Aging (HiHA), Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, Higashi-Hiroshima, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A flavanone derivative from the Asian medicinal herb (Perilla frutescens) potently suppresses IgE-mediated immediate hypersensitivity reactions</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="679" start="674">674-679</pages><volume><style face="normal" font="Arial">483</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Ca2+ influx</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exocytosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Structural analysis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Perilla frutescens is a dietary leafy herb consumed as a traditional Japanese condiment as well as used for Chinese medicine with anti-inflammatory activity. Here we report a hitherto-unrecognized P. frutescens phytochemical that potently suppresses IgE-mediated type I hypersensitivity reactions. Structural analysis reveals that the purified anti-allergic compound (Perilla-derived methoxyflavanone, PDMF) is identified as 8-hydroxy-5,7-dimethoxyflavanone. PDMF significantly inhibits IgE-mediated histamine release from RBL-2H3 rat basophilic leukemia cells as compared with those seen in known P. frutescens-derived anti-inflammatory polyphenols. We also show that oral administration of PDMF not only suppresses passive cutaneous anaphylaxis, but also prevents allergic rhinitis-like nasal symptoms in a murine model of Japanese cedar pollinosis. Mechanistically, PDMF negatively regulates Akt phosphorylation and intracellular Ca2+ influx, both of which are essential for mast cell secretory granule translocation and its exocytosis upon high-affinity IgE receptor (FcepsilonRI) cross-linking. These results represent PDMF as a new potent anti-allergic phytochemical useful for prevention of IgE-driven hypersensitivity reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20161217IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2016.12.083</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27986566">PM:27986566</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20161217-KameiR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20161217-KameiR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161217, Kamei R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2016.12.083</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cui,L.</style></author><author><style face="normal" font="Arial"> Bi,J.</style></author><author><style face="normal" font="Arial"> Yan,D.</style></author><author><style face="normal" font="Arial"> Ye,X.</style></author><author><style face="normal" font="Arial"> Zheng,M.</style></author><author><style face="normal" font="Arial"> Yu,G.</style></author><author><style face="normal" font="Arial"> Wan,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, School of Fundamental Medicine, Jinzhou Medical University, Jinzhou, 121000, China</style></auth-address><titles><title><style face="normal" font="Arial">JSI-124 inhibits IgE production in an IgE B cell line</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="673" start="669">669-673</pages><volume><style face="normal" font="Arial">483</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">IgE is a key effector molecule in atopic diseases; however, the regulation mechanisms of IgE production in IgE B cells remain poorly understood. In the present study, we demonstrate that JSI-124 (cucurbitacin I), a selective STAT3 inhibitor, selectively inhibits production of IgE by a human IgE B cell line, CRL-8033 cells, while does not affect the IgG production by IgG B cell lines. In the aspect of molecular mechanism, we found that Iglambda, but not Ighe, gene expression was suppressed by JSI-124. The above effects of JSI-124 were not mediated by affecting cellular proliferation or apoptosis. Furthermore, multiple B cell differentiation-related genes expression was not significantly affected by JSI-124. Taken together, we demonstrate a potential strategy of therapeutically suppressing IgE production without affecting IgG production in atopic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161218IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2016.12.085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27988336">PM:27988336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20161218-CuiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20161218-CuiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161218, Cui L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2016.12.085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Piao,C.H.</style></author><author><style face="normal" font="Arial"> Bui,T.T.</style></author><author><style face="normal" font="Arial"> Song,C.H.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author><author><style face="normal" font="Arial"> Shon,D.H.</style></author><author><style face="normal" font="Arial"> Chai,O.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy, Chonbuk National University Medical School, Jeonju, Jeonbuk, 54896, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Trigonella foenum-graecum alleviates airway inflammation of allergic asthma in ovalbumin-induced mouse model</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="1288" start="1284">1284-1288</pages><volume><style face="normal" font="Arial">482</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fabaceae</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin-induced mouse model</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Trigonella foenum-graecum, a member oldest medicinal plant in the fabaceae (legumes) family, is used as a herb, spice, and vegetable, and known for its olfactory, laxative, and galactogogue effects. However, the inhibitory effect of Trigonella foenum-graecum on allergic inflammatory response remains unclear, therefore, we investigated the precise role of Trigonella foenum-graecum in the allergic asthma and revealed the effects of Trigonella foenum-graecum in regulating airway inflammation and its possible mechanism. Allergic asthma was initiated in BALB/c mice by sensitized with OVA emulsified in aluminum on days 1 and 14, then aerosol challenged with OVA on days 27, 28 and 29. Some mice were administered Trigonella foenum-graecum by oral gavage before challenge. Then mice were evaluated for the presence of airway inflammation, production of allergen-specific cytokine response and lung pathology. Trigonella foenum-graecum significantly ameliorated the number of inflammatory cells in BALF and alleviated lung inflammation. It also reduced the collagen deposition and goblet cells. Meanwhile, Trigonella foenum-graecum treatment evidently decreased the high expression of Th2 cytokines and increased the Th1 cytokines in BALF and lung homogenates. Trigonella foenum-graecum showed a significant inhibition of serum IgE and anti-OVA IgG1. In this study, our data suggest that Trigonella foenum-graecum has a significant anti-inflammatory effect and it may prove to be an efficacious therapeutic regent on allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2016.12.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27939889">PM:27939889</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20161212-PiaoCH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20161212-PiaoCH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Piao CH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2016.12.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,X.</style></author><author><style face="normal" font="Arial"> Li,L.F.</style></author><author><style face="normal" font="Arial"> Zhao,D.Y.</style></author><author><style face="normal" font="Arial"> Shen,Y.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence and Clinical Features of Atopic Dermatitis in China</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="2568301">2568301-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Latitude</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background. The epidemiology of atopic dermatitis (AD) in Chinese outpatients is yet to be clarified. Objectives. To investigate population-based prevalence and clinical features of AD in Chinese outpatients. Methods. A multicenter cross-sectional study was conducted in outpatients with eczema or dermatitis from 39 tertiary hospitals in 15 provinces. Results. This study included 682 patients diagnosed with AD, with the mean age of 28.8 +/- 20.1 years and the median course of 5.3 +/- 6.9 years. AD patients had more severe itching (30.4% versus 13.8%, p &lt; 0.001) and clinically suspected bacterial infection (21.7% versus 16.1%, p &lt; 0.001) than those of other types of dermatitis. Older patients were more susceptible to have a history of flexion dermatitis (p &lt; 0.001), bacterial infection (p = 0.005), and severe itching (p &lt; 0.001). Outpatients with clinically suspected bacterial infection had 3.53-fold increased risk of AD than those without it (p &lt; 0.001). The morbidity rate of AD in the (20-25 degrees N) region is 2.86 times higher than that in the (40-45 degrees N) region [OR (95% CI): 0.352 (0.241-0.514), p &lt; 0.001]. Conclusions. AD is characterized by unique clinical/demographic features. Bacterial infection and latitude region may have an impact on the incidence of AD in China</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 2314-6141 (Electronic)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/2568301</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957490">PM:27957490</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2016-2016-2568301.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2016-2016-2568301.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Wang X</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/2568301</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stingeni,L.</style></author><author><style face="normal" font="Arial"> Bianchi,L.</style></author><author><style face="normal" font="Arial"> Tramontana,M.</style></author><author><style face="normal" font="Arial"> Moretta,I.</style></author><author><style face="normal" font="Arial"> Principato,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Clinical, Allergological and Venereological Dermatology, Department of Medicine, University of Perugia, Perugia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Indoor dermatitis due to Aeroglyphus robustus</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="456" start="454">454-456</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animals</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Mite Infestations</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2016">2016/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160213IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Case ReportsPT - LetterRN - 0 (Dust)SB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.14107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26302458">PM:26302458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\2016-174-454-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\2016-174-454-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160213, Stingeni L</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.14107</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weller,K.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Chariteplatz 1, 10117, Berlin, GermanyDepartment of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Chariteplatz 1, 10117, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Antihistamine updosing in chronic urticaria - is there enough evidence?</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="1135" start="1134">1134-1135</pages><volume><style face="normal" font="Arial">175</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15104</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996138">PM:27996138</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\2016-175-1134-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\2016-175-1134-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Weller K</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15104</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hanna,H.J.</style></author><author><style face="normal" font="Arial"> Emmanuel,J.</style></author><author><style face="normal" font="Arial"> Naim,S.</style></author><author><style face="normal" font="Arial"> Umasunthar,T.</style></author><author><style face="normal" font="Arial"> Boyle,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Allergy, Imperial College London, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Community healthcare professionals overestimate the risk of fatal anaphylaxis for food allergic children</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1595" start="1588">1588-1595</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood food allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Pharmacists</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fatal food anaphylaxis is rare, but a major concern for people with food allergy and their carers. We evaluated whether community healthcare professionals accurately estimate risk of fatal anaphylaxis for food allergic children, and whether accurate risk estimation is related to competence in recognizing and managing anaphylaxis. METHODS: We enrolled 90 community healthcare professionals in a cross-sectional survey - 30 primary care nurses, 30 school first aiders, 30 community pharmacists. Participant risk estimates for fatal and non-fatal anaphylaxis, and all-cause fatalities, were measured using a risk ladder. Participant anaphylaxis knowledge was assessed by questionnaire, and practical skills using a simulated anaphylaxis scenario. RESULTS: In all three groups, participants significantly overestimated the risk of fatal anaphylaxis for food allergic children, by a mean factor of 13.5-fold (95% CI 5.0, 31.6), but did not overestimate non-fatal anaphylaxis risk or all-cause fatality risk. We found no evidence of a relationship between successful adrenaline administration and risk estimation. CONCLUSIONS AND CLINICAL RELEVANCE: In conclusion, we have found evidence that community pharmacists, school first aiders and primary care nurses in the UK systematically overestimate the risk of fatal anaphylaxis for a food allergic child. This overestimation may result in increased patient and carer anxiety. Community practitioners who manage childhood food allergy and anaphylaxis need to be educated about the level of risk for fatal anaphylaxis in such children</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12846</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27893940">PM:27893940</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1588-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1588-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Hanna HJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12846</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Peanut allergy, anaphylaxis, adrenaline and exacerbations of asthma</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1505" start="1504">1504-1505</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161128IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12856</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27893943">PM:27893943</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1505-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2016-46-1505-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161128, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12856</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stensgaard,A.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Nielsen,D.</style></author><author><style face="normal" font="Arial"> Munch,M.</style></author><author><style face="normal" font="Arial"> DunnGalvin,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Odense Research Center for Anaphylaxis (ORCA), Department of Dermatology and Allergy Center, Odense University Hospital, Odense, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Quality of life in childhood, adolescence and adult food allergy: Patient and parent perspectives</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="539" start="530">530-539</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fathers</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Studies of children with food allergy typically only include the mother and have not investigated the relationship between the amount of allergen needed to elicit a clinical reaction (threshold) and health-related quality of life (HRQL). Our aims were (i) to compare self-reported and parent-reported HRQL in different age groups, (ii) to evaluate the impact of severity of allergic reaction and threshold on HRQL, and (iii) to investigate factors associated with patient-reported and parent-reported HRQL. METHODS: Age-appropriate Food Allergy Quality of Life Questionnaires (FAQLQ) were completed by 73 children, 49 adolescents and 29 adults with peanut, hazelnut or egg allergy. Parents (197 mothers, 120 fathers) assessed their child's HRQL using the FAQLQ-Parent form. Clinical data and threshold values were obtained from a hospital database. Significant factors for HRQL were investigated using univariate and multivariate regression. RESULTS: Female patients reported greater impact of food allergy on HRQL than males did. Egg and hazelnut thresholds did not affect HRQL, but lower peanut threshold was associated with worse HRQL. Both parents scored their child's HRQL better than the child's own assessment, but whereas mother-reported HRQL was significantly affected by limitations in the child's social life, father-reported HRQL was affected by limitations in the family's social life. Severity of allergic reaction did not contribute significantly to HRQL. CONCLUSION: The risk of accidental allergen ingestion and limitations in social life are associated with worse HRQL. Fathers provide a unique perspective and should have a greater opportunity to contribute to food allergy research</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12849</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27976436">PM:27976436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161215-StensgaardA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161215-StensgaardA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Stensgaard A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12849</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kolkhir,P.</style></author><author><style face="normal" font="Arial"> Andre,F.</style></author><author><style face="normal" font="Arial"> Church,M.K.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia</style></auth-address><titles><title><style face="normal" font="Arial">Potential blood biomarkers in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="36" start="19">19-36</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> D-dimer</style></keyword><keyword><style face="normal" font="Arial"> Dehydroepiandrosterone</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that is defined as the recurrence of wheals, angioedema, or both for >6 weeks due to known or unknown causes. As of yet, disease diagnosis is purely clinical. Objective tools are needed to monitor the activity of CSU and the efficacy of treatment. Recently, several reports have suggested that blood parameters may be considered as potential disease-related biomarkers. OBJECTIVE: To review available literature on blood biomarkers for CSU diagnosis, activity monitoring, duration, patient subgroups allocation or response to treatment. METHODS: We performed a Pubmed, Google Scholar and Web of Science search and identified and analysed 151 reports published prior to January 2016. RESULTS: We found strong evidence for significant differences between CSU patients and healthy controls in blood levels or values of D-dimer, C-reactive protein (CRP), matrix metalloproteinase-9 (MMP-9), mean platelet volume (MPV), factor VIIa, prothrombin fragment 1+2 (F1+2), tumor necrosis factor, dehydroepiandrosterone sulfate and vitamin D. Also, there is strong evidence for a significant association between CSU activity and blood levels or values of D-dimer, F1+2, CRP, IL-6 and MPV. Strong evidence for reduced basophil count and high levels of IgG anti-FcepsilonRI in the subgroup of CSU patients with positive autologous serum skin test was shown. In contrast, the evidence for all reported blood biomarkers for differentiating CSU from other diseases, or a role in prognosis, is weak, inconsistent or non-existent. CONCLUSIONS &amp; CLINICAL RELEVANCE: We identified ten biomarkers which are supported by strong evidence for distinguishing CSU patients from healthy controls, or for measuring CSU activity. There is a need for further research to identify biomarkers which predict outcome or treatment response in CSU. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Russia -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12870</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27926978">PM:27926978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161207-KolkhirP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161207-KolkhirP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Kolkhir P</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12870</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Francis,A.</style></author><author><style face="normal" font="Arial"> Bosio,E.</style></author><author><style face="normal" font="Arial"> Stone,S.F.</style></author><author><style face="normal" font="Arial"> Fatovich,D.M.</style></author><author><style face="normal" font="Arial"> Arendts,G.</style></author><author><style face="normal" font="Arial"> Nagree,Y.</style></author><author><style face="normal" font="Arial"> Macdonald,S.P.</style></author><author><style face="normal" font="Arial"> Mitenko,H.</style></author><author><style face="normal" font="Arial"> Rajee,M.</style></author><author><style face="normal" font="Arial"> Burrows,S.</style></author><author><style face="normal" font="Arial"> Brown,S.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Perth, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Neutrophil activation during acute human anaphylaxis: analysis of MPO and sCD62L</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="370" start="361">361-370</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD62L</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Activation</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The mechanisms involved in the amplification of the mast cell response during anaphylaxis are unclear. Mouse models of anaphylaxis demonstrate the critical involvement of neutrophils. These innate immune cells are highly abundant in peripheral blood and can be rapidly activated to trigger both local and systemic inflammation. OBJECTIVE: To investigate neutrophil activation in peripheral blood during acute human anaphylaxis. METHODS: Patients presenting to the Emergency Department with anaphylaxis underwent blood sampling upon enrolment and at up to three subsequent time points. Traditional anaphylaxis biomarkers, histamine and mast cell tryptase, were measured by ELISA and ImmunoCAP respectively. Plasma myeloperoxidase concentrations were measured by ELISA, serum soluble CD62L concentrations by cytometric bead array, and both compared to healthy controls. RESULTS: In 72 patients, 37 (51%) had severe anaphylaxis, 33 (60%) were histamine positive, and 47 (70%) were mast cell tryptase positive. At enrolment, myeloperoxidase concentrations were 2.9- (95% CI: 1.3, 6.5) and 5.0- (95% CI: 2.4, 10.5) fold higher in moderate and severe patients respectively, compared with healthy controls, and remained stable over the first 5 hours following symptom onset. At enrolment, soluble CD62L was 29% (95% CI: 19, 38) and 31% (95% CI: 22, 40) lower in moderate and severe patients respectively, than healthy controls, and was stable over the first 5 hours. There were no associations between myeloperoxidase or soluble CD62L concentrations and either histamine or mast cell tryptase concentrations. CONCLUSIONS AND CLINICAL RELEVANCE: These results provide compelling evidence for the involvement of neutrophils during acute human anaphylaxis, suggesting they are activated early in the reaction, regardless of mast cell activation. This important finding increases our understanding of the basic mechanisms of anaphylaxis, a necessary precursor to improving treatment and prevention. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12868</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906487">PM:27906487</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161201-FrancisA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161201-FrancisA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Francis A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12868</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ridolo,E.</style></author><author><style face="normal" font="Arial"> Melli,V.</style></author><author><style face="normal" font="Arial"> De' Angelis,G.</style></author><author><style face="normal" font="Arial"> Martignago,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical and Experimental Medicine, University of Parma, via Gramsci, 14, 43100 Parma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic disorders of the gastro-intestinal tract: an update</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Digestive System</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic disorders</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Eosinophilic diseases of the gastrointestinal tract, including eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis (EGE), are rare chronic pathologies of the digestive system, with an immuno-mediated pathogenesis. Recent data suggest that, together with the "classic" IgE-response to allergens, also a delayed hypersensitivity mechanism could be involved in the development of eosinophilic disorders. EoE and EGE were studied only in the latest decades and as a consequence accurate data are not yet available, concerning not only pathogenesis, but also epidemiology, treatment and outcomes. The diagnosis of EoE is centered on endoscopic findings but the certainty is obtained by histological examination from biopsy samples, that has a sensitivity of 100% when based on five samples. The currently available treatments include topical corticosteroids, specific diets and endoscopic treatment. Concerning EGE, three subtypes (mucosal, muscular, and serosal) were identified. The diagnosis is based, as for EoE, on endoscopic and histological assessment, and the treatment includes pharmacological and dietetic approaches. Further studies are warranted in order to better define the etiology and pathogenesis of eosinophilic diseases of the gastrointestinal tract, and thus to develop more appropriate and specific therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1476-7961 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-016-0055-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27956893">PM:27956893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-17.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Ridolo E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-016-0055-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Minciullo,P.L.</style></author><author><style face="normal" font="Arial"> Cascio,A.</style></author><author><style face="normal" font="Arial"> Isola,S.</style></author><author><style face="normal" font="Arial"> Gangemi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School and Division of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Messina, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Different clinical allergological features of Taenia solium infestation</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="18">18-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Causality</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cysticercosis</style></keyword><keyword><style face="normal" font="Arial"> Diffusion</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The tapeworm Taenia (T.) solium can be responsible for two different conditions: taeniasis and cysticercosis. Helminth infections in human host cause an immune response associated with elevated levels of IgE, tissue eosinophilia and mastocytosis, and with the presence of CD4+ T cells that preferentially produce IL-4, IL-5, and IL-13. Individuals exposed to helminth infections may have allergic inflammatory responses to parasites and parasite antigens. PubMed search of human cases of allergic reactions occurring during T. solium infestation was performed combining the terms (allergy, urticaria, angioedema, asthma, anaphylaxis) with T. solium. A study was considered eligible for inclusion in the review if it reported data on patients with T. solium infestation who had signs or symptoms of allergy. In literature we found six articles reporting the association between an allergic reaction and T. solium infestation: two cases of urticaria, two cases of relapsing angioedema, one case of asthma and two cases of anaphylaxis. Despite the large diffusion of T. solium infestation, we found only a few cases of concomitant allergic reaction and the presence of Taenia in the host. The association between T. solium infestation and allergic manifestations has never been clearly demonstrated, and in absence of a well-documented causality the hypotheses are merely speculative. Therefore, the association between Taenia infection and allergy needs to be thoroughly studied to better clarify if this association may really exist and which is the pathogenetic mechanism supported</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 1476-7961 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-016-0056-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27980457">PM:27980457</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2016-14-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Minciullo PL</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-016-0056-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Long,B.</style></author><author><style face="normal" font="Arial"> Tompkins,T.</style></author><author><style face="normal" font="Arial"> Decker,C.</style></author><author><style face="normal" font="Arial"> Jesaitis,L.</style></author><author><style face="normal" font="Arial"> Khan,S.</style></author><author><style face="normal" font="Arial"> Slasor,P.</style></author><author><style face="normal" font="Arial"> Harmatz,P.</style></author><author><style face="normal" font="Arial"> O'Neill,C.A.</style></author><author><style face="normal" font="Arial"> Schweighardt,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">BioMarin Pharmaceutical Inc., Novato, California.</style></auth-address><titles><title><style face="normal" font="Arial">Long-Term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study</style></title><secondary-title><style face="normal" font="Arial">Clin Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Ther</style></full-title></periodical><pages end="129" start="118">118-129</pages><volume><style face="normal" font="Arial">39</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mucopolysaccharidosis</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Elosulfase alfa is an enzyme replacement therapy for the treatment of Morquio A syndrome (mucopolysaccharidosis IVA), a lysosomal storage disorder caused by a deficiency of the enzyme N-acetylgalactose-amine-6-sulfatase. We previously reported immunogenicity data from our 24-week placebo-controlled Phase III study, MOR-004. Here, we report the long-term immunogenicity profile of elosulfase alfa from MOR-005, the Phase III extension trial to assess potential correlations between antidrug antibodies and efficacy and safety profile outcomes throughout 120 weeks of treatment. METHODS: The long-term immunogenicity of elosulfase alfa was evaluated in patients with Morquio A syndrome in an open-label extension study for a total of 120 weeks. All patients received 2.0 mg/kg elosulfase alfa either weekly or every other week before establishment of 2.0 mg/kg/wk as the recommended dose, at which time all patients received weekly treatment. Efficacy measures were compared with those from the MOR-004 baseline, enabling analysis of changes over 120 weeks. The primary efficacy measure was the change from baseline in 6-minute walk test. Secondary measures included changes from baseline in 3-minute stair climb test and normalized urine keratan sulfate, a pharmacodynamic metric. FINDINGS: All patients treated with elosulfase alfa developed antidrug total antibodies (TAb) by week 24 of MOR-004. In the extension study, all patients, including those who had previously received placebo, were TAb positive by study week 36 (MOR-005 week 12). All patients remained TAb positive throughout the study, and TAb titers were similar across treatment groups at week 120. Nearly all patients tested positive for neutralizing antibodies (NAb) at least once, with incidence of NAb positivity peaking at 85.9% at study week 36, then steadily declining to 66.0% at study week 120. In all treatment groups, mean urine keratan sulfate remained below treatment-naive baseline despite the presence of antidrug antibodies. No relationship was observed between TAb titers or NAb positivity and changes in urine keratan sulfate, 6-minute walk test, or 3-minute stair climb test from baseline to week 120. No consistent associations were detected between antidrug antibodies and the occurrence of hypersensitivity adverse events or anaphylaxis over the course of the study. IMPLICATIONS: Immunogenicity results from this long-term study are consistent with previously reported 24-week results. Despite the sustained presence of antidrug antibodies, elosulfase alfa was well tolerated, and patients continued to benefit from treatment through week 120. No associations were detected between higher TAb titers or NAb positivity and reduced treatment effect or worsened safety profile measures. ClinicalTrials.gov identifier: NCT01415427</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1879-114X (Electronic)IS - 0149-2918 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clinthera.2016.11.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27955919">PM:27955919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Ther\20161213-LongB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Ther\20161213-LongB.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Ther\20161213-LongB.csv</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Ther\20161213-LongB.csv</url></image-urls></urls><custom2><style face="normal" font="Arial">20161213, Long B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clinthera.2016.11.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thijs,J.L.</style></author><author><style face="normal" font="Arial"> Knipping,K.</style></author><author><style face="normal" font="Arial"> Bruijnzeel-Koomen,C.A.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> De Bruin-Weller,M.S.</style></author><author><style face="normal" font="Arial"> Hijnen,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="44">44-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> thymus and activation-regulated chemokine</style></keyword><keyword><style face="normal" font="Arial"> topical steroids</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although total IgE levels have been proposed as a biomarker for disease severity in atopic dermatitis (AD) and are increased in the majority of AD patients, they do not correlate with disease severity during short-term follow-up. During the synthesis of immunoglobulins, free light chains (Ig-FLCs) are produced in excess over heavy chains. In comparison with IgE molecules, Ig-FLCs have a very short serum half-life. Therefore, Ig-FLCs might be more suitable as a biomarker for disease severity during follow-up. Recent studies showed increased serum levels of kappa Ig-FLCs in infants with AD, correlating with disease severity. The aim of this study was to investigate serum kappa Ig-FLC levels in adults with AD, and their correlation to disease severity. METHODS: Serum kappa If-FLC and total IgE levels were measured in 82 moderate to severe AD patients and 49 non-atopic controls. Blood was collected from patients before start of treatment with potent topical steroids (European classification: III-IV). 32 patients were treated during a clinical admission, and in this subpopulation a second blood sample was taken after 2 weeks of treatment. Clinical severity was determined by the Six Area Six Sign Atopic Dermatitis (SASSAD) severity score and a panel of serum biomarkers, including thymus and activation-regulated chemokine (TARC). RESULTS: Serum kappa Ig-FLCs levels in adult AD patients were not increased compared to non-atopic controls. Moreover, we observed no correlation between kappa Ig-FLC serum levels and disease severity determined by SASSAD and a panel of serum biomarkers, including TARC. Serum kappa Ig-FLC levels did also not decrease during treatment. CONCLUSION: There are no differences in serum kappa Ig-FLC levels between adult patients suffering from moderate to severe AD compared to non-atopic controls. Moreover, serum levels of kappa Ig-FLCs cannot be used as a biomarker for disease severity in adult AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0132-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27980722">PM:27980722</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Thijs JL</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0132-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lotzsch,B.</style></author><author><style face="normal" font="Arial"> Dolle,S.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergology, Allergy-Center-Charite, Charite - Universitatsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Exploratory analysis of CD63 and CD203c expression in basophils from hazelnut sensitized and allergic individuals</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="45">45-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> CD203c</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sensitization to hazelnut (HN) is frequent and requires clarification to determine whether this sensitization is clinically relevant. The aim of this study was to investigate basophil activation profiles in HN-sensitized and allergic subjects. METHODS: Basophil activation was determined by flow cytometric analyses of CD63 and CD203c expression using several HN allergen concentrations. Depending on their clinical reaction pattern, an oral allergy symptom group (OAS, n = 20), a systemic reaction group (n = 12) and a sensitized group without clinical symptoms (n = 20) were identified. Additionally, 10 non-allergic and non-sensitized individuals served as controls. RESULTS: CD63 and CD203c expression differed between allergic (OAS and systemic group) and sensitized subjects. The HN concentration required to activate 30% of CD203c+ basophils [effective concentration (EC)30] was significantly higher in sensitized versus the allergic group (p = 0.0089). This was more pronounced when the basophil allergen threshold sensitivity (CD-sens) was calculated (CD63: p = 0.018; CD203c: p = 0.009). CONCLUSION: Our data indicate that the basophil activation test may provide information to better distinguish between sensitized and allergic subjects if several allergen concentrations are considered. CD203c expression displayed a better discrimination compared to CD63; therefore, its diagnostic value might be superior compared with CD63</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0134-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27999658">PM:27999658</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2016-6-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Lotzsch B</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0134-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bunning,B.J.</style></author><author><style face="normal" font="Arial"> Dekruyff,R.H.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Epigenetic Changes During Food-Specific Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="87">87-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food challenge outcome</style></keyword><keyword><style face="normal" font="Arial"> forkhead box protein 3</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene-environment</style></keyword><keyword><style face="normal" font="Arial"> gene-environment interaction</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The prevalence and severity of IgE-mediated food allergy has increased dramatically over the last 15 years and is becoming a global health problem. Multiple lines of evidence suggest that epigenetic modifications of the genome resulting from gene-environment interactions have a key role in the increased prevalence of atopic disease. In this review, we describe the recent evidence suggesting how epigenetic changes mediate susceptibility to food allergies, and discuss how immunotherapy (IT) may reverse these effects. We discuss the areas of the epigenome as yet unexplored in terms of food allergy and IT such as histone modification and chromatin accessibility, and new techniques that may be utilized in future studies. RECENT FINDINGS: Recent findings provide strong evidence that DNA methylation of certain promoter regions such as Forkhead box protein 3 is associated with clinical reactivity, and further, can be changed during IT treatment. Reports on other epigenetic changes are limited but also show evidence of significant change based on both disease status and treatment. In comparison to epigenetic studies focusing on asthma and allergic rhinitis, food allergy remains understudied. However, within the next decade, it is likely that epigenetic modifications may be used as biomarkers to aid in diagnosis and treatment of food-allergic patients. DNA methylation at specific loci has shown associations between food challenge outcomes, successful desensitization treatment, and overall phenotype compared to healthy controls</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0665-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27943047">PM:27943047</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-87.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Bunning BJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0665-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Bagnasco,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="88">88-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> dose-ranging</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Experimental design</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hayfever</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal route</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy (AIT) has been in use since more than one century, when Leonard Noon experimentally proved its efficacy in hayfever (Noon, in Lancet 1:1572-3, 1911). Since then, AIT was administered only as subcutaneous injections (SCIT) until the sublingual route (SLIT) was proposed in 1986. The use of SLIT was proposed following several surveys from the USA and UK that repeatedly reported fatalities due to SCIT (Lockey et al. in J Allergy Clin Immunol 75(1): 166, 1985; Lockey et al. in J Allergy Clin Immunol 660-77, 1985; Committee on the safety of medicines. CSM update. Desensitizing vaccines. Br Med J, 293: 948, 1986). These reports raised serious concerns about the safety and the risk/benefit ratio of AIT. Many cases of life-threatening events with SCIT were due to avoidable human errors in administration, but a relevant fraction of them remained unexplained and unpredictable (Aaronson and Gandhi in J Allergy Clin Immunol 113: 1117-21, 2014). Subsequently, in a few years, SLIT gained credibility and was included in the official documents and guidelines (Table 1) (Bousquet et al. in J Allergy Clin Immunol 108(5 Supp):S146-S150, 2001; Canonica et al. in Allergy 64 (Supp 91):1-59, 2009) as a viable alternative to traditional SCIT. Of note, the local bronchial (aerosol) and the intranasal route of administration were attempted after the 1970s as alternatives to SCIT: the bronchial route was soon abandoned due to the poor efficacy and/or side effects, and the local nasal route, although effective and safe, was judged substantially impractical (Canonica and Passalacqua in J Allergy Clin Immunol 111: 437-48, 2003). In contrast to SCIT, SLIT was tested in very large clinical trials (need references), including hundreds of patients and with dose-ranging experimental designs, so that some products (tablets) for grass, mite, and ragweed were officially approved as commercial drugs by regulatory agencies such as the Food and Drug Administration and the European Medicines Agency and the optimal content for the maintenance dose was identified for selected allergens. In parallel, the knowledge on the mechanisms of action of AIT was rapidly refined, leading to further improvements, such as the chemically modified extracts and the use of adjuvants to enhance efficacy and safety. In addition, in the last 10 years, there has been an increasing scientific and clinical interest in AIT applied to food allergies, in particular in children, with the use of orally administered extracts (Albin and Nowak-Wegrzyn in Immunol Allergy Clin North Am 35: 77-100, 2015). The results are so far encouraging, at least for cow's milk, egg, and peanut, although the use of treatment is still restricted to clinical trials or within specialized centers. Finally, the introduction of molecular- or component-resolved diagnosis has allowed detailing the prescription of AIT, by better delineating true sensitization versus cross-reactivity (Canonica et al. in World Allergy Organ J 6(1):17, 2013). This latter point is also in strict relation to the use of recombinant, engineered or highly purified molecules, instead of raw extracts, for the desensitization process</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0666-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957697">PM:27957697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-88.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-88.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Passalacqua G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0666-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Z.</style></author><author><style face="normal" font="Arial"> Reponen,T.</style></author><author><style face="normal" font="Arial"> Hershey,G.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma Research, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., MLC 7037, Cincinnati, OH, 45229, USA</style></auth-address><titles><title><style face="normal" font="Arial">Fungal Exposure and Asthma: IgE and Non-IgE-Mediated Mechanisms</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="86">86-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adult asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> immunomodulators</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Outdoor environment</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Fungi are ubiquitous in indoor and outdoor environments and have been associated with respiratory disease including childhood and adult asthma. A growing body of evidence from human and animal studies has revealed a link between fungal exposure, especially indoor fungal exposure, with asthma initiation, persistence, and exacerbation. Despite the overwhelming evidence linking mold exposure and asthma, the mechanistic basis for the association has remained elusive. It is now clear that fungi need not be intact to impart negative health effects. Fungal components and fungal fragments are biologically active and contribute to asthma development and severity. Recent mechanistic studies have demonstrated that fungi are potent immunomodulators and have powerful effects on asthma independent of their potential to act as antigens. This paper will review the connection between fungal exposure and asthma with a focus on the immunological mechanisms underlying this relationship</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-016-0667-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27943046">PM:27943046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2016-16-86.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Zhang Z</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-016-0667-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hsiao,K.C.</style></author><author><style face="normal" font="Arial"> Tang,M.L.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Novel Treatments for Established Food Allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Pediatr Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pediatr Rep</style></full-title></periodical><pages end="185" start="178">178-185</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental ingestion</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vigilance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2167-4841</style></isbn><abstract><style face="normal" font="Arial">Current management of food-allergic children centres on allergen avoidance and emergency management of allergic reactions due to accidental ingestion. These measures minimise harm to patients, but the need for constant vigilance and dietary restriction may have a major long-term negative impact on quality of life</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40124-016-0116-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40124-016-0116-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Pediatr Rep\2016-4-178-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Pediatr Rep\2016-4-178-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Hsiao KC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40124-016-0116-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Judson,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis: what's known and what's new</style></title><secondary-title><style face="normal" font="Arial">Curr Pulmonol Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Pulmonol Rep</style></abbr-1></periodical><pages end="183" start="177">177-183</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> new biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2199-2428</style></isbn><abstract><style face="normal" font="Arial">Recent investigations concerning ABPA have expanded our understanding of the disease. The diagnostic criteria for ABPA are not standardized. Novel analytic techniques have compared the varied diagnostic criteria even in the absence of a gold standard. Additional analyses have determined the sensitivity and specificity of various parameters for the diagnosis of ABPA, as well as combinations of several parameters that have extremely high specificity and sensitivity. New biomarkers have also been proposed to diagnosis and monitor ABPA. Research concerning specific antigenic triggers of the Th2 response and HLA polymorphisms in ABPA has led to relevant new insights concerning the immunopathogenesis of the disease. Treatment trials have further clarified the optimal corticosteroid dosing regimen and the role of antifungal therapy and anti-IgE therapy for the treatment of ABPA. We suspect that such research efforts will continue to accelerate our understanding of this disease that will benefit ABPA patients</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13665-016-0155-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13665-016-0155-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Pulmonol Rep\2016-5-177-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Pulmonol Rep\2016-5-177-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Judson MA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13665-016-0155-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wedi,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Christmas from an allergist's perspective]</style></title><secondary-title><style face="normal" font="Arial">Dtsch Med Wochenschr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dtsch Med Wochenschr</style></full-title></periodical><pages end="1834" start="1828">1828-1834</pages><volume><style face="normal" font="Arial">141</style></volume><number><style face="normal" font="Arial">25</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Mobile phone</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">The customs and traditions associated with Christmas may result in allergic reactions to allergens that are typical for this period. On the one hand the rise in prevalence of allergic diseases has continued in the industrialized world for the last decades and allergies are regarded as widespread diseases. On the other hand the 21th century is a time of "allergy delusion". This review summarizes the facts about allergic reactions to Christmas typical decoration, food and behavior. Taken together, allergic reactions to Christmas tree, poinsettia, Christmas cactus, perfumed candles, Christmas typical food, common gifts like mobile phones and laptops, frankincense, myrrh and pollens have been described but in very rare instances. The chance to survive Christmas without allergic symptoms is high, particularly for non-atopics</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1439-4413 (Electronic)IS - 0012-0472 (Linking)LA - gerPT - Journal ArticlePT - English AbstractCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1055/s-0042-117370</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27975355">PM:27975355</url></web-urls></urls><custom2><style face="normal" font="Arial">20161215, Wedi B</style></custom2><misc3><style face="normal" font="Arial">10.1055/s-0042-117370</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Slovick,A.</style></author><author><style face="normal" font="Arial"> Douiri,A.</style></author><author><style face="normal" font="Arial"> Muir,R.</style></author><author><style face="normal" font="Arial"> Guerra,A.</style></author><author><style face="normal" font="Arial"> Tsioulos,K.</style></author><author><style face="normal" font="Arial"> Haye,E.</style></author><author><style face="normal" font="Arial"> Lam,E.P.S.</style></author><author><style face="normal" font="Arial"> Kelly,J.</style></author><author><style face="normal" font="Arial"> Peacock,J.L.</style></author><author><style face="normal" font="Arial"> Ying,S.</style></author><author><style face="normal" font="Arial"> Shamji,M.H.</style></author><author><style face="normal" font="Arial"> Cousins,D.J.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Till,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A randomised placebo-controlled trial investigating efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic rhinitis.</style></title><secondary-title><style face="normal" font="Arial">Efficacy and Mechanism Evaluation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Efficacy and Mechanism Evaluation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen Phl p 5</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Area Under Curve</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> CXCR3</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Forearm</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Mouth</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Phl p 5</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Preseasonal</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">We previously reported that repeated low-dose grass pollen intradermal allergen injection suppresses allergen-induced cutaneous late-phase responses, comparable with conventional high-dose subcutaneous and sublingual immunotherapy. To evaluate the efficacy and mechanism of grass pollen intradermal immunotherapy for treatment of allergic rhinitis. A Phase II, double-blind, randomised controlled parallel-group trial. Single-centre UK study. Adults aged 18-65 years, with grass pollen-induced allergic rhinoconjunctivitis. Seven 2-weekly intradermal injections were given into the forearm, containing either Phleum pratense soluble grass pollen extract (7 ng of the major allergen Phl p 5) or histamine control. The primary outcome was a combined symptom and medication score (CSMS) during the 2013 grass pollen season. Secondary clinical outcomes were overall symptom scores; individual symptoms scores for nose, mouth, eyes and lungs; overall medication scores; CSMSs during the peak season; visual analogue scale (VAS) scores for nose and eye symptoms; Mini Rhinitis Quality of Life Questionnaire scores; health-related quality-of-life scores (European Quality of Life-5 Dimensions, 5-levels); a global evaluation of symptoms, number of symptom-free and medication-free days; number of days when prednisolone was used; and adverse events. Mechanistic studies included measurement of late-phase skin response sizes, allergen-specific antibody titres, analysis of skin biopsies and basophil activation tests. There was no significant difference in CSMSs between treatment arms [difference in median area under curve (AUC) 14, 95% confidence interval (CI) -172.5 to 215.1; p = 0.80]. Paradoxically, among the secondary outcomes, nasal symptoms measured with daily scores were higher in the active arm (difference in median AUC 35, 95% CI 4.0 to 67.5; p = 0.03), with a trend for higher nasal symptoms measured by VASs (difference in median AUC 53, 95% CI -11.6 to 125.2; p = 0.05). No differences were seen in other clinical outcomes in the main intention-to-treat analysis. In mechanistic studies, active treatment increased P. pratense-, Phl p 1- and Phl p 5-specific immunoglobulin E (all p = 0.001) compared with the control. T cells cultured from skin biopsies of active intradermal immunotherapy subjects showed higher T helper type 2 cell (Th2) marker CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) expression (p &lt; 0.05) and lower T helper type 1 cell marker CXCR3 [chemokine (C-X-C Motif) receptor 3] expression (p &lt; 0.05), respectively. Interleukin 5 messenger ribonucleic acid, measured by microarray, was more highly expressed by cultured skin T cells in the active arm (p &lt; 0.05). Late-phase skin responses to grass pollen were still inhibited up to 7 months after intradermal immunotherapy (p = 0.03), but not at 10-13 months' time points. Grass pollen doses were not increased during the course, as our proof-of-concept trial showed that repeating the same doses was sufficient to achieve almost complete late-response suppression. Injections were not continued throughout the season, as previous subcutaneous grass pollen immunotherapy trials have demonstrated preseasonal regimen efficacy. Intradermal immunotherapy suppressed late-phase skin responses to allergen, but was not clinically effective. The intervention appeared to have an immunological priming effect and exacerbated certain seasonal symptoms, notably in the nose. Further studies on low-dose intradermal grass pollen immunotherapy are not recommended because of our demonstrated worsening of allergic rhinitis symptoms and immunological priming. The findings are of great significance for other novel immunotherapies targeting the skin, such as epicutaneous techniques. Current Controlled Trials ISRCTN78413121. This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership</style></abstract><notes><style face="normal" font="Arial">DA - 20161216LA - engPT - ReviewPT - BookCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27977090">PM:27977090</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Efficacy and Mechanism Evaluation\20161216-SlovickA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Efficacy and Mechanism Evaluation\20161216-SlovickA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Slovick A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arram,E.O.</style></author><author><style face="normal" font="Arial"> Yousef,A.M.</style></author><author><style face="normal" font="Arial"> Fathy,A.</style></author><author><style face="normal" font="Arial"> Atwa,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical and immunological effect of subcutaneous immunotherapy in allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Egypt J Chest Dis Tuberc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Egypt J Chest Dis Tuberc</style></full-title></periodical><pages end="216" start="211">211-216</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function test</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0422-7638</style></isbn><abstract><style face="normal" font="Arial">Background Allergen immunotherapy is a potentially curative treatment approach in allergic diseases, subcutaneous immunotherapy is therapeutic option in treatment of allergic asthma. Aim of the study In the present study, subcutaneous immunotherapy (SCIT) using multiple allergen was administered to allergic asthmatic patients without allergic rhinitis or mixed allergy aiming to evaluate its efficacy, safety and evaluate the changes in the immune response. Patients and methods The study included 56 patients with allergic asthma alone, all patients received SCIT according to the results of skin prick test over a period of 1 year, initial clinical evaluation including the presence of exacerbation and need of inhalers treatment, pulmonary function tests were performed also total immunoglobulin E(IgE), immunoglobulin A(IgA) and leukotriene C4(LTC4) were measured and repeated after 1 year of initiation of the course of SCIT. Results There were highly significant clinical improvement as regard exacerbation presence, need for inhalers and improvement of the forced expiratory volume in the first second FEV1 also there were highly significant decrease in total IgE, LTC4 and highly significant increase of IgA, after one year of SCIT. Conclusion SCIT is a safe treatment strategy that significantly reduce exacerbation and medication requirement in allergic asthma without mixed allergy also improve immunological response</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejcdt.2016.10.004</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.ejcdt.2016.10.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Egypt J Chest Dis Tuberc\20161220-ArramEO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Egypt J Chest Dis Tuberc\20161220-ArramEO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Arram EO</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejcdt.2016.10.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Begin,P.</style></author><author><style face="normal" font="Arial"> Filion,C.</style></author><author><style face="normal" font="Arial"> Graham,F.</style></author><author><style face="normal" font="Arial"> Lacombe-Barrios,J.</style></author><author><style face="normal" font="Arial"> Paradis,J.</style></author><author><style face="normal" font="Arial"> Paradis,L.</style></author><author><style face="normal" font="Arial"> Des,Roches A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Consultation with registered dietitian to prevent accidental reactions to food: insight from an egg allergy influenza vaccination cohort</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Nutr</style></full-title></periodical><pages end="289" start="287">287-289</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dietitian</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy guidelines</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza vaccination</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Egg is an ubiquitous allergen found in many food products. Current food allergy guidelines recognize the importance of consultation with a registered dietitian to ensure nutritional adequacy. However, there is a lack of evidence on its impact on the implementation of allergen avoidance strategies. Taking advantage of a well-characterized cohort of influenza vaccination in egg-allergic children (n=397), we tested the hypothesis that real-life professional dietary advice was associated with a decrease in accidental reactions to egg in allergic children with retrospective questionnaires. Lack of consultation with a dietitian was associated with a 1.89-fold increase in the risk of accidental reactions to egg (confidence interval: 1.47-2.42). The only other independent variable that predicted reactions was having had a history of acute reaction to egg prior diagnosis (relative risk=2.02; confidence interval: 1.64-3.00). These findings support the usefulness of referral to a food allergy-specialized dietitian at time of diagnosis in order to prevent future accidental reactions to egg.European Journal of Clinical Nutrition advance online publication, 21 December 2016; doi:10.1038/ejcn.2016.241</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1476-5640 (Electronic)IS - 0954-3007 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1038/ejcn.2016.241</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000691">PM:28000691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Nutr\20161221-BeginP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Nutr\20161221-BeginP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Begin P</style></custom2><misc3><style face="normal" font="Arial">10.1038/ejcn.2016.241</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Habener,A.</style></author><author><style face="normal" font="Arial"> Behrendt,A.K.</style></author><author><style face="normal" font="Arial"> Skuljec,J.</style></author><author><style face="normal" font="Arial"> Jirmo,A.C.</style></author><author><style face="normal" font="Arial"> Meyer-Bahlburg,A.</style></author><author><style face="normal" font="Arial"> Hansen,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany</style></auth-address><titles><title><style face="normal" font="Arial">B-cell subsets are modulated during allergic airway inflammation but are not required for the development of respiratory tolerance in a murine model</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="562" start="552">552-562</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Breg</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Germinal Center</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a widespread chronic inflammatory disease of the airways. The role of different B-cell subsets in developing asthma and respiratory tolerance is not well-known. Especially regulatory B (Breg) cells are proposed to be important in asthma regulation. Using wildtype (WT) and B-cell-deficient (muMT) mice we investigated how B-cells are affected by induction of allergic airway inflammation and respiratory tolerance and whether they are necessary to develop these conditions. WT mice with an asthma-like phenotype, characterized by increased airway hyperreactivity, eosinophilic airway inflammation, mucus hypersecretion and elevated Th2 cytokines, exhibited increased MHCII and CD23 expression on follicular mature B-cells in lung, bronchial lymph nodes (bLN) and spleen, which contributed to allergen-specific T-cell proliferation in vitro. Germinal center B-cell numbers were elevated and associated with increased production of allergen-specific immunoglobulins especially in bLN. In contrast, respiratory tolerance clearly attenuated these B-cell alterations and directly enhanced marginal zone precursor B-cells, which induced regulatory T-cells in vitro. However, muMT mice developed asthma-like and tolerized phenotypes like WT mice. Our data indicate that although B-cell subsets are affected by asthma-like and respiratory tolerant phenotypes, B-cells are not required for tolerance induction. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201646518</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27995616">PM:27995616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20161220-HabenerA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Immunol\20161220-HabenerA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Habener A</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201646518</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Molina-Infante,J.</style></author><author><style face="normal" font="Arial"> Gonzalez-Cordero,P.L.</style></author><author><style face="normal" font="Arial"> Arias,A.</style></author><author><style face="normal" font="Arial"> Jose Lucendo,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Hospital Universitario San Pedro de Alcantara - Gastroenterology , Villalobos 11, Caceres, CACERES 10003 , Spain</style></auth-address><titles><title><style face="normal" font="Arial">Update on dietary therapy for eosinophilic esophagitis in children and adults</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Gastroenterol Hepatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Gastroenterol Hepatol</style></full-title></periodical><pages end="123" start="115">115-123</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="12/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary therapy</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elemental diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Eosinophilic esophagitis (EoE) is a chronic inflammatory esophageal disease triggered predominantly, but not excusively, by food antigens. Elimination diet thus remains the only therapy targeting the cause of the disease. Importantly, EoE is a unique form of non-IgE mediated food allergy, largely dependant upon delayed, cell-mediated hypersensitivity. Areas covered: A comprehensive review of literature to summarize and update the most relevant advances on dietary therapy for pediatric and adult EoE patients is conducted. Expert commentary: None of the currently available food allergy tests adequately predict food triggers for EoE, especially in adults. Elemental diet (exclusive feeding with aminoacid-based formulas) and empiric six-food elimination diet, withdrawing cow s milk, wheat, egg, soy, nuts and fish/seafood for 6 weeks, have consistently shown the best cure rates. However, their high level of restriction and need for multiple endoscopies (top-down approach) have been a deterrent for patients and physicians. Less restrictive empiric schemes, like a four-food (animal milk, gluten-containing cereals, egg, legumes) or a two-food (animal milk and gluten-containing cereals) elimination diet have lately shown encouraging results. Therefore, a novel step-up strategy (2-4-6) may enhance patient uptake and promptly identify most responders to empiric diets with few food triggers, besides saving unnecessary dietary restrictions and endoscopic procedures</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1747-4132 (Electronic)IS - 1747-4124 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/17474124.2017.1271324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27998193">PM:27998193</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Gastroenterol Hepatol\2017-11-115-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Gastroenterol Hepatol\2017-11-115-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Molina-Infante J</style></custom2><misc3><style face="normal" font="Arial">10.1080/17474124.2017.1271324</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ketnawa,S.</style></author><author><style face="normal" font="Arial"> Liceaga,A.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of Microwave Treatments on Antioxidant Activity and Antigenicity of Fish Frame Protein Hydrolysates</style></title><secondary-title><style face="normal" font="Arial">Food Bioprocess Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Bioprocess Technol</style></full-title></periodical><pages end="591" start="582">582-591</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alcalase</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degree of hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Low temperature</style></keyword><keyword><style face="normal" font="Arial"> Microwave</style></keyword><keyword><style face="normal" font="Arial"> Nutraceutical</style></keyword><keyword><style face="normal" font="Arial"> Nutraceuticals</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> protein solubility</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trout</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1935-5149</style></isbn><abstract><style face="normal" font="Arial">Protein solubility, protein recovery, antioxidant activity, and antigenicity of microwave pretreatment and/or microwave-assisted hydrolysis of trout frame protein hydrolysates was investigated. Treatments consisted of (1) microwave pretreatment at low temperature (55-á-¦C) followed by conventional enzymatic hydrolysis or (2) high temperature (90-á-¦C) followed by conventional enzymatic hydrolysis; (3) microwave pretreatment at high temperature (90-á-¦C) followed by microwave-assisted enzymatic hydrolysis, and (4) no microwave pretreatment followed by microwave-assisted enzymatic hydrolysis. Compared to controls, microwave treatments significantly improved (P-á&lt;-á0.05) protein solubility, protein recovery, degree of hydrolysis, and 2,2</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¦-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) free radical scavenging radical scavenging activity. Decrease of antigenicity (55</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô93-á%) was obtained in all microwave-treated samples. Based on the results of this study, the use of microwave pretreatment for 5-ámin at 90-á-¦C, followed by conventional enzymatic hydrolysis with alcalase for 2</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô10-ámin was the best treatment condition to produce fish peptides with antioxidant activity and the lowest immunoreactivity. These peptides have potential to be applied as hypoallergenic ingredients in food formulations and nutraceuticals</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11947-016-1841-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s11947-016-1841-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Bioprocess Technol\20161220-KetnawaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Bioprocess Technol\20161220-KetnawaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Ketnawa S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11947-016-1841-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumar,V.</style></author><author><style face="normal" font="Arial"> Rani,A.</style></author><author><style face="normal" font="Arial"> Hussain,L.</style></author><author><style face="normal" font="Arial"> Jha,P.</style></author><author><style face="normal" font="Arial"> Pal,V.</style></author><author><style face="normal" font="Arial"> Petwal,V.C.</style></author><author><style face="normal" font="Arial"> Dwivedi,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Impact of Electron Beam on Storage Protein Subunits, In Vitro Protein Digestibility and Trypsin Inhibitor Content in Soybean Seeds</style></title><secondary-title><style face="normal" font="Arial">Food Bioprocess Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Bioprocess Technol</style></full-title></periodical><pages end="412" start="407">407-412</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">11S</style></keyword><keyword><style face="normal" font="Arial"> Densitometry</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein digestibility</style></keyword><keyword><style face="normal" font="Arial"> Protein Subunits</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy products</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1935-5149</style></isbn><abstract><style face="normal" font="Arial">The present investigation was carried out to study the effect of 4.8, 9.2, 15.3 and 21.2-ákGy of electron beam (EB)-irradiation on major storage proteins viz. glycinin (11S) and +¦-conglycinin (7S), in vitro protein digestibility (IVPD), and trypsin inhibitor (TI) content in seeds of three soybean genotypes. Densitometry of SDS-PAGE protein profile revealed significant (P-á&lt;-á0.05) reduction in +¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ, +¦ and +¦ subunits of 7S fraction at all doses. This reduction was higher (P-á&lt;-á0.05) than the decline observed in acidic and basic subunit of 11S fraction. Basic subunit registered significant (P-á&lt;-á0.05) increase at specific doses in two genotypes. All the doses induced significant (P-á&lt;-á0.05) increase in IVPD, and the increase due to 9.2, 15.3 and 21.2-ákGy was higher (P-á&lt;-á0.05) compared to 4.8-ákGy dose. The impact on TI content was genotype-dependent. The study showed a higher (P-á&lt;-á0.05) decline in the concentration of 7S fraction compared to 11S fraction and improvement in IVPD of soybean seeds due to exposure to EB-irradiation, which may influence the functional and nutritional value of soy products processed from them</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11947-016-1823-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s11947-016-1823-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Bioprocess Technol\20161220-KumarV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Bioprocess Technol\20161220-KumarV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Kumar V</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11947-016-1823-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchiz,A.</style></author><author><style face="normal" font="Arial"> Ballesteros,I.</style></author><author><style face="normal" font="Arial"> Martin,A.</style></author><author><style face="normal" font="Arial"> Rueda,J.</style></author><author><style face="normal" font="Arial"> Pedrosa,M.M.</style></author><author><style face="normal" font="Arial"> Dieguez,M.</style></author><author><style face="normal" font="Arial"> Rovira,M.</style></author><author><style face="normal" font="Arial"> Cuadrado,C.</style></author><author><style face="normal" font="Arial"> Linacero,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Detection of pistachio allergen coding sequences in food products: A comparison of two real time PCR approaches</style></title><secondary-title><style face="normal" font="Arial">Food Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Control</style></full-title></periodical><pages end="270" start="262">262-270</pages><volume><style face="normal" font="Arial">75</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatment</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0956-7135</style></isbn><abstract><style face="normal" font="Arial">The labelled of pistachio on food products is mandatory and, as a consequence, the development of suitable analytical methodologies to detect this nut in processed foods is advisable. In this work, two different qPCR assays to detect pistachio, SYBR-«Green and locked nucleic acid (LNA) probes, are tested and compared. Pis v allergen coding sequences have been amplified and cloned in different pistachio varieties, and specific primers and probes for each allergen have been designed. According to our results, LNA probe-real time PCR appears to be the most sensitive and specific method, reaching 10-ámg/kg of pistachio. The effect of temperature and/or pressure on pistachio DNA detection was also analysed by LNA probe-based qPCR. Data showed a reduced amplificability of pistachio after thermal treatment under pressure, nevertheless, this effect was not observed after boiling. The applicability of this method has been studied by analysing 14 food products and by comparison with a commercial ELISA kit</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodcont.2016.12.015</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodcont.2016.12.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Control\20161220-SanchizA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Control\20161220-SanchizA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Sanchiz A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodcont.2016.12.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bucholska,J.</style></author><author><style face="normal" font="Arial"> Minkiewicz,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Warmia and Mazury in Olsztyn, Faculty of Food Sciences, Department of Food Biochemistry, Plac Cieszynski 1, PL-10-726 Olsztyn, PolandUniversity of Warmia and Mazury in Olsztyn, Faculty of Food Sciences, Department of Food Biochemistry, Plac Cieszynski 1, PL-10-726 Olsztyn, Poland</style></auth-address><titles><title><style face="normal" font="Arial">The Use of Peptide Markers of Carp and Herring Allergens as an Example of Detection of Sequenced and Non-Sequenced Proteins</style></title><secondary-title><style face="normal" font="Arial">Food Technol Biotechnol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Technol Biotechnol</style></abbr-1></periodical><pages end="274" start="266">266-274</pages><volume><style face="normal" font="Arial">54</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> Carp</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> herring</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">The objective of this study is to identify fish protein markers for detecting multiple species based on a comparative proteomic approach that relies on fragments with identical sequences. The possibilities and challenges of the use of peptides obtained from carp (Cyprinus carpio) and herring (Clupea harengus) proteins are discussed. A bioinformatic analysis was followed by an LC-MS/MS experiment to identify markers predicting the presence of fish allergenic proteins. Selected myosin peptides were found in carp protein hydrolysates with known sequences and in herring protein hydrolysates with unknown sequences. The results obtained for carp and herring proteins myosin and parvalbumin indicate that proteins with unknown sequences can be identified by peptide markers. Such markers can be designed by disregarding the principle that peptides should be unique (present in one sequence). The challenge is to determine a group of proteins that can be detected by peptide identification</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1330-9862 (Print)IS - 1330-9862 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.17113/ftb.54.03.16.4244</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27956857">PM:27956857</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Technol Biotechnol\2016-54-266-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Technol Biotechnol\2016-54-266-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Bucholska J</style></custom2><misc3><style face="normal" font="Arial">10.17113/ftb.54.03.16.4244</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Noll,A.J.</style></author><author><style face="normal" font="Arial"> Gourdine,J.P.</style></author><author><style face="normal" font="Arial"> Yu,Y.</style></author><author><style face="normal" font="Arial"> Lasanajak,Y.</style></author><author><style face="normal" font="Arial"> Smith,D.F.</style></author><author><style face="normal" font="Arial"> Cummings,R.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry, School of Medicine, Emory University, Atlanta, GA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Galectins are human milk glycan receptors</style></title><secondary-title><style face="normal" font="Arial">Glycobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Glycobiology</style></full-title></periodical><pages end="669" start="655">655-669</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Galactose</style></keyword><keyword><style face="normal" font="Arial"> Galectins</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycan microarray</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> hapten</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">The biological recognition of human milk glycans (HMGs) is poorly understood. Because HMGs are rich in galactose we explored whether they might interact with human galectins, which bind galactose-containing glycans and are highly expressed in epithelial cells and other cell types. We screened a number of human galectins for their binding to HMGs on a shotgun glycan microarray consisting of 247 HMGs derived from human milk, as well as to a defined HMG microarray. Recombinant human galectins (hGal)-1, -3, -4, -7, -8 and -9 bound selectively to glycans, with each galectin recognizing a relatively unique binding motif; by contrast hGal-2 did not recognize HMGs, but did bind to the human blood group A Type 2 determinants on other microarrays. Unlike other galectins, hGal-7 preferentially bound to glycans expressing a terminal Type 1 (Galbeta1-3GlcNAc) sequence, a motif that had eluded detection on non-HMG glycan microarrays. Interactions with HMGs were confirmed in a solution setting by isothermal titration microcalorimetry and hapten inhibition experiments. These results demonstrate that galectins selectively bind to HMGs and suggest the possibility that galectin-HMG interactions may play a role in infant immunity</style></abstract><notes><style face="normal" font="Arial">DA - 20160428IS - 1460-2423 (Electronic)IS - 0959-6658 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/glycob/cww002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26747425">PM:26747425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Glycobiology\2016-26-655-69.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Glycobiology\2016-26-655-69.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160428, Noll AJ</style></custom2><misc3><style face="normal" font="Arial">10.1093/glycob/cww002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kowalzick,L.</style></author><author><style face="normal" font="Arial"> Thiel,W.</style></author><author><style face="normal" font="Arial"> Bielfeld,C.</style></author><author><style face="normal" font="Arial"> Ziegler,H.</style></author><author><style face="normal" font="Arial"> Eickenscheidt,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Hautkrankheiten und Allergologie, HELIOS Vogtland-Klinikum Plauen GmbH, 100153, 08505, Plauen, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Partial response of solar urticaria to omalizumab therapy]</style></title><secondary-title><style face="normal" font="Arial">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hautarzt</style></full-title></periodical><pages end="496" start="492">492-496</pages><volume><style face="normal" font="Arial">68</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immediate type reactions</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sunlight</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The treatment of solar urticaria is regarded as difficult. In some cases good responses to the anti-IgE antibody omalizumab (Xolair(R)), approved for treatment of chronic spontaneous urticaria, have been reported. We report on a 50-year-old Caucasian woman who for the last 5 years has developed localized itching and stinging erythemas following exposure to sunlight accompanied sometimes by anaphylactic reactions. Oral antihistamines in three- to four-fold doses and a topical sun screen had been only partially effective in long-term use. Positive immediate-type reactions with whealing appeared in phototesting with low doses of UVB and UVA. Three weeks after s. c. injection of 300 mg omalizumab, the minimal urticarial dose (MUD) for UVB was increased at least 20-fold (from &lt;0.001 to 0.02 J/cm2) and for UVA four-fold (from 0.1 to 0.4 J/cm2) and the patient reported no itching at the test area. On the other hand, MUD for UVA1 remained unchanged (5.0 J/cm2). The weekly urticarial activity score (UAS7) was reduced from 30 points before omalizumab administration to 14 points in weeks two and three. Overall, a partial response of solar urticaria to omalizumab therapy could be observed in the present case</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - gerPT - Journal ArticlePT - English AbstractCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00105-016-3913-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27995273">PM:27995273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hautarzt\20161220-KowalzickL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hautarzt\20161220-KowalzickL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Kowalzick L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00105-016-3913-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mozzini Monteiro,T.</style></author><author><style face="normal" font="Arial"> Ferrera Costa,H.</style></author><author><style face="normal" font="Arial"> Carvalho Vieira,G.</style></author><author><style face="normal" font="Arial"> Rodrigues Salgado,P.R.</style></author><author><style face="normal" font="Arial"> da Silva Stiebbe Salvadori,M.G.</style></author><author><style face="normal" font="Arial"> de Almeida,R.N.</style></author><author><style face="normal" font="Arial"> de Fatima Vanderlei de Souza,M.</style></author><author><style face="normal" font="Arial"> Neves Matias,W.</style></author><author><style face="normal" font="Arial"> Andrade Braga,V.</style></author><author><style face="normal" font="Arial"> Nalivaiko,E.</style></author><author><style face="normal" font="Arial"> Piuvezam,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunopharmacology, Department of Physiology and Pathology Federal University of Paraiba Joao Pessoa Paraiba 58051-970 Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Anti-asthmatic and anxiolytic effects of Herissantia tiubae, a Brazilian medicinal plant</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="212" start="201">201-212</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aminophylline</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Diazepam</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Herissantia tiubae (HtE) is a Brazilian plant used in folk medicine to treat inflammatory diseases. Our aim was to determine whether the HtE has anti-inflammatory and anxiolytic effects in a murine model of asthma. Ovalbumin (OVA)-sensitized BALB/c mice were treated with HtE (50, 100, or 200 mg/kg) or dexamethasone before each OVA challenge. After the last challenge, animals were subjected to anxiety tests and respiratory measurements. Following euthanasia, we quantified immune cells in the bronchoalveolar lavage (BAL), serum IgE titer and cytokine levels, cellular infiltration and mucus content in the lung tissues, and cellular composition of the mediastinal lymph nodes. OVA challenge in sensitized animals caused: (1) reduction of mean respiratory and dominant respiratory rate (from 398 +/- 12 to 286 +/- 20 cicles per minute (cpm) and from 320 +/- 14 to 162 +/- 15 cpm, respectively); (2) increase in behavioral markers of anxiety tests; (3) substantial pro-inflammatory effects, including rise in OVA-specific IgE titer (from 0 to 1:2048) and these inflammatory effect diminished the titer to 1:512 after HtE treatment; rise in plasma IL-13 (from 13 ng/mL in saline to 227 ng/mL in OVA and HtE treatment restored to 1.29 ng/mL; rise in total BAL cell count (from 0.742 cells/mL in saline to 11.77 cells/mL in OVA), with prominent eosinophilia. H. tiubae extract affected respiratory parameters similarly to aminophylline, behavioral changes comparable to diazepam, and inflammation being as efficient as dexamethasone. H. tiubae extract (HtE) possesses both anti-inflammatory and anxiolytic properties in the murine model of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957328">PM:27957328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-201-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-201-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Mozzini Monteiro T</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.107</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weeratna,R.D.</style></author><author><style face="normal" font="Arial"> Chikh,G.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Fraser,J.D.</style></author><author><style face="normal" font="Arial"> Thorn,J.M.</style></author><author><style face="normal" font="Arial"> Merson,J.R.</style></author><author><style face="normal" font="Arial"> McCluskie,M.J.</style></author><author><style face="normal" font="Arial"> Champion,B.R.</style></author><author><style face="normal" font="Arial"> Davis,H.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pfizer Vaccine Immunotherapeutics Ottawa Laboratories Ottawa Ontario Canada</style></auth-address><titles><title><style face="normal" font="Arial">Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="147" start="135">135-147</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Primates</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">The anti-human immunoglobulin E (IgE) monoclonal antibody, omalizumab (Xolair(R), Genentech, South San Fransisco, CA), is effective in the treatment of poorly controlled moderate to severe allergic asthma and chronic idiopathic urticaria. It acts by specifically binding to the constant domain (C3) of free human IgE in the blood and interstitial fluid. Although efficacious, use of omalizumab is limited due to restrictions on patient weight and pre-existing IgE levels, and frequent dosing (q2-4 weeks). A vaccine inducing anti-IgE antibodies has the potential for similar clinical benefits with less frequent dosing and relatively lower cost of goods. We developed a vaccine containing two IgE peptide-conjugates targeting the C3 domain of human IgE. As part of preclinical evaluation of the vaccine to optimize formulation and dose prior to initiating clinical studies, we evaluated the vaccine in non-human primates, and demonstrate the induction of anti-peptide antibodies that can bind to conformationally intact human IgE and are capable, at least in some animals, of substantial lowering circulating IgE levels</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.98</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957325">PM:27957325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-135-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\2016-4-135-47.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Weeratna RD</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.98</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Kleer,I.M.</style></author><author><style face="normal" font="Arial"> Kool,M.</style></author><author><style face="normal" font="Arial"> de Bruijn,M.J.W.</style></author><author><style face="normal" font="Arial"> Willart,M.</style></author><author><style face="normal" font="Arial"> Van Moorleghem,J.</style></author><author><style face="normal" font="Arial"> Schuijs,M.J.</style></author><author><style face="normal" font="Arial"> Plantinga,M.</style></author><author><style face="normal" font="Arial"> Beyaert,R.</style></author><author><style face="normal" font="Arial"> Hams,E.</style></author><author><style face="normal" font="Arial"> Fallon,P.G.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author><author><style face="normal" font="Arial"> Hendriks,R.W.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Perinatal Activation of the Interleukin-33 Pathway Promotes Type 2 Immunity in the Developing Lung</style></title><secondary-title><style face="normal" font="Arial">Immunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunity</style></full-title></periodical><pages end="1298" start="1285">1285-1298</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> alveolarization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL1RL1</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung development</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> OX40L</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Symbiosis</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1074-7613</style></isbn><abstract><style face="normal" font="Arial">Allergic disease originates in early life and polymorphisms in interleukin-33 gene (IL33) and IL1RL1, coding for IL-33R and decoy receptor sST2, confer allergy risk. Early life T helper 2 (Th2) cell skewing and allergy susceptibility are often seen as remnants of feto-maternal symbiosis. Here we report that shortly after birth, innate lymphoid type 2 cells (ILC2s), eosinophils, basophils, and mast cells spontaneously accumulated in developing lungs in an IL-33-dependent manner. During the phase of postnatal lung alveolarization, house dust mite exposure further increased IL-33, which boosted cytokine production in ILC2s and activated CD11b+ dendritic cells (DCs). IL-33 suppressed IL-12p35 and induced OX40L in neonatal DCs, thus promoting Th2 cell skewing. Decoy sST2 had a strong preventive effect on asthma in the neonatal period, less so in adulthood. Thus, enhanced neonatal Th2 cell skewing to-áinhaled allergens results from postnatal hyperactivity of the IL-33 axis during a period of maximal lung remodeling</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -CO - Belgium -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.immuni.2016.10.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27939673">PM:27939673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunity\2016-45-1285-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunity\2016-45-1285-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, de Kleer IM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.immuni.2016.10.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahlakoiv,T.</style></author><author><style face="normal" font="Arial"> Artis,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jill Roberts Institute for Research in Inflammatory Bowel Disease, Joan and Sanford I. Weill Department of Medicine, Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA</style></auth-address><titles><title><style face="normal" font="Arial">Allergen Exposure: When Timing Is Everything</style></title><secondary-title><style face="normal" font="Arial">Immunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunity</style></full-title></periodical><pages end="1190" start="1188">1188-1190</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="12/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="20" Month="12" Year="2016">2016/12/20</year></dates><abstract><style face="normal" font="Arial">It is known that young children exposed to allergens are prone to develop asthma later in life. In this issue of Immunity, de Kleer et al. (2016) identify IL-33 as a key player in the developing lung for sensitization to environmental allergens and airway hyperreactivity</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1097-4180 (Electronic)IS - 1074-7613 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.immuni.2016.12.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28002727">PM:28002727</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunity\2016-45-1188-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunity\2016-45-1188-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Mahlakoiv T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.immuni.2016.12.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82631</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Z.</style></author><author><style face="normal" font="Arial"> Chen,T.</style></author><author><style face="normal" font="Arial"> Long,M.</style></author><author><style face="normal" font="Arial"> Chen,L.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Yin,N.</style></author><author><style face="normal" font="Arial"> Chen,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathogen Biology, College of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, 430065, China</style></auth-address><titles><title><style face="normal" font="Arial">Electro-acupuncture at Acupoint ST36 Ameliorates Inflammation and Regulates Th1/Th2 Balance in Delayed-Type Hypersensitivity</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic skin inflammation</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electroacupuncture</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="13" Month="12" Year="2016">2016/12/13</year></dates><abstract><style face="normal" font="Arial">Increasing evidence indicates anti-allergic and anti-inflammatory effects of electro-acupuncture (EA) therapy. However, its underlying mechanism on delayed-type hypersensitivity (DTH), a classic allergic inflammatory disease, still remains unclear. In this study, we aimed to explore the immunomodulatory mechanism of EA intervention in a mouse model of ovalbumin (OVA)-induced DTH. Mice were randomly divided into four groups: Control, OVA-DTH, DTH + EA, DTH + Sham. "Zusanli" acupoint (ST36) was used for DTH + EA, whereas a non-acupoint (localized 5 mm below the "Zusanli" acupoint) was selected for DTH + Sham. Footpad thickness was checked, and the infiltration of inflammatory cells was estimated by hematoxylin and eosin staining. Levels of IgG and IgE in serum of different groups and inflammatory cytokines in the supernatants from homogenized footpads, including IFN-gamma, TNF-alpha, IL-4, and IL-5, were determined by ELISA. Cell proliferation of spleen lymphocytes was assayed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT). The frequency of CD4+IFN-gamma+ and CD4+IL-4+ T cells was analyzed with flow cytometry. In addition, the mRNA and protein expression of T-bet and GATA-3 were evaluated by real-time PCR and Western blotting, respectively. Our data showed EA treatment at acupoint ST36 relieved the pathological progression of DTH responses via reduction in footpad swelling, infiltration of inflammatory cells, levels of IgG and IgE as well as decreased production of IFN-gamma and TNF-alpha in homogenized footpad tissue. Moreover, detailed studies were performed revealing that EA attenuated the percentage of CD4+IFN-gamma+ T cells and prevented Th cells differentiation into Th1 cells, and this results from inhibiting secretion of IFN-gamma and suppressing expression of T-bet, an IFN-gamma transcription factor. The results indicated that EA treatment improved Th1-mediated allergic skin inflammation via restoring Th1/Th2 balance by curbing Th1 differentiation. These findings suggested that EA at acupoint ST36 might be a useful and promising therapeutic for allergic inflammatory as well as Th1-mediated inflammation response</style></abstract><notes><style face="normal" font="Arial">DA - 20161214IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-016-0487-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27966183">PM:27966183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20161214-WangZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20161214-WangZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Wang Z</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-016-0487-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82632</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Trinh,H.K.</style></author><author><style face="normal" font="Arial"> Pham,D.L.</style></author><author><style face="normal" font="Arial"> Ban,G.Y.</style></author><author><style face="normal" font="Arial"> Lee,H.Y.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author><author><style face="normal" font="Arial"> Ye,Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Altered Systemic Adipokines in Patients with Chronic Urticaria</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="110" start="102">102-110</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adipokines</style></keyword><keyword><style face="normal" font="Arial"> adiponectin</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Leptin</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Increasing evidence suggests that adipokines affect immune responses and chronic urticaria (CU) is associated with an altered immune response related to chronic systemic inflammation. Our objectives were to investigate whether adipokines are involved in CU pathogenesis and to outline relationships between adipokines and urticaria severity and quality of life. METHODS: Serum adiponectin, leptin, lipocalin-2 (LCN2), interleukin (IL)-10, IL-6, and tumor necrosis factor (TNF)-alpha concentrations were measured by enzyme-linked immunosorbent assays in 191 CU patients and 89 healthy controls. The effect of LCN2 on N-formyl-methionine-leucine-phenylalanine (fMLP)-induced neutrophil chemotaxis was assessed using migration assays. CU severity was assessed based on the urticaria activity score (UAS). To explore relationships between adipokines and UAS and the chronic urticaria-specific quality of life (CU-QoL) questionnaire, a structural equation model was used. RESULTS: Mean levels of serum LCN2, TNF-alpha, IL-6, and IL-10 were significantly higher in CU patients than in controls. Adiponectin levels were significantly lower in patients with CU than in controls. While serum IL-6 levels were significantly higher in refractory CU patients, compared to responsive CU individuals, LCN2 levels were significantly lower. LCN2 inhibited fMLP-induced neutrophil migration. LCN2 showed a direct relationship with UAS (beta = -0.274, p &lt; 0.001), and UAS was found to contribute to CU-QoL (beta = 0.417, p &lt; 0.001). CONCLUSIONS: Our results highlighted an imbalance in pro- and anti-inflammatory adipokines in CU patients. We suggest that LCN2 could be a differential marker for disease activity and the clinical responses to antihistamine treatment in CU patients. Modulation of systemic inflammation may be a therapeutic strategy for treating severe, refractory CU</style></abstract><notes><style face="normal" font="Arial">DA - 20161130IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1159/000452626</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27902979">PM:27902979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-102-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-102-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161130, Trinh HK</style></custom2><misc3><style face="normal" font="Arial">10.1159/000452626</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Igarashi,S.</style></author><author><style face="normal" font="Arial"> Suzuki,K.</style></author><author><style face="normal" font="Arial"> Nakamura,Y.</style></author><author><style face="normal" font="Arial"> Ishimaru,K.</style></author><author><style face="normal" font="Arial"> Fukano,C.</style></author><author><style face="normal" font="Arial"> Masuyama,K.</style></author><author><style face="normal" font="Arial"> Ohashi-Doi,K.</style></author><author><style face="normal" font="Arial"> Nakao,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">The Efficacy of Sublingual Immunotherapy for Allergic Rhinitis May Vary with the Time of Day</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="118" start="111">111-118</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sublingual immunotherapy (SLIT) is a safe and effective treatment for allergic rhinitis (AR). However, many issues regarding SLIT remain to be resolved, including the optimal timing of administration. This study investigated the effect of time of day on SLIT efficacy with the goal of optimizing the therapeutic outcome. METHODS: We performed prophylactic SLIT at different times of day (10 a.m. or 10 p.m.) in 2 mouse models of AR: an ovalbumin (OVA)-induced AR model and Cry j 1-induced AR model, and compared the effects. RESULTS: In the OVA-induced AR model, mice sublingually receiving OVA at 10 a.m. exhibited a greater decrease in total and OVA-specific IgE levels than mice treated at 10 p.m. In addition, mice treated at 10 a.m. exhibited reductions in OVA-specific IL-4, IL-10, and IL-13 production by splenocytes relative to mice treated at 10 p.m. Furthermore, we observed a more efficient capture of sublingually administered OVA in submandibular lymph nodes at 10 a.m. than at 10 p.m. in mice. Similar results were observed in the Cry j 1-induced AR model using Japanese cedar pollen extract for SLIT. CONCLUSIONS: Given the allergen-specific antibody and T cell responses, we suggest that SLIT may be more effective in the resting phase than in the active phase (note that mice are nocturnal animals). Thus, we propose that a chronotherapeutic approach should be considered for SLIT to maximize its effectiveness</style></abstract><notes><style face="normal" font="Arial">DA - 20161130IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000450954</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27902978">PM:27902978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-111-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-111-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161130, Igarashi S</style></custom2><misc3><style face="normal" font="Arial">10.1159/000450954</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arik,Y.E.</style></author><author><style face="normal" font="Arial"> Karaatmaca,B.</style></author><author><style face="normal" font="Arial"> Sackesen,C.</style></author><author><style face="normal" font="Arial"> Sahiner,U.M.</style></author><author><style face="normal" font="Arial"> Cavkaytar,O.</style></author><author><style face="normal" font="Arial"> Sekerel,B.E.</style></author><author><style face="normal" font="Arial"> Soyer,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Parasitic Infections in Children with Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="135" start="130">130-135</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infections</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Parasites have been proposed to be an underlying cause of chronic spontaneous urticaria (CSU) in childhood, but a clear causal relationship between them has not been established. This study aimed to investigate the prevalence of parasitic infection-related CSU (PIRCSU) in children and to determine the factors associated with PIRCSU. METHOD: Data from 211 children with CSU were analyzed. Information on stool examination, antiparasitic medications received, and response to treatment was recorded. The disappearance of urticaria for more than 6 months is defined as remission, and remission of urticaria after antiparasitic treatment is defined as PIRCSU. RESULTS: Parasites were detected in 21 (10%) patients. Blastocystis hominis was the most common parasite. After antiparasitic medication, all samples became normal; urticaria continued in 5, was reduced in 6, and disappeared in 10 patients. The latter 10 patients were considered as cases of PIRCSU (4.7%). The erythrocyte sedimentation rate was significantly higher in patients with PIRCSU than in those without [8.5 mm/h (3.5-14.5) vs. 2 (0-7), p = 0.011]. Gastrointestinal complaints were significantly more frequent in patients with PIRCSU than in those without. The occurrence of abdominal pain was a significant risk factor that increased the probability of PIRCSU [OR = 6.60, 95% CI = 1.35-32.23, p = 0.020]. CONCLUSION: Parasites may cause CSU even in nontropical countries, and remission may only be possible with the treatment of the parasitic infection. The occurrence of abdominal pain points to parasitic infection in patients with CSU. Therefore, we suggest that parasites should be investigated routinely, especially if the patient has gastrointestinal symptoms of CSU in childhood</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1159/000450953</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27907915">PM:27907915</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-130-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-130-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Arik YE</style></custom2><misc3><style face="normal" font="Arial">10.1159/000450953</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korosec,P.</style></author><author><style face="normal" font="Arial"> Silar,M.</style></author><author><style face="normal" font="Arial"> Kopac,P.</style></author><author><style face="normal" font="Arial"> Erzen,R.</style></author><author><style face="normal" font="Arial"> Zidarn,M.</style></author><author><style face="normal" font="Arial"> Kosnik,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia</style></auth-address><titles><title><style face="normal" font="Arial">Distinct Contributory Factors Determine Basophil-Allergen Sensitivity in Grass Pollen Rhinitis and in Anaphylactic Wasp Venom Allergy</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="101" start="89">89-101</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophil sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera allergy</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Slovenia</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We sought to determine whether basophil-allergen sensitivity could be transferred to donor basophils by passive IgE sensitisation in allergic rhinitis and anaphylactic Hymenoptera venom hypersensitivity. METHODS: We studied 15 wasp venom-, 19 grass pollen- and 2 house dust mite-allergic patients, 2 healthy donors, and 8 wasp venom-allergic donors. In all subjects, we first evaluated the initial basophil response to wasp venom, grass pollen, or house dust mite allergen. Donor basophils were then stripped, sensitised with the different patients' serum IgE, and challenged with the corresponding allergen. The CD63 response of donor basophils was then compared with initial basophil responses. RESULTS: In wasp venom-allergic subjects, the IgE transfer did not reflect the initial basophil-allergen sensitivity, because the venom IgE of subjects with high or low basophil sensitivity induced comparable responsiveness in healthy donor basophils. Furthermore, vice versa, when we sensitised the donor basophils of wasp venom-allergic individuals with different wasp venom or house dust mite IgE, we demonstrated that their response was predictable by their initial basophil allergen sensitivity. In the rhinitis allergy model, the IgE transfer correlated with the patients' initial basophil responsiveness because the grass pollen IgE of the subjects with high basophil allergen sensitivity induced significantly higher responsiveness of donor basophils than the IgE of subjects with initially low basophil allergen sensitivity. CONCLUSIONS: Our results suggest that basophil allergen sensitivity evaluated by flow-cytometric CD63 analysis depends on two distinct contribution factors. In anaphylactic Hymenoptera allergy, the major factor was intrinsic cellular sensitivity, whereas in pollen allergy, the major factor was allergen-specific IgE on the cell surface</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Slovenia -</style></notes><work-type><style face="normal" font="Arial">10.1159/000452102</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27907922">PM:27907922</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-89-101.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2016-171-89-101.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Korosec P</style></custom2><misc3><style face="normal" font="Arial">10.1159/000452102</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Skora,J.</style></author><author><style face="normal" font="Arial"> Sulyok,M.</style></author><author><style face="normal" font="Arial"> Nowak,A.</style></author><author><style face="normal" font="Arial"> Otlewska,A.</style></author><author><style face="normal" font="Arial"> Gutarowska,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Toxinogenicity and cytotoxicity of Alternaria, Aspergillus and Penicillium moulds isolated from working environments</style></title><secondary-title><style face="normal" font="Arial">Int J Environ Sci Technol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Environ Sci Technol</style></abbr-1></periodical><pages end="608" start="595">595-608</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Culture Media</style></keyword><keyword><style face="normal" font="Arial"> Culture medium</style></keyword><keyword><style face="normal" font="Arial"> cyclopiazonic acid</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxins</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> working environment</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1735-2630</style></isbn><abstract><style face="normal" font="Arial">There is currently limited research available on the secondary metabolites of moulds in workplaces. The aim of this study was to determine the mould contamination in museums (N-á=-á4), composting plants (N-á=-á4) and tanneries (N-á=-á4) and the secondary metabolite profiles of Alternaria, Aspergillus and Penicillium isolates from these workplaces. Alternaria, Aspergillus and Penicillium species were identified using the ITS1/2 sequence of the rDNA region. Mould metabolites were quantitatively analysed on standard laboratory medium and mineral medium containing materials specific to each workplace using liquid chromatography-mass spectrometry. We also examined the cytotoxicity of the moulds using MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assays. Air microbiological contamination analyses showed a number of microorganisms, ranging from 2.4-á+ù-á103 CFU-ám</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3 (composting plants) to 6.8-á+ù-á104 CFU-ám</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3 (tanneries). We identified high percentages of Alternaria, Aspergillus and Penicillium moulds (air 57</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô59%, surfaces 10</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô65%) in all workplaces. The following moulds were the most cytotoxic (>90%): Alternaria alternata, A. limoniasperae, Aspergillus flavus, Penicillium biourgeianum, P. commune and P. spinulosum. The same mould species isolated from different working environments exhibited varying toxigenic and cytotoxic properties. Modifying the culture medium to simulate environmental conditions most often resulted in the inhibition of secondary metabolite production. Moulds isolated from the working environments produced the following mycotoxins (ng-ág</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1): chanoclavines (0.28</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô204), cyclopiazonic acid (27.1</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô1045), fumigaclavines (0.33</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô10,640,000), meleagrin (0.57</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô13,393), roquefortins (0.01</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô16,660), rugulovasines (112</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô220), viridicatin (0.12</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô957), viridicatol (4.23</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2753) and quinocitrinines (0.07</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô1104), which may have a negative impact on human health</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13762-016-1172-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13762-016-1172-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Environ Sci Technol\20161223-SkoraJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Environ Sci Technol\20161223-SkoraJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Skora J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13762-016-1172-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hurrass,J.</style></author><author><style face="normal" font="Arial"> Heinzow,B.</style></author><author><style face="normal" font="Arial"> Aurbach,U.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Bufe,A.</style></author><author><style face="normal" font="Arial"> Buzina,W.</style></author><author><style face="normal" font="Arial"> Cornely,O.A.</style></author><author><style face="normal" font="Arial"> Engelhart,S.</style></author><author><style face="normal" font="Arial"> Fischer,G.</style></author><author><style face="normal" font="Arial"> Gabrio,T.</style></author><author><style face="normal" font="Arial"> Heinz,W.</style></author><author><style face="normal" font="Arial"> Herr,C.E.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Koberle,M.</style></author><author><style face="normal" font="Arial"> Lichtnecker,H.</style></author><author><style face="normal" font="Arial"> Lob-Corzilius,T.</style></author><author><style face="normal" font="Arial"> Merget,R.</style></author><author><style face="normal" font="Arial"> Mulleneisen,N.</style></author><author><style face="normal" font="Arial"> Nowak,D.</style></author><author><style face="normal" font="Arial"> Rabe,U.</style></author><author><style face="normal" font="Arial"> Raulf,M.</style></author><author><style face="normal" font="Arial"> Seidl,H.P.</style></author><author><style face="normal" font="Arial"> Steiss,J.O.</style></author><author><style face="normal" font="Arial"> Szewszyk,R.</style></author><author><style face="normal" font="Arial"> Thomas,P.</style></author><author><style face="normal" font="Arial"> Valtanen,K.</style></author><author><style face="normal" font="Arial"> Wiesmuller,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Abteilung Infektions- und Umwelthygiene, Gesundheitsamt der Stadt Koln, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Medical diagnostics for indoor mold exposure</style></title><secondary-title><style face="normal" font="Arial">Int J Hyg Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Hyg Environ Health</style></full-title></periodical><pages end="328" start="305">305-328</pages><volume><style face="normal" font="Arial">220</style></volume><number><style face="normal" font="Arial">2 Pt B</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus infection</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical diagnostics</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Hemorrhage</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> Indoor environments</style></keyword><keyword><style face="normal" font="Arial"> Indoor mold</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Mucous Membrane</style></keyword><keyword><style face="normal" font="Arial"> Mycose</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxins</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk groups</style></keyword><keyword><style face="normal" font="Arial"> Sarcoidosis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Test method</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">In April 2016, the German Society of Hygiene, Environmental Medicine and Preventative Medicine (Gesellschaft fur Hygiene, Umweltmedizin und Praventivmedizin (GHUP)) together with other scientific medical societies, German and Austrian medical societies, physician unions and experts has provided an AWMF (Association of the Scientific Medical Societies) guideline 'Medical diagnostics for indoor mold exposure'. This guideline shall help physicians to advise and treat patients exposed indoors to mold. Indoor mold growth is a potential health risk, even without a quantitative and/or causal association between the occurrence of individual mold species and health effects. Apart from the allergic bronchopulmonary aspergillosis (ABPA) and the mycoses caused by mold, there is only sufficient evidence for the following associations between moisture/mold damages and different health effects: Allergic respiratory diseases, asthma (manifestation, progression, exacerbation), allergic rhinitis, exogenous allergic alveolitis and respiratory tract infections/bronchitis. In comparison to other environmental allergens, the sensitizing potential of molds is estimated to be low. Recent studies show a prevalence of sensitization of 3-10% in the total population of Europe. The evidence for associations to mucous membrane irritation and atopic eczema (manifestation, progression, exacerbation) is classified as limited or suspected. Inadequate or insufficient evidence for an association is given for COPD, acute idiopathic pulmonary hemorrhage in children, rheumatism/arthritis, sarcoidosis, and cancer. The risk of infections from indoor molds is low for healthy individuals. Only molds that are capable to form toxins can cause intoxications. The environmental and growth conditions and especially the substrate determine whether toxin formation occurs, but indoor air concentrations are always very low. In the case of indoor moisture/mold damages, everyone can be affected by odor effects and/or impairment of well-being. Predisposing factors for odor effects can be given by genetic and hormonal influences, imprinting, context and adaptation effects. Predisposing factors for impairment of well-being are environmental concerns, anxieties, conditioning and attributions as well as a variety of diseases. Risk groups that must be protected are patients with immunosuppression and with mucoviscidosis (cystic fibrosis) with regard to infections and individuals with mucoviscidosis and asthma with regard to allergies. If an association between mold exposure and health effects is suspected, the medical diagnosis includes medical history, physical examination, conventional allergy diagnosis, and if indicated, provocation tests. For the treatment of mold infections, it is referred to the AWMF guidelines for diagnosis and treatment of invasive Aspergillus infections. Regarding mycotoxins, there are currently no validated test methods that could be used in clinical diagnostics. From the perspective of preventive medicine, it is important that mold damages cannot be tolerated in indoor environments</style></abstract><notes><style face="normal" font="Arial">DA - 20161217IS - 1618-131X (Electronic)IS - 1438-4639 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijheh.2016.11.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27986496">PM:27986496</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Hyg Environ Health\20161220-HurassJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Hyg Environ Health\20161220-HurassJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Hurass J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijheh.2016.11.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Comberiati,P.</style></author><author><style face="normal" font="Arial"> Colavita,L.</style></author><author><style face="normal" font="Arial"> Minniti,F.</style></author><author><style face="normal" font="Arial"> Paiola,G.</style></author><author><style face="normal" font="Arial"> Capristo,C.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Peroni,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Scienze Chirurgiche, Odontostomatologiche e Materno-infantili, section of Paediatrics, University of Verona, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Utility of Specific IgE to Ara h 2 in Italian Allergic and Tolerant Children Sensitized to Peanut</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Cell Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Mol Cell Med</style></abbr-1></periodical><pages end="166" start="160">160-166</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immuno-CAP</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut components</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Emerging data suggest that measurement of serum IgE to peanut components can be clinically helpful and more accurate than IgE to whole peanut to predict peanut allergy. Not all studies have used prospective samples, multiple components and oral challenges. Currently, there are no data on this topic involving Italian children. 32 patients (23 males; median age 9 years) with reported history for peanut allergy and evidence of peanut sensitization (skin prick test to peanut extract >/= 3mm) have been analyzed for serum IgE to whole peanut and recombinant allergen components Ara h 1, 2, 3, 8, and 9 with Immuno CAP and completed an open oral food challenge with peanut. 12 (37.5%) children had a positive challenge to peanut and were considered allergic. No differences were seen between the median values of IgE to peanut, Ara h 1, 3, 8 and 9 in allergic and tolerant children to peanut challenge. Noteworthy, 5 of 20 tolerant children had IgE to peanut> 15 kUA/l which is commonly considered a predictive value of peanut allergy. Conversely, a significant difference was seen when comparing the median value of IgE to Ara h 2 in the two groups: 0.75 kUA/l (IQR: 0.22-4.34 kUA/l) in allergic children versus 0.1 kUA/l (IQR: 0.1-0.12 kUA/l) in tolerant ones (P&lt; 0.001). IgE levels to Ara h 2 are significantly higher in children that react to oral peanut challenge. Our findings in Italian children have been in line with recent reports in various populations of Northern Europe, the US and Australia and add confirmatory evidence that analysis of IgE to Ara h 2 could reduce the need for peanut challenge in suspected allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 2251-9637 (Print)IS - 2251-9637 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27942502">PM:27942502</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Cell Med\2016-5-160-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Cell Med\2016-5-160-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Comberiati P</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mattison,C.P.</style></author><author><style face="normal" font="Arial"> Grimm,C.C.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Chial,H.J.</style></author><author><style face="normal" font="Arial"> McCaslin,D.R.</style></author><author><style face="normal" font="Arial"> Chung,S.Y.</style></author><author><style face="normal" font="Arial"> Bren-Mattison,Y.</style></author><author><style face="normal" font="Arial"> Wasserman,R.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Identification and Characterization of Ana o 3 Modifications on Arginine Residue-111 in Heated Cashew Nuts</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="420" start="411">411-420</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Ana o 3</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Raw and roasted cashew nut extracts were evaluated for protein modifications by mass-spectrometry. Independent modifications on the Arg-111 residue of Ana o 3 were observed in roasted but not raw cashew nuts. The mass changes of 72.0064 or 53.9529 Da are consistent with formation of carboxyethyl and hydroimidazolone modifications at the Arg-111 residue. These same modifications were observed in Ana o 3 purified from roasted but not raw cashew nuts, albeit at a relatively low occurrence. Circular dichroism indicated that Ana o 3 purified from raw and roasted cashew nuts had similar secondary structure, and dynamic light scattering analysis indicated there was no observable difference in particle size. The stability of Ana o 3 purified from raw and roasted cashew nuts to trypsin was similar in the absence of or following treatment with a reducing agent. Only minor differences in IgE binding to Ana o 3 were observed by ELISA among a cohort of cashew allergic patient sera</style></abstract><notes><style face="normal" font="Arial">DA - 20161214IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b04134</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27966914">PM:27966914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-411-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-411-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Mattison CP</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b04134</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Geng,T.</style></author><author><style face="normal" font="Arial"> Stojsin,D.</style></author><author><style face="normal" font="Arial"> Liu,K.</style></author><author><style face="normal" font="Arial"> Schaalje,B.</style></author><author><style face="normal" font="Arial"> Postin,C.</style></author><author><style face="normal" font="Arial"> Ward,J.M.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.L.</style></author><author><style face="normal" font="Arial"> Li,B.</style></author><author><style face="normal" font="Arial"> Glenn,K.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Natural variability of allergen levels in conventional soybeans: assessing variation across North and South America from five production years</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="472" start="463">463-472</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> endogenous protein</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Gly m 4</style></keyword><keyword><style face="normal" font="Arial"> Gly m 5</style></keyword><keyword><style face="normal" font="Arial"> Gly m 6</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> Glycine max</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> South America</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> soybean allergens</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Soybean (Glycine max L. Merrill) is one of eight major allergenic foods with endogenous proteins identified as allergens. To better understand the natural variability of five soybean allergens (Gly m 4, Gly m 5, Gly m 6, Gly m Bd 28k and Gly m Bd 30k), validated enzyme-linked immunosorbent assays (ELISAs) were developed. These ELISAs measured allergens in 604 soybean samples collected from locations in North and South America over five growing seasons (2009-2013/14) and including 37 conventional varieties. Levels of these five allergens varied 5- to 19-fold. Multivariate statistical analyses and pairwise comparisons show that environmental factors have a larger effect on allergen levels than genetic factors. Therefore, from year to year, consumers are exposed to highly variable levels of allergens in soy-based foods, bringing into question whether quantitative comparison of endogenous allergen levels of new genetically modified soybean adds meaningful information to their overall safety risk assessment</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b04542</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27997188">PM:27997188</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-463-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-463-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Geng T</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b04542</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.</style></author><author><style face="normal" font="Arial"> Du,W.X.</style></author><author><style face="normal" font="Arial"> Fan,Y.</style></author><author><style face="normal" font="Arial"> Yi,J.</style></author><author><style face="normal" font="Arial"> Lyu,S.C.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author><author><style face="normal" font="Arial"> Thomas,A.L.</style></author><author><style face="normal" font="Arial"> McHugh,T.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Purification and characterization of a black walnut (Juglans nigra) allergen, Jug n 4</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="462" start="454">454-462</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">11S</style></keyword><keyword><style face="normal" font="Arial"> 11S globulin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> Ammonium Sulfate</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> Hydrophobic interaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> walnut allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Tree nuts as a group cause a significant number of fatal anaphylactic reactions to foods. Walnuts (Juglans spp.) were one of the leading causes of allergic reactions to tree nuts in the US and Japan. The purpose of this study was to purify and characterize potential food allergens from black walnut. Here, we report the isolation of the black walnuts allergen Jug n 4 (an 11S globulin) by ammonium sulfate precipitation, and hydrophobic interaction and size exclusion chromatography. Reducing SDS-PAGE analysis indicated that purified Jug n 4 consists of 3 major bands. N-terminal sequencing data of these bands indicated that they were the results of a post-transcriptional protease cleavage of the mature protein at a site that consists of a known conserved protease recognition motif, NGXEET. Western blot experiments revealed that 32% of the sera from 25 patients with double-blind, placebo-controlled clinical walnut allergy contained IgE antibodies that recognized Jug n 4, indicating that it is a walnut allergen. Identifying this and additional allergens may facilitate the understanding of the allergenicity of seed storage proteins in tree nuts and their cross-reactivity</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b04387</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27936684">PM:27936684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-454-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-454-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Zhang Y</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b04387</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chan,J.H.</style></author><author><style face="normal" font="Arial"> Chua,Y.L.</style></author><author><style face="normal" font="Arial"> Peh,H.Y.</style></author><author><style face="normal" font="Arial"> Jovanovic,V.</style></author><author><style face="normal" font="Arial"> Gascoigne,N.R.</style></author><author><style face="normal" font="Arial"> Wong,W.S.</style></author><author><style face="normal" font="Arial"> Chew,F.T.</style></author><author><style face="normal" font="Arial"> Hanson,B.J.</style></author><author><style face="normal" font="Arial"> Kemeny,D.M.</style></author><author><style face="normal" font="Arial"> MacAry,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore; Department of Microbiology &amp; Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Molecular engineering of a therapeutic antibody for Blo t 5-induced allergic asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1708" start="1705">1705-1708</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27923562">PM:27923562</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161207-ChanJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161207-ChanJH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Chan JH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paveglio,S.</style></author><author><style face="normal" font="Arial"> Bennett,E.</style></author><author><style face="normal" font="Arial"> Hawley,K.L.</style></author><author><style face="normal" font="Arial"> Matson,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatrics University of Connecticut School of Medicine, Farmington, Connecticut, USA</style></auth-address><titles><title><style face="normal" font="Arial">FcepsilonRI cross-linking reduces cord blood dendritic cell responsiveness to lipopolysaccharides</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1994" start="1992">1992-1994</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">blood</style></keyword><keyword><style face="normal" font="Arial"> Connecticut</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lipopolysaccharides</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Anti-FcepsilonRI stimulation was found to reduce the responsiveness of cord blood mDCs to lipopolysaccharides, thus supporting the growing body of evidence that DCs can play a regulatory role in the setting of IgE-mediated inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27919739">PM:27919739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161206-PaveglioS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161206-PaveglioS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Paveglio S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hofer,H.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Hauser,M.</style></author><author><style face="normal" font="Arial"> Nagl,B.</style></author><author><style face="normal" font="Arial"> Laimer,J.</style></author><author><style face="normal" font="Arial"> Himly,M.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Ebner,C.</style></author><author><style face="normal" font="Arial"> Lang,R.</style></author><author><style face="normal" font="Arial"> Hawranek,T.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Lackner,P.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Wallner,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg Austria</style></auth-address><titles><title><style face="normal" font="Arial">Tackling Bet v 1- and associated food allergies with a single hybrid protein</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="533" start="525">525-533</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> Hybrid molecule</style></keyword><keyword><style face="normal" font="Arial"> hybrid protein</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunogenic properties</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy vaccines should be easily applicable, safe and efficacious. For Bet v 1-mediated birch pollen and associated food allergies a single wildtype allergen does not provide a complete solution. OBJECTIVE: Thus, we aimed to combine immunologically relevant epitopes of Bet v 1 and the two clinically most important related food allergens from apple and hazelnut to a single hybrid protein, termed MBC4. METHODS: After identification of T cell epitope-containing parts on each of the three parental allergens, the hybrid molecule was designed to cover relevant epitopes and evaluated in silico. Thereby, a mutation was introduced into the hybrid sequence, which should alter the secondary structure without compromising immunogenic properties of the molecule. RESULTS: MBC4 as well as the parental allergens were purified to homogeneity. Analyses of secondary structure elements revealed substantial changes rendering the hybrid de facto non-reactive with patients serum IgE. Nevertheless, the protein was monomeric in solution. MBC4 was able to activate T cell lines from birch pollen allergic donors and from mice immunized with the parental allergens. Moreover, upon immunization of mice and rabbits MBC4 induced cross-reactive IgG antibodies, which were able to block the binding of human serum IgE. CONCLUSION: Directed epitope rearrangements combined with a knowledge-based structural modification resulted in a protein unable to bind IgE from allergic patients. Still, properties to activate specific T cells or to induce blocking antibodies were conserved. This suggests that MBC4 is a suitable vaccine candidate for the simultaneous treatment of Bet v 1- and associated food allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27939703">PM:27939703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161212-HoferH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161212-HoferH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Hofer H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sette,A.</style></author><author><style face="normal" font="Arial"> Schulten,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">La Jolla Institute for Allergy &amp; Immunology, La Jolla, CA 9203, USA</style></auth-address><titles><title><style face="normal" font="Arial">It's a lot of work to be non-allergic</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="770" start="769">769-770</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27993537">PM:27993537</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161220-SetteA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161220-SetteA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Sette A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stone,C.A.,Jr.</style></author><author><style face="normal" font="Arial"> Hemler,J.A.</style></author><author><style face="normal" font="Arial"> Commins,S.P.</style></author><author><style face="normal" font="Arial"> Schuyler,A.P.</style></author><author><style face="normal" font="Arial"> Phillips,E.J.</style></author><author><style face="normal" font="Arial"> Peebles,R.S.,Jr.</style></author><author><style face="normal" font="Arial"> Fahrenholz,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis after Zoster Vaccine: Implicating Alpha-Gal Allergy as a Possible Mechanism</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1713" start="1710">1710-1713</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A patient with alpha-gal allergy presented with anaphylaxis after receiving zoster vaccine. Subsequent testing of selected vaccines revealed the presence of alpha-gal allergen in MMR and zoster vaccines, which have in common a higher content of gelatin and content of bovine calf serum</style></abstract><notes><style face="normal" font="Arial">DA - 20161217IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27986511">PM:27986511</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161217-StoneCAJr.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161217-StoneCAJr.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161217, Stone CA Jr</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stemeseder,T.</style></author><author><style face="normal" font="Arial"> Freier,R.</style></author><author><style face="normal" font="Arial"> Wildner,S.</style></author><author><style face="normal" font="Arial"> Fuchs,J.E.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Lang,R.</style></author><author><style face="normal" font="Arial"> Batanero,E.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Liedl,K.R.</style></author><author><style face="normal" font="Arial"> Campo,P.</style></author><author><style face="normal" font="Arial"> Hawranek,T.</style></author><author><style face="normal" font="Arial"> Villalba,M.</style></author><author><style face="normal" font="Arial"> Brandstetter,H.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Crystal structure of Pla l 1 reveals both structural similarity and allergenic divergence within the Ole e 1-like protein family</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="280" start="277">277-280</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Ole e</style></keyword><keyword><style face="normal" font="Arial"> Pla l 1</style></keyword><keyword><style face="normal" font="Arial"> Plantain</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Solving the structure of Pla l 1 elucidated the preserved fold of Ole e 1-like proteins while IgE cross-reactivity in this family is limited to molecules with high sequence identity. Diagnostic accuracy using source-specific Ole e 1-like molecules is essential for discriminating plantain from other pollen allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20161214IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Spain -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27965108">PM:27965108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161214-StemesederT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161214-StemesederT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Stemeseder T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grant,T.</style></author><author><style face="normal" font="Arial"> Aloe,C.</style></author><author><style face="normal" font="Arial"> Perzanowski,M.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author><author><style face="normal" font="Arial"> Bollinger,M.E.</style></author><author><style face="normal" font="Arial"> Miller,R.</style></author><author><style face="normal" font="Arial"> Matsui,E.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy/Immunology, Johns Hopkins School of Medicine, Baltimore, Md</style></auth-address><titles><title><style face="normal" font="Arial">Mouse Sensitization and Exposure Are Associated with Asthma Severity in Urban Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1014" start="1008">1008-1014</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="12/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hispanic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> long-term outcome</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> minority children</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> mouse sensitization</style></keyword><keyword><style face="normal" font="Arial"> Mus m 1</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mouse sensitization and exposure are associated with uncontrolled asthma, but whether they are associated with asthma severity, an intrinsic disease characteristic and long-term outcome predictor, is unclear. OBJECTIVE: To examine relationships between mouse sensitization and/or exposure and asthma severity in urban children. METHODS: A total of 645 children (5-17 years) with uncontrolled asthma underwent mouse sensitization evaluation. Sensitized children had mouse allergen measured in bedroom dust. Relationships between mouse sensitization, allergen levels, and asthma severity measures (treatment step and Composite Asthma Severity Index [CASI]) were examined using regression models adjusted for age, sex, atopy, study site, race, ethnicity, and insurance. RESULTS: The study population was predominantly minority (69.6% black, 20.8% Hispanic), low income (61.8%), and mouse sensitized (54.4%). Mean +/- SD treatment step was 3.2 +/- 1.6, equivalent to medium-dose inhaled corticosteroid. Mean +/- SD CASI was 6.5 +/- 3.4, reflecting moderate persistent asthma. Mouse sensitization was associated with higher treatment step (3.5 vs 2.9, mouse-sensitized vs nonsensitized, P &lt; .001), independent of potential confounders (beta [95% CI], 0.36 [0.07-0.64]; P = .01). Mouse sensitization was associated independently with CASI (beta [95% CI], 0.82 [0.16-1.47]; P = .02). Among mouse-sensitized participants, higher bedroom floor and bed Mus m 1 were independently associated with treatment step (beta [95% CI], 0.26 [0.09-0.43]; P = .002 and beta [95% CI], 0.22 [0.01-0.43]; P = .04), respectively. Higher bedroom floor Mus m 1 was independently associated with CASI (beta [95% CI], 0.43 [0.05-0.81]; P = .03). CONCLUSIONS: Mouse sensitization and exposure are associated with asthma severity, among low-income, minority children. Further studies are needed to determine whether reducing allergen exposure among mouse-sensitized patients with asthma can reduce severity, ultimately altering childhood asthma natural history</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.10.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27923647">PM:27923647</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1008-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1008-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Grant T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.10.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pappalardo,A.A.</style></author><author><style face="normal" font="Arial"> Karavolos,K.</style></author><author><style face="normal" font="Arial"> Martin,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma and Allergy Center, Bloomingdale, Ill; Department of Pediatrics, University of Illinois at Chicago, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="Arial">What Really Happens in the Home: The Medication Environment of Urban, Minority Youth</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="770" start="764">764-770</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Latino</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> medication adherence</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Reliever</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma disproportionately affects minority youth. Understanding the home medication environment and its relation to medication adherence can shape interventions to improve health outcomes. OBJECTIVE: The objective of this study was to describe the asthma medication environment in the homes of urban minority youth and to determine predictors of medication use and technique in this population. METHODS: Baseline data from 2 cohorts of minority youth with asthma in Chicago were combined for cross-sectional analysis. Bilingual research assistants (RAs) collected data in the home. RAs asked caregivers and children to self-report medications using pictures and observed children's asthma medications and inhaler technique. RESULTS: The sample contained 175 mainly Latino youth (85.6%) ranging from 5 to 18 years old. Most were on public insurance (80%) and had uncontrolled asthma by self-report (89.7%). Only 27.4% had a spacer, 74.9% had a quick relief medicine, and 48.6% had any controller medicine. RA observations of controllers agreed with children (36%) and parental self-report (42.3%) but did not match the specific observed controllers. Children reported less parental help with medications (43%) than their parents (58.1%). One child was able to properly demonstrate 100% of the inhaler steps and 35.6% achieved >70% of inhaler steps. A better medication technique was associated with having a controller (b = 12.2, SE = 3.0, P &lt; .0001), quick reliever (b = 8.05, SE = 3.5, P = .023), and a spacer (b = 9.3, SE = 3.54, P = .009). CONCLUSIONS: This rigorous evaluation of the home medication environment of high-risk youth demonstrated that many families lack critical medications, devices, and a technique for proper management of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914817">PM:27914817</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161204-PappalardoAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161204-PappalardoAA.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20161204, Pappalardo AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meltzer,E.O.</style></author><author><style face="normal" font="Arial"> Farrar,J.R.</style></author><author><style face="normal" font="Arial"> Sennett,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology and Allergy, Department of Pediatrics, University of California San Diego School of Medicine, and Allergy and Asthma Medical Group and Research Center, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="789" start="779">779-789</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emotions</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ocular symptoms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pharmacists</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Seasonal allergic rhinoconjunctivitis (SARC) affects >/=16% of the US population annually. Telephone and in-office surveys have demonstrated negative effects of allergic rhinitis (AR) symptoms on sleep, daily activities, productivity, concentration, and emotions. OBJECTIVE: The objective of this study was to assess the patient-perceived burden of SARC in relation to newer treatments, increased access to treatments, and changing management protocols. METHODS: An online survey of symptom experience, impact on daily life, and management was conducted in US respondents who suffer (or whose child suffers) from SARC symptoms. RESULTS: A total of 1001 surveys were completed: 500 adults (>/=18 years old) and 501 children (12-17 years old, documented by their parents). Similar to earlier AR surveys, SARC symptoms negatively affected the patient's (and family's) quality of life, and were most severe in the spring. Before being treated, >50% of respondents reported daily symptoms during their season; 75% to 80% considered their symptoms moderate to severe. Patients saw a variety of health care professionals (including pharmacists) and used over-the-counter and prescription medications for symptoms. Those using prescription medications were generally more satisfied with treatment and less likely to switch or discontinue treatment. Nasal and/or ocular symptoms drove adherence, seeing a health care professional, and reviewing and/or changing treatment. CONCLUSIONS: The majority of patients with SARC report moderate-to-severe symptoms that significantly impair their quality of life. However, patients appear to be taking more responsibility for their (child's) condition, and patient expectations for therapy are increasingly being met. Continued efforts will be needed to examine the contribution of better information and/or increased access to and availability of medications to control the disease</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914815">PM:27914815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161204-MeltzerEO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161204-MeltzerEO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Meltzer EO</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.10.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nomura,T.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Advances in atopic dermatitis in 2015</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1555" start="1548">1548-1555</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adiposity</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> extracellular signal-regulated kinase</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Janus kinase</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transepidermal water loss</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">This review aims to highlight recently published articles on atopic dermatitis (AD). Updated are the insights into epidemiology, pathology, diagnostics, and therapy. Epidemiologic studies have revealed a positive correlation between AD and systemic conditions, such as rheumatoid arthritis, inflammatory bowel disease, and neonatal adiposity. Pathologic findings highlight the involvement of novel barrier factors (desmoplakin and claudin), novel immune cell subsets (pathogenic effector TH2 cells and group 2 innate lymphoid cells), and differential skewing of helper T cells (eg, TH17 dominance in Asians with AD). As diagnostics, noninvasive examinations of the transepidermal water loss of neonates, the density of epidermal Staphylococcus species, and the gut flora might prognosticate the onset of AD. As for therapy, various methods are proposed, including conventional (petrolatum and UV) and molecule-oriented regimens targeting Janus kinase, signal transducer and activator of transcription 3, extracellular signal-regulated kinase, sirtuin 1, or aryl hydrocarbon receptor</style></abstract><notes><style face="normal" font="Arial">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931536">PM:27931536</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1548-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1548-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161209, Nomura T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goldberg,M.R.</style></author><author><style face="normal" font="Arial"> Elizur,A.</style></author><author><style face="normal" font="Arial"> Nachshon,L.</style></author><author><style face="normal" font="Arial"> Appel,M.Y.</style></author><author><style face="normal" font="Arial"> Levy,M.B.</style></author><author><style face="normal" font="Arial"> Golobov,K.</style></author><author><style face="normal" font="Arial"> Goldberg,R.</style></author><author><style face="normal" font="Arial"> Stein,M.</style></author><author><style face="normal" font="Arial"> Rothenberg,M.E.</style></author><author><style face="normal" font="Arial"> Katz,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy, Immunology and Pediatric Pulmonary Institute, "Assaf-Harofeh" Medical Center, Israel.</style></auth-address><titles><title><style face="normal" font="Arial">Oral Immunotherapy-Induced Gastrointestinal Symptoms and Peripheral Blood Eosinophil Responses</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1390" start="1388">1388-1390</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Oral immunotherapy-induced gastrointestinal and eosinophilic responses (OITIGER) is an adverse response to OIT in approximately 8% of patients and is typically reversible by decreasing dosage administration. The peripheral blood eosinophil count serves as a biomarker marker for susceptibility and the medical course</style></abstract><notes><style face="normal" font="Arial">DA - 20161203IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Israel -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27913305">PM:27913305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161203-GoldbergMR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161203-GoldbergMR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161203, Goldberg MR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schellpfeffer,N.R.</style></author><author><style face="normal" font="Arial"> Leo,H.L.</style></author><author><style face="normal" font="Arial"> Ambrose,M.</style></author><author><style face="normal" font="Arial"> Hashikawa,A.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, University of Michigan, Ann Arbor, Mich.</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy Trends and Epinephrine Autoinjector Presence in Summer Camps</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="362" start="358">358-362</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="12/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> CAMP</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> Dyes</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lactose Intolerance</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pediatric campers with food allergies are at greater risk for exposure and anaphylaxis. A diagnosis of asthma increases risk for anaphylaxis. Epidemiological investigations of food-allergic children at high risk for allergic reactions requiring intervention in camp settings are lacking. OBJECTIVE: The objectives of this study were to estimate the prevalence of food allergies among otherwise healthy campers in summer camps throughout the United States and Canada, and to assess asthma comorbidity and determine rates of epinephrine autoinjector prescriptions present in this population. METHODS: We partnered with CampDoc.com, a web-based camp electronic health record system. Deidentified data were abstracted from 170 camps representing 122,424 campers. Only food allergies with a parental report of symptoms requiring intervention or with a camp prescription for an epinephrine autoinjector were included, whereas gluten, lactose intolerance, and food dyes were excluded. Asthma status and epinephrine presence on the camp medication list were assessed. RESULTS: Overall, 2.5% of campers (n = 3055) had documented food allergies. Of these campers, 22% had multiple food allergies. Median age was 11 years; 52% were female. Nuts (81%), seafood (17.4%), egg (8.5%), fruit (8.1%), and seeds (7.2%) were the top 5 food allergies reported. Of food-allergic campers, 44.3% had concurrent asthma and 34.7% of those campers were taking multiple asthma medications. Less than half (39.7%) of food-allergic children brought an epinephrine autoinjector to the camp. CONCLUSIONS: Life-saving epinephrine is not necessarily available for food-allergic children in camp settings. A substantial proportion of food-allergic campers are at higher risk for anaphylaxis based on concurrent asthma status</style></abstract><notes><style face="normal" font="Arial">DA - 20161207IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.10.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27923649">PM:27923649</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-358-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-358-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161207, Schellpfeffer NR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.10.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Confino-Cohen,R.</style></author><author><style face="normal" font="Arial"> Rosman,Y.</style></author><author><style face="normal" font="Arial"> Goldberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar-Saba, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Rush Venom Immunotherapy in Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="803" start="799">799-803</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Rush venom immunotherapy (VIT) is highly effective in Hymenoptera venom allergy. Still, specific data regarding its safety and efficiency in children are rather sparse. OBJECTIVES: The objective of this study was to better evaluate the safety and efficiency of rush VIT in this specific age group. METHODS: Children younger than 16 years with systemic reaction to insect sting involving, at least, one body system other than skin and children aged 16-18 years with any kind of systemic reaction were offered conventional or rush VIT with a build-up phase that lasted 3 days. RESULTS: Eighty-four of 127 children together with their caregivers chose to receive rush VIT. Seventy of them were allergic to bee venom only. There was no difference between the children receiving rush or conventional VIT in the incidence of systemic reactions during the build-up phase (19% and 23.2%, respectively), nor was there any difference in regard to the severity of these reactions. Efficiency was improved with rush VIT, as reflected by a higher number of patients achieving the 100 mcg maintenance dose with the primary protocol (83 of 84 patients, 98.8%, and 39 of 43, 90.7%, for rush and conventional, respectively, P = .04). CONCLUSIONS: Rush VIT in children is as safe as and more efficient than conventional VIT</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.10.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914814">PM:27914814</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161204-Confino-CohenR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161204-Confino-CohenR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Confino-Cohen R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.10.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Katz,Y.</style></author><author><style face="normal" font="Arial"> Goldberg,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="Arial">Is epicutaneous immunotherapy only skin deep?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1136" start="1135">1135-1136</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161214IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27964851">PM:27964851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161214-KatzY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161214-KatzY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Katz Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zafack,J.G.</style></author><author><style face="normal" font="Arial"> De Serres,G.</style></author><author><style face="normal" font="Arial"> Rouleau,I.</style></author><author><style face="normal" font="Arial"> Gariepy,M.C.</style></author><author><style face="normal" font="Arial"> Gagnon,R.</style></author><author><style face="normal" font="Arial"> Drolet,J.P.</style></author><author><style face="normal" font="Arial"> Skowronski,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Social and Preventive Medicine, Laval University, Quebec, QC, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="727" start="718">718-727</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="12/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical criteria</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Consultations</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Practice parameters</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The Joint Task Force on Practice Parameters (JTFPP) guidelines for the investigation and reimmunization of patients who experienced allergic-like events (ALEs) after immunization are predicated on the likelihood of anaphylaxis, assessed through the time to symptom onset (&lt;/= or >4 hours) and number of systems involved. OBJECTIVE: The objectives of this study were to compare the management of a series of patients with ALE in actual practice relative to JTFPP guidelines and to discuss key concepts and considerations in their use. METHODS: This retrospective study was based on a chart review of patients who consulted for suspected vaccine-associated ALEs at a large allergy department in Canada. RESULTS: Only 3 of the 135 patients who presented ALEs after immunization were referred for suspected anaphylaxis. There was no significant difference in the frequency of skin testing or reimmunization of patients whatever the time to symptom onset or number of systems involved in the ALE. Eight patients whose initial ALE occurred within 1 hour after immunization had a recurrence on reimmunization. Another patient whose initial ALE occurred 10 hours after influenza immunization had throat tightening and difficulty swallowing without objective signs. CONCLUSIONS: Most ALEs after immunization are not suggestive of anaphylaxis and should not be managed as such. The definition of anaphylaxis in the JTFPP guidelines is nonspecific and may need to be revisited. Restricting skin testing and graded dose reimmunization to patients whose ALE onset is &lt;/=1 hour (compatible with IgE-mediated reaction) and to those meeting specific clinical criteria for anaphylaxis (whatever the timing) is likely a sufficiently sensitive and cautious approach</style></abstract><notes><style face="normal" font="Arial">DA - 20161204IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914816">PM:27914816</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-718-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-718-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161204, Zafack JG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Czarnowicki,T.</style></author><author><style face="normal" font="Arial"> Esaki,H.</style></author><author><style face="normal" font="Arial"> Gonzalez,J.</style></author><author><style face="normal" font="Arial"> Renert-Yuval,Y.</style></author><author><style face="normal" font="Arial"> Brunner,P.</style></author><author><style face="normal" font="Arial"> Oliva,M.</style></author><author><style face="normal" font="Arial"> Estrada,Y.</style></author><author><style face="normal" font="Arial"> Xu,H.</style></author><author><style face="normal" font="Arial"> Zheng,X.</style></author><author><style face="normal" font="Arial"> Talasila,S.</style></author><author><style face="normal" font="Arial"> Haugh,I.</style></author><author><style face="normal" font="Arial"> Huynh,T.</style></author><author><style face="normal" font="Arial"> Lyon,S.</style></author><author><style face="normal" font="Arial"> Tran,G.</style></author><author><style face="normal" font="Arial"> Sampson,H.</style></author><author><style face="normal" font="Arial"> Suarez-Farinas,M.</style></author><author><style face="normal" font="Arial"> Krueger,J.G.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author><author><style face="normal" font="Arial"> Paller,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Alterations in B-cell subsets in early pediatric atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="144" start="134">134-144</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory B cell</style></keyword><keyword><style face="normal" font="Arial"> memory B cells</style></keyword><keyword><style face="normal" font="Arial"> memory T cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: B-cells undergo maturation and class-switching in response to antigen exposure and T-cell help. Early B-cell differentiation has not been defined in early onset atopic dermatitis (AD). OBJECTIVE: To define the frequency of B-cell subsets associated with progressive B-cell maturation and IgE class-switching. METHODS: We studied 27 children and 34 adults with moderate-severe AD (mean SCORing of AD/SCORAD 55 and 65, respectively) and age-matched controls (15 children and 27 adults). IgD/CD27 and CD24/CD38 core gating systems and an 11-color flow cytometry panel were used to determine frequencies of circulating B-cell subsets. Serum total and allergen-specific IgE (sIgEs) levels were measured using ImmunoCAP(R). RESULTS: Compared to adults, children showed T-cell predominance in skin. Circulating CD19+CD20+ B-cells were lower in pediatric AD than controls (24% vs. 33%, P=0.04), while CD3+ T-cells were higher (62% vs. 52%, P=0.05). A decreased B/T lymphocyte ratio with age was observed only in pediatric controls (r=-0.48, P=0.07). In pediatric AD, a positive correlation was observed between B/T ratio and non-switched memory B-cells (r=0.42, P=0.03). Higher frequencies of positive sIgEs were seen in pediatric AD (P&lt;0.0001). Diverse sIgEs correlated with SCORAD and age of pediatric AD (P&lt;0.01). Positive correlations were observed between activated B-cells and memory T-cells (P&lt;0.02). In AD, IgE sensitization to most allergens clustered with age, Th1, Th2, total IgE and B-cell memory subsets. CONCLUSIONS: Peripheral B-cells and T-cells are altered in early pediatric AD, but T-cells predominate in skin lesions</style></abstract><notes><style face="normal" font="Arial">DA - 20161214IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.060</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27965110">PM:27965110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161214-CzarnowickiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161214-CzarnowickiT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Czarnowicki T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.060</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uotila,R.</style></author><author><style face="normal" font="Arial"> Kukkonen,A.K.</style></author><author><style face="normal" font="Arial"> Greco,D.</style></author><author><style face="normal" font="Arial"> Pelkonen,A.S.</style></author><author><style face="normal" font="Arial"> Makela,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">the Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="Arial">Peanut oral immunotherapy decreases IgE to Ara h 2 and Ara h 6 but does not enhance sensitization to cross-reactive allergens</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1396" start="1393">1393-1396</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> 2S Albumins</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Neosensitization</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">During peanut OIT, the serological response is directed to the peanut storage proteins, especially, to the 2S albumins. No neosensitization to cross-reactive allergens emerges</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27916627">PM:27916627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161205-UotilaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161205-UotilaR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Uotila R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caillot,N.</style></author><author><style face="normal" font="Arial"> Bouley,J.</style></author><author><style face="normal" font="Arial"> Jain,K.</style></author><author><style face="normal" font="Arial"> Mariano,S.</style></author><author><style face="normal" font="Arial"> Luce,S.</style></author><author><style face="normal" font="Arial"> Horiot,S.</style></author><author><style face="normal" font="Arial"> Airouche,S.</style></author><author><style face="normal" font="Arial"> Beuraud,C.</style></author><author><style face="normal" font="Arial"> Beauvallet,C.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Chollet-Martin,S.</style></author><author><style face="normal" font="Arial"> Kellenberger,C.</style></author><author><style face="normal" font="Arial"> Mascarell,L.</style></author><author><style face="normal" font="Arial"> Chabre,H.</style></author><author><style face="normal" font="Arial"> Batard,T.</style></author><author><style face="normal" font="Arial"> Nony,E.</style></author><author><style face="normal" font="Arial"> Lombardi,V.</style></author><author><style face="normal" font="Arial"> Baron-Bodo,V.</style></author><author><style face="normal" font="Arial"> Moingeon,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Department, Stallergenes Greer, Antony, France</style></auth-address><titles><title><style face="normal" font="Arial">Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="770" start="759">759-770</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2D-DIGE</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Silencing</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Label-free</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eligibility to immunotherapy is based on the determination of IgE reactivity to a specific allergen by skin prick or in vitro testing. Biomarkers predicting the likelihood of clinical improvement during immunotherapy would significantly improve patient selection. METHODS: Proteins were differentially assessed by 2D-DiGE and label-free mass spectrometry in pre-treatment sera obtained from clinical responders and non-responders within a cohort of 82 grass pollen allergic patients receiving sublingual immunotherapy or placebo. Functional studies of Fetuin-A were conducted by using both gene silencing in a mouse asthma model, human dendritic cell in vitro stimulation assays and surface plasmon resonance. RESULTS: Analysis by quantitative proteomics of pre-treatment sera from grass-pollen allergic patients reveals that high levels of O-glycosylated sialylated Fetuin-A isoforms are found in those patients exhibiting a strong decrease in rhinoconjunctivitis symptoms following sublingual immunotherapy. Whereas Fetuin-A is involved in numerous inflammatory conditions, its potential role in allergy is unknown. In vivo silencing of the FETUA gene in BALB/c mice results in a dramatic upregulation of both airway hyperresponsiveness, lung resistance, as well as TH2 responses following allergic sensitization to ovalbumin. Both sialylated and non sialytated Fetuin-A bind to LPS, but only the former synergizes with LPS and grass pollen or mite allergens to enhance TLR4-mediated proallergic properties of human dendritic cells. CONCLUSIONS: As a reflection of the patient's inflammation status, pre-treatment levels of sialylated Fetuin-A in the blood are indicative of the likelihood of clinical responses during grass pollen immunotherapy. CLINICAL IMPLICATIONS: FetA plays either an inhibiting or amplifying role in allergic inflammation, depending upon post-translational modifications of the molecule. Patients with high levels of sialylated FetA glycoforms in their blood before treatment are more likely to benefit from grass pollen immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161214IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27965111">PM:27965111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161214-CaillotN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161214-CaillotN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Caillot N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wood,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Md.</style></auth-address><titles><title><style face="normal" font="Arial">Advances in food allergy in 2015</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1547" start="1541">1541-1547</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Ethnic Groups</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">This review highlights research advances in food allergy that were published in the Journal in 2015. The world of food allergy research continues to rapidly accelerate, with increasing numbers of outstanding submissions to the Journal. In 2015, important studies on the epidemiology of food allergy were published, suggesting differential rates of food allergy in specific racial and ethnic groups. Even more importantly, studies were published identifying specific risk factors for the development of peanut allergy, as well as specific prevention strategies. We also saw new studies on the diagnosis of food allergy and potential approaches to the treatment of food allergy, as well as novel mechanistic studies helping to explain the immunologic correlates of food allergy and food desensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931535">PM:27931535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1541-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2016-138-1541-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161209, Wood RA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rothbaum,R.</style></author><author><style face="normal" font="Arial"> McGee,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Boston University School of Medicine, Boston, MA, USADepartment of Dermatology, Boston University School of Medicine, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Aquagenic urticaria: diagnostic and management challenges</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="213" start="209">209-213</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cutaneous exposure</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physical urticaria</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tear</style></keyword><keyword><style face="normal" font="Arial"> Tears</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Aquagenic urticaria (AU) is a rare inducible form of physical urticaria, which occurs in response to cutaneous exposure to water, including sweat and tears. Patients present with characteristic 1-3 mm folliculocentric wheals with surrounding 1-3 cm erythematous flares within 20-30 minutes following skin contact with water. In rare cases, there are concomitant systemic symptoms, such as wheezing or shortness of breath. The pathogenesis of AU is poorly understood at this time, and it appears to be mediated in both a histamine-dependent and independent manner. Diagnosis is based on eliciting a thorough clinical history combined with a water challenge test. Some patients may need to undergo further testing to exclude other physical urticarias. Rarely, multiple physical urticarias can be present in one patient, which can complicate diagnosis and treatment. Currently, the first-line therapy for AU is an oral administration of nonsedating, second-generation H1 antihistamines, but many patients may require further interventions to have adequate symptomatic control. In this review, we discuss the diagnostic and management challenges of AU. We review the key diagnostic features that differentiate AU from other physical urticarias. We additionally describe a therapeutic ladder for the treatment of AU and the rationale supporting these treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1178-6965 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S91505</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27942227">PM:27942227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-209-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-209-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Rothbaum R</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S91505</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomes,P.J.</style></author><author><style face="normal" font="Arial"> Lane,K.J.</style></author><author><style face="normal" font="Arial"> Angjeli,E.</style></author><author><style face="normal" font="Arial"> Stein,L.</style></author><author><style face="normal" font="Arial"> Abelson,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ora, Inc., Andover, MA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Technical and clinical validation of an environmental exposure unit for ragweed</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="221" start="215">215-221</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis is a common condition, with ragweed pollen one of the more prevalent aeroallergens. Environmental exposure units such as the Allergen BioCube(R) are valuable models for clinical allergy studies. A study was conducted to validate the Allergen BioCube for uniform ragweed pollen concentrations and clinically relevant sign and symptom responses to ragweed exposure. METHODS: Ragweed pollen concentrations were measured on 3 consecutive days in the Allergen BioCube and verified by Rotorod collection and continuous laser particle count measurements. Subjects (N=10) were exposed to ragweed pollen in the BioCube for 3 hours per day for 3 consecutive days. Subjects assessed their nasal itching, sneezing, rhinorrhea, and nasal congestion during each BioCube exposure; total nasal symptom score was computed. Peak nasal inspiratory flow was also assessed during BioCube exposure. RESULTS: Uniform ragweed pollen concentrations were obtained throughout each of the 3-hour testing periods in the Allergen BioCube, both spatially and temporally, at all subject positions, with a low mean standard deviation of 10%. Pronounced increases in mean total nasal symptom scores (6.7+/-0.94 to 7.6+/-0.86, last 90 minutes of exposure) occurred for all three BioCube ragweed pollen exposure visits. Mean peak nasal inspiratory flow decreased 24% at 3 hours of BioCube exposure on Day 3. No safety issues of concern occurred in this study. CONCLUSION: The Allergen BioCube achieved technical and clinical validation for ragweed allergen. Ragweed pollen concentration was uniform both temporally and spatially. Allergic rhinitis signs and symptoms were induced in subjects during exposure to ragweed in the BioCube at clinically meaningful levels for allergy studies</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S123547</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28008277">PM:28008277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-215-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2016-9-215-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Gomes PJ</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S123547</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stensgaard,A.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Nielsen,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Odense Research Center for Anaphylaxis (ORCA), Department of Dermatology and Allergy Center, Odense University Hospital, Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Peanut allergy as a family project: social relations and transitions in adolescence</style></title><secondary-title><style face="normal" font="Arial">J Clin Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Nurs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="Arial">AIMS AND OBJECTIVE: to explore and better understand the impact that peanut allergy can have on family experiences in everyday life through interviews with individual family members. BACKGROUND: Peanut allergy affects adolescents' quality of life through the need to avoid eating peanut-containing food and the risk of anaphylaxis. Adolescence is a period of increasing separation from parents and has the highest risk of food fatalities. DESIGN: A qualitative interview study taking a phenomenological-hermeneutic approach. METHODS: Data were generated through semi-structured individual interviews with the adolescent with peanut allergy, and both parents and a sibling. Five families were interviewed, with 20 participants in total. The theoretical foundation was the family as an interactive system, and data were analyzed with Ricoeur's theory of interpretation. RESULTS: The consequences of peanut allergy appeared to affect all family members and required knowledge and understanding, especially in the social network. Siblings took responsibility and had concerns for the well-being of the adolescent with allergy, while parents expressed difficulties with their child's transition to independence and their subsequent loss of control. Social relations with new family members or friends were challenged by lack of knowledge about the potential seriousness of peanut allergy. CONCLUSIONS: Risk and uncertainly were permanent companions for the adolescents with peanut allergy and their families. It takes time to acquire the necessary understanding about peanut allergy and the risk of anaphylaxis. The adolescent's social network also needs this knowledge during the transition to independent living. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1365-2702 (Electronic)IS - 0962-1067 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/jocn.13696</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000310">PM:28000310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Nurs\20161221-StensgaardA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Nurs\20161221-StensgaardA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Stensgaard A</style></custom2><misc3><style face="normal" font="Arial">10.1111/jocn.13696</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mong,J.S.</style></author><author><style face="normal" font="Arial"> Ooi,C.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Emergency Department, Tan Tock Seng Hospital, SingaporeEmergency Department, Tan Tock Seng Hospital, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Transient Coagulopathy Due to Wasp Sting: A Case Report</style></title><secondary-title><style face="normal" font="Arial">J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Platelet Count</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="17" Month="12" Year="2016">2016/12/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Insect venom anaphylaxis is a potentially life-threatening disorder. Transient coagulopathy in insect venom anaphylaxis is a rare phenomenon. CASE REPORT: A 41-year-old man presented to the Emergency Department (ED) with hypotension after a run in a park. History and examination revealed signs of anaphylactic shock. A deranged coagulation profile with a normal platelet count led to the diagnosis of wasp sting anaphylaxis. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Transient deranged coagulation profile with a normal platelet count may arise from insect venom anaphylaxis. This specific finding may aid the emergency physician in making a diagnosis of anaphylactic shock in an otherwise healthy patient presenting with shock with no apparent cause</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 0736-4679 (Print)IS - 0736-4679 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jemermed.2016.11.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27998634">PM:27998634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Emerg Med\20161221-MongJS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Emerg Med\20161221-MongJS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Mong JS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jemermed.2016.11.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morel,L.J.</style></author><author><style face="normal" font="Arial"> Azevedo,B.C.</style></author><author><style face="normal" font="Arial"> Carmona,F.</style></author><author><style face="normal" font="Arial"> Contini,S.H.</style></author><author><style face="normal" font="Arial"> Teles,A.M.</style></author><author><style face="normal" font="Arial"> Ramalho,F.S.</style></author><author><style face="normal" font="Arial"> Bertoni,B.W.</style></author><author><style face="normal" font="Arial"> de Castro,Franca S.</style></author><author><style face="normal" font="Arial"> de Carvalho,Borges M.</style></author><author><style face="normal" font="Arial"> Pereira,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Biotecnologia em Plantas Medicinais, Universidade de Ribeirao Preto, Av. Costabile Romano 2201, 14096-900, Ribeirao Preto, SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">A standardized methanol extract of Eclipta prostrata (L.) L. (Asteraceae) reduces bronchial hyperresponsiveness and production of Th2 cytokines in a murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asteraceae</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Methanol</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> respiratory resistance</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> Th1 and Th2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="12" Year="2016">2016/12/9</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Eclipta prostrata (L.) L. (Asteraceae) has been used in Brazilian traditional medicine to treat asthma and other respiratory illnesses. AIMS OF THE STUDY: To investigate the effects of different doses of a standardized extract of E. prostrata using a murine model of allergen induced asthma. MATERIALS AND METHODS: Balb/c mice were sensitized twice with ovalbumin (OVA) administered intraperitoneally and challenged over four alternate days with nasal instillations of OVA solution. The standardized methanol extract of E. prostrata was administered in doses of 100, 250 and 500mgkg-1 concomitantly with nasal instillation over seven consecutive days. Control animals were treated with dexamethasone or saline solution. Bronchial hyperresponsiveness, production of Th1 and Th2 cytokines, allergen sensitization, airway and lung inflammation, mucous secretion and airway remodeling were assessed. RESULTS: The concentrations of chemical markers in the standardized methanol extract were 0.02% oroboside, 1.69% demethylwedelolactone and 1.71% wedelolactone. Treatment with 250mgkg-1 of extract, which provided 0.745, 4.22 and 4.30mgkg-1 day-1 of oroboside, demethylwedelolactone and wedelolactone, respectively, significantly reduced (P&lt;0.05) respiratory resistance and elastance. Such effects were comparable with those produced by dexamethasone. The total number of inflammatory cells and eosinophils in the bronchoalveolar lavage and the concentrations of interleukin (IL)-4, IL-5 and IL-13 in lung homogenate were significantly reduced (P&lt;0.05) by the methanol extract of E. prostrata. CONCLUSION: The results presented herein demonstrate for the first time the anti-inflammatory activity of E. prostrata in a murine model of asthma, thereby supporting the ethnopharmacological uses of the plant</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2016.12.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27956356">PM:27956356</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20161213-MorelLJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20161213-MorelLJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Morel LJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2016.12.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boushell,V.</style></author><author><style face="normal" font="Arial"> Pang,S.</style></author><author><style face="normal" font="Arial"> He,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Food Science, Univ. of Massachusetts Amherst, 100 Holdsworth Way, Amherst, MA, 01003, U.S.ADept. of Food Science, Univ. of Massachusetts Amherst, 100 Holdsworth Way, Amherst, MA, 01003, U.S.ADept. of Food Science, Univ. of Massachusetts Amherst, 100 Holdsworth Way, Amherst, MA, 01003, U.S.A</style></auth-address><titles><title><style face="normal" font="Arial">Aptamer-Based SERS Detection of Lysozyme on a Food-Handling Surface</style></title><secondary-title><style face="normal" font="Arial">J Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Aptamers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food Handling</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Raman spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Silver nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="14" Month="12" Year="2016">2016/12/14</year></dates><abstract><style face="normal" font="Arial">Undeclared food allergens due to cross contamination of processing equipment is a leading cause for food product recalls. Therefore, there is a great need for developing rapid and sensitive methods to detect food allergens. In this paper, an aptamer highly specific to egg white lysozyme was coupled to dendritic silver nanoparticles in order to perform surface enhanced Raman spectroscopy (SERS). The procedure was successfully tested in water and on a stainless steel food-handling surface. The lowest detectable concentration for lysozyme was 0.5 mug/mL in water and 5 mug/mL on a stainless steel food-handling surface. Principal component analysis shows a significant change in SERS spectra when lysozyme was present, suggesting the successful capture of lysozyme by the aptamer. Quantification of lysozyme target was also shown from 0 to 6 mug/mL, that is, 0, 0.5, 2, 6 mug/mL. Overall method took less than 40 min. The developed method can be extended to detect other food allergens using specific aptamers</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1750-3841 (Electronic)IS - 0022-1147 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/1750-3841.13582</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27973744">PM:27973744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci\20161215-BoushellV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci\20161215-BoushellV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Boushell V</style></custom2><misc3><style face="normal" font="Arial">10.1111/1750-3841.13582</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Otto,G.</style></author><author><style face="normal" font="Arial"> Lamote,A.</style></author><author><style face="normal" font="Arial"> Deckers,E.</style></author><author><style face="normal" font="Arial"> Dumont,V.</style></author><author><style face="normal" font="Arial"> Delahaut,P.</style></author><author><style face="normal" font="Arial"> Scippo,M.L.</style></author><author><style face="normal" font="Arial"> Pleck,J.</style></author><author><style face="normal" font="Arial"> Hillairet,C.</style></author><author><style face="normal" font="Arial"> Gillard,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A flow-cytometry-based method for detecting simultaneously five allergens in a complex food matrix</style></title><secondary-title><style face="normal" font="Arial">J Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci Technol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Competitive ELISA</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cookies</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mustard</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Simultaneous detection</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0975-8402</style></isbn><abstract><style face="normal" font="Arial">To avoid carry-over contamination with allergens, food manufacturers implement quality control strategies relying primarily on detection of allergenic proteins by ELISA. Although sensitive and specific, this method allowed detection of only one allergen per analysis and effective control policies were thus based on multiplying the number of tests done in order to cover the whole range of allergens. We present in this work an immunoassay for the simultaneous detection of milk, egg, peanut, mustard and crustaceans in cookies samples. The method was based on a combination of flow cytometry with competitive ELISA where microbeads were used as sorbent surface. The test was able to detect the presence of the five allergens with median inhibitory concentrations (IC50) ranging from 2.5 to 15-ámg/kg according to the allergen to be detected. The lowest concentrations of contaminants inducing a significant difference of signal between non-contaminated controls and test samples were 2-ámg/kg of peanut, 5-ámg/kg of crustaceans, 5-ámg/kg of milk, 5-ámg/kg of mustard and 10-ámg/kg of egg. Assay sensitivity was influenced by the concentration of primary antibodies added to the sample extract for the competition and by the concentration of allergenic proteins bound to the surface of the microbeads</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13197-016-2402-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13197-016-2402-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci Technol\20161222-OttoG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci Technol\20161222-OttoG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161222, Otto G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13197-016-2402-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kuo,C.H.</style></author><author><style face="normal" font="Arial"> Collins,A.M.</style></author><author><style face="normal" font="Arial"> Boettner,D.R.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Ono,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital, Medical Center, Cincinnati, OH 45229</style></auth-address><titles><title><style face="normal" font="Arial">Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="12" Year="2016">2016/12/12</year></dates><abstract><style face="normal" font="Arial">Molecules that are necessary for ocular hypersensitivity reactions include the receptors CCR1 and CCR3; CCL7 is a ligand for these receptors. Therefore, we explored the role of CCL7 in mast cell activity and motility in vitro and investigated the requirement for CCL7 in a murine model of IgE-mediated allergic conjunctivitis. For mast cells treated with IgE and Ag, the presence of CCL7 synergistically enhanced degranulation and calcium influx. CCL7 also induced chemotaxis in mast cells. CCL7-deficient bone marrow-derived mast cells showed decreased degranulation following IgE and Ag treatment compared with wild-type bone marrow-derived mast cells, but there was no difference in degranulation when cells were activated via an IgE-independent pathway. In vivo, CCL7 was upregulated in conjunctival tissue during an OVA-induced allergic response. Notably, the early-phase clinical symptoms in the conjunctiva after OVA challenge were significantly higher in OVA-sensitized wild-type mice than in control challenged wild-type mice; the increase was suppressed in CCL7-deficient mice. In the OVA-induced allergic response, the numbers of conjunctival mast cells were lower in CCL7-deficient mice than in wild-type mice. Our results demonstrate that CCL7 is required for maximal OVA-induced ocular anaphylaxis, mast cell recruitment in vivo, and maximal FcepsilonRI-mediated mast cell activation in vitro. A better understanding of the role of CCL7 in mediating ocular hypersensitivity reactions will provide insights into mast cell function and novel treatments for allergic ocular diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1502416</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27956527">PM:27956527</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20161213-KuoCH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20161213-KuoCH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Kuo CH</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1502416</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Finkelman,F.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Identification of IgE as the Allergy-Associated Ig Isotype</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="4" start="3">3-4</pages><volume><style face="normal" font="Arial">198</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601893</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27994163">PM:27994163</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2017-198-3-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2017-198-3-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161222, Finkelman FD</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601893</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumar,G.R.</style></author><author><style face="normal" font="Arial"> Kumar,S.</style></author><author><style face="normal" font="Arial"> GUPTA,K.</style></author><author><style face="normal" font="Arial"> Sharma,A.</style></author><author><style face="normal" font="Arial"> Roy,R.</style></author><author><style face="normal" font="Arial"> Kumar,V.A.</style></author><author><style face="normal" font="Arial"> Chaudhari,B.P.</style></author><author><style face="normal" font="Arial"> Das,M.</style></author><author><style face="normal" font="Arial"> Ahmad,A.I.</style></author><author><style face="normal" font="Arial"> Dwivedi,P.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Food Toxicology Laboratory, Food, Drug and Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR) , Lucknow , India</style></auth-address><titles><title><style face="normal" font="Arial">Cutaneous exposure to clinically-relevant pigeon pea (Cajanus cajan) proteins promote TH2-dependent sensitization and IgE-mediated anaphylaxis in Balb/c mice</style></title><secondary-title><style face="normal" font="Arial">J Immunotoxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunotoxicol</style></full-title></periodical><pages end="841" start="827">827-841</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cutaneous exposure</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Intestines</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> Pea</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Epicutaneous (EC) sensitization to food allergens may occur when the skin has been lightly damaged. The study here tested whether cutaneous exposure to pigeon pea protein(s) may cause allergic sensitization. BALB/c mice were either orally gavaged or epicutaneously sensitized by repeated application of pigeon pea crude protein extract (CPE) on undamaged areas of skin without any adjuvant; afterwards, both groups were orally challenged with the pigeon pea CPE. Anaphylactic symptoms along with measures of body temperature, MCPT-1, TSLP, pigeon pea-specific IgE and IgG1, myeloperoxidase (MPO) activity, TH2 cytokines, TH2 transcription factors (TFs) and filaggrin expression were determined. Mast cell staining, eosinophil levels and histopathological analysis of the skin and intestines were also performed. In the epicutaneously-sensitized mice, elevated levels of specific IgE and IgG1, as well as of MCPT-1, TSLP, TH2 cytokines and TFs, higher anaphylactic scores and histological changes in the skin and intestine were indicative of sensitization ability via both routes in the pigeon pea CPE-treated hosts. Elevated levels of mast cells were observed in both the skin and intestine; increased levels of eosinophils and MPO activity were noted only in the skin. Decreased levels of filaggrin in skin may have played a key role in the skin barrier dysfunction, increasing the chances of sensitization. Therefore, the experimental data support the hypothesis that in addition to oral exposure, skin exposure to food allergens can promote TH2-dependent sensitization, IgE-mediated anaphylaxis and intestinal changes after oral challenge. Based on this, an avoidance of cutaneous exposures to allergens might prevent development of food anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20161214IS - 1547-6901 (Electronic)IS - 1547-691X (Linking)LA - engPT - Journal ArticleCO - United States -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1080/1547691X.2016.1205159</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27967302">PM:27967302</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunotoxicol\2016-13-827-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunotoxicol\2016-13-827-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Kumar GR</style></custom2><misc3><style face="normal" font="Arial">10.1080/1547691X.2016.1205159</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saini,S.S.</style></author><author><style face="normal" font="Arial"> Omachi,T.A.</style></author><author><style face="normal" font="Arial"> Trzaskoma,B.</style></author><author><style face="normal" font="Arial"> Hulter,H.N.</style></author><author><style face="normal" font="Arial"> Rosen,K.</style></author><author><style face="normal" font="Arial"> Sterba,P.M.</style></author><author><style face="normal" font="Arial"> Courneya,J.P.</style></author><author><style face="normal" font="Arial"> Lackey,A.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, USA</style></auth-address><titles><title><style face="normal" font="Arial">Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="961" start="958">958-961</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2016.11.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27939380">PM:27939380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-958-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-958-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Saini SS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2016.11.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Popovic,B.</style></author><author><style face="normal" font="Arial"> Breed,J.</style></author><author><style face="normal" font="Arial"> Rees,D.G.</style></author><author><style face="normal" font="Arial"> Gardener,M.J.</style></author><author><style face="normal" font="Arial"> Vinall,L.M.</style></author><author><style face="normal" font="Arial"> Kemp,B.</style></author><author><style face="normal" font="Arial"> Spooner,J.</style></author><author><style face="normal" font="Arial"> Keen,J.</style></author><author><style face="normal" font="Arial"> Minter,R.</style></author><author><style face="normal" font="Arial"> Uddin,F.</style></author><author><style face="normal" font="Arial"> Colice,G.</style></author><author><style face="normal" font="Arial"> Wilkinson,T.</style></author><author><style face="normal" font="Arial"> Vaughan,T.</style></author><author><style face="normal" font="Arial"> May,R.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Antibody Discovery and Protein Engineering, MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Structural Characterisation Reveals Mechanism of IL-13 Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Ralpha1 and IL-13Ralpha2</style></title><secondary-title><style face="normal" font="Arial">J Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Mol Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Complementarity Determining Regions</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Engineering</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Structure analysis</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="9" Month="12" Year="2016">2016/12/9</year></dates><abstract><style face="normal" font="Arial">Interleukin-13 (IL-13) is a pleiotropic T helper type 2 (Th2) cytokine frequently associated with asthma and atopic dermatitis. IL-13-mediated signalling is initiated by binding to IL-13Ralpha1 which then recruits IL-4Ralpha to form a heterodimeric receptor complex. IL-13 also binds to IL-13Ralpha2, considered as either a decoy or key mediator of fibrosis. IL-13 neutralising antibodies act by preventing IL-13 binding to IL-13Ralpha1, IL-4Ralpha and/or IL-13Ralpha2. Tralokinumab (CAT-354) is an IL-13-neutralising human IgG4 monoclonal antibody that has shown clinical benefit in patients with asthma. To decipher how tralokinumab inhibits the effects of IL-13 we determined the structure of tralokinumab Fab in complex with human IL-13 to 2A resolution. The structure analysis reveals that tralokinumab prevents IL-13 from binding to both IL-13Ralpha1 and IL-13Ralpha2. This is supported by biochemical ligand-receptor interaction assay data. The tralokinumab epitope is mainly composed of residues in helices D and A of IL-13. It is mostly light chain complementarity determining regions (CDRs) that are driving paratope interactions; the variable light CDR2 plays a key role by providing residue contacts for a network of hydrogen bonds and a salt bridge in the core of binding. The key residues within the paratope contributing to binding were identified as Asp50, Asp51, Ser30 and Lys31. This study demonstrates that tralokinumab prevents the IL-13 pharmacodynamic effect by binding to IL-13 helices A and D, thus preventing IL-13 from interacting with IL-13Ralpha1 and IL-13Ralpha2</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1089-8638 (Electronic)IS - 0022-2836 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jmb.2016.12.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27956146">PM:27956146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Mol Biol\20161213-PopovicB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Mol Biol\20161213-PopovicB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Popovic B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jmb.2016.12.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Major,J.L.</style></author><author><style face="normal" font="Arial"> Boese,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ross Strategic, Seattle, Washington</style></auth-address><titles><title><style face="normal" font="Arial">Cross Section of Legislative Approaches to Reducing Indoor Dampness and Mold</style></title><secondary-title><style face="normal" font="Arial">J Public Health Manag Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Public Health Manag Pract</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adoption</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Building Codes</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> dampness</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Care Costs</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="13" Month="12" Year="2016">2016/12/13</year></dates><abstract><style face="normal" font="Arial">CONTEXT: Exposure to indoor dampness and mold is associated with numerous adverse respiratory conditions, including asthma. While no quantitative health-based threshold currently exists for mold, the conditions that support excessive dampness and mold are known and preventable; experts agree that controlling these conditions could lead to substantial savings in health care costs and improvement in public health. METHOD: This article reviews a sample of state and local policies to limit potentially harmful exposures. Adoption of laws to strengthen building codes, specify dampness and mold in habitability laws, regulate mold contractors, and other legislative approaches are discussed, as are key factors supporting successful implementation. IMPLICATIONS FOR POLICY AND PRACTICE: Communicating these lessons learned could accelerate the process for other jurisdictions considering similar approaches. Information about effectiveness of legislation as prevention is lacking; thus, evaluation could yield important information to inform the development of model state or local laws that significantly address mold as a public health concern.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1550-5022 (Electronic)IS - 1078-4659 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/PHH.0000000000000491</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27977504">PM:27977504</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Public Health Manag Pract\20161215-MajorJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Public Health Manag Pract\20161215-MajorJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Major JL</style></custom2><misc3><style face="normal" font="Arial">10.1097/PHH.0000000000000491</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Du,L.</style></author><author><style face="normal" font="Arial"> Ye,X.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Zhang,B.</style></author><author><style face="normal" font="Arial"> Zheng,R.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mechanisms of traditional Chinese medicines in the treatment of allergic rhinitis using a network biology approach</style></title><secondary-title><style face="normal" font="Arial">J Trad Chin Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Trad Chin Med Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cell Membrane</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Entity grammar systems</style></keyword><keyword><style face="normal" font="Arial"> Flower</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Herbs</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molting</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Xanthium</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2095-7548</style></isbn><abstract><style face="normal" font="Arial">Objective To apply network biology to systematically explore the effect and mechanism of traditional Chinese herbs in the treatment of allergic rhinitis. Methods Magnolia flower, xanthium fruit, astragalus root, paniculate cynanchum, scutellaria root, cicada molting, stephania root, small centipeda herb, and licorice root as traditional Chinese herbs are widely used to treat allergic rhinitis. Using multiple database integration and entity grammar systems, a model molecular interaction network of traditional Chinese herbs for treating allergic rhinitis was established. Bioinformatics approaches were adopted to integrate relevant data and biologic information by multiple databases. Constructional molecular interaction network of Chinese herbs for treating allergic rhinitis was based on entity grammar systems model. The network was then used for elucidating the anti-allergic rhinitis mechanism of the Chinese herbs holistically and on the molecular level. The subnetworks were also extracted to explicitly display the pathway where e</style><style face="normal" font="Symbol">Ç</style><style face="normal" font="Arial">¼Çective components acted on the related targets of allergic rhinitis. Results Traditional Chinese herbs could adjust various pathologic aspects in allergic rhinitis including the production of pro-inflammatory substances, such as histamine and cytokine IL-4, IL-13, lowering IgE level or blocking antigen binding, altering the structure of IgE, modulating the balance of Th or other cells by cell proliferation and differentiation, mediating cell-cell signaling and second-messenger-mediated signaling, stabilizing the cell membrane, and affecting regulation of cellular defense response. Conclusion The research theoretically confirms the mechanism of anti-allergic rhinitis by traditional Chinese herbs, provides important fundamental research information for treatment of allergic rhinitis, and may serve as a reference for new drug development and effective ingredients of compatibility</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jtcms.2016.11.007</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jtcms.2016.11.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Trad Chin Med Sci\20161216-DuL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Trad Chin Med Sci\20161216-DuL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Du L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jtcms.2016.11.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sakarin,S.</style></author><author><style face="normal" font="Arial"> Rungsipipat,A.</style></author><author><style face="normal" font="Arial"> Surachetpong,S.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary Medicine, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Galectin-3 in cardiac muscle and circulation of dogs with degenerative mitral valve disease</style></title><secondary-title><style face="normal" font="Arial">J Vet Cardiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Vet Cardiol</style></abbr-1></periodical><pages end="46" start="34">34-46</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Galectin 3</style></keyword><keyword><style face="normal" font="Arial"> Heart Valve Diseases</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mitral Valve</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Myocardium</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2016">2016/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: This study aimed to determine the association of cardiac fibrosis with the galectin-3 (Gal-3) expression, a fibrosis marker in the myocardium and to compare plasma Gal-3 levels in normal and degenerative mitral valve disease (DMVD) dogs. ANIMALS: Studies of muscle expression and plasma levels of Gal-3 were performed in separate groups of dogs. The tissue study was performed on cardiac tissues collected from 22 dogs. The plasma study was performed on 46 client-owned dogs. METHODS: Papillary muscle and left ventricular (LV) wall obtained from 10 normal and 12 DMVD dogs were stained with Masson trichrome and Gal-3 immunohistochemistry to determine fibrosis areas and Gal-3 expression. Plasma samples were collected from 19 normal and 27 DMVD dogs for Gal-3 measurement by ELISA. RESULTS: Percentage of fibrosis was higher in papillary muscle and LV wall of DMVD dogs (66.13 +/- 5.58%; 52.98 +/- 8.45%) than in normal dogs (35.40 +/- 8.46%; 27.41 +/- 7.91%; p &lt; 0.0001). Gal-3 was higher in papillary muscle and LV wall of DMVD dogs (27.95 +/- 6.94%; 17.25 +/- 8.76%) than in normal dogs (1.08 +/- 0.67%; 0.52 +/- 0.42%; p &lt; 0.0001). Fibrosis areas correlated strongly with the Gal-3 expression (r = 0.821, p &lt; 0.0001). Plasma Gal-3 levels were increased in DMVD dogs (1.50; 0.87-2.36 ng/mL) compared to normal dogs (0.42; 0.27-0.63 ng/mL; p &lt; 0.0001). CONCLUSIONS: Gal-3 expression in cardiac muscle was associated with cardiac fibrosis and was higher in DMVD dogs than in normal dogs. DMVD dogs had higher plasma Gal-3 concentrations than normal dogs. Tissue Gal-3 is a candidate of fibrosis biomarker in DMVD; however, further investigation of associations between plasma Gal-3 and myocardial fibrosis is necessary</style></abstract><notes><style face="normal" font="Arial">DA - 20160209IS - 1875-0834 (Electronic)IS - 1760-2734 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Galectin 3)SB - IMCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jvc.2015.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26786977">PM:26786977</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Vet Cardiol\2016-18-34-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Vet Cardiol\2016-18-34-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160209, Sakarin S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jvc.2015.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,J.B.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Song,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Thoracic and Cardiovascular Surgery, Dongsan Medical Center, Keimyung University School of MedicineDepartment of Thoracic and Cardiovascular Surgery, Dongsan Medical Center, Keimyung University School of MedicineDepartment of Thoracic and Cardiovascular Surgery, Dongsan Medical Center, Keimyung University School of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Catastrophic Bronchial Spasm Due to a Severe Anaphylactic Reaction to Protamine</style></title><secondary-title><style face="normal" font="Arial">Korean J Thorac Cardiovasc Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Korean J Thorac Cardiovasc Surg</style></abbr-1></periodical><pages end="474" start="472">472-474</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Spasm</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Protamine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spasm</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Fatal anaphylactic reactions to protamine sulfate during cardiac surgery are very rare. We report a case of catastrophic bronchial spasm due to an anaphylactic reaction to protamine. The patient was managed successfully using a bronchodilator, steroid treatment, and extracorporeal membrane oxygenation</style></abstract><notes><style face="normal" font="Arial">DA - 20161214IS - 2233-601X (Print)IS - 2233-601X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jtcms.2016.11.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27965927">PM:27965927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Thorac Cardiovasc Surg\2016-49-472-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Thorac Cardiovasc Surg\2016-49-472-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161214, Kim JB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jtcms.2016.11.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Natsume,O.</style></author><author><style face="normal" font="Arial"> Kabashima,S.</style></author><author><style face="normal" font="Arial"> Nakazato,J.</style></author><author><style face="normal" font="Arial"> Yamamoto-Hanada,K.</style></author><author><style face="normal" font="Arial"> Narita,M.</style></author><author><style face="normal" font="Arial"> Kondo,M.</style></author><author><style face="normal" font="Arial"> Saito,M.</style></author><author><style face="normal" font="Arial"> Kishino,A.</style></author><author><style face="normal" font="Arial"> Takimoto,T.</style></author><author><style face="normal" font="Arial"> Inoue,E.</style></author><author><style face="normal" font="Arial"> Tang,J.</style></author><author><style face="normal" font="Arial"> Kido,H.</style></author><author><style face="normal" font="Arial"> Wong,G.W.K.</style></author><author><style face="normal" font="Arial"> Matsumoto,K.</style></author><author><style face="normal" font="Arial"> Saito,H.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> heated egg</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> hen's egg allergy</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Labour</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0140-6736</style></isbn><abstract><style face="normal" font="Arial">Background Evidence is accumulating that early consumption is more beneficial than is delayed introduction as a strategy for primary prevention of food allergy. However, allergic reactions caused by early introduction of such solid foods have been a problematic issue. We investigated whether or not early stepwise introduction of eggs to infants with eczema combined with optimal eczema treatment would prevent egg allergy at 1 year of age. Methods In this randomised, double-blind, placebo-controlled trial, we enrolled infants 4</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô5 months of age with eczema from two centres in Japan. Exclusion criteria were being born before 37 weeks of gestational age, experience of ingestion of hen's eggs or egg products, history of immediate allergic reaction to hen's eggs, history of non-immediate allergic reaction to a particular type of food, and complications of any severe disease. Infants were randomly assigned (block size of four; stratified by institution and sex) to early introduction of egg or placebo (1:1). Participants in the egg group consumed orally 50 mg of heated egg powder per day from 6 months to 9 months of age and 250 mg per day thereafter until 12 months of age. We aggressively treated participants' eczema at entry and maintained control without exacerbations throughout the intervention period. Participants and physicians were masked to assignment, and allocation was concealed. The primary outcome was the proportion of participants with hen's egg allergy confirmed by open oral food challenges at 12 months of age, assessed blindly by standardised methods, in all randomly allocated participants who received the intervention. This trial is registered with the University Hospital Medical Information Network Clinical Trials Registry, number UMIN000008673. Findings Between Sept 18, 2012, and Feb 13, 2015, we randomly allocated 147 participants (73 [50%] to the egg group and 74 [50%] to the placebo group). This trial was terminated on the basis of the results of the scheduled interim analysis of 100 participants, which showed a significant difference between the two groups (four [9%] of 47 participants had an egg allergy in the egg group vs 18 [38%] of 47 in the placebo group; risk ratio 0-À222 [95% CI 0-À081</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0-À607]; p=0-À0012). In the primary analysis population, five (8%) of 60 participants had an egg allergy in the egg group compared with 23 (38%) of 61 in the placebo group (risk ratio 0-À221 [0-À090</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0-À543]; p=0-À0001). The only difference in adverse events between groups was admissions to hospital (six [10%] of 60 in the egg group vs none in the placebo group; p=0-À022). 19 acute events occurred in nine (15%) participants in the egg group versus 14 events in 11 (18%) participants in the placebo group after intake of the trial powder. Interpretation Introduction of heated egg in a stepwise manner along with aggressive eczema treatment is a safe and efficacious way to prevent hen's egg allergy in high-risk infants. In this study, we developed a practical approach to overcome the second wave of the allergic epidemic caused by food allergy. Funding Ministry of Health, Labour and Welfare, and National Centre for Child Health and Development, Japan</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(16)31418-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/S0140-6736(16)31418-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20161220-NatsumeO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20161220-NatsumeO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Natsume O</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(16)31418-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Another step towards prevention of food allergy</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">0140-6736</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(16)31661-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27939036">PM:27939036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20161220-RobertsG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20161220-RobertsG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, RobertsG</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(16)31661-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">The Lancet</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Building the evidence base for safety in food allergy</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="2838">2838-</pages><volume><style face="normal" font="Arial">388</style></volume><number><style face="normal" font="Arial">10062</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year><pub-dates><date Day="16" Month="12" Year="2016">2016/12/16</date></pub-dates></dates><isbn><style face="normal" font="Arial">0140-6736</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(16)32512-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/S0140-6736(16)32512-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\2016-388-2838.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\2016-388-2838.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, The Lancet</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(16)32512-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Faustino-Rocha,A.I.</style></author><author><style face="normal" font="Arial"> Ferreira,R.</style></author><author><style face="normal" font="Arial"> Gama,A.</style></author><author><style face="normal" font="Arial"> Oliveira,P.A.</style></author><author><style face="normal" font="Arial"> Ginja,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary Sciences, School of Agrarian and Veterinary Sciences, University of Tras-os-Montes and Alto Douro, UTAD, 5001-911 Vila Real, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Antihistamines as promising drugs in cancer therapy</style></title><secondary-title><style face="normal" font="Arial">Life Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Life Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> histamine receptors</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Melanoma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="13" Month="12" Year="2016">2016/12/13</year></dates><abstract><style face="normal" font="Arial">Histamine is a biogenic amine, synthetized and released by mast cells, which acts as a vasodilator in several pathologic processes, namely in allergies and conjunctivitis. Its role on cancer is not fully understood. High levels of histamine have been associated with a bivalent behavior in regulation of several tumors (i.e. cervical, ovarian, vaginal, uterine, vulvar, colorectal cancer, and melanoma), promoting or inhibiting their growth. Histamine receptors (H1, H2, H3 and H4) are present in a vast group of cells, including tumor cells, making them sensitive to histamine variations. In this work, we review the role of mast cells and histamine on cancer development and the possibility of use antihistamines in the clinical management of this disease</style></abstract><notes><style face="normal" font="Arial">DA - 20161217IS - 1879-0631 (Electronic)IS - 0024-3205 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.lfs.2016.12.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27986539">PM:27986539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Life Sci\20161217-FaustinoRochaAI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Life Sci\20161217-FaustinoRochaAI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161217, Faustino-Rocha AI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.lfs.2016.12.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weiss,R.</style></author><author><style face="normal" font="Arial"> Scheiblhofer,S.</style></author><author><style face="normal" font="Arial"> Thalhamer,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Molecular Biology, University of Salzburg, Hellbrunnerstrasse 34, 5020, Salzburg, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergy</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="139" start="123">123-139</pages><volume><style face="normal" font="Arial">1499</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA vaccine</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Due to the worldwide increase in allergies and a limited efficacy of therapeutic interventions, the need for prophylactic vaccination against allergies has been recognized. mRNA and DNA vaccines have demonstrated their high potential for preventing allergic sensitization by inducing an immunological bias that prevents TH2 sensitization. However, only mRNA vaccines fulfill the stringent safety requirements for vaccination of healthy children. In this chapter, we describe the generation of conventional as well as self-replicating mRNA vaccines and methods to test their prophylactic efficacy in animal models</style></abstract><notes><style face="normal" font="Arial">DA - 20161217IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6481-9_7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27987146">PM:27987146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1499-123-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1499-123-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161217, Weiss R</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6481-9_7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tarlo,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine and Dalla Lana School of Public Health, Toronto Western Hospital and St Michael's Hospital, University of Toronto, Toronto, Canada - susan.tarlo@utoronto.ca</style></auth-address><titles><title><style face="normal" font="Arial">Management and prevention of occupational asthma</style></title><secondary-title><style face="normal" font="Arial">Minerva Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Minerva Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status date="12/25/16" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="20" Month="12" Year="2016">2016/12/20</year></dates><abstract><style face="normal" font="Arial">Occupational asthma is a potential preventable form of asthma. This review of diagnosis, management and prevention focuses mainly on publications from the past three years. Early suspicion of the diagnosis is essential for a timely diagnosis and management and the possibility may first be raised by the patient or may need to be elicited by careful history from the health care provider. Objective diagnostic steps are needed, as have been detailed in consensus statements and guidelines. A combination of tests is often needed for diagnosis and these are most easily obtained while the patient is still employed. Management includes consideration of safe future workplace accommodation and of preventive measures for the patient and for other workers</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1827-1669 (Electronic)IS - 0026-4806 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28001013">PM:28001013</url></web-urls><pdf-urls><url ppv-ref="no">susan.tarlo@utoronto.ca</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161221, Tarlo SM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,X.</style></author><author><style face="normal" font="Arial"> Dreskin,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Departments of Medicine and Immunology, University of Colorado Denver, Aurora, CODivision of Allergy and Clinical Immunology, Departments of Medicine and Immunology, University of Colorado Denver, Aurora, CO</style></auth-address><titles><title><style face="normal" font="Arial">Application of phage peptide display technology for the study of food allergen epitopes</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mimotope</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="12" Year="2016">2016/12/20</year></dates><abstract><style face="normal" font="Arial">Phage peptide display technology has been used to identify IgE-binding mimotopes (mimics of natural epitopes) that mimic conformational epitopes. This approach is effective in the characterization of those epitopes that are important for eliciting IgE-mediated allergic responses by food allergens and those that are responsible for cross-reactivity among allergenic food proteins. Application of this technology will increase our understanding of the mechanisms whereby food allergens elicit allergic reactions, will facilitate the discovery of diagnostic reagents and may lead to mimotope-based immunotherapy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201600568</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27995755">PM:27995755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20161220-ChenX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20161220-ChenX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Chen X</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201600568</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Szajewska,H.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaffe Food Allergy Institute, Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029, USAThe Medical University of Warsaw, Department of Paediatrics, Zwirki i Wigury 63A, 02091 Warsaw, PolandKing's College London Academic Paediatric Allergy Service, Guy's &amp;St Thomas' NHS Foundation Trust Children's Allergies Department, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy and the gut</style></title><secondary-title><style face="normal" font="Arial">Nat Rev Gastroenterol Hepatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Rev Gastroenterol Hepatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood food allergy</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dysphagia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Failure to Thrive</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein-Losing Enteropathies</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="Arial">Food allergy develops as a consequence of a failure in oral tolerance, which is a default immune response by the gut-associated lymphoid tissues to ingested antigens that is modified by the gut microbiota. Food allergy is classified on the basis of the involvement of IgE antibodies in allergic pathophysiology, either as classic IgE, mixed pathophysiology or non-IgE-mediated food allergy. Gastrointestinal manifestations of food allergy include emesis, nausea, diarrhoea, abdominal pain, dysphagia, food impaction, protein-losing enteropathy and failure to thrive. Childhood food allergy has a generally favourable prognosis, whereas natural history in adults is not as well known. Elimination of the offending foods from the diet is the current standard of care; however, future therapies focus on gradual reintroduction of foods via oral, sublingual or epicutaneous food immunotherapy. Vaccines, modified hypoallergenic foods and modification of the gut microbiota represent additional approaches to treatment of food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1759-5053 (Electronic)IS - 1759-5045 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1038/nrgastro.2016.187</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27999436">PM:27999436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Rev Gastroenterol Hepatol\20161221-NowakWegrzynA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Rev Gastroenterol Hepatol\20161221-NowakWegrzynA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Nowak-Wegrzyn A</style></custom2><misc3><style face="normal" font="Arial">10.1038/nrgastro.2016.187</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bordon,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy: Pollutants drive atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Nat Rev Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nat Rev Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="12" Month="12" Year="2016">2016/12/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1474-1741 (Electronic)IS - 1474-1733 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/nri.2016.141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27941892">PM:27941892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Rev Immunol\20161212-BordonY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Rev Immunol\20161212-BordonY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Bordon Y</style></custom2><misc3><style face="normal" font="Arial">10.1038/nri.2016.141</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mark,Z.</style></author><author><style face="normal" font="Arial"> Bikov,A.</style></author><author><style face="normal" font="Arial"> Galffy,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tudogyogyintezet Torokbalint, Munkacsy M. u. 70., 2045</style></auth-address><titles><title><style face="normal" font="Arial">[Characterisctics of ragweed allergy in Hungary]</style></title><secondary-title><style face="normal" font="Arial">Orv Hetil</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Orv Hetil</style></full-title></periodical><pages end="1993" start="1989">1989-1993</pages><volume><style face="normal" font="Arial">157</style></volume><number><style face="normal" font="Arial">50</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> ragweed pollination</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Although the prevalence of ragweed allergy in Europe is still low, it is increasing according to recent statistics. In contrast, in Hungary ragweed is the most common allergen with very high sensitisation in the general Hungarian population. AIM: We investigated the number and clinical characteristics of ragweed allergy in the Hungarian population, as the first comprehensive study to evaluate ragweed allergy in Hungary. METHOD: One thousand Hungarian adult subjects were screened with a questionnaire for ragweed allergy. People with ragweed allergy answered further specific questions about their disease history, symptoms and medication use. RESULTS: 305 subjects reported allergy from which 218 patients had symptoms during ragweed pollination suggesting ragweed allergy. 40% of these had symptoms for more than 5 years. Asthma was reported in 18.3%. Around 24% of these patients were undiagnosed; they did not take any medications or visited professionals because of their symptoms. Compared to the non-ragweed allergic patients, subjects with ragweed allergy were older and better educated, but the dominance of female gender was less prominent than in the non-ragweed group (all p&lt;0.05). CONCLUSIONS: Around 22% of the Hungarian population suffers from ragweed allergy. Studies should focus on eradication strategy and improvement of patient care. Orv. Hetil., 2016, 157(50), 1989-1993</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 0030-6002 (Print)IS - 0030-6002 (Linking)LA - hunPT - Journal ArticlePT - English AbstractCO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1556/650.2016.30615</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27936878">PM:27936878</url></web-urls></urls><custom2><style face="normal" font="Arial">20161212, Nark Z</style></custom2><misc3><style face="normal" font="Arial">10.1556/650.2016.30615</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elliott,D.E.</style></author><author><style face="normal" font="Arial"> Weinstock,J.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology, University of Iowa, Iowa City, IA</style></auth-address><titles><title><style face="normal" font="Arial">Nematodes and human therapeutic trials for inflammatory disease</style></title><secondary-title><style face="normal" font="Arial">Parasite Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasite Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> intestinal flora</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Iowa</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Metabolic Diseases</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutic trials</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="Arial">Helminth infections likely provide a protective influence against some immune-mediated and metabolic diseases since helminth infection dramatically decreased in developed countries shortly before the explosive rise in the prevalence of these diseases. The capacity of helminths to activate immune-regulatory circuits in their hosts and to modulate the composition of intestinal flora appears to be the mechanisms of protective action. Animal models of disease show that various helminth species prevent and/or block inflammation in various organs in a diverse range of diseases. Clinical trials have demonstrated that medicinal exposure to T. suis or small numbers of N. americanus is safe with minor, if any, reported adverse effects. This includes exposure of inflamed intestine to T. suis, asthmathic lung to N. americanus, and in patients with atopy. Efficacy has been suggested in some small studies, but is absent in others. Factors that may have led to inconclusive results in some trials are discussed. To date, there have been no registered clinical trials using helminths to treat metabolic syndrome or its component conditions. However, the excellent safety profile of T. suis or N. americanus suggests that such studies should be possible. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1365-3024 (Electronic)IS - 0141-9838 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pim.12407</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27977856">PM:27977856</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasite Immunol\20161215-ElliottDE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasite Immunol\20161215-ElliottDE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Elliott DE</style></custom2><misc3><style face="normal" font="Arial">10.1111/pim.12407</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mastrorilli,C.</style></author><author><style face="normal" font="Arial"> Posa,D.</style></author><author><style face="normal" font="Arial"> Cipriani,F.</style></author><author><style face="normal" font="Arial"> Caffarelli,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Clinic, Department of Clinical and Experimental Medicine, University of Parma, Parma, ItalyDepartment of Pediatric Pneumology and Immunology, Charite Universitatsmedizin, Berlin, GermanyDepartment of Pediatric Pneumology and Immunology, Charite Universitatsmedizin, Berlin, GermanyPediatric Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyPediatric Clinic, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Asthma and allergic rhinitis in childhood: what's new</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="803" start="795">795-803</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary and secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Novel approaches are currently offered for the diagnostic workup and therapeutic management of allergic rhinitis and asthma. New predictive biomarkers of allergy and asthma are available. Primary and secondary prevention, earlier intervention, and modification of the natural history of allergic rhinitis and asthma are being intensively investigated. This review highlights advances in the understanding of the etiology, diagnosis, and management of atopic airway diseases in childhood, as well as prenatal and early-life risk factors and strategies for prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20161118IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12681</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27862336">PM:27862336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2016-27-795-803.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2016-27-795-803.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161118, Mastrorilli C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12681</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomez-Mateos,P.M.</style></author><author><style face="normal" font="Arial"> Navarro,M.C.</style></author><author><style face="normal" font="Arial"> Merino,E.G.</style></author><author><style face="normal" font="Arial"> Valero,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Parasitology, Faculty of Pharmacy , University of Granada , Granada , Spain</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of different Mediterranean essential oils as prophylactic agents in anisakidosis</style></title><secondary-title><style face="normal" font="Arial">Pharm Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharm Biol</style></full-title></periodical><pages end="461" start="456">456-461</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Apiaceae</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish muscle</style></keyword><keyword><style face="normal" font="Arial"> fresh fish</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Lamiaceae</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Musculature</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Oils</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">CONTEXT: Anisakis Dujardin 1845 (Anisakidae) nematodes can cause gastrointestinal and allergic diseases when humans eat raw or undercooked seafood containing larvae. There is currently no drug available in the market against this parasitic disease, and the study of plant-derived molecules could be useful in the discovery of effective compounds. OBJECTIVE: This research assesses the biocidal activity of a range of essential oils (EOs) from some Mediterranean plants against larvae found in the musculature of fresh fish. MATERIALS AND METHODS: EOs composition was analyzed by gas chromatography-mass spectroscopy. All the EOs were diluted at 5% v/v in olive oil to cover the fish with the solutions for 24 h. The larvae that abandoned the muscle and the larvae obtained from the artificial digestion of the fish were collected. Controls were carried out in parallel. Furthermore, Wistar rats were infected with the live larvae collected from the in vitro trials in order to find any larvae that may have penetrated the gastrointestinal wall. RESULTS: Between 60.8% and 87.6% of parasites treated with EOs abandoned the fish muscle, and the highest in vitro mortality rate was achieved with oregano EO (53.9%). Rats previously treated with oregano, cumin and Spanish lavender EOs showed no detectable lesions in the digestive tract due to the infection with larvae. CONCLUSIONS: Oregano (Origanum vulgare L. Lamiaceae), cumin (Cuminum cyminum L. Apiaceae) and Spanish lavender (Lavender stoechas L. Lamiaceae) EOs could be used as promising ingredients in the development of products for the control of anisakiasis</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1744-5116 (Electronic)IS - 1388-0209 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/13880209.2016.1247880</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27937075">PM:27937075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharm Biol\2017-55-456-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharm Biol\2017-55-456-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Gomez-Mateos PM</style></custom2><misc3><style face="normal" font="Arial">10.1080/13880209.2016.1247880</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barrionuevo Sanchez,M.I.</style></author><author><style face="normal" font="Arial"> Corbi Pascual,M.J.</style></author><author><style face="normal" font="Arial"> Cordoba Soriano,J.G.</style></author><author><style face="normal" font="Arial"> Ramirez Guijarro,C.</style></author><author><style face="normal" font="Arial"> Calero Nunez,S.</style></author><author><style face="normal" font="Arial"> Gallego Sanchez,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Kounis syndrome or allergic infarction: a relatively unknown entity</style></title><secondary-title><style face="normal" font="Arial">Med Intensiva</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Intensiva</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0210-5691</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.medin.2017.06.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.medin.2017.06.003</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170804, Barrionuevo Sanchez MI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.medin.2017.06.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Duan,L.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Watsky,K.</style></author><author><style face="normal" font="Arial"> Narayan,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Yale University School of Medicine and Departments of Plastic Surgery and Dermatology, Yale University, New Haven, Conn</style></auth-address><titles><title><style face="normal" font="Arial">Systemic Allergic Reaction to Red Tattoo Ink Requiring Excision</style></title><secondary-title><style face="normal" font="Arial">Plast Reconstr Surg Glob Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Plast Reconstr Surg Glob Open</style></abbr-1></periodical><pages end="" start="e1111">e1111-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Ink</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 2169-7574 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/GOX.0000000000001111</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27975018">PM:27975018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plast Reconstr Surg Glob Open\2016-4-e1111.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plast Reconstr Surg Glob Open\2016-4-e1111.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Duan L</style></custom2><misc3><style face="normal" font="Arial">10.1097/GOX.0000000000001111</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Acevedo,N.</style></author><author><style face="normal" font="Arial"> Bornacelly,A.</style></author><author><style face="normal" font="Arial"> Mercado,D.</style></author><author><style face="normal" font="Arial"> Unneberg,P.</style></author><author><style face="normal" font="Arial"> Mittermann,I.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Kennedy,M.</style></author><author><style face="normal" font="Arial"> Scheynius,A.</style></author><author><style face="normal" font="Arial"> Caraballo,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Immunological Research, University of Cartagena, Cartagena, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Genetic Variants in CHIA and CHI3L1 Are Associated with the IgE Response to the Ascaris Resistance Marker ABA-1 and the Birch Pollen Allergen Bet v 1</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0167453">e0167453-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ascaris</style></keyword><keyword><style face="normal" font="Arial"> Ascaris lumbricoides</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> CHIA</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chitinase</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic association</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infections</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Helminth infections and allergic diseases are associated with IgE hyperresponsiveness but the genetics of this phenotype remain to be defined. Susceptibility to Ascaris lumbricoides infection and antibody levels to this helminth are associated with polymorphisms in locus 13q33-34. We aimed to explore this and other genomic regions to identify genetic variants associated with the IgE responsiveness in humans. Forty-eight subjects from Cartagena, Colombia, with extreme values of specific IgE to Ascaris and ABA-1, a resistance marker of this nematode, were selected for targeted resequencing. Burden analyses were done comparing extreme groups for IgE values. One-hundred one SNPs were genotyped in 1258 individuals of two well-characterized populations from Colombia and Sweden. Two low-frequency coding variants in the gene encoding the Acidic Mammalian Chitinase (CHIA rs79500525, rs139812869, tagged by rs10494133) were found enriched in high IgE responders to ABA-1 and confirmed by genetic association analyses. The SNP rs4950928 in the Chitinase 3 Like 1 gene (CHI3L1) was associated with high IgE to ABA-1 in Colombians and with high IgE to Bet v 1 in the Swedish population. CHIA rs10494133 and ABDH13 rs3783118 were associated with IgE responses to Ascaris. SNPs in the Tumor Necrosis Factor Superfamily Member 13b gene (TNFSF13B) encoding the cytokine B cell activating Factor were associated with high levels of total IgE in both populations. This is the first report on the association between low-frequency and common variants in the chitinases-related genes CHIA and CHI3L1 with the intensity of specific IgE to ABA-1 in a population naturally exposed to Ascaris and with Bet v 1 in a Swedish population. Our results add new information about the genetic influences of human IgE responsiveness; since the genes encode for enzymes involved in the immune response to parasitic infections, they could be helpful for understanding helminth immunity and allergic responses. We also confirmed that TNFSF13B has an important and conserved role in the regulation of total IgE levels, which supports potential evolutionary links between helminth immunity and allergic response</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - Sweden -CO - Austria -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0167453</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27977724">PM:27977724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0167453.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0167453.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0167453.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0167453.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20161215, Acevedo N</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0167453</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,L.M.</style></author><author><style face="normal" font="Arial"> Ji,M.</style></author><author><style face="normal" font="Arial"> Sinha,M.</style></author><author><style face="normal" font="Arial"> Dong,M.B.</style></author><author><style face="normal" font="Arial"> Ren,X.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Lowell,C.A.</style></author><author><style face="normal" font="Arial"> Ghosh,S.</style></author><author><style face="normal" font="Arial"> Locksley,R.M.</style></author><author><style face="normal" font="Arial"> DeFranco,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Determinants of Divergent Adaptive Immune Responses after Airway Sensitization with Ligands of Toll-Like Receptor 5 or Toll-Like Receptor 9</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0167693">e0167693-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> IL-1</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> p40</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-Like Receptor 9</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Excessive type 2 helper T cell responses to environmental antigens can cause immunopathology such as asthma and allergy, but how such immune responses are induced remains unclear. We studied this process in the airways by immunizing mice intranasally with the antigen ovalbumin together with either of two Toll-like receptor (TLR) ligands. We found the TLR5 ligand flagellin promoted a type 2 helper T cell response, whereas, a TLR9 ligand CpG oligodeoxyribonucleotide (ODN) promoted a type 1 helper T cell response. CpG ODN induced mRNA encoding interleukin (IL)-12 p40, whereas, flagellin caused IL-33 secretion and induced mRNAs encoding IL-1 and thymic stromal lymphopoietin (TSLP). By using mice deficient in the TLR and IL-1R signaling molecule, myeloid differentiation primary response 88 (MyD88), in conventional dendritic cells (cDCs) and alveolar macrophages (AMs), and by cell sorting different lung populations after 2 hours of in vivo stimulation, we characterized the cell types that rapidly produced inflammatory cytokines in response to TLR stimulation. CpG ODN was likely recognized by TLR9 on cDCs and AMs, which made mRNA encoding IL-12. IL-12 was necessary for the subsequent innate and adaptive interferon-gamma production. In contrast, flagellin stimulated multiple cells of hematopoietic and non-hematopoietic origin, including AMs, DCs, monocytes, and lung epithelial cells. AMs were largely responsible for IL-1alpha, whereas lung epithelial cells made TSLP. Multiple hematopoietic cells, including AMs, DCs, and monocytes contributed to other cytokines, including IL-1beta and TNFalpha. MyD88-dependent signals, likely through IL-1R and IL-33R, and MyD88-independent signals, likely from TSLP, were necessary in cDCs for promotion of the early IL-4 response by CD4 T cells in the draining lymph node. Thus, the cell types that responded to TLR ligands were a critical determinant of the innate cytokines produced and the character of the resulting adaptive immune response in the airways</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0167693</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27977701">PM:27977701</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0167693.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0167693.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Lee LM</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0167693</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yasuda,T.</style></author><author><style face="normal" font="Arial"> Ura,T.</style></author><author><style face="normal" font="Arial"> Taniguchi,M.</style></author><author><style face="normal" font="Arial"> Yoshida,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory for Immunogenetics, RIKEN Research Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, JapanHospital Company R&amp;D Department, Terumo Corporation, Kanagawa, JapanLaboratory for Immune Regulation, RIKEN Research Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, JapanLaboratory for Immunogenetics, RIKEN Research Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Intradermal Delivery of Antigens Enhances Specific IgG and Diminishes IgE Production: Potential Use for Vaccination and Allergy Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0167952">e0167952-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunogenetics</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Needles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Skin is protected by a tough but flexible multilayered barrier and is a front line for immune responses against invading particles. For many years now, skin has been a tissue where certain vaccines are injected for the prevention of infectious disease, however, the detailed mechanisms of the skin immune response are not yet well understood. Using thin and small injection needles, we carefully injected OVA into a restricted region of mouse skin, i.e., intradermal (ID), and examined the antibody response in comparison with subcutaneous (SC) injection or epicutaneous patch administration of OVA. Epicutaneous patches induced a high IgE response against OVA, but IgG production was low. High IgG production was induced by both ID and SC injection, moreover, ID injection induced higher IgG production without any adjutants. Furthermore, OVA-specific IgE production was diminished by ID injection. We found that ID injection could efficiently stimulate skin resident DCs, drive Th1-biased conditions and diminish IgE production. The ID injection response was regulated by Langerin+ dermal DCs, because OVA was taken up mainly by these cells and, after transiently deleting them, the IgE response was no longer diminished and IgG1 production was enhanced. We also tested whether ID injection might be an effective allergy treatment by attempting to inhibit ongoing IgE production in mice with experimentally induced high serum IgE levels. Multiple ID injections of OVA were shown to prevent elevation of serum OVA-specific IgE after repeated allergen challenge. In contrast, SC OVA injection could only transiently inhibit the OVA-specific IgE production. These findings indicated that ID injection results in higher induction of antigen-specific IgG, and thus may be useful for vaccine delivery with little or no adjuvant components. Moreover, the observed diminishment of IgE and induction of Th1-biased immune responses suggest that ID may be a useful injection route for allergy immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0167952</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27973543">PM:27973543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0167952.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0167952.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Yasuda T</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0167952</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nyborg,A.C.</style></author><author><style face="normal" font="Arial"> Ward,C.</style></author><author><style face="normal" font="Arial"> Zacco,A.</style></author><author><style face="normal" font="Arial"> Chacko,B.</style></author><author><style face="normal" font="Arial"> Grinberg,L.</style></author><author><style face="normal" font="Arial"> Geoghegan,J.C.</style></author><author><style face="normal" font="Arial"> Bean,R.</style></author><author><style face="normal" font="Arial"> Wendeler,M.</style></author><author><style face="normal" font="Arial"> Bartnik,F.</style></author><author><style face="normal" font="Arial"> O'Connor,E.</style></author><author><style face="normal" font="Arial"> Gruia,F.</style></author><author><style face="normal" font="Arial"> Iyer,V.</style></author><author><style face="normal" font="Arial"> Feng,H.</style></author><author><style face="normal" font="Arial"> Roy,V.</style></author><author><style face="normal" font="Arial"> Berge,M.</style></author><author><style face="normal" font="Arial"> Miner,J.N.</style></author><author><style face="normal" font="Arial"> Wilson,D.M.</style></author><author><style face="normal" font="Arial"> Zhou,D.</style></author><author><style face="normal" font="Arial"> Nicholson,S.</style></author><author><style face="normal" font="Arial"> Wilker,C.</style></author><author><style face="normal" font="Arial"> Wu,C.Y.</style></author><author><style face="normal" font="Arial"> Wilson,S.</style></author><author><style face="normal" font="Arial"> Jermutus,L.</style></author><author><style face="normal" font="Arial"> Wu,H.</style></author><author><style face="normal" font="Arial"> Owen,D.A.</style></author><author><style face="normal" font="Arial"> Osbourn,J.</style></author><author><style face="normal" font="Arial"> Coats,S.</style></author><author><style face="normal" font="Arial"> Baca,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MedImmune LLC, Gaithersburg, Maryland, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0167935">e0167935-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Crystallization</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Gout</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> Haplotypes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Primates</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Engineering</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Uric Acid</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Humans and higher primates are unique in that they lack uricase, the enzyme capable of oxidizing uric acid. As a consequence of this enzyme deficiency, humans have high serum uric acid levels. In some people, uric acid levels rise above the solubility limit resulting in crystallization in joints, acute inflammation in response to those crystals causes severe pain; a condition known as gout. Treatment for severe gout includes injection of non-human uricase to reduce serum uric acid levels. Krystexxa(R) is a hyper-PEGylated pig-baboon chimeric uricase indicated for chronic refractory gout that induces an immunogenic response in 91% of treated patients, including infusion reactions (26%) and anaphylaxis (6.5%). These properties limit its use and effectiveness. An innovative approach has been used to develop a therapeutic uricase with improved properties such as: soluble expression, neutral pH solubility, high E. coli expression level, thermal stability, and excellent activity. More than 200 diverse uricase sequences were aligned to guide protein engineering and reduce putative sequence liabilities. A single uricase lead candidate was identified, which showed low potential for immunogenicity in >200 human donor samples selected to represent diverse HLA haplotypes. Cysteines were engineered into the lead sequence for site specific PEGylation and studies demonstrated >95% PEGylation efficiency. PEGylated uricase retains enzymatic activity in vitro at neutral pH, in human serum and in vivo (rats and canines) and has an extended half-life. In canines, an 85% reduction in serum uric acid levels was observed with a single subcutaneous injection. This PEGylated, non-immunogenic uricase has the potential to provide meaningful benefits to patients with gout</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0167935</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28002433">PM:28002433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0167935.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0167935.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0167935S1_Data.pzfC:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0167935S2_Data.pzfC:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0167935S3_Data.pzf</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0167935S1_Data.pzfF:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0167935S2_Data.pzfF:\A&amp;H HMW Papers\PLoS ONE\2016-11-e0167935S3_Data.pzf</url></image-urls></urls><custom2><style face="normal" font="Arial">20161221, Nyborg AC</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0167935</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Imperato,A.</style></author><author><style face="normal" font="Arial"> Consales,A.</style></author><author><style face="normal" font="Arial"> Ravegnani,M.</style></author><author><style face="normal" font="Arial"> Castagnola,E.</style></author><author><style face="normal" font="Arial"> Bandettini,R.</style></author><author><style face="normal" font="Arial"> Rossi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurosciences and Reproductive and Odontostomatological Sciences, Division of Neurosurgery, Universita Degli Studi Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Primary Hydatid Cyst of the Brain in a Child: A Case Report</style></title><secondary-title><style face="normal" font="Arial">Pol J Radiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Radiol</style></full-title></periodical><pages end="582" start="578">578-582</pages><volume><style face="normal" font="Arial">81</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Albendazole</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> CT scan</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hydrocephalus</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> MRI</style></keyword><keyword><style face="normal" font="Arial"> Neurosciences</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Primary intracranial hydatid cyst is a rare location of human echinococcosis whose spontaneous, traumatic or even iatrogenic rupture, as in case of misdiagnosis, may cause anaphylactic reactions and dissemination. CASE REPORT: We discuss the management of a 9-year-old boy who was admitted to our Emergency Department with an intracranial hypertension syndrome. Head CT scan and brain MRI showed a huge intra-axial right temporo-parieto-occipital cyst with a marginal calcification, associated with left ventricular uncompensated hydrocephalus. DTI showed displacement of the ipsilateral corticospinal tract, whereas MR spectroscopy showed absence of normal brain metabolites and presence of succinate and lactate within the cyst. A diagnosis of hydatid cyst was then presumed on the basis of the neuroradiological findings. Empiric chemotherapy with albendazole was instituted and surgical en bloc removal of the cyst was obtained, allowing the patient to recover without complications. Diagnosis of brain echinococcosis was confirmed by laboratory tests. CONCLUSIONS: HE is still an endemic manifestation in some rural areas of the world, and it should be included in the differential diagnosis of children living in or coming from an endemic country who present with an intracerebral cyst. Early diagnosis and complete surgical removal of the intact cyst are the main factors that determine a favourable outcome</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1733-134X (Print)IS - 1733-134X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.12659/PJR.898619</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27994696">PM:27994696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Radiol\2016-81-578-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Radiol\2016-81-578-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Imperato A</style></custom2><misc3><style face="normal" font="Arial">10.12659/PJR.898619</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,Z.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Zhan,S.</style></author><author><style face="normal" font="Arial"> Lian,J.</style></author><author><style face="normal" font="Arial"> Zhao,R.</style></author><author><style face="normal" font="Arial"> Li,K.</style></author><author><style face="normal" font="Arial"> Tong,P.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Yang,A.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China</style></auth-address><titles><title><style face="normal" font="Arial">Development of immunoaffinity chromatographic method for Ara h 2 isolation</style></title><secondary-title><style face="normal" font="Arial">Protein Expr Purif</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Protein Expr Purif</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dimer</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Selectivity</style></keyword><keyword><style face="normal" font="Arial"> Sepharose</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="Arial">Ara h 2 is considered a major allergen in peanut. Due to the difficulty of separation, Ara h 2 had not been fully studied. Immunoaffinity chromatography (IAC) column can separate target protein with high selectivity, which made it possible to purify Ara h 2 from different samples. In this study, IAC method was developed to purify Ara h 2 and its effect was evaluated. By coupling polyclonal antibody (pAb) on CNBr-activated Sepharose 4B, the column for specific extraction was constructed. The coupling efficiency of the IAC column was higher than 90%, which made the capacity of column reached 0.56 mg per 0.15 g medium (dry weight). The recovery of Ara h 2 ranged from 93% to 100% for different concentrations of pure Ara h 2 solutions in 15 min. After using a column 10 times, about 88% of the column capacity remained. When applied to extract Ara h 2 from raw peanut protein extract and boiled peanut protein extract, the IAC column could recovery 94% and 88% target protein from the mixture. SDS-PAGE and Western blotting analysis confirmed the purified protein was Ara h 2, its purity reached about 90%. Significantly, the IAC column could capture dimer of Ara h 2, which made it feasible to prepared derivative of protein after processing</style></abstract><notes><style face="normal" font="Arial">DA - 20161219IS - 1096-0279 (Electronic)IS - 1046-5928 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pep.2016.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27989798">PM:27989798</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Protein Expr Purif\20161219-WuZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Protein Expr Purif\20161219-WuZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161219, Wu Z</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pep.2016.12.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kesari,P.</style></author><author><style face="normal" font="Arial"> Chaudhary,N.</style></author><author><style face="normal" font="Arial"> Sharma,A.</style></author><author><style face="normal" font="Arial"> Katiki,M.</style></author><author><style face="normal" font="Arial"> Kumar,P.</style></author><author><style face="normal" font="Arial"> Gurjar,B.R.</style></author><author><style face="normal" font="Arial"> Tomar,S.</style></author><author><style face="normal" font="Arial"> Sharma,A.K.</style></author><author><style face="normal" font="Arial"> Kumar,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand-247667, India</style></auth-address><titles><title><style face="normal" font="Arial">Structural, Functional and Evolutionary Aspects of Seed Globulins</style></title><secondary-title><style face="normal" font="Arial">Protein Pept Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Protein Pept Lett</style></full-title></periodical><pages end="277" start="267">267-277</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">11S</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cupin</style></keyword><keyword><style face="normal" font="Arial"> Cupin superfamily</style></keyword><keyword><style face="normal" font="Arial"> Desiccation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> globulins</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Legumin</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Nutritional quality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Sucrose</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Vicilin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Globulins are a major class of seed storage proteins which were thought to be enzymatically inactive. These proteins belong to the most ancient cupin superfamily. They can be graded into 11S legumin types and 7S vicilin types based on their sedimentation coefficients. Members from both classes share structural homology are thought to have evolved from either one-domain germin predecessor by duplication or by horizontal gene transfer of two-domain gene from bacteria to eukaryotes. Globulins are known to define the nutritional quality of the seeds, however, they are also involved in sucrose binding, desiccation, defense against microbes, hormone binding and oxidative stress etc. Major drawback with globulin is their tendency to bind to IgE. Studying structural-functional behavior of such protein can help in modifying proteins for enhanced functionality in food processing industries</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1875-5305 (Electronic)IS - 0929-8665 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000570">PM:28000570</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161221, Kesari P</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amat,F.</style></author><author><style face="normal" font="Arial"> Bourgoin-Heck,M.</style></author><author><style face="normal" font="Arial"> Lambert,N.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Biomarkers associated with allergic asthma control in children</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="102" start="97">97-102</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergique</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biomarqueurs</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Uncontrol</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Frequent clinical evalutation is needed in allergic asthma in order to propose personnalized medicine. Various biomarkers linked to uncontrolled asthma and to inflammatory activity have been studied. Among them, pulmonary eosinophilia evaluated by FeNO and blood eosinophilia measured directly or via serum level of ECP, mostly if pooled together, seemed to reflect systemic inflammation sensitive to global anti-inflammatory action of omalizumab.</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.10.014</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.10.014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20161224-AmatF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20161224-AmatF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161224, Amat F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.10.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tataranu,E.</style></author><author><style face="normal" font="Arial"> Diaconescu,S.</style></author><author><style face="normal" font="Arial"> Ivanescu,C.G.</style></author><author><style face="normal" font="Arial"> Sarbu,I.</style></author><author><style face="normal" font="Arial"> Stamatin,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Mother and Child, "Grigore T. Popa" University of Medicine and Pharmacy, Iassy, Romania</style></auth-address><titles><title><style face="normal" font="Arial">Clinical, immunological and pathological profile of infants suffering from cow's milk protein allergy</style></title><secondary-title><style face="normal" font="Arial">Rom J Morphol Embryol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Rom J Morphol Embryol</style></abbr-1></periodical><pages end="1035" start="1031">1031-1035</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Alimentation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> familial</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> premature</style></keyword><keyword><style face="normal" font="Arial"> Premature Birth</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Cow's milk protein allergy (CMPA) is the most frequently encountered form of food allergy in pediatric patients and occurs secondary to cow's milk proteins (CMP) ingestion. The aim of this study is to define the profile of children suffering from CMPA and to describe the associated pathological findings. The authors performed a retrospective case-control study on 160 infants that presented with CMPA symptoms at "Sf. Maria" Emergency Clinical Hospital for Children, Iassy, Romania, between January 2013 and January 2015. Fifty-five infants were diagnosed with CMPA (Group 1 - cases group) and 105 had no proven allergy (Group 2 - control group). Mean age of patients, gender distribution and prevalence of premature birth registered no statistically significant difference between the two groups. The prevalence of familial history of allergy was higher in case of patients with CMPA (36.36% versus 20% in control group). The delay between the introduction of CMP into alimentation and symptoms' onset was significantly shorter in Group 1 (12 days) compared to Group 2 (42 days) (p=0.0051), thus pleading for an earlier onset of symptoms in case of CMPA. CMPA usually manifested through an association of gastrointestinal (76.36%), cutaneous and mucosal symptoms (70.91%). Specific IgE were positive values in 49 patients with CMPA (89.09%) and 32 patients (30.48%) without CMPA (p&lt;0.001). Endoscopic examinations with tissue sampling were performed in 26 infants with CMPA. Focal erythema, erosions and lymphoid nodular hyperplasia were signaled in 23 cases and eosinophilic infiltration was noticed in 15 cases. In conclusion, specific IgE and pathological changes offer highly reliable methods for CMPA diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1220-0522 (Print)IS - 1220-0522 (Linking)LA - engPT - Journal ArticleCO - Romania -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28002520">PM:28002520</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rom J Morphol Embryol\2016-57-1031-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rom J Morphol Embryol\2016-57-1031-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Tataranu E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,W.J.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Wang,W.D.</style></author><author><style face="normal" font="Arial"> Zhu,M.Y.</style></author><author><style face="normal" font="Arial"> Liu,C.C.</style></author><author><style face="normal" font="Arial"> Wang,J.H.</style></author><author><style face="normal" font="Arial"> Lu,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="39463">39463-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene</style></keyword><keyword><style face="normal" font="Arial"> prognostic factors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="Arial">Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and the long-term survival varies with different ages. We performed a retrospective analysis of 122 newly diagnosed adults with standard-risk ALL treated with Escherichia coli asparaginase (E. coli-asparaginase, n = 50) and polyethylene glycol-conjugated asparaginase (PEG-asparaginase, n = 72). No treatment-related mortality (TRM) occurred in the E. coli-asparaginase group, and 3 TRM events occurred in the PEG-asparaginase group without relation to asparaginase. In addition, 22 (44.0%) and 48 (66.7%) patients achieved a complete response (CR) on day 14 in the E. coli-asparaginase and PEG-asparaginase groups, respectively (P = 0.032). No different 5-year event-free survival (EFS) or overall survival (OS) rate (P = 0.632 and 0.769) was observed. Multivariate analysis revealed later CR (P = 0.008) and older age (P = 0.049) as adverse prognostic factors for both EFS and OS. In addition, we specifically monitored the known adverse effects of asparaginase, and no asparaginase-related death was observed. Allergy occurred in 9 patients using E. coli-asparaginase, and no patient in the PEG-asparaginase group suffered from allergies (P &lt; 0.001). The incidence of other asparaginase-related toxicities was similar. We conclude that PEG-asparaginase can be safely and effectively used as asparaginase in adults with newly diagnosed standard-risk ALL</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep39463</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000713">PM:28000713</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-39463.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-39463.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Liu WJ</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep39463</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dong,H.</style></author><author><style face="normal" font="Arial"> Hu,Y.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Zou,M.</style></author><author><style face="normal" font="Arial"> Huang,C.</style></author><author><style face="normal" font="Arial"> Luo,L.</style></author><author><style face="normal" font="Arial"> Yu,C.</style></author><author><style face="normal" font="Arial"> Wan,X.</style></author><author><style face="normal" font="Arial"> Zhao,H.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Xie,Z.</style></author><author><style face="normal" font="Arial"> Le,Y.</style></author><author><style face="normal" font="Arial"> Zou,F.</style></author><author><style face="normal" font="Arial"> Cai,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China</style></auth-address><titles><title><style face="normal" font="Arial">Distinct roles of short and long thymic stromal lymphopoietin isoforms in house dust mite-induced asthmatic airway epithelial barrier disruption</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="39559">39559-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma progression</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> beta Catenin</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> E-cadherin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> impaired barrier function</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lung function tests</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="12" Year="2016">2016/12/20</year></dates><abstract><style face="normal" font="Arial">Loss of airway epithelial integrity contributes significantly to asthma pathogenesis. Thymic stromal lymphopoietin (TSLP) may have dual immunoregulatory roles. In inflammatory disorders of the bowel, the long isoform of TSLP (lfTSLP) promotes inflammation while the short isoform (sfTSLP) inhibits inflammation. We hypothesize that lfTSLP contributes to house dust mite (HDM)-induced airway epithelial barrier dysfunction and that synthetic sfTSLP can prevent these effects. In vitro, airway epithelial barrier function was assessed by monitoring transepithelial electrical resistance, fluorescent-dextran permeability, and distribution of E-cadherin and beta-catenin. In vivo, BALB/c mice were exposed to HDM by nasal inhalation for 5 consecutive days per week to establish an asthma model. sfTSLP and 1alpha,25-Dihydroxyvitamin D3 (1,25D3) were administered 1 h before HDM exposure. After 8 weeks, animal lung function tests and pathological staining were performed to evaluate asthma progression. We found that HDM and lfTSLP impaired barrier function. Treatment with sfTSLP and 1,25D3 prevented HDM-induced airway epithelial barrier disruption. Moreover, sfTSLP and 1,25D3 treatment ameliorated HDM-induced asthma in mice. Our data emphasize the importance of the different expression patterns and biological properties of sfTSLP and lfTSLP. Moreover, our results indicate that sfTSLP and 1,25D3 may serve as novel therapeutic agents for individualized treatment of asthma</style></abstract><notes><style face="normal" font="Arial">-DA - 20161220IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China</style></notes><work-type><style face="normal" font="Arial">10.1038/srep39559</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996052">PM:27996052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2016-6-39559.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2016-6-39559.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Dong H</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep39559</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gelardi,M.</style></author><author><style face="normal" font="Arial"> Guglielmi,A.V.</style></author><author><style face="normal" font="Arial"> Iannuzzi,L.</style></author><author><style face="normal" font="Arial"> Quaranta,V.N.</style></author><author><style face="normal" font="Arial"> Quaranta,N.</style></author><author><style face="normal" font="Arial"> Landi,M.</style></author><author><style face="normal" font="Arial"> Correale,M.</style></author><author><style face="normal" font="Arial"> Sonnante,A.</style></author><author><style face="normal" font="Arial"> Rossini,M.</style></author><author><style face="normal" font="Arial"> Mariggio,M.A.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari, Bari, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Local allergic rhinitis: entopy or spontaneous response?</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal cytology</style></keyword><keyword><style face="normal" font="Arial"> nasal endoscopy</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assay</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The existence of a local allergic rhintis was proposed on the basis of the detection of nasal IgE in the absence of a systemic sensitization. Nevertheless, the significance of this phenomenon remains still unclear. We assessed the presence of mucosal nasal IgE in patients with ascertained allergic rhinitis, nonallergic rhinitis with inflammation and in healthy controls. METHODS: Consecutive patients with a well ascertained diagnosis (clinical history, skin prick test, specific IgE assay, nasal endoscopy, nasal cytology) underwent an immunoenzymatic measurement of specific IgE to grass, cypress, parietaria and olive in nasal scrapings. RESULTS: Fifteen patients with allergic rhinitis, 12 with non allergic rhinitis and 14 healthy subjects were studied. The patients with allergic and nonallergic rhinitis had higher nasal symptoms as compared to control subjects. Systemic sensitizatition (assessed by skin test and CAP-RAST) was obviously more frequent in allergic rhinitis, than in the other two groups. Allergen-specific nasal IgE could be detected in all groups (86,7, 33,3, and 50 % positive, respectively), even more frequently in the control group than in nonallergic rhinitis patients. No difference among allergens was identified. Out of the 26 non-allergic patients (non allergic rhinitis + controls) nasal IgE were positive in 11(42 %). DISCUSSION: According to the results, the presence of nasal IgE against allergens seems to be a non-specific phenomenon, since they can be detected also in non allergic rhinitis and in healthy subjects. CONCLUSION: It can be hypothesized that the nasal IgE production represents a form of spontaneous immune response</style></abstract><notes><style face="normal" font="Arial">DA - 20161216IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0126-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27980704">PM:27980704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161216, Gelardi M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0126-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wilches,P.</style></author><author><style face="normal" font="Arial"> Wilches,P.</style></author><author><style face="normal" font="Arial"> Calderon,J.C.</style></author><author><style face="normal" font="Arial"> Cherrez,A.</style></author><author><style face="normal" font="Arial"> Cherrez,O.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital Monte Sinai, Cuenca, Ecuador ; Universidad Estatal de Cuenca, School of Medicine, Cuenca, Ecuador</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab for chronic urticaria in Latin America</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="36">36-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Developing Countries</style></keyword><keyword><style face="normal" font="Arial"> developing country</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Latin America</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic urticaria (CU) is defined as the spontaneous appearance of wheals, with or without angioedema, persisting for >/=6 weeks. Chronic Spontaneous Urticaria (CSU) is a type of CU which affects 0.5-1 % of the global population, but it represents a high burden to patients. In recent years, omalizumab is available as treatment of disease. Our aim is to extend previous findings, analyzing effects of omalizumab on symptoms in Latin American patients with CSU. METHODS: Retrospective analysis of patients treated with omalizumab in Cuenca-Ecuador. 150 mg omalizumab was administered every 4 weeks, and its effects were measured by Urticaria Activity Score (UAS) at baseline and each month in follow up. Complete response was defined as a UAS of 0 or 1, and partial response was classified as a UAS of 2 or more. Also, demographic and clinical variables were collected. Descriptive analyses were employed. Response rates were summarized as counts and percentages after 3 and 5 months. Related Samples Wilcoxon signed rank tests were used to compare UAS at baseline and after 3 months. P values &lt;0.05 indicated statistical significance. RESULTS: 26 subjects were enrolled, almost half were female individuals (57.7 %), with mean age 47.8 years (range, 18-81 years). Mean duration of CU after diagnosis was 23.3 months (range, 2-180 months). Mean UAS at baseline was 5.7 points (range, 4-6 points). Nine patients (34.6 %) completed 3 months of treatment (33 % reported a complete response), with a mean difference in UAS of 3.33 (p = 0.01). Four patients completed 5 months of treatment (75.0 % showed a complete response). All patients previously treated with first-generation antihistamines plus corticosteroids showed no responses at neither 3 nor 5 months of treatment. CONCLUSION: Omalizumab is an effective treatment for patients with CU. It is necessary to conduct some future investigations where we can establish if 150 mg could be an option in developing countries</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Ecuador -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0127-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27942350">PM:27942350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Wilches P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0127-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Y.Z.</style></author><author><style face="normal" font="Arial"> Cai,M.Y.</style></author><author><style face="normal" font="Arial"> Zhang,B.Z.</style></author><author><style face="normal" font="Arial"> Zhou,B.X.</style></author><author><style face="normal" font="Arial"> Chen,R.</style></author><author><style face="normal" font="Arial"> Fang,R.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Zhangzhou Hospital, Fujian Medical University, Zhangzhou, Fujian 363000, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Risk factors for recurrent wheezing in infants and young children suffering from dust mite allergy after their first wheezing]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="1263" start="1259">1259-1263</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza virus</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mycoplasma</style></keyword><keyword><style face="normal" font="Arial"> Mycoplasma pneumoniae</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Recurrent wheezing</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the risk factors for recurrent wheezing in infants and young children suffering from dust mite allergy after their first wheezing. METHODS: A total of 1 236 infants and young children who experienced a first wheezing episode and were hospitalized between August 2014 and February 2015 were enrolled, among whom 387 were allergic to dust mites. These infants and young children were followed up to 1 year after discharge. A total of 67 infants and young children who experienced 3 or more recurrent wheezing episodes within 1 year were enrolled as the recurrent wheezing group, while 84 infants and young children who did not experience recurrent wheezing during follow-up were enrolled as the control group. Univariate analysis and multivariate logistic stepwise regression analysis were performed to investigate the risk factors for recurrent wheezing in these patients. RESULTS: The univariate analysis showed that the age on admission, wheezing time before admission, Mycoplasma pneumoniae infection rate, and influenza virus infection rate were associated with recurrent wheezing. The multivariate logistic stepwise regression analysis showed that the older age on admission (OR=2.21, P=0.04) and Mycoplasma pneumoniae infection (OR=3.54, P=0.001) were independent risk factors for recurrent wheezing. CONCLUSIONS: Infants and young children who are allergic to dust mites, especially young children, have a significantly increased risk of recurrent wheezing if they are complicated by Mycoplasma pneumoniae infection during the first wheezing episode</style></abstract><notes><style face="normal" font="Arial">DA - 20161215IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2016.12.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27974118">PM:27974118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2016-18-1259-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2016-18-1259-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161215, Yang YZ</style></custom2><misc3><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2016.12.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Broeks,S.A.</style></author><author><style face="normal" font="Arial"> Brand,P.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, ZGT hospital, Almelo, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis is associated with a five-fold increased risk of polysensitisation in children</style></title><secondary-title><style face="normal" font="Arial">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Paediatr</style></abbr-1></periodical><pages end="488" start="485">485-488</pages><volume><style face="normal" font="Arial">106</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Polysensitisation</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">AIM: It has been hypothesised that in atopic dermatitis the dysfunctional skin barrier facilitates the transcutaneous presentation of allergens to the immune system. This study examined whether atopic dermatitis increased the likelihood of polysensitisation, namely to five or more allergens. METHODS: We examined the electronic hospital charts of 1,743 children aged 0-17 years who had visited primary or secondary care physicians with allergic symptoms, whose blood was examined for the presence of specific immunoglobulin E (IgE) to the 10 most common inhaled and food allergens and whose files contained documentation of the presence of atopic dermatitis and other skin disorders. Sensitisation was defined as a specific IgE level of >/=0.35 kU/L. RESULTS: Polysensitisation was more common in children with atopic dermatitis (268/1197, 22.4%) than those without (30/546, 5.5%, p&lt;0.001). This remained significant after adjustment for gender and age in a multiple logistic regression model (odds ratio 5.63, 95% confidence interval 3.77-8.40). Other skin disorders did not show an increased risk of polysensitisation (5/97, 5.2%). CONCLUSION: Polysensitisation was considerably more common in children with atopic dermatitis than those without. This supports the hypothesis that sensitisation occurs through a defective skin barrier and appears to be specific for atopic dermatitis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161227IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/apa.13729</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28027409">PM:28027409</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Paediatr\20161227-BroeksSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Paediatr\20161227-BroeksSA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161227, Broeks SA</style></custom2><misc3><style face="normal" font="Arial">10.1111/apa.13729</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zamora,V.</style></author><author><style face="normal" font="Arial"> Garcia-Ballesteros,C.</style></author><author><style face="normal" font="Arial"> Benet-Campos,C.</style></author><author><style face="normal" font="Arial"> Ballester,F.</style></author><author><style face="normal" font="Arial"> Cuellar,C.</style></author><author><style face="normal" font="Arial"> Andreu-Ballester,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anti-Anisakis sp. antibodies in serum of healthy subjects. Relationship with alphabeta and gammadelta T cells</style></title><secondary-title><style face="normal" font="Arial">Acta Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Parasitol</style></full-title></periodical><pages end="103" start="97">97-103</pages><volume><style face="normal" font="Arial">62</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="01/21/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD8</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune suppression</style></keyword><keyword><style face="normal" font="Arial"> inverse correlation</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">Anisakiosis is nowadays one of the nematodoses more prevalent in Spain, with rates that oscillate between 0.43% in Galicia (N.W. Spain), and 15.7% and 22.1% in inland and southern regions, respectively. Likewise, it has been proved that Anisakis larvae have developed mechanisms to modulate the dichotomy of the host immune response for their own benefit. The experimental hypothesis of the present study was that Anisakis sp. larval products can be mediators of immune suppression and induce changes on the populations of alphabeta+ and gammadelta+ T cells. In the present study we determined the levels of anti-Anisakis antibodies in the serum of healthy people, and their relationship with the B and T cell subsets. Levels of anti-Anisakis antibodies (Ig's, IgG, IgM, IgA and IgE) were measured by ELISA, while B and T cell subsets were studied by flow cytometry. Cells were labelled with monoclonal antibodies against CD45, CD4, CD8, CD56, CD3, CD19, TCRalphabeta and TCRgammadelta. All the specific isotypes studied were negatively correlated with NKT cell rates with the exception of IgG. A previous contact with Anisakis was related to a decrease in CD56+alphabeta+ and all gammadelta+ T cell subsets. The CD3+gammadelta+ population was lower in the group of subjects that showed IgA anti-Anisakis. We observed an inverse correlation among alphabeta-gammadelta NKT cells and anti-Anisakis sp. antibodies. CD3+CD56+ cells showed a significant decrease in the group of anti-Anisakis positive subjects. This fact was especially significant with CD3+CD56+gammadelta+ cells in the case of the anti-Anisakis IgA positive group</style></abstract><notes><style face="normal" font="Arial">DA - 20161228IS - 1896-1851 (Electronic)IS - 1230-2821 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1515/ap-2017-0011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030343">PM:28030343</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Parasitol\2017-62-97-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Parasitol\2017-62-97-103.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161228, Zamora V</style></custom2><misc3><style face="normal" font="Arial">10.1515/ap-2017-0011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonczar,G.</style></author><author><style face="normal" font="Arial"> Walczycka,M.</style></author><author><style face="normal" font="Arial"> Duda,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Animal Products Technology Department, University of Agriculture in Krakow, Poland</style></auth-address><titles><title><style face="normal" font="Arial">The changes of proteins fractions shares in milk and fermented milk drinks</style></title><secondary-title><style face="normal" font="Arial">Acta Sci Pol Technol Aliment</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Sci Pol Technol Aliment</style></full-title></periodical><pages end="389" start="379">379-389</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregation</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Alpha-lactalbumin</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Caseins</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Drying</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kefir</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pasteurisation</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> yoghurt</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The aim of this research was to observe the changes which take place in the electrophoretic picture of milk proteins after pasteurisation and inoculation with different starter cultures (both traditional and probiotic). After incubation, the yoghurt, kefir, acidified milk, fermented Bifidobacterium bifidum drink and Lactobacillus acidophillus drink were chilled for 14 days to observe the changes which occurred. METHODS: The research materials were raw and pasteurised milk, as well as fermented milk- based drinks. The raw milk used for research came from Polish Holstein-Fresian black and white cows. The milk was sampled 3 times and divided into 5 parts, each of which was pasteurised at 95 degrees C for 10 min and then cooled for inoculation: yoghurt to 45 degrees C, kefir and acidified milk to 22 degrees C and drinks with Bifidobacterium bifidum and Lactobacillus acidophillus to 38 degrees C. Milk was inoculated with lyophilised, direct vat starter cultures, in an amount equal to 2% of the working starter. For the production of fermented drinks, the subsequent starters were applied: "YC-180" Christian Hansen for yoghurt, "D" Biolacta-Texel-Rhodia for kefir, CH-N--11 Christian Hansen for acidified milk, starter by Christian Hansen for the probiotic Bifidobacterium bifidum milk, starter by Biolacta-Texel-Rhodia for the probiotic Lactobacillus acidophillus milk. The analyses were conducted in raw, pasteurised and freshly fermented milk as well as in milk drinks stored for 14 days. The total solid content was estimated by the drying method; the fat content by the Gerber method; the lactose content by the Bertrand method; the protein content by the Kjeldahl method with Buchi apparatus; the density of milk was measured with lactodensimeter; acidity with a pH-meter; and potential acidity by Soxhlet-Henkl method (AOAC, 1990). The electrophoretic separation of proteins in raw and pasteurised milk, as well as in freshly produced milk drinks and those stored for 14 days, was performed with SDS-PAGE (on polyacrylamid gel) basing on procedure described by Laemmli (1970). RESULTS: It was shown that, in comparison with raw milk, the pasteurised milk had smaller amounts of alphas-, beta- and kappa-casein, whereas the shares of gamma-casein and peptides were greater, and there were no changes in immunoglobulin, alpha-lactalbumin or beta-lactoglobulin levels, which indicated that hydrolysis of caseins had occurred. In all freshly fermented milk drinks, a drop in alphas- and beta-casein was observed relative to raw milk. An increase in peptides and gamma-casein was also noticed (with the exception of acidified milk). There were differences in alpha-lactalbumin and beta-lactoglobulin levels between the different drinks: raw, pasteurised or freshly fermented milk. It was shown that kefir, compared to the other drinks, had the lowest levels of alphas- and beta-casein, alpha-lactalbumin and of peptides, as well as the highest level of gamma-casein, which is evidence of an increased rate of hydrolysis in that drink. It was stated that, during the storage of fermented milk drinks, the levels of lactoferrin, serum albumin and peptides significantly increased whereas the content of kappa-casein diminished. The proportions of serum albumin and lactoferrin in fermented milk drinks increased relative to raw milk and/or after storage, which is evidence of aggregation of proteins of low molecular mass into bigger conglomerates. CONCLUSIONS: The observed differences between fermented milks, including during chilled storage, in the amounts of individual proteins proves the different proteolytic abilities of starter cultures used in fermented milk production. alpha-lactoalbumin and beta-lactoglobulin are, besides caseins, the most allergenic milk proteins. So, kefir, because of its low alpha-lactoalbumin content, and Bifidobacterium bifidum milk, with the lowest content of beta-lactoglobulin, were the most advantageous and least allergenic drinks examined</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1898-9594 (Electronic)IS - 1644-0730 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.17306/J.AFS.2016.4.36</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28071015">PM:28071015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Sci Pol Technol Aliment\2016-15-379-89.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Sci Pol Technol Aliment\2016-15-379-89.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Bonczar G</style></custom2><misc3><style face="normal" font="Arial">10.17306/J.AFS.2016.4.36</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nasirian,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Entomology and Vector Control, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: hanasirian@yahoo.com</style></auth-address><titles><title><style face="normal" font="Arial">Infestation of cockroaches (Insecta: Blattaria) in the human dwelling environments: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Acta Trop</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Trop</style></full-title></periodical><pages end="98" start="86">86-98</pages><volume><style face="normal" font="Arial">167</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Blattella germanica</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Entomology</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sanitation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Periplaneta americana, Blatta orientalis, Blattella germanica and Supella longipalpa are the most common worldwide cockroaches that mentioned in the "22 common pest" or "22 dirty" species named as "group I". They are able to infest any type of buildings. A meta-analysis review was conducted between January 2015 and July 2016 on any literature published about infestation of cockroaches. Scientific reports and papers about infestation of cockroaches and relevant topics were collected from various specific scientific websites such as PubMed, Web of Science, ScienceDirect, Springer, Scopus, and Google Scholar. About 271 scientific reports and papers were collected and after a preliminary review, 63 were selected to become part of the detailed synthesis review and meta-analysis. Results showed that the global world mean infestation trend of cockroaches, and B. germanica and P. americana cockroach species ranged 49.0-55.0, 40.0-70.0 and 60.0-70.0%, respectively suggests that their infestation trend are increasing. The global world mean infestation of cockroaches, and B. germanica and P. americana cockroach species were 52.3, 55.2 and 65.4, respectively. There was a significant difference between the global world mean infestation of cockroaches and P. americana cockroach species (P=0.019). The global mean infestation trend of cockroaches in the human dwelling environments and world ranged 55.0-65.0 and 50.0-70.0%, respectively suggests that their infestation trend are increasing. The global world mean infestation of cockroaches in the human dwelling environments and world were 60.4 and 57.7%, respectively. Although some factors affect the infestation of cockroaches and the sanitation and quality structure of the buildings are also being improved. While as present study reveal that the globally the world infestation trend of cockroaches are being increased and recent studies also indicate that the prevalence of asthma has increased dramatically over the decades suggest that infestation of cockroaches can directly affect the development of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161225IS - 1873-6254 (Electronic)IS - 0001-706X (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.actatropica.2016.12.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28012906">PM:28012906</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Trop\20161225-NasirianH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Trop\20161225-NasirianH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161225, Nasirian H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.actatropica.2016.12.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cebrino,J.</style></author><author><style face="normal" font="Arial"> Portero de la Cruz,S.</style></author><author><style face="normal" font="Arial"> Barasona,M.J.</style></author><author><style face="normal" font="Arial"> Alcazar,P.</style></author><author><style face="normal" font="Arial"> Moreno,C.</style></author><author><style face="normal" font="Arial"> Dominguez-Vilches,E.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Airborne pollen in Cordoba City (Spain) and its implications for pollen allergy</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="291" start="281">281-291</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Andalusia</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> Volumetric spore trap</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Pollen allergy is among the most widespread allergic disease in Andalusia. However, few studies have examined patient information in conjunction with data on airborne pollen concentrations. This paper sought to identify the airborne pollen types prevalent in C+¦rdoba, to examine the relationship between airborne pollen and the occurrence of allergies, and to investigate the use of drugs to treat various symptoms displayed by pollen-allergy sufferers over the study period. A prospective longitudinal study was conducted in C+¦rdoba City between February and June in 2014 and 2015, using an original specific questionnaire to collect socio-demographic, symptom and pollen-allergy data. Airborne pollen was collected using a Hirst-type volumetric spore trap. Descriptive and inferential statistical analysis was applied. A total of 178 sensitive subjects were included in the study. The prevalence of allergy to olive, grass and plane-tree pollen was 70.73, 73.17 and 19.51%, respectively, in 2014, and 70.83, 70.83 and 21.12%, respectively, in 2015. In both years, rhinitis was the most common allergic symptom (93.90% in 2014, 87.75% in 2015) and a significant correlation between the occurrence of rhinitis and antihistamine consumption was found (p-á&lt;-á0.05 in 2014, p-á&lt;-á0.001 in 2015). The percentage of asthmatic subjects using an inhaler was significantly higher than those who did not used it (63.16% vs. 26.98%; p-á&lt;-á0.01). In conclusion, this paper supports previous studies showing that the most allergenic pollen types in spring were olive, grass and plane-tree pollen. In addition, we found that rhinitis was the main symptom and antihistamines the medication most widely used by the sensitized population in C+¦rdoba</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-016-9469-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-016-9469-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170110-CebrinoJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170110-CebrinoJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Cebrino J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-016-9469-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gimenez-Arnau,A.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author><author><style face="normal" font="Arial"> Bartra,J.</style></author><author><style face="normal" font="Arial"> Jauregui,I.</style></author><author><style face="normal" font="Arial"> Labrador-Horrillo,M.</style></author><author><style face="normal" font="Arial"> Frutos,J.O.</style></author><author><style face="normal" font="Arial"> Silvestre,J.F.</style></author><author><style face="normal" font="Arial"> Sastre,J.</style></author><author><style face="normal" font="Arial"> Velasco,M.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Service, Hospital del Mar, Parc de Salut Mar, Universitat Autonoma Barcelona [Autonomous University of Barcelona], Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="144" start="134">134-144</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> autoinflammatory syndrome</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Severity of the disease</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic spontaneous urticaria (CSU) is a frequent clinical entity that often presents a diagnostic and therapeutic challenge. OBJECTIVE: To explore the degree of agreement that exists among the experts caring for patients with CSU diagnosis, evaluation, and management. METHODS: An online survey was conducted to explore the opinions of experts in CSU, address controversial issues, and provide recommendations regarding its definition, natural history, diagnosis, and treatment. A modified Delphi method was used for the consensus. RESULTS: The questionnaire was answered by 68 experts (dermatologists, allergologists, and primary care physicians). A consensus was reached on 54 of the 65 items posed (96.4%). The experts concluded that CSU is a difficult-to-control disease of unpredictable evolution. Diagnostic tests should be limited and based on clinical history and should not be indiscriminate. Autoinflammatory syndromes and urticarial vasculitis must be ruled out in the differential diagnosis. A cutaneous biopsy is only recommended when wheals last more than 24h, to rule out urticarial vasculitis. The use of specific scales to assess the severity of the disease and the quality of life is recommended. In patients with severe and resistant CSU, second-generation H1-antihistamines could be used at doses up to four times the standard dose before giving second-line treatments. Omalizumab is a safe and effective treatment for CSU that is refractory to H1-antihistamines treatment. In general, diagnosis and treatment recommendations given for adults could be extrapolated to children. CONCLUSIONS: This work offers consensus recommendations that may be useful in the management of CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20161228IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.06.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28029407">PM:28029407</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161228-GimenezArnauA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20161228-GimenezArnauA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161228, Gimenez-Arnau A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.06.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez-Lopez,J.</style></author><author><style face="normal" font="Arial"> Gazquez,V.</style></author><author><style face="normal" font="Arial"> Rubira,N.</style></author><author><style face="normal" font="Arial"> Valdesoiro,L.</style></author><author><style face="normal" font="Arial"> Guilarte,M.</style></author><author><style face="normal" font="Arial"> Garcia-Moral,A.</style></author><author><style face="normal" font="Arial"> Depreux,N.</style></author><author><style face="normal" font="Arial"> Soto-Retes,L.</style></author><author><style face="normal" font="Arial"> De Molina,M.</style></author><author><style face="normal" font="Arial"> Luengo,O.</style></author><author><style face="normal" font="Arial"> Lleonart,R.</style></author><author><style face="normal" font="Arial"> Basagana,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unitat d'Al.lergia, Institut Clinic del Torax (ICT), Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy in Catalonia: Clinical manifestations and its association with airborne allergens</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="54" start="48">48-54</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Plant food allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy affects around 6% of the European population and its prevalence worldwide has been increasing in the last decades, but studies focused on investigating food allergy epidemiology in Europe are lacking. OBJECTIVE: The Cibus project was created to register the main culprit foods and their clinical manifestations in food allergic patients in Catalonia. METHODS: A specific online database was designed. Allergists from eight different Catalan hospitals registered the new diagnoses of food allergy. RESULTS: 618 food allergic patients were included. Egg and milk were the main elicitors in the early ages, while fruits and nuts were the most frequent in patients >14 years old. Fish was more frequent in children, while seafood and Anisakis allergy were more frequent in the >14-year-old group. Overall, peach was the most prevalent food eliciting an allergic reaction (10%). Food allergy diagnosis was reached using compatible clinical history and positive skin prick test to the involved food in 98% of cases. Globally, urticaria was the most frequently reported manifestation in our population (48.2%), followed by oral allergy syndrome (25.6%) and anaphylaxis (24.8%). CONCLUSIONS: The Cibus project gives a full overview of the profile of food allergic patients in Catalonia and reinforces the predominance of plant food allergies in the Mediterranean area</style></abstract><notes><style face="normal" font="Arial">DA - 20160904IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.06.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27592278">PM:27592278</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2017-45-48-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2017-45-48-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160904, Sanchez-Lopez J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.06.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sugiura,S.</style></author><author><style face="normal" font="Arial"> Sasaki,K.</style></author><author><style face="normal" font="Arial"> Matsui,T.</style></author><author><style face="normal" font="Arial"> Nakagawa,T.</style></author><author><style face="normal" font="Arial"> Kando,N.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Aichi Children's Health and Medical Center, Aichi, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Development of a prediction model for a severe reaction in cow's milk challenges</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="494" start="493">493-494</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161227IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.11.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28024702">PM:28024702</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20161227-SugiuraS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20161227-SugiuraS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161227, Sugiura S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.11.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82719</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Furue,M.</style></author><author><style face="normal" font="Arial"> Chiba,T.</style></author><author><style face="normal" font="Arial"> Tsuji,G.</style></author><author><style face="normal" font="Arial"> Ulzii,D.</style></author><author><style face="normal" font="Arial"> Kido-Nakahara,M.</style></author><author><style face="normal" font="Arial"> Nakahara,T.</style></author><author><style face="normal" font="Arial"> Kadono,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Kyushu University, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="403" start="398">398-403</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deviation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> self-antigens</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH22</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder mostly associated with IgE elevation and skin barrier dysfunction due to decreased filaggrin expression. The lesional skin of AD exhibits Th2- and Th22-deviated immune reactions that are progressive during disease chronicity. Th2 and Th22 cytokines further deteriorate the skin barrier by inhibiting filaggrin expression. Some IgEs are reactive to self-antigens. The IgE autoreactivity may precipitate the chronicity of AD. Upon activation of the ORAI1 calcium channel, atopic epidermis releases large amounts of thymic stromal lymphopoietin (TSLP), which initiates the Th2 and Th22 immune response. Th2-derived interleukin-31 and TSLP induce an itch sensation. Taken together, TSLP/Th2/Th22 pathway is a promising target for developing new therapeutics for AD. Enhancing filaggrin expression using ligands for the aryl hydrocarbon receptor may also be an adjunctive measure to restore the disrupted barrier function specifically for AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170106IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28057434">PM:28057434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170106-FurueM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170106-FurueM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170106, Furue M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.12.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kimura,M.</style></author><author><style face="normal" font="Arial"> Ito,Y.</style></author><author><style face="normal" font="Arial"> Shimomura,M.</style></author><author><style face="normal" font="Arial"> Morishita,H.</style></author><author><style face="normal" font="Arial"> Meguro,T.</style></author><author><style face="normal" font="Arial"> Adachi,Y.</style></author><author><style face="normal" font="Arial"> Seto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Shizuoka Children's Hospital, Shizuoka, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Cytokine profile after oral food challenge in infants with food protein-induced enterocolitis syndrome</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="457" start="452">452-457</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although food protein-induced enterocolitis syndrome (FPIES) is supposed to be caused by inflammation, the role of cytokines has not yet been clarified. METHODS: To elucidate the role of cytokines in the development of symptoms and abnormal laboratory findings at an oral food challenge (OFC), changes in serum cytokine levels were analyzed for 6 OFCs in 4 patients with FPIES. The result of OFC was judged positive if any gastrointestinal (GI) symptoms (vomiting, diarrhea, or bloody stool) were induced. RESULTS: Among 11 cytokines profiled, serum levels of interleukin (IL)-2, IL-5, and IL-8 were clearly increased in all 4 positive OFCs in which elevations of the serum level of C-reactive protein (CRP) and peripheral blood neutrophilia were also seen. The level of serum IL-10 also rose in 2 positive OFCs. Remarkable increases in the serum level of interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), IL-6, and IL-12 were observed in a positive OFC where the serum level of CRP rose markedly (6.75 mg/dL). The serum levels of IL-5 were also elevated in 2 negative OFCs. No apparent specific correlations were found between cytokines and GI symptoms. CONCLUSIONS: These results suggest that IL-2 and IL-8 are involved in the antigen-specific immune responses in most patients with FPIES. Further studies are needed to elucidate the significance of these cytokine in the pathogenesis of FPIES</style></abstract><notes><style face="normal" font="Arial">DA - 20170106IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.12.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28057433">PM:28057433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170106-KimuraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170106-KimuraM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170106, Kimura M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.12.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhami,S.</style></author><author><style face="normal" font="Arial"> Zaman,H.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> Sturm,G.J.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Antolin-Amerigo,D.</style></author><author><style face="normal" font="Arial"> Bilo,M.Beatrice</style></author><author><style face="normal" font="Arial"> Bokanovic,D.</style></author><author><style face="normal" font="Arial"> Cichocka-Jarosz,E.</style></author><author><style face="normal" font="Arial"> Oude Elberink,J.N.G.</style></author><author><style face="normal" font="Arial"> Gawlik,R.</style></author><author><style face="normal" font="Arial"> Jakob,T.</style></author><author><style face="normal" font="Arial"> Kosnik,M.</style></author><author><style face="normal" font="Arial"> Lange,J.</style></author><author><style face="normal" font="Arial"> Mingomataj,E.</style></author><author><style face="normal" font="Arial"> Mitsias,D.I.</style></author><author><style face="normal" font="Arial"> Mosbech,H.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Pitsios,C.</style></author><author><style face="normal" font="Arial"> Pravettoni,V.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author><author><style face="normal" font="Arial"> Sin,B.A.</style></author><author><style face="normal" font="Arial"> Netuveli,G.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="365" start="342">342-365</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergies</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> systemic sting reaction</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1398-9995</style></isbn><abstract><style face="normal" font="Arial">Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the management of insect venom allergy. To inform this process, we sought to assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy. Methods: We undertook a systematic review, which involved searching 15 international biomedical databases for published and unpublished evidence. Studies were independently screened and critically appraised using established instruments. Data were descriptively summarized and, where possible meta-analysed. Results: Our searches identified a total of 16,917 potentially eligible studies of which 17 satisfied our inclusion criteria. The available evidence was limited both in volume and quality, but suggested that venom immunotherapy (VIT) could substantially reduce the risk of subsequent severe systemic sting reactions (OR=0.08, 95% CI 0.03 to 0.26); meta-analysis showed that it also improved disease specific quality of life (risk difference=1.41, 95% CI 1.04 to 1.79). Adverse effects were experienced in both the build-up and maintenance phases, but most were mild with no fatalities being reported. The very limited evidence found on modeling cost-effectiveness suggested that VIT was likely to be cost-effective in those at high risk of repeated systemic sting reactions and/or impaired quality of life. Conclusions: The limited available evidence suggested that VIT is effective in reducing severe subsequent systemic sting reactions and in improving disease specific quality of life. VIT proved to be safe and no fatalities were recorded in the studies included in this review. The cost-effectiveness of VIT needs to be established. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Austria -CO - United Kingdom -CO - Italy -CO - Switzerland -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13077</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120424">PM:28120424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170110-DhamiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170110-DhamiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Dhami S</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13077</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meno,K.H.</style></author><author><style face="normal" font="Arial"> Kastrup,J.S.</style></author><author><style face="normal" font="Arial"> Kuo,I.C.</style></author><author><style face="normal" font="Arial"> Chua,K.Y.</style></author><author><style face="normal" font="Arial"> Gajhede,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Global Research, ALK-Abello A/S, Horsholm, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">The structure of the mite allergen Blo t 1 explains the limited antibody cross-reactivity to Der p 1</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="670" start="665">665-670</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Blo t 1</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> cysteine proteases</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage mite</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The Blomia tropicalis (Blo t) mite species is considered a storage mite in temperate climate zones and an important source of indoor allergens causing allergic asthma and rhinitis in tropical and subtropical regions. Here, we report the crystal structure of one of the allergens from Blo t, recombinant proBlo t 1 (rproBlo t 1), determined at 2.1 A resolution. Overall, the fold of rproBlo t 1 is characteristic for the pro-form of cysteine proteases from the C1A class. Structural comparison of experimentally mapped Der f 1/Der p1 IgG epitopes to the same surface patch on Blo t 1, as well as of sequence identity of surface exposed residues, suggests limited cross-reactivity between these allergens and Blo t 1. This is in agreement with ELISA inhibition results showing that, although cross-reactive human IgE epitopes exist, there are unique IgE epitopes for both Blo t 1 and Der p 1. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13111</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27997997">PM:27997997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161220-MenoKH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161220-MenoKH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Meno KH</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13111</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferrini,M.E.</style></author><author><style face="normal" font="Arial"> Hong,S.</style></author><author><style face="normal" font="Arial"> Stierle,A.</style></author><author><style face="normal" font="Arial"> Stierle,D.</style></author><author><style face="normal" font="Arial"> Stella,N.</style></author><author><style face="normal" font="Arial"> Roberts,K.</style></author><author><style face="normal" font="Arial"> Jaffar,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Environmental Health Sciences, University of Montana, Missoula, MT, USA</style></auth-address><titles><title><style face="normal" font="Arial">CB2 receptors regulate natural killer cells that limit allergic airway inflammation in a murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="947" start="937">937-947</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Eicosanoids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Killer Cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> natural killer cell</style></keyword><keyword><style face="normal" font="Arial"> Natural killer cells</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> NK cells</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic asthma is a chronic airway inflammatory disease involving the complementary actions of innate and adaptive immune responses. Endogenously generated cannabinoids, acting via CB2 receptors play important roles in both homeostatic and inflammatory processes. However, the contribution of CB2-acting eicosanoids to the innate events preceding sensitization to the common house dust mite (HDM) allergen, remain to be elucidated. We investigated the role of CB2 activation during allergen-induced pulmonary inflammation and NK cell effector function. METHODS: Lung mucosal responses in CB2-deficient (CB2-/- ) mice were examined and compared with wild type littermates following intranasal exposure to HDM allergen. RESULTS: Mice lacking CB2 receptors exhibited elevated numbers of pulmonary natural killer (NK) cells yet were resistant to the induction of allergic inflammation exemplified by diminished airway eosinophilia, type 2 cytokine production and mucus secretion after allergen inhalation. This phenomenon was corroborated when WT mice were treated with a CB2-specific antagonist that caused a pronounced inhibition of HDM-induced airway inflammation and goblet cell hyperplasia. Unexpectedly, the preponderance of NK cells in the lungs of CB2-/- mice correlated with reduced numbers of group 2 innate lymphoid cells (ILC2s). Depletion of NK cells restored the allergen responsiveness in the lungs and was associated with elevated ILC2 numbers. CONCLUSIONS: Collectively, these results reveal that CB2 activation is crucial in regulating pulmonary NK cell function, and suggest that NK cells serve to limit ILC2 activation and subsequent allergic airway inflammation. CB2 inhibition may present an important target to modulate NK cell response during pulmonary inflammation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161219IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27992060">PM:27992060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161219-FerriniME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161219-FerriniME.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161219, Ferrini ME</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13107</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zellweger,F.</style></author><author><style face="normal" font="Arial"> Gasser,P.</style></author><author><style face="normal" font="Arial"> Brigger,D.</style></author><author><style face="normal" font="Arial"> Buschor,P.</style></author><author><style face="normal" font="Arial"> Vogel,M.</style></author><author><style face="normal" font="Arial"> Eggel,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Research, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">A novel bispecific DARPin targeting FcgammaRIIB and FcepsilonRI-bound IgE inhibits allergic responses</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1183" start="1174">1174-1183</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG Fc receptor</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> SPR</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Binding of allergen-specific IgE to its high-affinity receptor FcepsilonRI on basophils and mast cells is a central event in the development of allergies. Exposure of these cells to allergens induces the release of soluble mediators causing allergic symptoms. The inhibitory low-affinity IgG Fc-receptor FcgammaRIIB is co-expressed on allergic effector cells and has been implicated in negative regulation of immediate hypersensitivity responses. In order to harvest the inhibitory function of this receptor we aimed to select specific binders against FcgammaRIIB and to generate a bispecific molecule simultaneously targeting FcgammaRIIB and FcepsilonRI-bound IgE on the surface of allergic effector cells. METHODS: We selected FcgammaRIIB-specific binding molecules from a library of designed ankyrin repeat proteins using ribosome display technology. The bispecific binding modality was generated by molecular cloning and recombinant protein expression. We determined binding characteristics on molecular and cellular levels using SPR, ELISA and flow cytometry. The inhibitory potential of the newly described molecules was assessed in different cellular degranulation assays ex vivo and in a mouse model of passive systemic anaphylaxis. RESULTS: We demonstrate that the selected DARPin(R) proteins recognize FcgammaRIIB with high affinity. Furthermore, the bispecific binding protein successfully interferes with allergen-induced cell degranulation and efficiently inhibits systemic anaphylaxis in vivo. Mechanistically, we report that FcgammaRIIB-mediated inhibition of effector cell activation requires direct ligation to an activating FcepsilonRI receptor. CONCLUSION: The described bispecific DARPin protein has the ability to co-ligate FcgammaRIIB with FcepsilonRI-bound IgE on allergic effector cells and represents an efficient dual-modality to interfere with allergic hypersensitivity reactions. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13109</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27997998">PM:27997998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161220-ZellwegerF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161220-ZellwegerF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Zellweger F</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13109</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chawes,B.L.</style></author><author><style face="normal" font="Arial"> Stokholm,J.</style></author><author><style face="normal" font="Arial"> Schoos,A.M.</style></author><author><style face="normal" font="Arial"> Rahman,N.</style></author><author><style face="normal" font="Arial"> Brix,S.</style></author><author><style face="normal" font="Arial"> Bisgaard,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Sensitization at School Age is a Systemic Low-grade Inflammatory Disorder</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1080" start="1073">1073-1080</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> CXCL8</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1beta</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Systemic low-grade inflammation has been demonstrated in a range of the frequent noncommunicable diseases (NCDs) proposing a shared mechanism, but is largely unexplored in relation to allergic sensitization. We therefore aimed to investigate the possible association with childhood allergic sensitization. METHODS: High sensitivity C-reactive protein (hs-CRP), interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha) and chemokine (C-X-C motif) ligand 8 (CXCL8) were measured in plasma at age 6mo (N=214) and 7yrs (N=277) in children from the Copenhagen Prospective Studies on Asthma in Childhood2000 (COPSAC2000 ) birth cohort. Allergic sensitization against common inhalant and food allergens was determined longitudinally at age (1/2), 1(1/2), 4 and 6yrs by specific-IgE assessments and skin prick tests. Associations between inflammatory biomarkers and sensitization phenotypes were tested with logistic regression and principle component analyses (PCA). RESULTS: Adjusted for gender, recent infections and a CRP genetic risk-score, hs-CRP at 7yrs was associated with concurrent elevated specific-IgE against any allergen (adjusted OR (aOR) =1.40; 95% CI, 1.14-1.72; p=0.001), aeroallergens (aOR, 1.43; 1.15-1.77; p=0.001), food allergens (aOR, 1.31; 95% CI, 1.02-1.67; p=0.04), sensitization without any clinical allergy symptoms (aOR=1.40; 1.06-1.85; p=0.02), and with similar findings for skin prick tests. The other inflammatory markers were not univariantly associated with sensitization, but multi-parametric PCA suggested a specific inflammatory response among sensitized children. Inflammatory markers at age 6mo were not associated with subsequent development of sensitization phenotypes. CONCLUSIONS: Elevated hs-CRP is associated with allergic sensitization in school-aged children suggesting systemic low-grade inflammation as a phenotypic characteristic of this early onset NCD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161219IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13108</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27992959">PM:27992959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161219-ChawesBL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161219-ChawesBL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161219, Chawes BL</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13108</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Bax,H.J.</style></author><author><style face="normal" font="Arial"> Bianchini,R.</style></author><author><style face="normal" font="Arial"> Capron,M.</style></author><author><style face="normal" font="Arial"> Corrigan,C.</style></author><author><style face="normal" font="Arial"> Castells,M.</style></author><author><style face="normal" font="Arial"> Dombrowicz,D.</style></author><author><style face="normal" font="Arial"> Daniels-Wells,T.R.</style></author><author><style face="normal" font="Arial"> Fazekas,J.</style></author><author><style face="normal" font="Arial"> Fiebiger,E.</style></author><author><style face="normal" font="Arial"> Gatault,S.</style></author><author><style face="normal" font="Arial"> Gould,H.J.</style></author><author><style face="normal" font="Arial"> Janda,J.</style></author><author><style face="normal" font="Arial"> Josephs,D.H.</style></author><author><style face="normal" font="Arial"> Karagiannis,P.</style></author><author><style face="normal" font="Arial"> Levi-Schaffer,F.</style></author><author><style face="normal" font="Arial"> Meshcheryakova,A.</style></author><author><style face="normal" font="Arial"> Mechtcheriakova,D.</style></author><author><style face="normal" font="Arial"> Mekori,Y.</style></author><author><style face="normal" font="Arial"> Mungenast,F.</style></author><author><style face="normal" font="Arial"> Nigro,E.A.</style></author><author><style face="normal" font="Arial"> Penichet,M.L.</style></author><author><style face="normal" font="Arial"> Redegeld,F.</style></author><author><style face="normal" font="Arial"> Saul,L.</style></author><author><style face="normal" font="Arial"> Singer,J.</style></author><author><style face="normal" font="Arial"> Spicer,J.F.</style></author><author><style face="normal" font="Arial"> Siccardi,A.G.</style></author><author><style face="normal" font="Arial"> Spillner,E.</style></author><author><style face="normal" font="Arial"> Turner,M.C.</style></author><author><style face="normal" font="Arial"> Untersmayr,E.</style></author><author><style face="normal" font="Arial"> Vangelista,L.</style></author><author><style face="normal" font="Arial"> Karagiannis,S.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The interuniversity Messerli Research Inst., Univ. of Vet. Medicine Vienna, Med. Univ. Vienna, Univ. Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">AllergoOncology - The impact of Allergy in Oncology. EAACI Position Paper</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="887" start="866">866-887</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> AllergoOncology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant antibody</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> shedding</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both anti-tumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Co-incident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intra-tumoural innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the cross-talk between allergic response and cancer is paving the way for new avenues of treatment. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - United Kingdom -CO - France -CO - United States -CO - Czech Republic -CO - Israel -CO - Italy -CO - Netherlands -CO - Denmark -CO - Spain -CO - Canada -CO - Kazakhstan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13119</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28032353">PM:28032353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161229-JensenJarolimE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161229-JensenJarolimE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Jensen-Jarolim E</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13119</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fedorova,O.S.</style></author><author><style face="normal" font="Arial"> Janse,J.J.</style></author><author><style face="normal" font="Arial"> Ogorodova,L.M.</style></author><author><style face="normal" font="Arial"> Fedotova,M.M.</style></author><author><style face="normal" font="Arial"> Achterberg,R.A.</style></author><author><style face="normal" font="Arial"> Verweij,J.J.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Versteeg,S.A.</style></author><author><style face="normal" font="Arial"> Potts,J.</style></author><author><style face="normal" font="Arial"> Minelli,C.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Burney,P.</style></author><author><style face="normal" font="Arial"> Yazdanbakhsh,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Faculty Pediatrics, Siberian State Medical University, Tomsk, Russian Federation</style></auth-address><titles><title><style face="normal" font="Arial">Opisthorchis felineus negatively associates with skin test reactivity in Russia - EuroPrevall-INCO study</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1104" start="1096">1096-1104</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Developing Countries</style></keyword><keyword><style face="normal" font="Arial"> developing country</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fish-borne</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food and aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Opisthorchis</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Most studies on the relationship between helminth infections and atopic disorders have been conducted in (sub)tropical developing countries where exposure to multiple parasites and lifestyle can confound the relationship. We aimed to study the relationship between infection with the fish-borne helminth Opishorchis felineus and specific IgE, skin prick testing and atopic symptoms in Western-Siberia, with lifestyle and hygiene standards of a developed country. METHODS: Schoolchildren aged 7 to 11 years were sampled from one urban and two rural regions. Skin prick tests (SPT) and specific IgE (sIgE) against food and aeroallergens were measured and data on allergic symptoms and on demographic and socio-economic factors were collected by questionnaire. Diagnosis of opisthorchiasis was based on PCR performed on stool samples. RESULTS: Of the 732 children included, 34.9% had opisthorchiasis. The sensitisation to any allergen when estimated by positive SPT was 12.8%, while much higher, 24.0%, when measured by sIgE. Atopic symptoms in the past year (flexural eczema and/or rhinoconjunctivitis) were reported in 12.4% of the children. SPT was positively related to flexural eczema and rhinoconjunctivitis, but not to wheezing. Opisthorchiasis showed association with lower SPT response, as well as borderline association with low IgE reactivity to any allergen. However, the effect of opisthorchiasis on SPT response was not mediated by IgE, suggesting that opisthorchiasis influences SPT response through another mechanism. Opisthorchiasis also showed borderline association with lower atopic symptoms. CONCLUSIONS: There is a negative association between a chronic helminth infection and skin prick test reactivity even in a developed country. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Russia -CO - Netherlands -CO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13120</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28032359">PM:28032359</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161229-FedorovaOS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161229-FedorovaOS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Fedorova OS</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13120</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Faber,M.A.</style></author><author><style face="normal" font="Arial"> Pascal,M.</style></author><author><style face="normal" font="Arial"> El Kharbouchi,O.</style></author><author><style face="normal" font="Arial"> Sabato,V.</style></author><author><style face="normal" font="Arial"> Hagendorens,M.M.</style></author><author><style face="normal" font="Arial"> Decuyper,I.I.</style></author><author><style face="normal" font="Arial"> Bridts,C.H.</style></author><author><style face="normal" font="Arial"> Ebo,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine and Health Science, Department of Immunology - Allergology - Rheumatology, University of Antwerp and Antwerp University Hospital, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Shellfish allergens: tropomyosin and beyond</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="848" start="842">842-848</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Arginine kinase</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hemocyanin</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Invertebrate tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mollusc</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> Myosin light chain</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sarcoplasmic</style></keyword><keyword><style face="normal" font="Arial"> sarcoplasmic calcium-binding protein</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shellfish allergy</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimps</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">IgE-mediated shellfish allergy constitutes an important cause of food-related adverse reactions. Shellfish are classified into molluscs and crustaceans, the latter belonging to the class of arthropoda. Among crustaceans, shrimps are the most predominant cause of allergic reactions and thus more extensively studied. Several major and minor allergens have been identified and cloned. Amongst them invertebrate tropomyosin, arginine kinase, myosin light chain, sarcoplasmic calcium-binding protein and hemocyanin are the most relevant. This review summarizes our current knowledge about these allergens. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161227IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13115</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28027402">PM:28027402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161227-FaberMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161227-FaberMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161227, Faber MA</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13115</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hsu,D.Y.</style></author><author><style face="normal" font="Arial"> Dalal,P.</style></author><author><style face="normal" font="Arial"> Sable,K.A.</style></author><author><style face="normal" font="Arial"> Voruganti,N.</style></author><author><style face="normal" font="Arial"> Nardone,B.</style></author><author><style face="normal" font="Arial"> West,D.</style></author><author><style face="normal" font="Arial"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611</style></auth-address><titles><title><style face="normal" font="Arial">Validation of international classification of disease ninth revision codes for atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1095" start="1091">1091-1095</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> ICD-10</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Evaluation of large-scale data sets is needed to better understand the epidemiology, cost and burden of atopic dermatitis (AD). We sought to validate the use of ICD-9-CM codes for identifying AD. METHODS: Patients from a large metropolitan quaternary care medical center with a diagnostic code of either 691.8 (AD) or 692.9 (eczema and contact dermatitis) were queried. Medical records were reviewed for demographics, Hanifin &amp; Rajka (H&amp;R) and United Kingdom Working Party (UKWP) criteria. Sensitivity, specificity and positive predictive values (PPV) of the codes were calculated. RESULTS: Of 43,278 patients identified with associated ICD-9 codes of 691.8 or 692.9, 519 and 253 with 691.8 and 692.9 were randomly selected for chart review. There was extensive overlap: 34.3% had >/=1 occurrences of 691.8 and 692.9; 25.6% had multiple occurrences of both codes. Among patients with >/=1 occurrence of 691.8, 29.9% and 30.8% met the H&amp;R and UKWP criteria, respectively. Similarly, among patients with >/=1 occurrence of 692.9, 33.7% and 32.2% met the H&amp;R and UKWP criteria. Increased PPV was associated with concomitant diagnoses of asthma, hay fever and food allergy, and increased disease severity. CONCLUSIONS: In the outpatient setting, the ICD-9-CM codes 691.8 and 692.9 alone have poor PPV. Incorporation of diagnoses of asthma, hay fever and food allergy improves PPV and specificity. In the inpatient setting, a primary discharge diagnosis of 691.8 had excellent PPV. Although ICD-10 has been adopted in Europe and more recently the US, the same systematic errors would likely occur unless providers standardize their coding. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27997983">PM:27997983</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161220-DsuDY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161220-DsuDY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Hsu DY</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Treudler,R.</style></author><author><style face="normal" font="Arial"> Franke,A.</style></author><author><style face="normal" font="Arial"> Schmiedeknecht,A.</style></author><author><style face="normal" font="Arial"> Ballmer-Weber,B.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Werfel,T.</style></author><author><style face="normal" font="Arial"> Jappe,U.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author><author><style face="normal" font="Arial"> Schmitt,J.</style></author><author><style face="normal" font="Arial"> Brehler,R.</style></author><author><style face="normal" font="Arial"> Kleinheinz,A.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Bruning,H.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author><author><style face="normal" font="Arial"> Ring,J.</style></author><author><style face="normal" font="Arial"> Saloga,J.</style></author><author><style face="normal" font="Arial"> Schakel,K.</style></author><author><style face="normal" font="Arial"> Holzhauser,T.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Dermatology, Venerology and Allergology, Universitat Leipzig</style></auth-address><titles><title><style face="normal" font="Arial">BASALIT-trial: Double blind placebo controlled allergen immunotherapy with rBet v 1-FV in birch related soy allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1253" start="1243">1243-1253</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> folding variant</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gly m 4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgG4</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy allergy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen related food allergy. We aimed to investigate the efficacy of one year AIT with the folding variant (FV) of recombinant (r) Bet v 1 on birch related soy allergy. METHODS: Out of 138 subjects with Bet v 1 sensitization, 82 were positive at double blind placebo controlled food challenge (DBPCFC) with soy. 56/82 were randomized 2:1 (active: placebo). Per protocol population (PPP) had received >150mug of allergen or placebo preparation. OUTCOME MEASURES: lowest observed adverse effect levels (LOAEL), post interventional occurrence of objective signs (objS) at any dose level, sIgE/IgG4 against Bet v 1 and Gly m 4. Between-group changes were investigated (ANCOVA, Mann-Whitney-U-, Fisher exact test). RESULTS: Baseline characteristics including LOAELs were comparable in both groups with objS and subjS occurring in 82% and 95% of active (n=38) versus 78% and 83% of placebo group (n=18). After AIT, objS occurred in 24% and 47%, respectively. LOAEL group differences showed a beneficial tendency (p=0.081) for LOAELobjective in PPP (30 verum, 15 placebo). sIgG4 raised only in active group (Bet v 1: p=0.054, Gly m 4: p=0.037), no relevant changes occurred for sIgE. Only 56% of the intended sample size was recruited. CONCLUSION: For the first time, we present data on the effect of rBet v 1-FV on birch related soy allergy. rBet v 1-FV AIT induced significant immunogenic effects. Clinical assessment showed a tendency in favor of the active group but did not reach statistical significance. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27998002">PM:27998002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20161220-TreudlerR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20161220-TreudlerR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Treudler R</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13112</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nurmatov,U.</style></author><author><style face="normal" font="Arial"> Dhami,S.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Pajno,G.B.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Akdis,C.</style></author><author><style face="normal" font="Arial"> Alvaro-Lozano,M.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Burks,W.</style></author><author><style face="normal" font="Arial"> du Toit.G.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author><author><style face="normal" font="Arial"> Eigenmann,P.</style></author><author><style face="normal" font="Arial"> Knol,E.</style></author><author><style face="normal" font="Arial"> Makela,M.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author><author><style face="normal" font="Arial"> O'Mahony,L.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.</style></author><author><style face="normal" font="Arial"> Poulsen,L.K.</style></author><author><style face="normal" font="Arial"> Sackesen,C.</style></author><author><style face="normal" font="Arial"> Sampson,H.</style></author><author><style face="normal" font="Arial"> Santos,A.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Timmermans,F.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cardiff University, School of Medicine, Division of Population Medicine Neuadd Meirionnydd, Heath Park, Cardiff, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1147" start="1133">1133-1147</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical recommendations</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines for Allergen Immunotherapy (AIT) for IgE-mediated Food Allergy. To inform the development of clinical recommendations, we sought to critically assess evidence on the effectiveness, safety and cost-effectiveness of AIT in the management of food allergy. METHODS: We undertook a systematic review and meta-analysis that involved searching nine international electronic databases for randomized controlled trials (RCTs) and non-randomized studies (NRS). Eligible studies were independently assessed by two reviewers against pre-defined eligibility criteria. The quality of studies was assessed using the Cochrane Risk of Bias tool for RCTs and the Cochrane ACROBAT-NRS tool for quasi-RCTs. Random-effects meta-analyses were undertaken, with planned subgroup and sensitivity analyses. RESULTS: We identified 1814 potentially relevant papers from which we selected 31 eligible studies, comprising of 25 RCTs and six NRS, studying a total of 1259 patients. Twenty-five trials evaluated oral immunotherapy (OIT), five studies investigated sublingual immunotherapy (SLIT) and one study evaluated epicutaneous immunotherapy (EPIT). The majority of these studies were in children. Twenty-seven studies assessed desensitization and nine studies investigated sustained unresponsiveness post-discontinuation of AIT. Meta-analyses demonstrated a substantial benefit in terms of desensitization (risk ratio (RR)=0.19, 95%CI 0.12, 0.29) and sustained unresponsiveness (RR=0.20, 95%CI 0.10, 0.59). Only one study reported on disease-specific quality of life (QoL), which reported no comparative results between OIT and control group. Meta-analyses revealed that the risk of experiencing a systemic adverse reaction was higher in those receiving AIT, with a more marked increase in the risk of local adverse reactions. Sensitivity analysis excluding those studies judged to be at high risk of bias demonstrated the robustness of summary estimates of effectiveness and safety of AIT for food allergy. None of the studies reported data on health economic analyses. CONCLUSIONS: AIT may be effective in raising the threshold of reactivity to a range of foods in children with IgE-mediated food allergy whilst receiving (i.e. desensitization) and post-discontinuation of AIT. It is however associated with a modest increased risk in serious systemic adverse reactions and a substantial increase in minor local adverse reactions. More data are needed in relation to adults, the impact on QoL and the cost-effectiveness of AIT. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170106IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United KIngdom -CO - Italy -CO - Germany -CO - Spain -CO - Switzerland -CO - Netherlands -CO - United States -CO - Denmark -CO - Finland -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13124</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28058751">PM:28058751</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170106-NurmatovU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170106-NurmatovU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170106, Nurmatov U</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13124</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> Caimmi,D.P.</style></author><author><style face="normal" font="Arial"> Bedbrook,A.</style></author><author><style face="normal" font="Arial"> Bewick,M.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Arnavielhe,S.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Chavannes,N.</style></author><author><style face="normal" font="Arial"> Cruz,A.A.</style></author><author><style face="normal" font="Arial"> Dahl,R.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> De Vries,G.</style></author><author><style face="normal" font="Arial"> Mathieu-Dupas,E.</style></author><author><style face="normal" font="Arial"> Fink,W.A.</style></author><author><style face="normal" font="Arial"> Fonseca,J.</style></author><author><style face="normal" font="Arial"> Guldemond,N.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Hellqvist-Dahl,B.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Kuitunen,M.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Kvedariene,V.</style></author><author><style face="normal" font="Arial"> Laune,D.</style></author><author><style face="normal" font="Arial"> Pereira,A.M.</style></author><author><style face="normal" font="Arial"> Carreiro-Martins,P.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Morais-Almeida,M.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Murray,R.</style></author><author><style face="normal" font="Arial"> Nogueira-Silva,L.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Portejoie,F.</style></author><author><style face="normal" font="Arial"> Price,D.</style></author><author><style face="normal" font="Arial"> Ryan,D.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Siroux,V.</style></author><author><style face="normal" font="Arial"> Spranger,O.</style></author><author><style face="normal" font="Arial"> Bom,A.T.</style></author><author><style face="normal" font="Arial"> Tomazic,P.V.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author><author><style face="normal" font="Arial"> Valovirta,E.</style></author><author><style face="normal" font="Arial"> Valiulis,A.</style></author><author><style face="normal" font="Arial"> Vandenplas,O.</style></author><author><style face="normal" font="Arial"> van der Meulen,S.</style></author><author><style face="normal" font="Arial"> van Eerd,M.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, France</style></auth-address><titles><title><style face="normal" font="Arial">Pilot study of mobile phone technology in allergic rhinitis in European countries. The MASK-rhinitis study</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="865" start="857">857-865</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mobile phone</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Ocular symptoms</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Running</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms). AIMS: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions. METHODS: The Allergy Diary users were classified into 6 groups according to the baseline data that they entered into the App: (1) asymptomatic; (2) nasal symptoms excluding rhinorrhea; (3) rhinorrhea; (4) rhinorrhea plus 1-2 nasal/ocular symptoms; (5) rhinorrhea plus >/=3 nasal /ocular symptoms and (6) rhinorrhea plus all nasal/ocular symptoms. RESULTS: By June 1, 2016, 3,260 users had registered with the Allergy Diary and 2,710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. CONCLUSIONS: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - France -CO - United Kingdom -CO - Belgium -CO - Germany -CO - Italy -CO - Netherlands -CO - Finland -CO - Austria -CO - Portugal -CO - Denmark -CO - Poland -CO - Lithuania -CO - Sweden -CO - Spain -CO - Ireland -CO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13125</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28072463">PM:28072463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170110-BousquetJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170110-BousquetJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13125</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Genuneit,J.</style></author><author><style face="normal" font="Arial"> Seibold,A.M.</style></author><author><style face="normal" font="Arial"> Apfelbacher,C.J.</style></author><author><style face="normal" font="Arial"> Konstantinou,G.N.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author><author><style face="normal" font="Arial"> La Grutta,S.</style></author><author><style face="normal" font="Arial"> Logan,K.</style></author><author><style face="normal" font="Arial"> Perkin,M.R.</style></author><author><style face="normal" font="Arial"> Flohr,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Overview of Systematic Reviews in Allergy Epidemiology</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="856" start="849">849-856</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biometry</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is a substantial body of evidence on the epidemiology of allergic conditions, which has advanced the understanding of these conditions. We aimed to systematically identify systematic reviews and meta-analyses on the epidemiology of allergic diseases to assess what has been studied comprehensively and what areas might benefit from further research. METHODS: We searched PubMed and EMBASE up to 12/2014 for systematic reviews on epidemiological research on allergic diseases. We indexed diseases and topics covered and extracted data on the search characteristics of each systematic review. RESULTS: The search resulted in 3,991 entries after removing duplicates, plus 20 other items found via references and conference abstracts; 421 systematic reviews were relevant and included in this overview. The majority contained some evidence on asthma (72.9%). Allergic rhinitis, atopic eczema, and food hypersensitivity were covered in 15.7%, 24.5%, and 9.0%, respectively. Commonly studied risk factors for atopic eczema included dietary and microbial factors, while for asthma, pollution and genetic factors were often investigated in systematic reviews. There was some indication of differing search characteristics across topics. CONCLUSION: We present a comprehensive overview with an indexed database of published systematic reviews in allergy epidemiology. We believe that this clarifies where most research interest has focussed and which areas could benefit from further research. We propose that this effort is updated every few years to include the most recently published evidence and to extend the search to an even broader list of hypersensitivity / allergic disorders. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170104IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -CO - Greece -CO - Australia -CO - Italy -CO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13123</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052339">PM:28052339</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170104-GenuneitJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170104-GenuneitJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170104, Genuneit J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13123</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Scala,E.</style></author><author><style face="normal" font="Arial"> Cecchi,L.</style></author><author><style face="normal" font="Arial"> Abeni,D.</style></author><author><style face="normal" font="Arial"> Guerra,E.C.</style></author><author><style face="normal" font="Arial"> Pirrotta,L.</style></author><author><style face="normal" font="Arial"> Locanto,M.</style></author><author><style face="normal" font="Arial"> Giani,M.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, IDI-IRCCS, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Pla a 2 and Pla a 3-reactivity identify Plane tree-allergic patients with respiratory symptoms or food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="674" start="671">671-674</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Jug r 3</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pla a 2</style></keyword><keyword><style face="normal" font="Arial"> Pla a 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Reactor</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="Arial">Nine hundred thirty-nine rPla a 1, nPla a 2 and rPla a 3 ImmunoCAP ISAC reactors were studied. nPla a 2pos MUXF3pos but Pla a 1/2neg subjects were excluded from the study because they were CCD reactors. Amongst the 764 remaining participants, 71.9% were Pla a 3pos , 54.1% Pla a 2po s and 10.9% Pla a 1pos . Among Pla a 3 reactors, 89.6% were Pru p 3pos and 86.8% Jug 3pos , but the strongest IgE recognition relationship was observed between Pla a 3 and Jug r 3. Distinctive clinical subsets could be documented among plane-tree allergic patients. Pla a 3 reactors had both local and systemic food-induced reactions, but lower past respiratory symptoms occurrence. Pla a 2 reactivity was associated with respiratory symptoms but inversely related to systemic reactions to food. Co-sensitization to Pla a 2 and Pla a 3 was associated with a lower past incidence of severe food-induced reactions. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170102IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13121</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042669">PM:28042669</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170102-ScalaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170102-ScalaE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170102, Scala E</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13121</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Molloy,J.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Tang,M.L.</style></author><author><style face="normal" font="Arial"> Collier,F.</style></author><author><style face="normal" font="Arial"> Carlin,J.B.</style></author><author><style face="normal" font="Arial"> Saffery,R.</style></author><author><style face="normal" font="Arial"> Burgner,D.</style></author><author><style face="normal" font="Arial"> Ranganathan,S.</style></author><author><style face="normal" font="Arial"> Dwyer,T.</style></author><author><style face="normal" font="Arial"> Ward,A.C.</style></author><author><style face="normal" font="Arial"> Moreno-Betancur,M.</style></author><author><style face="normal" font="Arial"> Clarke,M.</style></author><author><style face="normal" font="Arial"> Ponsonby,A.L.</style></author><author><style face="normal" font="Arial"> Vuillermin,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Deakin University, School of Medicine, Waurn Ponds, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D insufficiency in the first 6 months of infancy and challenge-proven IgE-mediated food allergy at 1 year of age: a case-cohort study</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Radiation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Ultraviolet</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ecological evidence suggests vitamin D insufficiency (VDI) due to lower ambient ultraviolet radiation (UVR) exposure may be a risk factor for IgE-mediated food allergy. However there are no studies relating directly measured VDI during early infancy to subsequent challenge-proven food allergy. OBJECTIVE: To prospectively investigate the association between VDI during infancy and challenge-proven food allergy at 1 year. METHODS: In a birth cohort (n=1074), we used a case-cohort design to compare 25-hydroxy-vitamin-D3 (25(OH)D3 ) levels among infants with food allergy versus a random subcohort (n=274). The primary exposures were VDI (25(OH)D3 &lt;50 nmol/L) at birth and 6 months of age. Ambient UVR and time in the sun were combined to estimate UVR exposure dose. IgE-mediated food allergy status at 1 year was determined by formal challenge. Binomial regression was used to examine associations between VDI, UVR exposure dose and food allergy, and investigate potential confounding. RESULTS: Within the random subcohort VDI was present in 45% (105/233) of newborns and 24% (55/227) of infants at 6 months. Food allergy prevalence at 1 year was 7.7% (61/786) and 6.5% (53/808) were egg allergic. There was no evidence of an association between VDI at either birth (aRR 1.25, 95% CI 0.70-2.22) or 6 months (aRR 0.93, 95% CI 0.41-2.14) and food allergy at 1 year. CONCLUSIONS: There was no evidence that VDI during the first 6 months of infancy is a risk factor for food allergy at 1 year of age. These findings primarily relate to egg allergy and larger studies are required. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170102IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13122</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042676">PM:28042676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170102-MolloyJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170102-MolloyJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170102, Molloy J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13122</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mukherjee,M.</style></author><author><style face="normal" font="Arial"> Lim,H.F.</style></author><author><style face="normal" font="Arial"> Thomas,S.</style></author><author><style face="normal" font="Arial"> Miller,D.</style></author><author><style face="normal" font="Arial"> Kjarsgaard,M.</style></author><author><style face="normal" font="Arial"> Tan,B.</style></author><author><style face="normal" font="Arial"> Sehmi,R.</style></author><author><style face="normal" font="Arial"> Khalidi,N.</style></author><author><style face="normal" font="Arial"> Nair,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, McMaster University &amp; St. Joseph's Healthcare, Hamilton, ON Canada</style></auth-address><titles><title><style face="normal" font="Arial">Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma. CASE PRESENTATION: A 62-year old woman diagnosed with severe eosinophilic asthma showed poor response to Mepolizumab therapy (100 mg subcutaneous dose/monthly) and subsequent worsening of symptoms. The treatment response to Mepolizumab was monitored using both blood and sputum eosinophil counts. The latter was superior in assessing deterioration in symptoms, suggesting that normal blood eosinophil count may not always indicate amelioration or adequate control of the ongoing eosinophil-driven disease process. This perplexing situation of persistent airway eosinophilia and increased steroid insensitivity despite an anti-eosinophil therapy can be explained if the administered dose of the mAb was inadequate in comparison to the target antigen. The resultant immune complexes could act as 'cytokine depots', protecting the potency of the 'bound' IL-5, thereby sustaining the eosinophilic inflammation within the target tissue. Molecular analysis of the sputum indicated the development of a polyclonal autoimmune response as well as an increase in group 2 innate lymphoid cells, two novel observations in severe eosinophilic asthma, which were associated with indices of disease severity and progression. This case highlights the possibility of a previously unrecognised autoimmune-mediated worsening of asthma perhaps triggered by immune complexes formed due to inadequate dosing of administered monoclonal antibodies in the target tissue. CONCLUSIONS: While anti-IL5 mAb therapy is an exciting novel option to treat patients with severe asthma, there is the rare possibility of worsening of asthma as observed in this case study, due to local autoimmune mechanisms precipitated by potential inadequate airway levels of the monoclonal antibody</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-016-0174-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28070196">PM:28070196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Mukherjee M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-016-0174-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Coop,C.A.</style></author><author><style face="normal" font="Arial"> Forester,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1Department of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center, Lackland Air Force Base, San Antonio, Texas, USA</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of pain during skin-prick testing, immunizations, and phlebotomy</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="97" start="93">93-97</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> skin-prick testing</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy skin prick testing is a medical procedure that is very useful for assessing a patient's sensitization to specific allergens. Some patients are worried about pain associated with prick skin testing. OBJECTIVE: To compare pain among different age groups, to look at pain during skin prick testing in younger children, and to compare the pain during skin prick testing to procedures including routine immunizations and phlebotomy. METHODS: A survey was provided to patients undergoing allergy skin testing, immunizations or phlebotomy at the Wilford Hall Medical Center. RESULTS: There were 197 patients and 26 parents of patients aged 3-8 years who completed surveys during allergy skin testing. The average anticipated (pre procedure) pain score was 4.3 for the patients aged 3-8 years, 4.6 for the patients aged 9-17 years and 3.2 for the patients older than 17 years. The average actual pain score of the patients during skin testing was 3.1 for the patients aged 3-8 years, 2.2 for the patients aged 9-17 years and 1.4 for the patients older than 17 years. For the parents of patients aged 3-8 years, the average anticipated average pain score was 3.0 and the average actual pain score was 1.7. CONCLUSIONS: The actual pain experienced from skin prick testing is perceived to be much less than the anticipated pain. Patients and referring physicians should not have a fear of pain from allergy skin prick testing</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3961</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27657516">PM:27657516</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-93-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-93-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Coop CA</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3961</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ledford,D.</style></author><author><style face="normal" font="Arial"> Broder,M.S.</style></author><author><style face="normal" font="Arial"> Antonova,E.</style></author><author><style face="normal" font="Arial"> Omachi,T.A.</style></author><author><style face="normal" font="Arial"> Chang,E.</style></author><author><style face="normal" font="Arial"> Luskin,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida and the James A. Haley Veterans Hospital, Tampa, Florida, USA</style></auth-address><titles><title><style face="normal" font="Arial">Corticosteroid-related toxicity in patients with chronic idiopathic urticariachronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="465" start="458">458-465</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Claims data</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Care Costs</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Osteoporosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Treatments for patients with chronic idiopathic urticaria (CIU)chronic spontaneous urticaria (CSU) who were unresponsive to antihistamines include oral corticosteroids (OCS). Risks of OCS-related side effects in these patients have not been described quantitatively. OBJECTIVE: To investigate the relationship between OCS use and the risk of developing side effects possibly attributable to OCS and associated health care costs in privately insured patients with CIU/CSU. METHODS: This retrospective cohort study analyzed a commercial claims data base from January 1, 2008, to December 31, 2012. Patients with CIU/CSU were identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes via a validated algorithm. Possible OCS-related side effects included the following: diabetes mellitus, hypertension, lipid disorders, cataracts, depression or mania, osteoporosis or fractures, and infectious diseases. A time-dependent Cox regression (adjusted for age, sex, Charlson Comorbidity Index, and immunomodulator use) was used to separately model cumulative oral prednisone-equivalent exposure and the risk of side effects. Incremental total adjusted health care costs were compared in patients with versus patients without possible OCS-related side effects. RESULTS: Among 12,647 patients with CIU/CSU, 55.4% used OCS. An additional 1 g of prednisone-equivalent exposure was associated with a 7% increase in the likelihood of developing a possible side effect (hazard ratio, 1.07 [95% confidence interval, 1.051.08]). From the period before to the period after OCS initiation, the total mean adjusted annual health care costs increased by 1833 in users of OCS with new possible side effects and decreased by 2183 in patients without new possible side effects (p 0.001). CONCLUSION: Patients with CIU/CSU who were treated with OCS had an increased risk of possible OCS-related side effects and higher total health care costs than their counterparts not treated with OCS</style></abstract><notes><style face="normal" font="Arial">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3999</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931301">PM:27931301</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-458-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-458-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161209, Ledford D</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3999</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Azkur,D.</style></author><author><style face="normal" font="Arial"> Civelek,E.</style></author><author><style face="normal" font="Arial"> Toyran,M.</style></author><author><style face="normal" font="Arial"> Msrlolu,E.D.</style></author><author><style face="normal" font="Arial"> Erkoolu,M.</style></author><author><style face="normal" font="Arial"> Kaya,A.</style></author><author><style face="normal" font="Arial"> Vezir,E.</style></author><author><style face="normal" font="Arial"> Gini,T.</style></author><author><style face="normal" font="Arial"> Akan,A.</style></author><author><style face="normal" font="Arial"> Kocaba,C.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy and Immunology, Faculty of Medicine, Kirikkale University, Kirikkale, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Clinical and etiologic evaluation of the children with chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="457" start="450">450-457</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune urticaria</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> Breath test</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> cold urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermographism</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic urticaria (CU) is a skin disorder defined as daily or almost daily exhibition of pruritic and transient wheals that last for 6 weeks. CU is divided into two subtypes: chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). OBJECTIVES: To evaluate the clinical features, possible causes, associated findings, and laboratory results of different subtypes of CU in children according to a new classification. METHODS: In this study, we evaluated the clinical features, laboratory investigations, and provocation tests of children with different subtypes of CU according to a new classification. RESULTS: Two hundred and twenty-two children (59.9% girls) were enrolled in the study. Of the study patients, 59.9% and 40.1% were diagnosed as having CSU and CIndU, respectively. Antithyroid antibody levels were positive in 7.1% of the patients with CSU, 32.8% of the children had positive 14C-urea breath test results, and 6.5% of the patients had positive stool examination results for parasites. Autologous serum skin test results were positive in 53.5% of the patients with CSU. Of the patients with CIndU, 77.5% had symptomatic dermographism, 16.8% had cold urticaria, 2.2% had cholinergic urticaria, 2.2% had solar urticaria, and 1.1% had aquagenic urticaria. CONCLUSION: Children with CSU represent the majority of patients with CU, and more than a half of these patients might have autoimmune urticaria. Symptomatic dermographism was the most common type of CIndU</style></abstract><notes><style face="normal" font="Arial">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.4010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931300">PM:27931300</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-450-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-450-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161209, Azkur D</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.4010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Utility of component diagnostic testing in guiding oral food challenges to milk and egg</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="442" start="439">439-442</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic testing</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> skin-prick testing</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergies affect up to 8% of children, and milk and egg allergies are the most common triggers. Accurately diagnosing these food allergies is important to prevent allergic reactions and to avoid unnecessary dietary restrictions. However, positive skin-prick tests and detectable levels of serum food specific immunoglobulin E (IgE) alone may not be diagnostic for food allergy. Advances in the identification of relevant allergens and the development of recombinant proteins now allow assessment of IgE binding to individual proteins within a food. Component-resolved diagnostics (CRD) have the potential to provide more accurate assessments of clinical reactivity to food allergens. OBJECTIVE: To examine the available data for CRD for milk and egg allergies. METHODS: This review discussed studies that evaluated the utility of CRD for guiding decisions about food challenges for milk and egg. RESULTS: Results of studies indicated that CRD may offer increased specificity, but sensitivity was lacking when compared with standard skin-prick testing and measurement of serum food specific IgE levels. CONCLUSION: The role of CRD in the diagnosis and management of milk and egg allergies is not well established at this time. Further studies are needed to explore the diagnostic value of CRD for milk and egg allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3997</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931298">PM:27931298</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-439-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-439-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161209, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3997</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gupta,R.S.</style></author><author><style face="normal" font="Arial"> Singh,A.M.</style></author><author><style face="normal" font="Arial"> Walkner,M.</style></author><author><style face="normal" font="Arial"> Caruso,D.</style></author><author><style face="normal" font="Arial"> Bryce,P.J.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Pongracic,J.A.</style></author><author><style face="normal" font="Arial"> Smith,B.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA</style></auth-address><titles><title><style face="normal" font="Arial">Hygiene factors associated with childhood food allergy and asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="146" start="140">140-146</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child care</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood food allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> pet exposure</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Childhood food allergy and asthma rates are increasing. The hygiene hypothesis has been proposed as an explanation for the increased incidence of allergic disease. OBJECTIVE: To describe the association of childhood food allergy and asthma with hygiene factors, such as the number of siblings, antibiotic use, infection history, pet exposure, child care exposure, and maternalchild factors. METHODS: Children ages 021 years old (N = 1359) were recruited for a cross-sectional family-based study, including children with food allergy and children without food allergy, and their siblings. We assessed the associations between childhood food allergy and asthma with hygiene factors. RESULTS: Of the 1359 children, 832 (61.2%) had food allergy, and 406 (30%) had asthma. In the adjusted analysis, the prevalence of food allergy was increased if there was a history of skin infection (prevalence ratio [RRR] 1.12 [95% confidence interval {CI}, 1.011.24]) or eczema (RRR 1.89 [95% CI, 1.702.10]). The prevalence of asthma was increased with a history of respiratory syncytial virus infection (RRR 1.60 [95% CI, 1.341.90]) or eczema (RRR 1.54 [95% CI, 1.271.86]). A greater number of siblings were associated with a decreased prevalence of food allergy (RRR 0.79 [95% CI, 0.750.84]) and asthma (RRR 0.82 [95% CI, 0.740.91]). CONCLUSION: Our findings supported the accumulating evidence of an association between skin infections and eczema with food allergy. Because these results could be subject to recall bias, additional prospective studies are needed to substantiate these findings</style></abstract><notes><style face="normal" font="Arial">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3988</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931290">PM:27931290</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-140-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-140-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161209, Gupta RS</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3988</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lang,K.</style></author><author><style face="normal" font="Arial"> Allen-Ramey,F.</style></author><author><style face="normal" font="Arial"> Huang,H.</style></author><author><style face="normal" font="Arial"> Rock,M.</style></author><author><style face="normal" font="Arial"> Kaufman,E.</style></author><author><style face="normal" font="Arial"> Dykewicz,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Quintiles Valuie &amp; Outcomes Advisory Services, Cambridge, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">Health care resource use and associated costs among patients with seasonal versus perennial allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="111" start="103">103-111</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Claims data</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Costs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Care Costs</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> resource use</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Health care resource use (HRU) and costs among patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) have not been widely studied. OBJECTIVE: To develop an algorithm to classify patients with SAR and patients with PAR, and to evaluate treatment patterns, HRU, and costs among these patients. METHODS: Patients with allergic rhinitis (AR) were identified retrospectively by using electronic medical records and administrative claims data, with an index date as the earlier of the date of AR diagnosis or allergy medication use. Patients with AR were followed-up from 12 months before the index date through 12 months after the index date (follow-up) and were classified as SAR or PAR based on medication patterns during follow-up. AR-related HRU, allergy immunotherapy administration, and costs per patient per year during follow-up were compared between patients with SAR and those with PAR, with analyses stratified by asthma diagnosis before the index date and by physician specialty (primary care physician versus specialist). RESULTS: Approximately 23% of patients with AR were classified as having PAR and 77% as having SAR. During follow-up, the patients with PAR had more allergy medication prescriptions versus the patients with SAR (8.0 versus 2.4 prescriptions), higher prescription medication costs ($1551 versus $313), higher allergy immunotherapy cost ($180 versus. $118), and higher total AR-related costs ($1944 versus $643); all with p &lt; 0.001. Patients with asthma had higher costs than those without asthma. Patients seen by a specialist has higher costs than those treated by a primary care physician. CONCLUSION: Patients with PAR experienced more AR-related prescription drug use and higher health care costs than patients with SAR, with prescription drug costs being the main cost driver. Treatments that reduce the need for ongoing prescription medication use have the potential to be cost saving</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3984</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27657517">PM:27657517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-103-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-103-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Lang K</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3984</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonilla,F.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Immunology Program, Boston Childrens Hospital, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">Intravenous and subcutaneous immunoglobulin G replacement therapy</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="431" start="426">426-431</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody deficiency</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hemolysis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Intravenous IgG</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> IVIg</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> SCIg</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Subcutaneous IgG</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Human polyclonal immunoglobulin G (IgG) for therapeutic use has been available for decades. This drug was developed for treatment of antibody deficiency (replacement therapy), although its use has expanded into many anti-inflammatory and immunomodulatory applications in recent years. This review focuses on IgG prescribing for replacement therapy. IgG for replacement is most often administered via the intravenous IgG (IVIG) or subcutaneous IgG (SCIG) routes. IVIG is usually administered every 34 weeks, and SCIG is usually administered weekly, although variations may be considered in all cases. Recently, a new product became available that uses hyaluronidase to facilitate absorption of large doses of SCIG less frequently (every 34 weeks, as with IVIG). There are important differences between the pharmacokinetics of these three routes of administration. IVIG therapy leads to high peaks and low troughs between infusions. IgG concentration fluctuates much less over time with SCIG. Hyaluronidase-facilitated SCIG is intermediate. SCIG may have lower bioavailability in comparison with IVIG and may require higher doses over time; this is not true for hyaluronidase SCIG. However, there are large variations in IgG half-life among individuals and with different products. Therefore, individualization of therapy is essential. Mild systemic flu-like adverse effects may affect up to 2025% of patients who receive IVIG, smaller fractions may experience more-severe symptoms, whereas anaphylaxis is exceedingly rare. General flu-like systemic adverse effects are minimal with SCIG (intermediate with hyaluronidase SCIG), but transient (24 hours), mild, local inflammatory symptoms at infusion sites are relatively common with both forms. Additional rare but important complications of IgG therapy include thrombotic events and hemolysis that can be seen at high doses with any route of administration. Renal adverse effects may occur with IVIG as well. The variety of IgG products and routes of administration available today creates many opportunities for physicians to work with patients to find the optimal therapy for all</style></abstract><notes><style face="normal" font="Arial">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3987</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931296">PM:27931296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-426-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-426-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161209, Bonilla FA</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3987</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larenas-Linnemann,D.E.</style></author><author><style face="normal" font="Arial"> Hauswirth,D.W.</style></author><author><style face="normal" font="Arial"> Calabria,C.W.</style></author><author><style face="normal" font="Arial"> Sher,L.D.</style></author><author><style face="normal" font="Arial"> Rank,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Medica Sur, Mexico City, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">American Academy of Allergy, Asthma &amp; Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="122" start="112">112-122</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mexico City</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Little data in the literature exist concerning patients with certain underlying medical conditions who receive allergen subcutaneous immunotherapy (SCIT). OBJECTIVE: To survey allergists' experience with SCIT in patients with medical conditions considered to impose an elevated risk for untoward outcomes. METHODS: A Web-based survey was conducted among members of the American Academy of Allergy, Asthma &amp; Immunology to query about their experience with SCIT in patients with certain medical conditions. RESULTS: There were 1085 replies (21% response), of whom, 86% were U.S. based, 51% were suburban, 31% were academic, 42% were medium-sized practices, and 54% had >15 years' experience. In responders' opinion, SCIT was "contraindicated" in patients with the following: acquired immune deficiency syndrome (AIDS) (48%), cancer (and still receiving active treatment) (33%), severe asthma (32%), and a history of transplantation (30%). Even so, survey responders collectively gave SCIT to >2400 patients for each of these conditions: severe asthma, coronary artery disease, cancer in remission, and autoimmune disorders; and to >/=5400 patients with hypertension and >/=4100 women who became pregnant. The experience of colleagues with these patients rarely resulted in major problems (i.e., activation of underlying disease, systemic reactions to SCIT, or SCIT discontinuation), with the exception of severe asthma (12.5%), initiation of SCIT during pregnancy (5.4%), and AIDS (4.2%). For most other conditions, it was &lt;/=1.5% (e.g., continue during pregnancy, cancer in remission, history of transplantation, positive human immunodeficiency virus and no AIDS). CONCLUSION: According to the experience of a large group of practicing allergists, the American Academy of Allergy, Asthma &amp; Immunology members, few medical conditions seemed to pose an elevated risk for untoward outcomes from SCIT. Because these are survey results, prospective research might yield even more solid data</style></abstract><notes><style face="normal" font="Arial">DA - 20160923IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2016.37.3981</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27657518">PM:27657518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-112-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2016-37-112-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160923, Larenas-Linnemann DE</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2016.37.3981</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berger,W.E.</style></author><author><style face="normal" font="Arial"> Granet,D.B.</style></author><author><style face="normal" font="Arial"> Kabat,A.G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Diagnosis and management of allergic conjunctivitis in pediatric patients</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="27" start="16">16-27</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug treatment</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic conjunctivitis (AC), although one of the most common ocular disorders in pediatric patients, is frequently overlooked, misdiagnosed, and undertreated in children. OBJECTIVE: To guide pediatric health care professionals in the optimal diagnosis and management of AC in pediatric patients. METHODS: To identify any existing best practice guidelines for the diagnosis and treatment of AC in pediatric patients, a review of the literature published between 2004 and January 2015 was conducted. Diagnosis and treatment algorithms and guidelines for pediatric patient referrals were then developed. RESULTS: A literature search to identify best practice guidelines for the treatment of AC in pediatric patients failed to return any relevant articles, which highlighted the need for best practice recommendations. Based on publications on adult AC and clinical experience, this review provides step-by-step guidance for pediatric health care professionals, including recognizing clinical features of AC, establishing a comprehensive medical history, and performing a thorough physical examination to ensure a correct diagnosis and the optimal treatment or referral to an eye care specialist or allergist when required. In addition to established drug treatments, the role of subcutaneous and sublingual immunotherapy is discussed to inform pediatric health care professionals about alternative treatment options for patients who do not tolerate pharmacotherapy or who do not respond sufficiently. CONCLUSION: The diagnostic and treatment algorithms and guidelines provided in this review help address the current literature and educational gap and may lead to improvements in diagnosis and management of pediatric AC</style></abstract><notes><style face="normal" font="Arial">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engCO - United States -PT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052798">PM:28052798</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-16-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-16-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170105, Berger WE</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ogg,J.</style></author><author><style face="normal" font="Arial"> Wong,J.</style></author><author><style face="normal" font="Arial"> Wan,M.W.</style></author><author><style face="normal" font="Arial"> Davis,N.</style></author><author><style face="normal" font="Arial"> Arkwright,P.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Factors that determine parents' perception of their child's risk of life-threatening food-induced anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="53" start="44">44-53</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Counseling</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mood</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although food allergy is known to be associated with increased disease burden, factors that shape parents' perception of their child's risk of future severe or fatal anaphylaxis are poorly understood. OBJECTIVE: This study aimed to evaluate factors associated with parents' perceived risk of food-induced anaphylaxis. METHODS: A questionnaire-based survey of 202 parents was conducted in a single specialist center outpatient clinic that treats children with food allergies. Parents' perceived risk of their child experiencing further food-induced anaphylaxis was assessed by using a validated food allergy independent measure. Demographic data as well as parents' anxiety and depression scores were assessed by using the Hospital Anxiety and Depression score. RESULTS: Nineteen percent of parents believed that their child had a moderate-to-high chance of dying from food-induced anaphylaxis. A lack of a university education, higher anxiety score, and, particularly, possession of an epinephrine autoinjector (relative risk 9.9 [95% confidence interval, 3.3-30]) were key factors associated with heightened risk perception. Caring for a child with multiple food allergies was the main factor associated with parents feeling less able to manage future reactions (relative risk 9.5 [95% confidence interval, 1.7-53]). Parents' risk perception of fatal anaphylaxis correlated with anxiety and mood scores. CONCLUSION: Parents' education, affect, and possession of an epinephrine autoinjector were associated with a heightened perceived risk of future anaphylaxis. Clinicians should consider not only the child's needs but should also provide counseling for parents, particularly those who possess autoinjectors. Parents of children with multiple food allergies may need additional education and training to help them cope with future reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engCO - United Kingdom -PT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052801">PM:28052801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-44-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-44-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170105, Ogg J</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yilmaz,E.A.</style></author><author><style face="normal" font="Arial"> Soyer,O.</style></author><author><style face="normal" font="Arial"> Cavkaytar,O.</style></author><author><style face="normal" font="Arial"> Karaatmaca,B.</style></author><author><style face="normal" font="Arial"> Buyuktiryaki,B.</style></author><author><style face="normal" font="Arial"> Sahiner,U.M.</style></author><author><style face="normal" font="Arial"> Sekerel,B.E.</style></author><author><style face="normal" font="Arial"> Sackesen,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Characteristics of children with food protein-induced enterocolitis and allergic proctocolitis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="62" start="54">54-62</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The aim of this study was to determine and compare the clinical and laboratory features of food protein-induced enterocolitis syndrome (FPIES) and food protein-induced allergic proctocolitis (FPIAP), and to provide information about the short-term prognoses. METHOD: Children diagnosed with FPIES or FPIAP between 2010 and 2015 were enrolled in this study. RESULTS: Overall, 64 infants (37 FPIAP, 27 FPIES) were evaluated, with the average age at the onset of symptoms being significantly lower in the patients with FPIAP than in the patients with FPIES (2 months [1-3 months] versus 4 months [1.5-6 months]; p = 0.043). Fifteen of the patients with FPIAP (40.5%) and six of the patients with FPIES (22.2%) were exclusively breast-fed at the time of the onset of symptoms. Cow's milk was the most frequent trigger (100% FPIAP, 74% FPIES); solid foods caused FPIES more frequently. Forty-eight of the 64 patients were followed up until at least 2 years of age, with the resolution rates being 91.3% for FPIAP and 60% for FPIES. The solid food-induced cases of FPIES (27.3%) had a significantly lower rate of resolution than the liquid food-induced FPIES (83.3%) (p = 0.003). CONCLUSION: Cow's milk is the most common trigger of both FPIAP and FPIES. The symptom onset age seemed to be earlier in FPIAP. The resolution age was similar, however, the recovery in FPIES may be later if the trigger food is solid. To our knowledge, this was the first clinical study to compare the clinical and laboratory characteristics of patients with FPIAP and FPIES</style></abstract><notes><style face="normal" font="Arial">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052802">PM:28052802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-54-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-54-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170105, Yilmaz EA</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dibek,M.E.</style></author><author><style face="normal" font="Arial"> Vezir,E.</style></author><author><style face="normal" font="Arial"> Toyran,M.</style></author><author><style face="normal" font="Arial"> Capanoglu,M.</style></author><author><style face="normal" font="Arial"> Guvenir,H.</style></author><author><style face="normal" font="Arial"> Civelek,E.</style></author><author><style face="normal" font="Arial"> Kocabas,C.N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical diagnosis and management of anaphylaxis in infancy</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="43" start="38">38-43</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis is increasingly reported in infancy. Diagnosis and management of anaphylaxis is difficult, and data are limited in infants. The aim of the present study was to determine the clinical course and management strategies used for anaphylaxis in infancy. METHODS: Patients attending to our clinic and who had anaphylaxis under 2 years old were evaluated. Sixty-three patients were enrolled for the study. The mean +/- standard deviation age was 10.6 +/- 6.1 months (median, 11 months). RESULTS: Anaphylaxis occurred at home in 48 infants (76.2%). Food was the most common causative agent (n = 52 [82.5%]), with cow's milk (n = 21 [40.4%]) and egg white (n = 13 [25%]) being the most frequent. Medication was the other causative agent (n = 9 [14.3%]), with antibiotics being the most frequent (n = 6 [66.7%]). The clinical manifestations were cutaneous (95.2%) and respiratory symptoms (79.4%). The median time lapse between contact and onset of symptoms was 10 minutes (5-15 minutes) (median, interquartile range [IQR] 25-75%). The total duration of symptoms was 2 hours (0.5-3 hours) (median, IQR 25-75%). Six patients had mild (9.5%), 40 moderate (63.5%), and 17 severe (27%) symptoms. A biphasic course was noticed in two infants (3.2%), with a symptom-free interval between a minimum of 30 minutes and a maximum of 4 hours. Forty-three (68.3%) received H1 antihistamines, 31 received corticosteroids (49.2%), and 23 received adrenaline (36.5%). Only one patient needed intensive care. CONCLUSION: This study provided detailed clinical information in the diagnosis of anaphylaxis in infants. Diagnosing and managing anaphylaxis are difficult in infancy. Arrangements for definition of symptoms should be made in the new anaphylaxis guidelines</style></abstract><notes><style face="normal" font="Arial">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052800">PM:28052800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-38-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-38-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170105, Dibek ME</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bellanti,J.A.</style></author><author><style face="normal" font="Arial"> Settipane,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">"I've got you under my skin": A challenge for both the allergist and the patient</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="2" start="1">1-2</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergist</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052793">PM:28052793</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-1-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-1-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170105, Bellanti JA</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ganapathy,S.</style></author><author><style face="normal" font="Arial"> Lwin,Z.</style></author><author><style face="normal" font="Arial"> Ting,D.H.</style></author><author><style face="normal" font="Arial"> Goh,L.S.</style></author><author><style face="normal" font="Arial"> Chong,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, KK Women's and Children's Hospital, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis in Children: Experience of 485 Episodes in 1,272,482 Patient Attendances at a Tertiary Paediatric Emergency Department from 2007 to 2014</style></title><secondary-title><style face="normal" font="Arial">Ann Acad Med Singapore</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Acad Med Singapore</style></full-title></periodical><pages end="548" start="542">542-548</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Biphasic reactions</style></keyword><keyword><style face="normal" font="Arial"> Central Nervous System</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Introduction: Anaphylaxis is a predominantly childhood disease. Most of the literature on anaphylaxis has emerged from Western countries. This study aimed to describe the incidence, triggers and clinical presentation of anaphylaxis among children in Singapore, look for predictors for anaphylaxis with severe outcomes, and study the incidence of biphasic reactions. Materials and Methods: We retrospectively reviewed records of children presenting with anaphylaxis to our paediatric emergency department from 1 January 2007 to 31 December 2014. Results: We identified 485 cases of anaphylaxis in 445 patients. Cutaneous symptoms (urticarial/angio-oedema) were the most common across all age groups (481 cases, 99%), followed by respiratory (412, 85%), gastrointestinal (118, 24%) and cardiovascular (35, 7.2%) symptoms. Central nervous system symptoms (drowsiness/ irritability) were rare across all age groups (11, 2.2%). Food was identified as the most common trigger across all age groups (45% to 63%). Seafood was the most common food trigger (57, 25%). A total of 420 (86.6%) children were treated with adrenaline, 451 (93%) received steroids and 411 (85%) received antihistamines. Sixty-three (13%) children fulfilled the criteria of severe anaphylaxis. There was no statistically significant association between severe anaphylaxis and the type of trigger (P = 0.851), nor an overall past history of atopy (P = 0.428). The only independent predictor for severe anaphylaxis was a previous drug allergy (P = 0.016). A very low prevalence of biphasic reactions (0.6% of study population) was noted in our study. Conclusion: We described the presentation and management of anaphylaxis in the Singapore population. A history of drug allergy is associated with severe presentation. Biphasic reactions are rare in our population</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 0304-4602 (Print)IS - 0304-4602 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28062882">PM:28062882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Acad Med Singapore\2016-45-542-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Acad Med Singapore\2016-45-542-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Ganapathy S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wojcik,A.</style></author><author><style face="normal" font="Arial"> Blaszkowska,J.</style></author><author><style face="normal" font="Arial"> Kurnatowski,P.</style></author><author><style face="normal" font="Arial"> Goralska,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology and Medical Parasitology, Medical University of Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Sandpits as a reservoir of potentially pathogenic fungi for children</style></title><secondary-title><style face="normal" font="Arial">Ann Agric Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Agric Environ Med</style></full-title></periodical><pages end="548" start="542">542-548</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcus</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcus neoformans</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Filamentous fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fusarium</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mycose</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rhodotorula</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Trichosporon</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="27" Month="9" Year="2016">2016/9/27</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION AND OBJECTIVE: Fungi belonging to various physiological and morphological groups present in the environment are potential human pathogens. Some of them are considered as emerging pathogens. Therefore, their presence in children's playgrounds should be regarded as health risk factor. MATERIALS AND METHOD: Sixty-eight samples of sand collected from 17 sandpits of different localities in Lodz, Poland, in autumn 2010 and 2011, and in spring 2011 and 2012 were evaluated. The fungi were isolated with classical mycological methods and identified on the basis of morphological and biochemical features. RESULTS: The prevalence of fungi in spring was 94.1% of sandpits in both layers of sand (depth 0-3 cm and 10-15 cm) and in one kindergarten sandpit, but only in a deeper layer. In autumn, fungi occurred in both layers in all sandpits (100%). The fungal concentration (CFU/g of sand) varied considerably (range 0 - uncountable) in both layers. A total of 352 isolates belonging to 80 species were found. There were 69 yeasts and yeast-like fungi isolates from 12 species (9 species in each season), and 283 filamentous fungi from 68 species: 35 species in spring and 55 in autumn, with 4 keratinolytic species. There were important causes of allergies, among them Cladosporium herbarum and Alternaria alternata, as well as of opportunistic mycoses: Cryptococcus neoformans, Aspergillus fumigatus and new and 'emerging' fungal pathogens e.g., Trichosporon, Rhodotorula, Fusarium and Scedosporium species. CONCLUSIONS: Potentially pathogenic fungi are present in the sand taken from sandpits in Lodz. This fact poses a significant threat to child health and therefore proper maintenance and periodic checking of sandpits are of great importance</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1898-2263 (Electronic)IS - 1232-1966 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5604/12321966.1226843</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030920">PM:28030920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Agric Environ Med\2016-23-542-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Agric Environ Med\2016-23-542-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Wojcik A</style></custom2><misc3><style face="normal" font="Arial">10.5604/12321966.1226843</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Minhas,J.</style></author><author><style face="normal" font="Arial"> Saryan,J.A.</style></author><author><style face="normal" font="Arial"> Balekian,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Lahey Hospital &amp; Medical Center, Burlington, Massachusetts.</style></auth-address><titles><title><style face="normal" font="Arial">Salmon roe (ikura)-induced anaphylaxis in a child</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="366" start="365">365-366</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Roe</style></keyword><keyword><style face="normal" font="Arial"> Salmon</style></keyword><keyword><style face="normal" font="Arial"> salmon roe</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017507">PM:28017507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161226-MinhasJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161226-MinhasJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161226, Minhas J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tuano,K.T.</style></author><author><style face="normal" font="Arial"> Dillard,K.H.</style></author><author><style face="normal" font="Arial"> Guffey,D.</style></author><author><style face="normal" font="Arial"> Davis,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine/Texas Children's Hospital, Houston, Texas</style></auth-address><titles><title><style face="normal" font="Arial">Development of sesame tolerance and cosensitization of sesame allergy with peanut and tree nut allergy in children</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="710" start="708">708-710</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nut allergy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28073703">PM:28073703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-708-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-708-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Tuano KT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chularojanamontri,L.</style></author><author><style face="normal" font="Arial"> Tuchinda,P.</style></author><author><style face="normal" font="Arial"> Pongparit,K.</style></author><author><style face="normal" font="Arial"> Pinkaew,S.</style></author><author><style face="normal" font="Arial"> Nuchkull,P.</style></author><author><style face="normal" font="Arial"> Kulthanan,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Contact urticaria caused by alcohol: Clinical characteristics and cross-reactions</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="723" start="721">721-723</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross-reactions</style></keyword><keyword><style face="normal" font="Arial"> crossreactions</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.09.434</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28073705">PM:28073705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-721-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2016-117-721-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Chularojanamontri L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.09.434</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsumoto,H.</style></author><author><style face="normal" font="Arial"> Kanemitsu,Y.</style></author><author><style face="normal" font="Arial"> Nagasaki,T.</style></author><author><style face="normal" font="Arial"> Tohda,Y.</style></author><author><style face="normal" font="Arial"> Horiguchi,T.</style></author><author><style face="normal" font="Arial"> Kita,H.</style></author><author><style face="normal" font="Arial"> Kuwabara,K.</style></author><author><style face="normal" font="Arial"> Tomii,K.</style></author><author><style face="normal" font="Arial"> Otsuka,K.</style></author><author><style face="normal" font="Arial"> Fujimura,M.</style></author><author><style face="normal" font="Arial"> Ohkura,N.</style></author><author><style face="normal" font="Arial"> Tomita,K.</style></author><author><style face="normal" font="Arial"> Yokoyama,A.</style></author><author><style face="normal" font="Arial"> Ohnishi,H.</style></author><author><style face="normal" font="Arial"> Nakano,Y.</style></author><author><style face="normal" font="Arial"> Oguma,T.</style></author><author><style face="normal" font="Arial"> Hozawa,S.</style></author><author><style face="normal" font="Arial"> Izuhara,Y.</style></author><author><style face="normal" font="Arial"> Ito,I.</style></author><author><style face="normal" font="Arial"> Oguma,T.</style></author><author><style face="normal" font="Arial"> Inoue,H.</style></author><author><style face="normal" font="Arial"> Tajiri,T.</style></author><author><style face="normal" font="Arial"> Iwata,T.</style></author><author><style face="normal" font="Arial"> Ono,J.</style></author><author><style face="normal" font="Arial"> Ohta,S.</style></author><author><style face="normal" font="Arial"> Hirota,T.</style></author><author><style face="normal" font="Arial"> Kawaguchi,T.</style></author><author><style face="normal" font="Arial"> Tamari,M.</style></author><author><style face="normal" font="Arial"> Yokoyama,T.</style></author><author><style face="normal" font="Arial"> Tabara,Y.</style></author><author><style face="normal" font="Arial"> Matsuda,F.</style></author><author><style face="normal" font="Arial"> Izuhara,K.</style></author><author><style face="normal" font="Arial"> Niimi,A.</style></author><author><style face="normal" font="Arial"> Mishima,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kinki Hokuriku Airway Disease Conference, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus enterotoxin sensitization involvement and its association with the CysLTR1 variant in different asthma phenotypes</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="203" start="197">197-203</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> asthma susceptibility</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> cysteinyl leukotriene receptor</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sensitization to Staphylococcus aureus enterotoxin (SE) is a known risk factor for asthma susceptibility and severity. However, how SE sensitization is involved in asthma, particularly nonatopic asthma and/or late-onset asthma, remains uncertain. OBJECTIVE: To clarify the involvement of SE sensitization in nonatopic and/or late-onset asthma and its association with a polymorphism of the cysteinyl leukotriene receptor 1 gene (CysLTR1), which was examined because CysLT signaling is closely associated with late-onset eosinophilic asthma. METHODS: We assessed associations between sensitization to SE (A and/or B) and clinical indexes in 224 patients with asthma (mean age, 62.3 years; 171 women) from a cohort of the Kinki Hokuriku Airway Disease Conference, particularly those with nonatopic asthma (not sensitized to common aeroallergens) and/or late-onset asthma. Associations between SE sensitization and CysLTR1 polymorphism (rs2806489), a potential regulatory variant for atopic predisposition in women, were also assessed in a sex-stratified manner. RESULTS: A total of 105 patients (47%) with asthma were sensitized to SE. Among patients with nonatopic asthma (n = 67) or with late-onset asthma (n = 124), those sensitized to SE had significantly higher serum total IgE and periostin levels than those not sensitized. In nonatopic patients, a rapid decrease in forced expiratory volume in 1 second was associated with SE sensitization. In women with asthma, rs2806489 was associated with sensitization to SEB and age at asthma onset. CONCLUSION: SE sensitization contributes to TH2 inflammation in nonatopic and/or late-onset asthma. In women with asthma, the CysLTR1 variant might be associated with sensitization to SEB and age at asthma onset</style></abstract><notes><style face="normal" font="Arial">DA - 20161230IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28034578">PM:28034578</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161230-MatsumotoH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161230-MatsumotoH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161230, Matsumoto H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohanty,R.P.</style></author><author><style face="normal" font="Arial"> Buchheim,M.A.</style></author><author><style face="normal" font="Arial"> Levetin,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biological Sciences, University of Tulsa, Tulsa, Oklahoma</style></auth-address><titles><title><style face="normal" font="Arial">Molecular approaches for the analysis of airborne pollen: A case study of Juniperus pollen</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="211" start="204">204-211</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Juniperus</style></keyword><keyword><style face="normal" font="Arial"> Labor</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Oklahoma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pollen monitoring is a common and vital tool in the field of allergy, creating awareness in pollen sensitive individuals. Traditionally, pollen monitoring has been based on conventional microscopic counting techniques that are labor intensive and limited in the identification to the genus or family level. Molecular techniques provide an alternative approach that is less labor intensive and enable identification of any species by its genetic fingerprint. OBJECTIVE: To use quantitative polymerase chain reaction (qPCR) to evaluate pollen concentrations in air samples. METHODS: Juniperus pollen was selected as our model because of the importance of this pollen in the southcentral United States. We analyzed 105 air samples collected with a Burkard spore trap from 2013 to 2015 using species-specific primers and probes. To evaluate the feasibility of a molecular approach, we used duplicate air samples that allowed us to compare results from classical identification based on light microscopy with our qPCR results. RESULTS: Pollen concentrations from the qPCR data were significantly correlated with concentrations determined through light microscopy (R = 0.902, P &lt; .001). We also confirmed an overlap in the pollination seasons between Juniperus ashei and Juniperus pinchotii and between J ashei and Juniperus virginiana. CONCLUSION: We found that this method correctly identified different Juniperus species present in mixed air samples in the southcentral United States, an accomplishment that cannot be achieved using microscopic identification. We conclude that the qPCR method is more accurate and sensitive than current pollen monitoring techniques and, therefore, has the potential to be used in various pollen monitoring stations</style></abstract><notes><style face="normal" font="Arial">DA - 20161227IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28024990">PM:28024990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161227-MohantyRP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161227-MohantyRP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161227, Mohanty RP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Sublett,J.L.</style></author><author><style face="normal" font="Arial"> Meadows,J.A.</style></author><author><style face="normal" font="Arial"> Calderon,M.</style></author><author><style face="normal" font="Arial"> Gross,G.N.</style></author><author><style face="normal" font="Arial"> Casale,T.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sirio Libanes, Sao Paulo, Brazil; University Hospital of Montpellier, Montpellier, France; Sorbonne Universites, Paris, France.</style></auth-address><titles><title><style face="normal" font="Arial">Perspectives on the International Classification of Diseases, 11th Revision, developments in allergy clinical practice in the United States</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="132" start="127">127-132</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161224IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - France -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28010916">PM:28010916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161224-TannoLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161224-TannoLK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161224, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Warren,K.J.</style></author><author><style face="normal" font="Arial"> Sweeter,J.M.</style></author><author><style face="normal" font="Arial"> Pavlik,J.A.</style></author><author><style face="normal" font="Arial"> Nelson,A.J.</style></author><author><style face="normal" font="Arial"> Devasure,J.M.</style></author><author><style face="normal" font="Arial"> Dickinson,J.D.</style></author><author><style face="normal" font="Arial"> Sisson,J.H.</style></author><author><style face="normal" font="Arial"> Wyatt,T.A.</style></author><author><style face="normal" font="Arial"> Poole,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary, Critical Care, Sleep &amp; Allergy Division, Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska</style></auth-address><titles><title><style face="normal" font="Arial">Sex differences in activation of lung-related type 2 innate lymphoid cells in experimental asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="234" start="233">233-234</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nebraska</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017508">PM:28017508</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161226-WarrenKJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20161226-WarrenKJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161226, Warren KJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Togias,A.</style></author><author><style face="normal" font="Arial"> Cooper,S.F.</style></author><author><style face="normal" font="Arial"> Acebal,M.L.</style></author><author><style face="normal" font="Arial"> Assa'ad,A.</style></author><author><style face="normal" font="Arial"> Baker,J.R.,Jr.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Block,J.</style></author><author><style face="normal" font="Arial"> Byrd-Bredbenner,C.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Fuchs,G.J.,III</style></author><author><style face="normal" font="Arial"> Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.J.</style></author><author><style face="normal" font="Arial"> Gupta,R.S.</style></author><author><style face="normal" font="Arial"> Habich,M.</style></author><author><style face="normal" font="Arial"> Jones,S.M.</style></author><author><style face="normal" font="Arial"> Keaton,K.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Plaut,M.</style></author><author><style face="normal" font="Arial"> Rosenwasser,L.J.</style></author><author><style face="normal" font="Arial"> Rotrosen,D.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Sidbury,R.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author><author><style face="normal" font="Arial"> Stukus,D.R.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Boyce,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Allergy and Infectious Diseases, Bethesda, Md</style></auth-address><titles><title><style face="normal" font="Arial">Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="173" start="166">166-173</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy. OBJECTIVES: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy. RESULTS: The addendum provides 3 separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation. CONCLUSIONS: Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28065802">PM:28065802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170109-TogiasA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170109-TogiasA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Togias A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jacobs,R.L.</style></author><author><style face="normal" font="Arial"> Ramirez,D.A.</style></author><author><style face="normal" font="Arial"> Rather,C.G.</style></author><author><style face="normal" font="Arial"> Andrews,C.P.</style></author><author><style face="normal" font="Arial"> Jupiter,D.C.</style></author><author><style face="normal" font="Arial"> Trujillo,F.</style></author><author><style face="normal" font="Arial"> Shulman,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biogenics Research Chamber, San Antonio, Texas.</style></auth-address><titles><title><style face="normal" font="Arial">Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="93" start="86">86-93</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge chamber</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> Late phase reaction</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase reaction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ocular symptoms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There are few direct data concerning symptom dynamics of allergic conjunctivitis (AC) in an allergen challenge chamber (ACC). OBJECTIVE: To determine the AC dynamics on subsequent exposures to ragweed pollen (RW) in individuals with allergic rhinitis in an ACC. To determine whether consecutive exposures in an ACC have any persistent detrimental ocular physical effects. METHODS: Participants underwent 3 exposures to RW in an ACC. Ocular symptoms of itching and tearing were self-assessed. Ocular redness and lid swelling were assessed by trained ophthalmic technicians. Complete ophthalmic examinations (COEs) were performed by an ophthalmologist. RESULTS: A total of 188 of 201 participants (93%) developed an ocular redness score of 2 or more in each eye in ACC exposure 1. Reproducibility of redness occurred in approximately 70% of individuals completing ACC exposures 1 through 3. There were no significant changes between baseline COE and end of study COE. Phenotypes were identified by redness responses during and after exposure. Baseline total ocular symptom scores, at 24 hours after a priming exposure, were identified as late-phase reactions rather than enhanced sensitivity. CONCLUSION: When assessed by trained professionals, AC was present with a very high frequency in selected individuals allergic to RW monitored in an ACC. Intrasubject reproducibility of redness was consistent across 3 ACC allergen exposures. Phenotypes were identified as early-phase responses, protracted early-phase responses, dual responses, and late-phase responses. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02079649</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Texas -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007090">PM:28007090</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-86-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-86-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Jacobs RL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,A.M.</style></author><author><style face="normal" font="Arial"> Wang,V.</style></author><author><style face="normal" font="Arial"> Philipp,A.</style></author><author><style face="normal" font="Arial"> Yusin,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, VA Greater Los Angeles Healthcare System, Los Angeles, California</style></auth-address><titles><title><style face="normal" font="Arial">Underuse of allergy services for patients having systemic reactions to Hymenoptera venom stings</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="367" start="366">366-367</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="7" Month="1" Year="2017">2017/1/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - California -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28073614">PM:28073614</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170111-PatelAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170111-PatelAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Patel AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Golden,D.B.</style></author><author><style face="normal" font="Arial"> Demain,J.</style></author><author><style face="normal" font="Arial"> Freeman,T.</style></author><author><style face="normal" font="Arial"> Graft,D.</style></author><author><style face="normal" font="Arial"> Tankersley,M.</style></author><author><style face="normal" font="Arial"> Tracy,J.</style></author><author><style face="normal" font="Arial"> Blessing-Moore,J.</style></author><author><style face="normal" font="Arial"> Bernstein,D.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Khan,D.</style></author><author><style face="normal" font="Arial"> Lang,D.</style></author><author><style face="normal" font="Arial"> Nicklas,R.</style></author><author><style face="normal" font="Arial"> Oppenheimer,J.</style></author><author><style face="normal" font="Arial"> Portnoy,J.</style></author><author><style face="normal" font="Arial"> Randolph,C.</style></author><author><style face="normal" font="Arial"> Schuller,D.</style></author><author><style face="normal" font="Arial"> Wallace,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Stinging insect hypersensitivity: A practice parameter update 2016</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="54" start="28">28-54</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007086">PM:28007086</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-28-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-28-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Golden DB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lawson,J.A.</style></author><author><style face="normal" font="Arial"> Chu,L.M.</style></author><author><style face="normal" font="Arial"> Rennie,D.C.</style></author><author><style face="normal" font="Arial"> Hagel,L.</style></author><author><style face="normal" font="Arial"> Karunanayake,C.P.</style></author><author><style face="normal" font="Arial"> Pahwa,P.</style></author><author><style face="normal" font="Arial"> Dosman,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence, risk factors, and clinical outcomes of atopic and nonatopic asthma among rural children</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="310" start="304">304-310</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma classification</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> overweight</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Saskatchewan</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Because of time and cost constraints, objective classification of atopic and nonatopic asthma has been limited in large epidemiologic studies. However, as we try to better understand exposure-outcome associations and ensure appropriate treatment of asthma, it is important to focus on phenotype-defined asthma classification. OBJECTIVE: To compare atopic and nonatopic asthma in rural children with regard to risk factors and clinical outcomes. METHODS: We conducted a cross-sectional study in rural Saskatchewan, Canada, in 2011. Parents of 6- to 14-year-old children completed a health and exposure survey. Skin prick tests were completed in a subsample of 529 children. Asthma was based physician diagnosis. Asthma status was defined as no asthma, nonatopic asthma, and atopic asthma. RESULTS: Asthma prevalence was 14.7% of which 32.1% of cases were atopic. After adjustment, early respiratory illness and a family history of asthma were predictors of childhood asthma, regardless of atopic status (P &lt; .05). Being overweight and having a dog in the home were associated with an increased risk of nonatopic asthma (P &lt; .05). A mother with a history of smoking increased the risk of atopic asthma (P = .01). Compared with those with nonatopic asthma, in the past 12 months, children with atopic asthma were more likely to report a sneezy, runny, or blocked nose or have shortness of breath (odds ratio >2), whereas those with nonatopic asthma were more likely to have parents who missed work (odd ratio >3). Those with nonatopic asthma had significantly lower forced expiratory volume in 1 second compared w2ith those with atopic asthma. CONCLUSION: Exposures may contribute differentially to atopic and nonatopic asthma and result in differential clinical presentation or burden. The study of these characteristics is important for etiologic understanding and management decisions</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087381">PM:28087381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170114-LawsonJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170114-LawsonJA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170114, Lawson JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perez-Rangel,I.</style></author><author><style face="normal" font="Arial"> Rodriguez Del,Rio P.</style></author><author><style face="normal" font="Arial"> Escudero,C.</style></author><author><style face="normal" font="Arial"> Sanchez-Garcia,S.</style></author><author><style face="normal" font="Arial"> Sanchez-Hernandez,J.J.</style></author><author><style face="normal" font="Arial"> Ibanez,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital Infantil Universitario Nino Jesus, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of high-dose rush oral immunotherapy in persistent egg allergic children: A randomized clinical trial</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="364" start="356">356-364</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Avoidance diet</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> egg oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold dose</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Egg oral immunotherapy is effective but time consuming. OBJECTIVE: To assess the efficacy and safety of egg rush oral immunotherapy (ROIT) with a targeted dose equivalent to a raw egg white. METHODS: Thirty-three persistent egg allergic children confirmed by double-blind, placebo-controlled food challenge (DBPCFC) were randomized to receive egg ROIT immediately after randomization (ROIT1 group), or to continue an egg avoidance diet for 5 months after randomization (control group [CG]). A 5-day build-up phase starting with the highest single tolerated dose at baseline DBPCFC was scheduled and several doses administered daily until achieving a dose of approximately 2,808 mg of egg white protein. In the maintenance phase, patients ate an undercooked egg every 48 hours for 5 months. The CG participants who failed the DBPCFC at 5 months began active treatment. Children from the ROIT1 group plus children from the CG who failed a second DBPCFC at 5 months and then received egg ROIT were randomized to the ROIT2 group. Adverse events (AEs) and immune marker evolution were recorded. RESULTS: A total of 17 (89%) of 19 children in the ROIT1 group and no CG patients were desensitized at 5 months (P &lt; .001). A total of 31 (97%) of the 32 children in the ROIT2 group completed the build-up phase in a median of 3 days (range, 1-14 days), and 30 (94%) of 32 maintained desensitization at 5 months. From baseline to 5 months of treatment, skin prick test, specific IgE, and specific IgE/IgG4 ratio to egg fractions significantly decreased, whereas specific IgG4 increased. During the build-up phase, AEs occurred in 69% of patients (50% had &lt;/=2 AEs) and 31% of doses (2% severe, 55% gastrointestinal). Lower threshold dose in the DBPCFC and higher egg white and ovalbumin specific IgE levels at baseline revealed an association with a higher rate of AEs. CONCLUSION: The proposed 5-day egg ROIT desensitized 94% of the allergic patients, with most AEs being mild or moderate</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087382">PM:28087382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170114-PerezRangelI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170114-PerezRangelI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170114, Perez-Rangel I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qi,S.</style></author><author><style face="normal" font="Arial"> Barnig,C.</style></author><author><style face="normal" font="Arial"> Charles,A.L.</style></author><author><style face="normal" font="Arial"> Poirot,A.</style></author><author><style face="normal" font="Arial"> Meyer,A.</style></author><author><style face="normal" font="Arial"> Clere-Jehl,R.</style></author><author><style face="normal" font="Arial"> de,Blay F.</style></author><author><style face="normal" font="Arial"> Geny,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universite de Strasbourg, Mitochondrie, Stress Oxydant et Protection Musculaire, Strasbourg, France</style></auth-address><titles><title><style face="normal" font="Arial">Effect of nasal allergen challenge in allergic rhinitis on mitochondrial function of peripheral blood mononuclear cells</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="369" start="367">367-369</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword></keywords><dates><year Day="7" Month="1" Year="2017">2017/1/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28073613">PM:28073613</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170111-QiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170111-QiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Qi S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sampath,V.</style></author><author><style face="normal" font="Arial"> Tupa,D.</style></author><author><style face="normal" font="Arial"> Graham,M.T.</style></author><author><style face="normal" font="Arial"> Chatila,T.A.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, California</style></auth-address><titles><title><style face="normal" font="Arial">Deciphering the black box of food allergy mechanisms</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="27" start="21">21-27</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> long-term follow-up</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To review our current understanding of immunotherapy, the immune mechanisms underlying food allergy, and the methodological advances that are furthering our understanding of the role of immune cells and other molecules in mediating food allergies. DATA SOURCES: Literature searches were performed using the following combination of terms: allergy, immunotherapy, food, and mechanisms. Data from randomized clinical studies using state-of-the-art mechanistic tools were prioritized. STUDY SELECTIONS: Articles were selected based on their relevance to food allergy. RESULTS: Current standard of care for food allergies is avoidance of allergenic foods and the use of epinephrine in case of severe reaction during unintentional ingestion. During the last few decades, great strides have been made in understanding the cellular and molecular mechanisms underlying food allergy, and this information is spearheading the development of exciting new treatments. CONCLUSION: Immunotherapy protocols are effective in desensitizing individuals to specific allergens; however, recurrence of allergic sensitization is common after discontinuation of therapy. Interestingly, in a subset of individuals, immunotherapy is protective against allergens even after discontinuation of immunotherapy. Whether this protection is permanent is currently unknown because of inadequate long-term follow-up data. Research on understanding the underlying mechanisms may assist in modifying protocols to improve outcome and enable sustained unresponsiveness, rather than a temporary relief against food allergies. The cellular changes brought about by immunotherapy are still a black box, but major strides in our understanding are being made at an exciting pace</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007085">PM:28007085</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-21-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-21-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Sampath V</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Estrada,A.</style></author><author><style face="normal" font="Arial"> Silvers,S.K.</style></author><author><style face="normal" font="Arial"> Klein,A.</style></author><author><style face="normal" font="Arial"> Zell,K.</style></author><author><style face="normal" font="Arial"> Wang,X.F.</style></author><author><style face="normal" font="Arial"> Lang,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Cleveland Clinic, Cleveland, Ohio.</style></auth-address><titles><title><style face="normal" font="Arial">Epidemiology of anaphylaxis at a tertiary care center: A report of 730 cases</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="85" start="80">80-85</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recent data reveal that the rate of anaphylaxis is increasing and suggest that idiopathic anaphylaxis may account for most of these cases. OBJECTIVE: To determine the pattern of anaphylaxis at a tertiary care referral center. METHODS: A retrospective electronic medical record review spanning 12 years (2002-2013) identified patients with anaphylaxis. RESULTS: Of the 4,777 records reviewed, 730 patients met our anaphylaxis definition. Median age was 34.0 years; 72.7% were adults, 58.6% were female, and 86.8% were white. Median time to evaluation by an allergist was 8.8 months. Foods were the most common cause (29.9%), followed by Hymenoptera venom (24.6%), idiopathic anaphylaxis (13.7%), and medications (13.3%). The most common foods were peanuts (23.9%), tree nuts (21.6%), shellfish (16.1%), and egg and milk (both 10.1%). The most common cause of anaphylaxis in adults was Hymenoptera venom. The most frequent symptoms were urticaria and/or angioedema, reported in 84.7% of cases. Atopy was present in 43.8%. In 15.4% of cases, anaphylaxis was not the chief reason for the office visit. CONCLUSION: We found food allergy was the most common overall cause of anaphylaxis, with peanut the most frequent food trigger. Idiopathic anaphylaxis was not the most common cause but accounted for 13.7% of all cases. Approximately 1 in 6 cases of anaphylaxis may be missed if a comprehensive evaluation is not performed</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007089">PM:28007089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-80-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-80-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Gonzalez-Estrada A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jiang,S.</style></author><author><style face="normal" font="Arial"> Han,S.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Che,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Food Science and Nutrition Engineering, China Agricultural University, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Inhibition effect of blunting Notch signaling on food allergy through improving TH1/TH2 balance in mice</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="102" start="94">94-102</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> intestinal permeability</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular permeability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Notch signaling regulates proliferation, differentiation, and function of dendritic cells, T cells, and mast cells, as well as many other immune cells, which act as important parts in food allergy, Notch signaling may play an important role in food allergy. OBJECTIVE: To investigate the role of Notch signaling in IgE-mediated food allergy. METHODS: An ovalbumin-induced food allergy mouse model was built (cholera toxin as adjuvant) and Notch signaling was blunted by FLI-06 and MW167, which inhibited Notch receptor-expressing phase and the gamma-secretase-affecting phase, respectively. Then food allergy indicators, including levels of serum antibodies, cytokines, and degranulation, were examined. Meanwhile, clinical features, such as vascular permeability changes, intestinal permeability changes, body temperature changes, and symptoms, were also observed. RESULTS: After blunting Notch signaling, the levels of serum ovalbumin specific IgE and IgG1 were decreased significantly, suggesting that blunting Notch signaling inhibited antibody responses. The levels of TH1 cytokines (interferon-gamma) were increased significantly, whereas the levels of TH2 cytokines (interleukin-4, -5, and -13) were decreased significantly, suggesting TH2 polarization was suppressed after blunting Notch signaling. The expression of T-bet was significantly increased, whereas the expression of Gata-3 was significantly reduced in both messenger RNA and protein levels, indicating TH2 polarization was inhibited and TH1 polarization was enhanced after blunting Notch signaling. Moreover, allergic clinical features of mice were alleviated after blunting Notch signaling. CONCLUSION: Food allergy was inhibited by blunting Notch signaling through suppressing TH2 polarization, enhancing TH1 cell differentiation and promoting TH1/TH2 balance in mice. Notch signaling plays a key role in IgE-mediated food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007091">PM:28007091</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-94-102.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-94-102.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Jiang S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agyemang,A.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="Arial">A 10-year-old girl with persistent ocular swelling</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="15" start="10">10-15</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.10.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007082">PM:28007082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-10-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-10-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Agyemang A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.10.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burmester,G.R.</style></author><author><style face="normal" font="Arial"> Choy,E.</style></author><author><style face="normal" font="Arial"> Kivitz,A.</style></author><author><style face="normal" font="Arial"> Ogata,A.</style></author><author><style face="normal" font="Arial"> Bao,M.</style></author><author><style face="normal" font="Arial"> Nomura,A.</style></author><author><style face="normal" font="Arial"> Lacey,S.</style></author><author><style face="normal" font="Arial"> Pei,J.</style></author><author><style face="normal" font="Arial"> Reiss,W.</style></author><author><style face="normal" font="Arial"> Pethoe-Schramm,A.</style></author><author><style face="normal" font="Arial"> Mallalieu,N.L.</style></author><author><style face="normal" font="Arial"> Wallace,T.</style></author><author><style face="normal" font="Arial"> Michalska,M.</style></author><author><style face="normal" font="Arial"> Birnboeck,H.</style></author><author><style face="normal" font="Arial"> Stubenrauch,K.</style></author><author><style face="normal" font="Arial"> Genovese,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Rheumatology and Clinical Immunology, Charite-University Medicine Berlin, Free University and Humboldt University of Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Low immunogenicity of tocilizumab in patients with rheumatoid arthritis</style></title><secondary-title><style face="normal" font="Arial">Ann Rheum Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Rheum Dis</style></abbr-1></periodical><pages end="1085" start="1078">1078-1085</pages><volume><style face="normal" font="Arial">76</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Subcutaneous (SC) and intravenous formulations of tocilizumab (TCZ) are available for the treatment of patients with rheumatoid arthritis (RA), based on the efficacy and safety observed in clinical trials. Anti-TCZ antibody development and its impact on safety and efficacy were evaluated in adult patients with RA treated with intravenous TCZ (TCZ-IV) or TCZ-SC as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODS: Data from 5 TCZ-SC and 8 TCZ-IV phase III clinical trials and 1 TCZ-IV clinical pharmacology safety study (>50 000 samples) were pooled to assess the immunogenicity profile of TCZ-SC and TCZ-IV (8974 total patients). The analysis included antidrug antibody (ADA) measurement following TCZ-SC or TCZ-IV treatment as monotherapy or in combination with csDMARDs, after dosing interruptions or in TCZ-washout samples, and the correlation of ADAs with clinical response, adverse events or pharmacokinetics (PK). RESULTS: The proportion of patients who developed ADAs following TCZ-SC or TCZ-IV treatment was 1.5% and 1.2%, respectively. ADA development was also comparable between patients who received TCZ monotherapy and those who received concomitant csDMARDs (0.7-2.0%). ADA development did not correlate with PK or safety events, including anaphylaxis, hypersensitivity or injection-site reactions, and no patients who developed ADAs had loss of efficacy. CONCLUSIONS: The immunogenicity risk of TCZ-SC and TCZ-IV treatment was low, either as monotherapy or in combination with csDMARDs. Anti-TCZ antibodies developed among the small proportion of patients had no evident impact on PK, efficacy or safety</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1468-2060 (Electronic)IS - 0003-4967 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United KIngdom -CO - United States -CO - Japan -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1136/annrheumdis-2016-210297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007755">PM:28007755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Rheum Dis\20161223-BurmesterGR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Rheum Dis\20161223-BurmesterGR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Burmester GR</style></custom2><misc3><style face="normal" font="Arial">10.1136/annrheumdis-2016-210297</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caldwell,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">TransAgra International, Inc., Storm Lake, IA 50588; email: jane.caldwell@transagra.com</style></auth-address><titles><title><style face="normal" font="Arial">Food Analysis Using Organelle DNA and the Effects of Processing on Assays</style></title><secondary-title><style face="normal" font="Arial">Annu Rev Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Annu Rev Food Sci Technol</style></full-title></periodical><pages end="74" start="57">57-74</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Authentication</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Fragmentation</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Analysis</style></keyword><keyword><style face="normal" font="Arial"> Food ingredients</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetically modified organism</style></keyword><keyword><style face="normal" font="Arial"> genetically modified organisms</style></keyword><keyword><style face="normal" font="Arial"> GMO</style></keyword><keyword><style face="normal" font="Arial"> GMOs</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Nuclear genes</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organelles</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">Extrachromosomal DNA such as organelle DNA are increasingly targeted in molecular detection assays where samples have been degraded by physical or chemical means. Owing to multiple organelles per cell and greater copy numbers than nuclear genes, organelle gene targets provide a more robust signal in polymerase chain reaction (PCR), quantitative PCR (qPCR), and other emerging molecular technologies. Because of these advantages, direct analysis of organelle DNA in food matrices is used for detection of contaminants and identification and authentication of food ingredients and allergens. Non-nuclear DNA is also used as an assay normalizer for detection of genetically modified organisms (GMOs) in foods. This review describes these protocols plus the effects of processing on efficacy, with special emphasis on thermally produced DNA fragmentation. Future research may incorporate molecular techniques beyond detection, used instead as time-temperature indicators in thermal food processing or quality indicators in food fermentation or acidification. Expected final online publication date for the Annual Review of Food Science and Technology Volume 8 is February 28, 2017. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 1941-1413 (Print)IS - 1941-1421 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1146/annurev-food-030216-030216</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28068490">PM:28068490</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Annu Rev Food Sci Technol\20170109-CaldwellJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Annu Rev Food Sci Technol\20170109-CaldwellJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Caldwell JM</style></custom2><misc3><style face="normal" font="Arial">10.1146/annurev-food-030216-030216</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,H.</style></author><author><style face="normal" font="Arial"> Hwang,M.H.</style></author><author><style face="normal" font="Arial"> Cho,M.</style></author><author><style face="normal" font="Arial"> Lee,D.G.</style></author><author><style face="normal" font="Arial"> Go,E.B.</style></author><author><style face="normal" font="Arial"> Cheong,Y.K.</style></author><author><style face="normal" font="Arial"> Kang,C.S.</style></author><author><style face="normal" font="Arial"> Lee,N.T.</style></author><author><style face="normal" font="Arial"> Chung,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison of blood glucose levels and allergic responses on treatment with six wheat cultivars</style></title><secondary-title><style face="normal" font="Arial">Appl Biol Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Biol Chem</style></full-title></periodical><pages end="16" start="11">11-16</pages><volume><style face="normal" font="Arial">60</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Glucose</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> glutenin</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Omega-5 gliadins</style></keyword><keyword><style face="normal" font="Arial"> Omega-5-gliadin</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2468-0842</style></isbn><abstract><style face="normal" font="Arial">Allergies and indigestion problems have increased in our society with increasing wheat consumption. Among wheat proteins, omega-5 gliadins (¤ë5-gliadins) and high molecular weight (HMW)-glutenin are known to be some of the major factors responsible for an allergic response and indigestion. Certain low molecular weight (LMW)-glutenin subunits are also able to promote local inflammation, and share common epitopes with ¤ë5-gliadins. It is known that different wheat cultivars have different combinations of HMW- and LMW-glutenins. We investigated the relationship between the composition of LMW-glutenins and the degree of allergic response or indigestion. The extent of allergic reaction and indigestion characteristics in response to six different wheat cultivars were compared. Patterns of the change of blood glucose level with time, which were employed to measure the indigestion, were quite different, depending on the type of wheat cultivars. The extent of allergic response, as measured with the histamine and IgE levels, was also quite different, depending on the type of wheat cultivars. In addition, the extents were not correlated with patterns of LMW-glutenin DNA and HMW/LMW glutenin protein of various wheat cultivars. The results from the present study suggest that some more other factors, together with factors studied above, need to be considered to better explain the physiological phenomena of variation in blood glucose level and allergic response</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13765-016-0241-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13765-016-0241-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Biol Chem\20170112-LeeH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Biol Chem\20170112-LeeH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Lee H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13765-016-0241-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uyeda,S.</style></author><author><style face="normal" font="Arial"> Sharmin,T.</style></author><author><style face="normal" font="Arial"> Satho,T.</style></author><author><style face="normal" font="Arial"> Irie,K.</style></author><author><style face="normal" font="Arial"> Watanabe,M.</style></author><author><style face="normal" font="Arial"> Hosokawa,M.</style></author><author><style face="normal" font="Arial"> Hiramatsu,Y.</style></author><author><style face="normal" font="Arial"> Koga,T.</style></author><author><style face="normal" font="Arial"> Nakashima,Y.</style></author><author><style face="normal" font="Arial"> Kashige,N.</style></author><author><style face="normal" font="Arial"> Toda,A.</style></author><author><style face="normal" font="Arial"> Mishima,K.</style></author><author><style face="normal" font="Arial"> Miake,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Enhancement and regulation effect of myrcene on antibody response in immunization with ovalbumin and Ag85B in mice</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="323" start="314">314-323</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mixing</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 immune response</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: MF59, which is an adjuvant belonging to C(3)(0) member of the terpene family, is a T helper type-2 (Th2)-biased immune enhancer. Our previous studies showed that pyriproxyfen, a member of the terpene family with fewer carbon atoms (C(2)(0)) than MF59, enhanced active T helper type-1 (Th1)-biased immune responses. OBJECTIVE: This study was performed to investigate the enhancement of antigen-specific immune responses by myrcene, a member of the terpene family with fewer carbon atoms (C(1)(0)) than pyriproxyfen. METHOD: Ovalbumin (OVA) was used as an antigen to determine the effects of myrcene on the immune response. The IgG subtypes and cytokines induced by immunization of OVA with or without myrcene were monitored. Thereafter, we determined the effects of myrcene in the immune response against Ag85B, which is a dominant protective antigen for tuberculosis. RESULTS: The results showed that 0.8 mg/dose of myrcene enhanced antigen-specific total IgG immune response to OVA. Direct mixing of the antigen with myrcene was required for the enhancement of antibody production. Myrcene increased OVA-specific IgG2a titer, suggesting induction of Th1-immune response. The level of Th1 cytokines, IFN-gamma was increased at 8 weeks after immunization, although IL-13 was also increased at the same time point. However, finally myrcene was found to increase Ag85B-specific total IgG titers at 5 weeks and specific IgG2a titer was increased at both 5 and 8 weeks. The results suggested that myrcene could enhance Th1 immune response. CONCLUSIONS: Myrcene enhanced specific immune responses against OVA and Ag85B. This study suggested the tendency of the enhancement of Th1 immune response by myrcene</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0734</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27543726">PM:27543726</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-314-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-314-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Uyeda S</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0734</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Visitsunthorn,N.</style></author><author><style face="normal" font="Arial"> Visitsunthorn,K.</style></author><author><style face="normal" font="Arial"> Aulla,S.</style></author><author><style face="normal" font="Arial"> Bunnag,C.</style></author><author><style face="normal" font="Arial"> Jirapongsananuruk,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of different local and imported histamine concentrations used as a skin prick test positive control</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="299" start="295">295-299</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The skin prick test (SPT) is a valid and approved tool that is used to diagnose atopic diseases. The SPT is accurate, safe, simple and inexpensive. However, the histamine concentration used as a positive control in the SPT varies among centers. OBJECTIVE: To compare SPT results using different concentrations of locally-prepared and imported histamine solutions. METHOD: This prospective, randomized, double-blind, self-controlled study was performed in healthy adult volunteers. The SPT was performed using 4 concentrations of histamine solutions (imported, 1 mg/mL; locally-prepared, 1, 5 and 10 mg/mL). Locally-prepared histamine positive controls were prepared from histamine biphosphate monohydrate using sterile technique. RESULTS: Seventy-five adult volunteers (mean age, 36 years) were included in the study. Eight volunteers were male and 9 had a history of atopy. Mean wheal diameter (MWD) for imported histamine was 3.49 mm for a concentration of 1 mg/mL, and that of locally-prepared histamine was 2.94 mm, 5.05 mm and 5.52 mm for concentrations of 1, 5 and 10 mg/mL histamine, respectively. Negative SPT results (MWD &lt;3 mm) were found in 11 subjects (14.7%) who received imported histamine and 26 subjects (34.7%) who received the locally-prepared histamine at concentration of 1 mg/mL. All subjects tested with locally-prepared histamine at concentrations of 5 and 10 mg/mL had a MWD > 3 mm. CONCLUSIONS: Locally-prepared histamine base at concentrations of 5 and 10 mg/mL yielded better positive results than both imported and locally-prepared histamine at a concentration of 1 mg/mL</style></abstract><notes><style face="normal" font="Arial">DA - 20160630IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0737</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27362402">PM:27362402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-295-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-295-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160630, Visitsunthorn N</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0737</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Komatsu,K.I.</style></author><author><style face="normal" font="Arial"> Takanari,J.</style></author><author><style face="normal" font="Arial"> Maeda,T.</style></author><author><style face="normal" font="Arial"> Kitadate,K.</style></author><author><style face="normal" font="Arial"> Sato,T.</style></author><author><style face="normal" font="Arial"> Mihara,Y.</style></author><author><style face="normal" font="Arial"> Uehara,K.</style></author><author><style face="normal" font="Arial"> Wakame,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hokkaido Pharmaceutical University School of Pharmacy, Sapporo, Hokkaido, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Perilla leaf extract prevents atopic dermatitis induced by an extract of Dermatophagoides farinae in NC/Nga mice</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="277" start="272">272-277</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> thymus and activation-regulated chemokine</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Perilla (Perilla frutescens Britton) leaf comprises many types of active components, mainly flavonoids, and acts as an anti-inflammatory agent in in vitro and in vivo atopic dermatitis (AD) models. OBJECTIVE: We investigated the effects of orally administered perilla leaf extract (PLE) on the symptoms of AD induced by Dermatophagoides farinae extract (DFE) in NC/Nga AD model mice. METHODS: The mice were allowed free intake of 0.5% PLE. Skin lesions were assessed, and blood was sampled from the caudal vein on days 0, 7, 14, 21, and 31. On day 31, all mice were sacrificed to obtain blood, skin, spleen, and intestinal tissue samples. RESULTS: The assessment scores of the skin lesions and total serum IgE levels of PLE-treated mice (PLE group) were significantly lower than DFE-treated mice (DFE group) on days 7, 14, and 21. On day 31, the serum periostin and thymus and activation-regulated chemokine (TARC) levels in the PLE group were significantly lower than those in the DFE group. Histological analysis of the skin revealed that hyperplasia of the epidermal and dermal layers and infiltration of inflammatory cells (cell infiltration in corium tissues) were suppressed by PLE. Periostin deposition was observed in the skin tissue obtained from the DFE group. Moreover, the CD4+/CD8+ ratio of splenic T cells was suppressed in the PLE group but not in the DFE group</style></abstract><notes><style face="normal" font="Arial">DA - 20160521IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0717</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27001658">PM:27001658</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-272-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2016-34-272-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160521, Komatsu KI</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0717</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,L.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> He,Q.</style></author><author><style face="normal" font="Arial"> Weng,X.</style></author><author><style face="normal" font="Arial"> Guan,M.</style></author><author><style face="normal" font="Arial"> Qiu,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Diseases, Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, China</style></auth-address><titles><title><style face="normal" font="Arial">Inhibition of TRPC3 downregulates airway hyperresponsiveness, remodeling of OVA-sensitized mouse</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="217" start="209">209-217</pages><volume><style face="normal" font="Arial">484</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous administration</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Airway hyperresponsiveness (AHR), airway remodeling and inflammation are the fundamental pathological alterations that occur in asthma. Transient receptor potential canonical 3 (TRPC3) has been implicated in diverse functions of airway smooth muscle cells (ASMCs) in asthma. However, the underlying mechanisms remain incompletely understood. We investigated the mRNA and protein expression of TRPC3 in ASMCs from normal and OVA-sensitized mouse. And the effects of inhibition or knockdown of TRPC3 with Ethyl-1- (4- (2,3,3-trichloroacrylamide) phenyl) -5 - (trifluoromethyl) -1H -pyrazole -4-carboxylate (Pyr3) and lentiviral shRNA on OVA-sensitized mouse AHR, airway remodeling, circulating inflammatory cytokines, cell proliferation and migration. We found that TRPC3 mRNA and protein expression levels were significantly increased in ASMCs from OVA-sensitized mouse. Inhibiting TRPC3 with continuous subcutaneous administration of Pyr3 decreased enhanced pause (Penh) of OVA-sensitized mouse. Meanwhile, both Pyr3 and lentiviral shRNA treatment of ASMCs in OVA-sensitized mouse significantly decreased their proliferation and migration. These results suggest that TRPC3 plays a critical role in asthma and represents a promising new target for asthma treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161230IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2016.12.138</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28034747">PM:28034747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20161230-WangL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20161230-WangL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161230, Wang L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2016.12.138</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Negi,S.S.</style></author><author><style face="normal" font="Arial"> Braun,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sealy Center for Structural Biology and Molecular Biophysics, Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555-0304, USASealy Center for Structural Biology and Molecular Biophysics, Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555-0304, USA</style></auth-address><titles><title><style face="normal" font="Arial">Cross-React: a new structural bioinformatics method for predicting allergen cross-reactivity</style></title><secondary-title><style face="normal" font="Arial">Bioinformatics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bioinformatics</style></full-title></periodical><pages end="1020" start="1014">1014-1020</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid composition</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Alignment</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="Arial">The phenomenon of cross-reactivity between allergenic proteins plays an important role to understand how the immune system recognizes different antigen proteins. Allergen proteins are known to cross-react if their sequence comparison shows a high sequence identity which also implies that the proteins have a similar 3D fold. In such cases, linear sequence alignment methods are frequently used to predict cross-reactivity between allergenic proteins. However, the prediction of cross-reactivity between distantly related allergens continues to be a challenging task. To overcome this problem, we developed a new structure-based computational method, Cross-React, to predict cross-reactivity between allergenic proteins available in the Structural Database of Allergens (SDAP). Our method is based on the hypothesis that we can find surface patches on 3D structures of potential allergens with amino acid compositions similar to an epitope in a known allergen. We applied the Cross-React method to a diverse set of seven allergens, and successfully identified several cross-reactive allergens with high to moderate sequence identity which have also been experimentally shown to cross-react. Based on these findings, we suggest that Cross-React can be used as a predictive tool to assess protein allergenicity and cross-reactivity. AVAILABILITY AND IMPLEMENTATION: Cross-React is available at: http://curie.utmb.edu/Cross-React.html CONTACT: ssnegi@utmb.edu</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1367-4811 (Electronic)IS - 1367-4803 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/bioinformatics/btw767</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28062447">PM:28062447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Bioinformatics\20170107-NegiSS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Bioinformatics\20170107-NegiSS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Negi SS</style></custom2><misc3><style face="normal" font="Arial">10.1093/bioinformatics/btw767</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tiwari,N.</style></author><author><style face="normal" font="Arial"> Gupta,V.K.</style></author><author><style face="normal" font="Arial"> Pandey,P.</style></author><author><style face="normal" font="Arial"> Patel,D.K.</style></author><author><style face="normal" font="Arial"> Banerjee,S.</style></author><author><style face="normal" font="Arial"> Darokar,M.P.</style></author><author><style face="normal" font="Arial"> Pal,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow 226015, India</style></auth-address><titles><title><style face="normal" font="Arial">Adjuvant effect of Asparagus racemosus Willd. derived saponins in antibody production, allergic response and pro-inflammatory cytokine modulation</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="561" start="555">555-561</pages><volume><style face="normal" font="Arial">86</style></volume><reprint-status date="01/15/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asparagus</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Safety evaluation</style></keyword><keyword><style face="normal" font="Arial"> Saponins</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="23" Month="12" Year="2016">2016/12/23</year></dates><abstract><style face="normal" font="Arial">The study manifests the immunoadjuvant potential of saponin rich fraction from Asparagus racemosus in terms of cellular and humoral immune response that can be exploited against microbial infections. Asparagus racemosus (AR) has been attributed as an adaptogen and rasayana in traditional medication systems for enhancing the host defence mechanism. Spectrophotometric and HPTLC analysis ensured the presence of saponins. The saponin rich fractions were tested for immunoadjuvant property in ovalbumin immunised mice for the humoral response, quantified in terms of prolonged antibody production upto a duration of 56days. Proinflammatory cytokines (IL-6 and TNF) were estimated for the cellular immune response in LPS stimulated primary murine macrophages. The safety evaluation in terms of cytotoxicity and allergic response has also been evaluated through in-vitro (MTT) and in-vivo (IgE) respectively. ARS significantly inhibited the pro-inflammatory cytokines, in LPS stimulated murine macrophages with no intrinsic cytotoxicity. The significant increase in IgG production infers the utility of ARS for prolonged humoral response. Further, the antigen specific response of IL-12 at early stage and IgE titres also suggests the generation of cellular immune response and low allergic reaction respectively, as compared to conventional adjuvants. IL-6 and TNF fluctuations in LPS stimulated and non-stimulated macrophages along with IgG and IL-12 also confirmed the Th1/Th2 modulating effect of ARS. The study indicates potential effect of ARS as an adjuvant for the stimulation of cellular immune response in addition to generating a sustained adaptive response without any adverse effects paving way for further validation with pathogenic organisms</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2016.11.087</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28024292">PM:28024292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2016-86-555-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2016-86-555-61.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2016-86-555-61mmc3.sml</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2016-86-555-61mmc3.sml</url></image-urls></urls><custom2><style face="normal" font="Arial">20161226, Tiwari N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2016.11.087</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ibeneme,S.</style></author><author><style face="normal" font="Arial"> Egbosionu,V.</style></author><author><style face="normal" font="Arial"> Ibeneme,G.</style></author><author><style face="normal" font="Arial"> Ezuma,A.</style></author><author><style face="normal" font="Arial"> Ettu,T.</style></author><author><style face="normal" font="Arial"> Nwankwo,J.</style></author><author><style face="normal" font="Arial"> Limaye,D.</style></author><author><style face="normal" font="Arial"> Nna,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evidence of Allergic Reactions and Cardiopulmonary Impairments among Traders Operating from Foodstuff Warehouses</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="1081258">1081258-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> Cardiac arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> forced vital capacity</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nigeria</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background. Foodstuff traders operating from warehouses (FTFW) are potentially exposed to dangerous rodenticides/pesticidesthat may have adverse effects on cardiopulmonary function. Methods. Fifty consenting male foodstuff traders, comprising 15traders (21-63 years) operating outside warehouses and 35 FTFW (20-64 years), were randomly recruited at Ogbete Market,Enugu, in a cross-sectional observational study of spirometric and electrocardiographic parameters. Seventeen FTFW (21-57 years)participated in focus group discussions. Qualitative and quantitative data were analysed thematically and with independent ..-testand Pearson correlation coefficient at .. &lt; 0.05, respectively. Results. Most FTFW experienced respiratory symptoms, especiallydry cough (97.1%) and wheezing (31.4%) with significant reductions in forced vital capacity (FVC) (.. = -2.654; .. = 0.011), forcedexpiratory volume in one second (FEV1) (.. = -2.240; .. = 0.030), maximum expiratory flow rate (FEF200-1200) (.. = -1.148;.. = -0.047), and forced end-expiratory flow (FEF25-75) (.. = -1.11; .. = 0.007). The maximum mid-expiratory flow (FEF25-75) wasmarginally decreased (.. > 0.05)with a significantly prolonged (.. &lt; 0.05)QTc interval. Conclusion. Allergic response was evident inthe FTFW. Significant decrease in FVC may negatively impact lung flow rates and explains themarginal decrease in FEF25-75, whichimplies a relative limitation in airflow of peripheral/distal airways and elastic recoil of the lungs.This is consistent with obstructivepulmonary disease; a significant decrease in FEF75-85/FEV1 supports this conclusion. Significant decrease in FEF200-1200 indicatesabnormalities in the large airways/larynx just as significantly prolonged ventricular repolarization suggests cardiac arrhythmias.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Nigeria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/1081258</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1155/2016/1081258</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2016-2016-1081258.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2016-2016-1081258.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Ibeneme S</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/1081258</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takashima,T.</style></author><author><style face="normal" font="Arial"> Ohnuma,T.</style></author><author><style face="normal" font="Arial"> Fukamizo,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Advanced Bioscience, Kindai University, 3327-204, Nakamachi, Nara, 631-8505, Japan</style></auth-address><titles><title><style face="normal" font="Arial">NMR assignments and ligand-binding studies on a two-domain family GH19 chitinase allergen from Japanese cedar (Cryptomeria japonica) pollen</style></title><secondary-title><style face="normal" font="Arial">Biomol NMR Assign</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomol NMR Assign</style></full-title></periodical><pages end="90" start="85">85-90</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Catalytic Domain</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chitin</style></keyword><keyword><style face="normal" font="Arial"> Chitinase</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria japonica</style></keyword><keyword><style face="normal" font="Arial"> dimer</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> NMR spectra</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A two-domain family GH19 chitinase from Japanese cedar (Cryptomeria japonica) pollen, CJP-4, which consists of an N-terminal CBM18 domain and a GH19 catalytic domain, is known to be an important allergen, that causes pollinosis. We report here the resonance assignments of the NMR spectrum of CJP-4. The backbone resonances were almost completely assigned, and the secondary structure was estimated based on the chemical shift values. The addition of a chitin dimer to the enzyme solution perturbed the chemical shifts of the resonances of amino acid residues forming a long extended binding site spanning from the CBM18 domain to the GH19 catalytic domain</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1874-270X (Electronic)IS - 1874-270X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12104-016-9725-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28032262">PM:28032262</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomol NMR Assign\20161229-TakashimaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomol NMR Assign\20161229-TakashimaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Takashima T</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12104-016-9725-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eissa,S.</style></author><author><style face="normal" font="Arial"> Zourob,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemistry, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Road, Riyadh 11533, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="Arial">In vitro selection of DNA aptamers targeting beta-lactoglobulin and their integration in graphene-based biosensor for the detection of milk allergen</style></title><secondary-title><style face="normal" font="Arial">Biosens Bioelectron</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biosens Bioelectron</style></abbr-1></periodical><pages end="174" start="169">169-174</pages><volume><style face="normal" font="Arial">91</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Aptamers</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Biosensor</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Detection methods</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electrochemical biosensor</style></keyword><keyword><style face="normal" font="Arial"> Electrodes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> Voltammetry</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="10" Month="12" Year="2016">2016/12/10</year></dates><abstract><style face="normal" font="Arial">Food allergy has increased rapidly in recent years affecting millions of people worldwide. With the increased consumption of packed food nowadays, a sensitive, accurate and rapid screening method for potential food allergens has become an urgent need in order to protect the sensitive consumers from life-threatening reactions. The current detection methods for food allergens are mostly based on immunoassays which are costly and times-consuming. In this work, we developed an aptamer/graphene-based electrochemical biosensor for on-step, sensitive and low cost detection of beta-lactoglobulin (beta-LG) milk protein, one of the most common food allergens specially in infants. The selection of DNA aptamers against the two beta-LG variants A and B was successfully realised using systemic evolution of ligands by exponential enrichment (SELEX) method. Among the selected aptamers, BLG14 aptamer sequence has shown high affinity and specificity to both beta-LG A and B with dissociation constants (Kds) of 82 and 80nM, respectively as calculated using fluorescence binding assays. The aptamer was then integrated in a voltammetric biosensor utilizing graphene-modified screen printed carbon electrodes. The binding is monitored by following the change in the square wave voltammetry (SWV) reduction peak signal of ferrocyanide/ferricyanide redox couple due to the removal of the negatively charged aptamers from the surface upon protein binding. This one-step "signal on" biosensor takes 20min for the sensitive and selective detection of beta-LG without using any labelling or sophisticated designs. The method was also tested in spiked food sample extract achieving good recovery percentage. The integration of the novel aptamer in the graphene biosensor allows a promising way for cost-effective, rapid and sensitive on-site detection of milk allergen in food stuff</style></abstract><notes><style face="normal" font="Arial">DA - 20161222IS - 1873-4235 (Electronic)IS - 0956-5663 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bios.2016.12.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28006685">PM:28006685</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biosens Bioelectron\2016-91-169-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biosens Bioelectron\2016-91-169-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161222, Eissa S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bios.2016.12.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valent,P.</style></author><author><style face="normal" font="Arial"> Akin,C.</style></author><author><style face="normal" font="Arial"> Metcalfe,D.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine I, Division of Hematology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Mastocytosis 2016: Updated WHO Classification and Novel Emerging Treatment Concepts</style></title><secondary-title><style face="normal" font="Arial">Blood</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Blood</style></abbr-1></periodical><pages end="1427" start="1420">1420-1427</pages><volume><style face="normal" font="Arial">129</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neoplasms</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Over the past few years substantial advances have been made in understanding the pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and prognostic parameters and novel therapeutic targets with demonstrable clinical impact have been identified. A number of these new markers, molecular targets, and therapeutic approaches have been validated and translated into clinical practice. At the same time, the classification of mastocytosis and related diagnostic criteria have been refined and updated by the consensus group and the World Health Organization (WHO). As a result, more specific therapies tailored towards prognostic sub-groups of patients have been developed. Emerging treatment concepts employ drugs directed against KIT and other relevant targets in neoplastic mast cells, and will hopefully receive recognition by health authorities in the near future. The current article provides an overview of recent developments in the field, with emphasis on the updated WHO classification, refined criteria, additional prognostic parameters, and novel therapeutic approaches. Based on these emerging concepts, the prognosis, quality of life, and survival of patients with advanced mastocytosis are expected to improve in the coming years</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1528-0020 (Electronic)IS - 0006-4971 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1182/blood-2016-09-731893</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28031180">PM:28031180</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Blood\20161229-ValentP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Blood\20161229-ValentP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Valent P</style></custom2><misc3><style face="normal" font="Arial">10.1182/blood-2016-09-731893</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barberan,J.</style></author><author><style face="normal" font="Arial"> Garcia-Perez,F.J.</style></author><author><style face="normal" font="Arial"> Villena,V.</style></author><author><style face="normal" font="Arial"> Fernandez-Villar,A.</style></author><author><style face="normal" font="Arial"> Malmierca,E.</style></author><author><style face="normal" font="Arial"> Salas,C.</style></author><author><style face="normal" font="Arial"> Gimenez,M.J.</style></author><author><style face="normal" font="Arial"> Granizo,J.J.</style></author><author><style face="normal" font="Arial"> Aguilar,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Internal Medicine Dpt., Hospital Universitario Monteprincipe, Universidad San Pablo-CEU, Boadilla del Monte, Avda. Monteprincipe 25, 28660, Boadilla del Monte, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Development of Aspergillosis in a cohort of non-neutropenic, non-transplant patients colonised by Aspergillus spp</style></title><secondary-title><style face="normal" font="Arial">BMC Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Infect Dis</style></full-title></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Respiratory samples</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A previous study explored factors discriminating colonization and true infection among non-transplant, non-neutropenic patients with repeated Aspergillus spp. isolation from lower respiratory samples. The present study explored the evolution of patients with Aspergillus colonization in that study to determine the percentage of cases progressing to aspergillosis and time to development. METHODS: Clinical records were retrospectively reviewed (for each patient from his end date in the past study) and data from all respiratory processes suffered by patients up to April 2015 were recorded. Comparisons of variables were performed between colonized patients that developed aspergillosis and those that did not. A Kaplan-Meier curve was used to describe time to development of aspergillosis in chronic obstructive pulmonary disease (COPD) patients for II-IV stages of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. RESULTS: Sixty seven colonized patients were followed, 12 of them (17.9%) developed aspergillosis. Diagnoses included six tracheobronchitis (4 invasive, 2 simple tracheobronchitis), four pulmonary disease (2 invasive pulmonary aspergillosis, 2 chronic pulmonary aspergillosis), one allergic bronchopulmonary aspergillosis and one pulmonary aspergilloma. Up to 47 (70.4%) of the study patients presented COPD. Among patients developing aspergillosis COPD was more frequent (100%) than among those that did not develop aspergillosis (35 out of 55; 63.6%) (p = 0.012), as well as GOLD IV patients were more frequent among COPD patients developing aspergillosis than among COPD patients that did not (50.0 vs. 26.1%, p = 0.046). Mean time to development of aspergillosis was 18.4 months (median: 8.5) with a wide range (1-58). Overtime, the percentage of patients developing aspergillosis was significantly higher among GOLD IV patients than among GOLD II-III patients (p = 0.032). CONCLUSIONS: The high percentage of cases progressing to aspergillosis among colonized patients, especially among those with COPD (25.5%), stresses the importance of colonization as risk factor, and creates awareness of the possible change from colonization to invasive disease in GOLD IV patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170106IS - 1471-2334 (Electronic)IS - 1471-2334 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12879-016-2143-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28056830">PM:28056830</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Infect Dis\2017-17-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Infect Dis\2017-17-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170106, Barberan J</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12879-016-2143-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Plant,J.D.</style></author><author><style face="normal" font="Arial"> Neradilek,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">SkinVet Clinic, 15800 Upper Boones Ferry Road, Suite 120, Lake Oswego, 97035, OR, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Effectiveness of regionally-specific immunotherapy for the management of canine atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">BMC Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Vet Res</style></full-title></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE assays</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Canine atopic dermatitis is a common pruritic skin disease often treated with allergen immunotherapy (AIT). AIT in dogs traditionally begins with attempting to identify clinically relevant environmental allergens. Current allergen testing methodologies and immunotherapy techniques in dogs are not standardized. Immunotherapy with a mixture of allergenic extracts selected based on regional aerobiology rather than intradermal tests or serum IgE assays has been described. The objective of this study was to evaluate the effectiveness of regionally-specific immunotherapy in dogs with atopic dermatitis. The medical records of a veterinary dermatology referral clinic were searched for dogs with atopic dermatitis that began regionally-specific subcutaneous immunotherapy from June, 2010 to May, 2013. An overall assessment of treatment effectiveness (excellent, good, fair, or poor) was assigned based upon changes in pruritus severity, lesion severity, and the reduction in concurrent medication(s) during a follow-up period of at least 270 days. Baseline characteristics that might predict treatment success were analyzed with the Spearman's correlation and the Kruskal-Wallis tests. RESULTS: Of the 286 dogs that began regionally-specific immunotherapy (RESPIT) during a 3 year period, 103 met the inclusion criteria. The overall response to RESPIT was classified as excellent in 19%, good in 38%, fair in 25%, and poor in 18% of dogs. The response classification correlated significantly with a reduction in pruritus severity (r = 0.72, p &lt; 0.001) and lesion severity (r = 0.54, p &lt; 0.001), but not with the dogs' baseline characteristics. Adverse reactions were reported in 7/286 (2.4%) of treated dogs. CONCLUSIONS: Under the conditions of this study, RESPIT was safe and effective for the treatment of atopic dermatitis in dogs</style></abstract><notes><style face="normal" font="Arial">DA - 20170106IS - 1746-6148 (Electronic)IS - 1746-6148 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12917-016-0917-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28056956">PM:28056956</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Vet Res\2017-13-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Vet Res\2017-13-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170106, Plant JD</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12917-016-0917-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wise,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">London</style></auth-address><titles><title><style face="normal" font="Arial">Processed meat is linked to asthma symptoms, study finds</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="i6807">i6807-</pages><volume><style face="normal" font="Arial">355</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> processed meat</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.i6807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007708">PM:28007708</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2016-355-i6807.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2016-355-i6807.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Wise J</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.i6807</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wise,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">London</style></auth-address><titles><title><style face="normal" font="Arial">Leucotriene receptor antagonists for asthma can save millions, says NICE</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="i6835">i6835-</pages><volume><style face="normal" font="Arial">355</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="27" Month="12" Year="2016">2016/12/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.i6835</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28031161">PM:28031161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2016-355-i6835.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2016-355-i6835.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Wise J</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.i6835</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tirado-Rodriguez,B.</style></author><author><style face="normal" font="Arial"> Huerta-Yepez,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergies: diseases closely related to cancer</style></title><secondary-title><style face="normal" font="Arial">Bol Med Hosp Infant Mexico</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bol Med Hosp Infant Mexico</style></full-title></periodical><pages end="445" start="432">432-445</pages><volume><style face="normal" font="Arial">73</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alergias</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> AllergoOncology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Carcinogens</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Immunosurveillance</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocitos</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TGF-+¦</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1665-1146</style></isbn><abstract><style face="normal" font="Arial">Allergies are hypersensitivity reactions that occur through specific type Th2 immunological mechanisms characterized by different soluble mediators, as well as specific cells of the immune system. In recent decades, evidence has emerged relating this disease with cancer development. However, most of the results of epidemiology studies have been controversial and contradictory. There are mainly two trends. While the first indicates that allergies can reduce the risk of cancer, the other indicates that they may increase this risk. The first trend can be explained by the immunosurveillance hypothesis, which states that the increased immune surveillance after the immune hyper-responsiveness can inhibit or exert a protective effect against the development of cancer. Similarly, the prophylaxis hypothesis suggests that the physical effects of allergy symptoms can prevent cancer by removing potential carcinogens. In contrast, the opposing hypothesis propose that there is a deviation of the immune response toward Th2, which favors the development of cancer, or that the process of chronic inflammation favors the generation of mutations, and therefore the development of cancer. With the purpose of understanding more about these two hypotheses, the main soluble and cellular factors of allergic diseases that could be playing a key role in the development or inhibition of cancer were considered in this review</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bmhimx.2016.11.006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.bmhimx.2016.11.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Bol Med Hosp Infant Mexico\2016-73-432-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Bol Med Hosp Infant Mexico\2016-73-432-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Tirado-Rodriguez B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bmhimx.2016.11.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nic Dhonncha,E.</style></author><author><style face="normal" font="Arial"> Clowry,J.</style></author><author><style face="normal" font="Arial"> Dunphy,M.</style></author><author><style face="normal" font="Arial"> Buckley,C.</style></author><author><style face="normal" font="Arial"> Field,S.</style></author><author><style face="normal" font="Arial"> Paul,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University Hospital Waterford, Waterford, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a common, chronic pruritic inflammatory condition, with an estimated prevalence of 15-30% in children, and 2-10% in adults.1 Pathogenesis of AD is complex, and remains incompletely understood. Th1, Th2 and Th17 have been reported to play a role.2 Treatment of severe AD is challenging, with currently licensed systemic agents being limited by adverse effects and suboptimal therapeutic responses. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161222IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15262</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28005276">PM:28005276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20161222-NicDhonnchaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20161222-NicDhonnchaE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161222, Nic Dhonncha E</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15262</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rahlenbeck,S.</style></author><author><style face="normal" font="Arial"> Utikal,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">German Federal Environmental Agency, Berlin, GermanySkin Cancer Unit, German Cancer Research Center, Heidelberg, and Department of Dermatology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany</style></auth-address><titles><title><style face="normal" font="Arial">The oak processionary moth: a new health hazard?</style></title><secondary-title><style face="normal" font="Arial">Br J Gen Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Gen Pract</style></abbr-1></periodical><pages end="436" start="435">435-436</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">637</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenal Cortex</style></keyword><keyword><style face="normal" font="Arial"> Adrenal Cortex Hormones</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Bronchodilator Agents</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Contact</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Antagonists</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insect Proteins</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Moths</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="8" Year="2015">2015/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20150727IS - 1478-5242 (Electronic)IS - 0960-1643 (Linking)LA - engPT - Journal ArticleRN - 0 (Adrenal Cortex Hormones)RN - 0 (Bronchodilator Agents)RN - 0 (Histamine Antagonists)RN - 0 (Insect Proteins)RN - 99332-51-1 (thaumetopoein protein, insect)SB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3399/bjgp15X686341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26212843">PM:26212843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Gen Pract\2015-65-435-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Gen Pract\2015-65-435-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150727, Rahlenbeck S</style></custom2><misc3><style face="normal" font="Arial">10.3399/bjgp15X686341</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brom,L.</style></author><author><style face="normal" font="Arial"> Mendonca,T.N.</style></author><author><style face="normal" font="Arial"> Oliveira,F.R.</style></author><author><style face="normal" font="Arial"> Sarti,W.</style></author><author><style face="normal" font="Arial"> Lima Melo,J.M.</style></author><author><style face="normal" font="Arial"> De Paula Arruda,L.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">New biologicals for asthma: anti interleukin-5 therapy</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="204" start="197">197-204</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biologicals</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-197-204.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-197-204.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170102, Brom L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yao,J.</style></author><author><style face="normal" font="Arial"> Sbihi,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Population and Public Health, University of British Columbia, Vancouver, BC.</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of non-food allergies among non-immigrants, long-time immigrants and recent immigrants in Canada</style></title><secondary-title><style face="normal" font="Arial">Can J Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Can J Public Health</style></full-title></periodical><pages end="e466" start="e461">e461-e466</pages><volume><style face="normal" font="Arial">107</style></volume><number><style face="normal" font="Arial">4-5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> health survey</style></keyword><keyword><style face="normal" font="Arial"> Immigrants</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="12" Year="2016">2016/12/27</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: The prevalence of allergic conditions has been increasing worldwide, with the highest rates seen in Western countries like Canada. The development of allergies is known to be related to both genetic and environmental factors, but the causal pathways remain unclear. Studies on immigrants provide a unique opportunity to disentangle these two factors and provide a better understanding of the disease aetiology. The aim of this study was to investigate the relationship between immigration status and prevalence of non-food allergies in a population-based study of Canadians. METHODS: Data of 116,232 respondents from the Canadian Community Health Survey (Cycle 3.1, 2005) were used in a multivariable logistic regression to assess the association between immigration status (non-immigrant, long-time immigrant [&amp;gt;10 years] and recent immigrant [&lt;/=10 years]) and self-reported doctor-diagnosed non-food allergies, adjusting for potential confounders. RESULTS: The highest prevalence of non-food allergies was found among non-immigrants (29.6%), followed by long-time immigrants (23.9%) and then recent immigrants (14.3%). The odds of non-food allergies were reduced by 60% (OR = 0.40, 95% CI: 0.35, 0.45) among recent immigrants and 25% (OR = 0.75, 95% CI: 0.70, 0.80) among long-time immigrants, compared with non-immigrants, after adjusting for sex, age, socio-economic status and rurality. CONCLUSION: This study finds a distinctly lower prevalence of non-food allergies among immigrants compared with non-immigrants, with the difference diminishing with longer duration of residence in Canada. The findings highlight the potential of environmental determinants of allergy development that warrant further investigation, and demonstrate the need for multicultural strategies to manage the public health burden of allergic conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20161227IS - 1920-7476 (Electronic)IS - 0008-4263 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.17269/cjph.107.5614</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28026714">PM:28026714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Can J Public Health\2016-107-e461-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Can J Public Health\2016-107-e461-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161227, Yao J</style></custom2><misc3><style face="normal" font="Arial">10.17269/cjph.107.5614</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boehm,T.</style></author><author><style face="normal" font="Arial"> Pils,S.</style></author><author><style face="normal" font="Arial"> Gludovacz,E.</style></author><author><style face="normal" font="Arial"> Szoelloesi,H.</style></author><author><style face="normal" font="Arial"> Petroczi,K.</style></author><author><style face="normal" font="Arial"> Majdic,O.</style></author><author><style face="normal" font="Arial"> Quaroni,A.</style></author><author><style face="normal" font="Arial"> Borth,N.</style></author><author><style face="normal" font="Arial"> Valent,P.</style></author><author><style face="normal" font="Arial"> Jilma,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Quantification of human diamine oxidase</style></title><secondary-title><style face="normal" font="Arial">Clin Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Biochem</style></full-title></periodical><pages end="451" start="444">444-451</pages><volume><style face="normal" font="Arial">50</style></volume><number><style face="normal" font="Arial">7-8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> DAO</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Heparin</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Diamine oxidase (DAO) is essential for extracellular degradation of histamine. For decades activity assays with inherent limitations were used to quantify the relative amounts of DAO. No reference DAO standard is available. Absolute DAO amounts cannot be determined. Controversy exists, whether DAO is circulating or not in non-pregnant individuals. The role of DAO as biomarker in various diseases is ambiguous. It is not clear, whether precise quantification of human DAO antigen using commercially available enzyme-linked immunosorbent assays (ELISAs) is possible. The objective was to develop a precise and robust ELISA to quantify DAO in various biological fluids. DESIGN AND METHODS: A research prototype ELISA was established using a mouse monoclonal antibody for capturing and a polyclonal rabbit serum IgG fraction for the detection of human DAO. The limit of blank (LoB), limit of detection (LoD) and estimated limit of quantification (eLoQ) and normal DAO concentrations in serum and plasma were determined. RESULTS: The LoB, LoD and eLoQ derived from 42 standard curves are 0.27, 0.48 and 0.7ng/mL respectively. The detection range using the LoD as the lower and the highest DAO standard as the upper boundary is 0.5 to 450ng/mL. Serum and plasma mean/median concentrations are between 0.5 and 1.5ng/mL in healthy volunteers (n=58) and mastocytosis patients (n=19) and plateau at approximately 145ng/mL (n=16) during pregnancy. Accurate quantification was not influenced by heparin (DAO is a heparin-binding protein), lipaemic or hemolytic serum. The measured DAO antigen concentrations are in close agreement with published enzymatic activity data using radioactive putrescine as substrate. CONCLUSIONS: This research prototype ELISA is able to reliably and accurately quantify human DAO in different biological fluids. The potential of DAO as biomarker in various diseases can be evaluated</style></abstract><notes><style face="normal" font="Arial">DA - 20170102IS - 1873-2933 (Electronic)IS - 0009-9120 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clinbiochem.2016.12.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28041932">PM:28041932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Biochem\20170102-BoehmT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Biochem\20170102-BoehmT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170102, Boehm T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clinbiochem.2016.12.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smiljanic,K.</style></author><author><style face="normal" font="Arial"> Apostolovic,D.</style></author><author><style face="normal" font="Arial"> Trifunovic,S.</style></author><author><style face="normal" font="Arial"> Ognjenovic,J.</style></author><author><style face="normal" font="Arial"> Perusko,M.</style></author><author><style face="normal" font="Arial"> Mihajlovic,L.</style></author><author><style face="normal" font="Arial"> Burazer,L.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Cirkovic,V.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Belgrade - Faculty of Chemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia</style></auth-address><titles><title><style face="normal" font="Arial">Sub-pollen particles are rich carriers of major short ragweed allergens and NADH dehydrogenases: quantitative proteomic and allergomic study</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="828" start="815">815-828</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amb a 1</style></keyword><keyword><style face="normal" font="Arial"> Amb a 3</style></keyword><keyword><style face="normal" font="Arial"> Amb a 4</style></keyword><keyword><style face="normal" font="Arial"> Amb a 6</style></keyword><keyword><style face="normal" font="Arial"> Amb a 8</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enolase</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Polygalacturonase</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Ragweed allergens</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shotgun proteomics</style></keyword><keyword><style face="normal" font="Arial"> Subpollen particles</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Short ragweed (Ambrosia artemisiifolia) allergies affect more than 36 million people annually. Ragweed pollen grains release sub-pollen particles (SPP) of respirable size upon hydration or a change in air electrical conditions. The aim of this study was to characterise the proteomes and allergomes of short ragweed SPP and total pollen protein extract (TOT), and compare their effects with those of standard aqueous pollen protein extract (APE) using sera from short ragweed pollen-sensitized patients. METHODS: Quantitative 2D gel-based and shotgun proteomics, 1D and 2D immunoblotting, and quantitative ELISA were applied. Novel SPP extraction and preparation protocols enabled appropriate sample preparation and further downstream analysis by quantitative proteomics. RESULTS: The SPP fraction contained the highest proportion (94%) of the allergome, with the largest quantities of the minor Amb a 4 and major Amb a 1 allergens, and as unique, NADH dehydrogenases. APE was the richest in Amb a 6, Amb 5, and Amb a 3, and TOT fraction was the richest in the Amb a 8 allergens (83% and 89% of allergome, respectively). Allergenic potency correlated well among the three fractions tested, with 1D immunoblots demonstrating a slight predominance of IgE-reactivity to SPP compared to TOT and APE. However, the strongest IgE binding in ELISA was noted against APE. New allergenic candidates, phosphoglycerate mutase and phosphoglucomutase, were identified in all the three pollen fractions. Enolase, UTP-glucose-1-phosphate uridylyltransferase, and polygalacturonase were observed in SPP and TOT fractions as novel allergens of the short ragweed pollen, as previously described. CONCLUSION AND CLINICAL RELEVANCE: We demonstrated that the complete major (Amb a 1 and 11) and almost all minor (Amb a 3, 4, 5, 6, 8, and 9) short ragweed pollen allergen repertoire as well as NADH oxidases are present in SPP, highlighting an important role for SPP in allergic sensitization to short ragweed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Serbia -CO - Sweden -CO - Serbia -CO - United States -CO - South Korea -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12874</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000951">PM:28000951</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161221-SmiljanicK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161221-SmiljanicK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Smiljanic K</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12874</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feldman,S.</style></author><author><style face="normal" font="Arial"> Kasjanski,R.</style></author><author><style face="normal" font="Arial"> Popowski,J.</style></author><author><style face="normal" font="Arial"> Hernandez,D.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Norton,J.E.</style></author><author><style face="normal" font="Arial"> Suh,L.</style></author><author><style face="normal" font="Arial"> Carter,R.G.</style></author><author><style face="normal" font="Arial"> Stevens,W.W.</style></author><author><style face="normal" font="Arial"> Peters,A.T.</style></author><author><style face="normal" font="Arial"> Kern,R.C.</style></author><author><style face="normal" font="Arial"> Conley,D.B.</style></author><author><style face="normal" font="Arial"> Tan,B.K.</style></author><author><style face="normal" font="Arial"> Shintani-Smith,S.</style></author><author><style face="normal" font="Arial"> Welch,K.C.</style></author><author><style face="normal" font="Arial"> Grammer,L.C.</style></author><author><style face="normal" font="Arial"> Harris,K.E.</style></author><author><style face="normal" font="Arial"> Kato,A.</style></author><author><style face="normal" font="Arial"> Schleimer,R.P.</style></author><author><style face="normal" font="Arial"> Hulse,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Airway Inflammation Provides a Unique Environment for B Cell Activation and Antibody Production</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="466" start="457">457-466</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antibody secreting cell</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> class switch recombination</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISpot</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Germinal Center</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Luminex assay</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tonsil</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: B cells play many roles in health and disease. However, little is known about the mechanisms that drive B cell responses in the airways, especially in humans. Chronic rhinosinusitis (CRS) is an inflammatory disease of the upper airways that affects 10% of Europeans and Americans. A subset of CRS patients develop nasal polyps (NP), which are characterized by type 2 inflammation, eosinophils and group 2 innate lymphoid cells (ILC2). We have reported that NP contain elevated levels of B cells and antibodies, making NP an ideal system for studying B cells in the airways. OBJECTIVE: We sought to determine the mechanisms that drive B cell activation and antibody production during chronic airway inflammation. METHODS: We analyzed B cells from NP or tonsil, or after ILC2 co-culture, by flow cytometry. Antibody production from tissue was measured using Luminex assays, and the frequency of antibody-secreting cells by ELISpot. Formation of B cell clusters was assessed using immunohistochemistry. Expression of genes associated with B cell activation and class switch recombination was measured by qRT-PCR. RESULTS: NP contained significantly elevated frequencies of plasmablasts, especially those that expressed the extra follicular marker Epstein-Barr virus-induced protein 2 (EBI2), but significantly fewer germinal center (GC) B cells compared to tonsil. Antibody production and the frequency of antibody-secreting cells were significantly elevated in NP, and there was evidence for local class switch recombination in NP. Finally, ILC2s directly induced EBI2 expression on B cells in vitro. CONCLUSIONS AND CLINICAL RELEVANCE: Our data suggest there is a unique B cell activation environment within NP that is distinct from classic GC-mediated mechanisms. We show for the first time that ILC2s directly induce EBI2 expression on B cells, indicating that ILC2s may play an important role in B cell responses. B cell-targeted therapies may provide new treatment options for CRSwNP. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12878</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000955">PM:28000955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20161221-FeldmanS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20161221-FeldmanS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Feldman S</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12878</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guevara,B.E.</style></author><author><style face="normal" font="Arial"> Dayrit,J.F.</style></author><author><style face="normal" font="Arial"> Haddad,V.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Southern Philippines Medical Center, Davao City, PhilippinesDepartment of Dermatology, Research Institute of Tropical Medicine, Muntinlupa, Metro Manila, PhilippinesDepartment of Dermatology, Botucatu Medical School, Sao Paulo State University, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Delayed allergic dermatitis presenting as a keloid-like reaction caused by sting from an Indo-Pacific Portuguese man-o'-war (Physalia utriculus)</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="184" start="182">182-184</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Philippines</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="Arial">Cnidarian envenomations are common occurrences in the tropics that can affect holidaymakers. The cutaneous reactions are classified as immediate or delayed types. Delayed allergic reactions are persistently recurring dermatitis, which can occur within 1-4 weeks from the initial sting, and may last for several months. Hypertrophic scar-like or keloid-like reactions are rare, and are believed to be a type IV hypersensitivity reaction to sequestered antigens from stinging filaments. We report an unusual case of delayed allergic dermatitis with keloid-like presentation caused by Physalia utriculus</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Philippines -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.13003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28044352">PM:28044352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20170103-GuevaraBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20170103-GuevaraBE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Guevara BE</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.13003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,H.J.</style></author><author><style face="normal" font="Arial"> Kim,B.M.</style></author><author><style face="normal" font="Arial"> Shin,S.</style></author><author><style face="normal" font="Arial"> Kim,T.Y.</style></author><author><style face="normal" font="Arial"> Chung,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Superoxide Dismutase 3 attenuates experimental Th2-driven allergic conjunctivitis</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="54" start="49">49-54</pages><volume><style face="normal" font="Arial">176</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">Allergic conjunctivitis is an inflammatory eye disease mediated by Th2 type immune response. The role of extracellular superoxide dismutase 3 (SOD3) in immune response and allergic conjunctival inflammation was examined in a murine model for experimental allergic conjunctivitis (EAC). Allergic conjunctivitis was induced in mice by allergen challenge with ovalbumin in alum via the conjunctival sac. SOD3 was topically applied and allergy indicators were compared. Clinical signs associated with conjunctivitis, such as OVA-specific IgE production, IgG1/G2a ratio and eosinophil infiltration, were drastically reduced in mice treated with SOD3. They also had less dendritic cells and CD4+ T cells in conjunctiva than controls. Attenuated allergic inflammation was accredited to reduced Th2 type cytokine responses and increased Treg cytokine in draining lymph node. The characteristics of EAC were attributed to the absence of SOD3. Our findings suggest that SOD3 might be considered as a potential target for Th2 driven allergic conjunctival inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170108IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2016.12.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063939">PM:28063939</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20170108-LeeHJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\20170108-LeeHJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170108, Lee HJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2016.12.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">da Silva,D.M.</style></author><author><style face="normal" font="Arial"> Vieira,T.M.</style></author><author><style face="normal" font="Arial"> Pereira,A.M.</style></author><author><style face="normal" font="Arial"> de Sousa Moreira,A.M.</style></author><author><style face="normal" font="Arial"> Delgado,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servico de Imunoalergologia, Centro Hospitalar Sao Joao, Porto, Portugal ; Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, Porto University, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Cross-reactive LTP sensitization in food-dependent exercise-induced urticaria/anaphylaxis: a pilot study of a component-resolved and in vitro depletion approach</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="46">46-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen microarray</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Ara h 9</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Art v 3</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baker's asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cor a 8</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> FDEIA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food-dependent exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ISAC 112</style></keyword><keyword><style face="normal" font="Arial"> Jug r 3</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Pla a 3</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tri a 14</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Challenge tests for food-dependent exercise-induced anaphylaxis (FDEIA) carry some risk and have a high rate of false negatives. Our aim was to explore the usefulness of an in vitro immunodepletion assay and an allergen microarray test in the identification of IgE-mediated cross-reactive food allergens in patients with suspected FDEIA or food-dependent exercise-induced urticaria and panallergen sensitization. METHODS: Three patients with a history of food dependent exercise induced urticaria/anaphylaxis and food panallergen sensitization in whom a food-exercise challenge was not feasible were selected: a 25-year-old man with cholinergic urticaria who experienced generalized urticaria and angioedema during a soccer match after drinking a peach-based soft drink; a 19-year-old woman with allergic rhinitis and controlled asthma who experienced anaphylactic shock while playing soccer, having eaten walnuts in the previous 90 min; and a 57-year-old man with baker's asthma who experienced four episodes of anaphylaxis during exercise after ingesting wheat-containing food. All individuals underwent a diagnostic work-up with skin prick tests, specific IgE (sIgE) and ImmunoCAP ISAC test. For the in vitro immunodepletion procedure, patients' serum was pre-incubated with the suspected native allergen (peach, walnut, or wheat) in solid phase (ImmunoCAP). The eluted serum, containing unbound IgE, was collected and samples were re-tested using Immunocap ISAC 112 and compared with baseline results. RESULTS: All individuals were sensitized to lipid transfer proteins. The first patient was sensitized to Pru p 3, Cor a 8, Jug r 3, and Ara h 9; after pre-incubation with peach there was 100% depletion of sIgE to all components. The second patient was sensitized to Pru p 3, Cor a 8, Jug r 3, and Ara h 9; immunodepletion with walnut depleted sIgE to Ara h 9 by 67%, Pru p 3 and Pla a 3 (60%), Art v 3 (75%), Jug r 3 (88%), and Cor a 8 (100%). The third patient was sensitized to Pru p 3, Jug r 3, Ara h 9, and Tri a 14; immunodepletion with wheat depleted Tri a 14 only (100%). CONCLUSIONS: In vitro immunodepletion might be a useful diagnostic tool in food dependent exercise induced urticaria/anaphylaxis with panallergen sensitization, particularly for identifying the culprit allergen and guiding dietary elimination recommendations</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0136-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28031785">PM:28031785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\2016-6-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\2016-6-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, da Silva DM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0136-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kocaturk,E.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Grattan,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Okmeydani Training and Research Hospital, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Looking forward to new targeted treatments for chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Ligelizumab</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU. Off-licence uses of currently available drugs include rituximab and tumour necrosis factor inhibitors. Ligelizumab (anti-IgE), canakinumab (anti-IL-1), AZD1981 (a PGD2 receptor antagonist) and GSK 2646264 (a selective Syk inhibitor) are currently in clinical trials for CSU. Examples of drugs that could target potential pathophysiological targets in CSU include substance P antagonists, designed ankyrin repeat proteins, C5a/C5a receptor inhibitors, anti-IL-4, anti-IL-5 and anti-IL-13 and drugs that target inhibitory mast cell receptors. Other mediators and receptors of likely pathogenic relevance should be explored in skin profiling and functional proof of concept studies. The exploration of novel therapeutic targets for their role and relevance in CSU should help to achieve a better understanding of its etiopathogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 2045-7022 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Turkey -CO - Germany -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0139-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078079">PM:28078079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Kocaturk E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0139-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brandt,N.</style></author><author><style face="normal" font="Arial"> Garvey,L.H.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,U.</style></author><author><style face="normal" font="Arial"> Kjaer,H.F.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Mortz,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Three cases of anaphylaxis following injection of a depot corticosteroid with evidence of IgE sensitization to macrogols rather than the active steroid</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Excipients</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Macrogol</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We present three cases with anaphylaxis after injection of a depot corticosteroid. First, the steroid was suspected as the elicitor, but after evaluation the excipient macrogol was found to be the elicitor. One of the patients had reactions to several unrelated drugs. Increased awareness of anaphylaxis to excipients such as macrogols is needed, especially when allergy tests for the active drug is negative and in patients with a history of repeated anaphylaxis to seemingly unrelated drugs. To establish the correct diagnosis it is important to test with the exact formulation of the culprit drug, as well as all the ingredients including excipients</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0138-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078080">PM:28078080</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Brandt N</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0138-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhital,S.</style></author><author><style face="normal" font="Arial"> Warren,F.J.</style></author><author><style face="normal" font="Arial"> Butterworth,P.J.</style></author><author><style face="normal" font="Arial"> Ellis,P.R.</style></author><author><style face="normal" font="Arial"> Gidley,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a ARC Centre of Excellence in Plant Cell Walls , Centre for Nutrition and Food Sciences, Queensland Alliance for Agriculture and Food Innovation, The University of Queensland , St Lucia , Australia</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms of starch digestion by alpha-amylase-Structural basis for kinetic properties</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="892" start="875">875-892</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> alpha-Amylase</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> cell walls</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme digestion</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro digestibility</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">Recent studies of the mechanisms determining the rate and extent of starch digestion by alpha-amylase are reviewed in the light of current widely-used classifications for (a) the proportions of rapidly-digestible (RDS), slowly-digestible (SDS), and resistant starch (RS) based on in vitro digestibility, and (b) the types of resistant starch (RS 1,2,3,4...) based on physical and/or chemical form. Based on methodological advances and new mechanistic insights, it is proposed that both classification systems should be modified. Kinetic analysis of digestion profiles provides a robust set of parameters that should replace the classification of starch as a combination of RDS, SDS, and RS from a single enzyme digestion experiment. This should involve determination of the minimum number of kinetic processes needed to describe the full digestion profile, together with the proportion of starch involved in each process, and the kinetic properties of each process. The current classification of resistant starch types as RS1,2,3,4 should be replaced by one which recognizes the essential kinetic nature of RS (enzyme digestion rate vs. small intestinal passage rate), and that there are two fundamental origins for resistance based on (i) rate-determining access/binding of enzyme to substrate and (ii) rate-determining conversion of substrate to product once bound</style></abstract><notes><style face="normal" font="Arial">DA - 20150309IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2014.922043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="25751598">PM:25751598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\2017-57-875-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\2017-57-875-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150309, Dhital S</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2014.922043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">James,C.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy: an updated review of safety</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="59" start="55">55-59</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Allergen immunotherapy is the only modality that can modify the immune response upon exposure to aeroallergens and venom allergens. This review will update the allergist on recent studies evaluating safety of sublingual and subcutaneous allergen immunotherapy. RECENT FINDINGS: Multiple clinical trials and retrospective studies have been published evaluating overall safety of these therapies. The risk of systemic reactions with subcutaneous immunotherapy remains quite low, but near-fatal and fatal anaphylaxis does occur, requiring physicians to be aware of potential risks for such events. Sublingual immunotherapy has a high incidence of local site application reactions, but severe anaphylactic events are very uncommon. SUMMARY: Subcutaneous immunotherapy and sublingual immunotherapy are beneficial in treating allergic rhinitis and venom hypersensitivity but should be administered only by physicians familiar with potential risk factors and able to manage treatment-related local and systemic allergic reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000335</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906697">PM:27906697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-55-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-55-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, James C</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000335</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ridolo,E.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Gritti,B.L.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDepartment of Clinical &amp; Experimental Medicine, University of Parma, Parma bASST Centro Specialistico G. Pini /CTO, Milan cAllergy and Respiratory Diseases, IRCCS San Martino-IST-University of Genoa, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">The current overuse and misuse of meta-analyses on sublingual immunotherapy: the case of grass pollen allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="16" start="12">12-16</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Meta-analysis provides the highest level of evidence-based efficacy of a medical treatment or intervention. Allergen immunotherapy in its two forms of subcutaneous immunotherapy and sublingual immunotherapy (SLIT) is an effective treatment of respiratory allergy as shown by meta-analyses, but in recent years there has been an overflow of meta-analyses on SLIT, with contrasting results that may generate confusion among physicians. RECENT FINDINGS: It can be observed that flaws are often present in meta-analyses including: incorrect selection of trials, inappropriate use of evaluation parameters for the analysis, and unsuitable analyses. For instance, it is clear that a meta-analysis of several small studies does not predict the results of a single large study that remains the gold standard to assess the efficacy and safety of a treatment. To assess the interest of the matter, we calculated the number of citations of meta-analyses on SLIT efficacy in the 10 years after the first publication in 2005 and detected a continuous decrease in citations. SUMMARY: Today, the appropriateness of a meta-analysis should be carefully evaluated, taking into account that a meta-analysis uses a statistical approach to combine the results from multiple small studies to increase power, to improve estimates of the size of the effect, and/or to resolve uncertainty when reports disagree. Editors and reviewers of medical journals should consider that to judge a meta-analysis requires a high level of expertise that is obvious in reviewers belonging to the Cochrane organization</style></abstract><notes><style face="normal" font="Arial">DA - 20161206IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000330</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27922912">PM:27922912</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-12-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-12-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161206, Ridolo E</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000330</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,T.R.</style></author><author><style face="normal" font="Arial"> Sur,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Internal Medicine, Department of Allergy and Immunology, UTMB Health, Galveston, Texas, USA</style></auth-address><titles><title><style face="normal" font="Arial">IgE and eosinophils as therapeutic targets in asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="49" start="42">42-49</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Asthma is a chronic inflammatory disorder characterized by reversible airflow obstruction, which is being more widely recognized as a broad-spectrum disease that encompasses multiple patient characteristics and pathophysiologic mechanisms. Suboptimal asthma control leads to increasing burden of healthcare costs and loss of productivity to society. Biologic therapies targeted at IgE and eosinophils can be used in poorly controlled allergic and eosinophilic asthma, respectively. The purpose of this review is to analyze the advancements in currently available biologic therapies targeted at IgE and eosinophils in asthma and to identify how these therapies may impact overall healthcare costs. RECENT FINDINGS: Omalizumab is an anti-IgE antibody that is approved for use of poorly controlled moderate-to-severe asthma. Many studies have confirmed that omalizumab not only improves quality of life and symptom scores, but also decreases urgent care and emergency department visits and hospitalizations. Dupilumab is a biologic agent targeted at TH2 cytokines, but indirectly impacts IgE and is an important biologic agent for atopic disease. Mepolizumab, reslizumab, and benralizumab target IL-5, a key cytokine for eosinophils. For patients with poorly controlled eosinophilic asthma, these biologic agents improve asthma symptoms, reduce exacerbations, and reduce emergency visits and hospitalizations. SUMMARY: Poorly controlled severe asthma affects a small portion of patients with asthma in the United States and yet it accounts for large portion of healthcare utilization. Biological therapies in poorly controlled severe persistent asthma have been identified to reduce healthcare utilization, including emergency visits and hospitalizations. Biologic agents have a clear beneficial role in the management of severe asthma, and further evaluations should be continued in identifying optimal patient characteristics for the various agents and overall benefit toward healthcare utilization and cost</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906698">PM:27906698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-42-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-42-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Patel TR</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000336</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reiber,R.</style></author><author><style face="normal" font="Arial"> Wolf,H.</style></author><author><style face="normal" font="Arial"> Schnitker,J.</style></author><author><style face="normal" font="Arial"> Wustenberg,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">HNO-Praxis, 73614, Schorndorf, GermanyALK-Abello Arzneimittel GmbH, Clinical Development/Medical Department, Griegstrasse 75, Haus 25, 22763, Hamburg, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study</style></title><secondary-title><style face="normal" font="Arial">Drugs Real World Outcomes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Drugs Real World Outcomes</style></abbr-1></periodical><pages end="74" start="65">65-74</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="1" Year="2017">2017/1/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: For causal treatment by allergy immunotherapy (AIT) a single or few allergen products for the clinically most relevant allergens are applied to treat multiple allergies, but few data on the tolerability of multiple AIT applications are available. OBJECTIVE: The aim of our study was to investigate safety and tolerability in patients treated by subcutaneous immunotherapy (SCIT) and concomitant SCIT or sublingual immunotherapy (SLIT) products. METHODS: In a non-interventional, observational study in Germany treatment of patients with a primary SCIT and concomitant AIT (SCIT or SLIT) was documented during the first 4 months of treatment. Adverse events (AEs) were recorded by the physicians and by patients in diaries, and coded using the Medical Dictionary for Regulatory Activities (MedDRA). RESULTS: Three hundred and seven patients were treated with the primary SCIT by 79 allergists, and 271 received a concomitant AIT. AEs were reported in 92 (33.9%) patients and adverse drug reactions (ADRs) in 63 (23.2%) patients related to the primary SCIT and in 69 (25.5%) to the concomitant AIT; six (2.2%) patients discontinued due to ADRs. ADRs were mild or moderate in 40 (14.8%) patients, severe in 23 (8.5%), and serious in one patient. The most frequent reactions were local swelling and pruritus. Overall tolerability was assessed as 'good' or 'very good' by 95.6% of patients and 96.7% of physicians. CONCLUSIONS: Compared with data from a large previous study no increase in the frequency of ADRs in real life or change in the tolerability profile was observed for SCIT with concomitant SCIT or SLIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 2199-1154 (Print)IS - 2198-9788 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40801-016-0103-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28070824">PM:28070824</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs Real World Outcomes\20170110-ReiberR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs Real World Outcomes\20170110-ReiberR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Reiber R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40801-016-0103-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tham,R.</style></author><author><style face="normal" font="Arial"> Katelaris,C.H.</style></author><author><style face="normal" font="Arial"> Vicendese,D.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Lowe,A.J.</style></author><author><style face="normal" font="Arial"> Bowatte,G.</style></author><author><style face="normal" font="Arial"> Taylor,P.</style></author><author><style face="normal" font="Arial"> Burton,P.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Erbas,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">The role of outdoor fungi on asthma hospital admissions in children and adolescents: A 5-year time stratified case-crossover analysis</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="49" start="42">42-49</pages><volume><style face="normal" font="Arial">154</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Chaetomium</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Coprinus</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> effect modification</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisations</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictive model</style></keyword><keyword><style face="normal" font="Arial"> Predictive models</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> spore count</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="12" Year="2016">2016/12/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Some fungal spores can trigger asthma exacerbation but knowledge of which outdoor fungal spores contribute to asthma hospitalisation is limited. OBJECTIVES: To examine the role of outdoor fungal spores in child and adolescent asthma hospitalisations. METHODS: We conducted a bi-directional time-stratified case-crossover study of child and adolescent asthma hospitalisations over 5 years. Conditional logistic regression assessed the role of 20 fungi taxa (Same day [L0] and lagged [L1-3]) adjusted for maximum temperature, humidity and grass pollen. Strata specific effects were explored if there was evidence of effect modification by age, sex, air pollutants or grass pollen. Non-linear effects examined with Generalized Additive Models. RESULTS: Of 2098 children hospitalised for asthma, 60% were boys; mean age was 5.5+/-3.7 years. Fungal spore counts peaked during warm months. Regression models found weak associations with Coprinus [L0,L1: OR=1.03, 1.01-1.06], Periconia [L0: OR=1.03, 1.001-1.07] and Chaetomium [L2: OR=1.08, 1.0-1.2]. Sex appeared to act as an effect modifier with girls having stronger associations with Cladosporium, Coprinus and total fungi. Older adolescent (14-18 years) hospitalisation was significantly associated with Coprinus and Ustilago/smuts. Air pollutants and grass pollen did not appear to act as effect modifiers. Non-linearity was not detected. CONCLUSION: There may be associations between some outdoor fungal spores and asthma hospitalisations. Further research needed to explore whether these findings can be replicated; and examine whether fungal sensitisation and/or human rhinovirus infections are associated with stronger effects. If findings are replicated, then the need to develop predictive models for fungal spore distribution and levels may become more important</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2016.12.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28024227">PM:28024227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2016-154-42-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2016-154-42-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161226, Tham R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2016.12.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dilidaer</style></author><author><style face="normal" font="Arial"> Zheng,Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Hu,X.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Hu,L.</style></author><author><style face="normal" font="Arial"> Han,M.</style></author><author><style face="normal" font="Arial"> Wang,D.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head and Neck Surgery, Affiliated Eye, Ear, Nose and Throat Hospital, Fudan University, No. 83, Fenyang Road, Shanghai, 200031, China</style></auth-address><titles><title><style face="normal" font="Arial">Increased BAFF expression in nasal polyps is associated with local IgE production, Th2 response and concomitant asthma</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="1890" start="1883">1883-1890</pages><volume><style face="normal" font="Arial">274</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-Cell Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> BAFF</style></keyword><keyword><style face="normal" font="Arial"> CD20</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory load</style></keyword><keyword><style face="normal" font="Arial"> Local IgE</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> real-time RT-PCR</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">B-cell activating factor of the TNF family is critical for the survival and maturation of B cells and play a role in the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP). In this study, nasal tissues were enrolled from 25 CRSwNP patients (asthmatic, 16; non-asthmatic, 9), 12 CRSsNP patients and ten control subjects, respectively. The immunoreactivity of BAFF, CD20 and CD138 were examined using immunohistochemistry staining. The mRNA expression of BAFF, CD20, epsilonGLT, AID, GATA3 and CRTH2 were examined using real-time RT-PCR. The protein levels of BAFF, IL-5 and IgE were measured using ELISA assays and the Unicap system, respectively. We found the numbers of BAFF+ cells, CD20+ cells (B cells) and CD138+ cells (plasma cells) were significantly increased in polyp tissues compared with control groups. The concentrations of BAFF, IgE and IL-5 in tissue homogenates were also significantly increased in polyp tissues compared with control groups, and the BAFF protein level in the polyp homogenates was significantly associated with the IgE and IL-5 levels and with concomitant asthma in CRSwNP patients. Our findings indicate that BAFF expression is significantly increased in CRSwNP patients and may orchestrate inflammatory load in polyp tissues by regulating T and B cell-mediated response</style></abstract><notes><style face="normal" font="Arial">DA - 20161230IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-016-4435-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28035475">PM:28035475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20161230-Dilidaer.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20161230-Dilidaer.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161230, Dilidaer</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-016-4435-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Crepy,M.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Occupational Diseases, Paris University Hospital, Centre Hotel-Dieu, AP-HP 1, Parvis Notre-Dame, 75004 Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Rubber: new allergens and preventive measures</style></title><secondary-title><style face="normal" font="Arial">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Dermatol</style></full-title></periodical><pages end="530" start="523">523-530</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Glove</style></keyword><keyword><style face="normal" font="Arial"> Glove Manufacturing</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> New allergens</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> Occupational skin diseases</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="Arial">Natural rubber latex (NRL) and rubber accelerators are well-known causes of occupational skin diseases. The latest epidemiological data on rubber allergy show that rubber additives are still among the allergens most strongly associated with occupational contact dermatitis, however, a decrease in NRL allergy has been confirmed. A review of recent publications on rubber allergens based on the Pubmed database is presented. New glove manufacturing processes have been developed, such as low-protein natural rubber gloves, vulcanisation accelerator-free gloves, or specific-purpose gloves containing antimicrobial agents or moisturisers. Several websites provide information on allergens found in gloves and/or glove choice according to occupation</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1684/ejd.2016.2765</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007673">PM:28007673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Dermatol\2016-26-523-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Dermatol\2016-26-523-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Crepy MN</style></custom2><misc3><style face="normal" font="Arial">10.1684/ejd.2016.2765</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carruthers,M.N.</style></author><author><style face="normal" font="Arial"> Park,S.</style></author><author><style face="normal" font="Arial"> Slack,G.W.</style></author><author><style face="normal" font="Arial"> Dalal,B.I.</style></author><author><style face="normal" font="Arial"> Skinnider,B.F.</style></author><author><style face="normal" font="Arial"> Schaeffer,D.F.</style></author><author><style face="normal" font="Arial"> Dutz,J.P.</style></author><author><style face="normal" font="Arial"> Law,J.K.</style></author><author><style face="normal" font="Arial"> Donnellan,F.</style></author><author><style face="normal" font="Arial"> Marquez,V.</style></author><author><style face="normal" font="Arial"> Seidman,M.</style></author><author><style face="normal" font="Arial"> Wong,P.C.</style></author><author><style face="normal" font="Arial"> Mattman,A.</style></author><author><style face="normal" font="Arial"> Chen,L.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, Canada</style></auth-address><titles><title><style face="normal" font="Arial">IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series</style></title><secondary-title><style face="normal" font="Arial">Eur J Hermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Hermatol</style></abbr-1></periodical><pages end="387" start="378">378-387</pages><volume><style face="normal" font="Arial">98</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To compare the clinical and laboratory features of IgG4-related disease (IgG4-RD) and lymphocyte variant-hypereosinophilic syndrome (L-HES), two rare diseases that often present with lymphadenopathy, gastrointestinal symptoms, eosinophilia and elevated immunoglobulins/IgE. METHOD: Comparative case series of 31 IgG4-RD and 13 L-HES patients. RESULTS: Peripheral blood eosinophilia was present in 8/31 IgG4-RD patients compared to 13/13 L-HES patients (median eosinophils 0.4 giga/L vs. 7.0 giga/L, P = 0.001) and 12/20 patients with IgG4-RD had increased serum IgE compared to 8/13 L-HES patients, P = 0.930. Twenty-seven of 30 IgG4-RD patients had elevated serum IgG4 compared to 5/12 L-HES patients (median IgG4 9.6 g/L vs. 0.80 g/L, P = 0.002). Flow cytometry demonstrated an aberrant T-cell phenotype in 7/23 IgG4-RD patients and 13/13 L-HES patients (P &lt; 0.001). T-cell clonality by PCR was positive in 12/23 IgG4-RD patients vs. 10/13 L-HES patients (P = 0.143). Patients in both groups received corticosteroids as first-line therapy. For refractory disease in IgG4-RD, rituximab was the most common steroid-sparing agent, whereas in L-HES it was pegylated interferon-alpha-2a. CONCLUSION: The overlapping features of these two diseases with divergent treatment options demonstrate the importance of familiarity with both entities in order to optimize diagnosis and treatment. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161222IS - 1600-0609 (Electronic)IS - 0902-4441 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/ejh.12842</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28005278">PM:28005278</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Hermatol\20161222-CarruthersMN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Hermatol\20161222-CarruthersMN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161222, Carruthers MN</style></custom2><misc3><style face="normal" font="Arial">10.1111/ejh.12842</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Djukanovic,R.</style></author><author><style face="normal" font="Arial"> Bruselle,G.</style></author><author><style face="normal" font="Arial"> Walker,S.</style></author><author><style face="normal" font="Arial"> Holgate,S.T.</style></author><author><style face="normal" font="Arial"> Skrgat,S.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Heaney,L.G.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Vestbo,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">The era of research collaborations: new models for working together</style></title><secondary-title><style face="normal" font="Arial">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Slovenia</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - EditorialCO - United Kingdom -CO - Poland -CO - Slovenia -CO - Italy -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1183/13993003.01848-2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049174">PM:28049174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Respir J\20170103-DjukanovicR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Respir J\20170103-DjukanovicR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Djukanovic R</style></custom2><misc3><style face="normal" font="Arial">10.1183/13993003.01848-2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guilleminault,L.</style></author><author><style face="normal" font="Arial"> Ouksel,H.</style></author><author><style face="normal" font="Arial"> Belleguic,C.</style></author><author><style face="normal" font="Arial"> Le Guen,Y.</style></author><author><style face="normal" font="Arial"> Germaud,P.</style></author><author><style face="normal" font="Arial"> Desfleurs,E.</style></author><author><style face="normal" font="Arial"> Leroyer,C.</style></author><author><style face="normal" font="Arial"> Magnan,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept of Pulmonary Medicine, Reunion Island University Hospital/South Reunion Island Hospital Group, Saint-Pierre, France</style></auth-address><titles><title><style face="normal" font="Arial">Personalised medicine in asthma: from curative to preventive medicine</style></title><secondary-title><style face="normal" font="Arial">Eur Respir Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Respir Rev</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">143</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly patients</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patient Education</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> personalised medicine</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reunion island</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">The concept of asthma has changed substantially in recent years. Asthma is now recognised as a heterogeneous entity that is complex to treat. The subdivision of asthma, provided by "cluster" analyses, has revealed various groups of asthma patients who share phenotypic features. These phenotypes underlie the need for personalised asthma therapy because, in contrast to the previous approach, treatment must be tailored to the individual patient. Determination of the patient's asthma phenotype is therefore essential but sometimes challenging, particularly in elderly patients with a multitude of comorbidities and a complex exposure history. This review first describes the various asthma phenotypes, some of which were defined empirically and others through cluster analysis, and then discusses personalisation of the patient's diagnosis and therapy, addressing in particular biological therapies and patient education. This personalised approach to curative medicine should make way in the coming years for personalised preventive and predictive medicine, focused on subjects at risk who are not yet ill, with the aim of preventing asthma before it occurs. The concept of personalised preventive medicine may seem a long way off, but is it really?</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1600-0617 (Electronic)IS - 0905-9180 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1183/16000617.0010-2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049124">PM:28049124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Respir Rev\20170103-GuilleminaultL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Respir Rev\20170103-GuilleminaultL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Guilleminault L</style></custom2><misc3><style face="normal" font="Arial">10.1183/16000617.0010-2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masieri,S.</style></author><author><style face="normal" font="Arial"> Cavaliere,C.</style></author><author><style face="normal" font="Arial"> Begvarfaj,E.</style></author><author><style face="normal" font="Arial"> Rosati,D.</style></author><author><style face="normal" font="Arial"> Minni,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Sensory Organs, "Sapienza" University, Rome, Azienda Policlinico Umberto I, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Effects of omalizumab therapy on allergic rhinitis: a pilot study</style></title><secondary-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></full-title></periodical><pages end="5255" start="5249">5249-5255</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">24</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hypertrophy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous administration</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The use of omalizumab, a humanized monoclonal antibody able to binding Ig-E, is currently authorized only for treatment of severe bronchial asthma. The use of omalizumab in other Ig-E related diseases is off-label, although some studies have provided promising results about it. The aim of this study was to evaluate if therapy with omalizumab in patients affected by asthma and allergic rhinitis has an impact also on allergic rhinitis-related symptoms. PATIENTS AND METHODS: A longitudinal study was conducted on 11 patients affected by severe asthma and a periodic allergic rhinitis. Patients were treated with omalizumab for 24 weeks with a monthly subcutaneous administration at the dosage recommended by the current guidelines. We observed at the start and at the end of treatment: rhinitis symptoms using the Visual Analogue Scale (VAS); the state of nasal mucosa with fiberoptic nasal endoscopy; airways inflammation by measuring the Fractional Exhaled Nitric Oxide (FeNO); asthmatic symptomatology by means of the Asthma Control Test; the amount of total Ig-E in a blood sample; and the use of symptomatic drugs before and after treatment. RESULTS: VAS scores to measure general symptomatology and symptoms including nasal obstruction, rhinorrhea, itching and sneezing were significantly reduced. Turbinate hypertrophy was resolved in six of nine patients. Furthermore, eight patients (73%) reduced or eliminated the use of symptomatic drugs. CONCLUSIONS: Our data confirm the efficacy of omalizumab in the treatment of allergic rhinitis. Controlled studies will now have to be carried out to confirm these preliminary data and will specify indications for a very efficacious but still significantly expensive therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170104IS - 2284-0729 (Electronic)IS - 1128-3602 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28051241">PM:28051241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Rev Med Pharmacol Sci\2016-20-5249-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Rev Med Pharmacol Sci\2016-20-5249-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170104, Masieri S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Allergy and Immunology, Children's Hospital Colorado, Aurora, Colorado, USADepartment of Pediatrics, Division of Allergy and Clinical Immunology, Cincinnatti Children's Hospital, Cincinnati, Ohio, USA</style></auth-address><titles><title><style face="normal" font="Arial">Having your cake and EATing it too: early timing of multiple allergen introduction does not increase the risk of developing food allergy in standard risk, breastfed infants</style></title><secondary-title><style face="normal" font="Arial">Evid Based Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Evid Based Med</style></abbr-1></periodical><pages end="" start="60">60-</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170105IS - 1473-6810 (Electronic)IS - 1356-5524 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1136/ebmed-2016-110488</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28053205">PM:28053205</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Evid Based Med\20170105-GreenhawtM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Evid Based Med\20170105-GreenhawtM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170105, Greenhawt M</style></custom2><misc3><style face="normal" font="Arial">10.1136/ebmed-2016-110488</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wahn,U.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Paediatric Pulmonology and Immunology , Charite Virchow-Klinikum, Humboldt University , Berlin , Germanyb Section of Allergy and Clinical Immunology , Imperial College London-National Heart and Lung Institute, Royal Brompton Hospital , London , UKc Department of Pulmonology, Division of Allergy , Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier and Sorbonne Universites, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR , Paris , France</style></auth-address><titles><title><style face="normal" font="Arial">Real-life clinical practice and management of polysensitized patients with respiratory allergies: a large, global survey of clinicians prescribing allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="289" start="283">283-289</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The allermix survey was conducted to gain insights into the most frequently diagnosed allergies worldwide, the use of allergen immunotherapy (AIT) in clinical practice, and to identify current clinical approaches for the management of polyallergic patients. METHODS: The survey was conducted in 19 countries worldwide during 2016. Clinicians currently prescribing AIT completed an online questionnaire, designed to gather data on their daily clinical practice, most commonly diagnosed and treated allergies among their patients, awareness and adherence to recommendations and guidelines on AIT, the AIT format(s) that they choose to prescribe, and management of polyallergic patients. RESULTS: Respondents (N = 1029) considered a clinical demonstration of safety and effectiveness, and quality and standardization of allergen extract, as key factors influencing their choice of which AIT formulation to prescribe. 98% of respondents reported managing polyallergic patients; 58% were treated with single-allergen AIT and 42% with multiple-allergen AIT. 74% of respondents were aware of latest AIT practice guidelines, while 67% had an awareness of recent recommendations for pharmaceutical manufacturers. CONCLUSION: These findings highlight the need for high-quality AIT products that are supported by robust efficacy and safety data, and address the treatment habits of allergy specialists in their real-life clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20161230IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United Kingdom -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1277142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28033731">PM:28033731</url></web-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20161230, Wahn U</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1277142</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Z.</style></author><author><style face="normal" font="Arial"> Shimizu,Y.</style></author><author><style face="normal" font="Arial"> Saeki,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Grey mullet roe contains yolk protein having IgE cross-reactivity to-áchum salmon roe major allergen (Onc k 5)</style></title><secondary-title><style face="normal" font="Arial">Fish Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Fish Sci</style></full-title></periodical><pages end="308" start="301">301-308</pages><volume><style face="normal" font="Arial">83</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> chum salmon</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> N-terminal amino acid sequence</style></keyword><keyword><style face="normal" font="Arial"> Onc k 5</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbit IgG</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Roe</style></keyword><keyword><style face="normal" font="Arial"> Salmon</style></keyword><keyword><style face="normal" font="Arial"> salmon roe</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Vitellogenin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> yolk protein</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1444-2906</style></isbn><abstract><style face="normal" font="Arial">The major allergenic protein in grey mullet roe was immunologically characterized using rabbit IgG against the +¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¦-component, which is a vitellogenin fragment and the major allergen in chum salmon roe, and the IgE cross-reactivity between salmon and mullet roe was examined using chum salmon roe-allergic patients' sera. Grey mullet +¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¦-component was identified in the yolk protein and consisted of 16 and 30-ákDa proteins that showed marked reaction with the anti-+¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¦-component IgG and shared N-terminal amino acid sequence similarity with vitellogenin. The grey mullet +¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¦-component consisted of six different isoforms generated from vitellogenin A and vitellogenin B, and they inhibited the IgE-binding reaction between chum salmon +¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¦-component and a chum salmon roe-allergic patient</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs serum. Thus, grey mullet roe may be an allergenic seafood capable of introducing IgE cross-reactivity to chum salmon roe through the +¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¦-component</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12562-016-1057-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s12562-016-1057-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Fish Sci\20170110-LiZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Fish Sci\20170110-LiZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Li Z</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12562-016-1057-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blanquiceth,Y.</style></author><author><style face="normal" font="Arial"> Rodriguez-Perea,A.L.</style></author><author><style face="normal" font="Arial"> Tabares Guevara,J.H.</style></author><author><style face="normal" font="Arial"> Correa,L.A.</style></author><author><style face="normal" font="Arial"> Sanchez,M.D.</style></author><author><style face="normal" font="Arial"> Ramirez-Pineda,J.R.</style></author><author><style face="normal" font="Arial"> Velilla,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Grupo Inmunovirologia, Departamento de Microbiologia y Parasitologia, Facultad de Medicina, Universidad de Antioquia UdeA , Medellin , Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Increase of Frequency and Modulation of Phenotype of Regulatory T Cells by Atorvastatin Is Associated with Decreased Lung Inflammatory Cell Infiltration in a Murine Model of Acute Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="620">620-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atorvastatin</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> OX40</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> statin</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Regulatory T cells (Tregs) play an important role by controlling allergic inflammation of airways. Recently, it has been shown that statins have immunomodulatory properties, probably mediated by their effects on Tregs. Therefore, we evaluated the in vivo effect of atorvastatin (ATV) on Tregs and its association with the inflammatory process in a model of allergic asthma. BALB/c mice were sensitized with ovalbumin (OVA) and then challenged with intranasal OVA. ATV (40 mg/kg) was delivered by daily intraperitoneal injection for 7 or 15 days before each OVA challenge. ATV treatment for 7 days increased the frequency of Tregs in mediastinal lymph nodes (MLN) and the interleukin (IL)-10 in lungs. After 15 days of treatment, ATV increased the percentage of glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR+) and programmed cell death protein 1 (PD-1+) Tregs in the lung, without enhancing their suppressive activity, but also increased the percentage of conventional T cells expressing GITR+, PD1+, and OX-40 (tumor necrosis factor receptor superfamily member 4). Although no significant changes were observed in the number of inflammatory cells in the bronchoalveolar lavage (BAL), OVA-specific immunoglobulin E in the serum, and type 2 helper (Th2) cytokines in the lungs, there was a significant decrease of peribronchial inflammation that negatively correlated with the Tregs in MLN and the concentration of IL-10 in the lung. These results suggest that ATV has an immunomodulatory role possibly mediated by their effects on Tregs, which could contribute to the control of inflammation during allergic asthma. Further studies are necessary to elucidate the contribution of Treg to immunomodulatory action of statins in the context of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2016.00620</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28066430">PM:28066430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2016-7-620.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2016-7-620.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Blanquiceth Y</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2016.00620</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kale,S.</style></author><author><style face="normal" font="Arial"> Agrawal,K.</style></author><author><style face="normal" font="Arial"> Arora,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Role of proteases in pathophysiology of allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="65" start="57">57-65</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Cell surface receptors</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chymase</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword></keywords><dates><year Day="1" Month="7" Year="2016">2016/7/1</year></dates><abstract><style face="normal" font="Arial">Prevalence of allergic diseases ranges from 20% to 30% worldwide and is increasing for the last few decades. Emerging studies have implicated proteases, both endogenous and exogenous in initiating, mediating, and exacerbating allergic responses. Mast Cells (MCs) are the critical effectors of the allergic diseases and upon activation release a wide variety of mediators and account for the majority of endogenous proteases including chymase, tryptase, and MC-carboxypeptidase A (MC-CPA). The substrates of MC proteases include extracellular matrix components, proenzymes, and cell surface receptors. These proteases are stored in a fully active state and upon release contribute to the tissue injury. Along with endogenous proteases, allergens having protease activity have also been implicated in the manifestation of allergic diseases. Protease allergens are known to modulate immune responses toward Th2 by (i) disrupting protease-antiprotease balance at the epithelial surfaces, (ii) disrupting airway epithelial barrier, (iii) activating airway epithelial cells, (iv) modulating the activity of immune cells, and (v) by cleaving cell surface receptors. As proteases play crucial roles in the manifestation of allergic reactions, they can be exploited as a target for the development of new generation therapies for allergic diseases</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.195210</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.195210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-57-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-57-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Kale S</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.195210</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mishra,V.D.</style></author><author><style face="normal" font="Arial"> Mahmood,T.</style></author><author><style face="normal" font="Arial"> Mishra,J.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of TB and Chest Diseases, Heritage Institute of Medical Sciences, Varanasi, Uttar Pradesh, India2 Department of TB and Chest Diseases, MLN Medical College, Allahabad, Uttar Pradesh, India3 Department of TB and Respiratory Diseases, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India</style></auth-address><titles><title><style face="normal" font="Arial">Identification of common allergens for united airway disease by skin prick test</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="79" start="76">76-79</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amaranthus</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cotton</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> dog dander</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Eucalyptus</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect allergen</style></keyword><keyword><style face="normal" font="Arial"> Insect allergens</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Ricinus</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2016">2016/7/1</year></dates><abstract><style face="normal" font="Arial">Objective: Identification of common allergens by skin prick test in patients of united airway disease. Materials and Methods: Skin prick test was performed in 60 patients of United Airway Disease to identify the common allergens. A total of 62 allergens consisting of 36 types of pollen, 5 fungi, 4 insects, 8 type of dusts, 4 dander, 3 fabrics, Dust mite and Parthenium leaves were tested. Result: Most common allergens were Dust mite (60%) followed by Parthenium leaves (45%), insects (18.75%), pollen (14.81%), dust allergens (8.51%), fabrics (8.33%), fungi (5.66%), dander (5%). Most common insect allergens were cockroach (female) (30%), cockroach (male) (23.33%). Common pollens were Ricinus communis (28.33%), Amaranthus spinosus (28.33%), Parthenium hysterophorus (26.66%), Eucalyptus tereticornis (26.66%) and Cynodon dactylon (25%). Common dust allergens were house dust (21.66%), paper dust (11.66%) and cotton mill dust (10%). Among fabrics kapok cotton (13.33%) showed maximum positivity. Among fungi Aspergillus fumigatus (10%) followed by A. niger (6.66%) were most common. In animal dander group common ones were cat dander followed by dog dander. Conclusion: In conclusion it can be said that the knowledge drawn by above study will help to treat patients by immunotherapy or avoidance strategy.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.195237</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.195237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-76-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-76-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Mishra S</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.195237</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kannan,A.</style></author><author><style face="normal" font="Arial"> Gopalan,S.</style></author><author><style face="normal" font="Arial"> Arthur,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis mimicking lung cancer in a nonasthmatic male patient</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="101" start="99">99-101</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung cancer</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword></keywords><dates><year Day="1" Month="7" Year="2016">2016/7/1</year></dates><abstract><style face="normal" font="Arial">Presentation of &lt;i>Aspergillus&lt;/i> infections of the lung is varied. Allergic bronchopulmonary aspergillosis (ABPA) is one such presentation in which there is hypersensitivity reaction to &lt;i>Aspergillus&lt;/i> antigens. It occurs commonly in asthmatics and patients with cystic fibrosis. We report a case of ABPA in a 55-year-old male initially evaluated for left lung cancer who had never been diagnosed with asthma</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.195264</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.195264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-99-101.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2016-30-99-101.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Kannan A</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.195264</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qiao,M.</style></author><author><style face="normal" font="Arial"> Xiao,D.</style></author><author><style face="normal" font="Arial"> Qian,L.</style></author><author><style face="normal" font="Arial"> Qiao,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Kingsbrook Jewish Medical Center, 585 Schenectady Ave, Brooklyn, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">The Natural Course of Atopic Dermatitis and the Association with Asthma</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Tacrolimus</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="Arial">In this paper, we aimed to explore the potential mechanism underlying atopic dermatitis (AD) and its association with asthma. The BALB/c mice were randomly assigned to three groups, including the vehicle control (VD) group, the AD group, and the treatment (TR) group. The AD mice model was successfully constructed in the AD and TR group. The dermatitis severity scores and skin lesions were significantly increased in AD mice after DNCB application. Airway responsiveness in the AD group was significantly higher than in the TR group. The number of inflammatory cells was increased in skin lesions and bronchoalveolar lavage fluid (BALF) of AD mice. The levels of IL-4, IL-5, IFN-gamma, and OVA-IgE in BALF supernatants of mice in the AD group were higher than those in the VC group. All the changes in AD mice were decreased by tacrolimus. These results indicate that AD may be a significant risk factor for atopic asthma development</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-016-0501-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063089">PM:28063089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20170107-QiaoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20170107-QiaoM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Qiao M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-016-0501-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Asaumi,T.</style></author><author><style face="normal" font="Arial"> Nagakura,K.</style></author><author><style face="normal" font="Arial"> Ogura,K.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sagamihara National Hospital, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Safety and Efficacy of Low-Dose Oral Immunotherapy for Hen's Egg Allergy in Children</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="268" start="265">265-268</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> hen's egg allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Whole egg</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The minimal dose for oral immunotherapy (OIT) tolerance is unknown. We investigated the efficacy and safety of low-dose OIT with 1/32 of the volume of a whole egg. METHODS: Thirty-three children (aged >/=5 years) with egg allergies confirmed by oral food challenge against 1/32 of a heated whole egg (194 mg of egg protein) were enrolled. The OIT group ingested a scrambled egg once a day. The volume was gradually increased up to a maximum of 1/32 of a heated whole egg. Egg consumption was completely absent in the control group. RESULTS: There were no significant differences in background between the OIT and control groups. Respectively, 71% (15/21) and 0% (0/12) of the patients in the OIT and control groups exhibited sustained unresponsiveness to 1/32 of a whole egg 2 weeks after stopping OIT after 12 months (p &lt; 0.001); 33% (7/21) and 0% (0/12; p = 0.032), respectively, showed sustained unresponsiveness to 1/2 of a whole egg. Egg white- or ovomucoid-specific IgE levels in the OIT group were significantly lower than at baseline after 12 months. Egg white- or ovomucoid-specific IgG as well as IgG4 levels in the OIT group were significantly higher than baseline levels after 1, 3, 6, and 12 months. Adverse allergic reactions were rare, and most symptoms were mild. CONCLUSIONS: Low-dose OIT induced sustained unresponsiveness to 1/32 and 1/2 of a whole egg, with no severe symptoms. To improve food allergies, continuous intake of small amounts of these foods may be as effective as the consumption of larger quantities</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000454807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049193">PM:28049193</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-265-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-265-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Yanagida N</style></custom2><misc3><style face="normal" font="Arial">10.1159/000454807</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silva,L.A.</style></author><author><style face="normal" font="Arial"> Silva,A.F.</style></author><author><style face="normal" font="Arial"> Ribeiro,A.C.</style></author><author><style face="normal" font="Arial"> Silva,A.O.</style></author><author><style face="normal" font="Arial"> Vieira,F.A.</style></author><author><style face="normal" font="Arial"> Segundo,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology Division, Pediatrics Department, Universidade Federal de Uberlandia, Uberlandia, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Adult Food Allergy Prevalence: Reducing Questionnaire Bias</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="264" start="261">261-264</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Self-administered questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy (FA) prevalence has increased in the last decades, but epidemiologic studies could show overestimated results. The objective of this study is to estimate the prevalence of immediate FA in adults in a region of Central Brazil, using a questionnaire to try to reduce misperceptions about FA reaction. METHODS: A cross-sectional study was conducted, enrolling an adult population aged 18-65 years comprised of families in a Central Brazilian city. In the first phase, participants answered a self-administered questionnaire for FA screening. In the second phase, the participants who reported an FA in the first questionnaire were visited to complete the second questionnaire applied by trained researchers. RESULTS: Of the 4,916 adults visited, 1,583 returned a completed questionnaire. Reported FA occurred in 171 (10.8%) subjects, and the more frequent citations were cow's milk, pork, fruits, shrimp, and vegetables. One hundred and four of these individuals completed the second questionnaire, and 15 (1.0%) were considered to have an FA diagnosis. The main foods were fruits, followed by cow's milk, shrimp, pork, and vegetables. CONCLUSION: After use of a specific questionnaire to recognize possible IgE-mediated FAs, a low frequency of FA was considered in this population. Use of a directed questionnaire administered by trained researchers could be an alternative for epidemiological IgE-mediated FA studies to achieve more accurate results</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1159/000453036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049191">PM:28049191</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-261-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-261-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Silva LA</style></custom2><misc3><style face="normal" font="Arial">10.1159/000453036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bavbek,S.</style></author><author><style face="normal" font="Arial"> Kendirlinan,R.</style></author><author><style face="normal" font="Arial"> Cerci,P.</style></author><author><style face="normal" font="Arial"> Altiner,S.</style></author><author><style face="normal" font="Arial"> Soyyigit,S.</style></author><author><style face="normal" font="Arial"> Celebi,Sozener Z.</style></author><author><style face="normal" font="Arial"> Aydin,O.</style></author><author><style face="normal" font="Arial"> Gumusburun,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="233" start="227">227-233</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Rapid drug desensitization (RDD) induces a temporary tolerance to biologics which induce hypersensitivity reactions (HSRs). Data are limited regarding the use of RDD outside the USA. Our purpose was to report our data on RDD to rituximab, infliximab, cetuximab, and trastuzumab. METHODS: The study was conducted as a retrospective chart review of patients with symptoms of HSRs to biologics. HSRs were classified as grades I, II, and III, based on their severity. Skin-prick tests/intradermal tests (IDTs) were performed with the implicated biologics. The 12-step RDD protocol was used. RESULTS: The study group comprised 11 women and 6 men (mean age: 47 +/- 11.7 years). Fourteen patients experienced HSRs to rituximab; 3 had HSRs to cetuximab, infliximab, and trastuzumab, respectively. HSRs to cetuximab, infliximab, and trastuzumab occurred during the first infusion and were all grade III. Twelve of the 14 patients with rituximab hypersensitivity had a reaction during the first infusion; 10 patients had grade II reactions and 4 had grade III reactions. Respiratory symptoms were the most frequent presentation of HSR. Skin tests with rituximab were performed on 10 patients; only 3 resulted in positive IDTs (with 1:100 dilutions) and the other tests were negative as were those performed with the other biologics. Of 96 RDDs, 89 desensitizations were performed with rituximab, 5 with cetuximab, 1 with infliximab, and 1 with trastuzumab. There were 12 (13.5%) breakthrough reactions, all of which were associated with rituximab and were less severe than the initial reactions. CONCLUSION: RDD was found to be safe and effective in the largest case series of RDDs with biologics in our country, Turkey</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1159/000454808</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049204">PM:28049204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-227-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-227-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Bavbek S</style></custom2><misc3><style face="normal" font="Arial">10.1159/000454808</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jimenez,M.</style></author><author><style face="normal" font="Arial"> Cervantes-Garcia,D.</style></author><author><style face="normal" font="Arial"> Munoz,Y.H.</style></author><author><style face="normal" font="Arial"> Garcia,A.</style></author><author><style face="normal" font="Arial"> Haro,L.M.,Jr.</style></author><author><style face="normal" font="Arial"> Salinas,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Basic Science Center, Autonomous University of Aguascalientes, Aguascalientes, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Novel Mechanisms Underlying the Therapeutic Effect of Glycomacropeptide on Allergy: Change in Gut Microbiota, Upregulation of TGF-beta, and Inhibition of Mast Cells</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="226" start="217">217-226</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteroides</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutic value</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of allergic diseases is globally increasing. We have previously described that glycomacropeptide (GMP), a bioactive milk peptide, has therapeutic value in experimental models of skin hypersensitivity, anaphylaxis, and asthma, as it prevents an excessive T helper type 2 cell immune response. The aim of this study was to analyze the effect of GMP on key elements directly involved in the development or control of allergy, in order to improve the precise knowledge about its mechanism of action. METHODS: Rats were systemically sensitized with ovalbumin and orally treated with GMP. Levels of Lactobacillus, Bifidobacterium, and Bacteroides were analyzed in their feces. Splenocytes were isolated and the production of transforming growth factor (TGF)-beta by allergens was measured. Intradermal skin reactions were developed to evaluate in vivo activation of mast cells. Peritoneal mast cells were isolated and activated by the allergen, and histamine secretion was determined. RESULTS: GMP administration increased the amount of intestinal Lactobacillus and Bifidobacterium of allergen-sensitized animals after 3 days of treatment. The increase in Bacteroides was also significant, but only after 17 days of GMP administration. Ten days after treatment cessation, Lactobacillus and Bacteroides were still elevated. GMP intake also elevated the production of TGF-beta in the splenocytes of sensitized animals. In addition, treatment with GMP attenuated mast cell activation by the allergen and inhibited histamine secretion, without affecting the number of mast cells. CONCLUSIONS: The prebiotic action of GMP on allergy-protective microbiota, an increase in TGF-beta production, and a reduction in mast cell response to allergens are novel mechanisms that explain the antiallergic activity of GMP</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1159/000453035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049206">PM:28049206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-217-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-217-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Jimenez M</style></custom2><misc3><style face="normal" font="Arial">10.1159/000453035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qi,S.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Huang,N.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Liu,G.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Hu,L.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Zhu,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</style></auth-address><titles><title><style face="normal" font="Arial">Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="240" start="234">234-240</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early intervention</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy (AIT) is the unique causal treatment for respiratory allergy. As AIT is expensive and of long duration, the availability of a marker predicting AIT responders is of crucial relevance. OBJECTIVE: To investigate clinical parameters correlated with effective AIT in allergic rhinitis (AR) patients. METHODS: This is a prospective, nonrandomized open study in which a total of 284 AR patients who had received house dust mite (HDM) subcutaneous AIT were enrolled from January 2011 to December 2015, and then followed up for 3 consecutive years. Demographic data, clinical history, laboratory tests (specific and total IgE levels), symptoms score, concomitant medication, and adverse reactions during AIT were collected. An AIT responder patient was defined when a visual analog score (assessing global symptoms) had decreased by >30% compared to baseline and concomitant medication was equal to or less than before AIT. RESULTS: Thirty-three patients dropped out, so 251 patients were analyzed; 175 (69.7%) patients were responders. This group had a higher baseline symptom score than the AIT nonresponder group (7.5 vs. 6.9). A significant negative correlation was found between AR symptom duration and the clinical response to AIT. Local reactions (LRs) during AIT had a positive correlation. Other variables such as a family history of atopy, combined asthma history, and the levels of specific and total IgE had no correlations with effective AIT. CONCLUSION: Early intervention with AIT helps to improve the efficacy of AR treatment. LRs might predict successful AIT. Highly symptomatic AR patients may develop increased clinical responses to AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1159/000452333</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049194">PM:28049194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-234-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-234-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Qi S</style></custom2><misc3><style face="normal" font="Arial">10.1159/000452333</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ha,E.K.</style></author><author><style face="normal" font="Arial"> Baek,J.H.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Park,Y.M.</style></author><author><style face="normal" font="Arial"> Kim,W.K.</style></author><author><style face="normal" font="Arial"> Sheen,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,S.J.</style></author><author><style face="normal" font="Arial"> Bae,Y.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Lee,K.J.</style></author><author><style face="normal" font="Arial"> Ahn,K.</style></author><author><style face="normal" font="Arial"> Kwon,H.J.</style></author><author><style face="normal" font="Arial"> Han,M.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, CHA University School of Medicine, Seongnam, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association of Polysensitization, Allergic Multimorbidity, and Allergy Severity: A Cross-Sectional Study of School Children</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="260" start="251">251-260</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> hierarchical clustering</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Korean children</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Aeroallergen sensitization is related to the coexistence of allergic diseases, but the nature of this relationship is poorly understood. The aim of this study was to clarify the relationship of polysensitization with allergic multimorbidities and the severity of allergic diseases. METHODS: This study is a cross-sectional analysis of 3,368 Korean children aged 6-7 years-old. We defined IgE-mediated allergic diseases based on structured questionnaires, and classified the sensitivity to 18 aeroallergens by logistic regression and the Ward hierarchical clustering method. The relationship of polysensitization (positive IgE responses against 2 or more aeroallergens classes) with allergic multimorbidities (coexistence of 2 or more of the following allergic diseases: asthma, rhinitis, eczema, and conjunctivitis) and severity of allergic diseases was determined by ordinal logistic regression analysis. RESULTS: The rate of polysensitization was 13.6% (n = 458, 95% CI 12.4-14.8) and that of allergic multimorbidity was 23.5% (n = 790, 95% CI 22.0-24.9). Children sensitized to more aeroallergens tended to have more allergic diseases (rho = 0.248, p &lt; 0.001), although the agreement between polysensitization and multimorbidity was poor (kappa = 0.11, p &lt; 0.001). The number allergen classes to which a child was sensitized increased the risk of wheezing attacks (1 allergen: adjusted odds ratio [aOR] 2.22, 4 or more allergens: aOR 9.39), absence from school (1 allergen: aOR 1.96, 3 allergens: aOR 2.08), and severity of nasal symptoms (1 allergen: aOR 1.61, 4 or more allergens: aOR 4.38). CONCLUSION: Polysensitization was weakly related to multimorbidity. However, the number of allergens to which a child is sensitized is related to the severity of IgE-mediated symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1159/000453034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049188">PM:28049188</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-251-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-251-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Ha EK</style></custom2><misc3><style face="normal" font="Arial">10.1159/000453034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,Z.</style></author><author><style face="normal" font="Arial"> Yu,J.</style></author><author><style face="normal" font="Arial"> Niu,Y.</style></author><author><style face="normal" font="Arial"> Sun,S.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Saxon,A.</style></author><author><style face="normal" font="Arial"> Zhang,K.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Enhanced Prophylactic and Therapeutic Effects of Polylysine-Modified Ara h 2 DNA Vaccine in a Mouse Model of Peanut Allergy</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="250" start="241">241-250</pages><volume><style face="normal" font="Arial">171</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA vaccination</style></keyword><keyword><style face="normal" font="Arial"> DNA vaccine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Lysine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Plasmid</style></keyword><keyword><style face="normal" font="Arial"> plasmid DNA</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of food allergy has been increasing, but treatment is very limited. DNA vaccination has been recognized as a promising method for the treatment of allergic diseases; however, poor immunogenicity has hindered its application. METHODS: BALB/c mice were intradermally injected with plasmid DNA encoding the peanut protein Ara h 2 (pAra h 2) or pAra h 2 pretreated with poly-L- lysine (PLL) before or after sensitization with Ara h 2 protein. Ara h 2-specific antibodies were measured by ELISA. CD207+ dendritic cells (DCs) and Treg cells in draining lymph nodes were analyzed by flow cytometry after DNA immunization, and cytokine production in splenocytes was also analyzed. RESULTS: In the prophylactic study, pretreatment with pAra h 2 or PLL-pAra h 2 resulted in lower levels of Ara h 2-specific IgG1, IgG2a, and IgE after sensitization with Ara h 2 protein, and mice in the PLL-pAra h 2 group had a significantly lower level of antibodies than those in the pAra h 2 group. In the treatment study, intradermal injection with pAra h 2 or PLL-pAra h 2 after Ara h 2 protein sensitization significantly decreased the level of Ara h 2-specific antibodies, and PLL- pAra h 2 had stronger effects than pAra h 2. There were increased numbers of CD207+ DCs and Treg cells in the mice receiving intradermal injection with PLL-pAra h 2, and splenocytes from PLL-pAra h 2-treated mice secreted increased levels of IFN-gamma and IL-10. CONCLUSIONS: Modification of pAra h 2 with PLL improved its prophylactic and therapeutic effects in peanut-allergic mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1159/000453264</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049187">PM:28049187</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-241-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-171-241-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Zhu Z</style></custom2><misc3><style face="normal" font="Arial">10.1159/000453264</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,X.</style></author><author><style face="normal" font="Arial"> Li,X.M.</style></author><author><style face="normal" font="Arial"> Gu,W.</style></author><author><style face="normal" font="Arial"> Wang,D.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Guo,X.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respirology Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China</style></auth-address><titles><title><style face="normal" font="Arial">LAT alleviates Th2/Treg imbalance in an OVA-induced allergic asthma mouse model through LAT-PLC-gamma1 interaction</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="15" start="9">9-15</pages><volume><style face="normal" font="Arial">44</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevention</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase C gamma</style></keyword><keyword><style face="normal" font="Arial"> Plasmid</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Low expression of linker for activation of T cells (LAT) is observed in asthma. LAT and its downstream regulator, phospholipase C-gamma 1 (PLC-gamma1) play important roles in the T cell antigen receptor signaling pathway, and their interaction is associated with CD4+ cell polarization. Here, we investigated whether LAT can alleviate the imbalance among CD4+ cell subgroups and the possible mechanism. METHODS: An ovalbumin-induced allergic asthma mouse model was established and LAT plasmid was delivered. The pathological changes in lung were evaluated by hematoxylin and eosin and periodic acid-Schiff staining. The typical cytokines released by T helper 2 (Th2) and regulatory T (Treg) cells were measured using enzyme-linked immunosorbent assay and the number of Th1, Th2, and Treg cells were determined using flow cytometry. Lung CD4+ T cells were isolated by magnetic isolation. The mRNA expression of LAT and PLC-gamma1 was determined by real-time PCR. Co-Immunoprecipitation was performed to confirm the interaction between LAT and PLC-gamma1. The protein expression of LAT, PLC-gamma1 and corresponding downstream signaling factors were determined by western blotting. RESULTS: The delivery of LAT DNA to the lung could suppress an overactive Th2 response by decreasing allergic response and Th2 cytokine secretion, and by increasing Treg cytokine secretion. The Th2/Treg imbalance in lung and decreased phosphorylated PLC-gamma1 expression in lung CD4+ T cells were rectified by LAT DNA delivery. Excessive activation of the Raf-MEK-ERK and PI3K-AKT-CREB pathways after asthma is attenuated by LAT. CONCLUSION: The site-specific delivery of LAT DNA to the lung could suppress an overactive Th2 response and rectify the Th2/Treg imbalance in asthmatic mouse model. LAT-PLC-gamma1 interaction may contribute to LAT activity in vivo and LAT protects against asthma partly via Raf-MEK-ERK and PI3K-AKT-CREB pathways. The delivery of LAT DNA could offer a novel and safe strategy for asthma prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2016.12.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063403">PM:28063403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-44-9-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-44-9-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Chen X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2016.12.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,H.S.</style></author><author><style face="normal" font="Arial"> Tu,H.P.</style></author><author><style face="normal" font="Arial"> Hong,C.H.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Science, National Pingtung University of Science and Technology, Pingtung 912, Taiwan.</style></auth-address><titles><title><style face="normal" font="Arial">Lifetime Increased Risk of Adult Onset Atopic Dermatitis in Adolescent and Adult Patients with Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E42">E42-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="12" Year="2016">2016/12/27</year></dates><abstract><style face="normal" font="Arial">Food allergy can result in life-threatening anaphylaxis. Atopic dermatitis (AD) causes intense itching and impaired quality of life. Previous studies have shown that patients with classical early-onset AD tend to develop food allergy and that 10% of adults with food allergies have concomitant AD. However, it is not known whether late-onset food allergy leads to adult-onset AD, a recently recognized disease entity. Using an initial cohort of one-million subjects, this study retrospectively followed-up 2851 patients with food allergy (age > 12 years) for 14 years and compared them with 11,404 matched controls. While 2.8% (81) of the 2851 food allergy patients developed AD, only 2.0% (227) of the 11,404 controls developed AD. Multivariate regression analysis showed that food allergy patients were more likely to develop AD (adjusted hazard ratio = 2.49, p &lt; 0.0001). Controls had a 1.99% risk of developing AD, while food allergy patients had a significantly higher risk (7.18% and 3.46% for patients with >/=3 and &lt;3 food allergy claims, respectively) of developing adult-onset AD. This is the first study to describe the chronological and dose-dependent associations between food allergy in adolescence and the development of adult-onset AD</style></abstract><notes><style face="normal" font="Arial">DA - 20161230IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18010042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28035995">PM:28035995</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\20161230-YuHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\20161230-YuHS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161230, Yu HS</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18010042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,D.Y.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author><author><style face="normal" font="Arial"> Hong,S.C.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author><author><style face="normal" font="Arial"> Kang,J.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Serum periostin level is not associated with allergic rhinitis or allergic sensitization in Korean children</style></title><secondary-title><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="29" start="24">24-29</pages><volume><style face="normal" font="Arial">93</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Korean children</style></keyword><keyword><style face="normal" font="Arial"> matricellular protein</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><isbn><style face="normal" font="Arial">0165-5876</style></isbn><abstract><style face="normal" font="Arial">Objectives Periostin is a matricellular protein, synthesized in the airway epithelium and induced by interleukin (IL)-4 and IL-13. The significance of periostin as a biomarker of T helper type 2-ácell (Th2)-induced airway inflammation, and as a measure of the response to Th2-targeted therapy, has recently been highlighted. We explored the relationship between serum periostin and allergic rhinitis in Korean children. Methods Data for fifth and sixth grade children from six randomly selected elementary schools located in Jeju and Seogwipo City, Korea, were investigated. Serum periostin levels were determined by enzyme-linked immunosorbent assay. Sex, school grade, body mass index, and presence of allergic nasal symptoms were obtained via a self-reported survey and skin prick testing was performed. Results There were no significant differences between groups, when stratification was applied according to sex, grade, presence of atopy, and presence of allergic nasal symptoms. Sex and body mass index were significantly associated with serum periostin levels in multivariate linear regression analysis. However, allergic rhinitis was not associated with serum periostin levels. Conclusion Allergic rhinitis or allergic sensitization in Korean children did not influence serum periostin levels. Further studies are required to investigate the significance of serum periostin levels in pediatric allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijporl.2016.12.013</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.ijporl.2016.12.013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-93-24-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-93-24-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170108, Kim DY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijporl.2016.12.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Remot,A.</style></author><author><style face="normal" font="Arial"> Descamps,D.</style></author><author><style face="normal" font="Arial"> Noordine,M.L.</style></author><author><style face="normal" font="Arial"> Boukadiri,A.</style></author><author><style face="normal" font="Arial"> Mathieu,E.</style></author><author><style face="normal" font="Arial"> Robert,V.</style></author><author><style face="normal" font="Arial"> Riffault,S.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.</style></author><author><style face="normal" font="Arial"> Langella,P.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author><author><style face="normal" font="Arial"> Thomas,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Micalis Institute, INRA, AgroParisTech, Universite Paris-Saclay, Jouy-en-Josas, France</style></auth-address><titles><title><style face="normal" font="Arial">Bacteria isolated from lung modulate asthma susceptibility in mice</style></title><secondary-title><style face="normal" font="Arial">ISME J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ISME J</style></full-title></periodical><pages end="1074" start="1061">1061-1074</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> asthma susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial components</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic, non-curable, multifactorial disease with increasing incidence in industrial countries. This study evaluates the direct contribution of lung microbial components in allergic asthma in mice. Germ-Free and Specific-Pathogen-Free mice display similar susceptibilities to House Dust Mice-induced allergic asthma, indicating that the absence of bacteria confers no protection or increased risk to aeroallergens. In early life, allergic asthma changes the pattern of lung microbiota, and lung bacteria reciprocally modulate aeroallergen responsiveness. Primo-colonizing cultivable strains were screened for their immunoregulatory properties following their isolation from neonatal lungs. Intranasal inoculation of lung bacteria influenced the outcome of allergic asthma development: the strain CNCM I 4970 exacerbated some asthma features whereas the pro-Th1 strain CNCM I 4969 had protective effects. Thus, we confirm that appropriate bacterial lung stimuli during early life are critical for susceptibility to allergic asthma in young adults.The ISME Journal advance online publication, 3 January 2017; doi:10.1038/ismej.2016.181</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1751-7370 (Electronic)IS - 1751-7362 (Linking)LA - engPT - Journal ArticleCO - France -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1038/ismej.2016.181</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28045458">PM:28045458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\ISME J\20170103-RemotA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\ISME J\20170103-RemotA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Remot A</style></custom2><misc3><style face="normal" font="Arial">10.1038/ismej.2016.181</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Giangrieco,I.</style></author><author><style face="normal" font="Arial"> Proietti,S.</style></author><author><style face="normal" font="Arial"> Moscatello,S.</style></author><author><style face="normal" font="Arial"> Tuppo,L.</style></author><author><style face="normal" font="Arial"> Battistelli,A.</style></author><author><style face="normal" font="Arial"> La Cara,F.</style></author><author><style face="normal" font="Arial"> Tamburrini,M.</style></author><author><style face="normal" font="Arial"> Famiani,F.</style></author><author><style face="normal" font="Arial"> Ciardiello,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Istituto di Bioscienze e Biorisorse, CNR , Via Pietro Castellino 111, I-80131 Napoli, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Influence of Geographical Location of Orchards on Green Kiwifruit Bioactive Components</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="9179" start="9172">9172-9179</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">48</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Actinidin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> kiwifruit</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Nutraceutical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="7" Month="12" Year="2016">2016/12/7</year></dates><abstract><style face="normal" font="Arial">Italy is one of the world's major kiwifruit producers and exporters with orchards located in different areas from the north to the south of the peninsula. This study sought to investigate for the first time the possible influence of the geographical location of kiwifruit orchards on some fruit components, selected because of their involvement in beneficial or negative effects on human health. The fruits harvested in 16 Italian areas were analyzed, and the results obtained show that the observed variations of the relative amounts of total proteins, kiwellin, the major allergen actinidin, ascorbate, polyphenols, and superoxide dismutase (SOD)-like activity seem not to be related to the geographical location of the orchards. In contrast, the high concentration of the nutraceutical peptide kissper seems to have some relationship with the cultivation area. In fact, its amount is much higher in the fruits from the Lazio region, thus providing added value to these kiwifruits</style></abstract><notes><style face="normal" font="Arial">DA - 20161209IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b03930</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27933987">PM:27933987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\2016-64-9172-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\2016-64-9172-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161209, Giangrieco I</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b03930</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Choi,Y.J.</style></author><author><style face="normal" font="Arial"> Kang,M.K.</style></author><author><style face="normal" font="Arial"> Park,S.H.</style></author><author><style face="normal" font="Arial"> Antika,L.D.</style></author><author><style face="normal" font="Arial"> Lee,E.J.</style></author><author><style face="normal" font="Arial"> Kim,D.Y.</style></author><author><style face="normal" font="Arial"> Kang,Y.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Astragalin inhibits allergic inflammation and airway thickening in ovalbumin-challenged mice</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> emphysema</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> H2O2</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="1" Year="2017">2017/1/9</year></dates><abstract><style face="normal" font="Arial">Lung inflammation and oxidative stress are the major contributors to developing obstructive pulmonary diseases. Macrophages are involved in pulmonary inflammation and alveolar damage in emphysema. Astragalin is an anti-inflammatory flavonoid present in persimmon leaves and green tea seeds. This study elucidated that astragalin inhibited inflammatory cell infiltration induced by 20 muM H2O2, and blocked airway thickening and alveolar emphysema induced by 20 mug ovalbumin (OVA) in mice. OVA induced mouse pulmonary MCP-1, and H2O2 enhanced the expression of MCP-1/ICAM-1/alphav integrin in bronchial airway epithelial BEAS-2B cells. Such induction was inhibited by supplying 10-20 mg/kg astragalin to OVA-challenged mice and 1-20 muM astragalin to oxidant-stimulated cells. Oral administration of 20 mg/kg astragalin reduced the induction of F4/80/CD68/D11b in airways of mice challenged to OVA. Additionally, emphysema tissue damage was observed in OVA-exposed alveoli. The mast cell recruitment in the airway subepithelium was blocked by supplementing astragalin to OVA-challenged mice. Orally-treating 20 mg/kg astragalin reduced alpha-SMA induction in inflammation-occurring airways and appeared to reverse airway thickening and constriction induced by OVA episode. These results revealed that astragalin may improve airway thickening and alveolar destruction with blockade of allergic inflammation in airways. Therefore, astragalin may be a therapeutic agent antagonizing asthma and obstructive pulmonary diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b05160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28064485">PM:28064485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170109-KimYH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170109-KimYH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Kim YH</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b05160</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Y.</style></author><author><style face="normal" font="Arial"> Zhang,Y.X.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author><author><style face="normal" font="Arial"> Maleki,S.J.</style></author><author><style face="normal" font="Arial"> Zhang,M.L.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Cao,M.J.</style></author><author><style face="normal" font="Arial"> Su,W.J.</style></author><author><style face="normal" font="Arial"> Liu,G.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Triosephosphate isomerase and filamin C share common epitopes as novel allergens of Procambarus clarkii</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> Crayfish</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Glycolysis</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> SPR</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">Triosephosphate isomerase (TIM) is a key enzyme in glycolysis and has been identified as an allergen in saltwater products. In this study, TIM with the molecular mass of 28 kDa was purified from the freshwater crayfish (Procambarus clarkii) muscle. A 90-kDa protein showed IgG/IgE cross-reactivity with TIM was purified and identified as filamin C (FLN c), which is an actin-binding proteins. TIM showed similar thermal and pH stability while better digestion resistant compared with FLN c. Result of surface plasmon resonance (SPR) experiment demonstrated the infinity of anti-TIM polyclonal antibody (pAb) to both TIM and FLN c. Five linear and 3 conformational epitopes of TIM, and 9 linear and 10 conformational epitopes of FLN c were mapped by phage display. Epitopes of TIM and FLN c showed the sharing of certain residues, the occurrence of common epitopes in the two allergens accounts for their cross-reactivity</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b04587</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28072528">PM:28072528</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170110-YangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170110-YangY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Yang Y</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b04587</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burk,C.M.</style></author><author><style face="normal" font="Arial"> Dellon,E.S.</style></author><author><style face="normal" font="Arial"> Steele,P.H.</style></author><author><style face="normal" font="Arial"> Virkud,Y.V.</style></author><author><style face="normal" font="Arial"> Kulis,M.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Vickery,B.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, NC</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="501" start="498">498-501</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="01/21/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophageal Diseases</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017628">PM:28017628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-498-501.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-498-501.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161226, Burk CM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berni Canani,R.</style></author><author><style face="normal" font="Arial"> Di Costanzo,M.</style></author><author><style face="normal" font="Arial"> Bedogni,G.</style></author><author><style face="normal" font="Arial"> Amoroso,A.</style></author><author><style face="normal" font="Arial"> Cosenza,L.</style></author><author><style face="normal" font="Arial"> Di Scala,C.</style></author><author><style face="normal" font="Arial"> Granata,V.</style></author><author><style face="normal" font="Arial"> Nocerino,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Translational Medical Science; European Laboratory for the Investigation of Food-Induced Diseases; CEINGE Advanced Biotechnologies, University of Naples "Federico II", Naples, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Extensively hydrolysed casein formula containing L. rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3-year randomized controlled trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1913" start="1906">1906-1913</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind food challenge</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Effect size</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> LGG</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Children with cow's milk allergy (CMA) have an increased risk of developing other allergic manifestations (AMs). OBJECTIVE: We performed a parallel-arm randomized controlled trial (RCT) to test whether the administration of an extensively hydrolysed casein formula (EHCF) containing the probiotic L. rhamnosus GG (LGG) can reduce the occurrence of other AMs in CMA children. METHODS: Children with IgE-mediated CMA were randomly allocated to EHCF or EHCF+LGG groups and followed for 36 months. The main outcome was the occurrence of at least one AM (eczema, urticaria, asthma and rhinoconjunctivitis). The secondary outcome was tolerance acquisition, defined as the negativization of a double-blind food challenge at 12 months, 24 months and 36 months. AMs were diagnosed according to standardized criteria. Tolerance acquisition was evaluated every 12 months. RESULTS: A total of 220 children (147 males, 67%) with a median (IQR) age of 5.0 (3.0-8.0) months were randomized and 110 children were placed in the EHCF group and 110 children were placed in the EHCF+LGG group. In the complete case analysis, the absolute risk difference (ARD) for the occurrence of at least one AM over 36 months was -0.23 [95%CI -0.36 to -0.10, p&lt;0.001] and the ARD for the acquisition of cow's milk tolerance was 0.20 (95%CI 0.05 to 0.35, p&lt;0.01) at 12 months, 0.24 (95%CI 0.08 to 0.41, p&lt;0.01) at 24 months and 0.27 (95%CI 0.11 to 0.43, p&lt;0.001) at 36 months. In the sensitivity analysis, the effect size of the main outcome was virtually unchanged when the occurrence of AM was assigned to all 27 missing children. CONCLUSIONS: EHCF+LGG reduces the incidence of other AMs and hastens the development of oral tolerance in children with IgE-mediated CMA</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28043872">PM:28043872</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170103-BerniCananiR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170103-BerniCananiR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Berni Canani R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paluel-Marmont,C.</style></author><author><style face="normal" font="Arial"> Bellon,N.</style></author><author><style face="normal" font="Arial"> Barbet,P.</style></author><author><style face="normal" font="Arial"> Leclerc-Mercier,S.</style></author><author><style face="normal" font="Arial"> Hadj-Rabia,S.</style></author><author><style face="normal" font="Arial"> Dupont,C.</style></author><author><style face="normal" font="Arial"> Bodemer,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric digestive functional explorations, gastroenterology and food allergies, Necker-Enfants Malades Hospital (AP-HP), Paris, France; Descartes-Sorbonne Paris Cite University, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic esophagitis and colonic mucosal eosinophilia in Netherton syndrome</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="2005" start="2003">2003-2005</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Netherton Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Nutritional management</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Nutritional management in Netherton syndrome (NS) is complicated by frequent digestive symptoms. We report the presence of eosinophilic esophagitis and colonic mucosal eosinophilia in NS. Digestive endoscopies should be considered in NS patients with growth retardation and digestive symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20161227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28025013">PM:28025013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161227-PaluelMarmontC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20161227-PaluelMarmontC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161227, Paluel-Marmont C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wolsk,H.M.</style></author><author><style face="normal" font="Arial"> Andersen,M.R.</style></author><author><style face="normal" font="Arial"> Bisgaard,H.</style></author><author><style face="normal" font="Arial"> Bonnelykke,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">No evidence of intrauterine sensitization against inhalant allergens</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="288" start="286">286-288</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> intrauterine</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Specific IgE against inhalant allergens in cord blood was a very rare finding when the risk of transfer from the mother was minimized; hence, findings of such IgE should be interpreted with caution</style></abstract><notes><style face="normal" font="Arial">DA - 20170101IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28040416">PM:28040416</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170101-WolskHM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170101-WolskHM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170101, Wolsk HM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hill,D.A.</style></author><author><style face="normal" font="Arial"> Dudley,J.W.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa</style></auth-address><titles><title><style face="normal" font="Arial">The Prevalence of Eosinophilic Esophagitis in Pediatric Patients with IgE-Mediated Food Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="375" start="369">369-375</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen pattern</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic esophagitis (EoE) is an allergic inflammatory disease that is triggered by food allergens and characterized by progressive esophageal dysfunction. Recently, EoE has been identified in patients who underwent oral immunotherapy (OIT) for IgE-mediated food allergy, suggesting an association. OBJECTIVE: We sought to ascertain whether significant associations exist between IgE-mediated food allergies and EoE. METHODS: Using the analysis of electronic medical record data and manual chart review, we examined our subspecialty care network of 35,528 children and adolescents to identify and characterize patients with IgE-mediated and EoE food allergy. The most common food allergens were defined, and the prevalence of EoE in patients with IgE-mediated food allergy was determined. Logistic regression was used to measure the extent to which IgE-mediated food allergy to specific foods is associated with EoE. RESULTS: The most common causes of EoE were milk, soy, egg, grains, and meats, an allergen pattern that is distinct from that of IgE-mediated food allergy. The prevalence of EoE in patients with IgE-mediated food allergy was higher than that reported in the general population (4.7% vs 0.04%). The distribution of IgE-mediated food allergens in patients with EoE was similar to that of the general population, and IgE-mediated allergy to egg (2.27; 1.91-2.64), milk (4.19; 3.52-4.97), or shellfish (1.55; 1.24-1.92) was significantly associated with an EoE diagnosis. CONCLUSIONS: Our findings support a clinical association between these conditions that has implications for the management of children with food allergy, and particular relevance to patients undergoing OIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170102IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042003">PM:28042003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-369-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-369-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170102, Hill DA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eyraud,A.</style></author><author><style face="normal" font="Arial"> Boursault,L.</style></author><author><style face="normal" font="Arial"> Darrigade,A.S.</style></author><author><style face="normal" font="Arial"> Taieb,A.</style></author><author><style face="normal" font="Arial"> Milpied,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hopital Saint-Andre, CHU de Bordeaux, Bordeaux, France.</style></auth-address><titles><title><style face="normal" font="Arial">First case of DRESS syndrome attributed to a spider bite</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1136" start="1135">1135-1136</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="01/21/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Bite</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017625">PM:28017625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1135-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1135-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161226, Eyraud A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Devine,R.E.</style></author><author><style face="normal" font="Arial"> McCleary,N.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Nwaru,B.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health, National Health Service Borders Headquarters, Borders General Hospital, Melrose, Roxburghshire, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Acid-suppressive medications during pregnancy and risk of asthma and allergy in children: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1988" start="1985">1985-1988</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081850">PM:28081850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170113-DevineRE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170113-DevineRE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Devine RE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Demoly,P.</style></author><author><style face="normal" font="Arial"> Makatsori,M.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France; Sorbonne Universites, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="648" start="640">640-648</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal asthma</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">For patients whose asthma is controlled and who have a low risk for future exacerbations, current guidelines recommend gradually stepping down pharmacotherapy to identify the lowest dose needed to maintain control. This review article will discuss the benefits and risks of step down in asthma management and the different strategies of achieving step down with particular focus on allergen immunotherapy (AIT). A literature search was conducted to identify studies that assessed the effect of AIT on asthma step down and evaluated this and asthma control as one of the outcomes. Six studies were identified: 2 subcutaneous and 4 sublingual AIT studies. Five studies assessed house dust mite-induced asthma, whereas 1 study focused on birch-induced seasonal asthma. Regarding house dust mite-induced asthma, the AIT studies reviewed suggest that individuals with moderate rather than mild asthma are the patients who are more likely to benefit from the addition of AIT for their asthma condition. The potential value of AIT is likely to be in enabling successful step down of the inhaled corticosteroid dose in Global Initiative for Asthma step 3 or 4. It is important to further explore this effect so that affected individuals can benefit from this treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170102IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -CO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042004">PM:28042004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170102-DemolyP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170102-DemolyP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170102, Demoly P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">DunnGalvin,A.</style></author><author><style face="normal" font="Arial"> Koman,E.</style></author><author><style face="normal" font="Arial"> Raver,E.</style></author><author><style face="normal" font="Arial"> Frome,H.</style></author><author><style face="normal" font="Arial"> Adams,M.</style></author><author><style face="normal" font="Arial"> Keena,A.</style></author><author><style face="normal" font="Arial"> Hourihane,J.O.</style></author><author><style face="normal" font="Arial"> Gallagher,P.L.</style></author><author><style face="normal" font="Arial"> Blok,B.F.</style></author><author><style face="normal" font="Arial"> Dubois,A.</style></author><author><style face="normal" font="Arial"> Pyrz,K.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Stensgaard,A.</style></author><author><style face="normal" font="Arial"> Boyle,R.</style></author><author><style face="normal" font="Arial"> Vickers,B.</style></author><author><style face="normal" font="Arial"> Smith,J.</style></author><author><style face="normal" font="Arial"> Thisanayagam,U.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Capella University, School of Social and Behavioral Sciences, Minneapolis, Minn</style></auth-address><titles><title><style face="normal" font="Arial">An Examination of the Food Allergy Quality of Life Questionnaire Performance in a Countrywide American Sample of Children: Cross-Cultural Differences in Age and Impact in the United States and Europe</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="368" start="363">363-368</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analysis of Variance</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It is important to ensure that tools are valid and reliable in the context in which they are used. The development of age and country norms is part of this process. OBJECTIVES: The primary aim of the present study was to examine the performance of the Food Allergy Quality of Life Questionnaire - Parent Form (FAQLQ-PF) in a countrywide American sample of children with food allergy. The secondary aim was to compare age differences in impact across 9 European countries. METHODS: In a cross-sectional quantitative design, questionnaires were completed by the parents of 1029 food-allergic children (0-12 years). Participants were recruited via support groups and allergists. Data were analyzed by using multivariate analysis of variance and tests for internal consistency and validity. The average score was calculated for each age group in 15 studies in Ireland, Switzerland, the Netherlands, Spain, Portugal, Germany, Italy, Denmark, Israel, and the United Kingdom. RESULTS: The FAQLQ-PF has high convergent validity (child: r = 0.49, n = 695, P = .01; parent: r = 0.36, n = 696, P = .01) and discriminant validity, parent: t (719) = 4.67, P = .001 (anaphylaxis yes vs no); t (513), P = .009 (single vs multiple allergens). Internal consistency was excellent (r = 0.96). US health-related quality of life was worse than European health-related quality of life, as indicated by higher FAQLQ-PF scores in US samples. Burden increased with age in all populations. CONCLUSIONS: The FAQLQ-PF is appropriate for use in an American population. Findings will form the basis for further work in the development of an online manual with food allergy-normed age scores to allow for precise measurement, interpretation of scores, and comparison across countries and cultures, in clinical and research settings</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Ireland -CO - Netherlands -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017626">PM:28017626</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161226-DunnGalvinA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20161226-DunnGalvinA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161226, DunnGalvin A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Medrek,S.K.</style></author><author><style face="normal" font="Arial"> Kao,C.C.</style></author><author><style face="normal" font="Arial"> Yang,D.H.</style></author><author><style face="normal" font="Arial"> Hanania,N.A.</style></author><author><style face="normal" font="Arial"> Parulekar,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Tex</style></auth-address><titles><title><style face="normal" font="Arial">Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1031" start="1025">1025-1031</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="01/21/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fungal sensitization in patients with asthma has been associated with severe asthma and worse asthma outcomes. OBJECTIVE: The purpose of this study was to determine the relationship between fungal and nonfungal sensitization, asthma severity, and clinical outcomes. METHODS: A retrospective review of patients with asthma evaluated in an urban pulmonary subspecialty clinic in the United States was performed. Patients with fungal and nonfungal allergen sensitization were identified based on serum-specific immunoglobulin E (sIgE) testing. Demographic, clinical, laboratory, and spirometric data were obtained. The relationship between fungal sensitization and asthma outcomes was examined. RESULTS: Of 390 patients with asthma identified, 307 had sIgE testing, of whom 53 (17.3%) had fungal sensitization, 117 (38.1%) had nonfungal sensitization, and 137 (44.6%) had no sensitization. Patients with fungal sensitization were more likely to be sensitized to >/=5 allergens than patients with nonfungal sensitization (66% for fungal vs 29% for nonfungal, P &lt; .001). Serum IgE concentrations were highest in patients with fungal sensitization compared with patients with no sensitization or nonfungal sensitization (median, 825, 42, and 203 IU/mL, respectively, P &lt; .001). Fungal sensitized patients were more likely to require intensive care unit (ICU) admission and mechanical ventilation than those with no sensitization or nonfungal sensitization (13.2%, 3.7%, and 3.4%, respectively, for ICU admission, P = .02; 11.3%, 1.5%, and 0.9%, respectively, for ventilation, P &lt; .001). CONCLUSIONS: Fungal sensitization is common in patients with asthma in an urban setting and is associated with greater sensitization to nonfungal allergens and increased risk of life-threatening asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017627">PM:28017627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1025-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1025-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161226, Medrek SK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rueter,K.</style></author><author><style face="normal" font="Arial"> Ta,B.</style></author><author><style face="normal" font="Arial"> Bear,N.</style></author><author><style face="normal" font="Arial"> Lucas,M.</style></author><author><style face="normal" font="Arial"> Prescott,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Paediatrics and Child Health, University of Western Australia, Perth, Australia; Department of Paediatric Immunology, Princess Margaret Hospital for Children, Perth, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Physician training programs significantly improve diagnosis in cases coded as anaphylaxis over time: A major factor compounding time-trend data?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="860" start="858">858-860</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="01/21/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Training program</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161224IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.10.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28011240">PM:28011240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-858-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-858-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161224, Rueter K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.10.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blakey,J.D.</style></author><author><style face="normal" font="Arial"> Price,D.B.</style></author><author><style face="normal" font="Arial"> Pizzichini,E.</style></author><author><style face="normal" font="Arial"> Popov,T.A.</style></author><author><style face="normal" font="Arial"> Dimitrov,B.D.</style></author><author><style face="normal" font="Arial"> Postma,D.S.</style></author><author><style face="normal" font="Arial"> Josephs,L.K.</style></author><author><style face="normal" font="Arial"> Kaplan,A.</style></author><author><style face="normal" font="Arial"> Papi,A.</style></author><author><style face="normal" font="Arial"> Kerkhof,M.</style></author><author><style face="normal" font="Arial"> Hillyer,E.V.</style></author><author><style face="normal" font="Arial"> Chisholm,A.</style></author><author><style face="normal" font="Arial"> Thomas,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Sciences, Liverpool School of Tropical Medicine, and Respiratory Medicine, Royal Liverpool Hospital, Liverpool, United Kingdom.</style></auth-address><titles><title><style face="normal" font="Arial">Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1024" start="1015">1015-1024</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="01/21/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Reliever</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma attacks are common, serious, and costly. Individual factors associated with attacks, such as poor symptom control, are not robust predictors. OBJECTIVE: We investigated whether the rich data available in UK electronic medical records could identify patients at risk of recurrent attacks. METHODS: We analyzed anonymized, longitudinal medical records of 118,981 patients with actively treated asthma (ages 12-80 years) and 3 or more years of data. Potential risk factors during 1 baseline year were evaluated using univariable (simple) logistic regression for outcomes of 2 or more and 4 or more attacks during the following 2-year period. Predictors with significant univariable association (P &lt; .05) were entered into multiple logistic regression analysis with backward stepwise selection of the model including all significant independent predictors. The predictive accuracy of the multivariable models was assessed. RESULTS: Independent predictors associated with future attacks included baseline-year markers of attacks (acute oral corticosteroid courses, emergency visits), more frequent reliever use and health care utilization, worse lung function, current smoking, blood eosinophilia, rhinitis, nasal polyps, eczema, gastroesophageal reflux disease, obesity, older age, and being female. The number of oral corticosteroid courses had the strongest association. The final cross-validated models incorporated 19 and 16 risk factors for 2 or more and 4 or more attacks over 2 years, respectively, with areas under the curve of 0.785 (95% CI, 0.780-0.789) and 0.867 (95% CI, 0.860-0.873), respectively. CONCLUSIONS: Routinely collected data could be used proactively via automated searches to identify individuals at risk of recurrent asthma attacks. Further research is needed to assess the impact of such knowledge on clinical prognosis</style></abstract><notes><style face="normal" font="Arial">DA - 20161226IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -CO - Singapore -CO - Brazil -CO - Bulgaria -CO - Netherlands -CO - Canada -CO - Italy -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017629">PM:28017629</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1015-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1015-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161226, Blakey JD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sturm,G.J.</style></author><author><style face="normal" font="Arial"> Schrautzer,C.</style></author><author><style face="normal" font="Arial"> Arzt,L.</style></author><author><style face="normal" font="Arial"> Aberer,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers To: Comparing sensitivity of Hymenoptera allergen components on different diagnostic assay systems: Comparing apples and oranges?)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1068" start="1067">1067-1068</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> orange</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.059</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28062119">PM:28062119</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170107-SturmGJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170107-SturmGJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Sturm GJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.059</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rowe,R.K.</style></author><author><style face="normal" font="Arial"> Pyle,D.M.</style></author><author><style face="normal" font="Arial"> Tomlinson,A.R.</style></author><author><style face="normal" font="Arial"> Lv,T.</style></author><author><style face="normal" font="Arial"> Hu,Z.</style></author><author><style face="normal" font="Arial"> Gill,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Texas Southwestern, Dallas, Texas</style></auth-address><titles><title><style face="normal" font="Arial">IgE cross-linking impairs monocyte antiviral responses and inhibits influenza-driven Th1 differentiation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="298" start="294">294-298</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">IgE-mediated allergic activation impairs the virus-induced Th1 lymphocyte priming capacity of human monocytes in response to influenza exposure. These findings represent one potential mechanism contributing to the link between viral infections and allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087327">PM:28087327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170114-RoweRK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170114-RoweRK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170114, Rowe RK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shoda,T.</style></author><author><style face="normal" font="Arial"> Matsuda,A.</style></author><author><style face="normal" font="Arial"> Nomura,I.</style></author><author><style face="normal" font="Arial"> Okada,N.</style></author><author><style face="normal" font="Arial"> Orihara,K.</style></author><author><style face="normal" font="Arial"> Mikami,H.</style></author><author><style face="normal" font="Arial"> Ishimura,N.</style></author><author><style face="normal" font="Arial"> Ishihara,S.</style></author><author><style face="normal" font="Arial"> Matsumoto,K.</style></author><author><style face="normal" font="Arial"> Kinoshita,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Esophagitis vs Proton Pump Inhibitor-Responsive Esophageal Eosinophilia: Transcriptome Analysis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="2013" start="2010">2010-2013</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor-responsive esophageal eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptome analysis</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">Transcriptome analysis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia suggests these are a single syndrome, which casts doubt on the current guideline leading to the two distinct disease examinations according to PPI responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170108IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063872">PM:28063872</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170108-ShodaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170108-ShodaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170108, Shoda T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Togias,A.</style></author><author><style face="normal" font="Arial"> Cooper,S.F.</style></author><author><style face="normal" font="Arial"> Acebal,M.L.</style></author><author><style face="normal" font="Arial"> Assa'ad,A.</style></author><author><style face="normal" font="Arial"> Baker,J.R.,Jr.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Block,J.</style></author><author><style face="normal" font="Arial"> Byrd-Bredbenner,C.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Fuchs,G.J.,III</style></author><author><style face="normal" font="Arial"> Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.J.</style></author><author><style face="normal" font="Arial"> Gupta,R.S.</style></author><author><style face="normal" font="Arial"> Habich,M.</style></author><author><style face="normal" font="Arial"> Jones,S.M.</style></author><author><style face="normal" font="Arial"> Keaton,K.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Plaut,M.</style></author><author><style face="normal" font="Arial"> Rosenwasser,L.J.</style></author><author><style face="normal" font="Arial"> Rotrosen,D.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Sidbury,R.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author><author><style face="normal" font="Arial"> Stukus,D.R.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Boyce,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Allergy and Infectious Diseases, Bethesda, Md</style></auth-address><titles><title><style face="normal" font="Arial">Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="44" start="29">29-44</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy. OBJECTIVES: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy. RESULTS: The addendum provides 3 separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation. CONCLUSIONS: Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28065278">PM:28065278</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-29-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-29-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Togias A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wood,R.A.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.</style></auth-address><titles><title><style face="normal" font="Arial">LEAPing forward with the new guidelines</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="53" start="52">52-53</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28065282">PM:28065282</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-52-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-52-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Wood RA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jakob,T.</style></author><author><style face="normal" font="Arial"> Spillner,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergology, University Medical Center Giebetaen and Marburg, Camous Giebetaen, Justus Liebig University Giebetaen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Comparing sensitivity of Hymenoptera allergen components on different diagnostic assay systems: Comparing apples and oranges?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1067" start="1066">1066-1067</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> orange</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.09.058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28062118">PM:28062118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170107-JakobT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170107-JakobT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Jakob T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.09.058</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jin,J.J.</style></author><author><style face="normal" font="Arial"> Li,J.T.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergic Diseases, Mayo Clinic, Rochester, Minn.</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual Immunotherapy Dosing Regimens: What Is Ideal?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="10" start="1">1-10</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Dosing regimens</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grass tablets</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy dosing</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Sublingual immunotherapy (SLIT) is a treatment for allergic respiratory diseases that has demonstrated efficacy and safety. Several formulations of SLIT are now available worldwide for treatment of allergic rhinitis (AR). Grass tablets containing 15 to 25 mug of group 5 major allergen reduced combined AR symptoms and medication use by 23% to 41% in 3 treatment years and 2 follow-up years. Ragweed pollen tablets (12 mug of Ambrosia artemisiifolia 1) and liquid extracts (50 mug of Ambrosia artemisiifolia 1) reduced combined AR symptoms and medication use by 26% and 43%, respectively. House dust mite tablets containing 300 index of reactivity (16 mug of Dermatophagoides pteronyssinus 1 and 68 mug of Dermatophagoides farinae 1) reduced AR symptoms by 17.9% and 17.0% in 1 treatment year and 1 follow-up year, respectively. A different house dust mite tablet (12 standardized quality house dust mite) was able to reduce the risk of asthma exacerbation compared with placebo (hazard ratio, 0.69; 95% CI, 0.50-0.96). Most adverse events were local and mild to moderate in severity. For SLIT products reviewed herein, effective doses range from 1.12 to 84 mug of major allergen(s). However, allergen content is not uniformly standardized, can be expressed in arbitrary or proprietary units (depending on the manufacturer), and assays for determination of allergen content are highly variable. Thus, results from one study of a given product cannot be extrapolated to other products. Despite these limitations, this Clinical Management Review aims to provide practitioners with relevant information on the dosing of selected SLIT formulations in the treatment of allergic respiratory disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28065336">PM:28065336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Jin JJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Trivedi,A.</style></author><author><style face="normal" font="Arial"> Hall,C.</style></author><author><style face="normal" font="Arial"> Hoffman,E.A.</style></author><author><style face="normal" font="Arial"> Woods,J.C.</style></author><author><style face="normal" font="Arial"> Gierada,D.S.</style></author><author><style face="normal" font="Arial"> Castro,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St Louis, Mo</style></auth-address><titles><title><style face="normal" font="Arial">Using imaging as a biomarker for asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="10" start="1">1-10</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Contrast Media</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Gases</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Imaging techniques</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">There have been significant advancements in the various imaging techniques being used for the evaluation of asthmatic patients, both from a clinical and research perspective. Imaging characteristics can be used to identify specific asthmatic phenotypes and provide a more detailed understanding of endotypes contributing to the pathophysiology of the disease. Computed tomography, magnetic resonance imaging, and positron emission tomography can be used to assess pulmonary structure and function. It has been shown that specific airway and lung density measurements using computed tomography correlate with clinical parameters, including severity of disease and pathology, but also provide unique phenotypes. Hyperpolarized 129Xe and 3He are gases used as contrast media for magnetic resonance imaging that provide measurement of distal lung ventilation reflecting small-airway disease. Positron emission tomography can be useful to identify and target lung inflammation in asthmatic patients. Furthermore, imaging techniques can serve as a potential biomarker and be used to assess response to therapies, including newer biological treatments and bronchial thermoplasty</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28065276">PM:28065276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170109-TrivediA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170109-TrivediA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Trivedi A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,X.</style></author><author><style face="normal" font="Arial"> Jiang,D.</style></author><author><style face="normal" font="Arial"> Shi,J.</style></author><author><style face="normal" font="Arial"> Yang,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Hybrid Rice, College of Life Sciences, Wuhan University, Wuhan 430072, China</style></auth-address><titles><title><style face="normal" font="Arial">Expression of alpha-1,6-fucosyltransferase (FUT8) in rice grain and immunogenicity evaluation of plant-specific glycans</style></title><secondary-title><style face="normal" font="Arial">J Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Biotechnol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Glutelin</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seed proteins</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="Arial">Rice seed is a cost-effective bioreactor for the large-scale production of pharmaceuticals. However, convincing evidence of the immunogenicity of plant-specific glycans is still limited although plant-specific glycans are considered potential allergic antigens. In the present study, we found that the alpha-1,3-fucose content of the glycoprotein produced from rice seed was much lower than that in leaf, and conversely, a higher beta-1,2-xylose content was detected in seed than that in leaf. We detected the alpha-1,6-fucose content in the glutelin and recombinant human alpha1-antitrypsin (OsrAAT). The further results in a line containing AAT and FUT8 genes indicated that the alpha-1,6-fucose content of modified glycosylated recombinant alpha1-antitrypsin (mgOsrAAT) was 38.4%, while glutelin was only 6.8%. Interestingly, the alpha-1,3-fucose content of mgOsrAAT was significantly reduced by 59.8% compared with that of OsrAAT. Furthermore, we assessed the immunogenicity of OsrAAT, mgOsrAAT and human alpha1-antitrypsin (hAAT) using an animal system. The PCA results indicated no significant differences in the IgG, IgM and IgE titers among OsrAAT, mgOsrAAT and hAAT. Further studies revealed that those antibodies were mainly from alpha-1,3-fucose, but not from beta-1,2-xylose, indicating that alpha-1,3-fucose was the major immunogenic resource. Our results demonstrated that alpha-1,3-fucose contents in seed proteins was much less than that of leaf, and could not be a plant-specific glycan because it also exists in human proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20161225IS - 1873-4863 (Electronic)IS - 0168-1656 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jbiotec.2016.12.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28013072">PM:28013072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biotechnol\20161225-WangX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biotechnol\20161225-WangX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161225, Wang X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jbiotec.2016.12.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">James,J.</style></author><author><style face="normal" font="Arial"> Thekkeveetil,A.K.</style></author><author><style face="normal" font="Arial"> Vadakkepurayil,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Junior Resident, Department of Pedodontics, Government Dental College , Calicut, Kerala, India</style></auth-address><titles><title><style face="normal" font="Arial">Oral Manifestations of Job's Syndrome in a Paediatric Dental Patient - A Case Report</style></title><secondary-title><style face="normal" font="Arial">J Clin Diagn Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Diagn Res</style></full-title></periodical><pages end="ZD05" start="ZD04">ZD04-ZD05</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Job's Syndrome</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> Tooth</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Job's syndrome or Hyperimmunoglobulin E Syndrome (HIES) is a rare primary immunodeficiency with marked increase in serum immunoglobulin E (IgE) levels and eczematous dermatitis. Individuals with HIES share characteristic facial features, with many oral manifestations like retained deciduous teeth, fissured tongue, missing permanent tooth buds, recurrent oral candidiasis, oral mucosal and gingival lesions. Two forms of disease have been identified based on the defective gene as autosomal dominant form and autosomal recessive form. The therapeutic strategies are usually directed towards prevention and management of recurrent infections which are refractory to the conventional strategies. About 200 cases of HIES have been reported so far, in the present case report authors present the oral manifestations of a paediatric dental patient affected with HIES</style></abstract><notes><style face="normal" font="Arial">DA - 20170104IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.7860/JCDR/2016/21340.8764</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28050511">PM:28050511</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Diagn Res\2016-10-ZD04-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Diagn Res\2016-10-ZD04-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170104, James J</style></custom2><misc3><style face="normal" font="Arial">10.7860/JCDR/2016/21340.8764</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ivens,K.O.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Hutkins,R.L.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska-Lincoln, PO Box 886207, Lincoln 68588</style></auth-address><titles><title><style face="normal" font="Arial">Effect of proteolysis during Cheddar cheese aging on the detection of milk protein residues by enzyme-linked immunosorbent assay</style></title><secondary-title><style face="normal" font="Arial">J Dairy Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dairy Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen control</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Cheese</style></keyword><keyword><style face="normal" font="Arial"> Chymosin</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Ripening</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="12" Year="2016">2016/12/29</year></dates><abstract><style face="normal" font="Arial">Cow milk is a common allergenic food, and cow milk-derived cheese retains an appreciable level of allergenicity. The specific and sensitive detection of milk protein residues in foods is needed to protect milk-allergic consumers from exposure to undeclared milk protein residues contained in foods made with milk or milk-derived ingredients or made on shared equipment or in shared facilities with milk or milk-derived ingredients. However, during cheese ripening, milk proteins are degraded by chymosin and milk-derived and bacterial proteases. Commercial allergen-detection methods are not validated for the detection of residues in fermented or hydrolyzed products. The objective of this research was to evaluate commercially available milk ELISA kits for their capability to detect milk protein residues in aged Cheddar cheese. Cheddar cheese was manufactured at a local dairy plant and was aged at 5 degrees C for 24 mo, with samples removed at various time points throughout aging. Milk protein residues and protein profiles were measured using 4 commercial milk ELISA kits and sodium dodecyl sulfate-PAGE. The ELISA data revealed a 90% loss of milk protein residue signal between the youngest and oldest Cheddar cheese samples (0.5 and 24 mo, respectively). Sodium dodecyl sulfate-PAGE analysis showed protein degradation throughout aging, with the highest level of proteolysis observed at 24 mo. Results suggest that current commercial milk ELISA methods can detect milk protein residues in young Cheddar cheese, but the detection signal dramatically decreases during aging. The 4 evaluated ELISA kits were not capable of detecting trace levels of milk protein residues in aged cheese. Reliable detection of allergen residues in fermented food products is critical for upholding allergen-control programs, maintaining product safety, and protecting allergic consumers. Furthermore, this research suggests a novel use of ELISA kits to monitor protein degradation as an indication of cheese ripening</style></abstract><notes><style face="normal" font="Arial">DA - 20170102IS - 1525-3198 (Electronic)IS - 0022-0302 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3168/jds.2016-11649</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28041732">PM:28041732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dairy Sci\20170112-IvensKO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dairy Sci\20170112-IvensKO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Ivens KO</style></custom2><misc3><style face="normal" font="Arial">10.3168/jds.2016-11649</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tong,P.L.</style></author><author><style face="normal" font="Arial"> West,N.P.</style></author><author><style face="normal" font="Arial"> Cox,A.J.</style></author><author><style face="normal" font="Arial"> Gebski,V.J.</style></author><author><style face="normal" font="Arial"> Watts,A.M.</style></author><author><style face="normal" font="Arial"> Dodds,A.</style></author><author><style face="normal" font="Arial"> de St Groth,B.F.</style></author><author><style face="normal" font="Arial"> Cripps,A.W.</style></author><author><style face="normal" font="Arial"> Shumack,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centenary Institute, Newtown, NSW, Australia; Discipline of Dermatology, Sydney Medical School, University of Sydney, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Oral supplementation with bovine whey-derived Ig-rich fraction and lactoferrin improves SCORAD and DLQI in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="12" Year="2016">2016/12/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161225IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2016.11.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28012820">PM:28012820</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20161225-TongPL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20161225-TongPL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161225, Tong PL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2016.11.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nosrati,A.</style></author><author><style face="normal" font="Arial"> Afifi,L.</style></author><author><style face="normal" font="Arial"> Danesh,M.J.</style></author><author><style face="normal" font="Arial"> Lee,K.</style></author><author><style face="normal" font="Arial"> Yan,D.</style></author><author><style face="normal" font="Arial"> Ahn,R.</style></author><author><style face="normal" font="Arial"> Liao,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Dermatology , University of California San Francisco , San Francisco , CA , USA</style></auth-address><titles><title><style face="normal" font="Arial">Dietary modifications in atopic dermatitis: patient-reported outcomes</style></title><secondary-title><style face="normal" font="Arial">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> fish oil</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients with Atopic Dermatitis (AD) commonly turn to dietary modifications to manage their skin condition. OBJECTIVES: To investigate patient-reported outcomes and perceptions regarding the role of diet in AD. METHODS: 169 AD patients were surveyed in this cross-sectional study. The 61-question survey asked about dietary modifications, perceptions and outcomes. RESULTS: 87% of participants reported a trial of dietary exclusion. The most common were junk foods (68%), dairy (49.7%), and gluten (49%). The best improvement in skin was reported when removing white flour products (37 of 69, 53.6%), gluten (37 of 72, 51.4%) and nightshades (18 of 35, 51.4%). 79.9% of participants reported adding items to their diet. The most common were vegetables (62.2%), fish oil (59.3%) and fruits (57.8%). The best improvement in skin was noted when adding vegetables (40 of 84, 47.6%), organic foods (17 of 43, 39.5%) and fish oil (28 of 80, 35%). Although 93.5% of patients believed it was important that physicians discuss with them the role of diet in managing skin disease, only 32.5% had consulted their dermatologist. CONCLUSION: Since dietary modifications are extremely common, the role of diet in AD and potential nutritional benefits and risks need to be properly discussed with patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/09546634.2016.1278071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28043181">PM:28043181</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatolog Treat\20170103-NosratiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatolog Treat\20170103-NosratiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Nosrati A</style></custom2><misc3><style face="normal" font="Arial">10.1080/09546634.2016.1278071</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,Y.L.</style></author><author><style face="normal" font="Arial"> Stubbington,M.J.</style></author><author><style face="normal" font="Arial"> Daly,M.</style></author><author><style face="normal" font="Arial"> Teichmann,S.A.</style></author><author><style face="normal" font="Arial"> Rada,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, England, UK</style></auth-address><titles><title><style face="normal" font="Arial">Intrinsic transcriptional heterogeneity in B cells controls early class switching to IgE</style></title><secondary-title><style face="normal" font="Arial">J Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Exp Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="19" Month="12" Year="2016">2016/12/19</year></dates><abstract><style face="normal" font="Arial">Noncoding transcripts originating upstream of the immunoglobulin constant region (I transcripts) are required to direct activation-induced deaminase to initiate class switching in B cells. Differential regulation of Iepsilon and Igamma1 transcription in response to interleukin 4 (IL-4), hence class switching to IgE and IgG1, is not fully understood. In this study, we combine novel mouse reporters and single-cell RNA sequencing to reveal the heterogeneity in IL-4-induced I transcription. We identify an early population of cells expressing Iepsilon but not Igamma1 and demonstrate that early Iepsilon transcription leads to switching to IgE and occurs at lower activation levels than Igamma1. Our results reveal how probabilistic transcription with a lower activation threshold for Iepsilon directs the early choice of IgE versus IgG1, a key physiological response against parasitic infestations and a mediator of allergy and asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1540-9538 (Electronic)IS - 0022-1007 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1084/jem.20161056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27994069">PM:27994069</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Exp Med\20161220-WuYL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Exp Med\20161220-WuYL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Wu YL</style></custom2><misc3><style face="normal" font="Arial">10.1084/jem.20161056</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weinberger,K.R.</style></author><author><style face="normal" font="Arial"> Kinney,P.L.</style></author><author><style face="normal" font="Arial"> Robinson,G.S.</style></author><author><style face="normal" font="Arial"> Sheehan,D.</style></author><author><style face="normal" font="Arial"> Kheirbek,I.</style></author><author><style face="normal" font="Arial"> Matte,T.D.</style></author><author><style face="normal" font="Arial"> Lovasi,G.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute at Brown for Environment and Society, Brown University, Providence, Rhode Island 02912, USA</style></auth-address><titles><title><style face="normal" font="Arial">Levels and determinants of tree pollen in New York City</style></title><secondary-title><style face="normal" font="Arial">J Expo Sci Environ Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Expo Sci Environ Epidemiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> New York City</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Rhode Island</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="Arial">Exposure to allergenic tree pollen is a risk factor for multiple allergic disease outcomes. Little is known about how tree pollen levels vary within cities and whether such variation affects the development or exacerbation of allergic disease. Accordingly, we collected integrated pollen samples at uniform height at 45 sites across New York City during the 2013 pollen season. We used these monitoring results in combination with adjacent land use data to develop a land use regression model for tree pollen. We evaluated four types of land use variables for inclusion in the model: tree canopy, distributed building height (a measure of building volume density), elevation, and distance to water. When included alone in the model, percent tree canopy cover within a 0.5 km radial buffer explained 39% of the variance in tree pollen (1.9% increase in tree pollen per one-percentage point increase in tree canopy cover, P&lt;0.0001). The inclusion of additional variables did not improve model fit. We conclude that intra-urban variation in tree canopy is an important driver of tree pollen exposure. Land use regression models can be used to incorporate spatial variation in tree pollen exposure in studies of allergic disease outcomes.Journal of Exposure Science and Environmental Epidemiology advance online publication, 21 December 2016; doi:10.1038/jes.2016.72</style></abstract><notes><style face="normal" font="Arial">DA - 20161221IS - 1559-064X (Electronic)IS - 1559-0631 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/jes.2016.72</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000684">PM:28000684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Expo Sci Environ Epidemiol\20161221-WeinbergerKR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Expo Sci Environ Epidemiol\20161221-WeinbergerKR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161221, Weinberger KR</style></custom2><misc3><style face="normal" font="Arial">10.1038/jes.2016.72</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hyung,K.E.</style></author><author><style face="normal" font="Arial"> Moon,B.S.</style></author><author><style face="normal" font="Arial"> Kim,B.</style></author><author><style face="normal" font="Arial"> Park,E.S.</style></author><author><style face="normal" font="Arial"> Park,S.Y.</style></author><author><style face="normal" font="Arial"> Hwang,K.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lactobacillus plantarum isolated from kimchi suppress food allergy by modulating cytokine production and mast cells activation</style></title><secondary-title><style face="normal" font="Arial">J Funct Foods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Funct Foods</style></full-title></periodical><pages end="68" start="60">60-68</pages><volume><style face="normal" font="Arial">29</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> commensal bacteria</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> intestinal microflora</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Kimchi</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> Lactobacilli</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus plantarum</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microflora</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><isbn><style face="normal" font="Arial">1756-4646</style></isbn><abstract><style face="normal" font="Arial">Commensal bacteria interact with mucosal immune or epithelial cells to modulate the immune system. Probiotics have been proposed as a novel preventive or therapeutic method for immunological diseases because of their ability to alter intestinal microflora. Herein, lactobacilli isolated from kimchi were tested for their capacity to modulate intestinal allergy in mice. Lactic acid bacteria suppressed IL-4, IL-5, IL-13, and IL-17A cytokine production in splenocytes from OVA-sensitized mice in vitro. In a mouse model of food allergy, lactobacilli significantly inhibited the expression of Th2-associated gene products such as GATA3, IL-4, IL-5, IL-9, and IL-13 in the small intestine. Moreover, pro-inflammatory cytokine levels were lower in the lactobacillus group. Lactic acid bacteria also modulated mast cell infiltration and activation. Serum IgE/IgG2a and IgG1/IgG2a ratios were altered to alleviate Th2 responses. In conclusion, lactobacilli from kimchi effectively regulated intestinal allergy by suppressing Th2 responses and modulating mast cell function and recruitment</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jff.2016.12.016</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jff.2016.12.016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Funct Foods\2017-29-60-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Funct Foods\2017-29-60-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Hyung KE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jff.2016.12.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Glesner,J.</style></author><author><style face="normal" font="Arial"> Vailes,L.D.</style></author><author><style face="normal" font="Arial"> Schlachter,C.</style></author><author><style face="normal" font="Arial"> Mank,N.</style></author><author><style face="normal" font="Arial"> Minor,W.</style></author><author><style face="normal" font="Arial"> Osinski,T.</style></author><author><style face="normal" font="Arial"> Chruszcz,M.</style></author><author><style face="normal" font="Arial"> Chapman,M.D.</style></author><author><style face="normal" font="Arial"> Pomes,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Indoor Biotechnologies Inc., Charlottesville, VA 22903</style></auth-address><titles><title><style face="normal" font="Arial">Antigenic Determinants of Der p 1: Specificity and Cross-Reactivity Associated with IgE Antibody Recognition</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Mutagenesis</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="12" Year="2016">2016/12/30</year></dates><abstract><style face="normal" font="Arial">Der p 1 and Der f 1 are major allergens from Dermatophagoides pteronyssinus and D. farinae, respectively. An analysis of antigenic determinants on both allergens was performed by site-directed mutagenesis. The analysis was based on the x-ray crystal structures of the allergens in complex with Fab fragments of three murine mAbs that interfere with IgE Ab binding: the two Der p 1-specific mAbs 5H8 and 10B9, and the cross-reactive mAb 4C1. On one hand, selected residues in the epitopes for mAb 5H8 and mAb 4C1 were substituted with amino acids that resulted in impaired Ab binding to Der p 1. On the other hand, an epitope for the Der p 1-specific mAb 10B9, which partially overlaps with mAb 4C1, was created in Der f 1. The mutation of 1-3 aa residues in Der f 1 was sufficient to bind mAb 10B9. These residues form hydrogen bonds with CDRs of the Ab other than H CDR3. This observation unveils an exception to the dominant role of H CDR3 commonly observed in Ag recognition. Overall, this study resulted in the identification of important residues for mAb and IgE Ab recognition in group 1 mite allergens. This information can be used to engineer allergen mutants with reduced IgE Ab binding for immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161231IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1600072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28039303">PM:28039303</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20161231-GlesnerJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20161231-GlesnerJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161231, Glesner J</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1600072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">James,J.</style></author><author><style face="normal" font="Arial"> Weaver,V.</style></author><author><style face="normal" font="Arial"> Cantorna,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary and Biomedical Science, Pennsylvania State University, University Park, PA 16802</style></auth-address><titles><title><style face="normal" font="Arial">Control of Circulating IgE by the Vitamin D Receptor In Vivo Involves B Cell Intrinsic and Extrinsic Mechanisms</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> CD1d</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D receptor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="Arial">Vitamin D deficiency is associated with the development of asthma and allergy. The active form of vitamin D [1,25(OH)2D] regulates B cells in vitro and mice without the vitamin D receptor (VDR knockout [KO]) have high serum IgE. Whole-body VDR KO, T cell-specific VDR (T-VDR) KO, B cell-specific VDR (B-VDR) KO, and vitamin D deficient mice were used to determine the targets of vitamin D in the regulation of IgE in vivo. Vitamin D deficient, VDR KO, and B-VDR KO mice developed hyper-IgE, whereas T-VDR KO mice did not. The data show that IL-10 secretion by B cells and CD1d expression on IL-10 secreting B cells was lower in VDR KO mice. Mesenteric lymph node cultures from VDR KO and B-VDR KO mice secreted higher IgE ex vivo than wild-type (WT) cultures, and the addition of IL-10 eliminated the difference in IgE production between VDR KO and WT cultures. The increase in IgE in VDR KO mice was 2-fold greater than in the B-VDR KO mice, suggesting that VDR deficiency in non-B cells contributes to hyper-IgE in vivo. Antibiotic depletion of the microbiota raised serum IgE 4-fold in both WT and VDR KO mice. The VDR directly and indirectly regulates IgE production in B cells. Through the VDR, vitamin D is an environmental factor that helps to maintain low serum IgE responses</style></abstract><notes><style face="normal" font="Arial">DA - 20161222IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601213</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28003380">PM:28003380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20161222-JamesJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20161222-JamesJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161222, James J</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601213</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahajan,A.</style></author><author><style face="normal" font="Arial"> Youssef,L.A.</style></author><author><style face="normal" font="Arial"> Cleyrat,C.</style></author><author><style face="normal" font="Arial"> Grattan,R.</style></author><author><style face="normal" font="Arial"> Lucero,S.R.</style></author><author><style face="normal" font="Arial"> Mattison,C.P.</style></author><author><style face="normal" font="Arial"> Erasmus,M.F.</style></author><author><style face="normal" font="Arial"> Jacobson,B.</style></author><author><style face="normal" font="Arial"> Tapia,L.</style></author><author><style face="normal" font="Arial"> Hlavacek,W.S.</style></author><author><style face="normal" font="Arial"> Schuyler,M.</style></author><author><style face="normal" font="Arial"> Wilson,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, University of New Mexico, Albuquerque, NM 87131</style></auth-address><titles><title><style face="normal" font="Arial">Allergen Valency, Dose, and FcepsilonRI Occupancy Set Thresholds for Secretory Responses to Pen a 1 and Motivate Design of Hypoallergens</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Dimerization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> gastric digestion</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hypoallergen</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mathematical modeling</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> New Mexico</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Pen a 1</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptor Aggregation</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergy</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="12" Year="2016">2016/12/30</year></dates><abstract><style face="normal" font="Arial">Ag-mediated crosslinking of IgE-FcepsilonRI complexes activates mast cells and basophils, initiating the allergic response. Of 34 donors recruited having self-reported shrimp allergy, only 35% had significant levels of shrimp-specific IgE in serum and measurable basophil secretory responses to rPen a 1 (shrimp tropomyosin). We report that degranulation is linked to the number of FcepsilonRI occupied with allergen-specific IgE, as well as the dose and valency of Pen a 1. Using clustered regularly interspaced palindromic repeat-based gene editing, human RBLralphaKO cells were created that exclusively express the human FcepsilonRIalpha subunit. Pen a 1-specific IgE was affinity purified from shrimp-positive plasma. Cells primed with a range of Pen a 1-specific IgE and challenged with Pen a 1 showed a bell-shaped dose response for secretion, with optimal Pen a 1 doses of 0.1-10 ng/ml. Mathematical modeling provided estimates of receptor aggregation kinetics based on FcepsilonRI occupancy with IgE and allergen dose. Maximal degranulation was elicited when approximately 2700 IgE-FcepsilonRI complexes were occupied with specific IgE and challenged with Pen a 1 (IgE epitope valency of >/=8), although measurable responses were achieved when only a few hundred FcepsilonRI were occupied. Prolonged periods of pepsin-mediated Pen a 1 proteolysis, which simulates gastric digestion, were required to diminish secretory responses. Recombinant fragments (60-79 aa), which together span the entire length of tropomyosin, were weak secretagogues. These fragments have reduced dimerization capacity, compete with intact Pen a 1 for binding to IgE-FcepsilonRI complexes, and represent a starting point for the design of promising hypoallergens for immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20161231IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Syria -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601334</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28039304">PM:28039304</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20161231-MahajanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20161231-MahajanA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161231, Mahajan A</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601334</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Plunkett,C.H.</style></author><author><style face="normal" font="Arial"> Nagler,C.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, The University of Chicago, Chicago</style></auth-address><titles><title><style face="normal" font="Arial">The Influence of the Microbiome on Allergic Sensitization to Food</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="589" start="581">581-589</pages><volume><style face="normal" font="Arial">198</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="15" Month="1" Year="2017">2017/1/15</year></dates><abstract><style face="normal" font="Arial">The alarming increase in the incidence and severity of food allergies has coincided with lifestyle changes in Western societies, such as dietary modifications and increased antibiotic use. These demographic shifts have profoundly altered the coevolved relationship between host and microbiota, depleting bacterial populations critical for the maintenance of mucosal homeostasis. There is increasing evidence that the dysbiosis associated with sensitization to food fails to stimulate protective tolerogenic pathways, leading to the development of the type 2 immune responses that characterize allergic disease. Defining the role of beneficial allergy-protective members of the microbiota in the regulation of tolerance to food has exciting potential for new interventions to treat dietary allergies by modulation of the microbiota</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601266</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28069753">PM:28069753</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2017-198-581-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2017-198-581-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Plunkett CH</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601266</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Standl,M.</style></author><author><style face="normal" font="Arial"> Tesch,F.</style></author><author><style face="normal" font="Arial"> Baurecht,H.</style></author><author><style face="normal" font="Arial"> Rodriguez,E.</style></author><author><style face="normal" font="Arial"> Muller-Nurasyid,M.</style></author><author><style face="normal" font="Arial"> Gieger,C.</style></author><author><style face="normal" font="Arial"> Peters,A.</style></author><author><style face="normal" font="Arial"> Wang-Sattler,R.</style></author><author><style face="normal" font="Arial"> Prehn,C.</style></author><author><style face="normal" font="Arial"> Adamski,J.</style></author><author><style face="normal" font="Arial"> Kronenberg,F.</style></author><author><style face="normal" font="Arial"> Schulz,H.</style></author><author><style face="normal" font="Arial"> Koletzko,S.</style></author><author><style face="normal" font="Arial"> Schikowski,T.</style></author><author><style face="normal" font="Arial"> Von Berg,A.</style></author><author><style face="normal" font="Arial"> Lehmann,I.</style></author><author><style face="normal" font="Arial"> Berdel,D.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Schmitt,J.</style></author><author><style face="normal" font="Arial"> Weidinger,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Epidemiology I, Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Neuherberg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Association of atopic dermatitis with cardiovascular risk factors and diseases</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="1081" start="1074">1074-1081</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Angina Pectoris</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Stroke</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="12" Year="2016">2016/12/20</year></dates><abstract><style face="normal" font="Arial">Epidemiological studies suggested an association between atopic dermatitis (AD) and cardiovascular disease (CVD). Therefore, we investigate associations and potential underlying pathways of AD and CVD in large cohort studies: the AOK PLUS cohort (n=1.2Mio), the GINIplus/LISAplus birth cohorts (n=2286), and the KORA F4 cohort (n=2990). Additionally, metabolomics in KORA F4 and established cardiovascular risk loci in genome-wide data on 10,788 AD cases and 30,047 controls were analyzed. Longitudinal analysis of AD patients in AOK PLUS showed slightly increased risk for incident angina pectoris (AP) (adjusted risk ratio 1.17; 95%-confidence interval 1.12-1.23), hypertension (1.04 (1.02-1.06)) and peripheral arterial disease (PAD) (1.15 (1.11-1.19)) but not for myocardial infarction (MI) (1.05 (0.99-1.12) and stroke (1.02 (0.98-1.07)). In KORA F4 and GINIplus/LISAplus, AD was not associated with cardiovascular risk factors (CVRFs) and no differences in metabolite levels were detected. There was no robust evidence for shared genetic risk variants of AD and CVD. This study indicates only a marginally increased risk for AP, hypertension and PAD and no increased risk for MI or stroke in AD patients. Relevant associations of AD with CVRFs reported in US-populations could not be confirmed. Likewise, AD patients did not have increased genetic risk factors for CVD</style></abstract><notes><style face="normal" font="Arial">DA - 20161224IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2016.11.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28011146">PM:28011146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-1074-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-1074-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161224, Standl M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2016.11.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kong,H.H.</style></author><author><style face="normal" font="Arial"> Andersson,B.</style></author><author><style face="normal" font="Arial"> Clavel,T.</style></author><author><style face="normal" font="Arial"> Common,J.E.</style></author><author><style face="normal" font="Arial"> Jackson,S.A.</style></author><author><style face="normal" font="Arial"> Olson,N.D.</style></author><author><style face="normal" font="Arial"> Segre,J.A.</style></author><author><style face="normal" font="Arial"> Traidl-Hoffmann,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Performing Skin Microbiome Research: A Method to the Madness</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="568" start="561">561-568</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA sequencing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">Growing interest in microbial contributions to human health and disease has increasingly led investigators to examine the microbiome in both healthy skin and cutaneous disorders, including acne, psoriasis, and atopic dermatitis. The need for common language, effective study design, and validated methods is critical for high-quality standardized research. Features, unique to skin, pose particular challenges when conducting microbiome research. This review discusses microbiome research standards and highlights important factors to consider, including clinical study design, skin sampling, sample processing, DNA sequencing, control inclusion, and data analysis</style></abstract><notes><style face="normal" font="Arial">DA - 20170108IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -CO - Singapore -CO - United States -CO - Switzerland -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2016.10.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063650">PM:28063650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-561-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-561-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170108, Kong HH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2016.10.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asero,R.</style></author><author><style face="normal" font="Arial"> Mistrello,G.</style></author><author><style face="normal" font="Arial"> Amato,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy</style></auth-address><titles><title><style face="normal" font="Arial">IgE Reactivity to Polcalcins Varies According to Pollen Source</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="365" start="362">362-365</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polcalcin</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Polcalcins are highly cross-reactive pollen panallergens. Less than 10% of allergic patients are sensitized to polcalcins. All pollen species are considered able to sensitize patients to this panallergen. OBJECTIVE: We aimed to assess the presence of polcalcins in various pollen extracts used in allergen immunotherapy. METHODS: ELISA inhibition experiments were performed with sera from patients sensitized to polcalcin and rPhl p 7 and rBet v 4. Recombinant polcalcin was used as the substrate and freshly prepared pollen extracts as inhibitors. RESULTS: All pollen extracts induced significant inhibition of IgE reactivity to rBet v 4, whereas only grass pollen extract induced marked inhibition of IgE reactivity to rPhl p 7. CONCLUSION: Grass polcalcin probably contains more epitopes than polcalcins from other pollen sources. Grass pollen could be responsible for sensitization to polcalcins, and grass pollen immunotherapy is likely to be an option for polcalcin-hypersensitive patients</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996942">PM:27996942</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-362-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-362-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Asero R</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Depreux,N.</style></author><author><style face="normal" font="Arial"> Quilez,E.</style></author><author><style face="normal" font="Arial"> Roger,A.</style></author><author><style face="normal" font="Arial"> Basagana,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Hospital Universitari Germans Trias i Pujol, UAB, Badalona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Component-Resolved Diagnosis: Impact on Indications for Therapy in Patients With Respiratory Allergy and Sensitization to Multiple Pollens in Catalonia, Spain</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="398" start="396">396-398</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0111</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996955">PM:27996955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Depreux N</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0111</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rick,E.M.</style></author><author><style face="normal" font="Arial"> Woolnough,K.</style></author><author><style face="normal" font="Arial"> Pashley,C.H.</style></author><author><style face="normal" font="Arial"> Wardlaw,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Lung Health, Department of Infection, Immunity &amp; Inflammation, University of Leicester and Department of Respiratory Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Fungal Airway Disease</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="354" start="344">344-354</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Filamentous fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> fungal allergens</style></keyword><keyword><style face="normal" font="Arial"> fungal allergy</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Fungi are ubiquitous and form their own kingdom. Up to 80 genera of fungi have been linked to type I allergic disease, and yet, commercial reagents to test for sensitization are available for relatively few species. In terms of asthma, it is important to distinguish between species unable to grow at body temperature and those that can (thermotolerant) and thereby have the potential to colonize the respiratory tract. The former, which include the commonly studied Alternaria and Cladosporium genera, can act as aeroallergens whose clinical effects are predictably related to exposure levels. In contrast, thermotolerant species, which include fungi from the Candida, Aspergillus, and Penicillium genera, can cause a persistent allergenic stimulus independent of their airborne concentrations. Moreover, their ability to germinate in the airways provides a more diverse allergenic stimulus, and may result in noninvasive infection, which enhances inflammation. The close association between IgE sensitization to thermotolerant filamentous fungi and fixed airflow obstruction, bronchiectasis, and lung fibrosis suggests a much more tissue-damaging process than that seen with aeroallergens. This review provides an overview of fungal allergens and the patterns of clinical disease associated with exposure. It clarifies the various terminologies associated with fungal allergy in asthma and makes the case for a new term (allergic fungal airway disease) to include all people with asthma at risk of developing lung damage as a result of their fungal allergy. Lastly, it discusses the management of fungirelated asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0122</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996940">PM:27996940</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-344-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-344-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Rick EM</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0122</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruiz,B.</style></author><author><style face="normal" font="Arial"> Serrano,P.</style></author><author><style face="normal" font="Arial"> Moreno,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Maimonides Biomedical Research Institute of Cordoba</style></auth-address><titles><title><style face="normal" font="Arial">IgE-Api m 4 Is Useful for Identifying a Particular Phenotype of Bee Venom Allergy</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="361" start="355">355-361</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Api m 4</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> beekeeping</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sting challenge</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Different clinical behaviors have been identified in patients allergic to bee venom. Compound-resolved diagnosis could be an appropriate tool for investigating these differences. The aims of this study were to analyze whether specific IgE to Api m 4 (sIgE-Api m 4) can identify a particular kind of bee venom allergy and to describe response to bee venom immunotherapy (bVIT). METHODS: Prospective study of 31 patients allergic to bee venom who were assigned to phenotype group A (sIgE-Api m 4 &lt;0.98 kU/L), treated with native aqueous (NA) extract, or phenotype group B (sIgE-Api m 4 >/=0.98 kU/L), treated with purified aqueous (PA) extract. Sex, age, cardiovascular risk, severity of preceding sting reaction, exposure to beekeeping, and immunological data (intradermal test, sIgE/sIgG4-Apis-nApi m 1, and sIgE-rApi m 2-Api m 4 were analyzed. Systemic reactions (SRs) during bVIT build-up were analyzed. Immunological and sting challenge outcomes were evaluated in each group after 1 and 2 years of bVIT. RESULTS: Phenotype B patients had more severe reactions (P=.049) and higher skin sensitivity (P=.011), baseline sIgE-Apis (P=.0004), sIgE-nApi m 1 (P=.0004), and sIgG4-Apis (P=.027) than phenotype A patients. Furthermore, 41% of patients in group B experienced SRs during the build-up phase with NA; the sting challenge success rate in this group was 82%. There were no significant reductions in serial intradermal test results, but an intense reduction in sIgE-nApi m 1 (P=.013) and sIgE-Api m 4 (P=.004) was observed after the first year of bVIT. CONCLUSION: Use of IgE-Api m 4 as the only discrimination criterion demonstrated differences in bee venom allergy. Further investigation with larger populations is necessary</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996941">PM:27996941</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-355-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-355-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Ruiz B</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gutierrez,F.D.</style></author><author><style face="normal" font="Arial"> Moreno-Ancillo,A.</style></author><author><style face="normal" font="Arial"> Fernandez,M.S.</style></author><author><style face="normal" font="Arial"> Dominguez-Noche,C.</style></author><author><style face="normal" font="Arial"> Galvez,R.P.</style></author><author><style face="normal" font="Arial"> Alfaya,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio Neumologia-Alergia, Hospital Universitario Puerta Mar, Cadiz, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Insect Venom Immunotherapy: Analysis of the Safety and Tolerance of 3 Buildup Protocols Frequently Used in Spain</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="373" start="366">366-373</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analysis of Variance</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Hymenoptera venom immunotherapy (VIT) is an effective treatment but not one devoid of risk, as both local and systemic adverse reactions may occur, especially in the initial phases. We compared the tolerance to 3 VIT buildup protocols and analyzed risk factors associated with adverse reactions during this phase. MATERIALS AND METHODS: We enrolled 165 patients divided into 3 groups based on the buildup protocol used (3, 4, and 9 weeks). The severity of systemic reactions was evaluated according to the World Allergy Organization model. Results were analyzed using exploratory descriptive statistics, and variables were compared using analysis of variance. RESULTS: Adverse reactions were recorded in 53 patients (32%) (43 local and 10 systemic). Local reactions were immediate in 27 patients (63%) and delayed in 16 (37%). The severity of the local reaction was slight/moderate in 15 patients and severe in 13. Systemic reactions were grade 1-2. No significant association was found between the treatment modality and the onset of local or systemic adverse reactions or the type of local reaction. We only found a statistically significant association between severity of the local reaction and female gender. As for the risk factors associated with systemic reactions during the buildup phase, we found no significant differences in values depending on the protocol used or the insect responsible. CONCLUSIONS: The buildup protocols compared proved to be safe and did not differ significantly from one another. In the population studied, patients undergoing the 9-week schedule presented no systemic reactions. Therefore, this protocol can be considered the safest approach</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0073</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996943">PM:27996943</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-366-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-366-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Gutierrez FD</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0073</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liccardi,G.</style></author><author><style face="normal" font="Arial"> Salzillo,A.</style></author><author><style face="normal" font="Arial"> Calzetta,L.</style></author><author><style face="normal" font="Arial"> Piccolo,A.</style></author><author><style face="normal" font="Arial"> Puxeddu,E.</style></author><author><style face="normal" font="Arial"> Rogliani,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Haematology and Oncology, Division of Pneumology and Allergology, High Speciality "A.Cardarelli" Hospital, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="405" start="403">403-405</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0100</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996958">PM:27996958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Liccardi G</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0100</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moreno-Ancillo,A.</style></author><author><style face="normal" font="Arial"> Gil-Adrados,A.C.</style></author><author><style face="normal" font="Arial"> Pineda,F.</style></author><author><style face="normal" font="Arial"> Jurado-Palomo,J.</style></author><author><style face="normal" font="Arial"> Gutierrez-Fernandez,D.</style></author><author><style face="normal" font="Arial"> Moreno-Gil,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Hospital General Ntra, Sra, del Prado, Talavera de la Reina, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Fungal Allergens in a Saxophonist Who Had Never Smoked With Allergic Bronchopulmonary Aspergillosis Previously Diagnosed as COPD</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="388" start="386">386-388</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> fungal allergens</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0104</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996950">PM:27996950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Moreno-Ancillo A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0104</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huerta-Vena,A.</style></author><author><style face="normal" font="Arial"> Gonzalez-de-Olano,D.</style></author><author><style face="normal" font="Arial"> Gonzalez-Mancebo,E.</style></author><author><style face="normal" font="Arial"> Sebastian-Viana,T.</style></author><author><style face="normal" font="Arial"> Lechuga-Suarez,L.A.</style></author><author><style face="normal" font="Arial"> Mohedano-Vicente,E.</style></author><author><style face="normal" font="Arial"> Gandolfo-Cano,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine, Universidad Rey Juan Carlos, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of Allergy Alerts Registered in a Hospital Electronic Health Record System</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="402" start="400">400-402</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996957">PM:27996957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Huerta-Vena A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vidal,C.</style></author><author><style face="normal" font="Arial"> Mendez-Brea,P.</style></author><author><style face="normal" font="Arial"> Lopez-Freire,S.</style></author><author><style face="normal" font="Arial"> Gonzalez-Vidal,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Vaginal Capsules: An Unsuspected Probable Source of Exposure to alpha-Gal</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="389" start="388">388-389</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Capsules</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0105</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996951">PM:27996951</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Vidal C</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0105</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Antolin-Amerigo,D.</style></author><author><style face="normal" font="Arial"> Rodriguez-Rodriguez,M.</style></author><author><style face="normal" font="Arial"> Barbarroja-Escudero,J.</style></author><author><style face="normal" font="Arial"> Sanchez-Gonzalez,M.J.</style></author><author><style face="normal" font="Arial"> Haroun-Diaz,E.</style></author><author><style face="normal" font="Arial"> Cuesta-Herranz,J.</style></author><author><style face="normal" font="Arial"> Pastor-Vargas,C.</style></author><author><style face="normal" font="Arial"> Alvarez-Mon,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Enfermedades del Sistema Inmune-Alergia, Hospital Universitario Principe de Asturias. Alcala de Henares, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Linseed Allergy Due to LTP: Another Food for LTP Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="377" start="376">376-377</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> LTP-syndrome</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0097</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996945">PM:27996945</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Antolin-Amerigo D</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0097</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caballero,M.L.</style></author><author><style face="normal" font="Arial"> Lluch-Bernal,M.</style></author><author><style face="normal" font="Arial"> Vila-Nadal,G.</style></author><author><style face="normal" font="Arial"> Lluncor,M.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">IgE-Mediated Anaphylaxis Induced by Macrogol 6000</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="400" start="398">398-400</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Macrogol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0089</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996956">PM:27996956</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Caballero ML</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0089</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sastre,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Fundacion Jimenez Diaz, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Reply to Liccardi et al</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="" start="406">406-</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0106</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996959">PM:27996959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Sastre J</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0106</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez-Mazariego,M.E.</style></author><author><style face="normal" font="Arial"> Fuentes,A.V.</style></author><author><style face="normal" font="Arial"> Bartolome,Z.B.</style></author><author><style face="normal" font="Arial"> Acevedo,M.M.</style></author><author><style face="normal" font="Arial"> Zapatero,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergia, Hospital Materno Infantil Gregorio Maranon, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Broad Bean-Induced Anaphylaxis: A Case Report</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="375" start="374">374-375</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0096</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996944">PM:27996944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161220, Rodriguez-Mazariego ME</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0096</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Torkildsen,G.</style></author><author><style face="normal" font="Arial"> Abelson,M.B.</style></author><author><style face="normal" font="Arial"> Gomes,P.J.</style></author><author><style face="normal" font="Arial"> McLaurin,E.</style></author><author><style face="normal" font="Arial"> Potts,S.L.</style></author><author><style face="normal" font="Arial"> Mah,F.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Andover Eye Associates , Andover, Massachusetts</style></auth-address><titles><title><style face="normal" font="Arial">Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model</style></title><secondary-title><style face="normal" font="Arial">J Ocul Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Ocul Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">PURPOSE: To evaluate the efficacy and safety of a sustained-release dexamethasone intracanalicular insert (Dextenza) in a model of allergic conjunctivitis. METHODS: This was a randomized, double-masked, vehicle-controlled, Phase 2 study. Subjects had to have a positive conjunctival allergen challenge (CAC) reaction to allergen (bilateral +2 itching and redness on 5-point, 0-4 scales) at Visit 1, and for 2 of 3 time points on subsequent visits. Subjects who met entry criteria were randomized to receive Dextenza or PV (vehicle insert). Challenges occurred over 42 days, with efficacy assessed at 14 (primary endpoint visit), 28, and 40 days postinsertion. Outcome measures included the evaluation of ocular itching, redness, tearing, chemosis, eyelid swelling, rhinorrhea, and congestion. RESULTS: Twenty-eight subjects completed the study in the Dextenza group and 31 in the vehicle group. At 14 days postinsertion, Dextenza was statistically superior to PV, with least square mean differences for ocular itching of -0.76, -0.97, and -0.87 at 3, 5, and 7 min post-CAC, and for conjunctival redness of -0.46, -0.66, and -0.68 at 7, 15, and 20 min post-CAC. Clinical significance, defined as a 1-U decrease from PV, was not met for primary efficacy. Secondary endpoints, including number of subjects reporting itching and conjunctival redness, indicated superior performance of Dextenza compared with vehicle. Eleven Dextenza-treated (35.5%) and 10 vehicle-treated (30.3%) subjects each experienced a single adverse event. CONCLUSION: This Phase 2 study demonstrated preliminary efficacy and safety data of Dextenza for treatment of allergic conjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1557-7732 (Electronic)IS - 1080-7683 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1089/jop.2016.0154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28072552">PM:28072552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ocul Pharmacol Ther\20170110-TorkildsenG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ocul Pharmacol Ther\20170110-TorkildsenG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Torkildsen G</style></custom2><misc3><style face="normal" font="Arial">10.1089/jop.2016.0154</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Habich,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Northwestern Medicine, Central DuPage Hospital, Winfield, IL. Electronic address: Michele.Habich@nm.org</style></auth-address><titles><title><style face="normal" font="Arial">WITHDRAWN: Introduction to the Addendum Guidelines for the Prevention of Peanut Allergy in the United States</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Nurs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="13" Month="12" Year="2016">2016/12/13</year></dates><abstract><style face="normal" font="Arial">The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy</style></abstract><notes><style face="normal" font="Arial">DA - 20161217IS - 1532-8449 (Electronic)IS - 0882-5963 (Linking)LA - engPT - Retraction of PublicationCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pedn.2016.12.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27986372">PM:27986372</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Nurs\20161217-HabichMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Nurs\20161217-HabichMM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161217, Habich MM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pedn.2016.12.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mousavi,F.</style></author><author><style face="normal" font="Arial"> Majd,A.</style></author><author><style face="normal" font="Arial"> Shahali,Y.</style></author><author><style face="normal" font="Arial"> Ghahremaninejad,F.</style></author><author><style face="normal" font="Arial"> Shourmasti,R.S.</style></author><author><style face="normal" font="Arial"> Pourpak,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Plant Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Immunoproteomics of tree of heaven (Ailanthus atltissima) pollen allergens</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="101" start="94">94-101</pages><volume><style face="normal" font="Arial">154</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Ailanthus</style></keyword><keyword><style face="normal" font="Arial"> Ailanthus altissima</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biological significance</style></keyword><keyword><style face="normal" font="Arial"> Calreticulin</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Enolase</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunoproteomics</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pectate lyase</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tree of heaven</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Ailanthus altissima pollen (AAP) is considered as an emerging cause of respiratory allergy in United States, Italy and Iran. However, the allergenic composition of AAP is still unknown and has yet to be characterized. The present study aimed to identify AAP allergens using a proteomics-based approach. For this purpose, optimized AAP protein extracts were analyzed using 1D- and 2D- gel electrophoresis and confronted to twenty sera from individuals with respiratory allergy during the AAP season. Candidate allergens were detected using the serum from an allergic patient with clinical history of AAP pollinosis. IgE-binding spots were identified using MALDI-TOF/TOF mass spectrometry and database searching. According to our results, AAP extracts were rich in proteins (up to 16.25mg/ml) with a molecular-weight distribution ranging from 10 to 175kDa. Two-D electrophoresis of AAP extracts revealed 125 protein spots from which 13 were IgE reactive. These IgE-binding proteins were identified as enolase, calreticulin, probable pectate lyase 6, conserved hypothetical protein and ras-related protein RHN1-like. By our knowledge, this study is the first report identifying AAP allergens. These findings will open up further avenues for the diagnosis and immunotherapy of the AAP allergy as well as for the cloning and molecular characterization of relevant allergens. BIOLOGICAL SIGNIFICANCE: Ailanthus altissima colonizes new areas every year in Iran and is spreading aggressively worldwide. According to USDA, the tree of heaven is now present as an invasive plant in 30 states in US (www.invasivespeciesinfo.gov/plants/treeheaven.shtml) and come to dominate large areas in many regions. Up to now, several cases of allergy to A. altissima pollen have been reported in United States, Italy and Iran [1-4]. However, there is still no information on the sensitizing allergens and the molecular origin of these clinical symptoms, which constitutes a serious threat to patients suffering from respiratory allergies in these regions. To our knowledge, the current study describes, therefore, the first panel of proteins responsible for IgE-mediated A. altissima pollinosis by using a gel-based proteomic approach. This work represents the pioneer proteomic investigation on Simaroubaceae spp. and provides useful insights for further studies on the allergens of this widely distributed plant family</style></abstract><notes><style face="normal" font="Arial">DA - 20170102IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2016.12.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28041857">PM:28041857</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\2017-154-94-101.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\2017-154-94-101.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170102, Mousavi F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2016.12.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Waiblinger,H.U.</style></author><author><style face="normal" font="Arial"> Boernsen,B.</style></author><author><style face="normal" font="Arial"> Geppert,C.</style></author><author><style face="normal" font="Arial"> Demmel,A.</style></author><author><style face="normal" font="Arial"> Peterseil,V.</style></author><author><style face="normal" font="Arial"> Koeppel,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Ring trial validation of single and multiplex real-time PCR methods for the detection and quantification of the allergenic food ingredients mustard, celery, soy, wheat and rye</style></title><secondary-title><style face="normal" font="Arial">J Verbr Lebensm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Verbr Lebensm</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Black mustard</style></keyword><keyword><style face="normal" font="Arial"> Brown mustard</style></keyword><keyword><style face="normal" font="Arial"> Calibrant</style></keyword><keyword><style face="normal" font="Arial"> Celery</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food ingredients</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Multiplex PCR</style></keyword><keyword><style face="normal" font="Arial"> Multiplex-PCR</style></keyword><keyword><style face="normal" font="Arial"> Mustard</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Simultaneous detection</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1661-5867</style></isbn><abstract><style face="normal" font="Arial">We describe an interlaboratory ring trial validation for quantification methods of 3 food allergens using real-time PCR: a real-time PCR method for the joint simultaneous detection and quantification of brown and black mustard, a real-time PCR method for the detection and quantification of wheat and rye, and a multiplex real-time PCR method combining the detection and quantification of brown/black mustard, white mustard, celery and soybean. Mixtures with defined copy numbers of the target sequences from brown mustard, white mustard, celery, soybean and wheat were applied as calibrants for the real-time PCR-based quantification. Boiled sausages incurred with these allergenic ingredients in the range of 0</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô100-ámg/kg were used as ring trial samples. Within the ring trial, we demonstrated that 40-ámg/kg of the respective allergens (wheat/rye 80-ámg/kg) can reliably be detected and quantified by all PCR systems even in boiled sausage meat. Brown/black mustard was detectable at the lowest concentration level of 10-ámg/kg even after autoclaving. Results for brown/black mustard in terms of sensitivity, trueness and precision were comparable in single- and multiplex PCR. The results of the study revealed the importance of matrix-matched control samples for allergen analysis in terms of both conversion to mg/kg and of normalization variations caused by different extraction procedures</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -CO - Austria -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00003-016-1063-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00003-016-1063-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Verbr Lebensm\20170110-WaiblingerHU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Verbr Lebensm\20170110-WaiblingerHU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Waiblinger HU</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00003-016-1063-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ierodiakonou,D.</style></author><author><style face="normal" font="Arial"> Garcia-Larsen,V.</style></author><author><style face="normal" font="Arial"> Boyle,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Paediatrics, Imperial College London, London, England</style></auth-address><titles><title><style face="normal" font="Arial">Allergenic Food Introduction and Childhood Risk of Allergic or Autoimmune Disease-Reply</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="" start="87">87-</pages><volume><style face="normal" font="Arial">317</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="01/18/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161228IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2016.18339</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030698">PM:28030698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-317-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-317-87.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161228, Ierodiakonou D</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2016.18339</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nwaru,B.I.</style></author><author><style face="normal" font="Arial"> Virtanen,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Health Sciences, University of Tampere, Tampere, FinlandNutrition Unit, National Institute for Health and Welfare, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Allergenic Food Introduction and Childhood Risk of Allergic or Autoimmune Disease</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="" start="86">86-</pages><volume><style face="normal" font="Arial">317</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161228IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2016.18329</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030695">PM:28030695</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-317-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-317-86.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161228, Nwaru BI</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2016.18329</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wooldridge,A.L.</style></author><author><style face="normal" font="Arial"> McMillan,M.</style></author><author><style face="normal" font="Arial"> Marshall,H.S.</style></author><author><style face="normal" font="Arial"> Gatford,K.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1Robinson Research Institute and School of Medicine, The University of Adelaide, Adelaide, Australia 2Vaccinology and Immunology Research Trials Unit (VIRTU), Women's and Children's Hospital, North Adelaide, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Relationship between birth weight or fetal growth rate and postnatal allergy: a systematic review protocol</style></title><secondary-title><style face="normal" font="Arial">JBI Database System Rev Implement Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">JBI Database System Rev Implement Rep</style></abbr-1></periodical><pages end="20" start="11">11-20</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fetal growth</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth rate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">REVIEW QUESTION/OBJECTIVE: The objective of this systematic review is to synthesize the best available evidence on the relationship between size at birth or fetal growth and postnatal allergy. Specifically, this review aims to assess evidence regarding relationships between absolute birth weight at term, birth weight corrected for gestational age, expressed as relative to population or customized growth data, or fetal growth measures and physician-diagnosed or parent- and self-reported postnatal clinical allergic disease (eczema/atopic dermatitis, hay fever/rhinitis, allergic asthma or anaphylaxis).The specific review question is: what is the association between the absolute birth weight at full-term or birth weight relative to population or customized data and corrected for gestational age or direct measures of fetal growth, and physician-diagnosed or parent- and self-reported clinical allergic disease (eczema/atopic dermatitis, hay fever/rhinitis, allergic asthma or anaphylaxis)?</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 2202-4433 (Electronic)IS - 2202-4433 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.11124/JBISRIR-2016-003177</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27941506">PM:27941506</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JBI Database System Rev Implement Rep\2016-14-11-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JBI Database System Rev Implement Rep\2016-14-11-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Wooldridge AL</style></custom2><misc3><style face="normal" font="Arial">10.11124/JBISRIR-2016-003177</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lortholary,O.</style></author><author><style face="normal" font="Arial"> Chandesris,M.O.</style></author><author><style face="normal" font="Arial"> Livideanu,C.B.</style></author><author><style face="normal" font="Arial"> Paul,C.</style></author><author><style face="normal" font="Arial"> Guillet,G.</style></author><author><style face="normal" font="Arial"> Jassem,E.</style></author><author><style face="normal" font="Arial"> Niedoszytko,M.</style></author><author><style face="normal" font="Arial"> Barete,S.</style></author><author><style face="normal" font="Arial"> Verstovsek,S.</style></author><author><style face="normal" font="Arial"> Grattan,C.</style></author><author><style face="normal" font="Arial"> Damaj,G.</style></author><author><style face="normal" font="Arial"> Canioni,D.</style></author><author><style face="normal" font="Arial"> Fraitag,S.</style></author><author><style face="normal" font="Arial"> Lhermitte,L.</style></author><author><style face="normal" font="Arial"> Lavialle,S.G.</style></author><author><style face="normal" font="Arial"> Frenzel,L.</style></author><author><style face="normal" font="Arial"> Afrin,L.B.</style></author><author><style face="normal" font="Arial"> Hanssens,K.</style></author><author><style face="normal" font="Arial"> Agopian,J.</style></author><author><style face="normal" font="Arial"> Gaillard,R.</style></author><author><style face="normal" font="Arial"> Kinet,J.P.</style></author><author><style face="normal" font="Arial"> Auclair,C.</style></author><author><style face="normal" font="Arial"> Mansfield,C.</style></author><author><style face="normal" font="Arial"> Moussy,A.</style></author><author><style face="normal" font="Arial"> Dubreuil,P.</style></author><author><style face="normal" font="Arial"> Hermine,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious Diseases and Tropical Medicine and Centre d'Infectiologie Necker-Pasteur, Universite Paris Descartes, Hopital Necker Enfants Malades, Assistance Publique Hopitaux de Paris, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> Enfants</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> indolent systemic mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Lyn</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safety and efficacy of masitinib versus placebo in severely symptomatic patients who were unresponsive to optimal symptomatic treatments. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on histological criteria, at 50 centres in 15 countries. We excluded patients with cutaneous or non-severe systemic mastocytosis after a protocol amendment. Patients were centrally randomised (1:1) to receive either oral masitinib (6 mg/kg per day over 24 weeks with possible extension) or matched placebo with minimisation according to severe symptoms. The primary endpoint was cumulative response (>/=75% improvement from baseline within weeks 8-24) in at least one severe baseline symptom from the following: pruritus score of 9 or more, eight or more flushes per week, Hamilton Rating Scale for Depression of 19 or more, or Fatigue Impact Scale of 75 or more. We assessed treatment effect using repeated measures methodology for rare diseases via the generalised estimating equation model in a modified intention-to-treat population, including all participants assigned to treatment minus those who withdrew due to a non-treatment-related cause. We assessed safety in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT00814073. FINDINGS: Between Feb 19, 2009, and July 15, 2015, 135 patients were randomly assigned to masitinib (n=71) or placebo (n=64). By 24 weeks, masitinib was associated with a cumulative response of 18.7% in the primary endpoint (122.6 responses of 656.5 possible responses [weighted generalised estimating equation]) compared with 7.4% for placebo (48.9 of 656.5; difference 11.3%; odds ratio 3.6; 95% CI 1.2-10.8; p=0.0076). Frequent severe adverse events (>4% difference from placebo) were diarrhoea (eight [11%] of 70 in the masitinib group vs one [2%] of 63 in the placebo group), rash (four [6%] vs none), and asthenia (four [6%] vs one [2%]). The most frequent serious adverse events were diarrhoea (three patients [4%] vs one [2%]) and urticaria (two [3%] vs none), and no life-threatening toxicities occurred. One patient in the placebo group died (unrelated to study treatment). INTERPRETATION: These study findings indicate that masitinib is an effective and well tolerated agent for the treatment of severely symptomatic indolent or smouldering systemic mastocytosis. FUNDING: AB Science (Paris, France)</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticleCO - France -CO - Poland -CO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(16)31403-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28069279">PM:28069279</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20170110-LortholaryO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20170110-LortholaryO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Lortholary O</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(16)31403-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Haspeslagh,E.</style></author><author><style face="normal" font="Arial"> Debeuf,N.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunoregulation and Mucosal Immunology, VIB Inflammation Research Center, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Murine Models of Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="136" start="121">121-136</pages><volume><style face="normal" font="Arial">1559</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immunology</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Rodents</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a heterogeneous inflammatory lung disease affecting millions of people worldwide and with a steadily increasing incidence. Mouse models have been of utmost importance in uncovering key inflammatory cell types, cytokines, and pathways in the development and maintenance of allergic asthma. Historically, the mainstay in experimental asthma research was sensitizing rodents to the model protein antigen ovalbumin (OVA) with the pro-Th2 adjuvant aluminum hydroxide, followed by repetitive OVA exposures to the airways to initiate a Th2-skewed adaptive immune response leading to eosinophilic airway inflammation and airway hyperreactivity (AHR). In the last 5 years, OVA is often replaced by naturally occurring allergens such as house dust mite (HDM) or cockroach extracts, but the principle of first sensitizing and then repetitively challenging mice with the same antigen is unchanged. Here, we describe an often used and relevant HDM-based protocol to establish acute allergic asthma, and the methods we have developed to rapidly analyze inflammatory cell infiltration in the bronchalveolar lavage fluid by flow cytometry. Moreover, we explain the methods to restimulate T cells from lung-draining mediastinal lymph nodes with HDM to allow the measurement of cytokine secretion profiles of allergen reactive T cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6786-5_10</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063042">PM:28063042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1559-121-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1559-121-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Haspeslagh E</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6786-5_10</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hesse,L.</style></author><author><style face="normal" font="Arial"> Nawijn,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology and Medical Biology, Laboratory of Experimental Pulmonology and Inflammation Research (EXPIRE), University Medical Center Groningen, University of Groningen, Hanzeplein 1 (EA52/T2.212), 9713 GZ, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="168" start="137">137-168</pages><volume><style face="normal" font="Arial">1559</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Luminex assay</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual administration</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Suspensions</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic asthma, caused by inhaled allergens such as house dust mite or grass pollen, is characterized by reversible airway obstruction, associated with an eosinophilic inflammation of the airways, as well as airway hyper responsiveness and remodeling. The inhaled allergens trigger a type-2 inflammatory response with involvement of innate lymphoid cells (ILC2) and Th2 cells, resulting in high production of immunoglobulin E (IgE) antibodies. Consequently, renewed allergen exposure results in a classic allergic response with a distinct early and late phase, both resulting in bronchoconstriction and shortness of breath. Allergen specific immunotherapy (AIT) is the only treatment that is capable of modifying the immunological process underlying allergic responses including allergic asthma and both subcutaneous AIT (SCIT) as well as sublingual AIT (SLIT) have proven clinical efficacy in long term suppression of the allergic response. Although these treatments are very successful for rhinitis, application of AIT in asthma is hampered by variable efficacy, long duration of treatment, and the risk of severe side-effects. A more profound understanding of the mechanisms by which AIT achieves tolerance to allergens in sensitized individuals is needed to improve its efficacy. Mouse models have been very valuable as a preclinical model to characterize the mechanisms of desensitization in AIT and to evaluate novel approaches for improved efficacy. Here, we present a rapid and reproducible mouse model for allergen-specific immunotherapy. In this model, mice are sensitized with two injections of allergen absorbed to aluminum hydroxide to induce allergic sensitization, followed by subcutaneous injections (SCIT) or sublingual administrations (SLIT) of the allergen as immunotherapy treatment. Finally, mice are challenged by three intranasal allergen administrations. We will describe the protocols as well as the most important read-out parameters including measurement of invasive lung function measurements, serum immunoglobulin levels, isolation of broncho-alveolar lavage fluid (BALF), and preparation of cytospins. Moreover, we describe how to restimulate lung single cell suspensions, perform flow cytometry measurements to identify populations of relevant immune cells, and perform ELISAs and Luminex assays to measure the cytokine concentrations in BALF and lung tissue</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6786-5_11</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063043">PM:28063043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1559-137-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1559-137-68.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Hesse L</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6786-5_11</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,B.W.</style></author><author><style face="normal" font="Arial"> Beerens,D.M.</style></author><author><style face="normal" font="Arial"> Brem,M.D.</style></author><author><style face="normal" font="Arial"> Hendriks,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Erasmus MC Rotterdam, 2040, 3000, CA, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Characterization of Group 2 Innate Lymphoid Cells in Allergic Airway Inflammation Models in the Mouse</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="183" start="169">169-183</pages><volume><style face="normal" font="Arial">1559</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a chronic inflammatory lung disease mediated by type 2 cytokines produced by T helper 2 (Th2) cells as well as the recently discovered group 2 innate lymphoid cells (ILC2). Due to a lack of unique markers, the accurate phenotypic characterization and quantification of ILC2 requires a comprehensive panel of fluorescently labeled antibodies. The markers that are currently used to characterize ILC2 have not been standardized and often vary between research groups, which poses significant challenges when comparing data. Intranasal administration of the pro-inflammatory cytokine IL-33 in mice is associated with strong, Th2 cell-independent ILC2 activation. ILC2 are also activated in mouse models of allergic asthma based on the physiologically relevant house dust mite (HDM) allergen, which parallel eosinophilic airway inflammation observed in asthma patients. Here, we describe the analysis of ILC2 by flow cytometry in these two commonly used allergic airway inflammation models in the mouse</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6786-5_12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063044">PM:28063044</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1559-169-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1559-169-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Li BW</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6786-5_12</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moosbrugger-Martinz,V.</style></author><author><style face="normal" font="Arial"> Schmuth,M.</style></author><author><style face="normal" font="Arial"> Dubrac,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Epidermal Biology Laboratory, Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria</style></auth-address><titles><title><style face="normal" font="Arial">A Mouse Model for Atopic Dermatitis Using Topical Application of Vitamin D3 or of Its Analog MC903</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="106" start="91">91-106</pages><volume><style face="normal" font="Arial">1559</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> alarmins</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamin D3</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease with pruritus and high prevalence. Indeed, 15-30 % of children and 2-10 % of adults from industrialized countries are affected. Acute AD lesions are characterized by epidermal hyperplasia associated with a dominant Th2/Th17 immune response and dermal inflammatory infiltrates. Moreover, the expression of alarmins such as TSLP, IL-33, and IL-25 is upregulated in acute AD lesions. Topical application of vitamin D3 or of its low-calcemic analog MC903 induces changes in skin morphology and inflammation resembling immune perturbations observed in acute lesions of patients with AD. Mice treated with MC903 or vitamin D3 additionally display increased serum IgE levels, as observed in patients with extrinsic AD. Interestingly, these symptoms are not dependent on mouse gender or on genetic background. Thus, the easiness of this mouse model renders it very attractive to study immunologic abnormalities involved in AD development or maintenance. Furthermore, this model might be useful for preclinical studies aiming at unraveling new therapeutic strategies to treat AD. In this chapter, we describe the induction and major features of MC903 and vitamin D3-induced AD-like inflammation in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170107IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6786-5_</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063040">PM:28063040</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1559-91-106.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1559-91-106.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170107, Moosbrugger-Martinz V</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6786-5_</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.</style></author><author><style face="normal" font="Arial"> Wu,Q.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Mo,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">DNA aptamer for use in a fluorescent assay for the shrimp allergen-átropomyosin</style></title><secondary-title><style face="normal" font="Arial">Microchim Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Microchim Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Aptamers</style></keyword><keyword><style face="normal" font="Arial"> Biosensor</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergy</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1436-5073</style></isbn><abstract><style face="normal" font="Arial">Shrimp allergy is a common cause of allergenic diseases. The authors describe an aptamer-based assay for tropomyosin, one of the major allergens of shrimp. After six rounds of SELEX based on nitrocellulose membrane, several aptamers with high affinity (Kd-á=-á109.6-ánM) were identified that can selectively recognize tropomyosin but not other proteins over a large range of concentrations. By using a fluorescent and graphene oxide based platform, a tropomyosin assay was worked out that has a 4.2-ánM detection limit and work in the 0.5 to 50-á++g-ÀmL</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1 concentration range. The aptamers selected hold a great potential for tropomyosin detection in practical biosensor assays</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00604-016-2042-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00604-016-2042-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microchim Acta\20170110-ZhangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microchim Acta\20170110-ZhangY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Zhang Y</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00604-016-2042-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baos,S.</style></author><author><style face="normal" font="Arial"> Calzada,D.</style></author><author><style face="normal" font="Arial"> Cremades,L.</style></author><author><style face="normal" font="Arial"> Sastre,J.</style></author><author><style face="normal" font="Arial"> Quiralte,J.</style></author><author><style face="normal" font="Arial"> Florido,F.</style></author><author><style face="normal" font="Arial"> Lahoz,C.</style></author><author><style face="normal" font="Arial"> Cardaba,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Department, IIS-Jimenez Diaz Foundation, UAM, Madrid, Spain; CIBERES, CIBER of Respiratory Diseases, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Biomarkers associated with disease severity in allergic and nonallergic asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="45" start="34">34-45</pages><volume><style face="normal" font="Arial">82</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="20" Month="12" Year="2016">2016/12/20</year></dates><abstract><style face="normal" font="Arial">Asthma is a complex, chronic respiratory disease with a wide clinical spectrum. Use of high-throughput technologies has generated a great deal of data that require validation. In this work the objective was to validate molecular biomarkers related to asthmatic disease types in peripheral blood samples and define their relationship with disease severity. With this purpose, ninety-four previously described genes were analyzed by qRT-PCR in 30 healthy control (HC) subjects, 30 patients with nonallergic asthma (NA), 30 with allergic asthma (AA), and 14 patients with allergy (rhinitis) but without asthma (AR). RNA was extracted from peripheral blood mononuclear cells (PBMCs) using the TRIzol method. After data normalization, principal component analysis (PCA) was performed, and multiple approaches were used to test for differential gene expression. Relevance was defined by RQ (relative quantification) and corrected P value (&lt;0.05). Protein levels of IL-8 and MSR1 were determined by ELISA and Western blot, respectively. PCA showed 4 gene expression clusters that correlated with the 4 clinical phenotypes. Analysis of differential gene expression between clinical groups and HCs revealed 26 statistically relevant genes in NA and 69 in AA. Protein interaction analysis revealed IL-8 to be a central protein. Average levels of IL-8 were higher in the asthma patients' sera (NA: 452.28+/-357.72, AA: 327.46+/-377pg/ml) than in HCs (286.09+/-179.10), but without reaching statistical significance. Nine genes, especially MSR1, were strongly associated with severe NA. In conclusion, several molecular biomarkers of asthma have been defined, some of which could be useful for the diagnosis or prognosis of disease severity</style></abstract><notes><style face="normal" font="Arial">DA - 20161224IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2016.12.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28011367">PM:28011367</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2016-82-34-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2016-82-34-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161224, Baos S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2016.12.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ming,M.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Luo,Z.</style></author><author><style face="normal" font="Arial"> Lv,S.</style></author><author><style face="normal" font="Arial"> Sun,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">The effect of inhaled inactived Mycobacterium phlei as a treatment for asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="783" start="777">777-783</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Mycobacteria</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a chronic airway disorder characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR). A murine model of asthma was used to examine the antiasthmatic effect of inhaled inactived Mycobacterium phlei (M. phlei). AHR, neutrophil levels, eosinophil levels and levels of interleukin (IL)17 and IL23 receptor (IL23R) were monitored. The results demonstrated that inactivated M. phlei alleviates the IL17+gammadeltaT cellmediated immune response and attenuates airway in fl ammation and airway hyperresponsiveness in the asthmatic murine lung, partially through inhibiting the expression of IL23R. In conclusion, inactivated M. phlei may be an effective antiasthmatic treatment, regulating IL17producing gammadeltaT (IL17+gammadeltaT) cellmediated airway in fl ammation and airway hyperresponsiveness to relieve the symptoms of mice with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161230IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2016.6087</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28035388">PM:28035388</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-15-777-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-15-777-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161230, Ming M</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2016.6087</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wangorsch,A.</style></author><author><style face="normal" font="Arial"> Jamin,A.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Grani,N.</style></author><author><style face="normal" font="Arial"> Lang,C.</style></author><author><style face="normal" font="Arial"> Ballmer-Weber,B.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Scheurer,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">VPr1 Research Group Molecular Allergology, Paul-Ehrlich-Institut, Langen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Identification and implication of an allergenic PR-10 protein from walnut in birch pollen associated walnut allergy</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Competitive ELISA</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic use</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Jug r 5</style></keyword><keyword><style face="normal" font="Arial"> Juglans regia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> walnut allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="1" Year="2017">2017/1/9</year></dates><abstract><style face="normal" font="Arial">SCOPE: English walnut (Juglans regia) belongs to the most important allergenic tree nuts. Co-sensitization with birch (Betula verrucosa) pollen has been reported. We aimed to identify a walnut allergen homologous to the major birch pollen allergen Bet v 1. METHODS AND RESULTS: A cDNA encoding a Bet v 1-homologous allergen (Jug r 5) in walnut kernels was cloned by RT-PCR. Jug r 5 was expressed in E.coli, purified by column chromatography and characterized by CD-spectroscopy. Specific IgE levels to walnut, Bet v 1 and Jug r 5 in birch pollen allergics (n = 16) with concomitant walnut allergy were measured by ImmunoCAP: 44% of the patients were tested positive to walnut while 94% were reactive to Jug r 5 and 100% to Bet v 1. Jug r 5 and Bet v 1 allergens showed bi-directional IgE-cross-reactivity by competitive ELISA and were capable of inducing histamine release from effector cells. Immunoblot competition experiments demonstrated the presence of IgE-reactive Jug r 5 in walnut extract, but at low levels. CONCLUSION: A Bet v 1-like allergen was identified in walnut. Diagnostic use of Jug r 5 will compensate for the low sensitivity of walnut extract for patients with birch pollen associated walnut allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Sweden -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201600902</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28070926">PM:28070926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170110-WangorschA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170110-WangorschA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Wangorsch A</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201600902</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jimenez,P.</style></author><author><style face="normal" font="Arial"> Cabrero,P.</style></author><author><style face="normal" font="Arial"> Cordoba-Diaz,D.</style></author><author><style face="normal" font="Arial"> Cordoba-Diaz,M.</style></author><author><style face="normal" font="Arial"> Garrosa,M.</style></author><author><style face="normal" font="Arial"> Girbes,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nutricion y Bromatologia, Facultad de Medicina, Universidad de Valladolid, Valladolid 47005, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Lectin Digestibility and Stability of Elderberry Antioxidants to Heat Treatment In Vitro</style></title><secondary-title><style face="normal" font="Arial">Molecules</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Molecules</style></full-title></periodical><pages end="" start="E95">E95-</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> anthocyanin</style></keyword><keyword><style face="normal" font="Arial"> Anthocyanins</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Nutraceutical</style></keyword><keyword><style face="normal" font="Arial"> Nutraceuticals</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="Arial">Elderberry contains healthy low molecular weight nutraceuticals and lectins which are sequence-related to the elderberry allergen Sam n1. Some of these lectins are type II ribosome-inactivating proteins. The sensitivity of native lectins present in elderberry fruits and bark to the proteolysis triggered by in vitro simulated gastric and duodenal fluids has been investigated. It was found that these lectins are refractory to proteolysis. Nonetheless, incubation for 5-10 min in a boiling water bath completely sensitized them to the hydrolytic enzymes in vitro. Under these conditions neither total Folin-Ciocalteau's reagent reactive compounds, total anthocyanins and the mixture of cyanidin-3-glucoside plus cyanidin-3-sambubioside, nor antioxidant and free-radical scavenging activities were affected by more than 10% for incubations of up to 20 min. Therefore, short-time heat treatment reduces potential allergy-related risks deriving from elderberry consumption without seriously affecting its properties as an antioxidant and free-radical scavenging food</style></abstract><notes><style face="normal" font="Arial">DA - 20170109IS - 1420-3049 (Electronic)IS - 1420-3049 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3390/molecules22010095</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28067841">PM:28067841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Molecules\2017-22-E95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Molecules\2017-22-E95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170109, Jimenez P</style></custom2><misc3><style face="normal" font="Arial">10.3390/molecules22010095</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bisgaard,H.</style></author><author><style face="normal" font="Arial"> Stokholm,J.</style></author><author><style face="normal" font="Arial"> Chawes,B.L.</style></author><author><style face="normal" font="Arial"> Vissing,N.H.</style></author><author><style face="normal" font="Arial"> Bjarnadottir,E.</style></author><author><style face="normal" font="Arial"> Schoos,A.M.</style></author><author><style face="normal" font="Arial"> Wolsk,H.M.</style></author><author><style face="normal" font="Arial"> Pedersen,T.M.</style></author><author><style face="normal" font="Arial"> Vinding,R.K.</style></author><author><style face="normal" font="Arial"> Thorsteinsdottir,S.</style></author><author><style face="normal" font="Arial"> Folsgaard,N.V.</style></author><author><style face="normal" font="Arial"> Fink,N.R.</style></author><author><style face="normal" font="Arial"> Thorsen,J.</style></author><author><style face="normal" font="Arial"> Pedersen,A.G.</style></author><author><style face="normal" font="Arial"> Waage,J.</style></author><author><style face="normal" font="Arial"> Rasmussen,M.A.</style></author><author><style face="normal" font="Arial"> Stark,K.D.</style></author><author><style face="normal" font="Arial"> Olsen,S.F.</style></author><author><style face="normal" font="Arial"> Bonnelykke,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From COPSAC (Copenhagen Prospective Studies on Asthma in Childhood), Herlev and Gentofte Hospital, University of Copenhagen</style></auth-address><titles><title><style face="normal" font="Arial">Fish Oil-Derived Fatty Acids in Pregnancy and Wheeze and Asthma in Offspring</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="2539" start="2530">2530-2539</pages><volume><style face="normal" font="Arial">375</style></volume><number><style face="normal" font="Arial">26</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> fish oil</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> long-chain polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="Arial"> lower respiratory tract infections</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> persistent wheeze</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="29" Month="12" Year="2016">2016/12/29</year></dates><abstract><style face="normal" font="Arial">Background Reduced intake of n-3 long-chain polyunsaturated fatty acids (LCPUFAs) may be a contributing factor to the increasing prevalence of wheezing disorders. We assessed the effect of supplementation with n-3 LCPUFAs in pregnant women on the risk of persistent wheeze and asthma in their offspring. Methods We randomly assigned 736 pregnant women at 24 weeks of gestation to receive 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day. Their children formed the Copenhagen Prospective Studies on Asthma in Childhood2010 (COPSAC2010) cohort and were followed prospectively with extensive clinical phenotyping. Neither the investigators nor the participants were aware of group assignments during follow-up for the first 3 years of the children's lives, after which there was a 2-year follow-up period during which only the investigators were unaware of group assignments. The primary end point was persistent wheeze or asthma, and the secondary end points included lower respiratory tract infections, asthma exacerbations, eczema, and allergic sensitization. Results A total of 695 children were included in the trial, and 95.5% completed the 3-year, double-blind follow-up period. The risk of persistent wheeze or asthma in the treatment group was 16.9%, versus 23.7% in the control group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.97; P=0.035), corresponding to a relative reduction of 30.7%. Prespecified subgroup analyses suggested that the effect was strongest in the children of women whose blood levels of eicosapentaenoic acid and docosahexaenoic acid were in the lowest third of the trial population at randomization: 17.5% versus 34.1% (hazard ratio, 0.46; 95% CI, 0.25 to 0.83; P=0.011). Analyses of secondary end points showed that supplementation with n-3 LCPUFA was associated with a reduced risk of infections of the lower respiratory tract (31.7% vs. 39.1%; hazard ratio, 0.75; 95% CI, 0.58 to 0.98; P=0.033), but there was no statistically significant association between supplementation and asthma exacerbations, eczema, or allergic sensitization. Conclusions Supplementation with n-3 LCPUFA in the third trimester of pregnancy reduced the absolute risk of persistent wheeze or asthma and infections of the lower respiratory tract in offspring by approximately 7 percentage points, or one third. (Funded by the Lundbeck Foundation and others; ClinicalTrials.gov number, NCT00798226 .)</style></abstract><notes><style face="normal" font="Arial">DA - 20161228IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa1503734</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28029926">PM:28029926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2016-375-2530-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2016-375-2530-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161228, Bisgaard H</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa1503734</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Czaja-Bulsa,G.</style></author><author><style face="normal" font="Arial"> Bulsa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatrics and Paediatric Nursery Unit, Pomeranian Medical University, Zolnierska 48, Szczecin 71-210, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">What Do We Know Now about IgE-Mediated Wheat Allergy in Children?</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Nurseries</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">IgE-mediated wheat allergy is a gluten-related disorder. Wheat is one of the five most common food allergens in children. However, the natural history of IgE-mediated wheat allergy has seldom been described in the research literature. This study presents the current state of knowledge about the IgE-mediated wheat allergy in children</style></abstract><notes><style face="normal" font="Arial">DA - 20170105IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9010035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28054973">PM:28054973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170105, Czaja-Bulsa G</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9010035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jones,M.</style></author><author><style face="normal" font="Arial"> Blair,S.</style></author><author><style face="normal" font="Arial"> MacNeill,S.</style></author><author><style face="normal" font="Arial"> Welch,J.</style></author><author><style face="normal" font="Arial"> Hole,A.</style></author><author><style face="normal" font="Arial"> Baxter,P.</style></author><author><style face="normal" font="Arial"> Cullinan,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Occupational and Environmental Medicine, Imperial College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Occupational allergy to fruit flies (Drosophila melanogaster) in laboratory workers</style></title><secondary-title><style face="normal" font="Arial">Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Drosophila</style></keyword><keyword><style face="normal" font="Arial"> Drosophila melanogaster</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> exposure-response relationship</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> work-related symptom</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="30" Month="12" Year="2016">2016/12/30</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Drosophila melanogaster (the 'fruit fly') is commonly used in genetic research, but there is only one report of IgE-associated allergy in exposed workers. 4 newly identified cases prompted us to examine the extent of this problem in a university laboratory. Our aim in this study is to determine the prevalence and determinants of sensitisation to fruit flies in a population of exposed workers. METHODS: In a cross-sectional study, we surveyed 286 employees working in a department carrying out research involving D. melanogaster. Sensitisation was assessed by specific IgE measurement in serum and examined in relation to symptoms and to estimated exposure to fruit flies. RESULTS: The overall prevalence of specific sensitisation was 6% with a clear relationship to increasing frequency/intensity of exposure (p trend&lt;0.001). Work-related eye/nose, chest or skin symptoms were reported by substantial proportions of participants but for most of these there was no evidence of specific sensitisation to fruit fly. The overall prevalence of any work-related symptoms and sensitisation was 2.4%, rising to 7.1% in those working in high exposure groups. CONCLUSIONS: We were able to demonstrate, for the first time, a clear exposure-response relationship between fruit fly exposure and specific sensitisation. Facilities housing fruit flies should carefully consider methods to reduce exposure levels in the workplace</style></abstract><notes><style face="normal" font="Arial">DA - 20161231IS - 1470-7926 (Electronic)IS - 1351-0711 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/oemed-2016-103834</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28039199">PM:28039199</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Occup Environ Med\20161231-JonesM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Occup Environ Med\20161231-JonesM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161231, Jones M</style></custom2><misc3><style face="normal" font="Arial">10.1136/oemed-2016-103834</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,B.Z.</style></author><author><style face="normal" font="Arial"> Bishop,J.A.</style></author><author><style face="normal" font="Arial"> Chien,W.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A case of allergic fungal otomastoiditis with aural polyps</style></title><secondary-title><style face="normal" font="Arial">Otolaryngol Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Otolaryngol Case Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic mucin</style></keyword><keyword><style face="normal" font="Arial"> Aural polyps</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> CT scan</style></keyword><keyword><style face="normal" font="Arial"> Debridement</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> Hyphae</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Middle ear</style></keyword><keyword><style face="normal" font="Arial"> Mucin</style></keyword><keyword><style face="normal" font="Arial"> Otitis</style></keyword><keyword><style face="normal" font="Arial"> Otitis Media</style></keyword><keyword><style face="normal" font="Arial"> Otomastoiditis</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2468-5488</style></isbn><abstract><style face="normal" font="Arial">While common in the paranasal sinuses, the presence of allergic mucin within the middle ear is rare. Here we describe a case of what has been termed allergic fungal otomastoiditis (AFOM), an unusual immunologic response to the presence of fungal hyphae within the middle ear, with a unique presentation of aural polyps. A 25-year-old woman presented with recurrent right-sided aural polyps and chronic otorrhea, despite two previous tympanomastoidectomy surgeries performed in India. CT scan of the temporal bones demonstrated complete opacification of the tympanic cavity and mastoid. Canal wall down tympanomastoidectomy was performed, revealing thick otorrhea and polyps filling the external auditory canal and middle ear, eroding the entire tympanic membrane and obstructing the antrum. Pathology revealed glandular and squamous metaplasia, marked inflammation with eosinophils, as well as allergic-type mucin with non-invasive fungal hyphae highlighted by GMS stain. The histopathologic findings of AFOM are reminiscent of allergic fungal rhinosinusitis (AFRS) and suggest a similar pathophysiology. Optimal treatment in these cases may require a combination of surgical debridement and medical management. AFOM should be considered in the differential diagnosis of chronic otitis media, particularly in the presence of aural polyps and thick otorrhea</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.xocr.2016.12.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.xocr.2016.12.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Otolaryngol Case Rep\20170112-ZhuBZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Otolaryngol Case Rep\20170112-ZhuBZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Zhu BZ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.xocr.2016.12.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foong,R.X.</style></author><author><style face="normal" font="Arial"> Meyer,R.</style></author><author><style face="normal" font="Arial"> Godwin,H.</style></author><author><style face="normal" font="Arial"> Dziubak,R.</style></author><author><style face="normal" font="Arial"> Lozinsky,A.C.</style></author><author><style face="normal" font="Arial"> Reeve,K.</style></author><author><style face="normal" font="Arial"> Knibb,R.</style></author><author><style face="normal" font="Arial"> Shah,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Great Ormond Street Hospital for Children NHS Foundation Trust, London, UKInstitute of Child Health, University College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Parental perception of their child's Quality of Life in children with non-Immunoglobulin-E mediated gastrointestinal allergies</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="256" start="251">251-256</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy can have a significant impact on health related quality of life (HRQoL). Parental proxy questionnaires are commonly used when children are too young to complete questionnaires themselves. Little data is available on HRQoL in children with non-IgE-mediated gastrointestinal food allergy (GIFA). The aim of this study was to evaluate HRQoL in these children by parent proxy. METHODS: A cross-sectional questionnaire study was conducted with children 2-16 years old with confirmed (GIFA). Parents of these children completed the Paediatric Quality of Life Inventory (PedsQL ) and the Family Impact module of the PedsQL. The PedsQL scores were compared to two published cohorts: functional abdominal pain (FAP) and IgE-mediated food allergy. RESULTS: Fifty-two parents of children with GIFA completed the PedsQL parent proxy. The GIFA cohort had significantly better overall HRQoL compared to the FAP cohort, but lower emotional functioning scores. The GIFA cohort also had poorer physical QoL compared to the IgE cohort (all p&lt;0.05). The more foods excluded, comorbidity of nasal congestion, abdominal pain, back arching, the persistence of flatus and gastrointestinal symptom severity after elimination diet were related to poorer QoL in this non-IgE cohort. Regression analyses showed that number of foods and nasal congestion significantly predicted total QoL score as perceived by parents. CONCLUSIONS: This study has shown that different areas of HRQoL of children with GIFA are affected compared to children with FAP or IgE-mediated food allergy, highlighting the need for a specific GIFA HRQoL questionnaire to better understand the impact on these children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161219IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12689</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27992662">PM:27992662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161219-FoongRX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161219-FoongRX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161219, Foong RX</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12689</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saleh-Langenberg,J.</style></author><author><style face="normal" font="Arial"> de Vries,S.</style></author><author><style face="normal" font="Arial"> Bak,E.</style></author><author><style face="normal" font="Arial"> Kollen,B.J.</style></author><author><style face="normal" font="Arial"> Flokstra-de Blok,B.M.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Groningen, University Medical Centre Groningen, Department of Pediatric Pulmonology and Pediatric Allergy, Groningen, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Incomplete and incorrect epinephrine auto-injector training to food-allergic patients by pharmacists in the Netherlands</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="244" start="238">238-244</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> epinephrine auto-injectors</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Pharmacists</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> quality of care</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Successful treatment of anaphylaxis in the community relies on early and correct use of epinephrine auto-injectors (EAI). In the Netherlands pharmacists supply EAIs to patients and have a crucial role in instructing patients in how and when to use EAI. However, there are currently no data in Europe on the quality of such instruction provided by pharmacists. Therefore, the aims of this study were to investigate the knowledge, attitudes, and beliefs regarding food allergy among pharmacists in the Netherlands, and to investigate the quality of EAI instructions and demonstrations to patients by pharmacists. METHODS: Pharmacists were asked to complete an online questionnaire. Quality of instructions and demonstration accuracy were assessed in mystery guest visits to randomly selected pharmacies. For the statistical analysis descriptive methods were used. RESULTS: In total 25 out of 115 questionnaires were completed. Only two (8%) respondents gave correct answers concerning the proper EAI demonstration. Twenty-one (84%) respondents thought that the provision of instructions was the responsibility of pharmacists. In total, ten pharmacies were included in simulated patient visits. Five of them (50%) demonstrated the EAI. None of them demonstrated the EAI use correctly. CONCLUSION: Food-allergic patients at high risk for anaphylaxis who receive their EAI from a community pharmacy are often not instructed on how to use an EAI or receive incorrect instructions. Pharmacists show considerable gaps in knowledge about food allergy and its management. These data suggest that opportunities exist to improve the quality of care provided by pharmacies to high risk food-allergic patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161219IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12688</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27992679">PM:27992679</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161219-SalehLangenbergJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161219-SalehLangenbergJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161219, Saleh-Langenberg J</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12688</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aitoro,R.</style></author><author><style face="normal" font="Arial"> Simeoli,R.</style></author><author><style face="normal" font="Arial"> Amoroso,A.</style></author><author><style face="normal" font="Arial"> Paparo,L.</style></author><author><style face="normal" font="Arial"> Nocerino,R.</style></author><author><style face="normal" font="Arial"> Pirozzi,C.</style></author><author><style face="normal" font="Arial"> Di Costanzo,M.</style></author><author><style face="normal" font="Arial"> Meli,R.</style></author><author><style face="normal" font="Arial"> De Caro,C.</style></author><author><style face="normal" font="Arial"> Picariello,G.</style></author><author><style face="normal" font="Arial"> Mamone,G.</style></author><author><style face="normal" font="Arial"> Calignano,A.</style></author><author><style face="normal" font="Arial"> Nagler,C.R.</style></author><author><style face="normal" font="Arial"> Berni Canani,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Translational Medical Science, University of Naples "Federico II", Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Extensively hydrolyzed casein formula alone or with L. rhamnosus GG reduces beta-lactoglobulin sensitization in mice</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="237" start="230">230-237</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acute allergic skin response</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intestinal permeability</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus rhamnosus</style></keyword><keyword><style face="normal" font="Arial"> LGG</style></keyword><keyword><style face="normal" font="Arial"> MALDI TOF mass spectrometry</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Extensively hydrolyzed casein formula (EHCF) has been proposed for the prevention and is commonly used for the treatment of cow's milk allergy (CMA). The addition of the probiotic Lactobacillus rhamnosus GG (LGG) to EHCF may induces faster acquisition of tolerance to cow's milk. The mechanisms underlying this effect are largely unexplored. We investigated the effects of EHCF alone or in combination with LGG on beta-lactoglobulin (BLG) sensitization in mice. METHODS: Three-weeks old C3H/HeOuJ mice were sensitized by oral administration of BLG using cholera toxin as adjuvant at weekly intervals for 5 weeks (sensitization period). Two experimental phases were conducted: 1. EHCF or EHCF+LGG given daily, starting 2 weeks before the sensitization period and then given daily for 5 weeks, and 2. EHCF or EHCF+LGG given daily for 4 weeks, starting 1 week after the sensitization period. Diet free of cow's milk protein was used as control. Acute allergic skin response, anaphylactic symptom score, body temperature, intestinal permeability, anti-BLG serum IgE and interleukin (IL)-4, IL-5, IL-10, IL-13, IFN-gamma mRNA expression were analysed. Peptide fractions of EHCF were characterized by reversed phase (RP)-HPLC, MALDI-TOF mass spectrometry and nano-HPLC ESI MS/MS. RESULTS: EHCF administration before or after BLG-induced sensitization significantly reduced acute allergic skin reaction, anaphylactic symptom score, body temperature decrease, intestinal permeability increase, IL-4, IL-5, IL-13 and anti-BLG IgE production. EHCF increased expression of IFN -gamma and IL-10. Many of these effects were significantly enhanced by LGG supplementation. The peptide panels were similar between the two study formulas and contained sequences that could have immunoregolatory activities. CONCLUSIONS: The data support dietary intervention with EHCF for CMA prevention and treatment through a favorable immunomodulatory action. The observed effects are significantly enhanced by LGG supplementation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161219IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12687</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27992668">PM:27992668</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161219-AitoroR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161219-AitoroR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161219, Aitoro R</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12687</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmer,D.J.</style></author><author><style face="normal" font="Arial"> Prescott,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Paediatrics and Child Health, The University of Western Australia, Perth, WA, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Early introduction of food reduces food allergy - Pro</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="221" start="214">214-221</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Over the past two decades we have been debating the question of whether the age of commencement of complementary feeding affects the risk of developing food allergy. We ate up the notion that delayed introduction of more allergenic foods in early childhood, would help overcome the increasing rates of food allergy, then we promptly spat it out again despite limited evidence. Recently high-quality randomised controlled trial evidence has given us the confidence to swallow the concept that allergenic foods, like egg and peanut, should be given to infants. We now need to recommend that when an infant is developmentally ready, a variety of nutritious foods should be introduced to ensure high diet diversity, including the 'more allergenic' foods during infancy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161231IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12692</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28039897">PM:28039897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161231-PalmerDJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20161231-PalmerDJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161231, Palmer DJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12692</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Togias,A.</style></author><author><style face="normal" font="Arial"> Cooper,S.F.</style></author><author><style face="normal" font="Arial"> Acebal,M.L.</style></author><author><style face="normal" font="Arial"> Assa'ad,A.</style></author><author><style face="normal" font="Arial"> Baker,J.R.,Jr.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Block,J.</style></author><author><style face="normal" font="Arial"> Byrd-Bredbenner,C.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Fuchs,G.J.,III</style></author><author><style face="normal" font="Arial"> Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.J.</style></author><author><style face="normal" font="Arial"> Gupta,R.S.</style></author><author><style face="normal" font="Arial"> Habich,M.</style></author><author><style face="normal" font="Arial"> Jones,S.M.</style></author><author><style face="normal" font="Arial"> Keaton,K.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Plaut,M.</style></author><author><style face="normal" font="Arial"> Rosenwasser,L.J.</style></author><author><style face="normal" font="Arial"> Rotrosen,D.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Sidbury,R.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author><author><style face="normal" font="Arial"> Stukus,D.R.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Boyce,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The National Institute of Allergy and Infectious Diseases, Bethesda, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel</style></title><secondary-title><style face="normal" font="Arial">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Dermatol</style></full-title></periodical><pages end="e21" start="e1">e1-e21</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy. OBJECTIVES: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy. RESULTS: The addendum provides three separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation. CONCLUSIONS: Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170105IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/pde.13093</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28054723">PM:28054723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Dermatol\2017-34-e1-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Dermatol\2017-34-e1-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170105, Togias A</style></custom2><misc3><style face="normal" font="Arial">10.1111/pde.13093</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stukus,D.R.</style></author><author><style face="normal" font="Arial"> Kempe,E.</style></author><author><style face="normal" font="Arial"> Leber,A.</style></author><author><style face="normal" font="Arial"> Thornton,D.</style></author><author><style face="normal" font="Arial"> Scherzer,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio</style></auth-address><titles><title><style face="normal" font="Arial">Use of Food Allergy Panels by Pediatric Care Providers Compared With Allergists</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20161602">e20161602-</pages><volume><style face="normal" font="Arial">138</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Immunoglobullin E (IgE)-mediated food allergies affect 5% to 8% of children. Serum IgE levels assist in diagnosing food allergies but have low positive predictive value. This can lead to misinterpretation, overdiagnosis, and unnecessary dietary elimination. Use of IgE food allergen panels has been associated with increased cost and burden. The scale of use of these panels has not been reported in the medical literature. METHODS: We conducted a retrospective review of a commercial laboratory database associated with a tertiary care pediatric academic medical center for food IgE tests ordered by all provider types during 2013. RESULTS: A total of 10 794 single-food IgE tests and 3065 allergen panels were ordered. Allergists ordered the majority of single-food IgE tests (58.2%) whereas 78.8% of food allergen panels were ordered by primary care providers (PCPs) (P &lt; .001). Of all IgE tests ordered by PCPs, 45.1% were panels compared with 1.2% of orders placed by allergists (P &lt; .001). PCPs in practice for >15 years ordered a higher number of food allergen panels (P &lt; .05) compared with PCPs with less experience. Compared with allergists, PCPs ordered more tests for unlikely causes of food allergies (P &lt; .001). Total cost of IgE testing and cost per patient were higher for PCPs compared with allergists. CONCLUSIONS: Review of food allergen IgE testing through a high volume outpatient laboratory revealed PCPs order significantly more food allergen panels, tests for uncommon causes of food allergy, and generate higher cost per patient compared with allergists. These results suggest a need for increased education of PCPs regarding proper use of food IgE tests</style></abstract><notes><style face="normal" font="Arial">DA - 20161212IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2016-1602</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27940693">PM:27940693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\2016-138-e20161602.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\2016-138-e20161602.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161212, Stukus DR</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2016-1602</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhakeer,Z.</style></author><author><style face="normal" font="Arial"> Hadeer,M.</style></author><author><style face="normal" font="Arial"> Tuerxun,Z.</style></author><author><style face="normal" font="Arial"> Tuerxun,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Function Test Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China</style></auth-address><titles><title><style face="normal" font="Arial">Bufalin Inhibits the Inflammatory Effects in Asthmatic Mice through the Suppression of Nuclear Factor-Kappa B Activity</style></title><secondary-title><style face="normal" font="Arial">Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharmacology</style></full-title></periodical><pages end="187" start="179">179-187</pages><volume><style face="normal" font="Arial">99</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Respiratory function</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">Asthma is an inflammatory airway disease characterized by increased infiltration of inflammatory cells into the airways and poor respiratory function. Bufalin is one of the biological ingredients obtained from Chansu. Bufalin was found to possess various pharmacological properties including anti-inflammatory activities. However, the effect of bufalin treatment on asthma has not yet been reported. Therefore, this study aimed to investigate the inhibitory effect of bufalin on asthmatic response in a murine model. A mouse asthma model was developed by ovalbumin (OVA) sensitization and challenge in the BALB/c mice. OVA-specific serum IgE and the levels of interleukin (IL)-4, IL-5, and IL-13 in bronchoalveolar lavage fluid (BALF) were determined by an enzyme-linked immunosorbent assay. Recruitment of inflammatory cells into BALF or lung tissues, and goblet cell hyperplasia were evaluated by histological staining. The expression levels of inhibitory subunit of nuclear factor-kappa B (NF-kappaB) alpha (IkappaBalpha) and phosphorylated p65 protein were measured by Western blot analyses. The results demonstrated that bufalin (5 and 10 mg/kg) markedly attenuated hyperresponsiveness, and strongly suppressed the OVA-induced increases of total inflammatory cells including macrophages, eosinophils, lymphocytes, and neutrophils in BALF. The levels of IL-4, IL-5, and IL-13 in BALF and OVA-specific IgE in serum were significantly reduced by bufalin. Histological staining of lung tissues showed that bufalin reduced inflammatory cell infiltration and goblet cell hyperplasia. The results of Western blotting indicated that bufalin suppressed the IkappaBalpha degradation from NF-kappaB, and reduced the level of phosphorylated p65 protein in the lung tissues. These data suggest that bufalin can exert its anti-inflammatory effects possibly through the inhibition of the NF-kappaB activity</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1423-0313 (Electronic)IS - 0031-7012 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1159/000450754</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049205">PM:28049205</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170103, Zhakeer Z</style></custom2><misc3><style face="normal" font="Arial">10.1159/000450754</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wong,T.H.</style></author><author><style face="normal" font="Arial"> Chen,H.A.</style></author><author><style face="normal" font="Arial"> Gau,R.J.</style></author><author><style face="normal" font="Arial"> Yen,J.H.</style></author><author><style face="normal" font="Arial"> Suen,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Heme Oxygenase-1-Expressing Dendritic Cells Promote Foxp3+ Regulatory T Cell Differentiation and Induce Less Severe Airway Inflammation in Murine Models</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0168919">e0168919-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Heme</style></keyword><keyword><style face="normal" font="Arial"> heme oxygenase 1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Dendritic cells (DCs) are critical for instructing immune responses toward inflammatory or anti-inflammatory status. Heme oxygenase-1 (HO-1) is known for its cytoprotective effect against oxidative stress and inflammation, suggesting its immune regulatory role in allergic lung inflammation. HO-1 has been implicated in affecting DC maturation; however, its role in DC-mediated T-cell differentiation is unclear. In this study, we demonstrated that HO-1-expressing bone marrow-derived dendritic cells (BM-DCs) displayed tolerogenic phenotypes, including their resistance to lipopolysaccharide (LPS)-induced maturation, high level expression of IL-10, and low T-cell stimulatory activity. In addition, HO-1-expressing DCs were able to induce antigen-specific Foxp3+ regulatory T cells (Treg) differentiation in vitro and in vivo. Also, HO-1-expressing DCs modulated the severity of lung inflammatory responses in two murine models of airway inflammation. This study provided evidence supporting the role of HO-1-expressing DCs in tolerance induction and as a potential therapeutic target for allergic asthma as well as other inflammatory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0168919</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28033400">PM:28033400</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0168919.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0168919.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Wong TH</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0168919</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schwarzer,M.</style></author><author><style face="normal" font="Arial"> Srutkova,D.</style></author><author><style face="normal" font="Arial"> Hermanova,P.</style></author><author><style face="normal" font="Arial"> Leulier,F.</style></author><author><style face="normal" font="Arial"> Kozakova,H.</style></author><author><style face="normal" font="Arial"> Schabussova,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Gnotobiology, Institute of Microbiology of the Czech Academy of Sciences, v. v. i., Novy Hradek, Czech Republic</style></auth-address><titles><title><style face="normal" font="Arial">Diet Matters: Endotoxin in the Diet Impacts the Level of Allergic Sensitization in Germ-Free Mice</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0167786">e0167786-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> commensal bacteria</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Germ-free animals have been used to define the vital role of commensal bacteria on the maturation of the host immune system. However, the role of bacterial residues in diet in this setting is poorly understood. Here we investigated the effect of bacterial contamination in sterile diet on the level of allergic sensitization in germ-free mice. Sterile grain-based diets ST1 and R03 were tested for the level of bacterial contamination. ST1 contained higher amount of bacterial DNA, approximately ten times more endotoxin, and induced higher, TLR4-dependent, cytokine production in dendritic cells compared to R03. In a germ-free mouse model of sensitization to the major birch pollen allergen Bet v 1, feeding on ST1 for at least two generations was associated with decreased production of allergen-specific IgE and IgG1 antibodies in sera in comparison to R03. Furthermore, reduced levels of allergen-specific and ConA-induced cytokines IL-4, IL-5 and IL-13 accompanied by increased levels of IFN-gamma were detected in splenocytes cultures of these mice. Our results show that contamination of experimental diet with bacterial residues, such as endotoxin, significantly affects the development of allergic sensitization in germ-free mice. Therefore, careful selection of sterile food is critical for the outcomes of germ-free or gnotobiotic experimental models of immune-deviated diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170104IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Czech Republic -CO - France -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0167786</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052076">PM:28052076</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0167786.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0167786.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170104, Schwarzer M</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0167786</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.L.</style></author><author><style face="normal" font="Arial"> Han,D.H.</style></author><author><style face="normal" font="Arial"> Kim,D.Y.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author><author><style face="normal" font="Arial"> Rhee,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology-head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Role of Interleukin-17A on the Chemotactic Responses to CCL7 in a Murine Allergic Rhinitis Model</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0169353">e0169353-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal inflammation</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The proinflammatory cytokine interleukin (IL)-17A is associated with eosinophil infiltration into the nasal mucosa in a mouse model of ovalbumin-induced allergic rhinitis. Chemotaxis of eosinophils is mediated primarily through C-C chemokine receptor type 3 (CCR3). However, the mechanism underlying the IL-17A-mediated enhancement of eosinophil recruitment via chemoattractants/chemokines remains unknown. OBJECTIVES: In this study, we assessed the contribution of IL-17A to eosinophil-related inflammation via the CCL7/CCR3 pathway in experimental allergic rhinitis. METHODS: IL-17A knockout (KO) and wild-type (WT) BALB/c mice were injected intraperitoneally and challenged intranasally with OVA to induce allergic rhinitis. Various parameters of the allergic response were evaluated, and mRNA and protein levels of CCL7 and CCR3 in nasal tissue and serum were compared between the two groups. The chemotactic response to CCL7 with or without IL-17A in bone marrow-derived eosinophils (bmEos) from BALB/c mice was measured. RESULTS: In the allergic rhinitis model, IL-17A deficiency significantly decreased nasal symptoms, serum IgE levels, and eosinophil recruitment to the nasal mucosa. CCL7 and CCR3 mRNA and protein levels were decreased in the nasal mucosa of IL-17A KO mice compared with the WT mice. BmEos showed a significantly increased chemotactic response to -low concentration of CCL7 in the presence of IL-17A compared with its absence. CONCLUSION: The suppression of nasal inflammation due of IL-17A deficiency in allergic rhinitis is partly responsible for the regulation of CCL7 secretion and eosinophil infiltration, which may be regulated via the CCL7/CCR3 pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0169353</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28046055">PM:28046055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0169353.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0169353.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Zhang YL</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0169353</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,H.</style></author><author><style face="normal" font="Arial"> Kim,E.K.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Kim,T.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0169209">e0169209-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Cell viability</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fluorescein</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Manganese</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Ocular surface</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> rapamycin</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tear</style></keyword><keyword><style face="normal" font="Arial"> Tears</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Based on previous findings that ozone can induce an inflammatory response in the ocular surface of an animal model and in cultured human conjunctival epithelial cells, we investigated whether exposure to ozone exacerbates symptoms of allergic conjunctivitis. We evaluated the effects of exposure to ozone on conjunctival chemosis, conjunctival injection, corneal and conjunctival fluorescein staining scores, production of inflammatory cytokines in tears, and aqueous tear production in a mouse model of allergic conjunctivitis. To validate our in vivo results, we used interleukin (IL)-1alpha-pretreated conjunctival epithelial cells as an in vitro substitute for the mouse model. We evaluated whether exposure to ozone increased the inflammatory response and altered oxidative status and mitochondrial function in IL-1alpha-pretreated conjunctival epithelial cells. In the in vivo study, ozone induced increases in conjunctival chemosis, conjunctival injection, corneal and conjunctival fluorescein staining scores, and production of inflammatory cytokines, accompanied by a decrease in tear volume. In the in vitro study, exposure to ozone led to additional increases in IL-6 and tumor necrosis factor-alpha mRNA levels, which were already induced by treatment with IL-1alpha. Ozone did not induce any changes in cell viability. Pretreatment with IL-1alpha increased the expression of manganese superoxide dismutase, and exposure to ozone led to additional increments in the expression of this antioxidant enzyme. Ozone did not induce any changes in mitochondrial activity or expression of mitochondrial enzymes and proteins related to mitochondrial function, with the exception of phosphor-mammalian target of rapamycin. Treatment with butylated hydroxyanisole, a free radical scavenger, attenuated the ozone-induced increases in IL-6 expression in IL-1alpha-pretreated conjunctival epithelial cells. Therefore, we conclude that exposure to ozone exacerbates the detrimental effects on the integrity of the ocular surface caused by conjunctival allergic reactions, and further increases the inflammatory response in IL-1alpha-pretreated conjunctival epithelial cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0169209</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28046113">PM:28046113</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0169209.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0169209.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0169209.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0169209.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170103, Lee H</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0169209</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stemeseder,T.</style></author><author><style face="normal" font="Arial"> Schweidler,B.</style></author><author><style face="normal" font="Arial"> Doppler,P.</style></author><author><style face="normal" font="Arial"> Klinglmayr,E.</style></author><author><style face="normal" font="Arial"> Moser,S.</style></author><author><style face="normal" font="Arial"> Lueftenegger,L.</style></author><author><style face="normal" font="Arial"> Himly,M.</style></author><author><style face="normal" font="Arial"> Lang,R.</style></author><author><style face="normal" font="Arial"> Zumbach,J.</style></author><author><style face="normal" font="Arial"> Oostingh,G.J.</style></author><author><style face="normal" font="Arial"> Hawranek,T.</style></author><author><style face="normal" font="Arial"> Bathke,A.C.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Exposure to Indoor Allergens in Different Residential Settings and Its Influence on IgE Sensitization in a Geographically Confined Austrian Cohort</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0168686">e0168686-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alt a 1</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Can f 1</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> multiplex array</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exposure to indoor allergens is crucial for IgE sensitization and development of allergic symptoms. Residential settings influence the allergen amount in house dust and hence allergic sensitization. Within this study, we investigated allergen exposure and molecule-based IgE levels in a geographically confined region and evaluated the impact of housing, pets and cleaning. METHODS: 501 adolescents from Salzburg, Austria participated in this cross-sectional study. House dust samples were examined regarding major mite, cat, dog, and mold allergens using a multiplex assay. Serum samples of participants were analyzed for specific IgE to Der p 1, Der p 2, Fel d 1, Can f 1 and Alt a 1 using the multiplex array ImmunoCAP ISAC. Information on allergies, living areas, dwelling form (house, flat, farm), pets, and household cleanliness were obtained by a questionnaire. RESULTS: In investigated house dust samples, the concentration of cat allergen was highest while the prevalence of mold allergens was very low. Participants showed IgE sensitization to Der p 1 (13.2%), Der p 2 (18.2%), Fel d 1 (14.4%), Can f 1 (2.4%) and Alt a 1 (2.0%). In alpine regions, lower mite allergen concentrations were detected which correlated with reduced IgE levels. A trend for increased sensitization prevalence from rural to alpine to urban regions was noted. Living on farms resulted in lower sensitization prevalence to mite and cat allergens, even though exposure to mites was significantly elevated. The presence of cats was associated with a lower sensitization rate and IgE levels to cat and mite allergens, and less frequent allergic diseases. Cleaning did not impact allergen concentrations, while IgE reactivity to mites and allergic diseases were more pronounced when living in cleaner homes. CONCLUSION: Allergen exposure to indoor allergens was influenced by setting of homes. Living in a farm environment and having a cat at home showed a protective effect for IgE sensitization and allergies. This cross-sectional study in combination with hereditary and lifestyle factors enables development of risk schemes for a more efficient management and potential prevention of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0168686</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28045938">PM:28045938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0168686.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0168686.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Stemeseder T</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0168686</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blazowski,L.</style></author><author><style face="normal" font="Arial"> Gregorczyk-Maslanka,K.</style></author><author><style face="normal" font="Arial"> Kurzawa,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Oral allergy syndrome (pollen food syndrome), anaphylaxis and molecular allergology. New endotypes and new horizons</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="143" start="137">137-143</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="01/22/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen food syndrome</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year><pub-dates><date Day="0" Month="12" Year="2016">2016/12</date></pub-dates></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">The main symptoms of oral allergy syndrome (OAS) usually involve oral cavity, but in the case of pollen food syndrome (PFS), symptoms may lead to development of systemic reactions. Precise diagnostics of primary sensitizer and symptoms trigger allow to give proper recommendations for the patient, which are crucial for diminishing the risk of anaphylaxis. Based on the case of a 12-year-old patient, the rules of component-resolved diagnostics and the benefits of PFS endotypes identification were discussed</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.11.008</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.11.008</url></web-urls><pdf-urls><url ppv-ref="no">l.blazowski@gmail.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170112, Blazowski L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.11.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gawlewicz-Mroczka,A.</style></author><author><style face="normal" font="Arial"> Zastrzezynska,W.</style></author><author><style face="normal" font="Arial"> Przybyszowski,M.</style></author><author><style face="normal" font="Arial"> Cmiel,A.</style></author><author><style face="normal" font="Arial"> Sladek,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effectiveness of omalizumab therapy in patients with highly severe allergic asthma treated in Department of Pulmonology in Krakow</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="133" start="127">127-133</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="01/22/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> astma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Therapeutic program</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year><pub-dates><date Day="0" Month="12" Year="2016">2016/12</date></pub-dates></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">Immunoglobulin E plays an important role in allergic diseases. In patients with allergic asthma, exposure to allergens releases a wide range of proinflamatory mediators, which are responsible for acute and chronic symptoms of the disease. IgE has become an attractive target in allergic asthma. In 2006, in Europe omalizumab became available. Objectives Our knowledge of who will derive the highest benefit from omalizumab therapy is still limited. The aim of this study was to evaluate the efficacy of omalizumab during one year of therapy carried out under real-life conditions in Polish patients with severe allergic asthma. We also attempted to identify predictors for very good responses to treatment. Methods We enrolled 15 patients due to inclusion criteria of the program for severe allergic asthma funded by the National Health Insurance. All the patients were assessed for asthma control, quality of life, daily dose of oral and inhaled corticosteroids, asthma exacerbation rate, and lung function. The effectiveness of the treatment was analyzed after 16 weeks and one year following the inclusion each patient to the therapy. The patients were divided into two groups according to their response to the treatment: very good and good, based on the GETE scale. Results Omalizumab decreased the severity of symptoms, improved asthma control and quality of life in patients. It helped to reduce episodes of asthma exacerbation and the use of systemic corticosteroids. At present, the overall assessment by physicians is still the best and most reliable method of identifying responders to the omalizumab therapy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.11.010</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.11.010</url></web-urls><pdf-urls><url ppv-ref="no">agawlewicz@wp.pl</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170112, Gawlewicz-Mroczka A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.11.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pawliczak,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Omalizumab - a gold standard in severe asthma treatment, future therapy in chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="126" start="124">124-126</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="01/22/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> glucocorticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pulse</style></keyword><keyword><style face="normal" font="Arial"> Pulses</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year><pub-dates><date Day="0" Month="12" Year="2016">2016/12</date></pub-dates></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">Omalizumab was introduced in the therapy regime of severe asthma treatment more than a decade ago. Nowadays, it is considered the gold standard to treat severe, allergic asthma. It allows patients to live normal, productive life, with significantly reduced number of asthma exacerbations, fewer parenteral glucocorticosteroid pulses, and reduced episodes of hospitalizations. Moreover, it is successfully employed in chronic urticaria treatment. In this short review, we summarize the importance of severe asthma diagnosis, the role of omalizumab in treatment of severe asthma, and the mechanism of action of omalizumab. The mechanism of action of omalizumab in chronic urticaria treatment remains to be fully elucidated. This paper is an introduction to the case series presented in this supplement</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2016.11.005</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.11.005</url></web-urls><pdf-urls><url ppv-ref="no">rafal.pawliczak@csk.umed.lodz.pl</url></pdf-urls></urls><custom2><style face="normal" font="Arial">201701012, Pawliczak R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2016.11.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lombardo,N.</style></author><author><style face="normal" font="Arial"> Preiano,M.</style></author><author><style face="normal" font="Arial"> Maggisano,G.</style></author><author><style face="normal" font="Arial"> Murfuni,M.S.</style></author><author><style face="normal" font="Arial"> Messina,L.</style></author><author><style face="normal" font="Arial"> Pelaia,G.</style></author><author><style face="normal" font="Arial"> Savino,R.</style></author><author><style face="normal" font="Arial"> Terracciano,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy</style></auth-address><titles><title><style face="normal" font="Arial">A rapid differential display analysis of nasal swab fingerprints to distinguish allergic from non-allergic rhinitis subjects by mesoporous silica particles and MALDI-TOF mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> MALDI TOF mass spectrometry</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="23" Month="12" Year="2016">2016/12/23</year></dates><abstract><style face="normal" font="Arial">Discriminating different rhinitis cases can sometimes be difficult as the diagnostic criteria used to identify the various subgroups are not always unambiguous. The nasal fluid (NF) highly reflects the pathophysiology of these inflammatory diseases. However, its collection, as nasal lavage fluid (NLF), may cause discomfort. Due to the non-invasiveness and rapidity of collection, nasal swab might represents an alternative to overcome these problems and also an ideal source of biomarkers. In this study we demonstrate that the combined use of mesoporous silica (MPS) with MALDI-TOF MS allows the rapid detection of differential nasal peptide profiles from nasal swabs of healthy (H), allergic rhinitis (AR) and non-allergic rhinitis (NAR) subjects. NF peptides from nasal swabs were captured by the mean of MPS then profiled by MALDI-TOF MS. As a proof-of-principle, we also explored the ability of our platform to discriminate between nasal swabs of patients with AR and NAR, and between these groups and H controls. Four peaks resulted differentially expressed between NAR and AR, two peaks discriminated AR from H while one peak segregated NAR from H group. Therefore, peptides selected and enriched by our platform could form part of a diagnostic ''rhinomic'' profile of the allergic and non-allergic patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20161224IS - 1615-9861 (Electronic)IS - 1615-9853 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1002/pmic.201600215</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28012241">PM:28012241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proteomics\20161224-LombardoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proteomics\20161224-LombardoN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161224, Lombardo N</style></custom2><misc3><style face="normal" font="Arial">10.1002/pmic.201600215</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hisamichi,M.</style></author><author><style face="normal" font="Arial"> Kawarazaki,H.</style></author><author><style face="normal" font="Arial"> Oroku,M.</style></author><author><style face="normal" font="Arial"> Tsuruoka,K.</style></author><author><style face="normal" font="Arial"> Sakurada,T.</style></author><author><style face="normal" font="Arial"> Shirai,S.</style></author><author><style face="normal" font="Arial"> Kido,R.</style></author><author><style face="normal" font="Arial"> Kimura,K.</style></author><author><style face="normal" font="Arial"> Shibagaki,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Risk factors for allergic reaction at initial therapeutic plasma exchange in a single-center study: beware of high rates of severe allergic reaction</style></title><secondary-title><style face="normal" font="Arial">Ren Replace Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ren Replace Ther</style></full-title></periodical><pages end="" start="67">67-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Plasma Exchange</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2059-1381</style></isbn><abstract><style face="normal" font="Arial">Therapeutic plasma exchange (TPE) is an important treatment modality for various diseases, but its use can be restricted by allergic reactions (AR). The aim of our study was to elucidate the frequency of and risk factors for AR at initial TPE using fresh frozen plasma (FFP)</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s41100-016-0076-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s41100-016-0076-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ren Replace Ther\2016-2-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ren Replace Ther\2016-2-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Hisamichi M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s41100-016-0076-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farnaz,S.</style></author><author><style face="normal" font="Arial"> Mojtaba,S.</style></author><author><style face="normal" font="Arial"> Maliheh,M.</style></author><author><style face="normal" font="Arial"> Abdol-Reza,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immuno-Biochemistry lab, Immunology Research Center, Mashhad University of medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Quantification of Pla or 3, a Platanus orientalis Allergen, Grown under Different Environmental Conditions, by Sandwich ELISA</style></title><secondary-title><style face="normal" font="Arial">Rep Biochem Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rep Biochem Mol Biol</style></full-title></periodical><pages end="45" start="40">40-45</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pla or 3</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Public Policy</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> traffic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Platanus species are widely cultured around the world and considered an important cause of allergic reactions. In the present study, we developed a sandwich ELISA to quantify Pla or 3 allergen in P. orientalis pollen extracts grown near high-traffic roads and compared it to pollen extracts collected from rural areas as control. METHODS: Pollen samples were collected from three polluted and two unpolluted sites in Mashhad, northeast Iran. Recombinant Pla or 3 was expressed and used for polyclonal antibody production in rabbit. A sandwich ELISA was developed and validated to quantify Pla or 3 levels in pollen extracts from the different sites. RESULTS: The coefficients of variation (CVs) for the intra- and inter- day assays were less than 5 and 18%, respectively. The working range of the standard curve was between 0.1 and 25 ng/ml, with the detection limit being 0.037 ng/ml. The recovery percentage was 88-106.4% at working concentrations from 0.31 to 26.5 ng/ml. Pla or 3 levels were significantly greater in pollens grown near high-traffic roads than in those grown in rural regions (p &lt; 0.0001). CONCLUSION: A sandwich ELISA was developed and validated to quantify Pla or 3 in pollen extracts. Using this validated ELISA, we showed a substantial difference between the amounts of Pla or 3 in pollens grown in different environments. This finding should be considered in developing public policies to reduce traffic pollution, which leads to reduced allergic reactions in atopic subjects</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 2322-3480 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28070533">PM:28070533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rep Biochem Mol Biol\2016-5-40-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rep Biochem Mol Biol\2016-5-40-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Farnaz S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De,H.</style></author><author><style face="normal" font="Arial"> Azad,S.M.</style></author><author><style face="normal" font="Arial"> Giri,P.P.</style></author><author><style face="normal" font="Arial"> Pal,P.</style></author><author><style face="normal" font="Arial"> Ghosh,A.</style></author><author><style face="normal" font="Arial"> Maitra,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Two cases of non-cystic fibrosis (CF) bronchiectasis with allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Respir Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med Case Rep</style></full-title></periodical><pages end="71" start="68">68-71</pages><volume><style face="normal" font="Arial">20</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic Bronchopulmonary Aspergillosis (ABPA)</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> chest infections</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Cystic fibrosis (CF)</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisations</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-0071</style></isbn><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction in patients with asthma or cystic fibrosis (CF), which is associated with bronchi colonized by the fungus Aspergillus species, most often Aspergillus fumigatus. ABPA is an important consideration for asthmatics that do not respond to asthma management or with recurrent chest infections and deteriorating lung function in children with cystic fibrosis. We present two cases of non CF bronchiectasis associated with ABPA who presented to our hospital with recurrent hospitalisations of undiagnosed aetiology</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmcr.2016.12.005</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.rmcr.2016.12.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med Case Rep\2017-20-68-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med Case Rep\2017-20-68-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, De H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmcr.2016.12.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,P.F.</style></author><author><style face="normal" font="Arial"> Ji,W.J.</style></author><author><style face="normal" font="Arial"> Zhang,X.H.</style></author><author><style face="normal" font="Arial"> Li,S.W.</style></author><author><style face="normal" font="Arial"> Yan,C.X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergy reduces the risk of meningioma: a meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="40333">40333-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Brain tumours</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inverse correlation</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meningioma</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> SCI</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">Meningiomas are the most common brain tumours; however, little is known regarding their aetiology. The data are inconsistent concerning atopic disease and the risk of developing meningioma. Thus, we conducted a meta-analysis to investigate the association between allergic conditions and the risk of developing meningioma. A systematic literature search was conducted using PubMed and Web of SCI from Jan 1979 to Feb 2016. Two investigators independently selected the relevant articles according to the inclusion criteria. Eight case-control studies and 2 cohort studies were included in the final analysis, comprising 5,679 meningioma cases and 55,621 control subjects. Compared with no history of allergy, the pooled odds ratio (OR) for allergic conditions was 0.81 (0.70-0.94) for meningioma in a random-effects meta-analysis. Inverse correlations of meningioma occurrence were also identified for asthma and eczema, in which the pooled ORs were 0.78 (0.70-0.86) and 0.78 (0.69-0.87), respectively. A reduced risk of meningioma occurrence was identified in hay fever; however, the association was weak (0.88, 95% CI = 0.78-0.99). The source of this heterogeneity could be the various confounding variables in individual studies. Overall, the current meta-analysis indicated that allergy reduced the risk of developing meningiomas. Large cohort studies are required to investigate this relationship</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep40333</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28071746">PM:28071746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-40333.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-40333.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Wang PF</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep40333</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rojo,J.</style></author><author><style face="normal" font="Arial"> Orlandi,F.</style></author><author><style face="normal" font="Arial"> Perez-Badia,R.</style></author><author><style face="normal" font="Arial"> Aguilera,F.</style></author><author><style face="normal" font="Arial"> Ben Dhiab,A.</style></author><author><style face="normal" font="Arial"> Bouziane,H.</style></author><author><style face="normal" font="Arial"> Diaz de la Guardia,C.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author><author><style face="normal" font="Arial"> Gutierrez-Bustillo,A.M.</style></author><author><style face="normal" font="Arial"> Moreno-Grau,S.</style></author><author><style face="normal" font="Arial"> Msallem,M.</style></author><author><style face="normal" font="Arial"> Trigo,M.M.</style></author><author><style face="normal" font="Arial"> Fornaciari,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Castilla-La Mancha, Institute of Environmental Sciences, 45071 Toledo, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Modeling olive pollen intensity in the Mediterranean region through analysis of emission sources</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="82" start="73">73-82</pages><volume><style face="normal" font="Arial">551-552</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Altitude</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean Region</style></keyword><keyword><style face="normal" font="Arial"> Meteorological variables</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> olive pollen</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis,Allergic,Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2016">2016/5/1</year></dates><abstract><style face="normal" font="Arial">Aerobiological monitoring of Olea europaea L. is of great interest in the Mediterranean basin because olive pollen is one of the most represented pollen types of the airborne spectrum for the Mediterranean region, and olive pollen is considered one of the major cause of pollinosis in this region. The main aim of this study was to develop an airborne-pollen map based on the Pollen Index across a 4-year period (2008-2011), to provide a continuous geographic map for pollen intensity that will have practical applications from the agronomical and allergological points of view. For this purpose, the main predictor variable was an index based on the distribution and abundance of potential sources of pollen emission, including intrinsic information about the general atmospheric patterns of pollen dispersal. In addition, meteorological variables were included in the modeling, together with spatial interpolation, to allow the definition of a spatial model of the Pollen Index from the main olive cultivation areas in the Mediterranean region. The results show marked differences with respect to the dispersal patterns associated to the altitudinal gradient. The findings indicate that areas located at an altitude above 300ma.s.l. receive greater amounts of olive pollen from shorter-distance pollen sources (maximum influence, 27km) with respect to areas lower than 300ma.s.l. (maximum influence, 59km)</style></abstract><notes><style face="normal" font="Arial">DA - 20160328IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleRN - 0 (Air Pollutants)RN - 0 (Allergens)SB - IMCO - Spain -CO - Italy -CO - Tunisia -CO - Morocco -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2016.01.193</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26874763">PM:26874763</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2016-551_552-73-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2016-551_552-73-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160328, Rojo J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2016.01.193</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ludwig,S.</style></author><author><style face="normal" font="Arial"> Jimenez-Bush,I.</style></author><author><style face="normal" font="Arial"> Brigham,E.</style></author><author><style face="normal" font="Arial"> Bose,S.</style></author><author><style face="normal" font="Arial"> Diette,G.</style></author><author><style face="normal" font="Arial"> McCormack,M.C.</style></author><author><style face="normal" font="Arial"> Matsui,E.C.</style></author><author><style face="normal" font="Arial"> Davis,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of home dust for Staphylococcus aureus and staphylococcal enterotoxin genes using quantitative PCR</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="755" start="750">750-755</pages><volume><style face="normal" font="Arial">581-582</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteremia</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> bedrooms</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA isolation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> SEC</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> Superantigens</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The bacterium Staphylococcus aureus (SA) is known to induce allergic inflammatory responses, including through secreted staphylococcal enterotoxin (SE) superantigens. To quantify indoor environmental exposures to these potential allergens, which may be associated with worse asthma, we developed a method for the assessment of S. aureus and SE in home dust and applied it to a study of homes of inner-city adults with asthma. METHODS: We conducted laboratory experiments to optimize sample processing and real-time PCR methods for detection and quantification of SA (femB) and SEA-D, based on published primers. We applied this method to dust and dust extract from 24 homes. We compared results from real-time PCR to culture-based results from the same homes. RESULTS: The bacteremia DNA isolation method provided higher DNA yield than alternative kits. Culture-based results from homes demonstrated 12 of 24 (50%) bedrooms were contaminated with S. aureus, only one of which carried a SE gene (SEC). In contrast, femB was detected in 23 of 24 (96%) bedrooms with a median of 1.1x106 gene copies detected per gram of raw dust. Prevalence and median copy number (shown in parenthesis) of SE gene detection in bedroom dust was: SEA 25% (1.4x102); SEB 63% (1.4x103); SEC 63% (1.1x103); SED 21% (1.3x102). CONCLUSIONS: Our culture-independent method to detect S. aureus and SE in home dust was more sensitive than our culture-based method. Prevalence of household exposure to S. aureus and SE allergens may be high among adults with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170108IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.01.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28063655">PM:28063655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\20170108-LudwigS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\20170108-LudwigS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170108, Ludwig S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.01.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harada,R.</style></author><author><style face="normal" font="Arial"> Hongo,T.</style></author><author><style face="normal" font="Arial"> Hashimoto,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chiba Prefectural Institute of Public Health</style></auth-address><titles><title><style face="normal" font="Arial">Survey of Allergenic Substances in Foods in Chiba Prefecture (Fiscal Years 2004-2014)</style></title><secondary-title><style face="normal" font="Arial">Shokuhin Eiseigaku Zasshi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Shokuhin Eiseigaku Zasshi</style></full-title></periodical><pages end="221" start="213">213-221</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">advisory labeling</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Screening test</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">We surveyed the presence of allergenic substances such as egg, milk, wheat, buckwheat, peanut, shrimp and crab in foods produced or distributed in Chiba Prefecture during the fiscal years 2004-2014. Six hundred and ninety-five samples that did not display the target allergenic substances were screened by using ELISA. Three percent of the samples (21/695 samples) were found to be positive. Wheat had the highest positivity rate of 9.7% (10/103 samples). Among the samples tested, advisory labeling was displayed in the case of 109 samples. Among these samples, 77.1%(84/109 samples) contained less than 1.0 mug/g of the specified allergen. Out of the 21 samples that tested positive in the screening-test, 16 did not display the advisory labeling</style></abstract><notes><style face="normal" font="Arial">DA - 20161227IS - 1882-1006 (Electronic)IS - 0015-6426 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3358/shokueishi.57.213</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28025456">PM:28025456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Shokuhin Eiseigaku Zasshi\2016-57-213-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Shokuhin Eiseigaku Zasshi\2016-57-213-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161227, Harada R</style></custom2><misc3><style face="normal" font="Arial">10.3358/shokueishi.57.213</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heymann,W.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, Departments of Medicine and Pediatrics, Cooper Medical School of Rowan University, Marlton, NJ; wrheymann@gmail.com</style></auth-address><titles><title><style face="normal" font="Arial">Conceptual Confluence: The Marriage of IgG4-Related Disease and Adult-Onset Asthma With Periocular Xanthogranulomas</style></title><secondary-title><style face="normal" font="Arial">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Skinmed</style></full-title></periodical><pages end="451" start="449">449-451</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="01/22/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28031133">PM:28031133</url></web-urls><pdf-urls><url ppv-ref="no">wrheymann@gmail.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161229, Heymann WR</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kang,H.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author><author><style face="normal" font="Arial"> Jin,S.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Lee,K.</style></author><author><style face="normal" font="Arial"> Jeon,H.</style></author><author><style face="normal" font="Arial"> Song,Y.G.</style></author><author><style face="normal" font="Arial"> Lee,S.W.</style></author><author><style face="normal" font="Arial"> Seo,J.</style></author><author><style face="normal" font="Arial"> Park,S.</style></author><author><style face="normal" font="Arial"> Choi,I.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Institute for Immunology and Immunological Diseases, Brain Korea</style></auth-address><titles><title><style face="normal" font="Arial">5 nm Silver Nanoparticles Amplify Clinical Features of Atopic Dermatitis in Mice by Activating Mast Cells</style></title><secondary-title><style face="normal" font="Arial">Small</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Small</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen Peroxide</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Silver nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The triggering effect of silver nanoparticles (NPs) on the induction of allergic reactions is evaluated, by studying the activation of mast cells and the clinical features of atopic dermatitis in a mouse model. Granule release is induced in RBL-2H3 mast cells by 5 nm, but not 100 nm silver NPs. Increases in the levels of reactive oxygen species (hydrogen peroxide and mitochondrial superoxide) and intracellular Ca++ in mast cells are induced by 5 nm silver NPs. In a mouse model of atopic dermatitis induced by a mite allergen, the skin lesions are more severe and appear earlier in mice treated simultaneously with 5 nm silver NPs and allergen compared with mice treated with allergen alone or 100 nm silver NPs and allergen. The histological findings reveal that number of tryptase-positive mast cells and total IgE levels in the serum increase in mice treated with 5 nm silver NPs and allergen. The results in this study indicate that cotreatment with 5 nm silver NPs stimulates mast cell degranulation and induces earlier and more severe clinical alterations in allergy-prone individuals</style></abstract><notes><style face="normal" font="Arial">DA - 20161222IS - 1613-6829 (Electronic)IS - 1613-6810 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1002/smll.201602363</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28005305">PM:28005305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Small\20161222-KangH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Small\20161222-KangH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161222, Kang H</style></custom2><misc3><style face="normal" font="Arial">10.1002/smll.201602363</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Omlor,A.J.</style></author><author><style face="normal" font="Arial"> Le,D.D.</style></author><author><style face="normal" font="Arial"> Schlicker,J.</style></author><author><style face="normal" font="Arial"> Hannig,M.</style></author><author><style face="normal" font="Arial"> Ewen,R.</style></author><author><style face="normal" font="Arial"> Heck,S.</style></author><author><style face="normal" font="Arial"> Herr,C.</style></author><author><style face="normal" font="Arial"> Kraegeloh,A.</style></author><author><style face="normal" font="Arial"> Hein,C.</style></author><author><style face="normal" font="Arial"> Kautenburger,R.</style></author><author><style face="normal" font="Arial"> Kickelbick,G.</style></author><author><style face="normal" font="Arial"> Bals,R.</style></author><author><style face="normal" font="Arial"> Nguyen,J.</style></author><author><style face="normal" font="Arial"> Dinh,Q.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Pneumology and Allergology, Saarland University Faculty of Medicine, Kirrberger Str. 100, D-66421, Homburg/Saar, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Local Effects on Airway Inflammation and Systemic Uptake of 5 nm PEGylated and Citrated Gold Nanoparticles in Asthmatic Mice</style></title><secondary-title><style face="normal" font="Arial">Small</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Small</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug delivery</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Hyperthermia</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Nanotechnology</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Nanotechnology is showing promise in many medical applications such as drug delivery and hyperthermia. Nanoparticles administered to the respiratory tract cause local reactions and cross the blood-air barrier, thereby providing a means for easy systemic administration but also a potential source of toxicity. Little is known about how these effects are influenced by preexisting airway diseases such as asthma. Here, BALB/c mice are treated according to the ovalbumin (OVA) asthma protocol to promote allergic airway inflammation. Dispersions of polyethylene-glycol-coated (PEGylated) and citrate/tannic-acid-coated (citrated) 5 nm gold nanoparticles are applied intranasally to asthma and control groups, and (i) airway resistance and (ii) local tissue effects are measured as primary endpoints. Further, nanoparticle uptake into extrapulmonary organs is quantified by inductively coupled plasma mass spectrometry. The asthmatic precondition increases nanoparticle uptake. Moreover, systemic uptake is higher for PEGylated gold nanoparticles compared to citrated nanoparticles. Nanoparticles inhibit both inflammatory infiltrates and airway hyperreactivity, especially citrated gold nanoparticles. Although the antiinflammatory effects of gold nanoparticles might be of therapeutic benefit, systemic uptake and consequent adverse effects must be considered when designing and testing nanoparticle-based asthma therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20161223IS - 1613-6829 (Electronic)IS - 1613-6810 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/smll.201603070</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28009478">PM:28009478</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Small\20161223-OmlorAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Small\20161223-OmlorAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161223, Omlor AJ</style></custom2><misc3><style face="normal" font="Arial">10.1002/smll.201603070</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,S.Y.</style></author><author><style face="normal" font="Arial"> Fan,X.L.</style></author><author><style face="normal" font="Arial"> Yu,Q.N.</style></author><author><style face="normal" font="Arial"> Deng,M.X.</style></author><author><style face="normal" font="Arial"> Sun,Y.Q.</style></author><author><style face="normal" font="Arial"> Gao,W.X.</style></author><author><style face="normal" font="Arial"> Li,C.L.</style></author><author><style face="normal" font="Arial"> Shi,J.B.</style></author><author><style face="normal" font="Arial"> Fu,Q.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China</style></auth-address><titles><title><style face="normal" font="Arial">The lncRNAs involved in mouse airway allergic inflammation following induced pluripotent stem cell-mesenchymal stem cell treatment</style></title><secondary-title><style face="normal" font="Arial">Stem Cell Res Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Stem Cell Res Ther</style></full-title></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory T cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> noncoding RNAs</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We have previously reported that induced pluripotent stem cell (iPSC)-mesenchymal stem cells (MSCs) alleviated asthma inflammation in mice. Long noncoding RNAs (lncRNAs) were recently reported as being involved in the immune responses. However, whether lncRNAs are associated with iPSC-MSC immunomodulation in allergic inflammation is still unclear. METHODS: Mice were induced into an asthmatic state and received treatment consisting of iPSC-MSCs. Memory T cells isolated from sensitized mice were challenged and co-cultured with iPSC-MSCs in vitro. Total RNA from the lungs and separated T cells were processed with an lncRNA/mRNA microarray. A series of bioinformatics technologies were used to screen the target lncRNAs. RESULTS: iPSC-MSCs significantly prevented asthma inflammation and decreased the Th2 cytokine levels. Over 1300 lncRNAs were differentially expressed after the induction of asthma, and 846 or 4176 lncRNAs were differentially expressed with iPSC-MSC treatment in mice or in vitro, respectively. After overlapping the differentially expressed lncRNAs produced in a similar manner in mice and in vitro, 23 lncRNAs and 96 mRNAs were selected, in which 58 protein-coding genes were predicted to be potential targets of the 23 lncRNAs. Furthermore, using a series of bioinformatics technologies, 9 lncRNAs co-expressed with the most differentially expressed mRNAs, which were enriched in terms of the immune response, were screened out via Pearson's correlation coefficient with mRNAs that were involved with inflammatory cytokines and receptors. lncRNAs MM9LINCRNAEXON12105+ and AK089315 were finally emphasized via quantitative real-time PCR validation. CONCLUSIONS: Our results suggested that aberrant lncRNA profiles were present after asthma induction and iPSC-MSC treatment, suggesting potential targets of allergic inflammation and iPSC-MSC-mediated immunomodulation</style></abstract><notes><style face="normal" font="Arial">DA - 20170106IS - 1757-6512 (Electronic)IS - 1757-6512 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13287-016-0456-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28057064">PM:28057064</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Stem Cell Res Ther\2017-8-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Stem Cell Res Ther\2017-8-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170106, Wang SY</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13287-016-0456-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lehmann,S.</style></author><author><style face="normal" font="Arial"> Sprunken,A.</style></author><author><style face="normal" font="Arial"> Wagner,N.</style></author><author><style face="normal" font="Arial"> Tenbrock,K.</style></author><author><style face="normal" font="Arial"> Ott,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pulmonology and Allergology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Clinical relevance of IgE-mediated sensitization against the mould Alternaria alternata in children with asthma</style></title><secondary-title><style face="normal" font="Arial">Ther Adv Respir Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ther Adv Respir Dis</style></full-title></periodical><pages end="39" start="30">30-39</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma in childhood has a prevalence of 5-10% in Germany and severe asthma accounts for about 5% in this patient group. Positive predictive values for severe asthma are atopy, a positive family history and sensitizations against inhalative allergens. Alternaria is an important inhalative allergen and sensitization is suspected to correlate with severe and lethal asthma. We investigated the prevalence and impact of Alternaria sensitization in paediatric asthma. METHODS: We reviewed paediatric patients with a diagnosis of low-grade, moderate and severe asthma. Data collection included concomitant atopic diseases, sensitization profiles, family history and prior hospitalization for asthma exacerbation. RESULTS: A total of 207 paediatric patients (aged 1-17 years) were included in the study. Overall, 25% had low-grade asthma, 31% moderate and 44% severe asthma and 26% were formerly hospitalized. Alternaria sensitization was the most common in moulds, although without significant correlation with hospitalization and severe asthma. Alternaria sensitization increased with age and was significantly associated with co-sensitization against other moulds, grass pollen and cat epithelia. Allergic rhinitis was significantly correlated with hospitalization, independent of Alternaria sensitization. CONCLUSIONS: Alternaria sensitization was common and increased with age. No significant correlation was found between asthma degree, hospitalization rates and sensitization profiles. Alternaria sensitization demonstrated no isolated risk factor for severe asthma and hospitalization</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1753-4666 (Electronic)IS - 1753-4658 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1177/1753465816680786</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28043213">PM:28043213</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ther Adv Respir Dis\2017-11-30-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ther Adv Respir Dis\2017-11-30-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Lehmann S</style></custom2><misc3><style face="normal" font="Arial">10.1177/1753465816680786</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lanza,G.M.</style></author><author><style face="normal" font="Arial"> Jenkins,J.</style></author><author><style face="normal" font="Arial"> Schmieder,A.H.</style></author><author><style face="normal" font="Arial"> Moldobaeva,A.</style></author><author><style face="normal" font="Arial"> Cui,G.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Zhong,Q.</style></author><author><style face="normal" font="Arial"> Keupp,J.</style></author><author><style face="normal" font="Arial"> Sergin,I.</style></author><author><style face="normal" font="Arial"> Paranandi,K.S.</style></author><author><style face="normal" font="Arial"> Eldridge,L.</style></author><author><style face="normal" font="Arial"> Allen,J.S.</style></author><author><style face="normal" font="Arial"> Williams,T.</style></author><author><style face="normal" font="Arial"> Scott,M.J.</style></author><author><style face="normal" font="Arial"> Razani,B.</style></author><author><style face="normal" font="Arial"> Wagner,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA</style></auth-address><titles><title><style face="normal" font="Arial">Anti-angiogenic Nanotherapy Inhibits Airway Remodeling and Hyper-responsiveness of Dust Mite Triggered Asthma in the Brown Norway Rat</style></title><secondary-title><style face="normal" font="Arial">Theranostics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Theranostics</style></abbr-1></periodical><pages end="389" start="377">377-389</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Micelles</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> vascularity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Although angiogenesis is a hallmark feature of asthmatic inflammatory responses, therapeutic anti-angiogenesis interventions have received little attention. Objective: Assess the effectiveness of anti-angiogenic Sn2 lipase-labile prodrugs delivered via alphavbeta3-micellar nanotherapy to suppress microvascular expansion, bronchial remodeling, and airway hyper-responsiveness in Brown Norway rats exposed to serial house dust mite (HDM) inhalation challenges. Results: Anti-neovascular effectiveness of alphavbeta3-mixed micelles incorporating docetaxel-prodrug (Dxtl-PD) or fumagillin-prodrug (Fum-PD) were shown to robustly suppress neovascular expansion (p&lt;0.01) in the upper airways/bronchi of HDM rats using simultaneous 19F/1H MR neovascular imaging, which was corroborated by adjunctive fluorescent microscopy. Micelles without a drug payload (alphavbeta3-No-Drug) served as a carrier-only control. Morphometric measurements of HDM rat airway size (perimeter) and vessel number at 21d revealed classic vascular expansion in control rats but less vascularity (p&lt;0.001) after the anti-angiogenic nanotherapies. CD31 RNA expression independently corroborated the decrease in airway microvasculature. Methacholine (MCh) induced respiratory system resistance (Rrs) was high in the HDM rats receiving alphavbeta3-No-Drug micelles while alphavbeta3-Dxtl-PD or alphavbeta3-Fum-PD micelles markedly and equivalently attenuated airway hyper-responsiveness and improved airway compliance. Total inflammatory BAL cells among HDM challenged rats did not differ with treatment, but alphavbeta3+ macrophages/monocytes were significantly reduced by both nanotherapies (p&lt;0.001), most notably by the alphavbeta3-Dxtl-PD micelles. Additionally, alphavbeta3-Dxtl-PD decreased BAL eosinophil and alphavbeta3+ CD45+ leukocytes relative to alphavbeta3-No-Drug micelles, whereas alphavbeta3-Fum-PD micelles did not. Conclusion: These results demonstrate the potential of targeted anti-angiogenesis nanotherapy to ameliorate the inflammatory hallmarks of asthma in a clinically relevant rodent model</style></abstract><notes><style face="normal" font="Arial">DA - 20170102IS - 1838-7640 (Electronic)IS - 1838-7640 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.7150/thno.16627</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042341">PM:28042341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Theranostics\2017-7-377-89.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Theranostics\2017-7-377-89.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170102, Lanza GM</style></custom2><misc3><style face="normal" font="Arial">10.7150/thno.16627</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okamura,I.</style></author><author><style face="normal" font="Arial"> Matsuyama,N.</style></author><author><style face="normal" font="Arial"> Yasui,K.</style></author><author><style face="normal" font="Arial"> Hirayama,F.</style></author><author><style face="normal" font="Arial"> Ikeda,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Clinical utility of the basophil activation test for analysis of allergic transfusion reactions: a pilot study</style></title><secondary-title><style face="normal" font="Arial">Vox Sang</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vox Sang</style></full-title></periodical><pages end="121" start="114">114-121</pages><volume><style face="normal" font="Arial">112</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> dasatinib</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> stem cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVES: In previous studies, we demonstrated that the basophil-activating effects of supernatants found in residual-transfused platelet concentrates (PC-SNs) on whole blood basophils in cases of allergic transfusion reactions (ATRs) could be assessed by the basophil activation test (BAT) in terms of allergen/IgE dependency. However, in these studies, the basophils were derived from third-party healthy volunteers. In this study, we performed BAT using patients' own blood basophils to analyse ATRs. MATERIALS AND METHODS: The BAT was performed in two cases of severe ATRs using residual PC-SNs and the patients' own basophils in the presence and absence of dasatinib, an inhibitor of IgE-mediated basophil activation. RESULTS: In both cases, PC-SNs exhibited basophil-activating activity against the patients' basophils, but not against basophils from third-party healthy volunteers. In addition, basophil activation was inhibited in the presence of dasatinib, indicating that the basophils were activated in an allergen/IgE-dependent manner. Of note, the basophils in Case 2, but not in Case 1, were activated by PC-SNs from some unrelated non-haemolytic transfusion reaction cases. CONCLUSION: This pilot study indicates that the BAT may be useful in clarifying the causal relationship between ATRs and transfused blood as well as in elucidating the mechanisms behind ATRs considering the allergen/IgE-dependent pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1423-0410 (Electronic)IS - 0042-9007 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/vox.12471</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28070919">PM:28070919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vox Sang\20170110-OkamuraI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vox Sang\20170110-OkamuraI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Okamura I</style></custom2><misc3><style face="normal" font="Arial">10.1111/vox.12471</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vianello,A.</style></author><author><style face="normal" font="Arial"> Caminati,M.</style></author><author><style face="normal" font="Arial"> Crivellaro,M.</style></author><author><style face="normal" font="Arial"> El Mazloum,R.</style></author><author><style face="normal" font="Arial"> Snenghi,R.</style></author><author><style face="normal" font="Arial"> Schiappoli,M.</style></author><author><style face="normal" font="Arial"> Dama,A.</style></author><author><style face="normal" font="Arial"> Rossi,A.</style></author><author><style face="normal" font="Arial"> Festi,G.</style></author><author><style face="normal" font="Arial"> Marchi,M.R.</style></author><author><style face="normal" font="Arial"> Bovo,C.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Senna,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Pathophysiology Division, University-City Hospital of Padua, Padua, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Fatal asthma; is it still an epidemic?</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="42">42-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Complementary Therapies</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug abuse</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma mortality has declined since the 1980s. Nevertheless the World Health Organization (WHO) identified asthma as responsible for 225.000 deaths worldwide in 2005, and 430.000 fatal cases are expected by 2030. Some unexpected and concentrated fatal asthma events all occurred between 2013 and 2015 in Veneto, a North Eastern region of Italy, which prompted a more in-depth investigation of characteristics and risk factors. METHODS: A web search including key words related to fatal asthma in Italy between 2013 and 2015 has been performed. Concerning the cases that occurred in Veneto, subjects' clinical records have been evaluated and details about concomitant weather conditions, pollutants and pollen count have been collected. RESULTS: Twenty-three cases of asthma deaths were found in Italy; 16 of them (69%) occurred in the Veneto Region. A prevalence of male and young age was observed. Most of patients were atopic, died in the night-time hours and during the weekends. The possible risk factors identified were the sensitization to alternaria, previous near fatal asthma attacks and the incorrect treatment of the disease. Weather condition did not appear to be related to the fatal exacerbations, whereas among the pollutants only ozone was detected over the accepted limits. Smoking habits, possible drug abuse and concomitant complementary therapies might be regarded as further risk factors. DISCUSSION: Although not free from potential biases, our web search and further investigations highlight an increasing asthma mortality trend, similarly to what other observatories report. The analysis of available clinical data suggests that the lack of treatment more than a severe asthma phenotype characterizes the fatal events. CONCLUSIONS: Asthma mortality still represents a critical issue in the management of the disease, particularly in youngsters. Once more the inadequate treatment and the lack of adherence seem to be not only related to the uncontrolled asthma but also to asthma mortality</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0129-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28031774">PM:28031774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2016-9-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Vianello A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0129-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mikhail,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nasser Mikhail, Department of Medicine, OliveView-UCLA Medical Center, Sylmar, CA 91342, United States</style></auth-address><titles><title><style face="normal" font="Arial">Place of technosphere inhaled insulin in treatment of diabetes</style></title><secondary-title><style face="normal" font="Arial">World J Diabetes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">World J Diabetes</style></abbr-1></periodical><pages end="604" start="599">599-604</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Hypoglycemia</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Gain</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="Arial">Technosphere insulin (TI), Afrezza, is a powder form of short-acting regular insulin taken by oral inhalation with meals. Action of TI peaks after approximately 40-60 min and lasts for 2-3 h. TI is slightly less effective than subcutaneous insulin aspart, with mean hemoglobin A1c (HbA1c) reduction of 0.21% and 0.4%, respectively. When compared with technosphere inhaled placebo, the decrease in HbA1c levels was 0.8% and 0.4% with TI and placebo, respectively. Compared with insulin aspart, TI is associated with lower risk of late post-prandial hypoglycemia and weight gain. Apart from hypoglycemia, cough is the most common adverse effect of TI reported by 24%-33% of patients vs 2% with insulin aspart. TI is contraindicated in patients with asthma and chronic obstructive pulmonary disease. While TI is an attractive option of prandial insulin, its use is limited by frequent occurrence of cough, need for periodic monitoring of pulmonary function, and lack of long-term safety data. Candidates for use of TI are patients having frequent hypoglycemia while using short-acting subcutaneous insulin, particularly late post-prandial hypoglycemia, patients with needle phobia, and those who cannot tolerate subcutaneous insulin due to skin reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1948-9358 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4239/wjd.v7.i20.599</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28031777">PM:28031777</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Diabetes\2016-7-599-604.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Diabetes\2016-7-599-604.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161229, Mikhail N</style></custom2><misc3><style face="normal" font="Arial">10.4239/wjd.v7.i20.599</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,H.</style></author><author><style face="normal" font="Arial"> Zhuang,L.</style></author><author><style face="normal" font="Arial"> Jin,R.</style></author><author><style face="normal" font="Arial"> Li,N.</style></author><author><style face="normal" font="Arial"> Zhou,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, First Affiliated Hospital, Nanjing Medical University, Nanjing 210000, China</style></auth-address><titles><title><style face="normal" font="Arial">[Recombinant platanus pollen allergen 2 (rPla a2) up-regulates the expression of ORMDL3 mediated by GATA3 in NIH3T3 cells]</style></title><secondary-title><style face="normal" font="Arial">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</style></full-title></periodical><pages end="32" start="27">27-32</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> ORMDL3</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Platanus pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Transfection</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Objective To identify the effect and mechanism of recombinant platanus pollen allergen 2 (rPla a2) on the transcription and expression of orosomucoid 1-like 3 (ORMDL3) gene in NIH3T3 cells. Methods Quantitative real-time PCR and Western blot analysis were used to detect the influence of rPla a2 on the mRNA and protein levels of ORMDL3 and GATA3. After transfection of GATA3 siRNA or pcDNA-GATA3, the role of GATA3 was evaluated in rPla a2 regulating ORMDL3 expression. Dual-luciferase reporter assay was performed to measure the influence of rPla a2 and GATA3 on ORMDL3 promoter activity. Results The rPla a2 induced mRNA and protein expressions of ORMDL3 and GATA3. Knockdown of GATA3 inhibited the induction of rPla a2 upon ORMDL3. In addition, the induction effect was enhanced by over-expression of GATA3. ORMDL3 promoter activity was significantly promoted by rPla a2 and inhibited by knockdown of GATA3. Conclusion The rPla a2 up-regulates the expression of ORMDL3 mRNA and protein, which is mediated by GATA3 through targeting promoter region of ORMDL3</style></abstract><notes><style face="normal" font="Arial">DA - 20161229IS - 1007-8738 (Print)IS - 1007-8738 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28031110">PM:28031110</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20161229, Zhang H</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kleiman,A.M.</style></author><author><style face="normal" font="Arial"> Littlewood,K.E.</style></author><author><style face="normal" font="Arial"> Groves,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Department of Anesthesiology, University of Virginia Health System, Charlottesville, Virginia</style></auth-address><titles><title><style face="normal" font="Arial">Delayed Anaphylaxis to Mammalian Meat Following Tick Exposure and Its Impact on Anesthetic Management for Cardiac Surgery: A Case Report</style></title><secondary-title><style face="normal" font="Arial">AA Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">AA Case Rep</style></abbr-1></periodical><pages end="177" start="175">175-177</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heparin</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">Hypersensitivity reactions to mammalian meat following tick exposure are increasing in prevalence and provide a unique challenge to anesthesiologists. The reactions, including anaphylaxis, are delayed and therefore may not be easily recognized and treated. The risk is especially high in cardiac surgery, where several potential triggers, including biological valves as well as heparin, are used frequently. In the presence of such hypersensitivity, prophylactic measures including preoperative testing and pharmacologic prophylaxis may be useful in modulating the immune response such that triggering agents may be used relatively safely. We present 3 patients with previous sensitization to meat protein following a tick bite with known allergic reactions to mammalian meat who presented for cardiac surgery involving exposure to potential allergens and discuss the perioperative management including possible prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 2325-7237 (Electronic)IS - 2325-7237 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1213/XAA.0000000000000457</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28118212">PM:28118212</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\AA Case Rep\20170124-KleimanAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\AA Case Rep\20170124-KleimanAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Kleiman AM</style></custom2><misc3><style face="normal" font="Arial">10.1213/XAA.0000000000000457</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brzezicka,K.</style></author><author><style face="normal" font="Arial"> Echeverria,B.</style></author><author><style face="normal" font="Arial"> Serna,S.</style></author><author><style face="normal" font="Arial"> van Diepen,A.</style></author><author><style face="normal" font="Arial"> Hokke,C.H.</style></author><author><style face="normal" font="Arial"> Reichardt,N.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">daggerGlycotechnology Laboratory, CIC biomaGUNE, Paseo Miramon 182, 20009 San Sebastian, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Synthesis and microarray-assisted binding studies of core xylose and fucose containing N-glycans</style></title><secondary-title><style face="normal" font="Arial">ACS Chem Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ACS Chem Biol</style></full-title></periodical><pages end="1302" start="1290">1290-1302</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Protozoan</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> Binding Properties</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> C-type lectin receptor</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate Sequence</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical synthesis</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> DC-SIGN</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fucose</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Lab-On-A-Chip Devices</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Molecular Sequence Data</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasitic helminth</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Lectins</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Schistosomiasis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> Xylose</style></keyword></keywords><dates><year Day="15" Month="5" Year="2015">2015/5/15</year></dates><abstract><style face="normal" font="Arial">The synthesis of a collection of 33 xylosylated and core-fucosylated N-glycans found only in nonmammalian organisms such as plants and parasitic helminths has been achieved by employing a highly convergent chemo-enzymatic approach. The influence of these core modifications on the interaction with plant lectins, with the human lectin DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Nonintegrin), and with serum antibodies from schistosome-infected individuals was studied. Core xylosylation markedly reduced or completely abolished binding to several mannose-binding plant lectins and to DC-SIGN, a C-type lectin receptor present on antigen presenting cells. Employing the synthetic collection of core-fucosylated and core-xylosylated N-glycans in the context of a larger glycan array including structures lacking these core modifications, we were able to dissect core xylose and core fucose specific antiglycan antibody responses in S. mansoni infection sera, and we observed clear and immunologically relevant differences between children and adult groups infected with this parasite. The work presented here suggests that, quite similar to bisecting N-acetylglucosamine, core xylose distorts the conformation of the unsubstituted glycan, with important implications for the immunogenicity and protein binding properties of complex N-glycans</style></abstract><notes><style face="normal" font="Arial">DA - 20150515IS - 1554-8937 (Electronic)IS - 1554-8929 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Antibodies, Protozoan)RN - 0 (Polysaccharides)RN - 3713-31-3 (Fucose)RN - A1TA934AKO (Xylose)SB - IMCO - Spain -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1021/cb501023u</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="25664929">PM:25664929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\ACS Chem Biol\2015-10-1290-302.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\ACS Chem Biol\2015-10-1290-302.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150515, Brzezicka K</style></custom2><misc3><style face="normal" font="Arial">10.1021/cb501023u</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Prohic,A.</style></author><author><style face="normal" font="Arial"> Jovovic,S.T.</style></author><author><style face="normal" font="Arial"> Kuskunovic-Vlahovljak,S.</style></author><author><style face="normal" font="Arial"> Baljic,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Professor Asja Prohic, MD, PhD, Department of Dermatovenerology, University Clinical Center of Sarajevo, Bolnicka 25, 71000 Sarajevo, Bosnia and Herzegovina</style></auth-address><titles><title><style face="normal" font="Arial">Distribution of Malassezia Species in Patients with Different Dermatological Disorders and Healthy Individuals</style></title><secondary-title><style face="normal" font="Arial">Acta Dermatovenerol Croat</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Dermatovenerol Croat</style></full-title></periodical><pages end="281" start="274">274-281</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Malassezia species</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microflora</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pityriasis</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> seborrheic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">There are differences with respect to the commonly isolated Malassezia species, not only between healthy individuals and the patients with various skin diseases, but also between different countries. We investigated the species composition of Malassezia microflora on the skin of patients with Malassezia-associated diseases and of healthy subjects (HS). Two hundred and fifty skin scrapings from patients with pityriasis versicolor (PV), seborrheic dermatitis (SD), atopic dermatitis (AD), psoriasis (PS), and healthy subjects (HS), fifty each, were inoculated into Sabouraud dextrose agar and into modified Dixon agar and identified using conventional culture-based methods. In PV and PS lesions, the most common species was M. globosa (62% and 52%, respectively), while M. restricta was predominant in SD lesions (28%). M. sympodialis was the most common species recovered from AD (52%) and healthy trunk skin (30%). Fewer cultures were positive for Malassezia growth in patients with AD than in patients with other skin conditions, and even in controls. Our data are in agreement with other studies and suggest that the pathogenic species of PV is M. globosa. The evidence that any given species is clinically important in the pathogenicity of SD, AD and PS is still lacking</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1847-6538 (Electronic)IS - 1330-027X (Linking)LA - engPT - Journal ArticleCO - Bosnia and Herzegovina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28128078">PM:28128078</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2016-24-274-81.PDF</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2016-24-274-81.PDF</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Prohic A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sadys,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">An analysis of the exposure time to very high concentrations of Cladosporium conidia in the air of an urban site</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Conidia</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Multivariate regression tree</style></keyword><keyword><style face="normal" font="Arial"> Outdoor environment</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Cladosporium spp. is a ubiquitous mould present both in indoor and outdoor environments and affecting a wide array of substrates. It is considered to be the second most important fungal aeroallergen in countries of temperate climates, after Alternaria species. In order to establish the time of exposure to very high concentrations of Cladosporium conidia by sensitised individuals, a 5-year study was undertaken in the UK in a densely populated area using a volumetric air sampler. Weather data, comprised air temperature, precipitation, relative humidity and wind speed were collected simultaneously. Cladosporium showed a mono-modal pattern with the majority of conidia observed between 09:30 and 19:00 as indicated by descriptive statistics and multivariate regression tree analysis. On the other hand, circular statistics showed that the maximum hourly concentrations were found within 1.5-h window before 09:30. The highest conidia concentrations were observed when dry conditions occurred (40</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô55%). The maximum temperature associated with peak concentrations was oscillating within the range of 20</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô25-á-¦C. All findings were confirmed using Kruskal</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôWallis, Friedman and sign tests</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9472-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9472-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170207-SadysM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170207-SadysM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Sadys M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9472-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghitarrini,S.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author><author><style face="normal" font="Arial"> Frenguelli,G.</style></author><author><style face="normal" font="Arial"> Tedeschini,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Phenological analysis of grasses (Poaceae) as a support for the dissection of their pollen season in Perugia (Central Italy)</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Dactylis</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Flowering phenology</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lolium</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen load</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Grasses (Poaceae) pollen is a major cause for allergic diseases worldwide. Pollen monitoring in the atmosphere is of primary importance for symptoms interpretation and therapy planning. Microscopic pollen identification and counts do not allow the detection at species or genus level because of the stenopalynous nature of the family. Nevertheless, the assessment of the flowering phenology of different species would be important, because not all grass allergens are cross-reacting and allergic patients could be differentially sensitized. In this work, a phenological survey was carried out in five stations located on the urban territory of Perugia (Central Italy), from April to September 2015, recording the alternation between flowering phenophases of 19 grass species and estimating their contribution to the airborne pollen load of the area through the calculation of a Phenological Index. Moreover, pollen grains of the different species were collected and observed, confirming the impossibility to make a discrimination during microscope pollen counts. The prevailing grasses in terms of contribution to the pollen detection in the studied area resulted to be Dactylis glomerata and Lolium perenne during spring and early summer, and Cynodon dactylon during late summer. Data should be validated repeating the survey in successive years and possibly using biomolecular tools, but the obtained information could be relevant for diagnosis and treatment of grass pollen allergies</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9473-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9473-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170207-GhitarriniS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170207-GhitarriniS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Ghitarrini S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9473-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bilinska,D.</style></author><author><style face="normal" font="Arial"> Skjoth,C.A.</style></author><author><style face="normal" font="Arial"> Werner,M.</style></author><author><style face="normal" font="Arial"> Kryza,M.</style></author><author><style face="normal" font="Arial"> Malkiewicz,M.</style></author><author><style face="normal" font="Arial"> Krynicka,J.</style></author><author><style face="normal" font="Arial"> Drzeniecka-Osiadacz,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Source regions of ragweed pollen arriving in south-western Poland and the influence of meteorological data on the HYSPLIT model results</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> HYSPLIT</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Ukraine</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">We have investigated the relationship between the inflow of air masses and the ragweed pollen concentration in SW Poland (Wroc+éaw) for a 10-year period of 2005</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2014. The HYSPLIT trajectory model was used to verify whether episodes of high concentrations can be related to regions outside of the main known ragweed centres in Europe, like Pannonian Plain, northern Italy and Ukraine. Furthermore, we used two different meteorological data sets (the global GDAS data set and from the WRF mesoscale model; the meteorological parameters were: U and V wind components, temperature and relative humidity) into HYSPLIT to evaluate the influence of meteorological input on calculated trajectories for high concentration ragweed episodes. The results show that the episodes of high pollen concentration (above 20-ápm</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3) represent a great part of total recorded ragweed pollen in Wroc+éaw, but occur rarely and not in all years. High pollen episodes are connected with air masses coming from south and south-west Europe, which confirms the existence of expected ragweed centres but showed that other centres near Wroc+éaw are not present. The HYSPLIT simulations with two different meteorological inputs indicated that footprint studies on ragweed benefit from a higher resolution meteorological data sets</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9471-9</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9471-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170207-BilinskaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170207-BilinskaD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Bilinska D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9471-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Warners,M.J.</style></author><author><style face="normal" font="Arial"> Vlieg-Boerstra,B.J.</style></author><author><style face="normal" font="Arial"> Verheij,J.</style></author><author><style face="normal" font="Arial"> van Rhijn,B.D.</style></author><author><style face="normal" font="Arial"> Van Ampting,M.T.</style></author><author><style face="normal" font="Arial"> Harthoorn,L.F.</style></author><author><style face="normal" font="Arial"> de Jonge,W.J.</style></author><author><style face="normal" font="Arial"> Smout,A.J.</style></author><author><style face="normal" font="Arial"> Bredenoord,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology &amp; Hepatology, Academic Medical Centre, Amsterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients</style></title><secondary-title><style face="normal" font="Arial">Aliment Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Aliment Pharmacol Ther</style></full-title></periodical><pages end="787" start="777">777-787</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elemental diet</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neocate</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic oesophagitis (EoE) is a chronic disease, driven by food allergens. Elemental diets are effective for the management of children with EoE, but studies on the effect of elemental diets in adults are scarce and poor palatability challenges dietary adherence. AIMS: To assess the effect of an elemental diet (Neocate, Nutricia, Utrecht, the Netherlands) on the inflammation, symptoms and endoscopic signs in adult EoE patients. METHODS: In this prospective study, 21 patients with active EoE, confirmed by biopsies showing >/=15 eosinophils per microscopic high power field (HPF) and symptoms of oesophageal dysfunction were included. Patients underwent endoscopy before and 4 weeks after diet. Histological disease activity (peak eosinophil count/HPF), and endoscopic signs were scored by physicians. Symptoms and adherence to the diet were evaluated by questionnaires. Serum total IgE levels and total eosinophil counts were determined and the expression of inflammatory cytokines was analysed by qPCR. RESULTS: In total, 17 (81%) of the patients completed the diet, of whom 12 (71%) showed complete histological response (&lt;/=15 eosinophils/HPF) and 4 (24%) showed partial histological response (>/=50% reduction of baseline eosinophil count). Peak eosinophil counts decreased significantly after the diet from 40 to 9 per HPF (P &lt;/= 0.001). A marked improvement in endoscopic signs was observed. Symptoms decreased significantly in all subjects, and 15 patients (88%) became completely asymptomatic (P &lt;/= 0.001). In 14 patients (82%), blood eosinophil count and serum IgE decreased (P &lt;/= 0.05). CONCLUSION: Elemental diet reduces eosinophilic inflammation and induces clinical remission in adult patients with eosinophilic oesophagitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 1365-2036 (Electronic)IS - 0269-2813 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/apt.13953</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28112427">PM:28112427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aliment Pharmacol Ther\20170123-WarnersMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aliment Pharmacol Ther\20170123-WarnersMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170123, Warners MJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/apt.13953</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lopata,A.L.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Kamath,S.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergens and molecular diagnostics of shellfish allergy</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="218" start="210">210-218</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Arginine kinase</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Ca2+-binding</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food groups</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> Myosin light chain</style></keyword><keyword><style face="normal" font="Arial"> pan-allergen</style></keyword><keyword><style face="normal" font="Arial"> Pan-allergens</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sarcoplasmic</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shellfish allergy</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Troponin</style></keyword><keyword><style face="normal" font="Arial"> Troponin C</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Shellfish belongs to </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£The Big 8</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ food groups causing allergy, which often does not outgrow during childhood. Shellfish is one of the main food allergens in adults and constitutes a diverse group of species subdivided into crustaceans and mollusks, which seem to include similar but also different allergens. Several pan-allergens are characterized in detail, including tropomyosin and arginine kinase, responsible for clinical cross-reactivity with other invertebrate allergen sources, embracing mites, insects, and parasites. Currently, at least seven different shellfish allergens have been identified, mostly from crustaceans. However, only three recombinant allergens are available for IgE-based routine diagnostic, including tropomyosin, arginine kinase, and sarcoplasmic Ca2+-binding protein. Other allergens include myosin light chain, troponin C, triosephosphate isomerase, and actin. This review summarizes the current advances on the molecular characterization of shellfish allergens, clinical cross-reactivity, and current diagnostic approaches for the management of this life-threatening disease</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0124-2</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0124-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2016-25-210-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2016-25-210-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Lopata AL</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0124-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bornemann,R.</style></author><author><style face="normal" font="Arial"> Hagemeister,K.</style></author><author><style face="normal" font="Arial"> Bresser,H.G.</style></author><author><style face="normal" font="Arial"> Hamelmann,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy and school: nothing to be sneezed at!</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="209" start="201">201-209</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Pupil</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> Social Environment</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Allergic diseases account for the largest proportion of chronic diseases in childhood and adolescence and place a significant burden on everyday family, social, and in particular school life. Without appropriate education, affected individuals often have little of the knowledge required to understand and deal safely with their allergic disease, and their social environment (school) generally offers insufficient information. An interdisciplinary project involving the Bielefeld Community Foundation (</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£Bielefelder B++rgerstiftung</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ), the Children</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs Center Bethel, and the local school authority investigated the current knowledge, possibilities for increasing that knowledge, as well as pupils</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ and teachers</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ perception of the problems experienced by fellow pupils, while at the same time collecting current prevalence figures on allergic diseases among primary school children</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0131-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0131-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2016-25-201-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2016-25-201-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Bornemann R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0131-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alvarez Zallo,N.</style></author><author><style face="normal" font="Arial"> Aguinaga-Ontoso,I.</style></author><author><style face="normal" font="Arial"> Alvarez-Alvarez,I.</style></author><author><style face="normal" font="Arial"> Guillen-Grima,F.</style></author><author><style face="normal" font="Arial"> Azcona San Julian,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Extrahospitalary Pediatric Emergency Service, Osasunbidea, Pamplona, Navarra, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">The influence of gender and atopy in the relationship between obesity and asthma in childhood</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="233" start="227">227-233</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> exercise-induced asthma</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> overweight</style></keyword><keyword><style face="normal" font="Arial"> overweight and obesity</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> teenagers</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The objective of the study was to examine the relationship between asthma and overweight-obesity in Spanish children and adolescents and to determine whether this relationship was affected by gender and atopy. METHODS: The study involves 8607 Spanish children and adolescents from the International Study of Asthma and Allergies in Childhood phase III. Unconditional logistic regression was used to obtain adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for the association between asthma symptoms and overweight-obesity in the two groups. Afterwards, it was stratified by sex and rhinoconjunctivitis. RESULTS: The prevalence of overweight and obesity in 6-7-year-old children was 18.6% and 5.2% respectively and in 13-14 year-old teenagers was 11.4% and 1.1% respectively. Only the obese children, not the overweight children, of the 6-7 year old group had a higher risk of any asthma symptoms (wheezing ever: OR 1.68 [1.15-2.47], asthma ever: OR 2.29 [1.43-3.68], current asthma 2.56 [1.54-4.28], severe asthma 3.18 [1.50-6.73], exercise-induced asthma 2.71 [1.45-5.05]). The obese girls had an increased risk of suffering any asthma symptoms (wheezing ever: OR 1.73 [1.05-2.91], asthma ever: OR 3.12 [1.67-5.82], current asthma 3.20 [1.65-6.19], severe asthma 4.83[1.94-12.04], exercise-induced asthma 3.68 [1.67-8.08]). The obese children without rhinoconjunctivitis had a higher risk of asthma symptoms. CONCLUSIONS: Obesity and asthma symptoms were associated in 6-7 year-old children but not in 13-14 year-old teenagers. The association was stronger in non-atopic children and obese girls</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28126313">PM:28126313</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170127-AlvarezZalloN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170127-AlvarezZalloN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Alvarez Zallo N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.09.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shimoda,T.</style></author><author><style face="normal" font="Arial"> Odajima,H.</style></author><author><style face="normal" font="Arial"> Okamasa,A.</style></author><author><style face="normal" font="Arial"> Kawase,M.</style></author><author><style face="normal" font="Arial"> Komatsubara,M.</style></author><author><style face="normal" font="Arial"> Mayer,B.</style></author><author><style face="normal" font="Arial"> Yancey,S.</style></author><author><style face="normal" font="Arial"> Ortega,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Fukuoka National Hospital, Fukuoka, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="451" start="445">445-451</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The MENSA trial assessed the efficacy and safety of mepolizumab in patients with severe eosinophilic asthma. This report describes the efficacy and safety of mepolizumab in Japanese patients from MENSA. METHODS: A post hoc analysis of the Japanese subgroup from the randomized, double-blind, placebo-controlled, double-dummy, Phase III MENSA trial (NCT01691521). Patients >/=12 years with severe eosinophilic asthma received mepolizumab 75 mg intravenously (IV), 100 mg subcutaneously (SC), or placebo, every 4 weeks for 32 weeks. The primary endpoint was the annualized rate of exacerbations. Secondary and other endpoints included annualized rate of exacerbations requiring emergency department (ED) visit/hospitalization, morning peak expiratory flow (PEF), St George's Respiratory Questionnaire (SGRQ) score and eosinophil counts. Adverse events (AEs) were monitored. RESULTS: In the Japanese subgroup (N = 50), the rate of clinically significant exacerbations was reduced by 90% (rate ratio [RR]: 0.10; 95% confidence interval [CI]: 0.02-0.57; P = 0.010) with mepolizumab IV and 62% (RR: 0.38; 95% CI: 0.12-1.18; P = 0.094) with mepolizumab SC, versus placebo. No exacerbations requiring ED visit/hospitalization were reported with mepolizumab IV; exacerbations were reduced by 73% (RR: 0.27; 95% CI: 0.06-1.29; P = 0.102) with mepolizumab SC versus placebo. Compared with placebo, mepolizumab IV and SC numerically increased morning PEF from baseline by 40 L/min and 13 L/min, improved quality of life by greater than the minimal clinically important difference (SGRQ: 9.5 [P = 0.083] and 7.9 [P = 0.171] points) and reduced eosinophil counts. AE incidence was similar between treatments. Results were broadly consistent with the overall population. CONCLUSIONS: Mepolizumab was efficacious and well tolerated in Japanese patients with severe eosinophilic asthma, producing similar responses to the overall MENSA population</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.11.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28110896">PM:28110896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170123-ShimodaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170123-ShimodaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170123, Shimoda T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.11.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iwasaki,A.</style></author><author><style face="normal" font="Arial"> Ito,T.</style></author><author><style face="normal" font="Arial"> Kawakami,H.</style></author><author><style face="normal" font="Arial"> Nishiwaki,K.</style></author><author><style face="normal" font="Arial"> Numata,T.</style></author><author><style face="normal" font="Arial"> Saito,M.</style></author><author><style face="normal" font="Arial"> Tsuboi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Tokyo Medical University, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A case of cholinergic urticaria with localized hypohidrosis showing sweat gland eosinophilic infiltration</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="496" start="495">495-496</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170121IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.11.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108244">PM:28108244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170121-IwasakiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170121-IwasakiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170121, Iwasaki A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.11.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosenfield,L.</style></author><author><style face="normal" font="Arial"> Tsoulis,M.W.</style></author><author><style face="normal" font="Arial"> Milio,K.</style></author><author><style face="normal" font="Arial"> Schnittke,M.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0004 1936 8227grid.25073.33Division of Clinical Immunology and Allergy, Department of Medicine Michael D. DeGroote School of Medicine, McMaster University, Hamilton, ON Canada</style></auth-address><titles><title><style face="normal" font="Arial">High rate of house dust mite sensitization in a shrimp allergic southern Ontario population</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="5">5-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Shrimp and house dust mite (HDM) allergies are common in Canadians. Often, both of these allergies occur in the same patient. This may be due to homology of tropomyosin or other potentially shared proteins. The aim of our study was to assess the frequency of house dust mite sensitization in a shrimp allergic Canadian population. METHODS: We undertook a retrospective chart review of shrimp allergic patients at an outpatient allergy clinic in Kitchener, Ontario, Canada. Our primary endpoint was to assess for presence of HDM sensitization in this population. Patients were categorized into approximate quartiles. We assessed the severity of the shrimp reactions, correlated shrimp skin test size to HDM skin test size, and measured the proportion of patients with atopic symptoms. RESULTS: We identified 95 shrimp allergic patients who were tested for house dust mite. 86 (90.5%) of these patients had a positive skin test to HDM. Patients with a shrimp skin test >/=5 mm were 5.31 times (95% CI, 1.55-18.14; p = 0.008) more likely to exhibit a dust mite skin test >/=5 mm than patients with a shrimp skin test &lt;5 mm. The odds of a patient with a shrimp skin test between 10 and 18 mm having a larger HDM skin test were 3.93 times (95% CI 1.03-14.98, p = 0.045) the odds for a patient with a shrimp skin test size between 3 and 4 mm. We did not find a correlation between shrimp skin test size and shrimp reaction symptom grade (p = 0.301). CONCLUSION: In our Canadian patients, we found a large majority of shrimp allergic patients to be sensitized to HDM. We found that patients with a large skin test to shrimp were more likely to have a large skin test to HDM compared to those patients with a small skin test to shrimp. We did not find a correlation between shrimp skin test size and shrimp reaction symptom severity. Most of these patients had symptoms of rhinitis and/or asthma that may have been caused by house dust mite allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0177-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28115965">PM:28115965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Rosenfield L</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0177-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bae,J.S.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Kim,E.H.</style></author><author><style face="normal" font="Arial"> Mo,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Dankook University College of Medicine, Cheonan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">The Role of IL-17 in a Lipopolysaccharide-Induced Rhinitis Model</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="176" start="169">169-176</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Gram-Negative Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Lipopolysaccharide (LPS) is a cell wall component of Gram-negative bacteria and important for pro-inflammatory mediators. This study aimed to establish a rhinitis model using ovalbumin (OVA) and LPS in order to evaluate the role of interleukin (IL)-17 in the pathogenesis of an LPS-induced non-eosionophilic rhinitis model. METHODS: Mice were divided into 4 groups and each group consisted of 10 mice (negative control group, allergic rhinitis model group, 1-mug LPS treatment group, and 10-mug LPS treatment group). BALB/c mice were sensitized with OVA and 1 or 10 mug of LPS, and challenged intranasally with OVA. Multiple parameters of rhinitis were also evaluated to establish the LPS-induced rhinitis model. IL-17 knockout mice were used to check if the LPS-induced rhinitis model were dependent on IL-17. Eosinophil and neutrophil infiltration, and mRNA and protein expression profiles of cytokine in nasal mucosa or spleen cell culture were evaluated using molecular, biochemical, histopathological, and immunohistological methods. RESULTS: In the LPS-induced rhinitis model, neutrophil infiltration increased in the nasal mucosa, and systemic and nasal IL-17 and interferon-gamma (IFN-gamma) levels also increased as compared with the OVA-induced allergic rhinitis model. These findings were LPS-dose-dependent. In IL-17 knockout mice, those phenotypes (neutrophil infiltration, IL-17, and IFN-gamma) were reversed, showing IL-17 dependency of LPS-induced rhinitis. The expression of vascular endothelial growth factor (VEGF), an important mediator for inflammation and angiogenesis, decreased in IL-17 knockout mice, showing the relationship between IL-17 and VEGF. CONCLUSIONS: This study established an LPS-induced rhinitis model dependent on IL-17, characterized by neutrophil infiltration and increased expression of IL-17</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.2.169</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102062">PM:28102062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-169-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-169-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Bae JS</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.2.169</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choi,I.S.</style></author><author><style face="normal" font="Arial"> Kim,S.J.</style></author><author><style face="normal" font="Arial"> Won,J.M.</style></author><author><style face="normal" font="Arial"> Park,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Chonnam National University Medical School and Research Institute of Medical Sciences, Gwangju, Korea.</style></auth-address><titles><title><style face="normal" font="Arial">Usefulness of House Dust Mite Nasal Provocation Test in Asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="157" start="152">152-157</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial provocation</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Provocation Tests</style></keyword><keyword><style face="normal" font="Arial"> bronchus</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">PURPOSE: We previously reported that the skin prick test was sensitive and the serum specific immunoglobulin E test was specific for predicting positive airway responses to house dust mites (HDMs) in patients with asthma. Because the nose and bronchus are one airway, the nasal provocation test would be more specific for predicting the bronchial responses to HDM than the skin test. METHODS: The allergy skin prick test and nasal and bronchial provocation tests using HDM (Dermatophagoides farinae) were performed in 41 young men (age, 19-28 years) who wanted military certification for asthma. The nasal responses to HDM was scored according to the severity of rhinorrhea, sneezing, and nose itching. RESULTS: The prevalence of a positive skin prick test to HDM did not significantly differ between patients with (n=24) and without (n=17) an early airway reaction (EAR; 79.2% vs 70.6%, P=0.534). However, the prevalence of a positive nasal test was significantly higher in the airway responders than in the others (37.5% vs 0%, P=0.005). The concordance of a positive response to the nasal test (kappa=0.332, P=0.004) but not to the skin prick test (kappa=0.091, P=0.529) was significant with an EAR. The diagnostic sensitivity of the nasal test (37.5%) was lower than that of the skin prick test (79.2%), but the specificity was higher (100% vs 29.4%). CONCLUSIONS: The skin prick test is more sensitive, whereas the nasal test is more specific and accurate, for predicting an EAR to HDM in patients with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.2.152</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102060">PM:28102060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-152-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-152-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Choi IS</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.2.152</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chu,H.</style></author><author><style face="normal" font="Arial"> Shin,J.U.</style></author><author><style face="normal" font="Arial"> Park,C.O.</style></author><author><style face="normal" font="Arial"> Lee,H.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Diversity of Atopic Dermatitis: A Review of 5,000 Patients at a Single Institute</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="168" start="158">158-168</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Koreans</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> topical steroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Atopic dermatitis (AD) is a chronic eczematous dermatitis that has a high prevalence and diverse clinical features. Although several hypotheses about its multifactorial pathogenesis have been suggested, the cause is not yet fully understood. A better understanding of the clinical features may helpful inelucidating the pathogenesis of AD. METHODS: This retrospective study analyzed the questionnaires, medical charts, and laboratory examination results of 5,000 patients diagnosed with AD at a single tertiary hospital in Korea. RESULTS: The demographics, allergic comorbidities, family history, severity, and treatment experiences of the patients were analyzed. Most of the patients were adults, 76.3% of whom were classified as havingan extrinsic type of AD. The mean eczema area and severity index (EASI) score was found to be 13.68, and adult patients were found to have higher severity than the other age groups. The anatomical involvements were different among the age groups, with more involvements of the head and neck in adults. The patients reported seasonal changes and stress as the factors that aggravated their symptoms the most. Topical steroids and oral cyclosporine were the most used medications at our clinic, whereas 10.1% of the patients underwent allergen-specific immunotherapy. CONCLUSIONS: This analysis of 5,000 patients would lead to a better understanding of various subtypes and diverse clinical features of AD in Koreans. Distinct characteristics were observed among different age groups; thus, treatment strategies may need to be differentiated accordingly</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.2.158</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102061">PM:28102061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-158-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-158-68.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Chu H</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.2.158</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larcombe,A.N.</style></author><author><style face="normal" font="Arial"> Kicic,A.</style></author><author><style face="normal" font="Arial"> Mullins,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Telethon Kids Institute, The University of Western Australia, Subiaco, Western Australia, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Comment on "Long-Term Effects of Diesel Exhaust Particles on Airway Inflammation and Remodeling in a Mouse Model" by Kim et al</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="186" start="185">185-186</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Diesel</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust</style></keyword><keyword><style face="normal" font="Arial"> diesel exhaust particle</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust particles</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.2.185</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102065">PM:28102065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-185-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-185-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Larcombe AN</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.2.185</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wawrzyniak,M.</style></author><author><style face="normal" font="Arial"> O'Mahony,L.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Role of Regulatory Cells in Oral Tolerance</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="115" start="107">107-115</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Breg</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> intestinal immune system</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Peripheral Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Tonsil</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">The immune system is continuously exposed to great amounts of different antigens from both food and intestinal microbes. Immune tolerance to these antigens is very important for intestinal and systemic immune homeostasis. Oral tolerance is a specific type of peripheral tolerance induced by exposure to antigen via the oral route. Investigations on the role of intestinal immune system in preventing hypersensitivity reactions to innocuous dietary and microbial antigens have been intensively performed during the last 2 decades. In this review article, we discuss how food allergens are recognized by the intestinal immune system and draw attention to the role of regulatory T (Treg) and B (Breg) cells in the establishment of oral tolerance and tolerogenic features of intestinal dendritic cells. We also emphasize the potential role of tonsils in oral tolerance induction because of their anatomical location, cellular composition, and possible usage to develop novel ways of specific immunotherapy for the treatment of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.2.107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102055">PM:28102055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-107-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-107-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Wawrzyniak M</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.2.107</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sohn,K.H.</style></author><author><style face="normal" font="Arial"> Kim,B.K.</style></author><author><style face="normal" font="Arial"> Kim,J.Y.</style></author><author><style face="normal" font="Arial"> Song,W.J.</style></author><author><style face="normal" font="Arial"> Kang,H.R.</style></author><author><style face="normal" font="Arial"> Park,H.W.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author><author><style face="normal" font="Arial"> Min,K.U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Fixed Food Eruption Caused by Actinidia arguta (Hardy Kiwi): A Case Report and Literature Review</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="184" start="182">182-184</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Actinidia</style></keyword><keyword><style face="normal" font="Arial"> Actinidia arguta</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Kiwi</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation test</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation tests</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Fixed drug eruption (FDE) is a common hypersensitivity reaction characterized by recurrent, well-circumscribed, erythematous patches that arise at the same site as a result of systemic drug exposure. However, fixed food eruption (FFE), a lesion triggered by food ingestion, is a rare allergy that was first defined in 1996. Based on their anti-inflammatory and anti-oxidant properties, the fruit and leaves of Actinidia arguta, the hardy kiwi, are widely consumed across Korea, Japan, and China. This report describes the first case of FFE caused by hardy kiwi leaves, known as Daraesun in Korean, confirmed by oral provocation tests and skin biopsy</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - LetterCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.2.182</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102064">PM:28102064</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-182-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-182-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Sohn KH</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.2.182</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghebre,M.A.</style></author><author><style face="normal" font="Arial"> Desai,D.</style></author><author><style face="normal" font="Arial"> Singapuri,A.</style></author><author><style face="normal" font="Arial"> Woods,J.</style></author><author><style face="normal" font="Arial"> Rapley,L.</style></author><author><style face="normal" font="Arial"> Cohen,S.</style></author><author><style face="normal" font="Arial"> Herath,A.</style></author><author><style face="normal" font="Arial"> Wardlaw,A.J.</style></author><author><style face="normal" font="Arial"> Pashley,C.H.</style></author><author><style face="normal" font="Arial"> May,R.</style></author><author><style face="normal" font="Arial"> Brightling,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Lung Health, NIHR Respiratory Biomedical Research Unit, Department of Infection, Immunity &amp; Inflammation, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Sputum Inflammatory Mediators Are Increased in Aspergillus fumigatus Culture-Positive Asthmatics</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="181" start="177">177-181</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Aspergillus fumigatus sensitization and culture in asthma are associated with disease severity and lung function impairment, but their relationship with airway inflammation is poorly understood. We investigated the profile of 24 sputum inflammatory mediators in A. fumigatus culture-positive or-negative moderate-to-severe asthmatics. Fifty-two subjects were recruited from a single center. A. fumigatus was cultured from 19 asthmatics. Asthma control, symptom score, lung function, and sputum cell count were not significantly different between the asthmatics with and without a positive A. fumigatus culture. All of the sputum mediators were numerically increased in subjects with a positive versus negative sputum A. fumigatus culture. Sputum TNF-R2 was significantly elevated (P=0.03) and the mediator that best distinguished A. fumigatus culture-positive from culture-negative subjects (receiver-operator characteristic area under the curve 0.66 [95% CI: 0.51 to 0.82, P=0.045]). A. fumigates-positive culture in moderate-to-severe asthma is associated with increased inflammatory sputum mediators</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.2.177</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102063">PM:28102063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-177-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-177-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Ghebre MA</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.2.177</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kido,J.</style></author><author><style face="normal" font="Arial"> Hirata,M.</style></author><author><style face="normal" font="Arial"> Ueno,H.</style></author><author><style face="normal" font="Arial"> Nishi,N.</style></author><author><style face="normal" font="Arial"> Mochinaga,M.</style></author><author><style face="normal" font="Arial"> Ueno,Y.</style></author><author><style face="normal" font="Arial"> Yanai,M.</style></author><author><style face="normal" font="Arial"> Johno,M.</style></author><author><style face="normal" font="Arial"> Matsumoto,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of the skin-prick test for predicting the outgrowth of cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="143" start="139">139-143</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation test</style></keyword><keyword><style face="normal" font="Arial"> Oral provocation tests</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although considerable efforts have been made to develop diagnostic tools for predicting the outcome of oral food challenges, tests for predicting the outgrowth of food allergies are lacking. OBJECTIVE: The aim of this study was to assess the diagnostic value of the wheal size and skin index (SI) (the ratio of an allergen-induced wheal to a histamine-induced wheal diameter) of the skin-prick test based on the outcome of a controlled oral provocation test for cow's milk. Moreover, we assessed whether wheal size and/or SI were useful for predicting the outgrowth of cow's milk allergy (CMA). METHODS: This study included 135 children with suspected CMA. Eighty-one patients were definitely diagnosed by oral provocation tests for cow's milk, and their wheal diameters, SIs, and cow milk's-specific serum immunoglobulin E concentrations were determined. RESULTS: The wheal diameters were significantly larger and the SIs significantly higher in children with positive oral provocation test results than in those with negative test results. We found that 50% of the patients were expected to be able to drink cow's milk by age 5 years. In these patients, the wheal diameters were significantly smaller and the SIs significantly lower at the time of CMA outgrowth than at the time of diagnosis, whereas these values were apt to increase in patients who did not outgrow CMA, with no significant difference. CONCLUSIONS: The skin-prick test can be used to diagnose CMA and predict CMA outgrowth. A wheal diameter of 8 mm or/and an SI of 1.0 is informative, not only in diagnosing CMA but also in predicting a natural CMA outgrowth</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0175</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107145">PM:28107145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-139-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-139-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Kido J</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0175</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ellenburg,J.T.</style></author><author><style face="normal" font="Arial"> Lieberman,J.A.</style></author><author><style face="normal" font="Arial"> Pattanaik,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Adherence and systemic reaction rates to allergy immunotherapy among veterans</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="130" start="127">127-130</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> Travel</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although allergen immunotherapy (AIT) is effective and safe, nonadherence is common. Limited data exist regarding adherence to AIT, factors that affect adherence, and systemic reactions associated with AIT among veteran populations. OBJECTIVE: To evaluate adherence to AIT and the prevalence of reactions secondary to AIT among patients at the Veterans Affairs Medical Center, Memphis, Tennessee. METHODS: A retrospective chart review was performed of veterans who received AIT at a single Veterans Affairs facility. Age, race, sex, the total number of shots, travel distance, a diagnosis of posttraumatic stress disorder (PTSD), and the number of severe adverse reactions were compared between the veterans who were adherent and veterans who were nonadherent. RESULTS: The overall adherence rate was 60.9%. Factors associated with adherence were a chart diagnosis of PTSD (29.3% [adherent group] versus 13.6% [nonadherent group]; p = 0.03) and home residence being a further distance from the facility (21.9 miles / 35.2 kilometers [adherent group] versus 18.0 miles / 28.9 kilometers [nonadherent group]; p = 0.03). Patients who were adherent received an average of more total injections compared with patients who were nonadherent. Age, sex, race, and history of systemic reactions during AIT displayed no statistically significant differences between the groups. There were a total of 20 systemic reactions, and the systemic reaction rate was 0.2% per AIT encounter and 0.1% per injection. CONCLUSION: AIT adherence and systemic reaction rates among veterans at our facility was comparable with similar studies. Adherence was associated with a chart diagnosis of PTSD and home residence that was further away from the clinic</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0170</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107142">PM:28107142</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-127-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-127-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Ellenburg JT</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0170</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Z.</style></author><author><style face="normal" font="Arial"> Shi,L.</style></author><author><style face="normal" font="Arial"> Pang,W.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Shi,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Is a high-fiber diet able to influence ovalbumin-induced allergic airway inflammation in a mouse model?</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="e222" start="e213">e213-e222</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Bacteroidetes</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary Fiber</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Firmicutes</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> high-fiber diet</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">More recently, a large amount of experimental and clinical discovered that dietary- fiber intake would decrease the susceptibility to allergic airway disease (AAD) and respiratory inflammation. Objective:To investigate whether a fiber-intake supplement is able to influence the induction of AAD and to elucidate the interactive relationship. Methods:AAD model mice and control mice were raised on a fundamental diet with standard 4% fiber content, whereas other mice were fed a 10% fiber-content diet in the high fiber-content group, along with a 25% fiber-content diet instead in very-high fiber-content group. All experimental mice were sensitized and challenged with ovalbumin to induce allergic inflammation in both the upper and lower airways. Hallmarks of AAD were examined in terms of eosinophil infiltration and goblet cell metaplasia in subepithelial mucosa, T-helper type 1 (Th1) to Th2 skewing of the immune response. Furthermore, to elucidate the interrelations, we generated 16S ribosomal DNA from fecal samples and further validated the variation of colony composition in each group. Results:The excessive high-fiber supplement induced a promoting effect rather than a suppressive effect, including a rise in nasal rubbing and sneezing, an increase in eosinophil inflammation and goblet cell metaplasia in subepithelial mucosa, and promoted Th2 skewing of the immune response as well as the production of serum levels of ovalbumin-specific immunoglobulin E. Moreover, overconsumption of dietary fiber greatly altered the construction of bacterial flora in the intestinal tract, including an increased proportion of Firmicutes, Actinobacteria, and Proteobacteria, and a decreased proportion of Bacteroidetes. Conclusion:Our work indicated that, instead of a protecting impact, excessive fiber intake preformed a negative influence on the induction of AAD. Therefore, we suspected that an excessive supplement of dietary fiber might not be an advisable method for the prevention and treatment of AADs</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0186</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2500/ar.2016.7.0186</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-e213-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-e213-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Zhang Z</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0186</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dominguez-Ortega,J.</style></author><author><style face="normal" font="Arial"> Lopez-Matas,M.A.</style></author><author><style face="normal" font="Arial"> Alonso,M.D.</style></author><author><style face="normal" font="Arial"> Feliu,A.</style></author><author><style face="normal" font="Arial"> Ruiz-Hornillos,J.</style></author><author><style face="normal" font="Arial"> Gonzalez,E.</style></author><author><style face="normal" font="Arial"> Moya,R.</style></author><author><style face="normal" font="Arial"> Carnes,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Prevalence of allergic sensitization to conifer pollen in a high cypress exposure area</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="e206" start="e200">e200-e206</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cedrus</style></keyword><keyword><style face="normal" font="Arial"> Conifers</style></keyword><keyword><style face="normal" font="Arial"> Cup a 1</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> Cupressus</style></keyword><keyword><style face="normal" font="Arial"> Cupressus allergy</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Juniperus</style></keyword><keyword><style face="normal" font="Arial"> Libocedrus</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pinaceae</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin-prick testing</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">Background:Sensitization to Pinales (Cupressaceae and Pinaceae) has increased dramatically in recent years. The prevalence of sensitization in different geographic areas is related to exposure to specific pollens. Objectives:To investigate the prevalence of allergy to different conifer pollens, describe the characteristics of patients with such allergy, and identify the involved allergens. Methods:Patients were recruited at five hospitals near Madrid. Extracts from conifer pollen were prepared and used in skin-prick testing. Wheal sizes were recorded, and serum samples obtained from patients with positive reactions to Cupressus arizonica and/or Pinus pinea. The specific immunoglobulin E value to C. arizonica and Cup a 1 was determined. Individual immunoblots for each patient and with a pool of sera were performed. Allergenic proteins were sequenced by using liquid chromatography-tandem mass spectrometry. Results:Of 499 individuals included in the study, 17 (14%) had positive skin-prick test results to some conifer pollen extracts. Sixty-four patients had positive results to C. arizonica (prevalence 12.8%) and 11 had positive results to P. pinea (2.2%). All the patients had respiratory symptoms (61.4% during the C. arizonica pollination period), and 62.9% had asthma. Approximately 86% of the patients had positive specific immunoglobulin E results to C. arizonica and 92.3% had positive results to Cup a 1. Fourteen different bands were recognized by immunoblot; the most frequent bands were those detected at 43, 18, 16, and 14 kDa. All sequenced proteins corresponded to Cup a 1.Conclusion:Allergy to conifer pollen could be considered a relevant cause of respiratory allergy in central Spain. Asthma was more frequent than in other studies. We only identified Cup a 1 as involved in sensitization</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0183</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2500/ar.2016.7.0183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-e200-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-e200-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Dominguez-Ortega J</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0183</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khalife,S.</style></author><author><style face="normal" font="Arial"> Marchica,C.</style></author><author><style face="normal" font="Arial"> Zawawi,F.</style></author><author><style face="normal" font="Arial"> Daniel,S.J.</style></author><author><style face="normal" font="Arial"> Manoukian,J.J.</style></author><author><style face="normal" font="Arial"> Tewfik,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Concha bullosa mucocele: A case series and review of the literature</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="e243" start="e233">e233-e243</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Concha bullosa</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="Arial"> middle turbinate</style></keyword><keyword><style face="normal" font="Arial"> mucocele</style></keyword><keyword><style face="normal" font="Arial"> mucopyocele</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal mass</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">Concha bullosa mucocele is a rare diagnosis that presents as a nasal mass. It impinges on surrounding structures and can easily be mistaken for a neoplasm. Objective:The objective of this study was to shed light on this rare entity and report its diagnostic features and treatment outcomes. Methods:A case series conducted in a tertiary health care center. Demographic data, clinical presentation, imaging, cultures, and treatments were recorded. Operative video illustration and key images were obtained. A review of the literature was also performed. Results:A total of five cases were reviewed, four of which were concha bullosa mucoceles and one was a mucopyocele. Three of the patients had some form of previous nasal trauma. Headache and nasal obstruction were the most common symptoms with a nasal mass finding on physical examination. Computed tomography was used in all the patients, and magnetic resonance imaging was used in four of the five patients. Four patients had coexistent chronic rhinosinusitis, and three had positive bacterial cultures. All these patients were treated endoscopically either with middle turbinate marsupialization or subtotal resection. No recurrence has been noted thus far. Conclusion:Concha bullosa mucocele is a rare diagnosis. Imaging characteristics are helpful in considering the diagnosis, although surgical intervention is often necessary to confirm the diagnosis and treat concha bullosa mucocele</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2016.7.0179</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2500/ar.2016.7.0179</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-e233-43pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2016-7-e233-43pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Khalife S</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2016.7.0179</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,N.R.</style></author><author><style face="normal" font="Arial"> Moon,P.D.</style></author><author><style face="normal" font="Arial"> Kim,N.R.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Jeong,H.J.</style></author><author><style face="normal" font="Arial"> Kim,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">* Department of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Schisandra chinensis and Its Main Constituent Schizandrin Attenuate Allergic Reactions by Down-Regulating Caspase-1 in Ovalbumin-Sensitized Mice</style></title><secondary-title><style face="normal" font="Arial">Am J Chin Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Chin Med</style></full-title></periodical><pages end="172" start="159">159-172</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Caspase 1</style></keyword><keyword><style face="normal" font="Arial"> caspase-1</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> RIP2</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">Schisandra chinensis (SC) and its main constituent, schizandrin (SCH) exhibit anti-inflammatory and anti-allergic activities. Allergic and inflammatory reactions are aggravated via caspase-1 signaling pathway. However, the regulatory effects of SC and SCH on caspase-1 activation have not been clarified yet. In this study, we aimed to clarify the anti-allergic effects of SC and SCH using an ovalbumin (OVA)-sensitized mice and anti-CD3 and anti-CD28 antibodies-stimulated splenocytes. SC or SCH significantly inhibited the levels of immunoglobulin (Ig)E, IgG1, or interleukin (IL)-4 in serum of OVA-sensitized mice. SC or SCH significantly inhibited the levels of IL-6, tumor necrosis factor (TNF)-[Formula: see text], and IL-1[Formula: see text] in spleen of the OVA-sensitized mice. SC or SCH significantly suppressed the expression of caspase-1 and receptor-interacting protein (RIP)-2 in spleen of the OVA-sensitized mice. In activated splenocytes, SC or SCH significantly decreased the expression of caspase-1 and RIP-2 as well as the production of IL-6 and TNF-[Formula: see text]. We suggest that SC and SCH exert an anti-allergic effect by down-regulating caspase-1 signaling</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 0192-415X (Print)IS - 0192-415X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1142/S0192415X17500112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081628">PM:28081628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Chin Med\2017-45-159-172.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Chin Med\2017-45-159-172.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Han NR</style></custom2><misc3><style face="normal" font="Arial">10.1142/S0192415X17500112</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosenberg,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Early Introduction Reduces Risk of Some Food Allergies</style></title><secondary-title><style face="normal" font="Arial">Am J Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Nurs</style></full-title></periodical><pages end="66" start="65">65-66</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1538-7488 (Electronic)IS - 0002-936X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/01.NAJ.0000512302.26264.91</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28125495">PM:28125495</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Nurs\2017-117-65-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Nurs\2017-117-65-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Rosenberg K</style></custom2><misc3><style face="normal" font="Arial">10.1097/01.NAJ.0000512302.26264.91</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,D.H.</style></author><author><style face="normal" font="Arial"> Kim,B.Y.</style></author><author><style face="normal" font="Arial"> Shin,J.H.</style></author><author><style face="normal" font="Arial"> Kim,S.W.</style></author><author><style face="normal" font="Arial"> Kim,S.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Intranasal azelastine and mometasone exhibit a synergistic effect on a murine model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Am J Otolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Otolaryngol</style></full-title></periodical><pages end="203" start="198">198-203</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The purpose of this study was to compare the anti-allergic effects of the combination of azelastine and mometasone with those of either agent alone in a Dermatophagoides farinae (Derf)-induced murine model of allergic rhinitis (AR). MATERIALS AND METHODS: Forty BALB/c mice were divided into five groups: azelastine (A), mometasone (M), a combination of azelastine and mometasone (MA), Derf, and control. Derf served as the allergen. Allergic symptom scores, eosinophil counts, and serum Derf-specific IgE levels were measured. The mucosal levels of mRNAs encoding interferon (IFN)-gamma, T-bet, interleukin (IL)-4, GATA-3, Foxp3, IL-17, and ROR-gammat were determined by real-time polymerase chain reaction. The T-bet, GATA-3, Foxp3, and ROR-gammat results were confirmed by Western blotting. RESULTS: Nose-rubbing motions; the levels of mRNAs encoding IL-4, GATA-3, and ROR-gammat; and tissue eosinophil count were reduced in the MA compared with those in the Derf group (all P values &lt;0.05). The levels of mRNAs encoding GATA3 and IL-4 mRNA [synthesized by T helper (Th)2 cells] were reduced and that of mRNA encoding Foxp3 was increased in the MA compared with those in the Derf and A groups. Western blotting confirmed these findings. CONCLUSION: We found that the combination of intranasal azelastine and mometasone synergistically suppressed Th17 responses and (reciprocally) elevated Treg responses. Therefore, this combination not only ameliorated allergic inflammation by suppressing Th2 responses, but also usefully modified the Treg/Th17 balance</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1532-818X (Electronic)IS - 0196-0709 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.amjoto.2017.01.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28117118">PM:28117118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Otolaryngol\20170124-KimDH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Otolaryngol\20170124-KimDH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Kim DH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.amjoto.2017.01.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shen,Z.J.</style></author><author><style face="normal" font="Arial"> Hu,J.</style></author><author><style face="normal" font="Arial"> Kashi,V.</style></author><author><style face="normal" font="Arial"> Kelly,E.A.</style></author><author><style face="normal" font="Arial"> Denlinger,L.C.</style></author><author><style face="normal" font="Arial"> Garza,K.</style></author><author><style face="normal" font="Arial"> Russell,D.</style></author><author><style face="normal" font="Arial"> Jarjour,N.N.</style></author><author><style face="normal" font="Arial"> Malter,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Texas Southwestern Medical Center, Dallas, Texas, United States</style></auth-address><titles><title><style face="normal" font="Arial">Epstein-Barr Virus Induced Gene 2 (EBI2) Mediates Allergen-induced, Leukocyte Migration into Airways</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="1585" start="1576">1576-1585</pages><volume><style face="normal" font="Arial">195</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> leukocyte migration</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Pertussis Toxin</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">Background Leukocyte recruitment to sites of allergic inflammation depends on the local production of priming cytokines, chemokines, and potentially other mediators as well. Previously, we showed that eosinophils (Eos) express numerous orphan G-protein coupled receptors (GPRs) including EBI2. Despite its contribution to inflammatory diseases, the role of EBI2 in pulmonary eosinophilia is unknown. Objectives To determine whether oxysterol ligands for EBI2 are increased in asthma exacerbation and if, or how they promote eosinophil pulmonary migration. Methods EBI2 ligands and pulmonary eosinophilia were measured in the BAL fluid from mild-asthmatic patients 48 h after acute allergen challenge. In vitro, the ability of EBI2 ligands alone, or in combination with IL-5 priming to induce the migration of human blood Eos was assessed. Results EBI2 was constitutively and stably expressed in peripheral blood Eos. Eos treated with the EBI2 ligands showed significantly increased trans-well migration that was enhanced by priming with physiologic doses of IL-5. Migration was suppressed by inhibitors of the prolyl isomerase Pin1 or ERK1/2 or by Pertussis toxin. EBI2 signaling activated Pin1 isomerase activity through a cascade that was sensitive to ERK inhibitors and Pertussis toxin. The concentration of EBI2 ligands was significantly increased in the BAL fluid 48 h post-segmental allergen challenge and strongly correlated with the increased numbers of Eos, lymphocytes and neutrophils in the airways. Conclusions Oxysterols are increased in inflamed airways after allergen challenge and through Galpha(i), ERK and Pin1 signaling, likely participates in the regulation of Eos migration into the lung in human asthmatics</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201608-1580OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28125291">PM:28125291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-1576-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-1576-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Shen ZJ</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201608-1580OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mochizuki,H.</style></author><author><style face="normal" font="Arial"> Kusuda,S.</style></author><author><style face="normal" font="Arial"> Okada,K.</style></author><author><style face="normal" font="Arial"> Yoshihara,S.</style></author><author><style face="normal" font="Arial"> Furuya,H.</style></author><author><style face="normal" font="Arial"> Simoes,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tokai University School of Medicine, pediatrics, Isehara, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing: 6 Year Follow Up Study</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="38" start="29">29-38</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Recurrent wheezing</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="Arial">RATIONALE: RSV (respiratory syncytial virus) induces not only infantile recurrent wheezing but also potentially atopic asthma. OBJECTIVES: To test the effect of RSV infection, on development of subsequent atopic asthma, we evaluated whether palivizumab, an anti-RSV monoclonal antibody, by preventing severe RSV disease in the first year of life, could impact subsequent recurrent wheezing and atopic asthma, at 6 years of age. METHODS: During the 2007-2008 RSV season, the decision to administer palivizumab was made based on standard medical practice, and an observational prospective multicenter (n=52) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed from 0 to 3 years (preceeding CREW study). The 52 investigators at hospitals now followed these subjects till 6 years of age, reported here. Parents of study subjects reported the infants' physician's assessment of recurrent wheezing, using a report card and a novel mobile phone-based reporting system using the Internet. The primary endpoint was the incidence of atopic asthma. RESULTS: Of 444 preterm infants enrolled, 349 received palivizumab during the first year of life. At 6 years, atopic asthma was not different in the groups, 15.3% and 18.2% of infants in the treated and untreated groups, respectively (p=0.57). On the other hand, physician-diagnosed recurrent wheezing was observed in 15.3% and 31.6% in the treated and untreated groups, respectively (p=0.003). CONCLUSION: Palivizumab prophylaxis administered to preterm infants did not suppress the onset of atopic asthma, but resulted in a significantly lower incidence of recurrent wheezing during the first 6 years. Clinical trial registration available at www.clinicaltrials.gov, ID NCT01545245</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201609-1812OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28152315">PM:28152315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-29-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-29-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Mochizuki H</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201609-1812OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhariwal,J.</style></author><author><style face="normal" font="Arial"> Cameron,A.</style></author><author><style face="normal" font="Arial"> Trujillo-Torralbo,M.B.</style></author><author><style face="normal" font="Arial"> Del Rosario,A.</style></author><author><style face="normal" font="Arial"> Bakhsoliani,E.</style></author><author><style face="normal" font="Arial"> Paulsen,M.</style></author><author><style face="normal" font="Arial"> Jackson,D.J.</style></author><author><style face="normal" font="Arial"> Edwards,M.R.</style></author><author><style face="normal" font="Arial"> Rana,B.M.</style></author><author><style face="normal" font="Arial"> Cousins,D.J.</style></author><author><style face="normal" font="Arial"> Hansel,T.T.</style></author><author><style face="normal" font="Arial"> Johnston,S.L.</style></author><author><style face="normal" font="Arial"> Walton,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Imperial College London, Airway Disease Infection Section, National Heart and Lung Institute , London, United Kingdom of Great Britain and Northern Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Mucosal Type 2 Innate Lymphoid Cells are a Key Component of the Allergic Response to Aeroallergen</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="1596" start="1586">1586-1596</pages><volume><style face="normal" font="Arial">195</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> Great Britain</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Newly characterised type 2 innate lymphoid cells display potent type 2 effector functionality, however their contribution to allergic airways inflammation and asthma is poorly understood. Mucosal biopsy used to characterise the airway mucosa is invasive, poorly tolerated and does not allow sequential sampling. OBJECTIVES: To assess the role of type 2 innate lymphoid cells during nasal allergen challenge in subjects with allergic rhinitis, using novel non-invasive methodology. METHODS: We used a human experimental allergen challenge model, with flow cytometric analysis of nasal curettage samples, to assess the recruitment of type 2 innate lymphoid cells and granulocytes to the upper airways of atopic and healthy subjects following allergen provocation. Soluble mediators in the nasal lining fluid were measured using nasosorption. MEASUREMENTS AND MAIN RESULTS: Following allergen challenge, atopic subjects displayed rapid induction of upper airway symptoms, an enrichment of type 2 innate lymphoid cells, eosinophils and neutrophils, along with increased production of interleukin-5, prostaglandin D2, and eosinophil and T-helper type 2 cell chemokines compared to healthy subjects. The most pronounced type 2 innate lymphoid cell recruitment was observed in patients with elevated serum IgE and airway eosinophilia. CONCLUSIONS: The rapid recruitment of type 2 innate lymphoid cells to the upper airways of allergic rhinitis patients, and their association with key type 2 mediators, highlights their likely important role in the early allergic response to aeroallergen in the airways. The novel methodology described herein enables the analysis of rare cell populations from non-invasive, serial tissue sampling</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201609-1846OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28085492">PM:28085492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-1586-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-1586-96.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Dhariwal J</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201609-1846OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krajewska-Wojtys,A.</style></author><author><style face="normal" font="Arial"> Jarzab,J.</style></author><author><style face="normal" font="Arial"> Gawlik,R.</style></author><author><style face="normal" font="Arial"> Bozek,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Local allergic rhinitis to pollens is underdiagnosed in young patients</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="201" start="198">198-201</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="11" Year="2016">2016/11/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Local allergic rhinitis (LAR) has been observed in patients without atopy. However, LAR is still underdiagnosed in patients with perennial or seasonal nasal symptoms. OBJECTIVE: The aim of this study was to determine the prevalence of LAR in young patients with a previous diagnosis of nonallergic rhinitis or suspicion of allergy. METHODS: A total of 121 patients, ages 12-18 years old, with confirmed nonallergic rhinitis and typical seasonal nasal symptoms were examined. Skin-prick tests; serum and nasal specific immunoglobulin E (IgE) measurements; and nasal provocation tests by using grass (Phleum partense), Artemisia, and birch pollens were performed. A control group of age-matched patients with a diagnosis of seasonal allergic rhinitis underwent the same procedures as the test group. RESULTS: LAR to grass pollen (P. partense), Artemisia, and birch was confirmed in 17 (16.6%), 6 (5.9%), and 9 (8.9%) of patients, respectively. Polyvalent allergy was established in 21 subjects (20.8%): grass and Artemisia, 11 patients (10.9%); and grass and birch, 10 patients (9.9%). The remaining 48 patients (47.5%) were diagnosed with nonallergic rhinitis. The results of the nasal provocation tests and the concentrations of nasal IgE were similar among the analyzed groups. Furthermore, the concentration of nasal IgE increased faster in patients with LAR than in patients with allergic rhinitis; however, this difference was not statistically significant. CONCLUSION: LAR is a serious problem in young patients; however, its significance is still unappreciated</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4369</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28124640">PM:28124640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-198-201.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-198-201.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Krajewska-Wojtys A</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4369</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aricigil,M.</style></author><author><style face="normal" font="Arial"> Muluk,N.B.</style></author><author><style face="normal" font="Arial"> Sakarya,E.U.</style></author><author><style face="normal" font="Arial"> Sakalar,E.G.</style></author><author><style face="normal" font="Arial"> Senturk,M.</style></author><author><style face="normal" font="Arial"> Reisacher,W.R.</style></author><author><style face="normal" font="Arial"> Cingi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Meram Medical Faculty, Necmettin Erbakan University, Konya Turkey</style></auth-address><titles><title><style face="normal" font="Arial">New routes of allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="197" start="193">193-197</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> ILIT</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> intralymphatic immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Langerhans Cells</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> LNIT</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modified allergens</style></keyword><keyword><style face="normal" font="Arial"> Mouth</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Nasal immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="11" Year="2016">2016/11/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Allergen immunotherapy is the only cure for immunoglobulin E mediated type I respiratory allergies. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most common treatments. In this article, we reviewed new routes of allergen immunotherapy. METHODS: Data on alternative routes to allow intralymphatic immunotherapy (ILIT), epicutaneous immunotherapy (EPIT), local nasal immunotherapy (LNIT), oral immunotherapy (OIT), and oral mucosal immunotherapy (OMIT) were gathered from the literature and were discussed. RESULTS: ILIT features direct injection of allergens into lymph nodes. ILIT may be clinically effective after only a few injections and induces allergen-specific immunoglobulin G, similarly to SCIT. A limitation of ILIT is that intralymphatic injections are required. EPIT features allergen administration by using patches mounted on the skin. EPIT seeks to target epidermal antigen-presenting Langerhans cells rather than mast cells or the vasculature; this should reduce both local and systemic adverse effects. LNIT involves the spraying of allergen extracts into the nasal cavity. Natural or chemically modified allergens (the latter, termed allergoids, lack immunoglobulin E reactivity) are prepared in a soluble form. OIT involves the regular administration of small amounts of a food allergen by mouth and commences with low oral doses, which are then increased as tolerance develops. OMIT seeks to deliver allergenic proteins to an expanded population of Langerhans cells in the mucosa of the oral cavity. CONCLUSIONS: ILIT, EPIT, LNIT, OIT, and OMIT are new routes for allergen immunotherapy. They are safe and effective</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4379</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28124639">PM:28124639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-193-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2016-30-193-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Aricigil M</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4379</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,J.</style></author><author><style face="normal" font="Arial"> Chen,F.H.</style></author><author><style face="normal" font="Arial"> Qiu,S.Q.</style></author><author><style face="normal" font="Arial"> Yang,L.T.</style></author><author><style face="normal" font="Arial"> Zhang,H.P.</style></author><author><style face="normal" font="Arial"> Liu,J.Q.</style></author><author><style face="normal" font="Arial"> Geng,X.R.</style></author><author><style face="normal" font="Arial"> Yang,G.</style></author><author><style face="normal" font="Arial"> Liu,Z.Q.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Li,H.B.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shenzhen Maternity &amp; Child Health HospitalShenzhen 518052, China; The Center of Allergy &amp; Immunology, School of Medicine, Shenzhen UniversityShenzhen 518060, ChinaThe Center of Allergy &amp; Immunology, School of Medicine, Shenzhen UniversityShenzhen 518060, China</style></auth-address><titles><title><style face="normal" font="Arial">Probiotics enhance the effect of allergy immunotherapy on regulating antigen specific B cell activity in asthma patients</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="5270" start="5256">5256-5270</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cells</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Immune regulatory system dysfunction plays a role in the pathogenesis of asthma. The therapeutic effect of allergic asthma is to be improved. The immune regulatory function of probiotics has been recognized. This study tests a hypothesis that Clostridium butyricum (CB) enhances the effect of allergen specific immunotherapy (AIT) on asthma. In this study patients with allergic asthma were treated with AIT or/and CB for six months. The therapeutic effect and IgE production of the patients were observed. The results showed that administration with AIT alone alleviated the asthma symptoms; but the serum levels of interleukin (IL)-4, IL-5, IL-13 and specific IgE were not altered, which was markedly improved by the administration with CB plus AIT. Such effects were maintained only for two months in the patients treated with AIT alone; but maintained more than 12 months in those patients treated with both AIT and CB. CB facilitated AIT to induce IL-10+ B cells (B10 cells) in asthma patients. AIT/CB therapy converted antigen specific B cells to antigen specific regulatory B cells. Butyrate modulated the gene transcription of IgE and IL-10 in the allergen specific B cells. In conclusion, administration of CB can enhance the therapeutic effect of AIT in the treatment of allergic asthma via facilitating generation of B10 cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170112LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078000">PM:28078000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5256-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5256-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Liu J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,H.</style></author><author><style face="normal" font="Arial"> Hu,W.</style></author><author><style face="normal" font="Arial"> Liang,Z.</style></author><author><style face="normal" font="Arial"> Zeng,L.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Yan,H.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Otolaryngology Institutes, Allergy and Immunology Research Center, Shenzhen UniversityShenzhen 518060, China</style></auth-address><titles><title><style face="normal" font="Arial">Thiol peroxiredoxin, a novel allergen from Bombyx mori, modulates functions of macrophages and dendritic cells</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="5329" start="5320">5320-5329</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2-DE</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B.mori</style></keyword><keyword><style face="normal" font="Arial"> Bombyx</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD40</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pupa</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Two dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional gel electrophoresis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Bombyx mori (B.mori, also known as silkworm) plays a role in the pathogenesis of allergic diseases. However, its allergens are to be characterized. The aim of this paper is to identify new silkworm allergens. Two-dimensional gel electrophoresis (2-DE) and mass spectrometry were employed to separate and identify potential allergens from silkworm pupa. Six potential allergens were identified in this study. Thiol peroxiredoxin (TP), one of the 6 allergens, reacted to serum IgE from patients sensitized to silkworm. By sensitizing with TP allergic asthma like symptoms were induced in mice, including elevation of the levels of serum IgE, IL-4 from bronchoalveolar lavage fluid and culture supernatant of spleen cells. In vitro experiments showed that TP significantly induced RAW264.7 cells (a macrophage cell line) apoptosis via modulating the BCL2 and Caspase9 pathways. The levels of CD80, CD40, CD83 and TNF-alpha in DC2.4 cells (a dendritic cell line) were increased in the culture after exposure to TP. In summary, TP is an allergic component of silkworm. It induces allergic asthma, and modulates the functions of macrophages and dendritic cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170112LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078005">PM:28078005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5320-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5320-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Wang H</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,L.T.</style></author><author><style face="normal" font="Arial"> Li,X.X.</style></author><author><style face="normal" font="Arial"> Qiu,S.Q.</style></author><author><style face="normal" font="Arial"> Zeng,L.</style></author><author><style face="normal" font="Arial"> Li,L.J.</style></author><author><style face="normal" font="Arial"> Feng,B.S.</style></author><author><style face="normal" font="Arial"> Zheng,P.Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Research Center of Allergy &amp; Immunology, Shenzhen University School of MedicineShenzhen 518060, China</style></auth-address><titles><title><style face="normal" font="Arial">Micro RNA-19a suppresses thrombospondin-1 in CD35+ B cells in the intestine of mice with food allergy</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="5511" start="5503">5503-5511</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Disruption of immune tolerance is associated in the pathogenesis of allergy. Thrombospondin-1 (TSP1) plays a role in the maintenance of immune tolerance, which is compromised in allergic disorders. Micro RNA (miR) is involved in the regulation of immune responses. This study tests a hypothesis that miR-17-92 cluster is involved in the regulation of TSP1 in the intestinal CD35+ B cells. In this study, a food allergy mouse model was developed. The intestinal B cells were isolated to be analyzed for the expression of a miR-17-92 cluster and TSP1. The role of miR-19a in the suppression of TSP1 in B cells was tested in a cell culture model. We observed that the levels of TSP1 were significantly decreased; the levels of miR-19a were significantly increased in intestinal CD35+ B cells of mice sensitized to ovalbumin (OVA) as compared with naive controls. Exposure to interleukin (IL)-4 suppressed the expression of TSP1 in B cells, which was abolished by inhibition of miR-19a. miR-19a mediated the effects of IL-4 on repressing TSP1 expression in B cells. We conclude that IL-4 suppresses the expression of TSP1 in the intestinal CD35+ B cells via up regulating miR-19a. The miR-19a may be a target to regulate the immune tolerant status in the body</style></abstract><notes><style face="normal" font="Arial">DA - 20170112LA - engPT - Journal ArticleCO - China -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078021">PM:28078021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5503-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5503-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Yang LT</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,N.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Liang,H.</style></author><author><style face="normal" font="Arial"> Jiang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of E. N. T., The First Hospital Affiliated of China Medical University 155 Nanjing Bei Street, Shenyang 110001, China</style></auth-address><titles><title><style face="normal" font="Arial">Bone marrow-derived mesenchymal stem cells reduce immune reaction in a mouse model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="5636" start="5628">5628-5636</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">OBJECT: To determine the potential of bone marrow-derived mesenchymal stem cells (BMSCs) for immunomodulatory mechanism in mice model of allergic rhinitis (AR). METHODS: BMSCs were isolated and the surface markers and stemness were analyzed. The effect of BMSCs was evaluated in BALB/c mice that were randomly divided into three groups (control group, ovalbumin (OVA) group, OVA+BMSCs group). BMSCs were administered intravenously to OVA sensitized mice on days 1, 7, 14 and 21, and subsequent OVA challenge was conducted daily from days 22 to 35. Several parameters of allergic inflammation were assessed. RESULTS: Mesenchymal stem cells can be successfully isolated from bone marrow of mice. Intravenous injection of BMSCs significantly reduced allergic symptoms, eosinophil infiltration, OVA-specific immunoglobulin E (IgE), T-helper 2 (Th2) cytokine profile (interleukin (IL)-4, IL-5 and IL-13) and regulatory cytokines (IL-10). In addition, level of Th1 (IFN-gamma) was significantly increased. CONCLUSION: Administration of BMSCs effectively reduced allergic symptoms and inflammatory parameters in the mice model of AR. BMSCs treatment is potentially an alternative therapeutic modality in AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170112LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078033">PM:28078033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5628-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5628-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Zhao N</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ye,Z.S.</style></author><author><style face="normal" font="Arial"> Fan,L.N.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Yang,B.</style></author><author><style face="normal" font="Arial"> Wang,L.F.</style></author><author><style face="normal" font="Arial"> Liu,Y.S.</style></author><author><style face="normal" font="Arial"> Ji,S.N.</style></author><author><style face="normal" font="Arial"> Xu,H.Z.</style></author><author><style face="normal" font="Arial"> Xiao,C.X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Zhongshan Hospital 201 Hubin South Road, Xiamen 361004, Fujian Province, China</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin E induces colon cancer cell apoptosis via enhancing cyp27b1 expression</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="5722" start="5715">5715-5722</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Calcitriol</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> CCA</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> CYP27B1</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The pathogenesis of colon cancer (Cca) is to be further investigated. Vitamin D deficiency is associated with cancer growth; the underlying mechanism is unclear. Published data indicate that Cca cells express CD23. This study tests a hypothesis that exposure to IgE induces Cca cell apoptosis. In this study, the effect of ligation of CD23 by IgE on the expression of cyp27b1 was performed with Cca cells. The induction of apoptosis of Cca cells by IgE was assessed in a cell culture model. We observed that Cca cells express CD23; ligation of CD23 with IgE on Cca cells increased the expression of cyp27b1 in Cca, which promoted the conversion of VD3 to calcitriol, the latter increased the expression of FasL by Cca cells, and induced apoptosis of Cca cells. In conclusion, IgE is capable of inducing the cancer cell apoptosis via ligating CD23 and converting VD3 to calcitriol. The results suggest that IgE may have therapeutic potential in the treatment of Cca</style></abstract><notes><style face="normal" font="Arial">DA - 20170112LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078042">PM:28078042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5715-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2016-8-5715-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Ye ZS</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Badran,A.A.</style></author><author><style face="normal" font="Arial"> Morais,S.</style></author><author><style face="normal" font="Arial"> Maquieira,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">IDM, Departamento de Quimica., Universitat Politecnica de Valencia, Camino de Vera s/n, 46022, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Simultaneous determination of four food allergens using compact disc immunoassaying technology</style></title><secondary-title><style face="normal" font="Arial">Anal Bioanal Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Bioanal Chem</style></full-title></periodical><pages end="2268" start="2261">2261-2268</pages><volume><style face="normal" font="Arial">409</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Beer</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Juice</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">A multiplex competitive microimmunoassay for the simultaneous determination of gliadin, casein, beta-lactoglobulin, and ovalbumin is presented. The assay in microarray format is performed on a DVD where the allergens are physisorbed on the polycarbonate surface of the disc. The immunointeraction is detected using a mixture of specific gold-labeled antibodies and the signal amplified with the silver enhancement method. The optical density of the precipitate, read by a DVD drive, is related to the concentration of the four allergens in sample. An optimized protocol for the simultaneous extraction of the allergen proteins from food samples is also addressed. The suitability of the method is demonstrated for the simultaneous quantitative extraction and determination of the targeted allergens in spiked baby foods, juices, and beers. The sensitivity (EC50) of the multiplexed assay was 0.04, 0.40, 0.08, and 0.16 mg L-1 for gliadin, casein, beta-lactoglobulin, and ovalbumin, respectively, and the recovery results from the analysis of food samples ranged from 72 to 117%. A portable, easy-to-use, array-based bioanalytical method is developed for quantification of food allergens with a limit of detection below the accepted levels of the international legislations, which allows promotion of food safety and quality. Graphical abstract GLI Gliadin, CAS Casein, beta-LAC beta-lactoglobulin, OVA Ovalbumin</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1618-2650 (Electronic)IS - 1618-2642 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00216-016-0170-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078412">PM:28078412</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Bioanal Chem\20170112-BadranAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Bioanal Chem\20170112-BadranAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Badran AA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00216-016-0170-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82977</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doll,R.</style></author><author><style face="normal" font="Arial"> Johnson,J.</style></author><author><style face="normal" font="Arial"> Peppers,B.P.</style></author><author><style face="normal" font="Arial"> Tcheurekdjian,H.</style></author><author><style face="normal" font="Arial"> Hostoffer,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Verde Valley Medical Center, Cottonwood, Arizona.</style></auth-address><titles><title><style face="normal" font="Arial">IgE-mediated anaphylactic shock caused by pumpkin seed in an adult</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="378" start="377">377-378</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28126432">PM:28126432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170127-DollR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170127-DollR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Doll R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blumenthal,K.G.</style></author><author><style face="normal" font="Arial"> Acker,W.W.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Holtzman,N.S.</style></author><author><style face="normal" font="Arial"> Zhou,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="Arial">Allergy entry and deletion in the electronic health record</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="381" start="380">380-381</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28126435">PM:28126435</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170127-BlumenthalKG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170127-BlumenthalKG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Blumenthal KG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Romberg,K.</style></author><author><style face="normal" font="Arial"> Tufvesson,E.</style></author><author><style face="normal" font="Arial"> Bjermer,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Medicine and Allergology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Health Care Centre, Nasets Lakargrupp, Hollviken, Sweden. Electronic address: kro@nlg.nuRespiratory Medicine and Allergology, Department of Clinical Sciences Lund, Lund University, Lund, SwedenRespiratory Medicine and Allergology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Sex differences in asthma in swimmers and tennis players</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="317" start="311">311-317</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> athlete</style></keyword><keyword><style face="normal" font="Arial"> Athletes</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> elite swimmers</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Behavior</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mannitol</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> sport</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> swimmers</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Elite athletes, independent of sport, have increased risk of developing asthma, but little is known about sex difference among adolescent athletes. OBJECTIVE: To investigate and compare sex-related differences according to symptoms and treatment of asthma, allergy, and health among elite athletes and a reference group. METHODS: Adolescent elite swimmers (n = 101), tennis players (n = 86), and a reference group (n = 1,628) responded to a questionnaire about respiratory symptoms, allergy, health behavior, psychosomatic symptoms, self- esteem, and well-being. The athletes performed a mannitol provocation and a sport-specific exercise provocation. Atopy was assessed by skin prick tests, and fractional exhaled nitric oxide was measured. RESULTS: The females reported more asthma symptoms than the males in both the reference group (29.1% vs 22.3%) and the athlete group (56.4% vs 40.2%). However, no significant differences were found in physician-diagnosed asthma or treatment with inhaled corticosteroids. More female athletes had a positive mannitol provocation result (48.7% vs 35.8% in male athletes), and more female swimmers had a positive exercise provocation result (15.1% vs 7.7% in male swimmers). The females in all groups had more psychosomatic symptoms compared with the respective males, and the males in the reference group reported higher self-esteem and felt more well-being compared with the reference group females. CONCLUSION: Overall, we found a higher prevalence of asthma symptoms in the females. However, the frequency of physician-diagnosed asthma and the prescription of inhaled corticosteroids were the same in both sexes. This finding demonstrates an insufficient diagnosis of asthma in females</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28126431">PM:28126431</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170127-RombergK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170127-RombergK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Romberg K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nazir,S.</style></author><author><style face="normal" font="Arial"> Tachamo,N.</style></author><author><style face="normal" font="Arial"> Fareedy,S.B.</style></author><author><style face="normal" font="Arial"> Khan,M.S.</style></author><author><style face="normal" font="Arial"> Lohani,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Reading Health System, West Reading, Pennsylvania.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="374" start="372">372-374</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28094120">PM:28094120</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170117-NazirS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170117-NazirS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Nazir S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perry,T.T.</style></author><author><style face="normal" font="Arial"> Marshall,A.</style></author><author><style face="normal" font="Arial"> Berlinski,A.</style></author><author><style face="normal" font="Arial"> Rettiganti,M.</style></author><author><style face="normal" font="Arial"> Brown,R.H.</style></author><author><style face="normal" font="Arial"> Randle,S.M.</style></author><author><style face="normal" font="Arial"> Luo,C.</style></author><author><style face="normal" font="Arial"> Bian,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas; Arkansas Children's Hospital Research Institute, Little Rock, Arkansas.</style></auth-address><titles><title><style face="normal" font="Arial">Smartphone-based vs paper-based asthma action plans for adolescents</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="303" start="298">298-303</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> African American</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Arkansas</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma action plan</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peak flow</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Adolescents with asthma are at risk of poor outcomes and are traditionally difficult to reach. OBJECTIVE: To examine adolescents' use of and asthma outcomes associated with smartphone- vs paper-based asthma action plans (AAPs). METHODS: We conducted a 6-month randomized clinical trial with adolescents (12-17 years old) with persistent asthma. Participants used their respective smartphone or paper AAPs for medication instructions and peak flow or asthma symptoms logging. AAP use was measured electronically for smartphone users and via mail-in diaries for the paper group. Changes in Asthma Control Test (ACT) and self-efficacy scores were examined. RESULTS: Thirty-four adolescents participated in this study (median age, 15.4 years). Participants were mostly African American (62%) with state-issued insurance (71%). Adolescents in the smartphone group accessed the AAP a median of 12.17 times per week or 4.36 days per week but only recorded medications or symptoms and peak flow data in the electronic diary a median of 10 days per month during the 6-month period. Participants in the paper group recorded data a median of 23.5 days per month on their paper diaries. Overall, there were no changes in ACT and self-efficacy scores between groups. Adolescents with uncontrolled asthma (baseline ACT score &lt;/=19) had an improvement in ACT for the smartphone group (before, 11; after, 20) ([P = .04) compared with no change in the paper group (before, 17; after, 17) (P = .64). Adolescent satisfaction with the application was high, with 100% stating they would recommend the smartphone AAP to a friend. CONCLUSION: Adolescents were frequent and highly satisfied users of the smartphone AAP with a subset of participants with uncontrolled asthma demonstrating possible clinical benefit. Findings suggest a need for larger-scale studies to determine the effectiveness of smartphone-based AAPs among high-risk patients with asthma. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02091869</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28111110">PM:28111110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170123-PerryTT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170123-PerryTT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170123, Perry TT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wunschel,J.</style></author><author><style face="normal" font="Arial"> Poole,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary, Critical Care, Sleep &amp; Allergy Division, Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska</style></auth-address><titles><title><style face="normal" font="Arial">Intrauterine uterine contraception and chronic urticaria: a case series</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="380" start="378">378-380</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Contraception</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> intrauterine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nebraska</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28111112">PM:28111112</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170123-WunschelJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170123-WunschelJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170123, Wunschel J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Herbert,L.J.</style></author><author><style face="normal" font="Arial"> Mehta,P.</style></author><author><style face="normal" font="Arial"> Sharma,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Children's National Health System, Washington, DC; The George Washington University, School of Medicine and Health Sciences, Washington, DC.</style></auth-address><titles><title><style face="normal" font="Arial">Mealtime behavior among parents and their young children with food allergy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="350" start="345">345-350</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parenting</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> type 1 diabetes</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergies are increasingly prevalent in the pediatric population. Balancing allergen avoidance with the promotion of healthy eating behaviors can be challenging for families. OBJECTIVE: To characterize mealtime behaviors among parents of young children with food allergy. METHODS: Seventy-four parents of young children with food allergies (&lt;/=7 years of age) completed measures of mealtime behavior, perceptions of food allergy risk and severity, pediatric parenting stress, and food allergy-related quality of life. Mealtime behavior reports were compared with published data regarding typically developing children, young children with type 1 diabetes, and children with diagnosed feeding disorders (with or without related medical factors). RESULTS: Parents of young children with food allergies reported frequent mealtime concerns. Specifically, they reported significantly more mealtime behavioral concerns than typically developing peers, comparable mealtime behavioral concerns to young children with type 1 diabetes, and significantly fewer mealtime behavioral concerns than children with diagnosed feeding disorders. Parental mealtime concerns were positively correlated with other parent perceptions of food allergy, such as risk of allergen exposure, illness-related parenting stress, and food allergy-related quality of life. CONCLUSION: Young children with food allergy and their parents are more likely to exhibit mealtime behavioral concerns than typically developing peers and their parents. Future research should investigate the effect of food allergies and maladaptive mealtime behaviors on children's nutrition to provide clinical guidelines for parents who may benefit from psychosocial and/or nutritional support</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28094121">PM:28094121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170117-HerbertLJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170117-HerbertLJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Herbert LJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hernandez,C.L.</style></author><author><style face="normal" font="Arial"> Waibel,K.H.</style></author><author><style face="normal" font="Arial"> Kosisky,S.E.</style></author><author><style face="normal" font="Arial"> Nelson,M.R.</style></author><author><style face="normal" font="Arial"> Banks,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy-Immunology Service, Walter Reed National Military Medical Center, Bethesda, Maryland.</style></auth-address><titles><title><style face="normal" font="Arial">15 years of allergen immunotherapy vial sterility testing</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="375" start="374">374-375</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Reed</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170122IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109834">PM:28109834</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170122-HernandezCL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170122-HernandezCL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170122, Hernandez CL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Johnston,J.D.</style></author><author><style face="normal" font="Arial"> Barney,T.</style></author><author><style face="normal" font="Arial"> Crandall,J.</style></author><author><style face="normal" font="Arial"> Brown,M.</style></author><author><style face="normal" font="Arial"> Westover,T.</style></author><author><style face="normal" font="Arial"> Paulson,S.</style></author><author><style face="normal" font="Arial"> Smith,M.</style></author><author><style face="normal" font="Arial"> Weber,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Health Science , Brigham Young University , Provo , Utah , United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of house dust mite allergens in low-income homes with evaporative coolers in a semi-arid climate</style></title><secondary-title><style face="normal" font="Arial">Arch Environ Occup Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Environ Occup Health</style></full-title></periodical><pages end="41" start="38">38-41</pages><volume><style face="normal" font="Arial">73</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Utah</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">House dust mites are typically absent in homes in arid and semi-arid climates due to low humidity. Evaporative "swamp" cooling significantly increases indoor humidity in dry climates, and is suspected of promoting dust mite survival in these regions. We investigated the prevalence and concentration of mite allergens in dust from low-income homes (n = 22) with evaporative coolers in Utah County, Utah. Overall, 15 (68.2%) homes were positive for either Der p 1 or Der f 1 in at least one location. Geometric mean allergen levels in mattresses were 0.107 and 0.087 ug/g dust for Der p 1 and Der f 1, respectively. In furniture, levels were 0.143 and 0.165 ug/g dust for Der p1 and Der f 1, respectively. The percentage of positive homes in this study was much higher than previously reported in larger homes with swamp coolers in the same community. These results suggest socio-economic factors may play a role in dust mite allergen prevalence in homes with evaporative coolers in dry climates</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1933-8244 (Print)IS - 1933-8244 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/19338244.2017.1282846</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098501">PM:28098501</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Environ Occup Health\2018-73-38-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Environ Occup Health\2018-73-38-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Johnson JD</style></custom2><misc3><style face="normal" font="Arial">10.1080/19338244.2017.1282846</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.H.</style></author><author><style face="normal" font="Arial"> Wang,Y.C.</style></author><author><style face="normal" font="Arial"> Wu,P.H.</style></author><author><style face="normal" font="Arial"> Hsu,L.</style></author><author><style face="normal" font="Arial"> Wang,C.Y.</style></author><author><style face="normal" font="Arial"> Jan,C.R.</style></author><author><style face="normal" font="Arial"> Su,H.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A cross-sectional study into the correlation of common household risk factors and allergic rhinitis in Taiwan's tropical environment</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Trop Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asian Pac J Trop Med</style></full-title></periodical><pages end="140" start="134">134-140</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal culture</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Indoor air quality</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1995-7645</style></isbn><abstract><style face="normal" font="Arial">Objective To discuss the effect of lesser-known potential risk factors, such as bedroom showers, on the prevalence of allergic rhinitis. Method A cross-sectional, population-based study was performed using both survey and fungal culturing in southern Taiwan. There were 998 participants enrolled in the survey, and 513 sets of fungal culture obtained. With score for allergic rhinitis (SFAR) more than 7, the patient was defined to have allergic rhinitis. Risks of allergic rhinitis were calculated as odds ratios for various predicted risk factors by logistic regression. Correlation between predicted risk factors and fungal level were examined with linear regression. Results The adjusted odds ratio of frequently using bedroom shower to having allergic rhinitis was 1.572 (95% confidence interval: 1.090</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2.265), and 0.962 for people with older age to have AR (95% confidence interval: 0.949</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.976). As to the 24-hour fungal level, the standardized coefficient was 0.254 for frequent use of bedroom shower, and 0.106 for window open hours. Conclusions Use of bedroom shower is a potential risk factor for allergic rhinitis development</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -CO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.apjtm.2017.01.012</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.apjtm.2017.01.012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Trop Med\20170207-WangYH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Trop Med\20170207-WangYH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Wang YH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.apjtm.2017.01.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,J.H.</style></author><author><style face="normal" font="Arial"> Long,L.</style></author><author><style face="normal" font="Arial"> Luo,Z.X.</style></author><author><style face="normal" font="Arial"> You,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physical Examination, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of PPARgamma agonist (rosiglitazone) on the secretion of Th2 cytokine in asthma mice</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Trop Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asian Pac J Trop Med</style></full-title></periodical><pages end="68" start="64">64-68</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To explore the effect of PPARgamma agonist (rosiglitazone) on the secretion of Th2 cytokines and the proportion of immune cell subsets in asthma mice. METHODS: Ovalbumin (OVA)-sensitized mice were used to build asthma models. Those mice were divided into the normal control group, model group and rosiglitazone group. Differences of the changes in lung histopathology of mice in the three groups were observed through hematoxylin and eosin (HE) strain, and the numbers of the total cells, eosinophils and neutrophils in BALF of mice in the three groups were compared. ELISA and real-time PCR were employed to detect the protein levels of interleukin (IL)-5, IL-13, IL-4 and IL-10 and mRNA level, respectively. Flow cytometry number was implied to analyze the proportion of immune cell subsets in peripheral blood of mice. RESULTS: Compared with the mice in the control group, and mice of the model group, the infiltration of inflammatory cells in BALF increased, bronchial smooth muscle became thickened, a large amount of collagen deposited, the secretion of Th2 cytokine increased significantly, the ratio of regulatory T cells (Treg) decreased, the ratio of T17 cells rose distinctly; while in mice of the rosiglitazone group, the changes of their lung histopathology were improved obviously, the number of infiltration of inflammatory cells declined, the thickened smooth muscle relieved, the deposition of collagen decreased, the secretion of Th2 cytokine was inhibited, the ratio of Treg went up, and the increased of the ratio of T17 cells was inhibited but still not return to normal level. CONCLUSIONS: Rosiglitazone can regulate the proportion of Treg and Th17 cells and inhibit the secretion of Th2 cytokines, which inhibit the airway inflammatory response for asthma mice effectively</style></abstract><notes><style face="normal" font="Arial">DA - 20170121IS - 2352-4146 (Electronic)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.apjtm.2016.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107868">PM:28107868</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Trop Med\2017-10-64-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Trop Med\2017-10-64-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170121, Yu JH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.apjtm.2016.10.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bicakci,A.</style></author><author><style face="normal" font="Arial"> Tosunoglu,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Adem Biçakçi, Aycan Tosunoglu</style></auth-address><titles><title><style face="normal" font="Arial">The Influence of Environmental and Atmospheric Variables on Allergenic Pollen</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="116" start="107">107-116</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Atmospheric pollen</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> global warming</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Rain</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Atmospheric pollen grains belong to mostly wind pollinated plants, which may cause respiratory allergies, and their concentrations in the air is largely influenced by climatic parameters. In general, the days with sun, high temperature and moderate wind, and without rain are the periods that have shown maximum pollen release. In the studies of the last century it has been shown that global warming and increasing CO2 concentrations in the world affected the starting and ending dates of pollination periods for some plants and their pollen concentrations in the atmosphere. The other important effect of atmospheric changes on pollen grains is seen in long-range transport. Additionally, the North Atlantic Oscillation (NAO) has an influence on long-range transport, especially affecting the plants in the early spring and leading to early or late onset of pollination.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/61</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-107-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2016-14-107-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Bicakci A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,Y.D.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Yin,L.M.</style></author><author><style face="normal" font="Arial"> Park,G.H.</style></author><author><style face="normal" font="Arial"> Ulloa,L.</style></author><author><style face="normal" font="Arial"> Yang,Y.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shanghai Research Institute of Acupuncture and Meridian, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">S100A8 protein attenuates airway hyperresponsiveness by suppressing the contraction of airway smooth muscle</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="188" start="184">184-188</pages><volume><style face="normal" font="Arial">484</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> Acupuncture</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscles</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> Myosin light chain</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> S100</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">Airway hyperresponsiveness (AHR) is a major clinical problem in allergic asthma mainly caused by the hypercontractility of airway smooth muscles (ASM). S100A8 is an important member of the S100 calcium-binding protein family with a potential to regulate cell contractility. Here, we analyze the potential of S100A8 to regulate allergen-induced AHR and ASM contraction. Treatment with recombinant S100A8 (rS100A8) diminished airway hyperresponsiveness in OVA-sensitized rats. ASM contraction assays showed that rS100A8 reduced hypercontractility in both isolated tracheal rings and primary ASM cells treated by acetylcholine. rS100A8 markedly rescued the phosphorylation level of myosin light chain induced by acetylcholine in ASM cells. These results show that rS100A8 plays a protective role in regulating AHR in asthma by inhibiting ASM contraction. These results support S100A8 as a novel therapeutic target to control ASM contraction in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170115IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2017.01.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28088518">PM:28088518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170115-XuYD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170115-XuYD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170115, Xu YD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2017.01.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qi,L.</style></author><author><style face="normal" font="Arial"> Zhou,L.</style></author><author><style face="normal" font="Arial"> Lu,M.</style></author><author><style face="normal" font="Arial"> Yuan,K.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Wu,G.</style></author><author><style face="normal" font="Arial"> Huang,X.</style></author><author><style face="normal" font="Arial"> Shen,Y.</style></author><author><style face="normal" font="Arial"> Zhao,M.</style></author><author><style face="normal" font="Arial"> Fu,W.</style></author><author><style face="normal" font="Arial"> Chu,B.</style></author><author><style face="normal" font="Arial"> Wang,G.</style></author><author><style face="normal" font="Arial"> Ren,F.</style></author><author><style face="normal" font="Arial"> Ma,D.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">OriGene Technologies, 9620 Medical Center Dr., Suite 200, Rockville, MD, 20850, USA</style></auth-address><titles><title><style face="normal" font="Arial">Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="254" start="248">248-254</pages><volume><style face="normal" font="Arial">484</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast cancer</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> EGFR</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Gastric Mucosa</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein chip</style></keyword><keyword><style face="normal" font="Arial"> Protein microarray</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">HER2 is an orphan receptor tyrosine kinase of the EGFR families and is considered to be a key tumor driver gene [1]. Breast cancer and gastric cancer with HER2 amplification can be effectively treated by its neutralizing antibody, Herceptin. In clinic, Immunohistochemistry (IHC) was used as the primary screening method to diagnose HER2 amplification [2]. However, recent evidence suggested that the frequently used rabbit HER2 antibody 4B5 cross reacted with another family member HER4 [3]. IHC staining with 4B5 also indicated that there was strong non-specific cytoplasmic and nuclear signals in normal gastric mucosal cells and some gastric cancer samples. Using a protein lysate array which covers 85% of the human proteome, we have confirmed that the 4B5 bound to HER4 and a nuclear protein ZSCAN18 besides HER2. The non-specific binding accounts for the unexpected cytoplasmic and nuclear staining of 4B5 of normal gastric epithelium. Finally, we have developed a novel mouse HER2 monoclonal antibody UMAB36 with similar sensitivity to 4B5 but only reacted to HER2 across the 17,000 proteins on the protein chip. In 129 breast cancer and 158 gastric cancer samples, UMAB36 showed 100% sensitivity and specificity comparing to the HER2 FISH reference results with no unspecific staining in the gastric mucosa layer. Therefore, UMAB36 could provide as an alternative highly specific IHC reagent for testing HER2 amplification in gastric cancer populations</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2017.01.086</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28111342">PM:28111342</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170123-QiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170123-QiL.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170123-QiL.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170123-QiL.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170123, Qi L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2017.01.086</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,W.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Tang,H.</style></author><author><style face="normal" font="Arial"> Sun,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, 266011, China</style></auth-address><titles><title><style face="normal" font="Arial">Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="402" start="396">396-402</pages><volume><style face="normal" font="Arial">484</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Leptin</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Satiety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> simvastatin</style></keyword><keyword><style face="normal" font="Arial"> statin</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">Obesity can cause or worsen asthma. Compared with common asthma, obese asthma is difficult to control. Statins are effective serum cholesterol-lowering agents in clinical practice, and they also have anti-inflammatory properties, which in theory are potentially beneficial in asthma. Many studies have shown that simvastatin has good therapeutic effect in animal models of asthma. However, the therapeutic effect and action mechanism of simvastatin for obese asthma remain unclear. Leptin, a satiety hormone, is in positive correlation with total body fat mass and may also play a significant role in the pathogenesis of asthma. In this study, we use the method of high-fat diet and ovalbumin (OVA) sensitization and challenge to establish the mouse model of obesity and asthma, and find that obese asthmatic mice has higher levels of glucose, lipid and leptin in serum, and neutrophil percentage in bronchoalveolar lavage fluid (BALF), and more severe airway inflammation and structural changes in lung tissues than non-obese asthmatic mice, and respond poorly to dexamethasone treatment, which indicates that obese asthma might belong to steroid-resistant (SR) asthma. Simvastatin treatment reduces the levels of glucose, lipid, leptin and neutrophil percentage, and improves airway inflammation and remodeling, which can be as a potential therapeutic target used in the treatment of obese asthma in humans. Correlation analysis shows that there is positive correlation between neutrophil percentage and serum leptin/cholesterol level, which indicates that the therapeutic efficacy of simvastatin on obese asthma might be associated with improving dyslipidemia and decreasing leptin level</style></abstract><notes><style face="normal" font="Arial">DA - 20170129IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2017.01.135</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28131832">PM:28131832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170129-HanW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170129-HanW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170129, Han W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2017.01.135</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fei,X.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Zhang,G.Q.</style></author><author><style face="normal" font="Arial"> Bao,W.P.</style></author><author><style face="normal" font="Arial"> Zhang,Y.Y.</style></author><author><style face="normal" font="Arial"> Zhang,M.</style></author><author><style face="normal" font="Arial"> Zhou,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, No. 100, Haining Road, Shanghai, 200080, China</style></auth-address><titles><title><style face="normal" font="Arial">Cordycepin inhibits airway remodeling in a rat model of chronic asthma</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="341" start="335">335-341</pages><volume><style face="normal" font="Arial">88</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="1" Year="2017">2017/1/21</year></dates><abstract><style face="normal" font="Arial">The potential suppression role of cordycepin (Cor) on airway remodeling in a rat model of chronic asthma was investigated in this paper. We evaluated the anti-remodeling of Cor (50mg/kg) combined with or without budesonide (BUD) and investigated the possible underlying molecular mechanisms. We found that Cor attenuated immunoglobulin (Ig) E, alleviated the airway wall thickness, and decreased eosinophils and neutrophils in the bronchoalveolar lavage fluid (BALF). Notably, Cor reduced the up-regulation of IL-5, IL-13 and TNF-alpha in the BALF. Cor also regulated the increase of A2AARmRNA and the decrease of TGF-beta1 expression. Furthermore, Cor markedly blocked p38MAPK signaling pathway activation in the OVA-driven asthmatic mice. The combination treatment of Cor and BUD showed profound efficacy in regulating the levels of inflammatory cells and the expression of IL-13, TGF-beta1 and A2AARmRNA. Collectively, this study demonstrated that Cor combined with glucocorticoids treatment shows synergistically profound efficacy in inhibiting airway remodeling, and some benefits of Cor may result from the increased A2AARmRNA expression, the reduced TGF-beta1 levels and the inhibition of Th2-cytokines through the suppression of the p38MAPK signaling pathways</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.01.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28119235">PM:28119235</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-88-335-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-88-335-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Fei X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.01.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.</style></author><author><style face="normal" font="Arial"> Lu,Y.</style></author><author><style face="normal" font="Arial"> Luo,M.</style></author><author><style face="normal" font="Arial"> Shi,X.</style></author><author><style face="normal" font="Arial"> Pan,Y.</style></author><author><style face="normal" font="Arial"> Zeng,H.</style></author><author><style face="normal" font="Arial"> Deng,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Changzhou Key Laboratory of Respiratory Medical Engineering, Institute of Biomedical Engineering and Health Sciences, Changzhou University, Changzhou, Jiangsu 213164, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of pharmacological relaxation effect of the natural product naringin on in vitro cultured airway smooth muscle cells and in vivo ovalbumin-induced asthma Balb/c mice</style></title><secondary-title><style face="normal" font="Arial">Biomed Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biomed Rep</style></abbr-1></periodical><pages end="722" start="715">715-722</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Engineering</style></keyword><keyword><style face="normal" font="Arial"> Bitter taste</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> calcium flux</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chloroquine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Developing Countries</style></keyword><keyword><style face="normal" font="Arial"> developing country</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Muscle Contraction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Relaxation</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Saccharin</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Asthma has become a common chronic respiratory disease worldwide and its prevalence is predicted to continue increasing in the next decade, particularly in developing countries. A key component in asthma therapy is to alleviate the excessive bronchial airway narrowing ultimately due to airway smooth muscle contraction, which is often facilitated by a smooth muscle relaxant, such as the beta2-adrenergic agonists. Recently, bitter taste receptor (TAS2R) agonists, including saccharin and chloroquine, have been found to potently relax the airway smooth muscle cells (ASMCs) via intracellular Ca2+ signaling. This inspires a great interest in screening the vast resource of natural bitter substances for potential bronchodilatory drugs. In the present study, the relaxation effect of naringin, a compound extracted from common grapefruit, on ASMCs cultured in vitro or bronchial airways of Balb/c mice in vivo was evaluated. The results demonstrated that, when exposed to increasing doses of naringin (0.125, 0.25, 0.5 and 1.0 mM), the traction force generated by the cultured ASMCs decreased progressively, while the intracellular calcium flux signaling in the ASMCs increased. When inhaled at increasing doses (15, 30 and 60 microg), naringin also dose-dependently reduced the bronchial airway resistance of the normal and ovalbumin-induced asthma Balb/c mice in response to challenge with methacholine. In conclusion, these findings indicate that naringin was able to effectively relax murine ASMCs in vitro and in vivo, thus suggesting that it is a promising drug agent to be further investigated in the development of novel bronchodilators for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2049-9434 (Print)IS - 2049-9434 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/br.2016.797</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101344">PM:28101344</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Rep\2016-5-715-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Rep\2016-5-715-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Wang Y</style></custom2><misc3><style face="normal" font="Arial">10.3892/br.2016.797</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al-Herz,W.</style></author><author><style face="normal" font="Arial"> Husain,K.</style></author><author><style face="normal" font="Arial"> Al-Khabaz,A.</style></author><author><style face="normal" font="Arial"> Moussa,M.A.</style></author><author><style face="normal" font="Arial"> Al-Refaee,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Faculty of Medicine, Kuwait University, P.O. Box: 24923, Safat, 13110, Kuwait city, Kuwait.</style></auth-address><titles><title><style face="normal" font="Arial">Awareness of food allergies: a survey of pediatricians in Kuwait</style></title><secondary-title><style face="normal" font="Arial">BMC Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMC Pediatr</style></abbr-1></periodical><pages end="" start="11">11-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Self-administered questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Early diagnosis of food allergies (FA) is important for a favorable prognosis. This study aimed to determine the level of awareness of FA among pediatricians in Kuwait. METHOD: A 43-item self-administered questionnaire was designed and distributed to pediatricians working at 4 government hospitals in Kuwait. RESULTS: A total of 140 pediatricians completed the questionnaire, with a participation rate of 51.1% (81 males and 59 females). The mean age of participants was 40.81 years, and the mean number of years working in pediatrics was 13.94 years. The mean overall knowledge score was 22.2. The pediatricians' overall knowledge scores were found to be significantly associated with their age (older pediatricians had higher overall scores) and years of experience as a pediatrician but were independent from hospital site, gender, or rank. A multiple linear regression revealed pediatrician age and gender were the only variables that were significantly associated with the overall knowledge score. Only 16.4% of the participants answered at least 2/3 of the survey questions correctly. The questions that were correctly answered by &lt;/= 2/3 of the participants constituted 80% of clinical presentation questions, 66.6% of diagnostics questions, 77.7% of treatment questions, and 42.8% of prevention questions. Interestingly, among 68 pediatricians (48.5%) who determined that they felt comfortable evaluating and treating patients with FA, only 12 (17.6%) passed the questionnaire. CONCLUSIONS: This survey demonstrates that there is a noteworthy deficiency of pediatricians' awareness about FA. The implementation of strategies to improve pediatricians' awareness is critical to diagnose food allergy patients early and improve their health and outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1471-2431 (Electronic)IS - 1471-2431 (Linking)LA - engPT - Journal ArticleCO - Kuwait -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12887-016-0773-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28077121">PM:28077121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pediatr\2017-17-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pediatr\2017-17-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Al-Herz W</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12887-016-0773-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tian,L.</style></author><author><style face="normal" font="Arial"> Peel,G.J.</style></author><author><style face="normal" font="Arial"> Lei,Z.</style></author><author><style face="normal" font="Arial"> Aziz,N.</style></author><author><style face="normal" font="Arial"> Dai,X.</style></author><author><style face="normal" font="Arial"> He,J.</style></author><author><style face="normal" font="Arial"> Watson,B.</style></author><author><style face="normal" font="Arial"> Zhao,P.X.</style></author><author><style face="normal" font="Arial"> Sumner,L.W.</style></author><author><style face="normal" font="Arial"> Dixon,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Plant Biology Division, Samuel Roberts Noble Foundation, Ardmore, OK 73401, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Transcript and proteomic analysis of developing white lupin (Lupinus albus L.) roots</style></title><secondary-title><style face="normal" font="Arial">BMC Plant Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Plant Biol</style></full-title></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">1--A BioChem3DBioFun</style></keyword><keyword><style face="normal" font="Arial"> 1--A NativeorNatModify</style></keyword><keyword><style face="normal" font="Arial"> 1--AAA Molecules</style></keyword><keyword><style face="normal" font="Arial"> 1--Allergeni Nativi</style></keyword><keyword><style face="normal" font="Arial"> Abiotic stress</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotic and abiotic stresses</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> cDNA library</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases,Genetic</style></keyword><keyword><style face="normal" font="Arial"> Databases,Protein</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> EST</style></keyword><keyword><style face="normal" font="Arial"> Expressed Sequence Tags</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression Regulation,Plant</style></keyword><keyword><style face="normal" font="Arial"> Gene Library</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> growth &amp; development</style></keyword><keyword><style face="normal" font="Arial"> Isoflavones</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Lup a 4</style></keyword><keyword><style face="normal" font="Arial"> Lupin</style></keyword><keyword><style face="normal" font="Arial"> Lupinus</style></keyword><keyword><style face="normal" font="Arial"> Lupinus albus</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Membrane Proteins</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Metals</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microsatellite Repeats</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide mass fingerprinting</style></keyword><keyword><style face="normal" font="Arial"> Peptide mass spectra</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant protein</style></keyword><keyword><style face="normal" font="Arial"> Plant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Plant Roots</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Rna,Plant</style></keyword><keyword><style face="normal" font="Arial"> Roots</style></keyword><keyword><style face="normal" font="Arial"> Seedling</style></keyword><keyword><style face="normal" font="Arial"> Seedlings</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="5" Month="1" Year="2009">2009/1/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: White lupin (Lupinus albus L.) roots efficiently take up and accumulate (heavy) metals, adapt to phosphate deficiency by forming cluster roots, and secrete antimicrobial prenylated isoflavones during development. Genomic and proteomic approaches were applied to identify candidate genes and proteins involved in antimicrobial defense and (heavy) metal uptake and translocation. RESULTS: A cDNA library was constructed from roots of white lupin seedlings. Eight thousand clones were randomly sequenced and assembled into 2,455 unigenes, which were annotated based on homologous matches in the NCBInr protein database. A reference map of developing white lupin root proteins was established through 2-D gel electrophoresis and peptide mass fingerprinting. High quality peptide mass spectra were obtained for 170 proteins. Microsomal membrane proteins were separated by 1-D gel electrophoresis and identified by LC-MS/MS. A total of 74 proteins were putatively identified by the peptide mass fingerprinting and the LC-MS/MS methods. Genomic and proteomic analyses identified candidate genes and proteins encoding metal binding and/or transport proteins, transcription factors, ABC transporters and phenylpropanoid biosynthetic enzymes. CONCLUSION: The combined EST and protein datasets will facilitate the understanding of white lupin's response to biotic and abiotic stresses and its utility for phytoremediation. The root ESTs provided 82 perfect simple sequence repeat (SSR) markers with potential utility in breeding white lupin for enhanced agronomic traits</style></abstract><notes><style face="normal" font="Arial">DA - 20090127IS - 1471-2229 (Electronic)IS - 1471-2229 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Research Support, U.S. Gov't, Non-P.H.SRN - 0 (Plant Proteins)RN - 0 (Proteome)RN - 0 (RNA, Plant)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/1471-2229-9-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="19123941">PM:19123941</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Plant Biol\2009-9-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Plant Biol\2009-9-1.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Plant Biol\2009-9-1-MOESM1_ESM.xlsC:\A&amp;H HMW Papers\BMC Plant Biol\2009-9-1-MOESM5_ESM.xls</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Plant Biol\2009-9-1-MOESM1_ESM.xlsF:\A&amp;H HMW Papers\BMC Plant Biol\2009-9-1-MOESM5_ESM.xls</url></image-urls></urls><custom1><style face="normal" font="Arial">2A</style></custom1><custom2><style face="normal" font="Arial">20090127, Tian L</style></custom2><misc3><style face="normal" font="Arial">10.1186/1471-2229-9-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maina,E.</style></author><author><style face="normal" font="Arial"> Pelst,M.</style></author><author><style face="normal" font="Arial"> Hesta,M.</style></author><author><style face="normal" font="Arial"> Cox,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunology, Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study</style></title><secondary-title><style face="normal" font="Arial">BMC Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Vet Res</style></full-title></periodical><pages end="" start="25">25-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urinalysis</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergies are increasing in prevalence but no treatment strategies are currently available to cure dogs with food allergy. Over the past decade, experimental food allergen-specific sublingual immunotherapy (FA-SLIT) has emerged as a potential treatment for food allergies in human medicine. However, FA-SLIT has not been investigated in dogs. Therefore, the objective of this study was to prospectively evaluate the safety, tolerability and dispenser sterility of FA-SLIT in healthy dogs before testing it in food allergic dogs. Eight experimental healthy beagle dogs, never orally exposed to peanut, were randomized in two groups to receive SLIT with peanut or placebo for 4 months. Subjects were monitored daily for local and systemic adverse effects. Blood samples for complete blood count and serum biochemistry, and urine for urinalysis were collected and the dogs' body weight was recorded at day 0, 35 and 119 of the SLIT treatment. Sera for the determination of peanut-specific IgG and IgE were collected at day 0, 35, 49, 70, 91, 105 and 119. Intradermal tests were performed before (day 0) and after (day 119) the experiment. The content of each dispenser used to administer treatment or placebo was tested for sterility after usage. In order to assess the presence or absence of sensitization, dogs were challenged 6 months after the end of the study with 2000 mug of peanut extract daily for 7 to 14 days. RESULTS: All dogs completed the study. The treatment did not provoke either local or systemic side-effects. Peanut-specific IgG significantly increased in treatment group. Even though a significant increase in peanut-specific IgE was also seen, intradermal tests were negative in all dogs before and after the experiment, and the challenge test did not trigger any adverse reactions in the treated dogs, which shows the protocol did not cause sensitization to peanut, but nevertheless primed the immune system as indicated by the humoral immune response. All dispenser solutions were sterile. CONCLUSIONS: Our results demonstrate that the used peanut-SLIT protocol is well tolerated and safe in healthy dogs. Further studies should evaluate tolerability, safety and efficacy in dogs with food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1746-6148 (Electronic)IS - 1746-6148 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12917-017-0947-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100257">PM:28100257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Vet Res\2017-13-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Vet Res\2017-13-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Maina E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12917-017-0947-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shalom,G.</style></author><author><style face="normal" font="Arial"> Magen,E.</style></author><author><style face="normal" font="Arial"> Dreiher,J.</style></author><author><style face="normal" font="Arial"> Freud,T.</style></author><author><style face="normal" font="Arial"> Bogen,B.</style></author><author><style face="normal" font="Arial"> Comaneshter,D.</style></author><author><style face="normal" font="Arial"> Vardy,D.A.</style></author><author><style face="normal" font="Arial"> Khoury,R.</style></author><author><style face="normal" font="Arial"> Agmon-Levin,N.</style></author><author><style face="normal" font="Arial"> Cohen,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, Soroka Medical Center, Beer-Sheva, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Urticaria and Atopic Disorders: a Cross-sectional Study of 11,271 Patients</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="Arial">Chronic urticaria (CU) and atopic disorders such as atopic dermatitis (AD), allergic rhinoconjunctivitis (AR), and asthma are related to aberrant immune function. The relationship between atopic disorders and CU is controversial, mostly since epidemiological data are lacking. The aim of our study was to investigate the association between CU and asthma, AD, and AR using a database of Clalit Health Services (CHS) - the largest healthcare provider organization in Israel. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15347</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28129676">PM:28129676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170127-ShalomG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170127-ShalomG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Shalom G</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15347</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dong,J.</style></author><author><style face="normal" font="Arial"> Liao,W.</style></author><author><style face="normal" font="Arial"> Peh,H.Y.</style></author><author><style face="normal" font="Arial"> Chan,T.K.</style></author><author><style face="normal" font="Arial"> Tan,W.S.</style></author><author><style face="normal" font="Arial"> Li,L.</style></author><author><style face="normal" font="Arial"> Yong,A.</style></author><author><style face="normal" font="Arial"> Wong,W.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Ribosomal Protein S3 Gene Silencing Protects Against Experimental Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Br J Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Br J Pharmacol</style></full-title></periodical><pages end="552" start="540">540-552</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Silencing</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transcriptional Activation</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND PURPOSE: Ribosomal protein S3 (RPS3) is a 40S ribosomal protein of the S3P family essential for executing protein translation. RPS3 has recently been found to interact with the p65 subunit of the NF-kappaB complex, and promote p65 DNA-binding activity. Persistent activation of the NF-kappaB pathway is evident in allergic asthma. We hypothesized that gene silencing of lung RPS3 can ameliorate allergic airway inflammation. EXPERIMENTAL APPROACH: Gene silencing efficacy of RPS3 siRNA was screened in three different mouse cell lines by real-time PCR and immunoblotting. Protective effects of intratracheal RPS3 siRNA in a house dust mite (HDM) mouse asthma model determined by measuring cell counts in lung lavage fluid and lung sections, lung cytokine profiles and airway hyperresponsiveness (AHR). KEY RESULTS: RPS3 siRNA markedly knocked down RPS3 levels in all mouse cell lines tested, and in mouse lung tissues, blocked TNF-alpha- or HDM-induced mediators release by the cultured cells, and reduced eosinophil counts in lung lavage fluid from HDM mouse asthma model. RPS3 siRNA abated HDM-induced airway mucus hypersecretion, cytokine production, and serum IgE elevation. Moreover, RPS3 knockdown significantly suppressed methacholine-induced AHR in experimental asthma. RPS3 siRNA disrupted TNF-alpha-induced NF-kappaB activation in an NF-kappaB reporter gene assay in vitro, and mitigated nuclear accumulation of p65 subunit and p65 transcriptional activation in HDM-challenged lungs and cells. CONCLUSIONS AND IMPLICATIONS: We reported here that RPS3 gene silencing ameliorated experimental asthma probably via interruption of the NF-kappaB activity, postulating that RPS3 is a novel therapeutic target for allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1476-5381 (Electronic)IS - 0007-1188 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/bph.13717</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093718">PM:28093718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Pharmacol\20170117-DongJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Pharmacol\20170117-DongJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Dong J</style></custom2><misc3><style face="normal" font="Arial">10.1111/bph.13717</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>82999</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mepolizumab (Nucala) [Internet].</style></title><secondary-title><style face="normal" font="Arial">CADTH Common Drug Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">CADTH Common Drug Rev</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">The objective of this review is to evaluate the beneficial and harmful effects of mepolizumab 100 mg subcutaneous (SC) for the maintenance treatment of adult patients with severe eosinophilic asthma (SEA) whose symptoms are inadequately controlled with high-dose inhaled corticosteroid(s)(ICS) and one or more additional asthma controllers)</style></abstract><notes><style face="normal" font="Arial">DA - 20170126LA - engPT - ReviewPT - BookCO - Canada -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28121100">PM:28121100</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\CADTH Common Drug Rev\20170126-noauthors.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\CADTH Common Drug Rev\20170126-noauthors.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">201701126, no authors</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83000</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Minty,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Staff physician at the Sioux Lookout Meno Ya Win Health Centre and undertook this report while a resident in family medicine at the Northern Ontario School of Medicine in Sioux Lookout.</style></auth-address><titles><title><style face="normal" font="Arial">Food-dependent exercise-induced anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Can Fam Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Can Fam Physician</style></full-title></periodical><pages end="43" start="42">42-43</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food-dependent exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1715-5258 (Electronic)IS - 0008-350X (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28115440">PM:28115440</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Can Fam Physician\2017-63-42-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Can Fam Physician\2017-63-42-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Minty B</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moriya,T.</style></author><author><style face="normal" font="Arial"> Nagahata,N.</style></author><author><style face="normal" font="Arial"> Odaka,R.</style></author><author><style face="normal" font="Arial"> Nakamura,H.</style></author><author><style face="normal" font="Arial"> Yoshikawa,J.</style></author><author><style face="normal" font="Arial"> Kurashima,K.</style></author><author><style face="normal" font="Arial"> Saito,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Enzymes and Pharmaceuticals Laboratory, GODO SHUSEI Co., Ltd., 250 Nakahara, Kamihongo, Matsudo City, Chiba, 271-0064, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Synthesis of an allergy inducing tetrasaccharide "4P-X"</style></title><secondary-title><style face="normal" font="Arial">Carbohydr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Carbohydr Res</style></full-title></periodical><pages end="49" start="44">44-49</pages><volume><style face="normal" font="Arial">439</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> beta-Galactosidase</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="27" Month="11" Year="2016">2016/11/27</year></dates><abstract><style face="normal" font="Arial">4P-X (beta-D-galactopyranosyl-(1 --> 4)-beta-D-galactopyranosyl-(1 --> 6)-[beta-D-galactopyranosyl-(1 --> 4)]-beta-D-glucopyranose) is included in galacto-oligosaccharides (GOSs) produced by beta-galactosidase derived from Bacillus circulans. 4P-X has been known to induce particularly strong allergies. High purity 4P-X is essential for use as a standard to quantify the amount of 4P-X in GOSs; however, the isolation of high purity 4P-X has never been reported. In this study, we achieved the synthesis of 4P-X by a combination of organic and enzymatic chemical syntheses in a short time. This is the first report of isolated, high purity 4P-X</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1873-426X (Electronic)IS - 0008-6215 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.carres.2016.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107656">PM:28107656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Carbohydr Res\2016-439-44-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Carbohydr Res\2016-439-44-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Moriya T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.carres.2016.11.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asai,Y.</style></author><author><style face="normal" font="Arial"> Uhara,H.</style></author><author><style face="normal" font="Arial"> Miyazaki,A.</style></author><author><style face="normal" font="Arial"> Saiki,M.</style></author><author><style face="normal" font="Arial"> Okuyama,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Late Onset of Acute Urticaria after Bee Stings</style></title><secondary-title><style face="normal" font="Arial">Case Rep Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Rep Dermatol</style></full-title></periodical><pages end="343" start="341">341-343</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Here we report the cases of five patients with a late onset of acute urticaria after a bee sting. The ages of the five Japanese patients ranged from 33 to 86 years (median: 61). All patients had no history of an allergic reaction to bee stings. The onset of urticaria was 6-14 days (median: 10) after a bee sting. Although four of the patients did not describe experiencing a bee sting at their presentation, the subsequent examination detected anti-bee-specific IgE antibodies. So, we think a history of a bee sting should thus be part of the medical interview sheet for patients with acute urticaria, and an examination of IgE for bees may help prevent a severe bee-related anaphylactic reaction in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1662-6567 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000449033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101020">PM:28101020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Dermatol\2016-8-341-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Dermatol\2016-8-341-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Asai Y</style></custom2><misc3><style face="normal" font="Arial">10.1159/000449033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klubicova,K.</style></author><author><style face="normal" font="Arial"> Szabova,M.</style></author><author><style face="normal" font="Arial"> Skultety,L.</style></author><author><style face="normal" font="Arial"> Libiakova,G.</style></author><author><style face="normal" font="Arial"> Hricova,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Revealing the seed proteome of the health benefitting grain amaranth (Amaranthus cruentus L.)</style></title><secondary-title><style face="normal" font="Arial">Chem Papers</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chem Papers</style></full-title></periodical><pages end="1335" start="1322">1322-1335</pages><volume><style face="normal" font="Arial">70</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2-DE</style></keyword><keyword><style face="normal" font="Arial"> Amaranth</style></keyword><keyword><style face="normal" font="Arial"> Amaranthus</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> grain amaranth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Nutritive Value</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seed proteins</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Slovakia</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1336-9075</style></isbn><abstract><style face="normal" font="Arial">Amaranth, a staple food source in ancient Aztec, Maya and Inca cultures, has been recognised as a 21st century crop. This superfood, known as Inca wheat, attracts the worldwide attention of researchers and farmers for its superior agronomical and technological properties but especially because of its exceptional nutritive value. A combination of two-dimensional electrophoresis (2-DE) with MS facilitating the effective differentiation of 13 classes of Amaranthus cruentus L. </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£Ficha</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ mature seed proteins was used in the current study. The best resolution results in the 2-DE were obtained using immobilised pH gradients strips with a pH range of 5</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô8. Out of the 461 spots detected, 249 were successfully identified by LC-MS/MS analysis, making this the most inclusive protein profile of mature amaranth seed. Unknown proteins represented the most abundant class of proteins (59), the second most abundant category was related to energy (46) and then to seed storage proteins (43). These results expand the knowledge of the amaranth seed proteome and it is expected that the data presented here will contribute to further in-depth characterisation of Amaranthus seeds</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Slovakia -</style></notes><work-type><style face="normal" font="Arial">10.1515/chempap-2016-0065</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1515/chempap-2016-0065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chem Papers\2016-70-1322-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chem Papers\2016-70-1322-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160702, Klubicova K</style></custom2><misc3><style face="normal" font="Arial">10.1515/chempap-2016-0065</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jin,J.M.</style></author><author><style face="normal" font="Arial"> Sun,Y.C.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Liu,X.F.</style></author><author><style face="normal" font="Arial"> Liu,G.J.</style></author><author><style face="normal" font="Arial"> Han,J.Y.</style></author><author><style face="normal" font="Arial"> Zeng,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">Hyper-IgE syndrome in adulthood: a case report and literature review</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Jie He He Hu Xi Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Jie He He Hu Xi Za Zhi</style></full-title></periodical><pages end="57" start="52">52-57</pages><volume><style face="normal" font="Arial">40</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> antibiotic treatment</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Scoliosis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="Arial">Objective: To describe the clinical features of hyper-IgE syndrome (HIES), with emphasis on refractory pulmonary cystic lesions as the initial presentation in adulthood. Methods: A case of HIES presenting with pulmonary cystic lesions in an adult patient was retrospectively analyzed. We used "hyper-IgE syndrome" as the Chinese keywords, "hyper-IgE syndrome, China" as the English keywords to retrieve the literature from Wanfang database/CNKI database and Pubmed database until April 2016. The clinical data were pooled and analyzed. Results: A 19 year old female patient was admitted to our hospital because of recurrent cough and expectoration as the chief complaint. Physical examination revealed broad nasal bridge and scoliosis, and chest CT showed gradually enlarged and increased cystic lesions. Laboratory studies demonstrated significantly increased blood eosinophils and serum level of total IgE, together with a definite chemotactic dysfunction of neutrophils. A further detection of STAT3 mutation was negative. The diagnosis of HIES was made and antibiotic treatment resulted in disease remission. Literature review found 45 reports including 37 in Chinese and 11 in English. Eight cases of adult HIES were reported, and all the patients were male, aging 18 to 31 years. Prolonged disease course, recurrent infection and formation of cystic lesions in the lungs were important features of HIES. Early diagnosis and treatment with specific antibiotics were important for improving outcome of the patients. Conclusion: Refractory pulmonary cystic lesions can be the initial presentation in adult HIES. Understanding of the clinical characteristics of HIES will be helpful to avoid misdiagnosis and improve prognosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1001-0939 (Print)IS - 1001-0939 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1001-0939.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100363">PM:28100363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Zhonghua Jie He He Hu Xi Za Zhi\2017-40-52-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Zhonghua Jie He He Hu Xi Za Zhi\2017-40-52-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Jin JM</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1001-0939.2017.01.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Athanasopoulou,P.</style></author><author><style face="normal" font="Arial"> Deligianni,E.</style></author><author><style face="normal" font="Arial"> Dean,T.</style></author><author><style face="normal" font="Arial"> Dewey,A.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Health Sciences and Social Work, University of Portsmouth, Portsmouth, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Use of baked milk challenges and milk ladders in clinical practice: a worldwide survey of healthcare professionals</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="434" start="430">430-434</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="21" Month="1" Year="2017">2017/1/21</year></dates><abstract><style face="normal" font="Arial">In previous years, the cornerstone of the management of Cow's Milk Allergy (CMA) was solely based on the strict avoidance of all cow's milk (CM) and foods containing CM from the patient's diet [1]. More recently, the importance of baked milk (BM) introduction into the diet of children with CMA has become well-recognised as a part of CMA management. Current research suggests that 75% of children become tolerant to baked/heated forms of CM such as muffin and waffles before they become tolerant to pure/uncooked forms of CM [2]. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170121IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12890</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109173">PM:28109173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170121-AthanasopoulouP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170121-AthanasopoulouP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170121, Athanasopoulou P</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12890</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mathias,C.B.</style></author><author><style face="normal" font="Arial"> Schramm,C.M.</style></author><author><style face="normal" font="Arial"> Guernsey,L.A.</style></author><author><style face="normal" font="Arial"> Wu,C.A.</style></author><author><style face="normal" font="Arial"> Polukort,S.H.</style></author><author><style face="normal" font="Arial"> Rovatti,J.</style></author><author><style face="normal" font="Arial"> Ser-Dolansky,J.</style></author><author><style face="normal" font="Arial"> Secor,E.</style></author><author><style face="normal" font="Arial"> Schneider,S.S.</style></author><author><style face="normal" font="Arial"> Thrall,R.S.</style></author><author><style face="normal" font="Arial"> Aguila,H.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmaceutical and Administrative Sciences, College of Pharmacy, Western New England University, Springfield, MA 01119</style></auth-address><titles><title><style face="normal" font="Arial">IL-15-deficient mice develop enhanced allergic responses to airway allergen exposure</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="655" start="639">639-655</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-15</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-15</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> New England</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Interleukin-15 is a pleiotropic cytokine that is critical for the development and survival of multiple hematopoietic lineages. Mice lacking IL-15 have selective defects in populations of several pro-allergic immune cells including natural killer (NK) cells, NKT cells, and memory CD8+ T cells. We therefore hypothesized that IL-15-/- mice will have reduced inflammatory responses during the development of allergic airway disease (AAD). OBJECTIVE: To determine whether IL-15-/- mice have attenuated allergic responses in a mouse model of AAD. METHODS: C57BL/6 wild-type (WT) and IL-15-/- mice were sensitized and challenged with ovalbumin (OVA) and the development of AAD was ascertained by examining changes in airway inflammatory responses, Th2 responses, and lung histopathology. RESULTS: Here we report that IL-15-/- mice developed enhanced allergic responses in an OVA-induced model of AAD. In the absence of IL-15, OVA-challenged mice exhibited enhanced bronchial eosinophilic inflammation, elevated IL-13 production, and severe lung histopathology in comparison with WT mice. In addition, increased numbers of CD4+ T and B cells in the spleens and broncholaveolar lavage (BAL) were also observed. Examination of OVA-challenged IL-15Ralpha-/- animals revealed a similar phenotype resulting in enhanced airway eosinophilia compared to WT mice. Adoptive transfer of splenic CD8+ T cells from OVA-sensitized WT mice suppressed the enhancement of eosinophilia in IL-15-/- animals to levels observed in WT mice, but had no further effects. CONCLUSION AND CLINICAL RELEVANCE: These data demonstrate that mice with an endogenous IL-15 deficiency are susceptible to the development of severe, enhanced Th2-mediated AAD, which can be regulated by CD8+ T cells. Furthermore, the development of disease as well as allergen-specific Th2 responses occurs despite deficiencies in several IL-15-dependent cell types including NK, NKT, and gammadelta T cells, suggesting that these cells or their subsets are dispensable for the induction of AAD in IL-15-deficient mice. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12886</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093832">PM:28093832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170117-MathiasCB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170117-MathiasCB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Mathias CB</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12886</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zanoni,G.</style></author><author><style face="normal" font="Arial"> Zanotti,R.</style></author><author><style face="normal" font="Arial"> Schena,D.</style></author><author><style face="normal" font="Arial"> Sabbadini,C.</style></author><author><style face="normal" font="Arial"> Opri,R.</style></author><author><style face="normal" font="Arial"> Bonadonna,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Unit Azienda Ospedaliera Universitaria Integrata, Verona, ItalyMultidisciplinary Outpatient Clinics for Mastocytosis, Azienda Ospedaliera Universitaria Integrata, Verona, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Vaccination Management In Children and Adults With Mastocytosis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="596" start="593">593-596</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="Arial">Mastocytosis includes a heterogeneous group of disorders characterized by the presence of clonal mast cells (MC) in cutaneous tissues and extracutaneous organs [1,2]. The disease presents in two primary age-related patterns, which may differ in their clinical manifestations and prognosis [1,2]. Pediatric-onset mastocytosis usually consists of cutaneous disease and tends to resolve itself by adolescence in most cases, in contrast to adult-onset mastocytosis which has a normal chronic course [2]. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12882</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28079293">PM:28079293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170112-ZanoniG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170112-ZanoniG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Zanoni G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12882</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barreto-Luis,A.</style></author><author><style face="normal" font="Arial"> Corrales,A.</style></author><author><style face="normal" font="Arial"> Acosta-Herrera,M.</style></author><author><style face="normal" font="Arial"> Gonzalez-Colino,C.</style></author><author><style face="normal" font="Arial"> Cumplido,J.</style></author><author><style face="normal" font="Arial"> Martinez-Tadeo,J.</style></author><author><style face="normal" font="Arial"> Carracedo,A.</style></author><author><style face="normal" font="Arial"> Villar,J.</style></author><author><style face="normal" font="Arial"> Carrillo,T.</style></author><author><style face="normal" font="Arial"> Pino-Yanes,M.</style></author><author><style face="normal" font="Arial"> Flores,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain</style></auth-address><titles><title><style face="normal" font="Arial">A pathway-based association study reveals variants from Wnt signaling genes contributing to asthma susceptibility</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="626" start="618">618-626</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma susceptibility</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association studies</style></keyword><keyword><style face="normal" font="Arial"> Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Linkage Disequilibrium</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Quantitative Trait Loci</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Smad</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Genetic susceptibility to asthma is currently linked to a handful of genes which have a limited ability to predict the overall disease risk, suggesting the existence of many other genes involved in disease development. Accumulated evidence from association studies in genes related by biological pathways could reveal novel asthma genes. OBJECTIVE: To reveal novel asthma susceptibility genes by means of a pathway-based association study. METHODS: Based on summary data from a previous a genome-wide association study (GWAS) of asthma, we first identified significant biological pathways using a gene-set enrichment analysis. We then mapped all tested single nucleotide polymorphisms (SNPs) on the genes contributing to significant pathways, and prioritized those with a disproportionate number of nominal significant associations for further studies. For those prioritized genes, association studies were performed for selected SNPs in independent case-control samples (n=1,765) using logistic regression models, and results were meta-analyzed with those from the GWAS. RESULTS: Two biological processes were significantly enriched: the cytokine-cytokine receptor interaction (p=0.002) and the Wnt signaling (p=0.012). From the 417 genes interacting in these two pathways, 10 showed an excess of nominal associations, including a known asthma susceptibility locus (encoding SMAD family member 3) and other novel candidate genes. From the latter, association studies of 14 selected SNPs evidenced replication in a locus near the frizzled class receptor 6 (FZD6) gene (p=9.90x10-4 ), which had a consistent direction of effects with the GWAS findings (meta-analyzed odds ratio=1.49; p=5.87x10-6 ), and was in high linkage disequilibrium with expression quantitative trait loci in lung tissues. CONCLUSIONS AND CLINICAL RELEVANCE: This study revealed the importance of two biological pathways in asthma pathogenesis and identified a novel susceptibility locus near Wnt signaling genes</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12883</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28079285">PM:28079285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170112-BarretoLuisA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170112-BarretoLuisA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Barreto-Luis A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12883</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stephen,J.N.</style></author><author><style face="normal" font="Arial"> Sharp,M.F.</style></author><author><style face="normal" font="Arial"> Ruethers,T.</style></author><author><style face="normal" font="Arial"> Taki,A.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author><author><style face="normal" font="Arial"> Lopata,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">James Cook University, Molecular and Cell Biology, Townsville, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Allergenicity of bony and cartilaginous fish - molecular and immunological properties</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="312" start="300">300-312</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Carp</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Fish species</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> molecular diversity</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Homology</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="Arial">Allergy to bony fish is common and probably increasing worldwide. The major heat stable pan-fish allergen, parvalbumin (PV), has been identified and characterized for numerous fish species. In contrast, there are very few reports of allergic reactions to cartilaginous fish despite widespread consumption. The molecular basis for this seemingly low clinical cross-reactivity between these two fish groups has not been elucidated. PV consists of two distinct protein lineages, alpha and beta. The alpha-lineage of this protein is predominant in muscle tissue of cartilaginous fish (Chondrichthyes), while beta-PV is abundant in muscle tissue of bony fish (Osteichthyes). The low incidence of allergic reactions to ingested rays and sharks is likely due to the lack of molecular similarity, resulting in reduced immunological cross-reactivity between the two PV lineages. Structurally and physiologically both protein lineages are very similar, however the amino acid homology is very low with 47% to 54%. Furthermore, PV from ancient fish species such as the coelacanth demonstrates 62% sequence homology to leopard shark alpha-PV and 70% to carp beta-PV. This indicates the extent of conservation of the PV isoforms lineages across millennia. This review highlights prevalence data on fish allergy and sensitization to fish, and details the molecular diversity of the two protein lineages of the major fish allergen PV among different fish groups, emphasizing the immunological and clinical differences in allergenicity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12892</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28117510">PM:28117510</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170124-StephenJN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170124-StephenJN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Stephen JN</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12892</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kondo,M.</style></author><author><style face="normal" font="Arial"> Tsuji,M.</style></author><author><style face="normal" font="Arial"> Hara,K.</style></author><author><style face="normal" font="Arial"> Arimura,K.</style></author><author><style face="normal" font="Arial"> Yagi,O.</style></author><author><style face="normal" font="Arial"> Tagaya,E.</style></author><author><style face="normal" font="Arial"> Takeyama,K.</style></author><author><style face="normal" font="Arial"> Tamaoki,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">First Department of Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, 162-8666, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Chloride ion transport and overexpression of TMEM16A in a guinea pig asthma model</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="804" start="795">795-804</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">air-liquid interface</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ion Transport</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucin</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ussing chamber</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="1" Year="2017">2017/1/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: TMEM16A, a Ca-activated Cl channel, regulates various physiological functions such as mucin secretion. However, the role of TMEM16A in hypersecretion in asthma is not fully understood. OBJECTIVE: The aim of this study is to evaluate Cl ion transport via TMEM16A and determine the localization of TMEM16A in a guinea pig asthma model. METHODS: Guinea pigs were sensitized with OVA ip. on Day 1 and Day 8. On Day 22, we assessed OVA challenge-induced Cl ion transport in the sensitized tracheas ex vivo in an Ussing chamber, compared with the non-sensitized tracheas. We then examined the effect of T16Ainh-A01, a TMEM16A inhibitor, on the increase in Cl ion transport. The tracheal epithelium was immunostained with an anti-TMEM16A antibody. Epithelial cells from guinea pig tracheas were cultured at the air-liquid interface in the presence of IL-13 for in vitro study. We studied the effect of TMEM16A inhibitors on Ca-dependent agonist, UTP-induced increases in Cl ion transport in the cultured cells. The cells were immunostained with an anti-TMEM16A antibody, an anti-MUC5AC antibody, and an anti-alpha-tubulin antibody. RESULTS: OVA challenge induced an increase in Isc within 1 min in the OVA-sensitized tracheas but not in the non-sensitized tracheas, which was inhibited by pretreatment of T16Ainh-A01. Sensitized tracheas showed goblet cell metaplasia with more positive TMEM16A immunostaining, particularly in the apical portion compared with the non-sensitized tracheas. The in vitro UTP-induced increase in Cl ion transport was strongly inhibited by pretreatment with T16Ainh-A01, benzbromarone, and niflumic acid. TMEM16A was positively immunostained at the apical portion and in the MUC5AC-positive area in IL-13-induced goblet cell metaplasia. CONCLUSIONS: Antigen challenge and Ca-dependent agonist treatment increased Cl ion transport via the overexpression of TMEM16A in goblet cell metaplasia in a guinea pig asthma model. TMEM16A inhibitors may be useful for the treatment of hypersecretion in asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170121IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12887</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109183">PM:28109183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170121-KondoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170121-KondoM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170121, Kondo M</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12887</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elkuch,M.</style></author><author><style face="normal" font="Arial"> Greiff,V.</style></author><author><style face="normal" font="Arial"> Berger,C.T.</style></author><author><style face="normal" font="Arial"> Bouchenaki,M.</style></author><author><style face="normal" font="Arial"> Daikeler,T.</style></author><author><style face="normal" font="Arial"> Bircher,A.</style></author><author><style face="normal" font="Arial"> Navarini,A.A.</style></author><author><style face="normal" font="Arial"> Heijnen,I.</style></author><author><style face="normal" font="Arial"> Recher,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunodeficiency Clinic, Medical Outpatient Unit and Immunodeficiency Laboratory, Department of Biomedicine, University Hospital Basel, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Low immunoglobulin E flags two distinct types of immune dysregulation</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Immunol</style></full-title></periodical><pages end="352" start="345">345-352</pages><volume><style face="normal" font="Arial">187</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> hierarchical clustering</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG2</style></keyword><keyword><style face="normal" font="Arial"> IgG3</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">During the last two decades, hyper-immunoglobulin (Ig)E syndromes have been characterized clinically and molecularly in patients with genetically determined primary immunodeficiencies. However, the detection of low IgE levels, defined here as below detection limit in the routine clinical immunology laboratory, has received little attention. We analysed the association of serum IgA, IgM and IgG levels (including IgG subclasses) with low, normal or high serum IgE levels in patients evaluated in a single-centre out-patient immunodeficiency and allergy clinic. The correlation of serum IgE levels with IgG subclasses depended on the clinical phenotype. In patients with immunodeficiencies, IgE correlated with IgG2 and IgG4 but not with IgG3. In contrast, in patients referred for signs of allergy, IgE correlated with IgG3 but not with IgG2. A low IgE result was associated with low IgG3 and IgG4 in allergy referrals, while immunodeficiency referrals with a low IgE result had significantly lower IgG1, IgG2 and IgG4 levels. Hierarchical clustering of non-IgE immunoglobulin profiles (IgM, IgA, IgG, IgG1-4) validated that non-IgE immunoglobulin levels predict the clinic referral, i.e. phenotype, of low-IgE patients. These results suggesto guide the clinical management of patients with low serum IgE levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1365-2249 (Electronic)IS - 0009-9104 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cei.12885</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078662">PM:28078662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Immunol\2017-187-345-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Immunol\2017-187-345-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Elkuch M</style></custom2><misc3><style face="normal" font="Arial">10.1111/cei.12885</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dewitz,C.</style></author><author><style face="normal" font="Arial"> McEachern,E.</style></author><author><style face="normal" font="Arial"> Shin,S.</style></author><author><style face="normal" font="Arial"> Akong,K.</style></author><author><style face="normal" font="Arial"> Nagle,D.G.</style></author><author><style face="normal" font="Arial"> Broide,D.H.</style></author><author><style face="normal" font="Arial"> Akuthota,P.</style></author><author><style face="normal" font="Arial"> Crotty Alexander,L.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary &amp; Critical Care Section, Department of Veterans Affairs San Diego Healthcare System (VASDHS), La Jolla, CA</style></auth-address><titles><title><style face="normal" font="Arial">Hypoxia Inducible Factor-1alpha Inhibition Modulates Airway Hyperresponsiveness and Nitric Oxide Levels in a BALB/c Mouse Model of Asthma</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="99" start="94">94-99</pages><volume><style face="normal" font="Arial">176</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway reactivity</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> hypoxia</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> systemic treatment</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">Hypoxia inducible factor (HIF)-1alpha is a master regulator of inflammation and is upregulated in alveolar macrophages and lung parenchyma in asthma. HIF-1alpha regulates select pathways in allergic inflammation, and thus may drive particular asthma phenotypes. This work examines the role of pharmacologic HIF-1alpha inhibition in allergic inflammatory airway disease (AIAD) pathogenesis in BALB/c mice, which develop an airway hyperresponsiveness (AHR) asthma phenotype. Systemic treatment with HIF-1alpha antagonist YC-1 suppressed the increase in HIF-1alpha expression seen in control AIAD mice. Treatment with YC-1 also decreased AHR, blood eosinophilia, and allergic inflammatory gene expression: IL-5, IL-13, myeloperoxidase and iNOS. AIAD mice had elevated BAL levels of NO, and treatment with YC-1 eliminated this response. However, YC-1 did not decrease BAL, lung or bone marrow eosinophilia. We conclude that HIF-1alpha inhibition in different genetic backgrounds, and thus different AIAD phenotypes, decreases airway resistance and markers of inflammation in a background specific manner. CAPSULE SUMMARY: Asthma is a common disease that can be difficult to control with current therapeutics. We describe how pharmacologic targeting of a specific transcription factor, HIF-1alpha, suppresses asthmatic airway reactivity and inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2017.01.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093362">PM:28093362</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20170117-DewitzC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\20170117-DewitzC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Dewitz C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2017.01.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chivato,T.</style></author><author><style face="normal" font="Arial"> Alvarez-Calderon,P.</style></author><author><style face="normal" font="Arial"> Panizo,C.</style></author><author><style face="normal" font="Arial"> Abengozar,R.</style></author><author><style face="normal" font="Arial"> Alias,C.</style></author><author><style face="normal" font="Arial"> Al-Baech,A.</style></author><author><style face="normal" font="Arial"> Arias-Irigoyen,J.</style></author><author><style face="normal" font="Arial"> Caballero,M.J.</style></author><author><style face="normal" font="Arial"> Conill,L.</style></author><author><style face="normal" font="Arial"> de Miguel,S.</style></author><author><style face="normal" font="Arial"> Laguna,R.</style></author><author><style face="normal" font="Arial"> Martinez-Benazet,J.</style></author><author><style face="normal" font="Arial"> Matoses,F.</style></author><author><style face="normal" font="Arial"> Martinez-Alonso,J.C.</style></author><author><style face="normal" font="Arial"> Mendizabal,L.</style></author><author><style face="normal" font="Arial"> Perez-Carral,C.</style></author><author><style face="normal" font="Arial"> Puerto,C.</style></author><author><style face="normal" font="Arial"> Serra-Batlles,J.</style></author><author><style face="normal" font="Arial"> Velez,A.</style></author><author><style face="normal" font="Arial"> Vicente,J.</style></author><author><style face="normal" font="Arial"> De la Torre,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Decanato. Facultad de Medicina, Facultad de Medicina Universidad CEU San Pablo. Grupo Hospitales HM, Avda. Monteprincipe s/n, Boadilla del Monte, 28668 Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="Arial">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass allergen tablet</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patient Compliance</style></keyword><keyword><style face="normal" font="Arial"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sublingual immunotherapy has been proven as a well-tolerated and effective treatment for allergic rhinitis. Within this type of treatment, GRAZAX(R) is the most documented product in terms of safety and efficacy. The objective of this study was to identify the patients' expectations and level of treatment satisfaction, as well as the clinical management of patients with moderate/severe allergic rhinoconjunctivitis treated with GRAZAX(R). METHODS: This was a non-interventional, observational, multi-centre, open-label study involving a total of 131 adult patients aged 18-66 years with confirmed diagnosis of grass-allergy and initiated treatment with GRAZAX(R) between June 2010 and April 2011. RESULTS: In the pollen season after starting treatment, 56.6% of patients stated that their symptoms were much less/less intense, 86% needed less symptomatic medication for control of their symptoms, and 74.4% manifested to have improved (quite/a lot) as regards their allergic disease since treatment was initiated as compared with previous grass pollen season. The patient satisfaction with GRAZAX(R) was measured using a visual analogue scale (VAS) between 0 (minimum satisfaction) and 100 (maximum satisfaction) comprising five different items: effectiveness, tolerability, cost, convenience and overall satisfaction. The results obtained for each item were [mean (SD)]: 74.7 (18.1), 70.3 (36.1), 39.3 (25.8), 86.2 (12.6), 78.4 (15.8) respectively. The patient's level of satisfaction is highly influenced, especially in terms of assessment of effectiveness, tolerability and convenience, by the information provided by the specialist. CONCLUSIONS: In summary, it can be concluded that improved communication leads to increased patient knowledge, greater patient compliance, and increased patient satisfaction</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Andorra -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-016-0057-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28096738">PM:28096738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Chivato T</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-016-0057-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feyzkhanova,G.</style></author><author><style face="normal" font="Arial"> Voloshin,S.</style></author><author><style face="normal" font="Arial"> Smoldovskaya,O.</style></author><author><style face="normal" font="Arial"> Arefieva,A.</style></author><author><style face="normal" font="Arial"> Filippova,M.</style></author><author><style face="normal" font="Arial"> Barsky,V.</style></author><author><style face="normal" font="Arial"> Pavlushkina,L.</style></author><author><style face="normal" font="Arial"> Butvilovskaya,V.</style></author><author><style face="normal" font="Arial"> Tikhonov,A.</style></author><author><style face="normal" font="Arial"> Reznikov,Y.</style></author><author><style face="normal" font="Arial"> Rubina,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Engelhardt Institute of Molecular Biology, Russian Academy of Sciences (EIMB RAS), Vavilova str., 32, Moscow, Russia 119991</style></auth-address><titles><title><style face="normal" font="Arial">Development of a microarray-based method for allergen-specific IgE and IgG4 detection</style></title><secondary-title><style face="normal" font="Arial">Clin Proteomics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Proteomics</style></abbr-1></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Calibration</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> Dyes</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Fluorescent Dyes</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Quantitative detection</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgG4</style></keyword><keyword><style face="normal" font="Arial"> Simultaneous detection</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: sIgE and sIgG4 detection is necessary for more accurate and effective type I hypersensitivity diagnostics and the estimation of disease development. Typically, the analyses of these antibodies are performed separately with the help of various specialized systems. The aim of this study was to develop a microarray-based method for the simultaneous quantitative detection of sIgE and sIgG4 to the most common allergens in a single sample. METHODS: A quantitative method for the simultaneous detection of sIgE and sIgG4 was developed based on the technology of hydrogel microchips previously designed at Engelhardt Institute of Molecular Biology, Russian Academy of Sciences (EIMB RAS). The microarray contained gel pads with immobilized allergens and gel pads that allow for the obtaining of sIgE and sIgG4 internal calibration curves for each allergen during the assay. The possibility of the simultaneous detection of sIgE and sIgG4 was developed using the corresponding Cy5 and Cy3 fluorescent dyes. RESULTS: The multiplex immunoassay method using hydrogel microarrays developed in this study allowed the quantitative detection of sIgE and sIgG4 to 31 allergens from different groups in a single assay. A comparison of the microarray with the existing plate-based analogues (i.e., ALLERG-O-LIQ and sIgG4 ELISA) was performed by analysing 152 blood serum samples and by evaluating Pearson correlation coefficients, ROC analysis, and Passing-Bablok linear regression results. CONCLUSION: The implementation of this method in allergy diagnostics will provide the possibility of simultaneously performing primary patient screening and obtaining additional information concerning the severity of the allergies and the choice of an appropriate therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1542-6416 (Print)IS - 1542-6416 (Linking)LA - engPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12014-016-9136-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28077935">PM:28077935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Proteomics\2017-14-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Proteomics\2017-14-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Feyzkhanova G</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12014-016-9136-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deroux,A.</style></author><author><style face="normal" font="Arial"> Dumestre-Perard,C.</style></author><author><style face="normal" font="Arial"> Dunand-Faure,C.</style></author><author><style face="normal" font="Arial"> Bouillet,L.</style></author><author><style face="normal" font="Arial"> Hoffmann,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Internal Medicine Department, Grenoble University Hospital, 38000, Grenoble, France.</style></auth-address><titles><title><style face="normal" font="Arial">Female Infertility and Serum Auto-antibodies: a Systematic Review</style></title><secondary-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiphospholipid Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Auto-immunity</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical criteria</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fertility</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunomodulators</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Thyroglobulin</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid function</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="14" Month="9" Year="2016">2016/9/14</year></dates><abstract><style face="normal" font="Arial">On average, 10 % of infertile couples have unexplained infertility. Auto-immune disease (systemic lupus erythematosus, anti-phospholipid syndrome) accounts for a part of these cases. In the last 20 years, aspecific auto-immunity, defined as positivity of auto-antibodies in blood sample without clinical or biological criteria for defined diseases, has been evoked in a subpopulation of infertile women. A systematic review was performed (PUBMED) using the MESH search terms "infertility" and "auto-immunity" or "reproductive technique" or "assisted reproduction" or "in vitro fertilization" and "auto-immunity." We retained clinical and physiopathological studies that were applicable to the clinician in assuming joint management of both infertility associated with serum auto-antibodies in women. Thyroid auto-immunity which affects thyroid function could be a cause of infertility; even in euthyroidia, the presence of anti-thyroperoxydase antibodies and/or thyroglobulin are related to infertility. The presence of anti-phospholipid (APL) and/or anti-nuclear (ANA) antibodies seems to be more frequent in the population of infertile women; serum auto-antibodies are associated with early ovarian failure, itself responsible for fertility disorders. However, there exist few publications on this topic. The methods of dosage, as well as the clinical criteria of unexplained infertility deserve to be standardized to allow a precise response to the question of the role of serum auto-antibodies in these women. The direct pathogenesis of this auto-immunity is unknown, but therapeutic immunomodulators, prescribed on a case-by-case basis, could favor pregnancy even in cases of unexplained primary or secondary infertility</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12016-016-8586-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27628237">PM:27628237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20160917-DerouxA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20160917-DerouxA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Deroux A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12016-016-8586-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elieh Ali,K.D.</style></author><author><style face="normal" font="Arial"> Shafaghat,F.</style></author><author><style face="normal" font="Arial"> Zwiener,R.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Research Center, Department of Immunology, and Student's Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Immunology of Bee Venom</style></title><secondary-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amines</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Biogenic Amines</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="Arial">Bee venom is a blend of biochemicals ranging from small peptides and enzymes to biogenic amines. It is capable of triggering severe immunologic reactions owing to its allergenic fraction. Venom components are presented to the T cells by antigen-presenting cells within the skin. These Th2 type T cells then release IL-4 and IL-13 which subsequently direct B cells to class switch to production of IgE. Generating venom-specific IgE and crosslinking FcepsilonR1(s) on the surface of mast cells complete the sensitizing stage in allergic individuals who are most likely to experience severe and even fatal allergic reactions after being stung. Specific IgE for bee venom is a double-edged sword as it is a powerful mediator in triggering allergic events but is also applied successfully in diagnosis of the venom allergic patient. The healing capacity of bee venom has been rediscovered under laboratory-controlled conditions using animal models and cell cultures. The potential role of enzymatic fraction of bee venom including phospholipase A2 in the initiation and development of immune responses also has been studied in numerous research settings. Undoubtedly, having insights into immunologic interactions between bee venom components and innate/specific immune cells both locally and systematically will contribute to the development of immunologic strategies in specific and epitope-based immunotherapy especially in individuals with Hymenoptera venom allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Iran -CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12016-017-8597-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28105558">PM:28105558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170120-EliehAliKD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170120-EliehAliKD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Elieh Ali KD</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12016-017-8597-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,B.</style></author><author><style face="normal" font="Arial"> Yan,L.</style></author><author><style face="normal" font="Arial"> Yao,Z.</style></author><author><style face="normal" font="Arial"> Roskos,L.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MedImmune LLC, Mountain View, California, USA</style></auth-address><titles><title><style face="normal" font="Arial">Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma</style></title><secondary-title><style face="normal" font="Arial">CPT Pharmacometrics Syst Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">CPT Pharmacometrics Syst Pharmacol</style></abbr-1></periodical><pages end="257" start="249">249-257</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacodynamics</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="21" Month="1" Year="2017">2017/1/21</year></dates><abstract><style face="normal" font="Arial">Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor alpha, immunoglobulin G (IgG) 1 kappa monoclonal antibody. We developed a population pharmacokinetic (PK)/pharmacodynamic (PD) model for benralizumab by analyzing PK and blood eosinophil count data from two healthy volunteer studies (N = 48) and four studies in patients with asthma (N = 152). Benralizumab PK was dose-proportional and adequately described by a two-compartment model with first-order elimination from the central compartment and first-order absorption from the subcutaneous dosing site. The estimated systemic clearance and volume of distribution were typical for human IgG. Body weight and high-titer antidrug antibodies were identified as relevant covariates influencing the PK of benralizumab. Depletion of blood eosinophil counts was depicted by a modified transit model in which benralizumab induced depletion of eosinophils in each age compartment. Stochastic simulations supported an every-8-week dosing schedule of benralizumab for a phase IIb study in patients with uncontrolled asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170121IS - 2163-8306 (Electronic)IS - 2163-8306 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/psp4.12160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109128">PM:28109128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\CPT Pharmacometrics Syst Pharmacol\20170121-WangB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\CPT Pharmacometrics Syst Pharmacol\20170121-WangB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170121, Wang B</style></custom2><misc3><style face="normal" font="Arial">10.1002/psp4.12160</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fu,L.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Key Laboratory for Food Microbial Technology of Zhejiang Province, School of Food Science and Biotechnology, Zhejiang Gongshang University , 18 Xue Zheng Street, Hangzhou 310018 , China</style></auth-address><titles><title><style face="normal" font="Arial">Seafood allergen-induced hypersensitivity at the microbiota-mucosal site: implications for prospective probiotic use in allergic response regulation</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immune system</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Seafood allergy</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">Food allergy is a serious disease worldwide; it can significantly lower the standard of living of affected individuals and may be life-threatening. In particular, hypersensitivity to seafood has been increasing in recent years owing to rising consumption. The mucosal immune system plays a critical role in the onset of seafood allergy and other allergic diseases. Recently, experimental and clinical evidence has shown that probiotics significantly modulate immune responses and thus suppress allergic reactions. Therefore, in this review, we summarized the basic knowledge of seafood allergy, the mucosal immune system and probiotic activities. We also reviewed the critical immune factors involved in allergic reactions, as well as the potential mechanism and the potential use of probiotics to ameliorate seafood allergy. The elucidation of these topics may help us to develop preventive and therapeutic approaches for seafood allergy and other immune disorders in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2016.1269719</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28084786">PM:28084786</url></web-urls><pdf-urls><url ppv-ref="no">wangyb@mail.zjgsu.edu.cn</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Fu L</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2016.1269719</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lozano-Ojalvo,D.</style></author><author><style face="normal" font="Arial"> Lopez-Fandino,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Instituto de Investigacion en Ciencias de la Alimentacion (CIAL, CSIC-UAM) , Madrid , Spain</style></auth-address><titles><title><style face="normal" font="Arial">Immunomodulating peptides for food allergy prevention and treatment</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immune system</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">Among the most promising strategies currently assayed against IgE-mediated allergic diseases stands the possibility of using immunomodulating peptides to induce oral tolerance towards offending food allergens or even to prevent allergic sensitization. This review focuses on the beneficial effects of food derived immunomodulating peptides on food allergy, which can be directly exerted in the intestinal tract or once being absorbed through the intestinal epithelial barrier to interact with immune cells. Food peptides influence intestinal homeostasis by maintaining and reinforcing barrier function or affecting intestinal cell-signalling to nearby immune cells and mucus secretion. In addition, they can stimulate cells of the innate and adaptive immune system while supressing inflammatory responses. Peptides represent an attractive alternative to whole allergens to enhance the safety and efficacy of immunotherapy treatments. The conclusions drawn from curative and preventive experiments in murine models are promising, although there is a need for more pre-clinical studies to further explore the immunomodulating strategy and its mechanisms and for a deeper knowledge of the peptide sequence and structural requirements that determine the immunoregulatory function</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2016.1275519</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102702">PM:28102702</url></web-urls><pdf-urls><url ppv-ref="no">rosina.lopez@csic.es</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Lozano-Ojalvo D</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2016.1275519</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pralong,J.A.</style></author><author><style face="normal" font="Arial"> Cartier,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Work and Health, Route de la Corniche 2, 1066, Epalinges, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Review of Diagnostic Challenges in Occupational Asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial responsiveness</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expiratory flows</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenges</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work-related asthma</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Occupational asthma (OA) is one of the most frequent occupational diseases and its diagnosis is often difficult. This review summarizes its current diagnostic challenges. RECENT FINDINGS: OA is associated with significant health and socio-economic burden. It is underdiagnosed and physicians need to adopt a stepwise approach to confirm the diagnosis. Although early removal from exposure to the offending agent is associated with a better prognosis, physicians should try to confirm the diagnosis of work-related asthma before taking a worker off work. A proper occupational and medical history is very important but is not enough to make the diagnosis of OA. Objective evidence of work-related asthma is required and this represents a serious challenge to most physicians. Measurement of non-specific bronchial responsiveness (NSBR) and spirometry may confirm the diagnosis of asthma but do not confirm the diagnosis of OA. Serial monitoring of peak expiratory flows (PEF), NSBR, and airway inflammation at and off work may confirm the diagnosis of OA but are often difficult to perform. Confirming sensitization by skin prick tests or specific IgE may help to support the diagnosis of OA. Specific inhalation challenges (SIC) in the lab or at work are considered the reference standard but are of limited access. Medical surveillance programs along with primary prevention (reducing exposure) may help to reduce the burden of OA, but the ideal program has yet to be defined. The diagnostic workup of OA remains a challenge and needs a rigorous stepwise evaluation</style></abstract><notes><style face="normal" font="Arial">DA - 20170116IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Switzerland -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0676-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28091866">PM:28091866</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170116, Pralong JA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0676-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mendez-Huergo,S.P.</style></author><author><style face="normal" font="Arial"> Blidner,A.G.</style></author><author><style face="normal" font="Arial"> Rabinovich,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Inmunopatologia, Instituto de Biologia y Medicina Experimental, Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), C1428 Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="15" start="8">8-15</pages><volume><style face="normal" font="Arial">45</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Galectins</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Killer Cells</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> natural killer cell</style></keyword><keyword><style face="normal" font="Arial"> Natural killer cells</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">Immune checkpoints, a plethora of inhibitory pathways aimed at maintaining immune cell homeostasis, may be co-opted by cancer cells to evade immune destruction. Therapies targeting immune checkpoints have reached a momentum yielding significant clinical benefits in patients with various malignancies by unleashing anti-tumor immunity. Galectins, a family of glycan-binding proteins, have emerged as novel regulatory checkpoints that promote immune evasive programs by inducing T-cell exhaustion, limiting T-cell survival, favoring expansion of regulatory T cells, de-activating natural killer cells and polarizing myeloid cells toward an immunosuppressive phenotype. Concomitantly, galectins can trigger vascular signaling programs, serving as bifunctional messengers that couple tumor immunity and angiogenesis. Thus, targeting galectin-glycan interactions may halt tumor progression by simultaneously augmenting antitumor immunity and suppressing aberrant angiogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2016.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28088061">PM:28088061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\2017-45-8-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\2017-45-8-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170114, Mendez-Huergo SP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2016.12.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Philpott,H.</style></author><author><style face="normal" font="Arial"> Thien,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory and Sleep Medicine Eastern Health, Monash University, 3 Arnold St Box Hill, Melbourne, 3128, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Allergy Testing in Eosinophilic Esophagitis: an Update of the Evidence</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Gastroenterol</style></full-title></periodical><pages end="34" start="26">26-34</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary therapy</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Design</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">OPINION STATEMENT: Allergy testing has been advocated for patients with eosinophilic esophagitis (EoE) as a means of defining food triggers and directing dietary therapy. Several recent and comprehensive studies have demonstrated the futility of skin prick (SPT), skin patch (APT) and serum food antigen specific IgE (SIgE) estimates in this context. Furthermore, if identification of food triggers is the endpoint (as opposed to the ability of an allergy test-directed diet merely to induce remission), previous positive studies have limitations. Evolving evidence that EoE may be a non-IgE-mediated disease has led to trials of new assays including serum IgG to food allergens, the cytokine thymic stromal lymphopoietin (TSLP) and basophil activation, all without success. Rather than using allergy test-directed diets, the clinician should use empirical elimination diets which are practical, and consider minimally invasive sampling of the oesophagus to facilitate dietary reintroduction. Research should be redoubled to consider not only assays to predict food triggers but also those that monitor disease activity. The anti-inflammatory effect of proton pump inhibitors and deficits in barrier integrity may influence the success of dietary therapy and the results of allergy tests and should be considered in future research design</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1092-8472 (Print)IS - 1092-8472 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11938-017-0125-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28124203">PM:28124203</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Gastroenterol\20170126-PhilpottH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Gastroenterol\20170126-PhilpottH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Philpott H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11938-017-0125-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zasloff,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MedStar Georgetown Transplant Institute, Washington, DC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Pollen has a microbiome: implications for plant reproduction, insect pollination and human allergies</style></title><secondary-title><style face="normal" font="Arial">Environ Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Microbiol</style></full-title></periodical><pages end="2" start="1">1-2</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Reproduction</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1462-2920 (Electronic)IS - 1462-2912 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/1462-2920.13661</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28097828">PM:28097828</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Microbiol\2017-19-1-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Microbiol\2017-19-1-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Zasloff M</style></custom2><misc3><style face="normal" font="Arial">10.1111/1462-2920.13661</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Petrovicova,O.</style></author><author><style face="normal" font="Arial"> Banovcin,P.</style></author><author><style face="normal" font="Arial"> Babusikova,E.</style></author><author><style face="normal" font="Arial"> Jesenak,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Factors modifying cord blood IgE levels - a pilot study</style></title><secondary-title><style face="normal" font="Arial">Epidemiol Mikrobiol Imunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Epidemiol Mikrobiol Imunol</style></abbr-1></periodical><pages end="231" start="226">226-231</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Caesarean section</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> cord blood IgE</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> In utero</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">AIM: The complex influence of internal and external environmental factors on the individual and his/her immune system and the lack of suitable markers to assess and reduce the risk of the development of allergies during the lifetime can explain the continuous increase in the number of people affected by some form of allergy. According to the results of some studies, cord blood IgE level could be a useful early marker for assessing the risk of atopic diseases, but the studies showed controversial results. In addition, several authors discuss the origin of these antibodies (synthesis in utero, peripartum contamination from maternal blood or placental transfer). The aim of our pilot study was to investigate the possible influence of modifying factors on cord blood IgE level. MATERIAL AND METHODS: Our group of patients consisted of 184 retrospectively selected neonates (98 boys, 53.3% and 86 girls, 46.7%) from whom cord blood was collected and cord blood IgE level was measured 25 years ago (PRIST method). The impact of selected modifying factors (sex, type of delivery or month of birth) on cord blood IgE level was assessed retrospectively. RESULTS: Higher cord blood IgE levels were found in boys than in girls, in neonates born by Caesarean section than in those born by natural delivery, and in those born in the winter months than in other seasons of the year. Our findings are in agreement with those of other authors. CONCLUSION: Based on our results and those of others, we assume that the selected factors affect the cord blood IgE levels to varying degrees. These facts should be taken into consideration while interpreting the cord blood IgE levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1210-7913 (Print)IS - 1210-7913 (Linking)LA - czePT - Journal ArticlePT - English AbstractCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078899">PM:28078899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Epidemiol Mikrobiol Imunol\2016-65-226-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Epidemiol Mikrobiol Imunol\2016-65-226-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Petrovicova O</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciccarelli,A.</style></author><author><style face="normal" font="Arial"> Calabro,C.</style></author><author><style face="normal" font="Arial"> Imperatore,C.</style></author><author><style face="normal" font="Arial"> Scala,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Loreto Crispi Hospital, ASL Napoli 1 - Centro, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Hymenoptera Venom Allergy. A closer collaboration is needed between allergists and emergency physicians</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="17" start="15">15-17</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Background. Hymenoptera stings are sometimes fatal in venom-allergic patients. Fatalities mostly occur in previously stung subjects, especially those with a history of systemic reactions, and could be avoided if patients were properly informed of the existence of a prevention strategy for insect stings, referred to an allergy follow-up and prescribed auto-injectable epinephrine and/or venom-specific immunotherapy (VIT). We sought to assess knowledge and awareness of Hymenoptera Venom Allergy (HVA) in a small sample of Emergency Physicians in our geographic area. Methods. An eight-point questionnaire on HVA was administered to Emergency Department physicians working in the six largest ED in Naples. Results. Twenty-seven physicians completed the questionnaire. Twenty/27 (74%) were unaware of the classification of Hymenoptera sting reactions, 11/27 (41%) were unaware of the existence of prevention strategies such as VIT, 18/27 (67%) did not refer HVA patients to a specialist follow up. One/27 (4%) prescribed auto-injectable epinephrine and 100% wish better information on the topic. Conclusions. In our survey we found a number of ED physicians whose knowledge of HVA, beyond the emergency treatment, is not satisfactory. A closer collaboration among ED physicians and allergists is urgently needed</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120601">PM:28120601</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-15-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-15-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Ciccarelli A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tontini,C.</style></author><author><style face="normal" font="Arial"> Marinangeli,L.</style></author><author><style face="normal" font="Arial"> Maiello,N.</style></author><author><style face="normal" font="Arial"> Abbadessa,S.</style></author><author><style face="normal" font="Arial"> Villalta,D.</style></author><author><style face="normal" font="Arial"> Antonicelli,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Medicina Interna, U.O. Allergologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti Ancona, Ancona, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Ara h 6 sensitization in peanut allergy: friend, foe or innocent bystander?</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="21" start="18">18-21</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Ara h 9</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">The clinical role of Ara h 6 sensitization in peanut allergy is a current matter of debate. We investigated the role of Ara h 6 sensitization patterns in a sample of young adults from different Italian cities. Sera of 33 patients with specific IgE against Ara h 6 were selected. According to clinical symptoms upon peanut ingestion, patients were divided into severe reaction (SR) and mild-tolerant (MT) subgroups. While the SR group mainly showed sensitization patterns involving Ara h 2 and other major allergenic components, a previously undescribed association between Ara h 6 and Ara h 9 was found in the MT group. This pattern seems to be clustered in Mediterranean Italy and associated with Pru p 3 sensitization. This finding might shed a new light on the role of Ara h 6 sensitization in peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120602">PM:28120602</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-18-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-18-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Tontini C</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perales,C.C.</style></author><author><style face="normal" font="Arial"> Saez,G.E.</style></author><author><style face="normal" font="Arial"> Marti,G.J.</style></author><author><style face="normal" font="Arial"> Lopez,S.R.</style></author><author><style face="normal" font="Arial"> Fernandez de Rojas,H.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Hospital La Fe, Valencia, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Esophageal dysfunction and immunological changes induced by grass sublingual immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="30" start="28">28-30</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G4</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Sublingual immunotherapy frequently causes local oropharyngeal adverse events which are usually of mild severity, and tend to be self-limited and disappear within the first weeks of therapy. The mechanism of action involves changes in the specific humoral response to allergens, with increases in allergen-specific immunoglobulin G4 (IgG4) and blunting of the seasonal increase in allergen-specific IgE. We describe the case of a 25-year-old man diagnosed with grass pollen induced allergic rhinoconjunctivitis, who was treated with a lyophilisate of Phleum pratense by sublingual route. After 5 weeks of therapy he developed repeatedly intense symptoms of esophageal dysfunction immediately after the administration. Symptoms recurred every day, subsided in some hours without treatment and disappeared with the termination of therapy. The episode coincided with a marked elevation of total and specific IgE. The immunological changes gradually declined during the three years of follow up. The reported case suggests the need to evaluate the role of the immunological changes detected after the first weeks of sublingual therapy with Phleum pratense, in the induction of esophageal disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120604">PM:28120604</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-28-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-28-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Perales CC</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaba,S.</style></author><author><style face="normal" font="Arial"> Keskindemirci,G.</style></author><author><style face="normal" font="Arial"> Aydogmus,C.</style></author><author><style face="normal" font="Arial"> Siraneci,R.</style></author><author><style face="normal" font="Arial"> Erol,C.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Yuzuncu Yil University, School of Medicine, Deparment of Pediatrics, Van, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="14" start="11">11-14</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Arthralgia</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chills</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Intravenous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> IVIg</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pre-medication</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Primary immunodeficiency diseases</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Secondary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Intravenous immunoglobulin (IVIG) is commonly used in primary and secondary immunodeficiency diseases as well as autoimmune conditions as immunomodulatator treatment. Immediate adverse events which are generally mild and occur during infusion are seen in 6 hours. Reported immediate adverse events are in a wide range from 1%-40% in pediatric patients. 115 patients who received IVIG (except newborns) were included into this crosssectional study. IVIG was given to patients for primary immunodeficiencies (n=8), ITP (n=65), Kawasaki disease (n=11), secondary immunosupression (n=28), and passive immunization (n=3). 5%, 10% IVIG preparations and pentaglobin were used. Headache, fever, chills, nausea, rash, arthralgia, myalgia and back pain were accepted as mild immediate events. There were 62 (54%) boys and 53 (46%) girls aged 1 month-18 years. Mean age of the group was 7.4+/-4.6 years. Immediate adverse events due to IVIG infusions were seen in 29 (25.2%) of all patients. Gender and types of the disease were not different in significance regarding the presence of adverse events. The rate of adverse events did not change with receiving pre-medication. The most common reaction was fever/chills. Immediate reactions were seen in first 6 hours in 7 patients and during infusion in the remaining. They were treated with slowing of the infusion rate and infusion was stopped in 3 patients because of moderate events. Because of the increasingly use of IVIG therapy, it is important to know the side effects. High doses, high infusion rates, accompanying infection may worsen the adverse effects especially in primary immunodeficiency diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120600">PM:28120600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-11-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-11-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Kaba S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ariano,R.</style></author><author><style face="normal" font="Arial"> Cecchi,L.</style></author><author><style face="normal" font="Arial"> Voltolini,S.</style></author><author><style face="normal" font="Arial"> Quercia,O.</style></author><author><style face="normal" font="Arial"> Scopano,E.</style></author><author><style face="normal" font="Arial"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ASL n. 1 Imperia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Parietaria pollination duration: myth or fact?</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="10" start="6">6-10</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> Parietaria pollen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Background. Even though the Parietaria pollen season may be rather long, it is commonly thought that Parietaria pollen is a perennial allergen present along the whole year. Objective. This study aimed at investigating the duration of Parietaria pollen season during a 10-year period in Italy, analysing also the annual pollen quantity and the differences among geographical areas. Methods. Pollen count was assessed daily for 10 years. Globally, ten Italian centers measured Parietaria pollen count. Start date, peak date, end date, duration (days), peak value, and seasonal pollen index were evaluated in each center. Results. Ten-year Parietaria pollen count demonstrates that the pollen season usually lasted for 6-7 months in Italy. There are important differences among centres, mainly attributable to geoclimatic factors. Conclusion. This study demonstrates that Parietaria pollen season lasts about 6-7 months with two peaks (mainly in spring and lower in autumn) in Italy with important geographical variations. This information may have clinical relevance in managing patients allergic to Parietaria</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120599">PM:28120599</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-6-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-6-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Ariano R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sopo Miceli,S.</style></author><author><style face="normal" font="Arial"> Monaco,S.</style></author><author><style face="normal" font="Arial"> Cerchiara,G.</style></author><author><style face="normal" font="Arial"> Bersani,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Department of Paediatrics, Agostino Gemelli Hospital, Sacred Heart Catholic University, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">A very unusual case of food allergy, between FPIES and IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="44" start="42">42-44</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Food protein induced enterocolitis syndrome (FPIES) is a food-related gastrointestinal hypersensitivity disorder, probably non-IgE-mediated. Over the years, various diagnostic criteria have been proposed to identify FPIES. In the last few years, there was an increased interest from researchers about FPIES's syndrome, that frequently brought to discover new aspects of this disease. We describe an unusual case of FPIES to egg in a 21-months-old child, because of its clinical characteristics that reflect some aspects of IgE-mediated allergy and other of non IgE-mediated allergy. Although we believe that the most correct diagnosis for our case is FPIES, we think also that this is undoubtedly an atypical form. This is in fact, the first description of a patient who simultaneously has both clinical expressions of IgE-mediated FA that of FPIES. Our case highlights the need to review criteria for FPIES diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120606">PM:28120606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-42-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-42-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Sopo Miceli S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martin-Munoz,M.F.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Cannabal,J.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital La Paz Instituto de Investigacion (idiPaz), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis to hidden potato allergens in a peach and egg allergic boy</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="48" start="45">45-48</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Candy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergen</style></keyword><keyword><style face="normal" font="Arial"> Peach allergens</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">More than 170 foods have been identified as being potentially allergenic. However, a minority of these foods cause the majority of reactions. Sweets are frequently implicated in allergic reactions in children with cow's milk, egg, nuts or fruits allergy, and they are the most relevant foods investigated as responsible allergens. We report an anaphylactic reaction to candies in an egg and peach allergic boy. We performed a study to identify responsible allergens for the reaction. We investigated hidden egg and peach allergens in the candies, but they were not found. Finally, the causative allergen resulted to be a vegetable protein from potato peel. We diagnosed a new allergy in our patient and Sol t 4 was identified as the responsible allergen of the anaphylactic reaction. We conclude that responsible allergens should always be studied and identified in whatever allergic reaction in order to prevent new reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120607">PM:28120607</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-45-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-45-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Martin-Munoz MF</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dalgic,A.</style></author><author><style face="normal" font="Arial"> Dinc,M.E.</style></author><author><style face="normal" font="Arial"> Ulusoy,S.</style></author><author><style face="normal" font="Arial"> Dizdar,D.</style></author><author><style face="normal" font="Arial"> Is,A.</style></author><author><style face="normal" font="Arial"> Topak,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head and Neck Surgery, Istanbul Gaziosmanpasa Taksim Research and Training Hospital, 34255 Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of the effects of nasal steroids and montelukast on olfactory functions in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Otorhinolaryngol Head Neck Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur Ann Otorhinolaryngol Head Neck Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene Antagonists</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Olfactory dysfunction is one of the comorbidities associated with allergic rhinitis (AR) and AR is one of the common causes of olfactory problems. We aimed to evaluate by the Sniffin' Sticks test the effects on olfactory functions of nasal steroids and leukotriene antagonists used for allergic rhinitis. METHODS: Thirty patients with seasonal rhinitis were included in this study. Patients were randomly divided into three groups of 10 patients; group 1 received montelukast sodium and mometasone furoate (MF) therapy, group 2 received only montelukast, and group 3 only MF. Patients' olfactory functions were determined using the Sniffin' Sticks olfactory test before and after a month treatment. RESULTS: Threshold, discrimination, identification, and the sum of threshold, discrimination, and identification (TDI) values were not significantly different among the groups before treatment. For Group 1 and Group 3 patients, there were statistically significant differences in threshold, discrimination, identification, and TDI values before and after treatment (P&lt;0.05) (Wilcoxon signed ranks analysis). For Group 2 patients, the before and after treatment values of threshold, discrimination, identification, and TDI showed no significant difference (P>0.05). CONCLUSION: According to the findings of our study, MF is superior to montelukast in improving olfactory function. Although montelukast has been shown to be effective against AR symptoms, its effect on olfactory function was not demonstrated in this study</style></abstract><notes><style face="normal" font="Arial">DA - 20170122IS - 1879-730X (Electronic)IS - 1879-7296 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anorl.2016.05.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109729">PM:28109729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Otorhinolaryngol Head Neck Dis\20170122-DalgicA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Otorhinolaryngol Head Neck Dis\20170122-DalgicA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170122, Dalgic A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anorl.2016.05.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,Y.Z.</style></author><author><style face="normal" font="Arial"> Shaari,K.</style></author><author><style face="normal" font="Arial"> Cheema,M.S.</style></author><author><style face="normal" font="Arial"> Tham,C.L.</style></author><author><style face="normal" font="Arial"> Sulaiman,M.R.</style></author><author><style face="normal" font="Arial"> Israf,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia</style></auth-address><titles><title><style face="normal" font="Arial">An orally active geranyl acetophenone attenuates airway remodeling in a murine model of chronic asthma</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="64" start="53">53-64</pages><volume><style face="normal" font="Arial">797</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methacholine challenge</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="Arial">2,4,6-trihydroxy-3-geranyl acetophenone (tHGA) is a synthetic compound that is naturally found in Melicope ptelefolia. We had previously demonstrated that parenteral administration of tHGA reduces pulmonary inflammation in OVA-sensitized mice. In this study, we evaluated the effect of orally administered tHGA upon airway remodeling in a murine model of chronic asthma. Female BALB/C mice were sensitized intraperitoneally with ovalbumin (OVA) on day 0, 7 and 14, followed by aerosolized 1% OVA 3 times per week for 6 weeks. Control groups were sensitized with saline. OVA sensitized animals were either treated orally with vehicle (saline with 1% DMSO and Tween 80), tHGA (80, 40, 20mg/kg) or zileuton (30mg/kg) 1h prior to each aerosolized OVA sensitization. On day 61, mice underwent methacholine challenge to determine airway hyperresponsiveness prior to collection of bronchoalveolar lavage (BAL) fluid and lung samples. BAL fluid inflammatory cell counts and cytokine concentrations were evaluated while histological analysis and extracellular matrix protein concentrations were determined on collected lung samples. Oral tHGA treatment attenuated airway hyperresponsiveness and inhibited airway remodeling in a dose-dependent fashion. tHGA's effect on airway remodeling could be attributed to the reduction of inflammatory cell infiltration and decreased expression of cytokines associated with airway remodeling. Oral administration of tHGA attenuates airway hyperresponsiveness and remodeling in OVA-induced BALB/c mice. tHGA is an interesting compound that should be evaluated further for its possible role as an alternative non-steroidal pharmacological approach in the management of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170116IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28089919">PM:28089919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20170116-LeeYZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20170116-LeeYZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170116, Lee YZ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.01.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mizutani,N.</style></author><author><style face="normal" font="Arial"> Nabe,T.</style></author><author><style face="normal" font="Arial"> Yoshino,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Kobe Pharmaceutical University, 4-19-1 Motoyamakita, Higashinada, Kobe 658-8558, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Topical ocular treatment with monoclonal antibody Fab fragments targeting Japanese cedar pollen Cry j 1 inhibits Japanese cedar pollen-induced allergic conjunctivitis in mice</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="112" start="105">105-112</pages><volume><style face="normal" font="Arial">798</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cry j 1</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eye-drops</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Papain</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="1" Year="2017">2017/1/21</year></dates><abstract><style face="normal" font="Arial">Fab fragments (Fabs) of antibodies having the ability only to bind to specific allergens lack effector functions due to the absence of the Fc portion. In the present study, we examined whether IgG1 monoclonal antibody (mAb) Fabs targeting Japanese cedar pollen (JCP) Cry j 1 were able to regulate JCP-induced allergic conjunctivitis in mice. BALB/c mice actively sensitized with JCP were repeatedly challenged by topical administration of JCP eye drops. Fabs prepared by the digestion of anti-JCP IgG1 mAbs (P1-3 and P1-8) with papain were applied to the eye 15min before the JCP challenges followed by measurement of the clinical conjunctivitis score. In the in vitro experiments, P1-3 and P1-8 showed specific binding to JCP Cry j 1. Furthermore, intact P1-3 binding to Cry j 1 was inhibited by P1-3 Fabs, but not P1-8 Fabs; additionally, P1-8 Fabs, but not P1-3 Fabs, suppressed the intact P1-8 binding, suggesting that the epitopes of Cry j 1 recognized by P1-3 and P1-8 were different. Topical ocular treatment with P1-3 Fabs or P1-8 Fabs was followed by marked suppression of JCP-induced conjunctivitis (P&lt;0.01). In histological evaluation, P1-8 Fabs showed a reduction in eosinophil infiltration in the conjunctiva (P&lt;0.01). These results demonstrated that topical ocular treatment with IgG1 mAb Fabs to Cry j 1 was effective in suppressing JCP-induced allergic conjunctivitis in mice. Furthermore, it suggests the possibility that some epitopes recognized by Fabs could be used as a tool to regulate allergic conjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.01.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28119075">PM:28119075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20170125-MizutaniN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20170125-MizutaniN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Mizutani N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.01.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ellwood,P.</style></author><author><style face="normal" font="Arial"> Asher,M.I.</style></author><author><style face="normal" font="Arial"> Billo,N.E.</style></author><author><style face="normal" font="Arial"> Bissell,K.</style></author><author><style face="normal" font="Arial"> Chiang,C.Y.</style></author><author><style face="normal" font="Arial"> Ellwood,E.M.</style></author><author><style face="normal" font="Arial"> El-Sony,A.</style></author><author><style face="normal" font="Arial"> Garcia-Marcos,L.</style></author><author><style face="normal" font="Arial"> Mallol,J.</style></author><author><style face="normal" font="Arial"> Marks,G.B.</style></author><author><style face="normal" font="Arial"> Pearce,N.E.</style></author><author><style face="normal" font="Arial"> Strachan,D.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Child and Youth Health, The University of Auckland, Auckland, New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors</style></title><secondary-title><style face="normal" font="Arial">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sudan</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - France -CO - Taiwan -CO - Sudan -CO - Spain -CO - Chile -CO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial"> 10.1183/13993003.01605-2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28077477">PM:28077477</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Respir J\20170112-EllwoodP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Respir J\20170112-EllwoodP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Ellwood P</style></custom2><misc3><style face="normal" font="Arial"> 10.1183/13993003.01605-2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kottahachchi,D.</style></author><author><style face="normal" font="Arial"> Topliss,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Endocrinology and Diabetes, The Alfred Hospital, Monash University, Melbourne, VIC, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin G4-Related Thyroid Diseases</style></title><secondary-title><style face="normal" font="Arial">Eur Thyroid J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur Thyroid J</style></abbr-1></periodical><pages end="239" start="231">231-239</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Antibody Reactions</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endocrine System</style></keyword><keyword><style face="normal" font="Arial"> Endocrinology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Graves Disease</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Hypothyroidism</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Tamoxifen</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Diseases</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin G4-related disease (IgG4-RD) is a new disease category involving many organ systems, including the endocrine system in general and the thyroid in particular. Since an initial association was made between hypothyroidism and autoimmune (IgG4-related) pancreatitis, more forms of IgG4-related thyroid disease (IgG4-RTD) have been recognized. Four subcategories of IgG4-RTD have so far been identified: Riedel thyroiditis (RT), fibrosing variant of Hashimoto thyroiditis (FVHT), IgG4-related Hashimoto thyroiditis, and Graves disease with elevated IgG4 levels. Although a male predominance is seen for IgG4-RD in general, RT and FVHT have a female preponderance. The pathogenesis of IgG4-RD is not completely understood; however, genetic factors, antigen-antibody reactions, and an allergic phenomenon have been described. Diagnosis of IgG4-RD requires a combination of clinical features, serological evidence, and histological features. Histology is the mainstay of diagnosis, with IgG4 immunostaining. Although serum IgG4 levels are usually elevated in IgG4-RD, raised serum IgG4 is neither necessary nor adequate for diagnosis. Imaging supports the diagnosis and is a useful tool in disease monitoring. Management of IgG4-RTD is both medical and surgical. Steroids are the first-line treatment and may produce a swift response. Tamoxifen and rituximab are second-line agents used in steroid-resistant patients. Surgical debulking is carried out in RT solely as a procedure to relieve obstruction. Other endocrine associations described with IgG4-RD are hypophysitis and Hashimoto encephalopathy. IgG4-RTD is an uncommon disease entity, and prompt diagnosis and treatment can improve outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 2235-0640 (Print)IS - 2235-0640 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1159/000452623</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101487">PM:28101487</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Thyroid J\2016-5-231-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Thyroid J\2016-5-231-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Kottahachchi D</style></custom2><misc3><style face="normal" font="Arial">10.1159/000452623</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hong,G.H.</style></author><author><style face="normal" font="Arial"> Kwon,H.S.</style></author><author><style face="normal" font="Arial"> Lee,K.Y.</style></author><author><style face="normal" font="Arial"> Ha,E.H.</style></author><author><style face="normal" font="Arial"> Moon,K.A.</style></author><author><style face="normal" font="Arial"> Kim,S.W.</style></author><author><style face="normal" font="Arial"> Oh,W.</style></author><author><style face="normal" font="Arial"> Kim,T.B.</style></author><author><style face="normal" font="Arial"> Moon,H.B.</style></author><author><style face="normal" font="Arial"> Cho,Y.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Internal Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">hMSCs suppress neutrophil-dominant airway inflammation in a murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Exp Mol Med</style></abbr-1></periodical><pages end="" start="e288">e288-</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="Arial">Although chronic eosinophilic inflammation is a common feature in patients with asthma, some patients have neutrophil-dominant inflammation, which is known to be associated with severe asthma.Human mesenchymal stem cells (hMSCs) have shown promise in treating various refractory immunological diseases. Thus, hMSCs may represent an alternative therapeutic option for asthma patients with neutrophil-dominant inflammation, in whom current treatments are ineffective. BALB/c mice exposed to ovalbumin and polyinosinic:polycytidylic acid (Poly I:C) to induce neutrophilic airway inflammation were systemically treated with hMSCs to examine whether the hMSCs can modulate neutrophilic airway inflammation. In addition, cytokine production was evaluated in co-cultures of hMSCs with either anti-CD3/CD28-stimulated peripheral blood mononuclear cells (PBMCs) obtained from asthmatic patients or cells of the human bronchial epithelial cell line BEAS-2B to assess the response to hMSC treatment. The total number of immune cells in bronchoalveolar lavage fluid (BALF) showed a dramatic decrease in hMSC-treated asthmatic mice, and, in particular, neutrophilic infiltration was significantly attenuated. This phenomenon was accompanied by reduced CXCL15 production in the BALF. BEAS-2B cells co-cultured with hMSCs showed reduced secretion of IL-8. Moreover, decreased secretion of IL-4, IL-13 and IFN-gamma was observed when human PBMCs were cultured with hMSCs, whereas IL-10 production was greatly enhanced. Our data imply that hMSCs may have a role in reducing neutrophilic airway inflammation by downregulating neutrophil chemokine production and modulating T-cell responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 2092-6413 (Electronic)IS - 1226-3613 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1038/emm.2016.135</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28127050">PM:28127050</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Mol Med\2017-49-e288.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Mol Med\2017-49-e288.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Hong GH</style></custom2><misc3><style face="normal" font="Arial">10.1038/emm.2016.135</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,L.</style></author><author><style face="normal" font="Arial"> Piao,H.</style></author><author><style face="normal" font="Arial"> Zheng,M.</style></author><author><style face="normal" font="Arial"> Jin,Z.</style></author><author><style face="normal" font="Arial"> Zhao,L.</style></author><author><style face="normal" font="Arial"> Yan,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy, Histology and Embryology, Yanbian University Medical College, Yanji, Jilin 133002, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Sesamin attenuates allergic airway inflammation through the suppression of nuclear factor-kappa B activation</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="4181" start="4175">4175-4181</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> embryology</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinases</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> p38 Mitogen-Activated Protein Kinases</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Protein Kinases</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">The aim of the present study is to determine the role of sesamin, the most abundant lignan in sesame seed oil, on the regulation of allergic airway inflammation in a murine asthma model. A BALB/c mouse model with allergic asthma was used to evaluate the effects of sesamin on nuclear factor-kappa B (NF-kappaB) activation. An enzyme-linked immunosorbent assay was used to determine protein expression in bronchoalveolar lavage (BAL) fluids. Hematoxylin and eosin staining was performed to examine histological changes. Moreover, western blot analysis was used to detect the expression of proteins in tissues. Prior to administering sesamin, the mice developed the following pathophysiological features of asthma: An increase in the number of inflammatory cells, increased levels of interleukin (IL)-4, IL-5 and IL-13, decreased levels of interferon-gamma in BAL fluids and lung tissues, increased immunoglobulin E (IgE) levels in the serum and an increased activation of NF-kappaB in lung tissues. Following treatment with sesamin, the mice had evidently reduced peribronchiolar inflammation and airway inflammatory cell recruitment, inhibited production of several cytokines in BAL fluids and lung tissues, and decreased IgE levels. Following inhalation of ovalbumin, the administration of sesamin also inhibited the activation of NF-kappaB. In addition, sesamin administration reduced the phosphorylation of p38 mitogen-activated protein kinases (MAPKs). The present study demonstrates that sesamin decreases the activation of NF-kappaB in order to attenuate allergic airway inflammation in a murine model of asthma, possibly via the regulation of phosphorylation of p38 MAPK. These observations provide an important molecular mechanism for the potential use of sesamin in preventing and/or treating asthma, as well as other airway inflammatory disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2016.3903</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28105144">PM:28105144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-12-4175-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-12-4175-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Li L</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2016.3903</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,X.</style></author><author><style face="normal" font="Arial"> Duan,W.</style></author><author><style face="normal" font="Arial"> Zhu,X.</style></author><author><style face="normal" font="Arial"> Xu,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Shanxi DAYI Hospital of Shanxi Medical University, Taiyuan, Shanxi 030032, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin G4-related acquired hemophilia: A case report</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="3992" start="3988">3988-3992</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Factor Viii</style></keyword><keyword><style face="normal" font="Arial"> fibronectin</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Hemophilia A</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> phlebitis</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Prothrombin Time</style></keyword><keyword><style face="normal" font="Arial"> SEC</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Acquired hemophilia A (AHA) is a relatively rare and life-threatening bleeding disorder whose pathogenesis is not completely understood. The present study reports a rare case of immunogubulin (IgG)4-related AHA with multisystemic involvement. A 55-year old male patient presented with symptoms of bronchial asthma and multiple subdermal hematomas. Chest computed tomography showed multiple diffuse nodular lesions with thickening of bronchovascular bundles, and scattered high-density spots in both lung lobes. Laboratory investigations showed increased activated partial prothrombin time (120.0 sec), a markedly decreased factor VIII (FVIII) activity (0.5%), a high-titer of FVIII inhibitor (27.2 Bethesda units/ml) and a marked increase in serum IgG4 (>4.03 g/l) level. Left inguinal lymph node biopsy revealed capsular thickening with marked lymphoplasmacytic infiltration, occlusive phlebitis and irregular fibrosis. Immunostaining revealed numerous IgG4-positive plasma cells (>100 cells/human plasma fibronectin) in the nodular lesions, with an IgG4/IgG ratio of >40%. The symptoms were markedly alleviated following corticosteroid therapy. The current study presents the first reported case of a rare IgG4-related AHA that presented with unusual clinical features and multisystemic involvement. The patient responded well to corticosteroid therapy. Documentation of such rare cases will help in characterizing the pathogenesis, and prompt recognition and timely treatment of this rare disorder</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2016.3898</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28105131">PM:28105131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2016-12-3988-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2016-12-3988-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Li X</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2016.3898</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,K.J.</style></author><author><style face="normal" font="Arial"> Wang,S.Q.</style></author><author><style face="normal" font="Arial"> Xu,Y.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Different roles of Staphylococcus aureus enterotoxin in different subtypes of nasal polyps</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="326" start="321">321-326</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial disease. The pathogenesis of CRSwNP remains unclear. This study was designed to investigate the role of inflammation and Staphylococcus aureus enterotoxin (SE) in this disease. The study included a total of 74 patients with CRSwNP and 6 controls. A serum Phadiatop assay was conducted to detect atopy status, and serum eosinophil cationic protein (ECP) and total immunoglobulin (Ig)E levels were determined using ELISA. SEA, SEB, total IgE, ECP and myeloperoxidase (MPO) levels in nasal tissue supernatant were measured using ELISA. The results indicated that 15 (22.1%) patients had systemic allergies. On the basis of the ECP/MPO ratio, the patients were divided into an eosinophilic CRSwNP group (n=18) and a non-eosinophilic CRSwNP group (n=56). The total ECP/MPO ratio was 0.572, with a notable bias toward neutrophilic inflammation. The supernatant ECP and MPO levels were elevated in the CRSwNP group compared with the control group, but no significant difference in the serum total IgE and ECP levels were observed between the CRSwNP and control groups. In addition, the non-eosinophilic and eosinophilic CRSwNP groups showed significant elevations in supernatant total IgE, SEA and SEB levels compared with the control group. Thus, it may be concluded that allergy is a common pathogenesis of CRSwNP, and neutrophilic inflammation is present in most Chinese CRSwNP patients. Additionally, local indicators reflect the inflammatory status more accurately than do serum indicators. SEs may act as an infection factor rather than as a superantigen in Chinese non-eosinophilic CRSwNP patients. Thus, long-term antibiotic therapy may be an option for Chinese non-eosinophilic CRSwNP patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2016.3951</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28123509">PM:28123509</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-13-321-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-13-321-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Cheng KJ</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2016.3951</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gimenez-Arnau,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Dermatology department, Hospital del Mar-Parc de Salut Mar , Universitat Autonoma-Universitat Pompeu Fabra , Passeig Maritim 25-29, 08003 Barcelona , Spain</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab for Treating Chronic Spontaneous Urticaria: an Expert Review on Efficacy and Safety</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></full-title></periodical><pages end="385" start="375">375-385</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">angioedema</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacodynamics</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, Phase II (X-QUISITE, MYSTIQUE), and pivotal Phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL). Expert opinion: Omalizumab is a clinically effective and safe biological therapy for treating H1-antihistamine refractory CSU patients. It significantly reduces CSU symptoms (hives, itch and angioedema), and improves patient health-related quality of life. While omalizumab is already integral to the treatment of antihistamine refractory CSU, widespread use will depend on legal and economic factors, as well as improvements in the early and accurate diagnosis of CSU patients who would benefit from treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1744-7682 (Electronic)IS - 1471-2598 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/14712598.2017.1285903</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28125304">PM:28125304</url></web-urls><pdf-urls><url ppv-ref="no">22505aga@comb.cat</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Gimenez-Arnau AM</style></custom2><misc3><style face="normal" font="Arial">10.1080/14712598.2017.1285903</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Licari,A.</style></author><author><style face="normal" font="Arial"> Castagnoli,R.</style></author><author><style face="normal" font="Arial"> De Sando,E.</style></author><author><style face="normal" font="Arial"> Marseglia,G.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pediatrics , Foundation IRCCS Policlinico San Matteo, University of Pavia , Pavia , Italy</style></auth-address><titles><title><style face="normal" font="Arial">Development of a Peptide Conjugate Vaccine for Inducing Therapeutic Anti-IgE Antibodies</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></full-title></periodical><pages end="434" start="429">429-434</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> Late phase reaction</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase reaction</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> multifaceted</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="28" Month="1" Year="2017">2017/1/28</year></dates><abstract><style face="normal" font="Arial">Introduction Given the multifaceted effector functions of IgE in immediate hypersensitivity, late-phase reactions, regulation of IgE receptor expression and immune modulation, IgE antibodies have long represented an attractive target for therapeutic agents in asthma and other allergic diseases. Effective pharmacologic blockade of the binding of IgE to its receptors has become one of most innovative therapeutic strategies in the field of allergic diseases in the last 10 years. Areas covered The latest strategies targeting IgE include the development of a therapeutic vaccine, able to trigger our own immune systems to produce therapeutic anti-IgE antibodies, potentially providing a further step forward in the treatment of allergic diseases. The aim of this review is to discuss the discovery strategy, preclinical and early clinical development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. Expert opinion Outside the area of development of humanized anti-IgE monoclonal antibodies, the research field of therapeutic IgE-targeted vaccines holds potential benefits for the treatment of allergic diseases. However, most of the experimental observations in animal models have not yet been translated into new treatments and evidence of human efficacy and safety of this new therapeutic strategy are still lacking</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1744-7682 (Electronic)IS - 1471-2598 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/14712598.2017.1289172</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132528">PM:28132528</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Opin Biol Ther\2017-17-429-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Opin Biol Ther\2017-17-429-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Licari A</style></custom2><misc3><style face="normal" font="Arial">10.1080/14712598.2017.1289172</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santini,G.</style></author><author><style face="normal" font="Arial"> Mores,N.</style></author><author><style face="normal" font="Arial"> Malerba,M.</style></author><author><style face="normal" font="Arial"> Mondino,C.</style></author><author><style face="normal" font="Arial"> Anzivino,R.</style></author><author><style face="normal" font="Arial"> Macis,G.</style></author><author><style face="normal" font="Arial"> Montuschi,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pharmacology, Faculty of Medicine , Catholic University of the Sacred Heart , Rome , Italy</style></auth-address><titles><title><style face="normal" font="Arial">Dupilumab for the treatment of asthma</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Investig Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Investig Drugs</style></full-title></periodical><pages end="366" start="357">357-366</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-4 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">Introduction Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma. Dupilumab is directed against the alpha-subunit of the interleukin (IL)-4 receptor and blocks the IL-4 and IL-13 signal transduction. Areas Covered Pathophysiological role of IL-4 and IL-13 in asthma; mechanism of action of dupilumab; pharmacology of IL-4 receptor; phase I and phase II studies with dupilumab; regulatory affair. Expert opinion Patients with severe asthma who are not sufficiently controlled with standard-of-care represent the target asthma population for dupilumab. If confirmed, efficacy of dupilumab in both eosinophilic and non-eosinophilic severe asthma phenotype might represent an advantage over approved biologics for asthma, including omalizumab, mepolizumab, and reslizumab. Head-to-head studies to compare dupilumab versus other biologics with different mechanism of action are required. Pediatric studies with dupilumab are currently lacking and should be undertaken to assess efficacy and safety of this drug in children with severe asthma. The lack of preclinical data and published results of the completed four phase I studies precludes a complete assessment of the pharmacological profile of dupilumab. Dupilumab seems to be generally well tolerated, but large studies are required to establish its long-term safety and tolerability</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1744-7658 (Electronic)IS - 1354-3784 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1080/13543784.2017.1282458</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28085503">PM:28085503</url></web-urls><pdf-urls><url ppv-ref="no">pmontuschi@rm.unicatt.it</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Santini G</style></custom2><misc3><style face="normal" font="Arial">10.1080/13543784.2017.1282458</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ricketti,P.A.</style></author><author><style face="normal" font="Arial"> Alandijani,S.</style></author><author><style face="normal" font="Arial"> Lin,C.H.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a University of South Florida Morsani College of Medicine, Division of Allergy and Immunology, Department of Internal Medicine , Tampa , FL USA</style></auth-address><titles><title><style face="normal" font="Arial">Investigational new drugs for allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Investig Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Investig Drugs</style></full-title></periodical><pages end="292" start="279">279-292</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Capsaicin</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> EIT</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> epitope peptide</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> ILIT</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Allergic rhinitis (AR) is a multifactorial disease characterized by paroxysmal symptoms of sneezing, rhinorrhea, postnasal drip and nasal congestion. For over a century, subcutaneous allergen immunotherapy (SCIT) has been recognized as the most effective therapy to date that may modify the underlying disease course and provide long-term benefits for individuals refractory to pharmacotherapy. However, over the past 25 years, there has been substantial growth in developing alternative therapies to traditional SCIT. Areas Covered: This article will review the most current literature focusing on advancements of AR therapies. Novel AR therapies that are currently under investigation include: the addition of omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody (mAb), to SCIT; altering the method of delivery of allergen immunotherapy (AIT) including sublingual (SLIT), epicutaneous (EIT), intralymphatic (ILIT), intranasal (INIT) and oral mucosal immunotherapy (OMIT); use of capsaicin spray; novel H3 and H4 antihistamines; activation of the innate immune system through Toll-like receptor agonists; and the use of chemically altered allergens, allergoids, recombinant allergens and relevant T-cell epitope peptides to improve the efficacy and safety of AIT. Expert Opinion: These promising novel therapies may offer more effective and/or safer treatment options for AR patients, and in some instances, induce immunologic tolerance</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1744-7658 (Electronic)IS - 1354-3784 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/13543784.2017.1290079</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28141955">PM:28141955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Opin Investig Drugs\20170131-RickettiPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Opin Investig Drugs\20170131-RickettiPA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Ricketti PA</style></custom2><misc3><style face="normal" font="Arial">10.1080/13543784.2017.1290079</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">James,C.</style></author><author><style face="normal" font="Arial"> Bernstein,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Internal Medicine, Division of Immunology, Rheumatology, and Allergy , University of Cincinnati College of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Current and future therapies for the treatment of histamine-induced angioedema</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Pharmacother</style></full-title></periodical><pages end="262" start="253">253-262</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Bradykinin</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="Arial">Introduction Angioedema, a sudden, self-limited swelling of localized areas of any part of the body that may or may not be associated with urticaria, is thought to be the result of a mast-cell mediated process versus a bradykinin etiology. Understanding the mechanism is key in determining the proper treatment. Areas Covered Clinical presentation of varying angioedema types may be similar; however, the appropriate treatment algorithm is dependent upon clinicians' knowledge of the underlying pathophysiology and classification of angioedema. Literature review of recent guidelines, available medications, and alternative therapies was completed to provide an overview of options. Conclusion There are no formal guidelines for treatment of acute or chronic histamine-mediated angioedema, and therefore, algorithms for the treatment of acute and chronic urticaria should be followed until such information becomes available. Differentiating histamine-mediated versus bradykinin mediated angioedema is essential, as treatments and treatment responses are quite different. Further research is needed to better understand idiopathic angioedema that is unresponsive to H1/H2 antagonists, LTMAs, or medications designed to treat bradykinin-mediated angioedema</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1744-7666 (Electronic)IS - 1465-6566 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/14656566.2017.1282461</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081650">PM:28081650</url></web-urls><pdf-urls><url ppv-ref="no">jonathan.bernstein@uc.edu</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170113, James C</style></custom2><misc3><style face="normal" font="Arial">10.1080/14656566.2017.1282461</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McCarthy,M.W.</style></author><author><style face="normal" font="Arial"> Aguilar-Zapata,D.</style></author><author><style face="normal" font="Arial"> Petraitis,V.</style></author><author><style face="normal" font="Arial"> Walsh,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Joan and Sanford I Weill Medical College of Cornell University Ringgold standard institution - Hospital Medicine , 525 East 68th Street, New York , New York 10065 , USA</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis, Classification, and Therapeutic Interventions for Sinopulmonary Aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Respir Med</style></full-title></periodical><pages end="238" start="229">229-238</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal Agents</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Detection methods</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lateral flow assay</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tissue Culture</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Sinopulmonary aspergillosis represents a diverse collection of allergic, invasive, and chronic sinus and respiratory conditions. These diseases can affect patients with and without immune impairment and in some cases may be life-threatening. Areas Covered: We review the diagnosis, classification, and therapeutic options available to treat sinopulmonary aspergillosis and look ahead to emerging diagnostic and therapeutic options that may soon play an important role in clinical practice. Expert Commentary: Histopathology and tissue culture remain the gold standard for the diagnosis of invasive sinopulmonary aspergillosis, but several new molecular detection methods have recently emerged, including various PCR-based platforms, MALDI-TOF, and lateral flow assays. We examine these methodologies as well as the barriers associated with the standardization, validation, and implementation. We also explore the pipeline of antifungal agents in development to treat sinopulmonary aspergillosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/17476348.2017.1283986</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095078">PM:28095078</url></web-urls><pdf-urls><url ppv-ref="no">mwm9004@med.cornell.edu</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170117, McCarthy MW</style></custom2><misc3><style face="normal" font="Arial">10.1080/17476348.2017.1283986</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gombedza,F.</style></author><author><style face="normal" font="Arial"> Kondeti,V.</style></author><author><style face="normal" font="Arial"> Al-Azzam,N.</style></author><author><style face="normal" font="Arial"> Koppes,S.</style></author><author><style face="normal" font="Arial"> Duah,E.</style></author><author><style face="normal" font="Arial"> Patil,P.</style></author><author><style face="normal" font="Arial"> Hexter,M.</style></author><author><style face="normal" font="Arial"> Phillips,D.</style></author><author><style face="normal" font="Arial"> Thodeti,C.K.</style></author><author><style face="normal" font="Arial"> Paruchuri,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemistry, University of Akron, Akron, Ohio, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mechanosensitive transient receptor potential vanilloid 4 regulates Dermatophagoides farinae-induced airway remodeling via 2 distinct pathways modulating matrix synthesis and degradation</style></title><secondary-title><style face="normal" font="Arial">FASEB J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">FASEB J</style></full-title></periodical><pages end="1570" start="1556">1556-1570</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fibroblasts</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Plasminogen</style></keyword><keyword><style face="normal" font="Arial"> Plasminogen activator inhibitor 1</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary fibrosis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">Contributions of mechanical signals to airway remodeling during asthma are poorly understood. Transient receptor potential vanilloid 4 (TRPV4), a mechanosensitive ion channel, has been implicated in cardiac and pulmonary fibrosis; however, its role in asthma remains elusive. Employing a Dermatophagoides farinae-induced asthma model, we report here that TRPV4 knockout mice were protected from D. farinae-induced airway remodeling. Furthermore, lung fibroblasts that were isolated from TRPV4 knockout mice showed diminished differentiation potential compared with wild-type mice. Fibroblasts from asthmatic lung exhibited increased TRPV4 activity and enhanced differentiation potential compared with normal human lung fibroblasts. Of interest, TGF-beta1 treatment enhanced TRPV4 activation in a PI3K-dependent manner in normal human lung fibroblasts in vitro Mechanistically, TRPV4 modulated matrix remodeling in the lung via 2 distinct but dependent pathways: one enhances matrix deposition by fibrotic gene activation, whereas the other slows down matrix degradation by increased plasminogen activator inhibitor 1. Of importance, both pathways are regulated by Rho/myocardin-related transcription factor-A and contribute to fibroblast differentiation and matrix remodeling in the lung. Thus, our results support a unique role for TRPV4 in D. farinae-induced airway remodeling and warrant further studies in humans for it to be used as a novel therapeutic target in the treatment of asthma.-Gombedza, F., Kondeti, V., Al-Azzam, N., Koppes, S., Duah, E., Patil, P., Hexter, M., Phillips, D., Thodeti, C. K., Paruchuri, S. Mechanosensitive transient receptor potential vanilloid 4 regulates Dermatophagoides farinae-induced airway remodeling via 2 distinct pathways modulating matrix synthesis and degradation</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1530-6860 (Electronic)IS - 0892-6638 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1096/fj.201601045R</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28073835">PM:28073835</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FASEB J\20170111-GombedzaF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FASEB J\20170111-GombedzaF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Gombedza F</style></custom2><misc3><style face="normal" font="Arial">10.1096/fj.201601045R</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,S.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Liang,B.</style></author><author><style face="normal" font="Arial"> Dong,H.</style></author><author><style face="normal" font="Arial"> Yao,S.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Xie,Y.</style></author><author><style face="normal" font="Arial"> Long,Y.</style></author><author><style face="normal" font="Arial"> Gong,S.</style></author><author><style face="normal" font="Arial"> Zhou,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No.318 Renminzhong Road, Yuexiu, Guangzhou, Guangdong, People's Republic of China.</style></auth-address><titles><title><style face="normal" font="Arial">Systemic and mucosal pre-administration of recombinant Helicobacter pylori neutrophil-activating protein prevents ovalbumin-induced allergic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">FEMS Microbiol Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">FEMS Microbiol Lett</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE serum level</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Previous epidemiologic studies have demonstrated an inverse association between Helicobacter pylori infection and the frequency of allergic asthma. The neutrophil-activating protein (NAP) of Helicobacter pylori has been identified as a modulator possessing anti-Th2 inflammation activity. Here, we sought to determine whether systemic or mucosal pre-administration of recombinant Helicobacter pylori NAP (rNAP) could prevent ovalbumin-induced allergic asthma in mice. METHODS: Mice were exposed to purified rNAP through intraperitoneal injection or inhalation and then sensitized with ovalbumin. Following a challenge with aerosolized ovalbumin, the bronchoalveolar lavage fluid (BALF) cell count, lung tissue histology, BALF cytokines, and serum IgE were evaluated. RESULTS: Both intraperitoneal injection and inhalation of rNAP prior to OVA sensitization significantly reduced eosinophil accumulation and inflammatory infiltration in lung tissue in OVA-induced asthma mice; eosinophils were reduced in the BALF of rNAP-treated mice. In addition, IL-4 and IL-13 levels were lower (P&lt;0.01), IL-10 and IFN-gamma levels were higher (P&lt;0.01), and IgE serum levels were lower (P&lt;0.01) in the treated groups compared to the control group. CONCLUSIONS: systemic and mucosal pre-administration of rNAP could suppress the development of OVA-induced asthma in mice, rNAP may be utilized as part of novel strategies for the prevention or treatment of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 1574-6968 (Electronic)IS - 0378-1097 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1093/femsle/fnw288</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087613">PM:28087613</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FEMS Microbiol Lett\20170114-ZhouS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FEMS Microbiol Lett\20170114-ZhouS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170114, Zhou S</style></custom2><misc3><style face="normal" font="Arial">10.1093/femsle/fnw288</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomez-Morales,M.A.</style></author><author><style face="normal" font="Arial"> Castro,C.M.</style></author><author><style face="normal" font="Arial"> Lalle,M.</style></author><author><style face="normal" font="Arial"> Fernandez,R.</style></author><author><style face="normal" font="Arial"> Pezzotti,P.</style></author><author><style face="normal" font="Arial"> Abollo,E.</style></author><author><style face="normal" font="Arial"> Pozio,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">UV-press method versus artificial digestion method to detect Anisakidae L3 in fish fillets: Comparative study and suitability for the industry</style></title><secondary-title><style face="normal" font="Arial">Fish Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Fish Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alternative methods</style></keyword><keyword><style face="normal" font="Arial"> Anisakid larvae</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis pegreffii</style></keyword><keyword><style face="normal" font="Arial"> Artificial digestion method</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> digestion method</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> false negative</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish muscle</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> inspection</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscles</style></keyword><keyword><style face="normal" font="Arial"> Ring trial</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Transferability</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UV press method</style></keyword><keyword><style face="normal" font="Arial"> UV-Press method</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0165-7836</style></isbn><abstract><style face="normal" font="Arial">To screen the presence of Anisakidae third stage larvae (L3) in fish, fast methods such as the visual inspection and candling have been widely used by the industry over the last 50 years, and they are regulated by the European Parliament and the Council. These methods are ineffective to detect L3 embedded in fish muscles, consequently alternative methods, such as the artificial digestion (AD) and the UV-Press (UVP) are increasingly applied, but their performance needs to be evaluated. The aims of the present work were: 1) to compare the performance of AD and UVP. methods by a Ring Trial (RT) involving highly experienced laboratories; and 2) to evaluate the potential transferability of the best performing method to the industry by a collaborative study involving industrial partners (+¦-testing). For RT, each participating laboratory (n = 5) received 6 samples of 100 g of fish fillets spiked with 1 L3 (1 sample), 3 L3 (2 samples), 7 L3 (2 samples), and a negative control sample (without L3). In each positive sample, there were live Anisakis pegreffii L3 collected from a naturally infected fish. The result evaluation was based on the agreement between the number of reported and the number of spiked L3. No false positive sample was detected. The L3 number detected by the UVP method showed higher (90%) level of agreement with the number of spiked L3 than the number of L3 detected by the AD method (83.3%); however, no significant difference in terms of accuracy (p = 0.32) was detected when the two methods were compared. Moreover, considering only the presence/absence of L3 in the samples, the UVP reached 100% of accuracy and 100% of sensitivity; whereas, AD showed 98% of accuracy and 96% of sensitivity. The variability of the UVP method was lower than that of the AD method, indicating a better reproducibility. On the basis of the RT results, the UVP method was selected for the +¦-testing. Each industrial partner (n = 3) received 15 samples of 100 g of fish fillet spiked with 1 L3 (2 samples), 2 L3 (2 samples), 3 L3 (2 samples), 4 L3 (2 samples), 5 L3 (2 samples) and 6 L3 (2 samples) and three negative control samples (without L3). The number of L3 counted in 34 out of 45 samples (75.6%) by the UVP method was in agreement with the number of spiked L3. One company reached 93.3% of agreement; whereas the other two companies reached an agreement of 66.7%. Two false negative results were found; whereas, no false positive results were obtained. Moreover, at the industrial level, considering only the presence/absence of larvae in the samples, the UVP reached 97% of accuracy, 94.4% of sensitivity, and 100% of specificity. However, the UVP method, in spite of its accuracy, needs further investigations to provide new time </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆtemperature combinations that could allow a reduction of the testing time and its integration in the fishing deck</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fishres.2016.12.011</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.fishres.2016.12.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Fish Res\20170207-GomezMoralesMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Fish Res\20170207-GomezMoralesMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Gomez-Morales MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fishres.2016.12.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wan,K.S.</style></author><author><style face="normal" font="Arial"> Wu,W.F.</style></author><author><style face="normal" font="Arial"> Liu,Y.C.</style></author><author><style face="normal" font="Arial"> Huang,C.S.</style></author><author><style face="normal" font="Arial"> Wu,C.S.</style></author><author><style face="normal" font="Arial"> Hung,C.W.</style></author><author><style face="normal" font="Arial"> Chang,Y.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of food allergens on asthma exacerbations in schoolchildren with atopic asthma</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="314" start="310">310-314</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch test</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch tests</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical criteria</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">Although the prevalence with which food causes asthma is not well known, food allergy is implicated in a variety of respiratory symptoms. Eighty-two asthmatic children aged 6?16 years with doctor-diagnosed sensitization to inhalants and presenting with asthma exacerbation participated in this study of food allergies linked to asthma exacerbations. The diagnosis of food allergy was established using a questionnaire, clinical criteria, serum-specific IgE antibody measurements, and an atopy patch test. Asthma exacerbation was determined using fractional exhaled nitric oxide management after the children were admitted to the hospital. On the basis of questionnaire data, suspected food allergy was identified in 59.8% children. The positive and negative rates of serum food-specific IgE tests were 54.9% and 45.1%, respectively. The results of atopy patch tests in radioallergosorbent-positive participants were 88.9% positive and 12.5% negative. Food allergy is a risk factor for asthma exacerbation, and evaluation of food allergy in selected patients with asthma is indicated</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2016.1270260</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2016.1270260</url></web-urls><pdf-urls><url ppv-ref="no">gwan1998@gmail.com</url></pdf-urls><text-urls><url ppv-ref="no">presto - 18 mesi</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Wan KS</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2016.1270260</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,S.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Tong,P.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development of sandwich ELISA for testing bovine +¦-lactoglobulin allergenic residues by specific polyclonal antibody against human IgE binding epitopes</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="40" start="33">33-40</pages><volume><style face="normal" font="Arial">227</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic residues</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine +¦-lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> Infant formulas</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergens</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">Bovine +¦-lactoglobulin (BLG) is the main allergen in cows' milk, and the most commonly used method for detecting BLG is enzyme-linked immunosorbent assay (ELISA). However, antibodies used in commercial ELISA kits do not recognize specifically BLG IgE epitopes. Here, an antibody specific to IgE linear epitopes for BLG was used to develop a sandwich ELISA using a rabbit anti-BLG polyclonal antibody. The linear range for BLG detection was 31.25</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô8,000 ng/mL and limit of detection was 1.96 ng/mL. BLG content in dairy samples was determined, and there was a good agreement between this immunoassay and reversed-phase high-performance liquid chromatography with high recovery. Additionally, BLG content in food samples had an average recovery of 104.25%. Allergenic residues were also detected in hydrolyzed infant formulas. The method developed could be a practical approach to determine BLG and its allergenic residues in food with a high degree of sensitivity, reliability and recovery</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.01.060</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.foodchem.2017.01.060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\20170207-HeS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\20170207-HeS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, He S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.01.060</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Selb,R.</style></author><author><style face="normal" font="Arial"> Wal,J.M.</style></author><author><style face="normal" font="Arial"> Moreno,F.J.</style></author><author><style face="normal" font="Arial"> Lovik,M.</style></author><author><style face="normal" font="Arial"> Mills,C.</style></author><author><style face="normal" font="Arial"> Hoffmann-Sommergruber,K.</style></author><author><style face="normal" font="Arial"> Fernandez,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">European Food Safety Authority, Parma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of endogenous allergenicity of genetically modified plants exemplified by soybean - Where do we stand?</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="148" start="139">139-148</pages><volume><style face="normal" font="Arial">101</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">According to EU regulation, genetically modified (GM) plants considered to be allergenic have to be assessed concerning their endogenous allergens before placement on the EU market, in line with the international standards described in Codex Alimentarius. Under such premises, a quantitative relevant increase in allergens might occur in GM plants as an unintended effect compared with conventionally produced crops, which could pose a risk to consumers. Currently, data showing a connection between dose and allergic sensitisation are scarce since the pathophysiological mechanisms of sensitisation are insufficiently understood. In contrast, data on population dose-distribution relationships acquired by oral food challenge are available showing a connection between quantity of allergenic protein consumed and the population of allergic individuals experiencing reactions. Soybean is currently the only recognised allergenic GM food by law for which EFSA has received applications and was therefore taken as an example for defining an assessment strategy. Identification of potential allergens, methodology for quantification as well as risk assessment considerations, are discussed. A strategy is proposed for the identification, assessment and evaluation of potential hazards/risks concerning endogenous allergenicity in food derived from plants developed by biotechnology. This approach could be expanded to other allergenic foods in the future, whenever required</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - France -CO - Spain -CO - Norway -CO - United Kingdom -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2017.01.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28111299">PM:28111299</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2017-101-139-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2017-101-139-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170123, Selb R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2017.01.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lv,L.</style></author><author><style face="normal" font="Arial"> Lin,H.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Ahmed,I.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Food Science and Engineering, Ocean University of China, No. 5, Yu Shan Road, Qingdao, Shandong Province 266003, P.R. China.Qingdao Municipal Hospital, Qingdao, 266011, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Changes of structure and IgE binding capacity of shrimp (Metapenaeus ensis) tropomyosin followed by acrolein treatment</style></title><secondary-title><style face="normal" font="Arial">Food Funct</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Funct</style></full-title></periodical><pages end="1036" start="1028">1028-1036</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acrolein</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Amines</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> fluorescence spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Histidine</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lysine</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="Arial">Tropomyosin, a major allergen of shrimp, presents high stability to various conditions owing to the high content of alpha-helix. Chemical modification of tropomyosin can induce structural changes and affects IgE binding capacity. Since lipid peroxidant such as acrolein commonly exists during shrimp preservation, it is necessary to evaluate its influence on tropomyosin structure and IgE binding capacity. Western blot and inhibition enzyme-linked immunosorbent assay were used to illustrate IgE binding capacity, while structural changes were investigated by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and fluorescence spectroscopy. Results revealed that IgE binding capacity reduced and the secondary structure denatured following treatment with increasing concentration of acrolein. Furthermore, the identification of LC-MS/MS indicated that the free amines of lysine, tyrosine, and histidine residues were altered by acrolein. These amino acid modifications resulted in the collapse of epitopes, as well as structural changes responsible for the decreased IgE binding capacity of shrimp tropomyosin</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 2042-650X (Electronic)IS - 2042-6496 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1039/c6fo01479h</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28128383">PM:28128383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Funct\20170127-LvL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Funct\20170127-LvL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Lv L</style></custom2><misc3><style face="normal" font="Arial">10.1039/c6fo01479h</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kostadinova,A.I.</style></author><author><style face="normal" font="Arial"> Meulenbroek,L.A.</style></author><author><style face="normal" font="Arial"> Van Esch,B.C.</style></author><author><style face="normal" font="Arial"> Hofman,G.A.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Willemsen,L.E.</style></author><author><style face="normal" font="Arial"> Knippels,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands; Immunology, Nutricia Research, Utrecht, Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">A Specific Mixture of Fructo-Oligosaccharides and Bifidobacterium breve M-16V Facilitates Partial Non-Responsiveness to Whey Protein in Mice Orally Exposed to beta-Lactoglobulin-Derived Peptides</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="673">673-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acute allergic skin response</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium breve</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Oral tolerance is a promising approach for allergy prevention in early life, but it strongly depends on allergen exposure and proper immune environment. Small tolerance-inducing peptides and dietary immunomodulatory components may comprise an attractive method for allergy prevention in at-risk infants. This study aimed to investigate whether early oral exposure to beta-lactoglobulin-derived peptides (BLG-peptides) and a specific synbiotic mixture of short- and long- chain fructo-oligosaccharides (scFOS/lcFOS, FF) and Bifidobacterium breve (Bb) M-16V (FF/Bb) can prevent cow's milk allergy (CMA). Three-week-old female C3H/HeOuJ mice were orally exposed to phosphate buffered saline (PBS), whey protein, or a mixture of four synthetic BLG-peptides combined with a FF/Bb-enriched diet prior to intragastric sensitization with whey protein and cholera toxin. To assess the acute allergic skin response and clinical signs of allergy, mice were challenged intradermally with whole whey protein. Serum immunoglobulins were analyzed after a whey protein oral challenge. Cytokine production by allergen-reactivated splenocytes was measured and changes in T cells subsets in the spleen, mesenteric lymph nodes, and intestinal lamina propria were investigated. Pre-exposing mice to a low dosage of BLG-peptides and a FF/Bb-enriched diet prior to whey protein sensitization resulted in a significant reduction of the acute allergic skin response to whey compared to PBS-pretreated mice fed a control diet. Serum immunoglobulins were not affected, but anaphylactic symptom scores remained low and splenocytes were non-responsive in whey-induced cytokine production. In addition, preservation of the Th1/Th2 balance in the small intestine lamina propria was a hallmark of the mechanism underlying the protective effect of the BLG-peptides-FF/Bb intervention. Prior exposure to BLG-peptides and a FF/Bb-enriched diet is a promising approach for protecting the intestinal Th1/Th2 balance and reducing the allergic response to whole whey protein. Therefore, it might have implications for developing successful nutritional strategies for CMA prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2016.00673</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28127297">PM:28127297</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2016-7-673.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2016-7-673.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Kostadinova AI</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2016.00673</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rossi,A.</style></author><author><style face="normal" font="Arial"> Caiazzo,E.</style></author><author><style face="normal" font="Arial"> Bilancia,R.</style></author><author><style face="normal" font="Arial"> Riemma,M.A.</style></author><author><style face="normal" font="Arial"> Pagano,E.</style></author><author><style face="normal" font="Arial"> Cicala,C.</style></author><author><style face="normal" font="Arial"> Ialenti,A.</style></author><author><style face="normal" font="Arial"> Zjawiony,J.K.</style></author><author><style face="normal" font="Arial"> Izzo,A.A.</style></author><author><style face="normal" font="Arial"> Capasso,R.</style></author><author><style face="normal" font="Arial"> Roviezzo,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacy, University of Naples Federico II Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Salvinorin A Inhibits Airway Hyperreactivity Induced by Ovalbumin Sensitization</style></title><secondary-title><style face="normal" font="Arial">Front Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pharmacol</style></full-title></periodical><pages end="" start="525">525-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> bronchial reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Central Nervous System</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> lipid mediators</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Salvia</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Salvinorin A, a neoclerodane diterpene isolated from Salvia divinorum, exerts a number of pharmacological actions which are not solely limited to the central nervous system. Recently it has been demonstrated that Salvinorin A inhibits acute inflammatory response affecting leukotriene (LT) production. Since LTs are potent lipid mediators implicated in allergic diseases, we evaluated the effect of Salvinorin A on allergic inflammation and on airways following sensitization in the mouse. Mice were sensitized with s.c. injection of ovalbumin (OVA) on days 1 and 8. Sensitized mice received on days 9 and 12 on the shaved dorsal surface air administration to induce the development of the air-pouches. On day 15 animals were challenged by injection of OVA into the air-pouch. Salvinorin A, administered (10 mg/kg) before each allergen exposure, significantly reduced OVA-induced LT increase in the air pouch. This effect was coupled to a reduction in cell recruitment and Th2 cytokine production. In another set of experiments, mice were sensitized with OVA and both bronchial reactivity and pulmonary inflammation were assessed. Salvinorin A abrogated bronchial hyperreactivity and interleukin (IL)-13 production, without effect on pulmonary inflammation. Indeed cell infiltration and peribronchial edema were still present following diterpenoid treatment. Similarly, pulmonary IL-4 and plasmatic IgE levels were not modulated. Conversely, Salvinorin A significantly reduced LTC4 production in the lung of sensitized mice. Finally mast cell activity was evaluated by means of toluidine blue staining. Data obtained evidenced that Salvinorin A significantly inhibited mast cell degranulation in the lung. Our study demonstrates that Salvinorin A inhibits airway hyperreactivity induced by sensitization by inhibition of LT production and mast cell degranulation. In conclusion Salvinorin A could represent a promising candidate for drug development in allergic diseases such as asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3389/fphar.2016.00525</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28133450">PM:28133450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pharmacol\2016-7-525.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pharmacol\2016-7-525.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Rossi A</style></custom2><misc3><style face="normal" font="Arial">10.3389/fphar.2016.00525</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jones,B.L.</style></author><author><style face="normal" font="Arial"> Sherwin,C.M.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Dai,H.</style></author><author><style face="normal" font="Arial"> Vyhlidal,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics University of Missouri-Kansas City, Children's Mercy Hospitals and ClinicsKansas City, MO, USA; Division of Pediatric Pharmacology and Therapeutic Innovation, Children's Mercy Hospitals and ClinicsKansas City, MO, USA; Division of Allergy, Asthma and Clinical Immunology, Children's Mercy Hospitals and ClinicsKansas City, MO, USA</style></auth-address><titles><title><style face="normal" font="Arial">Genetic Variation in the Histamine Production, Response, and Degradation Pathway Is Associated with Histamine Pharmacodynamic Response in Children with Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pharmacol</style></full-title></periodical><pages end="" start="524">524-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">African American</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA isolation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> Genetic Variation</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Iontophoresis</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Introduction: There is growing knowledge of the wide ranging effects of histamine throughout the body therefore it is important to better understand the effects of this amine in patients with asthma. We aimed to explore the association between histamine pharmacodynamic (PD) response and genetic variation in the histamine pathway in children with asthma. Methods: Histamine Iontophoresis with Laser Doppler Monitoring (HILD) was performed in children with asthma and estimates for area under the effect curve (AUEC), maximal response over baseline (Emax), and time of Emax (Tmax) were calculated using non-compartmental analysis and non-linear mixed-effects model with a linked effect PK/PD model. DNA isolation and genotyping were performed among participants to detect known single nucleotide polymorphisms (SNPs) (n = 10) among genes (HDC, HNMT, ABP1, HRH1, HRH4) within the histamine pathway. General linear model was used to identify associations between histamine related genetic variants and measured histamine PD response parameters. Results: Genotyping and HILD response profiles were completed for 163 children. ABP1 47 C/T, ABP1 4107, and HNMT-1639 C/Twere associated with Emax (ABP1 47 CC genotype mean Emax 167.21 vs. CT/TT genotype mean Emax 139.20, p = 0.04; ABP1 4107 CC genotype mean Emax 141.72 vs. CG/GG genotype mean Emax 156.09, p = 0.005; HNMT-1639 CC genotype mean Emax 132.62 vs. CT/TT genotype mean Emax 155.3, p = 0.02). In a stratified analysis among African American children only, ABP1 and HNMT SNPs were also associated with PD response; HRH4 413 CC genotype was associated with lower Emax, p = 0.009. Conclusions: We show for the first time that histamine pathway genetic variation is associated with measureable changes in histamine response in children with asthma. The variability in histamine response and impact of histamine pathway genotype is important to further explore in patients with asthma so as to improve disease phenotyping leading to more personalized treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3389/fphar.2016.00524</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101058">PM:28101058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pharmacol\2016-7-524.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pharmacol\2016-7-524.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Jones BL</style></custom2><misc3><style face="normal" font="Arial">10.3389/fphar.2016.00524</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Landschoot,S.</style></author><author><style face="normal" font="Arial"> Vandecasteele,M.</style></author><author><style face="normal" font="Arial"> De Baets,B.</style></author><author><style face="normal" font="Arial"> Hofte,M.</style></author><author><style face="normal" font="Arial"> Audenaert,K.</style></author><author><style face="normal" font="Arial"> Haesaert,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Applied Bioscience Engineering, Faculty of Bioscience Engineering, Ghent University, Valentin Vaerwyckweg 1, 9000 Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">Identification of A. arborescens, A. grandis, and A. protenta as new members of the European Alternaria population on potato</style></title><secondary-title><style face="normal" font="Arial">Fungal Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Fungal Biol</style></full-title></periodical><pages end="188" start="172">172-188</pages><volume><style face="normal" font="Arial">121</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Alt a 1</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Calmodulin</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth rate</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Alternaria species, primarily the small-spored Alternaria alternata and the large-spored Alternaria solani, are considered a serious threat to potato cultivation. To develop control strategies, it is important to gain insight into the Alternaria population. Based on the sequence analyses of the internal transcribed spacer region (ITS) and the glyceraldehyde-3-phosphate dehydrogenase gene, the small-spored and large-spored Alternaria isolates could be separated from each other. Sequence analyses of the calmodulin gene and the RNA polymerase second largest subunit showed that besides A. solani also A. grandis and A. protenta were present in the large-spored Alternaria population. Sequence analyses of the Alternaria major allergen gene Alt a 1 and the elongation factor-alpha revealed that both A. alternata and species belonging to the Alternaria arborescens species complex were present in the small-spored Alternaria population. Furthermore, according to the histone h3 sequence the members of the A. arborescens species complex could be subdivided into two groups. Concerning the fitness, it was concluded that the mycelium growth rate of the large-spored isolates was significantly lower compared to the growth rate of the small-spored isolates. In contrast, the spore-germinating capacity and early growth of the large-spored isolates was greater compared to those of the small-spored isolates. Within the groups of small-spored and large-spored isolates there were no significant differences in fitness between the species</style></abstract><notes><style face="normal" font="Arial">DA - 20170116IS - 1878-6146 (Print)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.funbio.2016.11.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28089048">PM:28089048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Fungal Biol\2017-121-172-88.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Fungal Biol\2017-121-172-88.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170116, Landschoot S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.funbio.2016.11.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Njokuocha,R.C.</style></author><author><style face="normal" font="Arial"> Agwu,C.O.C.</style></author><author><style face="normal" font="Arial"> Okezie,C.E.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of weather conditions on selected airborne fungal spores in the southern part of the state of Enugu, Nigeria</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="272" start="263">263-272</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> airborne fungal spore</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Curvularia</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Ganoderma</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Factors</style></keyword><keyword><style face="normal" font="Arial"> Nigeria</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen trap</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> spore count</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Ustilago</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">A study of airborne fungal spore was carried out at nine locations in the southern part of the state of Enugu, Nigeria, from March 2005 to February 2006. The aim of the study was to ascertain the variations in selected fungal spore types at the sites owing to weather conditions. The variation in airborne fungal spores of 14 taxa was studied using modified Tauber pollen traps including Alternaria, Corynespora, Curvularia, Drechslera type, Endophragmiella, Botryodiplodia, Ganoderma, Gliomastrix, Nigrospora, Pithomyces, Spegazzinia, Sporidesmium, Tetraploa and Ustilago. The frequency of the spore types recorded showed considerable variation. The highest spore counts were recorded in July, June and October. The highest numbers of fungal spores were recorded during the rainy season (June?October) to early dry season (November?December). The peak of occurrence of most selected fungal spore types was July. The highest percentages of fungal spores were documented at the recording stations Mgbowo Junction, UNTH Ituku Ozalla and Oji River Express Junction. Spearman?s correlation analyses were performed for the monthly amounts of the fungal spore types and monthly meteorological factors. The numbers of Curvularia, Nigrospora and Sporidesmium was significantly correlated with relative humidity, while those of Endophragmiella, Pithomyces and Nigrospora were significantly correlated with temperature. A significant correlation was also found between the number of Nigrospora spores and light intensity and Sporidesmium spores and wind velocity. Relative humidity and temperature seem to be the most important weather conditions affecting the frequency of the selected spore types in the atmosphere</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Nigeria -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2016.1248859</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2016.1248859</url></web-urls><pdf-urls><url ppv-ref="no">reginald.njokuocha@unn.edu.ng</url></pdf-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="Arial">20170205, Njokuocha RC</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2016.1248859</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Church,M.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Chariteplatz 1, D-10117, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Allergy, Histamine and Antihistamines</style></title><secondary-title><style face="normal" font="Arial">Handb Exp Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Handb Exp Pharmacol</style></abbr-1></periodical><pages end="331" start="321">321-331</pages><volume><style face="normal" font="Arial">241</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> H1 receptor</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Roots</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">This chapter concentrates on the role in allergic disease of histamine acting on H1-receptors. It is clear that allergy has its roots in the primary parasite rejection response in which mast cell-derived histamine creates an immediate hostile environment and eosinophils are recruited for killing. This pattern is seen in allergic rhinitis where the early events of mucus production and nasal itching are primarily histamine mediated whereas nasal blockage is secondary to eosinophil infiltration and activation. In asthma, the role of histamine is less clear. Urticaria is characterized by mast cell driven pruritic wheal and flare-type skin reactions that usually persist for less than 24 h. Although the events leading to mast cell degranulation have been unclear for many years, it is now becoming evident that urticaria has an autoimmune basis. Finally, the properties of first- and second-generation H1-antihistamines and their role in allergic is discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 0171-2004 (Print)IS - 0171-2004 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/164_2016_85</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101683">PM:28101683</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Handb Exp Pharmacol\20170119-ChurchMK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Handb Exp Pharmacol\20170119-ChurchMK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Church MK</style></custom2><misc3><style face="normal" font="Arial">10.1007/164_2016_85</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brehler,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Hautkrankheiten, Ambulanz fur Allergologie, Berufsdermatologie und Umweltmedizin, Universitatsklinikum Munster, Von-Esmarch-Str. 58, 48149, Munster, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Adjuvants]</style></title><secondary-title><style face="normal" font="Arial">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hautarzt</style></full-title></periodical><pages end="296" start="292">292-296</pages><volume><style face="normal" font="Arial">68</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> target cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="Arial">It is estimated that only 5% of all patients who can principally benefit from specific immunotherapy (SIT) undergo this treatment. SIT represents the only curative treatment for allergic disorders and efficacy has been demonstrated with various allergens. There is an urgent demand for the development of safe preparations with enhanced efficacy achievable by only a few administrations. Adjuvants are pharmacological or immunological acting molecules modifying the specific immunological response to allergens. In vaccine technology, adjuvants are broadly used to enhance immunogenicity of highly purified antigens with low immune stimulating activity. Adjuvants may target to a retarded allergen release, a modulation of the immune system, or can be used as vector systems to transport allergens and adjuvants effectively to target cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170128IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00105-017-3935-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28130604">PM:28130604</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hautarzt\20170128-BrehlerR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hautarzt\20170128-BrehlerR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170128, Brehler R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00105-017-3935-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grifantini,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Knowing What You Eat: Researchers Are Looking for Ways to Help People Cope with Food Allergies</style></title><secondary-title><style face="normal" font="Arial">IEEE Pulse</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">IEEE Pulse</style></abbr-1></periodical><pages end="34" start="31">31-34</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> admissions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Food allergies and sensitivities have always been a public health problem but are becoming more prevalent worldwide. The U.S. Food and Drug Administration (FDA) reports that millions of Americans have allergic reactions to food each year. More than 17 million Europeans have a food allergy, and hospital admissions for severe reactions in children have risen sevenfold over the past decade, according to the European Academy of Allergy and Clinical Immunology</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 2154-2317 (Electronic)IS - 2154-2287 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1109/MPUL.2016.2592239</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28113166">PM:28113166</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\IEEE Pulse\2016-7-31-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\IEEE Pulse\2016-7-31-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170123, Grifantini K</style></custom2><misc3><style face="normal" font="Arial">10.1109/MPUL.2016.2592239</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author><author><style face="normal" font="Arial"> Comite,P.</style></author><author><style face="normal" font="Arial"> Bruzzone,M.</style></author><author><style face="normal" font="Arial"> Fontana,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Can pan-allergens affect the sensitization pattern?</style></title><secondary-title><style face="normal" font="Arial">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunobiology</style></full-title></periodical><pages end="729" start="726">726-729</pages><volume><style face="normal" font="Arial">222</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 2</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Genoa</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> pan-allergen</style></keyword><keyword><style face="normal" font="Arial"> Pan-allergens</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Pru p 1</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Pru p 4</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> TA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0171-2985</style></isbn><abstract><style face="normal" font="Arial">The present study tested the hypothesis that a pan-allergen sensitization may affect the sensitization pattern. For this reason, 22 sensitization pattern allergens (SPA), common in Genoa (Italy), were selected for analyses. Successively, five of them, such as Pru p 3 as representative for LTP family, Bet v 1 and Pru p 1 for PR-10, and Bet v 2 and Pru p 4 for Profilin, were used as target allergens (TA). This retrospective study included 1059 subjects, (396 males and 663 females, mean age 42.8 years). The current study showed that sensitization to a pan-allergen entails higher odds to have other sensitizations. In addition, the co-sensitization pattern depends on the basis of the sensitizing pan-allergen family. LTP-sensitization is strongly associated with peanut sensitization, PR10 and profiling sensitization with hazelnut positivity. This study shows that a pan-allergen sensitization is frequently associated with co-sensitizations and the sensitization pattern depends on the sensitizing pan-allergen</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imbio.2017.01.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28159395">PM:28159395</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunobiology\20170207-CiprandiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunobiology\20170207-CiprandiG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imbio.2017.01.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumar,S.</style></author><author><style face="normal" font="Arial"> Adhikari,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Environmental Health, University of Cincinnati, Cincinnati, OH, USA</style></auth-address><titles><title><style face="normal" font="Arial">Dose-dependent immunomodulating effects of endotoxin in allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Innate Immun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Innate Immun</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> farming environment</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance mechanism</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">How very high exposure levels to endotoxin in a farming environment provide protection against respiratory allergic symptoms and low-to-moderate levels of endotoxin in urban homes promote allergic response is unclear. Dose-specific bacterial endotoxin or LPS-induced tolerance mechanisms can affect lung inflammations, coupled with the Th2 immune responses. Here, we explored the effects of intranasal exposure of LPS at two different doses (based on occupational exposures during handling of agricultural wastes) in OVA-sensitized allergic wild type (WT) and TLR4-KO mice, particularly, with respect to Th2 cytokines and Tregs level. Low-dose LPS (100 ng) exposure prohibited airway tolerance and failed to generate T-cell-dependent protection against lung inflammations in allergic mice. Furthermore, low Tregs at the inflammatory site and induced Th2 cytokines, as well as IL-6 and IL-25, suggested that low-dose LPS might be associated with the suppression of tolerance mechanisms. In contrast, high-dose LPS (20 microg) favored the suppression of Th2 cytokines, IL-6 and IL-25, but failed to induce Th1 cytokines (e.g. IFN-gamma). Our results suggest that low-dose LPS can enhance airway allergic inflammation through failing of antigen-dependent immune regulatory homeostasis. The exposure levels of LPS can determine the generation of inflammatory responses in airway allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170201IS - 1753-4267 (Electronic)IS - 1753-4259 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/1753425917690443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28142300">PM:28142300</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Innate Immun\20170201-KumarS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Innate Immun\20170201-KumarS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170201, Kumar S</style></custom2><misc3><style face="normal" font="Arial">10.1177/1753425917690443</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ye,P.</style></author><author><style face="normal" font="Arial"> Yang,X.L.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Shi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan 430060, China.</style></auth-address><titles><title><style face="normal" font="Arial">Hyperoside attenuates OVA-induced allergic airway inflammation by activating Nrf2</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="173" start="168">168-173</pages><volume><style face="normal" font="Arial">44</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">Allergic airways disease (AAD) is one of the most common medical illnesses that is associated with an increased allergic airway inflammation. Hyperoside, an active compound isolated from Rhododendron brachycarpum G. Don, has been reported to have anti-inflammatory effect. The aim of this study was to analyze the protective effect of hyperoside on OVA-induced allergic airway inflammation in mice. In the present study, the mouse asthma model was induced by given OVA and hyperoside was administrated 1h before OVA challenge. The levels of IL-4, IL-5, IL-13, and IgE were detected by ELISA. H&amp;E staining was used to assess lung histopathological changes. The expression of NF-kappaB p65, IkappaB, HO-1, and Nf-E2 related factor 2 (Nrf2) were measured by western blot analysis. The results showed that hyperoside significantly reduced the inflammatory cells infiltration and the levels of IL-4, IL-5, IL-13, and IgE. Hyperoside significantly inhibited OVA-induced oxidative stress as demonstrated by decreased MDA, and increased GSH and SOD levels. Treatment of hyperoside also inhibited OVA-induced airway hyperresponsiveness (AHR). Furthermore, the results showed that treatment of hyperoside significantly inhibited LPS-induced NF-kappaB activation. In addition, hyperoside was found to activate Nrf2/HO-1 signaling pathway. In conclusion, these results suggest that hyperoside ameliorates OVA-induced allergic airway inflammation by activating Nrf2 signaling pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.01.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107754">PM:28107754</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-44-168-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-44-168-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Ye P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.01.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,S.</style></author><author><style face="normal" font="Arial"> Goyal,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bioinformatics and Medical Informatics Research Center, San Diego State University, 5500 Campanile Dr, San Diego, CA 92182, USA. Electronic address: seemabiotech83@gmail.comDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India. Electronic address: arungoyl@iitg.ernet.in</style></auth-address><titles><title><style face="normal" font="Arial">Chitin and chitinase: Role in pathogenicity, allergenicity and health</style></title><secondary-title><style face="normal" font="Arial">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biol Macromol</style></full-title></periodical><pages end="338" start="331">331-338</pages><volume><style face="normal" font="Arial">97</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chitin</style></keyword><keyword><style face="normal" font="Arial"> Chitinase</style></keyword><keyword><style face="normal" font="Arial"> chitinases</style></keyword><keyword><style face="normal" font="Arial"> Chitosan</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis C</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Informatics</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="Arial">Chitin, a polysaccharide with particular abundance in fungi, nematodes and arthropods is immunogenic. It acts as a threat to other organisms, to tackle which they have been endowed with chitinase enzyme. Even if this enzyme is not present in all organisms, they possess proteins having chitin-binding domain(s) (ChtBD). Many lethal viruses like Ebola, and HCV (Hepatitis C virus) have these domains to manipulate their carriers and target organisms. In keeping with the basic rule of survival, the self-origin (own body component) chitins and chitinases are protective, but that of non-self origin (from other organisms) are detrimental to health. The exogenous chitins and chitinases provoke human innate immunity to generate a deluge of inflammatory cytokines, which injure organs (leading to asthma, atopic dermatitis etc.), and in persistent situations lead to death (multiple sclerosis, systemic lupus erythromatosus (SLE), cancer, etc.). Unfortunately, chitin-chitinase-stimulated hypersensitivity is a common cause of occupational allergy. On the other hand, chitin, and its deacetylated derivative chitosan are increasingly proving useful in pharmaceutical, agriculture, and biocontrol applications. This critical review discusses the complex nexus of chitin and chitinase and assesses both their pathogenic as well as utilitarian aspects</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.01.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093332">PM:28093332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biol Macromol\2017-97-331-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biol Macromol\2017-97-331-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Patel S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.01.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abdelghany,M.</style></author><author><style face="normal" font="Arial"> Subedi,R.</style></author><author><style face="normal" font="Arial"> Shah,S.</style></author><author><style face="normal" font="Arial"> Kozman,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome</style></title><secondary-title><style face="normal" font="Arial">Int J Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Cardiol</style></full-title></periodical><pages end="4" start="1">1-4</pages><volume><style face="normal" font="Arial">232</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic acute coronary syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic angina</style></keyword><keyword><style face="normal" font="Arial"> Allergic myocardial infarction</style></keyword><keyword><style face="normal" font="Arial"> Angina</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Coronary Vasospasm</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Stent thrombosis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Thrombosis</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0167-5273</style></isbn><abstract><style face="normal" font="Arial">Kounis syndrome (KS) is a hypersensitivity coronary disorder induced by exposure to drugs, food, environmental and other triggers. Vasospastic allergic angina, allergic myocardial infarction (MI) and stent thrombosis with occluding thrombus infiltrated by eosinophils and/or mast cells constitute the three main variants of this syndrome. We reviewed 175 patients who fulfilled the definition of one of the three types of KS. The epidemiology, diagnostic findings, management and complications were reviewed in this article</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijcard.2017.01.124</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153536">PM:28153536</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Cardiol\20170207-AbdelghanyM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Cardiol\20170207-AbdelghanyM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Abdelghany M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijcard.2017.01.124</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">MacArthur,K.M.</style></author><author><style face="normal" font="Arial"> Richardson,V.</style></author><author><style face="normal" font="Arial"> Novoa,R.A.</style></author><author><style face="normal" font="Arial"> Stewart,C.L.</style></author><author><style face="normal" font="Arial"> Rosenbach,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Carpet beetle dermatitis: a possibly under-recognized entity</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="579" start="577">577-579</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Beetles</style></keyword><keyword><style face="normal" font="Arial"> carpet</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160411IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Case ReportsPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.12952</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26475226">PM:26475226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\2016-55-577-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\2016-55-577-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160411, MacArthur KM</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.12952</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takikawa,Y.</style></author><author><style face="normal" font="Arial"> Matsuda,Y.</style></author><author><style face="normal" font="Arial"> Nonomura,T.</style></author><author><style face="normal" font="Arial"> Kakutani,K.</style></author><author><style face="normal" font="Arial"> Kusakari,S.I.</style></author><author><style face="normal" font="Arial"> Toyoda,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Plant Center, Institute of Advanced Technology, Kindai University, Wakayama 642-0017, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">An Electrostatic-Barrier-Forming Window that Captures Airborne Pollen Grains to Prevent Pollinosis</style></title><secondary-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria japonica</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="1" Year="2017">2017/1/15</year></dates><abstract><style face="normal" font="Arial">An electrostatic-barrier-forming window (EBW) was devised to capture airborne pollen, which can cause allergic pollinosis. The EBW consisted of three layers of insulated conductor wires (ICWs) and two voltage generators that supplied negative charges to the two outer ICW layers and a positive charge to the middle ICW layer. The ICWs generated an attractive force that captured pollen of the Japanese cedar, Cryptomeria japonica, from air blown through the EBW. The attractive force was directly proportional to the applied voltage. At >/=3.5 kV, the EBW exerted sufficient force to capture all pollen carried at an air flow of 3 m/s, and pollen-free air passed through the EBW. The findings demonstrated that the electrostatic barrier that formed inside the EBW was very effective at capturing airborne pollen; thus, it could allow a home to remain pollen-free and healthy despite continuous pollen exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijerph14010082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098835">PM:28098835</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Environ Res Public Health\20170118-TakikawaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Environ Res Public Health\20170118-TakikawaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Takikawa Y</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijerph14010082</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lai,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China.</style></auth-address><titles><title><style face="normal" font="Arial">Are Cockroaches an Important Source of Indoor Endotoxins?</style></title><secondary-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></full-title></periodical><pages end="" start="E91">E91-</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">Endotoxins are common indoor biocontaminants. Their levels have been shown to link to many sources and factors. One of them is cockroach infestation but the role of cockroaches and contamination mechanisms are unclear. We hypothesized that not only is cockroach infestation a sign of poor hygiene, but it also contributes to indoor endotoxins via fecal contamination. In this study, different cockroach species were caught in homes. The endotoxin and allergen levels and their ratios in cockroach feces were determined. To estimate the amount of indoor endotoxins that originated from cockroaches, a new approach of using these new cockroach endotoxin and allergen ratios to compare with environmental data was employed. We found that Supella (S.) longipalpa, Periplaneta (P.) australasiae, and Blattella (B.) germanica were dominant in homes. On average, P. australasiae feces had a higher level but greater variation of endotoxins. B. germanica feces had the highest levels of allergens measured. Depending on environmental bacterial load and the type of cockroaches present, cockroach endotoxins in the environment may vary greatly. Cockroaches directly contribute to indoor endotoxins rather than just being a sign of poor hygiene. The type and extent of cockroach infestation should be taken into consideration when assessing and remediating indoor endotoxin contamination</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijerph14010091</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28106812">PM:28106812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Environ Res Public Health\20170120-LaiKM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Environ Res Public Health\20170120-LaiKM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Lai KM</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijerph14010091</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Malmborg,A.</style></author><author><style face="normal" font="Arial"> Borrebaeck,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">SenzaGen AB, Medicon Village, S-223 81 Lund, Sweden.</style></auth-address><titles><title><style face="normal" font="Arial">Testing Human Skin and Respiratory Sensitizers-What Is Good Enough?</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E241">E241-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> alternative methods</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic technology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="Arial">Alternative methods for accurate in vitro assessment of skin and respiratory sensitizers are urgently needed. Sensitization is a complex biological process that cannot be evaluated accurately using single events or biomarkers, since the information content is too restricted in these measurements. On the contrary, if the tremendous information content harbored in DNA/mRNA could be mined, most complex biological processes could be elucidated. Genomic technologies available today, including transcriptional profiling and next generation sequencing, have the power to decipher sensitization, when used in the right context. Thus, a genomic test platform has been developed, denoted the Genomic Allergen Rapid Detection (GARD) assay. Due to the high informational content of the GARD test, accurate predictions of both the skin and respiratory sensitizing capacity of chemicals, have been demonstrated. Based on a matured dendritic cell line, acting as a human-like reporter system, information about potency has also been acquired. Consequently, multiparametric diagnostic technologies are disruptive test principles that can change the way in which the next generation of alternative methods are designed</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18020241</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28125016">PM:28125016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\20170126-MalmborgA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\20170126-MalmborgA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Malmborg A</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18020241</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pamornpathomkul,B.</style></author><author><style face="normal" font="Arial"> Wongkajornsilp,A.</style></author><author><style face="normal" font="Arial"> Laiwattanapaisal,W.</style></author><author><style face="normal" font="Arial"> Rojanarata,T.</style></author><author><style face="normal" font="Arial"> Opanasopit,P.</style></author><author><style face="normal" font="Arial"> Ngawhirunpat,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A combined approach of hollow microneedles and nanocarriers for skin immunization with plasmid DNA encoding ovalbumin</style></title><secondary-title><style face="normal" font="Arial">Int J Nanomedicine</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Nanomedicine</style></abbr-1></periodical><pages end="898" start="885">885-898</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Diffusion</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Plasmid</style></keyword><keyword><style face="normal" font="Arial"> plasmid DNA</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin immunization</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The aim of this study was to investigate the use of different types of microneedles (MNs) and nanocarriers for in vitro skin permeation and in vivo immunization of plasmid DNA encoding ovalbumin (pOVA). In vitro skin permeation studies indicated that hollow MNs had a superior enhancing effect on skin permeation compared with solid MN patches, electroporation (EP) patches, the combination of MN and EP patches, and untreated skin. Upon using hollow MNs combined with nanocarriers for pOVA delivery, the skin permeation was higher than for the delivery of naked pOVA, as evidenced by the increased amount of pOVA in Franz diffusion cells and immunoglobulin G (IgG) antibody responses. When the hollow MNs were used for the delivery of nanocarrier:pOVA complexes into the skin of mice, they induced a stronger IgG immune response than conventional subcutaneous (SC) injections. In addition, immunization of mice with the hollow MNs did not induce signs of skin infection or pinpoint bleeding. Accordingly, the hollow MNs combined with a nanocarrier delivery system is a promising approach for delivering pOVA complexes to the skin for promoting successful immunization.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.2147/IJN.S125945</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2147/IJN.S125945</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Nanomedicine\2017-12-885-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Nanomedicine\2017-12-885-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Pamornpathomkul B</style></custom2><misc3><style face="normal" font="Arial">10.2147/IJN.S125945</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hanagata,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nanotechnology Innovation Station, National Institute for Materials Science, Tsukuba, Ibaraki; Graduate School of Life Science, Hokkaido University, Sapporo, Hokkaido, Japan</style></auth-address><titles><title><style face="normal" font="Arial">CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies</style></title><secondary-title><style face="normal" font="Arial">Int J Nanomedicine</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Nanomedicine</style></abbr-1></periodical><pages end="531" start="515">515-531</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cellular immunity</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Nanomedicine</style></keyword><keyword><style face="normal" font="Arial"> Nanotechnology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-Like Receptor 9</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Unmethylated cytosine-guanine dinucleotide-containing oligodeoxynucleotides (CpG ODNs), which are synthetic agonists of Toll-like receptor 9 (TLR9), activate humoral and cellular immunity and are being developed as vaccine adjuvants to prevent or treat cancers, infectious diseases, and allergies. Free CpG ODNs have been used in many clinical trials implemented to verify their effects. However, recent research has reported that self-assembled CpG ODNs, protein/peptide-CpG ODN conjugates, and nanomaterial-CpG ODN complexes demonstrate higher adjuvant effects than free CpG ODNs, owing to their improved uptake efficiency into cells expressing TLR9. Moreover, protein/peptide-CpG ODN conjugates and nanomaterial-CpG ODN complexes are able to deliver CpG ODNs and antigens (or allergens) to the same types of cells, which enables a higher degree of prophylaxis or therapeutic effect. In this review, the author describes recent trends in the research and development of CpG ODN nanomedicines containing self-assembled CpG ODNs, protein/peptide-CpG ODN conjugates, and nanomaterial-CpG ODN complexes, focusing mainly on the results of preclinical and clinical studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170201IS - 1178-2013 (Electronic)IS - 1176-9114 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2147/IJN.S114477</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28144136">PM:28144136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Nanomedicine\2017-12-515-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Nanomedicine\2017-12-515-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170201, Hanagata N</style></custom2><misc3><style face="normal" font="Arial">10.2147/IJN.S114477</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aryan,Z.</style></author><author><style face="normal" font="Arial"> Rezaei,N.</style></author><author><style face="normal" font="Arial"> Camargo,C.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Students' Scientific Research Center, Tehran University of Medical Sciences , Tehran , Iran</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D status, aeroallergen sensitization, and allergic rhinitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Int Rev Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Rev Immunol</style></full-title></periodical><pages end="53" start="41">41-53</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The role of vitamin D status in the etiology of allergic diseases is uncertain. The aim of this study was to investigate the association of vitamin D status with risk of two main outcomes: aeroallergen sensitization and allergic rhinitis (AR). METHODS: We performed a systematic review of Medline, Scopus, Science Citation Index, and Google Scholar databases. Studies were included if they reported on prevalent or incident cases of aeroallergen sensitization or AR according to vitamin D status. Quality assessment, data extraction and meta-analysis were performed. RESULTS: A total of 21 observational studies were included. Children with serum 25(OH)D >/=75 nmol/L had significantly reduced odds of aeroallergen sensitization, but neither vitamin D intake in pregnancy nor vitamin D supplementation in infancy were associated with risk of AR. Individuals with serum 25(OH)D >/=75 nmol/L had lower prevalence of AR compared to those with serum 25(OH)D &lt;50 nmol/L (OR; 0.71, 95%CI; (0.56-0.89), p = 0.04). This association was mainly observed in adult men; prevalence of AR was lower in men with serum 25(OH)D >/=75 nmol/L compared to men with serum 25(OH)D &lt;50 nmol/L, while this association was not observed in women. CONCLUSIONS: The current literature suggests significant age- and sex-specific relations of vitamin D status to risk of aeroallergen sensitization and AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1563-5244 (Electronic)IS - 0883-0185 (Linking)LA - engPT - Journal ArticleCO - Iran -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/08830185.2016.1272600</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102718">PM:28102718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Rev Immunol\20170119-AryanZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Rev Immunol\20170119-AryanZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Aryan Z</style></custom2><misc3><style face="normal" font="Arial">10.1080/08830185.2016.1272600</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grace,M.</style></author><author><style face="normal" font="Arial"> Hunt,D.</style></author><author><style face="normal" font="Arial"> O'B,Hourihane J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatrics and Child Health, University College Cork</style></auth-address><titles><title><style face="normal" font="Arial">The Prevalence of Grass Pollen-Related Allergic Rhinoconjunctivitis in Elite Amateur Irish Athletes</style></title><secondary-title><style face="normal" font="Arial">Ir Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ir Med J</style></full-title></periodical><pages end="" start="448">448-</pages><volume><style face="normal" font="Arial">109</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> athlete</style></keyword><keyword><style face="normal" font="Arial"> Athletes</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> sport</style></keyword><keyword><style face="normal" font="Arial"> Sports</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> validated questionnaire</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="9" Year="2016">2016/9/9</year></dates><abstract><style face="normal" font="Arial">Allergic rhinoconjunctivitis (AR/C), has been shown to impact upon athletic performance. The championships of the unique, amateur Irish sports of hurling and Gaelic football (collectively known as GAA) take place during the prime pollen months of summer. Elite GAA players must perform optimally when most exposed to pollen. Elite GAA subjects (n=254) underwent skin prick testing to 6 aeroallergens and completed a validated questionnaire (AQUA), producing a score indicating likelihood of having allergy. The prevalence of allergy (positive to at least one aeroallergen on SPT and positive AQUA score) was 27.1% (n=69). Sixteen and a half percent (n=42) of the subjects tested had grass pollen AR/C while 22% (n=54) had house dust mite AR/C, though none were on standard medical therapies or had used allergen-specific immunotherapy. Grass pollen AR/C prevalence appears as common in elite Irish athletes as it is in other countries. It appears to be mild rather than well controlled in these subjects</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 0332-3102 (Print)IS - 0332-3102 (Linking)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28124848">PM:28124848</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ir Med J\2016-109-448.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ir Med J\2016-109-448.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Grace M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kianmeher,M.</style></author><author><style face="normal" font="Arial"> Ghorani,V.</style></author><author><style face="normal" font="Arial"> Boskabady,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Neurogenic Inflammation Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Animal Model of Asthma, Various Methods and Measured Parameters: A Methodological Review</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="465" start="445">445-465</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> neurogenic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory disease of the airway with extensive airway remodeling. The ethical issues associated with the studies in asthmatic patients, required development of animal model of asthma. Animal models of asthma can provide valuable information on several features of asthma pathogenesis and treatment. Although these models cannot carry out all clinical features, they are valuable to understand mechanisms of the disease and curative access. Related articles were searched in different databases from September 1994 to April 2016 using; animal model of asthma, animal sensitization, allergen-induced asthma in animals terms. Although there are several reviews on this topic, in the present article, induction of animal model of asthma in different animals, various methods used for this purpose, measured parameters and research purposes were reviewed, which will help investigators to use the appropriate animal, methods, and evaluating parameters depending on their study design. In this study various method used for induction of animal model of asthma in different animals and measured parameters were described, which will help investigators to use the appropriate animal, method and evaluating parameters depending on their study design</style></abstract><notes><style face="normal" font="Arial">DA - 20170128IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28129678">PM:28129678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-445-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-445-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170128, Kianmeher M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caglayan,S.S.</style></author><author><style face="normal" font="Arial"> Karaman,M.</style></author><author><style face="normal" font="Arial"> Cilaker,M.S.</style></author><author><style face="normal" font="Arial"> Isik,S.</style></author><author><style face="normal" font="Arial"> Bagriyanik,A.</style></author><author><style face="normal" font="Arial"> Arikan,A.Z.</style></author><author><style face="normal" font="Arial"> Uzuner,N.</style></author><author><style face="normal" font="Arial"> Anal,O.</style></author><author><style face="normal" font="Arial"> Karaman,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Pediatric Allergy and Immunology, Faculty of Medicine, Dokuz Eylul University, Izmir,Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Quercetin Treatment on Epithelium-derived Cytokines and Epithelial Cell Apoptosis in Allergic Airway Inflammation Mice Model</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="497" start="487">487-497</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Quercetin</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Quercetin is a dietary flavonoid which has anti-inflammatory effects. This study aimed to evaluate the influence of quercetin on histopathological aspects and airway epithelium in allergic airway inflammation mice model. Twenty-eight BALB/c mice were randomly divided into four groups: Group I (control), Group II (untreated mice with allergic airway inflammation), Group III (allergic airway inflammation quercetin-treated [16mg/kg/day]), Group IV (allergic airway inflammation dexamethasone-treated [1mg/kg/day]). Ovalbumin was administered intraperitoneally and via inhalation to achieve allergic airway inflammation mice model and treatments were also given intraperitoneally. Epithelium thickness, subepithelial smooth muscle thickness, number of mast and goblet cells, and basement membrane thickness were examined on samples isolated from lung. Immunohistochemical evaluationof lung tissues was performed using IL-25, IL-33, thymic stromal lymphopoietin (TSLP), terminal deoxynucleotidyl transferase-mediated dUTP nick endlabeling (TUNEL) and cysteine-dependent aspartate-specific proteases(caspase)-3 antibodies. IL-4, IL-25, IL-33, TSLP were quantified in bronchoalveolar lavage (BAL) and OVAspecific IgE levels was measured in serum by standard ELISA protocols. IL-25, IL-33, thymic stromal lymphopoietin (TSLP) and cysteine-dependent aspartate-specific proteases (caspase)-3. Quercetin treatment led to lower epithelial thickness, subepithelial smooth muscle thickness, goblet and mast cell numbers compared to untreated mice with allergic airway inflammation (p&lt;0.05). However, quercetin treatment was not effective on improving basal membane thickness. Immunohistochemical scores of IL-25, IL-33, TSLP, caspase-3 and TUNEL were lower in quercetin-treated mice t compared to untreated mice with allergic airway inflammation (p&lt;0.05). IL-4, IL-25, IL-33, TSLP levels in BAL and OVA-specific IgE in serum were lower in quercetin treated mice compared to untreated mice (p&lt;0.05). These findings suggest that quercetin improves chronic histopathological changes except basal membrane thickness in lung tissue and its beneficial effects on inflammation might be related to modulating epithelium derived cytokines and epithelial apoptosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170128IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28129681">PM:28129681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-487-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-487-97.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170128, Caglayan SS</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khayatzadeh,A.</style></author><author><style face="normal" font="Arial"> Gharaghozlou,M.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author><author><style face="normal" font="Arial"> Shokouhi,S.R.</style></author><author><style face="normal" font="Arial"> Movahedi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">A Safe and Effective Method for Wheat Oral Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="535" start="525">525-535</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">At present the only available management for food allergy is avoidance; however, abstaining from allergic foods can affect the quality of life. Oral Immunotherapy (OIT) is an efficient method for increasing tolerance towards food allergens. The aim of this study was desensitizing patients above five years of age with wheat allergy and evaluating the safety and efficacy of OIT for children with IgE-mediated wheat allergy. The method of Rush Oral Immunotherapy (ROIT) was performed on 8 anaphylactic wheat allergic patients as well as outpatient method on 5 non-anaphylactic ones. In ROIT, build-up phase was performed during several days, but in outpatient, the amount of ingestion gradually increased to 5.2 g wheat protein within several weeks. After that, maintenance doses were prescribed daily for 3 months. Then, if the oral food challenge (OFC) was negative, the patients were considered to be in desensitized state, which meant they had to continue eating same doses without interruption. In ROIT, build-up phase continued for about 4.6 days with 71 doses and 21 patients showed clinical symptoms (29.6%). On the contrary, outpatient method lasted approximately 72.4 days in which 356 doses were used and only 9 patients showed symptoms (2.5%). In total -regardless of type of build-up phase- 12 patients could complete the maintenance phase with 1080 doses that 28 of them (2.6%) developed mild symptoms. Our OIT study proved to be safe and effective, although it is utterly evident that further investigation on more patients is necessary</style></abstract><notes><style face="normal" font="Arial">DA - 20170128IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28129685">PM:28129685</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-525-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2016-15-525-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170128, Khayatzadeh A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Najafi,N.</style></author><author><style face="normal" font="Arial"> Soleymani,E.</style></author><author><style face="normal" font="Arial"> Sarvi,S.</style></author><author><style face="normal" font="Arial"> Marofi,A.</style></author><author><style face="normal" font="Arial"> Nosrati,A.</style></author><author><style face="normal" font="Arial"> Davoodi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Disseminated Strongyloidiasis in an Iranian Immunocompromised Patient: A Case Report</style></title><secondary-title><style face="normal" font="Arial">Iran J Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Parasitol</style></full-title></periodical><pages end="283" start="279">279-283</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Albendazole</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atrophy</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Duodenum</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Gastritis</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Glass</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Larva</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides stercoralis</style></keyword><keyword><style face="normal" font="Arial"> Strongyloidiasis</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="Arial">Strongyloides stercoralis is a soil-transmitted helminth (STH) widespread in various part of the world. A 78-yr-old peasant diabetic female from Mazandaran Province northern Iran, was admitted to Infection Department of the Razi Hospital in city of Qaemshahr, north of Iran complaining about abdominal skin rash, pruritus, itching, anorexia, nausea, vomiting, dysuria and cough. This patient had cutaneous migration effects of S. stercoralis larvae in her abdominal skin (larva currents and urticaria). Lung CT without contrast demonstrate s bilateral diffuse ground glass opacity draws attention. Upper gastrointestinal endoscopy revealed gastro esophageal reflux with antral gastritis. Duodenal endoscopy showed unusual mucosa and a biopsy from it sent to the pathology laboratory. Histopathology of duodenal bulb and duodenum biopsy showed mild villous atrophy and S. stercoralis infection. The patient was treated with albendazole and clinical sings improved completely after treatment. Strongyloidiasis should be carefully considered by clinicians who practice in endemic areas. Clinicians must keep a high level of skepticism for patients from endemic area</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1735-7020 (Print)IS - 1735-7020 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28096866">PM:28096866</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Parasitol\2016-11-279-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Parasitol\2016-11-279-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Najafi N</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shirvan,S.P.</style></author><author><style face="normal" font="Arial"> Borji,H.</style></author><author><style face="normal" font="Arial"> Movassaghi,A.</style></author><author><style face="normal" font="Arial"> Khakzad,M.</style></author><author><style face="normal" font="Arial"> Farzin,H.</style></author><author><style face="normal" font="Arial"> Maleki,M.</style></author><author><style face="normal" font="Arial"> Haghparast,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Anti-inflammatory Potentials of Excretory/Secretory (ES) and Somatic Products of Marshallagia marshalli on Allergic Airway Inflammation in BALB/c Mice</style></title><secondary-title><style face="normal" font="Arial">Iran J Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Parasitol</style></full-title></periodical><pages end="526" start="515">515-526</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Hypertrophy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE serum level</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Inverse relationship between helminths infection and immune-mediated diseases has inspired researchers to investigate therapeutic potential of helminths in allergic asthma. Helminth unique ability to induce immunoregulatory responses has already been documented in several experimental studies. This study was designed to investigate whether excretory/secretory (ES) and somatic products of Marshallagia marshalli modulate the development of ovalbumin-induced airway inflammation in a mouse model. METHODS: This study was carried out at the laboratories of Immunology and Parasitology of Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran during spring and summer 2015. Allergic airway inflammation was induced in mice by intraperitoneal (IP) injection with ovalbumin (OVA). The effects of ES and somatic products of M. marshalli were analyzed by inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF), pathological changes and IgE response. RESULTS: Treatment with ES and somatic products of M. marshalli decreased cellular infiltration into BALF when they were administered during sensitization with allergen. Pathological changes were decreased in helminth-treated group, as demonstrated by reduced inflammatory cell infiltration, goblet cell hyperplasia, epithelial lesion and smooth muscle hypertrophy. However, no significant differences were observed in IgE serum levels, cytokines and eosinophil counts between different groups. CONCLUSION: This study provides new insights into anti-inflammatory effects of ES and somatic products of M. marshalli, during the development of non-eosinophilic model of asthma. Further study is necessary to characterize immunomodulatory molecules derived from M. marshalli as a candidate for the treatment of airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1735-7020 (Print)IS - 1735-7020 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28127363">PM:28127363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Parasitol\2016-11-515-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Parasitol\2016-11-515-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Shirvan SP</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mattison,C.P.</style></author><author><style face="normal" font="Arial"> Rai,R.</style></author><author><style face="normal" font="Arial"> Settlage,R.</style></author><author><style face="normal" font="Arial"> Hinchliffe,D.J.</style></author><author><style face="normal" font="Arial"> Madison,C.</style></author><author><style face="normal" font="Arial"> Bland,J.M.</style></author><author><style face="normal" font="Arial"> Brashear,S.</style></author><author><style face="normal" font="Arial"> Graham,C.J.</style></author><author><style face="normal" font="Arial"> Tarver,M.R.</style></author><author><style face="normal" font="Arial"> Florane,C.</style></author><author><style face="normal" font="Arial"> Bechtel,P.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">RNA-Seq Analysis of Developing Pecan (Carya illinoinensis) Embryos Reveals Parallel Expression Patterns Among Allergen and Lipid Metabolism Genes</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen genes</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Car i 1</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dough</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Embryo</style></keyword><keyword><style face="normal" font="Arial"> Embryogenesis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Linoleic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid Metabolism</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">The pecan nut is a nutrient rich part of a healthy diet full of beneficial fatty acids and antioxidants, but can also cause allergic reactions in people suffering from food allergy to the nuts. The transcriptome of a developing pecan nut was characterized to identify the gene expression occurring during the process of nut development and to highlight those genes involved in fatty acid metabolism and those that commonly act as food allergens. Pecan samples were collected at several time points during the embryo development process including the water, gel, dough, and mature nut stages. Library preparation and sequencing was performed using Illumina based mRNA HiSeq with RNA from 4 time points during the growing season during August and September 2012. Sequence analysis with Trinotate software following the Trinity protocol identified 133,000 unigenes with 52,267 named transcripts and 45,882 annotated genes. A total of 27,312 genes were defined by GO annotation. Gene expression clustering analysis identified 12 different gene expression profiles, each containing a number of genes. Three pecan seed storage proteins that commonly act as allergens, Car i 1, 2, and 4 were significantly upregulated during the time course. Upregulated fatty acid metabolism genes that were identified included acyl-[ACP] desaturase and omega-6 desaturase genes involved in oleic and linoleic acid metabolism. Notably, a few of the upregulated acyl-[ACP] desaturase and omega-6 desaturase genes that were identified have expression patterns similar to the allergen genes based upon gene expression clustering and qPCR analysis. These findings suggest the possibility of coordinated accumulation of lipids and allergens during pecan nut embryogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b04199</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28121438">PM:28121438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170125-MattisonCP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170125-MattisonCP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Mattison CP</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b04199</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsai,J.J.</style></author><author><style face="normal" font="Arial"> Chang,C.Y.</style></author><author><style face="normal" font="Arial"> Liao,E.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison of Allergenicity at Gly m 4 and Gly m Bd 30K of soybean after the genetic modification</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Gly m 4</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> Glycine max</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> GM soybean</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> LC/MS/MS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="30" Month="1" Year="2017">2017/1/30</year></dates><abstract><style face="normal" font="Arial">Despite rapid growth of the genetic modified (GM) crops, effective evaluations of genetic modification on allergenicity are still lacking. Gly m Bd 30 K is cross-reactive with cow milk protein casein, Gly m 4, and with birch pollen allergen Bet v 1. Here we compared the allergenicity between GM and non-GM soybeans with respect to the foci Gly m 4 and Gly m Bd 30K. Recombinant allergens of Gly m Bd 30K and Gly m 4 were generated and polyclonal antibodies raised to identify these two allergenic components in soybeans. GM soybean was first PCR-confirmed using 35S-promoter. A total of 20 soybeans (half GM, half non-GM) obtained from food market were used to assess their allergenicity based on IgE-binding and histamine release. The concentrations of Gly m Bd 30K and Gly m 4 in soybeans were then determined. Most soybean-allergic patients (9 out of 10) showed IgE-positive reactions to the allergen of 30kDa in molecular weight. That allergen turned out to be Glycine max Gly m Bd 30K based on LC/MS/MS analyses. Gly m Bd 30K is therefore the major allergen in the soybean. An increase in the transcription of both the Gly m 4 (stress-induced protein SAM22) and Gly m Bd 28K (soybean allergen precursor) was found after GM. The protein concentrations of Gly m 4 and Gly m Bd 30K were no statistically significant differences between Non-GM and GM soybeans. There were also no statistical significances between them in the tests of IgE binding and histamine release. In conclusions, soybeans showed similar concentrations of Gly m Bd 30K and Gly m 4 regardless of genetically modified or not. The allergenicity of both Gly m Bd 30K and Gly m 4 were therefore not altered after genetic modification. Patients showing hypersensitivity to soybeans and who had pre-existing allergy to birch pollen and cow milk casein might not further increase their allergic reactions following exposures to the GM soybeans</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b05135</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132509">PM:28132509</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170130-TsaiJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170130-TsaiJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Tsai JJ</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b05135</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mishra,P.</style></author><author><style face="normal" font="Arial"> Singh,S.</style></author><author><style face="normal" font="Arial"> Rathinam,M.</style></author><author><style face="normal" font="Arial"> Nandiganti,M.</style></author><author><style face="normal" font="Arial"> Ram Kumar,N.</style></author><author><style face="normal" font="Arial"> Thangaraj,A.</style></author><author><style face="normal" font="Arial"> Thimmegowda,V.</style></author><author><style face="normal" font="Arial"> Krishnan,V.</style></author><author><style face="normal" font="Arial"> Mishra,V.</style></author><author><style face="normal" font="Arial"> Jain,N.</style></author><author><style face="normal" font="Arial"> Rai,V.</style></author><author><style face="normal" font="Arial"> Pattanayak,D.</style></author><author><style face="normal" font="Arial"> Sreevathsa,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparative proteomic and nutritional composition analysis of independent transgenic pigeon pea seeds harboring cry1AcF and cry2Aa genes and their non-transgenic counterparts</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cry genes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Nutritional composition</style></keyword><keyword><style face="normal" font="Arial"> Nutritional composition analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pea</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Substantial equivalence</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Transgenics</style></keyword><keyword><style face="normal" font="Arial"> Unintended effects</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">Safety assessment of genetically modified plants is an important aspect prior to de-regulation. Demonstration of substantial equivalence of the transgenics compared to its non-transgenic counterpart can be performed using various techniques at various molecular levels. The present study is a first ever comprehensive evaluation of pigeon pea transgenics harbouring two independent cry genes, cry2Aa and cry1AcF. The absence of unintended effects in the transgenic seed components was shown by proteome and nutritional composition analysis. Analysis revealed that no significant differences were found in the various nutritional compositional analysis performed. Additionally, 2-DGE-based proteome analysis of the transgenic and non-transgenic seed protein revealed that there were no major changes in the protein profile, though minor fold change in expression of a few proteins was observed. Further, the study also demonstrated that neither the integration of T-DNA nor the expression of the cry genes resulted in production of unintended effects in the form of new toxins or allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b05301</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28114755">PM:28114755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170124-MishraP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170124-MishraP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Mishra P</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b05301</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jones,S.M.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Leung,D.Y.</style></author><author><style face="normal" font="Arial"> Lindblad,R.W.</style></author><author><style face="normal" font="Arial"> Dawson,P.</style></author><author><style face="normal" font="Arial"> Henning,A.K.</style></author><author><style face="normal" font="Arial"> Berin,M.C.</style></author><author><style face="normal" font="Arial"> Chiang,D.</style></author><author><style face="normal" font="Arial"> Vickery,B.P.</style></author><author><style face="normal" font="Arial"> Pesek,R.D.</style></author><author><style face="normal" font="Arial"> Cho,C.B.</style></author><author><style face="normal" font="Arial"> Davidson,W.F.</style></author><author><style face="normal" font="Arial"> Plaut,M.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Wood,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.</style></auth-address><titles><title><style face="normal" font="Arial">Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1252" start="1242">1242-1252</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adherence</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Arkansas</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergy is common, life-threatening, and without therapeutic options. We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut allergy treatment. OBJECTIVE: We sought to evaluate the clinical, safety, and immunologic effects of EPIT for the treatment of peanut allergy. METHODS: In this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 mug (VP100; n = 24) or Viaskin Peanut 250 mug (VP250; n = 25; DBV Technologies, Montrouge, France). The primary outcome was treatment success after 52 weeks, which was defined as passing a 5044-mg protein oral food challenge or achieving a 10-fold or greater increase in successfully consumed dose from baseline to week 52. Adverse reactions and mechanistic changes were assessed. RESULTS: At week 52, treatment success was achieved in 3 (12%) placebo-treated participants, 11 (46%) VP100 participants, and 12 (48%) VP250 participants (P = .005 and P = .003, respectively, compared with placebo; VP100 vs VP250, P = .48). Median change in successfully consumed doses were 0, 43, and 130 mg of protein in the placebo, VP100, and VP250 groups, respectively (placebo vs VP100, P = .014; placebo vs VP250, P = .003). Treatment success was higher among younger children (P = 0.03; age, 4-11 vs >11 years). Overall, 14.4% of placebo doses and 79.8% of VP100 and VP250 doses resulted in reactions, predominantly local patch-site and mild reactions (P = .003). Increases in peanut-specific IgG4 levels and IgG4/IgE ratios were observed in peanut EPIT-treated participants, along with trends toward reduced basophil activation and peanut-specific TH2 cytokines. CONCLUSIONS: Peanut EPIT administration was safe and associated with a modest treatment response after 52 weeks, with the highest responses among younger children. This, when coupled with a high adherence and retention rate and significant changes in immune pathways, supports further investigation of this novel therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170116IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28091362">PM:28091362</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170116-JonesSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170116-JonesSM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170116, Jones SM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shemesh,E.</style></author><author><style face="normal" font="Arial"> D'Urso,C.</style></author><author><style face="normal" font="Arial"> Knight,C.</style></author><author><style face="normal" font="Arial"> Rubes,M.</style></author><author><style face="normal" font="Arial"> Picerno,K.M.</style></author><author><style face="normal" font="Arial"> Posillico,A.M.</style></author><author><style face="normal" font="Arial"> Atal,Z.</style></author><author><style face="normal" font="Arial"> Annunziato,R.A.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY.</style></auth-address><titles><title><style face="normal" font="Arial">Food-Allergic Adolescents at Risk for Anaphylaxis: A Randomized Controlled Study of Supervised Injection to Improve Comfort with Epinephrine Self-Injection</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="397" start="391">391-397</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Epinephrine self-injection is a key element in the management of food allergy, yet many adolescents report that they may not be able to use the autoinjector when needed. We hypothesized that supervised self-injection with an empty syringe would increase adolescents' comfort with self-injection. OBJECTIVE: The objective of this study was to examine the effect of supervised self-injection on self- and parent-reported comfort and anxiety during and after clinic visits in a food allergy center. METHODS: Sixty adolescent/parent pairs were randomized to self-injection versus control (education only). The predefined primary outcome was a self-reported comfort level with the injection before versus after the intervention on a Likert scale with scores of 1 (Not at all comfortable) to 10 (Extremely comfortable). The primary outcome was evaluated via within-group and between-group analyses. Secondary outcomes included adolescent and parent reports before versus after the injection, and changes in quality of life (QoL) and anxiety a month later. RESULTS: Self-injection was associated with a significant immediate increase in comfort levels (primary outcome; within-group comparison: mean scores: 6.93 preintervention vs 8.37 postintervention, P &lt; .01; between-group ANOVA: 8.37 vs 6.69, P &lt; .01) and with significant improvements in all other predefined (secondary) measures. On follow-up, QoL improved in 52% of intervention patients as compared with 25% of controls; similar differences were observed for anxiety. Those differences were not statistically significant. CONCLUSIONS: A self-injection (with an empty syringe) procedure in a clinic setting improves adolescents' and parents' comfort level with self-injecting. It may translate into substantial clinical benefits should self-injection be needed</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28117270">PM:28117270</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-391-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-391-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Shemesh E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Phillips-Angles,E.</style></author><author><style face="normal" font="Arial"> Barranco,P.</style></author><author><style face="normal" font="Arial"> Lluch-Bernal,M.</style></author><author><style face="normal" font="Arial"> Dominguez-Ortega,J.</style></author><author><style face="normal" font="Arial"> Lopez-Carrasco,V.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Hospital La Paz, Institute for Health Research (IdiPAZ), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="845" start="842">842-845</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28117272">PM:28117272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-842-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-842-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Phillips-Angles E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Price,D.W.</style></author><author><style face="normal" font="Arial"> Lang,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">American Board of Medical Specialties Research and Education Foundation, Chicago, Ill</style></auth-address><titles><title><style face="normal" font="Arial">Practical Quality Improvement for the Allergist/Immunologist</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="664" start="660">660-664</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="Arial">Quality improvement (QI) has long been part of organized medicine, but has become increasingly more important in the last few years. Clinical expertise and input into QI activities are critical to keep QI grounded in evidence and practice. Busy clinicians face many competing demands; practical strategies are needed to help busy clinicians successfully engage in QI. This article provides a brief history of QI in medicine, notes several commonly used frameworks for QI in health care, and presents a practical QI model that can be applied to the clinical practice of allergy and immunology</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28117271">PM:28117271</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-660-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-660-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Price DW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blankestijn,M.A.</style></author><author><style face="normal" font="Arial"> Remington,B.C.</style></author><author><style face="normal" font="Arial"> Houben,G.F.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author><author><style face="normal" font="Arial"> Blom,W.M.</style></author><author><style face="normal" font="Arial"> Klemans,R.J.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Threshold Dose Distribution in Walnut Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="380" start="376">376-380</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eliciting dose</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut allergy</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold dose</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> walnut allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In food allergy, eliciting doses (EDs) of foods on a population level can improve risk management and labeling strategies for the food industry and regulatory authorities. Previously, data available for walnut were unsuitable to determine EDs. OBJECTIVE: The objective of this study was to determine EDs for walnut allergic adults and to compare with previously established threshold data for peanut and tree nuts. METHODS: Prospectively, adult subjects with a suspected walnut allergy underwent a low-dose double-blind, placebo-controlled food challenge. Individual no observed and lowest observed adverse effect levels were determined and log-normal, log-logistic, and Weibull models were fit to the data. Estimated ED values were calculated for the ED5, ED10, and ED50, the dose respectively predicted to provoke an allergic reaction in 5%, 10%, and 50% of the walnut allergic population. RESULTS: Fifty-seven subjects were challenged and 33 subjects were confirmed to be walnut allergic. Objective symptoms occurred in 20 of the positive challenges (61%). The cumulative EDs in the distribution models ranged from 3.1 to 4.1 mg for the ED05, from 10.6 to 14.6 mg walnut protein for the ED10, and from 590 to 625 mg of walnut protein for the ED50. CONCLUSIONS: Our data indicate that population EDs for walnut are slightly higher compared with those for peanut and hazelnut allergy. Currently available data indicate that the ED values for hazelnut could be used as a conservative temporary placeholder when implementing risk management strategies for other tree nuts where little or no food challenge data are available</style></abstract><notes><style face="normal" font="Arial">DA - 20170122IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28110058">PM:28110058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170122-BlankestijnMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170122-BlankestijnMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170122, Blankestijn MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Picard,M.</style></author><author><style face="normal" font="Arial"> Galvao,V.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Medicine, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="609" start="600">600-609</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">Hypersensitivity reactions (HSRs) to monoclonal antibodies (mAbs) are increasingly frequent as this class of therapeutic agents is rapidly expanding. Immediate and nonimmediate HSRs have been reported with mAbs. Immediate HSRs can be explained by 3 main mechanisms: cytokine release syndrome, IgE-mediated, and IgG-mediated reactions. Importantly, IgE-mediated reactions can occur on first exposure due to preformed specific IgEs, as shown for cetuximab. Almost all patients with an immediate HSR can be safely re-exposed either through desensitization or challenge depending on the severity and mechanism of the initial reaction. An algorithm detailing the general approach to these HSRs and the preferred method of re-exposure is presented in this review. Also, the mAbs that are most frequently implicated in HSRs are discussed individually</style></abstract><notes><style face="normal" font="Arial">DA - 20170122IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28110056">PM:28110056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-600-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-600-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170122, Picard M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rabito,F.A.</style></author><author><style face="normal" font="Arial"> Carlson,J.C.</style></author><author><style face="normal" font="Arial"> He,H.</style></author><author><style face="normal" font="Arial"> Werthmann,D.</style></author><author><style face="normal" font="Arial"> Schal,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, La.</style></auth-address><titles><title><style face="normal" font="Arial">A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="570" start="565">565-570</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> multifaceted</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exposure to cockroaches is an important asthma trigger, particularly for children with asthma living in inner cities. Integrated pest management is the recommended approach to cockroach abatement; however, it is costly and difficult to implement. The impact of reducing cockroach exposure on asthma outcomes is not known. OBJECTIVE: We sought to test the use of a single intervention, insecticidal bait, to reduce cockroach exposure in the home of children with asthma in New Orleans and to examine the impact of cockroach reduction on asthma outcomes. METHODS: One hundred two children aged 5 to 17 years with moderate to severe asthma were enrolled in a 12-month randomized controlled trial testing the use of insecticidal bait on cockroach counts and asthma morbidity. Homes were visited 6 times and asthma symptoms were assessed every 2 months. RESULTS: After adjustment, intervention homes had significantly fewer cockroaches than did control homes (mean change in cockroaches trapped, 13.14; 95% CI, 6.88-19.39; P &lt; .01). Children in control homes had more asthma symptoms and unscheduled health care utilization in the previous 2 weeks (1.82, 95% CI, 0.14-3.50, P = .03; 1.17, 95% CI, 0.11-2.24, P = .03, respectively) and a higher proportion of children with FEV1 of less than 80% predicted (odds ratio, 5.74; 95% CI, 1.60-20.57; P = .01) compared with children living in intervention homes. CONCLUSIONS: Previous research has demonstrated improvement in asthma health outcomes using multifaceted interventions. The strategic placement of insecticidal bait, which is inexpensive, has low toxicity, and is widely available, resulted in sustained cockroach elimination over 12 months and was associated with improved asthma outcomes. This single intervention may be an alternative to multifaceted interventions currently recommended to improve asthma morbidity</style></abstract><notes><style face="normal" font="Arial">DA - 20170121IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108117">PM:28108117</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170121-RabitoFA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170121-RabitoFA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170121, Rabito FA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blankestijn,M.A.</style></author><author><style face="normal" font="Arial"> van de Donk,N.W.</style></author><author><style face="normal" font="Arial"> Sasser,K.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author><author><style face="normal" font="Arial"> Otten,H.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Could daratumumab be used to treat severe allergy?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1678" start="1677">1677-1678</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biologicals</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">In the management of allergic diseases, targeting IgE using biologicals is a current research focus. This proof of concept shows that plasma cell depletion using daratumumab results in decreased total and allergen-specific IgE levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170122IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.955</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109726">PM:28109726</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170122-BlankestijnMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170122-BlankestijnMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170122, Blankestijn MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.955</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Strzepa,A.</style></author><author><style face="normal" font="Arial"> Majewska-Szczepanik,M.</style></author><author><style face="normal" font="Arial"> Lobo,F.M.</style></author><author><style face="normal" font="Arial"> Wen,L.</style></author><author><style face="normal" font="Arial"> Szczepanik,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Biology, Faculty of Health Sciences, Jagiellonian University Medical College, ul. Kopernika 7a, 31-034 Krakow, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Broad spectrum antibiotic enrofloxacin modulates contact sensitivity through gut microbiota in a murine model</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="133" start="121">121-133</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bacteroidetes</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> commensal bacteria</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Medical advances in the field of infection therapy has led to an increasing use of antibiotics, which, apart from eliminating pathogens, also partially eliminate naturally existing commensal bacteria. It has become increasingly clear that less exposure to microbiota early in life may contribute to the observed rise in "immune-mediated" diseases including autoimmunity and allergy. OBJECTIVE: We sought to test whether the change of gut microbiota with the broad spectrum antibiotic enrofloxacin will modulate contact sensitivity (CS) in mice. METHODS: Natural gut microbiota were modified by oral treatment with enrofloxacin prior to sensitization with TNP-Cl followed by CS testing. Finally, adoptive cell transfers were performed to characterize the regulatory cells that are induced by microbiota modification. RESULTS: Oral treatment with enrofloxacin suppresses CS and production of anti-TNP IgG1 antibodies. Adoptive transfer experiments show that antibiotic administration favors induction of regulatory cells that suppress CS. Flow cytometry and adoptive transfer of purified cells show that antibiotic-induced suppression of CS is mediated by TCRalphabeta+CD4+CD25+FoxP3+ Treg, CD19+B220+CD5+IL-10+, IL-10+ Tr1, and IL-10+TCRgammadelta+ cells. Treatment with the antibiotic induces dysbiosis characterised by increased proportion of Clostridium coccoides (cluster XIVa), Clostridium coccoides - E. rectale (cluster XIVab), Bacteroidetes and Bifidobacterium spp., but decreased segmented filamentous bacteria. Transfer of antibiotic-modified gut microbiota inhibits CS, but this response can be restored through oral transfer of control gut bacteria to antibiotic-treated animals. CONCLUSION: Oral treatment with a broad spectrum antibiotic modifies gut microbiota composition and promotes anti-inflammatory response, suggesting that manipulation of gut microbiota can be a powerful tool to modulate the course of CS</style></abstract><notes><style face="normal" font="Arial">DA - 20170128IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - POland -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28130148">PM:28130148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170128-StrzepaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170128-StrzepaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170128, Strzepa A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.052</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iribarren,C.</style></author><author><style face="normal" font="Arial"> Rothman,K.J.</style></author><author><style face="normal" font="Arial"> Bradley,M.S.</style></author><author><style face="normal" font="Arial"> Carrigan,G.</style></author><author><style face="normal" font="Arial"> Eisner,M.D.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif</style></auth-address><titles><title><style face="normal" font="Arial">Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1680" start="1678">1678-1680</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">Among patients who participated in randomized clinical trials of omalizumab, no substantial overall increase in the risk of cardiovascular events was observed in the treatment arms compared with placebo.</style></abstract><notes><style face="normal" font="Arial">DA - 20170121IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.953</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108337">PM:28108337</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170121-IribarrenC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170121-IribarrenC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170121, Iribarren C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.953</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kalhan,T.A.</style></author><author><style face="normal" font="Arial"> Loo,E.X.</style></author><author><style face="normal" font="Arial"> Kalhan,A.C.</style></author><author><style face="normal" font="Arial"> Kramer,M.S.</style></author><author><style face="normal" font="Arial"> Karunakaran,B.</style></author><author><style face="normal" font="Arial"> Un,L.C.</style></author><author><style face="normal" font="Arial"> van Bever,H.</style></author><author><style face="normal" font="Arial"> Shek,L.P.</style></author><author><style face="normal" font="Arial"> Goh,A.</style></author><author><style face="normal" font="Arial"> Chong,Y.S.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Gluckman,P.</style></author><author><style face="normal" font="Arial"> Kwek,K.</style></author><author><style face="normal" font="Arial"> Saw,S.M.</style></author><author><style face="normal" font="Arial"> Godfrey,K.</style></author><author><style face="normal" font="Arial"> Hsu,C.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Discipline of Oral Sciences, Faculty of Dentistry, National University of Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis and early childhood caries: Results of the GUSTO study</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="2003" start="2000">2000-2003</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122670">PM:28122670</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170126-KalhanTA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170126-KalhanTA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Kalhan TA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krause,L.</style></author><author><style face="normal" font="Arial"> Mueller,N.S.</style></author><author><style face="normal" font="Arial"> Eyerich,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Reply (Refers To: Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1066" start="1065">1065-1066</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341481">PM:28341481</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170205-KrauseL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170205-KrauseL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Krause L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thijs,J.L.</style></author><author><style face="normal" font="Arial"> Herath,A.</style></author><author><style face="normal" font="Arial"> De Bruin-Weller,M.S.</style></author><author><style face="normal" font="Arial"> Hijnen,D.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="1065">1065-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.08.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341480">PM:28341480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170205-ThijsJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170205-ThijsJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Thijs JL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.08.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schussler,E.</style></author><author><style face="normal" font="Arial"> Cox,L.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Efficacy of House Dust Mite Sublingual Immunotherapy in Adults with Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="872" start="870">870-872</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="02/19/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-2198</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.032</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jaip.2016.11.032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-870-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-870-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Schussler E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamad,A.</style></author><author><style face="normal" font="Arial"> Kim,E.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Early Introduction of Allergenic Foods is Safe and May Be Beneficial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="532" start="531">531-532</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-2198</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.042</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jaip.2016.09.042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170205-HamadA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170205-HamadA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Hamad A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dawicki,W.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Town,J.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Gordon,J.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Therapeutic reversal of food allergen sensitivity by mature retinoic acid-differentiated dendritic cell induction of LAG3+CD49b-Foxp3- regulatory T cells.</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1620" start="1608">1608-1620</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Regulatory dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-ácells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">Background Anaphylaxis is a life-threatening condition for which we have limited therapeutic options. Although specific immunotherapy for food allergies is becoming more effective, it is still laborious and carries substantial risk of adverse events. On the other hand, regulatory dendritic cell (DC) therapy is effective in mouse models of allergic disease and has been shown to work with TH2 cells from atopic asthmatic patients. Objective We assessed whether DC immunotherapy could reverse food allergen sensitivity in mouse models to provide proof of concept relating to their use in the clinic. Methods We generated and characterized mature retinoic acid</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôskewed dendritic cells (DC-RAs) and assessed their abilities to reverse ovalbumin or peanut allergies in mouse models, as well as their operative mechanisms. Results DC-RAs displayed a mature yet tolerogenic phenotype, expressing IL-10, TGF-+¦, IL-27, and aldehyde dehydrogenase 1A2 but not IL-12 or IL-35; IL-10 and TGF-+¦ together drove their suppression of TH2 cell proliferation. Delivery of specific allergen-presenting DC-RAs to half-maximally sensitized mice with ovalbumin or peanut allergy reduced anaphylactic responses to oral allergen challenge by 84% to 90%, as well as diarrhea, mast cell activation, and TH2 cytokine responses and serum allergen-specific IgE/IgG1 levels. DC-RA expression of IL-27 was important to their induction of CD25+ lymphocyte activation gene 3 (LAG3)+, CD49b</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ, forkhead box P3 (Foxp3)</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ regulatory T-ácells in-ávitro, such that +¦ subunit of IL-27 (Ebi)</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ/</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ (ie, IL-27</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôincompetent) DC-RAs were ineffective in inducing food allergen tolerance. Conclusion Our data indicate that regulatory DC immunotherapy can be effective for food allergies and suggest that induction of Foxp3</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ regulatory T-ácells might be a useful strategy for tolerance induction in this context</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.07.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28277274">PM:28277274</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170205-DawickiW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170205-DawickiW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Dawicki W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.07.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alexis,N.E.</style></author><author><style face="normal" font="Arial"> Bennett,W.D.</style></author><author><style face="normal" font="Arial"> Peden,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a University of North Carolina School of Medicine, Center for Environmental Medicine, Asthma and Lung Biology, Division of Allergy and Immunology, UNC Chapel Hill</style></auth-address><titles><title><style face="normal" font="Arial">Safety and Benefits of Inhaled Hypertonic Saline Following Airway Challenges with Endotoxin and Allergen in Asthmatics</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Mucociliary Clearance</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Sulfur</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To determine whether induced sputum (IS) with hypertonic saline inhalation is safe to use in asthmatics within 24 hours of two commonly used airway challenges, namely endotoxin and dust mite allergen, and to assess whether IS can enhance mucociliary clearance (MCC) rates in asthmatics. METHODS: IS (three 7 minute inhalation periods of 3, 4, 5% hypertonic saline) was employed before (N = 29) and within 24 hours of inhaled challenges with endotoxin (N = 13) and dust mite allergen (N = 12) in a cohort of mild to moderate asthmatics. Safety was assessed by lung function (FEV1) and MCC was measured using a radiolabeled gamma scintigraphy method (Tcm99 sulfur colloid). IS was performed pre and post MCC. RESULTS: No significant lung function decrement was observed before or after inhaled challenges with endotoxin or dust mite allergen. IS significantly enhanced MCC rates before and after inhaled endotoxin challenge. CONCLUSION: Based on a small cohort, IS is safe to use in mild to moderate asthmatics before and within 24 hours of inhaled challenges with endotoxin and dust mite allergen. Furthermore, IS has beneficial effects on host defense function in asthmatics by enhancing MCC rates</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1278019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095128">PM:28095128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170117-AlexisNE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170117-AlexisNE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Alexis NE</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1278019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,H.</style></author><author><style face="normal" font="Arial"> Fan,X.</style></author><author><style face="normal" font="Arial"> Wang,N.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Yu,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nanjing University of Traditional Chinese Medicine, School of Basic Medicine?Library , Nanjing , 210046 China</style></auth-address><titles><title><style face="normal" font="Arial">Exacerbating effects of PM2.5 in OVA-sensitized and challenged mice and the expression of TRPA1 and TRPV1 protein in lung</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Compliance</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscles</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the effects of PM2.5 on asthma-related phenotypes and on the expression of TRPA1, V1 protein in lung in a mouse model of asthma. METHODS: Female Balb/c mice were utilized to establish 28 and 42 day asthma models. Mice were sensitized with OVA and challenged with OVA, OVA plus normal saline (NS), or OVA plus PM2.5 at two doses, 1.6 mg.kg-1 or 8.0 mg.kg-1. PM2.5 was administrated by intratracheal instillationwithout anesthesia. 24 hours after the final OVA challenge changes in airway resistance (RI) and lung compliance (Cdyn) in response to acetylcholine chloride (ACH) were evaluated, and blood, bronchoalveolar lavage fluid (BALF) and lung tissue samples were taken. Number of eosinophils in blood and various leukocytes in BALF were determined. Lung protein was extracted and probed by immunoblot for TRPA1, V1 expression. Levels of IL-13, SP, PGD2 and NGF in BALF were measured by ELISA. RESULTS: PM2.5 treated mice showed significantly greater changes in number of inflammatory cells in blood and BALF, in RI and Cdyn in response to ACH, and in lung injury, as indicated by inflammatory cell infiltration, increased tracheal secretions and thickened bronchial smooth muscles, compared to controls. In addition, higher expression of TRPA1, V1 in lung and IL-13, SP, PGD2 and NGF in BALF were seen in mice exposed to PM2.5. All effects were most pronounced in mice in the 42 day model exposed to 8.0 mg.kg-1 PM2.5. CONCLUSIONS: PM2.5 exacerbates effects of asthma in this animal model, possibly by regulating TRPA1, V1 and the relevant neurokines</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1266495</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102732">PM:28102732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170119-LiuH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170119-LiuH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Liu H</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1266495</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shoda,T.</style></author><author><style face="normal" font="Arial"> Futamura,M.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Narita,M.</style></author><author><style face="normal" font="Arial"> Saito,H.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Yogurt consumption in infancy is inversely associated with atopic dermatitis and food sensitization at 5 years of age: A hospital-based birth cohort study</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective birth cohort study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword><keyword><style face="normal" font="Arial"> Yogurt</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0923-1811</style></isbn><abstract><style face="normal" font="Arial">Background Several studies have suggested that habitual yogurt consumption is associated with favorable outcomes for health issues in children. However, the effects of yogurt consumption on allergic diseases and sensitization in children remain poorly understood. Objective This prospective birth cohort study aimed to investigate for associations between habitual yogurt consumption in infancy and development of allergic diseases/sensitization at 5 years of age. Methods Data were obtained from the Tokyo Children</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs Health, Illness and Development (T-CHILD) study. A total of 1550 children were born to the recruited women. Consumption of yogurt by children during infancy was determined by using questionnaires completed at 12 months of age. Outcome data for children were collected from the questionnaires and medical check-ups completed at 5 years of age. Possible associations between habitual yogurt consumption in infancy and allergic diseases/sensitization were analyzed by multiple logistic regression analyses. Results We analyzed the data for 1166 children whose parents responded at 5 years of age. Habitual yogurt consumption in infancy and atopic dermatitis at 5 years of age were significantly associated (UKWP criteria: aOR, 0.70; 95% CI, 0.51</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.97; P = 0.03). Children with habitual yogurt consumption in infancy were less likely to be sensitized to food allergens (aOR, 0.53; 95% CI, 0.31</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.93; P = 0.03), but no associations were seen in regard to any other allergens. Conclusions Our study demonstrated that habitual consumption of yogurt in infancy has the potential to prevent development of atopic dermatitis and food sensitization, but not other allergic diseases, at 5 years of age</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2017.01.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108060">PM:28108060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20170205-ShodaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20170205-ShodaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Shoda T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2017.01.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cho,Y.A.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Association of IL4, IL13, and IL4R polymorphisms with gastrointestinal cancer risk: A meta-analysis</style></title><secondary-title><style face="normal" font="Arial">J Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Epidemiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal cancer</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Heterozygote</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0917-5040</style></isbn><abstract><style face="normal" font="Arial">Background Previous studies have suggested that IL4, IL13, and IL4R are associated with serum IgE levels and allergies, and common variants of these genes may alter cancer risk. To clarify these associations, we conducted a meta-analysis to investigate the associations of IL4, IL13, and IL4R polymorphisms with gastrointestinal cancer risk. Methods We used 27 eligible case</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôcontrol studies describing the associations of six polymorphisms of IL4, IL13, and IL4R with gastrointestinal cancer risk to calculate summary odds ratios (ORs) and 95% confidence intervals (CIs) using five different genetic models. The Q-statistic and I2 statistic were calculated to examine heterogeneity. Results The IL4 rs2070874 T allele seems to be associated with an increased risk of gastrointestinal cancer (OR 1.11; 95% CI, 1.00</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô1.24 for T allele vs. C allele). This association was significant in studies conducted outside of Asia (OR 1.28; 95% CI, 1.03</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô1.58 for T allele vs. C allele) and in studies investigating the association with gastric cancer (OR 1.17; 95% CI, 1.03</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô1.34 for T allele vs. C allele). However, the IL4R rs1801275 heterozygote seems to be associated with a reduced risk of gastrointestinal cancer (OR 0.79; 95% CI, 0.65</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.96 for AG vs. AA). Other polymorphisms did not show any significant associations with gastrointestinal cancer risk in any of the genetic models and subgroup analyses. Conclusions Our results suggest that certain polymorphisms of IL4 and IL4R may affect susceptibility to gastrointestinal cancer. However, further studies are required to confirm these findings</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.je.2016.06.002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.je.2016.06.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Epidemiol\20170207-ChoYA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Epidemiol\20170207-ChoYA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Cho YA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.je.2016.06.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Birot,S.</style></author><author><style face="normal" font="Arial"> Madsen,C.B.</style></author><author><style face="normal" font="Arial"> Kruizinga,A.G.</style></author><author><style face="normal" font="Arial"> Christensen,T.</style></author><author><style face="normal" font="Arial"> Crepet,A.</style></author><author><style face="normal" font="Arial"> Brockhoff,P.B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A procedure for grouping food consumption data for use in food allergen risk assessment</style></title><secondary-title><style face="normal" font="Arial">J Food Compost Anal</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Compost Anal</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen contamination</style></keyword><keyword><style face="normal" font="Arial"> allergen risk assessment</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Automatic procedure</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergic consumers</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Analysis</style></keyword><keyword><style face="normal" font="Arial"> Food composition</style></keyword><keyword><style face="normal" font="Arial"> Food groups</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Food Consumption Surveys</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Probabilistic risk assessment</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0889-1575</style></isbn><abstract><style face="normal" font="Arial">Food allergic subjects need to avoid the allergenic food that triggers their allergy. However, foods can also contain unintended allergens. Food manufacturers or authorities need to perform a risk assessment to be able to decide if unintended allergen presence constitutes a risk to food allergic consumers. One of the input parameters in risk assessment is the amount of a given food consumed in a meal. There has been little emphasis on how food consumption data can be used in food allergen risk assessment. The aim of the study was to organize the complex datasets from National Food Consumption Surveys from different countries (France, Netherlands and Denmark) to be manageable in food allergen risk assessment. To do this, a two-step method was developed. First, based on initial groups of similar food items, the homogeneity of consumption was evaluated using a customized clustering method. Then, the risk was calculated for each initial food group and its subgroups to verify if it also represents a relevant difference in risk. Forty-eight food groups were designated in Denmark (53 in the Netherlands, 54 in France). Finally, summary statistics and names for each food group for the Danish data illustrate the results when applying the procedure</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Denmark -CO - Netherlands -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jfca.2017.01.008</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jfca.2017.01.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Compost Anal\20170207-BirotS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Compost Anal\20170207-BirotS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Birot S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jfca.2017.01.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,C.</style></author><author><style face="normal" font="Arial"> Lee,W.</style></author><author><style face="normal" font="Arial"> Han,Y.</style></author><author><style face="normal" font="Arial"> Oh,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">the Dept. of Food Science and Engineering, Ewha Womans Univ, Seodaemun-gu, Seoul 03760, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effect of Proteolysis with Alkaline Protease Following High Hydrostatic Pressure Treatment on IgE Binding of Buckwheat Protein</style></title><secondary-title><style face="normal" font="Arial">J Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> High hydrostatic pressure</style></keyword><keyword><style face="normal" font="Arial"> High hydrostatic pressure treatment</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Hydrostatic Pressure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">Buckwheat is a popular food material in many Asian countries and it contains major allergenic proteins. This study was performed to analyze the effects of hydrolysis with alkaline protease following high hydrostatic pressure (HHP) treatment on the IgE binding of buckwheat protein. Extracted buckwheat protein was treated with HHP at 600 MPa for 30 min and hydrolyzed with alkaline protease for 240 min. IgE binding was examined using an enzyme-linked immunosorbent assay (ELISA) with serum samples from 14 patients who were allergic to buckwheat. Depending on the serum samples, HHP treatment of buckwheat protein without enzymatic hydrolysis decreased the IgE binding by 8.9% to 73.2% or increased by 31% to 78%. The IgE binding of buckwheat protein hydrolyzed with alkaline protease decreased by 73.8% to 100%. The IgE binding of buckwheat protein hydrolyzed with alkaline protease following HHP treatment decreased by 83.8% to 100%. This suggested that hydrolysis with alkaline protease following HHP treatment could be applied to reduce the IgE binding of buckwheat protein</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1750-3841 (Electronic)IS - 0022-1147 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1111/1750-3841.13627</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28125769">PM:28125769</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci\20170126-LeeC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci\20170126-LeeC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Lee C</style></custom2><misc3><style face="normal" font="Arial">10.1111/1750-3841.13627</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,C.H.</style></author><author><style face="normal" font="Arial"> Lin,Y.C.</style></author><author><style face="normal" font="Arial"> Jan,T.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lactobacillus reuteri induces intestinal immune tolerance against food allergy in mice</style></title><secondary-title><style face="normal" font="Arial">J Funct Foods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Funct Foods</style></full-title></periodical><pages end="51" start="44">44-51</pages><volume><style face="normal" font="Arial">31</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus reuteri</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerogenic dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><isbn><style face="normal" font="Arial">1756-4646</style></isbn><abstract><style face="normal" font="Arial">The effect of Lactobacillus reuteri against food allergy was investigated in ovalbumin (OVA)-sensitized BALB/c mice. Oral administration with L. reuteri restored the deteriorated profile of enteric flora, and attenuated allergic diarrhoea, mast cell activation, and serum IgE production in allergic mice. The production of signature T helper (Th)1 and 2 cytokines, namely IFN-+¦ and IL-4, by splenocytes was suppressed by L. reuteri. Concordantly, the intestinal expression of IFN-+¦, IL-4, T-bet and GATA3 was down-regulated. However, L. reuteri augmented the expression of IL-10, TGF-+¦ and Foxp3, and the number of IL-10-secreting CD11c+CD103+ mesenteric lymph node (MLN) cells. Furthermore, direct exposure to heat-killed L. reuteri attenuated OVA-induced cell proliferation and IL-2 secretion by MLN cells. These results demonstrate that L. reuteri possesses anti-allergic activities via modulating enteric flora and promoting tolerogenic immune responses, and suggest L. reuteri as a functional probiotic against food allergy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jff.2017.01.034</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jff.2017.01.034</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Funct Foods\2017-31-44-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Funct Foods\2017-31-44-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Huang CH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jff.2017.01.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Z.</style></author><author><style face="normal" font="Arial"> Levast,B.</style></author><author><style face="normal" font="Arial"> Madrenas,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Microbiome and Disease Tolerance Centre, Department of Microbiology and Immunology, McGill University, Montreal, Quebec H3A 2B4, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus Downregulates IP-10 Production and Prevents Th1 Cell Recruitment</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Carrier State</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic sinusitis</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> STAT1</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> Superantigens</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Toxic shock</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">Staphylococcal superantigens cause toxic shock syndrome, which is characterized by massive T cell activation and a predominant Th1 profile of cytokine production. However, superantigen-producing Staphylococcus aureus strains are often part of the human nasal microbiome, and this carrier state has often been associated with some type 2 immune responses such as chronic sinusitis with polyps and atopic dermatitis. We have previously reported that the S. aureus cell wall downregulates the human T cell response to superantigens through a TLR2-dependent, IL-10-mediated mechanism. In this study, we show that S. aureus also regulates the profile of superantigen-induced T cell recruitment. The staphylococcal superantigen SEE induced the production of Th1 cell-recruiting chemokines, including IP-10, through an IFN-gamma-dependent mechanism. Such an induction was suppressed by the concomitant presence of S. aureus The downregulation of IP-10 by S. aureus was mediated by components of its cell wall, but was not due to peptidoglycan-induced IL-10 production. Instead, S. aureus triggered activation of MAPKs p38 and ERK, as well as inhibition of STAT1 signaling in monocytes, altogether contributing to the downregulation of IP-10 and other Th1 cell-recruiting chemokines (e.g., CXCL9 and CXCL11). These effects translated into inhibition of superantigen-induced Th1 cell recruitment. Taken together, our data may explain why colonization of superantigen-producing S. aureus can induce, under some circumstances, mucosal type 2 immune responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122962">PM:28122962</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170126-LiZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170126-LiZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Li Z</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601336</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Robinson,M.J.</style></author><author><style face="normal" font="Arial"> Prout,M.</style></author><author><style face="normal" font="Arial"> Mearns,H.</style></author><author><style face="normal" font="Arial"> Kyle,R.</style></author><author><style face="normal" font="Arial"> Camberis,M.</style></author><author><style face="normal" font="Arial"> Forbes-Blom,E.E.</style></author><author><style face="normal" font="Arial"> Paul,W.E.</style></author><author><style face="normal" font="Arial"> Allen,C.D.</style></author><author><style face="normal" font="Arial"> Le Gros,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Malaghan Institute of Medical Research, Wellington 6242, New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">IL-4 Haploinsufficiency Specifically Impairs IgE Responses against Allergens in Mice</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">Polymorphisms in genes involved in IL-4 responses segregate with allergic disease risk and correlate with IgE levels in humans, and IL-4 promotes IgE and IgG1 Ab production against allergens in mice. We report that mice with only one intact Il4 gene copy are significantly impaired in their ability to make specific IgE responses against allergens, whereas IgG1 responses to allergens remain unaffected. Il4-hemizygosity also resulted in a modest but detectable drop in IL-4 production by CD4+ T cells isolated from lymph nodes and prevented IgE-dependent oral allergen-induced diarrhea. We conclude that a state of haploinsufficiency for the Il4 gene locus is specifically relevant for IL-4-dependent IgE responses to allergens with the amount of IL-4 produced in the hemizygous condition falling close to the threshold required for switching to IgE production. These results may be relevant for how polymorphisms in genes affecting IL-4 responses influence the risk of IgE-mediated allergic disease in humans</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601434</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28115531">PM:28115531</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170124-RobinsonMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170124-RobinsonMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Robinson MJ</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601434</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Narayanan,M.</style></author><author><style face="normal" font="Arial"> Freidl,R.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> Baranyi,U.</style></author><author><style face="normal" font="Arial"> Wekerle,T.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Linhart,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, 1090 Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> epitope peptide</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="Arial">More than 40% of allergic patients suffer from grass pollen allergy. Phl p 1, the major timothy grass pollen allergen, belongs to the cross-reactive group 1 grass pollen allergens that are thought to initiate allergic sensitization to grass pollen. Repeated allergen encounter boosts allergen-specific IgE production and enhances clinical sensitivity in patients. To investigate immunological mechanisms underlying the boosting of allergen-specific secondary IgE Ab responses and the allergen epitopes involved, a murine model for Phl p 1 was established. A B cell epitope-derived peptide of Phl p 1 devoid of allergen-specific T cell epitopes, as recognized by BALB/c mice, was fused to an allergen-unrelated carrier in the form of a recombinant fusion protein and used for sensitization. This fusion protein allowed the induction of allergen-specific IgE Ab responses without allergen-specific T cell help. Allergen-specific Ab responses were subsequently boosted with molecules containing the B cell epitope-derived peptide without carrier or linked to other allergen-unrelated carriers. Oligomeric peptide bound to a carrier different from that which had been used for sensitization boosted allergen-specific secondary IgE responses without a detectable allergen-specific T cell response. Our results indicate that allergen-specific secondary IgE Ab responses can be boosted by repetitive B cell epitopes without allergen-specific T cell help by cross-linking of the B cell epitope receptor. This finding has important implications for the design of new allergy vaccines</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1501741</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093528">PM:28093528</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170117-NarayananM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170117-NarayananM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Narayanan M</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1501741</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Movassagh,H.</style></author><author><style face="normal" font="Arial"> Shan,L.</style></author><author><style face="normal" font="Arial"> Mohammed,A.</style></author><author><style face="normal" font="Arial"> Halayko,A.J.</style></author><author><style face="normal" font="Arial"> Gounni,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0T5, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Semaphorin 3E Deficiency Exacerbates Airway Inflammation, Hyperresponsiveness, and Remodeling in a Mouse Model of Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> irradiated</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="Arial">Semaphorin 3E (Sema3E) plays a crucial role in axon guidance, vascular patterning, and immune regulation. Nevertheless, the role of Sema3E in asthma is still elusive. In this study, we show that genetic ablation of Sema3E in mice results in increased lung granulocytosis, airway hyperresponsiveness, mucus overproduction, collagen deposition, and Th2/Th17 inflammation. Transfer of Sema3e-/- bone marrow progenitor cells to irradiated wild-type (WT) recipients exacerbates airway hyperresponsiveness and inflammation, whereas transfer of WT bone marrow progenitor cells ameliorates asthma pathology in Sema3e-/- recipients. Sema3e-/- mice display a higher frequency of CD11b+ pulmonary dendritic cells than their WT controls at the baseline and after sensitization with house dust mite. Adoptive transfer of CD11b+ pulmonary dendritic cells from Sema3e-/- mice into WT recipients increases house dust mite-induced Th2/Th17 inflammation in the airway. Together, these findings identify Sema3E as a novel regulatory molecule in allergic asthma that acts upstream of proallergic events and suggest that targeting this molecule could be a novel approach to treat allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170121IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601514</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108561">PM:28108561</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170121-MovassaghH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170121-MovassaghH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170121, Movassagh H</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601514</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Navines-Ferrer,A.</style></author><author><style face="normal" font="Arial"> Serrano-Candelas,E.</style></author><author><style face="normal" font="Arial"> Molina-Molina,G.J.</style></author><author><style face="normal" font="Arial"> Martin,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, SpainBiochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, SpainBiochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, SpainBiochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">IgE-Related Chronic Diseases and Anti-IgE-Based Treatments</style></title><secondary-title><style face="normal" font="Arial">J Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Res</style></full-title></periodical><pages end="" start="8163803">8163803-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acute allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies with a probable allergic basis. This review focuses on IgE-related chronic diseases, such as allergic asthma and chronic urticaria (CU), and on the role of the anti-IgE monoclonal antibody, omalizumab, in their treatment. We also assess the off-label use of omalizumab for other pathologies associated with IgE and report the latest findings concerning this drug and other new related drugs. To date, omalizumab has only been approved for severe allergic asthma and unresponsive chronic urticaria treatments. In allergic asthma, omalizumab has demonstrated its efficacy in reducing the dose of inhaled corticosteroids required by patients, decreasing the number of asthma exacerbations, and limiting the effect on airway remodeling. In CU, omalizumab treatment rapidly improves symptoms and in some cases achieves complete disease remission. In systemic mastocytosis, omalizumab also improves symptoms and its prophylactic use to prevent anaphylactic reactions has also been discussed. In other pathologies such as atopic dermatitis, food allergy, allergic rhinitis, nasal polyposis, and keratoconjunctivitis, omalizumab significantly improves clinical manifestations. Omalizumab acts in two ways: by sequestering free IgE and by accelerating the dissociation of the IgE-Fcepsilon receptor I complex</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/8163803</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28097159">PM:28097159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Res\2016-2016-8163803.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Res\2016-2016-8163803.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Navines-Ferrer A</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/8163803</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mattson,L.</style></author><author><style face="normal" font="Arial"> Lentini,A.</style></author><author><style face="normal" font="Arial"> Gawel,D.R.</style></author><author><style face="normal" font="Arial"> Badam,T.V.</style></author><author><style face="normal" font="Arial"> Benson,M.</style></author><author><style face="normal" font="Arial"> Ledin,T.</style></author><author><style face="normal" font="Arial"> Nestor,C.E.</style></author><author><style face="normal" font="Arial"> Gustafsson,M.</style></author><author><style face="normal" font="Arial"> Serra-Musach,J.</style></author><author><style face="normal" font="Arial"> Bjorkander,J.</style></author><author><style face="normal" font="Arial"> Xiang,Z.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Centre for Personalized Medicine, Department of Clinical and Experimental Medicine, Division of Pediatrics, Linkoping University, Linkoping, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Potential Involvement of Type I Interferon Signaling in Immunotherapy in Seasonal Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Res</style></full-title></periodical><pages end="" start="5153184">5153184-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferons</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Specific immunotherapy (SIT) reverses the symptoms of seasonal allergic rhinitis (SAR) in most patients. Recent studies report type I interferons shifting the balance between type I T helper cell (Th1) and type II T helper cells (Th2) towards Th2 dominance by inhibiting the differentiation of naive T cells into Th1 cells. As SIT is thought to cause a shift towards Th1 dominance, we hypothesized that SIT would alter interferon type I signaling. To test this, allergen and diluent challenged CD4+ T cells from healthy controls and patients from different time points were analyzed. The initial experiments focused on signature genes of the pathway and found complex changes following immunotherapy, which were consistent with our hypothesis. As interferon signaling involves multiple genes, expression profiling studies were performed, showing altered expression of the pathway. These findings require validation in a larger group of patients in further studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.1155/2016/5153184</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28097155">PM:28097155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Res\2016-2016-5153184.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Res\2016-2016-5153184.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Mattson L</style></custom2><misc3><style face="normal" font="Arial">10.1155/2016/5153184</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marshall,N.B.</style></author><author><style face="normal" font="Arial"> Lukomska,E.</style></author><author><style face="normal" font="Arial"> Nayak,A.P.</style></author><author><style face="normal" font="Arial"> Long,C.M.</style></author><author><style face="normal" font="Arial"> Hettick,J.M.</style></author><author><style face="normal" font="Arial"> Anderson,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Allergy and Clinical Immunology Branch , National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention , Morgantown , WV , USA</style></auth-address><titles><title><style face="normal" font="Arial">Topical application of the anti-microbial chemical triclosan induces immunomodulatory responses through the S100A8/A9-TLR4 pathway</style></title><secondary-title><style face="normal" font="Arial">J Immunotoxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunotoxicol</style></full-title></periodical><pages end="59" start="50">50-59</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Centers for Disease Control</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-Like Receptor 4</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">The anti-microbial compound triclosan is incorporated into numerous consumer products and is detectable in the urine of 75% of the general United States population. Recent epidemiological studies report positive associations with urinary triclosan levels and allergic disease. Although not sensitizing, earlier studies previously found that repeated topical application of triclosan augments the allergic response to ovalbumin (OVA) though a thymic stromal lymphopoietin (TSLP) pathway in mice. In the present study, early immunological effects following triclosan exposure were further evaluated following topical application in a murine model. These investigations revealed abundant expression of S100A8/A9, which reportedly acts as an endogenous ligand for Toll-like Receptor 4 (TLR4), in skin tissues and in infiltrating leukocytes during topical application of 0.75-3.0% triclosan. Expression of Tlr4 along with Tlr1, Tlr2 and Tlr6 increased in skin tissues over time with triclosan exposure; high levels of TLR4 were expressed on skin-infiltrating leukocytes. In vivo antibody blockade of the TLR4/MD-2 receptor complex impaired local inflammatory responses after four days, as evidenced by decreased Il6, Tnfalpha, S100a8, S100a9, Tlr1, Tlr2, Tlr4 and Tlr6 expression in the skin and decreased lymph node cellularity and production of IL-4 and IL-13 by lymph node T-cells. After nine days of triclosan exposure with TLR4/MD-2 blockade, impaired T-helper cell type 2 (TH2) cytokine responses were sustained, but other early effects on skin and lymph node cellularity were lost; this suggested alternative ligands/receptors compensated for the loss of TLR4 signaling. Taken together, these data suggest the S100A8/A9-TLR4 pathway plays an early role in augmenting immunomodulatory responses with triclosan exposure and support a role for the innate immune system in chemical adjuvancy</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1547-6901 (Electronic)IS - 1547-691X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1547691X.2016.1258094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28121465">PM:28121465</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunotoxicol\2017-14-50-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunotoxicol\2017-14-50-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Marshall NB</style></custom2><misc3><style face="normal" font="Arial">10.1080/1547691X.2016.1258094</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,S.</style></author><author><style face="normal" font="Arial"> Zhao,C.</style></author><author><style face="normal" font="Arial"> Che,N.</style></author><author><style face="normal" font="Arial"> Jing,L.</style></author><author><style face="normal" font="Arial"> Ge,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Tongji Hospital, Tongji University, 389 Xincun road, Putuo District, Shanghai, 200065 China</style></auth-address><titles><title><style face="normal" font="Arial">Hydrogen-rich saline attenuates eosinophil activation in a guinea pig model of allergic rhinitis via reducing oxidative stress</style></title><secondary-title><style face="normal" font="Arial">J Inflamm (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Inflamm (Lond)</style></full-title></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> real-time RT-PCR</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It is well considered that reactive oxygen species (ROS) plays a prominent causative role in the development of allergic rhinitis (AR), and eosinophils cells as important allergic inflammatory cells contribute to elevating oxidative stress. Hydrogen, emerging as a novel antioxidant, has been proven effective in selectively reducing ROS in animals models of oxidative damage. We herein aim to verify protective effects of hydrogen on eosinophils cells in guinea pigs models of AR. METHODS: Thirty two guinea pigs were random divided into four groups, and AR model was established through ovalbumin sensitization. The guinea pigs were injected with hydrogen-rich saline (Normal-HRS and AR-HRS group) or normal saline (control and AR group). The frequencies of sneezing and scratching were recorded. The IgE level, blood eosinophil count and eosinophil cationic protein (ECP) level in serum were measured. The serum malondialdehyde (MDA) and superoxide dismutase (SOD) assays were also measured to evaluate oxidative stress. The expression levels of eotaxin mRNA and protein in the nasal mucosa were also determined by real-time RT-PCR, Western blot and immunofluorescence. RESULTS: HRS reduced the ROS and MDA levels and increased SOD level in guinea pigs of AR-HRS group accompanied with decreased frequency of sneezing and scratches. Meanwhile, there was a decline of the number of eosinophils cells in blood and of thelevel of ECP in serum in the AR-HRS group. HRS also significantly decreased the expression of eotaxin in nasal mucosa. CONCLUSION: HRS may play a protective role in attenuating allergic inflammation, and suppressing the increase and activation of eosinophils in AR possibly through antioxidation effect of hydrogen</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1476-9255 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12950-016-0148-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100959">PM:28100959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Inflamm (Lond)\2017-14-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Inflamm (Lond)\2017-14-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Yu S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12950-016-0148-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camps-Bossacoma,M.</style></author><author><style face="normal" font="Arial"> Perez-Cano,F.J.</style></author><author><style face="normal" font="Arial"> Franch,A.</style></author><author><style face="normal" font="Arial"> Untersmayr,E.</style></author><author><style face="normal" font="Arial"> Castell,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of a cocoa diet on the small intestine and gut-associated lymphoid tissue composition in an oral sensitization model in rats</style></title><secondary-title><style face="normal" font="Arial">J Nutr Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Nutr Biochem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> CD11b</style></keyword><keyword><style face="normal" font="Arial"> CD62L</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Cocoa</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Oral sensitization</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Peyer's Patches</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> TCR+¦+¦ + cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0955-2863</style></isbn><abstract><style face="normal" font="Arial">Previous studies have attributed to the cocoa powder the capacity to attenuate the immune response in a rat oral sensitization model. To gain a better understanding of cocoa-induced mechanisms at small intestinal level, three-week-old female Lewis rats were fed either a standard diet or a diet containing 10% cocoa for four weeks with or without concomitant oral sensitization with ovalbumin (OVA). Thereafter, we evaluated the lymphocyte composition of the Peyer's patches (PPL), small intestine epithelium (IEL) and lamina propria (LPL). Likewise, gene expression of several immune molecules was quantified in the small intestine. Moreover, histological samples were used to evaluate the proportion of goblet cells, IgA+ cells and granzyme + cells, as well. In cocoa-fed animals, we identified a five time reduction in the percentage of IgA+ cells in intestinal tissue together with a decreased proportion of TLR4+ IEL. Analyzing the lymphocyte composition, almost a double proportion of TCR+¦+¦ + cells and an increase of NK cell percentage in PPL and IEL were found. In addition, a rise in CD25+, CD103+ and CD62L- cell proportions was observed in CD4+ PPL from cocoa-fed animals, along with a decrease in gene expression of CD11b, CD11c and IL-10. These results suggest that changes in PPL and IEL composition and in the gene expression induced by the cocoa diet could be involved, among other mechanisms, on its tolerogenic effect</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jnutbio.2017.01.005</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jnutbio.2017.01.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Nutr Biochem\20170207-CampsBossacomaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Nutr Biochem\20170207-CampsBossacomaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Camps-Bossacoma M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jnutbio.2017.01.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doulgeraki,A.E.</style></author><author><style face="normal" font="Arial"> Manousakis,E.M.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Bone health assessment of food allergic children on restrictive diets: a practical guide</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Endocrinol Metab</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Endocrinol Metab</style></full-title></periodical><pages end="139" start="133">133-139</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Avoidance diet</style></keyword><keyword><style face="normal" font="Arial"> avoidance diets</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rickets</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy in childhood is on the rise globally and is managed with avoidance diets; recent case reports of food allergic children with nutritional rickets in the literature highlight the importance of close monitoring of bone health in this population. METHODS: There is no consensus as yet with regard to bone health evaluation in food allergic children; therefore, extensive literature search was performed and the existing evidence is presented, along with a relevant algorithm. RESULTS: Children allergic to cow's milk protein or presenting with allergy in more than three food items, as well as patients with severe allergic phenotypes or comorbidities known to affect the skeleton, seem to be at risk of metabolic bone disorders. As a practical guide, suspicious cases can be investigated with basic bone profile, whereas more severe cases (persistent bone pain and fractures) may undergo advanced bone health assessment, with bone mineral density (BMD) and metabolic bone markers' evaluation. Of note, these diagnostic steps call for further studies in the field of food allergy, as they are not performed as a routine. Evidence is accumulating with regard to vitamin D deficiency, osteopenia and imbalanced bone metabolism in those food allergic children who show poor dietary compliance or have inadequate medical supervision. CONCLUSIONS: Ensuring optimal bone accrual in a food allergic child is an important task for the clinician and requires close monitoring of the restrictive diet and prompt therapeutic intervention, in an effort to avoid rickets or osteopenia</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 2191-0251 (Electronic)IS - 0334-018X (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1515/jpem-2016-0162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28099128">PM:28099128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Endocrinol Metab\2017-30-133-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Endocrinol Metab\2017-30-133-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Doulgeraki AE</style></custom2><misc3><style face="normal" font="Arial">10.1515/jpem-2016-0162</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Metrock,L.K.</style></author><author><style face="normal" font="Arial"> Qayed,M.</style></author><author><style face="normal" font="Arial"> Simon,D.</style></author><author><style face="normal" font="Arial"> Cash,T.</style></author><author><style face="normal" font="Arial"> O'Connor,M.G.</style></author><author><style face="normal" font="Arial"> Johnson,S.</style></author><author><style face="normal" font="Arial"> Esiashvili,N.</style></author><author><style face="normal" font="Arial"> Katzenstein,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta daggerDivision of Pediatric Pulmonology parallelDivision of Radiation Oncology, Emory University, Atlanta, GA double daggerDivision of Pediatric Allergy, Immunology, and Pulmonology Medicine section signDivision of Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, and Monroe Carell Jr Children's Hospital, Nashville, TN</style></auth-address><titles><title><style face="normal" font="Arial">Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Hematol Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Hematol Oncol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neuroblastoma</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Radiation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="Arial">Treatment of high-risk neuroblastoma now includes antibody based antitumor immunotherapy as part of standard care. Although this therapy has resulted in dramatic improvements in survival, it is associated with significant side effects. Children with underlying respiratory issues, and in particular asthma, may be more susceptible to immunotherapy associated respiratory compromise and pulmonary complications. Early routine involvement of pulmonology care is warranted for these patients in an effort to allow maximal delivery of immunotherapy and minimize acute and long-term complications</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1536-3678 (Electronic)IS - 1077-4114 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPH.0000000000000782</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28121746">PM:28121746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Hematol Oncol\20170125-MetrockLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Hematol Oncol\20170125-MetrockLK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Metrock LK</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPH.0000000000000782</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Togias,A.</style></author><author><style face="normal" font="Arial"> Cooper,S.F.</style></author><author><style face="normal" font="Arial"> Acebal,M.L.</style></author><author><style face="normal" font="Arial"> Assa'ad,A.</style></author><author><style face="normal" font="Arial"> Baker,J.R.,Jr.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Block,J.</style></author><author><style face="normal" font="Arial"> Byrd-Bredbenner,C.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Fuchs,G.J.,III</style></author><author><style face="normal" font="Arial"> Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.J.</style></author><author><style face="normal" font="Arial"> Gupta,R.S.</style></author><author><style face="normal" font="Arial"> Habich,M.</style></author><author><style face="normal" font="Arial"> Jones,S.M.</style></author><author><style face="normal" font="Arial"> Keaton,K.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Plaut,M.</style></author><author><style face="normal" font="Arial"> Rosenwasser,L.J.</style></author><author><style face="normal" font="Arial"> Rotrosen,D.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Sidbury,R.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author><author><style face="normal" font="Arial"> Stukus,D.R.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Boyce,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Allergy and Infectious Diseases, Bethesda</style></auth-address><titles><title><style face="normal" font="Arial">Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Nurs</style></full-title></periodical><pages end="98" start="91">91-98</pages><volume><style face="normal" font="Arial">32</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy. OBJECTIVES: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy. RESULTS: The addendum provides 3 separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation. CONCLUSIONS: Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1532-8449 (Electronic)IS - 0882-5963 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pedn.2016.12.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28137368">PM:28137368</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Nurs\2017-32-91-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Nurs\2017-32-91-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Togias A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pedn.2016.12.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,W.K.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author><author><style face="normal" font="Arial"> Kim,M.H.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Choi,H.Y.</style></author><author><style face="normal" font="Arial"> Yeo,Y.</style></author><author><style face="normal" font="Arial"> Park,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Traditional Medicine and Bioscience, Daejeon University, Daejeon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Inhalable Microparticles of Seonpyejeongcheon-Tang in an Asthma Mouse Model: - Effects of Microparticles of SJT</style></title><secondary-title><style face="normal" font="Arial">J Pharmacopuncture</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pharmacopuncture</style></full-title></periodical><pages end="311" start="303">303-311</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerodynamic diameter</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Herbs</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> inhalation therapy</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Leucine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Spray drying</style></keyword><keyword><style face="normal" font="Arial"> Spray-drying</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Allergic asthma generally presents with symptoms of wheezing, coughing, breathlessness, and airway inflammation. Seonpyejeongcheon-tang (SJT) consists of 12 herbs. It originated from Jeongcheon-tang (JT), also known as Ding-chuan-tang, composed of 7 herbs, in She-sheng-zhong-miao-fang. This study aimed to evaluate the effects of local delivery of SJT via inhalable microparticles in an asthma mouse model. METHODS: Microparticles containing SJT were produced by spray-drying with leucine as an excipient. SJT microparticles were evaluated with respect to their aerodynamic properties, in vitro cytotoxicity, in vivo toxicity, and therapeutic effects on ovalbumin (OVA)-induced asthma in comparison with orally-administered SJT. RESULTS: SJT microparticles provided desirable aerodynamic properties (fine particle fraction of 48.9% +/- 6.4% and mass median aerodynamic diameter of 3.7 +/- 0.3 mum). SJT microparticles did not show any cytotoxicity against RAW 264.7 macrophages at concentrations of 0.01 - 3 mg/mL. Inhaled SJT microparticles decreased the levels of IL-4, IL-5, IL-13, IL-17A, eotaxin and OVA-IgE in bronchoalveolar lavage fluid (BALF) in mice with OVA-induced asthma. These effects were verified by histological evaluation of the levels of infiltration of inflammatory cells and collagen, destructions of alveoli and bronchioles, and hyperplasia of goblet cells in lung tissues. The effects of SJT microparticles in the asthma model were equivalent to those of orally-administered SJT extract. CONCLUSION: This study suggests that SJT is a promising agent for inhalation therapy for patients with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 2093-6966 (Print)IS - 2093-6966 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3831/KPI.2016.19.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28097040">PM:28097040</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharmacopuncture\2016-19-303-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharmacopuncture\2016-19-303-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Yang WK</style></custom2><misc3><style face="normal" font="Arial">10.3831/KPI.2016.19.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kuda,Y.</style></author><author><style face="normal" font="Arial"> Shibamoto,T.</style></author><author><style face="normal" font="Arial"> Zhang,T.</style></author><author><style face="normal" font="Arial"> Yang,W.</style></author><author><style face="normal" font="Arial"> Tanida,M.</style></author><author><style face="normal" font="Arial"> Kurata,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physiology II, Kanazawa Medical University, Uchinada, Kahoku-gun, Ishikawa, 920-0293, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Gastric vascular and motor responses to anaphylactic hypotension in anesthetized rats, in comparison to those with hemorrhagic or vasodilator-induced hypotension</style></title><secondary-title><style face="normal" font="Arial">J Physiol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Physiol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gastric Emptying</style></keyword><keyword><style face="normal" font="Arial"> Hemodynamics</style></keyword><keyword><style face="normal" font="Arial"> Hemorrhage</style></keyword><keyword><style face="normal" font="Arial"> hemorrhagic</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vascular Resistance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">Anaphylactic shock is life-threatening, but pathophysiology of the stomach lesion remains unclear. We determined gastric hemodynamics and gastric functions during anaphylactic hypotension, as compared to hypotension induced by hemorrhage or sodium nitroprusside (SNP) in anesthetized and ovalbumin-sensitized Sprague-Dawley rats. Systemic arterial pressure, portal venous pressure, and gastric arterial blood flow were measured, and gastric vascular resistance (GVR) was determined. Separately, the intragastric pressure (IGP) and gastric effluent, as a measure of gastric flux, were continuously measured. During anaphylaxis, GVR decreased only transiently at 0.5 min, followed by an increase. IGP increased markedly, while gastric flux decreased. During hemorrhage, GVR and IGP increased, while gastric flux did not change. When SNP was injected, both GVR and IGP decreased and gastric flux increased only just after injection. In conclusion, gastric vasodilatation occurs only transiently after antigen injection, and gastric motility increases, but gastric emptying deceases during anaphylactic hypotension in anesthetized rats</style></abstract><notes><style face="normal" font="Arial">DA - 20170201IS - 1880-6562 (Electronic)IS - 1880-6546 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s12576-017-0527-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28144845">PM:28144845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Physiol Sci\20170201-KudaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Physiol Sci\20170201-KudaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170201, Kuda Y</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s12576-017-0527-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korte,R.</style></author><author><style face="normal" font="Arial"> Happe,J.</style></author><author><style face="normal" font="Arial"> Brummer,I.</style></author><author><style face="normal" font="Arial"> Brockmeyer,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Food Chemistry, Westfalische Wilhelms-Universitat Munster , Corrensstrasse 45, 48149 Munster, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Structural Characterization of the Allergenic 2S Albumin Cor a 14: Comparing Proteoform Patterns across Hazelnut Cultivars</style></title><secondary-title><style face="normal" font="Arial">J Proteome Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteome Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> 2S Albumins</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Cor a 14</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">The hazelnut allergen Cor a 14 belongs to the 2S albumins, a family of heterodimeric seed storage proteins exhibiting a high degree of structural diversity. Given its relevance as an allergen and the potential to elicit severe reactions, elucidation of the sequence heterogeneity of naturally occurring Cor a 14 is essential for the development of reliable diagnostics and risk evaluation. We therefore performed a comprehensive survey on the proteoforms of Cor a 14 and determined their quantitative distribution in three different hazelnut cultivars by a combinatory HPLC-HRMS approach including bottom-up and intact mass analysis. Compared with the Cor a 14 prototype sequence, we identified three sequence polymorphisms, two of the small and one of the large subunit, and elucidated their specific pairing on the protein level. Furthermore, we located a pronounced microheterogeneity on the protein termini and, for the first time, provide data on varying proteoform patterns between different cultivars of an allergenic seed. Together, these data present the basis for a more detailed investigation on the allergenicity of Cor a 14 in different cultivars and constitute, to be best of our knowledge, the largest set of proteoforms so far reported for a 2S albumin</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 1535-3907 (Electronic)IS - 1535-3893 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jproteome.6b00924</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28112517">PM:28112517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteome Res\20170123-KorteR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteome Res\20170123-KorteR.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteome Res\20170123-KorteR.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteome Res\20170123-KorteR.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170123, Korte R</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jproteome.6b00924</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lasekan,A.</style></author><author><style face="normal" font="Arial"> Cao,H.</style></author><author><style face="normal" font="Arial"> Maleki,S.</style></author><author><style face="normal" font="Arial"> Balunkeswar,B.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Science and Human Nutrition, School of Food and Agriculture, University of Maine, Orono, 04469, ME, United States</style></auth-address><titles><title><style face="normal" font="Arial">Shrimp Tropomyosin Retains Antibody Reactivity after Exposure to Acidic Condition</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extractability</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> myofibrillar</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein fraction</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although shrimp can be found in certain high acid food matrix, the allergenic capacity of shrimp tropomyosin exposed to low pH condition has not been fully clarified. Thus, a model marinade comprising white vinegar adjusted to different pH was used to determine the effects of acid-induced denaturation on the immunoreactivity of tropomyosin. RESULTS: Whole shrimp experienced either swelling or shrinkage after marination depending on the vinegar pH and the final muscle pH. The extractability of soluble myofibrillar proteins was reduced significantly among shrimp marinated in vinegar at pH 1.0 - 3.5 and a substantial amount of tropomyosin were retained in the insoluble pellets. Consequently, the IgE - binding capacity of tropomyosin was significantly lower in the soluble protein fraction of shrimp marinated at pH 1.0 - 3.5 compared with samples marinated at pH 4.8 and control. However, tropomyosin in the insoluble protein fraction of all marinated shrimp showed strong IgE - binding capacity at all marinating conditions. CONCLUSION: Thus, tropomyosin in shrimp exposed to low pH condition retained its allergenic capacity due to the conservation of its linear epitopes. Analysis of the insoluble protein fraction was crucial for the accurate determination of the effect of low pH condition on the immunoreactivity of this allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8221</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102019">PM:28102019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170119-LasekanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170119-LasekanA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Lasekan A</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8221</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matos Fialho,P.M.</style></author><author><style face="normal" font="Arial"> Correa,C.R.</style></author><author><style face="normal" font="Arial"> Lescano,S.Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculdade de Ciencias Medicas, Departamento de Saude Coletiva, Campinas, Sao Paulo, Brasil</style></auth-address><titles><title><style face="normal" font="Arial">Seroprevalence of Toxocariasis In Children With Urticaria: A Population-Based Study</style></title><secondary-title><style face="normal" font="Arial">J Trop Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Trop Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Toxocara</style></keyword><keyword><style face="normal" font="Arial"> Toxocariasis</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: This study described the prevalence of IgG class antibodies against Toxocara spp. and their association with urticaria in 2- to 12-year-old children. METHODS: This population-based cross-sectional study was conducted between May 2012 and September 2014. The study sample comprised 168 children. Blood samples were collected to verify the presence of toxocariasis by using ELISA to detect IgG antibodies. The guardians of the children were interviewed to characterize the presence or absence of other diseases, such as urticaria. RESULTS: The presence of urticaria was observed in 38% of participants. The seroprevalence of toxocariasis in this population was 16%. This study confirmed a positive association between urticaria and positive serology for Toxocara and a negative independent association with canine contact and the number of household residents. CONCLUSIONS: There are no previous reports in the literature of a population-based study that correlates the presence of urticaria with serology for toxocariasis</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1465-3664 (Electronic)IS - 0142-6338 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1093/tropej/fmw094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28077610">PM:28077610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Trop Pediatr\20170122-MatosFialhoPM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Trop Pediatr\20170122-MatosFialhoPM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Matos Fialho PM</style></custom2><misc3><style face="normal" font="Arial">10.1093/tropej/fmw094</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rickman,S.</style></author><author><style face="normal" font="Arial"> Duby,D.</style></author><author><style face="normal" font="Arial"> Peters,M.</style></author><author><style face="normal" font="Arial"> Freigeh,C.</style></author><author><style face="normal" font="Arial"> Archambault,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shelley Rickman, Desiree Duby, Michelle Peters, and Carla Freigeh are students in the PA program at High Point (N.C.) University. Mark E. Archambault is director of research and an associate professor at High Point University, and department editor of What's New in. The authors have disclosed no potential conflicts of interest, financial or otherwise</style></auth-address><titles><title><style face="normal" font="Arial">Early introduction of peanuts</style></title><secondary-title><style face="normal" font="Arial">JAAPA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAAPA</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">Peanut allergy is the most common food allergy and the leading cause of anaphylaxis and death due to food allergy. Despite previous guidelines created by the American Academy of Pediatrics in 2003, peanut allergy has continued to significantly increase over the past decade. Therefore, further research has been done to help clinicians provide more evidence-based recommendations about the timing of introduction of peanuts. The LEAP study, published in February 2015, demonstrated the value of much earlier introduction of peanuts to nonallergic patients than previously suggested. These findings have altered current practice, and recommendations supported by the American Academy of Pediatrics now allow the introduction of peanuts as early as age 4 months to reduce the likelihood of developing peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 1547-1896 (Print)IS - 0893-7400 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/01.JAA.0000512245.89365.e2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28151740">PM:28151740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAAPA\20170202-RickmanS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAAPA\20170202-RickmanS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Rickman S</style></custom2><misc3><style face="normal" font="Arial">10.1097/01.JAA.0000512245.89365.e2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sage,A.</style></author><author><style face="normal" font="Arial"> Roberts,C.</style></author><author><style face="normal" font="Arial"> Geryk,L.</style></author><author><style face="normal" font="Arial"> Sleath,B.</style></author><author><style face="normal" font="Arial"> Tate,D.</style></author><author><style face="normal" font="Arial"> Carpenter,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States</style></auth-address><titles><title><style face="normal" font="Arial">A Self-Regulation Theory-Based Asthma Management Mobile App for Adolescents: A Usability Assessment</style></title><secondary-title><style face="normal" font="Arial">JMIR Hum Factors</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">JMIR Hum Factors</style></abbr-1></periodical><pages end="" start="e5">e5-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> graphical displays</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Self-regulation theory suggests people learn to influence their own behavior through self-monitoring, goal-setting, feedback, self-reward, and self-instruction, all of which smartphones are now capable of facilitating. Several mobile apps exist to manage asthma; however, little evidence exists about whether these apps employ user-centered design processes that adhere to government usability guidelines for mobile apps. OBJECTIVE: Building upon a previous study that documented adolescent preferences for an asthma self-management app, we employed a user-centered approach to assess the usability of a high-fidelity wireframe for an asthma self-management app intended for use by adolescents with persistent asthma. METHODS: Individual interviews were conducted with adolescents (ages 11-18 years) with persistent asthma who owned a smartphone (N=8). Adolescents were asked to evaluate a PDF app wireframe consisting of 76 screen shots displaying app features, including log in and home screen, profile setup, settings and info, self-management features, and graphical displays for charting asthma control and medication. Preferences, comments, and suggestions for each set of screen shots were assessed using the audio-recorded interviews. Two coders reached consensus on adolescent evaluations of the following aspects of app features: (1) usability, (2) behavioral intentions to use, (3) confusing aspects, and (4) suggestions for improvement. RESULTS: The app wireframe was generally well received, and several suggestions for improvement were recorded. Suggestions included increased customization of charts and notifications, reminders, and alerts. Participants preferred longitudinal data about asthma control and medication use to be displayed using line graphs. All participants reported that they would find an asthma management app like the one depicted in the wireframe useful for managing their asthma. CONCLUSIONS: Early stage usability tests guided by government usability guidelines (usability.gov) revealed areas for improvement for an asthma self-management app for adolescents. Addressing these areas will be critical to developing an engaging and effective asthma self-management app that is capable of improving adolescent asthma outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 2292-9495 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2196/humanfactors.7133</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28148471">PM:28148471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JMIR Hum Factors\2017-4-e5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JMIR Hum Factors\2017-4-e5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Sage A</style></custom2><misc3><style face="normal" font="Arial">10.2196/humanfactors.7133</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ye,J.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Xuan,Y.</style></author><author><style face="normal" font="Arial"> Chen,S.</style></author><author><style face="normal" font="Arial"> Ma,L.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Zheng,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Factors Associated with Echinococcosis-Induced Perioperative Anaphylactic Shock</style></title><secondary-title><style face="normal" font="Arial">Korean J Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Korean J Parasitol</style></full-title></periodical><pages end="775" start="769">769-775</pages><volume><style face="normal" font="Arial">54</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cystic echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">This retrospective case-control study explored the factors associated with anaphylactic shock during surgery for cystic echinococcosis (CE) at the First Affiliated Hospital of Xinjiang Medical University between October 2008 and September 2013. Patients who suffered from anaphylactic shock (n=16) were age-matched 3:1 to patients who did not (n=43). Multivariate analysis suggested that IL-4 levels (odds ratio=1.096; 95% confidence interval=1.015-1.185; P=0.02) and cyst size (odds ratio=3.028, 95% confidence interval=1.259-7.283, P=0.013) were independently associated with CE-induced perioperative anaphylactic shock. Using the receiver operating characteristic (ROC) curves and a cut-off value of 415.7 ng/ml, IL-4 showed an area under the ROC (AUC) of 0.926, sensitivity of 75.0%, and specificity of 97.7%. Using a cut-off value of 7.8 cm, cyst size showed an AUC of 0.828, sensitivity of 81.3%, and specificity of 76.7%. In conclusion, results suggest that levels of IL-4 and cyst size were independently associated with echinococcosis-induced perioperative anaphylactic shock. These results could help identifying patients with echinococcosis at risk of anaphylactic shock in whom appropriate prophylaxis could be undertaken</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1738-0006 (Electronic)IS - 0023-4001 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3347/kjp.2016.54.6.769</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095662">PM:28095662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Parasitol\2016-54-769-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Parasitol\2016-54-769-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Ye J</style></custom2><misc3><style face="normal" font="Arial">10.3347/kjp.2016.54.6.769</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smith,W.B.</style></author><author><style face="normal" font="Arial"> Kette,F.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Royal Adelaide Hospital, Adelaide, SA</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy for respiratory allergic disease in Australia in 2016</style></title><secondary-title><style face="normal" font="Arial">Med J Aust</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med J Aust</style></full-title></periodical><pages end="61" start="60">60-61</pages><volume><style face="normal" font="Arial">206</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 1326-5377 (Electronic)IS - 0025-729X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.5694/mja16.00953</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28152347">PM:28152347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med J Aust\2017-206-60-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med J Aust\2017-206-60-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Smith WB</style></custom2><misc3><style face="normal" font="Arial">10.5694/mja16.00953</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,M.S.</style></author><author><style face="normal" font="Arial"> Kim,J.Y.</style></author><author><style face="normal" font="Arial"> Kim,B.K.</style></author><author><style face="normal" font="Arial"> Park,H.W.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author><author><style face="normal" font="Arial"> Min,K.U.</style></author><author><style face="normal" font="Arial"> Kang,H.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDepartment of Internal medicine, SMG-SNU Boramae Medical Center bInstitute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul cDepartment of Internal Medicine, Gyeongsang National University Hospital, Jinju dDepartment of Internal medicine, Seoul National University Bundang Hospital, Seongnam eDepartment of Internal medicine, Seoul National University College of Medicine fDrug Safety Monitoring Center, Seoul National University Hospital, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">True rise in anaphylaxis incidence: Epidemiologic study based on a national health insurance database</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e5750">e5750-</pages><volume><style face="normal" font="Arial">96</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">The incidence trend of anaphylaxis in Asia is not well investigated. The aim of this study is to estimate the entire population-based incidence of anaphylaxis in Korea using a nationwide administrative database.Data over a 7-year period (2008-2014) was obtained from the Korean National Health Insurance (NHI) claims database which covers 97.9% of the entire Korean population. Using diagnosis codes from the International Classification of Diseases-10 for anaphylaxis (T78.0, T78.2, T80.5, and T88.6), we identified the annual number of patients who had visited any hospital with a primary diagnosis of anaphylaxis. Incidence rates were calculated using the population distribution data of all NHI beneficiaries.The incidence of anaphylaxis in Korea was 32.19 episodes per 100,000 person-years in 2014, which nearly doubled from 2008 (16.02 episodes per 100,000 person-years). The incidence of anaphylaxis increased continuously throughout these years regardless of gender and age groups (P for trend &lt; 0.001). Female was significantly less predisposed than male (adjusted odds ratio [OR], 0.69; 95% confident interval [CI], 0.66-0.72; P &lt; 0.001). The incidence was the lowest in 0 to 19 age group and the highest in 40 to 69 age group (adjusted OR, 2.41; 95% CI, 2.29-2.54; P &lt; 0.001).In conclusion, we report the increasing time trend of anaphylaxis incidence rates using nationwide claims database for the first time in Asia</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000005750</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28151851">PM:28151851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2017-96-e5750.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2017-96-e5750.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Yang MS</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000005750</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamilton,R.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Microarray Technology Applied to Human Allergic Disease</style></title><secondary-title><style face="normal" font="Arial">Microarrays (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Microarrays (Basel)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody Specificity</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Glass</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immediate-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immulite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray assay</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> singleplex</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="28" Month="1" Year="2017">2017/1/28</year></dates><abstract><style face="normal" font="Arial">IgE antibodies serve as the gatekeeper for the release of mediators from sensitized (IgE positive) mast cells and basophils following a relevant allergen exposure which can lead to an immediate-type hypersensitivity (allergic) reaction. Purified recombinant and native allergens were combined in the 1990s with state of the art chip technology to establish the first microarray-based IgE antibody assay. Triplicate spots to over 100 allergenic molecules are immobilized on an amine-activated glass slide to form a single panel multi-allergosorbent assay. Human antibodies, typically of the IgE and IgG isotypes, specific for one or many allergens bind to their respective allergen(s) on the chip. Following removal of unbound serum proteins, bound IgE antibody is detected with a fluorophore-labeled anti-human IgE reagent. The fluorescent profile from the completed slide provides a sensitization profile of an allergic patient which can identify IgE antibodies that bind to structurally similar (cross-reactive) allergen families versus molecules that are unique to a single allergen specificity. Despite its ability to rapidly analyze many IgE antibody specificities in a single simple assay format, the chip-based microarray remains less analytically sensitive and quantitative than its singleplex assay counterpart (ImmunoCAP, Immulite). Microgram per mL quantities of allergen-specific IgG antibody can also complete with nanogram per mL quantities of specific IgE for limited allergen binding sites on the chip. Microarray assays, while not used in clinical immunology laboratories for routine patient IgE antibody testing, will remain an excellent research tool for defining sensitization profiles of populations in epidemiological studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 2076-3905 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/microarrays6010003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28134842">PM:28134842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microarrays (Basel)\20170130-HamiltonRG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microarrays (Basel)\20170130-HamiltonRG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Hamilton RG</style></custom2><misc3><style face="normal" font="Arial">10.3390/microarrays6010003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maizels,R.M.</style></author><author><style face="normal" font="Arial"> Hewitson,J.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Myeloid Cell Phenotypes in Susceptibility and Resistance to Helminth Parasite Infections</style></title><secondary-title><style face="normal" font="Arial">Microbiol Spectr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Microbiol Spectr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasite infection</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Many major tropical diseases are caused by long-lived helminth parasites that are able to survive by modulation of the host immune system, including the innate compartment of myeloid cells. In particular, dendritic cells and macrophages show markedly altered phenotypes during parasite infections. In addition, many specialized subsets such as eosinophils and basophils expand dramatically in response to these pathogens. The changes in phenotype and function, and their effects on both immunity to infection and reactivity to bystander antigens such as allergens, are discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 2165-0497 (Electronic)IS - 2165-0497 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1128/microbiolspec.MCHD-0043-2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087937">PM:28087937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microbiol Spectr\20170114-MaizelsRM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microbiol Spectr\20170114-MaizelsRM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170114, Maizels RM</style></custom2><misc3><style face="normal" font="Arial">10.1128/microbiolspec.MCHD-0043-2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gordon,J.</style></author><author><style face="normal" font="Arial"> Gandhi,P.</style></author><author><style face="normal" font="Arial"> Shekhawat,G.</style></author><author><style face="normal" font="Arial"> Frazier,A.</style></author><author><style face="normal" font="Arial"> Hampton-Marcell,J.</style></author><author><style face="normal" font="Arial"> Gilbert,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inspirotec LLC, 3307 Meadow Lane, Glenview, IL, 60025, USA.</style></auth-address><titles><title><style face="normal" font="Arial">A simple novel device for air sampling by electrokinetic capture</style></title><secondary-title><style face="normal" font="Arial">Microbiome</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Microbiome</style></abbr-1></periodical><pages end="" start="79">79-</pages><volume><style face="normal" font="Arial">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerosols</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air sampling</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> Equipment Design</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evaluation Studies</style></keyword><keyword><style face="normal" font="Arial"> filter</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> instrumentation</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="27" Month="12" Year="2015">2015/12/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A variety of different sampling devices are currently available to acquire air samples for the study of the microbiome of the air. All have a degree of technical complexity that limits deployment. Here, we evaluate the use of a novel device, which has no technical complexity and is easily deployable. RESULTS: An air-cleaning device powered by electrokinetic propulsion has been adapted to provide a universal method for collecting samples of the aerobiome. Plasma-induced charge in aerosol particles causes propulsion to and capture on a counter-electrode. The flow of ions creates net bulk airflow, with no moving parts. A device and electrode assembly have been re-designed from air-cleaning technology to provide an average air flow of 120 lpm. This compares favorably with current air sampling devices based on physical air pumping. Capture efficiency was determined by comparison with a 0.4 mum polycarbonate reference filter, using fluorescent latex particles in a controlled environment chamber. Performance was compared with the same reference filter method in field studies in three different environments. For 23 common fungal species by quantitative polymerase chain reaction (qPCR), there was 100 % sensitivity and apparent specificity of 87 %, with the reference filter taken as "gold standard." Further, bacterial analysis of 16S RNA by amplicon sequencing showed equivalent community structure captured by the electrokinetic device and the reference filter. Unlike other current air sampling methods, capture of particles is determined by charge and so is not controlled by particle mass. We analyzed particle sizes captured from air, without regard to specific analyte by atomic force microscopy: particles at least as low as 100 nM could be captured from ambient air. CONCLUSIONS: This work introduces a very simple plug-and-play device that can sample air at a high-volume flow rate with no moving parts and collect particles down to the sub-micron range. The performance of the device is substantially equivalent to capture by pumping through a filter for microbiome analysis by quantitative PCR and amplicon sequencing</style></abstract><notes><style face="normal" font="Arial">DA - 20151230IS - 2049-2618 (Linking)LA - engPT - Evaluation StudiesPT - Journal ArticlePT - Research Support, U.S. Gov't, Non-P.H.SRN - 0 (Aerosols)RN - 0 (Air Pollutants)SB - IMCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40168-015-0141-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26715467">PM:26715467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microbiome\2015-3-79.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microbiome\2015-3-79.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151230, Gordon J</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40168-015-0141-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moya,R.</style></author><author><style face="normal" font="Arial"> Rubio,V.</style></author><author><style face="normal" font="Arial"> Beitia,J.M.</style></author><author><style face="normal" font="Arial"> Carnes,J.</style></author><author><style face="normal" font="Arial"> Lopez-Matas,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">R&amp;D Department, Laboratorios LETI, S.L.U., C/del Sol 5, Tres Cantos, 28760, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Purification and immunochemical characterization of Pla l 2, the profilin from Plantago lanceolata</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="106" start="100">100-106</pages><volume><style face="normal" font="Arial">83</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunoblot inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> IUIS</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pho d 2</style></keyword><keyword><style face="normal" font="Arial"> Pla l 2</style></keyword><keyword><style face="normal" font="Arial"> Plantago</style></keyword><keyword><style face="normal" font="Arial"> Plantago lanceolata</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> trafficking</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">Profilins are small actin-binding proteins found in eukaryotes and involved in cell development, cytokinesis, membrane trafficking, and cell motility. From an allergenic point of view, profilins are panallergens usually involved in allergic polysensitization, although they are generally recognized as minor allergens. The objectives of this study were to identify and characterize the profilin from Plantago lanceolata pollen and to investigate the cross-reactivity between profilins from different pollen allergenic sources. Profilins from P. lancelolata (Pla l 2) and palm tree pollen (Pho d 2) were purified by affinity chromatography, deeply characterized and identified by mass spectrometry. Pla l 2 allergenicity was confirmed by immunoblot with serum samples from a patient population sensitized to profilin. Immunoblot inhibition was performed to study IgG reactivity between different pollen profilins. IgE cross-reactivity was demonstrated by ImmunoCAP inhibition. Pla l 2 is the second P. lanceolata allergen included in the IUIS Allergen Nomenclature database. Four peptides from purified Pla l 2 were identified with percentages of homology with other pollen profilins between 73 and 86%. Eighty-six percent (21/24) of the patient population recognized Pla l 2. The allergenic relatedness between Pla l 2, Pho d 2 and six pollen profilins was confirmed, and IgE cross-reactivity of Pla l 2 with rBet v 2 and rPhl p 12 was demonstrated. Pla l 2 is the profilin from P. lanceolata. The demonstrated allergenicity of this protein and its cross-reactivity with other pollen profilins support its use in profilin diagnostic assays</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2017.01.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28126622">PM:28126622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-83-100-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2017-83-100-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Moya R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2017.01.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teixeira,H.M.</style></author><author><style face="normal" font="Arial"> Alcantara-Neves,N.M.</style></author><author><style face="normal" font="Arial"> Barreto,M.</style></author><author><style face="normal" font="Arial"> Figueiredo,C.A.</style></author><author><style face="normal" font="Arial"> Costa,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Ciencias da Saude, Universidade Federal da Bahia, Bahia, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Adenylyl cyclase type 9 gene polymorphisms are associated with asthma and allergy in Brazilian children</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="145" start="137">137-145</pages><volume><style face="normal" font="Arial">82</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> CAMP</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cyclic AMP</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene polymorphism</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> In silico analysis</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Latin America</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Social Change</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory disease of the respiratory tract. This heterogeneous disease is caused by the interaction of interindividual genetic variability and environmental factors. The gene adenylyl cyclase type 9 (ADCY9) encodes a protein called adenylyl cyclase (AC), responsible for producing the second messenger cyclic AMP (cAMP). cAMP is produced by T regulatory cells and is involved in the down-regulation of T effector cells. Failures in cAMP production may be related to an imbalance in the regulatory immune response, leading to immune-mediated diseases, such as allergic disorders. The aim of this study was to investigate how polymorphisms in the ADCY9 are associated with asthma and allergic markers. The study comprised 1309 subjects from the SCAALA (Social Changes Asthma and Allergy in Latin America) program. Genotyping was accomplished using the Illumina 2.5 Human Omni bead chip. Logistic regression was used to assess the association between allergy markers and ADCY9 variation in PLINK 1.07 software with adjustments for sex, age, helminth infection and ancestry markers. The ADCY9 candidate gene was associated with different phenotypes, such as asthma, specific IgE, skin prick test, and cytokine production. Among 133 markers analyzed, 29 SNPs where associated with asthma and allergic markers in silico analysis revealed the functional impact of the 6 SNPs on ADCY9 expression. It can be concluded that polymorphisms in the ADCY9 gene are significantly associated with asthma and/or allergy markers. We believe that such polymorphisms may lead to increased expression of adenylyl cyclase with a consequent increase in immunoregulatory activity. Therefore, these SNPs may offer an impact on the occurrence of these conditions in admixture population from countries such as Brazil</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28076799">PM:28076799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-82-137-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2017-82-137-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Teixeira HM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2017.01.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agarwal,R.</style></author><author><style face="normal" font="Arial"> Bhogal,S.</style></author><author><style face="normal" font="Arial"> Choudhary,H.</style></author><author><style face="normal" font="Arial"> Aggarwal,A.N.</style></author><author><style face="normal" font="Arial"> Sehgal,I.S.</style></author><author><style face="normal" font="Arial"> Dhooria,S.</style></author><author><style face="normal" font="Arial"> Behera,D.</style></author><author><style face="normal" font="Arial"> Chakrabarti,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India</style></auth-address><titles><title><style face="normal" font="Arial">Aspergillus sensitisation in bidi smokers with and without chronic obstructive lung disease</style></title><secondary-title><style face="normal" font="Arial">Mycoses</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycoses</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Precipitins</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> radiography</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">Recent studies have described fungal sensitisation in patients with chronic obstructive pulmonary disease (COPD). However, no study has evaluated fungal sensitisation specifically in bidi smokers. Herein, we evaluate the prevalence of Aspergillus sensitisation in bidi smokers. Bidi smokers with and without COPD underwent chest radiography, spirometry, Aspergillus skin test, A. fumigatus precipitins, A. fumigatus-specific IgE and total IgE. Aspergillus sensitisation was defined as the presence of either immediate cutaneous hyperreactivity to Aspergillus antigen or raised A. fumigatus-specific IgE level >0.35 kUA/L. Bidis were obtained from a subset of cases and controls and cultured for the growth of any fungus. Two hundred subjects with COPD and 72 chronic bidi smokers without COPD were included in the study (258 men; mean age, 56.8 years). Aspergillus sensitisation was found to be significantly higher in bidi smokers without COPD (27.8%) compared to the COPD cases (16%). Age, COPD, lung function, severity of smoking and current smoking were not associated with Aspergillus sensitisation, on a multivariate logistic regression analysis. We found a high prevalence of Aspergillus sensitisation in bidi-smoking subjects. More studies are required to confirm the findings of our study</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1439-0507 (Electronic)IS - 0933-7407 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1111/myc.12605</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28139853">PM:28139853</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycoses\20170131-AgarwalR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycoses\20170131-AgarwalR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Agarwal R</style></custom2><misc3><style face="normal" font="Arial">10.1111/myc.12605</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">JanssenDuijghuijsen,L.M.</style></author><author><style face="normal" font="Arial"> van Norren,K.</style></author><author><style face="normal" font="Arial"> Grefte,S.</style></author><author><style face="normal" font="Arial"> Koppelman,S.J.</style></author><author><style face="normal" font="Arial"> Lenaerts,K.</style></author><author><style face="normal" font="Arial"> Keijer,J.</style></author><author><style face="normal" font="Arial"> Witkamp,R.F.</style></author><author><style face="normal" font="Arial"> Wichers,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Wageningen Food and Biobased Research, Wageningen University and Research, P.O. Box 17, 6700 AA Wageningen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Endurance Exercise Increases Intestinal Uptake of the Peanut Allergen Ara h 6 after Peanut Consumption in Humans</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> intestinal permeability</style></keyword><keyword><style face="normal" font="Arial"> Lactulose</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> peanut consumption</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword><keyword><style face="normal" font="Arial"> Workload</style></keyword></keywords><dates><year Day="21" Month="1" Year="2017">2017/1/21</year></dates><abstract><style face="normal" font="Arial">Controlled studies on the effect of exercise on intestinal uptake of protein are scarce and underlying mechanisms largely unclear. We studied the uptake of the major allergen Ara h 6 following peanut consumption in an exercise model and compared this with changes in markers of intestinal permeability and integrity. Ten overnight-fasted healthy non-allergic men (n = 4) and women (n = 6) (23 +/- 4 years) ingested 100 g of peanuts together with a lactulose/rhamnose (L/R) solution, followed by rest or by 60 min cycling at 70% of their maximal workload. Significantly higher, though variable, levels of Ara h 6 in serum were found during exercise compared to rest (Peak p = 0.03; area under the curve p = 0.006), with individual fold changes ranging from no increase to an increase of over 150-fold in the uptake of Ara h 6. Similarly, uptake of lactulose (2-18 fold change, p = 0.0009) and L/R ratios (0.4-7.9 fold change, p = 0.04) were significantly increased which indicates an increase in intestinal permeability. Intestinal permeability and uptake of Ara h 6 were strongly correlated (r = 0.77, p &lt; 0.0001 for lactulose and Ara h 6). Endurance exercise after consumption may lead to increased paracellular intestinal uptake of food proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9010084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28117717">PM:28117717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\20170124-JanssenDuijghuijsenLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\20170124-JanssenDuijghuijsenLM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, JanssenDuijghuijsen LM</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9010084</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kyogoku,N.</style></author><author><style face="normal" font="Arial"> Ikeda,H.</style></author><author><style face="normal" font="Arial"> Tsuchikawa,T.</style></author><author><style face="normal" font="Arial"> Abiko,T.</style></author><author><style face="normal" font="Arial"> Fujiwara,A.</style></author><author><style face="normal" font="Arial"> Maki,T.</style></author><author><style face="normal" font="Arial"> Yamamura,Y.</style></author><author><style face="normal" font="Arial"> Ichinokawa,M.</style></author><author><style face="normal" font="Arial"> Tanaka,K.</style></author><author><style face="normal" font="Arial"> Imai,N.</style></author><author><style face="normal" font="Arial"> Miyahara,Y.</style></author><author><style face="normal" font="Arial"> Kageyama,S.</style></author><author><style face="normal" font="Arial"> Shiku,H.</style></author><author><style face="normal" font="Arial"> Hirano,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel</style></title><secondary-title><style face="normal" font="Arial">Oncol Lett</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Oncol Lett</style></abbr-1></periodical><pages end="4504" start="4493">4493-4504</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Melanoma</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">A phase I+II clinical trial of vaccination with MAGE-A4 protein complexed with cholesteryl pullulan melanoma antigen gene-A4 nanogel (CHP-MAGE-A4) is currently underway in patients with MAGE-A4-expressing cancer. In the present study, the primary phase I endpoint was to test the safety of the administration of 300 microg CHP-MAGE-A4 with and without OK-432. Another aim of the study was to clarify the details of the specific humoral immune response to vaccination. The 9 patients enrolled for phase I were vaccinated 6 times, once every 2 weeks: 3 patients with 100 microg and 3 patients with 300 microg CHP-MAGE-A4, and 3 patients with 300 microg CHP-MAGE-A4 plus 0.5 clinical units of OK-432. Toxicities were assessed using Common Terminology Criteria for Adverse Events v3.0. Clinical response was evaluated by modified Response Evaluation Criteria in Solid Tumours. Immunological monitoring of anti-MAGE-A4-specific antibodies was performed by ELISA of pre- and post-vaccination patient sera. The 6 vaccinations produced no severe adverse events. Stable disease was assessed in 4/9 patients. Anti-MAGE-A4 total immunoglobulin (Ig)G titers increased in 7/9 patients. Efficacious anti-MAGE-A4 IgG1, 2 and 3 antibody responses were observed in 7/9 patients. Among them, positive conversions to T helper 2 (Th2)-type antibody responses (IgG4 and IgE) were observed after frequent vaccination in 4/7 patients. The Th2 conversion was possibly associated with undesirable clinical observations, including progressive disease and the appearance of a new relapse lesion. The present study suggested that frequent vaccinations activated a Th2-dominant status in the cancer patients. The identification of a time-dependent IgG subclass and IgE antibody production during vaccination protocols may be a useful surrogate marker indicating a potentially undesirable change of the immunological environment for an effective antitumor immune response in cancer patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1792-1074 (Print)IS - 1792-1074 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3892/ol.2016.5253</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28105158">PM:28105158</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncol Lett\2016-12-4493-504.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncol Lett\2016-12-4493-504.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Kyogoku N</style></custom2><misc3><style face="normal" font="Arial">10.3892/ol.2016.5253</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xie,R.D.</style></author><author><style face="normal" font="Arial"> Xu,L.Z.</style></author><author><style face="normal" font="Arial"> Yang,L.T.</style></author><author><style face="normal" font="Arial"> Wang,S.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Research Center of Allergy &amp; Immunology, Shenzhen University School of Medicine, Shenzhen, China</style></auth-address><titles><title><style face="normal" font="Arial">Galectin-1 inhibits oral-intestinal allergy syndrome</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="13222" start="13214">13214-13222</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Galectin 1</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral mucosa</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND AIMS: The pathogenesis of oral-intestinal allergy syndrome (OIAS) has not been well understood. Published data indicate that galectin (Gal) 1 has immune regulatory functions. This study tests a hypothesis that Gal1 inhibits oral-intestinal allergy syndrome. METHODS: Mice were sensitized to peanut extracts (PE) via the buccal mucosa with or without using Gal1 together. RESULTS: Upon re-exposure to specific antigen, the OIAS mice showed the systemic allergic response, the oral allergic reactions, and intestinal allergic inflammation, including increases in serum histamine, drop of the core temperature, higher levels of PE-specific IgE and interleukin (IL)-4. Increases in mast cell and eosinophil in the oral mucosa and intestinal mucosa were also observed. The OIAS was inhibited by co-administration with Gal1 via a mechanism of suppressing micro RNA (miR)-98 and reversing the expression of IL-10 in CD14+ cells in the intestine. CONCLUSIONS: The OIAS can be induced by applying specific antigens to the oral mucosa, which can be inhibited by co-administration with Gal1</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.14571</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28086216">PM:28086216</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170113-XieRD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170113-XieRD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Xie RD</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.14571</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ye,J.</style></author><author><style face="normal" font="Arial"> Talaiti,A.</style></author><author><style face="normal" font="Arial"> Ma,Y.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Ma,L.</style></author><author><style face="normal" font="Arial"> Zheng,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergies and risk of colorectal cancer: a systematic review and meta-analysis of observational studies</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> Rectum</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">A history of allergy or allergic condition has been reported to be associated with reduced risk of some types of malignancies. However, the understanding of this association for colorectal cancer (CRC) is controversial. We conducted a meta-analysis of CRC risk in individuals who had history of allergy compared to those without the history of allergic condition. Pumbed and Embase databases were searched for relevant studies. The adjusted relative risk (RR) and 95% confidence interval (CI) were pooled using the random-effects model. Nine studies, including 775, 178 individuals, were eligible for inclusion. The pooled estimate showed no significant association between history of allergy and CRC risk (adjusted RR 1.01, 95 % CI 0.88-1.17). Subgroup analyses confirmed the neutral association stratified by tumor location (colon: n = 6 studies; adjusted RR 1.01, 95 % CI 0.81-1.25; rectum: n = 6 studies; adjusted RR 0.94, 95% CI 0.77-1.15; colorectum: n = 3 studies; adjusted RR 0.92, 95 % CI 0.70 to 1.21), sex (male: n = 4 studies; adjusted RR 0.93, 95 % CI 0.81-1.07; female: n = 6 studies; adjusted RR 0.94, 95 % CI 0.80-1.09) or by allery type (asthma: n = 5 studies; adjusted RR 1.16, 95 % CI 0.96-1.42; hay fever: n = 4 studies; adjusted RR 0.93, 95 % CI 0.86-1.03). Meta-analysis of existing evidence provides a neutral association between allergies and CRC risk. Future well-designed prospective cohort studies should be conducted to better understand this association</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.14599</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28086228">PM:28086228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170113-YeJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170113-YeJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Ye J</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.14599</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,C.H.</style></author><author><style face="normal" font="Arial"> Lin,H.H.</style></author><author><style face="normal" font="Arial"> Kuo,C.Y.</style></author><author><style face="normal" font="Arial"> Kao,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> extracellular signal-regulated kinase</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inositol</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung cancer</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> Plasminogen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Src</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="Arial">House dust mite (HDM) allergens are one of the major causes leading to respiratory hypersensitiveness and airway remodeling. Here we hypothesized that a major HDM allergen Der p 2 could increase cell motility and invasiveness of non-small cell lung cancer (NSCLC) cells. Our results showed that low dose (1 and 3 mug/mL) recombinant Der p 2 protein (DP2) enhanced the migration and invasiveness of human NSCLC cell A549, H1299 and CL1-5, but nonsignificantly altered their growth. Further investigation revealed that integrin alphaV level was increased and its downstream signaling including focal adhesion kinase (FAK) and paxillin were activated in A549 cells exposed to DP2. In parallel, DP2 also activated the FAK-associated signaling effectors such as Src, phosphatidyl inositol 3-kinase (PI3K), AKT, p38 mitogen-activated protein kinase (P38), extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK). Our findings also revealed that DP2 increased expression level of urokinase type plasminogen-activated kinase (uPA) and uPA receptor (uPAR), and subsequently enhanced the binding of uPAR to integrin alphaV. Moreover, the involvement of toll-like receptor 2/4 (TLR2/4)-triggered ERK1/2 activation in the increased expression of uPA and uPAR was also demonstrated. Collectively, these findings indicate that DP2 can enhance cell motility and invasiveness of NSCLC cells, attributing to TLR2/4-ERK1/2 activation, increased uPA and uPAR expression, enhanced binding of uPAR to integrin alphaV, and the consequent FAK signaling cascades. Thus, we suggest that DP2 may exacerbate NSCLC via promoting metastatic ability of carcinoma cell</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.14514</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28076322">PM:28076322</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170111-LinCH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170111-LinCH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Lin CH</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.14514</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,M.T.</style></author><author><style face="normal" font="Arial"> Wu,C.C.</style></author><author><style face="normal" font="Arial"> Ou,C.Y.</style></author><author><style face="normal" font="Arial"> Chang,J.C.</style></author><author><style face="normal" font="Arial"> Liu,C.A.</style></author><author><style face="normal" font="Arial"> Wang,C.L.</style></author><author><style face="normal" font="Arial"> Chuang,H.</style></author><author><style face="normal" font="Arial"> Kuo,H.C.</style></author><author><style face="normal" font="Arial"> Hsu,T.Y.</style></author><author><style face="normal" font="Arial"> Chen,C.P.</style></author><author><style face="normal" font="Arial"> Yang,K.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">A prospective birth cohort study of different risk factors for development of allergic diseases in offspring of non-atopic parents</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cesarean</style></keyword><keyword><style face="normal" font="Arial"> Cesarean Section</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> filter</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective birth cohort study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="1" Year="2017">2017/1/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic diseases are thought to be inherited. Prevalence of allergic diseases has, however, increased dramatically in last decades, suggesting environmental causes for the development of allergic diseases. OBJECTIVE: We studied risk factors associated with the development of atopic dermatitis (AD), allergic rhinitis (AR) and asthma (AS) in children of non-atopic parents in a subtropical country. METHODS: In a birth cohort of 1,497 newborns, parents were prenatally enrolled and validated for allergic diseases by questionnaire, physician-verified and total or specific Immunoglobulin E (IgE) levels; 1,236 and 756 children, respectively, completed their 3-year and 6-year follow-up. Clinical examination, questionnaire, and blood samples for total and specific IgE of the children were collected at each follow-up visit. RESULTS: Prevalence of AD, AR and AS was, respectively, 8.2%, 30.8% and 12.4% in children of non-atopic parents. Prevalence of AR (p&lt;.001) and AS (p=.018) was significantly higher in children of parents who were both atopic. A combination of Cesarean section (C/S) and breastfeeding for more than 1 month showed the highest risk for AD (OR=3.111, p=.006). Infants living in homes with curtains and no air filters had the highest risk for AR (OR=2.647, p&lt;.001), and male infants of non-atopic parents living in homes without air filters had the highest risk for AS (OR=1.930, p=.039). CONCLUSIONS: Breastfeeding and C/S affect development of AD. Gender, use of curtains and/or air filters affect AR and AS, suggesting that control of the perinatal environment is necessary for the prevention of atopic diseases in children of non-atopic parents</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.14565</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28086237">PM:28086237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170113-LeeMT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170113-LeeMT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Lee MT</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.14565</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qu,Y.L.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Zhang,L.X.</style></author><author><style face="normal" font="Arial"> Wu,C.M.</style></author><author><style face="normal" font="Arial"> Chu,A.J.</style></author><author><style face="normal" font="Arial"> Wen,B.L.</style></author><author><style face="normal" font="Arial"> Ma,C.</style></author><author><style face="normal" font="Arial"> Yan,X.Y.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Wang,D.M.</style></author><author><style face="normal" font="Arial"> Lv,X.</style></author><author><style face="normal" font="Arial"> Hou,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, Hospital of PLA, Qingdao 266071, Shandong, China</style></auth-address><titles><title><style face="normal" font="Arial">Asthma and the risk of lung cancer: a meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adenocarcinoma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung cancer</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">Some studies found that there was a significant association between asthma and the risk of lung cancer. However, the results are inconclusive. Therefore, we performed a meta-analysis. We searched the electronic databases for all relevant articles. Odds ratio (OR) with 95% confidence interval (CI) were used to calculate the strength of the association between asthma and lung cancer risk. Asthma was significantly associated with the increased risk of lung cancer (OR = 1.44; 95% CI 1.31-1.59; P &lt; 0.00001; I2 = 83%). Additionally, asthma patients without smoking also had the increased lung cancer risk. In the subgroup analysis of race and gender, Caucasians, Asians, male, and female patients with asthma showed the increased risk of lung cancer. However, asthma was not significantly associated with lung adenocarcinoma risk. In the stratified analysis by asthma definition, significant associations were found between asthma and lung cancer in self-reported subgroup, questionnaire subgroup, and register databases subgroup. However, no significant association was observed in physician-diagnosed asthma subgroup. In conclusion, this meta-analysis suggested that asthma might be significantly associated with lung cancer risk</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.14595</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28086224">PM:28086224</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170113-QuYL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170113-QuYL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Qu YL</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.14595</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Simons,F.E.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Ayme,S.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sirio Libanes, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Fatal anaphylaxis registries data support changes in the who anaphylaxis mortality coding rules</style></title><secondary-title><style face="normal" font="Arial">Orphanet J Rare Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Orphanet J Rare Dis</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cause of Death</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Death Certificates</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> ICD</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. The difficulty of coding anaphylaxis fatalities under the World Health Organization (WHO) International Classification of Diseases (ICD) system is recognized as an important reason for under-notification of anaphylaxis deaths. On current death certificates, a limited number of ICD codes are valid as underlying causes of death, and death certificates do not include the word anaphylaxis per se. In this review, we provide evidences supporting the need for changes in WHO mortality coding rules and call for addition of anaphylaxis as an underlying cause of death on international death certificates. This publication will be included in support of a formal request to the WHO as a formal request for this move taking the 11th ICD revision</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 1750-1172 (Electronic)IS - 1750-1172 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Brazil -CO - France -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13023-016-0554-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28086972">PM:28086972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Orphanet J Rare Dis\2017-12-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Orphanet J Rare Dis\2017-12-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170114, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13023-016-0554-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Keller,M.</style></author><author><style face="normal" font="Arial"> Arora,R.</style></author><author><style face="normal" font="Arial"> Schmiedle,G.</style></author><author><style face="normal" font="Arial"> Kastenberger,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department fur Unfallchirurgie, Medizinische Universitat Innsbruck, Anichstrasse 35, 6020, Innsbruck, Osterreich</style></auth-address><titles><title><style face="normal" font="Arial">[Treatment of Dupuytren's disease with collagenase Clostridium histolyticum]</style></title><secondary-title><style face="normal" font="Arial">Orthopade</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Orthopade</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Clostridium histolyticum</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Fascia</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="1" Year="2017">2017/1/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dupuytren's disease as a benign fibroproliferative disease leads to hyperplasia of the collagen fibers of the fascia of the palm, which can result in severe impairment of the functionality of the hand. OBJECTIVES: Examination of the significance of non-operative treatment of Dupuytren's disease with injectable collagenase clostridium histolyticum (CCH) METHODS: Observation of 120 patients treated with injectable collagenase. Documentation of the range of motion before the intervention, 12 months after the intervention, and documentation of any adverse events. RESULTS: All in all, 120 patients were treated (107 male, 13 female) (mean age 62 years, range 30-84 years). In 49% the little finger, in 44% the ring finger, in 4% the middle finger, and in 3% the index finger were treated. Full release was accomplished in 71%, partial release in 26%, and no change in 3% of the patients. The median contracture before the treatment was 37 degrees for the metacarpophalangeal (MP) joint (range 25-100 degrees ) and 51 degrees for the proximal interphalangeal (PIP) joint (range 30-97 degrees ). After 12 months, the mean contracture for the MP joint was 9 degrees (range 0-25 degrees ) and 21 degrees (range 10-36 degrees ) or the PIP joint. Adverse events occurred in 96% of patients within 3 months after treatment. No tendon ruptures, anaphylactic reactions, nerve, or ligament injuries were observed</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1433-0431 (Electronic)IS - 0085-4530 (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00132-017-3386-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28138723">PM:28138723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Orthopade\20170131-KellerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Orthopade\20170131-KellerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Keller M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00132-017-3386-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sheele,J.M.</style></author><author><style face="normal" font="Arial"> Ridge,G.E.</style></author><author><style face="normal" font="Arial"> Coppolino,K.</style></author><author><style face="normal" font="Arial"> Bonfield,T.</style></author><author><style face="normal" font="Arial"> Young,A.B.</style></author><author><style face="normal" font="Arial"> Gaines,S.L.</style></author><author><style face="normal" font="Arial"> McCormick,T.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Hospitals Cleveland Medical Center &amp; Case Western Reserve University, Department of Emergency Medicine, 11100 Euclid Ave. B-517, Cleveland, OH 44106</style></auth-address><titles><title><style face="normal" font="Arial">Antibody and cytokine levels in humans fed on by the common bed bug, Cimex lectularius L</style></title><secondary-title><style face="normal" font="Arial">Parasite Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasite Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG2</style></keyword><keyword><style face="normal" font="Arial"> IgG3</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">Little is known about cimicosis, the resultant dermal reaction from feeding activity by the common bed bug, Cimex lectularius L. We fed C. lectularius on human study subjects four times over four weeks, measured serum cytokine and antibody levels, and subjects recorded any cimicosis. The average time for subjects to develop cimicosis decreased with each feeding from 8.4, to 2.1, 1.5, and 1.3 days, respectively. There were no significant changes in total IgG, IgG1, IgG2, IgG4, or IgE levels between the first and fourth bed bug feedings, but there was a significant decrease in total IgG3 levels (p &lt; 0.001). IgG4 was not required for cimicosis. Higher IgG2 and IgG4 levels at study visit 4 were associated with an increased duration of cimicosis (p = 0.04) and lower pruritis (p = 0.03), respectively. There were no significant changes in serum TNF-alpha, IL-1beta, IL-4, IL-5, IL-6, IL-10, IFN-gamma, and IL-17A levels before and one hour after the C. lectularius feeding. Lower post-C. lectularius feeding IL-6 levels were associated with increased pruritis (p = 0.001) and the time to maximum pruritis (p = 0.04), respectively. Higher post-C. lectularius feeding IL-5 levels were associated with a longer duration of pruritis (p = 0.05). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1365-3024 (Electronic)IS - 0141-9838 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pim.12411</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28075502">PM:28075502</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasite Immunol\20170111-SheeleJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasite Immunol\20170111-SheeleJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Sheele JM</style></custom2><misc3><style face="normal" font="Arial">10.1111/pim.12411</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,L.F.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author><author><style face="normal" font="Arial"> Luo,S.Q.</style></author><author><style face="normal" font="Arial"> Xie,H.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Wu,Z.D.</style></author><author><style face="normal" font="Arial"> Sun,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology of Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis of Strongyloides stercoralis by morphological characteristics combine with molecular biological methods</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> emphysema</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hookworm</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Phylogenetic analysis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides stercoralis</style></keyword><keyword><style face="normal" font="Arial"> Strongyloidiasis</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">Strongyloidiasis is one of the neglected tropical diseases caused by infection with the nematode Strongyloides genus and distributed worldwide. Strongyloidiasis can be fatal in immunosuppressed patients induced hyperinfection or disseminated strongyloidiasis. Unfortunately, until now, due to the unspecific clinical symptom in infected individuals and the low sensitivity diagnosis of strongyloidiasis, many patients were misdiagnosed every year. Furthermore, the larvae of the Strongyloides stercoralis (S. stercoralis) is similar to other nematodes such as hookworm, Trichostrongylus increased the difficulty of diagnosis. In this case, the patient is a 63-year-old male person, who had a nearly 30 years medical history of asthma and emphysema, and 4-5-year medical history of diabetes. The sputum examination found some parasite larvae, then we identify the larvae using clinical observation and morphological characteristics combine with examined cytochrome oxidase subunit 1 (COX1) and 18S rRNA genes by PCR, sequence analysis and finally classified by phylogenetic analysis, the larvae were diagnosed as S. stercoralis. Our results showed that diagnosis with strongyloidiasis by morphological characteristics combine with molecular biological methods can improve the sensitive of diagnosis and provide a final diagnosis for the disease in the clinics</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1432-1955 (Electronic)IS - 0932-0113 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-017-5389-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28124134">PM:28124134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20170126-WangLF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20170126-WangLF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Wang LF</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-017-5389-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lemberg,M.L.</style></author><author><style face="normal" font="Arial"> Berk,T.</style></author><author><style face="normal" font="Arial"> Shah-Hosseini,K.</style></author><author><style face="normal" font="Arial"> Kasche,E.M.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine, Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center</style></title><secondary-title><style face="normal" font="Arial">Patient Prefer Adherence</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Patient Prefer Adherence</style></full-title></periodical><pages end="70" start="63">63-70</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patient adherence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Many placebo-controlled studies have demonstrated that allergen immunotherapy (AIT) is an effective therapy for treating allergies. Both commonly used routes, subcutaneous (SCIT) and sublingual immunotherapy (SLIT), require high patient adherence to be successful. In the literature, numbers describing adherence vary widely; this investigation compares these two routes of therapy directly. METHODS: All data were retrieved from the patient data management system of a center for dermatology, specific allergology, and environmental medicine in Germany. All 330 patients (aged 13-89 years) included in this study had commenced AIT between 2003 and 2011, thus allowing a full 3-year AIT cycle to be considered for each investigated patient. RESULTS: In this specific center, SCIT was prescribed to 62.7% and SLIT to 37.3% of all included patients. The total dropout rate of the whole patient cohort was 34.8%. Overall, SLIT patients showed a higher dropout rate (39.0%) than did SCIT patients (32.4%); however, the difference between these groups was not significant. Also, no significant difference between the overall dropout rates for men and for women was observed. A Kaplan-Meier curve of the patient collective showed a remarkably high dropout rate for the first year of therapy. CONCLUSION: The analysis presented in this single-center study shows that most patients who discontinue AIT do so during the first year of therapy. Patients seem likely to finish the 3-year therapy cycle if they manage to adhere to treatment throughout the first year. Strategies for preventing nonadherence in AIT, therefore, need to be developed and standardized in future investigations</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1177-889X (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.2147/PPA.S122948</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28115832">PM:28115832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Patient Prefer Adherence\2017-11-63-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Patient Prefer Adherence\2017-11-63-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Lemberg ML</style></custom2><misc3><style face="normal" font="Arial">10.2147/PPA.S122948</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hammer,S.C.</style></author><author><style face="normal" font="Arial"> Sonneveld,L.J.</style></author><author><style face="normal" font="Arial"> van de Kant,K.D.</style></author><author><style face="normal" font="Arial"> Hendriks,H.J.</style></author><author><style face="normal" font="Arial"> Heynens,J.W.</style></author><author><style face="normal" font="Arial"> Droog,R.</style></author><author><style face="normal" font="Arial"> Dompeling,E.</style></author><author><style face="normal" font="Arial"> Jobsis,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Introduction of a new paediatric asthma guideline: effects on asthma control levels</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="272" start="266">266-272</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In 2008, a new national paediatric asthma management guideline based on the international Global Initiative for Asthma (GINA) guideline, was launched in the Netherlands. We studied whether asthma control and treatment regimens improved after introduction of the guideline by comparing survey data before and after the guideline introduction. METHODS: Two comparable groups of children (6-16 years) with asthma were included before (2004) and after (2013) the introduction of the guideline. Children, parents and paediatricians completed questionnaires about asthma symptoms, medication and healthcare use. Spirometry was performed. RESULTS: Data of 209 patients were analysed. Level of asthma control did not improve between 2004 and 2013 with a proportion of (partly) controlled asthmatics of 51% in 2004 and 59% in 2013 (p=0.28). In 2013, paediatricians characterised 76% of children as (partly) controlled, while 59% of children was (partly) controlled according to GINA criteria (p&lt;0.05). Step-down treatment in controlled patients was more applied by paediatricians in 2013 compared to 2004 (from 8 to 40%, p&lt;0.05). Step-up treatment in uncontrolled patients did not improve. CONCLUSIONS: Asthma control did not improve after the introduction of the new guideline. Compared to 2004, an improvement was observed in step-down treatment in patients with controlled disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12697</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107572">PM:28107572</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170120-HammerSC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170120-HammerSC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Hammer SC</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12697</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boersma,N.A.</style></author><author><style face="normal" font="Arial"> Meijneke,R.W.</style></author><author><style face="normal" font="Arial"> Kelder,J.C.</style></author><author><style face="normal" font="Arial"> van der Ent,C.K.</style></author><author><style face="normal" font="Arial"> Balemans,W.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, St. Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization predicts asthma development among wheezing toddlers in secondary healthcare</style></title><secondary-title><style face="normal" font="Arial">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Pulmonol</style></full-title></periodical><pages end="736" start="729">729-736</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parental atopy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Periodicals</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> toddler</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Some wheezing toddlers develop asthma later in childhood. Sensitization is known to predict asthma in birth cohorts. However, its predictive value in secondary healthcare is uncertain. AIM: This study examines the predictive value of sensitization to inhalant allergens among wheezing toddlers in secondary healthcare for the development of asthma at school age (>/=6 years). METHODS: Preschool children (1-3 years) who presented with wheezing in secondary healthcare were screened on asthma at school age with the International Study of Asthma and Allergies in Childhood questionnaire. The positive and negative predictive value (PPV and NPV) of specific IgE to inhalant allergens (cut-off concentration 0.35 kU/L) and several non-invasive variables from a child's history (such as hospitalization, eczema, and parental atopy) were calculated. The additional predictive value of sensitization when combined with non-invasive predictors was examined in multivariate analysis and by ROC curves. RESULTS: Of 116 included children, 63% developed asthma at school age. Sensitization to inhalant allergens was a strong asthma predictor. The odds ratio (OR), PPV and NPV were 7.4%, 86%, and 55%, respectively. Eczema (OR 3.4) and hospital admission (OR 2.6) were significant non-invasive determinants. Adding sensitization to these non-invasive predictors in multivariate analysis resulted in a significantly better asthma prediction. The area under the ROC curve increased from 0.70 with only non-invasive predictors to 0.79 after adding sensitization. CONCLUSION: Sensitization to inhalant allergens is a strong predictor of school age asthma in secondary healthcare and has added predictive value when combined with non-invasive determinants. Pediatr Pulmonol. 2017; 9999:XX-XX. (c) 2017 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1002/ppul.23668</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28076664">PM:28076664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Pulmonol\20170111-BoersmaNA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Pulmonol\20170111-BoersmaNA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Boersma NA</style></custom2><misc3><style face="normal" font="Arial">10.1002/ppul.23668</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia,L.P.</style></author><author><style face="normal" font="Arial"> Munoz,J.L.</style></author><author><style face="normal" font="Arial"> Alonso-Lebrero,E.</style></author><author><style face="normal" font="Arial"> Reula,E.S.</style></author><author><style face="normal" font="Arial"> Pion,M.</style></author><author><style face="normal" font="Arial"> Correa-Rocha,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Bioactivity and Food Analysisof theCIAL-CSIC, Madrid (Spain)</style></auth-address><titles><title><style face="normal" font="Arial">The Establishment of Cow's Milk Protein Allergy in Infants is Related with a Deficit of Regulatory T cells (Treg) and Vitamin D</style></title><secondary-title><style face="normal" font="Arial">Pediatr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Res</style></full-title></periodical><pages end="730" start="722">722-730</pages><volume><style face="normal" font="Arial">81</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cow's milk protein allergy (CMPA) is the most common food allergy in infants. However, little is known about which specific immune mechanisms are related with the CMPA onset. The objective was to investigate which immune alterations constitute differential factors between allergy and tolerance, and hence could be implicated in the CMPA establishment in infants. METHODS: An extensive analysis of immune subsets, including Treg and cytokine-secreting cells was performed in blood samples from 28 infants younger than 9 months obtained 1-4 days after the first adverse reaction to milk. RESULTS: Less than 4 days after first allergic reaction, infants who developed CMPA had decreased Treg counts and increased frequency of IL4-secreting CD4 T cells compared to controls. The deficit of Tregs was correlated with decreased serum levels of vitamin D. Values of Tregs, IL4-secreting cells and vitamin D were good predictors of CMPA diagnosis. Basal vitamin D levels in CMPA infants also predicted those CMPA patients developing spontaneous tolerance in the first year. CONCLUSIONS: Establishment of CMPA in infants was related with lower Treg and vitamin D levels. These immune alterations would be crucial factors behind the CMPA establishment and they could constitute a therapeutic target for treatment of CMPA.Pediatric Research (2017); doi:10.1038/pr.2017.12</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1530-0447 (Electronic)IS - 0031-3998 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1038/pr.2017.12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28099424">PM:28099424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Res\20170118-GarciaLP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Res\20170118-GarciaLP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Garcia LP</style></custom2><misc3><style face="normal" font="Arial">10.1038/pr.2017.12</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Diepen,A.</style></author><author><style face="normal" font="Arial"> Smit,C.H.</style></author><author><style face="normal" font="Arial"> van Egmond,L.</style></author><author><style face="normal" font="Arial"> Kabatereine,N.B.</style></author><author><style face="normal" font="Arial"> Pinot de Moira,A.</style></author><author><style face="normal" font="Arial"> Dunne,D.W.</style></author><author><style face="normal" font="Arial"> Hokke,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Differential anti-glycan antibody responses in Schistosoma mansoni-infected children and adults studied by shotgun glycan microarray</style></title><secondary-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></full-title></periodical><pages end="" start="e1922">e1922-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Age Factors</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Helminth</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antigens,Helminth</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Binding Properties</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Glycan antigen</style></keyword><keyword><style face="normal" font="Arial"> glycan microarray</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin M</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray Analysis</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma mansoni</style></keyword><keyword><style face="normal" font="Arial"> Schistosomiasis</style></keyword><keyword><style face="normal" font="Arial"> Schistosomiasis mansoni</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2012">2012</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Schistosomiasis (bilharzia) is a chronic and potentially deadly parasitic disease that affects millions of people in (sub)tropical areas. An important partial immunity to Schistosoma infections does develop in disease endemic areas, but this takes many years of exposure and maturation of the immune system. Therefore, children are far more susceptible to re-infection after treatment than older children and adults. This age-dependent immunity or susceptibility to re-infection has been shown to be associated with specific antibody and T cell responses. Many antibodies generated during Schistosoma infection are directed against the numerous glycans expressed by Schistosoma. The nature of glycan epitopes recognized by antibodies in natural schistosomiasis infection serum is largely unknown. METHODOLOGY/PRINCIPAL FINDINGS: The binding of serum antibodies to glycans can be analyzed efficiently and quantitatively using glycan microarray approaches. Very small amounts of a large number of glycans are presented on a solid surface allowing binding properties of various glycan binding proteins to be tested. We have generated a so-called shotgun glycan microarray containing natural N-glycan and lipid-glycan fractions derived from 4 different life stages of S. mansoni and applied this array to the analysis of IgG and IgM antibodies in sera from children and adults living in an endemic area. This resulted in the identification of differential glycan recognition profiles characteristic for the two different age groups, possibly reflecting differences in age or differences in length of exposure or infection. CONCLUSIONS/SIGNIFICANCE: Using the shotgun glycan microarray approach to study antibody response profiles against schistosome-derived glycan elements, we have defined groups of infected individuals as well as glycan element clusters to which antibody responses are directed in S. mansoni infections. These findings are significant for further exploration of Schistosoma glycan antigens in relation to immunity</style></abstract><notes><style face="normal" font="Arial">DA - 20121204IS - 1935-2735 (Electronic)IS - 1935-2727 (Linking)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Antibodies, Helminth)RN - 0 (Antigens, Helminth)RN - 0 (Immunoglobulin G)RN - 0 (Immunoglobulin M)RN - 0 (Polysaccharides)SB - IMCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pntd.0001922</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="23209862">PM:23209862</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2012-6-e1922.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2012-6-e1922.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20121204, van Diepen A</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pntd.0001922</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choi,J.</style></author><author><style face="normal" font="Arial"> Choi,B.K.</style></author><author><style face="normal" font="Arial"> Kim,J.S.</style></author><author><style face="normal" font="Arial"> Lee,J.W.</style></author><author><style face="normal" font="Arial"> Park,H.A.</style></author><author><style face="normal" font="Arial"> Ryu,H.W.</style></author><author><style face="normal" font="Arial"> Lee,S.U.</style></author><author><style face="normal" font="Arial"> Hwang,K.W.</style></author><author><style face="normal" font="Arial"> Yun,W.K.</style></author><author><style face="normal" font="Arial"> Kim,H.C.</style></author><author><style face="normal" font="Arial"> Ahn,K.S.</style></author><author><style face="normal" font="Arial"> Oh,S.R.</style></author><author><style face="normal" font="Arial"> Lee,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungbuk, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Picroside II Attenuates Airway Inflammation by Downregulating the Transcription Factor GATA3 and Th2-Related Cytokines in a Mouse Model of HDM-Induced Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0167098">e0167098-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Picroside II isolated from Pseudolysimachion rotundum var. subintegrum has been used as traditional medicine to treat inflammatory diseases. In this study, we assessed whether picroside II has inhibitory effects on airway inflammation in a mouse model of house dust mite (HDM)-induced asthma. In the HDM-induced asthmatic model, picroside II significantly reduced inflammatory cell counts in the bronchoalveolar lavage fluid (BALF), the levels of total immunoglobulin (Ig) E and HDM-specific IgE and IgG1 in serum, airway inflammation, and mucus hypersecretion in the lung tissues. ELISA analysis showed that picroside II down-regulated the levels of Th2-related cytokines (including IL-4, IL-5, and IL-13) and asthma-related mediators, but it up-regulated Th1-related cytokine, IFNgamma in BALF. Picroside II also inhibited the expression of Th2 type cytokine genes and the transcription factor GATA3 in the lung tissues of HDM-induced mice. Finally, we demonstrated that picroside II significantly decreased the expression of GATA3 and Th2 cytokines in developing Th2 cells, consistent with in vivo results. Taken together, these results indicate that picroside II has protective effects on allergic asthma by reducing GATA3 expression and Th2 cytokine bias</style></abstract><notes><style face="normal" font="Arial">DA - 20161121IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0167098</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27870920">PM:27870920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0167098.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0167098.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161121, Choi J</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0167098</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">George,T.</style></author><author><style face="normal" font="Arial"> Bell,M.</style></author><author><style face="normal" font="Arial"> Chakraborty,M.</style></author><author><style face="normal" font="Arial"> Siderovski,D.P.</style></author><author><style face="normal" font="Arial"> Giembycz,M.A.</style></author><author><style face="normal" font="Arial"> Newton,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Airways Inflammation Research Group, Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Protective Roles for RGS2 in a Mouse Model of House Dust Mite-Induced Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0170269">e0170269-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> bronchoprotection</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The GTPase-accelerating protein, regulator of G-protein signalling 2 (RGS2) reduces signalling from G-protein-coupled receptors (GPCRs) that signal via Galphaq. In humans, RGS2 expression is up-regulated by inhaled corticosteroids (ICSs) and long-acting beta2-adrenoceptor agonists (LABAs) such that synergy is produced in combination. This may contribute to the superior clinical efficacy of ICS/LABA therapy in asthma relative to ICS alone. In a murine model of house dust mite (HDM)-induced airways inflammation, three weeks of intranasal HDM (25 mug, 3x/week) reduced lung function and induced granulocytic airways inflammation. Compared to wild type animals, Rgs2-/- mice showed airways hyperresponsiveness (increased airways resistance and reduced compliance). While HDM increased pulmonary inflammation observed on hematoxylin and eosin-stained sections, there was no difference between wild type and Rgs2-/- animals. HDM-induced mucus hypersecretion was also unaffected by RGS2 deficiency. However, inflammatory cell counts in the bronchoalveolar lavage fluid of Rgs2-/- animals were significantly increased (57%) compared to wild type animals and this correlated with increased granulocyte (neutrophil and eosinophil) numbers. Likewise, cytokine and chemokine (IL4, IL17, IL5, LIF, IL6, CSF3, CXCLl, CXCL10 and CXCL11) release was increased by HDM exposure. Compared to wild type, Rgs2-/- animals showed a trend towards increased expression for many cytokines/chemokines, with CCL3, CCL11, CXCL9 and CXCL10 being significantly enhanced. As RGS2 expression was unaffected by HDM exposure, these data indicate that RGS2 exerts tonic bronchoprotection in HDM-induced airways inflammation. Modest anti-inflammatory and anti-remodelling roles for RGS2 are also suggested. If translatable to humans, therapies that maximize RGS2 expression may prove advantageous</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0170269</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107494">PM:28107494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0170269.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0170269.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, George T</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0170269</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nagata,Y.</style></author><author><style face="normal" font="Arial"> Yamamoto,T.</style></author><author><style face="normal" font="Arial"> Hayashi,M.</style></author><author><style face="normal" font="Arial"> Hayashi,S.</style></author><author><style face="normal" font="Arial"> Kadowaki,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastrointestinal Pathophysiology, Institute of Natural Medicine, University of Toyama, Toyama, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a Murine Food Allergy Model</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0170577">e0170577-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Oral immunotherapy (OIT) has been considered a promising approach for food allergies (FAs). However, the current OIT strategy is limited in terms of the long-term efficacy and safety. We have previously demonstrated that kakkonto, a traditional Japanese herbal medicine, suppresses the occurrence of allergic symptoms in a murine model of ovalbumin (OVA)-induced FA, which is attributed to the induction of the Foxp3+ CD4+ regulatory T cells. In this study, we established an OIT model using the FA mice with already established allergic symptoms and determined whether kakkonto could improve the efficacy of OIT. The OIT method consisted of initially administrating a very small amount of OVA and slowly increasing the amount. Allergic symptoms decreased in the OIT-treated FA mice. OIT significantly downregulated Th2 immune response-related gene expression in the FA mouse colon, and decreased the level of mouse mast cell protease-1, a marker of mast cell degranulation in the FA mouse plasma. Moreover, the concomitant use of kakkonto significantly enhanced the effectiveness of OIT on the allergic symptoms, and the combination therapy further suppressed the Th2 immune responses and the mast cell degranulation. In addition, OIT significantly increased the population of Foxp3+ CD4+ regulatory T cells in the FA mouse colon, and this population was further increased by OIT in combination with kakkonto. Furthermore, the combined therapy with kakkonto reduced the expression of RA-degrading enzyme CYP26B1 mRNA in the FA mouse colon. These findings indicated that the combination of OIT with kakkonto represents a promising approach for FA treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0170577</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107533">PM:28107533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0170577.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0170577.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Nagata Y</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0170577</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,F.</style></author><author><style face="normal" font="Arial"> Cheng,H.</style></author><author><style face="normal" font="Arial"> Zhang,Y.T.</style></author><author><style face="normal" font="Arial"> Ju,Y.H.</style></author><author><style face="normal" font="Arial"> Li,Y.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, Jilin, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Early Postnatal Exposure to Cigarette Smoke Leads to Later Airway Inflammation in Asthmatic Mice</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0171021">e0171021-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adult asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cigarette smoke</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Asthma is one of the most common airway inflammatory diseases. In most cases, asthma development is related to ubiquitous harmful environmental exposure factors in early-life. Previous studies have indicated that smoking can promote asthma development and increase the difficulty of asthma control. The aim of this study was to determine the effects of early-life CS exposure on ovalbumin (OVA)-sensitized asthmatic mice. METHODS: Pathological and immunological functions were analyzed in an adult asthma mice model in which mice were sensitized with OVA combined with early-life CS exposure. RESULTS: Mice exposed to CS for only 5 weeks demonstrated significantly reduced pulmonary compliance, increased airway inflammation, and augmented cellular and humoral immune responses. In addition, CS inhalation was sufficient to facilitate OVA sensitization and challenge asthmatic development. Meanwhile, CS exposure amplified regulatory T cell-mediated immunity inhibition, but still did not offset the increased effector T cell-mediated inflammatory response. CONCLUSION: Early-life CS exposure is significantly associated with later pulmonary injury and aggravation of T-cell immunologic derangement in asthmatic mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0171021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28135326">PM:28135326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0171021.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0171021.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Huang F</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0171021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sancho,A.I.</style></author><author><style face="normal" font="Arial"> Wallner,M.</style></author><author><style face="normal" font="Arial"> Hauser,M.</style></author><author><style face="normal" font="Arial"> Nagl,B.</style></author><author><style face="normal" font="Arial"> Himly,M.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Ebner,C.</style></author><author><style face="normal" font="Arial"> Jahn-Schmid,B.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Christian Doppler Laboratory for Allergy Diagnosis and Therapy, Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">T Cell Epitope-Containing Domains of Ragweed Amb a 1 and Mugwort Art v 6 Modulate Immunologic Responses in Humans and Mice</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0169784">e0169784-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Amb a 1</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Art v 6</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Artemisia vulgaris</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blocking IgG</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISpot</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hybrid molecule</style></keyword><keyword><style face="normal" font="Arial"> hypoallergen</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> Immunisation</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> mugwort pollen</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pectate lyase</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ragweed (Ambrosia artemisiifolia) and mugwort (Artemisia vulgaris) are the major cause of pollen allergy in late summer. Allergen-specific lymphocytes are crucial for immune modulation during immunotherapy. We sought to generate and pre-clinically characterise highly immunogenic domains of the homologous pectate lyases in ragweed (Amb a 1) and mugwort pollen (Art v 6) for immunotherapy. METHODS: Domains of Amb a 1 (Amb a 1alpha) and Art v 6 (Art v 6alpha) and a hybrid molecule, consisting of both domains, were designed, expressed in E. coli and purified. Human IgE reactivity and allergenicity were assessed by ELISA and mediator release experiments using ragweed and mugwort allergic patients. Moreover, T cell proliferation was determined. Blocking IgG antibodies and cytokine production in BALB/c mice were studied by ELISA and ELISPOT. RESULTS: The IgE binding capacity and in vitro allergenic activity of the Amb a 1 and Art v 6 domains and the hybrid were either greatly reduced or abolished. The recombinant proteins induced T cell proliferative responses comparable to those of the natural allergens, indicative of retained allergen-specific T cell response. Mice immunisation with the hypoallergens induced IL-4, IL-5, IL-13 and IFN-gamma production after antigen-specific in vitro re-stimulation of splenocytes. Moreover, murine IgG antibodies that inhibited specific IgE binding of ragweed and mugwort pollen allergic patients were detected. CONCLUSION: Accumulation of T cell epitopes and deletion of IgE reactive areas of Amb a 1 and Art v 6, modulated the immunologic properties of the allergen immuno-domains, leading to promising novel candidates for therapeutic approach</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0169784</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081194">PM:28081194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0169784.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0169784.pdf</url></text-urls><related-urls><url ppv-ref="no">xls in cartella</url></related-urls></urls><custom2><style face="normal" font="Arial">20170112, Sancho AI</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0169784</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salehi,S.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Juvet,S.</style></author><author><style face="normal" font="Arial"> Scott,J.A.</style></author><author><style face="normal" font="Arial"> Chow,C.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respirology, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Syk Regulates Neutrophilic Airway Hyper-Responsiveness in a Chronic Mouse Model of Allergic Airways Inflammation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0163614">e0163614-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mechanics</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Mechanics</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a chronic inflammatory disease characterized by airways hyper-responsiveness (AHR), reversible airway obstruction, and airway inflammation and remodeling. We previously showed that Syk modulates methacholine-induced airways contractility in naive mice and in mice with allergic airways inflammation. We hypothesize that Syk plays a role in the pathogenesis of AHR; this was evaluated in a chronic 8-week mouse model of house dust mite (HDM)-induced allergic airways inflammation. METHODS: We used the Sykflox/flox//rosa26CreERT2 conditional Syk knock-out mice to assess the role of Syk prior to HDM exposure, and treated HDM-sensitized mice with the Syk inhibitor, GSK143, to evaluate its role in established allergic airways inflammation. Respiratory mechanics and methacholine (MCh)-responsiveness were assessed using the flexiVent(R) system. Lungs underwent bronchoalveolar lavage to isolate inflammatory cells or were frozen for determination of gene expression in tissues. RESULTS: MCh-induced AHR was observed following HDM sensitization in the Syk-intact (Sykflox/flox) and vehicle-treated BALB/c mice. MCh responsiveness was reduced to control levels in HDM-sensitized Sykdel/del mice and in BALB/c and Sykflox/flox mice treated with GSK143. Both Sykdel/del and GSK143-treated mice mounted appropriate immune responses to HDM, with HDM-specific IgE levels that were comparable to Sykflox/flox and vehicle-treated BALB/c mice. HDM-induced increases in bronchoalveolar lavage cell counts were attenuated in both Sykdel/del and GSK143-treated mice, due primarily to decreased neutrophil recruitment. Gene expression analysis of lung tissues revealed that HDM-induced expression of IL-17 and CXCL-1 was significantly attenuated in both Sykdel/del and GSK143-treated mice. CONCLUSION: Syk inhibitors may play a role in the management of neutrophilic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0163614</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28107345">PM:28107345</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0163614.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0163614.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170120, Salehi S</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0163614</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sharma,A.</style></author><author><style face="normal" font="Arial"> Sharma,N.</style></author><author><style face="normal" font="Arial"> Bhalla,P.</style></author><author><style face="normal" font="Arial"> Singh,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Plant Molecular Biology and Biotechnology Laboratory, Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Parkville, Melbourne, VIC, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Comparative and Evolutionary Analysis of Grass Pollen Allergens Using Brachypodium distachyon as a Model System</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0169686">e0169686-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen genes</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anther</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Brachypodium</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromosomes</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Expansin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene family</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introns</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mining</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen-specific</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Structure analysis</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Comparative genomics have facilitated the mining of biological information from a genome sequence, through the detection of similarities and differences with genomes of closely or more distantly related species. By using such comparative approaches, knowledge can be transferred from the model to non-model organisms and insights can be gained in the structural and evolutionary patterns of specific genes. In the absence of sequenced genomes for allergenic grasses, this study was aimed at understanding the structure, organisation and expression profiles of grass pollen allergens using the genomic data from Brachypodium distachyon as it is phylogenetically related to the allergenic grasses. Combining genomic data with the anther RNA-Seq dataset revealed 24 pollen allergen genes belonging to eight allergen groups mapping on the five chromosomes in B. distachyon. High levels of anther-specific expression profiles were observed for the 24 identified putative allergen-encoding genes in Brachypodium. The genomic evidence suggests that gene encoding the group 5 allergen, the most potent trigger of hay fever and allergic asthma originated as a pollen specific orphan gene in a common grass ancestor of Brachypodium and Triticiae clades. Gene structure analysis showed that the putative allergen-encoding genes in Brachypodium either lack or contain reduced number of introns. Promoter analysis of the identified Brachypodium genes revealed the presence of specific cis-regulatory sequences likely responsible for high anther/pollen-specific expression. With the identification of putative allergen-encoding genes in Brachypodium, this study has also described some important plant gene families (e.g. expansin superfamily, EF-Hand family, profilins etc) for the first time in the model plant Brachypodium. Altogether, the present study provides new insights into structural characterization and evolution of pollen allergens and will further serve as a base for their functional characterization in related grass species</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0169686</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28103252">PM:28103252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0169686.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0169686.pdf</url></text-urls><related-urls><url ppv-ref="no">xls in cartella</url></related-urls></urls><custom2><style face="normal" font="Arial">20170119, Sharma A</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0169686</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guerra,E.S.</style></author><author><style face="normal" font="Arial"> Lee,C.K.</style></author><author><style face="normal" font="Arial"> Specht,C.A.</style></author><author><style face="normal" font="Arial"> Yadav,B.</style></author><author><style face="normal" font="Arial"> Huang,H.</style></author><author><style face="normal" font="Arial"> Akalin,A.</style></author><author><style face="normal" font="Arial"> Huh,J.R.</style></author><author><style face="normal" font="Arial"> Mueller,C.</style></author><author><style face="normal" font="Arial"> Levitz,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Central Role of IL-23 and IL-17 Producing Eosinophils as Immunomodulatory Effector Cells in Acute Pulmonary Aspergillosis and Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">PLoS Pathog</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS Pathog</style></abbr-1></periodical><pages end="" start="e1006175">e1006175-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> Conidia</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> Immunocompromised Host</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">Aspergillus fumigatus causes invasive pulmonary disease in immunocompromised hosts and allergic asthma in atopic individuals. We studied the contribution of lung eosinophils to these fungal diseases. By in vivo intracellular cytokine staining and confocal microscopy, we observed that eosinophils act as local sources of IL-23 and IL-17. Remarkably, mice lacking eosinophils had a >95% reduction in the percentage of lung IL-23p19+ cells as well as markedly reduced IL-23 heterodimer in lung lavage fluid. Eosinophils killed A. fumigatus conidia in vivo. Eosinopenic mice had higher mortality rates, decreased recruitment of inflammatory monocytes, and decreased expansion of lung macrophages after challenge with conidia. All of these functions underscore a potential protective role for eosinophils in acute aspergillosis. Given the postulated role for IL-17 in asthma pathogenesis, we assessed whether eosinophils could act as sources of IL-23 and IL-17 in models where mice were sensitized to either A. fumigatus antigens or ovalbumin (OVA). We found IL-23p19+ IL-17AF+ eosinophils in both allergic models. Moreover, close to 95% of IL-23p19+ cells and >90% of IL-17AF+ cells were identified as eosinophils. These data establish a new paradigm in acute and allergic aspergillosis whereby eosinophils act not only as effector cells but also as immunomodulatory cells driving the IL-23/IL-17 axis and contributing to inflammatory cell recruitment</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1553-7374 (Electronic)IS - 1553-7366 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.ppat.1006175</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095479">PM:28095479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS Pathog\2017-13-e1006175.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS Pathog\2017-13-e1006175.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Guerra ES</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.ppat.1006175</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pastuszka,R.</style></author><author><style face="normal" font="Arial"> Barlowska,J.</style></author><author><style face="normal" font="Arial"> Litwinczuk,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Katedra Towaroznawstwa i Przetworstwa Surowcow Zwierzecych, Uniwersytet Przyrodniczy w Lublinie</style></auth-address><titles><title><style face="normal" font="Arial">Allergenicity of milk of different animal species in relation to human milk</style></title><secondary-title><style face="normal" font="Arial">Postepy Hig Med Dosw (Online)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Hig Med Dosw (Online)</style></full-title></periodical><pages end="1459" start="1451">1451-1459</pages><volume><style face="normal" font="Arial">70</style></volume><number><style face="normal" font="Arial">0</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibacterial</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> dimer</style></keyword><keyword><style face="normal" font="Arial"> Donkey</style></keyword><keyword><style face="normal" font="Arial"> Donkey milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> flavour</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Goat milk</style></keyword><keyword><style face="normal" font="Arial"> Goats</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monomer</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Ruminants</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="31" Month="12" Year="2016">2016/12/31</year></dates><abstract><style face="normal" font="Arial">Protein content in cow milk (with over 20 proteins, and peptides may also occur as a result of enzymatic hydrolysis) ranges from 2.5% to 4.2% and is about 1.5-2 times higher than in human milk. Its most important allergens are considered to be beta-lactoglobulin (absent in human milk) and alphas1-casein. The most similar in composition to human milk is horse and donkey milk. It contains considerably more whey proteins (35-50%) than cow milk (about 20%), and the concentration of the most allergenic casein fraction alphas1 is 1.5-2.5 g/l. In comparison, the content of alphas1-casein in cow milk is about 10 g/l. beta-lactoglobulin present in donkey milk is a monomer, while in milk of ruminants it is a dimer. Like human milk, it contains a substantial amount of lactose (about 7%), which determines its flavour and facilitates calcium absorption. The high lysozyme content (about 1 g/l) gives it antibacterial properties (compared to trace amounts in ruminants). Camel milk is also more digestible and induces fewer allergic reactions, because it lacks beta-lactoglobulin, and its beta-casein has a different structure. It also contains (compared to cow milk) more antibacterial substances such as lysozyme, lactoferrin and immunoglobulins, and furthermore the number of immunoglobulins is compatible with human ones. Goat milk components have a higher degree of assimilability as compared to cow milk. Its main protein is beta-casein, with total protein content depending on the alphas1-casein genetic variant. Goats with the '0' variant do not synthesize this allergenic protein. Clinical and immunochemical studies indicate, however, that it cannot be a substitute for cow milk without the risk of an anaphylactic reaction</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1732-2693 (Electronic)IS - 0032-5449 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5604/17322693.1227842</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100852">PM:28100852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Hig Med Dosw (Online)\2016-70-1451-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Hig Med Dosw (Online)\2016-70-1451-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Pastuszka R</style></custom2><misc3><style face="normal" font="Arial">10.5604/17322693.1227842</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shim,S.Y.</style></author><author><style face="normal" font="Arial"> Lee,M.</style></author><author><style face="normal" font="Arial"> Lee,K.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy, Sunchon National University, Jeonnam 57922, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Achyranthes japonica Nakai Water Extract Suppresses Binding of IgE Antibody to Cell Surface FcvarepsilonRI</style></title><secondary-title><style face="normal" font="Arial">Prev Nutr Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prev Nutr Food Sci</style></full-title></periodical><pages end="329" start="323">323-329</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antioxidative activity</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Achyranthes japonica Nakai (AJN) water extract has a variety of physiological properties, including anti-diabetic, anti-cancer, anti-inflammatory, anti-microbial, and anti-oxidative activities. In the present study, the inhibitory effects of AJN extract were investigated in high affinity immunoglobulin E receptor (FcvarepsilonRI)-mediated KU812F cells activation. AJN extract showed suppressive effects on histamine release and intracellular calcium [Ca2+]i elevation from anti-FcvarepsilonRI antibody (CRA-1)-stimulated cells in a dose-dependent manner. Flow cytometric analysis showed that AJN extract treatment caused a dose-dependent decrease in the cell surface FcvarepsilonRI expression and the binding between the cell surface FcvarepsilonRI and the IgE antibody. Moreover, reverse transcription-polymerase chain reaction analysis showed that levels of the mRNA for the FcvarepsilonRI alpha chain was decreased by treatment with AJN extract. These results indicate that AJN extract may exert anti-allergic effects via the inhibition of calcium influx and histamine release, which occurs as a result from the down-regulation of the binding of IgE antibody to cell surface FcvarepsilonRI. This mechanism may occur through FcvarepsilonRI expression inhibition</style></abstract><notes><style face="normal" font="Arial">DA - 20170112IS - 2287-1098 (Print)IS - 2287-1098 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3746/pnf.2016.21.4.323</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078254">PM:28078254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prev Nutr Food Sci\2016-21-323-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prev Nutr Food Sci\2016-21-323-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170112, Shim SY</style></custom2><misc3><style face="normal" font="Arial">10.3746/pnf.2016.21.4.323</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ogasawara,T.</style></author><author><style face="normal" font="Arial"> Hatano,M.</style></author><author><style face="normal" font="Arial"> Satake,H.</style></author><author><style face="normal" font="Arial"> Ikari,J.</style></author><author><style face="normal" font="Arial"> Taniguchi,T.</style></author><author><style face="normal" font="Arial"> Tsuruoka,N.</style></author><author><style face="normal" font="Arial"> Watanabe-Takano,H.</style></author><author><style face="normal" font="Arial"> Fujimura,L.</style></author><author><style face="normal" font="Arial"> Sakamoto,A.</style></author><author><style face="normal" font="Arial"> Hirata,H.</style></author><author><style face="normal" font="Arial"> Sugiyama,K.</style></author><author><style face="normal" font="Arial"> Fukushima,Y.</style></author><author><style face="normal" font="Arial"> Nakae,S.</style></author><author><style face="normal" font="Arial"> Matsumoto,K.</style></author><author><style face="normal" font="Arial"> Saito,H.</style></author><author><style face="normal" font="Arial"> Fukuda,T.</style></author><author><style face="normal" font="Arial"> Kurasawa,K.</style></author><author><style face="normal" font="Arial"> Tatsumi,K.</style></author><author><style face="normal" font="Arial"> Tokuhisa,T.</style></author><author><style face="normal" font="Arial"> Arima,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respirology (B2), Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Development of chronic allergic responses by dampening Bcl6-mediated suppressor activity in memory T helper 2 cells</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></full-title></periodical><pages end="E750" start="E741">E741-E750</pages><volume><style face="normal" font="Arial">114</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> repressor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T helper 2 cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">Mice deficient in the transcriptional repressor B-cell CLL/lymphoma 6 (Bcl6) exhibit similar T helper 2 (TH2) immune responses as patients with allergic diseases. However, the molecular mechanisms underlying Bcl6-directed regulation of TH2 cytokine genes remain unclear. We identified multiple Bcl6/STAT binding sites (BSs) in TH2 cytokine gene loci. We found that Bcl6 is modestly associated with the BSs, and it had no significant effect on cytokine production in newly differentiated TH2 cells. Contrarily, in memory TH2 (mTH2) cells derived from adaptively transferred TH2 effectors, Bcl6 outcompeted STAT5 for binding to TH2 cytokine gene loci, particularly Interleukin4 (Il4) loci, and attenuated GATA binding protein 3 (GATA3) binding to highly conserved intron enhancer regions in mTH2 cells. Bcl6 suppressed cytokine production epigenetically in mTH2 cells to negatively tune histone acetylation at TH2 cytokine gene loci, including Il4 loci. In addition, IL-33, a pro-TH2 cytokine, diminished Bcl6's association with loci to which GATA3 recruitment was inversely augmented, resulting in altered IL-4, but not IL-5 and IL-13, production in mTH2 cells but no altered production in newly differentiated TH2 cells. Use of a murine asthma model that generates high levels of pro-TH2 cytokines, such as IL-33, suggested that the suppressive function of Bcl6 in mTH2 cells is abolished in severe asthma. These findings indicate a role of the interaction between TH2-promoting factors and Bcl6 in promoting appropriate IL-4 production in mTH2 cells and suggest that chronic allergic diseases involve the TH2-promoting factor-mediated functional breakdown of Bcl6, resulting in allergy exacerbation</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1073/pnas.1613528114</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28096407">PM:28096407</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2017-114-E741-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2017-114-E741-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, Ogasawara T</style></custom2><misc3><style face="normal" font="Arial">10.1073/pnas.1613528114</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oh,J.E.</style></author><author><style face="normal" font="Arial"> Oh,D.S.</style></author><author><style face="normal" font="Arial"> Jung,H.E.</style></author><author><style face="normal" font="Arial"> Lee,H.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Host Defenses, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">A mechanism for the induction of type 2 immune responses by a protease allergen in the genital tract</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Papain</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasite infection</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="1" Year="2017">2017/1/30</year></dates><abstract><style face="normal" font="Arial">The genital mucosa is a barrier that is constantly exposed to a variety of pathogens, allergens, and external stimuli. Although both allergen exposure and parasite infections frequently occur in the genital area, the mechanism by which immune responses-particularly type 2 immunity-are induced has rarely been studied in the genital mucosa. Here, we demonstrate the induction of T helper type 2 (Th2) immunity in the genital mucosa in response to a model allergen, the protease papain. Intravaginal papain immunization induced type 2 immunity in a manner that was dependent on protease activity and the estrous phase of the mice. In addition, IL-33 was released from the vaginal epithelia after intravaginal papain immunization, leading to the activation of type 2 innate lymphoid cells (ILC2s). Moreover, the IL-33-MyD88 (myeloid differentiation primary response gene 88) signaling pathway was critical for the induction of type 2 immunity. We also found that Th2 differentiation in response to intravaginal papain treatment requires a specific dendritic cell (DC) subset that is controlled by interferon regulatory factor 4 (IRF4). These findings suggest that type 2 immunity is induced by a unique mechanism in the genital tract, which is an important, but often overlooked, barrier surface</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1073/pnas.1612997114</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28137851">PM:28137851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\20170131-OhJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\20170131-OhJE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Oh JE</style></custom2><misc3><style face="normal" font="Arial">10.1073/pnas.1612997114</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,Y.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Ni,R.</style></author><author><style face="normal" font="Arial"> Jia,W.Q.</style></author><author><style face="normal" font="Arial"> Wang,Y.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiration Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China.</style></auth-address><titles><title><style face="normal" font="Arial">IL-4R suppresses airway inflammation in bronchial asthma by inhibiting the IL-4/STAT6 pathway</style></title><secondary-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mastocyte</style></keyword><keyword><style face="normal" font="Arial"> mastocytes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Periodic Acid</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiration</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Suppressor of cytokine signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: This study aims to explore the mechanisms of how IL-4R suppresses airway inflammation in bronchial asthma by inhibiting the IL-4/STAT6 pathway. METHODS: A total of 27 BALB/c male mice were selected and divided into control, asthma and IL-4R groups. Ovalbumin-induced mouse asthma model was established. Maximal pulmonary resistance was recorded. Hematoxylin and eosin (HE) and periodic acid Schiff (PAS) staining were conducted to observe the pathological changes in lung tissue. Optical microscope was used to detect numbers of total cells, mastocytes, eosinophils (EOS), neutrophils, and lymphocytes. Enzyme-linked immunosorbent assay (ELISA) was adopted for the levels of immunoglobulin (IgE), IL-4, IL-5, IL-13 and interferon (IFN)-gamma, flow cytometry for the percentages of IL-4+ CD4+, IFN-gamma+ CD4+ and IFN-gamma+/IL-4+ in total thymus-derived (T) cells, qRT-PCR for the mRNA expressions of IL-4, IL-5, IL-13, STAT6, pSTAT6, suppressor of cytokine signaling (SOCS), inducible nitric oxide synthase (iNOS) and vascular cell adhesion molecule (VCAM)-1, and Western blotting for the protein expressions of STAT6 and pSTAT6. RESULTS: Compared with the control group, the asthma group had irregular tissue structure and severe inflammation, increases in maximal pulmonary resistance, numbers of total cells, EOS, neutrophils, and lymphocytes, levels of IgE, IL-4, IL-5 and IL-13, percentages of IFN-gamma+ CD4+ and IFN-gamma+/IL-4+ in total T cells, mRNA expressions of IL-4, IL-5, IL-13, STAT6, pSTAT6, SOCS, iNOS and VCAM-1, and protein expressions of STAT6 and pSTAT6, but decreases in IFN-gamma level and percentage of IL-4+ CD4+ in total T cells. Compared with the asthma group, the IL-4R group had relatively regular tissue structure and light inflammation, declined maximal RL, numbers of total cells, EOS, neutrophils, and lymphocytes, contents of IgE, IL-4, IL-5 and IL-13, percentages of IFN-gamma+ CD4+ and IFN-gamma+/IL-4+ in total T cells, mRNA expressions of IL-4, IL-5, IL-13, STAT6, pSTAT6, SOCS, iNOS and VCAM-1, and protein expressions of STAT6 and pSTAT6, but elevated IFN-gamma content and percentage of IL-4+ CD4+ in total T cells. CONCLUSION: Our results demonstrate that IL-4R can suppress airway inflammation in bronchial asthma by inhibited the IL-4/STAT6 pathway, which may provide a new therapeutic approach for the treatment of bronchial asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pupt.2017.01.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093225">PM:28093225</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170117-LiuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170117-LiuY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Liu Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pupt.2017.01.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cockle,S.M.</style></author><author><style face="normal" font="Arial"> Stynes,G.</style></author><author><style face="normal" font="Arial"> Gunsoy,N.B.</style></author><author><style face="normal" font="Arial"> Parks,D.</style></author><author><style face="normal" font="Arial"> Alfonso-Cristancho,R.</style></author><author><style face="normal" font="Arial"> Wex,J.</style></author><author><style face="normal" font="Arial"> Bradford,E.S.</style></author><author><style face="normal" font="Arial"> Albers,F.C.</style></author><author><style face="normal" font="Arial"> Willson,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Value Evidence and Outcomes, GSK, GSK House, Brentford, Middlesex, UK</style></auth-address><titles><title><style face="normal" font="Arial">Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison</style></title><secondary-title><style face="normal" font="Arial">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med</style></full-title></periodical><pages end="148" start="140">140-148</pages><volume><style face="normal" font="Arial">123</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Decision Making</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Severe asthma is a heterogeneous disease. Patients with both eosinophilic and allergic asthma phenotypes may be eligible for treatment with mepolizumab and omalizumab. Evidence on the relative effectiveness of these treatments in this 'overlap' population would be informative for clinical and payer decision making. METHODS: A systematic literature review and indirect treatment comparison (Bayesian framework) were performed to assess the comparative effectiveness and tolerability of mepolizumab and omalizumab, as add-ons to standard of care. Studies included in the primary analysis were double-blind, randomized controlled trials, >/=12 weeks' duration enrolling patients with severe asthma with a documented exacerbation history and receiving high-dose inhaled corticosteroids plus >/=1 additional controller. Two populations were examined: patients potentially eligible for 1) both treatments (Overlap population) and 2) either treatment (Trial population). RESULTS: In the Overlap population, no differences between treatments in clinically significant exacerbations and exacerbations requiring hospitalization were found, although trends favored mepolizumab (rate ratio [RR]:0.66 [95% credible intervals (Crl):0.37,1.19]; 0.19[0.02,2.32], respectively). In the Trial population, mepolizumab treatment produced greater reductions in clinically significant exacerbations (RR:0.63 [95% CrI:0.45,0.89]) but not exacerbations requiring hospitalization compared with omalizumab (RR:0.58 [95% Crl: 0.16,2.13]), although the trend favored mepolizumab. Both treatments had broadly comparable effects on lung function, and similar tolerability profiles. CONCLUSIONS: Whilst this analysis has limitations due to a restricted evidence base and residual heterogeneity, it showed that in patients with severe asthma, mepolizumab seems to be at least as effective as omalizumab and that the tolerability profiles of the two treatments did not meaningfully differentiate</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmed.2016.12.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28137490">PM:28137490</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2017-123-140-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2017-123-140-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Cockle SM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmed.2016.12.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mansur,A.H.</style></author><author><style face="normal" font="Arial"> Srivastava,S.</style></author><author><style face="normal" font="Arial"> Mitchell,V.</style></author><author><style face="normal" font="Arial"> Sullivan,J.</style></author><author><style face="normal" font="Arial"> Kasujee,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety</style></title><secondary-title><style face="normal" font="Arial">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med</style></full-title></periodical><pages end="43" start="36">36-43</pages><volume><style face="normal" font="Arial">124</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACQ</style></keyword><keyword><style face="normal" font="Arial"> Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> admissions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Employment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisations</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> long-term outcome</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0954-6111</style></isbn><abstract><style face="normal" font="Arial">Omalizumab has been shown to be an effective add-on therapy for patients with uncontrolled severe persistent allergic asthma. There has been a steady accumulation of evidence on the long-term effectiveness of omalizumab; however, data on real-life outcomes beyond one year of treatment is limited. In this study, we report on long-term outcomes of omalizumab treatment. We collected data from our severe asthma registry on hospitalisations, exacerbations, corticosteroid sparing, asthma control, lung function, biomarkers and side effects, to determine if the benefit was sustained and treatment was safe on the long term. Forty-five patients [mean age 44.9 years (range 19</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô69), females 37/45 (82%), mean duration of omalizumab treatment-á=-á60.7-á-¦-á30.9 months (range 23</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô121) were included in the analysis. We observed a reduction in the annual acute asthma related hospital admissions for the total population from 207-áat baseline to 40 on treatment (80.7% reduction), whilst the per patient annual hospitalisations were reduced from a mean of 4.8 to 0.89 post-omalizumab treatment (p-á&amp;lt;-á0.00001). There was a 76.7% reduction in daily mean maintenance OCS dose (prednisolone equivalent) from 25.8-ámg (n-á=-á43) to 6.0-ámg (p-á&amp;lt;-á0.0001), associated with clinically significant improvement in asthma control questionnaire (ACQ) from mean score of 4.1 (range 3.7</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô4.7) to 2.27 (range 0.5</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô4.1) p-á&amp;lt;-á0.0001. The mean % predicted FEV1 has improved from 59.2% at baseline to 75.7% on treatment (p-á=-á0.001). There was a statistically non-significant reduction in median peripheral blood eosinophils (PBE) from 300-ácells/++l (range 40</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô1050) at baseline to 175-ácells/++l (range 0</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô1500) post-treatment (p-á=-á0.068), and statistically significant reduction of median fraction exhaled nitric oxide (FeNO) level from 37-áparts per billion (range 12</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô178) to 24-áppb (range 7</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô50) (p-á=-á0.0067). The work/school missed days were reduced in 17/19 patients who were at employment or school. The overall safety profile of the treatment seemed acceptable and was consistent with published experience. In conclusion, results from this real-life study demonstrate that improved outcomes in patients with severe allergic asthma are sustained with longer-term omalizumab therapy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United KIngdom -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmed.2017.01.008</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.rmed.2017.01.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\20170207-MansurAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\20170207-MansurAH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Mansur AH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmed.2017.01.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Fu,Y.</style></author><author><style face="normal" font="Arial"> Wei,Z.</style></author><author><style face="normal" font="Arial"> He,X.</style></author><author><style face="normal" font="Arial"> Shi,M.</style></author><author><style face="normal" font="Arial"> Kou,J.</style></author><author><style face="normal" font="Arial"> Zhou,E.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author><author><style face="normal" font="Arial"> Yang,Z.</style></author><author><style face="normal" font="Arial"> Guo,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anti-asthmatic activity of osthole in an ovalbumin-induced asthma murine model</style></title><secondary-title><style face="normal" font="Arial">Respir Physiol Neurobiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Physiol Neurobiol</style></full-title></periodical><pages end="69" start="64">64-69</pages><volume><style face="normal" font="Arial">239</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> NF-+¦B</style></keyword><keyword><style face="normal" font="Arial"> Osthole</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1569-9048</style></isbn><abstract><style face="normal" font="Arial">Osthole, an active coumarin extracted from the dried fruits of Cnidium monnieri (L.) Cusson, is known to possess a variety of pharmacological activities. In the present study, we investigated and illuminated the mechanisms underlying the protective effects of osthole in an experimental model of allergic asthma. Our results show that osthole treatment significantly reduced the OVA-induced increase in serum IgE and inflammatory cytokines (IL-4, IL-5, IL-13) in bronchoalveolar lavage fluid (BALF), and decreased the recruitment of inflammatory cells in BALF and the lung. It also effectively attenuated goblet cell hyperplasia and mucus overproduction in lung tissue. In addition, western blot analysis demonstrated that osthole blocked NF-+¦B activation, which may be associated with a reduction in inflammatory cytokine production. These data suggest that osthole attenuated OVA-induced allergic asthma inflammation by inhibiting NF-+¦B activation. The present study identified the molecular mechanisms of action of osthole, which support the potential pharmaceutical application of osthole treatment for asthma and other airway inflammation disorders</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.resp.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28143779">PM:28143779</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Physiol Neurobiol\20170207-WangJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Physiol Neurobiol\20170207-WangJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.resp.2017.01.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fujii,U.</style></author><author><style face="normal" font="Arial"> Miyahara,N.</style></author><author><style face="normal" font="Arial"> Taniguchi,A.</style></author><author><style face="normal" font="Arial"> Oda,N.</style></author><author><style face="normal" font="Arial"> Morichika,D.</style></author><author><style face="normal" font="Arial"> Murakami,E.</style></author><author><style face="normal" font="Arial"> Nakayama,H.</style></author><author><style face="normal" font="Arial"> Waseda,K.</style></author><author><style face="normal" font="Arial"> Kataoka,M.</style></author><author><style face="normal" font="Arial"> Kakuta,H.</style></author><author><style face="normal" font="Arial"> Tanimoto,M.</style></author><author><style face="normal" font="Arial"> Kanehiro,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Effect of a retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness in a murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Respir Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Res</style></full-title></periodical><pages end="" start="23">23-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Periodic Acid</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin A</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D receptor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Retinoid X receptors (RXRs) are members of the nuclear receptor (NR) superfamily that mediate signaling by 9-cis retinoic acid, a vitamin A (retinol) derivative. RXRs play key roles not only as homodimers but also as heterodimeric partners-e.g., retinoic acid receptors (RARs), vitamin D receptors (VDRs), liver X receptors (LXRs), and peroxisome proliferator-activated receptors (PPARs). The NR family was recently associated with allergic diseases, but the role of RXRs in allergen-induced airway responses is not well defined. The goal of this study is to elucidate the role of RXRs in asthma pathogenesis and the potency of RXR partial agonist in the treatment of allergic airway inflammation and airway hyperresponsiveness using a murine model of asthma. METHODS: We investigated the effect of a novel RXR partial agonist (NEt-4IB) on the development of allergic airway inflammation and airway hyperresponsiveness (AHR) in a murine model of asthma. Balb/c mice were sensitized (days 0 and 14) and challenged (days 28-30) with ovalbumin (OVA), and airway inflammation and airway responses were monitored 48 h after the last OVA challenge. NEt-4IB was administered orally on days 25 to 32. RESULTS: Oral administration of NEt-4IB significantly suppressed AHR and inflammatory cell accumulation in the airways and attenuated the levels of TNF-alpha in the lung and IL-5, IL-13 and NO levels in bronchoalveolar lavage (BAL) fluid and the number of periodic acid Schiff (PAS)-positive goblet cells in lung tissue. Treatment with NEt-4IB also significantly suppressed NF-kappaB expression. CONCLUSION: These data suggest that RXRs may be of crucial importance in the mechanism of allergic asthma and that the novel RXR partial agonist NEt-4IB may be a promising candidate for the treatment of allergic airway inflammation and airway hyperresponsiveness in a model of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12931-017-0507-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28114934">PM:28114934</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2017-18-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2017-18-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Fujii U</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12931-017-0507-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Juan,Z.</style></author><author><style face="normal" font="Arial"> Zhao-Ling,S.</style></author><author><style face="normal" font="Arial"> Ming-Hua,Z.</style></author><author><style face="normal" font="Arial"> Chun,W.</style></author><author><style face="normal" font="Arial"> Hai-Xia,W.</style></author><author><style face="normal" font="Arial"> Meng-Yun,L.</style></author><author><style face="normal" font="Arial"> Jian-Qiong,H.</style></author><author><style face="normal" font="Arial"> Yue-Jie,Z.</style></author><author><style face="normal" font="Arial"> Xin,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, China</style></auth-address><titles><title><style face="normal" font="Arial">Oral administration of Clostridium butyricum CGMCC0313-1 reduces ovalbumin-induced allergic airway inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respirology</style></full-title></periodical><pages end="904" start="898">898-904</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Probiotic bacteria can induce immune regulation or immune tolerance in patients with allergic diseases, but the underlying mechanisms are still unclear. There has been a growing interest in the use of beneficial bacteria for allergic diseases recently. This study aimed at exploring whether Clostridium butyricum CGMCC0313-1 (C. butyricum) can reduce ovalbumin (OVA)-induced allergic airway inflammation in a mouse model. METHODS: Mouse model of allergic airway inflammation induced via OVA was used in this study. C. butyricum was administered daily by the oral route during or after the sensitization. Airway function, pulmonary airway inflammation, mast cell degranulation, T helper (Th)-specific and anti-inflammatory cytokines, OVA-specific Ig, matrix metalloproteinase 9 (MMP-9) and histopathological alterations were examined. RESULTS: C. butyricum significantly reduced lung resistance in the asthmatic mice. Pulmonary airway inflammation, mast cell degranulation, airway remodelling and the expression of OVA-specific IgE/G1 were suppressed by oral C. butyricum. It also reversed the imbalance of Th1/Th2 and increased the anti-inflammatory cytokine IL-10. CONCLUSION: C. butyricum reduces OVA-induced allergic airway inflammation in mice and might be an additional or supplementary therapy for allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/resp.12985</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122397">PM:28122397</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respirology\20170125-JuanZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respirology\20170125-JuanZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Juan Z</style></custom2><misc3><style face="normal" font="Arial">10.1111/resp.12985</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galindo-Rodriguez,G.</style></author><author><style face="normal" font="Arial"> Jaime-Perez,J.C.</style></author><author><style face="normal" font="Arial"> Salinas-Carmona,M.C.</style></author><author><style face="normal" font="Arial"> Gonzalez-Diaz,S.N.</style></author><author><style face="normal" font="Arial"> Castro-Corona,A.</style></author><author><style face="normal" font="Arial"> Cavazos-Gonzalez,R.</style></author><author><style face="normal" font="Arial"> Trevino-Villarreal,H.</style></author><author><style face="normal" font="Arial"> Heredia-Salazar,A.C.</style></author><author><style face="normal" font="Arial"> Gomez-Almaguer,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study</style></title><secondary-title><style face="normal" font="Arial">Rev Bras Hematol Hemoter</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Bras Hematol Hemoter</style></full-title></periodical><pages end="209" start="202">202-209</pages><volume><style face="normal" font="Arial">39</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> L-asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Silent antibodies</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1516-8484</style></isbn><abstract><style face="normal" font="Arial">Background l-Asparaginase is essential in the treatment of childhood acute lymphoblastic leukemia. If immunoglobulin G anti-l-asparaginase antibodies develop, they can lead to faster plasma clearance and reduced efficiency as well as to hypersensitivity reactions, in which immunoglobulin E can also participate. This study investigated the presence of immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies and their clinical associations. Methods Under 16-year-old patients at diagnosis of B-cell acute lymphoblastic leukemia confirmed by flow cytometry and treated with a uniform l-asparaginase and chemotherapy protocol were studied. Immunoglobulin G anti-l-asparaginase antibodies were measured using an enzyme-linked immunosorbent assay. Intradermal and prick skin testing was performed to establish the presence of specific immunoglobulin E anti-l-asparaginase antibodies in vivo. Statistical analysis was used to investigate associations of these antibodies with relevant clinical events and outcomes. Results Fifty-one children were studied with 42 (82.35%) having anti-l-asparaginase antibodies. In this group IgG antibodies alone were documented in 10 (23.8%) compared to immunoglobulin E alone in 18 (42.8%) patients. Immunoglobulin G together with immunoglobulin E were simultaneously present in 14 patients. Children who produced exclusively IgG or no antibodies had a lower event-free survival (p-value = 0.024). Eighteen children (35.3%) relapsed with five of nine of this group who had negative skin tests suffering additional relapses (range: 2</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô4), compared to none of the nine children who relapsed who had positive skin tests (p-value &amp;lt; 0.001). Conclusion Children with acute lymphoblastic leukemia and isolated immunoglobulin G anti-l-asparaginase antibodies had a higher relapse rate, whereas no additional relapses developed in children with immunoglobulin E anti-l-asparaginase antibodies after the first relapse</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.bjhh.2016.11.006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.bjhh.2016.11.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Bras Hematol Hemoter\20170207-GalindoRodriguezG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Bras Hematol Hemoter\20170207-GalindoRodriguezG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Galindo-Rodriguez G</style></custom2><misc3><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.bjhh.2016.11.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Villamil-Munevar,P.A.</style></author><author><style face="normal" font="Arial"> Sanchez-Solanilla,L.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Kounis syndrome or allergic angina</style></title><secondary-title><style face="normal" font="Arial">Rev Colomb Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Colomb Cardiol</style></full-title></periodical><pages end="387" start="382">382-387</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic angina</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Angina</style></keyword><keyword><style face="normal" font="Arial"> Arterioesclerosis</style></keyword><keyword><style face="normal" font="Arial"> Arteriosclerosis</style></keyword><keyword><style face="normal" font="Arial"> Cardiovascular System</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Ischemia</style></keyword><keyword><style face="normal" font="Arial"> Isquemia</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocitos</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Respuesta inflamatoria</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> thromboxane</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Tromboxano</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0120-5633</style></isbn><abstract><style face="normal" font="Arial">Resumen El s+¡ndrome de Kounis es la asociaci+¦n de s+¡ndrome coronario agudo secundario a una reacci+¦n de anafilaxis, la cual es producida por mediadores inflamatorios y vasoactivos liberados principalmente por activaci+¦n y degranulaci+¦n de mastocitos que act+¦an en el sistema cardiovascular. Es una patolog+¡a subdiagnosticada por cuanto no es considerada en los servicios de urgencias y cuidado coronario pues son pocos los registros en la literatura m+®dica. El s+¡ndrome de Kounis es producido por diferentes mediadores como medicamentos, medios de contraste, enfermedades al+®rgicas, mastocitosis, venenos de insectos, etc.; en s+¡ todo lo que conlleve a la activaci+¦n de mastocitos puede producir el s+¡ndrome. Se puede presentar en cualquier grupo et+íreo dado que ha sido descrito en ni+¦os y adultos. Debido a la falta de estudios cl+¡nicos, hasta el momento no hay un consenso acerca del tratamiento de esta patolog+¡a. Abstract Kounis syndrome is the concurrence of acute coronary syndromes with conditions associated to an anaphylaxis reaction, which is produced by vasoactive and inflammatory mediators, released mostly by activation and degranulation of mast cells that act in the cardiovascular system. It is an underdiagnosed condition, not included in the emergency room services or coronary care, as there are only few registers in medical literature. Kounis syndrome is produced by different mediators, such as drugs, contrast agents, allergic diseases, mastocytosis, insect stings, etc.; anything that could activate mast cells may trigger the syndrome. It can appear in any age group, in fact it has been described in children and adults. Due to the lack of clinical studies, until today there is no consensus on the treatment for this condition</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rccar.2016.10.042</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.rccar.2016.10.042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Colomb Cardiol\20170207-VillamilMunevarPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Colomb Cardiol\20170207-VillamilMunevarPA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Villamil-Munevar PA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rccar.2016.10.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ando,J.</style></author><author><style face="normal" font="Arial"> Masuda,A.</style></author><author><style face="normal" font="Arial"> Iizuka,K.</style></author><author><style face="normal" font="Arial"> Ochiai,T.</style></author><author><style face="normal" font="Arial"> Takaku,T.</style></author><author><style face="normal" font="Arial"> Osawa,T.</style></author><author><style face="normal" font="Arial"> Shimada,E.</style></author><author><style face="normal" font="Arial"> Watanabe,Y.</style></author><author><style face="normal" font="Arial"> Komatsu,N.</style></author><author><style face="normal" font="Arial"> Osaka,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Hematology, Juntendo University School of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Congenital haptoglobin deficiency discovered on the occasion of anaphylaxis induced by platelet concentrate transfusion</style></title><secondary-title><style face="normal" font="Arial">Rinsho Ketsueki</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rinsho Ketsueki</style></full-title></periodical><pages end="2511" start="2507">2507-2511</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> hemorrhagic</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Peritonitis</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">A 77-year-old man with myelodysplastic syndrome suffered from duodenal perforation after undergoing endoscopic submucosal dissection (ESD) for treatment of duodenal cancer. He presented with hemorrhagic shock, peritonitis and disseminated intravascular coagulation (DIC), and received transfusions of red blood cells (RBC), fresh frozen plasma (FFP), gamma-globulin and albumin (Alb). One month after the last RBC transfusion, prolonged thrombocytopenia was observed, and platelet concentrate (PC) was transfused. However, immediately after starting PC transfusion, he developed dyspnea, hypotension and rash, and was thus diagnosed as being in anaphylactic shock. Analysis of the patient's serum revealed absence of haptoglobin (Hp) and the presence of anti-Hp antibody. Further studies, using PCR detected Hpdel, yielded a diagnosis of congenital Hp deficiency. Thus, the anaphylactic shock was considered to have been induced by Hp in the transfused PC reacting with pre-existing anti-Hp antibodies. Thereafter, transfusions were safely carried out with the use of washed PC. Congenital Hp deficiency is relatively prevalent, and in such cases transfusions should be carried out using washed RBC, washed PC and congenital Hp deficiency donor derived FFP to avoid anaphylactic transfusion reactions. Transfusions would be even safer if production of congenital Hp deficiency donor derived PC were to be made available in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170116IS - 0485-1439 (Print)IS - 0485-1439 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.11406/rinketsu.57.2507</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28090018">PM:28090018</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170116, Ando J</style></custom2><misc3><style face="normal" font="Arial">10.11406/rinketsu.57.2507</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">El-Reshaid,K.</style></author><author><style face="normal" font="Arial"> Al-Bader,S.</style></author><author><style face="normal" font="Arial"> Madda,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait</style></auth-address><titles><title><style face="normal" font="Arial">Membranous glomerulopathy and massive cervical lymphadenopathy due to immunoglobulin G4-disease</style></title><secondary-title><style face="normal" font="Arial">Saudi J Kidney Dis Transpl</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Saudi J Kidney Dis Transpl</style></full-title></periodical><pages end="153" start="149">149-153</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdomen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mycophenolate</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nephrotic Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Pelvis</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Proteinuria</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tacrolimus</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">A 32-year-old male presented with acute and severe nephrotic syndrome as well as massive right cervical lymphadenopathy for &lt;2 years. Computed tomography scan of the chest, abdomen, and pelvis did not reveal any lymphadenopathy. Histopathology and immunohistochemical testing of his lymph node biopsy showed infiltrate enriched with immunoglobulin G4 (IgG4)-positive plasma cells. His kidney biopsy showed granular membranous deposits of IgG4 in the basement membrane without interstitial infiltrate. Antiphospholipid 2 receptor antibodies were absent excluding its "idiopathic" nature. Since he was allergic to rituximab, he was treated with corticosteroids for two months and a combination of tacrolimus and mycophenolate. His lymphadenopathy disappeared, and his proteinuria abated. The dose of the latter two medications was reduced to half after four months and will be maintained for a minimum of two years to prevent relapse of his disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170118IS - 1319-2442 (Print)IS - 1319-2442 (Linking)LA - engPT - Case ReportsCO - Kuwait -</style></notes><work-type><style face="normal" font="Arial">10.4103/1319-2442.198167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098116">PM:28098116</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Saudi J Kidney Dis Transpl\2017-28-149-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Saudi J Kidney Dis Transpl\2017-28-149-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170118, El-Reshaid K</style></custom2><misc3><style face="normal" font="Arial">10.4103/1319-2442.198167</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruiz,O.A.</style></author><author><style face="normal" font="Arial"> Mikkelsen,S.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Mortz,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Sdr. Boulevard 29, Odense, DK-5000, Denmark.</style></auth-address><titles><title><style face="normal" font="Arial">Pre-hospital treatment of bee and wasp induced anaphylactic reactions: a retrospective study</style></title><secondary-title><style face="normal" font="Arial">Scand J Trauma Resusc Emerg Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Scand J Trauma Resusc Emerg Med</style></abbr-1></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> ICD-10</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="14" Month="1" Year="2017">2017/1/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bee and wasp stings are among the most common triggers of anaphylaxis in adults representing around 20% of fatal anaphylaxis from any cause. Data of pre-hospital treatment of bee and wasp induced anaphylactic reactions are sparse. This study aimed to estimate the incidence of bee and wasp induced anaphylactic reactions, the severity of the reactions and to correlate the pre-hospital treatment with the severity of the anaphylactic reaction. METHODS: Retrospective and descriptive study based on data from the Mobile Emergency Care Units (MECUs) in the Region of Southern Denmark (2008 only for Odense and 2009-2014 for the whole region). Discharge summaries with diagnosis related to anaphylaxis according to the International Classification of Diseases 10 (ICD-10) were reviewed to identify bee and wasp induced anaphylactic reactions. The severity of the anaphylactic reaction was assessed according to Sampson's severity score and Mueller's severity score. Treatment was evaluated in relation to administration of adrenaline, glucocorticoids and antihistamine. RESULTS: We identified 273 cases (Odense 2008 n = 14 and Region of Southern Denmark 2009-2014 n = 259) of bee and wasp induced anaphylaxis. The Incidence Rate was estimated to 35.8 cases per 1,000,000 person year (95% CI 25.9-48.2) in the Region of Southern Denmark during 2009-2014. According to Sampson's severity score, 65% (n = 177) of the cases were graded as moderate to severe anaphylaxis (grade 3-5). Almost one third of cases could not be graded according to Mueller's severity score. Adrenaline was administrated in 54% (96/177) of cases with moderate to severe anaphylaxis according to Sampson's severity score, compared to 88% receiving intravenous glucocorticoids (p &lt; 0.001) and 91% receiving intravenous antihistamines (p &lt; 0.001). Even in severe anaphylaxis (grade 5) adrenaline was administered in only 80% of the cases. CONCLUSION: Treatment with adrenaline is not administered in accordance with international guidelines. However, making an assessment of the severity of the anaphylactic reaction is difficult in retrospective studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170115IS - 1757-7241 (Electronic)IS - 1757-7241 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13049-016-0344-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28088250">PM:28088250</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Scand J Trauma Resusc Emerg Med\2017-25-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Scand J Trauma Resusc Emerg Med\2017-25-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170115, Ruiz OA</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13049-016-0344-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakamura,Y.</style></author><author><style face="normal" font="Arial"> Ishimaru,K.</style></author><author><style face="normal" font="Arial"> Shibata,S.</style></author><author><style face="normal" font="Arial"> Nakao,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Regulation of plasma histamine levels by the mast cell clock and its modulation by stress</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="39934">39934-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="Arial">At steady state, plasma histamine levels exhibit circadian variations with nocturnal peaks, which is implicated in the nighttime exacerbation of allergic symptoms. However, the regulatory mechanisms are largely unexplored. This study determined how steady-state plasma histamine levels are regulated and affected by environmental factors. We found that plasma histamine levels decreased in mast cell-deficient mice and their circadian variations were lost in mast cell-deficient mice reconstituted with bone marrow-derived mast cells (BMMCs) harboring a mutation in the circadian gene Clock. Clock temporally regulates expression of organic cation transporter 3 (OCT3), which is involved in histamine transport, in mast cells; OCT inhibition abolished circadian variations in plasma histamine levels. Mice housed under aberrant light/dark conditions or suffering from restraint stress exhibited de-synchronization of the mast cell clockwork, concomitant with the loss of circadian variations in OCT3 expression and plasma histamine levels. The degree of compound 48/80-induced plasma extravasation in mice was correlated with plasma histamine levels. Collectively, the mast cell clock mediates circadian regulation of plasma histamine levels at steady state, in part by controlling OCT3 expression, which can be modulated by stress. Additionally, we propose that plasma histamine levels potentiate mast cell-mediated allergic reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep39934</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28074918">PM:28074918</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-39934.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-39934.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Nakamura Y</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep39934</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.</style></author><author><style face="normal" font="Arial"> Deng,Y.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Urban Agriculture (South), Ministry of Agriculture, SJTU-Bor S. Luh Food Safety Center, Department of Food Science and Technology, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China</style></auth-address><titles><title><style face="normal" font="Arial">Structure-based modelling of hemocyanin allergenicity in squid and its response to high hydrostatic pressure</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="40021">40021-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregation</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Hemocyanin</style></keyword><keyword><style face="normal" font="Arial"> High hydrostatic pressure</style></keyword><keyword><style face="normal" font="Arial"> Hydrophobicity</style></keyword><keyword><style face="normal" font="Arial"> Hydrostatic Pressure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Modelling</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Squid</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Structure analysis</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">The secondary, tertiary, and quaternary structures of squid hemocyanin (Hc) were characterised, and the relationship between Hc structure and allergenicity responses to high hydrostatic pressure (HHP) was modelled. The Hc allergenicity varied with its protein structure. Electrophoresis analysis revealed that HHP treatment significantly decreased the band intensity of Hc when increasing pressure from 200 and 400 MPa to 600 MPa. The protein structure analysis of squid Hc showed that while HHP treatment decreased the alpha-helix content, free sulfhydryl content, and Rg, it increased the random coil content, surface hydrophobicity index (Ho), Guinier aggregation number (NaggG) and average aggregation number (NaggQ). The alpha-helix and random coil contents of the 600 MPa treated samples were 23.67% and 37.54%, respectively, compared to 32.37% and 32.02% in the control, respectively. HHP treatment decreased the IgE and IgG-binding capacities, indicating a significant decrease in the allergenicity (P&lt; 0.05) of squid Hc. This study provided meaningful information of applying HHP to reduce allergenicity, and explained the responses of Hc protein structure to HHP for lowering the allergenicity of squid</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep40021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28112159">PM:28112159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-40021.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-40021.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170123, Zhang Y</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep40021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez,M.J.</style></author><author><style face="normal" font="Arial"> Aranda,A.</style></author><author><style face="normal" font="Arial"> Fernandez,T.D.</style></author><author><style face="normal" font="Arial"> Cubells-Baeza,N.</style></author><author><style face="normal" font="Arial"> Torres,M.J.</style></author><author><style face="normal" font="Arial"> Gomez,F.</style></author><author><style face="normal" font="Arial"> Palomares,F.</style></author><author><style face="normal" font="Arial"> Perkins,J.R.</style></author><author><style face="normal" font="Arial"> Rojo,J.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Mayorga,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Laboratory, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="Arial">LPS promotes Th2 dependent sensitisation leading to anaphylaxis in a Pru p 3 mouse model</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="40449">40449-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergen</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="Arial">Pru p 3 is the major peach allergen in the Mediterranean area. It frequently elicits severe reactions, limiting its study in humans, raising the need for animal models to investigate the immunological mechanisms involved. However, no anaphylaxis model exists for Pru p 3. We aimed to develop a model of peach anaphylaxis by sensitising mice with Pru p 3 in combination with lipopolysaccharide (LPS) as an adjuvant. Four groups of mice were sensitised intranasally: untreated; treated with Pru p 3; treated with LPS; treated with Pru p 3 + LPS. After sensitisation mice were intraperitoneally challenged with Pru p 3 and in vivo and in vitro parameters were evaluated. Only mice in the Pru p 3 + LPS group showed anaphylaxis symptoms, including a decrease in temperature. Determination of in vitro parameters showed a Th2 response with an increase of Pru p 3-specific IgE and IgG1. Moreover, at the cellular level, we found increased levels of IgE and IgG1 secreting Pru p 3-specific cells and a proliferative CD4+ T-cell response. These results demonstrate that Pru p 3-specific anaphylaxis can be generated after nasal sensitisation to Pru p 3 in combination with LPS. This is a promising model for evaluating food allergy immunotherapies</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep40449</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28084419">PM:28084419</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-40449.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-40449.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Rodriguez MJ</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep40449</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salimifard,P.</style></author><author><style face="normal" font="Arial"> Rim,D.</style></author><author><style face="normal" font="Arial"> Gomes,C.</style></author><author><style face="normal" font="Arial"> Kremer,P.</style></author><author><style face="normal" font="Arial"> Freihaut,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Architectural Engineering, Pennsylvania State University, University Park, PA 16802, USA</style></auth-address><titles><title><style face="normal" font="Arial">Resuspension of biological particles from indoor surfaces: Effects of humidity and air swirl</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="247" start="241">241-247</pages><volume><style face="normal" font="Arial">583</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> Bacillus thuringiensis</style></keyword><keyword><style face="normal" font="Arial"> Biological particles</style></keyword><keyword><style face="normal" font="Arial"> carpet</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> cat fur</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation Exposure</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Quartz</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vibration</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="Arial">Human exposure to airborne particles can lead to adverse health outcomes such as respiratory and allergic symptoms. Understanding the transport mechanism of respirable particles in occupied spaces is a first step towards assessing inhalation exposure. Several studies have contributed to the current knowledge of particle resuspension from indoor surfaces; however, few published studies are available on resuspension of biological particles from indoor surfaces. The objective of this study is to investigate the impacts of humidity and air swirl on resuspension of biological particles from floor and duct surfaces. Controlled laboratory experiments were conducted under varying degrees of humidity and airflow conditions. Resuspension rates of five types of particles (quartz, dust mite, cat fur, dog fur, and bacterial spore-Bacillus thuringiensis as an anthrax simulant) were determined for two types of floor surface (carpet and linoleum) and a duct surface (galvanized sheet metal). The results show that the particle property of being hydrophilic or hydrophobic plays an important role in particle resuspension rate. Resuspension rates of hydrophilic dust mite particles increase up to two orders of magnitude as relative humidity (RH) decreased from 80% to 10% at 25 degrees C. However, resuspension rates of cat fur and dog fur particles that are hydrophobic are within the measurement error range (+/-15%) over 10-80% RH. With regard to resuspension of bacterial spores (Bacillus thuringiensis) from a duct surface, the resuspension rates are substantially affected by air swirl velocity and particle size. However, no discernible increase in particle resuspension was observed with duct vibration</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.01.058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28117152">PM:28117152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\20170124-SalimifardP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\20170124-SalimifardP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Salimifard P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.01.058</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elvira-Rendueles,B.</style></author><author><style face="normal" font="Arial"> Zapata,J.J.</style></author><author><style face="normal" font="Arial"> Miralles,J.C.</style></author><author><style face="normal" font="Arial"> Moreno,J.M.</style></author><author><style face="normal" font="Arial"> Garcia-Sanchez,A.</style></author><author><style face="normal" font="Arial"> Negral,L.</style></author><author><style face="normal" font="Arial"> Moreno-Grau,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departament of Chemical and Environmental Engineering, Technical University of Cartagena, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Aerobiological importance and allergic sensitization to Amaranthaceae under arid climate conditions</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="486" start="478">478-486</pages><volume><style face="normal" font="Arial">583</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosol</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> Volumetric sampler</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="1" Year="2017">2017/1/22</year></dates><abstract><style face="normal" font="Arial">Species of the Amaranthaceae family are abundant in the Southeast of Spain, one of the driest areas in Europe. The Amaranthaceae include species of interest from the point of view of allergic diseases. With the expansion of aridity, many species belonging to this family will be favoured. The objectives of this study were: first, to define the prevalence of sensitization to Amaranthaceae pollen in allergic patients in the Southeast of Spain; second, to present the aerobiological features of this taxon; and, finally, to demarcate those periods of increased risk of suffering allergic symptoms with the aim of improving the diagnosis and prevention of hay fever. Skin prick tests with extracts of pollen were performed on patients with symptoms of respiratory allergy referred for consultation for the first time in Almeria and Murcia. Samples of the atmospheric bioaerosol were taken using a Lanzoni VPPS 2000 volumetric sampler, samples treatment and subsequent counts being carried out according to the methodology approved by the Spanish Aerobiological Network. The statistical significance of the correlation between aerobiological and meteorological data from this arid region in 2010-2014 was determined. The aerobiological study revealed the presence of two distinct peaks responsible for pollen symptoms. The flowering of this taxon is especially noteworthy in the city of Cartagena, where it supposes 94% of the total pollen collected in these periods. This situation converts Amaranthaceae pollen in the second leading cause of hay fever in the Southeast of Spain. With the expansion of aridity, an increase in the presence of these species is expected. Bearing in mind their prevalence in the spring and summer/autumn periods and their extensive presence in the bioaerosol, this makes data from Southeastern Spanish a benchmark with respect to the aerobiology of this type of pollen</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.01.119</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122685">PM:28122685</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\20170126-ElviraRenduelesB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\20170126-ElviraRenduelesB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Elvira-Rendueles B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.01.119</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perez-Fuentes,L.</style></author><author><style face="normal" font="Arial"> Drummond,C.</style></author><author><style face="normal" font="Arial"> Faraudo,J.</style></author><author><style face="normal" font="Arial"> Bastos-Gonzalez,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biocolloid and Fluid Physics Group, Department of Applied Physics. University of Granada, Av. Fuentenueva S/N, 18071 Granada, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Interaction of organic ions with proteins</style></title><secondary-title><style face="normal" font="Arial">Soft Matter</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Soft Matter</style></full-title></periodical><pages end="1131" start="1120">1120-1131</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hydrophobicity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Microspheres</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Quartz</style></keyword><keyword><style face="normal" font="Arial"> Quartz crystal microbalance</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">In this study we have investigated how different proteins interact with big organic ions. Two ions that are similar in size and chemical structure (Ph4B- anion and Ph4As+ cation) were studied. The proteins chosen are the two major allergenic proteins of cow's milk, beta-lactoglobulin and beta-casein, and bovine serum albumin, BSA, as the reference protein. First, a quantitative study to determine the hydrophobic degree of the proteins was performed. Then, electrokinetic and stability measurements on protein-coated polystyrene (PS) microspheres as a function of the tetraphenyl ion concentration were carried out. Our results show that the affinity of the organic ions depends on the hydrophobicity of the interface. Big charge inversions and re-stabilization patterns were observed at very low concentrations of tetraphenyl ions for the most hydrophobic protein studied (with beta-casein). Besides, the ionic concentrations needed to destabilize these colloidal systems were roughly one order of magnitude lower for the anion than for the cation. In addition, we studied conformational changes of the adsorbed proteins with a quartz crystal microbalance. Proteins were adsorbed onto hydrophobic flat substrates and then exposed to the tetraphenyl ions. The protein films swelled or collapsed as a function of the accumulation of tetraphenyl ions. Similarly to the electrokinetic/stability studies, the ionic concentration necessary to trigger structural changes of the protein films was one order of magnitude larger for the cation than for the anion. All the results evidence that the accumulation of these organic ions on an interface depends directly on its degree of hydrophobicity. We attribute the different interactions of the anion and the cation with these interfaces to their dissimilar hydration, which makes the anion show a more hydrophobic behaviour than the cation</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1744-6848 (Electronic)IS - 1744-683X (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1039/c6sm02048h</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093583">PM:28093583</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Soft Matter\20170117-PerezFuentesL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Soft Matter\20170117-PerezFuentesL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Perez-Fuentes L</style></custom2><misc3><style face="normal" font="Arial">10.1039/c6sm02048h</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate School of Medical Science and Engineering, Biomedical Research Center, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Mitochondrial reactive oxygen species regulate fungal protease-induced inflammatory responses</style></title><secondary-title><style face="normal" font="Arial">Toxicology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicology</style></full-title></periodical><pages end="94" start="86">86-94</pages><volume><style face="normal" font="Arial">378</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> AP1</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Bronchopneumonia</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cell migration</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> intercellular adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Mitochondria</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="Arial">Epidemiological studies have shown that fungal infections are a main cause of respiratory tract diseases, such as asthma, bronchopneumonia, intoxication, and invasive fungal disease. Fungi such as Aspergillus and Candida species have become increasingly important pathogens as the global climate changes. Accordingly, in this study, we evaluated the toxicological potential of Aspergillus protease in the lower respiratory tract. Exposure of Aspergillus protease to A549 cells induced upregulation of tumor necrosis factor (TNF)-alpha, monocyte chemoattractant protein (MCP)-1, and intercellular adhesion molecule (ICAM)-1 mRNAs and increased production of interleukin (IL)-8 and MCP-1 protein through enhanced mitochondrial reactive oxygen species (ROS) generation and activation of mitogen-activated protein kinase (MAPK) and activator protein (AP)-1. Furthermore, the mitochondrial ROS scavenger Mito-TEMPO, which inhibited MAPK and AP-1, significantly reduced MCP-1 and IL-1beta mRNA expression and reduced HL-60 cell migration through the suppression of MCP-1 and IL-8 protein secretion. Thus, our results demonstrated that mitochondria were an important source of Aspergillus protease-stimulated ROS and that regulation of mitochondrial ROS modulated inflammatory responses by preventing activation of MAPK and AP-1 in A549 cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 1879-3185 (Electronic)IS - 0300-483X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tox.2017.01.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087464">PM:28087464</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicology\20170114-KimYH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicology\20170114-KimYH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170114, Kim YH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tox.2017.01.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garraud,O.</style></author><author><style face="normal" font="Arial"> Martin,C.</style></author><author><style face="normal" font="Arial"> Haddad,A.</style></author><author><style face="normal" font="Arial"> Bagge Hansen,M.</style></author><author><style face="normal" font="Arial"> Rautmann,G.</style></author><author><style face="normal" font="Arial"> MacLennan,S.</style></author><author><style face="normal" font="Arial"> Norda,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A European survey on donor deferral for allergy: Rationale and initial results of a survey in 35 countries</style></title><secondary-title><style face="normal" font="Arial">Transfus Clin Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfus Clin Biol</style></full-title></periodical><pages end="35" start="34">34-35</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood donor</style></keyword><keyword><style face="normal" font="Arial"> Blood Donors</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hemovigilance</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1246-7820</style></isbn><abstract><style face="normal" font="Arial">Allergy accounts to near 0.5% of all reported transfusion adverse events. The responsibility of blood components themselves and </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô-átherefore-á</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô of blood donors is still questioned. The European Community undertook a large international survey to address the consistency and homogeneity of medical selection of blood donors with regard to the risk of allergy, and especially of transferring allergy to recipients. This short report presents the salient points of the survey, stressing that there is inconsistency in addressing the allergy question within countries or systems, with paths of improvement</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -CO - Lebanon -CO - Denmark -CO - United Kingdom -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tracli.2016.12.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.tracli.2016.12.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfus Clin Biol\20170207-GarraudO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfus Clin Biol\20170207-GarraudO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Garraud O</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tracli.2016.12.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uysal,P.</style></author><author><style face="normal" font="Arial"> Avcil,S.</style></author><author><style face="normal" font="Arial"> Erge,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Clinical Immunology, Adnan Menderes University School of Medicine, Aydin, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">High-dose anti-histamine use and risk factors in children with urticaria</style></title><secondary-title><style face="normal" font="Arial">Turk Pediatri Ars</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Turk Pediatri Ars</style></abbr-1></periodical><pages end="203" start="198">198-203</pages><volume><style face="normal" font="Arial">51</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parental atopy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">AIM: The drugs of choice in the treatment of urticaria in children are H1-antihistamines. The aim of the study was to evaluate children with urticaria and define risk factors for requirement of high-dose H1-antihistamines in children with urticaria. MATERIAL AND METHODS: The medical data of children who were diagnosed as having urticaria admitted to our outpatient clinic between January 2014 and January 2016 were searched. The medical histories, concomitant atopic diseases, parental atopy histories, medications, treatment responses, blood eosinophil and basophil counts, and serum total IgE levels were recorded. In addition, the urticaria activity score for seven days, autoimmune antibody tests, and skin prick test results were evaluated in children with chronic urticaria. RESULTS: The numbers of the children with acute and chronic urticaria were 138 and 92, respectively. The age of the children with chronic urticaria was higher than that of those with acute urticaria (p&lt;0.0001). There was no difference between the two groups in terms of blood eosinophil and basophil counts, and serum total IgE levels (p>0.05). There was a negative correlation between blood eosinophil count and the UAS7 score in children with chronic urticaria (r=-0.276, p=0.011). Chronic urticaria and requirement of high dose H1-antihistamines were significant in children aged >/=10 years (p&lt;0.001, p=0.015). High UAS7 score (OR: 1.09; CI 95%: [1.03-1.15]) and basopenia (OR: 6.77; CI 95%: [2.01-22.75]) were associated with the requirement of high-dose H1-AH in children with chronic urticaria. CONCLUSION: The requirement of high-dose H1-antihistamines was higher with children's increasing age. Disease severity and basopenia were risk factors for the requirement of high-dose H1-antihistamines</style></abstract><notes><style face="normal" font="Arial">DA - 20170126IS - 1306-0015 (Print)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5152/TurkPediatriArs.2016.4202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28123332">PM:28123332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Turk Pediatri Ars\2016-51-198-203.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Turk Pediatri Ars\2016-51-198-203.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170126, Uysal P</style></custom2><misc3><style face="normal" font="Arial">10.5152/TurkPediatriArs.2016.4202</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakayama,M.</style></author><author><style face="normal" font="Arial"> Itoh,Y.</style></author><author><style face="normal" font="Arial"> Shichinohe,S.</style></author><author><style face="normal" font="Arial"> Nakabayashi,R.</style></author><author><style face="normal" font="Arial"> Ishigaki,H.</style></author><author><style face="normal" font="Arial"> Sakoda,Y.</style></author><author><style face="normal" font="Arial"> Le,Q.M.</style></author><author><style face="normal" font="Arial"> Kawaoka,Y.</style></author><author><style face="normal" font="Arial"> Kida,H.</style></author><author><style face="normal" font="Arial"> Ogasawara,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pathology and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus</style></title><secondary-title><style face="normal" font="Arial">Vaccine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vaccine</style></full-title></periodical><pages end="1017" start="1008">1008-1017</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Influenza virus</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macaque</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="Arial">The efficacy and detrimental effect of mucosal vaccination with an inactivated influenza vaccine were examined in a macaque model by intranasal administration with small amounts of inactivated whole virus particles and challenge by a human-derived H5N1 highly pathogenic avian influenza virus infection. Repeated nasal inoculation with the whole particle vaccine of an inactivated virus, A/duck/Hokkaido/Vac-3/2007 (H5N1) (Vac-3), induced antigen-specific IgA and IgG antibody production in nasal swabs and plasma. Vac-3-specific IgE production was also found in the nasal swabs. Nasal vaccination with Vac-3 induced broader cross-clade neutralization activity than did subcutaneous vaccination. After challenge infection, repeated nasal vaccination almost completely prevented the propagation of virus in the upper and lower airways and protected cynomolgus macaques from viral pneumonia by induction of IgA-producing B cells in the lungs. On the other hand, eosinophil clusters were observed in the lungs of vaccinated macaques. Although Vac-3-specific IgE antibody and IL-13 levels were decreased after infection compared to those before infection and no anaphylaxis in vaccinated macaques was detected after challenge infection, our results suggest that we have to pay attention to potential allergic responses at repeated nasal vaccination, especially in people who have an airway allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170122IS - 1873-2518 (Electronic)IS - 0264-410X (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Viet Nam -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.vaccine.2017.01.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109707">PM:28109707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vaccine\20170122-NakayamaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vaccine\20170122-NakayamaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170122, Nakayama M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.vaccine.2017.01.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jun,H.</style></author><author><style face="normal" font="Arial"> Jung,C.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Surgery, Korea University Anam Hospital, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin G4-Related Inflammatory Abdominal Aortic Aneurysm Associated With Myasthenia Gravis, With Contained Rupture</style></title><secondary-title><style face="normal" font="Arial">Vasc Endovascular Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Vasc Endovascular Surg</style></abbr-1></periodical><pages end="574" start="571">571-574</pages><volume><style face="normal" font="Arial">50</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Myasthenia Gravis</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin (Ig) G4-related disease is reportedly among the various causes of inflammatory abdominal aortic aneurysm (IAAA). Many IgG4-related diseases are closely related to allergic constitution and autoimmune disease. We report a case of a 72-year-old man with IgG4-related IAAA associated with myasthenia gravis, with contained rupture</style></abstract><notes><style face="normal" font="Arial">DA - 20170113IS - 1938-9116 (Electronic)IS - 1538-5744 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1177/1538574416678557</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081690">PM:28081690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vasc Endovascular Surg\2016-50-571-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vasc Endovascular Surg\2016-50-571-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170113, Jun H</style></custom2><misc3><style face="normal" font="Arial">10.1177/1538574416678557</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">DeBoer,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, 2015 Linden Drive, Madison, WI, 53706, USA</style></auth-address><titles><title><style face="normal" font="Arial">The future of immunotherapy for canine atopic dermatitis: a review</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="e6" start="25">25-e6</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human food</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunomodulators</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> intralymphatic immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> patient management</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual administration</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> virus-like particle</style></keyword><keyword><style face="normal" font="Arial"> Virus-like particles</style></keyword><keyword><style face="normal" font="Arial"> viruslike particles</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Allergen specific immunotherapy (ASIT) is a foundation treatment for canine atopic dermatitis (CAD), though few critical studies have documented its effectiveness as a disease-modifying treatment in dogs. The mechanisms by which ASIT works in dogs have not been elucidated, although they are likely to parallel those known for humans. Current ASIT approaches in CAD focus on either subcutaneous or sublingual administration. Greater knowledge of major allergens in dogs, ideal dosage regimes and details of allergen admixture are likely to lead to better efficacy in CAD. Evaluation of biomarkers for successful therapy may also be of benefit. Potentially important advances in human medicine, that have yet to be explored in dogs, include use of modified allergen preparations such as allergoids, recombinant major allergens or allergen peptides; modification with adjuvants; or packaging of the above in virus-like particles. Co-administration of immunomodulators such as CpG oligodeoxynucleotides or specific monoclonal antibodies might direct the immune response in the desired direction while calming the "cytokine storm" of active disease. Initial trials of alternative routes of administration such as intralymphatic immunotherapy have yielded exciting results in humans, and continuing study in dogs is underway. Progress in ASIT of human food allergy may provide clues that will assist with improved diagnosis and patient management of CAD. Importantly, further study must be undertaken to clarify the conditions under which ASIT is a valuable treatment modality for dogs</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12416</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28133873">PM:28133873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\2017-28-25-e6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\2017-28-25-e6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, DeBoer DJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12416</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Favrot,C.</style></author><author><style face="normal" font="Arial"> Linek,M.</style></author><author><style face="normal" font="Arial"> Fontaine,J.</style></author><author><style face="normal" font="Arial"> Beco,L.</style></author><author><style face="normal" font="Arial"> Rostaher,A.</style></author><author><style face="normal" font="Arial"> Fischer,N.</style></author><author><style face="normal" font="Arial"> Couturier,N.</style></author><author><style face="normal" font="Arial"> Jacquenet,S.</style></author><author><style face="normal" font="Arial"> Bihain,B.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinic for Small Animal Internal Medicine, University of Zurich, Winterthurerstrasse 204, CH-8057, Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Western blot analysis of sera from dogs with suspected food allergy</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="189">189-</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Potatoes</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is often suspected in dogs with clinical signs of atopic dermatitis. This diagnosis is confirmed with an elimination diet and a subsequent challenge with regular food. Laboratory tests for the diagnosis of food allergy in dogs are unreliable and/or technically difficult. Cyno-DIAL(R) is a Western blot method that might assist with the selection of an appropriate elimination diet. HYPOTHESIS/OBJECTIVES: To evaluate the performance of Cyno-DIAL(R) for the selection of an elimination diet and diagnosis of food allergy. ANIMALS/METHODS: Thirty eight dogs with atopic dermatitis completed an elimination diet. Combining the results of the diet trials and the challenges, 14 dogs were classified as food allergic (FA), 22 as nonfood-allergic and two as ambiguous cases. RESULTS: Amongst all dogs and amongst dogs with a clinical diagnosis of FA, 3% and 7% (respectively) were positive to Royal Canin Anallergenic(R) , Vet-Concept Kanguru(R) or Vet-Concept Dog Sana(R) ; 8% and 7% to Hill's d/d Duck and Rice(R) ; 8% and 21% to Hill's z/d Ultra Allergen Free(R) ; 53% and 64% to Eukanuba Dermatosis FP(R) ; and 32% and 43% to a home-cooked diet of horse meat, potatoes and zucchini. The specificity and sensitivity of Cyno-DIAL(R) for diagnosing food allergy were 73% and 71%, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE: Although Cyno-DIAL(R) was considered potentially useful for identifying appropriate foods for elimination diet trials, it cannot be recommended for the diagnosis of food allergy. The Cyno-DIAL(R) test performed better than some previously evaluated ELISA-based tests</style></abstract><notes><style face="normal" font="Arial">DA - 20170116IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Germany -CO - Belgium -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12412</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28090706">PM:28090706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170116-FavrotC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170116-FavrotC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170116, Favrot C</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12412</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hagen-Plantinga,E.A.</style></author><author><style face="normal" font="Arial"> Leistra,M.H.G.</style></author><author><style face="normal" font="Arial"> Sinke,J.D.</style></author><author><style face="normal" font="Arial"> Vroom,M.W.</style></author><author><style face="normal" font="Arial"> Savelkoul,H.F.J.</style></author><author><style face="normal" font="Arial"> Hendriks,W.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Measurement of allergen-specific IgG in serum is of limited value for the management of dogs diagnosed with cutaneous adverse food reactions</style></title><secondary-title><style face="normal" font="Arial">Vet J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet J</style></full-title></periodical><pages end="116" start="111">111-116</pages><volume><style face="normal" font="Arial">220</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous adverse food reactions</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food ingredients</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgG ELISA</style></keyword><keyword><style face="normal" font="Arial"> Individual variation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><isbn><style face="normal" font="Arial">1090-0233</style></isbn><abstract><style face="normal" font="Arial">Conflicting results have been reported in the literature in terms of the usefulness of serological testing for IgG against food allergens in dogs with cutaneous adverse food reaction (CAFR). The aim of the present study was to evaluate the suitability of a commercially available IgG ELISA for identifying food allergens in dogs, by challenging dogs with specific food ingredients, selected on the basis of IgG reactivity in serum samples. A total of 24 adult dogs with CAFR were enrolled into the study and 16 healthy dogs were included as a control group. Blood samples were obtained for measurement of specific IgG antibodies against 39 commonly used pet food ingredients by ELISA. Participating owners were surveyed to obtain information on their pet's dietary history. Eleven healthy control dogs and 12 dogs with CAFR were subsequently challenged in a blinded cross-over design experiment with both positive and negative food ingredients, selected on the basis of the ELISA test results. There was substantial individual variation in ELISA test results to the various food allergens, but no significant difference in IgG reactivity comparing the CAFR and control groups. None of the control dogs developed any clinical signs of an allergic reaction during the dietary challenge study. In the CAFR group, six of 12 dogs developed clinical signs after the negative challenge, and two of nine dogs developed clinical signs after the positive challenge. It was concluded that the ELISA test for dietary allergen-specific IgG is of limited value in the management of dogs with CAFR</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tvjl.2017.01.009</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.tvjl.2017.01.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet J\2017-220-111-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet J\2017-220-111-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170201, Hagen-Plantinga EA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tvjl.2017.01.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ziegler,A.</style></author><author><style face="normal" font="Arial"> Gerber,V.</style></author><author><style face="normal" font="Arial"> Marti,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Research and Veterinary Public Health, Vetsuisse Faculty, University of Bern, Langgass-Strasse 124, Bern CH-3001, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">In vitro effects of the toll-like receptor agonists monophosphoryl lipid A and CpG-rich oligonucleotides on cytokine production by equine cells</style></title><secondary-title><style face="normal" font="Arial">Vet J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet J</style></full-title></periodical><pages end="11" start="6">6-11</pages><volume><style face="normal" font="Arial">219</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Culicoides</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IBH</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insect bite hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid A</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Oligonucleotides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Insect bite hypersensitivity (IBH) is an equine allergic dermatitis to Culicoides spp. antigens. Attempts at using allergen-specific immunotherapy (AIT) as a treatment for IBH have so far proven unsuccessful. Toll-like receptor (TLR) agonists can promote a shift in the immune response from the allergy-promoting T helper cell 2 (Th2) response towards a Th1 and/or regulatory response. The aim of this study was to evaluate two immunomodulatory TLR agonists in vitro as potential vaccine adjuvants for a more efficacious AIT in IBH. Peripheral blood mononuclear cells (PBMCs) from healthy and IBH-affected horses were stimulated with the TLR-agonists monophosphoryl lipid A (MPLA) or CpG-rich oligodeoxynucleotides (CpG-ODN) in the presence or absence of Culicoides spp. allergens. Cytokine concentrations of interferon (IFN)-alpha, IFN-gamma, interleukin (IL)-4, IL-10 and IL-17 were quantified in the supernatants of stimulated PBMCs. MPLA induced IL-10 secretion in all horses, regardless of presence and nature of antigens, while suppressing antigen-induced production of IFN-gamma, IL-4 and IL-17. CpG-ODN significantly increased IFN-alpha, IFN-gamma and IL-4 production, but had little effect on IL-10 production. In conclusion, MPLA promotes a regulatory immune response and is therefore a promising adjuvant candidate for allergy vaccines in horses. While C-class CpG-ODN is an unsuitable adjuvant for AIT, it induces IFN-gamma and IFN-alpha, and thus may be a useful adjuvant in combination with vaccines for equine infectious or neoplastic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170117IS - 1532-2971 (Electronic)IS - 1090-0233 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tvjl.2016.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093114">PM:28093114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet J\2017-219-6-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet J\2017-219-6-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170117, Ziegler A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tvjl.2016.11.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lombardi,C.</style></author><author><style face="normal" font="Arial"> Savi,E.</style></author><author><style face="normal" font="Arial"> Ridolo,E.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departmental Unit of Allergology- Clinical Immunology, and Respiratory Diseases, Fondazione Poliambulanza, Via Bissolati, 57, Brescia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Is allergic sensitization relevant in severe asthma? Which allergens may be culprit?</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> thunderstorm</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Severe asthma is a major health concern. The allergic (IgE-mediated) form of asthma is well known from a pathogenic viewpoint. We searched the available literature to identify which allergens are most frequently associated with severe, refractory or life threatening asthma. According to the results, molds, pet dander, cockroach and ragweed were more frequently responsible for severe asthma. Thunderstorm asthma, in addition, represents a special association between allergic sensitization and an external climatic factor. A detailed knowledge of the most harmful allergens is mandatory for an appropriate diagnostic and preventive approach</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1939-4551 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0138-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101292">PM:28101292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Lombardi C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0138-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foong,R.X.</style></author><author><style face="normal" font="Arial"> Meyer,R.</style></author><author><style face="normal" font="Arial"> Dziubak,R.</style></author><author><style face="normal" font="Arial"> Lozinsky,A.C.</style></author><author><style face="normal" font="Arial"> Godwin,H.</style></author><author><style face="normal" font="Arial"> Reeve,K.</style></author><author><style face="normal" font="Arial"> Hussain,S.T.</style></author><author><style face="normal" font="Arial"> Nourzaie,R.</style></author><author><style face="normal" font="Arial"> Shah,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatric Gastroenterology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK ; Institute of Child Health, University College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Establishing the prevalence of low vitamin D in non-immunoglobulin-E mediated gastrointestinal food allergic children in a tertiary centre</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid formula</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ethics</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is no data on the prevalence of vitamin D deficiency in children with non-immunoglobulin-E (IgE) mediated gastrointestinal food allergy. The aims of our study were to understand the prevalence of vitamin D insufficiency and deficiency in children with non-IgE mediated gastrointestinal food allergy and identify predisposing factors. METHODS: This was a retrospective study which looked at data from Great Ormond Street Hospital from January 2002 to September 2015. Children 0-18 years old with a confirmed diagnosis of non-IgE mediated gastrointestinal food allergy who had a vitamin D level measured during the course of their disease were included. Low vitamin D levels were defined as &lt;50 nmol/L; insufficient levels were defined as 25-50 nmol/L and deficient levels as &lt;25 nmol/L. Patient characteristics and clinical factors were also recorded. RESULTS: Ninety-two patients met the study criteria; 49% were female and median age was 10 years 2 months [IQR: 4 years 8 months to 13 years 7 months]. Of the cohort, 26% (24/92) had low vitamin D levels; 16% had insufficient vitamin D levels and 10% had vitamin D deficiency. Gender (p = 0.043) and age (p = 0.035) were significantly associated with low vitamin D levels. Twelve percent of children who were on an amino acid formula (AAF) had low vitamin D compared to 31% of children who were not (p = 0.06). No other clinical factors were found to be significantly associated with low vitamin D levels. CONCLUSIONS: Children with non-IgE mediated gastrointestinal food allergy are at risk of vitamin D insufficiency and deficiency. Further prospective studies need to be performed in all children with non-IgE mediated gastrointestinal food allergies. TRIAL REGISTRATION: The study was registered with the GOSH Research &amp; Development department as a retrospective case note review. The Health Research Authority confirmed that NHS Research and Ethics Committee approval was not required; thus there is no trial registration number</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0135-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101293">PM:28101293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Foong RX</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0135-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ramon,G.D.</style></author><author><style face="normal" font="Arial"> Croce,V.H.</style></author><author><style face="normal" font="Arial"> Cherrez,Ojeda,I</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Alergia e Inmunologia del Sur., Bahia Blanca, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis in a 4-year-old male caused by contact with grasses: a case report</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="5">5-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Dactylis</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Festuca</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phalaris</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Acute urticaria is the presence of urticaria for &lt;6 weeks, and it is the most common type of urticaria in children. Sometimes, it may be associated with anaphylaxis, a life-threatening condition. Urticaria must be differentiated from anaphylaxis because the latter may require emergency treatment. We describe a child with anaphylaxis exposed to grasses on two occasions. CASE PRESENTATION: We described a 4-year-old male child with anaphylaxis exposed to grasses. Patient also suffered mild neurologic/respiratory symptoms but it is unlikely that he had anaphylaxis. Skin-prick tests were positive to Cynodon dactylis, Phalaris arundinacea and Festuca elatior. Little is known about the importance of pollens as a cause of urticaria in young children. CONCLUSIONS: The case reported here is particularly interesting because, to the best of our knowledge, anaphylaxis due to pollen exposure in children aged &lt;4 years has not been reported before. We strongly encourage all physicians searching for the cause of acute urticaria (allergists, dermatologists, primary-care physicians) to consider the possibility of pollen allergy, and to screen these patients for pollen sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Argentina -CO - Ecuador -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0133-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28138352">PM:28138352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Ramon GD</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0133-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Poddighe,D.</style></author><author><style face="normal" font="Arial"> Gelardi,M.</style></author><author><style face="normal" font="Arial"> Licari,A.</style></author><author><style face="normal" font="Arial"> Del Giudice,M.M.</style></author><author><style face="normal" font="Arial"> Marseglia,G.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dimitri Poddighe, Department of Pediatrics, ASST Melegnanoe Martesana, 20070 Milano, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management</style></title><secondary-title><style face="normal" font="Arial">World J Methodol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Methodol</style></full-title></periodical><pages end="213" start="200">200-213</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal cytology</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword></keywords><dates><year Day="26" Month="12" Year="2016">2016/12/26</year></dates><abstract><style face="normal" font="Arial">Chronic rhinitis is a very common disease, as the prevalence in the general population resulted to be 40%. Allergic rhinitis has been considered to be the most frequent form of chronic rhinitis, as non-allergic rhinitis has been estimated to account for 25%. However, several evidences suggested that non-allergic rhinitis have been underrated, especially in children. In pediatrics, the diagnostic definition of non-allergic rhinitis has been often limited to the exclusion of an allergic sensitization. Actually, local allergic rhinitis has been often misdiagnosed as well as mixed rhinitis has not been recognized in most cases. Nasal cytology is a diagnostic procedure being suitable for routine clinical practice with children and could be a very useful tool to characterize and diagnose non-allergic rhinitis, providing important clues for epidemiological analysis and clinical management</style></abstract><notes><style face="normal" font="Arial">DA - 20170111IS - 2222-0682 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.5662/wjm.v6.i4.200</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28074172">PM:28074172</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Methodol\2016-6-200-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Methodol\2016-6-200-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Poddighe D</style></custom2><misc3><style face="normal" font="Arial">10.5662/wjm.v6.i4.200</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meng,N.</style></author><author><style face="normal" font="Arial"> Hou,Y.</style></author><author><style face="normal" font="Arial"> Gui,Y.</style></author><author><style face="normal" font="Arial"> Xi,K.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Child Care, the First Hospital of Lanzhou University, Lanzhou 730000, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effect of methyleugenol on expression of MUC5AC in nasal mucosa of rats with allergic rhinitis]</style></title><secondary-title><style face="normal" font="Arial">Zhejiang Da Xue Xue Bao Yi Xue Ban</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhejiang Da Xue Xue Bao Yi Xue Ban</style></full-title></periodical><pages end="485" start="477">477-485</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child care</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Loratadine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2016">2016/5/25</year></dates><abstract><style face="normal" font="Arial">Objective: To investigate the effect of methyleugenol on expression of MUC5AC in nasal mucosa of rats with allergic rhinitis (AR). Methods: Seventy-two Wistar rats were randomly divided into 6 groups:normal control group, AR group, loratadine group, low-dose methyleugenol group, middle-dose methyleugenol group and high-dose methyleugenol group with 12 rats in each group. AR was induced by intraperitoneal injection of ovalbumin in latter 5 groups. 10 mg loratadine q.d was given to rats in loratadine group by gavage; and 10 mg/kg, 20 mg/kg and 40 mg/kg methyleugenol were given by gavege q.d to rats in low-, middle-and high-dose methyleugenol groups, respectively. Nasal mucosa samples were obtained from rats at 1, 2, 4 and 6 weeks after drug intervention. The expression of MUC5AC protein and mRNA in nasal mucosa was detected by immunohistochemistry and real-time fluorescence quota PCR (RT-PCR), respectively. Results: Compared with AR, the percentage of cells staining positively for MUC5AC protein and the relative quantity of MUC5AC mRNA in middle-and high-dose methyleugenol groups were significantly decreased after 2 and 4 weeks of drug intervention (P&lt;0.05), but no such decrease was observed in low-dose methyleugenol group at all time points (P>0.05). The percentage of cells with positive expression of MUC5AC protein and mRNA in loratadine group were significantly decreased after 1 week of administration (P&lt;0.05). The percentage of cells with positive MUC5AC protein in middle-dose methyleugenol group was higher than that in loratadine group (P&lt;0.05) after 6 week of drug intervention, but the difference was not seen in high-dose group (P>0.05). There was no significant difference in relative quantities of MUC5AC mRNA after 4 weeks of administration between high-and middle-dose methyeugenol groups and loratadine group (P>0.05). Conclusion: Methyleugenol can attenuate AR through inhibiting the expression of MUC5AC mRNA and protein in nasal mucosa of AR rats</style></abstract><notes><style face="normal" font="Arial">DA - 20170114IS - 1008-9292 (Print)IS - 1008-9292 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087907">PM:28087907</url></web-urls></urls><custom2><style face="normal" font="Arial">20170114, Meng N</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,L.</style></author><author><style face="normal" font="Arial"> Zhang,Y.L.</style></author><author><style face="normal" font="Arial"> Wang,X.F.</style></author><author><style face="normal" font="Arial"> Song,Z.</style></author><author><style face="normal" font="Arial"> Wang,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Expression and significance of mTOR/4EBP1/HIF-1alpha/VEGF signaling pathway in lung tissues of asthmatic mice]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="110" start="104">104-110</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rapamycin</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To study the expression and significance of the mammalian target of rapamycin (mTOR)/eukaryote initiating factor 4E binding protein 1(4EBP1)/hypoxia inducible factor-1alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) signaling pathway in asthmatic mice. METHODS: Forty SPF level 6-8 week-old female Balb/C mice were randomly divided into control, asthma, budesonide and mTOR inhibitor (rapamycin) intervention groups (n=10 each). The asthmatic mouse model was prepared via OVA induction and challenge test. The intervention groups were administered with rapamycin at the dosage of 3 mg/kg by an intraperitoneal injection or budesonide suspension at the dosage of l mg by aerosol inhalation respectively 30 minutes before the OVA challenge. The control and asthma groups were treated with normal saline instead. The concentrations of HIF-1alpha and VEGF in bronchoalveolar lavage fluid (BALF) were examined using ELISA 24 hours after the last challenge. The pathological changes of lung tissue were observed by hematoxylin-eosin (HE) staining. The p-mTOR and p-4EBP1 from the lung tissues were detected by immunohistochemistry and Western blot. Pearson analysis was used to study the correlation between p-mTOR, p-4EBP1, HIF-1alpha, and VEGF expression. RESULTS: Compared with the control group, inflammatory cell infiltration and secretions in the trachea increased in the asthma group. The levels of HIF-1alpha and VEGF in BALF and p-mTOR and p-4EBP1 expression in lung tissues also increased (P&lt;0.01). Compared with the asthma group, inflammatory cell infiltration and secretions in the trachea were reduced in the two intervention groups, and the levels of HIF-1alpha and VEGF in BALF and p-mTOR and p-4EBP1 expression in lung tissues were also reduced (P&lt;0.01). There were no significant differences in the above changes between the two intervention groups and control group (P>0.05). In the asthma group, there was a pairwise positive correlation between lung p-mTOR and p-4EBP1 expression and HIF-1alpha and VEGF levels in BALF (P&lt;0.05). However, there were no correlations in the above indexes in the intervention groups and control group. CONCLUSIONS: p-mTOR, p-4EBP1, HIF-1alpha and VEGF together are involved in the pathogenesis of asthma. Rapamycin treatment can block this signaling pathway, suggesting that this pathway can be used as a novel target for asthma treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100332">PM:28100332</url></web-urls></urls><custom2><style face="normal" font="Arial">20170119, Wang L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qiao,J.Y.</style></author><author><style face="normal" font="Arial"> Song,L.</style></author><author><style face="normal" font="Arial"> Zhang,Y.L.</style></author><author><style face="normal" font="Arial"> Luan,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. junying.qiao@163.com</style></auth-address><titles><title><style face="normal" font="Arial">[HMGB1/TLR4/NF-kappaB signaling pathway and role of vitamin D in asthmatic mice]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="103" start="95">95-103</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> progression of asthma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-Like Receptor 4</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the changes in the mRNA and protein expression of high-mobility group box 1 (HMGB1), Toll-like receptor 4 (TLR4), and nuclear factor-kappa B (NF-kappaB) in lung tissues of asthmatic mice and the interventional effect of vitamin D. METHODS: A total of 48 BALB/c mice were randomly divided into control group, asthma group, and 1,25-(OH)2D3 intervention group, with 16 mice in each group. An animal model of asthma was established, and lung tissue samples were taken in each group at weeks 1 and 2 of ovalbumin challenging. Conventional hematoxylin-eosin staining was used to measure airway wall thickness. Immunohistochemical staining was used to observe the expression of HMGB1, TLR4, and NF-kappaB in lung tissues. Quantitative real-time PCR and Western blot were used to investigate the changes in the mRNA and protein expression of HMGB1, TLR4, and NF-kappaB. RESULTS: At weeks 1 and 2 of ovalbumin challenging, compared with the control group, the asthma group had a significant increase in airway wall thickness and the intervention group had a significant reduction compared with the asthma group (P&lt;0.05). The asthma group had significantly higher mRNA expression of HMGB1, TLR4, and NF-kappaB in lung tissues than the control group, and the intervention group had significantly lower mRNA expression of TLR4 and NF-kappaB than the asthma group (P&lt;0.05). At week 1 of ovalbumin challenging, there was no significant difference in the mRNA expression of HMGB1 between the intervention group and the asthma group (P>0.05). At week 2, the intervention group had a significant reduction in the mRNA expression of HMGB1 compared with the asthma group (P&lt;0.05). At weeks 1 and 2 of ovalbumin challenging, the asthma group had significantly higher protein expression of HMGB1, TLR4, and NF-kappaB in lung tissues than the control group, and the intervention group had significantly lower expression than the asthma group (P&lt;0.05). Airway wall thickness was positively correlated with the mRNA expression of HMGB1, TLR4, and NF-kappaB in lung tissues (r=0.804, 0.895, and 0.834; P&lt;0.05). CONCLUSIONS: The HMGB1/TLR4/NF-kappaB signaling pathway plays an important role in the pathogenesis of asthma, and an appropriate amount of 1,25-(OH)2D3 has a regulatory effect on this pathway and may prevent the progression of asthma. Therefore, 1,25-(OH)2D3 is expected to become a new choice for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100331">PM:28100331</url></web-urls></urls><custom2><style face="normal" font="Arial">20170119, Qiao JY</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hu,W.N.</style></author><author><style face="normal" font="Arial"> Zhu,L.</style></author><author><style face="normal" font="Arial"> Xie,L.F.</style></author><author><style face="normal" font="Arial"> Zhang,F.Z.</style></author><author><style face="normal" font="Arial"> Bai,M.Y.</style></author><author><style face="normal" font="Arial"> Wang,N.</style></author><author><style face="normal" font="Arial"> Sun,Z.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology Head and Neck Surgery, Peking University Third Hospital, Beijing 100191, China</style></auth-address><titles><title><style face="normal" font="Arial">[Correlation between the visiting rate of patients with allergic rhinitis and airborne pollen concentrations in Beijing in recent 3 years]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="36" start="31">31-36</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Ash</style></keyword><keyword><style face="normal" font="Arial"> Ash tree</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Chenopodiaceae</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Humulus</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="1" Year="2017">2017/1/7</year></dates><abstract><style face="normal" font="Arial">Objective: To evaluate the daily airborne pollen concentrations and visiting rate of patients with allergic rhinitis (AR) and their correlation during 2012-2014 in Beijing. Methods: Daily airborne pollen concentrations (55 998 numbers in total and 549 numbers in average) and its constitution from April to September each year (2012 to 2014) were compared. The number of patients with AR (44 203 in total) who visited the outpatient department of Otorhinolaryngology Head and Neck Surgery, Peking University Third Hospital between January 2012 and December 2014 was analyzed by month. Using SPSS 22.0 software, Kruskal-Wallis test was done for the comparison of visiting rate of patients with AR and airborne pollen concentrations. Correlation analysis between them was made as well. Results: chi(2) value of airborne pollen concentrations between different months in 2012 to 2014 was 110.7, 108.4 and 121.4, respectively; all P&lt;0.01. The airborne pollen concentrations had two peaks per year, respectively: April to May, August to September. chi(2) value of visiting rate of patients with AR between different months in 2012 to 2014 was 175.0, 185.1 and 134.5, respectively; all P&lt;0.01. Visiting rate of patients with AR showed two scattering peaks each year, respectively: April to May, August to September. The highest pollen concentration of spring (April to May) was in early and middle April. Tree pollen was the major portion in spring, which were poplar pollen, pine tree pollen, ash tree pollen, cypress tree pollen and birch trees pollen. The highest pollen concentration of autumn (August to September) was in late August and early September. Weed pollen was the major portion in summer and autumn, which were artemisia pollen, chenopodiaceae pollen and humulus japonicas pollen. The visiting rate of patients with AR showed significant correlation with airborne pollen concentrations (r value was 0.537, 0.484 and 0.566, respectively; all P&lt;0.01). Conclusion: The visiting rate of patients with AR showed positive correlation with airborne pollen concentrations in recent three years</style></abstract><notes><style face="normal" font="Arial">DA - 20170120IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.01.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28104013">PM:28104013</url></web-urls></urls><custom2><style face="normal" font="Arial">20170120, Hu WN</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.01.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Sehlinger,T.</style></author><author><style face="normal" font="Arial"> Gildemeister,J.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A novel experimental technology for testing efficacy of air purifiers on pollen reduction</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="6" start="1">1-6</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> indoor exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen load</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Allergenic pollen exposure is mostly seen as an outdoor phenomenon but studies have shown an indoor exposure: different pollen species including birch and grass pollen in houses, schools, and shops are leading to long-lasting symptoms even after the pollen season because pollen settle on surfaces and re-enter the indoor air depending on ventilation. To reduce indoor pollen load, windows need to be closed and devices should be used: as pure wiping and cleaning of surfaces is mostly not sufficient, air cleaners may be helpful in reducing pollen counts in indoor environment</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0001-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0001-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-1-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-1-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Bergmann KC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0001-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Hellings,P.</style></author><author><style face="normal" font="Arial"> Jung,K.</style></author><author><style face="normal" font="Arial"> Merk,H.</style></author><author><style face="normal" font="Arial"> Olze,H.</style></author><author><style face="normal" font="Arial"> Schlenter,W.</style></author><author><style face="normal" font="Arial"> Stock,P.</style></author><author><style face="normal" font="Arial"> Ring,J.</style></author><author><style face="normal" font="Arial"> Wagenmann,M.</style></author><author><style face="normal" font="Arial"> Wehrmann,W.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="24" start="16">16-24</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Visual analogue scales (VAS) are psychometric measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients and use this to achieve a rapid (statistically measurable and reproducible) classification of symptom severity and disease control.VAS can also be used in routine patient history taking and to monitor the course of a chronic disease such as allergic rhinitis (AR). More specifically, the VAS has been used to assess effectiveness of AR therapy in real life, both in intermittent and persistent disease</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -CO - France -CO - Netherlands -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0006-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0006-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-16-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-16-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0006-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reinhold,T.</style></author><author><style face="normal" font="Arial"> Bruggenjurgen,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="15" start="7">7-15</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Whereas specific immunotherapy (SIT) has already been shown to be cost-effective in the treatment of allergic rhinitis compared with symptomatic treatment, only a-ásmall number of investigations have compared sublingual (SLIT) and subcutaneous (SCIT) immunotherapeutic approaches. This analysis discusses the cost-effectiveness of SCIT compared with SLIT and a-ásymptomatic treatment modality. At the same time, particular attention is paid to preparation-specific characteristics</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0002-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0002-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-7-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-7-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Reinhold T</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0002-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barbosa,C.P.</style></author><author><style face="normal" font="Arial"> Castro,A.P.</style></author><author><style face="normal" font="Arial"> Yonamine,G.H.</style></author><author><style face="normal" font="Arial"> Gushken,A.K.</style></author><author><style face="normal" font="Arial"> Beck,C.M.</style></author><author><style face="normal" font="Arial"> Macedo,P.R.</style></author><author><style face="normal" font="Arial"> Dorna,M.B.</style></author><author><style face="normal" font="Arial"> Santos,C.J.</style></author><author><style face="normal" font="Arial"> Pastorino,A.C.</style></author><author><style face="normal" font="Arial"> Jacob,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology Unit, Department of Pediatrics, Instituto da Crianca, Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Baked milk tolerant patient: Is there any special feature?</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="289" start="283">283-289</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alpha-lactalbumin</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Determining whether patients with cow's milk allergy (CMA) can tolerate foods produced with baked milk could provide a better quality of life, a better prognosis, and an option for desensitization. OBJECTIVES: The aim of this study was to identify which patients over four years of age with persistent CMA could tolerate baked milk, to compare the clinical and laboratory characteristics of reactive and non-reactive groups and to describe their clinical evolution. MATERIALS AND METHODS: A cross-sectional study was conducted (January/13 to November/14) that included all the patients followed at a food allergy center who met the inclusion criteria. The patients underwent an oral food challenge (OFC) with a muffin (2.8g of cow's milk protein). To exclude cow's milk (CM) tolerance, the patients were subsequently challenged with unheated CM. RESULTS: Thirty patients met all the inclusion criteria. Fourteen patients (46.7%) were considered non-reactive to baked milk and reactive to unheated CM. When the groups that were reactive and non-reactive to baked milk were compared, no statistically significant differences in clinical features were found. The prick test for alpha-lactalbumin (p=0.01) and casein (p=0.004) and the serum specific IgE for casein (p=0.05) presented statistical differences. After one year, none of the patients who were reactive to baked milk were ingesting CM, while 28% of the tolerant patients were consuming fresh CM (p=0.037). CONCLUSIONS: Baked milk can be tolerated by patients with CMA, especially those with lower levels of casein and alpha-lactalbumin. This option can improve quality of life and accelerate tolerance</style></abstract><notes><style face="normal" font="Arial">DA - 20170204IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28159383">PM:28159383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170204-BarbosaCP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170204-BarbosaCP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Barbosa CP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tosca,M.A.</style></author><author><style face="normal" font="Arial"> Silvestri,M.</style></author><author><style face="normal" font="Arial"> Olcese,R.</style></author><author><style face="normal" font="Arial"> Pistorio,A.</style></author><author><style face="normal" font="Arial"> Rossi,G.A.</style></author><author><style face="normal" font="Arial"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Pneumology and Allergy, IRCCS Istituto Giannina Gaslini, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">The impact of age on serum allergen-specific IgE to inhaled molecular components</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="271" start="265">265-271</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Fel d1</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Genoa</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="1" Year="2017">2017/1/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Respiratory allergy is characterised by an IgE-mediated reaction. The immune system functions, including IgE production, progressively decline over time, such as growing up and ageing. Molecular-based allergy diagnostic defines sensitisation profile. This study aimed to evaluate the impact of age on serum allergen-specific IgE to molecular component levels in a large sample of subjects. METHODS: Serum IgE to: Phl p1, Bet v1, Ole e1, Cup a1, Par j2, Can f1, Der p2, and Fel d1 were assessed by ISAC method. Sera from 2788 patients, 1230 males (44.1%) and 1558 females (55.9%), median age 23 years (1st and 3rd quartiles: 9.7-49.7 years; age range: 1 month-103 years) were analysed. RESULTS: The number of positive tests (i.e. sensitisation) tended to increase between birth and school-age till young adulthood and then decreased (p&lt;0.0001) with the exception of Fel d 1 (p=0.14). A similar age-dependent trend was observed considering the levels of each allergen components: the levels of each allergen component, with the exception of Fel d 1, tended to increase till early adulthood and then to decrease reaching the lowest levels in the elderly. CONCLUSIONS: Allergen-specific IgE production to inhaled molecular components trend to reduce with ageing, but with differences between allergens. This phenomenon should be adequately evaluated managing allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170203IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153352">PM:28153352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170203-ToscaMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170203-ToscaMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170203, Tosca MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Movahedi,M.</style></author><author><style face="normal" font="Arial"> Tavakol,M.</style></author><author><style face="normal" font="Arial"> Rahmani,F.</style></author><author><style face="normal" font="Arial"> Amirzargar,A.A.</style></author><author><style face="normal" font="Arial"> Bidoki,A.Z.</style></author><author><style face="normal" font="Arial"> Heidari,K.</style></author><author><style face="normal" font="Arial"> Gharagozlou,M.</style></author><author><style face="normal" font="Arial"> Aghamohammadi,A.</style></author><author><style face="normal" font="Arial"> Nabavi,M.</style></author><author><style face="normal" font="Arial"> Soltani,S.</style></author><author><style face="normal" font="Arial"> Rezaei,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Single nucleotide polymorphisms of IL-2, but not IL-12 and IFN-gamma, are associated with increased susceptibility to chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="338" start="333">333-338</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> Heterozygote</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2-cytokines</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A clear picture of interaction of Th1/Th2 cytokines in pathogenesis of chronic spontaneous urticaria (CSU), remains elusive. Impaired IFN-gamma production and decreased levels of IL-2 have been reported. The aim of this study was to evaluate the association of Th1 cytokines; IL-2, IL-12 and IFN-gamma polymorphisms with CSU. METHODS: 90 patients with CSU and 140 age-sex matched subjects were included in this study. DNA samples were evaluated through PCR-SSP assay in order to detect single nucleotide polymorphisms of IL-12 (A/C -1188) or (rs3212227), IFN-gamma (A/T UTR5644) or (rs2069717) and IL-2 (G/T -330 and G/T +166) or (rs2069762 and rs2069763). RESULTS: G allele at -330 at promoter region of IL-2 gene was overrepresented in CSU. Heterozygotes (GT) at this locus and heterozygotes at +166 of IL-2 gene (GT) were more prevalent in CSU group. Additionally, the haplotype GT for loci -330 and +166 of IL-2 gene was powerfully associated with CSU (OR (95%CI)=57.29 (8.43-112.7)). CONCLUSIONS: SNP at position -330 and +166 of IL-2 gene are differently expressed in CSU. The haplotype GT of IL-2 at -330 and +166 might confer vulnerability to a number of immunological disorders in Iranian region</style></abstract><notes><style face="normal" font="Arial">DA - 20170204IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Iran -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28159384">PM:28159384</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170204-MovahediM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170204-MovahediM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Movahedi M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Erdem,S.B.</style></author><author><style face="normal" font="Arial"> Nacaroglu,H.T.</style></author><author><style face="normal" font="Arial"> Karaman,S.</style></author><author><style face="normal" font="Arial"> Erdur,C.B.</style></author><author><style face="normal" font="Arial"> Karkiner,C.U.</style></author><author><style face="normal" font="Arial"> Can,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dr Behcet Uz Children's Hospital, Pediatric Allergy and Immunology, Izmir, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Tolerance development in food protein-induced allergic proctocolitis: Single centre experience</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="219" start="212">212-219</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food protein-induced allergic proctocolitis (FPIAP) is characterised by inflammation of the distal colon in response to one or more food proteins. It is a benign condition of bloody stools in a well-appearing infant, with usual onset between one and four weeks of age. OBJECTIVE: Our objective was to examine the clinical properties of patients with FPIAP, tolerance development time as well as the risk factors that affect tolerance development. METHODS: The clinical symptoms, offending factors, laboratory findings, methods used in the diagnosis and tolerance development for 77 patients followed in the Paediatric Allergy and Gastroenterology Clinics with the diagnosis of FPIAP during January 2010-January 2015 were examined in our retrospective cross-sectional study. RESULTS: The starting age of the symptoms was 3.3+/-4.7 months (0-36). Milk was found as the offending substance for 78% of the patients, milk and egg for 13% and egg for 5%. Mean tolerance development time of the patients was 14.7+/-11.9 months (3-66 months). Tolerance developed before the age of one year in 40% of the patients. Tolerance developed between the age of 1-2 years in 27%, between the age of 2-3 years in 9% and after the age of 3 years in 5% of the patients. CONCLUSIONS: Smaller onset age and onset of symptoms during breastfeeding were found associated with early tolerance development. In the majority of the patients, FPIAP resolves before the age of one year, however in some of the patients this duration may be much longer</style></abstract><notes><style face="normal" font="Arial">DA - 20170204IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28159385">PM:28159385</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170204-ErdemSB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170204-ErdemSB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Erdem SB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shamji,M.H.</style></author><author><style face="normal" font="Arial"> Kappen,J.H.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Knol,E.F.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Chaker,A.M.</style></author><author><style face="normal" font="Arial"> Till,S.J.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Poulsen,L.K.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Durham,L.J.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Biomarkers for Monitoring Clinical Efficacy of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Allergic Asthma: an EAACI Position Paper</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1173" start="1156">1156-1173</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma (1-12). AIT has disease modifying properties and confers long-term clinical benefit after cessation of treatment (6, 7, 13-17). AIT is routinely used in daily practice and can be administered either subcutaneously (SCIT) or sublingually (SLIT) (3-12). Although AIT is effective, the degree of remission strongly varies depending on the complex interaction between patient, allergy, symptomatology and vaccines used for AIT (3-9). Clinical management of patients receiving AIT and efficacy in randomised controlled trials for drug development could be significantly enhanced if there were means to identify those who are most likely to respond, when to stop treatment, how to predict relapse and when to perform booster AIT. Furthermore, biomarkers in AIT can play a central role in personalized medicine (18). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Netherlands -CO - Austria -CO - Germany -CO - Denmark -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13138</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28152201">PM:28152201</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170202-ShamjiMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170202-ShamjiMH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Shamji MH</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13138</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Bousquet,P.J.</style></author><author><style face="normal" font="Arial"> D'Amato,G.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> De Vries,G.</style></author><author><style face="normal" font="Arial"> Eller,E.</style></author><author><style face="normal" font="Arial"> Fokkens,W.</style></author><author><style face="normal" font="Arial"> Fonseca,J.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Carlsen,K.C.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Murray,R.</style></author><author><style face="normal" font="Arial"> Nekam,K.</style></author><author><style face="normal" font="Arial"> Onorato,G.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Thibaudon,M.</style></author><author><style face="normal" font="Arial"> Tomazic,P.</style></author><author><style face="normal" font="Arial"> Triggiani,M.</style></author><author><style face="normal" font="Arial"> Valiulis,A.</style></author><author><style face="normal" font="Arial"> Valovirta,E.</style></author><author><style face="normal" font="Arial"> van Eerd,M.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Google Trends terms reporting rhinitis and related topics differ in European countries</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1266" start="1261">1261-1266</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cultural differences</style></keyword><keyword><style face="normal" font="Arial"> Cyprus</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Estonia</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Malta</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">Google Trends (GT) searches trends of specific queries in Google and reflects the real-life epidemiology of allergic rhinitis. We compared Google Trends terms related to allergy and rhinitis in all European Union countries, Norway and Switzerland from January 1, 2011 to December 20, 2016. The aim was to assess whether the same terms could be used to report the seasonal variations of allergic diseases. Using the Google Trend 5-year graph, an annual and clear seasonality of queries was found in all countries apart from Cyprus, Estonia, Latvia, Lithuania and Malta. Different terms were found to demonstrate seasonality depending on the country - namely: "hay fever"; "allergy"; and "pollen" - showing cultural differences. A single set of terms cannot be used across all European countries, but allergy seasonality can be compared across Europe providing the above three terms are used. Using longitudinal data in different countries and multiple terms, we identified an awareness-related spike of searches (December 2016). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Belgium -CO - France -CO - Italy -CO - Netherlands -CO - Denmark -CO - Portugal -CO - Finland -CO - Germany -CO - Poland -CO - Norway -CO - Ireland -CO - Hungary -CO - United Kingdom -CO - Greece -CO - Switzerland -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13137</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28140507">PM:28140507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170131-BousquetJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170131-BousquetJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13137</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hoffmann,H.J.</style></author><author><style face="normal" font="Arial"> Valovirta,E.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Moingeon,P.</style></author><author><style face="normal" font="Arial"> Schmid,J.M.</style></author><author><style face="normal" font="Arial"> Skaarup,S.H.</style></author><author><style face="normal" font="Arial"> Cardell,L.O.</style></author><author><style face="normal" font="Arial"> Simonsen,K.</style></author><author><style face="normal" font="Arial"> Larche,M.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Sorensen,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Medicine, HEALTH, Aarhus University, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Novel Approaches and Perspectives in Allergen Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1034" start="1022">1022-1034</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Harmonization</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> intralymphatic immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> new biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">In this review we report on relevant current topics in allergen immunotherapy (AIT) which were broadly discussed during the 1st Aarhus Immunotherapy Symposium (Aarhus, Denmark) in December, 2015 by leading clinicians, scientists and industry representatives in the field. The aim of this symposium was to highlight AIT-related aspects of public health, clinical efficacy evaluation, mechanisms, development of new biomarkers and an overview of novel therapeutic approaches. Allergy is a public health issue of high socioeconomic relevance, and development of evidence-based action plans to address allergy as a public health issue ought to be on national and regional agendae. The underlying mechanisms are in the focus of current research that lays the ground for innovative therapies. Standardization and harmonization of clinical endpoints in AIT trials as well as current knowledge about potential biomarkers have substantiated proof of effectiveness of this disease-modifying therapeutic option. Novel treatments like peptide immunotherapy, intralymphatic immunotherapy and use of recombinant allergens herald a new age in which AIT may address treatment of allergy as a public health issue by reaching a large fraction of patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -CO - Finland -CO - Germany -CO - France -CO - Sweden -CO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13135</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122129">PM:28122129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170125-HoffmannHJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170125-HoffmannHJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Hoffmann HJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13135</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pfaar,O.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Andrews,C.P.</style></author><author><style face="normal" font="Arial"> Angjeli,E.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Bonlokke,J.H.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Ellis,A.K.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Hohlfeld,J.</style></author><author><style face="normal" font="Arial"> Horak,F.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Jacobs,R.L.</style></author><author><style face="normal" font="Arial"> Jacobsen,L.</style></author><author><style face="normal" font="Arial"> Kaul,S.</style></author><author><style face="normal" font="Arial"> Larche,M.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Nolte,H.</style></author><author><style face="normal" font="Arial"> Patel,P.</style></author><author><style face="normal" font="Arial"> Peoples,L.</style></author><author><style face="normal" font="Arial"> Rabin,R.L.</style></author><author><style face="normal" font="Arial"> Rather,C.</style></author><author><style face="normal" font="Arial"> Salapatek,A.M.</style></author><author><style face="normal" font="Arial"> Sigsgaard,T.</style></author><author><style face="normal" font="Arial"> Thaarup,S.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author><author><style face="normal" font="Arial"> Zieglmayer,P.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, Universitatsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergen Exposure Chambers (AEC): harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1042" start="1035">1035-1042</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Marketing</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">BACKGOUND: Allergen exposure chambers (AEC) are clinical facilities allowing for controlled exposure of subjects to allergens in an enclosed environment. AEC have contributed towards characterizing the pathophysiology of respiratory allergic diseases and the pharmacological properties of new therapies. In addition, they are complementary to and offer some advantages over traditional multi-centre field trials for evaluation of novel therapeutics. To date, AEC studies conducted have been monocentric and have followed protocols unique to each center. Because there are technical differences among AEC, it may be necessary to define parameters to standardize the AEC so that studies may be extrapolated for driving basic immunological research and for marketing authorization purposes by regulatory authorities. METHODS: For this task force initiative of the European Academy of Allergy and Clinical Immunology (EAACI) experts from academia and regulatory agencies met with chamber operators to list technical, clinical and regulatory unmet needs as well as the prerequisites for clinical validation. RESULTS: The latter covered the validation process, standardization of challenges and outcomes, intra- and inter-chamber variability and reproducibility, in addition to comparability with field trials and specifics of paediatric trials and regulatory issues. CONCLUSION: This EAACI Position Paper aims to harmonize current concepts in AEC and to project unmet needs with the intent to enhance progress towards use of these facilities in determining safety and efficacy of new therapeutics in the future. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United KIngdom -CO - United States -CO - Denmark -CO - France -CO - Canada -CO - Mexico -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13133</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122133">PM:28122133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170125-PfaarO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170125-PfaarO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Pfaar O</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13133</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Graauw,E.</style></author><author><style face="normal" font="Arial"> Sitaru,C.</style></author><author><style face="normal" font="Arial"> Horn,M.</style></author><author><style face="normal" font="Arial"> Borradori,L.</style></author><author><style face="normal" font="Arial"> Yousefi,S.</style></author><author><style face="normal" font="Arial"> Simon,H.U.</style></author><author><style face="normal" font="Arial"> Simon,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Pharmacology, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Evidence for a role of eosinophils in blister formation in bullous pemphigoid</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1113" start="1105">1105-1113</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune bullous disease</style></keyword><keyword><style face="normal" font="Arial"> Blister</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> BP180</style></keyword><keyword><style face="normal" font="Arial"> BP230</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> CD18</style></keyword><keyword><style face="normal" font="Arial"> CD64</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood eosinophils</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="1" Year="2017">2017/1/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bullous pemphigoid (BP) is an autoimmune bullous disease of the skin characterized by subepidermal blister formation due to tissue-bound and circulating autoantibodies to the hemidesmosomal antigens BP180 and BP230. Although eosinophils and their toxic mediators are found abundantly in BP lesions, their role in blister formation has remained unclear. OBJECTIVE: To investigate the role of eosinophils in the pathogenesis of BP with a specific focus on blister formation and to define conditions inducing dermal-epidermal separation (DES). METHODS: In an ex vivo human model of BP, normal human skin cryosections were incubated with purified human peripheral blood eosinophils with or without activation in the presence or absence of BP autoantibodies, brefeldin A, diphenyleneiodonium (DPI), DNase, or blocking F(ab')2 fragments to CD16, CD18, CD32 and CD64. DES was assessed by light microscopy studies and quantified using Fiji software. RESULTS: Following activation with IL-5 and in the presence of BP autoantibodies, eosinophils induced separation along the dermal-epidermal junction of ex vivo skin. DES was significantly reduced by blocking any of the following: Fcgamma receptor binding (p=0.048), eosinophil adhesion (p=0.046), reactive oxygen species (ROS) production (p=0.002), degranulation (p&lt;0.0001), or eosinophil extracellular trap (EET) formation (p=0.048). CONCLUSIONS: Our results provide evidence that IL-5-activated eosinophils directly contribute to BP blister formation in the presence of BP autoantibodies. DES by IL-5-activated eosinophils depends on adhesion and Fcgamma receptor activation, requires elevated ROS production and degranulation, and involves EET formation. Thus, targeting eosinophils may be a promising therapeutic approach for BP. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28135772">PM:28135772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170130-deGraauwE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170130-deGraauwE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, de Graauw E</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13131</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Muraro,A.</style></author><author><style face="normal" font="Arial"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="Arial"> Castells,M.</style></author><author><style face="normal" font="Arial"> Torres,M.J.</style></author><author><style face="normal" font="Arial"> Khan,D.</style></author><author><style face="normal" font="Arial"> Simon,H.U.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Burks,W.</style></author><author><style face="normal" font="Arial"> Poulsen,L.K.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Precision Medicine in Allergic Disease - Food Allergy, Drug Allergy, and Anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma &amp; Immunology</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1021" start="1006">1006-1021</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">This consensus document summarizes the current knowledge on the potential for precision medicine in food allergy, drug allergy and anaphylaxis under the auspices of the PRACTALL collaboration platform. PRACTALL is a joint effort of the European Academy of Allergy and Clinical Immunology (EAACI) and the American Academy of Allergy, Asthma and Immunology (AAAAI), which aims to synchronize the European and American approaches to allergy care. Precision medicine is an emerging approach for disease treatment based on disease endotypes, which are phenotypic subclasses associated with specific mechanisms underlying the disease. Although significant progress has been made in defining endotypes for asthma, definitions of endotypes for food and drug allergy or for anaphylaxis lag behind. Progress has been made in discovery of biomarkers to guide a precision medicine approach to treatment of food and drug allergy, but further validation and quantification of these biomarkers is needed to allow their translation into practice in the clinical management of allergic disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - United States -CO - Spain -CO - Switzerland -CO - Denmark -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13132</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122115">PM:28122115</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170125-MuraroA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170125-MuraroA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Muraro A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13132</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gawlik,R.</style></author><author><style face="normal" font="Arial"> Marcak,M.</style></author><author><style face="normal" font="Arial"> Kolodziej,I.</style></author><author><style face="normal" font="Arial"> Dzienniak,A.</style></author><author><style face="normal" font="Arial"> Bozek,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">First-line treatment of hymenoptera venom anaphylaxis: a 23-year real-life experience</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="377" start="375">375-377</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132738">PM:28132738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170130-GawlikR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170130-GawlikR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Gawlik R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hemler,J.A.</style></author><author><style face="normal" font="Arial"> Sharma,H.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.</style></auth-address><titles><title><style face="normal" font="Arial">Management of children with anaphylaxis in an urban emergency department</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="383" start="381">381-383</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132736">PM:28132736</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170130-HemlerJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170130-HemlerJA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Hemler JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zheng,R.</style></author><author><style face="normal" font="Arial"> Chen,F.H.</style></author><author><style face="normal" font="Arial"> Gao,W.X.</style></author><author><style face="normal" font="Arial"> Wang,D.</style></author><author><style face="normal" font="Arial"> Yang,Q.T.</style></author><author><style face="normal" font="Arial"> Wang,K.</style></author><author><style face="normal" font="Arial"> Lai,Y.Y.</style></author><author><style face="normal" font="Arial"> Deng,J.</style></author><author><style face="normal" font="Arial"> Jiang,L.J.</style></author><author><style face="normal" font="Arial"> Sun,Y.Q.</style></author><author><style face="normal" font="Arial"> Shi,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China</style></auth-address><titles><title><style face="normal" font="Arial">The TH2-polarizing function of atopic interleukin 17 receptor B-positive dendritic cells up-regulated by lipopolysaccharide</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="482" start="474">474-482</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Granulocyte-Macrophage Colony-Stimulating Factor</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-25 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-17</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OX40</style></keyword><keyword><style face="normal" font="Arial"> OX40L</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> ST2</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin receptor</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recent studies suggest that epithelial cell (EC)-derived cytokines contribute to allergic airway disease exacerbation. OBJECTIVE: To confirm our hypothesis that atopic dendritic cells (DCs) are activated to up-regulate the receptors of cytokines that mainly derived from ECs and enhance TH2 responses. METHODS: The expressions of interleukin 17 receptor B (IL-17RB) (IL-25 receptor), membrane-bound ST2 (IL-33 receptor), thymic stromal lymphopoietin receptor (TSLPR), granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), and several functional markers on CD1c+ monocyte-derived DCs (mo-DCs) were detected by flow cytometry. Lipopolysaccharide (LPS)-activated mo-DCs were cocultured with autologous CD4+ T cells, and cytokine production by these T cells was determined by intracellular flow cytometry. RESULTS: LPS activated both nonatopic and atopic mo-DCs to express a higher level of GM-CSFR but only activated atopic mo-DCs to express increased IL-17RB, which was subsequently activated by IL-25 involved with signal transducer and activator of transcription 5 phosphorylation. In addition, LPS increased the expression of the OX40 ligand (OX40L) but decreased inducible costimulator ligand on atopic CD86+ mo-DCs. More importantly, IL-25 further up-regulated OX40L on atopic CD86+ mo-DCs. After coculturing with LPS-activated mo-DCs from atopic individuals, CD4+ T cells had enhanced inflammatory responses by increased production of IL-4, IL-5, IL-13, and interferon gamma (IFN-gamma). In contrast, further addition of IL-25 led CD4+ T cells to produce higher level of IL-4 but lower level of IFN-gamma. CONCLUSION: Atopic IL-17RB+ DCs can be up-regulated by LPS and promote a TH2-type response, implying that the IL-25/IL-17RB pathway may represent a potential molecular mechanism underlying the regulation of ECs on DCs in allergic airway disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132739">PM:28132739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170130-ZhengR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170130-ZhengR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Zheng R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schiavoni,G.</style></author><author><style face="normal" font="Arial"> D'Amato,G.</style></author><author><style face="normal" font="Arial"> Afferni,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">The dangerous liaison between pollens and pollution in respiratory allergy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="275" start="269">269-275</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="28" Month="1" Year="2017">2017/1/28</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To recapitulate the more recent epidemiologic studies on the association of air pollution with respiratory allergic diseases prevalence and to discuss the main limitations of current approaches used to establish a link between pollinosis and pollution. DATA SOURCES: Through the use of PubMed, we conducted a broad literature review in the following areas: epidemiology of respiratory allergic diseases, effect of pollution and climate changes on pollen grains, and immunomodulatory properties of pollen substances. STUDY SELECTION: Studies on short- and long-term exposure to air pollutants, such as gaseous and particulate materials, on allergic sensitization, and on exacerbation of asthma symptoms were considered. RESULTS: Trend in respiratory allergic disease prevalence has increased worldwide during the last 3 decades. Although recent epidemiologic studies on a possible association of this phenomenon with increasing pollution are controversial, botanic studies suggest a clear effect of several pollutants combined to climatic changes on the increased expression of allergenic proteins in several pollen grains. The current literature suggests the need for considering both pollen allergen and pollutant contents for epidemiologic evaluation of environmental determinants in respiratory allergies. We propose that a measure of allergenic potential of pollens, indicative of the increase in allergenicity of a polluted pollen, may be considered as a new risk indicator for respiratory health in urban areas. CONCLUSION: Because public greens are located in strict proximity to the anthropogenic sources of pollution, the identification of novel more reliable parameters for risk assessment in respiratory allergic diseases is an essential need for public health management and primary prevention area</style></abstract><notes><style face="normal" font="Arial">DA - 20170201IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28143681">PM:28143681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170201-SchiavoniG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170201-SchiavoniG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170201, Schiavoni G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dilley,M.A.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Boston Children's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="Arial">Environmental control measures for the management of atopy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="160" start="154">154-160</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Atopy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control measures</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170203IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2015.12.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153081">PM:28153081</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-154-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-154-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170203, Dilley MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2015.12.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Assa'ad,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: amal.assa'ad@cchmc.org</style></auth-address><titles><title><style face="normal" font="Arial">Guidelines for the prevention of peanut allergy in the United States: From development to prospective outcomes</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="126" start="125">125-126</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170203IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153078">PM:28153078</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-125-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-125-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170203, Assa'ad A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yokoi,H.</style></author><author><style face="normal" font="Arial"> Yoshitake,H.</style></author><author><style face="normal" font="Arial"> Matsumoto,Y.</style></author><author><style face="normal" font="Arial"> Kawada,M.</style></author><author><style face="normal" font="Arial"> Takato,Y.</style></author><author><style face="normal" font="Arial"> Shinagawa,K.</style></author><author><style face="normal" font="Arial"> Sakurai,H.</style></author><author><style face="normal" font="Arial"> Saito,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Kyorin University School of Medicine, Tokyo 181-8611, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Involvement of cross-reactive carbohydrate determinants-specific IgE in pollen allergy testing</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="36" start="29">29-36</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Ascorbate Oxidase</style></keyword><keyword><style face="normal" font="Arial"> Bromelain</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Horseradish Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> HRP</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition tests</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Specific IgE antibodies against the low-molecular-weight carbohydrate antigen that does not bridge IgE molecules on mast cells are not associated with clinical symptoms. Cross reactivity can be determined in allergen-specific IgE detection assays when the carbohydrate structures between pollen allergens and plant derived food allergens are similar; in such cases, false positive results for grain or legume allergens can be reported for pollen allergic patients who are not sensitized to those allergens. This phenomenon arises owing to the presence of cross-reactive carbohydrate determinants (CCDs). OBJECTIVE: This study aimed to assess the impact of CCD interference on the results for pollen allergen-specific IgE antibodies in the general adult population and to perform CCD inhibition tests evaluating the involvement of CCD on samples positive to pollen allergens. METHODS: Serum samples from 322 subjects were tested for IgE antibodies to pollens and CCD. The research subjects were given questionnaires about pollen allergic symptoms to help assess the presence of allergies. Allergen IgE antibodies for Japanese cedar, Japanese cypress, orchard grass, ragweed, MUXF, bromelain, horseradish peroxidase (HRP), and ascorbate oxidase (ASOD) were analyzed. RESULTS: It was observed that among individuals who tested positive to any of the pollen allergens, the positive ratio of CCD-specific IgE antibody was the highest for HRP (13.5%-50.0%). The results from the inhibition tests revealed that CCD was marginally present. Although IgE antibodies for cedar pollen did not react with CCD, IgE antibodies for Japanese cypress, orchard grass, and ragweed might be detected by the presence of CCD. CONCLUSION: The results of the inhibition tests revealed the obvious presence of CCD suggesting its involvement. Considering these findings, careful evaluation of patient IgE results should be performed for Japanese cypress, orchard grass, and ragweed</style></abstract><notes><style face="normal" font="Arial">DA - 20170203IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.1.29</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28154803">PM:28154803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-29-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-29-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170203, Yokoi H</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.1.29</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aguiar,R.</style></author><author><style face="normal" font="Arial"> Duarte,F.C.</style></author><author><style face="normal" font="Arial"> Mendes,A.</style></author><author><style face="normal" font="Arial"> Bartolome,B.</style></author><author><style face="normal" font="Arial"> Barbosa,M.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department Immunoallergology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, E.P.E, 1649-035 Lisbon, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis caused by honey: a case report</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="50" start="48">48-50</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Food</style></keyword><keyword><style face="normal" font="Arial"> Honey</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Honey allergy is a very rare, but serious health condition. In this study, we presented 1 patient who had anaphylaxis after the honey allergological investigation with skin prick-prick test with honey. Honey as a food has been associated to allergic reactions and as the increased consumption of honey in health food may increase the incidence of honey-related allergic reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170203IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Portugal -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.1.48</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28154806">PM:28154806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-48-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-48-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170203, Aguiar R</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.1.48</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author><author><style face="normal" font="Arial"> De Amici,M.</style></author><author><style face="normal" font="Arial"> Di Martino,M.L.</style></author><author><style face="normal" font="Arial"> Barocci,F.</style></author><author><style face="normal" font="Arial"> Comite,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Laboratory Medicine Department, IRCCS-AOU San Martino-IST, 16132 Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">The impact of age on Pru p 3 IgE production in Italy</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="47" start="42">42-47</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Genoa</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen food syndrome</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pollen allergy may be frequently associated with fruit-vegetables: the so-called pollen food syndrome. Pru p 3 is the most relevant peach allergen. Previously, it has been reported that serum specific IgE level to Pru p 3 depends on age in a limited geographic area. OBJECTIVE: This study aimed to to test the hypothesis about the differences of Pru p 3 sensitization across Italy, mainly concerning the impact of age. METHODS: The current study was retrospective and multicentre, involving 2 labs in Northern Italy (709 subjects), 1 in Genoa (1,040 subjects), and 1 in Southern Italy (2,188 subjects). All of them referred to labs for IgE testing because of suspected food allergy. Serum IgE to Pru p 3 was assessed in all subjects. RESULTS: Sixteen point seven percent (16.7%) of subjects were sensitized to Pru p 3. Sensitization percentage sigificantly decreased over time. The serum IgE levels increased up to young adulthood and then decreased until aging. CONCLUSION: Our experience demonstrates that Pru p 3 sensitization and production are closely age-dependent phenomena</style></abstract><notes><style face="normal" font="Arial">DA - 20170203IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.1.42</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28154805">PM:28154805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-42-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-42-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170203, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.1.42</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cohen,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Depatment of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, BRF2 MC 0687, La Jolla, CA 92093-0687, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Notable Aspects of Glycan-Protein Interactions</style></title><secondary-title><style face="normal" font="Arial">Biomolecules</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biomolecules</style></abbr-1></periodical><pages end="2072" start="2056">2056-2072</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Physiological Phenomena</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Host-Pathogen Interactions</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Molecular Mimicry</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> target cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virus Physiological Phenomena</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="1" Month="9" Year="2015">2015/9/1</year></dates><abstract><style face="normal" font="Arial">This mini review highlights several interesting aspects of glycan-mediated interactions that are common between cells, bacteria, and viruses. Glycans are ubiquitously found on all living cells, and in the extracellular milieu of multicellular organisms. They are known to mediate initial binding and recognition events of both immune cells and pathogens with their target cells or tissues. The host target tissues are hidden under a layer of secreted glycosylated decoy targets. In addition, pathogens can utilize and display host glycans to prevent identification as foreign by the host's immune system (molecular mimicry). Both the host and pathogens continually evolve. The host evolves to prevent infection and the pathogens evolve to evade host defenses. Many pathogens express both glycan-binding proteins and glycosidases. Interestingly, these proteins are often located at the tip of elongated protrusions in bacteria, or in the leading edge of the cell. Glycan-protein interactions have low affinity and, as a result, multivalent interactions are often required to achieve biologically relevant binding. These enable dynamic forms of adhesion mechanisms, reviewed here, and include rolling (cells), stick and roll (bacteria) or surfacing (viruses)</style></abstract><notes><style face="normal" font="Arial">DA - 20150905IS - 2218-273X (Electronic)IS - 2218-273X (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Polysaccharides)RN - 0 (Proteins)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/biom5032056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26340640">PM:26340640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomolecules\2015-5-2056-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomolecules\2015-5-2056-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150905, Cohen M</style></custom2><misc3><style face="normal" font="Arial">10.3390/biom5032056</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arruda,L.K.</style></author><author><style face="normal" font="Arial"> Melo,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Alpha-gal allergy and delayed anaphylaxis to red meat: does this syndrome exist in Brazil?</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="232" start="227">227-232</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-227-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-227-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Arruda LK</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferreira,M.D.</style></author><author><style face="normal" font="Arial"> Piaia Neto,L.</style></author><author><style face="normal" font="Arial"> Ribeiro,R.G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy to alpha-gal: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="250" start="241">241-250</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Glycolipids</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">Allergy to the carbohydrate galactose-á-1,3-galactose (alpha-gal) has been associated with twodifferent presentations of anaphylaxis: immediate onset anaphylaxis, following the first intravenousexposure to monoclonal antibody cetuximab, and delayed onset anaphylaxis, starting 3-6 hoursafter the ingestion of meat from non-primate mammals (red meat), in patients previously sensitizedby tick bites. Recently, this kind of anaphylaxis has been described in patients who have specificIgE to alpha-gal, a carbohydrate that is a component of non-primate mammalian glycoproteinsand glycolipids. These patients develop delayed symptoms, such as urticaria, angioedema,gastrointestinal manifestations, and anaphylaxis, which may be serious or even fatal, after eatingred meat or organs from non-primate mammals. Faster reactions, approximately 2 hours afterfood ingestion, in individuals with IgE to alpha-gal, have been reported in European patients whoingested pork kidney and in patients who reported concomitant consumption of alcohol and redmeat. Cetuximab is a humanized IgG1 monoclonal antibody containing alpha-gal, and allergicreactions to this antibody have been reported after the first use of this medication. Knowledge ofthe clinical manifestations of this syndrome has improved, and the number of cases has grownin the United States and in other countries, improving our understanding of allergy to alpha-galand allowing it to be more readily diagnosed in recent years.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-241-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-241-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Ferreira MD</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olivier,C.E.</style></author><author><style face="normal" font="Arial"> Patussi dos Santos Lima,R.</style></author><author><style face="normal" font="Arial"> Pinto Argentao,D.G.</style></author><author><style face="normal" font="Arial"> Dias da Silva,M.</style></author><author><style face="normal" font="Arial"> Pereira Goncalves dos Santos,R.A.</style></author><author><style face="normal" font="Arial"> Castro Oliveira,J.</style></author><author><style face="normal" font="Arial"> Vaz Bortolozzo,P.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The immunodominant allergen of genetically improved farmed tilapia (Oreochromis niloticus) is a 100-kDa protein susceptible to pepsin digestion in four fish-allergic Brazilian patients</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="265" start="261">261-265</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Farmed</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergens</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Pepsin digestion</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tilapia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">Characterization of Brazilian fish allergens is still poor. This study was conducted with four Braziliansubjects who presented immediate reactions following tilapia ingestion. The IgE-mediated natureof their hypersensitivity was demonstrated by skin testing as well by IgE immunoblotting. A yetuncharacterized protein with approximately 100 kDa was identified by IgE immunoblotting asthe allergen of the undigested natural extract of the genetically improved farmed Nile tilapia(Oreochromis niloticus) (GIFT). This protein was susceptible to pepsin activity, as demonstrated bySDS-PAGE, which showed a single protein band around 12 to 19 kDa after pepsin digestion. Skintesting with the digested GIFT extract did not demonstrate any reaction, and IgE immunoblottingdid not stain any bands at the electrophoretic lane.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-261-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2015-3-261-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Olivier CE</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blake,M.K.</style></author><author><style face="normal" font="Arial"> Carr,B.J.</style></author><author><style face="normal" font="Arial"> Mauldin,G.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">VCA West Coast Specialty and Emergency Animal Hospital, 18300 Euclid Street, Fountain Valley, California 92708, USA</style></auth-address><titles><title><style face="normal" font="Arial">Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012</style></title><secondary-title><style face="normal" font="Arial">Can Vet J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Can Vet J</style></full-title></periodical><pages end="182" start="176">176-182</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antineoplastic Combined Chemotherapy Protocols</style></keyword><keyword><style face="normal" font="Arial"> Asparaginase</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat diseases</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> chemically induced</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Cyclophosphamide</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dog Diseases</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Doxorubicin</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> L-asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Vincristine</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="2" Year="2016">2016/2</year></dates><abstract><style face="normal" font="Arial">Clinically significant hypersensitivity reactions (HSRs) to the chemotherapy drug L-asparaginase are reported in humans and dogs, but frequency in small animals is not well-defined. This study retrospectively evaluated the frequency of HSR to L-asparaginase given by IM injection to dogs and cats with lymphoid malignancies. The medical records of all dogs and cats treated with at least 1 dose of L-asparaginase chemotherapy over a 5-year period were reviewed. A total of 370 doses of L-asparaginase were administered to the dogs, with 88 of 142 dogs receiving multiple doses, and 6 dogs experiencing an HSR. A total of 197 doses were administered to the cats, with 33 of 68 cats receiving multiple doses, and no cats experiencing an HSR. Hypersensitivity reactions were documented in 4.2% of dogs, and in association with 1.6% of L-asparaginase doses administered. These results show that HSRs occur uncommonly among dogs and cats, even with repeated dosing</style></abstract><notes><style face="normal" font="Arial">DA - 20160202IS - 0008-5286 (Print)IS - 0008-5286 (Linking)LA - engPT - Journal ArticleRN - 5J49Q6B70F (Vincristine)RN - 80168379AG (Doxorubicin)RN - 8N3DW7272P (Cyclophosphamide)RN - EC 3.5.1.1 (Asparaginase)RN - VB0R961HZT (Prednisone)RN - CHOP protocolSB - IMCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26834270">PM:26834270</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Can Vet J\2016-57-176-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Can Vet J\2016-57-176-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160202, Blake MK</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lindvik,H.</style></author><author><style face="normal" font="Arial"> Lodrup Carlsen,K.C.</style></author><author><style face="normal" font="Arial"> Mowinckel,P.</style></author><author><style face="normal" font="Arial"> Navaratnam,J.</style></author><author><style face="normal" font="Arial"> Borres,M.P.</style></author><author><style face="normal" font="Arial"> Carlsen,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Oslo University hospital, PO Box 4956, Nydalen, NO-0424, Oslo, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Conjunctival provocation test in diagnosis of peanut allergy in children</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="794" start="785">785-794</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> conjunctival provocation test</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Positive oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergy frequently cause severe allergic reactions. Diagnosis include detection of IgE to peanuts in serum or by skin prick tests. While children may have allergic sensitisation without having clinical peanut allergy, oral peanut challenge is often required for accurate diagnosis. The conjunctival provocation test is used for diagnosis and evaluation of treatment effect in inhalant allergies, but it has not been evaluated as a tool for diagnosing peanut allergy. OBJECTIVE: To investigate if the conjunctival provocation tests may be feasible, accurate and safe in diagnosing clinically relevant peanut allergy in patients with suspected peanut allergy. METHODS: This cross-sectional case-control study in children with clinical or laboratory suspected peanut allergy included 102 children recruited from the regional paediatric departments and specialist practices during one year from April 2011. A peanut tolerant control group of 28 children of similar age was recruited locally. A double-blind placebo-controlled conjunctival provocation test with peanut extract was performed in all children, while oral peanut provocation was performed as double-blind placebo-controlled challenge in children with suspected peanut allergy and as an open challenge in the control children. RESULTS: All 81 children with a positive double-blind placebo-controlled oral food challenge also had a positive conjunctival provocation test. None of the children with negative conjunctival provocation test had a positive oral food challenge. The sensitivity and the specificity of the conjunctival provocation test was 0.96 and 0.83 respectively. No children had severe adverse reaction caused by the conjunctival provocation test, whereas 23 children suffered an anaphylactic reaction to the oral food challenge. CONCLUSION &amp; CLINICAL RELEVANCE: Conjunctival allergen challenge appears to be a feasible, accurate and safe in diagnosing children referred for suspected peanut allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170204IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Norway -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12899</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160326">PM:28160326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170204-LindvikH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170204-LindvikH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Lindvik H</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12899</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Markevych,I.</style></author><author><style face="normal" font="Arial"> Baumbach,C.</style></author><author><style face="normal" font="Arial"> Standl,M.</style></author><author><style face="normal" font="Arial"> Koletzko,S.</style></author><author><style face="normal" font="Arial"> Lehmann,I.</style></author><author><style face="normal" font="Arial"> Bauer,C.P.</style></author><author><style face="normal" font="Arial"> Hoffmann,B.</style></author><author><style face="normal" font="Arial"> Von Berg,A.</style></author><author><style face="normal" font="Arial"> Berdel,D.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Epidemiology I, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Early life travelling does not increase risk of atopic outcomes until 15 years: Results from GINIplus and LISAplus</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="400" start="395">395-400</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Epidemics</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Home environment</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Length of Stay</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Vegetation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Westernized lifestyle has been blamed for allergy epidemics. One of its characteristics is increased distances and frequency of travelling from early life onwards. Early life travelling to places which substantially differ from home environment in terms of climate, vegetation and food could increase the exposure to further unknown allergens and hence promote the development of allergies, but no epidemiological study has investigated this speculation. METHODS: Detailed data on travelling during the first two years of life as well as a range of atopic outcomes along with potential confounders up to age 15 years were collected prospectively within two large population-based multicentre German birth cohorts - GINIplus and LISAplus. Farthest travelling destination (within Germany; middle/northern/eastern Europe; southern Europe; outside Europe), total number of trips and their combination were considered as exposures. Six atopic outcomes were used: (1) doctor diagnosed asthma, (2) doctor diagnosed allergic rhinitis, (3) nose and eyes symptoms, (4) sensitization to food allergens, (5) sensitization to indoor and (6) outdoor inhalant allergens. Longitudinal associations between each exposure and health outcome pair were analyzed using generalized estimation equations (GEE). RESULTS: The results of our longitudinal analyses of 5674 subjects do not support the research hypothesis that travelling abroad to different regions in Europe or beyond Europe and frequency of travelling increases prevalence of doctor diagnosed asthma and allergic rhinitis, nose and eyes symptoms and allergic sensitization up to 15 years of age. Furthermore, there was no indication of age-varying effects. CONCLUSIONS: Early life travelling does not seem to increase risk of atopic outcomes. Nevertheless, as we could not account for the type of visited environment or length of stay, these first findings should be interpreted with caution. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12891</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122145">PM:28122145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170125-MarkevychI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170125-MarkevychI.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170125-MarkevychI.xls</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170125-MarkevychI.xls</url></image-urls></urls><custom2><style face="normal" font="Arial">20170125, Markevych I</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12891</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gao,X.</style></author><author><style face="normal" font="Arial"> Li,N.</style></author><author><style face="normal" font="Arial"> Zhang,J.S.</style></author><author><style face="normal" font="Arial"> He,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Qingdao University, Qingdao 266003, China</style></auth-address><titles><title><style face="normal" font="Arial">[The comparation of establishing the allergic rhinitis model between Kunming mice and BALB/c mice]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="505" start="501">501-505</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> aluminium hydroxide</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">Objective: To discusses the feasibility of establishing the allergic rhinitis (AR) model in Kunming mice. Methods: Kunming mice (n=20) and BALB/c mice (n=20) were sensitized and motivated by ovalbumin (OVA) and aluminium hydroxide. The symptoms rating scale (symptoms score>5 as successful model) was used to evaluate AR symptoms of two kinds of mice after the AR model were set up. The differences of OVA serum specific IgE (OVA-sIgE) and the levels of interleukin 4 (IL-4) in Kunming mice model group and Kunming mice blank group were evaluated, the symptom scores, OVA serum specific IgE (OVA-sIgE) and the levels of interleukin 4 (IL-4) of successful model of Kunming mice and BALB/c mice were compared, and the difference between two kinds of animal models. SPSS 22.0 statistical software was used for statistical analysis was analysed. SPSS 22.0 statistical software was used for statistical analysis. Results: During the experiment, 2 mice died in BALB/c mouse model group, and no mouse died in Kunming mouse model group. Kunming model group gained a certain incease of weight. The clinical symptom scores, OVA - sIgE levels, serum IL - 4 levels of Kunming mouse model group were significantly higher than those of blank control group. The difference was statistically significant [(6.100+/-0.568) vs (2.700+/-0.823), (29.083+/-10.470) ng/ml vs (3.908+/-1.984) ng/ml, (219.250+/-30.821) pg/ml vs (140.056+/-27.684) pg/ml, all P&lt;0.05]. Compared with BALB/c mice model group, the symptom score and serum level of IL-4 of Kunming mice model group had no statistically significant differences (6.100+/-0.568) vs (6.313+/-0.704), (219.250+/-30.821) pg/ml vs (253.294+/-53.953) pg/ml, all P>0.05), and the difference of serum level of OVA-sIgE was statistically significant ((29.083+/-10.470) ng/ml vs (76.277+/-25.724) ng/ml, P&lt;0.05). Conclusions: Kunming mice are able to obtain a clinically significant AR model through OVA modeling, with a significant increase in serum OVA-SIgE and IL-4. Kunming mice AR model shows good tolerance, and could reduce the losses in animal experiment</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28728238">PM:28728238</url></web-urls></urls><custom2><style face="normal" font="Arial">20170720, Gao X</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruokolainen,L.</style></author><author><style face="normal" font="Arial"> Paalanen,L.</style></author><author><style face="normal" font="Arial"> Karkman,A.</style></author><author><style face="normal" font="Arial"> Laatikainen,T.</style></author><author><style face="normal" font="Arial"> Von Hertzen,L.</style></author><author><style face="normal" font="Arial"> Vlasoff,T.</style></author><author><style face="normal" font="Arial"> Markelova,O.</style></author><author><style face="normal" font="Arial"> Masyuk,V.</style></author><author><style face="normal" font="Arial"> Auvinen,P.</style></author><author><style face="normal" font="Arial"> Paulin,L.</style></author><author><style face="normal" font="Arial"> Alenius,H.</style></author><author><style face="normal" font="Arial"> Fyhrquist,N.</style></author><author><style face="normal" font="Arial"> Hanski,I.</style></author><author><style face="normal" font="Arial"> Makela,M.J.</style></author><author><style face="normal" font="Arial"> Zilber,E.</style></author><author><style face="normal" font="Arial"> Jousilahti,P.</style></author><author><style face="normal" font="Arial"> Vartiainen,E.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biosciences, University of Helsinki, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Significant disparities in allergy prevalence and microbiota between the young people in Finnish and Russian Karelia</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="674" start="665">665-674</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disparities</style></keyword><keyword><style face="normal" font="Arial"> disparity</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Forearm</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Hayfever</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic allergy has been more common among schoolchildren in Finland, as compared to Russian Karelia. These adjacent regions show one of the most contrasting socio-economically differences in the world. OBJECTIVE: We explored changes in allergy from school age to young adulthood from 2003 to 2010/2012 in these two areas. The skin and nasal microbiota were also compared. METHODS: Randomly selected children from Finnish (n = 98) and Russian Karelia (n = 82) were examined in 2003, when the children were 7-11 years of age, and again in 2010 (Finnish Karelia) and 2012 (Russian Karelia). We analysed self-reported allergy symptoms and sensitization to common allergens by serum sIgE values. The skin (volar forearm) and nasal mucosa microbiota, collected in 2012 (age 15-20 yrs), identified from DNA samples, were compared with multivariate methods. RESULTS: Asthma, hay-fever, atopic eczema, self-reported rhinitis, as well as atopic sensitization, were 3-10 fold more common in Finland, as compared to Russian Karelia. Hay-fever and peanut sensitization were almost non-existent in Russia. These patterns remained throughout the 10-year follow-up. Skin microbiota, as well as bacterial and fungal communities in nasal mucosa was contrastingly different between the populations, best characterised by the diversity and abundance of genus Acinetobacter; more abundant and diverse in Russia. Overall, diversity was significantly higher among Russian subjects (Pskin &lt; 0.0001, Pnasal-bacteria &lt; 0.0001, and Pnasal-fungi &lt; 0.01). Allergic diseases were not associated with microbial diversity in Finnish subjects. CONCLUSIONS &amp; CLINICAL RELEVANCE: Differences in allergic phenotype, developed in early life, remain between populations. A parallel difference in the composition of skin and nasal microbiota suggests a potential underlying mechanism. Our results also suggest that high abundance and diversity of Acinetobacter might contribute to the low allergy prevalence in Russia. Implications of early life exposure to Acinetobacter should be further investigated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170206IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12895</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28165640">PM:28165640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170206-RuokolainenL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170206-RuokolainenL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170206, Ruokolainen L</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12895</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Villasenor,A.</style></author><author><style face="normal" font="Arial"> Rosace,D.</style></author><author><style face="normal" font="Arial"> Obeso,D.</style></author><author><style face="normal" font="Arial"> Perez-Gordo,M.</style></author><author><style face="normal" font="Arial"> Chivato,T.</style></author><author><style face="normal" font="Arial"> Barbas,C.</style></author><author><style face="normal" font="Arial"> Barber,D.</style></author><author><style face="normal" font="Arial"> Escribese,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">IMMA, Institute of Applied Molecular Medicine, Faculty of Medicine, CEU San Pablo University, Campus Monteprincipe, Boadilla del Monte, 28668, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Asthma: An Overview of Metabolomic Strategies leading to the Identification of Biomarkers in the Field</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="456" start="442">442-456</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disease heterogeneity</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a prominent disease especially during childhood. Indoor allergens, in general, and particularly house dust mites (HDM) are the most prevalent sensitizers associated with allergic asthma. Available data shows that 65 to 130 million people are mite-sensitized worldwide and as many as 50% of these are asthmatic. In fact, sensitization to HDM in the first years of life can produce devastating effects on pulmonary function leading to asthmatic syndromes that can be fatal. To date, there has been considerable research into the pathological pathways and structural changes associated with allergic asthma. However, limitations related to the disease heterogeneity and a lack of knowledge into its pathophysiology have impeded the generation of valuable data needed to appropriately phenotype patients and, subsequently, treat this disease. Here, we report a systematic and integral analysis of the disease, from airway remodeling to the immune response taking place throughout the disease stages. We present an overview of metabolomics, the management of complex multifactorial diseases through the analysis of all possible metabolites in a biological sample, obtaining a global interpretation of biological systems. Special interest is placed on the challenges to obtain biological samples and the methodological aspects to acquire relevant information, focusing on the identification of novel biomarkers associated with specific phenotypes of allergic asthma. We, also, present an overview of the metabolites cited in the literature, which have been related to inflammation and immune response in asthma and other allergy-related diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170204IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12902</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160515">PM:28160515</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170204-VillasenorA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170204-VillasenorA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Villasenor A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12902</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maurer,M.</style></author><author><style face="normal" font="Arial"> Staubach,P.</style></author><author><style face="normal" font="Arial"> Raap,U.</style></author><author><style face="normal" font="Arial"> Richter-Huhn,G.</style></author><author><style face="normal" font="Arial"> Bauer,A.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author><author><style face="normal" font="Arial"> Jakob,T.</style></author><author><style face="normal" font="Arial"> Yazdi,A.S.</style></author><author><style face="normal" font="Arial"> Mahler,V.</style></author><author><style face="normal" font="Arial"> Wagner,N.</style></author><author><style face="normal" font="Arial"> Lippert,U.</style></author><author><style face="normal" font="Arial"> Hillen,U.</style></author><author><style face="normal" font="Arial"> Schwinn,A.</style></author><author><style face="normal" font="Arial"> Pawlak,M.</style></author><author><style face="normal" font="Arial"> Behnke,N.</style></author><author><style face="normal" font="Arial"> Chaouche,K.</style></author><author><style face="normal" font="Arial"> Chapman-Rothe,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">H1-antihistamine-refractory chronic spontaneous urticaria: It's worse than we thought - first results of the multicenter real-life AWARE study</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="692" start="684">684-692</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Resource utilization</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Most data on chronic spontaneous urticaria (CSU) originate from highly selected patient populations treated at specialized centers. Little is known about CSU patient characteristics and the burden of CSU in routine clinical practice. AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is an ongoing global study designed to assess chronic urticaria in the real-life setting. OBJECTIVE: To describe the baseline characteristics of the first 1,539 German AWARE patients with H1-antihistamine-refractory CSU. METHODS: This prospective non-interventional study included patients (18 to 75 years) with a diagnosis of H1-antihistamine-refractory CSU for >2 months. Baseline demographic and disease characteristics, comorbidities, and pharmacological treatments were recorded. Quality of life (QoL) was assessed using the dermatology life quality index (DLQI), chronic urticaria QoL questionnaire (CU-Q2 oL), and angioedema QoL questionnaire (AE-QoL; in cases of angioedema). Previous healthcare resource utilization and sick leave data were collected retrospectively. RESULTS: Between March and December 2014, 1,539 patients were assessed in 256 sites across Germany. The percentage of females, mean age, and mean body mass index was 70%, 46.3 years, and 27 kg/m2 , respectively. The mean UCT score was 7.9, 1 in 2 patients had angioedema, and the most frequent comorbidities were chronic inducible urticaria (CIndU; 24%), allergic rhinitis (18.2%), hypertension (18.1%), asthma (12%), and depression (9.5%). Overall, 57.6% of patients were receiving at least one pharmacological treatment including second generation H1-antihistamines (46.3%), first generation H1-antihistamines (9.1%), and corticosteroids (15.8%). The mean DLQI, total CU-Q2 oL, and total AE-QoL scores were 8.3, 36.2, and 46.8, respectively. CSU patients reported frequent use of healthcare resources, including emergency services (29.7%), general practitioners (71.9%), and additional allergists or dermatologists (50.7%). CONCLUSION &amp; CLINICAL RELEVANCE: This study reveals that German H1-antihistamine-refractory CSU patients have high rates of uncontrolled disease, angioedema, and comorbid CIndU, are undertreated, have impaired QoL, and rely heavily on healthcare resources. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170204IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12900</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160338">PM:28160338</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170204-MaurerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170204-MaurerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Maurer M</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12900</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Trikojat,K.</style></author><author><style face="normal" font="Arial"> Buske-Kirschbaum,A.</style></author><author><style face="normal" font="Arial"> Plessow,F.</style></author><author><style face="normal" font="Arial"> Schmitt,J.</style></author><author><style face="normal" font="Arial"> Fischer,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Psychology, Technische Universitat Dresden, Dresden, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Memory and multitasking performance during acute allergic inflammation in seasonal allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="487" start="479">479-487</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In previous research patients with seasonal allergic rhinitis (SAR) showed poorer school and work performance during periods of acute allergic inflammation, supporting the idea of an impact of SAR on cognitive functions. However, the specific cognitive domains particularly vulnerable to inflammatory processes are unclear. OBJECTIVE: In the present study the influence of SAR on memory and multitasking performance, as two potentially vulnerable cognitive domains essential in everyday life functioning, was investigated in SAR patients. METHODS: Non-medicated patients with SAR (n=41) and healthy non-allergic controls (n=42) performed a dual-task paradigm and a verbal learning and memory test during and out of symptomatic allergy periods (pollen vs. non-pollen season). Disease-related factors (e.g., symptom severity, duration of symptoms, duration of disease) and allergy-related quality of life were evaluated as potential influences of cognitive performance. RESULTS: During the symptomatic allergy period, patients showed (a) poorer performance in word list-based learning (p = .028) and (b) a general slowing in processing speed (p &lt; .001) and a shift in processing strategy (p &lt; .001) in multitasking. Yet, typical parameters indicating specific multitasking costs were not affected. A significant negative association was found between learning performance and duration of disease (r = -.451, p = .004), whereas symptom severity (r = .326; p = .037) and quality of life (r = .379; p = .015) were positively associated with multitasking strategy. CONCLUSIONS: Our findings suggest that SAR has a differentiated and complex impact on cognitive functions, which should be considered in the management of SAR symptoms. They also call attention to the importance of selecting sensitive measures and carefully interpreting cognitive outcomes. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12893</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122395">PM:28122395</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170125-TrikojatK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170125-TrikojatK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Trikojat K</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12893</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UKNIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UKThe David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK</style></auth-address><titles><title><style face="normal" font="Arial">Vocal cord dysfunction, food allergy and a RCT</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="147" start="146">146-147</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vocal cord dysfunction</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12884</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28134503">PM:28134503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-146-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-146-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12884</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ventura,M.T.</style></author><author><style face="normal" font="Arial"> Scichilone,N.</style></author><author><style face="normal" font="Arial"> Paganelli,R.</style></author><author><style face="normal" font="Arial"> Minciullo,P.L.</style></author><author><style face="normal" font="Arial"> Patella,V.</style></author><author><style face="normal" font="Arial"> Bonini,M.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Lombardi,C.</style></author><author><style face="normal" font="Arial"> Simioni,L.</style></author><author><style face="normal" font="Arial"> Ridolo,E.</style></author><author><style face="normal" font="Arial"> Del Giacco,S.R.</style></author><author><style face="normal" font="Arial"> Gangemi,S.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 0120 3326grid.7644.1Interdisciplinary Department of Medicine, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="Arial">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly people</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Pollution</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Contamination</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Life expectancy and the number of elderly people are progressively increasing around the world. Together with other pathologies, allergic diseases also show an increasing incidence in geriatric age. This is partly due to the growing emphasis on a more accurate and careful diagnosis of the molecular mechanisms that do not allow to ignore the real pathogenesis of many symptoms until now unknown, and partly to the fact that the allergic people from 20 years ago represent the elderly population now. Moreover, environmental pollution predisposes to the onset of allergic asthma and dermatitis which are the result of internal pathologies more than the expression of allergic manifestations. At the same time the food contamination permits the onset of allergic diseases related to food allergy. In this review we provide the state of the art on the physiological changes in the elderly responsible for allergic diseases, their biological characteristics and the major immunological and extra immunological mechanisms. Much emphasis is given to the management of several diseases in the elderly, including anaphylactic reactions. Moreover, some new features are discussed, such as management of asthma with the support of physical activity and the use of the AIT as prevention of respiratory diseases and for the purpose of a real and long lasting benefit. The mechanisms of adverse reactions to drugs are also discussed, due to their frequency in this age, especially in polytherapy regimens. Study of the modifications of the immune system is also of great importance, as regards to the distribution of the lymphocytes and also the presence of a chronic inflammatory disease related to the production of cytokines, especially in prevision of all the possible therapies to be adopted to allow an active and healthy aging</style></abstract><notes><style face="normal" font="Arial">DA - 20170208IS - 1476-7961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-017-0059-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28174512">PM:28174512</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170208, Ventura MT</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-017-0059-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Larsen,V.</style></author><author><style face="normal" font="Arial"> Arthur,R.</style></author><author><style face="normal" font="Arial"> Potts,J.F.</style></author><author><style face="normal" font="Arial"> Howarth,P.H.</style></author><author><style face="normal" font="Arial"> Ahlstrom,M.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Loureiro,C.</style></author><author><style face="normal" font="Arial"> Bom,A.T.</style></author><author><style face="normal" font="Arial"> Brozek,G.</style></author><author><style face="normal" font="Arial"> Makowska,J.</style></author><author><style face="normal" font="Arial"> Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Thilsing,T.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author><author><style face="normal" font="Arial"> Toren,K.</style></author><author><style face="normal" font="Arial"> Van Zele,T.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Rymarczyk,B.</style></author><author><style face="normal" font="Arial"> Janson,C.</style></author><author><style face="normal" font="Arial"> Forsberg,B.</style></author><author><style face="normal" font="Arial"> Nizankowska-Mogilnicka,E.</style></author><author><style face="normal" font="Arial"> Burney,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Population Health and Occupational Medicine Group, National Heart and Lung Institute, Imperial College London, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Is fruit and vegetable intake associated with asthma or chronic rhino-sinusitis in European adults? Results from the Global Allergy and Asthma Network of Excellence (GA2LEN) Survey</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="3">3-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allium</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fruits and vegetables are rich in compounds with proposed antioxidant, anti-allergic and anti-inflammatory properties, which could contribute to reduce the prevalence of asthma and allergic diseases. OBJECTIVE: We investigated the association between asthma, and chronic rhino-sinusitis (CRS) with intake of fruits and vegetables in European adults. METHODS: A stratified random sample was drawn from the Global Allergy and Asthma Network of Excellence (GA2LEN) screening survey, in which 55,000 adults aged 15-75 answered a questionnaire on respiratory symptoms. Asthma score (derived from self-reported asthma symptoms) and CRS were the outcomes of interest. Dietary intake of 22 subgroups of fruits and vegetables was ascertained using the internationally validated GA2LEN Food Frequency Questionnaire. Adjusted associations were examined with negative binomial and multiple regressions. Simes procedure was used to control for multiple testing. RESULTS: A total of 3206 individuals had valid data on asthma and dietary exposures of interest. 22.8% reported having at least 1 asthma symptom (asthma score >/=1), whilst 19.5% had CRS. After adjustment for potential confounders, asthma score was negatively associated with intake of dried fruits (beta-coefficient -2.34; 95% confidence interval [CI] -4.09, -0.59), whilst CRS was statistically negatively associated with total intake of fruits (OR 0.73; 95% CI 0.55, 0.97). Conversely, a positive association was observed between asthma score and alliums vegetables (adjusted beta-coefficient 0.23; 95% CI 0.06, 0.40). None of these associations remained statistically significant after controlling for multiple testing. CONCLUSION AND CLINICAL RELEVANCE: There was no consistent evidence for an association of asthma or CRS with fruit and vegetable intake in this representative sample of European adults</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Finland -CO - Portugal -CO - Poland -CO - Denmark -CO - Germany -CO - Sweden -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-016-0140-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28149501">PM:28149501</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Garcia-Larsen V</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-016-0140-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">MacGinnite,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Boston Children's Hospital, 300 Longwood Ave/Fegan 6, Boston, MA, 02115, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Update on Potential Therapies for IgE-Mediated Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Herbs</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> self-injectable</style></keyword><keyword><style face="normal" font="Arial"> self-injectable epinephrine</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Food allergy is common, affecting up to 8% of children in the USA. Currently, therapy is limited to avoidance of the implicated allergen and availability of self-injectable epinephrine. However, several new approaches to food allergy are under investigation. This article reviews the published data on these new approaches. RECENT FINDINGS: Oral immunotherapy, in which allergic subjects are exposed to increasing amounts of antigen, can be accomplished in the majority of allergic individuals. However, this approach is not a cure as most patients will react after cessation of regular intake. In addition, there is a high rate of side effects. Other approaches include epicutaneous immunotherapy, therapy with anti-IgE medications, and use of Chinese herbs. Several novel approaches on food allergy are under study. At the current time, these approaches show promise for preventing severe reactions to accidental exposures. However, there is little evidence that current approaches will represent a true cure for food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170209IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0671-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28181151">PM:28181151</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170209, MacGinnite A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0671-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Emanuel,S.</style></author><author><style face="normal" font="Arial"> Hawarden,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Egg Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="192" start="190">190-192</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-190-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-190-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Emanuel S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Du Toit,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="" start="170">170-</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-170.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-170.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, du Toit G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tankama,E.</style></author><author><style face="normal" font="Arial"> Gray,C.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy to apple seeds in a peanut-allergic child</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="195" start="194">194-195</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> flesh</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pulp</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergic reactions to fruits are commonly described,resulting most frequently in symptoms of the oralallergy syndrome (pollen fruit syndrome), and less often inmore severe reactions and anaphylaxis. The flesh or pulpof the fruit is most commonly the cause of such reactions.Less commonly described are allergic reactions to theseeds ('pips') of fruits, reported in only a handful of casereports, but probably under-recognised. This case reportdescribes a young boy, with a known allergy to peanuts,who experiences an allergic reaction when biting intoseeds of both apples and watermelons, but is tolerant ofthe fruit pulp. It is one of very few cases in the literaturethat describe an allergy to a non-citrus fruit seed.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-194-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-194-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Tankama E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Furman,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Eosinophilic oesophagitis in children: management option for inducing and maintaining disease control</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="175" start="172">172-175</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> topical steroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Over the past decade the incidence of eosinophilic oesophagitis (EoE) has risen significantly and hasbecome a common condition seen in paediatric gastroenterology centres around the world. The associationwith atopic disease is well known, and treatment options remain concentrated on acid suppression, dietaryeliminations and topical corticosteroids. One of the greatest challenges is planning long-term diseasemanagement. Currently there is little published data on maintenance treatment for EoE in children. Manychildren remain on long-term elimination diets or topical steroids and undergo multiple repeat endoscopies.Large multicentre studies are required to gain a better understanding of this challenging condition, tostandardise maintenance treatment and to find better methods for reliable disease surveillance.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-172-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-172-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Furman M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Emanuel,S.</style></author><author><style face="normal" font="Arial"> Hawarden,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Peanut Allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="263" start="262">262-263</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-262-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2016-29-262-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Emanuel S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ramezani-Rad,P.</style></author><author><style face="normal" font="Arial"> Rickert,R.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tumor Microenvironment and Cancer Immunology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA</style></auth-address><titles><title><style face="normal" font="Arial">Murine models of germinal center derived-lymphomas</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="36" start="31">31-36</pages><volume><style face="normal" font="Arial">45</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> affinity maturation</style></keyword><keyword><style face="normal" font="Arial"> Antibody-Producing Cells</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Germinal Center</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory B cell</style></keyword><keyword><style face="normal" font="Arial"> memory B cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Transformation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">The germinal center (GC) reaction is an adaptive immune response to select B cells bearing high-affinity B cell receptors (BCRs) to undergo further differentiation into antibody-producing cells or memory B cells. To drive affinity maturation, (GC) B cells undergo rounds of hypermutation and rapid proliferation, which can enhance susceptibility to malignant transformation. Lymphomas frequently originate from GC B cells, but the etiology for most lymphoma subtypes is unknown. Work in the past decade has more fully documented the mutational landscape in lymphomas, but the impact of these genomic lesions is often difficult to ascertain. In addition, while mutations affecting BCR signaling are well studied, the impact of extrinsic microenvironmental factors has not been widely addressed. Murine models are useful tools to study lymphomagenesis and disease progression, as well as potential treatment in a pre-clinical setting. Herein we discuss advances in murine models of lymphoma and how they inform on key characteristics of human lymphomas</style></abstract><notes><style face="normal" font="Arial">DA - 20170204IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2016.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160624">PM:28160624</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\2017-45-31-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\2017-45-31-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Ramezani-Rad P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2016.12.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caraballo,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Institute for Immunological Research, University of Cartagena , Cartagena , Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Mite allergens</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="299" start="297">297-299</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170206IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1292132</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28162009">PM:28162009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\20170206-CaraballoL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\20170206-CaraballoL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170206, Caraballo L</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1292132</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kraft,M.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergology , Allergy-Center-Charite, Charite - Universitatsmedizin Berlin , Germany</style></auth-address><titles><title><style face="normal" font="Arial">Dupilumab in the treatment of moderate-to-severe atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="310" start="301">301-310</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Calcineurin</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emollients</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> topical calcineurin inhibitors</style></keyword><keyword><style face="normal" font="Arial"> topical therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Atopic dermatitis is a common inflammatory skin disease with an increasing prevalence. Treatment of patients suffering from mild or moderate disease includes the use of emollients and topical glucocorticoids or topical calcineurin inhibitors. Patients with chronic and severe atopic dermatitis where topical therapy is usually insufficient require the use of systemic immunosuppressive drugs, which is often limited due to toxicity and severe adverse effects. Areas covered: This review summarizes the literature on the mechanism of action, clinical efficacy and safety of dupilumab, a monoclonal antibody that targets the alpha-subunit of the interleukin-4 receptor (IL-4Ralpha) leading to the inhibition of both the IL-4 and IL-13 pathways. A literature search was performed on Pubmed and ClinicalTrials.gov using key words "dupilumab", "REGN668", "IL-4"/"IL-13" and "atopic dermatitis". Expert Commentary: Dupilumab offers an innovative therapeutic approach for moderate-to-severe atopic dermatitis. It is not approved for clinical use in any country yet; however, due to its excellent clinical efficacy and a favorable safety profile, dupilumab may revolutionize the treatment of moderate-to-severe atopic dermatitis in the next upcoming years</style></abstract><notes><style face="normal" font="Arial">DA - 20170206IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1292134</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28165826">PM:28165826</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\20170206-KraftM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\20170206-KraftM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170206, Kraft M</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1292134</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.B.</style></author><author><style face="normal" font="Arial"> Kramer,M.F.</style></author><author><style face="normal" font="Arial"> Skinner,M.A.</style></author><author><style face="normal" font="Arial"> Heath,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Center for Rhinology and Allergology , An den Quellen 10, D-65183 Wiesbaden , Germany</style></auth-address><titles><title><style face="normal" font="Arial">Clinical use of adjuvants in allergen-immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="610" start="599">599-610</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">Introduction Allergen-specific Immunotherapy (AIT) is the only available treatment aimed to tackle the underlying causes of allergy. The active components of subcutaneous vaccines traditionally consist of natural or modified allergen extracts which can be combined with adjuvant platforms. In recent years new targets have been further developed in an attempt to raise the safety and efficacy profile of AIT. Areas Covered In this review, we discuss the desirable attributes of adjuvants and delivery systems from empiricism to rational design, for current and future clinical applications in AIT. Expert Summary The introduction of novel adjuvants, in combination with active targets, has been demonstrated to reduce side-effects of AIT, increase clinical efficacy of allergy treatment and reduce the number of doses. The evolution of vaccine development for AIT is entering a phase of scientific progress that challenges dogmas. Over the past century the traditional concept of immunotherapy, entailing long-course administration of native extract preparations and first generation adjuvants has seen evolution in the past decade from proof-of-concept to clinical development pipelines encompassing the advent of second generation adjuvants and delivery systems that form essential components of modern AIT development</style></abstract><notes><style face="normal" font="Arial">DA - 20170206IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1292133</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28162007">PM:28162007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-599-610.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-599-610.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170206, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1292133</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Decuyper,I.I.</style></author><author><style face="normal" font="Arial"> Faber,M.A.</style></author><author><style face="normal" font="Arial"> Sabato,V.</style></author><author><style face="normal" font="Arial"> Bridts,C.H.</style></author><author><style face="normal" font="Arial"> Hagendorens,M.M.</style></author><author><style face="normal" font="Arial"> Rihs,H.P.</style></author><author><style face="normal" font="Arial"> De Clerck,L.S.</style></author><author><style face="normal" font="Arial"> Ebo,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology-Allergology-Rheumatology, University of Antwerp-University Hospital of Antwerp, Edegem, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Where there's smoke, there's fire: cannabis allergy through passive exposure</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="865" start="864">864-865</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cannabis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Belgium -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.10.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161151">PM:28161151</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170205-DecuyperII.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170205-DecuyperII.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Decuyper II</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.10.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,Y.Y.</style></author><author><style face="normal" font="Arial"> Forno,E.</style></author><author><style face="normal" font="Arial"> Badellino,H.A.</style></author><author><style face="normal" font="Arial"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Pulmonary Medicine, Allergy, and Immunology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pa</style></auth-address><titles><title><style face="normal" font="Arial">Antibiotic Use in Early Life, Rural Residence, and Allergic Diseases in Argentinean Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1118" start="1112">1112-1118</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Bronchiolitis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paracetamol</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> Rural environment</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> Urban environment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> validated questionnaire</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Little is known about differential effects of antibiotic use on allergic diseases in rural versus urban environments. OBJECTIVE: To examine whether area of residence in the first year of life modifies the relation between antibiotic use in early life and allergic diseases during childhood. METHODS: Cross-sectional study of allergic diseases in 1517 children (ages 6-7 years) attending 101 schools in urban and rural areas of San Francisco (Cordoba, Argentina). Current asthma, wheeze, and allergic rhinoconjunctivitis were defined on the basis of responses to a validated questionnaire from the International Study of Asthma and Allergies in Childhood. Multivariate logistic regression was used for the analysis of antibiotic use and allergic diseases. RESULTS: After adjustment for paracetamol use, bronchiolitis, and other covariates, antibiotic use in the first year of life was associated with increased odds of current wheeze (odds ratio [OR], 1.8; 95% CI, 1.3-2.6) and allergic rhinoconjunctivitis (OR, 1.9; 95% CI, 1.3-2.7). After stratification by area of residence, antibiotic use was associated with current wheeze (OR, 2.4; 95% CI, 1.5-4.0) and allergic rhinoconjunctivitis (OR, 2.1; 95% CI, 1.3-3.4) among children who lived in an urban area in their first year of life, but not among those who lived in a rural area in their first year of life. CONCLUSIONS: Early-life antibiotic use is associated with current wheeze and allergic rhinoconjunctivitis in Argentinean children who lived in urban areas during their first year of life. Exposure to a rural environment early in life may protect against the adverse effects of antibiotics on atopic diseases in children</style></abstract><notes><style face="normal" font="Arial">DA - 20170208IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28174014">PM:28174014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170208-Han YY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170208-Han YY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170208, Han YY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Chehade,M.</style></author><author><style face="normal" font="Arial"> Groetch,M.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author><author><style face="normal" font="Arial"> Wood,R.A.</style></author><author><style face="normal" font="Arial"> Allen,K.</style></author><author><style face="normal" font="Arial"> Atkins,D.</style></author><author><style face="normal" font="Arial"> Bahna,S.</style></author><author><style face="normal" font="Arial"> Barad,A.</style></author><author><style face="normal" font="Arial"> Berin,C.</style></author><author><style face="normal" font="Arial"> Brown Whitehorn,T.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Caubet,J.C.</style></author><author><style face="normal" font="Arial"> Cianferoni,A.</style></author><author><style face="normal" font="Arial"> Conte,M.</style></author><author><style face="normal" font="Arial"> Davis,C.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Grimshaw,K.</style></author><author><style face="normal" font="Arial"> Gupta,R.</style></author><author><style face="normal" font="Arial"> Hofmeister,B.</style></author><author><style face="normal" font="Arial"> Hwang,J.B.</style></author><author><style face="normal" font="Arial"> Katz,Y.</style></author><author><style face="normal" font="Arial"> Konstantinou,G.N.</style></author><author><style face="normal" font="Arial"> Leonard,S.A.</style></author><author><style face="normal" font="Arial"> Lightdale,J.</style></author><author><style face="normal" font="Arial"> McGhee,S.</style></author><author><style face="normal" font="Arial"> Mehr,S.</style></author><author><style face="normal" font="Arial"> Miceli Sopo.S.</style></author><author><style face="normal" font="Arial"> Monti,G.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Noel,S.</style></author><author><style face="normal" font="Arial"> Nomura,I.</style></author><author><style face="normal" font="Arial"> Noone,S.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Schultz,F.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Thompson,C.</style></author><author><style face="normal" font="Arial"> Turner,P.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Westcott-Chavez,A.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">International Consensus Guidelines for the Diagnosis and Management of Food Protein-Induced Enterocolitis Syndrome: Workgroup Report of the Adverse Reactions to Foods Committee, American Academy of Allergy, Asthma, and Immunology</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1126" start="1111">1111-1126</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> International consensus</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="3" Month="2" Year="2017">2017/2/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.966</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28167094">PM:28167094</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170207-NowakWegrzynA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170207-NowakWegrzynA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Nowak-Wegrzyn A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.966</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Unal,D.</style></author><author><style face="normal" font="Arial"> Coskun,R.</style></author><author><style face="normal" font="Arial"> Demir,S.</style></author><author><style face="normal" font="Arial"> Gelincik,A.</style></author><author><style face="normal" font="Arial"> Colakoglu,B.</style></author><author><style face="normal" font="Arial"> Buyukozturk,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul University, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Successful beef desensitization in 2 adult patients with a delayed-type reaction to red meat</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="503" start="502">502-503</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132797">PM:28132797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-502-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-502-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Unal D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jackson,D.J.</style></author><author><style face="normal" font="Arial"> Gern,J.E.</style></author><author><style face="normal" font="Arial"> Lemanske,R.F.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wis.</style></auth-address><titles><title><style face="normal" font="Arial">Lessons learned from birth cohort studies conducted in diverse environments</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="386" start="379">379-386</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Infections</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> natural history of asthma</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Childhood asthma develops from a complex interaction among host and environmental factors in early life. Birth cohort studies have provided valuable insight into asthma risk factors and the natural history of wheezing and asthma through childhood and beyond. Early life aeroallergen sensitization and wheezing illnesses associated with virus and bacterial infections have been identified as pivotal risk factors for asthma inception. Recently, focus has turned toward protective factors that promote lung health in children. Studies in a variety of environments, including farms and urban communities, suggest that diverse exposures to microbes in early life lead to a lower risk of allergy and asthma in childhood. The mechanisms underlying how these exposures and the gut and airway microbiomes alter the host response to allergens and viruses are of interest and an area of ongoing study. Longitudinal follow up of birth cohorts in diverse environments worldwide will continue to provide critical knowledge about the factors that impact the natural history of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170210IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.941</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28183432">PM:28183432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-379-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-379-86.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170210, Jackson DJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.941</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Warren,C.M.</style></author><author><style face="normal" font="Arial"> Dyer,A.A.</style></author><author><style face="normal" font="Arial"> Otto,A.K.</style></author><author><style face="normal" font="Arial"> Smith,B.M.</style></author><author><style face="normal" font="Arial"> Kauke,K.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author><author><style face="normal" font="Arial"> Gupta,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Northwestern University Feinberg School of Medicine, Chicago, Ill</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy-Related Risk-Taking and Management Behaviors Among Adolescents and Young Adults</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="390.e13" start="381">381-390.e13</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> latent class analysis</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> risk taking</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy (FA) affects 8% of children and adolescents in the United States. Nearly 40% of those affected have experienced severe reactions. Fatal food-induced anaphylaxis is most common among adolescents and young adults (AYA); however, FA-related risk behaviors persist in this population and factors associated with these behaviors remain unclear. OBJECTIVE: To characterize FA-related risk-taking and self-management behaviors of AYA with FA. METHODS: A cross-sectional survey was administered to 200 AYA with FA. Latent class analysis was used to identify distinct behavioral risk classes and predictors of risk class membership. RESULTS: Two distinct FA behavioral risk classes were identified, representing less (N = 120) and more (N = 80) risky subpopulations. After adjusting for age, sex, and anaphylaxis history, odds of more risky class membership were significantly reduced for AYA with peanut allergy (odds ratio [OR], 0.27; 95% CI, 0.11-0.65), supportive female friends (OR, 0.27; 95% CI, 0.07-0.99), overprotective mothers (OR, 0.42; 95% CI, 0.18-0.97), teachers who are aware of their FA (OR, 0.39; 95% CI, 0.17-0.91), a history of being bullied (OR, 0.22; 95% CI, 0.09-0.51), and an established 504 education plan (OR, 0.35; 95% CI, 0.15-0.81). AYA also reported numerous positive outcomes of their FA, such as greater responsibility, empathy, and improved diet, which was significantly associated with reduced odds of risky class membership (OR, 0.38; 95% CI, 0.18-0.80). CONCLUSIONS: Among AYA, increased FA-related risk-taking was associated with clinical, demographic, and social factors, including peanut allergy, greater age, as well as absence of social support and specific school FA policies. These associations may be used to inform future interventions designed to address FA-related risk and management behaviors</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132799">PM:28132799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-381-90.e13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-381-90.e13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Warren CM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kreiner,E.</style></author><author><style face="normal" font="Arial"> Waage,J.</style></author><author><style face="normal" font="Arial"> Standl,M.</style></author><author><style face="normal" font="Arial"> Brix,S.</style></author><author><style face="normal" font="Arial"> Pers,T.H.</style></author><author><style face="normal" font="Arial"> Couto,Alves A.</style></author><author><style face="normal" font="Arial"> Warrington,N.M.</style></author><author><style face="normal" font="Arial"> Tiesler,C.M.</style></author><author><style face="normal" font="Arial"> Fuertes,E.</style></author><author><style face="normal" font="Arial"> Franke,L.</style></author><author><style face="normal" font="Arial"> Hirschhorn,J.N.</style></author><author><style face="normal" font="Arial"> James,A.</style></author><author><style face="normal" font="Arial"> Simpson,A.</style></author><author><style face="normal" font="Arial"> Tung,J.Y.</style></author><author><style face="normal" font="Arial"> Koppelman,G.H.</style></author><author><style face="normal" font="Arial"> Postma,D.S.</style></author><author><style face="normal" font="Arial"> Pennell,C.E.</style></author><author><style face="normal" font="Arial"> Jarvelin,M.R.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author><author><style face="normal" font="Arial"> Timpson,N.</style></author><author><style face="normal" font="Arial"> Ferreira,M.A.</style></author><author><style face="normal" font="Arial"> Strachan,D.P.</style></author><author><style face="normal" font="Arial"> Henderson,J.</style></author><author><style face="normal" font="Arial"> Hinds,D.</style></author><author><style face="normal" font="Arial"> Bisgaard,H.</style></author><author><style face="normal" font="Arial"> Bonnelykke,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Copenhagen Prospective Studies on Asthma in Childhood, Health Sciences, University of Copenhagen, Danish Pediatric Asthma Center, Copenhagen University Hospital, Gentofte, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Shared genetic variants suggest common pathways in allergy and autoimmune diseases</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="781" start="771">771-781</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Loci</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The relationship between allergy and autoimmune disorders is complex and poorly understood. OBJECTIVE: To investigate commonalities in genetic loci and pathways between allergy and autoimmune diseases to elucidate shared disease mechanisms. METHODS: We meta-analyzed two GWAS on self-reported allergy and sensitization comprising a total of 62,330 individuals. These results were used to calculate enrichment for SNPs previously associated with autoimmune diseases. Furthermore, we probed for enrichment within genetic pathways and of transcription factor binding sites, and characterized commonalities in the variant burden on tissue-specific regulatory sites by calculating the enrichment of allergy SNPs falling in gene regulatory regions in various cells using Encode Roadmap DHS data, and compared the allergy data with all known diseases. RESULTS: Among 290 loci previously associated with 16 autoimmune diseases, we found a significant enrichment of loci also associated with allergy (p=1.4e-17) encompassing 29 loci at a false discovery rate&lt;0.05. Such enrichment seemed to be a general characteristic for all autoimmune diseases. Among the common loci, 48% had the same direction of effect for allergy and autoimmune diseases. Additionally, we observed an enrichment of allergy SNPs falling within immune pathways and regions of chromatin accessible in immune cells that was also represented in autoimmune diseases, but not in other diseases. CONCLUSION: We identified shared susceptibility loci and commonalities in pathways between allergy and autoimmune diseases, suggesting shared diseases mechanisms. Further studies of these shared genetic mechanisms might help understanding the complex relationship between these diseases, including the parallel increase in disease prevalence</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Germany -CO - United States -CO - United KIngdom -CO - Australia -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.10.055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188724">PM:28188724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170211-KreinerE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170211-KreinerE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Kreiner E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.10.055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anto,J.M.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author><author><style face="normal" font="Arial"> Auffray,C.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Momas,I.</style></author><author><style face="normal" font="Arial"> Postma,D.S.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Cambon-Thomsen,A.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Lodrup Carlsen,K.C.</style></author><author><style face="normal" font="Arial"> Koppelman,G.H.</style></author><author><style face="normal" font="Arial"> Sunyer,J.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Arno,A.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> De Carlo,G.</style></author><author><style face="normal" font="Arial"> Forastiere,F.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Maier,D.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Smit,H.A.</style></author><author><style face="normal" font="Arial"> Standl,M.</style></author><author><style face="normal" font="Arial"> Wright,J.</style></author><author><style face="normal" font="Arial"> Asarnoj,A.</style></author><author><style face="normal" font="Arial"> Benet,M.</style></author><author><style face="normal" font="Arial"> Ballardini,N.</style></author><author><style face="normal" font="Arial"> Garcia-Aymerich,J.</style></author><author><style face="normal" font="Arial"> Gehring,U.</style></author><author><style face="normal" font="Arial"> Guerra,S.</style></author><author><style face="normal" font="Arial"> Hohmann,C.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Lupinek,C.</style></author><author><style face="normal" font="Arial"> Pinart,M.</style></author><author><style face="normal" font="Arial"> Skrindo,I.</style></author><author><style face="normal" font="Arial"> Westman,M.</style></author><author><style face="normal" font="Arial"> Smagghe,D.</style></author><author><style face="normal" font="Arial"> Akdis,C.</style></author><author><style face="normal" font="Arial"> Andersson,N.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Ballereau,S.</style></author><author><style face="normal" font="Arial"> Ballester,F.</style></author><author><style face="normal" font="Arial"> Basagana,X.</style></author><author><style face="normal" font="Arial"> Bedbrook,A.</style></author><author><style face="normal" font="Arial"> Bergstrom,A.</style></author><author><style face="normal" font="Arial"> Von Berg,A.</style></author><author><style face="normal" font="Arial"> Brunekreef,B.</style></author><author><style face="normal" font="Arial"> Burte,E.</style></author><author><style face="normal" font="Arial"> Carlsen,K.H.</style></author><author><style face="normal" font="Arial"> Chatzi,L.</style></author><author><style face="normal" font="Arial"> Coquet,J.M.</style></author><author><style face="normal" font="Arial"> Curin,M.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Eller,E.</style></author><author><style face="normal" font="Arial"> Fantini,M.P.</style></author><author><style face="normal" font="Arial"> Von Hertzen,L.</style></author><author><style face="normal" font="Arial"> Hovland,V.</style></author><author><style face="normal" font="Arial"> Jacquemin,B.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Keller,T.</style></author><author><style face="normal" font="Arial"> Kiss,R.</style></author><author><style face="normal" font="Arial"> Kogevinas,M.</style></author><author><style face="normal" font="Arial"> Koletzko,S.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Lehmann,I.</style></author><author><style face="normal" font="Arial"> Lemonnier,N.</style></author><author><style face="normal" font="Arial"> Makela,M.</style></author><author><style face="normal" font="Arial"> Mestres,J.</style></author><author><style face="normal" font="Arial"> Mowinckel,P.</style></author><author><style face="normal" font="Arial"> Nadif,R.</style></author><author><style face="normal" font="Arial"> Nawijn,M.C.</style></author><author><style face="normal" font="Arial"> Pellet,J.</style></author><author><style face="normal" font="Arial"> Pin,I.</style></author><author><style face="normal" font="Arial"> Porta,D.</style></author><author><style face="normal" font="Arial"> Ranciere,F.</style></author><author><style face="normal" font="Arial"> Rial-Sebbag,E.</style></author><author><style face="normal" font="Arial"> Saeys,Y.</style></author><author><style face="normal" font="Arial"> Schuijs,M.J.</style></author><author><style face="normal" font="Arial"> Siroux,V.</style></author><author><style face="normal" font="Arial"> Tischer,C.G.</style></author><author><style face="normal" font="Arial"> Torrent,M.</style></author><author><style face="normal" font="Arial"> Varraso,R.</style></author><author><style face="normal" font="Arial"> Wenzel,K.</style></author><author><style face="normal" font="Arial"> Xu,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ISGLoBAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="399" start="388">388-399</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy phenotypes</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association studies</style></keyword><keyword><style face="normal" font="Arial"> Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Machine Learning</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> MeDALL</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> puberty</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Asthma, rhinitis, and eczema are complex diseases with multiple genetic and environmental factors interlinked through IgE-associated and non-IgE-associated mechanisms. Mechanisms of the Development of ALLergy (MeDALL; EU FP7-CP-IP; project no: 261357; 2010-2015) studied the complex links of allergic diseases at the clinical and mechanistic levels by linking epidemiologic, clinical, and mechanistic research, including in vivo and in vitro models. MeDALL integrated 14 European birth cohorts, including 44,010 participants and 160 cohort follow-ups between pregnancy and age 20 years. Thirteen thousand children were prospectively followed after puberty by using a newly standardized MeDALL Core Questionnaire. A microarray developed for allergen molecules with increased IgE sensitivity was obtained for 3,292 children. Estimates of air pollution exposure from previous studies were available for 10,000 children. Omics data included those from historical genome-wide association studies (23,000 children) and DNA methylation (2,173), targeted multiplex biomarker (1,427), and transcriptomic (723) studies. Using classical epidemiology and machine-learning methods in 16,147 children aged 4 years and 11,080 children aged 8 years, MeDALL showed the multimorbidity of eczema, rhinitis, and asthma and estimated that only 38% of multimorbidity was attributable to IgE sensitization. MeDALL has proposed a new vision of multimorbidity independent of IgE sensitization, and has shown that monosensitization and polysensitization represent 2 distinct phenotypes. The translational component of MeDALL is shown by the identification of a novel allergic phenotype characterized by polysensitization and multimorbidity, which is associated with the frequency, persistence, and severity of allergic symptoms. The results of MeDALL will help integrate personalized, predictive, preventative, and participatory approaches in allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170210IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -CO - France -CO - Switzerland -CO - Germany -CO - Netherlands -CO - Austria -CO - Sweden -CO - Finland -CO - Belgium -CO - Norway -CO - Denmark -CO - Italy -CO - Poland -CO - United Kingdom -CO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.940</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28183433">PM:28183433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-388-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-388-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170210, Anto JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.940</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Forno,E.</style></author><author><style face="normal" font="Arial"> Sordillo,J.</style></author><author><style face="normal" font="Arial"> Brehm,J.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Benos,T.</style></author><author><style face="normal" font="Arial"> Yan,Q.</style></author><author><style face="normal" font="Arial"> Avila,L.</style></author><author><style face="normal" font="Arial"> Soto-Quiros,M.</style></author><author><style face="normal" font="Arial"> Cloutier,M.M.</style></author><author><style face="normal" font="Arial"> Colon-Semidey,A.</style></author><author><style face="normal" font="Arial"> Alvarez,M.</style></author><author><style face="normal" font="Arial"> Acosta-Perez,E.</style></author><author><style face="normal" font="Arial"> Weiss,S.T.</style></author><author><style face="normal" font="Arial"> Litonjua,A.A.</style></author><author><style face="normal" font="Arial"> Canino,G.</style></author><author><style face="normal" font="Arial"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Pulmonary Medicine, Allergy, and Immunology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; University of Pittsburgh School of Medicine, Pittsburgh, PA</style></auth-address><titles><title><style face="normal" font="Arial">Genome-wide interaction study of dust mite allergen on lung function in children with asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> CAMP</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Costa Rica</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Genetic polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Hispanic</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Puerto Rican</style></keyword><keyword><style face="normal" font="Arial"> Puerto Rico</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="3" Month="2" Year="2017">2017/2/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Childhood asthma is likely the result of gene-by-environment (GxE) interactions. Dust mite is a known risk factor for asthma morbidity. Yet, there have been no genome-wide GxE studies of dust mite allergen on asthma-related phenotypes. OBJECTIVE: To identify genetic variants whose effects on lung function in children with asthma are modified by level of dust mite allergen exposure. METHODS: A genome-wide interaction analysis of dust mite allergen level and lung function was performed in a cohort of Puerto Rican children with asthma (PRGOAL). Replication was attempted in two independent cohorts, the Childhood Asthma Management Program (CAMP) and the Genetics of Asthma in Costa Rica Study. RESULTS: SNP rs117902240 showed a significant interaction with dust mite allergen level on FEV1 in PRGOAL (interaction P=3.1x10-8), and replicated in the same direction in CAMP White children and CAMP Hispanic children (combined interaction P=0.0065 for replication cohorts and 7.4 x10-9 for all cohorts). Rs117902240 was positively associated with FEV1 in children exposed to low dust mite allergen levels, but negatively associated with FEV1 in children exposed to high levels. This SNP is on chromosome 8q24, adjacent to a binding site for CEBPbeta, a transcription factor that forms part of the IL-17 signaling pathway. None of the SNPs identified for FEV1/FVC replicated in the independent cohorts. CONCLUSIONS: Dust mite allergen exposure modifies the estimated effect of rs117902240 on FEV1 in children with asthma. Analysis of existing data suggests this SNP may have transcription factor regulatory functions. CAPSULE SUMMARY: Dust mite allergen exposure modifies the effect of certain genetic polymorphisms on lung function in children with asthma. CLINICAL IMPLICATIONS: The effect of certain genetic polymorphisms on lung function in children with asthma varies depending on their dust mite allergen exposure level. Future studies should assess whether personalized interventions for these children have a greater impact on lung function</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Costa Rica -CO - Puerto Rico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.967</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28167095">PM:28167095</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170207-FornoE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170207-FornoE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Forno E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.967</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berglund,J.P.</style></author><author><style face="normal" font="Arial"> Szczepanski,N.</style></author><author><style face="normal" font="Arial"> Penumarti,A.</style></author><author><style face="normal" font="Arial"> Beavers,A.</style></author><author><style face="normal" font="Arial"> Kesselring,J.</style></author><author><style face="normal" font="Arial"> Orgel,K.</style></author><author><style face="normal" font="Arial"> Burnett,B.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Kulis,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC</style></auth-address><titles><title><style face="normal" font="Arial">Preparation and Analysis of Peanut Flour Used in Oral Immunotherapy Clinical Trials</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1104" start="1098">1098-1104</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aflatoxin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1 and Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gels</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Salmonella</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oral immunotherapy (OIT) is an investigational therapeutic approach for the treatment of food allergies. Characterization of the drug product used in oral immunotherapy trials for peanut allergy has not been reported. OBJECTIVE: To quantify relative amounts of the major peanut allergens and microbial load present in peanut flour used in OIT trials and assess whether these parameters change over a 12-month period. We also anticipate that this report will serve as a guide for investigators seeking to conduct OIT trials under Food and Drug Administration-approved Investigational New Drug applications. METHODS: Densitometric scanning of Ara h 1 and Ara h 2 resolved on SDS-PAGE gels was used to assess allergen content in peanut flour extracts. Microbial testing was conducted on peanut flour under US Pharmacopeia guidelines for the presence of Escherichia coli, salmonella, yeast, mold, and total aerobic bacteria. In addition, aflatoxin was quantified in peanut flour. Reported results were obtained from 4 unique lots of peanut flour. RESULTS: Relative amounts of the major peanut allergens were similar between different lots of peanut flour and remained stable over a 12-month period. E coli and salmonella were absent from all lots of flour. Yeast, mold, total aerobic bacteria, and aflatoxin were within established US Pharmacopeia guidelines on all lots tested and remained within the criteria over a 12-month period. CONCLUSIONS: Peanut flour used as a drug product contains the major peanut allergens and has low levels of potentially harmful microbes. Both these parameters remain stable over a 12-month period</style></abstract><notes><style face="normal" font="Arial">DA - 20170130IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132800">PM:28132800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170130-BerglundJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170130-BerglundJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170130, Berglund JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Di Mario,S.</style></author><author><style face="normal" font="Arial"> Basevi,V.</style></author><author><style face="normal" font="Arial"> Panza,C.</style></author><author><style face="normal" font="Arial"> Conti Nibali,S.</style></author><author><style face="normal" font="Arial"> Cattaneo,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">SaPeRiDoc-Documentation Centre on Perinatal and Reproductive Health, Regional Health Authority of Emilia-Romagna, Bologna, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Early or delayed introduction of food? Misunderstanding is in the air</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1406" start="1405">1405-1406</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28139317">PM:28139317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170131-DiMarioS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170131-DiMarioS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Di Mario S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,A.Y.</style></author><author><style face="normal" font="Arial"> Enarson,P.</style></author><author><style face="normal" font="Arial"> Clarke,A.E.</style></author><author><style face="normal" font="Arial"> La Vieille,S.</style></author><author><style face="normal" font="Arial"> Eisman,H.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Mill,C.</style></author><author><style face="normal" font="Arial"> Joseph,L.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Residency Program, Department of Pediatrics, University of British Columbia, BC Children's Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis across two Canadian pediatric centers: evaluating management disparities</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="7" start="1">1-7</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> disparities</style></keyword><keyword><style face="normal" font="Arial"> disparity</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine use</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Training program</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There are no data on the percentage of visits due to anaphylaxis in the emergency department (ED), triggers, and management of anaphylaxis across different provinces in Canada. OBJECTIVE: To compare the percentage of anaphylaxis cases among all ED visits, as well as the triggers and management of anaphylaxis between two Canadian pediatric EDs (PEDs). METHODS: As part of the Cross-Canada Anaphylaxis Registry (C-CARE), children presenting to the British Columbia Children's Hospital (BCCH) and Montreal Children's Hospital (MCH) EDs with anaphylaxis were recruited. Characteristics, triggers, and management of anaphylaxis were documented using a standardized data entry form. Differences in demographics, triggers, and management were determined by comparing the difference of proportions and 95% confidence interval. RESULTS: Between June 2014 and June 2016, there were 346 visits due to anaphylaxis among 93,730 PED visits at the BCCH ED and 631 anaphylaxis visits among 164,669 pediatric visits at the MCH ED. In both centers, the majority of cases were triggered by food (BCCH 91.3% [88.7, 94.0], MCH 82.4% [79.7, 85.3]), of which peanuts were the most common culprit (24.7% [20.9, 29.9] and 19.0% [15.8, 22.7], respectively). Pre-hospital administration of epinephrine (BCCH 27.7% [23.2, 32.8], MCH 33.1% [29.5, 37.0]) and antihistamines (BCCH 50.6% [45.2, 56.0], MCH 47.1% [43.1, 51.0]) was similar. In-hospital management differed in terms of increased epinephrine, antihistamine, and steroid use at the BCCH (59.2% [53.9, 64.4], 59.8% [54.4, 65.0], and 60.1% [54.7, 65.3], respectively) compared to the MCH (42.2% [38.3, 46.2], 36.2% [32.5, 40.1], and 11.9% [9.5, 14.8], respectively). Despite differences in management, percentage of cases admitted to the intensive care unit was similar between the two centers. CONCLUSION: Compared to previous European and North American reports, there is a high percentage of anaphylaxis cases in two PEDs across Canada with substantial differences in hospital management practices. It is crucial to develop training programs that aim to increase epinephrine use in anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S123053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28115856">PM:28115856</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-1-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-1-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Lee AY</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S123053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sroka-Bartnicka,A.</style></author><author><style face="normal" font="Arial"> Karlsson,I.</style></author><author><style face="normal" font="Arial"> Ndreu,L.</style></author><author><style face="normal" font="Arial"> Quaranta,A.</style></author><author><style face="normal" font="Arial"> Pijnappel,M.</style></author><author><style face="normal" font="Arial"> Thorsen,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Science and Analytical Chemistry, Stockholm University, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Particle-based N-linked glycan analysis of selected proteins from biological samples using nonglycosylated binders</style></title><secondary-title><style face="normal" font="Arial">J Pharm Biomed Anal</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pharm Biomed Anal</style></full-title></periodical><pages end="132" start="125">125-132</pages><volume><style face="normal" font="Arial">132</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alpha-1-antitrypsin</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analytical chemistry</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> cerebrospinal fluid</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Deglycosylation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic beads</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Neurodegenerative Diseases</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Transferrin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="Arial">Glycosylation is one of the most common and important post-translational modifications, influencing both the chemical and the biological properties of proteins. Studying the glycosylation of the entire protein population of a sample can be challenging because variations in the concentrations of certain proteins can enhance or obscure changes in glycosylation. Furthermore, alterations in the glycosylation pattern of individual proteins, exhibiting larger variability in disease states, have been suggested as biomarkers for different types of cancer, as well as inflammatory and neurodegenerative diseases. In this paper, we present a rapid and efficient method for glycosylation analysis of individual proteins focusing on changes in the degree of fucosylation or other alterations to the core structure of the glycans, such as the presence of bisecting N-acetylglucosamines and a modified degree of branching. Streptavidin-coated magnetic beads are used in combination with genetically engineered immunoaffinity binders, called VHH antibody fragments. A major advantage of the VHHs is that they are nonglycosylated; thus, enzymatic release of glycans from the targeted protein can be performed directly on the beads. After deglycosylation, the glycans are analyzed by MALDI-TOF-MS. The developed method was evaluated concerning its specificity, and thereafter implemented for studying the glycosylation pattern of two different proteins, alpha-1-antitrypsin and transferrin, in human serum and cerebrospinal fluid. To our knowledge, this is the first example of a protein array-type experiment that employs bead-based immunoaffinity purification in combination with mass spectrometry analysis for fast and efficient glycan analysis of individual proteins in biological fluid</style></abstract><notes><style face="normal" font="Arial">DA - 20161008IS - 1873-264X (Electronic)IS - 0731-7085 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jpba.2016.09.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27718394">PM:27718394</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharm Biomed Anal\2017-132-125-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharm Biomed Anal\2017-132-125-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161008, Sroka-Bartnicka A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jpba.2016.09.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Szabo,Z.</style></author><author><style face="normal" font="Arial"> Guttman,A.</style></author><author><style face="normal" font="Arial"> Bones,J.</style></author><author><style face="normal" font="Arial"> Shand,R.L.</style></author><author><style face="normal" font="Arial"> Meh,D.</style></author><author><style face="normal" font="Arial"> Karger,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Barnett Institute, Northeastern University, Boston, Massachusetts 02115, United States</style></auth-address><titles><title><style face="normal" font="Arial">Ultrasensitive capillary electrophoretic analysis of potentially immunogenic carbohydrate residues in biologics: galactose-alpha-1,3-galactose containing oligosaccharides</style></title><secondary-title><style face="normal" font="Arial">Mol Pharm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Pharm</style></full-title></periodical><pages end="1619" start="1612">1612-1619</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Monoclonal</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Capillaries</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis,Capillary</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Galactose</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Glycoside Hydrolases</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hydrolases</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> instrumentation</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="6" Year="2012">2012/6/4</year></dates><abstract><style face="normal" font="Arial">With the recent growth of the global monoclonal antibody market, ultrasensitive techniques are required for rapid analysis of possible immunogenic residues, such as galactose-alpha-1,3-galactose (alpha-1,3-Gal) on therapeutic proteins expressed in murine or CHO cell lines. We report a capillary electrophoretic approach in conjunction with exoglycosidase digestion for structural elucidation of IgG N-glycans containing the above immunogenic epitope. The method uses commercially available reagents and instrumentation, thus making it readily available for implementation and validation within the biotechnology industry. The method was first evaluated using polyclonal mouse IgG N-glycans which are known to contain alpha-1,3-Gal containing epitopes. High reproducibility in migration time enabled determination of GU values for five alpha-1,3-Gal containing structures when the data from all samples analyzed was combined. The method was successfully applied to the analysis of a NCI reference standard monoclonal antibody and two development phase monoclonal antibodies. The limit of detection and limit of quantitation were 1 and 2 mug of intact protein IgG starting material, respectively, further indicating the high sensitivity of the described method</style></abstract><notes><style face="normal" font="Arial">DA - 20120604IS - 1543-8392 (Electronic)IS - 1543-8384 (Linking)LA - engPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralRN - 0 (Antibodies, Monoclonal)RN - 0 (Carbohydrates)RN - 0 (Oligosaccharides)RN - EC 3.2.1.- (Glycoside Hydrolases)RN - X2RN3Q8DNE (Galactose)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/mp200612n</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="22571495">PM:22571495</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Pharm\2012-9-1612-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Pharm\2012-9-1612-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20120604, Szabo Z</style></custom2><misc3><style face="normal" font="Arial">10.1021/mp200612n</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vargas-Correa,J.B.</style></author><author><style face="normal" font="Arial"> Bracamonte-Peraza,R.</style></author><author><style face="normal" font="Arial"> Espinosa-Morales,S.M.</style></author><author><style face="normal" font="Arial"> Vazquez-Nava,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Hospital Regional Merida, Coordinacion de Medicina Interna, Merida, Yucatan, Mexico. jbvcmer@prodigy.net.mx</style></auth-address><titles><title><style face="normal" font="Arial">Clinical experience with omalizumab in patients with severe asthma. Real-world data</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="226" start="216">216-226</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Omalizumab is a monoclonal antibody that is prescribed in a stepwise addition regimen for the treatment of severe asthma. OBJECTIVE: To report the experience of patients with severe asthma who were given omalizumab in accordance with international guides, in a context of real-world data. METHODS: Open, analytical, cross-sectional, retrospective, observational clinical study with real-world data. GINA 2006 Asthma Control Scheme was used to evaluate patients, and a questionnaire was used to evaluate patient characteristics, effectiveness, safety, and tolerance to omalizumab. RESULTS: 48 patients were studied, 34 women and 14 men with an average age of 39 years. The average disease duration was 26 years. Average serum IgE was 522 IU. At the beginning of treatment, all patients had uncontrolled asthma; at the end, 69% asthma control was obtained, 19% was partially controlled and 12% unchanged. The changes were observed at seven months on average. CONCLUSION: Omalizumab is effective and safe for treating severe asthma when applied in accordance with international guidelines for the management of bronchial asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27560910">PM:27560910</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-216-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-216-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Vargas-Correa JB</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">White,M.</style></author><author><style face="normal" font="Arial"> Goss,D.</style></author><author><style face="normal" font="Arial"> Hollis,K.</style></author><author><style face="normal" font="Arial"> Millar,K.</style></author><author><style face="normal" font="Arial"> Silvia,S.</style></author><author><style face="normal" font="Arial"> Siegel,P.H.</style></author><author><style face="normal" font="Arial"> Bennett,M.E.</style></author><author><style face="normal" font="Arial"> Wooddell,M.J.</style></author><author><style face="normal" font="Arial"> Hogue,S.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis Triggers and Treatments by Grade Level and Staff Training: Findings from the EPIPEN4SCHOOLS Pilot Survey</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="85" start="80">80-85</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="6" Year="2016">2016/6/1</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">This pilot survey was designed to evaluate the characteristics of anaphylactic events and epinephrine autoinjector (EAI) use in children in U.S. schools. A cross-sectional, web-based, pilot survey of schools participating in the EPIPEN4SCHOOLS® program (Mylan Specialty L.P., Canonsburg, PA) assessed characteristics of anaphylactic events and EAI use during the 2013-2014 academic year. Respondents reported 757 anaphylactic events experienced by students; student grade level was noted for 724 events. Of these events, 32.3% (234/724) were experienced by students in grade school, 18.6% (135/724) by students in middle school, and 49.0% (355/724) by students in high school. Frequency of food-related triggers was consistently high across grade levels. However, many events experienced by students in high school (22.3%, 79/355), middle school (15.0%, 20/135), and grade school (14.1%, 33/234) had an unknown trigger. In 36.0% of schools (2008/5579), only the school nurse and select staff received training to recognize anaphylaxis; most staff or all staff received training in 28.9% (1610/5579) and 30.9% (1722/5579) of schools, respectively. In a majority of schools (54.2%, 3003/5544), only the school nurse and select staff were permitted to administer epinephrine, whereas most staff or all staff were permitted to administer epinephrine in 15.8% (876/5544) and 21.9% (1212/5544) of schools, respectively. Risk of anaphylaxis may be particularly high during adolescence, and some students encounter staff members who are untrained in anaphylaxis recognition or management, or both. These findings support the need for continued anaphylaxis training for the protection of all students, staff, and visitors.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2015.0614</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2015.0614</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-80-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-80-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160215, White M</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2015.0614</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">White,M.</style></author><author><style face="normal" font="Arial"> Hogue,S.L.</style></author><author><style face="normal" font="Arial"> Odom,D.</style></author><author><style face="normal" font="Arial"> Cooney,D.</style></author><author><style face="normal" font="Arial"> Bartsch,J.</style></author><author><style face="normal" font="Arial"> Goss,D.</style></author><author><style face="normal" font="Arial"> Hollis,K.</style></author><author><style face="normal" font="Arial"> Herrem,C.</style></author><author><style face="normal" font="Arial"> Silvia,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis in Schools: Results of the EPIPEN4SCHOOLS Survey Combined Analysis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="154" start="149">149-154</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> epinephrine auto-injectors</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">A pilot survey described the characteristics of anaphylactic events occurring in an initial set of participating U.S. schools during the 2013-2014 school year. This survey was subsequently readministered to large school districts, which were underrepresented in initial results. A cross-sectional survey was administered to the U.S. schools that were participating in the EPIPEN4SCHOOLS® program (Mylan Specialty L.P., Canonsburg, PA) to assess characteristics of anaphylactic events. Data from large school districts were added to initial findings in this comprehensive combined analysis. A total of 1,140 anaphylactic events were reported among 6,574 responding schools. Of 1,063 anaphylactic events with data on who experienced the event, it was observed that it occurred mostly in students (89.5%, 951/1,063). For students, anaphylactic events were reported across all grades, with 44.9% (400/891) occurring in high school students, 18.9% (168/891) in middle school students, and 32.5% (290/891) in elementary school students. Food was identified as the most common trigger (60.1%, 622/1,035). A majority of schools (55.0%, 3,332/6,053) permitted only the school nurse and select staff to administer epinephrine to treat anaphylaxis. The unpredictability of anaphylaxis is emphasized by its high occurrence in individuals with no known allergies (25.0%). A majority of schools permitted only the school nurse and select staff to treat anaphylaxis. Thus, individuals experiencing an anaphylactic event may frequently encounter staff members not being permitted to administer potentially life-saving epinephrine. Epinephrine auto-injectors provided by the EPIPEN4SCHOOLS program were used to treat 38.0% of events. Anaphylaxis can occur in children with no previously known allergies, illustrating the importance of public access to epinephrine.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2016.0675</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.0675</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-149-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-149-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, White M</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2016.0675</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wiecek,S.</style></author><author><style face="normal" font="Arial"> Wos,S.</style></author><author><style face="normal" font="Arial"> Horowska-Ziaja,S.</style></author><author><style face="normal" font="Arial"> Flak-Wancerz,A.</style></author><author><style face="normal" font="Arial"> Grzybowska-Chlebowczyk,U.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lactose Intolerance in Children with IgE-Dependent Allergy to Milk Proteins</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="90" start="86">86-90</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy to cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Atrophy</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Lactase</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lactose Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="6" Year="2016">2016/6/1</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">The aim of this study was to assess the frequency of the occurrence of lactose intolerance in children with an IgE-dependent allergy to cow's milk. The study group consisted of 48 children diagnosed with IgE-dependent allergy to cow's milk proteins (group I). The control group (group II) included 40 children, in a similar age range and with normal architecture of the mucosa of the small intestine, with excluded food allergy. All patients underwent gastroduodenoscopy with biopsy, in which the activity of lactase was determined. The average activities of lactase in the group of patients with allergy were lower than in group II and amounted to 5.6 and 8.64?U/1?g. Lactase deficiency was observed in 6/48 patients in the group of patients with allergy. In group II, lactase deficiency was observed in 20%, which corresponds to the frequency of lactase intolerance in Poland. Lower activity of lactase was statistically significantly more common in older children. A reduced activity of lactase was more frequent in children with atrophy of the intestinal villi; however, that difference was not statistically significant. Lactose intolerance was less frequent in children with a diagnosed IgE-dependent milk proteins allergy. Due to the positive role of lactose in the diet, it seems that including a lactose-free formula in patients with diagnosed IgE-dependent allergy to milk is not necessary</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2016.0654</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.0654</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-86-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-86-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170215, Wiecek S</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2016.0654</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Genuneit,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Attention: this is one itchy problem!</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="52" start="51">51-52</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Attention</style></keyword><keyword><style face="normal" font="Arial"> Biometry</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12668</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28127841">PM:28127841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-51-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-51-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Genuneit J</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12668</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asaumi,T.</style></author><author><style face="normal" font="Arial"> Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Takahashi,K.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Negative Act d 8 indicates systemic kiwifruit allergy among kiwifruit-sensitized children</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="294" start="291">291-294</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Act d 8</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> kiwifruit</style></keyword><keyword><style face="normal" font="Arial"> kiwifruit allergy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prick by prick</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">Kiwifruit allergy appears to be increasing (1). Symptoms of kiwifruit allergy vary from localized oral symptoms to life-threatening anaphylaxis (2, 3). Kiwifruit allergy is generally diagnosed based on medical history, positive specific immunoglobulin E (IgE) to kiwifruit, and oral food challenge (OFC). It is important to identify biomarkers to differentiate severe symptoms from localized oral symptoms. However, commercially available in vitro tests for specific IgE antibodies to crude kiwifruit extracts cannot predict severe kiwifruit allergy (4, 5). Although the prick by prick test has high sensitivity, it has low specificity and cannot predict severe symptoms (2). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12700</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28140468">PM:28140468</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170131-AsaumiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170131-AsaumiT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Asaumi T</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12700</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wahn,U.</style></author><author><style face="normal" font="Arial"> Valovirta,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department for Pediatric Pneumology and Immunology, Charite University Hospital, Berlin, GermanyDepartment of Lung Diseases &amp; Clinical Allergology, University of Turku &amp; Terveystalo Allergy Clinic, Turku, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Real-life safety of allergen immunotherapy in children and adolescents</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="71">71-</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170127IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12683</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28127839">PM:28127839</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170127, Wahn U</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12683</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Ara,C.</style></author><author><style face="normal" font="Arial"> Pedrosa,M.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author><author><style face="normal" font="Arial"> Caballero,T.</style></author><author><style face="normal" font="Arial"> Boyano-Martinez,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy.Hospital La Paz Institute for Health Research (IdiPAZ).Paseo de la Castellana, 261 28046, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to microarrayed species-specific plant components precedes that of cross-reacting allergens</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="291" start="288">288-291</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy to cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> cross-reacting allergens</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Components</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Vegetal allergens</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">Microarrayed allergen immunoassays are increasingly being used to determine sensitization to multiple allergenic components1 . However, there is scarce data on the development and progression of sensitization to vegetal allergens in early life. This study aimed to detect the profile of sensitization to allergenic components from vegetal foods and pollens using ISAC-IgE microarray (ISAC-IgE) (Thermo Fisher Scientific, Uppsala, Sweden) over 4 years in children diagnosed with allergy to cow's milk proteins (CMPA). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12701</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28140470">PM:28140470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170131-GarciaAraC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170131-GarciaAraC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Garcia-Ara C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12701</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawamoto,N.</style></author><author><style face="normal" font="Arial"> Kamemura,N.</style></author><author><style face="normal" font="Arial"> Hiroshi,K.</style></author><author><style face="normal" font="Arial"> Fukao,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, , Graduate School of Medicine, Gifu University, Gifu, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Detection of ovomucoid-specific low-affinity IgE in infants and its relationship to eczema</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="361" start="355">355-361</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific low-affinity IgE was previously detected in cord blood by a highly sensitive densely carboxylated protein (DCP) chip, but not by ImmunoCAP. Here, we investigated the presence of low-affinity IgE during the early life of infants and observed its relationship with eczema. METHODS: We conducted a birth cohort study, collecting sera at birth and 6 (6M) and 14 months (14M) of age (n=110). We monitored the ovomucoid (OM)- and egg white (EW)-specific-IgE (sIgE) by ImmunoCAP or DCP-chip and analyzed the antigen-affinity of sIgE by binding inhibition assays in the presence or absence of a mild chaotropic agent, diethyl amine (DEA). The low- and high-affinity OM-sIgEs and sensitization risk factors were analyzed by a multivariate logistic analysis. RESULTS: The OM-sIgE measured by DCP-chip significantly correlated with that measured by ImmunoCAP, but some samples assessed as OM-sIgE-positive by DCP-chip were considered OM-sIgE-negative by ImmunoCAP. Binding inhibition analysis after DEA treatment was performed for participants judged as OM-sIgE-positive by DCP-chip at 14M. The group assessed as negative for OM- and EW-sIgE by ImmunoCAP at 6M and 14M showed a larger binding inhibition curve shift after DEA treatment than did the group assessed as positive at these times, indicating the presence of low-affinity sIgE antibodies at 14M. The logistic regression analysis found that persistent eczema from 6M to 14M is a significant risk factor for developing high-affinity, but not low-affinity, sIgE. CONCLUSIONS: Human infant peripheral blood contains allergen-specific low-affinity sIgE. Persistent eczema is related to the development of high-affinity, but not low-affinity, IgE. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12702</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28140473">PM:28140473</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170131-KawamotoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170131-KawamotoN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Kawamoto N</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12702</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cousin,M.</style></author><author><style face="normal" font="Arial"> Verdun,S.</style></author><author><style face="normal" font="Arial"> Seynave,M.</style></author><author><style face="normal" font="Arial"> Vilain,A.C.</style></author><author><style face="normal" font="Arial"> Lansiaux,A.</style></author><author><style face="normal" font="Arial"> Decoster,A.</style></author><author><style face="normal" font="Arial"> Sauvage,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service d'Allergologie et d'Education Therapeutique, Hopital Saint-Vincent de Paul, Boulevard de Belfort - BP 387, 59020, Lille Cedex, France</style></auth-address><titles><title><style face="normal" font="Arial">Phenotypical characterization of peanut allergic children with differences in cross-allergy to tree nuts and other legumes</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="250" start="242">242-250</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-allergy</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergy in children is often associated with allergies to tree nuts and/or legumes. The aim of the present study was to analyze in cluster a cohort of children allergic to peanuts and assessed for cross-reactivity to nuts and legumes and to identify different phenotypes. METHODS: We included retrospectively 317 children with peanut allergy evaluated at the Allergy Unit of the Saint Vincent Hospital of Lille in the last 12 years. A complete work-up for peanut allergy and nuts and legumes was carried out for each patient. A hierarchical agglomerative clustering method was used to search for clusters of individuals in the evaluated cohort. RESULTS: Cross-allergy to TN and/or other legumes was identified in 137 patients (43.2%), atopic dermatitis being a major risk factor (adjusted OR = 16 [95%CI: 7.4-37]; p&lt;0.001). Three phenotypes emerged from cluster analysis. Cluster 1 (72 patients) is characterized by high level of rAra h 2, low threshold reactive doses for peanut and high proportion of asthma; Cluster 2 (93 patients) is characterized by high threshold reactive doses for peanut and the lowest proportion of cross-allergy to TN and/or legumes; Cluster 3 (152 patients) has a high risk of cross-allergy to TN and/or legumes and most patients suffer from eczema. CONCLUSIONS: The three phenotypes highlighted by the present study could be useful to identify children with high risk of cross-allergic reaction to TNs and legumes early after PA diagnosis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12698</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28140482">PM:28140482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170131-CousinM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170131-CousinM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Cousin M</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12698</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wen,S.</style></author><author><style face="normal" font="Arial"> Zhou,G.</style></author><author><style face="normal" font="Arial"> Song,S.</style></author><author><style face="normal" font="Arial"> Xu,X.</style></author><author><style face="normal" font="Arial"> Voglmeir,J.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Zhao,F.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Li,L.</style></author><author><style face="normal" font="Arial"> Yu,X.</style></author><author><style face="normal" font="Arial"> Bai,Y.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Meat Processing and Quality Control, MOE, Synergetic Innovation Center of Food Safety and Nutrition, Jiangsu Innovation Center of Meat Production and Processing, Key Laboratory of Animal Products Processing, MOA, Synergetic Innovation Center of Meat Processing and Quality Control, Nanjing Agricultural University, Nanjing, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Discrimination of in vitro and in vivo digestion products of meat proteins from pork, beef, chicken, and fish</style></title><secondary-title><style face="normal" font="Arial">Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proteomics</style></full-title></periodical><pages end="3698" start="3688">3688-3698</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">21</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Cattle</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Chickens</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography,Liquid</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> Dietary Proteins</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fishes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro digestibility</style></keyword><keyword><style face="normal" font="Arial"> in vitro digestion</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> In vivo digestion</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Molecular Sequence Data</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Proteins</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Pepsin A</style></keyword><keyword><style face="normal" font="Arial"> Pepsin digestion</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequence Alignment</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry,Mass,Matrix-Assisted Laser Desorption-Ionization</style></keyword><keyword><style face="normal" font="Arial"> Swine</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="11" Year="2015">2015/11</year></dates><abstract><style face="normal" font="Arial">In vitro digestion products of proteins were compared among beef, pork, chicken, and fish. Gastric and jejunal contents from the rats fed these meat proteins were also compared. Cooked pork, beef, chicken, and fish were homogenized and incubated with pepsin alone or followed by trypsin. The digestion products with molecular weights of less than 3000 Da were identified with MALDI-TOF-MS and nano-LC-MS/MS. Gastric and jejunal contents obtained from the rats fed the four meat proteins for 7 days were also analyzed. After pepsin digestion, pork, and beef samples had a greater number of fragments in similarity than chicken and fish samples, but the in vitro digestibility was the greatest (p &lt; 0.05) for pork and the smallest for beef samples. After trypsin digestion, the species differences were less pronounced (p > 0.05). A total of 822 and 659 peptides were identified from the in vitro and in vivo digestion products, respectively. Our results could interpret for the differences in physiological functions after the ingestion of different species of meat</style></abstract><notes><style face="normal" font="Arial">DA - 20151027IS - 1615-9861 (Electronic)IS - 1615-9853 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Dietary Proteins)RN - 0 (Muscle Proteins)RN - EC 3.4.21.4 (Trypsin)RN - EC 3.4.23.1 (Pepsin A)SB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/pmic.201500179</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26227428">PM:26227428</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proteomics\2015-15-3688-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proteomics\2015-15-3688-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151027, Wen S</style></custom2><misc3><style face="normal" font="Arial">10.1002/pmic.201500179</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Diaz,S.N.</style></author><author><style face="normal" font="Arial"> Arias-Cruz,A.</style></author><author><style face="normal" font="Arial"> Rivero-Arias,D.M.</style></author><author><style face="normal" font="Arial"> Partida-Ortega,A.B.</style></author><author><style face="normal" font="Arial"> Elizondo-Villarreal,B.</style></author><author><style face="normal" font="Arial"> Ibarra-Chavez,J.A.</style></author><author><style face="normal" font="Arial"> Ramos-Valencia,L.</style></author><author><style face="normal" font="Arial"> Monge-Ortega,O.P.</style></author><author><style face="normal" font="Arial"> Macouzet-Sanchez,C.</style></author><author><style face="normal" font="Arial"> Salinas-Diaz,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidad Autonoma de Nuevo Leon. Centro Regional de Alergia e Inmunologia Clinica, Monterrey, Nuevo Leon, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">[Cross-reactivity in allergic fungal sinusitis. Case report]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="319" start="316">316-319</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic mucin</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Endoscopic surgery</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Helminthosporium</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mucin</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Silver Staining</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The presence of allergic mucin in allergic fungal sinusitis (AFS) is a manifestation that identifies it as a hypersensitivity process. AFS has a phenomenon of cross-reactivity to IgE-bound proteins having at least two shared epitopes. CLINICAL REPORT: A 13-year-old male with nasal obstructive symptoms of three years of evolution. An obstructive mass was identified in the sinuses through physical examination and CT. In endoscopic surgery, the left nostril polyp was identified with the macroscopic appearance of allergic mucin; the polyp was resected. Final histopathological examination using periodic acid-Schiff and Grocott's methenamine silver staining indicated Aspergillus. Two weeks after surgery, percutaneous tests showed sensitization to Alternaria, Helminthosporium sativum, and Deramatophagoides farianae with negativity to Aspergillus fumigatus. CONCLUSIONS: The absence of significant titers of specific IgE antibodies to Aspergillus fumigatus was the evidence that the hypersensitivity response was triggered by a pathogen other than that isolated in histopathological study, which coupled with positive tests for other fungi may be explained by the cross-reactivity phenomenon in a phenomenon of likely hypersensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleSB - IMCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27560920">PM:27560920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-316-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-316-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Gonzalez-Diaz SN</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Egea,E.</style></author><author><style face="normal" font="Arial"> Garavito,G.</style></author><author><style face="normal" font="Arial"> Fang,L.</style></author><author><style face="normal" font="Arial"> Mendoza,D.L.</style></author><author><style face="normal" font="Arial"> Escamilla,J.M.</style></author><author><style face="normal" font="Arial"> De Los Rios,E.</style></author><author><style face="normal" font="Arial"> Dennis,R.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidad del Norte, Division Ciencias de la Salud, Grupo de Investigacion en Inmunologia y Biologia Molecular, Barranquilla, Colombia. eegea@uninorte.edu.co</style></auth-address><titles><title><style face="normal" font="Arial">[Influence of serum levels of vitamin D on IgE response in schoolchildren with asthma in poor communities]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="269" start="252">252-269</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Ascaris</style></keyword><keyword><style face="normal" font="Arial"> Ascaris lumbricoides</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Helminthiasis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Poverty</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a common disease in the world and vitamin D (Vit-D) has been associated with the presence and severity of this disease. OBJECTIVE: To establish the association between levels of Vit-D and IgE response in schoolchildren with asthma living in four cities in Colombia. METHODS: Case-control study in 1340 schoolchildren (687 asthmatic and 653 controls) from communities in extreme poverty in Barranquilla, Cartagena, Santa Marta, and Monteria. Serum concentrations of Vit-D, total IgE, and anti-Dermatophagoides farinae, Periplaneta americana, and Ascaris lumbricoides (AL) specific IgE were measured. RESULTS: Controls reported higher concentrations of Vit-D [61.9 +/- 28.4 ng/mL] than cases [53 +/- 23.3 ng / mL] (p &lt; 0.05). Total IgE was higher in cases (p &lt; 0.05). Only anti-AL IgE showed a clear difference: in controls, optical density was 0.27 +/- 0.25; in cases, 0.22 +/- 0.24 (p &lt; 0.05). Vit-D showed differences between cases and controls in each population. CONCLUSIONS: An association could not be demonstrated between Vit-D deficiency and asthma, as total IgE was elevated in patients and controls. The results suggest that Vit-D influences the specif IgE response in poor asthmatic children in areas endemic for helminthiasis</style></abstract><notes><style face="normal" font="Arial">DA - 20160826IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleSB - IMCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27560913">PM:27560913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-252-69.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-252-69.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160826, Egea E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alcantara-Montiel,J.C.</style></author><author><style face="normal" font="Arial"> Vega-Torres,B.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidad Nacional Autonoma de Mexico, Facultad de Estudios Superiores Zaragoza, Facultad de Medicina. Ciudad de Mexico, Mexico. jcalcantara@comunidad.unam.mx</style></auth-address><titles><title><style face="normal" font="Arial">[Hyper-IgE syndrome. Lessons from function and defects of STAT-3 or DOCK-8]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="396" start="385">385-396</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abscess</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DOCK8</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otitis</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> Scoliosis</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> STAT-3</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Zaragoza</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">In the classification of primary immunodeficiencies, hyper-IgE syndrome, identified with OMIM code # 147060 in the Online Mendelian Inheritance in Man catalog, belongs to the group of syndromes associated with combined immunodeficiencies. It is characterized by elevated levels of IgE, eosinophilia, recurrent skin abscesses, pneumonia, lung parenchyma lesions, recurrent infections, rashes in newborns, eczema, sinusitis, otitis, and mucocutaneous candidiasis. Hyper-IgE syndrome can be transmitted by autosomal dominant or autosomal recessive modes of inheritance. Hyper-IgE syndrome in its dominant form includes non-immunological manifestations like characteristic facies, pathological dentition, scoliosis, bone disorders, and joint hyperextensibility. The reported cause of the dominant form is the loss of function of the signal transducer and activator of transcription 3 (STAT-3, with MIM # 102582). Mutations in dedicator of cytokines 8 (DOCK-8) is the most common cause of the autosomal recessive form of hyper-IgE syndrome</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticlePT - English AbstractCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795219">PM:27795219</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-385-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-385-96.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Alcantara-Montiel JC</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez,J.</style></author><author><style face="normal" font="Arial"> Sanchez,A.</style></author><author><style face="normal" font="Arial"> Cardona,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidad de Antioquia, Grupo de Alergologia Clinica y Experimental, IPS Universitaria. Medellin, Colombia.</style></auth-address><titles><title><style face="normal" font="Arial">[Economic consequences in real life of allergen immunotherapy in asthma, rhinitis and dermatitis]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="333" start="323">323-333</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Drug treatment</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy has proved effective in the treatment of various allergies, but whether the clinical benefits outweigh the economic costs has been little evaluated. OBJECTIVE: To explore the economic consequences of immunotherapy in asthma, rhinitis and dermatitis. METHODS: Descriptive study. Patients with at least 18 months' follow-up were selected, whose medical history allowed evaluation of drugs received, manner of use, check-ups, treatment changes, reasons for these, and so on. Patients were classified according to whether they received drug treatment + immunotherapy (active group) or drug therapy alone (control group). RESULTS: 1848 patients were included: 648 in the active group and 1200 in the control. Immunotherapy increased the cost of treatment during the first few months, but after 9 to 12 months drug treatment decreased significantly compared to the control group. In patients with asthma or various diseases, immunotherapy reduced costs of treatment (p &lt; 0.05). The active group saw fewer relapses at 18 months (p &lt; 0.05). CONCLUSION: Allergen immunotherapy allows the sustained reduction in drug treatment, with medium-term financial savings for the patient and the health system</style></abstract><notes><style face="normal" font="Arial">DA - 20161031IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticlePT - English AbstractCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795212">PM:27795212</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-323-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2016-63-323-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161031, Sanchez J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de la Fuente Tornero,E.</style></author><author><style face="normal" font="Arial"> Vega Castro,A.</style></author><author><style face="normal" font="Arial"> Alvarez de Sierra,H.P.</style></author><author><style face="normal" font="Arial"> Balaguer Recena,J.</style></author><author><style face="normal" font="Arial"> Zaragoza Casares,S.C.</style></author><author><style face="normal" font="Arial"> Serrano Baylin,F.M.</style></author><author><style face="normal" font="Arial"> Gallardo Culebradas,P.</style></author><author><style face="normal" font="Arial"> Amoros,A.B.</style></author><author><style face="normal" font="Arial"> Rodriguez,F.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Departments of *Anesthesiology, daggerAllergy, and section signCardiology, Hospital Universitario de Guadalajara, Castilla-La Mancha, Spain; double daggerDepartment of Surgery, Hospital Universitario Quironsalud Madrid, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Kounis Syndrome During Anesthesia: Presentation of Indolent Systemic Mastocytosis: A Case Report</style></title><secondary-title><style face="normal" font="Arial">AA Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">AA Case Rep</style></abbr-1></periodical><pages end="228" start="226">226-228</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> indolent systemic mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> intraoperative anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Ischemia</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Ischemia</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="8" Month="2" Year="2017">2017/2/8</year></dates><abstract><style face="normal" font="Arial">Mastocytosis comprises a heterogeneous group of disorders characterized by mast cell accumulation and proliferation in distinct organs. Kounis syndrome is defined as the concurrence of acute coronary syndromes with mast cell activation in a setting of allergic or hypersensitivity reactions. This is the first reported case of an intraoperative Kounis syndrome as the onset of an indolent systemic mastocytosis probably triggered by succinylated gelatin infusion during general anesthesia. The presentation of this case is intended to contribute to the knowledge of mastocytosis and Kounis syndrome at the time of diagnostic workup during intraoperative anaphylaxis or myocardial ischemia</style></abstract><notes><style face="normal" font="Arial">DA - 20170209IS - 2325-7237 (Electronic)IS - 2325-7237 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1213/XAA.0000000000000474</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28181948">PM:28181948</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\AA Case Rep\20170209-delaFuenteTorneroE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\AA Case Rep\20170209-delaFuenteTorneroE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170209, de la Fuente Tornero E</style></custom2><misc3><style face="normal" font="Arial">10.1213/XAA.0000000000000474</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mermiri,D.T.</style></author><author><style face="normal" font="Arial"> Lappa,T.</style></author><author><style face="normal" font="Arial"> Papadopoulou,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergology and Pulmonology Unit, Penteli's Children Hospital, Palaia Penteli, Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Review suggests that the immunoregulatory and anti-inflammatory properties of allergenic foods can provoke oral tolerance if introduced early to infants' diets</style></title><secondary-title><style face="normal" font="Arial">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Paediatr</style></abbr-1></periodical><pages end="726" start="721">721-726</pages><volume><style face="normal" font="Arial">106</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weaning</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="Arial">For years, the advice was to postpone introducing allergenic foods, in order to prevent food allergies. However, food allergies have escalated rather than declined and our review of the latest epidemiological, immunological and nutritional research suggests that early weaning practices may be beneficial. The most allergenic foods, such as fish, eggs and peanuts, have proved to be inherently rich in tolerogenic substances that can play a significant role in preventing allergies. CONCLUSION: We found evidence that the immunoregulatory and anti-inflammatory properties of allergenic foods can provoke oral tolerance if introduced early to both low-risk and high-risk infants. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1111/apa.13778</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28173607">PM:28173607</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Paediatr\20170207-MermiriDT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Paediatr\20170207-MermiriDT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Mermiri DT</style></custom2><misc3><style face="normal" font="Arial">10.1111/apa.13778</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Combalia,A.</style></author><author><style face="normal" font="Arial"> Fernandez-Sartorio,C.</style></author><author><style face="normal" font="Arial"> Aguilera,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Department, Hospital Clinic de Barcelona, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Refractory solar urticaria successfully treated with omalizumab with normalization of phototest</style></title><secondary-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></full-title></periodical><pages end="594" start="593">593-594</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="3" Month="2" Year="2017">2017/2/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ad.2016.11.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28168968">PM:28168968</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Actas Dermosifiliogr\20170207-CombaliaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Actas Dermosifiliogr\20170207-CombaliaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Combalia A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ad.2016.11.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klis,K.</style></author><author><style face="normal" font="Arial"> Wronka,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anthropology, Institute of Zoology, Jagiellonian University, 9 Gronostajowa Street, 30-387, Cracow, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Association of Estrogen-Related Traits with Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Adv Exp Med Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Exp Med Biol</style></full-title></periodical><pages end="78" start="71">71-78</pages><volume><style face="normal" font="Arial">968</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> estrogen</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hip</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Menarche</style></keyword><keyword><style face="normal" font="Arial"> Menstrual Cycle</style></keyword><keyword><style face="normal" font="Arial"> Menstruation</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">Estrogen's role in allergic diseases has recently been of considerable interest. The present article seeks to determine the relationship between estrogen-dependent traits and allergic rhinitis. The following traits were considered: digit ratio, age at menarche, regularity of menstrual cycles, and the waist to hip ratio. The study consisted of surveys and measurement data collected from 768 female university undergraduates. One hundred and sixty eight undergraduates (21.9%) had been diagnosed with allergic rhinitis. The results of logistic regression show that in women with a high digit ratio, indicating exposure to a higher estrogen level in the prenatal period, the risk of allergic rhinitis was almost twice as high as that in those with an average value of the ratio. The difference in the digit ratio was greater for the right than left hand. A significantly higher risk of allergic rhinitis was also observed in women who experienced first menstruation at a younger age. No differences in risk of allergic rhinitis were noted due to general obesity, abdominal obesity, or irregularity of menstrual cycles. We conclude that a higher digit ratio is suggestive of a propensity to allergies in adulthood plausibly having to do with greater exposure to estrogen at early stages of ontogenetic development</style></abstract><notes><style face="normal" font="Arial">DA - 20170209IS - 0065-2598 (Print)IS - 0065-2598 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/5584_2016_190</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28181196">PM:28181196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Exp Med Biol\2017-968-71-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Exp Med Biol\2017-968-71-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170209, Klis K</style></custom2><misc3><style face="normal" font="Arial">10.1007/5584_2016_190</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawashima,S.</style></author><author><style face="normal" font="Arial"> Thibaudon,M.</style></author><author><style face="normal" font="Arial"> Matsuda,S.</style></author><author><style face="normal" font="Arial"> Fujita,T.</style></author><author><style face="normal" font="Arial"> Lemonis,N.</style></author><author><style face="normal" font="Arial"> Clot,B.</style></author><author><style face="normal" font="Arial"> Oliver,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Automated pollen monitoring system using laser optics for observing seasonal changes in the concentration of total airborne pollen</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">The development of a simple and automatic pollen measurement methodology is required to manage allergic problems caused by airborne pollen. We developed a device and algorithm to automatically monitor airborne pollen by using basic laser optics technology. The device measures the sideward and forward scattering intensities of laser light from each particle. Because this device provides detailed temporal variation in the pollen concentration, the dispersal dynamics of airborne pollen can be effectively analyzed. We compared the pollen counts obtained with the automated method and standard Hirst-type method. Scatter-plot graphs were constructed of the forward and sideward scattering intensities of the observed particles. An extract window methodology was used to estimate the concentrations of the major allergenic pollens. The extract window parameters were obtained for major types of allergenic pollen. The results suggest the possibility of developing a device for monitoring several types of airborne pollen simultaneously. We determined the standard extract window to be used for estimating the concentration of all types of airborne pollen together. A field experiment was performed to evaluate the automated monitoring system with the standard extract window. The estimated temporal variation pattern of the total airborne pollen concentration agreed well with the observed temporal variation pattern for the whole pollen season. The pollen monitor was able to estimate the overall features of seasonal changes in the total airborne pollen concentration</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -CO - Japan -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9474-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9474-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170223-KawashimaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170223-KawashimaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Kawashima S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9474-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Plaza,M.P.</style></author><author><style face="normal" font="Arial"> Alcazar,P.</style></author><author><style face="normal" font="Arial"> Velasco-Jimenez,M.J.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Aeroallergens: a comparative study of two monitoring methods</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean Region</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Ole e</style></keyword><keyword><style face="normal" font="Arial"> Ole e 1</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phl p 5</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> Volumetric spore trap</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Olive and grass pollen grains are the major causes of hay fever in the Mediterranean region. A number of samplers and methods have been developed in recent years in order to obtain reliable data regarding airborne allergen concentrations. This paper reports on a detailed comparison of two samplers</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇöCyclone and ChemVol</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çöand on the parameters that could influence their efficiency. Airborne concentrations of two key olive and grass allergens, Ole e 1 and Phl p 5, respectively, were monitored over two years with different weather patterns, 2012 and 2014. Allergenic particles were quantified by ELISA assay, and results were compared with pollen concentrations monitored using a Hirst-type volumetric spore trap over the same study periods. The influence of weather-related parameters on local airborne pollen and allergen concentrations was also analysed. Although a positive correlation was detected between results obtained using the two samplers during the pollen season, results for the cumulative annual Allergen Index varied considerably. The two samplers revealed a positive correlation between pollen concentrations and both minimum temperature during the warmer year (2012) and maximum temperature during the cooler year (2014); a negative significant correlation was observed in both cases with rainfall and relative humidity. In summary, although some differences were observed between the two samplers studied, both may be regarded as suitable for allergen detection</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9475-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9475-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170223-PlazaMP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170223-PlazaMP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Plaza MP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9475-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,C.</style></author><author><style face="normal" font="Arial"> Yu,S.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Xu,W.</style></author><author><style face="normal" font="Arial"> Ge,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Tongji Hospital, Tongji University, Shanghai 200065, China</style></auth-address><titles><title><style face="normal" font="Arial">Changes in IL-4 and IL-13 expression in allergic-rhinitis treated with hydrogen-rich saline in guinea-pig model</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="355" start="350">350-355</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Medical gas hydrogen (H2) has a special role in airway inflammation; however, the effect of H2 on allergic rhinitis (AR) remains unclear. This study explored the possible roles of H2 on the pathogenesis of AR and observed the influences of H2 on cytokines IL-4 and IL-13. METHODS: An AR guinea pig model was established by nasal ovalbumin sensitisation. Eighteen guinea pigs were divided into three groups, namely, saline control, AR-sensitised, and hydrogen-rich saline (HRS)-treated groups, with each group having six guinea pigs. The frequencies of sneezing and scratching were recorded. The IgE level and cytokine (IL-4 and IL-13) levels in the serum were measured. The expression levels of IL-4 and IL-13 mRNA and protein in the nasal mucosa were also determined by real-time reverse transcriptase-polymerase chain reaction and Western blot. We also observed the infiltration of cytokine (IL-4 and IL-13) in nasal mucosa by immunofluorescence. RESULTS: The frequencies of sneezing and scratching, as well as the levels of IgE, IL-4, and IL-13, in the serum were higher in the AR group than in the control group (p&lt;0.01), whereas all these parameters were decreased significantly after HRS treatment (p&lt;0.05). The expression levels of IL-4 and IL-13 mRNA and protein in the nasal mucosa were also lower in guinea pigs treated with HRS than those in the AR group (p&lt;0.05). CONCLUSIONS: HRS could affect anti-inflammation in AR and decreased the expression of IL-4 and IL-13</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28215576">PM:28215576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170220-ZhaoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170220-ZhaoC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Zhao C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ercan,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Immunology and Allergy, Dr Sami Ulus Obstetrics, Children's Health and Diseases Training and Research Hospital, Ankara, 06080, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Corticosteroid use in urticaria multiforme cases</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="489" start="488">488-489</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2016.11.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216057">PM:28216057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170220-ErcanN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170220-ErcanN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Ercan N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2016.11.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okada,Y.</style></author><author><style face="normal" font="Arial"> Akasawa,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of General Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Niijima Clinic, Tokyo, Japan; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">A successful case of egg allergy tolerance achieved at a local clinic</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="506" start="504">504-506</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.01.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216056">PM:28216056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170220-OkadaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170220-OkadaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Okada Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.01.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valero,A.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author><author><style face="normal" font="Arial"> Davila,I.</style></author><author><style face="normal" font="Arial"> Delgado,J.</style></author><author><style face="normal" font="Arial"> Dominguez-Ortega,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pneumology and Allergy Department, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS; CIBERES; Hospital Clinic, Barcelona</style></auth-address><titles><title><style face="normal" font="Arial">Allergic respiratory disease: different allergens, different symptoms</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1316" start="1305">1305-1316</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergens</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Spanish population is rather homogeneous in its genetic and socio-cultural characteristics, but allergen sensitization shows wide geographical variations. We aimed at assessing whether sensitization to different allergens in the diverse geographical areas induced different clinical and quality of life characteristics in adult patients with a first-time diagnosis of rhinitis and/or asthma. METHODS: Two sequential, identically designed studies were carried out to evaluate such associations (PERFILAR I and II). PERFILAR II was an extension of PERFILAR I with additional allergens being included. Both phases were epidemiological, descriptive, cross-sectional, non-intervention multicenter studies. Participants were required to have lived for at least the last 2 years in the geographical zone. Asthma control assessment was based on ACQ5. Health-related quality of life was evaluated with validated scales for rhinitis (ESPRINT-15) and asthma (Mini-AQLQ). Skin prick tests were used to identify sensitization to involved allergens. RESULTS: 301 physicians recruited 2711 patients for PERFILAR I+II. Sensitization to allergens was significantly different in patients with rhinitis with/without asthma. Seasonal allergens were associated with rhinitis, a longer time to asthma development, and more severe and commonly intermittent rhinitis. HDM were associated with more common rhinitis, and Alternaria was associated with asthma. The study confirms an association of geographical areas with relevant allergens and allergic clinical picture. CONCLUSION: Different types of aeroallergens and specific sensitization profiles are associated with different allergic clinical pictures (rhinitis with/without asthma), different clinical symptoms and severity. This could have implications to predict later clinical course and to select appropriate management approaches. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28208220">PM:28208220</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170216-ValeroA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170216-ValeroA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Valero A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13141</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pineiro-Hermida,S.</style></author><author><style face="normal" font="Arial"> Gregory,J.A.</style></author><author><style face="normal" font="Arial"> Lopez,I.P.</style></author><author><style face="normal" font="Arial"> Torrens,R.</style></author><author><style face="normal" font="Arial"> Ruiz-Martinez,C.</style></author><author><style face="normal" font="Arial"> Adner,M.</style></author><author><style face="normal" font="Arial"> Pichel,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centro de Investigacion Biomedica de la Rioja (CIBIR), Fundacion Rioja Salud, Logrono, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Attenuated airway hyperresponsiveness and mucus secretion in HDM exposed Igf1r-deficient mice</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1326" start="1317">1317-1326</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a common chronic lung disease characterized by airflow obstruction, airway hyperresponsiveness (AHR) and inflammation. IGFs have been reported to play a role in asthma but little is known about how the Insulin-like Growth Factor 1 Receptor (IGF1R) affects asthma pathobiology. METHODS: Female Igf1r-deficient and control mice were intranasally challenged with house dust mite (HDM) extract or PBS five days per week for four weeks. Lung function measurements, and bronchioalveolar lavage fluid (BALF), serum and lungs were collected on day 28 for further cellular, histological and molecular analysis. RESULTS: Following HDM exposure, the control mice responded with a marked AHR and airway inflammation. The Igf1r-deficient mice exhibited an increased expression of the IGF system and surfactant genes, which were decreased in a similar manner for control and Igf1r-deficient mice after HDM exposure. On the other hand, the Igf1r-deficient mice exhibited no AHR, and a selective decrease of blood and BALF eosinophils, lung Il13 levels, collagen and smooth muscle, as well as a significant depletion of goblet cell metaplasia and mucus secretion markers after HDM exposure. The Igf1r-deficient mice displayed a distinctly thinner epithelial layer than control mice, but this was not altered by HDM. CONCLUSIONS: Herein, we demonstrate by the first time that the Igf1r plays an important role in murine asthma, mediating both AHR and mucus secretion after HDM exposure. Thus, our study identifies IGF1R as a potential therapeutic target, not only for asthma but also for hypersecretory airway diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28207927">PM:28207927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170216-PineiroHermidaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170216-PineiroHermidaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Pineiro-Hermida S</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13142</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Quinn,K.D.</style></author><author><style face="normal" font="Arial"> Schedel,M.</style></author><author><style face="normal" font="Arial"> Nkrumah-Elie,Y.</style></author><author><style face="normal" font="Arial"> Joetham,A.</style></author><author><style face="normal" font="Arial"> Armstrong,M.</style></author><author><style face="normal" font="Arial"> Cruickshank-Quinn,C.</style></author><author><style face="normal" font="Arial"> Reisdorph,R.</style></author><author><style face="normal" font="Arial"> Gelfand,E.W.</style></author><author><style face="normal" font="Arial"> Reisdorph,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, 12850 E. Montview Blvd, Aurora, CO 80045</style></auth-address><titles><title><style face="normal" font="Arial">Dysregulation of Metabolic Pathways in a Mouse Model of Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1337" start="1327">1327-1337</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> neurotrophin</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Proline</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a complex lung disease resulting from the interplay of genetic and environmental factors. To understand the molecular changes that occur during the development of allergic asthma without genetic and environmental confounders, an experimental model of allergic asthma in mice was used. Our goals were to (1) identify changes at the small molecule level due to allergen exposure, (2) determine perturbed pathways due to disease, and (3) determine whether small molecule changes correlate with lung function. METHODS: In this experimental model of allergic asthma, matched bronchoalveolar lavage (BAL) fluid and plasma were collected from three groups of C57BL6 mice (control vs sensitized and/or challenged with ovalbumin, n=3-5/group) 6h, 24h, and 48h after the last challenge. Samples were analyzed using liquid chromatography mass spectrometry-based metabolomics. Airway hyperresponsiveness (AHR) measurements and differential cell counts were performed. RESULTS: In total, 398 and 368 dysregulated metabolites in the BAL fluid and plasma of sensitized and challenged mice were identified, respectively. These belonged to four, interconnected pathways relevant to asthma pathogenesis: sphingolipid metabolism (p=6.6x10-5 ), arginine and proline metabolism (p=1.12x10-7 ), glycerophospholipid metabolism (p=1.3x10-10 ), and the neurotrophin signaling pathway (p=7.0x10-6 ). Furthermore, within the arginine and proline metabolism pathway, a positive correlation between urea-1-carboxyate and AHR was observed in plasma metabolites, while ornithine revealed a reciprocal effect. In addition, agmatine positively correlated with lung eosinophilia. CONCLUSION: These findings point to potential targets and pathways that may be central to asthma pathogenesis and can serve as novel therapeutic targets. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170218IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13144</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28213886">PM:28213886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170218-QuinnKD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170218-QuinnKD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170218, Quinn KD</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13144</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ashley,S.E.</style></author><author><style face="normal" font="Arial"> Tan,H.T.</style></author><author><style face="normal" font="Arial"> Vuillermin,P.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Tang,M.L.</style></author><author><style face="normal" font="Arial"> Koplin,J.</style></author><author><style face="normal" font="Arial"> Gurrin,L.C.</style></author><author><style face="normal" font="Arial"> Lowe,A.</style></author><author><style face="normal" font="Arial"> Lodge,C.</style></author><author><style face="normal" font="Arial"> Ponsonby,A.L.</style></author><author><style face="normal" font="Arial"> Molloy,J.</style></author><author><style face="normal" font="Arial"> Martin,P.</style></author><author><style face="normal" font="Arial"> Matheson,M.C.</style></author><author><style face="normal" font="Arial"> Saffery,R.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Ellis,J.A.</style></author><author><style face="normal" font="Arial"> Martino,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Murdoch Childrens Research Institute, Royal Children's Hospital, Australia</style></auth-address><titles><title><style face="normal" font="Arial">The skin barrier function gene SPINK5 is associated with challenge proven IgE-mediated food allergy in infants</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1364" start="1356">1356-1364</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dietary antigens</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Peptidase</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier function</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TEWL</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> transepidermal water loss</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A defective skin barrier is hypothesised to be an important route of sensitisation to dietary antigens, and may lead to food allergy in some children. Missense mutations in the Serine peptidase inhibitor kazal type 5 (SPINK5) skin barrier gene have previously been associated with allergic conditions. OBJECTIVE: To determine whether genetic variants in and around SPINK5 are associated with IgE mediated food allergy. METHOD: We genotyped 71 'tag' single nucleotide polymorphisms (tag-SNPs) within a region spanning ~263 kilobases (kb) including SPINK5 (~61kb) in n=722 (n=367 food allergic, n=199 food sensitised, tolerant and n=156 non-food allergic controls) 12-month infants (discovery sample) phenotyped for food allergy with the gold standard oral food challenge (OFC). Transepidermal water loss (TEWL) measures were collected at 12-months from a subset (n=150) of these individuals. SNPs were tested for association with food allergy using the Cochran-Mantel-Haenszel test adjusting for ancestry strata. Associations analyses were replicated in an independent sample group derived from four paediatric cohorts, total n=533 (n=203 food allergic, n=330 non-food allergic), mean age 2.5 years, with food allergy defined by either clinical history of reactivity, 95% positive predictive value (PPV) or challenge, corrected for ancestry by principal components. RESULTS: SPINK5 variant rs9325071 (AG) was associated with challenge proven food allergy in the discovery sample (P=0.001 | OR=2.95 | CI=1.49-5.83). This association was further supported by replication (P=0.007 | OR=1.58 | CI=1.13-2.20) and by meta-analysis (P=0.0004 | OR=1.65). Variant rs9325071 is associated with decreased SPINK5 gene expression in the skin in publicly available genotype-tissue expression data, and we generated preliminary evidence for association of this SNP with elevated TEWL also. CONCLUSIONS: We report, for the first time, association between SPINK5 variant rs9325071 and challenge-proven IgE-mediated food allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170218IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13143</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28213955">PM:28213955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170218-AshleySE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170218-AshleySE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170218, Ashley SE</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13143</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wjst,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Linking vitamin D, the microbiome and allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="330" start="329">329-330</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161228IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - NewsCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13116</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28029174">PM:28029174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\2017-72-329-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\2017-72-329-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161228, Wjst M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13116</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lingblom,C.</style></author><author><style face="normal" font="Arial"> Kappi,T.</style></author><author><style face="normal" font="Arial"> Bergquist,H.</style></author><author><style face="normal" font="Arial"> Bove,M.</style></author><author><style face="normal" font="Arial"> Arkel,R.</style></author><author><style face="normal" font="Arial"> Saalman,R.</style></author><author><style face="normal" font="Arial"> Wenneras,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Differences in eosinophil molecular profiles between children and adults with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1414" start="1406">1406-1414</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic esophagitis (EoE) afflicts both children and adults. It has been debated whether pediatric and adult EoE represent different disease entities. The objectives of this study were to determine if the blood eosinophil molecular pattern of children with EoE is: 1) distinct from that of healthy children; and 2) different from that of adults with EoE. METHODS: Blood eosinophils from children and adults with EoE, and healthy controls, were analyzed with flow cytometry regarding levels of CD23, CD44, CD54, CRTH2, FOXP3 and galectin-10. Eosinophil FOXP3 and galectin-10 mRNA levels were determined by qPCR. The data was analyzed by using a multivariate method of pattern recognition. RESULTS: An eosinophil molecular pattern capable of distinguishing children with EoE from control children was identified. A smaller fraction of eosinophils from children with EoE expressed CD44 and a larger fraction expressed CRTH2 than the controls. Eosinophils from children with EoE also had higher levels of galectin-10 mRNA and lower levels of FOXP3 mRNA. The eosinophils from children with EoE had lower levels of surface CD54 and of FOXP3 mRNA compared with the eosinophils from the adult patients. A key finding was the detection in healthy individuals of age-related differences in the levels of several eosinophil markers. CONCLUSIONS: Children with EoE can be distinguished from healthy children based on the molecular patterns of their blood eosinophils. Age-related physiologic differences in eosinophil molecular patterns may partly explain the different blood eosinophil phenotypes in children versus adults with EoE. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13140</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194801">PM:28194801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170214-LingblomC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170214-LingblomC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Lingblom C</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13140</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lok,S.D.</style></author><author><style face="normal" font="Arial"> Davis,B.E.</style></author><author><style face="normal" font="Arial"> Cockcroft,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 2154 235Xgrid.25152.31Department of Internal Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK S7N 0W8 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of allergen sensitization in 1000 adults in Saskatchewan</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="9">9-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> cat ownership</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse sensitization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> ownership</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Saskatchewan</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of sensitization varies geographically based on multiple environmental factors including humidity. The aim of this study was to determine the prevalence of atopy in symptomatic adults. More importantly we aimed to obtain a regional statistic of sensitization to common allergens given Saskatchewan's dry climate. METHODS: One thousand consecutive symptomatic adults were screened for atopy via skin prick test over 10 years (2006-2016) in the Division of Respirology. An atopic screen was performed with twenty common aeroallergens by a single investigator, Dr. D. Cockcroft. A positive test was considered to be a wheal >/=3 mm and markedly positive reactions >/=8 mm were also documented. RESULTS: The prevalence of atopy by means of a positive skin test (>/=3 mm) was 45.5%. The prevalence of one or more markedly positive reactions (>/=8 mm) was 29.5% of the total population. The most frequent sensitization was to cat dander (58.2%), followed by mixed grass (32.1%), and birch (26.8%). Dust mite sensitization was 22.4% and mouse 6.2%. A positive epidemiology screen for cat/grass/mite would have incorporated 82.0% (n = 373) of subjects with positive skin tests. Those who failed the cat/grass/mite screen were mainly sensitized to trees (n = 34), molds (n = 22), weeds (n = 7), and animals (n = 8). CONCLUSIONS: There is a high prevalence of cat sensitization in Saskatchewan, much higher than recorded in other centers internationally. This is likely due to a high proportion of cat ownership. The prevalence of mite sensitization is lower than those mentioned at other centres likely due to Saskatchewan's dry climate. The significance of the rate of markedly positive reactions (>/=8 mm wheal) when compared to humid areas with higher burden of mite is unknown. There is a low prevalence of roach also likely due to the dry climate and mouse sensitization was low but still identified as a significant indoor allergen. A cat/grass/mite screen may be useful with a 82.0% sensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0181-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194190">PM:28194190</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Lok SD</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0181-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simms,E.</style></author><author><style face="normal" font="Arial"> Foster,G.</style></author><author><style face="normal" font="Arial"> Arias,K.</style></author><author><style face="normal" font="Arial"> Larche,M.</style></author><author><style face="normal" font="Arial"> Freitag,T.</style></author><author><style face="normal" font="Arial"> Walker,T.</style></author><author><style face="normal" font="Arial"> Goncharova,S.</style></author><author><style face="normal" font="Arial"> Marrin,A.</style></author><author><style face="normal" font="Arial"> Freitag,A.</style></author><author><style face="normal" font="Arial"> Jordana,M.</style></author><author><style face="normal" font="Arial"> Waserman,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0004 1936 8227grid.25073.33Michael G. DeGroote School of Medicine, St Joseph's Hospital L314, McMaster University, 50 Charlton Avenue East, Hamilton, ON L8N 4A6 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012-2015</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="10">10-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decision Making</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut sensitization does not necessarily indicate clinical peanut allergy, and uncertainty as to whether or not there is true peanut allergy can lead to increased anxiety and decreased quality of life for patients and their families. The gold standard for diagnosing clinical peanut allergy is the oral food challenge, but this method is time-consuming and can cause severe allergic reactions. It would therefore be beneficial to develop a tool for predicting clinical peanut allergy in peanut-sensitized individuals whose peanut allergy status is unknown so as to better determine who requires an oral food challenge for diagnosis. METHODS: Two separate studies were conducted. In Study 1, we recruited 100 participants from the allergy clinic at McMaster University and community allergy outpatient clinics in the greater Hamilton area. We examined 18 different variables from participants and used univariate and multivariable logistic regression analysis to determine how well these variables, singly and in combination, were able to predict clinical peanut allergy status. In Study 2, we conducted a retrospective chart review of a second cohort of 194 participants to investigate the reproducibility of our findings. This was a matched case-control study where 97 peanut-allergic participants were gender- and age-matched to 97 non-allergic control participants. RESULTS: Peanut skin prick test wheal size was the best predictor of clinical peanut allergy in both study cohorts. For every 1 mm increase in wheal size, the odds ratio of an individual having clinical peanut allergy was 2.36 in our first cohort and 4.85 in our second cohort. No other variable approached the predictive power of wheal size. CONCLUSIONS: Peanut skin prick test wheal size is a robust predictor of clinical peanut reactivity. The findings of this study may be useful in guiding clinician decision-making regarding peanut allergy diagnostics</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0179-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194191">PM:28194191</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Simms E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0179-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hildebrand,K.J.</style></author><author><style face="normal" font="Arial"> Abrams,E.M.</style></author><author><style face="normal" font="Arial"> Vander Leek,T.K.</style></author><author><style face="normal" font="Arial"> Upton,J.E.</style></author><author><style face="normal" font="Arial"> Mack,D.P.</style></author><author><style face="normal" font="Arial"> Kirste,L.</style></author><author><style face="normal" font="Arial"> McCusker,C.</style></author><author><style face="normal" font="Arial"> Kapur,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 2288 9830grid.17091.3eProgram Director Clinical Immunology &amp; Allergy Training Program, Faculty of Medicine, Department of Pediatrics, University of British Columbia, British Columbia Children's Hospital, 4480 Oak Street, Room 1C31B, Vancouver, BC V6H 3V4 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Primum non nocere-first do no harm. And then feed peanut</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="7">7-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy guidelines</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paradigm shift</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Training program</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The Addendum Guidelines for the Prevention of Peanut Allergy in the United States-Report of the NIAID-Sponsored Expert Panel were developed to build on previous food allergy guidelines after several key studies demonstrated the benefit of early introduction of allergenic foods. These landmark studies including the Learning Early about Peanut (LEAP), LEAP-On and Enquiring about Tolerance trials created a paradigm shift in food allergy prevention. The "take home" messages of this guideline include that peanut should be introduced early in the first year of life, and for the majority of infants, peanut can be introduced at home. The only group of infants for which medical assessment is recommended is those with severe eczema, egg allergy or both. Here we summarize the Guideline recommendations, endorsed by the Canadian Society of Allergy and Clinical Immunology, and highlight important aspects relevant to Canadian practitioners</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0180-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194188">PM:28194188</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Hildebrand KJ</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0180-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dai,Q.</style></author><author><style face="normal" font="Arial"> Duan,C.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Yu,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Eye, Ear, Nose &amp; Throat Hospital, Shanghai Key Clinical Disciplines of Otorhinolaryngology, Fudan University, 83 Fenyang Road, Shanghai 200031, China163.com</style></auth-address><titles><title><style face="normal" font="Arial">Effect of nebulized budesonide on decreasing the recurrence of allergic fungal rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Am J Otholaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Am J Otholaryngol</style></abbr-1></periodical><pages end="324" start="321">321-324</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Budesonide inhalation suspension</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The aim of this study was to evaluate the clinical efficacy and the effects on decreasing the recurrence of AFRS (allergic fungal rhinosinusitis) of a budesonide inhalation suspension delivered via transnasal nebulization to patients following endoscopic sinus surgery. SUBJECTS AND METHODS: Thirty-five patients were recruited into this study. Final diagnoses were reached using Bent and Kuhn's criteria. The eligible patients were randomly divided into two groups: the budesonide transnasal nebulization group (group A) and the topical nasal steroids group (group B). Nasal symptoms, Lund-Mackay scores, and Kupferberg grades were evaluated before surgery, after surgery and during the follow-up to assess the effects of these two approaches. RESULTS: A total of 30 patients with AFRS who were eligible were included in the study. Four of the 15 patients in group B (26.67%) developed recurrent disease, whereas no patients in group A developed recurrent disease. This difference was statistically significant (p=0.032). CONCLUSION: Nebulized budesonide is an effective and safe treatment for patients with AFRS following endoscopic sinus surgery, as evidenced by the reduced recurrence rate observed in the budesonide transnasal nebulization group relative to the topical nasal steroids group</style></abstract><notes><style face="normal" font="Arial">DA - 20170210IS - 1532-818X (Electronic)IS - 0196-0709 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.amjoto.2017.01.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28185668">PM:28185668</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Otholaryngol\20170210-DaiQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Otholaryngol\20170210-DaiQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170210, Dai Q</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.amjoto.2017.01.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shah,K.</style></author><author><style face="normal" font="Arial"> Ferastraoaru,D.</style></author><author><style face="normal" font="Arial"> Jariwala,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Eosinophilia associated with Strongyloides infection, severe asthma, and central bronchiectasis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="511" start="510">510-511</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1081-1206</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28254204">PM:28254204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170224-ShahK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170224-ShahK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Shah K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.01.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rouelle,C.</style></author><author><style face="normal" font="Arial"> Arion,A.</style></author><author><style face="normal" font="Arial"> Prevost,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pharmacie Clemenceau, 14000 Caen, France. Electronic address: cathy.rouelle@gmail.comPediatrie medicale, CHU de Caen, 14000 Caen, FranceUFR des sciences pharmaceutiques, universite de Caen Normandie, 14000 Caen, France</style></auth-address><titles><title><style face="normal" font="Arial">[Management and prevention of cow's milk protein allergy: Contribution of community pharmacists]</style></title><secondary-title><style face="normal" font="Arial">Ann Pharm Fr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Pharm Fr</style></full-title></periodical><pages end="244" start="236">236-244</pages><volume><style face="normal" font="Arial">75</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Education program</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrie</style></keyword><keyword><style face="normal" font="Arial"> Personalized care project</style></keyword><keyword><style face="normal" font="Arial"> Pharmacists</style></keyword><keyword><style face="normal" font="Arial"> Posture</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic education</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="Arial">Cow's milk protein allergy (CMPA) is a public health issue in children whose quality of life is strongly affected. The objective of this article is to review the present state of knowledge on the CMPA, and highlight some emerging alternatives in its management and in its prevention. Good knowledge in the appropriate infant formula, exclusion diets, the handling of the emergency treatment thanks to the use of epinephrine auto-injector pens, the use of personalized care project and accessibility to allergic patients' association are factors that secure the management. Breastfeeding and appropriate dietary diversification are for their part major preventive measures. The use of probiotics and desensitization immunotherapy are interesting emerging tracks. The role of community pharmacists in all these steps is discussed. It is indeed a nearby health professional involved both in improving prevention and in the optimization of the management. Its educational posture is crucial in assisting patients to help them better understand the CMPA and its treatment; as part of its new tasks, he can be integrated into therapeutic education programs to help allergic children and their families in a multidisciplinary context to better manage their daily life</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 0003-4509 (Print)IS - 0003-4509 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pharma.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28187880">PM:28187880</url></web-urls></urls><custom2><style face="normal" font="Arial">20170211, Rouelle C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pharma.2017.01.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Viegas,C.</style></author><author><style face="normal" font="Arial"> Sabino,R.</style></author><author><style face="normal" font="Arial"> Botelho,D.</style></author><author><style face="normal" font="Arial"> dos Santos,M.</style></author><author><style face="normal" font="Arial"> Gomes,A.Q.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Assessment of exposure to the Penicillium glabrum complex in cork industry using complementing methods</style></title><secondary-title><style face="normal" font="Arial">Arh Hig Rada Toksikol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arh Hig Rada Toksikol</style></full-title></periodical><pages end="207" start="203">203-207</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution,Indoor</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chemically induced</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Forest species</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxins</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2015">2015/9/1</year></dates><abstract><style face="normal" font="Arial">Cork oak is the second most dominant forest species in Portugal and makes this country the world leader in cork export. Occupational exposure to Chrysonilia sitophila and the Penicillium glabrum complex in cork industry is common, and the latter fungus is associated with suberosis. However, as conventional methods seem to underestimate its presence in occupational environments, the aim of our study was to see whether information obtained by polymerase chain reaction (PCR), a molecular-based method, can complement conventional findings and give a better insight into occupational exposure of cork industry workers. We assessed fungal contamination with the P. glabrum complex in three cork manufacturing plants in the outskirts of Lisbon using both conventional and molecular methods. Conventional culturing failed to detect the fungus at six sampling sites in which PCR did detect it. This confirms our assumption that the use of complementing methods can provide information for a more accurate assessment of occupational exposure to the P. glabrum complex in cork industry</style></abstract><notes><style face="normal" font="Arial">DA - 20151008IS - 1848-6312 (Electronic)IS - 0004-1254 (Linking)LA - engPT - Journal ArticleRN - 0 (Air Pollutants)RN - 0 (Mycotoxins)SB - IMCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1515/aiht-2015-66-2614</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26444341">PM:26444341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arh Hig Rada Toksikol\2015-66-203-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arh Hig Rada Toksikol\2015-66-203-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151008, Viegas C</style></custom2><misc3><style face="normal" font="Arial">10.1515/aiht-2015-66-2614</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abd-Elmoniem,K.Z.</style></author><author><style face="normal" font="Arial"> Ramos,N.</style></author><author><style face="normal" font="Arial"> Yazdani,S.K.</style></author><author><style face="normal" font="Arial"> Ghanem,A.M.</style></author><author><style face="normal" font="Arial"> Holland,S.M.</style></author><author><style face="normal" font="Arial"> Freeman,A.F.</style></author><author><style face="normal" font="Arial"> Gharib,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Diabetes and Digestive and Kidney Diseases, Biomedical and Metabolic Imaging Branch, United States</style></auth-address><titles><title><style face="normal" font="Arial">Coronary atherosclerosis and dilation in hyper IgE syndrome patients: Depiction by magnetic resonance vessel wall imaging and pathological correlation</style></title><secondary-title><style face="normal" font="Arial">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Atherosclerosis</style></full-title></periodical><pages end="25" start="20">20-25</pages><volume><style face="normal" font="Arial">258</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Atherosclerosis</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dilation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Kidney Diseases</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MRI</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> post-mortem</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND AIMS: Autosomal dominant hyper-IgE (AD-HIES) is a primary immunodeficiency caused by mutations in STAT3. Elevated levels of IgE, an ineffective immune response, connective tissue abnormalities, and coronary arterial dilation and tortuosity characterize AD-HIES. To date, coronary artery evaluation in AD-HIES patients has been limited to lumenography measurements. Direct in vivo coronary vessel wall (VW) imaging may allow for better interrogation of coronary vessel abnormalities. The goal of this prospective study was to evaluate the coronary VW of AD-HIES patients using Magnetic Resonance Imaging (MRI) and histology. VW image findings were compared in healthy subjects and subjects with coronary atherosclerotic disease (CAD). METHODS: A total of 28 subjects (10 with AD-HIES, 8 healthy, 10 with CAD) were studied by coronary VW MRI imaging. Additionally, a post-mortem coronary artery from one VW imaged AD-HIES patient was examined. RESULTS: Coronary VW in AD-HIES was thicker than in healthy controls but not significantly different from VW thickness in CAD subjects. AD-HIES coronaries showed increased VW area compared to healthy controls and CAD subjects. On histology, the AD-HIES coronary artery had findings consistent with atherosclerotic plaque, but had minimal luminal narrowing, deficient adventitia thickening and absence of both internal and external elastic laminae. CONCLUSIONS: This is the first study to demonstrate subclinical coronary atherosclerosis in AD-HIES patients on VW imaging by MRI. Histologic evaluation confirmed the presence of atherosclerosis with lack of supportive adventitial thickening and elastic components. These findings suggest mechanisms for coronary dilation in AD-HIES and thereby help direct clinical management</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 1879-1484 (Electronic)IS - 0021-9150 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.atherosclerosis.2017.01.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28167354">PM:28167354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Atherosclerosis\2017-258-20-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Atherosclerosis\2017-258-20-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Abd-Elmoniem KZ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.atherosclerosis.2017.01.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ettinger,R.</style></author><author><style face="normal" font="Arial"> Karnell,J.L.</style></author><author><style face="normal" font="Arial"> Henault,J.</style></author><author><style face="normal" font="Arial"> Panda,S.K.</style></author><author><style face="normal" font="Arial"> Riggs,J.M.</style></author><author><style face="normal" font="Arial"> Kolbeck,R.</style></author><author><style face="normal" font="Arial"> Sanjuan,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Respiratory , Inflammation &amp; Autoimmunity, MedImmune LLC , Gaithersburg , MD , USA</style></auth-address><titles><title><style face="normal" font="Arial">Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses</style></title><secondary-title><style face="normal" font="Arial">Autoimmunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Autoimmunity</style></full-title></periodical><pages end="36" start="25">25-36</pages><volume><style face="normal" font="Arial">50</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE receptors</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferons</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phagocytosis</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Autoantibodies of the IgG subclass are pathogenic in a number of autoimmune disorders such as systemic lupus erythomatosus. The presence of circulating IgE autoantibodies in autoimmune patients has also been known for almost 40 years. Despite their role in allergies, IgE autoantibodies are not associated with a higher rate of atopy in these patients. However, recently they have been recognized as active drivers of autoimmunity through mechanisms involving the secretion of Type I interferons by plasmacytoid dendritic cells (pDC), the recruitment of basophils to lymph nodes, and the activation of adaptive immune responses through B and T cells. Here, we will review the formation, prevalence, affinity, and roles of the IgE autoantibodies that have been described in autoimmunity. We also present novel evidence supporting that triggering of IgE receptors in pDC induces LC3-associated phagocytosis, a cellular process also known as LAP that is associated with interferon responses. The activation of pDC with immune complexes formed by DNA-specific IgE antibodies also induce potent B-cell differentiation and plasma cell formation, which further define IgE's role in autoimmune humoral responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 1607-842X (Electronic)IS - 0891-6934 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/08916934.2017.1280670</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28166684">PM:28166684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Autoimmunity\2017-50-25-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Autoimmunity\2017-50-25-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Ettinger R</style></custom2><misc3><style face="normal" font="Arial">10.1080/08916934.2017.1280670</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Habib,M.A.</style></author><author><style face="normal" font="Arial"> Gan,C.Y.</style></author><author><style face="normal" font="Arial"> Othman,F.</style></author><author><style face="normal" font="Arial"> Zainudin,N.N.</style></author><author><style face="normal" font="Arial"> Abdul,L.A.</style></author><author><style face="normal" font="Arial"> Ismail,M.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universiti Sains Malaysia, 26689, Analytical Biochemistry Research Centre , Universiti Sains Malaysia , 11800 USM , Pulau Pinang , Minden, Pulau Pinang, Malaysia</style></auth-address><titles><title><style face="normal" font="Arial">Proteomics Analysis of Latex from Hevea brasiliensis (Clone RRIM 600)</style></title><secondary-title><style face="normal" font="Arial">Biochem Cell Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Cell Biol</style></full-title></periodical><pages end="242" start="232">232-242</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> de novo sequencing</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disease resistance</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Hevea</style></keyword><keyword><style face="normal" font="Arial"> Hevea brasiliensis</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex allergens</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Photosynthesis</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Qatar</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Ultracentrifugation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The natural rubber latex extracted from the bark of Hevea brasiliensis plays various important roles in today's modern society. Following ultracentrifugation, the latex can be separated into 3 layers; C-serum, lutoids, and rubber particle. Previous studies showed that a large number of proteins were present inside these three layers. However, a complete proteome for this important plant is still unavailable. Protein sequences have been recently translated from the completed draft genome database of H. brasiliensis leading to the creation of annotated protein databases of H. brasiliensis biosynthetic pathways; photosynthesis, latex allergens, rubberwood formation, latex biosynthesis, and disease resistance. This research was conducted to identify the proteins contained within the latex by way of de novo sequencing from mass spectric data obtained from the 3 layers of the latex. Peptides from these proteins were fragmented using collision-induced dissociation (CID), higher-energy collisional dissociation (HCD) and electron-transfer dissociation (ETD) activation methods. A large percentage of proteins from the biosynthetic pathways were successfully identified, ranging from 63% to 100%. In addition, a total of 1839 unique proteins were identified from the whole translated draft genome database (AnnHBM)</style></abstract><notes><style face="normal" font="Arial">DA - 20170208IS - 1208-6002 (Electronic)IS - 0829-8211 (Linking)LA - engPT - Journal ArticleCO - Malaysia -CO - Qatar -</style></notes><work-type><style face="normal" font="Arial">10.1139/bcb-2016-0144</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28177774">PM:28177774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Cell Biol\2017-95-232-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Cell Biol\2017-95-232-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170208, Habib MA</style></custom2><misc3><style face="normal" font="Arial">10.1139/bcb-2016-0144</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaneko,S.</style></author><author><style face="normal" font="Arial"> Murota,H.</style></author><author><style face="normal" font="Arial"> Murata,S.</style></author><author><style face="normal" font="Arial"> Katayama,I.</style></author><author><style face="normal" font="Arial"> Morita,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Usefulness of Sweat Management for Patients with Adult Atopic Dermatitis, regardless of Sweat Allergy: A Pilot Study</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="8746745">8746745-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> Sweating</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background. Sweat is an aggravating factor in atopic dermatitis (AD), regardless of age. Sweat allergy may be involved in AD aggravated by sweating. Objective. We investigated whether sweat exacerbates adult AD symptoms and examined the extent of sweat allergy's involvement. Method. We asked 34 AD patients (17 men, 17 women; mean age: 27.8 years) to record the extent to which sweat aggravated their symptoms on a 10-point numerical scale. Participant responses were compared with histamine release tests (HRT). Furthermore, 24 of the patients received instructions on methods of sweat management, and their outcomes were evaluated on a 10-point scale. Results. Sweat HRT results were class >/= 2 in 13 patients, but HRT results were not correlated with the patients' self-assessments of symptom aggravation by sweat. One month after receiving sweat management instructions, a low mean score of 4.6 was obtained regarding whether active sweating was good, but a high mean score of 7.0 was obtained in response to whether the sweat management instructions had been helpful. Conclusion. Our investigation showed that patients' negative impressions of sweat might derive from crude personal experiences that are typically linked to sweating. Sweat management for patients with adult atopic dermatitis was extremely useful regardless of sweat allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 2314-6141 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/8746745</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28210628">PM:28210628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-8746745.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-8746745.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Kaneko S</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/8746745</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olivry,T.</style></author><author><style face="normal" font="Arial"> Mueller,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Drive, Raleigh, NC, 27607, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Critically appraised topic on adverse food reactions of companion animals (3): prevalence of cutaneous adverse food reactions in dogs and cats</style></title><secondary-title><style face="normal" font="Arial">BMC Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Vet Res</style></full-title></periodical><pages end="" start="51">51-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous adverse food reactions</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinarian</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of cutaneous adverse food reactions (CAFRs) in dogs and cats is not precisely known. This imprecision is likely due to the various populations that had been studied. Our objectives were to systematically review the literature to determine the prevalence of CAFRs among dogs and cats with pruritus and skin diseases. RESULTS: We searched two databases for pertinent references on August 18, 2016. Among 490 and 220 articles respectively found in the Web of Science (Science Citation Index Expanded) and CAB Abstract databases, we selected 22 and nine articles that reported data usable for CAFR prevalence determination in dogs and cats, respectively. The prevalence of CAFR in dogs and cats was found to vary depending upon the type of diagnoses made. Among dogs presented to their veterinarian for any diagnosis, the prevalence was 1 to 2% and among those with skin diseases, it ranged between 0 and 24%. The range of CAFR prevalence was similar in dogs with pruritus (9 to 40%), those with any type of allergic skin disease (8 to 62%) and in dogs diagnosed with atopic dermatitis (9 to 50%). In cats presented to a university hospital, the prevalence of CAFR was less than 1% (0.2%), while it was fairly homogeneous in cats with skin diseases (range: 3 to 6%), but higher in cats with pruritus (12 to 21%) than in cats with allergic skin disease (5 to 13%). CONCLUSIONS: Among dogs and cats with pruritus and those suspected of allergic skin disease, the prevalence of CAFR is high enough to justify this syndrome to be ruled-out with a restriction (elimination)-provocation dietary trial. This must especially be considered in companion animals with nonseasonal pruritus or signs of allergic dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1746-6148 (Electronic)IS - 1746-6148 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12917-017-0973-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28202060">PM:28202060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Vet Res\2017-13-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Vet Res\2017-13-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Olivry T</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12917-017-0973-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Diwakar,L.</style></author><author><style face="normal" font="Arial"> Cummins,C.</style></author><author><style face="normal" font="Arial"> Lilford,R.</style></author><author><style face="normal" font="Arial"> Roberts,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Health Economics Unit, University of Birmingham, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="Arial">Systematic review of pathways for the delivery of allergy services</style></title><secondary-title><style face="normal" font="Arial">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ Open</style></full-title></periodical><pages end="" start="e012647">e012647-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Care pathways</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> patient management</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: The incidence and prevalence of allergies worldwide has been increasing and allergy services globally are unable to keep up with this increase in demand. This systematic review aims to understand the delivery of allergy services worldwide, challenges faced and future directions for service delivery. METHODS: A systematic scoping review of Ovid, EMBASE, HMIC, CINAHL, Cochrane, DARE, NHS EED and INAHTA databases was carried out using predefined inclusion and exclusion criteria. Data on the geographical region, study design and treatment pathways described were collected, and the findings were narratively reported. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. RESULTS: 205 publications were screened and 27 selected for review. Only 3 were prospective studies, and none included a control group. There were no eligible publications identified from North America, Africa, Australia and most parts of Asia. Most publications relate to allergy services in the UK. In general, allergy services globally appear not to have kept pace with increasing demand. The review suggests that primary care practitioners are not being adequately trained in allergy and that there is a paucity of appropriately trained specialists, especially in paediatric allergy. There appear to be considerable barriers to service improvement, including lack of political will and reluctance to allocate funds from local budgets. CONCLUSIONS: Demand for allergy services appears to have significantly outpaced supply. Primary and secondary care pathways in allergy seem inadequate leading to poor referral practices, delays in patient management and consequently poor outcomes. Improvement of services requires strong public and political engagement. There is a need for well-planned, prospective studies in this area and a few are currently underway. There is no evidence to suggest that any given pathway of service provision is better than another although data from a few long-term, prospective studies look very promising</style></abstract><notes><style face="normal" font="Arial">DA - 20170208IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmjopen-2016-012647</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28174222">PM:28174222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2017-7-e012647.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Open\2017-7-e012647.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170208, Diwakar L</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmjopen-2016-012647</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Peeters,C.</style></author><author><style face="normal" font="Arial"> Herman,A.</style></author><author><style face="normal" font="Arial"> Baeck,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Donkey's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinique</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Donkey's milk</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emollients</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="2" Year="2017">2017/2/11</year></dates><abstract><style face="normal" font="Arial">A 25 years-old woman, with a history of personal atopic dermatitis, allergic asthma and hay fever, experienced a facial angioedema 5 minutes after consuming fresh donkey's milk for the first time (Fig. 1). She developed dyspnea and collapsed after a few minutes. The patient required administration of adrenaline and corticosteroids. During her childhood, her atopic dermatitis was treated with different topical treatments including donkey's milk based emollients. She never presented reactions to this topical treatment and she had no history of food allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15367</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188610">PM:28188610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170211-PeetersC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170211-PeetersC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Peeters C</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15367</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Draikiwicz,S.</style></author><author><style face="normal" font="Arial"> Oppenheimer,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, New Jersey Medical School, Newark, NJ</style></auth-address><titles><title><style face="normal" font="Arial">Use of Biological Agents in Asthma: Pharmacoeconomic Lessons Learned From Omalizumab</style></title><secondary-title><style face="normal" font="Arial">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chest</style></full-title></periodical><pages end="251" start="249">249-251</pages><volume><style face="normal" font="Arial">151</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New Jersey</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170210IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.chest.2016.06.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28183482">PM:28183482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chest\2017-151-249-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chest\2017-151-249-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170210, Draikiwicz S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.chest.2016.06.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Siew,L.Q.</style></author><author><style face="normal" font="Arial"> Wu,S.Y.</style></author><author><style face="normal" font="Arial"> Ying,S.</style></author><author><style face="normal" font="Arial"> Corrigan,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma, Allergy and Lung Biology, MRC-Asthma UK Centre for Allergic Mechanisms of Asthma, Guy's Hospital, King's College London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Cigarette smoking increases bronchial mucosal IL-17A expression in asthmatics, which acts in concert with environmental aeroallergens to engender neutrophilic inflammation</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="750" start="740">740-750</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic mechanism</style></keyword><keyword><style face="normal" font="Arial"> Allergic mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cigarette smoke</style></keyword><keyword><style face="normal" font="Arial"> cigarette smoking</style></keyword><keyword><style face="normal" font="Arial"> costimulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="2" Year="2017">2017/2/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mild asthmatics who smoke cigarettes may develop unstable disease and neutrophilic infiltration of the airways, features more usually associated with severe asthmatic disease. The mechanisms giving rise to this response remain unclear. OBJECTIVE: To address the hypothesis that smoking increases bronchial mucosal production of IL-17A which acts on bronchial epithelial cells directly and in concert with other environmental stimuli to induce the production of IL-6 and neutrophil chemotaxins. METHODS: IL-17A, IL-8, IL-6, neutrophils and eosinophils was detected and quantified by immunohistochemistry in endobronchial biopsy sections from smoking and non-smoking asthmatics. Human tracheal epithelial cells (HTEpC) were cultured with IL-17A in the presence/absence of cigarette smoke extract (CSE) and aeroallergens lacking intrinsic protease activity, and IL-6 and IL-8 production measured in vitro. RESULTS: Expression of IL-17A, IL-6 and IL-8 and neutrophil numbers were significantly elevated in the bronchial mucosa of the asthmatic smokers compared to the non-smokers. Expression of IL-17A correlated with that of IL-8 and neutrophil numbers. In the smoking asthmatics, eosinophil numbers also correlated with expression of IL-8 and IL-17A. Exposure of HTEpC cells to both CSE and IL-17A increased expression of IL-6 and IL-8 in a concentration-dependent and synergistic manner. Co-stimulation with CSE, IL-17A and aeroallergens further increased IL-6 and IL-8 production synergistically. CONCLUSIONS: The data support the hypothesis that asthmatic smokers develop neutrophilic inflammation of the airways propagated at least partly by smoke-induced production of IL-17A which together with smoke and other environmental stimuli acts on airways epithelial cells to induce neutrophil chemotaxins. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12907</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211191">PM:28211191</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170217-SiewLQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170217-SiewLQ.pdfv</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Siew LQ</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12907</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bertelsen,R.J.</style></author><author><style face="normal" font="Arial"> Rava,M.</style></author><author><style face="normal" font="Arial"> Carsin,A.E.</style></author><author><style face="normal" font="Arial"> Accordini,S.</style></author><author><style face="normal" font="Arial"> Benediktsdottir,B.</style></author><author><style face="normal" font="Arial"> Dratva,J.</style></author><author><style face="normal" font="Arial"> Franklin,K.A.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Holm,M.</style></author><author><style face="normal" font="Arial"> Janson,C.</style></author><author><style face="normal" font="Arial"> Johannessen,A.</style></author><author><style face="normal" font="Arial"> Jarvis,D.L.</style></author><author><style face="normal" font="Arial"> Jogi,R.</style></author><author><style face="normal" font="Arial"> Leynaert,B.</style></author><author><style face="normal" font="Arial"> Norback,D.</style></author><author><style face="normal" font="Arial"> Omenaas,E.R.</style></author><author><style face="normal" font="Arial"> Raherison,C.</style></author><author><style face="normal" font="Arial"> Sanchez-Ramos,J.L.</style></author><author><style face="normal" font="Arial"> Schlunssen,V.</style></author><author><style face="normal" font="Arial"> Sigsgaard,T.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Svanes,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Science, University of Bergen, Bergen, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Clinical markers of asthma and IgE assessed in parents before conception predicts asthma and hay fever in the offspring</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="638" start="627">627-638</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ECRHS</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> Estonia</style></keyword><keyword><style face="normal" font="Arial"> European Community Respiratory Health Survey</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health survey</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mice models suggest epigenetic inheritance induced by parental allergic disease activity. However, we know little of how parental disease activity before conception influences offspring's asthma and allergy in humans. OBJECTIVE: We aimed to assess the associations of parental asthma severity, bronchial hyperresponsiveness (BHR), and total and specific IgEs, measured before conception vs after birth, with offspring asthma and hay fever. METHODS: The study included 4293 participants (mean age 34, 47% men) from the European Community Respiratory Health Survey (ECRHS) with information on asthma symptom severity, BHR, total and specific IgEs from 1991-1993, and data on 9100 offspring born 1972-2012. Adjusted relative risk ratios (aRRR) for associations of parental clinical outcome with offspring allergic disease were estimated with multinomial logistic regressions. RESULTS: Offspring asthma with hay fever was more strongly associated with parental BHR and specific IgE measured before conception than after birth (BHR: aRRR=2.96 [95% CI: 1.92, 4.57] and 1.40[1.03, 1.91], respectively; specific IgEs: 3.08[2.13, 4.45] and 1.83[1.45, 2.31], respectively). This was confirmed in a sensitivity analysis of a subgroup of offspring aged 11-22 years with information on parental disease activity both before and after birth. CONCLUSION &amp; CLINICAL RELEVANCE: Parental BHR and specific IgE were associated with offspring asthma and hay fever, with the strongest associations observed with before conception as compared to after birth of the child. If the hypothesis is confirmed in other studies, parental disease activity assessed before conception may prove useful for identifying children at risk for developing asthma with hay fever. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170215IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Norway -CO - France -CO - Spain -CO - Italy -CO - Iceland -CO - Switzerland -CO - Sweden -CO - Germany -CO - United Kingdom -CO - Estonia -CO - Denmark -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12906</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28199764">PM:28199764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170215-BertelsenRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170215-BertelsenRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170215, Bertelsen RJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12906</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stentzel,S.</style></author><author><style face="normal" font="Arial"> Hagl,B.</style></author><author><style face="normal" font="Arial"> Felicitas,A.</style></author><author><style face="normal" font="Arial"> Kahl,B.C.</style></author><author><style face="normal" font="Arial"> Rack-Hoch,A.</style></author><author><style face="normal" font="Arial"> Broker,B.M.</style></author><author><style face="normal" font="Arial"> Renner,E.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, University Medicine, Ernst Moritz Arndt University, Greifswald (Germany)</style></auth-address><titles><title><style face="normal" font="Arial">Reduced IgG response to Staphylococcus aureus in STAT3 hyper-IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Infect Dis</style></full-title></periodical><pages end="1282" start="1279">1279-1282</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1537-6591 (Electronic)IS - 1058-4838 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1093/cid/cix140</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28203787">PM:28203787</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Infect Dis\20170216-StentzelS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Infect Dis\20170216-StentzelS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Stentzel S</style></custom2><misc3><style face="normal" font="Arial">10.1093/cid/cix140</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van den Elzen,M.T.</style></author><author><style face="normal" font="Arial"> van Os-Medendorp,H.</style></author><author><style face="normal" font="Arial"> van den Brink,I.</style></author><author><style face="normal" font="Arial"> van den Hurk,K.</style></author><author><style face="normal" font="Arial"> Kouznetsova,O.I.</style></author><author><style face="normal" font="Arial"> Lokin,A.S.H.J.</style></author><author><style face="normal" font="Arial"> Laheij-de Boer,A.</style></author><author><style face="normal" font="Arial"> Rockmann,H.</style></author><author><style face="normal" font="Arial"> Bruijnzeel-Koomen,C.A.F.M.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Up-dosing</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2045-7022</style></isbn><abstract><style face="normal" font="Arial">Treatment with second-generation antihistamines is recommended in patients with chronic spontaneous urticaria (CSU). Some patients remain unresponsive even after up-dosing up to fourfold. Many third line treatment options have limited availability and/or give rise to significant side effects. We investigated effectiveness and safety of antihistamine treatment with dosages up to fourfold and higher</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0141-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s13601-017-0141-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, van den Elzen MT</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0141-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Knaysi,G.</style></author><author><style face="normal" font="Arial"> Smith,A.R.</style></author><author><style face="normal" font="Arial"> Wilson,J.M.</style></author><author><style face="normal" font="Arial"> Wisniewski,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA</style></auth-address><titles><title><style face="normal" font="Arial">The Skin as a Route of Allergen Exposure: Part II. Allergens and Role of the Microbiome and Environmental Exposures</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="7">7-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> commensal bacteria</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Penetration</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin bacteria</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: This second part of the article aims to highlight recent contributions in the literature that enhance our understanding of the cutaneous immune response to allergen. RECENT FINDINGS: Several properties of allergens facilitate barrier disruption and cutaneous sensitization. There is a strong epidemiologic relationship between the microbiome, both the gut and skin, and atopic dermatitis (AD). The mechanisms connecting these two entities remain enigmatic; however, recent murine models show that commensal skin bacteria play an active role in supporting skin barrier homeostasis and defense against microbial penetration. Likewise, the association between the lack of colonization with Staph species and AD development suggests a potentially functional role for these organisms in regulating the skin barrier and response to environmental allergens. In undisrupted skin, evidence suggests that the cutaneous route may promote allergen tolerance. Properties of environmental allergens and commensal bacteria add to the complex landscape of skin immunity. Further investigation is needed to elucidate how these properties regulate the cutaneous immune response to allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0675-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28210979">PM:28210979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Knaysi G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0675-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smith,A.R.</style></author><author><style face="normal" font="Arial"> Knaysi,G.</style></author><author><style face="normal" font="Arial"> Wilson,J.M.</style></author><author><style face="normal" font="Arial"> Wisniewski,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA</style></auth-address><titles><title><style face="normal" font="Arial">The Skin as a Route of Allergen Exposure: Part I. Immune Components and Mechanisms</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="6">6-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cornea</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Ontogeny</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier function</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Stratum corneum</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: To highlight recent contributions in the literature that enhance our understanding of the cutaneous immune response to allergen. RECENT FINDINGS: Defects in skin barrier function in infancy set the stage for the development of atopic dermatitis (AD) and allergy. Both genetic and environmental factors can contribute to damage of the stratum corneum (SC), with activation of specific protease enzymes under high pH conditions playing a key role. Immune cells and mediators in the dermis and epidermis impair SC repair mechanisms and support allergy development. In barrier-disrupted skin, type 2 innate lymphoid cells (ILC2s), mast cells (MCs), and basophils have been shown to promote AD and pathogenic Th2 responses in murine models. Skin barrier disruption favors induction of systemic Th2-associated inflammatory pathways. A better understanding of the ontogeny and regulation of these complex networks in infant skin is needed to guide future strategies for allergy treatment and prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170210IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0674-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28185161">PM:28185161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170210, Smith AR</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0674-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rasmussen,A.</style></author><author><style face="normal" font="Arial"> Jacob,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Department of Dermatology, Loma Linda University, CA</style></auth-address><titles><title><style face="normal" font="Arial">Dandelion: An Important Allergen in Atopic Children</style></title><secondary-title><style face="normal" font="Arial">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dermatitis</style></full-title></periodical><pages end="" start="166">166-</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/DER.0000000000000262</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28169854">PM:28169854</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dermatitis\20170207-RasmussenA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dermatitis\20170207-RasmussenA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Rasmussen A</style></custom2><misc3><style face="normal" font="Arial">10.1097/DER.0000000000000262</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wong-See,H.</style></author><author><style face="normal" font="Arial"> Gray,P.</style></author><author><style face="normal" font="Arial"> Krishnan,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sydney Children's Hospital, SYDNEY, AustraliaDepartment of Immunology and Infectious Diseases, Sydney Children's Hospital, SYDNEY, AustraliaDepartment of Paediatric Gastroenterology, Sydney Children's Hospital, SYDNEY, Australia</style></auth-address><titles><title><style face="normal" font="Arial">P-13: Rates of Allergic Sensitization in Children With esophageal Atresia and Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="Arial">Dis Esophagus</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dis Esophagus</style></full-title></periodical><pages end="" start="292">292-</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword></keywords><dates><year Day="1" Month="4" Year="2016">2016/4/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1442-2050 (Electronic)IS - 1120-8694 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1093/dote/29.3.292</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28205704">PM:28205704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dis Esophagus\2016-29-292.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dis Esophagus\2016-29-292.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Wong-See H</style></custom2><misc3><style face="normal" font="Arial">10.1093/dote/29.3.292</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leceta,A.</style></author><author><style face="normal" font="Arial"> Sologuren,A.</style></author><author><style face="normal" font="Arial"> Valiente,R.</style></author><author><style face="normal" font="Arial"> Campo,C.</style></author><author><style face="normal" font="Arial"> Labeaga,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Department, Faes Farma SA, 48940-Leioa, Bizkaia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department</style></title><secondary-title><style face="normal" font="Arial">Drugs Context</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Drugs Context</style></abbr-1></periodical><pages end="" start="212500">212500-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anticoagulants</style></keyword><keyword><style face="normal" font="Arial"> Bilastine</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Decision Making</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Isoenzymes</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Oral anticoagulants</style></keyword><keyword><style face="normal" font="Arial"> Oral contraceptives</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bilastine is a safe and effective commonly prescribed non-sedating H1-antihistamine approved for symptomatic treatment in patients with allergic disorders such as rhinoconjunctivitis and urticaria. It was evaluated in many patients throughout the clinical development required for its approval, but clinical trials generally exclude many patients who will benefit in everyday clinical practice (especially those with coexisting diseases and/or being treated with concomitant drugs). Following its introduction into clinical practice, the Medical Information Specialists at Faes Farma have received many practical queries regarding the optimal use of bilastine in different circumstances. DATA SOURCES AND METHODS: Queries received by the Medical Information Department and the responses provided to senders of these queries. RESULTS: The most frequent questions received by the Medical Information Department included the potential for drug-drug interactions with bilastine and commonly used agents such as anticoagulants (including the novel oral anticoagulants), antiretrovirals, antituberculosis regimens, corticosteroids, digoxin, oral contraceptives, and proton pump inhibitors. Most of these medicines are not usually allowed in clinical trials, and so advice needs to be based upon the pharmacological profiles of the drugs involved and expert opinion. The pharmacokinetic profile of bilastine appears favourable since it undergoes negligible metabolism and is almost exclusively eliminated via renal excretion, and it neither induces nor inhibits the activity of several isoenzymes from the CYP 450 system. Consequently, bilastine does not interact with cytochrome metabolic pathways. Other queries involved specific patient groups such as subjects with renal impairment, women who are breastfeeding or who are trying to become pregnant, and patients with other concomitant diseases. Interestingly, several questions related to topics that are well covered in the Summary of Product Characteristics (SmPC), which suggests that this resource is not being well used. CONCLUSIONS: Overall, this analysis highlights gaps in our knowledge regarding the optimal use of bilastine. Expert opinion based upon an understanding of the science can help in the decision-making, but more research is needed to provide evidence-based answers in certain circumstances</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1745-1981 (Print)IS - 1740-4398 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.7573/dic.212500</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28210286">PM:28210286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs Context\2017-6-212500.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs Context\2017-6-212500.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Leceta A</style></custom2><misc3><style face="normal" font="Arial">10.7573/dic.212500</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lupinek,C.</style></author><author><style face="normal" font="Arial"> Derfler,K.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Prikoszovich,T.</style></author><author><style face="normal" font="Arial"> Movadat,O.</style></author><author><style face="normal" font="Arial"> Wollmann,E.</style></author><author><style face="normal" font="Arial"> Cornelius,C.</style></author><author><style face="normal" font="Arial"> Weber,M.</style></author><author><style face="normal" font="Arial"> Froschl,R.</style></author><author><style face="normal" font="Arial"> Selb,R.</style></author><author><style face="normal" font="Arial"> Blatt,K.</style></author><author><style face="normal" font="Arial"> Smiljkovic,D.</style></author><author><style face="normal" font="Arial"> Schoder,V.</style></author><author><style face="normal" font="Arial"> Cervenka,R.</style></author><author><style face="normal" font="Arial"> Plaichner,T.</style></author><author><style face="normal" font="Arial"> Stegfellner,G.</style></author><author><style face="normal" font="Arial"> Huber,H.</style></author><author><style face="normal" font="Arial"> Henning,R.</style></author><author><style face="normal" font="Arial"> Kozik-Jaromin,J.</style></author><author><style face="normal" font="Arial"> Perkmann,T.</style></author><author><style face="normal" font="Arial"> Niederberger,V.</style></author><author><style face="normal" font="Arial"> Petkov,V.</style></author><author><style face="normal" font="Arial"> Valent,P.</style></author><author><style face="normal" font="Arial"> Gauly,A.</style></author><author><style face="normal" font="Arial"> Leinenbach,H.P.</style></author><author><style face="normal" font="Arial"> Uhlenbusch-Koerwer,I.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy</style></title><secondary-title><style face="normal" font="Arial">EBioMedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EBioMedicine</style></full-title></periodical><pages end="133" start="119">119-133</pages><volume><style face="normal" font="Arial">17</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Basophil sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE receptors</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgEnio</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> Immunoadsorption</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peak flow</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> threshold level</style></keyword><keyword><style face="normal" font="Arial"> threshold levels</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2352-3964</style></isbn><abstract><style face="normal" font="Arial">Background Prevention of IgE-binding to cellular IgE-receptors by anti-IgE (Omalizumab) is clinically effective in allergic asthma, but limited by IgE threshold-levels. To overcome this limitation, we developed a single-use IgE immunoadsorber column (IgEnio). IgEnio is based on a recombinant, IgE-specific antibody-fragment and can be used for the specific extracorporeal desorption of IgE. Objective To study safety and efficacy of IgEnio regarding the selective depletion of IgE in a randomized, open-label, controlled pilot trial in patients with allergic asthma and to investigate if IgEnio can bind IgE-Omalizumab immune complexes. Methods Fifteen subjects were enrolled and randomly assigned to the treatment group (n = 10) or to the control group (n = 5). Immunoadsorption was done by veno-venous approach, processing the twofold calculated plasma volume during each treatment. A minimum average IgE-depletion of 50% after the last cycle in the intention-to-treat population was defined as primary endpoint. Safety of the treatment was studied as secondary endpoint. In addition, possible changes in allergen-specific sensitivity were investigated, as well as clinical effects by peak flow measurement and symptom-recording. The depletion of IgE-Omalizumab immune complexes was studied in vitro. The study was registered at clinicaltrials.gov (NCT02096237) and conducted from December 2013 to July 2014. Results IgE immunoadsorption with IgEnio selectively depleted 86.2% (-¦ 5.1% SD) of IgE until the end of the last cycle (p &amp;lt; 0.0001). Removal of pollen allergen-specific IgE was associated with a reduction of allergen-specific basophil-sensitivity and prevented increases of allergen-specific skin-sensitivity and clinical symptoms during pollen seasons. IgEnio also depleted IgE-Omalizumab immune complexes in vitro. The therapy under investigation was safe and well-tolerated. During a total of 81 aphereses, 2 severe adverse events (SAE) were recorded, one of which, an episode of acute dyspnea, possibly was related to the treatment and resolved after administration of antihistamines and corticosteroids. Conclusions This pilot study indicates that IgE immunoadsorption with IgEnio may be used to treat patients with pollen-induced allergic asthma. Furthermore, the treatment could render allergic patients with highly elevated IgE-levels eligible for the administration of Omalizumab and facilitate the desorption of IgE-Omalizumab complexes. This study was funded by Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ebiom.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28254561">PM:28254561</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EBioMedicine\20170224-LupinekC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EBioMedicine\20170224-LupinekC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Lupinek C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ebiom.2017.02.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moghtaderi,M.</style></author><author><style face="normal" font="Arial"> Hosseini,T.S.</style></author><author><style face="normal" font="Arial"> Farjadsh,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Clinic of Ali-Asghar Hospital, Shiraz University of Medical Sciences, Shiraz, IranClinical Research Development Center of Children Hospital, Hormozgan University of Medical Sciences, Bandar-Abbas, IranDepartment of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to common allergens among patients with allergy in major Iranian cities: A systemic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Epidemiol Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Epidemiol Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroach allergens</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="2" Year="2017">2017/2/5</year></dates><abstract><style face="normal" font="Arial">Purpose: Various allergens are implicated in the pathogenesis of allergic diseases in different regions. This study attempted to identify the most common allergens among patients with allergy based on results of skin prick tests in different parts of Iran. Methods: Relevant studies were identified from the Medline database from 2000 to 2016. Six common groups of allergens including animals, cockroaches, foods, fungi, house dust mites and pollen were considered. Subgroup analysis was performed to determine prevalence of each type of allergens. Egger's test was used to assess publication bias. Results: We included 44 studies in this meta-analysis, the overall prevalence of positive skin tests to at least one allergen estimated 59% in patients with allergy in various parts of Iran. The number of patients was 11646 (56% male and 44% female) with mean age of 17.46+/-11.12 years. most source of allergens were pollen 47%, mites 35.2% and food 15.3%.Prevalence of sensitization to food and cockroach allergens among children was more than adults. Conclusion: Pollens are the most common allergens in cities of Iran with warm and dry climate, however, sensitization to house dust mites is predominant in northern and southern coastal areas of Iran</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 2092-7193 (Electronic)IS - 2092-7193 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.4178/epih.e2017007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28171712">PM:28171712</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Epidemiol Health\20170207-MoghtaderiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Epidemiol Health\20170207-MoghtaderiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Moghtaderi M</style></custom2><misc3><style face="normal" font="Arial">10.4178/epih.e2017007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bustamante,B.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author><author><style face="normal" font="Arial"> Campos,P.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martin de Porres, Lima 31, Lima, Peru. ana.bustamante@upch.peThe University of Manchester and The National Aspergillosis Centre, University Hospital of South Manchester in association with the LIFE program at www.LIFE-Worldwide.org, Manchester, UKInvestigaciones Medicas en Salud, Calle Riso 390, 4to piso, Lince, Lima14, Lima, Peru</style></auth-address><titles><title><style face="normal" font="Arial">Serious fungal infections in Peru</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="948" start="943">943-948</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Peru</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Transplants</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="Arial">Epidemiological data about mycotic diseases are limited in Peru and estimation of the fungal burden has not been previously attempted. Data were obtained from the Peruvian National Institute of Statistics and Informatics, UNAIDS and from the Ministry of Health's publications. We also searched the bibliography for Peruvian data on mycotic diseases, asthma, COPD, cancer and transplants. Incidence or prevalence for each fungal disease were estimated in specific populations at risk. The Peruvian population for 2015 was 31,151,543. In 2014, the estimated number of HIV/AIDS and pulmonary tuberculosis cases was 88,625, 38,581 of them not on ART, and 22,027, respectively. A total of 581,174 cases of fungal diseases were estimated, representing approximately 1.9% of the Peruvian population. This figure includes 498,606, 17,361 and 4,431 vulvovaginal, oral and esophageal candidiasis, respectively, 1,557 candidemia cases, 3,593 CPA, 1,621 invasive aspergillosis, 22,453 allergic bronchopulmonary aspergilllosis, 29,638 severe asthma with fungal sensitization, and 1,447 Pneumocystis pneumonia. This first attempt to assess the fungal burden in Peru needs to be refined. We believe the figure obtained is an underestimation, because of under diagnosis, non-mandatory reporting and lack of a surveillance system and of good data about the size of populations at risk</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - Peru -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2924-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188491">PM:28188491</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170211-BustamanteB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170211-BustamanteB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Bustamante B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2924-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chayakulkeeree,M.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.</style></auth-address><titles><title><style face="normal" font="Arial">Serious fungal infections in Thailand</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="935" start="931">931-935</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meningitis</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mycose</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">The burden of serious fungal infection in Thailand is increasing but data regarding its incidence and prevalence are lacking. In this study we aimed to estimate the burden of serious fungal diseases in Thailand based on the size of the populations at risk and available epidemiological databases. Data derived from The Bureau of Epidemiology, Department of Disease Control, Thai Ministry of Public Health, World Health Organisation, international and local reports, and some unreported data were used. When no data existed, risk populations were used to estimate frequencies of fungal infections, using previously described methodology by LIFE. Recurrent vulvovaginal candidiasis (>4 episodes per year) is estimated to occur in 3,310 per 100,000 population. Using a previously described rate that 14/10,000 admissions are with fungaemia and 94% of those are Candida, we estimated 8,650 patients with candidaemia. The prevalence of chronic pulmonary aspergillosis is relatively high with a total of 19,044, approximately half subsequent to pulmonary tuberculosis. Invasive aspergillosis is estimated to affect 941 patients following leukaemia therapy, transplantations, and chronic obstructive pulmonary disease, approximately 1.4/100,000. In addition, allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitisation were estimated at approximately 58.4/100,000 and 77/100,000, respectively. Given approximately 8,134 new cases of AIDS annually, cryptococcal meningitis, Pneumocystis pneumonia, and Talaromyces marneffei infection are estimated at 1.9/100,000, 2.6/100,000, and 0.3/100,000, respectively. The present study indicates that about 1.93% (1,254,562) of the population is affected by serious fungal infections. Owing to the lack of data, reports, and statistics, the number of patients with mycoses in Thailand can only be estimated</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - Thailand -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2927-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161742">PM:28161742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-ChayakulkeereeM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-ChayakulkeereeM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Chayakulkeeree M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2927-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huh,K.</style></author><author><style face="normal" font="Arial"> Ha,Y.E.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author><author><style face="normal" font="Arial"> Peck,K.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Serious fungal infections in Korea</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="963" start="957">957-963</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Policy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meningitis</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">Information on the incidence and prevalence of fungal infections is of critical value in public health policy. However, nationwide epidemiological data on fungal infections are scarce, due to a lack of surveillance and funding. The objective of this study was to estimate the disease burden of fungal infections in the Republic of Korea. An actuarial approach using a deterministic model was used for the estimation. Data on the number of populations at risk and the frequencies of fungal infections in those populations were obtained from national statistics reports and epidemiology papers. Approximately 1 million people were estimated to be affected by fungal infections every year. The burdens of candidemia (4.12 per 100,000), cryptococcal meningitis (0.09 per 100,000), and Pneumocystis pneumonia (0.51 per 100,000) in South Korea were estimated to be comparable to those in other countries. The prevalence of chronic pulmonary aspergillosis (22.4 per 100,000) was markedly high, probably due to the high burden of tuberculosis in Korea. The low burdens of allergic bronchopulmonary aspergillosis (56.9 per 100,000) and severe asthma with fungal sensitization (75.1 per 100,000) warrant further study. Oral candidiasis (539 per 100,000) was estimated to affect a much larger population than noted in previous studies. Our work provides valuable insight on the epidemiology of fungal infections; however, additional studies are needed</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2923-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161743">PM:28161743</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-HuhK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-HuhK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Huh K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2923-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jabeen,K.</style></author><author><style face="normal" font="Arial"> Farooqi,J.</style></author><author><style face="normal" font="Arial"> Mirza,S.</style></author><author><style face="normal" font="Arial"> Denning,D.</style></author><author><style face="normal" font="Arial"> Zafar,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.</style></auth-address><titles><title><style face="normal" font="Arial">Serious fungal infections in Pakistan</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="956" start="949">949-956</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Chronic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hiv</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mucormycosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">The true burden of fungal infection in Pakistan is unknown. High-risk populations for fungal infections [tuberculosis (TB), diabetes, chronic respiratory diseases, asthma, cancer, transplant and human immunodeficiency virus (HIV) infection] are numerous. Here, we estimate the burden of fungal infections to highlight their public health significance. Whole and at-risk population estimates were obtained from the WHO (TB), BREATHE study (COPD), UNAIDS (HIV), GLOBOCAN (cancer) and Heartfile (diabetes). Published data from Pakistan reporting fungal infections rates in general and specific populations were reviewed and used when applicable. Estimates were made for the whole population or specific populations at risk, as previously described in the LIFE methodology. Of the 184,500,000 people in Pakistan, an estimated 3,280,549 (1.78%) are affected by a serious fungal infection, omitting all cutaneous infection, oral candidiasis and allergic fungal sinusitis, which we could not estimate. Compared with other countries, the rates of candidaemia (21/100,000) and mucormycosis (14/100,000) are estimated to be very high, and are based on data from India. Chronic pulmonary aspergillosis rates are estimated to be high (39/100,000) because of the high TB burden. Invasive aspergillosis was estimated to be around 5.9/100,000. Fungal keratitis is also problematic in Pakistan, with an estimated rate of 44/100,000. Pakistan probably has a high rate of certain life- or sight-threatening fungal infections</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - Pakistan -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2919-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161741">PM:28161741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-JabeenK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-JabeenK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Jabeen K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2919-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zurita,J.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author><author><style face="normal" font="Arial"> Paz,Y.M.</style></author><author><style face="normal" font="Arial"> Solis,M.B.</style></author><author><style face="normal" font="Arial"> Arias,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Facultad de Medicina, Pontificia Universidad Catolica del Ecuador, Quito, Ecuador.</style></auth-address><titles><title><style face="normal" font="Arial">Serious fungal infections in Ecuador</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="981" start="975">975-981</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Histoplasma</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Meningitis</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">There is a dearth of data from Ecuador on the burden of life-threatening fungal disease entities; therefore, we estimated the burden of serious fungal infections in Ecuador based on the populations at risk and available epidemiological databases and publications. A full literature search was done to identify all epidemiology papers reporting fungal infection rates. WHO, ONU-AIDS, Index Mundi, Global Asthma Report, Globocan, and national data [Instituto Nacional de Estadistica y Censos (INEC), Ministerio de Salud Publica (MSP), Sociedad de Lucha Contra el Cancer (SOLCA), Instituto Nacional de Donacion y Trasplante de Organos, Tejidos y Celulas (INDOT)] were reviewed. When no data existed, risk populations were used to estimate frequencies of fungal infections, using previously described methodology by LIFE. Ecuador has a variety of climates from the cold of the Andes through temperate to humid hot weather at the coast and in the Amazon basin. Ecuador has a population of 15,223,680 people and an average life expectancy of 76 years. The median estimate of the human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) population at risk for fungal disease (&lt;200 CD4 cell counts) is approximately 10,000, with a rate of 11.1% (1100) of histoplasma, 7% (700) of cryptococcal meningitis, and 11% (1070) of Pneumocystis pneumonia. The burden of candidemia is 1037. Recurrent Candida vaginitis (>/=4 episodes per year) affects 307,593 women aged 15-50 years. Chronic pulmonary aspergillosis probably affects approximately 476 patients following tuberculosis (TB). Invasive aspergillosis is estimated to affect 748 patients ( approximately 5.5/100,000). In addition, allergic bronchopulmonary aspergillosis (ABPA) in asthma and severe asthma with fungal sensitization (SAFS) were estimated to affect 26,642 and 45,013 people, respectively. Our estimates indicate that 433,856 (3%) of the population in Ecuador is affected by serious fungal infection</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - Ecuador -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2928-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161740">PM:28161740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-ZuritaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-ZuritaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Zurita J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2928-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gugnani,H.C.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author><author><style face="normal" font="Arial"> Rahim,R.</style></author><author><style face="normal" font="Arial"> Sadat,A.</style></author><author><style face="normal" font="Arial"> Belal,M.</style></author><author><style face="normal" font="Arial"> Mahbub,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology &amp; Epidemiology, Saint James School of Medicine, British West Indies, Anguilla.</style></auth-address><titles><title><style face="normal" font="Arial">Burden of serious fungal infections in Bangladesh</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="997" start="993">993-997</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asia-Pacific</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bangladesh</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Hiv</style></keyword><keyword><style face="normal" font="Arial"> HIV infection</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meningitis</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mycose</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Trichophyton</style></keyword><keyword><style face="normal" font="Arial"> Trichophyton rubrum</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> West Indies</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">In Bangladesh there are several published papers on superficial mycoses. Deep mycoses are also recognized as an important emerging problem. Here, we estimate the annual incidence and prevalence of serious fungal infections in Bangladesh. Demographic data were obtained from world population reports and the data on TB and HIV extracted from the online publications on tuberculosis in Bangladesh and Asia Pacific research statistical data information resources AIDS Data HUB. All the published papers on fungal infections in Bangladesh were identified through extensive search of literature. We estimated the number of affected people from populations at risk and local epidemiological data. Bangladesh has a population of approximately 162.6 million, 31% children and only 6% over the age of 60 years. The pulmonary TB caseload reported in 2014 was 119,520, and we estimate a prevalence of 30,178 people with chronic pulmonary aspergillosis, 80% attributable to TB. An anticipated 90,262 and 119,146 patients have allergic bronchopulmonary aspergillosis or severe asthma with fungal sensitization. Only 8,000 people are estimated to be HIV-infected, of whom 2900 are not on ART with a CD4 count &lt;350 muL, Pneumocystis pneumonia and cryptococcal meningitis being rare. Superficial mycoses are very common with Trichophyton rubrum as the predominant etiological agent (80.6%). Numerous cases of mycotic keratitis have been reported from several parts of Bangladesh. Candida bloodstream infection was estimated based on a 5 per 100,000 rate (8100 cases) and invasive aspergillosis based primarily on leukemia and COPD rates, at 5166 cases. Histoplasmosis was documented in 16 cases mostly with disseminated disease and presumed in 21 with HIV infection. This study constitutes the first attempt to estimate the burden of several types of serious fungal infections in Bangladesh</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - Anguilla -CO - United Kingdom -CO - Bangladesh -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2921-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161744">PM:28161744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-GugnaniHC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-GugnaniHC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Gugnani HC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2921-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dufresne,S.F.</style></author><author><style face="normal" font="Arial"> Cole,D.C.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author><author><style face="normal" font="Arial"> Sheppard,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious Diseases and Medical Microbiology, Maisonneuve-Rosemont Hospital Research Center, Universite de Montreal, Montreal, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Serious fungal infections in Canada</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="992" start="987">987-992</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Mycose</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">There are currently no nationwide epidemiological data on fungal infections in Canada. We estimated the burden of serious fungal diseases using literature review and modeling, as per a methodology previously described by the LIFE program ( http://www.LIFE-worldwide.org ). Among the population of Canada (35.5 million in 2014), it was estimated that approximately 1.8% are affected by a serious fungal infection. Recurrent vulvovaginal candidiasis, severe asthma with fungal sensitization, and allergic bronchopulmonary aspergillosis are the most frequent infections, with population prevalences of 498,688 (1403/100,000), 73,344 (206/100,000), and 61,854 (174/100,000) cases, respectively. Over 3000 invasive fungal infections are estimated to occur annually, with incidences of 2068 cases (5.8/100,000) of invasive candidiasis, 566 cases (1.6/100,000) of invasive aspergillosis, 252 cases (0.71/100,000) of Pneumocystis pneumonia, 99 cases (0.28/100,000) of endemic mycoses, and 63 cases (0.18/100,000) of cryptococcosis. These estimates warrant validation through more formal epidemiological studies in Canada</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2922-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161745">PM:28161745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-DufresneSF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170205-DufresneSF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Dufresne SF</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2922-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sabino,R.</style></author><author><style face="normal" font="Arial"> Verissimo,C.</style></author><author><style face="normal" font="Arial"> Brandao,J.</style></author><author><style face="normal" font="Arial"> Martins,C.</style></author><author><style face="normal" font="Arial"> Alves,D.</style></author><author><style face="normal" font="Arial"> Pais,C.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge-Reference Unit for Parasitic and Fungal Infections, Lisbon, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">Serious fungal infections in Portugal</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcosis</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="Arial">There is a lack of knowledge on the epidemiology of fungal infections worldwide because there are no reporting obligations. The aim of this study was to estimate the burden of fungal disease in Portugal as part of a global fungal burden project. Most published epidemiology papers reporting fungal infection rates from Portugal were identified. Where no data existed, specific populations at risk and fungal infection frequencies in those populations were used in order to estimate national incidence or prevalence, depending on the condition. An estimated 1,510,391 persons develop a skin or nail fungal infection each year. The second most common fungal infection in Portugal is recurrent vulvovaginal candidiasis, with an estimated 150,700 women (15-50 years of age) suffering from it every year. In human immunodeficiency virus (HIV)-infected people, oral or oesophageal candidiasis rates were estimated to be 19.5 and 16.8/100,000, respectively. Candidaemia affects 2.19/100,000 patients, in a total of 231 cases nationally. Invasive aspergillosis is less common than in other countries as chronic obstructive pulmonary disease (COPD) is uncommon in Portugal, a total of 240 cases annually. The estimated prevalence of chronic pulmonary aspergillosis after tuberculosis (TB) is 194 cases, whereas its prevalence for all underlying pulmonary conditions was 776 patients. Asthma is common (10% in adults) and we estimate 16,614 and 12,600 people with severe asthma with fungal sensitisation and allergic bronchopulmonary aspergillosis, respectively. Sixty-five patients develop Pneumocystis pneumonia in acquired immune deficiency syndrome (AIDS) and 13 develop cryptococcosis. Overall, we estimate a total number of 1,695,514 fungal infections starting each year in Portugal</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - Portugal -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2930-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188492">PM:28188492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170210-SabinoR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170210-SabinoR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Sabino R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2930-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamada,Y.</style></author><author><style face="normal" font="Arial"> Ueda,Y.</style></author><author><style face="normal" font="Arial"> Nakamura,A.</style></author><author><style face="normal" font="Arial"> Kanayama,S.</style></author><author><style face="normal" font="Arial"> Tamura,R.</style></author><author><style face="normal" font="Arial"> Hashimoto,K.</style></author><author><style face="normal" font="Arial"> Matsumoto,T.</style></author><author><style face="normal" font="Arial"> Ishii,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Drug Development Research Laboratories, Kyoto R&amp;D Center, Maruho Co., Ltd., Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Immediate-type allergic and protease-mediated reactions are involved in scratching behavior induced by topical application of Dermatophagoides farinae extract in NC/Nga mice</style></title><secondary-title><style face="normal" font="Arial">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Chlorpheniramine</style></keyword><keyword><style face="normal" font="Arial"> Cromoglycate</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> H1 receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAR-2</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Serine protease inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> vascular permeability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD)-like dermatitis can be induced by repeated topical application of an ointment containing Dermatophagoides farinae body (Dfb) extract in NC/Nga mice. This AD-like murine model also exhibits a biphasic increase in the number of scratching behavior after topical application of Dfb ointment. In this study, we investigated the possible mechanisms underlying the scratching behavior in each phase. An increase in the content of mast cell derived mediators such as histamine and 5-hydroxytryptamine in the lesional skin and increased vascular permeability were observed in the early phase after the Dfb ointment application. Chlorpheniramine (H1 receptor antagonist) and cromoglycate (mast cell stabilizer) reduced the scratching behavior in the early phase but not that in the later phase. Furthermore, the content of various endogenous pruritogens such as interleukin-31 and thymic stromal lymphopoietin in the lesional skin was increased 1 or 24 hours after the Dfb ointment application. Elevated expression of proteinase-activated receptor-2 (PAR-2) was also observed in the epidermis. Finally, gabexate (serine protease inhibitor) reduced the scratching behavior in both phases, and anti-PAR2 antibody also showed a tendency to reduce both scratching behaviors. These findings suggest that immediate-type allergic reactions caused by mast cell degranulation and PAR-2 activation by proteases are involved in the scratching behavior in this AD-like model. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170213IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/exd.13322</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28191683">PM:28191683</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Dermatol\20170213-YamadaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Dermatol\20170213-YamadaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170213, Yamada Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/exd.13322</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adiletta,G.</style></author><author><style face="normal" font="Arial"> Russo,P.</style></author><author><style face="normal" font="Arial"> Crescitelli,A.</style></author><author><style face="normal" font="Arial"> Di Matteo,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Combined Pretreatment for Enhancing Quality of Dried and Rehydrated Eggplant</style></title><secondary-title><style face="normal" font="Arial">Food Bioprocess Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Bioprocess Technol</style></full-title></periodical><pages end="1923" start="1912">1912-1923</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> cell walls</style></keyword><keyword><style face="normal" font="Arial"> colour</style></keyword><keyword><style face="normal" font="Arial"> Drying</style></keyword><keyword><style face="normal" font="Arial"> eggplant</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Microstructure</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Texture</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trehalose</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">1935-5149</style></isbn><abstract><style face="normal" font="Arial">A combined pretreatment of trehalose (0.5-á%) and NaCl (0.5-á%) solution was applied prior to drying eggplant to reduce shrinkage, browning and loss of polyphenols. Drying behaviour of eggplant slabs was experimentally examined in a convective dryer at temperatures of 50, 60 and 70-á-¦C and at 2.3-ám/s air velocity. Then the effects of pretreatment and drying temperature on the quality of the eggplant slabs in terms of microstructure, porosity, colour, total phenolic content, rehydration ratio and texture were investigated. It was noted that the pretreated eggplants (TR) dried more rapidly than the untreated ones (UTR) with a reduction of up to 1/4 of drying time. After drying at 50 and 60-á-¦C, they showed no significant differences (p-á&lt;-á0.05) in terms of White index compared with fresh eggplant (78.59-á-¦-á0.63). They had higher total phenolic content (19.86 and 18.24-ámg/g (db), respectively) than the UTR ones (11.91 and 12.89-ámg/g (db)), but only for the TR samples at 50-á-¦C the value is not statistically different (p-á&lt;-á0.05) from the fresh ones (20.00-ámg/g (db)). The pretreatment can hold also a higher porosity (85, 86-á% at 50 and 60-á-¦C, respectively) than the UTR ones (78, 82-á%), but scanning electron microscopy (SEM) images indicated a total damage structure of the UTR samples. On the contrary, after the pretreatment, the porous structure was more uniform with more not lacerated cellular walls. Hence, the main effect of pretreatment was of protecting the microstructure of the eggplants by reinforcing the cell walls and to reduce the resistance of the water evaporation by avoiding the structural changes. After rehydration, the pretreated samples absorbed more water (rehydration ratio had almost doubled) than the untreated ones and showed lower firmness (95,500-áNm</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1) compared with the untreated ones (132,000-áNm</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1)</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11947-016-1778-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s11947-016-1778-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Bioprocess Technol\2016-9-1912-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Bioprocess Technol\2016-9-1912-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Adiletta G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11947-016-1778-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,W.C.</style></author><author><style face="normal" font="Arial"> Fang,L.W.</style></author><author><style face="normal" font="Arial"> Liou,C.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Phloretin Attenuates Allergic Airway Inflammation and Oxidative Stress in Asthmatic Mice</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="134">134-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> adipocyte</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1664-3224</style></isbn><abstract><style face="normal" font="Arial">Phloretin, isolated from the apple tree, was previously demonstrated to have anti-oxidative and anti-inflammatory effects in macrophages and anti-adiposity effects in adipocytes. Inflammatory immune cells generate high levels of reactive oxygen species for stimulated severe airway hyperresponsiveness (AHR) and airway inflammation. In this study, we investigated whether phloretin could reduce oxidative stress, airway inflammation, and eosinophil infiltration in asthmatic mice, and ameliorate oxidative and inflammatory responses in tracheal epithelial cells. BALB/c mice were sensitized with ovalbumin (OVA) to induce asthma symptoms. Mice were randomly assigned to the five experimental groups: normal controls; OVA-induced asthmatic mice; and OVA-induced mice injected intraperitoneally with one of the three phloretin doses (5 mg/kg, 10 mg/kg, or 20 mg/kg). In addition, we treated inflammatory human tracheal epithelial cells (BEAS-2B cells) with phloretin to assess oxidative responses and the levels of proinflammatory cytokines and chemokines. We found that phloretin significantly reduced goblet cell hyperplasia and eosinophil infiltration, which decreased AHR, inflammation, and oxidative responses in the lungs of OVA-sensitized mice. Phloretin also decreased malondialdehyde levels in the lung, and reduced Th2 cytokine production in bronchoalveolar lavage fluids. Furthermore, phloretin reduced reactive oxygen species, proinflammatory cytokines, and eotaxin production in BEAS-2B cells. Phloretin also suppressed monocyte cell adherence to inflammatory BEAS-2B cells. These findings suggested that phloretin alleviated pathological changes, inflammation, and oxidative stress by inhibiting Th2 cytokine production in asthmatic mice. Phloretin showed therapeutic potential for ameliorating asthma symptoms in the future</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00134</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.3389/fimmu.2017.00134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-134.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-134.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Huang WC</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00134</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ianovici,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Summer airborne mycoflora of Timi+</style><style face="normal" font="Symbol">¦</style><style face="normal" font="Arial">oara (Romania) and relationship to meteorological parameters</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="435" start="424">424-435</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airborne fungal spore</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atmospheric Pressure</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Helminthosporium</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> Meteorological variables</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mycoflora</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Soil</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spore concentration</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> Volumetric sampler</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="17" Month="2" Year="2017">2017/2/17</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">The present aeromycological investigation was undertaken to study atmospheric fungal spores in Timi?oara (western Romania). This study was carried out using a Hirst type volumetric sampler. The study revealed the existence of a rich airborne mycoflora. The atmospheric fungal spores were classified and evaluated into three groups (?major?, ?minor? and ?sporadic?) depending upon their catch percentage in the air. Cladosporium/Fusarium/Leptosphaeria-group, Alternaria, Helminthosporium airborne fungal spores and airborne fungal fragments regularly recorded (frequency 100% of days). Cladosporium accounted for 81.09% of the outdoor fungal spores. The airborne fungal fragments have been identified as abundant in our geographic area. Spearman?s correlations were applied to meteorological parameters and airborne fungal spore concentrations. In addition, correlations were calculated between the fungal spore concentrations and the meteorological variables from the previous day. A total of eleven weather factors were selected for this investigation. Following Spearman?s correlations, I identified two patterns of behaviour: most of the airborne fungal spores prefer cloudiness, lower near-surface soil temperature, lower atmospheric pressure, higher relative humidity and precipitation (pattern A) while other spore concentrations favour increased sunshine, higher near-surface soil temperature and dry conditions (pattern B). The behaviour of some fungal spores during the warm season has proven unclear (pattern C). This study demonstrates the need for investigations throughout the year and the evaluation with complementary statistical methods, regarding the correct interpretation of airborne mycoflora relationships with meteorological parameters</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Romania -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2016.1271823</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2016.1271823</url></web-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="Arial">20170224, Ianovici N</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2016.1271823</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wedi,B.</style></author><author><style face="normal" font="Arial"> Wieczorek,D.</style></author><author><style face="normal" font="Arial"> Kapp,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Dermatologie, Allergologie und Venerologie, Comprehensive Allergy Center (CAC), Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Placebo effect in clinical trials with allergen-specific immunotherapy with inhalant allergens]</style></title><secondary-title><style face="normal" font="Arial">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hautarzt</style></full-title></periodical><pages end="306" start="297">297-306</pages><volume><style face="normal" font="Arial">68</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cultural differences</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> Placebo Effect</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Subcutaneous route</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="Arial">Placebo effects play an important role in the treatment of allergic diseases. Therefore, in this study, we analysed the described effects of placebo in all double-blind placebo-controlled clinical trials of allergen-specific immunotherapy (ASIT) with inhalant allergens (birch, grass, house dust mites) listed in the tables (updated July 2016) attached to the German S2k guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. The most common placebo consisted of verum without allergen, but when the subcutaneous route was used, histamine was sometimes added. From the 33 studies analysed no conclusions could be drawn regarding the pure placebo effect. The symptom medication score (SMS) from an adequate baseline period was described in one single study. An untreated population was not included in any study. Indirect evidence points to substantial placebo effects in up to 77% of the subjects with respect to retrospective, subjective parameters. Well-known factors influencing the placebo effect such as age, gender, application route/composition of the placebo, individual and cultural differences, severity of symptoms at the beginning and the probability of receiving verum have not been addressed regarding ASIT and could not be estimated from available data. Taken together regarding ASIT the placebo effect has been investigated inadequately. In spite of significant expenditure of time and costs future ASIT studies should include assessment of the SMS in an adequate baseline period and preferably include an untreated trial arm. A better understanding of placebo effects in ASIT trials will improve the design of clinical trials and the assessment of therapeutic effects</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00105-017-3937-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194483">PM:28194483</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hautarzt\20170214-WediB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hautarzt\20170214-WediB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Wedi B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00105-017-3937-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Furuhashi,K.</style></author><author><style face="normal" font="Arial"> Chua,Y.L.</style></author><author><style face="normal" font="Arial"> Wong,K.H.</style></author><author><style face="normal" font="Arial"> Zhou,Q.</style></author><author><style face="normal" font="Arial"> Lee,D.C.</style></author><author><style face="normal" font="Arial"> Liong,K.H.</style></author><author><style face="normal" font="Arial"> Teo,G.H.</style></author><author><style face="normal" font="Arial"> Hutchinson,P.E.</style></author><author><style face="normal" font="Arial"> Kemeny,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Immunology Programme, National University of Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Priming with high and low respiratory allergen dose induces differential CD4+ Th2 cells and IgE/IgG1 antibody responses in mice</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="238" start="227">227-238</pages><volume><style face="normal" font="Arial">151</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cumulative dose</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Mucus hyper-secretion</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="11" Month="2" Year="2017">2017/2/11</year></dates><abstract><style face="normal" font="Arial">Sensitization of allergic patients normally takes place over several years and is the result of repeated exposure to low levels of allergen. Most mouse asthma models use a high dose of allergen administered over a short period. We have investigated the role of dose in the immune response to an inhaled respiratory allergen (Blomia tropicalis). We observed the effect of priming dose on the allergic response in mice intranasally immunized with low (0.5mug) and high dose (50mug) of B. tropicalis extract and sacrificed one day after the last challenge. For both doses of allergen, T helper type 2 (Th2) cells and Th2 cytokines were evident as well as eosinophilic inflammation accompanied by mucus hyper-secretion. By contrast IgE and IgG1 antibody responses were normally only detected at high dose priming. To investigate the mechanism for these effects, we found group 2 innate lymphoid cells (ILC2s) were increased 48 hours after challenge in the low but not high dose treated mice. Furthermore, we determined whether repeated low dose exposure with different priming protocols could induce an antibody response. Repeated low dose exposure to 0.5mug three times weekly for 4 weeks (cumulative 6mug) had the same effect as a shorter high dose exposure (cumulative 80mug) and increasing cumulative dose induced antibody responses. These data indicate low doses of allergen are sufficient to prime Th2 cells and ILC2s, but insufficient to induce antibody responses. Cumulative exposure to small amounts of allergen induces both Th2 and antibody responses and may better reflect natural sensitization. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170212IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12726</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28190273">PM:28190273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20170212-FuruhashiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20170212-FuruhashiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170212, Furuhashi K</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12726</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Igetei,J.E.</style></author><author><style face="normal" font="Arial"> El-Faham,M.</style></author><author><style face="normal" font="Arial"> Liddell,S.</style></author><author><style face="normal" font="Arial"> Doenhoff,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Life Sciences, University of Nottingham, Nottingham, UK NG7 2RD</style></auth-address><titles><title><style face="normal" font="Arial">Antigenic cross-reactivity between Schistosoma mansoni and peanut: a role for cross-reactive carbohydrate determinants (CCDs) and implications for the hygiene hypothesis</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="517" start="506">506-517</pages><volume><style face="normal" font="Arial">150</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigenic epitopes</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Arachis</style></keyword><keyword><style face="normal" font="Arial"> Arachis hypogaea</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Nigeria</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbit IgG</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma mansoni</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">The antigenic reactivity of constituents of Schistosoma mansoni and peanut (Arachis hypogaea) was investigated to determine whether identical antigenic epitopes possessed by both organisms provided a possible explanation for the negative correlation between chronic schistosome infection and atopy to allergens. Aqueous extracts of peanuts were probed in Western immunoblots with rabbit IgG antibodies raised against the egg, cercarial and adult worm stages of S. mansoni. Several molecules in the peanut extract were antigenically reactive with antibodies from the various rabbit anti-schistosome sera. A pair of cross-reactive peanut molecules at ~30 000-33 000 molecular weight was purified and both proteins were identified by mass spectrometric analysis as the peanut allergen Ara h 1. Anti-S. mansoni soluble egg antigen antibodies that were eluted off the peanut molecules reacted with two S. mansoni egg antigens identified by mass spectrometry as IPSE/alpha-1 and kappa-5. Alignments of the amino acid sequences of Ara h 1 and either IPSE/alpha-1 or kappa-5 revealed a low level of peptide sequence identity. Incubation of nitrocellulose paper carrying electrophoresed peanut molecules, six constituents of other allergic plants and S. mansoni egg antigens in a mild solution of sodium metaperiodate before probing with antibodies, inhibited most of the cross-reactivities. The results are consistent with the antigenic cross-reactive epitopes of S. mansoni egg antigens, peanut and other allergic plants being cross-reactive carbohydrate determinants (CCDs). These findings are novel and an explanation based on 'blocking antibodies' could provide an insight for the inverse relationship observed between schistosome infection and allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170215IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Nigeria -CO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12711</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28201853">PM:28201853</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20170215-IgeteiJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20170215-IgeteiJE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170215, Igetei JE</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12711</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dilek,F.</style></author><author><style face="normal" font="Arial"> Ozceker,D.</style></author><author><style face="normal" font="Arial"> Ozkaya,E.</style></author><author><style face="normal" font="Arial"> Guler,E.M.</style></author><author><style face="normal" font="Arial"> Yazici,M.</style></author><author><style face="normal" font="Arial"> Tamay,Z.</style></author><author><style face="normal" font="Arial"> Kocyigit,A.</style></author><author><style face="normal" font="Arial"> Guler,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatric Allergy and Immunology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Elevated Nitrosative Stress in Children with Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="39" start="33">33-39</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> nitrosative stress</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic spontaneous urticaria (CSU) is an idiopathic condition that seriously affects quality of life. It is well known that oxidative stress and nitrosative stress (NS) are generally involved in many chronic inflammatory diseases. This study aimed to evaluate the possible role of NS in the pathogenesis of CSU. METHODS: Thirty-two children with CSU and 22 healthy control subjects were enrolled in the study. Demographic and clinical features were defined, and disease activity was quantified using the urticaria activity score (UAS). Serum NS was assessed by the plasma levels of total nitric oxide (NOx) metabolites and nitrite and nitrate measurements using a Griess method-based commercial kit. RESULTS: Plasma NOx levels were 82.5 +/- 11.3 micromol/L in the CSU group and 50.9 +/- 9.4 micromol/L in the control group. The difference was statistically significant (p &lt; 0.001). CSU patients also had higher plasma nitrite levels than controls (53.3 +/- 13.8 vs. 30.2 +/- 10.1 micromol/L, respectively, p &lt; 0.001). The median values of plasma nitrate were 27.5 micromol/L (IQR 19.1-35.5) in CSU patients and 20.9 micromol/L (IQR 17.9-23.2) in the control group, and the difference was statistically significant (p = 0.009). In addition, plasma NOx and nitrite levels were positively correlated with the UAS (rho = 0.512, p = 0.03 and rho = 0.452, p = 0.011, respectively). CONCLUSION: Plasma NS is elevated and positively correlated with disease activity in children with CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1159/000453334</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219063">PM:28219063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-33-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-33-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Dilek F</style></custom2><misc3><style face="normal" font="Arial">10.1159/000453334</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moverare,R.</style></author><author><style face="normal" font="Arial"> Blume,K.</style></author><author><style face="normal" font="Arial"> Lind,P.</style></author><author><style face="normal" font="Arial"> Crevel,R.</style></author><author><style face="normal" font="Arial"> Marknell deWitt,A.</style></author><author><style face="normal" font="Arial"> Cochrane,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Thermo Fisher Scientific, ImmunoDiagnostics, Uppsala University, Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Human Allergen-Specific IgG Subclass Antibodies Measured Using ImmunoCAP Technology</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="10" start="1">1-10</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Calibrator</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Compensation</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG2</style></keyword><keyword><style face="normal" font="Arial"> IgG3</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Paraproteins</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Knowledge of human IgG subclass antibody responses to various allergens has been hampered by a lack of reliable standardized assays. The aim here was to develop quantitative immunoassays for human IgG1, IgG2, and IgG3 antibodies using ImmunoCAP(R) technology and to evaluate their application. METHODS: Enzyme conjugates with isotype-specific monoclonal antibodies and calibrators composed of purified myeloma paraproteins were developed for each assay and used together with other standardized assay reagents for the Phadia(R) 100 instrument. The calibrators were adjusted to the international reference preparation IRP 67/86. The assays were characterized and used together with other standard ImmunoCAP assays to measure antibodies to various allergens in preliminary studies. RESULTS: The new assays had limits of quantitation of 1.0 (IgG1), 4.6 (IgG2), and 0.04 mgA/L (IgG3), and coefficients of variation of &lt;20%. Only some minor cross-reactivity with IgG2 was observed for the specific IgG1 assay. The specific IgG2 assay showed a bias for the allotype G2m(23) and compensation factors were used to adjust the measured concentrations accordingly. Preliminary studies indicated a strong and stable IgG4 antibody response to beta-lactoglobulin in healthy individuals, a high IgG1 and even higher IgG2 antibody response to house dust mite in sensitized and nonsensitized subjects, and a mixed IgG subclass response to venom allergens in allergic patients with increasing IgG4 antibody levels during venom immunotherapy. CONCLUSIONS: The new research assays are valuable tools for immunological studies, enabling the characterization of antibody profiles using a standardized approach, and facilitating data interpretation and the comparison of results across studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1159/000455098</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219072">PM:28219072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-1-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-1-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Moverare R</style></custom2><misc3><style face="normal" font="Arial">10.1159/000455098</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Worm,M.</style></author><author><style face="normal" font="Arial"> Ernst,D.</style></author><author><style face="normal" font="Arial"> Kraller,M.</style></author><author><style face="normal" font="Arial"> Babina,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="26" start="20">20-26</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> CD203c</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HLA-DR</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid A</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-Like Receptor 4</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The clinical efficacy and safety of allergoid immunotherapy have been demonstrated in clinical trials. However, simultaneous monitoring of the immunological changes by allergoids versus allergens in the cells of the same individual has not been extensively performed, and the impact of concurrent Toll-like receptor 4 (TLR4) ligation has not been specified. METHODS: Three types of birch allergen were utilized: glutaraldehyde-treated allergoid (extract A), the same allergoid plus monophosphoryl lipid A (MPL), i.e., TLR4 ligand (extract A*), and native allergen (extract B). Antigen-specific responses after the in vitro stimulation of blood cells with the extracts were assessed by studying costimulatory receptors on the B cell surface by flow cytometry, cytokine responses by ELISA, and CD63 and CD203c upregulation (basophil activation test) in allergic versus nonallergic subjects. RESULTS: HLA-DR selectively increased upon allergen or allergoid treatment in the allergic group only. The extract types elicited similar cytokine responses, with IL-6 and IL-10 production detected only in certain atopic subjects. The allergoids revealed a strong reduction (100- to &lt;10,000-fold) in basophil activation versus native allergen. Reactivity was undetectable in the basophils from nonallergic subjects. CONCLUSION: The allergenicity of the allergoid employed was sharply reduced when compared to the native allergen, while its immunogenicity was largely retained, especially in the presence of MPL. We also provide further evidence that allergic and nonallergic individuals show preexisting differences in their immune repertoires</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000455047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219062">PM:28219062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-20-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-20-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Worm M</style></custom2><misc3><style face="normal" font="Arial">10.1159/000455047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,X.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Sun,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Synergistic Actions of Histamine-Releasing Factor and Histamine Releasing Factor-Reactive IgE in Chronic Urticaria</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="32" start="27">27-32</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> histamine-releasing factor</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">The etiology of chronic urticaria (CU) remains elusive. Histamine-releasing factor (HRF) is reported to have a proinflammatory role in asthma and immediate hypersensitivity of the skin. The aim of this study was to examine the role of HRF in the pathogenesis of CU. Forty patients with CU were enrolled and their serum HRF concentrations were determined by ELISA. The results demonstrated that the concentrations of HRF and HRF-reactive IgE in the CU group were significantly higher than those in the control group, and there was a significant linear correlation between HRF and HRF-reactive IgE concentrations (r = 0.859, p &lt; 0.001) in CU patients. Additionally, the HRF-reactive IgE concentration was significantly correlated with the disease activity (r = 0.693, p &lt; 0.0001). HRF and HRF-reactive IgE alone failed to activate LAD2 cells. After being primed by the patient sera with the highest IgE concentrations and stimulated by HRF, beta-hexosaminidase can be released from LAD2 cells. Our findings suggest that the synergistic actions of HRF and HRF-reactive IgE may play important roles in the pathogenesis of CU</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1159/000455099</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219065">PM:28219065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-27-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-27-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Huang X</style></custom2><misc3><style face="normal" font="Arial">10.1159/000455099</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asero,R.</style></author><author><style face="normal" font="Arial"> Marzano,A.V.</style></author><author><style face="normal" font="Arial"> Ferrucci,S.</style></author><author><style face="normal" font="Arial"> Cugno,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy</style></auth-address><titles><title><style face="normal" font="Arial">D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="44" start="40">40-44</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> D-dimer</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fibrin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">Omalizumab is very effective in the majority of patients with severe chronic spontaneous urticaria (CSU), but its mechanism of action is still unclear. In CSU the coagulation cascade is activated with an intensity that parallels the disease severity, and elevated plasma D-dimer levels are associated with a poor response to both antihistamines and cyclosporin. We measured D-dimer plasma levels before and after the first administration of omalizumab in 32 patients with severe CSU. A number of clinical and laboratory parameters were recorded, including the urticaria activity score, presence of angioedema, disease duration, C-reactive protein, anti-nuclear, and anti-thyroid antibodies. Baseline D-dimer levels were elevated in 19 (59%) cases. Omalizumab induced a complete response in 25 patients (78%), in most cases already after the first administration. At baseline, 14/25 responders had increased D-dimer plasma levels versus 5/7 non-responders. All responders showed a dramatic decrease of D-dimer plasma levels after the first administration of the drug (from 1,024 +/- 248 [mean +/- SE] to 251 +/- 30 ng/mL; p = 0.003). In contrast, non-responders did not show any reduction in D-dimer levels after omalizumab administration (from 787 +/- 206 to 1,230 +/- 429 ng/mL; p = ns). In conclusion, plasma levels of D-dimer are frequently elevated in patients with severe CSU before omalizumab administration and decrease according to the clinical response of the disease to the drug, suggesting a possible effect of omalizumab on coagulation activation and fibrin degradation in a subset of CSU patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1159/000453453</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219067">PM:28219067</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-40-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-40-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Asero R</style></custom2><misc3><style face="normal" font="Arial">10.1159/000453453</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">London,N.R.,Jr.</style></author><author><style face="normal" font="Arial"> Tharakan,A.</style></author><author><style face="normal" font="Arial"> Lane,A.P.</style></author><author><style face="normal" font="Arial"> Biswal,S.</style></author><author><style face="normal" font="Arial"> Ramanathan,M.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD</style></auth-address><titles><title><style face="normal" font="Arial">Nuclear erythroid 2-related factor 2 activation inhibits house dust mite-induced sinonasal epithelial cell barrier dysfunction</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="541" start="536">536-541</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> air-liquid interface</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Fluorescein</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sinonasal epithelial</style></keyword><keyword><style face="normal" font="Arial"> sulforaphane</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dysregulated sinonasal epithelial cell (SNEC) barrier function has been proposed to contribute to the pathogenesis of sinonasal inflammatory conditions such as allergic rhinitis (AR) and chronic rhinosinusitis (CRS). Allergens such as house dust mite (HDM) have been reported to disrupt SNEC barrier integrity. We have recently identified nuclear erythroid 2-related factor 2 (Nrf2) activation via sulforaphane (SFN) stimulation to stabilize SNEC barrier function. The purpose of this study was to explore whether Nrf2 activation could ameliorate HDM-induced SNEC barrier dysfunction. METHODS: Human SNECs (HSNECs) were grown from patients at the air-liquid interface (ALI). HSNECs were stimulated with HDM with or without pharmacologic activation of Nrf2 with SFN. HSNECs were then stained for the epithelial cell junction protein zonula occludens-1 (ZO-1) and cell surface localization was evaluated by confocal microscopy. Transepithelial electrical resistance (TER) and paracellular fluorescein isothiocyanate (FITC)-dextran permeability was measured in response to stimulation with HDM and SFN. RESULTS: HDM stimulation caused a global disruption of the protein ZO-1 along with an associated decrease in TER (p &lt; 0.001) and increased FITC-dextran paracellular permeability (p &lt; 0.0001). Enhancing Nrf2 activation through treatment with SFN prior to stimulation with HDM was associated with increased localization of ZO-1 at the cell surface and statistically significant increases in TER (p &lt; 0.05) and decrease in paracellular FITC-dextran permeability (p &lt; 0.001). CONCLUSION: This is the first study to demonstrate that HDM-induced SNEC barrier dysfunction may be preventable by Nrf2 activation. The Nrf2 antioxidant pathway may represent a potential therapeutic target for allergen-induced sinonasal inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21916</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28151586">PM:28151586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-536-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-536-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, London NR Jr</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21916</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,T.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Wang,F.</style></author><author><style face="normal" font="Arial"> Zhou,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, The First Affiliated Hospital of Chinese People's Liberation Army General Hospital, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="392" start="389">389-392</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> premature</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: To sustain the long-lasting beneficial effects of allergen-specific sublingual immunotherapy (SLIT), an adequate duration of treatment is required. Nevertheless, many patients discontinue prematurely and therefore fail to obtain satisfactory therapeutic effect in clinical practice. The aim of this study was to analyze the causes leading to premature discontinuation of SLIT in allergic rhinitis (AR), and to provide the corresponding countermeasures for the following SLIT course. METHODS: We performed a retrospective analysis of data from 142 patients with AR who started SLIT during the period from December 2009 to February 2015. Patients were contacted at 1, 3, 6, and 12 months into SLIT as part of our standard of care. The patients who claimed to have stopped treatment were asked to provide a reason during one of the phone calls. RESULTS: Overall, 76 (54%) patients with AR terminated immunotherapy during the first year of treatment. Among the 76 patients, the following reasons were cited for nonadherence to immunotherapy: patients could not be reached (25%); ineffectiveness (24%); the long course (18%); improvement of symptoms (13%); side effects (4%); lack of confidence in the treatment (4%); or other reasons (12%). CONCLUSION: Fifty-four percent of AR patients terminated their treatment within the first year of SLIT. The top reasons for treatment discontinuation included patients not be reached, ineffectiveness, and length of course</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21909</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28151587">PM:28151587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-389-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-389-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Wang T</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21909</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumar,M.S.</style></author><author><style face="normal" font="Arial"> Oh,M.S.</style></author><author><style face="normal" font="Arial"> Leader,B.</style></author><author><style face="normal" font="Arial"> Rotella,M.</style></author><author><style face="normal" font="Arial"> Stillman,L.</style></author><author><style face="normal" font="Arial"> DelGaudio,J.M.</style></author><author><style face="normal" font="Arial"> Wise,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Emory University School of Medicine, Atlanta, GA</style></auth-address><titles><title><style face="normal" font="Arial">Perceived compliance and barriers to care in sublingual immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="529" start="525">525-529</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patient Compliance</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: For allergy immunotherapy to be effective, patient compliance is critical. However, aqueous sublingual immunotherapy (SLIT) may be considered demanding for patients, requiring strict daily dosing and refilling of medication at regular intervals. In this study we sought to determine how patients perceive their own compliance with SLIT and identify barriers that may hinder compliance. METHODS: Using a retrospective review, 46 patients currently undergoing aqueous SLIT were identified to have less-than-excellent compliance based on frequency of clinic visits for SLIT refills. Twenty-eight of these patients completed a phone survey regarding symptom improvement, compliance, and barriers to care. In addition, 56 patients who withdrew from therapy before completion were polled about barriers to adherence. RESULTS: Of the 28 patients participating in the initial phone survey, 24 (86%) reported subjective improvement in symptoms on SLIT, despite less-than-excellent compliance. Nineteen (68%) of these patients perceived their own compliance to be excellent. Eighteen patients (65%) reported the inconvenience of scheduling and attending clinic appointments to be the main reason for noncompliance. The most common reasons for withdrawal from therapy were cost (27%), lack of effectiveness (25%), and difficulty with compliance (14%). CONCLUSION: The majority of aqueous SLIT patients perceived their compliance to be excellent, although, based on a previous study, these patients did not reach excellent compliance benchmarks. Inconvenience of clinic visits and cost of therapy were found to be the most common barriers to care. Despite what providers perceived as less-than-excellent compliance, 82% of patients reported symptom improvement with SLIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170209IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21920</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28182329">PM:28182329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-525-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-525-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170209, Kumar MS</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21920</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zuska-Prot,M.</style></author><author><style face="normal" font="Arial"> Maslanka,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowskiego Street 13, 10-719 Olsztyn, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of inhaled and systemic glucocorticoid treatment on CD4+ regulatory and effector T cells in a mouse model of allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="109" start="98">98-109</pages><volume><style face="normal" font="Arial">45</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">To achieve a better understanding of mechanisms underlying the anti-asthmatic action of inhaled and systemic glucocorticoids (GCs) and to provide more data regarding the risk of a negative effect of inhaled GCs on CD4+ T cells, a study was conducted on the effect of ciclesonide and methylprednisolone on CD4+ effector (Teff), regulatory (Treg) and resting (Trest) T cells within respiratory and extra-respiratory tissues in a mouse model of allergic asthma. The study indicated that one, and possibly a key mechanism, underlying the anti-asthmatic action of inhaled and systemic GCs is the prevention of the activation and clonal expansion of CD4+ Teff cells in the mediastinal lymph nodes (MLNs), which consequently prevents infiltration of the lungs with CD4+ Teff cells. The beneficial effects of GCs in asthma treatment were not mediated through increased recruitment of Treg cells into the MLNs and lungs and/or local generation of Treg cells. The results demonstrated that inhaled and systemic GCs induced comparable depletion of normal CD4+ Teff, Trest and Treg cells in the MLNs, head and neck lymph nodes and peripheral blood. Furthermore, inhaled, but not systemic GC therapy, led to the loss of these cells in the lungs. Thus, the study suggests that inhaled GC therapy may not be safer at all than systemic one with respect to the adverse effect on CD4+ T cells present within and outside the respiratory tract. Moreover, administration of inhaled GCs can produce negative effects on lung-residing CD4+ T cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170212IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.02.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28189974">PM:28189974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-45-98-109.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-45-98-109.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170212, Zuska-Prot M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.02.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,N.</style></author><author><style face="normal" font="Arial"> Srivastava,K.</style></author><author><style face="normal" font="Arial"> Song,Y.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Cho,S.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Li,X.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States</style></auth-address><titles><title><style face="normal" font="Arial">Berberine as a chemical and pharmacokinetic marker of the butanol-extracted Food Allergy Herbal Formula-2</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="127" start="120">120-127</pages><volume><style face="normal" font="Arial">45</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> Caco 2 cell</style></keyword><keyword><style face="normal" font="Arial"> Caco-2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Food Allergy Herbal Formula 2 (FAHF-2) provided protection against peanut anaphylaxis in a murine model and induced beneficial immune-modulation in humans. Butanol-refined FAHF-2, B-FAHF-2, retained safety and efficacy in the peanut allergic murine model at only 1/5 of FAHF-2 dosage. One compound, berberine, was isolated and identified in vitro as a bioactive component present in FAHF-2 and B-FAHF-2. The aim of this study was to investigate berberine as a chemical and pharmacokinetic marker of B-FAHF-2. METHODS: The consistency of constituents between B-FAHF-2 and FAHF-2 was tested. Peanut allergic C3H/HeJ mice were orally administered with 1mg of berberine or B-FAHF-2 containing anequivalent amount of berberine, and the ability to protect against peanut anaphylaxis and pharmacokinetic parameters were determined. Human intestinal epithelial cells (Caco-2) were cultured with berberine with or without the nine individual herbal constituents in B-FAHF-2, and the absorbed berberine levels were determined. RESULTS: Berberine is one of the major components in B-FAHF-2 and FAHF-2 formula. In a peanut allergic mouse model, B-FAHF-2, but not berberine, protected mice from anaphylaxis reactions. Pharmacokinetic profiles showed that the Cmax of B-FAHF-2 fed mice was 289.30+/-185.40ng/mL; whereas berberine alone showed very low bioavailability with Cmax value of 35.13+/-47.90ng/mL. Caco-2 cells influx assay showed that 7 of 9 herbal constituents in B-FAHF-2 increased berberine absorption at rates ranging from 18 to 205%. CONCLUSIONS: B-FAHF-2 remarkably increased the bioavailability of berberine. Berberine can be used as chemical and pharmacokinetic marker of B-FAHF-2. Other herbal components in B-FAHF-2 may facilitate the absorption of berberine</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - United states -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.01.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28208101">PM:28208101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-45-120-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-45-120-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Yang N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.01.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silvares,M.R.</style></author><author><style face="normal" font="Arial"> Fortes,M.R.</style></author><author><style face="normal" font="Arial"> Nascimento,R.A.</style></author><author><style face="normal" font="Arial"> Padovani,C.R.</style></author><author><style face="normal" font="Arial"> Miot,H.A.</style></author><author><style face="normal" font="Arial"> Nogueira,C.R.</style></author><author><style face="normal" font="Arial"> Mazeto,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Radiotherapy, Botucatu Medical School, Sao Paulo State University - Unesp, Botucatu, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Thyrotropin receptor gene expression in the association between chronic spontaneous urticaria and Hashimoto's thyroiditis</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="552" start="547">547-552</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Hashimoto's thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> radiotherapy</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Diseases</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="8" Month="2" Year="2017">2017/2/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic spontaneous urticaria (CSU) may be associated with autoimmune thyroid diseases, and the Autologous Serum Skin Test (ASST) is an autoreactivity marker. The thyrotropin (TSH) and TSH receptor (TSHR) could play a role in the pathogenesis of CSU. The aim of this study was to evaluate ASST positivity and TSHR gene expression in healthy skin and ASST wheals in euthyroid women with CSU, with (14 patients) and without (15 patients) Hashimoto's thyroiditis (HT). METHODS: ASST was performed and TSHR gene expression studied in wheals induced by ASST and in healthy skin. RESULTS: ASST presented greater positivity (86% x 40%) and larger diameter (10.8 x 9.6 mm) in the HT group (P &lt; 0.05). TSHR gene expression was higher in the ASST area and healthy skin of HT group (P &lt; 0.01). Positive correlation of antibodies levels with ASST wheal measurements and TSHR gene expression was seen. CONCLUSIONS: Women with CSU and HT presented greater positivity and larger measurements for ASST and higher TSHR expression in the skin, suggesting association between CSU, thyroid autoimmunity, and TSHR</style></abstract><notes><style face="normal" font="Arial">DA - 20170209IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.13487</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28181228">PM:28181228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\20170209-SilvaresMR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\20170209-SilvaresMR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170209, Silvares MR</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.13487</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kolkhir,P.</style></author><author><style face="normal" font="Arial"> Pogorelov,D.</style></author><author><style face="normal" font="Arial"> Kochergin,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia</style></auth-address><titles><title><style face="normal" font="Arial">Chronic spontaneous urticaria associated with vitiligo and thyroiditis (autoimmune polyglandular syndrome IIIC): case series</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="e90" start="e89">e89-e90</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vitiligo</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - LetterCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.13538</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188623">PM:28188623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\20170211-KolkhirP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\20170211-KolkhirP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Kolkhir P</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.13538</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jing,R.</style></author><author><style face="normal" font="Arial"> Li,H.Q.</style></author><author><style face="normal" font="Arial"> Hu,C.L.</style></author><author><style face="normal" font="Arial"> Jiang,Y.P.</style></author><author><style face="normal" font="Arial"> Qin,L.P.</style></author><author><style face="normal" font="Arial"> Zheng,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacognosy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.</style></auth-address><titles><title><style face="normal" font="Arial">Phytochemical and Pharmacological Profiles of Three Fagopyrum Buckwheats</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E589">E589-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-Allergic Agents</style></keyword><keyword><style face="normal" font="Arial"> Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic agents</style></keyword><keyword><style face="normal" font="Arial"> Antibacterial</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antineoplastic Agents</style></keyword><keyword><style face="normal" font="Arial"> Antineoplastic Agents,Phytogenic</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Common buckwheat</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fagopyrum</style></keyword><keyword><style face="normal" font="Arial"> Fagopyrum esculentum</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hypoglycemic Agents</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> phenolic compounds</style></keyword><keyword><style face="normal" font="Arial"> Phenolics</style></keyword><keyword><style face="normal" font="Arial"> Phytochemicals</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protective Agents</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2016">2016/4/19</year></dates><abstract><style face="normal" font="Arial">The genus Fagopyrum (Polygonaceae), currently comprising 15 species of plants, includes three important buckwheat species: Fagopyrum esculentum (F. esculentum) Moench. (common buckwheat), Fagopyrum tataricum (F. tataricum) (L.) Gaertn. (tartary buckwheat) and Fagopyrum dibotrys (F. dibotrys) (D. Don) Hara. (perennial buckwheat), which have been well explored due to their long tradition of both edible and medicinal use. This review aimed to present an up-to-date and comprehensive analysis of the phytochemistry and pharmacology of the three Fagopyrum buckwheats. In addition, the scope for future research was also discussed. All available references included in this paper were compiled from major databases, such as MEDLINE, Pubmed, Scholar, Elsevier, Springer, Wiley and CNKI. A total of 106 compounds isolated from three Fagopyrum buckwheats can be mainly divided into six classes: flavonoids, phenolics, fagopyritols, triterpenoids, steroids and fatty acids. Flavonoids and phenolic compounds were considered to be the major active components. Considerable pharmacological experiments both in vitro and in vivo have validated that Fagopyrum buckwheats possess antitumor, anti-oxidant, anti-inflammatory, hepatoprotective, anti-diabetic activities, etc. All reported data lead us to conclude that Fagopyrum buckwheats have convincing medicinal potential. However, further research is needed to explore its bioactive constituents, the relationship to their structural activities and the molecular mechanisms of action</style></abstract><notes><style face="normal" font="Arial">DA - 20160423IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Anti-Allergic Agents)RN - 0 (Anti-Bacterial Agents)RN - 0 (Anti-Inflammatory Agents)RN - 0 (Antineoplastic Agents, Phytogenic)RN - 0 (Antioxidants)RN - 0 (Hypoglycemic Agents)RN - 0 (Phytochemicals)RN - 0 (Protective Agents)SB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms17040589</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27104519">PM:27104519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2016-17-E589.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2016-17-E589.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160423, Jing R</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms17040589</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perot,M.</style></author><author><style face="normal" font="Arial"> Lupi,R.</style></author><author><style face="normal" font="Arial"> Guyot,S.</style></author><author><style face="normal" font="Arial"> Delayre-Orthez,C.</style></author><author><style face="normal" font="Arial"> Gadonna-Widehem,P.</style></author><author><style face="normal" font="Arial"> Thebaudin,J.Y.</style></author><author><style face="normal" font="Arial"> Bodinier,M.</style></author><author><style face="normal" font="Arial"> Larre,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Polyphenol interactions mitigate the immunogenicity and allergenicity of gliadins</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> artichoke</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="Arial">Wheat allergy is an IgE-mediated disorder. Polyphenols, which are known to interact with certain proteins, could be used to reduce allergic reactions. In this study, we screened several polyphenol sources for their ability to interact with gliadins, mask epitopes and impact basophil degranulation. Polyphenol extracts from artichoke leaves, cranberries, apples and green tea leaves were examined. Of these extracts, the first three formed insoluble complexes with gliadins. Only the cranberry and apple extracts masked epitopes in dot blot assays using anti-gliadin IgG and IgE antibodies from patients with wheat allergies. The cranberry and artichoke extracts limited cellular degranulation by reducing mouse anti-gliadin IgE recognition. In conclusion, the cranberry extract is the most effective polyphenol source at reducing the immunogenicity and allergenicity of wheat gliadins</style></abstract><notes><style face="normal" font="Arial">DA - 20170213IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b05371</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28190352">PM:28190352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170213-PerotM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170213-PerotM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170213, Perot M</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b05371</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Serhane,H.</style></author><author><style face="normal" font="Arial"> Amro,L.</style></author><author><style face="normal" font="Arial"> Sajiai,H.</style></author><author><style face="normal" font="Arial"> Alaoui Yazidi,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Prevalence of Skin Sensitization to Pollen of Date Palm in Marrakesh, Morocco</style></title><secondary-title><style face="normal" font="Arial">J Allergy (Cairo)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy (Cairo)</style></full-title></periodical><pages end="" start="6425869">6425869-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Morocco</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin sensitization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Morocco -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/6425869</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1155/2017/6425869</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy (Cairo)\2017-2017-6425869.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy (Cairo)\2017-2017-6425869.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Serhane H</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/6425869</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leung,D.Y.</style></author><author><style face="normal" font="Arial"> Jepson,B.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Hanifin,J.M.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> Paller,A.S.</style></author><author><style face="normal" font="Arial"> Monti,K.</style></author><author><style face="normal" font="Arial"> David,G.</style></author><author><style face="normal" font="Arial"> Canniff,J.</style></author><author><style face="normal" font="Arial"> Lorenzo,M.G.</style></author><author><style face="normal" font="Arial"> Weinberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">the Department of Pediatrics, National Jewish Health, Denver, Colo.</style></auth-address><titles><title><style face="normal" font="Arial">A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1582" start="1575">1575-1582</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza vaccination</style></keyword><keyword><style face="normal" font="Arial"> Influenza Vaccine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Antibody responses to the inactivated seasonal influenza vaccine in patients with atopic dermatitis (AD) have not been carefully characterized. OBJECTIVE: The primary objective of this study was to compare antibody responses to intradermal vaccination in participants with moderate/severe AD with those in nonatopic participants. Secondary objectives were to evaluate the effect of route of administration, Staphylococcus aureus skin colonization, and disease severity on vaccine response. METHODS: This was an open-label study conducted in the 2012-2013 influenza season at 5 US clinical sites. A total of 360 participants with moderate/severe AD or nonatopic subjects were assessed for eligibility, 347 of whom received intradermal or intramuscular vaccination per label and were followed for 28 days after vaccination. The primary outcome was the difference in the proportion of participants achieving seroprotection (hemagglutination-inhibition antibody titer >/=1:40 on day 28 after vaccination). RESULTS: Seroprotection rates for influenza B, H1N1, and H3N2 were not different (1) between participants with AD and nonatopic participants receiving intradermal vaccination and (2) between AD participants receiving intradermal and intramuscular vaccination. After intradermal, but not intramuscular, vaccination, participants with AD with S aureus colonization experienced (1) lower seroprotection and seroconversion rates and lower hemagglutination-inhibition antibody titer geometric mean fold increase against influenza B and (2) lower seroconversion rates against influenza H1N1 than noncolonized participants with AD. CONCLUSION: Participants with AD colonized with S aureus exhibited a reduced immune response to influenza vaccination compared with noncolonized participants after intradermal but not intramuscular vaccination. Because most patients with AD are colonized with S aureus, intramuscular influenza vaccination should be given preference in these patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.952</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28209343">PM:28209343</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170217-LeungDY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170217-LeungDY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Leung DY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.952</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deckers,J.</style></author><author><style face="normal" font="Arial"> Sichien,D.</style></author><author><style face="normal" font="Arial"> Plantinga,M.</style></author><author><style face="normal" font="Arial"> Van Moorleghem,J.</style></author><author><style face="normal" font="Arial"> Vanheerswynghels,M.</style></author><author><style face="normal" font="Arial"> Hoste,E.</style></author><author><style face="normal" font="Arial"> Malissen,B.</style></author><author><style face="normal" font="Arial"> Dombrowicz,D.</style></author><author><style face="normal" font="Arial"> Guilliams,M.</style></author><author><style face="normal" font="Arial"> De Bosscher,K.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">VIB Inflammation Research Center, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Epicutaneous sensitization to house dust mite allergen requires IRF4-dependent dermal dendritic cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Langerhans Cells</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier function</style></keyword><keyword><style face="normal" font="Arial"> skin sensitization</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exposure to allergens like house dust mite (HDM) via the skin often precedes allergic inflammation in the lung. It was proposed that Th2 sensitization via the skin occurs when skin barrier function is disrupted for example by genetic predisposition, mechanical damage or enzymatic activity of allergens. OBJECTIVE: To study how HDM applied to unmanipulated skin leads to Th2 sensitization and to study which antigen presenting cells mediate this process METHODS: HDM was applied epicutaneously by painting HDM on unmanipulated ear skin, or under an occlusive tape. HDM challenge was via the nose. Mouse strains lacking different dendritic cell (DC) populations were used, and 1-DER T cells carrying a transgenic TCR reactive to Der p 1 allergen used as readout for antigen presentation. The Th2-inducing capacity of sorted skin-derived DC subsets was determined by adoptive transfer to naive mice. RESULTS: Epicutaneous HDM application led to Th2 sensitization and eosinophilic airway inflammation upon intranasal HDM challenge. Skin sensitization did not require prior skin damage or enzymatic activity within HDM extract, yet was facilitated by applying the allergen under an occlusive tape. Primary proliferation of 1-DER T cells occurred only in the regional skin draining lymph nodes. Epicutaneous sensitization was found to be driven by two variants of IRF4-dependent dermal conventional dendritic cell (cDC2) subsets, and not by epidermal Langerhans cells. CONCLUSION: These findings identify skin cDC2 as crucial players in Th2 sensitization to common inhaled allergens that enter the body through the skin, and can provoke features of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170212IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Netherlands -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.970</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28189772">PM:28189772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170212-DeckersJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170212-DeckersJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170212, Deckers J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.970</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Steer,C.A.</style></author><author><style face="normal" font="Arial"> Martinez-Gonzalez,I.</style></author><author><style face="normal" font="Arial"> Ghaedi,M.</style></author><author><style face="normal" font="Arial"> Allinger,P.</style></author><author><style face="normal" font="Arial"> Matha,L.</style></author><author><style face="normal" font="Arial"> Takei,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, B.C., Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, B.C., Canada</style></auth-address><titles><title><style face="normal" font="Arial">Group 2 innate lymphoid cell activation in the neonatal lung drives type 2 immunity and allergen sensitization</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="595" start="593">593-595</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Foxes</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">Neonatal lung immunity is unique due to allergen-independent endogenous IL-33 mediated activation of group 2 innate lymphoid cells (ILC2s) that promote Th2 cell responses, making neonates prone to allergen sensitization and allergic lung diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.984</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216436">PM:28216436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170220-SteerCA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170220-SteerCA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Steer CA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.984</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goswami,R.</style></author><author><style face="normal" font="Arial"> Blazquez,A.B.</style></author><author><style face="normal" font="Arial"> Kosoy,R.</style></author><author><style face="normal" font="Arial"> Rahman,A.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Berin,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaffe Food Allergy Institute</style></auth-address><titles><title><style face="normal" font="Arial">Systemic Innate Immune Activation in Food Protein Induced Enterocolitis Syndrome (FPIES)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1896" start="1885">1885-1896</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune activation</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> NK cells</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food protein induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy of infancy whose pathophysiology is poorly understood. OBJECTIVES: We set out to identify and phenotype allergen-responsive cells in peripheral blood of a cohort of subjects undergoing supervised food challenge for FPIES. METHODS: We profiled antigen-responsive cells in peripheral blood mononuclear cells by flow cytometry, and examined cells in whole blood obtained before and after challenge by CyTOF mass cytometry and RNAseq. RESULTS: Using a CD154-based detection approach, we observed that milk, soy, or rice-responsive T cells, and TNFalpha-producing CD154+ T cells were significantly lower in those with outgrown FPIES compared to active FPIES. However, levels were within the normal range and were inconsistent with a role in the pathophysiology of FPIES. Profiling of whole blood by CyTOF demonstrated profound activation of cells of the innate immune system after food challenge, including monocytes, neutrophils, NK cells, and eosinophils. Activation was not observed in children with outgrown FPIES. We confirmed this pattern of innate immune activation in a larger cohort by RNAseq. Furthermore, we observed pan-T cell activation and redistribution from the circulation after a positive food challenge but not in those who had outgrown their FPIES. CONCLUSIONS: Our data demonstrate a compelling role of systemic innate immune activation in adverse reactions elicited by foods in FPIES. Further investigation is needed to identify the mechanism of antigen specificity of adverse reactions to foods in FPIES</style></abstract><notes><style face="normal" font="Arial">DA - 20170213IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.971</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192147">PM:28192147</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170213-GoswamiR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170213-GoswamiR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170213, Goswami R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.971</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jimenez-Saiz,R.</style></author><author><style face="normal" font="Arial"> Chu,D.K.</style></author><author><style face="normal" font="Arial"> Mandur,T.S.</style></author><author><style face="normal" font="Arial"> Walker,T.D.</style></author><author><style face="normal" font="Arial"> Gordon,M.E.</style></author><author><style face="normal" font="Arial"> Chaudhary,R.</style></author><author><style face="normal" font="Arial"> Koenig,J.</style></author><author><style face="normal" font="Arial"> Saliba,S.</style></author><author><style face="normal" font="Arial"> Galipeau,H.J.</style></author><author><style face="normal" font="Arial"> Utley,A.</style></author><author><style face="normal" font="Arial"> King,I.L.</style></author><author><style face="normal" font="Arial"> Lee,K.</style></author><author><style face="normal" font="Arial"> Ettinger,R.</style></author><author><style face="normal" font="Arial"> Waserman,S.</style></author><author><style face="normal" font="Arial"> Kolbeck,R.</style></author><author><style face="normal" font="Arial"> Jordana,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">McMaster Immunology Research Centre (MIRC), Dept. of Pathology &amp; Molecular Medicine, McMaster University, Hamilton, ON, L8N 3Z5, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Lifelong Memory Responses Perpetuate Humoral Th2 Immunity and Anaphylaxis in Food Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germinal Center</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> humoral immunity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory B cell</style></keyword><keyword><style face="normal" font="Arial"> memory B cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A number of food allergies (e.g. fish, shellfish, nuts) are lifelong, without any disease-transforming therapies and unclear in their underlying immunology. Clinical manifestations of food allergy are largely mediated by IgE. Although persistent IgE titres have conventionally been attributed to long-lived IgE+ plasma cells (PCs), this has not been directly and comprehensively tested. OBJECTIVE: To evaluate mechanisms underlying persistent IgE and allergic responses to food allergens. METHODS: We used a model of peanut allergy and anaphylaxis, various knockout mice, adoptive transfer experiments and in vitro assays, to identify mechanisms underlying persistent IgE humoral immunity over almost the entire life-span of the mouse (18-20 months). RESULTS: Contrary to conventional paradigms, our data show that clinically relevant lifelong IgE titres are not sustained by long-lived IgE+ PCs. Instead, lifelong reactivity is conferred by allergen-specific long-lived memory B cells that replenish the IgE+ PC compartment. B cell re-activation requires allergen re-exposure and IL-4 production by CD4 T cells. We define the half-lives of antigen-specific: germinal centers (23.3 days); IgE+ and IgG1+ PCs (60 days and 234.4 days respectively) and clinically-relevant cell-bound IgE (67.3 days). CONCLUSIONS: These findings can explain lifelong food allergies observed in humans as the consequence of allergen exposures that recurrently activate memory B cells and identify these as a therapeutic target with disease-transforming potential</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216433">PM:28216433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170220-JimenezSaizR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170220-JimenezSaizR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Jimenez-Saiz R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asarnoj,A.</style></author><author><style face="normal" font="Arial"> Hamsten,C.</style></author><author><style face="normal" font="Arial"> Lupinek,C.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Andersson,N.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology and Allergy Unit, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: the BAMSE population-based birth cohort</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="590" start="587">587-590</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> BAMSE</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">IgE signatures to peanut allergen measured in early childhood allow predicting the likelihood of peanut allergy in adolescence. Peanut symptoms and Ara h 2 IgE >2.0 ISU-E at 4 years predict peanut allergy in adolescence</style></abstract><notes><style face="normal" font="Arial">DA - 20170213IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Austria -CO - Spain -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.973</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192142">PM:28192142</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170213-AsarnojA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170213-AsarnojA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170213, Asarnoj A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.973</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Richgels,P.K.</style></author><author><style face="normal" font="Arial"> Yamani,A.</style></author><author><style face="normal" font="Arial"> Chougnet,C.A.</style></author><author><style face="normal" font="Arial"> Lewkowich,I.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati OH</style></auth-address><titles><title><style face="normal" font="Arial">Maternal house dust mite exposure during pregnancy enhances severity of HDM-induced asthma in murine offspring</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> In utero</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Maternal Exposure</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic status of the mother and maternal exposure to environmental factors is associated with increased asthma risk. Moreover, animal models demonstrate that exposure to allergens in strongly sensitized mothers influences offspring asthma development, suggesting that in utero exposures can influence offspring asthma. However, it is unclear whether maternal exposure to common human allergens like house dust mite (HDM), in the absence of additional adjuvants, influences offspring asthma development. OBJECTIVE: To determine if maternal HDM exposure influences asthma development in offspring. METHODS: Pregnant female mice were exposed to PBS or HDM during pregnancy. Using offspring of PBS or HDM-exposed mothers, the magnitude of HDM or Aspergillus fumigatus (AF) extract-induced airway hyperresponsiveness (AHR), airway inflammation, immunoglobulin production, Th2-associated cytokine synthesis and pulmonary dendritic cell activity was assessed. RESULTS: Compared to offspring of PBS-exposed mothers, offspring of HDM-exposed mothers demonstrate increased AHR, airway inflammation, Th2 cytokine production, immunoglobulin levels and a modest decrease in the phagocytic capacity of pulmonary macrophage populations following HDM exposure. Increased sensitivity to AF-induced airway disease was not observed. Offspring of HDM-exposed B cell deficient mothers also demonstrated increased HDM-induced AHR, suggesting transfer of maternal immunoglobulins is not required. CONCLUSIONS: Our data demonstrate that maternal exposure to HDM during pregnancy increases asthma sensitivity in offspring in an HDM-specific manner, suggesting that vertical transmission of maternal immune responses may be involved. These findings have important implications for regulation of asthma risk, and suggest that exposure to HDM in the developed world may have under-appreciated influences on the overall prevalence of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170213IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.972</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192144">PM:28192144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170213-RichgelsPK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170213-RichgelsPK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170213, Richgels PK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.972</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oliveria,J.P.</style></author><author><style face="normal" font="Arial"> Salter,B.M.</style></author><author><style face="normal" font="Arial"> Phan,S.</style></author><author><style face="normal" font="Arial"> Obminski,C.D.</style></author><author><style face="normal" font="Arial"> Munoz,C.E.</style></author><author><style face="normal" font="Arial"> Smith,S.G.</style></author><author><style face="normal" font="Arial"> Scime,T.X.</style></author><author><style face="normal" font="Arial"> Watson,R.M.</style></author><author><style face="normal" font="Arial"> Sehmi,R.</style></author><author><style face="normal" font="Arial"> Gauvreau,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario</style></auth-address><titles><title><style face="normal" font="Arial">Allergic asthmatic subjects have elevated levels of IgE+B-cells in the airways</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="593" start="590">590-593</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170218IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.981</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28213181">PM:28213181</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170218-OliveriaJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170218-OliveriaJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170218, Oliveria JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.981</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ellis,A.K.</style></author><author><style face="normal" font="Arial"> Frankish,C.W.</style></author><author><style face="normal" font="Arial"> O'hehir,R.E.</style></author><author><style face="normal" font="Arial"> Armstrong,K.</style></author><author><style face="normal" font="Arial"> Steacy,L.</style></author><author><style face="normal" font="Arial"> Larche,M.</style></author><author><style face="normal" font="Arial"> Hafner,R.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Treatment with grass allergen peptides improves symptoms of grass pollen</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôinduced allergic rhinoconjunctivitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="496" start="486">486-496</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen peptides</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cyn d 1</style></keyword><keyword><style face="normal" font="Arial"> Dac g 5</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> environmental exposure unit</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hol l 5</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lol p 5</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phl p 5</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Synthetic peptide immunoregulatory epitope</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">Background Synthetic peptide immunoregulatory epitopes are a new class of immunotherapy to treat allergic rhinoconjunctivitis (ARC). Grass allergen peptides, comprising 7 synthetic T-cell epitopes derived from Cyn d 1, Lol p 5, Dac g 5, Hol l 5, and Phl p 5, is investigated for treatment of grass pollen</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôinduced ARC. Objective We sought to evaluate the efficacy, safety, and tolerability of intradermally administered grass allergen peptides. Methods A multicenter, randomized, double-blind, placebo-controlled study evaluated 3 regimens of grass allergen peptides versus placebo in patients with grass pollen</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôinduced allergy (18-65-áyears). After a 4-day baseline challenge to rye grass in the environmental exposure unit (EEU), subjects were randomized to receive grass allergen peptides at 6-ánmol at 2-week intervals for a total of 8 doses (8x6Q2W), grass allergen peptides at 12-ánmol at 4-week intervals for a total of 4 doses (4x12Q4W), or grass allergen peptides at 12-ánmol at 2-week intervals for a total of 8 doses (8x12Q2W) or placebo and treated before the grass pollen season. The primary efficacy end point was change from baseline in total rhinoconjunctivitis symptom score across days 2 to 4 of a 4-day posttreatment challenge (PTC) in the EEU after the grass pollen season. Secondary efficacy end points and safety were also assessed. Results Two hundred eighty-two subjects were randomized. Significantly greater improvement (reduction of total rhinoconjunctivitis symptom score from baseline to PTC) occurred across days 2 to 4 with grass allergen peptide 8x6Q2W versus placebo (</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ5.4 vs </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3.8, respectively; P-á=-á.0346). Greater improvement at PTC also occurred for grass allergen peptide 8x6Q2W versus placebo (P-á=-á.0403) in patients with more symptomatic ARC. No safety signals were detected. Conclusion Grass allergen peptide 8x6Q2W significantly improved ARC symptoms after rye grass allergen challenge in an EEU with an acceptable safety profile</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28236469">PM:28236469</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170224-EllisAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170224-EllisAK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Ellis AK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berings,M.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> De Ruyck,N.</style></author><author><style face="normal" font="Arial"> Perna,S.</style></author><author><style face="normal" font="Arial"> Resch,Y.</style></author><author><style face="normal" font="Arial"> Lupinek,C.</style></author><author><style face="normal" font="Arial"> Chen,K.W.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author><author><style face="normal" font="Arial"> Pajno,G.B.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Dullaers,M.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author><author><style face="normal" font="Arial"> Gevaert,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Reliable mite-specific IgE testing in nasal secretions by means of allergen microarray</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="303" start="301">301-303</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen microarray</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal secretion</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Belgium -CO - Germany -CO - Italy -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238352">PM:28238352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170224-BeringsM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170224-BeringsM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Berings M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McFarlane,A.J.</style></author><author><style face="normal" font="Arial"> McSorley,H.J.</style></author><author><style face="normal" font="Arial"> Davidson,D.J.</style></author><author><style face="normal" font="Arial"> Fitch,P.M.</style></author><author><style face="normal" font="Arial"> Errington,C.</style></author><author><style face="normal" font="Arial"> Mackenzie,K.J.</style></author><author><style face="normal" font="Arial"> Gollwitzer,E.S.</style></author><author><style face="normal" font="Arial"> Johnston,C.J.</style></author><author><style face="normal" font="Arial"> MacDonald,A.S.</style></author><author><style face="normal" font="Arial"> Edwards,M.R.</style></author><author><style face="normal" font="Arial"> Harris,N.L.</style></author><author><style face="normal" font="Arial"> Marsland,B.J.</style></author><author><style face="normal" font="Arial"> Maizels,R.M.</style></author><author><style face="normal" font="Arial"> Schwarze,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MRC- Centre for Inflammation Research, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Enteric helminth-induced type-I interferon signalling protects against pulmonary virus infection through interaction with the microbiota</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> co-infection</style></keyword><keyword><style face="normal" font="Arial"> Coinfection</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duodenum</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viruses</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> type I IFN</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> Viral Load</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="2" Year="2017">2017/2/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Helminth parasites have been reported to have beneficial immune modulatory effects in allergic and autoimmune conditions and detrimental consequences in tuberculosis and some viral infections. Their role in co-infection with respiratory viruses is not clear. OBJECTIVE: Here, we investigated the effects of strictly enteric helminth infection with Heligmosomoides polygyrus on respiratory syncytial virus (RSV) infection in a mouse model. METHODS: A murine helminth/ RSV co-infection model was developed. Mice were infected by oral gavage with 200 stage 3 H. polygyrus larvae. 10 days later, mice were infected with either RSV or UV-inactivated RSV (UV-RSV) intranasally. RESULTS: H. polygyrus infected mice showed significantly less disease and pulmonary inflammation after RSV infection, associated with reduced viral load. Adaptive immune responses including Th2 responses were not essential since protection against RSV was maintained in RAG1-/- and IL-4Ralpha-/- mice. Importantly, H. polygyrus infection upregulated expression of type I IFNs and IFN stimulated genes (ISG) in both the duodenum and the lung, and its protective effects were lost in both IFNAR1-/- and germ-free mice, revealing essential roles for type I IFN signalling and microbiota in H. polygyrus induced protection against RSV. CONCLUSION: These data demonstrate that a strictly enteric helminth infection can have remote protective antiviral effects in the lung through induction of a microbiota-dependent type I IFN response</style></abstract><notes><style face="normal" font="Arial">DA - 20170215IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28196762">PM:28196762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170215-McFarlaneAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170215-McFarlaneAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170215, McFarlane AJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cevikbas,F.</style></author><author><style face="normal" font="Arial"> Braz,J.M.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Solorzano,C.</style></author><author><style face="normal" font="Arial"> Sulk,M.</style></author><author><style face="normal" font="Arial"> Buhl,T.</style></author><author><style face="normal" font="Arial"> Steinhoff,M.</style></author><author><style face="normal" font="Arial"> Basbaum,A.I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Synergistic antipruritic effects of GABA-A and GABA-B agonists in a mouse model of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="464" start="454">454-464</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> baclofen</style></keyword><keyword><style face="normal" font="Arial"> Chloroquine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic itch</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> GABA</style></keyword><keyword><style face="normal" font="Arial"> GABAergic progenitor cell transplants</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> muscimol</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> pruritogens</style></keyword><keyword><style face="normal" font="Arial"> Qatar</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Spinal Cord</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0091-6749</style></isbn><abstract><style face="normal" font="Arial">Background Despite recent insights into the pathophysiology of acute and chronic itch, chronic itch remains an often intractable condition. Among major contributors to chronic itch is dysfunction of spinal cord GABAergic inhibitory controls. Objective To test the hypothesis that selective GABA agonists as well as cell transplant-derived GABA are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by overexpression of the TH2 cell-associated cytokine, IL-31 (IL-31Tg mice). Methods We injected wild-type and IL-31Tg mice with combinations of GABA-A (muscimol) or GABA-B (baclofen) receptor agonists 15-20 min prior to injection of various pruritogens (histamine, chloroquine or endothelin-1) and recorded spontaneous scratching before and after drug administration. We also tested the antipruritic properties of intraspinal transplantation of precursors of GABAergic interneurons in the IL-31Tg mice. Results Systemic muscimol or baclofen are antipruritic against both histamine-dependent and independent pruritogens, but the therapeutic window using either ligand alone was very small. In contrast, combined subthreshold doses of baclofen and muscimol produced a significant synergistic antipruritic effect, with no sedation. Finally, transplant-mediated long term enhancement of GABAergic signaling not only reduced spontaneous scratching in the IL-31Tg mice but also dramatically resolved the associated skin lesions. Conclusion Although additional research is clearly needed, existing approved GABA agonists should be considered in the management of chronic itch, notably atopic dermatitis. Clinical implications Preclinical data encourage the design of human studies to explore the use of GABA-agonists, such as FDA-approved baclofen in the management of acute and chronic itch</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -CO - Germany -CO - Ireland -CO - Qatar -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28232084">PM:28232084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170224-CevikbasF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170224-CevikbasF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Cevikbas F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Citek,J.</style></author><author><style face="normal" font="Arial"> Vostry,L.</style></author><author><style face="normal" font="Arial"> Vostra-Vydrova,H.</style></author><author><style face="normal" font="Arial"> Brzakova,M.</style></author><author><style face="normal" font="Arial"> Prantlova,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Genetic parameters of insect bite hypersensitivity in the Old Grey Kladruber horse</style></title><secondary-title><style face="normal" font="Arial">J Anim Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Anim Sci</style></full-title></periodical><pages end="58" start="53">53-58</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> Altitude</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IBH</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insect bite hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mare</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">The objective of this study was to assess the genetic parameters of insect bite hypersensitivity (IBH) in the Old Grey Kladruber horse, an original Czech warmblood horse breed. Insect bite hypersensitivity is a recurrent allergic skin disease affecting horses worldwide. Its etiology is multifactorial. The defect is genetically controlled, and the starting impulse is a bite by midges of the spp. and less frequently spp. Knowledge about the associated genes is limited. Horses were kept by the National Stud in Kladruby (1,146 measurements) and by 10 private breeders (63 measurements). The horses were visually scored by the same inspector over a period of 13 yr from 1996 to 2009. A linear logistic model with a binary variable was used for subsequent statistical analysis. The fixed effects of the farm, year of evaluation, age of evaluation, and sex were significant, and the nonsignificant effect was the intensity of greying. The animals from the National Stud were more strongly affected by IBH than animals from private studs. The National Stud is located near the Labe River, at an altitude of 206 m; there are bottomland pastures in the vicinity, blind river arms, and numerous pools and marshes, and the climate is mild. These conditions are convenient for horse keeping but also for the propagation of . The stallions were less affected than the mares. The occurrence in years of age was influenced by selection; scoring began in the first year of age, and when the young animal was repeatedly positive, it was eliminated from breeding. The estimated h differed significantly from 0, and the direct h were 0.626 in the animal model with a maternal effect, 0.359 in the animal model without a maternal effect, and 0.363 in the animal model without correlation between direct and maternal effect. The maternal h was 0.305. The estimated repeatabilities were 0.636 with a maternal effect, 0.615 without a maternal effect, and 0.623 without correlation. The h of IBH was found to be medium to high, so there is a possibility to reduce the prevalence of IBH by selection</style></abstract><notes><style face="normal" font="Arial">DA - 20170208IS - 1525-3163 (Electronic)IS - 0021-8812 (Linking)LA - engPT - Journal ArticleCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.2527/jas.2016.0745</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28177358">PM:28177358</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Anim Sci\2017-95-53-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Anim Sci\2017-95-53-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170208, Citek J</style></custom2><misc3><style face="normal" font="Arial">10.2527/jas.2016.0745</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,J.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Tian,Z.Q.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Gong,R.L.</style></author><author><style face="normal" font="Arial"> Chen,T.X.</style></author><author><style face="normal" font="Arial"> Hong,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review</style></title><secondary-title><style face="normal" font="Arial">J Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Autosomal dominant hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic analysis</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Otitis</style></keyword><keyword><style face="normal" font="Arial"> Otitis Media</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PID</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> STAT3 mutations</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Autosomal dominant hyper-IgE syndrome (AD-HIES) is a rare complicated primary immunodeficiency disease (PID). Signal transducer and activator of transcription 3 (STAT3) gene mutation is found to cause AD-HIES. The distribution of AD-HIES patients with STAT3 deficiency in the Chinese population is not clear. Herein, we retrospectively report 17 AD-HIES patients with STAT3 deficiency and demonstrate their clinical, immunological, and genetic features. METHODS: Patients' clinical data were collected from their medical records. Routine laboratory testing results included lymphocyte subset analysis and immunoglobulin quantification. STAT3 mutations were investigated by sequencing of genomic DNA. RESULTS: Among 575 patients with PID, 28 (4.87%) were clinically diagnosed as HIES. Among them, 17 (2.96%) were confirmed as STAT3 mutant AD-HIES. The ratio of male to female patients was 8:9. All of the 17 patients had NIH scores over 40 points. The mean ages at onset and diagnosis were 1.05 and 10.35 years, respectively. Three patients (17.65%, 3/17) died with a mean age of 13.33 years. Eczema, recurrent skin infection, and respiratory tract infection were the most common clinical symptoms and are present in all of the 17 patients in this study. Six patients (37.5%, 6/16) suffered complication from BCG vaccination. Noninfection symptoms are characteristic facial features in 17 patients (100%, 17/17), retention of primary teeth in 10 patients (90.91%, 10/11), and abnormal bone fractures in 7 patients (41.18%, 7/17). Eleven types of STAT3 mutations were identified in 17 patients, including 1 novel mutation. CONCLUSIONS: We here retrospectively report the largest Chinese cohort of AD-HIES patients with STAT3 mutation. Unique features, when compared to existing literature reports, include (1) later age of diagnosis, (2) significantly higher rate of BCG complications, and (3) lower rate of candidiasis and chronic otitis media</style></abstract><notes><style face="normal" font="Arial">DA - 20170215IS - 1573-2592 (Electronic)IS - 0271-9142 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10875-017-0369-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28197791">PM:28197791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Immunol\20170215-WuJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Immunol\20170215-WuJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170215, Wu J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10875-017-0369-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy</style></auth-address><titles><title><style face="normal" font="Arial">ACE inhibitors may interfere with omalizumab in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACE</style></keyword><keyword><style face="normal" font="Arial"> ACE inhibitors</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> D-dimer</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">The extrinsic pathway of coagulation cascade is activated in chronic spontaneous urticaria (CSU), and such activation parallels disease severity (1). D-dimer levels are elevated in cases resistant to antihistamines (2) and/or cyclosporine (3). Omalizumab is highly effective in most patients with severe, antihistamine-resistant CSU. Two cases of severe CSU in which ACE-inhibitor was associated with the loss of response to omalizumab are reported. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170209IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14155</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28181317">PM:28181317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170209-AseroR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170209-AseroR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170209, Asero R</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14155</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Usatine,R.P.</style></author><author><style face="normal" font="Arial"> Jacob,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Texas Health Science Center at San Antonio, TX, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Rash on eyebrows and periumbilical region</style></title><secondary-title><style face="normal" font="Arial">J Fam Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Fam Pract</style></full-title></periodical><pages end="47" start="45">45-47</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact allergen</style></keyword><keyword><style face="normal" font="Arial"> contact allergens</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fragrance</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Neomycin</style></keyword><keyword><style face="normal" font="Arial"> Nickel</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perfume</style></keyword><keyword><style face="normal" font="Arial"> Peru</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> Thimerosal</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Patch testing data indicate that the 5 most prevalent contact allergens out of more than 3700 that are known are: nickel (14.3% of patients tested), fragrance mix (14%), the topical antibiotic neomycin (11.6%), balsam of Peru (used in some perfumes, toiletries, and pharmaceutical items) (10.4%), and the mercury-based vaccine preservative thimerosal (10.4%)</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 1533-7294 (Electronic)IS - 0094-3509 (Linking)LA - engPT - Case ReportsCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188316">PM:28188316</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Fam Pract\2017-66-45-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Fam Pract\2017-66-45-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Usatine RP</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wigglesworth,K.M.</style></author><author><style face="normal" font="Arial"> Racki,W.J.</style></author><author><style face="normal" font="Arial"> Mishra,R.</style></author><author><style face="normal" font="Arial"> Szomolanyi-Tsuda,E.</style></author><author><style face="normal" font="Arial"> Greiner,D.L.</style></author><author><style face="normal" font="Arial"> Galili,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Surgery, University of Massachusetts Medical School, Worcester, MA 01655, USA</style></auth-address><titles><title><style face="normal" font="Arial">Rapid recruitment and activation of macrophages by anti-Gal/alpha-Gal liposome interaction accelerates wound healing</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="4432" start="4422">4422-4432</pages><volume><style face="normal" font="Arial">186</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">(Gal-Gal)</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites,Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cell Movement</style></keyword><keyword><style face="normal" font="Arial"> Chemotactic Factors</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Complement Activation</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> enzymology</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Galactosyltransferases</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Glycolipids</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> liposome</style></keyword><keyword><style face="normal" font="Arial"> Liposomes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophage Activation</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Macrophages,Peritoneal</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice,Knockout</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Regeneration</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sonication</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Swine</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trisaccharides</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Wound Healing</style></keyword></keywords><dates><year Day="1" Month="4" Year="2011">2011/4/1</year></dates><abstract><style face="normal" font="Arial">Macrophages are pivotal in promoting wound healing. We hypothesized that topical application of liposomes with glycolipids that carry Galalpha1-3Galbeta1-4GlcNAc-R epitopes (alpha-gal liposomes) on wounds may accelerate the healing process by rapid recruitment and activation of macrophages in wounds. Immune complexes of the natural anti-Gal Ab (constituting approximately 1% of Ig in humans) bound to its ligand, the alpha-gal epitope on alpha-gal liposomes would induce local activation of complement and generation of complement chemotactic factors that rapidly recruit macrophages. Subsequent binding of the Fc portion of anti-Gal coating alpha-gal liposomes to FcgammaRs on recruited macrophages may activate macrophage genes encoding cytokines that mediate wound healing. We documented the efficacy of this treatment in alpha1,3galactosyltrasferase knockout mice. In contrast to wild-type mice, these knockout mice lack alpha-gal epitopes and can produce the anti-Gal Ab. The healing time of excisional skin wounds treated with alpha-gal liposomes in these mice is twice as fast as that of control wounds. Moreover, scar formation in alpha-gal liposome-treated wounds is much lower than in physiologic healing. Additional sonication of alpha-gal liposomes resulted in their conversion into submicroscopic alpha-gal nanoparticles. These alpha-gal nanoparticles diffused more efficiently in wounds and further increased the efficacy of the treatment, resulting in 95-100% regeneration of the epidermis in wounds within 6 d. The study suggests that alpha-gal liposome and alpha-gal nanoparticle treatment may enhance wound healing in the clinic because of the presence of high complement activity and high anti-Gal Ab titers in humans</style></abstract><notes><style face="normal" font="Arial">DA - 20110322IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralRN - 0 (Epitopes)RN - 0 (Glycolipids)RN - 0 (Liposomes)RN - 0 (Trisaccharides)RN - 0 (alpha-galactosyl epitope)RN - EC 2.4.1.- (Galactosyltransferases)RN - EC 2.4.1.- (alpha-1,3-galactosyltransferase 1, porcine)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1002324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="21357545">PM:21357545</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2011-186-442-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2011-186-442-32.pdf</url></text-urls></urls><custom1><style face="normal" font="Arial">3D</style></custom1><custom2><style face="normal" font="Arial">20110322, Wigglesworth KM</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1002324</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jara-Gutierrez,P.</style></author><author><style face="normal" font="Arial"> Zafra,M.P.</style></author><author><style face="normal" font="Arial"> Sanz,V.</style></author><author><style face="normal" font="Arial"> del Pozo,V.</style></author><author><style face="normal" font="Arial"> Fernandez-Nieto,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department Fundacion Jimenez Diaz, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Asthma Due to Swiss Chard: Identification of a New Allergen</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="68" start="67">67-68</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0120</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211350">PM:28211350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Jara-Gutierrez P</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0120</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Poussel,M.</style></author><author><style face="normal" font="Arial"> Penven,E.</style></author><author><style face="normal" font="Arial"> Essari,L.A.</style></author><author><style face="normal" font="Arial"> Chabot,F.</style></author><author><style face="normal" font="Arial"> Barbaud,A.</style></author><author><style face="normal" font="Arial"> Paris,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Function Testing and Exercise Physiology, CHRU Nancy, Nancy, France</style></auth-address><titles><title><style face="normal" font="Arial">Occupational Asthma to Detergent Protease Associated With a Late-Phase Neutrophilic Cutaneous Response</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="62" start="60">60-62</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0115</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211347">PM:28211347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Poussel M</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0115</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cabrera,M.</style></author><author><style face="normal" font="Arial"> Ortiz-Menendez,J.C.</style></author><author><style face="normal" font="Arial"> Garzon,B.</style></author><author><style face="normal" font="Arial"> Barrios,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergia, Hospital "Los Madronos, Brunete, MadridDepartamento Servicios Sanitarios Calidad y Consumo, ImFINE Research Group, Universidad Politecnica de Madrid, Madrid</style></auth-address><titles><title><style face="normal" font="Arial">Need for Emergency Epinephrine to Treat Food Allergy Reactions in Schools in the Hortaleza District in Madrid</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="60" start="58">58-60</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0114</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211346">PM:28211346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Cabrera M</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0114</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Mancebo,E.</style></author><author><style face="normal" font="Arial"> Alonso Diaz de Durana,M.D.</style></author><author><style face="normal" font="Arial"> Garcia Estringana,Y.</style></author><author><style face="normal" font="Arial"> Melendez Baltanas,A.</style></author><author><style face="normal" font="Arial"> Rodriguez-Alvarez,M.</style></author><author><style face="normal" font="Arial"> de la Hoz Caballer,B.</style></author><author><style face="normal" font="Arial"> Del Prado,N.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital Universitario de Fuenlabrada, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Validation of Recipes for Double-Blind Placebo-Controlled Challenges With Milk, Egg White, and Hazelnut</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="45" start="40">40-45</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sensory evaluation</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The double-blind, placebo-controlled food challenge (DBPCFC) is considered the definitive diagnostic test for food allergy. Nevertheless, validated recipes for masking the foods are scarce, have not been standardized, and differ between centers. Sensory evaluation techniques such as the triangle test are necessary to validate the recipes used for DBPCFC. METHODS: We developed 3 recipes for use in DBPCFC with milk, egg white, and hazelnut and used the triangle test to validate them in a 2-phase study in which 197 volunteers participated. In each phase, participants tried 3 samples (2 active-1 placebo or 2 placebo-1 active) and had to identify the odd one. In phase 1, the 3 samples were given simultaneously, whereas in phase 2, the 3 samples of foods that failed validation in phase 1 were given sequentially. A visual analog scale (VAS) ranging from 1 to 10 was used to evaluate how much participants liked the recipes. RESULTS: In phase 1, the egg white recipe was validated (n=89 volunteers, 38.9% found the odd sample, P=.16). Milk and hazelnut recipes were validated in phase 2 (for both foods, n=30 participants, 36.7% found the odd sample, P=.36). Median VAS scores for the 3 recipes ranged from 6.6 to 9.7. CONCLUSIONS: We used sensory testing to validate milk, egg white, and hazelnut recipes for use in DBPCFC. The validated recipes are easy to prepare in a clinical setting, provide the equivalent of 1 serving dose, and were liked by most participants</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211344">PM:28211344</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-40-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-40-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Gonzalez-Mancebo E</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0084</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alfaya Arias,T.</style></author><author><style face="normal" font="Arial"> Soriano Gomis,V.</style></author><author><style face="normal" font="Arial"> Soto Mera,T.</style></author><author><style face="normal" font="Arial"> Vega Castro,A.</style></author><author><style face="normal" font="Arial"> Vega Gutierrez,J.M.</style></author><author><style face="normal" font="Arial"> Alonso Llamazares,A.</style></author><author><style face="normal" font="Arial"> Antolin,A.D.</style></author><author><style face="normal" font="Arial"> Carballada Gonzalez,F.J.</style></author><author><style face="normal" font="Arial"> Dominguez Noche,C.</style></author><author><style face="normal" font="Arial"> Gutierrez,F.D.</style></author><author><style face="normal" font="Arial"> Marques,A.L.</style></author><author><style face="normal" font="Arial"> Martinez,A.A.</style></author><author><style face="normal" font="Arial"> Martinez,S.I.</style></author><author><style face="normal" font="Arial"> Moreno,A.A.</style></author><author><style face="normal" font="Arial"> Puente,C.Y.</style></author><author><style face="normal" font="Arial"> Ruiz,L.B.</style></author><author><style face="normal" font="Arial"> Sanchez,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital General Universitario de Ciudad Real, Ciudad Real, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Key Issues in Hymenoptera Venom Allergy: An Update</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="31" start="19">19-31</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera allergy</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndrome</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">In this review, the Hymenoptera Allergy Committee of the SEAIC analyzes the most recent scientific literature addressing problems related to the diagnosis of hymenoptera allergy and to management of venom immunotherapy. Molecular diagnosis and molecular risk profiles are the key areas addressed. The appearance of new species of hymenoptera that are potentially allergenic in Spain and the associated diagnostic and therapeutic problems are also described. Finally, we analyze the issue of mast cell activation syndrome closely related to hymenoptera allergy, which has become a new diagnostic challenge for allergists given its high prevalence in patients with venom anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0123</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211342">PM:28211342</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-19-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-19-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Alfaya Arias T</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0123</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Jarocka-Cyrta,E.</style></author><author><style face="normal" font="Arial"> Moschione Castro,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaffe Food Allergy Institute, Department of Pediatrics, Division of Allergy and Immunology, Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Food Protein-Induced Enterocolitis Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="18" start="1">1-18</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Dehydration</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> International consensus</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Lethargy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> oat</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy formula</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-, cell-mediated food allergy of unknown prevalence and pathophysiology. Onset is typically during the first year of life; seafood-induced FPIES may start in adulthood. Acute FPIES manifests within 1-4 hours after ingestion with repetitive emesis, pallor, and lethargy progressing to dehydration and hypovolemic shock in 15% of cases. Chronic FPIES manifests with intermittent emesis, watery diarrhea, and poor growth progressing to dehydration and hypovolemic shock over a period of days to weeks. Chronic FPIES has been only reported in infants aged less than 3 months fed with cow milk (CM) or soy formula. The most common triggers are CM, soy, rice, and oat. Diagnosis of FPIES relies on recognition of a pattern of clinical symptoms and may be missed owing to the absence of typical allergic symptoms (eg, urticaria, wheezing) and delayed onset in relation to food ingestion. Physician-supervised food challenge is recommended if diagnosis or the trigger food is not clear and to evaluate for resolution. Testing for food-specific IgE is usually negative, although a subset of patients, usually with CM-induced FPIES may develop sensitization to foods. Such atypical FPIES tends to have a more prolonged course. Despite the potential severity of the reactions, no fatalities have been reported, and FPIES has a favorable prognosis. In most cases, FPIES resolves by age 3-5 years, although persistence of CM-induced FPIES and soy FPIES into adulthood has been reported. The first international consensus guidelines on diagnosis and management of FPIES were published in 2017. Given that the pathophysiology of FPIES is poorly understood, there are no diagnostic biomarkers and no therapies to accelerate resolution. These unmet needs warrant future investigations to improve the care of patients with FPIES</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Poland -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0135</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211341">PM:28211341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-1-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-1-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Nowak-Wegrzyn A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0135</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lodde,B.</style></author><author><style face="normal" font="Arial"> Cros,P.</style></author><author><style face="normal" font="Arial"> Roguedas-Contios,A.M.</style></author><author><style face="normal" font="Arial"> Pougnet,R.</style></author><author><style face="normal" font="Arial"> Lucas,D.</style></author><author><style face="normal" font="Arial"> DeWitte,J.D.</style></author><author><style face="normal" font="Arial"> Misery,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 2359 716Xgrid.412143.1Universite Europeenne de Bretagne, Rennes, France</style></auth-address><titles><title><style face="normal" font="Arial">Occupational contact dermatitis from protein in sea products: who is the most affected, the fisherman or the chef?</style></title><secondary-title><style face="normal" font="Arial">J Occup Med Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Occup Med Toxicol</style></full-title></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Glove</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Protein contact dermatitis has frequently been reported in case studies (usually in cases involving contact with seafood products), but there are very few descriptive series. The objectives of this present study were firstly to determine the incidence of protein contact dermatitis among fishermen in France and compare it with data from onshore work involving seafood exposure. Second, to discover what factors could explain any differences. In order to answer these questions we analysed data from the French national occupational disease surveillance and prevention network (RNV3P) and occupational diseases declared to the French National Network for Monitoring and Prevention of Occupational Disease. This retrospective study was done for a 13 year period. CASE PRESENTATION: Between 2000 and 2012, we only found eight cases of protein contact dermatitis in the French network. There were no cases of protein contact dermatitis in the seafaring population. The eight cases from the French network are essentially allergies to different fish and chefs are the professionals most affected. Atopy is present in half of these cases. In the seafaring population we found several cases of allergic delayed-time contact dermatitis due to bryozoans and to gloves but no protein contact dermatitis. CONCLUSIONS: Chefs who have to cook seafood are more at risk of occupational protein contact dermatitis than fishermen. We think that skin protection (that is to say glove wearing) is better implemented in the fishing sector than in the catering profession on shore in France</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1745-6673 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12995-017-0150-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28203266">PM:28203266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Occup Med Toxicol\2017-12-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Occup Med Toxicol\2017-12-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Lodde B</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12995-017-0150-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Buhler,S.</style></author><author><style face="normal" font="Arial"> Akkerdaas,J.H.</style></author><author><style face="normal" font="Arial"> Pertinhez,A.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Dossena,A.</style></author><author><style face="normal" font="Arial"> Sforza,S.</style></author><author><style face="normal" font="Arial"> Tedeschi,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food and Drug Department, University of Parma, Viale delle Scienze 17/A, 43124, Parma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Development of a strategy for the total chemical synthesis of an allergenic protein: the peach LTP Pru p 3</style></title><secondary-title><style face="normal" font="Arial">J Pept Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pept Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alanine</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemical synthesis</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition tests</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pan-allergen</style></keyword><keyword><style face="normal" font="Arial"> Pan-allergens</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide fragment</style></keyword><keyword><style face="normal" font="Arial"> Peptide Fragments</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant DNA</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="Arial">The possibility to obtain allergenic proteins by means of total chemical synthesis would be a big step forward in the development of cures to food allergy and in the study of the mechanism of allergic reactions, because this would allow to achieve control at the molecular level over the structure of the product and to study its relationship with the allergenic activity in fine details. This is instead not possible by using allergens produced by extraction from natural sources or by recombinant DNA techniques. In this work, we aimed to test for the first time the feasibility of the total chemical synthesis of an allergenic protein. Pru p 3, the most studied member of the family of lipid transfer proteins, relevant plant food pan-allergens, was used as model target. Strategies for the convergent assembly of the target protein, starting from five peptide fragments to be bound by means of either native chemical ligation or peptide hydrazide ligation, followed by desulfurization, to achieve ligations at alanine, were developed and tested. All the reaction conditions were set up and optimized. Two large peptides covering the two halves of the protein sequence were synthesized and structurally characterized by means of circular dichroism, and their immunogenicity was proved by means of immunoblot, using antibodies against Pru p 3, and immunoCAP inhibition tests. Finally, the five peptides were bound together to produce the whole protein stretch. The obtained results demonstrate the feasibility of total chemical synthesis as a new way to obtain pure allergens. Copyright (c) 2017 European Peptide Society and John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="Arial">DA - 20170210IS - 1099-1387 (Electronic)IS - 1075-2617 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1002/psc.2981</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28185350">PM:28185350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pept Sci\20170210-BuhlerS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pept Sci\20170210-BuhlerS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170210, Buhler S</style></custom2><misc3><style face="normal" font="Arial">10.1002/psc.2981</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alizadeh,M.</style></author><author><style face="normal" font="Arial"> Khodaei,H.</style></author><author><style face="normal" font="Arial"> Mesgari,A.M.</style></author><author><style face="normal" font="Arial"> Saleh-Ghadimi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Assessing the effect of 5-hydroxymethylfurfuralon on selected components of immune responses in mice immunized with ovalbumin</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword></keywords><dates><year Day="11" Month="2" Year="2017">2017/2/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: 5-hydroxymethylfurfural (5-HMF) is one of the most important products of the maillard reaction. In recent years, many profitable biological effects of this compound have been demonstrated. This study sought to elucidate the anti-allergic effect of 5-HMF by investigating some selected components of the immune response in BALB/c mice immunized with ovalbumin (OVA). RESULTS: Immunized animals had an increased level of serum total and OVA-specific antibodies when compared to the control (P &lt; 0.01).We found that the OVA-induced increase in serum IgE and OVA-specific IgE were significantly suppressed in the groups treated with 5-HMF (P &lt; 0.05). Moreover, IL-4 and IFN-gamma were significantly reduced in a dose-independent manner when compared to the sensitized group (P &lt; 0.05). CONCLUSION: 5-HMF inhibited the up-regulation of total and OVA-specific IgE through the suppression of the Th2-type immune response in immunized BALB/c mice. 5-HMF could therefore be a novel therapeutic approach for the prevention of IgE-mediated allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188638">PM:28188638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170211-AlizadehM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170211-AlizadehM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Alizadeh M</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8261</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chaves-Moreira,D.</style></author><author><style face="normal" font="Arial"> Senff-Ribeiro,A.</style></author><author><style face="normal" font="Arial"> Wille,A.C.</style></author><author><style face="normal" font="Arial"> Gremski,L.H.</style></author><author><style face="normal" font="Arial"> Chaim,O.M.</style></author><author><style face="normal" font="Arial"> Veiga,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 1941 472Xgrid.20736.30Department of Cell Biology, Federal University of Parana (UFPR), Curitiba, PR Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Highlights in the knowledge of brown spider toxins</style></title><secondary-title><style face="normal" font="Arial">J Venom Anim Toxins Incl Trop Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Venom Anim Toxins Incl Trop Dis</style></full-title></periodical><pages end="" start="6">6-</pages><volume><style face="normal" font="Arial">23</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Crystallography</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hemolysis</style></keyword><keyword><style face="normal" font="Arial"> histamine releasing factors</style></keyword><keyword><style face="normal" font="Arial"> histamine-releasing factor</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Metalloproteases</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase D</style></keyword><keyword><style face="normal" font="Arial"> Phospholipases</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> serine proteases</style></keyword><keyword><style face="normal" font="Arial"> Serpin</style></keyword><keyword><style face="normal" font="Arial"> Serpins</style></keyword><keyword><style face="normal" font="Arial"> Spiders</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Brown spiders are venomous arthropods that use their venom for predation and defense. In humans, bites of these animals provoke injuries including dermonecrosis with gravitational spread of lesions, hematological abnormalities and impaired renal function. The signs and symptoms observed following a brown spider bite are called loxoscelism. Brown spider venom is a complex mixture of toxins enriched in low molecular mass proteins (4-40 kDa). Characterization of the venom confirmed the presence of three highly expressed protein classes: phospholipases D, metalloproteases (astacins) and insecticidal peptides (knottins). Recently, toxins with low levels of expression have also been found in Loxosceles venom, such as serine proteases, protease inhibitors (serpins), hyaluronidases, allergen-like toxins and histamine-releasing factors. The toxin belonging to the phospholipase-D family (also known as the dermonecrotic toxin) is the most studied class of brown spider toxins. This class of toxins single-handedly can induce inflammatory response, dermonecrosis, hemolysis, thrombocytopenia and renal failure. The functional role of the hyaluronidase toxin as a spreading factor in loxoscelism has also been demonstrated. However, the biological characterization of other toxins remains unclear and the mechanism by which Loxosceles toxins exert their noxious effects is yet to be fully elucidated. The aim of this review is to provide an insight into brown spider venom toxins and toxicology, including a description of historical data already available in the literature. In this review article, the identification processes of novel Loxosceles toxins by molecular biology and proteomic approaches, their biological characterization and structural description based on x-ray crystallography and putative biotechnological uses are described along with the future perspectives in this field</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 1678-9180 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40409-017-0097-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194160">PM:28194160</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Venom Anim Toxins Incl Trop Dis\2017-23-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Venom Anim Toxins Incl Trop Dis\2017-23-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Chaves-Moreira D</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40409-017-0097-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Togias,A.</style></author><author><style face="normal" font="Arial"> Cooper,S.F.</style></author><author><style face="normal" font="Arial"> Acebal,M.L.</style></author><author><style face="normal" font="Arial"> Assa'ad,A.</style></author><author><style face="normal" font="Arial"> Baker,J.R.,Jr.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Block,J.</style></author><author><style face="normal" font="Arial"> Byrd-Bredbenner,C.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Fuchs,G.J.,III</style></author><author><style face="normal" font="Arial"> Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.J.</style></author><author><style face="normal" font="Arial"> Gupta,R.S.</style></author><author><style face="normal" font="Arial"> Habich,M.</style></author><author><style face="normal" font="Arial"> Jones,S.M.</style></author><author><style face="normal" font="Arial"> Keaton,K.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Plaut,M.</style></author><author><style face="normal" font="Arial"> Rosenwasser,L.J.</style></author><author><style face="normal" font="Arial"> Rotrosen,D.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Sidbury,R.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author><author><style face="normal" font="Arial"> Stukus,D.R.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Boyce,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">In the Division of Allergy, Immunology, and Transplantation at the National Institute of Allergy and Infectious Diseases in Bethesda, Md., Alkis Togias is the chief of the Allergy, Asthma, and Airway Biology Branch (AAABB), Susan F. Cooper is a health specialist in the Office of Program Planning and Scientific information, Marshall Plaut is the chief of the Food Allergy, Atopic Dermatitis and Allergic Mechanisms Section in AAABB, and Daniel Rotrosen is division director. The affiliations of the other authors are listed in Table 2. The authors have disclosed no potential conflicts of interest, financial or otherwise. This work was written by employees of the National Institutes of Health and the expert panelists reviewed, edited, and approved the work, which is in the public domain in the United States</style></auth-address><titles><title><style face="normal" font="Arial">Addendum guidelines for the prevention of peanut allergy in the United States</style></title><secondary-title><style face="normal" font="Arial">JAAPA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAAPA</style></full-title></periodical><pages end="5" start="1">1-5</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic mechanism</style></keyword><keyword><style face="normal" font="Arial"> Allergic mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 1547-1896 (Print)IS - 0893-7400 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/01.JAA.0000512231.15808.66</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28151739">PM:28151739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAAPA\2017-30-1-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAAPA\2017-30-1-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Togias A</style></custom2><misc3><style face="normal" font="Arial">10.1097/01.JAA.0000512231.15808.66</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Minami,C.A.</style></author><author><style face="normal" font="Arial"> Barnard,C.</style></author><author><style face="normal" font="Arial"> Bilimoria,K.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery and Center for Healthcare Studies, Feinberg School of Medicine, Northwestern University, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="Arial">Management of a Patient With a Latex Allergy</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="310" start="309">309-310</pages><volume><style face="normal" font="Arial">317</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Colectomy</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Device Removal</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> Diverticulitis,Colonic</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Intraoperative Complications</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Latex Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical Errors</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> organization &amp; administration</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Preoperative Care</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> Root Cause Analysis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urinary Catheterization</style></keyword><keyword><style face="normal" font="Arial"> Urinary Catheters</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170123IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Case ReportsPT - Journal ArticleSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2016.20034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28114556">PM:28114556</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-317-309-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-317-309-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170123, Minami CA</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2016.20034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cox,L.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Miami Miller School of Medicine at Holy Cross Hospital, Ft Lauderdale, Florida</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual Immunotherapy for Allergic Rhinitis: Is 2-Year Treatment Sufficient for Long-term Benefit?</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="593" start="591">591-593</pages><volume><style face="normal" font="Arial">317</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2017.0128</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28196239">PM:28196239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-317-591-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-317-591-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Cox LS</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2017.0128</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Scadding,G.W.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Shamji,M.H.</style></author><author><style face="normal" font="Arial"> Eifan,A.O.</style></author><author><style face="normal" font="Arial"> Penagos,M.</style></author><author><style face="normal" font="Arial"> Dumitru,F.</style></author><author><style face="normal" font="Arial"> Sever,M.L.</style></author><author><style face="normal" font="Arial"> Bahnson,H.T.</style></author><author><style face="normal" font="Arial"> Lawson,K.</style></author><author><style face="normal" font="Arial"> Harris,K.M.</style></author><author><style face="normal" font="Arial"> Plough,A.G.</style></author><author><style face="normal" font="Arial"> Panza,J.L.</style></author><author><style face="normal" font="Arial"> Qin,T.</style></author><author><style face="normal" font="Arial"> Lim,N.</style></author><author><style face="normal" font="Arial"> Tchao,N.K.</style></author><author><style face="normal" font="Arial"> Togias,A.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Imperial College, London, and Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="625" start="615">615-625</pages><volume><style face="normal" font="Arial">317</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="Arial">Importance: Sublingual immunotherapy and subcutaneous immunotherapy are effective in seasonal allergic rhinitis. Three years of continuous treatment with subcutaneous immunotherapy and sublingual immunotherapy has been shown to improve symptoms for at least 2 years following discontinuation of treatment. Objective: To assess whether 2 years of treatment with grass pollen sublingual immunotherapy, compared with placebo, provides improved nasal response to allergen challenge at 3-year follow-up. Design, Setting, and Participants: A randomized double-blind, placebo-controlled, 3-parallel-group study performed in a single academic center, Imperial College London, of adult patients with moderate to severe seasonal allergic rhinitis (interfering with usual daily activities or sleep). First enrollment was March 2011, last follow-up was February 2015. Interventions: Thirty-six participants received 2 years of sublingual immunotherapy (daily tablets containing 15 microg of major allergen Phleum p 5 and monthly placebo injections), 36 received subcutaneous immunotherapy (monthly injections containing 20 microg of Phleum p 5 and daily placebo tablets) and 34 received matched double-placebo. Nasal allergen challenge was performed before treatment, at 1 and 2 years of treatment, and at 3 years (1 year after treatment discontinuation). Main Outcomes and Measures: Total nasal symptom scores (TNSS; range; 0 [best] to 12 [worst]) were recorded between 0 and 10 hours after challenge. The minimum clinically important difference for change in TNSS within an individual is 1.08. The primary outcome was TNSS comparing sublingual immunotherapy vs placebo at year 3. Subcutaneous immunotherapy was included as a positive control. The study was not powered to compare sublingual immunotherapy with subcutaneous immunotherapy. Results: Among 106 randomized participants (mean age, 33.5 years; 34 women [32.1%]), 92 completed the study at 3 years. In the intent-to-treat population, mean TNSS score for the sublingual immunotherapy group was 6.36 (95% CI, 5.76 to 6.96) at pretreatment and 4.73 (95% CI, 3.97 to 5.48) at 3 years, and for the placebo group, the score was 6.06 (95% CI, 5.23 to 6.88) at pretreatment and 4.81 (95% CI, 3.97 to 5.65) at 3 years. The between-group difference (adjusted for baseline) was -0.18 (95% CI, -1.25 to 0.90; [P = .75]). Conclusions and Relevance: Among patients with moderate to severe seasonal allergic rhinitis, 2 years of sublingual grass pollen immunotherapy was not significantly different from placebo in improving the nasal response to allergen challenge at 3-year follow-up. Trial Registration: clinicaltrials.gov Identifier: NCT01335139; EudraCT Number: 2010-023536-16</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2016.21040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28196255">PM:28196255</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-317-615-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-317-615-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Scadding GW</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2016.21040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sebag,S.C.</style></author><author><style face="normal" font="Arial"> Koval,O.M.</style></author><author><style face="normal" font="Arial"> Paschke,J.D.</style></author><author><style face="normal" font="Arial"> Winters,C.J.</style></author><author><style face="normal" font="Arial"> Jaffer,O.A.</style></author><author><style face="normal" font="Arial"> Dworski,R.</style></author><author><style face="normal" font="Arial"> Sutterwala,F.S.</style></author><author><style face="normal" font="Arial"> Anderson,M.E.</style></author><author><style face="normal" font="Arial"> Grumbach,I.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mitochondrial CaMKII inhibition in airway epithelium protects against allergic asthma</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="e88297">e88297-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Iowa</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mitochondria</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">Excessive ROS promote allergic asthma, a condition characterized by airway inflammation, eosinophilic inflammation, and increased airway hyperreactivity (AHR). The mechanisms by which airway ROS are increased and the relationship between increased airway ROS and disease phenotypes are incompletely defined. Mitochondria are an important source of cellular ROS production, and our group discovered that Ca2+/calmodulin-dependent protein kinase II (CaMKII) is present in mitochondria and activated by oxidation. Furthermore, mitochondrial-targeted antioxidant therapy reduced the severity of allergic asthma in a mouse model. Based on these findings, we developed a mouse model of CaMKII inhibition targeted to mitochondria in airway epithelium. We challenged these mice with OVA or Aspergillus fumigatus. Mitochondrial CaMKII inhibition abrogated AHR, inflammation, and eosinophilia following OVA and A. fumigatus challenge. Mitochondrial ROS were decreased after agonist stimulation in the presence of mitochondrial CaMKII inhibition. This correlated with blunted induction of NF-kappaB, the NLRP3 inflammasome, and eosinophilia in transgenic mice. These findings demonstrate a pivotal role for mitochondrial CaMKII in airway epithelium in mitochondrial ROS generation, eosinophilic inflammation, and AHR, providing insights into how mitochondrial ROS mediate features of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.88297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194433">PM:28194433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2017-2-e88297.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2017-2-e88297.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Sebag SC</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.88297</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,N.</style></author><author><style face="normal" font="Arial"> Thatcher,T.H.</style></author><author><style face="normal" font="Arial"> Sime,P.J.</style></author><author><style face="normal" font="Arial"> Phipps,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology and Immunology</style></auth-address><titles><title><style face="normal" font="Arial">Corticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="e88588">e88588-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> repressor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">Specialized proresolving mediators (SPMs) promote the resolution of inflammation and exert beneficial effects in animal models of chronic inflammatory diseases, including asthma. Previously, we have shown that certain SPMs reduce IgE production in B cells from healthy individuals, which has a critical role in allergic asthma. Here, we investigated the effects of SPMs on B cell IgE production in asthma patients. Peripheral blood mononuclear cells from asthma patients were treated with 17-HDHA or RvD1, and IgE levels were measured. RvD1 and 17-HDHA dampened IgE production in B cells from most asthma patients, whereas B cells from a subset of patients taking oral steroids were refractory to SPM treatment. Molecular mechanisms underlying the interaction between corticosteroids and SPMs were investigated by treating B cells from nonasthmatic donors with corticosteroids in vitro. Corticosteroids blocked the inhibitory effects of 17-HDHA and RvD1 on B cell IgE production by abolishing the suppressive activity of these mediators on IgE class switching. Corticosteroids decreased the expression of transcriptional repressor Bcl-6 as well as its suppressive activity on epsilon germline transcription. We conclude that 17-HDHA and RvD1 can reduce IgE production in asthma patients not taking high doses of steroids but that corticosteroids interfere with the ability of B cells to respond to proresolving mediators</style></abstract><notes><style face="normal" font="Arial">DA - 20170214IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.88588</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194434">PM:28194434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2017-2-e88588.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2017-2-e88588.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170214, Kim N</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.88588</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Dorn,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A third of patients diagnosed with asthma have no current symptoms, lending support to guideline recommendations</style></title><secondary-title><style face="normal" font="Arial">Lancet Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Respir Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2213-2600(17)30038-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161215">PM:28161215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet Respir Med\20170205-vanDornA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet Respir Med\20170205-vanDornA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, van Dorn A</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2213-2600(17)30038-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bursztejn,A.C.</style></author><author><style face="normal" font="Arial"> Lipsker,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University Hospital of Strasbourg, Strasbourg, France</style></auth-address><titles><title><style face="normal" font="Arial">Delayed effort-induced swelling with myofasciitis and systemic manifestations: A so far unrecognized type of pressure-induced urticaria</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e6112">e6112-</pages><volume><style face="normal" font="Arial">96</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> anakinra</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Extremities</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> Forearm</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1</style></keyword><keyword><style face="normal" font="Arial"> Leg</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Diseases characterized by recurrent symptoms with prolonged intervals without any clinical manifestations can pose diagnostic difficulties. Some diagnoses will be obvious but other situations can be very challenging.To nosologically delineate a new entity characterized by recurrent flares of induration of the forearms and legs with swelling of the extremities accompanied by intense fatigue and variable other symptoms.Retrospective observational study of patients recorded from 2000 to 2015. All patients included were seen during a consultation at the Dermatology Department of the University Hospital of Strasbourg, France. We retrieved the medical records from patients seen and recorded over the last 16 years having induration of the extremities, the forearm and the legs occurring between 4 and 12 hours after a physical effort accompanied by systemic signs that lasted for a few days. We analyzed in detail the clinical and biological features, evolution, and treatments of these patients.We included 6 males, with a mean age of 47 years; mean age at disease onset was 42. All patients were initially misdiagnosed as having rheumatic disorders. The mean delay before diagnosis was 5 years. The main complaint was painful induration or muscle soreness of the forearms and the legs associated with transient functional impairment and prolonged asthenia for a mean duration of 3.5 days. Induration of the deep soft tissues was very suggestive of myofasciitis. The delay between the triggering physical effort and the swelling was between 6 and 12 hours. Physical effort as triggering factor was never spontaneously mentioned. Two patients had partial response to high dose antihistamines and 2 other patients to the interleukin-1 inhibitor anakinra. One patient responded to hydroxychloroquine.The very stereotypical presentation in those 6 patients suggests that this is a recognizable entity characterized by effort-induced induration of forearms and/or legs, due to deep edematous myofascial involvement, occurring a few hours after a physical effort. We suggest to name this entity delayed effort-induced swelling with myofasciitis and systemic manifestations</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000006112.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28207531">PM:28207531</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2017-96-e6112.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2017-96-e6112.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Bursztejn AC</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000006112.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Y.</style></author><author><style face="normal" font="Arial"> Chen,Z.W.</style></author><author><style face="normal" font="Arial"> Hurlburt,B.K.</style></author><author><style face="normal" font="Arial"> Li,G.L.</style></author><author><style face="normal" font="Arial"> Zhang,Y.X.</style></author><author><style face="normal" font="Arial"> Fei,D.X.</style></author><author><style face="normal" font="Arial"> Shen,H.W.</style></author><author><style face="normal" font="Arial"> Cao,M.J.</style></author><author><style face="normal" font="Arial"> Liu,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Food and Biological Engineering, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources, Xiamen Key Laboratory of Marine Functional Food, Jimei University, 43 Yindou Road, Xiamen, Fujian, 361021, China</style></auth-address><titles><title><style face="normal" font="Arial">Identification of triosephosphate isomerase as a novel allergen in Octopus fangsiao</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="46" start="35">35-46</pages><volume><style face="normal" font="Arial">85</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding activity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Octopus</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> simulated gastric fluid</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="Arial">Octopus is an important mollusk in human dietary for its nutritional value, however it also causes allergic reactions in humans. Major allergens from octopus have been identified, while the knowledge of novel allergens remains poor. In the present study, a novel allergen with molecular weight of 28kDa protein was purified from octopus (Octopus fangsiao) and identified as triosephosphate isomerase (TIM) by mass spectrometry. TIM aggregated beyond 45 degrees C, and its IgE-binding activity was affected under extreme pH conditions due to the altered secondary structure. In simulated gastric fluid digestion, TIM can be degraded into small fragments, while retaining over 80% of the IgE-binding activity. The full-length cDNA of O. fangsiao TIM (1140bp) was cloned, which encodes 247 amino acid residues, and the entire recombinant TIM was successfully expressed in Escherichia coli BL21, which showed similar immunoreactivity to the native TIM. Different intensity of cross-reactivity among TIM from related species revealed the complexity of its epitopes. Eight linear epitopes of TIM were predicted following bioinformatic analysis. Furthermore, a conformational epitope (A71G74S69D75T73F72V67) was confirmed by the phage display technology. The results revealed the physicochemical and immunological characteristics of TIM, which is significant in the development of hyposensitivity food and allergy diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2017.02.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28208072">PM:28208072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-85-35-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2017-85-35-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Yang Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2017.02.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anzengruber,J.</style></author><author><style face="normal" font="Arial"> Bublin,M.</style></author><author><style face="normal" font="Arial"> Bonisch,E.</style></author><author><style face="normal" font="Arial"> Janesch,B.</style></author><author><style face="normal" font="Arial"> Tscheppe,A.</style></author><author><style face="normal" font="Arial"> Braun,M.L.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> Hafner,C.</style></author><author><style face="normal" font="Arial"> Breiteneder,H.</style></author><author><style face="normal" font="Arial"> Schaffer,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of NanoBiotechnology, NanoGlycobiology Unit, Universitat fur Bodenkultur Wien, Muthgasse 11, 1190 Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Lactobacillus buchneri S-layer as carrier for an Ara h 2-derived peptide for peanut allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="88" start="81">81-88</pages><volume><style face="normal" font="Arial">85</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbit IgG</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="Arial">Peanut allergy is an IgE-mediated severe hypersensitivity disorder. The lack of a treatment of this potentially fatal allergy has led to intensive research on vaccine development. Here, we describe the design and initial characterization of a carrier-bound peptide derived from the most potent peanut allergen, Ara h 2, as a candidate vaccine. Based on the adjuvant capability of bacterial surface (S-) layers, a fusion protein of the S-layer protein SlpB from Lactobacillus buchneri CD034 and the Ara h 2-derived peptide AH3a42 was produced. This peptide comprised immunodominant B-cell epitopes as well as one T cell epitope. The fusion protein SlpB-AH3a42 was expressed in E. coli, purified, and tested for its IgE binding capacity as well as for its ability to activate sensitized rat basophil leukemia (RBL) cells. The capacity of Ara h 2-specific IgG rabbit-antibodies raised against SlpB-AH3a42 or Ara h 2 to inhibit IgE-binding was determined by ELISA inhibition assays using sera of peanut allergic patients sensitized to Ara h 2. IgE specific to the SlpB-AH3a42 fusion protein was detected in 69% (25 of 36) of the sera. Despite the recognition by IgE, the SlpB-AH3a42 fusion protein was unable to induce beta-hexosaminidase release from sensitized RBL cells at concentrations up to 100ng per ml. The inhibition of IgE-binding to the natural allergen observed after pre-incubation of the 20 sera with rabbit anti-SlpB-AH3a42 IgG was more than 30% for four sera, more than 20% for eight sera, and below 10% for eight sera. In comparison, anti-Ara h 2 rabbit IgG antibodies inhibited binding to Ara h 2 by 48% +/-13.5%. Our data provide evidence for the feasibility of this novel approach towards the development of a peanut allergen peptide-based carrier-bound vaccine. Our experiments further indicate that more than one allergen-peptide will be needed to induce a broader protection of patients allergic to Ara h 2</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2017.02.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28212503">PM:28212503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-85-81-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2017-85-81-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Anzengruber J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2017.02.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McClain,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Syngenta Crop Protection, LLC, 9 Davis Drive, Durham, NC, 27709, USA</style></auth-address><titles><title><style face="normal" font="Arial">Bioinformatic screening and detection of allergen cross-reactive IgE-binding epitopes</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen database</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1 and Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Pen a 1</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="Arial">Protein allergens can be related by cross-reactivity. Allergens that share relevant sequence can cross-react, those lacking similarity in their IgE antibody-binding epitopes do not cross-react. Cross-reactivity is based on shared epitopes which is due to shared sequence and higher level structure (charge and shape). Epitopes can be important in predicting cross-reactivity potential and may provide the potential to establish criteria that identify homology among allergens. Selected allergen's IgE binding epitope sequences were used to determine how the FASTA algorithm could be used to identify a threshold of significance. A statistical measure (E-value) was used to identify a threshold specific to identifying cross-reactivity potential. Peanut Ara h 1 and Ara h 2, shrimp tropomyosin Pen a 1, and Birch tree pollen allergen, Bet v 1 were sources of known epitopes. Each epitope or set of epitopes was inserted into random amino acid sequence to create hypothetical proteins used as queries to an allergen database. Alignments with allergens were noted for the ability to match the epitope's source allergen as well as any cross-reactive or other homologous allergens. A FASTA E-value range (1x10-5 - 1x10-6 ) was identified that could act as a threshold to help identify cross-reactivity potential. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170213IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201600676</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28191711">PM:28191711</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170213-McClainS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170213-McClainS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170213, McClain S</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201600676</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,J.F.</style></author><author><style face="normal" font="Arial"> Nwaru,B.I.</style></author><author><style face="normal" font="Arial"> McCleary,N.</style></author><author><style face="normal" font="Arial"> Stoddart,A.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma UK Centre for Applied Research, Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="Arial">Investigating the accuracy, risk impact, and cost-effectiveness of component-resolved diagnostic test for food allergy: a systematic review protocol</style></title><secondary-title><style face="normal" font="Arial">NPJ Prim Care Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">NPJ Prim Care Respir Med</style></full-title></periodical><pages end="" start="10">10-</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Informatics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170210IS - 2055-1010 (Electronic)IS - 2055-1010 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41533-017-0015-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28184046">PM:28184046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\NPJ Prim Care Respir Med\2017-27-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\NPJ Prim Care Respir Med\2017-27-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170210, Kim JF</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41533-017-0015-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gu,Z.W.</style></author><author><style face="normal" font="Arial"> Wang,Y.X.</style></author><author><style face="normal" font="Arial"> Cao,Z.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, China Medical University Affiliated Shengjing Hospital, Shenyang, Liaoning, ChinaHematological Laboratory, China Medical University Affiliated Shengjing Hospital, Shenyang, Liaoning, ChinaDepartment of Otorhinolaryngology, China Medical University Affiliated Shengjing Hospital, Shenyang, Liaoning, China</style></auth-address><titles><title><style face="normal" font="Arial">Neutralization of interleukin-9 ameliorates symptoms of allergic rhinitis by reducing Th2, Th9, and Th17 responses and increasing the Treg response in a murine model</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-9</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse model of AR</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="Arial">A novel independent Th-cell subset, characterized by high expression of interleukin (IL)-9, has been recognized as the "Th9" subset. Although Th9 cells are important in many diseases, their contribution to allergic rhinitis (AR) remains unclear. We therefore first determined whether Th9 cells were present in a mouse model of AR. We then investigated the their involvement in the distribution of CD4+ T-cell subsets and the symptoms of AR by treating mice with anti-IL-9 antibodies (Abs). Anti-IL-9 Abs were administered intranasally during rechallenge of ovalbumin (OVA)-induced AR in BALB/c mice. We measured nasal rubbing motion, sneezing and eosinophils, as well as the Th1 (Th1 cell percentage, Ifn-gamma mRNA/protein, T-bet mRNA), Th2 (Th2 cell percentage, Il-4 mRNA/protein, Gata3 mRNA), Th9 (Th9 cell percentages Il-9 mRNA/protein, PU.1 and Irf4 mRNA), Th17 (Th17 cell percentage, Il-17 mRNA/protein, Rorgammat mRNA), and Treg (Treg cell percentage, Foxp3 mRNA) responses in the nasal mucosa. Treatment with anti-IL-9 Abs markedly reduced nasal rubbing, sneezing, eosinophil infiltration, and Th2, Th9, and Th17 responses, and increased the Treg response. Our findings emphasize the importance of IL-9/Th9 in the pathogenesis of AR, and suggest that anti-IL-9 Ab treatment may be an effective therapeutic strategy for AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170210IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.15177</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28187441">PM:28187441</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170210-GuZW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170210-GuZW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170210, Gu ZW</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.15177</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Asaumi,T.</style></author><author><style face="normal" font="Arial"> Ogura,K.</style></author><author><style face="normal" font="Arial"> Borres,M.P.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sagamihara National Hospital, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Safety and feasibility of heated egg yolk challenge for children with egg allergies</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="354" start="348">348-354</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood food allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> heated egg</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> hen's egg allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hen's egg allergy is a frequent cause of childhood food allergy. Egg yolk is used in various commonly consumed foods; if children with allergy to hen's egg could eat heated egg yolk, their quality of life (QOL) would improve. No reports exist regarding oral food challenges (OFCs) for heated egg yolk. We aimed to clarify whether pediatric patients allergic to hen's egg could consume heated egg yolk. METHODS: Data from pediatric patients who had undergone OFCs for heated egg yolk were evaluated retrospectively. RESULTS: Among 919 patients, positive OFC results were obtained in 17.0% of patients; seven presented with severe symptoms. Older age, high specific IgE value for ovomucoid, low total IgE levels, and history of anaphylaxis related to food other than hen's egg were risk factors for positive OFC results. Specific IgE values for egg white, ovomucoid, and egg yolk, indicative of a negative predictive value >95%, were 0.71 kUA /L, 0.41 kUA /L, and 0.17 kUA /L, respectively. A specific IgE to ovomucoid levels of 100 kUA /L predicted heated egg yolk positive OFCs for 38.3% of patients. Among 763 patients with a negative OFC, seven (0.9%) reacted to heated egg yolk at home, and 756 (99.1%) consumed hen's egg yolk safely. CONCLUSIONS: Most pediatric patients allergic to heated hen's egg safely consumed heated egg yolk. Heated egg yolk OFCs rarely provoked severe symptoms, and may be recommended for improving the QOL of children with allergy to hen's egg. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12705</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211100">PM:28211100</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170217-YanagidaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170217-YanagidaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Yanagida N</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12705</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cavaleiro,R.J.</style></author><author><style face="normal" font="Arial"> Madureira,J.</style></author><author><style face="normal" font="Arial"> Paciencia,I.</style></author><author><style face="normal" font="Arial"> Aguiar,L.</style></author><author><style face="normal" font="Arial"> Pereira,C.</style></author><author><style face="normal" font="Arial"> Silva,D.</style></author><author><style face="normal" font="Arial"> Padrao,P.</style></author><author><style face="normal" font="Arial"> Moreira,P.</style></author><author><style face="normal" font="Arial"> Delgado,L.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Oliveira,F.E.</style></author><author><style face="normal" font="Arial"> Teixeira,J.P.</style></author><author><style face="normal" font="Arial"> Moreira,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine, University of Porto, Porto, Portugal &amp; Centro Hospitalar Sao Joao, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Indoor fungal diversity in primary schools may differently influence allergic sensitization and asthma in children</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="339" start="332">332-339</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Classroom</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Childhood exposure to microbiological agents may influence the development of allergic and respiratory diseases. Apart from home, children spend most of their time at school, which represents an environment of significant exposure to indoor air microbes. Therefore, we aimed to assess how the prevalence of allergic sensitization and asthma in schoolchildren is affected by microbiological exposure within classrooms. METHODS: Spirometry with bronchodilation, exhaled nitric oxide measurements and skin-prick tests data were retrieved from 858 children aged 8 to 10 years old attending 71 classrooms in 20 primary schools. Air samples were collected in all classrooms using a single-stage microbiological air impactor through agar plates. Gram-negative endotoxins were collected using flow control pumps and analysed by limulus amebocyte lysate assay. Diversity scores were established as the number of different fungal species found in each classroom. RESULTS: Classrooms with increased diversity scores showed a significantly lower prevalence of children with atopic sensitization, but not asthma. The risk of sensitization increased with increasing endotoxin exposure in classrooms. Similarly, significantly higher concentrations of Penicillium spp were found in classrooms with a higher number of children with atopic sensitization. CONCLUSIONS: Although no causal relationships could be established, exposure to higher fungal diversity was protective against allergic sensitization but this was not seen for asthma. In contrast, higher exposure to gram-negative endotoxins and Penicillium spp in primary school's classrooms was associated with increasing odds of allergic sensitization in children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12704</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28208225">PM:28208225</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170216-CavaleiroRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170216-CavaleiroRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Cavaleiro RJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12704</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ogata,Y.</style></author><author><style face="normal" font="Arial"> Monji,M.</style></author><author><style face="normal" font="Arial"> Kai,K.</style></author><author><style face="normal" font="Arial"> Matsuo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Saga University Faculty of Medicine, Saga, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Nasal hemophilic pseudotumor in a patient with mild hemophilia A and allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Int</style></full-title></periodical><pages end="239" start="237">237-239</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Factor Viii</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Hemophilia A</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Hemophilic pseudotumor is a rare complication, even in patients with severe hemophilia. Herein we report on a case of hemophilic pseudotumor in a patient with mild hemophilia A and allergic rhinitis, initially suspected to be a nasal tumor. The pseudotumor was cured by supplementation with recombinant factor VIII concentrates, and medication for allergic rhinitis. Pseudotumor should always be considered in hemophiliac patients, even in those with only mild deficiency of coagulation factors</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 1442-200X (Electronic)IS - 1328-8067 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/ped.13197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211222">PM:28211222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Int\2017-59-237-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Int\2017-59-237-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, Ogata Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/ped.13197</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,X.</style></author><author><style face="normal" font="Arial"> Hui,Y.</style></author><author><style face="normal" font="Arial"> Zhao,L.</style></author><author><style face="normal" font="Arial"> Hao,Y.</style></author><author><style face="normal" font="Arial"> Guo,H.</style></author><author><style face="normal" font="Arial"> Ren,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Beijing Advanced Innovation Center for Food Nutrition and Human Health, China Agricultural University, Beijing, ChinaBeijing Higher Institution Engineering Research Center of Animal Product, College of Food Science &amp; Nutritional Engineering, China Agricultural University, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Oral administration of Lactobacillus paracasei L9 attenuates PM2.5-induced enhancement of airway hyperresponsiveness and allergic airway response in murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0171721">e0171721-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus paracasei</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Metals</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">This study investigated allergy immunotherapy potential of Lactobacillus paracasei L9 to prevent or mitigate the particulate matter 2.5 (PM2.5) enhanced pre-existing asthma in mice. Firstly, we used a mouse model of asthma (a 21-day ovalbumin (OVA) sensitization and challenge model) followed by PM2.5 exposure twice on the same day of the last challenge. PM2.5 was collected from the urban area of Beijing and underwent analysis for metals and polycyclic aromatic hydrocarbon contents. The results showed that PM2.5 exposure enhanced airway hyper-responsiveness (AHR) and lead to a mixed Th2/ IL-17 response in asthmatic mice. Secondly, the PM2.5 exposed asthmatic mice were orally administered with L9 (4x107, 4x109 CFU/mouse, day) from the day of first sensitization to the endpoint, for 20 days, to investigate the potential mitigative effect of L9 on asthma. The results showed that L9 ameliorated PM2.5 exposure enhanced AHR with an approximate 50% decrease in total airway resistance response to methacholine (48 mg/ml). L9 also prevented the exacerbated eosinophil and neutrophil infiltration in bronchoalveolar lavage fluid (BALF), and decreased the serum level of total IgE and OVA-specific IgG1 by 0.44-fold and 0.3-fold, respectively. Additionally, cytokine production showed that L9 significantly decreased T-helper cell type 2 (Th2)-related cytokines (IL-4, -5, -13) and elevated levels of Th1 related IFN-gamma in BALF. L9 also reduced the level of IL-17A and increased the level of TGF-beta. Taken together, these results indicate that L9 may exert the anti-allergic benefit, possibly through rebalancing Th1/Th2 immune response and modulating IL-17 pro-inflammatory immune response. Thus, L9 is a promising candidate for preventing PM exposure enhanced pre-existing asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170215IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0171721</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28199353">PM:28199353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0171721.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0171721.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170215, Wang X</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0171721</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Medina,J.L.</style></author><author><style face="normal" font="Arial"> Brooks,E.G.</style></author><author><style face="normal" font="Arial"> Chaparro,A.</style></author><author><style face="normal" font="Arial"> Dube,P.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Mycoplasma pneumoniae CARDS toxin elicits a functional IgE response in Balb/c mice</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0172447">e0172447-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mycoplasma</style></keyword><keyword><style face="normal" font="Arial"> Mycoplasma pneumoniae</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Mycoplasma pneumoniae is strongly associated with new onset asthma and asthma exacerbations. Until recently, the molecular mechanisms utilized by M. pneumoniae to influence asthma symptoms were unknown. However, we recently reported that an ADP-ribosylating and vacuolating toxin called the Community Acquired Respiratory Distress Syndrome toxin, CARDS toxin, produced by M. pneumoniae was sufficient to promote allergic inflammation and asthma-like disease in mice. A mouse model of CARDS toxin exposure was used to evaluate total and CARDS-toxin specific serum IgE responses. Mast cell sensitization, challenge, and degranulation studies determined functionality of the CARDS toxin-specific IgE. In the current study, we report that a single mucosal exposure to CARDS toxin was sufficient to increase total serum IgE and CARDS toxin-specific IgE in mice. Mice given a second mucosal challenge of CARDS toxin responded with significant increases in total and CARDS toxin-specific IgE. CARDS toxin-specific IgE bound to an N-terminal peptide of CARDS toxin but not the C-terminal peptide. Likewise, full-length CARDS toxin and the N-terminal peptide induced mast cell degranulation. Altogether, these data demonstrate that exposure to CARDS toxin is sufficient to generate functional IgE in mice. M. pneumoniae and CARDS toxin are strongly associated with asthma exacerbations raising the possibility that the CARDS toxin-specific IgE-mast cell axis contributes to disease pathogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20170215IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0172447</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28199385">PM:28199385</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0172447.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0172447.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170215, Medina JL</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0172447</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,R.</style></author><author><style face="normal" font="Arial"> Edrington,T.C.</style></author><author><style face="normal" font="Arial"> Storrs,S.B.</style></author><author><style face="normal" font="Arial"> Crowley,K.S.</style></author><author><style face="normal" font="Arial"> Ward,J.M.</style></author><author><style face="normal" font="Arial"> Lee,T.C.</style></author><author><style face="normal" font="Arial"> Liu,Z.L.</style></author><author><style face="normal" font="Arial"> Li,B.</style></author><author><style face="normal" font="Arial"> Glenn,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Monsanto Company, St. Louis, Missouri, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Analyzing pepsin degradation assay conditions used for allergenicity assessments to ensure that pepsin susceptible and pepsin resistant dietary proteins are distinguishable</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0171926">e0171926-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Dietary Proteins</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Horseradish Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> HRP</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword><keyword><style face="normal" font="Arial"> Safety assessments</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> soybean trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The susceptibility of a dietary protein to proteolytic degradation by digestive enzymes, such as gastric pepsin, provides information on the likelihood of systemic exposure to a structurally intact and biologically active macromolecule, thus informing on the safety of proteins for human and animal consumption. Therefore, the purpose of standardized in vitro degradation studies that are performed during protein safety assessments is to distinguish whether proteins of interest are susceptible or resistant to pepsin degradation via a study design that enables study-to-study comparison. Attempting to assess pepsin degradation under a wide-range of possible physiological conditions poses a problem because of the lack of robust and consistent data collected under a large-range of sub-optimal conditions, which undermines the needs to harmonize in vitro degradation conditions. This report systematically compares the effects of pH, incubation time, and pepsin-to-substrate protein ratio on the relative degradation of five dietary proteins: three pepsin susceptible proteins [ribulose 1,5-bisphosphate carboxylase-oxygenase (Rubisco), horseradish peroxidase (HRP), hemoglobin (Hb)], and two pepsin resistant proteins [lipid transfer protein (LTP) and soybean trypsin inhibitor (STI)]. The results indicate that proteins susceptible to pepsin degradation are readily distinguishable from pepsin-resistant proteins when the reaction conditions are within the well-characterized optima for pepsin. The current standardized in vitro pepsin resistant assay with low pH and high pepsin-to-substrate ratio fits this purpose. Using non-optimal pH and/or pepsin-to-substrate protein ratios resulted in susceptible proteins no longer being reliably degraded by this stomach enzyme, which compromises the ability of this in vitro assay to distinguish between resistant and susceptible proteins and, therefore, no longer providing useful data to an overall weight-of-evidence approach to assessing safety of proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0171926</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28207780">PM:28207780</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0171926.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0171926.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Wang R</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0171926</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tiotiu,A.</style></author><author><style face="normal" font="Arial"> Chenuel,B.</style></author><author><style face="normal" font="Arial"> Foucaud,L.</style></author><author><style face="normal" font="Arial"> Demoulin,B.</style></author><author><style face="normal" font="Arial"> Demoulin-Alexikova,S.</style></author><author><style face="normal" font="Arial"> Christov,C.</style></author><author><style face="normal" font="Arial"> Poussel,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">EA 3450 DevAH - Development, Adaptation and Disadvantage, Cardiorespiratory regulations and motor control, Universite de Lorraine, Vandoeuvre-les-Nancy, France</style></auth-address><titles><title><style face="normal" font="Arial">Lack of desensitization of the cough reflex in ovalbumin-sensitized rabbits during exercise</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0171862">e0171862-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hindlimb</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Reflex</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Cough is a major symptom of asthma frequently experienced during exercise but little is known about interactions between cough and exercise. The goal of our study was to clarify the potential modulation of the cough reflex (CR) by exercise in a spontaneously breathing anaesthetized animal model of airway eosinophilic inflammation. MATERIALS &amp; METHODS: Ten ovalbumin (OVA) sensitized adult rabbits and 8 controls were studied. The ventilatory response to direct tracheal stimulation, performed both at rest and during exercise was determined to quantify the incidence and the sensitivity of the CR. Broncho-alveolar lavages (BAL) and cell counts were performed to assess the level of the airway inflammation following OVA-induced sensitization. Exercise was mimicked by Electrically induced hindlimb Muscular Contractions (EMC). RESULTS: Among 494 tracheal stimulations, 261 were performed at rest and 233 at exercise. OVA challenges in sensitized rabbits caused a significant increase in the percentage of eosinophils (p = 0.008) in BAL. EMC increased minute ventilation by 36% and 35% in OVA and control rabbits respectively, compared to rest values. The sensitivity of the CR decreased during exercise compared to baseline in control rabbits (p = 0.0313) while it remained unchanged in OVA rabbits. CONCLUSION: The desensitization of the CR during exercise in control rabbits was abolished in OVA rabbits. The precise role of airway inflammation in this lack of CR desensitization needs to be further investigated but it might contribute to the exercise-induced cough in asthmatics</style></abstract><notes><style face="normal" font="Arial">DA - 20170209IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0171862</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28182749">PM:28182749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0171862.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0171862.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170209, Tiotiu A</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0171862</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Skaaby,T.</style></author><author><style face="normal" font="Arial"> Husemoen,L.L.</style></author><author><style face="normal" font="Arial"> Thuesen,B.H.</style></author><author><style face="normal" font="Arial"> Fenger,R.V.</style></author><author><style face="normal" font="Arial"> Linneberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Centre for Prevention and Health, Capital region of Denmark, Glostrup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">IgE sensitization to inhalant allergens and the risk of airway infection and disease: A population-based study</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0171525">e0171525-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Immunoglobulin E (IgE) sensitization, which is the propensity to develop IgE antibodies against common environmental allergens, is associated with a lymphocyte T-helper type 2 (Th2) skewed immune response and a high risk of allergic respiratory disease. Little is known about whether IgE sensitization confers an increased risk of respiratory infections in adults. We investigated the association between IgE sensitization and the incidence of acute airway infections, other infections and chronic lower airway disease events as recorded in nation-wide registries. METHODS: We included 14,849 persons from five population-based studies with measurements of serum specific IgE positivity against inhalant allergens. Participants were followed by linkage to Danish national registries (median follow-up time 11.3 years). The study-specific relative risks were estimated by Cox regression analysis, meta-analysed, and expressed as hazard ratios, HRs (95% confidence intervals, CIs). RESULTS: The relative risks for IgE sensitized vs. non-sensitized were: for pneumonia (HR = 1.20, 95% CI: 1.01, 1.41), other acute airway infection (HR = 0.86, 95% CI: 0.60, 1.22), infection (HR = 1.06, 95% CI: 0.90, 1.24), asthma (HR = 2.26, 95% CI: 1.79, 2.86), and other chronic lower airway disease (HR = 1.31, 95% CI: 1.08, 1.58). In never smokers, the higher risk of pneumonia (HR = 1.73, 95% CI: 1.23, 2.44) and asthma (HR = 3.17, 95% CI: 2.10, 4.76) among IgE sensitized was more pronounced. CONCLUSIONS: IgE sensitization was associated with a higher risk of asthma, other chronic lower airway diseases, and pneumonia. However, the association between IgE sensitization and pneumonia may be explained by undiagnosed asthma causing the pneumonia. Further studies are needed for confirmation</style></abstract><notes><style face="normal" font="Arial">DA - 20170209IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0171525</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28182643">PM:28182643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0171525.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0171525.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170209, Skaaby T</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0171525</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dunston,C.R.</style></author><author><style face="normal" font="Arial"> Choudhury,K.</style></author><author><style face="normal" font="Arial"> Griffiths,H.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Life and Health Sciences, Aston University, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="Arial">Terminal galactose residues on transferrin are increased in midlife adults compared to young adults</style></title><secondary-title><style face="normal" font="Arial">Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proteomics</style></full-title></periodical><pages end="3153" start="3147">3147-3153</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">21</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Age Factors</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Complement C3b</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Galactose</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> N-Acetylneuraminic Acid</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Transferrin</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="0" Month="11" Year="2012">2012/11</year></dates><abstract><style face="normal" font="Arial">Humans undergo biological ageing at different rates. This associates with functional decline in a number of physiological systems and increasing incidence of age-related pathologies. The discovery of robust biomarkers of ageing could be used to identify early divergence from a path of healthy ageing towards age-related disease. In the present study, we undertook proteomic analysis of plasma from healthy young men (mean age = 21.4 +/- 1.5 years) and healthy midlife men (mean age = 57.0 +/- 1.6 years). We identified 12 spots including transferrin, complement C3b and transthyretin that differed in abundance between the age groups. Transferrin spots showed an acidic pI shift in older males. Sandwich ELISAs were used to investigate the changes further. C3b levels were below the level of detection by ELISA and plasma concentrations of total transferrin or transthyretin were not different between the age groups studied here. However, analysis of transferrin N-glycan structures showed an increase in terminal galactose residues in older men, suggesting that the loss of terminal N-acetyl neuraminic acid residues contributes to the more acid pI of transferrin spots observed with age. Terminal galactosylation of transferrin may be a biomarker of healthy ageing and is now under investigation in the MARK-AGE study</style></abstract><notes><style face="normal" font="Arial">DA - 20121030IS - 1615-9861 (Electronic)IS - 1615-9853 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Biomarkers)RN - 0 (Glycoproteins)RN - 0 (Proteome)RN - 0 (Transferrin)RN - GZP2782OP0 (N-Acetylneuraminic Acid)RN - X2RN3Q8DNE (Galactose)SB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1002/pmic.201100506</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="22930475">PM:22930475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proteomics\2012-12-3147-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proteomics\2012-12-3147-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20121030, Dunston CR</style></custom2><misc3><style face="normal" font="Arial">10.1002/pmic.201100506</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Calderon,M.</style></author><author><style face="normal" font="Arial"> Linzer,J.F.,Sr.</style></author><author><style face="normal" font="Arial"> Chalmers,R.J.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sirio Libanes, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Collaboration between specialties for respiratory allergies in the International Classification of Diseases (ICD)-11</style></title><secondary-title><style face="normal" font="Arial">Respir Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Res</style></full-title></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity disorders</style></keyword><keyword><style face="normal" font="Arial"> ICD</style></keyword><keyword><style face="normal" font="Arial"> ICD-11</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The International Classification of Diseases (ICD) has been grouping the allergic and hypersensitivity disorders involving the respiratory tract under topographic distribution, regardless of the underlying mechanisms, triggers or concepts currently in use for allergic and hypersensitivity conditions. In order to strengthen awareness and deliberate the creation of the new "Allergic or hypersensitivity disorders involving the respiratory tract" section of the ICD-11, we here propose make the building process public. METHODS: The new frame has been constructed to cover the gaps previously identified and was based on consensus academic reports and ICD-11 principles. Constant and bilateral discussion was kept with relevant groups representing specialties and resulted in proposals submission into the ICD-11 online platform. RESULTS: The "Allergic or hypersensitivity disorders involving the respiratory tract" section covers 64 entities distributed across five main categories. All the 79 proposals submitted resulted from an intensive collaboration of the Allergy working group, relevant Expert working groups and the WHO ICD governance. CONCLUSION: The establishment of the ICD-11 "Allergic or hypersensitivity disorders involving the respiratory tract" section will allow the dissemination of the updated concepts to be used in clinical practice by many different specialties and health professionals</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - France -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12931-017-0513-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28187789">PM:28187789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2017-18-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2017-18-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12931-017-0513-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonnet,B.</style></author><author><style face="normal" font="Arial"> Vinot,P.A.</style></author><author><style face="normal" font="Arial"> Bellier,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Targets and innovative immunotherapies for the treatment of food allergy</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="336" start="327">327-336</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cibles</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-2</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pressing</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutic value</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Allergic diseases are a major public health problem today due to the constant increase in their prevalence in industrialized countries. The absence of effective curative treatment coupled with the increased risk of anaphylactic shock following renewed allergen exposure could result in a resurgence of hospitalizations and medical interventions, especially for food allergies. The development of new therapies to prevent and treat food allergies thus appears to be a pressing need. The extensive and growing knowledge of the pathophysiological mechanisms of allergic reactions have opened up new therapeutic perspectives. Regulatory T cells (Tregs) are a perfect example. A quantitative and/or qualitative deficit of these cells was observed in allergic patients, which may partly explain their allergen hypersensitivity. Thus, the strategy to recruit and activate Tregs in vivo offers a new therapeutic path. In this context, interleukin 2 (IL-2) is a promising candidate having immunosuppressive properties when used in low-doses. The clinical results obtained recently in the context of autoimmune diseases and the associated safety profile suggests the need for its evaluation in humans for other immune dysfunctions, including food allergy. Through a literature review detailing the pathophysiological bases of food allergy, as well as currently available and future therapies, we show therapeutic value of the use of low-dose IL-2 with particular emphasis on proof of concepts and the different clinical trials to date</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.11.003</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.11.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170223-BonnetB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170223-BonnetB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Bonnet B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.11.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barre,A.</style></author><author><style face="normal" font="Arial"> Delplanque,A.</style></author><author><style face="normal" font="Arial"> Simplicien,M.</style></author><author><style face="normal" font="Arial"> Benoist,H.</style></author><author><style face="normal" font="Arial"> Rouge,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Molecular basis of cross-reactivity between Act c 12 and other seed 11S-globulin allergens</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="66" start="58">58-66</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">11S globulin</style></keyword><keyword><style face="normal" font="Arial"> 11S globulins</style></keyword><keyword><style face="normal" font="Arial"> 2S albumin</style></keyword><keyword><style face="normal" font="Arial"> Act c 12</style></keyword><keyword><style face="normal" font="Arial"> Act d 1</style></keyword><keyword><style face="normal" font="Arial"> Act d 2</style></keyword><keyword><style face="normal" font="Arial"> Act d 8</style></keyword><keyword><style face="normal" font="Arial"> Actinidia</style></keyword><keyword><style face="normal" font="Arial"> Actinidia deliciosa</style></keyword><keyword><style face="normal" font="Arial"> Actinidin</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chitinase</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cupin</style></keyword><keyword><style face="normal" font="Arial"> Cupin superfamily</style></keyword><keyword><style face="normal" font="Arial"> cupins</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruit allergens</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Globulines-á11S</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> Kiwi</style></keyword><keyword><style face="normal" font="Arial"> Kiwi fruit</style></keyword><keyword><style face="normal" font="Arial"> Legumin</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Three-dimensional structures</style></keyword><keyword><style face="normal" font="Arial"> TLP</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Kiwi fruit (Actinidia deliciosa, A. chinensis) is an important source of food allergy in children and adults in Western countries. The allergens responsible for this food allergy consist primarily of typical fruit allergens, e.g. the PR10 Bet v 1-like allergen Act d 8, the cysteine protease actinidin Act d 1, the TLP Act d 2, and a chitinase. All of these allergens from A. deliciosa fruits have their counterparts in A. chinensis fruits. Recently, two other allergens belonging to the cupin superfamily (Act c 12) and the 2S albumin family (Act c 13), found in the kernels of A. chinensis fruit, have been identified as hidden fruit allergens responsible for IgE-binding cross-reactivity with peanuts and tree nuts. The sequential IgE-binding epitope regions of Act c 12 were predicted using a combination of in silico predictive approaches. Sequential IgE-binding epitopes of Act c 12 were predicted on a three-dimensional model of the protein from the amino acid sequence comparisons of the IgE-binding regions of cross-reacting cupins of peanuts and tree nuts. Residues of the sequence stretches exposed at the molecular surface were assigned as cross-reacting IgE-binding regions of Act c 12. In addition to their conformational similarities, these putative IgE-binding epitopes share a high degree of sequence similarity with the corresponding IgE-binding regions of peanut and tree-nut cupin allergens. The Act c 12 allergen offers an interesting example of a hidden fruit allergen likely to trigger allergic responses in individuals previously sensitized to peanut and other three-nut cupin allergens.</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.11.002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.11.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170223-BarreA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170223-BarreA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Barre A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.11.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perotin,J.M.</style></author><author><style face="normal" font="Arial"> Barnig,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service des maladies respiratoires, Inserm UMRS 903, centre hospitalier universitaire, 45, rue Cognacq-Jay, 51100 Reims, France.</style></auth-address><titles><title><style face="normal" font="Arial">[Omalizumab: Beyond anti-IgE properties]</style></title><secondary-title><style face="normal" font="Arial">Rev Mal Respir</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Mal Respir</style></full-title></periodical><pages end="133" start="121">121-133</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mastocyte</style></keyword><keyword><style face="normal" font="Arial"> mastocytes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="8" Month="2" Year="2017">2017/2/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Omalizumab is used as a treatment for severe allergic asthma. Its intended mechanism of action is based on its anti-IgE proprieties. However, recent studies have highlighted other mechanisms of action. STATE OF THE ART: Omalizumab treatment is associated with a decrease in the number of dendritic cells, T and B lymphocytes and eosinophils. This anti-inflammatory activity is characterized by a decrease in the levels of several cytokines involved in the recruitment, activation and survival of eosinophils and mastocytes, and in a Th2 orientation of the immune response. A modulation of bronchial remodeling by omalizumab has recently been shown. A decrease in the production of extracellular matrix components and in the proliferation of smooth muscle cells could be involved in this modulation. These mechanisms of action could explain in part the clinical efficiency of omalizumab in non-allergic conditions such as non-allergic asthma, non-allergic urticaria or nasal polyposis. CONCLUSION: A precise knowledge of the mechanisms of action of omalizumab could allow the identification of biomarkers predictive of efficacy of this treatment. These could be useful tools in the phenotyping of severe asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170212IS - 1776-2588 (Electronic)IS - 0761-8425 (Linking)LA - frePT - English AbstractPT - Journal ArticlePT - ReviewCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmr.2016.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28189435">PM:28189435</url></web-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170212, Perotin JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmr.2016.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Sousa,M.D.</style></author><author><style face="normal" font="Arial"> Ferreira,C.</style></author><author><style face="normal" font="Arial"> Arrobas,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centro Hospitalar Tondela Viseu, Viseu, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab in severe asthma: Evaluation of the clinical impact after its withdrawal</style></title><secondary-title><style face="normal" font="Arial">Rev Port Pneumol (2006)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Pneumol (2006)</style></full-title></periodical><pages end="109" start="108">108-109</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170217IS - 2173-5115 (Electronic)IS - 0873-2159 (Linking)LA - engPT - LetterCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rppnen.2016.12.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28209342">PM:28209342</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Pneumol (2006)\20170217-DeSousaMD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Pneumol (2006)\20170217-DeSousaMD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170217, De Sousa MD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rppnen.2016.12.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kale,S.L.</style></author><author><style face="normal" font="Arial"> Agrawal,K.</style></author><author><style face="normal" font="Arial"> Gaur,S.N.</style></author><author><style face="normal" font="Arial"> Arora,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology Section, CSIR-Institute of Genomics and Integrative Biology, Delhi University Campus, Mall road, Delhi-110007, India</style></auth-address><titles><title><style face="normal" font="Arial">Cockroach protease allergen induces allergic airway inflammation via epithelial cell activation</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="42341">42341-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> CD25</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> occludin</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> Per a 10</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Uric Acid</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">Protease allergens are known to enhance allergic inflammation but their exact role in initiation of allergic reactions at mucosal surfaces still remains elusive. This study was aimed at deciphering the role of serine protease activity of Per a 10, a major cockroach allergen in initiation of allergic inflammation at mucosal surfaces. We demonstrate that Per a 10 increases epithelial permeability by disruption of tight junction proteins, ZO-1 and occludin, and enhances the migration of Monocyte derived dendritic cell precursors towards epithelial layer as exhibited by trans-well studies. Per a 10 exposure also leads to secretion of IL-33, TSLP and intracellular Ca2+ dependent increase in ATP levels. Further, in vivo experiments revealed that Per a 10 administration in mice elevated allergic inflammatory parameters along with high levels of IL-33, TSLP, IL-1alpha and uric acid in the mice lungs. We next demonstrated that Per a 10 cleaves CD23 (low affinity IgE receptor) from the surface of PBMCs and purified B cells and CD25 (IL-2 receptor) from the surface of PBMCs and purified T cells in an activity dependent manner, which might favour Th2 responses. In conclusion, protease activity of Per a 10 plays a significant role in initiation of allergic airway inflammation at the mucosal surfaces</style></abstract><notes><style face="normal" font="Arial">DA - 20170215IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep42341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28198394">PM:28198394</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-42341.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-42341.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170215, Kale SL</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep42341</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,X.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Luo,D.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Zhong,N.</style></author><author><style face="normal" font="Arial"> Wu,M.</style></author><author><style face="normal" font="Arial"> Li,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inflammation &amp;Allergic Diseases Research Unit, Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China</style></auth-address><titles><title><style face="normal" font="Arial">Lyn regulates mucus secretion and MUC5AC via the STAT6 signaling pathway during allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="42675">42675-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> chromatin immunoprecipitation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunoprecipitation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lyn</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucin</style></keyword><keyword><style face="normal" font="Arial"> mucin gene</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">Hypersecretion of mucus is an important component of airway remodeling and contributes to the mucus plugs and airflow obstruction associated with severe asthma phenotypes. Lyn has been shown to down-regulate allergen-induced airway inflammation. However, the role of Lyn in mucin gene expression remains unresolved. In this study, we first demonstrate that Lyn overexpression decreased the mucus hypersecretion and levels of the muc5ac transcript in mice exposed to ovalbumin (OVA). Lyn overexpression also decreased the infiltration of inflammatory cells and the levels of IL-13 and IL-4 in OVA-challenged airways. Whereas Lyn knockdown increased the IL-4 or IL-13-induced MUC5AC transcript and protein levels in the human bronchial epithelial cell line, 16HBE, Lyn overexpression decreased IL-4- or IL-13-induced MUC5AC transcript and protein levels. Overexpression of Lyn also decreased the expression and phosphorylation of STAT6 in OVA-exposed mice, whereas Lyn knockdown increased STAT6 and MUC5AC levels in 16HBE cells. Finally, chromatin immunoprecipitation analysis confirmed that Lyn overexpression decreased the binding of STAT6 to the promoter region of Muc5ac in mice exposed to OVA. Collectively, these findings demonstrated that Lyn overexpression ameliorated airway mucus hypersecretion by down-regulating STAT6 and its binding to the MUC5AC promoter</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep42675</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28205598">PM:28205598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-42675.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-42675.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170216, Wang X</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep42675</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marchetti,P.</style></author><author><style face="normal" font="Arial"> Pesce,G.</style></author><author><style face="normal" font="Arial"> Villani,S.</style></author><author><style face="normal" font="Arial"> Antonicelli,L.</style></author><author><style face="normal" font="Arial"> Ariano,R.</style></author><author><style face="normal" font="Arial"> Attena,F.</style></author><author><style face="normal" font="Arial"> Bono,R.</style></author><author><style face="normal" font="Arial"> Bellisario,V.</style></author><author><style face="normal" font="Arial"> Fois,A.</style></author><author><style face="normal" font="Arial"> Gibelli,N.</style></author><author><style face="normal" font="Arial"> Nicolis,M.</style></author><author><style face="normal" font="Arial"> Olivieri,M.</style></author><author><style face="normal" font="Arial"> Pirina,P.</style></author><author><style face="normal" font="Arial"> Scopano,E.</style></author><author><style face="normal" font="Arial"> Siniscalco,C.</style></author><author><style face="normal" font="Arial"> Verlato,G.</style></author><author><style face="normal" font="Arial"> Marcon,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Pollen concentrations and prevalence of asthma and allergic rhinitis in Italy: Evidence from the GEIRD study</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="1099" start="1093">1093-1099</pages><volume><style face="normal" font="Arial">584-585</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> oleaceae</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaceae</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="3" Month="2" Year="2017">2017/2/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pollen exposure has acute adverse effects on sensitized individuals. Information on the prevalence of respiratory diseases in areas with different pollen concentrations is scanty. AIM: We performed an ecologic analysis to assess whether the prevalence of allergic rhinitis and asthma in young adults varied across areas with different pollen concentrations in Italy. METHODS: A questionnaire on respiratory diseases was delivered to random samples of 20-44year-old subjects from six centers in 2005-2010. Data on the daily air concentrations of 7 major allergologic pollens (Poaceae, Urticaceae, Oleaceae, Cupressaceae, Coryloideae, Betula and Ambrosia) were collected for 2007-2008. Center-specific pollen exposure indicators were calculated, including the average number of days per year with pollens above the low or high concentration thresholds defined by the Italian Association of Aerobiology. Associations between pollen exposure and disease prevalence, adjusted for potential confounders, were estimated using logistic regression models with center as a random-intercept. RESULTS: Overall, 8834 subjects (56.8%) filled in the questionnaire. Allergic rhinitis was significantly less frequent in the centers with longer periods with high concentrations of at least one (OR per 10days=0.989, 95%CI: 0.979-0.999) or at least two pollens (OR=0.974, 95%CI: 0.951-0.998); associations with the number of days with at least one (OR=0.988, 95%CI: 0.972-1.004) or at least two (OR=0.985, 95%CI: 0.970-1.001) pollens above the low thresholds were borderline significant. Asthma prevalence was not associated with pollen concentrations. CONCLUSIONS: Our study does not support that the prevalence of allergic rhinitis and asthma is greater in centers with higher pollen concentrations. It is not clear whether the observed ecologic associations hold at the individual level</style></abstract><notes><style face="normal" font="Arial">DA - 20170207IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.01.168</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28169023">PM:28169023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\20170207-MarchettiP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\20170207-MarchettiP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170207, Marchetti P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.01.168</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soh,J.Y.</style></author><author><style face="normal" font="Arial"> Chiang,W.C.</style></author><author><style face="normal" font="Arial"> Huang,C.H.</style></author><author><style face="normal" font="Arial"> Woo,C.K.</style></author><author><style face="normal" font="Arial"> Ibrahim,I.</style></author><author><style face="normal" font="Arial"> Heng,K.</style></author><author><style face="normal" font="Arial"> Pramanick,A.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">An unusual cause of food-induced anaphylaxis in mothers</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="3">3-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1939-4551</style></isbn><abstract><style face="normal" font="Arial">Galacto-oligosaccharides (GOS) are prebiotics added to commercial milk formula of infants and mothers. In recent years, cases of allergy related to GOS in atopic children have been reported in the South East Asian region</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0136-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s40413-016-0136-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Soh JY</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0136-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marogna,M.</style></author><author><style face="normal" font="Arial"> Massolo,A.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of adjuvanted and standard sublingual immunotherapy on respiratory function in pure rhinitis due to house dust mite over a 5-year period</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="7">7-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Respiratory function</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1939-4551</style></isbn><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (AIT) still remains the only causal treatment for IgE mediated respiratory diseases (rhinitis/asthma) In addition to the observed clinical decrease in symptoms, AIT can provide a long-lasting and preventive effect. In particular it can modify the progression from rhinitis to asthma</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0132-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s40413-016-0132-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Marogna M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0132-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Xin,L.H.</style></author><author><style face="normal" font="Arial"> Cheng,W.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Second Department of Respiratory Medicine, Children's Hospital of Xi'an, Xi'an 710003, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Effect of heat shock factor 1 on airway hyperresponsiveness and airway inflammation in mice with allergic asthma]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="228" start="222">222-228</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> small interfering RNA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the effect of heat shock factor 1 (HSF1) on airway hyperresponsiveness and airway inflammation in mice with asthma and possible mechanisms. METHODS: A total of 36 mice were randomly divided into four groups: control, asthma, HSF1 small interfering RNA negative control (siHSF1-NC), and siHSF1 intervention (n=9 each). Ovalbumin (OVA) sensitization and challenge were performed to induce asthma in the latter three groups. The mice in the siHSF1-NC and siHSF1 groups were treated with siHSF1-NC and siHSF1, respectively. A spirometer was used to measure airway responsiveness at 24 hours after the last challenge. The direct count method was used to calculate the number of eosinophils. ELISA was used to measure the serum level of OVA-specific IgE and levels of interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), and interferon-gamma (IFN-gamma) in lung tissues and bronchoalveolar lavage fluid (BALF). Quantitative real-time PCR was used to measure the mRNA expression of HSF1 in asthmatic mice. Western blot was used to measure the protein expression of HSF1, high-mobility group box 1 (HMGB1), and phosphorylated c-Jun N-terminal kinase (p-JNK). RESULTS: The asthma group had significant increases in the mRNA and protein expression of HSF1 compared with the control group (P&lt;0.05). The siHSF1 group had significantly reduced mRNA and protein expression of HSF1 compared with the siHSF1-NC group (P&lt;0.05). The knockdown of HSF1 increased airway wall thickness, airway hyperresponsiveness, OVA-specific IgE content, and the number of eosinophils (P&lt;0.05). Compared with the siHSF1-NC group, the siHSF1 group had significantly increased levels of IL-4, IL-5, and IL-13 and significantly reduced expression of IFN-gamma in lung tissues and BALF (P&lt;0.05), as well as significantly increased expression of HMGB1 and p-JNK (P&lt;0.05). CONCLUSIONS: Knockdown of HSF1 aggravates airway hyperresponsiveness and airway inflammation in asthmatic mice, and its possible mechanism may involve the negative regulation of HMGB1 and JNK</style></abstract><notes><style face="normal" font="Arial">DA - 20170216IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28202124">PM:28202124</url></web-urls></urls><custom2><style face="normal" font="Arial">20170216, Wang J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,Y.S.</style></author><author><style face="normal" font="Arial"> Sun,W.Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Family Medicine, Cathay General Hospital, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Epidemiology of anaphylaxis: A retrospective cohort study in Taiwan</style></title><secondary-title><style face="normal" font="Arial">Acta Anaesthesiol Taiwan</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Anaesthesiol Taiwan</style></abbr-1></periodical><pages end="12" start="9">9-12</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amoxicillin</style></keyword><keyword><style face="normal" font="Arial"> Analgesics</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> NSAID</style></keyword><keyword><style face="normal" font="Arial"> NSAIDs</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Medication-induced anaphylaxis is a potentially fatal event. Little is known at present about the patterns of medication-induced anaphylaxis in Asian countries. The current study aims to examine the pattern of documented incidences of drug-associated anaphylaxis in Taiwan over a 9-year period. METHODS: Cases of medication-associated anaphylaxis documented in the Taiwan National Health Insurance claims database during a span of 9 years (from January, 1997 to December, 2005) encompassing approximately 23 million person-years were reviewed. The database quantifies the drugs dispensed, clinical diagnoses, and patient demographics. RESULTS: Overall, 92 reports of medication-associated anaphylaxis in 92 patients were identified with potential causative agents documented. In this group, nonsteroidal anti-inflammatory drugs (NSAIDs) and antibiotics were the main classes of medications most frequently implicated as the causative agent(s) in 89% of the cases. NSAIDs alone were implicated in 28% of cases, whereas antibiotics alone were implicated in another 28% of these cases. The use of multiple medications including either antibiotics or analgesics was documented in an additional one-third of the cases. A number of different NSAIDs including aspirin, diclofenac, ketoprofen, ketorolac, and meperidine were documented as the causative agents. Among the reported cases of antibiotics-induced anaphylaxis, cefazolin was the most frequently reported causative agent with 11 cases, followed by amoxicillin with four cases. CONCLUSION: Antibiotics and NSAIDs were the two main classes of medications most frequently implicated in the reports of anaphylaxis in the Taiwanese population. Although this may be related to the frequent use of these medications in the Taiwanese population, the observation here does advocate for reduced combination of NSAIDs and antibiotics, and more careful patient monitoring when they are combined</style></abstract><notes><style face="normal" font="Arial">DA - 20170304IS - 1875-452X (Electronic)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aat.2016.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258852">PM:28258852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Anaesthesiol Taiwan\20170304-LeeYS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Anaesthesiol Taiwan\20170304-LeeYS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Lee YS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aat.2016.12.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gimenez Arnau,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Dermatologia, Hospital del Mar, Barcelona, Espana.</style></auth-address><titles><title><style face="normal" font="Arial">Understanding Patients With Chronic Urticaria Will Have an Impact on Quality of Management</style></title><secondary-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></full-title></periodical><pages end="" start="325">325-</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ad.2017.02.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283173">PM:28283173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Actas Dermosifiliogr\2017-108-325.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Actas Dermosifiliogr\2017-108-325.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Gimenez Arnau AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ad.2017.02.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Qi,M.</style></author><author><style face="normal" font="Arial"> Huang,H.</style></author><author><style face="normal" font="Arial"> Ye,R.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Neal Stewart,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Atmospheric pollen dispersion from herbicide-resistant horseweed (Conyza canadensis L.)</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Atmospheric pollen</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Flow</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Herbicide</style></keyword><keyword><style face="normal" font="Arial"> Herbicide Resistance</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> South America</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Horseweed (Conyza canadensis (L.) Cronq.) with evolved herbicide resistance has become an especially problematic weed in crop production across the USA and on four continents (North America, South America, Asia, and Europe). Spread of herbicide resistance can occur through pollen-mediated gene flow between resistant and susceptible horseweed populations. However, there are little knowledge, preventive guidelines, and mechanism modeling for pollen transport in this system. We need to better understand pollen dispersion and deposition in the context of atmospheric conditions, herbicide-resistant horseweed patch size, and buffer crop type, height, and field size. A mechanistic model is needed to account for these. A pollen dispersion and deposition model was calibrated and validated using 2013 experimental field data. The validated model was run for various combinations of atmospheric conditions, horseweed characteristics (source strength), and buffer species and size (pollen can be intercepted by crop plants). Large fields with crops with a high leaf area density and tall plants can effectively prevent pollen dispersion. The information will help provide guidelines for preventing herbicide resistance spread from herbicide-resistant weeds and genetically modified plants in general</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9477-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9477-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170318-WangJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170318-WangJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9477-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,X.</style></author><author><style face="normal" font="Arial"> Lin,H.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Huang,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology &amp; Head and Neck Surgery, Hainan General Hospital, Haikou 570311, China.</style></auth-address><titles><title><style face="normal" font="Arial">The efficacy and safety of sublingual immunotherapy in children and adult patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="462" start="457">457-462</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Clinical research has shown that sublingual immunotherapy (SLIT) is effective and safe in moderate-severe allergic rhinitis (AR) induced by house dust mite (HDM). However, the sample size in many studies is small. Meanwhile, the controversy on the efficacy and safety in the very young children younger than four years old still existed. OBJECTIVE: The aim of this retrospective study is to evaluate the efficacy and safety of SLIT with Dermatophagoides farinae (Der.f) extracts in children and adult patients with allergic rhinitis, particularly in the very young children. METHOD: A total of 573 subjects aged 3-69 with AR received a three-year course of sublingual immunotherapy with Der.f extracts along with pharmacotherapy. The total nasal symptoms score (TNSS), total medication score (TMS), visual analogue score (VAS) and adverse events (AEs) were evaluated at each visit. RESULT: TNSS, TMS, VAS were significantly improved during the three-year course of treatment in comparison to the baseline values (P&lt;0.01). Besides, significant improvement in nasal symptoms and reduction of medication use were also observed in young children aged 3-6 years (P&lt;0.01). No severe systemic adverse events (AEs) were reported. CONCLUSION: SLIT with Der.f drops is clinically effective and safe in children and adult patients with HDM-induced AR, including the very young children less than four years old</style></abstract><notes><style face="normal" font="Arial">DA - 20170226IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237130">PM:28237130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170226-LinX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170226-LinX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170226, Lin X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bioinformatics and Medical Informatics Research Center, San Diego State University, San Diego 92182, USA.</style></auth-address><titles><title><style face="normal" font="Arial">A critical review on serine protease: Key immune manipulator and pathology mediator</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Chymotrypsin</style></keyword><keyword><style face="normal" font="Arial"> Collagenase</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Informatics</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Serine protease inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Subtilisin</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Thrombin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">Proteolytic activity is fundamental to survival, so it is not surprising that all living organisms have proteases, especially seine protease. This enzyme in its numerous isoforms and homologues, constitutes the quintessential offence and defence factors, in the form of surface proteins, secreted molecules, gut digestive enzymes, venom in specialised glands or plant latex, among other manifestations. Occurring as trypsin, chymotrypsin, elastase, collagenase, thrombin, subtilisin etc., it mediates a diverse array of functions, including pathological roles as inflammatory, coagulatory to haemorrhagic. This review emphasizes that despite the superficial differences in mechanisms, most health issues, be they infectious, allergic, metabolic, or neural have a common conduit. This enzyme, in its various glycosylated forms leads to signal misinterpretations, wreaking havoc. However, organisms are endowed with serine protease inhibitors which might restrain this ubiquitous yet deleterious enzyme. Hence, serine proteases-driven pathogenesis and antagonising role of inhibitors is the focal point of this critical review</style></abstract><notes><style face="normal" font="Arial">DA - 20170225IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28236540">PM:28236540</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170225-PatelS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170225-PatelS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170225, Patel S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Celiksoy,M.H.</style></author><author><style face="normal" font="Arial"> Sancak,R.</style></author><author><style face="normal" font="Arial"> Yildiran,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ondokuz Mayis University, Faculty of Medicine, Department of Pediatric Allergy and Immunology, Samsun, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">The role of active B cells in allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="444" start="439">439-444</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte Subsets</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The purpose of this study is to examine the changes in B lymphocyte subsets in patients receiving allergen immunotherapy. METHODS: B lymphocyte subsets of patients before immunotherapy and one year after immunotherapy began were examined using the flow cytometric method. Age-matched healthy children served as the control group. RESULTS: Twenty-two patients with asthma and/or allergic rhinitis and 14 healthy, age-matched controls were included in the study. The median age of the patients was 13 years old (range: 6-20 years), and eleven (50.0%) were male. The median age of the healthy controls was also 13 years old (range: 7-17), and seven (50.0%) were male. In the age group from 11 to 15 years; the patients' relative and absolute counts of active and mature sensitive B cells were higher than those of the healthy children (p=0.027-0.012 and p=0.032-0.010, respectively) before immunotherapy. The relative and absolute counts of active B cells before immunotherapy were also significantly higher than those of after immunotherapy (p=0.001-0.001, p=0.025-0.037, and p=0.029-0.035, respectively). Before immunotherapy, the relative and absolute counts of mature sensitive B cells were significantly higher than those obtained after immunotherapy (p=0.024-0.006) in the 11-15-year-old age group. CONCLUSIONS: Allergen immunotherapy directly influences B cell differentiation and causes a decrease in the count of active B cells. This finding is relevant because the B cell count can be used as a guide in the assessment of an individual patient's treatment response and also when determining whether to continue the immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170225IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28236542">PM:28236542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170225-CeliksoyMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170225-CeliksoyMH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170225, Celiksoy MH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Isik,S.</style></author><author><style face="normal" font="Arial"> Karaman,M.</style></author><author><style face="normal" font="Arial"> Cilaker Micili,S.</style></author><author><style face="normal" font="Arial"> Caglayan-Sozmen,S.</style></author><author><style face="normal" font="Arial"> Bagriyanik,H.A.</style></author><author><style face="normal" font="Arial"> Arikan-Ayyildiz,Z.</style></author><author><style face="normal" font="Arial"> Uzuner,N.</style></author><author><style face="normal" font="Arial"> Karaman,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dokuz Eylul University, Department of Pediatric Allergy and Immunology, Izmir, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="349" start="339">339-349</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Liver Diseases</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND AIMS: In previous studies, anti-inflammatory, anti-apoptotic and immunomodulatory effects of ursodeoxycholic acid (UDCA) on liver diseases have been shown. In this study, we aimed to investigate the effects of UDCA on airway remodelling, epithelial apoptosis, and T Helper (Th)-2 derived cytokine levels in a murine model of chronic asthma. METHODS: Twenty-seven BALB/c mice were divided into five groups; PBS-Control, OVA-Placebo, OVA-50mg/kg UDCA, OVA-150mg/kg UDCA, OVA-Dexamethasone. Mice in groups OVA-50mg/kg UDCA, OVA-150mg/kg UDCA, OVA-Dexamethasone received the UDCA (50mg/kg), UDCA (150mg/kg), and dexamethasone, respectively. Epithelium thickness, sub-epithelial smooth muscle thickness, number of mast and goblet cells of samples isolated from the lung were measured. Immunohistochemical scorings of the lung tissue for matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor (VEG-F), transforming growth factor-beta (TGF-beta), terminal deoxynucleotidyl transferase-mediated dUTP nick endlabeling (TUNEL) and cysteine-dependent aspartate-specific proteases (caspase)-3 were determined. IL-4, IL-5, IL-13, Nitric oxide, ovalbumin-specific immunoglobulin (Ig) E levels were quantified. RESULTS: The dose of 150mg/kg UDCA treatment led to lower epithelial thickness, sub-epithelial smooth muscle thickness, goblet and mast cell numbers compared to placebo. Except for MMP-9 and TUNEL all immunohistochemical scores were similar in both UDCA treated groups and the placebo. All cytokine levels were significantly lower in group IV compared to the placebo. CONCLUSIONS: These findings suggested that the dose of 150mg/kg UDCA improved all histopathological changes of airway remodelling and its beneficial effects might be related to modulating Th-2 derived cytokines and the inhibition of apoptosis of airway epithelial cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170303IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28256288">PM:28256288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170303-IsikS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170303-IsikS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170303, Isik S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.12.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,C.</style></author><author><style face="normal" font="Arial"> Zhu,Q.X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Anhui No. 2 Province People's Hospital, Hefei City, Anhui Province, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergy is associated with reduced risk of glioma: A meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Glioma</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Increasing evidences suggest that allergy may reduce the risk of glioma, so it is necessary to perform an up-to-data literature search and investigate this relationship by meta-analysis. METHODS: We identified the included studies by searching PubMed and Web of Science and excluding irrelevant or ineligible articles. Nineteen studies from 15 articles, including 8435 cases and 118,719 controls, were selected for data extraction and synthesis. RESULTS: Pooled outcomes showed that there was an inverse association between allergy and risk of glioma (OR=0.64, 95% CI=0.52-0.78, P&lt;0.001). Meanwhile, asthma and eczema would reduce the risk of glioma by 33% and 23% (OR=0.67, 95% CI=0.59-0.75, P&lt;0.001; OR=0.77, 95% CI=0.68-0.86, P&lt;0.001), respectively. Sensitivity analyses confirmed the stability of these findings. Besides, no publication biases were detected regarding all the investigations. CONCLUSIONS: Overall or specific allergy is protective against glioma. More prospective cohort studies or molecular laboratory experiments are warranted to elucidate the causation and key mechanism</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.12.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28262389">PM:28262389</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170306-ZhangC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170306-ZhangC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Zhang C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.12.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Holt,P.G.</style></author><author><style face="normal" font="Arial"> Strickland,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Telethon Kids Institute, The University of Western Australia, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Low dose treatment of mice with bacterial extract (OM-85) for attenuation of experimental atopic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="311" start="310">310-311</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170226IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237132">PM:28237132</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170226-HoltPG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170226-HoltPG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170226, Holt PG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.12.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nacaroglu,H.T.</style></author><author><style face="normal" font="Arial"> Erdem,S.B.</style></author><author><style face="normal" font="Arial"> Karaman,S.</style></author><author><style face="normal" font="Arial"> Dogan,D.</style></author><author><style face="normal" font="Arial"> Karkiner.C.S.</style></author><author><style face="normal" font="Arial"> Kanik,T.</style></author><author><style face="normal" font="Arial"> Can,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Allergy, Dr Behcet Uz Children's Hospital Izmir, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Diagnostic values for egg white specific IgE levels with the skin prick test in Turkish children with egg white allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="451" start="445">445-451</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The diagnostic values for the skin prick test (SPT) diameters and egg white-specific IgE (EW-sIgE) levels that will allow us to predict the result of the oral food challenge test (OFC) in the diagnosis of egg white allergy vary by the community where the study is carried out. OBJECTIVE: This study aimed to determine the diagnostic values of SPT and EW-sIgE levels in the diagnosis of egg white allergy. METHODS: 59 patients followed with the diagnosis of egg allergy September 2013 to September 2015 were included in our retrospective cross-sectional study. The patients were investigated in terms of egg and anaphylaxis history or the requirement of the OFC positivity. The demographic, clinical and laboratory findings of the cases were recorded, and they were compared with the patients with the suspected egg allergy but negative OFC (n=47). RESULTS: In the study, for all age groups, the value of 5mm in SPT was found to be significant at 96.4% positive predictive value (PPV) and 97.8% specificity and the value of 5.27kU/L for EW-sIgE was found to be significant at 76% PPV and 86.6% specificity for egg white. The diagnostic power of the SPT for egg white (AUC: 72.2%) was determined to be significantly higher compared to the diagnostic power of the EW-sIgE (AUC: 52.3%) (p&lt;0.05). CONCLUSION: Along with the determination of the diagnostic values of communities, the rapid and accurate diagnosis of the children with a food allergy will be ensured, and the patient follow-up will be made easier</style></abstract><notes><style face="normal" font="Arial">DA - 20170226IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237131">PM:28237131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170226-NacarogluHT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170226-NacarogluHT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170226, Nacaroglu HT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Andersen,K.F.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Rehm,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ALK, Boege Alle 1, DK-2970, Hoersholm, DenmarkALK, Horsholm</style></auth-address><titles><title><style face="normal" font="Arial">Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alle</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> sublingual tablet</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">Treatment with SQ house dust mite sublingual tablet for 1 year resulted in a decreased probability of having an allergic rhinitis exacerbation day (from 11% (placebo) to 5% (SQ house dust mite sublingual tablet)) and an increased probability of having a mild allergic rhinitis day (from 16% (placebo) to 34% (SQ house dust mite sublingual tablet)). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - France -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13155</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273339">PM:28273339</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170308-AndersenKF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170308-AndersenKF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Andersen KF</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13155</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fischer,J.</style></author><author><style face="normal" font="Arial"> Lupberger,E.</style></author><author><style face="normal" font="Arial"> Hebsaker,J.</style></author><author><style face="normal" font="Arial"> Blumenstock,G.</style></author><author><style face="normal" font="Arial"> Aichinger,E.</style></author><author><style face="normal" font="Arial"> Yazdi,A.S.</style></author><author><style face="normal" font="Arial"> Reick,D.</style></author><author><style face="normal" font="Arial"> Oehme,R.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Faculty of Medicine, Eberhard Karls University Tuebingen, Tuebingen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of type I sensitization to alpha-gal in forest service employees and hunters</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Red meat allergy</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> Ticks</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The production of IgE molecules specific to the carbohydrate galactose-alpha-1,3-galactose (alpha-gal) is known to induce delayed anaphylaxis against mammalian meat. Tick bites constitute the primary sensitization source, as ticks transfer alpha-gal in their saliva to a host during a bite. The reported prevalence of alpha-gal-specific IgE (alpha-gal-sIgE) positivity varies between different populations from diverse geographic regions. OBJECTIVE: To investigate the prevalence of alpha-gal-sIgE positivity in a population of forest service employees who are highly exposed to ticks in comparison with a residential population and a historic sample. METHODS: A cross-sectional study evaluating 300 forest service employees and hunters from Southwest Germany was performed. Alpha-gal-sIgE levels were assessed by ImmunoCAP assay. The prevalence of alpha-gal-sIgE-positive individuals was compared with a matched cohort composed of a residential population and blood samples from forest service employees collected 15 years ago. RESULTS: In the study population, the prevalence of alpha-gal-sIgE-positive (>0.10 kUA /L) individuals was 35.0%, whereas the prevalence of individuals with alpha-gal-sIgE levels >0.35 kUA /L was 19.3%. Alpha-gal-sIgE positivity was associated with total IgE levels and recent tick bites. Mammalian meat-induced delayed anaphylaxis was found in 8.6% of the participants with alpha-gal-sIgE levels >0.35 kUA /L. For forest service employees and hunters, the odds ratio for alpha-gal-sIgE positivity was 2.48 compared to the residential population. The prevalence of alpha-gal-sIgE positivity in the current and historic cohort was comparable. CONCLUSION: Forest service employees and hunters compose a population with a high prevalence of alpha-gal-sIgE positivity and carry a considerable risk of red meat allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13156</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273338">PM:28273338</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170308-FischerJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170308-FischerJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Fischer J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13156</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,H.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Wang,P.</style></author><author><style face="normal" font="Arial"> Su,H.</style></author><author><style face="normal" font="Arial"> Wang,W.</style></author><author><style face="normal" font="Arial"> Chu,Z.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Transplantation Biology Research Division, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">mTORC2 controls Th9 polarization and allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: T helper type 9 (Th9) cells, a subpopulation of CD4+ T cells, play a critical role in the pathogenesis of allergic airway inflammation. However, it remains unknown whether mTORC2 regulates Th9 differentiation or function during allergic inflammation. METHODS: T cell-specific Rictor-deficient mice, a mouse model of allergic airway inflammation induced by OVA sensitization and a mouse model of adoptive transfer of induced Th9 cells were used to address the roles of mTORC2 in the pathogenesis of allergic airway inflammation. The in vitro Th9 induction, multiple-colors flow cytometry, real-time PCR, western blots were used to investigate the molecular effects of mTORC2 in Th9 induction. RESULTS: The differentiation of naive CD4+ T cells into Th9 cells was significantly diminished in the absence of Rictor, the core component of mTORC2. By using a mouse model of allergic airway inflammation induced by OVA sensitization, T cell-specific Rictor-deficient mice show much less severe allergic airway inflammation characterized by decreased pathological alterations and fibrosis of the lungs, which was accompanied with reduced Th9 differentiation and infiltration. Importantly, the isolated Rictor-deficient Th9 cells mediate less severe allergic pathogenesis upon adoptive transfer. Rictor deficiency impairs Th9 cell differentiation by reducing IRF4 expression rather than affecting Foxo1/Foxo3a transcriptional activity, which is likely due to decreased Akt or/and STAT6 activation. CONCLUSIONS: These findings uncover a novel role of mTORC2 in Th9 cell differentiation and may have important implications for therapeutic intervention of allergic diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13152</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273354">PM:28273354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170308-ChenH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170308-ChenH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Chen H</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13152</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arzt,L.</style></author><author><style face="normal" font="Arial"> Bokanovic,D.</style></author><author><style face="normal" font="Arial"> Schrautzer,C.</style></author><author><style face="normal" font="Arial"> Schwarz,I.</style></author><author><style face="normal" font="Arial"> Laipold,K.</style></author><author><style face="normal" font="Arial"> Aberer,W.</style></author><author><style face="normal" font="Arial"> Sturm,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venerology, Medical University of Graz, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Questionable diagnostic benefit of the commercially available panel of bee venom components</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1422" start="1419">1419-1422</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Api m 2</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross-reacting allergens</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immulite</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">For many years, only the major allergen rApi-m-1 has been available on the ImmunoCAP system for routine diagnosis of bee venom (BV) allergy. Now, there are 5 components available and we aimed to detect sensitivity and specificity of rApi m 1, 2, 3, 5 and 10 in BV allergic patients. We further evaluated sensitivity of rApi-m-1 and 2 of an alternative platform and investigated possible differences in the sensitization profile between monosensitization and clinically relevant double sensitization. Analysis of the whole panel of BV allergens of the CAP system still resulted in a lower sensitivity than the combination of rApi-m-1 and 2 of the Immulite (71.6 vs 85.8%). Sensitization rate of rApi-m-5 was more than doubled in double-sensitized patients, while there was no difference for Api-m-2. The benefit of the commercially available panel of BV components is questionable, due to the insufficient sensitivity and still unavailable important cross-reacting allergens. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273336">PM:28273336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170308-ArztL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170308-ArztL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Arzt L</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13154</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,R.</style></author><author><style face="normal" font="Arial"> Guo,Y.</style></author><author><style face="normal" font="Arial"> Huang,L.</style></author><author><style face="normal" font="Arial"> Hao,F.</style></author><author><style face="normal" font="Arial"> Gao,X.</style></author><author><style face="normal" font="Arial"> Bieber,T.</style></author><author><style face="normal" font="Arial"> Yao,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Current status in diagnosis of atopic dermatitis in China</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1278" start="1277">1277-1278</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> seborrheic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">In China, eczema and atopic dermatitis (AD) have been traditionally considered as 2 distinct entities. Eczema typically referred to the milder phenotypes or to phenotypes with atypical morphology and distribution of lesions and many dermatologists have ever recognized that the "eczema" diagnosed clinically by them is actually milder phenotypes or phenotypes with atypical morphology and distribution of lesions of AD. Moreover, AD, contact dermatitis, diaper dermatitis, perioral dermatitis, halo dermatitis, pompholyx, seborrheic dermatitis, etc. are not included in category of "eczema" in Chinese textbook of dermatology2 . This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13149</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235139">PM:28235139</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170224-ChengR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170224-ChengR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Cheng R</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13149</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mothes-Luksch,N.</style></author><author><style face="normal" font="Arial"> Raith,M.</style></author><author><style face="normal" font="Arial"> Stingl,G.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> Razzazi-Fazeli,E.</style></author><author><style face="normal" font="Arial"> Zieglmayer,R.</style></author><author><style face="normal" font="Arial"> Wohrl,S.</style></author><author><style face="normal" font="Arial"> Swoboda,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Comparative Immunology and Oncology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Pru p 3, a marker allergen for lipid transfer protein (LTP)-sensitization also in Central Europe</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1418" start="1415">1415-1418</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Central Europe</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Plant food allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="Arial">In the Mediterranean area, lipid transfer proteins (LTPs) are important causes of plant food allergies often associated with severe allergic reactions. There, peach LTP (Pru p 3) seems to be the primary sensitizer, whereas in Central Europe little is known about the importance of LTP-sensitization. In this region allergen extract based diagnosis is often complicated by co-sensitization to Bet v 1, the major birch pollen allergen, its cross-reactive food allergens and profilins. We investigated the role of LTP-sensitization in Central European patients displaying strong allergic reactions to plant-derived food. Analysis of IgE-reactivity revealed that ten of thirteen patients were sensitized to Pru p 3, nine to Bet v 1and two to profilin. Our results showed that LTP-sensitization represents a risk factor for severe allergic symptoms in Central Europe. Furthermore, the strong IgE reactivity detected in immunoblots of plant food extracts indicated that Pru p 3 can be used as a marker allergen for LTP-sensitization also in Central European patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170302IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13151</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28252802">PM:28252802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170302-MothesLukschN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170302-MothesLukschN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170302, Mothes-Luksch N</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13151</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chauveau,A.</style></author><author><style face="normal" font="Arial"> Dalphin,M.L.</style></author><author><style face="normal" font="Arial"> Mauny,F.</style></author><author><style face="normal" font="Arial"> Kaulek,V.</style></author><author><style face="normal" font="Arial"> Schmausser-Hechfellner,E.</style></author><author><style face="normal" font="Arial"> Renz,H.</style></author><author><style face="normal" font="Arial"> Riedler,J.</style></author><author><style face="normal" font="Arial"> Pekkanen,J.</style></author><author><style face="normal" font="Arial"> Karvonen,A.M.</style></author><author><style face="normal" font="Arial"> Lauener,R.</style></author><author><style face="normal" font="Arial"> Roduit,C.</style></author><author><style face="normal" font="Arial"> Vuitton,D.A.</style></author><author><style face="normal" font="Arial"> von Mutius,E.</style></author><author><style face="normal" font="Arial"> Dalphin,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatrics Department, University Hospital of Besancon, Besancon, France</style></auth-address><titles><title><style face="normal" font="Arial">Skin prick tests and specific IgE in 10 year old children: agreement and association with allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1373" start="1365">1365-1373</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Rural environment</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Accurate assessment of atopic sensitization is pivotal to clinical practice and research. Skin prick test (SPT) and specific IgE (sIgE) are often used interchangeably. Some studies have suggested a disagreement between these two methods, and little is known about their association with allergic diseases. The aims of our study were to evaluate agreement between SPT and sIgE, and to compare their association with allergic diseases in 10-year old children. METHODS: SPT, sIgE measurements and assessment of allergic diseases were performed in children aged 10 years old in the Protection against Allergy: STUdy of Rural Environment (PASTURE) cohort. The agreement between SPT and sIgE was assessed by Cohen's kappa coefficient with different cutoff values. RESULTS: SPTs and sIgE were performed in 529 children. The highest agreement (kappa=0.44) was found with a cutoff value of 3 and 5 mm for SPT, and 3.5 IU/mL for sIgE. The AUC obtained with SPT were not significantly different from those obtained with sIgE. For asthma and hay fever, SPT (cutoff value at 3 mm) had a significantly higher specificity (p&lt;0.0001) than sIgE (cutoff value at 0.35 IU/mL) and the specificity was not different between both tests (p=0.1088). CONCLUSION: SPT and sIgE display moderate agreement, but have a similar AUC for allergic diseases. At the cutoff value of 3 mm for SPT and 0.35 IU/mL for sIgE, SPT has a higher specificity for asthma and hay fever than sIgE without difference for sensitivity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - France -CO - Germany -CO - Austria -CO - Finland -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13148</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235151">PM:28235151</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170224-ChauveauA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170224-ChauveauA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Chauveau A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13148</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cantillo,J.F.</style></author><author><style face="normal" font="Arial"> Puerta,L.</style></author><author><style face="normal" font="Arial"> Puchalska,P.</style></author><author><style face="normal" font="Arial"> Lafosse-Marin,S.</style></author><author><style face="normal" font="Arial"> Subiza,J.L.</style></author><author><style face="normal" font="Arial"> Fernandez-Caldas,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Immunological Research/University of Cartagena, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Allergenome characterization of the mosquito Aedes aegypti</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aedes</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Creatine Kinase</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Saliva and muscle derived mosquito allergens have been purified and characterized. However, the complete set of allergens remains to be elucidated. In this study, we identified and characterized IgE-binding proteins from the mosquito species A. aegypti. METHODS: Serum was obtained from 15 allergic individuals with asthma and/or rhinitis and sensitized to mosquito. IgE-binding was determined by ELISA. Total proteins from freeze dried bodies of A. aegypti were extracted and IgE reactive proteins were identified by 2D-gel electrophoresis, followed by Western blot with pooled or individual sera. IgE-reactive spots were further characterized by mass spectrometry. RESULTS: Twenty five IgE-reactive spots were identified, corresponding to 10 different proteins, some of which appeared as different variants or isoforms. Heat shock cognate 70 (HSC-70) and Tropomyosin showed IgE reactivity with 60% of the sera, Lysosomal aspartic protease and "AAEL006070-PA" (Uniprot: Q177P3) with 40% and the other proteins with less than 33.3% of the sera. Different variants, or isoforms of Tropomyosin, Arginine or Creatine kinase, Glyceraldehyde-3-phosphate dehydrogenase (GPDH), Calcium-binding protein and Phosphoglycerate mutase were also identified. The mixture of three allergens (Aed a 6, Aed a 8 and Aed a 10) seems to identify more than 80% of A. aegypti sensitized individuals, indicating that these allergens should be considered when designing of improved mosquito allergy diagnostic tools. CONCLUSIONS: The newly identified allergens may play a role in the pathophysiology of mosquito allergy in the Tropics, and some of them might be important arthropod-related proteins involved in cross-reactivity between A. aegypti and other allergenic arthropods. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - Martinique -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13150</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235135">PM:28235135</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170224-CantilloJF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170224-CantilloJF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Cantillo JF</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13150</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author><author><style face="normal" font="Arial"> Natoli,V.</style></author><author><style face="normal" font="Arial"> Puccinelli,P.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0004 1756 7871grid.410345.7Department of Internal Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.), Azienda Ospedaliera Universitaria San Martino-IST, Largo R. Benzi 10, 16132 Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="11">11-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug treatment</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Genoa</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">As standard drug treatment of allergic rhinitis (AR) is not completely satisfactory, allergen immunotherapy (AIT) represents the only current treatment with the potential to modify the natural history. House dust mite (HDM) allergy is very common. The aim of the current experience was to describe the clinical profile of HDM-allergic patients with AR who received AIT in a real world model, such as allergy clinics. Globally, 239 patients (126 adults and 113 children; 107 females and 132 males; mean age 21 years, age range 6-56 years) were evaluated. AIT was prescribed in 59 patients (24.7%), 44 adults (35%) and 15 children (13.3%). The current findings deriving from this real world multicentre study are consistent with previous investigations on HDM-AIT and define some clinical characteristics of the eligible candidate to this treatment. In fact, severity of ocular-nasal symptoms and over-use of symptomatic medications may typify the ideal candidate to HDM-AIT and SLIT was the preferred choice</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0185-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28239397">PM:28239397</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0185-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brabant,S.</style></author><author><style face="normal" font="Arial"> Facon,A.</style></author><author><style face="normal" font="Arial"> Provot,F.</style></author><author><style face="normal" font="Arial"> Labalette,M.</style></author><author><style face="normal" font="Arial"> Wallaert,B.</style></author><author><style face="normal" font="Arial"> Chenivesse,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy-Immunology, Pole de Biologie Pathologie Genetique Medicale du CHRU de Lille, Boulevard du professeur Leclercq, 59037 Lille Cedex, France</style></auth-address><titles><title><style face="normal" font="Arial">An avoidable cause of thymoglobulin anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="13">13-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetique</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunisation</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> rabbit allergy</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> renal transplantation</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Thymoglobulin(R) (anti-thymocyte globulin [rabbit]) is a purified pasteurised, gamma immune globulin obtained by immunisation of rabbits with human thymocytes. Anaphylactic allergic reactions to a first injection of thymoglobulin are rare. CASE PRESENTATION: We report a case of serious anaphylactic reaction occurring after a first intraoperative injection of thymoglobulin during renal transplantation in a patient with undiagnosed respiratory allergy to rabbit allergens. CONCLUSIONS: This case report reinforces the importance of identifying rabbit allergy by a simple combination of clinical interview followed by confirmatory skin testing or blood tests of all patients prior to injection of thymoglobulin, which is formally contraindicated in patients with a history of hypersensitivity to rabbit proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170302IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0186-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28250777">PM:28250777</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170302, Brabant S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0186-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hauk,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">.</style></auth-address><titles><title><style face="normal" font="Arial">Early Peanut Introduction and Prevention of Peanut Allergy in High-Risk Infants: Consensus Communication</style></title><secondary-title><style face="normal" font="Arial">Am Fam Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am Fam Physician</style></full-title></periodical><pages end="62" start="61">61-62</pages><volume><style face="normal" font="Arial">93</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arachis</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Family Practice</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160114IS - 1532-0650 (Electronic)IS - 0002-838X (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26760846">PM:26760846</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am Fam Physician\20160114-HaukL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am Fam Physician\20160114-HaukL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160114, Hauk L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bernard,P.</style></author><author><style face="normal" font="Arial"> Antonicelli,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Reference Centre for Autoimmune Bullous Diseases, Robert Debre Hospital, University of Reims Champagne-Ardenne, Cedex, France.</style></auth-address><titles><title><style face="normal" font="Arial">Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment</style></title><secondary-title><style face="normal" font="Arial">Am J Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Clin Dermatol</style></full-title></periodical><pages end="528" start="513">513-528</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune bullous disease</style></keyword><keyword><style face="normal" font="Arial"> Blister</style></keyword><keyword><style face="normal" font="Arial"> Blistering disease</style></keyword><keyword><style face="normal" font="Arial"> BP180</style></keyword><keyword><style face="normal" font="Arial"> BP230</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dementia</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Diuretics</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> hemidesmosome</style></keyword><keyword><style face="normal" font="Arial"> Hemidesmosomes</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence microscopy</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease in Western countries, and typically affects the elderly. BP is immunologically characterized by tissue-bound and circulating autoantibodies directed against either the BP antigen 180 (BP180, or BPAG2) or the BP antigen 230 (BP230, or BPAG1e), or even both, which are components of hemidesmosomes involved in the dermal-epidermal cohesion. Risk factors for BP include old age, neurologic diseases (dementia, Parkinson's disease, cerebrovascular disease), and some particular drugs, including loop diuretics, spironolactone and neuroleptics. The spectrum of clinical presentations is extremely broad. Clinically, BP is an intensely pruritic erythematous eruption with widespread blister formation. In the early stages, or in atypical, non-bullous variants of the disease, only excoriated, eczematous or urticarial lesions (either localized or generalized) are present. The diagnosis of BP relies on immunopathologic findings, especially based on both direct and indirect immunofluorescence microscopy observations, as well as on anti-BP180/BP230 enzyme-linked immunosorbent assays (ELISAs). BP is usually a chronic disease, with spontaneous exacerbations and remissions, which may be accompanied by significant morbidity. In the past decade, potent topical corticosteroids have emerged as an effective and safe first-line treatment for BP, but their long-term feasibility is still controversial. Newer therapeutic agents targeting molecules involved in the inflammatory cascade associated with BP represent future alternatives to classical immunosuppressant drugs for maintenance therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170301IS - 1179-1888 (Electronic)IS - 1175-0561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40257-017-0264-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28247089">PM:28247089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Clin Dermatol\20170301-BernardP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Clin Dermatol\20170301-BernardP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170301, Bernard P</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40257-017-0264-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dennis-Wall,J.C.</style></author><author><style face="normal" font="Arial"> Culpepper,T.</style></author><author><style face="normal" font="Arial"> Nieves,C.,Jr.</style></author><author><style face="normal" font="Arial"> Rowe,C.C.</style></author><author><style face="normal" font="Arial"> Burns,A.M.</style></author><author><style face="normal" font="Arial"> Rusch,C.T.</style></author><author><style face="normal" font="Arial"> Federico,A.</style></author><author><style face="normal" font="Arial"> Ukhanova,M.</style></author><author><style face="normal" font="Arial"> Waugh,S.</style></author><author><style face="normal" font="Arial"> Mai,V.</style></author><author><style face="normal" font="Arial"> Christman,M.C.</style></author><author><style face="normal" font="Arial"> Langkamp-Henken,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Science and Human Nutrition Department</style></auth-address><titles><title><style face="normal" font="Arial">Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial</style></title><secondary-title><style face="normal" font="Arial">Am J Clin Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Clin Nutr</style></full-title></periodical><pages end="767" start="758">758-767</pages><volume><style face="normal" font="Arial">105</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fasting</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergies</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spring allergy</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">Background: Rhinoconjunctivitis-specific quality of life is often reduced during seasonal allergies. The Mini Rhinoconjunctivitis Quality of Life Questionnaire (MRQLQ) is a validated tool used to measure quality of life in people experiencing allergies (0 = not troubled to 6 = extremely troubled). Probiotics may improve quality of life during allergy season by increasing the percentage of regulatory T cells (Tregs) and inducing tolerance.Objective: The objective of this study was to determine whether consuming Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and B. longum MM-2 compared with placebo would result in beneficial effects on MRQLQ scores throughout allergy season in individuals who typically experience seasonal allergies. Secondary outcomes included changes in immune markers as part of a potential mechanism for changes in MRQLQ scores.Design: In this double-blind, placebo-controlled, parallel, randomized clinical trial, 173 participants (mean +/- SEM: age 27 +/- 1 y) who self-identified as having seasonal allergies received either a probiotic (2 capsules/d, 1.5 billion colony-forming units/capsule) or placebo during spring allergy season for 8 wk. MRQLQ scores were collected weekly throughout the study. Fasting blood samples were taken from a subgroup (placebo, n = 37; probiotic, n = 35) at baseline and week 6 (predicted peak of pollen) to determine serum immunoglobulin (Ig) E concentrations and Treg percentages.Results: The probiotic group reported an improvement in the MRQLQ global score from baseline to pollen peak (-0.68 +/- 0.13) when compared with the placebo group (-0.19 +/- 0.14; P = 0.0092). Both serum total IgE and the percentage of Tregs increased from baseline to week 6, but changes were not different between groups.Conclusions: This combination probiotic improved rhinoconjunctivitis-specific quality of life during allergy season for healthy individuals with self-reported seasonal allergies; however, the associated mechanism is still unclear. This trial was registered at clinicaltrials.gov as NCT02349711</style></abstract><notes><style face="normal" font="Arial">DA - 20170223IS - 1938-3207 (Electronic)IS - 0002-9165 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3945/ajcn.116.140012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28228426">PM:28228426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Clin Nutr\20170223-DennisWallJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Clin Nutr\20170223-DennisWallJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Dennis-Wall JC</style></custom2><misc3><style face="normal" font="Arial">10.3945/ajcn.116.140012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wicher,S.A.</style></author><author><style face="normal" font="Arial"> Jacoby,D.B.</style></author><author><style face="normal" font="Arial"> Fryer,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Oregon Health &amp; Science University</style></auth-address><titles><title><style face="normal" font="Arial">Newly Divided Eosinophils Limit Ozone-Induced Airway Hyperreactivity In Non-Sensitized Guinea Pigs</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L982" start="L969">L969-L982</pages><volume><style face="normal" font="Arial">312</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hematopoiesis</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oregon</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="3" Year="2017">2017/3/3</year></dates><abstract><style face="normal" font="Arial">Ozone causes vagally-mediated airway hyperreactivity and recruits inflammatory cells, including eosinophils, to lungs where they mediate ozone-induced hyperreactivity one day after exposure, but are paradoxically protective three days later. To test the role of newly divided eosinophils in ozone-induced airway hyperreactivity in sensitized and non-sensitized guinea pigs. Non-sensitized and sensitized guinea pigs were treated with 5-bromo-2-deoxyuridine (BrdU) to label newly divided cells and were exposed to air or ozone for 4 hours. One or three days later, vagally-induced bronchoconstriction was measured and inflammatory cells harvested from bone marrow, blood, and bronchoalveolar lavage. Ozone induced eosinophil hematopoiesis. One day post ozone, mature eosinophils dominate the inflammatory response and potentiate vagally-induced bronchoconstriction. However, by three days, newly divided eosinophils have reached the lungs where they inhibit ozone-induced airway hyperreactivity, since depleting them with AbIL-5 or a TNFalpha antagonist, worsened vagally-induced bronchoconstriction. In sensitized guinea pigs, both ozone-induced eosinophil hematopoiesis and subsequent recruitment of newly divided eosinophils to lungs three days later failed to occur. Thus, mature eosinophils dominated the ozone-induced inflammatory response in sensitized guinea pigs. Depleting these mature eosinophils prevented ozone-induced airway hyperreactivity in sensitized animals. Ozone induces eosinophil hematopoiesis and recruitment to lungs where three days later, newly divided eosinophils attenuate vagally-mediated hyperreactivity. Ozone-induced hematopoiesis of beneficial eosinophils is blocked by a TNFalpha antagonist, or by prior sensitization. In these animals, mature eosinophils are associated with hyperreactivity. Thus, interventions targeting eosinophils, while beneficial in atopic individuals, may delay resolution of airway hyperreactivity in non-atopic individuals</style></abstract><notes><style face="normal" font="Arial">DA - 20170304IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00530.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258108">PM:28258108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170304-WicherSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170304-WicherSA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Wicher SA</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00530.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,C.</style></author><author><style face="normal" font="Arial"> Lin,R.L.</style></author><author><style face="normal" font="Arial"> Hong,J.</style></author><author><style face="normal" font="Arial"> Khosravi,M.</style></author><author><style face="normal" font="Arial"> Lee,L.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Kentucky Medical Center</style></auth-address><titles><title><style face="normal" font="Arial">Cough and expiration reflexes elicited by inhaled irritant gases are intensified in ovalbumin sensitized mice</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Regul Integr Comp Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Regul Integr Comp Physiol</style></full-title></periodical><pages end="R726" start="R718">R718-R726</pages><volume><style face="normal" font="Arial">312</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gases</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Kentucky</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Reflex</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensory nerves</style></keyword><keyword><style face="normal" font="Arial"> Sulfur</style></keyword><keyword><style face="normal" font="Arial"> Sulfur Dioxide</style></keyword><keyword><style face="normal" font="Arial"> Telemetry</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">This study was designed to determine the effect of active sensitization with ovalbumin (Ova) on cough responses to inhaled irritant gases in mice. Conscious mice moved freely in a recording chamber while the pressure change in the chamber, audio and video signals of the mouse movements were recorded simultaneously to measure the frequencies of cough reflex (CR) and expiration reflex (ER). To further verify the accuracy of cough analysis, the intra-pleural pressure was also recorded by a telemetry sensor surgically implanted in the intra-pleural space in a subgroup of mice. During the irritant gas inhalation challenge, sulfur dioxide (SO2; 200 &amp; 400 ppm) or ammonia (NH3; 0.1% &amp; 0.2%) was drawn into the chamber at a constant flowrate for 8 minutes. Ova sensitization and sham sensitization with vehicle (Veh) were performed over a 25-day period in separate groups of mice. Our results showed: 1) Both SO2 and NH3 inhalation challenges increased CR and ER frequencies in a concentration-dependent manner before Ova sensitization. 2) The baseline CR frequency was significantly elevated after Ova sensitization, accompanied by pronounced airway inflammation. 3) Ova sensitization also markedly augmented the responses of CR and ER to both SO2 and NH3 inhalation challenges; in sharp contrast, the cough responses did not change after sham sensitization in the Veh group. In conclusion, Ova sensitization caused distinct and lingering increases in baseline cough frequency, and also intensified both CR and ER responses to inhaled irritant gases, which probably resulted from an allergic inflammation-induced hypersensitivity of airway sensory nerves</style></abstract><notes><style face="normal" font="Arial">DA - 20170223IS - 1522-1490 (Electronic)IS - 0363-6119 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajpregu.00444.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28228416">PM:28228416</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Regul Integr Comp Physiol\20170223-ZhangC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Regul Integr Comp Physiol\20170223-ZhangC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Zhang C</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajpregu.00444.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,X.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author><author><style face="normal" font="Arial"> Tan,Q.</style></author><author><style face="normal" font="Arial"> Shoenfeld,Y.</style></author><author><style face="normal" font="Arial"> Zeng,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shenzhen Key Laboratory of Reproductive Immunology for Peri-implantation, Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, Shenzhen Zhongshan Urology Hospital, Shenzhen, Guangdong, China</style></auth-address><titles><title><style face="normal" font="Arial">Microbiome, autoimmunity, allergy, and helminth infection: The importance of the pregnancy period</style></title><secondary-title><style face="normal" font="Arial">Am J Reprod Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Reprod Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fertility</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy Outcome</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Reproduction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Urology</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Gain</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">Pregnancy is a special physical period in reproductive age women, which has a beneficial influence on the course of certain autoimmune diseases. It has been recently suggested that the microbiome undergoes profound changes during pregnancy that are associated with host physiological and immunological adaptations. The maternal microbiome remodeling during pregnancy is an active response of the mother, possibly to alter immune system status and to facilitate metabolic and immunological adaptations, which are needed for a successful pregnancy. In this review, we attempt to discuss (i) the role of maternal microbiome in pregnancy outcomes known to adversely influence neonatal and infant health, including preterm birth, cardiometabolic complications of pregnancy, and gestational weight gain; (ii) the association of microbiome with autoimmunity, allergy diseases, and asthma during pregnancy; and (iii) the impact of helminth infection during pregnancy</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1600-0897 (Electronic)IS - 1046-7408 (Linking)LA - engPT - Journal ArticleCO - China -CO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/aji.12654</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28224678">PM:28224678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Reprod Immunol\20170222-ChenX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Reprod Immunol\20170222-ChenX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Chen X</style></custom2><misc3><style face="normal" font="Arial">10.1111/aji.12654</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Murray,C.S.</style></author><author><style face="normal" font="Arial"> Foden,P.</style></author><author><style face="normal" font="Arial"> Sumner,H.</style></author><author><style face="normal" font="Arial"> Shepley,E.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author><author><style face="normal" font="Arial"> Simpson,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Manchester, 5292, Division of Infection, Immunity and Respiratory Medicine , Manchester, Greater Manchester, United Kingdom of Great Britain and Northern Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Preventing Severe Asthma Exacerbations in Children: A Randomised Trial of Mite Impermeable Bedcovers</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="158" start="150">150-158</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Great Britain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hospital attendance</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Allergen exposure in sensitised asthmatics interacts with viruses in increasing the risk of asthma exacerbation. OBJECTIVES: To evaluate the use of house dust mite impermeable bedding on severe asthma exacerbations in children. METHODS: We randomized mite-sensitised asthmatic children (3-17 years), following an emergency hospital attendance with an asthma exacerbation, to receive mite-impermeable (Active) or control (Placebo) bed encasings. MEASUREMENTS AND MAIN RESULTS: Over a 12-month intervention period the occurrence of severe asthma exacerbations were investigated. Of 434 asthmatic children who consented, 286 (mean age 7.7 years, 65.8% male) were mite sensitised and 284 were randomised (146 Active; 138 Placebo). At 12 months, significantly fewer children in the Active group had attended hospital with an exacerbation compared to the Placebo group (36/123 [29.3%] versus 49/118 [41.5%], p=0.047). In the multivariable analysis, the risk of emergency hospital attendance was 45% lower in the Active group (Hazard Ratio 0.55[95%CI, 0.36-0.85], p=0.006) compared with the Placebo group. The annual rate of emergency hospital attendance with exacerbations was 27% lower in the Active compared with the Placebo group, but this did not reach significance (Estimated marginal mean [95% CI]: Active 0.38[0.26-0.56] vs Placebo 0.52[0.35-0.76], p=0.18). No difference between the groups in the risk of prednisolone use for exacerbation was found (Hazard Ratio 0.82[0.58-1.17], p=0.28). CONCLUSIONS: Mite-impermeable encasings are effective in reducing the number of mite sensitised asthmatic children attending hospital with asthma exacerbations, but not the number requiring oral prednisolone. This simple measure may reduce the health care burden of asthma exacerbations in children. Clinical trial registration available at www.isrctn.com, ID 69543196</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201609-1966OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28282501">PM:28282501</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-150-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-150-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Murray CS</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201609-1966OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pan,E.</style></author><author><style face="normal" font="Arial"> Botts,N.</style></author><author><style face="normal" font="Arial"> Jordan,H.</style></author><author><style face="normal" font="Arial"> Olinger,L.</style></author><author><style face="normal" font="Arial"> Donahue,M.</style></author><author><style face="normal" font="Arial"> Hsing,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Westat, Rockville, MD; US Department of Veterans Affairs, Washington, DC</style></auth-address><titles><title><style face="normal" font="Arial">Assessments of the Veteran Medication Allergy Knowledge Gap and Potential Safety Improvements with the Veteran Health Information Exchange (VHIE)</style></title><secondary-title><style face="normal" font="Arial">AMIA Annu Symp Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">AMIA Annu Symp Proc</style></full-title></periodical><pages end="1009" start="1004">1004-1009</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> medication allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Private Sector</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The U.S. Department of Veterans Affairs (VA) Veteran Health Information Exchange (VHIE, formerly Virtual Lifetime Electronic Record, or VLER) had been deployed at all VA sites and used to exchange clinical information with private sector healthcare partners nationally. This paper examined VHIE's effect on allergy documentation. Review of all inbound VHIE transactions in FY14 showed that VHIE use was associated with a nearly eight-fold increase in allergy documentation rate. Preliminary manual document review further showed that VA and partners had shared knowledge of only 38% ofpatient allergies, while VA had exclusive knowledge of another 58% ofpatient allergies, and partners had exclusive knowledge of the last 5% of patient allergies. To our knowledge, this is the first study that examined the effect of HIE on allergy documentation</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1942-597X (Electronic)IS - 1559-4076 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28269897">PM:28269897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\AMIA Annu Symp Proc\2016-2016-1004-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\AMIA Annu Symp Proc\2016-2016-1004-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Pan E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Oppenheimer,J.</style></author><author><style face="normal" font="Arial"> Nelson,M.</style></author><author><style face="normal" font="Arial"> Nelson,H.</style></author><author><style face="normal" font="Arial"> Lockey,R.</style></author><author><style face="normal" font="Arial"> Lieberman,P.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Peters,A.</style></author><author><style face="normal" font="Arial"> Collins,C.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> Blessing-Moore,J.</style></author><author><style face="normal" font="Arial"> Khan,D.</style></author><author><style face="normal" font="Arial"> Lang,D.</style></author><author><style face="normal" font="Arial"> Nicklas,R.A.</style></author><author><style face="normal" font="Arial"> Portnoy,J.M.</style></author><author><style face="normal" font="Arial"> Randolph,C.R.</style></author><author><style face="normal" font="Arial"> Schuller,D.E.</style></author><author><style face="normal" font="Arial"> Spector,S.L.</style></author><author><style face="normal" font="Arial"> Tilles,S.A.</style></author><author><style face="normal" font="Arial"> Wallace,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="282" start="276">276-282</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.12.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284533">PM:28284533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-276-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-276-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Greenhawt M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.12.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Badorrek,P.</style></author><author><style face="normal" font="Arial"> Muller,M.</style></author><author><style face="normal" font="Arial"> Koch,W.</style></author><author><style face="normal" font="Arial"> Hohlfeld,J.M.</style></author><author><style face="normal" font="Arial"> Krug,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="297" start="290">290-297</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge chamber</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dactylis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> filter</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> nasal secretion</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis is an inflammatory disease that causes cellular influx and mediator release in the nose. These inflammatory changes might be used as nasal biomarkers to assess the efficacy of novel anti-allergic treatments. OBJECTIVE: To assess the specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after grass pollen exposure in an allergen challenge chamber. METHODS: In a monocenter pilot study, 15 patients with allergic rhinitis and 19 healthy individuals underwent two 4-hour Dactylis glomerate pollen challenges in the challenge chamber with an interval of 21 days. Before challenge, on exit, and after 2 and 22 hours, a nasal lavage was performed and nasal secretions were collected on filter paper to determine a wide panel of cells and mediators. Furthermore, total nasal symptom score, nasal flow, and nasal nitric oxide were measured. RESULTS: Pollen exposure significantly increased eosinophil, interleukin (IL) 5, IL-6, IL-13, and macrophage inflammatory protein 1beta levels in allergic patients but not in healthy individuals. The effect could be reproduced for eosinophils, IL-5, IL-6, and macrophage inflammatory protein 1beta after the second allergen challenge. By contrast, the IL-13 levels were higher and eotaxin levels first increased after repetitive allergen challenge. There was no correlation between total nasal symptom score and elevated cell or cytokine levels. Nasal nitric oxide levels were nonspecifically elevated in both patients with allergy and healthy controls. CONCLUSION: A subset of cellular and soluble biomarkers in nasal lavage and secretion reveals specificity and reproducibility in patients with allergic rhinitis. These can be used to measure the immunologic efficacy of antiallergic treatments in an allergen challenge chamber. Carryover effects attributable to priming must be considered when designing cross-over studies. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00297843</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.01.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284536">PM:28284536</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-290-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-290-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Badorrek P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.01.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carnes,J.</style></author><author><style face="normal" font="Arial"> Iraola,V.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author><author><style face="normal" font="Arial"> Esch,R.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research &amp; Development Department, Laboratorios LETI, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Mite allergen extracts and clinical practice</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="256" start="249">249-256</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acaridae</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Books</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage mite</style></keyword><keyword><style face="normal" font="Arial"> storage mites</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To provide physicians, researchers, and other interested health care professionals with information about how mite source materials and allergen extracts are manufactured, including the critical process parameters that can affect the final composition of allergenic extracts available for clinical use. DATA SOURCES: A PubMed search was performed using focused keywords combined with relevant regulatory documents and industry guidelines. STUDY SELECTIONS: The information obtained through literature and specialized books was evaluated and combined with the personal expertise and experience of the authors. RESULTS: Dermatophagoides farinae and Dermatophagoides pteronyssinus are the primary species responsible for allergen sensitizations and allergy symptoms in genetically predisposed individuals. Storage mites belonging to the families Glycyphagidae, Echimyopodidae, and Acaridae can also be relevant sources of indoor mite allergens. The cultivation and purification processes used to produce mite raw materials play a critical role in the final composition of mite allergen extracts. Mite extract standardization in the United States is based on total allergenic activity with respect to a single national standard, whereas in Europe consistency is ensured by in-house standards and international references. Because of the limitation of allergen avoidance and pharmacotherapy for patients with severe allergic rhinitis and asthma, house dust mite subcutaneous immunotherapy or sublingual immunotherapy can be an invaluable treatment option for them. CONCLUSION: Differences in manufacturing processes and extract standardization approaches may lead to differences in extract quality and potency. Physicians should be aware of these potential sources of mite extract variability. Use of well-standardized house dust mite extracts would be critical for success in the diagnosis and treatment of house dust mite allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.08.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284531">PM:28284531</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-249-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-249-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Carnes J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.08.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gouder,C.</style></author><author><style face="normal" font="Arial"> Asciak,R.</style></author><author><style face="normal" font="Arial"> Montefort,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Mater Dei Hospital, Msida, Malta.</style></auth-address><titles><title><style face="normal" font="Arial">Sex differences in the efficacy, safety, and tolerability of omalizumab after 1 year in Maltese patients with asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="514" start="513">513-514</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Malta</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Malta</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.01.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283278">PM:28283278</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170311-GouderC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170311-GouderC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Gouder C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.01.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Golden,D.B.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> Freeman,T.M.</style></author><author><style face="normal" font="Arial"> Tracy,J.M.</style></author><author><style face="normal" font="Arial"> Lang,D.M.</style></author><author><style face="normal" font="Arial"> Nicklas,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, Md.</style></auth-address><titles><title><style face="normal" font="Arial">AAAAI/ACAAI Joint Venom Extract Shortage Task Force Report</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="285" start="283">283-285</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284534">PM:28284534</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-283-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-283-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Golden DB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Portnoy,J.M.</style></author><author><style face="normal" font="Arial"> Murphy,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Asthma &amp; Immunology, Children's Mercy Kansas City, Kansas City, Missouri.</style></auth-address><titles><title><style face="normal" font="Arial">Is it time for asthma action plan apps?</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="240" start="239">239-240</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma action plan</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284528">PM:28284528</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-239-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-239-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Portnoy JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.01.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pettersson,M.E.</style></author><author><style face="normal" font="Arial"> Koppelman,G.H.</style></author><author><style face="normal" font="Arial"> Flokstra-de Blok,B.M.</style></author><author><style face="normal" font="Arial"> van Ginkel,C.D.</style></author><author><style face="normal" font="Arial"> Roozendaal,C.</style></author><author><style face="normal" font="Arial"> Muller-Kobold,A.C.</style></author><author><style face="normal" font="Arial"> Kollen,B.J.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; GRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Apolipoprotein B: a possible new biomarker for anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="516" start="515">515-516</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="3" Year="2017">2017/3/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.01.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274733">PM:28274733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170309-PetterssonME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170309-PetterssonME.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Pettersson ME</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.01.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Epstein,T.G.</style></author><author><style face="normal" font="Arial"> Liss,G.M.</style></author><author><style face="normal" font="Arial"> Murphy-Berendts,K.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Allergy, and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio; Allergy Partners of Central Indiana, Indianapolis, Indiana.</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of the risk of infection associated with subcutaneous allergen immunotherapy: American Academy of Allergy, Asthma, and Immunology and American College of Allergy, Asthma, and Immunology National Surveillance Study on Allergen Immunotherapy, 2014-2015</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="512" start="511">511-512</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170305IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.01.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259390">PM:28259390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170305-EpsteinTG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170305-EpsteinTG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170305, Epstein TG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.01.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ma,H.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Luo,Y.</style></author><author><style face="normal" font="Arial"> Guo,S.</style></author><author><style face="normal" font="Arial"> Song,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Anhui Provincial Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui, China</style></auth-address><titles><title><style face="normal" font="Arial">Mir-20b-Induced Increase in Myeloid-Derived Suppressor Cells in the Lungs of Mice with Chronic Asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Clin Lab Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Clin Lab Sci</style></full-title></periodical><pages end="82" start="76">76-82</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Bronchial asthma is a common chronic airway inflammatory disease. MicroRNAs (miRNAs) play an important role in the pathogenesis of asthma. We have previously shown that miR-20b can inhibit airway inflammation in asthmatic mice, but the exact mechanism is unknown. In the present study, we show that administration of nasal drops containing miR-20b induced an increase in the percentage of Gr1+CD11b+ myeloid-derived suppressor cells (MDSCs) in lung tissue from asthmatic mice, and the content of TGF-beta in lung tissues also increased after treatment. However, there was no significant change in the number of Gr1+CD11b+ MDSCs in bone marrow, peripheral blood, or spleens of asthmatic mice receiving the miR-20b nasal drip compared with untreated asthmatic mice. Since MDSCs originate in the bone marrow, these results suggest that miR-20b nasal drops may promote the increase of Gr1+CD11b+ MDSCs in the lungs of asthmatic mice by the mechanism of inducing expansion</style></abstract><notes><style face="normal" font="Arial">DA - 20170302IS - 1550-8080 (Electronic)IS - 0091-7370 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28249921">PM:28249921</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto - 2 anni</url></related-urls></urls><custom2><style face="normal" font="Arial">20170302, Ma H</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Son,J.H.</style></author><author><style face="normal" font="Arial"> Jin,H.</style></author><author><style face="normal" font="Arial"> You,H.S.</style></author><author><style face="normal" font="Arial"> Shim,W.H.</style></author><author><style face="normal" font="Arial"> Kim,J.M.</style></author><author><style face="normal" font="Arial"> Kim,G.W.</style></author><author><style face="normal" font="Arial"> Kim,H.S.</style></author><author><style face="normal" font="Arial"> Ko,H.C.</style></author><author><style face="normal" font="Arial"> Kim,M.B.</style></author><author><style face="normal" font="Arial"> Kim,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Five Cases of Phytophotodermatitis Caused by Fig Leaves and Relevant Literature Review</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="90" start="86">86-90</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Blister</style></keyword><keyword><style face="normal" font="Arial"> Celery</style></keyword><keyword><style face="normal" font="Arial"> Cellulitis</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parsnip</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Tinea</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ultraviolet</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Phytophotodermatitis is a condition caused by sequential exposure to photosensitizing substances present in plants followed by ultraviolet light. Several plants (e.g., limes, celery, fig, and wild parsnip) contain furocoumarin compounds (psoralens). It is important for dermatologists to be aware of phytophotodermatitis because it may be misdiagnosed as cellulitis, tinea, or allergic contact dermatitis. We present five patients with a sharply defined erythematous swollen patch with bullae on both feet. They described soaking their feet in a fig leaves decoction to treat their underlying dermatologic diseases. Within 24 hours, all patients had a burning sensation in their feet, and erythema and edema had developed on the feet dorsa with exception of the portion of the skin covered by the sandals. Histopathologic examinations revealed sub-epithelial blisters with intensive epidermal necrosis. Phytophotodermatitis was ultimately diagnosed and, after several days, the patients' skin lesions began to recover upon treatment with systemic and topical corticosteroids. Unfortunately, since there are no studies providing sufficient evidence on the benefits of fig leaves, they should be used with caution</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2017.29.1.86</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28223753">PM:28223753</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2017-29-86-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2017-29-86-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Son JH</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2017.29.1.86</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,J.H.</style></author><author><style face="normal" font="Arial"> Lee,Y.J.</style></author><author><style face="normal" font="Arial"> Lee,J.Y.</style></author><author><style face="normal" font="Arial"> Park,Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Topical Application of Eupatilin Ameliorates Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="68" start="61">61-68</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is an inflammatory skin disorder with severe pruritus. Despite advancements in medicine, therapeutic treatments for AD are still limited. Eupatilin (5,7-dihydroxy-30,40,6-trimethoxyflavone) is one of the lipophilic flavonoids from Artemisia umbelliformis Lam. and Artemisia genipi Weber. OBJECTIVE: Although it has been reported to act a role in improving inflammation, its action on AD is uncertain. In this study, we examined the role of eupatilin on AD-like skin lesions in NC/Nga mice. METHODS: 2,4-dinitrochlorobenzene was repeatedly applied to the ear of NC/Nga mice to produce AD-like skin lesions. Eupatilin (1%, once a day for 5 consecutive days/week) was applied topically for four weeks for the evaluation of its therapeutic effects. RESULTS: 1% eupatilin cream significantly reduced the clinical severity score of AD-like lesions, compared to the vehicle (p&lt;0.005). A histopathological analysis revealed that 1% eupatilin cream significantly decreased the mast cell infiltration as well as inflammatory cell infiltration, compared to the vehicle (p&lt;0.005). We showed that 1% eupatilin cream significantly reduced the expression of thymic stromal lymphopoietin, tumor necrosis factor-alpha, interleukin-4, and interleukin-19, but not interferon-gamma, compared to the vehicle (p&lt;0.005). CONCLUSION: Considering the therapeutic reaction of eupatilin on AD-like lesions as in this study, the substance has a promising to be an adjuvant topical agent for the control of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South KOrea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2017.29.1.61</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28223748">PM:28223748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2017-29-61-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2017-29-61-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Lee JH</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2017.29.1.61</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">You,H.S.</style></author><author><style face="normal" font="Arial"> Yang,M.Y.</style></author><author><style face="normal" font="Arial"> Kim,G.W.</style></author><author><style face="normal" font="Arial"> Cho,H.H.</style></author><author><style face="normal" font="Arial"> Kim,W.J.</style></author><author><style face="normal" font="Arial"> Mun,J.H.</style></author><author><style face="normal" font="Arial"> Song,M.</style></author><author><style face="normal" font="Arial"> Kim,H.S.</style></author><author><style face="normal" font="Arial"> Ko,H.C.</style></author><author><style face="normal" font="Arial"> Kim,M.B.</style></author><author><style face="normal" font="Arial"> Kim,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Pusan National University School of Medicine, Busan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effectiveness of Specific Sublingual Immunotherapy in Korean Patients with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="5" start="1">1-5</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE assays</style></keyword><keyword><style face="normal" font="Arial"> IgE serum level</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Lip</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assay</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assays</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sublingual immunotherapy (SLIT) with house dust mites (HDM) preparation has recently been proven to be beneficial for treating allergic rhinitis and asthma. However, there has been no report regarding the efficacy and safety of SLIT in Korean patients with atopic dermatitis (AD). OBJECTIVE: We intended to investigate the efficacy and safety of SLIT in Korean patients with AD. METHODS: A total of 34 patients with AD and immunoglobulin E (IgE)-proven HDM sensitization (Class >/=3) were recruited. Eczema area and severity index (EASI) score, total serum IgE level, specific IgE assays to Dermatophagoides pteronyssinus, D. farinae, and adverse effects were recorded during follow-up. "Responder" was defined as a patient with >/=30% improvement in EASI score after SLIT. RESULTS: Twenty-three patients continued SLIT for 12 months or more, whereas 3 patients (8.8%) dropped out because of exacerbation of dermatitis, and 8 patients (23.5%) were lost to follow-up. The average duration of SLIT treatment was 22.4 months (range, 12~32 months). EASI scores reduced significantly after 6 months of treatment (p&lt;0.05) compared with those at baseline. A total of 18 patients were determined to be responders to SLIT after 6 months. Total and specific IgE serum levels did not significantly reduce after SLIT. No patients experienced serious adverse events, with the exception of two patients who developed transient lip and tongue swelling. CONCLUSION: Our study demonstrated that SLIT with HDM extracts is effective and tolerable in Korean patients with AD. Further controlled long-term trials are required to reinforce the current results</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South KOrea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2017.29.1.1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28223739">PM:28223739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2017-29-1-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2017-29-1-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, You HS</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2017.29.1.1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khumra,S.</style></author><author><style face="normal" font="Arial"> Chan,J.</style></author><author><style face="normal" font="Arial"> Urbancic,K.</style></author><author><style face="normal" font="Arial"> Worland,T.</style></author><author><style face="normal" font="Arial"> Angus,P.</style></author><author><style face="normal" font="Arial"> Jones,B.</style></author><author><style face="normal" font="Arial"> Grayson,M.L.</style></author><author><style face="normal" font="Arial"> Trubiano,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Antibiotic allergy 'labels' in Liver Transplant recipients (ALT) Study</style></title><secondary-title><style face="normal" font="Arial">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Antimicrob Agents Chemother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">Patient-reported antibiotic allergies (so-called antibiotic allergy labels [AALs]) are associated with suboptimal prescribing and inferior clinical outcomes, especially in the immunocompromised (1, 2)....</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1098-6596 (Electronic)IS - 0066-4804 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1128/AAC.00078-17CO - Australia -</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28264847">PM:28264847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Antimicrob Agents Chemother\20170307-KhumraS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Antimicrob Agents Chemother\20170307-KhumraS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Khumra S</style></custom2><misc3><style face="normal" font="Arial">10.1128/AAC.00078-17CO - Australia -</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Delahaye,C.</style></author><author><style face="normal" font="Arial"> Chauveau,A.</style></author><author><style face="normal" font="Arial"> Kiefer,S.</style></author><author><style face="normal" font="Arial"> Dumond,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unite d'allergologie pediatrique, service de medecine infantile, hopital d'Enfants, CHRU de Nancy, rue du Morvan, 54511 Vandoeuvre-les-Nancy, France.</style></auth-address><titles><title><style face="normal" font="Arial">[Food protein-induced enterocolitis syndrome (FPIES) in 14 children]</style></title><secondary-title><style face="normal" font="Arial">Arch Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Pediatr</style></full-title></periodical><pages end="316" start="310">310-316</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lethargy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mussels</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Salmon</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tuna</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Food protein-induced enterocolitis syndrome (FPIES) is a particular non-IgE-mediated food allergy, manifested by profuse and repetitive vomiting with hypotonia and lethargy in its acute form. METHODS: A retrospective descriptive single-center study was conducted. Subjects included in this study were children with acute FPIES who consulted the allergy outpatient clinic of the Nancy Regional University Hospital between November 2013 and June 2016. RESULTS: Among the 14 patients (eight boys and six girls), nine had a history of atopy: a family history for six (42.8%) and a personal history for five (35.7%). Three had chronic FPIES turning into acute FPIES. Cow milk was the most common triggering food (50%), followed by fish (21.4%), mussels (14.3%), wheat (7.1%), egg (7.1%), and poultry (7.1%). The average time from ingestion to symptom onset was 90minutes. The symptoms were typical and diarrhea was not systematic (42.8%). Six children were hospitalized, some of them several times, including once in intensive care for one patient. The treatments established were, in order of frequency: oral or intravenous rehydration, corticosteroids, antihistamines, and antiemetics. Diagnosis time was 7.6 months on average; it was significantly shorter for milk than for solid foods (1.4 vs. 12 months, P-value=0.02), on average after two episodes. Another diagnosis than FPIES was raised at first for five patients (acute gastroenteritis, gastroesophageal reflux, and bowel obstruction caused by bowel volvulus). Allergy tests were initially negative. Two chronic FPIES cases (one milk FPIES and one milk and wheat FPIES) developed an acute FPIES to another food (fish and mussels); one patient changed from an acute fish FPIES to an IgE-mediated phenotype over time. FPIES resolved for four patients: three milk FPIES, on average 15.7 months after the first reaction, and one wheat FPIES, 2.5 years after the first reaction. A child with a white fish FPIES was able to introduce salmon and tuna. CONCLUSION: FPIES is a pathology that has suffered from a lack of knowledge, delaying diagnosis for many months. The progression of chronic forms to acute forms and acute forms to an IgE-mediated allergy is not rare. Doctors need more detailed knowledge: profuse and repetitive vomiting accompanied by hypotonia and/or lethargy should suggest the diagnosis of acute FPIES. To improve the management of acute FPIES, a treatment protocol is proposed here</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1769-664X (Electronic)IS - 0929-693X (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.arcped.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28233719">PM:28233719</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Pediatr\20170224-DelahayeC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Pediatr\20170224-DelahayeC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Delahaye C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.arcped.2017.01.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takano,K.</style></author><author><style face="normal" font="Arial"> Yamamoto,M.</style></author><author><style face="normal" font="Arial"> Takahashi,H.</style></author><author><style face="normal" font="Arial"> Himi,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Sapporo Medical University School of Medicine, S1W16, Chuo-ku, Sapporo 060-8543, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Recent advances in knowledge regarding the head and neck manifestations of IgG4-related disease</style></title><secondary-title><style face="normal" font="Arial">Auris Naus Larynx</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Auris Naus Larynx</style></abbr-1></periodical><pages end="17" start="7">7-17</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenal Cortex</style></keyword><keyword><style face="normal" font="Arial"> Adrenal Cortex Hormones</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Hypophysitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dacryocystitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lymphadenitis</style></keyword><keyword><style face="normal" font="Arial"> Mastoiditis</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Neuritis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Orbit</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Otitis</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Salivary Glands</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sialadenitis</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis,Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">IgG4-related disease (IgG4-RD) is a chronic inflammatory disorder, characterized by elevated serum IgG4 levels as well as abundant infiltration of IgG4-positive plasmacytes and fibrosis in various organs, including the head and neck region. In particular, the salivary glands, orbit, and thyroid are common sites of disease involvement. IgG4-RD is diagnosed based on various clinical, serological, and histopathological findings, none of which are pathognomonic. Hence, various differential diagnoses, which exhibit elevated serum IgG4 levels and infiltration of IgG4-postive cells into tissues, need to be excluded, especially malignant diseases and mimicking disorders. Systemic corticosteroids are generally effective in inducing IgG4-RD remission; however, recurrent or refractory cases are common. In addition, although the pathogenic mechanisms of IgG4-RD remain unclear, an antigen-driven inflammatory condition is believed to be involved. Recent studies have indicated the important pathogenic role of B cell/T cell collaboration and innate immunity in this disease. Nevertheless, additional research and discussions are needed to resolve many remaining questions. In this review, we provide an overview of the recent insights on the history, clinical features, diagnosis, and treatment of IgG4-RD in the head and neck region. Furthermore, we have also addressed the pathogenesis of this disease</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1879-1476 (Electronic)IS - 0385-8146 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Adrenal Cortex Hormones)RN - 0 (Immunoglobulin G)SB - IMCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anl.2016.10.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27956101">PM:27956101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Auris Naus Larynx\2017-44-7-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Auris Naus Larynx\2017-44-7-17.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Takano K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anl.2016.10.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Otsu,A.</style></author><author><style face="normal" font="Arial"> Kawasaki,H.</style></author><author><style face="normal" font="Arial"> Tominaga,M.</style></author><author><style face="normal" font="Arial"> Shigenaga,A.</style></author><author><style face="normal" font="Arial"> Matsuda,H.</style></author><author><style face="normal" font="Arial"> Takahashi,N.</style></author><author><style face="normal" font="Arial"> Nakajima,T.</style></author><author><style face="normal" font="Arial"> Naito,H.</style></author><author><style face="normal" font="Arial"> Baba,T.</style></author><author><style face="normal" font="Arial"> Ogawa,H.</style></author><author><style face="normal" font="Arial"> Tomooka,Y.</style></author><author><style face="normal" font="Arial"> Yamakura,F.</style></author><author><style face="normal" font="Arial"> Takamori,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biological Science and Technology, Faculty of Industrial Science and Technology, Tokyo University of Science, 6-3-1 Niijuku, Katsushika-ku, Tokyo 125-8585, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Accumulation of immunoglobulin G against Dermatophagoides farinae tropomyosin in dorsal root ganglia of NC/Nga mice with atopic dermatitis-like symptoms</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="712" start="707">707-712</pages><volume><style face="normal" font="Arial">485</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dorsal root ganglia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD), a chronic inflammatory skin disease, manifests as intractable itch, but its underlying mechanisms are poorly understood. This study assessed the relationship between immunoglobulin G (IgG) and dorsal root ganglia (DRG) in NC/Nga mice, a model of AD that manifests AD-like symptoms including itch. Immunohistochemical analysis showed large amounts of IgG in DRG extracts of NC/Nga mice with AD-like dermatitis, with a large fraction of the IgG distributed in satellite glial cells of the DRG. Proteomic analysis showed that this IgG was reactive against tropomyosin of Dermatophagoides farinae. These findings indicate that the accumulation of anti-tropomyosin IgG in DRG of atopic NC/Nga mice may be associated with the pathogenesis of AD-like symptoms, including itch</style></abstract><notes><style face="normal" font="Arial">DA - 20170226IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2017.02.109</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237704">PM:28237704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\2017-485-707-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\2017-485-707-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170226, Otsu A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2017.02.109</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cho,B.O.</style></author><author><style face="normal" font="Arial"> Che,D.N.</style></author><author><style face="normal" font="Arial"> Yin,H.H.</style></author><author><style face="normal" font="Arial"> Shin,J.Y.</style></author><author><style face="normal" font="Arial"> Jang,S.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Institute, Ato Q&amp;A Corporation, Jeonju 55069, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Diospyros lotus leaf and grapefruit stem extract synergistically ameliorate atopic dermatitis-like skin lesion in mice by suppressing infiltration of mast cells in skin lesions</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="826" start="819">819-826</pages><volume><style face="normal" font="Arial">89</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Diospyros</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Lotus</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis, a chronic relapsing and pruritic inflammation of the skin also thought to be involved in, or caused by immune system destruction is an upsetting health problem due to its continuously increasing incidence especially in developed countries. Mast cell infiltration in atopic dermatitis skin lesions and its IgE-mediated activation releases various cytokines and chemokines that have been implicated in the pathogenesis of atopic dermatitis. This study was aimed at investigating synergistic anti-inflammatory, anti-pruritic and anti-atopic dermatitis effects of Diospyros lotus leaf extract (DLE) and Muscat bailey A grapefruit stem extract (GFSE) in atopic dermatitis-like induced skin lesions in mice. Combinations of DLE and GFSE inhibited TNF-alpha and IL-6 production more than DLE or GFSE in PMA plus calcium ionophore A23187-activated HMC-1 cells. DLE and GFSE synergistically inhibited compound 48/80-induced dermal infiltration of mast cells and reduced scratching behavior than DLE or GFSE. Furthermore, DLE and GFSE synergistically showed a stronger ameliorative effect in skin lesions by reducing clinical scores; dermal infiltration of mast cells; ear and dorsal skin thickness; serum IgE and IL-4 production in atopic dermatitis-like mice. Collectively, these results suggest that DLE and GFSE synergistically exhibit anti-atopic dermatitis effects in atopic dermatitis-like skin lesions in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.01.145</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28282783">PM:28282783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-89-819-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-89-819-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Cho BO</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.01.145</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morales,M.</style></author><author><style face="normal" font="Arial"> Gallego,M.</style></author><author><style face="normal" font="Arial"> Iraola,V.</style></author><author><style face="normal" font="Arial"> Taules,M.</style></author><author><style face="normal" font="Arial"> de Oliveira,E.</style></author><author><style face="normal" font="Arial"> Moya,R.</style></author><author><style face="normal" font="Arial"> Carnes,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research &amp; Development, Laboratorios LETI, S.L., Calle del Sol n degrees 5, 28760, Madrid, Tres Cantos, Spain</style></auth-address><titles><title><style face="normal" font="Arial">In vitro evidence of efficacy and safety of a polymerized cat dander extract for allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">BMC Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Immunol</style></full-title></periodical><pages end="" start="10">10-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> cat dander extract</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Fel d 2</style></keyword><keyword><style face="normal" font="Arial"> Fel d 3</style></keyword><keyword><style face="normal" font="Arial"> Fel d 4</style></keyword><keyword><style face="normal" font="Arial"> Fel d 7</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy to cat epithelia is highly prevalent, being the major recommendation for allergy sufferers its avoidance. However, this is not always feasible. Allergen specific immunotherapy is therefore recommended for these patients. The use of polymerized allergen extracts, allergoids, would allow to achieve the high allergen doses suggested to be effective while maintaining safety. RESULTS: Cat native extract and its depigmented allergoid were manufactured and biochemically and immunochemically characterized. Protein and chromatographic profiles showed significant modification of the depigmented allergoid with respect to its corresponding native extract. However, the presence of different allergens (Fel d 1, Fel d 2, Fel d 3, Fel d 4 and Fel d 7) was confirmed in the allergoid. Differences in IgE-binding capacity were observed as loss of biological potency and lower stability of the IgE-allergen complex on surface plasmon resonance. The allergoid induced production of IgG antibodies able to block IgE-binding to native extract. Finally, studies carried out with peripheral-blood mononuclear cells from cat allergic patients showed that the allergoid induced IFN-gamma and IL-10 production similar to that induced by native extract. CONCLUSIONS: Cat depigmented allergoid induced production of cytokines involved in a Th1 and Treg response, was able to induce production of IgG-antibodies that blocks IgE-binding to cat native extract, and showed reduced interaction with IgE, suggesting greater safety than native extract while maintaining in vitro efficacy</style></abstract><notes><style face="normal" font="Arial">DA - 20170225IS - 1471-2172 (Electronic)IS - 1471-2172 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12865-017-0193-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235411">PM:28235411</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Immunol\2017-18-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Immunol\2017-18-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170225, Morales M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12865-017-0193-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,S.</style></author><author><style face="normal" font="Arial"> Villarreal,M.</style></author><author><style face="normal" font="Arial"> Stewart,S.</style></author><author><style face="normal" font="Arial"> Choi,J.</style></author><author><style face="normal" font="Arial"> Indra,G.</style></author><author><style face="normal" font="Arial"> Babineau,D.C.</style></author><author><style face="normal" font="Arial"> Philpot,C.</style></author><author><style face="normal" font="Arial"> David,G.</style></author><author><style face="normal" font="Arial"> Yoshida,T.</style></author><author><style face="normal" font="Arial"> Boguniewicz,M.</style></author><author><style face="normal" font="Arial"> Hanifin,J.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Leung,D.</style></author><author><style face="normal" font="Arial"> Simpson,E.</style></author><author><style face="normal" font="Arial"> Indra,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University-Oregon Health &amp; Science University, OR</style></auth-address><titles><title><style face="normal" font="Arial">Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Ceramides</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cornea</style></keyword><keyword><style face="normal" font="Arial"> corneocytes</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oregon</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Stratum corneum</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Triglycerides</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by disrupted epidermal barrier functions.1 Stratum corneum (SC) consists of corneocytes and a lipid-rich extracellular matrix, which plays a key role in epidermal permeability barrier (EPB) functions.2,3 Major lipid constituents of the SC are ceramides (CERs), free fatty acids (FFAs), cholesterol and triglycerides (TGs).2,3 Staphylococcus aureus (S.aureus) colonization is an important trigger of AD.4 Comprehensive profiling of SC lipids using S.aureus colonization status, and association between S.aureus colonization and skin lipid composition, has never been documented. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170228IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15409</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28244066">PM:28244066</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170228-LiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170228-LiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170228, Li S</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15409</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hammersley,V.S.</style></author><author><style face="normal" font="Arial"> Harris,J.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Davidson,E.</style></author><author><style face="normal" font="Arial"> Walker,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Trials and Evaluation Unit, University of Bristol, Bristol</style></auth-address><titles><title><style face="normal" font="Arial">Developing and testing of a screening tool to predict people without IgE-mediated allergy: a quantitative analysis of the predictive value of a screening tool</style></title><secondary-title><style face="normal" font="Arial">Br J Gen Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Gen Pract</style></abbr-1></periodical><pages end="e299" start="e293">e293-e299</pages><volume><style face="normal" font="Arial">67</style></volume><number><style face="normal" font="Arial">657</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Consultations</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> General practice</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Scotland</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Consultations in primary care for allergies are common. It can be difficult to differentiate between IgE-mediated (atopic) symptoms - which respond to allergen-specific interventions - and those that are non-atopic, without performing objective tests that are largely unavailable in UK general practice. AIM: To develop and test a screening tool that can accurately discriminate between atopic and non-atopic individuals. DESIGN AND SETTING: A validation study that took place in 2012 in adult volunteers aged >16 years in Scotland. METHOD: A questionnaire screening tool was developed using questions from a large cohort study and through consultation with experts. Participants answered the questions and had skin prick tests for four aeroallergens (house dust mite, cat, dog, and mixed grasses). Participants were classified as atopic if any average wheal diameter was >/=3 mm bigger than the negative control. Sensitivity, specificity, and positive and negative predictive values of individual and combinations of questions were calculated. RESULTS: In all, 143 participants completed the questionnaire and underwent skin prick testing. Of these, 81 (56.6%) were atopic. Negative predictive values for the individual questions ranged from 48.2% (55 not atopic out of 114 negative answers) to 72.0% (18/25). An optimum combination of four questions was identified, in which a negative answer to all four questions was reported by 24 participants, 21 (87.5%) of whom were not atopic. CONCLUSION: The authors have identified a set of questions that correctly predict negative skin prick tests to common aeroallergens 88% of the time. These may be useful to exclude patients who do not warrant further investigation and who can reliably be advised that allergen avoidance is neither necessary nor helpful</style></abstract><notes><style face="normal" font="Arial">DA - 20170301IS - 1478-5242 (Electronic)IS - 0960-1643 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.3399/bjgp17X689869</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28246099">PM:28246099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Gen Pract\20170301-HammersleyVS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Gen Pract\20170301-HammersleyVS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170301, Hammersley VS</style></custom2><misc3><style face="normal" font="Arial">10.3399/bjgp17X689869</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Walsh,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Castle Partnership, Norwich</style></auth-address><titles><title><style face="normal" font="Arial">NICE food allergy and anaphylaxis quality standards: a review of the 2016 quality standards</style></title><secondary-title><style face="normal" font="Arial">Br J Gen Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Gen Pract</style></abbr-1></periodical><pages end="139" start="138">138-139</pages><volume><style face="normal" font="Arial">67</style></volume><number><style face="normal" font="Arial">656</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1478-5242 (Electronic)IS - 0960-1643 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.3399/bjgp17X689833</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28232362">PM:28232362</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Gen Pract\2017-67-138-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Gen Pract\2017-67-138-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Walsh J</style></custom2><misc3><style face="normal" font="Arial">10.3399/bjgp17X689833</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Forshaw,N.</style></author><author><style face="normal" font="Arial"> Smith,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Post CCT-Clinical Fellow in Paediatric Anaesthesia, Great Ormond Street Hospital, London WC1N 3JHConsultant Anaesthetist and College Tutor, Department of Anaesthesia, Great Ormond Street Hospital, London</style></auth-address><titles><title><style face="normal" font="Arial">Is propofol safe to use in children with food allergies?</style></title><secondary-title><style face="normal" font="Arial">Br J Hosp Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Br J Hosp Med (Lond)</style></full-title></periodical><pages end="" start="178">178-</pages><volume><style face="normal" font="Arial">78</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaesthesia</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1750-8460 (Print)IS - 1750-8460 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.12968/hmed.2017.78.3.178</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28277763">PM:28277763</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170309, Forshaw N</style></custom2><misc3><style face="normal" font="Arial">10.12968/hmed.2017.78.3.178</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loekmanwidjaja,J.</style></author><author><style face="normal" font="Arial"> Carneiro,A.C.</style></author><author><style face="normal" font="Arial"> Nishinaka,M.L.</style></author><author><style face="normal" font="Arial"> Munhoes,D.A.</style></author><author><style face="normal" font="Arial"> Benezoli,G.</style></author><author><style face="normal" font="Arial"> Wandalsen,G.F.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sleep disorders in children with moderate to severe persistent allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Braz J Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Braz J Otorhinolaryngol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Crian+ºas</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dist+¦rbios de sono</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> objective markers</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Question+írio escrito</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rinite al+®rgica</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Sleep Disorders</style></keyword><keyword><style face="normal" font="Arial"> Subscale</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Written questionnaire-chave</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1808-8694</style></isbn><abstract><style face="normal" font="Arial">AbstractIntroduction Allergic rhinitis is associated with several complications, including sleep disorders. The Children's Sleep Habits Questionnaire has been recently translated and validated in Portuguese for the evaluation of sleep disorders in children. Objective To assess sleep disorders in children with moderate to severe persistent allergic rhinitis and to correlate the findings with disease severity markers. Methods We evaluated 167 children (4</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô10 years), 112 with allergic rhinitis and 55 controls. Parents/guardians of the children answered the Children's Sleep Habits Questionnaire, consisting of 33 questions divided into eight subscales, which refers to the previous week. Patients with rhinitis were also evaluated regarding the score of nasal and extra-nasal symptoms related to the previous week and the peak nasal inspiratory flow. Results There were no significant differences between groups of different age. All patients with rhinitis were being treated with nasal topical corticosteroids. The total Children's Sleep Habits Questionnaire score was significantly higher among children with rhinitis than in controls (median 48 vs. 43, p &amp;lt; 0.001). Significantly higher values were also observed for the parasomnia (9 vs. 8), respiratory disorders (4 vs. 3) and daytime sleepiness (14 vs. 12) subscales. Among the patients with rhinitis, no significant correlation was observed between the total Children's Sleep Habits Questionnaire score and disease activity variables, but moderate correlations were observed for the respiratory distress subscale vs. nasal symptom score (r = 0.32) and vs. extra-nasal symptom score (r = 0.32). Conclusion Children with moderate to severe persistent allergic rhinitis, even when submitted to regular treatment, have a higher frequency of sleep disorders than controls, particularly concerning nocturnal breathing disorders, daytime sleepiness, and parasomnias. The intensity of sleep disorders found in some subscales was correlated with objective markers of allergic rhinitis severity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bjorl.2017.01.008</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.bjorl.2017.01.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Otorhinolaryngol\20170310-LoekmanwidjajaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Otorhinolaryngol\20170310-LoekmanwidjajaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Loekmanwidjaja J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bjorl.2017.01.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Buckley,G.J.</style></author><author><style face="normal" font="Arial"> Corrie,C.</style></author><author><style face="normal" font="Arial"> Bandt,C.</style></author><author><style face="normal" font="Arial"> Schaer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Florida College of Veterinary Medicine - Small Animal Clinical Sciences, Gainesville, Florida, USA</style></auth-address><titles><title><style face="normal" font="Arial">Kidney injury in a dog following bee sting-associated anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Can Vet J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Can Vet J</style></full-title></periodical><pages end="269" start="265">265-269</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Kidney Injury</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Urea Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Creatinine</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urea</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">This report describes a case of honeybee envenomation in a dog that developed anaphylaxis after being stung by approximately 10 bees. The dog subsequently developed acute kidney injury. The dog had a previous mild increase in blood urea nitrogen with normal creatinine, possibly indicating an insidious chronic renal degenerative process that went into acute decompensation at the time of bee envenomation</style></abstract><notes><style face="normal" font="Arial">DA - 20170301IS - 0008-5286 (Print)IS - 0008-5286 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28246414">PM:28246414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Can Vet J\2017-58-265-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Can Vet J\2017-58-265-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170301, Buckley GJ</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsilingiri,K.</style></author><author><style face="normal" font="Arial"> Fornasa,G.</style></author><author><style face="normal" font="Arial"> Rescigno,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Vascular Pathophysiology Area, Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, SpainDepartment of Experimental Oncology, European Institute of Oncology, Milan, Italy and University of MilanDepartment of Experimental Oncology, European Institute of Oncology, Milan, Italy and University of Milan</style></auth-address><titles><title><style face="normal" font="Arial">Thymic Stromal Lymphopoietin: To Cut a Long Story Short</style></title><secondary-title><style face="normal" font="Arial">Cell Mol Gastroenterol Hepatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Cell Mol Gastroenterol Hepatol</style></abbr-1></periodical><pages end="182" start="174">174-182</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Differential expression</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Thymic stromal lymphopoietin (TSLP) was identified more than 20 years ago as a secreted factor of a mouse thymic stromal cell line; later, a human orthologue was also identified. The signaling pathway triggered by TSLP has been extensively studied, and upregulation of the cytokine itself is linked to the pathogenesis of numerous Th2-related diseases, including atopic dermatitis, asthma, allergic responses, as well as certain types of cancers. On the other hand, TSLP mediates several immune homeostatic functions in both the gut and the thymus. Thus, a paradox occurs; why is TSLP homeostatic in certain tissues and a hallmark of exacerbated Th2 responses in the aforementioned pathologies? We and others have recently shown that in humans a novel isoform exists; this is a shorter isoform of TSLP whose expression is constitutive and controlled by a separate promoter. Short TSLP isoform mediates the homeostatic functions, whereas the long isoform is expressed at low/undetectable level at steady state and upregulated during inflammation in several tissues. Here we review the most recent data concerning the differential expression of the 2 isoforms and provide a potential explanation to the paradox. TSLP is regarded as a promising target for treatment of relevant pathologies, with a number of clinical trials already underway. It is important to design new strategies aimed at leaving intact the homeostatic effects of the short isoform while targeting the inflammatory effects of the long isoform</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 2352-345X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jcmgh.2017.01.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28275684">PM:28275684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Mol Gastroenterol Hepatol\2017-3-174-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Mol Gastroenterol Hepatol\2017-3-174-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Tsilingiri K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jcmgh.2017.01.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy with lipid protein syndrome and diagnosing asthma</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="299" start="298">298-299</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170228IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12908</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28244260">PM:28244260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-298-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-298-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170228, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12908</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomez,F.</style></author><author><style face="normal" font="Arial"> Bogas,G.</style></author><author><style face="normal" font="Arial"> Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Campo,P.</style></author><author><style face="normal" font="Arial"> Salas,M.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Rodriguez,M.J.</style></author><author><style face="normal" font="Arial"> Prieto,A.</style></author><author><style face="normal" font="Arial"> Barber,D.</style></author><author><style face="normal" font="Arial"> Blanca,M.</style></author><author><style face="normal" font="Arial"> Torres,M.J.</style></author><author><style face="normal" font="Arial"> Mayorga,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, Spain</style></auth-address><titles><title><style face="normal" font="Arial">The clinical and immunological effects of Pru p 3 sublingual immunotherapy on peach and peanut allergy in patients with systemic reactions</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="350" start="339">339-350</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 9</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgG4</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The peach non-specific lipid transfer protein, Pru p 3, is the primary sensitizer in fruits and responsible for severe reactions in the Mediterranean area. Peach allergy is frequently associated with other allergies such as peanut. Therefore, it is important to assess how specific immunotherapy to Pru p 3 could affect both peach and peanut tolerance. OBJECTIVES: To evaluate peach and peanut desensitization and immunological changes after 1 year of Pru p 3 sublingual immunotherapy (SLIT) in patients with systemic allergic reactions to peach and/or peanut. METHODS: Forty-eight peach allergic patients, 36 treated with SLIT and 12 non-treated, were monitored for 12 months. Treated patients were subclassified as peanut allergic (Group A), sensitized (Group B) or tolerant (Group C). SLIT effect was evaluated by skin prick test (SPT) reactivity and food challenge. Immunological changes were evaluated by monitoring sIgE and sIgG4 levels and basophil reactivity. RESULTS: After 1 year of SLIT, the weal area in SPT significantly decreased and a significant increase in peach threshold in treated patients was observed (P &lt; 0.001). Patients in Group A showed a significant decrease in peanut SPT weal area and an increase in peanut threshold (P &lt; 0.001). Immunological changes were observed in treated patients only, with a significant decrease in sIgE and a parallel increase in sIgG4, sIgG4/sIgE and basophil reactivity for both Pru p 3 and Ara h 9. CONCLUSIONS AND CLINICAL RELEVANCE: After 1 year, Pru p 3 SLIT induces both desensitization and immunological changes not only for peach but also for other food allergens relevant in the induction of severe reactions such as peanut</style></abstract><notes><style face="normal" font="Arial">DA - 20170204IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12901</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160513">PM:28160513</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-339-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-339-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Gomez F</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12901</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gref,A.</style></author><author><style face="normal" font="Arial"> Rautiainen,S.</style></author><author><style face="normal" font="Arial"> Gruzieva,O.</style></author><author><style face="normal" font="Arial"> Hakansson,N.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Pershagen,G.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Wolk,A.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Bergstrom,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Dietary total antioxidant capacity in early school age and subsequent allergic disease</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="759" start="751">751-759</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant capacity</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BAMSE</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effect modification</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dietary antioxidant intake has been hypothesized to influence the development of allergic diseases, however, few prospective studies have investigated this association. OBJECTIVE: Our aim was to study the association between total antioxidant capacity (TAC) of the diet at age 8 years and the subsequent development of asthma, rhinitis and sensitization to inhalant allergens between 8 and 16 years, and to assess potential effect modification by known risk factors. METHODS: 2359 children from the Swedish birth cohort BAMSE were included. Dietary TAC at age 8 years was estimated by combining information on the child's diet the past 12 months from a food frequency questionnaire with a database of common foods analyzed with the oxygen radical absorbance capacity method. Classification of asthma and rhinitis was based on questionnaires and sera IgE antibodies were measured at 8 and 16 years. RESULTS: A statistically significant inverse association was observed between TAC of the diet and incident sensitization to inhalant allergens (adjusted Odds Ratio: 0.73, 95% Confidence Interval: 0.55-0.97 for the 3rd compared to the 1st tertile, p-value for trend = 0.031). Effect modification by traffic-related air pollution exposure was observed, with a stronger association between dietary TAC and sensitization among children with low traffic-related air pollution exposure (p-value for interaction=0.029). There was no evidence for effect modification by GSTP1 or TNF genotypes, although these results should be interpreted with caution. No clear associations were observed between TAC and development of rhinitis or asthma, although a significant inverse association was observed for allergic asthma (ORadj 0.57, 95%CI 0.34-0.94). CONCLUSIONS AND CLINICAL RELEVANCE: Higher TAC of the diet in early school age may decrease the risk of developing sensitization to inhalant allergens from childhood to adolescence. These findings indicate that implementing an antioxidant-rich diet in childhood may contribute to the prevention of allergic disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170221IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12911</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28222232">PM:28222232</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170221-GrefA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170221-GrefA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170221, Gref A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12911</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burte,E.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Siroux,V.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Jacquemin,B.</style></author><author><style face="normal" font="Arial"> Nadif,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">INSERM, U1168, VIMA: Aging and chronic diseases, Epidemiological and Public health approaches, F-94807, Villejuif, France</style></auth-address><titles><title><style face="normal" font="Arial">The sensitization pattern differs according to rhinitis and asthma multimorbidity in adults: the EGEA study</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="529" start="520">520-529</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> EGEA</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="2" Year="2017">2017/2/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mono- and polysensitization are different IgE-mediated allergic phenotypes in children. Allergic sensitization is associated with both allergic asthma and allergic rhinitis, however, associations between the sensitization pattern and particularly polysensitization with asthma and rhinitis remains poorly studied in adults. AIM: The aim of this study was to assess how the allergic sensitization pattern associates with asthma, rhinitis and their multimorbidity. METHODS: 1,199 adults from the EGEA study, with extensive phenotypic characterization and all data available on skin prick tests to 10 allergens, total IgE and blood eosinophils were included. Using questionnaires only, participants were classified into 6 groups: asymptomatic (no asthma, no rhinitis), non-allergic rhinitis alone, allergic rhinitis alone, asthma alone, asthma+non-allergic rhinitis and asthma+allergic rhinitis. Mono- and polysensitization were defined by a positive skin prick test to one or more than one allergen respectively. RESULTS: Asymptomatic participants and those with non-allergic rhinitis alone were mostly non-sensitized (around 72%) while around 12% were polysensitized. Between 32 and 43% of participants with allergic rhinitis alone, asthma alone and asthma+non-allergic rhinitis were non-sensitized and between 37 and 46% of them were polysensitized. 65% of the participants with asthma+allergic rhinitis were polysensitized. The level of total IgE followed a similar trend to that of allergic sensitization. Eosinophils were increased in asthma, especially when associated with rhinitis. Nasal symptoms were more severe and eczema more common in participants with both asthma and allergic rhinitis than in the other groups. CONCLUSIONS: Allergic sensitization and particularly polysensitization rates widely differ according to asthma and rhinitis status. This study emphasized the importance of taking into account multimorbidity between asthma and rhinitis and showed that allergic sensitization is not a dichotomic variable. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170225IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12897</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28236637">PM:28236637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170225-BurteE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170225-BurteE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170225, Burte E</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12897</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lewis,A.</style></author><author><style face="normal" font="Arial"> Macglashan,D.W.,Jr.</style></author><author><style face="normal" font="Arial"> Suvarna,S.K.</style></author><author><style face="normal" font="Arial"> Peachell,P.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Academic Unit of Respiratory Medicine, University of Sheffield, The Medical School, Beech Hill Road, Sheffield, S10 2RX, UKJohns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD, 21224, USADepartment of Histopathology, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UKAcademic Unit of Respiratory Medicine, University of Sheffield, The Medical School, Beech Hill Road, Sheffield, S10 2RX, UK</style></auth-address><titles><title><style face="normal" font="Arial">Recovery from desensitization of IgE-dependent responses in human lung mast cells</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1031" start="1022">1022-1031</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Beech</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine content</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human lung mast cell</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="2" Year="2017">2017/2/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Clinical desensitization and oral food immunotherapy are therapeutic interventions that allow individuals who react adversely to an allergen (drug or food) to be made tolerant to the allergen. However, tolerance is brief and allergen hypersensitivity can recur within days following allergen withdrawal. OBJECTIVE: We hypothesize that the reason these treatments are temporary reflects rapid recovery of mast cells from a desensitized state. We sought to test this. METHODS: Desensitization of IgE-mediated histamine release from human lung mast cells was explored by methods that partially replicate the pattern of treatment during clinical desensitization. Specific and nonspecific desensitization and changes in surface IgE were examined following desensitization. Recovery from desensitization was also studied. RESULTS: Desensitization of mast cell responses was readily induced with concentrations of antigen or anti-IgE that were suboptimal for secretion. There was little or no nonspecific desensitization when lung mast cells were exposed to antigens. There was no loss of cell surface IgE following desensitization. Removing the desensitizing stimulus from the media following desensitization allowed the cells to recover with half-point of recovery of ~1.5 days and complete recovery after 5 days. Both the functional response and histamine content recovered within this timeframe. The recovery appeared possible because both antigens and anti-IgE dissociated rapidly from cells after washing to remove excess stimulus. CONCLUSION AND CLINICAL RELEVANCE: Human lung mast cells readily recover from a desensitized state following removal of desensitizing antigen. This finding provides a potential explanation for the ephemeral nature of clinical desensitization. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170225IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12912</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28236656">PM:28236656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170225-LewisA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170225-LewisA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170225, Lewis A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12912</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jauregui,I.</style></author><author><style face="normal" font="Arial"> Azofra,J.</style></author><author><style face="normal" font="Arial"> Diaz,C.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital Universitario Basurto, 18 Avenida de Montevideo, 48013, Bilbao, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Angio-oedema without hives, IgE and omalizumab</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Montevideo</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.13079</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28262970">PM:28262970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20170306-JaureguiI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20170306-JaureguiI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Jauregui I</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.13079</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fueyo-Casado,A.</style></author><author><style face="normal" font="Arial"> Campos-Munoz,L.</style></author><author><style face="normal" font="Arial"> Gonzalez-Guerra,E.</style></author><author><style face="normal" font="Arial"> Pedraz-Munoz,J.</style></author><author><style face="normal" font="Arial"> Cortes-Toro,J.A.</style></author><author><style face="normal" font="Arial"> Lopez-Bran,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital Clinico Universitario San Carlos, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Effectiveness of omalizumab in a case of urticarial vasculitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Antimalarials</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Colchicine</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dapsone</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">Urticarial vasculitis (UV) is a mainly leucocytoclastic vasculitis with urticarial plaques. Treating these patients is challenging as the available treatments have poor efficacy. Oral corticosteroids are considered the first-line treatment, but H1 antihistamines, dapsone, colchicine, antimalarials, ciclosporin and antileucotrienes have all been tried also. However, because of their adverse effects and/or lack of efficacy, new agents are still needed. Omalizumab, an anti-IgE antibody, shows efficacy in chronic spontaneous urticaria, and might also be a good treatment for angio-oedema and urticarial vasculitis. To our knowledge, there have been only seven relevant case reports published in the English literature. We add a new case of severe chronic recurrent urticarial vasculitis refractory to all of the drugs mentioned above. We started the patient on subcutaneous omalizumab 300 mg every 4 weeks, which produced clinical improvement within the first month and total remission in the fifth month. The patient has remained stable for 23 months, and follow-up is ongoing</style></abstract><notes><style face="normal" font="Arial">DA - 20170301IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.13076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28247460">PM:28247460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20170301-FueyoCasadoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20170301-FueyoCasadoA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170301, Fueyo-Casado A</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.13076</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silva,F.M.</style></author><author><style face="normal" font="Arial"> Oliveira,E.E.</style></author><author><style face="normal" font="Arial"> Gouveia,A.C.</style></author><author><style face="normal" font="Arial"> Brugiolo,A.S.</style></author><author><style face="normal" font="Arial"> Alves,C.C.</style></author><author><style face="normal" font="Arial"> Correa,J.O.</style></author><author><style face="normal" font="Arial"> Gameiro,J.</style></author><author><style face="normal" font="Arial"> Mattes,J.</style></author><author><style face="normal" font="Arial"> Teixeira,H.C.</style></author><author><style face="normal" font="Arial"> Ferreira,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Microbiology, and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Obesity promotes prolonged ovalbumin-induced airway inflammation modulating Th1, Th2 and Th17 immune responses in BALB/c mice</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Immunol</style></full-title></periodical><pages end="59" start="47">47-59</pages><volume><style face="normal" font="Arial">189</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Forum</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Leptin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">Clinical and epidemiological studies indicate that obesity affects the development and phenotype of asthma by inducing inflammatory mechanisms in addition to eosinophilic inflammation. The aim of this study was to assess the effect of obesity on allergic airway inflammation and T helper 2 (Th2) immune responses using an experimental model of asthma in BALB/c mice. Mice fed a high-fat diet (HFD) for 10 weeks were sensitized and challenged with ovalbumin (OVA), and analysis were performed at 24 and 48 hours after the last OVA challenge. Obesity induced an increase of iNOS-expressing macrophages and neutrophils which peaked at 48 h after the last OVA challenge, and was associated with higher levels of interleukin (IL)-4, IL-9, IL-17A, leptin and IFN-gamma in the lungs. Higher goblet cell hyperplasia was associated with elevated mast cell influx into the lungs and trachea in the obese allergic mice. In contrast, early eosinophil influx, and lower levels of IL-25, thymic stromal lymphopoietin (TSLP), CCL11 and OVA-specific IgE were observed in the obese allergic mice in comparison to non-obese allergic mice. Moreover, obese mice showed higher numbers of mast cells regardless of OVA challenge. These results indicate that obesity affects allergic airway inflammation through mechanisms involving mast cell influx and the release of TSLP and IL-25, which favored a delayed immune response with an exacerbated Th1, Th2, and Th17 profile. In this scenario, an intense mixed inflammatory granulocyte influx, classically activated macrophage accumulation, and intense mucus production may contribute to a refractory therapeutic response and exacerbate asthma severity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1365-2249 (Electronic)IS - 0009-9104 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1111/cei.12958</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28263381">PM:28263381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Immunol\20170306-SIlvaFM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Immunol\20170306-SIlvaFM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Silva FM</style></custom2><misc3><style face="normal" font="Arial">10.1111/cei.12958</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Culver,E.L.</style></author><author><style face="normal" font="Arial"> Sadler,R.</style></author><author><style face="normal" font="Arial"> Bateman,A.C.</style></author><author><style face="normal" font="Arial"> Makuch,M.</style></author><author><style face="normal" font="Arial"> Cargill,T.</style></author><author><style face="normal" font="Arial"> Ferry,B.</style></author><author><style face="normal" font="Arial"> Aalberse,R.</style></author><author><style face="normal" font="Arial"> Barnes,E.</style></author><author><style face="normal" font="Arial"> Rispens,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK; Nuffield Department of Medicine, Oxford University, Oxford, UK</style></auth-address><titles><title><style face="normal" font="Arial">Increases in IgE, Eosinophils, and Mast Cells can be Used in Diagnosis and to Predict Relapse of IgG4-related Disease</style></title><secondary-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></full-title></periodical><pages end="1452" start="1444">1444-1452</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Likelihood ratio</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND &amp; AIMS: Immunoglobulin G4-related disease (IgG4-RD) is characterized by increased serum levels of IgG4 and infiltration of biliary, and pancreatic, and other tissues by IgG4-positive plasma cells. We assessed the prevalence of allergy and/or atopy, serum and tissue IgE antibodies, and blood and tissue eosinophils in patients with IgG4-RD. We investigated the association between serum IgE and diagnosis and relapse of this disease. METHODS: We performed a prospective study of 48 patients with IgG4-RD, 42 patients with an increased serum level of IgG4 with other inflammatory and autoimmune conditions (disease controls), and 51 healthy individuals (healthy controls) recruited from Oxford, United Kingdom from March 2010 through March 2014, and followed for a median of 41 months (range 3-73 months). Serum levels of Ig were measured at diagnosis, during steroid treatment, and at disease relapse for patients with IgG4-RD; levels at diagnosis were compared with baseline levels of controls. Allergen-specific IgEs were measured using the IgE ImmunoCAP. Levels and distribution of IgG4 and IgE antibodies in lymphoid, biliary, and pancreatic tissues from patients with IgG4-RD and disease controls were measured by immunohistochemistry. We analyzed data using the Spearman rank correlation and receiver operator characteristic curves. RESULTS: Serum levels of IgG4 increased to 1.4 g/l or more, and IgE increased to 125 kIU/L or more, in 81% and 54% of patients with IgG4-RD, respectively, compared with 6% and 16% of healthy controls (P&lt;.0001). Peripheral blood eosinophilia was detected in 38% of patients with IgG4-RD vs 9% of healthy controls (P=.004). Of patients with IgG4-RD, 63% had a history of allergy and 40% had a history of atopy with an IgE-specific response-these values were 60% and 53% in patients with increased serum levels of IgE (P&lt;.05). Level of IgE at diagnosis above 480 kIU/L distinguished patients with IgG4-RD from disease controls with 86% specificity, 36% sensitivity, and a likelihood ratio of 3.2. Level of IgE at diagnosis above 380 kIU/L identified patients with disease relapse with 88% specificity, 64% sensitivity, and a likelihood ratio of 5.4. IgE-positive mast cells and eosinophilia were observed in lymphoid, biliary, and pancreatic tissue samples from 50% and 86% of patients with IgG4-RD, respectively. CONCLUSION: In a prospective study, we associated IgG4-RD with allergy, atopy, eosinophilia, increased serum levels of IgE, and IgE-positive mast cells in lymphoid, biliary, and pancreatic tissue. An IgE-mediated allergic response therefore appears to develop in most patients with IgG4-RD; levels of IgE might be used in diagnosis and predicting relapse</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1542-7714 (Electronic)IS - 1542-3565 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cgh.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28223204">PM:28223204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Gastroenterol Hepatol\20170222-CulverEL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Gastroenterol Hepatol\20170222-CulverEL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Culver EL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cgh.2017.02.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,X.</style></author><author><style face="normal" font="Arial"> Zheng,P.</style></author><author><style face="normal" font="Arial"> Wei,N.</style></author><author><style face="normal" font="Arial"> Huang,H.</style></author><author><style face="normal" font="Arial"> Luo,W.</style></author><author><style face="normal" font="Arial"> Lin,Y.</style></author><author><style face="normal" font="Arial"> Sun,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparative Analysis of Serum Allergen sIgE Detected by Western Blotting and Fluorescent Enzyme Immunoassay</style></title><secondary-title><style face="normal" font="Arial">Clin Lab</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Lab</style></full-title></periodical><pages end="493" start="487">487-493</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> enzyme immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiallergen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Various new methods to diagnose allergens have gradually developed in recent years. The present study aimed to evaluate the diagnostic performance and clinical utility of Allergy-Q detection system (Proteometech Inc., Korea) on serum allergen-specific IgE (sIgE). METHODS: Immunoblotting (Allergy-Q system) and fluorescent enzyme immunoassay (ImmunoCAP system, Phadia Inc., Sweden) were used to detect serum total IgE and allergen sIgE of 244 cases of allergic diseases, followed by comparative analysis of the results. The study focused on analyzing 15 kinds of common allergens. RESULTS: Comparison of the two methods showed that the diagnostic performance of qualitative results of AllergyQ system for the majority of allergens was satisfactory, with Dermatophagoides farinae having the highest agreement (96.4%) and sensitivity (97.8%) and Dermatophagoides pteronyssinus having the highest specificity (100%), positive predictive value (100%), and Youden's index (J = 0.951). Scatter plots and Spearman's correlation analysis showed correlations between the quantitative results of the two methods, with the highest correlation for Dermatophagoides pteronyssinus (r = 0.875, p &lt; 0.001). CONCLUSIONS: For most common allergens, the Allergy-Q system is an effective method for diagnosis. It is safe, convenient, economical, accurate, and efficient in screening multi-allergens. Moreover, it is good for semi-quantitative detection of allergens in the basic hospitals that are unable to carry out the ImmunoCAP detection, and also for patients with fewer samples. However, its clinical application needs to be validated using a number of samples from a variety of countries and regions</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1433-6510 (Print)IS - 1433-6510 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.7754/Clin.Lab.2016.160904</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28271691">PM:28271691</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170308, Chen X</style></custom2><misc3><style face="normal" font="Arial">10.7754/Clin.Lab.2016.160904</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nagao,M.</style></author><author><style face="normal" font="Arial"> Borres,M.P.</style></author><author><style face="normal" font="Arial"> Sugimoto,M.</style></author><author><style face="normal" font="Arial"> Petersson,C.J.</style></author><author><style face="normal" font="Arial"> Nakayama,S.</style></author><author><style face="normal" font="Arial"> Kuwabara,Y.</style></author><author><style face="normal" font="Arial"> Masuda,S.</style></author><author><style face="normal" font="Arial"> Dykiel,P.</style></author><author><style face="normal" font="Arial"> Fujisawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0004 0621 2362grid.415573.1Allergy Center and Department of Clinical Research, Mie National Hospital, IDD, Tsu, Mie Japan</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to secretoglobin and lipocalins in a group of young children with risk of developing respiratory allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="Arial">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Can f 1</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> lipocalin</style></keyword><keyword><style face="normal" font="Arial"> Lipocalins</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Multiple sensitization</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> ownership</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Multiple sensitizations in early age have been reported to be a risk for development of asthma. This study evaluates the emergence and evolution of IgE to aeroallergens among a cohort of children with physician-diagnosed atopic dermatitis and/or showing food allergy symptoms and to examine the relation to asthma development. METHODS: Three-hundred and four children (median age 13.4 months at entry) with food allergy symptoms and/or atopic dermatitis without asthma at inclusion were analysed for IgE antibodies against food-, indoor- and outdoor-allergens and pet allergen components and correlated to the individuals' outcome on asthma inception. RESULTS: At 2 years of follow-up, physician-diagnosed asthma was 19.7% (n = 49) and asthma diagnosed any time was 24% (n = 67). History of persistent cough and asthma of father, combination of milk- and wheat-allergy symptoms and dual sensitization to house dust mite and Japanese cedar were independent risk factors for asthma. Sensitization to dog was the most prevalent inhalant allergen at entry. Asthma children had a higher proportion of sensitization to dog, cat and horse allergens at entry compared with non-asthma children. Being sensitized to both food, house dust mite and pet allergens was strongly associated with asthma (p = 0.0006). Component resolved diagnosis for dog and cat allergens showed that IgE antibodies to Can f 1 and Fel d 1 was common even at very young age. CONCLUSIONS: Early sensitization to inhalant allergens increases the risk of developing asthma as well as having milk and wheat allergy symptoms. Sensitization to dog, was common at an early age despite dog ownership. Sensitization to secretoglobin and lipocalins and less to serum albumins explained the pet sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-017-0061-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28270741">PM:28270741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Nagao M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-017-0061-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Peng,Y.H.</style></author><author><style face="normal" font="Arial"> Chen,K.F.</style></author><author><style face="normal" font="Arial"> Liao,W.C.</style></author><author><style face="normal" font="Arial"> Hsia,T.C.</style></author><author><style face="normal" font="Arial"> Chen,H.J.</style></author><author><style face="normal" font="Arial"> Yin,M.C.</style></author><author><style face="normal" font="Arial"> Ho,W.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health, China Medical University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Association of migraine with asthma risk: A retrospective population-based cohort study</style></title><secondary-title><style face="normal" font="Arial">Clin Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Respir J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urbanization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Both migraine and asthma are common health problems in the general population. However, the association between these two disorders is yet to be fully explored. OBJECTIVE: We examined whether adult patients with migraine are at a higher risk of asthma development. METHODS: We used data retrieved from the National Health Insurance Research Database in Taiwan to conduct this nationwide population-based cohort study. We identified 6647 patients aged 20-60 years who were newly diagnosed with migraine between 2000 and 2005 for the migraine group and identified 26 588 patients without migraine for the nonmigraine group. Both groups were followed up until the end of 2011 to examine the incidence of asthma. Cox proportional hazards regression analysis was used to measure the hazard ratio (HR) of asthma in the migraine group compared with the nonmigraine group. RESULTS: The HR of asthma development was 1.37 (95% confidence interval = 1.21-1.56) for the migraine group compared with the nonmigraine group after adjustment for age, sex, occupational status, insurance premium, urbanization, comorbidities, and annual outpatient department visits. Further stratified analysis revealed that this risk was also significantly higher for both sexes and in the 40-60-year age group. The main limitation of this study was that some relevant data were unavailable, such as pain medication prescriptions and family history of migraine and asthma. CONCLUSION: Adult patients with migraine are at a higher future risk of asthma development. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1752-699X (Electronic)IS - 1752-6981 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1111/crj.12623</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28268255">PM:28268255</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Respir J\20170307-PengYH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Respir J\20170307-PengYH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Peng YH</style></custom2><misc3><style face="normal" font="Arial">10.1111/crj.12623</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Green,W.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Hahn-Pedersen,J.</style></author><author><style face="normal" font="Arial"> Norgaard Andreasen,J.</style></author><author><style face="normal" font="Arial"> Taylor,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">York Health Economics Consortium, University of York, York, UKAllergy and Asthma Center, Westend, BerlinCenter for Rhinology and Allergology, Wiesbaden, GermanyALK-Abello, Horsholm, DenmarkALK-Abello, Horsholm, DenmarkYork Health Economics Consortium, University of York, York, UK</style></auth-address><titles><title><style face="normal" font="Arial">Cost-effectiveness of SQ(R) HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany</style></title><secondary-title><style face="normal" font="Arial">Clinicoecon Outcomes Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clinicoecon Outcomes Res</style></full-title></periodical><pages end="84" start="77">77-84</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Care Costs</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> resource use</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis is a global health problem that burdens society due to associated health care costs and its impact on health. Standardized quality (SQ(R)) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet is a sublingually administered allergy immunotherapy tablet for patients with persistent moderate to severe HDM allergic rhinitis despite use of allergy pharmacotherapy. OBJECTIVE: To assess the cost-effectiveness of SQ HDM SLIT-tablet in Germany for patients suffering from HDM allergic rhinitis. METHODS: A pharmacoeconomic analysis, based on data collected in a double-blinded, phase III randomized placebo-controlled trial (n=992), was undertaken to compare SQ HDM SLIT-tablet in addition to allergy pharmacotherapy to placebo plus allergy pharmacotherapy. Quality-adjusted life year (QALY) scores and health care resource use data recorded in the trial were applied to each treatment group and extrapolated over a nine-year time horizon. A series of scenarios were used to investigate the impact of changes on long-term patient health for both treatment groups, which was measured by annual changes in QALY scores. Deterministic and probabilistic sensitivity analyses were also performed. RESULTS: In the base case analysis, compared with allergy pharmacotherapy, SQ HDM SLIT-tablet led to a QALY gain of 0.31 at an incremental cost of euro2,276 over the nine-year time horizon, equating to an incremental cost-effectiveness ratio of euro7,519. The treatment was cost-effective for all scenarios analyzed; however, results were sensitive to changes in individual parameter values during the deterministic sensitivity analysis. CONCLUSION: SQ HDM SLIT-tablet in addition to pharmacotherapy is cost-effective compared with allergy pharmacotherapy plus placebo for the treatment of persistent moderate to severe HDM allergic rhinitis that is not well controlled by allergy pharmacotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170228IS - 1178-6981 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.2147/CEOR.S115931</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28243132">PM:28243132</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clinicoecon Outcomes Res\2017-9-77-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clinicoecon Outcomes Res\2017-9-77-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170228, Green W</style></custom2><misc3><style face="normal" font="Arial">10.2147/CEOR.S115931</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmiere,C.</style></author><author><style face="normal" font="Arial"> Tettamanti,C.</style></author><author><style face="normal" font="Arial"> Scarpelli,M.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cristian Palmiere, CURML, Chemin de la Vulliette 4, 1000 Lausanne 25, Switzerland, cristian.palmiere@chuv.ch</style></auth-address><titles><title><style face="normal" font="Arial">Vaccination and anaphylaxis: a forensic perspective</style></title><secondary-title><style face="normal" font="Arial">Croat Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Croat Med J</style></full-title></periodical><pages end="25" start="14">14-25</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Autopsy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laryngeal Edema</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Myocardium</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">AIM: To review the available literature pertaining to fatalities following vaccine administration and, in particular, cases of vaccine-related fatal anaphylaxis. METHOD: The MEDLINE database was systematically searched up to March 2016 to identify all relevant articles pertaining to fatal cases of anaphylaxis following vaccine administration. RESULTS: Six papers pertaining to fatal anaphylaxis following vaccination were found relevant. Mast cell tryptase and total IgE concentration was assessed exclusively in one case. Laryngeal edema was not detected in any of these cases, whereas eosinophil or mast cell infiltration was observed in lymphoid organs. In one case, immunohistochemical investigations using anti-tryptase antibodies allowed pulmonary mast cells and degranulating mast cells with tryptase-positive material outside to be identified. CONCLUSION: In any suspected IgE-mediated fatal anaphylactic cases, biochemical investigations should be systematically performed for forensic purposes. Splenic tissue should be routinely sampled for immunohistochemical investigations in all suspected anaphylaxis-related deaths and mast cell/eosinophil infiltrations should be systematically sought out in the spleen, myocardium, and coronary artery wall. The hypothesis of fatal anaphylaxis following vaccination should be formulated exclusively when circumstantial data, available medical records, laboratory investigations, and autopsy or histology findings converge in a consistent pattern. The reasonable exclusion of alternative causes of death after all postmortem investigations is also imperative in order to establish or rule out a cause-and-effect relationship between vaccine administration and any presumptive temporarily-related death</style></abstract><notes><style face="normal" font="Arial">DA - 20170302IS - 1332-8166 (Electronic)IS - 0353-9504 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.3325/cmj.2017.58.14</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28252871">PM:28252871</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Croat Med J\2017-58-14-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Croat Med J\2017-58-14-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170302, Palmiere C</style></custom2><misc3><style face="normal" font="Arial">10.3325/cmj.2017.58.14</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wilson,J.M.</style></author><author><style face="normal" font="Arial"> Schuyler,A.J.</style></author><author><style face="normal" font="Arial"> Schroeder,N.</style></author><author><style face="normal" font="Arial"> Platts-Mills,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Asthma, and Immunology, University of Virginia Health System, PO Box 801355, Charlottesville, VA, 22908, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Galactose-alpha-1,3-Galactose: Atypical Food Allergen or Model IgE Hypersensitivity?</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Co-factors</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Ticks</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Galactose-alpha-1,3-galactose (alpha-gal) is a carbohydrate allergen with several unique characteristics. In this article, we discuss some recent advances in our understanding of the 'alpha-gal syndrome,' highlight data supporting the role of ticks in pathogenesis, and speculate on immune mechanisms that lead to sensitization. RECENT FINDINGS: First described as the target of IgE in individuals suffering immediate hypersensitivity reactions to the novel anti-EGF monoclonal antibody cetuximab, it is now clear that alpha-gal sensitization is associated with mammalian meat allergy as well as reactions to other mammalian products. Unlike traditional IgE-mediated food allergies, reactions to alpha-gal often do not manifest until several hours following an exposure, although co-factors can influence the presentation. Multiple pieces of evidence, including recent work with a mouse model, point to the fact that sensitization is mediated by exposure to certain hard ticks and increasingly we are aware of its globally widespread impact. The oligosaccharide alpha-gal represents a novel allergen with several unusual clinical features. It has been recognized now on multiple continents and its clinical presentation can be quite variable. Moreover, efforts to delineate the mechanisms leading to alpha-gal sensitization may have ramifications for our broader understanding of type 2 immunity</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0672-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28224342">PM:28224342</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Wilson JM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0672-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vandenplas,O.</style></author><author><style face="normal" font="Arial"> Raulf,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chest Medicine, Universite Catholique de Louvain, Centre Hospitalier Universitaire UCL Namur, B-5530, Yvoir, Belgium. olivier.vandenplas@uclouvain.beIPA Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-Universitat Bochum, Bochum, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Occupational Latex Allergy: the Current State of Affairs</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="14">14-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword><keyword><style face="normal" font="Arial"> Workplace exposure</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Allergy to natural rubber latex (NRL) reached epidemic proportions during the nineties and led to intense preventive efforts. The aim of this review was to provide a comprehensive compilation of the current status of occupational NRL allergy. RECENT FINDINGS: Recent advances led to the characterization of 15 NRL allergens and the development of assays for measuring the allergen content of NRL materials and specific IgE antibodies against NRL allergen components. Preventive measures aimed at reducing workplace exposure to NRL allergens were associated with decreasing incidence rates of NRL allergy. However, a pooled analysis of epidemiological surveys published during the last 10 years provided prevalence estimates of NRL sensitization and allergy similar to those derived from studies conducted before 2003. Substantial progress has been made in the understanding and prevention of NRL allergy, although the disease may still remain a worldwide cause of concern</style></abstract><notes><style face="normal" font="Arial">DA - 20170302IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Belgium -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0682-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28251426">PM:28251426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170302, Vandenplas O</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0682-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rowe,R.K.</style></author><author><style face="normal" font="Arial"> Gill,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390-9063, USA</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Allergic Sensitization on Antiviral Immunity: Allergen, Virus, and Host Cell Mechanisms</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="9">9-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Multiple clinical and epidemiological studies demonstrate links between allergic sensitization and virus-induced atopic disease exacerbations. This review summarizes the recent findings regarding allergen, viral, and host cellular mechanisms relevant to these observations. RECENT FINDINGS: Recent studies have focused on the molecular pathways and genetic influences involved in allergen-mediated inhibition of innate antiviral immune responses. Multiple tissue and cell types from atopic individuals across the atopy spectrum exhibit deficient interferon responses to a variety of virus infections. Impairment in barrier function, viral RNA and DNA recognition by intracellular sensing molecules, and dysregulation of signaling components are broadly affected by allergic sensitization. Finally, genetic predisposition by numerous nucleotide polymorphisms also impacts immune pathways and potentially contributes to virus-associated atopic disease pathogenesis. Allergen-virus interactions in the setting of atopy involve complex tissue and cellular mechanisms. Future studies defining the pathways underlying these interactions could uncover potential therapeutic targets. Available data suggest that therapies tailored to restore specific components of antiviral responses will likely lead to improved clinical outcomes in allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0677-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28233152">PM:28233152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Rowe RK</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0677-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anderson,H.M.</style></author><author><style face="normal" font="Arial"> Jackson,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA</style></auth-address><titles><title><style face="normal" font="Arial">Microbes, allergic sensitization, and the natural history of asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="122" start="116">116-122</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthma progression</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> natural history of asthma</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Understanding factors that lead to asthma development in early life is essential to developing strategies aimed at primary or secondary prevention. RECENT FINDINGS: This article will review current evidence addressing the development of early life allergic sensitization in relation to microbes and the gut and airway microbiome. Wheezing illnesses, particularly viral, remain a significant risk factor for asthma inception; however, bacterial pathogens have recently emerged as an additional important contributor to asthma risk, either alone or as cofactors with viral infections. The combined influence and interaction of early life viral wheezing and aeroallergen sensitization is important, with allergic sensitization preceding the onset of viral wheeze. Lastly, we review recent data from longitudinal studies regarding the development of irreversible airway obstruction and its impact on the natural history of asthma. SUMMARY: The development of asthma remains complex and incompletely understood. There is interplay between genetic predisposition and environmental exposures, including allergens and microbes. Interventions aimed at these risk factors during the preschool years may prevent the longitudinal course of asthma progression to irreversible airway obstruction</style></abstract><notes><style face="normal" font="Arial">DA - 20161228IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000338</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030377">PM:28030377</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-116-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-116-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161228, Anderson HM</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000338</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harber,P.</style></author><author><style face="normal" font="Arial"> Leroy,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aEnvironment and Policy Department, Mel and Enid Zuckerman College of Public Health, International Collaborative Occupational Medicine Program bDepartment of Management Information Systems, Eller College of Management, University of Arizona, Tucson, Arizona, USA</style></auth-address><titles><title><style face="normal" font="Arial">Social media use for occupational lung disease</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="77" start="72">72-77</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Data quality</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Information Dissemination</style></keyword><keyword><style face="normal" font="Arial"> Information Systems</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Social media have great impact on all aspects of life throughout the world. The utilization of social media for occupational lung disease, however, has been much more limited. This article summarizes recent literature concerning social media for occupational lung disease and identifies areas for additional use. RECENT FINDINGS: Social media are used in six relevant areas: information dissemination, peer-to-peer communication, survey research data collection, participatory research and exposome data acquisition, assessing public concerns, and knowledge generation. There are very clear advantages for information dissemination from experts to workers and on a peer-to-peer basis, although variable credibility and accuracy concerns persist. For research, social media have been used for acquiring data posted for nonresearch purposes and for efficiently collecting information specifically for research. The benefits of efficiency, democracy, and very large data sources may counterbalance concerns about inadequate specification of recruitment strategies and limited control over data quality. SUMMARY: The potential benefits of using social media for lung health-workplace interactions are much greater than the very limited current utilization</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000345</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28141625">PM:28141625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-72-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-72-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Harber P</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000345</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tarlo,S.M.</style></author><author><style face="normal" font="Arial"> Maestrelli,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aRespiratory Division, Toronto Western Hospital, University Health Network, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada bDepartment of Cardiologic, Thoracic and Vascular Sciences, University of Padova, Padova, Italy</style></auth-address><titles><title><style face="normal" font="Arial">A wide scope of new developments in occupational allergy and clinical immunology</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="63" start="61">61-63</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170131IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000354</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28141629">PM:28141629</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-61-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-61-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170131, Tarlo SM</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000354</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Walsh,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunity, Infection and Inflammation Programme, School of Medicine, Medical Sciences and Nutrition Institute of Medical Sciences University of Aberdeen, Foresterhill, Aberdeen, UK</style></auth-address><titles><title><style face="normal" font="Arial">Biologics for asthma and allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Otolaryngol Head Neck Surg</style></full-title></periodical><pages end="234" start="231">231-234</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Difficult-to-treat</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The development of monoclonal antibody-based biologics targeted at inhibition of the Th2 cytokines interleukin-4, interleukin-5 and interleukin-13 represent potentially effective treatments for asthma and allergic diseases. This short review is based on English-language original articles in PubMed or MedLine that reported significant clinical findings on the evidence demonstrating the effectiveness or otherwise of the targeting of interleukin-4, interleukin-5 or interleukin-13 in asthma or allergic disease. RECENT FINDINGS: Asthma exhibits marked heterogeneity both clinically and at the molecular phenotypic level requiring specifically targeted treatments to block the key pathways of the disease. It is becoming apparent that significant clinical effects with anticytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. Biologics aimed at interleukin-4/13, interleukin-5 or immunoglobulin E are potentially effective treatments for patients with difficult to treat allergic disease. The development of reproducible and straightforward discriminatory biomarkers may aid identification of those patients most likely to benefit from treatment with these expensive interventions. SUMMARY: Overall these biologics-based therapies are effective treatments for difficult to treat asthma and allergic disease with a safety profile comparable with placebo in the majority of published studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1531-6998 (Electronic)IS - 1068-9508 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOO.0000000000000352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234780">PM:28234780</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Otolaryngol Head Neck Surg\20170224-WalshGM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Otolaryngol Head Neck Surg\20170224-WalshGM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Walsh GM</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOO.0000000000000352</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Depince-Berger,A.E.</style></author><author><style face="normal" font="Arial"> Sidi-Yahya,K.</style></author><author><style face="normal" font="Arial"> Jeraiby,M.</style></author><author><style face="normal" font="Arial"> Lambert,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology laboratory/University Hospital Saint-Etienne, FRE-CNRS 3312, 42055, Saint-Etienne Cedex 2, France</style></auth-address><titles><title><style face="normal" font="Arial">Basophil activation test: Implementation and standardization between systems and between instruments</style></title><secondary-title><style face="normal" font="Arial">Cytometry A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cytometry A</style></full-title></periodical><pages end="269" start="261">261-269</pages><volume><style face="normal" font="Arial">91</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="Arial">The basophil activation test (BAT) is a good ex vivo alternative for measuring hypersensitivity to an allergen in sensitized patients but still lacks standardization. In this present study, we have implemented one of the systems and proposed inter-systems, inter-instrument standardization. Our method for basophil activation and labeling on whole blood: EDTA in one step using BasoflowEx(R) and FlowCast(R) . Setup on Navios and fluorescence targets converted to set up FACSCanto instrument. Our results: 1) A CD203c/CD63 (BasoflowEx) method was adapted for EDTA samples and simplified. 2) Final washing and concentration and use of time parameter help acquiring as many basophils as possible, spare acquisition time and noise. 3) The modified method was validated according to ISO15189 with a precision at 5.1% RCV, linearity between 1 and 1/8 of anti-IgE stimulation. Results were very close with CCR3/CD63 system (FlowCast). 4) Standardization, between systems and even between instruments. Mean Fluorescence Intensity targets are proposed using standard beads (Cytocal(R) ) middle peak: FITC = 19.4; PE = 28.8 on Navios(R) corresponding to FITC = 4,966; PE = 7,373 for FACSCanto. Data analyzed on common software (Kaluza(R) ) were very closely correlated. 5) Co-labeling of B cells (CD20+) gives the possibility to monitor a significant drop of basophils under stimulation that could explain some underestimation in case of strong hypersensitivity. In conclusion, BAT would strongly benefit from easy implementation [EDTA, one step stimulation/labeling, wash, full sample analysis over time parameter, B cell relative basophil count] and standardization of instrument settings on MFI targets whatever system or instrument is used. (c) 2017 International Society for Advancement of Cytometry</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1552-4930 (Electronic)IS - 1552-4922 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1002/cyto.a.23078</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28281330">PM:28281330</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytometry A\20170310-DepinceBergerAE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytometry A\20170310-DepinceBergerAE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Depince-Berger AE</style></custom2><misc3><style face="normal" font="Arial">10.1002/cyto.a.23078</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lang,C.</style></author><author><style face="normal" font="Arial"> Kaya,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology and Venereology, University Hospital of Geneva, Geneva, SwitzerlandDivision of Dermatology and Venereology, University Hospital of Geneva, Geneva, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">A Case of Adrenergic Urticaria Associated with Vitiligo</style></title><secondary-title><style face="normal" font="Arial">Dermatopathology (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Dermatopathology (Basel)</style></abbr-1></periodical><pages end="86" start="83">83-86</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Norepinephrine</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vitiligo</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Adrenergic urticaria is a rare form of urticaria, induced by a stress-induced concomitant release of epinephrine and norepinephrine. Here we describe the case of a 60-year-old female patient presenting with disseminated erythematous papules surrounded by a white halo and vitiligo lesions on the hands, arms, and feet. Histological examination of one of the erythematous papules showed a dermal inflammatory infiltrate composed of lymphocytes and eosinophils of perivascular and interstitial localization. After 2 weeks of treatment with antihistamines, the lesions disappeared completely</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 2296-3529 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1159/000452302</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28232908">PM:28232908</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dermatopathology (Basel)\2016-3-83-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dermatopathology (Basel)\2016-3-83-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Lang C</style></custom2><misc3><style face="normal" font="Arial">10.1159/000452302</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singal,M.</style></author><author><style face="normal" font="Arial"> Kouides,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Rochester General Hospital,Rochester, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease</style></title><secondary-title><style face="normal" font="Arial">Drugs Today (Barc)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs Today (Barc)</style></full-title></periodical><pages end="664" start="653">653-664</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Factor Viii</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Thrombosis</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">von Willebrand disease (VWD) is caused by quantitative or qualitative defects in von Willebrand factor (VWF). The mainstay of therapy is desmopressin, which is, however, not useful in certain forms of VWD notwithstanding adverse events. For these patients, plasma-derived factor VIII (pdFVIII)/VWF concentrates have been available for close to three decades but have a theoretical risk of disease transmission, hypersensitivity/allergic reactions, inhibitors and thrombosis. A recombinant VWF (vonicog alfa, Vonvendi; manufactured by Baxalta, now part of Shire) was approved by the U.S. Food and Drug Administration (FDA) in December 2015. This review will survey the literature based on a MEDLINE review on the safety, efficacy and pharmacokinetics of Vonvendi. It will also summarize the ongoing studies on Vonvendi available in the public domain. Vonvendi may have an important role in the management of VWD. However, more studies are needed, especially in special populations such as surgical patients, patients with major gastrointestinal bleeding from arteriovenous malformations and pregnant women and children, who are most likely to benefit from it</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1699-3993 (Print)IS - 1699-3993 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1358/dot.2016.52.12.2570978</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28276537">PM:28276537</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs Today (Barc)\2016-52-653-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs Today (Barc)\2016-52-653-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Singal M</style></custom2><misc3><style face="normal" font="Arial">10.1358/dot.2016.52.12.2570978</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Riario-Sforza,G.G.</style></author><author><style face="normal" font="Arial"> Ridolo,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future</style></title><secondary-title><style face="normal" font="Arial">EBioMedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EBioMedicine</style></full-title></periodical><pages end="17" start="16">16-17</pages><volume><style face="normal" font="Arial">17</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ASST</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170305IS - 2352-3964 (Electronic)IS - 2352-3964 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ebiom.2017.02.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259589">PM:28259589</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EBioMedicine\20170305-IncorvaiaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EBioMedicine\20170305-IncorvaiaC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170305, Incorvaia C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ebiom.2017.02.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heutte,N.</style></author><author><style face="normal" font="Arial"> Andre,V.</style></author><author><style face="normal" font="Arial"> Dubos,Arvis C.</style></author><author><style face="normal" font="Arial"> Bouchart,V.</style></author><author><style face="normal" font="Arial"> Lemarie,F.</style></author><author><style face="normal" font="Arial"> Legendre,P.</style></author><author><style face="normal" font="Arial"> Votier,E.</style></author><author><style face="normal" font="Arial"> Louis,M.Y.</style></author><author><style face="normal" font="Arial"> Madelaine,S.</style></author><author><style face="normal" font="Arial"> Seguin,V.</style></author><author><style face="normal" font="Arial"> Gente,S.</style></author><author><style face="normal" font="Arial"> Verite,P.</style></author><author><style face="normal" font="Arial"> Garon,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CETAPS EA 3832, Normandie Universite, UNIROUEN, 76821, Mont Saint Aignan cedex, France</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of multi-contaminant exposure in a cancer treatment center: a 2-year monitoring of molds, mycotoxins, endotoxins, and glucans in bioaerosols</style></title><secondary-title><style face="normal" font="Arial">Environ Monit Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Monit Assess</style></full-title></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="Arial">189</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Microbiology</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution,Indoor</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus niger</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus versicolor</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosol</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosols</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Glucans</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor air quality</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Mycoflora</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxins</style></keyword><keyword><style face="normal" font="Arial"> Neoplasms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Indoor air quality in health care facilities is a major public health concern, particularly for immunocompromised patients who may be exposed to microbiological contaminants such as molds, mycotoxins, endotoxins, and (1,3)-ss-D-glucans. Over 2 years, bioaerosols were collected on a monthly basis in a cancer treatment center (Centre F. Baclesse, Normandy, France), characterized from areas where there was no any particular air treatment. Results showed the complexity of mycoflora in bioaerosols with more than 100 fungal species identified. A list of major strains in hospital environments could be put forward due to the frequency, the concentration level, and/or the capacity to produce mycotoxins in vitro: Aspergillus fumigatus, Aspergillus melleus, Aspergillus niger, Aspergillus versicolor, Cladosporium herbarum, Purpureocillium lilacinum, and Penicillium brevicompactum. The mean levels of viable airborne fungal particles were less than 30.530 CFU per m3 of air and were correlated to the total number of 0.30 to 20 mum particles. Seasonal variations were observed with fungal particle peaks during the summer and autumn. Statistical analysis showed that airborne fungal particle levels depended on the relative humidity level which could be a useful indicator of fungal contamination. Finally, the exposure to airborne mycotoxins was very low (only 3 positive samples), and no mutagenic activity was found in bioaerosols. Nevertheless, some fungal strains such as Aspergillus versicolor or Penicillium brevicompactum showed toxigenic potential in vitro</style></abstract><notes><style face="normal" font="Arial">DA - 20161224IS - 1573-2959 (Electronic)IS - 0167-6369 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Endotoxins)RN - 0 (Glucans)RN - 0 (Mycotoxins)SB - IMCO - France -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s10661-016-5751-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28012082">PM:28012082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161224, Heutte N</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s10661-016-5751-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carinanos,P.</style></author><author><style face="normal" font="Arial"> Casares-Porcel,M.</style></author><author><style face="normal" font="Arial"> Diaz de la Guardia,C.</style></author><author><style face="normal" font="Arial"> Aira,M.J.</style></author><author><style face="normal" font="Arial"> Belmonte,J.</style></author><author><style face="normal" font="Arial"> Boi,M.</style></author><author><style face="normal" font="Arial"> Elvira-Rendueles,B.</style></author><author><style face="normal" font="Arial"> De Linares,C.</style></author><author><style face="normal" font="Arial"> Fernandez-Rodriguez,S.</style></author><author><style face="normal" font="Arial"> Maya-Manzano,J.M.</style></author><author><style face="normal" font="Arial"> Perez-Badia,R.</style></author><author><style face="normal" font="Arial"> Rodriguez-de la Cruz,D.</style></author><author><style face="normal" font="Arial"> Rodriguez-Rajo,F.J.</style></author><author><style face="normal" font="Arial"> Rojo-Ubeda,J.</style></author><author><style face="normal" font="Arial"> Romero-Zarco,C.</style></author><author><style face="normal" font="Arial"> Sanchez-Reyes,E.</style></author><author><style face="normal" font="Arial"> Sanchez-Sanchez,J.</style></author><author><style face="normal" font="Arial"> Tormo-Molina,R.</style></author><author><style face="normal" font="Arial"> Vega Maray,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Botany, University of Granada, Spain; Andalusian Institute for Earth System Research, IISTA-CEAMA, Granada, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Assessing allergenicity in urban parks: A nature-based solution to reduce the impact on public health</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="227" start="219">219-227</pages><volume><style face="normal" font="Arial">155</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Ecosystem</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="Arial">Urban parks play a key role in the provision of ecosystem services, actively participating in improving the quality of life and welfare of local residents. This paper reports on the application of an index designed to quantify the allergenicity of urban parks in a number of Spanish cities. The index, which records biological and biometric parameters for the tree species growing there, classifies parks in terms of the risk they pose for allergy sufferers, graded as null, low, moderate or high. In this initial phase, the index was applied to 26 green areas in 24 Spanish cities; green areas varied in type (urban park, historical or modern garden, boulevard, square or urban forest), size 1-100 ha), geographical location, species richness, number of trees and tree density (number of trees / ha.). The data obtained were used to calculate the percentage of allergenic species in each park, which varied between 17-67%; density ranged from 100 to 300 trees/ha. The index values recorded ranged from a minimum of .07 to a maximum of .87; a significant correlation was found between index value and both number of trees and tree density. Taking an index value of .30 as the threshold considered sufficient to trigger allergy symptoms in the sensitive population, 12 of the parks studied may be regarded as unhealthy at any time of the year. Corrective measures to mitigate the impact of pollen emissions include the implementation of nature-based solutions at various levels: planning and design, handling and management, and strengthening of urban green-infrastructure elements. The index proved to be a useful tool for environmental analysis, and complies with the principles of portability and scalability central to current and horizon scientific research</style></abstract><notes><style face="normal" font="Arial">DA - 20170223IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2017.02.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28231549">PM:28231549</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-155-219-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-155-219-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Carinanos P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2017.02.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alves Marcelino,J.L.</style></author><author><style face="normal" font="Arial"> Cardoso de Aguiar,R.</style></author><author><style face="normal" font="Arial"> Cabral Duarte,F.</style></author><author><style face="normal" font="Arial"> Celia Costa,A.</style></author><author><style face="normal" font="Arial"> Pereira-Barbosa,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte E.P.E., Av. Professor Egas Moniz, 1649 035, Lisbon, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">Pediatric eosinophilic esophagitis in Portugal</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="74" start="66">66-74</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysphagia</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food and aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Summary: Eosinophilic esophagitis (EoE) is an increasingly frequent diagnosis in our clinical practice, mainly in pediatric age. Allergic responses to food and aeroallergens have been increasingly implicated in the etiology of this disease. We describe a retrospective data analysis of pediatric EoE patients followed in our Immunoallergology Department. Of the 25 children (22 male, average 10.8 years), 88% had prior history of rhinoconjunctivitis, 76% asthma, 48% eczema and 36% food allergy. After evaluation, we identified in 76% and 92% of patients food and aeroallergen sensitization, respectively; 68% had simultaneously food and inhalant sensitization and 96% had at least one positive test to aeroallergens or food allergens. The first (44%) and the most frequent (56%) symptom was dysphagia. The time between symptoms onset and the EoE diagnosis averaged 18.6 +/- 29.4 months. A multidisciplinary approach is needed for a correct evaluation, intervention and follow-up of these patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294586">PM:28294586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-66-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-66-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Alves Marcelino JL</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author><author><style face="normal" font="Arial"> Comite,P.</style></author><author><style face="normal" font="Arial"> Ferrero,F.</style></author><author><style face="normal" font="Arial"> Montaruli,R.</style></author><author><style face="normal" font="Arial"> Mussap,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Internal Medicine Department, IRCCS-AOU San Martino - IST, Largo R. Benzi 10, 16132 Genoa, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Prescriptive appropriateness using inhalant and food allergen panels: a comparison between General Practitioners' and Allergists' prescription in Genoa (Italy)</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="83" start="80">80-83</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy workup</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> Genoa</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Summary: Background. Prescriptive appropriateness is an actual claim in healthcare, and it also concerns in vitro tests used in the allergy work-up, such as the serum allergen-specific IgE (sIgE) assay. In the Liguria Region, two panels were defined (for inhaled and food allergens) including 12 allergens. Their composition changed over time. Objectives. The aims of the present retrospective study were: i) to evaluate the percentage of positive tests, and ii) to compare the findings of sIgE assay on the basis of the general practictioners' (GPs) or specialist' prescription, considering both the old panels and the new panels. Methods. This retrospective study considered a population of adult patients, which consisted of 2368 subjects (68% females; mean age 50 years; age range: 10-103 years). Serum sIgE were measured by ImmunoCap system. Results. The percentages of positive tests were very low for food allergens and low for inhaled ones (ranging between 5% to 35%). There was change of prevalent prescriptor with new panels. Conclusions. This study underlines the relevance of prescriptive appropriateness in the allergy work-up. The sIgE assay should be limited to those allergens that have a clinical relevance, based on clinical history</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294588">PM:28294588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-80-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-80-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liccardi,G.</style></author><author><style face="normal" font="Arial"> Calzetta,L.</style></author><author><style face="normal" font="Arial"> Salzillo,A.</style></author><author><style face="normal" font="Arial"> Billeri,L.</style></author><author><style face="normal" font="Arial"> Luca,G.</style></author><author><style face="normal" font="Arial"> Rogliani,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Haematology and Oncology, Division of Pulmonology and Allergology, High Speciality "A. Cardarelli" Hospital, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="96" start="92">92-96</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> lipocalin</style></keyword><keyword><style face="normal" font="Arial"> Lipocalins</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Summary: It has been shown that allergen immunotherapy (AIT) is effective in reducing symptoms of allergic asthma and rhinitis. Data on the efficacy are less convincing with regard to AIT for allergens of common pets (cats/dogs). We describe a case of dog allergy in which we explored if dog AIT (DAI) could reduce a concomitant allergic sensitization to other allergens of furry animals. Our case demonstrates the efficacy of sublingual DAI on SPTs, symptom score, and spirometric responses despite persistent exposure to dog allergens at home in a patient sensitized, but not exposed, to several other furry animals. Moreover, this is the first report suggesting that DAI is able to reduce SPTs responses not only to dog, but also to other furry animals such as rabbit, horse, mouse, rat, hamster, cow. We recommend an accurate anamnesis and diagnosis of dog allergy before prescribing DAI. In particular, the use of ImmunoCAP ISAC is essential to verify the presence of IgE to lipocalins / albumins belonging to other furry animals. Obviously further studies carried out by using different DAI schedules, allergen amount and time of re-evaluation, laboratory procedure should be performed to confirm our findings</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294591">PM:28294591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-92-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-92-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Liccardi G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iemoli,E.</style></author><author><style face="normal" font="Arial"> Niero,F.</style></author><author><style face="normal" font="Arial"> Borgonovo,L.</style></author><author><style face="normal" font="Arial"> Cossu,M.V.</style></author><author><style face="normal" font="Arial"> Piconi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology and 1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Successful Omalizumab treatment in HIV positive patient with chronic spontaneous urticaria: a case report</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="91" start="88">88-91</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hiv</style></keyword><keyword><style face="normal" font="Arial"> HIV infection</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> Viral Load</style></keyword><keyword><style face="normal" font="Arial"> Viremia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Summary: We described a case of a 56 year old homosexual HIV positive man who presented a history of CSU since one year (2012). All the allergologic, immunologic and microbiologic tests to evaluate the pathogenesis of wheals resulted negative. Therefore in June 2015 we decided to start therapy with Omalizumab while the patient kept on effective antiretroviral therapy with 310 cells/mm3 TCD4 counts and undetectable HIV viremia. After two monthly subcutaneuous injection of 150 mg of Omalizumab the patient had no more urticarial symptoms. UAS7 (Urticaria Activity Score over 7 days) and Cu-Q2oL (chronic urticarial quality of life questionnaire) dropped respectively to 14 from 42 and to 0 from 40 with increase of TCD4 counts while viral load remained undetectable. In November 2015, i.e. 4 months after the end of Omalizumab therapy, the patient was still asymptomatic with persistent effective immune-virological response to antiretroviral therapy. This case report confirms the excellent tolerability and efficacy of anti-IgE therapy in the treatment of spontaneous chronic urticarial even in an immunodepressed patient for HIV infection. Omalizumab therapy shows a remarkable clinical success and had no effect on peripheral TCD4 counts and HIV viral load</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294590">PM:28294590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-88-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-88-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Iemoli E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ventura,M.T.</style></author><author><style face="normal" font="Arial"> Rodriguez-Perez,R.</style></author><author><style face="normal" font="Arial"> Caballero,M.L.</style></author><author><style face="normal" font="Arial"> Garcia-Alonso,M.</style></author><author><style face="normal" font="Arial"> Antonicelli,L.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Interdisciplinary Department of Medicine (DIM), University of Bari Medical School, Policlinico, Bari, Italy</style></auth-address><titles><title><style face="normal" font="Arial">IgE, IgG1 and IgG4 response to specific allergens in sensitized subjects showing different clinical reactivity to Anisakis simplex</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="58" start="52">52-58</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ani s 1</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Summary: Background. Anisakis simplex hypersensitive subjects may be sensitized without clinical allergy, or experience acute symptoms or chronic urticaria induced by raw fish. We studied whether the 3 subgroups differ in IgE, IgG1 or IgG4 reactivity to specific Anisakis simplex allergens. Methods. 28 Anisakis simplex-hypersensitive adults, 11 with acute symptoms, 9 with chronic urticaria, and 8 sensitized were studied. IgE, IgG1 and IgG4 to rAni s 1, 5, 9 and 10 were sought by ELISA. IgE and IgG4 to nAni s 4 were determined by WB. Results. IgE to Ani s 1, 4, 5, 9, and 10 were found in 8, 3, 2, 5, and 9 sera, respectively. Nine sera did not react to any allergen. IgG1 to Ani s 1, 5, 9, and 10 were detected in 5, 16, 14, and 4 sera, respectively. Four sera did not react to any of the 4 allergens. IgG4 to Ani s 1, 4, 5, 9, and 10 were detected in 10, 0, 2, 6 and 1 sera, respectively. Fifteen subjects did not react to any of the 5 allergens. On ELISA sensitized subjects showed lower IgE and IgG1 levels than patients. IgG4 levels were highest in the sensitized group. The prevalence of IgE, IgG1 or IgG4 reactivity to any of the studied allergens did not differ between the 3 subgroups. Conclusion. The clinical expression of Anisakis simplex sensitization does not seem to depend on IgE reactivity to a specific allergen of the parasite, nor on the presence of IgG antibodies possibly related with blocking activity</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294584">PM:28294584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-52-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-52-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Ventura MT</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Penel,V.</style></author><author><style face="normal" font="Arial"> Calleja,M.</style></author><author><style face="normal" font="Arial"> Pichot,C.</style></author><author><style face="normal" font="Arial"> Charpin,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratoire du Microenvironnement et des Pollens, Valence, France</style></auth-address><titles><title><style face="normal" font="Arial">Static and elevated pollen traps do not provide an accurate assessment of personal pollen exposure</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="65" start="59">59-65</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen trap</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Summary: Background. Volumetric pollen traps are commonly used to assess pollen exposure. These traps are well suited for estimating the regional mean airborne pollen concentration but are likely not to provide an accurate index of personal exposure. In this study, we tested the hypothesis that hair sampling may provide different pollen counts from those from pollen traps, especially when the pollen exposure is diverse. Methods. We compared pollen counts in hair washes to counts provided by stationary volumetric and gravimetric pollen traps in 2 different settings: urban with volunteers living in short distance from one another and from the static trap and suburban in which volunteers live in a scattered environment, quite far from the static trap. Results. Pollen counts in hair washes are in full agreement with trap counts for uniform pollen exposure. In contrast, for diverse pollen exposure, .individual pollen counts in hair washes vary strongly in quantity and taxa composition between individuals and dates. These results demonstrate that the pollen counts method (hair washes vs. stationary pollen traps) may lead to different absolute and relative contributions of taxa to the total pollen count. Conclusions. In a geographic area with a high diversity of environmental exposure to pollen, static pollen traps, in contrast to hair washes, do not provide a reliable estimate of this higher diversity</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294585">PM:28294585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-59-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-59-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Penel V</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yenigun,A.</style></author><author><style face="normal" font="Arial"> Elbay,A.</style></author><author><style face="normal" font="Arial"> Dogan,R.</style></author><author><style face="normal" font="Arial"> Ozturan,O.</style></author><author><style face="normal" font="Arial"> Ozdemir,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bezmialem Vakif University, Faculty of Medicine, Department of Otorhinolaryngology, Adnan Menderes Boulevard, Vatan Street, Fatih, 34093, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">The effect of allergic rhinitis with positive skin prick test on choroidal thickness</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="2481" start="2477">2477-2481</pages><volume><style face="normal" font="Arial">274</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dilation</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Pupil</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis is an inflammatory disease that develops through immunoglobulin E in the rhino-ocular mucosa due to allergy. The main symptoms are runny nose, nasal congestion, sneezing and itchy nose. This study was designed to investigate the effect of allergic rhinitis on choroidal thickness. This study was planned as a case-control study. This study performed in a tertiary referral center. The study included 61 patients with allergic rhinitis and 35 healthy subjects. Patients in both groups underwent skin prick test. In allergic rhinitis patients and healthy persons; subfoveal, temporal and nasal choroidal thickness measurement was performed. The choroidal thicknesses were measured without pupil dilation using the Spectralis Optical Coherence Tomography. In the subfoveal and temporal region, choroidal tissue was followed up significantly thicker in allergic rhinitis patients statistically compared to healthy persons (p = 0.031, p = 0.049). However, no significant difference was followed up between the nasal choroidal thickness measurements statistically (p = 0.54). Runny nose (67.2%), sneeze (65.5%), stuffiness (62.2%), itching of the nose (40.9%), and nasal discharge (21.3%) complaints were observed significantly higher in the group having allergic rhinitis. The effect of allergic rhinitis on choroidal thickness were assessed and compared with the control group. Our study revealed that there was significant association between increased choroidal thickness and allergic rhinitis. Allergic sensitivity may play an important role in increased choroidal thickness</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s00405-017-4513-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28265747">PM:28265747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170307-YenigunA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170307-YenigunA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Yenigun A</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s00405-017-4513-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pradere,P.</style></author><author><style face="normal" font="Arial"> Michot,J.M.</style></author><author><style face="normal" font="Arial"> Champiat,S.</style></author><author><style face="normal" font="Arial"> Danlos,F.X.</style></author><author><style face="normal" font="Arial"> Marabelle,A.</style></author><author><style face="normal" font="Arial"> Lambotte,O.</style></author><author><style face="normal" font="Arial"> Albiges,L.</style></author><author><style face="normal" font="Arial"> Le Pavec,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Thoracic Department, Marie Lannelongue Surgical Center, Le Plessis Robinson, 92350, France</style></auth-address><titles><title><style face="normal" font="Arial">Allergic broncho-pulmonary aspergillosis following treatment with an anti-program death 1 monoclonal antibody therapy</style></title><secondary-title><style face="normal" font="Arial">Eur J Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Cancer</style></full-title></periodical><pages end="309" start="308">308-309</pages><volume><style face="normal" font="Arial">75</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170304IS - 1879-0852 (Electronic)IS - 0959-8049 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejca.2016.12.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259013">PM:28259013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Cancer\2017-75-308-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Cancer\2017-75-308-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Pradere P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejca.2016.12.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kato,T.</style></author><author><style face="normal" font="Arial"> Iwasaki,H.</style></author><author><style face="normal" font="Arial"> Kobayashi,H.</style></author><author><style face="normal" font="Arial"> Miyagawa,N.</style></author><author><style face="normal" font="Arial"> Matsuo,A.</style></author><author><style face="normal" font="Arial"> Hata,T.</style></author><author><style face="normal" font="Arial"> Matsushita,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="8" start="1">1-8</pages><volume><style face="normal" font="Arial">801</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenosine</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic drug</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> spleen tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">Mast cells stimulated by immunoglobulin E (IgE)-crosslinking secrete mediators, which are mainly categorized into three groups: granule contents, arachidonate metabolites, and cytokines. These mediators play important roles in pathogenesis of allergic diseases; indeed, some conventional drugs which target the mediators are used in clinical practices. However, these drugs are not yet sufficient enough in their efficacy. That is because most of them are blockers of single mediators and are unable to prevent simultaneously various reactions caused by the three group mediators. Spleen tyrosine kinase (Syk) is a non-receptor protein tyrosine kinase. In mast cells, Syk locates at almost top of the signal cascades induced by IgE-crosslinking and plays pivotal roles in secretion of the three groups of mediators. Therefore, inhibition of Syk would suppress the secretion of all the mediators from mast cells and be a promising-treatment strategy for allergic diseases. In the present study, we characterized pharmacological profiles of JTE-852, which was identified as a novel Syk inhibitor. JTE-852 inhibited kinase activity of Syk in an adenosine 5'-triphosphate (ATP)-competitive fashion. JTE-852 also blocked the secretion of granule contents, arachidonate metabolites, and cytokines from mast cells stimulated by IgE-crosslinking, with similar potencies. The results suggest that JTE-852 is supposed to prevent various allergic reactions caused by the three group mediators in vivo. In fact, oral gavage of JTE-852 attenuated an allergic reaction mediated by histamine, which is a representative of the three groups of mediators. JTE-852 is expected to be a novel, highly-efficacious, and orally available anti-allergic drug</style></abstract><notes><style face="normal" font="Arial">DA - 20170305IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.02.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259713">PM:28259713</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20170305-KatoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20170305-KatoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170305, Kato T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.02.048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gandhi,N.</style></author><author><style face="normal" font="Arial"> Pirozzi,G.</style></author><author><style face="normal" font="Arial"> Graham,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Regeneron Pharmaceuticals , Tarrytown , New York , 10591 , USA</style></auth-address><titles><title><style face="normal" font="Arial">Commonality of the IL-4/IL-13 Pathway in Atopic Diseases</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="437" start="425">425-437</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Allergy results from an aberrant Type 2 inflammatory response, triggered by a wide range of environmental antigens (allergens) that lead to various immune responses, culminating in the production of immunoglobulin E (IgE). Two key cytokines, interleukin (IL)-4 and IL-13, are critical to the induction and perpetuation of the Type 2 response, and have been implicated in multiple atopic diseases. Area covered: This review summarizes recent milestone developments that have elucidated components of the pathogenesis of atopic diseases such as atopic dermatitis (AD), asthma, and chronic sinusitis with nasal polyposis (CSwNP). Expert commentary: Several therapeutic agents that selectively target potentiators of the Type 2 pathway have shown efficacy in one or more of these atopic diseases, but few agents have proven to be broadly applicable across all three atopic diseases. Dupilumab, a human monoclonal antibody that simultaneously inhibits signaling of IL-4 and IL-13, has demonstrated significant clinical efficacy in AD, asthma, and CSwNP. The fact that these diseases often occur as co-morbidities and respond to the same therapy suggests that there is a common underlying pathogenic pathway, and that IL-4 and IL-13 cytokines are central to regulating the pathogenesis of these atopic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1298443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28277826">PM:28277826</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-425-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-425-37.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Gandhi N</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1298443</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Basu,A.</style></author><author><style face="normal" font="Arial"> Dalal,A.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Forshag,M.</style></author><author><style face="normal" font="Arial"> Yancey,S.W.</style></author><author><style face="normal" font="Arial"> Nagar,S.</style></author><author><style face="normal" font="Arial"> Bell,C.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Pharmaceutical Outcomes Research and Policy Program , University of Washington , Seattle , Washington , USA</style></auth-address><titles><title><style face="normal" font="Arial">Economic analysis of the Phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Pharmacoecon Outcomes Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Expert Rev Pharmacoecon Outcomes Res</style></abbr-1></periodical><pages end="131" start="121">121-131</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cost Savings</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Design</style></keyword><keyword><style face="normal" font="Arial"> Resource utilization</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo). RESEARCH DESIGN AND METHODS: A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization. RESULTS: Mean medical costs of asthma-related exacerbations at 8 months were $969, $852, and $1692 in the mepolizumab 75 mg intravenous (IV), mepolizumab 100 mg subcutaneous (SC), and placebo groups, respectively (p = 0.16). Mean medical costs from emergency department visits or hospitalizations due to asthma-related exacerbations were $901, $795, and $1557 in the mepolizumab 75 mg IV, mepolizumab 100 mg SC, and placebo groups (p = 0.020). Asthma-related healthcare resource utilization (all services) was lower for the mepolizumab groups versus placebo. CONCLUSIONS: Adding mepolizumab to standard-of-care treatment for severe eosinophilic asthma lowered asthma exacerbation-related medical costs/healthcare resource utilization; although the cost savings ranged from $723-$840 per patient, differences were not statistically significant</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1744-8379 (Electronic)IS - 1473-7167 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/14737167.2017.1298444</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28277854">PM:28277854</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170309, Basu A</style></custom2><misc3><style face="normal" font="Arial">10.1080/14737167.2017.1298444</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,Z.</style></author><author><style face="normal" font="Arial"> Lian,J.</style></author><author><style face="normal" font="Arial"> Zhao,R.</style></author><author><style face="normal" font="Arial"> Li,K.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Yang,A.</style></author><author><style face="normal" font="Arial"> Tong,P.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China</style></auth-address><titles><title><style face="normal" font="Arial">Ara h 2 cross-linking catalyzed by MTGase decreases its allergenicity</style></title><secondary-title><style face="normal" font="Arial">Food Funct</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Funct</style></full-title></periodical><pages end="1203" start="1195">1195-1203</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Dithiothreitol</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> SGF</style></keyword><keyword><style face="normal" font="Arial"> simulated gastric fluid</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">Peanuts, whose major allergen is Ara h 2, are included among the eight major food allergens. After reduction using dithiothreitol (DTT), cross-linking of Ara h 2 could be catalyzed by microbial transglutaminase (MTGase), a widely used enzyme in the food industry. In this study, Ara h 2 cross-linking was catalyzed by MTGase after it was reduced by DTT. Using mass spectrometry and PLINK software, five cross-linkers were identified, and five linear allergen epitopes were found to be involved in the reactions. The IgE binding capacity of cross-linked Ara h 2 was found to be significantly lower compared to that of native and reduced Ara h 2. After simulated gastric fluid (SGF) digestion, the digested products of the cross-linked Ara h 2, again, had a significantly lower IgE binding capacity compared to untreated and reduced Ara h 2. Furthermore, reduced and cross-linked Ara h 2 (RC-Ara h 2) induced lower sensitization in mice, indicating its lower allergenicity. Reduction and MTGase-catalyzed cross-linking are effective methods to decrease the allergenicity of Ara h 2. The reactions involved linear allergen epitopes destroying the material basis of the allergenicity, and this might develop a new direction for protein desensitization processes</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 2042-650X (Electronic)IS - 2042-6496 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1039/c6fo01365a</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28224143">PM:28224143</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Funct\20170222-WuZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Funct\20170222-WuZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Wu Z</style></custom2><misc3><style face="normal" font="Arial">10.1039/c6fo01365a</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83498</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,C.E.</style></author><author><style face="normal" font="Arial"> Yang,J.T.</style></author><author><style face="normal" font="Arial"> Fan,G.J.</style></author><author><style face="normal" font="Arial"> Li,T.T.</style></author><author><style face="normal" font="Arial"> Tang,Z.X.</style></author><author><style face="normal" font="Arial"> Cao,F.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic identification for ginkgo kernel protein in guinea pigs</style></title><secondary-title><style face="normal" font="Arial">Food Sci Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Sci Biotechnol</style></full-title></periodical><pages end="919" start="915">915-919</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous allergy</style></keyword><keyword><style face="normal" font="Arial"> Ginkgo biloba</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Intestines</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="Arial">2092-6456</style></isbn><abstract><style face="normal" font="Arial">Ginkgo biloba L. can cause allergic reactions when consumed. In this paper, an allergy test to guinea pig was investigated. Guinea pigs were sensitized with 50 mg/mL of ginkgo kernel protein orally on days 1, 3, and 5, and intraperitoneally challenged with 100mg/mL of the protein on day 7 after the last sensitization. The volume of sensitization and challenge was 0.20mL/100 g weight. The results showed the average allergy grade for guinea pigs reached four and the allergy rate was 100%. The immunoglobulin G and E levels in sera were significantly higher than those in the controls. Footpads swelled distinctly, and the passive cutaneous allergy test manifested a positive response. There were inflammatory changes in the lungs and intestines. In conclusion, the present results may indicate that gingko kernel protein has an allergenic capacity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10068-016-0150-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10068-016-0150-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Sci Biotechnol\2016-25-915-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Sci Biotechnol\2016-25-915-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Wu CE</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10068-016-0150-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Konstantinovas,C.</style></author><author><style face="normal" font="Arial"> de Oliveira Mendes,T.A.</style></author><author><style face="normal" font="Arial"> Vannier-Santos,M.A.</style></author><author><style face="normal" font="Arial"> Lima-Santos,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Ciencias Biologicas, Universidade Estadual de Santa Cruz Ilheus, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Modulation of Human Immune Response by Fungal Biocontrol Agents</style></title><secondary-title><style face="normal" font="Arial">Front Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Microbiol</style></full-title></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biocontrol agent</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cyclosporin A</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxins</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Although the vast majority of biological control agents is generally regarded as safe for humans and environment, the increased exposure of agriculture workers, and consumer population to fungal substances may affect the immune system. Those compounds may be associated with both intense stimulation, resulting in IgE-mediated allergy and immune downmodulation induced by molecules such as cyclosporin A and mycotoxins. This review discusses the potential effects of biocontrol fungal components on human immune responses, possibly associated to infectious, inflammatory diseases, and defective defenses</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1664-302X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.3389/fmicb.2017.00039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28217107">PM:28217107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Microbiol\2017-8-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Microbiol\2017-8-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Konstantinovas C</style></custom2><misc3><style face="normal" font="Arial">10.3389/fmicb.2017.00039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fritzsching,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Pulmonology and Allergy, Children's Doctor Service, Heidelberg, Germany; Heidelberg University Hospital, Heidelberg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Personalized Medicine in Allergic Asthma: At the Crossroads of Allergen Immunotherapy and "Biologicals"</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy therapy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Major allergic disease can be viewed as clinical syndromes rather than discrete disease entities. Emerging evidence indicates that allergic asthma includes several disease phenotypes. Immunological deviation toward high T helper cell type 2 cytokine levels has been demonstrated for a subgroup of pediatric asthma patients, and now, several novel monoclonal antibodies have been approved for treatment of this subgroup as a stratified approach of "personalized" medicine in allergy. Introduction of component-based IgE testing before allergen immunotherapy (AIT), i.e., testing for IgE cross-reactivity before initiation of AIT, has also brought stratified medicine into allergy therapy. Improved responder criteria, which identify treatment-responders previous to therapy, might foster this stratification and even individualized AIT might have an impact for tailor-made therapy in the future. Furthermore, combining antibody-based treatment with AIT could help to establish more rapid AIT protocols even for allergens with a high risk of anaphylactic reactions. Efforts to advance such "personalized" medicine in pediatric allergy might be challenged by several issues including high costs for the health-care system, increasing complexity of allergy therapy, the need for physician allergy expertise, and furthermore ethical considerations and data safety issues</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261576">PM:28261576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Fritzsching B</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cantani,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Atopic Dermatitis and Allergen Hypersensitivity: State of the Art</style></title><secondary-title><style face="normal" font="Arial">Glob J Immunol Allerg Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Glob J Immunol Allerg Dis</style></full-title></periodical><pages end="7" start="1">1-7</pages><volume><style face="normal" font="Arial">4</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy to goat's milk</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Goat's milk</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vertebrates</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Abstract: The current growing enthusiasm for atopic dermatitis (AD) is clearly reflected in the range of current attitudes on the subject. What are considered to be its protean manifestations are frequent challenges to the paediatrician and other specialists working with children. AD may occur not only in man, but also in other vertebrates. However, it must be assumed that AD has always been an affection of our species. Hippocrates (460-370 BC) reported urticaria and gastrointestinal upset following cow's milk (CM) ingestion. Lucretius (98-55 BC) wrote that one man's meat is another man's poison. Galen (131- 219) described allergy to goat's milk. At the turn of this century the first description of acute shock due to CM allergy (CMA) and fatal CMA were published. In his pioneer studies of food allergy (FA), Schloss was the first to evaluate skin tests for the diagnosis of FA. Since then, a vast array of symptoms and disorders have been attributed to FA, many of which occur with other conditions. In addition to this, the lack of a single, practical diagnostic test has contributed to the polarization of the scientific controversy between those who believe in and those who deny FA existence. Terminology has also been confusing. A correct use of definitions is necessary for a proper epidemiologic evaluation of the conditions and an accurate diagnostic and therapeutic approach. While this concept was fundamentally correct, it was also too easily weakened by ignoring this prerequisite to be fully acceptable, and this led to an equally disordered use of the term hypersensitivity, since allergy had become a word used to embrace all possible forms of adverse reactions. AD is associated with patchy, characteristically distributed areas of cutaneous eczema, with intense itching and subsequent lichenification of the skin. Cutaneous automic dysfunction (increased vasoconstriction) and xerosis (dryness of the skin) commonly occur in the affected children. In addition, profound immunological dysregulation with various immune alterations has been described in affected children. Most children produce IgE antibodies to a number of food and inhalants allergens, at the point that a minuscule offending quantity can trigger a reaction by skin contact or by inhalation.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.20941/2310-6980.2016.04.1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.20941/2310-6980.2016.04.1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Glob J Immunol Allerg Dis\20170226-CantaniA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Glob J Immunol Allerg Dis\20170226-CantaniA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170226, Cantani A</style></custom2><misc3><style face="normal" font="Arial">10.20941/2310-6980.2016.04.1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83502</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wong,K.V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Oats for You</style></title><secondary-title><style face="normal" font="Arial">Glob J Immunol Allerg Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Glob J Immunol Allerg Dis</style></full-title></periodical><pages end="11" start="8">8-11</pages><volume><style face="normal" font="Arial">4</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> boil</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health benefit</style></keyword><keyword><style face="normal" font="Arial"> Health benefits</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Microwave</style></keyword><keyword><style face="normal" font="Arial"> oat</style></keyword><keyword><style face="normal" font="Arial"> Oats</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">With respect to baby food and other foods, there is a current scare about the arsenic in rice. The objective of the current work is to suggest oats as a possible substitute for rice. Oats could be a viable substitute because it thrives on land, which is typically poor, which is not as fertile as the river valleys ideal for rice. In addition, the preparation of instant oats takes three minutes or so in a microwave oven, compared to five to seven times the length required to boil white rice, and maybe three more times as long again for brown rice. In this day and age of dual working couples, it is a boon to have easy recipes which take minimal time to prepare, and yet nutritious and free of preservatives. The health benefits of oats have also been the focus in the literature review.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.20941/2310-6980.2016.04.2</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.20941/2310-6980.2016.04.2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Glob J Immunol Allerg Dis\2016-4-1-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Glob J Immunol Allerg Dis\2016-4-1-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170225, Wong KV</style></custom2><misc3><style face="normal" font="Arial">10.20941/2310-6980.2016.04.2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,J.</style></author><author><style face="normal" font="Arial"> Su,H.</style></author><author><style face="normal" font="Arial"> Li,Q.</style></author><author><style face="normal" font="Arial"> Wu,H.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author><author><style face="normal" font="Arial"> Huang,J.</style></author><author><style face="normal" font="Arial"> Zeng,M.</style></author><author><style face="normal" font="Arial"> Zheng,Y.</style></author><author><style face="normal" font="Arial"> Sun,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Xijing Hospital, the Fourth Military Medical University, Xi'an, 710032 China</style></auth-address><titles><title><style face="normal" font="Arial">Oral administration of Clostridium butyricum CGMCC0313-1 inhibits beta-lactoglobulin-induced intestinal anaphylaxis in a mouse model of food allergy</style></title><secondary-title><style face="normal" font="Arial">Gut Pathog</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Gut Pathog</style></abbr-1></periodical><pages end="" start="11">11-</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Probiotic bacteria can induce immune regulation or immune tolerance in patients with allergic diseases, but the underlying mechanisms are still unclear. There has been a growing interest in the use of beneficial bacteria for allergic diseases recently. This study aimed at exploring whether Clostridium butyricum CGMCC0313-1 (C. butyricum) can reduce beta-lactoglobulin(BLG)-induced intestinal anaphylaxis in a murine model of food allergy. METHODS: The preventive and therapeutic effects of oral C. butyricum on anaphylactic symptoms induced via BLG in food allergy mice were investigated. Intestinal anaphylaxis, T helper (Th)-specific cytokines and transcription factors, secretory IgA (sIgA), CD4+ CD25+ Foxp3Treg cell and histopathological alterations were examined. RESULTS: Clostridium butyricum significantly ameliorated intestinal anaphylaxis symptoms in the food allergy mice. sIgA and CD4+ CD25+ Foxp3Treg cell were increased by oral C. butyricum. It also reversed the imbalance of Th1/Th2 andTh17/Treg. CONCLUSIONS: Clostridium butyricum reduces BLG-induced intestinal anaphylaxis in mice and might be an additional or supplementary therapy for food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170302IS - 1757-4749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13099-017-0160-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28250847">PM:28250847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Gut Pathog\2017-9-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Gut Pathog\2017-9-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170302, Zhang J</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13099-017-0160-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Angjeli,E.</style></author><author><style face="normal" font="Arial"> Gomes,P.</style></author><author><style face="normal" font="Arial"> Lane,K.J.</style></author><author><style face="normal" font="Arial"> Stein,L.</style></author><author><style face="normal" font="Arial"> Abelson,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ora, Inc. Andover Massachusetts USA</style></auth-address><titles><title><style face="normal" font="Arial">Technical and clinical validation of the Allergen BioCube(R) for timothy grass</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="84" start="78">78-84</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> Nasal inflammation</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="Arial"> Peak Expiratory Flow Rate</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Field studies for allergic rhinitis (AR) commonly have inconsistent allergen concentrations and subject exposure patterns due to varying environmental conditions and subject behaviors. A technical and clinical validation study was conducted for the Allergen BioCube(R) using timothy grass to confirm uniform allergen concentration and clinically relevant subject symptom responses. METHODS: Allergen concentrations were verified by laser particle counts. Subjects (N = 14) with positive skin test reactions and no symptoms at screening received four 3-h timothy grass exposures in the BioCube over consecutive days. Subjects evaluated nasal itching, sneezing, rhinorrhea, and nasal congestion while in the BioCube; Total Nasal Symptom Score (TNSS) was computed. Peak Nasal Inspiratory Flow (PNIF), Peak Expiratory Flow Rate (PEFR), sIgE blood tests, and Nasal Inflammation Score (NIS) were assessed. A correlation analysis was conducted for mean sIgE, skin test, and TNSS. RESULTS: Uniform timothy grass concentrations were achieved in the BioCube, both spatially and temporally, at all subject positions. Mean TNSS increased substantially from pre-exposure levels (0.36 +/- 0.74 to 1.86 +/- 2.14) to maximums of 7.07 +/- 2.76 at 1.5 h and 6.71 +/- 2.70 at 3 h BioCube exposure. Twelve (86%) subjects had TNSS increases >/=6 units. PNIF decreased 12-24% from baseline at 3-h BioCube exposure. NIS increased (baseline = 0) to 3.7 (maximum score = 4). A low/moderate correlation (r = 0.485) occurred between mean sIgE blood levels and mean skin tests; neither sIgE or skin tests correlated with mean TNSS. However, subjects with high skin test scores or positive blood IgE tended to also have higher TNSS. CONCLUSIONS: The Allergen BioCube achieved technical and clinical validation for uniform timothy grass concentration and clinically meaningful AR sign and symptom responses. The Allergen BioCube can be used to assess the efficacy of therapies for reduction of AR signs and symptoms resulting from grass exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20170302IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.143</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28250927">PM:28250927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\2017-5-78-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\2017-5-78-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170302, Angjeli E</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.143</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mukai,K.</style></author><author><style face="normal" font="Arial"> Karasuyama,H.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author><author><style face="normal" font="Arial"> Kubo,M.</style></author><author><style face="normal" font="Arial"> Galli,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Stanford University School of Medicine, Stanford, California, USA</style></auth-address><titles><title><style face="normal" font="Arial">Differences in the importance of mast cells, basophils, IgE and IgG, versus CD4+ T cells and ILC2 cells, in primary and secondary immunity to Strongyloides venezuelensis</style></title><secondary-title><style face="normal" font="Arial">Infect Immun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Infect Immun</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> c-kit</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> effector mechanisms</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Interleukin 3</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-3</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">There is evidence that mast cells, basophils and IgE can contribute to immune responses to parasites, however, the relative importance of these effector elements in parasite immunity is not fully understood. Previous work in Il3-deficient and c-kit mutant KitW/W-v mice indicated that interleukin-3 and c-Kit contribute to expulsion of the intestinal nematode Strongyloides venezuelensis (S.v.) during primary infection. Our findings in mast cell-deficient KitW-sh/W-sh mice and two types of mast cell-deficient mice that have normal c-kit: "Hello Kitty" and MasTRECK mice, confirmed prior work in KitW/W-v mice suggesting that mast cells play an important role in S.v. egg clearance in primary infections. We also assessed a possible contribution of basophils in immune responses to S.v By immunohistochemistry, we found that numbers of basophils and mast cells, were markedly increased in the jejunal mucosa during primary infections with S.v Studies in basophil-deficient Mcpt8DTR mice revealed a small but significant contribution of basophils to S.v. egg clearance in primary infections. Studies in mice deficient in various components of immune responses showed that CD4+ T cells and ILC2 cells, IgG, FcRgamma, and to a lesser extent, IgE and FcRI, contribute to effective immunity in primary S.v infections. These findings support the conclusion that the hierarchy of importance of immune effector mechanisms in primary S.v. infection is: CD4+ T cells/ILC2 cells, IgG and FcRgamma>mast cells>IgE and FcRI>basophils. By contrast, in secondary S.v infection, our evidence indicates that CD4+ T cells are critical but mast cells, antibodies, and basophils have little or no non-redundant roles</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1098-5522 (Electronic)IS - 0019-9567 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Japan -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1128/IAI.00053-17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28264908">PM:28264908</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Infect Immun\20170307-MukaiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Infect Immun\20170307-MukaiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Mukai K</style></custom2><misc3><style face="normal" font="Arial">10.1128/IAI.00053-17</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feng,Y.</style></author><author><style face="normal" font="Arial"> Chen,X.M.</style></author><author><style face="normal" font="Arial"> Zhao,M.</style></author><author><style face="normal" font="Arial"> He,Z.</style></author><author><style face="normal" font="Arial"> Sun,L.</style></author><author><style face="normal" font="Arial"> Wang,C.Y.</style></author><author><style face="normal" font="Arial"> Ding,W.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Institute of Resource Insects, Chinese Academy of Forestry, Kunming, 650233, China</style></auth-address><titles><title><style face="normal" font="Arial">Edible Insects in China: Utilization and Prospects</style></title><secondary-title><style face="normal" font="Arial">Insect Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Insect Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animal Feed</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Chitin</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Edible insects</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Entomophagy</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Ethnic Groups</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Forestry</style></keyword><keyword><style face="normal" font="Arial"> Habitat</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human food</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Livestock</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Minerals</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Requirements</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">The use of edible insects has a long history in China, where they have been consumed for more than two thousand years. In general, the level of acceptance is high for the consumption of insects in China. Many studies on edible insects have been conducted in the last twenty years, and the scope of the research includes the culture of entomophagy and the identification, nutritional value, farming and breeding of edible insects, in addition to food production and safety. Currently, 324 species of insects from 11 orders are documented that are either edible or associated with entomophagy in China, which include the common edible species, some less commonly consumed species, and some medicinal insects. However, only approximately 10 to 20 types of insects are consumed regularly. The nutritional values for 174 species are available in China, including edible, feed and medicinal species. Although the nutritional values vary among species, all the insects examined contain protein, fat, vitamins and minerals at levels that meet human nutritional requirements. Edible insects were, and continue to be, consumed by different ethnic groups in many parts of China. People directly consume insects or food products made from insects. The processing of products from insect protein powder, oil, and chitin and the development of health care foods has been studied in China. People also consume insects indirectly by eating livestock that were fed insects, which may be a more acceptable pathway to use insects in human diets. Although limited, the data on the food safety of insects indicate that insects are safe for food or feed. Incidences of allergic reactions after consuming silkworm pupae, cicades and crickets have been reported in China. Insect farming is a unique breeding industry in rural China and is a source of income for local people. Insects are reared and bred for human food, medicine and animal feed using two approaches in China: the insects are either fully domesticated and reared completely in captivity or are partially raised in captivity, and the insect habitat is manipulated to increase production. Depending on the type of relationship the insect has with humans, plants, and the environment, different farming strategies are used. The social and scientific communities must work together to promote the use of insects as food and feed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1744-7917 (Electronic)IS - 1672-9609 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/1744-7917.12449</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28225201">PM:28225201</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Insect Sci\20170222-FengY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Insect Sci\20170222-FengY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Feng Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/1744-7917.12449</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomes Camara Camacho,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Life Sciences, Madeira University, Funchal, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Inhalant Allergens in Portugal</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="88" start="67">67-88</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic testing</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="Arial">This review aims to present in a simple manner the work performed in Portugal regarding the identification of the most prevalent aeroallergens in the country and the sensitization levels in Portuguese patients. Much of the data was summarized in tables and illustrated on maps, enabling the community of clinicians, researchers, and patient organizations to access the knowledge about the research performed. This study provides an overview about the distribution of aeroallergens in Portugal, signaling regions and critical periods of exposure of the sensitized population. The illustrated data can help the community of allergy specialists to view the temporal and spatial distribution of aeroallergens across the country. In addition, this information can guide clinicians to select the most appropriate allergens for allergy diagnostic testing, treatment, and allergen avoidance</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1159/000458150</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28226321">PM:28226321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-67-88.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-67-88.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Gomes Camara Camacho I</style></custom2><misc3><style face="normal" font="Arial">10.1159/000458150</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Babaie,D.</style></author><author><style face="normal" font="Arial"> Mesdaghi,M.</style></author><author><style face="normal" font="Arial"> Nishino,M.</style></author><author><style face="normal" font="Arial"> Mansouri,M.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Mofid Children's Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Oral and Sublingual Immunotherapy: Potential Causes for Eosinophilic Gastrointestinal Disorders?</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="98" start="89">89-98</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental exposure</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic colitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastritis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disorders</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> food immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Gastritis</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="Arial">Food allergy is a common health problem worldwide, with increasing prevalence during recent decades. The only approved treatments for food allergy are food avoidance and administration of emergency medications in case of accidental exposure, which negatively affects patients' quality of life, so new treatments are highly desirable. Different food immunotherapy modalities have recently been used, with variable success rates in the induction of desensitization and tolerance, and different numbers and types of adverse reactions. Adverse reactions, especially intolerable gastrointestinal symptoms, are the most important causes of immunotherapy withdrawal. Eosinophilic esophagitis has been reported as a complication of milk, egg, and peanut oral immunotherapies and sublingual immunotherapy for respiratory allergies, but not for food allergies. Eosinophilic gastritis and eosinophilic colitis also rarely happened following egg and milk oral immunotherapies. The patients undergoing oral and sublingual immunotherapies should be closely followed up for a long time, and those with gastrointestinal symptoms should be evaluated by endoscopy of the gastrointestinal tract. These complications are usually reversible after early diagnosis and stopping the immunotherapy protocol</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1159/000457796</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28226319">PM:28226319</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-89-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-89-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Babaie D</style></custom2><misc3><style face="normal" font="Arial">10.1159/000457796</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blockhuys,M.</style></author><author><style face="normal" font="Arial"> Faber,M.A.</style></author><author><style face="normal" font="Arial"> Sabato,V.</style></author><author><style face="normal" font="Arial"> Hubens,G.</style></author><author><style face="normal" font="Arial"> Ebo,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Abdominal Surgery, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Bariatric Surgery: A Novel Risk Factor for Food Allergy?</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="66" start="64">64-66</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bariatric surgery</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="Arial">In this case report, we describe a birch pollen-allergic patient in whom a Fobi pouch gastric bypass was associated with the transition from a mild, localized, birch pollen-related oral allergy syndrome to more severe, generalized allergic reactions to peach</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1159/000455123</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28226314">PM:28226314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-64-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-64-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222. Blockhuys M</style></custom2><misc3><style face="normal" font="Arial">10.1159/000455123</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Takahashi,K.</style></author><author><style face="normal" font="Arial"> Nagakura,K.I.</style></author><author><style face="normal" font="Arial"> Ogura,K.</style></author><author><style face="normal" font="Arial"> Asaumi,T.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Reactions of Buckwheat-Hypersensitive Patients during Oral Food Challenge Are Rare, but Often Anaphylactic</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="122" start="116">116-122</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Buckwheat (BW) is a common cause of life-threatening allergy in Asia. Few have examined oral food challenges (OFCs) using BW. We here describe the OFC outcomes for the diagnosis or confirmation of tolerance acquisition and clarify risk factors for positive OFCs. METHODS: Between July 2005 and March 2014, we retrospectively reviewed data from children who underwent OFCs using 3,072 mg of BW protein at Sagamihara National Hospital. Children were suspected of having BW allergy because of positive results for BW-specific IgE or because they had been previously diagnosed with BW allergy owing to immediate reactions to BW. RESULTS: Of 476 such patients, we analyzed 419 aged 1-17 years (median age 6.7 years). Forty-four (10.5%) reacted to the BW OFC and 24 (54.5%) experienced anaphylaxis. Among patients with suspected BW allergies (n = 369), 30 (8.1%) reacted to OFC. However, among patients with definitive BW allergies (n = 50) who underwent OFCs a median of 7.0 years after their last immediate reaction, 14 (28.0%) reacted to OFC. Among 12 patients with past anaphylactic reactions to BW, 8 exhibited tolerance to BW. A history of immediate reaction to BW and high BW-specific IgE levels were significant risk factors for a positive OFC. CONCLUSIONS: BW allergies are rare among children suspected of having BW allergies due to positivity for BW-specific IgE. Most children with definitive BW allergies can tolerate BW, even after anaphylactic reactions. Nevertheless, careful observation is needed when performing BW OFCs, considering the high incidence of anaphylactic reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000456008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28268211">PM:28268211</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-116-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-116-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Yanagida N</style></custom2><misc3><style face="normal" font="Arial">10.1159/000456008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Price,D.</style></author><author><style face="normal" font="Arial"> Ackland,M.L.</style></author><author><style face="normal" font="Arial"> Suphioglu,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Cellular and Molecular Biology (CCMB), School of Life and Environmental Sciences, Deakin University, Burwood, VIC, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Identifying Epithelial Endocytotic Mechanisms of the Peanut Allergens Ara h 1 and Ara h 2</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="115" start="106">106-115</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1 and Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 3</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Caco 2 cell</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endocytosis</style></keyword><keyword><style face="normal" font="Arial"> Endosomes</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intestinal epithelium</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lysosomes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanuts are still one of the highest contributors to anaphylactic deaths after ingestion of a food allergen. At the molecular level, interactions between peanut allergens and the intestinal epithelium are largely unexplored. Previous findings by our research group demonstrated that the major peanut allergens, i.e., Ara h 1, Ara h 2, Ara h 3, and Ara h 6, were able to cross the Caco-2 human cell culture model of the intestinal epithelium. This research broadened our investigation to identify the mechanisms by which the Caco-2 monolayers uptake peanut allergens, specifically by endocytosis. Here, we aim to increase our understanding of allergen-epithelial interactions and, more broadly, the pathway from allergen to allergy. METHODS: The human Caco-2 cell culture model was exposed to peanut extract and a combination of confocal microscopy and inhibition studies were used to identify the endocytotic mechanisms of peanut allergens in intestinal epithelia. RESULTS: Our findings demonstrate that the peanut allergens Ara h 1 and Ara h 2 are transported through intestinal epithelia initially via early endosomes using multiple endocytotic mechanisms. From there, they are then transported to late endosomes and ultimately to lysosomes. CONCLUSIONS: These novel findings provide insight into the allergen-epithelial interactions of peanut allergens with the intestinal epithelium. Consequently, this opens the possibility of the use of these endocytotic pathways as targets for inhibitors in therapeutic development and preventative measures for peanut allergy in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1159/000451085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28268214">PM:28268214</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-106-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-106-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Price D</style></custom2><misc3><style face="normal" font="Arial">10.1159/000451085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,C.</style></author><author><style face="normal" font="Arial"> He,X.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Zhou,C.</style></author><author><style face="normal" font="Arial"> Duan,Z.</style></author><author><style face="normal" font="Arial"> Lu,Q.</style></author><author><style face="normal" font="Arial"> Yan,X.</style></author><author><style face="normal" font="Arial"> Zhang,Z.</style></author><author><style face="normal" font="Arial"> Zheng,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Bioactive Peptides of Yunnan Province/Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences &amp; Yunnan Province, Kunming Institute of Zoology, Kunming 650223, Yunnan, China; University of Chinese Academy of Sciences, Beijing 100009, China</style></auth-address><titles><title><style face="normal" font="Arial">An inhibitor peptide of toll-like receptor 2 shows therapeutic potential for allergic conjunctivitis</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="15" start="9">9-15</pages><volume><style face="normal" font="Arial">46</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> bioactive peptides</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal enterotoxin B</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2-cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 2</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="2" Year="2017">2017/2/25</year></dates><abstract><style face="normal" font="Arial">Allergic conjunctivitis (AC) is an inflammatory disease of the conjunctiva, which is characterized by antigen challenge and toll-like receptor 2 (TLR2) activation. Here, a designed small peptide ZY12 was found to contain therapeutic potential in staphylococcal enterotoxin B (SEB)-induced AC model. ZY12 treatment showed the remission of clinical signs, plasma total IgE levels, number of mast cells and the proportion of degranulated mast cell in AC mice. Levels of Th2 cytokines (IL-4, IL-5, IL-13) in the lymph nodes or spleen were significantly decreased while those of Th1 cytokine (IFN-gamma) were increased in ZY12 treated group, suggesting a protective role of ZY12 in AC by mediating the balance of Th1/Th2 cytokines. Importantly, ZY12 significantly inhibited TLR2 expression in conjunctival tissue. Combined its therapeutic effects with TLR2 inhibitory function, ZY12 might be an ideal candidate for the development of new therapeutic agent for allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170301IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.02.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28246054">PM:28246054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-46-9-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-46-9-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170301, Xu C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.02.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,F.Q.</style></author><author><style face="normal" font="Arial"> Han,X.P.</style></author><author><style face="normal" font="Arial"> Zhang,F.</style></author><author><style face="normal" font="Arial"> Ma,X.</style></author><author><style face="normal" font="Arial"> Xiang,D.</style></author><author><style face="normal" font="Arial"> Yang,X.M.</style></author><author><style face="normal" font="Arial"> Ou-Yang,H.F.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Xijing Hospital of the Fourth Military Medical University, Xi'an, China</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic efficacy of a co-blockade of IL-13 and IL-25 on airway inflammation and remodeling in a mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="140" start="133">133-140</pages><volume><style face="normal" font="Arial">46</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-25 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="Arial">Repeated airway inflammation and unremitting remodeling provoke irreversible pulmonary dysfunction and resistance to current drugs in patients with chronic bronchial asthma. Interleukin (IL)-13 and IL-25 play an important role in airway inflammation and remodeling in asthma. We aimed to investigate whether co-inhibiting IL-13 and IL-25 can effectively down-regulate allergen-induced airway inflammation and remodeling in mice. Mice with asthma induced by chronic exposure to ovalbumin (OVA) were given soluble IL-13 receptor alpha2 (sIL-13R) or soluble IL-25 receptor (sIL-25R) protein alone and in combination to neutralize the bioactivity of IL-13 and IL-25, and relevant airway inflammation and remodeling experiments were performed. We found that the co-blockade of IL-13 and IL-25 with sIL-13R and sIL-25R was more effective than either agent alone at decreasing inflammatory cell infiltration, airway hyperresponsiveness (AhR) and airway remodeling including mucus production, extracellular collagen deposition, smooth muscle cell hyperplasia and angiogenesis in mice exposed to OVA. These results suggest that the combined inhibition of IL-13 and IL-25 may provide a novel therapeutic strategy for asthma, especially for patients who are resistant to current treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28282577">PM:28282577</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-46-133-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-46-133-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Zhang FQ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.03.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Celenk,S.</style></author><author><style face="normal" font="Arial"> Malyer,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Science and Art Faculty, Biology Department, Aerobiology Laboratory, Uludag University, 16059, Gorukle, Bursa, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">The occurrence of Ambrosia pollen in the atmosphere of Northwest Turkey: investigation of possible source regions</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Long-distance transport</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Ukraine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">Ambrosia pollen was first reported as an important allergen in North America at the end of the nineteenth century, and many European countries have recently reported its increasing significance for pollen allergy. The aims of this study were to determine whether the highly allergenic Ambrosia pollen recorded during the studied period could be the result of long-distance transport (LDT) and to identify the potential sources of Ambrosia pollen grains. The study investigates Ambrosia pollen episodes during the peak term of six yearly periods between 2010 and 2015 by examining source regions in Ambrosia pollen in Bursa, Turkey. A volumetric trap was used for collecting the pollen samples, and the back-trajectory model was used to identify a potential source of atmospheric Ambrosia pollen. The days when pollen levels exceeded 30 P m-3 were computed, and clusters were shown on the figures. The study indicates that the Ambrosia pollen grains recorded during the episode in Bursa were not produced by local sources but transported long distances from potential source regions around the Azov Sea in Russia and Ukraine, Black Sea region of Turkey, Romania, and Bulgaria. Note that atmospheric concentrations of Ambrosia pollen exceeded the clinical threshold during 28 days during the investigation period. Taking into consideration the high allergenicity of Ambrosia pollen, the present findings suggest that the number of ragweed-sensitized individuals might increase in the near future in the region</style></abstract><notes><style face="normal" font="Arial">DA - 20170228IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-017-1328-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28243727">PM:28243727</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\20170228-CelenkS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biometeorol\20170228-CelenkS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170228, Celenk S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-017-1328-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,Y.</style></author><author><style face="normal" font="Arial"> Liang,X.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Feng,W.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Zhang,F.</style></author><author><style face="normal" font="Arial"> Linhardt,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemical Engineering, Zhejiang Gongshang University, Hangzhou 310025, China</style></auth-address><titles><title><style face="normal" font="Arial">A comparative secretome analysis of industrial Aspergillus oryzae and its spontaneous mutant ZJGS-LZ-21</style></title><secondary-title><style face="normal" font="Arial">Int J Food Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Food Microbiol</style></full-title></periodical><pages end="9" start="1">1-9</pages><volume><style face="normal" font="Arial">248</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus oryzae</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Cellulose</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Differential protein</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy Proteins</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein</style></keyword><keyword><style face="normal" font="Arial"> Soybean Proteins</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="2" Year="2017">2017/2/8</year></dates><abstract><style face="normal" font="Arial">Aspergillus oryzae koji plays a crucial role in fermented food products due to the hydrolytic activities of secreted enzymes. In the present study, we performed a comparative secretome analysis of the industrial strain of Aspergillus oryzae 3.042 and its spontaneous mutantZJGS-LZ-21. One hundred and fifty two (152) differential protein spots were excised (p&lt;0.05), and 25 proteins were identified. Of the identified proteins, 91.3% belonged to hydrolytic enzymes acting on carbohydrates or proteins. Consistent with their enzyme activities, the expression of 14 proteins involved in the degradation of cellulose, hemicellulose, starch and proteins, increased in the ZJGS-LZ-21isolate. In particular, increased levels of acid protease (Pep) may favor the degradation of soy proteins in acidic environments and promote the cleavage of allergenic soybean proteins in fermentation, resulting in improvements of product safety and quality. The ZJGS-LZ-21 isolate showed higher protein secretion and increased hydrolytic activities than did strain 3.042, indicating its promising application in soybean paste fermentation</style></abstract><notes><style face="normal" font="Arial">DA - 20170226IS - 1879-3460 (Electronic)IS - 0168-1605 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237882">PM:28237882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Food Microbiol\2017-248-1-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Food Microbiol\2017-248-1-9.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Food Microbiol\2017-248-1-9.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Food Microbiol\2017-248-1-9.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170226, Zhu Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.02.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Domingo,C.</style></author><author><style face="normal" font="Arial"> Pomares,X.</style></author><author><style face="normal" font="Arial"> Navarro,A.</style></author><author><style face="normal" font="Arial"> Rudi,N.</style></author><author><style face="normal" font="Arial"> Sogo,A.</style></author><author><style face="normal" font="Arial"> Davila,I.</style></author><author><style face="normal" font="Arial"> Mirapeix,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary Service, Corporacio Sanitaria Parc Tauli, Parc Tauli, 1, 08208 Sabadell, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="521">521-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobuline E</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergens</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">Omalizumab is marketed for chronic severe asthma patients who are allergic to perennial allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were treated with Omalizumab according to the dosing table. For each patient with asthma due to seasonal allergens, we recruited the next two consecutive patients with asthma due to perennial allergens. The dose of oral methyl prednisolone was tapered at a rate of 2 mg every two weeks after the start of treatment with omalizumab depending on tolerance. At each monthly visit, a forced spirometry and fractional exhaled nitric oxide (FeNO) measurement were performed and the accumulated monthly methyl prednisolone dose was calculated. At entry, there were no differences between groups in terms of gender, body mass index or obesity, year exacerbation rate, monthly dose of methyl-prednisolone (MP), FeNO and blood immunoglobuline E (IgE) MP, FeNO and IgE values, or spirometry (perennial: FVC: 76%; FEV(1): 62%; seasonal: FVC: 79%; FEV(1): 70%). The follow-up lasted 76 weeks. One patient in each group was considered a non-responder. Spirometry did not worsen in either group. There was a significant intragroup reduction in annual exacerbation rate and methyl prednisolone consumption but no differences were detected in the intergroup comparison. Omalizumab offered the same clinical benefits in the two cohorts regardless of whether the asthma was caused by a seasonal or a perennial allergen. These results strongly suggest that allergens are the trigger in chronic asthma but that it is the persistent exposure to IgE that causes the chronicity</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18030521</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28264494">PM:28264494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-521.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-521.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Domingo C</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18030521</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tang,M.L.</style></author><author><style face="normal" font="Arial"> Mullins,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immune Disorders, Murdoch Children's Research Institute, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy: is prevalence increasing?</style></title><secondary-title><style face="normal" font="Arial">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Intern Med J</style></full-title></periodical><pages end="261" start="256">256-261</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">It is generally accepted that the prevalence of food allergy has been increasing in recent decades, particularly in westernised countries, yet high-quality evidence that is based on challenge confirmed diagnosis of food allergy to support this assumption is lacking because of the high cost and potential risks associated with conducting food challenges in large populations. Accepting this caveat, the use of surrogate markers for diagnosis of food allergy (such as nationwide data on hospital admissions for food anaphylaxis or clinical history in combination with allergen-specific IgE (sIgE) measurement in population-based cohorts) has provided consistent evidence for increasing prevalence of food allergy at least in western countries, such as the UK, United States and Australia. Recent reports that children of East Asian or African ethnicity who are raised in a western environment (Australia and United States respectively) have an increased risk of developing food allergy compared with resident Caucasian children suggest that food allergy might also increase across Asian and African countries as their economies grow and populations adopt a more westernised lifestyle. Given that many cases of food allergy persist, mathematical principles would predict a continued increase in food allergy prevalence in the short to medium term until such time as an effective treatment is identified to allow the rate of disease resolution to be equal to or greater than the rate of new cases</style></abstract><notes><style face="normal" font="Arial">DA - 20170305IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/imj.13362</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28260260">PM:28260260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med J\2017-47-256-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med J\2017-47-256-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170305, Tang ML</style></custom2><misc3><style face="normal" font="Arial">10.1111/imj.13362</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pajno,G.B.</style></author><author><style face="normal" font="Arial"> Bernardini,R.</style></author><author><style face="normal" font="Arial"> Peroni,D.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Martelli,A.</style></author><author><style face="normal" font="Arial"> Landi,M.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> La Grutta,S.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Indinnimeo,L.</style></author><author><style face="normal" font="Arial"> Caffarelli,C.</style></author><author><style face="normal" font="Arial"> Calamelli,E.</style></author><author><style face="normal" font="Arial"> Comberiati,P.</style></author><author><style face="normal" font="Arial"> Duse,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Allergy Unit, University of Messina, Via Consolare Valeria-Gazzi, Messina, 98124, Italy. g</style></auth-address><titles><title><style face="normal" font="Arial">Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report</style></title><secondary-title><style face="normal" font="Arial">Ital J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ital J Pediatr</style></full-title></periodical><pages end="" start="13">13-</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> disease-modifying effect</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (AIT) is currently recognized as a clinically effective treatment for allergic diseases, with a unique disease-modifying effect. AIT was introduced in clinical practice one century ago, and performed in the early years with allergenic extracts of poor quality and definition. After the mechanism of allergic reaction were recognized, the practice of AIT was refined, leading to remarkable improvement in the efficacy and safety profile of the treatment. Currently AIT is accepted and routinely prescribed worldwide for respiratory allergies and hymenoptera venom allergy. Both the subcutaneous (SCIT) and sublingual (SLIT) routes of administration are used in the pediatric population.AIT is recommended in allergic rhinitis/conjunctivitis with/without allergic asthma, with an evidence of specific IgE-sensitization towards clinically relevant inhalant allergens. Long-term studies provided evidence that AIT can also prevent the onset of asthma and of new sensitizations. The favorable response to AIT is strictly linked to adherence to treatment, that lasts 3-5 years. Therefore, several factors should be carefully evaluated before starting this intervention, including the severity of symptoms, pharmacotherapy requirements and children and caregivers' preference and compliance.In recent years, there have been increasing interest in the role of AIT for the treatment of IgE-associated food allergy and extrinsic atopic dermatitis. A growing body of evidence shows that oral immunotherapy represents a promising treatment option for IgE-associated food allergy. On the contrary, there are still controversies on the effectiveness of AIT for patients with atopic dermatitis.This consensus document was promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP) to provide evidence-based recommendations on AIT in order to implement and optimize current prescription practices of this treatment for allergic children</style></abstract><notes><style face="normal" font="Arial">DA - 20170304IS - 1824-7288 (Electronic)IS - 1720-8424 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13052-016-0315-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28257631">PM:28257631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Pediatr\2017-43-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Pediatr\2017-43-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Pajno GB</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13052-016-0315-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,G.</style></author><author><style face="normal" font="Arial"> Hu,M.</style></author><author><style face="normal" font="Arial"> Sun,L.C.</style></author><author><style face="normal" font="Arial"> Han,X.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Alcocer,M.</style></author><author><style face="normal" font="Arial"> Fei,D.</style></author><author><style face="normal" font="Arial"> Cao,M.J.</style></author><author><style face="normal" font="Arial"> Liu,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources, Jimei University , 43 Yindou Road, Xiamen 361021, Fujian, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Allergenicity and Oral Tolerance of Enzymatic Cross-Linked Tropomyosin Evaluated Using Cell and Mouse Models</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="2213" start="2205">2205-2213</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Endocytosis</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> Horseradish Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding activity</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">The enzymatic cross-linking of proteins to form high-molecular-weight compounds may alter their sensitization potential. The IgG-/IgE-binding activity, digestibility, allergenicity, and oral tolerance of cross-linked tropomyosin with tyrosinase (CTC) or horseradish peroxidase (CHP) were investigated. ELISA results demonstrated CTC or CHP reduced its IgE-binding activity by 34.5 +/- 1.8 and 63.5 +/- 0.6%, respectively. Compared with native tropomyosin or CTC, CHP was more easily digested into small fragments; CHP decreased the degranulation of RBL-2H3 cells and increased endocytosis by dendritic cells. CHP can induce oral tolerance and reduce allergenicity in mice by decreasing IgE and IgG1 levels in serum, the production of T-cell cytokines, and the percentage composition of dendritic cells. These findings demonstrate CHP has more potential of reducing the allergenicity than CTC via influencing the morphology of protein, changing the original method of antigen presentation, modulating the Th1/Th2 immunobalance, and inducing the oral tolerance of the allergen tropomyosin</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.6b05816</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234465">PM:28234465</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-2205-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-2205-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Liu G</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.6b05816</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feldweg,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy/Immunology, Brigham and Women's Hospital, Chestnut Hill, Mass.</style></auth-address><titles><title><style face="normal" font="Arial">Food-Dependent, Exercise-Induced Anaphylaxis: Diagnosis and Management in the Outpatient Setting</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="288" start="283">283-288</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chestnut</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Food-dependent, exercise-induced anaphylaxis is a disorder in which anaphylaxis develops most predictably during exercise, when exercise takes place within a few hours of ingesting a specific food. IgE to that food should be demonstrable. It is the combination of the food and exercise that precipitates attacks, whereas the food and exercise are each tolerated independently. Recently, it was demonstrated that exercise is not essential for the development of symptoms, and that if enough of the culprit food is ingested, often with additional augmentation factors, such as alcohol or acetylsalicylic acid, symptoms can be induced at rest in the challenge setting. Thus, food-dependent, exercise-induced anaphylaxis appears to be more correctly characterized as a food allergy syndrome in which symptoms develop only in the presence of various augmentation factors, with exercise being the primary one. However, additional factors are not usually present when the patient exercises normally, so ongoing investigation is needed into the physiologic and cellular changes that occur during exercise to facilitate food-induced anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283153">PM:28283153</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-283-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-283-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Feldweg AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heffler,E.</style></author><author><style face="normal" font="Arial"> Fichera,S.</style></author><author><style face="normal" font="Arial"> Nicolosi,G.</style></author><author><style face="normal" font="Arial"> Crimi,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Medicine and Allergology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="854" start="852">852-854</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Progesterone</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170304IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.01.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258855">PM:28258855</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170304-HefflerE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170304-HefflerE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Heffler E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.01.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy &amp; Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy: Unmet Needs and New Perspectives</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="295">295-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.01.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283155">PM:28283155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-295.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-295.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.01.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY.</style></auth-address><titles><title><style face="normal" font="Arial">Should Peanut Be Banned in Schools?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="294" start="290">290-294</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.01.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283154">PM:28283154</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-290-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-290-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.01.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santos,A.F.</style></author><author><style face="normal" font="Arial"> Brough,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma, Allergy and Lung Biology, Department of Paediatric Allergy, King's College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Making the Most of In Vitro Tests to Diagnose Food Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="248" start="237">237-248</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen peptides</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Various in vitro tests assess different aspects of the underlying immune mechanism of IgE-mediated food allergy. Some can be used for diagnostic purposes; specific IgE to allergen extracts is widely available; specific IgE to allergen components is used in most specialist centers, and the basophil activation test is becoming increasingly used clinically. IgE to allergen peptides, T-cell assays, allergen-specific/total IgE ratios, and allergen-specific IgG4/IgE ratios are currently reserved for research. Different factors can modulate the likelihood of IgE-mediated food allergy of a given allergy test result, namely, the patients' age, ethnicity, previous allergic reaction to the identified food, concomitant atopic conditions, and geographical location, and need to be taken into account when interpreting the allergy test results in the clinic. The importance of the specific food, the clinical resources available, and patient preferences are additional aspects that need to be considered when deciding whether an oral food challenge is required to reach an accurate diagnosis of IgE-mediated food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283150">PM:28283150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-237-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-237-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Santos AF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83525</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lockey,R.F.</style></author><author><style face="normal" font="Arial"> Teng,M.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Fla.</style></auth-address><titles><title><style face="normal" font="Arial">Human passive cutaneous anaphylaxis in the 21st century: Worth the risk?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1796" start="1795">1795-1796</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170305IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259447">PM:28259447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170305-LockeyRF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170305-LockeyRF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170305, Lockey RF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Macglashan,D.W.,Jr.</style></author><author><style face="normal" font="Arial"> Saini,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical Allergy and Immunology, Johns Hopkins University, Baltimore, Md.</style></auth-address><titles><title><style face="normal" font="Arial">Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1682" start="1680">1680-1682</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170305IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.965</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259446">PM:28259446</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170305-MacGlashanDWJr.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170305-MacGlashanDWJr.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170305, MacGlashan DW Jr</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.965</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gernez,Y.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, Kravis Children's Hospital, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy for Food Allergy: Are We There Yet?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="272" start="250">250-272</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen structure</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Current clinical research focuses on food allergen-specific immunotherapy through oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. Immunotherapy relies on the delivery of gradually increasing doses of specific allergens to induce desensitization (defined as temporary antigen hyporesponsiveness that depends on regular food ingestion) and, ultimately, tolerance (defined as the ability to ingest food without symptoms despite prolonged periods of avoidance or irregular intake). Although the majority of the patients treated with OIT achieve desensitization, only a minority achieves tolerance. OIT involves higher maintenance doses of food protein (300 mg-4g) compared with SLIT (2.5-7.5 mg) and EPIT (250-500 mcg). OIT efficacy is higher compared with SLIT, but OIT is associated with higher rate of systemic adverse events compared with SLIT and EPIT. OIT is also associated with a minor risk of eosinophilic esophagitis. Combined treatment of OIT and anti-IgE monoclonal antibody has improved safety but not efficacy compared with OIT alone. Early initiation of peanut OIT in peanut-allergic infants and young children may afford superior efficacy and safety. In this review, we discuss the allergen-specific strategies currently explored for the treatment of food allergy, including immunotherapy with native and heat-modified food proteins. Additional research employs strategies to improve the safety and efficacy of allergen immunotherapy through modifications of allergen structure and addition of immunomodulatory adjuvants</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283151">PM:28283151</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-250-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-250-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Gernez Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83528</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lieberman,P.L.</style></author><author><style face="normal" font="Arial"> Umetsu,D.T.</style></author><author><style face="normal" font="Arial"> Carrigan,G.J.</style></author><author><style face="normal" font="Arial"> Rahmaoui,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Internal Medicine and Pediatrics, Divisions of Allergy and Immunology, University of Tennessee College of Medicine, Memphis, Tenn.</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers To: Omalizumab anaphylaxis occurring outside the recommended observation times)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1719" start="1718">1718-1719</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="3" Year="2017">2017/3/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.976</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28268016">PM:28268016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170307-LiebermanPL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170307-LiebermanPL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Lieberman PL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.976</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Groetch,M.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Skypala,I.</style></author><author><style face="normal" font="Arial"> Vlieg-Boerstra,B.</style></author><author><style face="normal" font="Arial"> Grimshaw,K.</style></author><author><style face="normal" font="Arial"> Durban,R.</style></author><author><style face="normal" font="Arial"> Cassin,A.</style></author><author><style face="normal" font="Arial"> Henry,M.</style></author><author><style face="normal" font="Arial"> Kliewer,K.</style></author><author><style face="normal" font="Arial"> Kabbash,L.</style></author><author><style face="normal" font="Arial"> Atkins,D.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Holbreich,M.</style></author><author><style face="normal" font="Arial"> Chehade,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY.</style></auth-address><titles><title><style face="normal" font="Arial">Dietary Therapy and Nutrition Management of Eosinophilic Esophagitis: A Work Group Report of the American Academy of Allergy, Asthma, and Immunology</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="324" start="312">312-324</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary therapy</style></keyword><keyword><style face="normal" font="Arial"> Dietitian</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Nutrition Assessment</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Status</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is a chronic/immune-antigen-mediated disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Dietary elimination therapy has been shown to be an effective, drug-free prescription for the treatment of EoE. A range of different dietary elimination therapies have been used. Regardless of the elimination diet chosen, dietary therapy requires in-depth nutrition assessment and management. Elimination diets are not without risk and may impact nutritional status, eating pleasure, and overall quality of life. With adequate guidance, dietary therapy can be effective and nutritionally balanced, and the adverse impact on lifestyle can be minimized. This work group report addresses the potential challenges of implementing an elimination diet for the management of EoE and provides instructions and tools for physicians, dietitians, and other allied health professionals to help guide them in planning elimination diets for both children and adults</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283156">PM:28283156</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-312-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-312-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Groetch M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leonard,S.A.</style></author><author><style face="normal" font="Arial"> Chehade,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of California, San Diego, Rady Children's Hospital, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">Food Protein-Induced Enterocolitis Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="526" start="525">525-526</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">California</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.10.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283168">PM:28283168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-525-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-525-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Leonard SA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.10.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vazquez-Ortiz,M.</style></author><author><style face="normal" font="Arial"> Machinena,A.</style></author><author><style face="normal" font="Arial"> Dominguez,O.</style></author><author><style face="normal" font="Arial"> Alvaro,M.</style></author><author><style face="normal" font="Arial"> Calvo-Campoverde,K.</style></author><author><style face="normal" font="Arial"> Giner,M.T.</style></author><author><style face="normal" font="Arial"> Jimenez-Feijoo,R.</style></author><author><style face="normal" font="Arial"> Lozano,J.</style></author><author><style face="normal" font="Arial"> Piquer,M.</style></author><author><style face="normal" font="Arial"> Dias,M.</style></author><author><style face="normal" font="Arial"> Folque,M.D.</style></author><author><style face="normal" font="Arial"> Plaza,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome to fish and egg usually resolves by age 5 years in Spanish children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="515" start="512">512-515</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283165">PM:28283165</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-512-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-512-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Vazquez-Ortiz M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Altman,M.C.</style></author><author><style face="normal" font="Arial"> Lenington,J.</style></author><author><style face="normal" font="Arial"> Bronson,S.</style></author><author><style face="normal" font="Arial"> Ayars,A.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Washington Medical Center, Seattle, Wash</style></auth-address><titles><title><style face="normal" font="Arial">Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1139" start="1137">1137-1139</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.01.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28279664">PM:28279664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170310-AltmanMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170310-AltmanMC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Altman MC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.01.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Robbins,K.A.</style></author><author><style face="normal" font="Arial"> Uygungil,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Children's National Health System, Washington, DC.</style></auth-address><titles><title><style face="normal" font="Arial">Nutritional Deficiencies and Food Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="529" start="528">528-529</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutritional deficiency</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.01.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283169">PM:28283169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-528-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-528-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Robbins KA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.01.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Che,C.T.</style></author><author><style face="normal" font="Arial"> Douglas,L.</style></author><author><style face="normal" font="Arial"> Liem,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Case reports of peanut-fenugreek and cashew-sumac cross-reactivity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="511" start="510">510-511</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Saskatchewan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283164">PM:28283164</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-510-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-510-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Che CT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beigelman,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Mo.</style></auth-address><titles><title><style face="normal" font="Arial">To Eat or Not to Eat? Introduction of Food After Negative Oral Food Challenge</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="478" start="477">477-478</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283161">PM:28283161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-477-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-477-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Beigelman A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.09.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chan,J.C.</style></author><author><style face="normal" font="Arial"> Peters,R.L.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Gurrin,L.C.</style></author><author><style face="normal" font="Arial"> Wake,M.</style></author><author><style face="normal" font="Arial"> Tang,M.L.</style></author><author><style face="normal" font="Arial"> Prescott,S.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Murdoch Childrens Research Institute, Parkville, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Food Challenge and Community-Reported Reaction Profiles in Food-Allergic Children Aged 1 and 4 Years: A Population-Based Study</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="409" start="398">398-409</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental ingestion</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oral food challenge is the main tool for diagnosing food allergy, but there is little data on the reaction profiles of young children undergoing challenges, nor how these reactions compare to reactions on accidental ingestion in the community. OBJECTIVES: To compare reaction profiles from food challenges and parent-reported reactions on accidental ingestion, and assess predictors of severe reactions. METHODS: HealthNuts is a longitudinal population-based cohort study of 5276 1-year-old infants. Infants underwent skin prick tests and those with identifiable wheals were offered food challenges. Food challenges were repeated at age 4 years in those with previous food allergy or reporting new food allergies. Community-reported reactions were ascertained from parent questionnaires. RESULTS: Food challenges were undertaken in 916 children at age 1 year and 357 children at age 4 years (a total of 2047 peanut, egg, or sesame challenges). Urticaria was the most common sign in positive challenges at both ages (age 1 year, 88.7%, and age 4 years, 71.2%) although angioedema was significantly more common at age 4 years (40.1%) than at age 1 year (12.9%). Anaphylaxis was equally uncommon at both ages (2.1% and 2.8% of positive challenges at ages 1 and 4 years, respectively) but more common for peanut than for egg (4.5% and 1.2% of positive challenges at ages 1 and 4 years, respectively). The patterns of presenting signs reported during community reactions were similar to those observed in formal food challenges. Serum food-specific IgE levels of 15 kU/L or more were associated with moderate to severe reactions but skin prick test was not. CONCLUSIONS: There was a shift from the most common presenting reaction of urticaria during food challenges toward more angioedema in older children. Serum food-specific IgE levels were associated with reaction severity</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -CO - New Zealand -CO - Hong Kong -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283159">PM:28283159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-398-409.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-398-409.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Chan JC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chiriac,A.M.</style></author><author><style face="normal" font="Arial"> Bourrain,J.L.</style></author><author><style face="normal" font="Arial"> Lepicard,E.</style></author><author><style face="normal" font="Arial"> Molinari,N.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of sensitization and allergy to potato in a large population</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="509" start="507">507-509</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283163">PM:28283163</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-507-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-507-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Chiriac AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Karam,M.</style></author><author><style face="normal" font="Arial"> Scherzer,R.</style></author><author><style face="normal" font="Arial"> Ogbogu,P.U.</style></author><author><style face="normal" font="Arial"> Green,T.D.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, University of Michigan Medical School, Ann Arbor, Mich</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy prevalence, knowledge, and behavioral trends among college students - A 6-year comparison</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="506" start="504">504-506</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> college students</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Lebanon -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283162">PM:28283162</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-504-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-504-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Karam M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Aceves,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology, Children's Hospital of Colorado</style></auth-address><titles><title><style face="normal" font="Arial">The National Biome Initiative: An Allergy Perspective</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1134" start="1131">1131-1134</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170304IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28257973">PM:28257973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170304-FurutaGT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170304-FurutaGT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Furuta GT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Demoly,P.</style></author><author><style face="normal" font="Arial"> Maigret,P.</style></author><author><style face="normal" font="Arial"> EliasBillon,I.</style></author><author><style face="normal" font="Arial"> Allaert,F.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Head of department. Allergy Investigation, Department of Respiratory Medicine and Addiction Medicine, Arnaud de Villeneuve Hospital, Montpellier University Hospital, France</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Rhinitis Increases the Risk of Driving Accidents</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="616" start="614">614-616</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Accidents</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis, especially those involving severe nasal, ocular, pharyngeal and respiratory symptoms, have a strong impact on the risk of driving accidents and should be managed specifically</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284972">PM:28284972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170312-DemolyP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170312-DemolyP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Demoly P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Bird,J.A.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo</style></auth-address><titles><title><style face="normal" font="Arial">Trends in Provider Management of Patients with Food Protein-Induced Enterocolitis Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1324" start="1319">1319-1324</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Colic</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food reintroduction</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy formula</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy. OBJECTIVE: To better understand provider-level variation in FPIES knowledge and management. METHODS: A 23-question online survey was administered to AAAAI members during the spring and summer of 2014. RESULTS: Among 470 respondents, 64% reported "full understanding" of FPIES diagnosis/management; 78.8% reported managing 1 or more patient with FPIES; and 80.4% correctly identified an FPIES case vignette. FPIES was correctly differentiated from infantile colic or food protein-induced allergic proctocolitis by 82.5% and 71.3%, respectively. Among providers currently managing patients with FPIES, 47.5% indicated soy formula, 73.8% breast milk, and 94.5% elemental formula as appropriate substitutes in cow milk (CM)-FPIES. Skin testing is performed by 73.4%; 62.2% obtain serum food-specific IgE testing, 12.7% patch testing, 36.8% oral challenge, and 28% perform no tests. Eighty-four percent provide patients with FPIES with allergy action plans, 72.8% provide a personalized action plan, and 21% prescribe epinephrine autoinjectors. Odds of prescribing epinephrine were lower among those reporting "full understanding" of FPIES (odds ratio [OR], 0.41; 95% CI, 0.21-0.79). Academic providers had higher odds of providing an action plan (OR, 2.4; 95% CI, 1.17-4.98) and performing diagnostic oral food challenge (OR, 1.99; 95% CI, 1.99-3.25), but not of correct vignette differentiation of FPIES from other conditions, correct identification of appropriate CM-FPIES substitutes, or timing for food reintroduction. More years in practice were associated with lower odds of reporting full understanding of FPIES diagnosis/management (OR, 0.96; 95% CI, 0.94-0.99). CONCLUSIONS: Nearly one-third of respondents reported poor familiarity with FPIES. Considerable variation exists in the use of diagnostic tests, management, and choice of "safe" nutrition, indicating a strong need for FPIES practice guidelines</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284784">PM:28284784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170312-GreenhawtM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170312-GreenhawtM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Greenhawt M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Broekman,H.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author><author><style face="normal" font="Arial"> den Hartog Jager,C.F.</style></author><author><style face="normal" font="Arial"> van Bilsen,J.H.</style></author><author><style face="normal" font="Arial"> Raymakers,F.M.</style></author><author><style face="normal" font="Arial"> Kruizinga,A.G.</style></author><author><style face="normal" font="Arial"> Gaspari,M.</style></author><author><style face="normal" font="Arial"> Gabriele,C.</style></author><author><style face="normal" font="Arial"> Bruijnzeel-Koomen,C.A.</style></author><author><style face="normal" font="Arial"> Houben,G.F.</style></author><author><style face="normal" font="Arial"> Verhoeckx,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Medical Center Utrecht, Utrecht, the Netherlands; Utrecht Centre for Food Allergy, Utrecht, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Primary respiratory and food allergy to mealworm</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="603" start="600">600-603</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="3" Year="2017">2017/3/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274747">PM:28274747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170309-BroekmanH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170309-BroekmanH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Broekman H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kantor,D.B.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author><author><style face="normal" font="Arial"> Hirschhorn,J.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Boston Children's Hospital, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers To: IgE and antiviral immune response in asthma)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1718" start="1717">1717-1718</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="5" Month="3" Year="2017">2017/3/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274584">PM:28274584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170309-KantorDB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170309-KantorDB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Kantor DB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tam,J.S.</style></author><author><style face="normal" font="Arial"> Grayson,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital Los Angeles, Los Angeles, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">IgE and antiviral immune response in asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="1717">1717-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="5" Month="3" Year="2017">2017/3/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.11.055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274583">PM:28274583</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170309-TamJS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170309-TamJS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Tam JS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.11.055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brestoff,J.R.</style></author><author><style face="normal" font="Arial"> Zaydman,M.A.</style></author><author><style face="normal" font="Arial"> Scott,M.G.</style></author><author><style face="normal" font="Arial"> Gronowski,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, MO.</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis of red meat allergy with antigen-specific IgE tests in serum</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="610" start="608">608-610</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Red meat allergy</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28279684">PM:28279684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170310-BrestoffJR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170310-BrestoffJR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Brestoff JR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Claverie,C.</style></author><author><style face="normal" font="Arial"> Labreuche,J.</style></author><author><style face="normal" font="Arial"> Dorkenoo,A.</style></author><author><style face="normal" font="Arial"> Renaudin,J.M.</style></author><author><style face="normal" font="Arial"> Eb,M.</style></author><author><style face="normal" font="Arial"> Lejeune,S.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Leteurtre,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Children's Hospital, F-59056 Roubaix, France</style></auth-address><titles><title><style face="normal" font="Arial">Fatal anaphylaxis in France: analysis of national anaphylaxis data, 1979-2011</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="612" start="610">610-612</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anaphylaxis treatment</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment guidelines</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="Arial">The anaphylaxis mortality rate has fallen about 2% per year in France over the past 3 decades. Increased awareness of anaphylaxis treatment guidelines will hopefully continue this trend</style></abstract><notes><style face="normal" font="Arial">DA - 20170311IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283420">PM:28283420</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170311-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170311-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170311, Pouessel G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kelso,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab anaphylaxis occurring outside the recommended observation times</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="1718">1718-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="3" Month="3" Year="2017">2017/3/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.977</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28268017">PM:28268017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170307-KelsoJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170307-KelsoJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Kelso JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.977</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saenz de Santa Maria Garcia,M.</style></author><author><style face="normal" font="Arial"> Noguerado-Mellado,B.</style></author><author><style face="normal" font="Arial"> Rojas-Perez-Ezquerra,P.</style></author><author><style face="normal" font="Arial"> Prieto-Garcia,A.</style></author><author><style face="normal" font="Arial"> Bartolome-Zavala,B.</style></author><author><style face="normal" font="Arial"> Tornero,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Gregorio Maranon Health Research Institute (IiSGM), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">First case of allergy to nivolumab</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1141" start="1140">1140-1141</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.01.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284782">PM:28284782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170312-SaenzdeSantaMariaGarciaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170312-SaenzdeSantaMariaGarciaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Saenz de Santa Maria Garcia M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.01.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zieglmayer,P.</style></author><author><style face="normal" font="Arial"> Lemell,P.</style></author><author><style face="normal" font="Arial"> Chen,K.W.</style></author><author><style face="normal" font="Arial"> Schmutz,R.</style></author><author><style face="normal" font="Arial"> Zieglmayer,R.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Horak,F.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Vienna Challenge Chamber, Allergy Center Vienna West, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Validation of a house dust mite environmental challenge chamber model</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="268" start="266">266-268</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> dose finding</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinomanometry</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="Arial">Mite allergy causes significant socioeconomic burden. Environmental allergen exposure can be difficult to assess, and topical challenge offers limited value. In our investigation we evaluated a challenge chamber system in terms of correlation between mite allergen concentration and rhinitis symptoms, retest reproducibility as well as inter chamber variability. Data was obtained from adult mite allergic subjects from 4 different studies. Total nasal symptom score (TNSS) data was analysed for dose finding. TNSS and active anterior rhinomanometry (RMM) data was analyzed for retest reproducibility and inter chamber variability. Allergen dose deliveredand allergenic profile were specified, for dose quantification particle counting and weighing were correlated. In 85 subjects dose response was defined with five challenges of increasing allergen concentration and six challenges of stable allergen concentration. A clear dose response was shown with a mean TNSS of 6.6 at 0.3g mite material. For evaluation of retest reproducibility TNSS and RMM of 158 placebo- treated subjects were compared. Curves were matching with a mean plateau TNSS of 6.7 and a mean flow decrease of 34%. For definition of inter-chamber variability 28 subjects were challenged in two chamber systems. A mean TNSS without "nasal blockage"of 3.9 in VCC2 and of 4.0 in VCC3 with a SD of 0.2% each and a mean reduction in nasal flow sum of 36.3% in VCC2 and 39.6% in VCC3 with a SD of 1.2 and 2.3, respectively, was determined.. No bronchial adverse events were observed. Thus, a clear and reproducible dose response in terms of mite allergen concentration was demonstrated. Similar symptoms scores were elicited between studies and between chambers. We conclude that the mite challenge chamber model offers a safe and reproducible option for investigation of mite allergic subjects</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.986</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238743">PM:28238743</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170227-ZieglmayerP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170227-ZieglmayerP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Zieglmayer P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.986</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hourihane,J.O.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Shreffler,W.G.</style></author><author><style face="normal" font="Arial"> Dunngalvin,G.</style></author><author><style face="normal" font="Arial"> Nordlee,J.A.</style></author><author><style face="normal" font="Arial"> Zurzolo,G.A.</style></author><author><style face="normal" font="Arial"> DunnGalvin,A.</style></author><author><style face="normal" font="Arial"> Gurrin,L.C.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatrics and Child Health, University College, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="Arial">Peanut Allergen Threshold Study (PATS): Novel single-dose oral food challenge study to validate eliciting doses in peanut allergic children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1590" start="1583">1583-1590</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eliciting dose</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Reactor</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold dose</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eliciting doses (ED) of allergenic foods can be defined by the distribution of threshold doses for individuals within a specific population. ED05 is the dose that elicits a reaction in 5% of allergic subjects. The predicted ED05 for peanut (PN) is 1.5 mg of peanut protein (6 mg whole peanut). OBJECTIVE: We sought to validate the predicted peanut ED05 (1.5 mg) with a novel single dose challenge. METHODS: Consecutive eligible peanut allergic children in 3 centres were prospectively invited to participate, irrespective of previous reaction severity. Predetermined criteria for objective reactions were used to identify ED05 single dose reactors. RESULTS: 518 children (mean age 6.8 years) were eligible. No significant demographic or clinical differences were identified between 381(74%) participants and 137 (26%) non-participants or between subjects recruited at each centre. 378 children (206 male) completed the study. Almost half the group reported ignoring precautionary allergen labelling. 245 (65%) experienced no reaction to the single dose of peanut. 67 (18%) reported a subjective reaction without objective findings. 58 (15%) experienced signs of a mild and transient nature that did not meet the pre-determined criteria. Only 8 subjects (2.1%, 95% CI 0.6%-3.4%) met the pre-determined criteria for an objective and likely related event. No child experienced more than a mild reaction, 4 of the 8 received oral antihistamines only and none received epinephrine. Food allergy related quality of life improved from baseline to 1 month post challenge regardless of outcome (eta squared = 0.2, p &lt;0.0001). Peanut SPT, peanut and Ara h 2 spIgE levels were not associated with objective reactivity to PN ED05. CONCLUSION: A single administration of 1.5 mg PN protein elicited objective reactions in fewer than the predicted 5% of peanut-allergic subjects. The novel single dose OFC appears clinically safe and patient-acceptable, regardless of the outcome. It identifies the most highly dose-sensitive food allergic population, not otherwise identifiable using routinely available peanut SPT or spIgE levels but this single-dose approach has not yet been validated for risk assessment of individual patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Ireland -CO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238744">PM:28238744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170227-HourihaneJO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170227-HourihaneJO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Hourihane JO</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,Y.</style></author><author><style face="normal" font="Arial"> Underwood,J.</style></author><author><style face="normal" font="Arial"> Macmillan,D.</style></author><author><style face="normal" font="Arial"> Shariff,L.</style></author><author><style face="normal" font="Arial"> O'Shaughnessy,R.</style></author><author><style face="normal" font="Arial"> Harper,J.I.</style></author><author><style face="normal" font="Arial"> Pickard,C.</style></author><author><style face="normal" font="Arial"> Friedmann,P.S.</style></author><author><style face="normal" font="Arial"> Healy,E.</style></author><author><style face="normal" font="Arial"> Di,W.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Infection, Immunity, Inflammation and Physiological Medicine Programme, Immunobiology Section, UCL Institute of Child Health, 30 Guildford Street, London WC1N 1EH, UK</style></auth-address><titles><title><style face="normal" font="Arial">Persistent kallikrein5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Desmoglein</style></keyword><keyword><style face="normal" font="Arial"> Desmoglein 1</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> DSG1</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> kallikrein</style></keyword><keyword><style face="normal" font="Arial"> Kallikreins</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> PAR-2</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> protease activated receptor</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Up-regulation of kallikreins (KLK) including KLK5 has been reported in atopic dermatitis (AD). KLK5 has biological functions which include degrading desmosomal proteins and inducing pro-inflammatory cytokine secretion through protease activated receptor 2 (PAR2). However, due to the complex interactions between various cells in AD inflamed skin, it is difficult to dissect the precise and multiple roles of up-regulated KLK5 in AD skin. OBJECTIVE: We investigated the effect of up-regulated KLK5 on the expression of epidermal related proteins and cytokines in keratinocytes and on skin architecture. METHODS: Lesional and non-lesional AD skin biopsies were collected for analysis of morphology and protein expression. The relationship between KLK5 and barrier related molecules was investigated using an ex-vivo dermatitis skin model with transient KLK5 expression and a cell model with persistent KLK5 expression. The influence of up-regulated KLK5 on epidermal morphology was investigated using an in vivo skin graft model. RESULTS: Up-regulation of KLK5 and abnormal expression of desmoglein 1 (DSG1) and filaggrin (FLG), but not PAR2 were identified in AD skin. PAR2 was increased in response to transient up-regulation of KLK5, while persistently up-regulated KLK5 did not show this effect. Persistently up-regulated KLK5 degraded DSG1 and stimulated secretion of IL-8, IL-10 and TSLP independent of PAR2 activity. With control of higher KLK5 activity by the inhibitor SFTI-G, restoration of DSG1 expression and a reduction in AD-related cytokine IL-8, TLSP and IL-10 secretion were observed. Furthermore, persistently elevated KLK5 could induce AD-like skin architecture in an in vivo skin graft model. . CONCLUSION: Persistently up-regulated KLK5 resulted in AD-like skin architecture and secretion of AD-related cytokines from keratinocytes in a PAR-2 independent manner. Inhibition of KLK5-mediated effects may offer potential as a therapeutic approach in AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238749">PM:28238749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170227-ZhuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170227-ZhuY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Zhu Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Siroux,V.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France</style></auth-address><titles><title><style face="normal" font="Arial">The multimorbid polysensitized phenotype is associated with the severity of allergic diseases</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1408" start="1407">1407-1408</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170226IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Spain -CO - France -CO - Germany -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.961</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237729">PM:28237729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170226-BousquetJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170226-BousquetJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170226, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.961</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Staton,T.L.</style></author><author><style face="normal" font="Arial"> Arron,J.R.</style></author><author><style face="normal" font="Arial"> Olsson,J.</style></author><author><style face="normal" font="Arial"> Holweg,C.T.</style></author><author><style face="normal" font="Arial"> Matthews,J.G.</style></author><author><style face="normal" font="Arial"> Choy,D.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genentech, Inc. South San Francisco, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Seasonal Variability of Severe Asthma Exacerbations and Clinical Benefit from Lebrikizumab</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1684" start="1682">1682-1684</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="Arial">Post-hoc analyses of two Phase III studies of lebrikizumab in moderate to severe asthma suggest that IL-13 inhibition is effective at preventing seasonal exacerbations in subjects with high blood eosinophil counts. Further work is required to understand and treat exacerbations that are independent of seasonal and Type 2 pathway factors</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238745">PM:28238745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170227-StatonTL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170227-StatonTL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Staton TL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohammad,A.A.</style></author><author><style face="normal" font="Arial"> Wu,S.Z.</style></author><author><style face="normal" font="Arial"> Ibrahim,O.</style></author><author><style face="normal" font="Arial"> Bena,J.</style></author><author><style face="normal" font="Arial"> Rizk,M.</style></author><author><style face="normal" font="Arial"> Piliang,M.</style></author><author><style face="normal" font="Arial"> Bergfeld,W.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">St George's University School of Medicine, True Blue, Grenada, West Indies</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of atopic comorbidities in eosinophilic esophagitis: A case-control study of 449 patients</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="560" start="559">559-560</pages><volume><style face="normal" font="Arial">76</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> West Indies</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170218IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2016.08.068</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28212761">PM:28212761</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\2017-76-559-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\2017-76-559-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170218, Mohammad AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2016.08.068</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agelebe,E.</style></author><author><style face="normal" font="Arial"> Musa,T.L.</style></author><author><style face="normal" font="Arial"> Ajayi,I.A.</style></author><author><style face="normal" font="Arial"> Oyedeji,O.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Senior Registrar, Department of Paediatrics and Child Health, Ladoke Akintola University of Technology Teaching Hospital , Osogbo, Osun State, Nigeria</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis Complicated by Acute Respiratory Distress and Fatal Outcome in A Nigerian Family</style></title><secondary-title><style face="normal" font="Arial">J Clin Diagn Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Diagn Res</style></full-title></periodical><pages end="SD03" start="SD01">SD01-SD03</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aminophylline</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fatal Outcome</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Nigeria</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> senior</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Teaching</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Reports on hypersensitivity diseases in Nigerians are rare. We report the incidence of anaphylaxis in three siblings following fatal outcome in their mother. Urticarial rashes were noticed in three siblings' resident in a South Western Nigerian town, one week before presentation at our facility. All the three siblings developed respiratory distress four days after the rash was noticed. Onset of respiratory distress made the family seek care at a private hospital, where they were admitted and treated with intravenous aminophylline and ceftriaxone. The mother of the children had experienced the same symptoms earlier also. She took treatment and died in the same private hospital, where her children received care. Death of the mother and worsening respiratory distress in the children made the father effect transfer of the children to the paediatric emergency unit of Ladoke Akintola University of Technology Teaching Hospital, Osogbo. The three children made a slow but uneventful recovery after instituting appropriate management for anaphylaxis and acute respiratory distress syndrome. The cases are discussed with a view to create awareness amongst health practitioners about the occurrence of anaphylaxis in our society. The need for prompt recognition and appropriate management, when confronted with this disease is also underscored</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - Nigeria -</style></notes><work-type><style face="normal" font="Arial">10.7860/JCDR/2017/21449.9158</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274015">PM:28274015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-SD01-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-SD01-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Agelebe E</style></custom2><misc3><style face="normal" font="Arial">10.7860/JCDR/2017/21449.9158</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hiragun,T.</style></author><author><style face="normal" font="Arial"> Hiragun,M.</style></author><author><style face="normal" font="Arial"> Ishii,K.</style></author><author><style face="normal" font="Arial"> Kan,T.</style></author><author><style face="normal" font="Arial"> Hide,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sweat allergy: extrinsic or intrinsic?</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial peptides</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil histamine release</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Malassezia globosa</style></keyword><keyword><style face="normal" font="Arial"> Malassezia species</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> MGL_1304</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pichia</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> Sweat antigen</style></keyword><keyword><style face="normal" font="Arial"> Sweating</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tannic Acid</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0923-1811</style></isbn><abstract><style face="normal" font="Arial">Abstract Sweat has been recognized as an exacerbation factor in all age groups of atopic dermatitis (AD). Elevation of body core temperature with sweating is a trigger of cholinergic urticaria (CholU). Recently, we reported the improvement of AD symptoms by spray containing tannic acid, which suppresses basophil histamine release by semi-purified sweat antigen in vitro, and by showering that removes antigens in sweat from the skin surface. Sweat contains small amount of proteins including proteases, protease inhibitors, and anti-microbial peptides. We finally identified MGL_1304 secreted by Malassezia (M.) globosa as a major histamine releasing antigen in human sweat. MGL_1304 is detected as a 17-kDa protein in sweat and exhibits almost the highest histamine release ability from basophils of patients with AD and CholU among antigens derived from Malassezia species. Moreover, serum levels of anti-MGL_1304 IgE of patients with AD and CholU were significantly higher than those of normal controls. The recombinant protein produced by Pichia pastoris possessed comparable allergenicity to native MGL_1304. We found a monoclonal IgE antibody against MGL_1304 which did not elicit histamine release from sensitized mast cells. Desensitization therapy using autologous sweat, or MGL_1304 purified from culture of M. globosa or its cognates might be beneficial for patients with intractable CholU due to sweat allergy. (207 &amp;lt; 250 words)</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2017.03.002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jdermsci.2017.03.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20170318-HiragunT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20170318-HiragunT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Hiragun T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2017.03.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Can,P.K.</style></author><author><style face="normal" font="Arial"> Kocaturk,E.</style></author><author><style face="normal" font="Arial"> Akbas,P.E.</style></author><author><style face="normal" font="Arial"> Copur,M.</style></author><author><style face="normal" font="Arial"> Degirmentepe,E.N.</style></author><author><style face="normal" font="Arial"> Kiziltac,K..</style></author><author><style face="normal" font="Arial"> Singer,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Management of chronic inducible urticaria according to the guidelines: Do the same treatment algorithms work for all? A prospective controlled study</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inducible urticaria</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> combination antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> updosing antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria control test</style></keyword><keyword><style face="normal" font="Arial"> urticaria guidelines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0923-1811</style></isbn><abstract><style face="normal" font="Arial">AbstractBackground The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options. Objective We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU. Methods This prospective parallel group controlled study included 70 CIndU and 66 CSU patients. The same treatment algorithm recommended by the European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization (EAACI/GA2LEN/EDF/WAO) was implemented to both CSU and CIndU patients. Exception to this was implementation of updosing as well as combining second generation antihistamines (sg-AHs) in CIndU to compare their safety and efficacy. Treatment responses of the groups were evaluated with urticaria control test (UCT) and dermatology life quality questionnaire (DLQI) scores at the 0, 4, 8, 12 and 24th weeks for CIndU and 0, 4, 12 and 24 weeks for CSU. Results Fourteen patients (20,9%) with CIndU and 25 (37,9%) with CSU responded to standard doses of H1-AHs which was significantly higher in the CSU group (p = 0,031; p &amp;lt; 0,05). Patients with CIndU and CSU showed statistically similar responses to second line treatment (combining or updosing AHs) (p = 0,979; p &amp;gt; 0,05). There were no statistically significant differences observed between treatment responses (p = 0,674; p &amp;gt; 0,05) and mean changes in UCT and DLQI scores of updosing and combining AHs in CIndU patients (p = 0,113, 0,728; p &amp;gt; 0,05). Twenty-seven (40,3%) of CIndU patients and 21 (31,8%) of CSU patients were diagnosed as AH-resistant urticaria. Omalizumab was implemented in 15 CSU patients and 17 CIndU patients. Response rates to omalizumab were similar in both groups. Total response rates increased from 37,9% (n:25) to 68,2% (n:45) with the 2nd line treatments in CSU group while it increased from 20,9% (n:14) to 59,7% (n:40) in CIndU group. When omalizumab was introduced to AH-refractory cases as a 3rd line treatment, total response rates evaluated at the 12th week were 76,1% (n:51) in patients with CIndU and 83,3% (n:55) in CSU. Continuing omalizumab treatment for 24 weeks increased response rates in patients who were unresponsive at week 12. Conclusion CIndU seem to be more resistant to standard doses of AHs and higher doses of AHs are required for the control of symptoms. Combination of different sg-AHs was found to be as effective as updosing treatment in CIndU. The same guidelines for CSU may be implemented to patients with CIndU</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2017.02.283</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jdermsci.2017.02.283</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20170318-KanPK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20170318-KanPK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Can PK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2017.02.283</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Almeida,D.A.</style></author><author><style face="normal" font="Arial"> Rosa,S.I.</style></author><author><style face="normal" font="Arial"> da Cruz,T.C.</style></author><author><style face="normal" font="Arial"> Pavan,E.</style></author><author><style face="normal" font="Arial"> Sabino,D.A.</style></author><author><style face="normal" font="Arial"> Mendes,S.I.</style></author><author><style face="normal" font="Arial"> Donizeti,A.S.</style></author><author><style face="normal" font="Arial"> Macho,A.</style></author><author><style face="normal" font="Arial"> Martins,D.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Basic Sciences in Health, Faculty of Medicine, Federal University of Mato Grosso, Av. Fernando Correa da Costa, n. 2367, Cuiaba, Mato Grosso, Brazil Zip Code: 78060-900</style></auth-address><titles><title><style face="normal" font="Arial">Mandevilla longiflora (Desf.) Pichon improves airway inflammation in a murine model of allergic asthma</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Complementary Therapies</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> leukocyte migration</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> South America</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Mandevilla longiflora, popularly known as "velame" in central Brazil, is a subshrub and widely distributed in South America. Its xylopodium is used in the form of a decoction or infusion to treat inflammation and other ailments. AIM OF THE STUDY: This study aimed to evaluate the anti-inflammatory potential of M. longiflora in an in vivo model of ovalbumin-induced immediate hypersensitivity, identifying its effects on leukocyte infiltration, IgE and LTB4 levels, and Th2 cytokine production. In addition, HPLC fingerprint of the extract was performed. MATERIAL AND METHODS: The hydroethanolic extract 70% of M. longiflora (HEMI) was obtained by maceration of the plant xylopodium. Swiss mice were sensitized i.p. injection OVA-aluminium hydroxide on days 1 and 10. Nine days after the last sensitisation animals were challenged for 6 consecutive days with OVA solution for 20min daily in a closed chamber under continuous flow of aerosol. The animals were treated with HEMl (20, 50 and 200mg/kg p.o.), 2 times per day, and euthanized 24h later. Animals treated with vehicle (2% Tween-20) or dexamethasones were used as negative and positive controls, respectively. The recruitment of inflammatory cells into the pulmonary cavity was evaluated by counting cells present in broncho-alveolar lavage fluid (BALF) and lung tissue collected for histopathology and infiltration analysis. Quantification of IL-4, IL-5 and IL-13 from the LBA, and IgE, and LTB4 from plasma, were conducted by immunoassay. RESULTS AND CONCLUSIONS: The HEMl attenuated leukocyte migration into the airways, which was evidenced by a decrease in eosinophils, neutrophils and mononuclear cells, both in BALF quantification and by histopathological analysis, as well as decreasing the concentrations of IL-4, IL-5, IL-13, IgE and LTB4. All of these events are typical of air-mucosa inflammatory disease. These findings scientifically evidence for the first time the ethnopharmacological use of M. longiflora to treat chronic inflammatory events, such as asthma, and suggest a potential therapeutic use or complementary therapy for this plant extract</style></abstract><notes><style face="normal" font="Arial">DA - 20170223IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.02.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28229922">PM:28229922</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20170223-deAlmeidaDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20170223-deAlmeidaDA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, de Almeida DA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.02.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aurich,S.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Leipzig</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab does not improve skin lesions in a patient with Hypocomplementemic Urticarial Vasculitis Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare immune complex- mediated disease being characterized by persistent urticarial lesions, hypocomplementemia and possible organ involvement [1]. Therapy of HUVS is reported to be challenging [2]. We report on a 36 year old non atopic female who first presented in our university allergy centre with 18 months history of recurrent urticarial flares. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273376">PM:28273376</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170308-AurichS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170308-AurichS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Aurich S</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14202</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Radke,T.J.</style></author><author><style face="normal" font="Arial"> Brown,L.G.</style></author><author><style face="normal" font="Arial"> Hoover,E.R.</style></author><author><style face="normal" font="Arial"> Faw,B.V.</style></author><author><style face="normal" font="Arial"> Reimann,D.</style></author><author><style face="normal" font="Arial"> Wong,M.R.</style></author><author><style face="normal" font="Arial"> Nicholas,D.</style></author><author><style face="normal" font="Arial"> Barkley,J.</style></author><author><style face="normal" font="Arial"> Ripley,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centers for Disease Control and Prevention, National Center for Environmental Health, 4770 Buford Highway, Mailstop F58, Atlanta, Georgia 30341</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy Knowledge and Attitudes of Restaurant Managers and Staff: An EHS-Net Study</style></title><secondary-title><style face="normal" font="Arial">J Food Prot</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Prot</style></full-title></periodical><pages end="1598" start="1588">1588-1598</pages><volume><style face="normal" font="Arial">79</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> Centers for Disease Control</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Forum</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> restaurant</style></keyword><keyword><style face="normal" font="Arial"> Restaurants</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Dining outside of the home can be difficult for persons with food allergies who must rely on restaurant staff to properly prepare allergen-free meals. The purpose of this study was to understand and identify factors associated with food allergy knowledge and attitudes among restaurant managers, food workers, and servers. This study was conducted by the Environmental Health Specialists Network (EHS-Net), a collaborative forum of federal, state, and local environmental health specialists working to understand the environmental factors associated with food safety issues. EHS-Net personnel collected data from 278 randomly selected restaurants through interviews with restaurant managers, food workers, and servers. Results indicated that managers, food workers, and servers were generally knowledgeable and had positive attitudes about accommodating customers' food allergies. However, we identified important gaps, such as more than 10% of managers and staff believed that a person with a food allergy can safely consume a small amount of that allergen. Managers and staff also had lower confidence in their restaurant's ability to properly respond to a food allergy emergency. The knowledge and attitudes of all groups were higher at restaurants that had a specific person to answer food allergy questions and requests or a plan for answering questions from food allergic customers. However, food allergy training was not associated with knowledge in any of the groups but was associated with manager and server attitudes. Based on these findings, we encourage restaurants to be proactive by training staff about food allergies and creating plans and procedures to reduce the risk of a customer having a food allergic reaction</style></abstract><notes><style face="normal" font="Arial">DA - 20170221IS - 1944-9097 (Electronic)IS - 0362-028X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28221943">PM:28221943</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Prot\2016-79-1588-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Prot\2016-79-1588-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170221, Radke TJ</style></custom2><misc3><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masiri,J.</style></author><author><style face="normal" font="Arial"> Benoit,L.</style></author><author><style face="normal" font="Arial"> Meshgi,M.</style></author><author><style face="normal" font="Arial"> Day,J.</style></author><author><style face="normal" font="Arial"> Nadala,C.</style></author><author><style face="normal" font="Arial"> Samadpour,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Molecular Epidemiology, Inc., 15300 Bothell Way N.E., Lake Forest Park, Washington 98155, USA</style></auth-address><titles><title><style face="normal" font="Arial">A Novel Immunoassay Test System for Detection of Modified Allergen Residues Present in Almond-, Cashew-, Coconut-, Hazelnut-, and Soy-Based Nondairy Beverages</style></title><secondary-title><style face="normal" font="Arial">J Food Prot</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Prot</style></full-title></periodical><pages end="1582" start="1572">1572-1582</pages><volume><style face="normal" font="Arial">79</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Beverages</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Coconut</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Detection methods</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> lateral flow immunoassay</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk substitutes</style></keyword><keyword><style face="normal" font="Arial"> Modified allergens</style></keyword><keyword><style face="normal" font="Arial"> Molecular epidemiology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Selectivity</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy Milk</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">A growing number of plant-based milk substitutes have become commercially available, providing an array of options for consumers with dietary restrictions. Though several of these products rival cow's milk in terms of their nutritional profiles, beverages prepared with soy and tree nuts can be a significant concern to consumers because of potential contamination with food allergens. Adding to this concern is the fact that allergen residues from plant-based beverages are modified during manufacturing, thereby decreasing the sensitivity of antibody-based detection methods. Consequently, many commercially available allergen detection kits are less effective for allergens derived from nondairy milk substitutes. To address this limitation, we developed a panel of polyclonal antibodies directed against the modified proteins present in almond, cashew, coconut, hazelnut, and soy milks and incorporated them into rapid lateral flow immunoassay tests configured in both sandwich and competitive format. The tests had robust detection capabilities when used with a panel of various brand-name products, with a sensitivity of 1 ppm and selectivity values of 3 to 5 ppm in nondairy beverages. Minimal cross-reactivity to extracts prepared from common commodities was observed. The development of a highly sensitive and rapid test specifically designed to detect trace quantities of highly modified allergen residues in plant-based, dairy-free beverages will aid food manufacturers and regulatory agencies in monitoring products for these modified allergens when testing environmental and food samples</style></abstract><notes><style face="normal" font="Arial">DA - 20170221IS - 1944-9097 (Electronic)IS - 0362-028X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4315/0362-028X.JFP-15-493</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28221944">PM:28221944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Prot\2016-79-1572-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Prot\2016-79-1572-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170221, Masin J</style></custom2><misc3><style face="normal" font="Arial">10.4315/0362-028X.JFP-15-493</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83562</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Courtney,R.C.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Science and Technology, Food Allergy Research and Resource Program, Room 279, Food Innovation Center, University of Nebraska-Lincoln, 1901 North 21st Street, P.O. Box 886207, Lincoln, Nebraska 68588-6207, USADepartment of Food Science and Technology, Food Allergy Research and Resource Program, Room 279, Food Innovation Center, University of Nebraska-Lincoln, 1901 North 21st Street, P.O. Box 886207, Lincoln, Nebraska 68588-6207, USA</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of Commercial Milk-Specific Lateral Flow Devices</style></title><secondary-title><style face="normal" font="Arial">J Food Prot</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Prot</style></full-title></periodical><pages end="1774" start="1767">1767-1774</pages><volume><style face="normal" font="Arial">79</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> detectability</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Drying</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> false negative</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Nebraska</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">The requirement for validation of allergen cleaning processes is increasing. The use of lateral flow devices (LFDs) to identify allergens has rapidly expanded, but the best practices for use of these devices are still developing. The goal of this study was to compare commercially available milk-specific LFDs and a general protein identification method. Five milk proteins and seven milk-derived ingredients were tested at several concentrations with eight milk-specific LFDs and a general protein identification kit. Nonfat dry milk (NFDM) was prepared at 100 to 10,000 ppm of milk protein and analyzed by the LFDs to determine the concentration at which a false-negative result (overload concentration or hook effect) was obtained. NFDM was also prepared in 0.025 M phosphate-buffered saline (pH 7.4, 0.85% NaCl) and applied to stainless steel panels (100, 30, 10, or 3 mug of NFDM protein) with various drying methods and sampled with various swab methods to determine the level of detectability. Several total milk LFD kits did not detect whey proteins or whey-derived ingredients. The overload concentration of the various kits ranged from 100 to 10,000 ppm of milk protein. The small dynamic range observed for some kits would necessitate multiple dilutions of a sample to ensure that the result would fall within the range of detection. For swab sampling of stainless steel for LFD analysis, milk protein residues from surfaces onto which the residues were dried with high heat were more difficult to detect than were residues dried with low heat. No differences in sensitivity were observed as a result of moistening the residue or the swab before sampling. These results highlight the importance of understanding the detection capabilities of LFDs as indicated by the variability in the performance of the milk-specific LFDs tested</style></abstract><notes><style face="normal" font="Arial">DA - 20170221IS - 1944-9097 (Electronic)IS - 0362-028X (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28221844">PM:28221844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Prot\2016-79-1767-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Prot\2016-79-1767-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170221, Courtney RC</style></custom2><misc3><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-127</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bianchi,D.M.</style></author><author><style face="normal" font="Arial"> Adriano,D.</style></author><author><style face="normal" font="Arial"> Astegiano,S.</style></author><author><style face="normal" font="Arial"> Gallina,S.</style></author><author><style face="normal" font="Arial"> Caramelli,M.</style></author><author><style face="normal" font="Arial"> Decastelli,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, via Bologna 148, 10154 Torino, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Egg and Milk Proteins as Hidden Allergens in Food: 5-Year (2010 to 2014) Results of Food Allergen Monitoring in Piedmont, Italy</style></title><secondary-title><style face="normal" font="Arial">J Food Prot</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Prot</style></full-title></periodical><pages end="1587" start="1583">1583-1587</pages><volume><style face="normal" font="Arial">79</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen control</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eliciting dose</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hidden allergens</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Cow's milk and egg allergies are two of the most common food allergies. Manufacturers of food products containing milk or eggs or their derivatives as an ingredient are required by European Union regulations to list their presence on the ingredient label. Under European Union legislation, member states are mandated to carry out food safety monitoring programs to verify compliance with food labeling requirements. Through the Regional Integrated Plan for Food Safety, the Piedmont (Italy) regional authority carries out an annual program to determine the presence of undeclared allergens in foods. In the 5-year period from 2010 to 2014, a total of 1,566 food samples were analyzed for the presence of hidden egg and milk proteins. The average positive percentage was 2.8% (3.6% egg and 2% milk proteins). Comparison between the allergen concentration and the published eliciting dose (ED) for egg proteins (0.03 mg) and for total milk proteins (0.1 mg) indicated a high risk of allergen exposure for sensitized consumers. The calculated exposure was up to 135x (for milk) the ED01 reported in the literature. Food manufacturers will need to improve their allergen control programs to reduce allergen exposure and risk</style></abstract><notes><style face="normal" font="Arial">DA - 20170221IS - 1944-9097 (Electronic)IS - 0362-028X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28221935">PM:28221935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Prot\2016-79-1583-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Prot\2016-79-1583-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170221, Bianchi DM</style></custom2><misc3><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mizusaki,A.</style></author><author><style face="normal" font="Arial"> Nishi,K.</style></author><author><style face="normal" font="Arial"> Nishiwaki,H.</style></author><author><style face="normal" font="Arial"> Ishida,M.</style></author><author><style face="normal" font="Arial"> Tamamoto,T.</style></author><author><style face="normal" font="Arial"> Sugahara,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Suppressive effect of ethanol extract from passion fruit seeds on IgE production</style></title><secondary-title><style face="normal" font="Arial">J Funct Foods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Funct Foods</style></full-title></periodical><pages end="184" start="176">176-184</pages><volume><style face="normal" font="Arial">32</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antiallergy effect</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> functional foods</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Passion fruit</style></keyword><keyword><style face="normal" font="Arial"> Piceatannol</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> real-time RT-PCR</style></keyword><keyword><style face="normal" font="Arial"> Resveratrol</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><isbn><style face="normal" font="Arial">1756-4646</style></isbn><abstract><style face="normal" font="Arial">Abstract An array of foodstuffs was screened for the suppressive effect on production of IgE, a key molecule in the type I allergic reaction, using U266 cells. An ethanol extract from passion fruit seeds (PFS) has emerged as a food material with the IgE production-suppressive effect as the result of screening. Real-time RT-PCR analysis revealed that the IgE production-suppressive effect was caused by downregulated IgE gene expression. In addition, PFS selectively suppressed IgE production and did not affect the production of IgG, IgA, or IgM by mouse splenocytes. Resveratrol and piceatannol were identified as bioactive ingredients contained in passion fruit seeds. The effect of oral administration of PFS, resveratrol, and piceatannol was evaluated using a mouse model of allergic contact dermatitis. Both stilbenoids significantly suppressed IgE production in orally administered mice. Overall results indicated that passion fruit seeds are a promising candidate with the antiallergy effect for development of functional foods</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jff.2017.02.030</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jff.2017.02.030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Funct Foods\2017-32-176-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Funct Foods\2017-32-176-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Mizusaki A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jff.2017.02.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Massoud,A.H.</style></author><author><style face="normal" font="Arial"> Kaufman,G.N.</style></author><author><style face="normal" font="Arial"> Xue,D.</style></author><author><style face="normal" font="Arial"> Beland,M.</style></author><author><style face="normal" font="Arial"> Dembele,M.</style></author><author><style face="normal" font="Arial"> Piccirillo,C.A.</style></author><author><style face="normal" font="Arial"> Mourad,W.</style></author><author><style face="normal" font="Arial"> Mazer,B.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Translational Research in Respiratory Diseases Program, Research Institute of the McGill University Health Centre, Montreal, Quebec H4A 3J1, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Peripherally Generated Foxp3+ Regulatory T Cells Mediate the Immunomodulatory Effects of IVIg in Allergic Airways Disease</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cell Cycle</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cellular immunity</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> IVIg</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transgene</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="Arial">IVIg is widely used as an immunomodulatory therapy. We have recently demonstrated that IVIg protects against airway hyperresponsiveness (AHR) and inflammation in mouse models of allergic airways disease (AAD), associated with induction of Foxp3+ regulatory T cells (Treg). Using mice carrying a DTR/EGFP transgene under the control of the Foxp3 promoter (DEREG mice), we demonstrate in this study that IVIg generates a de novo population of peripheral Treg (pTreg) in the absence of endogenous Treg. IVIg-generated pTreg were sufficient for inhibition of OVA-induced AHR in an Ag-driven murine model of AAD. In the absence of endogenous Treg, IVIg failed to confer protection against AHR and airway inflammation. Adoptive transfer of purified IVIg-generated pTreg prior to Ag challenge effectively prevented airway inflammation and AHR in an Ag-specific manner. Microarray gene expression profiling of IVIg-generated pTreg revealed upregulation of genes associated with cell cycle, chromatin, cytoskeleton/motility, immunity, and apoptosis. These data demonstrate the importance of Treg in regulating AAD and show that IVIg-generated pTreg are necessary and sufficient for inhibition of allergen-induced AAD. The ability of IVIg to generate pure populations of highly Ag-specific pTreg represents a new avenue to study pTreg, the cross-talk between humoral and cellular immunity, and regulation of the inflammatory response to Ags</style></abstract><notes><style face="normal" font="Arial">DA - 20170221IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1502361</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219891">PM:28219891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170221-MassoudAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170221-MassoudAH.pdf</url></text-urls><related-urls><url ppv-ref="no">xls in cartella</url></related-urls></urls><custom2><style face="normal" font="Arial">20170221, Massoud AH</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1502361</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Narla,S.</style></author><author><style face="normal" font="Arial"> Hsu,D.Y.</style></author><author><style face="normal" font="Arial"> Thyssen,J.P.</style></author><author><style face="normal" font="Arial"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611</style></auth-address><titles><title><style face="normal" font="Arial">Inpatient financial burden of atopic dermatitis in the United States</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">Little is known about the inpatient burden of atopic dermatitis (AD). We sought to determine some risk factors and financial-burden of hospitalizations for AD in the US. Data were analyzed from the 2002-2012 National Inpatient Sample, including of a 20% representative sample of all hospitalizations in the US. Hospitalization rates for AD or eczema (AD-E) were highest in the northeast during the winter and south during the summer. Geometric mean cost of care [95% CI] was lower for a primary diagnosis of AD-E vs. no AD-E in adults ($3,502 [$3,360-$3,651] vs. $6,849 [$6,775-$6,925]; P=0.0004) and children ($2,716 [$2,542-$2,903] vs. $4,488 [$4,302-$4,682]; P=0.0004). However, the high prevalence of hospitalization resulted in total inpatient costs of $8,288,083 per-year for adults and $3,333,868 per-year for children. In conclusion, there is a substantial inpatient financial-burden of AD in the US</style></abstract><notes><style face="normal" font="Arial">DA - 20170305IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.02.975</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259687">PM:28259687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\20170305-NarlaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\20170305-NarlaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170305, Narla S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.02.975</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83567</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ochi,H.</style></author><author><style face="normal" font="Arial"> Takai,T.</style></author><author><style face="normal" font="Arial"> Shimura,S.</style></author><author><style face="normal" font="Arial"> Maruyama,N.</style></author><author><style face="normal" font="Arial"> Nishioka,I.</style></author><author><style face="normal" font="Arial"> Kamijo,S.</style></author><author><style face="normal" font="Arial"> Iida,H.</style></author><author><style face="normal" font="Arial"> Nakae,S.</style></author><author><style face="normal" font="Arial"> Ogawa,H.</style></author><author><style face="normal" font="Arial"> Okumura,K.</style></author><author><style face="normal" font="Arial"> Ikeda,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan; Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Skin Treatment with Detergent Promotes Protease Allergen-Dependent Epicutaneous Sensitization in a Manner Different from Tape Stripping in Mice</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170305IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.02.970</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259686">PM:28259686</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\20170305-OchiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\20170305-OchiH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170305, Ochi H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.02.970</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Standing,A.S.</style></author><author><style face="normal" font="Arial"> Yanez,D.C.</style></author><author><style face="normal" font="Arial"> Ross,R.</style></author><author><style face="normal" font="Arial"> Crompton,T.</style></author><author><style face="normal" font="Arial"> Furmanski,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Life Sciences, University of Bedfordshire, Luton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Frontline Science: Shh production and Gli signaling is activated in vivo in lung, enhancing the Th2 response during a murine model of allergic asthma</style></title><secondary-title><style face="normal" font="Arial">J Leukoc Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Leukoc Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Repression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">The pathophysiology of allergic asthma is driven by Th2 immune responses after aeroallergen inhalation. The mechanisms that initiate, potentiate, and regulate airway allergy are incompletely characterized. We have shown that Hh signaling to T cells, via downstream Gli transcription factors, enhances T cell conversion to a Th2 phenotype. In this study, we showed for the first time, to our knowledge, that Gli-dependent transcription is activated in T cells in vivo during murine AAD, a model for the immunopathology of asthma, and that genetic repression of Gli signaling in T cells decreases the differentiation and recruitment of Th2 cells to the lung. T cells were not the only cells that expressed activated Gli during AAD. A substantial proportion of eosinophils and lung epithelial cells, both central mediators of the immunopathology of asthma, also underwent Hh/Gli signaling. Finally, Shh increased Il-4 expression in eosinophils. We therefore propose that Hh signaling during AAD is complex, involving multiple cell types, signaling in an auto- or paracrine fashion. Improved understanding of the role of this major morphogenetic pathway in asthma may give rise to new drug targets for this chronic condition</style></abstract><notes><style face="normal" font="Arial">DA - 20170225IS - 1938-3673 (Electronic)IS - 0741-5400 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1189/jlb.3HI1016-438RR</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235772">PM:28235772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Leukoc Biol\20170225-StandingAS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Leukoc Biol\20170225-StandingAS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170225, Standing AS</style></custom2><misc3><style face="normal" font="Arial">10.1189/jlb.3HI1016-438RR</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bourne,T.</style></author><author><style face="normal" font="Arial"> Waltz,M.</style></author><author><style face="normal" font="Arial"> Casper,T.C.</style></author><author><style face="normal" font="Arial"> Kavak,K.</style></author><author><style face="normal" font="Arial"> Aaen,G.</style></author><author><style face="normal" font="Arial"> Belman,A.</style></author><author><style face="normal" font="Arial"> Benson,L.</style></author><author><style face="normal" font="Arial"> Candee,M.</style></author><author><style face="normal" font="Arial"> Chitnis,T.</style></author><author><style face="normal" font="Arial"> Graves,J.</style></author><author><style face="normal" font="Arial"> Greenberg,B.</style></author><author><style face="normal" font="Arial"> Gorman,M.</style></author><author><style face="normal" font="Arial"> Harris,Y.</style></author><author><style face="normal" font="Arial"> Krupp,L.</style></author><author><style face="normal" font="Arial"> Lotze,T.</style></author><author><style face="normal" font="Arial"> Mar,S.</style></author><author><style face="normal" font="Arial"> Ness,J.</style></author><author><style face="normal" font="Arial"> Olsen,C.</style></author><author><style face="normal" font="Arial"> Roalstad,S.</style></author><author><style face="normal" font="Arial"> Rodriguez,M.</style></author><author><style face="normal" font="Arial"> Rose,J.</style></author><author><style face="normal" font="Arial"> Rubin,J.</style></author><author><style face="normal" font="Arial"> Schreiner,T.</style></author><author><style face="normal" font="Arial"> Tillema,J.M.</style></author><author><style face="normal" font="Arial"> Kahn,I.</style></author><author><style face="normal" font="Arial"> Waldman,A.</style></author><author><style face="normal" font="Arial"> Barcellos,L.</style></author><author><style face="normal" font="Arial"> Waubant,E.</style></author><author><style face="normal" font="Arial"> Weinstock-Guttman,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population</style></title><secondary-title><style face="normal" font="Arial">J Neurol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Neurol Sci</style></full-title></periodical><pages end="375" start="371">371-375</pages><volume><style face="normal" font="Arial">375</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="4" Year="2017">2017/4/15</year></dates><isbn><style face="normal" font="Arial">0022-510X</style></isbn><abstract><style face="normal" font="Arial">AbstractBackground Multiple sclerosis (MS) and allergies are both considered to be related to imbalanced Th1 and Th2 immune responses. Previous studies evaluating the relationship between MS and allergies provide conflicting results. Objective To assess allergies and asthma as risk factors for MS and as predictors of MS relapses in a pediatric cohort. Methods The environment and genetic risk factors for pediatric MS study is a national case-control project with 16 participating US sites. An environmental questionnaire is used that includes history of allergies in the first five years of life. Case-control data are entered in the pediatric MS Network database and cases at 12 of the 16 sites enter relapse data prospectively. Annualized relapse rate was calculated for patients with follow-up and adjusted for age at disease onset, gender, race, ethnicity, and use of disease-modifying therapy (DMT). Results We included 271 cases (mean age at disease onset of 15.7 years and 62% female) and 418 controls. Relapse data were available for 193 cases. There was no difference in prevalence of allergies or asthma between cases and controls. Patients with food allergies had fewer relapses compared to patients without food allergies (0.14 vs 0.48, p = 0.01). Conclusions While allergies and asthma are not associated with pediatric MS, cases with food allergies have fewer relapses compared to those without food allergies</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jns.2017.02.041</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jns.2017.02.041</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Neurol Sci\2017-375-371-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Neurol Sci\2017-375-371-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Bourne T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jns.2017.02.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liccardi,G.</style></author><author><style face="normal" font="Arial"> Calzetta,L.</style></author><author><style face="normal" font="Arial"> Barrile,A.</style></author><author><style face="normal" font="Arial"> Giorgino,F.M.</style></author><author><style face="normal" font="Arial"> Sapio,C.</style></author><author><style face="normal" font="Arial"> Rogliani,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Haematology and Oncology. Division of Pneumology and Allergology. High Speciality "A. Cardarelli" Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals?</style></title><secondary-title><style face="normal" font="Arial">J Occup Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Occup Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword></keywords><dates><year Day="3" Month="3" Year="2017">2017/3/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1348-9585 (Electronic)IS - 1341-9145 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1539/joh.17-0025-LTE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28260737">PM:28260737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Occup Health\20170306-LiccardiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Occup Health\20170306-LiccardiG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Liccardi G</style></custom2><misc3><style face="normal" font="Arial">10.1539/joh.17-0025-LTE</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fleischer,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Allergy and Immunology, University of Colorado Denver School of Medicine, Children's Hospital Colorado, Aurora, Colorado, United States</style></auth-address><titles><title><style face="normal" font="Arial">Life after LEAP: How to implement advice on introducing peanuts in early infancy</style></title><secondary-title><style face="normal" font="Arial">J Paediatr Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Paediatr Child Health</style></full-title></periodical><pages end="9" start="3">3-9</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">S1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">The increase in food allergies worldwide has led to mounting concern among healthcare providers, families, schools, and the food industry. Of particular interest is the growing prevalence of peanut allergy. The Learning Early About Peanut Allergy (LEAP) study confirms that the early introduction of peanut significantly decreases the risk of developing peanut allergy among high-risk children. However, a number of issues, such as a unified definition of high risk and whether or not to screen patients before peanut introduction, remain. This article will review the LEAP findings and the new peanut allergy prevention guidelines, and then briefly discuss recommendations on the introduction of other allergenic foods based on results from other food allergy prevention randomised controlled trials</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1440-1754 (Electronic)IS - 1034-4810 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/jpc.13491</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28276109">PM:28276109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Paediatr Child Health\2017-53S1-3-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Paediatr Child Health\2017-53S1-3-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Fleischer DM</style></custom2><misc3><style face="normal" font="Arial">10.1111/jpc.13491</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,Z.</style></author><author><style face="normal" font="Arial"> Xie,Y.</style></author><author><style face="normal" font="Arial"> Guan,W.</style></author><author><style face="normal" font="Arial"> Gao,Y.</style></author><author><style face="normal" font="Arial"> Huang,R.</style></author><author><style face="normal" font="Arial"> Xia,S.</style></author><author><style face="normal" font="Arial"> Jian,W.</style></author><author><style face="normal" font="Arial"> Liang,Z.</style></author><author><style face="normal" font="Arial"> Zheng,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of leukotriene D4 nasal challenge on bronchial responsiveness and inflammation in asthmatic patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Thorac Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Thorac Dis</style></full-title></periodical><pages end="277" start="271">271-277</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial provocation</style></keyword><keyword><style face="normal" font="Arial"> bronchial responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cumulative dose</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene D4</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> nasal challenge</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In asthmatic patients with allergic rhinitis (AR), increased cysteinyl leukotrienes (CysLTs) production in the secretion of nasal mucosa has been associated with greater bronchial hyperresponsiveness (BHR) after nasal allergen challenge. However, the role of CysLTs in eliciting BHR after nasal allergen challenge has not been evaluated. The aim of this study is to evaluate the effect of LTD4 nasal challenge on BHR and inflammation in asthmatic patients with AR. METHODS: In this self-controlled study, fifteen eligible consecutively recruited subjects underwent methacholine (Mch) bronchial provocation test before and 30 minutes after LTD4 nasal provocation test. The cumulative concentration of LTD4 inducing a 60% increase in nasal airway resistance (PC60NAR) was calculated. The mean values of cumulative doses inducing a 20% decrease in forced expiratory flow in one second (PD20FEV1) for Mch before and after nasal challenge were compared. Fractional exhaled nitric oxide (FeNO), differential inflammatory cell counts in nasal lavage and induced sputum before and after nasal challenge were compared. RESULTS: House dust mites were the major allergens accounting for 10/15 (66.7%) of asthmatic patients with AR. The PC60NAR for LT was (8.39+/-3.48)x10-3 mg.mL-1. The PD20FEV1 before and after nasal challenge was 3.05+/-3.81 and 2.70+/-3.81 micromol, respectively (P=0.45). The percentages of eosinophils were (38.36+/-23.14)% and (45.70+/-24.86)% in nasal lavage, and (17.51+/-11.05)% and (24.29+/-16.52)% in induced sputum before and 24 hours after nasal challenge. The neutrophil counts were (60.64+/-23.14)% and (53.30+/-24.46)% in nasal lavage, and (53.83+/-23.27)% and (56.19+/-22.28)% in induced sputum before and 24 hours after nasal challenge. The values of FeNO were 40 [35] and 43 [30] ppb before and 24 hours after nasal challenge. No severe adverse effects were reported during the tests. CONCLUSIONS: Although most asthmatic patients with AR were sensitive to LTD4 nasal challenge, LTD4 nasal provocation tests do not confer any major effect on BHR. LTD4 might not play a vital role in eliciting bronchial responsiveness induced by nasal allergen challenge</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 2072-1439 (Print)IS - 2072-1439 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.21037/jtd.2017.02.36</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28275474">PM:28275474</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Thorac Dis\2017-9-271-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Thorac Dis\2017-9-271-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Zhu Z</style></custom2><misc3><style face="normal" font="Arial">10.21037/jtd.2017.02.36</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsui,E.C.</style></author><author><style face="normal" font="Arial"> Perzanowski,M.</style></author><author><style face="normal" font="Arial"> Peng,R.D.</style></author><author><style face="normal" font="Arial"> Wise,R.A.</style></author><author><style face="normal" font="Arial"> Balcer-Whaley,S.</style></author><author><style face="normal" font="Arial"> Newman,M.</style></author><author><style face="normal" font="Arial"> Cunningham,A.</style></author><author><style face="normal" font="Arial"> Divjan,A.</style></author><author><style face="normal" font="Arial"> Bollinger,M.E.</style></author><author><style face="normal" font="Arial"> Zhai,S.</style></author><author><style face="normal" font="Arial"> Chew,G.</style></author><author><style face="normal" font="Arial"> Miller,R.L.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy/Immunology, School of Medicine, Johns Hopkins University, Baltimore, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Effect of an Integrated Pest Management Intervention on Asthma Symptoms Among Mouse-Sensitized Children and Adolescents With Asthma: A Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="1036" start="1027">1027-1036</pages><volume><style face="normal" font="Arial">317</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">Importance: Professionally delivered integrated pest management (IPM) interventions can reduce home mouse allergen concentrations, but whether they reduce asthma morbidity among mouse-sensitized and exposed children and adolescents is unknown. Objective: To determine the effect of an IPM intervention on asthma morbidity among mouse-sensitized and exposed children and adolescents with asthma. Design, Setting, and Participants: Randomized clinical trial conducted in Baltimore, Maryland, and Boston, Massachusetts. Participants were mouse-sensitized and exposed children and adolescents (aged 5-17 years) with asthma randomized to receive professionally delivered IPM plus pest management education or pest management education alone. Enrollment occurred between May 2010 and August 2014; the final follow-up visit occurred on September 25, 2015. Interventions: Integrated pest management consisted of application of rodenticide, sealing of holes that could serve as entry points for mice, trap placement, targeted cleaning, allergen-proof mattress and pillow encasements, and portable air purifiers. Infestation was assessed every 3 months, and if infestation persisted or recurred, additional treatments were delivered. All participants received pest management education, which consisted of written material and demonstration of the materials needed to set traps and seal holes. Main Outcomes and Measures: The primary outcome was maximal symptom days defined as the highest number of days of symptoms in the previous 2 weeks among 3 types of symptoms (days of slowed activity due to asthma; number of nights of waking with asthma symptoms; and days of coughing, wheezing, or chest tightness) across 6, 9, and 12 months. Results: Of 361 children and adolescents who were randomized (mean [SD] age, 9.8 [3.2] years; 38% female; 181 in IPM plus pest management education group and 180 in pest management education alone group), 334 were included in the primary analysis. For the primary outcome, there was no statistically significant between-group difference for maximal symptom days across 6, 9, and 12 months with a median of 2.0 (interquartile range, 0.7-4.7) maximal symptom days in the IPM plus pest management education group and 2.7 (interquartile range, 1.3-5.0) maximal symptom days in the pest management education alone group (P = .16) and a ratio of symptom frequencies of 0.86 (95% CI, 0.69-1.06). Conclusions and Relevance: Among mouse-sensitized and exposed children and adolescents with asthma, an intensive year-long integrated pest management intervention plus pest management education vs pest management education alone resulted in no significant difference in maximal symptom days from 6 to 12 months. Trial Registration: clinicaltrials.gov Identifier: NCT01251224</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2016.21048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28264080">PM:28264080</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-137-1027-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-137-1027-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Matsui EC</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2016.21048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bacharier,L.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, School of Medicine, Washington University, St Louis, Missouri2St Louis Children's Hospital, St Louis, Missouri</style></auth-address><titles><title><style face="normal" font="Arial">Reducing Exposure to Mouse Allergen Among Children and Adolescents With Asthma Is Achievable, but Is It Enough?</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="1025" start="1023">1023-1025</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2016.21181</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28264092">PM:28264092</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-137-1023-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-137-1023-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Bacharier LB</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2016.21181</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cerri,S.</style></author><author><style face="normal" font="Arial"> Bernabeo,F.</style></author><author><style face="normal" font="Arial"> Valsecchi,E.</style></author><author><style face="normal" font="Arial"> Chiappino,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ASST Lecco Ospedale A Manzoni Lecco.</style></auth-address><titles><title><style face="normal" font="Arial">Occupational asthma due to chamomile: case report</style></title><secondary-title><style face="normal" font="Arial">Med Lav</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Lav</style></full-title></periodical><pages end="68" start="64">64-68</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial provocation</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Chamomile</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Flower</style></keyword><keyword><style face="normal" font="Arial"> Flowers</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> rast</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="Arial">We report the case of a worker employed in the packaging of herb infusions who came to our attention because he was suffering from breathing disorders caused by occupational exposure to chamomile dusts. The diagnostic procedure we followed highlighted a baseline lung function within the normal range, while the skin prick tests and the RAST test were positive to both seasonal aeroallergens and chamomile. To perform a specific bronchial provocation test, the patient was challenged in an exposure chamber with nebulization of an extract from chamomile flowers. This procedure, that we had already applied for other occupational allergens, induced in the patient an immediate bronchospastic type reaction, documented by a 17% reduction of FEV1 from baseline. It also produced a significant increase in bronchial non specific hyperresponsiveness and a remarkable rise of nitric oxide, in comparison with the pre exposure observed values. We concluded for a diagnosis of occupational asthma caused by chamomile</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 0025-7818 (Print)IS - 0025-7818 (Linking)LA - itaPT - English AbstractPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.23749/mdl.v108i1.5733</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28240734">PM:28240734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Lav\2017-108-64-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Lav\2017-108-64-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Cerri S</style></custom2><misc3><style face="normal" font="Arial">10.23749/mdl.v108i1.5733</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zgorzelska-Kowalik,J.</style></author><author><style face="normal" font="Arial"> Walusiak-Skorupa,J.</style></author><author><style face="normal" font="Arial"> Nowakowska-Swirta,E.</style></author><author><style face="normal" font="Arial"> Wiszniewska,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instytut Medycyny Pracy im. prof. J. Nofera / Nofer Institute of Occupational Medicine, Lodz, Poland (Klinika Chorob Zawodowych i Zdrowia Srodowiskowego, Oddzial Chorob Zawodowych / Department of Occupational Diseases and Environmental Health, Department of Occupational Diseases).</style></auth-address><titles><title><style face="normal" font="Arial">[Diagnostic accuracy of specific IgE antibodies measurements in occupational airway allergy to high molecular weight agents]</style></title><secondary-title><style face="normal" font="Arial">Med Pr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Pr</style></full-title></periodical><pages end="43" start="31">31-43</pages><volume><style face="normal" font="Arial">68</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> alpha-Amylase</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> baker</style></keyword><keyword><style face="normal" font="Arial"> Bakers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> Feathers</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The performance of specific inhalation challenge test (SICT) - reference method in diagnostics of occupational allergy - has some limitations due to health status of a particular patient. Therefore, it is extremely important to identify usefulness of other tests, and the evaluation of diagnostic accuracy of commercially available serum specific immunoglobulin E (sIgE) kits to the most common high molecular weight agents has been launched. MATERIAL AND METHODS: The study group comprised 141 subjects - 110 bakers and 31 farmers - with suspicion of occupational airway allergy. All patients underwent evaluation of serum sIgE to occupational allergens with the use of Phadia and Allergopharma kits: in bakers to flour mix and alpha-amylase, in farmers to epithelium of cow, pig and feathers. Specific inhalation challenge test with workplace allergens performed in all subjects was a reference method for further analysis. RESULTS: Serum specific IgE to flour mix had the highest sensitivity (Phadia - 95.6%, Allergopharma - 88.3%), while its specificity was relatively low (Phadia - 47.8%, Allergopharma - 25%). There were numerous discrepancies between the results of sIgE estimation for particular single allergens (k87, e4, e83), as well as for their mixtures (fx901, fx20, ex71), performed with the kits of both companies (Phadia vs. Allergopharma). CONCLUSIONS: Evaluation of serum specific IgE is characterized by inadequate sensitivity, specificity and predictive value to take the place of specific inhalation challenge test in diagnostics of occupational respiratory allergy. Med Pr 2017;68(1):31-43</style></abstract><notes><style face="normal" font="Arial">DA - 20170228IS - 0465-5893 (Print)IS - 0465-5893 (Linking)LA - polPT - English AbstractPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.13075/mp.5893.00486</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28245002">PM:28245002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Pr\2017-68-31-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Pr\2017-68-31-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170228, Zgorzelska-Kowalik J</style></custom2><misc3><style face="normal" font="Arial">10.13075/mp.5893.00486</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ali,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A Survey of Self-Reported Food Allergy and Food-related Anaphylaxis among Young Adult Students at Kuwait University, Kuwait</style></title><secondary-title><style face="normal" font="Arial">Med Princ Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Princ Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy testing</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Perceived food allergy</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Probable food allergy</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Self-reported food allergy</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To conduct a survey on self-reported food allergy to milk, egg, peanuts, tree nuts, fish, shellfish, wheat and sesame as well as reported food-related anaphylaxis and epinephrine prescription practices among Kuwaiti students attending Kuwait University. SUBJECTS AND METHODS: One thousand (1,000) questionnaires that included data on age, gender, presence of food allergies and associated details were distributed. All participants reporting an allergy were categorized as having a perceived food allergy. Those with a convincing clinical history and history of undergoing diagnostic food allergy testing were further categorized as having a probable food allergy. RESULTS: Of the1000 questionnaires, 865 (86.5 %) were completed. Of the 865 students, 104(12.02%) reported food allergy (perceived) and of these 104 perceived food allergy 47(45.19%) were probable food allergy. For milk (46.7%), peanut (35.7%), fish (60%) and sesame (50%), probable food allergy occurred in early childhood (&lt;/=5 years) while those of egg (44.4%) and wheat (57.1%) occurred in late childhood (6-10 yrs.) and shellfish (40%) occurred in early adolescence (11-15yrs). Of the 47 students with probable food allergy,28 (59.6%) were moderate to severe; 20 (71%) of them reported at least one food-related anaphylactic episode while 8 (29%) denied such episodes. Equally important, of the 28 students, 6 (21%) received an autoinjectable epinephrine prescription while 22 (79%) did not receive any. CONCLUSIONS: In this study the reported occurrence of perceived food allergy was low and probable food allergy occurred mostly in early childhood. Milk, egg and nut allergies were the most commonly reported in both groups</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1423-0151 (Electronic)IS - 1011-7571 (Linking)LA - engPT - Journal ArticleCO - Kuwait -</style></notes><work-type><style face="normal" font="Arial">10.1159/000464361</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28226324">PM:28226324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Princ Pract\20170222-AliF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Princ Pract\20170222-AliF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Ali F</style></custom2><misc3><style face="normal" font="Arial">10.1159/000464361</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shilovskiy,I.P.</style></author><author><style face="normal" font="Arial"> Eroshkina,D.V.</style></author><author><style face="normal" font="Arial"> Babakhin,A.A.</style></author><author><style face="normal" font="Arial"> Khaitov,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Immunology, Federal Biomedical Agency, Moscow, 115478 Russia</style></auth-address><titles><title><style face="normal" font="Arial">[Anticytokine therapy of allergic asthma]</style></title><secondary-title><style face="normal" font="Arial">Mol Biol (Mosk)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Biol (Mosk)</style></full-title></periodical><pages end="17" start="3">3-17</pages><volume><style face="normal" font="Arial">51</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> emphysema</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Emphysema</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic animals</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Bronchial asthma is a chronic inflammatory disease of the airways that is characterized by episodes of shortness of breath, expiratory dyspnea, cough, wheezing, and pulmonary emphysema. At the present time, asthma is a global public health problem and affects about 5% of the worldwide population. Although a wide range of anti-inflammatory drugs is available, uncontrolled or poorly controlled asthma is still a problem, requiring the development of novel therapeutic approaches. Intense studies of the molecular mechanisms of asthma in transgenic animals performed since the 1990s implicated cytokines, such as IL-4, IL-5, and IL-13, and their receptors in the initiation and maintenance of asthma. These findings led to anticytokine therapy as a novel approach for bronchial asthma treatment. To date, many preclinical and clinical studies have been performed in this field especially with drugs based on humanized monoclonal antibodies, soluble receptors, peptide inhibitors, etc. The review summarizes the data from preclinical and clinical studies of anti-cytokine therapeutics in humans</style></abstract><notes><style face="normal" font="Arial">DA - 20170302IS - 0026-8984 (Print)IS - 0026-8984 (Linking)LA - rusPT - English AbstractPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.7868/S0026898416060197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28251961">PM:28251961</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170302, Shilovskiy IP</style></custom2><misc3><style face="normal" font="Arial">10.7868/S0026898416060197</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yi,L.</style></author><author><style face="normal" font="Arial"> Cheng,D.</style></author><author><style face="normal" font="Arial"> Zhang,K.</style></author><author><style face="normal" font="Arial"> Huo,X.</style></author><author><style face="normal" font="Arial"> Mo,Y.</style></author><author><style face="normal" font="Arial"> Shi,H.</style></author><author><style face="normal" font="Arial"> Di,H.</style></author><author><style face="normal" font="Arial"> Zou,Y.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Zhao,J.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Erle,D.J.</style></author><author><style face="normal" font="Arial"> Zhen,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</style></auth-address><titles><title><style face="normal" font="Arial">Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Mucosal Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mucosal Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor receptor</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">The epithelial and epidermal innate cytokines IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) have pivotal roles in the initiation of allergic inflammation in asthma and atopic dermatitis (AD). However, the mechanism by which the expression of these innate cytokines is regulated remains unclear. Intelectin (ITLN) is expressed in airway epithelial cells and promotes allergic airway inflammation. We hypothesized that ITLN is required for allergen-induced IL-25, IL-33, and TSLP expression. In two asthma models, Itln knockdown reduced allergen-induced increases in Il-25, Il-33, and Tslp and development of type 2 response, eosinophilic inflammation, mucus overproduction, and airway hyperresponsiveness. Itln knockdown also inhibited house dust mite (HDM)-induced early upregulation of Il-25, Il-33, and Tslp in a model solely inducing airway sensitization. Using human airway epithelial cells, we demonstrated that HDM-induced increases in ITLN led to phosphorylation of epidermal growth factor receptor and extracellular-signal regulated kinase, which were required for induction of IL-25, IL-33, and TSLP expression. In two AD models, Itln knockdown suppressed expression of Il-33, Tslp, and Th2 cytokines and eosinophilic inflammation. In humans, ITLN1 expression was significantly increased in asthmatic airways and in lesional skin of AD. We conclude that ITLN contributes to allergen-induced Il-25, Il-33, and Tslp expression in asthma and AD.Mucosal Immunology advance online publication 22 February 2017. doi:10.1038/mi.2017.10</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1935-3456 (Electronic)IS - 1933-0219 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/mi.2017.10</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28224996">PM:28224996</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mucosal Immunol\20170222-YiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mucosal Immunol\20170222-YiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Yi L</style></custom2><misc3><style face="normal" font="Arial">10.1038/mi.2017.10</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83580</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruzicka,T.</style></author><author><style face="normal" font="Arial"> Hanifin,J.M.</style></author><author><style face="normal" font="Arial"> Furue,M.</style></author><author><style face="normal" font="Arial"> Pulka,G.</style></author><author><style face="normal" font="Arial"> Mlynarczyk,I.</style></author><author><style face="normal" font="Arial"> Wollenberg,A.</style></author><author><style face="normal" font="Arial"> Galus,R.</style></author><author><style face="normal" font="Arial"> Etoh,T.</style></author><author><style face="normal" font="Arial"> Mihara,R.</style></author><author><style face="normal" font="Arial"> Yoshida,H.</style></author><author><style face="normal" font="Arial"> Stewart,J.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="835" start="826">826-835</pages><volume><style face="normal" font="Arial">376</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Monoclonal,Humanized</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Body Surface Area</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> chemically induced</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intention to Treat Analysis</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Receptors,Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="Arial">Background Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis. Methods In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per kilogram every 8 weeks. The primary end point was the percentage improvement from baseline in the score on the pruritus visual-analogue scale (on which a negative change indicates improvement) at week 12. Secondary end points included changes in the score on the Eczema Area and Severity Index (EASI, on which a negative change indicates improvement), and body-surface area of atopic dermatitis. Results Of 264 patients who underwent randomization, 216 (82%) completed the study. At week 12, among the patients who received nemolizumab every 4 weeks, changes on the pruritus visual-analogue scale were -43.7% in the 0.1-mg group, -59.8% in the 0.5-mg group, and -63.1% in the 2.0-mg group, versus -20.9% in the placebo group (P&lt;0.01 for all comparisons). Changes on the EASI were -23.0%, -42.3%, and -40.9%, respectively, in the nemolizumab groups, versus -26.6% in the placebo group. Respective changes in body-surface area affected by atopic dermatitis were -7.5%, -20.0%, and -19.4% with nemolizumab, versus -15.7% with placebo. Among the patients receiving nemolizumab every 4 weeks, treatment discontinuations occurred in 9 of 53 patients (17%) in the 0.1-mg group, in 9 of 54 (17%) in the 0.5-mg group, and in 7 of 52 (13%) in the 2.0-mg group, versus in 9 of 53 (17%) in the placebo group. Conclusions In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .)</style></abstract><notes><style face="normal" font="Arial">DA - 20170301IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Clinical Trial, Phase IIPT - Journal ArticlePT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tRN - 0 (Antibodies, Monoclonal, Humanized)RN - 0 (CIM331)RN - 0 (IL31RA protein, human)RN - 0 (Receptors, Interleukin)SB - AIMSB - IMCO - Germany -CO - Japan -CO - Poland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa1606490</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28249150">PM:28249150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-376-826-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-376-826-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170301, Ruzicka T</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa1606490</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schneider,L.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Division of Immunology, Boston Children's Hospital, Boston</style></auth-address><titles><title><style face="normal" font="Arial">Ditching the Itch with Anti-Type 2 Cytokine Therapies for Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="879" start="878">878-879</pages><volume><style face="normal" font="Arial">376</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170301IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - EditorialPT - CommentRN - 0 (Cytokines)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMe1616072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28249132">PM:28249132</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-376-878-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-376-878-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170301, Schneider LC</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMe1616072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brown,R.C.</style></author><author><style face="normal" font="Arial"> Yong,L.C.</style></author><author><style face="normal" font="Arial"> Gray,A.R.</style></author><author><style face="normal" font="Arial"> Tey,S.L.</style></author><author><style face="normal" font="Arial"> Chisholm,A.</style></author><author><style face="normal" font="Arial"> Leong,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Human Nutrition, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.</style></auth-address><titles><title><style face="normal" font="Arial">Perceptions and Knowledge of Nuts amongst Health Professionals in New Zealand</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="220">220-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dietitian</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health benefit</style></keyword><keyword><style face="normal" font="Arial"> Health benefits</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Selenium</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Gain</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">Despite their nutritional value, population-level nut consumption remains low. Studies suggest that individuals would eat more nuts on their doctor's advice, making health professionals potentially important for promoting nut consumption. This cross-sectional study aimed to examine the perceptions and knowledge of nuts and the predictors of nut promotion among health professionals in New Zealand. Dietitians, general practitioners (GPs), and practice nurses were identified from the Electoral Roll and invited to complete a questionnaire (n = 318, 292, and 149 respondents respectively). Over one-fifth of GPs and practice nurses believed that eating nuts could increase blood cholesterol concentrations and cause weight gain. The most common perceptions overall were that nuts are healthy; high in protein, fat, and calories; and are satiating. Nut consumption was recommended for reasons relating to these perceptions and because of nuts' selenium content. Conversely, reasons for suggesting the consumption of fewer nuts included that they were high in calories and fat, would cause weight gain, and concerns regarding allergies and cost. All groups of health professionals were more likely to promote nut consumption if they perceived nuts to reduce the risk of diabetes (all p &lt;/= 0.034). Education could improve health professionals' knowledge regarding the effects of nut consumption on blood cholesterol and body weight, alongside other health benefits, which should improve the advice given to patients and may thereby increase nut consumption</style></abstract><notes><style face="normal" font="Arial">DA - 20170303IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9030220</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28257045">PM:28257045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-220.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-220.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170303, Brown RC</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9030220</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhanapala,P.</style></author><author><style face="normal" font="Arial"> Withanage-Dona,D.</style></author><author><style face="normal" font="Arial"> Tang,M.L.</style></author><author><style face="normal" font="Arial"> Doran,T.</style></author><author><style face="normal" font="Arial"> Suphioglu,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Neuro Allergy Research Laboratory (NARL), School of Life and Environmental Sciences, Faculty of Science, Engineering and Built Environment, Deakin University, 75 Pigdons Road, Geelong 3216 VIC, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Hypoallergenic Variant of the Major Egg White Allergen Gal d 1 Produced by Disruption of Cysteine Bridges</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="171">171-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alanine</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Gal d 1</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic variant</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic variants</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutagenesis</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Sodium Dodecyl Sulfate</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Gal d 1 (ovomucoid) is the dominant allergen in the chicken egg white. Hypoallergenic variants of this allergen can be used in immunotherapy as an egg allergy treatment approach. We hypothesised that disruption of two of the nine cysteine-cysteine bridges by site-directed mutagenesis will allow the production of a hypoallergenic variant of the protein; Methods: Two cysteine residues at C192 and C210 in domain III of the protein were mutated to alanine using site-directed mutagenesis, to disrupt two separate cysteine-cysteine bridges. The mutated and non-mutated proteins were expressed in Escherichia coli (E. coli) by induction with isopropyl beta-d-1-thiogalactopyranoside (IPTG). The expressed proteins were analysed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting to confirm expression. Immunoglobulin E (IgE) reactivity of the two proteins was analysed, by immunoblotting, against a pool of egg-allergic patients' sera. A pool of non-allergic patients' sera was also used in a separate blot as a negative control; Results: Mutant Gal d 1 showed diminished IgE reactivity in the immunoblot by showing lighter bands when compared to the non-mutated version, although there was more of the mutant protein immobilised on the membrane when compared to the wild-type protein. The non-allergic negative control showed no bands, indicating an absence of non-specific binding of secondary antibody to the proteins; Conclusion: Disruption of two cysteine bridges in domain III of Gal d 1 reduces IgE reactivity. Following downstream laboratory and clinical testing, this mutant protein can be used in immunotherapy to induce tolerance to Gal d 1 and in egg allergy diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170223IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9020171</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28230769">PM:28230769</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-171.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-171.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Dhanapala P</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9020171</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83584</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chaker,A.M.</style></author><author><style face="normal" font="Arial"> Zissler,U.M.</style></author><author><style face="normal" font="Arial"> Wagenmann,M.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology and Head and Neck Surgery, Medical School, Technical University of Munich, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Biomarkers in Allergic Airway Disease: Simply Complex</style></title><secondary-title><style face="normal" font="Arial">ORL J Otorhinolaryngol Relat Spec</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ORL J Otorhinolaryngol Relat Spec</style></full-title></periodical><pages end="77" start="72">72-77</pages><volume><style face="normal" font="Arial">79</style></volume><number><style face="normal" font="Arial">1-2</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergen</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergen diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergens</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">Clinical diagnoses of allergic airway disease need confirmation of a relevant sensitization to allergens. Serum-based component-resolved diagnosis has become increasingly popular and allows the precise assessment of specific IgE to molecular allergens. Molecular allergen diagnosis has improved our understanding of disease phenotypes in allergic patients, including cross-reactive patterns and food allergy. Beyond sensitization profiles, characterization of the (endo-)type and severity of a local allergic disease is useful for targeted therapy with biologics in advanced allergic airway disease. Surrogate markers of treatment efficacy are increasingly under validation. Prognostic and predictive biomarkers will represent a promising option for stratified prevention strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20170223IS - 1423-0275 (Electronic)IS - 0301-1569 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000455725</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28231574">PM:28231574</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\ORL J Otorhinolaryngol Relat Spec\2017-79-72-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\ORL J Otorhinolaryngol Relat Spec\2017-79-72-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170223, Chaker AM</style></custom2><misc3><style face="normal" font="Arial">10.1159/000455725</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camps-Bossacoma,M.</style></author><author><style face="normal" font="Arial"> Perez-Cano,F.J.</style></author><author><style face="normal" font="Arial"> Franch,A.</style></author><author><style face="normal" font="Arial"> Castell,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Physiology, Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain; Nutrition and Food Safety Research Institute (INSA-UB), 08921 Santa Coloma de Gramenet, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Gut Microbiota in a Rat Oral Sensitization Model: Effect of a Cocoa-Enriched Diet</style></title><secondary-title><style face="normal" font="Arial">Oxid Med Cell Longev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oxid Med Cell Longev</style></full-title></periodical><pages end="" start="7417505">7417505-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cocoa</style></keyword><keyword><style face="normal" font="Arial"> Cyanobacteria</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Firmicutes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Oral sensitization</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Increasing evidence is emerging suggesting a relation between dietary compounds, microbiota, and the susceptibility to allergic diseases, particularly food allergy. Cocoa, a source of antioxidant polyphenols, has shown effects on gut microbiota and the ability to promote tolerance in an oral sensitization model. Taking these facts into consideration, the aim of the present study was to establish the influence of an oral sensitization model, both alone and together with a cocoa-enriched diet, on gut microbiota. Lewis rats were orally sensitized and fed with either a standard or 10% cocoa diet. Faecal microbiota was analysed through metagenomics study. Intestinal IgA concentration was also determined. Oral sensitization produced few changes in intestinal microbiota, but in those rats fed a cocoa diet significant modifications appeared. Decreased bacteria from the Firmicutes and Proteobacteria phyla and a higher percentage of bacteria belonging to the Tenericutes and Cyanobacteria phyla were observed. In conclusion, a cocoa diet is able to modify the microbiota bacterial pattern in orally sensitized animals. As cocoa inhibits the synthesis of specific antibodies and also intestinal IgA, those changes in microbiota pattern, particularly those of the Proteobacteria phylum, might be partially responsible for the tolerogenic effect of cocoa</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 1942-0994 (Electronic)IS - 1942-0994 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/7417505</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28239436">PM:28239436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oxid Med Cell Longev\2017-2017-7417505.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oxid Med Cell Longev\2017-2017-7417505.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Camps-Bossacoma M</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/7417505</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fernandez,P.G.</style></author><author><style face="normal" font="Arial"> Mikhael,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USADepartment of Anesthesia and Pain Management, Cook County Hospital, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="Arial">Perioperative considerations for the food-allergic pediatric patient</style></title><secondary-title><style face="normal" font="Arial">Paediatr Anaesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Paediatr Anaesth</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food intolerance</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Pain Management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="Arial">Patients with a history of food allergy and food intolerance are common in the pediatric population and are encountered frequently in the perioperative setting by pediatric anesthesiologists. Perioperatively, food allergy can present on a spectrum ranging from minor acute urticaria to more severe hypovolemia and anaphylactic shock. Allergy to foods including fruits, fish, egg, soy, and peanut are most concerning for their potential to cross-react with perioperative medications. There is little in the anesthesia literature that focuses on the perioperative management of children with food allergies. This educational review will provide a brief overview of classic immunoglobulin E (IgE)-mediated food allergies, less common non-IgE food allergies, and present perioperative considerations for these patients. An audio summary of this topic is included as Supplementary Audio S1</style></abstract><notes><style face="normal" font="Arial">DA - 20170228IS - 1460-9592 (Electronic)IS - 1155-5645 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pan.13131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28244622">PM:28244622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Paediatr Anaesth\20170228-FernandezPG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Paediatr Anaesth\20170228-FernandezPG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170228, Fernandez PG</style></custom2><misc3><style face="normal" font="Arial">10.1111/pan.13131</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matangkasombut,P.</style></author><author><style face="normal" font="Arial"> Padungpak,S.</style></author><author><style face="normal" font="Arial"> Thaloengsok,S.</style></author><author><style face="normal" font="Arial"> Kamchaisatian,W.</style></author><author><style face="normal" font="Arial"> Sasisakulporn,C.</style></author><author><style face="normal" font="Arial"> Jotikasthira,W.</style></author><author><style face="normal" font="Arial"> Benjaponpitak,S.</style></author><author><style face="normal" font="Arial"> Manuyakorn,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Microbiology, Faculty of Science , Mahidol University , Bangkok , Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Detection of beta-lactoglobulin in human breast-milk 7 days after cow milk ingestion</style></title><secondary-title><style face="normal" font="Arial">Paediatr Int Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Paediatr Int Child Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: beta-lactoglobulin (BLG), a major allergen in cow milk (CM) can be detected in human breast-milk (BM) and is associated with exacerbation of symptoms in breastfed infants with cow milk protein allergy (CMPA). Currently, it is not known how long lactating mothers who consume dairy products need to withhold breastfeeding. OBJECTIVE: To elucidate the kinetics of BLG in BM after maternal ingestion of a single dose of CM. METHODS: Nineteen lactating mothers, four of whom had infants with CMPA, were instructed to avoid CM for 7 days before ingesting a single dose of CM and to continue to withhold CM thereafter throughout the study period. BLG was measured by ELISA in BM from 15 mothers of healthy infants before and at 3, 6 and 24 h, and 3 and 7 days after CM ingestion. Four pairs of mothers and CMPA infants were enrolled for BM challenge after the mothers had ingested CM. RESULTS: After CM ingestion, the level of BLG in BM increased significantly from 0.58 ng/ml (0.58 g/L) (IQR 0.38-0.88) to a peak level of 1.23 ng/ml (IQR 1.03-2.29), p &lt; 0.001. The BLG level on day 3 (1.15 ng/ml, IQR 0.89-1.45) and day 7 (1.08 ng/ml (IQR 0.86-1.25) after CM ingestion was significantly higher than baseline (p = 0.01 and p = 0.001, respectively). BLG was detected in all BM samples from the four mothers of CMPA infants after CM ingestion, and the level was not different from that in the mothers of the 15 healthy infants. Three of the four CMPA infants developed symptoms such as maculopapular rash and hypersecretion in the airways after BM challenge. CONCLUSIONS: BLG can be detected in BM up to 7 days after CM ingestion. Lactating mothers should suspend breastfeeding to CMPA infants more than 7 days after CM ingestion</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 2046-9055 (Electronic)IS - 2046-9047 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1080/20469047.2017.1289310</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28222656">PM:28222656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Paediatr Int Child Health\20170222-MatangkasombutP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Paediatr Int Child Health\20170222-MatangkasombutP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Matangkasombut P</style></custom2><misc3><style face="normal" font="Arial">10.1080/20469047.2017.1289310</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turkalj,M.</style></author><author><style face="normal" font="Arial"> Banic,I.</style></author><author><style face="normal" font="Arial"> Anzic,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital Srebrnjak, Zagreb; Faculty of Medicine, JJ Strossmayer University of Osijek, Osijek, Croatia</style></auth-address><titles><title><style face="normal" font="Arial">A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia)</style></title><secondary-title><style face="normal" font="Arial">Patient Prefer Adherence</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Patient Prefer Adherence</style></full-title></periodical><pages end="257" start="247">247-257</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> disease-modifying effect</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modified allergens</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient adherence</style></keyword><keyword><style face="normal" font="Arial"> Patient Education</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> synthetic peptides</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis is a common health problem in both children and adults. The number of patients allergic to ragweed (Ambrosia artemisiifolia) is on the rise throughout Europe, having a significant negative impact on the patients' and their family's quality of life. Allergen-specific immunotherapy (AIT) has disease-modifying effects and can induce immune tolerance to allergens. Both subcutaneous immunotherapy and sublingual immunotherapy with ragweed extracts/preparations have clear positive clinical efficacy, especially over pharmacological treatment, even years after the treatment has ended. AIT also has very good safety profiles with extremely rare side effects, and the extracts/preparations used in AIT are commonly well tolerated by patients. However, patient adherence to treatment with AIT seems to be quite low, mostly due to the fact that treatment with AIT is relatively time-demanding and, moreover, due to patients not receiving adequate information and education about the treatment before it starts. AIT is undergoing innovations and improvements in clinical efficacy, safety and patient adherence, especially with new approaches using new adjuvants, recombinant or modified allergens, synthetic peptides, novel routes of administration (epidermal or intralymphatic), and new protocols, which might make AIT more acceptable for a wider range of patients and novel indications. Patient education and support (eg, recall systems) is one of the most important goals for AIT in the future, to further enhance treatment success</style></abstract><notes><style face="normal" font="Arial">DA - 20170228IS - 1177-889X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Croatia -</style></notes><work-type><style face="normal" font="Arial">10.2147/PPA.S70411</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28243068">PM:28243068</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Patient Prefer Adherence\2017-11-247-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Patient Prefer Adherence\2017-11-247-57.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170228, Turkalj M</style></custom2><misc3><style face="normal" font="Arial">10.2147/PPA.S70411</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Du Toit,G.</style></author><author><style face="normal" font="Arial"> Foong,R.X.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma, Allergy and Lung Biology, Department of Paediatric Allergy, King's College London and Guy's and St. Thomas' NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">The role of dietary interventions in the prevention of IgE-mediated food allergy in children</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="229" start="222">222-229</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><abstract><style face="normal" font="Arial">Over the last 30 years, the prevalence of food allergy has been on the rise and remains a disease that can have a significant impact on the quality of life of children and their families. There are several hypotheses that have been suggested to account for the increasing prevalence but this review will focus on the impact dietary factors have on food allergy development. In the past food allergy prevalence has largely focused on allergen avoidance; however there is increasing evidence from interventional studies that have shown that early introduction to potential food allergens may have a beneficial role in allergy prevention. This review aims to look at the evidence in support of early introduction of allergens into infant diets to prevent against the development of food allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170304IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12711</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258631">PM:28258631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170304-DuToitG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170304-DuToitG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Du Toit G</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12711</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aranda,C.S.</style></author><author><style face="normal" font="Arial"> Wandalsen,G.F.</style></author><author><style face="normal" font="Arial"> Dela Bianca,A.C.</style></author><author><style face="normal" font="Arial"> Moraes,L.</style></author><author><style face="normal" font="Arial"> Lamenha,M.</style></author><author><style face="normal" font="Arial"> Mallol,J.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy, Clinical Immunology and Rheumatology, Federal University of Sao Paulo, Allergy, Clinical,Immunology and Rheumatology, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Wheezing and the first thousand days of life</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="400" start="397">397-400</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">There is a recent discussion on the importance of the first thousand days of a child's life. This period covers from conception to the end of the second year of life (1). Recent studies suggest that this period is an open window for interventions and that such interventions may spread to the rest of life (2,3). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Brazil -CO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12710</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235137">PM:28235137</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170224-ArandaCS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170224-ArandaCS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Aranda CS</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12710</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Y.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Wong,G.W.</style></author><author><style face="normal" font="Arial"> Zhong,N.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical College, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergen sensitization affected the change trend of prevalence of symptoms of rhinitis co-existing with wheeze among adolescents in Guangzhou city from 1994 to 2009</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="347" start="340">340-347</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time trends</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Few studies have assessed the time trends of prevalence of symptoms of rhinitis (SR) with wheezing and their associations in Chinese adolescents. OBJECTIVE: To explore the trend of prevalence of SR with wheezing and allergen sensitization in adolescents during the past 15 years. METHODS: A total of 7165 adolescents aged 13-14 years in 2009 were recruited for the study using the Phase III Protocol of the International Study of Asthma and Allergic disease in Childhood (ISAAC) and allergic sensitization to seven inhalant allergens in 2531 was assessed by skin prick test in 2010. The results were compared to those obtained in the Phase I (1994/95) and III (2001/02) ISAAC studies. RESULTS: The prevalence of "SR ever" and "current symptoms of rhino-conjunctivitis" increased from 46.3% and 8.7% in 1994 to 53.2% and 11.1% in 2001 (P&lt;0.001), respectively, and remained stable at 52.6% and 10.4% in 2009 (P>0.05). The prevalence of "SR ever and wheeze ever" and "SR ever and current wheeze" increased from 6.2% and 3.4% in 1994 to 8.6% and 4.8% in 2001 (P&lt;0.001) to 10.9% and 5.9% (P&lt;0.001). The sensitization rate to common inhaled allergens was higher in 2010 than in 2002 (P&lt;0.001). Sensitization to house dust mites (HDMs) was associated with increases in the prevalence of SR (OR, 2.06-2.86), especially with coexistence of wheeze (OR, 6.07-7.43). CONCLUSION: The prevalence of symptoms of rhinitis and coexistence with wheezing has increased significantly since 1994. Sensitization to HDMs is the main risk factor associated with this increase. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12709</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235144">PM:28235144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170224-ChenY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170224-ChenY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Chen Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12709</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jasser-Nitsche,H.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> Borkenstein,H.M.</style></author><author><style face="normal" font="Arial"> Hontzsch,J.</style></author><author><style face="normal" font="Arial"> Suppan,E.</style></author><author><style face="normal" font="Arial"> Weinhandl,G.</style></author><author><style face="normal" font="Arial"> Pieringer,L.</style></author><author><style face="normal" font="Arial"> Avian,A.</style></author><author><style face="normal" font="Arial"> Frohlich-Reiterer,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of General Pediatrics, Medical University of Graz, Graz, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Type 1 diabetes in children and adolescents is not associated with a reduced prevalence of atopy and allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Pediatr Diabetes</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Diabetes</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> type 1 diabetes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Type 1 diabetes mellitus (T1D) as well as allergies in childhood have increased worldwide during the last 2 decades. The reasons for this increase are still unknown but early life origins are being discussed, such as dietary and hygiene factors that may play a role in the development of both diseases. The aim of this study was to compare the prevalence of allergies in children with and without T1D and to define potential influencing factors. MATERIALS AND METHODS: Data were collected from 104 patients with T1D (n = 104; mean age 11.4 +/- 4.4 years; m/f: 77/27) and 104 healthy controls (CG) (n = 104; mean age 11.4 +/- 4.3 years; m/f: 77/27). A questionnaire on allergic symptoms was obtained from each individual. In parallel, ImmunoCAP tests to detect specific allergen sensitization were performed. RESULTS: Allergen sensitization rates were not significantly different between both groups (T1D: 42% vs CG 38%; P = 0.625). In both groups, a comparable number of patients reported allergic symptoms in the questionnaire (T1D: 20% vs CG 26%; P = 0.43). Allergen sensitization and allergic symptoms were independent of breastfeeding, pets at home or diabetes duration. However, in T1D, fewer family members smoked (T1D: 10% vs CG 56%; P &lt; 0.001). CONCLUSIONS: The present cohort study shows the same prevalence of allergy and atopy in a pediatric diabetes population compared to healthy controls. Diabetes per se does not seem to influence the development of allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 1399-5448 (Electronic)IS - 1399-543X (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/pedi.12504</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28239959">PM:28239959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Diabetes\20170227-JasserNitscheH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Diabetes\20170227-JasserNitscheH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Jasser-Nitsche H</style></custom2><misc3><style face="normal" font="Arial">10.1111/pedi.12504</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83593</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ballardini,N.</style></author><author><style face="normal" font="Arial"> Nopp,A.</style></author><author><style face="normal" font="Arial"> Hamsten,C.</style></author><author><style face="normal" font="Arial"> Vetander,M.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Nilsson,C.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Flohr,C.</style></author><author><style face="normal" font="Arial"> Kuehn,A.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Environmental Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylactic Reactions to Novel Foods: Case Report of a Child With Severe Crocodile Meat Allergy</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20161404">e20161404-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Chicken meat</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> novel foods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Homology</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Travel</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">Availability of "exotic" foods is steadily increasing. In this report, we describe the first case of anaphylaxis to crocodile meat. The patient was a 13-year-old boy with severe immunoglobulin E-mediated allergy to chicken meat. When tasting crocodile meat for the first time, he developed an anaphylactic reaction. Cross-reactivity between chicken and crocodile meat was suspected to have triggered this reaction. Basophil activation and immunoglobulin E testing confirmed the boy's allergic reaction to crocodile meat proteins. Molecular analysis identified a crocodile alpha-parvalbumin, with extensive sequence homology to chicken alpha-parvalbumin, as the main cross-reactive allergen. We conclude that crocodile meat can be a potent food allergen and patients with allergy to chicken meat should be advised to avoid intake of meat from crocodile species. Both foods and people travel around the world and accessibility to exotic foods is steadily growing. As a result, novel allergic cross-reactivities are likely to become a challenge in the management of food allergy and, as our report illustrates, cross-reactivity has to be considered even between foods that might not intuitively be perceived as related</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United KIngdom -CO - Denmark -CO - Luxembourg -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2016-1404</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28275203">PM:28275203</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\20170309-BallardiniN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\20170309-BallardiniN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Ballardini N</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2016-1404</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83594</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tonacci,A.</style></author><author><style face="normal" font="Arial"> Billeci,L.</style></author><author><style face="normal" font="Arial"> Pioggia,G.</style></author><author><style face="normal" font="Arial"> Navarra,M.</style></author><author><style face="normal" font="Arial"> Gangemi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Physiology Institute, National Research Council of Italy (IFC-CNR), via Moruzzi 1, 56124, Pisa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature</style></title><secondary-title><style face="normal" font="Arial">Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharmacotherapy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Caribbean</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">Omalizumab is recombinant humanized monoclonal antibody to immunoglobulin E. Guidelines for the treatment of chronic idiopathic urticaria (also known as chronic spontaneous urticaria) recommend the use of omalizumab as third-line therapy in addition to high doses of histamine receptor type 1 (H1 ) antihistamines when they are unsuccessful as first- and second-line therapy. We performed a systematic review of the literature to identify studies that evaluated the efficacy of omalizumab for the treatment of chronic idiopathic urticaria, both in controlled and real-world settings, to assess its potential role as a preferred therapy. The PubMed, ScienceDirect, LILACS (Latin American and Caribbean Health Sciences Literature), and Google Scholar databases were searched between January 1, 2000 and November 21, 2016. The search was limited to articles published in peer-reviewed journals in the English language, and 29 studies were included in this review. Omalizumab 300 mg administered every 4 weeks appears to be the most effective and safe dosage, with a rapid response time, for the treatment of chronic idiopathic urticaria, with few minor adverse effects, and appears to be safe in the offspring of pregnant patients who received the drug. However, as published studies of omalizumab are sparse, future studies are warranted. When findings are confirmed in larger studies, due to its efficacy, safety, and increased benefit/cost ratio, omalizumab could become the preferred method of treatment for chronic idiopathic urticaria in patients unresponsive to H1 antihistamines. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1875-9114 (Electronic)IS - 0277-0008 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1002/phar.1915</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28226418">PM:28226418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharmacotherapy\20170222-TonacciA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharmacotherapy\20170222-TonacciA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Tonacci A</style></custom2><misc3><style face="normal" font="Arial">10.1002/phar.1915</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kassas-Guediri,A.</style></author><author><style face="normal" font="Arial"> Coudrat,J.</style></author><author><style face="normal" font="Arial"> Pacreau,E.</style></author><author><style face="normal" font="Arial"> Launay,P.</style></author><author><style face="normal" font="Arial"> Monteiro,R.C.</style></author><author><style face="normal" font="Arial"> Blank,U.</style></author><author><style face="normal" font="Arial"> Charles,N.</style></author><author><style face="normal" font="Arial"> Benhamou,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">INSERM U1149, Faculte de Medecine Xavier Bichat, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Phospholipid scramblase 1 amplifies anaphylactic reactions in vivo</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0173815">e0173815-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> high affinity receptor for immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> the high-affinity receptor for immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Mast cells are critical actors of hypersensitivity type I (allergic) reactions by the release of vasoactive and proinflammatory mediators following their activation by aggregation of the high-affinity receptor for immunoglobulin E (FcepsilonRI). We have previously identified Phospholipid Scramblase 1 (PLSCR1) as a new molecular intermediate of FcepsilonRI signaling that amplifies degranulation of the rat mast cell line RBL-2H3. Here we characterized primary mast cells from Plscr1-/- mice. The absence of PLSCR1 expression did not impact mast cell differentiation as evidenced by unaltered FcepsilonRI expression, general morphology, amount of histamine stored and expression of FcepsilonRI signal effector molecules. No detectable mast cell deficiency was observed in Plscr1-/- adult mice. In dose-response and time-course experiments, primary cultures of mast cells (bone marrow-derived mast cells and peritoneal cell-derived mast cells) generated from Plscr1-/- mice exhibited a reduced release of beta-hexosaminidase upon FcepsilonRI engagement as compared to their wild-type counterparts. In vivo, Plscr1-/- mice were protected in a model of passive systemic anaphylaxis when compared to wild-type mice, which was consistent with an observed decrease in the amounts of histamine released in the serum of Plscr1-/- mice during the reaction. Therefore, PLSCR1 aggravates anaphylactic reactions by increasing FcepsilonRI-dependent mast cell degranulation. PLSCR1 could be a new therapeutic target in allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0173815</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28282470">PM:28282470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0173815.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0173815.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Kassas-Guediri A</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0173815</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Penberthy,K.K.</style></author><author><style face="normal" font="Arial"> Buckley,M.W.</style></author><author><style face="normal" font="Arial"> Arandjelovic,S.</style></author><author><style face="normal" font="Arial"> Ravichandran,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, Virginia, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Ex vivo modulation of the Foxo1 phosphorylation state does not lead to dysfunction of T regulatory cells</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0173386">e0173386-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Okadaic Acid</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Peripheral regulatory CD4+ T cells (Treg cells) prevent maladaptive inflammatory responses to innocuous foreign antigens. Treg cell dysfunction has been linked to many inflammatory diseases, including allergic airway inflammation. Glucocorticoids that are used to treat allergic airway inflammation and asthma are thought to work in part by promoting Treg cell differentiation; patients who are refractory to these drugs have defective induction of anti-inflammatory Treg cells. Previous observations suggest that Treg cells deficient in the transcription factor FoxO1 are pro-inflammatory, and that FoxO1 activity is regulated by its phosphorylation status and nuclear localization. Here, we asked whether altering the phosphorylation state of FoxO1 through modulation of a regulatory phosphatase might affect Treg cell function. In a mouse model of house dust mite-induced allergic airway inflammation, we observed robust recruitment of Treg cells to the lungs and lymph nodes of diseased mice, without an apparent increase in the Treg cytokine interleukin-10 in the airways. Intriguingly, expression of PP2A, a serine/threonine phosphatase linked to the regulation of FoxO1 phosphorylation, was decreased in the mediastinal lymph nodes of HDM-treated mice, mirroring the decreased PP2A expression seen in peripheral blood monocytes of glucocorticoid-resistant asthmatic patients. When we asked whether modulation of PP2A activity alters Treg cell function via treatment with the PP2A inhibitor okadaic acid, we observed increased phosphorylation of FoxO1 and decreased nuclear localization. However, dysregulation of FoxO1 did not impair Treg cell differentiation ex vivo or cause Treg cells to adopt a pro-inflammatory phenotype. Moreover, inhibition of PP2A activity did not affect the suppressive function of Treg cells ex vivo. Collectively, these data suggest that modulation of the phosphorylation state of FoxO1 via PP2A inhibition does not modify Treg cell function ex vivo. Our data also highlight the caveat in using ex vivo assays of Treg cell differentiation and function, in that while these assays are useful, they may not fully recapitulate Treg cell phenotypes that are observed in vivo</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0173386</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28267764">PM:28267764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0173386.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0173386.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Penberthy KK</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0173386</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abramovitch,J.B.</style></author><author><style face="normal" font="Arial"> Lopata,A.L.</style></author><author><style face="normal" font="Arial"> O'hehir,R.E.</style></author><author><style face="normal" font="Arial"> Rolland,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Effect of thermal processing on T cell reactivity of shellfish allergens - Discordance with IgE reactivity</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0173549">e0173549-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Banana</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> Crabs</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustacean allergen</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte Subsets</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Prawn</style></keyword><keyword><style face="normal" font="Arial"> Prawns</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell reactivity</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> TIGER</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Crustacean allergy is a major cause of food-induced anaphylaxis. We showed previously that heating increases IgE reactivity of crustacean allergens. Here we investigate the effects of thermal processing of crustacean extracts on cellular immune reactivity. Raw and cooked black tiger prawn, banana prawn, mud crab and blue swimmer crab extracts were prepared and IgE reactivity assessed by ELISA. Mass spectrometry revealed a mix of several allergens in the raw mud crab extract but predominant heat-stable tropomyosin in the cooked extract. PBMC from crustacean-allergic and non-atopic control subjects were cultured with the crab and prawn extracts and proliferation of lymphocyte subsets was analysed by CFSE labelling and flow cytometry. Effector responses were assessed by intracellular IL-4 and IFN-gamma, and regulatory T (CD4+CD25+CD127loFoxp3+) cell proportions in cultures were also compared by flow cytometry. For each crustacean species, the cooked extract had greater IgE reactivity than the raw (mud crab p&lt;0.05, other species p&lt;0.01). In contrast, there was a trend for lower PBMC proliferative responses to cooked compared with raw extracts. In crustacean-stimulated PBMC cultures, dividing CD4+ and CD56+ lymphocytes showed higher IL-4+/IFN-gamma+ ratios for crustacean-allergic subjects than for non-atopics (p&lt;0.01), but there was no significant difference between raw and cooked extracts. The percentage IL-4+ of dividing CD4+ cells correlated with total and allergen-specific IgE levels (prawns p&lt;0.01, crabs p&lt;0.05). Regulatory T cell proportions were lower in cultures stimulated with cooked compared with raw extracts (mud crab p&lt;0.001, banana prawn p&lt;0.05). In conclusion, cooking did not substantially alter overall T cell proliferative or cytokine reactivity of crustacean extracts, but decreased induction of Tregs. In contrast, IgE reactivity of cooked extracts was increased markedly. These novel findings have important implications for improved diagnostics, managing crustacean allergy and development of future therapeutics. Assessment of individual allergen T cell reactivity is required</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0173549</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273149">PM:28273149</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0173549.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0173549.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Abramovitch JB</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0173549</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohanty,R.P.</style></author><author><style face="normal" font="Arial"> Buchheim,M.A.</style></author><author><style face="normal" font="Arial"> Anderson,J.</style></author><author><style face="normal" font="Arial"> Levetin,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biological Sciences, The University of Tulsa, Tulsa, Oklahoma, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Molecular analysis confirms the long-distance transport of Juniperus ashei pollen</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0173465">e0173465-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Backward trajectories</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Juniperus</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Long-distance transport</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Oklahoma</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Although considered rare, airborne pollen can be deposited far from its place of origin under a confluence of favorable conditions. Temporally anomalous records of Cupressacean pollen collected from January air samples in London, Ontario, Canada have been cited as a new case of long-distance transport. Data on pollination season implicated Juniperus ashei (mountain cedar), with populations in central Texas and south central Oklahoma, as the nearest source of the Cupressacean pollen in the Canadian air samples. This finding is of special significance given the allergenicity of mountain cedar pollen. While microscopy is used extensively to identify particles in the air spora, pollen from all members of the Cupressaceae, including Juniperus, are morphologically indistinguishable. Consequently, we implemented a molecular approach to characterize Juniperus pollen using PCR in order to test the long-distance transport hypothesis. Our PCR results using species-specific primers confirmed that the anomalous Cupressacean pollen collected in Canada was from J. ashei. Forward trajectory analysis from source areas in Texas and the Arbuckle Mountains in Oklahoma and backward trajectory analysis from the destination area near London, Ontario were completed using models implemented in HYSPLIT4 (Hybrid Single-Particle Lagrangian Integrated Trajectory). Results from these trajectory analyses strongly supported the conclusion that the J. ashei pollen detected in Canada had its origins in Texas or Oklahoma. The results from the molecular findings are significant as they provide a new method to confirm the long-distance transport of pollen that bears allergenic importance</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0173465</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273170">PM:28273170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0173465.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0173465.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Mohanty RP</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0173465</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakajima-Adachi,H.</style></author><author><style face="normal" font="Arial"> Shibahara,K.</style></author><author><style face="normal" font="Arial"> Fujimura,Y.</style></author><author><style face="normal" font="Arial"> Takeyama,J.</style></author><author><style face="normal" font="Arial"> Hiraide,E.</style></author><author><style face="normal" font="Arial"> Kikuchi,A.</style></author><author><style face="normal" font="Arial"> Murakami,H.</style></author><author><style face="normal" font="Arial"> Hosono,A.</style></author><author><style face="normal" font="Arial"> Nochi,T.</style></author><author><style face="normal" font="Arial"> Wakatsuki,Y.</style></author><author><style face="normal" font="Arial"> Shimojo,N.</style></author><author><style face="normal" font="Arial"> Kaminogawa,S.</style></author><author><style face="normal" font="Arial"> Sato,R.</style></author><author><style face="normal" font="Arial"> Kiyono,H.</style></author><author><style face="normal" font="Arial"> Hachimura,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Critical role of intestinal interleukin-4 modulating regulatory T cells for desensitization, tolerance, and inflammation of food allergy</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0172795">e0172795-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptor</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptors</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Loss</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: The mechanism inducing either inflammation or tolerance to orally administered food allergens remains unclear. To investigate this we analyzed mouse models of food allergy (OVA23-3) and tolerance (DO11.10 [D10]), both of which express ovalbumin (OVA)-specific T-cell receptors. METHODS: OVA23-3, recombination activating gene (RAG)-2-deficient OVA23-3 (R23-3), D10, and RAG-2-deficient D10 (RD10) mice consumed a diet containing egg white (EW diet) for 2-28 days. Interleukin (IL)-4 production by CD4+ T cells was measured as a causative factor of enteropathy, and anti-IL-4 antibody was used to reveal the role of Foxp3+ OVA-specific Tregs (aiTreg) in this process. RESULTS: Unlike OVA23-3 and R23-3 mice, D10 and RD10 mice did not develop enteropathy and weight loss on the EW diet. On days 7-10, in EW-fed D10 and RD10 mice, splenic CD4+ T cells produced significantly more IL-4 than did those in the mesenteric lymph nodes (MLNs); this is in contrast to the excessive IL-4 response in the MLNs of EW-fed OVA23-3 and R23-3 mice. EW-fed R23-3 mice had few aiTregs, whereas EW-fed RD10 mice had them in both tissues. Intravenous injections of anti-IL-4 antibody recovered the percentage of aiTregs in the MLNs of R23-3 mice. On day 28, in EW-fed OVA23-3 and R23-3 mice, expression of Foxp3 on CD4+ T cells corresponded with recovery from inflammation, but recurrence of weight loss was observed on restarting the EW diet after receiving the control-diet for 1 month. No recurrence developed in D10 mice. CONCLUSIONS: Excessive IL-4 levels in the MLNs directly inhibited the induction of aiTregs and caused enteropathy. The aiTregs generated in the attenuation of T cell-dependent food allergic enteropathy may function differently than aiTregs induced in a tolerance model. Comparing the two models enables to investigate their aiTreg functions and to clarify differences between inflammation with subsequent desensitization versus tolerance</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0172795</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234975">PM:28234975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0172795.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0172795.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Nakajima-Adachi H</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0172795</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grzybowska-Chlebowczyk,U.</style></author><author><style face="normal" font="Arial"> Horowska-Ziaja,S.</style></author><author><style face="normal" font="Arial"> Kajor,M.</style></author><author><style face="normal" font="Arial"> Wiecek,S.</style></author><author><style face="normal" font="Arial"> Chlebowczyk,W.</style></author><author><style face="normal" font="Arial"> Wos,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Eosinophilic colitis in children</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="59" start="52">52-59</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic colitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disease</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic gastrointestinal diseases</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Diseases</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1642-395X</style></isbn><abstract><style face="normal" font="Arial">Introduction: Eosinophilic colitis, which is a rare form of eosinophilic gastrointestinal diseases, occurs as primary and secondary allergic eosinophilic colitis of the gastrointestinal tract infection, inflammatory bowel disease, celiac disease, and vasculitis. The diagnosis is based on a significant amount of eosinophils in the inflammatory infiltrate of the colon wall. Aim: To analyze the clinical picture taking into account comorbidities and endoscopic picture in children with eosinophilic colitis. Material and methods : The test group consisted of 43 children, the average age </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô 12.1 years diagnosed with eosinophilic colitis (according to the Whitington scale) hospitalized in the Gastroenterology Unit, Department of Pediatrics of the Medical University of Silesia in Katowice. Testing for food allergies, celiac disease, inflammatory bowel disease, gastrointestinal diseases and parasitic diseases was performed in the group of children and the analysis concerned the intensity of eosinophilic infiltration of the colon mucosa with the severity of clinical symptoms, endoscopic picture, the presence of inflammatory bowel disease, and food allergy. Results: Half of the tested children suffered from isolated eosinophilic colitis but the rest of them had eosinophilic infiltrate with inflammatory bowel disease more often, however, the Crohn</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs disease. The endoscopic image was uncharacteristic, and grade III in the Whitington scale was predominant in the histopathological examination, in most cases located in the entire large intestine. The higher level of total IgE was found in less than half of the patients and it did not correlate with the severity of eosinophilic infiltration. It was shown that the severity of eosinophilic infiltration correlated with exacerbation of clinical symptoms, endoscopic image, and the presence of inflammatory bowel disease. The higher level of antibodies of ASCA and ANCA was found in approximately 20% of the children with isolated eosinophilic colitis and 63% of children with Crohn</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs disease. Conclusions : The higher concentration of total IgE in less than half of the patients with eosinophilic colitis indicates the need for improving allergy diagnosis also in terms of IgE-independent allergy. The presence of higher levels of antibodies of ASCA and ANCA in some of the patients with isolated eosinophilic colitis indicates the need for further observation for the occurrence of inflammatory bowel disease</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2017.65622</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5114/ada.2017.65622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-52-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-52-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Grzybowska-Chlebowczyk U</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2017.65622</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martins,L.M.</style></author><author><style face="normal" font="Arial"> Marques,A.G.</style></author><author><style face="normal" font="Arial"> Pereira,L.M.</style></author><author><style face="normal" font="Arial"> Semiao-Santos,S.J.</style></author><author><style face="normal" font="Arial"> Bento,O.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy to grass pollen: mapping of Dactylis glomerata and Phleum pratense allergens for dogs by two-dimensional immunoblotting</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="69" start="60">60-69</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Dactylis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IEF</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Isoelectric Focusing</style></keyword><keyword><style face="normal" font="Arial"> Membranes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular epidemiology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> two-dimensional immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1642-395X</style></isbn><abstract><style face="normal" font="Arial">Introduction: Much less is known about grass-pollen allergens to dogs, when compared with humans. Genetic-based patterns might play an important role in sensitization profiles, conditioning the success of allergen-specific immunotherapy. Aim : Mapping of Dactylis glomerata ( D. glomerata ) and Phleum pratense ( P. pratense ) allergens for grass pollen-sensitized atopic dogs, for better understanding how individual allergograms may influence the response to grass-pollen immunotherapy. Material and methods : To identify D. glomerata and P. pratense allergoms for dogs, 15 individuals allergic to grass pollen and sensitized to D. glomerata and P. pratense were selected. D. glomerata and P. pratense proteomes were separated by isoelectric focusing (IEF), one-dimensional (1-D) and two-dimensional (2-D) sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were blotted onto Polyvinylidene difluoride (PVDF) membranes and allergens were identified by patient sera IgE in Western Blotting (WB). Results : In D. glomerata , 17 allergens were identified from IEF and 11 from 1-D SDS-PAGE, while from P. pratense , 18 and 6 allergens were identified, respectively. From 2-D SDS-PAGE 13 spots were identified from D. glomerata and 27 from P. pratense . Conclusions : Several similarities were found between dog and human D. glomerata and P. pratense sensitization profiles but no relationship between clinical signs and a specific pattern of allergen recognition was observed. Similarities were found in each patient pattern of sensitization between D. glomerata and P. pratense , also suggesting cross-reactive phenomena. Further molecular epidemiology approach is needed to understand the role of the sensitization pattern in allergen-specific immunotherapy effectiveness in grass-pollen allergic dogs</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Portugal -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2017.65623</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5114/ada.2017.65623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-60-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-60-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170304, Martins LM</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2017.65623</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomulka,K.</style></author><author><style face="normal" font="Arial"> Wolanczyk-Medrala,A.</style></author><author><style face="normal" font="Arial"> Barg,W.</style></author><author><style face="normal" font="Arial"> Medrala,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food-dependent, exercise-induced anaphylaxis triggered by co-incidence of culprit food, physical effort and a very high dose of ibuprofen or menstruation: a case report</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="88" start="87">87-88</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Menstruation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2017.65629</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5114/ada.2017.65629</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-87-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-87-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Gomulka K</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2017.65629</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nobauer,K.</style></author><author><style face="normal" font="Arial"> Hummel,K.</style></author><author><style face="normal" font="Arial"> Mayrhofer,C.</style></author><author><style face="normal" font="Arial"> Ahrens,M.</style></author><author><style face="normal" font="Arial"> Setyabudi,F.M.</style></author><author><style face="normal" font="Arial"> Eisenacher,M.</style></author><author><style face="normal" font="Arial"> Razzazi-Fazeli,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">VetCore Facility for Research, University of Veterinary Medicine,, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Comprehensive proteomic analysis of Penicillium verrucosum</style></title><secondary-title><style face="normal" font="Arial">Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Shotgun proteomics</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="Arial">Mass spectrometric identification of proteins in species lacking validated sequence information is a major problem in veterinary science. In the present study we used ochratoxin A (OTA) producing Penicillium verrucosum to identify and quantitatively analyse proteins of an organism with yet no protein information available. The work presented here aimed to provide a comprehensive protein identification of P. verrucosum using shotgun proteomics. We were able to identify 3631 proteins in an "ab initio" translated database from DNA sequences of P. verrucosum. Additionally a Sequential Window Acquisition of all Theoretical fragment-ion spectra analysis (SWATH) was done to find differentially regulated proteins at two different time points of the growth curve. We compared the proteins at the beginning (day 3) and at the end of the log phase (day 12). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170307IS - 1615-9861 (Electronic)IS - 1615-9853 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/pmic.201600467</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28267294">PM:28267294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proteomics\20170307-NobauerK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proteomics\20170307-NobauerK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Nobauer K</style></custom2><misc3><style face="normal" font="Arial">10.1002/pmic.201600467</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saji,J.</style></author><author><style face="normal" font="Arial"> Yamamoto,T.</style></author><author><style face="normal" font="Arial"> Arai,M.</style></author><author><style face="normal" font="Arial"> Mineshita,M.</style></author><author><style face="normal" font="Arial"> Miyazawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory Diseases, Department of Internal Medicine, Kawasaki Municipal Tama Hospital, 1-30-37 Syukugawara, Tama-ku, Kawasaki, Kanagawa 214-8525, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of long-term omalizumab therapy in patients with severe asthma</style></title><secondary-title><style face="normal" font="Arial">Respir Investig</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Investig</style></full-title></periodical><pages end="120" start="114">114-120</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intervention Studies</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The efficacy of omalizumab, an anti-immunoglobulin E (IgE) antibody, has been studied in patients with severe bronchial asthma. We conducted a study to evaluate, on the basis of both objective and subjective measures, the efficacy of omalizumab as a long-term therapy in patients with severe and persistent asthma. METHODS: Omalizumab was administered subcutaneously every two or four weeks. The results of pulmonary function tests, Asthma Control Test (ACT) and Asthma Health Questionnaire (AHQ)-33 scores, the dosage of methylprednisolone during the 12-month treatment period, and the number of emergency visits prior to the start of treatment with omalizumab were compared in patients pre- and post-treatment with omalizumab. RESULTS: Fourteen patients were enrolled in the study between June 2010 and February 2012. Ten patients completed the study. With omalizumab treatment, there was no improvement in lung function; however, the number of emergency visits (19.3 before treatment vs. 1.2 after treatment, p=0.020) and the dosage of methylprednisolone (871.5mg before treatment vs. 119.0mg after treatment, p=0.046) decreased significantly. ACT and AHQ-33 scores at 16 weeks after treatment were significantly better than baseline scores. Four patients continued treatment with omalizumab for four years, and a reduction in their corticosteroid usage was noted. CONCLUSIONS: Long-term omalizumab therapy in our patients was found to significantly reduce corticosteroid usage and the number of emergency visits. Long-term omalizumab therapy was effective and might have potential to reduce the frequency of asthma exacerbations. The trial has not been registered because it is not an intervention study</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 2212-5353 (Electronic)IS - 2212-5345 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.resinv.2016.11.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274526">PM:28274526</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Investig\2017-55-114-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Investig\2017-55-114-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Saji J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.resinv.2016.11.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jaumally,B.A.</style></author><author><style face="normal" font="Arial"> Salem,A.M.</style></author><author><style face="normal" font="Arial"> Sagar,A.E.</style></author><author><style face="normal" font="Arial"> Pyrgos,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Medstar Harbor Hospital, 3001 South Hanover Street, Baltimore, MD 21225, United States</style></auth-address><titles><title><style face="normal" font="Arial">Invasive pulmonary aspergillosis in a steroid-dependent asthmatic</style></title><secondary-title><style face="normal" font="Arial">Respir Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med Case Rep</style></full-title></periodical><pages end="159" start="156">156-159</pages><volume><style face="normal" font="Arial">20</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 2213-0071 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmcr.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28275535">PM:28275535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med Case Rep\2017-20-156-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med Case Rep\2017-20-156-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Jaumally BA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmcr.2017.02.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rouge,P.</style></author><author><style face="normal" font="Arial"> Barre,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">New sweeteners: Potential food allergens</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="205" start="203">203-205</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Brazzein</style></keyword><keyword><style face="normal" font="Arial"> Brazzeine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Mabinlin</style></keyword><keyword><style face="normal" font="Arial"> Mabinline</style></keyword><keyword><style face="normal" font="Arial"> Miraculin</style></keyword><keyword><style face="normal" font="Arial"> Miraculine</style></keyword><keyword><style face="normal" font="Arial"> Monellin</style></keyword><keyword><style face="normal" font="Arial"> Monelline</style></keyword><keyword><style face="normal" font="Arial"> Stevia</style></keyword><keyword><style face="normal" font="Arial"> Sweeteners</style></keyword><keyword><style face="normal" font="Arial"> thaumatin</style></keyword><keyword><style face="normal" font="Arial"> Thaumatine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.01.004</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2017.01.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-RougeP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-RougeP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170319, Rouge P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.01.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klein,R.</style></author><author><style face="normal" font="Arial"> Lefevre,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Study of declarative knowledge concerning anaphylaxis among general medical students in Alsace and Lorraine</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="297" start="292">292-297</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergist</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Declarative knowledge</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical students</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Introduction The aim of this study was to assess the declarative knowledge of primary-care interns regarding the diagnosis and management of anaphylaxis. Methods A descriptive observational study among 650-áprimary-care students via an online survey. Results Sixty-six responses were obtained (10.2-á% response rate). A percentage of 62.1-áof primary care students considered training to be inadequate. Only 30.3-á% of them were aware of the recommendations concerning the management of anaphylaxis. Concerning diagnosis, symptoms such as respiratory or digestive signs were not recognised as being evocative of anaphylaxis. Treatment was consistent with the recommendations for grades-á1-áand 3-áon the Ring and Messmer classification, rather than grade-á2. Regarding follow-up, 93.8-á% of respondents referred their patients to an allergist. Conclusion Our work suggests that training in the recognition and management of anaphylaxis requires improvement. The creation of a degree in allergology and the development of postgraduate education will help improve knowledge of this disease</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.12.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.12.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-KleinR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-KleinR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170319, Klein R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.12.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rame,J.M.</style></author><author><style face="normal" font="Arial"> Doc,A.</style></author><author><style face="normal" font="Arial"> Raibaut,J.</style></author><author><style face="normal" font="Arial"> Lalaurie,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food allergy (FA) and mass catering: How to better accommodate allergic schoolchildren? Taking stock of an experience conducted in Franche-Comté, France</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="76" start="67">67-76</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aliment</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Catering</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Local authorities</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> PAI</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Restauration</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> School canteen</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Catering for children with food allergies in school canteens falls entirely within the ambit of the Individualised Meal Project (PAI). Although national educational staff enjoy the support of medical personnel, canteen staff to prepare and occasionally package meals, are employed by local authorities and thus only rarely undergo training in good practices in catering for children with food allergies. The Franche-Comté and Ecology Network (Réseau d'allergologie de Franche-comTé - RAFT) has created and now proposes training for such staff. The present article sets out the methodology of the course, the tools developed, and its evaluation. To date, 23 training sessions have been conducted in the region, and have enabled training of 439 staff members, from institutions dealing with small children to secondary schools. The evaluation questionnaire comprising 11 questions enabling the collection of spontaneous comments, was sent out to 127 of the primary school staff who underwent training. Sixty-one questionnaires (48%) were completed. The majority of staff answering the questionnaire indicated that they had acquired new knowledge, in particular regarding allergen labeling. They have a greater working knowledge of the procedures recommended under the PAI. They felt themselves to be better prepared in catering for children with food allergies. They had a better understanding of the various people involved and after their training, they were able to cater more successfully for children with food allergies without offering separate meals for this population. The success of this project was partly due to the creation of a training course developed over time, with the complete involvement of the actors concerned and within an institutional framework. Further training sessions have been scheduled, and these will be given by RAFT staff members. A partnership programme will soon enable this action to be extended to the entire Bourgogne-Franche-Comté region. It is our hope that the experience acquired in this project may soon be utilised by other regions.</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.10.017</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.10.017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-RameJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-RameJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170319, Rame JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.10.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Demoly,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Dust mite allergy. Diagnosis, management and AIT methods in multiple allergy patients</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="90" start="83">83-90</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergie</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE assays</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mixing</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Multi-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergies</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Poly-allergie</style></keyword><keyword><style face="normal" font="Arial"> Polysensibilisation</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">The majority of patients presenting allergic rhinitis and asthma are sensitised to several allergens. Dust mites are the chief culprits, with the two most important species in France being Dermatophagoides pteronyssinus and Dermatophagoides farinae. Studies indicate that 50 to 70% of patients are multi-sensitised. However, it is important to distinguish between sensitisation and allergy: "sensitisation" is an exclusively biological phenomenon (positive prick-tests or IgE assays), while the term "allergy" implies the existence of clinical symptoms detectable by precise history-taking. Management of dust mite allergies is based upon fastidious elimination of the offending source, suitable symptomatically treatment and allergy immunotherapy (AIT), chiefly by the sublingual route (SLIT). Successful elimination of dust mites depends on the degree of patient sensitisation, the extent of exposure to dust mites, the measures taken, and any other allergies and domestic pollutants present. Removal, which is difficult for dust mites, is random in the case of most other allergens (pollens, moulds, cockroaches, etc.). AIT is the only form of treatment able to modify the immune status of allergic individuals and is indicated in cases of poor control of rhinitis and/or asthma by means of global allergen removal or systematic treatments. In multi-allergic patients, where two sources of allergens are required, these may be administered either in parallel (using two allergen preparations) or in a mixture (using a single preparation). When AIT is given in parallel, for example with dust mites and grass pollens, a recommended interval of 30 minutes should be left between the two allergens. Where AIT is performed using a mixture of allergens within a single preparation, it is recommended that the preparation be made up of a 50/50 mixture of mutually compatible allergen sources. The prescription of multiple AIT underlines the importance of the "dilution factor": mixing several allergens reduces the doses of each allergen in keeping with the number of components used. SLIT is currently the reference pathway, and practically the only approach utilised in children because of its ease of use, as well as the absence of pain and of any serious adverse effects. It must be performed using high-quality standardised allergen extracts with particular attention to the clinical relevance of the allergens used, their safety of use and the patient's quality of life</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.reval.2017.02.004</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2017.02.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-DemolyP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-DemolyP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170319, Demoly P</style></custom2><misc3><style face="normal" font="Arial">http://dx.doi.org/10.1016/j.reval.2017.02.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Grandjean-Ceccon,V.</style></author><author><style face="normal" font="Arial"> Sergeant,P.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Lapeyre-Santos,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Regulation (EU) No. 1169/2011 (FIC-INCO) may help reduce food allergy reactions at school</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="96" start="91">91-96</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergie alimentaire</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Education program</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> FIC Directive</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Food labelling</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> precautionary labelling</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulation 1169/2011</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> School canteen</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic education</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Regulation (EU) No. 1169/2011 (FIC-INCO) updates, simplifies, harmonises and improves information and understanding with regards to food labelling in Europe. It applies to everyone in the food industry, including school canteens. The regulation improves visibility and legibility concerning the 14 allergenic foods that must necessarily be labelled when present in a product. Allergen information on non-prepacked foods must also be made available to consumers. This regulation is designed to facilitate management of children with food allergies attending school, although the readability of the allergen list requires further improvement and use of precautionary labelling must be more clearly circumscribed. Therapeutic education programs for food allergy patients should take into account the information set out in the regulation. It is vital that the public authorities ensure that these provisions are followed in reality and that canteen staff receive training on the correct implementation of the regulation</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.01.002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2017.01.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170319-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170319, Poueesel G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.01.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,H.</style></author><author><style face="normal" font="Arial"> Mo,L.</style></author><author><style face="normal" font="Arial"> Xiao,X.</style></author><author><style face="normal" font="Arial"> An,S.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Ba,J.</style></author><author><style face="normal" font="Arial"> Wu,W.</style></author><author><style face="normal" font="Arial"> Ran,P.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy &amp;Immunology, Shenzhen University School of Medicine, Shenzhen, China</style></auth-address><titles><title><style face="normal" font="Arial">Pplase of Dermatophagoides farinae promotes ovalbumin-induced airway allergy by modulating the functions of dendritic cells in a mouse model</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="43322">43322-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="Arial">Our previous studies revealed that many proteins in addition to the known allergens of D. farinae have not been fully characterized. We observed that Pplase did not respond to serum collected from patients sensitized to D. farinae. In a mouse model, Pplase significantly enhanced airway hyperresponsiveness (AHR) and Th2 responses induced by ovalbumin (OVA) compared with mice treated with OVA alone. Moreover, exposure to Pplase significantly increased the expression of IRF4, CD80, CD83, MHCII and TNF-alpha in DC2.4 cells, which was abolished in the presence of a TLR4 inhibitor. In vitro T cell polarization experiments revealed that Pplase alone could not induce T cell polarization but enhanced T cell polarization together with OVA. In addition, transfer of Pplase-primed bone marrow-derived DCs (BMDCs) to naive mice enhanced AHR and Th2 immune responses in mice sensitized to OVA. In conclusion, Pplase is not an allergen of D. farinae but can activate DC cells to facilitate OVA-induced allergic responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170227IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep43322</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28240301">PM:28240301</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-43322.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-43322.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170227, Wang H</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep43322</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,K.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Liang,K.Y.</style></author><author><style face="normal" font="Arial"> Xu,S.</style></author><author><style face="normal" font="Arial"> Zhou,X.J.</style></author><author><style face="normal" font="Arial"> Tan,K.</style></author><author><style face="normal" font="Arial"> Lin,J.</style></author><author><style face="normal" font="Arial"> Bai,X.C.</style></author><author><style face="normal" font="Arial"> Yang,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cell Biology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong, China</style></auth-address><titles><title><style face="normal" font="Arial">Rheb1 deletion in myeloid cells aggravates OVA-induced allergic inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="42655">42655-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophage polarization</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> rapamycin</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">The small GTPase ras homolog enriched in brain (Rheb) is a downstream target of tuberous sclerosis complex 1/2 (TSC1/2) and an upstream activator of the mechanistic target of rapamycin complex 1 (mTORC1), the emerging essential modulator of M1/M2 balance in macrophages. However, the role and regulatory mechanisms of Rheb in macrophage polarization and allergic asthma are not known. In the present study, we utilized a mouse model with myeloid cell-specific deletion of the Rheb1 gene and an ovalbumin (OVA)-induced allergic asthma model to investigate the role of Rheb1 in allergic asthma and macrophage polarization. Increased activity of Rheb1 and mTORC1 was observed in myeloid cells of C57BL/6 mice with OVA-induced asthma. In an OVA-induced asthma model, Rheb1-KO mice demonstrated a more serious inflammatory response, more mucus production, enhanced airway hyper-responsiveness, and greater eosinophil numbers in bronchoalveolar lavage fluid (BALF). They also showed increased numbers of bone marrow macrophages and BALF myeloid cells, elevated M2 polarization and reduced M1 polarization of macrophages. Thus, we have established that Rheb1 is critical for the polarization of macrophages and inhibition of allergic asthma. Deletion of Rheb1 enhances M2 polarization but decreases M1 polarization in alveolar macrophages, leading to the aggravation of OVA-induced allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep42655</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28225024">PM:28225024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-42655.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-42655.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Li K</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep42655</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hong,L.L.</style></author><author><style face="normal" font="Arial"> Yu,H.B.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Jiao,W.H.</style></author><author><style face="normal" font="Arial"> Cheng,B.H.</style></author><author><style face="normal" font="Arial"> Yang,F.</style></author><author><style face="normal" font="Arial"> Zhou,Y.J.</style></author><author><style face="normal" font="Arial"> Gu,B.B.</style></author><author><style face="normal" font="Arial"> Song,S.J.</style></author><author><style face="normal" font="Arial"> Lin,H.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Center for Marine Drugs, State Key Laboratory of Oncogenes and Related Genes, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Unusual Anti-allergic Diterpenoids from the Marine Sponge Hippospongia lachne</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="43138">43138-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> X-Ray Diffraction</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">Hipposponlachnins A (1) and B (2), possessing an unprecedented tetracyclo [9.3.0.02,8.03,7] tetradecane ring system, and the probable biogenetic precursor [3, (1R*,2E,4R*,7E,10S*,11S*,12R*)-10, 18-diacetoxydolabella-2,7-dien-6-one] of 12 were isolated from the South China Sea marine sponge Hippospongia lachne. The structures of the novel compounds were determined using integrated spectroscopic methods in combination with single-crystal X-ray diffraction analysis. Compounds 12 showed potent inhibitory activity on the release of beta-hexosaminidase, a biomarker for degranulation, as well as the production of pro-inflammatory cytokine IL-4 and lipid mediator LTB4 in DNP-IgE-stimulated RBL-2H3 cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep43138</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28224981">PM:28224981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-43138.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-43138.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Hong LL</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep43138</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,M.T.</style></author><author><style face="normal" font="Arial"> Chen,Y.L.</style></author><author><style face="normal" font="Arial"> Lien,C.I.</style></author><author><style face="normal" font="Arial"> Liu,W.L.</style></author><author><style face="normal" font="Arial"> Hsu,L.C.</style></author><author><style face="normal" font="Arial"> Yagita,H.</style></author><author><style face="normal" font="Arial"> Chiang,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Research, National Taiwan University Hospital, Taipei, 100, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Notch Ligand DLL4 Alleviates Allergic Airway Inflammation via Induction of a Homeostatic Regulatory Pathway</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="43535">43535-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg expansion</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">Notch is a pleiotropic signaling family that has been implicated in pathogenesis of allergic airway diseases; however, the distinct function of individual Notch ligands remains elusive. We investigated whether Notch ligands, Jagged1 and DLL4, exert differential effects in OVA-induced allergic asthma. We found that whilst Jagged1 inhibition mitigated Th2-dominated airway inflammation, blockage of DLL4 aggravated the Th2-mediated asthma phenotypes. Additionally, Jagged1 signaling blockage enhanced IL-17 production and neutrophilic airway infiltration. In vitro, exogenous Jagged1 induced Th2-skewed responses, whereas augmented DLL4 signaling displayed a dual role by promoting expansion of both Tregs and Th17. In vivo, DLL4 blockage impaired Treg differentiation which plausibly resulted in exaggerated asthma phenotypes. On the contrary, administration of DLL4-expressing antigen-presenting cells promoted endogenous Treg expansion and ameliorated the allergic responses. Therefore, whilst Jagged1 induces Th2-skewed inflammation, DLL4 elicits an essential self-regulatory mechanism via Treg-mediated pathway that counterbalances Jagged1-induced Th2 responses and facilitates resolution of the airway inflammation to restore homeostasis. These findings uncover a disparate function of Jagged1 and DLL4 in allergic airway diseases, hinting feasibility of Notch ligand-specific targeting in therapy of allergic airway diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep43535</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28262821">PM:28262821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-43535.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-43535.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Huang MT</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep43535</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Manni,M.L.</style></author><author><style face="normal" font="Arial"> Mandalapu,S.</style></author><author><style face="normal" font="Arial"> Salmeron,A.</style></author><author><style face="normal" font="Arial"> Lora,J.M.</style></author><author><style face="normal" font="Arial"> Kolls,J.K.</style></author><author><style face="normal" font="Arial"> Alcorn,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA USA</style></auth-address><titles><title><style face="normal" font="Arial">Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="43139">43139-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunomodulators</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Compliance</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="Arial">Atopic asthma is a prevalent respiratory disease that is characterized by inflammation, mucus hypersecretion, and airway hyperresponsiveness. The complexity of this heterogeneous disorder has commanded the need to better define asthma phenotypes based on underlying molecular mechanisms of disease. Although classically viewed as a type 2-regulated disease, type 17 helper T (Th17) cells are known to be influential in asthma pathogenesis, predominantly in asthmatics with neutrophilia and severe refractory disease. Bromodomain and extra-terminal domain (BET) chromatin adaptors serve as immunomodulators by directly regulating Th17 responses and Th17-mediated pathology in murine models of autoimmunity and infection. Based on this, we hypothesized that BET proteins may also play an essential role in neutrophil-dominant allergic airway disease. Using a murine model of neutrophil-dominant allergic airway disease, we demonstrate that BET inhibition limits pulmonary inflammation and alters the Th17-related inflammatory milieu in the lungs. In addition, inhibition of BET proteins improved lung function (specifically quasi-static lung compliance and tissue elastance) and reduced mucus production in airways. Overall, these studies show that BET proteins may have a critical role in asthma pathogenesis by altering type 17 inflammation, and thus interfering with BET-dependent chromatin signaling may provide clinical benefits to patients suffering from asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep43139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28233801">PM:28233801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-43139.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-43139.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170204, Manni ML</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep43139</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jung,K.H.</style></author><author><style face="normal" font="Arial"> Baek,H.</style></author><author><style face="normal" font="Arial"> Kang,M.</style></author><author><style face="normal" font="Arial"> Kim,N.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Bae,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Science in Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemoon-gu, Seoul 02447, Korea.</style></auth-address><titles><title><style face="normal" font="Arial">Bee Venom Phospholipase A2 Ameliorates House Dust Mite Extract Induced Atopic Dermatitis Like Skin Lesions in Mice</style></title><secondary-title><style face="normal" font="Arial">Toxins (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxins (Basel)</style></full-title></periodical><pages end="" start="68">68-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> Epidermal barrier defect</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2-cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a biphasic inflammatory skin disease that is provoked by epidermal barrier defects, immune dysregulation, and increased skin infections. Previously, we have demonstrated that bvPLA2 evoked immune tolerance by inducing regulatory T cells (Treg), and thus alleviated Th2 dominant allergic asthma in mice. Here, we would like to determine whether treatment with bvPLA2 exacerbates the AD-like allergic inflammations induced by house dust mite extract (DFE) in a murine model. Epidermal thickness, immune cell infiltration, serum immunoglobulin, and cytokines were measured. Ear swelling, skin lesions, and the levels of total serum IgE and Th1/Th2 cytokines were elevated in DFE/DNCB-induced AD mice. Topical application of bvPLA2 elicited significant suppression of the increased AD symptoms, including ear thickness, serum IgE concentration, inflammatory cytokines, and histological changes. Furthermore, bvPLA2 treatment inhibited mast cell infiltration into the ear. On the other hand, Treg cell depletion abolished the anti-atopic effects of bvPLA2, suggesting that the effects of bvPLA2 depend on the existence of Tregs. Taken together, the results revealed that topical exposure to bvPLA2 aggravated atopic skin inflammation, suggesting that bvPLA2 might be a candidate for the treatment of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 2072-6651 (Electronic)IS - 2072-6651 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3390/toxins9020068</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28218721">PM:28218721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxins (Basel)\2017-9-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxins (Basel)\2017-9-68.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Jung KH</style></custom2><misc3><style face="normal" font="Arial">10.3390/toxins9020068</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83617</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Silva,R.</style></author><author><style face="normal" font="Arial"> Dasanayake,W.M.</style></author><author><style face="normal" font="Arial"> Wickramasinhe,G.D.</style></author><author><style face="normal" font="Arial"> Karunatilake,C.</style></author><author><style face="normal" font="Arial"> Weerasinghe,N.</style></author><author><style face="normal" font="Arial"> Gunasekera,P.</style></author><author><style face="normal" font="Arial"> Malavige,G.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Medical Research Institute, Colombo 08, Sri Lanka.</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to bovine serum albumin as a possible cause of allergic reactions to vaccines</style></title><secondary-title><style face="normal" font="Arial">Vaccine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vaccine</style></full-title></periodical><pages end="1500" start="1494">1494-1500</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chick Embryo</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Diphtheria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Embryo</style></keyword><keyword><style face="normal" font="Arial"> Excipients</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Measles</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rubella</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sri Lanka</style></keyword><keyword><style face="normal" font="Arial"> Tetanus</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Immediate type hypersensitivity to vaccines containing bovine/porcine excipients, such as the measles, mumps and rubella (MMR) vaccine is probably due to sensitization to bovine/porcine gelatin. Most patients with such reactions in Sri Lanka have cow's milk (CM) or beef allergy. OBJECTIVES: We investigated whether those who had beef and CM allergy had a higher incidence of hypersensitivity reactions to vaccines and the possible trigger of such reactions. MATERIAL AND METHODS: Twenty patients with immediate type hypersensitivity reactions to vaccines containing bovine/porcine excipients, controls with allergy to beef/pork (n=11) or CM (n=11), and 8 non atopic controls were recruited. Total serum IgE, specific IgE to beef, CM, casein, beta lactoglobulin, gelatin and bovine serum albumin (BSA) by Phadia ImmunoCap and IgE to porcine gelatin by Western blot were evaluated. RESULTS: 11/20, 5/20, 2/20, 2/20, 1/20 and 1/20 patients reported allergic reactions to measles containing, JE, rabies primary chick embryo, pentavalent, diphtheria and tetanus, and adult diphtheria and tetanus vaccines, respectively. Only one patient with allergy to vaccines had gelatin specific IgE, whereas IgE to BSA was seen in 73.3%, 90%, 66.6% and 0 of vaccine, beef or CM allergic and non-atopic controls, respectively. The mean IgE to BSA was higher in patients with allergy to vaccines, although not significant. Specific IgE to BSA was present in 54.7% of children with allergy to CM, of whom 11.8% had high levels (>17.5kUA/L). In contrast, 66.6% of these children did not have specific IgE to beta-lactoglobulin, which is one of the major components of whey protein. CONCLUSION AND CLINICAL RELEVANCE: Gelatin does not appear to play a major role in Sri Lankan children with allergy to vaccines. In contrast, due to the higher levels of BSA specific IgE, sensitization to BSA is possibly playing a role</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1873-2518 (Electronic)IS - 0264-410X (Linking)LA - engPT - Journal ArticleCO - Sri Lanka -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.vaccine.2017.02.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216185">PM:28216185</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vaccine\20170220-deSIlvaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vaccine\20170220-deSIlvaR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, de Silva R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.vaccine.2017.02.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olivry,T.</style></author><author><style face="normal" font="Arial"> Paps,J.S.</style></author><author><style face="normal" font="Arial"> Dunston,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, College of Veterinary Medicine, NC State University, 1060 William Moore Drive, Raleigh, NC, 27607, USA</style></auth-address><titles><title><style face="normal" font="Arial">Proof of concept of the preventive efficacy of high-dose recombinant mono-allergen immunotherapy in atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 2</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="e40" start="183">183-e40</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Der f 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy is currently the only intervention proposed to specifically prevent clinical flares after allergen challenges. The low molecular weight Der f 2 (Df2) is a major allergen in Japanese dogs sensitized to Dermatophagoides farinae house dust mites. OBJECTIVES: Pilot, blinded, placebo-controlled experiment testing the efficacy of subcutaneous immunotherapy (SCIT) with high doses of recombinant Df2 conjugated to the maltotriose pullulan (rDf2-P). METHODS: Eight Maltese beagle atopic dogs were sensitized to rDf2 then randomized to SCIT with rDf2-P (six dogs) or placebo (two). The immunotherapy consisted of six weekly injections of increasing doses (0.1-10.0 mug) of rDf2-P followed by four monthly injections of 10 mug of this allergen. Epicutaneous rDf2 challenges, rDf2-specific IgE serology and intradermal reactivity, as well as serum cytokine level measurements, were performed throughout the study. RESULTS: Subcutaneous injections of placebo did not alter the cutaneous reactivity after rDf2 challenge, while that of the dogs treated with rDf2-P SCIT disappeared in five of six dogs (83%) and was reduced in one of six (17%). During SCIT maintenance, skin lesion scores were significantly lower in dogs receiving SCIT compared to those treated with placebo. This clinical improvement was accompanied by a concurrent, yet not significant, decrease in rDf2-specific IgE serology and immediate intradermal reactivity. Cytokine serum levels were inconclusive. There were no adverse events seen with rDf2-P SCIT. CONCLUSIONS AND CLINICAL IMPORTANCE: The new mono-allergen SCIT appears safe and effective for reducing skin lesions after allergen challenges; it deserves further testing in dogs with spontaneous atopic dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12395</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261915">PM:28261915</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\2017-28-183-e40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\2017-28-183-e40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170307, Olivry T</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12395</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olivry,T.</style></author><author><style face="normal" font="Arial"> Dunston,S.M.</style></author><author><style face="normal" font="Arial"> Favrot,C.</style></author><author><style face="normal" font="Arial"> Prelaud,P.</style></author><author><style face="normal" font="Arial"> Tsukui,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, College of Veterinary Medicine, NC State University, 1060 William Moore Drive, Raleigh, NC, 27607, USA</style></auth-address><titles><title><style face="normal" font="Arial">The novel high molecular weight Dermatophagoides farinae protein Zen-1 is a major allergen in North American and European mite allergic dogs with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="e38" start="177">177-e38</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Der f 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intradermal testing</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> MW</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dogs with hypersensitivity to Dermatophagoides farinae (Df) have IgE recognizing high molecular weight (MW) allergens more often than the low MW Der f 1 and 2. A new high MW Df allergen, Zen-1, has been identified recently. OBJECTIVES: To determine the IgE reactivity of American and European Df-hypersensitive dogs to Zen-1, Der f 1 and Der f 2. METHODS: We tested sera from 33 Df-reactive dogs from the USA, 29 from Europe and 15 experimentally sensitized to Df, by ELISA against crude Df, Der f 1, Der f 2 and Zen-1. ELISA inhibition was performed with sera reactive to Zen-1. Intradermal testing (IDT) was also done with the same allergens in 25 other American atopic dogs. RESULTS: Altogether, IgE seropositivity to Zen-1 was more prevalent (86%) than that to Der f 1 (17%) or Der f 2 (19%). The IgE reactivity to Zen-1 was correlated to that against crude Df; this allergen alone inhibited a high percentage (median: 50%; range: 22-84%) of the binding to the crude mite extract. The seropositivity to low MW allergens was highest in experimentally sensitized dogs. Serum IgE recognition of Der f 1 was low in dogs with AD; that to Der f 2 was significantly lower in American dogs (6%) than in European ones (28%). A high prevalence of positive immediate IDT reactions to Zen-1 confirmed the likely relevance of serological results. CONCLUSIONS AND CLINICAL IMPORTANCE: This study establishes Zen-1 as a major allergen in atopic dogs sensitized to Df</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - United States -CO - France -CO - Japan -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12393</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261917">PM:28261917</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\2017-28-177-e38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\2017-28-177-e38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Olivry T</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12393</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rostaher,A.</style></author><author><style face="normal" font="Arial"> Fischer,N.M.</style></author><author><style face="normal" font="Arial"> Kummerle-Fraune,C.</style></author><author><style face="normal" font="Arial"> Couturier,N.</style></author><author><style face="normal" font="Arial"> Jacquenet,S.</style></author><author><style face="normal" font="Arial"> Favrot,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057, Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Probable walnut-induced anaphylactic reaction in a dog</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="e66" start="251">251-e66</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hazelnuts</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis due to nuts is frequent in humans; to the best of the authors' knowledge, it has not been reported previously in dogs. CASE REPORT: A 5-year-old female, intact, Vizsla dog was presented with acute diarrhoea, vomiting, respiratory distress and erythematous wheals. The dog had eaten walnuts, which she had been fed in small amounts for years, hours before the onset of clinical signs. A diagnosis of generalized anaphylaxis was made. Skin testing and Western blotting revealed positive results with walnuts and hazelnuts. CONCLUSIONS AND CLINICAL IMPORTANCE: This case report illustrates the need for a thorough food history and for recognition that a dog may experience severe allergic reactions to unusual and regularly fed food items. It also shows that allergen specific tests may help to confirm the diagnosis and help in planning the dog's future dietary regime</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Case ReportsCO - Switzerland -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/(ISSN)1365-3164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261916">PM:28261916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\2017-28-251-e66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\2017-28-251-e66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Rostaher A</style></custom2><misc3><style face="normal" font="Arial">10.1111/(ISSN)1365-3164</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meyer,R.</style></author><author><style face="normal" font="Arial"> Godwin,H.</style></author><author><style face="normal" font="Arial"> Dziubak,R.</style></author><author><style face="normal" font="Arial"> Panepinto,J.A.</style></author><author><style face="normal" font="Arial"> Foong,R.M.</style></author><author><style face="normal" font="Arial"> Bryon,M.</style></author><author><style face="normal" font="Arial"> Lozinsky,A.C.</style></author><author><style face="normal" font="Arial"> Reeve,K.</style></author><author><style face="normal" font="Arial"> Shah,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 2113 8111grid.7445.2Department Paediatrics, Imperial College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">The impact on quality of life on families of children on an elimination diet for Non-immunoglobulin E mediated gastrointestinal food allergies</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> non-IgE mediated allergy</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sickle cell disease</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The impact on health related quality of life (HRQL) has been well studied in children with Immunoglobulin E (IgE)-mediated food allergy. However limited data exists on related quality of life (QOL) of families who have a child suffering from food protein induced non-IgE mediated gastrointestinal allergies. We aimed to establish the QOL of families with children at the beginning of following an elimination diet for non-IgE mediated gastrointestinal food allergies. METHODS: A prospective, observational study was performed. Parents of children aged 4 weeks-16 years who improved after 4-8 weeks of following an elimination diet for suspected non-IgE mediated allergies were included. The Family Impact Module (FIM) of the Pediatric Quality of Life (PedsQL) was used and we compared our data to two historical cohorts: one with sickle cell disease and another with intestinal failure. RESULTS: One hundred and twenty three children with a median age of 20 months were included (84 boys). The total FIM Score was 57.43 (SD 22.27) and particularly low for daily activities and worry. Factors that impacted significantly included age (p &lt; 0.0001), number of foods excluded (p = 0.008), symptom severity (p = 0.041) and chronic nasal congestion (p = 0.012). Children with non-IgE mediated food allergies had worse scores in all domains (p &lt; 0.0001) compared to sickle cell disease and worse physical (p = 0.04), emotional (p = 0.04) and worry (p = 0.01) domains compared to intestinal failure. CONCLUSIONS: This study found that parent QOL and family functioning was worse in those families who had a child on an elimination diet for non-IgE mediated allergies compared to those with sickle cell disease and intestinal failure, highlighting the impact this disease has on families</style></abstract><notes><style face="normal" font="Arial">DA - 20170306IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-016-0139-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261374">PM:28261374</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170306, Meyer R</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-016-0139-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pali-Scholl,I.</style></author><author><style face="normal" font="Arial"> Namazy,J.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 2286 1424grid.10420.37Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinarplatz 1, 1210 Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Allergic diseases and asthma in pregnancy, a secondary publication</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="10">10-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Every fifth pregnant woman is affected by allergies, especially rhinitis and asthma. Allergic symptoms existing before pregnancy may be either attenuated, or equally often promoted through pregnancy. Optimal allergy and asthma diagnosis and management during pregnancy is vital to ensure the welfare of mother and baby. For allergy diagnosis in pregnancy, preferentially anamnestic investigation as well as in vitro testing should be applied, whereas skin testing or provocation tests should be postponed until after birth. Pregnant women with confirmed allergy should avoid exposure to, or consumption of the offending allergen. Allergen immunotherapy should not be initiated during pregnancy. In patients on immunotherapy since before pregnancy, maintenance treatment may be continued, but the allergen dose should not be increased further. Applicable medications for asthma, rhinitis or skin symptoms in pregnancy are discussed and listed. In conclusion, i) allergies in pregnancy should preferentially be diagnosed in vitro; ii) AIT may be continued, but not started, and symptomatic medications must be carefully selected; iii) management of asthma and allergic diseases is important during pregnancy for welfare of mother and child</style></abstract><notes><style face="normal" font="Arial">DA - 20170313IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Austria -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0141-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286601">PM:28286601</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170313, Pali-Scholl I</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0141-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gao,Q.</style></author><author><style face="normal" font="Arial"> Ren,Y.X.</style></author><author><style face="normal" font="Arial"> Liu,Y.G.</style></author><author><style face="normal" font="Arial"> Ma,L.</style></author><author><style face="normal" font="Arial"> Gu,X.H.</style></author><author><style face="normal" font="Arial"> Zhang,W.X.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Zhai,X.J.</style></author><author><style face="normal" font="Arial"> Xiang,L.</style></author><author><style face="normal" font="Arial"> Shen,K.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Beijing Children's Hospital, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergy march of Chinese children with infantile allergic symptoms: a prospective multi-center study</style></title><secondary-title><style face="normal" font="Arial">World J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Pediatr</style></full-title></periodical><pages end="340" start="335">335-340</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> long-term follow-up</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Screening test</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy march refers to progression of allergic diseases from infantile food allergy to the development of asthma and allergic rhinitis (AR). Evidence come mostly from studies in European countries. This study aimed to investigate allergy march in Chinese children with infantile food protein allergy (FPA) with a special focus on the effect of different formula interventions. METHODS: From 2008 to 2010, 153 infants diagnosed with FPA were recruited in five tertiary hospitals across China. They were randomly treated with amino-acid-based formula or soy-protein-based formula for a period of 3 months. Long-term follow-up was performed when they reached early school age, using questionnaires, physical examinations, and serum-specifi c immunoglobulin E. RESULTS: The overall follow-up rate was 73.20%. In patients who reached their early school years, the prevalence of physician-diagnosed AR and asthma were 43.75% and 23.21%, respectively. Only 40% of the subjects remained positive for food sensitizations upon follow-up. Twenty-six subjects receiving aeroallergen screening tests in infancy all proved negative, but upon follow-up, 65.57% were sensitized to aeroallergens (P=0.005). No signifi cant difference between the effects of amino-acid-based formula and soy-protein-based formula on children's allergy march was observed. CONCLUSIONS: A high proportion (47.32%) of Chinese infants with early allergic symptoms developed respiratory allergies by their early school years. Most food-sensitized infants outgrew their condition several years later, but then aeroallergen sensitization often occurred. Amino-acid-based formula showed no advantages over soy protein-based formula with respect to arresting the allergy march</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1867-0687 (Electronic)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12519-017-0024-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28276001">PM:28276001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Pediatr\20170309-GaoQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Pediatr\20170309-GaoQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Gao Q</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12519-017-0024-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pan,T.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author><author><style face="normal" font="Arial"> Ding,Y.J.</style></author><author><style face="normal" font="Arial"> Lu,Z.Y.</style></author><author><style face="normal" font="Arial"> Ma,F.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology Head and Neck Surgery, Third Hospital, Peking University, Beijing 100191, China</style></auth-address><titles><title><style face="normal" font="Arial">[The pilot study of type allergic reaction in Meniere's disease patients]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="92" start="89">89-92</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endolymphatic hydrops</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Inpatients</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Meniere's Disease</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vertigo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="Arial">Objective: To evaluate the correlation between type allergic reaction and pathogenesis of Meniere's disease. Methods: A total of 35 (10 male vs. 25 female) patients aged between 21-66 years diagnosed with Meniere's disease were recruited to this study, mean age of them was (47.3+/-13.6) years. The control group consisted of 15 inpatients (5 male vs. 10 female) with pharyngolaryngeal diseases but without otologic and rhinologic abnormity, mean age was 45.4+/-12.8 years. Allergic prevalence, serous total immunoglobulin E( tIgE ) levels, serous specific immunoglobulin E( sIgE ) levels and subtypes of T lymphocytes were measured and compared in patients with Meniere's disease and the control group. Severity of vertigo, tinnitus and sensation of fullness were compared between Meniere's disease patients with or without allergy. Results: Allergic prevalence were significantly different (Pearson chi-square 5.832, P&lt;0.05) between patients with Meniere's disease and the control group(57.1% vs. 20.0%). Patients with Meniere's disease report higher level of serous tIgE compared with controls, the difference is statistically significant (Z=168.000, P&lt;0.05). However, positive rates of sIgE of food allergens and inhalant allergens were not significantly different between patients with Meniere's disease and the control group. Scores of vertiginous severity, dizziness handicap inventory (DHI) and tinnitus handicap inventory (THI) were significantly different between Meniere's disease patients with or without allergy (P&lt;0.05). Treg and Treg/Th17 levels (Z=26.000) were much higher in Meniere's disease patients with allergy than in the controls(P&lt;0.05). Conclusions: Patients with Meniere's disease report higher rate of allergy than the control group. Type allergic reaction is thought to be one of the possible reasons that may induce endolymphatic hydrops and lead to Meniere's disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170221IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219165">PM:28219165</url></web-urls></urls><custom2><style face="normal" font="Arial">20170221, Pan T</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.02.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Braga,E.N.</style></author><author><style face="normal" font="Arial"> Antonia do Nascimento,G.M.</style></author><author><style face="normal" font="Arial"> Castro,B.W.</style></author><author><style face="normal" font="Arial"> Ryuichi,N.C.</style></author><author><style face="normal" font="Arial"> Gomes,V.E.</style></author><author><style face="normal" font="Arial"> Faria,P.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Bioquimica, Pos-Graduacao em Imunologia e Doencas Infecto Parasitarias/Genetica e Biotecnologia, Instituto de Ciencias Biologicas, Universidade Federal de Juiz de Fora, Juiz de Fora, MG 36015-400, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Identification of a linear IgE inducing epitope on the SmATPDase1 surface</style></title><secondary-title><style face="normal" font="Arial">Acta Biochim Biophys Sin (Shanghai)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Biochim Biophys Sin (Shanghai)</style></full-title></periodical><pages end="566" start="564">564-566</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Brazil</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Forum</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1745-7270 (Electronic)IS - 1672-9145 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1093/abbs/gmx031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398461">PM:28398461</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Biochim Biophys Sin (Shanghai)\20170411-BragaEn.pdf</url></pdf-urls><text-urls><url ppv-ref="no">f:\A&amp;H HMW Papers\Acta Biochim Biophys Sin (Shanghai)\20170411-BragaEn.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Braga EN</style></custom2><misc3><style face="normal" font="Arial">10.1093/abbs/gmx031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alsterholm,M.</style></author><author><style face="normal" font="Arial"> Strombeck,L.</style></author><author><style face="normal" font="Arial"> Ljung,A.</style></author><author><style face="normal" font="Arial"> Karami,N.</style></author><author><style face="normal" font="Arial"> Widjestam,J.</style></author><author><style face="normal" font="Arial"> Gillstedt,M.</style></author><author><style face="normal" font="Arial"> Ahren,C.</style></author><author><style face="normal" font="Arial"> Faergemann,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, Sahlgrenska University Hospital, SE-413 45 Goteborg, Sweden.</style></auth-address><titles><title><style face="normal" font="Arial">Variation in Staphylococcus aureus Colonization in Relation to Disease Severity in Adults with Atopic Dermatitis during av Five-month Follow-up</style></title><secondary-title><style face="normal" font="Arial">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Derm Venereol</style></full-title></periodical><pages end="807" start="802">802-807</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> NARES</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Tonsil</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">The aim of this study was to monitor Staphylococcus aureus colonization and disease severity in adults with atopic dermatitis (AD) during 5 months. Twenty-one patients attended 3 visits each for severity SCORing of Atopic Dermatitis (SCORAD) assessment, quantitative cultures from the skin and conventional cultures from the anterior nares, tonsils and perineum. S. aureus isolates were typed for strain identity with pulsed-field gel electrophoresis (PFGE). Seventy-one percent of patients were colonized with S. aureus on lesional skin at least once. Density (colony-forming units (CFU)/cm2) was higher on lesional skin than on non-lesional skin (p &lt; 0.05). Density on lesional skin and number of colonized body sites were positively correlated with SCORAD (p = 0.0003 and p = 0.007, respectively). Persistent carriers of the same strain on lesional skin had higher mean SCORAD index than intermittent/non-carriers (36.3 and 17.1, respectively, p = 0.002). The results show a temporal correlation between several aspects of S. aureus colonization and disease severity in AD raising the question of the importance of this in pathogenesis and treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.2340/00015555-2667</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28374043">PM:28374043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Derm Venereol\20170404-AlsterholmM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Derm Venereol\20170404-AlsterholmM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Alsterholm M</style></custom2><misc3><style face="normal" font="Arial">10.2340/00015555-2667</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zallmann,M.</style></author><author><style face="normal" font="Arial"> Smith,P.K.</style></author><author><style face="normal" font="Arial"> Tang,M.L.</style></author><author><style face="normal" font="Arial"> Spelman,L.J.</style></author><author><style face="normal" font="Arial"> Cahill,J.L.</style></author><author><style face="normal" font="Arial"> Wortmann,G.</style></author><author><style face="normal" font="Arial"> Katelaris,C.H.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Su,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Monash University, Eastern Health, Box Hill Victoria; Murdoch Childrens Research Institute, Victoria, 3168 Melbourne, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Debunking the Myth of Wool Allergy: Reviewing the Evidence for Immune and Non-immune Cutaneous Reactions</style></title><secondary-title><style face="normal" font="Arial">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Derm Venereol</style></full-title></periodical><pages end="915" start="905">905-915</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chromium</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact allergy</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> fibre</style></keyword><keyword><style face="normal" font="Arial"> Formaldehyde</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> Wool</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">Although wool is commonly believed to cause irritant (non-immune) and hypersensitivity (immune) cutaneous reactions, the evidence basis for this belief and its validity for modern garments have not been critically examined. Publications from the last 100 years, using MEDLINE and Google Scholar, were analysed for evidence that wool causes cutaneous reactions, both immune-mediated (atopic dermatitis exacerbation, contact urticaria, allergic contact dermatitis) and non-immune-mediated (irritant contact dermatitis, itch). Secondary aims of this paper were to examine evidence that lanolin and textile-processing additives (formaldehyde, chromium) cause cutaneous reactions in the context of modern wool-processing techniques. Current evidence does not suggest that wool-fibre is a cutaneous allergen. Furthermore, contact allergy from lanolin, chromium and formaldehyde is highly unlikely with modern wool garments. Cutaneous irritation from wool relates to high fibre diameters (>/= 30-32 microm). Superfine and ultrafine Merino wool do not activate sufficient c-fibres to itch, are well tolerated and may benefit eczema management</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.2340/00015555-2655</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28350041">PM:28350041</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Derm Venereol\20170328-ZallmannM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Derm Venereol\20170328-ZallmannM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Zallmann M</style></custom2><misc3><style face="normal" font="Arial">10.2340/00015555-2655</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deza,G.</style></author><author><style face="normal" font="Arial"> Bertolin-Colilla,M.</style></author><author><style face="normal" font="Arial"> Pujol,R.M.</style></author><author><style face="normal" font="Arial"> Curto-Barredo,L.</style></author><author><style face="normal" font="Arial"> Soto,D.</style></author><author><style face="normal" font="Arial"> Garcia,M.</style></author><author><style face="normal" font="Arial"> Hernandez,P.</style></author><author><style face="normal" font="Arial"> Gimeno,R.</style></author><author><style face="normal" font="Arial"> Gimenez-Arnau,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mediques, Universitat Autonoma de Barcelona (UAB), Passeig Maritim, 25-29, ES-08003 Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Basophil FcepsilonRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy</style></title><secondary-title><style face="normal" font="Arial">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Derm Venereol</style></full-title></periodical><pages end="704" start="689">689-704</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="Arial">Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcepsilonRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcepsilonRI after 4 weeks, which was maintained throughout the total duration of the treatment. Such evolution was not observed in non-responder patients. Furthermore, non-responders showed significantly lower baseline levels of FcepsilonRI than responders. Baseline basophil FcepsilonRI expression was found to be a potential immunological predictor of response to omalizumab (100% sensitivity and 73.2% specificity). The results of this study contribute to our knowledge of the therapeutic benefit and mechanism of action of anti-IgE therapy in CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.2340/00015555-2654</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28303277">PM:28303277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Derm Venereol\20170317-DezaG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Derm Venereol\20170317-DezaG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Deza G</style></custom2><misc3><style face="normal" font="Arial">10.2340/00015555-2654</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tuokkola,J.</style></author><author><style face="normal" font="Arial"> Luukkainen,P.</style></author><author><style face="normal" font="Arial"> Nevalainen,J.</style></author><author><style face="normal" font="Arial"> Ahonen,S.</style></author><author><style face="normal" font="Arial"> Toppari,J.</style></author><author><style face="normal" font="Arial"> Ilonen,J.</style></author><author><style face="normal" font="Arial"> Veijola,R.</style></author><author><style face="normal" font="Arial"> Knip,M.</style></author><author><style face="normal" font="Arial"> Virtanen,S.M.</style></author><author><style face="normal" font="Arial"> Kaila,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Eliminating cows' milk, but not wheat, barley or rye, increases the risk of growth deceleration and nutritional inadequacies</style></title><secondary-title><style face="normal" font="Arial">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Paediatr</style></abbr-1></periodical><pages end="1149" start="1142">1142-1149</pages><volume><style face="normal" font="Arial">106</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Barley</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Fats</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> type 1 diabetes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin C</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">AIM: Our study examined the growth and nutritional intake of children on milk and, or, wheat, barley or rye elimination diets. METHODS: This was a nested case-control study within the Finnish Type 1 Diabetes Prediction and Prevention Study. It investigated 295 children born in the Tampere University Hospital area between 1997-2004 on a diet without cows' milk and, or, wheat, barley or rye due to food allergies and 265 matched controls. Nutritional intake was recorded with three-day food records at the ages of one, two and three years. Serial growth measurements were recorded annually up to the age of five years. RESULTS: Despite consuming a balanced diet with sufficient energy and protein, the children on milk elimination diets grew slower than the control children (p=0.009). Wheat, barley or rye elimination was not associated with growth. The intakes of protein and calcium were lower in children in the milk elimination group than the controls, at p &lt; 0.05 for all. However, children on elimination diets consumed less saturated fats and sugar and more vitamin C and iron than the control children. CONCLUSION: Children on elimination diets faced an increased risk of growth deceleration and suboptimal intake of several micronutrients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170327IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/apa.13846</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28345135">PM:28345135</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Paediatr\20170327-TuokkolaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Paediatr\20170327-TuokkolaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170327, Tuokkola J</style></custom2><misc3><style face="normal" font="Arial">10.1111/apa.13846</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iwanczak,B.M.</style></author><author><style face="normal" font="Arial"> Ryzko,J.</style></author><author><style face="normal" font="Arial"> Jankowski,P.</style></author><author><style face="normal" font="Arial"> Sladek,M.</style></author><author><style face="normal" font="Arial"> Wasilewska,A.</style></author><author><style face="normal" font="Arial"> Szczepanik,M.</style></author><author><style face="normal" font="Arial"> Sienkiewicz,E.</style></author><author><style face="normal" font="Arial"> Szaflarska-Poplawska,A.</style></author><author><style face="normal" font="Arial"> Wiecek,S.</style></author><author><style face="normal" font="Arial"> Czaja-Bulsa,G.</style></author><author><style face="normal" font="Arial"> Korczowski,B.</style></author><author><style face="normal" font="Arial"> Maslana,J.</style></author><author><style face="normal" font="Arial"> Iwanczak,F.</style></author><author><style face="normal" font="Arial"> Kacperska,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department and Clinic of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of the infliximab therapy of severe form of pediatric Crohn's disease in Poland: Retrospective, multicenter studies</style></title><secondary-title><style face="normal" font="Arial">Adv Clin Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Clin Exp Med</style></full-title></periodical><pages end="56" start="51">51-56</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Registration of infliximab in Poland has increased chances to induce clinical remission and mucosal healing in the severe form of pediatric Crohn's disease. OBJECTIVES: The aim of this retrospective study was to assess the results and safety of infliximab therapy in the severe form of pediatric Crohn's disease. MATERIAL AND METHODS: The study included 153 children with severe form of non-fistulizing Crohn's disease treated with infliximab. The clinical activity of Crohn's disease was assessed according to PCDAI scale, endoscopic scoring was graded according to SES-CD, body mass was measured with body mass index (BMI). Infliximab was administered at the dose 5 mg/kg body mass in the 0.2 and 6th week, and then, after clinical response, every 8 for the period of 12 months. RESULTS: One hundred thirty-six children (88.89%) achieved clinical response after induction therapy and 75.21% of children after the maintenance therapy. 39.68% of children achieved remission as graded with endoscopic scoring SES-CD. There was a statistically significant increase in body weight following the treatment. Side effects such as anaphylaxis, rash, and the activation of EBV infection appeared in 9 children at the time of infliximab injection. In other children the drug was well tolerated. CONCLUSIONS: Induction and maintenance therapy with infliximab resulted in clinical remission of Crohn's disease in 75.21% of children, and in the intestinal mucosa healing in 39.68% of children</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1899-5276 (Print)IS - 1899-5276 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.17219/acem/35802</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28397432">PM:28397432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Clin Exp Med\2017-26-51-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Clin Exp Med\2017-26-51-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Iwanczak BM</style></custom2><misc3><style face="normal" font="Arial">10.17219/acem/35802</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83631</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iwanczak,B.M.</style></author><author><style face="normal" font="Arial"> Kierkus,J.</style></author><author><style face="normal" font="Arial"> Ryzko,J.</style></author><author><style face="normal" font="Arial"> Szczepanik,M.</style></author><author><style face="normal" font="Arial"> Wiecek,S.</style></author><author><style face="normal" font="Arial"> Czaja-Bulsa,G.</style></author><author><style face="normal" font="Arial"> Kacperska,M.</style></author><author><style face="normal" font="Arial"> Korczowski,B.</style></author><author><style face="normal" font="Arial"> Maslana,J.</style></author><author><style face="normal" font="Arial"> Iwanczak,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">2nd Department of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study</style></title><secondary-title><style face="normal" font="Arial">Adv Clin Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Clin Exp Med</style></full-title></periodical><pages end="61" start="57">57-61</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colectomy</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Early treatment</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> surgical treatment</style></keyword><keyword><style face="normal" font="Arial"> Tacrolimus</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ulcerative Colitis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pediatric ulcerative colitis (UC) is a severe disease characterised by the presence of extensive inflammatory lesions in the colon. The administration of intravenous corticosteroids is recommended in patients with acute relapse of the disease, whereas early treatment with cyclosporine, tacrolimus or infliximab is recommended if there is no improvement. OBJECTIVES: The aim of this study was to retrospectively evaluate the efficacy and safety of infliximab therapy in the treatment of moderate-to-severe and severe relapse of pediatric UC. MATERIAL AND METHODS: The analysis included 42 children aged 4-18 years (23 girls, 19 boys) treated in 7 pediatric gastroenterology departments in Poland during the past 4 years. The disease duration ranged from 2 to 100 months. The clinical activity of UC ranged from 35 to 85 points according to the PUCAI scale. Twenty-one children were diagnosed with pancolitis, 10 children with extensive UC, and the remaining with the left-sided UC. In the induction therapy infliximab was administered at doses of 5 mg/kg in the 0.2 and 6 weeks, and after the clinical response every 8 weeks to 12 months. Treatment results were assessed in 10 and 54 weeks. RESULTS: After the induction therapy the clinical response was achieved in 14 children (33.33%) and clinical remission in 11 children (26.19%). Two children required surgical treatment, and the remaining 2 suffered from anaphylactic shock. After the maintenance therapy clinical remission was maintained in 12 children (57.14%), whereas 3 children required surgery (colectomy). CONCLUSIONS: Infliximab therapy in children with moderate-to-severe UC induces remission and, in some children, proves to be effective in preventing early colectomy</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1899-5276 (Print)IS - 1899-5276 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.17219/acem/42197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28397433">PM:28397433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Clin Exp Med\2017-26-57-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Clin Exp Med\2017-26-57-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Iwanczak BM</style></custom2><misc3><style face="normal" font="Arial">10.17219/acem/42197</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83632</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Linares,C.</style></author><author><style face="normal" font="Arial"> Delgado,R.</style></author><author><style face="normal" font="Arial"> Aira,M.J.</style></author><author><style face="normal" font="Arial"> Alcazar,P.</style></author><author><style face="normal" font="Arial"> Alonso-Perez,S.</style></author><author><style face="normal" font="Arial"> Boi,M.</style></author><author><style face="normal" font="Arial"> Carinanos,P.</style></author><author><style face="normal" font="Arial"> Cuevas,E.</style></author><author><style face="normal" font="Arial"> Diaz de la Guardia,C.</style></author><author><style face="normal" font="Arial"> Elvira-Rendueles,B.</style></author><author><style face="normal" font="Arial"> Fernandez-Gonzalez,D.</style></author><author><style face="normal" font="Arial"> Galan,C.</style></author><author><style face="normal" font="Arial"> Gutierrez-Bustillo,A.M.</style></author><author><style face="normal" font="Arial"> Perez-Badia,R.</style></author><author><style face="normal" font="Arial"> Rodriguez-Rajo,F.J.</style></author><author><style face="normal" font="Arial"> Ruiz-Valenzuela,L.</style></author><author><style face="normal" font="Arial"> Tormo-Molina,R.</style></author><author><style face="normal" font="Arial"> del Mar Trigo,M.</style></author><author><style face="normal" font="Arial"> Valencia-Barrera,R.M.</style></author><author><style face="normal" font="Arial"> Valle,A.</style></author><author><style face="normal" font="Arial"> Belmonte,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Changes in the Mediterranean pine forest: pollination patterns and annual trends of airborne pollen</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Canary Islands</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth rate</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen production</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">In some areas, forests are being affected in diverse aspects such as structure, composition and biodiversity showing an increase or a decrease in the growth rates. Pinus is one of the most dominant genera in the forests of the Northern Hemisphere. This study analyzes the pine pollination patterns in 30 locations of Spain with an average of 21-year dataset. The aim is to evaluate possible changes in flowering intensity as well as in annual pollen production trends, according to the airborne pollen patterns. Annual Pollen Indices show three threshold values: (1) over 4000 grains per year in Catalonia, the Central System Mountains and Ourense (Galicia), (2) between 4000 and 1000 grains in central-south Spain and in the Balearic Islands, and (3) under 1000 in eastern Spain, Cartagena and the Canary Islands. Airborne pollen patterns were also influenced by Pinus species: The species located in the littoral and low land areas pollinated in the first pollination phase, from February to April, and the mountain pine species did in the second one, from April to June. The statistical analyses reveal increasing significant trends in 12 sites and significant decreasing trends in two. The Pinus flowering intensity is showing an earlier start and a delay in the end of the pollination period, thus a longer period of pollen in the air. This study suggests that the aerobiological monitoring is an interesting bio-indicator of changes happening in Pinus landscapes, and therefore explains the vulnerability of this genus in Spain</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9476-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9476-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170405-DeLinaresC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170405-DeLinaresC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, De Linares G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9476-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lenart-Boron,A.</style></author><author><style face="normal" font="Arial"> Wolny-Koladka,K.</style></author><author><style face="normal" font="Arial"> Juraszek,K.</style></author><author><style face="normal" font="Arial"> Kasprowicz,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Phenotypic and molecular assessment of antimicrobial resistance profile of airborne Staphylococcus spp. isolated from flats in Krak+¦w</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Erythromycin</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> macrolide</style></keyword><keyword><style face="normal" font="Arial"> Macrolides</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staphylococci</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Bacteria of the genus Staphylococcus were isolated from air sampled from living spaces in Krak+¦w (Poland). In total, 55 strains belonging to the genus Staphylococcus were isolated from 45 sites, and 13 species of coagulase-negative staphylococci were identified. The species composition of studied airborne microbiota contains Staphylococcus species that are rarely infectious to humans. Most commonly isolated species comprised S. hominis and S. warneri. The disk-diffusion tests showed that the collected isolates were most frequently resistant to erythromycin. The PCR technique was employed to search for genes conferring the resistance in staphylococci to antibiotics from the group of macrolides, lincosamides and streptogramins. The analyzed Staphylococcus isolates possessed simultaneously 4 different resistance genes. The molecular analysis with the use of specific primers allowed to determine the most prevalent gene which is mphC, responsible for the resistance to macrolides and for the enzymatic inactivation of the drug by phosphotransferase. The second most often detected gene was msrA1, which confers the resistance of staphylococci to macrolides and is responsible for active pumping of antimicrobial particles out of bacterial cells</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9481-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9481-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170419-LenartBoronA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170419-LenartBoronA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Lenart-Boron A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9481-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grundstrom,M.</style></author><author><style face="normal" font="Arial"> Dahl,A.</style></author><author><style face="normal" font="Arial"> Ou,T.</style></author><author><style face="normal" font="Arial"> Chen,D.</style></author><author><style face="normal" font="Arial"> Pleijel,H..</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The relationship between birch pollen, air pollution and weather types and their effect on antihistamine purchase in two Swedish cities</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Atmospheric Pressure</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> PM10</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Exposure to elevated air pollution levels can aggravate pollen allergy symptoms. The aim of this study was to investigate the relationships between airborne birch (Betula) pollen, urban air pollutants NO2, O3 and PM10 and their effects on antihistamine demand in Gothenburg and Malm+Â, Sweden, 2006</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2012. Further, the influence of large-scale weather pattern on pollen-/pollution-related risk, using Lamb weather types (LWTs), was analysed. Daily LWTs were obtained by comparing the atmospheric pressure over a 16-point grid system over southern Sweden (scale ~3000-ákm). They include two non-directional types, cyclonic (C) and anticyclonic (A) and eight directional types depending on the wind direction (N, NE, E</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çª). Birch pollen levels were exceptionally high under LWTs E and SE in both cities. Furthermore, LWTs with dry and moderately calm meteorological character (A, NE, E, SE) were associated with strongly elevated air pollution (NO2 and PM10) in Gothenburg. For most weather situations in both cities, simultaneously high birch pollen together with high air pollution had larger over-the-counter (OTC) sales of antihistamines than situations with high birch pollen alone. LWTs NE, E, SE and S had the highest OTC sales in both cities. In Gothenburg, the city with a higher load of both birch pollen and air pollution, the higher OTC sales were especially obvious and indicate an increased effect on allergic symptoms from air pollution. Furthermore, Gothenburg LWTs A, NE, E and SE were associated with high pollen and air pollution levels and thus classified as high-risk weather types. In Malm+Â, corresponding high-risk LWTs were NE, E, SE and S. Furthermore, occurrence of high pollen and air pollutants as well as OTC sales correlated strongly with vapour pressure deficit and temperature in Gothenburg (much less so in Malm+Â). This provides evidence that the combination of meteorological properties associated with LWTs can explain high levels of birch pollen and air pollution. Our study shows that LWTs represent a useful tool for integrated daily air quality forecasting/warning</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Sweden -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9478-2</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9478-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170419-GrundstromM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170419-GrundstromM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Grundstrom M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9478-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adams-Groom,B.</style></author><author><style face="normal" font="Arial"> Skjoth,C.A.</style></author><author><style face="normal" font="Arial"> Baker,M.</style></author><author><style face="normal" font="Arial"> Welch,T.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Modelled and observed surface soil pollen deposition distance curves for isolated trees of Carpinus betulus, Cedrus atlantica, Juglans nigra and Platanus acerifolia</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cedrus</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen deposition</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Soil</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Source</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôdistance relationships for pollen deposited directly into surface soil have been rarely undertaken, particularly for a single or isolated source, rather than a forest, grove or plantation. This study aimed to determine surface soil pollen deposition patterns from single, isolated source trees and to compare the results to Gaussian model curves for the same trees. Four isolated tree pollen sources were chosen in Worcester, UK: Carpinus betulus, Cedrus atlantica, Juglans nigra and Platanus acerifolia. Surface soil samples were collected at 1, 5 and then every 10-ám, up to 100-ám distance from the main trunk of each source along the prevailing wind direction during flowering. A Gaussian dispersion model was used to estimate source strength using tree height and width and wind speeds on days when flowering was occurring and when the wind direction flowed along the sampling transect. This model simulated the expected concentration and deposition along the sampling transect. Modelled and observed results showed that most pollen was deposited beneath the canopy (range 63</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô94%) in an exponentially decreasing curve and the tailing off started from around the outer edge of the canopy in most cases. The amount of pollen deposited at 50-ám was no more than 2.6% of total deposition in the samples for any tree and at 100-ám no more than 0.2%. Tree height, width and wind speed during the pollination period were found to be the main parameters affecting deposition away from the source</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9479-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9479-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170405-AdamsGroomB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170405-AdamsGroomB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Adams-Groom B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9479-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83636</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Martinis,M.</style></author><author><style face="normal" font="Arial"> Sirufo,M.M.</style></author><author><style face="normal" font="Arial"> Ginaldi,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Life, Health, &amp; Environmental Sciences, University of L'Aquila, L'Aquila, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Allergy and Aging: An Old/New Emerging Health Issue</style></title><secondary-title><style face="normal" font="Arial">Aging Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Aging Dis</style></abbr-1></periodical><pages end="175" start="162">162-175</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Allergy reactions are the most common immunological diseases and represent one of the most widespread and fast growing chronic human health problems among people over 15 years of age in developed countries. As populations get older worldwide, allergy manifestations in aged persons will occur more often in the future. To date, there has been much more studies on allergies in children than in adults. As the population ages, clinicians must be prepared to meet all the elderly's health care needs, including these new and emerging health issue. Allergic diseases represent an old/new emerging health issue. Because many common illnesses masquerade as atopic disease, the differential diagnosis of suspected allergic diseases becomes more expanded in an aging population. Research in the field needs to focus on both human and animal model systems to investigate the impact of the aging process on the immunologic pathways underpinning allergy and its different facets</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 2152-5250 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.14336/AD.2016.0831</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400983">PM:28400983</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aging Dis\2017-8-162-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aging Dis\2017-8-162-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, De Martinis M</style></custom2><misc3><style face="normal" font="Arial">10.14336/AD.2016.0831</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Esparza-Carrillo,D.</style></author><author><style face="normal" font="Arial"> Rodriguez-Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Azamar-Jacome,A.A.</style></author><author><style face="normal" font="Arial"> Venegas-Montoya,E.</style></author><author><style face="normal" font="Arial"> Falck-Fuentes,C.A.</style></author><author><style face="normal" font="Arial"> Lopez-Hernandez,G.</style></author><author><style face="normal" font="Arial"> Ramirez-Uribe,N.</style></author><author><style face="normal" font="Arial"> Mendoza-Hernandez,D.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Rituximab desensitization: report of a pediatric patient in hematopoietic cell transplantation protocol [Desensibilización a rituximab: reporte de un paciente pediátrico en protocolo de trasplante de células hematopoyéticas]</style></title><secondary-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="101" start="96">96-101</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anemia</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Capillaries</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> hematopoietic cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Rapid desensitization</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Salicylic Acid</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">We present the case of an eight-year-old female girl with the diagnosis of Fanconi's anemia. The patient isgoing through the process of a stem cell transplant. The donor in this case is the father; it is a haploidentic,peripheral blood transplant with selective cell depletion with a CD 34+ marker. Donor specific antibodies(DSA) against HLA are positive, so a conditioning protocol with rituximab is prescribed. Thirty minutes afterthe first rituximab infusion (dose received 50 mg at infusion rate of 100 mL/h) the patient presents with ananaphylactic reaction: sudden onset of wheezing, shortness of breath, prolonged capillary refill, weak pulsesand fever. The use of rituximab is considered essential in this patient given the high risk of primary graftfailure, so it is decided to use a rapid desensitization protocol as described by Castell and Hong aiming toachieve a transitory tolerance by administering a drug with a previous type 1 hypersensitivity reaction. Theprocedure is performed under strictly supervised conditions. The infusion is administered in 12 steps, with 3solutions, each of these with a dilution of 1:100, 1:10 and the usual dilution. The rate of infusion is augmentedgradually. Before the infusion the patient is treated with montelukast, acetyl salicylic acid and cloropiramine.The total dose of 375 mg/m2BS/do is administered without hypersensitivity reactions. The patient successfullyreceives four complete doses of rituximab as prescribed, all of these infusions administered under the sameprotocol of rapid desensitization. There were no adverse effects nor allergic reactions reported. Conclusion: Monoclonal antibodies are highly effective therapies with a high specifity and affinity for a protein or targetmolecule. Rituximab is used in desensitization protocols in patients undergoing haploidentic stem celltransplant who are positive for donor specific antibodies anti-HLA, thus reducing the risk of primary graftfailure. Rituximab use is limited by the hypersensitivity reactions caused by it, with anaphylaxis being the mostserious of them. Using rapid desensitization protocols as described in this case the drug can be administeredsafely thus eliminating the need to use therapeutic alternatives that could have serious adverse effectsor be less effective. Rapid desensitization procedures should be individualized to the clinical presentationof previous reactions and to the existing protocols. These procedures should be performed under expertsupervision. This is the first pediatric case reporting successful rituximab desensitization.</style></abstract><notes><style face="normal" font="Arial">LA - SPA CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/resumen.cgi?IDARTICULO=69607</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2016-25-96-101.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2016-25-96-101.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Esparza-Carrillo D</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez,G.M.</style></author><author><style face="normal" font="Arial"> Mendoza-Hernandez,D.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cows' milk exclusion diet... how? [Dieta de exclusión de leche de vaca... ¿cómo?]</style></title><secondary-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="77" start="75">75-77</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy to cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergy to cow's milk is the most common food allergy in infants and young children. Once diagnosis isestablished, treatment consists of elimination of cow milk's protein from the diet. It is easy to say but hardto do. In this paper we describe a simple classification and management algorithm of CMA, a brief aboutwhat it is an elimination diet y nutrition facts about which food may be sources of vitamins and mineralsinstead of milk. This has shown to be practical for pediatric patients at Allergy Department of the NationalInstitute of Pediatrics.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/resumen.cgi?IDARTICULO=69603</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2016-25-75-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2016-25-75-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160410, Rodriguez GM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Edwards,A.M.</style></author><author><style face="normal" font="Arial"> Hide,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Carl Prausnitz Giles </style><style face="normal" font="Symbol">-</style><style face="normal" font="Arial"> family doctor and father of reagin detection</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="71" start="67">67-71</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diphtheria</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> General practice</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Plague</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reagin</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Dr. Carl Prausnitz Giles was born in Hamburg, Germany in 1876, the son of Otto Prausnitz, a Physician in the army reserve of the King of Prussia and Edith Giles, daughter of George and Elizabeth Giles of Bonchurch, Isle of Wight, United Kingdom. Carl qualified in Medicine at the Universities of Leipzig, Kiel and Breslau. He began work at the Hamburg Hygiene Institute, undertaking diagnostic work on cholera, plague, typhoid, diphtheria and tuberculosis. Carl frequently visited his mother</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs home in Bonchurch and became proficient in both German and English and obtained British medical qualifications, MRCS. LRCP.The key work, for which he is mainly remembered, was the discovery of the principle responsible for the supersensitivity of his co-worker, K++stner, to cooked fish. In a classic paper published in 1921, he showed this could be transferred to non-sensitive individuals. He called it reagin, eventually shown to be IgE antibody. The test demonstrating its existence, the Prausnitz-K++stner reaction, was used for many years to demonstrate allergy in patients.In 1926, Prausnitz was appointed Professor and Director of the Institute of Hygiene in Breslau. Due to his Jewish antecedents, in 1934 he was compulsorily retired from his Chair in Breslau and moved his family to England.In 1935 he moved to Bonchurch. At the age of 60 years he embarked on a career in General Practice in partnership with a childhood friend, Dr. Bruce Williamson. He took his mother</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs maiden name and became Dr. CP Giles of Ventnor, Isle of Wight. UK</style></abstract><notes><style face="normal" font="Arial">LA . ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0004-9</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0004-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-67-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-67-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Edwards AM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0004-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wojtalewicz,N.</style></author><author><style face="normal" font="Arial"> Goseberg,S.</style></author><author><style face="normal" font="Arial"> Kabrodt,K.</style></author><author><style face="normal" font="Arial"> Schellenberg,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">grid.427932.9Center of Life Sciences, AG IBAS, Hochschule Anhalt, Stenzfelder Allee 28, 06406 Bernburg (Saale), Germany</style></auth-address><titles><title><style face="normal" font="Arial">Six years of INSTAND e. V. sIgE proficiency testing: An evaluation of in vitro allergy diagnostics</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="52" start="43">43-52</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic testing</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Proficiency testing</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality assurance</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Standard material</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Even though allergies are an important health issue, wide manufacturer-dependent differences in the detected amounts of allergen-specific IgE (sIgE) have repeatedly been found. These discrepancies hinder diagnostics and research into clinically significant cutoff points for life-threatening symptoms. METHODS: To evaluate whether the reported differences have led to changes in diagnostic testing, we analyzed data from six years of round robin testing (RRT, also known as proficiency testing) at the Gesellschaft zur Forderung der Qualitatssicherung in medizinischen Laboratorien e.V. (Society for Promoting Quality Assurance in medical Laboratories) for the important allergen sources bee venom, wasp venom, and birch pollen. The results of the four main suppliers of in vitro diagnostic sIgE testing were compared in a pseudo-anonymized form using overlay images of box plot graphs for the semiquantitative data and allergen class results. Coefficients of variation (CV) were obtained to study the development of interlaboratory comparability. RESULTS: We found that the large differences between the manufacturer collectives remained constant between January 2010 and April 2015 without any real improvement. The CVs were good for two of the four analyzed suppliers, one was marginal and one above the quality level of 20%. CONCLUSION: The numerous publications that have found discrepancies in the sIgE results of the different suppliers did not change the status quo within the last six years. Unfortunately, this is unlikely to change until there is a characterized standard material with known values of sIgE</style></abstract><notes><style face="normal" font="Arial">DA - 20170327IS - 2197-0378 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-016-0005-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28344920">PM:28344920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-43-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-43-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170327, Wojtalewicz N</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-016-0005-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">di Coste,A.</style></author><author><style face="normal" font="Arial"> Occasi,F.</style></author><author><style face="normal" font="Arial"> De Castro,G.</style></author><author><style face="normal" font="Arial"> Zicari,A.M.</style></author><author><style face="normal" font="Arial"> Galandrini,R.</style></author><author><style face="normal" font="Arial"> Giuffrida,A.</style></author><author><style face="normal" font="Arial"> Indinnimeo,L.</style></author><author><style face="normal" font="Arial"> Duse,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sapienza University of Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Predictivity of clinical efficacy of sublingual immunotherapy (SLIT) based on sensitisation pattern to molecular allergens in children with allergic rhinoconjunctivitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="456" start="452">452-456</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> combined score</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergen</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergens</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen molecular allergens</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The diagnostic and therapeutic approach to grass pollen allergy is now possible by detecting specific IgE (sIgE) to its allergenic components. AIM: To evaluate the correlation between the sensitisation to different molecular Phleum pratense (Phl p) allergens and clinical efficacy of SLIT. METHODS: The pilot study included 36 patients affected by allergic rhinoconjunctivitis, all treated with SLIT actively. We performed serum analysis of sIgE to Phl p 1, 2, 4, 5, 6, 7, 11 and 12. The Average Rhinoconjunctivitis Total Symptom Score (ARTSS) and the Average Combined Score (ACS) were evaluated before and after one year of immunotherapy. RESULTS: Three different groups of sensitisation were defined based on the range of IgE reactivity to Phleum pratense allergens at baseline: group I (sIgE reactive to 1-3 allergens); group II (sIgE reactive to 4-5 allergens); and group III (sIgE reactive to 6-8 allergens). At T0 ACS was 1.79+/-0.18 in group I; 1.81+/-0.23 in group II; and 1.95+/-0.34 in group III. At T1 ACS was 0.85+/-0.55 in group I; 1.01+/-0.31 in group II; and 1.44+/-0.39 in group III. At T1 there was a significant improvement of ARTSS and ACS for group I (p=0.001). CONCLUSIONS: Sublingual immunotherapy with a grass pollen is efficacious irrespective of the patients' baseline sensitisation to either single or multiple grass pollen molecular allergens. We found that patients with few sensitisations have a greater improvement in combined symptom and medication score. SLIT improves the clinical course of allergic patients although new sensitisations may appear</style></abstract><notes><style face="normal" font="Arial">DA - 20170415IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410874">PM:28410874</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170415-diCosteA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170415-diCosteA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170415, di Coste A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.01.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez-Salguero,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Puerto Real University Hospital, Cadiz, Spain; University of Cadiz, Cadiz, Spain</style></auth-address><titles><title><style face="normal" font="Arial">FPIES: The dark side of food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="211" start="209">209-211</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - EditorialCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.04.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28411905">PM:28411905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2017-45-209-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2017-45-209-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Sanchez-Salguero CA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.04.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bolat,E.</style></author><author><style face="normal" font="Arial"> Arikoglu,T.</style></author><author><style face="normal" font="Arial"> Sungur,M.A.</style></author><author><style face="normal" font="Arial"> Batmaz,S.B.</style></author><author><style face="normal" font="Arial"> Kuyucu,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Metrolife Hospital, Department of Pediatrics, Urfa, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence and risk factors for wheezing and allergic diseases in preschool children: A perspective from the Mediterranean coast of Turkey</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="368" start="362">362-368</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> complementary foods</style></keyword><keyword><style face="normal" font="Arial"> dampness</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean Region</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: The aim of the present study was to determine the prevalence and risk factors of allergic diseases in preschool children from one of the biggest cities in the Mediterranean Region of Turkey. METHODS: The study population included 396 preschool children attending to urban daycare centres in Mersin. In the first stage, a comprehensive standardised questionnaire modified from the International Study of Asthma and Allergies in Childhood (ISAAC) was employed. In the second stage, serum food and inhalant specific IgE, and skin tests were performed in 45 children with frequent wheezing and 28 children with no wheezing. RESULTS: The prevalence of ever wheezing, current wheezing, physician-diagnosed asthma, allergic rhinitis and eczema were 53% (210), 33.3% (132), 27.3% (108), 13.4% (53) and 8.3% (33), respectively. A family history of atopy (OR=2.5, 95% CI: 1.3-4.7, p=0.004), dampness at home (OR=2.4, 95% CI: 1.2-4.8, p=0.008), a history of intestinal parasites (OR=4.3, 95% CI: 1.7-10.9, p=0.002), previous history of pneumonia (OR=6.9, 95% CI: 1.9-25.9, p=0.004), initiation of complementary foods before the age of three months (OR=6.1, 95%CI: 1.4-26.9, p=0.02) and presence of food allergy (OR=3.1, 95% CI: 1.1-9.2, p=0.03) were found to be significant risk factors for physician-diagnosed asthma. The risk factors for frequent wheezing were maternal smoking during pregnancy (OR=5.2, 95% CI: 0.9-28.7, p=0.05) and high serum IgE levels (OR=2.9, 95% CI: 0.9-9.0, p=0.05) at borderline significance. CONCLUSION: Our study was the first epidemiological study in preschool children in the Mediterranean region of Turkey and demonstrated a high prevalence of asthma and allergic diseases, probably related to humid climatic properties in addition to other environmental and genetic factors</style></abstract><notes><style face="normal" font="Arial">DA - 20170415IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engCO - Turkey -PT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.01.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410872">PM:28410872</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170415-BolatE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170415-BolatE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170415, Bolat E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.01.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Armentia,A.</style></author><author><style face="normal" font="Arial"> Santos,J.</style></author><author><style face="normal" font="Arial"> Serrano,Z.</style></author><author><style face="normal" font="Arial"> Martin,B.</style></author><author><style face="normal" font="Arial"> Martin,S.</style></author><author><style face="normal" font="Arial"> Barrio,J.</style></author><author><style face="normal" font="Arial"> Fernandez,S.</style></author><author><style face="normal" font="Arial"> Gonzalez-Sagrado,M.</style></author><author><style face="normal" font="Arial"> Pineda,F.</style></author><author><style face="normal" font="Arial"> Palacios,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergia, Hospital Universitario Rio Hortega, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Molecular diagnosis of allergy to Anisakis simplex and Gymnorhynchus gigas fish parasites</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="472" start="463">463-472</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> Cephalopod</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Marine food</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray Analysis</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There has been an increase in the prevalence of hypersensitivity to Anisakis simplex. There are fish parasites other than Anisakis simplex whose allergenicity has not yet been studied. OBJECTIVE: To assess IgE hypersensitivity caused by fish parasite allergens in patients with gastro-allergic symptoms after consumption of fish, shellfish or cephalopods, compared with healthy subjects, pollen allergic individuals and children with digestive symptoms after eating marine food. METHODS: We carried out in vivo tests (skin prick) and in vitro tests (specific IgE determination, Western blot) and component resolved diagnostics (CRD) using microarray analysis in all patients. RESULTS: CRD better detected sensitisation to allergens from marine parasites than skin prick tests and determination of specific IgE by CAP. Sensitisation to Gymnorhynchus gigas was detected in 26% of patients measured by skin prick tests and 36% measured by IgE. CONCLUSIONS: The prevalence of hypersensitivity to marine parasite allergens other than Anisakis simplex should be studied, and the most appropriate technique for this is CRD</style></abstract><notes><style face="normal" font="Arial">DA - 20170325IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.12.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341528">PM:28341528</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170325-ArmentiaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170325-ArmentiaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170325, Armentia A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.12.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bioinformatics and Medical Informatics Research Center, San Diego State University, 5500 Campanile Dr, San Diego, CA 92182, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Under the superficial dichotomy pathogen and allergen are two manifestations of same immune activation and pathogenesis mechanisms</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Coagulation</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> In silico analysis</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Informatics</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">Pathogens and allergens are deemed as two contrasting facets of host immune status, deficiency and exuberant. In silico domain analysis of a diverse panel of pathogen and allergen proteins has revealed the shortcoming of this notion. Both the pathogen and allergen proteins elicit immune activation, with the outcome of immune agitation depending on the pathogen strain, allergen exposure duration, and host factors. Pathogens can replicate within the host and constantly irritate the immune system, leading to blood coagulation, respiratory collapse and death. Allergens, being non-viable, can only provoke the immune system transiently; however, depending on the allergen dose and extent exposed to, inflammation and fatality can occur. In silico analysis of pathogen and allergen proteins showed the conserved domains to be AAA, WR1, VKc, Kelch, Hr1, HAMP, HELICc, Dak2, CHAD, CHASE2, Galanin, PKS_TE, Robl_LC7, Excalibur, DISIN, etc. This exciting discovery can have far-reaching effects in drug target identification approaches</style></abstract><notes><style face="normal" font="Arial">DA - 20170415IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.01.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410873">PM:28410873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170415-PatelS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170415-PatelS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170415, Patel S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.01.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Praena-Crespo,M.</style></author><author><style face="normal" font="Arial"> Aquino-Llinares,N.</style></author><author><style face="normal" font="Arial"> Fernandez-Truan,J.C.</style></author><author><style face="normal" font="Arial"> Castro-Gomez,L.</style></author><author><style face="normal" font="Arial"> Segovia-Ferrera,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Sevilla, La Candelaria Medical Center, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Asthma education taught by physical education teachers at grade schools: A randomised cluster trial</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="386" start="375">375-386</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absenteeism</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma education</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> sport</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Assess whether the Asthma, Sport and Health (ASAH) programme taught by teachers improves asthmatics' quality of life, asthma knowledge, and reduces school absenteeism. DESIGN: Randomised cluster trial parallel group. PARTICIPANTS: 2293 students (203 asthmatic) in the Intervention School group (IS) and 2214 in the Comparison School (CS) (224 asthmatic) belonging to primary school. INTERVENTION: Implementation of the educational programme "Asthma, Sport and Health" at grade schools, taught by physical education teachers. MAIN OUTCOME: Quality of life according to the Pediatric Asthma Quality of Life Questionnaire (PAQLQ). SECONDARY OUTCOMES: Asthma knowledge, asthma control, school absenteeism. RESULTS: After implementing the programme in the IS group, global quality of life improved significantly (p&lt;0.001) as did their domains, symptoms (p&lt;0.001), emotional function (p&lt;0.001) and activity limitations (p&lt;0.01), while in the CS group improvement was seen in global life quality (p&lt;0.01) without any significant changes in the domains for emotional function and activity limitations. Asthma knowledge only increased in IS, among asthmatic students from 16.51 (CI 95% 16.04-16.98) to 18.16 (CI 95% 17.69-18.62) (p&lt;0.001) and students without asthma from 15.49 (CI95% 15.36-15.63) to 17.50 (CI95% 17.36-17.64) (p&lt;0.001). The multiple regression analysis showed that quality of life and its domains depend on asthma knowledge and above all, having well-controlled asthma. We found no decrease in school absenteeism. CONCLUSIONS: The ASAH programme improved certain quality of life aspects regarding asthma (emotional function and limitation of activities) and asthma knowledge, but it failed to reduce school absenteeism NCT01607749</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.10.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318759">PM:28318759</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170320-PraenaCrespoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170320-PraenaCrespoM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Praena-Crespo M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.10.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shinoda,K.</style></author><author><style face="normal" font="Arial"> Hirahara,K.</style></author><author><style face="normal" font="Arial"> Nakayama,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Maintenance of pathogenic Th2 cells in allergic disorders</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="376" start="369">369-376</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological memory</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">Immunological memory is an important protective mechanism that enables host organisms to respond rapidly and vigorously to pathogens that have been previously encountered. In addition to the protective function, memory CD4+ T helper (Th) cells play a central role in the pathogenesis of chronic inflammatory disorders, including asthma. Recently, several investigators have identified phenotypically and functionally distinct memory Th2 cell subsets that produce IL-5. These memory Th2 cell subsets play an important role in the pathology of allergic inflammation and function as memory-type "pathogenic Th2 (Tpath2) cells" both in mice and humans. We review the role of lung Tpath2 cells in the development of allergic inflammation and, in the context of recent findings, propose a mechanism by which Tpath2 cells not only survive but also continue to function at the sites where antigens were encountered. A greater understanding of the functional molecules or signaling pathways that regulate the inflammatory niche for Tpath2 cells may aid in the design of more effective treatments for chronic inflammatory disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.03.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28391979">PM:28391979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170410-ShinodaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170410-ShinodaK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Shinoda K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.03.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagimoto,Y.</style></author><author><style face="normal" font="Arial"> Taniuchi,S.</style></author><author><style face="normal" font="Arial"> Ishizaki,Y.</style></author><author><style face="normal" font="Arial"> Nakano,K.</style></author><author><style face="normal" font="Arial"> Hosaka,N.</style></author><author><style face="normal" font="Arial"> Kaneko,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Kansai Medical University, Osaka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic gastroenteritis caused by eating hens' eggs: A case report</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Case Report</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28279648">PM:28279648</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170310-YanagimotoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170310-YanagimotoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Yanagimoto Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.02.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inada,N.</style></author><author><style face="normal" font="Arial"> Shoji,J.</style></author><author><style face="normal" font="Arial"> Shiraki,Y.</style></author><author><style face="normal" font="Arial"> Aso,H.</style></author><author><style face="normal" font="Arial"> Yamagami,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Histamine H1 and H4 receptor expression on the ocular surface of patients with chronic allergic conjunctival diseases</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctival Diseases</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Major Basic Protein</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-1</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-2</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-3</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> H4 receptor</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> histamine H4 receptor</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Ocular surface</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> real-time RT-PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: This study investigated the histamine H1 and H4 receptors mRNA (H1R and H4R, respectively) expression on the ocular surface of patients with chronic forms of allergic conjunctival diseases to determine whether they can serve as biomarkers for allergic inflammation in the conjunctiva. METHODS: We examined 19 patients with vernal or atopic keratoconjunctivitis (AKC/VKC group) and 15 healthy volunteers (control group). The AKC/VKC group was divided into active and stable stage subgroups. Specimens were obtained from the upper tarsal conjunctiva of each participant using a modified impression cytology method. H1R, H4R, and eotaxin-1, -2, and -3 mRNA (eotaxin-1, eotaxin-2, eotaxin-3, respectively) expression was determined by real-time RT-PCR. Immunohistochemical analysis for eosinophil cationic protein (ECP), eosinophil major basic protein (MBP), eotaxin-2, and histamine H4 receptor (H4R) were performed using conjunctival smears. RESULTS: The number of H4R-positive patients was higher in the active than the stable stage subgroup and control group, whereas no difference was observed for H1R. H1R levels were higher in the active than in the stable stage subgroup, while those of H4R were higher in the active stage subgroup than in the control group. H1R and H4R levels were correlated with eotaxin-2 level. In immunohistochemical analysis, H4R revealed their expression on eosinophils in conjunctival smears of patients with AKC/VKC. CONCLUSIONS: H4R is useful as biomarkers of allergic inflammation on ocular surfaces. Most notably, H4R expressed on eosinophils is useful as a biomarker of eosinophilic inflammation of the ocular surface</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28391980">PM:28391980</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170410-InadaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170410-InadaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Inada N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.03.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takabayashi,T.</style></author><author><style face="normal" font="Arial"> Imoto,Y.</style></author><author><style face="normal" font="Arial"> Sakashita,M.</style></author><author><style face="normal" font="Arial"> Kato,Y.</style></author><author><style face="normal" font="Arial"> Tokunaga,T.</style></author><author><style face="normal" font="Arial"> Yoshida,K.</style></author><author><style face="normal" font="Arial"> Narita,N.</style></author><author><style face="normal" font="Arial"> Ishizuka,T.</style></author><author><style face="normal" font="Arial"> Fujieda,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Otorhinolaryngology Head and Neck Surgery, Department of Sensory and Locomotor Medicine, University of Fukui, Fukui, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> Bacillus subtilis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Fibrin</style></keyword><keyword><style face="normal" font="Arial"> Fibrinolysis</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Viscosity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is often comorbid with asthma and resistant to therapeutic interventions. We recently reported that excessive fibrin deposition caused by impairment of fibrinolysis might play pivotal role in forming nasal polyp. Nattokinase (NK), a serine protease produced by Bacillus subtilis, has been reported to be a strong fibrinolytic enzyme. NK could be a promising drug candidate for use in the treatment of both CRSwNP and asthma. The objective of this study was to investigate the effects of NK on nasal polyp tissues from patients with CRSwNP. The nasal discharge from patients with CRSwNP and sputum from subjects with asthma were also used to investigate whether NK influences the viscosity of mucus. METHODS: To examine the effects on NK on nasal polyp tissues, pieces of nasal polyps were incubated either with saline or NK (10-1000 FU/ml) at 37 degrees C for 24 h. We assessed the presence of fibrin in nasal polyp tissue incubated with NK by means of immunohistochemistry. To examine the effects of NK on nasal discharge and sputum from patients with CRSwNP and asthma, respectively, were incubated with NK solution at 37 degrees C for 1 h. RESULTS: NK effectively shrinks the nasal polyp tissue through fibrin degradation. We also found that the viscosity of the nasal discharge and sputum from patients with CRSwNP and asthma, respectively, was significantly reduced by incubation with NK solution. CONCLUSIONS: NK may be an effective alternative therapeutic option in patients with CRSwNP and comorbid asthma by causing fibrin degradation</style></abstract><notes><style face="normal" font="Arial">DA - 20170408IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.03.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389065">PM:28389065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170408-TakabayashiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170408-TakabayashiT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Takabayashi T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.03.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ohta,K.</style></author><author><style face="normal" font="Arial"> Izuhara,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Hospital Organization Tokyo National Hospital, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Japanese guidelines for allergic diseases 2017</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="162" start="161">161-162</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - EditorialCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359401">PM:28359401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\2017-66-161-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\2017-66-161-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Ohta K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.03.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakano,M.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author><author><style face="normal" font="Arial"> Yuno,T.</style></author><author><style face="normal" font="Arial"> Soma,N.</style></author><author><style face="normal" font="Arial"> Aburakawa,S.</style></author><author><style face="normal" font="Arial"> Kasai,K.</style></author><author><style face="normal" font="Arial"> Nakamura,T.</style></author><author><style face="normal" font="Arial"> Takami,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Aomori, Japan</style></auth-address><titles><title><style face="normal" font="Arial">UDP/P2Y6 receptor signaling regulates IgE-dependent degranulation in human basophils</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Ca2+ influx</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> CAMP</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human basophils</style></keyword><keyword><style face="normal" font="Arial"> Hydrolases</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> Inositol</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nucleotides</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Kinase C</style></keyword><keyword><style face="normal" font="Arial"> purinergic receptor</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: P2Y purinergic receptors (P2YR) are G protein-coupled receptors that are stimulated by extracellular nucleotides. They mediate cellular effects by regulating cAMP production, protein kinase C activation, inositol trisphosphate generation, and Ca2+ release from intracellular stores. The P2Y6 receptor of this family is selectively stimulated by UDP, and selectively inhibited by MRS2578. In the present study, we examined the effect of UDP/P2Y6 receptor signaling on IgE-dependent degranulation in human basophils. METHODS: Basophils were purified from human peripheral blood. The mRNA expression of genes encoding P2YR and ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase) was measured by RT-PCR. Intracellular Ca2+ influx via UDP/P2Y6 receptor signaling in basophils was detected using a calcium probe. The effect of UDP/P2Y6 receptor signaling on IgE-dependent degranulation in basophils was confirmed by measuring CD63 expression by flow cytometry. Autocrine secretion of nucleotides was detected by HPLC analysis. RESULTS: We showed that purified basophils express P2Y6 mRNA and that UDP increased intracellular Ca2+, which was reduced by MRS2578 treatment. UDP promoted IgE-dependent degranulation. Furthermore, MRS2578 inhibited IgE-dependent degranulation in basophils. HPLC analysis indicated that basophils spontaneously secrete UTP. In addition, basophils expressed the extracellular nucleotide hydrolases ENTPDase2, ENTPDase3, and ENTPDase8. CONCLUSIONS: This study showed that UDP/P2Y6 receptor signaling is involved in the regulation of IgE-dependent degranulation in basophils, which might stimulate the P2Y6 receptor via the autocrine secretion of UTP. Thus, this receptor represents a potential target to regulate IgE-dependent degranulation in basophils during allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.02.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318884">PM:28318884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170320-NakanoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170320-NakanoM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Nakano M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.02.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kamioka,N.</style></author><author><style face="normal" font="Arial"> Nomura,T.</style></author><author><style face="normal" font="Arial"> Kato,T.</style></author><author><style face="normal" font="Arial"> Yoneyama,M.</style></author><author><style face="normal" font="Arial"> Sobajima,T.</style></author><author><style face="normal" font="Arial"> Tanida,H.</style></author><author><style face="normal" font="Arial"> Morishita,T.</style></author><author><style face="normal" font="Arial"> Sugiura,S.</style></author><author><style face="normal" font="Arial"> Suda,Y.</style></author><author><style face="normal" font="Arial"> Hirabayashi,Y.</style></author><author><style face="normal" font="Arial"> Misawa,C.</style></author><author><style face="normal" font="Arial"> Tanaka,H.</style></author><author><style face="normal" font="Arial"> Mizuno,M.</style></author><author><style face="normal" font="Arial"> Terada,A.</style></author><author><style face="normal" font="Arial"> Kanda,Y.</style></author><author><style face="normal" font="Arial"> Saitoh,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Nagoya City West Medical Center, Nagoya, Japan; Department of Pediatrics and Neonatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Probability curves for predicting symptom severity during an oral food challenge with wheat</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.02.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284490">PM:28284490</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170312-KamiokaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170312-KamiokaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Kamioka N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.02.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ebisawa,M.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author><author><style face="normal" font="Arial"> Fujisawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Japanese guidelines for food allergy 2017</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="264" start="248">248-264</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food-dependent exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Five years have passed since the Japanese Pediatric Guideline for Food Allergy (JPGFA) was first revised in 2011 from its original version. As many scientific papers related to food allergy have been published during the last 5 years, the second major revision of the JPGFA was carried out in 2016. In this guideline, food allergies are generally classified into four clinical types: (1) neonatal and infantile gastrointestinal allergy, (2) infantile atopic dermatitis associated with food allergy, (3) immediate-type of food allergy (urticaria, anaphylaxis, etc.), and (4) special forms of immediate-type of food allergy such as food-dependent exercise-induced anaphylaxis and oral allergy syndrome (OAS). Much of this guideline covers the immediate-type of food allergy that is seen during childhood to adolescence. Infantile atopic dermatitis associated with food allergy type is especially important as the onset of most food allergies occurs during infancy. We have discussed the neonatal and infantile gastrointestinal allergy and special forms of immediate type food allergy types separately. Diagnostic procedures are highlighted, such as probability curves and component-resolved diagnosis, including the recent advancement utilizing antigen-specific IgE. The oral food challenge using a stepwise approach is recommended to avoid complete elimination of causative foods. Although oral immunotherapy (OIT) has not been approved as a routine treatment by nationwide insurance, we included a chapter for OIT, focusing on efficacy and problems. Prevention of food allergy is currently the focus of interest, and many changes were made based on recent evidence. Finally, the contraindication between adrenaline and antipsychotic drugs in Japan was discussed among related medical societies, and we reached an agreement that the use of adrenaline can be allowed based on the physician's discretion. In conclusion, this guideline encourages physicians to follow the principle to let patients consume causative foods in any way and as early as possible</style></abstract><notes><style face="normal" font="Arial">DA - 20170313IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.02.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28285847">PM:28285847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\2017-66-248-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\2017-66-248-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170313, Ebisawa M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.02.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leonardi,A.</style></author><author><style face="normal" font="Arial"> Doan,S.</style></author><author><style face="normal" font="Arial"> Fauquert,J.L.</style></author><author><style face="normal" font="Arial"> Bozkurt,B.</style></author><author><style face="normal" font="Arial"> Allegri,P.</style></author><author><style face="normal" font="Arial"> Marmouz,F.</style></author><author><style face="normal" font="Arial"> Rondon,C.</style></author><author><style face="normal" font="Arial"> Jedrzejczak,M.</style></author><author><style face="normal" font="Arial"> Hellings,P.</style></author><author><style face="normal" font="Arial"> Delgado,L.</style></author><author><style face="normal" font="Arial"> Calder,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neuroscience, Ophthalmology Unit, University of Padua, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Diagnostic Tools in Ocular Allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity disorders</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Ocular allergy</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="Arial">Ocular allergy (OA) includes a group of common and less frequent hypersensitivity disorders frequently misdiagnosed and not properly managed. The diagnosis of OA is usually based on clinical history and signs and symptoms, with the support of in vivo and in vitro tests when identification of the specific allergen is required. To date, no specific test is available for the diagnosis of the whole spectrum of the different forms of OA. The lack of recommendations on diagnosis of OA is considered a medical need not only for allergists but also for ophthalmologists. This position paper aims to provide a comprehensive overview of the currently available tools for diagnosing OA to promote a common nomenclature and procedures to be used by different specialists. Questionnaires, sign and symptom grading scales, tests and potential biomarkers for OA are reviewed. We also identified several unmet needs in the diagnostic tools to generate interest, increase understanding and inspire further investigations. Tools, recommendations and algorithms for the diagnosis of OA are proposed for use by both allergists and ophthalmologists. Several unmet needs in the diagnostic tools should be further improved by specific clinical research in OA. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - France -CO - Turkey -CO - Spain -CO - Poland -CO - Belgium -CO - Portugal -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13178</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28387947">PM:28387947</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170407-LeonardiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170407-LeonardiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170407, Leonardi A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13178</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> Bewick,M.</style></author><author><style face="normal" font="Arial"> Arnavielhe,S.</style></author><author><style face="normal" font="Arial"> Mathieu-Dupas,E.</style></author><author><style face="normal" font="Arial"> Murray,R.</style></author><author><style face="normal" font="Arial"> Bedbrook,A.</style></author><author><style face="normal" font="Arial"> Caimmi,D.P.</style></author><author><style face="normal" font="Arial"> Vandenplas,O.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Bosnic-Anticevitch,S.</style></author><author><style face="normal" font="Arial"> Bouchard,J.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Chavannes,N.H.</style></author><author><style face="normal" font="Arial"> Cruz,A.A.</style></author><author><style face="normal" font="Arial"> Dahl,R.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> De Vries,G.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Fink-Wagner,A.</style></author><author><style face="normal" font="Arial"> Fokkens,W.J.</style></author><author><style face="normal" font="Arial"> Fonseca,J.</style></author><author><style face="normal" font="Arial"> Guldemond,N.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Hellqvist-Dahl,B.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Kvedariene,V.</style></author><author><style face="normal" font="Arial"> Laune,D.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Pereira,A.M.</style></author><author><style face="normal" font="Arial"> Carreiro-Martins,P.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Morais-Almeida,M.</style></author><author><style face="normal" font="Arial"> Nogueira-Silva,L.</style></author><author><style face="normal" font="Arial"> O'hehir,R.E.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Portejoie,F.</style></author><author><style face="normal" font="Arial"> Price,D.</style></author><author><style face="normal" font="Arial"> Ryan,D.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Simons,F.E.</style></author><author><style face="normal" font="Arial"> Spranger,O.</style></author><author><style face="normal" font="Arial"> Bom,A.T.</style></author><author><style face="normal" font="Arial"> Tomazic,P.V.</style></author><author><style face="normal" font="Arial"> Triggiani,M.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author><author><style face="normal" font="Arial"> Valovirta,E.</style></author><author><style face="normal" font="Arial"> Valiulis,A.</style></author><author><style face="normal" font="Arial"> van Eerd,M.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Young,I.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Work productivity in rhinitis using cell phones: The MASK pilot study</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1484" start="1475">1475-1484</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mobile phone</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis often impairs social life and performance. The aim of this cross-sectional study was to assess the impact of uncontrolled rhinitis assessed by visual analogue score VAS on work productivity using cell phone data collection. A mobile phone app Allergy Diary, Android and Apple stores collects daily visual analogue scales VAS data for overall allergic symptoms VAS-global measured, nasal VAS-nasal, ocular VAS-ocular, asthma symptoms VAS-asthma and work VAS-work. A combined nasal-ocular score is calculated. Allergy Diary is available in 20 countries. The App includes the Work Productivity and Activity Impairment Allergic Specific Questionnaire WPAI:AS questionnaire in 6 EU countries. All consecutive users who filled the VAS-work from June 1 to October 31, 2016 were included in the study. A total of 1,136 users filled in 5,818 days of VAS-work. Symptoms of allergic rhinitis were controlled VAS-global&lt;20 in approximately 60% of days. In users with uncontrolled rhinitis, approximately 90% had some work impairment and over 50% had severe work impairment VAS-work>50. There was a significant correlation between VAS-global calculated and VAS-work Rho=0.83, p&lt;0.00001, Spearman rank test. In 144 users, there was a significant correlation between VAS-work and WPAI:AS Rho=0.53, p&lt;0.0001. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - France -CO - United KIngdom -CO - Belgium -CO - Sweden -CO - Netherlands -CO - Germany -CO - Italy -CO - Austria -CO - Portugal -CO - Canada -CO - Poland -CO - Greece -CO - Australia -CO - Mexico - CO - Lithuania -CO - Denmark -CO - Finland -CO - Brazil -CO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13177</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28387952">PM:28387952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170407-BousquetJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170407-BousquetJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170407, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13177</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wittenberg,M.</style></author><author><style face="normal" font="Arial"> Nassiri,M.</style></author><author><style face="normal" font="Arial"> Francuzik,W.</style></author><author><style face="normal" font="Arial"> Lehmann,K.</style></author><author><style face="normal" font="Arial"> Babina,M.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy- Center-Charite, CCM, Dpt. of Dermatology and Allergology, Charite-Universitatsmedizin Berlin</style></auth-address><titles><title><style face="normal" font="Arial">Serum levels of 9alpha,11beta-PGF2 and apolipoprotein A1 achieve high predictive power as biomarkers of anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Apolipoprotein A1</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipoproteins</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a life-threatening hypersensitivity reaction. To identify biomarkers for the condition, we assessed serum levels of apolipoprotein (Apo)A and ApoE. We found a reduction of both lipoproteins in anaphylactic mice as well as in orally challenged food allergic patients. We then compared patients after acute anaphylaxis with several control groups (non-allergic, history of allergen-triggered anaphylaxis, acute cardiovascular/febrile reactions). In this unpaired setting, ApoE levels were unaltered, while ApoA1 was reduced in the anaphylactic group. Though unable to discriminate between anaphylaxis and cardiovascular/febrile reactions, ROC curve analysis revealed a reasonably high area under the curve (AUC) of 0.91 for ApoA1. Serum 9alpha,11ss-PGF2 , recently identified as a suitable biomarker for anaphylaxis, outperformed ApoA1 with AUC=0.95. Intriguingly however, its power further increased upon combination of both mediators reaching AUC=1. Our data suggest that ApoA1 combined with 9alpha,11ss-PGF2 represents a useful composite biomarker of anaphylaxis, achieving superior diagnostic power over either factor alone. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13176</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378321">PM:28378321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170405-WittenbergM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170405-WittenbergM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Wittenberg M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13176</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pali-Scholl,I.</style></author><author><style face="normal" font="Arial"> De Lucia,M.</style></author><author><style face="normal" font="Arial"> Jackson,H.</style></author><author><style face="normal" font="Arial"> Janda,J.</style></author><author><style face="normal" font="Arial"> Mueller,R.S.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University of Vienna and University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Comparing immediate type food allergy in humans and companion animals - revealing unmet needs</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Knowledge gaps</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="10" Month="4" Year="2017">2017/4/10</year></dates><abstract><style face="normal" font="Arial">Adverse food reactions occur in human as well as veterinary patients and systematic comparison may lead to improved recommendations for prevention and treatment in both. In this position paper, we summarize the current knowledge on immediate type food allergy versus other food-adverse reactions in companion animals, and compare this to the human situation. While the prevalence of food allergy in humans has been well studied for some allergens, this remains to be investigated for animal patients, where owner-reported as well as veterinarian-diagnosed food adverse reactions are on the increase. The characteristics of the disease in humans versus dogs, cats, and horses are most often caused by similar, but sometimes species-dependent different, pathophysiological mechanisms, prompting the specific clinical symptoms, diagnoses and treatments. Furthermore, little is known about the allergen molecules causative for type I food allergy in animals which, like in human patients, could represent predictive biomarkers for risk evaluation. The definite diagnosis of food allergy relies -as in humans- on elimination diet and provocation tests. Besides allergen avoidance in daily practice, novel treatment options and tolerization strategies are underway. Taken together, numerous knowledge gaps were identified in veterinary food allergy, which need to be filled by systematic comparative studies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Italy -CO - United Kingdom -CO - Czech Republic -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13179</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28394404">PM:28394404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170410-PaliSchollI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170410-PaliSchollI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Pali-Scholl I</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13179</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gimenez-Arnau,A.</style></author><author><style face="normal" font="Arial"> Curto-Barredo,L.</style></author><author><style face="normal" font="Arial"> Nonell,L.</style></author><author><style face="normal" font="Arial"> Puigdecanet,E.</style></author><author><style face="normal" font="Arial"> Yelamos,J.</style></author><author><style face="normal" font="Arial"> Gimeno,R.</style></author><author><style face="normal" font="Arial"> Ruberg,S.</style></author><author><style face="normal" font="Arial"> Santamaria-Babi,L.</style></author><author><style face="normal" font="Arial"> Pujol,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital del Mar IMIM, Universitat Autonoma de Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cell Cycle</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Differentially expressed gene</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptome analysis</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The knowledge about chronic spontaneous urticaria (CSU) phenotypes is based on its clinical characteristics, associated comorbidities, course of the disease and its response to the available effective drugs. Genotype expression and its further correlation with CSU phenotypes are still unknown. We describe the cutaneous transcriptome of patients suffering a severely active CSU refractory to antihistamine treatment. METHODS: Through the bioinformatic analysis of the whole Human Genome with Oligo Microarrays and Quantitative real-time polymerase chain reaction (qPCR), relevant genes expressed in non-lesional [NLS-CSU] and lesional skin [LS-CSU]) and peripheral blood were identified in 20 patients suffering from severely active CSU and 10 healthy controls (HCs) RESULTS: From 39 genes differentially expressed in NLS-CSU when compared with HCs, 31 (79.48%) were confirmed by qPCR corresponding to genes involved in epidermal homeostasis and dermal repair. From the analysis comparing LS-CSU with NLS-CSU, a selection of 142 genes was studied with qPCR, and 103 (72.53%) were confirmed. Differentially expressed genes in the phenomenon of wheal development are involved in a variety of biological functions as, epidermal differentiation, intracellular signal function, transcriptional factors cell cycle differentiation, inflammation or coagulation. Differentially expressed genes that uniformly increase or decrease along the skin worsening until the wheal appearance are shown. CONCLUSION: The skin of CSU patients with a severely active disease shows an overall immunological skin involvement showing a peculiar gene profile. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170413IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13183</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28407332">PM:28407332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170413-GimenezArnauA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170413-GimenezArnauA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170413, Gimenez-Arnau A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13183</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perez-Calderon,R.</style></author><author><style face="normal" font="Arial"> Gonzalo-Garijo,M.A.</style></author><author><style face="normal" font="Arial"> Rodriguez-Velasco,F.J.</style></author><author><style face="normal" font="Arial"> Sanchez-Vega,S.</style></author><author><style face="normal" font="Arial"> Bartolome-Zavala,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Infanta Cristina University Hospital. Allergology Department, Badajoz, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Occupational respiratory allergy in peach crop workers</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Badajoz</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial challenge test</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> IgE-immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunodetection</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Occupational respiratory diseases in workers of peach tree crops have been reported punctually and have been associated with sensitization to proteins present in both pollen and leaf tree. We report the study of 37 workers with respiratory symptoms related to occupational exposure to peach trees. METHODS: Prick tests and specific IgE determinations were performed with extracts from leaves and branches of peach tree. Immunodetection in leaf extract was realized by SDS-PAGE-immunoblotting with patient sera and rabbit serum anti-Pru p 3. Immunodetection inhibition was performed with rPru p 3 and pollen profilins. The clinical relevance of sensitization was demonstrated by specific bronchial challenge test (SBCT) with peach leaf extract. RESULTS: Most patients suffered symptoms when peach trees had leaves, specifically during thinning and harvesting fruit (rhinoconjunctivitis: 100% and asthma: 67.5%). Sensitization to leaf extract was demonstrated in 86% of patients. IgE-immunoblotting with peach leaf extract revealed in 6 patient sera a pair of bands of 10 and 16 kDa, and in 9 a 16 kDa band. Those bands could be two isoforms of peach leaf LTP, so the recognition frequency of some LTP isoform by our patient sera was 42%. 33% of the sera recognized a doubled band of about 14.5 kDa and this recognition was inhibited by nPho d 2. The SBCT with peach leaf extract was positive in the asthmatic sensitized patients tested. CONCLUSIONS: Sensitization to peach leaves was the cause of occupational respiratory symptoms in our patients. Some patient sera revealed IgE-binding proteins matching LTP and/or profilin. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13163</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317175">PM:28317175</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170320-PerezCalderonR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170320-PerezCalderonR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Perez-Calderon R</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13163</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kolkhir,P.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Altrichter,S.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">I.M. Sechenov First Moscow State Medical University, Department of Dermatology and Venereology, Moscow, RussiaCharite - Universitatsmedizin Berlin, Department of Dermatology and Allergy, Berlin, GermanyCharite - Universitatsmedizin Berlin, Department of Dermatology and Allergy, Berlin, GermanyCharite - Universitatsmedizin Berlin, Department of Dermatology and Allergy, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> autoantigen</style></keyword><keyword><style face="normal" font="Arial"> Autoantigens</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Hashimoto's thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Hyperthyroidism</style></keyword><keyword><style face="normal" font="Arial"> Hypothyroidism</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Diseases</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="Arial">Chronic spontaneous urticaria (CSU) patients are widely held to often have other autoimmune disorders, including autoimmune thyroid disease. Here, we systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice versa. There is a strong link between CSU and elevated levels of IgG anti-thyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of >/=10%. Levels of IgG against thyroid peroxidase (TPO) are more often elevated in CSU than those of other IgG anti-thyroid AAbs (strong evidence). Levels of IgG anti-thyroid AAbs are more often elevated in adult CSU patients than in children (strong evidence). CSU patients exhibit significantly higher levels of IgG anti-thyroid AAbs (strong evidence) and IgE-anti-TPO (weak evidence) than controls. Elevated IgG anti-thyroid AAbs in CSU are linked to the use of glucocorticoids (weak evidence) but not to disease duration or severity/activity, gender, age or ASST response (inconsistent evidence). Thyroid dysfunction rates are increased in CSU patients (strong evidence). Hypothyroidism and Hashimoto's thyroiditis are more common than hyperthyroidism and Graves' disease (strong evidence). Thyroid dysfunction is more common in adult CSU patients than in children (strong evidence) and in female than male CSU patients (weak evidence). Urticaria including CSU is more prevalent in patients with thyroid autoimmunity than in healthy controls (weak evidence). CSU can improve in response to treatment with levothyroxine or other thyroid drugs (strong evidence). Pathogenic mechanisms in CSU patients with thyroid autoimmunity may include IgE against autoantigens, immune complexes and complement. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170413IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Russia -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13182</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28407273">PM:28407273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170413-KolkhirP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170413-KolkhirP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170413, Kolkhir P</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13182</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sorensen,M.</style></author><author><style face="normal" font="Arial"> Klingenberg,C.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Sollid,J.U.</style></author><author><style face="normal" font="Arial"> Furberg,A.S.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric and Adolescent medicine, University Hospital of North Norway, Tromso, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus enterotoxin-sensitization is associated with allergic poly-sensitization and allergic multimorbidity in adolescents</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Enterotoxins</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> MeDALL</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> poly-sensitization</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Staphylococcus aureus (S. aureus) carriage and sensitization to S. aureus enterotoxins (SEs) has been associated with allergic diseases. From the Tromso Study Fit Futures 2, we have previously shown an association between S. aureus carriage and severe allergic disease and allergic multimorbidity. However, the role of S. aureus carriage and SE-sensitization on allergic multimorbidity and allergic sensitization is unclear. OBJECTIVE: To study associations of both nasal S. aureus carriage and SE-sensitization to allergic disease and allergic sensitization. METHODS: A cross-sectional study of a school-based cohort in late adolescence (age 18-19 years: The Tromso Study Fit Futures 2). Self-reported allergic diseases were assessed using the Mechanisms of the Development of ALLergy questionnaire (MeDALL). Participants were tested for nasal S. aureus carriage, serum total IgE and specific IgE to SEs and food and inhalant allergens. RESULTS: 868 participants were studied. Sensitization to at least one food or inhalant allergen was found in 319/765 (41.7%), and to at least one SE in 173/656 (26.2%) of the participants. SE-sensitization, but not S. aureus carriage, was associated with poly-sensitization to food and inhalant allergens. SE-sensitized participants had higher median specific IgE to inhalant allergens (41.4 kUA /L, IQR 10.1-118.4) compared to non-SE-sensitized participants (18.0 kUA /L, IQR 5.5-48.6, p=0.004), but not to food allergens. SE-sensitization was associated to allergic multimorbidity. CONCLUSION: Sensitization to SEs may play a role in the development of allergen poly-sensitization and allergic multimorbidity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Norway -CO - Belgium -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13175</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378344">PM:28378344</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170405-SorensenM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170405-SorensenM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Sorensen M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13175</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,P.P.</style></author><author><style face="normal" font="Arial"> Wang,G.X.</style></author><author><style face="normal" font="Arial"> Ge,W.T.</style></author><author><style face="normal" font="Arial"> Tang,L.X.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Ni,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">grid.24696.3fDepartment of Otorhinolaryngology Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University, 56 Nan Li Shi Road Xi Cheng District, Beijing, 100045 People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Nasal nitric oxide in allergic rhinitis in children and its relationship to severity and treatment</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Nitrous Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Nasal nitrous oxide (nNO) is increased in allergic rhinitis (AR), but not in asthma, and is a non-invasive marker for inflammation in the nasal passages. METHODS: Levels of nNO were measured and compared in healthy children and children with mild and moderate-to-severe AR. Levels of nNO before and after treatment with steroids and/or antihistamine were then compared in the 2 AR groups. Their relationship to quality of life and nasal symptom and reactivity to outdoor and outdoor allergens were examined. RESULTS: nNO levels were higher in mild AR than in healthy children and higher in moderate-to-severe AR than in mild AR. One month steroid and/or antihistamine treatment lowered nNO levels to control levels in mild AR and approximately halfway to control levels in moderate-to-severe AR. nNO levels had a weak correlation to quality of life questions and a fair correlation to nasal symptom scores before treatment. This correlation was weakened or lost after treatment, and no correlation was seen between nNO levels and responses to indoor or outdoor allergens. CONCLUSION: nNO levels in children with AR may be useful for assessing the response to treatment. Their relationship to quality of life, nasal symptoms, and sensitivity to specific allergens needs further study</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0191-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396691">PM:28396691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Wang PP</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0191-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marra,C.A.</style></author><author><style face="normal" font="Arial"> Harvard,S.</style></author><author><style face="normal" font="Arial"> Grubisic,M.</style></author><author><style face="normal" font="Arial"> Galo,J.</style></author><author><style face="normal" font="Arial"> Clarke,A.</style></author><author><style face="normal" font="Arial"> Elliott,S.</style></author><author><style face="normal" font="Arial"> Lynd,L.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">grid.29980.3aSchool of Pharmacy, Otago University, Dunedin, New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">Consumer preferences for food allergen labeling</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="19">19-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> consumer preferences</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergen labeling is an important tool to reduce risk of exposure and prevent anaphylaxis for individuals with food allergies. Health Canada released a Canadian food allergen labeling regulation (2008) and subsequent update (2012) suggesting that research is needed to guide further iterations of the regulation to improve food allergen labeling and reduce risk of exposure. OBJECTIVE: The primary objective of this study was to examine consumer preferences in food labeling for allergy avoidance and anaphylaxis prevention. A secondary objective was to identify whether different subgroups within the consumer population emerged. METHODS: A discrete choice experiment using a fractional factorial design divided into ten different versions with 18 choice-sets per version was developed to examine consumer preferences for different attributes of food labeling. RESULTS: Three distinct subgroups of Canadian consumers with different allergen considerations and food allergen labeling needs were identified. Overall, preferences for standardized precautionary and safety symbols at little or no increased cost emerged. CONCLUSION: While three distinct groups with different preferences were identified, in general the results revealed that the current Canadian food allergen labeling regulation can be improved by enforcing the use of standardized precautionary and safety symbols and educating the public on the use of these symbols</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0189-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392808">PM:28392808</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-19.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Marra CA</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0189-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ratner,P.</style></author><author><style face="normal" font="Arial"> Andrews,C.P.</style></author><author><style face="normal" font="Arial"> Hampel,F.C.</style></author><author><style face="normal" font="Arial"> Martin,B.</style></author><author><style face="normal" font="Arial"> Mohar,D.E.</style></author><author><style face="normal" font="Arial"> Bourrelly,D.</style></author><author><style face="normal" font="Arial"> Danaietash,P.</style></author><author><style face="normal" font="Arial"> Mangialaio,S.</style></author><author><style face="normal" font="Arial"> Dingemanse,J.</style></author><author><style face="normal" font="Arial"> Hmissi,A.</style></author><author><style face="normal" font="Arial"> van Bavel,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">grid.477956.eSylvana Research Associates, 7711 Louis Pasteur Drive, Suite 406, San Antonio, TX 78229 USA</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="18">18-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cetirizine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Antagonism of chemoattractant receptor-homologous molecule on T-helper type-2 cells (CRTH2), a G-protein coupled receptor for prostaglandin D2, could be beneficial for treating allergic disorders. We present findings on the efficacy and safety/tolerability of a CRTH2 antagonist (setipiprant) in participants with seasonal allergic rhinitis (AR) in a real-life setting over 2 weeks. METHODS: A Phase 2 trial and a Phase 3 trial were conducted at seven centers in Texas, USA during the Mountain Cedar pollen season. Both were prospective, randomized, double-blind, placebo- and active-referenced (cetirizine) studies. The Phase 2 trial assessed setipiprant 100-1000 mg b.i.d. and 1000 mg o.d. versus placebo in adult and elderly participants. The Phase 3 trial assessed setipiprant 1000 mg b.i.d. in adolescent, adult, and elderly participants. Efficacy was assessed using daytime nasal symptom scores (DNSS), night-time nasal symptom scores (NNSS) and daytime eye symptom scores (DESS). RESULTS: 579 participants were randomized in the Phase 2 trial (mean age 41.6-43.4 years); 630 were randomized in the Phase 3 trial (mean age 37.5-40.7 years). A statistically significant, dose-related improvement in mean change from baseline DNSS was observed over 2 weeks with setipiprant 1000 mg b.i.d. versus placebo in the Phase 2 trial (-0.15 [95% CI -0.29, -0.01]; p = 0.030). Setipiprant 1000 mg b.i.d. had no significant effect on this endpoint in the Phase 3 trial (-0.02 [95% CI -0.12, 0.07]; p = 0.652). Total and individual NNSS and DESS symptom scores were significantly improved with setipiprant 1000 mg b.i.d. versus placebo in the Phase 2 but not the Phase 3 trial. Setipiprant showed a favorable safety/tolerability profile. CONCLUSIONS: The Phase 2 trial was the first large clinical study to assess a CRTH2 antagonist in seasonal AR in a real-life setting. Setipiprant dose-related efficacy in the Phase 2 trial was not confirmed during Phase 3. Setipiprant was well tolerated in both studies. Trial registration NCT01241214 and NCT01484119</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0183-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392807">PM:28392807</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Ratner P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0183-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,B.G.</style></author><author><style face="normal" font="Arial"> Lee,P.H.</style></author><author><style face="normal" font="Arial"> Lee,S.H.</style></author><author><style face="normal" font="Arial"> Park,M.K.</style></author><author><style face="normal" font="Arial"> Jang,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effect of TiO(2) Nanoparticles on Inflammasome-Mediated Airway Inflammation and Responsiveness</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="264" start="257">257-264</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Caspase 1</style></keyword><keyword><style face="normal" font="Arial"> caspase-1</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Titanium</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Nanoparticles (NPs) may cause cell and tissue damage, leading to local and systemic inflammatory responses and adverse effects on health due to the inhalation of particulate matter. The inflammasome is a major regulator of inflammation through its activation of pro-caspase-1, which cleaves pro-interleukin-1beta (pro-IL-1beta) into its mature form and may induce acute and chronic immune responses to NPs. However, little is known about the response of the inflammasome to NP exposure via the airways in asthma. The aim of this study was to identify the impact of titanium dioxide (TiO(2)) NPs on inflammasome in a mouse model of allergic asthma. METHODS: Mice were treated with ovalbumin (OVA) or TiO(2) NPs. IL-1beta, IL-18, NAIP, CIITA, HET-E, TP-2 (NACHT), leucine-rich repeat (LRR), pyrin domain-containing protein 3 (NLRP3), and caspase-1 were assessed by Western blotting. Caspase-1 was assessed by immunohistochemistry (IHC). Levels of reactive oxygen species (ROS)-as markers of oxidative damage-and the mediators 8-isoprostane and carbonyl were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: Airway hyperresponsiveness (AHR) and inflammation were increased in OVA-sensitized/challenged mice, and these responses were exacerbated by exposure to TiO(2) NPs. NP treatment increased IL-1beta and IL-18 expression in OVA-sensitized/challenged mice. NPs augmented the expression of NLRP3 and caspase-1, leading to production of active caspase-1 in the lung. Caspase-1 expression was increased and exacerbated by TiO(2) NP exposure in OVA-sensitized/challenged mice. ROS levels tended to be increased in OVA-sensitized/challenged and OVA-sensitized/challenged-plus-TiO(2) NP-exposed mice. CONCLUSIONS: Our data demonstrated that inflammasome activation occured in asthmatic lungs following NP exposure, suggesting that targeting the inflammasome may assist in controling NP-induced airway inflammation and hyperresponsiveness</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.3.257</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293932">PM:28293932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-257-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-257-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Kim BG</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.3.257</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83667</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shin,J.H.</style></author><author><style face="normal" font="Arial"> Kim,D.H.</style></author><author><style face="normal" font="Arial"> Kim,B.Y.</style></author><author><style face="normal" font="Arial"> Kim,S.W.</style></author><author><style face="normal" font="Arial"> Hwang,S.H.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Kim,S.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Anti-Interleukin-9 Antibody Increases the Effect of Allergen-Specific Immunotherapy in Murine Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="246" start="237">237-246</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Induction of tolerance</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Interleukin (IL)-9 induces allergic responses; however, the roles of anti-IL-9 antibody in the induction of tolerance remain unclear. This study investigated the effects of anti-IL-9 antibody on oral tolerance (OT) in a mouse model of allergic rhinitis (AR). METHODS: BALB/c mice were divided into 4 groups: the control, AR, OT, and OT with anti-IL-9 antibody (OT+IL9AB) groups. Ovalbumin (OVA) was used for sensitization and challenge. Mice in the OT and OT+IL9AB groups were fed OVA for immunotherapy. During immunotherapy, OT+IL9AB mice were injected with anti-IL-9 antibody. Allergic symptoms, tissue eosinophil counts, and serum OVA-specific immunoglobulin E (IgE) were measured. The mRNA expressions of cytokines and transcription factors of T cells of nasal mucosa were determined by real-time polymerase chain reaction (PCR). The protein levels of GATA3, ROR-gammat, and Foxp3 in nasal mucosa were determined by Western blot. CD4(+)CD25(+)Foxp3(+) T cells in the spleen were analyzed by flow cytometry. RESULTS: Administration of anti-IL-9 antibody decreased allergic symptoms, OVA-specific IgE levels, and eosinophil counts. In addition, it inhibited T-helper (Th) 2 responses, but had no effect on Th1 responses. Protein levels of ROR-gammat and mRNA levels of PU.1 and ROR-gammat were reduced by anti-IL-9 antibody. Anti-IL-9 antibody increased Foxp3 and IL-10 mRNA expression, Foxp3 protein, and induction of CD4(+)CD25(+)Foxp3(+) T cells. CONCLUSIONS: Anti-IL-9 antibody decreased allergic inflammation through suppression of Th2 and Th17 cells. Anti-IL-9 antibody enhanced the tolerogenic effects of regulatory T cells. These results suggest that anti-IL-9 antibody might represent a potential therapeutic agent for allergen immunotherapy in patients with uncontrolled allergic airway disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.3.237</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293930">PM:28293930</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-237-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-237-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Shin JH</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.3.237</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kennedy,M.D.</style></author><author><style face="normal" font="Arial"> Steinback,C.D.</style></author><author><style face="normal" font="Arial"> Skow,R.</style></author><author><style face="normal" font="Arial"> Parent,E.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Is Performance of a Modified Eucapnic Voluntary Hyperpnea Test in High Ventilation Athletes Reproducible?</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="236" start="229">229-236</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> athlete</style></keyword><keyword><style face="normal" font="Arial"> Athletes</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> exercise-induced bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> swimmers</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Exercise-induced bronchoconstriction (EIB) is common in "high ventilation" athletes, and the Eucapnic Voluntary Hyperpnea (EVH) airway provocation test is the standard EIB screen. Although the EVH test is widely used, the in-test performance in high ventilation athletes as well as the reproducibility of that performance has not been determined. Reproducibility of pre- and post-test spirometry and self-reported atopy/cough was also examined. METHODS: High ventilation athletes (competitive swimmers; n=11, 5 males) completed an atopy/cough questionnaire and EVH testing (operator controlled FiCO(2)) on 2 consecutive days. RESULTS: Swimmers achieved 85%+/-9% and 87%+/-9% of target FEV1 volume on days 1 and 2, respectively, (P=0.45; ICC 0.57 [0.00-0.86]) resulting in a total ventilation of 687 vs 684 L [P=0.89, ICC 0.89 (0.65-0.97]) equating to 83%+/-8% and 84%+/-9% of predicted total volume (ICC 0.54 [0.00-0.85]) between days 1 and 2. FiCO(2) required to maintain eucapnic conditions was 2.5%. Pre-test FEV1 was less on day 2 (P=0.04; ICC >0.90). Day 1 to 2 post-test FEV1 was not different, and 4 swimmers were EIB positive (>10% fall in pre-post FEV1) on day 1 (3 on day 2). CONCLUSIONS: EVH in-test performance is reproducible however required less FiCO(2) than standard protocol and the swimmers under-ventilated by 125 and 139 L/min for days 1 and 2, respectively. How this affects EIB diagnosis remains to be determined; however, our results indicate a post-test FEV1 fall of >/=20% may be recommended as the most consistent diagnostic criterion</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.3.229</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293929">PM:28293929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-229-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-229-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Kennedy MD</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.3.229</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feng,B.</style></author><author><style face="normal" font="Arial"> Xiang,H.</style></author><author><style face="normal" font="Arial"> Jin,H.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Huang,S.</style></author><author><style face="normal" font="Arial"> Shi,Y.</style></author><author><style face="normal" font="Arial"> Chen,R.</style></author><author><style face="normal" font="Arial"> Chen,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, the Second Affiliated Hospital &amp; Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis: A Meta-Analysis of Randomized Controlled Trials</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="228" start="220">220-228</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Allergic rhinitis (AR) has become a global issue for a large part of the general population. Sublingual immunotherapy (SLIT) has been used extensively to treat persistent allergic rhinitis (PAR). Although systematic reviews have confirmed the effectiveness of SLIT for the treatment of AR, a considerable number of studies using extracts of house dust mites (HDMs) for immunotherapy found no consensus on basic treatment parameters and questioned the efficacy of SLIT. METHODS: In this study, we evaluated SLIT for PAR by a meta-analysis of randomized controlled trials (RCTs). Medline, Embase, and Cochrane Library database searches were performed for RCTs on the treatment of PAR by SLIT that assessed clinical outcomes related to efficacy through May 2016. Descriptive and quantitative information was abstracted. An analysis was performed with standardized mean differences (SMDs) under a fixed or random effects model. Subgroup analyses were performed. Heterogeneity was assessed using the I(2) metric. RESULTS: In total, 25 studies were eligible for inclusion in the meta-analysis for symptom scores and 15 studies for medication scores. SLIT was significantly different from the controls for symptom scores (SMD=1.23; 95% confidence interval [CI]=1.74 to 0.73; P&lt;0.001). For medication scores, significant differences for SLIT were also observed versus the controls (SMD=-1.39; 95% CI=-1.90 to -0.88; P&lt;0.001). CONCLUSIONS: Our meta-analysis indicates that SLIT provided significant symptom relief and reduced the need for medications in PAR. In this study, significant evidence was obtained despite heterogeneity with regard to the use of mite extract. Specifically, the mite extract used was provided by the patients with PAR. Furthermore, to confirm both the objective outcomes and the effective doses of HDM allergen extracts, experimental data should be obtained from large high-quality population-based studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.3.220</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293928">PM:28293928</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-220-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-220-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Feng B</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.3.220</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83670</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,S.P.</style></author><author><style face="normal" font="Arial"> Choi,S.J.</style></author><author><style face="normal" font="Arial"> Joe,E.</style></author><author><style face="normal" font="Arial"> Lee,S.M.</style></author><author><style face="normal" font="Arial"> Lee,M.W.</style></author><author><style face="normal" font="Arial"> Shim,J.W.</style></author><author><style face="normal" font="Arial"> Kim,Y.J.</style></author><author><style face="normal" font="Arial"> Kyung,S.Y.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author><author><style face="normal" font="Arial"> Jeong,S.H.</style></author><author><style face="normal" font="Arial"> Jung,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonology and Allergy, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="277" start="272">272-277</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> ILIT</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> intralymphatic immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Several recent clinical trials reported that intralymphatic immunotherapy (ILIT) for some allergens, such as cat dander and pollen, induce tolerance more rapidly than conventional subcutaneous or sublingual immunotherapy, have a comparable duration of effect after only 3 injections, and do not provoke serious local or systemic reactions. However, the efficacy and safety of ILIT are using Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), and dog, which are indoor allergens that are commonly found globally, need to be evaluated. Furthermore, use of multiple allergens in ILIT should be investigated. We assessed the clinical efficacy and adverse effects of ILIT using aqueous Df, Dp, dog, and cat allergens or mixtures thereof in patients with allergic rhinitis. A total of 11 subjects with AR sensitized to Df, Dp, cat, and/or dog allergens received 3 intralymphatic inguinal injections of sensitized allergen extract (HollisterStier, New Orleans, LA, USA). Clinical parameters were assessed before ILIT, and 4 months and 1 year after the first injection. Rhinitis symptoms were alleviated and quality of life was improved 4 months after ILIT (P=0.012 and P=0.007, respectively), and these improvements lasted for 1 year after ILIT (P=0.047 and P=0.009, respectively). However, we observed 2 cases of anaphylaxis, one case of a moderate-to-severe systemic hypersensitivity reaction and the other case of a severe local reaction at the injection site after ILIT. In conclusion, ILIT can rapidly improve allergy symptoms and quality of life, and this effect lasts for 1 year. In hypersensitized patients, however, ILIT can provoke severe systemic and/or local hypersensitivity reactions when performed using aqueous allergen extracts</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.3.272</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293934">PM:28293934</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-272-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-272-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Lee SP</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.3.272</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83671</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jara,D.</style></author><author><style face="normal" font="Arial"> Portnoy,J.</style></author><author><style face="normal" font="Arial"> Dhar,M.</style></author><author><style face="normal" font="Arial"> Barnes,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Relation of indoor and outdoor airborne fungal spore levels in the Kansas City metropolitan area</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="135" start="130">130-135</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Microbiology</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution,Indoor</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airborne fungal spore</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Chaetomium</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> spore count</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Spores,Fungal</style></keyword><keyword><style face="normal" font="Arial"> Stachybotrys</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Environmental control is an important component of asthma management for persons with asthma. A damp indoor environment and elevated airborne spore levels are factors in housing environmental control. OBJECTIVES: We investigated if indoor airborne fungal spore levels correlated with outdoor ground-level airborne fungal spores or outdoor centrally collected spore levels as to types and abundance. METHODS: Air collections were taken from home interiors, outdoor areas adjacent to the homes, and at a central location in the metropolitan area at the approximate same time. All air collections were examined and enumerated microscopically, and airborne spore estimates per cubic meter of air were reported for total fungal spores and for 11 identifiable spore groups. RESULTS: The 244 homes in the study were typical of the North American Midwest. The overall mean total spore counts in spores per cubic meter of air was indoors (4076 spores/m3), outdoors at ground level (8899 spores/m3), and outdoor metropolitan area (8342 spores/m3). All of the major indoor taxa were strongly correlated with the mean total spores present in the home. Total outdoor ground spore levels were highly correlated with levels of major outdoor taxa, such as ascospores and Cladosporium. Correlations of indoor spore levels with outdoor spore levels are strong for most major outdoor taxa. Indoor Aspergillus-Penicillium and Chaetomium are significantly correlated between indoor and local ground-level outdoor air. CONCLUSION: Although conditions may exist where indoor or outdoor spore levels were not well aligned, in most circumstances, the outdoor airborne spore community was reflected in the indoor airborne spore community</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Particulate Matter)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234050">PM:28234050</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-130-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-130-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Jara D</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calabria,C.W.</style></author><author><style face="normal" font="Arial"> Hauswirth,D.W.</style></author><author><style face="normal" font="Arial"> Rank,M.</style></author><author><style face="normal" font="Arial"> Sher,L.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">American Academy of Asthma, Allergy &amp; Immunology membership experience with venom immunotherapy in chronic medical conditions and pregnancy, and in young children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="129" start="121">121-129</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acquired Immunodeficiency Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Age Factors</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropod Venoms</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attitude of Health Personnel</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Transplantation</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cerebrovascular Disorders</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="Arial"> Desensitization,Immunologic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> HIV Infections</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity,Immediate</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Insect Bites and Stings</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Neoplasms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> organ transplantation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Practice Patterns,Physicians'</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy Complications</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Societies,Medical</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Few data exist regarding the use of venom immunotherapy (VIT) in specific high-risk chronic medical conditions and pregnancy, and in young children. METHODS: A Web-based survey was sent to American Academy of Asthma Allergy &amp; Immunology members to explore their VIT experience in potential high-risk medical conditions and pregnancy, and in young children. Major problems were defined as "activation of underlying disease and/or VIT not well tolerated (systemic adverse events) and/or VIT discontinued for medical reasons." Results were expressed descriptively. RESULTS: A total of 697 of 5123 surveys (14%) were completed: 87% of the respondents were based in the United States, and 28% worked in an academic setting. Most respondents (71%) believed that pregnancy was a contraindication for starting VIT. Most were comfortable continuing VIT (51%) if the woman became pregnant after starting therapy. Of the allergists who treated children, many would give VIT down to age 5 years (42%) or younger, ages 1-4 years (35%). The following list is of the specific medical condition, the number of allergists who used VIT in patients with this condition, and the percentage who reported major problems: severe asthma, 212 (4.2%); hypertension, 287 (1.1%); coronary artery disease, 222 (3.6%); arrhythmias, 136 (3.4%); cerebrovascular disease, 104 (5.1%); cancer in remission, 166 (0%); cancer stable but still under treatment, 44 (7.2%); a history of bone marrow transplantation, 15 (4.9%); a history of solid organ transplantation, 29 (3.6%); human immunodeficiency virus, 53 (1.4%); acquired immunodeficiency syndrome, 24 (6.2%); stable autoimmune disease, 164 (2.8%); mastocytosis, 66 (18.4%); elevated serum tryptase, 101 (10.8%); immunodeficiency 59 (2.5%). CONCLUSION: Many allergists were comfortable using VIT in young children and continuing but not starting pregnant women on VIT. VIT was commonly used in patients with hypertension, coronary artery disease, arrhythmias, cancer in remission, and stable autoimmune disease. Major problems were most frequently reported in use with mastocytosis, elevated tryptase, and cancer still under treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleRN - 0 (Arthropod Venoms)SB - IMCO - United States -CO - Mexico -</style></notes><work-type><style face="normal" font="Arial"> 10.2500/aap.2017.38.4024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234049">PM:28234049</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-121-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-121-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Calabria CW</style></custom2><misc3><style face="normal" font="Arial"> 10.2500/aap.2017.38.4024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bellanti,J.A.</style></author><author><style face="normal" font="Arial"> Settipane,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Can the burden of disease due to food allergy be prevented?</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="87" start="85">85-87</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234045">PM:28234045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-85-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-85-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Bellanti JA</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Karam,M.</style></author><author><style face="normal" font="Arial"> Holland,C.</style></author><author><style face="normal" font="Arial"> Yang,Z.</style></author><author><style face="normal" font="Arial"> Samuels,K.</style></author><author><style face="normal" font="Arial"> Sanders,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergen immunotherapy at university health services and allergist's reasons for guidelines nonadherence</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="120" start="115">115-120</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Attitude of Health Personnel</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Competence</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Desensitization,Immunologic</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guideline Adherence</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Logistic Models</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patient safety</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="Arial"> Practice parameters</style></keyword><keyword><style face="normal" font="Arial"> Practice Patterns,Physicians'</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="Arial"> Student health services</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> Workflow</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Our previous pilot study conducted at the University of Michigan Health Services showed that fewer than 25% of the non-university allergen immunotherapy (AIT) prescribers adhered to AIT labeling guidelines which impacted both patients and healthcare personnel involved in AIT administration. OBJECTIVES: We expand our study to characterize AIT labeling compliance and impact of practice variability at the "Big 10" University Health Services, and investigate prescribers motives for nonadherence to practice parameter guidelines. METHODS: Three online surveys were distributed: AIT Administrator and Manager surveys for healthcare personnel at the "Big 10"; University Health Services and Physician Survey for physician members of the AAAAI. Data were analyzed using frequency/bivariate analysis and logistic regression. RESULTS: 21 AIT administrators from 10 University Health Services responded. 90.4% (20/21) felt labels containing all recommended practice parameter guidelines, components would decrease error; and standardization of labels, buildup and missed dose schedules would increase workflow efficiency (76%; 16/21). 90% (17/19) felt standardized protocols for treatment of systemic reactions would increase patient safety, workflow efficiency and comfort level of administrators. Only 28.6% of AIT extract vial labels at University Health Services were in accordance with practice parameter guidelines. Despite familiarity with the guidelines (91.5%; 697/762), only 64% (488/762) of surveyed physicians had practice parameter adherent AIT extracts labels with higher odds of a complete label when physicians were in group practice (odds ratio 1.51; [95% confidence interval, 1.06-2.15]; P=0.02). Reasons for nonadherence included having personalized labeling systems (55.4%, 174/314), unfamiliarity (14%, 44/314) and disagreement (9%, 29/314) with practice parameter guidelines. CONCLUSION: Poor adherence with AIT practice parameters labeling guidelines is an important concern in nonallergy offices. It is imperative that allergists comply with the highest recommended standards to provide the best clinical outcomes and ensure excellent and efficient care in both allergy and non-allergy offices</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - Lebanon -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234048">PM:28234048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-115-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-115-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Karam M</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenhawt,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The National Institutes of Allergy and Infectious Diseases sponsored guidelines on preventing peanut allergy: A new paradigm in food allergy prevention</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="97" start="92">92-97</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Age Factors</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feeding Behavior</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy guidelines</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Institute of Allergy and Infectious Diseases (U.S.)</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Risk Reduction Behavior</style></keyword><keyword><style face="normal" font="Arial"> Secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weaning</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">Peanut allergy is a significant public health problem without proven treatment or cure at present. In 2000, the American Academy of Pediatrics recommended that solid-food introduction be delayed in infants at high risk, including peanut introduction, until age 3 years. In 2008, the American Academy of Pediatrics revised these recommendations based on limited evidence of benefit and, instead, recommended solid-food introduction not be delayed past 4-6 months of life. In 2015, the Learning Early About Peanut Allergy study showed that early peanut introduction (between 4 and 11 months of life) was associated with a significant absolute and relative risk reduction in the development of peanut allergy compared with delayed introduction. Based on these findings, the National Institutes of Allergy and Infectious Diseases sponsored an expert panel to create an addendum to the 2010 Food Allergy Guidelines that specifically focuses on peanut allergy prevention. The addendum recommends that children with severe eczema, egg allergy, or both have peanut introduced as early as 4-6 months of life, after assessment by a trained allergy specialist. For children with mild-to-moderate eczema, peanut can be introduced at approximately 6 months, without the need for specialist evaluation. For children with no eczema, peanut can be introduced in accordance with family and cultural preferences, without the need for specialist evaluation. Adherence to these clinical practice recommendations can help potentially reduce the number of cases of peanut allergy per year. However, this can only be accomplished with the cooperation of parents and health care providers who adhere to these recommendations</style></abstract><notes><style face="normal" font="Arial">DA - 20170125IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120742">PM:28120742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-92-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-92-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170125, Greenhawt M</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yilmaz,E.A.</style></author><author><style face="normal" font="Arial"> Karaatmaca,B.</style></author><author><style face="normal" font="Arial"> Cetinkaya,P.G.</style></author><author><style face="normal" font="Arial"> Soyer,O.</style></author><author><style face="normal" font="Arial"> Sekerel,B.E.</style></author><author><style face="normal" font="Arial"> Sahiner,U.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The persistence of chronic spontaneous urticaria in childhood is associated with the urticaria activity score</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="142" start="136">136-142</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Blastocystis Infections</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Dientamoebiasis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Giardiasis</style></keyword><keyword><style face="normal" font="Arial"> Hashimoto Disease</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Remission,Spontaneous</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis,Allergic,Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> skin-prick testing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urinary Tract</style></keyword><keyword><style face="normal" font="Arial"> Urinary Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is little information regarding the etiology and natural course of chronic spontaneous urticaria (CSU) in childhood. OBJECTIVE: To investigate the etiology, prognosis, and the factors associated with the prognosis of CSU in children. METHOD: Data from children with CSU who had been diagnosed between 1992 and 2015 were analyzed. A telephone interview was done to assess the current status of these patients. Remission was defined as the disappearance of urticaria for >6 months. RESULTS: A total of 222 children with CSU were evaluated. The median age of symptom onset was 8.8 years (interquartile range [IQR], 4.6-12.3 years), median duration of urticaria was 23 months (IQR, 7-48 months), and the median sum of the daily urticaria activity score of 7 consecutive days (UAS7) was 28 (IQR, 21-42). Accompanying angioedema was reported by 107 patients (48.2%), whereas 27.1% of the study population had autoantibody positivity. Autologous serum skin testing results were positive in 43 (34.1%); skin-prick testing results revealed atopy in 55 children (27.9%). Parasites (4.8%), pollen sensitization (1.5%), food allergy (0.9%), urinary tract infection (0.9%), and Hashimoto thyroiditis (0.5%) were determined as etiologic factors of CSU. The patients were followed up for a median time of 15 months (IQR, 5-36.5 months). Remission was observed in 10.6, 29.3, and 44.5% of the patients in 1, 3, and 5 years, respectively. In multivariate regression analysis, a UAS7 of >28 at admission was found to be a risk factor for persistence of urticaria (odds ratio 6.22 [95% confidence interval, 1.54-25.15; p = 0.010). CONCLUSION: The etiology of CSU in children was mostly idiopathic despite detailed investigation. In childhood, the natural course of CSU was favorable, and nearly half of the patients recovered after 5 years of disease duration. A high UAS7 at admission seemed to be a significant risk factor for the persistence of symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234051">PM:28234051</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-136-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-136-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Yilmaz EA</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,N.</style></author><author><style face="normal" font="Arial"> Herbert,L.</style></author><author><style face="normal" font="Arial"> Green,T.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The emotional, social, and financial burden of food allergies on children and their families</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="91" start="88">88-91</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cost of Illness</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Health Care Costs</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Stress,Psychological</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> Toll</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: As the prevalence of food allergy has risen among children and young adults, both in the United States and around the world, investigators have become increasingly aware of the daily emotional toll on patients and their families of living with food allergy. OBJECTIVE: To review the literature regarding the emotional, social, and financial impact of food allergy on pediatric patients and their families, and to provide evidence-based suggestions for clinicians on how to most effectively address these issues. METHODS: A literature search was performed to identify relevant articles related to the emotional, social, and financial impact of food allergy. RESULTS: There is a growing body of literature that demonstrates that living with food allergy adversely affects patients and families in the domains above. CONCLUSION: Food allergy can significantly impact pediatric patients and their families in all areas of their lives. Clinicians should be aware of these issues when working with these families. Implementing a multidisciplinary approach can help families cope with emotional, social, and financial burdens</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234046">PM:28234046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-88-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-88-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Patel N</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Corsico,A.G.</style></author><author><style face="normal" font="Arial"> De Amici,M.</style></author><author><style face="normal" font="Arial"> Ronzoni,V.</style></author><author><style face="normal" font="Arial"> Giunta,V.</style></author><author><style face="normal" font="Arial"> Mennitti,M.C.</style></author><author><style face="normal" font="Arial"> Viscardi,A.</style></author><author><style face="normal" font="Arial"> Marseglia,G.L.</style></author><author><style face="normal" font="Arial"> Ciprandi,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergen-specific immunoglobulin E and allergic rhinitis severity</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="4" start="1">1-4</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Calibrator</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> enzyme immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) is a common disorder. The diagnosis is based on the concordance between allergy sensitization and history. Serum allergen specific immunoglobulin E (sIgE) assessment allows characterization of the relevant sensitizing allergens. Presently, Allergic Rhinitis and its Impact on Asthma (ARIA) classification subdivides AR based on symptoms severity and duration. However, the relationship between sIgE levels and symptom severity is still a matter of debate. OBJECTIVE: Therefore, this study aimed at relating sIgE levels with symptom severity assessed by ARIA classification in a group of patients with AR. METHODS: We enrolled 217 patients with AR (123 women; median age, 39.5 years). The sIgE levels (expressed in kUA/L) to house-dust mite were detected by the fluorescence enzyme immunoassay in peripheral blood samples. The IgE calibrators were traceable to the second international reference preparation 75/502 of human serum IgE from the World Health Organization. Symptom severity was assessed by ARIA classification. RESULTS: We found a significant difference in sIgE levels in patients with mild intermittent versus mild persistent symptoms (p &lt; 0.05), mild intermittent versus moderate-to-severe persistent symptoms (p &lt; 0.001), moderate-to-severe intermittent versus moderate-to-severe persistent symptoms (p &lt; 0.01), and mild persistent versus moderate-to-severe persistent symptoms (p &lt; 0.05). CONCLUSION: Analysis of these findings indicated that the sIgE level to house-dust mite might be a reliable biomarker for symptom severity in patients with AR. This outcome might be clinically relevant, particularly in candidates for immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170406IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2017.8.0187</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28381320">PM:28381320</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2017-8-1-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2017-8-1-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170406, Corsico AG</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2017.8.0187</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,T.F.</style></author><author><style face="normal" font="Arial"> Chan,Y.Y.</style></author><author><style face="normal" font="Arial"> Shi,W.Y.</style></author><author><style face="normal" font="Arial"> Jhong,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan 71005, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Uncovering the Molecular Mechanism of Anti-Allergic Activity of Silkworm Pupa-Grown Cordyceps militaris Fruit Body</style></title><secondary-title><style face="normal" font="Arial">Am J Chin Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Chin Med</style></full-title></periodical><pages end="513" start="497">497-513</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> Human serum albumin</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> lipid mediators</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="2" Month="4" Year="2017">2017/4/2</year></dates><abstract><style face="normal" font="Arial">Cordyceps militaris has been widely used as an herbal drug and tonic food in East Asia and has also been recently studied in the West because of its various pharmacological activities such as antitumoral, anti-inflammatory and immunomodulatory effects. In this study, we examined the molecular mechanism underlying the anti-allergic activity of ethanol extract prepared from silkworm pupa-cultivated Cordyceps militaris fruit bodies in activated mast cells. Our results showed that ethanol extract treatment significantly inhibited the release of beta-hexosaminidase (a degranulation marker) and mRNA levels of tumor necrosis factor-[Formula: see text] as well as interleukin-4 in RBL-2H3 cells. The cells were sensitized with 2,4-dinitrophenol specific IgE and then stimulated with human serum albumin conjugated with 2,4-dinitrophenol. Oral administration of 300[Formula: see text]mg/kg ethanol extract significantly ameliorated IgE-induced allergic reaction in mice with passive cutaneous anaphylaxis. Western immunoblotting results demonstrated that ethanol extract incubation significantly inhibited Syk/PI3K/MEKK4/JNK/c-jun biochemical cascade in activated RBL-2H3 cells, which activated the expression of various allergic cytokines. In addition, it suppressed Erk activation and PLC[Formula: see text] evocation, which would respectively evoke the synthesis of lipid mediators and Ca[Formula: see text] mobilization to induce degranulation in stimulated RBL-2H3 cells. A compound, identified as beta-sitostenone, was shown to inhibit beta-hexosaminidase secretion from activated mast cells. Our study demonstrated that ethanol extract contained the ingredients, which could inhibit immediate degranulation and de novo synthesis of allergic lipid mediators and cytokines in activated mast cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 0192-415X (Print)IS - 0192-415X (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1142/S0192415X17500306</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28367714">PM:28367714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Chin Med\2017-45-497-513.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Chin Med\2017-45-497-513.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Wu TF</style></custom2><misc3><style face="normal" font="Arial">10.1142/S0192415X17500306</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Di Berardino,F.</style></author><author><style face="normal" font="Arial"> Zanetti,D.</style></author><author><style face="normal" font="Arial"> D'Amato,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Nasal rinsing with an atomized spray improves mucociliary clearance and clinical symptoms during peak grass pollen season</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="43" start="40">40-43</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mucociliary Clearance</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peak pollen season</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Nasal rinsing with an atomizer spray was found to be effective in the treatment of allergic rhinitis. Two parameters express the nasal functions: (1) mucociliary clearance (MCC), and (2) the pH and its stability. MCC is the main factor that defines the time of pollen transition on the nasal mucosa and, therefore, the amount of the allergen glycoprotein elution. OBJECTIVE: We hypothesized that the nasal wash efficacy could be due to the reduction of contact time of the grass pollen on the nasal mucosa (improving MCC). METHODS: Forty patients with seasonal grass pollen oculorhinitis were randomized in two groups: 20 received three times daily nasal rinsing with hypertonic solution buffered to pH 6.1, before and during the peak pollen season in 2015 (active group), and another 20 patients were allocated to the control group and received no nasal treatment. The daily symptoms score and the use of oral antihistamines when required were evaluated during the grass pollen peak season. All the patients completed the study. RESULTS: In comparison with the control group, in the active group, a significant decrease of both nasal symptoms (p = 0.01) and consumption of antihistamines (p = 0.035) was found. Furthermore, the MCC was significantly worse (p = 0.011) only in the control group. CONCLUSION: The nasal treatment maintained the efficiency of the MCC in the patients in the active group, who showed a significant reduction of symptoms and medication score. The MCC decreased the transit time of the pollen on the nasal mucosa, which favored an elution of the allergenic proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2016.30.4383</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234152">PM:28234152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-40-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-40-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Di Berardino F</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2016.30.4383</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahmadi,N.</style></author><author><style face="normal" font="Arial"> Christensen,J.M.</style></author><author><style face="normal" font="Arial"> Barham,H.P.</style></author><author><style face="normal" font="Arial"> Oakley,G.M.</style></author><author><style face="normal" font="Arial"> Sacks,R.</style></author><author><style face="normal" font="Arial"> Harvey,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Allergic sensitization does not predispose to sinus inflammation in externalized paranasal sinuses</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="6" start="3">3-6</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> mucosal inflammation</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Skull</style></keyword><keyword><style face="normal" font="Arial"> Skull Base</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic rhinosinusitis (CRS) has a multifactorial etiology, with a debate about the role of inhalant allergy in the pathogenesis of CRS. OBJECTIVE: This study assessed the impact of allergy status on externalized paranasal sinuses after tumor resection to determine if a predisposition to inhalant allergy brought about additional inflammation after sinus surgery. METHODOLOGY: A case-control study was performed on patients who had no history of CRS who underwent paranasal sinus tumor resection. Allergic sensitization was defined by a positive serum ImmunoCAP test result. Outcomes were measured at least 6 months after surgery by using the modified Lund-MacKay endoscopic score and the 22-item Sino-Nasal Outcome test, with rhinitis, sleep, psychological, ear and/or facial, and sinus subscores to assess the impact of allergy status on mucosal inflammation. RESULTS: A total of 103 patients (53.44 +/- 17.46 years; 46% women) were assessed. Of these, 61.17% were allergically sensitized at the time of surgery. Postsurgery endoscopic assessment was similar [the modified Lund-Mackay endoscopic score allergic sensitized 0.5 (1.7) versus nonallergic sensitized 0.0 (0.9); p = 0.15]. Sinonasal symptoms were also similar between the groups' 22-item Sino-Nasal Outcome test scores, allergic sensitized versus allergic nonsensitized, (allergic 28.9 +/- 20.8 versus nonallergic 33.5 +/- 19.7; p = 0.31), rhinitis score (5.9 +/- 5.5 versus 6.4 +/- 4.7; p = 0.66), sleep score (6.9 +/- 5.9 versus 7.7 +/- 4.8; p = 0.50), ear and/or facial symptom score (3.4 +/- 3.6 versus 4.3 +/- 3.3; p = 0.22), psychological score (6.9 +/- 6.0 versus 8.3 +/- 6.7; p = 0.29), and of nasal symptom score (6.4 +/- 5.2 versus 7.0 +/- 5.3; p = 0.61). CONCLUSIONS: Externalization of the sinuses in patients with inhalant allergy did not bring about significant additional inflammation in patients after tumor surgery</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2017.31.4388</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234140">PM:28234140</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-3-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-3-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Ahmadi N</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2017.31.4388</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feng,B.</style></author><author><style face="normal" font="Arial"> Wu,J.</style></author><author><style face="normal" font="Arial"> Chen,B.</style></author><author><style face="normal" font="Arial"> Xiang,H.</style></author><author><style face="normal" font="Arial"> Chen,R.</style></author><author><style face="normal" font="Arial"> Li,B.</style></author><author><style face="normal" font="Arial"> Chen,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of sublingual immunotherapy for allergic rhinitis in pediatric patients: A meta-analysis of randomized controlled trials</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="35" start="27">27-35</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) has become a global health problem that constantly affects a large part of the general population, especially children. OBJECTIVE: Sublingual allergen immunotherapy (SLIT) has been used extensively for pediatric AR, although its efficacy and safety are often questioned. In this meta-analysis of randomized controlled trials (RCT), we evaluated the use of SLIT for pediatric AR. METHODS: A number of medical literature data bases were searched through January 2016 to identify RCTs that examined the use of SLIT for pediatric AR and that assessed clinical outcomes related to efficacy. Descriptive and quantitative information was abstracted. Standardized mean differences (SMD) were calculated by using fixed- and random-effects models. Subgroup analyses were performed. Heterogeneity was assessed by using the I2 metric. A network meta-analysis was used to estimate SMDs between two SLIT protocols for pediatric seasonal AR. All data were extracted from publications or received from the authors. RESULTS: Twenty-six studies were eligible for inclusion in the meta-analysis of rhinitis or rhinoconjunctivitis symptom scores, and 19 studies were eligible for the meta-analysis of medication scores. Descriptive and quantitative data were extracted. SLIT differed significantly from placebo in terms of symptom scores (SMD -0.55 [95% confidence interval {CI}, -0.86 to -0.25]; p = 0.0003, I2 = 90%) and medication scores (SMD -0.67 [95% CI, -0.96 to -0.38]; p &lt; 0.00001, I2 = 83%). Oral pruritus was the adverse effect, which occurred most commonly in children who were receiving SLIT. Network meta-analysis revealed no significant difference between the pre-coseasonal and continuous SLIT protocols for seasonal AR in symptom scores (SMD -6.55 [95% CI, -25.38 to 12.29]; p = 0.496) and medication scores (SMD -8.83 [95% CI, -22.10 to 4.43]; p = 0.192). CONCLUSIONS: Our meta-analysis results indicated that SLIT provided significant symptom relief and reduced the need for medication in pediatric patients. Moreover, the safety of SLIT needs to be confirmed in RCTs with larger samples</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2017.31.4382</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234149">PM:28234149</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-27-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-27-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Feng B</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2017.31.4382</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsumoto,F.Y.</style></author><author><style face="normal" font="Arial"> Goncalves,T.R.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author><author><style face="normal" font="Arial"> Wandalsen,G.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Specific nasal provocation test with Dermatophagoides pteronyssinus, monitored by acoustic rhinometry, in children with rhinitis</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="11" start="7">7-11</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acoustic rhinometry</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Currently, the diagnosis of allergic rhinitis (AR) is arrived at predominantly by a clinical history and by systemic sensitization tests, but specific nasal provocation tests (NPT) may establish a better direct correlation between etiologic surveyed allergens and nasal symptoms. OBJECTIVES: To standardize the specific NPT with one of the most important house-dust mites, Dermatophagoides pteronyssinus, monitored by acoustic rhinometry, in children and adolescents, and propose a simplified specific NPT to improve its clinical applicability as a diagnostic tool. METHODS: Sixteen controls (group 1) and 17 patients with an AR diagnosis sensitized to D. pteronyssinus (group 2) underwent a specific NPT with D. pteronyssinus. The acoustic rhinometry was performed after instillation of 0.15 mL of increasing concentrations of D. pteronyssinus (5000 BU/mL). The test was finalized after (1) instillation of the final concentration of D. pteronyssinus, or (2) after a 20% or more reduction in the volume of the first 5 cm of the nasal cavity (V5), or (3) a score of >3 in the symptoms questionnaire (a score from 0 to 7). A simplified specific NPT with two concentrations was proposed and implemented in a group of 10 patients with AR (group 3). RESULTS: At the end of the specific NPT, the median (range) variation in V5 was -5.7% (-9 to 4%) in the control group and -22.8% (-24 to -20%) in group 2. None of the patients in the control group and 88% of group 2 (15/17) showed positive specific NPT results. The simplified specific NPT triggered a positive response in 80% of patients in group 3, with median (range) V5 variation of -30.4% (-36 to -20%). CONCLUSION: This protocol has been proven safe and useful to differentiate between children and adolescents with AR and controls. Concentrations of 1:1000 and 1:100 D. pteronyssinus were the best for use in simplified specific NPT, which made it simpler and faster, and expanded its clinical applicability</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2017.31.4392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234142">PM:28234142</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-7-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-7-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Matsumoto FY</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2017.31.4392</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brook,C.D.</style></author><author><style face="normal" font="Arial"> Kuperstock,J.E.</style></author><author><style face="normal" font="Arial"> Rubin,S.J.</style></author><author><style face="normal" font="Arial"> Ryan,M.W.</style></author><author><style face="normal" font="Arial"> Platt,M.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Boston University School of Medicine, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">The association of allergic sensitization with radiographic sinus opacification</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="15" start="12">12-15</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The relationship between allergic sensitization and radiographic sinus inflammation remains unclear. OBJECTIVES: To determine whether specific allergen sensitization is correlated with sinonasal radiographic opacification. METHODS: Patients with chronic sinonasal symptoms were selected and included if they had allergy testing and a computed tomography (CT) of the paranasal sinuses. Data regarding demographic characteristics, in vitro allergy test results, and comorbidities were collected. CTs were reviewed, and an overall Lund-Mackay score (LMS) was calculated for each patient. A two-sample t-test was used to compare mean LMS between patients who were sensitized and patients who were not sensitized. A multiple linear regression model was used to determine whether a relationship existed among LMS and allergy results, asthma, nasal polyps, immunoglobulin E (IgE) level, medication usage, in-season versus out-of-season CTs, age, and sex. Significance was determined at an alpha level of 0.05. RESULTS: There were 437 patients included, of whom, 251 had positive specific allergen test results and 186 had negative test results. A total of 282 patients had allergic rhinitis symptoms without a documented diagnosis of sinusitis, and 155 carried a diagnosis of chronic rhinosinusitis. The mean LMS did not differ between patients who were sensitized and patients who were not sensitized (5.56 versus 5.28; p = 0.61). Linear regression demonstrated an increase in LMS in patients with asthma (p = 0.02), male sex (p &lt; 0.01), elevated IgE (p &lt; 0.01), a history of anaphylaxis (p = 0.03), and nasal polyps (p &lt; 0.01). There was a statistically significant decrease in LMS in patients with an in-season CT (p = 0.02). CONCLUSIONS: Patients with a positive specific in vitro allergen test result did not have higher overall rates of radiographic sinus inflammation. Asthma, male sex, polyps, elevated IgE, and a history of anaphylaxis were associated with higher LMS</style></abstract><notes><style face="normal" font="Arial">DA - 20170224IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2017.31.4394</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234144">PM:28234144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-12-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-12-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170224, Brook CD</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2017.31.4394</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,B.</style></author><author><style face="normal" font="Arial"> Xiao,L.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Luo,Y.</style></author><author><style face="normal" font="Arial"> Ji,Q.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Allergy and Immunology, School of Medicine, Shenzhen UniversityShenzhen 518060, China; Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen UniversityShenzhen 518060, China</style></auth-address><titles><title><style face="normal" font="Arial">Exploration of the effect of probiotics supplementation on intestinal microbiota of food allergic mice</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="385" start="376">376-385</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Environmental factor-induced alterations in intestinal microbiota have been demonstrated to be associated with increasing prevalence of food allergy. However, it is not clear to what extent oral administration of probiotics can affect gut microbiota composition, thus inhibiting food allergy development. Using ovalbumin (OVA)-sensitized murine model, it was demonstrated that probiotics ameliorated allergic symptoms, including reducing OVA specific-IgE, and -IgG1 levels in the serum, Th2 cytokines release in spleen, and occurrence of diarrhea. Moreover, 16S rRNA analysis showed that the probiotics-mediated protection was conferred by an enrichment of Coprococcus and Rikenella. The present study supports the theory that probiotics can treat food allergy by modulating specific genera of the gut microbiota</style></abstract><notes><style face="normal" font="Arial">DA - 20170324LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28337267">PM:28337267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2017-9-376-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2017-9-376-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Yang B</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Duman,H.</style></author><author><style face="normal" font="Arial"> Topal,I.O.</style></author><author><style face="normal" font="Arial"> Kocaturk,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Okmeydani Training and Research Hospital - Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Follicular traction urticaria</style></title><secondary-title><style face="normal" font="Arial">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">An Bras Dermatol</style></full-title></periodical><pages end="65" start="64">64-65</pages><volume><style face="normal" font="Arial">91</style></volume><number><style face="normal" font="Arial">5 suppl 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sunlight</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vibration</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">Inducible urticaria is a heterogeneous subgroup of chronic urticarias caused by a wide variety of environmental stimuli, such as exercise, cold, heat, pressure, sunlight, vibration, and water. A new term, follicular traction urticaria, was suggested as an unusual form of inducible urticarias. We report a patient who was diagnosed with follicular traction urticaria</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Case ReportsCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1590/abd1806-4841.20164654</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28300897">PM:28300897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\An Bras Dermatol\2016-91S5-64-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\An Bras Dermatol\2016-91S5-64-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Duman H</style></custom2><misc3><style face="normal" font="Arial">10.1590/abd1806-4841.20164654</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ke,X.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Lai,S.</style></author><author><style face="normal" font="Arial"> Chen,Q.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Jiang,Y.</style></author><author><style face="normal" font="Arial"> Mo,W.</style></author><author><style face="normal" font="Arial"> Ren,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Chemical Engineering, Zhejiang University of Technology, Hangzhou, 310014, China</style></auth-address><titles><title><style face="normal" font="Arial">Quantitative analysis of cow whole milk and whey powder adulteration percentage in goat and sheep milk products by isotopic dilution-ultra-high performance liquid chromatography-tandem mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">Anal Bioanal Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Bioanal Chem</style></full-title></periodical><pages end="224" start="213">213-224</pages><volume><style face="normal" font="Arial">409</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adulteration</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Caseins</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> Infant formulas</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> matrix effect</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk powder</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Sheep milk</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">The aim of the study was to develop a method for quantification of cow's whey and whole milk powder in goat or sheep milk products including infant formula. A ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was established for simultaneous quantification of four caseins and two major whey proteins by detecting their signature peptides, which were able to act as markers for differentiating goat or sheep from cow whey and whole milk powder in infant formulas. The signature peptides were screened based on the computational prediction by Biolynx software, and confirmed by database searching after analysis of liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry (LC-Q-TOF-MS). The isotopic-labeled signature peptide was used as internal standard to compensate the matrix effect. The limits of quantification were 0.01-0.05 g/100 g for target proteins. The observed recovery rates ranged from 82.3 to 116.6 % and the reproducibility was excellent (RSD &lt;12 %) at different spiking levels. The RSDs of intra- and inter-day precision were 2.8-6.2 and 3.3-9.8 %, respectively. The multiple reaction monitoring method was successfully applied to milk powder with different composition, showing high specificity and accuracy in detection of species involved. The calculating formula was designed to assess the composition of adulteration in the actual detection of infant formulas. These results highlight applicability of this method for the detection of infant formulas with complicated matrix</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1618-2650 (Electronic)IS - 1618-2642 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s00216-016-9987-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27761616">PM:27761616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Bioanal Chem\2017-409-213-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Bioanal Chem\2017-409-213-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Ke X</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s00216-016-9987-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kruczek,A.</style></author><author><style face="normal" font="Arial"> Puc,M.</style></author><author><style face="normal" font="Arial"> Wolski,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Biology, Department of Botany and Nature Conservation, University of Szczecin, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Poaceae, Secale spp. and Artemisia spp. pollen in the air at two sites of different degrees of urbanisation</style></title><secondary-title><style face="normal" font="Arial">Ann Agric Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Agric Environ Med</style></full-title></periodical><pages end="74" start="70">70-74</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen count</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross-reactions</style></keyword><keyword><style face="normal" font="Arial"> crossreactions</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> main allergens</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant allergen</style></keyword><keyword><style face="normal" font="Arial"> plant allergens</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen calendar</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Among herbal plants, most cases of allergic reactions, like seasonal inflammation of nasal mucosa, conjunctivitis and pollen asthma, are related to the allergens from grass pollen. As the blossoming and pollination of rye is known to start the pollen season of grasses, information about the airborne rye pollen count permits alerting the people allergic to certain allergens contained in rye pollen. An important cause of allergy is also the pollen from wormwood, blossoming in late summer, as its two main allergens produce cross-reactions with many other plant allergens. OBJECTIVE: The aim of the study was to evaluate the risk of allergic reactions in persons with pollinosis on the basis of the pollen calendar, analysis of concentrations of pollen grains of grass and rye, and comparison of diurnal pattern of airborne pollen grain concentrations at two sites with different degrees of urbanisation (Gudowo in the country and the city of Szczecin) in 2012-2014. MATERIALS AND METHODS: The concentration of pollen was measured by the volume method. Length of the pollination season was determined by the method of 98%, assuming that the beginning and the end of the pollen season are the days on which 1% and 99% of the annual sum of pollen appeared. RESULTS: The first pollen grains to appear in the air are those produced by rye, followed by those produced by grass and wormwood. The pollen seasons of grasses and wormwood started about one week earlier in Gudowo than in Szczecin, while the pollen season of rye started at almost the same time in the country and in the city. Airborne pollen counts of grasses, rye and wormwood were much higher in the country than in the city. The differences most probably result from the different floristic composition at these two sites and reflect the local contribution of the taxa studied in the country. CONCLUSIONS: The risk of allergy caused by the pollen of the taxa analysed was much higher in Gudowo (in the country), than in Szczecin city</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1898-2263 (Electronic)IS - 1232-1966 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5604/12321966.1233895</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378978">PM:28378978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Agric Environ Med\2017-24-70-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Agric Environ Med\2017-24-70-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Kruczek A</style></custom2><misc3><style face="normal" font="Arial">10.5604/12321966.1233895</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Akenroye,A.T.</style></author><author><style face="normal" font="Arial"> Iammatteo,M.</style></author><author><style face="normal" font="Arial"> de Vos,G.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York. Electronic address: ayobami.akenroye@post.harvard.eduDivision of Allergy and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New YorkDepartment of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York; Division of Allergy and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York</style></auth-address><titles><title><style face="normal" font="Arial">Hyper-immunoglobulin E-like syndrome in a patient with multiple genetic mutations</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="644" start="643">643-644</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366583">PM:28366583</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170403-AkenroyeAT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170403-AkenroyeAT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Akenroye AT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,E.</style></author><author><style face="normal" font="Arial"> Lee,S.H.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Cho,H.J.</style></author><author><style face="normal" font="Arial"> Yoon,J.</style></author><author><style face="normal" font="Arial"> Yang,S.I.</style></author><author><style face="normal" font="Arial"> Jung,Y.H.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Seo,J.H.</style></author><author><style face="normal" font="Arial"> Kwon,J.W.</style></author><author><style face="normal" font="Arial"> Kim,H.B.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Kwon,H.J.</style></author><author><style face="normal" font="Arial"> Hong,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Chonnam National University Hospital, Gwangju, KoreaAsan Institute for Life Sciences, University of Ulsan College of Medicine, Sonapa-gu, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association of atopy phenotypes with new development of asthma and bronchial hyperresponsiveness in school-aged children</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="550" start="542">542-550</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> latent class analysis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> School-age children</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="3" Year="2017">2017/3/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although previous studies have investigated the association between atopy phenotypes and allergic diseases, atopy characterizations in association with the development of allergic diseases remain poorly understood. OBJECTIVE: To identify atopy phenotypes in school-age children and to evaluate the association between atopy phenotypes and allergic diseases. METHODS: We enrolled 616 children with atopy defined as 1 or more positive allergen responses on skin prick tests and 665 children without atopy from the Children's Health and Environmental Research (CHEER) study. All children were followed up for 4 years at 2-year intervals. Atopy phenotypes were classified using latent class analysis. RESULTS: Four atopy phenotypes were characterized: later sensitization to indoor allergens (cluster 1); multiple early sensitization (cluster 2); early sensitization to outdoor allergens, especially Alternaria, and later sensitization to indoor allergens, including Aspergillus (cluster 3); and early sensitization to indoor allergens and later sensitization to outdoor allergens (cluster 4). New cases of asthma during follow-up were increased in clusters 2 and 3 (adjusted odds ratio [aOR], 2.76 and 4.25, respectively). The risk of new-onset bronchial hyperresponsiveness was highest in cluster 3 (aOR, 5.03). Clusters 2 and 4 had an increased risk of allergic rhinitis (aOR, 7.21 and 2.37, respectively). CONCLUSION: Identification of atopy phenotypes facilitates prediction of the development of asthma and bronchial hyperresponsiveness in school-age children. Our study suggests prevention of additional sensitization is required to modify the progression of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170402IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28364972">PM:28364972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170402-LeeE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170402-LeeE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170402, Lee E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Duffy,J.</style></author><author><style face="normal" font="Arial"> Lewis,M.</style></author><author><style face="normal" font="Arial"> Harrington,T.</style></author><author><style face="normal" font="Arial"> Baxter,R.</style></author><author><style face="normal" font="Arial"> Belongia,E.A.</style></author><author><style face="normal" font="Arial"> Jackson,L.A.</style></author><author><style face="normal" font="Arial"> Jacobsen,S.J.</style></author><author><style face="normal" font="Arial"> Lee,G.M.</style></author><author><style face="normal" font="Arial"> Naleway,A.L.</style></author><author><style face="normal" font="Arial"> Nordin,J.</style></author><author><style face="normal" font="Arial"> Daley,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia.</style></auth-address><titles><title><style face="normal" font="Arial">Live attenuated influenza vaccine use and safety in children and adults with asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="444" start="439">439-444</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> Centers for Disease Control</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza vaccination</style></keyword><keyword><style face="normal" font="Arial"> Influenza Vaccine</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mild persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Recurrent wheezing</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Live attenuated influenza vaccine (LAIV) might increase the risk of wheezing in persons with asthma or children younger than 5 years with a history of recurrent wheezing. OBJECTIVE: To describe the use and assess the safety of LAIV in persons with asthma in the Vaccine Safety Datalink population. METHODS: We identified persons with asthma using diagnosis codes and medication records in 7 health care organizations over 3 influenza seasons (2008-2009 through 2010-2011) and determined their influenza vaccination rates. Using the self-controlled risk interval method, we calculated the incidence rate ratio of medically attended respiratory events in the 14 days after LAIV compared with 29 to 42 days after vaccination in persons 2 through 49 years old. RESULTS: In our population of 6.3 million, asthma prevalence was 5.9%. Of persons with asthma, approximately 50% received any influenza vaccine but less than 1% received LAIV. The safety study included 12,354 LAIV doses (75% in children; 93% in those with intermittent or mild persistent asthma). The incidence rate ratio for inpatient and emergency department visits for lower respiratory events (including asthma exacerbation and wheezing) was 0.98 (95% confidence interval 0.63-1.51) and the incidence rate ratio for upper respiratory events was 0.94 (95% confidence interval 0.48-1.86). The risk of lower respiratory events was similar for intermittent and mild persistent asthma, across age groups, and for seasonal trivalent LAIV and 2009 H1N1 pandemic monovalent LAIV. CONCLUSION: LAIV use in asthma was mostly in persons with intermittent or mild persistent asthma. LAIV was not associated with an increased risk of medically attended respiratory adverse events</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.01.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390584">PM:28390584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-439-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-439-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Duffy J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.01.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goldstein,S.</style></author><author><style face="normal" font="Arial"> Gabriel,S.</style></author><author><style face="normal" font="Arial"> Kianifard,F.</style></author><author><style face="normal" font="Arial"> Ortiz,B.</style></author><author><style face="normal" font="Arial"> Skoner,D.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Asthma Care of Long Island, New York, New York.</style></auth-address><titles><title><style face="normal" font="Arial">Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="504" start="500">500-504</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> CIU</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL. OBJECTIVE: To describe the baseline clinical profile of adolescent patients with CIU enrolled in the omalizumab trials to add to the limited literature available on CIU in this population. METHODS: Data for patient demographics, baseline clinical disease characteristics, medical history, and previous CIU medication information (not efficacy assessments) from phase 3 omalizumab trials were pooled and descriptive statistical analyses performed for adolescent (12 to &lt;18 years old) and adult (>/=18 years old) subgroups. Inferential analysis was inappropriate, partly because of small sample size in the adolescent subgroup. RESULTS: The pooled population of 975 patients with CIU included 39 adolescents (4.0%). Demographics of adolescents and adults with CIU were similar, but compared with adults, fewer adolescents had positive Chronic Urticaria Index test results. Baseline clinical disease characteristics were also similar between the subgroups, with the number of previous CIU medications slightly lower in adolescents compared with adults. Medical history and existing conditions in adolescents tended to be more allergy than cardiovascular related, and fewer experienced angioedema compared with adults. CONCLUSION: Pooled data indicate differences in baseline demographic and clinical characteristics between adult and adolescent patient subgroups. This finding helps augment our understanding of the clinical profile of CIU in adolescents, but larger-scale studies in this population are warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390587">PM:28390587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-500-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-500-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Goldstein S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Couch,C.</style></author><author><style face="normal" font="Arial"> Franxman,T.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, The University of Michigan Medical School, Ann Arbor, Michigan; Allergy Asthma Clinic, Ltd, Phoenix, ArizonaFamily Allergy and Asthma Center, Florence, KentuckyDivision of Allergy and Clinical Immunology, The University of Michigan Medical School, Ann Arbor, Michigan</style></auth-address><titles><title><style face="normal" font="Arial">Characteristics of tree nut challenges in tree nut allergic and tree nut sensitized individuals</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="596" start="591">591-596</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> brazil nut</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Kentucky</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Characteristics and outcomes of tree nut (TN) oral food challenges (OFCs) in patients with TN allergy or sensitization alone are poorly studied. OBJECTIVE: To determine the relation between TN sensitization levels and OFC outcomes. METHODS: Open TN OFCs performed from 2007 through 2015 at a referral center were analyzed to compare outcome based on skin prick test (SPT) wheal size, food-specific immunoglobulin E (sIgE), peanut co-allergy, and TN sensitization only vs TN allergy with sensitization to other TNs. Delayed OFC was defined as longer than 12 months from the time of an sIgE level lower than 2 kUA/L. RESULTS: Overall passage rate was 86% for 156 TN OFCs in 109 patients (54 almond, 28 cashew, 27 walnut, 18 hazelnut, 14 pecan, 13 pistachio, and 2 Brazil nut). Passage rates were 76% (n = 67) in patients with a history of TN allergy who were challenged to another TN to which they were sensitized and 91% (n = 65) in those with TN sensitization only (mean sIgE 1.53 kUA/L; range 0.35-9.14). Passage rates were 89% (n = 110 of 124) for a TN sIgE level lower than 2 kUA/L and 69% (11 of 16) for a TN sIgE level of at least 2 kUA/L. In 44 challenges in patients with peanut allergy and TN co-sensitization, the TN OFC passage rate was 96%. In 41 TN OFCs with a TN SPT wheal size of at least 3 mm, 61% passed, with a mean wheal size of 4.8 mm (range 3-11) in those passing vs 9 mm (range 3-20) in those failing. CONCLUSION: TN challenges are frequently passed in patients with TN sensitization with or without a history of TN reactivity despite a TN SPT wheal of at least 3 mm or a TN sIgE level of at least 2 kUA/L. Nearly all patients with peanut allergy and TN co-sensitization passed the TN challenge, questioning the clinical relevance of "co-allergy."</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359600">PM:28359600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170331-CouchC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170331-CouchC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Couch C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Cervera,J.</style></author><author><style face="normal" font="Arial"> Arias,A.</style></author><author><style face="normal" font="Arial"> Redondo-Gonzalez,O.</style></author><author><style face="normal" font="Arial"> Cano-Mollinedo,M.M.</style></author><author><style face="normal" font="Arial"> Terreehorst,I.</style></author><author><style face="normal" font="Arial"> Lucendo,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Hospital General de Tomelloso, Tomelloso, Spain; Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Madrid, SpainCentro de Investigacion en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Madrid, Spain; Research Unit, Hospital General Mancha Centro, Alcazar de San Juan, SpainResearch Unit, Hospital General Mancha Centro, Alcazar de San Juan, SpainDepartment of Allergy, Hospital General de Tomelloso, Tomelloso, SpainDepartment of ENT and Pediatrics, Academisch Medisch Centrum, Amsterdam, the NetherlandsCentro de Investigacion en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Madrid, Spain; Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain. Electronic address: alucendo@vodafone.es</style></auth-address><titles><title><style face="normal" font="Arial">Association between atopic manifestations and eosinophilic esophagitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="590" start="582">582-590</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> funnel plot</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic esophagitis (EoE) has repeatedly been associated with atopic manifestations, which are reported more frequently in these patients than in the general population. OBJECTIVE: To systematically assess the evidence and strength of the associations between EoE and atopy. METHODS: We performed a systematic search of the MEDLINE, EMBASE, and SCOPUS databases for case-control studies comparing the frequency of atopic diatheses among patients with EoE and control subjects representing the general population without EoE. Using random-effects meta-analyses, we calculated summary estimates, including 95% confidence intervals (CIs), for bronchial asthma, atopic rhinitis, and eczema. Publication bias risks were assessed by means of funnel plot analysis and specific statistical tests. RESULTS: Of the 2,954 references identified, data were collected from 21 studies, including a total of 53,542 patients with EoE and 54,759 controls. The criteria for defining a diagnosis of atopy in patients with EoE or controls was not structurally considered in most of the studies. Overall, allergic rhinitis was significantly more common among patients with EoE compared with control subjects (odds ratio [OR], 5.09; 95% CI, 2.91-8.90; I2 = 86.7%) as were bronchial asthma (OR, 3.01; 95% CI, 1.96-4.62; I2 = 84.5%) and eczema (OR, 2.85; 95% CI, 1.87-4.34; I2 = 57.1%). Food allergies and other atopic conditions were also assessed. No significant publication bias was found for studies dealing with allergic rhinitis and eczema in EoE. CONCLUSIONS: Despite pointing to a significant association between atopy and EoE, most of the studies provided no normalized diagnostic criteria for atopy. Further research should provide clear and standardized definitions of such conditions. TRIAL REGISTRATION: www.crd.york.ac.uk/PROSPERO Trial Identifier: CRD42016036161</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366582">PM:28366582</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170403-GonzalezCerveraJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170403-GonzalezCerveraJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Gonzalez-Cervera J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wright,C.D.</style></author><author><style face="normal" font="Arial"> Longjohn,M.</style></author><author><style face="normal" font="Arial"> Lieberman,P.L.</style></author><author><style face="normal" font="Arial"> Lieberman,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatrics, The University of Tennessee Health Science Center, Memphis, Tennessee</style></auth-address><titles><title><style face="normal" font="Arial">An analysis of anaphylaxis cases at a single pediatric emergency department during a 1-year period</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="464" start="461">461-464</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">African American</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Case series of anaphylaxis can vary regarding causes, treatments, and follow-up of patients. Unfortunately, case series that are specific to the pediatric population are few. OBJECTIVE: To describe confirmed cases of pediatric anaphylaxis in patients presenting to a pediatric hospital emergency department (ED). METHODS: We identified all ED visits with the International Classification of Diseases, Ninth Revision (ICD-9) codes 995.XX (allergic reactions) and 989.5 (sting or venom reaction) for 1 calendar year (January 1, 2014, through December 31, 2014). Cases were reviewed by an allergist and an emergency medicine physician to identify true anaphylaxis cases using National Institute of Health/National Institute of Allergy and Infectious Diseases criteria. Any questionable or debatable cases were evaluated and adjudicated by a second allergist. RESULTS: We identified 927 unique ED visits. Of these visits, 40 were determined to definitively meet anaphylaxis criteria. Median age of the patients was 6.5 years. A total of 70% of patients were male, and 80% were African American. Causes included foods (65%), venom or insect sting (12.5%), and medications (5%), and 17.5% were idiopathic. All patients had multiorgan involvement, with 98% having skin involvement, 78% having lower respiratory tract symptoms, and 40% having gastrointestinal symptoms. There were no deaths. Only 33% of patients received epinephrine at some point in their care. Only 12 patients were referred to an allergist, and only 4 of these were actually seen by an allergist. CONCLUSION: At our center, foods are the most common trigger for pediatric anaphylaxis. Patients continue to be undertreated, and referral to an allergist from the ED is rare</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390586">PM:28390586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-461-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-461-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Wright CD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Knox,S.M.</style></author><author><style face="normal" font="Arial"> Erwin,E.A.</style></author><author><style face="normal" font="Arial"> Mosser-Goldfarb,J.L.</style></author><author><style face="normal" font="Arial"> Scherzer,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization patterns among patients with atopic dermatitis evaluated in a large tertiary care pediatric center</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="647" start="645">645-647</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28372896">PM:28372896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170404-KnoxSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170404-KnoxSM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Knox SM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Esch,R.E.</style></author><author><style face="normal" font="Arial"> Codina,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Natural Sciences, Lenoir-Rhyne University, Hickory, North Carolina.</style></auth-address><titles><title><style face="normal" font="Arial">Fungal raw materials used to produce allergen extracts</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="405" start="399">399-405</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Books</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To review the topic of fungal raw materials used for the production of allergen extracts and the associated challenges and highlight candidate areas for development before standardized fungal allergen extracts can be commercially produced. DATA SOURCES: A PubMed search was performed using focused keywords and combined with a review of regulatory documents and industry guidelines. Several books on mycology also were consulted. STUDY SELECTIONS: The information obtained through the literature, books, and industry was scrutinized and combined with personal experience and expertise to write this article. RESULTS: Fungi are complex ubiquitous organisms on Earth. They are beneficial and detrimental for humans. Fungi can cause hypersensitivity reactions, including types I, III, and IV. The procurement of fungal raw materials to prepare allergen extracts for diagnosis and possible allergen immunotherapy is complex owing to the intrinsic nature of fungi and their complex genome. Allergen manufacturers produce allergen extracts with variable qualitative and quantitative compositions, which can lead to unpredictable clinical outcomes. CONCLUSION: The clinician should be aware of the factors responsible for the qualitative and quantitative compositions of fungal allergen extracts and the reasons that currently preclude their standardization. Scientific advances and collaboration and cooperation between allergen manufacturing companies and regulatory agencies are necessary to improve the quality and consistency of fungal extracts. Moreover, clinicians should understand the limitations of currently available fungal extracts</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.05.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390581">PM:28390581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-399-405.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-399-405.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Esch RE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.05.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pham,M.N.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Icahn School of Medicine, Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="Arial">Mammalian milk allergy: case presentation and review of prevalence, diagnosis, and treatment</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="410" start="406">406-410</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390582">PM:28390582</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-406-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-406-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Pham MN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Groetch,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Icahn School of Medicine, Mount Sinai, New York, New York.</style></auth-address><titles><title><style face="normal" font="Arial">Preventing food allergies with tweaks to the infant diet: A practical reality?</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="388" start="385">385-388</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390578">PM:28390578</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-385-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-385-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Manti,S.</style></author><author><style face="normal" font="Arial"> Leonardi,S.</style></author><author><style face="normal" font="Arial"> Salpietro,A.</style></author><author><style face="normal" font="Arial"> Del Campo,G.</style></author><author><style face="normal" font="Arial"> Salpietro,C.</style></author><author><style face="normal" font="Arial"> Cuppari,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Unit of Pediatric Genetics and Immunology, University of Messina, Messina, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">A systematic review of food protein-induced enterocolitis syndrome from the last 40 years</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="418" start="411">411-418</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To provide a complete, exhaustive summary of current literature relevant to food protein-induced enterocolitis syndrome (FPIES). DATA SOURCES: Data have been extracted from PubMed and Science Direct databases. STUDY SELECTIONS: Following the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines, a literature search for peer-reviewed journal articles in English through January 1975 with updates through October 2016 was conducted. Relevant publications were reviewed that included pediatric and adult populations. Information on the study design, sample, intervention, comparators, outcome, timeframe, and risk of bias were abstracted for each article. RESULTS: Of 135 reviewed reports, 52 were included in this systematic review. In accordance with the age at onset, clinical features, and offending foods, it is possible to distiguish different types of FPIES. An immune systemic involvement can occur in patients with FPIES. In addition to the most common causative foods (cow's milk, soy, and rice), any food can potentially cause FPIES. Although specific diagnostic tests are not available, open food challenge remains the gold standard for FPIES diagnosis. Moreover, because of the lack of randomized clinical trials and of use of different adopted methods, confounding factors might mask critical findings, leading to poor knowledge of this pleiotropic clinical entity. CONCLUSION: Multicenter studies are needed to better develop an evidence-based approach to pathophysiology, prevalence, diagnosis, and natural history of the disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390583">PM:28390583</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-411-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-411-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Manti S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Racette,S.D.</style></author><author><style face="normal" font="Arial"> Wijewickrama,R.C.</style></author><author><style face="normal" font="Arial"> Jayaprakash,V.</style></author><author><style face="normal" font="Arial"> Sherris,D.A.</style></author><author><style face="normal" font="Arial"> Santos,C.</style></author><author><style face="normal" font="Arial"> Kita,H.</style></author><author><style face="normal" font="Arial"> O'Donnell,F.E.,Jr.</style></author><author><style face="normal" font="Arial"> Ponikau,J.U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Otorhinolaryngology, University at Buffalo School of Medicine and Biomedical Sciences, The State University of New York, Gromo Institute and Sinus Center, Buffalo, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Correlation of Symptoms, Clinical Signs, and Biomarkers of Inflammation in Postsurgical Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Ann Otol Rhinol Laryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Otol Rhinol Laryngol</style></full-title></periodical><pages end="462" start="455">455-462</pages><volume><style face="normal" font="Arial">126</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Buffalo</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil-Derived Neurotoxin</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Interleukins</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> mucosal inflammation</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal endoscopy</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Smell</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The study aimed to evaluate symptoms described by patients with chronic rhinosinusitis with polypoid changes/nasal polyps and their correlation with computed tomography (CT), nasal endoscopy, and intranasal biomarkers. STUDY DESIGN: Prospective multicenter study symptom data from postsurgical adult chronic rhinosinusitis study participants with recurrent disease refractory to medical therapy were analyzed in comparison with objective data. METHODS: Using logistic regression analysis, participant-rated 16-question surveys from 258 participants were assessed for correlation with nasal endoscopy scores, CT percentage of sinus occlusion, and intranasal biomarkers of fungal antigens (Alternaria and Aspergillus), eosinophilic inflammation (eosinophil-derived neurotoxin [EDN] and major basic protein [MBP]), and inflammatory cytokines (interleukins 5 and 13). RESULTS: Study participant assessments revealed increased CT occlusion in participants presenting with greater inability to smell ( P &lt; .019). Mucosal inflammation identified on nasal endoscopy was positively correlated with congestion ( P &lt; .028), runny nose ( P &lt; .002), and ear pain ( P &lt; .007). Elevated EDN was positively correlated in patients with bothersome congestion ( P &lt; .031) and runny nose ( P &lt; .011). Sneezing was positively correlated with multiple markers: Alternaria ( P &lt; .024), interleukin-13 ( P &lt; .027), MBP ( P &lt; .034), and interleukin-5 ( P &lt; .019). CONCLUSION: Nasal endoscopy, not CT imaging, has the strongest correlation with the 2 cardinal symptoms of congestion and runny nose in CRS patients; these correlate with biomarkers of eosinophilic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1943-572X (Electronic)IS - 0003-4894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/0003489417701939</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28376637">PM:28376637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Otol Rhinol Laryngol\2017-126-455-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Otol Rhinol Laryngol\2017-126-455-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Racette SD</style></custom2><misc3><style face="normal" font="Arial">10.1177/0003489417701939</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Petrova,N.V.</style></author><author><style face="normal" font="Arial"> Emelyanova,A.G.</style></author><author><style face="normal" font="Arial"> Gorbunov,E.A.</style></author><author><style face="normal" font="Arial"> Edwards,M.R.</style></author><author><style face="normal" font="Arial"> Walton,R.P.</style></author><author><style face="normal" font="Arial"> Bartlett,N.W.</style></author><author><style face="normal" font="Arial"> Aniscenko,J.</style></author><author><style face="normal" font="Arial"> Gogsadze,L.</style></author><author><style face="normal" font="Arial"> Bakhsoliani,E.</style></author><author><style face="normal" font="Arial"> Khaitov,M.R.</style></author><author><style face="normal" font="Arial"> Johnston,S.L.</style></author><author><style face="normal" font="Arial"> Tarasov,S.A.</style></author><author><style face="normal" font="Arial"> Epstein,O.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results</style></title><secondary-title><style face="normal" font="Arial">Antiviral Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Antiviral Res</style></abbr-1></periodical><pages end="192" start="185">185-192</pages><volume><style face="normal" font="Arial">142</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Common Cold</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Hela Cells</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Rhinoviruses</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmaceutical ingredients) in in vitro and in vivo experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-stimulated gene (ISG), 2'-5'-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In a mouse model of RV-induced exacerbation of allergic airway inflammation we administered Ergoferon and analyzed its effect on type I (IFN-beta), type II (IFN-gamma) and type III (IFN-lambda) IFNs induction, cell counts in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10/IP-10; CXCL1/KC) levels. It was shown that AC increased OAS1-capital A, Cyrillic production and significantly decreased viral replication in vitro. Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon in vivo. However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess effects against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170330IS - 1872-9096 (Electronic)IS - 0166-3542 (Linking)LA - engPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.antiviral.2017.03.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28356234">PM:28356234</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Antiviral Res\2017-142-185-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Antiviral Res\2017-142-185-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170330, Petrova NV</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.antiviral.2017.03.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Melik-Nubarov,N.S.</style></author><author><style face="normal" font="Arial"> Grozdova,I.D.</style></author><author><style face="normal" font="Arial"> Lomakina,G.Yu</style></author><author><style face="normal" font="Arial"> Pokrovskaya,M.V.</style></author><author><style face="normal" font="Arial"> Pokrovski,V.S.</style></author><author><style face="normal" font="Arial"> Aleksandrova,S.S.</style></author><author><style face="normal" font="Arial"> Abakumova,O.Yu</style></author><author><style face="normal" font="Arial"> Podobed,O.V.</style></author><author><style face="normal" font="Arial"> Grishin,D.V.</style></author><author><style face="normal" font="Arial"> Sokolov,N.N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">PEGylated recombinant L-asparaginase from Erwinia carotovora: Production, properties, and potential applications</style></title><secondary-title><style face="normal" font="Arial">Appl Biochem Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Biochem Microbiol</style></full-title></periodical><pages end="172" start="165">165-172</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Applications</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Erwinia</style></keyword><keyword><style face="normal" font="Arial"> Filtration</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> L-asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene glycol</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Sepharose</style></keyword><keyword><style face="normal" font="Arial"> tetramer</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1608-3024</style></isbn><abstract><style face="normal" font="Arial">N-hydroxysuccinimide ester of monomethoxy polyethylene glycol hemisuccinate was synthesized. It acylated amino groups in a molecule of recombinant L-asparaginase from Erwinia carotovora. A method of L-asparaginase modification by the obtained activated polyethylene glycol derivative was developed. The best results were produced by modification of the enzyme with a 25-fold excess of reagent relative to the enzyme tetramer. The modified L-asparaginase was isolated from the reaction mixture by gel filtration on Sepharose CL-6B. The purified bioconjugate did not contain PEG unbound to the protein, demonstrated high catalytic activity, and exhibited antiproliferative action on cell cultures</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1134/S0003683817020119</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1134/S0003683817020119</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Biochem Microbiol\2017-53-165-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Biochem Microbiol\2017-53-165-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Melik-Nubarov NS</style></custom2><misc3><style face="normal" font="Arial">10.1134/S0003683817020119</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jeon,Y.J.</style></author><author><style face="normal" font="Arial"> Lee,S.G.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Acaricidal and insecticidal activities of essential oils of Cinnamomum zeylanicum barks cultivated from France and India against Dermatophagoides spp., Tyrophagus putrescentiae and Ricania sp</style></title><secondary-title><style face="normal" font="Arial">Appl Biol Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Biol Chem</style></full-title></periodical><pages end="264" start="259">259-264</pages><volume><style face="normal" font="Arial">60</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acaricide</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Bioassay</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Cinnamaldehyde</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides spp</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> filter</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Nymph</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Oils</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus putrescentiae</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2468-0842</style></isbn><abstract><style face="normal" font="Arial">The chemical composition of Cinnamomum zeylanicum bark oils cultivated from France and India was analyzed by GC</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôMS. The main components of C. zeylanicum oil were cinnamaldehyde (63.97 and 67.21%) and eugenol (6.84 and 19.79%) from France and India, respectively. Acaricidal and insecticidal activities of C. zeylanicum oils against Dermatophagoides sp, T. putrescentiae and Ricania sp. were evident. The LC50 values of C. zeylanicum oil were 123.77 and 93.06-ámg/L in samples from France and India, respectively, against Ricania sp. adults in the spray bioassay. Using the leaf-dipping bioassay, the LC50 values of the oil from France and India were 80.99 and 57.44-ámg/L, respectively, against Ricania sp. nymphs. Acaricidal activity of the C. zeylanicum oil from India in the fabric disk bioassay (LD50, 0.64, 0.51 and 1.72-á++g/cm3, respectively) was greater than France oil (LD50, 0.92, 0.81 and 1.82-á++g/cm3, respectively). In the filter paper bioassay, india oil (LD50, 1.82, 1.55 and 3.08-á++g/cm2, respectively) was more potent than France oil (LD50, 2.07, 1.94 and 6.20-á++g/cm2, respectively) against D. farinae, D. pteronyssinus and T. putrescentiae. The results indicate that the essential oils of C. zeylanicum barks could be an effective natural acaricide and insecticide for controlling house dust mites, stored food mites and fruit pests</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13765-017-0276-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13765-017-0276-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Biol Chem\20170410-JeonYJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Biol Chem\20170410-JeonYJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Jeon YJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13765-017-0276-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Belkheir,K.</style></author><author><style face="normal" font="Arial"> Zadi Karam,H.</style></author><author><style face="normal" font="Arial"> Karam,N.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">New Proteolytic Pathway with Probable Hypoallergenic Properties of Lactobacillus Isolated from Dromedary Milk</style></title><secondary-title><style face="normal" font="Arial">Arab J Sci Eng</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Arab J Sci Eng</style></abbr-1></periodical><pages end="2246" start="2241">2241-2246</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algeria</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Cow milk proteins</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus plantarum</style></keyword><keyword><style face="normal" font="Arial"> Leuconostoc</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteinase</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2191-4281</style></isbn><abstract><style face="normal" font="Arial">Cow milk is a nutritious product that could be the first food introduced into infant</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs diet when breastfeeding is not possible. However, ingestion of cow milk can cause allergenic reaction in subjects which adverse immunologic response to bovine milk proteins. Clinical trials demonstrated that the microbial fermentation of bovine milk could be a possible strategy to reduce allergic symptoms in childhood. During fermentation process, some epitopes of milk proteins are destroyed by digestive enzymes of lactic acid bacteria. The antigenicity reduction depends on the specificity of the proteinases from these bacteria. In this study, functional three autochthonous Lactobacillus plantarum, Lactobacillus brevis and Leuconostoc mesenteroides ssp dextranicum isolated from Algerian dromedary milk were tested for their proteolytic and hypoallergenic properties. Hydrolysis of cow milk proteins by isolates was assayed using different techniques. Results revealed that Lactobacillus plantarum C22P was associated with rapid growth and pronounced proteolytic activity when cultured in the presence of cow milk proteins. A total degradation of beta lactoglobulin and k-casein was obtained by this strain. Results presented in this manuscript suggest that Lb plantarum C22P could be used as new potential adjunct bacteria with interesting proteolytic and hypoallergenic activities</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Algeria -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13369-017-2442-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13369-017-2442-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arab J Sci Eng\20170410-BelkheirK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arab J Sci Eng\20170410-BelkheirK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Belkheir K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13369-017-2442-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tuncel,T.</style></author><author><style face="normal" font="Arial"> Sancakli,O.</style></author><author><style face="normal" font="Arial"> Ozdogru,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Izmir Katip Celebi University Medical Faculty, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Izmir Tepecik Training and Research Hospital, Department of Pediatrics. Izmir, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination</style></title><secondary-title><style face="normal" font="Arial">Arch Argent Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Argent Pediatr</style></full-title></periodical><pages end="e91" start="e89">e89-e91</pages><volume><style face="normal" font="Arial">115</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunization Schedule</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">Egg allergy is one of the most common food allergies during childhood along with cow's milk allergy. The measles-mumpsrubella (MMR) vaccine is included in the pediatric immunization schedule and contains egg protein. The currently accepted opinion is that the MMR vaccination should be done in a single dose under medical observation in patients with egg allergy. Although it is reported that the MMR vaccine is safe for that patients, there are some patients who developed anaphylaxis. Generally, the development of anaphylaxis after the previous vaccination is reported as a contraindication. We present a successful administration of MMR vaccine by gradually increased doses for a patient who developed anaphylaxis after the previous vaccination</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1668-3501 (Electronic)IS - 0325-0075 (Linking)LA - engLA - spaPT - Case ReportsCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5546/aap.2017.eng.e89</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318190">PM:28318190</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Argent Pediatr\2017-115-e89-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Argent Pediatr\2017-115-e89-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Tuncel T</style></custom2><misc3><style face="normal" font="Arial">10.5546/aap.2017.eng.e89</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cap,M.</style></author><author><style face="normal" font="Arial"> Drumez,E.</style></author><author><style face="normal" font="Arial"> Lejeune,S.</style></author><author><style face="normal" font="Arial"> Thumerelle,C.</style></author><author><style face="normal" font="Arial"> Mordacq,C.</style></author><author><style face="normal" font="Arial"> Neve,V.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">L'allergie alimentaire a-t-elle un impact sur la morbidité de l'asthme ?</style></title><secondary-title><style face="normal" font="Arial">Arch Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Pediatr</style></full-title></periodical><pages end="509" start="508">508-509</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergique</style></keyword><keyword><style face="normal" font="Arial"> Arachide</style></keyword><keyword><style face="normal" font="Arial"> Asthme</style></keyword><keyword><style face="normal" font="Arial"> Asthme allergique</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> Enfants</style></keyword><keyword><style face="normal" font="Arial"> EST</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> Fonction respiratoire</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Lait</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Traitement</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><isbn><style face="normal" font="Arial">0929-693X</style></isbn><abstract><style face="normal" font="Arial">Objectif L'allergie alimentaire (AA) est souvent associée à l'asthme. Nous avons étudié l'impact de l'AA sur le contrôle de l'asthme. Les exacerbations, le niveau de traitement et la fonction respiratoire étaient également évalués. Sujets et méthodes Étude prospective, monocentrique réalisée entre août 2015 et mars 2016. Les enfants suivis pour asthme allergique âgés d'au moins 7 ans, avec ou sans AA étaient inclus. Les caractéristiques de l'asthme et de l'AA étaient recueillies. Le contrôle de l'asthme était défini par les critères du GINA 2014. Le score ACT ou ACT pédiatrique, le nombre d'exacerbations, de corticothérapies systémiques et d'hospitalisations dans l'année précédente, le niveau de traitement, la dose de corticostéroïdes inhalés (CSI) et la fonction respiratoire (VEMS, VEMS/CV, FeNO) étaient étudiés dans les groupes d'enfants avec et sans AA. Résultats Deux cent douze patients asthmatiques (âge médian : 11,5 ans) étaient inclus, dont 57 avaient une AA (27 %) (fruits à coque = 26, arachide = 23, œuf = 11, lait = 3, autre = 20, AA multiples = 41). L'antécédent d'asthme aigu grave n'était pas différent entre les 2 groupes (p = 0,4). Trente-neuf enfants avaient un antécédent d'anaphylaxie. Trente et un enfants (15 %) étaient traités par Omalizumab, dont 10 avaient une AA. Trente-huit enfants avec AA (67 %) avaient un asthme contrôlé versus 94 enfants sans AA (61 %) (p = 0,42) ; il n'y avait pas de différence pour le score ACT/pACT (p = 0,26). Le nombre d'exacerbations (p = 0,1), de corticothérapies systémiques (p = 0,08) et d'hospitalisations (p = 0,41), le niveau de traitement selon GINA (p = 0,17), la dose de CSI (p = 0,16), le VEMS/CV [moyenne 84 % si AA versus 83 % ; p = 0,12] et la FeNO [médiane : 42 ppb si AA versus 24 ppb (p = 0,55)] n'étaient pas différents. Le type, le nombre d'aliments et la sévérité des réactions allergiques n'influaient pas sur le contrôle de l'asthme. Le sous-groupe de patients « asthme-dermatite atopique-AA » (A-DA-AA) avait plus d'exacerbations (p = 0,0094) et une dose de CSI quotidienne plus élevée (p = 0,017) par rapport aux patients avec asthme et AA sans DA. Conclusion Notre étude ne montre pas une morbidité de l'asthme plus importante chez les enfants ayant une AA. Toutefois, l'association DA-AA paraît être associée à un phénotype d'A plus sévère.</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.arcped.2017.02.006</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.arcped.2017.02.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Pediatr\2017-24-508-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Pediatr\2017-24-508-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170415, Cap M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.arcped.2017.02.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Couture,J.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author><author><style face="normal" font="Arial"> Pineau,C.A.</style></author><author><style face="normal" font="Arial"> Scott,S.</style></author><author><style face="normal" font="Arial"> Clarke,A.E.</style></author><author><style face="normal" font="Arial"> Bernatsky,S.</style></author><author><style face="normal" font="Arial"> Vinet,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Rheumatology, McGill University Health Centre, Montreal, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Risk of Allergic Conditions in Children Born to Women with Systemic Lupus Erythematosus</style></title><secondary-title><style face="normal" font="Arial">Arthritis Care Res (Hoboken)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arthritis Care Res (Hoboken)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In utero</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Maternal Age</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Obstetrical complications</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Limited evidence suggests a potentially increased risk of allergic conditions in offspring born to women with systemic lupus erythematosus (SLE). In a large population-based study, we aimed to determine if children born to SLE mothers have an increased risk of allergic conditions compared to children born to mothers without SLE. METHODS: Using the "Offspring of SLE mothers Registry (OSLER)", we identified children born live to SLE mothers and their matched controls, and ascertained allergic conditions (including asthma, allergic rhinitis, eczema, urticaria, angioedema, and anaphylaxis) based on >/=1 hospitalization or >/=1 or 2 physician(s) visit(s) with a relevant diagnostic code. We adjusted for maternal age, education, race/ethnicity, obstetrical complications, calendar year of birth, sex of the child, and maternal medication. RESULTS: 509 women with SLE had 719 children, while 5824 matched controls had 8493 children. Mean follow-up was 9.1 (SD 5.8) years. As opposed to controls, more children born to mothers with SLE had evidence of allergic conditions [43.9% (95% CI 40.4, 47.6) versus 38.1% (95% CI 37.0, 39.1]. In multivariate analysis (n=9212), children born to SLE mothers had an increased risk of allergic conditions versus control children (OR 1.35, 95% CI 1.13, 1.61). CONCLUSION: Compared to children from the general population, children born to women with SLE may have an increased risk of allergic conditions. Genetics, shared environmental exposures, as well as in utero exposure to maternal autoantibodies and cytokines may mediate this increased risk. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170406IS - 2151-4658 (Electronic)IS - 2151-464X (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1002/acr.23251</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28382783">PM:28382783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arthritis Care Res (Hoboken)\20170406-CoutureJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arthritis Care Res (Hoboken)\20170406-CoutureJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170406, Couture J</style></custom2><misc3><style face="normal" font="Arial">10.1002/acr.23251</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iacono,G.</style></author><author><style face="normal" font="Arial"> Scalici,C.</style></author><author><style face="normal" font="Arial"> Iacono,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Chronic Costipation as a Symptom of Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Austin J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Austin J Allergy</style></full-title></periodical><pages end="" start="1024">1024-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://austinpublishinggroup.com/allergy/fulltext/aja-v3-id1024.php#Top</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Austin J Allergy\2016-3-1024.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Austin J Allergy\2016-3-1024.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160410, Iacono G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bavaro,S.L.</style></author><author><style face="normal" font="Arial"> Monaci,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Peanut Allergy and Strategies for Allergenicity Reduction</style></title><secondary-title><style face="normal" font="Arial">Austin J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Austin J Allergy</style></full-title></periodical><pages end="" start="1022">1022-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Non-thermal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatment</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatments</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Peanut allergy is a typical IgE mediated immune disease and has become a major health concern worldwide. Even a low intake of peanuts or peanut containing foods can cause severe and sometimes fatal allergic reactions in sensitive individuals. Differences in the preparation of peanuts before consumption could contribute to whether an individual will eventually display an allergic reaction. Several thermal and non thermal treatments might account for this change in allergenicity due to an alteration of the allergenic proteins therein contained. Such paper will report and review the different strategies aimed to reduce peanuts allergenicity.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://austinpublishinggroup.com/allergy/fulltext/aja-v3-id1022.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Austin J Allergy\2016-3-1022.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Austin J Allergy\2016-3-1022.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160410, Bavaro SL</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barton,J.S.</style></author><author><style face="normal" font="Arial"> Schomacker,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemistry, Washburn University, 1700 S College Avenue, Topeka, KS 66621, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Comparative protein profiles of the Ambrosia plants</style></title><secondary-title><style face="normal" font="Arial">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochim Biophys Acta</style></full-title></periodical><pages end="639" start="633">633-639</pages><volume><style face="normal" font="Arial">1865</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Enolase</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="Arial">Ragweed pollen is primarily responsible for the hay fever allergies of sufferers throughout the world. A proteome study of three ragweed plants (Ambrosia artemisiifolia, Ambrosia trifida, and Ambrosia psilostachya) was undertaken to document and compare their protein profiles. Proteins extracted from the pollen of the three plants were subjected to one dimensional electrophoresis followed by tandem liquid chromatography-mass spectroscopy. Peptide sequence mapping permitted discovery of proteins not previously reported for all three plants and 45% of the identified proteins were shared by all three of them. Application of stringent criteria revealed not only a majority of known allergens for short ragweed but also allergens not previously reported for the other two plants. Additionally, potentially allergy inducing enolases are reported for the three plants. These results suggest that all three ragweed plants could contribute to the allergy malady</style></abstract><notes><style face="normal" font="Arial">DA - 20170319IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbapap.2017.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315734">PM:28315734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\2017-1865-633-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\2017-1865-633-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170319, Barton JS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbapap.2017.03.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shrimanker,R.</style></author><author><style face="normal" font="Arial"> Pavord,I.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nuffield Department of Medicine, University of Oxford, NDM Research Building, Old Road Campus, Oxford, OX3 7FZ, UK</style></auth-address><titles><title><style face="normal" font="Arial">Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook</style></title><secondary-title><style face="normal" font="Arial">BioDrugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BioDrugs</style></full-title></periodical><pages end="103" start="93">93-103</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">In this review, we outline the pathophysiology of severe asthma and discuss the role of anti-interleukin (IL)-5 inhibitors for the treatment of asthma. Anti-IL-5 treatments have shown efficacy in reducing the rate of severe asthma attacks in eosinophilic asthma. We review the history of the development of these agents, lessons learnt about severe asthma along the way and key clinical trials supporting efficacy of the three anti-IL-5 treatments that are clinically available or undergoing clinical trials in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170401IS - 1179-190X (Electronic)IS - 1173-8804 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40259-017-0215-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28364396">PM:28364396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BioDrugs\2017-31-93-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BioDrugs\2017-31-93-103.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170401, Shrimanker R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40259-017-0215-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ito,Y.</style></author><author><style face="normal" font="Arial"> Matsumoto,K.</style></author><author><style face="normal" font="Arial"> Osakama,N.</style></author><author><style face="normal" font="Arial"> Yoshioka,R.</style></author><author><style face="normal" font="Arial"> Kobuchi,S.</style></author><author><style face="normal" font="Arial"> Sakaeda,T.</style></author><author><style face="normal" font="Arial"> Takada,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacokinetics, Kyoto Pharmaceutical University</style></auth-address><titles><title><style face="normal" font="Arial">Dissolving Microneedles as Skin Allergy Test Device</style></title><secondary-title><style face="normal" font="Arial">Biol Pharm Bull</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biol Pharm Bull</style></full-title></periodical><pages end="534" start="531">531-534</pages><volume><style face="normal" font="Arial">40</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> dextran</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin allergy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The possibility of using dissolving microneedles (DMs) as a skin allergy test device was studied in rats. Poly-L-arginine was used as a model allergen. Dextran was used to prepare three kinds of DM array chips containing different doses of poly-L-arginine: 17.1+/-0.5 microg (low-dose DM), 42.2+/-0.8 microg (medium-dose DM), and 87.4+/-1.1 microg (high-dose DM); each 1.0 cm2 chip contained 300 DMs. The mean lengths of the low-, medium-, and high-dose DM were 489+/-3, 485+/-3, and 492+/-1 microm and mean diameters of the base were 301+/-2, 299+/-1, and 299+/-2 microm, respectively. Furthermore, for the low-, medium-, and high-dose DM, the administered doses of poly-L-arginine were estimated to be 9.3+/-1.9, 31.1+/-1.3, and 61.9+/-4.7 microg and the scratching behavior per 30 min was 9.8+/-3.4, 60.4+/-8.3, and 95.7+/-10.6 times, respectively. These results demonstrate the dose dependence of the immunoreactivity of the poly-L-arginine DMs, suggesting that DMs can be used an alternative skin allergy device</style></abstract><notes><style face="normal" font="Arial">DA - 20170406IS - 1347-5215 (Electronic)IS - 0918-6158 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1248/bpb.b16-00768</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28381808">PM:28381808</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biol Pharm Bull\2017-40-531-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biol Pharm Bull\2017-40-531-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170406, Ito Y</style></custom2><misc3><style face="normal" font="Arial">10.1248/bpb.b16-00768</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Plchova,H.</style></author><author><style face="normal" font="Arial"> Cerovska,N.</style></author><author><style face="normal" font="Arial"> Vaculik,P.</style></author><author><style face="normal" font="Arial"> Moravec,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Plant viruses as scaffolds for the presentation of vaccine epitopes</style></title><secondary-title><style face="normal" font="Arial">Biol Plant</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biol Plant</style></full-title></periodical><pages end="12" start="1">1-12</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antigenic epitopes</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-8264</style></isbn><abstract><style face="normal" font="Arial">Within the last two decades, plant viral vectors have emerged as an excellent tool for the expression of foreign peptides and proteins. Virus particles carrying foreign antigenic epitopes present some interesting advantages for vaccine design and other applications. This review covers recent advances in the use of some typical plant viruses with helical particles that present heterologous peptides with particular emphasis on particles derived from the Potato virus X (PVX) and its uses</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10535-016-0690-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10535-016-0690-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biol Plant\2017-61-1-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biol Plant\2017-61-1-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Plchova H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10535-016-0690-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,X.</style></author><author><style face="normal" font="Arial"> Calvert,R.A.</style></author><author><style face="normal" font="Arial"> Sutton,B.J.</style></author><author><style face="normal" font="Arial"> Dore,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Basic Veterinary, College of Veterinary Medicine, Northwest A&amp;F University, Yangling, 712100, China</style></auth-address><titles><title><style face="normal" font="Arial">IgY: a key isotype in antibody evolution</style></title><secondary-title><style face="normal" font="Arial">Biol Rev Camb Philos Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biol Rev Camb Philos Soc</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Biotechnological applications</style></keyword><keyword><style face="normal" font="Arial"> Birds</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Evolutionary relationship</style></keyword><keyword><style face="normal" font="Arial"> Fc receptors</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Igd</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> IgY</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Reptiles</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin Y (IgY) is central to our understanding of immunoglobulin evolution. It has links to antibodies from the ancestral IgM to the mucosal IgX and IgA, as well as to mammalian serum IgG and IgE. IgY is found in amphibians, birds and reptiles, and as their most abundant serum antibody, is orthologous to mammalian IgG. However, IgY has the same domain architecture as IgM and IgE, lacking a hinge region and comprising four heavy-chain constant domains. The relationship between IgY and the mucosal antibodies IgX and IgA is discussed herein, in particular the question of how IgA could have contributed to the emergence of IgY. Although IgY does not contain a hinge region, amphibian IgF and duck-billed platypus IgY/O, which are closely related to IgY, do contain this region, as does mammalian IgG, IgA and IgD. A hinge region must therefore have evolved at least three times independently by convergent evolution. In the absence of three-dimensional structural information for the complete Fc fragment of chicken IgY (IgY-Fc), it remains to be discovered whether IgY displays the same conformational properties as IgM and IgE, which exhibit substantial flexibility in their Fc regions. IgY has three characterised Fc receptors, chicken Ig-like receptor AB1 (CHIR-AB1), the chicken yolk sac IgY receptor (FcRY) and Gallus gallus Fc receptor (ggFcR). These receptors bind to IgY at sites that are structurally homologous to mammalian counterparts; IgA/FcalphaRI for CHIR-AB1, IgG/FcRn for FcRY and IgE/FcRI and IgG/FcgammaR for ggFcR. These resemblances reflect the close evolutionary relationships between IgY and IgA, IgG and IgE. However, the evolutionary distance between birds and mammals allows for the ready generation of IgY antibodies to conserved mammalian proteins for medical and biotechnological applications. Furthermore, the lack of reactivity of IgY with mammalian Fc receptors, and the fact that large quantities of IgY can be made quickly and cheaply in chicken eggs, offers important advantages and considerable potential for IgY in research, diagnostics and therapeutics</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1469-185X (Electronic)IS - 0006-3231 (Linking)LA - engPT - Journal ArticleCO - China -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/brv.12325</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28299878">PM:28299878</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biol Rev Camb Philos Soc\20170316-ZhangX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biol Rev Camb Philos Soc\20170316-ZhangX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Zhang X</style></custom2><misc3><style face="normal" font="Arial">10.1111/brv.12325</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Makchuchit,S.</style></author><author><style face="normal" font="Arial"> Rattarom,R.</style></author><author><style face="normal" font="Arial"> Itharat,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate School, Faculty of Medicine, Thammasat University, Klongluang, Pathumthani 12120, Thailand.</style></auth-address><titles><title><style face="normal" font="Arial">The anti-allergic and anti-inflammatory effects of Benjakul extract (a Thai traditional medicine), its constituent plants and its some pure constituents using in vitro experiments</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="1026" start="1018">1018-1026</pages><volume><style face="normal" font="Arial">89</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chlorpheniramine</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flatulence</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="Arial">Benjakul (BJK), a Thai traditional medicine preparation, has long been used for balanced health, controlled abnormal of element in the body, carminative, and relief of flatulence. It is composed of five plants: Piper interruptum Opiz., Piper longum L., Piper sarmentosum Roxb., Plumbago indica L., and Zingiber officinale Roscoe. The ethanolic extracts of BJK, its five individual plants, and pure constituents of BJK were investigated for their anti-allergic activity using immunoglobulin E (IgE)-sensitized beta-hexosaminidase in the rat basophilic leukemia-2H3 (RBL-2H3) cells and anti-inflammatory activity using lipopolysaccharide (LPS)-induced nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) in the murine macrophage (RAW 264.7) cells. The ethanolic extracts of BJK showed anti-allergic activity (IC50=12.69mug/ml) and exhibited potent NO inhibitory effect (IC50=16.60mug/ml), but inactive on TNF-alpha release. Moreover, 6-shogaol and plumbagin, two pure compounds from BJK, showed higher anti-allergic activity than the ethanolic BJK extract with IC50 values of 0.28 and 4.03mug/ml, respectively. These compounds were significantly higher than chlorpheniramine (CPM), standard drug, with IC50 value of 17.98mug/ml. Determination of the anti-inflammatory activity by measuring the inhibition of NO production presented that plumbagin and 6-shogaol exhibited higher than crude BJK extract with IC50 values of 0.002 and 0.92mug/ml, respectively. In particular, plumbagin also showed higher anti-inflammatory than prednisolone, positive control, with IC50 value of 0.59mug/ml. 6-Shogaol also showed inhibitory effect on TNF-alpha release (IC50=9.16mug/ml). These preliminary results may provide some scientific support for the use of BJK for the anti-allergic treatment and inflammatory disorders through the inhibition of NO production</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.02.066</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28292010">PM:28292010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-89-1018-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-89-1018-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Makchuchit S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.02.066</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Herrera,M.</style></author><author><style face="normal" font="Arial"> Sanchez,M.</style></author><author><style face="normal" font="Arial"> Machado,A.</style></author><author><style face="normal" font="Arial"> Ramirez,N.</style></author><author><style face="normal" font="Arial"> Vargas,M.</style></author><author><style face="normal" font="Arial"> Villalta,M.</style></author><author><style face="normal" font="Arial"> Sanchez,A.</style></author><author><style face="normal" font="Arial"> Segura,A.</style></author><author><style face="normal" font="Arial"> Gomez,A.</style></author><author><style face="normal" font="Arial"> Solano,G.</style></author><author><style face="normal" font="Arial"> Gutierrez,J.M.</style></author><author><style face="normal" font="Arial"> Leon,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto Clodomiro Picado, Facultad de Microbiologia, Universidad de Costa Rica, San Jose, Costa Rica</style></auth-address><titles><title><style face="normal" font="Arial">Effect of premedication with subcutaneous adrenaline on the pharmacokinetics and immunogenicity of equine whole IgG antivenom in a rabbit model</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="743" start="740">740-743</pages><volume><style face="normal" font="Arial">90</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Pressure</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Costa Rica</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Heart Rate</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous administration</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword></keywords><dates><year Day="15" Month="4" Year="2017">2017/4/15</year></dates><abstract><style face="normal" font="Arial">Subcutaneous administration of a low dose of adrenaline is used to prevent the early adverse reactions (EARs) induced by snake antivenoms. We used a rabbit model to study the effect of premedication with adrenaline on the potential of antivenoms to exert therapeutic effects and to induce late adverse reactions. We found that premedication with adrenaline did not change the heart rate or blood pressure of normal rabbits, but reduced the rise in temperature in rabbits previously sensitized with antivenom. Pharmacokinetic studies suggest that premedication with adrenaline does not affect the ability of the antivenom to exert the initial control of envenomation nor the susceptibility of rabbits to develop recurrence of antigenemia and envenomation. Our results also indicate that it is unlikely that premedication with adrenaline decreases the incidence of late reactions induced by the antivenom administration, although it reduces the extent of early reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - Costa Rica -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.04.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28419970">PM:28419970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-90-740-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-90-740-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Herrera M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.04.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bedere,N.</style></author><author><style face="normal" font="Arial"> Bovenhuis,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">PEGASE, Agrocampus Ouest, INRA, 35590, Saint-Gilles, France</style></auth-address><titles><title><style face="normal" font="Arial">Characterizing a region on BTA11 affecting beta-lactoglobulin content of milk using high-density genotyping and haplotype grouping</style></title><secondary-title><style face="normal" font="Arial">BMC Genet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Genet</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Cattle</style></keyword><keyword><style face="normal" font="Arial"> Cheese</style></keyword><keyword><style face="normal" font="Arial"> cheese yield</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Genetic Variation</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> Haplotypes</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Milk beta-lactoglobulin (beta-LG) content is of interest as it is associated with nutritional and manufacturing properties. It is known that milk beta-LG content is strongly affected by genetic factors. In cattle, most of the genetic differences are associated with a chromosomal region on BTA11, which contains the beta-LG gene. The aim of this study was to characterize this region using 777 k SNP data (BovineHDbeadChip) and perform a haplotype-based association study. A statistical approach was developed to build haplotypes that capture the genetic variation associated with this genomic region. RESULTS: The SNP with the most significant effect on beta-lactoglobulin content was one of the 2 causal mutations responsible for the beta-lactoglobulin protein variants A/B. Haplotypes based on 2 to 5 selected lead SNP were clustered in groups with different effects on beta-lactoglobulin content. Four different groups were identified suggesting that beta-lactoglobulin variant A and B can be further refined in A1, A2, B1 and B2. CONCLUSIONS: This study showed that beta-lactoglobulin protein variants A/B do not explain all genetic variation associated with the tail part of BTA11 but this region contains more than one mutation with an effect on beta-lactoglobulin content. These findings can be used for selection of cows with higher cheese yield, which is desirable for the dairy industry</style></abstract><notes><style face="normal" font="Arial">DA - 20170222IS - 1471-2156 (Electronic)IS - 1471-2156 (Linking)LA - engPT - Journal ArticleCO - France -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial"> 10.1186/s12863-017-0483-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28222684">PM:28222684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Genet\2017-18-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Genet\2017-18-17.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170222, Bedere N</style></custom2><misc3><style face="normal" font="Arial"> 10.1186/s12863-017-0483-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83719</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Libert,X.</style></author><author><style face="normal" font="Arial"> Packeu,A.</style></author><author><style face="normal" font="Arial"> Bureau,F.</style></author><author><style face="normal" font="Arial"> Roosens,N.H.</style></author><author><style face="normal" font="Arial"> De Keersmaecker,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Platform Biotechnology and Molecular Biology, Scientific Institute of Public Health (WIV-ISP), J. Wytsmanstraat 14, 1050, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Discrimination of three genetically close Aspergillus species by using high resolution melting analysis applied to indoor air as case study</style></title><secondary-title><style face="normal" font="Arial">BMC Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Microbiol</style></full-title></periodical><pages end="" start="84">84-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne fungi</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus versicolor</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> HRM analysis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor air pollution</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Indoor air pollution caused by fungal contamination is suspected to have a public health impact. Monitoring of the composition of the indoor airborne fungal contaminants is therefore important. To avoid problems linked to culture-dependent protocols, molecular methods are increasingly being proposed as an alternative. Among these molecular methods, the polymerase chain reaction (PCR) and the real-time PCR are the most frequently used tools for indoor fungal detection. However, even if these tools have demonstrated their appropriate performance, some of them are not able to discriminate between species which are genetically close. A solution to this could be the use of a post-qPCR high resolution melting (HRM) analysis, which would allow the discrimination of these species based on the highly accurate determination of the difference in melting temperature of the obtained amplicon. In this study, we provide a proof-of-concept for this approach, using a dye adapted version of our previously developed qPCR SYBR(R)Green method to detect Aspergillus versicolor in indoor air, an important airborne fungus in terms of occurrence and cause of health problems. Despite the good performance observed for that qPCR method, no discrimination could previously be made between A. versicolor, Aspergillus creber and Aspergillus sydowii. METHODS: In this study, we developed and evaluated an HRM assay for the discrimination between A. versicolor, Aspergillus creber and Aspergillus sydowii. RESULTS: Using HRM analysis, the discrimination of the 3 Aspergillus species could be made. No false positive, nor false negatives were observed during the performance assessment including 20 strains of Aspergillus. The limit of detection was determined for each species i.e., 0.5 pg of gDNA for A. creber and A. sydowii, and 0.1 pg of gDNA for A. versicolor. The HRM analysis was also successfully tested on environmental samples. CONCLUSION: We reported the development of HRM tools for the discrimination of A. versicolor, A. creber and A. sydowii. However, this study could be considered as a study case demonstrating that HRM based on existing qPCR assays, allows a more accurate identification of indoor air contaminants. This contributes to an improved insight in the diversity of indoor airborne fungi and hence, eventually in the causal link with health problems</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1471-2180 (Electronic)IS - 1471-2180 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12866-017-0996-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28376723">PM:28376723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Microbiol\2017-17-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Microbiol\2017-17-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Libert X</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12866-017-0996-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">DAS,S.</style></author><author><style face="normal" font="Arial"> Pasari,A.S.</style></author><author><style face="normal" font="Arial"> Sangwan,V.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cornea, L V Prasad Eye Institute, Hyderabad, Telangana, IndiaDepartment of Cornea, L V Prasad Eye Institute, Hyderabad, Telangana, IndiaCentre for Ocular Regeneration, L V Prasad Eye Institute, Hyderabad, Telangana, India</style></auth-address><titles><title><style face="normal" font="Arial">Vernal keratoconjunctivitis: culmination of management using immunosuppression, surgical and prosthetic therapy over quarter century</style></title><secondary-title><style face="normal" font="Arial">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenal Cortex</style></keyword><keyword><style face="normal" font="Arial"> Adrenal Cortex Hormones</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cataract</style></keyword><keyword><style face="normal" font="Arial"> Cataract Extraction</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis,Allergic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cornea</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressants</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Lens Implantation,Intraocular</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Ocular surface</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Prostheses and Implants</style></keyword><keyword><style face="normal" font="Arial"> Regeneration</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Visual Acuity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="Arial">A 22-year-old male patient presented in 1988 with active vernal keratoconjunctivitis. He was treated with topical mast cell stabilisers and corticosteroids. Chronic inflammation despite topical treatment necessitated oral immunosuppressants. Active disease came under control with this; however, the patient gradually developed limbal stem cell deficiency. He underwent bilateral pannus resection with amniotic membrane transplantation that resulted in improved ocular surface. In 2007, patient was found to have significant bilateral posterior subcapsular cataracts and underwent bilateral cataract surgery with intraocular lens implantation with good visual outcome. In 2016, he was provided with scleral lens prosthetic device, which further improved vision. At last follow-up, more than 25 years after his initial visit, his visual acuity was 20/25 in both eyes with a stable surface. With a comprehensive approach using immunosuppression, surgical therapy and scleral lens prosthetic device, chronic vernal keratoconjunctivitis can be well managed as illustrated in this case</style></abstract><notes><style face="normal" font="Arial">DA - 20161124IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Case ReportsPT - Journal ArticleRN - 0 (Adrenal Cortex Hormones)SB - IMCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1136/bcr-2016-217759</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27881591">PM:27881591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Case Rep\20161124-DasS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Case Rep\20161124-DasS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161124, Das S</style></custom2><misc3><style face="normal" font="Arial">10.1136/bcr-2016-217759</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,L.</style></author><author><style face="normal" font="Arial"> Pan,Y.</style></author><author><style face="normal" font="Arial"> Zhu,Y.</style></author><author><style face="normal" font="Arial"> Song,Y.</style></author><author><style face="normal" font="Arial"> Su,X.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Association between rhinovirus wheezing illness and the development of childhood asthma: a meta-analysis</style></title><secondary-title><style face="normal" font="Arial">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ Open</style></full-title></periodical><pages end="" start="e013034">e013034-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="3" Month="4" Year="2017">2017/4/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The relation between early-life rhinovirus (RV) wheezing illness and later onset of wheezing/asthma remains a subject of debate. Therefore, we conducted this meta-analysis to evaluate the association between RV wheezing illness in the first 3 years of life and the subsequent development of wheezing/asthma. DESIGN: Systematic review and meta-analysis. METHODS: The PubMed, EMBASE, Web of Science, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases were systematically searched for studies published between 1988 and February 2017, and additional studies were found by searching reference lists of relevant articles. 2 reviewers independently extracted data and assessed the quality of each study. Results were pooled using fixed-effect models or random-effects models as appropriate. RESULTS: The meta-analysis included 15 original articles which met the criteria, while 10 articles reported the results of 4 longitudinal cohort studies with different follow-up periods. RV wheezing illness in the first 3 years of life was associated with an increased risk of wheezing/asthma in later life (relative risk (RR)=2.00, 95% CI 1.62 to 2.49, p&lt;0.001). In subgroup analysis by age at follow-up, the association still remained significant in &lt;10 years (RR=2.02, 95% CI 1.70 to 2.39, p&lt;0.001) and >/=10 years (RR=1.92, 95% CI 1.36 to 2.72, p&lt;0.001). CONCLUSIONS: The meta-analysis suggests an association between RV-induced wheezing in the first 3 years of life and the subsequent development of wheezing/asthma. Large-scale and well-designed studies that adequately address concerns for potential confounding factors are required to validate the risk identified in the current meta-analysis</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmjopen-2016-013034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28373249">PM:28373249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2017-7-e013034.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Open\2017-7-e013034.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Liu L</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmjopen-2016-013034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Clausen,M.L.</style></author><author><style face="normal" font="Arial"> Edslev,S.M.</style></author><author><style face="normal" font="Arial"> Andersen,P.S.</style></author><author><style face="normal" font="Arial"> Clemmensen,K.</style></author><author><style face="normal" font="Arial"> Krogfelt,K.A.</style></author><author><style face="normal" font="Arial"> Agner,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus colonization in atopic eczema and its association with filaggrin gene mutations</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> filaggrin gene</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene mutations</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="3" Year="2017">2017/3/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a prevalent disease with significant impact on physical health and quality of life. Staphylococcus aureus (S. aureus) has been directly correlated to disease severity, and may also be a contributing causal factor in the pathogenesis of AD. The primary aim of the present study was to assess differences in S. aureus colonization in AD patients with and without filaggrin gene (FLG) mutations. Secondarily, to assess disease severity in relation to S. aureus colonization. Exploratory analyses were performed to investigate S. aureus genetic lineages in relation to FLG mutations and disease severity (SCORAD). METHODS: 101 adult AD patients were included in the study. Bacterial swabs were taken from lesional skin, non-lesional skin and nose. Swabs positive for S. aureus were characterized by spa and the respective clonal complex (CC) type assigned. Patients were characterized with respect to disease severity (SCORAD) and FLG mutations (n=88). Fischer's exact test was used to analyze differences in S. aureus colonization in relation to FLG mutations. RESULTS: Of the 101 patients included, 74 patients (73%) were colonized with S. aureus. Of the colonized patients, 70 patients (95%) carried only one CC type in all three different sampling sites. In lesional skin S. aureus was found in 24 patients with FLG mutations (n=31), versus 24 wild-type patients (n=54) (p=0.0004). S. aureus CC1 clonal lineage was more prevalent in patients with FLG mutations (n=10) than in wild-type patients (n=2) (p=0.003). No specific bacterial lineage was linked to disease severity. CONCLUSION: Increased S. aureus colonization in AD patients with FLG mutations, and increased prevalence of CC1 in patients with FLG mutations, suggest that host-microbe interactions and clonal differences in S. aureus are important for colonization of AD skin. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15470</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317091">PM:28317091</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170320-ClausenML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170320-ClausenML.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Clausen ML</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15470</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saeki,H.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author><author><style face="normal" font="Arial"> Tokura,Y.</style></author><author><style face="normal" font="Arial"> Murata,Y.</style></author><author><style face="normal" font="Arial"> Shiraishi,A.</style></author><author><style face="normal" font="Arial"> Tamamura,R.</style></author><author><style face="normal" font="Arial"> Randazzo,B.</style></author><author><style face="normal" font="Arial"> Imanaka,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Nippon Medical School, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and Safety of Ustekinumab in Japanese Patients with Severe Atopic Dermatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="427" start="419">419-427</pages><volume><style face="normal" font="Arial">177</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ustekinumab, a fully human monoclonal antibody against interleukin-12/23, may be potentially effective for severe atopic dermatitis (AD) treatment. OBJECTIVES: To evaluate efficacy and safety of ustekinumab 45 mg and 90 mg in severe AD patients. METHODS: In this placebo-controlled, randomised, phase 2 study, adult Japanese patients (aged 20-65 years) with severe or very severe AD entered a 12-week double-blind treatment period to receive (1:1:1) ustekinumab 45 mg, 90 mg or placebo subcutaneous injections at weeks 0 and 4; follow-up until week 24. Primary efficacy endpoint was percent change from baseline in Eczema Area and Severity Index (EASI) score at week 12. Major secondary efficacy endpoints: proportion of patients achieving EASI-50, EASI-75, Investigator's Global Assessment score 0-1, change from baseline Atopic Dermatitis Itch Scale and Dermatology Life Quality Index, all at week 12. RESULTS: 79 patients were randomised (ustekinumab 45 mg: n=24, 90 mg: n=28, placebo: n=27). Ustekinumab treatment showed nonsignificant improvement in least-square mean change from baseline EASI score at week 12 (45 mg: -38.2%, 95% confidence interval [CI] -21.02; 19.51, p&lt;0.94 and 90 mg: -39.8%, 95% CI, -21.84; 17.14, p&lt;0.81) versus placebo (-37.5%). Nonsignificant improvement in major secondary efficacy endpoints was also observed in both ustekinumab groups versus placebo. The most common (>2 patients) treatment-emergent adverse events were nasopharyngitis (similar incidence among all groups); and worsened AD (higher in placebo vs ustekinumab groups). CONCLUSION: Ustekinumab at 45 mg and 90 mg did not demonstrate meaningful efficacy in Japanese patients with severe AD. The treatment was generally well-tolerated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15493</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28338223">PM:28338223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170324-SaekiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170324-SaekiH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Saeki H</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15493</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Andersen,Y.M.</style></author><author><style face="normal" font="Arial"> Egeberg,A.</style></author><author><style face="normal" font="Arial"> Gislason,G.H.</style></author><author><style face="normal" font="Arial"> Skov,L.</style></author><author><style face="normal" font="Arial"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Burden of respiratory comorbidities in patients with atopic dermatitis and psoriasis</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Sleep apnea</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD), a skin disease with an estimated lifetime prevalence of up to 20%, represents a major global healthcare burden.1 Patients with AD have a propensity to develop asthma due to a combination of genetic, immunological and environmental factors, yet descriptive studies on the impact of respiratory diseases in adults with AD are scarce.2 In contrast, psoriasis, another chronic inflammatory skin disease, has been associated with respiratory comorbidities such as chronic obstructive pulmonary disease (COPD)3 , asthma4 and obstructive sleep apnea (OSA). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15489</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28334421">PM:28334421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170323-AndersenYM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170323-AndersenYM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Andersen YM</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15489</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kuda,Y.</style></author><author><style face="normal" font="Arial"> Shibamoto,T.</style></author><author><style face="normal" font="Arial"> Yang,W.</style></author><author><style face="normal" font="Arial"> Zhang,T.</style></author><author><style face="normal" font="Arial"> Tanida,M.</style></author><author><style face="normal" font="Arial"> Kurata,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Kanazawa Medical University. shibamo@kanazawa-med.ac.jp</style></auth-address><titles><title><style face="normal" font="Arial">Blockade of beta2-adrenoceptor, rather than beta1-adrenoceptor, deteriorates cardiac anaphylaxis in isolated blood-perfused rat hearts</style></title><secondary-title><style face="normal" font="Arial">Cardiol J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cardiol J</style></full-title></periodical><pages end="408" start="403">403-408</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Atenolol</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Coronary spasm</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perfusion</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Propranolol</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Spasm</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vascular Resistance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="3" Year="2017">2017/3/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cardiac anaphylaxis is one of the features of anaphylactic hypotension. Patients treated with propranolol, a nonselective b-adrenoceptor (AR) antagonist, develop severe anaphylaxis, but the mechanism remains unknown. Under examination were the effects of b(1)- and b(2)-AR antagonist on anaphylaxis-induced coronary vasoconstriction and cardiac dysfunction in isolated blood-perfused rat hearts. METHODS: Isolated hearts from ovalbumin-sensitized Wistar rats were subjected to coronary perfusion with blood at a constant pressure and measurements were made of coronary blood flow and left ventricular (LV) pressure. Following pretreatment with selective b(2)-AR antagonist ICI118,551 or selective b(1)-AR antagonist atenolol, cardiac anaphylaxis was induced by intracoronary injections of ovalbumin antigen. LV contractility was evaluated by the maximum increasing rate of systolic LV pressure (dP/dtmax). RESULTS: In response to antigen administrations, ICI118,551 pretreated hearts showed a greater decrease in coronary blood flow and consequently a greater increase in coronary vascular resistance than the atenolol pretreated hearts. Pretreatment with ICI118,551 caused a greater decrease in dP/dtmax than those with atenolol. CONCLUSIONS: Cardiac anaphylaxis-induced contractile dysfunction and coronary spasm are severe in beta(2)-AR, rather than beta(1)-AR, pretreated isolated blood-perfused rat hearts</style></abstract><notes><style face="normal" font="Arial">DA - 20170329IS - 1897-5593 (Electronic)IS - 1898-018X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.5603/CJ.a2017.0034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28353311">PM:28353311</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cardiol J\20170329-KudaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cardiol J\20170329-KudaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170329, Kuda Y</style></custom2><misc3><style face="normal" font="Arial">10.5603/CJ.a2017.0034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bilgic,T.A.</style></author><author><style face="normal" font="Arial"> Bassorgun,C.I.</style></author><author><style face="normal" font="Arial"> Akman-Karakas,A.</style></author><author><style face="normal" font="Arial"> Alpsoy,E.</style></author><author><style face="normal" font="Arial"> Uzun,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Akdeniz University Faculty of Medicine, Dermatology and Venereology Department, Antalya, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments</style></title><secondary-title><style face="normal" font="Arial">Case Rep Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Rep Dermatol</style></full-title></periodical><pages end="44" start="38">38-44</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antalya</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pemphigus</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcepsilonRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. A specific protocol for the use of rituximab to treat BP patients is not yet available. There are only small case series and case reports about the efficacy and safety of rituximab in BP. Here we present a young BP patient who responded well to rituximab therapy and was refractory to conventional and omalizumab therapies although he had elevated IgE levels and eosinophilia. Our case supports the knowledge about the effectiveness and safety of rituximab not only in pemphigus but also in BP. On the other hand, although it did not work in our case, omalizumab may be a potentially effective agent in some carefully selected patients with certain subtypes of BP</style></abstract><notes><style face="normal" font="Arial">DA - 20170417IS - 1662-6567 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1159/000452828</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28413387">PM:28413387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Dermatol\2017-9-38-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Dermatol\2017-9-38-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170417, Bilgic TA</style></custom2><misc3><style face="normal" font="Arial">10.1159/000452828</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teixeira de Abreu,A.P.</style></author><author><style face="normal" font="Arial"> Ribeiro de Oliveira,L.R.</style></author><author><style face="normal" font="Arial"> Teixeira de Abreu,A.F.</style></author><author><style face="normal" font="Arial"> Ribeiro de Oliveira,E.</style></author><author><style face="normal" font="Arial"> Santos de Melo,I.</style></author><author><style face="normal" font="Arial"> Aarestrup,F.M.</style></author><author><style face="normal" font="Arial"> Aarestrup,M.F.</style></author><author><style face="normal" font="Arial"> Aarestrup,P.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Evandro Ribeiro, Rua Catarina de Castro, 75 Morro da Gloria, 36036-060 Juiz de Fora, MG, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Perioperative Anaphylaxis to Chlorhexidine during Surgery and Septoplasty</style></title><secondary-title><style face="normal" font="Arial">Case Rep Otolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Rep Otolaryngol</style></full-title></periodical><pages end="" start="9605804">9605804-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Chlorhexidine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Forum</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Hydrocortisone</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> maxillary</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Promethazine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Chlorhexidine is an antiseptic and disinfectant used in surgical and clinical practice since 1954 and is available in aqueous or alcoholic solutions 0.5%-4.0% and has a broad-spectrum activity. Despite their widespread use, allergic reactions with chlorhexidine are rarely reported. We describe a case of anaphylaxis with chlorhexidine during a septoplasty, turbinectomy, and maxillary sinusectomy. The patient presented with periorbital edema, hives, hypotension, and wheezing. Immediately after the diagnosis of anaphylaxis promethazine, hydrocortisone, and epinephrine were administered with immediate clinical improvement. This case highlights the importance of assessing whether there is a previous clinical history of hypersensitivity to chlorhexidine in patients who will undergo surgical procedures</style></abstract><notes><style face="normal" font="Arial">DA - 20170414IS - 2090-6765 (Print)IS - 2090-6773 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/9605804</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28409044">PM:28409044</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Otolaryngol\2017-2017-9605804.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Otolaryngol\2017-2017-9605804.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170414, Teixeira de Abreu AP</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/9605804</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bansal,R.A.</style></author><author><style face="normal" font="Arial"> Tadros,S.</style></author><author><style face="normal" font="Arial"> Bansal,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Department, St Helier Hospital, Wrythe Lane, Carshalton, Surrey SM5 1AA, UK</style></auth-address><titles><title><style face="normal" font="Arial">Beer, Cider, and Wine Allergy</style></title><secondary-title><style face="normal" font="Arial">Case Reports Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Reports Immunol</style></full-title></periodical><pages end="" start="7958924">7958924-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Alcoholic Beverages</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Barley</style></keyword><keyword><style face="normal" font="Arial"> Beer</style></keyword><keyword><style face="normal" font="Arial"> Beverages</style></keyword><keyword><style face="normal" font="Arial"> Cheese</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food groups</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Grape</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE testing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wine</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background. Allergy to beer is often due to specific proteins in barley and sometimes to lipid transfer protein. Allergy to wine is frequently due to a sensitivity to grape proteins. We present a rare case of allergy to beer, wine, and cider resulting from IgE reactivity to yeasts and moulds which also explained the patient's additional sensitivity to yeast extracts and blue cheese. Case Presentation. The patient's symptoms included throat and facial itching accompanied by mild wheeze and severe urticaria. Diagnosis of allergy to yeast was confirmed by specific IgE testing as well as that to relevant foods and beverages. The patient's ongoing management included advice to avoid beer, wine, and other food groups containing specific yeasts, in addition to carrying a short acting nonsedating antihistamine as well as an adrenaline autoinjector. Conclusions. Cases of yeast allergy are extremely rare in medical literature but may be underrecognised and should be considered in patients presenting with reactions to alcoholic beverages and other yeast-containing products</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 2090-6609 (Print)IS - 2090-6617 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/7958924</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396809">PM:28396809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Reports Immunol\2017-2017-7958924.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Reports Immunol\2017-2017-7958924.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Bansal RA</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/7958924</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burmann,B.M.</style></author><author><style face="normal" font="Arial"> Knauer,S.H.</style></author><author><style face="normal" font="Arial"> Sevostyanova,A.</style></author><author><style face="normal" font="Arial"> Schweimer,K.</style></author><author><style face="normal" font="Arial"> Mooney,R.A.</style></author><author><style face="normal" font="Arial"> Landick,R.</style></author><author><style face="normal" font="Arial"> Artsimovitch,I.</style></author><author><style face="normal" font="Arial"> Rosch,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Lehrstuhl Biopolymere und Forschungszentrum fur Bio-Makromolekule, Universitat Bayreuth, Universitatsstrasse 30, 95447 Bayreuth, Germany</style></auth-address><titles><title><style face="normal" font="Arial">An alpha helix to beta barrel domain switch transforms the transcription factor RfaH into a translation factor</style></title><secondary-title><style face="normal" font="Arial">Cell</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell</style></full-title></periodical><pages end="303" start="291">291-303</pages><volume><style face="normal" font="Arial">150</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli Proteins</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Models,Molecular</style></keyword><keyword><style face="normal" font="Arial"> Molecular Sequence Data</style></keyword><keyword><style face="normal" font="Arial"> Operon</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide Elongation Factors</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> Protein Folding</style></keyword><keyword><style face="normal" font="Arial"> Protein Structure,Secondary</style></keyword><keyword><style face="normal" font="Arial"> Protein Structure,Tertiary</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Ribosomal Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Sequence Alignment</style></keyword><keyword><style face="normal" font="Arial"> Trans-Activators</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword></keywords><dates><year Day="20" Month="7" Year="2012">2012/7/20</year></dates><abstract><style face="normal" font="Arial">NusG homologs regulate transcription and coupled processes in all living organisms. The Escherichia coli (E. coli) two-domain paralogs NusG and RfaH have conformationally identical N-terminal domains (NTDs) but dramatically different carboxy-terminal domains (CTDs), a beta barrel in NusG and an alpha hairpin in RfaH. Both NTDs interact with elongating RNA polymerase (RNAP) to reduce pausing. In NusG, NTD and CTD are completely independent, and NusG-CTD interacts with termination factor Rho or ribosomal protein S10. In contrast, RfaH-CTD makes extensive contacts with RfaH-NTD to mask an RNAP-binding site therein. Upon RfaH interaction with its DNA target, the operon polarity suppressor (ops) DNA, RfaH-CTD is released, allowing RfaH-NTD to bind to RNAP. Here, we show that the released RfaH-CTD completely refolds from an all-alpha to an all-beta conformation identical to that of NusG-CTD. As a consequence, RfaH-CTD binding to S10 is enabled and translation of RfaH-controlled operons is strongly potentiated. PAPERFLICK:</style></abstract><notes><style face="normal" font="Arial">DA - 20120723IS - 1097-4172 (Electronic)IS - 0092-8674 (Linking)LA - engPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tRN - 0 (Escherichia coli Proteins)RN - 0 (NusG protein, E coli)RN - 0 (Peptide Elongation Factors)RN - 0 (RfaH protein, E coli)RN - 0 (Ribosomal Proteins)RN - 0 (Trans-Activators)RN - 0 (Transcription Factors)RN - 0 (ribosomal protein S10)SB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cell.2012.05.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="22817892">PM:22817892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell\2012-150-291-303.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell\2012-150-291-303.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20130723, Burmann BM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cell.2012.05.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Litus,E.A.</style></author><author><style face="normal" font="Arial"> Permyakov,S.E.</style></author><author><style face="normal" font="Arial"> Uversky,V.N.</style></author><author><style face="normal" font="Arial"> Permyakov,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Biological Instrumentation of the Russian Academy of Sciences, Pushchino, 142290, Moscow Region, Russia</style></auth-address><titles><title><style face="normal" font="Arial">Intrinsically Disordered Regions in Serum Albumin: What Are They For?</style></title><secondary-title><style face="normal" font="Arial">Cell Biochem Biophys</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Cell Biochem Biophys</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Bilirubin</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> instrumentation</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="Arial">Serum albumin is a major plasma protein in mammalian blood. The importance of this protein lies in its roles in both bioregulation and transport phenomena. Serum albumin binds various metal ions and participates in the transport and storage of fatty acids, bilirubin, steroids amino acids, and many other ligands, usually with regions of hydrophobic surface. Although the primary role of serum albumin is to transport various ligand, its versatile binding capacities and high concentration mean that it can assume a number of additional functions. The major goal of this article is to show how intrinsic disorder is encoded in the amino acid sequence of serum albumin, and how intrinsic disorder is related to functions of this important serum protein</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1559-0283 (Electronic)IS - 1085-9195 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Russia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12013-017-0785-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28281231">PM:28281231</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Biochem Biophys\20170310-LitusEA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Biochem Biophys\20170310-LitusEA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Litus EA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12013-017-0785-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Z.</style></author><author><style face="normal" font="Arial"> Pan,J.</style></author><author><style face="normal" font="Arial"> Jia,Y.</style></author><author><style face="normal" font="Arial"> Li,D.</style></author><author><style face="normal" font="Arial"> Min,Z.</style></author><author><style face="normal" font="Arial"> Su,X.</style></author><author><style face="normal" font="Arial"> Yuan,H.</style></author><author><style face="normal" font="Arial"> Shen,G.</style></author><author><style face="normal" font="Arial"> Cao,S.</style></author><author><style face="normal" font="Arial"> Zhu,L.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Division of Zhongshan Hospital, Shanghai Institute of Respiratory Disease, Fudan University, No. 180 Fenglin Road, Shanghai, 200032, China</style></auth-address><titles><title><style face="normal" font="Arial">Effect of memory CD4+ T cells' signal transducer and activator of transcription (STATs) functional shift on cytokine-releasing properties in asthma</style></title><secondary-title><style face="normal" font="Arial">Cell Biol Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Cell Biol Toxicol</style></abbr-1></periodical><pages end="39" start="27">27-39</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CCR7</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> CD62L</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disease heterogeneity</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Memory cells</style></keyword><keyword><style face="normal" font="Arial"> memory T cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> signal transducer and activator of transcription 6</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> STAT</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 memory</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recent data have demonstrated that long-lived memory T cells are present in the human lung and can play significant roles in the pathogenesis of specific allergic and autoimmune diseases. However, most evidence has been obtained from mouse studies, and the potential roles of memory T cells in human allergic diseases, such as asthma, remain largely unknown. METHODS: Thirty-three asthmatics, 26 chronic obstructive pulmonary disease (COPD) patients, and 22 healthy volunteers were enrolled in this study. Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood, and cell surface staining (CD4, CD45RO, CRTH2, CD62L, and CCR7) was performed for the detection of memory CD4+ T cells in blood. After stimulation with interleukin-27 (IL-27) or IL-4 for 15 min, the STAT1/STAT6 phosphorylation of memory CD4+ T cells was measured separately by flow cytometric techniques. The cytokine-releasing profiles after 6 days of culture under neutralization, TH2, TH2 + lipopolysaccharide (LPS), and TH2 + house dust mite (HDM) conditions were detected by intracellular protein (IL-5, IL-17, and interferon (IFN)-gamma) staining. Correlation analyses between the profile of memory CD4+ T cells and clinical characteristics of asthma were performed. RESULTS: The number of circulating memory CD4+ T (CD4+ Tm) cells in asthmatics was increased compared with that in the healthy subjects (48 +/- 5.7 % vs. 32 +/- 4.1 %, p &lt; 0.05). Compared with COPD and healthy subjects, the phosphorylation of signal transducer and activator of transcription 1 (STAT1-py) was impaired in asthmatics, whereas the phosphorylation of signal transducer and activator of transcription 6 (STAT6-py) was slightly enhanced. This imbalance of STAT1-py/STAT6-py was attributed to TH2 memory cells but not non-TH2 memory cells in blood. The cytokine-releasing profiles of asthmatics was unique, specifically IL-5high, IL-17high, and IFN-rlow, compared with those of COPD patients and healthy subjects. The IL-17 production levels in CD4+ Tm cells are associated with disease severity and positively correlated with medication consumption in asthma. CONCLUSIONS: The long-lived, antigen-specific memory CD4+ T cells, rather than PBMCs or peripheral lymphocytes, might be the ideal T cell subset candidates for analyzing the endotype of asthma. Memory CD4+ T cells exhibiting a shift in STAT phosphorylation and specific cytokine-releasing profiles have the potential to facilitate the understanding of disease heterogeneity and severity, allowing the more personalized treatment of patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160901IS - 1573-6822 (Electronic)IS - 0742-2091 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10565-016-9357-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27581546">PM:27581546</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Biol Toxicol\2017-33-27-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Biol Toxicol\2017-33-27-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160901, Chen Z</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10565-016-9357-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Knauer,S.H.</style></author><author><style face="normal" font="Arial"> Artsimovitch,I.</style></author><author><style face="normal" font="Arial"> Rosch,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Transformer proteins</style></title><secondary-title><style face="normal" font="Arial">Cell Cycle</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Cycle</style></full-title></periodical><pages end="4290" start="4289">4289-4290</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">23</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Argentina</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> DNA-Directed RNA Polymerases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli Proteins</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Nuclear Magnetic Resonance,Biomolecular</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide Elongation Factors</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> Protein Structure,Tertiary</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Trans-Activators</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Transcription,Genetic</style></keyword></keywords><dates><year Day="1" Month="12" Year="2012">2012/12/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20121210IS - 1551-4005 (Electronic)IS - 1551-4005 (Linking)LA - engPT - EditorialRN - 0 (Escherichia coli Proteins)RN - 0 (NusG protein, E coli)RN - 0 (Peptide Elongation Factors)RN - 0 (RfaH protein, E coli)RN - 0 (Trans-Activators)RN - 0 (Transcription Factors)RN - EC 2.7.7.6 (DNA-Directed RNA Polymerases)SB - IMCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.4161/cc.22468</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="23095672">PM:23095672</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Cycle\2012-11-4289-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Cycle\2012-11-4289-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20121210, Knauer SH</style></custom2><misc3><style face="normal" font="Arial">10.4161/cc.22468</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hu,Y.</style></author><author><style face="normal" font="Arial"> Dong,H.</style></author><author><style face="normal" font="Arial"> Zou,M.</style></author><author><style face="normal" font="Arial"> Huang,C.</style></author><author><style face="normal" font="Arial"> Luo,L.</style></author><author><style face="normal" font="Arial"> Yu,C.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Xie,Z.</style></author><author><style face="normal" font="Arial"> Zhao,H.</style></author><author><style face="normal" font="Arial"> Le,Y.</style></author><author><style face="normal" font="Arial"> Zou,F.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Cai,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China</style></auth-address><titles><title><style face="normal" font="Arial">TSLP signaling blocking alleviates E-cadherin dysfunction of airway epithelium in a HDM-induced asthma model</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="63" start="56">56-63</pages><volume><style face="normal" font="Arial">315</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherens Junctions</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> beta Catenin</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> E-cadherin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="Arial">Recent studies have indicated that Thymic stromal lymphopoietin (TSLP) plays an important role in the prevention and treatment of asthma. However the role of TSLP in dysfunction of airway epithelial adherens junctions E-cadherin in house dust mite (HDM)-induced asthma has not been addressed. We hypothesized that TSLP contributed to HDM-induced E-cadherin dysfunction in asthmatic BALB/c mice and 16HBE cells. In vivo, a HDM-induced asthma mouse model was set up for 8weeks. Mice inhaled an anti-TSLP monoclonal antibody (mAb) before HDM. The mice treated with the anti-TSLP mAb ameliorated airway inflammation, the decreasing and aberrant distribution of E-cadherin and beta-catenin as well as phosphorylation(p)-AKT induced by HDM. In vitro, HDM increased the expression of TSLP and E-cadherin dysfunction by PI3K/Akt signaling pathway. The exposure of 16HBE to TSLP resulted in redistribution of E-cadherin. These results indicate that TSLP may be an important contributor in E-cadherin dysfunction of HDM-induced asthma. TSLP signaling blocking shows a protective effect in mice and that the PI3K/Akt pathway may play a role in this process</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 1090-2163 (Electronic)IS - 0008-8749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400057">PM:28400057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20170412-HuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20170412-HuY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Hu Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2017.02.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schmit,D.</style></author><author><style face="normal" font="Arial"> Le,D.D.</style></author><author><style face="normal" font="Arial"> Heck,S.</style></author><author><style face="normal" font="Arial"> Bischoff,M.</style></author><author><style face="normal" font="Arial"> Tschernig,T.</style></author><author><style face="normal" font="Arial"> Herr,C.</style></author><author><style face="normal" font="Arial"> Beisswenger,C.</style></author><author><style face="normal" font="Arial"> Kobelt,P.</style></author><author><style face="normal" font="Arial"> Lepper,P.M.</style></author><author><style face="normal" font="Arial"> Chung,K.F.</style></author><author><style face="normal" font="Arial"> Bals,R.</style></author><author><style face="normal" font="Arial"> Dinh,Q.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Pneumology and Allergology, Saarland University Hospital and Saarland University Faculty of Medicine, Kirrberger Strasse, Geb. 61.4, 66421, Homburg/Saar, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergic airway inflammation induces migration of mast cell populations into the mouse airway</style></title><secondary-title><style face="normal" font="Arial">Cell Tissue Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Tissue Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nerve Endings</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="Arial">Mast cells (MCs) and airway nerves play an important role in allergic asthma. However, little is known about the MCs and their interaction with airway nerves during allergic airway inflammation. This study aims to investigate the distribution and proliferation of MC populations in different lung compartments, along with the association of mast cells with nerve endings, using a house dust mite (HDM) model for allergic airway inflammation. BALB/c mice were exposed to HDM extract intranasally (25 mug/50 mul) for 5 consecutive days a week over 7 weeks. Immunofluorescence and Edu stains were used to examine the colocalisation of MCs and nerves and the proliferation of MCs, respectively. HDM treatment caused an increased migration of MCs into bronchi, alveolar parenchyma and airway vessels. The proportions of tryptase-chymase expressing MC (MCTC) increased significantly in the bronchi and the alveolar parenchyma but not in the vascular tissues, by allergic airway inflammation. The association of MCs with nerves was found only in the bronchi and there were no changes in comparison of controls to HDM-treated animals. The present study shows a strong migration of tryptase expressing MC (MCT) and MCTC into the bronchi and the alveolar parenchyma, as well as of MCT in the vascular compartment under HDM treatment. This supports the hypothesis that these mast cell populations may contribute to allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170326IS - 1432-0878 (Electronic)IS - 0302-766X (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00441-017-2597-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28343320">PM:28343320</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Tissue Res\20170326-SchmitD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Tissue Res\20170326-SchmitD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170326, Schmit D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00441-017-2597-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zheng,W.</style></author><author><style face="normal" font="Arial"> Ren,H.</style></author><author><style face="normal" font="Arial"> Ke,X.</style></author><author><style face="normal" font="Arial"> Xue,M.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Xie,Y.</style></author><author><style face="normal" font="Arial"> Lin,N.</style></author><author><style face="normal" font="Arial"> Tu,M.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author><author><style face="normal" font="Arial"> Ping,L.</style></author><author><style face="normal" font="Arial"> Ying,Z.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author><author><style face="normal" font="Arial"> Deng,L.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Song,Y.</style></author><author><style face="normal" font="Arial"> Zhu,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital &amp; Institute, Beijing 100142, China</style></auth-address><titles><title><style face="normal" font="Arial">PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma</style></title><secondary-title><style face="normal" font="Arial">Chin J Cancer Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Chin J Cancer Res</style></abbr-1></periodical><pages end="74" start="66">66-74</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Digestive tract</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fibrinogen</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> L-asparaginase</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Neutropenia</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> radiotherapy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Translational research</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Although L-asparaginase (L-ASP) is a standard treatment for lymphoblastic lymphoma (LBL), hypersensitivity reactions by some patients limit its application. Polyethylene glycol-conjugated asparaginase (PEG-ASP) has a lower immunogenicity and is a standard treatment in all pediatric acute lymphoblastic leukemia (ALL). In this study, we investigated the efficacy and toxicity of PEG-ASP instead of L-ASP as used in the BFM-90 regimen (PEG-ASP-BFM-90) for adult LBL. METHODS: Between June 2012 and July 2015, we treated 30 adult patients with newly diagnosed LBL, using PEG-ASP-BFM-90 in a prospective, multicenter and single-arm clinical study at 5 participating institutions in China. RESULTS: All the 30 patients, including 19 males and 11 females with a median age of 30 (range: 18-62) years, completed 128 times of the PEG-ASP, with the median of 4 (range: 2-6) times. Patients did not receive radiotherapy at this time. The overall response rate was 86.7% (26/30), with 50.0% (15/30) complete response and 36.7% (11/30) partial response. The 3-year overall survival was 46.0% [95% confidence interval (95% CI), 28.2%-64.8%], and the 3-year progression-free survival was 43.0% (95% CI, 25.7%-62.0%). Major adverse events were myelosuppression, reduced fibrinogen, liver dysfunction and digestive tract toxicities. No allergic reaction and no treatment-related mortality or severe complications were recorded. CONCLUSIONS: Our clinical data and observed outcomes indicate that 1 dose of PEG-ASP can replace multiple doses of native L-ASP in BFM-90, with predominantly grade 3-4 neutropenia for adult LBL, and no therapy-related deaths. The effect is similar to previous reports of PEG-ASP-containing regimens for adult ALL. Major advantages include less serious allergic reactions, 2-3 weeks of action duration, and convenience for patients and physicians</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1000-9604 (Print)IS - 1000-9604 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.21147/j.issn.1000-9604.2017.01.08</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28373755">PM:28373755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin J Cancer Res\2017-29-66-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin J Cancer Res\2017-29-66-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Zheng W</style></custom2><misc3><style face="normal" font="Arial">10.21147/j.issn.1000-9604.2017.01.08</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Toorenenbergen,A.W.</style></author><author><style face="normal" font="Arial"> Kurstjens,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Chemistry, Erasmus University Medical Center, Room NA-420, PO Box 2040, 3000 CA Rotterdam</style></auth-address><titles><title><style face="normal" font="Arial">Between-laboratory analysis of IgG antibodies against Aspergillus fumigatus in paired quality control samples</style></title><secondary-title><style face="normal" font="Arial">Clin Chem Lab Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chem Lab Med</style></full-title></periodical><pages end="e235" start="e233">e233-e235</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical chemistry</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1437-4331 (Electronic)IS - 1434-6621 (Linking)LA - engPT - LetterCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1515/cclm-2016-1053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28375842">PM:28375842</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170404, Toorenenbergen AW</style></custom2><misc3><style face="normal" font="Arial">10.1515/cclm-2016-1053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bjorstad,A.</style></author><author><style face="normal" font="Arial"> Cardell,L.O.</style></author><author><style face="normal" font="Arial"> Hahn-Pedersen,J.</style></author><author><style face="normal" font="Arial"> Svard,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nordic Health Economics AB, Gothenburg, Sweden.ALK, Kungsbacka, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting</style></title><secondary-title><style face="normal" font="Arial">Clin Drug Investig</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Drug Investig</style></full-title></periodical><pages end="549" start="541">541-549</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cost Savings</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> resource use</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVES: In Sweden, approximately 6% of children and 10% of adults suffer from house dust mite (HDM) allergy with symptoms of allergic rhinitis and allergic asthma. Treatment is aimed at reducing HDM exposure and to control the symptoms of allergic rhinitis and allergic asthma by symptom-relieving pharmacotherapy. This pharmacotherapy is often effective, but some patients remain inadequately controlled. For these patients, allergy immunotherapy (AIT, subcutaneous or sublingual) with repeated administration of HDM allergen should be considered. The objective of this study was to compare the costs for sublingual AIT (SLIT; SQ(R) SLIT-tablet) to the costs for subcutaneous AIT (SCIT; SQ(R) SCIT) for the treatment of HDM allergy in a cost-minimisation analysis (CMA). METHODS: The CMA included resources (and costs) for treatment, healthcare visits, travelling and lost productivity. Resource use based on Swedish clinical treatment practice and costs were obtained from medical price lists. Analyses were conducted from the societal, as well as healthcare perspective, by use of a time horizon of 3 years. RESULTS: The results show that SQ(R) SLIT-tablet is a cost-saving treatment as compared to SQ(R) SCIT for the treatment of HDM allergy (euro6800 over 3 years). The results are mainly driven by the cost of healthcare visits and the frequency of SCIT administrations. CONCLUSION: In conclusion, cost-savings of euro6800 over 3 years are expected from treating HDM allergy with SQ(R) SLIT-tablet as compared to SQ(R) SCIT, including costs for treatment, healthcare visits, travelling and lost productivity. The reduced number of healthcare visits compensates for higher medication costs</style></abstract><notes><style face="normal" font="Arial">DA - 20170322IS - 1179-1918 (Electronic)IS - 1173-2563 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40261-017-0516-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28326466">PM:28326466</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Drug Investig\20170322-BjorstadA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Drug Investig\20170322-BjorstadA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170322, Bjorstad A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40261-017-0516-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sievers,S.</style></author><author><style face="normal" font="Arial"> Cretich,M.</style></author><author><style face="normal" font="Arial"> Gagni,P.</style></author><author><style face="normal" font="Arial"> Ahrens,B.</style></author><author><style face="normal" font="Arial"> Grishina,G.</style></author><author><style face="normal" font="Arial"> Sampson,H.</style></author><author><style face="normal" font="Arial"> Niggemann,B.</style></author><author><style face="normal" font="Arial"> Chiari,M.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Charite Universitatsmedizin, Pediatric Pneumology and Immunology, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Performance of a polymer coated silicon microarray for simultaneous detection of food allergen specific IgE and IgG4</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1068" start="1057">1057-1068</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergen specific IgG4</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Calibration</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnostics</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> Dyes</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Fluorescent Dyes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Silicon</style></keyword><keyword><style face="normal" font="Arial"> Simultaneous detection</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Microarray-based component-resolved diagnostics (CRD) has become an accepted tool to detect allergen specific IgE-sensitization towards hundreds of allergens in parallel from one drop of serum. Nevertheless specificity and sensitivity as well as a simultaneous detection of allergen specific IgG4, as a potential parameter for tolerance development, remain to be optimized. OBJECTIVE: We applied the recently introduced silicon chip coated with a functional polymer named copoly(DMA-NAS-MAPS) to the simultaneous detection of food allergen specific IgE and IgG4, and compared it with ImmunoCAP and ImmunoCAP ISAC. Inter- and intra- slide variation, linearity of signal and working range, sensitivity and application of internal calibrations for IgE and IgG4 were assessed. METHODS: Native and recombinant allergenic proteins from hen's egg and cow's milk were spotted on silicon chips coated with copoly(DMA-NAS-MAPS) along with known concentrations for human IgE and IgG4 . A serum pool and 105 patient samples were assessed quantitatively and semi-quantitatively with the ImmunoCAP and ImmunoCAP ISAC and correlated with IgE- and IgG4 -specific fluorescence on silicon microarrays. RESULTS: Allergen specific IgE and IgG4 were detected in parallel using two fluorescent dyes with no crosstalk. Results from the ImmunoCAP correlated better with microarray fluorescence than with ImmunoCAP ISAC except for the allergen ovomucoid. The working range of the silicon microarray for total hen's egg specific IgE was comparable to the range of 0.1 to >100 kUA /l of the ImmunoCAP system, whereas for total cow's milk the silicon microarray was less sensitive. Detectable allergen specific IgG4 could be determined only for low concentrations, but still correlated positively with ImmunoCAP results. CONCLUSIONS: We confirmed the ability of the polymer coated silicon microarray to be comparably sensitive to the ImmunoCAP ISAC for various food allergens. This suggests that the copoly(DMA-NAS-MAPS) microarray is a low cost, self-producible alternative to the commercial ImmunoCAP ISAC in allergy research. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170327IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12929</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28346705">PM:28346705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170327-SieversS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170327-SieversS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170327, Sievers S</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12929</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ro,A.D.</style></author><author><style face="normal" font="Arial"> Simpson,M.R.</style></author><author><style face="normal" font="Arial"> Ro,T.B.</style></author><author><style face="normal" font="Arial"> Storro,O.</style></author><author><style face="normal" font="Arial"> Johnsen,R.</style></author><author><style face="normal" font="Arial"> Videm,V.</style></author><author><style face="normal" font="Arial"> Oien,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU (Norwegian University of Science and Technology), Trondheim, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Reduced Th22 cell proportion and prevention of atopic dermatitis in infants following maternal probiotic supplementation</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1021" start="1014">1014-1021</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus acidophilus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus rhamnosus</style></keyword><keyword><style face="normal" font="Arial"> LGG</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH22</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">In the randomized, controlled study Probiotics in the Prevention of Allergy among Children in Trondheim (ProPACT), maternal probiotic supplementation reduced the incidence of atopic dermatitis (AD) in the offspring. In the current study, we hypothesized that the effect was mediated by a shift in the T helper (Th) cells in the children. OBJECTIVE: To examine whether Th cell proportions were affected by maternal probiotic supplementation and thus could mediate the preventive effect of probiotics on AD. METHODS: 415 pregnant women were randomized to ingest a combination of Lactobacillus rhamnosus GG (LGG), Bifidobacterium animalis subsp. lactis Bb-12 (Bb-12), and Lactobacillus acidophilus La-5 (La-5) or placebo, and their offspring were assessed for AD during the first 2 years of life. Peripheral blood collected at 3 months of age was analyzed for regulatory T cells (n = 140) and Th subsets (n = 77) including Th1, Th2, Th9, Th17 and Th22. RESULTS: The proportion of Th22 cells was reduced in children in the probiotic group compared to the placebo group (median 0.038% vs 0.064%, p=0.009). The difference between the probiotic and placebo group was also observed in the children who did not develop AD during the 2-year follow-up. The proportion of Th22 cells was increased in children who developed AD compared to the children who did not develop AD (0.090% vs 0.044%, p&lt;0.001). Mediation analysis indicated that the preventive effect of probiotics was partially mediated through the reduction of Th22 cells. CONCLUSION: Perinatal maternal probiotic supplementation with a combination of LGG, Bb-12 and La-5 reduced the proportion of Th22 cells in 3-month-old children. This may partially explain the preventive effect of probiotics on AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170327IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12930</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28346719">PM:28346719</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170327-RoAD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170327-RoAD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170327, Ro AD</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12930</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamashita,H.</style></author><author><style face="normal" font="Arial"> Matsuhara,H.</style></author><author><style face="normal" font="Arial"> Miotani,S.</style></author><author><style face="normal" font="Arial"> Sako,Y.</style></author><author><style face="normal" font="Arial"> Matsui,T.</style></author><author><style face="normal" font="Arial"> Tanaka,H.</style></author><author><style face="normal" font="Arial"> Inagaki,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University, Daigakunishi 1-25-4, Gifu, 501-1196, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Artificial sweeteners and mixture of food additives cause to break oral tolerance and induce food allergy in murine oral tolerance model for food allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1213" start="1204">1204-1213</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Additives</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Induction of oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Saccharin</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Sweeteners</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="3" Year="2017">2017/3/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Processed foods are part of daily life. Almost all processed foods contain food additives such as sweeteners, preservatives and colourants. From childhood, it is difficult to avoid consuming food additives. It is thought that oral tolerance for food antigens is acquired during early life. If tolerance fails, adverse immune responses to food proteins may occur. OBJECTIVE: We hypothesised that food additives prevent acquisition of oral tolerance and aimed to verify the safety of food additives. METHODS: We induced experimental oral tolerance in mice for ovalbumin (OVA), a food antigen, by previous oral treatment with OVA before sensitisation with OVA injections. Food additives were administered at the induction of oral tolerance, and food allergy was induced by repeated administration of OVA. Symptoms of food allergy were defined as a change in body temperature and allergic diarrhoea. RESULTS: Saccharin sodium and a mixture of food additives inhibited acquisition of oral tolerance. Hypothermia and allergic diarrhoea with elevation of OVA-specific IgE were induced in the murine model of oral tolerance. Analyses of antigen presenting cells in mesenteric lymph nodes showed that food additives affected their manner of migration. Additionally, food additives decreased the proportion of CD25hi regulatory T cells among CD4+ T cells in the mesenteric lymph nodes. CONCLUSIONS AND CLINICAL RELEVANCE: A large amount of food additives may prevent acquisition of oral tolerance. Intake of food additives in early life may increase the risk of food allergies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12928</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28370609">PM:28370609</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170403-YamashitaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170403-YamashitaH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Yamashita H</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12928</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Srivastava,K.D.</style></author><author><style face="normal" font="Arial"> Song,Y.</style></author><author><style face="normal" font="Arial"> Yang,N.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Goldberg,I.E.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Li,X.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Jaffe Food Allergy Institute, Center for Integrative Medicine for Immunology and Wellness, Icahn School of Medicine at Mount Sinai, New York, NY, 10029</style></auth-address><titles><title><style face="normal" font="Arial">B-FAHF-2 plus oral immunotherapy (OIT) is safer and more effective than OIT alone in a murine model of concurrent peanut/tree nut allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1049" start="1038">1038-1049</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> integrative medicine</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Concurrent sensitization to peanut (PN) and tree nuts (TN), the most dangerous food allergies, is common. Current oral immunotherapy (OIT) is not fully satisfactory. OBJECTIVE: To determine if the herbal formula B-FAHF-2 (BF2) ameliorates PN/TN OIT adverse reactions and enhances persistence of a tolerant state. METHODS: Concurrently sensitized peanut, walnut (WN) and cashew (CSH) allergic mice received 1 day PN/WN/CSH rush OIT plus 3 weeks of maintenance dosing, with or without 3-weeks prior and 3-weeks BF2 co-treatment. Anaphylactic symptom scores, core body temperatures, plasma histamine levels, basophil numbers, antigen-specific IgE, cytokine levels, and IL-4, INF-gamma and Foxp3 gene promoter DNA methylation status, and their correlation with final challenge symptom scores were determined. RESULTS: BF2+OIT treated mice experienced significantly fewer and less severe adverse reactions than OIT only treated mice (p&lt;0.01) during the one-day rush OIT buildup dose phase. Both OIT only and BF2+OIT mice showed significant desensitization (p&lt;0.01 and 0.001 respectively) at one-week post therapy challenge; being greater in BF2+OIT mice. All sham treated and 91% of OIT treated mice experienced anaphylaxis whereas only 21% of BF2+OIT treated mice exhibited reactions during 5-6 weeks of dose escalation single PN and TN challenges. Greater and more persistent protection in BF2+OIT mice was associated with significantly lower plasma histamine and IgE levels, increased IFN- gamma/IL-4 and IL-10/IL-4 ratios, DNA re-methylation at the IL-4 promoter and de-methylation at IFN-gamma and Foxp3 promoters. Final challenge symptom scores were inversely correlated with IL-4 DNA methylation levels (p&lt;0.0002), and positively correlated with IFN-gamma and Foxp3 gene promoter methylation levels (p&lt;0.0011) (p&lt;0.0165). CONCLUSIONS AND CLINICAL RELEVANCE: Combined BF2/OIT therapy was safer and produced longer post treatment protection, and more tolerance-prone immunological and epigenetic modifications than OIT alone. BF2/OIT may provide an additional OIT option for patients with concurrent peanut/ tree nut and other food allergies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12936</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28397379">PM:28397379</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170411-SrivastavaKD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170411-SrivastavaKD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Srivastava KD</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12936</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Spiric,J.</style></author><author><style face="normal" font="Arial"> Reuter,A.</style></author><author><style face="normal" font="Arial"> Rabin,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunobiochemistry, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccine Research and Review, CBER/FDA, Silver Spring, MD, USADivision of Allergology, Paul-Ehrlich-Institut, Langen, GermanyLaboratory of Immunobiochemistry, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccine Research and Review, CBER/FDA, Silver Spring, MD, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mass Spectrometry to complement standardization of house dust mite and other complex allergenic extracts</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="617" start="604">604-617</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Standardized extracts</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">In the United States, the Center for Biologics Evaluation and Research (CBER) of the US Food and Drug Administration regulates biologics used for diagnosis and treatment of allergic diseases. The Code of Federal Regulations 21CFR680.3(e) states that when measured, the potency of an allergenic extract is assessed according to its allergenic activity. As of 2016, 19 allergenic extracts are standardized for potency in the United States. While these standardized extracts constitute a minority of those available, they treat the most prevalent allergies (e.g. grass and ragweed pollens, dust mites and cat) and those that induce life-threatening anaphylaxis (e.g. Hymenoptera venom). Standardization for potency enhances safety and efficacy of immunotherapy by minimizing the risks of variations in allergen dosing when switching from one lot of manufactured extract to another, and by providing an objective measure of stability of each lot of allergenic extract over time. Allergenic extracts that have multiple immunodominant allergenic proteins are standardized with little or no information about compositional differences among extracts. Here we propose application of mass spectrometry towards measurement of compositional differences among extracts that may affect the efficacy and safety of allergen immunotherapy. In addition, we discuss of house dust mite allergen extracts as a prototypical complex extract that may be standardized by mass spectrometry. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12931</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28370618">PM:28370618</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170403-SpiricJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170403-SpiricJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Spiric J</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12931</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hirano,I.</style></author><author><style face="normal" font="Arial"> Spechler,S.</style></author><author><style face="normal" font="Arial"> Furuta,G.</style></author><author><style face="normal" font="Arial"> Dellon,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL</style></auth-address><titles><title><style face="normal" font="Arial">White Paper AGA: Eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></full-title></periodical><pages end="1183" start="1173">1173-1183</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Chicago</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170326IS - 1542-7714 (Electronic)IS - 1542-3565 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cgh.2017.03.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342955">PM:28342955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Gastroenterol Hepatol\20170326-HiranoI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Gastroenterol Hepatol\20170326-HiranoI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170326, Hirano I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cgh.2017.03.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tartarisco,G.</style></author><author><style face="normal" font="Arial"> Tonacci,A.</style></author><author><style face="normal" font="Arial"> Minciullo,P.L.</style></author><author><style face="normal" font="Arial"> Billeci,L.</style></author><author><style face="normal" font="Arial"> Pioggia,G.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Gangemi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Messina Unit, National Research Council of Italy (CNR)-Institute of Applied Science and Intelligent System (ISASI), Messina, Italy</style></auth-address><titles><title><style face="normal" font="Arial">The soft computing-based approach to investigate allergic diseases: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="10">10-</pages><volume><style face="normal" font="Arial">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Artificial neural network</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Neural networks</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Early recognition of inflammatory markers and their relation to asthma, adverse drug reactions, allergic rhinitis, atopic dermatitis and other allergic diseases is an important goal in allergy. The vast majority of studies in the literature are based on classic statistical methods; however, developments in computational techniques such as soft computing-based approaches hold new promise in this field. OBJECTIVE: The aim of this manuscript is to systematically review the main soft computing-based techniques such as artificial neural networks, support vector machines, bayesian networks and fuzzy logic to investigate their performances in the field of allergic diseases. METHODS: The review was conducted following PRISMA guidelines and the protocol was registered within PROSPERO database (CRD42016038894). The research was performed on PubMed and ScienceDirect, covering the period starting from September 1, 1990 through April 19, 2016. RESULTS: The review included 27 studies related to allergic diseases and soft computing performances. We observed promising results with an overall accuracy of 86.5%, mainly focused on asthmatic disease. The review reveals that soft computing-based approaches are suitable for big data analysis and can be very powerful, especially when dealing with uncertainty and poorly characterized parameters. Furthermore, they can provide valuable support in case of lack of data and entangled cause-effect relationships, which make it difficult to assess the evolution of disease. CONCLUSIONS: Although most works deal with asthma, we believe the soft computing approach could be a real breakthrough and foster new insights into other allergic diseases as well</style></abstract><notes><style face="normal" font="Arial">DA - 20170417IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-017-0066-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28413358">PM:28413358</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170417, Tartarisco G</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-017-0066-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lombardi,C.</style></author><author><style face="normal" font="Arial"> Melli,V.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Ridolo,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0004 1763 5424grid.415090.9Allergy and Pneumology Departmental Unit, Fondazione Poliambulanza Hospital, Brescia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="5">5-</pages><volume><style face="normal" font="Arial">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indirect costs</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Severity of the disease</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis has a very high burden regarding both direct and indirect costs. This makes essential in the management of AR to reduce the clinical severity of the disease and thus to lessen its costs. This particularly concerns allergen immunotherapy (AIT), that, based on its immunological action on the causes of allergy, extends its benefit also after discontinuation of the treatment. From the pharmacoeconomic point of view, any treatment must be evaluated according to its cost-effectiveness, that is, the ratio between the cost of the intervention and its effect. A favorable cost-benefit ratio for AIT was defined, starting from the first studies in the 1990s on subcutaneous immunotherapy (SCIT) in AR patients, that highlighted a clear advantage on costs over the treatment with symptomatic drugs. Such outcome was confirmed also for sublingual immunotherapy (SLIT), that has also the advantage on SCIT to be free of the cost of the injections. Here we review the available literature on pharmacoeconomic data for SLIT with the 5-grass pollen tablets</style></abstract><notes><style face="normal" font="Arial">DA - 20170313IS - 1476-7961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-017-0058-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286421">PM:28286421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170313, Lombardi C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-017-0058-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Djuric-Filipovic,I.</style></author><author><style face="normal" font="Arial"> Caminati,M.</style></author><author><style face="normal" font="Arial"> Filipovic,D.</style></author><author><style face="normal" font="Arial"> Salvottini,C.</style></author><author><style face="normal" font="Arial"> Zivkovic,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0000 8615 0106grid.413004.2Faculty of Medical Science, University of Kragujevac, Svetozara Markovica 64, 34000 Kragujevac, Serbia</style></auth-address><titles><title><style face="normal" font="Arial">Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="7">7-</pages><volume><style face="normal" font="Arial">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Biological Markers</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Specific allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific immunotherapy (AIT) is the only treatment able to change the natural course of allergic diseases. We aimed at investigating the clinical efficacy of SLITOR (Serbian registered vaccine for sublingual allergen specific immunotherapy). METHODS: 7-18 years old children with allergic asthma and rhinitis were enrolled and addressed to the active (AIT plus pharmacological treatment) or control (standard pharmacological treatment only) group. Clinical and medications scores, lung function and exhaled FeNO were measured at baseline and at every follow-up. RESULTS: There was a significant improvement in both nasal and asthma symptom scores as well as in medication score in SLIT group. SLIT showed an important influence on lung function and airway inflammation. CONCLUSIONS: Our data showed that SLITOR was effective not only in terms of patient reported outcomes but an improvement of pulmonary function and decrease of lower airway inflammation were also observed</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Serbia -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-017-0064-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392751">PM:28392751</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Djuric-Filipovic I</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-017-0064-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Charpin,D.</style></author><author><style face="normal" font="Arial"> Pichot,C.</style></author><author><style face="normal" font="Arial"> Belmonte,J.</style></author><author><style face="normal" font="Arial"> Sutra,J.P.</style></author><author><style face="normal" font="Arial"> Zidkova,J.</style></author><author><style face="normal" font="Arial"> Chanez,P.</style></author><author><style face="normal" font="Arial"> Shahali,Y.</style></author><author><style face="normal" font="Arial"> Senechal,H.</style></author><author><style face="normal" font="Arial"> Poncet,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pneumonology and Allergy, APHM and Inserm U1067 CNRS UMR 7333, Aix-Marseille University, Marseille, France</style></auth-address><titles><title><style face="normal" font="Arial">Cypress Pollinosis: from Tree to Clinic</style></title><secondary-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> Cupressus</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Cypress pollen</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> global warming</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Juniperus</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis-related protein</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Pectate lyase</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen food syndrome</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Polygalacturonase</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergies</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Homology</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Taxus</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">Cypress (Cupressus sp.pl) is a genus within the Cupressaceae family. This family covers all of the Earth's continents except for Antarctica, and it includes about 160 species. The most important taxa for allergic diseases belong to five different genera: Cupressus, Hesperocyparis, Juniperus, Cryptomeria, and Chamaecyparis. Cupressaceae species share a common pollen type that can even include the genus Taxus (Taxaceae) when this plant is also present. As Juniperus oxycedrus pollinates in October, Cupressus sempervirens in January and February, Hesperocyparis arizonica (prev. Cupressus arizonica) in February and March, and Juniperus communis in April, the symptomatic period is long-lasting. Due to global warming, the pollination period tends to last longer, and there is a trend for Cupressaceae bioclimate niches to migrate north. In Mediterranean areas, C. sempervirens (Italian cypress or Mediterranean cypress) is by far the most common pollinating species. It accounts for half of the total pollination level. The group 1 major allergens belong to the pectate-lyase family, and members share 70 to 97% sequence homology within the different Cupressaceae. Group 2 allergens correspond to the polygalacturonase protein family, while group 3, a minor allergen, belongs to the family of "thaumatin-like proteins," a pathogenesis-related protein 5. Group 4 allergens are Ca++-binding protein (4 EF-hands). Aside from these four groups, about 15 other allergens have been reported. Prominent among these is a basic low-molecular mass cross-reactive allergen that was identified recently, and which is suspected to be involved in pollen food syndromes which are common with peach and citrus. The prevalence of cypress allergy in the general population ranges from 0.6 to 3%, depending on the degree of exposure to the pollen. Depending on the geographic area and the studied population, 9 to 65% of outpatients consulting an allergist may have sensitization to cypress pollen. Repeated cross-sectional studies performed at different time intervals have demonstrated a threefold increase in the percentage of cypress allergy around the Mediterranean area. Risk factors include a genetic predisposition and/or a strong exposure to pollen, and the natural history of cypress allergy allows identification of a subgroup of patients as allergic rather than atopic. Concerning the clinical expression, rhinitis is the most prevalent symptom, while conjunctivitis is the most disabling. Pharmacological treatment of cypress allergies is not different from that of other seasonal allergies. Immunotherapy has been used, initially by subcutaneous injections, but currently mostly through the sublingual route. Although clinical trials have included only a limited number of patients, it has proven effective and safe. Avoidance can be implemented at the individual level, as well as at the community level, through the use of alternative plants, low-pollinating cypresses, or by trimming hedges before pollination</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -CO - Spain -CO - Czech Republic -CO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12016-017-8602-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401436">PM:28401436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170412-CharpinD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170412-CharpinD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Charpin D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12016-017-8602-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Borchers,A.T.</style></author><author><style face="normal" font="Arial"> Chang,C.</style></author><author><style face="normal" font="Arial"> Gershwin,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Allergy and Clinical Immunology, Davis School of Medicine, University of California, 451 Health Sciences Drive, Suite 6510, Davis, CA, 95616, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mold and Human Health: a Reality Check</style></title><secondary-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></full-title></periodical><pages end="322" start="305">305-322</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal Agents</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Farmer's Lung</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hemorrhage</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="Arial">There are possibly millions of mold species on earth. The vast majority of these mold spores live in harmony with humans, rarely causing disease. The rare species that does cause disease does so by triggering allergies or asthma, or may be involved in hypersensitivity diseases such as allergic bronchopulmonary aspergillosis or allergic fungal sinusitis. Other hypersensitivity diseases include those related to occupational or domiciliary exposures to certain mold species, as in the case of Pigeon Breeder's disease, Farmer's lung, or humidifier fever. The final proven category of fungal diseases is through infection, as in the case of onchomycosis or coccidiomycosis. These diseases can be treated using anti-fungal agents. Molds and fungi can also be particularly important in infections that occur in immunocompromised patients. Systemic candidiasis does not occur unless the individual is immunodeficient. Previous reports of "toxic mold syndrome" or "toxic black mold" have been shown to be no more than media hype and mass hysteria, partly stemming from the misinterpreted concept of the "sick building syndrome." There is no scientific evidence that exposure to visible black mold in apartments and buildings can lead to the vague and subjective symptoms of memory loss, inability to focus, fatigue, and headaches that were reported by people who erroneously believed that they were suffering from "mycotoxicosis." Similarly, a causal relationship between cases of infant pulmonary hemorrhage and exposure to "black mold" has never been proven. Finally, there is no evidence of a link between autoimmune disease and mold exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12016-017-8601-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28299723">PM:28299723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170316-BorchersAT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170316-BorchersAT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Borchers AT</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12016-017-8601-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ragusa,F.</style></author><author><style face="normal" font="Arial"> Fallahi,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, PisaDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">IP-10 in occupational asthma: review of the literature and case-control study</style></title><secondary-title><style face="normal" font="Arial">Clin Ter</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Ter</style></full-title></periodical><pages end="e157" start="e151">e151-e157</pages><volume><style face="normal" font="Arial">168</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> Late phase reaction</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase reaction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reliever</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Translational research</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin C</style></keyword><keyword><style face="normal" font="Arial"> vitamin D3</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: T-helper (Th)2 cytokines are thought to mediate most of the allergic inflammatory responses associated with atopic asthma. But the Th1-related chemokine, interferon (IFN)-gamma-induced protein 10 (IP-10)/chemokine (C-X-C motif) ligand (CXCL)10, was the predominant chemokine measured during human allergic pulmonary late-phase reaction. Viral infection and allergens can exacerbate asthma by inducing the accumulation of these chemokines and inflammatory cells in the airway. Short-acting beta2-adrenoreceptor agonists, budesonide and formoterol (all important relievers in asthma exacerbation), such as vitamin D3, vitamin C, have been shown to inhibit airway cells inflammatory responses by modulating these chemokines. Furthemore it has been suggested that Th1-related IP-10 and monokine induced by IFN-gamma (MIG)/CXCL9 may be useful inflammatory markers of asthma exacerbation. PATIENTS AND METHODS: In this study we have evaluated serum levels of the Th1-related CXC chemokine IP-10, in 8 patients with occupational asthma (OA) during exacerbation due to occupational exposure, and after 2-3 months, when patients were in stable conditions, in comparison with 8 age and gender matched healthy subjects. RESULTS: A significant increase in the serum levels of IP-10 were found in OA patients with an acute exacerbation in contrast to healthy controls (p&lt;0.01), and in comparison with same OA patients after 2-3 months, when they were without any respiratory symptoms or disorders. CONCLUSIONS: These results suggest that the Th1-related CXC chemokines IP-10 is an useful inflammatory marker of OA exacerbation. However, other studies in larger number of patients are needed</style></abstract><notes><style face="normal" font="Arial">DA - 20170406IS - 1972-6007 (Electronic)IS - 0009-9074 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.7417/CT.2017.1998</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28383629">PM:28383629</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Ter\2017-168-e151-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Ter\2017-168-e151-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170406, Ragusa F</style></custom2><misc3><style face="normal" font="Arial">10.7417/CT.2017.1998</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lamb,T.</style></author><author><style face="normal" font="Arial"> de Haro,L.</style></author><author><style face="normal" font="Arial"> Lonati,D.</style></author><author><style face="normal" font="Arial"> Brvar,M.</style></author><author><style face="normal" font="Arial"> Eddleston,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pharmacology, Toxicology, and Therapeutics , University/BHF Centre for Cardiovascular Science, University of Edinburgh , Edinburgh , UK</style></auth-address><titles><title><style face="normal" font="Arial">Antivenom for European Vipera species envenoming</style></title><secondary-title><style face="normal" font="Arial">Clin Toxicol (Phila)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Toxicol (Phila)</style></full-title></periodical><pages end="568" start="557">557-568</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hemorrhage</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Length of Stay</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Manufacture</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Slovenia</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: European viper bite is relatively uncommon but can cause serious envenoming, particularly swelling and hemorrhage spreading from limb to trunk that can cause long term disability. Systemic features are relatively mild compared to many other venomous species. Moderate-to-severe envenoming requires antivenom, which is given many hundreds of times each year across the continent. Several Vipera spp antivenoms are produced in Europe, but there is little comparative information available for the antivenoms and none is licensed with the European Medicines Agency. We aimed to collect descriptive data on European viper antivenoms and assess their relative effectiveness. METHODS: A systematic review of articles relating to antivenom in Europe was performed using the Medline medical database. The following keywords "Europ*" or the individual names of each European country and "antiven*" or "immun*" or "envenom*" and "snake" or "viper*" or "adder" were used. Articles published between 1 January 1996 and 11 March 2016 pertaining to clinical outcome, including case reports, were selected. Referenced articles in the indexed articles were explored for suitability and included if they met any of the criteria: specific antivenom used, route of antivenom administration, adverse reactions to antivenom therapy and length of hospital admission. All accepted abstracts from EAPCCT conferences since 2000 were searched and abstracts relating to Vipera spp envenoming were assessed for suitability. We extracted data on study type, safety and effectiveness. We sought information on antivenoms from manufacturers and individual patient data from authors of publications. Since individual patient data were only rarely available, we compared median length of stay between case series reporting each antivenom. We identified 40 papers and six published abstracts, and one unpublished paper that reported clinical cases and case series of envenomed patients treated with antivenom. No publication reported randomized controlled trials comparing any European Vipera antivenom with either placebo or another antivenom. 25 reports were of retrospective hospital- (n = 13) or poison center-based (n = 12) case series including five or more patients; a further 12 reports were either case reports or case series with less than five patients and one paper was a limited literature review. An additional nine papers reported prospective data; seven collected data remotely through poison service telephone communication with the attending physicians. Antivenoms available in Europe: Eight antivenoms are available for European Vipera spp envenoming; a material safety data sheet providing information on manufacture was available for seven. Six are raised against V. berus or V. ammodytes venom; the seventh is raised against a mixture of V. ammodytes, V. aspis and V. berus venom and the eighth is raised against V. ammodytes, Macrovipera lebetina and Montivipera xanthina venom. Six manufacturers recommended intramuscular administration while two recommended intravenous administration. No randomized control trials comparing the effectiveness of antivenoms were identified. Pre-clinical data: We found two papers presenting comparative preclinical data. Clinical data: Clinical studies were predominantly retrospective and contained clinical data on antivenom used in 2602 patients; where the antivenom was identified (n = 2174), 2061 (94.8%) received Zagreb, ViperFAV or ViperaTAb antivenoms. There were few published data on the other antivenoms. Repeated use of antivenom: Repeat doses were reported in 230/1491 of cases (15.4%) where this information was recorded. Outcome and length of hospital stay: Intravenous administration of antivenom was associated with shorter length of hospital stay (median length of hospital stay in studies of intravenous ViperFAV or ViperaTAb ranged from 1 to 4.8 days versus 2 to 18 days for intramuscular Bulbio or Zagreb antivenoms). Antivenom versus no antivenom: Some small studies demonstrated no difference in the length of hospital stay in patients with equivalent envenomation grading who either did or did not receive antivenom. Adverse events: Adverse reactions were reported in 37 of 2408 cases (1.5%) including seven cases of anaphylaxis. CONCLUSIONS: There are very limited pre-clinical comparative data and no randomised controlled trials assessing effectiveness of the antivenoms against different Vipera species. Most descriptive data suggest the efficacy of Zagreb, ViperFAV and ViperaTAb antivenoms by the intravenous route but not intramuscular route, although this is level D evidence. Reported adverse reactions were rare, suggesting that the modern intravenous antivenoms are of good quality. Better and more systematic data, including perhaps randomized controlled trials comparing different antivenoms, are required for the many hundreds of antivenom administrations that occur annually across Europe</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1556-9519 (Electronic)IS - 1556-3650 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - France -CO - Slovenia -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/15563650.2017.1300261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28349771">PM:28349771</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Toxicol (Phila)\20170328-LambT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Toxicol (Phila)\20170328-LambT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Lamb T</style></custom2><misc3><style face="normal" font="Arial">10.1080/15563650.2017.1300261</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Christiansen,E.S.</style></author><author><style face="normal" font="Arial"> Kjaer,H.F.</style></author><author><style face="normal" font="Arial"> Eller,E.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Host,A.</style></author><author><style face="normal" font="Arial"> Mortz,C.G.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 0728 0170grid.10825.3eDepartment of Dermatology and Allergy Center, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, 5000 Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Early childhood risk factors for rhinoconjunctivitis in adolescence: a prospective birth cohort study</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="9">9-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective birth cohort study</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Rhinoconjunctivitis is a global health problem and one of the most common chronic conditions in children. Development of rhinoconjunctivitis depends on both genetic and environmental factors. Many studies have investigated rhinoconjunctivitis, but only few studies have evaluated the risk factors for non-allergic rhinoconjunctivitis in children finding family history of atopic diseases and gender to be of importance. The aim of this study was to investigate possible risk factors in early life for rhinoconjunctivitis, allergic as well as non-allergic, in adolescence. METHODS: The children in the Danish Allergy Research Center cohort were examined eight times from birth to 14 years of age. Visits included questionnaire-based interview, clinical examination, skin prick test and specific IgE. We used univariate and multivariate logistic regression to investigate the relationship between early-life risk factors and the development of rhinoconjunctivitis, allergic as well as non-allergic, in adolescence. RESULTS: Follow-up rate at 14-years was 66.2%. The prevalence of rhinoconjunctivitis was 32.8%. Family history of atopic diseases (aOR 2.25), atopic dermatitis (aOR 3.24), food allergy (aOR 3.89), early sensitization to inhalant and food allergens (aOR 2.92 and aOR 3.13) and male gender (aOR 1.90) were associated with allergic rhinoconjunctivitis but not with non-allergic rhinoconjunctivitis. Early environmental tobacco exposure was inversely associated with rhinoconjunctivitis (aOR 0.42), allergic (aOR 0.47) as well as non-allergic (aOR 0.43). CONCLUSION: Different patterns of associations were revealed when stratifying rhinoconjunctivitis in allergic and non-allergic suggesting that allergic rhinoconjunctivitis and non-allergic-rhinoconjunctivitis are different phenotypes</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0147-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392911">PM:28392911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Christiansen ES</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0147-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Riccio,A.M.</style></author><author><style face="normal" font="Arial"> Mauri,P.</style></author><author><style face="normal" font="Arial"> De Ferrari,L.</style></author><author><style face="normal" font="Arial"> Rossi,R.</style></author><author><style face="normal" font="Arial"> Di Silvestre,D.</style></author><author><style face="normal" font="Arial"> Benazzi,L.</style></author><author><style face="normal" font="Arial"> Chiappori,A.</style></author><author><style face="normal" font="Arial"> Dal Negro,R.W.</style></author><author><style face="normal" font="Arial"> Micheletto,C.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0001 2151 3065grid.5606.5Respiratory Diseases and Allergy Unit, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="6">6-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial biopsies</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix Proteins</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Galectin 3</style></keyword><keyword><style face="normal" font="Arial"> Genoa</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Keratin</style></keyword><keyword><style face="normal" font="Arial"> Keratins</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> reticular basement membrane</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bronchial asthma is a heterogeneous disease characterized by three cardinal features: chronic inflammation, variable airflow obstruction, and airway hyperresponsiveness. Asthma has traditionally been defined using nonspecific clinical and physiologic variables that encompass multiple phenotypes and are treated with nonspecific anti-inflammatory therapies. Based on the modulation of airway remodeling after 12 months of anti-immunoglobulin E (IgE) treatment, we identified two phenotypes (omalizumab responder, OR; and non-omalizumab responder, NOR) and performed morphometric analysis of bronchial biopsy specimens. We also found that these two phenotypes were correlated with the presence/absence of galectin-3 (Gal-3) at baseline (i.e., before treatment). The aims of the present study were to investigate the histological and molecular effects of long-term treatment (36 months) with anti-IgE and to analyze the behavior of OR and NOR patients. METHODS: All patients were treated with the monoclonal antibody anti-IgE omalizumab for 36 months. The bronchial biopsy specimens were evaluated using morphometric, eosinophilic, and proteomic analysis (MudPIT). New data were compared with previous data, and unsupervised cluster analysis of protein profiles was performed. RESULTS: After 36 months of treatment with omalizumab, reduction of reticular basement membrane (RBM) thickness was confirmed in OR patients (Gal-3-positive at baseline); similarly, the protein profiles (over 500 proteins identified) revealed that, in the OR group, levels of proteins specifically related to fibrosis and inflammation (e.g., smooth muscle and extracellular matrix proteins (including periostin), Gal-3, and keratins decreased by between 5- and 50-fold. Eosinophil levels were consistent with molecular data and decreased by about tenfold less in ORs and increased by twofold to tenfold more in NORs. This tendency was confirmed (p &lt; 0.05) based on both fold change and DAVE algorithms, thus indicating a clear response to anti-IgE treatment in Gal-3-positive patients. CONCLUSIONS: Our results showed that omalizumab can be considered a disease-modifying treatment in OR. The proteomic signatures confirmed the presence of Gal-3 at baseline to be a biomarker of long-term reduction in bronchial RBM thickness, eosinophilic inflammation, and muscular and fibrotic components in omalizumab-treated patients with severe asthma. Our findings suggest a possible relationship between Gal-3 positivity and improved pulmonary function</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0143-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293414">PM:28293414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Riccio AM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0143-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van del Valk,J.P.</style></author><author><style face="normal" font="Arial"> Bouche,R.E.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> de Groot,H.</style></author><author><style face="normal" font="Arial"> Wichers,H.J.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">000000040459992Xgrid.5645.2Department of Internal Medicine, Section of Allergology, Erasmus MC, Office Gk 323, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Low percentage of clinically relevant pistachio nut and mango co-sensitisation in cashew nut sensitised children</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mango</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cashew nut, pistachio nut and mango belong to the Anacardiaceae family and are botanically related. Therefore, cashew nut sensitised children are frequently advised to eliminate cashew nuts and pistachio nuts from their diet. The 'Improvement of Diagnostic mEthods for ALlergy assessment (IDEAL trial number NTR3572) study showed that cashew nut sensitised children were co-sensitised to pistachio nut in 98% of cases and to mango in 21% of cases. The aim of this follow-up study to IDEAL is to assess the clinical relevance of co-sensitisation to pistachio nut and mango in cashew nut sensitised children. METHODS: Children were recruited from the study: 'Improvement of Diagnostic mEthods for ALlergy assessment (IDEAL trial number NTR3572). Inclusion criterion for the IDEAL study was sensitization to cashew nut as demonstrated by either SPT or sIgE, and a clinical history of reactions to cashew nuts or no previous (known) exposure. Sensitized children who were tolerant to cashew nuts were excluded. Inclusion criterion for this IDEAL follow-up study was co-sensitization to pistachio nut, regardless the result of the DBPCFC with cashew nut. In this follow-up study a double-blind placebo-controlled food challenge with pistachio nut and an open food challenge with mango were performed. RESULTS: Twenty-nine children (mean age of 11.6 years, 62% male) were included. Pistachio nut sensitisation was clinically relevant in only 34% of cashew-sensitised children and only 31% of cashew challenge positive children. None of the children was challenge positive to mango. CONCLUSION: Although co-sensitisation between cashew nut and pistachio nut was observed in 98%, pistachio nut sensitisation was only clinically relevant in 34% of the children. Therefore, a challenge test with pistachio nut is recommended in children with cashew nut and pistachio nut sensitisation. Trial registration The study was registered in the Dutch trial register (registration number 3572) on 10 August 2012 (retrospectively registered)</style></abstract><notes><style face="normal" font="Arial">DA - 20170321IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0145-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28321292">PM:28321292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170321, van del Valk JP</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0145-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abrams,E.M.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Paediatric Allergy and Clinical Immunology (Abrams), University of Manitoba, Winnipeg, Man.</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis and management of food allergy</style></title><secondary-title><style face="normal" font="Arial">CMAJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">CMAJ</style></full-title></periodical><pages end="1093" start="1087">1087-1093</pages><volume><style face="normal" font="Arial">188</style></volume><number><style face="normal" font="Arial">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Egg Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Injections,Intramuscular</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Sympathomimetics</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="18" Month="10" Year="2016">2016/10/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160907IS - 1488-2329 (Electronic)IS - 0820-3946 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Sympathomimetics)RN - 0 (Vaccines)RN - 37341-29-0 (Immunoglobulin E)RN - YKH834O4BH (Epinephrine)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1503/cmaj.160124</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27601605">PM:27601605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\CMAJ\2016-188-1087-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\CMAJ\2016-188-1087-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160907, Abrams EM</style></custom2><misc3><style face="normal" font="Arial">10.1503/cmaj.160124</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Osborn,D.A.</style></author><author><style face="normal" font="Arial"> Sinn,J.K.</style></author><author><style face="normal" font="Arial"> Jones,L.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Central Clinical School, Discipline of Obstetrics, Gynaecology and Neonatology, University of Sydney, Sydney, NSW, Australia, 2050</style></auth-address><titles><title><style face="normal" font="Arial">Infant formulas containing hydrolysed protein for prevention of allergic disease and food allergy</style></title><secondary-title><style face="normal" font="Arial">Cochrane Database Syst Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cochrane Database Syst Rev</style></full-title></periodical><pages end="" start="CD003664">CD003664-</pages><volume><style face="normal" font="Arial">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood allergy</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cow's milk formula</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> eHF</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> formula feeding</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> Infant Food</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> Infant formulas</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy is common and may be associated with foods, including cow's milk formula (CMF). Formulas containing hydrolysed proteins have been used to treat infants with allergy. However, it is unclear whether hydrolysed formulas can be advocated for prevention of allergy in infants. OBJECTIVES: To compare effects on allergy and food allergy when infants are fed a hydrolysed formula versus CMF or human breast milk. If hydrolysed formulas are effective, to determine what type of hydrolysed formula is most effective, including extensively or partially hydrolysed formula (EHF/PHF). To determine which infants at low or high risk of allergy and which infants receiving early, short-term or prolonged formula feeding may benefit from hydrolysed formulas. SEARCH METHODS: We used the standard search strategy of the Cochrane Neonatal Review Group supplemented by cross referencing of previous reviews and publications (updated August 2016). SELECTION CRITERIA: We searched for randomised and quasi-randomised trials that compared use of a hydrolysed formula versus human milk or CMF. Trials with >/= 80% follow-up of participants were eligible for inclusion. DATA COLLECTION AND ANALYSIS: We independently assessed eligibility of studies for inclusion, methodological quality and data extraction. Primary outcomes included clinical allergy, specific allergy and food allergy. We conducted meta-analysis using a fixed-effect (FE) model. MAIN RESULTS: Two studies assessed the effect of three to four days' infant supplementation with an EHF whilst in hospital after birth versus pasteurised human milk feed. Results showed no difference in infant allergy or childhood cow's milk allergy (CMA). No eligible trials compared prolonged hydrolysed formula versus human milk feeding.Two studies assessed the effect of three to four days' infant supplementation with an EHF versus a CMF. One large quasi-random study reported a reduction in infant CMA of borderline significance among low-risk infants (risk ratio (RR) 0.62, 95% confidence interval (CI) 0.38 to 1.00).Prolonged infant feeding with a hydrolysed formula compared with a CMF was associated with a reduction in infant allergy (eight studies, 2852 infants; FE RR 0.82, 95% CI 0.72 to 0.95; risk difference (RD) -0.04, 95% CI -0.08 to -0.01; number needed to treat for an additional beneficial outcome (NNTB) 25, 95% CI 12.5 to 100) and infant CMA (two studies, 405 infants; FE RR 0.38, 95% CI 0.16 to 0.86). We had substantial methodological concerns regarding studies and concerns regarding publication bias, as substantial numbers of studies including those in high-risk infants have not comprehensively reported allergy outcomes (GRADE quality of evidence 'very low').Prolonged infant feeding with a hydrolysed formula compared with a CMF was not associated with a difference in childhood allergy and led to no differences in specific allergy, including infant and childhood asthma, eczema and rhinitis and infant food allergy. Many of the analyses assessing specific allergy are underpowered.Subroup analyses showed that infant allergy was reduced in studies that enrolled infants at high risk of allergy who used a hydrolysed formula compared with a CMF; used a PHF compared with a CMF; used prolonged and exclusive feeding of a hydrolysed formula compared with a CMF; and used a partially hydrolysed whey formula compared with a CMF. Studies that enrolled infants at high risk of allergy; used a PHF compared with a CMF; used prolonged and exclusive feeding of a hydrolysed formula compared with a CMF; and used a partially hydrolysed whey formula compared with a CMF found a reduction in infant CMA. AUTHORS' CONCLUSIONS: We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergy. Very low-quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA.In infants at high risk of allergy not exclusively breast fed, very low-quality evidence suggests that prolonged hydrolysed formula feeding compared with CMF feeding reduces infant allergy and infant CMA. Studies have found no difference in childhood allergy and no difference in specific allergy, including infant and childhood asthma, eczema and rhinitis and infant food allergy.Very low-quality evidence shows that prolonged use of a partially hydrolysed formula compared with a CMF for partial or exclusive feeding was associated with a reduction in infant allergy incidence and CMA incidence, and that prolonged use of an EHF versus a PHF reduces infant food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1469-493X (Electronic)IS - 1361-6137 (Linking)LA - engPT - Journal ArticlePT - ReviewPT - Research Support, N.I.H., ExtramuralPT - Research Support, Non-U.S. Gov'tCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1002/14651858.CD003664.pub4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293923">PM:28293923</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cochrane Database Syst Rev\2017-3-CD003664.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cochrane Database Syst Rev\2017-3-CD003664.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Osborn DA</style></custom2><misc3><style face="normal" font="Arial">10.1002/14651858.CD003664.pub4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shimojo,N.</style></author><author><style face="normal" font="Arial"> Yagami,A.</style></author><author><style face="normal" font="Arial"> Nakamura,M.</style></author><author><style face="normal" font="Arial"> Nagai,A.</style></author><author><style face="normal" font="Arial"> Matsunaga,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Toyoake 470-1192, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Occupational fish allergy caused by percutaneous sensitization with alpha-actinin-3</style></title><secondary-title><style face="normal" font="Arial">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Contact Dermatitis</style></full-title></periodical><pages end="323" start="322">322-323</pages><volume><style face="normal" font="Arial">76</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/cod.12753</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386978">PM:28386978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2017-76-322-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2017-76-322-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170407, Shimojo N</style></custom2><misc3><style face="normal" font="Arial">10.1111/cod.12753</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kapoor,S.</style></author><author><style face="normal" font="Arial"> Rafiq,A.</style></author><author><style face="normal" font="Arial"> Sharma,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Protein engineering and its applications in food industry</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="2329" start="2321">2321-2329</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Engineering</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Engineering</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">1040-8398</style></isbn><abstract><style face="normal" font="Arial">Protein engineering is a young discipline that has been branched out from the field of genetic engineering. Protein engineering is based on the available knowledge about the proteins structure/function(s), tools/instruments, software, bioinformatics database, available cloned gene, knowledge about available protein, vectors, recombinant strains and other materials that could lead to change in the protein backbone. Protein produced properly from genetic engineering process means a protein that is able to fold correctly and to do particular function(s) efficiently even after being subjected to engineering practices. Protein is modified through its gene or chemically. However, modification of protein through gene is easier. There is no specific limitation of Protein Engineering tools; any technique that can lead to change the protein constituent of amino acid and result in the modification of protein structure/function is in the frame of Protein Engineering. Meanwhile, there are some common tools used to reach a specific target. More active industrial and pharmaceutical based proteins have been invented by the field of Protein Engineering to introduce new function as well as to change its interaction with surrounding environment. A variety of protein engineering applications have been reported in the literature. These applications range from biocatalysis for food and industry to environmental, medical and nanobiotechnology applications. Successful combinations of various protein engineering methods had led to successful results in food industries and have created a scope to maintain the quality of finished product after processing</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2014.1000481</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26065315">PM:26065315</url></web-urls><pdf-urls><url ppv-ref="no">aasima20@gmail.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Kapoor S</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2014.1000481</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nelson,H.S.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Andersen,J.S.</style></author><author><style face="normal" font="Arial"> Esch,R.</style></author><author><style face="normal" font="Arial"> Cox,L.S.</style></author><author><style face="normal" font="Arial"> Nolte,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Jewish Health, 1400 Jackson St, Denver, CO, 80206, USA. ALK, Horsholm, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="18">18-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> Government Agencies</style></keyword><keyword><style face="normal" font="Arial"> Harmonization</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Progress has been made in the harmonization of efficacy and safety outcome measures for allergen immunotherapy (AIT) trials, but unresolved issues still remain. Furthermore, there are discrepancies in recommendations from professional medical societies and regulatory agencies regarding requirements for AIT trials. In this article, we reviewed published recommendations and current data from recent clinical trials, as well as the criteria applied by regulatory authorities for approval of AIT products, to provide updated considerations for conducting phase 3 AIT trials. Topics discussed include analysis of outcomes and trial designs for pediatric and asthma indications, as well as trial designs for perennial allergic rhinoconjunctivitis. In addition, the need for harmonization of safety reporting is emphasized. Considerations presented in this article may further effort to find common ground among professional medical societies and government agencies in developing future recommendations for AIT trial design</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - United Kingdom -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0687-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293909">PM:28293909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Nelson HS</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0687-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rust,B.</style></author><author><style face="normal" font="Arial"> Wambre,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Translational Immunology, Benaroya Research Institute, Seattle, WA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Human Immune Monitoring Techniques during Food Allergen Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="22">22-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peripheral Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Encouraging results from recent food allergen immunotherapy clinical trials indicate that the immune system plays an essential role in peripheral tolerance to food allergen. Thus, the monitoring of changes in immune responses and their possible correlation with clinical outcome in allergic patients receiving immunotherapies could theoretically serve as surrogate markers and be harnessed as rationale for food allergen immunotherapy development. RECENT FINDINGS: A shift towards antigen specificity in recent assays has provided a solid foundation for the elucidation of cellular mechanisms involved in food allergen immunotherapy as well as the tracking of allergen-specific immune cells. In this review, we overview the current challenges and technologies used in immune monitoring during immunotherapy in allergic patients with a focus on cell-mediated immunity. We also discuss critical steps involved in some of the cellular immune assays utilized in clinical trials</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0689-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28361386">PM:28361386</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Rust B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0689-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Angiolella,L.</style></author><author><style face="normal" font="Arial"> Carradori,S.</style></author><author><style face="normal" font="Arial"> Maccallini,C.</style></author><author><style face="normal" font="Arial"> Giusiano,G.</style></author><author><style face="normal" font="Arial"> Supuran,C.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Infectious Diseases, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome. Italy</style></auth-address><titles><title><style face="normal" font="Arial">Targeting Malassezia species for novel synthetic and natural antidandruff agents</style></title><secondary-title><style face="normal" font="Arial">Curr Med Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Chem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lipase</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Malassezia species</style></keyword><keyword><style face="normal" font="Arial"> microflora</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pityriasis</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">Malassezia spp. are lipophilic yeasts not only present in the normal skin microflora, but also responsible of skin-related diseases (pityriasis versicolor, seborrheic/atopic dermatitis and dandruff) as well as systemic fungal infections in humans and animals. Their treatment and eradication are mainly based on old azole drugs, which are characterized by poor compliance, unpredictable clinical efficacy, emerging resistance and several side effects. These drawbacks have prompted the research toward novel synthetic and natural derivatives/nanomaterials targeting other pivotal enzymes/pathways such as carbonic anhydrase (MgCA) and lipases, alone or in combination, in order to improve the eradication rate of this fungus. This review accomplished an update on this important topic dealing with the latest discoveries of synthetic scaffolds and natural products for the treatment of Malassezia spp.-related diseases, thus suggesting new opportunities to design innovative and alternative anti-dandruff drugs</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1875-533X (Electronic)IS - 0929-8673 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.2174/0929867324666170404110631</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393697">PM:28393697</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170410, Angiolella L</style></custom2><misc3><style face="normal" font="Arial">10.2174/0929867324666170404110631</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heinrich,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aGerman Center for Lung Research (DZL), Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital Munich, Ludwig Maximilians University Munich bHelmholtz Zentrum Munchen-German Research Center for Environmental Health, Institute of Epidemiology I, Neuherberg, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Modulation of allergy risk by breast feeding</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Clin Nutr Metab Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Clin Nutr Metab Care</style></full-title></periodical><pages end="221" start="217">217-221</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Breastfeeding has been suggested as a candidate for primary prevention of allergies. However, recent comprehensive and thoughtfully written systematic reviews reported mixed results and that overall there is only little evidence for breastfeeding being protective against allergic disorders. As these reviews last searched for relevant studies on 2 October 2014, the aim of our review is to shed light on the association between breastfeeding and allergic disorders (asthma, eczema, allergic rhinitis) recently published. RECENT FINDINGS: These recent studies are varied and differ in size, settings, design, depth of data collecting, and quality of the study. Thus far, the results on the association between nonexclusive and exclusive breastfeeding with regards to asthma are mixed especially in young ages. Additionally, if eczema and allergic rhinitis are the outcomes of interest, this recent review does not provide a clearer picture. SUMMARY: The current guidelines by WHO and European Academy of Allergy and Clinical Immunology (EAACI) on breastfeeding till 6 months and exclusively breastfeeding for 4-6 months, respectively, for the prevention of allergies are not supported by the recent study results. Nevertheless, breastfeeding should be strongly recommended for other beneficial health effects than allergy prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1473-6519 (Electronic)IS - 1363-1950 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1097/MCO.0000000000000366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28376053">PM:28376053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Clin Nutr Metab Care\2017-20-217-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Clin Nutr Metab Care\2017-20-217-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Heinrich J</style></custom2><misc3><style face="normal" font="Arial">10.1097/MCO.0000000000000366</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reisacher,W.R.</style></author><author><style face="normal" font="Arial"> Davison,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDepartment of Otolaryngology, Head &amp; Neck Surgery, Weill Cornell Medical College bNewYork-Presbyterian Hospital, New York, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy for food allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Otolaryngol Head Neck Surg</style></full-title></periodical><pages end="241" start="235">235-241</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> optimal dose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The current review discusses strategies for administering specific immunotherapy (SIT) for the treatment of food allergy. It focuses on three delivery routes for food allergens, immunomodulatory adjuvants and allergen modifications. RECENT FINDINGS: Interest in SIT for food allergy has been increasing significantly. Sublingual immunotherapy is effective for desensitization with a very favorable adverse event profile. Epicutaneous immunotherapy is also effective, most notably in younger children, with a high rate of local reactions. Oral immunotherapy demonstrates high efficacy, but with a higher risk of gastrointestinal and systemic adverse events. The need for long-term application to sustain desensitization is currently unclear. Immunomodulatory adjuvants may be added to enhance or diminish the immunogenicity of proteins, whereas genetic modifications of food allergens are designed to limit the risk of adverse reactions and address the issues of standardization and supply. SUMMARY: SIT for food allergy is reaching the point where it may soon be used routinely in clinical practice. Current research focuses on new delivery routes and methods to enhance the effectiveness of the therapy while minimizing the risk of adverse reactions. Future efforts are underway to determine the optimal dose for each delivery method and the length of maintenance dosing required to retain the protective effect</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1531-6998 (Electronic)IS - 1068-9508 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOO.0000000000000353</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28319482">PM:28319482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Otolaryngol Head Neck Surg\20170320-ReisacherWR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Otolaryngol Head Neck Surg\20170320-ReisacherWR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Reisacher WR</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOO.0000000000000353</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Happel,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</style></auth-address><titles><title><style face="normal" font="Arial">Rash diagnostics: an update on the diagnosis of allergic rashes</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pediatr</style></full-title></periodical><pages end="378" start="371">371-378</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic test</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The purpose of this review is to summarize recent research regarding the diagnosis of allergic rashes and to suggest future directions for the promotion of accurate diagnosis and endotype specification. RECENT FINDINGS: Multiple cohort studies demonstrate that with appropriate clinical evaluation, drug allergy labels can be removed in up to 90% of cases. Genetic tests can predict severe adverse cutaneous drug reactions in some cases and in vitro tests are being sought to identify causative drugs in others. Biomarkers to define endotypes of atopic dermatitis are needed to predict which patients will benefit from evolving targeted therapies. Hyperspectral imaging is a rapidly evolving technology in medical diagnostics; additional research is needed to demonstrate whether this promising technology can be used to distinguish allergic rashes and/or endotypes in atopic dermatitis. SUMMARY: Diagnostic tools for the assessment of allergic rashes are primitive in that they frequently rely on challenges to ascertain whether suspected allergens were causative. Validated in vitro tests with high sensitivity and specificity for drug allergies would benefit the field, particularly in delayed type reactions, as would identification of any hyperspectral signatures that could identify endotypes in atopic dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1531-698X (Electronic)IS - 1040-8703 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOP.0000000000000489</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28319560">PM:28319560</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pediatr\20170320-HappelCS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pediatr\20170320-HappelCS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Happel CS</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOP.0000000000000489</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferrando,M.</style></author><author><style face="normal" font="Arial"> Bagnasco,D.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Puggioni,F.</style></author><author><style face="normal" font="Arial"> Varricchi,G.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy &amp; Respiratory Diseases, DIMI Dept of Internal Medicine. Italy</style></auth-address><titles><title><style face="normal" font="Arial">New Suggestions In Sublingual Immunotherapy for House Dust Mite-Related Allergic Diseases</style></title><secondary-title><style face="normal" font="Arial">Curr Pharm Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pharm Biotechnol</style></full-title></periodical><pages end="383" start="378">378-383</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="17" Month="4" Year="2017">2017/4/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The indications for Allergen immunotherapy (AIT) in patients suffering from House Dust Mite (HDM)-related allergic diseases are presently based on incomplete data. This is essentially based on the fact that HDM allergy is difficult to evaluate in clinical trials, due to the largely variable allergen exposure and symptoms, and to the long periods of observation needed to assess the effects. In addition, at variance with pollen allergy, in HDM allergy asthma is more prevalent. However, several AIT products have been approved for HDM-induced allergic rhinitis, according to their ascertained clinical efficacy, tolerability and safety profile, particularly in the sublingual form (SLIT). OBJECTIVE: We reviewed herein the available data on AIT in patients with HDM-induced allergic diseases, with a particular attention to the new product MK-8237 HDM-SLIT tablets, concerning its efficacy and safety profile. METHOD: In the recent years, several randomized placebo-controlled clinical trials were performed in Europe, North America and Japan to evaluate the efficacy of HDM-sublingual tablets in patients with HDM-induced allergic asthma and allergic rhinitis, mainly assessing the reduction of symptoms, exacerbations and corticosteroid intake. RESULTS: The results of the published clinical trials were encouraging and led to the approval and commercialization of MK-8237 HDM-SLIT tablet. CONCLUSION: The favorable efficacy and safety profile of MK-8237 HDM-SLIT tablets provided a consolidated therapeutic option for patients with HDM-induced allergic rhinitis and asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170417IS - 1873-4316 (Electronic)IS - 1389-2010 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2174/1389201018666170417103316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28413977">PM:28413977</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Pharm Biotechnol\20170417-FerrandoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Pharm Biotechnol\20170417-FerrandoM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170417, Ferrando M</style></custom2><misc3><style face="normal" font="Arial">10.2174/1389201018666170417103316</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kouser,L.</style></author><author><style face="normal" font="Arial"> Kappen,J.</style></author><author><style face="normal" font="Arial"> Walton,R.P.</style></author><author><style face="normal" font="Arial"> Shamji,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, Faculty of Medicine, Imperial College London, National Heart and Lung Institute, London, SW7 2AZ UK</style></auth-address><titles><title><style face="normal" font="Arial">Update on Biomarkers to Monitor Clinical Efficacy Response During and Post Treatment in Allergen Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="53" start="43">43-53</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Breg</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy (AIT) is an immune modulating treatment for allergic diseases. Although highly effective, some patients do not respond to the treatment. To date there are no surrogate biomarkers that are predictive of the clinical response to AIT. More and more is known about the underlying immunological mechanism involved in AIT. Through modulation of both innate and adaptive immune responses, involving reduced ILC2 and enhanced Treg and Breg induction and functionality, along with induction of IgG4 antibody production which have the capacity to inhibit both allergen-induced basophil responsiveness and CD23-mediated IgE-facilitated allergen presentation, the result is an immune skewing towards a more balanced Type I response. So far, however there is not a clear correlation with the observed immunological changes and predictive correlates of clinical efficacy. The most promising biomarker of successful AIT is IgE-FAB as a reflection of functional IgG4. Cellular responses and cytokine analysis gives a great deal of insight into the mechanisms of AIT but may not represent useful or indeed reliable biomarkers in a clinical setting. There is a need for more research for confirmation and interpretation of the possible association with biomarkers and clinical response to AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170417LA - engPT - Journal ArticlePT - ReviewCO - United KIngdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0117-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28413769">PM:28413769</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-43-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-43-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170417, Kouser L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0117-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reynolds,H.H.</style></author><author><style face="normal" font="Arial"> Elston,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Department, Training Air Wing SIX, Naval Air Station Pensacola, Florida, USA</style></auth-address><titles><title><style face="normal" font="Arial">What's eating you? lone star tick (Amblyomma americanum)</style></title><secondary-title><style face="normal" font="Arial">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cutis</style></full-title></periodical><pages end="114" start="111">111-114</pages><volume><style face="normal" font="Arial">99</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> Early treatment</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> Tick Control</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Wing</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Amblyomma americanum, also known as the lone star tick, is found in much of the eastern United States. Since the mid-20th century, the lone star tick has been implicated in human disease. Today, A americanum remains an important vector for tick-borne illness. In addition to others, species of Rickettsia, Ehrlichia, and Borrelia are all transmitted by the lone star tick. Recently described conditions such as Southern tick-associated rash illness and anaphylaxis to red meat following tick bites have been attributed to the lone star tick. Impressive local reactions also can result after bites from A americanum. Early treatment of tick-borne illness is crucial to ensure good patient outcomes. Tick-control measures also are an important part of disease management in endemic areas. We discuss the tick's biology, human illnesses associated with A americanum, and methods to control tick numbers and eliminate disease in local reservoirs</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28319627">PM:28319627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cutis\2017-99-111-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cutis\2017-99-111-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Reynolds HH</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Latif,I.</style></author><author><style face="normal" font="Arial"> Hassan,I.</style></author><author><style face="normal" font="Arial"> Akhtar,S.</style></author><author><style face="normal" font="Arial"> Rasool,F.</style></author><author><style face="normal" font="Arial"> Zeerak,S.</style></author><author><style face="normal" font="Arial"> Sheikh,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Address reprint requests to Iffat Hassan, MD, Department of Dermatology, Sexually Transmitted Diseases &amp; Leprosy, Government Medical College, Srinagar, University of Kashmir, J&amp;K, India</style></auth-address><titles><title><style face="normal" font="Arial">Identification of Contact Allergens in Food Handlers of Kashmir Valley in North India</style></title><secondary-title><style face="normal" font="Arial">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact allergen</style></keyword><keyword><style face="normal" font="Arial"> contact allergens</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Leprosy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Sexually Transmitted Diseases</style></keyword><keyword><style face="normal" font="Arial"> Transmitted diseases</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170327IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1097/DER.0000000000000267</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28346306">PM:28346306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dermatitis\20170327-LatifI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dermatitis\20170327-LatifI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170327, Latif I</style></custom2><misc3><style face="normal" font="Arial">10.1097/DER.0000000000000267</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kruszewski,P.G.</style></author><author><style face="normal" font="Arial"> Russo,J.M.</style></author><author><style face="normal" font="Arial"> Franciosi,J.P.</style></author><author><style face="normal" font="Arial"> Varni,J.W.</style></author><author><style face="normal" font="Arial"> Platts-Mills,T.A.</style></author><author><style face="normal" font="Arial"> Erwin,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA</style></auth-address><titles><title><style face="normal" font="Arial">Prospective, comparative effectiveness trial of cow's milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Dis Esophagus</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dis Esophagus</style></full-title></periodical><pages end="384" start="377">377-384</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-Allergic Agents</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic agents</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> diet therapy</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophageal biopsy</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Multiple foods</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Symptom Assessment</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease in which food antigens play a key role. Current therapeutic options are limited to long-term steroid medication and dietary elimination of multiple foods, each of which is challenging. Our objective was to compare single food elimination of cow's milk to swallowed fluticasone in pediatric EoE patients. This is a prospective, comparative effectiveness trial of newly diagnosed EoE patients (ages 2-18 years) treated with swallowed fluticasone (n = 24) or elimination of cow's milk (n = 20). The dual outcome measures of repeat esophageal biopsy (6-8 weeks) and change in Pediatric Quality of Life Inventor (PedsQL) EoE Module and Symptoms Scales were used to assess response to treatment. After 6-8 weeks of treatment, peak esophageal eosinophil counts decreased to below the threshold of 15 eosinophils/high-power field in 64% of patients treated with cow's milk elimination and 80% of patients treated with swallowed fluticasone (P = 0.4). Mean PedsQL EoE Module total scores (69 vs. 82; P &lt; 0.005) and Total Symptoms scores (58 vs. 75; P = 0.001) showed significant improvement with cow's milk elimination. Among children treated with swallowed fluticasone, mean PedsQL EoE Module total scores (64 vs. 75; P &lt; 0.05) and Total Symptoms scores (58 vs. 69; P &lt; 0.01) were also significantly improved after 6-8 weeks of therapy. Removal of cow's milk from the diet is an effective single food elimination treatment for pediatric patients with EoE as assessed by statistically significant histologic and symptomatic improvement. Cow's milk elimination may be more desirable for EoE patients who do not want to take chronic, long-term steroid medications</style></abstract><notes><style face="normal" font="Arial">DA - 20160527IS - 1442-2050 (Electronic)IS - 1120-8694 (Linking)LA - engPT - Comparative StudyPT - Journal ArticleRN - 0 (Anti-Allergic Agents)RN - CUT2W21N7U (Fluticasone)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/dote.12339</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="25721813">PM:25721813</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dis Esophagus\2016-29-377-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dis Esophagus\2016-29-377-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160527, Kruszewski PG</style></custom2><misc3><style face="normal" font="Arial">10.1111/dote.12339</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Markham,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.</style></auth-address><titles><title><style face="normal" font="Arial">Baricitinib: First Global Approval</style></title><secondary-title><style face="normal" font="Arial">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs</style></full-title></periodical><pages end="704" start="697">697-704</pages><volume><style face="normal" font="Arial">77</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cell surface receptors</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> growth factors</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Methotrexate</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Baricitinib (Olumiant) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus. JAKs transduce intracellular signals from cell surface receptors for various cytokines and growth factors involved in inflammation and immune function, suggesting JAK inhibitors may be of therapeutic benefit in inflammatory conditions. In February 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Regulatory approval to market baricitinib as a treatment for RA has also been sought in the USA and Japan. This article summarizes the milestones in the development of baricitinib leading to this first global approval for the treatment for moderate to severe active RA in adult patients who have responded inadequately to, or are intolerant to one or more DMARDs</style></abstract><notes><style face="normal" font="Arial">DA - 20170314IS - 1179-1950 (Electronic)IS - 0012-6667 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40265-017-0723-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290136">PM:28290136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs\2017-77-697-704.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs\2017-77-697-704.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170314, Markham A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40265-017-0723-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hansel,T.T.</style></author><author><style face="normal" font="Arial"> Tunstall,T.</style></author><author><style face="normal" font="Arial"> Trujillo-Torralbo,M.B.</style></author><author><style face="normal" font="Arial"> Shamji,B.</style></author><author><style face="normal" font="Arial"> Del-Rosario,A.</style></author><author><style face="normal" font="Arial"> Dhariwal,J.</style></author><author><style face="normal" font="Arial"> Kirk,P.D.</style></author><author><style face="normal" font="Arial"> Stumpf,M.P.</style></author><author><style face="normal" font="Arial"> Koopmann,J.</style></author><author><style face="normal" font="Arial"> Telcian,A.</style></author><author><style face="normal" font="Arial"> Aniscenko,J.</style></author><author><style face="normal" font="Arial"> Gogsadze,L.</style></author><author><style face="normal" font="Arial"> Bakhsoliani,E.</style></author><author><style face="normal" font="Arial"> Stanciu,L.</style></author><author><style face="normal" font="Arial"> Bartlett,N.</style></author><author><style face="normal" font="Arial"> Edwards,M.</style></author><author><style face="normal" font="Arial"> Walton,R.</style></author><author><style face="normal" font="Arial"> Mallia,P.</style></author><author><style face="normal" font="Arial"> Hunt,T.M.</style></author><author><style face="normal" font="Arial"> Hunt,T.L.</style></author><author><style face="normal" font="Arial"> Hunt,D.G.</style></author><author><style face="normal" font="Arial"> Westwick,J.</style></author><author><style face="normal" font="Arial"> Edwards,M.</style></author><author><style face="normal" font="Arial"> Kon,O.M.</style></author><author><style face="normal" font="Arial"> Jackson,D.J.</style></author><author><style face="normal" font="Arial"> Johnston,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Airway Disease Infection Section, National Heart and Lung Institute (NHLI), Imperial College (IC), London, UK; MRC &amp; Asthma, UK</style></auth-address><titles><title><style face="normal" font="Arial">A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-gamma and IFN-lambda) and Type 2 Inflammation (IL-5 and IL-13)</style></title><secondary-title><style face="normal" font="Arial">EBioMedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EBioMedicine</style></full-title></periodical><pages end="138" start="128">128-138</pages><volume><style face="normal" font="Arial">19</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Area Under Curve</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> expiratory flows</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-15</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferons</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Rhinovirus infection is a major cause of asthma exacerbations. OBJECTIVES: We studied nasal and bronchial mucosal inflammatory responses during experimental rhinovirus-induced asthma exacerbations. METHODS: We used nasosorption on days 0, 2-5 and 7 and bronchosorption at baseline and day 4 to sample mucosal lining fluid to investigate airway mucosal responses to rhinovirus infection in patients with allergic asthma (n=28) and healthy non-atopic controls (n=11), by using a synthetic absorptive matrix and measuring levels of 34 cytokines and chemokines using a sensitive multiplex assay. RESULTS: Following rhinovirus infection asthmatics developed more upper and lower respiratory symptoms and lower peak expiratory flows compared to controls (all P&lt;0.05). Asthmatics also developed higher nasal lining fluid levels of an anti-viral pathway (including IFN-gamma, IFN-lambda/IL-29, CXCL11/ITAC, CXCL10/IP10 and IL-15) and a type 2 inflammatory pathway (IL-4, IL-5, IL-13, CCL17/TARC, CCL11/eotaxin, CCL26/eotaxin-3) (area under curve day 0-7, all P&lt;0.05). Nasal IL-5 and IL-13 were higher in asthmatics at day 0 (P&lt;0.01) and levels increased by days 3 and 4 (P&lt;0.01). A hierarchical correlation matrix of 24 nasal lining fluid cytokine and chemokine levels over 7days demonstrated expression of distinct interferon-related and type 2 pathways in asthmatics. In asthmatics IFN-gamma, CXCL10/IP10, CXCL11/ITAC, IL-15 and IL-5 increased in bronchial lining fluid following viral infection (all P&lt;0.05). CONCLUSIONS: Precision sampling of mucosal lining fluid identifies robust interferon and type 2 responses in the upper and lower airways of asthmatics during an asthma exacerbation. Nasosorption and bronchosorption have potential to define asthma endotypes in stable disease and at exacerbation</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 2352-3964 (Electronic)IS - 2352-3964 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ebiom.2017.03.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28373098">PM:28373098</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EBioMedicine\20170404-HanselTT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EBioMedicine\20170404-HanselTT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Hansel TT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ebiom.2017.03.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Div. of Immunopathology, Dept. of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria. Electronic address: rudolf.valenta@meduniwien.ac.at</style></auth-address><titles><title><style face="normal" font="Arial">Mucosal Lining Fluid Biomarkers in Asthma: Basis for Rational Use of New Targeted Therapies?</style></title><secondary-title><style face="normal" font="Arial">EBioMedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EBioMedicine</style></full-title></periodical><pages end="13" start="12">12-13</pages><volume><style face="normal" font="Arial">19</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 2352-3964 (Electronic)IS - 2352-3964 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ebiom.2017.04.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412250">PM:28412250</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EBioMedicine\20170416-ValentaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EBioMedicine\20170416-ValentaR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Valenta R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ebiom.2017.04.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Erickson,T.B.</style></author><author><style face="normal" font="Arial"> Cheema,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Humanitarian Initiative &amp; Harvard Medical School, Neville House, 75 Francis Street, Boston, MA 02115, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Arthropod Envenomation in North America</style></title><secondary-title><style face="normal" font="Arial">Emerg Med Clin North Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Emerg Med Clin North Am</style></abbr-1></periodical><pages end="375" start="355">355-375</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Ants</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Bites and Stings</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Scorpions</style></keyword><keyword><style face="normal" font="Arial"> Snake Bites</style></keyword><keyword><style face="normal" font="Arial"> Spiders</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Ticks</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Arthropods (phylum Arthopoda) account for a higher percentage of morbidity and mortality to humans than do mammalian bites, snake bites, or marine envenomation. They are ubiquitous in domestic dwellings, caves, and campsites and in wilderness settings such as deserts, forests, and lakes. Although arthropods are most intrusive during warmer months, many are active throughout the winter, particularly indoors. Arthropods are also nocturnal and often bite unsuspecting victims while they are sleeping. Encounters with humans are generally defensive, accidental, or reactive. An individual stung by an insect or bitten by an arachnid may experience pain and local swelling, an anaphylactic reaction, or life-threatening toxicity. This review discusses the clinical presentation and latest treatment recommendations for bites and stings from spiders, scorpions, bees, ants, ticks and centipedes of North America</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 1558-0539 (Electronic)IS - 0733-8627 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.emc.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28411932">PM:28411932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Emerg Med Clin North Am\2017-35-355-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Emerg Med Clin North Am\2017-35-355-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Erickson TB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.emc.2017.01.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hornbeak,K.B.</style></author><author><style face="normal" font="Arial"> Auerbach,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, Stanford Kaiser Emergency Medicine Residency, 300 Pasteur Drive, Alway Building M121, MC 5119, Stanford, CA 94305-2200, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Marine Envenomation</style></title><secondary-title><style face="normal" font="Arial">Emerg Med Clin North Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Emerg Med Clin North Am</style></abbr-1></periodical><pages end="337" start="321">321-337</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cnidaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Octopus</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Snail</style></keyword><keyword><style face="normal" font="Arial"> snails</style></keyword><keyword><style face="normal" font="Arial"> Snakes</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> swimmers</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Venomous aquatic animals are hazardous to swimmers, surfers, divers, and fishermen. Exposures include mild stings, bites, abrasions, and lacerations. Severe envenomations can be life threatening. This article reviews common marine envenomations, exploring causative species, clinical presentation, and current treatment recommendations. Recommendations are included for cnidaria, sponges, bristle worms, crown-of-thorns starfish, sea urchins, venomous fish, stingrays, cone snails, stonefish, blue-ringed octopus, and sea snakes. Immediate and long-term treatment options and management of common sequelae are reviewed. Antivenom administration, treatment of anaphylaxis, and surgical indications are discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 1558-0539 (Electronic)IS - 0733-8627 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.emc.2016.12.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28411930">PM:28411930</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Emerg Med Clin North Am\2017-35-321-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Emerg Med Clin North Am\2017-35-321-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Hornbeak KB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.emc.2016.12.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tabouri,S.</style></author><author><style face="normal" font="Arial"> Nicolaou,N.</style></author><author><style face="normal" font="Arial"> Douros,K.</style></author><author><style face="normal" font="Arial"> Papadopoulou,A.</style></author><author><style face="normal" font="Arial"> Priftis,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Child Health Department, School of Medicine University of Ioannina, Ioannina. Greece</style></auth-address><titles><title><style face="normal" font="Arial">Food protein induced proctocolitis: a benign condition with an obscure immunologic mechanism</style></title><secondary-title><style face="normal" font="Arial">Endocr Metab Immune Disord Drug Targets</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Endocr Metab Immune Disord Drug Targets</style></full-title></periodical><pages end="37" start="32">32-37</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> intestinal permeability</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">Food protein-induced proctocolitis (FPIP) is the most common colonic manifestation of food allergy in infants, accounting for up to 60% of exclusively breast-fed children. The causative foods derive from the mother's diet that are then excreted in her milk. The suggested risk factors for the development of FPIP are an immature immune system, altered intestinal permeability and other factors that activate local immune function, such as genetic susceptibility in combination with particularly sensitizing foods. FPIP is an enhanced immune responsiveness of some infants to very small amounts of food antigens, inducing an inflammatory mucosal response, mediated by T cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 2212-3873 (Electronic)IS - 1871-5303 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.2174/1871530316666170331165356</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28376708">PM:28376708</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170405, Tabouri S</style></custom2><misc3><style face="normal" font="Arial">10.2174/1871530316666170331165356</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vuitton,D.A.</style></author><author><style face="normal" font="Arial"> Dalphin,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">From Farming to Engineering: The Microbiota and Allergic Diseases</style></title><secondary-title><style face="normal" font="Arial">Engineering</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Engineering</style></abbr-1></periodical><pages end="109" start="98">98-109</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> cowshed</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> farming environment</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactococcus</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbial biodiversity</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Translational research</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> War</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><isbn><style face="normal" font="Arial">2095-8099</style></isbn><abstract><style face="normal" font="Arial">The steady increase of IgE-dependent allergic diseases after the Second World War is a unique phenomenon in the history of humankind. Numerous cross-sectional studies, comprehensive longitudinal cohort studies of children living in various types of environment, and mechanistic experimental studies have pointed to the disappearance of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£protective factors</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ related to major changes in lifestyle and environment. A common unifying concept is that of the immunoregulatory role of the gut microbiota. This review focuses on the protection against allergic disorders that is provided by the farming environment and by exposure to microbial diversity. It also questions whether and how microbial bioengineering will be able in the future to restore an interplay that was beneficial to the proper immunological development of children in the past and that was irreversibly disrupted by changes in lifestyle. The protective </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£farming environment</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ includes independent and additional influences: contact with animals, stay in barns/stables, and consumption of unprocessed milk and milk products, by mothers during pregnancy and by children in early life. More than the overall quantity of microbes, the biodiversity of the farm microbial environment appears to be crucial for this protection, as does the biodiversity of the gut microbiota that it may provide. Use of conventional probiotics, especially various species or strains of Lactobacillus and Bifidobacterium, has not fulfilled the expectations of allergists and pediatricians to prevent allergy. Among the specific organisms present in cowsheds that could be used for prevention, Acinetobacter (A.) lwoffii F78, Lactococcus (L.) lactis G121, and Staphylococcus (S.) sciuri W620 seem to be the most promising, based on experimental studies in mouse models of allergic respiratory diseases. However, the development of a new generation of probiotics based on very productive research on the farming environment faces several obstacles that cannot be overcome without a close collaboration between microbiologists, immunologists, and bioengineers, as well as pediatricians, allergists, specialists of clinical trials, and ethical committees</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/J.ENG.2017.01.019</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/J.ENG.2017.01.019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Engineering\2017-3-98-109.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Engineering\2017-3-98-109.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Vuitton DA</style></custom2><misc3><style face="normal" font="Arial">10.1016/J.ENG.2017.01.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sakata,S.</style></author><author><style face="normal" font="Arial"> Konishi,S.</style></author><author><style face="normal" font="Arial"> Ng,C.F.</style></author><author><style face="normal" font="Arial"> Kishikawa,R.</style></author><author><style face="normal" font="Arial"> Watanabe,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Association of Asian Dust with daily medical consultations for pollinosis in Fukuoka City, Japan</style></title><secondary-title><style face="normal" font="Arial">Environ Health Prev Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Health Prev Med</style></full-title></periodical><pages end="" start="25">25-</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asian</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Consultations</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1347-4715</style></isbn><abstract><style face="normal" font="Arial">The objective is to examine the association between AD and the daily number of medical consultations for pollinosis in Fukuoka City</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12199-017-0623-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s12199-017-0623-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Health Prev Med\2017-22-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Health Prev Med\2017-22-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Sakata S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12199-017-0623-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Werchan,B.</style></author><author><style face="normal" font="Arial"> Werchan,M.</style></author><author><style face="normal" font="Arial"> Mucke,H.G.</style></author><author><style face="normal" font="Arial"> Gauger,U.</style></author><author><style face="normal" font="Arial"> Simoleit,A.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Foundation German Pollen Information Service, Chariteplatz 1, 10117, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Spatial distribution of allergenic pollen through a large metropolitan area</style></title><secondary-title><style face="normal" font="Arial">Environ Monit Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Monit Assess</style></full-title></periodical><pages end="" start="169">169-</pages><volume><style face="normal" font="Arial">189</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Large city</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> mugwort pollen</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen trap</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">For nearly a decade, the majority of the world's population has been living in cities, including a considerable percentage of people suffering from pollen allergy. The increasing concentration of people in cities results in larger populations being exposed to allergenic pollen at the same time. There is almost no information about spatial distribution of pollen within cities as well as a lack of information about the possible impact to human health. To obtain this increasing need for pollen exposure studies on an intra-urban scale, a novelty screening network of 14 weekly changed pollen traps was established within a large metropolitan area-Berlin, Germany. Gravimetric pollen traps were placed at a uniform street-level height from March until October 2014. Three important allergenic pollen types for Central Europe-birch (Betula), grasses (Poaceae), and mugwort (Artemisia)-were monitored. Remarkable spatial and temporal variations of pollen sedimentation within the city and the influences by urban local sources are shown. The observed differences between the trap with the overall highest and the trap with the overall lowest amount of pollen sedimentation were in the case of birch pollen 245%, grass pollen 306%, and mugwort pollen 1962%. Differences of this magnitude can probably lead to different health impacts on allergy sufferers in one city. Therefore, pollen should be monitored preferably in two or more appropriate locations within large cities and as a part of natural air quality regulations</style></abstract><notes><style face="normal" font="Arial">DA - 20170319IS - 1573-2959 (Electronic)IS - 0167-6369 (Linking)LA - engPT - Journal ArticleCO - Czech Republic -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10661-017-5876-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28316024">PM:28316024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-169.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-169.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170319, Werchan B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10661-017-5876-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,F.</style></author><author><style face="normal" font="Arial"> Durner,J.</style></author><author><style face="normal" font="Arial"> Winkler,J.B.</style></author><author><style face="normal" font="Arial"> Traidl-Hoffmann,C.</style></author><author><style face="normal" font="Arial"> Strom,T.M.</style></author><author><style face="normal" font="Arial"> Ernst,D.</style></author><author><style face="normal" font="Arial"> Frank,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biochemical Plant Pathology, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Pollen of common ragweed (Ambrosia artemisiifolia L.): Illumina-based de novo sequencing and differential transcript expression upon elevated NO2/O3</style></title><secondary-title><style face="normal" font="Arial">Environ Pollut</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Pollut</style></full-title></periodical><pages end="514" start="503">503-514</pages><volume><style face="normal" font="Arial">224</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Common ragweed</style></keyword><keyword><style face="normal" font="Arial"> de novo sequencing</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fumigation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> ontology</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant growth</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen production</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Systems Biology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Common ragweed (Ambrosia artemisiifolia L.) is a highly allergenic annual ruderal plant and native to Northern America, but now also spreading across Europe. Air pollution and climate change will not only affect plant growth, pollen production and duration of the whole pollen season, but also the amount of allergenic encoding transcripts and proteins of the pollen. The objective of this study was to get a better understanding of transcriptional changes in ragweed pollen upon NO2 and O3 fumigation. This will also contribute to a systems biology approach to understand the reaction of the allergenic pollen to air pollution and climate change. Ragweed plants were grown in climate chambers under controlled conditions and fumigated with enhanced levels of NO2 and O3. Illumina sequencing and de novo assembly revealed significant differentially expressed transcripts, belonging to different gene ontology (GO) terms that were grouped into biological process and molecular function. Transcript levels of the known Amb a ragweed encoding allergens were clearly up-regulated under elevated NO2, whereas the amount of allergen encoding transcripts was more variable under elevated O3 conditions. Moreover transcripts encoding allergen known from other plants could be identified. The transcriptional changes in ragweed pollen upon elevated NO2 fumigation indicates that air pollution will alter the transcriptome of the pollen. The changed levels of allergenic encoding transcripts may have an influence on the total allergenic potential of ragweed pollen</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1873-6424 (Electronic)IS - 0269-7491 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envpol.2017.02.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284545">PM:28284545</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Pollut\2017-224-503-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Pollut\2017-224-503-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Zhao F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envpol.2017.02.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">O'Lenick,C.R.</style></author><author><style face="normal" font="Arial"> Winquist,A.</style></author><author><style face="normal" font="Arial"> Chang,H.H.</style></author><author><style face="normal" font="Arial"> Kramer,M.R.</style></author><author><style face="normal" font="Arial"> Mulholland,J.A.</style></author><author><style face="normal" font="Arial"> Grundstein,A.</style></author><author><style face="normal" font="Arial"> Sarnat,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Health, Rollins School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30322, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of individual and area-level factors as modifiers of the association between warm-season temperature and pediatric asthma morbidity in Atlanta, GA</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="144" start="132">132-144</pages><volume><style face="normal" font="Arial">156</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> Bronchiolitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> effect modification</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Linear Models</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicaid</style></keyword><keyword><style face="normal" font="Arial"> Meteorology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> neighborhood</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Poisson</style></keyword><keyword><style face="normal" font="Arial"> Poverty</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Previous studies have found associations between respiratory morbidity and high temperatures; however, few studies have explored associations in potentially sensitive sub-populations. METHODS: We evaluated individual and area-level factors as modifiers of the association between warm-season (May-Sept.) temperature and pediatric respiratory morbidity in Atlanta. Emergency department (ED) visit data were obtained for children, 5-18 years old, with primary diagnoses of asthma or respiratory disease (diagnoses of upper respiratory infections, bronchiolitis, pneumonia, chronic obstructive pulmonary disease, asthma, or wheeze) in 20-county Atlanta during 1993-2012. Daily maximum temperature (Tmax) was acquired from the automated surface observing station at Atlanta Hartsfield International Airport. Poisson generalized linear models were used to estimate rate ratios (RR) between daily Tmax and asthma or respiratory disease ED visits, controlling for time and meteorology. Tmax effects were estimated for single-day lags of 0-6 days, for 3-, 5-, and 7-day moving averages and modeled with cubic terms to allow for non-linear relationships. Effect modification by individual factors (sex, race, insurance status) and area-level socioeconomic status (SES; ZIP code levels of poverty, education, and the neighborhood deprivation index) was examined via stratification. RESULTS: Estimated RRs for Tmax and pediatric asthma ED visits were positive and significant for lag days 1-5, with the strongest single day association observed on lag day 2 (RR=1.06, 95% CI: 1.03, 1.09) for a change in Tmax from 27 degrees C to 32 degrees C (25th to 75th percentile). For the moving average exposure periods, associations increased as moving average periods increased. We observed stronger RRs between Tmax and asthma among males compared to females, non-white children compared to white children, children with private insurance compared to children with Medicaid, and among children living in high compared to low SES areas. Associations between Tmax and respiratory disease ED visits were weak and non-significant (p-value>0.05). CONCLUSIONS: Results suggest socio-demographic factors (race/ethnicity, insurance status, and area-level SES) may confer vulnerability to temperature-related pediatric asthma morbidity. Our findings of weaker associations among children with Medicaid compared to other health insurance types and among children living in low compared to high SES areas run counter to our belief that children from disadvantaged households or ZIP codes would be more vulnerable to the respiratory effects of temperature. The potential reasons for these unexpected results are explored in the discussion</style></abstract><notes><style face="normal" font="Arial">DA - 20170325IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2017.03.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342349">PM:28342349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-156-132-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-156-132-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170325, OLenick CR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2017.03.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Phosri,A.</style></author><author><style face="normal" font="Arial"> Ueda,K.</style></author><author><style face="normal" font="Arial"> Tasmin,S.</style></author><author><style face="normal" font="Arial"> Kishikawa,R.</style></author><author><style face="normal" font="Arial"> Hayashi,M.</style></author><author><style face="normal" font="Arial"> Hara,K.</style></author><author><style face="normal" font="Arial"> Uehara,Y.</style></author><author><style face="normal" font="Arial"> Phung,V.L.H.</style></author><author><style face="normal" font="Arial"> Yasukouchi,S.</style></author><author><style face="normal" font="Arial"> Konishi,S.</style></author><author><style face="normal" font="Arial"> Honda,A.</style></author><author><style face="normal" font="Arial"> Takano,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Engineering, Graduate School of Engineering, Kyoto University, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Interactive effects of specific fine particulate matter compositions and airborne pollen on frequency of clinic visits for pollinosis in Fukuoka, Japan</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="419" start="411">411-419</pages><volume><style face="normal" font="Arial">156</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Consultations</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gaseous pollutants</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous studies have revealed the interactive effects of airborne pollen and particulate matter on the daily consultations for pollinosis, but it is uncertain which compositions are responsible. This study aimed to investigate the interactive effects of specific PM2.5 compositions and airborne pollen on the daily number of clinic visits for pollinosis in Fukuoka. METHODS: We obtained daily data on pollen concentrations, PM2.5 compositions, PM2.5 mass, gaseous pollutants (SO2, NO2, CO, and O3), and weather variables monitored in Fukuoka between February and April, 2002-2012. In total, 73,995 clinic visits for pollinosis were made at 10 clinics in Fukuoka Prefecture during the study period. A time-stratified case-crossover design was applied to examine the interactive effects. The concentrations of PM2.5 and its compositions were stratified into low (&lt;15th percentile), moderate (15th-85th percentile), and high (>85th percentile) levels, and the association between airborne pollen and daily clinic visits for pollinosis was analyzed within each level. RESULTS: We found a significant interaction between specific PM2.5 compositions and airborne pollen. Specifically, the odds ratio of daily clinic visits for pollinosis per interquartile increase in pollen concentration (39.8 grains/cm2) at the average cumulative lag of 0 and 2 days during high levels of non-sea-salt Ca2+ was 1.446 (95% CI: 1.323-1.581), compared to 1.075 (95% CI: 1.067-1.083) when only moderate levels were observed. This result remained significant when other air pollutants were incorporated into the model and was fairly persistent even when different percentile cut-off points were used. A similar interaction was found when we stratified the data according to non-sea-salt</style></abstract><notes><style face="normal" font="Arial">DA - 20170414IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410518">PM:28410518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-156-411-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-156-411-9.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-156-411-9.csv</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-156-411-9.csv</url></image-urls></urls><custom2><style face="normal" font="Arial">20170414, Phosri A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2017.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reinmuth-Selzle,K.</style></author><author><style face="normal" font="Arial"> Kampf,C.J.</style></author><author><style face="normal" font="Arial"> Lucas,K.</style></author><author><style face="normal" font="Arial"> Lang-Yona,N.</style></author><author><style face="normal" font="Arial"> Frohlich-Nowoisky,J.</style></author><author><style face="normal" font="Arial"> Shiraiwa,M.</style></author><author><style face="normal" font="Arial"> Lakey,P.S.</style></author><author><style face="normal" font="Arial"> Lai,S.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Kunert,A.T.</style></author><author><style face="normal" font="Arial"> Ziegler,K.</style></author><author><style face="normal" font="Arial"> Shen,F.</style></author><author><style face="normal" font="Arial"> Sgarbanti,R.</style></author><author><style face="normal" font="Arial"> Weber,B.</style></author><author><style face="normal" font="Arial"> Bellinghausen,I.</style></author><author><style face="normal" font="Arial"> Saloga,J.</style></author><author><style face="normal" font="Arial"> Weller,M.G.</style></author><author><style face="normal" font="Arial"> Duschl,A.</style></author><author><style face="normal" font="Arial"> Schuppan,D.</style></author><author><style face="normal" font="Arial"> Poschl,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Multiphase Chemistry Department, Max Planck Institute for Chemistry , Mainz, 55128, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Air Pollution and Climate Change Effects on Allergies in the Anthropocene: Abundance, Interaction, and Modification of Allergens and Adjuvants</style></title><secondary-title><style face="normal" font="Arial">Environ Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Sci Technol</style></full-title></periodical><pages end="4141" start="4119">4119-4141</pages><volume><style face="normal" font="Arial">51</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosol</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosols</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Carbon Dioxide</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chemical modifications</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> nitrogen oxide</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen Oxides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxides</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">Air pollution and climate change are potential drivers for the increasing burden of allergic diseases. The molecular mechanisms by which air pollutants and climate parameters may influence allergic diseases, however, are complex and elusive. This article provides an overview of physical, chemical and biological interactions between air pollution, climate change, allergens, adjuvants and the immune system, addressing how these interactions may promote the development of allergies. We reviewed and synthesized key findings from atmospheric, climate, and biomedical research. The current state of knowledge, open questions, and future research perspectives are outlined and discussed. The Anthropocene, as the present era of globally pervasive anthropogenic influence on planet Earth and, thus, on the human environment, is characterized by a strong increase of carbon dioxide, ozone, nitrogen oxides, and combustion- or traffic-related particulate matter in the atmosphere. These environmental factors can enhance the abundance and induce chemical modifications of allergens, increase oxidative stress in the human body, and skew the immune system toward allergic reactions. In particular, air pollutants can act as adjuvants and alter the immunogenicity of allergenic proteins, while climate change affects the atmospheric abundance and human exposure to bioaerosols and aeroallergens. To fully understand and effectively mitigate the adverse effects of air pollution and climate change on allergic diseases, several challenges remain to be resolved. Among these are the identification and quantification of immunochemical reaction pathways involving allergens and adjuvants under relevant environmental and physiological conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170322IS - 1520-5851 (Electronic)IS - 0013-936X (Linking)LA - engPT - Journal ArticleCO - Germany -CO - China -CO - Austria -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.est.6b04908</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28326768">PM:28326768</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Sci Technol\2017-51-4119-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Sci Technol\2017-51-4119-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170322, Reinmuth-Selzle K</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.est.6b04908</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,S.H.</style></author><author><style face="normal" font="Arial"> Hong,J.H.</style></author><author><style face="normal" font="Arial"> Lee,J.E.</style></author><author><style face="normal" font="Arial"> Lee,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Traditional Medicine &amp; Bioscience, Daejeon University, Daejeon 300-716, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">18beta-Glycyrrhetinic acid, the major bioactive component of Glycyrrhizae Radix, attenuates airway inflammation by modulating Th2 cytokines, GATA-3, STAT6, and Foxp3 transcription factors in an asthmatic mouse model</style></title><secondary-title><style face="normal" font="Arial">Environ Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Toxicol Pharmacol</style></full-title></periodical><pages end="113" start="99">99-113</pages><volume><style face="normal" font="Arial">52</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="Arial">18beta-Glycyrrhetinic acid (18Gly), the major bioactive component of Glycyrrhizae Radix, possesses anti-ulcerative, anti-inflammatory, and other pharmacological properties. Although 18Gly is associated with immunoregulatory functions of allergic diseases, the pathophysiological mechanisms of 18Gly action in allergic inflammatory lung disease have not been examined. Moreover, there are no in vivo studies on the anti-asthmatic effects of 18Gly in allergic asthma. We investigated its effect and mechanism of action in airway inflammation in a BALB/c mouse model of allergic asthma. Interestingly, 18Gly strongly suppressed airway hyperresponsiveness, accumulation of inflammatory cells, and levels of T helper type 2 (Th2) cytokines (interleukin (IL)-5 and IL-13) in bronchoalveolar lavage fluid (BALF). It also attenuated lung IL-5, IL-13, and IL-4 expression, but it upregulated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA expression in lungs. Moreover, it exerted immunomodulatory effects by suppressing Th2 cytokines (IL-5, IL-13) production through upregulation of forkhead box p3 (Foxp3), and downregulation of signal transducer and activator of transcription (STAT6), GATA-binding protein 3 (GATA-3), and retinoic acid-related orphan receptor gamma t (RORgammat) expression. These results suggest that the anti-asthmatic activity of 18Gly may occur by the suppression of IL-5, IL-13, and OVA-specific Immunoglobulin E (IgE) production through inhibition of the RORgammat, STAT6, GATA-3 pathways and upregulation of the Foxp3 transcription pathway. Also, 18Gly treatment was protective against the oxidative stress by inducing significant decrease of reactive oxygen species (ROS) generation in MH-S alveolar macrophage cells. Our results suggest that 18Gly can improve allergic asthma and can be a novel therapeutic component for the treatment of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170414IS - 1872-7077 (Electronic)IS - 1382-6689 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.etap.2017.03.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410469">PM:28410469</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Toxicol Pharmacol\2017-52-99-113.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Toxicol Pharmacol\2017-52-99-113.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170414, Kim SH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.etap.2017.03.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ek,W.E.</style></author><author><style face="normal" font="Arial"> Ahsan,M.</style></author><author><style face="normal" font="Arial"> Rask-Andersen,M.</style></author><author><style face="normal" font="Arial"> Liang,L.</style></author><author><style face="normal" font="Arial"> Moffatt,M.F.</style></author><author><style face="normal" font="Arial"> Gyllensten,U.</style></author><author><style face="normal" font="Arial"> Johansson,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Genetics &amp; Pathology, Science for Life Laboratory, Uppsala University, Box 815 75108 Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Epigenome-wide DNA methylation study of IgE concentration in relation to self-reported allergies</style></title><secondary-title><style face="normal" font="Arial">Epigenomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Epigenomics</style></full-title></periodical><pages end="418" start="407">407-418</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune development</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">AIM: Epigenetic mechanisms are critical for normal immune development and epigenetic alterations might therefore be possible contributors to immune diseases. To investigate if DNA methylation in whole blood is associated with total and allergen-specific IgE levels. METHODS: We performed an epigenome-wide association study to investigate the association between DNA methylation and IgE level, allergen-specific IgE and self-reported immune diseases and allergies in 728 individuals. RESULTS: We identified and replicated 15 CpG sites associated with IgE, mapping to biologically relevant genes, including ACOT7, ILR5A, KCNH2, PRG2 and EPX. A total of 331 loci were associated with allergen-specific IgE, but none of these CpG sites were associated with self-reported allergies and immune diseases. CONCLUSION: This study shows that IgE levels are associated with DNA methylation levels at numerous CpG sites, which might provide new leads for investigating the links between IgE and allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170321IS - 1750-192X (Electronic)IS - 1750-192X (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United States -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.2217/epi-2016-0158</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28322575">PM:28322575</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170321, Ek WE</style></custom2><misc3><style face="normal" font="Arial">10.2217/epi-2016-0158</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calzetta,L.</style></author><author><style face="normal" font="Arial"> Roncada,P.</style></author><author><style face="normal" font="Arial"> di Cave,D.</style></author><author><style face="normal" font="Arial"> Bonizzi,L.</style></author><author><style face="normal" font="Arial"> Urbani,A.</style></author><author><style face="normal" font="Arial"> Pistocchini,E.</style></author><author><style face="normal" font="Arial"> Rogliani,P.</style></author><author><style face="normal" font="Arial"> Matera,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Equine Vet J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Equine Vet J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">agonists</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Chromones</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> funnel plot</style></keyword><keyword><style face="normal" font="Arial"> Furosemide</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Compliance</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Equine asthma is a disease characterised by reversible airflow obstruction, bronchial hyper-responsiveness and airway inflammation following exposure of susceptible horses to specific airborne agents. Although clinical remission can be achieved in a low-airborne dust environment, repeated exacerbations may lead to irreversible airway remodelling. The available data on the pharmacotherapy of equine asthma result from several small studies, and no head-to-head clinical trials have been conducted among the available medications. OBJECTIVES: To assess the impact of the pharmacological interventions in equine asthma and compare the effect of different classes of drugs on lung function. STUDY DESIGN: Pair-wise and network meta-analysis. METHODS: Literature searches for clinical trials on the pharmacotherapy of equine asthma were performed. The risk of publication bias was assessed by funnel plots and Egger's test. Changes in maximum transpulmonary or pleural pressure, pulmonary resistance and dynamic lung compliance vs. control were analysed via random-effects models and Bayesian networks. RESULTS: The results obtained from 319 equine asthma-affected horses were extracted from 32 studies. Bronchodilators, corticosteroids and chromones improved maximum transpulmonary or pleural pressure (range: -8.0 to -21.4 cmH2 O; P&lt;0.001). Bronchodilators, corticosteroids and furosemide reduced pulmonary resistance (range: -1.2 to -1.9 cmH2 O/L/s; P&lt;0.001), and weakly increased dynamic lung compliance. Inhaled beta2 -adrenoreceptor (beta2 -AR) agonists and inhaled corticosteroids had the highest probability of being the best therapies. Long-term treatments were more effective than short-term treatments. MAIN LIMITATIONS: Weak publication bias was detected. CONCLUSIONS: This study demonstrates that long-term treatments with inhaled corticosteroids and long-acting beta2 -AR agonists may represent the first choice for treating equine asthma. Further high quality clinical trials are needed to clarify whether inhaled bronchodilators should be preferred to inhaled corticosteroids or vice versa, and to investigate the potential superiority of combination therapy in equine asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2042-3306 (Electronic)IS - 0425-1644 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/evj.12680</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28295526">PM:28295526</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Equine Vet J\20170315-CalzettaL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Equine Vet J\20170315-CalzettaL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Calzetta L</style></custom2><misc3><style face="normal" font="Arial">10.1111/evj.12680</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bakhshaee,M.</style></author><author><style face="normal" font="Arial"> Bojdi,A.</style></author><author><style face="normal" font="Arial"> Allahyari,A.</style></author><author><style face="normal" font="Arial"> Majidi,M.R.</style></author><author><style face="normal" font="Arial"> Tavakol,S.</style></author><author><style face="normal" font="Arial"> Najafzadeh,M.J.</style></author><author><style face="normal" font="Arial"> Asghari,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sinus and Surgical Endoscopic Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Acute invasive fungal rhinosinusitis: our experience with 18 cases</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="4287" start="4281">4281-4287</pages><volume><style face="normal" font="Arial">273</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Disease</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal Agents</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Debridement</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunocompromised Host</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Mucor</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Paresthesia</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Rhizopus</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">Acute invasive fungal rhinosinusitis (AIFRS) is a rapidly progressive life threatening infection that is seen most commonly among immunocompromised patients. We present a case series of 18 patients clinically and histopathologically diagnosed with AIFRS with a mean follow-up of 9.11 +/- 2.51 months (range 6-17). Demographic data, apparent symptoms and signs, underlying disorders, and outcomes are discussed. The mean age was 39.56 +/- 20.66 years (range 2-75). The most common underlying diseases were diabetes mellitus (50 %) and leukemia (44.44 %). Mucosal biopsy confirmed fungal invasion of the nasal mucosa in all cases. The main fungi were Rhizopus oryzae (55.56 %), Absidia mucor (16.67 %), and Aspergillus fumigatus (27.78 %). Headache and facial pain (77.8 %), facial paresthesia (55.6 %), and ophthalmoplegia (33.3 %) were the most common symptoms and signs. Computed tomography and endoscopic findings showed various stages of sinonasal (100 %), pterygopalatine fossa (55.56 %), orbital (44.45 %), and cerebral (5.56 %) involvement. All patients underwent serial surgical debridement (3.78 +/- 1.80 times; range 2-8) simultaneously with systemic antifungal therapy and proper management of the underlying disease. The most extreme case with brain involvement survived and recovered with no evidence of recurrent disease following treatment. All patients were considered cured after two endoscopic negative histopathologic evaluations. Three patients (16.67 %) died, one from uncontrolled leukemia and two due to renal failure. AIFRS is a potentially fatal condition, however, early diagnosis and management of the underlying disease accompanied with systemic antifungal and aggressive serial surgical intervention appears to be effective in reducing mortality in most patients</style></abstract><notes><style face="normal" font="Arial">DA - 20160608IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleRN - 0 (Antifungal Agents)SB - IMCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-016-4109-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27272179">PM:27272179</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\2016-273-4281-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\2016-273-4281-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160608, Bakhshaee M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-016-4109-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yao,Y.</style></author><author><style face="normal" font="Arial"> Xie,S.</style></author><author><style face="normal" font="Arial"> Yang,C.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Wu,X.</style></author><author><style face="normal" font="Arial"> Sun,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China</style></auth-address><titles><title><style face="normal" font="Arial">Biomarkers in the evaluation and management of chronic rhinosinusitis with nasal polyposis</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinases</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> nasal secretion</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a group of multifactorial and heterogeneous disorders with a significant economic strain on society, likely made up of different endotypes, each with a unique pathomechanism. In addition to the traditional clinical measures, there is a recognized need for reliable biomarkers to provide predictive information regarding diagnosis, endotypes, treatment responses, and future risk of recurrence. Fueled by the advances in basic research, various biomarkers have been explored in recent years. Biomarkers of CRSwNP can originate from a variety of sources, including nasal secretions, nasal biopsies, exhaled breath, and peripheral blood. In this review, we aim to summarize the existing and emerging biomarkers available for the evaluation and management of CRSwNP. Currently, eosinophil count in nasal mucosa has proved particularly valuable for endotyping, assessing disease severity, and predicting steroid responsiveness and surgical outcomes. Blood eosinophilia may be used as a surrogate for tissue eosinophilic inflammation, whereas its utility remains limited. Type 2 cytokines, such as IL-4, IL-5, and IL-13, and IgE have been identified as potential therapeutic targets. Moreover, matrix metalloproteinases (MMP)-9 is linked to healing quality after sinus surgery. Nasal nitric oxide (nNO) appears to fill the niche as a noninvasive measure for sinus ostial patency. In addition, recent data have shown some promising biomarkers involved in corticosteroid resistance and olfactory dysfunction. However, rigorous validation using large cohort studies is necessary before these biomarkers can be mainstreamed into clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20170402IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4547-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28365802">PM:28365802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170402-YaoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170402-YaoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170402, Yao Y</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4547-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rambeau,A.</style></author><author><style face="normal" font="Arial"> Gervais,R.</style></author><author><style face="normal" font="Arial"> De Raucourt,D.</style></author><author><style face="normal" font="Arial"> Babin,E.</style></author><author><style face="normal" font="Arial"> Dugue,A.E.</style></author><author><style face="normal" font="Arial"> Florescu,C.</style></author><author><style face="normal" font="Arial"> Blanchard,D.</style></author><author><style face="normal" font="Arial"> Gery,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Oncology Department, Centre Francois Baclesse, Av general Harris, 14000, Caen, France.</style></auth-address><titles><title><style face="normal" font="Arial">Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="2889" start="2883">2883-2889</pages><volume><style face="normal" font="Arial">274</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Folliculitis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> radiotherapy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">Radiotherapy associated with cetuximab (Cet-RT) is an alternative treatment to platinum-based chemoradiotherapy in locally advanced head and neck carcinoma (LAHNC). Reviews suggest that the use of cetuximab is associated with poorer tolerance in patients unfit for chemotherapy than in pivotal trial. We retrospectively studied patients first treated by Cet-RT for LAHNC presenting contraindications to chemoradiotherapy. Objectives were treated population description, acute tolerance, progression-free survival (PFS), overall survival (OS), and 3-month clinical response. Eighty-eight patients were included. Treatment was completed without delay for 43 patients. Grade 3-4 acute toxicity was described in 44.3%: mucositis (n = 20), radiodermatitis (n = 25) folliculitis (n = 10), and anaphylaxis (n = 6). Fourteen patients died during treatment. Median PFS and OS were 6.3 and 18.7 months, respectively. We confirm that Cet-RT tolerance in unfit patients is poorer than that in trials. Survival data illustrate patients' frailty and suggest that balanced use of Cet-RT is required in this population</style></abstract><notes><style face="normal" font="Arial">DA - 20170406IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4550-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28382396">PM:28382396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170406-RambeauA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170406-RambeauA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170406, Rambeau A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4550-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.C.</style></author><author><style face="normal" font="Arial"> Lin,T.Y.</style></author><author><style face="normal" font="Arial"> Shang,S.T.</style></author><author><style face="normal" font="Arial"> Chen,H.J.</style></author><author><style face="normal" font="Arial"> Kao,C.H.</style></author><author><style face="normal" font="Arial"> Wu,C.C.</style></author><author><style face="normal" font="Arial"> Yang,T.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Helicobacter pylori infection increases the risk of adult-onset asthma: a nationwide cohort study</style></title><secondary-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> cigarette smoking</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="4" Year="2017">2017/4/8</year></dates><abstract><style face="normal" font="Arial">Helicobacter pylori infection (HPI) appears to reduce risk of childhood-onset asthma, but the relationship between HPI and adult-onset asthma is inconclusive. This study explored the potential association between HPI and risk of adult-onset asthma. We conducted a national insurance retrospective cohort study using the longitudinal health insurance database (LHID 2000) in Taiwan. We enrolled the HPI group consisting of 1664 patients with HPI diagnosis between 2000 and 2007, and the non-HPI group consisting of 6,656 age- and sex-matched subjects without HPI. All study participants had been followed up from index date to the diagnostic date of asthma, withdrawal from the National Health Insurance program, or the end of 2011, which came first. We analyzed risk of adult-onset asthma with respect to sex, age, and comorbidities by using Cox models. Cigarette smoking status, which could not be obtained from the program, was adjusted indirectly by considering chronic obstructive pulmonary diseases in our statistical models because the disease is related to heavy smoking. After adjustment for sex, age, and comorbidities, HPI was significantly associated with an increased 1.38-fold risk of adult-onset asthma. Moreover, among people without comorbidities, the 1.85-fold risk of adult-onset asthma remained higher for the HPI population compared with the non-HPI population. In this study, patients with HPI exhibited a significantly higher risk of adult-onset asthma than did the subjects without HPI</style></abstract><notes><style face="normal" font="Arial">DA - 20170408IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10096-017-2972-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389738">PM:28389738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170408-WangYC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Clin Microbiol Infect Dis\20170408-WangYC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Wang YC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10096-017-2972-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bascunan,K.A.</style></author><author><style face="normal" font="Arial"> Vespa,M.C.</style></author><author><style face="normal" font="Arial"> Araya,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Nutrition, Faculty of Medicine, University of Chile, Av. Independencia 1027, Independencia, Santiago, Chile. kbascunan@med.uchile.clLaboratory of Gastroenterology, Institute of Nutrition and Food Technology, INTA, University of Chile, Independencia, ChileLaboratory of Gastroenterology, Institute of Nutrition and Food Technology, INTA, University of Chile, Independencia, Chile</style></auth-address><titles><title><style face="normal" font="Arial">Celiac disease: understanding the gluten-free diet</style></title><secondary-title><style face="normal" font="Arial">Eur J Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Nutr</style></full-title></periodical><pages end="459" start="449">449-459</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Technology</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten free food</style></keyword><keyword><style face="normal" font="Arial"> Gluten free foods</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free diet</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Minerals</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Gain</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The only effective and safe treatment of celiac disease (CD) continues being strict exclusion of gluten for life, the so-called gluten-free diet (GFD). Although this treatment is highly successful, following strict GFD poses difficulties to patients in family, social and working contexts, deteriorating his/her quality of life. We aimed to review main characteristics of GFD with special emphasis on factors that may interfere with adherence to it. METHODS: We conducted a search of various databases, such as PubMed, Google Scholar, Embase, and Scielo, with focus on key words such as "gluten-free diet", "celiac disease", "gluten" and "gluten-free diet adherence". Available literature has not reached definitive conclusions on the exact amount of gluten that is harmless to celiac patients, although international agreements establish cutoff points for gluten-free products and advise the use of clinical assessment to tailor the diet according to individual needs. Following GFD must include eliminating gluten as ingredient as well as hidden component and potential cross contamination in foods. There are numerous grains to substitute wheat but composition of most gluten-free products tends to include only a small number of them, especially rice. The diet must be not only free of gluten but also healthy to avoid nutrient, vitamins and minerals deficiencies or excess. Overweight/obesity frequency has increased among celiac patients so weight gain deserves attention during follow up. Nutritional education by a trained nutritionist is of great relevance to achieve long-term satisfactory health status and good compliance. CONCLUSIONS: A balanced GFD should be based on a combination of naturally gluten-free foods and certified processed gluten-free products. How to measure and improve adherence to GFD is still controversial and deserves further study</style></abstract><notes><style face="normal" font="Arial">DA - 20160623IS - 1436-6215 (Electronic)IS - 1436-6207 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Chile -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s00394-016-1238-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27334430">PM:27334430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Nutr\2017-56-449-59.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Nutr\2017-56-449-59.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160623, Bascunan KA</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s00394-016-1238-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turner,D.L.</style></author><author><style face="normal" font="Arial"> Ford,W.R.</style></author><author><style face="normal" font="Arial"> Kidd,E.J.</style></author><author><style face="normal" font="Arial"> Broadley,K.J.</style></author><author><style face="normal" font="Arial"> Powell,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cathays Park, Cardiff CF10 3NB, Wales, UK</style></auth-address><titles><title><style face="normal" font="Arial">Effects of nebulised magnesium sulphate on inflammation and function of the guinea-pig airway</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="85" start="79">79-85</pages><volume><style face="normal" font="Arial">801</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway conductance</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchoprotection</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Late asthmatic response</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Magnesium</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="4" Year="2017">2017/4/15</year></dates><abstract><style face="normal" font="Arial">Magnesium sulphate is a potential treatment for acute severe asthma. However, the mechanisms and dose-response relationships are poorly understood. The first objective of this study was to examine whether inhaled magnesium sulphate exerts bronchodilator activity measured as bronchoprotection against histamine-induced bronchoconstriction in conscious guinea-pigs alone and combined with salbutamol. Secondly, we examined whether inhaled magnesium sulphate inhibits airways inflammation and function in models of neutrophilic and eosinophilic lung inflammation induced, respectively, by inhaled lipopolysaccharide or the inhaled antigen, ovalbumin (OVA). Airway function was measured in conscious guinea-pigs as specific airway conductance (sGaw) by whole-body plethysmography. Anti-inflammatory activity was measured against lung inflammatory cell influx induced by OVA inhalation in OVA-sensitised animals or by lipopolysaccharide (LPS) exposure of non-sensitised animals. Airway function (sGaw) was measured over 24h after OVA exposure. Airway hyperresponsiveness to inhaled histamine and inflammatory cells in bronchoalveolar lavage fluid were recorded 24h after OVA or LPS challenge. Histamine-induced bronchoconstriction was inhibited by inhaled magnesium sulphate or salbutamol alone and in combination, they produced synergistic bronchoprotection. LPS-induced neutrophil influx was inhibited by 6 days pretreatment with magnesium sulphate. Early and late asthmatic responses in OVA sensitised and challenged animals were attenuated by magnesium sulphate. Lung inflammatory cells were increased by OVA, macrophages being significantly reduced by magnesium sulphate. Nebulised magnesium sulphate protects against histamine-induced bronchoconstriction in conscious guinea-pigs and exerts anti-inflammatory activity against pulmonary inflammation induced by allergen (OVA) or LPS. These properties of magnesium sulphate explain its beneficial actions in acute asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170312IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284753">PM:28284753</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\2017-801-79-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\2017-801-79-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170312, Turner DL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.03.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Oliveira,J.R.</style></author><author><style face="normal" font="Arial"> da Silva,P.R.</style></author><author><style face="normal" font="Arial"> Rogerio,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Health Sciences, Department of Clinical Medicine, Laboratory of Experimental Immunopharmacology, Federal University of Triangulo Mineiro, Uberaba, MG 38025-350, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">AT-RvD1 modulates the activation of bronchial epithelial cells induced by lipopolysaccharide and Dermatophagoides pteronyssinus</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="50" start="46">46-50</pages><volume><style face="normal" font="Arial">805</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> CCL2</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> lipid mediators</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> STAT1</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="3" Year="2017">2017/3/18</year></dates><abstract><style face="normal" font="Arial">Bronchial epithelial cells are essential to airways homeostasis; however, they are also involved in exacerbation of airway inflammatory responses of patients with conditions such as asthma. Dermatophagoides pteronyssinus (Dp), the most important allergen, and lipopolysaccharide (LPS), both of which are present in house dust mites (HDM), can activate immune and structural cells (such as bronchial epithelial cells) and modulate the airway inflammation in asthma patients. Resolvin D1 (RvD1) and its epimer aspirin-triggered-resolvin D1 (AT-RvD1) are lipid mediators that are produced during the resolution of inflammation and demonstrate anti-inflammatory and pro-resolution effects in several experimental models including experimental models of allergic airway inflammation. Here, we evaluated the effects of AT-RvD1 (10-12-10-10 M) on human bronchial epithelial cells (BEAS-2B) stimulated with LPS (2mug/ml) or Dp (10mug/ml). After 24h, the C-C motif chemokine ligand 2 (CCL-2) production was increased in cells that had been stimulated with LPS and Dp compared to the control. However, AT-RvD1 (10-11 and 10-10 M) significantly reduced the concentration of CCL-2 in a manner that was dependent on the N-formyl peptide receptor 2 (FPR2/ALX) and nuclear factor kappa B (NF-kappaB) pathways in cells stimulated with LPS or Dp compared to controls. In addition, AT-RvD1 reduced the phosphorylation of signal transducer and activator of transcription (STAT)6 and STAT1 in cells stimulated with Dp and LPS, respectively. In conclusion, AT-RvD1 demonstrated significant anti-inflammatory effects in bronchial epithelial cells that were stimulated with LPS or Dp, which provides new perspectives for therapeutic strategies to control inflammatory airway diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170321IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.03.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28322829">PM:28322829</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20170321-deOliveiraJR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20170321-deOliveiraJR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170321, de Oliveira JR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.03.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Siciliano,I.</style></author><author><style face="normal" font="Arial"> Gilardi,G.</style></author><author><style face="normal" font="Arial"> Ortu,G.</style></author><author><style face="normal" font="Arial"> Gisi,U.</style></author><author><style face="normal" font="Arial"> Gullino,M.L.</style></author><author><style face="normal" font="Arial"> Garibaldi,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Identification and characterization of Alternaria species causing leaf spot on cabbage, cauliflower, wild and cultivated rocket by using molecular and morphological features and mycotoxin production</style></title><secondary-title><style face="normal" font="Arial">Eur J Plant Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Plant Pathol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> cabbage</style></keyword><keyword><style face="normal" font="Arial"> Cauliflower</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxin</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Phylogenetic analysis</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sporulation</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> Virulence</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-8469</style></isbn><abstract><style face="normal" font="Arial">Alternaria species are common pathogens of fruit and vegetables able to produce secondary metabolites potentially affecting human health. Twenty-nine isolates obtained from cabbage, cauliflower, wild and cultivated rocket were characterized and identified based on sporulation pattern and virulence; the phylogenetic analysis was based on the +¦-tubulin gene. Isolates were identified as A. alternata, A. tenuissima, A. arborescens, A. brassicicola and A. japonica. Pathogenicity was evaluated on plants under greenhouse conditions. Two isolates showed low level of virulence on cultivated rocket while the other isolates showed medium or high level of virulence. Isolates were also characterized for their mycotoxin production on a modified Czapek-Dox medium. Production of the five Alternaria toxins, tenuazonic acid, alternariol, alternariol monomethyl ether, altenuene and tentoxin were evaluated. Under these conditions, about 80% of the isolates showed the ability to produce at least one mycotoxin</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10658-017-1190-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10658-017-1190-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Plant Pathol\20170418-SicilianoI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Plant Pathol\20170418-SicilianoI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Siciliano I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10658-017-1190-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,H.Y.</style></author><author><style face="normal" font="Arial"> Lee,H.Y.</style></author><author><style face="normal" font="Arial"> Choi,J.Y.</style></author><author><style face="normal" font="Arial"> Hur,J.</style></author><author><style face="normal" font="Arial"> Kim,I.K.</style></author><author><style face="normal" font="Arial"> Kim,Y.K.</style></author><author><style face="normal" font="Arial"> Kang,J.Y.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine , The Catholic University of Korea , Seoul , South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Inhibition of MicroRNA-21 by an antagomir ameliorates allergic inflammation in a mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Lung Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Lung Res</style></full-title></periodical><pages end="119" start="109">109-119</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagomiR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> miR-21</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">AIM OF THE STUDY: MicroRNA-21 (miR-21) is up-regulated during allergic airway inflammation, reflecting a Th2 immune response. We investigated the effects of an miR-21 antagomir and its mechanism of action in a mouse model of acute bronchial asthma. MATERIALS AND METHODS: BALB/c mice were sensitized and challenged with ovalbumin (OVA). The anti-miR-21 antagomir was administered by intranasal inhalation from the day of sensitization. Changes in cell counts, Th2 cytokine levels in bronchoalveolar (BAL) fluid, and airway hyper-responsiveness (AHR) were examined. Histopathological changes and expression levels of miR-21 in lung tissues were analyzed. The mechanism of action of the antagomir was investigated by counting CD4+/CD8- T cells in splenocytes and by measuring the expression levels of transcription factors associated with T cell polarization. RESULTS: MiR-21 expression was selectively down-regulated in the lung tissues of mice treated with anti-miR-21. The antagomir suppressed AHR compared with that of the OVA-challenged and scrambled RNA-treated groups. It also reduced the total cell and eosinophil counts in BAL fluid and the levels of Th2 cytokines, including IL-4, IL-5, and IL-13. The direct target of miR-21, IL-12p35, was induced in the antagomir-treated group, decreasing the CD4+/CD8- T cell proportions in splenocytes. The levels of transcription factors involved in the Th2-signaling pathway were reduced in lung tissues on treatment with the antagomir. CONCLUSIONS: The miR-21 antagomir suppresses the development of allergic airway inflammation in a mouse model of acute bronchial asthma, inhibiting Th2 activation. These results suggest that this antagomir might be useful for treating bronchial asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1521-0499 (Electronic)IS - 0190-2148 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1080/01902148.2017.1304465</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28379062">PM:28379062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Lung Res\20170405-LeeHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Lung Res\20170405-LeeHY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Lee HY</style></custom2><misc3><style face="normal" font="Arial">10.1080/01902148.2017.1304465</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fan,Q.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Huang,S.</style></author><author><style face="normal" font="Arial"> Ni,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Desensitization Treatment Center in the Department of Otolaryngology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325009, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Comparative analysis of cluster versus conventional immunotherapy in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="722" start="717">717-722</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> cluster immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">The present study aimed to compare the efficacy and safety of subcutaneous immunotherapy with Dermatophagoides pteronyssinus standardized extract administered in conventional and cluster immunotherapy regiments for patients with persistent allergic rhinitis. A total of 60 patients with moderate to severe allergic rhinitis caused by dust mites were treated for 1 year with either conventional immunotherapy (n=30) or cluster immunotherapy (n=30). Nasal conjunctival symptoms and signs were assessed to evaluate the clinical efficacy of the two regimens, and the incidence of local and systemic adverse reactions were also evaluated. The findings demonstrated that the cluster regimen reduced the duration between the initial and maintenance dose by >60%, and resulted in a significant improvement, as compared with the conventional regimen, after 6 weeks of observation (P&lt;0.05). However, the incidence of local and systemic adverse reactions in the cluster regimen during the dose accumulation phase and the dose maintenance phase was not significantly different, as compared with the conventional immunotherapy regimen. These results suggest that cluster immunotherapy is efficacious and safe to treat patients who are clinically sensitive to dust mites</style></abstract><notes><style face="normal" font="Arial">DA - 20170329IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28352357">PM:28352357</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-13-717-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-13-717-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170329, Fan Q</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,H.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Wang,D.W.</style></author><author><style face="normal" font="Arial"> Wei,J.F.</style></author><author><style face="normal" font="Arial"> He,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylactic shock caused by haemocoagulase injection in China</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="1553" start="1547">1547-1553</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Bothrops</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mannitol</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteinase</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Haemocoagulase injection is a mixture of purified enzymes isolated from the venom of Bothrops atrox, which is used for the prevention and treatment of haemorrhage. It is a relatively safe pharmacological agent that does not require a skin test prior to administration. However, following a literature search, 14 reported cases of anaphylactic shock caused by haemocoagulase injection were identified, including one lethal case in China. Using SDS-PAGE and protein identification, four primary components in haemocoagulase injection were characterized, including one metalloproteinase, which may be a thromboplastin-like enzyme, and two serine proteinases, which may be thrombin-like enzymes. Administering concentrated haemocoagulase injections failed to provoke a positive skin reaction in allergic patients. Basophil activation tests revealed that haemocoagulase injections did not upregulate cluster of differentiation 63 or C-C chemokine receptor type 3 expression. These findings suggest that haemocoagulase injection may cause fetal anaphylaxis. Although it is difficult to determine a clear conclusion without being able to evaluate the patients that underwent haemocoagulase injection-induced shock, it is unlikely that the venomous components of haemocoagulase injection cross-react with common allergens in allergic patients. It is possible that haemocoagulase injection-induced anaphylaxis is caused by its additive components, such as mannitol and succinylated gelatin</style></abstract><notes><style face="normal" font="Arial">DA - 20170417IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4121</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28413507">PM:28413507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-13-1547-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-13-1547-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170417, Yang H</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4121</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gong,F.</style></author><author><style face="normal" font="Arial"> Pan,Y.H.</style></author><author><style face="normal" font="Arial"> Huang,X.</style></author><author><style face="normal" font="Arial"> Zhu,H.Y.</style></author><author><style face="normal" font="Arial"> Jiang,D.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, The Third Hospital Affiliated to Nantong University, Wuxi, Jiangsu 214041, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">From bench to bedside: Therapeutic potential of interleukin-9 in the treatment of asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="394" start="389">389-394</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-9</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Initially identified as a T cell and mast cell growth factor, interleukin (IL)-9 has long been recognized as an important mediator of asthma. Recently, accumulating results from transgenic mice demonstrated that systemic or lung-specific overexpression of IL-9 caused asthma-associated symptoms. Moreover, anti-mIL-9 antibody (Ab) blocking treatment alleviated disease in animal models of asthma. In light of the large quantity of data from the murine models, MEDI-528, a humanized anti-IL-9 monoclonal Ab has been produced to assess the activity of IL-9 on human asthma. In order to ascertain whether it is a successful translation from bench to bedside, the biological features of IL-9 were evaluated and up-to-date information regarding the role of IL-9 in different experimental murine models and human asthma were summarized</style></abstract><notes><style face="normal" font="Arial">DA - 20170329IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28352305">PM:28352305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-13-389-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-13-389-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170329, Gong F</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Antoniu,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Medicine II-Nursing/Palliative Care , University of Medicine and Pharmacy Grigore T Popa Iasi, Romania , Str Universitatii 16, Iasi , 700115 , Romania</style></auth-address><titles><title><style face="normal" font="Arial">Benralizumab as a potential treatment of asthma</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></full-title></periodical><pages end="900" start="895">895-900</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene modifier</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Current anti-inflammatory asthma therapies including inhaled corticosteroids and leukotriene modifiers, are not always able to appropriately control the disease and other approaches are needed. These therapies specific target IgE (omalizumab) or IL-5 (mepolizumab). However, there is research underway investigating interleukin-based monoclonal antibodies such as benralizumab, an anti-IL-5R monoclonal antibody which is currently in phase III clinical development. Areas covered: This review summarizes the existing preclinical and clinical data of benralizumab. Data reviewed includes benralizumab's efficacy and safety data. The author also provides their expert opinion on this potential therapeutic and provide their perspectives for its future development. Expert opinion: Benralizumab was able to interfere significantly with disease-related morbidity and in particular with hospitalizations due to asthma exacerbation rates in a subset of patients with higher systemic eosinophil burden and higher doses of inhaled corticosteroids. The sustained inhibitory effect on eosinophilic inflammation might be an advantage which can be translated in less frequent dosing. Further attempts should be made to better define the asthma endotype in which such an antibody would be the most efficacious</style></abstract><notes><style face="normal" font="Arial">DA - 20170413IS - 1744-7682 (Electronic)IS - 1471-2598 (Linking)LA - engPT - Journal ArticleCO - Romania -</style></notes><work-type><style face="normal" font="Arial">10.1080/14712598.2017.1319471</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28406319">PM:28406319</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170413, Antoniu SA</style></custom2><misc3><style face="normal" font="Arial">10.1080/14712598.2017.1319471</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saco,T.V.</style></author><author><style face="normal" font="Arial"> Pepper,A.</style></author><author><style face="normal" font="Arial"> Lockey,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Division of Allergy and Immunology, Department of Internal Medicine , University of South Florida Morsani College of Medicine and James A. Haley Veterans Affairs Medical Center , Tampa , FL , USA</style></auth-address><titles><title><style face="normal" font="Arial">Benralizumab for the treatment of asthma</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="413" start="405">405-413</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The classification of asthma into phenotypes and endotoypes allows for the use of targeted therapies, including three biologics which target interleukin 5 (IL-5) signaling in eosinophilic asthma. Areas covered: As of December 2016, two monoclonal antibodies, mepolizumab and reslizumab, are approved by U.S. Food and Drug Administration and one, benralizumab, is in clinical development. Two phase 3 trials for benralizumab, SIROCCO and CALIMA, were published in September 2016. Although there are no direct comparisons among these three anti-IL-5 therapies, the goal of this review is to summarize the current data and discuss their potential similarities and differences, with a focus on benralizumab. Expert Review: Compared to mepolizumab and reslizumab, the main advantages of benralizumab are less frequent dosing and a potential to reduce exacerbations irrespective of the blood eosinophil count. Some improvements in asthma symptom scores and quality of life occur with all three biologics, but the clinical meaningfulness of these improvements is less clear. A more defined reference range for eosinophil levels is necessary to determine which subjects will best benefit from these medications. Until quality randomized controlled trials directly compare the three, choosing among them for the treatment of eosinophilic asthma remains difficult</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1316194</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28379047">PM:28379047</url></web-urls></urls><custom2><style face="normal" font="Arial">20170405, Saco TV</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1316194</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cipriani,P.</style></author><author><style face="normal" font="Arial"> Sbaraglia,G.L.</style></author><author><style face="normal" font="Arial"> Palomba,M.</style></author><author><style face="normal" font="Arial"> Giulietti,L.</style></author><author><style face="normal" font="Arial"> Bellisario,B.</style></author><author><style face="normal" font="Arial"> Buselic,I.</style></author><author><style face="normal" font="Arial"> Mladineo,I.</style></author><author><style face="normal" font="Arial"> Cheleschi,R.</style></author><author><style face="normal" font="Arial"> Nascetti,G.</style></author><author><style face="normal" font="Arial"> Mattiucci,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anisakis pegreffii (Nematoda: Anisakidae) in European anchovy Engraulis encrasicolus from the Mediterranean Sea: Fishing ground as a predictor of parasite distribution</style></title><secondary-title><style face="normal" font="Arial">Fish Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Fish Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Adriatic Sea</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis pegreffii</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> body-cavity</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Engraulis encrasicolus</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish flesh</style></keyword><keyword><style face="normal" font="Arial"> Fish-borne</style></keyword><keyword><style face="normal" font="Arial"> Fishing ground</style></keyword><keyword><style face="normal" font="Arial"> flesh</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hysterothylacium</style></keyword><keyword><style face="normal" font="Arial"> Hysterothylacium aduncum</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean Sea</style></keyword><keyword><style face="normal" font="Arial"> mtDNA</style></keyword><keyword><style face="normal" font="Arial"> Nematoda</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sicily</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Viscera</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zoonosis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0165-7836</style></isbn><abstract><style face="normal" font="Arial">European anchovy Engraulis encrasicolus represents one of the principal target species for commercial fishing in Europe. This fish is mostly consumed in different raw dish preparations, which represents a major risk for the fish-borne zoonosis anisakiasis. The present study provides a detailed epidemiological report on ascaridoid larvae in E. encrasicolus from several fishing areas in the Mediterranean basin. Between June 2013 and June 2016, a total of 4152 specimens of E. encrasicolus were obtained from 13 sampling areas. Parasitological analysis was carried out using the UV-press detection method. Anisakis larvae (N = 547), identified by diagnostic allozymes and analyses of partial sequences of the EF1 +¦-1 region of nDNA and mtDNA cox2 gene, corresponded to Anisakis pegreffii. Additionally, sequence analyses of the ITS region of rDNA revealed the presence of Hysterothylacium aduncum larvae. The levels of infection with A. pegreffii significantly varied between the selected fishing areas. Fish from the Central and South Adriatic Sea showed the highest levels of infection. In contrast, anchovies from Southern Sicily, Ionian and Alboran Seas, were uninfected. A great majority of A. pegreffii larvae (95.8%) were located in the body cavity, whereas only a small percentage of them (4.2%) were detected in the flesh of the fish. A significant positive correlation between fish length and abundance of A. pegreffii was observed. The fish body condition index and infection levels observed in different sampling areas did not correlate significantly. The infection levels by H. aduncum also showed a significantly uneven distribution between different fishing areas of the Mediterranean Sea, and no larval specimens of H. aduncum were detected in examined fish flesh. This study is the first Mediterranean-wide epidemiological assessment of infection in the viscera and flesh of E. encrasicolus by A. pegreffii, an important causative agent of human anisakiasis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -CO - Croatia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fishres.2017.03.020</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.fishres.2017.03.020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Fish Res\20170423-CiprianiP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Fish Res\20170423-CiprianiP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Cipriani P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fishres.2017.03.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83800</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kiyota,K.</style></author><author><style face="normal" font="Arial"> Kawatsu,K.</style></author><author><style face="normal" font="Arial"> Sakata,J.</style></author><author><style face="normal" font="Arial"> Yoshimitsu,M.</style></author><author><style face="normal" font="Arial"> Akutsu,K.</style></author><author><style face="normal" font="Arial"> Satsuki-Murakami,T.</style></author><author><style face="normal" font="Arial"> Ki,M.</style></author><author><style face="normal" font="Arial"> Kajimura,K.</style></author><author><style face="normal" font="Arial"> Yamano,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development of monoclonal antibody-based ELISA for the quantification of orange allergen Cit s 2 in fresh and processed oranges</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="48" start="43">43-48</pages><volume><style face="normal" font="Arial">232</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cit s 2</style></keyword><keyword><style face="normal" font="Arial"> Citrus sinensis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Juice</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> orange</style></keyword><keyword><style face="normal" font="Arial"> Orange allergy</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">The aim of this study was to develop a monoclonal antibody (mAb)-based enzyme-linked immunosorbent assay (ELISA) for the quantification of a major allergen (Cit s 2) in fresh and processed oranges. Purified recombinant Cit s 2 (rCit s 2)-small ubiquitin-like modifier (SUMO) was used for the production of mAbs. In the optimized ELISA, the recovery of rCit s 2 from Navel oranges or orange juice was 107</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô132%, and the intra- and inter-assay coefficients of variation were 3.1</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô8.8% and 4.4</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô11%, respectively. The Cit s 2 content in fresh oranges was determined to be 1,800 -¦ 430 ng/g, while this content was much lower in the processed foods. The developed ELISA demonstrated high reproducibility, sensitivity, and accuracy, and this assay may help individuals with orange allergy by determining Cit s 2 quantities in food products and controlling their Cit s 2 intake</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">http://doi.org/10.1016/j.foodchem.2017.03.140</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.foodchem.2017.03.140</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-232-43-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-232-43-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Kiyota K</style></custom2><misc3><style face="normal" font="Arial">http://doi.org/10.1016/j.foodchem.2017.03.140</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83801</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feketea,G.</style></author><author><style face="normal" font="Arial"> Tsabouri,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Department, Amaliada Hospital Unit, Ilias General Hospital, Amaliada, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Common food colorants and allergic reactions in children: Myth or reality?</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="588" start="578">578-588</pages><volume><style face="normal" font="Arial">230</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Colorants</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Various additives, including food colorants (FCs), are used in the food industry to make food appealing to consumers and to add variety. Despite the widespread usage of FCs, adverse reactions related to their consumption, including reactions triggered by immune (immediate and delayed-type hypersensitivity) and non-immune (intolerance) mechanisms, are considered rare. There is a discrepancy between the perception of patients and parents (7.4%) and the reported prevalence of adverse reactions to additives (0.01-0.23%), which is higher in atopic individuals (2-7%). Documented reactions are mild, involving mainly the skin, and, rarely, anaphylaxis. A major problem in diagnosing reactions to FCs is identification of the offending agent(s), which is based on careful dietary history taking. Allergy testing is usually unrevealing, except for reaction to some natural colorants. Treatment consists of avoidance of the offending colorant as no successful desensitization procedures have been reported</style></abstract><notes><style face="normal" font="Arial">DA - 20170414IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.03.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28407952">PM:28407952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-230-578-88.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-230-578-88.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170414, Feketea G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.03.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. Electronic address: fzhu5@yahoo.com</style></auth-address><titles><title><style face="normal" font="Arial">Encapsulation and delivery of food ingredients using starch based systems</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="552" start="542">542-552</pages><volume><style face="normal" font="Arial">229</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">amylose</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carotenoids</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Complexation</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Drying</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> flavour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food ingredients</style></keyword><keyword><style face="normal" font="Arial"> Functional ingredients</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Polymers</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spray drying</style></keyword><keyword><style face="normal" font="Arial"> Spray-drying</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> Structural properties</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">Functional ingredients can be encapsulated by various wall materials for controlled release in food and digestion systems. Starch, as one of the most abundant natural carbohydrate polymers, is non-allergenic, GRAS, and cheap. There has been increasing interest of using starch in native and modified forms to encapsulate food ingredients such as flavours, lipids, polyphenols, carotenoids, vitamins, enzymes, and probiotics. Starches from various botanical sources in granular or amorphous forms are modified by chemical, physical, and/or enzymatic means to obtain the desired properties for targeted encapsulation. Other wall materials are also employed in combination with starch to facilitate some types of encapsulation. Various methods of crafting the starch-based encapsulation such as electrospinning, spray drying, antisolvent, amylose inclusion complexation, and nano-emulsification are introduced in this mini-review. The physicochemical and structural properties of the particles are described. The encapsulation systems can positively influence the controlled release of food ingredients in food and nutritional applications</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.02.101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28372213">PM:28372213</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-229-542-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-229-542-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Zhu F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.02.101</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Plundrich,N.J.</style></author><author><style face="normal" font="Arial"> Bansode,R.R.</style></author><author><style face="normal" font="Arial"> Foegeding,E.A.</style></author><author><style face="normal" font="Arial"> Williams,L.L.</style></author><author><style face="normal" font="Arial"> Lila,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Plants for Human Health Institute, Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, North Carolina Research Campus, 600 Laureate Way, Kannapolis, NC 28081, USA</style></auth-address><titles><title><style face="normal" font="Arial">Protein-bound Vaccinium fruit polyphenols decrease IgE binding to peanut allergens and RBL-2H3 mast cell degranulation in vitro</style></title><secondary-title><style face="normal" font="Arial">Food Funct</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Funct</style></full-title></periodical><pages end="1621" start="1611">1611-1621</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Binding Properties</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> Ionomycin</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanut proteins</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quercetin</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="Arial">Peanut allergy is a worldwide health concern. In this study, the natural binding properties of plant-derived polyphenols to proteins was leveraged to produce stable protein-polyphenol complexes comprised of peanut proteins and cranberry (Vaccinium macrocarpon Ait.) or lowbush blueberry (Vaccinium angustifolium Ait.) pomace polyphenols. Protein-bound and free polyphenols were characterized and quantified by multistep extraction of polyphenols from protein-polyphenol complexes. Immunoblotting was performed with peanut-allergic plasma to determine peanut protein-specific IgE binding to unmodified peanut protein, or to peanut protein-polyphenol complexes. In an allergen model system, RBL-2H3 mast cells were exposed to peanut protein-polyphenol complexes and evaluated for their inhibitory activity on ionomycin-induced degranulation (beta-hexosaminidase and histamine). Among the evaluated polyphenolic compounds from protein-polyphenol complex eluates, quercetin, - in aglycone or glycosidic form - was the main phytochemical identified to be covalently bound to peanut proteins. Peanut protein-bound cranberry and blueberry polyphenols significantly decreased IgE binding to peanut proteins at p &lt; 0.05 (38% and 31% decrease, respectively). Sensitized RBL-2H3 cells challenged with antigen and ionomycin in the presence of protein-cranberry and blueberry polyphenol complexes showed a significant (p &lt; 0.05) reduction in histamine and beta-hexosaminidase release (histamine: 65.5% and 65.8% decrease; beta-hexosaminidase: 60.7% and 45.4% decrease, respectively). The modification of peanut proteins with cranberry or blueberry polyphenols led to the formation of peanut protein-polyphenol complexes with significantly reduced allergenic potential. Future trials are warranted to investigate the immunomodulatory mechanisms of these protein-polyphenol complexes and the role of quercetin in their hypoallergenic potential</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2042-650X (Electronic)IS - 2042-6496 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1039/C7FO00249A</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294257">PM:28294257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Funct\20170315-PlundrichNJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Funct\20170315-PlundrichNJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Plundrich NJ</style></custom2><misc3><style face="normal" font="Arial">10.1039/C7FO00249A</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Angelis,E.</style></author><author><style face="normal" font="Arial"> Pilolli,R.</style></author><author><style face="normal" font="Arial"> Bavaro,S.L.</style></author><author><style face="normal" font="Arial"> Monaci,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Sciences of Food Production, National Research Council of Italy (ISPA-CNR), Via Amendola 122/O, 70126, Bari, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Insight into the gastro-duodenal digestion resistance of soybean proteins and potential implications for residual immunogenicity</style></title><secondary-title><style face="normal" font="Arial">Food Funct</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Funct</style></full-title></periodical><pages end="1610" start="1599">1599-1610</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> duodenal digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein</style></keyword><keyword><style face="normal" font="Arial"> Soybean Proteins</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Trypsin Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="Arial">Soy is an important component of the human diet thanks to its nutritional value and high protein content; however, it also represents a risk for allergenic consumers due to its potential to trigger adverse reactions in sensitized individuals. The putative correlation between immunoreactivity and resistance to the human gastrointestinal (GI) digestion has drawn attention to investigating soybean proteins digestibility. In this work, we provided further insights into this field by performing in vitro simulated GI digestion experiments directly on ground soybean seeds, to provide more realistic results obtained from the digestion of the whole food matrix. Soybean digestion products were analyzed by SDS-PAGE followed by untargeted HPLC-MS/MS analysis and the final data were software treated to enable protein/peptide identification. The latter allowed monitoring the proteolytic degradation of the main soybean proteins during the gastric and duodenal phases. In particular, beta-conglycinin and trypsin inhibitors showed the highest resistance to the combined activity of GI enzymes, showing a partial degradation at the end of the duodenal phase as ascertained by the strong electrophoretic bands displayed at 50 kDa and 20 kDa, respectively. Glycinin subunits also presented, even if to a lower extent, resistance to the complete proteolytic degradation, as demonstrated by polypeptide fragments with molecular weight lower than 20 kDa displayed in the gel at the end of duodenal digestion. In addition, by bioinformatics analysis it was demonstrated that the GI resistant fragments of the allergenic proteins, beta-conglycinin and glycinin, retained in their primary structure linear epitopes potentially able to trigger an immunoreaction when exposed to the intestinal mucosa. Moreover, such resistant peptides also presented a structural homology with epitope sequences recognized in other legume species, presenting a potential risk of adverse cross-reaction for a larger category of allergic consumers</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2042-650X (Electronic)IS - 2042-6496 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1039/c6fo01788f</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294226">PM:28294226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Funct\20170315-DeAngelisE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Funct\20170315-DeAngelisE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, De Angelis E</style></custom2><misc3><style face="normal" font="Arial">10.1039/c6fo01788f</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmiere,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Center of Legal Medicine, Chemin de la Vulliette 4, 1000, Lausanne 25, Switzerland. Electronic address: cristian.palmiere@chuv.ch</style></auth-address><titles><title><style face="normal" font="Arial">Determination of specific IgE in pericardial fluid</style></title><secondary-title><style face="normal" font="Arial">Forensic Sci Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Forensic Sci Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1872-6283 (Electronic)IS - 0379-0738 (Linking)LA - engPT - LetterCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.forsciint.2017.02.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28336197">PM:28336197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Forensic Sci Int\20170324-PalmiereC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Forensic Sci Int\20170324-PalmiereC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Palmiere C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.forsciint.2017.02.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uribe-Echeverry,P.T.</style></author><author><style face="normal" font="Arial"> Lopez-Gartner,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Health Faculty, University of Manizales, Street 9a # 19-03, Manizales, ColombiaDepartment, Natural Sciences Faculty, University of Caldas, Street 65 # 26-10, Manizales, Colombia, german.lopez@ucaldas.edu.co</style></auth-address><titles><title><style face="normal" font="Arial">Fungal immunomodulatory proteins in the context of biomedicine</style></title><secondary-title><style face="normal" font="Arial">Front Biosci (Elite Ed)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Biosci (Elite Ed)</style></full-title></periodical><pages end="306" start="286">286-306</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharides</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">Fungi represent a large group of biodiverse microorganisms with potential applications ranging from industrial fields to the treatment for human diseases. A large number of pharmacologically active compounds including terpenoids, polysaccharides and proteins have been derived from these microorganisms. Fungal Immunomodulatory Proteins (FIPs) are a group of active compounds that are being considered for the treatment of asthma, allergy, autoimmune diseases and cancer. Here, we discuss the discovery, heterologous production bioactive mechanisms of action and their potential use in biomedicine</style></abstract><notes><style face="normal" font="Arial">DA - 20170414IS - 1945-0508 (Electronic)IS - 1945-0494 (Linking)LA - engPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410152">PM:28410152</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170414, Uribe-Echeverry PT</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dimitriades,V.R.</style></author><author><style face="normal" font="Arial"> Devlin,V.</style></author><author><style face="normal" font="Arial"> Pittaluga,S.</style></author><author><style face="normal" font="Arial"> Su,H.C.</style></author><author><style face="normal" font="Arial"> Holland,S.M.</style></author><author><style face="normal" font="Arial"> Wilson,W.</style></author><author><style face="normal" font="Arial"> Dunleavy,K.</style></author><author><style face="normal" font="Arial"> Shah,N.N.</style></author><author><style face="normal" font="Arial"> Freeman,A.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Infectious Diseases, Immunology &amp; Allergy, University of California Davis Medical Center , Sacramento, CA , USA</style></auth-address><titles><title><style face="normal" font="Arial">DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> CT scan</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> DOCK8</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory B cell</style></keyword><keyword><style face="normal" font="Arial"> memory B cells</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Transplants</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Warts</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Dedicator of cytokinesis 8 (DOCK8) deficiency is an autosomal recessive, combined immunodeficiency within the spectrum of hyper-IgE syndromes. Epstein-Barr virus-positive lymphomatoid granulomatosis (LYG) (EBV + LYG) is a rare diagnosis and a previously unreported presentation of DOCK8 deficiency. A 10-year-old girl was initially evaluated for mild eczema and recurrent sinopulmonary infections. She had normal immunoglobulins with elevated IgE, poor polysaccharide response with low switched memory B cells, low CD4 count, and normal mitogen and antigen responses. Despite clinical improvement following immunoglobulin replacement, a prolonged cough prompted a CT scan, which showed nodules. Biopsy identified a Grade 2 EBV + LYG. Due to an inadequate response with chemotherapy, further workup for primary immunodeficiency was performed. With her symptoms of eczema and IgE elevation, along with her brother's history of recurrent sinopulmonary infections and warts, targeted sequencing of DOCK8 was performed revealing compound heterozygous mutations for the two siblings. Both patients were successfully transplanted with resolution of the LYG and warts, respectively. This is the first reported case of LYG in DOCK8 deficiency. The EBV-driven lymphoproliferative disease along with the infection history in the brother led to the diagnosis of DOCK8 deficiency and curative hematopoietic stem cell transplants</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2296-2360 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293550">PM:28293550</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\20170315-DimitriadesVR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\20170315-DimitriadesVR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Dimitriades VR</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wagh,A.D.</style></author><author><style face="normal" font="Arial"> Sharma,M.</style></author><author><style face="normal" font="Arial"> Mahapatra,J.</style></author><author><style face="normal" font="Arial"> Chatterjee,A.</style></author><author><style face="normal" font="Arial"> Jain,M.</style></author><author><style face="normal" font="Arial"> Addepalli,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, SPP SPTM, SVKM's NMIMSMumbai, India</style></auth-address><titles><title><style face="normal" font="Arial">Investigation into the Role of PI3K and JAK3 Kinase Inhibitors in Murine Models of Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pharmacol</style></full-title></periodical><pages end="" start="82">82-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Janus kinase</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is a clinical disorder commonly characterized by chronic eosinophilic inflammation, remodeling and hyper responsiveness of the airways. However, the kinases like Phosphoinositide 3 kinase (PI3K) and Janus kinase 3 (JAK3) are involved in mast cell proliferation, activation, recruitment, migration, and prolonged survival of inflammatory cells. The present study was designed to evaluate the in-vivo comparative effects of two kinase inhibitors on airway inflammation and airway remodeling in acute and chronic models of asthma. Mice were sensitized twice intra-peritoneally and then challenged by inhalation with ovalbumin (OVA). They developed an extensive inflammatory response, goblet cell hyperplasia, collagen deposition, airway smooth muscle thickening similar to pathologies observed in human asthma. The effects of PI3K inhibitor (30 mg/kg, p.o), JAK3 inhibitor (30 mg/kg, p.o) and Dexamethasone (0.3 mg/kg) on airway inflammation and remodeling in OVA sensitized/challenged BALB/c mice were evaluated. Twenty-four hours after the final antigen challenge, bronchoalveolar lavage (BAL) and histological examinations were carried out. It was observed that kinase inhibitors significantly reduced airway inflammation as evidenced by the decrease in pro inflammatory cytokines in BALF and lung homogenate and inflammatory cell count in sensitized mice after allergen challenge. Lung histological analysis showed increased infiltration of inflammatory cells, hyperplasia of goblet cells and the collagen deposition, which were significantly reduced with kinase inhibitor. In conclusion, our data suggest that PI3K and JAK3 inhibitors showed promising alternative therapeutic activity in asthma, which might significantly counteract the airway inflammation in patients with allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.3389/fphar.2017.00082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293189">PM:28293189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pharmacol\2017-8-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pharmacol\2017-8-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Wagh AD</style></custom2><misc3><style face="normal" font="Arial">10.3389/fphar.2017.00082</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maerle,A.V.</style></author><author><style face="normal" font="Arial"> Voronina,D.V.</style></author><author><style face="normal" font="Arial"> Dobrochaeva,K.L.</style></author><author><style face="normal" font="Arial"> Galanina,O.E.</style></author><author><style face="normal" font="Arial"> Alekseev,L.P.</style></author><author><style face="normal" font="Arial"> Bovin,N.V.</style></author><author><style face="normal" font="Arial"> Zavriev,S.K.</style></author><author><style face="normal" font="Arial"> Ryazantsev,D.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">JSC NPF DNA-Technology, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="Arial">Immuno-PCR technology for detection of natural human antibodies against Lec disaccharide</style></title><secondary-title><style face="normal" font="Arial">Glycoconj J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Glycoconj J</style></full-title></periodical><pages end="205" start="199">199-205</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> immuno-PCR</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">The development of an immuno-PCR assay for quantitation of low amounts of anti-glycan human antibodies is described. The sensitivity of the assay for determination of low-affinity anti-LeC IgM has been found to be 4 ng/ml (~100 pg per sample), thus being two orders of magnitude higher compared to the conventional ELISA with the same antigen</style></abstract><notes><style face="normal" font="Arial">DA - 20170116IS - 1573-4986 (Electronic)IS - 0282-0080 (Linking)LA - engPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10719-016-9751-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28091939">PM:28091939</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Glycoconj J\2017-34-199-205.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Glycoconj J\2017-34-199-205.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170116, Maerle AV</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10719-016-9751-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Borriello,F.</style></author><author><style face="normal" font="Arial"> Iannone,R.</style></author><author><style face="normal" font="Arial"> Marone,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), School of Medicine, University of Naples Federico II, Via S. Pansini 5, 80131, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Histamine Release from Mast Cells and Basophils</style></title><secondary-title><style face="normal" font="Arial">Handb Exp Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Handb Exp Pharmacol</style></abbr-1></periodical><pages end="139" start="121">121-139</pages><volume><style face="normal" font="Arial">241</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Amines</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil histamine release</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cytoplasmic Granules</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inhibitory receptors</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Proteoglycans</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serotonin</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="Arial">Mast cells and basophils represent the most relevant source of histamine in the immune system. Histamine is stored in cytoplasmic granules along with other amines (e.g., serotonin), proteases, proteoglycans, cytokines/chemokines, and angiogenic factors and rapidly released upon triggering with a variety of stimuli. Moreover, mast cell and basophil histamine release is regulated by several activating and inhibitory receptors. The engagement of different receptors can trigger different modalities of histamine release and degranulation. Histamine released from mast cells and basophils exerts its biological activities by activating four G protein-coupled receptors, namely H1R, H2R, H3R (expressed mainly in the brain), and the recently identified H4R. While H1R and H2R activation accounts mainly for some mast cell- and basophil-mediated allergic disorders, the selective expression of H4R on immune cells is uncovering new roles for histamine (possibly derived from mast cells and basophils) in allergic, inflammatory, and autoimmune disorders. Thus, the in-depth knowledge of mast cell and basophil histamine release and its biologic effects is poised to uncover new therapeutic avenues for a wide spectrum of disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 0171-2004 (Print)IS - 0171-2004 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/164_2017_18</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332048">PM:28332048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Handb Exp Pharmacol\20170323-BorrielloF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Handb Exp Pharmacol\20170323-BorrielloF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Borriello F</style></custom2><misc3><style face="normal" font="Arial">10.1007/164_2017_18</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jappe,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Forschungsgruppe Klinische und Molekulare Allergologie, Forschungszentrum Borstel, Parkallee 35, 23845, Borstel, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Molecular-allergological aspects of allergen-specific immunotherapy]</style></title><secondary-title><style face="normal" font="Arial">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hautarzt</style></full-title></periodical><pages end="281" start="271">271-281</pages><volume><style face="normal" font="Arial">68</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (SIT) does not achieve 100% efficacy, nor is there a reliable marker for therapy failure. However, advances in molecular allergology over the past few years have allowed a significantly improved characterization of the patients using molecular-allergological analysis methods (molecular phenotyping). Thus, major and minor allergens can be identified. In addition, the marker allergens for the severity of an allergic reaction, the pathological and therapeutic predictive marker allergens, and sensitization patterns are identified</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00105-017-3958-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293695">PM:28293695</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hautarzt\2017-68-271-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hautarzt\2017-68-271-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Jappe U</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00105-017-3958-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Allam,J.P.</style></author><author><style face="normal" font="Arial"> Novak,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik und Poliklinik fur Dermatologie und Allergologie, Universitatsklinikum Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Deutschland</style></auth-address><titles><title><style face="normal" font="Arial">[Immunological mechanisms of allergen-specific immunotherapy]</style></title><secondary-title><style face="normal" font="Arial">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hautarzt</style></full-title></periodical><pages end="270" start="265">265-270</pages><volume><style face="normal" font="Arial">68</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy is accompanied by multiple changes on the cellular and humoral level. A shift of Th2 immune responses towards immune responses of the Th1 type, which goes along with an increase of regulatory T cells and B cells, IL-10 as well as reduction of effector cells and eosinophils in the tissue, combined with lower IgE production in favor of higher IgG4 production, are regarded as key mechanisms of allergen-specific immunotherapy . A better understanding of immunologic pathways of specific immunotherapy would be essential for the improvement of this therapy as well as for the development of reliable biomarkers capable to monitor therapeutic responses as well as compliance of the patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00105-017-3961-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28299382">PM:28299382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hautarzt\2017-68-265-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hautarzt\2017-68-265-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Allam JP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00105-017-3961-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomas,K.S.</style></author><author><style face="normal" font="Arial"> Bradshaw,L.E.</style></author><author><style face="normal" font="Arial"> Sach,T.H.</style></author><author><style face="normal" font="Arial"> Cowdell,F.</style></author><author><style face="normal" font="Arial"> Batchelor,J.M.</style></author><author><style face="normal" font="Arial"> Lawton,S.</style></author><author><style face="normal" font="Arial"> Harrison,E.F.</style></author><author><style face="normal" font="Arial"> Haines,R.H.</style></author><author><style face="normal" font="Arial"> Ahmed,A.</style></author><author><style face="normal" font="Arial"> Dean,T.</style></author><author><style face="normal" font="Arial"> Burrows,N.P.</style></author><author><style face="normal" font="Arial"> Pollock,I.</style></author><author><style face="normal" font="Arial"> Buckley,H.K.</style></author><author><style face="normal" font="Arial"> Williams,H.C.</style></author><author><style face="normal" font="Arial"> Llewellyn,J.</style></author><author><style face="normal" font="Arial"> Crang,C.</style></author><author><style face="normal" font="Arial"> Grundy,J.D.</style></author><author><style face="normal" font="Arial"> Guiness,J.</style></author><author><style face="normal" font="Arial"> Gribbin,A.</style></author><author><style face="normal" font="Arial"> Wake,E.V.</style></author><author><style face="normal" font="Arial"> Mitchell,E.J.</style></author><author><style face="normal" font="Arial"> Brown,S.J.</style></author><author><style face="normal" font="Arial"> Montgomery,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK</style></auth-address><titles><title><style face="normal" font="Arial">Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial</style></title><secondary-title><style face="normal" font="Arial">Health Technol Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Health Technol Assess</style></full-title></periodical><pages end="260" start="1">1-260</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">16</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> Adherence</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clothing</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Decision Making</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emollients</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisations</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Silk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects the quality of life of children and their families. The role of specialist clothing in the management of AE is poorly understood. OBJECTIVES: To assess the effectiveness and cost-effectiveness of silk garments for the management of AE in children with moderate to severe disease. DESIGN: Parallel-group, observer-blind, randomised controlled trial of 6 months' duration, followed by a 2-month observational period. A nested qualitative study evaluated the beliefs of trial participants, health-care professionals and health-care commissioners about the use of silk garments for AE. SETTING: Secondary care and the community in five UK centres. PARTICIPANTS: Children aged 1-15 years with moderate or severe AE. INTERVENTIONS: Participants were randomised (1 : 1 using online randomisation) to standard care or standard care plus 100% silk garments made from antimicrobially protected knitted sericin-free silk [DermaSilkTM (AlPreTec Srl, San Dona di Piave, Italy) or DreamSkinTM (DreamSkin Health Ltd, Hatfield, UK)]. Three sets of garments were supplied per participant, to be worn for up to 6 months (day and night). At 6 months the standard care group received the garments to use for the remaining 2-month observational period. MAIN OUTCOME MEASURES: Primary outcome - AE severity using the Eczema Area and Severity Index (EASI) assessed at 2, 4 and 6 months, by nurses blinded to treatment allocation. EASI scores were log-transformed for analysis. Secondary outcomes - patient-reported eczema symptoms (Patient Oriented Eczema Measure); global assessment of severity (Investigator Global Assessment); quality of life of the child (Atopic Dermatitis Quality of Life, Child Health Utility - 9 Dimensions), family (Dermatitis Family Impact Questionnaire) and main carer (EuroQoL-5 Dimensions-3 Levels); use of standard eczema treatments (e.g. emollients, topical corticosteroids); and cost-effectiveness. The acceptability and durability of the clothing, and adherence to wearing the garments, were assessed by parental/carer self-report. Safety outcomes - number of skin infections and hospitalisations for AE. RESULTS: A total of 300 children were randomised (26 November 2013 to 5 May 2015): 42% female, 79% white, mean age 5 years. The primary analysis included 282 out of 300 (94%) children (n = 141 in each group). Garments were worn for at least 50% of the time by 82% of participants. Geometric mean EASI scores at baseline, 2, 4 and 6 months were 8.4, 6.6, 6.0, 5.4 for standard care and 9.2, 6.4, 5.8, 5.4 for silk clothing, respectively. There was no evidence of difference between the groups in EASI score averaged over all follow-up visits adjusted for baseline EASI score, age and centre (ratio of geometric means 0.95, 95% confidence interval 0.85 to 1.07; p = 0.43). This confidence interval is equivalent to a difference of -1.5 to 0.5 in the original EASI scale units. Skin infections occurred in 39 out of 141 (28%) and 36 out of 142 (25%) participants for standard care and silk clothing groups, respectively. The incremental cost per QALY of silk garments for children with moderate to severe eczema was pound56,811 from a NHS perspective in the base case. Sensitivity analyses supported the finding that silk garments do not appear to be cost-effective within currently accepted thresholds. LIMITATIONS: Knowledge of treatment allocation may have affected behaviour and outcome reporting for some of the patient-reported outcomes. CONCLUSIONS: The addition of silk garments to standard AE care is unlikely to improve AE severity, or to be cost-effective compared with standard care alone, for children with moderate or severe AE. This trial adds to the evidence base to guide clinical decision-making. FUTURE WORK: Non-pharmacological interventions for the management of AE remain a research priority among patients. TRIAL REGISTRATION: Current Controlled Trials ISRCTN77261365. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 16. See the NIHR Journals Library website for further project information</style></abstract><notes><style face="normal" font="Arial">DA - 20170414IS - 2046-4924 (Electronic)IS - 1366-5278 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.3310/hta21160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28409557">PM:28409557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Health Technol Assess\2017-21-1-260.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Health Technol Assess\2017-21-1-260.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170414, Thomas KS</style></custom2><misc3><style face="normal" font="Arial">10.3310/hta21160</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barfod,K.K.</style></author><author><style face="normal" font="Arial"> Roggenbuck,M.</style></author><author><style face="normal" font="Arial"> Al-Shuweli,S.</style></author><author><style face="normal" font="Arial"> Fakih,D.</style></author><author><style face="normal" font="Arial"> Sorensen,S.J.</style></author><author><style face="normal" font="Arial"> Sorensen,G.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Research Centre for the Working Environment, Lerso Parkalle 105, 2100 Copenhagen O, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Alterations of the murine gut microbiome in allergic airway disease are independent of surfactant protein D</style></title><secondary-title><style face="normal" font="Arial">Heliyon</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Heliyon</style></abbr-1></periodical><pages end="" start="e00262">e00262-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> SP-D</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> surfactant protein D</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> working environment</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: SP-D is an important host defense lectin in innate immunity and SP-D deficient mice show several abnormal immune effects and are susceptible to allergen-induced airway disease. At the same time, host microbiome interactions play an important role in the development of allergic airway disease, and alterations to gut microbiota have been linked to airway disease through the gut-lung axis. Currently, it is unknown if the genotype (Sftpd-/- or Sftpd+/+) of the standard SP-D mouse model can affect the host microbiota to such an degree that it would overcome the cohousing effect on microbiota and interfere with the interpretation of immunological data from the model. Generally, little is known about the effect of the SP-D protein in itself and in combination with airway disease on the microbiota. In this study, we tested the hypothesis that microbiome composition would change with the lack of SP-D protein and presence of allergic airway disease in the widely used SP-D-deficient mouse model. RESULTS: We describe here for the first time the lung and gut microbiota of the SP-D mouse model with OVA induced allergic airway disease. After the challenge animals were killed and fecal samples were taken from the caecum and lungs were subjected to bronchoalveolar lavage for comparison of gut and lung microbiota by Illumina 16S rRNA gene sequencing. A significant community shift was observed in gut microbiota after challenge with OVA. However, the microbial communities were not significantly different between SP-D deficient and wild type mice from the same cages in either naive or OVA treated animals. Wild type animals did however show the largest variation between mice. CONCLUSIONS: Our results show that the composition of the microbiota is not influenced by the SP-D deficient genotype under naive or OVA induced airway disease. However, OVA sensitization and pulmonary challenge did alter the gut microbiota, supporting a bidirectional lung-gut crosstalk. Future mechanistic investigations of the influence of induced allergic airway disease on gut microbiota are warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 2405-8440 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.heliyon.2017.e00262</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28367508">PM:28367508</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Heliyon\2017-3-e00262.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Heliyon\2017-3-e00262.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Barfod KK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.heliyon.2017.e00262</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rode,N.O.</style></author><author><style face="normal" font="Arial"> Soroye,P.</style></author><author><style face="normal" font="Arial"> Kassen,R.</style></author><author><style face="normal" font="Arial"> Rundle,H.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, University of Ottawa, Ottawa, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Air-borne genotype by genotype indirect genetic effects are substantial in the filamentous fungus Aspergillus nidulans</style></title><secondary-title><style face="normal" font="Arial">Heredity (Edinb)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Heredity (Edinb)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus nidulans</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth rate</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="Arial">Genotype by genotype indirect genetic effects (G x G IGEs) occur when the phenotype of an individual is influenced by an interaction between its own genotype and those of neighbour individuals. Little is known regarding the relative importance of G x G IGEs compared with other forms of direct and indirect genetic effects. We quantified the relative importance of IGEs in the filamentous fungus Aspergillus nidulans, a species in which IGEs are likely to be important as air-borne social interactions are known to affect growth. We used a collection of distantly related wild isolates, lab strains and a set of closely related mutation accumulation lines to estimate the contribution of direct and indirect genetic effects on mycelium growth rate, a key fitness component. We found that indirect genetic effects were dominated by G x G IGEs that occurred primarily between a focal genotype and its immediate neighbour within a vertical stack, and these accounted for 11% of phenotypic variation. These results indicate that G x G IGEs may be substantial, at least in some systems, and that the evolutionary importance of these interactions may be underappreciated, especially in microbes. We advocate for a wider use of the IGE framework in both applied (for example, choice of varietal mixtures in plant breeding) and evolutionary genetics (kin selection/kin competition studies).Heredity advance online publication, 15 March 2017; doi:10.1038/hdy.2017.9</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1365-2540 (Electronic)IS - 0018-067X (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1038/hdy.2017.9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28295032">PM:28295032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Heredity (Edinb)\20170315-RodeNO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Heredity (Edinb)\20170315-RodeNO.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Heredity (Edinb)\20170315-RodeNO.xls</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Heredity (Edinb)\20170315-RodeNO.xls</url></image-urls></urls><custom2><style face="normal" font="Arial">20170315, Rode NO</style></custom2><misc3><style face="normal" font="Arial">10.1038/hdy.2017.9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Haxel,B.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Hals-, Nasen- und Ohrenheilkunde, AMEOS Klinikum Haldensleben, Kiefholzstr. 27, 39340, Haldensleben, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Relevance of nasal provocation testing in house dust mite allergy]</style></title><secondary-title><style face="normal" font="Arial">HNO</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">HNO</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="Arial">Patients with house dust mite allergies frequently exhibit very different symptoms to those allergic to other inhalant allergens. The frequency of comorbid allergic asthma in these patients is increased. Therefore, diagnosing patients with suspected house dust mite allergies can be difficult. It is important to distinguish between sensitization to an allergen and a clinically relevant allergy. Nasal provocation testing (NPT) is a reliable method to identify patients suitable for a causal treatment (specific immunotherapy). Position papers on methodology and interpretation of NPT data are available. Skin prick and allergen-specific IgE tests reveal a reasonable correlation with NPT results, although this is inexact to some extent. Performance of NPT in patients with suspected house dust mite allergy is important in individuals with questionable symptoms and unclear skin and blood test results, particularly prior to initiation of allergen immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 1433-0458 (Electronic)IS - 0017-6192 (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00106-017-0342-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28303289">PM:28303289</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\HNO\20170317-HaxelBR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\HNO\20170317-HaxelBR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Haxel BR</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00106-017-0342-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pavic,I.</style></author><author><style face="normal" font="Arial"> Kolacek,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Growth of Children with Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Horm Res Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Horm Res Paediatr</style></abbr-1></periodical><pages end="100" start="91">91-100</pages><volume><style face="normal" font="Arial">88</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietician</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> nutrient deficiencies</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Requirements</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of food allergy in children is increasing worldwide. Strict avoidance of identified allergens from the diet is still the cornerstone of the management of food allergies. There are widespread concerns that food allergy and elimination diet may predispose children to nutrient deficiencies and growth failure. AIM: The aim of this paper was to review the current evidence on growth of children suffering from food allergy. Summarised is literature on the effects of the number and type of offending allergens, the child's age and affected organ system, as well as the importance of supervision by a dietician/nutritionist. CONCLUSION: Children suffering from food allergy are stunted at the time of diagnosis and during the elimination diets, irrespective whether or not their nutritional requirements were fulfilled, and/or were under the control of a dietician. This underscores the need for further studies to obtain more precise insight into and better understanding of the mechanisms contributing to growth failure in children suffering from food allergy.</style></abstract><notes><style face="normal" font="Arial">DA - 20170330IS - 1663-2826 (Electronic)IS - 1663-2818 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.1159/000462973</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359060">PM:28359060</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="Arial">20170330, Pavic I</style></custom2><misc3><style face="normal" font="Arial">10.1159/000462973</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mo,Z.</style></author><author><style face="normal" font="Arial"> Nong,Y.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author><author><style face="normal" font="Arial"> Shao,M.</style></author><author><style face="normal" font="Arial"> Liao,X.</style></author><author><style face="normal" font="Arial"> Go,K.</style></author><author><style face="normal" font="Arial"> Lavis,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control , Guangxi , China</style></auth-address><titles><title><style face="normal" font="Arial">Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="7" start="1">1-7</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hemagglutination</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="Arial">A split-virion trivalent inactivated influenza vaccine produced according to the Chinese pharmacopeia (Shz-IIV3) has been commercially available in China since 2014. Here, we describe the results of a phase IV open-label trial to describe the immunogenicity and safety of the 2014-2015 Northern Hemisphere formulation of Shz-IIV3 in individuals >/= 6 months of age. Subjects 6-35 months of age received 2 half-doses of Shz-IIV3 (0.25 ml) 28 d apart, and subjects >/= 3 y of age received a single full dose (0.5 ml). The study included 602 subjects. Except for the A (H3N2) strain in subjects 3-17 years, geometric mean hemagglutination inhibition titer ratios were >/= 10 and rates of seroconversion/significant increase in titer were >/= 78% in all age groups. For the H3N2 strain in subjects 3-17 years, the geometric mean titer ratio was 3.8 and the rate of seroconversion/significant increase was 56%. Post-vaccination seroprotection rates were >/= 88% for all strains in all age groups. The most common solicited reactions were injection-site pain/tenderness and fever, most of which were grade 1 and resolved within 3 d. Vaccine-related unsolicited adverse events were reported only by subjects 6-23 months, most of which were mild abnormal crying and irritability. No vaccine-related serious adverse events and no deaths were reported. No new safety signals or unexpected safety events occurred, although an immediate anaphylactic skin reaction occurred in one subject. This study confirmed that the 2014-2015 Northern Hemisphere formulation of Shz-IIV3 was well tolerated and highly immunogenic in subjects >/= 6 months of age</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - China -CO - France -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1285475</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28301266">PM:28301266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170316-MoZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170316-MoZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Mo Z</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1285475</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Justo,X.</style></author><author><style face="normal" font="Arial"> Diaz,I.</style></author><author><style face="normal" font="Arial"> Gil,J.J.</style></author><author><style face="normal" font="Arial"> Gastaminza,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Medical Device for Automated Prick Test Reading</style></title><secondary-title><style face="normal" font="Arial">IEEE J Biomed Health Inform</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">IEEE J Biomed Health Inform</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Device</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="Arial">Allergy tests are routinely performed in most hospitals everyday. However, measuring the outcomes of these tests is still a very laborious manual task. Current methods and systems lack of precision and repeatability. This work presents a novel mechatronic system that is able to scan a patient's entire arm and provide allergists with precise measures of wheals for diagnosis. The device is based on 3D laser technology and specific algorithms have been developed to process the information gathered. This system aims to automate the reading of skin prick tests and make gains in speed, accuracy and reliability. Several experiments have been performed to evaluate the performance of the system</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 2168-2208 (Electronic)IS - 2168-2194 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1109/JBHI.2017.2680840</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362597">PM:28362597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\IEEE J Biomed Health Inform\20170331-JustoX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\IEEE J Biomed Health Inform\20170331-JustoX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Justo X</style></custom2><misc3><style face="normal" font="Arial">10.1109/JBHI.2017.2680840</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sabatel,C.</style></author><author><style face="normal" font="Arial"> Radermecker,C.</style></author><author><style face="normal" font="Arial"> Fievez,L.</style></author><author><style face="normal" font="Arial"> Paulissen,G.</style></author><author><style face="normal" font="Arial"> Chakarov,S.</style></author><author><style face="normal" font="Arial"> Fernandes,C.</style></author><author><style face="normal" font="Arial"> Olivier,S.</style></author><author><style face="normal" font="Arial"> Toussaint,M.</style></author><author><style face="normal" font="Arial"> Pirottin,D.</style></author><author><style face="normal" font="Arial"> Xiao,X.</style></author><author><style face="normal" font="Arial"> Quatresooz,P.</style></author><author><style face="normal" font="Arial"> Sirard,J.C.</style></author><author><style face="normal" font="Arial"> Cataldo,D.</style></author><author><style face="normal" font="Arial"> Gillet,L.</style></author><author><style face="normal" font="Arial"> Bouabe,H.</style></author><author><style face="normal" font="Arial"> Desmet,C.J.</style></author><author><style face="normal" font="Arial"> Ginhoux,F.</style></author><author><style face="normal" font="Arial"> Marichal,T.</style></author><author><style face="normal" font="Arial"> Bureau,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Cellular and Molecular Immunology, GIGA Research, University of Liege, 4000 Liege, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Exposure to Bacterial CpG DNA Protects from Airway Allergic Inflammation by Expanding Regulatory Lung Interstitial Macrophages</style></title><secondary-title><style face="normal" font="Arial">Immunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunity</style></full-title></periodical><pages end="473" start="457">457-473</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> CpG DNA</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> trafficking</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="Arial">Living in a microbe-rich environment reduces the risk of developing asthma. Exposure of humans or mice to unmethylated CpG DNA (CpG) from bacteria reproduces these protective effects, suggesting a major contribution of CpG to microbe-induced asthma resistance. However, how CpG confers protection remains elusive. We found that exposure to CpG expanded regulatory lung interstitial macrophages (IMs) from monocytes infiltrating the lung or mobilized from the spleen. Trafficking of IM precursors to the lung was independent of CCR2, a chemokine receptor required for monocyte mobilization from the bone marrow. Using a mouse model of allergic airway inflammation, we found that adoptive transfer of IMs isolated from CpG-treated mice recapitulated the protective effects of CpG when administered before allergen sensitization or challenge. IM-mediated protection was dependent on IL-10, given that Il10-/- CpG-induced IMs lacked regulatory effects. Thus, the expansion of regulatory lung IMs upon exposure to CpG might underlie the reduced risk of asthma development associated with a microbe-rich environment</style></abstract><notes><style face="normal" font="Arial">DA - 20170322IS - 1097-4180 (Electronic)IS - 1074-7613 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - United Kingdom -CO - France -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.immuni.2017.02.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28329706">PM:28329706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunity\20170322-SabatelC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunity\20170322-SabatelC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170322, Sabatel C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.immuni.2017.02.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tauber,P.A.</style></author><author><style face="normal" font="Arial"> Pickl,W.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Immunology, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacological targeting of allergen-specific T lymphocytes</style></title><secondary-title><style face="normal" font="Arial">Immunol Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Lett</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immune system</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic drug</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic drugs</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="Arial">Allergic disorders are the result of a complex pathophysiology, involving major cellular lineages and a multitude of humoral factors of the innate and adaptive immune system, and has the tendency to involve multiple organs. Consequently, even standard pharmacological treatment of allergies is rarely specific but usually targets more than one pathway/cellular system at a time. Accordingly, many of the classic anti-allergic drugs have a critical impact also on T helper cells, which are pivotal not only during the sensitization but also the maintenance phase of allergic diseases. Recent years have seen a dramatic increase of novel drugs with the potency to interfere, more or less specifically, with T lymphocyte function, which might, possibly together with classic anti-allergic drugs, help harnessing one of the central cellular players in allergic responses. A major theme in the years to come will be a thoughtful combination of previously established with recently developed treatment modalities</style></abstract><notes><style face="normal" font="Arial">DA - 20170321IS - 1879-0542 (Electronic)IS - 0165-2478 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imlet.2017.03.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28322861">PM:28322861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Lett\20170321-TauberPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Lett\20170321-TauberPA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170321, Tauber PA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imlet.2017.03.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farrokhi,S.</style></author><author><style face="normal" font="Arial"> Abbasirad,N.</style></author><author><style face="normal" font="Arial"> Movahed,A.</style></author><author><style face="normal" font="Arial"> Khazaei,H.A.</style></author><author><style face="normal" font="Arial"> Pishjoo,M.</style></author><author><style face="normal" font="Arial"> Rezaei,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Asthma &amp; Allergy, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran</style></auth-address><titles><title><style face="normal" font="Arial">TLR9-based immunotherapy for the treatment of allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Immunotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunotherapy</style></full-title></periodical><pages end="346" start="339">339-346</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immune system</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> pathogen-associated molecular pattern</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 immune response</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TLRs</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Toll-like receptors (TLRs), a family of pattern recognition receptors expressed on many cell types of innate immunity, recognize the pathogen-associated molecular patterns of microbes. The hygiene hypothesis suggests that a reduced microbial exposure in early childhood increases the susceptibility to allergic diseases due to deviation in development of the immune system. TLRs are key roles in the right and healthy direction of adaptive immunity with the induction of T-helper 2 toward Th1 immune responses and regulatory T cells. TLR ligand CpG-ODN-based immunomodulation is independent of allergen and it mainly affects innate immune system. While, CpG-oligodeoxynucleotide-based vaccination is allergen specific and induces adaptive immune system. The use of agonists of TLR9 in two distinct strategies of immunotherapy, immunomodulation and vaccination, could be presented as the curative method for the treatment of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 1750-7448 (Electronic)IS - 1750-743X (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.2217/imt-2016-0104</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28303762">PM:28303762</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170317, Farrokhi S</style></custom2><misc3><style face="normal" font="Arial">10.2217/imt-2016-0104</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chai,R.</style></author><author><style face="normal" font="Arial"> Liu,B.</style></author><author><style face="normal" font="Arial"> Qi,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of immunology, China Medical University, Shenyang 110010, China</style></auth-address><titles><title><style face="normal" font="Arial">The significance of the levels of IL-4, IL-31 and TLSP in patients with asthma and/or rhinitis</style></title><secondary-title><style face="normal" font="Arial">Immunotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunotherapy</style></full-title></periodical><pages end="337" start="331">331-337</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">AIM: To investigate the clinical significance of the levels of IL-4, IL-33 and thymic stromal lymphopoietin (TLSP) in patients with asthma and/or rhinitis, then do the simple verification in animals. METHODS: Levels of IL-4 IL-31, IL-33 and TLSP were detected by ELISA and real-time PCR in 64 asthma patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases), 64 rhinitis patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases), 64 asthma complicated with allergic rhinitis patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases) and 32 healthy controls. Then we detected the IL-4, IL-31, IL-33 and TLSP in the sensitized mice. RESULTS: Results showed that levels of IL-4, IL-31, IL-33 and TSLP in asthma and rhinitis patients, and those complicated with allergic rhinitis, had significant differences compared with the control group (p &lt; 0.05). It was found that the indicators of mugwort and dust mite allergic patients were significantly higher than that of other allergic patients (p &lt; 0.05). We got the same tendency in in vivo experiments. CONCLUSION: IL-4, IL-31, IL-33 and TSLP may be involved in the pathogenesis of asthma and rhinitis; dust mite and mugwort allergy could increase them significantly</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 1750-7448 (Electronic)IS - 1750-743X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.2217/imt-2016-0131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28303765">PM:28303765</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170317, Chai R</style></custom2><misc3><style face="normal" font="Arial">10.2217/imt-2016-0131</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonul,M.Z.</style></author><author><style face="normal" font="Arial"> Keseroglu,H.O.</style></author><author><style face="normal" font="Arial"> Ergin,C.</style></author><author><style face="normal" font="Arial"> Ozcan,I.</style></author><author><style face="normal" font="Arial"> Erdem,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Bullous pemphigoid successfully treated with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Indian J Dermatol Venereol Leprol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Dermatol Venereol Leprol</style></full-title></periodical><pages end="579" start="577">577-579</pages><volume><style face="normal" font="Arial">82</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-Allergic Agents</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic agents</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Injections,Subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Pemphigoid,Bullous</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160809IS - 0973-3922 (Electronic)IS - 0378-6323 (Linking)LA - engPT - Case ReportsPT - LetterRN - 0 (Anti-Allergic Agents)RN - 2P471X1Z11 (Omalizumab)SB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.4103/0378-6323.183628</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27297272">PM:27297272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Dermatol Venereol Leprol\2016-82-577-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Dermatol Venereol Leprol\2016-82-577-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160809, Gonul MZ</style></custom2><misc3><style face="normal" font="Arial">10.4103/0378-6323.183628</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,H.</style></author><author><style face="normal" font="Arial"> Dai,C.</style></author><author><style face="normal" font="Arial"> Pan,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Anhui Provincial Hospital, No. 17, Lu Jiang Road, Hefei, 230001, China</style></auth-address><titles><title><style face="normal" font="Arial">Pediatric Asthma and Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Indian J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Pediatr</style></full-title></periodical><pages end="590" start="585">585-590</pages><volume><style face="normal" font="Arial">84</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To quantitatively summarize the evidence from observational studies on the relation between pediatric asthma and food allergy. METHODS: A literature search was conducted in Medline and EMBASE (August 2016). Two independent reviewers appraised the studies and extracted the estimates of interest. Methodological quality of the included studies was assessed using National Heart Lung and Blood Institute (NHLBI) Quality Assessment Tools. Data were pooled using random-effects meta-analysis. RESULTS: A total of 32 relevant studies were identified but only 8 studies met the inclusion criteria. Using random-effect model, food allergy showed strong association with asthma in children (OR = 2.87 [95% CI: 2.05-4.00]; P &lt; 0.0001). CONCLUSIONS: This study suggested that food allergy is associated with an increased risk of asthma in children</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 0973-7693 (Electronic)IS - 0019-5456 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12098-017-2326-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386780">PM:28386780</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Pediatr\20170407-ZhouH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Pediatr\20170407-ZhouH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170407, Zhou H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12098-017-2326-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vincent,M.</style></author><author><style face="normal" font="Arial"> Percier,P.</style></author><author><style face="normal" font="Arial"> Prins,S.</style></author><author><style face="normal" font="Arial"> Huygen,K.</style></author><author><style face="normal" font="Arial"> Potemberg,G.</style></author><author><style face="normal" font="Arial"> Muraille,E.</style></author><author><style face="normal" font="Arial"> Romano,M.</style></author><author><style face="normal" font="Arial"> Michel,O.</style></author><author><style face="normal" font="Arial"> Denis,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Scientific Service Immunology, WIV-ISP. Engelandstraat 642, B-1180, Bruxelles, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Investigation of inflammatory and allergic responses to common mold species: results from in vitro experiments, from a mouse model of asthma and from a group of asthmatic patients</style></title><secondary-title><style face="normal" font="Arial">Indoor Air</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indoor Air</style></full-title></periodical><pages end="945" start="933">933-945</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="2" Month="4" Year="2017">2017/4/2</year></dates><abstract><style face="normal" font="Arial">Most studies on molds focus on A. alternata and A. fumigatus. Here we report on inflammatory and allergenic properties of more typical indoor species A. versicolor, P. chrysogenum, C. cladosporioides and C. sphaerospermum that were compared to A. alternata and A. fumigatus. In a mouse model, after intranasal instillation, A. alternaria, A. versicolor and C. sphaerospermum induced the early recruitment of neutrophils and the strong expression of inflammatory markers in the broncho-alveolar lavages fluids. A. fumigatus also induced the early accumulation of neutrophils but with lower levels of inflammatory markers. Chronic treatment induced variable response according to species: P. chrysogenum and A. fumigatus appeared strong pro-allergenic inducers compared to A. alternata and C. sphaerospermum while A. versicolor, and C. cladosporioides induced a mixed pro-allergenic/pro-inflammatory response. In mold-sensitized asthmatics, mold-specific Immunoglobulin E (IgE) were detected with an in-house dot-blot assay. A. fumigatus and A. alternata were the most frequent sensitizers. Altogether, P. chrysogenum, P. brevicompactum, C. sphaerospermum and C. cladosporioides were the "major sensitizer" (defined as the strongest response against a single mold species) for almost 30% of the asthmatics. These results show that, not only A. alternata and A. fumigatus, but also indoor species have strong inflammatory and allergic properties and a harmful potency. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1600-0668 (Electronic)IS - 0905-6947 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/ina.12385</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28370571">PM:28370571</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indoor Air\20170403-VincentM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indoor Air\20170403-VincentM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Vincent M</style></custom2><misc3><style face="normal" font="Arial">10.1111/ina.12385</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fleury,O.M.</style></author><author><style face="normal" font="Arial"> McAleer,M.A.</style></author><author><style face="normal" font="Arial"> Feuillie,C.</style></author><author><style face="normal" font="Arial"> Formosa-Dague,C.</style></author><author><style face="normal" font="Arial"> Sansevere,E.</style></author><author><style face="normal" font="Arial"> Bennett,D.E.</style></author><author><style face="normal" font="Arial"> Towell,A.M.</style></author><author><style face="normal" font="Arial"> McLean,W.H.</style></author><author><style face="normal" font="Arial"> Kezic,S.</style></author><author><style face="normal" font="Arial"> Robinson,D.A.</style></author><author><style face="normal" font="Arial"> Fallon,P.G.</style></author><author><style face="normal" font="Arial"> Foster,T.J.</style></author><author><style face="normal" font="Arial"> Dufrene,Y.F.</style></author><author><style face="normal" font="Arial"> Irvine,A.D.</style></author><author><style face="normal" font="Arial"> Geoghegan,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College Dublin, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Clumping factor B promotes adherence of Staphylococcus aureus to corneocytes in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Infect Immun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Infect Immun</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Adhesion</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Proteins</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> binding affinity</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cornea</style></keyword><keyword><style face="normal" font="Arial"> corneocytes</style></keyword><keyword><style face="normal" font="Arial"> cornified envelope</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Stratum corneum</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="4" Year="2017">2017/4/3</year></dates><abstract><style face="normal" font="Arial">Staphylococcus aureus skin infection is a frequent and recurrent problem in children with the common inflammatory skin disease atopic dermatitis (AD). S. aureus colonises the skin of the majority of children with AD and exacerbates the disease. The first step during colonisation and infection is bacterial adhesion to the cornified envelope of corneocytes in the outer layer stratum corneum. Corneocytes from AD skin are structurally different to corneocytes from normal healthy skin. The objective of this study was to identify bacterial proteins that promote the adherence of S. aureus to AD corneocytes. S. aureus strains from clonal complex 1 and 8 were more frequently isolated from infected AD skin than from the nasal cavity of healthy children. AD strains had increased ClfB ligand binding activity compared to normal nasal carriage strains. Adherence of single S. aureus bacteria to corneocytes from AD patients ex vivo was studied using atomic force microscopy. Bacteria expressing ClfB recognised ligands distributed over the entire corneocyte surface. The ability of an isogenic ClfB-deficient mutant to adhere to AD corneocytes was greatly reduced compared to its parent clonal complex 1 clinical strain. ClfB from clonal complex 1 strains had a slightly higher binding affinity for its ligand compared to ClfB from other clonal complexes. Our results provide new insights into the first step in the establishment of S. aureus colonisation in AD patients. ClfB is a key adhesion molecule for the interaction of S.aureus with AD corneocytes and represents a target for intervention</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1098-5522 (Electronic)IS - 0019-9567 (Linking)LA - engPT - Journal ArticleCO - Ireland -CO - Belgium -CO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1128/IAI.00994-16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28373353">PM:28373353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Infect Immun\20170404-FleuryOM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Infect Immun\20170404-FleuryOM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Fleury OM</style></custom2><misc3><style face="normal" font="Arial">10.1128/IAI.00994-16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nesi,R.T.</style></author><author><style face="normal" font="Arial"> Kennedy-Feitosa,E.</style></author><author><style face="normal" font="Arial"> Lanzetti,M.</style></author><author><style face="normal" font="Arial"> Avila,M.B.</style></author><author><style face="normal" font="Arial"> Magalhaes,C.B.</style></author><author><style face="normal" font="Arial"> Zin,W.A.</style></author><author><style face="normal" font="Arial"> Faffe,D.S.</style></author><author><style face="normal" font="Arial"> Porto,L.C.</style></author><author><style face="normal" font="Arial"> Valenca,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Ciencias Biomedicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Inflammatory and Oxidative Stress Markers in Experimental Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid peroxidation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> redox signaling</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="4" Year="2017">2017/4/8</year></dates><abstract><style face="normal" font="Arial">Ovalbumin-induced allergic lung inflammation (ALI) is a condition believed to be mediated by cytokines, extracellular matrix remodeling, and redox imbalance. In this study, we evaluated pulmonary function together with inflammatory markers as interleukin-4 (IL-4), myeloperoxidase (MPO), eosinophil cells, and redox markers in the lungs of BALB/c mice after ovalbumin (OVA) sensitization and challenge. Our results showed an increase in bronchial hyperresponsiveness stimulated by methacholine (Mch), inflammatory cell influx, especially eosinophils together with an increase of high mobility group box 1 (HMGB1) and altered lipid peroxidation (LP) and antioxidant defenses in the OVA group compared to the control group (p &lt;/= 0.5). Thus, we demonstrated that OVA-induced ALI altered redox status concomitantly with impaired lung function, which was associated with HMGB1 expression and proteolytic remodeling. Taken together all results found here, we may suggest HMGB1 is an important therapeutic target for asthma, once orchestrates the redox signaling, inflammation, and remodeling that contribute to the disease development</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-017-0560-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28391514">PM:28391514</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20170409-NesiRT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20170409-NesiRT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Nesi RT</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-017-0560-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tashiro,H.</style></author><author><style face="normal" font="Arial"> Takahashi,K.</style></author><author><style face="normal" font="Arial"> Sadamatsu,H.</style></author><author><style face="normal" font="Arial"> Kato,G.</style></author><author><style face="normal" font="Arial"> Kurata,K.</style></author><author><style face="normal" font="Arial"> Kimura,S.</style></author><author><style face="normal" font="Arial"> Sueoka-Aragane,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Saturated Fatty Acid Increases Lung Macrophages and Augments House Dust Mite-Induced Airway Inflammation in Mice Fed with High-Fat Diet</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1beta</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocyte Chemoattractant Protein-1</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Palmitic Acid</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">Obesity is one of the phenotypes of severe asthma, which is considered to be a heterogeneous syndrome; however, its interaction with airway inflammation is not fully understood. The aim of this study was to clarify the role of saturated fatty acids in augmenting airway inflammation induced by house dust mite (HDM) in obesity. Subjects were Balb/c mice fed a high-fat diet (HFD) for 10 weeks, followed by sensitization and exposure to HDM. Subjects were also administered palmitic acid (PA) for 4 weeks with concurrent sensitization and exposure to HDM. Airway inflammation was assessed by quantifying the amount of inflammatory cells in bronchoalveolar lavage (BAL) and airway resistance was measured. In vitro, lipopolysaccharide (LPS)-primed macrophages were stimulated by PA. The amount of monocyte chemoattractant protein-1 (MCP-1), interleukin-1beta (IL-1beta), and tumor necrosis factor alpha (TNF-alpha) was examined in the supernatant. Compared to normal chow mice, HFD mice underwent significant increases in body weight; increases in number of lung macrophages, including circulating monocytes and alveolar macrophages; and increases in bronchoalveolar lavage fluid (BALF) total cell count, including neutrophils but not eosinophils, after HDM sensitization and exposure. In vitro, PA induced MCP-1 and augmented LPS-primed production of IL-1beta and TNF-alpha in macrophages. Among HDM mice that were administered PA, there was an increase BALF total cell count, including neutrophils but not eosinophils, compared to vehicle mice. In conclusion, saturated fatty acid increased the number of lung macrophages and augmented HDM-induced neutrophilic airway inflammation in a HFD mouse model</style></abstract><notes><style face="normal" font="Arial">DA - 20170402IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-017-0550-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28365872">PM:28365872</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20170402-TashiroH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20170402-TashiroH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170402, Tashiro H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-017-0550-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al-Sawalha,N.A.</style></author><author><style face="normal" font="Arial"> Migdadi,A.M.</style></author><author><style face="normal" font="Arial"> Alzoubi,K.H.</style></author><author><style face="normal" font="Arial"> Khabour,O.F.</style></author><author><style face="normal" font="Arial"> Qinna,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Faculty of Pharmacy , Jordan University of Science and Technology , Irbid , Jordan</style></auth-address><titles><title><style face="normal" font="Arial">Effect of waterpipe tobacco smoking on airway inflammation in murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Inhal Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inhal Toxicol</style></full-title></periodical><pages end="52" start="46">46-52</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: There has been an increase in the popularity of waterpipe tobacco smoking (WTS) worldwide, especially in the younger population, including asthma patients. In this study, we investigated the effects of waterpipe smoking on airway inflammation, cytokine levels and oxidative stress markers in an antigen-driven murine model of asthma. MATERIALS AND METHODS: Balb/c mice were divided into four groups; (1) control (received fresh air, ovalbumin sensitization and saline challenge), (2) WTS (received WTS, ovalbumin sensitization and saline challenge), (3) Ova S/C (received fresh air, ovalbumin sensitization and ovalbumin challenge) and (4) simultaneous WTS and Ova S/C (received WTS, ovalbumin sensitization and ovalbumin challenge). Airway inflammatory cells were evaluated in the broncho-alveolar lavage fluid. Cytokines [interleukin (IL)-13, 10 and 18] and oxidative stress markers [superoxide dismutase (SOD), catalase and glutathione peroxidase (GPx)] were evaluated in the lung homogenates. RESULTS: Chronic exposure to WTS significantly increased the number of airway inflammatory cells in mice, specifically: eosinophils, neutrophils, macrophages and lymphocytes. The level of IL-13 in the lungs was increased and the level of IL-10 was reduced (p &lt; 0.05) by WTS. Chronic WTS potentiated the increase in inflammatory cells induced by Ova S/C (p &lt; 0.05). The level of IL-13 in the lungs was increased by simultaneous WTS and Ova S/C (p &lt; 0.05) while, levels of IL-10, IL-18, SOD, catalase and GPx in the lungs were not affected. CONCLUSIONS: Chronic WTS exposure induced airway inflammation in control mice and enhanced airway inflammation in murine model of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1091-7691 (Electronic)IS - 0895-8378 (Linking)LA - engPT - Journal ArticleCO - Jordan -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1080/08958378.2017.1280105</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28330430">PM:28330430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inhal Toxicol\2017-29-46-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inhal Toxicol\2017-29-46-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Al-Sawalha NA</style></custom2><misc3><style face="normal" font="Arial">10.1080/08958378.2017.1280105</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Johansson,M.</style></author><author><style face="normal" font="Arial"> Gustafsson,A.</style></author><author><style face="normal" font="Arial"> Johanson,G.</style></author><author><style face="normal" font="Arial"> Oberg,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Institute of Environmental Medicine, Karolinska Institutet , Stockholm , Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of airway response in naive and ovalbumin-sensitized mice during short-term inhalation exposure to chlorine</style></title><secondary-title><style face="normal" font="Arial">Inhal Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inhal Toxicol</style></full-title></periodical><pages end="91" start="82">82-91</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial reactivity</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Chlorine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation Exposure</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritants</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mechanics</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory function</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Mechanics</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: It has been suggested that asthmatics are more susceptible than healthy individuals to airborne irritating chemicals in general. However, there is limited human data available to support this hypothesis due to ethical and practical difficulties. We explored a murine model of ovalbumin (OVA)-induced airway inflammation to study susceptibility during acute exposure to chemicals with chlorine as a model substance. METHODS: Naive and OVA sensitized female BALB/c mice were exposed to chlorine at four different concentrations (0, 5, 30 and 80 ppm) for 15 minutes with online recording of the respiratory function by plethysmography. The specific effects on respiratory mechanics, inflammatory cells and inflammatory mediators (cytokines and chemokines) of the airways were measured 24 hours after the chlorine exposure as well as histopathological examination of the lungs. RESULTS: Similar concentration-dependent reductions in respiratory frequency were seen in the two groups, with a 50% reduction (RD50) slightly above 5 ppm. Decreased body weight 24 hours after exposure to 80 ppm was also observed in both groups. Naive, but not OVA-sensitized, mice showed increased bronchial reactivity and higher number of neutrophils in bronchoalveolar lavage fluid at 80 ppm. CONCLUSIONS: The results do not support an increased susceptibility to chlorine among OVA-sensitized mice. This animal model, which represents a phenotype of eosinophilic airway inflammation, seems unsuitable to study susceptibility to inhalation of irritants in relation to asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1091-7691 (Electronic)IS - 0895-8378 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1080/08958378.2017.1299260</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28330427">PM:28330427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inhal Toxicol\2017-29-82-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inhal Toxicol\2017-29-82-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Johansson M</style></custom2><misc3><style face="normal" font="Arial">10.1080/08958378.2017.1299260</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jones,J.T.</style></author><author><style face="normal" font="Arial"> Tassew,D.D.</style></author><author><style face="normal" font="Arial"> Herrera,L.K.</style></author><author><style face="normal" font="Arial"> Walton-Filipczak,S.R.</style></author><author><style face="normal" font="Arial"> Montera,M.A.</style></author><author><style face="normal" font="Arial"> Chand,H.S.</style></author><author><style face="normal" font="Arial"> Delgado,M.</style></author><author><style face="normal" font="Arial"> Mebratu,Y.A.</style></author><author><style face="normal" font="Arial"> Tesfaigzi,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a COPD Program, Lovelace Respiratory Research Institute , Albuquerque , NM , USA</style></auth-address><titles><title><style face="normal" font="Arial">Extent of allergic inflammation depends on intermittent versus continuous sensitization to house dust mite</style></title><secondary-title><style face="normal" font="Arial">Inhal Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inhal Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="16" Month="4" Year="2017">2017/4/16</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: House dust mite (HDM) exposure is used to model experimental asthma in mice. However, a direct comparison of inflammatory responses following continuous versus intermittent HDM exposure has not been reported. Therefore, we investigated whether the HDM dose at sensitization or challenge affects extent of inflammation in mice that were either continuously or intermittently sensitized with HDM. MATERIALS AND METHODS: C57BL/6 mice received either 10 continuous exposures with 10 mug HDM per exposure or two intermittent HDM exposures over a period of two weeks and were subsequently challenged by three instillations with HDM during the third week. For the intermittent model, mice were sensitized with 1 or 10 mug HDM and challenged on three consecutive days with 1 or 10 mug HDM. Inflammatory cells in the bronchoalveolar lavage fluid and epithelial cell hyperplasia and mucous cell metaplasia were quantified. RESULTS: Significantly higher levels of inflammation and mucous cell metaplasia were observed when mice were sensitized intermittently compared with continuously. Intermittent sensitization and challenge with 10 mug HDM caused maximum inflammation, mucous cell metaplasia, and epithelial cell hyperplasia. However, sensitization with 1 mug HDM only also showed increased inflammation when challenged with 10 mug HDM. DISCUSSION: These findings suggest major differences in adaptive immunity, depending on the sensitization protocol. CONCLUSIONS: Because of significant differences, the HDM sensitization protocol should be carefully considered when designing studies to investigate the underlying mechanisms of immunity in mouse models of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170417IS - 1091-7691 (Electronic)IS - 0895-8378 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/08958378.2017.1311389</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28413916">PM:28413916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inhal Toxicol\20170417-JonesJT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inhal Toxicol\20170417-JonesJT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170417, Jones JT</style></custom2><misc3><style face="normal" font="Arial">10.1080/08958378.2017.1311389</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vila-Hereter,F.</style></author><author><style face="normal" font="Arial"> Rivera-Mariani,F.E.</style></author><author><style face="normal" font="Arial"> Bolanos-Rosero,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR, USA</style></auth-address><titles><title><style face="normal" font="Arial">Serological Reactivity and Identification of Immunoglobulin E-Binding Polypeptides of Ganoderma applanatum Crude Spore Cytoplasmic Extract in Puerto Rican Subjects</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="149" start="139">139-149</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Basidiospore</style></keyword><keyword><style face="normal" font="Arial"> Basidiospores</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enolase</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergy</style></keyword><keyword><style face="normal" font="Arial"> Ganoderma</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Puerto Rican</style></keyword><keyword><style face="normal" font="Arial"> Puerto Rico</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The allergenic potential of Ganoderma applanatum basidiospores has been demonstrated previously in Puerto Rico. However, basidiomycete allergens are not available for inclusion in allergy diagnostic panels. Therefore, we sought to confirm allergic sensitization to G. applanatum crude spore cytoplasmic extract through reactivity in serological assays and detection of immunoglobulin E (IgE)-binding polypeptides. METHODS: Via an indirect ELISA, serological reactivity was compared between groups of individuals with different allergic profiles. Group 1 (n = 51) consisted of individuals with sIgE to the allergens included in the diagnostic panels; group 2 (n = 14) comprised individuals with no sIgE to the allergens tested; and group 3 (n = 22) included individuals with no allergic history. To visualize IgE-binding polypeptides, group 1 sera were examined via Western blotting (WB). Polypeptide bands with the highest reactivity were analyzed by mass spectrometry (MS) for putative identification. RESULTS: The serological reactivity of group 1 was significantly higher than that of group 3 in an indirect ELISA (p = 0.03). Sixty-five percent of group 1 individuals showed reactivity to polypeptide bands in WB. Bands of 81 and 56 kDa had the highest reactivity proportions among the reactive sera, followed by a 45-kDa band. MS analysis of these 3 polypeptides suggests that they are basidiomycete-derived enzymes with aconitate hydratase, catalase, and enolase functions. CONCLUSIONS: G. applanatum spores have allergenic components recognized by Puerto Rican individuals, which could eventually be considered as markers in cases of fungal allergy and be included in diagnostic allergen panels in Puerto Rico and tropical regions</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000455254</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28380479">PM:28380479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-139-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-139-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Vila-Hereter F</style></custom2><misc3><style face="normal" font="Arial">10.1159/000455254</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takejima,P.</style></author><author><style face="normal" font="Arial"> Agondi,R.C.</style></author><author><style face="normal" font="Arial"> Rodrigues,H.</style></author><author><style face="normal" font="Arial"> Aun,M.V.</style></author><author><style face="normal" font="Arial"> Kalil,J.</style></author><author><style face="normal" font="Arial"> Giavina-Bianchi,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Immunology and Allergy Division, University of Sao Paulo School of Medicine, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Allergic and Nonallergic Asthma Have Distinct Phenotypic and Genotypic Features</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="160" start="150">150-160</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Identification of asthma phenotypes enables a better understanding and management of this heterogeneous disease. Studies have reported associations between human leukocyte antigens (HLA) and asthma in different populations, but the results have been inconclusive and they have rarely considered the distinct disease phenotypes. Our objective was to characterize allergic and nonallergic asthma phenotypes and evaluate possible associations with the HLA system. METHODS: A total of 109 patients with asthma were prospectively followed during 2 years. They were divided into 2 groups, i.e., allergic and nonallergic asthma, according to their clinical history and skin prick test and serum-specific immunoglobulin E (IgE) results. The control group comprised 297 deceased donors of solid organs. Patients' features and HLA class I and II genotypes were assessed and compared. RESULTS: This study showed different features between asthma phenotypes. Nonallergic patients were older at the onset of asthma symptoms and had a higher rate of intolerance to nonsteroidal anti-inflammatory drugs. Allergic patients had higher total serum IgE levels, reported atopic dermatitis and rhinoconjunctivitis more frequently, and, unexpectedly, had a greater disease severity. New associations between the HLA genotypes and allergic and nonallergic asthma were identified. The HLA-B*42, HLA-C*17, HLA-DPA1*03, and HLA-DPB1*105 genotypes were associated with allergic asthma and the HLA-B*48 genotype with the nonallergic phenotype. The presence of the haplotype HLA-DPA1*03 DQA*05 was associated with allergic asthma, and the presence of HLA-DPA1*03 and the absence of HLA-DQA*05 with nonallergic asthma. CONCLUSIONS: Allergic and nonallergic asthma have distinct phenotypic and genotypic features. New associations between asthma phenotypes and HLA class I and II were identified</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1159/000458151</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28380482">PM:28380482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-150-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-150-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Takejima P</style></custom2><misc3><style face="normal" font="Arial">10.1159/000458151</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Asaumi,T.</style></author><author><style face="normal" font="Arial"> Ogura,K.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sagamihara National Hospital, Sagamihara, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Risk Factors for Severe Reactions during Double-Blind Placebo-Controlled Food Challenges</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="182" start="173">173-182</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Resuscitation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Severe anaphylactic symptoms can occur during oral food challenges (OFCs). Thus, high-risk patients (e.g., patients with a history of anaphylaxis or high antigen-specific immunoglobulin E [IgE] levels) must carefully undergo OFCs in hospitals. We attempted to identify the risk factors for severe symptoms during OFC testing among high-risk patients. METHODS: We retrospectively evaluated patients' characteristics and severe symptoms that were experienced during a double-blind placebo-controlled food challenge test performed before the patients underwent oral immunotherapy between June 2008 and June 2012. Patients were >/=5 years old and had an anaphylactic history or antigen-specific IgE (>30 kUA/L). Severe symptoms were defined using the grading of the Japanese Anaphylaxis Guidelines, which are modified from the European Academy of Allergology and Clinical Immunology Guidelines. RESULTS: We evaluated 393 cases with positive test results, including 98 cases with severe symptoms. The most frequent severe symptoms were respiratory (77%), gastrointestinal (28%), cardiovascular (27%), and neurological (13%) symptoms. Multivariate analysis revealed that the significant factors for a severe reaction were a history of anaphylaxis to the causative food (adjusted odds ratio [OR]: 2.147, p = 0.003), older age (per 1 year increase, adjusted OR: 1.102, p = 0.044), and an egg OFC (adjusted OR: 0.433, p = 0.003). CONCLUSIONS: The risk factors for a severe reaction to OFCs were a history of an anaphylactic reaction and older age. An egg OFC was associated with low risk of severe symptoms during OFC. Therefore, OFCs for patients with these risk factors should only be performed under specialist supervision with access to rapid treatment and full resuscitation equipment</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000458724</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28380495">PM:28380495</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-173-82pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-173-82pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Yanagida N</style></custom2><misc3><style face="normal" font="Arial">10.1159/000458724</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Buczylko,K.</style></author><author><style face="normal" font="Arial"> van der Werf,J.F.</style></author><author><style face="normal" font="Arial"> Boot,D.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">NZOZ Centrum Alergologii, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="186" start="183">183-186</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> New allergens</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Up-dosing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Early pollen flight and new allergens prolonging the pollen season means that the time for up-dosing of allergen-specific subcutaneous immunotherapy (SCIT) outside the pollen season becomes shorter. Hence, for patients who wish or need to be up-dosed faster, an accelerated induction regimen would provide a useful treatment option. METHODS: An accelerated up-dosing regimen (0.1-0.3-0.5 mL at weekly intervals) was compared to conventional up-dosing (0.05-0.1-0.2-0.3-0.4-0.5 mL at weekly intervals) using an allergoid birch pollen SCIT preparation. After up-dosing, the maintenance dose (0.5 mL) was given 3 times at biweekly intervals. The multicenter study was performed according to an open randomized, parallel-group design. RESULTS: A total of 123 birch pollen-allergic patients (81 adults and 42 adolescents) presenting with rhinitis or rhinoconjunctivitis with or without mild asthma (FEV1 >70%) were randomized to either the conventional registered up-dosing or an accelerated regimen. In total, 96.7 and 98.4% successfully reached the maintenance dose for the conventional and accelerated regimen, respectively, without relevant differences between adults and adolescents. Both regimens were safe and well tolerated. Furthermore, significant increases (similar in size) in specific IgG and IgG4 after 3 months of treatment were observed in both groups, independent of age. CONCLUSION: The accelerated SCIT regimen was revealed to be as safe as the conventional regimen, and the immunological effects of both regimens are similar. Accordingly, the accelerated regimen may be used to up-dose patients of adult as well adolescent age within 2 weeks</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Poland -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1159/000464103</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28380494">PM:28380494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-183-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-183-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Buczylko K</style></custom2><misc3><style face="normal" font="Arial">10.1159/000464103</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kitsioulis,N.A.</style></author><author><style face="normal" font="Arial"> Xepapadaki,P.</style></author><author><style face="normal" font="Arial"> Roussaki-Schulze,A.V.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.</style></author><author><style face="normal" font="Arial"> Zafiriou,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="166" start="161">161-166</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> D-dimer</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressants</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Nonsedating antihistamines are the treatment of choice for chronic spontaneous urticaria (CSU), while omalizumab and immunosuppressants have also been approved as an add-on treatment. Autologous whole-blood injection (AWBI) has been used in previous studies with ambiguous results. The aim of our study was to evaluate changes in the Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and Chronic Urticaria Quality of Life (CU-Q2oL) score, and also the association of serologic markers with disease severity measures after AWBI. METHODS: In this observational study, AWBIs were performed (8 courses on a weekly basis) in adults with refractory CSU, who refused an add-on treatment with either omalizumab or immunosuppressants. UAS7, DLQI, and CU-Q2oL questionnaires and serum concentrations of total IgE, C-reactive protein (CRP), and D-dimer were evaluated before and after the intervention. RESULTS: Nineteen patients (12 females; mean age 54 +/- 20.8 years) completed the protocol. Following AWBI, significant improvements in the UAS7 (34.26 +/- 8.04 vs. 12.52 +/- 10.83, p &lt; 0.001), DLQI (11.63 +/- 5.51 vs. 3.47 +/- 2.85, p &lt; 0.001), and CU-Q2oL score (32.97 +/- 18.71 vs. 10.94 +/- 7.71, p &lt; 0.001) were recorded. A negative correlation between the baseline D-dimer levels and UAS7 and DLQI variations (p = 0.002 and p = 0.001, respectively) was noted. D-dimer levels >/=292 ng/mL have been associated with poor responsiveness (sensitivity 75%; specificity 83.3%). No correlation with either total immunoglobulin E or CRP levels was observed. CONCLUSION: AWBI appears to be a safe, alternative, add-on therapeutic option in refractory CSU, particularly in patients with low plasma levels of D-dimer</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1159/000458152</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28380487">PM:28380487</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-161-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-161-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Kitsioulis NA</style></custom2><misc3><style face="normal" font="Arial">10.1159/000458152</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fiedler,C.</style></author><author><style face="normal" font="Arial"> Miehe,U.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author><author><style face="normal" font="Arial"> Kiess,W.</style></author><author><style face="normal" font="Arial"> Prenzel,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Pneumology and Allergy, University Hospital for Children and Adolescents, Leipzig, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Long-Term Follow-Up of Children after Venom Immunotherapy: Low Adherence to Anaphylaxis Guidelines</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="172" start="167">167-172</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis education</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Education program</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency kit</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> long-term follow-up</style></keyword><keyword><style face="normal" font="Arial"> long-term outcome</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Data on the long-term outcome of children after specific venom immunotherapy (VIT) are limited. Therefore, we assessed sting recurrence and anaphylaxis relapse rates as well as adherence to anaphylaxis guidelines with regard to the availability of emergency equipment and education status. METHODS: For this long-term survey, data of 311 children with a history of anaphylactic reactions to hymenoptera stings were collected by chart review. We included patients who were treated with a 3-year VIT between 1993 and 2009 and had completed a questionnaire. RESULTS: Forty of the 311 patients were included. Mean VIT duration was 3.1 years. Of the 40 patients included, 29 children (72.5%) received VIT with vespid venom, 9 with bee venom, and 2 patients with both venoms. During a mean follow-up period of 13 years, 20/40 patients (50%) suffered re-stings. Six of the 20 (30%) patients developed again anaphylactic symptoms (grade 1 n = 5, grade 3 n = 1); 2 were allergic to vespid and 4 to bee venom. Of the entire cohort, only 5/40 (12.5%) had appropriate emergency kits according to the guidelines of the European Academy of Allergy and Clinical Immunology. Among the patients who had emergency kits available, one third (5/15) felt uncertain about the correct application of the medication. Less than two thirds of our population (25/40) affirmed that they have been educated in emergency management. The vast majority (95%; 38/40) of our patients did not have allergy follow-ups after VIT completion. CONCLUSIONS: Anaphylactic relapses are not uncommon, and there are considerable deficits in the emergency management of patients. Hence, comprehensive standardized anaphylaxis education programs as well as regular follow-ups of the allergy status are crucial</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000458707</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28380475">PM:28380475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-167-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-167-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Fiedler C</style></custom2><misc3><style face="normal" font="Arial">10.1159/000458707</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moitra,S.</style></author><author><style face="normal" font="Arial"> Datta,A.</style></author><author><style face="normal" font="Arial"> Mondal,S.</style></author><author><style face="normal" font="Arial"> Hazra,I.</style></author><author><style face="normal" font="Arial"> Faruk,S.M.</style></author><author><style face="normal" font="Arial"> Das,P.K.</style></author><author><style face="normal" font="Arial"> Basu,A.K.</style></author><author><style face="normal" font="Arial"> Tripathi,S.K.</style></author><author><style face="normal" font="Arial"> Chaudhuri,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Laboratory Medicine, School of Tropical Medicine, 108 C. R. Avenue, Kolkata 700073, West Bengal, India</style></auth-address><titles><title><style face="normal" font="Arial">Modulation of regulatory T cells by intranasal allergen immunotherapy in an experimental rat model of airway allergy</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="19" start="9">9-19</pages><volume><style face="normal" font="Arial">47</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Kolkata</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OX40</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peripheral Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">Allergic airway diseases such as asthma and allergic rhinitis are increasing in prevalence worldwide. The theory of an altered Th1/Th2 balance in allergic diathesis has recently been termed a "procrustean paradigm" as it failed to explain many preclinical findings. Regulatory T cells (Treg) have now been shown to be critical in T-cell homeostasis and in the maintenance of peripheral tolerance to allergens. Allergen specific immunotherapy (SIT) has been shown to induce regulatory T cells in allergic patients. Among various types of SIT, intranasal immunotherapy had not been studied in detail for the treatment of allergic airway diseases. So, there was a need to study the contribution of regulatory T cells and their mechanistic pathways following intranasal immunotherapy in-vivo. It had been previously shown that intranasal allergen immunotherapy using Alstonia scholaris pollen extract abrogates allergic airway inflammation with decline in IgE and Th2 cytokine levels. The present study for the first time offers a multi-targeted approach towards attenuation of airway allergy by the generation of CD4+CD25+Foxp3+T cells and other subsets of Treg cells like Tr1 cells, Th3 cells, CTLA4+Treg cells, and also modulation of various Treg cell surface molecules like GITR, OX40, CD39 and CD73 by intranasal immunotherapy in the same animal model. This animal experiment will thus help to chart out newer molecular targets for treating allergic asthma or rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.03.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28349869">PM:28349869</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-47-9-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-47-9-19.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Moitra S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.03.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,B.</style></author><author><style face="normal" font="Arial"> Qu,S.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Ye,L.</style></author><author><style face="normal" font="Arial"> Zhang,S.</style></author><author><style face="normal" font="Arial"> Qin,T.</style></author><author><style face="normal" font="Arial"> Fan,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of 1,25-dihydroxyvitamin D3 in an ovalbumin-induced allergic rhinitis model</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="189" start="182">182-189</pages><volume><style face="normal" font="Arial">47</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence microscopy</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> NALT</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> Th17 response</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="Arial">IL-17-producing Th17 cells play an important role in allergic airway diseases, but their local expression and regulation in allergic rhinitis (AR) is not well understood. This study investigated the effects of 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on T-bet expression, Th1 cells, Th2 cells, Th17 cells and IL-33-positive epithelial cells in AR. C57BL/6 mice were intranasally sensitized and challenged with ovalbumin (OVA), and 1,25-(OH)2D3 was intraperitoneally injected into AR mice. Cytokine levels were measured with enzyme-linked immunosorbent assays, phenotypic analysis of Th1, Th2 and Th17 cells in the spleen was completed with flow cytometry, and the CD4+IL-17+ cells in the Nasopharynx-associated lymphoid tissue (NALT) and IL-33-positive cells in nasal mucosa was evaluated with immunofluorescence microscopy. AR mice shown significantly increased Th2 and Th17 cell ratio in spleen, IL-17 level in serum, IL-5 and IL-13 levels in NALF but a lower number of IL-33-positive epithelial cells and Th1 response (Th1 and Tbet+Th1 cell ratio in the spleen and serum IFN-gamma level) than the control mice.1,25-(OH)2D3 treatment significantly decreased the number of sneezing, nasal rubbing, OVA-sIgE and IL-17 in serum, IL-5 and IL-13 levels in NALF, Th17 cell ratio in the spleen and the histological of nasal mucosal but increased the number of IL-33-positive epithelial cells in AR mice. However, 1,25-(OH)2D3 treatment did not significantly influence IFN-gamma level in serum, and Th1, Tbet+Th1 and Th2 cell ratio in spleen. Thus, 1,25-(OH)2D3 may exert anti-allergic effects by suppressing Th17 responses and local production of IL-5 and IL-13 cytokines</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412624">PM:28412624</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-47-182-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-47-182-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Chen B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.04.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bakiri,A.</style></author><author><style face="normal" font="Arial"> Skenderaj,S.</style></author><author><style face="normal" font="Arial"> Kraja,D.</style></author><author><style face="normal" font="Arial"> Petrela,E.</style></author><author><style face="normal" font="Arial"> Mingomataj,C.</style></author><author><style face="normal" font="Arial"> Rama,A.</style></author><author><style face="normal" font="Arial"> Mingomataj,E.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Hypersensitivity to Latex Gloves among Dental Students: Is the Pre-Matriculation Evaluation and Periodic Health Surveillance Necessary?</style></title><secondary-title><style face="normal" font="Arial">Int J Clin Med Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Clin Med Allergy</style></full-title></periodical><pages end="61" start="52">52-61</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Albania</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Glove</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> healthcare workers</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Latex Gloves</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> precautions</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Latex allergy is a common occupational disease among healthcare workers who use latex gloves. Self-administrated questionnaires, physical examination and diverse allergic tests are largely used to assess data about natural history, risk factors, type of allergic reaction, etc. The aim of the present study was to determine the prevalence of allergy to latex gloves among dental students.In this prospective study, a total of 240 students separated as non-exposed, shortly-exposed and longer-exposed during school practice completed a self-administrated questionnaire that comprised of a total of different items and gave information about the participants and their glove use, working habits and glove use, signs and symptoms related to glove use, precautions taken to minimize it, etc. Challenge and patch tests were performed through latex gloves, skin prick test with commercial extracts.Questionnaire items and diagnostic tests revealed that one-fourth of subjects were suspicious for latex gloves hypersensitivity. Their mean value for skin reactions like contact urticaria, irritant or allergic dermatitis was between 10% and 14%, while for other symptoms the mean value was under 5%. In general, students who experienced latex exposure over 2 years during their school practice have shown about a two-fold positive response for statements or diagnostic tests about latex gloves hypersensitivity. Also the Kendall tau coefficient progressed from non-exposed group to longer-exposed one for the majority of items.Because of relationship between allergic reactions to latex gloves and some medical histories, it seems to be necessary for pre-matriculation evaluation and periodic health surveillance of dental students.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Albania -</style></notes><work-type><style face="normal" font="Arial">10.19070/2332-2799-1700011</style></work-type><urls><web-urls><url ppv-ref="no">http://scidoc.org/IJCMA-2332-2799-05-101.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Clin Med Allergy\2017-5-52-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Clin Med Allergy\2017-5-52-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Bakiri A</style></custom2><misc3><style face="normal" font="Arial">10.19070/2332-2799-1700011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stratakis,N.</style></author><author><style face="normal" font="Arial"> Roumeliotaki,T.</style></author><author><style face="normal" font="Arial"> Oken,E.</style></author><author><style face="normal" font="Arial"> Ballester,F.</style></author><author><style face="normal" font="Arial"> Barros,H.</style></author><author><style face="normal" font="Arial"> Basterrechea,M.</style></author><author><style face="normal" font="Arial"> Cordier,S.</style></author><author><style face="normal" font="Arial"> de Groot,R.</style></author><author><style face="normal" font="Arial"> den Dekker,H.T.</style></author><author><style face="normal" font="Arial"> Duijts,L.</style></author><author><style face="normal" font="Arial"> Eggesbo,M.</style></author><author><style face="normal" font="Arial"> Fantini,P.M.</style></author><author><style face="normal" font="Arial"> Forastiere,F.</style></author><author><style face="normal" font="Arial"> Gehring,U.</style></author><author><style face="normal" font="Arial"> Gielen,M.</style></author><author><style face="normal" font="Arial"> Gori,D.</style></author><author><style face="normal" font="Arial"> Govarts,E.</style></author><author><style face="normal" font="Arial"> Inskip,H.M.</style></author><author><style face="normal" font="Arial"> Iszatt,N.</style></author><author><style face="normal" font="Arial"> Jansen,M.</style></author><author><style face="normal" font="Arial"> Kelleher,C.</style></author><author><style face="normal" font="Arial"> Mehegan,J.</style></author><author><style face="normal" font="Arial"> Molto-Puigmarti,C.</style></author><author><style face="normal" font="Arial"> Mommers,M.</style></author><author><style face="normal" font="Arial"> Oliveira,A.</style></author><author><style face="normal" font="Arial"> Olsen,S.F.</style></author><author><style face="normal" font="Arial"> Pele,F.</style></author><author><style face="normal" font="Arial"> Pizzi,C.</style></author><author><style face="normal" font="Arial"> Porta,D.</style></author><author><style face="normal" font="Arial"> Richiardi,L.</style></author><author><style face="normal" font="Arial"> Rifas-Shiman,S.L.</style></author><author><style face="normal" font="Arial"> Robinson,S.M.</style></author><author><style face="normal" font="Arial"> Schoeters,G.</style></author><author><style face="normal" font="Arial"> Strom,M.</style></author><author><style face="normal" font="Arial"> Sunyer,J.</style></author><author><style face="normal" font="Arial"> Thijs,C.</style></author><author><style face="normal" font="Arial"> Vrijheid,M.</style></author><author><style face="normal" font="Arial"> Vrijkotte,T.G.</style></author><author><style face="normal" font="Arial"> Wijga,A.H.</style></author><author><style face="normal" font="Arial"> Kogevinas,M.</style></author><author><style face="normal" font="Arial"> Zeegers,M.P.</style></author><author><style face="normal" font="Arial"> Chatzi,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Social Medicine, University of Crete, Heraklion, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Fish and seafood consumption during pregnancy and the risk of asthma and allergic rhinitis in childhood: a pooled analysis of 18 European and US birth cohorts</style></title><secondary-title><style face="normal" font="Arial">Int J Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Epidemiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood wheeze</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Translational research</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> validated questionnaire</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="Arial">Background: It has been suggested that prenatal exposure to n-3 long-chain fatty acids protects against asthma and other allergy-related diseases later in childhood. The extent to which fish intake in pregnancy protects against child asthma and rhinitis symptoms remains unclear. We aimed to assess whether fish and seafood consumption in pregnancy is associated with childhood wheeze, asthma and allergic rhinitis. Methods: We pooled individual data from 60 774 mother-child pairs participating in 18 European and US birth cohort studies. Information on wheeze, asthma and allergic rhinitis prevalence was collected using validated questionnaires. The time periods of interest were: infancy (0-2 years), preschool age (3-4 years), and school age (5-8 years). We used multivariable generalized models to assess associations of fish and seafood (other than fish) consumption during pregnancy with child respiratory outcomes in cohort-specific analyses, with subsequent random-effects meta-analyses. Results: The median fish consumption during pregnancy ranged from 0.44 times/week in The Netherlands to 4.46 times/week in Spain. Maternal fish intake during pregnancy was not associated with offspring wheeze symptoms in any age group nor with the risk of child asthma [adjusted meta-analysis relative risk (RR) per 1-time/week = 1.01, 95% confidence interval 0.97-1.05)] and allergic rhinitis at school age (RR = 1.01, 0.99-1.03). These results were consistently found in further analyses by type of fish and seafood consumption and in sensitivity analyses. Conclusion: We found no evidence supporting a protective association of fish and seafood consumption during pregnancy with offspring symptoms of wheeze, asthma and allergic rhinitis from infancy to mid childhood</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1464-3685 (Electronic)IS - 0300-5771 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - Netherlands -CO - United States -CO - Spain -CO - Portugal -CO - France -CO - Norway -CO - United KIngdom -CO - Italy -CO - Ireland -CO - Denmark -CO - United States -CO - Belgium -CO - Faroe Islands -</style></notes><work-type><style face="normal" font="Arial">10.1093/ije/dyx007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28338907">PM:28338907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Epidemiol\20170324-StratakisN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Epidemiol\20170324-StratakisN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Stratakis N</style></custom2><misc3><style face="normal" font="Arial">10.1093/ije/dyx007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pacharra,M.</style></author><author><style face="normal" font="Arial"> Kleinbeck,S.</style></author><author><style face="normal" font="Arial"> Schaper,M.</style></author><author><style face="normal" font="Arial"> Blaszkewicz,M.</style></author><author><style face="normal" font="Arial"> Golka,K.</style></author><author><style face="normal" font="Arial"> van Thriel,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Does seasonal allergic rhinitis increase sensitivity to ammonia exposure?</style></title><secondary-title><style face="normal" font="Arial">Int J Hyg Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Hyg Environ Health</style></full-title></periodical><pages end="848" start="840">840-848</pages><volume><style face="normal" font="Arial">220</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chemical sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritants</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinomanometry</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensory irritant</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Stress response</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Trigeminal chemoreception</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1438-4639</style></isbn><abstract><style face="normal" font="Arial">Allergic inflammation in the upper airways represents a wide-spread health issue: Little is known about whether it increases sensitivity to airborne chemicals thereby challenging established exposure limits that neglect such differences in susceptibility. To investigate the role of pre-existing allergic inflammation, 19 subjects with seasonal allergic rhinitis (SAR) and 18 control subjects with low risk of sensitization were exposed for 4 h to ammonia in two concentrations (cross-over design): 2.5 ppm (odor threshold) and 0</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô40 ppm (occupational exposure limit: 20 ppm TWA). Prior to the whole-body exposure, it was confirmed that subjects with SAR showed persistent inflammation outside the pollen season as indicated by increased exhaled nitric oxide and total immunoglobulin E in serum compared to controls. Despite concentration-dependent increases in chemosensory perceptions and acute symptoms, SAR status did not modulate subjective effects of exposure. Moreover, SAR status did not affect the investigated physiological endpoints of sensory irritation: While eye-blink recordings confirmed weak ocular irritation properties of ammonia at 0</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô40 ppm, this effect was not enhanced in SAR subjects compared to controls. Irrespective of SAR status, exposure to 0</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô40 ppm ammonia did not result in a cortisol stress response, objective nasal obstruction as measured with anterior active rhinomanometry, or an inflammatory response as indexed by substance P, tumor-necrosis-factor +¦, and high-mobility-group protein 1 in nasal lavage fluid. At least for the malodorous compound ammonia, these results do not support the hypothesis that SAR enhances chemosensory effects in response to local irritants. Before generalizing this finding, more compounds as well as sensitization to perennial allergens need to be investigated</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijheh.2017.03.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392402">PM:28392402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Hyg Environ Health\20170423-PacharraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Hyg Environ Health\20170423-PacharraM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, Pacharra M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijheh.2017.03.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Overton,N.L.</style></author><author><style face="normal" font="Arial"> Simpson,A.</style></author><author><style face="normal" font="Arial"> Bowyer,P.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Infection Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, The University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Genetic susceptibility to severe asthma with fungal sensitization</style></title><secondary-title><style face="normal" font="Arial">Int J Immunogenet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Immunogenet</style></full-title></periodical><pages end="106" start="93">93-106</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenosine</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> CCL2</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic association</style></keyword><keyword><style face="normal" font="Arial"> Genetic Association Studies</style></keyword><keyword><style face="normal" font="Arial"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Mannose-Binding Lectin</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasminogen</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 3</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">Severe asthma is problematic and its pathogenesis poorly understood. Fungal sensitization is common, and many patients with severe asthma with fungal sensitization (SAFS), used to denote this subgroup of asthma, respond to antifungal therapy. We have investigated 325 haplotype-tagging SNPs in 22 candidate genes previously associated with aspergillosis in patients with SAFS, with comparisons in atopic asthmatics and healthy control patients, of whom 47 SAFS, 279 healthy and 152 atopic asthmatic subjects were genotyped successfully. Significant associations with SAFS compared with atopic asthma included Toll-like receptor 3 (TLR3) (p = .009), TLR9 (p = .025), C-type lectin domain family seven member A (dectin-1) (p = .043), interleukin-10 (IL-10) (p = .0010), mannose-binding lectin (MBL2) (p = .007), CC-chemokine ligand 2 (CCL2) (2 SNPs, p = .025 and .041), CCL17 (p = .002), plasminogen (p = .049) and adenosine A2a receptor (p = .024). These associations differ from those found in ABPA in asthma, indicative of contrasting disease processes. Additional and broader genetic association studies in SAFS, combined with experimental work, are likely to contribute to our understanding of different phenotypes of problematic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1744-313X (Electronic)IS - 1744-3121 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/iji.12312.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28371335">PM:28371335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Immunogenet\20170403-OvertonNL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Immunogenet\20170403-OvertonNL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Overton NL</style></custom2><misc3><style face="normal" font="Arial">10.1111/iji.12312.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mastrorilli,C.</style></author><author><style face="normal" font="Arial"> Rizzuti,L.</style></author><author><style face="normal" font="Arial"> Cangelosi,A.M.</style></author><author><style face="normal" font="Arial"> Iovane,B.</style></author><author><style face="normal" font="Arial"> Chiari,G.</style></author><author><style face="normal" font="Arial"> Caffarelli,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Clinica Pediatrica, Azienda Ospedaliero-Universitaria di Parma, Unit of Allergy and Immunology in Evolutive Age, Department of Medicine and Surgery, University of Parma, Parma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Long-acting insulin allergy in a diabetic child</style></title><secondary-title><style face="normal" font="Arial">Int J Immunopathol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Immunopathol Pharmacol</style></full-title></periodical><pages end="" start="394632017700431">394632017700431-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Insulin allergy</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick by prick</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">Insulin allergy has been uncommon since the introduction of human recombinant insulin preparations; the prevalence is 2.4%. Insulin injection could elicit immediate reactions, which are usually induced by an IgE-mediated mechanism, within the first hour after drug administration. In the present study, we describe the case of a child who experienced immediate urticaria after long-acting insulin injection. A 9-year-old girl affected by type I diabetes mellitus referred a history of three episodes of urticaria 30 min after insulin subcutaneous injection. During the first week of insulin therapy, she developed generalized immediate urticaria twice after long-acting insulin glargine first and then once after insulin degludec administration. Symptoms resolved within a few hours after treatment with oral antihistamine. She tolerated rapid insulin lispro. Her personal allergological history was negative. Skin prick tests with degludec, glargine and detemir were performed, showing negative results. Intradermal 1:100000-diluted tests were immediately positive for both degludec and glargine but not for detemir. In light of these findings, detemir was administered without any reaction. Our results show that detemir is tolerated by patients with clinical hypersensitivity reactions to degludec and glargine. Although reactions could be attributable to additives allergy, such as zinc or metacresol, this was excluded since all three preparations contain the same components. So, insulin itself acted as offending allergen. Detemir differs from degludec and glargine in a few aminoacids. Therefore, it is possible that the conformational rather than the linear epitope may be responsible for the reaction. This result suggests integrating intradermal tests in the diagnostic flowchart for insulin allergy. Insulin allergy should always be suspected in patients with immediate symptoms after drug injection. As allergologic work-up, prick by prick test and intradermal test to insulin preparations should be performed. In case of negative results of cutaneous tests, insulin analogs may be administered</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 2058-7384 (Electronic)IS - 0394-6320 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1177/0394632017700431</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28368217">PM:28368217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Immunopathol Pharmacol\20170403-MastrorilliC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Immunopathol Pharmacol\20170403-MastrorilliC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Mastrorilli C</style></custom2><misc3><style face="normal" font="Arial">10.1177/0394632017700431</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,M.</style></author><author><style face="normal" font="Arial"> Jia,H.M.</style></author><author><style face="normal" font="Arial"> Cui,F.X.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author><author><style face="normal" font="Arial"> Yang,M.H.</style></author><author><style face="normal" font="Arial"> Zou,Z.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</style></auth-address><titles><title><style face="normal" font="Arial">The Effect of Chinese Herbal Medicine Formula mKG on Allergic Asthma by Regulating Lung and Plasma Metabolic Alternations</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E602">E602-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Chinese herbal medicines</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> herbal medicines</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Development</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> TCM</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thromboxane</style></keyword><keyword><style face="normal" font="Arial"> Thromboxane B2</style></keyword><keyword><style face="normal" font="Arial"> traditional Chinese herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory disorder of the airway and is characterized by airway remodeling, hyperresponsiveness, and shortness of breath. Modified Kushen Gancao Formula (mKG), derived from traditional Chinese herbal medicines (TCM), has been demonstrated to have good therapeutic effects on experimental allergic asthma. However, its anti-asthma mechanism remains currently unknown. In the present work, metabolomics studies of biochemical changes in the lung tissue and plasma of ovalbumin (OVA)-induced allergic asthma mice with mKG treatment were performed using ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS). Partial least squares-discriminate analysis (PLS-DA) indicated that the metabolic perturbation induced by OVA was reduced after mKG treatment. A total of twenty-four metabolites involved in seven metabolic pathways were identified as potential biomarkers in the development of allergic asthma. Among them, myristic acid (L3 or P2), sphinganine (L6 or P4), and lysoPC(15:0) (L12 or P16) were detected both in lung tissue and plasma. Additionally, l-acetylcarnitine (L1), thromboxane B2 (L2), 10-HDoHE (L10), and 5-HETE (L11) were first reported to be potential biomarkers associated with allergic asthma. The treatment of mKG mediated all of those potential biomarkers except lysoPC(15:0) (P16). The anti-asthma mechanism of mKG can be achieved through the comprehensive regulation of multiple perturbed biomarkers and metabolic pathways</style></abstract><notes><style face="normal" font="Arial">DA - 20170313IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18030602</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28287417">PM:28287417</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E602.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E602.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170313, Yu M</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18030602</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van der Vlugt,L.E.</style></author><author><style face="normal" font="Arial"> Obieglo,K.</style></author><author><style face="normal" font="Arial"> Ozir-Fazalalikhan,A.</style></author><author><style face="normal" font="Arial"> Sparwasser,T.</style></author><author><style face="normal" font="Arial"> Haeberlein,S.</style></author><author><style face="normal" font="Arial"> Smits,H.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Schistosome-induced pulmonary B cells inhibit allergic airway inflammation and display a reduced Th2-driving function</style></title><secondary-title><style face="normal" font="Arial">Int J Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Parasitol</style></full-title></periodical><pages end="554" start="545">545-554</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Breg</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">Chronic schistosome infections protect against allergic airway inflammation (AAI) via the induction of IL-10-producing splenic regulatory B (Breg) cells. Previous experiments have demonstrated that schistosome-induced pulmonary B cells can also reduce AAI, but act independently of IL-10. We have now further characterized the phenotype and inhibitory activity of these protective pulmonary B cells. We excluded a role for regulatory T (Treg) cell induction as putative AAI-protective mechanisms. Schistosome-induced B cells showed increased CD86 expression and reduced cytokine expression in response to Toll-like receptor (TLR) ligands compared with control B cells. To investigate the consequences for T cell activation we cultured ovalbumin (OVA)-pulsed, schistosome-induced B cells with OVA-specific transgenic T cells and observed less Th2 cytokine expression and T cell proliferation compared with control conditions. This suppressive effect was preserved even under optimal T cell stimulation by anti-CD3/28. Blocking of the inhibitory cytokines IL-10 or TGF-beta only marginally restored Th2 cytokine induction. These data suggest that schistosome-induced pulmonary B cells are impaired in their capacity to produce cytokines to TLR ligands and to induce Th2 cytokine responses independent of their antigen-presenting function. These findings underline the presence of distinct B cell subsets with different stimulatory or inhibitory properties even if induced by the same type of helminth</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 1879-0135 (Electronic)IS - 0020-7519 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijpara.2017.02.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28385494">PM:28385494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Parasitol\20170407-vanderVlugtLE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Parasitol\20170407-vanderVlugtLE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170407, van der Vlugt LE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijpara.2017.02.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ogulur,I.</style></author><author><style face="normal" font="Arial"> Kiykim,A.</style></author><author><style face="normal" font="Arial"> Baris,S.</style></author><author><style face="normal" font="Arial"> Ozen,A.</style></author><author><style face="normal" font="Arial"> Yuce,E.G.</style></author><author><style face="normal" font="Arial"> Karakoc-Aydiner,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Basophil activation test for inhalant allergens in pediatric patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="201" start="197">197-201</pages><volume><style face="normal" font="Arial">97</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometer</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0165-5876</style></isbn><abstract><style face="normal" font="Arial">Objective Flow cytometric quantification of in vitro basophil activation can be quite performant and reliable tool to measure IgE-dependent allergen-specific responses in allergic patients. Current study aimed to evaluate the clinical relevance of basophil activation test (BAT) for the diagnosis of pediatric grass pollen and house dust mite (HDM) allergies. Methods Forty-seven patients suffering from allergic rhinitis with HDM and grass pollen co-sensitization with clinical history of allergic rhinitis and/or asthma and 15 non-allergic healthy subjects were enrolled. BAT was determined by flow cytometry upon double staining with anti-IgE/anti-CD63 mAb. Results Regarding HDM with cut-off point greater than 12.5% for CD63+ basophils sensitivity and specificity of the BAT were 90% and 73%, with positive predictive value (PPV) and negative predictive value (NPV) as 0.70 and 0.91, respectively. The analysis of concordance of being either allergic or healthy in comparison to BAT results for HDM revealed a substantial concordance (+¦ index= 0.61, p&amp;lt;0.001). Grass pollen with cut-off point greater than 11%, BAT attained a sensitivity, specificity, PPV, and NPV of 96%, 93%, 0.98, and 0.88, respectively. The analysis of concordance of being either allergic or healthy in comparison to BAT results for grass pollen revealed an almost perfect concordance (+¦ index= 0.87, p&amp;lt;0.001). Conclusion Our findings concluded that BAT is reliable technique in the diagnosis of sensitization to grass pollen and HDM. The sensitivity of BAT in pollen allergic children was found to be remarkably higher in our cohort compared to other studies</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijporl.2017.04.006</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.ijporl.2017.04.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-97-197-201.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-97-197-201.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170422, Ogulur I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijporl.2017.04.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camargo Hizume-Kunzler,D.</style></author><author><style face="normal" font="Arial"> Greiffo,F.R.</style></author><author><style face="normal" font="Arial"> Fortkamp,B.</style></author><author><style face="normal" font="Arial"> Ribeiro,F.G.</style></author><author><style face="normal" font="Arial"> Keller,N.J.</style></author><author><style face="normal" font="Arial"> Regina,B.T.</style></author><author><style face="normal" font="Arial"> Melo,A.L.</style></author><author><style face="normal" font="Arial"> Perini,A.</style></author><author><style face="normal" font="Arial"> Bobinski,F.</style></author><author><style face="normal" font="Arial"> Duarte,S.M.</style></author><author><style face="normal" font="Arial"> Rocha,L.F.</style></author><author><style face="normal" font="Arial"> Paula,V.R.</style></author><author><style face="normal" font="Arial"> Vargas,H.V.</style></author><author><style face="normal" font="Arial"> Soares Dos Santos,A.R.</style></author><author><style face="normal" font="Arial"> Cattelan,B.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State University of Santa Catarina, Physical Therapy, Florianopolis, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Aerobic Exercise Decreases Lung Inflammation by IgE Decrement in an OVA Mice Model</style></title><secondary-title><style face="normal" font="Arial">Int J Sports Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Sports Med</style></full-title></periodical><pages end="480" start="473">473-480</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> lung function decline</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="Arial">Aerobic exercise (AE) reduces lung function decline and risk of exacerbations in asthmatic patients. However, the inflammatory lung response involved in exercise during the sensitization remains unclear. Therefore, we evaluated the effects of exercise for 2 weeks in an experimental model of sensitization and single ovalbumin-challenge. Mice were divided into 4 groups: mice non-sensitized and not submitted to exercise (Sedentary, n=10); mice non-sensitized and submitted to exercise (Exercise, n=10); mice sensitized and exposed to ovalbumin (OVA, n=10); and mice sensitized, submitted to exercise and exposed to OVA (OVA+Exercise, n=10). 24 h after the OVA/saline exposure, we counted inflammatory cells from bronchoalveolar fluid (BALF), lung levels of total IgE, IL-4, IL-5, IL-10 and IL-1ra, measurements of OVA-specific IgG1 and IgE, and VEGF and NOS-2 expression via western blotting. AE reduced cell counts from BALF in the OVA group (p&lt;0.05), total IgE, IL-4 and IL-5 lung levels and OVA-specific IgE and IgG1 titers (p&lt;0.05). There was an increase of NOS-2 expression, IL-10 and IL-1ra lung levels in the OVA groups (p&lt;0.05). Our results showed that AE attenuated the acute lung inflammation, suggesting immunomodulatory properties on the sensitization process in the early phases of antigen presentation in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 1439-3964 (Electronic)IS - 0172-4622 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1055/s-0042-121638</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28388779">PM:28388779</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170407, Camargo Hizume-Kunzler D</style></custom2><misc3><style face="normal" font="Arial">10.1055/s-0042-121638</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shakeri,F.</style></author><author><style face="normal" font="Arial"> Soukhtanloo,M.</style></author><author><style face="normal" font="Arial"> Boskabady,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Neurogeneeic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranNeurogeneeic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">The effect of hydro-ethanolic extract of Curcuma longa rhizome and curcumin on total and differential WBC and serum oxidant, antioxidant biomarkers in rat model of asthma</style></title><secondary-title><style face="normal" font="Arial">Iran J Basic Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Basic Med Sci</style></full-title></periodical><pages end="165" start="155">155-165</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Curcumin</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: The effects of Curcuma longa (C. longa) and curcumin on total and differential WBC count and oxidant, antioxidant biomarkers, in rat model of asthma were evaluated. MATERIALS AND METHODS: Total and differential WBC count in the blood, NO2, NO3, MDA, SOD, CAT and thiol levels in serum were examined in control, asthma, Asthmatic rats treated with C. longa (0.75, 1.50, and 3.00 mg/ml), curcumin (0.15, 0.30, and 0.60 mg/ml), and dexamethasone (1.25 mug/ml) rats. RESULTS: Total and most differential WBC count, NO2, NO3 and MDA were increased but lymphocytes, SOD, CAT and thiol were decreased in asthmatic animals compared to controls (P&lt;0.001). Total WBC, NO2 and NO3 were significantly reduced in treated groups with dexamethasone and all concentrations of C. longa and curcumin compared to asthmatic group (P&lt;0.001 for all cases). MDA was significantly decreased, but SOD, CAT and thiol increased in treated asthma animals with dexamethasone and two higher concentrations of C. longa and curcumin (P&lt;0.01 to P&lt;0.001). There were significant improvement in eosinophil percentage due to treatment of highest concentration of the extract and curcumin, neutrophil and monocyte due to highest concentration of curcumin and lymphocyte due to highest concentration of the extract and two higher concentrations of curcumin compared to asthmatic group (P&lt;0.01 to P&lt;0.001). Dexamethasone treatment improved monocyte (P&lt;0.001) and lymphocyte (P&lt;0.01) percentages. CONCLUSION: Antioxidant and anti-inflammatory effects of C. longa extract and its constituent curcumin in animal model of asthma was observed which suggest a therapeutic potential for the plant and its constituent on asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2008-3866 (Print)IS - 2008-3866 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.22038/ijbms.2017.8241</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293392">PM:28293392</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Basic Med Sci\2017-20-155-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Basic Med Sci\2017-20-155-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Shakeri F</style></custom2><misc3><style face="normal" font="Arial">10.22038/ijbms.2017.8241</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahboubi,O.Y.</style></author><author><style face="normal" font="Arial"> Farid,H.R.</style></author><author><style face="normal" font="Arial"> Ahanchian,H.</style></author><author><style face="normal" font="Arial"> Jarahi,L.</style></author><author><style face="normal" font="Arial"> Ariaee,N.</style></author><author><style face="normal" font="Arial"> Jabbari,A.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Report of Common Aeroallergens among Allergic Patients in Northeastern Iran</style></title><secondary-title><style face="normal" font="Arial">Iran J Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Otorhinolaryngol</style></full-title></periodical><pages end="94" start="89">89-94</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">91</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Ash</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross-reactions</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> crossreactions</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> fraxinus excelsior</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Salsola</style></keyword><keyword><style face="normal" font="Arial"> Salsola kali</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The prevalence of atopic diseases has increased in recent decades dramatically. The most common aeroallergens in Northeastern Iran have not been fully defined. Determining the most common aeroallergens in allergic patients based on the skin prick test (SPT) was aimed in this investigation. MATERIALS AND METHODS: This cross-sectional study enrolled 1,006 allergic patients (aged 1-86 years) from October 2010 to February 2014 referred to the Allergy clinics of Mashhad University of Medical Science. After completing a checklist including demographic information, the SPT was performed according to the patients' history of aeroallergen sensitivity. RESULTS: Patients with symptoms of asthma, allergic rhinitis, atopic dermatitis, and urticaria were enrolled. Ninety seven percent of patients had a positive skin test to at least one aeroallergen. The most prevalent allergens were Russian thistle (Salsola kali) (50.2%), ash (Fraxinus excelsior) (36.7%), grass mix (29.1%), tree mix (21.6%), and pigweed mix (19.5%). Common allergens in patients with different symptoms of allergic disorders were as follows: asthma (Russian thistle, grass mix, ash, tree mix, and Dermatophagoides pteronyssinus); allergic rhinitis (Russian thistle, ash, grass mix, tree mix, and pigweed mix); urticaria (Russian thistle, ash, grass mix, pigweed mix, and tree mix) and atopic dermatitis (Russian thistle, grass mix, ash, tree mix, and pigweed mix). In the spring, the most prevalent allergens were Russian thistle, ash, grass mix, tree mix, and pigweed mix. In the summer, Russian thistle, ash, grass mix, tree mix, and pigweed mix accounted for the most prevalent allergens. During the autumn, Russian thistle, ash, grass mix, pigweed mix and lamb's quarter were the most common aeroallergens, while in the winter, Russian thistle, ash, grass mix, pigweed mix, and tree mix were shown to be the most common aeroallergens. CONCLUSION: Determination of the most common aeroallergens in this area is unavoidable in the diagnosis and management of allergic disorders. Understanding the prevalence of the most common aeroallergens such as Russian thistle in 50.2% of people or other common aeroallergens can help patients and specialists to more easily identify suspected allergens, reduce costs, and support immunotherapy of allergic patients in this area. Moreover, it is helpful in avoiding pollens or cross-reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 2251-7251 (Print)IS - 2251-7251 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393056">PM:28393056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Otorhinolaryngol\2017-29-89-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Otorhinolaryngol\2017-29-89-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Mahboubi OY</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Traversa,A.</style></author><author><style face="normal" font="Arial"> Adriano,D.</style></author><author><style face="normal" font="Arial"> Bellio,A.</style></author><author><style face="normal" font="Arial"> Bianchi,D.M.</style></author><author><style face="normal" font="Arial"> Gallina,S.</style></author><author><style face="normal" font="Arial"> Ippolito,C.</style></author><author><style face="normal" font="Arial"> Romano,A.</style></author><author><style face="normal" font="Arial"> Durelli,P.</style></author><author><style face="normal" font="Arial"> Pezzana,A.</style></author><author><style face="normal" font="Arial"> Decastelli,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Control and Production Hygiene Unit, Institute for Experimental Veterinary Medicine of Piedmont, Liguria and Aosta Valley , Turin, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Food Safety and Sustainable Nutrition Workshops: Educational Experiences for Primary School Children in Turin, Italy</style></title><secondary-title><style face="normal" font="Arial">Ital J Food Saf</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ital J Food Saf</style></abbr-1></periodical><pages end="" start="6177">6177-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Freezing</style></keyword><keyword><style face="normal" font="Arial"> fresh fish</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hidden allergens</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="Arial">European control and prevention policies are focused to guarantee a high level of protection of consumers' health. Food-borne diseases as obesity, diabetes, food allergy, and food-borne outbreaks are increasing. To prevent food-borne diseases, it is fundamental to involve consumers, in particular children, in educational experiences aimed to learn the proper behaviours to be applied. In this context, we designed and performed 5 educational workshops about food safety, hidden allergens in food and nutrition aimed to involve children attending primary and summer school. These experiences let us collect observations about children knowledge and behaviours. From May to October 2015, a total of 1708 children aged 6 to 11 years joined our workshops. Children were involved in listening activities, laboratory experiments, handling games and sensory experiences. All participants were familiar with food allergy and were interested to know how to behave with allergic people. Children showed great curiosity in discovering that many foods normally contain live bacteria. Less than 25% of children reported to skip breakfast, to have it watching TV or to spend few minutes for it. Many of them (>75%) thought that fruits and vegetables are all year-round available and are not related to a specific period. Very few participants (&lt;25%) knew that freezing is the treatment to be applied to make fresh fish safe from parasites. Children involved in food safety and nutrition educational experiences have the opportunity to increase their awareness about the correct behaviours to prevent food-borne diseases and to improve their own critical thinking about food consumption</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 2239-7132 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4081/ijfs.2017.6177</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28299288">PM:28299288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Food Saf\2017-6-6177.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Food Saf\2017-6-6177.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Traversa A</style></custom2><misc3><style face="normal" font="Arial">10.4081/ijfs.2017.6177</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Del Giudice,M.M.</style></author><author><style face="normal" font="Arial"> Indolfi,C.</style></author><author><style face="normal" font="Arial"> Capasso,M.</style></author><author><style face="normal" font="Arial"> Maiello,N.</style></author><author><style face="normal" font="Arial"> Decimo,F.</style></author><author><style face="normal" font="Arial"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Woman, Child and General and Specialized Surgery, Second University of Naples, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma</style></title><secondary-title><style face="normal" font="Arial">Ital J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ital J Pediatr</style></full-title></periodical><pages end="" start="25">25-</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Cetirizine</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) and allergic asthma are caused by an IgE-mediated inflammatory reaction. Probiotics may exert anti-inflammatory and immune-modulatory activity. Thus, this study aimed at investigating whether a Bifidobacteria mixture could be able to relieve nasal symptoms, and affect quality of life (QoL) in children with AR and intermittent asthma due to Parietaria allergy. MATERIALS AND METHODS: The present study was conducted as placebo-controlled, double-blinded, and randomized. Globally, 40 children (18 males; mean age 9 +/- 2.2 years) were enrolled. They were treated with probiotics or placebo: 1 sachet/day for 4 weeks. AR symptoms, and QoL were assessed at baseline and after treatment. Use of rescue medications, such as cetirizine syrup and salbutamol spray, was also permitted and recorded. RESULTS: Children treated with probiotic mixture achieved a significant improvement of symptoms (p &lt; 0.005), and QoL ((p &lt; 0.001). Placebo group had worsening of symptoms (p &lt; 0.005) and QoL (p &lt; 0.001). The use of rescue medications was overlapping in the two groups. The intergroup analysis showed that probiotic mixture was significantly superior than placebo for all parameters. CONCLUSIONS: The current study demonstrated that a Bifidobacteria mixture was able of significantly improving AR symptoms and QoL in children with pollen-induced AR and intermittent asthma. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT02807064</style></abstract><notes><style face="normal" font="Arial">DA - 20170308IS - 1824-7288 (Electronic)IS - 1720-8424 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13052-017-0340-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28270216">PM:28270216</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Pediatr\2017-43-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Pediatr\2017-43-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170308, Del Giudice MM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13052-017-0340-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,S.S.</style></author><author><style face="normal" font="Arial"> Liu,Q.M.</style></author><author><style face="normal" font="Arial"> Xiao,A.F.</style></author><author><style face="normal" font="Arial"> Maleki,S.J.</style></author><author><style face="normal" font="Arial"> Alcocer,M.</style></author><author><style face="normal" font="Arial"> Gao,Y.Y.</style></author><author><style face="normal" font="Arial"> Cao,M.J.</style></author><author><style face="normal" font="Arial"> Liu,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Food and Biological Engineering, Xiamen Key Laboratory of Marine Functional Food, Fujian Provincial Engineering Technology Research Center of Marine Functional Food, Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources, Jimei University , 43 Yindou Road, Xiamen 361021, Fujian, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Eucheuma cottonii Sulfated Oligosaccharides Decrease Food Allergic Responses in Animal Models by Up-regulating Regulatory T (Treg) Cells</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="3222" start="3212">3212-3222</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy activity</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic degradation</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> forkhead box protein 3</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">In the present study, the anti-food allergy activity of Eucheuma cottonii sulfated oligosaccharide (ESO) was investigated. ESO was obtained by enzymatic degradation and purified by column chromatography. RBL-2H3 cells and BALB/c mouse model were used to test the anti-food allergy activity of ESO. The effects of ESO on the regulatory T (Treg) cells and bone marrow-derived mast cells (BMMCs) were investigated by flow cytometry. The results of in vivo assay showed that ESO decreased the levels of mast cell protease-1 and histamine and inhibited the levels of specific IgE by 77.7%. In addition, the production of interleukin (IL)-4 and IL-13 was diminished in the ESO groups compared to the non-ESO-treated group. Furthermore, ESO could up-regulate Treg cells by 22.2-97.1%. In conclusion, ESO decreased the allergy response in mice by reducing basophil degranulation, up-regulating Treg cells via Forkhead box protein 3 (Foxp3), and releasing IL-10. ESO may have preventive and therapeutic potential in allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b00389</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359154">PM:28359154</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-3212-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-3212-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Xu SS</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b00389</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tuppo,L.</style></author><author><style face="normal" font="Arial"> Alessandri,C.</style></author><author><style face="normal" font="Arial"> Pasquariello,M.S.</style></author><author><style face="normal" font="Arial"> Petriccione,M.</style></author><author><style face="normal" font="Arial"> Giangrieco,I.</style></author><author><style face="normal" font="Arial"> Tamburrini,M.</style></author><author><style face="normal" font="Arial"> Mari,A.</style></author><author><style face="normal" font="Arial"> Ciardiello,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biosciences and BioResources, CNR , I-80131 Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Pomegranate Cultivars: Identification of the New IgE-Binding Protein Pommaclein and Analysis of Antioxidant Variability</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="2710" start="2702">2702-2710</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">13</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Nutraceutical</style></keyword><keyword><style face="normal" font="Arial"> Nutraceuticals</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergen</style></keyword><keyword><style face="normal" font="Arial"> Pomegranate</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pru p 7</style></keyword><keyword><style face="normal" font="Arial"> pulp</style></keyword><keyword><style face="normal" font="Arial"> Pun g 1</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> RP-HPLC</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">The consumption of pomegranate is increasing as it is considered a health-promoting food. Nevertheless, it can trigger allergic reactions, sometimes severe. The LTP Pun g 1 is the only pomegranate allergen so far reported. Based on preliminary clinical observations, the main aim of this study was the investigation of still unknown allergens contained in this fruit. Pommaclein, a homologue of peamaclein, the peach allergen Pru p 7, was isolated, identified by protein sequencing, and characterized as an IgE-binding protein by different test systems. RP-HPLC protein profiles revealed significant variations of LTP and pommaclein content in the red pulp of selected cultivars and accessions. Conversely, the mesocarp appeared free of proteins and much richer in antioxidants. In conclusion, a new allergen has been identified, and it could contribute to improving allergy diagnosis. The study highlights that pomegranate mesocarp could represent a rich and safe source of nutraceuticals also for allergic subjects</style></abstract><notes><style face="normal" font="Arial">DA - 20170314IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b00092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290690">PM:28290690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-2702-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\2017-65-2702-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170314, Tuppo L</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b00092</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lim,C.E.</style></author><author><style face="normal" font="Arial"> Sison,C.P.</style></author><author><style face="normal" font="Arial"> Ponda,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Cohen Children's Medical Center, Hofstra Northwell School of Medicine, New Hyde Park, NY</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of Pediatric and Adult Systemic Reactions to Subcutaneous Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1247" start="1241">1241-1247</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Subcutaneous immunotherapy (SCIT) has been used to treat allergic rhinitis for over a century, and current regimens have wide variability with an array of practice styles and dosing strategies. Although there are some statements about contraindications and cautions, no specific formal age- or weight-based dosing guidelines are utilized when administering SCIT. OBJECTIVE: The primary objective of this study was to estimate the overall incidence rate of any reaction to SCIT and to consider the severity of the reaction by grade in children and adults. METHODS: A retrospective chart review was conducted to document the number and severity of episodes of systemic reactions (SRs) in pediatric and adult subjects. Crude incidence rates were estimated as the number of SRs relative to the total injections administered. Adjusted incidence rate ratios were generated using a generalized estimating equation approach, which accounted for multiple visits within subjects. RESULTS: The incidence rate for any SR was 0.2%. The unadjusted incidence rate of any SR was significantly higher in children compared with adults (P &lt; .001), although not significant when adjusted for asthma, gender, and phase of SCIT (P &lt; .054). However, the incidence rate for grade 1 and 2 SRs in children was 1.89 times the incidence rate for adults, adjusting for these variables (P &lt; .015). CONCLUSIONS: These results suggest that current SCIT practices are associated with a higher rate of SRs, specifically of grade 1 and 2 SRs, in children than adults. Further studies are necessary to evaluate if changes in dosing strategies for children, such as a lower starting dose, a decrease in target maintenance dose, or a slower build-up phase, are warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20170325IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.01.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341172">PM:28341172</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170325-LimCE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170325-LimCE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170325, Lim CE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.01.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schwager,C.</style></author><author><style face="normal" font="Arial"> Kull,S.</style></author><author><style face="normal" font="Arial"> Behrends,J.</style></author><author><style face="normal" font="Arial"> Rockendorf,N.</style></author><author><style face="normal" font="Arial"> Schocker,F.</style></author><author><style face="normal" font="Arial"> Frey,A.</style></author><author><style face="normal" font="Arial"> Homann,A.</style></author><author><style face="normal" font="Arial"> Becker,W.M.</style></author><author><style face="normal" font="Arial"> Jappe,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical and Molecular Allergology, Research Center Borstel, Priority Research Area Asthma and Allergy, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Peanut oleosins associated with severe peanut allergy - Importance of lipophilic allergens for comprehensive allergy diagnostics</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Roasting</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergy is one of the most common and most severe food allergies in Western countries and its accurate diagnosis to prevent potential life-threatening allergic reactions is crucial. However, aqueous extracts used for routine diagnostic measurements are devoid of lipophilic allergens such as oleosins. We have recently succeeded in the isolation and purification of these unique proteins, and the current study evaluates their allergenic potential and clinical relevance. OBJECTIVE: We sought to assess allergenicity and sensitization prevalence of oleosins obtained from both raw and in-shell roasted peanuts. Additionally, we tested the utilization of natural and recombinant oleosins for allergy diagnostic purposes. METHODS: Oleosin sensitization, prevalence, and impact of thermal processing were analyzed by immunoblot with sera from 52 peanut-allergic individuals displaying different clinical phenotypes. The application of natural and recombinant oleosins for allergy diagnostics was investigated by basophil activation test (BAT). IgE-binding epitopes were identified by oligopeptide microarray. RESULTS: Sensitization to oleosins was observed exclusively in peanut-allergic subjects suffering from severe systemic reactions. IgE-binding capacity of oleosins derived from in-shell roasted peanuts was increased as shown by immunoblot analysis and BAT. Both natural and recombinant molecules can be used to identify oleosin-sensitized patients by BAT. A linear epitope of Ara h 15 was determined which displays high similarity to other seed-derived oleosins. CONCLUSION: Oleosins are clinically relevant peanut allergens and most likely associated with severe allergic symptoms. In-shell roasting increases their allergenicity, which is consistent with the observation that most allergic reactions are in connection with roasted peanuts</style></abstract><notes><style face="normal" font="Arial">DA - 20170326IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342912">PM:28342912</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170326-SchwagerC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170326-SchwagerC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170326, Schwager C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Archila,L.D.</style></author><author><style face="normal" font="Arial"> Khan,F.S.</style></author><author><style face="normal" font="Arial"> Bhatnagar,N.</style></author><author><style face="normal" font="Arial"> Robinson,D.</style></author><author><style face="normal" font="Arial"> Farrington,M.L.</style></author><author><style face="normal" font="Arial"> Kwok,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Benaroya Research Institute at Virginia Mason</style></auth-address><titles><title><style face="normal" font="Arial">alphaS1-casein Elucidate Major T Cell Responses in Cow's Milk Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="857" start="854">854-857</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergens</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="Arial">Cow's milk allergy (CMA) is increasing in prevalence, affecting approximately 4% of children. Cow's milk (CM) is a common cause of fatal/ near fatal anaphylactic reactions. Understanding of CM-specific CD4+ T-cells responses to milk allergens should help elucidate the pathological mechanisms of persistent CMA. Milk allergen epitopes specific T-cells were examined in CMA subjects. Frequencies and phenotypes of these T-cells were found to be different between older and younger subjects</style></abstract><notes><style face="normal" font="Arial">DA - 20170327IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28343843">PM:28343843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170327-ArchilaLD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170327-ArchilaLD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170327, Archila LD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alhossan,A.</style></author><author><style face="normal" font="Arial"> Lee,C.S.</style></author><author><style face="normal" font="Arial"> MacDonald,K.</style></author><author><style face="normal" font="Arial"> Abraham,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy, King Saud University, Riyadh, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="Arial">"Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1370" start="1362">1362-1370</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Effect size</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: After the approval of omalizumab for severe allergic asthma, a total of 25 studies have evaluated the effectiveness of omalizumab under "real-life" conditions of heterogeneity in patients, clinicians, sites, and treatment patterns. OBJECTIVE: We conducted a meta-analysis to evaluate the effectiveness of omalizumab focusing on treatment response, lung function, quality of life, symptom control, corticosteroid use, and exacerbations and hospitalizations at 4-6, 12, and 24 months. METHODS: We searched PubMed and Embase for real-life studies on omalizumab in severe asthma published up to 2015. Three effect size types were extracted: single-point proportions; mean +/- SD of change relative to baseline as raw numbers and standardized as Cohen's d; and changes in proportions of patients as relative risk. Random-effects meta-analyses were performed to account for within- and between-study heterogeneity. Studies were weighted by the DerSimonian and Laird method. RESULTS: Per data available at the 3 time points, omalizumab therapy was consistently associated with large proportions of patients classified as "good" to "excellent" treatment responders (Global Evaluation of Treatment Effectiveness scale); improvements in forced expiratory volume in 1 second, quality of life (Asthma-related Quality-of-Life Questionnaire scale), and asthma symptom control (Asthma Control Test scale); reductions in oral and inhaled corticosteroid (ICS) use; and reductions in exacerbations and hospitalizations. CONCLUSIONS: This meta-analysis of noncontrolled studies documents the real-life pharmacotherapeutic effectiveness of omalizumab, as add-on treatment to ICS +/- long-acting beta2-agonists agents, in improving outcomes in patients with severe allergic asthma under conditions of heterogeneity in patients, clinicians, sites, and treatment patterns. The results mirror, complement, and extend the efficacy data from randomized controlled trials</style></abstract><notes><style face="normal" font="Arial">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.02.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351783">PM:28351783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170329-AlhossanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170329-AlhossanA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170329, Alhossan A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.02.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doong,J.C.</style></author><author><style face="normal" font="Arial"> Chichester,K.</style></author><author><style face="normal" font="Arial"> Oliver,E.T.</style></author><author><style face="normal" font="Arial"> Schwartz,L.B.</style></author><author><style face="normal" font="Arial"> Saini,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Johns Hopkins University School of Medicine, Baltimore, Md</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Idiopathic Urticaria: Systemic Complaints and Their Relationship with Disease and Immune Measures</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1318" start="1314">1314-1318</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil histamine release</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> CIU</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flushing</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="13" Month="3" Year="2017">2017/3/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria sometimes report systemic complaints (SCs). OBJECTIVE: We sought to determine the frequency and characteristics of SCs among patients with CIU, as well as the association of SCs with disease measures, basophil histamine release, and serum tryptase. METHODS: Adult patients with CIU were recruited from a university allergy clinic. Patients completed a disease symptom survey and underwent blood sampling for subsequent basophil histamine release and serum tryptase measurement. RESULTS: A total of 155 patients with CIU were surveyed, with 103 reporting SCs with concomitant hives as follows: joint pain or swelling (55.3%), headache/fatigue (47.6%), flushing (42.7%), wheezing (30.1%), gastrointestinal complaints (26.2%), and palpitations (9.7%). Patients with SCs (CIU-SC) were compared with those with no SCs (CIU-NSC). Both groups had similar demographic characteristics (average age in 40s, majority female and white) and basophil histamine release profiles. CIU-SC had significantly greater disease duration (51.5% CIU-SC vs 30.8% CIU-NSC had >4 years duration), emergency department visits (41.7% vs 23.1% had >1 visit in the last year), CIU-related work absences (65% vs 27.5% had >1 day), oral corticosteroid use (84.5% vs 59.6%), quality-of-life impairment (76.1 vs 59.2 SkinDex score), and serum tryptase levels (5.1 ng/mL vs 3.9 ng/mL). CONCLUSIONS: Despite similar demographic characteristics and basophil profiles as patients with CIU-NSC, patients with CIU-SC have features of greater disease burden (work absences, emergency department visits, and corticosteroid use), quality-of-life impairment, and baseline serum tryptase levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.11.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28302451">PM:28302451</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170317-DoongJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170317-DoongJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Doong JC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.11.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gulen,T.</style></author><author><style face="normal" font="Arial"> Ljung,C.</style></author><author><style face="normal" font="Arial"> Nilsson,G.</style></author><author><style face="normal" font="Arial"> Akin,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine and Allergy, Karolinska University Hospital Huddinge, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1255" start="1248">1248-1255</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy workup</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bone marrow biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictive markers</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Systemic mastocytosis (SM) is a rare disorder of abnormal mast cells in at least 1 extracutaneous organ/tissue. Anaphylaxis is an acute, severe systemic hypersensitivity reaction, and a strong association between SM and anaphylaxis has been shown. However, not all patients with SM experience anaphylaxis. Presently, there are no predictive markers to discriminate patients with SM at high risk of anaphylaxis from those at low risk. OBJECTIVE: This study sought to determine risk factors for the occurrence of anaphylaxis in patients with SM. METHODS: A cross-sectional study was conducted in 122 consecutive adult patients with SM admitted to the Mastocytosis Center at Karolinska University Hospital. All patients underwent medical evaluation, including bone marrow biopsy and a thorough allergy workup. To determine risk factors, study subjects were categorized into 2 groups according to the presence (n = 55) or absence (n = 67) of anaphylaxis and compared for their demographic, clinical, and biochemical characteristics. RESULTS: Patients with SM with anaphylaxis had less frequent presence of mastocytosis in the skin (P &lt; .001), more atopic predisposition (P = .021), higher total IgE levels (P &lt; .001), and lower baseline tryptase levels (27 ng/mL vs 42 ng/mL; P = .024) compared with patients with SM without anaphylaxis. CONCLUSIONS: Patients with SM with anaphylaxis display unique clinical and laboratory features. Hence, a risk analysis tool that is capable of discriminating patients with SM at high risk of anaphylaxis from those at low risk with 86% sensitivity was developed by using the variables male sex, absence of mastocytosis in the skin, presence of atopy, IgE levels of 15 kU/L or more, and baseline tryptase levels of less than 40 ng/mL</style></abstract><notes><style face="normal" font="Arial">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.02.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351784">PM:28351784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170329-GulenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170329-GulenT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170329, Gulen T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.02.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abonia,J.P.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author><author><style face="normal" font="Arial"> Cianferoni,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Esophagitis: A Primary Disease of the Esophageal Mucosa</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="955" start="951">951-955</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170401IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.02.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28363400">PM:28363400</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170401-AboniaJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170401-AboniaJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170401, Abonia JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.02.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Colomb,S.</style></author><author><style face="normal" font="Arial"> Bourrain,J.L.</style></author><author><style face="normal" font="Arial"> Leduc,V.</style></author><author><style face="normal" font="Arial"> Burmester,T.</style></author><author><style face="normal" font="Arial"> Marin,G.</style></author><author><style face="normal" font="Arial"> Lesage,F.X.</style></author><author><style face="normal" font="Arial"> Dhivert-Donnadieu,H.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Department of Pulmonology, Montpellier University Hospital, Montpellier, France.</style></auth-address><titles><title><style face="normal" font="Arial">Identification of the larval serum proteins as major fruit fly (Drosophila melanogaster) occupational allergens</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1155" start="1153">1153-1155</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Drosophila</style></keyword><keyword><style face="normal" font="Arial"> Drosophila melanogaster</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170401IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.02.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28363399">PM:28363399</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170401-ColombS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170401-ColombS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170401, Colomb S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.02.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Regan,J.A.</style></author><author><style face="normal" font="Arial"> Cao,Y.</style></author><author><style face="normal" font="Arial"> Dispenza,M.C.</style></author><author><style face="normal" font="Arial"> Ma,S.</style></author><author><style face="normal" font="Arial"> Gordon,L.I.</style></author><author><style face="normal" font="Arial"> Petrich,A.M.</style></author><author><style face="normal" font="Arial"> Bochner,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine Division of Allergy-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611</style></auth-address><titles><title><style face="normal" font="Arial">Ibrutinib, a BTK inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="879" start="875">875-879</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Bruton's tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Lymphoproliferative Disorders</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was shown to eliminate skin test reactivity in vivo and IgE-dependent basophil activation testing ex vivo. Blockade of the BTK pathway may represent a novel therapeutic strategy for the effective reduction of allergic reactivity</style></abstract><notes><style face="normal" font="Arial">DA - 20170408IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389390">PM:28389390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170408-ReganJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170408-ReganJA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Regan JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Metz,M.</style></author><author><style face="normal" font="Arial"> Schutz,A.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author><author><style face="normal" font="Arial"> Gorczyza,M.</style></author><author><style face="normal" font="Arial"> Zimmer,S.</style></author><author><style face="normal" font="Arial"> Staubach,P.</style></author><author><style face="normal" font="Arial"> Merk,H.F.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab is Effective in Cold Urticaria - Results of a Randomized, Placebo Controlled Trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="867" start="864">864-867</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> cold urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170408IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389393">PM:28389393</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170408-MetzM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170408-MetzM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Metz M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, IR</style></auth-address><titles><title><style face="normal" font="Arial">Serum IgE as biomarker for predicting allergen immunotherapy effectiveness</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="2029">2029-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170415IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.987</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410740">PM:28410740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170415-CiprandiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170415-CiprandiG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170415, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.987</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Karta,M.R.</style></author><author><style face="normal" font="Arial"> Rosenthal,P.S.</style></author><author><style face="normal" font="Arial"> Beppu,A.</style></author><author><style face="normal" font="Arial"> Vuong,C.Y.</style></author><author><style face="normal" font="Arial"> Miller,M.</style></author><author><style face="normal" font="Arial"> DAS,S.</style></author><author><style face="normal" font="Arial"> Kurten,R.C.</style></author><author><style face="normal" font="Arial"> Doherty,T.A.</style></author><author><style face="normal" font="Arial"> Broide,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of California San Diego, La Jolla, California</style></auth-address><titles><title><style face="normal" font="Arial">beta2 Integrins Rather than beta1 Integrins Mediate Alternaria-induced ILC2 Trafficking to the Lung</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> CD18</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> Integrins</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> trafficking</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Group 2 innate lymphoid cells (ILC2s) expand in the lungs of mice during type 2 inflammation induced by the fungal allergen Alternaria alternata. The increase in ILC2 numbers in the lung has been largely attributed to local proliferation and whether ILC2s migrate from the circulation to the lung following Alternaria exposure is unknown. OBJECTIVE: We examined whether human (lung, lymph node, blood) and mouse lung ILC2s express beta1 and beta2 integrin adhesion molecules, and whether these integrins are required for trafficking of ILC2 into the lungs of mice METHODS: Human and mouse ILC2s were assessed for surface expression of beta1 and beta2 integrins adhesion molecules by flow cytometry. The role of beta1 and beta2 integrins in ILC2 trafficking to the lungs was assessed by in vivo blocking of these integrins prior to airway exposure to Alternaria in mice. RESULTS: Both human and mouse lung ILC2s express high levels of beta1 and beta2 integrin adhesion receptors. Intranasal administration of Alternaria challenge reduced ILC2s in the bone marrow and concurrently increased blood and lung ILC2 levels. In vivo blocking of beta2 integrins (CD18) significantly reduced ILC2 levels in the lungs, but did not alter ILC2 proliferation, apoptosis, and function. In contrast, in vivo blocking of beta1 integrins or alpha4 integrins did not affect lung ILC2 levels. CONCLUSION: ILC2s increase in number in the mouse lung not only through local proliferation, but also through trafficking from the circulation into the lung using beta2 rather than beta1 or alpha4 integrins</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366795">PM:28366795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170403-KartaMR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170403-KartaMR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Karta MR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cunha,C.</style></author><author><style face="normal" font="Arial"> Goncalves,S.M.</style></author><author><style face="normal" font="Arial"> Duarte-Oliveira,C.</style></author><author><style face="normal" font="Arial"> Leite,L.</style></author><author><style face="normal" font="Arial"> Lagrou,K.</style></author><author><style face="normal" font="Arial"> Marques,A.</style></author><author><style face="normal" font="Arial"> Lupianez,C.B.</style></author><author><style face="normal" font="Arial"> Mesquita,I.</style></author><author><style face="normal" font="Arial"> Gaifem,J.</style></author><author><style face="normal" font="Arial"> Barbosa,A.M.</style></author><author><style face="normal" font="Arial"> Pinho Vaz,C.</style></author><author><style face="normal" font="Arial"> Branca,R.</style></author><author><style face="normal" font="Arial"> Campilho,F.</style></author><author><style face="normal" font="Arial"> Freitas,F.</style></author><author><style face="normal" font="Arial"> Ligeiro,D.</style></author><author><style face="normal" font="Arial"> Lass-Florl,C.</style></author><author><style face="normal" font="Arial"> Loffler,J.</style></author><author><style face="normal" font="Arial"> Jurado,M.</style></author><author><style face="normal" font="Arial"> Saraiva,M.</style></author><author><style face="normal" font="Arial"> Kurzai,O.</style></author><author><style face="normal" font="Arial"> Rodrigues,F.</style></author><author><style face="normal" font="Arial"> Castro,A.G.</style></author><author><style face="normal" font="Arial"> Silvestre,R.</style></author><author><style face="normal" font="Arial"> Sainz,J.</style></author><author><style face="normal" font="Arial"> Maertens,J.A.</style></author><author><style face="normal" font="Arial"> Torrado,E.</style></author><author><style face="normal" font="Arial"> Jacobsen,I.D.</style></author><author><style face="normal" font="Arial"> Lacerda,J.F.</style></author><author><style face="normal" font="Arial"> Campos,A.,Jr.</style></author><author><style face="normal" font="Arial"> Carvalho,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimaraes, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">IL-10 Overexpression Predisposes to Invasive Aspergillosis by Suppressing Antifungal Immunity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="870" start="867">867-870</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> stem cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">We show that the genetically-determined overexpression of IL-10 is a risk factor for invasive aspergillosis after stem-cell transplantation. Our results identify an IL-10-mediated mechanism that regulates the balance between anti- and proinflammatory antifungal immunity</style></abstract><notes><style face="normal" font="Arial">DA - 20170408IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Portugal -CO - Belgium -CO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389392">PM:28389392</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170408-CunhaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170408-CunhaC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Cunha C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hussain,M.</style></author><author><style face="normal" font="Arial"> Borcard,L.</style></author><author><style face="normal" font="Arial"> Walsh,K.P.</style></author><author><style face="normal" font="Arial"> Pena Rodriguez,M.</style></author><author><style face="normal" font="Arial"> Mueller,C.</style></author><author><style face="normal" font="Arial"> Kim,B.S.</style></author><author><style face="normal" font="Arial"> Kubo,M.</style></author><author><style face="normal" font="Arial"> Artis,D.</style></author><author><style face="normal" font="Arial"> Noti,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Pathology, Division of Experimental Pathology, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Basophil-derived interleukin-4 promotes epicutaneous antigen sensitization concomitant with the development of food allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antigen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exaggerated TSLP production and infiltration of basophils are associated with the pathogenesis of atopic dermatitis (AD), a recognized risk factor for the development of food allergies. While TSLP and basophils have been implicated to promote food-induced allergic disorders in response to epicutaneous sensitization, the mechanisms by which TSLP-elicited basophils guide the progression of allergic inflammation in the skin to distant mucosal sites such as the gastrointestinal tract are poorly understood. OBJECTIVE: We sought to test the role of basophil-intrinsic IL-4 production in TH2 sensitization to food antigens in the skin and effector food allergic responses in the gut. METHODS: Mice were epicutaneously sensitized with ovalbumin on an AD-like skin lesion, followed by intra-gastric antigen challenge to induce IgE-mediated food allergy. The requirement for basophil-derived IL-4 production for TH2 polarization and the pathogenesis of IgE-mediated food allergy was assessed in vitro by co-culture experiments with naive T cells and in vivo using IL-4 3'UTR mice that selectively lack IL-4 production in basophils. RESULTS: Epicutaneous food antigen sensitization is associated with the infiltration of IL-4 competent innate immune cells to the skin with basophils and eosinophils representing the predominant populations. In contrast to basophils, absence of eosinophils did not alter disease outcome. Co-culture of IL-4 competent basophils together with dendritic cells and naive T cells was sufficient to promote TH2 polarization in an IL-4 dependent manner in vitro, while absence of basophil-intrinsic IL-4 production in vivo was associated with reduced food allergic responses. CONCLUSION: TSLP-elicited basophils promote epicutaneous sensitization to food antigens and subsequent IgE-mediated food allergy via IL-4. Strategies to target the TSLP-basophil-IL4 axis in patients with AD may lead to innovative therapies that can prevent the progression of allergies to distant mucosal sites</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United States -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390860">PM:28390860</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170409-HussainM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170409-HussainM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Hussain M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jahreis,S.</style></author><author><style face="normal" font="Arial"> Trump,S.</style></author><author><style face="normal" font="Arial"> Bauer,M.</style></author><author><style face="normal" font="Arial"> Bauer,T.</style></author><author><style face="normal" font="Arial"> Thurmann,L.</style></author><author><style face="normal" font="Arial"> Feltens,R.</style></author><author><style face="normal" font="Arial"> Wang,Q.</style></author><author><style face="normal" font="Arial"> Gu,L.</style></author><author><style face="normal" font="Arial"> Grutzmann,K.</style></author><author><style face="normal" font="Arial"> Roder,S.</style></author><author><style face="normal" font="Arial"> Averbeck,M.</style></author><author><style face="normal" font="Arial"> Weichenhan,D.</style></author><author><style face="normal" font="Arial"> Plass,C.</style></author><author><style face="normal" font="Arial"> SACK,U.</style></author><author><style face="normal" font="Arial"> Borte,M.</style></author><author><style face="normal" font="Arial"> Dubourg,V.</style></author><author><style face="normal" font="Arial"> Schuurmann,G.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author><author><style face="normal" font="Arial"> von Bergen,M.</style></author><author><style face="normal" font="Arial"> Hackermuller,J.</style></author><author><style face="normal" font="Arial"> Eils,R.</style></author><author><style face="normal" font="Arial"> Lehmann,I.</style></author><author><style face="normal" font="Arial"> Polte,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Immunology</style></auth-address><titles><title><style face="normal" font="Arial">Maternal Phthalate Exposure Promotes Allergic Airway Inflammation over Two Generations Via Epigenetic Modifications</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> LINA</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> phthalates</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> repressor</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Prenatal and early postnatal exposures to environmental factors are considered responsible for the increasing prevalence of allergic diseases. Although there is some evidence for allergy-promoting effects in children due to exposure to plasticizers like phthalates, findings of previous studies are inconsistent and lack mechanistic information. OBJECTIVE: We investigated the effect of maternal phthalate exposure on asthma development in the subsequent generations and their underlying mechanisms including epigenetic alterations. METHODS: Phthalate metabolites were measured within the prospective mother-child cohort LINA and correlated with asthma development in the children. A murine trans-generational asthma model was used to identify involved pathways. RESULTS: In LINA maternal urinary concentrations of mono-n-butyl phthalate, a metabolite of butyl benzyl phthalate (BBP), were associated with an increased asthma risk in the children. Using a murine trans-generational asthma model, we demonstrate a direct effect of BBP on asthma severity in the offspring with a persistently increased airway inflammation up to the F2 generation. This disease-promoting effect was mediated by a BBP-induced global DNA hypermethylation in CD4+ T cells of the offspring as treatment with a DNA demethylating agent alleviated exacerbation of allergic airway inflammation. 13 transcriptionally down-regulated genes linked to promoter or enhancer hypermethylation were identified. Among these, the GATA-3 repressor Zfpm1 emerged as a potential mediator of the enhanced susceptibility for Th2-driven allergic asthma. CONCLUSION: These data provide strong evidence that maternal BBP exposure increases the risk for allergic airway inflammation in the offspring by modulating the expression of genes involved in Th2 differentiation via epigenetic alterations</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392331">PM:28392331</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170410-JahreisS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170410-JahreisS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Jahreis S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thijs,J.L.</style></author><author><style face="normal" font="Arial"> Strickland,I.</style></author><author><style face="normal" font="Arial"> Bruijnzeel-Koomen,C.A.F.M.</style></author><author><style face="normal" font="Arial"> Nierkens,S.</style></author><author><style face="normal" font="Arial"> Giovannone,B.</style></author><author><style face="normal" font="Arial"> Csomor,E.</style></author><author><style face="normal" font="Arial"> Sellman,B.R.</style></author><author><style face="normal" font="Arial"> Mustelin,T.</style></author><author><style face="normal" font="Arial"> Sleeman,M.A.</style></author><author><style face="normal" font="Arial"> de Bruin-Weller,S.</style></author><author><style face="normal" font="Arial"> Herath,A.</style></author><author><style face="normal" font="Arial"> Drylewicz,J.</style></author><author><style face="normal" font="Arial"> May,R.D.</style></author><author><style face="normal" font="Arial"> Hijnen,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Moving towards endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="737" start="730">730-737</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> IL-1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intervention trial</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease with a diverse clinical presentation. It is however unclear whether this diversity exists at a biological level. OBJECTIVE: To test the hypothesis that AD is heterogeneous at the biological level of individual inflammatory mediators. METHODS: Serum from 193 moderate to severe adult AD patients (geomean (95%CI) SASSAD of 22.3 (21.3, 23.3) and 39.1 (37.5, 40.9) respectively) and 30 non-AD healthy controls was analysed for 147 serum mediators, total IgE and 130 allergen specific IgEs. Population heterogeneity was assessed by principal component analysis (PCA) followed by unsupervised k-means cluster analysis of the principal components. RESULTS: AD patients showed pronounced evidence of inflammation compared to healthy controls. PCA of AD serum data revealed the presence of four potential AD patient clusters. Fifty-seven principal components (PCs) described approximately 90% of the variance. Unsupervised k-means cluster analysis of the 57 largest PCs delivered 4 distinct clusters of AD patients. Cluster 1 had high SASSAD and BSA with the highest levels of PARC, TIMP-1 and sCD14. Cluster 2 had low SASSAD with the lowest levels of IFN-alpha, TIMP-1 and VEGF. Cluster 3 had high SASSAD with the lowest levels of IFN-beta, IL-1 and epithelial cytokines. Cluster 4 had low SASSAD but highest levels of inflammatory markers: IL-1, IL-4, IL-13 and TSLP. CONCLUSION: AD is a heterogeneous disease both clinically and biologically. Four distinct AD patient clusters have been identified that could represent endotypes with unique biological mechanisms. Elucidation of these endotypes warrants further investigation and will require future intervention trials with specific agents such as biologics</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412391">PM:28412391</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170416-ThijsJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170416-ThijsJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Thijs JL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gensollen,T.</style></author><author><style face="normal" font="Arial"> Blumberg,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="Arial">Correlation between early-life regulation of the immune system by microbiota and allergy development</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1091" start="1084">1084-1091</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Early postnatal life is a key time for development of the immune system and colonization of the host by microbiota. Recent studies have shown that specific limbs of the immune system can be regulated by microbiota in a time-restricted period during early life. Studies in mouse models have shown that perturbations of the microbiota during early life can cause immune effects that can persist into adulthood and create increased host susceptibility to certain diseases. Here we discuss the role of early-life regulation of the immune system by the microbiota and how it can be related to allergy development</style></abstract><notes><style face="normal" font="Arial">DA - 20170409IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390575">PM:28390575</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170409-GensollenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170409-GensollenT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Gensollen T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Andorf,S.</style></author><author><style face="normal" font="Arial"> Borres,M.P.</style></author><author><style face="normal" font="Arial"> Block,W.</style></author><author><style face="normal" font="Arial"> Tupa,D.</style></author><author><style face="normal" font="Arial"> Bollyky,J.B.</style></author><author><style face="normal" font="Arial"> Sampath,V.</style></author><author><style face="normal" font="Arial"> Elizur,A.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Jones,J.E.</style></author><author><style face="normal" font="Arial"> Galli,S.J.</style></author><author><style face="normal" font="Arial"> Chinthrajah,R.S.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, Calif; Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, Calif</style></auth-address><titles><title><style face="normal" font="Arial">Association of Clinical Reactivity with Sensitization to Allergen Components in Multifood-Allergic Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1334" start="1325">1325-1334</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> 2S Albumins</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnostics</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergies</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergy</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Thirty percent of children with food allergies have multiple simultaneous allergies; however, the features of these multiple allergies are not well characterized serologically or clinically. OBJECTIVE: We comprehensively evaluated 60 multifood-allergic patients by measuring serum IgE to key allergen components, evaluating clinical histories and medication use, performing skin tests, and conducting double-blind, placebo-controlled food challenges (DBPCFCs). METHODS: Sixty participants with multiple food allergies were characterized by clinical history, DBPCFCs, total IgE, specific IgE, and component-resolved diagnostics (IgE and IgG4) data. The food allergens tested were almond, egg, milk, sesame, peanut, pecan, walnut, hazelnut, cashew, pistachio, soy, and wheat. RESULTS: Our data demonstrate that of the reactions observed during a graded DBPCFC, gastrointestinal reactions occurred more often in boys than in girls, as well as in individuals with high levels of IgE to 2S albumins from cashew, walnut, and hazelnut. Certain food allergies often occurred concomitantly in individuals (ie, cashew/pistachio and walnut/pecan/hazelnut). IgE testing to components further corroborated serological relationships between and among these clustered food allergies. CONCLUSIONS: Associations of certain food allergies were shown by DBPCFC outcomes as well as by correlations in IgE reactivity to structurally related food allergen components. Each of these criteria independently demonstrated a significant association between allergies to cashew and pistachio, as well as among allergies to walnut, pecan, and hazelnut</style></abstract><notes><style face="normal" font="Arial">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.01.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351786">PM:28351786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170329-AndorfS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170329-AndorfS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170329, Andorf S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.01.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Frischmeyer-Guerrerio,P.A.</style></author><author><style face="normal" font="Arial"> Masilamani,M.</style></author><author><style face="normal" font="Arial"> Gu,W.</style></author><author><style face="normal" font="Arial"> Brittain,E.</style></author><author><style face="normal" font="Arial"> Wood,R.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Nadeau,K.</style></author><author><style face="normal" font="Arial"> Jarvinen,K.M.</style></author><author><style face="normal" font="Arial"> Grishin,A.</style></author><author><style face="normal" font="Arial"> Lindblad,R.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Allergic Diseases, Food Allergy Research Unit, NIAID, NIH, Bethesda, MD</style></auth-address><titles><title><style face="normal" font="Arial">Mechanistic Correlates of Clinical Responses to Omalizumab in the Setting of Oral Immunotherapy for Milk Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> NIAID</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy improved safety but no significant clinical benefit was detected. OBJECTIVE: To investigate mechanisms by which omalizumab modulates immunity in the context of OIT, and to identify baseline biomarkers that predict subgroups of patients most likely to benefit from omalizumab. METHODS: Blood was obtained at baseline and multiple time-points during a placebo-controlled trial of OIT for milk allergy where subjects were randomized to receive omalizumab or placebo. Immunologic outcomes included measurement of basophil CD63 expression and histamine release (HR), and casein-specific CD4+ T regulatory (Treg) cell proliferation. Biomarkers were analyzed in relationship to measurements of safety and efficacy. RESULTS: Milk-induced basophil CD63 expression was transiently reduced in whole blood samples from both omalizumab and placebo subjects. However, IgE-dependent HR increased in washed cell preparations from omalizumab but not placebo subjects. No increase in Treg frequency was evident in either group. Subjects with lower rates of adverse reactions, regardless of arm, experienced better clinical outcomes. Pre-OIT basophil reactivity positively associated with occurrence of symptoms during OIT, while the baseline milk IgE/total IgE ratio correlated with the likelihood of achieving sustained unresponsiveness (SU). A combination of baseline basophil and serologic biomarkers defined a subset of patients where adjunctive therapy with omalizumab was associated with attainment of SU and a reduction in adverse reactions. CONCLUSIONS: Combining omalizumab therapy with milk OIT led to distinct alterations in basophil reactivity but not T cell responses. Baseline biomarkers may identify subjects most likely to benefit from adjunctive therapy with omalizumab</style></abstract><notes><style face="normal" font="Arial">DA - 20170417IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28414061">PM:28414061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170417-FrischmeyerGuerrerioPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170417-FrischmeyerGuerrerioPA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170417, Frischmeyer-Guerrerio PA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galli,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pathology and Microbiology and Immunology and Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, Calif. Electronic address: sgalli@stanford.edu</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers To: Serum IgE as biomarker for predicting allergen immunotherapy effectiveness)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="2031" start="2029">2029-2031</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170415IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.988</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410741">PM:28410741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170415-GalliSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170415-GalliSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170415, Galli SJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.988</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,P.C.</style></author><author><style face="normal" font="Arial"> Hsieh,M.H.</style></author><author><style face="normal" font="Arial"> Wen-ShuoKuo,P.</style></author><author><style face="normal" font="Arial"> Kao,H.F.</style></author><author><style face="normal" font="Arial"> Hsu,C.L.</style></author><author><style face="normal" font="Arial"> Wang,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Water-soluble chitosan inhibits nerve growth factor and attenuates allergic inflammation in mite allergen-induced allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Chitosan</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal inflammation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> nerve growth factor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="Arial">Nerve growth factor induces nasal inflammation by augmenting the existing TH2 immune response, and this can be suppressed bywater-soluble chitosan, a natural, nontoxic product that provides new therapy for allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412394">PM:28412394</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170416-ChenPC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170416-ChenPC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Chen PC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tacquard,C.</style></author><author><style face="normal" font="Arial"> Boudjedir,K.</style></author><author><style face="normal" font="Arial"> Carlier,M.</style></author><author><style face="normal" font="Arial"> Muller,J.Y.</style></author><author><style face="normal" font="Arial"> Gomis,P.</style></author><author><style face="normal" font="Arial"> Mertes,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of anesthesia and intensive care, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg, France</style></auth-address><titles><title><style face="normal" font="Arial">Hypersensitivity transfusion reactions due to IgA deficiency are rare according to French hemovigilance data</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="885" start="884">884-885</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hemovigilance</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgA Deficiency</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="Arial">In an analysis of a large French hemovigilance database (2004-2014), hypersensitivity transfusion reactions (HTRs) due to IgA deficiency were extremely rare with an frequency far lower than reported so far. In depth investigation of HTRs for IgA deficiency should be limited to moderate to severe recurrent reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170417IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28414063">PM:28414063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170417-TacquardC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170417-TacquardC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170417, Tacquard C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thostesen,L.M.</style></author><author><style face="normal" font="Arial"> Stensballe,L.G.</style></author><author><style face="normal" font="Arial"> Pihl,G.T.</style></author><author><style face="normal" font="Arial"> Kjaergaard,J.</style></author><author><style face="normal" font="Arial"> Birk,N.M.</style></author><author><style face="normal" font="Arial"> Nissen,T.N.</style></author><author><style face="normal" font="Arial"> Jensen,A.K.</style></author><author><style face="normal" font="Arial"> Aaby,P.</style></author><author><style face="normal" font="Arial"> Olesen,A.W.</style></author><author><style face="normal" font="Arial"> Jeppesen,D.L.</style></author><author><style face="normal" font="Arial"> Benn,C.S.</style></author><author><style face="normal" font="Arial"> Kofoed,P.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Kolding Hospital, Skovvangen 2-8, DK-6000 Kolding and Institute of Regional Health Research, University of Southern Denmark, Denmark.</style></auth-address><titles><title><style face="normal" font="Arial">Neonatal BCG-vaccination has no effect on recurrent wheeze in the first year of life. A randomized clinical trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> recurrent wheeze</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recurrent wheeze is frequent in childhood. Studies have suggested that Bacillus Calmette-Guerin (BCG) vaccination may have non-specific effects, reducing general non-tuberculosis morbidity, including respiratory infections and atopic diseases. The mechanisms behind these non-specific effects of BCG are not fully understood, but a shift from Th2 to Th1-response has been suggested as a possible explanation. OBJECTIVE: We hypothesized that BCG at birth would reduce the cumulative incidence of recurrent wheeze during the first year of life. METHODS: The Danish Calmette Study is a multicenter randomized trial conducted from 2012-2015 at three Danish hospitals. The 4262 newborns of 4184 included mothers were randomized 1:1 to BCG (SSI strain 1331) or to a no-intervention control group within 7 days of birth; siblings were randomized together as one randomization unit. Exclusion criteria were gestational age &lt;32 weeks, birth weight &lt;1000g, known immunodeficiency, or no Danish-speaking parent. Information was collected through telephone interviews and clinical examinations at 3 and 13 months of age; the data collectors were blinded to randomization group. Recurrent wheeze was defined in several ways, the main definition being: "physician-diagnosed and medically treated recurrent wheeze up to 13 months of age". RESULTS: By 13 months 211/2100 (10.0%) children in the BCG group and 195/2071 (9.4%) children in the control group had been diagnosed by a medical doctor with recurrent wheeze and received anti-asthmatic treatment (relative risk 1.07 (95% confidence intervals 0.89-1.28)). Supplementary analyses were made, including an analysis of baseline risk factors for developing RW. CONCLUSION: Neonatal BCG had no effect on the development of recurrent wheeze before 13 months of age</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.990</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28347733">PM:28347733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170328-ThostesenLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170328-ThostesenLM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Thostesen LM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.990</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dowling,D.J.</style></author><author><style face="normal" font="Arial"> Scott,E.A.</style></author><author><style face="normal" font="Arial"> Scheid,A.</style></author><author><style face="normal" font="Arial"> Bergelson,I.</style></author><author><style face="normal" font="Arial"> Joshi,S.</style></author><author><style face="normal" font="Arial"> Pietrasanta,C.</style></author><author><style face="normal" font="Arial"> Brightman,S.</style></author><author><style face="normal" font="Arial"> Sanchez-Schmitz,G.</style></author><author><style face="normal" font="Arial"> van Haren,S.D.</style></author><author><style face="normal" font="Arial"> Ninkovic,J.</style></author><author><style face="normal" font="Arial"> Kats,D.</style></author><author><style face="normal" font="Arial"> Guiducci,C.</style></author><author><style face="normal" font="Arial"> de Titta,A.</style></author><author><style face="normal" font="Arial"> Bonner,D.K.</style></author><author><style face="normal" font="Arial"> Hirosue,S.</style></author><author><style face="normal" font="Arial"> Swartz,M.A.</style></author><author><style face="normal" font="Arial"> Hubbell,J.A.</style></author><author><style face="normal" font="Arial"> Levy,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="Arial">Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> BCG Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Newborns display distinct immune responses, leaving them vulnerable to infections and impairing immunization. Targeting newborn dendritic cells (DCs), which integrate vaccine signals into adaptive immune responses, might enable development of age-specific vaccine formulations to overcome suboptimal immunization. OBJECTIVE: Small-molecule imidazoquinoline Toll-like receptor (TLR) 8 agonists robustly activate newborn DCs but can result in reactogenicity when delivered in soluble form. We used rational engineering and age- and species-specific modeling to construct and characterize polymer nanocarriers encapsulating a TLR8 agonist, allowing direct intracellular release after selective uptake by DCs. METHODS: Chemically similar but morphologically distinct nanocarriers comprised of amphiphilic block copolymers were engineered for targeted uptake by murine DCs in vivo, and a range of TLR8 agonist-encapsulating polymersome formulations were then synthesized. Novel 96-well in vitro assays using neonatal human monocyte-derived DCs and humanized TLR8 mouse bone marrow-derived DCs enabled benchmarking of the TLR8 agonist-encapsulating polymersome formulations against conventional adjuvants and licensed vaccines, including live attenuated BCG vaccine. Immunogenicity of the TLR8 agonist adjuvanted antigen 85B (Ag85B)/peptide 25-loaded BCG-mimicking nanoparticle formulation was evaluated in vivo by using humanized TLR8 neonatal mice. RESULTS: Although alum-adjuvanted vaccines induced modest costimulatory molecule expression, limited TH-polarizing cytokine production, and significant cell death, BCG induced a robust adult-like maturation profile of neonatal DCs. Remarkably, TLR8 agonist polymersomes induced not only newborn DC maturation profiles similar to those induced by BCG but also stronger IL-12p70 production. On subcutaneous injection to neonatal mice, the TLR8 agonist-adjuvanted Ag85B peptide 25 formulation was comparable with BCG in inducing Ag85B-specific CD4+ T-cell numbers. CONCLUSION: TLR8 agonist-encapsulating polymersomes hold substantial potential for early-life immunization against intracellular pathogens. Overall, our study represents a novel approach for rational design of early-life vaccines</style></abstract><notes><style face="normal" font="Arial">DA - 20170327IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.985</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28343701">PM:28343701</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170327-DowlingDJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170327-DowlingDJ.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170327-DowlingDJ.mp4</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170327-DowlingDJ.mp4</url></image-urls></urls><custom2><style face="normal" font="Arial">20170327, Dowling DJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.985</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bartnikas,L.M.</style></author><author><style face="normal" font="Arial"> Huffaker,M.F.</style></author><author><style face="normal" font="Arial"> Sheehan,W.J.</style></author><author><style face="normal" font="Arial"> Kanchongkittiphon,W.</style></author><author><style face="normal" font="Arial"> Petty,C.R.</style></author><author><style face="normal" font="Arial"> Leibowitz,R.</style></author><author><style face="normal" font="Arial"> Hauptman,M.</style></author><author><style face="normal" font="Arial"> Young,M.C.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="Arial">Impact of School Peanut-Free Policies on Epinephrine Administration</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="473" start="465">465-473</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Classroom</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Public school</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Children with food allergies spend a large proportion of time in school but characteristics of allergic reactions in schools are not well studied. Some schools self-designate as peanut-free or have peanut-free areas, but the impact of policies on clinical outcomes has not been evaluated. OBJECTIVE: We sought to determine the effect of peanut-free policies on rates of epinephrine administration for allergic reactions in Massachusetts public schools. METHODS: In this retrospective study, we analyzed (1) rates of epinephrine administration in all Massachusetts public schools and (2) Massachusetts public school nurse survey reports of school peanut-free policies from 2006-2011 and whether schools self-designated as "peanut-free" based on policies. Rates of epinephrine administration were compared for schools with or without peanut restrictive policies. RESULTS: The percentage of schools with peanut restrictive policies did not change significantly in the study timeframe. There was variability in policies used by schools self-designated as peanut-free. No policy was associated with complete absence of allergic reactions. Both self-designated peanut-free schools and schools banning peanuts from being served in school or brought from home had allergic reactions to nuts. Policies restricting peanuts from home, served in schools or having peanut-free classrooms did not affect epinephrine administration rates. Schools with peanut-free tables, compared to without, had lower rates of epinephrine administration (IR per 10,000 students 0.2 and 0.6, respectively, P=0.009). CONCLUSIONS: These data provide a basis for evidence-based school policies for children with food allergies. Further studies are required before decisions can be made regarding peanut-free policies in schools</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28347736">PM:28347736</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170328-BartnikasLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170328-BartnikasLM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Bartnikas LM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schoos,A.M.</style></author><author><style face="normal" font="Arial"> Chawes,B.L.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Bergstrom,A.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Bonnelykke,K.</style></author><author><style face="normal" font="Arial"> Bisgaard,H.</style></author><author><style face="normal" font="Arial"> Rasmussen,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Copenhagen Prospective Studies on Asthma in Childhood, Faculty of Health and Medical Sciences, University of Copenhagen &amp; Danish Pediatric Asthma Center, Gentofte Hospital, University of Copenhagen; Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Novel Sensitization Trajectories in Childhood revealed by a Cluster Analysis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BAMSE</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Assessment of sensitization at an isolated time-point during childhood provides limited clinical information. We hypothesized that sensitization develops as specific patterns with respect to age at debut, development over time, and involved allergens, and that such patterns might be more biologically and clinically relevant. OBJECTIVE: To explore latent patterns of sensitization during the first 6 years of life and investigate whether such patterns associate to development of asthma, rhinitis, and eczema. METHODS: We investigated 398 children from the at-risk Copenhagen Prospective Studies on Asthma in Childhood 2000 birth cohort (COPSAC2000) with specific-IgE against 13 common food and inhalant allergens at ages (1/2), 1(1/2), 4, and 6yrs. An unsupervised cluster analysis for three-dimensional data (NNS-PARAFAC) was used to extract latent patterns explicitly characterizing temporal development of sensitization, while clustering allergens and children. Subsequently, these patterns were investigated in relation to asthma, rhinitis, and eczema. Verification was sought in an independent unselected birth cohort, BAMSE, constituting 3051 children with specific-IgE against the same allergens at 4 and 8yrs. RESULTS: The NNS-PARAFAC analysis indicated a complex latent structure involving seven age- and allergen-specific patterns in the COPSAC2000 data: (1) dog/cat/horse; (2) timothy grass/birch; (3) molds; (4) house dust mites; (5) peanut/wheat flour/mugwort; (6) peanut/soybean; and (7) egg/milk/wheat flour. Asthma was solely associated with pattern 1 (OR=3.3 [1.5-7.2]), rhinitis with patterns 1-4 and 6 (ORs=2.2-4.3) and eczema with patterns 1-3 and 5-7 (ORs=1.6-2.5). All seven patterns were verified in the independent BAMSE cohort (R2>0.89). CONCLUSION: This study suggests the presence of specific sensitization patterns in early childhood differentially associated to development of clinical outcomes. Using such patterns in future research might provide more robust and clinically relevant results</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28347735">PM:28347735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170328-SchoosAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170328-SchoosAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Scoos AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'Amato,G.</style></author><author><style face="normal" font="Arial"> Annesi Maesano,I.</style></author><author><style face="normal" font="Arial"> Antonio,M.</style></author><author><style face="normal" font="Arial"> Vitale,C.</style></author><author><style face="normal" font="Arial"> D'Amato,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory and Allergic Diseases, Department of Chest Diseases, High Speciality A. Cardarelli Hospital, Napoli, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Thunderstorm Related Asthma Attacks</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1787" start="1786">1786-1787</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> thunderstorm</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170326IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Italy -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342913">PM:28342913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170326-DAmatoG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170326-DAmatoG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170326, DAmato G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonini,S.</style></author><author><style face="normal" font="Arial"> Bonini,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Campania Luigi Vanvitelli (previously Second University of Naples), Department of Clinical and Experimental Medicine, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Biosimilars and drug development in allergic and immunologic diseases</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359671">PM:28359671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170331-BoniniS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170331-BoniniS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Bonini S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maurer,M.</style></author><author><style face="normal" font="Arial"> Schutz,A.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author><author><style face="normal" font="Arial"> Schoepke,N.</style></author><author><style face="normal" font="Arial"> Peveling-Oberhag,A.</style></author><author><style face="normal" font="Arial"> Staubach,P.</style></author><author><style face="normal" font="Arial"> Muller,S.</style></author><author><style face="normal" font="Arial"> Jakob,T.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab is Effective in Symptomatic Dermographism - results of a Randomized, Placebo Controlled Trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="873" start="870">870-873</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermographism</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170408IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389391">PM:28389391</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170408-MaurerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170408-MaurerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Maurer M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korosec,P.</style></author><author><style face="normal" font="Arial"> Turner,P.J.</style></author><author><style face="normal" font="Arial"> Silar,M.</style></author><author><style face="normal" font="Arial"> Kopac,P.</style></author><author><style face="normal" font="Arial"> Kosnik,M.</style></author><author><style face="normal" font="Arial"> Gibbs,B.F.</style></author><author><style face="normal" font="Arial"> Shamji,M.H.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author><author><style face="normal" font="Arial"> Rijavec,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Hospital of Respiratory and Allergic Diseases, Golnik, Slovenia.</style></auth-address><titles><title><style face="normal" font="Arial">Basophils, high-affinity IgE receptors and CCL2 in human anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="758" start="750">750-758</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> activation marker</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> CCL2</style></keyword><keyword><style face="normal" font="Arial"> CD203c</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE receptors</style></keyword><keyword><style face="normal" font="Arial"> IL-3</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Slovenia</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The role of basophils in anaphylaxis is unclear. OBJECTIVE: To investigate whether basophils have an important role in human anaphylaxis. METHODS: In an emergency department study, we recruited 31 patients with acute anaphylaxis, predominantly to hymenoptera venom. We measured expression of basophil activation markers (CD63, CD203c), the absolute number of circulating basophils, whole-blood FcepsilonRI, CPA3 and HDC gene expression, and serum markers (CCL2, CCL5, CCL11, IL-3, TSLP) at three time points (during the anaphylactic episode, and in convalescent samples 7 and 30 days later). We recruited 134 hymenoptera-allergic and 76 healthy controls for comparison. We then investigated whether the changes observed during venom-related anaphylaxis also occur during allergic reactions to food in 22 peanut-allergic individuals undergoing double-blind placebo-controlled food challenge to peanut (DBPCFC). RESULTS: The number of circulating basophils was significantly lower during anaphylaxis (median 3.5 cells/mul) than 7 and 30 days later (17.5 and 24.7 cells/mul, P&lt;0.0001), and compared to venom-allergic and healthy controls (21 and 23.4 cells/mul, P&lt;0.0001). FcepsilonRI expression during anaphylaxis was also significantly lower than in convalescent samples (P&lt;/=0.002) and venom-allergic controls (P&lt;0.0001). CCL2 (but not other serum markers) was significantly higher during anaphylaxis (median 658 pg/ml) than in convalescent samples (314 and 311 pg/ml, 7 and 30 days, P&lt;0.001). Peanut-induced allergic reactions resulted in a significant decrease in circulating basophils compared to pre-challenge samples (P=0.016), a decrease in FcepsilonRI expression (P=0.007), and an increase in CCL2 (P=0.003). CONCLUSIONS: Our findings imply an important and specific role for basophils in the pathophysiology of human anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170326IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Slovenia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.989</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342911">PM:28342911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170326-KorosecP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170326-KorosecP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170326, Korosec P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.989</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lukkarinen,M.</style></author><author><style face="normal" font="Arial"> Koistinen,A.</style></author><author><style face="normal" font="Arial"> Turunen,R.</style></author><author><style face="normal" font="Arial"> Lehtinen,P.</style></author><author><style face="normal" font="Arial"> Vuorinen,T.</style></author><author><style face="normal" font="Arial"> Jartti,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, University of Turku and Turku University Hospital.</style></auth-address><titles><title><style face="normal" font="Arial">Rhinovirus-induced first wheezing episode predicts atopic but not non-atopic asthma at school-age</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> early intervention</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> parental smoking</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Persistent childhood asthma is mainly atopy-driven. However, limited data exist on the risk factors for childhood asthma phenotypes. OBJECTIVE: To identify risk factors at the first severe wheezing episode for the current asthma 7 years later, and separately for atopic and non-atopic asthma. METHODS: One hundred and twenty-seven steroid-naive children with the first severe wheezing episode (90% hospitalized/10% emergency room treated) were followed for 7 years. The primary outcome was current asthma at age 8 years, which was also analyzed separately as atopic and non-atopic asthma. Risk factors including sensitization, viral etiology and other main asthma risk factors were analyzed. RESULTS: At study entry, median age was 11 months (interquartile range 6;16 months), 17% were sensitized and 98% were virus-positive. Current asthma (n = 37) at 8 years was divided to atopic (n = 19) and non-atopic (n = 18) asthma. The risk factors for current atopic asthma at study entry were sensitization (adjusted odds ratio 12; P&lt;.001), eczema (4.8; P .014, respectively) and wheezing with rhinovirus (5.0; P .035). The risk factors for non-atopic asthma were the first severe respiratory syncytial virus/rhinovirus-negative wheezing episode (adjusted odds ratio 8.0; P .001), first wheezing episode at age &lt;12 months (7.3; P = .007, respectively), and parental smoking (3.8; P .028). CONCLUSIONS: The data suggest diverse asthma phenotypes and mechanisms that can be predicted using simple clinical markers at the time of the first severe wheezing episode. Findings are important in designing early intervention strategies for secondary prevention of asthma. (ClinicalTrials.gov number, NCT00494624 and NCT00731575)</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2016.12.991</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28347734">PM:28347734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170328-LukkarinenM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170328-LukkarinenM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Lukkarinen M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2016.12.991</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bauer,F.</style></author><author><style face="normal" font="Arial"> Singh,A.</style></author><author><style face="normal" font="Arial"> Zotl,B.</style></author><author><style face="normal" font="Arial"> Seng,D.</style></author><author><style face="normal" font="Arial"> Bauer,C.P.</style></author><author><style face="normal" font="Arial"> Pecquet,S.</style></author><author><style face="normal" font="Arial"> Steenhout,P.</style></author><author><style face="normal" font="Arial"> Nutten,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">High Tolerability of a Rice and Carob-Based Cereal Demonstrated in Highly Allergic Infants and Children: A Randomized Open-Food Challenge Trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="244">244-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergy</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutritional deficiency</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background: Food allergy is the most common cause of atopic symptoms in early childhood. Standard care isan exclusion diet to avoid symptoms, but is associated with a risk of nutritional deficiencies. Sinlac® is a rice- andcarob-based infant cereal free from major allergens, providing full nutritional support for children suffering from foodallergies. Apple polyphenols (AP) have been shown to have favorable anti-allergy properties.Methods: A randomized clinical trial (NCT01029184) based on open-label food challenges was conducted tocompare the tolerability of Sinlac® cereals with or without AP, with that of well-known allergenic foods, in subjectswith severe food allergy (aged 4-40 months). Study products were Sinlac®, Sinlac®AP (0.3% in matrix), wheat,potato, milk and hen's egg. The primary endpoint was a positive reaction to open-label food challenges.Results: Of the 51 subjects randomized, 48 completed the study. Both Sinlac® and Sinlac®AP were significantlybetter tolerated by atopic infants than other allergenic foods: incidence of allergic reactions was 2% with Sinlac® andSinlac®AP, versus 49% with wheat, potato, milk or hen's egg.Conclusion: Sinlac® and Sinlac®AP are very well tolerated and offer a nutritionally balanced option for atopicinfants and children. Studies are needed to assess the benefit of adding AP to low allergenic products.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000244</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2016-7-244.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2016-7-244.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160410, Bauer F</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000244</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Makri,E.</style></author><author><style face="normal" font="Arial"> Ridolo,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Evidence Based Efficacy of Sublingual Immunotherapy for Allergic Rhinitis, which is the Most Appropriate Estimate?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="118">118-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000e118</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000e118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2016-7-118.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2016-7-118.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160410, Incorvaia C</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000e118</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mujtaba,H.S.</style></author><author><style face="normal" font="Arial"> Iqbal,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mujtaba Hasan Siddiqui1 and Iqbal Akhtar Khan</style></auth-address><titles><title><style face="normal" font="Arial">Fascinating Giardia Lamblia and Vexing Chronic Spontaneous Urticaria: An Under-appreciated Association</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="241">241-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Giardia</style></keyword><keyword><style face="normal" font="Arial"> Giardia lamblia</style></keyword><keyword><style face="normal" font="Arial"> Giardiasis</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background: Chronic Spontaneous Urticaria (CSU) has been found to have a negative impact on all aspects of patients' lives - physical, mental, social and emotional. The ubiquitous and fascinating Giardia lamblia is primarily a gastrointestinal pathogen but it may present atypically (with or without gastroenterological manifestations). A link between Giardiasis and CSU was identified in the past. However, the possibility of this combination has been under-appreciated in clinical practice, even in developed world, resulting in inordinate delay in reaching correct diagnosis and instituting targeted pharmacotherapy. Such a situation adds to the miseries of the patients, both mental anguish and physical suffering. Objectives: -To determine the role of Giardia lamblia in the causation of CSU -To ratify the effects of eradication of Giardia lamblia on the course of CSU Methods: The present study was conducted on 63 referred cases of CSU (with insignificant improvement from the treatment already instituted). In view of the possibility of concomitant Giardial infection stool microscopy was advised and three fresh stool specimens, taken on alternate days, were collected from every case and examined for parasites. The two validated instruments employed for comparing Patient Related Outcome Measures (PROMs), before and after treatment, were UAS7 (Urticaria Activity Score of 7days) and CU-Q2oL (Chronic Urticaria Quality of Life Questionnaire). Results: Twenty two percent of those tested were found to have sole infection with Giardia lamblia. Secnidazole Sodium, as a single oral dose, resulted in complete parasitological and clinical cure in 93% of the cases. The results of the PROMs were compared and correlated with the clinical picture. Conclusion: The effects of eradication of Giardia lamblia on the course of the urticaria were excellent. Complete resolution of symptoms was seen in 93% of cases (and no recurrence in the follow up period of 16 weeks) with specific anti-giardial therapy alone proving that the causative agent was Giardia lamblia and that there was no role for any concomitant dermatological pathology. There is a dire need for meaningful cooperation between specialists of Dermatology and Tropical Medicine, in the management of otherwise unexplained urticaria.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Pakistan -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000241</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2016-7-241.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2016-7-241.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160410, Mujtaba HS</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000241</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohanty,B.</style></author><author><style face="normal" font="Arial"> Mahanty,A.</style></author><author><style face="normal" font="Arial"> Ganguly,S.</style></author><author><style face="normal" font="Arial"> Sankar,T.V.</style></author><author><style face="normal" font="Arial"> Chakraborty,K.</style></author><author><style face="normal" font="Arial"> Rangasamy,A.</style></author><author><style face="normal" font="Arial"> Paul,B.</style></author><author><style face="normal" font="Arial"> Sarma,D.</style></author><author><style face="normal" font="Arial"> Mathew,S.</style></author><author><style face="normal" font="Arial"> Asha,K.K.</style></author><author><style face="normal" font="Arial"> Behera,B.</style></author><author><style face="normal" font="Arial"> Aftabuddin,M.</style></author><author><style face="normal" font="Arial"> Debnath,D.</style></author><author><style face="normal" font="Arial"> Vijayagopal,P.</style></author><author><style face="normal" font="Arial"> Sridhar,N.</style></author><author><style face="normal" font="Arial"> Akhtar,M.S.</style></author><author><style face="normal" font="Arial"> Sahi,N.</style></author><author><style face="normal" font="Arial"> Mitra,T.</style></author><author><style face="normal" font="Arial"> Banerjee,S.</style></author><author><style face="normal" font="Arial"> Paria,P.</style></author><author><style face="normal" font="Arial"> Das,D.</style></author><author><style face="normal" font="Arial"> Das,P.</style></author><author><style face="normal" font="Arial"> Vijayan,K.K.</style></author><author><style face="normal" font="Arial"> Laxmanan,P.T.</style></author><author><style face="normal" font="Arial"> Sharma,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ICAR-Central Inland Fisheries Research Institute, Barrackpore, Kolkata 700120, India</style></auth-address><titles><title><style face="normal" font="Arial">Amino Acid compositions of 27 food fishes and their importance in clinical nutrition</style></title><secondary-title><style face="normal" font="Arial">J Amino Acids</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Amino Acids</style></abbr-1></periodical><pages end="" start="269797">269797-</pages><volume><style face="normal" font="Arial">2014</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid composition</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal proteins</style></keyword><keyword><style face="normal" font="Arial"> Aspartic Acid</style></keyword><keyword><style face="normal" font="Arial"> Carp</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Counseling</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fisheries</style></keyword><keyword><style face="normal" font="Arial"> Fishes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Glutamic Acid</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> Habitat</style></keyword><keyword><style face="normal" font="Arial"> Histidine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Kolkata</style></keyword><keyword><style face="normal" font="Arial"> Leucine</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Lysine</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2014">2014</year></dates><abstract><style face="normal" font="Arial">Proteins and amino acids are important biomolecules which regulate key metabolic pathways and serve as precursors for synthesis of biologically important substances; moreover, amino acids are building blocks of proteins. Fish is an important dietary source of quality animal proteins and amino acids and play important role in human nutrition. In the present investigation, crude protein content and amino acid compositions of important food fishes from different habitats have been studied. Crude protein content was determined by Kjeldahl method and amino acid composition was analyzed by high performance liquid chromatography and information on 27 food fishes was generated. The analysis showed that the cold water species are rich in lysine and aspartic acid, marine fishes in leucine, small indigenous fishes in histidine, and the carps and catfishes in glutamic acid and glycine. The enriched nutrition knowledge base would enhance the utility of fish as a source of quality animal proteins and amino acids and aid in their inclusion in dietary counseling and patient guidance for specific nutritional needs</style></abstract><notes><style face="normal" font="Arial">DA - 20141107IS - 2090-0104 (Print)IS - 2090-0112 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1155/2014/269797</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="25379285">PM:25379285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Amino Acids\2014-2014-269-797.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Amino Acids\2014-2014-269-797.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20141107, Mohanty B</style></custom2><misc3><style face="normal" font="Arial">10.1155/2014/269797</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Planque,M.</style></author><author><style face="normal" font="Arial"> Arnould,T.</style></author><author><style face="normal" font="Arial"> Renard,P.</style></author><author><style face="normal" font="Arial"> Delahaut,P.</style></author><author><style face="normal" font="Arial"> Dieu,M.</style></author><author><style face="normal" font="Arial"> Gillard,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CER Groupe, Health Department, rue du Point du Jour, 8, 6900 Marloie, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Highlight on Bottlenecks in Food Allergen Analysis: Detection and Quantification by Mass Spectrometry</style></title><secondary-title><style face="normal" font="Arial">J AOAC Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J AOAC Int</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> matrix effect</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Processed allergen</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reference materials</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="Arial">Food laboratories have developed methods for testing allergens in foods. The efficiency of qualitative and quantitativemethods is of prime importance in protecting allergic populations. Unfortunately, food laboratories encounter barriers to developing efficient methods. Bottlenecks include the lack of regulatory thresholds, delays in the emergence of reference materials and guidelines, and the need to detect processed allergens. In this study, ultra-HPLC coupled to tandem MS was used to illustrate difficulties encountered in determining method performances. We measured the major influences of both processing and matrix effects on the detection of egg, milk, soy, and peanut allergens in foodstuffs. The main goals of this work were to identify difficulties that food laboratories still encounter in detecting and quantifying allergens and to sensitize researchers to them</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1060-3271 (Print)IS - 1060-3271 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.5740/jaoacint.17-0005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28330529">PM:28330529</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J AOAC Int\20170323-PlanqueM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J AOAC Int\20170323-PlanqueM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Planque M</style></custom2><misc3><style face="normal" font="Arial">10.5740/jaoacint.17-0005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nagai,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Gifu Prefectural Research Institute for Health and Environmental Science, 1-1 Naka-Fudougaoka, Kakamigahara, 504-0838, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Development of a Method for Determination of Buckwheat Allergens Using Liquid Chromatography with Tandem Mass Spectrometry</style></title><secondary-title><style face="normal" font="Arial">J AOAC Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J AOAC Int</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">13S globulin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food ingredients</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> marker peptides</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Powders</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="3" Month="3" Year="2017">2017/3/3</year></dates><abstract><style face="normal" font="Arial">An analysis technique using LC with tandem MS (MS/MS) has been developed for the determination of buckwheat proteins, including major allergens. A protein solution extracted from buckwheat was reduced, alkylated, and digested by trypsin. Peptide spectra were obtained using full-scan LC-MS/MS analysis, and peptide sequences were determined through a protein search. Nine peptides of the 13S globulin seed storage protein and one peptide of a 16 kDa allergen were selected as the marker peptides, and multiple reaction monitoring conditions were optimized. Using the conditions, different kinds of buckwheat noodles, powders, and other food ingredients were analyzed. As a result, buckwheat samples present all the fragment peaks, whereas other foods, including &lt;em>Sesamum indicum&lt;/em>, wheat, and soybeans, are not detected at all. These findings indicate that LC-MS/MS analysis may be applied to the detection of buckwheat food allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170303IS - 1060-3271 (Print)IS - 1060-3271 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.5740/jaoacint.16-0243</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28256184">PM:28256184</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170303, Nagai H</style></custom2><misc3><style face="normal" font="Arial">10.5740/jaoacint.16-0243</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guo,Q.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Sun,Z.</style></author><author><style face="normal" font="Arial"> Zhou,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an , Shaanxi , China</style></auth-address><titles><title><style face="normal" font="Arial">Tunicamycin aggravates endoplasmic reticulum stress and airway inflammation via PERK-ATF4-CHOP signaling in a murine model of neutrophilic asthma</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="133" start="125">125-133</pages><volume><style face="normal" font="Arial">54</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Endoplasmic Reticulum</style></keyword><keyword><style face="normal" font="Arial"> endoplasmic reticulum stress</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Endoplasmic reticulum (ER) stress has been considered to be an important regulator of airway inflammation in the pathogenesis of bronchial asthma, but the mechanism of ER stress involved in neutrophilic asthma remain not fully understood. METHODS: Tunicamycin is a mixture of homologous nucleoside antibiotics, which is used to induce ER stress. In the present study, Tunicamycin was administered to mouse bronchial epithelial cells and a neutrophilic asthma model (OVALPS-OVA mice), and ER stress indicators and inflammatory cytokines were measured by Western blotting and Elisa. RESULTS: Tunicamycin not only induced ER stress in mouse bronchial epithelial cells, but also increased expression of inflammation indicators such as IL-6, IL-8, and TNF-alpha via PERK-ATF4-CHOP signaling. Additionally, the phosphorylation of PERK and the expression levels of ATF4 and CHOP proteins and inflammatory cytokines (IL-6, IL-8 and TNF-alpha) were elevated in the lung tissue of OVALPS-OVA mice. Administering tunicamycin further increased protein expression levels of ER stress indicators and inflammatory cytokines, and resulted in more severe asthma phenotypes in OVALPS-OVA mice, suggesting that PERK-ATF4-CHOP signaling is associated with airway inflammation in neutrophil-dominant asthma. CONCLUSIONS: These data support the emerging notion that regulation of ER stress could be strongly associated with the development of neutrophilic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20160707IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1205085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27383524">PM:27383524</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\2017-54-125-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\2017-54-125-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160707, Guo Q</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1205085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al-Asad,K.</style></author><author><style face="normal" font="Arial"> Al-Nazer,S.</style></author><author><style face="normal" font="Arial"> Al-Faqih,A.</style></author><author><style face="normal" font="Arial"> Hashem,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Private practice, Amman, Jordan</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of a sublingual immunotherapy solution in olive-induced respiratory allergy in Jordan: a retrospective observational study</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="30" start="23">23-30</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle East</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Ole e</style></keyword><keyword><style face="normal" font="Arial"> Ole e 1</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> olive pollen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Private Practice</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Standardized extracts</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Olive pollen is an important cause of respiratory allergy in the Middle East. In this study, the clinical characteristics of adults and children with confirmed allergic rhinitis (AR; with or without asthma) in Jordan were described, and the use of sublingual immunotherapy (SLIT) in a real-life clinical setting was assessed. METHODS: This retrospective observational study evaluated the clinical features of olive-induced allergy and the use of an SLIT solution of standardized extracts toward Ole e 1 given in a pre- and coseasonal scheme with a daily dose of 300 index of reactivity for two consecutive seasons. Inclusion criteria were as follows: >/=5 years of age, AR, proven olive sensitization, and at least 2 years follow-up after SLIT initiation. The following data were recorded at SLIT initiation: clinical characteristics, rhinitis and asthma symptom scores, and concomitant symptomatic medications. During follow-up and at the end of each season, the following data were recorded: symptom progression/scores, any changes to symptomatic medications, and treatment compliance. The secondary objective was to determine any effect on quality of life, use of concomitant AR medications, and treatment compliance. RESULTS: Eighty-six patients with seasonal AR were included in this analysis (52.3% with coexisting asthma). Between the initiation of treatment and the end of second pollen season, symptoms of AR and asthma were decreased by 79.5% and 41.7%, respectively, with an improvement in quality of life score in 71.5% of the patients (P&lt;0.0001 for all). Physicians reported that after 2 years of SLIT, there was an improvement in the symptoms of both AR (95.2%) and asthma (93.3%), with 98.8% of the patients showing good treatment compliance. A reduction in symptomatic medications was also found. SLIT was well tolerated with no systemic reactions being reported. CONCLUSION: In children and adults with olive-associated respiratory allergy in Jordan, the use of a pre- and coseasonal SLIT with a 300 index of reactivity daily dose is effective in reducing the clinical burden of AR and asthma with no tolerability issues</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Jordan -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S96153</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28280371">PM:28280371</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-23-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-23-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Al-Asad K</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S96153</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dosanjh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Rady Childrens Hospital, San Diego, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Pediatric anaphylaxis and hyper IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="33" start="31">31-33</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Job syndrome</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Patients with autosomal-dominant (AD) hyper immunoglobulin E (IgE) syndrome (HIES) or Job syndrome develop frequent dermatologic and pulmonary infections. As patients have an extreme elevation of IgE levels, this database analysis study sought to study the association between AD HIES, Job syndrome, and anaphylaxis. HIES is a heterogeneous group of immune disorders characterized by extremely elevated levels of serum IgE. Although the molecular defects and clinical phenotypes found in association with Job syndrome are well characterized, the association with severe allergic reactions and anaphylaxis is a subject of ongoing investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20170310IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S129160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28280372">PM:28280372</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-31-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-31-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170310, Dosajh A</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S129160</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Siqueira,V.P.</style></author><author><style face="normal" font="Arial"> Evangelista,M.I.S.</style></author><author><style face="normal" font="Arial"> Dos,Santos A.</style></author><author><style face="normal" font="Arial"> Marcos,R.L.</style></author><author><style face="normal" font="Arial"> Ligeiro-de-Oliveira,A.P.</style></author><author><style face="normal" font="Arial"> Pavani,C.</style></author><author><style face="normal" font="Arial"> Damazo,A.S.</style></author><author><style face="normal" font="Arial"> Lino-dos-Santos-Franco,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Post Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Light-Emitting Diode treatment ameliorates allergic lung inflammation in experimental model of asthma induced by ovalbumin</style></title><secondary-title><style face="normal" font="Arial">J Biophotonics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Biophotonics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phototherapy</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="Arial">Since asthma is a multifactorial disease where treatment sometimes is not effective, new therapies that improve the respiratory discomfort of patients are of great importance. Phototherapy as Light-emitting diode (LED) has emerged as a treatment that presents good results for diseases that are characterized by inflammation. Thus, our objective was to investigate the effects of LED on lung inflammation, by an evaluation of lung cell infiltration, mucus secretion, oedema, and the production of cytokines. Male Balb/c mice were or not sensitized and challenged with ovalbumin (OVA) and treated or not with LED therapy (1 h and 4 h after each OVA challenge). Twenty-four hours after the last OVA challenge, analyzes were performed. Our results showed that LED treatment in asthmatic mice reduced the lung cell infiltration, the mucus production, the oedema, and the tracheal's contractile response. It also increased the IL-10 and the IFN-gamma levels. The effects of LED treatment on lung inflammation may be modulated by IL-10, IFN-gamma, and by mast cells. This study may provide important information about the effects of LED, and in addition, it may open the possibility of a new approach for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1864-0648 (Electronic)IS - 1864-063X (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1002/jbio.201600247</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28417574">PM:28417574</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biophotonics\20170418-SiqueiraVP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biophotonics\20170418-SiqueiraVP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Siqueira VP</style></custom2><misc3><style face="normal" font="Arial">10.1002/jbio.201600247</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maddy,E.M.</style></author><author><style face="normal" font="Arial"> Schmoker,J.D.</style></author><author><style face="normal" font="Arial"> Tharp,W.G.</style></author><author><style face="normal" font="Arial"> Bender,S.P.</style></author><author><style face="normal" font="Arial"> Anderson,E.P.</style></author><author><style face="normal" font="Arial"> Martin,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, University of Vermont Medical Center, Burlington, VT.</style></auth-address><titles><title><style face="normal" font="Arial">Deep Hypothermic Circulatory Arrest in a Patient with Cold-Induced Urticaria</style></title><secondary-title><style face="normal" font="Arial">J Cardiothorac Vasc Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cardiothorac Vasc Anesth</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Cold induced urticaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vermont</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1532-8422 (Electronic)IS - 1053-0770 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1053/j.jvca.2016.12.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28372956">PM:28372956</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cardiothorac Vasc Anesth\20170423-MaddyEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cardiothorac Vasc Anesth\20170423-MaddyEM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, Maddy EM</style></custom2><misc3><style face="normal" font="Arial">10.1053/j.jvca.2016.12.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leong,C.</style></author><author><style face="normal" font="Arial"> Buttafuoco,A.</style></author><author><style face="normal" font="Arial"> Glatz,M.</style></author><author><style face="normal" font="Arial"> Bosshard,P.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University and University Hospital of Zurich, Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Antifungal susceptibility testing of Malassezia spp. with an optimized colorimetric broth microdilution method</style></title><secondary-title><style face="normal" font="Arial">J Clin Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Microbiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal drug</style></keyword><keyword><style face="normal" font="Arial"> antifungals</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Azoles</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Echinocandins</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> Ketoconazole</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pityriasis</style></keyword><keyword><style face="normal" font="Arial"> posaconazole</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> voriconazole</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">Malassezia is a genus of lipid dependent yeasts. It is associated with common skin diseases such as pityriasis versicolor or atopic dermatitis and can cause systemic infections in immunocompromised individuals. Owing to slow growth and lipid requirements of these fastidious yeasts, convenient and reliable antifungal drug susceptibility testing assays for Malassezia spp. are not widely available. We have therefore optimized a broth microdilution assay for the testing of Malassezia that is based on the assays from CLSI and EUCAST for Candida and other yeasts. The addition of ingredients such as lipids and esculin provided a broth medium formulation, which enabled the growth of all Malassezia spp. and could be read with the colorimetric indicator resazurin by visual and by fluorescence reading. We have tested the susceptibility of 52 strains of 13 species of Malassezia against 11 commonly used antifungals. MIC values determined by visual reading were in good agreement with MIC values determined by fluorescence reading. The lowest MICs were found for the azoles itraconazole, posaconazole and voriconazole with MIC90 values of 0.03-1.0 mug/ml, 0.06-0.5 mug/ml and 0.03-2.0 mug/ml, respectively. All Malassezia spp. were resistant to echinocandins and griseofulvin. Some Malassezia spp. also showed high MIC values for ketoconazole, which is the most widely recommended topical antifungal to treat Malassezia skin infections. In summary, our assay enables the fast and reliable susceptibility testing of Malassezia spp. against a large panel of different antifungals</style></abstract><notes><style face="normal" font="Arial">DA - 20170406IS - 1098-660X (Electronic)IS - 0095-1137 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1128/JCM.00338-17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28381607">PM:28381607</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Microbiol\20170406-LeongC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Microbiol\20170406-LeongC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170406, Leong C</style></custom2><misc3><style face="normal" font="Arial">10.1128/JCM.00338-17</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morawska,A.</style></author><author><style face="normal" font="Arial"> Mitchell,A.</style></author><author><style face="normal" font="Arial"> Burgess,S.</style></author><author><style face="normal" font="Arial"> Fraser,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Parenting and Family Support Centre, School of Psychology, The University of Queensland</style></auth-address><titles><title><style face="normal" font="Arial">Randomized controlled trial of Triple P for parents of children with asthma or eczema: Effects on parenting and child behavior</style></title><secondary-title><style face="normal" font="Arial">J Consult Clin Psychol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Consult Clin Psychol</style></abbr-1></periodical><pages end="296" start="283">283-296</pages><volume><style face="normal" font="Arial">85</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child Behavior</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parenting</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Parents play an important role in children's illness management, in promoting child adjustment and reducing behavior problems. Little research has focused on the evaluation of parenting interventions in the context of childhood chronic illness. The aim of this study was to test the efficacy of a brief, group parenting intervention (Healthy Living Triple P) in improving parenting skills and parent adjustment, and reducing child behavioral and emotional difficulties in the context of childhood asthma and eczema. METHOD: One hundred seven parents of children with a diagnosis of asthma and/or eczema were randomly assigned to intervention (n = 52) or care as usual (CAU; n = 55). Parents completed self-report measures of their child's behavioral and emotional adjustment, their own parenting, and their own level of adjustment at pre- and postintervention and at 6-month follow-up. Parent-child interactions were observed and coded at each time point. The intervention consisted of 2 group sessions of 2 hr each delivered by trained, accredited practitioners. RESULTS: Attrition was low, with T2 and T3 assessment completed by 84.6% and 80.8% of intervention families and 92.7% and 81.8% of CAU families, respectively. Intention-to-treat analyses indicated that overall parent-reported ineffective parenting as well as parental overreactivity reduced as a result of intervention. Parent report of child behavior problems also decreased, but there were no changes in children's emotional adjustment. No changes in observed parent or child behavior were found. Stress reduced for parents in the intervention group compared to the CAU group, but there were no changes in parental anxiety or depression. Effects showed evidence of reliable and clinical change and were maintained at 6-month follow-up. CONCLUSIONS: The intervention shows promise as an addition to clinical services for children with asthma and eczema and may have broader application to other chronic health conditions. (PsycINFO Database Record</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1939-2117 (Electronic)IS - 0022-006X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1037/ccp0000177</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28333531">PM:28333531</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Consult Clin Psychol\2017-85-283-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Consult Clin Psychol\2017-85-283-96.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Morawska A</style></custom2><misc3><style face="normal" font="Arial">10.1037/ccp0000177</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">DeKoven,S.</style></author><author><style face="normal" font="Arial"> DeKoven,J.</style></author><author><style face="normal" font="Arial"> Holness,D.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Schulich School of Medicine and Dentistry, London, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">(Meth)Acrylate Occupational Contact Dermatitis in Nail Salon Workers</style></title><secondary-title><style face="normal" font="Arial">J Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cutan Med Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acrylates</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cheek</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Forearm</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Thigh</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recently, many cases of acrylate-associated allergic contact dermatitis have appeared among nail salon workers. Common acrylate-containing products in nail salons include traditional nail polish, ultraviolet-cured shellac nail polish, ultraviolet-cured gel nails, and press-on acrylic nails. METHODS: Nail salon technicians seen in the occupational medicine clinic in 2015 and 2016 were identified, and their patch test results and clinical features were summarized. Patch testing was done with the Chemotechnique (Meth)Acrylate nail series, and either the North American Standard series or the North American Contact Dermatitis Group screening series. RESULTS: Six patients were identified, all women, ages 38 to 58. Common presentations included erythematous dermatitis of the dorsa of the hands, palms, and forearms and fissures on the fingertips. Less common sites of eruptions included the periorbital region, cheeks, posterior ears, neck, sacral area, lateral thighs, and dorsa of the feet. All patients reacted to hydroxyethyl methacrylate, and 5 patients reacted to ethyl acrylate. Each patient also reacted to (meth)acrylates that are not found on either standard series, including ethyleneglycol dimethacrylate, 2-hydroxypropyl methacrylate, and 2-hydroxyethyl acrylate. CONCLUSIONS: The authors report 6 cases of allergic contact dermatitis to acrylates in nail technicians seen over the past year, representing a new trend in their clinic. These cases are reflective of a growing trend of nail technicians with allergic contact dermatitis associated with occupational (meth)acrylate exposure. Efforts to improve prevention are needed</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1615-7109 (Electronic)IS - 1203-4754 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1177/1203475417701420</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362114">PM:28362114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cutan Med Surg\20170331-DeKovenS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cutan Med Surg\20170331-DeKovenS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, DeKoven S</style></custom2><misc3><style face="normal" font="Arial">10.1177/1203475417701420</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kondo,M.</style></author><author><style face="normal" font="Arial"> Nakagawa,T.</style></author><author><style face="normal" font="Arial"> Yamanaka,K.</style></author><author><style face="normal" font="Arial"> Mizutani,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Case with acute urticaria by red meat after Haemaphysalis longicornis bite</style></title><secondary-title><style face="normal" font="Arial">J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="17" Month="4" Year="2017">2017/4/17</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/1346-8138.13865</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28419520">PM:28419520</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol\20170418-KondoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol\20170418-KondoM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Kondo M</style></custom2><misc3><style face="normal" font="Arial">10.1111/1346-8138.13865</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inomata,N.</style></author><author><style face="normal" font="Arial"> Miyakawa,M.</style></author><author><style face="normal" font="Arial"> Aihara,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan</style></auth-address><titles><title><style face="normal" font="Arial">High prevalence of sensitization to gibberellin-regulated protein (peamaclein) in fruit allergies with negative immunoglobulin E reactivity to Bet v 1 homologs and profilin: Clinical pattern, causative fruits and cofactor effect of gibberellin-regulated protein allergy</style></title><secondary-title><style face="normal" font="Arial">J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruit allergy</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> orange</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen-food allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">Gibberellin-regulated protein (GRP) is a new allergen in peach allergy, with an amino acid sequence very well conserved through several botanical species. We investigated the allergenicity of GRP in fruit allergies other than peaches and identified the clinical characteristics of fruit allergy patients with GRP sensitization. One hundred consecutive Japanese patients with fruit allergies were enrolled in the present study. To identify the features of GRP sensitization, we selected patients with negative ImmunoCAP results for Bet v 1 homologs and profilin, which are marker allergens for pollen-food allergy syndrome (PFAS), or lipid transfer protein. These patients underwent specific immunoglobulin E measurements by enzyme-linked immunosorbent assay (ELISA) and skin prick tests (SPT) using purified nPru p 7. Twenty of 100 consecutive patients with fruit allergies had negative ImmunoCAP results for Bet v 1 homologs and profilin. Thirteen (65.0%) of the 20 patients had positive ELISA and/or SPT results using nPru p 7, whereas one of the 20 patients had positive ImmunoCAP results for Pru p 3. In 13 nPru p 7-sensitized patients, the causative foods were peaches (92.3%), apricots (61.5%), oranges (46.2%) and apples (30.8%). Ten patients (76.9%) had multiple causative fruits. Frequent symptoms included facial edema (92.3%) and laryngeal tightness (66.7%). In eight patients (61.5%), exercise or aspirin intake enhanced the allergic reaction onset as cofactors. The prevalence of GRP sensitization was high in Japanese fruit allergy patients except for PFAS patients. In conclusion, GRP-sensitized patients may have allergies to multiple fruits and may show peculiar characteristics such as facial swelling and cofactor dependence</style></abstract><notes><style face="normal" font="Arial">DA - 20170322IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/1346-8138.13795</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28326616">PM:28326616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol\20170322-InomataN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol\20170322-InomataN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170322, Inomata N</style></custom2><misc3><style face="normal" font="Arial">10.1111/1346-8138.13795</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hide,M.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author><author><style face="normal" font="Arial"> Igarashi,A.</style></author><author><style face="normal" font="Arial"> Ye,Y.M.</style></author><author><style face="normal" font="Arial"> Kim,T.B.</style></author><author><style face="normal" font="Arial"> Yagami,A.</style></author><author><style face="normal" font="Arial"> Roh,J.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Chinuki,Y.</style></author><author><style face="normal" font="Arial"> Youn,S.W.</style></author><author><style face="normal" font="Arial"> Lee,S.K.</style></author><author><style face="normal" font="Arial"> Inomata,N.</style></author><author><style face="normal" font="Arial"> Choi,J.H.</style></author><author><style face="normal" font="Arial"> Fukunaga,A.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Matsushima,S.</style></author><author><style face="normal" font="Arial"> Greenberg,S.</style></author><author><style face="normal" font="Arial"> Khalil,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Many patients with chronic spontaneous/idiopathic urticaria (CSU/CIU) do not respond adequately to treatment with non-sedating H1 antihistamines (H1AH). There are limited studies on use of omalizumab as add-on therapy for treatment of CSU in an Asian population. OBJECTIVE: The POLARIS study (NCT02329223), representing the first randomized, double-blind, placebo-controlled phase III trial of omalizumab for CSU in an Eastern Asian population, evaluated efficacy and safety of omalizumab as add-on therapy for treatment of CSU. METHODS: This 26-week multicenter (41 Japanese/Korean sites) study enrolled patients (12-75 years) who were symptomatic despite H1AH treatment. Eligible participants (N=218) were randomized 1:1:1 to receive three subcutaneous injections of omalizumab 300mg, 150mg, or placebo every 4 weeks, followed by 12 weeks of follow-up. Primary outcome was change from baseline to Week 12 (Wk12) in weekly itch severity score (ISS7). Safety was assessed through the summary of adverse events (AEs). RESULTS: Baseline demographics and disease characteristics were generally well balanced across treatment groups. At Wk12, statistically significant decreases from baseline were observed in ISS7 with omalizumab vs placebo (mean changes -10.22, -8.80, and -6.51 for omalizumab 300mg, 150mg and placebo; p&lt;0.001 and p=0.006 vs placebo, respectively). Overall AE incidence was similar across treatment groups (54.8%, 57.7%, and 55.4% in omalizumab 300mg, 150mg, and placebo groups, respectively); nasopharyngitis was the most frequently reported AE in all treatment arms. CONCLUSION: The POLARIS study demonstrates that omalizumab is an efficacious and well-tolerated add-on therapy in Japanese and Korean H1AH-refractory patients with CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - South Korea -CO - United States -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2017.03.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366435">PM:28366435</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20170403-HideM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20170403-HideM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Hide M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2017.03.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kocaturk,E.</style></author><author><style face="normal" font="Arial"> Can,P.K.</style></author><author><style face="normal" font="Arial"> Akbas,P.E.</style></author><author><style face="normal" font="Arial"> Copur,M.</style></author><author><style face="normal" font="Arial"> Degirmentepe,E.N.</style></author><author><style face="normal" font="Arial"> Kiziltac,K.</style></author><author><style face="normal" font="Arial"> Singer,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Okmeydani Training and Research Hospital, Department of Dermatology, Kaptanpasa Mah. Darulaceze Cad. No: 27, 34384 Okmeydani, Sisli, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Management of chronic inducible urticaria according to the guidelines: A prospective controlled study</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inducible urticaria</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria control test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options. OBJECTIVE: We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU. METHODS: This prospective parallel group controlled study included 70 CIndU and 66 CSU patients. The same treatment algorithm recommended by the European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization (EAACI/GA2LEN/EDF/WAO) was implemented to both CSU and CIndU patients. Treatment responses of the groups were evaluated with urticaria control test (UCT) and dermatology life quality questionnaire (DLQI) scores at the 0, 4, 8, 12 and 24th weeks for CIndU and 0, 4, 12 and 24 weeks for CSU. RESULTS: Fourteen patients (20,9%) with CIndU and 25 (37,9%) with CSU responded to standard doses of H1-AHs which was significantly higher in the CSU group (p=0,031, p&lt;0,05). Patients with CIndU and CSU showed statistically similar responses to 2nd line treatments (combining or updosing AHs) (p=0,979; p>0,05). Twenty-seven (40,3%) of CIndU patients and 21 (31,8%) of CSU patients were diagnosed as AH-resistant urticaria. Omalizumab was administered to 15 CSU patients and 17 CIndU patients. Response rates to omalizumab were similar in both groups. Total response rates increased from 37,9% (n:25) to 68,2% (n:45) with the 2nd line treatments in CSU group while it increased from 20,9% (n:14) to 59,7% (n:40) in CIndU group. When omalizumab was introduced to AH-refractory cases as a 3rd line treatment, total response rates evaluated at the 12th week were 76,1% (n:51) in patients with CIndU and 83,3% (n:55) in CSU. Continuing omalizumab treatment for 24 weeks increased response rates in patients who were unresponsive at week 12. CONCLUSION: CIndU seem to be more resistant to standard doses of AHs and higher doses of AHs are required for the control of symptoms. The same guidelines for CSU may be implemented to patients with CIndU</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2017.02.283</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28314658">PM:28314658</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20170317-KocaturkE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20170317-KocaturkE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Kocaturk E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2017.02.283</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kwiek,B.</style></author><author><style face="normal" font="Arial"> Lesniewska,A.</style></author><author><style face="normal" font="Arial"> Kowalewski,C.</style></author><author><style face="normal" font="Arial"> Wozniak,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Immunodermatology, Medical University of Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Langerhans cells are predominant high affinity immunoglobulin E receptor bearing cells in the epidermis of bullous pemphigoid skin</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="63" start="60">60-63</pages><volume><style face="normal" font="Arial">85</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antigens,CD</style></keyword><keyword><style face="normal" font="Arial"> Antigens,CD1</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Major Basic Protein</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Langerhans Cells</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> Lectins,C-Type</style></keyword><keyword><style face="normal" font="Arial"> Mannose-Binding Lectin</style></keyword><keyword><style face="normal" font="Arial"> Mannose-Binding Lectins</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Pemphigoid,Bullous</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteoglycans</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Receptors,IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161114IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Comparative StudyPT - LetterRN - 0 (Antigens, CD)RN - 0 (Antigens, CD1)RN - 0 (CD1a antigen)RN - 0 (CD207 protein, human)RN - 0 (Lectins, C-Type)RN - 0 (Mannose-Binding Lectins)RN - 0 (Proteoglycans)RN - 0 (Receptors, IgE)RN - 147016-17-9 (PRG2 protein, human)RN - 37341-29-0 (Immunoglobulin E)RN - EC 3.1.27.- (Eosinophil Major Basic Protein)SB - IMCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2016.09.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27839901">PM:27839901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\2017-85-60-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\2017-85-60-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161114, Kwiek B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2016.09.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sridharan,K.</style></author><author><style face="normal" font="Arial"> Sivaramakrishnan,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Pharmacology, Department of Health Sciences , Fiji National University , Suva , Fijib Prosthodontics, Department of Oral Health, College of Medicine, Nursing and Health Sciences , Fiji National University , Suva , Fiji</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual immunotherapy in patients with latex allergy: systematic review and meta-analysis of randomized controlled trials</style></title><secondary-title><style face="normal" font="Arial">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatolog Treat</style></full-title></periodical><pages end="6" start="1">1-6</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glove</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="Arial">Latex allergy (LA) is a commonly observed entity for which sublingual immunotherapy (SLIT) has been shown to be effective in many small randomized clinical trials. The present study was conducted with an aim of systematically reviewing the existing literature on the efficacy and safety of SLIT in patients with LA and to apply the principles of meta-analysis. A search for randomized controlled trials with appropriate search strategy in PubMed and CENTRAL was conducted. Studies with documented clinical history of LA and SLIT administered in any dose, duration and regimen compared with placebo were included. Outcome measures were symptom scores, glove provocation test score, serum IgE levels, induration following latex skin prick test, medication scores and adverse effects. Random effects model was used when moderate to severe heterogeneity was observed and fixed effects model when there was mild heterogeneity. Forest plots for standardized mean difference (95% confidence interval) for all the continuous outcome measures were created. A total of 152 records were identified from the electronic databases and four studies were finally included in the meta-analysis. A statistically significant reduction for induration following glove provocation test (pooled results from two studies) was observed in the SLIT group with SMD of -0.9 [-1.71, -0.08]. No significant differences were observed in any other outcome measures between the interventions. We did not identify significant reduction in most of the outcome measures with SLIT in patients with LA except for glove provocation test score wherein only two studies were included. Large and more randomized controlled trials are required to ascertain and confirm the utility of SLIT in such patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170321IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - engPT - Journal ArticleCO - Fiji -</style></notes><work-type><style face="normal" font="Arial">10.1080/09546634.2017.1303567</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28320227">PM:28320227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatolog Treat\20170321-SridharanK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatolog Treat\20170321-SridharanK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170321, Shridharan K</style></custom2><misc3><style face="normal" font="Arial">10.1080/09546634.2017.1303567</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonati,L.M.</style></author><author><style face="normal" font="Arial"> Epstein,G.K.</style></author><author><style face="normal" font="Arial"> Strugar,T.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Microneedling in All Skin Types: A Review</style></title><secondary-title><style face="normal" font="Arial">J Drugs Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Drugs Dermatol</style></full-title></periodical><pages end="313" start="308">308-313</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Alopecia</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Graft Survival</style></keyword><keyword><style face="normal" font="Arial"> Granuloma</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Microneedling procedures are growing in popularity for a wide variety of skin conditions. This paper comprehensively reviews the medical literature regarding skin needling efficacy and safety in all skin types and in multiple dermatologic conditions.&lt;/p> &lt;p>METHODS: A PubMed literature search was conducted in all languages without restriction and bibliographies of relevant articles reviewed. Search terms included: "microneedling," "percutaneous collagen induction," "needling," "skin needling," and "dermaroller."&lt;/p> &lt;p>RESULTS: Microneedling is most commonly used for acne scars and cosmetic rejuvenation, however, treatment benefit has also been seen in varicella scars, burn scars, keloids, acne, alopecia, and periorbital melanosis, and has improved flap and graft survival, and enhanced transdermal delivery of topical products. Side effects were mild and self-limited, with few reports of post-inflammatory hyperpigmentation, and isolated reports of tram tracking, facial allergic granuloma, and systemic hypersensitivity.&lt;/p> &lt;p>DISCUSS: Microneedling represents a safe, cost-effective, and efficacious treatment option for a variety of dermatologic conditions in all skin types. More double-blinded, randomized, controlled trials are required to make more definitive conclusions.</style></abstract><notes><style face="normal" font="Arial">DA - 20170413IS - 1545-9616 (Print)IS - 1545-9616 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28403263">PM:28403263</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170413, Bonati LM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosa,S.I.</style></author><author><style face="normal" font="Arial"> Rios-Santos,F.</style></author><author><style face="normal" font="Arial"> Balogun,S.O.</style></author><author><style face="normal" font="Arial"> de Almeida,D.A.</style></author><author><style face="normal" font="Arial"> Damazo,A.S.</style></author><author><style face="normal" font="Arial"> da Cruz,T.C.</style></author><author><style face="normal" font="Arial"> Pavan,E.</style></author><author><style face="normal" font="Arial"> Barbosa,R.D.</style></author><author><style face="normal" font="Arial"> Alvim,T.D.</style></author><author><style face="normal" font="Arial"> Mendes,Soares,I</style></author><author><style face="normal" font="Arial"> Ascencio,S.D.</style></author><author><style face="normal" font="Arial"> Macho,A.</style></author><author><style face="normal" font="Arial"> de Oliveira Martins,D.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pharmacology Area, Department of Basic Sciences in Health, Faculty of Medicine, Federal University of Mato Grosso, UFMT, 78060-900, Cuiaba, MT, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Hydroethanolic extract from Echinodorus scaber Rataj leaves inhibits inflammation in ovalbumin-induced allergic asthma</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="199" start="191">191-199</pages><volume><style face="normal" font="Arial">203</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alkaloids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood plasma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> phenolic compounds</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Leaves</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rutin</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Echinodorus scaber, Alismataceae, is popularly known in Brazil as "chapeu-de-couro". The plant leaves are used by the population as decoction, infusion, or maceration in bottled spirits, to treat inflammatory respiratory diseases. AIM OF THE STUDY: To investigate the anti-inflammatory mechanism of the hydroethanolic extract of leaves of Echinodorus scaber (HEEs) in allergic asthma. A phytochemical analysis of the extract was performed as well. MATERIALS AND METHODS: The leaves of Echinodorus scaber were prepared by maceration in 75% ethanol. Preliminary phytochemical analysis was carried out using basic classical methods, and the secondary metabolites detected in HEEs were analyzed and confirmed by high-performance liquid chromatography (HPLC). The in vivo anti-inflammatory activity of HEEs was evaluated in Swiss male albino mice sensitized and challenged by OVA. The HEEs (1, 5 and 30mg/kg, p.o.) was administered to mice twice a day, 1h before the challenge, from days 19 through 24. The mechanism of action of HEEs was studied by evaluating the levels of TH2 cytokines (IL-4, IL-5 and IL-13) in bronchoalveolar lavage fluid (BALF) and IgE production in blood plasma. Histopathological changes triggered by OVA-sensitization/challenge in the lung tissue were also investigated. RESULTS: HEEs reduced total leukocyte, eosinophil, neutrophil, and mononuclear cell counts at all doses tested, with maximum effect at 30mg/kg (73.9%, 75.9%, 75.5%, and 65.2% reduction, p&lt;0.001, respectively). Increases in TH2 cytokine secretion (IL-4, IL-5 and IL-13) and in IgE levels were also attenuated by HEEs. Preliminary phytochemical screening seems to indicated the presence of phenolic compounds, flavonoids and alkaloids. HPLC analyses evidenced the presence of phenolic compounds, such as gallic acid, rutin and vitexin. CONCLUSION: Our findings provided pharmacological preclinical evidence for the popular use of the leaves of Echinodorus scaber in allergic inflammation. Its anti-inflammatory effect was dependent on the decrease in migratory inflammatory cells, and both TH2 cytokines and IgE levels. It is suggested that vitexin, gallic acid and rutin, known anti-inflammatory compounds, may participate in the anti-asthamtic effect of the HEEs, by acting jointly along with other components present in the extract</style></abstract><notes><style face="normal" font="Arial">DA - 20170326IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.03.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342859">PM:28342859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\2017-203-191-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\2017-203-191-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170326, Rosa SI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.03.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Caballero-Fonseca,F.</style></author><author><style face="normal" font="Arial"> Capriles-Hulett,A.</style></author><author><style face="normal" font="Arial"> Gonzalez-Aveledo,L.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Department, Centro Medico Docente La Trinidad, Caracas, Venezuela</style></auth-address><titles><title><style face="normal" font="Arial">Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Biological Markers</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Coagulation pathway</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="Arial">Biomarkers useful for the evaluation and management of patients with chronic spontaneous urticaria (CSU) are not currently available. A review of various clinical and laboratory markers that have been studied to assess their value for determining the severity or predicting the evolution of disease in adult patients with CSU was carried out. A search of the medical literature on PubMed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, CSU, severity, prognosis and treatment was performed. Based on our review of the literature, among the clinical markers studied, higher age at onset, being female, long disease duration and aspirin/NSAID hypersensitivity may be linked to both severe CSU and a long time to spontaneous remission. In addition, a positive autologous serum skin test (ASST) may be associated with severe CSU, and comorbidity of inducible urticaria and concomitant recurrent angio-oedema may be linked to longer CSU duration. Potential biomarkers of CSU severity and/or duration include basophil numbers and susceptibility to activation, inflammatory markers, markers of activation of the extrinsic coagulation pathway, immunoglobulin E and vitamin D. Although the described markers are promising, further studies on representative and well-characterized patient populations are needed to determine the value of these clinical and biological markers for predicting the severity and course of disease in patients with CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Venezuela -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14221</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28299827">PM:28299827</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170316-SanchezBorgesM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170316-SanchezBorgesM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Sanchez-Borges M</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14221</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Beaudouin,E.</style></author><author><style face="normal" font="Arial"> Birnbaum,J.</style></author><author><style face="normal" font="Arial"> Neukirch,C.</style></author><author><style face="normal" font="Arial"> Meininger,C.</style></author><author><style face="normal" font="Arial"> Leroy,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Who should have an epinephrine autoinjector? Position statement of the French Allergology Society's Anaphylaxis, Food Allergy and Stinging insects working groups ?</style></title><secondary-title><style face="normal" font="Arial">J Eur Urg Reanim</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Eur Urg Reanim</style></full-title></periodical><pages end="70" start="60">60-70</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Recommandations</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Stinging insects</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><isbn><style face="normal" font="Arial">2211-4238</style></isbn><abstract><style face="normal" font="Arial">Intramuscular epinephrine is the first-line treatment for anaphylaxis. For certain allergic patients, an epinephrine autoinjector (EAI) should be prescribed and educational training should be provided. In 2014, the European Academy of Allergy and Clinical Immunology (EAACI) Taskforce on Anaphylaxis provided evidence-based guidelines for the diagnosis, risk factor assessment and management of anaphylaxis. Our aim here is to provide up-to-date guidelines for the prescription of an EAI for use in children and in adults as well, a prescription for a second EAI to be carried in the same sack in case the initial injection is not successful. This position statement, prepared by the Anaphylaxis, Food Allergy and Stinging insects working groups of the French Allergology Society, is based on the EAACI anaphylaxis guidelines and it provides a critical review of their recommendations</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jeurea.2017.02.009</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.jeurea.2017.02.009</url></web-urls></urls><custom2><style face="normal" font="Arial">20170423, Pouessel G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jeurea.2017.02.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meltzer,E.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Professor of Pediatrics, Division of Allergy and Immunology, University of California, San Diego, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Hot Topics in Primary Care: Sublingual Immunotherapy: A Guide for Primary Care</style></title><secondary-title><style face="normal" font="Arial">J Fam Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Fam Pract</style></full-title></periodical><pages end="S63" start="S58">S58-S63</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">4 Suppl</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy (AIT), the only potential disease-modifying treatment for allergic disease, has been used for more than a century. Hankin et al showed significant reduction in pharmacy, outpatient, and inpatient resources in the 6 months following vs the 6 months preceding AIT in Medicaid-enrolled children with allergic rhinitis (AR). A 2013 analysis showed sustained cost reduction over 18 months in patients with AR treated with AIT compared with matched control subjects not treated with AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1533-7294 (Electronic)IS - 0094-3509 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28375410">PM:28375410</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Fam Pract\2017-66S4-58-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Fam Pract\2017-66S4-58-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Meltzer EO</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ashtekar,R.</style></author><author><style face="normal" font="Arial"> Shah,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Pediatric TB Clinic, B. J. Wadia Hospital for Children, Mumbai, Maharashtra, India</style></auth-address><titles><title><style face="normal" font="Arial">Tuberculosis in a case of hyper immunoglobulin E syndrome</style></title><secondary-title><style face="normal" font="Arial">J Family Med Prime Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Family Med Prime Care</style></abbr-1></periodical><pages end="872" start="871">871-872</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Hyper immunoglobulin E syndrome (HIES) is a rare primary immunodeficiency disorder characterized by elevated serum IgE, dermatitis, and immunodeficiency that predisposes to multiple skin and lung infections. The most frequent pathogen responsible for infections in these patients is Staphylococcus aureus. Tuberculosis (TB) in patients with HIES is an uncommon finding, and there are only a few reports of mycobacterial infections in known cases of HIES. We present a case of abdominal TB that developed in a 15-year-old boy who also had HIES</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 2249-4863 (Print)IS - 2249-4863 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/2249-4863.201167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28349010">PM:28349010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Family Med Prime Care\2016-5-871-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Family Med Prime Care\2016-5-871-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Ashtekar R</style></custom2><misc3><style face="normal" font="Arial">10.4103/2249-4863.201167</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sharma,T.</style></author><author><style face="normal" font="Arial"> Sharma,A.</style></author><author><style face="normal" font="Arial"> Bhatnagar,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Civil Hospital, Kangra, Tanda, Himachal Pradesh, India</style></auth-address><titles><title><style face="normal" font="Arial">An unusual case of sustained ventricular tachycardia following a wasp bite</style></title><secondary-title><style face="normal" font="Arial">J Family Med Prime Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Family Med Prime Care</style></abbr-1></periodical><pages end="881" start="879">879-881</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Tachycardia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">Sustained ventricular tachycardia (VT) is a life-threatening condition which requires immediate intervention. We report a case of unusual etiology of sustained VT in a 42-year-old male after a wasp bite in the absence of anaphylaxis. The patient was treated with amiodarone and improved within 48 h. Thus, wasp stings can lead to serious tachyarrhythmias which can be life-threatening. Emergency care physicians should be aware of such arrhythmias in the setting of wasp bites which can be fatal</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 2249-4863 (Print)IS - 2249-4863 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/2249-4863.201165</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28349013">PM:28349013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Family Med Prime Care\2016-5-879-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Family Med Prime Care\2016-5-879-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Sharma T</style></custom2><misc3><style face="normal" font="Arial">10.4103/2249-4863.201165</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Holzmuller,W.</style></author><author><style face="normal" font="Arial"> Kulozik,U.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Quantification of MFGM proteins in buttermilk and butter serum by means of a stain free SDS-PAGE method</style></title><secondary-title><style face="normal" font="Arial">J Food Compost Anal</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Compost Anal</style></full-title></periodical><pages end="109" start="102">102-109</pages><volume><style face="normal" font="Arial">49</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Butter</style></keyword><keyword><style face="normal" font="Arial"> Butter serum</style></keyword><keyword><style face="normal" font="Arial"> Buttermilk</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Membrane Proteins</style></keyword><keyword><style face="normal" font="Arial"> MFGM</style></keyword><keyword><style face="normal" font="Arial"> MFGM proteins</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk fat globule membrane</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein quantification</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Protein structures</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stain free technology</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Standard material</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Tryptophan</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><isbn><style face="normal" font="Arial">0889-1575</style></isbn><abstract><style face="normal" font="Arial">In comparison to skim milk and whey, buttermilk and butter serum contain high amounts of functional milk fat globule membrane (MFGM) proteins. Quantification of MFGM proteins is difficult because no analytical standard material is available. By means of conventional SDS-PAGE with subsequent staining, MFGM proteins are analytically separated. However, due to various protein structures (e.g., glycosylation) the affinity to the dye is inconsistent. A direct correlation between measured band intensity and protein concentration and, therefore, absolute protein quantification is not possible. The purpose of this study was to apply a novel stain free SDS-PAGE technique that relies on measuring UV light fluorescence of tryptophan in order to quantify MFGM proteins. Thus, proteins can be quantified without the need for analytical standards, provided that the relative tryptophan content relative to the molecular weight is known. In this study, buttermilk and butter serum obtained from raw cream were examined and the three most abundant membrane proteins were absolutely quantified. Higher amounts of peripheral MFGM proteins were determined in buttermilk (0.9 g/L) and butter serum (2.7 g/L), in comparison to integral MFGM proteins (0.3</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.5 g/L). Conclusions were drawn regarding the absolute protein amount of MFGM material surrounding native milk fat globules</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jfca.2016.04.003</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jfca.2016.04.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Compost Anal\2016-49-102-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Compost Anal\2016-49-102-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170402, Holzmuller W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jfca.2016.04.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bedford,B.</style></author><author><style face="normal" font="Arial"> Yu,Y.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Garber,E.A.</style></author><author><style face="normal" font="Arial"> Jackson,L.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Food Safety, Division of Food Processing Science &amp; Technology, 6502 South Archer Road, Bedford Park, Illinois 60501</style></auth-address><titles><title><style face="normal" font="Arial">A Limited Survey of Dark Chocolate Bars Obtained in the United States for Undeclared Milk and Peanut Allergens</style></title><secondary-title><style face="normal" font="Arial">J Food Prot</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Prot</style></full-title></periodical><pages end="702" start="692">692-702</pages><volume><style face="normal" font="Arial">80</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Chocolate</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Undeclared allergens in chocolate products have been responsible for numerous allergen-related recalls in the United States. A survey was conducted to determine the prevalence of undeclared milk and peanut in 88 and 78 dark chocolate bars, respectively. Concentrations of milk (as nonfat dry milk) or peanut in three samples of each chocolate product were determined with two milk- or peanut-specific enzyme-linked immunosorbent assay kits. In 75% of the chocolate bar products with a milk advisory statement, milk concentrations were above the limit of quantitation (2.5 mug/g [ppm]), with the majority having concentrations >1,000 ppm. An additional 67% of chocolate bars with a "traces of milk" statement contained 3 to 6,700 ppm of milk. Fifteen percent of chocolates labeled dairy free or lactose free and 25% labeled vegan were positive for milk, all with concentrations >1,000 ppm. Even for chocolates with no reference to milk on the label, 33% of these products contained 60 to 3,400 ppm of milk. The survey of chocolate products for peanuts revealed that 8% of products with an advisory statement contained peanut, with the highest concentration of 550 ppm. All nine chocolates bearing the peanut-free or allergen-free statement were negative for peanut, but 17% of chocolates with no label statement for peanut were positive for peanut at concentrations of 9 to 170 ppm. Evaluation of multiple lots of four chocolate products revealed that milk was consistently present or absent for the products investigated, but mixed results were obtained when multiple lots were tested for peanut. This study indicates that a large proportion of dark chocolate bars contain undeclared milk. The type of advisory statement or the absence of a milk advisory statement on products did not predict the amount or absence of milk protein. In contrast, a lower proportion of chocolates containing undeclared peanut was found. Consumers with food allergies should be cautious when purchasing dark chocolate products, particularly those that have an advisory label statement</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 1944-9097 (Electronic)IS - 0362-028X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28304196">PM:28304196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Prot\2017-80-692-702.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Prot\2017-80-692-702.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Bedford B</style></custom2><misc3><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-443</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Petriccione,M.</style></author><author><style face="normal" font="Arial"> Mastrobuoni,F.</style></author><author><style face="normal" font="Arial"> Zampella,L.</style></author><author><style face="normal" font="Arial"> Nobis,E.</style></author><author><style face="normal" font="Arial"> Capriolo,G.</style></author><author><style face="normal" font="Arial"> Scortichini,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Consiglio per la Ricerca in Agricoltura e l'analisi dell'Economia Agraria (CREA), Centro di Ricerca per Olivicoltura, Frutticoltura e Agrumicoltura-Sede di Caserta, Via Torrino 3, 81100 Caserta, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Effect of chitosan treatment on strawberry allergen-related gene expression during ripening stages</style></title><secondary-title><style face="normal" font="Arial">J Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci Technol</style></full-title></periodical><pages end="1345" start="1340">1340-1345</pages><volume><style face="normal" font="Arial">54</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">A3</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Chitosan</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fragaria</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Ripening</style></keyword><keyword><style face="normal" font="Arial"> Strawberry</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">The effectiveness of a chitosan coating treatment on the allergen-related genes expression of three strawberry cultivars (Fragaria x ananassa Duch., namely cvs. "Sabrina", "Candonga" and "Jonica") harvested at three ripening stages was evaluated. Fruits were treated with a 1% chitosan coating and stored at 20 degrees C for 48 h. Three genes, encoding Fra a1, Fra a3 and Fra a4 allergens, were evaluated by real-time qPCR. The transcript levels of several genes showed different patterns during ripening stages in strawberry cultivars but were up-regulated by chitosan treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 0022-1155 (Print)IS - 0022-1155 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13197-017-2554-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28416885">PM:28416885</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci Technol\2017-54-1340-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci Technol\2017-54-1340-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Petriccione M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13197-017-2554-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mao,J.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author><author><style face="normal" font="Arial"> Ai,M.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author><author><style face="normal" font="Arial"> Wang,D.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Hu,K.</style></author><author><style face="normal" font="Arial"> Gao,X.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, 211198, China</style></auth-address><titles><title><style face="normal" font="Arial">A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety</style></title><secondary-title><style face="normal" font="Arial">J Hematol Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Hematol Oncol</style></full-title></periodical><pages end="" start="71">71-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Discovery</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Melittin</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Safety evaluation</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="Arial">Melittin is the main effective component of bee venom and has extensive biological functions; however, serious side effects have restricted its clinical application. Preclinical and clinical studies showed that the main adverse events were allergic reaction and pain at the administration site. To decrease the toxicity, we prepared melittin nano-liposomes by encapsulating melittin with poloxamer 188 and explored the inhibitory activities on liver cancer together with biological safety. Here, we showed that melittin nano-liposomes significantly inhibited the survival of hepatocellular carcinoma (HCC) cells in vitro and prominently suppressed the growth of subcutaneous and orthotopic HCC transplantation tumors in vivo. It was important that it induced less inflammation and allergy in mice compared with melittin. Overall, melittin nano-liposomes would have a better application in HCC therapy due to its significant anti-tumor activity and better biological safety</style></abstract><notes><style face="normal" font="Arial">DA - 20170321IS - 1756-8722 (Electronic)IS - 1756-8722 (Linking)LA - engPT - LetterCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13045-017-0442-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28320480">PM:28320480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Hematol Oncol\2017-10-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Hematol Oncol\2017-10-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170321, Mao J</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13045-017-0442-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,K.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Truong,T.</style></author><author><style face="normal" font="Arial"> Zukin,E.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Saxon,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sixal Inc., Los Angeles, CA 90095</style></auth-address><titles><title><style face="normal" font="Arial">Blocking Allergic Reaction through Targeting Surface-Bound IgE with Low-Affinity Anti-IgE Antibodies</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> CD203c</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human basophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="4" Year="2017">2017/4/10</year></dates><abstract><style face="normal" font="Arial">Allergic disorders have now become a major worldwide public health issue, but the effective treatment options remain limited. We report a novel approach to block allergic reactivity by targeting the surface-bound IgE of the allergic effector cells via low-affinity anti-human IgE Abs with dissociation constants in the 10-6 to 10-8 M range. We demonstrated that these low-affinity anti-IgE mAbs bind to the cell surface-bound IgE without triggering anaphylactic degranulation even at high concentration, albeit they would weakly upregulate CD203c expression on basophils. This is in contrast to the high-affinity anti-IgE mAbs that trigger anaphylactic degranulation at low concentration. Instead, the low-affinity anti-IgE mAbs profoundly block human peanut- and cat-allergic IgE-mediated basophil CD63 induction indicative of anaphylactic degranulation; suppress peanut-, cat-, and dansyl-specific IgE-mediated passive cutaneous anaphylaxis; and attenuate dansyl IgE-mediated systemic anaphylaxis in human FcepsilonRIalpha transgenic mouse model. Mechanistic studies reveal that the ability of allergic reaction blockade by the low-affinity anti-IgE mAbs was correlated with their capacity to downregulate the surface IgE and FcepsilonRI level on human basophils and the human FcepsilonRIalpha transgenic mouse bone marrow-derived mast cells via driving internalization of the IgE/FcepsilonRI complex. Our studies demonstrate that targeting surface-bound IgE with low-affinity anti-IgE Abs is capable of suppressing allergic reactivity while displaying an excellent safety profile, indicating that use of low-affinity anti-IgE mAbs holds promise as a novel therapeutic approach for IgE-mediated allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1602022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396318">PM:28396318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170411-ZhangK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170411-ZhangK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Zhang K</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1602022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Peng,W.</style></author><author><style face="normal" font="Arial"> Grobe,W.</style></author><author><style face="normal" font="Arial"> Walgenbach-Brunagel,G.</style></author><author><style face="normal" font="Arial"> Flicker,S.</style></author><author><style face="normal" font="Arial"> Yu,C.</style></author><author><style face="normal" font="Arial"> Sylvester,M.</style></author><author><style face="normal" font="Arial"> Allam,J.P.</style></author><author><style face="normal" font="Arial"> Oldenburg,J.</style></author><author><style face="normal" font="Arial"> Garbi,N.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Novak,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, University of Bonn, 53127 Bonn, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Distinct Expression and Function of FcepsilonRII in Human B Cells and Monocytes</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="3034" start="3033">3033-3034</pages><volume><style face="normal" font="Arial">198</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> multifunctional</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="Arial">FcepsilonRII is a multifunctional low-affinity IgER that is involved in the pathogenesis of allergic, inflammatory, and neoplastic diseases. Although discrepancies in FcepsilonRII-mediated functions are being increasingly recognized, the consequences of FcepsilonRII activation are not completely understood. In this study, we evaluated the expression of FcepsilonRII on human blood cells and found that it was primarily expressed on monocytes and B cells. Although IL-4 promoted expression of the FcepsilonRIIb isoform on B cells and monocytes, the expression of the FcepsilonRIIa isoform was not dependent on IL-4. Furthermore, FcepsilonRII predominantly bound allergen-IgE complexes on B cells but not on monocytes. FcepsilonRII-mediated allergen-IgE complex uptake by B cells directed Ags to MHC class II-rich compartments. FcepsilonRII-bearing monocytes and B cells expressed high levels of the FcepsilonRII sheddase a disintegrin and metalloproteinase 10, which implies that they are important sources of soluble FcepsilonRII. Moreover, we identified that IgE immune complex stimulation of FcepsilonRII activated intracellular tyrosine phosphorylation via Syk in B cells but not in monocytes. Importantly, FcepsilonRII-mediated signaling by allergen-IgE immune complexes increased IFN-gamma production in B cells of allergic patients during the build-up phase of allergen-specific immunotherapy. Together, our results demonstrate that FcepsilonRII mediates cell type-dependent function in allergic reactions. In addition, the results identify a novel allergen-IgE complex/FcepsilonRII/Syk/IFN-gamma pathway in allergic responses and suggest that FcepsilonRII may play a role in regulating allergic reactions via modulating IFN-gamma production in B cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170309IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.5740/jaoacint.16-0243</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28275138">PM:28275138</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2017-109-3033-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2017-109-3033-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170309, Peng W</style></custom2><misc3><style face="normal" font="Arial">10.5740/jaoacint.16-0243</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Addison,K.J.</style></author><author><style face="normal" font="Arial"> Morse,J.</style></author><author><style face="normal" font="Arial"> Robichaud,A.</style></author><author><style face="normal" font="Arial"> Daines,M.O.</style></author><author><style face="normal" font="Arial"> Ledford,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Arizona, Tucson, Arizona, USA</style></auth-address><titles><title><style face="normal" font="Arial">A Novel in vivo System to Test Bronchodilators</style></title><secondary-title><style face="normal" font="Arial">J Infect Pulm Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Infect Pulm Dis</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">The incidence and severity of asthma continue to rise worldwide. beta-agonists are the most commonly prescribed therapeutic for asthma management but have less efficacy for some subsets of asthmatic patients and there are concerns surrounding the side effects from their long-term persistent use. The demand to develop novel asthma therapeutics highlights the need for a standardized approach to effectively screen and test potential bronchoprotective compounds using relevant in vivo animal models. Here we describe a validated method of testing potential therapeutic compounds for their fast-acting efficacy during the midst of an induced bronchoconstriction in a house dust mite challenged animal model</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 2470-3176 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.16966/2470-3176.120</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28367537">PM:28367537</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Infect Pulm Dis\20170403-AddisonKJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Infect Pulm Dis\20170403-AddisonKJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Addison KJ</style></custom2><misc3><style face="normal" font="Arial">10.16966/2470-3176.120</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nijsten,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Atopic Dermatitis and Comorbidities: Added Value of Comprehensive Dermatoepidemiology</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="1011" start="1009">1009-1011</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mental Health</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis is common and in its severe form is devastating. This chronic inflammatory dermatosis is part of the atopic syndrome, which includes asthma, food allergies, and hay fever and is known to be associated with mental health disorders. In line with psoriasis, several recent observational studies using national survey and linkage data have suggested a link between atopic dermatitis and cardiovascular disease. The atopic dermatitis field can benefit from the past experiences in psoriasis research and should not follow the same path, but, rather, aim for a more comprehensive approach from the beginning. A recent German consortium studying links between atopic dermatitis and cardiovascular disease first screened a large claims database, followed by analyses of more deeply phenotyped (birth) cohorts with longitudinal data. In addition, genetic and metabolic analyses assessing the predisposition of patients with atopic dermatitis for cardiovascular disease were performed. Overall, the association between atopic dermatitis and cardiovascular disease was at most modest, but in more refined cohorts the cardiovascular risk profile and genetic architecture was comparable. A more integrated approach could create clarity about the clinical relevance of cardiovascular disease in individuals with atopic dermatitis sooner, avoid speculation that affects patient care, and save scientific resources</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28411833">PM:28411833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-1009-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-1009-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Nijsten T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.02.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anbunathan,H.</style></author><author><style face="normal" font="Arial"> Bowcock,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Heart and Lung Institute, Imperial College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">The Molecular Revolution in Cutaneous Biology: The Era of Genome-Wide Association Studies and Statistical, Big Data, and Computational Topics</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="e118" start="e113">e113-e118</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Alopecia</style></keyword><keyword><style face="normal" font="Arial"> Alopecia Areata</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Susceptibility</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Markers</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association studies</style></keyword><keyword><style face="normal" font="Arial"> Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> heritability</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Vitiligo</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">The investigation of biological systems involving all organs of the body including the skin is in era of big data. This requires heavy-duty computational tools, and novel statistical methods. Microarrays have allowed the interrogation of thousands of common genetic markers in thousands of individuals from the same population (termed genome wide association studies or GWAS) to reveal common variation associated with disease or phenotype. These markers are usually single nucleotide polymorphisms (SNPs) that are relatively common in the population. In the case of dermatological diseases such as alopecia areata, vitiligo, psoriasis and atopic dermatitis, common variants have been identified that are associated with disease, and these provide insights into biological pathways and reveal possible novel drug targets. Other skin phenotypes such as acne, color and skin cancers are also being investigated with GWAS. Analyses of such large GWAS datasets require a consideration of a number of statistical issues including the testing of multiple markers, population substructure, and ultimately a requirement for replication. There are also issues regarding the missing heritability of disease that cannot be entirely explained with current GWAS approaches. Next generation sequencing technologies such as exome and genome sequencing of similar patient cohorts will reveal additional variants contributing to disease susceptibility. However, the data generated with these approaches will be orders of magnitude greater than that those generated with arrays, with concomitant challenges in the identification of disease causing variants</style></abstract><notes><style face="normal" font="Arial">DA - 20170416IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2016.03.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28411841">PM:28411841</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170416, Anbunathan H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2016.03.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mashima,E.</style></author><author><style face="normal" font="Arial"> Sawada,Y.</style></author><author><style face="normal" font="Arial"> Yamaguchi,T.</style></author><author><style face="normal" font="Arial"> Ohmori,S.</style></author><author><style face="normal" font="Arial"> Haruyama,S.</style></author><author><style face="normal" font="Arial"> Yoshioka,M.</style></author><author><style face="normal" font="Arial"> Okada,E.</style></author><author><style face="normal" font="Arial"> Nakamura,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Cellulitis Possibly Due to Mosquito Bite With High IL-5 Production</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="150" start="149">149-150</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Bite</style></keyword><keyword><style face="normal" font="Arial"> Cellulitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic cellulitis</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398209">PM:28398209</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Mashima E</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0142</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silvestre Salvador,J.F.</style></author><author><style face="normal" font="Arial"> Romero-Perez,D.</style></author><author><style face="normal" font="Arial"> Encabo-Duran,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Dermatologia, Hospital General Universitario de Alicante, Alicante, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Atopic Dermatitis in Adults: A Diagnostic Challenge</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="88" start="78">78-88</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> head and neck dermatitis</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prurigo</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) has a prevalence of 1%-3% in adults. Adult-onset AD has only been defined recently, and lack of familiarity with this condition and confusion regarding the appropriate terminology persist. AD may first appear in childhood or de novo in adults and is characterized by pronounced clinical heterogeneity. The disease often deviates from the classic pattern of flexural dermatitis, and there are forms of presentation that are specific to adults, such as head-and-neck dermatitis, chronic eczema of the hands, multiple areas of lichenification, or prurigo lesions. Although diagnosis is clinical, adult-onset AD frequently does not fit the traditional diagnostic criteria for the disease, which were developed for children. Thus, AD is often a diagnosis of exclusion, especially in de novo cases. Additional diagnostic tests, such as the patch test, prick test, skin biopsy, or blood test, are usually necessary to rule out other diseases or other types of eczema appearing concomitantly with AD. This article presents an update of the different forms of clinical presentation for AD in adults along with a proposed diagnostic approach, as new treatments will appear in the near future and many patients will not be able to benefit from them unless they are properly diagnosed</style></abstract><notes><style face="normal" font="Arial">DA - 20170110IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0138</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28071589">PM:28071589</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-78-88.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-78-88.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170110, Silvestre Salvador JF</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0138</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nieto-Nieto,A.</style></author><author><style face="normal" font="Arial"> Tejedor-Alonso,M.A.</style></author><author><style face="normal" font="Arial"> Farias-Aquino,E.</style></author><author><style face="normal" font="Arial"> Moro-Moro,M.</style></author><author><style face="normal" font="Arial"> Rosado,I.A.</style></author><author><style face="normal" font="Arial"> Gonzalez-Moreno,A.</style></author><author><style face="normal" font="Arial"> Gil de Miguel,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Hospital Universitario Fundacion Alcorcon, Alcorcon, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Profile of Patients With Severe Anaphylaxis Hospitalized in the Spanish Hospital System: 1997-2011</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="126" start="111">111-126</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> Cardiac arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Echinococcus</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Length of Stay</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Studies assessing the severity of anaphylaxis lack a comprehensive approach to collecting data on comorbidities that may worsen prognosis. Objective: Using the Elixhauser score (a systematic index associated with longer stay, hospital charges, and mortality), we determined which comorbidities were associated with more severe anaphylaxis. METHODS: We based our study on the Spanish Ministry of Health database of hospital discharges in Spain between 1997 and 2011. We constructed logistic regression models in which the dependent variables were outcomes related to greater severity (death, cardiac arrest, need for invasive mechanical ventilation or vasopressor drugs, admission to the intensive care unit, and length of stay) and the independent variables were the 30 comorbidities that comprise the Elixhauser score, age, sex, and main causes of anaphylaxis. RESULTS: We found that a higher risk of severe anaphylaxis was associated (3 or more logistic regressions) with age >50 years or having experienced cardiac arrhythmia, coagulation disorder, associated fluid-electrolyte imbalance, chronic pulmonary disease, or Echinococcus anaphylaxis. Likewise, in the adjusted analysis, a higher Elixhauser score was associated with most of the outcomes analyzed for severity of anaphylaxis. CONCLUSIONS: Cardiovascular and respiratory diseases increase the severity of anaphylaxis, and the resulting poor health status (represented as a higher Elixhauser score) is associated with more severe anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170202IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0146</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28151396">PM:28151396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-111-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-111-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170202, Nieto-Nieto A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0146</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carballo,I.</style></author><author><style face="normal" font="Arial"> Carballada,F.</style></author><author><style face="normal" font="Arial"> Nunez-Orjales,R.</style></author><author><style face="normal" font="Arial"> Martin-Lazaro,J.</style></author><author><style face="normal" font="Arial"> Vidal,C.</style></author><author><style face="normal" font="Arial"> Gonzalez-Quintela,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Hospital and University of Santiago de Compostela, Santiago de Compostela, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Total and Honeybee Venom-Specific Serum IgG4 and IgE in Beekeepers</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="148" start="146">146-148</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398208">PM:28398208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Carballo I</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0141</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alcantara,M.</style></author><author><style face="normal" font="Arial"> Saenz de San Pedro,B.</style></author><author><style face="normal" font="Arial"> Canada,C.</style></author><author><style face="normal" font="Arial"> Munoz,M.A.</style></author><author><style face="normal" font="Arial"> Jimeno,L.</style></author><author><style face="normal" font="Arial"> Villalba,M.</style></author><author><style face="normal" font="Arial"> De la Torre,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergology Unit of the Complejo Hospitalario de Jaen, Jaen, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Steps Towards Clarifying the Clinical Relevance of Minor Olive Allergens in Areas With Extremely High Levels of Olive Pollen</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="140" start="138">138-140</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> olive pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0134</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398204">PM:28398204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Alcantara M</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0134</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomez Torrijos,E.</style></author><author><style face="normal" font="Arial"> Mendez,D.Y.</style></author><author><style face="normal" font="Arial"> Moreno,L.L.</style></author><author><style face="normal" font="Arial"> Extremera Ortega,A.M.</style></author><author><style face="normal" font="Arial"> Borja,S.J.</style></author><author><style face="normal" font="Arial"> Feo Brito,J.F.</style></author><author><style face="normal" font="Arial"> Rodriguez,S.J.</style></author><author><style face="normal" font="Arial"> Garcia,R.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Frequency and Course of Eosinophilic Esophagitis During Oral Immunotherapy for Cow's Milk Allergy in a Series of 57 Children</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="133" start="132">132-133</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0130</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398201">PM:28398201</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Gomez Torrijos E</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0130</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nittner-Marszalska,M.</style></author><author><style face="normal" font="Arial"> Kowal,A.</style></author><author><style face="normal" font="Arial"> Szewczyk,P.</style></author><author><style face="normal" font="Arial"> Guranski,K.</style></author><author><style face="normal" font="Arial"> Ejma,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Diseases and Allergology, Wroclaw Medical University, Wroclaw, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Wasp Venom Immunotherapy in a Patient With Immune-Mediated Inflammatory Central Nervous System Disease: Is it Safe?</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="129" start="127">127-129</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Central Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398199">PM:28398199</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Nittner-Marszalska M</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0126</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tripodi,S.</style></author><author><style face="normal" font="Arial"> Pingitore,G.</style></author><author><style face="normal" font="Arial"> Calvani,M.</style></author><author><style face="normal" font="Arial"> Scala,G.</style></author><author><style face="normal" font="Arial"> Rodriguez-Perez,R.</style></author><author><style face="normal" font="Arial"> Sfika,I.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Department and Pediatric Allergology Unit, Sandro Pertini Hospital, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Anisakis Sensitivity in Italian Children: A Prospective Study</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="143" start="142">142-143</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398206">PM:28398206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Tripodi S</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0139</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Munoz-Garcia,E.</style></author><author><style face="normal" font="Arial"> Luengo-Sanchez,O.</style></author><author><style face="normal" font="Arial"> Moreno-Perez,N.</style></author><author><style face="normal" font="Arial"> Cuesta-Herranz,J.</style></author><author><style face="normal" font="Arial"> Pastor-Vargas,C.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Section, Department of Internal Medicine, Hospital Vall d Hebron, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Lettuce Allergy Is a Lipid Transfer Syndrome-Related Food Allergy With a High Risk of Severe Reactions</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="103" start="98">98-103</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Lettuce</style></keyword><keyword><style face="normal" font="Arial"> Lettuce allergy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> LTP-syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergy</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Lipid transfer protein (LTP) sensitization is the most common cause of food allergy in the Mediterranean area, with peach allergy acting as the primary sensitizer in most cases. Lettuce has been described as a common offending food in patients with LTP syndrome. The aim of the study was to investigate the frequency and clinical expression of LTP syndrome in a sample of lettuceallergic patients. METHODS: We determined specific IgE to Pru p 3 and lettuce in a sample of 30 patients with a diagnosis of lettuce allergy. Symptoms elicited by other LTP-containing plant-derived foods and the presence of cofactors were assessed. RESULTS: The clinical symptoms of lettuce allergy were frequently severe, with 18 of the 30 patients experiencing anaphylaxis. All the patients had allergic reactions to other plant foods. Cofactors were involved in the clinical reactions of 13 of the 30 patients. Sensitization to pollens was found in 90% of patients. CONCLUSIONS: Lettuce allergy is found not as an isolated condition but in the context of LTP syndrome and it is characterized by severe reactions and frequent cofactor association</style></abstract><notes><style face="normal" font="Arial">DA - 20160909IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0110</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27609533">PM:27609533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-98-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-98-103.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160909, Munoz-Garcia E</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0110</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomez,T.E.</style></author><author><style face="normal" font="Arial"> Sanchez,M.P.</style></author><author><style face="normal" font="Arial"> Donado,P.P.</style></author><author><style face="normal" font="Arial"> Castro,J.A.</style></author><author><style face="normal" font="Arial"> Rodriguez,S.J.</style></author><author><style face="normal" font="Arial"> Mendez,D.Y.</style></author><author><style face="normal" font="Arial"> Moreno,L.L.</style></author><author><style face="normal" font="Arial"> Garcia,R.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Esophagitis: Demographic, Clinical, Endoscopic, Histologic, and Atopic Characteristics of Children and Teenagers in a Region in Central Spain</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="110" start="104">104-110</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysphagia</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gastritis</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> teenagers</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Eosinophilic esophagitis (EoE) is an increasingly prevalent chronic inflammatory disease of the esophagus with an immunoallergic etiology. Few studies have been published on EoE in children and adolescents. The objective of this study was to analyze the demographic, clinical, serologic, endoscopic-histologic, and atopic characteristics of pediatric patients with EoE and to identify atopic and digestive comorbidities. METHODS: We conducted a prospective observational study in children and adolescents (&lt;16 years) assessed in a specialized multidisciplinary EoE unit in a tertiary referral hospital in a central region of Spain between 2011 and 2015. RESULTS: Thirty-five patients were included in the study. Twenty-eight (80%) were male. The mean age was 9.6 years, 83% were atopic, and 28% reported a family history of atopy. The most common symptom was dysphagia (51%). Eosinophilia was detected in the blood of 60% of patients. Eosinophil cationic protein and total IgE were elevated in 88% and 77% of patients, respectively. The most frequent endoscopic finding was linear grooves (57%). Skin tests with aeroallergens were positive in 82% of patients (pollen 62% and food 60%). The main atopic comorbidities were asthma (48%) and rhinoconjunctivitis (37%). Digestive diseases were more often associated with gastritis and Helicobacter pylori infection (17%). CONCLUSIONS: Our results are similar to those previously reported. EoE is more common in boys and in individuals with a history of atopy and sensitization to airborne allergens and food. These results support the consideration of EoE as an atopic disease and underline the important role of allergists in early diagnosis and treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20161011IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27727140">PM:27727140</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-104-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-104-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161011, Gomez TE</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0112</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ysquierdo,C.A.</style></author><author><style face="normal" font="Arial"> Olafson,P.U.</style></author><author><style face="normal" font="Arial"> Thomas,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Health &amp; Biomedical Science, University of Texas Rio Grande Valley, One West University Blvd., Brownsville, TX 78521</style></auth-address><titles><title><style face="normal" font="Arial">Fungi Isolated From House Flies (Diptera: Muscidae) on Penned Cattle in South Texas</style></title><secondary-title><style face="normal" font="Arial">J Med Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Entomol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> Agaricales</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Cattle</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Diptera</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Muscidae</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trichophyton</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">Musca domestica L. were collected from cattle diagnosed with bovine ringworm to evaluate the potential of the house fly to disseminate Trichophyton verrucosum E. Bodin, a fungal dermatophyte that is the causative agent for ringworm in cattle. Fungal isolates were cultured from 45 individual flies on supplemented Sabouraud dextrose agar, and isolates were identified using morphological and microscopic approaches. Each isolate was identified further by PCR amplification of the ribosomal DNA locus with fungal-specific primers and subsequent amplicon sequencing. Trichophyton verrucosum was not identified using these approaches. However, 35 different fungal species representing 17 genera were cultured from collected flies, including several species that are allergenic and pathogenic to humans and animals. Several species within the fungal orders Hypocreales, Microascales, Onygenales, Saccharomycetales, Xylaniales, and Agaricales were observed for the first time on house flies. The most frequent fungus recovered was Cladosporium cladosporoides Fresen, which is known to be a ubiquitous, airborne allergen to humans</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1938-2928 (Electronic)IS - 0022-2585 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/jme/tjw214</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28399217">PM:28399217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Entomol\20170411-YsquierdoCA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Entomol\20170411-YsquierdoCA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Ysquierdo CA</style></custom2><misc3><style face="normal" font="Arial">10.1093/jme/tjw214</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,Y.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Zhang,M.</style></author><author><style face="normal" font="Arial"> Zhu,M.</style></author><author><style face="normal" font="Arial"> Wang,M.</style></author><author><style face="normal" font="Arial"> Sun,Y.</style></author><author><style face="normal" font="Arial"> Gu,H.</style></author><author><style face="normal" font="Arial"> Cao,J.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Zhang,S.</style></author><author><style face="normal" font="Arial"> Lu,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for rapid identification of fungal rhinosinusitis pathogens</style></title><secondary-title><style face="normal" font="Arial">J Med Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Microbiol</style></full-title></periodical><pages end="333" start="328">328-333</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus nidulans</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus oryzae</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus versicolor</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical laboratory</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Filamentous fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Rhizopus</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis,DNA</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Species identification</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry,Mass,Matrix-Assisted Laser Desorption-Ionization</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Filamentous fungi are among the most important pathogens, causing fungal rhinosinusitis (FRS). Current laboratory diagnosis of FRS pathogens mainly relies on phenotypic identification by culture and microscopic examination, which is time consuming and expertise dependent. Although matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS has been employed to identify various fungi, its efficacy in the identification of FRS fungi is less clear. METHODOLOGY: A total of 153 FRS isolates obtained from patients were analysed at the Clinical Laboratory at the Beijing Tongren Hospital affiliated to the Capital Medical University, between January 2014 and December 2015. They were identified by traditional phenotypic methods and Bruker MALDI-TOF MS (Bruker, Biotyper version 3.1), respectively. Discrepancies between the two methods were further validated by sequencing. RESULTS: Among the 153 isolates, 151 had correct species identification using MALDI-TOF MS (Bruker, Biot 3.1, score >/=2.0 or 2.3). MALDI-TOF MS enabled identification of some very closely related species that were indistinguishable by conventional phenotypic methods, including 1/10 Aspergillus versicolor, 3/20 Aspergillus flavus, 2/30 Aspergillus fumigatus and 1/20 Aspergillus terreus, which were misidentified by conventional phenotypic methods as Aspergillus nidulans, Aspergillus oryzae, Aspergillus japonicus and Aspergillus nidulans, respectively. In addition, 2/2 Rhizopus oryzae and 1/1 Rhizopus stolonifer that were identified only to the genus level by the phenotypic method were correctly identified by MALDI-TOF MS. CONCLUSION: MALDI-TOF MS is a rapid and accurate technique, and could replace the conventional phenotypic method for routine identification of FRS fungi in clinical microbiology laboratories</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1473-5644 (Electronic)IS - 0022-2615 (Linking)LA - engPT - Journal ArticleSB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1099/jmm.0.000435</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100314">PM:28100314</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="Arial">20170119, Huang Y</style></custom2><misc3><style face="normal" font="Arial">10.1099/jmm.0.000435</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rho,M.K.</style></author><author><style face="normal" font="Arial"> Kim,Y.E.</style></author><author><style face="normal" font="Arial"> Rho,H.I.</style></author><author><style face="normal" font="Arial"> Kim,T.R.</style></author><author><style face="normal" font="Arial"> Kim,Y.B.</style></author><author><style face="normal" font="Arial"> Sung,W.K.</style></author><author><style face="normal" font="Arial"> Kim,T.W.</style></author><author><style face="normal" font="Arial"> Kim,D.O.</style></author><author><style face="normal" font="Arial"> Kang,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Science and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Enterococcus faecium FC-K derived from kimchi is a probiotc lactic acid bacteria that shows anti-allergic activity</style></title><secondary-title><style face="normal" font="Arial">J Microbiol Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Microbiol Biotechnol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Kimchi</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="Arial">A rise in the occurrence of allergic diseases is attributed to the dysregulated balance of type 1/type 2 immunity, where type 2 T helper (Th2) cells predominate over type 1 T helper (Th1) cells, leading to an abnormally increased production of IgE in response to unharmful antigens. Kimchi, a traditional Korean fermented food, is a rich source of beneficial lactic acid bacteria. In this study, we investigated the ability of Enterococcus faecium FC-K derived from kimchi to induce type I immunity in the presence of Th2 polarizing conditions in vitro and in vivo. Stimulation of mouse peritoneal macrophages with E. faecium induced the production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-12. Under the in vitro Th2 conditions in which splenic T cells were activated in the presence of IL-4, E. faecium enhanced the ability of T cells to produce interferon (IFN)-gamma. Using the ovalbumin (OVA)-induced allergy model, mice receiving E. faecium reduced the serum level of total IgE, but not that of OVA-specific IgE. Furthermore, the population of activated splenic B cells during OVA immunization was decreased in E. faecium-treated mice, accounting for a reduction of total IgE in the serum. Restimulating splenocytes from OVA immunized mice with OVA ex vivo resulted in an increased production of IFN-gamma, with no effect on IL-4, in E. faecium-treated mice. These observations provide the evidence that E. faecium can be a beneficial probiotic strain that can modulate the Th2-mediated pathologic response</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1738-8872 (Electronic)IS - 1017-7825 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4014/jmb.1611.11020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28297747">PM:28297747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Microbiol Biotechnol\20170315-RhoMK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Microbiol Biotechnol\20170315-RhoMK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Rho MK</style></custom2><misc3><style face="normal" font="Arial">10.4014/jmb.1611.11020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chekiri-Talbi,M.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pharmacy department, university Saad Dahlab, Blida, Algerie.</style></auth-address><titles><title><style face="normal" font="Arial">[The burden of fungal infections in Algeria]</style></title><secondary-title><style face="normal" font="Arial">J Mycol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Mycol Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> Algeria</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal asthma</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mycose</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">In Algeria, superficial mycoses are very commonly diagnosed. Deep fungal infections are less often observed. Few data from Algeria are found in the literature. We report for the first time the main causes of these diseases in our country and provide burden estimates. We searched for existing data and estimated the incidence and prevalence of fungal diseases based on the population at risk and available epidemiological data. Demographic data were derived from the Service (Office) of the Statistics (ONES), World Health Organization (WHO), The Joint Nations Programme on HIV/AIDS (UNAIDS) and national published reports. When no data existed, risk populations were used to estimate frequencies of fungal infections, using previously described methodology. Algeria has 40.4 million inhabitants and probably at least 568,900 (1.41 %) of Algerians have a serious fungal infection each year. Recurrent vulvovaginal candidiasis (485,000) and fungal asthma (72,000) are probably the commonest problems as there are over 1 million adult asthmatics. Candidaemia is estimated in 2020, invasive aspergillosis in 2865, intra-abdominal candidiasis in 303 people and are the most common life-threatening problems. AIDS is uncommon, but cancer is not (45,000 new cases of cancer among including 1500 in children) and nor is COPD (an estimated 317,762 patients of whom 20.3 % are admitted to hospital each year). A focus on improving the diagnosis and epidemiological data related to fungal infection is necessary in Algeria</style></abstract><notes><style face="normal" font="Arial">DA - 20170326IS - 1773-0449 (Electronic)IS - 1156-5233 (Linking)LA - frePT - English AbstractPT - Journal ArticlePT - ReviewCO - Algeria -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mycmed.2017.02.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342778">PM:28342778</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Mycol Med\20170326-ChekiriTalbiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Mycol Med\20170326-ChekiriTalbiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170326, Chekiri-Talbi M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mycmed.2017.02.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tam,C.J.</style></author><author><style face="normal" font="Arial"> John,R.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food-dependent Exercise-induced Anaphylaxis: A Review</style></title><secondary-title><style face="normal" font="Arial">J Nurse Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Nurse Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> FDEIA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-dependent exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric primary care</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> urgent care</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1555-4155</style></isbn><abstract><style face="normal" font="Arial">Food-dependent exercise-induced anaphylaxis (FDEIA), a subtype of exercise-induced anaphylaxis (EIA), is underdiagnosed and unreported. FDEIA is unpredictable and difficult to diagnose because its manifestation relies on the presence of several modifiable factors but can be fatal for the individual if not properly assessed and treated. A proper diagnosis of FDEIA will help prevent unnecessary food and exercise limitations and provide a patient with FDEIA an adaptable lifestyle. The purpose of this article is to review FDEIA characteristics, diagnostic tools, management, and the role of the nurse practitioner in diagnosing and caring for children or adolescents with suspected FDEIA</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.nurpra.2017.01.006</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.nurpra.2017.01.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Nurse Pract\20170416-TamCJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Nurse Pract\20170416-TamCJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Tam CJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.nurpra.2017.01.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abrams,E.M.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, MB, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Early Solid Food Introduction: Role in Food Allergy Prevention and Implications for Breastfeeding</style></title><secondary-title><style face="normal" font="Arial">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="3" Year="2017">2017/3/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170414IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jpeds.2017.01.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410085">PM:28410085</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr\20170414-AbramsEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr\20170414-AbramsEM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170414, Abrams EM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jpeds.2017.01.053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kiely,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Eosinophilic Esophagitis: A Case Study of a 12-Year-Old Boy</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Health Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical recommendations</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis is an underrecognized chronic condition in which symptoms of gastroesophageal reflux are accompanied by eosinophilia in the esophagus. This disorder affects both children and adults and is associated with a history of other atopic disorders, particularly food allergies. This case study discusses the epidemiology of eosinophilic esophagitis and the proper procedures for diagnosis, referral, and management using the dietary restrictions and pharmacologic treatment included in the clinical recommendations issued by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; the American Academy of Allergy, Asthma, and Immunology; and the American College of Gastroenterologists</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1532-656X (Electronic)IS - 0891-5245 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pedhc.2017.02.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396105">PM:28396105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Health Care\20170411-KielyK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Health Care\20170411-KielyK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Kiely K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pedhc.2017.02.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mendez,C.</style></author><author><style face="normal" font="Arial"> Martinez,E.</style></author><author><style face="normal" font="Arial"> Lopez,E.</style></author><author><style face="normal" font="Arial"> Garcon,I.</style></author><author><style face="normal" font="Arial"> Carrion,C.</style></author><author><style face="normal" font="Arial"> Prats,N..</style></author><author><style face="normal" font="Arial"> Baldellou,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Analysis of Environmental Conditions in the Operating Room for Latex-Allergic Patients'-Safety</style></title><secondary-title><style face="normal" font="Arial">J PeriAnesth Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J PeriAnesth Nurs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Decontamination</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> kinetics of particles</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> operating room</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> traffic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1089-9472</style></isbn><abstract><style face="normal" font="Arial">Purpose Most current protocols agree that latex-sensitive patients should be scheduled for elective surgery as the first case of the day with a 12-hour activity-free interval before surgically treating latex-allergic patients. Design To understand the kinetics of decontamination of airborne particles in the operating room (OR) after a surgical procedure to determine the activity-free interval necessary between surgeries for latex-allergic patients. Methods This observational study included 12 ORs in four hospitals. Baseline levels of airborne particles were established before surgery. Findings Mean recovery time of ORs was 18.9 -¦ 6.5 minutes. To guarantee an efficacy of 99.9%, two standard deviations were added to the maximum time (28 minutes). Total recovery time: 32 minutes. Conclusions ORs that complied with the requirements of our study before performing surgery on latex-allergic patients obtained the same environmental conditions as first thing in the morning after thorough cleaning of the OR and a 32-minute activity-free interval and staff traffic restriction</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jopan.2015.12.017</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.jopan.2015.12.017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J PeriAnesth Nurs\20170419-MendezC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J PeriAnesth Nurs\20170419-MendezC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Mendez</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jopan.2015.12.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Montero-Morales,L.</style></author><author><style face="normal" font="Arial"> Maresch,D.</style></author><author><style face="normal" font="Arial"> Castilho,A.</style></author><author><style face="normal" font="Arial"> Turupcu,A.</style></author><author><style face="normal" font="Arial"> Ilieva,K.</style></author><author><style face="normal" font="Arial"> Crescioli,S.</style></author><author><style face="normal" font="Arial"> Karagiannis,S.</style></author><author><style face="normal" font="Arial"> Lupinek,C.</style></author><author><style face="normal" font="Arial"> Oostenbrink,C.</style></author><author><style face="normal" font="Arial"> Altmann,F.</style></author><author><style face="normal" font="Arial"> Steinkellner,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Recombinant plant-derived human IgE glycoproteomics</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="87" start="81">81-87</pages><volume><style face="normal" font="Arial">1</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Modelling</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> N-glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant IgE</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="4" Year="2017">2017/4/8</year></dates><abstract><style face="normal" font="Arial">The increasing biotechnological interest in human IgE antibodies demands advanced systems which allow their proper expression. However, this is still a challenge due to the complexity of the molecule, particularly regarding the diverse N-glycosylation pattern. Here, we present the expression of recombinant IgE in wild type and glycan-engineered Nicotiana benthamiana plants and in-depth N-glycosylation analyses. Mass spectrometric profiling revealed that plant IgE has a site occupancy rate that ranges from non-occupied at glycosite 6 (GS6) to 100% occupancy at GS1 and 2. Similarly to human cell-derived IgE, plant versions carry complex N-glycans at GS1-5 and oligomannosidic structures at GS7. Computational modelling suggests that spatial position (or orientation) of glycans can impair processing or site occupancy on adjacent glycosites. IgE expressed in glycoengineered and wild type plants carry, respectively, GnGn and plant-typical GnGnXF structures at large homogeneity. This contrasts with the glycan diversity of HEK cell-derived IgE, carrying at least 20 different glycoforms. Importantly, IgE glycoengineering allows the control of its glycosylation, a so far unmet need when using well-established expression systems. This enables the elucidation of possible carbohydrate-dependent IgE functions. SIGNIFICANCE: Targeted glycosylation of recombinant proteins may provide an advantage in therapeutic applications. Despite increasing biotechnological interest in IgE antibodies, knowledge and impact of glycosylation on this antibody class are scarce. With ability to glyco-engineer recombinant IgE, we provide an important step towards the generation of IgE with other targeted N-glycans. This will facilitate detailed structure-function studies and may lead to the production of IgE with optimized activities</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2017.04.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400175">PM:28400175</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170412-MonteroMoralesL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170412-MonteroMoralesL.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170412-MonteroMoralesL.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170412-MonteroMoralesL.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170412, Montero-Morales L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2017.04.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lv,L.</style></author><author><style face="normal" font="Arial"> Hong,L.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Ahmed,I.</style></author><author><style face="normal" font="Arial"> Chen,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Lab of Food Safety, College of Food Science and Engineering, Ocean University of China, Qingdao, 266003, Shandong, China</style></auth-address><titles><title><style face="normal" font="Arial">Determining the effect of malondialdehyde on the IgE-binding capacity of shrimp tropomyosin upon in vitro digestion</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vitro digestion</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid oxidation</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Pepsin digestion</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> simulated gastric fluid</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Stability in simulated gastric fluids is considered an important parameter for the estimation of food allergenicity. Moreover, proteins in food are highly susceptible to lipid oxidation during processing and preservation. In this study, the change in the IgE-binding capacity of malondialdehyde (MDA)-treated shrimp tropomyosin (TM) following in vitro digestion was investigated by SDS-PAGE and Western blot. RESULTS: Shrimp TM treated with different concentrations of MDA was slightly degraded and became increasingly resistant to pepsin digestion over time. While untreated TM was rapidly degraded, MDA-treated TM showed some resistance and was degraded by trypsin only after increasing the digestion time. Results of immunoblotting studies on IgE using sera from patients allergic to shrimp indicated that the IgE-binding capacity of TM and MDA (50 mM)-treated TM decreased slightly after pepsin digestion and significantly decreased after trypsin digestion. CONCLUSION: The study indicated that the resistance of TM to degradation increased after oxidation. The treatment with proteases, especially trypsin, is quite effective in decreasing the IgG/IgE-binding capacity of shrimp TM</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8328</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28349532">PM:28349532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170328-LvL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170328-LvL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Lv L</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8328</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,W.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The School of Law, Zhejiang University of Finance &amp; Economics, 310018, Hangzhou, Zhejiang</style></auth-address><titles><title><style face="normal" font="Arial">Predicament of Chinese Legislation on GMF Labeling Management and Solutions-From the Perspective of the New Food Safety Law</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> genetically modified food</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="2" Month="4" Year="2017">2017/4/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: This paper considers the background of Article 69 of the newly revised Food Safety Law in China, in combination with the current situation of Chinese legislation on genetically modified foods(GMFs)labeling management, compares with foreign genetically modified food labeling management system, reveals the deficiencies in Chinese legislation on GMFs labeling management, to note the institutionalize, systemic consider of GMFs labeling management system in China. RESULTS: China adheres to the principle of mandatory labeling based on both product and process in relation to GMFs and implements the system of process-centered mandatory labeling under the negotiation-construction form. However, China has not finally defined the supervision mode of mandatory labeling of GMFs through laws, and it's a challenge for GMFs labeling management in the event the two mandatory labeling modes coexist. CONCLUSION: There're flaws in the mandatory labeling of GMFs in Article 69 of the newly revised Food Safety Law of China, only principle-based terms have been included in Article 69 of the newly revised Food Safety Law, it's theoretically and practically difficult for mandatory labeling of GMFs in juridical practices. Moreover, the GMFs labeling management system has been lagging behind. This paper describes and analyses the Article 69 of the newly revised Food Safety Law, through defining GMFs, adding the concept of threshold, allergization, unique code, potential toxicity, to expand the scope of the definition of GMFs and realize regulation of GMFs, and improve GMFs labeling management legislation</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8342</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28369963">PM:28369963</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170403-LiW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170403-LiW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Li W</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8342</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kadaifciler,D.G.</style></author><author><style face="normal" font="Arial"> Demirel,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Science, Department of Biology, Istanbul University, 34314 Vezneciler, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Fungal biodiversity and mycotoxigenic fungi in cooling-tower water systems in Istanbul, Turkey</style></title><secondary-title><style face="normal" font="Arial">J Water Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Water Health</style></abbr-1></periodical><pages end="320" start="308">308-320</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aerosols</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus niger</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus versicolor</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxin</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">This is the first study to assess fungal diversity and mycotoxigenic fungi in open recirculating cooling-tower (CT) water systems (biofilm and water phase). The production capability of mycotoxin from fungal isolates was also examined. The mean fungal count in 21 different water and biofilm samples was determined as 234 CFU/100 mL and 4 CFU/cm2. A total of 32 species were identified by internal transcribed spacer (ITS) sequencing. The most common isolated fungi belonged to the genera Aspergillus and Penicillium, of which the most prevalent fungi were Aspergillus versicolor, Aspergillus niger, and Penicillium dipodomyicola. From 42% of the surveyed CTs, aflatoxigenic A. flavus isolates were identified. The detection of opportunistic pathogens and/or allergen species suggests that open recirculating CTs are a possible source of fungal infection for both the public and for occupational workers via the inhalation of aerosols and/or skin contact</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1477-8920 (Print)IS - 1477-8920 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.2166/wh.2017.274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362312">PM:28362312</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170331, Kadaifciler DG</style></custom2><misc3><style face="normal" font="Arial">10.2166/wh.2017.274</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turner,P.J.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Paediatrics, Imperial College London, London, United Kingdom2Discipline of Child and Adolescent Health, University of Sydney, Sydney, AustraliaDiscipline of Child and Adolescent Health, University of Sydney, Sydney, Australia3Children's Hospital at Westmead, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Implementing Primary Prevention for Peanut Allergy at a Population Level</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="1112" start="1111">1111-1112</pages><volume><style face="normal" font="Arial">317</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Age Factors</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Intention to Treat Analysis</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medical Overuse</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> National Institute of Allergy and Infectious Diseases (U.S.)</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="Arial"> Pre-Exposure Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170213IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tSB - AIMSB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2017.0922</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192569">PM:28192569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-317-1111-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-317-1111-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170213, Turner PJ</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2017.0922</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsoucalas,G.</style></author><author><style face="normal" font="Arial"> Sgantzos,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy &amp; History of Medicine, University of Thessaly, Larissa, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Oribasius-Pediatric Skin Eruptions and the Origins of the Allergic Reaction to Breast Milk</style></title><secondary-title><style face="normal" font="Arial">JAMA Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Dermatol</style></full-title></periodical><pages end="" start="303">303-</pages><volume><style face="normal" font="Arial">153</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170413IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamadermatol.2016.0531</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28403445">PM:28403445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Dermatol\2017-153-303.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Dermatol\2017-153-303.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170413, Tsoucalas G</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamadermatol.2016.0531</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fitzgerald,J.M.</style></author><author><style face="normal" font="Arial"> Emery,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Heart and Lung Health, Gordon and Leslie Diamond Health Care Centre, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Modifying the trajectory of asthma-are there lessons from the use of biologics in rheumatology?</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="1084" start="1082">1082-1084</pages><volume><style face="normal" font="Arial">389</style></volume><number><style face="normal" font="Arial">10074</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">biologics</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="18" Month="3" Year="2017">2017/3/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170321IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(17)30600-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28322805">PM:28322805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\2017-389-1082-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\2017-389-1082-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170321, FitzGerald JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(17)30600-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pavord,I.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Mepolizumab, quality of life, and severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="Arial">Lancet Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Respir Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2213-2600(17)30132-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28395935">PM:28395935</url></web-urls></urls><custom2><style face="normal" font="Arial">20170411, Pavord ID</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2213-2600(17)30132-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chupp,G.L.</style></author><author><style face="normal" font="Arial"> Bradford,E.S.</style></author><author><style face="normal" font="Arial"> Albers,F.C.</style></author><author><style face="normal" font="Arial"> Bratton,D.J.</style></author><author><style face="normal" font="Arial"> Wang-Jairaj,J.</style></author><author><style face="normal" font="Arial"> Nelsen,L.M.</style></author><author><style face="normal" font="Arial"> Trevor,J.L.</style></author><author><style face="normal" font="Arial"> Magnan,A.</style></author><author><style face="normal" font="Arial"> Ten Brinke,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Yale Center for Asthma and Airway Disease, Yale School of Medicine, New Haven, CT, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial</style></title><secondary-title><style face="normal" font="Arial">Lancet Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Respir Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mepolizumab, an anti-interleukin-5 monoclonal antibody approved as add-on therapy to standard of care for patients with severe eosinophilic asthma, has been shown in previous studies to reduce exacerbations and dependency on oral corticosteroids compared with placebo. We aimed to further assess mepolizumab in patients with severe eosinophilic asthma by examining its effect on health-related quality of life (HRQOL). METHODS: We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial (MUSCA) in 146 hospitals or research centres in 19 countries worldwide. Eligible participants were patients aged 12 years or older with severe eosinophilic asthma and a history of at least two exacerbations requiring treatment in the previous 12 months before screening despite regular use of high-dose inhaled corticosteroids plus other controller medicines. Exclusion criteria included current smokers or former smokers with a history of at least ten pack-years. We randomly assigned participants (1:1) by country to receive a subcutaneous injection of either mepolizumab 100 mg or placebo, plus standard of care, every 4 weeks for 24 weeks (the final dose was given at week 20). We did the randomisation using an interactive voice response system and a centralised, computer-generated, permuted-block design of block size six. The two treatments were identical in appearance and administered in a masked manner; patients, investigators, other site staff and the entire study team including those assessing outcomes data were also masked to group assignment. The primary endpoint was the mean change from baseline in the St George's Respiratory Questionnaire (SGRQ) total score at week 24 in the modified intention-to-treat (modified ITT) population (analysed according to their randomly assigned treatment). Safety was assessed in all patients who received at least one dose of trial medication (analysed according to the actual treatment received). This trial is registered with ClinicalTrials.gov, number NCT02281318. FINDINGS: We recruited patients between Dec 11, 2014, and Nov 20, 2015, and the study was undertaken between Dec 11, 2014, and June 10, 2016. The modified ITT population comprised 274 patients assigned to mepolizumab 100 mg and 277 assigned to placebo. Mepolizumab versus placebo showed significant improvements at week 24 from baseline in SGRQ total score (least squares mean [SE] change from baseline -15.6 (1.0) vs -7.9 (1.0), a treatment difference of -7.7 (95% CI -10.5 to -4.9; p&lt;0.0001). No deaths occurred during the study. 192 (70%) of 273 patients who received mepolizumab and 207 (74%) of 278 who received placebo reported at least one on-treatment adverse event, the most common of which were headache (in 45 [16%] given mepolizumab vs 59 [21%] given placebo) and nasopharyngitis (in 31 [11%] given mepolizumab vs 46 [17%] given placebo). 15 (5%) and 22 (8%) patients had an on-treatment serious adverse event in the mepolizumab and placebo groups, respectively; the most common was asthma in both groups (in three [1%] given mepolizumab vs nine [3%] given placebo). INTERPRETATION: Mepolizumab was associated with significant improvements in HRQOL in patients with severe eosinophilic asthma, and had a safety profile similar to that of placebo. These results add to and support the use of mepolizumab as a favourable add-on treatment option to standard of care in patients with severe eosinophilic asthma. FUNDING: GlaxoSmithKline</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United KIngdom -CO - France -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2213-2600(17)30125-X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28395936">PM:28395936</url></web-urls><pdf-urls><url ppv-ref="no">geoffrey.chupp@yale.edu</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Chupp GL</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2213-2600(17)30125-X</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kato,Y.</style></author><author><style face="normal" font="Arial"> Jimbo,M.</style></author><author><style face="normal" font="Arial"> Sakakibara,Y.</style></author><author><style face="normal" font="Arial"> Onizuka,R.</style></author><author><style face="normal" font="Arial"> Takahashi,T.</style></author><author><style face="normal" font="Arial"> Matsuhashi,S.</style></author><author><style face="normal" font="Arial"> Mita,H.</style></author><author><style face="normal" font="Arial"> Amada,K.</style></author><author><style face="normal" font="Arial"> Imahara,Y.</style></author><author><style face="normal" font="Arial"> Tanabe,K.</style></author><author><style face="normal" font="Arial"> Toda,A.</style></author><author><style face="normal" font="Arial"> Kamiya,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Electronics Research Laboratory, Comprehensive Research Organization, Fukuoka Institute of Technology, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Characterization of a novel allergenic protein from the octocoral Scleronephthya gracillima (Kuekenthal) that corresponds to a new GFP-like family named Akane</style></title><secondary-title><style face="normal" font="Arial">Luminescence</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Luminescence</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronics</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mascot</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">Certain marine organisms have been known to cause allergic reactions among occupational fishermen. We have previously reported that bronchial asthma among the workers engaged in spiny lobster fishing in Japan was caused by octocorals such as Dendronephthya sp. and Scleronephthya gracillima (previously named Alcyonium gracillimum). Now we have found another octocoral, Scleronephthya gracillima (Kuekenthal), which causes the allergic disease in fishermen. The octocoral was characterized as a new green fluorescent protein (GFP)-like family. The new allergen has a molecular mass of 27 kDa in 1D and 2D SDS-PAGE under reduced conditions. The 27 kDa component was determined to be an allergen by western blotting, ECL immune staining method and absorption of patient sera with the antigen. Furthermore, the combination of analysis with LC-ESI-MS/MS and MASCOT search in the NCBInr database concluded the 27 kDa component had the sequence YPADI/LPDYFK, and that the 22 kDa component had the sequence QSFPEGFSWER, which both matched a GFP-like protein in Acropora aculeus and in Montastraea annularis. Further analysis by MALDI-TOF/MS/MS and MASCOT search in the NCBInr database of all 27 kDa eight spot components from 2D SDS-PAGE indicated that the sequence QSFPEGFSWER also matched as GFP-like protein in Lobophyllia hemprichii and Scleractinia sp. To our knowledge, this is the first report of the new allergenic protein that corresponds to a new GFP-like protein named Akane, and which has fluorescent emissions in the red and green part of the spectra at 628 nm and 508 nm, respectively</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1522-7243 (Electronic)IS - 1522-7235 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1002/bio.3284</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378893">PM:28378893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Luminescence\20170405-KatoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Luminescence\20170405-KatoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Kato Y</style></custom2><misc3><style face="normal" font="Arial">10.1002/bio.3284</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nath,A.</style></author><author><style face="normal" font="Arial"> Khan,A.</style></author><author><style face="normal" font="Arial"> Hashim,Z.</style></author><author><style face="normal" font="Arial"> Patra,J.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma at a tertiary care center in North India</style></title><secondary-title><style face="normal" font="Arial">Lung India</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lung India</style></full-title></periodical><pages end="154" start="150">150-154</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> and ABPA</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of Aspergillus hypersensitivity (AH) and allergic bronchopulmonary aspergillosis (ABPA) has been variably reported. Systematic data regarding Aspergillus sensitization and ABPA are lacking from this part of the country. OBJECTIVES: The aim of this study was to evaluate the prevalence of AH and ABPA in Uttar Pradesh. SETTING AND DESIGN: This was prospective observational study. All patients attending outpatient Department of Pulmonary Medicine of our institute were included in the study. SUBJECTS AND METHODS: Consecutive asthmatic patients underwent screening for ABPA using Aspergillus skin test (AST). Those showing a positive response to AST were further evaluated for ABPA. RESULTS: During the study, 350 patients (192 males, 158 females, mean +/- standard deviation age: 38.3 +/- 12.8) were screened with AST. One hundred and twenty-three patients (35.1%) were tested positive for AST and 21.7% of patients were diagnosed as ABPA. CONCLUSIONS: A high prevalence rate of ABPA was observed at our chest clinic. Although comparable with published data from other tertiary centers, it does not represent the true prevalence rates in asthmatics because of high chances of referral bias</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 0970-2113 (Print)IS - 0970-2113 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0970-2113.201300</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28360463">PM:28360463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lung India\2017-34-150-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lung India\2017-34-150-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Nath A</style></custom2><misc3><style face="normal" font="Arial">10.4103/0970-2113.201300</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singh,N.</style></author><author><style face="normal" font="Arial"> Singh,U.</style></author><author><style face="normal" font="Arial"> Singh,D.</style></author><author><style face="normal" font="Arial"> Daya,M.</style></author><author><style face="normal" font="Arial"> Singh,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Asthma Bhawan, Jaipur, Rajasthan, India</style></auth-address><titles><title><style face="normal" font="Arial">Correlation of pollen counts and number of hospital visits of asthmatic and allergic rhinitis patients</style></title><secondary-title><style face="normal" font="Arial">Lung India</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lung India</style></full-title></periodical><pages end="131" start="127">127-131</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiological sampling</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chenopodium album</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen calendar</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">AIMS AND OBJECTIVES: Environmental pollens are known to cause exacerbation of symptoms of patients with allergic rhinitis (AR) and asthma. During pollen months, number of patients visiting hospital has been shown to increase in some studies. However, in India, such studies are lacking. Therefore, we aimed to study pollen counts and to find its correlation with number of new patients attending Asthma Bhawan for 2 years. MATERIALS AND METHODS: Aerobiological sampling was done using Burkard 24 h spore trap system. The site selected for the entrapment of the air spore was the building of Asthma Bhawan situated at Vidhyadhar Nagar, Jaipur. New patients coming with problems of respiratory allergy such as AR or asthma were recruited in the study. Skin prick tests (SPTs) were carried out after obtaining consent in these patients. Monthly pollen counts of trees, weeds and grasses were correlated with the number of new patients. Pollen calendar was prepared for 2 years. RESULTS: Average annual pollen count during 2011 and 2012 were 14,460.5. In the analysis, 37 types of species or families were identified. Pollen count showed two seasonal peaks during March-April and from August to October. January and June showed the lowest pollen counts in 2 years. Average monthly count of grass pollens showed significant correlation with number of new patients (r = 0.59). However, monthly pollen count of trees and weeds did not correlate. The correlation of the pollen count of individual pollen with the SPT positivity to that pollen showed significant correlation with Chenopodium album only. CONCLUSIONS: It can be concluded that there were two peaks of pollen count in a year during March-April and August-October. Average monthly pollen counts of grass were significantly correlated with the number of hospital visits of new patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 0970-2113 (Print)IS - 0970-2113 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0970-2113.201313</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28360459">PM:28360459</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lung India\2017-34-127-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lung India\2017-34-127-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Singh N</style></custom2><misc3><style face="normal" font="Arial">10.4103/0970-2113.201313</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xie,C.L.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Xia,J.M.</style></author><author><style face="normal" font="Arial"> Gao,Y.</style></author><author><style face="normal" font="Arial"> Yang,Q.</style></author><author><style face="normal" font="Arial"> Shao,Z.Z.</style></author><author><style face="normal" font="Arial"> Liu,G.</style></author><author><style face="normal" font="Arial"> Yang,X.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory Breeding Base of Marine Genetic Resources, Key Laboratory of Marine Genetic Resources, Fujian Key Laboratory of Marine Genetic Resources, Third Institute of Oceanography, State Oceanic Administration, 184 Daxue Road, Xiamen 361005, China</style></auth-address><titles><title><style face="normal" font="Arial">Anti-Allergic Compounds from the Deep-Sea-Derived Actinomycete Nesterenkonia flava MCCC 1K00610</style></title><secondary-title><style face="normal" font="Arial">Mar Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mar Drugs</style></full-title></periodical><pages end="" start="71">71-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic compounds</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Indoles</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Loratadine</style></keyword><keyword><style face="normal" font="Arial"> macrolide</style></keyword><keyword><style face="normal" font="Arial"> Macrolides</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> Phenolics</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="Arial">A novel cyclic ether, nesterenkoniane (1), was isolated from the deep-sea-derived actinomycete Nesterenkonia flava MCCC 1K00610, together with 12 known compounds, including two macrolides (2, 3), two diketopiperazines (4, 5), two nucleosides (6, 7), two indoles (8, 9), three phenolics (10-12), and one butanol derivate (13). Their structures were established mainly on detailed analysis of the NMR and MS spectroscopic data. All 13 compounds were tested for anti-allergic activities using immunoglobulin E (IgE) mediated rat mast RBL-2H3 cell model. Under the concentration of 20 mug/mL, 1 exhibited moderate anti-allergic activity with inhibition rate of 9.86%, compared to that of 37.41% of the positive control, loratadine. While cyclo(d)-Pro-(d)-Leu (4) and indol-3-carbaldehyde (8) showed the most potent effects with the IC50 values of 69.95 and 57.12 mug/mL, respectively, which was comparable to that of loratadine (IC50 = 35.01 mug/mL). To the best of our knowledge, it is the first report on secondary metabolites from the genus of Nesterenkonia</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1660-3397 (Electronic)IS - 1660-3397 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3390/md15030071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28335419">PM:28335419</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mar Drugs\2017-15-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mar Drugs\2017-15-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Xie CL</style></custom2><misc3><style face="normal" font="Arial">10.3390/md15030071</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Commins,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Allergy and Immunology, Department of Medicine, Thurston Research Center, University of North Carolina, 3300 Thurston Building, CB 7280, Chapel Hill, NC 27599-7280, USA</style></auth-address><titles><title><style face="normal" font="Arial">Outpatient Emergencies: Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Med Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Clin North Am</style></full-title></periodical><pages end="536" start="521">521-536</pages><volume><style face="normal" font="Arial">101</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Anaphylactic fatalities are rare; however, mild reactions can rapidly progress to cardiovascular and respiratory arrest. The clinical course of anaphylaxis can be unpredictable. Prompt and early use of epinephrine should be considered. Most anaphylaxis episodes have an immunologic mechanism involving immunoglobulin E (IgE). Foods are the most common cause in children; medications and insect stings are more common in adults. When the cause is not completely avoidable or cannot be determined, a patient should be supplied with autoinjectable epinephrine and be instructed its use. They should keep the device with them at all times and taught the signs and symptoms of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1557-9859 (Electronic)IS - 0025-7125 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mcna.2016.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28372711">PM:28372711</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Clin North Am\2017-101-521-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Clin North Am\2017-101-521-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Commins SP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mcna.2016.12.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Isbister,G.K.</style></author><author><style face="normal" font="Arial"> Palmer,D.J.</style></author><author><style face="normal" font="Arial"> Weir,R.L.</style></author><author><style face="normal" font="Arial"> Currie,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Newcastle, Newcastle, NSW</style></auth-address><titles><title><style face="normal" font="Arial">Hot water immersion v icepacks for treating the pain of Chironex fleckeri stings: a randomised controlled trial</style></title><secondary-title><style face="normal" font="Arial">Med J Aust</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med J Aust</style></full-title></periodical><pages end="261" start="258">258-261</pages><volume><style face="normal" font="Arial">206</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Analgesics</style></keyword><keyword><style face="normal" font="Arial"> Analgesics,Opioid</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bites and Stings</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Cubozoa</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hot Temperature</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Ice</style></keyword><keyword><style face="normal" font="Arial"> Immersion</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> jellyfish</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Pain Management</style></keyword><keyword><style face="normal" font="Arial"> Pain Measurement</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword></keywords><dates><year Day="3" Month="4" Year="2017">2017/4/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the effectiveness of hot water immersion for relieving the pain of major box jellyfish (Chironex fleckeri) stings.Design, interventions: Open label, randomised controlled trial comparing the effects of hot water immersion (45 degrees C) and icepacks.Setting, participants: 42 patients with suspected C. fleckeri stings treated in the emergency department of the Royal Darwin Hospital during September 2</style></abstract><notes><style face="normal" font="Arial">DA - 20170330IS - 1326-5377 (Electronic)IS - 0025-729X (Linking)LA - engPT - Comparative StudyPT - Journal ArticlePT - Randomized Controlled TrialRN - 0 (Analgesics, Opioid)RN - 0 (Ice)SB - IMCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.5694/mja16.00990</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359008">PM:28359008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med J Aust\2017-206-258-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med J Aust\2017-206-258-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170330, Isbister GK</style></custom2><misc3><style face="normal" font="Arial">10.5694/mja16.00990</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Dupilumab (Dupixent) for moderate to severe atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Med Lett Drugs Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Lett Drugs Ther</style></full-title></periodical><pages end="66" start="64">64-66</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">1519</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1523-2859 (Electronic)IS - 0025-732X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28419072">PM:28419072</url></web-urls></urls><custom2><style face="normal" font="Arial">20170418, no authors</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fernandez Rivas,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Diagnostic protocol for IgE-mediated food allergy</style></title><secondary-title><style face="normal" font="Arial">Medicine (Madrid)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Madrid)</style></full-title></periodical><pages end="1797" start="1793">1793-1797</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">30</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><isbn><style face="normal" font="Arial">0304-5412</style></isbn><abstract><style face="normal" font="Arial">Introduction Diagnosing IgE-mediated food allergy (FA) is of great importance to establish a proper elimination diet, which remains the only therapeutic alternative for most patients. Diagnostic procedure In the first stage of diagnosis, by means of the clinical history, an attempt is made to identify the suspicious food, to establish whether an immune mechanism is involved and to decide which diagnostic tests need to be conducted. The second stage aims to prove the presence of specific IgE against the suspected food by means of skin prick testing and serum-specific IgE determinations, which are not diagnostic per se of FA. To confirm diagnosis it is necessary to assess them within the context of the medical history, and to conduct oral food challenges. The recent developments of molecular diagnosis with individual food allergens has improved the diagnostic capability of IgE determinations. Conclusion A correct diagnosis of FA allows patients to have a safe diet and preserves their quality of life</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.med.2017.03.015</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.med.2017.03.015</url></web-urls><pdf-urls><url ppv-ref="no">mariamontserrat.fernandez@salud.madrid.org</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170420, Fernandez Rivas M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.med.2017.03.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Antolin Amerigo,D.</style></author><author><style face="normal" font="Arial"> Barbarroja Escudero,J.</style></author><author><style face="normal" font="Arial"> Sanchez Gonzalez,M.J.</style></author><author><style face="normal" font="Arial"> Rodriguez Rodriguez,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Protocol for indications for immune therapy according to allergen type and clinical form</style></title><secondary-title><style face="normal" font="Arial">Medicine (Madrid)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Madrid)</style></full-title></periodical><pages end="1803" start="1798">1798-1803</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">30</style></number><reprint-status date="04/30/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> Immune therapy</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><isbn><style face="normal" font="Arial">0304-5412</style></isbn><abstract><style face="normal" font="Arial">Background Allergen-specific immunotherapy (ASIT) consists of the gradual administration of doses of extracts from the allergen that causes hypersensitivity or allergies in the patient. The objective of ASIT is to reduce allergic symptoms, decrease the use of drugs, improve the patient's health-related quality of life and change the immunological parameters. To date, ASIT is the only treatment capable of modifying the natural course of the allergic disease, preventing exacerbations and attenuating the inflammatory response in the tissues. ASIT induces the body to produce antibody blockers, tolerance inducer cells and mediators. Indications for immunotherapy Numerous studies have supported the efficacy of immunotherapy, provided that it is correctly indicated. The efficacy is determined by appropriate patient selection, the selection of a quality extract and proper administration. Regarding the monitoring of immunotherapy Immunotherapy has a long-term positive effect, preventing the progress of the respiratory allergic disease and new sensitisations</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.med.2017.03.016</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.med.2017.03.016</url></web-urls><pdf-urls><url ppv-ref="no">dario.antolin@gmail.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">2017020, Antolin Amerigo D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.med.2017.03.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Neophytou,M.</style></author><author><style face="normal" font="Arial"> Alcocer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Biosciences, University of Nottingham, College Road, Sutton Bonington Campus, Sutton Bonington, Loughborough, LE12 5RD, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Recombinant Allergens Production in Yeast</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="56" start="47">47-56</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Pichia</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Folding</style></keyword><keyword><style face="normal" font="Arial"> Protein processing</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The methylotropic yeast Pichia pastoris has been extensively used in large-scale production of properly folded recombinant proteins. As an eukaryotic organism P. pastoris presents a series of advantages at expression and processing of heterologous proteins such as post-translational modifications, protein processing, and a reasonably sophisticated quality control of protein folding when compared against Escherichia coli. In this chapter, we describe the modified lab procedure for cloning and expression in Pichia pastoris of common food allergens sequences from the raw fruit to the fully folded biotinylated protein product</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315210">PM:28315210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-47-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-47-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Neophytou M</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,C.</style></author><author><style face="normal" font="Arial"> Willison,L.N.</style></author><author><style face="normal" font="Arial"> Sathe,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Exercise and Nutritional Sciences, San Diego State University, 308 ENS Bldg., 5500 Campanile Drive, San Diego, CA, 92182-7251, USA</style></auth-address><titles><title><style face="normal" font="Arial">Recombinant Allergen Production in E. coli</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="45" start="23">23-45</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitope Mapping</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Sciences</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Recombinant protein allergens have been used in allergy studies, allergy diagnosis, and epitope mapping. Messenger RNAs (mRNAs) are isolated from tissues of interest for complementary DNA (cDNA) library construction. Subsequently, the allergen gene is amplified by polymerase chain reaction (PCR) and sequenced. The amplified gene is then cloned into an expression vector, expressed in Escherichia coli cells, and purified from the cell lysate. This chapter describes the protocols for recombinant allergen production</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315209">PM:28315209</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-23-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-23-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Liu C</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masilamani,M.</style></author><author><style face="normal" font="Arial"> Pascal,M.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, The Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, Icahn Building, Room 11-23B, 1089, New York, NY, 10029, USA.</style></auth-address><titles><title><style face="normal" font="Arial">T-Cell Proliferation Assay: Determination of Immunodominant T-Cell Epitopes of Food Allergens</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="198" start="189">189-198</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Cross-link</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> synthetic peptides</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Characterization of allergen-specific T cells is critical to understand their contribution to disease pathogenesis. The identification of immunodominant T-cell epitopes is crucial for development of T-cell-based vaccines. Peptide-specific T-cell proliferation studies are usually performed in a library of short synthetic peptides (15mer or 20mer) with 3 or 5 offset spanning the entire length of the allergen. T-cell peptide epitopes lack the primary and tertiary structure of the native protein to cross-link IgE, but retain the ability to stimulate T cells. The peptides sequences can also be obtained either by in silico approaches and in vitro binding assays. The efficacy of T-cell epitope-based peptide immunotherapy has been proven in certain allergies. The present methodology describes T-cell proliferation assays using whole blood sample from allergic subjects</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_15</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315221">PM:28315221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-189-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-189-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Masilamani M</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_15</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grishina,G.</style></author><author><style face="normal" font="Arial"> Bardina,L.</style></author><author><style face="normal" font="Arial"> Grishin,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Elliot and Roslyn Jaffe Food Allergy Institute, Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, 10029, NY, USA.</style></auth-address><titles><title><style face="normal" font="Arial">2D-Electrophoresis and Immunoblotting in Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="69" start="59">59-69</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2D electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> 2D-electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional polyacrylamide gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Two-dimensional polyacrylamide gel electrophoresis (2DE) and Western immunoblotting have proven to be invaluable and fundamental techniques for comprehensive characterization of food allergens. Here, we describe and discuss detailed protocols used in our studies on identification of allergenic proteins in shrimp, sesame, hazelnut, and pistachio</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315211">PM:28315211</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-59-69.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-59-69.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Grishina G</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Archila,L.L.</style></author><author><style face="normal" font="Arial"> Kwok,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Benaroya Research Institute at Virginia Mason, 1201 Ninth Avenue, Seattle, WA, 98101, USA</style></auth-address><titles><title><style face="normal" font="Arial">Tetramer-Guided Epitope Mapping: A Rapid Approach to Identify HLA-Restricted T-Cell Epitopes from Composite Allergens</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="209" start="199">199-209</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitope Mapping</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptor</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptors</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> tetramer</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Tetramer-guided epitope mapping (TGEM) is a technique in immunology that permits the rapid identification of allergenic epitopes through peptide screening procedures utilizing human lymphocyte antigen (HLA) class II tetramers as staining reagents for detection. The identification of allergenic epitopes is a prerequisite for the accurate characterization of allergen-specific CD4+ T cells without in vitro stimulation. Additionally, these MHC-II/peptide complexes that interact with T-cell receptors (TCR) of pathogenic CD4+ T cells are compatible with a different number of assays like Intracelullar Cytokine Staining (ICS), and Carboxyfluorescein succinimidyl ester (CFSE) making it a robust technology to study the functionality of allergen-specific CD4+ T cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315222">PM:28315222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-199-209.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-199-209.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Archila LL</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Benede,S.</style></author><author><style face="normal" font="Arial"> Lopez-Fandino,R.</style></author><author><style face="normal" font="Arial"> Molina,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Investigacion en Ciencias de la Alimentacion (CIAL, CSIC-UAM), Nicolas Cabrera 9, Madrid, 28049, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of IgE Reactivity of beta-Casein by Western Blotting After Digestion with Simulated Gastric Fluid</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="175" start="165">165-175</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> gastric digestion</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> hen's egg allergy</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide fragment</style></keyword><keyword><style face="normal" font="Arial"> Peptide Fragments</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Simulated digestion</style></keyword><keyword><style face="normal" font="Arial"> simulated gastric fluid</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Cow's milk allergy is defined as an immunologically mediated adverse reaction to cow's milk proteins and it is usually, along with hen's egg allergy, the first food allergy identified in childhood.One of the main aspects to consider when evaluating the allergenic potential of food proteins is the effect of gastric digestion. It is known that allergens are usually able to survive the harsh acidic environment of the stomach, tolerate the presence of surfactants, and resist digestion by pepsin. They might also be digested into high molecular weight peptide fragments, which retain the same, or sometimes increased, IgE-binding. In this respect, western blotting is a highly sensitive and efficient technique that we have used to detect IgE-binding to the digests of milk and egg proteins. Given the importance of the resistance of food proteins to gastric digestion in their capacity to modulate the immune response, we describe in this chapter the assessment of IgE reactivity of a relevant cow's milk allergen, beta-casein, by western blotting after simulated digestion under relevant physiological conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_13</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315219">PM:28315219</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-165-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-165-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Benede S</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_13</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ali,E.A.</style></author><author><style face="normal" font="Arial"> Nakamura,R.</style></author><author><style face="normal" font="Arial"> Falcone,F.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham, Boots Science Bldg., Science Road, Nottingham, NG7 2RD, UK</style></auth-address><titles><title><style face="normal" font="Arial">Use of Humanized RS-ATL8 Reporter System for Detection of Allergen-Specific IgE Sensitization in Human Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="161" start="147">147-161</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human food</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergen-specific Immunoglobulin E (IgE) determination lies at the heart of diagnosis of sensitization to food and other allergens. In the past few years, reporter systems capable of detecting the presence of allergen-specific IgE have been developed by several labs. These rely on humanized rat basophil leukemia cell lines stably transfected with reporter genes such as firefly luciferase. In this chapter, we describe protocols for the use of the RS-ATL8 cell line (IgE cross-linking-induced luciferase expression; EXiLE) in 96-well and 384-well formats. We also describe optional treatment steps for enveloped virus and complement inactivation</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315218">PM:28315218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-147-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-147-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Ali EA</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_12</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,J.</style></author><author><style face="normal" font="Arial"> Alcocer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bioinformatics Institute, A*STAR, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Overview of the Commonly Used Methods for Food Allergens</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="9" start="1">1-9</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergy has become a major public health problem worldwide. In the past two decades, development in molecular biology and immunology has led to many new techniques that had improved traditional methods in the food allergy field. These methods greatly facilitate identification, characterization, and quantification of food allergen and are certainly leading to better diagnostics and therapeutics for food allergic diseases. Here we review methods commonly used for food allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - United KIngdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315207">PM:28315207</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-1-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-1-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Lin J</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cases,B.</style></author><author><style face="normal" font="Arial"> Pastor-Vargas,C.</style></author><author><style face="normal" font="Arial"> Perez-Gordo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research and Development Department, Inmunotek S.L., Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Allergen Extraction and Purification from Natural Products: Main Chromatographic Techniques</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="22" start="13">13-22</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ion Exchange</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The development of techniques and methods for allergen purification is essential for diagnosis and the development of safe immunotherapeutic agents. The most common purification techniques include chromatographic methodologies. In this chapter, we review and describe the details of the methodologies of using ion-exchange, gel-filtration, and affinity chromatography to purify two well-known panallergens, profilin and parvalbumin</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315208">PM:28315208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-13-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-13-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Cases B</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,J.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bioinformatics Institute, A*STAR, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">IgE Epitope Mapping Using Peptide Microarray Immunoassay</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="187" start="177">177-187</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody Affinity</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitope Mapping</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide microarray</style></keyword><keyword><style face="normal" font="Arial"> Peptide microarray immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">IgE epitope mapping has the potential to become an additional tool for food allergy diagnosis/prognosis and to lead to a better understanding of the pathogenesis and tolerance induction of food allergy. Due to its ability to screen thousands of targets in parallel using small volumes of sample, peptide microarray has greatly facilitated large-scale IgE epitope mapping. In the past 10 years, we have developed and optimized a reliable and sensitive peptide microarray immunoassay, which has been successfully applied for IgE epitope mapping of many food allergens in our lab. Here, we describe the method of performing the peptide microarray immunoassay for IgE epitope mapping. In addition, we have upgraded the microarray platform to measure antibody affinity by adding one additional competition step, which is also described in this chapter</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_14</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315220">PM:28315220</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-177-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-177-87.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Lin J</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_14</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de la Cuesta,F.</style></author><author><style face="normal" font="Arial"> Alvarez-Llamas,G.</style></author><author><style face="normal" font="Arial"> Barderas,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="Arial">Two-Dimensional Electrophoresis and Identification by Mass Spectrometry</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="78" start="71">71-78</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2-DE</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Isoelectric Point</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Two-dimensional electrophoresis (2-DE) is a classical separation technique for complex protein mixtures based on a first-separation step by isoelectric point (pI) followed by SDS-PAGE. Due to its high resolving power (including protein isoforms) and the capability to display post-translational modifications, 2-DE has been the technique of choice in many studies focused in characterizing allergens. In this chapter, we describe a standard protocol which enables efficient protein separation and subsequent protein identification by tandem mass spectrometry (MALDI-MS/MS)</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315212">PM:28315212</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-71-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-71-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, de la Cuesta F</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de la Cruz,S.</style></author><author><style face="normal" font="Arial"> Lopez-Calleja,I.</style></author><author><style face="normal" font="Arial"> Martin,R.</style></author><author><style face="normal" font="Arial"> Gonzalez,I.</style></author><author><style face="normal" font="Arial"> Alcocer,M.</style></author><author><style face="normal" font="Arial"> Garcia,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Facultad de Veterinaria, Departamento de Nutricion, Bromatologia y Tecnologia de los Alimentos, Universidad Complutense de Madrid, Av. Puerta de Hierro s/n, 28040, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Recent Advances in the Detection of Allergens in Foods</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="295" start="263">263-295</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alimentos</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergic consumers</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide fragment</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergy is a public health issue that has significantly increased worldwide in the past decade affecting consumers' quality of life and making increasing demands on health service resources. Despite recent advances in many areas of diagnosis and treatment, our general knowledge of the basic mechanisms of the disease remained limited, i.e., not at pace with the exponential number of new cases and the explosion of the new technologies. For sensitized individuals, the only effective way to prevent allergic reactions is the strict avoidance of the offending food. For this reason, a number of regulatory bodies in several countries have recognized the importance of providing information about the presence of food allergens by enacting laws, regulations, or standards for food labeling of "priority allergens." This has resulted in the need for the development of analytical methods for protection of food-allergic consumers that should be among others highly specific, sensitive, and not influenced by the presence of the food matrix components. Several analytical approaches target either the allergen itself or a corresponding allergen marker such as peptide fragment or gene segment and have been used in the detection and quantification of allergens in food products. In this short review, some of the conventional and new methods for the detection of allergens in food are listed and briefly discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_20</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315226">PM:28315226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-263-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-263-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, de la Cruz S</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_20</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Konstantinou,G.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, 11 Eleftheriou Venizelou Street, Kalamaria, 55 133, Thessaloniki, Greece.</style></auth-address><titles><title><style face="normal" font="Arial">T-Cell Epitope Prediction</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="222" start="211">211-222</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Mathematics</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope prediction</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell clone</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptor</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptors</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">An epitope is a part of an immunogenic protein that can be recognized by the immune system. The peptides that can be recognized by the T-cell receptors after a particular antigen has been intracellularly processed, bound to at least one MHC molecule and expressed on the surface of the antigen presenting cell as a MHC-peptide complex, are called a T-cell epitope. Individuals who have at least one MHC molecule able to most avidly bind to allergenic amino acid sequences from an allergen, and at the same time have the appropriate T-cell clone that can recognize this MHC-peptide complex, are expected to be genetically prone to allergic reactions against that allergen. This possibility can be examined in silico by utilizing modern computational techniques that are based on sophisticated mathematics and statistics. The design principles of these techniques are different and therefore variations in their predictions are expected. The available software programs that have been developed on this basis are able to combine the increasing amount and complexity of the available experimental data that have been organized in immunoinformatics databases to predict potential allergen T-cell epitopes. All relevant T-cell epitope prediction methods can be accessed online as a freeware</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315223">PM:28315223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-211-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-211-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Konstantinou GN</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_17</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fu,Z.</style></author><author><style face="normal" font="Arial"> Lin,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genome Institute of Singapore, A*STAR, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">An Overview of Bioinformatics Tools and Resources in Allergy</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="245" start="223">223-245</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> allergens and epitopes</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> Machine Learning</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The rapidly increasing number of characterized allergens has created huge demands for advanced information storage, retrieval, and analysis. Bioinformatics and machine learning approaches provide useful tools for the study of allergens and epitopes prediction, which greatly complement traditional laboratory techniques. The specific applications mainly include identification of B- and T-cell epitopes, and assessment of allergenicity and cross-reactivity. In order to facilitate the work of clinical and basic researchers who are not familiar with bioinformatics, we review in this chapter the most important databases, bioinformatic tools, and methods with relevance to the study of allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_18</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315224">PM:28315224</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-223-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-223-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Fu Z</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_18</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia,A.</style></author><author><style face="normal" font="Arial"> Madrid,R.</style></author><author><style face="normal" font="Arial"> Garcia,T.</style></author><author><style face="normal" font="Arial"> Martin,R.</style></author><author><style face="normal" font="Arial"> Gonzalez,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Nutricion, Bromatologia y Tecnologia de los Alimentos, Facultad de Veterinaria, Universidad Complutense de Madrid, Av. Puerta de Hierro s/n, 28040, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Detection of Food Allergens by Taqman Real-Time PCR Methodology</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="108" start="95">95-108</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alimentos</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> commercial food products</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Macadamia</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> TaqMan</style></keyword><keyword><style face="normal" font="Arial"> TaqMan real-time PCR</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Real-time PCR (polymerase chain reaction) has shown to be a very effective technology for the detection of food allergens. The protocol described herein consists on a real-time PCR assay targeting the plant ITS (Internal Transcribed Spacer) region, using species-specific primers and hydrolysis probes (Taqman) dual labeled with a reporter fluorophore at the 5' end (6-carboxyfluorescein, FAM) and a quencher fluorophore at the 3' end (Blackberry, BBQ). The species-specific real-time PCR systems (primers/probe) described in this work allowed the detection of different nuts (peanut, hazelnut, pistachio, almond, cashew, macadamia, walnut and pecan), common allergens present in commercial food products, with a detection limit of 0.1 mg/kg</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315214">PM:28315214</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-95-108.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-95-108.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Garcia A</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Konstantinou,G.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, 11 Eleftheriou Venizelou Street, Kalamaria, 55 133, Thessaloniki, Greece.</style></auth-address><titles><title><style face="normal" font="Arial">Enzyme-Linked Immunosorbent Assay (ELISA)</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="94" start="79">79-94</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergy is a public health concern especially after recognizing its constantly increased prevalence and severity. Despite careful reading of food ingredient statements, food allergic individuals may experience reactions caused by "hidden", "masked", or "contaminated" proteins that are known major allergens. Many techniques have been developed to detect even small traces of food allergens, for clinical or laboratory purposes. Enzyme-linked immunosorbent assay (ELISA) is one of the best validated and most routinely used immunoassay in allergy research, in allergy diagnosis in allergy-related quality control in various industries. Although as a technique it has been implemented for the last 45 years, the evolution in biochemistry allowed the development of ultrasensitive ELISA variations that are capable of measuring quantities in the scale of picograms, rendering ELISA attractive, robust, and very famous</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315213">PM:28315213</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-79-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-79-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Konstantinou GN</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jambari,N.N.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Alcocer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Sciences, Faculty of Food Sciences and Technology, University of Putra Malaysia, UPM Serdang, 43400, Serdang, Selangor, Malaysia.</style></auth-address><titles><title><style face="normal" font="Arial">Protein Microarray-Based IgE Immunoassay for Allergy Diagnosis</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="137" start="129">129-137</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein microarray</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Protein microarray is a miniaturized multi-analyte, solid-phased immunoassay where thousands of immobilized individual protein spots on a microscopic slide bind are bound to specific antibodies (immunoglobulins) from serum samples, which are then detected by fluorescent labeling. The image processing and pattern recognition are then quantitatively analyzed using advanced algorithms. Here, we describe the use of an in-house-produced complex protein microarray containing extracts and pure proteins that has been probed with antibodies present in the horse sera and detection by fluorophore-conjugated antibody and data analysis. The flexibility of the number and types of proteins that can be printed on the microarray allows different set of specific IgE immunoassay analysis to be carried out</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Malaysia -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_10</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315216">PM:28315216</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-129-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-129-37.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Jambari NN</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_10</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Madrid,R.</style></author><author><style face="normal" font="Arial"> de la Cruz,S.</style></author><author><style face="normal" font="Arial"> Garcia,A.</style></author><author><style face="normal" font="Arial"> Martin,R.</style></author><author><style face="normal" font="Arial"> Gonzalez,I.</style></author><author><style face="normal" font="Arial"> Garcia,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Nutricion, Bromatologia y Tecnologia de los Alimentos, Facultad de Veterinaria, Universidad Complutense de Madrid, Av. Puerta de Hierro a/n, 28040, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Detection of Food Allergens by Phage-Displayed Produced Antibodies</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="128" start="109">109-128</pages><volume><style face="normal" font="Arial">1592</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alimentos</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Bacteriophages</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> commercial food products</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Engineering</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant antibody</style></keyword><keyword><style face="normal" font="Arial"> scFv</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Phage display is a powerful tool to produce recombinant antibodies against a given antigen without animal immunization. This technology employs libraries of recombinant bacteriophages that display billions of different functional antibody fragments on their surface. They are selected by panning in vitro against the target antigen in search for specific binders. In this chapter, we describe the selection of single chain variable fragment (scFv) antibodies to be used for detection of allergenic proteins from nuts in food products. The artificial libraries TomLinson I+J (MRC Laboratory of Molecular Biology and MRC Centre for Protein Engineering) were employed that resulted in successful phage-ELISA systems for detection of almond and walnut proteins in commercial food products</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315215">PM:28315215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-109-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1592-109-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Madrid R</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-6925-8_9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83977</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,M.</style></author><author><style face="normal" font="Arial"> Wang,H.Y.</style></author><author><style face="normal" font="Arial"> Chen,J.C.</style></author><author><style face="normal" font="Arial"> Zhao,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of critical care medicine, The Third People's Hospital of Jinan, Jinan 250132, Shandong, PR China.</style></auth-address><titles><title><style face="normal" font="Arial">Regulation of airway inflammation and remodeling in asthmatic mice by TLR3/TRIF signal pathway</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="272" start="265">265-272</pages><volume><style face="normal" font="Arial">85</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Hydroxyproline</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interferon-beta</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">This paper aims to investigate the effect of Toll-like receptors 3 (TLR3)/TIR-domain-containing adapter-inducing interferon-beta (TRIF) signal pathway on the airway inflammation and remodeling in asthmatic mice. C57BL/6 and TLR3-/- mice were randomly divided into three groups (10 mice per group), including Control group (mice inhaled phosphate buffer saline (PBS)), Asthma group (mice inhaled ovalbumin (OVA)) and polyriboinosinic-ribocytidylic acid (poly (I: C)) group (asthmatic mice were injected intraperitoneally with TLR3 agonist poly (I: C)). Hematoxylin-eosin (HE) staining, Wright-Giemsa staining, Enzyme-linked immunosorbent assay (ELISA), Immunohistochemistry, Hydroxyproline assay, quantitative real time polymerase chain reaction (qRT-PCR) and Western blot were used to assess for the indices of airway inflammation and remodeling. In terms of WT mice, all asthma groups with or without the addition of poly (I: C) showed exaggerated inflammation and remodeling in the airways as compared to Control group, which were more seriously in poly (I: C) group than Asthma group. Furthermore, we observed the significant inhibition of airway inflammation and remodeling in the TLR3-/- mice in both Asthma no matter with or without addition of poly (I: C) than the WT mice. TLR3 knockout could obviously relieve the airway inflammation and remodeling in asthma through inhibiting TLR3/TRIF signaling pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20170326IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2017.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342933">PM:28342933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-85-265-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2017-85-265-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170326, Yang M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2017.03.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Laumonnier,Y.</style></author><author><style face="normal" font="Arial"> Wiese,A.V.</style></author><author><style face="normal" font="Arial"> Figge,J.</style></author><author><style face="normal" font="Arial"> Karsten,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Systemic Inflammation Research, University of Lubeck, 23562 Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Regulation and function of anaphylatoxins and their receptors in allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="56" start="51">51-56</pages><volume><style face="normal" font="Arial">84</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immune system</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Anaphylatoxins</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> C3a</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Complement Activation</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> endothelial cells</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a disease of the airways driven by maladaptive T helper 2 (Th2) and Th17 immune response against harmless, airborne substances. The hallmarks of this disease are airway hyperresponsiveness (AHR), eosinophilic and neutrophilic airway inflammation and mucus overproduction. Distinct dendric cell (DC) subsets together with airway epithelial and pulmonary vascular endothelial cells play critical roles in allergen sensing and in driving T cell differentiation towards Th2 and Th17 effector or regulatory T cells (Treg). Previous studies suggested already a pivotal role for the anaphylatoxins (C5a, C3a) in the pathogenesis of allergic asthma. During sensitization for example it is described, that C3a promotes, whereas C5a protects from the development of maladaptive immunity during allergen sensitization. Here we will discuss the role of the anaphylatoxins (C3a, C5a) and their receptors during the pathogenesis of allergic asthma, and specifically in lung DC biology. We will also have a look on canonical and non-canonical complement activation and we will discuss novel concepts on how the adaptive immune system can regulate the function of ATRs also in the context of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2016.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27916272">PM:27916272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-84-51-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-84-51-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Laumonnier Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2016.11.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,F.</style></author><author><style face="normal" font="Arial"> Sun,Y.</style></author><author><style face="normal" font="Arial"> Yu,J.</style></author><author><style face="normal" font="Arial"> Ding,Z.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Zhang,T.</style></author><author><style face="normal" font="Arial"> Bai,Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">ORMDL3 is associated with airway remodeling in asthma via the ERK/MMP-9 pathway</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> ORMDL3</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="Arial">ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) has been previously implicated in asthma pathogenesis, its effect on airway remodeling remains to be elucidated. The present study examined the expression levels of ORMDL3 in a mouse model of asthma. Mice were divided into three groups: Asthmatic model (n=10), budesonidetreated (n=10) and a control group (n=8). Asthma was induced by sensitization with ovalbumin (OVA) and aluminum hydroxide on day 1, 7 and 14. Subsequently mice were exposed to OVA three times per week from day 28. In order to investigate the mechanism of airway remodeling 100 microg/kg aerosol budesonide was administered to 6 animals prior to exposure to OVA. The condition of lung tissues was assessed through histology, and the expression levels of ORMDL3, phosphorylatedextracellularsignal regulated kinase (pERK) and matrix metallopeptidase9 (MMP9) were quantified using immunohistochemistry, reverse transcriptionquantitative polymerase chain reaction and western blotting. A severe inflammatory response and airway remodeling were pretreatment with budesonide. Expression levels of ORMDL3, phosphorylated (p)ERK and MMP9 were significantly greater in the asthmamodel group; however, in the group pretreated with budesonide their expression was reduced. Expression levels of ORMDL3, pERK and MMP9 were significantly positively correlated with bronchial wall thickness. ORMDL3 expression was significantly positively correlated with pERK and MMP9. Therefore, increased ORMDL3 expression may induce the pERK/MMP9 pathway to promote pathological airway remodeling in patients with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170330IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6413</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28358425">PM:28358425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\20170330-YuF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\20170330-YuF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170330, Yu F</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6413</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jeong,K.Y.</style></author><author><style face="normal" font="Arial"> Han,I.S.</style></author><author><style face="normal" font="Arial"> Lee,J.Y.</style></author><author><style face="normal" font="Arial"> Park,K.H.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul 03722, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Role of tropomyosin in silkworm allergy</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="3270" start="3264">3264-3270</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Arginine kinase</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Bomb m 1</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pupa</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> tropomyosins</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">Silkworm pupae are widely consumed in Asian countries and allergic reactions following consumption have been described. However, falsepositive responses in skin prick allergy tests or nonspecific immunoglobulin E (IgE) responses to total extract of silkworm pupa make diagnosis difficult. Although improved allergy diagnosis is required, molecular characterization of silkworm allergens has not been performed to date, except for Bomb m 1, an arginine kinase. This study aimed to evaluate the allergenicity of tropomyosin, a wellestablished invertebrate panallergen, from silkworm pupa. The silkworm tropomyosin gene was cloned by reverse transcription and polymerase chain reaction, and the protein was overexpressed in Escherichia coli and purified by affinity chromatography using Nickelresin. IgE reactivity of the recombinant protein was examined by ELISA and competitive inhibition analyses. Silkworm pupa tropomyosin shared 73.592.3% amino acid sequence identity with previously identified allergenic tropomyosins. Sera from eight of 15 patients with silkworm allergy (53.3%) exhibited binding of IgE to the recombinant protein. However, recombinant protein was able to inhibit less than 10% of IgE reactivity to silkworm pupa extract. Of the eight sera tested, six that specifically reacted with silkworm tropomyosin also demonstrated IgE reactivity to shrimp and crab. In the present study, specific IgE to silkworm tropomyosin was detected in patients with silkworm allergy, suggesting that it may be useful in diagnosis of allergy to silkworm pupa</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6373</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28339033">PM:28339033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-15-3264-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-15-3264-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Jeong KY</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6373</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,B.</style></author><author><style face="normal" font="Arial"> Huang,S.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Fang,S.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Antiinflammatory effects of dihydromyricetin in a mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="4" Year="2017">2017/4/3</year></dates><abstract><style face="normal" font="Arial">Dihydromyricetin (DHM) is a plant flavonoid and is the primary active ingredient isolated from the medicinal herb, Ampelopsis grossedentata. DHM has been shown to possess various pharmacological activities, including antiinflammatory effects. However, the possible role of DHM in asthma treatment remains to be elucidated. The present study aimed to investigate its antiinflammatory properties in mice with symptoms of allergic asthma. The C57BL/6 mice were sensitized and challenged with ovalbumin (OVA) to induce asthma. DHM or phosphatebuffered saline treatment was administered 1 h prior to the OVA challenge. The levels of interleukin (IL)4, IL5 and IL13 in the bronchoalveolar lavage (BAL) fluid were measured by enzymelinked immunosorbent assay (ELISA), and OVAspecific serum IgE and IgG1 levels were also determined by ELISA. Histopathological staining was performed to evaluate the infiltration of inflammatory cells into the BAL fluid, lung tissues and goblet cell hyperplasia. DHM treatment significantly reduced the total number of inflammatory cells, including eosinophils, neutrophils, lymphocytes and macrophages, in the BAL fluid. DHM also reduced the levels of IL4, IL5 and IL13 in the BAL fluid, and reduced the secretion of OVAspecific IgE and IgG1 in the serum. The histological staining demonstrated that DHM treatment effectively suppressed the OVAinduced inflammatory cells in the lung tissues and in the mucus hypersecreted by goblet cells in the airway. These results showed that DHM had a potent antiinflammatory effect in an OVAinduced mouse model of asthma, offering potential as an antiinflammatory agent for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6428</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393183">PM:28393183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\20170410-XuB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\20170410-XuB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Xu B</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6428</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shaw,M.</style></author><author><style face="normal" font="Arial"> Nyanhanda,T.</style></author><author><style face="normal" font="Arial"> McGhie,K.</style></author><author><style face="normal" font="Arial"> Harper,L.</style></author><author><style face="normal" font="Arial"> Hurst,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food &amp; Wellness Group, The New Zealand Institute for Plant &amp; Food Research Ltd, Palmerston North, New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">Blackcurrant anthocyanins modulate CCL11 secretion and suppress allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anthocyanin</style></keyword><keyword><style face="normal" font="Arial"> Anthocyanins</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Functional food</style></keyword><keyword><style face="normal" font="Arial"> functional foods</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword></keywords><dates><year Day="9" Month="4" Year="2017">2017/4/9</year></dates><abstract><style face="normal" font="Arial">CCL11, a chemokine, is linked to the early development of airways eosinophilia in allergic asthma. Therefore, CCL11 production is a target for abrogating eosinophilic-driven airway inflammation. Blackcurrants are high in compounds that regulate inflammation, particularly anthocyanins. In this study we investigated the effect of oral blackcurrant supplementation on allergen-induced eosinophilia and CCL11 production; we also profiled key compounds in blackcurrants that were linked to this effect. 10 mg/kg (total anthocyanins) of a commercially available, anthocyanin-rich New Zealand 'Ben Ard' blackcurrant extract ('Currantex 30') attenuated ovalbumin-induced inflammation, eosinophilia (by 52.45 +/- 38.50%) and CCL11 production (by 48.55 +/- 28.56%) in a mouse model of acute allergic lung inflammation. Ten blackcurrant polyphenolic extracts were also found to suppress CCL11 secretion by stimulated human lung epithelial cells in vitro. Correlation analysis identified potential blackcurrant polyphenolic anthocyanin constituents specifically delphinidins and cyanidins, involved in CCL11 suppression. Our findings show oral supplementation with New Zealand blackcurrant is effective in reducing lung inflammation, and highlight the potential benefit of developing cultivars with specific polyphenolic profiles for the creation of functional foods with desirable biological activity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201600868</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393456">PM:28393456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170410-ShawM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170410-ShawM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Shaw M</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201600868</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maiga,M.A.</style></author><author><style face="normal" font="Arial"> Morin,S.</style></author><author><style face="normal" font="Arial"> Bernard,H.</style></author><author><style face="normal" font="Arial"> Rabot,S.</style></author><author><style face="normal" font="Arial"> Patient,K.A.</style></author><author><style face="normal" font="Arial"> Hazebrouck,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">UMR Service de Pharmacologie et d'Immunoanalyse, CEA, INRA, Universite Paris-Saclay, F-91191, Gif-sur-Yvette, France</style></auth-address><titles><title><style face="normal" font="Arial">Neonatal mono-colonization of germ-free mice with Lactobacillus casei enhances casein immunogenicity after oral sensitization to cow's milk</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus casei</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Oral sensitization</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pharmacologie</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="Arial">SCOPE: Food allergy is an increasing global health problem and perinatal administration of probiotic bacteria is currently under investigation in order to prevent the development of allergic diseases. Here, we investigated the impact of neonatal mono-colonization of mice with Lactobacillus casei BL23 on an oral sensitization to cow's milk. METHODS AND RESULTS: Mono-colonized (LC) mice were obtained by inoculating L. casei to germ-free (GF) parents. Nine-week-old GF, LC and conventional (CV) mice were orally sensitized to cow's milk with cholera toxin as adjuvant. Compared to GF and CV mice, LC mice developed higher casein-specific IgG responses. In contrast, no significant differences between GF and LC mice were observed for the humoral responses against whey proteins. Immunoblotting experiments performed on alphaS1-casein hydrolysates revealed the presence of small peptides immunoreactive with sera from LC mice but not from GF mice. After in vitro reactivation of splenocytes, secretion of IL-17 was higher in LC mice than in GF and CV mice. CONCLUSIONS: Neonatal monocolonization by L. casei BL23 modulated the allergic sensitization toward food antigens. Furthermore, our data suggest that casein-specific humoral responses in LC mice were enhanced because of casein hydrolysis by L. casei into immunogenic peptides. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201600862</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318108">PM:28318108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170320-MaigaMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170320-MaigaMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Maiga MA</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201600862</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shao,Y.Y.</style></author><author><style face="normal" font="Arial"> Zhou,Y.M.</style></author><author><style face="normal" font="Arial"> Hu,M.</style></author><author><style face="normal" font="Arial"> Li,J.Z.</style></author><author><style face="normal" font="Arial"> Chen,C.J.</style></author><author><style face="normal" font="Arial"> Wang,Y.J.</style></author><author><style face="normal" font="Arial"> Shi,X.Y.</style></author><author><style face="normal" font="Arial"> Wang,W.J.</style></author><author><style face="normal" font="Arial"> Zhang,T.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100050, China.</style></auth-address><titles><title><style face="normal" font="Arial">The Anti-Allergic Rhinitis Effect of Traditional Chinese Medicine of Shenqi by Regulating Mast Cell Degranulation and Th1/Th2 Cytokine Balance</style></title><secondary-title><style face="normal" font="Arial">Molecules</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Molecules</style></full-title></periodical><pages end="" start="504">504-</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Bioactive substances</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">Shenqi is a traditional Chinese polyherbal medicine has been widely used for the treatment of allergic rhinitis (AR). The aim of this study was to investigate the anti-allergic rhinitis activity of Shenqi and explore its underlying molecular mechanism. Ovalbumin (OVA)-induced allergic rhinitis rat model was used to evaluate the anti-allergic rhinitis effect of Shenqi. The effect of Shenqi on IgE-mediated degranulation was measured using rat basophilic leukemia (RBL-2H3) cells. Primary spleen lymphocytes were isolated to investigate the anti-allergic mechanism of Shenqi by detecting the expression of transcription factors via Western blot and the level of cytokines (IL-4 and IFN-gamma) via ELISA. In OVA-induced AR rat models, Shenqi relieved the allergic rhinitis symptoms, inhibited the histopathological changes of nasal mucosa, and reduced the levels of IL-4 and IgE. The results from the in vitro study certified that Shenqi inhibited mast cell degranulation. Furthermore, the results of GATA3, T-bet, p-STAT6, and SOCS1 expression and production of IFN-gamma and IL-4 demonstrated that Shenqi balanced the ratio of Th1/Th2 (IFN-gamma/IL-4) in OVA-stimulated spleen lymphocytes. In conclusion, these results suggest that Shenqi exhibits an obvious anti-allergic effect by suppressing the mast cell-mediated allergic response and by improving the imbalance of Th1/Th2 ratio in allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170322IS - 1420-3049 (Electronic)IS - 1420-3049 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3390/molecules22030504</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28327534">PM:28327534</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Molecules\2017-22-504.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Molecules\2017-22-504.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170322, Shao YY</style></custom2><misc3><style face="normal" font="Arial">10.3390/molecules22030504</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,B.</style></author><author><style face="normal" font="Arial"> Butterfield,J.H.</style></author><author><style face="normal" font="Arial"> Weiler,C.R.</style></author><author><style face="normal" font="Arial"> Kane,S.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Division of Allergic Diseases, The Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic , Rochester, Minnesota</style></auth-address><titles><title><style face="normal" font="Arial">Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis</style></title><secondary-title><style face="normal" font="Arial">Monoclon Antib Immunodiagn Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Monoclon Antib Immunodiagn Immunother</style></full-title></periodical><pages end="303" start="300">300-303</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies,Monoclonal,Humanized</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Colitis,Ulcerative</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug effects</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Drug Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Agents</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Factors</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> Ulcerative Colitis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">The development and utilization of monoclonal antibodies (mAbs) have been of great interest in all fields of medicine. A substantial increase in the production and development of mAbs has occurred because these biologic agents are proving to be effective and less toxic given their targeted mechanism of action. However, data are limited on coadministration of two or more mAbs. With the increasing availability of mAbs and the comorbidities of some patients, assessment is needed of the ability to safely use multiple mAbs for an individual patient. Although the efficacy of coadministered mAbs may be inferred from their specific targets, we could find no literature reporting such a finding. Herein, we report our experience using two different classes of mAbs to treat hypereosinophilic syndrome and ulcerative colitis in a single patient</style></abstract><notes><style face="normal" font="Arial">DA - 20161202IS - 2167-9436 (Electronic)IS - 2167-9436 (Linking)LA - engPT - Case ReportsPT - Journal ArticleRN - 0 (Antibodies, Monoclonal, Humanized)RN - 0 (Gastrointestinal Agents)RN - 0 (Immunologic Factors)RN - 0 (mepolizumab)RN - B72HH48FLU (Infliximab)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1089/mab.2016.0038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27911676">PM:27911676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Monoclon Antib Immunodiagn Immunother\2016-35-300-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Monoclon Antib Immunodiagn Immunother\2016-35-300-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161202, Patel B</style></custom2><misc3><style face="normal" font="Arial">10.1089/mab.2016.0038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mennini,M.</style></author><author><style face="normal" font="Arial"> Dahdah,L.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bambino Gesu Children's Research Hospital, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="" start="1090">1090-</pages><volume><style face="normal" font="Arial">376</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - LetterPT - CommentSB - AIMSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMc1700366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28301105">PM:28301105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-376-1090.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-376-1090.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Mennini M</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMc1700366</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McDaniel,D.K.</style></author><author><style face="normal" font="Arial"> Jo,A.</style></author><author><style face="normal" font="Arial"> Ringel-Scaia,V.M.</style></author><author><style face="normal" font="Arial"> Coutermarsh-Ott,S.</style></author><author><style face="normal" font="Arial"> Rothschild,D.E.</style></author><author><style face="normal" font="Arial"> Powell,M.D.</style></author><author><style face="normal" font="Arial"> Zhang,R.</style></author><author><style face="normal" font="Arial"> Long,T.E.</style></author><author><style face="normal" font="Arial"> Oestreich,K.J.</style></author><author><style face="normal" font="Arial"> Riffle,J.S.</style></author><author><style face="normal" font="Arial"> Davis,R.M.</style></author><author><style face="normal" font="Arial"> Allen,I.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">TIPS pentacene loaded PEO-PDLLA core-shell nanoparticles have similar cellular uptake dynamics in M1 and M2 macrophages and in corresponding in vivo microenvironments</style></title><secondary-title><style face="normal" font="Arial">Nanomedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nanomedicine</style></full-title></periodical><pages end="1266" start="1255">1255-1266</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug delivery</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phagocytosis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary drug delivery</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><isbn><style face="normal" font="Arial">1549-9634</style></isbn><abstract><style face="normal" font="Arial">Nanoparticle based drug delivery platforms have the potential to transform disease treatment paradigms and therapeutic strategies, especially in the context of pulmonary medicine. Once administered, nanoparticles disperse throughout the lung and many are phagocytosed by macrophages. However, there is a paucity of knowledge regarding cellular up-take dynamics of nanoparticles due largely to macrophage heterogeneity. To address this issue, we sought to better define nanoparticle up-take using polarized M1 and M2 macrophages and novel TIPS-pentacene loaded PEO-PDLLA nanoparticles. Our data reveal that primary macrophages polarized to either M1 or M2 phenotypes have similar levels of nanoparticle phagocytosis. Similarly, M1 and M2 polarized macrophages isolated from the lungs of mice following either acute (Th1) or allergic (Th2) airway inflammation also demonstrated equivalent levels of nanoparticle up-take. Together, these studies provide critical benchmark information pertaining to cellular up-take dynamics and biodistribution of nanoparticles in the context of clinically relevant inflammatory microenvironments</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.nano.2016.12.015</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.nano.2016.12.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nanomedicine\2017-13-1255-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nanomedicine\2017-13-1255-66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, McDaniel DK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.nano.2016.12.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chan,Y.Y.</style></author><author><style face="normal" font="Arial"> Wang,P.</style></author><author><style face="normal" font="Arial"> Rogers,L.</style></author><author><style face="normal" font="Arial"> Tignor,N.</style></author><author><style face="normal" font="Arial"> Zweig,M.</style></author><author><style face="normal" font="Arial"> Hershman,S.G.</style></author><author><style face="normal" font="Arial"> Genes,N.</style></author><author><style face="normal" font="Arial"> Scott,E.R.</style></author><author><style face="normal" font="Arial"> Krock,E.</style></author><author><style face="normal" font="Arial"> Badgeley,M.</style></author><author><style face="normal" font="Arial"> Edgar,R.</style></author><author><style face="normal" font="Arial"> Violante,S.</style></author><author><style face="normal" font="Arial"> Wright,R.</style></author><author><style face="normal" font="Arial"> Powell,C.A.</style></author><author><style face="normal" font="Arial"> Dudley,J.T.</style></author><author><style face="normal" font="Arial"> Schadt,E.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">The Asthma Mobile Health Study, a large-scale clinical observational study using ResearchKit</style></title><secondary-title><style face="normal" font="Arial">Nat Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Biotechnol</style></full-title></periodical><pages end="362" start="354">354-362</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Security</style></keyword><keyword><style face="normal" font="Arial"> Selection Bias</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">The feasibility of using mobile health applications to conduct observational clinical studies requires rigorous validation. Here, we report initial findings from the Asthma Mobile Health Study, a research study, including recruitment, consent, and enrollment, conducted entirely remotely by smartphone. We achieved secure bidirectional data flow between investigators and 7,593 participants from across the United States, including many with severe asthma. Our platform enabled prospective collection of longitudinal, multidimensional data (e.g., surveys, devices, geolocation, and air quality) in a subset of users over the 6-month study period. Consistent trending and correlation of interrelated variables support the quality of data obtained via this method. We detected increased reporting of asthma symptoms in regions affected by heat, pollen, and wildfires. Potential challenges with this technology include selection bias, low retention rates, reporting bias, and data security. These issues require attention to realize the full potential of mobile platforms in research and patient care</style></abstract><notes><style face="normal" font="Arial">DA - 20170313IS - 1546-1696 (Electronic)IS - 1087-0156 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/nbt.3826</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28288104">PM:28288104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Biotechnol\2017-35-354-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Biotechnol\2017-35-354-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170313, Chan YY</style></custom2><misc3><style face="normal" font="Arial">10.1038/nbt.3826</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sharma,S.</style></author><author><style face="normal" font="Arial"> Rasal,V.P.</style></author><author><style face="normal" font="Arial"> Patil,P.A.</style></author><author><style face="normal" font="Arial"> Joshi,R.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pharmacology , KLE University, College of Pharmacy , Belagavi , India</style></auth-address><titles><title><style face="normal" font="Arial">Mentha arvensis essential oil suppressed airway changes induced by histamine and ovalbumin in experimental animals</style></title><secondary-title><style face="normal" font="Arial">Nat Prod Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Prod Res</style></full-title></periodical><pages end="472" start="468">468-472</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscles</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">The present investigation aimed to evaluate the activity of the essential oil of Mentha arvensis L. on exogenously induced bronchoconstriction in experimental animals. The anti-asthmatic effect of M. arvensis essential oil (MAEO) was studied using histamine aerosol-induced bronchoconstriction in guinea pigs and ovalbumin (OVA) sensitised albino mice. Treatment with M. arvensis oil significantly (p &lt; 0.001) increased the time of preconvulsive dyspnoea in histamine-induced guinea pigs. Oral treatment of MAEO significantly (p &lt; 0.001) decreased absolute eosinophil count, serum level of IgE and the number of eosinophils, neutrophils in BALF. Histopathological examination of lungs showed that essential oil rescinded bronchial asthma. The present investigation provides evidence that MAEO relaxes bronchial smooth muscles and suppressed immunological response to OVA</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 1478-6427 (Electronic)IS - 1478-6419 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1080/14786419.2017.1311891</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28385073">PM:28385073</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Prod Res\2018-32-468-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Prod Res\2018-32-468-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170407, Sharma S</style></custom2><misc3><style face="normal" font="Arial">10.1080/14786419.2017.1311891</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berends,M.A.</style></author><author><style face="normal" font="Arial"> Oude Elberink,J.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Rijksuniversiteit Groningen/Universitair Medisch Centrum Groningen, afd. Interne Geneeskunde, onderafdeling Allergologie, Groningen</style></auth-address><titles><title><style face="normal" font="Arial">The alpha-gal syndrome: an allergic reaction to mammalian meat secondary to a tick bite</style></title><secondary-title><style face="normal" font="Arial">Ned Tijdschr Geneeskd</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ned Tijdschr Geneeskd</style></full-title></periodical><pages end="" start="D1062">D1062-</pages><volume><style face="normal" font="Arial">161</style></volume><number><style face="normal" font="Arial">0</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Meat Products</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Here we present the case of a 68-year-old patient with alpha-gal syndrome. This is a delayed-onset allergic reaction, characteristically occurring 2-6 hours after ingestion of mammalian meat products. The reaction occurs because the patient has developed IgE antibodies to a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal); tick bites induce this IgE antibody response. Presentation varies from chronic urticaria to life-threatening anaphylaxis. The alpha-gal syndrome is usually self-limiting as long as there are no new tick bites. Clinicians should be aware of this syndrome, which is often not recognized as such</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1876-8784 (Electronic)IS - 0028-2162 (Linking)LA - dutPT - English AbstractPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294930">PM:28294930</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ned Tijdschr Geneeskd\2017-161-D1062.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ned Tijdschr Geneeskd\2017-161-D1062.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Berends MA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmer,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Paediatrics and Child Health, University of Western Australia, Princess Margaret Hospital, Subiaco, WA, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Update on Timing and Source of 'Allergenic' Foods</style></title><secondary-title><style face="normal" font="Arial">Nestle Nutr Inst Workshop Ser</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nestle Nutr Inst Workshop Ser</style></full-title></periodical><pages end="48" start="39">39-48</pages><volume><style face="normal" font="Arial">87</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">As the prevalence of food allergies in many communities continues to rise, the question of when in infancy to introduce any solid foods, or specific 'more allergenic' foods, as a food allergy prevention strategy has been debated. Observational studies have found that introducing any solid foods prior to 4 months of age was associated with an increased risk of allergic disease. Hence, the current allergy prevention consensus recommendation is that the introduction of any solid foods should commence after 4 months of age. Over recent years, several randomized controlled trials have been conducted to investigate the 'ideal' timing of introduction of some specific 'more allergenic' foods (including peanuts and eggs) into infant diets. To date, the results from three of these trials have determined that there is no reason to delay the introduction of the 'more allergenic' foods into the infant's diet after solid foods have commenced. However, these trials have also highlighted the finding that some infants are sensitized to food allergens before any known ingestion of solid foods. Thus, future research needs to focus on strategies to prevent early-life food allergen sensitization prior to complementary feeding</style></abstract><notes><style face="normal" font="Arial">DA - 20170319IS - 1664-2155 (Electronic)IS - 1664-2147 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1159/000448936</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315886">PM:28315886</url></web-urls></urls><custom2><style face="normal" font="Arial">20170319, Palmer DJ</style></custom2><misc3><style face="normal" font="Arial">10.1159/000448936</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Coghlan,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Virus triggers allergic reaction to gluten</style></title><secondary-title><style face="normal" font="Arial">New Scientist</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">New Scientist</style></full-title></periodical><pages end="" start="16">16-</pages><volume><style face="normal" font="Arial">234</style></volume><number><style face="normal" font="Arial">3121</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword></keywords><dates><year Day="15" Month="4" Year="2017">2017/4/15</year></dates><isbn><style face="normal" font="Arial">0262-4079</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0262-4079(17)30715-7</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/S0262-4079(17)30715-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\New Scientist\2017-234-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\New Scientist\2017-234-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170422, Coghlan A</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0262-4079(17)30715-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hosseini,B.</style></author><author><style face="normal" font="Arial"> Berthon,B.S.</style></author><author><style face="normal" font="Arial"> Wark,P.</style></author><author><style face="normal" font="Arial"> Wood,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Fruit and Vegetable Consumption on Risk of Asthma, Wheezing and Immune Responses: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="341">341-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Respiratory function</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="29" Month="3" Year="2017">2017/3/29</year></dates><abstract><style face="normal" font="Arial">Evidence suggests that reduced intake of fruit and vegetables may play a critical role in the development of asthma and allergies. The present review aimed to summarize the evidence for the association between fruit and vegetable intake, risk of asthma/wheeze and immune responses. Databases including PubMed, Cochrane, CINAHL and EMBASE were searched up to June 2016. Studies that investigated the effects of fruit and vegetable intake on risk of asthma/wheeze and immune responses were considered eligible (n = 58). Studies used cross-sectional (n = 30), cohort (n = 13), case-control (n = 8) and experimental (n = 7) designs. Most of the studies (n = 30) reported beneficial associations of fruit and vegetable consumption with risk of asthma and/or respiratory function, while eight studies found no significant relationship. Some studies (n = 20) reported mixed results, as they found a negative association between fruit only or vegetable only, and asthma. In addition, the meta-analyses in both adults and children showed inverse associations between fruit intake and risk of prevalent wheeze and asthma severity (p &lt; 0.05). Likewise, vegetable intake was negatively associated with risk of prevalent asthma (p &lt; 0.05). Seven studies examined immune responses in relation to fruit and vegetable intake in asthma, with n = 6 showing a protective effect against either systemic or airway inflammation. Fruit and vegetable consumption appears to be protective against asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170329IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9040341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28353635">PM:28353635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-341.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-341.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170329, Hosseini B</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9040341</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jonaid,B.S.</style></author><author><style face="normal" font="Arial"> Rooyackers,J.</style></author><author><style face="normal" font="Arial"> Stigter,E.</style></author><author><style face="normal" font="Arial"> Portengen,L.</style></author><author><style face="normal" font="Arial"> Krop,E.</style></author><author><style face="normal" font="Arial"> Heederik,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Predicting occupational asthma and rhinitis in bakery workers referred for clinical evaluation</style></title><secondary-title><style face="normal" font="Arial">Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> baker</style></keyword><keyword><style face="normal" font="Arial"> Baker's asthma</style></keyword><keyword><style face="normal" font="Arial"> Bakers</style></keyword><keyword><style face="normal" font="Arial"> Bakery</style></keyword><keyword><style face="normal" font="Arial"> Baking</style></keyword><keyword><style face="normal" font="Arial"> Calibration</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Self-administered questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Occupational allergic diseases are a major problem in some workplaces like in the baking industry. Diagnostic rules have been used in surveillance but not yet in the occupational respiratory clinic. OBJECTIVE: To develop diagnostic models predicting baker's asthma and rhinitis among bakery workers at high risk of sensitisation to bakery allergens referred to a specialised clinic. METHODS: As part of a medical surveillance programme, clinical evaluation was performed on 436 referred Dutch bakery workers at high risk for sensitisation to bakery allergens. Multivariable logistic regression analyses were developed to identify the predictors of onset of baker's asthma and rhinitis using a self-administered questionnaire and compared using a structured medical history. Performance of models was assessed by discrimination (area under the receiver operating characteristics curve) and calibration (Hosmer-Lemeshow test). Internal validity of the models was assessed by a bootstrapping procedure. RESULTS: The prediction models included the predictors of work-related upper and lower respiratory symptoms, the presence of allergy and allergic symptoms, use of medication (last year), type of job, type of shift and working years with symptoms (>/=10 years). The developed models derived from both self-administered questionnaire and the medical history showed a relatively good discrimination and calibration. The internal validity showed that the models developed had satisfactory discrimination. To improve calibrations of models, shrinkage factors were applied to model coefficients. CONCLUSION: The probability of allergic asthma and rhinitis in referred bakers could be estimated by diagnostic models based on both a self-administered questionnaire and by taking a structured medical history</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1470-7926 (Electronic)IS - 1351-0711 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1136/oemed-2016-103934</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28314756">PM:28314756</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Occup Environ Med\20170318-JonaidBS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Occup Environ Med\20170318-JonaidBS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Jonaid BS</style></custom2><misc3><style face="normal" font="Arial">10.1136/oemed-2016-103934</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lemaire,M.</style></author><author><style face="normal" font="Arial"> Oppliger,A.</style></author><author><style face="normal" font="Arial"> Hotz,P.</style></author><author><style face="normal" font="Arial"> Renauld,J.C.</style></author><author><style face="normal" font="Arial"> Braun,J.</style></author><author><style face="normal" font="Arial"> Maggi,M.</style></author><author><style face="normal" font="Arial"> Barresi,F.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Huaux,F.</style></author><author><style face="normal" font="Arial"> Dressel,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">de Duve Institute, Universite catholique de Louvain, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Can serum cytokine profile discriminate irritant-induced and allergen-induced symptoms? A cross-sectional study in workers mostly exposed to laboratory animals</style></title><secondary-title><style face="normal" font="Arial">Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug consumption</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-1</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hierarchical clustering</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritants</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> Laboratory animals</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> organic dust</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="4" Year="2017">2017/4/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In workers exposed mostly to laboratory animals (LA), symptoms may be due to irritants or allergens. Correct aetiological diagnosis is important for health surveillance. OBJECTIVES: This study aims to test whether work-related (WR) allergen-induced symptoms are associated with a cytokine profile distinct from that due to irritants. METHODS: In a cross-sectional study (n=114), WR respiratory and/or skin symptoms were assessed through a standardised clinical examination and sensitisation to rat and/or mouse allergen determined by serum immunoglobulin E. Serum cytokine concentrations were measured by multiplex assays. The predefined cytokine profiles 'sensitiser' (interleukin (IL)-4, IL-5, IL-13, eotaxin-1) and 'irritation' (IL-8, IL-17A, IL-17F, IL-22) were considered positive, when >/=3 concentrations exceeded the 95th percentile of the asymptomatic non-sensitised group. Results were examined by hierarchical clustering analyses (HCA) and multiple linear regression. Explorative analyses were carried out for nine additional cytokines. Exposure to allergens and endotoxin was assessed in a subpopulation. RESULTS: The prevalence of the profile 'irritation' was comparable in 28 symptomatic non-sensitised workers and 71 asymptomatic non-sensitised workers. HCA showed that nearly all symptomatic non-sensitised workers were gathered in two subclusters, characterised by high IL-17A levels, but different IL-8 levels. Multiple linear regression identified drug consumption and current complaints as confounders. Sensitised subjects were too few (n=14) for testing the profile 'sensitiser'. CONCLUSIONS: In this unselected population of LA workers, the profile 'irritation' did not prove to be a valuable health surveillance tool. Low power precluded assessment of the profile 'sensitiser'. The increased IL-17A concentration may originate from irritative constituents of organic dust</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1470-7926 (Electronic)IS - 1351-0711 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1136/oemed-2016-104137</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28416643">PM:28416643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Occup Environ Med\20170418-LemaireM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Occup Environ Med\20170418-LemaireM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Lemaire M</style></custom2><misc3><style face="normal" font="Arial">10.1136/oemed-2016-104137</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Menzel,M.</style></author><author><style face="normal" font="Arial"> Akbarshahi,H.</style></author><author><style face="normal" font="Arial"> Tufvesson,E.</style></author><author><style face="normal" font="Arial"> Persson,C.</style></author><author><style face="normal" font="Arial"> Bjermer,L.</style></author><author><style face="normal" font="Arial"> Uller,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Immunopharmacology, Department of Experimental Medical Science, Lund University, 22184 Lund, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Azithromycin augments rhinovirus-induced IFNbeta via cytosolic MDA5 in experimental models of asthma exacerbation</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> bronchial epithelium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferons</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> Viral Load</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="3" Year="2017">2017/3/18</year></dates><abstract><style face="normal" font="Arial">Deficient production of anti-viral interferons (IFNs) may be involved in causing viral-induced asthma exacerbations. Hence, drugs inducing lung IFN production would be warranted. Azithromycin may reduce asthma exacerbations but its modus operandi is unknown. Here, we investigated if azithromycin induces IFNbeta expression in vitro in rhinovirus-infected bronchial epithelial cells from asthmatic donors and in vivo in our allergic inflammation-based mouse model of viral stimulus-induced asthma exacerbations. Azithromycin dose-dependently augmented viral-induced IFNbeta expression in asthmatic, but not in healthy bronchial epithelial cells. The effect negatively correlated with viral load. Knockdown of MDA5 and RIG-I by siRNA showed involvement of MDA5 but not RIG-I in azithromycin's IFN-inducing effects in vitro. In vivo azithromycin induced IFNbeta protein, restoring a reduced lung IFN response exclusively in allergic exacerbating mice. This was associated with induction of interferon-stimulated genes and MDA5, but not RIG-I. We suggest that clinically relevant concentrations of azithromycin produce MDA5-dependent, anti-viral, IFN-inducing effects in bronchial epithelium distinctly from asthmatic donors. Similarly, azithromycin induced MDA5-associated IFN in virally stimulated lungs in vivo exclusively in allergic mice. Effects of azithromycin and MDA5-active drugs on viral-induced exacerbations deserve further research</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.16364</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28415826">PM:28415826</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170418-MenzelM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170418-MenzelM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Menzel M</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.16364</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feller,L.</style></author><author><style face="normal" font="Arial"> Wood,N.H.</style></author><author><style face="normal" font="Arial"> Khammissa,R.A.</style></author><author><style face="normal" font="Arial"> Lemmer,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Periodontology and Oral Medicine, Sefako Makgatho Health Sciences University, Pretoria, South Africa.</style></auth-address><titles><title><style face="normal" font="Arial">Review: allergic contact stomatitis</style></title><secondary-title><style face="normal" font="Arial">Oral Surg Oral Med Oral Pathol Oral Radiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oral Surg Oral Med Oral Pathol Oral Radiol</style></full-title></periodical><pages end="565" start="559">559-565</pages><volume><style face="normal" font="Arial">123</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metals</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral mucosa</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Stomatitis</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Allergic contact stomatitis (ACS) is an oral mucosal immunoinflammatory disorder variably characterized clinically by erythematous plaques, vesiculation, ulceration, and/or hyperkeratosis and by pain, burning sensation, or itchiness. ACS is brought about by a T cell-mediated, delayed hypersensitivity immune reaction generated by a second or subsequent contact exposure of an allergen with the oral mucosa, in a genetically susceptible, sensitized subject. Lichenoid contact reaction is a variant of ACS brought about by direct contact with the oral mucosa of certain metals in dental restorations. The features of ACS are neither clinically nor histopathologically specific, so the diagnosis is usually presumptive and can only be confirmed by resolution of the inflammation after withdrawal or removal of the suspected causative allergen. When ACS is suspected but an allergen cannot be identified, patch testing is necessary. In persistent cases, topical corticosteroids are the treatment of choice, but for severe and extensive lesions, systemic corticosteroid and systemic antihistamines may be indicated. In this short review, we highlight the clinical, immunologic, and histopathological features of ACS, and provide some guidelines for diagnosis and management</style></abstract><notes><style face="normal" font="Arial">DA - 20170414IS - 2212-4411 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.oooo.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28407984">PM:28407984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oral Surg Oral Med Oral Pathol Oral Radiol\2017-123-559-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oral Surg Oral Med Oral Pathol Oral Radiol\2017-123-559-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170414, Feller L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.oooo.2017.02.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Chalmers,R.J.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Ayme,S.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sirio Libanes, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Reaching multidisciplinary consensus on classification of anaphylaxis for the eleventh revision of the World Health Organization's (WHO) International Classification of Diseases (ICD-11)</style></title><secondary-title><style face="normal" font="Arial">Orphanet J Rare Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Orphanet J Rare Dis</style></full-title></periodical><pages end="" start="53">53-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> ICD</style></keyword><keyword><style face="normal" font="Arial"> ICD-11</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although currently misclassified in the International Classification of Diseases (ICD) and still not officially listed as a rare disease, anaphylaxis is a well-known clinical emergency. Anaphylaxis is now one of the principal headings in the "Allergic and hypersensitivity conditions" section recently compiled for the forthcoming 11th Revision of ICD (ICD-11). We here report the building process used for the pioneering "Anaphylaxis" subsection of ICD-11 in which we aimed for transparency as recommended in the ICD-11 revision guidelines. RESULTS: During an online intensive scientific and technical discussions with ICD-11 Topic Advisory Groups and Expert Working Groups, we drafted a total of 35 proposals for the classification of anaphylaxis. From all the 35 proposals, 77% were implemented, 20% remain to be implemented, and the others being partially implemented (1.5%) or rejected (1.5%). CONCLUSION: For the first time, anaphylaxis is now properly classified and has attained greater visibility within ICD. In addition to all the benefits expected from the actions we have undertaken in updating the terminology, definitions and classification of allergic and hypersensitivity conditions for ICD-11, we strongly believe that anaphylaxis should be a public health priority and that it should therefore be formally added into the list of rare diseases in order to support awareness and quality clinical management of patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 1750-1172 (Electronic)IS - 1750-1172 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - France -CO - United KIngdom -</style></notes><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28302183">PM:28302183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Orphanet J Rare Dis\2017-12-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Orphanet J Rare Dis\2017-12-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Tanno LK</style></custom2></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>83999</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Ruiter,K.</style></author><author><style face="normal" font="Arial"> Tahapary,D.L.</style></author><author><style face="normal" font="Arial"> Wammes,L.</style></author><author><style face="normal" font="Arial"> Wiria,A.E.</style></author><author><style face="normal" font="Arial"> Hamid,F.</style></author><author><style face="normal" font="Arial"> van Lieshout,L.</style></author><author><style face="normal" font="Arial"> Smit,J.W.</style></author><author><style face="normal" font="Arial"> Houwing-Duistermaat,J.J.</style></author><author><style face="normal" font="Arial"> Sartono,E.</style></author><author><style face="normal" font="Arial"> Supali,T.</style></author><author><style face="normal" font="Arial"> Yazdanbakhsh,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">The effect of three-monthly albendazole treatment on Th2 responses: Differential effects on IgE and IL-5</style></title><secondary-title><style face="normal" font="Arial">Parasite Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasite Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Albendazole</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Indonesia</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> PHA</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">Helminth parasites induce a strong Th2 response, characterized by high levels of IgE and elevated signature cytokines such as IL-5. As many global deworming programs are underway, there is concern that this might lead to emergence of Th1-mediated pathologies when the counterbalancing helminth-induced Th2 response is absent. Therefore, we assessed the effect of deworming on Th2 mediated responses in a household-clustered randomised controlled trial in Indonesia. Total plasma IgE and whole-blood IL-5 responses to mitogen phytohaemagglutinin (PHA) were measured in 1494 and 682 subjects respectively, at baseline, 9 and 21 months after three-monthly single dose treatment with albendazole or placebo. Anthelmintic treatment did not result in complete removal of helminth infections in the community. However, treatment significantly decreased IgE levels in albendazole compared to placebo-treated subjects. IL-5 responses to PHA were not significantly affected by anthelmintic treatment and tended to increase in albendazole-treated subjects, indicating that intensive treatment of helminth parasites has different outcomes on B cell (IgE levels) and T cell (IL-5) responses. The data shows that two years of deworming can have differential effects on responses typified as Th2 mediated, which needs to be taken into account when examining the impact of helminths on non-communicable diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1365-3024 (Electronic)IS - 0141-9838 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Indonesia -</style></notes><work-type><style face="normal" font="Arial">10.1111/pim.12428</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28370210">PM:28370210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasite Immunol\20170403-deRuiterK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasite Immunol\20170403-deRuiterK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, de Ruiter K</style></custom2><misc3><style face="normal" font="Arial">10.1111/pim.12428</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84000</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Norquist,J.</style></author><author><style face="normal" font="Arial"> Flood,E.</style></author><author><style face="normal" font="Arial"> Tanzosh,T.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author><author><style face="normal" font="Arial"> Iskold,B.</style></author><author><style face="normal" font="Arial"> Ganser,T.R.</style></author><author><style face="normal" font="Arial"> Marson-Smith,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Merck Research Laboratories, Merck Sharp &amp; Dohme, Corp., North Wales, PA, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Development of a Report Card for Identifying Local Sublingual Immunotherapy Events in Clinical Trials</style></title><secondary-title><style face="normal" font="Arial">Patient</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Patient</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Ulcer</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The sublingual immunotherapy (SLIT) Report Card was developed to capture patient-reported local reactions from the administration of SLIT, based on the World Allergy Organization side-effect grading system. The objective was to evaluate understandability, usability, and translatability of the paper and electronic versions of the SLIT Report Card. METHODS: Adults (aged 18+ years), adolescents (aged 12-17 years), and parents/caregivers and their children (aged 5-11 years) participated in two rounds of interviews, testing the paper version in Round 1, and both the paper and electronic versions in Round 2. Interviews assessed comprehension and usability by subjects. Translatability identified potential issues related to translation or cultural relevance. RESULTS: Ten adults, ten adolescents, and ten parent/child dyads were interviewed. In general, subjects demonstrated a clear understanding of the instrument's content. However, some subjects were uncertain of or suggested clarifying the meaning of certain terms, including tablet, ulcer, taste alteration, uvula, nausea, and itching in the ear. The translatability assessment also identified uvula and nausea as potentially problematic for translation. Subjects could use the electronic device and found navigation 'easy', with only a few minor suggestions made to improve usability. Some wording and formatting changes were made based on subjects' feedback and the translatability assessment. CONCLUSION: The SLIT Report Card was refined following best practices for instrument development, including cognitive interviewing, usability, and translatability assessment. The refined SLIT Report Card is appropriate for comprehensively and systematically collecting SLIT-related local reactions directly from subjects in a clinical trial setting, taking into account the World Allergy Organization grading system</style></abstract><notes><style face="normal" font="Arial">DA - 20170205IS - 1178-1661 (Electronic)IS - 1178-1653 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40271-017-0217-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161735">PM:28161735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Patient\20170205-NorquistJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Patient\20170205-NorquistJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170205, Norquist J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40271-017-0217-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kosse,R.C.</style></author><author><style face="normal" font="Arial"> Bouvy,M.L.</style></author><author><style face="normal" font="Arial"> de Vries,T.W.</style></author><author><style face="normal" font="Arial"> Kaptein,A.A.</style></author><author><style face="normal" font="Arial"> Geers,H.C.</style></author><author><style face="normal" font="Arial"> van Dijk,L.</style></author><author><style face="normal" font="Arial"> Koster,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht</style></auth-address><titles><title><style face="normal" font="Arial">mHealth intervention to support asthma self-management in adolescents: the ADAPT study</style></title><secondary-title><style face="normal" font="Arial">Patient Prefer Adherence</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Patient Prefer Adherence</style></full-title></periodical><pages end="577" start="571">571-577</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Chat</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> medication adherence</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Pharmacoepidemiology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Poor medication adherence in adolescents with asthma results in poorly controlled disease and increased morbidity. The aim of the ADolescent Adherence Patient Tool (ADAPT) study is to develop an mHealth intervention to support self-management and to evaluate the effectiveness in improving medication adherence and asthma control. INTERVENTION: The ADAPT intervention consists of an interactive smartphone application (app) connected to a desktop application for health care providers, in this study, the community pharmacist. The app contains several functions to improve adherence as follows: 1) a questionnaire function to rate asthma symptoms and monitor these over time; 2) short movie clips with medication and disease information; 3) a medication reminder; 4) a chat function with peers; and 5) a chat function with the pharmacist. The pharmacist receives data from the patient's app through the desktop application, which enables the pharmacist to send information and feedback to the patient. STUDY DESIGN: The ADAPT intervention is tested in a community pharmacy-based cluster randomized controlled trial in the Netherlands, aiming to include 352 adolescents with asthma. The main outcome is adherence, measured by patient's self-report and refill adherence calculated from pharmacy dispensing records. In addition, asthma control, illness perceptions, medication beliefs, and asthma-related quality of life are measured. CONCLUSION: This study will provide in-depth knowledge on the effectiveness of an mHealth intervention to support asthma self-management in adolescents. These insights will also be useful for adolescents with other chronic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170330IS - 1177-889X (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.2147/PPA.S124615</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28356720">PM:28356720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Patient Prefer Adherence\2017-11-571-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Patient Prefer Adherence\2017-11-571-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170330, Kosse RC</style></custom2><misc3><style face="normal" font="Arial">10.2147/PPA.S124615</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pecora,V.</style></author><author><style face="normal" font="Arial"> Prencipe,G.</style></author><author><style face="normal" font="Arial"> Valluzzi,R.</style></author><author><style face="normal" font="Arial"> Dahdah,L.</style></author><author><style face="normal" font="Arial"> Insalaco,A.</style></author><author><style face="normal" font="Arial"> Cianferoni,A.</style></author><author><style face="normal" font="Arial"> De Benedetti,F.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, IRCCS Ospedale Pediatrico Bambino Gesu, Rome</style></auth-address><titles><title><style face="normal" font="Arial">Inflammatory events during Food Protein-Induced Enterocolitis Syndrome reactions</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="470" start="464">464-470</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An increasing number of infants are diagnosed with food protein induced enterocolitis syndrome (FPIES), a non-IgE-mediated food allergy. Until now, T-cell, food-specific mechanisms have been hypothesized. METHODS: 16 children (11M, 5F), affected by FPIES from cow's milk, wheat, fruit, rice and others, experienced 25 acute episodes managed at our Emergency Department (ED) and eight FPIES reactions during oral food challenges (OFC). We compared the laboratory data in resting conditions, in absence of infectious diseases, with data collected during the 25 acute ED episodes (blood samples drawn at 2 to 12 hours) and the eight positive OFCs (three samples at 2, 6 and 12 hours). The onset of symptoms was used as a reference time-point. RESULTS: In basal conditions, total IgE, WBC, neutrophil and eosinophil count, CRP, and SGPT were found normal. LDH and SGOT values were high (627.81 +/- 97.88 and 45.75 +/- 10.26 UI/L, respectively). During ED reactions LDH and SGOT increased to 794.21 +/- 247.28 (p=0.028) and 51.08 +/- 16.99 UI/L (p=0.14), neutrophils count and CRP to 8.44 +/- 3.82 x 103 /muL (p=0.0009) and 3.27 +/- 5.73 mg/dL (p=0.0014) respectively. During positive OFC, LDH and SGOT did not vary significantly; CRP increased from 0.14 +/- 0.18 to 2.49 +/- 3.65 mg/dL (p=0.00189) and neutrophil count from 2.79 +/- 1.42 to 7.10 +/- 3.98 x 103 /muL (p=0.00096). CONCLUSIONS: FPIES reactions are characterized by neutrophilia and by a time-dependent, significant increase of CRP, indicating that inflammatory mechanisms are in place. This suggests new directions for research on FPIES pathogenesis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12723</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28375580">PM:28375580</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170404-PecoraV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170404-PecoraV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Pecora V</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12723</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Atkins,D.</style></author><author><style face="normal" font="Arial"> Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Liacouras,C.A.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Gastrointestinal Eosinophilic Diseases Program, Children's Hospital Colorado, Aurora, CO, 80045</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Oesophagitis phenotypes: Ready for primetime?</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="319" start="312">312-319</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietary therapy</style></keyword><keyword><style face="normal" font="Arial"> Dilation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysphagia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> molecular signature</style></keyword><keyword><style face="normal" font="Arial"> Oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Translational research</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">Eosinophilic Oesophagitis (EoE) is one of the most common causes of reflux like symptoms and feeding problems in children and food impaction and dysphagia in adults with a prevalence of 1:2500. Therapeutic options include diet, use of swallowed corticosteroids or dilation. In the last several years, recent clinical and translational research have identified some common and distinctive features, for example, the varying response to diet and medications. As EoE shares some characteristics with both asthma and inflammatory bowel disease, the advances in these fields suggests that various phenotypes may also exist in patients with EoE. Here we provide a rationale for EoE phenotypes and provide some suggestions for potential phenotypes based on histology, molecular signature, response to therapy or dietary therapy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12715</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28339136">PM:28339136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170324-AtkinsD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170324-AtkinsD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Atkins D</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12715</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camarca,A.</style></author><author><style face="normal" font="Arial"> Auricchio,R.</style></author><author><style face="normal" font="Arial"> Picascia,S.</style></author><author><style face="normal" font="Arial"> Fierro,O.</style></author><author><style face="normal" font="Arial"> Maglio,M.</style></author><author><style face="normal" font="Arial"> Miele,E.</style></author><author><style face="normal" font="Arial"> Malamisura,B.</style></author><author><style face="normal" font="Arial"> Greco,L.</style></author><author><style face="normal" font="Arial"> Troncone,R.</style></author><author><style face="normal" font="Arial"> Gianfrani,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Food Sciences, National Research Council, Avellino, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Gliadin-reactive T cells in Italian Children from PreventCD Cohort at High Risk for Celiac Disease</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="369" start="362">362-369</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Deamidation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Intestinal biopsy</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell reactivity</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Newborns at high risk for celiac disease (CD) were recruited in Italy in the context of the PreventCD Study and closely monitored for CD, from 4 months up to a mean age of 8 years at follow-up. The aim of our study was to investigate intestinal T cell reactivity to gliadin at the first clinical and/or serological signs of CD. METHODS: Gliadin-reactive T cell lines were generated from intestinal biopsies of 19 HLA-DQ2 or HLA-DQ8 positive children. At biopsy, 11 children had a diagnosis of acute CD, two of potential CD, and six were non-celiac controls. Immune reactivity was evaluated against gliadin and known immunogenic peptides from alpha-, gamma- or omega-gliadins. The role of deamidation by transglutaminase (tTG) in determining the immunogenicity of gliadin was also investigated. RESULTS: Most of the children with CD (either acute or potential) had an inflammatory response to gliadin. Notably, signs of T cell reactivity to gliadin were also found in some non-celiac subjects, in which IFN-gamma responses occurred mainly when regulatory IL-10 and TGF-beta cytokines were blocked. Interestingly, PreventCD children reacted to gliadin peptides found active in adult CD patients, and tTG-deamidation markedly enhanced gliadin recognition. CONCLUSIONS: T cells reactive to gliadin can be detected in the intestine of children at high risk of developing CD, in some cases also in the presence of a normal mucosa and negative CD-associated antibodies. Furthermore, children at a very early stage of CD recognize the same gliadin epitopes that are active in adult CD patients. Tissue transglutaminase strongly enhances gluten T cell immunogenicity in early CD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12720</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28339124">PM:28339124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170324-CamarcaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170324-CamarcaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Camarca A</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12720</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Egan,M.</style></author><author><style face="normal" font="Arial"> Lee,T.</style></author><author><style face="normal" font="Arial"> Andrade,J.</style></author><author><style face="normal" font="Arial"> Grishina,G.</style></author><author><style face="normal" font="Arial"> Mishoe,M.</style></author><author><style face="normal" font="Arial"> Gimenez,G.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Bunyavanich,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Pediatric Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, Aurora, CO, USA</style></auth-address><titles><title><style face="normal" font="Arial">Partially Hydrolyzed Whey Formula Intolerance in Cow's Milk Allergic Patients</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="405" start="401">401-405</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">Cow's milk allergy (CMA) is one of the most common food allergies in young children, affecting 2-3% of the pediatric population (1). Hypoallergenic formula is recommended for infants with CMA who are not breastfeeding (2). Extensively hydrolyzed or amino acid-based formulas are tolerated in over 90% of infants with CMA(2). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12718</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28339130">PM:28339130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170324-EganM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170324-EganM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Egan M</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12718</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lule,S.A.</style></author><author><style face="normal" font="Arial"> Mpairwe,H.</style></author><author><style face="normal" font="Arial"> Nampijja,M.</style></author><author><style face="normal" font="Arial"> Akello,F.</style></author><author><style face="normal" font="Arial"> Kabagenyi,J.</style></author><author><style face="normal" font="Arial"> Namara,B.</style></author><author><style face="normal" font="Arial"> Nkurunungi,G.</style></author><author><style face="normal" font="Arial"> Kizito,D.</style></author><author><style face="normal" font="Arial"> Kahwa,J.</style></author><author><style face="normal" font="Arial"> Muhangi,L.</style></author><author><style face="normal" font="Arial"> Nash,S.</style></author><author><style face="normal" font="Arial"> Muwanga,M.</style></author><author><style face="normal" font="Arial"> Webb,E.L.</style></author><author><style face="normal" font="Arial"> Elliott,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK</style></auth-address><titles><title><style face="normal" font="Arial">Life-course of atopy and allergy-related disease events in tropical sub-Saharan Africa: a birth cohort study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="383" start="377">377-383</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> life course</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Sub-Saharan Africa</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Uganda</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In high-income countries, allergy related-diseases (ARDs) follow a typical sequence, the "Atopic March". Little is known about the life-course of ARDs in the markedly different, low-income, tropical environment. We describe ARDs in a tropical, African birth cohort. METHODS: Ugandan children were followed from birth to nine years. ISAAC questionnaires were completed at intervals; doctor-diagnosed ARDs were recorded throughout follow-up. Skin prick tests (SPTs) were done at three and nine years. Atopy was defined as >/=1 positive SPT. RESULTS: Of 2345 live-born children, 1214 (52%) were seen at nine years. Wheeze and eczema were common in infancy but by nine years only 4% reported recent wheeze, 5% eczema and 5% rhinitis. Between three and nine years, atopy prevalence increased from 19% to 25%. Atopy at three or nine years was associated with reported ARD events at nine years, for example OR=5.2 (95% CI 2.9-10.7) for atopy and recent wheeze at nine years. Reported or doctor-diagnosed ARD events in early childhood were associated with the same events in later childhood, for example OR=4.4 (2.3-8.4) for the association between reported wheeze before three years with reported recent wheeze at nine years, but progression from early eczema to later rhinitis or asthma was not observed. CONCLUSION: Allergen sensitisation started early in childhood and increased with age. Eczema and wheeze were common in infancy and declined with age. Atopy was strongly associated with ARD among the few affected children. The typical Atopic March did not occur. Environmental exposures during childhood may dissociate atopy and ARD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Uganda -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12719</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28339128">PM:28339128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170324-LuleSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170324-LuleSA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Lule SA</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12719</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nosan,G.</style></author><author><style face="normal" font="Arial"> Jakic,M.</style></author><author><style face="normal" font="Arial"> Jager,M.</style></author><author><style face="normal" font="Arial"> Paro-Panjan,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatrics, Department of Neonatology, University Medical Centre Ljubljana, Ljubljana, Slovenia</style></auth-address><titles><title><style face="normal" font="Arial">Prognostic Accuracy of Clinical Signs and Diagnostic Tests in Cow's Milk Allergy in Newborns</style></title><secondary-title><style face="normal" font="Arial">Pediatr Neonatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Pediatr Neonatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exanthema</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Slovenia</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The aim of the study was to explore the correlation between clinical signs and confirmatory tests for cow's milk allergy (CMA) in the neonatal period and their relation to family history and the occurrence of food allergies in the postneonatal period. METHODS: The medical documentation of 361 newborns with suspected CMA and exclusion of other comorbidities was analyzed. The correlations between clinical signs and methods to confirm CMA [elevated levels of total immunoglobulin E (IgE) and/or specific IgE for cow's milk, improvement after the introduction of a cow's milk-free diet and positive challenge procedure] were studied. In 90 children, the data were additionally analyzed in relation to outcome (at the age of 1-11 years), evaluated by questionnaires, which inquired about signs and symptoms of food allergy, methods of CMA confirmation, and the presence of other food allergies. RESULTS: There was a positive correlation between exanthema and confirmed CMA in the neonatal period (R = 0.184; p = &lt;0.001; n = 361), and hematochezia and confirmed CMA in the neonatal (R = 0.203; p &lt; 0.001; n = 361) and postneonatal period (R = 0.215; p = 0.042; n = 90). Additional food allergies in the postneonatal period were positively correlated with neonatal CMA (R = 0.275; p = 0.009; n = 90). No correlation was found between a positive family history of food allergies and CMA in the neonatal (R = -0.66; p = 0.398; n = 165) and postneonatal periods (R = 0.00; p = 1.000; n = 116). CONCLUSION: Neonatal exanthema and hematochezia were the predominant clinical signs in neonates with CMA. Allergies to other food allergens appeared more frequently in children with CMA in the neonatal period. Neonatal CMA did not occur more frequently in families with food allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 2212-1692 (Electronic)IS - 1875-9572 (Linking)LA - engPT - Journal ArticleCO - Slovenia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pedneo.2016.09.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28416249">PM:28416249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Neonatol\20170418-NosanG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Neonatol\20170418-NosanG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Nosan G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pedneo.2016.09.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rasmussen,K.</style></author><author><style face="normal" font="Arial"> Thyrring,J.</style></author><author><style face="normal" font="Arial"> Muscarella,R.</style></author><author><style face="normal" font="Arial"> Borchsenius,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section for Ecoinformatics &amp; Biodiversity, Department of Bioscience, Aarhus University, Aarhus C, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Climate-change-induced range shifts of three allergenic ragweeds (Ambrosia L.) in Europe and their potential impact on human health</style></title><secondary-title><style face="normal" font="Arial">PeerJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PeerJ</style></full-title></periodical><pages end="" start="e3104">e3104-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plant</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Habitat</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Invasive allergenic plant species may have severe health-related impacts. In this study we aim to predict the effects of climate change on the distribution of three allergenic ragweed species (Ambrosia spp.) in Europe and discuss the potential associated health impact. We built species distribution models based on presence-only data for three ragweed species, using MAXENT software. Future climatic habitat suitability was modeled under two IPCC climate change scenarios (RCP 6.0 and RCP 8.5). We quantify the extent of the increase in 'high allergy risk' (HAR) areas, i.e., parts of Europe with climatic conditions corresponding to the highest quartile (25%) of present day habitat suitability for each of the three species. We estimate that by year 2100, the distribution range of all three ragweed species increases towards Northern and Eastern Europe under all climate scenarios. HAR areas will expand in Europe by 27-100%, depending on species and climate scenario. Novel HAR areas will occur mostly in Denmark, France, Germany, Russia and the Baltic countries, and overlap with densely populated cities such as Paris and St. Petersburg. We conclude that areas in Europe affected by severe ragweed associated allergy problems are likely to increase substantially by year 2100, affecting millions of people. To avoid this, management strategies must be developed that restrict ragweed dispersal and establishment of new populations. Precautionary efforts should limit the spread of ragweed seeds and reduce existing populations. Only by applying cross-countries management plans can managers mitigate future health risks and economical consequences of a ragweed expansion in Europe</style></abstract><notes><style face="normal" font="Arial">DA - 20170321LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.7717/peerj.3104</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28321366">PM:28321366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PeerJ\2017-5-e3104.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PeerJ\2017-5-e3104.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170321, Rasmussen K</style></custom2><misc3><style face="normal" font="Arial">10.7717/peerj.3104</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Desai,S.H.</style></author><author><style face="normal" font="Arial"> Kaplan,M.S.</style></author><author><style face="normal" font="Arial"> Chen,Q.</style></author><author><style face="normal" font="Arial"> Macy,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fellow-In-Training in the Allergy Department of the Los Angeles Medical Center in CA.</style></auth-address><titles><title><style face="normal" font="Arial">Morbidity in Pregnant Women Associated with Unverified Penicillin Allergies, Antibiotic Use, and Group B Streptococcus Infections</style></title><secondary-title><style face="normal" font="Arial">Perm J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Perm J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">21</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> cesarean</style></keyword><keyword><style face="normal" font="Arial"> Cesarean Section</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> Clostridium difficile</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> penicillin</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">CONTEXT: The morbidity potentially associated with unverified penicillin allergy in pregnant women, with and without group B streptococcus (GBS) infections, is unknown. Penicillin allergy testing is safe during pregnancy but is done infrequently. OBJECTIVE: To determine morbidity associated with antibiotic use in a large cohort of pregnant women, with and without an unverified history of penicillin allergy, and with and without GBS. DESIGN: Retrospective. All pregnant women who delivered live infants in Kaiser Permanente Southern California between January 1, 2009, and December 31, 2014, were identified. MAIN OUTCOME MEASURES: Penicillin allergy status at delivery, delivery method, maternal and infant hospital utilization, peripartum antibiotic exposures, new antibiotic-associated adverse drug reactions, and new Clostridium difficile infections. RESULTS: There were 170,379 unique women who had 201,316 pregnancies during the study period. There were 16,084 pregnancies in women with an active, but unverified, penicillin allergy at delivery. There were 42,524 pregnancies in GBS-positive women, and 3500 also had a penicillin allergy. Women with a penicillin allergy, with or without GBS, had significantly (about 10%) higher cesarean section rates and spent significantly more (about 0.1) days in the hospital after delivery. Among GBS-positive women, those with an unverified penicillin allergy were exposed to significantly more cefazolin, clindamycin, vancomycin, and gentamicin and had significantly higher rates of adverse drug reactions associated with all antibiotic use. CONCLUSIONS: Unverified penicillin allergy is associated with more hospital utilization and additional morbidity. Penicillin allergy testing of pregnant women with a history of penicillin allergy may help reduce these unwanted outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1552-5775 (Electronic)IS - 1552-5767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.7812/TPP/16-080</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28333608">PM:28333608</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Perm J\20170323-DesaiSH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Perm J\20170323-DesaiSH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Desai SH</style></custom2><misc3><style face="normal" font="Arial">10.7812/TPP/16-080</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zemmouri,H.</style></author><author><style face="normal" font="Arial"> Sekiou,O.</style></author><author><style face="normal" font="Arial"> Ammar,S.</style></author><author><style face="normal" font="Arial"> El Feki,A.</style></author><author><style face="normal" font="Arial"> Bouaziz,M.</style></author><author><style face="normal" font="Arial"> Messarah,M.</style></author><author><style face="normal" font="Arial"> Boumendjel,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Laboratory of Biochemistry and Environmental Toxicology , Department of Biochemistry, Faculty of Sciences, University of Badji Mokhtar , Annaba , Algeria</style></auth-address><titles><title><style face="normal" font="Arial">Urtica dioica attenuates ovalbumin-induced inflammation and lipid peroxidation of lung tissues in rat asthma model</style></title><secondary-title><style face="normal" font="Arial">Pharm Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharm Biol</style></full-title></periodical><pages end="1568" start="1561">1561-1568</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Algeria</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Erythrocytes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Herbs</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid peroxidation</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urtica</style></keyword><keyword><style face="normal" font="Arial"> Urticaceae</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">CONTEXT: To find bioactive medicinal herbs exerting anti-asthmatic activity, we investigated the effect of an aqueous extract of Urtica dioica L. (Urticaceae) leaves (UD), the closest extract to the Algerian traditional use. OBJECTIVE: In this study, we investigated the in vivo anti-asthmatic and antioxidant activities of nettle extract. MATERIALS AND METHODS: Adult male Wistar rats were divided into four groups: Group I: negative control; group II: Ovalbumin sensitized/challenged rats (positive control); group III: received UD extract (1.5 g/kg/day) orally along the experimental protocol; group IV: received UD extract (1.5 g/kg/day) orally along the experimental protocol and sensitized/challenged with ovalbumin. After 25 days, blood and tissue samples were collected for haematological and histopathological analysis, respectively. The oxidative stress parameters were evaluated in the lungs, liver and erythrocytes. Then, correlations between markers of airway inflammation and markers of oxidative stress were explored. RESULTS: UD extract significantly (p &lt; 0.01) inhibited eosinophilia increases in BALF (-60%) and the levels of leucocytes (-32.75%) and lymphocytes (-29.22%) in serum, and effectively suppressed inflammatory cells recruitment in the asthmatic rat model. Besides, the lipid peroxidation generated by allergen administration was significantly (p &lt; 0.05) diminished by UD treatment in lung tissue (-48.58%). The nettle extract was also investigated for the total phenolic content (30.79 +/- 0.96 mg gallic acid/g dry extract) and shows DPPH radical scavenging activity with 152.34 +/- 0.37 mug/mL IC50 value. CONCLUSIONS: The results confirmed that UD administration might be responsible for the protective effects of this extract against airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 1744-5116 (Electronic)IS - 1388-0209 (Linking)LA - engPT - Journal ArticleCO - Algeria -CO - Tunisia -</style></notes><work-type><style face="normal" font="Arial">10.1080/13880209.2017.1310905</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28385108">PM:28385108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharm Biol\2017-55-1561-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharm Biol\2017-55-1561-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170407, Zemmouri H</style></custom2><misc3><style face="normal" font="Arial">10.1080/13880209.2017.1310905</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nam,J.H.</style></author><author><style face="normal" font="Arial"> Jung,H.W.</style></author><author><style face="normal" font="Arial"> Chin,Y.W.</style></author><author><style face="normal" font="Arial"> Yang,W.M.</style></author><author><style face="normal" font="Arial"> Bae,H.S.</style></author><author><style face="normal" font="Arial"> Kim,W.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Physiology , Dongguk University College of Medicine , Gyeongju , Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Spirodela polyrhiza extract modulates the activation of atopic dermatitis-related ion channels, Orai1 and TRPV3, and inhibits mast cell degranulation</style></title><secondary-title><style face="normal" font="Arial">Pharm Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharm Biol</style></full-title></periodical><pages end="1329" start="1324">1324-1329</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Araceae</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="Arial"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="Arial"> drug effects</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hek293 Cells</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Ion Channels</style></keyword><keyword><style face="normal" font="Arial"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Methanol</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> ORAI1 Protein</style></keyword><keyword><style face="normal" font="Arial"> Patch-Clamp Techniques</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Extracts</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TRPV Cation Channels</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">CONTEXT: Spirodela polyrhiza (L.) Schleid. (Lemnaceae), Spirodelae Herba (SH), has been known to relieve inflammation, urticaria and skin symptoms including pruritus, eczema and rash. OBJECTIVE: The effects of SH extract on two calcium ion channels, Orai1 and TRPV3, and their potential as novel therapeutics for atopic dermatitis (AD) were investigated. The regulatory role of Orai1 on mast cell degranulation was evaluated. MATERIALS AND METHODS: The dried leaves of SH were extracted by 70% methanol. Effects of SH extract (100 mug/mL) in an HEK293T cell line overexpressing human Orai1 or TRPV3 were assessed. Ion channel modulation in transfected HEK293T cells was measured using a conventional whole-cell patch-clamp technique. IgE-antigen complex-stimulated mast cell degranulation was measured by beta-hexosaminidase assay with morphological observation after treatment with 20, 50 and 100 mug/mL SH extract. RESULTS: SH extract (100 mug/mL) significantly inhibited Orai1 activity (63.8 +/- 0.97%) in Orai1-STIM1 co-overexpressed HEK293T cells. SH extract significantly increased TRPV3 activity (81.29 +/- 0.05% at -100 mV) compared with the positive control 2-APB (100 muM), which induced full activation. SH extract inhibited degranulation in IgE-antigen complex-stimulated RBL-2H3 mast cells by decreasing beta-hexosaminidase activity (3.14 +/- 0.03, 2.56 +/- 0.12 and 2.29 +/- 0.08 mU/mg, respectively). CONCLUSION: Our results suggested that SH extract could treat abnormal skin barrier pathologies in AD through modulation of the activities of the calcium ion channels Orai1 and TRPV3 and inhibition of mast cell degranulation. This is the first report of an herbal effect on the modulation of ion channels associated with skin barrier disruption in AD pathogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20170314IS - 1744-5116 (Electronic)IS - 1388-0209 (Linking)LA - engPT - Journal ArticleRN - 0 (ORAI1 Protein)RN - 0 (ORAI1 protein, human)RN - 0 (Plant Extracts)RN - 0 (TRPV Cation Channels)RN - 0 (TRPV3 protein, human)SB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1080/13880209.2017.1300819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290212">PM:28290212</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharm Biol\2017-55-1324-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharm Biol\2017-55-1324-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170314, Nam JH</style></custom2><misc3><style face="normal" font="Arial">10.1080/13880209.2017.1300819</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maguire,A.</style></author><author><style face="normal" font="Arial"> Johnson,M.E.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author><author><style face="normal" font="Arial"> Ferreira,G.L.</style></author><author><style face="normal" font="Arial"> Cassidy,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">OXON Epidemiology Ltd, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Identifying rare diseases using electronic medical records: the example of allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Pharmacoepidemiol Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharmacoepidemiol Drug Saf</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Feasibility Studies</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The purpose of the study is to evaluate whether primary care electronic medical records (EMRs) from patients with severe asthma can be used to identify allergic bronchopulmonary aspergillosis (ABPA) cases. METHODS: This cross-sectional feasibility study was conducted in adults with active and severe asthma registered with the Clinical Practice Research Datalink. A set of keywords flagged terms potentially indicative of ABPA in free-text comments of patients' EMRs to produce a grid on the basis of keywords' hit or miss. The grid was examined for occurrence and concurrence of keywords to discern patterns of concurrence potentially indicative of an underlying diagnosis of ABPA. RESULTS: The analyses included 3 653 169 free-text items from 21 054 patients. In total, 52 patients (0.25%) had at least one mention of 'ABPA' in their medical record; 67% of these patients also had a mention of 'aspergillus/aspergillosis', 54% of 'bronchiectasis', 42% of 'itraconazole' and 62% of 'IgE'. The term 'aspergillus/aspergillosis' occurred with a proportion of 1.84% (N = 387); 9% of these patients also had a mention of 'ABPA', and the remaining 91% were potential additional cases of ABPA. From the observed concurrence of keywords, we were able to devise a potential algorithm to identify cases with varying degrees of specificity. CONCLUSIONS: This study suggests that analysis of free text within asthmatic patients' EMRs may be used to identify potential cases of ABPA. This could be an efficient approach to identify rare conditions and to quantify their potential burden. Copyright (c) 2017 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1099-1557 (Electronic)IS - 1053-8569 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Spain -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1002/pds.4204</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28370596">PM:28370596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharmacoepidemiol Drug Saf\20170403-MaguireA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharmacoepidemiol Drug Saf\20170403-MaguireA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Maguire A</style></custom2><misc3><style face="normal" font="Arial">10.1002/pds.4204</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Buzzacott,P.</style></author><author><style face="normal" font="Arial"> Dolen,W.K.</style></author><author><style face="normal" font="Arial"> Chimiak,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Divers Alert Network, Durham, North Carolina</style></auth-address><titles><title><style face="normal" font="Arial">Case report: acute facial swelling in a recreational technical diver</style></title><secondary-title><style face="normal" font="Arial">Physiol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Physiol Rep</style></full-title></periodical><pages end="" start="e13240">e13240-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Ethylene</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">A recreational scuba diver wore a second scuba regulator against his face during a scuba dive, attached by an elastic rubber cord necklace. After surfacing, the diver's left face became swollen. Through a process of elimination all other items of scuba equipment were excluded as potential causes. A dive with the same equipment minus the necklace confirmed the involvement of the necklace in the pathogenesis of the hypersensitive reaction. In vitro ImmunoCap IgE assay was positive to latex (1.30 kUa/L), subsequent patch testing for contact dermatitis provoked a reaction for benzophenone-4, (a UV stabalizer) and Fourier Transform Infra Red spectroscopy identified the elastic as ethylene propylene rubber, containing additional unidentified compounds. Allergy to natural rubber latex occurs in as many as 6% of Americans and Australians. Around three million American residents are thought to scuba dive each year. Recreational divers are, therefore, advised to check such necklaces, which are typically worn around the throat, for frayed ends and exposed rubber filaments</style></abstract><notes><style face="normal" font="Arial">DA - 20170401IS - 2051-817X (Electronic)IS - 2051-817X (Linking)LA - engPT - Journal ArticleCO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.14814/phy2.13240</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28364033">PM:28364033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Physiol Rep\2017-5-e13240.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Physiol Rep\2017-5-e13240.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170401, Buzzacott P</style></custom2><misc3><style face="normal" font="Arial">10.14814/phy2.13240</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wajdner,H.E.</style></author><author><style face="normal" font="Arial"> Farrington,J.</style></author><author><style face="normal" font="Arial"> Barnard,C.</style></author><author><style face="normal" font="Arial"> Peachell,P.T.</style></author><author><style face="normal" font="Arial"> Schnackenberg,C.G.</style></author><author><style face="normal" font="Arial"> Marino,J.P.,Jr.</style></author><author><style face="normal" font="Arial"> Xu,X.</style></author><author><style face="normal" font="Arial"> Affleck,K.</style></author><author><style face="normal" font="Arial"> Begg,M.</style></author><author><style face="normal" font="Arial"> Seward,E.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Science, University of Sheffield Western Bank, Sheffield, UK</style></auth-address><titles><title><style face="normal" font="Arial">Orai and TRPC channel characterization in FcepsilonRI-mediated calcium signaling and mediator secretion in human mast cells</style></title><secondary-title><style face="normal" font="Arial">Physiol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Physiol Rep</style></full-title></periodical><pages end="" start=" e13166"> e13166-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Calcium Signaling</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> cell signaling</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eicosanoids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exocytosis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human lung mast cell</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Inappropriate activation of mast cells via the FcepsilonRI receptor leads to the release of inflammatory mediators and symptoms of allergic disease. Calcium influx is a critical regulator of mast cell signaling and is required for exocytosis of preformed mediators and for synthesis of eicosanoids, cytokines and chemokines. Studies in rodent and human mast cells have identified Orai calcium channels as key contributors to FcepsilonRI-initiated mediator release. However, until now the role of TRPC calcium channels in FcepsilonRI-mediated human mast cell signaling has not been published. Here, we show evidence for the expression of Orai 1,2, and 3 and TRPC1 and 6 in primary human lung mast cells and the LAD2 human mast cell line but, we only find evidence of functional contribution of Orai and not TRPC channels to FcepsilonRI-mediated calcium entry. Calcium imaging experiments, utilizing an Orai selective antagonist (Synta66) showed the contribution of Orai to FcepsilonRI-mediated signaling in human mast cells. Although, the use of a TRPC3/6 selective antagonist and agonist (GSK-3503A and GSK-2934A, respectively) did not reveal evidence for TRPC6 contribution to FcepsilonRI-mediated calcium signaling in human mast cells. Similarly, inactivation of STIM1-regulated TRPC1 in human mast cells (as tested by transfecting cells with STIM1-KK684-68</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2051-817X (Electronic)IS - 2051-817X (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.14814/phy2.13166</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28292887">PM:28292887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Physiol Rep\2017-5-e13166.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Physiol Rep\2017-5-e13166.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Wajdner HE</style></custom2><misc3><style face="normal" font="Arial">10.14814/phy2.13166</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,Y.L.</style></author><author><style face="normal" font="Arial"> Cao,J.</style></author><author><style face="normal" font="Arial"> Shang,J.H.</style></author><author><style face="normal" font="Arial"> Liu,Y.P.</style></author><author><style face="normal" font="Arial"> Khan,A.</style></author><author><style face="normal" font="Arial"> Wang,H.S.</style></author><author><style face="normal" font="Arial"> Qian,Y.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Ye,M.</style></author><author><style face="normal" font="Arial"> Luo,X.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China</style></auth-address><titles><title><style face="normal" font="Arial">Airways antiallergic effect and pharmacokinetics of alkaloids from Alstonia scholaris</style></title><secondary-title><style face="normal" font="Arial">Phytomedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Phytomedicine</style></full-title></periodical><pages end="72" start="63">63-72</pages><volume><style face="normal" font="Arial">27</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Alkaloids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Apocynaceae</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid peroxidation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Diseases</style></keyword><keyword><style face="normal" font="Arial"> Retention time</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> TA</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="15" Month="4" Year="2017">2017/4/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Alstonia scholaris (L.) R. Br. (Apocynaceae), an important herbal medicine, has been widely used to treat respiratory tract diseases, such as cough, asthma, phlegm, and chronic obstructive pulmonary disease. PURPOSE: To evaluate pharmacological effect of alkaloids from A. scholaris on ovalbumin induced airways allergic inflammatory model, and explore whether the dosing frequency is related to pharmacokinetics. STUDY DESIGN: After oral administration of total alkaloids, the pharmacokinetic study of it was investigated. In addition, anti-allergic studies were carried out on ovalbumin-sensitized airways allergic inflammatory model of mice. METHODS: The pharmacokinetics of total alkaloids (TA) was investigated in SD rat plasma by a fully-validated LC-MS/MS method. Then, an ovalbumin (OVA)-sensitized airways allergic inflammatory model was established, in which mice were intra-gastrically administrated by 3 times a day (8.3 and 16.7mg/kg) based on the pharmacokinetic behavior of TA) and single (25, 50mg/kg) treatment regimen. Dexamethasone was used as a positive control for corticosteroid drugs. Cellular infiltration was assessed in the broncho-alveolar lavage fluid (BALF). Expressions of interleukin-4 (IL-4) and interleukin-10 (IL-10) in the BALF were determined, levels of immunoglobulin E (IgE) and eotaxin in serum were measured, and superoxide dismutase (SOD) activities as well as malondialdehyde (MDA) content in the serum and BALF were examined. Finally, histopathological examination in the lung was assessed by H. E. staining. RESULTS: The time course of plasma concentration of 4 bioactive indole alkaloids fitted an open two-compartment model after oral administration of total alkaloids at doses of 10, 25, and 50mg/kg. The area under the curve and the maximum concentration values of four major alkaloids increased dose-dependently, and half-life suggested a short-lasting pharmacological effect. Then, an ovalbumin-provoked airways allergic inflammatory model indicated that the pharmacological effect of administration of total alkaloids 3 times a day was a little better than that of single dose daily. The percentage of eosinophils in BALF was reduced obviously and the pathological damage of lung was also attenuated. There was also a significant reduction in IL-4 and promotion in IL-10 in the BALF. Serum IgE and eotaxin expression also significantly decreased in treated animals. Furthermore, the activity of SOD elevated remarkably and lipid peroxidation product (MDA) decreased in the administrated mice. CONCLUSION: The pharmacological effects administrated for 3 times a day had precedence over single dose daily, which was related to the prolonged retention time and the maintained plasma concentration. Moreover, scholaricine and vallesamine might be responsible for the treatment of allergic asthma, mainly in total alkaloids</style></abstract><notes><style face="normal" font="Arial">DA - 20170318IS - 1618-095X (Electronic)IS - 0944-7113 (Linking)LA - engPT - Journal ArticleCO - China -CO - Pakistan -</style></notes><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28314480">PM:28314480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Phytomedicine\2017-27-63-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Phytomedicine\2017-27-63-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170318, Zhao YL</style></custom2></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cubells-Baeza,N.</style></author><author><style face="normal" font="Arial"> Gomez-Casado,C.</style></author><author><style face="normal" font="Arial"> Tordesillas,L.</style></author><author><style face="normal" font="Arial"> Ramirez-Castillejo,C.</style></author><author><style face="normal" font="Arial"> Garrido-Arandia,M.</style></author><author><style face="normal" font="Arial"> Gonzalez-Melendi,P.</style></author><author><style face="normal" font="Arial"> Herrero,M.</style></author><author><style face="normal" font="Arial"> Pacios,L.F.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Plant Biotechnology and Genomics (UPM-INIA), Campus de Montegancedo, 28223, Pozuelo de Alarcon, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Identification of the ligand of Pru p 3, a peach LTP</style></title><secondary-title><style face="normal" font="Arial">Plant Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Mol Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Anthesis</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flower</style></keyword><keyword><style face="normal" font="Arial"> Flowers</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> pulp</style></keyword><keyword><style face="normal" font="Arial"> Ripening</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="Arial">KEY MESSAGE: Pru p 3, a peach LTP, is located in pollinated flower styles and secreting downy hairs, transporting a derivative of camptothecin bound to phytosphingosine. Pru p 3 may inhibit a second pollination and may keep away herbivores until seed maturation. The allergen Pru p 3, a peach lipid transfer protein, has been well studied. However, its physiological function remains to be elucidated. Our results showed that Pru p 3 usually carries a lipid ligand that play an essential role in its function in plants. Using ESI-qToF, we observed that the ligand was a derivative of camptothecin binding to phytosphingosine, wich that is inserted into the hydrophobic tunnel of the protein. In addition, the described ligand displayed topoisomerase I activity inhibition and self-fluorescence, both recognized as camptothecin properties. During flower development, the highest expression of Pru p 3 was detected in the styles of pollinated flowers, in contrast to its non-expression in unpollinated pistils, where expression decreased after anthesis. During ripening, the expression of Pru p 3 were observed mainly in peel but not in pulp. In this sense, Pru p 3 protein was also localized in trichomes covering the fruit epidermis</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1573-5028 (Electronic)IS - 0167-4412 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11103-017-0590-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28299506">PM:28299506</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Mol Biol\20170316-CubellsBaezaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Mol Biol\20170316-CubellsBaezaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Cubells-Baeza N</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11103-017-0590-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nahirnak,V.</style></author><author><style face="normal" font="Arial"> Almasia,N.I.</style></author><author><style face="normal" font="Arial"> Fernandez,P.V.</style></author><author><style face="normal" font="Arial"> Hopp,H.E.</style></author><author><style face="normal" font="Arial"> Estevez,J.M.</style></author><author><style face="normal" font="Arial"> Carrari,F.</style></author><author><style face="normal" font="Arial"> Vazquez-Rovere,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Biotecnologia, Centro de Investigacion en Ciencias Veterinarias y Agronomicas, Centro Nacional de Investigaciones Agropecuarias, Instituto Nacional de Tecnologia Agropecuaria, Repetto y De Los Reseros s/n, CP 1686, Hurlingham, Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Potato snakin-1 gene silencing affects cell division, primary metabolism, and cell wall composition</style></title><secondary-title><style face="normal" font="Arial">Plant Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Physiol</style></full-title></periodical><pages end="263" start="252">252-263</pages><volume><style face="normal" font="Arial">158</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> agroinfiltration</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arabidopsis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Cell Division</style></keyword><keyword><style face="normal" font="Arial"> Cell Membrane</style></keyword><keyword><style face="normal" font="Arial"> Cell Size</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> Gas chromatography</style></keyword><keyword><style face="normal" font="Arial"> Gas Chromatography-Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression Regulation,Plant</style></keyword><keyword><style face="normal" font="Arial"> Gene Silencing</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Green Fluorescent Proteins</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth and Development</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infrared spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Molecular Sequence Data</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Epidermis</style></keyword><keyword><style face="normal" font="Arial"> Plant Leaves</style></keyword><keyword><style face="normal" font="Arial"> plant protein</style></keyword><keyword><style face="normal" font="Arial"> Plant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Plants,Genetically Modified</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Solanaceae</style></keyword><keyword><style face="normal" font="Arial"> Solanum tuberosum</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy,Fourier Transform Infrared</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="1" Year="2012">2012/1</year></dates><abstract><style face="normal" font="Arial">Snakin-1 (SN1) is an antimicrobial cysteine-rich peptide isolated from potato (Solanum tuberosum) that was classified as a member of the Snakin/Gibberellic Acid Stimulated in Arabidopsis protein family. In this work, a transgenic approach was used to study the role of SN1 in planta. Even when overexpressing SN1, potato lines did not show remarkable morphological differences from the wild type; SN1 silencing resulted in reduced height, which was accompanied by an overall reduction in leaf size and severe alterations of leaf shape. Analysis of the adaxial epidermis of mature leaves revealed that silenced lines had 70% to 90% increases in mean cell size with respect to wild-type leaves. Consequently, the number of epidermal cells was significantly reduced in these lines. Confocal microscopy analysis after agroinfiltration of Nicotiana benthamiana leaves showed that SN1-green fluorescent protein fusion protein was localized in plasma membrane, and bimolecular fluorescence complementation assays revealed that SN1 self-interacted in vivo. We further focused our study on leaf metabolism by applying a combination of gas chromatography coupled to mass spectrometry, Fourier transform infrared spectroscopy, and spectrophotometric techniques. These targeted analyses allowed a detailed examination of the changes occurring in 46 intermediate compounds from primary metabolic pathways and in seven cell wall constituents. We demonstrated that SN1 silencing affects cell division, leaf primary metabolism, and cell wall composition in potato plants, suggesting that SN1 has additional roles in growth and development beyond its previously assigned role in plant defense</style></abstract><notes><style face="normal" font="Arial">DA - 20120103IS - 1532-2548 (Electronic)IS - 0032-0889 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Plant Proteins)RN - 0 (SN1 protein, Solanum tuberosum)RN - 147336-22-9 (Green Fluorescent Proteins)SB - IMCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1104/pp.111.186544</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="22080603">PM:22080603</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Physiol\2012-158-252-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Physiol\2012-158-252-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20120103, Nahirnak V</style></custom2><misc3><style face="normal" font="Arial">10.1104/pp.111.186544</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nahirnak,V.</style></author><author><style face="normal" font="Arial"> Almasia,N.I.</style></author><author><style face="normal" font="Arial"> Hopp,H.E.</style></author><author><style face="normal" font="Arial"> Vazquez-Rovere,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Biotecnologia, CICVyA, CNIA, Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Snakin/GASA proteins: involvement in hormone crosstalk and redox homeostasis</style></title><secondary-title><style face="normal" font="Arial">Plant Signal Behav</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Signal Behav</style></full-title></periodical><pages end="1008" start="1004">1004-1008</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abiotic stress</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression Regulation,Plant</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormone crosstalk</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Oxidation-Reduction</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Development</style></keyword><keyword><style face="normal" font="Arial"> Plant growth</style></keyword><keyword><style face="normal" font="Arial"> Plant Growth Regulators</style></keyword><keyword><style face="normal" font="Arial"> plant protein</style></keyword><keyword><style face="normal" font="Arial"> Plant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> redox homeostasis</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic plants</style></keyword></keywords><dates><year Day="0" Month="8" Year="2012">2012/8</year></dates><abstract><style face="normal" font="Arial">Snakin/GASA proteins are widely distributed among plant species. They are expressed in different plant organs with high tissue and temporal specificity, and their subcellular localization varies among the different members. Interestingly, all of them maintain 12 cysteines of the C-terminus in highly conserved positions of the aminoacid sequences that are essential for their biochemical activity and probably responsible for their protein structure. Despite their common features, their functions are not completely elucidated and little is known about their mode of action. This review focuses on the current knowledge about this intriguing family of peptides and advances comprising gene regulation analyses, expression pattern studies and phenotypic characterization of mutants and transgenic plants. Furthermore, we discuss the roles of Snakin/GASA proteins in several aspects of plant development, plant responses to biotic or abiotic stress and their participation in hormone crosstalk and redox homeostasis</style></abstract><notes><style face="normal" font="Arial">DA - 20121016IS - 1559-2324 (Electronic)IS - 1559-2316 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - ReviewRN - 0 (Plant Growth Regulators)RN - 0 (Plant Proteins)SB - IMCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.4161/psb.20813</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="22836500">PM:22836500</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Signal Behav\2012-7-1004-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Signal Behav\2012-7-1004-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20121016, Nahirnak V</style></custom2><misc3><style face="normal" font="Arial">10.4161/psb.20813</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Indarte,M.</style></author><author><style face="normal" font="Arial"> Lazza,C.M.</style></author><author><style face="normal" font="Arial"> Assis,D.</style></author><author><style face="normal" font="Arial"> Caffini,N.O.</style></author><author><style face="normal" font="Arial"> Juliano,M.A.</style></author><author><style face="normal" font="Arial"> Aviles,F.X.</style></author><author><style face="normal" font="Arial"> Daura,X.</style></author><author><style face="normal" font="Arial"> Lopez,L.M.</style></author><author><style face="normal" font="Arial"> Trejo,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">PHusisTherapeutics, 3210 Merryfield Row, San Diego, CA, 92121, USA</style></auth-address><titles><title><style face="normal" font="Arial">A Bowman-Birk protease inhibitor purified, cloned, sequenced and characterized from the seeds of Maclura pomifera (Raf.) Schneid</style></title><secondary-title><style face="normal" font="Arial">Planta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Planta</style></full-title></periodical><pages end="353" start="343">343-353</pages><volume><style face="normal" font="Arial">245</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide mass fingerprinting</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> RP-HPLC</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">MAIN CONCLUSION: A new BBI-type protease inhibitor with remarkable structural characteristics was purified, cloned, and sequenced from seeds of Maclura pomifera , a dicotyledonous plant belonging to the Moraceae family. In this work, we report a Bowman-Birk inhibitor (BBI) isolated, purified, cloned, and characterized from Maclura pomifera seeds (MpBBI), the first of this type from a species belonging to Moraceae family. MpBBI was purified to homogeneity by RP-HPLC, total RNA was extracted from seeds of M. pomifera, and the 3'RACE-PCR method was applied to obtain the cDNA, which was cloned and sequenced. Peptide mass fingerprinting (PMF) analysis showed correspondence between the in silico-translated protein and MpBBI, confirming that it corresponds to a new plant protease inhibitor. The obtained cDNA encoded a polypeptide of 65 residues and possesses 10 cysteine residues, with molecular mass of 7379.27, pI 6.10, and extinction molar coefficient of 9105 M-1 cm-1. MpBBI inhibits strongly trypsin with K i in the 10-10 M range and was stable in a wide array of pH and extreme temperatures. MpBBI comparative modeling was applied to gain insight into its 3D structure and highlighted some distinguishing features: (1) two non-identical loops, (2) loop 1 (CEEESRC) is completely different from any known BBI, and (3) the amount of disulphide bonds is also different from any reported BBI from dicot plants</style></abstract><notes><style face="normal" font="Arial">DA - 20161025IS - 1432-2048 (Electronic)IS - 0032-0935 (Linking)LA - engPT - Journal ArticleCO - Argentina -CO - United States -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00425-016-2611-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27778107">PM:27778107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Planta\2017-245-343-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Planta\2017-245-343-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161025, Indarte M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00425-016-2611-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Orellano,P.</style></author><author><style face="normal" font="Arial"> Quaranta,N.</style></author><author><style face="normal" font="Arial"> Reynoso,J.</style></author><author><style face="normal" font="Arial"> Balbi,B.</style></author><author><style face="normal" font="Arial"> Vasquez,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Effect of outdoor air pollution on asthma exacerbations in children and adults: Systematic review and multilevel meta-analysis</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0174050">e0174050-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> funnel plot</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> inspection</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PM10</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Several observational studies have suggested that outdoor air pollution may induce or aggravate asthma. However, epidemiological results are inconclusive due to the presence of numerous moderators which influence this association. The goal of this study was to assess the relationship between outdoor air pollutants and moderate or severe asthma exacerbations in children and adults through a systematic review and multilevel meta-analysis. MATERIAL AND METHODS: We searched studies published in English on PubMed, Scopus, and Google Scholar between January 2000 and October 2016. Studies following a case-crossover design with records of emergency departments and/or hospital admissions as a surrogate of moderate or severe asthma exacerbations were selected. A multilevel meta-analysis was employed, taking into account the potential clustering effects within studies examining more than one lag. Odds ratios (ORs) and 95% confidence intervals were estimated. A subgroup analysis in children aged 0 to 18 years and a sensitivity analysis based on the quality of the included studies as defined in the Newcastle-Ottawa Scale were performed. Publication bias was evaluated through visual inspection of funnel plots and by a complementary search of grey literature. (Prospero Registration number CRD42015032323). RESULTS: Database searches retrieved 208 records, and finally 22 studies were selected for quantitative analysis. All pollutants except SO2 and PM10 showed a significant association with asthma exacerbations (NO2: 1.024; 95% CI: 1.005,1.043, SO2: 1.039; 95% CI: 0.988,1.094), PM10: 1.024; 95% CI: 0.995,1.053, PM2.5: 1.028; 95% CI: 1.009,1.047, CO: 1.045; 95% CI: 1.005,1.086, O3: 1.032; 95% CI: 1.005,1.060. In children, the association was significant for NO2, SO2 and PM2.5. CONCLUSION: This meta-analysis provides evidence of the association between selected air pollutants and asthma exacerbations for different lags</style></abstract><notes><style face="normal" font="Arial">DA - 20170320IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0174050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28319180">PM:28319180</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0174050.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0174050.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170320, Orellano P</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0174050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alcantara-Neves,N.M.</style></author><author><style face="normal" font="Arial"> Veiga,R.V.</style></author><author><style face="normal" font="Arial"> Ponte,J.C.</style></author><author><style face="normal" font="Arial"> da Cunha,S.S.</style></author><author><style face="normal" font="Arial"> Simoes,S.M.</style></author><author><style face="normal" font="Arial"> Cruz,A.A.</style></author><author><style face="normal" font="Arial"> Yazdanbakhsh,M.</style></author><author><style face="normal" font="Arial"> Matos,S.M.</style></author><author><style face="normal" font="Arial"> Silva,T.M.</style></author><author><style face="normal" font="Arial"> Figueiredo,C.A.</style></author><author><style face="normal" font="Arial"> Pontes-de-Carvalho,L.C.</style></author><author><style face="normal" font="Arial"> Rodrigues,L.C.</style></author><author><style face="normal" font="Arial"> Fiaccone,R.L.</style></author><author><style face="normal" font="Arial"> Cooper,P.J.</style></author><author><style face="normal" font="Arial"> Barreto,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Ciencias da Saude, Universidade Federal da Bahia, Salvador, Bahia, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Dissociation between skin test reactivity and anti-aeroallergen IgE: Determinants among urban Brazilian children</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0174089">e0174089-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen skin test reactivity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Ascaris</style></keyword><keyword><style face="normal" font="Arial"> Ascaris lumbricoides</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Genetic polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> herpes</style></keyword><keyword><style face="normal" font="Arial"> Herpes Simplex</style></keyword><keyword><style face="normal" font="Arial"> herpes simplex virus</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> neighborhood</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Rodents</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trichuris</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The dissociation between specific IgE and skin prick test reactivity to aeroallergens, a common finding in populations living in low and middle-income countries, has important implications for the diagnosis and treatment of allergic diseases. Few studies have investigated the determinants of this dissociation. In the present study, we explored potential factors explaining this dissociation in children living in an urban area of Northeast Brazil, focusing in particular on factors associated with poor hygiene. METHODS: Of 1445 children from low income communities, investigated for risk factors of allergies, we studied 481 with specific IgE antibodies to any of Blomia tropicalis, Dermatophagoides pteronyssinus, Periplaneta americana and Blatella germanica allergens. Data on demographic, environmental and social exposures were collected by questionnaire; serum IgG and stool examinations were done to detect current or past infections with viral, bacterial, protozoan and intestinal helminth pathogens. We measured atopy by skin prick testing (SPT) and specific IgE (sIgE) to aerollergens in serum (by ImmunoCAP). SIgE reactivity to B. tropicalis extract depleted of carbohydrates was measured by an in-house ELISA. Total IgE was measured by in house capture ELISA. SNPs were typed using Illumina Omni 2.5. RESULTS: Negative skin prick tests in the presence of specific IgE antibodies were frequent. Factors independently associated with a reduced frequency of positive skin prick tests were large number of siblings, the presence of IgG to herpes simplex virus, Ascaris lumbricoides and Trichuris trichiura infections, living in neighborhoods with infrequent garbage collection, presence of rodents and cats in the household and sIgE reactivity to glycosylated B. tropicalis allergens. Also, SNP on IGHE (rs61737468) was negatively associated with SPT reactivity. CONCLUSIONS: A variety of factors were found to be associated with decreased frequency of SPT such as unhygienic living conditions, infections, total IgE, IgE response to glycosylated allergens and genetic polymorphisms, indicating that multiple mechanisms may be involved. Our data, showing that exposures to an unhygienic environment and childhood infections modulate immediate allergen skin test reactivity, provide support for the "hygiene hypothesis"</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Ecuador -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0174089</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28350867">PM:28350867</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0174089.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0174089.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Alcantara-Neves NM</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0174089</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bodemer,C.</style></author><author><style face="normal" font="Arial"> Guillet,G.</style></author><author><style face="normal" font="Arial"> Cambazard,F.</style></author><author><style face="normal" font="Arial"> Boralevi,F.</style></author><author><style face="normal" font="Arial"> Ballarini,S.</style></author><author><style face="normal" font="Arial"> Milliet,C.</style></author><author><style face="normal" font="Arial"> Bertuccio,P.</style></author><author><style face="normal" font="Arial"> La Vecchia,C.</style></author><author><style face="normal" font="Arial"> Bach,J.F.</style></author><author><style face="normal" font="Arial"> de Prost,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Assistance Publique-Hopitaux de Paris, Hopital Necker-Enfants Malades, Department of Dermatology, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0161555">e0161555-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bacterial lysate</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emollients</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Environmental factors play a major role on atopic dermatitis (AD) which shows a constant rise in prevalence in western countries over the last decades. The Hygiene Hypothesis suggesting an inverse relationship between incidence of infections and the increase in atopic diseases in these countries, is one of the working hypothesis proposed to explain this trend. OBJECTIVE: This study tested the efficacy and safety of oral administration of the bacterial lysate OM-85 (Broncho-Vaxom(R), Broncho-Munal(R), Ommunal(R), Paxoral(R), Vaxoral(R)), in the treatment of established AD in children. METHODS: Children aged 6 months to 7 years, with confirmed AD diagnosis, were randomized in a double-blind, placebo-controlled trial to receive, in addition to conventional treatment with emollients and topical corticosteroids, 3.5mg of the bacterial extract OM-85 or placebo daily for 9 months. The primary end-point was the difference between groups in the occurrence of new flares (NF) during the study period, evaluated by Hazard Ratio (HR) derived from conditional Cox proportional hazard regression models accounting for repeated events. RESULTS: Among the 179 randomized children, 170 were analysed, 88 in the OM-85 and 82 in the placebo group. As expected most children in both treatment groups experienced at least 1 NF during the study period (75 (85%) patients in the OM-85 group and 72 (88%) in the placebo group). Patients treated with OM-85 as adjuvant therapy had significantly fewer and delayed NFs (HR of repeated flares = 0.80; 95% confidence interval (CI): 0.67-0.96), also when potential confounding factors, as family history of atopy and corticosteroids use, were taken into account (HR = 0.82; 95% CI: 0.69-0.98). No major side effect was reported, with comparable and good tolerability for OM-85 and placebo. CONCLUSIONS: Results show an adjuvant therapeutic effect of a well standardized bacterial lysate OM-85 on established AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - France -CO - Switzerland -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0161555</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28333952">PM:28333952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0161555.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0161555.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Bodemer C</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0161555</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brunton,S.</style></author><author><style face="normal" font="Arial"> Nelson,H.S.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> Lawton,S.</style></author><author><style face="normal" font="Arial"> Lu,S.</style></author><author><style face="normal" font="Arial"> Nolte,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Primary Care Respiratory Group , Lake View Terrace , CA , USA</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma</style></title><secondary-title><style face="normal" font="Arial">Postgrad Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postgrad Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> disease-modifying effect</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Office Visits</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) with or without conjunctivitis (AR/C) is associated with a significant health and economic burden, and is often accompanied by asthma. Pharmacotherapies are the mainstay treatment options for AR and asthma, but guidelines also recommend allergy immunotherapy (AIT). Unlike pharmacotherapies, AIT has the ability to modify the underlying immunologic mechanisms of AR and asthma with the potential for long-term benefits after treatment is discontinued. Immunotherapy may also prevent progression of AR/C to asthma. Sublingual immunotherapy (SLIT)-tablets are a self-administered alternative to subcutaneous immunotherapy that provide the benefits of AIT without the cost and inconvenience of frequent office visits or the discomfort of injections. SLIT-tablets are also an option that can be utilized by primary care clinicians. Pharmacotherapies are generally effective in mild disease although a number of patients remain uncontrolled. SLIT-tablets have proven efficacy for AR in adults, children, and poly-sensitized allergic patients. Indirect comparisons indicate that SLIT-tablets have superior or comparable efficacy compared with traditional pharmacotherapies for seasonal AR, and superior efficacy for perennial AR. House dust mite (HDM) SLIT-tablets have also demonstrated clinically relevant benefits for asthma, with significant observed reductions in daily inhaled corticosteroid use, risk of asthma exacerbations, and asthma symptoms. SLIT-tablets are well tolerated, with minimal risk of systemic allergic reactions. The most common treatment-related adverse events are oral site reactions such as oral pruritus and throat irritation. Based on the favorable efficacy and safety profile, as well as the convenience of at-home oral administration and disease-modifying effects, SLIT-tablets should be considered as an alternative or add-on treatment to pharmacotherapy for AR/C, and as an add-on treatment for HDM allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170322IS - 1941-9260 (Electronic)IS - 0032-5481 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1080/00325481.2017.1308208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28326908">PM:28326908</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postgrad Med\20170322-BruntonS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postgrad Med\20170322-BruntonS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170322, Brunton S</style></custom2><misc3><style face="normal" font="Arial">10.1080/00325481.2017.1308208</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> Bardelas,J.A.,Jr.</style></author><author><style face="normal" font="Arial"> Svanholm,F.B.</style></author><author><style face="normal" font="Arial"> Kaur,A.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Nolte,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Bernstein Clinical Research Center and Department of Medicine and Environmental Health , University of Cincinnati , Cincinnati , OH , USA</style></auth-address><titles><title><style face="normal" font="Arial">A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice</style></title><secondary-title><style face="normal" font="Arial">Postgrad Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postgrad Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Treatment with allergy immunotherapy improves allergic rhinoconjunctivitis, but can also improve comorbidities associated with allergic rhinitis such as asthma. Sublingual immunotherapy (SLIT)-tablets are a convenient and efficacious method of allergy immunotherapy. They are self-administered after the first tablet has been provided under medical supervision. Therapy may elicit local reactions or, rarely, systemic allergic reactions. The objective of this report is to inform healthcare practitioners about the safety and tolerability profile of SLIT-tablets and use this information to provide practical guidance that may inform patients regarding potential adverse reactions and how to manage them. METHODS: Pooled analyses of safety data from completed randomized, multicenter, double-blind, placebo-controlled phase 2 and phase 3 US and EU trials of timothy grass, short ragweed, and SQ house dust mite SLIT-tablets were conducted to characterize safety and tolerability. RESULTS: SLIT-tablets are generally well tolerated. No life-threatening events, serious systemic allergic reactions, or events that compromised the airway have been reported. The most common treatment-related adverse events (AEs) are oral site reactions, most of which begin on day 1 of treatment, recur for less than 2 weeks, and resolve after approximately 30-60 minutes. Systemic allergic reactions have been managed with conventional pharmacotherapy. Reactions treated with epinephrine are uncommon, but have been reported. Treatment of AEs, treatment discontinuation considerations, and patient FAQs regarding SLIT-tablet safety/tolerability are discussed. CONCLUSIONS: This report gives healthcare providers valuable information to educate patients regarding what to expect in terms of SLIT-tablet safety and tolerability. Practical guidance is also provided to ensure proper treatment of any adverse reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170322IS - 1941-9260 (Electronic)IS - 0032-5481 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1080/00325481.2017.1302306</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28326906">PM:28326906</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postgrad Med\20170322-BernsteinDI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postgrad Med\20170322-BernsteinDI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170322, Bernstein DI</style></custom2><misc3><style face="normal" font="Arial">10.1080/00325481.2017.1302306</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shim,S.Y.</style></author><author><style face="normal" font="Arial"> Lee,K.D.</style></author><author><style face="normal" font="Arial"> Lee,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy, Sunchon National University, Jeonnam 57922, KoreaDepartment of Oriental Medicine Materials, Dongsin University, Jeonnam 58245, KoreaCollege of Pharmacy, Sunchon National University, Jeonnam 57922, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Vaccinium angustifolium Root Extract Suppresses FcvarepsilonRI Expression in Human Basophilic KU812F Cells</style></title><secondary-title><style face="normal" font="Arial">Prev Nutr Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prev Nutr Food Sci</style></full-title></periodical><pages end="15" start="9">9-15</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> extracellular signal-regulated kinase</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Vaccinium angustifolium, commonly known as the lowbush blueberry, is a rich source of flavonoids, with which various human physiological activities have been associated. The present study focuses on the investigation of the effect of the methanolic extract of V. angustifolium root extract (VAE) on high affinity immunoglobulin E receptor (FcvarepsilonRI) alpha chain antibody (CRA-1)-induced allergic reaction in human basophilic KU812F cells. The total phenolic content of VAE was found to be 170+/-1.9 mg gallic acid equivalents/g. Flow cytometry analysis revealed that the cell surface expression of FcvarepsilonRI was suppressed in a concentration-dependent manner upon culture with VAE. Reverse-transcriptase polymerase chain reaction analysis showed that the mRNA level of the FcvarepsilonRI alpha chain was reduced in a concentration-dependent manner as a result of VAE treatment. Western blot analysis revealed that the protein expression of FcvarepsilonRI and the phosphorylation of extracellular signal-regulated kinases (ERK) 1/2 were concentration-dependently inhibited by VAE. We determined that VAE inhibited anti-CRA-1-induced histamine release, in addition to the elevation of intracellular calcium concentration ([Ca2+]i), in a concentration-dependent manner. These results indicate that VAE may exert an anti-allergic effect via the inhibition of calcium influx and histamine release, which occurs as a result of the down-regulation of FcvarepsilonRI expression through inhibition of ERK 1/2 activation</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 2287-1098 (Print)IS - 2287-1098 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3746/pnf.2017.22.1.9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401082">PM:28401082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prev Nutr Food Sci\2017-22-9-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prev Nutr Food Sci\2017-22-9-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Shim SY</style></custom2><misc3><style face="normal" font="Arial">10.3746/pnf.2017.22.1.9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kostarnoy,A.V.</style></author><author><style face="normal" font="Arial"> Gancheva,P.G.</style></author><author><style face="normal" font="Arial"> Lepenies,B.</style></author><author><style face="normal" font="Arial"> Tukhvatulin,A.I.</style></author><author><style face="normal" font="Arial"> Dzharullaeva,A.S.</style></author><author><style face="normal" font="Arial"> Polyakov,N.B.</style></author><author><style face="normal" font="Arial"> Grumov,D.A.</style></author><author><style face="normal" font="Arial"> Egorova,D.A.</style></author><author><style face="normal" font="Arial"> Kulibin,A.Y.</style></author><author><style face="normal" font="Arial"> Bobrov,M.A.</style></author><author><style face="normal" font="Arial"> Malolina,E.A.</style></author><author><style face="normal" font="Arial"> Zykin,P.A.</style></author><author><style face="normal" font="Arial"> Soloviev,A.I.</style></author><author><style face="normal" font="Arial"> Riabenko,E.</style></author><author><style face="normal" font="Arial"> Maltseva,D.V.</style></author><author><style face="normal" font="Arial"> Sakharov,D.A.</style></author><author><style face="normal" font="Arial"> Tonevitsky,A.G.</style></author><author><style face="normal" font="Arial"> Verkhovskaya,L.V.</style></author><author><style face="normal" font="Arial"> Logunov,D.Y.</style></author><author><style face="normal" font="Arial"> Naroditsky,B.S.</style></author><author><style face="normal" font="Arial"> Gintsburg,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunobiotechnology, N. F. Gamaleya Federal Research Center of Epidemiology and Microbiology, 123098 Moscow, Russia</style></auth-address><titles><title><style face="normal" font="Arial">Receptor Mincle promotes skin allergies and is capable of recognizing cholesterol sulfate</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></full-title></periodical><pages end="E2765" start="E2758">E2758-E2765</pages><volume><style face="normal" font="Arial">114</style></volume><number><style face="normal" font="Arial">13</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> allergic skin inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> C-type lectin receptor</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin allergy</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">Sterile (noninfected) inflammation underlies the pathogenesis of many widespread diseases, such as allergies and autoimmune diseases. The evolutionarily conserved innate immune system is considered to play a key role in tissue injury recognition and the subsequent development of sterile inflammation; however, the underlying molecular mechanisms are not yet completely understood. Here, we show that cholesterol sulfate, a molecule present in relatively high concentrations in the epithelial layer of barrier tissues, is selectively recognized by Mincle (Clec4e), a C-type lectin receptor of the innate immune system that is strongly up-regulated in response to skin damage. Mincle activation by cholesterol sulfate causes the secretion of a range of proinflammatory mediators, and s.c. injection of cholesterol sulfate results in a Mincle-mediated induction of a severe local inflammatory response. In addition, our study reveals a role of Mincle as a driving component in the pathogenesis of allergic skin inflammation. In a well-established model of allergic contact dermatitis, the absence of Mincle leads to a significant suppression of the magnitude of the skin inflammatory response as assessed by changes in ear thickness, myeloid cell infiltration, and cytokine and chemokine secretion. Taken together, our results provide a deeper understanding of the fundamental mechanisms underlying sterile inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - engPT - Journal ArticleCO - Russia -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1073/pnas.1611665114</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28292894">PM:28292894</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2017-114-E2758-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2017-114-E2758-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Kostarnoy AV</style></custom2><misc3><style face="normal" font="Arial">10.1073/pnas.1611665114</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sekioka,T.</style></author><author><style face="normal" font="Arial"> Kadode,M.</style></author><author><style face="normal" font="Arial"> Osakada,N.</style></author><author><style face="normal" font="Arial"> Fujita,M.</style></author><author><style face="normal" font="Arial"> Matsumura,N.</style></author><author><style face="normal" font="Arial"> Yamaura,Y.</style></author><author><style face="normal" font="Arial"> Nakade,S.</style></author><author><style face="normal" font="Arial"> Nabe,T.</style></author><author><style face="normal" font="Arial"> Kawabata,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Minase Research Institute, Ono Pharmaceutical Co., Ltd, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">A new CysLT1 and CysLT2 receptors-mediated anaphylaxis guinea pig model</style></title><secondary-title><style face="normal" font="Arial">Prostaglandins Leukot Essent Fatty Acids</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Prostaglandins Leukot Essent Fatty Acids</style></full-title></periodical><pages end="24" start="18">18-24</pages><volume><style face="normal" font="Arial">119</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CysLT1</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> LC/MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Although the effectiveness of CysLT1 receptor antagonists on asthma has been clinically established, the effects of CysLT2 receptor antagonists are still unclear. The purpose of this study was to develop a new CysLT1 and CysLT2 receptors-mediated anaphylaxis guinea pig model using S-hexyl GSH, a gamma-glutamyl transpeptidase (GTP) inhibitor, to suppress conversion of LTC4 to LTD4. Actively sensitized guinea pigs were challenged with OVA in the absence or presence of S-hexyl GSH, and survival rate following anaphylactic response was monitored. OVA-induced fatal anaphylaxis in the absence of S-hexyl GSH was almost completely inhibited by montelukast, a CysLT1 receptor antagonist, but not by the CysLT2 receptor antagonist BayCysLT2RA. However, under treatment with S-hexyl-GSH, the inhibitory effect of motelukast was dramatically diminished, whereas that of BayCysLT2RA was markedly increased. The dual CysLT1/2 receptor antagonist ONO-6950 effectively inhibited anaphylactic response in both S-hexyl GSH-treated and non-treated animals. LC/MS/MS analysis revealed that S-hexyl GSH treatment actually inhibited LTC4 metabolism in the blood and lung tissues. Using S-hexyl GSH, we developed a novel CysLT1 and CysLT2 receptors-mediated anaphylaxis guinea pig model that can be useful for not only screening both CysLT2 and CysLT1/2 receptors antagonists, but also for functional analysis of CysLT2 receptors</style></abstract><notes><style face="normal" font="Arial">DA - 20170415IS - 1532-2823 (Electronic)IS - 0952-3278 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.plefa.2017.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410666">PM:28410666</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prostaglandins Leukot Essent Fatty Acids\2017-119-18-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prostaglandins Leukot Essent Fatty Acids\2017-119-18-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170415, Sekioka T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.plefa.2017.03.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Czerwionka-Szaflarska,M.</style></author><author><style face="normal" font="Arial"> Los-Rycharska,E.</style></author><author><style face="normal" font="Arial"> Gawryjolek,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Allergology, and Gastroenterology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Allergic enteritis in children</style></title><secondary-title><style face="normal" font="Arial">Prz Gastroenterol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Prz Gastroenterol</style></abbr-1></periodical><pages end="5" start="1">1-5</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colic</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Digestive tract</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Enteritis</style></keyword><keyword><style face="normal" font="Arial"> Flatulence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The gastrointestinal form of food allergy is very common in children. The most frequently observed types are allergic proctitis and proctocolitis. In most cases the symptoms subside within the first 2 months of life. The babies seem healthy, and the only abnormality is a small amount of blood in stool. Symptoms can also include small intestine inflammation and colitis. Patients may present with irritability, abdominal pain, flatulence, colic, postprandial vomiting, chronic diarrhoea, and hindered physical development. The diagnosis of allergic enteritis is based on the clinical examination and the results of additional tests including an endoscopy of the lower digestive tract with histopathological assessment. Cow's milk proteins are the most common nutrition proteins responsible for the development of the symptoms of allergic enteritis. The most essential method of treating allergic enteritis is the elimination diet. The symptoms should subside within 1-2 weeks from the beginning of the diet</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1895-5770 (Print)IS - 1895-5770 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/pg.2017.65677</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28337229">PM:28337229</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prz Gastroenterol\2017-12-1-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prz Gastroenterol\2017-12-1-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Czerwionka-Szaflarska M</style></custom2><misc3><style face="normal" font="Arial">10.5114/pg.2017.65677</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sposato,B.</style></author><author><style face="normal" font="Arial"> Scalese,M.</style></author><author><style face="normal" font="Arial"> Latorre,M.</style></author><author><style face="normal" font="Arial"> Novelli,F.</style></author><author><style face="normal" font="Arial"> Scichilone,N.</style></author><author><style face="normal" font="Arial"> Milanese,M.</style></author><author><style face="normal" font="Arial"> Olivieri,C.</style></author><author><style face="normal" font="Arial"> Perrella,A.</style></author><author><style face="normal" font="Arial"> Paggiaro,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pneumologia, Ospedale Misericordia, Grosseto, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Can the response to Omalizumab be influenced by treatment duration? A real-life study</style></title><secondary-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></full-title></periodical><pages end="45" start="38">38-45</pages><volume><style face="normal" font="Arial">44</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> FEV1 decline</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="3" Year="2017">2017/3/13</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. METHODS: 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: &lt;12, between 12 and 24, between 24 and 60 and >60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. RESULTS: ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linear regression model, corrected for all confounding variables, a higher significant positive increase in FEV1% in subjects treated for 12-24 (beta = 9.49; p = 0.034) or 24-60 months (beta = 8.56; p = 0.043) was found when compared with subjects treated for a shorter period. Treatment duration was positively associated with a step down of the other associated therapies (OR: 1.013; p = 0.019). This association was more relevant (OR: 4.167; p = 0.005) when we considered Omalizumab treatment duration >60 months compared to the shorter therapy. In particular, the percentage of subjects that were taking Montelukast, LABAs and oral corticosteroids (OCS) was lower in the group treated with Omalizumab for a longer period of time. CONCLUSION: In real-life, the positive Omalizumab response remained stable for over 60 months. Long term Omalizumab treatment may lead to a discontinuation of some associated medications and to a slowing down of FEV1 decline</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pupt.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28302544">PM:28302544</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Pharmacol Ther\2017-44-38-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Pharmacol Ther\2017-44-38-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Sposato B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pupt.2017.03.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tjan,T.F.</style></author><author><style face="normal" font="Arial"> Wolf,H.</style></author><author><style face="normal" font="Arial"> Schnitker,J.</style></author><author><style face="normal" font="Arial"> Wustenberg,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Treatment Satisfaction During Routine Treatment with the SQ-«-Standardised Grass Allergy Immunotherapy Tablet: A Non-interventional Observational Study</style></title><secondary-title><style face="normal" font="Arial">Pulm Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Pulm Ther</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass allergy immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2364-1746</style></isbn><abstract><style face="normal" font="Arial">Therapy with the SQ-«-standardised grass sublingual immunotherapy (SLIT)-tablet has been shown to be efficacious and well-tolerated in a large clinical development programme. The objective of this study was to investigate patients' satisfaction with treatment by the SQ-« grass SLIT-tablet during routine application</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s41030-017-0030-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s41030-017-0030-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Ther\20170420-TjanTF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Ther\20170420-TjanTF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Tjan TF</style></custom2><misc3><style face="normal" font="Arial">10.1007/s41030-017-0030-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Phleum pratense</style></title><secondary-title><style face="normal" font="Arial">Reactions Weekly</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Reactions Weekly</style></full-title></periodical><pages end="240" start="240">240-240</pages><volume><style face="normal" font="Arial">1645</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1179-2051</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><work-type><style face="normal" font="Arial">10.1007/s40278-017-28322-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40278-017-28322-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Reactions Weekly\2017-1645-240.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Reactions Weekly\2017-1645-240.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170422, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40278-017-28322-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shirkani,A.</style></author><author><style face="normal" font="Arial"> Mansouri,A.</style></author><author><style face="normal" font="Arial"> Abbaszadegan,M.R.</style></author><author><style face="normal" font="Arial"> Faridhosseini,R.</style></author><author><style face="normal" font="Arial"> Jabbari,A.F.</style></author><author><style face="normal" font="Arial"> Gholamin,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of medicine allergy and clinical immunology department, Blusher University of medical science, Blusher Iran</style></auth-address><titles><title><style face="normal" font="Arial">GATA3 Gene Polymorphisms Associated with Allergic Rhinitis in an Iranian Population</style></title><secondary-title><style face="normal" font="Arial">Rep Biochem Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rep Biochem Mol Biol</style></full-title></periodical><pages end="102" start="97">97-102</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene polymorphism</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The development of allergic rhinitis (AR) is caused by the interaction between genetic predisposition and environmental factors. In this study, the association between GATA3 single nucleotide polymorphisms and AR in an Iranian population was identified. METHODS: This case-control study was performed on 86 patients with AR and 86 healthy subjects. This study aimed to evaluate a potential association between two GATA3 SNPs, rs1269486 and rs2229360, and AR. Blood samples were collected and DNA was extracted for the evaluation of these SNPs by RFLP-PCR. RESULTS: A statistically-significant association was found between rs1269486 and AR (P&lt;0.001). The frequencies of the A and GA genotypes were less in patients than in controls. The frequencies of the G allele and the GG genotype were greater in patients than in controls (P &lt; 0.001). CONCLUSIONS: SNP rs1269486 of GATA3 was associated with AR and sensitivity to aeroallergens in our population. Because of the significance of this gene in AR, studying the association between GATA3 polymorphisms and AR is recommended for other populations</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 2322-3480 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28367470">PM:28367470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rep Biochem Mol Biol\2017-5-97-102.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rep Biochem Mol Biol\2017-5-97-102.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Shirkani A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Viteri,E.</style></author><author><style face="normal" font="Arial"> Foray,N.</style></author><author><style face="normal" font="Arial"> Song,M.</style></author><author><style face="normal" font="Arial"> Long,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Southern Illinois University School of Medicine, PO Box 19636, Springfield, IL 62794, USA</style></auth-address><titles><title><style face="normal" font="Arial">A Case of Chronic Cough in a Winemaker</style></title><secondary-title><style face="normal" font="Arial">Respir Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med Case Rep</style></full-title></periodical><pages end="48" start="46">46-48</pages><volume><style face="normal" font="Arial">21</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary mycosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Bronchoscopy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic cough</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> CT scan</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Hobbies</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methacholine challenge</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function test</style></keyword><keyword><style face="normal" font="Arial"> Saccharomyces</style></keyword><keyword><style face="normal" font="Arial"> Saccharomyces cerevisiae</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fungi have been known to cause a variety of respiratory conditions, ranging from mold- associated asthma to allergic bronchopulmonary mycosis and invasive disease. More recently some fungal species have been implicated in a non-asthmatic chronic cough syndrome. CASE PRESENTATION: A 59-year-old male presented to the pulmonary clinic with chronic nonproductive cough. Workup included pulmonary function tests with methacholine challenge, sputum cultures, CT scans of the chest and therapeutic trial with proton pump inhibitors. Sputum cultures repeatedly showed Saccharomyces cerevisiae and patient had elevated specific IgA and IgG. Bronchoscopy was unremarkable, except for tracheal mucosa biopsies revealing acute and chronic inflammation. A one-month course of steroids provided temporary relief of chronic cough, but symptoms returned once steroids were discontinued. He also experienced temporary relief away from home. Upon further evaluation, the patient described his hobby of wine making which was believed to be the source of Saccharomyces cerevisiae. Once he stopped wine making at home and cleared his cellar, his symptoms stopped and have not returned since. CONCLUSION: We describe a rare presentation of non-asthmatic chronic cough associated with exposure to Saccharomyces cerevisiae. This is the first report of fungi associated chronic cough without asthmatic features outside of Japan and the first one associated with Saccharomyces cerevisiae. This report provides further evidence linking fungi with chronic cough syndrome without the features of asthma or allergic bronchopulmonary mycosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 2213-0071 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmcr.2017.03.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393005">PM:28393005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med Case Rep\2017-21-46-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med Case Rep\2017-21-46-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Viteri E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmcr.2017.03.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baker,K.</style></author><author><style face="normal" font="Arial"> Raemdonck,K.</style></author><author><style face="normal" font="Arial"> Snelgrove,R.J.</style></author><author><style face="normal" font="Arial"> Belvisi,M.G.</style></author><author><style face="normal" font="Arial"> Birrell,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Pharmacology, Airway Disease Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, Exhibition Road, London, SW7 2AZ, UK</style></auth-address><titles><title><style face="normal" font="Arial">Characterisation of a murine model of the late asthmatic response</style></title><secondary-title><style face="normal" font="Arial">Respir Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Res</style></full-title></periodical><pages end="" start="55">55-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Late asthmatic response</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sensory nerves</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The incidence of asthma is increasing at an alarming rate. While the current available therapies are effective, there are associated side effects and they fail to adequately control symptoms in all patient subsets. In the search to understand disease pathogenesis and find effective therapies hypotheses are often tested in animal models before progressing into clinical studies. However, current dogma is that animal model data is often not predictive of clinical outcome. One possible reason for this is the end points measured such as antigen-challenge induced late asthmatic response (LAR) is often used in early clinical development, but seldom in animal model systems. As the mouse is typically selected as preferred species for pre-clinical models, we wanted to characterise and probe the validity of a murine model exhibiting an allergen induced LAR. METHODS: C57BL/6 mice were sensitised with antigen and subsequently topically challenged with the same antigen. The role of AlumTM adjuvant, glucocorticoid, long acting muscarinic receptor antagonist (LAMA), TRPA1, CD4+ and CD8+ T cells, B cells, Mast cells and IgE were determined in the LAR using genetically modified mice and a range of pharmacological tools. RESULTS: Our data showed that unlike other features of asthma (e.g. cellular inflammation, elevated IgE levels and airway hyper-reactivity (AHR) the LAR required AlumTMadjuvant. Furthermore, the LAR appeared to be sensitive to glucocorticoid and required CD4+ T cells. Unlike in other species studied, the LAR was not sensitive to LAMA treatment nor required the TRPA1 ion channel, suggesting that airway sensory nerves are not involved in the LAR in this species. Furthermore, the data suggested that CD8+ T cells and the mast cell-B-cell - IgE axis appear to be protective in this murine model. CONCLUSION: Together we can conclude that this model does feature steroid sensitive, CD4+ T cell dependent, allergen induced LAR. However, collectively our data questions the validity of using the murine pre-clinical model of LAR in the assessment of future asthma therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12931-017-0541-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28399855">PM:28399855</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2017-18-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2017-18-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Baker K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12931-017-0541-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maltby,S.</style></author><author><style face="normal" font="Arial"> Tay,H.L.</style></author><author><style face="normal" font="Arial"> Yang,M.</style></author><author><style face="normal" font="Arial"> Foster,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hunter Medical Research Institute, Priority Research Centre for Healthy Lungs, Newcastle, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Mouse models of severe asthma: Understanding the mechanisms of steroid resistance, tissue remodelling and disease exacerbation</style></title><secondary-title><style face="normal" font="Arial">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respirology</style></full-title></periodical><pages end="885" start="874">874-885</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">Severe asthma has significant disease burden and results in high healthcare costs. While existing therapies are effective for the majority of asthma patients, treatments for individuals with severe asthma are often ineffective. Mouse models are useful to identify mechanisms underlying disease pathogenesis and for the preclinical assessment of new therapies. In fact, existing mouse models have contributed significantly to our understanding of allergic/eosinophilic phenotypes of asthma and facilitated the development of novel targeted therapies (e.g. anti-IL-5 and anti-IgE). These therapies are effective in relevant subsets of severe asthma patients. Unfortunately, non-allergic/non-eosinophilic asthma, steroid resistance and disease exacerbation remain areas of unmet clinical need. No mouse model encompasses all features of severe asthma. However, mouse models can provide insight into pathogenic pathways that are relevant to severe asthma. In this review, as examples, we highlight models relevant to understanding steroid resistance, chronic tissue remodelling and disease exacerbation. Although these models highlight the complexity of the immune pathways that may underlie severe asthma, they also provide insight into new potential therapeutic approaches</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/resp.13052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401621">PM:28401621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respirology\20170412-MaltbyS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respirology\20170412-MaltbyS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Maltby S</style></custom2><misc3><style face="normal" font="Arial">10.1111/resp.13052</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doyen,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Non-drug cofactors in anaphylactic reactions to food</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="221" start="219">219-221</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Exercice</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Anaphylactic reaction to food is the most severe type of type 1 hypersensitivity reaction. While the factors affecting the expression of IgE sensitisation are little-known, certain conditions that lower the reactivity threshold and/or increase the severity of clinical reaction have been identified. According to available records, a number of such cofactors, are involved in around one third of cases of anaphylaxis. Questioning of the patient is crucial, and challenge tests may also be useful in some situations. The physiopathology is poorly understood and a number of hypotheses exist but do not provide satisfactory answers in terms of actual clinical needs. The study of these factors could prove useful for understanding the trigger mechanisms of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.147</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.147</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DoyenV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DoyenV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Doyen V</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.147</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bourrier,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">I (routinely) prescribe allergic component analysis before selecting food immunotherapy. No</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="212" start="210">210-212</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic component</style></keyword><keyword><style face="normal" font="Arial"> Allergie alimentaire</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Food immunotherapy is our form of treatment currently at the frontier between assessment of its efficacy and risks through double-blind, placebo-controlled trials and use and standard clinical practice. Herein, we will show that for clinical practice, prior assay of allergenic components is not essential for diagnosis of the condition</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.150</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-BourrierT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-BourrierT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Bourrier T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.150</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saintot,M.</style></author><author><style face="normal" font="Arial"> Flabbee,J.A.</style></author><author><style face="normal" font="Arial"> Ziegler,O.</style></author><author><style face="normal" font="Arial"> Schmutz,J.L.</style></author><author><style face="normal" font="Arial"> Barbaud,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Gastrointestinal disorders due to wheat intolerance</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="326" start="317">317-326</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> Aliment</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Coeliac disease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fructans</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Non-coeliac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword><keyword><style face="normal" font="Arial"> Wheat anaphylaxis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Although a key food in western diets, wheat can cause certain gastrointestinal disorders requiring its withdrawal. Some diseases are specifically associated with wheat or gluten, while others may be caused by wheat or by other foods, such as food protein-induced enterocolitis syndrome (FPIES) and eosinophilic esophagitis. A new entity has recently emerged: non-coeliac gluten sensitivity. Its physiopathology, which is probably multifactorial, is poorly understood, and there are no specific signs. Diagnosis requires the exclusion of coeliac disease and wheat allergy, which is not always easy. In addition, there is wheat intolerance of non-immunological origin, related to the presence of fructans, which cause fermentation and gas production due to their poor absorption and their osmotic effects that induce functional gastrointestinal troubles. The present review provides an overview of current knowledge and of the various therapeutic procedures suited to these different diseases associated with wheat consumption</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2016.12.002</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2016.12.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170419-SaintotM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170419-SaintotM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Saintot M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2016.12.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Decuyper,I.I.</style></author><author><style face="normal" font="Arial"> Ebo,D.G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cannabis-fruits/vegetables syndrome: New developments in 2017</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="151" start="150">150-151</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Belgium</style></keyword><keyword><style face="normal" font="Arial"> Can s 3</style></keyword><keyword><style face="normal" font="Arial"> Cannabis sativa</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.020</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DecuyperII.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DecuyperII.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Decuyper II</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Frealle,E.</style></author><author><style face="normal" font="Arial"> Gosset,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Interactions of molds with the immune system</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="120" start="118">118-120</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Moisissures</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxin</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxine</style></keyword><keyword><style face="normal" font="Arial"> Th17 response</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.234</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.234</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-FrealleE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-FrealleE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Frealle E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.234</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Just,J.</style></author><author><style face="normal" font="Arial"> Fontaine,J.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Foods and allergies: A question for specialists</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="113">113-</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.030</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170409-JustJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170409-JustJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Just J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Delebarre-Sauvage,C.</style></author><author><style face="normal" font="Arial"> Seynave,M.</style></author><author><style face="normal" font="Arial"> Vilain,A.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Oral immunotherapy for food allergies must always be initiated in a hospital setting: FOR (arguments)</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="154" start="152">152-154</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arachide</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Ewe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy allergy</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nut allergy</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Food allergy has doubled since 2003, with increasing severity. In Europe as in the US, this phenomenon is partly responsible for emergency admissions, particularly peanut and tree-nut allergies, which are associated with 90% of fatal cases of anaphylaxis. Until recent years, the sole consensual food allergy management was food allergen avoidance. Now, however, food immunotherapy is proposed to allergic patients under strict conditions of use. For safety reasons, immunotherapy requires initiation in a hospital setting. Certain allergens such as peanut or tree-nut allergies, as well as milk (cow, goat, ewe) and soy allergies are particularly associated with anaphylactic reactions. Proving food allergy persistence in order to justify immunotherapy involves carrying out allergen rechallenge until a clinic reaction is obtained, allowing determination of the reactive dose or of a reactivity threshold. For all of the foregoing reasons, it essential to initiate immunotherapy in a hospital setting</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.015</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DelebarreSauvageC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DelebarreSauvageC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Delebarre-Sauvage C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Decline,J.L.</style></author><author><style face="normal" font="Arial"> Cohen,J.</style></author><author><style face="normal" font="Arial"> Gonzales,E.</style></author><author><style face="normal" font="Arial"> Taoufik,Y.</style></author><author><style face="normal" font="Arial"> Jacquemin,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Transplant and allergic risk; management of food allergy after liver transplant in children</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="185" start="184">184-185</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic risk</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Liver transplant</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.001</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DeclineJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DeclineJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Decline JL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garnier,L.</style></author><author><style face="normal" font="Arial"> Bienvenu,J.</style></author><author><style face="normal" font="Arial"> Lombard,C.</style></author><author><style face="normal" font="Arial"> Bienvenu,F.</style></author><author><style face="normal" font="Arial"> Viel,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Genetic influence on the development of food allergies</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="224" start="222">222-224</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopie</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Maladie alimentaire</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.017</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-GarnierL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-GarnierL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Garnier L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morel-Codreanu,F.</style></author><author><style face="normal" font="Arial"> Charatsi,A.M.</style></author><author><style face="normal" font="Arial"> Kuehn,A.</style></author><author><style face="normal" font="Arial"> Hilger,C.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Morisset,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Short- and long-term benefits of peanut immunotherapy in 2017</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="166" start="164">164-166</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arachide</style></keyword><keyword><style face="normal" font="Arial"> Court terme</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long terme</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Luxembourg -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.005</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-MorelCodreanuF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-MorelCodreanuF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Morel-Codreanu F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Labbe,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Breastfeeding and aeroallergens</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="175" start="174">174-175</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies respiratoires</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthme</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.019</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-LabbeA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-LabbeA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Labbe A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bidat,E.</style></author><author><style face="normal" font="Arial"> Benoist,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic exposure or exclusion in severe food allergy: Management and immunotherapy in this population</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="145" start="140">140-145</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Aliment</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Co-factors</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Management of severe food allergy first requires definition of this entity. Before considering a specific course of management, one must ensure that food allergy is really severe. Herein we consider some peculiarities of diet and of adrenaline auto-injection treatment by patients or their family, which requires a suitable educational approach. Co-factors of the allergic reaction must also be considered. We will discuss oral immunotherapy (ITO) in foods, for which there is no consensus concerning routine clinical use. All of these reflections will be based upon our daily experience with this condition</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.010</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-BidatE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-BidatE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Bidat E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deluze,C.</style></author><author><style face="normal" font="Arial"> Beaumont,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food allergy to amaranth seed</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="340" start="337">337-340</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergie alimentaire</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amarante</style></keyword><keyword><style face="normal" font="Arial"> Amaranth</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxie alimentaire</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Inca wheat</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Rajgira</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">The authors report the case of a 42-year-old man who developed severe food anaphylaxis to amaranth seed ingested in a vegetarian meal. Then, they provide a review of this rare allergy. This is the second published observation concerning food allergy to this amaranthaceae plant</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.007</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DeluzeC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DeluzeC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Deluze C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paidassi,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Regulatory T cells and oral tolerance: Role of dendritic cell avß8 integrin</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="127" start="125">125-127</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cells</style></keyword><keyword><style face="normal" font="Arial"> Cellule dendritique</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> Integrin alpha-V/beta-8 (ITGB8)</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.016</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-PaidassiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-PaidassiH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Paidassi H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bidat,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Atopy Patch Tests in food allergy: Against</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="209" start="208">208-209</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aliment</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch test</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch tests</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Atopy Patch Tests (APT) to foods are used in current practice solely in France. They have no longer been recommended in the diagnosis of food allergies by European and American allergology societies for several years now</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.008</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170409-BidatE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170409-BidatE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170409, Bidat E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Payot,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Oral immunotherapy for food allergies must always be initiated in a hospital setting: Against</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="156" start="155">155-156</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergie alimentaire</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.006</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-Payot F.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-Payot F.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Payot F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deschildre,A.</style></author><author><style face="normal" font="Arial"> Lejeune,S.</style></author><author><style face="normal" font="Arial"> Cap,M.</style></author><author><style face="normal" font="Arial"> Darmaun,L.</style></author><author><style face="normal" font="Arial"> Meurisse,C.</style></author><author><style face="normal" font="Arial"> Mordacq,C.</style></author><author><style face="normal" font="Arial"> Thumerelle,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Serious food allergies and anti-IgE therapy</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="130" start="128">128-130</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Arachide</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Groundnut</style></keyword><keyword><style face="normal" font="Arial"> Lait</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.026</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DeschildreA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DeschildreA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Deschildre A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Evrard,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The role of intestinal dendritic cells in oral tolerance</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="124" start="123">123-124</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cells</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.014</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-EvrardB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-EvrardB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Evrard B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chandesris,M.O.</style></author><author><style face="normal" font="Arial"> Lortholary,O.</style></author><author><style face="normal" font="Arial"> Hermine,O.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mastocytosis and food</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="188" start="186">186-188</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Activation mastocytaire</style></keyword><keyword><style face="normal" font="Arial"> Alimentation</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Food is a frequent trigger of mast cell activation. Reactions may be serious like anaphylactic shock. Prevention is based on the targeted removal of the implicated foods</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.011</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-ChandesrisMO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-ChandesrisMO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Chandesris MO</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Just,J.</style></author><author><style face="normal" font="Arial"> Amat,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Results of the European survey on adverse systemic reactions in allergen immunotherapy in all forms of reaction</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="157">157-</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthme</style></keyword><keyword><style face="normal" font="Arial"> European Survey</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.138</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.138</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-JustJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-JustJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Just J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.138</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lachaux,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Exploration of digestive signs of food allergy in children</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="117" start="116">116-117</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Digestive tract</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Explorations</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.238</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.238</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-LachauxA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-LachauxA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Lachaux A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.238</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Michaud,B.</style></author><author><style face="normal" font="Arial"> Amat,F.</style></author><author><style face="normal" font="Arial"> Bourgoin-Heck,M.</style></author><author><style face="normal" font="Arial"> Lambert,N.</style></author><author><style face="normal" font="Arial"> Talon,P.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Can oral food challenge be replaced by a laboratory test?</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="115" start="114">114-115</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Challenge</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Oral Food Challenge (OFC)</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.232</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.232</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-MichaudB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-MichaudB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Michaud B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.232</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dainese,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Gastrointestinal food allergy in adults</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="139" start="138">138-139</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disorders</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal food allergy</style></keyword><keyword><style face="normal" font="Arial"> Non-IgE-mediated food-induced syndromes</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.027</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DaineseR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-DaineseR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Dainese R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kuehn,A.</style></author><author><style face="normal" font="Arial"> Codreanu-Morel,F.</style></author><author><style face="normal" font="Arial"> Lehners-Weber,C.</style></author><author><style face="normal" font="Arial"> Doyen,V.</style></author><author><style face="normal" font="Arial"> Gomez-Andre,S.A.</style></author><author><style face="normal" font="Arial"> Bienvenu,F.</style></author><author><style face="normal" font="Arial"> Fischer,J.</style></author><author><style face="normal" font="Arial"> Ballardini,N.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Perotin,J.M.</style></author><author><style face="normal" font="Arial"> Silcret-Grieu,S.</style></author><author><style face="normal" font="Arial"> Chabane,H.</style></author><author><style face="normal" font="Arial"> Hentges,F.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Morisset,M.</style></author><author><style face="normal" font="Arial"> Hilger,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Fish-chicken syndrome: A new form of clinical cross-reactivity</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="207" start="206">206-207</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Chicken</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -CO - Luxembourg -CO - Sweden -CO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.012</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-KuehnA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-KuehnA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Kuehn A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caubet,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome (FPIES) and clinical manifestations of non-IgE-mediated gastrointestinal food allergies</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="137" start="136">136-137</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergie alimentaire</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal food allergy</style></keyword><keyword><style face="normal" font="Arial"> Non-IgE-mediated gastrointestinal food allergies</style></keyword><keyword><style face="normal" font="Arial"> SEIPA</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.009</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-CaubetJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-CaubetJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Caubet JC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Specificities of paediatric anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="135" start="133">133-135</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Aliment</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.01.006</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.01.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170408-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Poue4ssel G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.01.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Van Obberghen,E.K.</style></author><author><style face="normal" font="Arial"> Cohen,M.</style></author><author><style face="normal" font="Arial"> Rocher,F.</style></author><author><style face="normal" font="Arial"> Lebrun-Frenay,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de neurologie, hopital Pasteur 2, centre hospitalier universitaire de Nice, 30, voie Romaine, 06000 Nice cedex 1, France.</style></auth-address><titles><title><style face="normal" font="Arial">Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?</style></title><secondary-title><style face="normal" font="Arial">Rev Neurol (Paris)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Neurol (Paris)</style></full-title></periodical><pages end="224" start="222">222-224</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> familial</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> glatiramer acetate</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hypothyroidism</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune reconstitution</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> MRI</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">Natalizumab (NTZ) is an effective treatment for patients with highly active relapsing remitting multiple sclerosis (MS). However, when the therapy must be interrupted, it is important to anticipate the withdrawal to avoid reactivation or disease rebound. Described here is the case of a 35-year-old woman, with a past history of beta thalassemia, bulimia and asthma, who was diagnosed with MS at age 26. She was treated initially with first-line subcutaneous (sc) immunomodulatory treatments. However, due to liver toxicity, interferon beta-1a sc was interrupted and replaced by glatiramer acetate treatment, which was well tolerated and used for several years. Unfortunately, disease progression with numerous relapses and contrast enhancement on brain MRI led to initiation of NTZ treatment. After more than 2 years of treatment, NTZ was interrupted because of pregnancy, and the patient was again put on glatiramer acetate. Eight weeks after interruption of NTZ therapy, the first signs of diabetes were observed, together with an increase in blood levels of hepatic enzymes, skin reactions such as angioedema and giant urticaria, and hypothyroidism requiring hormone supplementation. The patient delivered her baby without complications, and NTZ was reintroduced several months later. At the present time, the patient's hypothyroidism, diabetes and increased blood levels of hepatic enzymes persist, although no new skin reactions have been observed. Withdrawal of NTZ can not only lead to reactivation of the disease or its rebound, but also to autoimmune manifestations within the framework of immune reconstitution inflammatory syndrome (IRIS). This risk needs to be considered when therapy has to be interrupted, especially when a personal and/or familial past history of autoimmune disease is present</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 0035-3787 (Print)IS - 0035-3787 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.neurol.2017.03.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28372806">PM:28372806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Neurol (Paris)\2017-173-222-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Neurol (Paris)\2017-173-222-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Van Obberghen EK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.neurol.2017.03.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Costa,A.C.</style></author><author><style face="normal" font="Arial"> Duarte,F</style></author><author><style face="normal" font="Arial"> Pedro,E.</style></author><author><style face="normal" font="Arial"> Melo,A.C.</style></author><author><style face="normal" font="Arial"> Pereira-Barbosa,M.</style></author><author><style face="normal" font="Arial"> Pereira Santos,M.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sublingual immunotherapy with peach (Pru p 3): Efficacy and safety</style></title><secondary-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></full-title></periodical><pages end="222" start="211">211-222</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><publisher><style face="normal" font="Arial">scielopt</style></publisher><isbn><style face="normal" font="Arial">0871-9721</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212015000400002&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2015-23-211-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2015-23-211-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150401, Costa AC</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cosme,J.</style></author><author><style face="normal" font="Arial"> Santos,A.S.</style></author><author><style face="normal" font="Arial"> Barbosa,M.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Tropomyosin as a panallegen: Review</style></title><secondary-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></full-title></periodical><pages end="153" start="143">143-153</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Portugal</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="Arial">scielopt</style></publisher><isbn><style face="normal" font="Arial">0871-9721</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000300002&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2016-24-143-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2016-24-143-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160401, Cosme J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosa,S.</style></author><author><style face="normal" font="Arial"> Ribeiro,F.</style></author><author><style face="normal" font="Arial"> Pinto,P.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Baked food ingestion in cow's milk and egg allergy</style></title><secondary-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></full-title></periodical><pages end="24" start="9">9-24</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="Arial">scielopt</style></publisher><isbn><style face="normal" font="Arial">0871-9721</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000100002&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2016-24-9-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2016-24-9-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160401, Rosa S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Almeida,J.P.</style></author><author><style face="normal" font="Arial"> Lopes,A.</style></author><author><style face="normal" font="Arial"> Barbosa,M.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Hypersensitivity to proton pump inhibitors: A rare case report</style></title><secondary-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></full-title></periodical><pages end="36" start="31">31-36</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> Exanthema</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lansoprazole</style></keyword><keyword><style face="normal" font="Arial"> Lip</style></keyword><keyword><style face="normal" font="Arial"> Omeprazole</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="Arial">scielopt</style></publisher><isbn><style face="normal" font="Arial">0871-9721</style></isbn><abstract><style face="normal" font="Arial">Introduction: Hypersensitivity to proton pump inhibitors (PPIs) is rare and cross-reactivity between PPIs must be taken into account. The authors document a case report of delayed hypersensitivity to all PPIs available in Portugal. Case report: 39 year-old woman referred due to drug allergy suspicion, with past history of allergic rhinitis and gastro-esophageal reflux. In 2007 due to a flu-like syndrome she was administered with aspirin and omeprazole intravenously, and generalized itchy rash with lips angioedema was observed 3h later; in 2008 in a similar clinical picture, after oral intake of ibuprofen and omeprazole a reproducible reaction after 6-8h was observed. In 2010, due to gastric complaints she started on omeprazole (40mg/day) but suffered from a generalized rash 6h after the first administration. The sequential intake of lansoprazole, pantoprazole and esomeprazole originated a reproducible reaction. Rabeprazole originated a bullous exanthema in the upper limbs. Our allergological investigation has shown negative prick tests, but intradermal tests were positive (with delayed lecture at 10h) for the 5 PPIs. Conclusion: This is the first reported case of delayed PPI hypersensitivity to all PPIs</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000100004&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2016-24-31-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2016-24-31-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160401, Almeida JP</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,Z.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing 400014, ChinaDepartment of Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing 400014, China</style></auth-address><titles><title><style face="normal" font="Arial">Intrauterine sensitization of ovalbumin in the third trimester increases the risk of food allergy in progeny</style></title><secondary-title><style face="normal" font="Arial">Saudi J Biol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Saudi J Biol Sci</style></full-title></periodical><pages end="677" start="672">672-677</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> First trimester</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> intrauterine</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> lymphocyte proliferation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Intrauterine sensitization caused by food allergens plays an important role in the food allergy development in progeny. The aim of our study was to determine the critical period of intrauterine sensitization during pregnancy. Female mice were exposed to ovalbumin (OVA) during different trimesters of pregnancy. Lymphocytes from their offspring were isolated and cultured, and proliferation was evaluated by CCK-8 assay. The levels of IFN-gamma and IL-4 in serum were measured using ELISA. In addition, the expressions of IFN-gamma and IL-4 mRNAs and proteins were detected by real-time PCR and western blot. The mice were divided into the first trimester pregnancy (FTP1 and FTP2) group, the second trimester pregnancy (STP1 and STP2) group, and the third trimester pregnancy (TTP1 and TTP2) group based on the stages of pregnancy in which their mothers were exposed to OVA and their ages. The OVA-specific lymphocyte proliferation of the TTP1 group was statistically significantly greater that in the FTP1 and STP1 groups. The serum level of IFN-gamma in the TTP1 group was significantly decreased, and the serum level of IL-4 in the TTP1 group was significantly increased compared with the levels in the FTP1 and STP1 groups. The mRNA and protein expression levels of IFN-gamma in the TTP1 group were significantly decreased and the mRNA and protein expression levels of IL-4 in this group were significantly increased compared with the levels in the FTP1 and STP1 groups. Our results suggest that OVA-induced intrauterine sensitization in the third trimester may increase the risk of food allergy after birth</style></abstract><notes><style face="normal" font="Arial">DA - 20170407IS - 1319-562X (Print)IS - 1319-562X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.sjbs.2017.01.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386195">PM:28386195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Saudi J Biol Sci\2017-24-672-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Saudi J Biol Sci\2017-24-672-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170407, Song Z</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.sjbs.2017.01.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Murakami,D.</style></author><author><style face="normal" font="Arial"> Sawatsubashi,M.</style></author><author><style face="normal" font="Arial"> Omori,H.</style></author><author><style face="normal" font="Arial"> Saito,A.</style></author><author><style face="normal" font="Arial"> Kato,A.</style></author><author><style face="normal" font="Arial"> Komune,S.</style></author><author><style face="normal" font="Arial"> Nakagawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a randomized controlled trial</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="46142">46142-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">Current allergen-specific immunotherapy (AIT) for pollinosis requires long-term treatment with potentially severe side effects. Therefore, development of an AIT that is safe and more convenient with a shorter regimen is needed. This prospective, double-blind, placebo-controlled trial randomized 55 participants with Japanese cedar pollinosis (JCP) to active or placebo groups to test the safety and efficacy of short-term oral immunotherapy (OIT) with Cry j 1-galactomannan conjugate for JCP. Mean symptom-medication score as the primary outcome in the active group improved 27.8% relative to the placebo group during the entire pollen season. As the secondary outcomes, mean medication score in active group improved significantly, by 56.2%, compared with placebo during the entire pollen season. Mean total symptom score was similar between active and placebo groups during the entire pollen season. There were no severe treatment-emergent adverse events in the active and placebo groups. Therefore short-term OIT with Cry j 1-galactomannan conjugate is safe, and effective for reducing the amount of medication use for JCP</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep46142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28397833">PM:28397833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-46142.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-46142.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Murakami D</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep46142</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhaliwal,B.</style></author><author><style face="normal" font="Arial"> Pang,M.O.</style></author><author><style face="normal" font="Arial"> Keeble,A.H.</style></author><author><style face="normal" font="Arial"> James,L.K.</style></author><author><style face="normal" font="Arial"> Gould,H.J.</style></author><author><style face="normal" font="Arial"> McDonnell,J.M.</style></author><author><style face="normal" font="Arial"> Sutton,B.J.</style></author><author><style face="normal" font="Arial"> Beavil,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre and Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, U.K</style></auth-address><titles><title><style face="normal" font="Arial">IgE binds asymmetrically to its B cell receptor CD23</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="45533">45533-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Cell surface receptors</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE synthesis</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">The antibody IgE plays a central role in allergic disease mechanisms. Its effector functions are controlled through interactions between the Fc region and two principal cell surface receptors FcepsilonRI and CD23. The interaction with FcepsilonRI is primarily responsible for allergic sensitization and the inflammatory response, while IgE binding to CD23 is involved in the regulation of IgE synthesis and allergen transcytosis. Here we present the crystal structure of a CD23/IgE-Fc complex and conduct isothermal titration calorimetric binding studies. Two lectin-like "head" domains of CD23 bind to IgE-Fc with affinities that differ by more than an order of magnitude, but the crystal structure reveals only one head bound to one of the two identical heavy-chains in the asymmetrically bent IgE-Fc. These results highlight the subtle interplay between receptor binding sites in IgE-Fc and their affinities, the understanding of which may be exploited for therapeutic intervention in allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep45533</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28361904">PM:28361904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-45533.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-45533.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Dhaliwal B</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep45533</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,X.</style></author><author><style face="normal" font="Arial"> Wong,C.C.</style></author><author><style face="normal" font="Arial"> Yu,I.T.</style></author><author><style face="normal" font="Arial"> Zhang,Z.</style></author><author><style face="normal" font="Arial"> Tan,L.</style></author><author><style face="normal" font="Arial"> Lau,A.P.</style></author><author><style face="normal" font="Arial"> Lee,A.</style></author><author><style face="normal" font="Arial"> Yeoh,E.K.</style></author><author><style face="normal" font="Arial"> Lao,X.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China</style></auth-address><titles><title><style face="normal" font="Arial">Dietary patterns and the risk of rhinitis in primary school children: a prospective cohort study</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="44610">44610-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Butter</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Potatoes</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="Arial">This study was to investigate the association between dietary patterns and rhinitis in primary school children. 1,599 students without rhinitis at baseline survey were selected from a primary school children cohort. Information on food consumption, respiratory symptoms, and confounders was collected using questionnaires. Dietary patterns were defined using principal component analysis. Logistic regression was performed to calculate odds ratio (OR) with 95% confidence intervals (95% CI). The incidence of rhinitis during 12 months follow-up was 21.2%. Three patterns were extracted and labeled as pattern I, II and III. Dietary pattern II which had higher factor loadings of legumes, butter, nuts and potatoes was associated with an increased risk of rhinitis (OR: 1.34, 95% CI: 1.01-1.87) when the highest tertile of pattern score was compared to the lowest tertile, after adjusted for confounders. Besides, every 1-unit increase of score of pattern II was also associated with an increased risk of rhinitis (OR: 1.19, 95% CI: 1.05-1.35). Neither pattern I nor Pattern III was observed to be associated with risk of rhinitis. A diet with higher levels of consumption of legumes, butter, nuts and potatoes may increase the risk of allergic rhinitis in primary school children</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep44610</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294150">PM:28294150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-44610.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-44610.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170315, Liu X</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep44610</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wilbers,R.H.</style></author><author><style face="normal" font="Arial"> Westerhof,L.B.</style></author><author><style face="normal" font="Arial"> van Noort,K.</style></author><author><style face="normal" font="Arial"> Obieglo,K.</style></author><author><style face="normal" font="Arial"> Driessen,N.N.</style></author><author><style face="normal" font="Arial"> Everts,B.</style></author><author><style face="normal" font="Arial"> Gringhuis,S.I.</style></author><author><style face="normal" font="Arial"> Schramm,G.</style></author><author><style face="normal" font="Arial"> Goverse,A.</style></author><author><style face="normal" font="Arial"> Smant,G.</style></author><author><style face="normal" font="Arial"> Bakker,J.</style></author><author><style face="normal" font="Arial"> Smits,H.H.</style></author><author><style face="normal" font="Arial"> Yazdanbakhsh,M.</style></author><author><style face="normal" font="Arial"> Schots,A.</style></author><author><style face="normal" font="Arial"> Hokke,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Nematology, Plant Sciences Group, Wageningen University and Research, Droevendaalsesteeg 1, 6708 PB Wageningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Production and glyco-engineering of immunomodulatory helminth glycoproteins in plants</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="45910">45910-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> glycoprotein antigen</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Glycosyltransferases</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Motifs</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> N-glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma mansoni</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="10" Month="4" Year="2017">2017/4/10</year></dates><abstract><style face="normal" font="Arial">Helminth parasites control host-immune responses by secreting immunomodulatory glycoproteins. Clinical trials and mouse model studies have demonstrated the potential of helminth-derived glycoproteins for the treatment of immune-related diseases, like allergies and autoimmune diseases. Studies are however hampered by the limited availability of native parasite-derived proteins. Moreover, recombinant protein production systems have thus far been unable to reconstitute helminth-like glycosylation essential for the functionality of some helminth glycoproteins. Here we exploited the flexibility of the N-glycosylation machinery of plants to reconstruct the helminth glycoproteins omega-1 and kappa-5, two major constituents of immunomodulatory Schistosoma mansoni soluble egg antigens. Fine-tuning transient co-expression of specific glycosyltransferases in Nicotiana benthamiana enabled the synthesis of Lewis X (LeX) and LDN/LDN-F glycan motifs as found on natural omega-1 and kappa-5, respectively. In vitro and in vivo evaluation of the introduction of native LeX motifs on plant-produced omega-1 confirmed that LeX on omega-1 contributes to the glycoprotein's Th2-inducing properties. These data indicate that mimicking the complex carbohydrate structures of helminths in plants is a promising strategy to allow targeted evaluation of therapeutic glycoproteins for the treatment of inflammatory disorders. In addition, our results offer perspectives for the development of effective anti-helminthic vaccines by reconstructing native parasite glycoprotein antigens</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Germany -</style></notes><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393916">PM:28393916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-45910.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-45910.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Wilbers RH</style></custom2></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,Z.J.</style></author><author><style face="normal" font="Arial"> Zeng,L.</style></author><author><style face="normal" font="Arial"> Luo,X.Q.</style></author><author><style face="normal" font="Arial"> Geng,X.R.</style></author><author><style face="normal" font="Arial"> Xu,R.</style></author><author><style face="normal" font="Arial"> Chen,K.</style></author><author><style face="normal" font="Arial"> Yang,G.</style></author><author><style face="normal" font="Arial"> Luo,X.</style></author><author><style face="normal" font="Arial"> Liu,Z.Q.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Liu,D.B.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author><author><style face="normal" font="Arial"> Li,H.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Affiliated Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510115, China</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D3 inhibits micro RNA-17-92 to promote specific immunotherapy in allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="546">546-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamin D3</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="3" Month="4" Year="2017">2017/4/3</year></dates><abstract><style face="normal" font="Arial">It is recognized that T helper 2 (Th2) polarization plays a critical role in a large number of immune disorders. Yet, the remedies for reconciling the established Th2 polarization are still limited currently. Published data indicate that micro RNA-17-92 cluster is associated with the skewed immune response; 25 vitamin D3 (VD3) can regulate multiple bioactivities in the body. This study tests a hypothesis that VD3 facilitates the effect of specific immunotherapy (SIT) on Th2 response. We observed that treatment with either SIT or VD3 alleviated AR symptoms as well as reduced serum levels of specific IgE and T helper (Th) 2 cytokines, suppressed miR-19a (one of the members of the miR-17-92 cluster) and increased IL-10 in peripheral B cells, which was further improved in those AR patients treated with both SIT and VD3. The expression of miR-19a and IL-10 was significantly negatively correlated with each other in peripheral B cells of AR patients. Metabolites of VD3 formed a complex with retinoid acid receptor to repress the expression of miR-19a in B cells. We conclude that administration with VD3 promotes the effect of SIT on suppression of AR via repressing the expression of miR-19a in peripheral B cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-00431-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28373650">PM:28373650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-546.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-546.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Yu ZJ</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-00431-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sharma,P.</style></author><author><style face="normal" font="Arial"> Yi,R.</style></author><author><style face="normal" font="Arial"> Nayak,A.P.</style></author><author><style face="normal" font="Arial"> Wang,N.</style></author><author><style face="normal" font="Arial"> Tang,F.</style></author><author><style face="normal" font="Arial"> Knight,M.J.</style></author><author><style face="normal" font="Arial"> Pan,S.</style></author><author><style face="normal" font="Arial"> Oliver,B.</style></author><author><style face="normal" font="Arial"> Deshpande,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Center for Translational Medicine, Thomas Jefferson University, Philadelphia, PA, 19107, USA</style></auth-address><titles><title><style face="normal" font="Arial">Bitter Taste Receptor Agonists Mitigate Features of Allergic Asthma in Mice</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="46166">46166-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bitter taste</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Chloroquine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disease models</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="Arial">Asthma is characterized by airway inflammation, mucus secretion, remodeling and hyperresponsiveness (AHR). Recent research has established the bronchodilatory effect of bitter taste receptor (TAS2R) agonists in various models. Comprehensive pre-clinical studies aimed at establishing effectiveness of TAS2R agonists in disease models are lacking. Here we aimed to determine the effect of TAS2R agonists on features of asthma. Further, we elucidated a mechanism by which TAS2R agonists mitigate features of asthma. Asthma was induced in mice using intranasal house dust mite or aerosol ova-albumin challenge, and chloroquine or quinine were tested in both prophylactic and treatment models. Allergen challenge resulted in airway inflammation as evidenced by increased immune cells infiltration and release of cytokines and chemokines in the lungs, which were significantly attenuated in TAS2R agonists treated mice. TAS2R agonists attenuated features of airway remodeling including smooth muscle mass, extracellular matrix deposition and pro-fibrotic signaling, and also prevented mucus accumulation and development of AHR in mice. Mechanistic studies using human neutrophils demonstrated that inhibition of immune cell chemotaxis is a key mechanism by which TAS2R agonists blocked allergic airway inflammation and exerted anti-asthma effects. Our comprehensive studies establish the effectiveness of TAS2R agonists in mitigating multiple features of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep46166</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28397820">PM:28397820</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-46166.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-46166.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170411, Sharma P</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep46166</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bartel,S.</style></author><author><style face="normal" font="Arial"> Schulz,N.</style></author><author><style face="normal" font="Arial"> Alessandrini,F.</style></author><author><style face="normal" font="Arial"> Schamberger,A.C.</style></author><author><style face="normal" font="Arial"> Pagel,P.</style></author><author><style face="normal" font="Arial"> Theis,F.J.</style></author><author><style face="normal" font="Arial"> Milger,K.</style></author><author><style face="normal" font="Arial"> Noessner,E.</style></author><author><style face="normal" font="Arial"> Stick,S.M.</style></author><author><style face="normal" font="Arial"> Kicic,A.</style></author><author><style face="normal" font="Arial"> Eickelberg,O.</style></author><author><style face="normal" font="Arial"> Freishtat,R.J.</style></author><author><style face="normal" font="Arial"> Krauss-Etschmann,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Early origins of chronic lung disease, Priority Area Asthma &amp;Allergy, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Borstel, Germanys</style></auth-address><titles><title><style face="normal" font="Arial">Pulmonary microRNA profiles identify involvement of Creb1 and Sec14l3 in bronchial epithelial changes in allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="46026">46026-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">air-liquid interface</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> bronchial epithelium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miR-21</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">Asthma is highly prevalent, but current therapies cannot influence the chronic course of the disease. It is thus important to understand underlying early molecular events. In this study, we aimed to use microRNAs (miRNAs) - which are critical regulators of signaling cascades - to identify so far uncharacterized asthma pathogenesis pathways. Therefore, deregulation of miRNAs was assessed in whole lungs from mice with ovalbumin (OVA)-induced allergic airway inflammation (AAI). In silico predicted target genes were confirmed in reporter assays and in house-dust-mite (HDM) induced AAI and primary human bronchial epithelial cells (NHBE) cultured at the air-liquid interface. We identified and validated the transcription factor cAMP-responsive element binding protein (Creb1) and its transcriptional co-activators (Crtc1-3) as targets of miR-17, miR-144, and miR-21. Sec14-like 3 (Sec14l3) - a putative target of Creb1 - was down-regulated in both asthma models and in NHBE cells upon IL13 treatment, while it's expression correlated with ciliated cell development and decreased along with increasing goblet cell metaplasia. Finally, we propose that Creb1/Crtc1-3 and Sec14l3 could be important for early responses of the bronchial epithelium to Th2-stimuli. This study shows that miRNA profiles can be used to identify novel targets that would be overlooked in mRNA based strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20170406IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep46026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28383034">PM:28383034</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-46026.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-46026.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170406, Bartel S</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep46026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hong,M.</style></author><author><style face="normal" font="Arial"> Park,J.B.</style></author><author><style face="normal" font="Arial"> Kim,Y.S.</style></author><author><style face="normal" font="Arial"> Lee,D.H.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Lee,J.I.</style></author><author><style face="normal" font="Arial"> Ahn,H.S.</style></author><author><style face="normal" font="Arial"> Sohn,T.S.</style></author><author><style face="normal" font="Arial"> Lee,T.K.</style></author><author><style face="normal" font="Arial"> Song,J.Y.</style></author><author><style face="normal" font="Arial"> Jeong,S.C.</style></author><author><style face="normal" font="Arial"> Yeo,C.D.</style></author><author><style face="normal" font="Arial"> Chae,H.S.</style></author><author><style face="normal" font="Arial"> Do,Han K.</style></author><author><style face="normal" font="Arial"> Vu,D.</style></author><author><style face="normal" font="Arial"> Lee,Y.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Epidemiology Study Cluster of Uijeongbu St. Mary's Hospital, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association between Cockroach-specific Immunoglobulin E and periodontitis in Korean male adults Based on Korean National Health and Nutrition Examination Survey</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="46373">46373-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> dentist</style></keyword><keyword><style face="normal" font="Arial"> Dentists</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Insulin Resistance</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Periodontitis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Tooth</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="Arial">Periodontitis is an inflammatory disease affecting the tooth supporting tissues (periodontium) and associated with chronic diseases such as cardiovascular disease and insulin resistance. However, there has been no nation-wide population based epidemiologic study regarding any association between periodontitis and serum IgE. Among the 8,958 participants in the 2010 Korean National Health and Nutrition Examination Survey (KNHANES V-1), 1,731 adults aged 19 to 64 who had measured serum IgE were included in the analysis. Dentists examined the periodontal status of the participants. Multiple logistic regression analyses were used to evaluate the odds ratio of periodontitis in association with total IgE and specific IgE to cockroach and house dust mite. In males, total IgE showed a positive correlation with the presence of periodontitis. The participants in the highest tertile of cockroach specific IgE (T3, >31.6 kU/L) had a significantly increased risk of periodontitis (OR = 2.108; 95% CI, 1.233-3.606). In females, the inverse association occurred between total IgE and periodontitis (OR = 0.409; 95% CI, 0.200-0.839). The present study firstly demonstrated the association between periodontitis and serum IgE, using the Korean nationwide, population-based, cross-sectional health examination and survey. This study suggested a positive correlation between periodontitis and cockroach-specific IgE in Korean male adults</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep46373</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401926">PM:28401926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-46373.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-46373.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Hong M</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep46373</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roth-Walter,F.</style></author><author><style face="normal" font="Arial"> Bergmayr,C.</style></author><author><style face="normal" font="Arial"> Meitz,S.</style></author><author><style face="normal" font="Arial"> Buchleitner,S.</style></author><author><style face="normal" font="Arial"> Stremnitzer,C.</style></author><author><style face="normal" font="Arial"> Fazekas,J.</style></author><author><style face="normal" font="Arial"> Moskovskich,A.</style></author><author><style face="normal" font="Arial"> Muller,M.A.</style></author><author><style face="normal" font="Arial"> Roth,G.A.</style></author><author><style face="normal" font="Arial"> Manzano-Szalai,K.</style></author><author><style face="normal" font="Arial"> Dvorak,Z.</style></author><author><style face="normal" font="Arial"> Neunkirchner,A.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Comparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Janus-faced Acrolein prevents allergy but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse model for passive respiratory exposure</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="45067">45067-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acrolein</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Resveratrol</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="Arial">Acrolein, a highly reactive unsaturated aldehyde, is generated in large amounts during smoking and is best known for its genotoxic capacity. Here, we aimed to assess whether acrolein at concentrations relevant for smokers may also exert immunomodulatory effects that could be relevant in allergy or cancer. In a BALB/c allergy model repeated nasal exposure to acrolein abrogated allergen-specific antibody and cytokine formation, and led to a relative accumulation of regulatory T cells in the lungs. Only the acrolein-treated mice were protected from bronchial hyperreactivity as well as from anaphylactic reactions upon challenge with the specific allergen. Moreover, grafted D2F2 tumor cells grew faster and intratumoral Foxp3+ cell accumulation was observed in these mice compared to sham-treated controls. Results from reporter cell lines suggested that acrolein acts via the aryl-hydrocarbon receptor which could be inhibited by resveratrol and 3'-methoxy-4'-nitroflavone Acrolein- stimulation of human PBMCs increased Foxp3+ expression by T cells which could be antagonized by resveratrol. Our mouse and human data thus revealed that acrolein exerts systemic immunosuppression by promoting Foxp3+ regulatory cells. This provides a novel explanation why smokers have a lower allergy, but higher cancer risk</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1038/srep45067</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332605">PM:28332605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-45067.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-45067.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Roth-Walter F</style></custom2><misc3><style face="normal" font="Arial">10.1038/srep45067</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,H.S.</style></author><author><style face="normal" font="Arial"> Park,M.K.</style></author><author><style face="normal" font="Arial"> Kang,S.A.</style></author><author><style face="normal" font="Arial"> Cho,K.S.</style></author><author><style face="normal" font="Arial"> Mun,S.J.</style></author><author><style face="normal" font="Arial"> Roh,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Pusan National University School of Medicine, Yangsan, 626-870, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Culture supernatant of adipose stem cells can ameliorate allergic airway inflammation via recruitment of CD4+CD25+Foxp3 T cells</style></title><secondary-title><style face="normal" font="Arial">Stem Cell Res Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Stem Cell Res Ther</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Adipose tissue</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> CTLA-4</style></keyword><keyword><style face="normal" font="Arial"> CTLA4</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Culture Media</style></keyword><keyword><style face="normal" font="Arial"> Culture medium</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In a previous study, we demonstrated that intravenous administration of adipose tissue stem cells (ASCs) could significantly reduce allergic symptoms and suppress eosinophilic inflammation. METHODS: To evaluate the secretome of ASCs, we administrated culture supernatant of ASCs (ASC sup, which contains the ASC secretome) and uncultured fresh medium (con sup) into a mouse model of allergic airway inflammation. Subsequently we observed the mice for signs of inflammation and investigated Th1-, Th2-, and Treg-related cytokine levels as well as recruitment of Treg cells into the airway. RESULTS: We found that ASC sup could ameliorate allergic airway inflammation in this model; the value of airway hyperresponsiveness, and the occurrence of inflammatory cell infiltration in the lung, as well as the number of eosinophils, and goblet cells in the lung epithelium were all significantly decreased by ASC sup treatment. In addition, ASC sup treatment significantly decreased the levels of IL-4, IL-5, and IL-13 in the bronchial alveolar lavage fluid and in culture medium of lung-draining lymph node cells of the animal model of acute asthma. We detected numerous CTLA-4 and Foxp3-expressing cells in the lung after ASC sup treatment. ASC sup was found to have a higher concentration of IL-10 and TGF-beta compared to con sup. CONCLUSIONS: Stem cells have powerful potential for therapeutic functions in various diseases, but they also have many drawbacks. In this study, we found strong immunosuppressive ability of ASC sup in an allergic airway mouse model. It may be possible to use ASC sup for treatment of many immunological diseases in the near future</style></abstract><notes><style face="normal" font="Arial">DA - 20170124IS - 1757-6512 (Electronic)IS - 1757-6512 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13287-016-0462-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28114970">PM:28114970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Stem Cell Res Ther\2017-8-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Stem Cell Res Ther\2017-8-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170124, Yu HS</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13287-016-0462-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dumont,C.</style></author><author><style face="normal" font="Arial"> Barroso,J.</style></author><author><style face="normal" font="Arial"> Matys,I.</style></author><author><style face="normal" font="Arial"> Worth,A.</style></author><author><style face="normal" font="Arial"> Casati,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Joint Research Centre, European Commission, Ispra, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of the Local Lymph Node Assay (LLNA) variability for assessing the prediction of skin sensitisation potential and potency of chemicals with non-animal approaches</style></title><secondary-title><style face="normal" font="Arial">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicol In Vitro</style></full-title></periodical><pages end="228" start="220">220-228</pages><volume><style face="normal" font="Arial">34</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal Testing Alternatives</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> hapten</style></keyword><keyword><style face="normal" font="Arial"> Haptens</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">The knowledge of the biological mechanisms leading to the induction of skin sensitisation has favoured in recent years the development of alternative non-animal methods. During the formal validation process, results from the Local Lymph Node Assay (LLNA) are generally used as reference data to assess the predictive capacity of the non-animal tests. This study reports an analysis of the variability of the LLNA for a set of chemicals for which multiple studies are available and considers three hazard classification schemes: POS/NEG, GHS/CLP and ECETOC. As the type of vehicle used in a LLNA study is known to influence to some extent the results, two analyses were performed: considering the solvent used to test the chemicals and without considering the solvent. The results show that the number of discordant classifications increases when a chemical is tested in more than one solvent. Moreover, it can be concluded that study results leading to classification in the strongest classes (1A and EXT) seem to be more reliable than those in the weakest classes. This study highlights the importance of considering the variability of the reference data when evaluating non-animal tests</style></abstract><notes><style face="normal" font="Arial">DA - 20160610IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Journal ArticleRN - 0 (Haptens)SB - IMCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tiv.2016.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27085510">PM:27085510</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol In Vitro\2016-34-220-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol In Vitro\2016-34-220-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160610, Dumont C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tiv.2016.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Urbisch,D.</style></author><author><style face="normal" font="Arial"> Honarvar,N.</style></author><author><style face="normal" font="Arial"> Kolle,S.N.</style></author><author><style face="normal" font="Arial"> Mehling,A.</style></author><author><style face="normal" font="Arial"> Ramirez,T.</style></author><author><style face="normal" font="Arial"> Teubner,W.</style></author><author><style face="normal" font="Arial"> Landsiedel,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Peptide reactivity associated with skin sensitization: The QSAR Toolbox and TIMES compared to the DPRA</style></title><secondary-title><style face="normal" font="Arial">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicol In Vitro</style></full-title></periodical><pages end="203" start="194">194-203</pages><volume><style face="normal" font="Arial">34</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Butanones</style></keyword><keyword><style face="normal" font="Arial"> Chalcones</style></keyword><keyword><style face="normal" font="Arial"> Computer Simulation</style></keyword><keyword><style face="normal" font="Arial"> Cyclohexanones</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Furans</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hapten</style></keyword><keyword><style face="normal" font="Arial"> Haptens</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> in silico tools</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Models,Theoretical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pyruvates</style></keyword><keyword><style face="normal" font="Arial"> QSAR</style></keyword><keyword><style face="normal" font="Arial"> Quantitative Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin sensitization</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Transformation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="Arial">The molecular initiating event (MIE) of skin sensitization is the binding of a hapten to dermal proteins. This can be assessed using the in chemico direct peptide reactivity assay (DPRA) or in silico tools such as the QSAR Toolbox and TIMES SS. In this study, the suitability of these methods was analyzed by comparing their results to in vivo sensitization data of LLNA and human studies. Compared to human data, 84% of non-sensitizers and sensitizers yielded consistent results in the DPRA. In silico tools resulted in 'no alert' for 83%-100% of the non-sensitizers, but alerted only 55%-61% of the sensitizers. The inclusion of biotic and abiotic transformation simulations yielded more alerts for sensitizers, but simultaneously dropped the number of non-alerted non-sensitizers. In contrast to the DPRA, in silico tools were more consistent with results of the LLNA than human data. Interestingly, the new "DPRA profilers" (QSAR Toolbox) provided unsatisfactory results. Additionally, the results were combined in the '2 out of 3' prediction model with in vitro data derived from LuSens and h-CLAT. Using DPRA results, the model identified 90% of human sensitizers and non-sensitizers; using in silico results (including abiotic and biotic activations) instead of DPRA results led to a comparable high predictivity</style></abstract><notes><style face="normal" font="Arial">DA - 20160610IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Journal ArticleRN - 0 (Butanones)RN - 0 (Chalcones)RN - 0 (Cyclohexanones)RN - 0 (Furans)RN - 0 (Haptens)RN - 0 (Peptides)RN - 0 (Pyruvates)RN - 0 (alpha-furil)RN - 3KJM65G5XL (methyl pyruvate)RN - 874-23-7 (2-acetylcyclohexanone)RN - I3RUV8U115 (benzoylacetone)RN - ZB5XA3GD0I (1-phenyl-1,2-propanedione)SB - IMCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tiv.2016.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27090964">PM:27090964</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol In Vitro\2016-34-194-203.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol In Vitro\2016-34-194-203.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160610, Urbisch D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tiv.2016.04.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hwang,Y.H.</style></author><author><style face="normal" font="Arial"> Paik,M.J.</style></author><author><style face="normal" font="Arial"> Yee,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy, Sunchon National University, 255 Jungangno, Suncheon 540-950, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Diisononyl phthalate induces asthma via modulation of Th1/Th2 equilibrium</style></title><secondary-title><style face="normal" font="Arial">Toxicol Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicol Lett</style></full-title></periodical><pages end="59" start="49">49-59</pages><volume><style face="normal" font="Arial">272</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Caspase 1</style></keyword><keyword><style face="normal" font="Arial"> caspase-1</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Equilibrium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Polyvinyl Chloride</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="3" Year="2017">2017/3/12</year></dates><abstract><style face="normal" font="Arial">Diisononyl phthalate (DINP), a member of the phthalate family, is used to plasticize polyvinyl chloride (PVC). This chemical is known to enhance airway inflammation in the OVA-induced asthma model (adjuvant effects) and aggravate allergic dermatitis. Moreover, DINP enhances the production of interleukin-4 in activated CD4+ T cells. However, the effect of DINP itself on the differentiation of naive CD4+ T cells into T helper cells (Th1/Th2) in vitro and allergic asthma in vivo has not yet been studied. In this study, DINP was shown to suppress the polarization of Th1 and enhance the polarization of Th2 from naive CD4+ T cells in vitro. Also, DINP induced allergic asthma via the production of IL-4, IL-5, IgE and IgG1 and the reduction of IFN-gamma and IgG2a. Finally, we confirmed that exposure to DINP induces the infiltration of inflammatory cells and PAS positive cells and increases the expression of caspase-1 and caspase-3 in asthmatic mice. In conclusion, we suggest that DINP as an environmental pollutant or endocrine disruptor (ECD) induces asthma via the modulation of the Th1/Th2 equilibrium and production of Th2 mediated cytokines and immunoglobulin</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1879-3169 (Electronic)IS - 0378-4274 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.toxlet.2017.03.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28300662">PM:28300662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol Lett\2017-272-49-59.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol Lett\2017-272-49-59.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Hwang YH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.toxlet.2017.03.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,C.</style></author><author><style face="normal" font="Arial"> Song,Y.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Zhao,L.</style></author><author><style face="normal" font="Arial"> Kang,H.</style></author><author><style face="normal" font="Arial"> Ma,X.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Zhang,T.</style></author><author><style face="normal" font="Arial"> Shumin,W.</style></author><author><style face="normal" font="Arial"> Ma,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Cardiology , the Second Affiliated Hospital, Medical School of Xi?an Jiaotong University , Xi'an , P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">The effects of chrysophanol on ovalbumin (OVA)-induced chronic lung toxicology by inhibiting Th17 response</style></title><secondary-title><style face="normal" font="Arial">Toxicol Mech Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicol Mech Methods</style></full-title></periodical><pages end="334" start="327">327-334</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-6</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> Th17 response</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Chrysophanol (CH), extracted from plants of Rheum genus, possesses various pharmacological effects including anti-inflammatory activity. The purpose of the present study was to evaluate the protective effects and the underlying mechanisms of CH on ovalbumin (OVA)-induced asthma in mice. Fifty mice were randomly assigned to five experimental groups: control group, model group, dexamethasone (2 mg/kg) group and CH (5 and 10 mg/kg) groups. The number of eosinophil cells and the production of interleukin-6 (IL-6), IL-1beta, IL-17 A and tumor necrosis factor-alpha in bronchoalveolar lavage fluid (BALF) were measured. In addition, pulmonary histopathology, airway resistance (Raw), T-helper17 (Th17) cells frequency and RORgammat expression were evaluated. Our study demonstrated that CH effectively decreased eosinophil count and inflammatory cytokines production in BALF. In addition, treatment with CH significantly inhibited the Raw, Th17 percentage and RORgammat expression in OVA-induced animals compared with those in model group. Histological studies also demonstrated that CH significantly suppressed OVA-induced eosinophilia in lung tissue compared with model group. Our findings supported that CH can prevent allergic asthma in the mouse model</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 1537-6524 (Electronic)IS - 1537-6516 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3109/15376516.2015.1053653</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28399782">PM:28399782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol Mech Methods\2017-27-327-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol Mech Methods\2017-27-327-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Zhang C</style></custom2><misc3><style face="normal" font="Arial">10.3109/15376516.2015.1053653</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouzot-Nevoret,C.</style></author><author><style face="normal" font="Arial"> Cambournac,M.</style></author><author><style face="normal" font="Arial"> Viole,A.</style></author><author><style face="normal" font="Arial"> Goy-Thollot,I.</style></author><author><style face="normal" font="Arial"> Bourdoiseau,G.</style></author><author><style face="normal" font="Arial"> Barthelemy,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Intensive Care Unit (SIAMU), Univ Lyon, VetAgro Sup, APCSe, F-69280, Marcy l'Etoile, France.</style></auth-address><titles><title><style face="normal" font="Arial">Pine processionary caterpillar Thaumetopoea pityocampa envenomation in 109 dogs: A retrospective study</style></title><secondary-title><style face="normal" font="Arial">Toxicon</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicon</style></full-title></periodical><pages end="5" start="1">1-5</pages><volume><style face="normal" font="Arial">132</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flushing</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> long-term follow-up</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="Arial">Contact with the caterpillars of the pine processionary moth (CPPM) Thaumetopoea pityocampa induces severe local allergic reactions. The purpose of this large-scale retrospective cohort-study was to describe the clinical manifestations and related risk factors of CPPM exposure. This cohort-study included 109 dogs between the years of 2000 and 2016. Tongue lesions ranging from oedema to severe necrosis were observed in 94/109 dogs (86%). The following systemic signs were observed in 60/109 dogs (55%): vomiting (52/109, 48%), dyspnoea (6/109, 5%), hypovolemia (4/109, 4%) and diarrhoea (2/109, 2%). Based on the time elapsed from CPPM contact to the first oral flushing, three groups were defined: &lt;2 h (group 1, 37/105, 35%), 2 h-6 h (group 2, 39/105, 37%) and >6 h (group 3, 29/105, 28%). Tongue necrosis (TN) at admission was significantly more common in the dogs in group 3 than those in groups 1 and 2 (45% vs. 5% and 5% respectively, p = 0.0002). In addition, the development of TN during hospitalisation was significantly more common in the dogs in group 3 (65%) than in those in the other groups (21% in group 1, p = 0.02) and 31% in group 2, p = 0.001). The dogs in group 3 presented a 14.63-fold higher risk of TN at admission and a 3.78-fold higher risk of developing necrosis during hospitalisation compared with the other groups. The survival rate after exposure was 97%. Long-term follow-up data were available for 69/109 dogs (63%). Twenty-three dogs (37%) had persistent, definitive TN without major consequences on quality of life. Elapsed time between contact and first oral flushing appears to be a key determinant for the progression of necrotic lesions, and the best results were observed when flushing occurred within 6 h of contact. The prognosis of CPPM envenomation is excellent, with a short hospitalisation duration</style></abstract><notes><style face="normal" font="Arial">DA - 20170330IS - 1879-3150 (Electronic)IS - 0041-0101 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.toxicon.2017.03.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28356233">PM:28356233</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicon\2017-132-1-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicon\2017-132-1-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170330, Pouzot-Nevoret C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.toxicon.2017.03.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lambert,T.</style></author><author><style face="normal" font="Arial"> Rothschild,C.</style></author><author><style face="normal" font="Arial"> Volot,F.</style></author><author><style face="normal" font="Arial"> Borel-Derlon,A.</style></author><author><style face="normal" font="Arial"> Trossaert,M.</style></author><author><style face="normal" font="Arial"> Claeyssens-Donadel,S.</style></author><author><style face="normal" font="Arial"> Attal,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Haemophilia Care Centre, Bicetre APHP University Hospital, Le Kremlin, Bicetre, France</style></auth-address><titles><title><style face="normal" font="Arial">A national French noninterventional study to assess the long-term safety and efficacy of reformulated nonacog alfa</style></title><secondary-title><style face="normal" font="Arial">Transfusion</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfusion</style></full-title></periodical><pages end="1071" start="1066">1066-1071</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Agglutination</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Factor IX</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Haemophilia</style></keyword><keyword><style face="normal" font="Arial"> Hemophilia B</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Nonacog alfa, the recombinant Factor IX (F IX) used for the treatment of hemophilia B, was approved in Europe in 1998. A reformulated version was approved for European use in 2007. STUDY DESIGN AND METHODS: This postmarketing study, as recommended by the risk management plan, was conducted to confirm the safety of reformulated nonacog alfa in a usual care setting in France. This open-label, noninterventional, prospective, longitudinal postmarketing study comprised 19 French hemophilia centers. Patients with hemophilia B receiving reformulated nonacog alfa for prophylaxis or on-demand treatment were followed up on usual care schedule. RESULTS: A total of 58 subjects were enrolled, of whom 29 (50%) were less than 18 years of age. Hemophilia was severe (baseline F IX activity &lt; 1%) in 47 (81%) patients. All subjects except one were already treated with reformulated nonacog alfa before enrollment. One subject was receiving reformulated nonacog alfa as immune tolerance induction at time of enrollment. At enrollment, treatment regimen was mainly prophylactic in subjects less than 18 years and on-demand in subjects 18 years or older. Median duration of follow-up in the survey was 3.3 (2.3-3.8) years. The median annualized bleeding rate was 3.9 (1.5-5.2) for prophylaxis regimen and 12.2 (3.9-22.1) for on-demand regimen. One subject, a previously untreated patient, developed F IX inhibitors during follow-up. No allergic reaction, no blood cell agglutination, no lack of efficacy or recovery, and no thrombotic events were reported. CONCLUSION: Reformulated nonacog alfa was shown to be safe in a usual care setting</style></abstract><notes><style face="normal" font="Arial">DA - 20170324IS - 1537-2995 (Electronic)IS - 0041-1132 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/trf.13988</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28337764">PM:28337764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfusion\2017-57-1066-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfusion\2017-57-1066-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170324, Lambert C</style></custom2><misc3><style face="normal" font="Arial">10.1111/trf.13988</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Priyadarshan,P.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Refinements to Hevea rubber breeding</style></title><secondary-title><style face="normal" font="Arial">Tree Genet Genom</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Tree Genet Genom</style></full-title></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Chloroplast DNA</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> EST</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic analysis</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Hevea</style></keyword><keyword><style face="normal" font="Arial"> Hevea brasiliensis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seedling</style></keyword><keyword><style face="normal" font="Arial"> Seedlings</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> Soil</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1614-2950</style></isbn><abstract><style face="normal" font="Arial">Hevea brasiliensis (Willd. Ex. A. de. Juss. M++ell-Arg.) is the prime source of natural rubber. Domestication of rubber began since 1876 with Wickham collecting 70,000 seeds from Upper Amazon and transported them to Kew Botanic Gardens. Somehow, rubber trees covering millions of hectares are believed to be derived from </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£22 seedlings</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ of Wickham</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs original stock. Improving dry rubber yield is the exclusive and ultimate objective of Hevea breeding with consistent yield of 70 to 80-ág/tree/tapping. Ultimately, in a small holding, a planter must gain an average yield of around 2200 to 2400 kg/ha from his stand (under optimal conditions), after accommodating tree-to-tree variations due to stock-scion interactions and soil heterogeneity. This is arduous, but achievable. Initial production of high-yielding clones gave 1600 kg/ha against 496-ákg/ha of unselected seedlings. Adaptation and yielding potential of clones to specific environments are optimized through localized experimentation. Studies on adaptation of clones to new environments, especially to sub-optimal or marginal areas, are gaining momentum. As this extension happens, demand for new clones is on the rise. Possibilities of using rubber trees for reforestation, carbon sequestration and application of genomics in deriving climate resilient clones may come up in future, which breeders may have to take up with required priority. Five major methodologies followed are (a) primary clones and seed gardens, (b) derivation of recombinants and clone selection, (c) genetic analysis and variability management (d) early selection and estimation of genetic value and (e) application of genomics. Primary clones have immensely contributed in exploiting heterosis and production of new clones. For evaluation of recombinants, families are to be raised in closer spacing (2 or 3-ám) and allowed to attain tappable girth for evaluation. While a normal breeding cycle takes 35 to 40-áyears, through skipping SSCTs and LSCTs, the scheme proposed can derive a clone in 17-áyears. Recent advances like transcriptome sequencing of bark and EST sequences generated from suppression subtractive hybridization-cDNA libraries could facilitate marker-assisted selection that could very well be used for selecting high-yielding genotypes at juvenile stage. Paternity identification can be done through breeding without breeding (BwB) in half-sibs and poly-cross (open pollinated) seedlings. Transcriptome studies have to come a long way to yield meaningful results to tag vivid genes responsible for QTLs, resistance and other quality traits, especially markers for cold/drought stress. It is opined that instead of subjecting plants for artificial cold/drought conditions, plants continuously exposed to such stress conditions must be used for analyses that can give a comprehensive indication of stress tolerance. The application of genotyping-by-sequencing (GBS) technique to simultaneously discover and delineate single nucleotide polymorphism (SNP) markers is a robust and cost-effective approach for generating a common set of genome-wide SNP data suitable for constructing integrated linkage maps from multiple populations. Studies on mitochondrial and chloroplast DNAs are welcome steps towards understanding ATP efficiency of accessions that need to be augmented further, so that clones with higher ATP efficiency can be used for breeding. Such innovative techniques shall govern breeding Hevea rubber in the future, only when breeders and genomic specialists are working in tandem</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11295-017-1101-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s11295-017-1101-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Tree Genet Genom\2017-13-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Tree Genet Genom\2017-13-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170422, Priyadarshan PM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11295-017-1101-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cabezas-Cruz,A.</style></author><author><style face="normal" font="Arial"> Mateos-Hernandez,L.</style></author><author><style face="normal" font="Arial"> Chmelar,J.C.</style></author><author><style face="normal" font="Arial"> Villar,M.</style></author><author><style face="normal" font="Arial"> de la Fuente,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Parasitology, Biology Center of the Academy of Sciences of the Czech Republic</style></auth-address><titles><title><style face="normal" font="Arial">Salivary Prostaglandin E2: Role in Tick-Induced Allergy to Red Meat</style></title><secondary-title><style face="normal" font="Arial">Trends Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Trends Parasitol</style></full-title></periodical><pages end="498" start="495">495-498</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antibody class switching</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin E2</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick-induced allergies</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="29" Month="3" Year="2017">2017/3/29</year></dates><abstract><style face="normal" font="Arial">Tick-induced allergy to red meat is associated with anti-alpha-Gal IgE antibody levels. We propose that tick salivary prostaglandin E2 triggers antibody class switching in mature B cells, increasing the levels of anti-alpha-Gal IgE antibodies. Immune tolerance to alpha-Gal in blood type B individuals might reduce the risk to this allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170402IS - 1471-5007 (Electronic)IS - 1471-4922 (Linking)LA - engPT - Journal ArticleCO - Czech Republic -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pt.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28365087">PM:28365087</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trends Parasitol\20170402-CabezasCruzA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trends Parasitol\20170402-CabezasCruzA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170402, Cabezas-Cruz A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pt.2017.03.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chan,S.</style></author><author><style face="normal" font="Arial"> Cornelius,V.</style></author><author><style face="normal" font="Arial"> Chen,T.</style></author><author><style face="normal" font="Arial"> Radulovic,S.</style></author><author><style face="normal" font="Arial"> Wan,M.</style></author><author><style face="normal" font="Arial"> Jahan,R.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Guy's and St. Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial</style></title><secondary-title><style face="normal" font="Arial">Trials</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Trials</style></full-title></periodical><pages end="" start="136">136-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood eczema</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> objective SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> systemic treatment</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The evidence for systemic treatments for severe childhood eczema is limited and largely based on extrapolation of data from adult studies. Current therapies are often immunosuppressant and may be associated with both short- and long-term side effects. There is increasing in vitro and murine-model evidence for the role of IgE in the immunopathogenesis of atopic eczema. The aim of the study is to assess whether anti-IgE treatment (omalizumab) improves eczema, compared to placebo. METHODS/DESIGN: The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a randomised, double-blind, placebo-controlled study assessing the role of anti-IgE in the management of severe paediatric eczema. Children with severe atopic eczema, with an objective SCORing Atopic Dermatitis (SCORAD) score of over 40 will be recruited. These children are candidates for systemic therapy, have failed systemic therapy or have experienced side effects from systemic therapy. Sixty-two patients aged between 4 and 19 years will receive anti-IgE for 6 months. The primary outcome measure will be the validated eczema score, the objective SCORAD at 24 weeks. This study has 90% power to detect a 33% relative reduction in SCORAD between active and placebo groups, with 5% significance. DISCUSSION: IgE may have a role to play in eczema, particularly in childhood. This forms the basis for the hypothesis that anti-IgE may be an effective treatment in this patient population. This will be the largest study to evaluate the efficacy of anti-IgE (omalizumab) versus placebo in children with severe eczema. The findings will help to clarify the role of anti-IgE as a potential treatment option in patients with severe childhood eczema. TRIAL REGISTRATION: European Clinical Trials Database (EudraCT) Number: 2010-020841-29 . Assigned on 14 May 2010. ISRCTN Registry, Identifier: ISRCTN15090567 . Retrospectively assigned on 3 December 2014. ClinicalTrials.gov, Identifier: NCT02300701 . First received 21 November 2014</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1745-6215 (Electronic)IS - 1745-6215 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13063-017-1809-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28330497">PM:28330497</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trials\2017-18-136.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trials\2017-18-136.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Chan S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13063-017-1809-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Andersen,R.M.</style></author><author><style face="normal" font="Arial"> Zachariae,C.</style></author><author><style face="normal" font="Arial"> Johansen,J.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">[Aluminium allergy and granulomas induced by vaccinations for children]</style></title><secondary-title><style face="normal" font="Arial">Ugeskr Laeger</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ugeskr Laeger</style></abbr-1></periodical><pages end="871" start="868">868-871</pages><volume><style face="normal" font="Arial">177</style></volume><number><style face="normal" font="Arial">18</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> chemically induced</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Granuloma</style></keyword><keyword><style face="normal" font="Arial"> granulomas</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="27" Month="4" Year="2015">2015/4/27</year></dates><abstract><style face="normal" font="Arial">Vaccination with aluminium-adsorbed vaccines can induce aluminium allergy with persistent itching subcutaneous nodules at the injection site - vaccination granulomas. In this article we give an overview of childhood aluminium-adsorbed vaccines available in Denmark. Through literature studies we examine the incidence, the symptoms and the prognosis for the vaccination granulomas and the allergy. Finally we discuss the status in Denmark</style></abstract><notes><style face="normal" font="Arial">DA - 20151104IS - 1603-6824 (Electronic)IS - 0041-5782 (Linking)LA - danPT - Journal ArticlePT - ReviewRN - 0 (Vaccines)RN - CPD4NFA903 (Aluminum)SB - IMCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26539576">PM:26539576</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20151104, Andersen RM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,D.</style></author><author><style face="normal" font="Arial"> Song,Q.</style></author><author><style face="normal" font="Arial"> Zhu,R.</style></author><author><style face="normal" font="Arial"> Qian,Y.</style></author><author><style face="normal" font="Arial"> Sun,Y.</style></author><author><style face="normal" font="Arial"> Deng,J.</style></author><author><style face="normal" font="Arial"> Wang,F.</style></author><author><style face="normal" font="Arial"> Ding,Y.</style></author><author><style face="normal" font="Arial"> Tian,R.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Zhu,W.</style></author><author><style face="normal" font="Arial"> Zhao,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Virology, Beijing Key Laboratory of Etiology of Viral Diseases in Children, Capital Institute of Pediatrics, Beijing, 100020, China</style></auth-address><titles><title><style face="normal" font="Arial">Human rhinovirus C infection is associated with asthma in children determined by xTAG respiratory viral panel FAST</style></title><secondary-title><style face="normal" font="Arial">Virol Sin</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Virol Sin</style></abbr-1></periodical><pages end="174" start="171">171-174</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virology</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170408IS - 1995-820X (Electronic)IS - 1995-820X (Linking)LA - engPT - LetterCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12250-016-3935-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389993">PM:28389993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Virol Sin\20170408-ChenD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Virol Sin\20170408-ChenD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170408, Chen D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12250-016-3935-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bastl,K.</style></author><author><style face="normal" font="Arial"> Berger,M.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Kmenta,M.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Forschungsgruppe Aerobiologie und Polleninformation, HNO-Klinik, Medizinische Universitat Wien, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">The medical and scientific responsibility of pollen information services</style></title><secondary-title><style face="normal" font="Arial">Wien Klin Wochenschr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Wien Klin Wochenschr</style></full-title></periodical><pages end="74" start="70">70-74</pages><volume><style face="normal" font="Arial">129</style></volume><number><style face="normal" font="Arial">1-2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiologie</style></keyword><keyword><style face="normal" font="Arial"> Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biological particles</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Information Services</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Pollen information as such is highly valuable and was considered so far as a self-evident good free for the public. The foundation for reliable and serious pollen information is the careful, scientific evaluation of pollen content in the air. However, it is essential to state and define now the requirements for pollen data and qualifications needed for institutions working with pollen data in the light of technical developments such as automated pollen counting and various political interests in aerobiology including attempts to finally acknowledge pollen and spores as relevant biological particles in the air worth being considered for pollution and health directives. It has to be emphasized that inadequate pollen forecasts are a considerable health risk for pollen allergy sufferers. Therefore, the responsibility of institutions involved in pollen monitoring and forecasting is high and should be substantiated with respective qualifications and know-how. We suggest here for the first time a portfolio of quality criteria and demand rigorous scientific monitoring and certification of such institutions in the interest and for the protection of persons affected by a pollen allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20161020IS - 1613-7671 (Electronic)IS - 0043-5325 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00508-016-1097-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27761736">PM:27761736</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Wien Klin Wochenschr\2017-129-70-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Wien Klin Wochenschr\2017-129-70-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161020, Bastl K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00508-016-1097-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Domenech,W.J.</style></author><author><style face="normal" font="Arial"> Jover,C.V.</style></author><author><style face="normal" font="Arial"> Gil,G.V.</style></author><author><style face="normal" font="Arial"> Domenech Clar,J.B.</style></author><author><style face="normal" font="Arial"> Rodriguez,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">0000 0004 1771 1327grid.414736.3Hospital General de Elda, Seccion de Alergologia. H. Elda, Carretera de Sax, 03600 Elda, Alicante Spain</style></auth-address><titles><title><style face="normal" font="Arial">Assessing eosinophilic cationic protein as a biomarker for monitoring patients with eosinophilic esophagitis treated with specific exclusion diets</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="12">12-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic esophagitis (EoE) is a complex pathology. Attempts have been made in order to relate EoE with the intake of certain food. The problem is to establish which foods are really involved in the pathophysiology of this condition and to objectify a reliable inflammation biomarker for the follow-up of patients undergoing pharmacological treatment and/or diets. Our aim is to assess the food sensitization profile of patients with objective diagnosis of EoE and objectify the utility of ECP as an inflammation biomarker for the follow-up of patients with EoE treated with specific diets, based on the hypothesis that we will observe a decrease and clinical improvement after maintenance of these diets. METHODS: A total of 19 subjects were included between 1 January 2012 and 30 June 2015. Diets based on allergy testing were established. Prior to the initiation of the diets, baseline ECP was determined. Appointments were arranged for the patients between 4 and 6 months later to assess the clinical response to the specific diets and to request a second blood sample for blood counts and serum ECP levels to compare with the previous baseline. RESULTS: 19 patients diagnosed with EoE (12 males and 7 females) between January 2012 and June 2015, aged between 17 and 68 (33.52; SD 13.67 years), were included consecutively, 15 of whom showed optimum response to specific diets based on allergy testing. A statistically significant difference ECP decrease was observed in our patients. DISCUSSION: Until now most of the studies previously published in reference to the use of ECP as a biomarker for monitoring patients on treatment with diets show consistent but insignificant decreases in ECP levels. However, ECP seems to be a good marker of inflammation if the determinations are performed avoiding confounding factors. CONCLUSION: The serial determination of ECP is useful when monitoring patients with EoE treated with specific diets</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0143-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28360963">PM:28360963</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Domenech WJ</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0143-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tzanis,G.</style></author><author><style face="normal" font="Arial"> Bonou,M.</style></author><author><style face="normal" font="Arial"> Mikos,N.</style></author><author><style face="normal" font="Arial"> Biliou,S.</style></author><author><style face="normal" font="Arial"> Koniari,I.</style></author><author><style face="normal" font="Arial"> Kounis,N.G.</style></author><author><style face="normal" font="Arial"> Barbetseas,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Georgios Tzanis, Maria Bonou, Smaragda Biliou, John Barbetseas, Department of Cardiology, "Laiko" General Hospital, 11527 Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Early stent thrombosis secondary to food allergic reaction: Kounis syndrome following rice pudding ingestion</style></title><secondary-title><style face="normal" font="Arial">World J Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Cardiol</style></full-title></periodical><pages end="288" start="283">283-288</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> cardiomyopathy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Coronary spasm</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Spasm</style></keyword><keyword><style face="normal" font="Arial"> Stent thrombosis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thrombosis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="3" Year="2017">2017/3/26</year></dates><abstract><style face="normal" font="Arial">Kounis syndrome is the concurrence of coronary spasm, acute myocardial infarction or stent thrombosis, with allergic reactions in the setting of mast-cell and platelet activation. In this report Kounis syndrome manifesting as stent thrombosis with left ventricular thrombus formation was triggered by a food-induced allergic reaction. The allergic reaction to food was confirmed by oral rice pudding ingredients challenge test while skin tests were inconclusive. To our knowledge, this is first report of early stent thrombosis secondary to food allergic reaction in a 70-year-old man patient who was found to have left ventricular thrombus and undiagnosed hypertrophic cardiomyopathy</style></abstract><notes><style face="normal" font="Arial">DA - 20170412LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.4330/wjc.v9.i3.283</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400926">PM:28400926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Cardiol\2017-9-283-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Cardiol\2017-9-283-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Tzanis G</style></custom2><misc3><style face="normal" font="Arial">10.4330/wjc.v9.i3.283</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,M.Y.</style></author><author><style face="normal" font="Arial"> Yang,Z.Y.</style></author><author><style face="normal" font="Arial"> Dai,W.K.</style></author><author><style face="normal" font="Arial"> Huang,J.Q.</style></author><author><style face="normal" font="Arial"> Li,Y.H.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Qiu,C.Z.</style></author><author><style face="normal" font="Arial"> Wei,C.</style></author><author><style face="normal" font="Arial"> Zhou,Q.</style></author><author><style face="normal" font="Arial"> Sun,X.</style></author><author><style face="normal" font="Arial"> Feng,X.</style></author><author><style face="normal" font="Arial"> Li,D.F.</style></author><author><style face="normal" font="Arial"> Wang,H.P.</style></author><author><style face="normal" font="Arial"> Zheng,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Meng-Yun Liu, Jian-Qiong Huang, He-Ping Wang, Yue-Jie Zheng, Department of Respiratory, Shenzhen Children's Hospital, Shenzhen 518026, China</style></auth-address><titles><title><style face="normal" font="Arial">Protective effect of Bifidobacterium infantis CGMCC313-2 on ovalbumin-induced airway asthma and beta-lactoglobulin-induced intestinal food allergy mouse models</style></title><secondary-title><style face="normal" font="Arial">World J Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Gastroenterol</style></full-title></periodical><pages end="2158" start="2149">2149-2158</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">AIM: To determine whether oral administration of Bifidobacterium infantis CGMCC313-2 (B. infantis CGMCC313-2) inhibits allergen-induced airway inflammation and food allergies in a mouse model. METHODS: Ovalbumin (OVA)-induced allergic asthma and beta-lactoglobulin-induced food allergy mouse models were used in this study. Following oral administration of B. infantis CGMCC313-2 during or after allergen sensitization, histopathologic changes in the lung and intestine were evaluated by hematoxylin and eosin (HE) staining. In the allergic asthma mouse model, we evaluated the proportion of lung-infiltrating inflammatory cells. OVA-specific IgE and IgG1 levels in serum and cytokine levels in bronchoalveolar lavage fluid (BALF) were also assessed. In the food allergy mouse model, the levels of total IgE and cytokines in serum were measured. RESULTS: Oral administration of B. infantis CGMCC313-2 during or after allergen sensitization suppressed allergic inflammation in lung and intestinal tissues, while the proportion of infiltrating inflammatory cells was significantly decreased in the BALF of allergic asthma mice. Moreover, B. infantis CGMCC313-2 decreased the serum levels of total IgE in food allergy mice, and reductions in IgE and IgG1 were also observed in OVA-induced allergic asthma mice. The expression of interleukin-4 (IL-4) and IL-13 in both serum and BALF was suppressed following the administration of B. infantis CGMCC313-2, while an effect on serum IL-10 levels was not observed. CONCLUSION: B. infantis CGMCC313-2 inhibits the secretion of allergen-induced IgE, IL-4 and IL-13, and attenuates allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170413IS - 2219-2840 (Electronic)IS - 1007-9327 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3748/wjg.v23.i12.2149</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28405142">PM:28405142</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Gastroenterol\2017-23-2149-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Gastroenterol\2017-23-2149-58.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170413, Liu MY</style></custom2><misc3><style face="normal" font="Arial">10.3748/wjg.v23.i12.2149</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,X.</style></author><author><style face="normal" font="Arial"> Zou,H.</style></author><author><style face="normal" font="Arial"> Chen,Q.J.</style></author><author><style face="normal" font="Arial"> Lu,C.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic fungal sinusitis caused by Schizophyllum commune</style></title><secondary-title><style face="normal" font="Arial">World J Otorhinolaryngol Head Neck Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">World J Otorhinolaryngol Head Neck Surg</style></abbr-1></periodical><pages end="63" start="59">59-63</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> maxillary</style></keyword><keyword><style face="normal" font="Arial"> Molecular Typing</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Schizophyllum</style></keyword><keyword><style face="normal" font="Arial"> Schizophyllum commune</style></keyword><keyword><style face="normal" font="Arial"> Sinonasal infection</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><isbn><style face="normal" font="Arial">2095-8811</style></isbn><abstract><style face="normal" font="Arial">A case of allergic fungal sinusitis (AFS) due to Schizophyllum commune was reported. The pathogen was identified using molecular bioanalysis. The patient underwent the functional endoscopic sinus surgery followed by the radical maxillary sinusotomy with canine fossa trephine. This case suggested that complete surgery allowed optimal disease clearance for AFS caused by Schizophyllum commune</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.wjorl.2017.02.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29204581">PM:29204581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Otorhinolaryngol Head Neck Surg\2017-3-59-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Otorhinolaryngol Head Neck Surg\2017-3-59-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170416, Liu X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.wjorl.2017.02.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bakhit,M.S.</style></author><author><style face="normal" font="Arial"> Fujii,M.</style></author><author><style face="normal" font="Arial"> Jinguji,S.</style></author><author><style face="normal" font="Arial"> Sato,T.</style></author><author><style face="normal" font="Arial"> Sakuma,J.</style></author><author><style face="normal" font="Arial"> Saito,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurosurgery, Fukushima Medical University, Fukushima city, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Jugular Foramen Collision Tumor (Schwannoma and Plasma Cell Pseudotumor), a Probable IgG4-Related Disease: A Case Report</style></title><secondary-title><style face="normal" font="Arial">World Neurosurg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">World Neurosurg</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meningioma</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pancreas</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">Lower cranial nerve sheath tumors are relatively rare, and cases of schwannoma collision tumors have rarely been reported, with most of the reported cases describing schwannoma and meningioma collision tumors. We report a very rare case of a cerebellopontine angle collision tumor of the 9th cranial nerve schwannoma with an IgG4 plasma cell pseudotumor. IgG4 plasma cell pseudotumors comprise a group of diseases called IgG4-related diseases (IgG4-RDs). These diseases usually affect organs such as the pancreas and salivary gland. Few cases of nervous system IgG4-RDs have been reported. Under intraoperative microscopy, the tumor in our case did not appear different from usual cases of schwannoma, but histopathology showed significant infiltration of IgG4 plasma cells. IgG4-RDs have a distinctive histopathological pattern; however, their pathophysiology remains unclear. Special attention must be paid to the diagnosis of such diseases because they mimic other diseases and can be missed</style></abstract><notes><style face="normal" font="Arial">DA - 20170410IS - 1878-8769 (Electronic)IS - 1878-8750 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.wneu.2017.03.142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392497">PM:28392497</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Neurosurg\20170410-BakhitMS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Neurosurg\20170410-BakhitMS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170410, Bakhit MS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.wneu.2017.03.142</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feng,S.</style></author><author><style face="normal" font="Arial"> Zhu,S.</style></author><author><style face="normal" font="Arial"> Han,F.</style></author><author><style face="normal" font="Arial"> Zhu,J.</style></author><author><style face="normal" font="Arial"> Zhang,M.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Affiliated Hospital, Xuzhou Medical University, Xuzhou 221006, China</style></auth-address><titles><title><style face="normal" font="Arial">[Estrogen shortens the latent period of inducing asthma and promotes airway inflammation]</style></title><secondary-title><style face="normal" font="Arial">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</style></full-title></periodical><pages end="454" start="450">450-454</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> estrogen</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Tamoxifen</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Objective To investigate the effect of estrogen on the latent period of inducing asthma and airway inflammation in mice with asthma. Methods Forty male BALB/c mice were randomly divided into normal control group, OVA-induced asthma group, 400 mug/kg estradiol treatment group, 400 mug/kg estradiol combined with 7 mg/kg tamoxifen group, with 10 mice in each group. The OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group were sensitized and challenged by OVA; the normal control group was treated with normal saline instead. The estradiol treatment group and estradiol combined with tamoxifen group were given intraperitoneal injection of 400 mug/kg estradiol 4 hours before each challenge, and the latter was given additionally intraperitoneal injection of 7 mg/kg tamoxifen at 30 minutes before the injection of estradiol; the normal control group and OVA-induced asthma group were injected with normal saline as controls. The latent period of inducing asthma of all the mice was determined 24 hours after the final OVA challenge. Bronchoalveolar lavage fluid (BALF) was collected for counting total leukocyte cells and the percentages of eosinophils and lymphocytes. The concentrations of interleukin 4 (IL-4) and IL-13 in BALF were detected by ELISA. The pathologic change of lung tissues was examined by HE staining. Results Compared with the normal control group, the latent period of inducing asthma were shortened in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the latent period of inducing asthma of the estradiol treatment group were shortened; there was no significant difference in the latent period between the OVA-induced asthma group and the estradiol combined with tamoxifen group. Compared with the normal control group, the levels of IL-4 and IL-13 increased in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with the OVA-induced asthma group and estradiol combined with tamoxifen group, the levels of IL-4 and IL-13 increased in the estradiol treatment group; there was also no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group. Compared with the normal control group, the total leukocytes and the percentages of eosinophils and lymphocytes in BALF were raised in the OVA-induced asthma group, estradiol treatment group, and estradiol combined with tamoxifen group; compared with OVA-induced asthma group and estradiol combined with tamoxifen group, the total leukocytes and the percentage of eosinophils and lymphocytes of BALF were elevated in the estradiol treatment group; there was no significant difference between the OVA-induced asthma group and the estradiol combined with tamoxifen group. There was no infiltration of inflammatory cells in bronchial walls or airway mucosal edema in the normal control group. There were infiltration of inflammatory cells in bronchial walls and airway mucosal edema in the OVA-induced asthma group and estradiol combined with tamoxifen group, in addition, the estradiol treatment group was more serious than the two groups in these pathologic changes. Conclusion Estrogen can shorten the latent period of inducing asthma, promote the airway inflammatory cell infiltration and upgrade the expressions of IL-4 and IL-13</style></abstract><notes><style face="normal" font="Arial">DA - 20170411IS - 1007-8738 (Print)IS - 1007-8738 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28395712">PM:28395712</url></web-urls></urls><custom2><style face="normal" font="Arial">20170411, Feng S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,H.J.</style></author><author><style face="normal" font="Arial"> Han,H.</style></author><author><style face="normal" font="Arial"> Lee,S.C.</style></author><author><style face="normal" font="Arial"> Son,Y.W.</style></author><author><style face="normal" font="Arial"> Sim,D.W.</style></author><author><style face="normal" font="Arial"> Park,K.H.</style></author><author><style face="normal" font="Arial"> Park,Y.H.</style></author><author><style face="normal" font="Arial"> Jeong,K.Y.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Soluble CD93 in Serum as a Marker of Allergic Inflammation</style></title><secondary-title><style face="normal" font="Arial">Yonsei Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yonsei Med J</style></full-title></periodical><pages end="603" start="598">598-603</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation. MATERIALS AND METHODS: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naive BA patients who were serially followed-up. RESULTS: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean+/-standard deviation, 153.1+/-58.4) were significantly higher than in patients without AR (132.2+/-49.0) or with stable AR (122.3+/-42.1). Serum sCD93 levels in exacerbated CSU (169.5+/-42.8) were also significantly higher than those in non-CSU (132.4+/-51.6) and stable CSU (122.8+/-36.2). This trend was also seen in BA. Serum levels in patients with ICS-naive BA (161.4+/-53.1) were significantly higher than those in healthy controls without BA (112.2+/-30.8), low- and medium-dose ICS users. Serum sCD93 levels in high-dose ICS users (72.2+/-20.6) were significantly lower than those in low- and medium-dose users. The serum sCD93 levels in steroid-naive patients with BA (195.1+/-72.7) decreased after ICS use for 4 weeks (134.4+/-42.8) and 8 weeks (100.7+/-13.4), serially. CONCLUSION: Elevated serum sCD93 levels reflected exacerbated status of allergic diseases, including CSU, AR, and asthma. ICS use significantly diminished serum sCD93 levels in steroid-naive patients with BA. This result may suggest sCD93 in serum as a therapeutic marker for allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170323IS - 1976-2437 (Electronic)IS - 0513-5796 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3349/ymj.2017.58.3.598</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332366">PM:28332366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yonsei Med J\2017-58-598-603.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yonsei Med J\2017-58-598-603.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170323, Park HJ</style></custom2><misc3><style face="normal" font="Arial">10.3349/ymj.2017.58.3.598</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,S.G.</style></author><author><style face="normal" font="Arial"> Zhang,X.S.</style></author><author><style face="normal" font="Arial"> Zhao,Y.F.</style></author><author><style face="normal" font="Arial"> Sun,L.</style></author><author><style face="normal" font="Arial"> Pan,X.T.</style></author><author><style face="normal" font="Arial"> Wan,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Child Health Care, Wuhu Maternal and Child Health Care Hospital, Wuhu, Anhui 241000, China. wsgwh@126.com</style></auth-address><titles><title><style face="normal" font="Arial">[Risk factors for allergic diseases in children aged 0-24 months in the Wuhu urban area, Anhui Province, China]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="307" start="303">303-307</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> Crabs</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimps</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the prevalence of allergic diseases in children aged 0-24 months in the Wuhu urban area of Anhui Province and risk factors for allergic diseases. METHODS: Cluster random sampling was performed to select 600 children aged 0-24 months and their mothers from the Wuhu urban area, and a questionnaire survey was conducted to collect the data of disease history, family history, mothers' conditions during pregnancy, and child-rearing situation. Univariate analysis and multivariate logistic regression analysis were performed for such data. RESULTS: Among the 597 children included in the analysis, 56 (9.4%) were diagnosed with allergic diseases in the past. The univariate analysis showed that the age, use of antipyretic and analgesic drugs, a history of allergy in the father or grandparents, and the consumption of fish, shrimps, crabs, and shellfish during pregnancy were significantly associated with past allergic diseases (P&lt;0.05). The multivariate logistic regression analysis showed that the age and a history of allergy in the father or grandparents were positively associated with past allergic diseases (OR=4.0-4.9, 2.7, and 2.4 respectively; P&lt;0.05), while frequent consumption of fish, shrimps, crabs, and shellfish during pregnancy was negatively associated with past allergic diseases (OR=0.3; P&lt;0.05). CONCLUSIONS: A family history of allergy is an independent risk factor for allergic diseases in children aged 0-24 months in the Wuhu urban area of Anhui Province, while frequent consumption of fish, shrimps, crabs, and shellfish during pregnancy is a protective factor</style></abstract><notes><style face="normal" font="Arial">DA - 20170317IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2017.03.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28302201">PM:28302201</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2017-19-303-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2017-19-303-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170317, Wang SG</style></custom2><misc3><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2017.03.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,X.</style></author><author><style face="normal" font="Arial"> Dang,Y.J.</style></author><author><style face="normal" font="Arial"> Wang,G.F.</style></author><author><style face="normal" font="Arial"> Jin,X.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China</style></auth-address><titles><title><style face="normal" font="Arial">[The regulative effects of Aspergillus fumigatus on expression of glucocorticoid receptor in asthmatic rats]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Jie He He Hu Xi Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Jie He He Hu Xi Za Zhi</style></full-title></periodical><pages end="187" start="182">182-187</pages><volume><style face="normal" font="Arial">40</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">A.fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchus</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Steroid-resistant asthma</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="12" Month="3" Year="2017">2017/3/12</year></dates><abstract><style face="normal" font="Arial">Objective: To study the regulative effects of Aspergillus fumigatus (A.fumigatus) on expression of glucocorticoid receptor (GCR) in asthmatic rats. Methods: Wistar rats were randomly divided into 4 groups: a normal control group (UC), a normal control with A. fumigatus group (UC+ AF), an OVA group (OVA), and an OVA with A. fumigatus group (OVA+ AF). OVA and OVA+ AF groups were sensitized and challenged with OVA to establish asthmatic models. UC and UC+ AF groups were given normal saline as controls. After the last challenge, OVA+ AF and UC+ AF groups were given A. fumigatus spores intranasally. Airway hyper-responsiveness, eosinophil percentage (Eos%) and serum IgE level were measured to confirm the establishment of asthmatic models. Sections of pulmonary tissue were stained with hematoxylin-eosin (HE) and the expression of GCR mRNA and protein in lung tissues were measured by qRT-PCR and Western blot. Lung tissues and blood were plated on the potato dextrose agar(PDA)medium and cultured for 24 h to measure the number of colony. Results: The Penh value, Eos% in BALF and serum IgE level in UC+ AF group were slightly higher than those in the UC group (all the P>0.05). The Penh value, Eos% in BALF and serum IgE level in OVA group were significantly higher than those in the UC group (all the P&lt;0.05). The Penh value in OVA+ AF group was significantly increased compared with the OVA group at the concentration of 25 g/L and 50 g/L of methacholine (all the P>0.05). Pulmonary histology revealed that both OVA group and OVA+ AF group showed high levels of inflammatory cell infiltration of bronchus and lung vessels, interstitial edema and smooth muscle thickening, while the UC and UC + AF groups were normal. Compared with the UC group, the expressions of GCR mRNA and protein in UC+ AF group and OVA group were decreased significantly (GCR mRNA in UC, UC+ AF and OVA group were 0.93+/-0.15, 0.65+/-0.10, 0.72+/-0.22, respectively, F=10.744, P&lt;0.01; GCR protein in UC, UC+ AF and OVA group were 100+/-0, 89+/-8, 82+/-15, respectively, F=18.939, P&lt;0.01). The expressions of GCR mRNA and protein in OVA+ AF group were further decreased than those in OVA group (GCR mRNA: OVA group: 0.72+/-0.22 vs OVA+ AF group: 0.52+/-0.08, t=2.462, P&lt;0.05; GCR protein: OVA group: 81.88+/-15.41 vs OVA+ AF group: 59.09+/-7.60, t=2.997, P&lt;0.05). The ratio of A. fumigatus colonization in lung tissues in OVA+ AF group (4/8) was higher than the UC+ AF group (0/8). Conclusion:A. fumigatus exposure can down-regulate the expression of GCR in the lung, which maybe an important mechanism of steroid-resistant asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170315IS - 1001-0939 (Print)IS - 1001-0939 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1001-0939.2017.03.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28297812">PM:28297812</url></web-urls></urls><custom2><style face="normal" font="Arial">20170315, Zhou X</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1001-0939.2017.03.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Allaerts,W.</style></author><author><style face="normal" font="Arial"> Chang,T.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biological Publishing A&amp;O and Immunology Department, Erasmus MC, Rotterdam, CA, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Skewed Exposure to Environmental Antigens Complements Hygiene Hypothesis in Explaining the Rise of Allergy</style></title><secondary-title><style face="normal" font="Arial">Acta Biotheor</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Biotheor</style></abbr-1></periodical><pages end="134" start="117">117-134</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Habits</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Publishing</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">The Hygiene Hypothesis has been recognized as an important cornerstone to explain the sudden increase in the prevalence of asthma and allergic diseases in modernized culture. The recent epidemic of allergic diseases is in contrast with the gradual implementation of Homo sapiens sapiens to the present-day forms of civilization. This civilization forms a gradual process with cumulative effects on the human immune system, which co-developed with parasitic and commensal Helminths. The clinical manifestation of this epidemic, however, became only visible in the second half of the twentieth century. In order to explain these clinical effects in terms of the underlying IgE-mediated reactions to innocuous environmental antigens, the low biodiversity of antigens in the domestic environment plays a pivotal role. The skewing of antigen exposure as a cumulative effect of reducing biodiversity in the immediate human environment as well as in changing food habits, provides a sufficient and parsimonious explanation for the rise in allergic diseases in a highly developed and helminth-free modernized culture. Socio-economic tendencies that incline towards a further reduction of environmental biodiversity may provide serious concern for future health. This article explains that the "Hygiene Hypothesis", the "Old Friends Hypothesis", and the "Skewed Antigen Exposure Hypothesis" are required to more fully explain the rise of allergy in modern societies</style></abstract><notes><style face="normal" font="Arial">DA - 20170325IS - 1572-8358 (Electronic)IS - 0001-5342 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10441-017-9306-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342137">PM:28342137</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Biotheor\2017-65-117-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Biotheor\2017-65-117-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170325, Allaerts W</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10441-017-9306-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shah-Hosseini,K.</style></author><author><style face="normal" font="Arial"> Krudewig,E.M.</style></author><author><style face="normal" font="Arial"> Hadler,M.</style></author><author><style face="normal" font="Arial"> Karagiannis,E.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Medical Statistics, Informatics and Epidemiology, Faculty of Medicine, University of Cologne, Cologne, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study</style></title><secondary-title><style face="normal" font="Arial">Adv Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Ther</style></full-title></periodical><pages end="1397" start="1382">1382-1397</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine use</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Polyallergies</style></keyword><keyword><style face="normal" font="Arial"> Polyallergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Allergen immunotherapy is the only treatment option for allergic rhinitis with disease-altering potential. It was the objective of this study to assess the effectiveness and tolerability of a 5-grass pollen tablet in a large population of non-selected grass pollen allergic patients, i.e. patients with different clinical profiles in daily clinical practice. METHODS: In a 2-year, prospective, open-label, multicenter, non-controlled, observational study patients were included from 327 centers across Germany. Rhinoconjunctivitis symptoms, symptomatic medication intake and adverse events were recorded. RESULTS: A total of 1482 patients aged 4-75 years were included. During the 2-year period of 5-grass pollen tablet therapy, mean rhinoconjunctivitis score decreased significantly in the overall study population by 65.5% (P &lt; 0.001). The percentage of patients taking symptomatic medication decreased from 83.8% to 42.7%. Mean 2-year improvements in rhinoconjunctivitis scores and decreases in the percentage of patients taking symptomatic medication were broadly similar in adults, adolescents and children, in patients with polyallergy versus monoallergy, and in patients with/without asthma. Among polyallergic patients, concomitant application of another specific immunotherapy did not impair treatment outcomes. Adverse drug reactions, predominantly affecting the local application area, occurred in 15.4% of the overall patient population (n = 229). No cases of anaphylaxis or epinephrine use were documented. CONCLUSION: This study indicates that sublingual immunotherapy with the 5-grass pollen tablet is well tolerated and provides sustained effectiveness over 2 years in patients with different clinical profiles, producing a significant decrease in allergic symptoms and a reduction in the use of symptomatic medication. FUNDING: Stallergenes GmbH</style></abstract><notes><style face="normal" font="Arial">DA - 20170429IS - 1865-8652 (Electronic)IS - 0741-238X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s12325-017-0535-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28455783">PM:28455783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Ther\20170429-ShahHosseiniK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Ther\20170429-ShahHosseiniK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170429, Shah-Hosseini K</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s12325-017-0535-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tripp,C.S.</style></author><author><style face="normal" font="Arial"> Cuff,C.</style></author><author><style face="normal" font="Arial"> Campbell,A.L.</style></author><author><style face="normal" font="Arial"> Hendrickson,B.A.</style></author><author><style face="normal" font="Arial"> Voss,J.</style></author><author><style face="normal" font="Arial"> Melim,T.</style></author><author><style face="normal" font="Arial"> Wu,C.</style></author><author><style face="normal" font="Arial"> Cherniack,A.D.</style></author><author><style face="normal" font="Arial"> Kim,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">AbbVie, Global Pharmaceutical R&amp;D, Worcester, MA, USA</style></auth-address><titles><title><style face="normal" font="Arial">RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 alpha1 and alpha2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study</style></title><secondary-title><style face="normal" font="Arial">Adv Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Ther</style></full-title></periodical><pages end="1381" start="1364">1364-1381</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacodynamics</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: A unique anti-interleukin (IL)-13 monoclonal antibody, RPC4046, was generated on the basis of differential IL-13 receptor (R) blockade as assessed in a murine asthma model; the safety, tolerability, pharmacokinetics, and pharmacodynamics of RPC4046 were evaluated in a first-in-human study. METHODS: Anti-IL-13 antibodies with varying receptor blocking specificity were evaluated in the ovalbumin-induced murine asthma model. A randomized, double-blind, placebo-controlled, dose-escalation first-in-human study (NCT00986037) was conducted with RPC4046 in healthy adults and patients with mild to moderate controlled asthma. RESULTS: In the ovalbumin model, blocking IL-13 binding to both IL-13Rs (IL-13Ralpha1 and IL-13Ralpha2) inhibited more asthma phenotypic features and more fully normalized the distinct IL-13 gene transcription associated with asthma compared with blocking IL-13Ralpha1 alone. In humans, RPC4046 exposure increased dose-dependently; pharmacokinetics were similar in healthy and asthmatic subjects, and blockade of both IL-13Rs uniquely affected IL-13 gene transcription. A minority of participants (28%) had antidrug antibodies, which were transient and appeared not to affect pharmacokinetics. Adverse event profiles were similar in healthy and asthmatic subjects, without dose-related or administration route differences, systemic infusion-related reactions, or asthma symptom worsening. Adverse events were mild to moderate, with none reported as probably related to RPC4046 or leading to discontinuations. Non-serious upper respiratory tract infections were more frequent with RPC4046 versus placebo. CONCLUSION: RPC4046 is a novel anti-IL-13 antibody that blocks IL-13 binding to both receptors and more fully blocks the asthma phenotype. These results support further investigation of RPC4046 for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). FUNDING: AbbVie Inc. sponsored the studies and contributed to the design and conduct of the studies, data management, data analysis, interpretation of the data, and in the preparation and approval of the manuscript</style></abstract><notes><style face="normal" font="Arial">DA - 20170429IS - 1865-8652 (Electronic)IS - 0741-238X (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12325-017-0525-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28455782">PM:28455782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Ther\20170429-TrippCS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Ther\20170429-TrippCS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170429, Tripp CS</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12325-017-0525-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sadys,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of wind speed and direction on monthly fluctuations of Cladosporium conidia concentration in the air</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="12" start="">-12</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conidia</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spore concentration</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">This study determined the relationship between airborne concentration of Cladosporium spp. spores and wind speed and direction using real data (local wind measured by weather station) and modelled data (air mass flow computed with the aid of HYbrid Single-áParticle Lagrangian Trajectory model). Air samples containing fungal conidia were taken at an urban site (Worcester, UK) for a period of five consecutive years using a spore trap of the Hirst design. A threshold of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ6000-ás-ám</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ3 (double the clinical value) was applied in order to select high spore concentration days, when airborne transport of conidia at a regional scale was more likely to occur. Collected data were then examined using geospatial and statistical tools, including circular statistics. Obtained results showed that the greatest numbers of spore concentrations were detected in July and August, when C. herbarum, C. cladosporioides and C. macrocarpum sporulate. The circular correlation test was found to be more sensitive than Spearman</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs rank test. The dominance of either local wind or the air mass on Cladosporium spore distributions varied between examined months. Source areas of this pathogen had an origin within the UK territory. Very high daily mean concentrations of Cladosporium spores were observed when daily mean local wind speed was v s-á</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëñ-á2.5-ám-ás</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1 indicating warm days with a light breeze</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9482-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9482-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170510-SadysM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170510-SadysM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Sadys M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9482-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mauss,V.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Identification of bee and wasp taxa relevant in systemic allergic reactions to Hymenoptera stings in Central Europe</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="87" start="81">81-87</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Bumblebee</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Central Europe</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sting challenge</style></keyword><keyword><style face="normal" font="Arial"> Subfamily</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Vespula</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Wasps</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Correct identification of the Hymenoptera that was responsible for stinging a-ápatient is crucial when establishing the indication for specific immunotherapy (SIT) using Hymenoptera venom immunotherapy (VIT), advising the patient on allergen avoidance, and in terms evaluating accidental stings or sting challenges during VIT. There are around 15-áspecies of social bees and wasps that most frequently cause stings in Central Europe. Even lay people are normally able to correctly classify causal insects into their respective families, i.</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çëe., Apidae or Vespidae. On the other hand, a-ámore precise taxonomic classification and distinction within the subfamily and the genus is often imprecise or incorrect; for example, within the family Apidae (true bees), Apis (honeybees) is often mistaken for Bombus (bumblebees), while within the family Vespidae (folded-winged wasps), there is confusion between Polistes (paper wasps), Vespa (hornets), Dolichovespula (yellow jackets, long-cheeked wasps), and Vespula (yellow jackets, short-cheeked wasps)</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0019-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-017-0019-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-81-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-81-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Mauss V</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0019-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Koschel,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Impaired quality of life in patients with insect venom allergy</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="92" start="88">88-92</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergies</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Although documented fatalities following insect stings are only rarely reported, insect venom allergy is a-ápotentially life-threatening disease. Experiencing anaphylaxis due to an insect sting represents a-áthreatening event for patients</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0017-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-017-0017-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-88-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-88-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Koschel D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0017-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jakob,T.</style></author><author><style face="normal" font="Arial"> Rafei-Shamsabadi,D.</style></author><author><style face="normal" font="Arial"> Spillner,E.</style></author><author><style face="normal" font="Arial"> Muller,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="105" start="93">93-105</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">The high rate of asymptomatic sensitization to Hymenoptera venom, difficulty in correctly identifying Hymenoptera and loss of sensitization over time make an accurate diagnosis of Hymenoptera venom allergy challenging. Although routine diagnostic tests encompassing skin tests and the detection of venom-specific IgE antibodies with whole venom preparations are reliable, they offer insufficient precision in the case of double sensitized patients or in those with a-áhistory of sting anaphylaxis, in whom sensitization cannot be proven or only to the presumably wrong venom</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0014-2</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-017-0014-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-93-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-93-105.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Jakob T</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0014-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bedolla-Barajas,M.</style></author><author><style face="normal" font="Arial"> Javier Ramirez-Cervantes,F.</style></author><author><style face="normal" font="Arial"> Morales-Romero,J.</style></author><author><style face="normal" font="Arial"> Jesus Perez-Molina,J.</style></author><author><style face="normal" font="Arial"> Meza-Lopez,C.</style></author><author><style face="normal" font="Arial"> Delgado-Figueroa,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergia e Inmunologia Clinica, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Salvador de Quevedo y Zubieta No. 750, Colonia La Perla, Guadalajara, Jalisco C.P. 44340, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">A rural environment does not protect against asthma or other allergic diseases amongst Mexican children</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paternal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Rural environment</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The commonly held notion that a rural environment decreases the frequency of allergic diseases has proven to be inconsistent amongst children. OBJECTIVE: Our objective was to contrast the prevalence of bronchial asthma (BA), allergic rhinitis (AR), and atopic dermatitis (AD) between children that live in a rural environment and those that live in urban areas. METHODS: We carried out a cross-sectional study amongst children aged six to seven; they were selected through probabilistic, stratified and conglomerated sampling. The prevalence of BA, AR, and AD was identified with the use of the questionnaire provided by The International Study of Asthma and Allergies in Childhood, additionally, we inquired about each child's family history of atopy, their exposure to farm animals, the intake of unpasteurised cow's milk, and the number of siblings related to every child. We used logistic regression and multivariate analysis to determine the correlation between asthma, allergic diseases, and rural environment. RESULTS: We included 189/1003 (18.8%) children from a rural environment, and 814/1003 (81.2%) from an urban area. BA and AR were associated to a family history of atopy (OR=2.15, p=0.001; OR=2.58, p=0.002, respectively). BA was more prevalent in males (OR=1.92, p=0.007). Notably, a higher number of siblings seems to protect against AR (OR=0.45, p=0.008). A paternal history of allergies was associated to AD. CONCLUSIONS: In our study, we were unable to find protective factors in a rural environment that might decrease the prevalence of asthma or allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.01.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477854">PM:28477854</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170507-BedollaBarajasM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170507-BedollaBarajasM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Bedolla-Barajas M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.01.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aydogmus,C.</style></author><author><style face="normal" font="Arial"> Ayaz,N.A.</style></author><author><style face="normal" font="Arial"> Cakan,M.</style></author><author><style face="normal" font="Arial"> Cipe,F.</style></author><author><style face="normal" font="Arial"> Topal,N.</style></author><author><style face="normal" font="Arial"> Oner,O.B.</style></author><author><style face="normal" font="Arial"> Keskindemirci,G.</style></author><author><style face="normal" font="Arial"> Akcay,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Istanbul Kanuni Sultan Suleyman Education and Research Hospital, Pediatric Allergy-Immunology Unit, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Is there any difference regarding atopy between children with familial Mediterranean fever and healthy controls?</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> familial</style></keyword><keyword><style face="normal" font="Arial"> Familial Mediterranean Fever</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: There are only a few studies regarding the prevalence of atopy in Familial Mediterranean fever (FMF) patients, and their results are conflicting. METHODS: In this study children with the diagnosis of FMF were evaluated for the presence of atopy by comparing with controls. One hundred and eighteen children diagnosed as FMF and 50 healthy age and sex matched controls were enrolled. They were evaluated for the presence of rhinitis, atopic dermatitis, urticaria and asthma. Laboratory assessment was done by measuring IgA, IgM, IgG, IgE levels, total eosinophil count and by performing skin prick test (SPT) panels for common allergens to children with FMF and healthy controls. RESULTS: One hundred and eighteen children (61girls and 57 boys) diagnosed as FMF with a median age of 120+/-47 months (range 36-204 months) were compared with 50 healthy controls (31 girls and 19 boys) having a median age of 126+/-37 (range 48-192 months). The mean percentage of total eosinophil count of patients was similar to that of the control group. The mean level of IgE was significantly higher in children with FMF than controls (136+/-268, 87+/-201, respectively; p values &lt;0.05). The percentage of skin prick test positivity was similar for both patients and controls (13% and 8.2%, respectively; p>0.05). The prevalences of atopic dermatitis, allergic rhinitis, and asthma in the patient group were 5.08%, 28.8%, and 15.25%, respectively, while the control group had the prevalences of 0%, 36%, and 14% respectively. CONCLUSION: Children with FMF did not show an increase of atopic dermatitis, allergic rhinitis and asthma with respect to controls</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2016.12.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28465037">PM:28465037</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170503-AydogmusC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170503-AydogmusC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Aydogmus C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2016.12.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Opri,R.</style></author><author><style face="normal" font="Arial"> Zanoni,G.</style></author><author><style face="normal" font="Arial"> Caffarelli,C.</style></author><author><style face="normal" font="Arial"> Bottau,P.</style></author><author><style face="normal" font="Arial"> Caimmi,S.</style></author><author><style face="normal" font="Arial"> Crisafulli,G.</style></author><author><style face="normal" font="Arial"> Franceschini,F.</style></author><author><style face="normal" font="Arial"> Liotti,L.</style></author><author><style face="normal" font="Arial"> Saretta,F.</style></author><author><style face="normal" font="Arial"> Vernich,M.</style></author><author><style face="normal" font="Arial"> Peroni,D.G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">True and false contraindications to vaccines</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Contraindication</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Immunisation</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Precaution</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0301-0546</style></isbn><abstract><style face="normal" font="Arial">Nowadays, the awareness of risks related to infectious diseases has decreased, whereas THE perception of risks related to vaccination is growing. Therefore, it may be difficult for health care providers to convince people of the importance of vaccination and adherence to the immunisation schedule. Selected situations that might raise uncertainties about vaccine recommendations are discussed in order to help health care providers to identify real and perceived contraindications to vaccines, and cases to be referred to specialised pre-vaccination consultation due to an increased risk of adverse events to vaccines</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28495398">PM:28495398</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170511-OpriR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170511-OpriR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Opri R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.02.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morii,W.</style></author><author><style face="normal" font="Arial"> Sakai,A.</style></author><author><style face="normal" font="Arial"> Ninomiya,T.</style></author><author><style face="normal" font="Arial"> Kidoguchi,M.</style></author><author><style face="normal" font="Arial"> Sumazaki,R.</style></author><author><style face="normal" font="Arial"> Fujieda,S.</style></author><author><style face="normal" font="Arial"> Noguchi,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Association of Japanese cedar pollinosis and sensitization with HLA-DPB1 in the Japanese adolescent</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Glutamic Acid</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Methionine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Threonine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) is a heterogeneous disorder that significantly affects daily activity, work productivity, sleep, learning, and quality of life in all generations. Japanese cedar (JC) pollen is the most common allergen responsible for the development of AR in Japan. AR caused by JC pollen is considered to be a multifactorial inheritance disease that is caused by both environmental and genetic factors. The aim of this study was to investigate whether Human Leukocyte Antigen-DPB1 (HLA-DPB1) is associated with JC sensitization/pollinosis. METHODS: Subjects in the present study were 544 students at the University of Tsukuba from 2013 to 2015. PCR-SSOP was performed to determine each individual's HLA-DPB1 alleles. Logistic regression analysis was performed to examine relationships between JC-related phenotypes and alleles/amino acid polymorphisms of HLA-DPB1. RESULTS: HLA-DPB1*02 allele were significantly associated with both JC sensitization/pollinosis (q &lt; 0.05). Furthermore, HLA-DPB1*02:01 and HLA-DPB1*02:02 had a protective tendency for JC sensitization/pollinosis, and HLA-DPB1*05:01 had a susceptible tendency for sensitization (P &lt; 0.05). In amino acid polymorphism analyses, Glutamic acid in position 69, Glycine-Glycine-Proline-Methionine in positions 84-87, Threonine in position 170 and Methionine in position 205 were also observed to have a protective tendency for JC sensitization (P &lt; 0.05). Amino acid positions 69 and 84-87 were located in binding pocket 5 and 1 of HLA-DPbeta1, respectively. CONCLUSIONS: Amino acid changes in the allergen-binding pocket of HLA-DPbeta1 are likely to influence pollinosis/sensitization to the allergenic peptide of JC pollen and determine the pollinosis risk for each individual exposed to JC pollen</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.04.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28460831">PM:28460831</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170502-MoriiW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170502-MoriiW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Morii W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.04.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Takahashi,K.</style></author><author><style face="normal" font="Arial"> Nagakura,K.I.</style></author><author><style face="normal" font="Arial"> Ogura,K.</style></author><author><style face="normal" font="Arial"> Asaumi,T.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sagamihara National Hospital, Kanagawa, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Skin prick test is more useful than specific IgE for diagnosis of buckwheat allergy: A retrospective cross-sectional study</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Buckwheat (BW) is a potentially life-threatening allergen. Usefulness of BW-specific immunoglobulin-E (BW-sIgE) level for diagnosis of BW allergy is controversial, while the skin prick test (SPT) is widely used because of its less invasive procedure and immediate results. However, there are no data comparing usefulness of the SPT and BW-sIgE level. Therefore, our study aimed to clarify efficacy of the SPT for diagnosis of BW allergy. METHODS: This retrospective cross-sectional study evaluated patients who underwent an oral food challenge (OFC) for diagnosis or confirmation of acquired tolerance using 3072 mg of BW protein between July 2006 and April 2014. We then compared the diagnostic performance of BW sIgE and SPT to predict positive OFC results. RESULTS: We analyzed 126 patients aged 2-16 years (median, 7.7 years), 18 (14%) of whom showed positive OFC results. Between patients with positive and negative OFC results, there was no significant difference in BW-sIgE level. However, patients with positive OFC results had a larger SPT wheal diameter. Area under the curve for positive OFC results for BW-sIgE level and SPT wheal diameter were 0.583 and 0.791, respectively. The 5%, 10%, 50%, and 90% positive predictive values of SPT wheal diameter were 2.0 mm, 5.2 mm, 14.7 mm, and 24.1 mm, respectively. CONCLUSIONS: Our study revealed that the SPT was more useful than BW-sIgE level for diagnosis of BW allergy. Thus, an OFC may be avoided if the patient's SPT wheal diameter is at least 24.1 mm</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479284">PM:28479284</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170508-YanagidaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170508-YanagidaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Yanagida N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.04.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korematsu,S.</style></author><author><style face="normal" font="Arial"> Nagashima,K.</style></author><author><style face="normal" font="Arial"> Sato,Y.</style></author><author><style face="normal" font="Arial"> Nagao,M.</style></author><author><style face="normal" font="Arial"> Hasegawa,S.</style></author><author><style face="normal" font="Arial"> Nakamura,H.</style></author><author><style face="normal" font="Arial"> Sugiura,S.</style></author><author><style face="normal" font="Arial"> Miura,K.</style></author><author><style face="normal" font="Arial"> Okada,K.</style></author><author><style face="normal" font="Arial"> Fujisawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Oita University Faculty of Medicine, Oita, Japan</style></auth-address><titles><title><style face="normal" font="Arial">"Spike" in acute asthma exacerbations during enterovirus D68 epidemic in Japan: A nation-wide survey</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> admissions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthma hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Causality</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterovirus</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In September 2015, Japan experienced an unusual increase in acute asthma hospitalizations of children that coincided with an enterovirus D68 (EV-D68) epidemic. The objective of this study is to investigate whether EV-D68 had a causal relationship with the spike in asthma hospitalizations. METHODS: A nation-wide retrospective survey of asthma hospitalizations of children was performed for the period from January 2010 through October 2015. The Japanese Society of Pediatric Allergy and Clinical Immunology asked its affiliated hospitals to report monthly numbers of hospitalizations, ICU admissions and mechanical ventilations due to acute asthma exacerbation. The data were retrieved from medical databases using predefined search criteria: diagnosis of asthma or asthmatic bronchitis, admission, and age &lt;20 years. Monthly numbers of EV-D68 detection were also obtained from the Infectious Disease Surveillance Center of Japan. A Granger causality test was used to analyze the association of EV-D68 detections for asthma exacerbation. RESULTS: A total of 157 hospitals reported 87,189 asthma hospitalizations, including 477 ICU admissions and 1193 mechanical ventilations, during the survey period of 5 years and 10 months. The numbers of these events increased drastically in September 2015. The Granger causality test verified the association between EV-D68 and asthma hospitalizations/mechanical ventilations. The most-affected age group was 3-6 years old. CONCLUSIONS: The spike in pediatric asthma hospitalizations in Japan in September 2015 was found to be associated with the EV-D68 epidemic. Respiratory pathogens can cause "epidemics" of asthma exacerbation. Coordinated surveillance of infectious diseases and asthma may be beneficial for prevention and better control of both illnesses</style></abstract><notes><style face="normal" font="Arial">DA - 20170429IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.04.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28455155">PM:28455155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170429-KorematsuS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170429-KorematsuS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170429, Korematsu S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.04.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olle-Monge,M.</style></author><author><style face="normal" font="Arial"> Cruz,M.J.</style></author><author><style face="normal" font="Arial"> Gomez-Olles,S.</style></author><author><style face="normal" font="Arial"> Ojanguren,I.</style></author><author><style face="normal" font="Arial"> Vanoirbeek,J.</style></author><author><style face="normal" font="Arial"> Munoz,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Neumologia, Hospital Universitario Vall d'Hebron, Barcelona</style></auth-address><titles><title><style face="normal" font="Arial">Effect of anti-IgE in occupational asthma caused by exposure to low molecular weight agents</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Dimethyl Sulfoxide</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Salts</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The role of immunoglobulin (Ig)-E in occupational asthma (OA) due to low molecular weight (LMW) agents is not well established compared to classical atopic asthma. In the present study we evaluate whether anti-IgE monoclonal antibody (mAb) has an effect in a mouse model of OA, using persulfate salts. METHODS: On days 1 and 8, BALB/C mice were dermally sensitized with 5% ammonium persulfate (AP) or dimethyl sulfoxide (DMSO). On days 15, 18 and 21 animals were injected intraperitoneally with anti-IgE mAb or PBS 6 hours before challenge with AP or saline. Airway hyperresponsiveness (AHR) using a methacholine test, airway inflammation in bronchoalveolar lavage (BAL) and lung tissue and total free IgE in serum samples were analyzed 24, 48 and 96 hours after the last challenge. RESULTS: Anti-IgE mAb treatment almost completely neutralized free serum IgE. In AP sensitized and challenged mice, anti-IgE mAb treatment abolished AHR 24h and 48h after the last challenge and significantly reduced the total number of eosinophils and neutrophils 48h and 96h after the last AP challenge compared with non-treated mice. Levels of interleukin (IL)-13 in BAL were also significantly decreased after anti-IgE administration 24h and 48h after the last AP challenge. Histological analysis of the lung sections from anti-IgE-treated mice revealed normal inflammatory patterns similar to control groups 48h after the last challenge. CONCLUSIONS: Anti-IgE-treated mice showed a significant improvement in asthma features related to the AHR and airway inflammation. Anti-IgE mAb has positive effects in OA induced by persulfate salts. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13190</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28439933">PM:28439933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170425-OlleMongeM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170425-OlleMongeM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Olle-Monge M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13190</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elbert,N.J.</style></author><author><style face="normal" font="Arial"> van Meel,E.R.</style></author><author><style face="normal" font="Arial"> den Dekker,H.T.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author><author><style face="normal" font="Arial"> Nijsten,T.E.C.</style></author><author><style face="normal" font="Arial"> Jaddoe,V.W.V.</style></author><author><style face="normal" font="Arial"> De Jongste,J.C.</style></author><author><style face="normal" font="Arial"> Pasmans,S.G.M.A.</style></author><author><style face="normal" font="Arial"> Duijts,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Duration and exclusiveness of breastfeeding and risk of childhood atopic diseases</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Breastfeeding may have immune modulatory effects that influence the development of childhood allergic sensitization and atopic diseases. We aimed to examine the associations of breastfeeding with childhood allergic sensitization, inhalant or food allergy and eczema, and whether any association was affected by disease-related modification of the exposure or modified by maternal history of maternal history of allergy, eczema or asthma. METHODS: This study among 5,828 children was performed in a population-based prospective cohort from fetal life onwards. We collected information on duration (&lt;2 months, 2-4 months, 4-6 months and >/=6 months) and exclusiveness (non-exclusive vs. exclusive for 4 months) of breastfeeding in infancy by postal questionnaires. At age 10 years, inhalant and food allergic sensitization were measured by skin prick tests, and physician-diagnosed inhalant and food allergy by a postal questionnaire. Data on parental-reported eczema were available from birth until age 10 years. RESULTS: We observed no association of breastfeeding with any allergic sensitization, physician-diagnosed allergy, or combination of these outcomes. Shorter breastfeeding duration was associated with an overall increased risk of eczema (p-value for trend &lt;0.05). Non-exclusively breastfed children had an overall increased risk of eczema (aOR (95% CI): 1.11 (1.01, 1.23)), compared with children exclusively breastfed for 4 months. Risk period-specific sensitivity analyses, additional adjustment for ointment use for eczema at age 2 months, and cross-lagged modeling showed no consistent results for disease-related modification of the exposure. Results were not modified by maternal history of allergy, eczema or asthma (lowest p-value for interaction =0.13). CONCLUSIONS: Shorter duration or non-exclusiveness of breastfeeding is associated with a weak overall increased risk of eczema but not allergic sensitization or physician-diagnosed allergy at age 10 years This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170427IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13195</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449362">PM:28449362</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170427-ElbertNJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170427-ElbertNJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170427, Elbert NJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13195</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Toppila-Salmi,S.</style></author><author><style face="normal" font="Arial"> Luukkainen,A.</style></author><author><style face="normal" font="Arial"> Lemmetyinen,R.</style></author><author><style face="normal" font="Arial"> Karjalainen,J.</style></author><author><style face="normal" font="Arial"> Huhtala,H.</style></author><author><style face="normal" font="Arial"> Renkonen,R.</style></author><author><style face="normal" font="Arial"> Wang,D.Y.</style></author><author><style face="normal" font="Arial"> Makela,M.J.</style></author><author><style face="normal" font="Arial"> Pekkanen,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Haartman Institute, University of Helsinki, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Birth decade affects the sensitization pattern and asthma-risk in Finnish adult population</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adult asthma</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lung function tests</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multiple sensitization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We have previously shown that sensitizations to several types of allergens distinguishes subjects with and without adult-onset asthma in Finland. The aim was to analyze how age affects sensitization and asthma-risk. METHODS: We used previous population-based case-control data (N=523) from Finnish adult asthma patients with one or two matched controls. Asthma was diagnosed based on a typical history of asthmatic symptoms and lung function tests. Allergic sensitization was determined by skin prick test (SPT) to 17 aeroallergens. Information on demographics was obtained by a questionnaire. RESULTS: Sensitization to more than one allergen type and the number of positive SPT reactions associated with younger age and asthma. Atopic subjects aged 65 or over were characterized by sensitization to only 1-2 allergens, with very few animal danders and without an association with asthma. CONCLUSIONS: Multiple sensitizations and animal dander sensitization are more common among Finnish asthmatic adults aged under 56 than among older asthmatics. Cohort studies are needed to understand timing of host-environmental interactions behind this. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13194</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28444953">PM:28444953</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170426-ToppillaSalmiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170426-ToppillaSalmiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170426, Toppilla-Salmi S</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13194</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shahali,Y.</style></author><author><style face="normal" font="Arial"> Sutra,J.P.</style></author><author><style face="normal" font="Arial"> Hilger,C.</style></author><author><style face="normal" font="Arial"> Swiontek,K.</style></author><author><style face="normal" font="Arial"> Haddad,I.</style></author><author><style face="normal" font="Arial"> Vinh,J.</style></author><author><style face="normal" font="Arial"> Guilloux,L.</style></author><author><style face="normal" font="Arial"> Charpin,D.</style></author><author><style face="normal" font="Arial"> Senechal,H.</style></author><author><style face="normal" font="Arial"> Poncet,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry, Allergy &amp; Environment Team, Armand Trousseau Children Hospital, AP-HP, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Identification of a polygalacturonase (Cup s 2) as the major CCD-bearing allergen in Cupressus sempervirens pollen</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Bromelain</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Concanavalin A</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cup s 2</style></keyword><keyword><style face="normal" font="Arial"> Cupressus</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Cypress pollen</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Polygalacturonase</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">Since IgE glyco-epitopes, also referred to as cross-reactive carbohydrate determinants (CCDs), can share significant structural homologies between different plants, they are prone to extensive cross-reactivity among allergen pollen extracts. Here, cypress pollen allergens, especially a polygalacturonase (PG), were further characterized using double one dimensional electrophoresis (D1-DE). The presence of specific IgE directed against CCDs was investigated by bromelain IgE inhibition and concanavalin A binding assays using sera of cypress pollen sensitized patients. Our results showed that IgE reactivity to CCDs in Cupressus sempervirens pollen extracts is mainly related to bromelain-type epitopes of a newly-identified cypress PG. This glycoprotein has been further characterized through an immunoproteomic approach and officially indexed as Cup s 2 by the WHO/IUIS allergen nomenclature. Cup s 2 could thus be associated with the increased prevalence of IgE reactivity to cypress pollen extracts because of CCD interference. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Irn -CO - France -CO - Luxembourg -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13191</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28439939">PM:28439939</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170425-ShahaliY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170425-ShahaliY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Shahali Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13191</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fujimura,T.</style></author><author><style face="normal" font="Arial"> Aki,T.</style></author><author><style face="normal" font="Arial"> Isobe,T.</style></author><author><style face="normal" font="Arial"> Matsuoka,A.</style></author><author><style face="normal" font="Arial"> Hayashi,T.</style></author><author><style face="normal" font="Arial"> Ono,K.</style></author><author><style face="normal" font="Arial"> Kawamoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hiroshima Research Center for Healthy Aging (HiHA), Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, Higashi-Hiroshima</style></auth-address><titles><title><style face="normal" font="Arial">Der f 35: an MD-2-like house dust mite allergen that cross-reacts with Der f 2 and Pso o 2</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aging</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Der f 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pso o 2</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Scab-mite</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage mite</style></keyword><keyword><style face="normal" font="Arial"> storage mites</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dermatophagoides farinae is a source of airborne house dust mite (HDM) allergens. We elucidated IgE-reactive allergens from D. farinae by two-dimensional immunoblotting-based allergenome analysis, and identified one new allergen, named Der f 35, that possesses IgE-binding capacity comparable to that of Der f 2. The aim of this study is to clarify the allergenic capacity of new HDM allergen Der f 35. METHODS: We cloned der f 35 from D. farinae mRNA and produced recombinant Der f 35 in Escherichia coli. The IgE-binding capacity of Der f 35 and its cross-reactivity with group 2 allergens from D. farinae and Psoroptes ovis were determined by ELISA and ELISA inhibition assays, respectively. RESULTS: The deduced amino acid sequence for der f 35, which possesses the MD-2-related lipid-recognition domain, showed higher identity with group 2 allergens from P. ovis (61.5%) and Blomia tropicalis (50.7%) than with Der f 2 (40.8%). Der f 35 showed IgE-binding frequencies of 77.5% (31/40) for the native form upon allergenome analysis and 51.4% (18/35) for recombinant structure by ELISA. Der f 35 showed cross-reactivity with Der f 2 and Pso o 2 in reaction with HDM-allergic patients' IgE by ELISA inhibition assay. CONCLUSION: Der f 35 is a candidate major allergen from D. farinae, which is more similar to group 2 allergens from sheep scab mite and storage mites. Der f 35 could be responsible for the cross-reactivity among group 2 mite allergens. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13192</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28439905">PM:28439905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170425-FujimuraT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170425-FujimuraT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Fujimura T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13192</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wolf,M.</style></author><author><style face="normal" font="Arial"> Twaroch,T.E.</style></author><author><style face="normal" font="Arial"> Huber,S.</style></author><author><style face="normal" font="Arial"> Reithofer,M.</style></author><author><style face="normal" font="Arial"> Steiner,M.</style></author><author><style face="normal" font="Arial"> Aglas,L.</style></author><author><style face="normal" font="Arial"> Hauser,M.</style></author><author><style face="normal" font="Arial"> Aloisi,I.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Hofer,H.</style></author><author><style face="normal" font="Arial"> Parigiani,M.A.</style></author><author><style face="normal" font="Arial"> Ebner,C.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Angela,N.</style></author><author><style face="normal" font="Arial"> Stolz,F.</style></author><author><style face="normal" font="Arial"> Jahn-Schmid,B.</style></author><author><style face="normal" font="Arial"> Wallner,M.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Amb a 1 isoforms: unequal siblings with distinct immunological features</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Amb a 1</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding activity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ragweed pollen represents a major allergy risk factor. Ragweed extracts contain five different isoforms of the major allergen Amb a 1. However, the immunologic characteristics of Amb a 1 isoforms are not fully investigated. Here we compared the physicochemical and immunological properties of three most important Amb a 1 isoforms. METHODS: After purification, the isoforms were physicochemically characterized, tested for antibody-binding and induction of human T cell proliferative responses. Their immunologic properties were further evaluated in vitro and in vivo in a mouse model. RESULTS: Amb a 1 isoforms exhibited distinct patterns of IgE-binding and immunogenicity. Compared to Amb a 1.02 or 03 isoforms, Amb a 1.01 showed higher IgE-binding activity. Isoforms 01 and 03 were the most potent stimulators of patients' T cells. In a mouse model of immunization, Amb a 1.01 induced higher levels of IgG and IgE antibodies when compared to isoforms 02 and 03. Interestingly, ragweed-sensitized patients also displayed an IgG response to Amb a 1 isoforms. However, unlike therapy-induced antibodies, sensitization-induced IgG did not show IgE-blocking activity. CONCLUSION: The present study showed that naturally occurring isoforms of Amb a 1 possess different immunogenic and sensitizing properties. These findings should be considered when selecting sequences for molecule-based diagnosis and therapy of ragweed allergy. Due to its high IgE-binding activity, isoform Amb a 1.01 should be included in diagnostic tests. In contrast, due to their limited B and T cell cross-reactivity patterns, a combination of different isoforms might be a more attractive strategy for ragweed immunotherapy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13196</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28464293">PM:28464293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170502-WolfM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170502-WolfM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Wolf M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13196</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Remington,B.C.</style></author><author><style face="normal" font="Arial"> Westerhout,J.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author><author><style face="normal" font="Arial"> Turner,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">TNO, Zeist, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Minimal impact of extensive heating of hen's egg and cow's milk in a food matrix on threshold dose-distribution curves</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Baking</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">We analyzed reaction threshold data from 352 children undergoing open food challenges to hen's egg or cow's milk, either fresh or extensively heated into a muffin. There was no significant shift in dose-distribution curves due to the baking process, implying that existing threshold data for these allergens can be applied to allergen risk management, even when these allergens are heat-processed into baked foods. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13198</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474471">PM:28474471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170505-RemingtonBC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170505-RemingtonBC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Remington BC</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13198</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hellings,P.W.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Cingi,C.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Akdis,C.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Gevaert,P.</style></author><author><style face="normal" font="Arial"> Hox,V.</style></author><author><style face="normal" font="Arial"> Hupin,C.</style></author><author><style face="normal" font="Arial"> Kalogjera,L.</style></author><author><style face="normal" font="Arial"> Manole,F.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Muluk,N.B.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.</style></author><author><style face="normal" font="Arial"> Pawankar,R.</style></author><author><style face="normal" font="Arial"> Rondon,C.</style></author><author><style face="normal" font="Arial"> Rundenko,M.</style></author><author><style face="normal" font="Arial"> Seys,S.F.</style></author><author><style face="normal" font="Arial"> Toskala,E.</style></author><author><style face="normal" font="Arial"> Van Gerven,L.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Zhang,N.</style></author><author><style face="normal" font="Arial"> Fokkens,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical division of Otorhinolaryngology, Head &amp; Neck Surgery, University Hospitals Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Non-Allergic Rhinitis: Position paper of the European Academy of Allergology and Clinical Immunology</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">This EAACI position paper aims at providing a state-of-the-art overview on non-allergic rhinitis (NAR). A significant number of patients suffering from persistent rhinitis are defined as non-allergic non-infectious rhinitis (NANIR) patients, often denominated in short as having NAR. NAR is defined as a symptomatic inflammation of the nasal mucosa with the presence of minimal 2 nasal symptoms like nasal obstruction, rhinorrhoea, sneezing, and/or itchy nose, without clinical evidence of endonasal infection and without systemic signs of sensitization to inhalant allergens. Symptoms of NAR may have a wide range of severity, and be either continuously present and/or induced by exposure to unspecific triggers, also called nasal hyperresponsiveness (NHR). NHR represents a clinical feature of both AR and NAR patients. NAR involves different subgroups: drug-induced rhinitis, (non-allergic) occupational rhinitis, hormonal rhinitis (including pregnancy rhinitis), gustatory rhinitis, senile rhinitis and idiopathic rhinitis (IR). NAR should be distinguished from those rhinitis patients with an allergic reaction confined to the nasal mucosa, also called 'entopy' or local allergic rhinitis (LAR). We here provide an overview of the current consensus on phenotypes of NAR, recommendations for diagnosis, a treatment algorithm and defining the unmet needs in this neglected area of research. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Germany -CO - Turkey -CO - Romania -CO - Switzerland -CO - France -CO - Croatia -CO - Spain -CO - Italy -CO - Greece -CO - Japan -CO - United Kingdom -CO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13200</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474799">PM:28474799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170505-HellingsPW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170505-HellingsPW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Hellings PW</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13200</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suzuki,Y.</style></author><author><style face="normal" font="Arial"> Wakahara,K.</style></author><author><style face="normal" font="Arial"> Nishio,T.</style></author><author><style face="normal" font="Arial"> Ito,S.</style></author><author><style face="normal" font="Arial"> Hasegawa,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Airway basophils are increased and activated in eosinophilic asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD203c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function test</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The impact of basophils on asthma pathogenesis remains largely unexplored, particularly in humans. Here, we evaluated the frequencies and activation status of basophils in the sputum of adult asthmatic patients and related our findings to other parameters of eosinophilic airway inflammation. METHODS: We enrolled 44 adult asthmatic patients who were being treated with inhaled corticosteroids (ICS). Analysis of the induced sputum, exhaled nitric oxide fraction (FeNO) measurement, and Asthma Control Test (ACT) were carried out together with standard blood and pulmonary function tests. The cellular composition of the sputum was examined by flow cytometry, and the phenotypes of blood and sputum basophils were compared. RESULTS: Basophils were increased in the sputum of asthmatic patients. The expression of CD203c on sputum basophils was significantly higher than that on blood basophils. The percentage of sputum basophils was positively correlated with those of eosinophils and mast cells; it was also correlated with that of blood eosinophils and FeNO. However, sputum basophils were not correlated with serum IgE, lung function, or the percentage of blood basophils. A receiver operating characteristics (ROC) curve showed the superiority of sputum basophils as a surrogate marker of the percentages of sputum eosinophils compared with absolute numbers of blood eosinophils and FeNO. CONCLUSION: The number of activated basophils was increased in the sputum of patients with eosinophilic asthma and correlated with airway and blood eosinophils. Our observations suggest that sputum basophils may serve as a biomarker to monitor new therapeutic approaches for the treatment of eosinophilic asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474352">PM:28474352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170505-SuzukiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170505-SuzukiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Suzuki Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13197</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pohlit,H.</style></author><author><style face="normal" font="Arial"> Bellinghausen,I.</style></author><author><style face="normal" font="Arial"> Frey,H.</style></author><author><style face="normal" font="Arial"> Saloga,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Medical Center of the Johannes Gutenberg-University Mainz, Department of Dermatology, Mainz, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Recent Advances in the Use of Nanoparticles for Allergen-specific Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biodegradable</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dendrimers</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA vaccine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> liposome</style></keyword><keyword><style face="normal" font="Arial"> Liposomes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Nanostructures</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polymers</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Rodents</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> virus-like particle</style></keyword><keyword><style face="normal" font="Arial"> Virus-like particles</style></keyword><keyword><style face="normal" font="Arial"> viruslike particles</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">The number of patients suffering from allergic asthma and rhino-conjunctivitis has increased dramatically within the last decades. Allergen-specific immunotherapy (AIT) is the only available cause-oriented therapy so far. AIT reduces symptoms, but has also a disease modifying effect. Disadvantages are a long-lasting procedure, and in a few cases potential systemic adverse reactions. Encapsulation of allergens or DNA vaccines into nanostructures may provide advantages compared to the conventional AIT with non-capsulated allergen extracts: The protein/DNA molecule can be protected from degradation, higher local concentrations and targeted delivery to the site of action appears possible and most importantly, recognition of encapsulated allergen by the immune system, especially by IgE antibodies is prevented. AIT with nanoparticles (NPs) may offer a safer and potentially more efficient way of treatment for allergic diseases. In this review we summarize the use of biodegradable NPs consisting of synthetic or natural polymers, liposomes and virus-like particles as well as non-biodegradable NPs like dendrimers, carbon- or metal-based NPs for AIT. More or less successful applications of these NPs in prophylactic as well as therapeutic vaccination approaches in rodents or other animals as well as first human clinical trials are discussed in detail. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13199</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474379">PM:28474379</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170505-PohlitH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170505-PohlitH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Pohlit H</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13199</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Oliveira,M.G.</style></author><author><style face="normal" font="Arial"> Oliveira,L.M.</style></author><author><style face="normal" font="Arial"> Lira,A.A.L.</style></author><author><style face="normal" font="Arial"> Sgnotto,F.D.R.</style></author><author><style face="normal" font="Arial"> Duarte,A.J.D.S.</style></author><author><style face="normal" font="Arial"> Sato,M.N.</style></author><author><style face="normal" font="Arial"> Victor,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Medical Investigation LIM-56, Division of Clinical Dermatology, Medical School, University of Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar, 500, 3rd Floor, 05403-000 Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Preconception allergen sensitization can induce B10 cells in offspring: a potential main role for maternal IgG</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="22">22-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The mechanisms through which allergies can be inhibited after preconception immunization with allergens are not fully understood. We aimed to evaluate whether maternal immunization can induce a regulatory B (B10) cell population in offspring in concert with allergy inhibition. METHODS: C57BL/6 females were or were not immunized with OVA and were mated with normal WT males. Their offspring were evaluated at 3 days of age or 20 days after neonatal immunization. Human peripheral B cells from atopic and non-atopic individuals were also evaluated. RESULTS: Preconception OVA immunization induced B10 cells in offspring, and IL-10 production appeared to be critical for FcgammaRIIB upregulation in offspring B cells. Murine and human IL-10-producing B cells responded in vitro to IgG according to the atopic repertoire of the cells. CONCLUSIONS: Our results reveal that maternal immunization induces allergen-specific B10 cells in offspring and a pivotal role for the IgG repertoire in IL-10 production by murine and human B cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0195-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428801">PM:28428801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, de Oliveira MG</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0195-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,S.W.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Kwon,O.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="Arial">Spontaneously resolved STEMI after a hymenoptera sting</style></title><secondary-title><style face="normal" font="Arial">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Emerg Med</style></full-title></periodical><pages end="362" start="360">360-362</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Electrocardiography</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine H1 Antagonists</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Insect Bites and Stings</style></keyword><keyword><style face="normal" font="Arial"> Isotonic Solutions</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> Remission,Spontaneous</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> ST Elevation Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161121IS - 1532-8171 (Electronic)IS - 0735-6757 (Linking)LA - engPT - Case ReportsPT - LetterRN - 0 (Anti-Inflammatory Agents)RN - 0 (Histamine H1 Antagonists)RN - 0 (Isotonic Solutions)RN - 0 (crystalloid solutions)RN - X4W7ZR7023 (Methylprednisolone)RN - YKH834O4BH (Epinephrine)SB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ajem.2016.10.073</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27866694">PM:27866694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Emerg Med\2017-35-360-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Emerg Med\2017-35-360-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161121, Kim SW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ajem.2016.10.073</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goklemez,S.</style></author><author><style face="normal" font="Arial"> Pirsl,F.</style></author><author><style face="normal" font="Arial"> Curtis,L.M.</style></author><author><style face="normal" font="Arial"> Steinberg,S.M.</style></author><author><style face="normal" font="Arial"> Cowen,E.W.</style></author><author><style face="normal" font="Arial"> Mays,J.W.</style></author><author><style face="normal" font="Arial"> Kenyon,M.</style></author><author><style face="normal" font="Arial"> Baruffaldi,J.</style></author><author><style face="normal" font="Arial"> Hakim,F.T.</style></author><author><style face="normal" font="Arial"> Pavletic,S.Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Experimental Transplantation and Immunology Branch, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Significance of IgE in a Large Cohort of Patients with Moderate or Severe Chronic Graft-versus-Host Disease</style></title><secondary-title><style face="normal" font="Arial">Am J Hematol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Hematol</style></full-title></periodical><pages end="e164" start="E162">E162-e164</pages><volume><style face="normal" font="Arial">92</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cancer</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> graft-versus-host disease</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170424IS - 1096-8652 (Electronic)IS - 0361-8609 (Linking)LA - engPT - LetterCO - United States -CO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1002/ajh.24768</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28437849">PM:28437849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Emerg Med\20170424-GoklemezS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Emerg Med\20170424-GoklemezS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170424, Goklemez S</style></custom2><misc3><style face="normal" font="Arial">10.1002/ajh.24768</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zaidman,N.A.</style></author><author><style face="normal" font="Arial"> O'Grady,K.E.</style></author><author><style face="normal" font="Arial"> Patil,N.</style></author><author><style face="normal" font="Arial"> Milavetz,F.</style></author><author><style face="normal" font="Arial"> Maniak,P.J.</style></author><author><style face="normal" font="Arial"> Kita,H.</style></author><author><style face="normal" font="Arial"> O'Grady,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Minnesota</style></auth-address><titles><title><style face="normal" font="Arial">Airway epithelial anion secretion and barrier function following exposure to fungal aeroallergens: Role of oxidative stress</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Cell Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Cell Physiol</style></full-title></periodical><pages end="C79" start="C68">C68-C79</pages><volume><style face="normal" font="Arial">313</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cl-</style></keyword><keyword><style face="normal" font="Arial"> dextran</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ion Transport</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> Mucociliary Clearance</style></keyword><keyword><style face="normal" font="Arial"> MW</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="Arial">Aeroallergens produced by Alternaria alternata can elicit life-threatening exacerbations of asthma in patients sensitized to this fungus. In this study, the effect of Alternaria on ion transport mechanisms underlying mucociliary clearance and airway epithelial barrier function was investigated in human airway epithelial cells. Apical exposure to Alternaria induced an increase in anion secretion that was inhibited by blockers of CFTR and Ca2+-activated Cl- channels. Stimulation of anion secretion was dependent on Ca2+ uptake from the apical solution. Alternaria exposure also produced an increase in reactive oxygen species (ROS) that was blocked by pretreatment with the oxidant scavenger glutathione (GSH). GSH and the NADPH oxidase inhibitor/complex 1 electron transport inhibitor diphenylene iodonium chloride (DPI) blocked ATP release and the increase in intracellular [Ca2+] evoked by Alternaria Alternaria also decreased transepithelial resistance and a portion of this affect was dependent on the increase in ROS. However, the Alternaria-induced increase in unidirectional dextran (mw = 4000 Da) flux across the epithelium could not be accounted for by increased oxidative stress. These results support the conclusion that oxidative stress induced by Alternaria was responsible for regulating Ca2+-dependent anion secretion and tight junction electrical resistance that would be expected to affect mucociliary clearance</style></abstract><notes><style face="normal" font="Arial">DA - 20170427IS - 1522-1563 (Electronic)IS - 0363-6143 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajpcell.00043.2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28446427">PM:28446427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Cell Physiol\2017-313-C68-79.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Cell Physiol\2017-313-C68-79.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170427, Zaidman NA</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajpcell.00043.2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turturice,B.A.</style></author><author><style face="normal" font="Arial"> Ranjan,R.</style></author><author><style face="normal" font="Arial"> Nguyen,B.</style></author><author><style face="normal" font="Arial"> Hughes,L.M.</style></author><author><style face="normal" font="Arial"> Andropolis,K.E.</style></author><author><style face="normal" font="Arial"> Gold,D.R.</style></author><author><style face="normal" font="Arial"> Litonjua,A.A.</style></author><author><style face="normal" font="Arial"> Oken,E.</style></author><author><style face="normal" font="Arial"> Perkins,D.L.</style></author><author><style face="normal" font="Arial"> Finn,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Illinois at Chicago, Department of Microbiology and Immunology, Chicago, Illinois, United StatesUniversity of Illinois at Chicago, Department of Medicine, Division of Pulmonary, Critical Care, Sleep, and Allergy, Chicago, Illinois, United States</style></auth-address><titles><title><style face="normal" font="Arial">Perinatal Bacterial Exposure Contributes to IL-13 Aeroallergen Response</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="427" start="419">419-427</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">16S rDNA</style></keyword><keyword><style face="normal" font="Arial"> Abundance</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> High throughput sequencing</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="Arial">There is a high prevalence of aeroallergen sensitivity in asthmatic populations, and seroreactivity to aeroallergens early in infancy is associated with increased risk of developing asthma later in life. In addition to allergen sensitivity, asthma development has been associated with differential microbial exposure and infection in early life. We have has previously shown that cord blood mononuclear cells respond to common aeroallergens (i.e., house dust mite (Der f1), cockroach (Bla g2)) as assayed by lymphoproliferation and cytokine (IL-13, IFN-gamma) production. We hypothesized a relationship between perinatal microbial exposure and response to specific aeroallergens. To test this hypothesis, we isolated DNA from cord blood serum samples with known lymphoproliferative and cytokine responses to Bla g2 and Der f1. Bacterial 16S rDNA amplicon libraries were generated and analyzed using high throughput sequencing of cord blood serum samples. In our analysis, we identified major compositional differences, including diversity and abundance of specific taxa, between groups whose IL-13 response to Der f1 and Bla g2 differed. We demonstrate a strong association between the ratio of Acinetobacter to Proteobaceteria and IL-13 production and the probability of IL-13 production after allergen exposure. IL-13 concentrations in serum were also significantly correlated with the diversity of bacterial DNA. Together, these results underscore a relationship between immune responses to allergens and bacterial exposure during perinatal development</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2017-0027OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28443674">PM:28443674</url></web-urls><pdf-urls><url ppv-ref="no">bturtu2@uic.edu</url><url ppv-ref="no">pwfinn@uic.edu</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170426, Turturice BA</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2017-0027OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,R.</style></author><author><style face="normal" font="Arial"> Smith,S.G.</style></author><author><style face="normal" font="Arial"> Salter,B.</style></author><author><style face="normal" font="Arial"> El-Gammal,A.</style></author><author><style face="normal" font="Arial"> Oliveria,J.P.</style></author><author><style face="normal" font="Arial"> Obminski,C.</style></author><author><style face="normal" font="Arial"> Watson,R.</style></author><author><style face="normal" font="Arial"> O'Byrne,P.M.</style></author><author><style face="normal" font="Arial"> Gauvreau,G.M.</style></author><author><style face="normal" font="Arial"> Sehmi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-induced Increases in Sputum Levels of Group 2 Innate Lymphoid Cells in Asthmatic Subjects</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="712" start="700">700-712</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Group 2 innate lymphoid cells (ILC2), a major source of type 2 cytokines, initiate eosinophilic inflammatory responses in murine models of asthma. OBJECTIVES: Investigate the role of ILC2 in allergen-induced airway eosinophilic responses in atopic asthmatics. METHODS: Using a diluent-controlled allergen challenge cross-over study, where all subjects (n=10) developed allergen-induced early and late responses , airway eosinophilia and increased methacholine airway responsiveness, bone marrow, blood and sputum samples were collected pre- and post-inhalation challenge. MEASUREMENTS: ILC2s (lin-FcepsilonRI-CD45+CD127+ST2+) and CD4+T lymphocytes were enumerated by flow cytometry, as well as intracellular IL-5 and IL-13 expression. Steroid sensitivity of ILC2s and CD4+T cells was investigated in vitro. MAIN RESULTS: A significant increases in total, IL-5+, IL-13+ and CRTH2+ ILC2s were found in sputum, 24h post allergen, co-incident with a significant decrease in blood ILC2s. Total, IL-5+, IL-13+, but not CRTH2+, CD4+ T cells significantly increased at 24h and 48h post allergen in sputum. In blood and bone marrow, only CD4+ cells demonstrated increased activation post-allergen. Airway eosinophilia correlated with IL-5+ILC2s at all time points and allergen induced changes in IL-5+CD4+ cells at 48h post-Ag. Dexamethasone significantly attenuated IL-2 and IL-33 stimulated IL-5 and IL-13 production by both cell types. CONCLUSIONS: Both innate and adaptive immune cells are increased in the airways associated with allergic asthmatic responses. Total and type 2 cytokine positive ILC2s are increased only within the airways whereas CD4+ T lymphocytes demonstrated local and systemic increases. Steroid sensitivity of both cells may explain effectiveness of this therapy in mild asthmatics</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - China -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201612-2427OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28422515">PM:28422515</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20170419-ChenR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20170419-ChenR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Chen R</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201612-2427OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cantillo,J.F.</style></author><author><style face="normal" font="Arial"> Puerta,L.</style></author><author><style face="normal" font="Arial"> Lafosse-Marin,S.</style></author><author><style face="normal" font="Arial"> Subiza,J.L.</style></author><author><style face="normal" font="Arial"> Caraballo,L.</style></author><author><style face="normal" font="Arial"> Fernandez-Caldas,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Immunological Research, University of Cartagena, Cartagena, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Allergens involved in the cross-reactivity of Aedes aegypti with other arthropods</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="718" start="710">710-718</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aedes</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Blo t 10</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cytochrome C</style></keyword><keyword><style face="normal" font="Arial"> Der p 10</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lit v 1</style></keyword><keyword><style face="normal" font="Arial"> Litopenaeus vannamei</style></keyword><keyword><style face="normal" font="Arial"> Magnesium</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Per a 7</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> tropomyosins</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cross-reactivity between Aedes aegypti and mites, cockroaches, and shrimp has been previously suggested, but the involved molecular components have not been fully described. OBJECTIVE: To evaluate the cross-reactivity between A aegypti and other arthropods. METHODS: Thirty-four serum samples from patients with asthma and/or allergic rhinitis were selected, and specific IgE to A aegypti, Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blomia tropicalis, Periplaneta americana. and Litopenaeus vannamei was measured by enzyme-linked immunosorbent assay. Cross-reactivity was investigated using pooled serum samples from allergic patients, allergenic extracts, and the recombinant tropomyosins (Aed a 10.0201, Der p 10, Blo t 10, Lit v 1, and Per a 7). Four IgE reactive bands were further characterized by matrix-assisted laser desorption/ionization tandem time of flight. RESULTS: Frequency of positive IgE reactivity was 82.35% to at least one mite species, 64.7% to A aegypti, 29.4% to P americana, and 23.5% to L vannamei. The highest IgE cross-reactivity was seen between A aegypti and D pteronyssinus (96.6%) followed by L vannamei (95.4%), B tropicalis (84.4%), and P americana (75.4%). Recombinant tropomyosins from mites, cockroach, or shrimp inhibited the IgE reactivity to the mosquito at a lower extent than the extracts from these arthropods. Several bands of A aegypti cross-reacted with arthropod extracts, and 4 of them were identified as odorant binding protein, mitochondrial cytochrome C, peptidyl-prolyl cis-trans isomerase, and protein with hypothetical magnesium ion binding function. CONCLUSION: We identified 4 novel cross-reactive allergens in A aegypti allergenic extract. These molecules could influence the manifestation of allergy to environmental allergens in the tropics</style></abstract><notes><style face="normal" font="Arial">DA - 20170424IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - Spain -CO - Martinique -CO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28434865">PM:28434865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170424-CantilloJF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170424-CantilloJF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170424, Cantillo JF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lanz,M.J.</style></author><author><style face="normal" font="Arial"> Gonzalez,M.M.</style></author><author><style face="normal" font="Arial"> Efaw,B.J.</style></author><author><style face="normal" font="Arial"> Harbeck,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">AAADRS Clinical Research Center, Coral Gables, Florida.</style></auth-address><titles><title><style face="normal" font="Arial">Higher fractional exhaled nitric oxide and Der p 1 exposure in children with asthma living in tropical environments</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="732" start="731">731-732</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170430IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456485">PM:28456485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170430-LanzMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170430-LanzMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170430, Lanz MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wasan,A.</style></author><author><style face="normal" font="Arial"> Nanda,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Asthma Center, McLean, Virginia</style></auth-address><titles><title><style face="normal" font="Arial">Systemic reaction to timothy grass pollen sublingual immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="733" start="732">732-733</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457642">PM:28457642</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170501-WasanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170501-WasanA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Wasan A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Massey,J.</style></author><author><style face="normal" font="Arial"> Kumar,K.</style></author><author><style face="normal" font="Arial"> Ng,K.</style></author><author><style face="normal" font="Arial"> Yun,J.</style></author><author><style face="normal" font="Arial"> Fernando,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurology, Royal North Shore Hospital, Sydney, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Skeletal myositis as the sole feature of relapsing drug reaction with eosinophilia and systemic symptoms syndrome</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="728" start="726">726-728</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170423IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433575">PM:28433575</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170423-MasseyJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170423-MasseyJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, Massey J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,H.</style></author><author><style face="normal" font="Arial"> Fu,Y.</style></author><author><style face="normal" font="Arial"> Wang,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Jingmen No. 2 People's Hospital, Jingmen, Hubei, China.</style></auth-address><titles><title><style face="normal" font="Arial">Asthma and risk of coronary heart disease: A meta-analysis of cohort studies</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="695" start="689">689-695</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Few studies have investigated the incidence of coronary heart disease (CHD) in patients with asthma, and their results remain inconclusive. OBJECTIVE: To conduct a meta-analysis to determine whether asthma increases the risk of CHD. METHODS: A systematic literature search of the PubMed and Embase databases from inception to August 2016, complemented with references screening of relevant articles and reviews, was performed to identify eligible studies. Only longitudinal cohort studies were included in our meta-analysis. RESULTS: The retrieval process yielded 7 studies (12 asthma cohorts) with 495,024 patients. Data pooling across the cohorts revealed that asthma was associated with an increased risk of CHD (hazard ratio [HR], 1.42; 95% confidence interval [CI], 1.30-1.57; P &lt; .001), without significant heterogeneity across the studies (I2 = 26%, P = .19). This epidemiologic association was more pronounced in female than in male patients (female: HR, 1.50; 95% CI, 1.41-1.59; male: HR, 1.31; 95% CI, 1.16-1.47; P for interaction = .046). In addition, subgroup and sensitivity analyses supported the positive correlation between asthma and incident CHD. CONCLUSION: Asthma is related to an increased incidence of CHD, particularly in women. Clinicians should be aware of this association when faced with a patient with asthma. Further investigations are required to examine how this excess risk should be managed in routine practice</style></abstract><notes><style face="normal" font="Arial">DA - 20170423IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433577">PM:28433577</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170423-LiuH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170423-LiuH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, Liu H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bobart,S.A.</style></author><author><style face="normal" font="Arial"> Dimov,V.</style></author><author><style face="normal" font="Arial"> Sider,D.</style></author><author><style face="normal" font="Arial"> Gallego,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Cleveland Clinic Florida, Weston, Florida.</style></auth-address><titles><title><style face="normal" font="Arial">Proptosis and vision loss as grave complications of allergic fungal sinusitis and polyposis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="729" start="728">728-729</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170423IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433576">PM:28433576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170423-BobartSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170423-BobartSA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, Bobart SA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wudy,A.E.</style></author><author><style face="normal" font="Arial"> Negro,C.</style></author><author><style face="normal" font="Arial"> Adami,A.</style></author><author><style face="normal" font="Arial"> Larese,Filon F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Occupational Medicine, University of Trieste, Trieste, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Atopic status and latex sensitization in a cohort of 1,628 students of health care faculties</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="607" start="603">603-607</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Gloves</style></keyword><keyword><style face="normal" font="Arial"> latex sensitization</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic diseases have increased since the second half of the previous century. Atopic workers are at higher risk to be sensitized to latex, and the first years of exposure are supposed to be especially risky. OBJECTIVE: To assess atopic status and rate of latex sensitization in health care students starting their exposure to latex gloves. METHODS: We analyzed medical surveillance data from 1,628 health care students from 2010 to 2016. Students completed a questionnaire focused on their previous and current latex exposure and personal and family histories of allergic diseases; underwent skin prick testing with common allergens and latex extract (and/or total and latex-specific immunoglobulin E in serum); and underwent a medical examination. RESULTS: Skin prick test results for common inhalant allergens showed that 807 of 1,628 students (49.6%) had atopy. Atopy by skin prick testing was associated with male sex (odds ratio 1.49, 95% confidence interval 1.18-1.86), a personal history of oculorhinitis or asthma (odds ratio 10.22, 95% confidence interval 7.4-14.13), and atopic eczema (odds ratio 1.87, 95% confidence interval 1.05-3.36) at multivariate regression analysis. Eleven students (0.7% of total population) were found to be sensitized to latex and all had atopy. CONCLUSION: Despite the high prevalence of atopy in health care students of Trieste, the latex sensitization rate is very low and comparable to general population. This is reasonably due to the low exposure to latex gloves at the time of the evaluation and to low latex release from the gloves currently used in our hospital</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477790">PM:28477790</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-603-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-603-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Wudy AE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nam,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Comparison between skin prick test and serum immunoglobulin E by CAP system to inhalant allergens</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="613" start="608">608-613</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus putrescentiae</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Skin prick tests (SPTs) and measurements of serum specific immunoglobulin E (sIgE) antibodies are the most commonly used diagnostic tools for confirming sensitization. However, disagreement between the tests has been observed. OBJECTIVE: To compare SPT and the CAP system for diagnosis of sensitization to common inhalant allergens. METHODS: Subjects included 2,635 patients 10 to 90 years old who underwent analyses by SPT and CAP at the Dong-A University Hospital (Busan, Korea) from June 2011 through May 2016. The 2 test results were compared for 17 inhalant allergens. RESULTS: Agreement between the SPT and sIgE level was 75.3%. Overall agreement was moderate (kappa = 0.59), with strong agreement for house dust mites and birch (kappa > 0.7) and weak agreement for Tyrophagus putrescentiae and dog (kappa &lt; 0.3). When CAP was compared with SPT as the reference, the sensitivity was 75.8% and the specificity was 75.2%. Mean wheal size by SPT showed a positive correlation with sIgE levels (r = 0.59), which decreased with age. CONCLUSION: There was a discrepancy between SPT and CAP for diagnosing allergic sensitization among inhalant allergens. The allergic sensitization and correlation between the tests decreased with age. Cautious interpretation of the clinical relevance of allergen sensitization based on SPT and CAP results is required, especially in older patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477791">PM:28477791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-608-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-608-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Nam YH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez del Rio,P.</style></author><author><style face="normal" font="Arial"> Pitsios,C.</style></author><author><style face="normal" font="Arial"> Tsoumani,M.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Paraskevopoulos,G.</style></author><author><style face="normal" font="Arial"> Gawlik,R.</style></author><author><style face="normal" font="Arial"> Valovirta,E.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Section, Children's University Hospital "Nino Jesus", Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Physicians' experience and opinion on contraindications to allergen immunotherapy: The CONSIT survey</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="628" start="621">621-628</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acquired Immunodeficiency Syndrome</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Beta-blockers</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Contraindication</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Coronary Disease</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Cyprus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methotrexate</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> organ transplantation</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy (AIT) is the only disease-modifying treatment in allergy but several contraindications limit its use. OBJECTIVE: To collect the outcome of using AIT in theoretically contraindicated situations in real patients in the Contraindications to Specific ImmunoTherapy (CONSIT) survey. METHODS: The CONSIT is an electronic European Academy of Allergy and Clinical Immunology survey conducted to gather the safety outcomes of patients undergoing subcutaneous, sublingual, or venom AIT and the opinions of physicians on each of 17 selected conditions: children younger than 5 years; starting AIT during pregnancy; controlled severe asthma; arrhythmias; coronary disease; cancer; autoimmune disease; bone marrow and solid organ transplantation; human immunodeficiency virus and acquired immunodeficiency syndrome; previous anaphylaxis during AIT; use of beta-blockers, angiotensin-converting inhibitors, cyclosporine, and methotrexate; and inability to communicate. Safety using AIT was reported in a 3-point scale: 1, "no problems"; 2, "minor problems" (requiring only dose modifications); and 3, "major problems" (AIT not tolerated). Each physician was asked about the degree of contraindication that each condition should have: no contraindication (score 1), relative contraindication (score 2), or absolute contraindication (score 3). RESULTS: Five hundred twenty physicians (75% Europeans, 89% allergists) reported on approximately 45,000 patients undergoing AIT with any of these conditions. Major problems were infrequent, occurring more frequently in patients with asthma (9.9%) and with previous anaphylaxis from AIT (9.5%). Regarding opinions, experienced physicians scored a significantly lower mean for all conditions than non-experienced physicians for all routes. CONCLUSION: Major problems were infrequent and experienced physicians were less likely to be restrictive in the use of AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Cyprus -CO - United Kingdom -CO - Germany -CO - Greece -CO - Poland -CO - Finland -CO - Mexico -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477792">PM:28477792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-621-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-621-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Rodriguez del Rio P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loo,E.X.L.</style></author><author><style face="normal" font="Arial"> Sim,J.Z.T.</style></author><author><style face="normal" font="Arial"> Loy,S.L.</style></author><author><style face="normal" font="Arial"> Goh,A.</style></author><author><style face="normal" font="Arial"> Chan,Y.H.</style></author><author><style face="normal" font="Arial"> Tan,K.H.</style></author><author><style face="normal" font="Arial"> Yap,F.</style></author><author><style face="normal" font="Arial"> Gluckman,P.D.</style></author><author><style face="normal" font="Arial"> Godfrey,K.M.</style></author><author><style face="normal" font="Arial"> van Bever,H.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Chong,Y.S.</style></author><author><style face="normal" font="Arial"> Shek,L.P.</style></author><author><style face="normal" font="Arial"> Koh,M.J.A.</style></author><author><style face="normal" font="Arial"> Ang,S.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Associations between caesarean delivery and allergic outcomes: Results from the GUSTO study</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="638" start="636">636-638</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477794">PM:28477794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-636-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-636-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Loo EX</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,P.H.</style></author><author><style face="normal" font="Arial"> Wagner,A.</style></author><author><style face="normal" font="Arial"> Rutkowski,R.</style></author><author><style face="normal" font="Arial"> Rutkowski,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Vaccine allergy: A decade of experience from 2 large UK allergy centers</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="731" start="729">729-731</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.03.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457644">PM:28457644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170501-LiPH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170501-LiPH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Li PH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.03.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khurana,T.</style></author><author><style face="normal" font="Arial"> Bridgewater,J.L.</style></author><author><style face="normal" font="Arial"> Rabin,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Vaccines and Related Products Applications, US Food and Drug Administration, Silver Spring, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Allergenic extracts to diagnose and treat sensitivity to insect venoms and inhaled allergens</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="536" start="531">531-536</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ants</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Honeybee venom</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect allergen</style></keyword><keyword><style face="normal" font="Arial"> Insect allergens</style></keyword><keyword><style face="normal" font="Arial"> insect allergy</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Moths</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Wasps</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To review allergenic extracts used to diagnose or treat insect allergies, including how the extracts are manufactured and their measurements of potency or concentration. DATA SOURCES: Peer-reviewed articles derived from searching PubMed (National Center for Biotechnology Information) about insect allergies and extract preparation. Encyclopedia of Life (http://www.eol.org/) and http://allergome.org/ were also referenced for background information on insects and associated allergens. STUDY SELECTIONS: Search terms used for the PubMed searches included insect allergens and allergies, Apidae, Vespidae, fire ants, cockroach allergies, insect allergen extract preparation, and standardization. RESULTS: Humans may be sensitized to insect allergens by inhalation or through stings. Cockroaches and moths are predominantly responsible for inhalation insect allergy and are a major indoor allergen in urban settings. Bees, fire ants, and wasps are responsible for sting allergy. In the United States, there are multiple insect allergen products commercially available that are regulated by the US Food and Drug Administration. Of those extracts, honeybee venom and insect venom proteins are standardized with measurements of potency. The remaining insect allergen extracts are nonstandardized products that do not have potency measurements. CONCLUSION: Sensitization to inhalational and stinging insect allergens is reported worldwide. Crude insect allergen extracts are used for diagnosis and specific immunotherapy. A variety of source materials are used by different manufacturers to prepare these extracts, which may result in qualitative differences that are not reflected in measurements of potency or protein concentration</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.05.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477785">PM:28477785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-531-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-531-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Khurana T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.05.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Podlecka,D.</style></author><author><style face="normal" font="Arial"> Stelmach,I.</style></author><author><style face="normal" font="Arial"> Jerzynska,J.</style></author><author><style face="normal" font="Arial"> Polanska,K.</style></author><author><style face="normal" font="Arial"> Janasik,B.</style></author><author><style face="normal" font="Arial"> Gromadzinska,J.</style></author><author><style face="normal" font="Arial"> Wasowicz,W.</style></author><author><style face="normal" font="Arial"> Hanke,W.</style></author><author><style face="normal" font="Arial"> Majak,P.</style></author><author><style face="normal" font="Arial"> Stelmach,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics and Allergy, Medical University of Lodz, Copernicus Memorial Hospital in Lodz, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Early childhood allergy symptoms in relation to plasma selenium in pregnant mothers</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="634" start="632">632-634</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood allergy</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Selenium</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.02.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477793">PM:28477793</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-632-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-632-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Podlecka D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.02.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tarlo,S.M.</style></author><author><style face="normal" font="Arial"> Arif,A.A.</style></author><author><style face="normal" font="Arial"> Delclos,G.L.</style></author><author><style face="normal" font="Arial"> Henneberger,P.</style></author><author><style face="normal" font="Arial"> Patel,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University Health Network, University of Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Opportunities and obstacles in translating evidence to policy in occupational asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Epidemiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protective Devices</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work-related asthma</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Occupational asthma (OA), a common respiratory disorder in Western countries, is caused by exposures at the workplace. It is part of a broader definition of work-related asthma (WRA) that also includes pre-existing asthma aggravated by substances present in the workplace environment, and it is potentially preventable. The purpose of this paper is to illustrate preventive measures for occupational asthma by case studies. METHODS: In three case studies we discuss preventive measures that have been associated with reductions in incidence of occupational asthma from natural rubber latex and from diisocyanates as supported by published literature. We also discuss challenges in relation to asthma from cleaning products in healthcare work. RESULTS AND CONCLUSIONS: Several preventive measures have been associated with reduction in incidence of occupational asthma from natural rubber latex and from diisocyanates, and may provide lessons for prevention of other causes of occupational asthma. Cleaning products remain an unresolved problem at present with respect to asthma risks but potential measures include the use of safer products and safer applications such as avoidance of spray products, use of occupational hygiene methods such as improving local ventilation, and when appropriate, the use of personal protective devices</style></abstract><notes><style face="normal" font="Arial">DA - 20170424IS - 1873-2585 (Electronic)IS - 1047-2797 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.annepidem.2017.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28434545">PM:28434545</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Epidemiol\20170424-TarloSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Epidemiol\20170424-TarloSM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170424, Tarlo SM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.annepidem.2017.03.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Schie,K.A.</style></author><author><style face="normal" font="Arial"> Ooijevaar-de Heer,P.</style></author><author><style face="normal" font="Arial"> Kruithof,S.</style></author><author><style face="normal" font="Arial"> Plasencia,C.</style></author><author><style face="normal" font="Arial"> Jurado,T.</style></author><author><style face="normal" font="Arial"> Pascual Salcedo,D.</style></author><author><style face="normal" font="Arial"> Brandse,J.F.</style></author><author><style face="normal" font="Arial"> d'Haens,G.R.</style></author><author><style face="normal" font="Arial"> Wolbink,G.J.</style></author><author><style face="normal" font="Arial"> Rispens,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunopathology, Sanquin Research Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies</style></title><secondary-title><style face="normal" font="Arial">Ann Rheum Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Rheum Dis</style></abbr-1></periodical><pages end="1288" start="1285">1285-1288</pages><volume><style face="normal" font="Arial">76</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Controversy exists on the role of IgE antidrug antibodies (IgE-ADA) in infusion reactions (IR) on infliximab treatment, partly due to the lack of a positive control used for assay validation. We sought to (1) develop a robust assay to measure IgE-ADA, including a positive control, (2) determine the association between IgE-ADA and IR and (3) determine the incidence of IgE-ADA in infliximab treated patients. METHODS: A recombinant human IgE anti-infliximab monoclonal antibody was developed as standard and positive control. With this antibody, we set up a novel robust assay to measure IgE-ADA. IgE-ADA was determined in three retrospective cohorts (n=159) containing IR+ (n=37) and IR- (n=39), and longitudinal sera of 83 spondyloarthritis. RESULTS: IgE-ADA was found in 0/39 IR-, whereas 4/37 (11%) IR+ showed low levels (0.1-0.3 IU/mL, below the 0.35 IU/mL threshold associated with elevated risk of allergic symptoms). All patients who were IgE-ADA positive also had (very) high IgG-ADA levels. The incidence of IgE-ADA in patients with infliximab-treated spondyloarthritis was estimated at less than approximately 1%. CONCLUSIONS: IgE-ADA is rarely detected in infliximab-treated patients. Moreover, the absence of IgE-ADA in the majority of IR+ patients suggests that IgE-ADA is not associated with infusion reactions</style></abstract><notes><style face="normal" font="Arial">20170429IS - 1468-2060 (Electronic)IS - 0003-4967 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1136/annrheumdis-2016-211035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28455438">PM:28455438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Rheum Dis\20170429-vanSchieKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Rheum Dis\20170429-vanSchieKA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170429, van Schie KA</style></custom2><misc3><style face="normal" font="Arial">10.1136/annrheumdis-2016-211035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miao,S.</style></author><author><style face="normal" font="Arial"> Xie,P.</style></author><author><style face="normal" font="Arial"> Zou,M.</style></author><author><style face="normal" font="Arial"> Fan,L.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author><author><style face="normal" font="Arial"> Zhao,L.</style></author><author><style face="normal" font="Arial"> Ding,D.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Tan,W.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, No. 130 Meilong Road, Shanghai, 200237, China</style></auth-address><titles><title><style face="normal" font="Arial">Identification of multiple sources of the acidic charge variants in an IgG1 monoclonal antibody</style></title><secondary-title><style face="normal" font="Arial">Appl Microbiol Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Microbiol Biotechnol</style></full-title></periodical><pages end="5638" start="5627">5627-5638</pages><volume><style face="normal" font="Arial">101</style></volume><number><style face="normal" font="Arial">14</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> binding affinity</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Competitive ELISA</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Disulfide bond</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">Charge variants, especially acidic charge variants, of recombinant monoclonal antibodies are the major critical quality attributes in the biotechnology industry due to their potential influence on stability and biological activity. The chemical properties of the acidic charge variants have been challenging to fully characterize, and it is critical for process development and optimization. To completely understand the multiple sources of acidic charge variants, the major charge forms of an IgG1 monoclonal antibody were firstly isolated and then analyzed by a battery of characterization tools. It was found that various degrees of disulfide bond reduction, the deamination of HC-T8 Asn84 and HC-T35 Asn388 and aggregation account for the majority of acidic charge heterogeneity and the terminal galactosylation content was in relation to the acidic charge heterogeneity. The correlation between acidic charge heterogeneity and galactosylation content was further explored by weak cation exchange chromatography with the use of beta1-4 galactosidase digestion. The results showed that galactosylation was not the source of the acidic charge variants per se. Meanwhile, to gain insights into the impact on binding affinity of monoclonal antibody to IgE and FcRn, charge variants were also analyzed by competitive ELISA and surface plasmon resonance, respectively. All isolated charge variants had similar affinity binding to IgE and FcRn binding relative to the starting material</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 1432-0614 (Electronic)IS - 0175-7598 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00253-017-8301-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28439623">PM:28439623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Microbiol Biotechnol\20170425-MiaoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Microbiol Biotechnol\20170425-MiaoS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Miao S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00253-017-8301-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Megna,M.</style></author><author><style face="normal" font="Arial"> Patruno,C.</style></author><author><style face="normal" font="Arial"> Balato,A.</style></author><author><style face="normal" font="Arial"> Rongioletti,F.</style></author><author><style face="normal" font="Arial"> Stingeni,L.</style></author><author><style face="normal" font="Arial"> Balato,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease</style></title><secondary-title><style face="normal" font="Arial">Arch Dermatol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dermatol Res</style></full-title></periodical><pages end="452" start="443">443-452</pages><volume><style face="normal" font="Arial">309</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease which predominantly affects children. However, AD may persist until adulthood (persistent AD), or directly start in adults (adult-onset AD). AD often shows a non-flexural rash distribution, and atypical morphologic variants in adults and specific diagnostic criteria are lacking. Moreover, adult AD prevalence as well as detailed data which can characterize persistent vs adult-onset subtype are scant. The aim of this study was to investigate on the main features of adult AD particularly highlighting differences between persistent vs adult-onset form. An Italian multicentre observational study was conducted between April 2015-July 2016 through a study-specific digital database. 253 adult AD patients were enrolled. Familiar history of AD was negative in 81.0%. Erythemato-desquamative pattern was the most frequent clinical presentation (74.3%). Flexural surface of upper limbs was most commonly involved (47.8%), followed by eyelid/periocular area (37.9%), hands (37.2%), and neck (32%). Hypertension (7.1%) and thyroiditis (4.3%) were the most frequent comorbidities. A subgroup analysis between persistent (59.7%) vs adult-onset AD patients (40.3%) showed significant results only regarding AD severity (severe disease was more common in persistent group, p &lt; 0.05), itch intensity (higher in adult-onset disease), and comorbidities (hypertension was more frequent in adult-onset group, p &lt; 0.01). Adult AD showed uncommon features such as significant association with negative AD family history and lacking of association with systemic comorbidities respect to general population. No significant differences among persistent vs adult-onset subgroup were registered except for hypertension, itch intensity, and disease severity</style></abstract><notes><style face="normal" font="Arial">DA - 20170422IS - 1432-069X (Electronic)IS - 0340-3696 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00403-017-1739-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28432437">PM:28432437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dermatol Res\20170422-MegnaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dermatol Res\20170422-MegnaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170422, Megna M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00403-017-1739-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Son,J.Y.</style></author><author><style face="normal" font="Arial"> Jung,M.H.</style></author><author><style face="normal" font="Arial"> Koh,K.W.</style></author><author><style face="normal" font="Arial"> Park,E.K.</style></author><author><style face="normal" font="Arial"> Heo,J.H.</style></author><author><style face="normal" font="Arial"> Choi,G.S.</style></author><author><style face="normal" font="Arial"> Kim,H.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Kosin University College of Medicine, Busan 49267, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Changes in skin reactivity and associated factors in patients sensitized to house dust mites after 1 year of allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="91" start="82">82-91</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen skin reactivity</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reactivity</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific immunotherapy (SIT) can significantly improve symptoms and reduce the need for symptomatic medication. OBJECTIVE: The aim of this study was to investigate changes in skin reactivity to house dust mites (HDMs) as an immunologic response and associated factors after 1 year of immunotherapy. METHODS: A total of 80 patients with allergic airway diseases who received subcutaneous SIT with HDMs from 2009 to 2014 were evaluated. The investigated parameters were basic demographic characteristics, skin reactivity and specific IgE for HDM, serum total IgE level, blood eosinophil counts, and medication score. RESULTS: The mean levels of skin reactivity to HDMs, blood eosinophil counts, and medication scores after 1 year were significantly reduced from baseline. In univariate comparison of the changes in skin reactivity to HDMs, age &lt;/=30 years, HDMs only as target of immunotherapy, and high initial skin reactivity (>/=2) to HDMs were significantly associated with the reduction in skin test reactivity. In multivariate analysis, high initial skin reactivity and HDMs only as target allergens were significantly associated with changes in skin reactivity to HDMs. In the receiver operating characteristic curve of the initial mean skin reactivity to HDMs for more than 50% reduction, the optimal cutoff value was 2.14. CONCLUSION: This study showed significant reductions in allergen skin reactivity to HDMs after 1 year of immunotherapy in patients sensitized to HDMs. The extent of initial allergen skin reactivity and only HDMs as target allergen were important predictive factors for changes in skin reactivity</style></abstract><notes><style face="normal" font="Arial">DA - 20170510IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.2.82</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28487839">PM:28487839</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-82-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-82-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Sin JY</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.2.82</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thong,B.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore 308433, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Allergic conjunctivitis in Asia</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="64" start="57">57-64</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asia-Pacific</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Calcineurin</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust storms</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental tobacco smoke</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> phthalates</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> tobacco smoke</style></keyword><keyword><style face="normal" font="Arial"> topical calcineurin inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Translational research</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Allergic conjunctivitis (AC), which may be acute or chronic, is associated with rhinitis in 30%-70% of affected individuals, hence the term allergic rhinoconjunctivitis (AR/C). Seasonal and perennial AC is generally milder than the more chronic and persistent atopic and vernal keratoconjunctivitis. Natural allergens like house dust mites (HDM), temperate and subtropical grass and tree pollen are important triggers that drive allergic inflammation in AC in the Asia-Pacific region. Climate change, environmental tobacco smoke, pollutants derived from fuel combustion, Asian dust storms originating from central/north Asia and phthalates may also exacerbate AR/C. The Allergies in Asia Pacific study and International Study of Asthma and Allergies in Childhood provide epidemiological data on regional differences in AR/C within the region. AC significantly impacts the quality of life of both children and adults, and these can be measured by validated quality of life questionnaires on AR/C. Management guidelines for AC involve a stepped approach depending on the severity of disease, similar to that for allergic rhinitis and asthma. Topical calcineurin inhibitors are effective in certain types of persistent AC, and sublingual immunotherapy is emerging as an effective treatment option in AR/C to grass pollen and HDM. Translational research predominantly from Japan and Korea involving animal models are important for the potential development of targeted pharmacotherapies for AC</style></abstract><notes><style face="normal" font="Arial">DA - 20170510IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - SIngapore -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.2.57</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28487836">PM:28487836</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-57-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-57-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Thong BY</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.2.57</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korematsu,S.</style></author><author><style face="normal" font="Arial"> Toyokuni,K.</style></author><author><style face="normal" font="Arial"> Handa,Y.</style></author><author><style face="normal" font="Arial"> Gotoh,C.</style></author><author><style face="normal" font="Arial"> Wasada,R.</style></author><author><style face="normal" font="Arial"> Kato,R.</style></author><author><style face="normal" font="Arial"> Kawano,N.</style></author><author><style face="normal" font="Arial"> Ikeuchi,M.</style></author><author><style face="normal" font="Arial"> Okamoto,T.</style></author><author><style face="normal" font="Arial"> Kiriya,M.</style></author><author><style face="normal" font="Arial"> Takahashi,M.</style></author><author><style face="normal" font="Arial"> Takano,T.</style></author><author><style face="normal" font="Arial"> Haigo,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Educational Support for Regional Pediatrics, Oita University Faculty of Medicine, Oita 879-5593, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Medical certification reduces the number of children requiring allergen elimination diets for school lunches</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="96" start="92">92-96</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental ingestion</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Following the increase in the number of children with food allergies, support systems are now required for school lunches, but a large-scale factual investigation has not been carried out. OBJECTIVE: We evaluated the features of elimination diet due to food allergy and the support system in kindergartens and schools. METHODS: A prefecture-based questionnaire survey regarding measures for food allergies in school lunches of all kindergartens, public elementary schools, and public junior high schools (631 facilities) was conducted in Oita Prefecture, Japan. RESULTS: The recovery rate of the questionnaire was 99.5%, which included 106,008 students in total. A total of 1,562 children (1.5%) required elimination diets. The rate of children on elimination diets in kindergartens and elementary/junior high schools that required medical certification by a physician was 1.2% (324 among 27,761 children), which was significantly lower than the 1.8% of children (1,227 among 68,576 students) on elimination diets at the request of guardians without the need for medical certification (p &lt; 0.0001). A total of 43.9% of the kindergartens and schools said that they would contact guardians if symptoms were observed after accidental ingestion, while a low 8.1% stated that they provided support to children themselves, including the administration of adrenaline auto-injectors. CONCLUSION: Medical certification reduces the number of children requiring elimination diets, but it has not been adequately implemented. Furthermore, waiting to contact guardians after symptoms are observed may lead to the delayed treatment of anaphylaxis. Cooperation between physicians and teachers is desired to avoid the overdiagnosis and undertreatment of children with food allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170510IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.2.92</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28487840">PM:28487840</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-92-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-92-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Korematsu S</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.2.92</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Unal,D.</style></author><author><style face="normal" font="Arial"> Gelincik,A.</style></author><author><style face="normal" font="Arial"> Elitok,A.</style></author><author><style face="normal" font="Arial"> Demir,S.</style></author><author><style face="normal" font="Arial"> Olgac,M.</style></author><author><style face="normal" font="Arial"> Coskun,R.</style></author><author><style face="normal" font="Arial"> Kocaaga,M.</style></author><author><style face="normal" font="Arial"> Colakoglu,B.</style></author><author><style face="normal" font="Arial"> Buyukozturk,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34015, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Impact of high serum Immunoglobulin E levels on the risk of atherosclerosis in humans</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="81" start="74">74-81</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Atherosclerosis</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Echocardiography</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Intercellular Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-6</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vascular Cell Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Epidemiological studies show that immunoglobulin E (IgE) levels were higher in subjects with acute coronary events. However, it is unknown if the increased IgE level is a marker of future coronary incidents and whether it may be regarded as a risk factor of an ischemic heart disease. OBJECTIVE: Our aim was to investigate the relationship between IgE levels and some atherosclerotic markers in patients without known atherosclerotic disease. METHODS: Fifty patients (mean age, 40.96 +/- 10.8 years) with high serum IgE levels due to various conditions who did not display evidence of an atherosclerotic disease and 30 healthy control subjects (mean age, 47 +/- 8.27 years) were included in the study. Atherosclerotic disease markers including adhesion molecules like vascular cell adhesion molecule-1, intercellular adhesion molecule-1, proinflammatory cytokines such as interleukin-6, endothelin-1, and systemic inflammatory markers such as high sensitivity C-reactive protein were determined by enzyme-linked immunosorbent assay (ELISA). Endothelial functions of the coronary arteries were determined by coronary flow reserve (CFR) measurements and carotid intima media thickness using transthoracic Doppler echocardiography. RESULTS: CFR was significantly lower in the patient group when compared with the control group (p&lt;0.001; 95% confidence interval, -0.79 to-0.20) while carotid media thicknesses were not different between 2 groups. There were no differences in ELISA test results between the 2 groups. CONCLUSION: Our results showed that CFR as an early marker of endothelial dysfunction was significantly lower in patients with high IgE levels. This finding seems to support the role of IgE in the vascular pathology of atherosclerosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170510IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.2.74</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28487838">PM:28487838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-74-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-74-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Unal D</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.2.74</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Visitsunthorn,N.</style></author><author><style face="normal" font="Arial"> Sripramong,C.</style></author><author><style face="normal" font="Arial"> Bunnag,C.</style></author><author><style face="normal" font="Arial"> Jirapongsananuruk,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics</style></auth-address><titles><title><style face="normal" font="Arial">Comparison between specific IgE levels and skin prick test results of local and imported American cockroach, dog, cat, dust mites and mold allergen extracts</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="65" start="60">60-65</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Likelihood ratio</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Skin prick test (SPT) and specific IgE (sIgE) are approved for evaluation of allergen sensitization. Local allergen extracts are less expensive and more available but need to be standardized. OBJECTIVE: To compare SPT results of local and imported allergen extracts and sIgE levels in response to the American cockroach, dog, cat, Dermatophagoides pteronyssinus (Dp), Dermatophagoides farinae (Df) and Cladosporium spp. allergens. METHOD: This prospective, randomized, double-blind, self-controlled study was performed in respiratory allergic volunteers. Each subject was pricked with local and imported allergen extracts and sIgE levels were measured. RESULTS: The agreement between SPT results from each local and imported allergen extract was statistically significant, and the level of agreement for dog allergens was very good (kappa > 0.8). All patients with a positive SPT in response to imported Dp allergen extract had positive SPT in response to local Dp allergen extract. Mean wheal diameter of each allergen in both groups showed significant correlation with sIgE levels. The correlation coefficient (CC) for cat allergens showed a very good-to-excellent relationship (CC> 0.75). When compared with sIgE levels, SPT results for imported and local allergen extracts showed comparable sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio (LR)+ and LR-. CONCLUSIONS: When the SPT results are compared between local and imported allergen extracts, all were found to have significant agreement, with very good agreement for cat allergens. When the SPT results are compared with specific IgE levels, both local and imported allergen extract provided comparable validity</style></abstract><notes><style face="normal" font="Arial">DA - 20160630IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0745</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27362401">PM:27362401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-60-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-60-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160630, Visitsunthorn N</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0745</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sun,L.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Lou,Y.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Guo,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China</style></auth-address><titles><title><style face="normal" font="Arial">Species and quantity of airborne pollens in Shanghai as monitored by gravitational and volumetric methods</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="45" start="38">38-45</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Humulus</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of allergic diseases has markedly increased in the last decades. It is therefore important to assess the distribution of airborne pollen, the most important aeroallergen, for allergic disease prevention and control. OBJECTIVE: To identify the species and quantity of airborne pollens, and observe their distribution characteristics in Shanghai, using gravitational (Durham Sampler) and volumetric (Rotorod Sampler 40) methods simultaneously. In addition, the correlation between both methods was analyzed to provide effective preventive measures for pollen-sensitized individuals. METHOD: Pollen counts were monitored in the same area from November 1, 2009 to October 31, 2010 by samplers set at the same height and site. Pollen concentrations as well as any association between the two methods were determined. RESULTS: Two pollen concentration peaks in Shanghai were observed from March to May (spring) and September to October (autumn). In spring, tree pollen was the main species, with a predominance of Broussonetia. In autumn, grass pollen predominated, with mostly Humulus. Thirty-two species were identified by both gravitational and volumetric methods. Five and seven additional species were identified exclusively by the gravitational and volumetric methods, respectively. Pollen counts obtained from both devices were significantly correlated (P&lt;0.05). CONCLUSIONS: Two methods were used simultaneously for the first time to monitor pollen counts in central urban Shanghai, showing two annual peaks. Broussonetia and Humulus were the predominant spring and autumn pollens, respectively. Pollen counts obtained by both methods were clearly correlated. Regional airborne pollen monitoring offers preventive measures for sensitized individuals and provides useful clinical information</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0743</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27543732">PM:27543732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-38-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-38-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Sun L</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0743</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suwarsa,O.</style></author><author><style face="normal" font="Arial"> Adi,S.</style></author><author><style face="normal" font="Arial"> Idjradinata,P.</style></author><author><style face="normal" font="Arial"> Sutedja,E.</style></author><author><style face="normal" font="Arial"> Avriyanti,E.</style></author><author><style face="normal" font="Arial"> Asfara,A.</style></author><author><style face="normal" font="Arial"> Gunawan,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Hasan Sadikin General Hospital, Bandung, West Java, Indonesia</style></auth-address><titles><title><style face="normal" font="Arial">Interleukin-18 correlates with interleukin-4 but not interferon-gamma production in lymphocyte cultures from atopic dermatitis patients after staphylococcal enterotoxin B stimulation</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="59" start="54">54-59</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Indonesia</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-18</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal enterotoxin B</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Staphylococcus aureus (S. aureus) triggers exacerbation of atopic dermatitis (AD) and causes chronic inflammation through the action of various proteins such as staphylococcal enterotoxin B (SEB). SEB has a role in activating interleukin (IL)-18, an important regulator of interferon (IFN)-gamma and IL-4, in regards to a therapeutic strategy. OBJECTIVE: To determine the correlation of IL-18 level with the IL-4 and IFN-gamma level in lymphocyte cultures from AD patients following SEB stimulation. METHOD: Twenty patients with AD based on the Hanifin and Rajka criteria and 20 healthy subjects as a control group were selected. A 5 ml blood sample from each subject was taken for lymphocyte culture. The culture was stimulated with SEB for two days and the outcomes were assessed by enzyme-linked immunosorbent assays (ELISA) to evaluate the levels of IL-18, IL-4, and IFN-gamma. RESULTS: In the AD group, the levels of IL-18, IL-4, and IFN-gamma in lymphocyte cultures with SEB were significantly increased compared with non-SEB exposed cells (each p&lt;0.001); similar results were found in the control group. The level of IL-18 was significantly elevated in lymphocyte cultures with SEB stimulation in AD vs. control (p&lt;0.05) and without SEB in AD vs. control (p&lt;0.05). Furthermore, IL-18 levels were significantly correlated with IL-4 levels and score atopic dermatitis (SCORAD) values in AD patients with SEB (r=0.41, p&lt;0.05; and r=0.70, p&lt;0.05, respectively); on the in contrary, there was no correlation between IL-18 and IFN-gamma levels (p=0.469). CONCLUSIONS: Our results suggest that IL-18 is correlated with increased of IL-4 levels in SEB-stimulated AD lymphocyte cultures</style></abstract><notes><style face="normal" font="Arial">DA - 20160820IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Indonesia -</style></notes><work-type><style face="normal" font="Arial">10.12932/AP0787</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27543731">PM:27543731</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-54-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-54-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160820, Suwarsa O</style></custom2><misc3><style face="normal" font="Arial">10.12932/AP0787</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sasihuseyinoglu,A.S.</style></author><author><style face="normal" font="Arial"> Ozhan,A.K.</style></author><author><style face="normal" font="Arial"> Serbes,M.</style></author><author><style face="normal" font="Arial"> Duyuler,G.A.</style></author><author><style face="normal" font="Arial"> Bingol,G.</style></author><author><style face="normal" font="Arial"> Yilmaz,M.</style></author><author><style face="normal" font="Arial"> Altintas,D.U.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Distribution Of Alergen Sensitization In Childhood By the Use Of Skin Test</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="48" start="43">43-48</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Chestnut</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: Skin prick testing (SPT) is widely used for assessing the clinical reactivity to aeroallergens, foods, and drugs. The aim of our study was to investigate the prevalence of allergic sensitivity in the patients presenting to our clinic. Materials and Methods: The retrospective study included 2,512 patients who presented to our clinic and underwent SPT due to suspected atopy between January and December 2014. SPT was based on sensitivity against house dust mites, molds, pollens, and foods including milk, egg, wheat, chestnut, and latex. Based on their ages, the patients were divided into four groups: Group I; 2 years or younger, Group II; 3-5 years, Group III; 6-12 years, and Group IV; over 12 years. The SPT scores were evaluated based on the age groups, gender, and the month. Results: The 2,512 patients included 1,444 (57.5%) boys and 1,068 (42.5%) girls. At least one SPT was positive in 1,058 (42.3%) patients. Skin test was positive in 44.8% of boys as compared to 38.4% of girls. Multiple allergen sensitivity was present in 93% of the patients. Most of the patients were allergic to house dust mites [Dermatophagoides pteronyssinus (%73.8) and Dermatophagoides farinae (%71.6)], followed by mold (23.4%) and grasses-cereals mix (23.8%). Among the foods, eggs (3.8%) and milk (3.1%) had the highest rate of allergic reaction. No patient had allergic reaction to latex. Among the age groups, Group III had the highest rate (50.4%) of positivity. An evaluation based on the months revealed that the patients were sensitive against aeroallergens, particularly pollens, in May and June, against molds in May and September, and against house dust mites all year round. Conclusion: The skin prick test is a practical method for the assessment of allergic sensitivity.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="FrutigerRoman">10.21911/aai.24</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.21911/aai.24</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-43-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-43-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Sasihuseyinoglu AS</style></custom2><misc3><style face="normal" font="FrutigerRoman">10.21911/aai.24</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bayam,Y.S:</style></author><author><style face="normal" font="Arial"> Ayyildiz,Z.A:</style></author><author><style face="normal" font="Arial"> Sozmen,S.C.</style></author><author><style face="normal" font="Arial"> Isik,S.</style></author><author><style face="normal" font="Arial"> Tezcan,D.</style></author><author><style face="normal" font="Arial"> Asilsoy,S.</style></author><author><style face="normal" font="Arial"> Karaman,O.</style></author><author><style face="normal" font="Arial"> Uzuner,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Role of Food Allergy in Children with Chronic Constipation</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="42" start="38">38-42</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch test</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch tests</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> constipation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy allergy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: We aimed to evaluate the role of food allergies in the etiology of constipation in children who presented with chronic constipation. We investigated the effects of the allergens on constipation by eliminating the relevant allergen from diet in cases with positive food allergy testing in the study. Materials and Methods: The study included 75 patients aged 6 months-10 years with functional constipation. The severity of constipation was assessed with the constipation symptom score. Food-specific IgE levels were evaluated in the sera while skin prick and atopy patch tests were performed by using milk, egg white, egg yolk, wheat, and soybean in all patients. For the patients with positive test results, the allergen was eliminated from the diet over 2 months. Two months later, these patients were re-evaluated by using the constipation symptom score. Results: There was a female predominance (62.7%) in the study group. The mean age was 4.69±0.295 (mean±SD) years. The mean duration of constipation was 24±2 (mean±SD) months. The atopy patch test was positive in 4 of the 75 (5.3%) patients. Atopy patch test positivity was found for egg white and yolk in the first patient, wheat and soy in the second, wheat alone in the third, and soy alone in the fourth. The skin prick test was found to be negative in all four patients. Food mixed specific IgE levels were positive in three of the four patients with a positive atopy patch test (2.31kU/L, 2.35 kU/L, 0.1 kU/L and 1.16 kU/L, respectively). When patients were reevaluated after an elimination diet by using the constipation symptom score, the symptom score had improved in only one patient, the one with soy allergy. Conclusion: Our findings support that food allergy has no role in chronic constipation. The atopy patch test did not make an additional contribution to the diagnosis of food allergy.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="FrutigerRoman">10.21911/aai.18</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.21911/aai.18</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-38-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-38-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Bayam YS</style></custom2><misc3><style face="normal" font="FrutigerRoman">10.21911/aai.18</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sekerel,E.S.</style></author><author><style face="normal" font="Arial"> Misirligil,Z.</style></author><author><style face="normal" font="Arial"> Orhan,F.</style></author><author><style face="normal" font="Arial"> Mungan,D.</style></author><author><style face="normal" font="Arial"> Buyuktiryaki,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy Skin Tests: Where, When, How and How Many?</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="22" start="17">17-22</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy skin test</style></keyword><keyword><style face="normal" font="Arial"> Allergy skin tests</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Precaution</style></keyword><keyword><style face="normal" font="Arial"> precautions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">In recent years, allergy skin testing has increasingly become an area of interest and is being widely performed by physicians other than allergists and immunologists. In this article, the indications, necessity, selection of allergens to be used, risks and adverse events, essential precautions during application, evaluation methods, and disadvantages of evaluation mistakes of allergy skin tests and why they should be performed by an allergist or immunologist are reviewed.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">1</style><style face="normal" font="FrutigerRoman">0.21911/aai.338</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.21911/aai.338</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-17-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-17-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Sekerel ES</style></custom2><misc3><style face="normal" font="Arial">1</style><style face="normal" font="FrutigerRoman">0.21911/aai.338</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Emeksiz,Z.S.</style></author><author><style face="normal" font="Arial"> Cavkaytar,O.</style></author><author><style face="normal" font="Arial"> Aksoy,I.</style></author><author><style face="normal" font="Arial"> Daller,Y.</style></author><author><style face="normal" font="Arial"> Soyer,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zeynep Sengül Emeksiz, Özlem Cavkaytar, Ilknur Aksoy, Yildiz Daller, Özge Soyer</style></auth-address><titles><title><style face="normal" font="FrutigerRoman">Food Hypersensitivity in Atopic Dermatitis During Infancy: Skin Prick Testing for Whom?</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="37" start="32">32-37</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Status</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: Atopic dermatitis (AD) is a common disease during infancy. The data on food hypersensitivity (FH) in the first six months and especially in the first three months of life is limited in children with AD. The aim of this study was to find out the frequency of FH and related factors in infants with AD in regard to their referral age. Materials and Methods: Infants younger than 1 years of age who were diagnosed as AD at the Ankara Training and Research Hospital's Department of Pediatrics were included in our study. The demographic features, nutritional status, disease severity and skin test results were recorded. A diagnosis of FH was made in the presence of a positive skin test with the related allergen. All the patients with FH had resolution of the symptoms with the elimination of the relevant food from the diet. Results: One-hundred and ten patients (70% male) were included. In patients younger than 3 months of age, the SCORAD-index and total IgE levels were higher in the patients with FH compared to patients without FH [(25.2(20.9-34.9) vs. 19.2(13.1-24.2), (p=0.034) and 22.2(11.6-52.6)kU/L vs. 4(4-10)kU/L, (p=0.04), respectively]. In patients aged between 3 and 6 months of age, the SCORAD index, total IgE and eosinophil levels were higher in patients with FH compared to patients without FH [36.2(29.3-44.7) vs. 18.8(13.3- 26.7), (p&lt;0.001)], [42.1(6.3-283)kU/L vs. 8.3(4.8-8.3)kU/L, (p=0.033)], [7.5%(3.9-9.7) vs. 3.5%(1.8-5.8), (p=0.01)]. In patients older than 6 months of age, the SCORAD index, eosinophil and IgE levels were similar between patients with and without FH. Conclusion: In infants with AD, the prevalence of food allergy in early life (=3 months) might be higher in patients with a higher SCORAD index and IgE levels. These laboratory features are useful tools in order to predict food hypersensitivity and in relevant clinical conditions food allergy, and might avoid unnecessary testing.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="FrutigerRoman">10.21911/aai.16</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.21911/aai.16</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-32-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-32-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Emeksiz ZS</style></custom2><misc3><style face="normal" font="FrutigerRoman">10.21911/aai.16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ceren,C.</style></author><author><style face="normal" font="Arial"> Yazicioglu,M.</style></author><author><style face="normal" font="Arial"> Gurkan,H.</style></author><author><style face="normal" font="Arial"> Gorgulu,A.</style></author><author><style face="normal" font="Arial"> Sut,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lack of Association between Toll-like Receptor 2 Polymorphisms (R753Q and A-16934T) and Atopic Dermatitis in Children from Thrace Region of Turkey</style></title><secondary-title><style face="normal" font="Arial">Balkan Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Balkan Med J</style></full-title></periodical><pages end="238" start="232">232-238</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allele frequency</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TLRs</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 2</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. A complex interaction of both genetic and environmental factors is thought to contribute to the disease. Recently relations between single nucleotide polymorphisms (SNPs) of toll-like receptors (TLRs) and AD have been reported. AIMS: The aim of the study was to evaluate whether SNPs in the TLR2 gene c.2258C>T (R753Q) (rs5743708) and TLR2 c.-148+1614T>A (A-16934T) (rs4696480) (NM_0032643) are associated with AD in Turkish children. STUDY DESIGN: Case-control study. METHODS: The study was conducted on 70 Turkish children with AD aged 0.5-18 years, The clinical severity of AD was evaluated by the severity scoring of AD (SCORAD) index. Serum total IgE levels, specific IgE antibodies to inhalant and food allergens were measured in both AD patients and controls, skin prick tests were done on 70 children with AD. Genotyping for TLR2 (R753Q and A-16934T) SNPs was performed in both AD patients and controls. RESULTS: Cytosine (C) - C (CC) and C - thymine (CT) genotype frequencies of TLR2 R753Q SNP in the AD group were determined as being 98.6% and 1.4%, respectively; CC and CT genotype frequencies of TLR2 R753Q SNP in the control group were 95.7% and 4.3%, respectively (p=0.366). CONCLUSION: In the AD group, C allele frequency for TLR2 R753Q SNP was determined as 99.29% and T allele frequency was 0.71%, whereas in the control group C and T allele frequencies for TLR2 R753Q SNP were 97.83% and 2.17%, respectively (p=0.853)</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 2146-3131 (Electronic)IS - 2146-3123 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.4274/balkanmedj.2015.1253</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28443596">PM:28443596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Balkan Med J\2017-34-232-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Balkan Med J\2017-34-232-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170426, Ceren C</style></custom2><misc3><style face="normal" font="Arial">10.4274/balkanmedj.2015.1253</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Najarian,D.R.</style></author><author><style face="normal" font="Arial"> Hilton,K.</style></author><author><style face="normal" font="Arial"> McCauley,T.</style></author><author><style face="normal" font="Arial"> Qiu,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bioanalytical &amp; Biomarker Development, 300 Shire Way, Lexington, MA 02421, USA</style></auth-address><titles><title><style face="normal" font="Arial">A comparison study of bioanalytical methods for detection and characterization of anti-velaglucerase alfa antibodies</style></title><secondary-title><style face="normal" font="Arial">Bioanalysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bioanalysis</style></full-title></periodical><pages end="786" start="775">775-786</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">AIM: To provide more efficient and timely immunogenicity testing service to support routine patient care, the original complex testing algorithm for evaluation of anti-velaglucerase alfa antibodies has been simplified and individual methods (screen, confirm, titer, neutralizing antibody [NAb] and IgE) have been redeveloped/optimized and validated. RESULTS: To compare the performance of different methods, 50 velaglucerase alfa-treated patient samples were analyzed using both old and new methods for the presence of antidrug antibodies (ADAs) and 31 ADA-positive samples were analyzed for neutralizing capacity. The ADA and NAb statuses are almost identical from both methods and both ADA and NAb titer results are highly correlated with a Spearman's correlation of 0.96 and 0.86, respectively. CONCLUSION: The original and new testing methods can be considered interchangeable for the measurement of total and neutralizing anti-velaglucerase alfa antibodies</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1757-6199 (Electronic)IS - 1757-6180 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4155/bio-2016-0274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28453301">PM:28453301</url></web-urls><pdf-urls><url ppv-ref="no">yqiu@shire.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Najarian DR</style></custom2><misc3><style face="normal" font="Arial">10.4155/bio-2016-0274</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hikosaka,M.</style></author><author><style face="normal" font="Arial"> Murata,A.</style></author><author><style face="normal" font="Arial"> Yoshino,M.</style></author><author><style face="normal" font="Arial"> Hayashi,S.I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Correlation between cell aggregation and antibody production in IgE-producing plasma cells</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Rep</style></full-title></periodical><pages end="231" start="224">224-231</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> aggregates</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody production</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cell aggregation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Fc gamma receptor</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> hybridoma</style></keyword><keyword><style face="normal" font="Arial"> Hybridomas</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><isbn><style face="normal" font="Arial">2405-5808</style></isbn><abstract><style face="normal" font="Arial">Allergic conditions result in the increase of immunoglobulin (Ig)E-producing plasma cells (IgE-PCs); however, it is unclear how IgE production is qualitatively controlled. In this study, we found that IgE-PCs in spleen of immunized mice formed homotypic cell aggregates. By employing IgE-producing hybridomas (IgE-hybridomas) as a model of IgE-PCs, we showed that these cells formed aggregates in the presence of specific antigens (Ags). The formation of the Ag-induced cell aggregation involved secreted IgE and Fc+¦ receptor (Fc+¦R)II/Fc+¦RIII, but not Fc+ÁRs. Ag-induced cell aggregation plus lipopolysaccharide signaling resulted in an enhancement of IgE production in aggregated IgE-hybridomas. Furthermore, the administration of anti-Fc+¦RII/Fc+¦RIII antagonistic monoclonal antibody to immunized mice tended to reduce the splenic IgE-PC aggregation as well as the serum IgE levels. Taken together, our results suggested that Ag-IgE complexes induced IgE-PCs aggregation via Fc+¦RII/Fc+¦RIII, leading to the enhancement of IgE production. These findings suggest the presence of a novel mechanism for regulation of IgE production</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrep.2017.04.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28955750">PM:28955750</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Rep\2017-10-224-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Rep\2017-10-224-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Hikosaka M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrep.2017.04.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vandenplas,Y.</style></author><author><style face="normal" font="Arial"> AlFrayh,A.S.</style></author><author><style face="normal" font="Arial"> AlMutairi,B.</style></author><author><style face="normal" font="Arial"> Elhalik,M.S.</style></author><author><style face="normal" font="Arial"> Green,R.J.</style></author><author><style face="normal" font="Arial"> Haddad,J.</style></author><author><style face="normal" font="Arial"> Koshak,E.A.</style></author><author><style face="normal" font="Arial"> Miqdady,M.</style></author><author><style face="normal" font="Arial"> Mouane,N.</style></author><author><style face="normal" font="Arial"> Salah,M.</style></author><author><style face="normal" font="Arial"> Samy,G.</style></author><author><style face="normal" font="Arial"> Tavakol,M.</style></author><author><style face="normal" font="Arial"> Von Berg,A.</style></author><author><style face="normal" font="Arial"> Szajewska,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Physician practice in food allergy prevention in the Middle East and North Africa</style></title><secondary-title><style face="normal" font="Arial">BMC Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMC Pediatr</style></abbr-1></periodical><pages end="" start="118">118-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Middle East</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> United Arab Emirates</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A number of scientific organisations have developed guidelines for the primary prevention of allergic disease through nutritional interventions. However, even if the best evidence-based guidelines are available, these guidelines do not necessarily lead to adherence and improved health outcomes. METHOD: To determine how closely the practice of physicians in select Middle Eastern and North African countries compares with the current recommendations on the primary prevention of allergy a survey study was performed using a structured questionnaire and convenience sampling. RESULTS: A total of 1481 physicians responded, of which 66.1% were pediatricians. A total of 76.6% of responding physicians routinely identify infants who are at risk for developing allergy. In infants at risk for developing allergy, 89.1% recommend exclusive breastfeeding for at least 4 months. In contrast to current recommendations, 51.6% routinely recommend avoidance of any allergenic food in the lactating mother. In infants at risk of developing allergy who are completely formula fed, standard infant formula was recommended by 22.5% of responders. Of the responding physicians, 50.6% would recommend delaying the introduction of complementary food in infants at risk of allergy compared to those not at risk, whereas 62.5% would recommend postponing the introduction of potentially allergenic foods. Only 6.6% stated they follow all current recommendations on food allergy prevention. CONCLUSION: The results of this survey suggest that a substantial part of responding physicians from select Middle Eastern and North African (MENA) countries do not follow current recommendations on primary prevention of allergic disease through nutritional interventions</style></abstract><notes><style face="normal" font="Arial">DA - 20170506IS - 1471-2431 (Electronic)IS - 1471-2431 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Saudi Arabia -CO - Kuwait -CO - United Arab Emirates -CO - South Africa -CO - Lebanon -CO - Morocco -CO - Egypt -CO - Iran -CO - Germany -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12887-017-0871-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28476129">PM:28476129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pediatr\2017-17-118.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pediatr\2017-17-118.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170506, Vandenplas Y</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12887-017-0871-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tarro,L.</style></author><author><style face="normal" font="Arial"> Aceves-Martins,M.</style></author><author><style face="normal" font="Arial"> Tinena,Y.</style></author><author><style face="normal" font="Arial"> Parisi,J.L.</style></author><author><style face="normal" font="Arial"> Blasi,X.</style></author><author><style face="normal" font="Arial"> Giralt,M.</style></author><author><style face="normal" font="Arial"> Llaurado,E.</style></author><author><style face="normal" font="Arial"> Sola,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Restaurant-based intervention to facilitate healthy eating choices and the identification of allergenic foods at a family-oriented resort and a campground</style></title><secondary-title><style face="normal" font="Arial">BMC Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Public Health</style></full-title></periodical><pages end="" start="393">393-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulation 1169/2011</style></keyword><keyword><style face="normal" font="Arial"> restaurant</style></keyword><keyword><style face="normal" font="Arial"> Restaurants</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1471-2458</style></isbn><abstract><style face="normal" font="Arial">Restaurant-based interventions can be an enjoyable way to encourage healthier eating choices by all members of a family. Thus, the principal aims of this study were a) to promote healthy diets by increasing healthy food offerings and b) to increase the number of foods offered specifically as gluten-free and lactose-free and to inform patrons by including nutritional and allergen information that complies with Regulation 1169/2011 regarding the food served in restaurants, takeaways and snack bars</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12889-017-4333-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s12889-017-4333-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Public Health\2017-17-393.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Public Health\2017-17-393.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Tarro L</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12889-017-4333-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reece,E.</style></author><author><style face="normal" font="Arial"> Segurado,R.</style></author><author><style face="normal" font="Arial"> Jackson,A.</style></author><author><style face="normal" font="Arial"> McClean,S.</style></author><author><style face="normal" font="Arial"> Renwick,J.</style></author><author><style face="normal" font="Arial"> Greally,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, Trinity Centre for Health Science, Tallaght Hospital, Dublin 24, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis</style></title><secondary-title><style face="normal" font="Arial">BMC Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Pulm Med</style></full-title></periodical><pages end="" start="70">70-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobials</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cause of Death</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisations</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pulmonary infection is the main cause of death in cystic fibrosis (CF). Aspergillus fumigatus (AF) and Pseudomonas aeruginosa (PA) are the most prevalent fungal and bacterial pathogens isolated from the CF airway, respectively. Our aim was to determine the effect of different colonisation profiles of AF and PA on the clinical status of patients with CF. METHODS: A retrospective analysis of data from the Cystic Fibrosis Registry of Ireland from 2013 was performed to determine the effect of intermittent and persistent colonisation with AF or PA or co-colonisation with both microorganisms on clinical outcome measures in patients with CF. Key outcomes measured included forced expiratory volume in one second (FEV1), number of hospitalisations, respiratory exacerbations and antimicrobials prescribed, and complications of CF, including CF related diabetes (CFRD) and allergic bronchopulmonary aspergillosis (ABPA). RESULTS: The prevalence of AF and PA colonisation were 11% (5% persistent, 6% intermittent) and 31% (19% persistent, 12% intermittent) in the Irish CF population, respectively. Co-colonisation with both pathogens was associated with a 13.8% reduction in FEV1 (p = 0.016), higher levels of exacerbations (p = 0.042), hospitalisations (p = 0.023) and antimicrobial usage (p = 0.014) compared to non-colonised patients and these clinical outcomes were comparable to those persistently colonised with PA. Intermittent and persistent AF colonisation were not associated with poorer clinical outcomes or ABPA. Patients with persistent PA had a higher prevalence of CFRD diagnosis (p = 0.012). CONCLUSIONS: CF patients co-colonised with AF and PA had poor clinical outcomes comparable to patients persistently colonised with PA, emphasising the clinical significance of co-colonisation with these microorganisms</style></abstract><notes><style face="normal" font="Arial">DA - 20170422IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12890-017-0416-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28431569">PM:28431569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pulm Med\2017-17-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pulm Med\2017-17-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170422, Reece E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12890-017-0416-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Henriquez,C.</style></author><author><style face="normal" font="Arial"> Moran,G.</style></author><author><style face="normal" font="Arial"> Carrasco,C.</style></author><author><style face="normal" font="Arial"> Sarmiento,J.</style></author><author><style face="normal" font="Arial"> Barria,M.</style></author><author><style face="normal" font="Arial"> Folch,H.</style></author><author><style face="normal" font="Arial"> Uberti,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pharmacology and Morphophysiology Department, Faculty of Veterinary Sciences, Universidad Austral de Chile, Valdivia, Chile</style></auth-address><titles><title><style face="normal" font="Arial">Modulatory role of regulatory T cells in a murine model of severe equine asthma</style></title><secondary-title><style face="normal" font="Arial">BMC Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Vet Res</style></full-title></periodical><pages end="" start="117">117-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cyclophosphamide</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Hypertrophy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It is accepted that T regulatory cells (Treg) control different types of immune responses. In connection with this role, we have recently described an important increase in CD4+, CD25high, Foxp3+ lymphocytes in the airway system of horses coursing with an exacerbation of severe equine asthma (EA). To explore the potential role of this population in the resolution of EA inflammation, we used a murine experimental model in which airway neutrophilic inflammation, which is similar to that observed in EA, is induced in mice by continual exposure to Aspergillus fumigatus contaminated hay. This model has the advantage that in mice we may induce a reduction of the Treg population using low doses of cyclophosphamide (Cy). RESULTS: The results indicated that the percentage of Treg cells increased with allergen exposure, as in horses; and animals partially depleted of Treg cells by treatment with Cy showed increased airway inflammation, demonstrated by an increased percentage of neutrophils and specific immunoglobulins in bronchoalveolar lavage fluid (BALF). Furthermore, a histopathologic study of animals that were pretreated with Cy before antigenic challenge showed higher cellular infiltration in the lung and deeper remodeling changes in the bronchi, including epithelial and goblet cell hyperplasia as well as airway smooth muscle hypertrophy. CONCLUSION: In this murine model of EA, the reduced number and function of Treg induced by low doses of Cy, which directly correlates with increased airway inflammation and lung infiltration, indicates that Treg may play a major role in the regulation and resolution of EA</style></abstract><notes><style face="normal" font="Arial">DA - 20170429IS - 1746-6148 (Electronic)IS - 1746-6148 (Linking)LA - engPT - Journal ArticleCO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12917-017-1037-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28454585">PM:28454585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Vet Res\2017-13-117.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Vet Res\2017-13-117.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170429, Henriquez C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12917-017-1037-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">William Frankland: From Fleming to Saddam Hussein</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="i4824">i4824-</pages><volume><style face="normal" font="Arial">354</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biography</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Famous Persons</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> History,20th Century</style></keyword><keyword><style face="normal" font="Arial"> History,21st Century</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Military Personnel</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Portraits</style></keyword><keyword><style face="normal" font="Arial"> Travel</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> World War II</style></keyword></keywords><dates><year Day="14" Month="9" Year="2016">2016/9/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20160916IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - BiographyPT - Historical ArticlePT - Journal ArticlePT - PortraitsSB - AIMSB - IM</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.i4824</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27630162">PM:27630162</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2016-354-i4824.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2016-354-i4824.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160916, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.i4824</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rigopoulou,E.I.</style></author><author><style face="normal" font="Arial"> Ioannou,M.</style></author><author><style face="normal" font="Arial"> Papadamou,G.</style></author><author><style face="normal" font="Arial"> Dalekos,G.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Larissa, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Ascites in a patient with episodic angio-oedema and eosinophilia: thinking outside the box</style></title><secondary-title><style face="normal" font="Arial">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Ascites</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Neoplasms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Gain</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="Arial">Episodic angio-oedema with eosinophilia (EAE) or Gleich's syndrome is a rare condition characterised by recurrent episodes of oedema and eosinophilia, accompanied by urticaria, fever and weight gain. The presence of ascites has not been reported so far. We report a 21-year-old Caucasian woman who presented with marked ocular oedema and ascites. Laboratory evaluation revealed marked eosinophilia. During the last 3 months, three episodes of facial and neck oedema were reported, which resolved spontaneously over a period of 3-5 days. The diagnosis of EAE was established after exclusion of secondary causes (infections, allergic reactions, collagen diseases, neoplasms) and clonal disorders associated with marked eosinophilia. Low-dose steroids resulted in eosinophil decrease and complete resolution of symptoms, including ascites. This case highlights that ascites can be a very rare manifestation of EAE particularly if other more frequent causes of ascites have been excluded and the clinical and laboratory findings are supportive of EAE</style></abstract><notes><style face="normal" font="Arial">DA - 20170422IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1136/bcr-2017-219467</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28432171">PM:28432171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Case Rep\20170422-RigopoulouEI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Case Rep\20170422-RigopoulouEI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170422, Rigopoulou EI</style></custom2><misc3><style face="normal" font="Arial">10.1136/bcr-2017-219467</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">English,J.</style></author><author><style face="normal" font="Arial"> Reddy,K.</style></author><author><style face="normal" font="Arial"> Gonzalez-Estrada,A.</style></author><author><style face="normal" font="Arial"> Bajaj,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">East Tennessee State University, Johnson City, Tennessee, USA</style></auth-address><titles><title><style face="normal" font="Arial">Physical urticaria</style></title><secondary-title><style face="normal" font="Arial">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> physical urticaria</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170423IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1136/bcr-2017-220286</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433981">PM:28433981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Case Rep\20170423-EnglishJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Case Rep\20170423-EnglishJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, English J</style></custom2><misc3><style face="normal" font="Arial">10.1136/bcr-2017-220286</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Paula Arruda,L.K.</style></author><author><style face="normal" font="Arial"> Sella,J.A.</style></author><author><style face="normal" font="Arial"> Nociti Mendonca,T.</style></author><author><style face="normal" font="Arial"> Lima Melo,J.M.</style></author><author><style face="normal" font="Arial"> Leme Ferriani,M.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mechanism of action of the therapy with omalizumab in chronic spontaneous urticaria: is there a role for autoimmunity?</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="8" start="1">1-8</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2318-5015.20160001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2318-5015.20160001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2016-4-1-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2016-4-1-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, de Paula Arruda LK</style></custom2><misc3><style face="normal" font="Arial">10.5935/2318-5015.20160001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oliveira Rodrigues Valle,S.</style></author><author><style face="normal" font="Arial"> Abilio Motta,A.</style></author><author><style face="normal" font="Arial"> Soïdo Falcão do Amaral,C.</style></author><author><style face="normal" font="Arial"> Chiaverini Ensina,L.F.</style></author><author><style face="normal" font="Arial"> Carvalho Mallozi,M.</style></author><author><style face="normal" font="Arial"> das Graças de Melo Teixeira Spengler,M.</style></author><author><style face="normal" font="Arial"> Fernanda Ferraro,M.</style></author><author><style face="normal" font="Arial"> Pires,M.C.</style></author><author><style face="normal" font="Arial"> Martins,M.</style></author><author><style face="normal" font="Arial"> Bastos Cordeiro,N.G.</style></author><author><style face="normal" font="Arial"> Tavares Franca,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">What is new in chronic spontaneous urticaria?</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="25" start="9">9-25</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Chronic spontaneous urticaria (CSU) is the most common form of chronic urticaria (CU) and hasmajor negative impact on the quality of life of patients and their families. The pathogenesis of CUis complex and not fully understood. However, there has been tremendous progress in the pastdecade with regard to the mechanism of activation of mast cells, which play a central role in thepathophysiology of this disease. In most cases, thorough clinical history and physical examinationare considered sufficient to establish a diagnosis of CSU, unless the history suggests the need forfurther testing. In addition, physicians should be alert to potential differential diagnoses. A varietyof tools and questionnaires are available to assist physicians in the diagnosis and monitoringof patients with CU. The main treatment objective is to control symptoms. Second generationantihistamines at standard doses are recommended as first-line treatment. However, refractorypatients may require higher doses. Still, many patients will continue to experience symptomsof urticaria. In these cases, adding other medications, such as omalizumab, cyclosporine, ormontelukast, is recommended. Among these, omalizumab is the only medication licensed forthe treatment of CSU. In this article, we review the newest and most important publications onchronic spontaneous urticaria.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2318-5015.20160002</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2318-5015.20160002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2016-4-9-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2016-4-9-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Oliveira Rodrigues Valle S</style></custom2><misc3><style face="normal" font="Arial">10.5935/2318-5015.20160002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abreu Maciel Pereira,G.A.</style></author><author><style face="normal" font="Arial"> Arsie Contin,L.</style></author><author><style face="normal" font="Arial"> Fonseca Noriega,L.</style></author><author><style face="normal" font="Arial"> Lino Vieira,M.L.</style></author><author><style face="normal" font="Arial"> Ozores Michalany,A.</style></author><author><style face="normal" font="Arial"> Bet,D.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Undercooked shiitake mushrooms and flagellate dermatitis</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="53" start="51">51-53</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Erythema Multiforme</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Mushrooms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Shiitake Mushrooms</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The term flagellate dermatitis refers to skin lesions characterized by linear erythematouspapules with a whiplash-like pattern. Shiitake is an edible mushroom that, when eaten raw orundercooked, may induce a pruritic rash associated with systemic symptoms. We report a casewith typical clinical manifestations in which the pathological examination suggested erythemamultiforme. Clinical history and physical examination were essential to differentiate betweenthe two entities.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2318-5015.20160005</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2318-5015.20160005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2016-4-51-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2016-4-51-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Abreu Maciel Pereira GA</style></custom2><misc3><style face="normal" font="Arial">10.5935/2318-5015.20160005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Apiwattanakul,N.</style></author><author><style face="normal" font="Arial"> Palipane,M.</style></author><author><style face="normal" font="Arial"> Samarasinghe,A.E.i</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immune responses to fungal aeroallergen in Heligmosomoides polygyrus infected mice vary by age</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="36" start="26">26-36</pages><volume><style face="normal" font="Arial">317</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal asthma</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Gut parasite</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasite infection</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0008-8749</style></isbn><abstract><style face="normal" font="Arial">Parasite infections in the developing world have been considered to promote resistance to immune-mediated diseases such as asthma. Mouse studies have shown that helminths and their products reduce the development of allergic asthma. Since epidemiologic studies that show similar protection are in relation to geohelminth infections that occur in early life, we hypothesized that the parasite-mediated protection against asthma may differ by age. Mice infected with Heligmosomoides polygyrus at 3-weeks of age had similar asthma phenotype compared to mice infected at 28-weeks of age wherein airways eosinophilia was unaltered but tissue inflammation and GC metaplasia were reduced. In contrast, mice infected at 18-weeks of age had elevated macrophagic airways inflammation with accompanying tissue pathology. The presence of airways +¦+¦ T cells and Treg cells were also regulated by age at worm infection. Our findings demonstrate the importance of age in immune responses that may regulate gut and lung diseases</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -CO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2017.04.009</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.cellimm.2017.04.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20170510-ApiwattanakulN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20170510-ApiwattanakulN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Apiwattanakul N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2017.04.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Davies,B.</style></author><author><style face="normal" font="Arial"> Gilchrist,F.J.</style></author><author><style face="normal" font="Arial"> Saunders,A.</style></author><author><style face="normal" font="Arial"> Carroll,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Hospitals of the North Midlands, Newcastle Road, Stoke-on-Trent, UKKeele University, Keele, UK</style></auth-address><titles><title><style face="normal" font="Arial">Annual hospitalisation rates for children with asthma are inversely associated with total hours of sunshine in English regions</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="840" start="838">838-840</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">During childhood, exacerbation of asthma is the most common medical reason for admission to hospital in the UK. Each year 44,000 children are admitted to hospital in the UK with 40-50 children dying as a result of asthma [1]. Weather patterns and seasonality have distinct, measurable effects on the rates of hospitalisation for asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12946</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28452084">PM:28452084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170428-DaviesB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170428-DaviesB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Davies B</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12946</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Seppo,A.E.</style></author><author><style face="normal" font="Arial"> Savilahti,E.M.</style></author><author><style face="normal" font="Arial"> Berin,M.C.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Jarvinen,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology &amp; Center for Food Allergy, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Breast milk IgA to foods has different epitope-specificity than serum IgA - Evidence for entero-mammary link for food-specific IgA?</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antibody repertoire</style></keyword><keyword><style face="normal" font="Arial"> antibody secreting cell</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide microarray</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We have previously shown that maternal cow's milk (CM) elimination results in down-regulation of CM-specific IgA antibody levels in BM, but not in serum, suggesting that an entero-mammary link may exist for food-specific antibody-secreting cells. OBJECTIVE: We sought to investigate whether food-specific IgA epitope profiles differ intra-individually between mother's serum and BM. We also examined how infants' food epitope-specific IgA develops in early infancy and the relationship of IgA epitope recognition with development of cow's milk allergy (CMA). METHODS: We measured specific IgA to a series of overlapping peptides in major CM allergens (alphas1 -, alphas2 -, beta- and kappa-caseins and beta-lactoglobulin) in paired maternal and infant serum as well as BM samples in 31 mother-infant dyads within the first 15 postpartum months utilizing peptide microarray. RESULTS: There was significant discordance in epitope specificity between BM and maternal sera ranging from only 13% of sample pairs sharing at least one epitope in alphas1 -casein to 73% in kappa-casein. Epitope-specific IgA was detectable in infants' sera starting at less than 3 months of age. Sera of mothers with a CMA infant had increased binding of epitope-specific IgA to CM proteins compared to those with a non-CMA infant. CONCLUSION &amp; CLINICAL RELEVANCE: These findings support the concept that mother's milk has a distinct anti-food antibody repertoire when compared to the antibody repertoire of the peripheral blood. Increased binding of serum epitope-specific IgA to CM in mothers of infants with CMA may reflect inherited systemic immunogenicity of CM proteins in these families, although specific IgA in breast milk was not proportionally upregulated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170427IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12945</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449395">PM:28449395</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170427-SeppoAE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170427-SeppoAE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170427, Seppo AE</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12945</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saranz,R.J.</style></author><author><style face="normal" font="Arial"> Lozano,A.</style></author><author><style face="normal" font="Arial"> Lozano,N.A.</style></author><author><style face="normal" font="Arial"> Ponzio,M.F.</style></author><author><style face="normal" font="Arial"> Cruz,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology Division, Clinica Universitaria Reina Fabiola, Facultad de Medicina Universidad Catolica de Cordoba, Cordoba, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Subclinical lower airways correlates of chronic allergic and non-allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="997" start="988">988-997</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> bronchial inflammation</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">The upper and lower airways behave as a physiological and pathophysiological unit. Subclinical lower airways abnormalities have been described in patients with rhinitis without asthma. These are expressed as bronchial hyperreactivity, abnormalities in lung function and bronchial inflammation, likely as a result of the same phenomenon with systemic inflammatory impact that reaches both the nose and the lungs, which for unknown reasons does not always have a full clinical expression. Patients with rhinitis are at increased risk of developing asthma; therefore most authors suggest a careful clinical evaluation and monitoring of these patients, especially if symptoms related to inflammation in the lower airways are observed. Although current treatments, such as H1-antihistamines, intranasal steroids and allergen immunotherapy are quite effective for the management of rhinitis, it is difficult to prove their capacity to prevent asthma among subjects with rhinitis. Evidence showing that the treatment of rhinitis has a favorable impact on indicators of bronchial hyperreactivity and inflammation among subjects that have no symptoms of asthma, is more frequently described. In this review we address the frequency and characteristics of lower airway abnormalities in subjects with rhinitis, both in pediatric and adult populations, their likely predictive value for the development of asthma and the possibilities for therapeutic intervention that could modify the risk of subjects with rhinitis towards presenting asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Argentina -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12938</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28421631">PM:28421631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170418-SaranzRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170418-SaranzRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Saranz RJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12938</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berings,M.</style></author><author><style face="normal" font="Arial"> Jult,A.</style></author><author><style face="normal" font="Arial"> Vermeulen,H.</style></author><author><style face="normal" font="Arial"> De Ruyck,N.</style></author><author><style face="normal" font="Arial"> Derycke,L.</style></author><author><style face="normal" font="Arial"> Ucar,H.</style></author><author><style face="normal" font="Arial"> Ghekiere,P.</style></author><author><style face="normal" font="Arial"> Temmerman,R.</style></author><author><style face="normal" font="Arial"> Ellis,J.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Dullaers,M.</style></author><author><style face="normal" font="Arial"> Gevaert,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Upper Airways Research Laboratory, Ghent University, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Probiotics-impregnated bedding covers for house dust mite allergic rhinitis: a pilot randomised clinical trial</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1096" start="1092">1092-1096</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="Arial">Allergic Rhinitis (AR) affects up to one third of the adult population and causes illness and disability worldwide.[1] Main symptoms include sneezing, rhinorrhea and nasal obstruction. AR is often accompanied with conjunctivitis, characterised by watery, itchy and sometimes red or swollen eyes. House Dust Mite (HDM) allergens are one of the most relevant indoor allergy triggers.[2] Treatment of AR consists of symptomatic medications (mainly antihistamines and nasal corticosteroids) and allergen specific immunotherapy (in more severe cases).[1] This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12937</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28418228">PM:28418228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170418-BeringsM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170418-BeringsM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Berings M</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12937</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UKNIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UKThe David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK</style></auth-address><titles><title><style face="normal" font="Arial">Inheritance and the sunshine vitamin</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="603" start="602">602-603</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170427IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12932</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449333">PM:28449333</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-602-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-602-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170427, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12932</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rutkowski,K.</style></author><author><style face="normal" font="Arial"> Grattan,C.E.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Urticaria Clinic, St John's Institute of DermatologyDepartment of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, UKUrticaria Clinic, St John's Institute of Dermatology</style></auth-address><titles><title><style face="normal" font="Arial">How to manage chronic urticaria 'beyond' guidelines: a practical algorithm</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="718" start="710">710-718</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">Chronic urticaria (CU) is a disease characterised by pruritic weals, angio-oedema or both occurring for at least 6 weeks. It encompasses spontaneous and inducible urticarias. The national and international guidelines outline the principles of treatment. Omalizumab, an anti-immunoglobulin E monoclonal antibody has transformed the management of many severe and treatment-refractory patients. However, current UK guidance on its use does not address the needs of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema without weals as a presentation of CU and omalizumab non-responders. Our algorithm and a summary of the evidence to support its principles offers guidance and a more systematic targeted approach to using a range of 'off-label' agents for specific phenotypes of CU. It will be of use when guideline-recommended mast cell mediator antagonists fail to control symptoms and/or using omalizumab is ineffective, not practical or unfunded. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12944</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28452145">PM:28452145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170428-RutkowskiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170428-RutkowskiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Rutkowski K</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12944</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saleem,R.</style></author><author><style face="normal" font="Arial"> Keymer,C.</style></author><author><style face="normal" font="Arial"> Patel,D.</style></author><author><style face="normal" font="Arial"> Egner,W.</style></author><author><style face="normal" font="Arial"> Rowbottom,A.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Pathology Directorate, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK</style></auth-address><titles><title><style face="normal" font="Arial">UK NEQAS survey of allergen component testing across the United Kingdom and other European countries</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Immunol</style></full-title></periodical><pages end="393" start="387">387-393</pages><volume><style face="normal" font="Arial">188</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Component testing</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunochemistry</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut components</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality assurance</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Teaching</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">The clinical utility of molecular diagnostic approaches in allergy investigation is being recognized increasingly to play a significant role in the management of allergic patients. Determining the sensitization pattern, which is best achieved through the use of component resolved diagnostics (CRD), allows effective risk stratification, appropriate treatment and patient selection for immunotherapy. In order to assess the diagnostic service provisions for in-vitro allergy testing across Europe, a survey was carried out via the total immunoglobulin (Ig)E and specific IgE external quality assurance schemes run by UK National External Quality Assessment Service (NEQAS) Immunology, Immunochemistry and Allergy. This survey assessed allergy testing, and in particular allergen components offered by the laboratories, and found a wide variability in service provision, particularly between the United Kingdom and other European Union (EU) countries. Furthermore, there was lack of standardization for acquisition of clinical information to aid allergen (and component) selection, gating strategy, testing algorithms and clinical interpretation. Interestingly, a significant proportion of laboratories (the majority from EU) stated that they 'used' the results for peanut components for risk stratification. However, the vast majority of participants were unaware of guidelines relating to the use of allergen component testing, and agreed that further education would assist in reaching a common platform. Hence, this survey has highlighted that although CRD has been adopted into routine diagnostics across Europe, it is potentially compromised by lack of standardized protocols and guidance sources. Consequently, there is a need for local or national standards and education through External Quality Assurance services on the performance and application of CRD into allergy investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1365-2249 (Electronic)IS - 0009-9104 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cei.12950</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28423454">PM:28423454</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Immunol\2017-188-387-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Immunol\2017-188-387-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Saleem R</style></custom2><misc3><style face="normal" font="Arial">10.1111/cei.12950</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,H.S.</style></author><author><style face="normal" font="Arial"> Won,S.</style></author><author><style face="normal" font="Arial"> Lee,E.K.</style></author><author><style face="normal" font="Arial"> Chun,Y.H.</style></author><author><style face="normal" font="Arial"> Yoon,J.S.</style></author><author><style face="normal" font="Arial"> Kim,J.T.</style></author><author><style face="normal" font="Arial"> Kim,H.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effect of Proparacaine in a Mouse Model of Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lidocaine</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">Objectives: Lidocaine, a local anaesthetic is a treatment option in uncontrolled asthma due to its immunomodulatory effects. In the present study, proparacaine (PPC), a derivative of lidocaine was examined for its therapeutic application in a mouse model of allergic rhinitis. Methods: The mice were grouped into 4 groups: control group, allergic rhinitis (AR) group, ciclesonide (CIC) group, and PPC group. Nasal symptom scores, eosinophil counts, goblet cell counts, and mast cells counts in the nasal mucosa were measured. Serum ovalbumin (OVA)-specific immunoglobulin (Ig) E, OVA-specific IgG1, OVA-specific IgG2a, interleukin (IL)-4, IL-5, and cortisol levels were measured. Results: Intranasal administration of PPC significantly decreased nasal symptoms, number of eosinophils, goblet cells, and mast cells in the lamina propria of the nasal mucosa. Serum OVA-specific IgE, OVA-specific IgG1, OVA-specific IgG2a was significantly higher in the AR compared with the control group. Serum level of IL-4 was significantly lower in the CIC group and PPC group in comparison with AR group. Serum IL-5 showed no significant difference among all groups. No significant difference in serum cortisol levels was observed among the 4 groups. Conclusion: PPC appears to have a therapeutic potential in treatment of allergic rhinitis in a mouse model by reducing eosinophil, goblet cell, and mast cell infiltration in the nasal mucosa</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1976-8710 (Print)IS - 1976-8710 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.21053/ceo.2017.00101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449552">PM:28449552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Otorhinolaryngol\20170428-KimHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Otorhinolaryngol\20170428-KimHS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Kim HS</style></custom2><misc3><style face="normal" font="Arial">10.21053/ceo.2017.00101</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carlson,J.C.</style></author><author><style face="normal" font="Arial"> Rabito,F.A.</style></author><author><style face="normal" font="Arial"> Werthmann,D.</style></author><author><style face="normal" font="Arial"> Fox,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Tulane University School of Medicine, New Orleans, LA, USA</style></auth-address><titles><title><style face="normal" font="Arial">The Distribution and Movement of American Cockroaches in Urban Niches of New Orleans</style></title><secondary-title><style face="normal" font="Arial">Clin Pediatr (Phila)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Pediatr (Phila)</style></abbr-1></periodical><pages end="1012" start="1008">1008-1012</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Household allergens</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> Nymph</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">American cockroaches are an important source of household allergens in tropical and semitropical climates. To determine which outdoor niches produce American cockroaches, traps were placed at 40 homes in New Orleans to collect nymphs. Nymphs were collected from the sewers, yards, and within the homes themselves. To compare sewers and yards as sources of cockroaches entering homes, adult cockroaches were collected, marked, and released into yards and sewers. No sewer-released cockroaches were collected in homes. Cockroaches released into yards were collected in the homes, suggesting that yards, rather than sewers, are a more important source niche. A field trial applying boric acid granules to the yard was performed in an effort to reduce entry of cockroaches. There was a significant reduction in the cockroach antigen collected in intervention homes compared with controls</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1938-2707 (Electronic)IS - 0009-9228 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/0009922817701169</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28429621">PM:28429621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Pediatr (Phila)\20170421-CarlsonJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Pediatr (Phila)\20170421-CarlsonJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Carlson JC</style></custom2><misc3><style face="normal" font="Arial">10.1177/0009922817701169</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rizer,J.</style></author><author><style face="normal" font="Arial"> Brill,K.</style></author><author><style face="normal" font="Arial"> Charlton,N.</style></author><author><style face="normal" font="Arial"> King,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Emergency Medicine, Division of Medical Toxicology , University of Virginia , Charlottesville , VA , USA</style></auth-address><titles><title><style face="normal" font="Arial">Acute hypersensitivity reaction to Crotalidae polyvalent immune Fab (CroFab) as initial presentation of galactose-alpha-1,3-galactose (alpha-gal) allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Toxicol (Phila)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Toxicol (Phila)</style></full-title></periodical><pages end="669" start="668">668-669</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Diphenhydramine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> Famotidine</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> papaya</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="Arial">Crotalidae polyvalent immune Fab antivenom (CroFab), commonly used for the treatment of clinically significant North American crotalinae envenomation, is generally well-tolerated. A novel form of anaphylaxis due to an IgE antibody response to the mammalian oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) has been established following red-meat consumption as well as IV administration of cetuximab, which contain the alpha-gal epitope. We present a case of alpha-gal allergy discovered after acute hypersensitivity reaction to FabAV. A 61-year-old healthy female was bitten on her left ankle by Agkistrodon contortrix. Given the patient's rapid progression of pain and swelling, she was given FabAV. During infusion of FabAV, she developed diffuse hives over her entire body and itching, but denied respiratory or gastrointestinal symptoms and her vital signs remained stable. The FabAV was immediately discontinued and she received intravenous diphenhydramine and famotidine with gradual resolution of symptoms. On further discussion, she denied a history of alpha-gal or papaya allergy but rarely ate red meat and endorsed sustaining frequent tick bites. Subsequent antibody testing was significant for an alpha-1,3-galactose IgE concentration of 45,000 U/L (normal &lt;3500 U/L), confirming alpha-gal allergy. To our knowledge, this is the first report of FabAV hypersensitivity associated with an underlying alpha-gal allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1556-9519 (Electronic)IS - 1556-3650 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/15563650.2017.1313981</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28443380">PM:28443380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Toxicol (Phila)\20170426-RizerJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Toxicol (Phila)\20170426-RizerJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170426, Rizer J</style></custom2><misc3><style face="normal" font="Arial">10.1080/15563650.2017.1313981</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamad,A.</style></author><author><style face="normal" font="Arial"> Burks,W.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, 27517, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Emerging Approaches to Food Desensitization in Children</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="32">32-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The purpose of this review is to highlight the recent advances in food desensitization in children with food allergy. RECENT FINDINGS: Recent advancements in epicutaneous, sublingual, and oral immunotherapy for food allergy in the future may offer children with food allergy and their families a viable option to reduce risk or severity of anaphylaxis with phase III trials ongoing for two of these treatment modalities. Food allergy prevalence in children is estimated to be up to 8%. These children are at risk of significant allergic reactions and anaphylaxis. Food avoidance and use of antihistamines or epinephrine has been the standard of care for these patients. This approach also has a significant socioeconomic effects on patients and their families. Recent advancements in understanding food allergy have allowed for exploring new methods of treatment. There is an increasing interest in oral immunotherapy, epicutaneous immunotherapy, or sublingual immunotherapy for food allergy. There have been also innovative approaches to immunotherapy by modification of food allergens (to make them less allergenic while maintain their immunogenicity) or adding adjunctive treatments (probiotics, anti-IgE, etc.) to increase efficacy or safety</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0700-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28429307">PM:28429307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Hamad A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0700-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pomes,A.</style></author><author><style face="normal" font="Arial"> Mueller,G.A.</style></author><author><style face="normal" font="Arial"> Randall,T.A.</style></author><author><style face="normal" font="Arial"> Chapman,M.D.</style></author><author><style face="normal" font="Arial"> Arruda,L.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Indoor Biotechnologies, Inc., 700 Harris Street, Charlottesville, VA, 22903, USA.Department of Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Av. Bandeirantes 3900, Ribeirao Preto, SP, 14049-900, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">New Insights into Cockroach Allergens</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="25">25-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergen standardization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroach allergens</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental intervention</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: This review addresses the most recent developments on cockroach allergen research in relation to allergic diseases, especially asthma. RECENT FINDINGS: The number of allergens relevant to cockroach allergy has recently expanded considerably up to 12 groups. New X-ray crystal structures of allergens from groups 1, 2, and 5 revealed interesting features with implications for allergen standardization, sensitization, diagnosis, and therapy. Cockroach allergy is strongly associated with asthma particularly among children and young adults living in inner-city environments, posing challenges for disease control. Environmental interventions targeted at reducing cockroach allergen exposure have provided conflicting results. Immunotherapy may be a way to modify the natural history of cockroach allergy and decrease symptoms and asthma severity among sensitized and exposed individuals. The new information on cockroach allergens is important for the assessment of allergen markers of exposure and disease, and for the design of immunotherapy trials</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0694-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28421512">PM:28421512</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Pomes A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0694-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenhawt,M.J.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Allergy/Immunology Section, Children's Hospital Colorado, University of Colorado Denver School of Medicine, 13123 East 16th Avenue, Box 518, Aurora, CO, 80045, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Primary Prevention of Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="26">26-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy guidelines</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Food allergy is estimated to affect approximately 8% of children in the USA. This is a disease without any known treatment or cure and, for some, a disease that can be quite severe, even life-threatening. While recent advances in potential treatment have made remarkable strides, with two food-targeted immunotherapy products now in phase III trials, perhaps the biggest gains in the field have come in the advent of potential preventative strategies to avoid the development of food allergy in high-risk individuals. There have been multiple, randomized, controlled trials (RCTs) performed in the past 5 years that have demonstrated significant risk reduction from early allergen introduction. These include two trials for early peanut introduction and five trials for early egg introduction in the first year of life. The results indicate that primary prevention of food allergy through early allergen introduction may represent a strategy that could potentially avert tens of thousands of children from becoming food allergic. In support of the data for peanut, the National Institute of Allergy and Infectious Diseases recently sponsored an addendum to the 2010 food allergy guidelines, specifically recommending peanut be introduced in both high- and standard-risk infants to reduce the risk of developing peanut allergy. To date, no formal recommendations have been made for egg, however. This review will focus on the latest evidence supporting early introduction as a strategy to prevent food allergy, as well as on practical aspects for its successful implementation</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0692-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28421513">PM:28421513</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Greenhawt MJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0692-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Green,L.</style></author><author><style face="normal" font="Arial"> Dolen,W.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Department of Pediatrics, Allergy-Immunology and Pediatric Rheumatology Division, Medical College of Georgia at Augusta University, 1120 15th Street, Augusta, GA, 30912, USA</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Candidiasis in Children</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candida albicans</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic mucocutaneous candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic testing</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Healthy children may develop candidal infections as the result of exposure to antibiotics or corticosteroids, but chronic candidiasis in children after the newborn period is unusual. Chronic mucocutaneous candidiasis (CMC) refers to a group of conditions characterized by recurrent or persistent infections with Candida species, particularly Candida albicans. CMC is a phenotype observed in a spectrum of immunologic disorders, some with endocrinologic and autoimmune features. RECENT FINDINGS: CMC can arise secondary to inherited or acquired T cell deficiencies, but in children is largely due to inborn errors impairing the dectin pathway and IL-17 immunity. We review the current understanding of the pathogenesis of chronic mucocutaneous candidiasis and discuss the immunologic pathways by which the immune system handles Candida. We highlight the historical and recent knowledge of CMC in children, emphasizing recent insights into basic science aspects of the dectin pathway, IL-17 signaling, consequences of AIRE gene defects, and clinical aspects of inheritance, and features that distinguish the different syndromes. The clinical phenotype of CMC has many underlying genetic causes. Genetic testing is required for definitive diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0699-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28429308">PM:28429308</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Green L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0699-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gray,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergology, Red Cross War Memorial Children's Hospital, Klipfontein Road, Cape Town, 7700, South Africa.</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy in South Africa</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Developing Countries</style></keyword><keyword><style face="normal" font="Arial"> developing country</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> false positives</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Urban Population</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> War</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF THE REVIEW: Whilst food allergy seems to have increased significantly in many developed countries in the past few decades, quality data on the burden of food allergy in many developing countries is scanty. Until recently, South Africa had a dearth of robustly designed food allergy studies. This article summarizes some of the recent research and observations regarding food allergy from the South African setting. RECENT FINDINGS: South Africa has recently seen two important food allergy prevalence studies in selected and unselected populations. Both show allergy rates in keeping with those in several westernized countries. The major difference between sensitization and allergy rates in these studies emphasizes the vital role of the food challenge in differentiating true food allergy from asymptomatic sensitisation in equivocal cases. Eczema, young age and living in an urban population are important risk factors for food allergy in South Africa. Egg and peanut allergy are the most common food allergies in both selected and unselected populations in South Africa. In peanut allergy, Ara h 2 is the most useful component in differentiating true allergy from tolerance in peanut-sensitized patients. Use of internationally derived 95% positive predictive values for peanut and egg allergy produced many false positives in South African studies. Studies in South Africa show a trend towards more conservative introduction of peanut in eczema patients, which needs to be addressed in the light of recent studies showing a protective effect of earlier introduction of peanut. "Novel" allergies such as galactose-alpha-1,3-galactose allergy, food protein-induced enterocolitis syndrome and eosinophilic oesophagitis are being described with increasing frequency in South Africa. The surprisingly high prevalence of food allergy in South Africa points towards possible involvement of South Africa in the so-called "food allergy epidemic". This has major implications on the planning of health services in the allergy sector. Food challenges will form a vital role in allergy services. Ninety-five percent positive predictive values for peanut and egg allergy may need revision to be more applicable to the local population</style></abstract><notes><style face="normal" font="Arial">DA - 20170504IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0703-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28470372">PM:28470372</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170504, Gray CL</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0703-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moneo,I.</style></author><author><style face="normal" font="Arial"> Carballeda-Sangiao,N.</style></author><author><style face="normal" font="Arial"> Gonzalez-Munoz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">, Calle Travesia de Navaluenga 38, Majadahonda, Madrid, 28221, Spain</style></auth-address><titles><title><style face="normal" font="Arial">New Perspectives on the Diagnosis of Allergy to Anisakis spp</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="27">27-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross-reactions</style></keyword><keyword><style face="normal" font="Arial"> crossreactions</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> false positives</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> purified allergens</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: To compare the prevalence of sensitization in different countries based on specific IgE values and to evaluate the use of isolated native or recombinant allergens for diagnosis. RECENT FINDINGS: Isolated allergens help in the diagnosis of truly sensitized patients avoiding false positives due to cross-reactions. Their use is therefore highly recommended, especially when used as a combination of several relevant allergens. The use of purified allergens allows an accurate diagnosis and this has led to three important findings: (1) in addition to the digestive route of sensitization, occupational and non-digestive exposure seems to be clinically relevant. (2) The parasite appears as an important agent for chronic urticaria. And (3) in endemic countries, the amount of highly sensitized subjects in the general population could be as high as 7%. Adequate information to asymptomatic patients on fish consumption habits would avoid new contacts with parasite allergens and decrease their specific IgE levels and consequently the appearance of acute or chronic episodes induced by the parasite</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0698-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28429304">PM:28429304</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Moneo I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0698-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Posa,D.</style></author><author><style face="normal" font="Arial"> Hofmaier,S.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Pneumology &amp; Immunology, Charite - Universitatsmedizin Berlin, Augustenburger Platz, 1, 13353, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Natural Evolution of IgE Responses to Mite Allergens and Relationship to Progression of Allergic Disease: a Review</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="28">28-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Der p 23</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> PAF</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Allergenic molecules of the house dust mite (HDM) are crucially important indoor allergens, contributing to allergic rhinitis and asthma around the globe. In the past years, recombinant molecules for diagnostics opened new pathways to investigate individual sensitization profiles and new chances for the prevention and treatment of HDM allergy. This review summarizes the latest findings on the evolution of IgE responses towards mite allergens. RECENT FINDINGS: Several cross-sectional and longitudinal studies confirmed the role of Der p 1 and Der p 2 as major allergenic proteins of the HDM. A newly identified player is the major allergen Der p 23. Apart from identifying the early sensitization towards this molecule as a risk factor for asthma in school age, a recent longitudinal study described sensitization patterns showing that the production of IgE usually starts towards a group of initiator proteins and may stay monomolecular or expand to an oligo- or even polymolecular stage. This phenomenon also correlates to clinical symptoms. A relation between a broad sensitization pattern and symptom severity has also been shown cross-sectionally. Individual sensitization profiles towards HDM allergens provide important information to evaluate a patient's current stage and risk for clinical symptoms. This knowledge paves the way for an early and adequate prevention and/or treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s11882-017-0697-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28429303">PM:28429303</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Posa D</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s11882-017-0697-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ren,J.</style></author><author><style face="normal" font="Arial"> Ni,H.</style></author><author><style face="normal" font="Arial"> Kim,M.</style></author><author><style face="normal" font="Arial"> Cooley,K.L.</style></author><author><style face="normal" font="Arial"> Valenzuela,R.M.</style></author><author><style face="normal" font="Arial"> Asche,C.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Center for Outcomes Research, University of Illinois College of Medicine at Peoria , Peoria , Illinois , USA</style></auth-address><titles><title><style face="normal" font="Arial">Allergies, antibiotics use, and multiple sclerosis</style></title><secondary-title><style face="normal" font="Arial">Curr Med Res Opin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Res Opin</style></full-title></periodical><pages end="1456" start="1451">1451-1456</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> penicillin</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The associations between allergies, antibiotics use, and multiple sclerosis (MS) remain controversial and their mediating or moderating effects have not yet been examined. We aimed to assess the direct and indirect influences of allergies and antibiotics use on MS development, and their interactions. METHODS: A 1:3 matched case-control study was performed using the National Ambulatory Medical Care Survey database from 2006 to 2013 in the USA. Multiple sclerosis was identified based on the ICD-9 code (340.0) in any position. Cases were matched to their controls based on survey year, age, gender, race, payer type, region, and tobacco use. Allergy diseases and antibiotics prescriptions were extracted by ICD-9 code and drug classification code, respectively. Both generalized structural equation model and MacArthur approach were used to examine their intrinsic relationships. RESULTS: The weighted prevalence of MS was 133.7 per 100,000 visits. A total of 829 MS patients and 2,441 controls were matched. Both respiratory tract allergies (OR = 0.29, 95%CI: 0.18, 0.49) and other allergies (OR = 0.38, 95%CI: 0.19, 0.77) were associated with a reduction of the risk of MS. Patients with respiratory tract allergies were more likely to use penicillin (OR = 8.73, 95%CI: 4.12, 18.53) and other antibiotics (OR = 3.77, 95%CI: 2.72, 5.21), and those with other allergies had a higher likelihood of penicillin use (OR = 4.15, 95%CI: 1.27, 13.54); however, the link between antibiotics use and MS was not confirmed although penicillin use might mediate the relationship between allergies and MS. CONCLUSIONS: The findings supported allergy as a protective factor for MS development. We also suggest antibiotics use might be not a suitable indicator of bacterial infection to investigate the cause of MS</style></abstract><notes><style face="normal" font="Arial">DA - 20170429IS - 1473-4877 (Electronic)IS - 0300-7995 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/03007995.2017.1325575</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28454489">PM:28454489</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Med Res Opin\20170429-RenJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Med Res Opin\20170429-RenJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170429, Ren J</style></custom2><misc3><style face="normal" font="Arial">10.1080/03007995.2017.1325575</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Mazzocchi,A.</style></author><author><style face="normal" font="Arial"> Maslin,K.</style></author><author><style face="normal" font="Arial"> Agostoni,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDivision of Allergy and Immunology, Cincinnati Center for Eosinophilic Disorders, Cincinnati Children's Hospital Medical Center Cincinnati, Cincinnati, Ohio, USA bPediatric Intermediate Care Unit, Fondazione IRCCS Ospedale Ca' Granda-Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy cMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Impact of elimination diets on nutrition and growth in children with multiple food allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="226" start="220">220-226</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietitian</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic disorders</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> Food Preferences</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Growth and nutritional intake of children with cows' milk allergy and other food allergens has been thoroughly investigated in recent years across many different countries and age groups. An impaired growth in atopic children should not be attributed only to a high number of allergens and foods to be avoided, but to a general condition of 'sub-inflammation', which unfavorably affects the absorption and utilization of fuel and substrates. Atopic study participants may represent a good target for personalized nutrition and in this review we sought to outline many of the issues that should be taken into account when dietitians advise patients regarding food avoidance and expected effects on growth. RECENT FINDINGS: The dietary management of food allergy requires appropriate dietary choices to maintain adequate growth, starting with special formulas in infancy. An emerging area of research is the fussy eating related to the exclusion of cow's milk and other foods during infancy and the long-term effects on eating habits and food preferences. SUMMARY: Study participants with either mono or polyallergic diseases should ideally undergo the definition of their allergic and metabolic characteristics, to precisely adjust dietary interventions on an individual basis to support the genetic potential of growth and prevent unfavorable outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20170321IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Italy -CO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000358</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28323676">PM:28323676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-220-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-220-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170321, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000358</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dahdah,L.</style></author><author><style face="normal" font="Arial"> Leone,G.</style></author><author><style face="normal" font="Arial"> Artesani,M.</style></author><author><style face="normal" font="Arial"> Riccardi,C.</style></author><author><style face="normal" font="Arial"> Mazzina,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aUniversity Department of Pediatrics, Division of Allergy bDepartment of Pediatric Hematology and Oncology, Unit of Immuno-Hematology and Transfusion Medicine, Pediatric Hospital Bambino Gesu, Rome, Vatican City, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Apheresis in food allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="231" start="227">227-231</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> Immunoapheresis</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The prevalence of IgE-mediated food allergy and anaphylaxis has risen rapidly in developed countries, and countries with rapid industrialization may follow. Therapies include elimination diets, Oral ImmunoTherapy, and the administration of biologics, but high serum IgE levels may preclude their use. Consequently, decreasing IgE becomes a rational approach and could be obtained by immunoapheresis. The aim of this review is to evaluate the rationale and advantages of immunoapheresis. RECENT FINDINGS: The majority of the available adsorbers remove aspecifically all classes of immunoglobulins. Recently, IgE-specific adsorbers have been approved. Data on immunoapheresis for the treatment of allergic diseases with pathologically elevated IgE levels are emerging. In atopic dermatitis, this therapy alone seems to be beneficial. IgE-selective apheresis appears to be sufficient to reduce the risk of anaphylaxis in multiple food allergy (MFA) and, when IgE titers are high, to open the way to treatment with Omalizumab. SUMMARY: Prospective studies, with well designed protocols, are needed to assess the efficacy, tolerability, and cost-effectiveness of immunoapheresis in the field of food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170328IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28350555">PM:28350555</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-227-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-227-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170328, Dahdah L</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000366</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Pecora,V.</style></author><author><style face="normal" font="Arial"> Valluzzi,R.L.</style></author><author><style face="normal" font="Arial"> Fierro,V.</style></author><author><style face="normal" font="Arial"> Mennini,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ospedale Pediatrico Bambino Gesu, Dipartimento Pediatrico Universitario Ospedaliero (DPUO), UOC Allergologia, Rome, Vatican City, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Use of biologics in severe food allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="238" start="232">232-238</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Therapy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Severe cases of food allergy account for the majority of the burden in terms of risks, quality of life, and resource expenditure. The traditional approach to these forms has been strict avoidance. More recently, Oral ImmunoTherapy (OIT) has gained a role in their management. However, in severe food allergies OIT is often infeasible. RECENT FINDINGS: Case reports, observational, and prospective studies have recently proposed different approaches to severe food allergy. The majority of them include the use of biologics. Omalizumab has been the most studied drug for severe food allergies, and its role as adjuvant treatment to OIT is well established. Interest has been raised on other biologics, as dupilumab, reslizumab, and mepolizumab. Toll-like receptor agonists, and gene therapy using adeno-associated virus coding for Omalizumab are promising alternatives. SUMMARY: The recent studies are deeply influencing the clinical practice. We review the modifications of the clinical approach to severe food allergies so far available. We indicate the possible evolutions of treatment with biologics in severe food allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000357</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28375933">PM:28375933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-232-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-232-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Fiocchi A</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000357</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nagakura,K.I.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Yanagida,N.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aSagamihara National Hospital, Sagamihara, Kanagawa bDepartment of Pediatrics, Jikei University School of Medicine, Tokyo cDepartment of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Novel immunotherapy and treatment modality for severe food allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="219" start="212">212-219</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: In recent years, many studies on oral immunotherapy (OIT) have been conducted; however, few have focused on severe food allergies. The purpose of this review was to assess the efficacy and safety of oral immunotherapies for patients with severe food allergy. RECENT FINDINGS: We reviewed multiple immunotherapy reports published within a few years or reports focusing on severe food allergies. We also investigated recent studies on OIT and novel food allergy management. SUMMARY: Immunotherapies targeting low-dose antigen exposure and oral food challenges using low-dose target volumes may be safer than conventional OIT. It is necessary to consider which immunotherapy regimen is appropriate based on allergy severity of the patient</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000365</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362675">PM:28362675</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-212-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-212-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170331, Nagakura KI</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000365</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Pali-Scholl,I.</style></author><author><style face="normal" font="Arial"> Roth-Walter,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aInstitute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology bThe Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Outstanding animal studies in allergy II. From atopic barrier and microbiome to allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="187" start="180">180-187</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microflora</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamin D3</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Animal studies published within the past 18 months were assessed, focusing on innate and specific immunomodulation, providing knowledge of high translational relevance for human atopic and allergic diseases. RECENT FINDINGS: Allergic companion animals represent alternative models, but most studies were done in mice. Atopic dermatitis mouse models were refined by the utilization of cytokines like IL-23 and relevant skin allergens or enzymes. A novel IL-6 reporter mouse allows biomonitoring of inflammation. Both skin pH and the (transferable) microflora have a pivotal role in modulating the skin barrier. The microflora of the gastrointestinal mucosa maintains tolerance to dietary compounds and can be disturbed by antiacid drugs. A key mouse study evidenced that dust from Amish households, but not from Hutterites protected mice against asthma. In studies on subcutaneous and sublingual allergen-specific immunotherapy, much focus was given on delivery and adjuvants, using poly-lacto-co-glycolic particles, CpGs, probiotics or Vitamin D3. The epicutaneous and intralymphatic routes showed promising results in mice and horses in terms of prophylactic and therapeutic allergy treatment. SUMMARY: In atopic dermatitis, food allergies and asthma, environmental factors, together with the resident microflora and barrier status, decide on sensitization versus tolerance. Also allergen-specific immunotherapy operates with immunomodulatory principles</style></abstract><notes><style face="normal" font="Arial">DA - 20170404IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000364</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28375932">PM:28375932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-180-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-180-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170404, Jensen-Jarolim E</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000364</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Pali-Scholl,I.</style></author><author><style face="normal" font="Arial"> Roth-Walter,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aInstitute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna bThe Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna, University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Outstanding animal studies in allergy I. From asthma to food allergy and anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="179" start="169">169-179</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> domestic animals</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptor</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Animal models published within the past 18 months on asthma, food allergy and anaphylaxis, all conditions of rising public health concern, were reviewed. RECENT FINDINGS: While domestic animals spontaneously develop asthma, food allergy and anaphylaxis, in animal models, divergent sensitization and challenge routes, dosages, intervals and antigens are used to induce asthmatic, food allergic or anaphylactic phenotypes. This must be considered in the interpretation of results. Instead of model antigens, gradually relevant allergens such as house dust mite in asthma, and food allergens like peanut, apple and peach in food allergy research were used. Novel engineered mouse models such as a mouse with a T-cell receptor for house dust mite allergen Der p 1, or with transgenic human hFcgammaR genes, facilitated the investigation of single molecules of interest. Whole-body plethysmography has become a state-of-the-art in-vivo readout in asthma research. In food allergy and anaphylaxis research, novel techniques were developed allowing real-time monitoring of in-vivo effects following allergen challenge. Networks to share tissues were established as an effort to reduce animal experiments in allergy which cannot be replaced by in-vitro measures. SUMMARY: Natural and artificial animal models were used to explore the pathophysiology of asthma, food allergy and anaphylaxis and to improve prophylactic and therapeutic measures. Especially the novel mouse models mimicking molecular aspects of the complex immune network in asthma, food allergy and anaphylaxis will facilitate proof-of-concept studies under controlled conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170327IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000363</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28346234">PM:28346234</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-169-79.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-169-79.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170327, Jensen-Jarolim E</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000363</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fierro,V.</style></author><author><style face="normal" font="Arial"> Di Girolamo,F.</style></author><author><style face="normal" font="Arial"> Marzano,V.</style></author><author><style face="normal" font="Arial"> Dahdah,L.</style></author><author><style face="normal" font="Arial"> Mennini,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDepartment of Allergy bHuman Microbiome Unit, Bambino Gesu Children Hospital, Vatican City, Holy See, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Food labeling issues in patients with severe food allergies: solving a hamlet-like doubt</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="211" start="204">204-211</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food label</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> threshold level</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: We review the laws on labeling in the international community, the difficulties they pose to the food manufacturers to prepare the food labels and the methodologies to determine the concentration of potential allergens in foods. RECENT FINDINGS: European Food Safety Authority and International Life Sciences Institute Europe are evaluating strategies to identify the threshold level of allergen that can trigger a reaction in individuals. The most used techniques to detect the presence of protein in food are Enzyme-linked immunosorbent assay, polymerase chain reaction and real time polymerase chain reaction. Researchers are now trying to apply proteomics to estimate the amount of protein within the food.In order to protect the health of consumers, the Codex Alimentarius Commission updates constantly the list of allergens. In response to these regulations, some industries have also added some precautionary allergen labeling (PAL). It was generally agreed that PAL statements needed to be visible, simple, and safe. It was suggested that PAL be standardized, an action that would occur if the 'Voluntary Incidental Trace Allergen Labelling' process was made mandatory. SUMMARY: So far, no laboratory technique is able to reassure the consumers about the composition of foods found on the packaging. International authorities produced increasingly stringent laws, but more is still to do</style></abstract><notes><style face="normal" font="Arial">DA - 20170413IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000362</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28403019">PM:28403019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-204-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-204-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170413, Fierro V</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000362</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDivision of Allergy, Pediatric Hospital Bambino Gesu, Piazza Sant'Onofrio, Rome, Vatican City, Italy bDepartment of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Severe food allergies: can they be considered rare diseases?</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Allergy Clin Immunol</style></abbr-1></periodical><pages end="203" start="201">201-203</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170405IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1097/ACI.0000000000000368</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28379865">PM:28379865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-201-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2017-17-201-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170405, Fiocchi A</style></custom2><misc3><style face="normal" font="Arial">10.1097/ACI.0000000000000368</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lieu,T.J.</style></author><author><style face="normal" font="Arial"> Bird,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Oral Immunotherapy, Sublingual Immunotherapy, or Epicutaneous Immunotherapy: Which Is the Right Solution?</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="13" start="1">1-13</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">The current standard of care treatment for food allergy relies on avoidance. However, as outlined in this review, over the past decade, the literature has grown significantly showing promising results for interventional therapies for IgE-mediated food allergies utilizing oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). Within the near future, we expect to have multiple FDA-approved products on the market for treatment of life-threatening food allergies and will have options to present to our patients. As we move into this next phase of our practice, we will need to consider meaningful endpoints for our patients (e.g., likelihood of inducing desensitization versus sustained unresponsiveness, the relevance of various threshold changes induced by therapy, effects on quality of life, etc.). This review provides a comprehensive overview of the currently published literature and will prepare the practicing allergist for a thoughtful discussion with their patients and colleagues on the most recent developments in the field</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0116-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0116-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-1-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-1-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Lieu TJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0116-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Campo,P.</style></author><author><style face="normal" font="Arial"> Barrionuevo,E.</style></author><author><style face="normal" font="Arial"> Eguiluz,I.</style></author><author><style face="normal" font="Arial"> Salas,M.</style></author><author><style face="normal" font="Arial"> Torres,M.J.</style></author><author><style face="normal" font="Arial"> Rondon,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Nasal Provocation Tests With Allergens: Just a Research Tool or Suitable for Everyday Clinical Practice?</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="109" start="98">98-109</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> controlled clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Controlled Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Nasal provocation test (NPT) with allergens is a simple and safe technique recommended in different diagnostic and research settings. In the daily practice, NPT has proved to be very useful when there are discrepancies between patient</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs symptoms and the results of skin or blood testing, for confirming the clinical relevance of a certain allergen in polysensitized patients and also for the diagnosis of new rhinitis phenotypes such as local allergic rhinitis (LAR). In the research field, nasal provocation test with allergens has been widely used in the study of mechanisms of inflammation and allergic response in subjects with allergic rhinitis (AR) and LAR and the study of pathophysiological mechanisms of response allergens to evaluate the therapeutic effect of drugs or immunotherapy in controlled clinical trials. There are key aspects necessary to achieve the best safety and reproducibility of the test, such as the characteristics of the allergen, application techniques, and measurement of the response that must be as objective as possible. The use of short protocols and simple methods of measurement allows the use of NPT in the daily practice as a diagnostic aid and not only a research tool reserved for clinical trials</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0118-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0118-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-98-109.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-98-109.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Campo P</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0118-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Gennaro,M.S.</style></author><author><style face="normal" font="Arial"> Serrano,F.S.</style></author><author><style face="normal" font="Arial"> Maspero,J.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pharmacologic Management of Allergic Rhinitis During Pregnancy</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="61" start="54">54-61</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth defects</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Allergic rhinitis is a common condition that affects women during pregnancy and causes them great discomfort at this stage of life. Although there are many medications available to be indicated with the aim of reducing the symptoms so annoying, the doctor must very conscientiously evaluate the drug that causes the control of symptoms and obviously must do this minimizing the potential risks of birth defects. As the population is vulnerable, it is practically impossible to test the use of drugs during pregnancy in the context of clinical research for the consequent occurrence of birth defects. Apart from environmental control that clearly does not carry risks at all, there are many medications available to treat this allergic condition so common that also worsens in patients with rhinitis who become pregnant. It is the duty of the physician who treats these patients carefully to elicit the medication that has more benefits than risks and thus help the pregnant patient to overcome this disease that greatly affects their quality of life</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0111-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0111-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-54-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-54-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, De Gennaro MS</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0111-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bush,R.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Dust Mite Tablet Immunotherapy: How Does It Compare and Where Does It Fit?</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="21" start="14">14-21</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">House dust mite (HDM) sensitization plays a major role in allergic rhinitis and asthma worldwide. Sublingual immunotherapy (SLIT) in its various formulations has been increasingly utilized for the treatment of these conditions in the past several years. HDM-SLIT tablets have been recently introduced with three formulations currently under investigation. SLIT tablets offer the advantage of a more standardized dose than liquid SLIT products. Several studies suggest that HDM-SLIT tablets may be safe and effective in the treatment of allergic rhinitis and asthma in adults, though further investigations will be necessary to fully establish their use in adults and especially in children. The use of HDM-SLIT tablets appears to be very promising and can usher in a new era to potentially stop the </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£allergic march</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ from HDM sensitization in early life to the development of asthma</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0114-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0114-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-14-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-14-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Bush RK</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0114-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soliman,M.</style></author><author><style face="normal" font="Arial"> Ellis,A.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Role of Synthetic Peptide Immuno-Regulatory Epitope (SPIRE) in the Treatment of Allergic Disease</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="29" start="22">22-29</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Synthetic peptide immunoregulatory epitope</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> Th cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Immunotherapy has been used for over a century for the treatment of allergic rhinitis, starting with the administration of whole allergens which are still in use today. Up-titration of allergen concentrations is thought to induce immune-tolerance, reducing symptoms upon exposure of the same allergen in the natural environment. More recently, peptide immunotherapy research aims to reduce sensitization to the allergen while utilizing a much shorter treatment schedule and avoiding the risk of anaphylactic reactions associated with whole allergen administration. Other immunotherapies undergoing clinical trials utilize linear joined peptides of the natural antigen, which are thought to avoid triggering anaphylaxis by selectively joining non-IgE binding allergen proteins. These novel therapies have been investigated using a variety of methods, including at controlled allergen challenge facilities (CACF) and in phase 3 trials in the </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£real world</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ setting. Experimental phase 2 trial designs were also used, the nasal allergen challenge (NAC) protocols, involving the direct exposure of the nasal mucosa to the allergen. The mechanism of action of peptide immunotherapies is thought to vary from that of conventional immunotherapies, though more research is needed to understand how desensitization occurs in each case. A shift from CD4+ to CD8+ Th cells is thought to be one way to explain this and is backed by change in cytokine expression in various experimental models</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0115-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0115-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-22-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-22-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Soliman M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0115-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moingeon,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Update on Biomarkers to Predict Responders to Allergen Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="42" start="30">30-42</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> anergy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Most investigations aiming to identify biomarkers (BMKs) have focused on immunological changes reflecting our understanding of allergen-specific immunotherapy (AIT) mechanisms of action. The upregulation of allergen-specific regulatory CD4+ T cells, the downregulation or anergy of Th2 cells, the induction of specific </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£blocking</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ IgG4s, and the decrease of basophil activation are all thought to contribute to AIT efficacy. To this date, however, none of these immunological alterations can be used to predict AIT efficacy. Changes in the blood at the level of dendritic cells (DCs) reflecting the induction of regulatory DCs concomitantly with a downregulation of pro-allergic DC2s are the only parameters which have been correlated at an individual patient level with AIT efficacy. In this context, the search for BMKs should be extended beyond currently existing boundaries</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0113-9</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0113-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-30-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-30-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Moingeon P</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0113-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deeks,E.D.</style></author><author><style face="normal" font="Arial"> Brusselle,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.</style></auth-address><titles><title><style face="normal" font="Arial">Reslizumab in Eosinophilic Asthma: A Review</style></title><secondary-title><style face="normal" font="Arial">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs</style></full-title></periodical><pages end="784" start="777">777-784</pages><volume><style face="normal" font="Arial">77</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Reslizumab (Cinqaero(R); Cinqair(R)) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation. Reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the BREATH phase III clinical trial programme. In three double-blind BREATH studies of up to 52 weeks' duration, adding intravenous reslizumab (3 mg/kg, once every 4 weeks) to the current asthma therapy of patients (aged 12-75 years) with eosinophilic asthma inadequately controlled with inhaled corticosteroids resulted in significant reductions in clinical asthma exacerbation frequency and significant improvements in lung function, asthma control and health-related quality of life relative to adding placebo. Pooled data from the two trials of 52 weeks' duration indicated similar benefits with reslizumab across various patient subgroups, including patients with severe eosinophilic asthma. Reslizumab was generally well tolerated, with very few recipients experiencing severe or serious treatment-related adverse events. Moreover, in an open-label extension study, continued use of reslizumab for up to 2 years was associated with durable lung function benefit, without any new tolerability concerns. Thus, intravenous reslizumab extends the valuable add-on treatment options for adults with severe eosinophilic asthma inadequately controlled with standard therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1179-1950 (Electronic)IS - 0012-6667 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40265-017-0740-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28421429">PM:28421429</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs\2017-77-777-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs\2017-77-777-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Deeks ED</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40265-017-0740-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Combalia,A.</style></author><author><style face="normal" font="Arial"> Ferrando,J.</style></author><author><style face="normal" font="Arial"> Mascaro,J.M.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology department, Hospital Clinic de Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Widespread eruption in a patient with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Emerg Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Emerg Med J</style></full-title></periodical><pages end="" start="314">314-</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1472-0213 (Electronic)IS - 1472-0205 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1136/emermed-2016-206194</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428433">PM:28428433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Emerg Med J\2017-34-314.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Emerg Med J\2017-34-314.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Combalia A</style></custom2><misc3><style face="normal" font="Arial">10.1136/emermed-2016-206194</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miller,R.L.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Jezioro,J.</style></author><author><style face="normal" font="Arial"> De Planell Saguer,M.</style></author><author><style face="normal" font="Arial"> Lovinsky-Desir,S.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Perzanowski,M.</style></author><author><style face="normal" font="Arial"> Divjan,A.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author><author><style face="normal" font="Arial"> Matsui,E.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Columbia University Medical Center, PH8E-101B, 630 W. 168th St., New York City, NY 10032, USA</style></auth-address><titles><title><style face="normal" font="Arial">Reduced mouse allergen is associated with epigenetic changes in regulatory genes, but not mouse sensitization, in asthmatic children</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="624" start="619">619-624</pages><volume><style face="normal" font="Arial">156</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental intervention</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic regulation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> inner-city asthma</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intervention trial</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> mouse sensitization</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> New York City</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Public health importance</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">Chronic exposure to mouse allergen may contribute greatly to the inner-city asthma burden. We hypothesized that reducing mouse allergen exposure may modulate the immunopathology underlying symptomatic pediatric allergic asthma, and that this occurs through epigenetic regulation. To test this hypothesis, we studied a cohort of mouse sensitized, persistent asthmatic inner-city children undergoing mouse allergen-targeted integrated pest management (IPM) vs education in a randomized controlled intervention trial. We found that decreasing mouse allergen exposure, but not cockroach, was associated with reduced FOXP3 buccal DNA promoter methylation, but this was unrelated to mouse specific IgE production. This finding suggests that the environmental epigenetic regulation of an immunomodulatory gene may occur following changing allergen exposures in some highly exposed cohorts. Given the clinical and public health importance of inner-city pediatric asthma and the potential impact of environmental interventions, further studies will be needed to corroborate changes in epigenetic regulation following changing exposures over time, and determine their impact on asthma morbidity in susceptible children</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2017.04.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28454014">PM:28454014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-156-619-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-156-619-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Miller RL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2017.04.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tetzlaff,C.</style></author><author><style face="normal" font="Arial"> Made,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development of a real-time PCR system for the detection of the potential allergen fish in food</style></title><secondary-title><style face="normal" font="Arial">Eur Food Res Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Food Res Technol</style></full-title></periodical><pages end="857" start="849">849-857</pages><volume><style face="normal" font="Arial">243</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish species</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Oligonucleotides</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1438-2385</style></isbn><abstract><style face="normal" font="Arial">Fish is one of the most important triggers of food-allergic reactions. Regulation (EU) No 1169/2011 governs the labelling of allergenic ingredients including fish. A real-time PCR assay, using TaqMan-« probes, was applied to detect fish in food. For generating primer and probes, the Hoxc13 gene was selected. Based on the alignment of available DNA sequences from this gene from different fish species in public nucleic acid database, specific oligonucleotides were generated. To cover all relevant species of the phylogenetic class fish, the CTfish-system consists of two forward primers, three reverse primers and one TaqMan-« probe. The real-time PCR method is able to detect specifically fish species belonging to the subclass Teleostei. The sensitivity is in an animal food product 100-ámg/kg and in a vegetable food matrix 10-ámg/kg relating to the fresh weight. The calculated limit of detection (LOD95-á%) of fish DNA in background DNA is 2.5 copies. The method developed is robust against small, deliberate changes in the reaction conditions. The CTfish-system can be used to sensitively and selectively identify the presence of fish DNA in food</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00217-016-2799-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00217-016-2799-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Food Res Technol\2017-243-849-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Food Res Technol\2017-243-849-57.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Tetzlaff C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00217-016-2799-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rudert,A.</style></author><author><style face="normal" font="Arial"> Portnoy,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Allergy, Asthma &amp; Immunology Fellow , Children's Mercy Hospitals &amp; Clinics</style></auth-address><titles><title><style face="normal" font="Arial">Mold allergy: Is it real and what do we do about it?</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="835" start="823">823-835</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergy</style></keyword><keyword><style face="normal" font="Arial"> fungal exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Mold allergy</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxin</style></keyword><keyword><style face="normal" font="Arial"> Mycotoxins</style></keyword><keyword><style face="normal" font="Arial"> PAMP</style></keyword><keyword><style face="normal" font="Arial"> pathogen-associated molecular pattern</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Stachybotrys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Fungi produce substances that contain pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) which bind to pattern recognition receptors, stimulating innate immune responses in humans. They also produce allergens that induce production of specific IgE. Areas Covered: In this review we cover both innate and adaptive immune responses to fungi. Some fungal products can activate both innate and adaptive responses and in doing so, cause an intense and complex health effects. Methods of testing for fungal allergy and evidence for clinical treatment including environmental control are also discussed. In addition, we describe controversial issues including the role of Stachybotrys and mycotoxins in adverse health effects. Expert Commentary: Concerns about long-term exposure to fungi have led some patients, attorneys and fungus advocates to promote fears about a condition that has been termed toxic mold syndrome. This syndrome is associated with vague symptoms and is believed to be due to exposure to mycotoxins, though this connection has not been proven. Ultimately, more precise methods are needed to measure both fungal exposure and the resulting health effects. Once that such methods become available, much of the speculation will be replaced by knowledge</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1324298</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28453304">PM:28453304</url></web-urls><pdf-urls><url ppv-ref="no">jportnoy@cmh.edu</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170428, Rudert A</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1324298</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nelson,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Medicine, Division of Allergy/Immunology , National Jewish Health , Denver , CO , USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy coming of age: notable advances during the first hundred years</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="392" start="389">389-392</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1292136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28443797">PM:28443797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-389-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-389-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170426, Nelson HS</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1292136</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ozdogan,H.</style></author><author><style face="normal" font="Arial"> Ugurlu,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Division of Rheumatology, Department of Internal Medicine , Cerrahpasa Medical Faculty, Istanbul University , Fatih , Istanbul , Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Canakinumab for the treatment of familial Mediterranean fever</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="404" start="393">393-404</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Amyloidosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> autoinflammatory syndrome</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Colchicine</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> familial</style></keyword><keyword><style face="normal" font="Arial"> Familial Mediterranean Fever</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-1</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Familial Mediterranean fever (FMF) is the most frequent of all hereditary autoinflammatory syndromes. It is characterized by recurrent attacks of fever and serositis. If not treated it may be complicated with AA amyloidosis. It is caused by mutations in the MEFV gene that encodes pyrin which is involved in the regulation of IL-1beta. The mainstay of treatment is colchicine, however a subset of patients requires an alternative treatment either due to inadequate response or intolerance. The accumulating data indicates that anti IL-1 drugs are effective in treating colchicine resistant FMF cases and improving their quality of life. Areas covered: This review focuses on canakinumab, a fully human anti IL-1beta antibody, treatment in FMF. The data obtained from case reports, case series, two Phase II studies and an ongoing double-blind, randomized, placebo controlled Phase III trial are analyzed. Efficacy and safety profiles of canakinumab are discussed. Expert commentary: Canakinumab became the first approved therapy by the Food and Drug Administration for FMF very recently, which highlights its importance as the alternative treatment in FMF</style></abstract><notes><style face="normal" font="Arial">DA - 20170331IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1313116</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362189">PM:28362189</url></web-urls><pdf-urls><url ppv-ref="no">huriozdogan@yahoo.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170331, Ozdogan H</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1313116</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Besu,I.</style></author><author><style face="normal" font="Arial"> Srdic-Rajic,T.</style></author><author><style face="normal" font="Arial"> Matic,I.</style></author><author><style face="normal" font="Arial"> Jankovic,L.</style></author><author><style face="normal" font="Arial"> Besu,V.</style></author><author><style face="normal" font="Arial"> Konic-Ristic,A.</style></author><author><style face="normal" font="Arial"> Juranic,Z.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The absence of immunoreactivity to donkey's milk in patients with recurrent aphthous ulcers and immunoreactivity to cow's milk</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="462" start="452">452-462</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="07/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> aphthous</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Donkey's milk</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Goat's milk</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Ulcer</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">Despite the numerous benefits of milk constituents for human health a considerable number of the general population follow a milk-restricted diet due to clinically confirmed or self-assessed adverse reactions to cow's milk consumption. Recurrent aphthous ulcers (RAU) are currently one of the most common oral disorders, with a worldwide distribution and insufficiently defined etiology, which, among other factors, implies the immunological reaction to food proteins. The aim of this study was to determine the immune-reactivity to donkey's milk proteins in patients with RAU and compare it to the reactivity towards the proteins from cow's and goat's milks, in a set of simultaneous experiments. Levels of serum IgA, IgG and IgE antibodies to the same quantity of the examined antigens were determined by enzyme-linked immunosorbent assay. The results indicate that patients with RAU with increased immunity to cow's milk proteins could consider the use of donkey's milk as the best protein source</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Serbia -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1293017</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1293017</url></web-urls><pdf-urls><url ppv-ref="no">irina.besu@ncrc.ac.rs</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="Arial">20170511, Besu I</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1293017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,T.</style></author><author><style face="normal" font="Arial"> Han,S.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> He,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Purification and Quantification of Kunitz Trypsin Inhibitor in Soybean Using Two-Dimensional Liquid Chromatography</style></title><secondary-title><style face="normal" font="Arial">Food Anal Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Anal Methods</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> Kunitz trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1936-976X</style></isbn><abstract><style face="normal" font="Arial">Kunitz trypsin inhibitor (KTI) is one of the major antinutritional factors in soybean and results in inhibition of digestion of dietary protein. In this study, we developed a novel strategy to purify and quantify KTI from soybean using two-dimensional liquid chromatography. Lipids from ground soybean were removed using hexane after which the ground soybean was extracted with protein extraction buffer. The crude extract was first purified by weak anion exchange chromatography, and then the fraction containing KTI was further separated by size exclusion chromatography. The fraction containing KTI was collected and analyzed by SDS-PAGE and electrospray ionization mass spectrometry. Results indicated that purified KTI has a molecular mass of 20-ákDa and a purity of ~98% with inhibitory activity of 2425-áTIU/mg protein. This assay was used for the quantification of KTI in soybean samples. The assay showed concentrations with a range between 7.81 and 500.00-á++g/mL and a limit of detection of 0.12-ámg/g. The recoveries of KTI in spiked soybean samples were between 82.19% and 86.65%, and intra- and interday precisions (% CV) were less than 7.35% and 8.42%. The developed method was used to analyze soybean samples from different sources and soybean products derived from different processing techniques, which demonstrated that the developed procedure provided an accurate and sensitive tool for separation and quantification of intact KTI in soybean</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12161-017-0902-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s12161-017-0902-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Anal Methods\20170509-ZhouT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Anal Methods\20170509-ZhouT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Zhou T</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12161-017-0902-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lu,F.</style></author><author><style face="normal" font="Arial"> Huang,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, ChinaKey Laboratory of Tropical Disease Control Sun Yat-sen University, Ministry of Education, Guangzhou, ChinaSchool of Stomatology, Jinan University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">The Roles of Mast Cells in Parasitic Protozoan Infections</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="363">363-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Experimental animal model</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Leishmania</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasite infection</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infections</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> plasmodium</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protozoa</style></keyword><keyword><style face="normal" font="Arial"> Protozoan Infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Toxoplasma</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Protozoan parasites such as Plasmodium spp., Leishmania spp., Trypanosoma spp., and Toxoplasma gondii are major causes of parasitic diseases in both humans and animals. The immune system plays a critical role against protozoa, but their immune mechanism remains poorly understood. This highlights the need to investigate the function of immune cells involved in the process of parasite infections and the responses of host immune system to parasite infections. Mast cells (MCs) are known to be central players in allergy and anaphylaxis, and it has been demonstrated that MCs have crucial roles in host defense against a number of different pathogens, including parasites. To date, there are many studies that have examined the interaction of helminth-derived antigens and MCs. As one of the major effector cells, MCs also play an important role in the immune response against some parasitic protozoa, but their role in protozoan infections is, however, less well characterized. Herein, we review the current knowledge about the roles of MCs and their mediators during infections involving highly pathogenic protozoa including Plasmodium spp., Leishmania spp., Trypanosoma spp., and T. gondii. We offer a general review of the data from patients and experimental animal models infected with the aforementioned protozoa, which correlate MCs and MC-derived mediators with exacerbated inflammation and disease progression as well as protection against the parasitic infections in different circumstances. This review updates our current understanding of the roles of MCs during parasitic protozoan infections, and the participation of MCs in parasitic protozoan infections could be of a potential therapeutic target</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00363</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428784">PM:28428784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-363.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-363.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Lu F</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00363</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sgnotto,F.D.R.</style></author><author><style face="normal" font="Arial"> Oliveira,M.G.</style></author><author><style face="normal" font="Arial"> Lira,A.A.L.</style></author><author><style face="normal" font="Arial"> Bento-de-Souza,L.</style></author><author><style face="normal" font="Arial"> Duarte,A.J.D.S.</style></author><author><style face="normal" font="Arial"> Victor,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Laboratory of Medical Investigation LIM-56, Division of Clinical Dermatology, Medical School, University of Sao Paulo , Sao Paulo , Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Low doses of IgG from atopic individuals can modulate in vitro IFN-gamma production by human intra-thymic TCD4 and TCD8 cells: an IVIg comparative approach</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Intravenous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> IVIg</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">The regulatory effect of allergic responses induced by IgG antibodies on human intra-thymic cells has not been reported in the literature. The aim of this study was to evaluate the possible differential effect of purified IgG from atopic and non-atopic individuals on human intra-thymic alphabetaT cell cytokine production. Thymic tissues were obtained from 14 patients who were less than seven days old. Additionally, blood samples were collected from atopic and non-atopic volunteers. Thymocytes and peripheral blood mononuclear cells were cultured with purified atopic or non-atopic IgG, and intracellular cytokine production was assessed. Purified IgG did not influence the frequency or viability of human intra-thymic alphabetaT cells. Purified non-atopic IgG induced greater IFN-gamma production by intra-thymic CD4+CD8+ T cells than did the mock treatment and atopic IgG. A similar effect of purified non-atopic IgG on TCD8 cells was observed compared with the mock treatment. Atopic IgG inhibited IFN-gamma and TGF-beta production by intra-thymic TCD4 cells. Treatment with intravenous immunoglobulin resulted in intermediate levels of IFN-gamma and TGF-beta in intra-thymic TCD4 cells compared to treatment with atopic and non-atopic IgG. Peripheral TCD4 cells from non-atopic individuals produced IFN-gamma only in response to atopic IgG. This report describes novel evidence revealing that IgG from atopic individuals may influence intracellular IFN-gamma production by intra-thymic alphabetaT cells in a manner that may favour allergy development</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1299299</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441069">PM:28441069</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170425-SgnottoFD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170425-SgnottoFD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Sgnotto FD</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1299299</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tabatabaian,F.</style></author><author><style face="normal" font="Arial"> Ledford,D.K.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal medicine, Morsani College of Medicine, University of South Florida, 13330 USF Laurel Dr. 5th Floor, MDC 80, Tampa, FL 33612-4799, USA</style></auth-address><titles><title><style face="normal" font="Arial">Biologic and New Therapies in Asthma</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="343" start="329">329-343</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Several biologics are currently FDA approved for asthma that target Th2 high patients. Unfortunately, 50% of patients with severe asthma do not fit this phenotype of disease and have fewer effective therapeutic options. In the clinical setting, total IgE, FeNO and peripheral blood eosinophils are important tools in defining Th2 high patients with asthma. However, precise biomarkers to predict better response to one specific Th2 high asthma therapy versus another is lacking. It is important to recognize that none of the current medications targeting the Th2 pathway induces persistent immunomodulation or remission</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366480">PM:28366480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-329-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-329-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Tabatabaian F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Corren,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Section of Clinical Immunology and Allergy, David Geffen School of Medicine at UCLA, 10780 Santa Monica Boulevard, Suite 280, Los Angeles, CA 90025, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Inflammatory Disorders Associated with Allergy: Overview of Immunopathogenesis and Implications for Treatment</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="246" start="233">233-246</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">A number of chronic inflammatory diseases are associated with IgE-mediated immunologic hypersensitivity, including atopic dermatitis, chronic rhinosinusitis, and asthma. Pathogenetic studies of well-characterized patient groups has allowed investigators to more precisely define the molecular pathways involved in these diseases. Specific cytokines and chemokines, as well as other unique proteins, have now been identified in each of these common disorders and a number of medications are currently in development for inhibiting their actions. Continual refinement of our understanding of the pathogenesis of these diseases will undoubtedly yield increasingly precise, and potentially more effective, treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366474">PM:28366474</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-233-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-233-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Corren J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Polk,B.I.</style></author><author><style face="normal" font="Arial"> Rosenwasser,L.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Asthma and Immunology, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Biological Therapies of Immunologic Diseases: Strategies for Immunologic Interventions</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="259" start="247">247-259</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">The immune system possesses a vast number of potential targets for therapeutic intervention. Although therapies for many pathways have been pursued, only few have yielded significant success. Hindrances in altering biologic pathways include the potential for unwanted downstream effects, ineffectiveness owing to biological redundancy, recognition of a therapeutic molecule as foreign by the body's innate immune system, and the risks of subsequent malignancy and/or autoimmunity. This article covers currently available biotherapeutic agent classes as well as potential direction for future therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366475">PM:28366475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-247-59.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-247-59.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Polk BI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Draikiwicz,S.</style></author><author><style face="normal" font="Arial"> Oppenheimer,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, New Jersey Medical School, Newark, NJ, USA</style></auth-address><titles><title><style face="normal" font="Arial">Patient Characteristics and Individualization of Biologic Therapy</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="281" start="261">261-281</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> C1 inhibitor</style></keyword><keyword><style face="normal" font="Arial"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="Arial"> C1-inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New Jersey</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Progress in the understanding of disease processes has provided additional therapeutic targets, best exemplified by the increasing role of biologics in the clinical armamentarium. This article provides a focused review of current treatment paradigms and pathophysiology for asthma, atopic dermatitis, urticaria, as well as C1 inhibitor deficiency. It elucidates the populations in which biologics were studied for the aforementioned disease states, emphasizing characteristics to consider when selecting therapy. It is important to correctly estimate patient outcome before starting therapy based on cost analysis. Treatment decisions need to be guided by appropriate patient stratification based on each individual's underlying phenotype</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366476">PM:28366476</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-261-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-261-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Draikiwicz S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chipps,B.E.</style></author><author><style face="normal" font="Arial"> Peters,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">American College of Allergy, Asthma &amp; Immunology, Capital Allergy &amp; Respiratory Disease Center, 5609 J Street, Suite C, Sacramento, CA 95819, USA. Electronic address: bchipps@capitalallergy.comSection on Pulmonary, Critical Care, Allergy &amp; Immunologic Diseases, Internal Medicine, Pediatrics and Translational Science, Center for Genomics and Personalized Medicine Research, Respiratory Service Line, Wake Forest Baptist Health, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Biologic Therapies of Immunologic Diseases</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="xviii" start="xvii">xvii-xviii</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.02.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366489">PM:28366489</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-xvii-xviii.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-xvii-xviii.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Chipps BE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.02.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Willson,T.J.</style></author><author><style face="normal" font="Arial"> Naclerio,R.M.</style></author><author><style face="normal" font="Arial"> Lee,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head &amp; Neck Surgery, University of Pittsburgh Medical Center, 1400 Locust Street, Suite 2100, Building D, Pittsburgh, PA 15219, USA</style></auth-address><titles><title><style face="normal" font="Arial">Monoclonal Antibodies for the Treatment of Nasal Polyps</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="367" start="357">357-367</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Biologics are novel therapeutic medications developed for the targeted therapy for a variety of inflammatory conditions. The biologics currently investigated for the treatment of chronic rhinosinusitis (CRS) with nasal polyps modulate specific inflammatory pathways involved in the pathogenesis of disease. Investigations have focused on the most severe form of the disease, namely, CRS with nasal polyps. It is hoped that specific targeted therapies using these biologics can significantly modulate the immune system, offering both disease control and symptomatic relief. This review summarizes those therapies that have been used to treat nasal polyps</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366482">PM:28366482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-357-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-357-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Willson TJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bukstein,D.A.</style></author><author><style face="normal" font="Arial"> Luskin,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy, Asthma &amp; Sinus Center, Madison, WI, USA; Allergy, Asthma &amp; Sinus Center, Milwaukee, WI, USA. Healthy Airways, Madison, WI, USA</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacoeconomics of Biologic Therapy</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="430" start="413">413-430</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Novel biologic agents have allowed clinicians to achieve improved patient outcomes. Appropriate pharmacoceconomic analyses demand evaluation of all relevant costs, including the treatments, the disease and comorbidities, and costs of alternative treatments, including their short- and long-term side effects. Only with complete data can the value of therapies be correctly estimated. By assessing costs, pharmacoeconomic studies complement studies of efficacy and safety, helping to determine the relationships of treatment and outcome. This article provides a broad framework for understanding and evaluating published economic analyses and identifying the key costs and benefits caring for patients with asthma and other immune diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366485">PM:28366485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-413-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-413-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Bukstein DA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumar,S.</style></author><author><style face="normal" font="Arial"> Ward,B.R.</style></author><author><style face="normal" font="Arial"> Irani,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Children's Hospital of Richmond, Virginia Commonwealth University, CHoR Pavilion, 5th Floor, 1000 East Broad Street, Richmond, VA 23298-0225, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Future Prospects of Biologic Therapies for Immunologic Diseases</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="448" start="431">431-448</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">This article presents an overview of future uses for biologic therapies in the treatment of immunologic and allergic conditions. Discussion is centered on the use of existing therapies outside of their current indication or on new therapies that are close to approval. This information may help familiarize practicing allergists and immunologists with therapies they may soon encounter in their practice as well as help identify conditions and treatments that will require further study in the near future</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366486">PM:28366486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-431-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-431-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Kumar S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Otani,I.M.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, CA, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="396" start="369">369-396</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin (Ig) E-mediated food allergy and eosinophilic esophagitis (EoE) are chronic, allergen-mediated disorders characterized by an aberrant TH2 immune response. The development and investigation of biologics for the treatment of IgE-mediated food allergy and eosinophilic esophagitis have provided further insight into the pathophysiology and management of these disorders. This article provides an overview of biologic therapies that are being investigated or have potential as treatments for IgE-mediated food allergy and eosinophilic esophagitis. Identification of EoE phenotypes that are responsive to biologics and investigation of biologics combined with other therapies may help elucidate a role for biologics in EoE</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366483">PM:28366483</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-369-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-369-96.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Otani IM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,S.V.</style></author><author><style face="normal" font="Arial"> Khan,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, F4.206, Dallas, TX 75390-8859, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Adverse Reactions to Biologic Therapy</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="412" start="397">397-412</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions. As expansion in the number of FDA-approved agents continue to be seen, more unanticipated adverse reactions are likely to occur. Currently, the diagnostic tools, including skin testing and in vitro testing, to evaluate for immediate hypersensitivity reactions are insufficient. In this review, management strategies for common acute infusion reactions, injection site reactions, and immediate reactions suggestive of IgE-mediated mechanisms are discussed. Desensitization can be considered for reactions suggestive of IgE-mediated mechanisms, but allergists/immunologists should be involved in managing these patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170403IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.01.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366484">PM:28366484</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-397-412.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-397-412.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170403, Patel SV</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.01.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valenta,R.</style></author><author><style face="normal" font="Arial"> Campana,R.</style></author><author><style face="normal" font="Arial"> Niederberger,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Recombinant allergy vaccines based on allergen-derived B cell epitopes</style></title><secondary-title><style face="normal" font="Arial">Immunol Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Lett</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen characterization</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hayfever</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergen</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy</style></keyword><keyword><style face="normal" font="Arial"> Molecular Structure</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0165-2478</style></isbn><abstract><style face="normal" font="Arial">Immunoglobulin E (IgE)-associated allergy is the most common immunologically-mediated hypersensitivity disease. It affects more than 25% of the population. In IgE-sensitized subjects, allergen encounter can causes a variety of symptoms ranging from hayfever (allergic rhinoconjunctivitis) to asthma, skin inflammation, food allergy and severe life-threatening anaphylactic shock. Allergen-specific immunotherapy (AIT) is based on vaccination with the disease-causing allergens. AIT is an extremely effective, causative and disease-modifying treatment. However, administration of natural allergens can cause severe side effects and the quality of natural allergen extracts limits its application. Research in the field of molecular allergen characterization has allowed deciphering the molecular structures of the disease-causing allergens and it has become possible to engineer novel molecular allergy vaccines which precisely target the mechanisms of the allergic immune response and even appear suitable for prophylactic allergy vaccination. Here we discuss recombinant allergy vaccines which are based on allergen-derived B cell epitopes regarding their molecular and immunological properties and review the results obtained in clinical studies with this new type of allergy vaccines</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imlet.2017.04.015</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.imlet.2017.04.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Lett\20170508-ValentaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Lett\20170508-ValentaR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Valenta R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imlet.2017.04.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bien,K.</style></author><author><style face="normal" font="Arial"> Zmigrodzka,M.</style></author><author><style face="normal" font="Arial"> Orlowski,P.</style></author><author><style face="normal" font="Arial"> Fruba,A.</style></author><author><style face="normal" font="Arial"> Szymanski,L.</style></author><author><style face="normal" font="Arial"> Stankiewicz,W.</style></author><author><style face="normal" font="Arial"> Nowak,Z.</style></author><author><style face="normal" font="Arial"> Malewski,T.</style></author><author><style face="normal" font="Arial"> Krzyzowska,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-163, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Involvement of Fas/FasL pathway in the murine model of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Inflamm Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflamm Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE AND DESIGN: The aim of this study was to elucidate the role of apoptosis mediated through Fas/FasL pathway using the mouse model of atopic dermatitis (AD). MATERIALS AND TREATMENT: AD was induced by epicutaneous application of ovalbumin (OVA) in wild-type C57BL/6, B6. MRL-Faslpr/J (Fas-) and B6Smn.C3-Faslgld/J (FasL-) mouse strains. METHODS: Skin samples were subjected to staining for Fas/FasL expression, M30 epitope and assessment of inflammatory response via immunohistochemical staining. Cytokine and chemokine production was assessed by real-time PCR. RESULTS: In comparison to wild-type mice, OVA sensitization of Fas- and FasL-deficient mice led to increased epidermal and dermal thickness, collagen deposition and local inflammation consisting of macrophages, neutrophils and CD4+ T cells. Fas- and FasL-deficient mice showed increased total counts of regulatory T cells (Tregs) and IgE levels in blood as well as increased expression of IL-1beta, IL-4, IL-5, IL-13 and TGF-1beta mRNA in comparison to wild-type mice. On the other hand, expression of CXCL9 and CXCL10, IL-17 mRNAs in the skin samples in Fas- and FasL-deficient mice was decreased. CONCLUSIONS: Our results show that lack of the Fas-induced apoptosis leads to exacerbation of AD characteristics such as Th2 inflammation and dermal thickening. Therefore, Fas receptor can play an important role in AD pathogenesis by controlling development of the local inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170423IS - 1420-908X (Electronic)IS - 1023-3830 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00011-017-1049-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28434120">PM:28434120</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflamm Res\20170423-BienK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflamm Res\20170423-BienK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, Bien K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00011-017-1049-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Charpin,D.</style></author><author><style face="normal" font="Arial"> Ramadour,M.</style></author><author><style face="normal" font="Arial"> Lavaud,F.</style></author><author><style face="normal" font="Arial"> Raherison,C.</style></author><author><style face="normal" font="Arial"> Caillaud,D.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Pauli,G.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pneumonology and Allergy, Hopital Nord and INSERM U 1067, Aix Marseille Universite, Marseille, France</style></auth-address><titles><title><style face="normal" font="Arial">Climate and Allergic Sensitization to Airborne Allergens in the General Population: Data from the French Six Cities Study</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="241" start="236">236-241</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroach allergens</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergens</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The results of international epidemiological surveys show large geographical variations in skin test reactivity but do not provide a rationale for such variations. OBJECTIVE: To assess the relationship between climate and allergic sensitization in schoolchildren. METHODS: In the present study, we analyzed data from a multicenter, epidemiological survey that included 6,461 schoolchildren, aged 9-11 years, living in 6 French cities scattered around France. The protocol also included a battery of skin prick tests to common airborne allergens. The crude prevalence of sensitization to each allergen was estimated for each city and then adjusted for potential confounding factors. This analysis was repeated for monosensitization and for allergens grouped into 2 categories: indoor allergens, i.e., house dust mite (HDM), cat, and cockroach allergens, and outdoor allergens, i.e., birch pollen, grass pollen, and Alternaria. We also grouped cities according to their location on the coast, i.e., Marseille and Bordeaux, or inland, i.e., Creteil, Clermont-Ferrand, Reims, and Strasbourg. RESULTS: A difference in prevalence of sensitization to each airborne allergen or allergens grouped into indoor and outdoor categories was found between cities, even after adjusting for potential confounding factors. Also, a higher prevalence of sensitization to HDM, cat dander, and, broadly speaking, indoor allergens, was found in children living on the coast than in those living inland, whereas they showed a lower prevalence of sensitization to birch pollen. Between-city differences in the prevalence of monosensitization were also statistically significant. Children living in coastal cities had a higher rate of monosensitization to indoor allergens and a lower prevalence of sensitization to birch pollen. The higher prevalence of allergic sensitization in children from coastal cities is most likely due to climatic conditions, such as proximity from sea and humidity. Differences in sensitization to birch allergens could be due to differential exposure to these pollen. CONCLUSION: These results indicate a role of environmental exposure in sensitization to perennial as well as seasonal allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170430IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1159/000471511</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456804">PM:28456804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-236-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-236-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170430, Charpin D</style></custom2><misc3><style face="normal" font="Arial">10.1159/000471511</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Radauer,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Navigating through the Jungle of Allergens: Features and Applications of Allergen Databases</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="11" start="1">1-11</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen database</style></keyword><keyword><style face="normal" font="Arial"> allergen nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AllFam</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetically modified crops</style></keyword><keyword><style face="normal" font="Arial"> Histocompatibility</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Structural Database of Allergenic Proteins</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="Arial">The increasing number of available data on allergenic proteins demanded the establishment of structured, freely accessible allergen databases. In this review article, features and applications of 6 of the most widely used allergen databases are discussed. The WHO/IUIS Allergen Nomenclature Database is the official resource of allergen designations. Allergome is the most comprehensive collection of data on allergens and allergen sources. AllergenOnline is aimed at providing a peer-reviewed database of allergen sequences for prediction of allergenicity of proteins, such as those planned to be inserted into genetically modified crops. The Structural Database of Allergenic Proteins (SDAP) provides a database of allergen sequences, structures, and epitopes linked to bioinformatics tools for sequence analysis and comparison. The Immune Epitope Database (IEDB) is the largest repository of T-cell, B-cell, and major histocompatibility complex protein epitopes including epitopes of allergens. AllFam classifies allergens into families of evolutionarily related proteins using definitions from the Pfam protein family database. These databases contain mostly overlapping data, but also show differences in terms of their targeted users, the criteria for including allergens, data shown for each allergen, and the availability of bioinformatics tools</style></abstract><notes><style face="normal" font="Arial">DA - 20170430IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000471806</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456806">PM:28456806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-1-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-1-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170430, Radauer C</style></custom2><misc3><style face="normal" font="Arial">10.1159/000471806</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tscheppe,A.</style></author><author><style face="normal" font="Arial"> Breiteneder,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="202" start="187">187-202</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antibody repertoire</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Chimera</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hypoallergen</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein microarray</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> recombinant hypoallergen</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">The years 1988-1995 witnessed the beginning of allergen cloning and the generation of recombinant allergens, which opened up new avenues for the diagnosis and research of human allergic diseases. Most crystal and solution structures of allergens have been obtained using recombinant allergens. Structural information on allergens allows insights into their evolutionary biology, illustrates clinically observed cross-reactivities, and makes the design of hypoallergenic derivatives for allergy vaccines possible. Recombinant allergens are widely used in molecule-based allergy diagnosis such as protein microarrays or suspension arrays. Recombinant technologies have been used to produce well-characterized, noncontaminated vaccine components with known biological activities including a variety of allergen derivatives with reduced IgE reactivity. Such recombinant hypoallergens as well as wild-type recombinant allergens have been used successfully in several immunotherapy trials for more than a decade to treat birch and grass pollen allergy. As a more recent application, the development of antibody repertoires directed against conformational epitopes during immunotherapy has been monitored by recombinant allergen chimeras. Although much progress has been made, the number and quality of recombinant allergens will undoubtedly increase and keep improving our knowledge in basic scientific investigations, diagnosis, and therapy of human allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000464104</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28467993">PM:28467993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-187-202.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-187-202.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Tscheppe A</style></custom2><misc3><style face="normal" font="Arial">10.1159/000464104</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santos da Silva,E.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Lackner,P.</style></author><author><style face="normal" font="Arial"> Hofer,H.</style></author><author><style face="normal" font="Arial"> Wallner,M.</style></author><author><style face="normal" font="Arial"> Silva,Pinheiro C.</style></author><author><style face="normal" font="Arial"> Alcantara-Neves,N.M.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Alergia e Acarologia, Instituto de Ciencias da Saude, Universidade Federal da Bahia, Salvador, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Allergens of Blomia tropicalis: An Overview of Recombinant Molecules</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="214" start="203">203-214</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Developing Countries</style></keyword><keyword><style face="normal" font="Arial"> developing country</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> New allergens</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="Arial">Allergic diseases are considered a major problem for healthcare systems in both developed and developing countries. House dust mites are well-known triggers of allergic manifestations. While the Dermatophagoides genus is widely distributed globally, Blomia tropicalis is the most prominent mite species in the tropical and subtropical regions of the world. Over the last decades, an increase in sensitization rates to B. tropicalis has been reported, leading to increased research efforts on Blomia allergens. In fact, 8 new allergens have been identified and characterized to different degrees. Here, we provide an overview of recent developments concerning the identification and production of recombinant Blomia allergens, as well as their structural and immunological characterization. Although considerable progress has been achieved, detailed molecule-based studies are still needed to better define the clinical relevance of Blomia allergens. Thus, the establishment of a well-standardized and fully characterized panel of allergens remains a challenge for the development of better diagnosis and therapy of allergic diseases induced by B. tropicalis</style></abstract><notes><style face="normal" font="Arial">DA - 20170430IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000464325</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456805">PM:28456805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-203-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-203-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170430, Santos da SIlva</style></custom2><misc3><style face="normal" font="Arial">10.1159/000464325</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Griffiths,R.L.M.</style></author><author><style face="normal" font="Arial"> El-Shanawany,T.</style></author><author><style face="normal" font="Arial"> Jolles,S.R.A.</style></author><author><style face="normal" font="Arial"> Selwood,C.</style></author><author><style face="normal" font="Arial"> Heaps,A.G.</style></author><author><style face="normal" font="Arial"> Carne,E.M.</style></author><author><style face="normal" font="Arial"> Williams,P.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, University Hospital of Wales, Cardiff, UK</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of the Performance of Skin Prick, ImmunoCAP, and ISAC Tests in the Diagnosis of Patients with Allergy</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="223" start="215">215-223</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen chip</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy is diagnosed from typical symptoms, and tests are performed to incriminate the suspected precipitant. Skin prick tests (SPTs) are commonly performed, inexpensive, and give immediate results. Laboratory tests (ImmunoCAP) for serum allergen-specific IgE antibodies are usually performed more selectively. The immuno-solid phase allergen chip (ISAC) enables testing for specific IgE against multiple allergen components in a multiplex assay. METHODS: We retrospectively analysed clinic letters, case notes, and laboratory results of 118 patients attending the National Adult Allergy Service at the University Hospital of Wales who presented diagnostic difficulty, to evaluate which testing strategy (SPT, ImmunoCAP, or ISAC) was the most appropriate to use to confirm the diagnosis in these complex patients, evaluated in a "real-life" clinical service setting. RESULTS: In patients with nut allergy, the detection rates of SPTs (56%) and ISAC (65%) were lower than those of ImmunoCAP (71%). ISAC had a higher detection rate (88%) than ImmunoCAP (69%) or SPT (33%) in the diagnosis of oral allergy syndrome. ImmunoCAP test results identified all 9 patients with anaphylaxis due to wheat allergy (100%), whereas ISAC was positive in only 6 of these 9 (67%). CONCLUSIONS: In this difficult diagnostic group, the ImmunoCAP test should be the preferred single test for possible allergy to nuts, wheat, other specific foods, and anaphylaxis of any cause. In these conditions, SPT and ISAC tests give comparable results. The most useful single test for oral allergy syndrome is ISAC, and SPT should be the preferred test for latex allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170430IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1159/000464326</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456812">PM:28456812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-215-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-215-23.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-215-23.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-215-23.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170430, Griffiths RL</style></custom2><misc3><style face="normal" font="Arial">10.1159/000464326</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pinart,M.</style></author><author><style face="normal" font="Arial"> Keller,T.</style></author><author><style face="normal" font="Arial"> Reich,A.</style></author><author><style face="normal" font="Arial"> Frohlich,M.</style></author><author><style face="normal" font="Arial"> Cabieses,B.</style></author><author><style face="normal" font="Arial"> Hohmann,C.</style></author><author><style face="normal" font="Arial"> Postma,D.S.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Sex-Related Allergic Rhinitis Prevalence Switch from Childhood to Adulthood: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="235" start="224">224-235</pages><volume><style face="normal" font="Arial">172</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A sex-related switch in the prevalence of asthma from childhood (male predominance) to adulthood (female predominance) has been described, but for allergic rhinitis this remains unclear. We aimed to examine sex- and age-group-specific differences in allergic rhinitis prevalence by systematically evaluating studies from across the globe. METHODS: A systematic search of MEDLINE and Embase for population-based cross-sectional studies was performed regardless of the language of publication. The search was restricted to the present millennium (2000 to June 2014). Study quality was defined by the sampling method, response rate, sample size, and data collection method. To assess sex differences in the prevalence of self- or parent-reported symptoms of rhinitis, calculated pooled estimates of the male-female ratio (MFR) were obtained using random-effects model meta-analyses due to heterogeneity. A meta-regression analysis was also performed. RESULTS: Out of 6,539 publications identified, 67 cross-sectional population-based studies (291,726 males and 301,781 females) were included in our meta-analysis. In children (&lt;11 years of age) significantly more boys than girls had rhinitis symptoms (MFR 1.21, 95% CI 1.17-1.25), whereas in adolescents (11 to &lt;18 years of age) males were significantly less often affected than females (MFR 0.90, 95% CI 0.85-0.95). No sex-specific prevalence difference was observed in adults (MFR 0.96, 95% CI 0.83-1.17). These findings were consistent in all continents except in Asia, where the male predominance remained beyond childhood. CONCLUSIONS: The male predominance of rhinitis prevalence in childhood changed towards a female predominance in adolescence across the globe, except in Asia. Longitudinal studies are needed to confirm these cross-sectional data and examine possible determinants and underlying mechanisms</style></abstract><notes><style face="normal" font="Arial">DA - 20170430IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Chile -CO - Netherlands -CO - Germany -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1159/000464324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456795">PM:28456795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-224-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-172-224-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170430, Pinart M</style></custom2><misc3><style face="normal" font="Arial">10.1159/000464324</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schelkle,M.</style></author><author><style face="normal" font="Arial"> Braun,J.</style></author><author><style face="normal" font="Arial"> Jorres,R.</style></author><author><style face="normal" font="Arial"> Schierl,R.</style></author><author><style face="normal" font="Arial"> Dressel,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Respiratory allergies among veterinarians: two cross-sectional surveys from 2006 to 2012</style></title><secondary-title><style face="normal" font="Arial">Int Arch Occup Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Occup Environ Health</style></full-title></periodical><pages end="643" start="639">639-643</pages><volume><style face="normal" font="Arial">90</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> veterinarian</style></keyword><keyword><style face="normal" font="Arial"> Veterinarians</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1432-1246</style></isbn><abstract><style face="normal" font="Arial">Animal-related allergy is known to be an occupational hazard among veterinarians; however, there is a lack of data showing to which extent these are affected. We aimed at describing the prevalence of respiratory allergies in this population</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00420-017-1226-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28478545">PM:28478545</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Occup Environ Health\20170503-SchelkleM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Occup Environ Health\20170503-SchelkleM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Schelkle M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00420-017-1226-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shibagaki,S.</style></author><author><style face="normal" font="Arial"> Tahara-Hanaoka,S.</style></author><author><style face="normal" font="Arial"> Hiroyama,T.</style></author><author><style face="normal" font="Arial"> Nakamura,Y.</style></author><author><style face="normal" font="Arial"> Shibuya,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Faculty of Medicine, University of Tsukuba</style></auth-address><titles><title><style face="normal" font="Arial">Long-term survival of the mouse ES cell-derived mast cell, MEDMC-BRC6, in mast cell-deficient Kitw-sh/w-sh mice</style></title><secondary-title><style face="normal" font="Arial">Int Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunol</style></full-title></periodical><pages end="242" start="235">235-242</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> c-kit</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Peritoneal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="Arial">Mast cells (MCs) play pivotal roles in allergic reactions and the host defense against microbial infection through the immunoglobulin E (IgE)-dependent and IgE-independent signaling pathways. MC lines that can be analyzed both in vitro and in vivo would be useful for the study of MC-dependent immune responses. Here we investigated the functional characteristics of a mouse ES cell-derived mast cell-like cell line, MEDMC-BRC6. The cell line expressed FcepsilonRI and c-Kit and showed degranulation and production of inflammatory cytokines and chemokine, including TNF-alpha, IL-6 and MCP-1, upon crosslinking FcepsilonRI with IgE. These cytokines and chemokine were also produced by the cell line by stimulation of Toll-like receptor (TLR) 2 and TLR4. MEDMC-BRC6 survived in the peritoneal cavity and the ear skin for at least six months after the transfer into genetically compatible MC-deficient Kitw-sh/w-sh mice, in which systemic anaphylaxis was successfully induced. Thus, MEDMC-BRC6 cells represent a potent tool for investigating the functions of MCs in vitro and in vivo</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1460-2377 (Electronic)IS - 0953-8178 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1093/intimm/dxx022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28431112">PM:28431112</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunol\20170421-ShibagakiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunol\20170421-ShibagakiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Shibagaki S</style></custom2><misc3><style face="normal" font="Arial">10.1093/intimm/dxx022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Malone,M.</style></author><author><style face="normal" font="Arial"> Kennedy,T.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Review: Side Effects of Some Commonly Used Allergy Medications (Decongestants, Anti-Leukotriene Agents, Antihistamines, Steroids, and Zinc) and Their Safety in Pregnancy</style></title><secondary-title><style face="normal" font="Arial">Int J Allergy Medic</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Allergy Medic</style></full-title></periodical><pages end="" start="024">024-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Pressure</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cetirizine</style></keyword><keyword><style face="normal" font="Arial"> constipation</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> decongestants</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hallucinations</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Loratadine</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> Mouth</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Stroke</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> topical steroids</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: The aim of this study was to evaluate the safety and side-effects of common allergy medications.Methodology: A literature search was undertaken. We searched the databases of Pubmed, MEDLINE, EMBASE databases, and Cochrane Library from 1990 to October 2016, using key words: Allergy, Medications, Antihistamines, Decongestants, Montelukast, Side effects, Adverse Events, Adverse, Effects, Zinc, Steroids, Pregnancy, Reviews, RCT, and Case Report.Results: Antihistamines can cause undesired anti-cholinergic effects including mydraisais, sedation, dry eyes, dry mouth, constipation and urinary retention. Significant overdose of antihistamines can cause serious toxicity and even death. Cetirizine or loratadine are preferred based on their good safety profile and recommendation in multiple guidelines during pregnancy. Side effects are more common with oral decongestants than with topical sprays. Decongestant side-effects include nausea, vomiting, insomnia, dizziness, elevated blood pressure, restlessness, anxiety, hallucinations, seizure, psychosis, headache, urinary dysfunction, stroke, intracranial bleed, arrhythmias, and myocardial infarction. Anti-leukotriene agents, topical steroids, and intranasal steroids are generally well tolerated. Intranasal zinc has been reported to cause zinc-induced anosmia syndrome which is characterized by nasal burning followed by anosmia and can be distinguished from post-viral anosmia based on history.Conclusion: Although serious side-effects can occur, the majority of the common allergy medications reviewed in this article was well-tolerated and had only rare serious side effects.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.23937/2572-3308.1510024</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.23937/2572-3308.1510024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Allergy Medic\2017-3-024.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Allergy Medic\2017-3-024.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Malone M</style></custom2><misc3><style face="normal" font="Arial">10.23937/2572-3308.1510024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dantas,M.D.A.</style></author><author><style face="normal" font="Arial"> Tenorio,H.A.</style></author><author><style face="normal" font="Arial"> Lopes,T.I.B.</style></author><author><style face="normal" font="Arial"> Pereira,H.J.V.</style></author><author><style face="normal" font="Arial"> Marsaioli,A.J.</style></author><author><style face="normal" font="Arial"> Figueiredo,I.M.</style></author><author><style face="normal" font="Arial"> Santos,J.C.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Chemistry and Biotechnology, Federal University of Alagoas, A. C. Simoes Campus, Tabuleiro dos Martins, s/n, 57072-900, Maceio, Alagoas, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Interactions of tetracyclines with ovalbumin, the main allergen protein from egg white: Spectroscopic and electrophoretic studies</style></title><secondary-title><style face="normal" font="Arial">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biol Macromol</style></full-title></periodical><pages end="514" start="505">505-514</pages><volume><style face="normal" font="Arial">102</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Quenching</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tetracyclines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> UV-VIS spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="17" Month="4" Year="2017">2017/4/17</year></dates><abstract><style face="normal" font="Arial">The interactions of tetracycline (TC), oxytetracycline (OTC) and chlortetracycline (CTC) with ovalbumin (OVA), the main allergen protein of egg white, were investigated by molecular spectroscopy and electrophoresis at three pH conditions (1.5, 4.6 and 7.4). Molecular and synchronous fluorescence, UV-vis spectroscopy, electrophoresis and 1H NMR were used to study the interaction process. Tetracyclines interact with ovalbumin fluorescence by a static quenching mechanism with non-fluorescent complex formation changing the native protein structure. The binding constant (Kb) ranged from 2.11x104 to 58.4x104Lmol-1, and corresponding thermodynamic parameters were measured at different temperatures and pH values. The binding process was spontaneous (DeltaG&lt;0), and the magnitude of the interaction increased in the following order: TC&lt;CTC&lt;OTC. Hydrogen, electrostatic, and Van der Waals forces played a major role in stabilizing the complex. The distances between the donor (protein) and receptors (TC, OTC and CTC) were determined by FRET and varied of 2.95-3.52nm. Fe(III) and Zn(II) ions increase the affinities of TC and CTC for OVA, while OTC did not suffer a significant influence by the competitor metallic species evaluated</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.04.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428126">PM:28428126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biol Macromol\2017-102-505-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biol Macromol\2017-102-505-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Dantas MD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.04.052</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomassen,M.R.</style></author><author><style face="normal" font="Arial"> Aasmoe,L.</style></author><author><style face="normal" font="Arial"> Bang,B.E.</style></author><author><style face="normal" font="Arial"> Braaten,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Occupational and Environmental Medicine , University Hospital North Norway , Tromso , Norway</style></auth-address><titles><title><style face="normal" font="Arial">Lung function and prevalence of respiratory symptoms in Norwegian crab processing workers</style></title><secondary-title><style face="normal" font="Arial">Int J Circumpolar Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Circumpolar Health</style></full-title></periodical><pages end="" start="1313513">1313513-</pages><volume><style face="normal" font="Arial">76</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Seafood processing workers have an increased risk of developing occupational asthma. This has not been studied among Norwegian crab processing workers, nor has the respiratory health of exposed workers been compared to a control group. OBJECTIVES: Assessing the impact of working in the crab processing industry on workers' respiratory health. DESIGN: A cross-sectional study of the respiratory health in two types of crab processing workers compared to a control group. METHODS: The study included 148 king crab (Paralithodes camtschaticus) workers, 70 edible crab (Cancer pagurus) workers and 215 controls. Workers answered a questionnaire and performed spirometry measurements. chi2 and Fishers exact tests were performed on self-reported respiratory symptoms. Regression analyses and t-tests were used to assess lung function values. RESULTS: Self-reported respiratory symptoms were higher among crab processing workers compared to controls, and higher among king crab workers compared to edible crab workers. There was no significant difference between crab processing workers and controls in lung function measurements. Self-reported doctor-diagnosed asthma prevalence was highest in the control group. CONCLUSIONS: Increased respiratory symptoms reported by crab processing workers were not reflected in impaired lung function values or asthma diagnose. We suggest a healthy worker effect among crab processing workers in Norway</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 2242-3982 (Electronic)IS - 1239-9736 (Linking)LA - engPT - Journal ArticleCO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.1080/22423982.2017.1313513</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425826">PM:28425826</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Circumpolar Health\2017-76-1313513.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Circumpolar Health\2017-76-1313513.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Thomassen MR</style></custom2><misc3><style face="normal" font="Arial">10.1080/22423982.2017.1313513</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soto Del Rio,M.L.D.</style></author><author><style face="normal" font="Arial"> Dalmasso,A.</style></author><author><style face="normal" font="Arial"> Civera,T.</style></author><author><style face="normal" font="Arial"> Bottero,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Scienze Veterinarie, Universita di Torino, Largo Braccini 2, 10095 Grugliasco, TO, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Characterization of bacterial communities of donkey milk by high-throughput sequencing</style></title><secondary-title><style face="normal" font="Arial">Int J Food Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Food Microbiol</style></full-title></periodical><pages end="72" start="67">67-72</pages><volume><style face="normal" font="Arial">251</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bacteroidetes</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Donkey</style></keyword><keyword><style face="normal" font="Arial"> Donkey milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> Firmicutes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food intolerance</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> Gram-Negative Bacteria</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> High throughput sequencing</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactococcus</style></keyword><keyword><style face="normal" font="Arial"> Leuconostoc</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Soil</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="Arial">The interest in donkey milk (DM) is growing because of its functional properties and nutritional value, especially for children with allergies and food intolerances. However, most of the available reports of DM microbiota are based on culture-dependent methods to investigate food safety issues and the presence of lactic acid bacteria (LAB). The aim of this study was to determine the composition of DM bacterial communities using a high-throughput sequencing (HTS) approach. Bulk milk samples from Italian donkey dairy farms from two consecutive years were analysed using the MiSeq Illumina platform. All sample reads were classified into five phyla: Proteobacteria, Firmicutes, Bacteroidetes, Actinobacteria, and Verrucomicrobia. The most prevalent genera-Pseudomonas, Ralstonia, Acinetobacter, Cupriavidus, Citrobacter and Sphingobacterium-were Gram-negative bacteria. The core microbiota was composed of genera that comprise commonly associated milk bacteria, LAB and species normally found in soil, water and plants. Reads assigned to LAB genera-Streptococcus, Lactococcus, Enterococcus, Leuconostoc, Lactobacillus, and Carnobacterium-corresponded on average to 2.55% of the total reads per sample. Among these, the distribution of reads assigned to coccus- and bacillus-shaped LAB was variable between and within the farms, confirming their presence and suggesting a complex population of these bacteria in DM. The present study represents a general snapshot of the DM microbial population, underlining its variability and motivating further studies for the exploitation of the technological potential of bacteria naturally present in DM</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1879-3460 (Electronic)IS - 0168-1605 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.03.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28431310">PM:28431310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Food Microbiol\2017-251-67-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Food Microbiol\2017-251-67-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Soto Del Rio ML</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.03.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaikiri,H.</style></author><author><style face="normal" font="Arial"> Miyamoto,J.</style></author><author><style face="normal" font="Arial"> Kawakami,T.</style></author><author><style face="normal" font="Arial"> Park,S.B.</style></author><author><style face="normal" font="Arial"> Kitamura,N.</style></author><author><style face="normal" font="Arial"> Kishino,S.</style></author><author><style face="normal" font="Arial"> Yonejima,Y.</style></author><author><style face="normal" font="Arial"> Hisa,K.</style></author><author><style face="normal" font="Arial"> Watanabe,J.</style></author><author><style face="normal" font="Arial"> Ogita,T.</style></author><author><style face="normal" font="Arial"> Ogawa,J.</style></author><author><style face="normal" font="Arial"> Tanabe,S.</style></author><author><style face="normal" font="Arial"> Suzuki,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Graduate School of Biosphere Science , Hiroshima University , Higashi-Hiroshima , Japan</style></auth-address><titles><title><style face="normal" font="Arial">Supplemental feeding of a gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, alleviates spontaneous atopic dermatitis and modulates intestinal microbiota in NC/nga mice</style></title><secondary-title><style face="normal" font="Arial">Int J Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Food Sci Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Claudin-1</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin A</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Linoleic Acid</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Peyer's Patches</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">The present study investigated the antiallergic and anti-inflammatory effects of 10-hydroxy-cis-12-octadecenoic acid (HYA), a novel gut microbial metabolite of linoleic acid, in NC/Nga mice, a model of atopic dermatitis (AD). Feeding HYA decreased the plasma immunoglobulin E level and skin infiltration of mast cells with a concomitant decrease in dermatitis score. HYA feeding decreased TNF-alpha and increased claudin-1, a tight junction protein, levels in the mouse skin. Cytokine expression levels in the skin and intestinal Peyer's patches cells suggested that HYA improved the Th1/Th2 balance in mice. Immunoglobulin A concentration in the feces of the HYA-fed mice was approximately four times higher than that in the control mice. Finally, denaturing gradient gel electrophoresis of the PCR-amplified 16 S rRNA gene of fecal microbes indicated the modification of microbiota by HYA. Taken together, the alterations in the intestinal microbiota might be, at least in part, associated with the antiallergic effect of HYA</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 1465-3478 (Electronic)IS - 0963-7486 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/09637486.2017.1318116</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28438083">PM:28438083</url></web-urls><pdf-urls><url ppv-ref="no">takuya@hiroshima-u.ac.jp</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Kaikiri H</style></custom2><misc3><style face="normal" font="Arial">10.1080/09637486.2017.1318116</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marino-Sanchez,F.</style></author><author><style face="normal" font="Arial"> Valls-Mateus,M.</style></author><author><style face="normal" font="Arial"> Cardenas-Escalante,P.</style></author><author><style face="normal" font="Arial"> Haag,O.</style></author><author><style face="normal" font="Arial"> Ruiz-Echevarria,K.</style></author><author><style face="normal" font="Arial"> Jimenez-Feijoo,R.</style></author><author><style face="normal" font="Arial"> Lozano-Blasco,J.</style></author><author><style face="normal" font="Arial"> Giner-Munoz,M.T.</style></author><author><style face="normal" font="Arial"> Plaza-Martin,A.M.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Influence of nasal septum deformity on nasal obstruction, disease severity, and medical treatment response among children and adolescents with persistent allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="154" start="145">145-154</pages><volume><style face="normal" font="Arial">95</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Nasal septum</style></keyword><keyword><style face="normal" font="Arial"> Nose deformities</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> persistent allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Septal deviation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgical treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><isbn><style face="normal" font="Arial">0165-5876</style></isbn><abstract><style face="normal" font="Arial">Objective To evaluate the impact of different types of nasal septum deformity (NSD) on nasal obstruction, rhinitis severity and response to medical treatment among pediatric persistent allergic rhinitis (PER) patients. Methods In a prospective, real-life study, 150 children and adolescents (mean age 13-á-¦-á2.8 years, females 32.6%) diagnosed with PER according to ARIA guidelines were assessed by nasal endoscopy for NSD according to Mladina's classification, their response to medical treatment (intranasal steroids and antihistamines or antileucotriens), the presence of comorbidities, rhinitis severity (modified-ARIA criterion) and nasal obstruction visual analog scale score (VAS). Results Most patients (87%) had 1 of the 7 types of septal deformities. There was a high prevalence of bilateral (types 4 and 6; 46%) and anterior unilateral (types 1 and 2; 25%) NSD in patients not responding to medical treatment. Type 4 (OR-á=-á6.4; p-á=-á0.005) or type 6 (OR-á=-á4.4; p-á=-á0.03) NSD increased the risk of lack of improvement with medical treatment. Coexistence of anterior unilateral or bilateral NSD with severe turbinate enlargement increased &amp;gt;20-fold the risk of lack of improvement. Patients with bilateral NSD presented greater rhinitis severity. Non-responder adolescents displayed higher prevalence of bilateral NSD than children (53% vs. 23%; p-á=-á0.02). Nasal obstruction VAS was higher for patients with anterior than posterior NSD, and greater for patients with bilateral NSD than any other type of septal morphology. Conclusion Nasal endoscopy shows that bilateral and unilateral anterior nasal septum deformities are strongly associated with a poor response to medical treatment, greater rhinitis severity and higher nasal obstruction VAS. Consequently, nasal endoscopy is necessary in the PER patients to understand the disease severity as well as to plan a specific surgical treatment in order to improve nasal obstruction, disease severity, and patient's quality of life</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijporl.2017.02.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ijporl.2017.02.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-95-145-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-95-145-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Marino-Sanchez F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijporl.2017.02.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shi,L.</style></author><author><style face="normal" font="Arial"> Ma,Y.</style></author><author><style face="normal" font="Arial"> Zheng,C.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The effect of blocking Notch signaling by +¦-secretase inhibitor on allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="38" start="32">32-38</pages><volume><style face="normal" font="Arial">98</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> Notch signaling</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> Th cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><isbn><style face="normal" font="Arial">0165-5876</style></isbn><abstract><style face="normal" font="Arial">Objective This study aimed to investigate the effect of blocking Notch signaling by +¦-secretase inhibitor (GSI) on allergic rhinitis. Method GSI, N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butylester (DAPT) was administered to ovalbumin-induced AR mice models intranasally. We observed symptoms of sneezing and nose rubbing. To detect the inflammatory state, the serum OVA-specific-IgE, IFN-+¦, IL-4, and IL-5 were analyzed by ELISA, and Th cell cytokines in nasal mucosa were analyzed by RT-PCR, including T-bet, IFN-+¦, GATA-3, IL-4, and IL-5. In addition, hematoxylin-eosin (HE) and periodic acid-Schiff (PAS) were applied for histopathological examination. As for the evaluation of Notch signaling, we analyzed the Notch-1, Notch signaling target Hes-1, and Hes-5 in mucosa by RT-PCR, besides, used western blotting and immunohistochemistry to assess NICD (Notch intracellular domain). Results The results showed that the DAPT ameliorated the development of AR and suppressed Th2 cytokine levels significantly, alleviating eosinophils infiltration and goblet cells metaplasia, suggesting that the GSI can regulate Th2 response and weaken airway inflammation in AR. Conclusion Our findings provide evidence that blocking Notch signaling by GSI offers high value in treating AR</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijporl.2017.04.036</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ijporl.2017.04.036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-98-32-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-98-32-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Shi L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijporl.2017.04.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Raghunath,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, School of Medicine, Texila American University, Georgetown, Guyana</style></auth-address><titles><title><style face="normal" font="Arial">Role of Gut Microbiota and Infectious Burden in the Development of Autoimmune and Allergic Diseases</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="78" start="77">77-78</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Guyana -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28417628">PM:28417628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-77-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-77-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Raghunath P</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author><author><style face="normal" font="Arial"> Comite,P.</style></author><author><style face="normal" font="Arial"> Ferrero,F.</style></author><author><style face="normal" font="Arial"> Mussap,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Istituto di Ricovero e Cura a Carattere Scientifico - Azienda Ospedaliera-Universitaria (IRCCS-AOU), San Martino, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">A Real Life Comparison between Allergenic Extracts and Allergenic Molecules</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="44" start="39">39-44</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Betulaceae</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Genoa</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Par j 2</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> Parietaria judaica</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Serum IgE assay is a mainstay step in the allergy work up. Allergenic extracts and molecular components are available at present. This real life study compared the serum specific IgE levels against allergenic extracts with allergenic molecules in patients allergic to Parietaria, Betulaceae, and mites. This retrospective real life study included 489 subjects with respiratory allergy. Inclusion criteria were 1) documented diagnosis of allergic rhinitis (AR) and/or allergic asthma, and 2) documented allergy to Parietaria judaica (Par j) 2 (216 patients: 112 females, mean age 42 years), or to Betula verrucosa (Bet v) 1 (62 patients: 35 females, mean age 3 years), or Dermatophagoides pteronyssinus (Der p) 1 (211 patients: 107 females, mean age 34 years); and mono-allergy. Serum IgE, specific both for total/crude allergen extracts and individual purified/recombinant allergens, were assessed by ImmunoCap system. The serum IgE levels to birch extract were very strongly (R2=0.96) related to IgE to Bet v 1. There was a strong (R2=0.71) correlation between Dermatophagoides pteronyssinus IgE and Der p 1. A very strong (R2=0.87) correlation also existed between Parietaria extract IgE and Par j 2 IgE levels. However, there was discrepancy between percentages of positivity between allergenic extracts and molecules. Therefore, allergen molecular diagnostics may represent a useful way in allergy work up, but deserves caution in particular circumstances</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28417623">PM:28417623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-39-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-39-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qing,M.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Zhen,L.</style></author><author><style face="normal" font="Arial"> Hui,G.</style></author><author><style face="normal" font="Arial"> Xiao-Ying,L.</style></author><author><style face="normal" font="Arial"> Hui-Jie,H.</style></author><author><style face="normal" font="Arial"> Yan,W.</style></author><author><style face="normal" font="Arial"> Yi-Xin,R.</style></author><author><style face="normal" font="Arial"> Yong-Ge,L.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Influence of Sensitization Patterns on Fractional Exhaled Nitric Oxide in Asthmatic Children</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="59" start="53">53-59</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Fractional exhaled nitric oxide (FeNO) has been suggested as a non-invasive biomarker of airway inflammation, which is increased in atopic subjects. Whether sensitization to particular allergens is a predictive factor for increased FeNO levels is not yet fully understood. We conducted a retrospective cross-sectional study. From October to December in 2015, the medical documents of 127 mild, steroid-naive asthmatic children and 34 healthy age-matched children were enrolled in this study. The results of the FeNO measurements, skin prick test, and the spirometry were collected for analysis. Sensitization patterns to the 18 aeroallergens (5 categories: mites, molds, animal dander, pollen, and other) were determined in study population. A significant increase in FeNO level was observed in poly-sensitized asthmatic children (34.7 part per billion, (ppb) [28.3-41.1 p.p.b]), compared with mono-sensitized asthmatics (30.7 p.p.b [18.3-43.2 p.p.b]) and with non-sensitized asthmatics (17.3 p.p.b [10.8-24.5 p.p.b]). With sensitization to perennial allergens (mites, mold, and animal dander), blood eosinophil counts were significantly associated with increased FeNO (p&lt;0.05 for all). The highest FeNO level was identified in children sensitized to a combination of the perennial, seasonal, and other allergens, when compared with those sensitized to one category of allergen alone (p=0.004). Our study showed that variations in FeNO level were associated with individuals' sensitization patterns. Being sensitized to some particular allergens might contribute to prompt the airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28417625">PM:28417625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-53-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-53-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Qing M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Internal Medicine Department, IRCCS AOU San Martino, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Symptom Severity and Allergen-specific IgE in Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="81" start="79">79-81</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Genoa</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28417629">PM:28417629</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-79-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-79-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Babaie,D.</style></author><author><style face="normal" font="Arial"> Nabavi,M.</style></author><author><style face="normal" font="Arial"> Arshi,S.</style></author><author><style face="normal" font="Arial"> Mesdaghi,M.</style></author><author><style face="normal" font="Arial"> Chavoshzadeh,Z.</style></author><author><style face="normal" font="Arial"> Bemanian,M.H.</style></author><author><style face="normal" font="Arial"> Tafakori,M.</style></author><author><style face="normal" font="Arial"> Amirmoini,M.</style></author><author><style face="normal" font="Arial"> Esmailzadeh,H.</style></author><author><style face="normal" font="Arial"> Molatefi,R.</style></author><author><style face="normal" font="Arial"> Rekabi,M.</style></author><author><style face="normal" font="Arial"> Akbarpour,N.</style></author><author><style face="normal" font="Arial"> Masoumi,F.</style></author><author><style face="normal" font="Arial"> Fallahpour,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Cow's Milk Desensitization in Anaphylactic Patients: A New Personalized-dose Method</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="52" start="45">45-52</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergens</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Positive oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk groups</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Cow's milk allergy (CMA) is the most frequent food allergy in children and oral immunotherapy (OIT) is a promising approach for treatment of patients. The most challenging cases are anaphylactic with coexisting asthma and proposing safe protocols is crucial especially in high risk groups. Considering that CMA varies among patients, an individualized OIT protocol would be beneficial to achieve a safer and more efficient method of desensitization. 18 children more than 3 years of age with IgE-mediated CMA were enrolled. CMA was confirmed by positive skin prick test (SPT) and positive oral food challenge (OFC) and 60% of individuals had a convincing history of persistent asthma. SPT with milk extracts, whole fresh milk and serially diluted milk concentrations were performed. The dilution of milk that induced 3-5 mm of wheal in each individual was selected as the starting dilution for OIT. Desensitization began by 1 drop of the defined dilution and continued increasingly. Overall, 16 out of 18 children (88.8%) achieved the daily intake of 120 mL of milk. Four out of these 16 children accomplished the protocol without any adverse allergic reactions. 12 patients experienced mild to severe reactions. Wheal and erythema in SPT (p&lt;/=0.001), and sIgE (p&lt;/=0.003) to most milk allergens were significantly decreased following desensitization. We successfully desensitized 16 of 18 children with IgE-mediated CMA by individualized desensitization protocol. Individualizing the OIT protocol would be helpful to save time and perhaps to relieve the allergic symptoms after ingesting cow's milk intake</style></abstract><notes><style face="normal" font="Arial">DA - 20170418IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28417624">PM:28417624</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-45-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-45-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170418, Babaie D</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moloney,L.</style></author><author><style face="normal" font="Arial"> Wickstrom,D.L.</style></author><author><style face="normal" font="Arial"> Schofield,M.</style></author><author><style face="normal" font="Arial"> Hand,R.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Academy Approves NIAID Addendum Guidelines for the Prevention of Peanut Allergy</style></title><secondary-title><style face="normal" font="Arial">J Acad Nutr Diet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Acad Nutr Diet</style></full-title></periodical><pages end="787" start="786">786-787</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> NIAID</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 2212-2672 (Print)IS - 2212-2672 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jand.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449792">PM:28449792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Acad Nutr Diet\2017-117-786-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Acad Nutr Diet\2017-117-786-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Moloney L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jand.2017.03.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Claude,M.</style></author><author><style face="normal" font="Arial"> Bouchaud,G.</style></author><author><style face="normal" font="Arial"> Lupi,R.</style></author><author><style face="normal" font="Arial"> Castan,L.</style></author><author><style face="normal" font="Arial"> Tranquet,O.</style></author><author><style face="normal" font="Arial"> Denery-Papini,S.</style></author><author><style face="normal" font="Arial"> Bodinier,M.</style></author><author><style face="normal" font="Arial"> Brossard,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">How proteins aggregate can reduce allergenicity: comparison of ovalbumin heated under opposite electrostatic conditions</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregates</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> RBL</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">Heated foods are recommended for avoiding sensitization to food proteins but depending on the physicochemical conditions during heating, more or less unfolded proteins aggregate differently. Whether the aggregation process could modulate allergenicity was investigated. Heating ovalbumin in opposite electrostatic conditions led to small (A-s, about 50 nm) and large (A-L, about 65 microm) aggregates that were used to sensitize mice. The symptoms upon oral challenge and RBL degranulation with native ovalbumin differed based on which aggregates were used during the sensitization. IgE production was significantly lower with A-s than A-L. Although two common linear IgE-epitopes were found, the aggregates bound and cross-linked IgE similarly or differently, depending on the sensitizing aggregate. The ovalbumin aggregates thus displayed a lower allergenic potential when formed under repulsive than non-repulsive electrostatic conditions. This further demonstrates that food structure modulates the immune response during the sensitization phase with some effects on the elicitation phase of an allergic reaction and argues for the need to characterize the aggregation state of allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170424IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b00676</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28434227">PM:28434227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170424-ClaudeM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170424-ClaudeM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170424, Claude M</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b00676</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Majowicz,S.E:</style></author><author><style face="normal" font="Arial"> Jung,J.</style></author><author><style face="normal" font="Arial"> Courtney,S.</style></author><author><style face="normal" font="Arial"> Harrington,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Exploring the Concern about Food Allergies among Secondary School and University Students in Ontario, Canada: A Descriptive Analysis</style></title><secondary-title><style face="normal" font="Arial">J Allergy (Cairo)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy (Cairo)</style></full-title></periodical><pages end="" start="2051916">2051916-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> descriptive analysis</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Our objective was to explore the perceived risk of food allergies among students in Ontario, Canada. We analyzed blinding questions ('I am concerned about food allergies', 'food allergies are currently a big threat to my health') from three existing food safety surveys, administered to high school and university undergraduate students (n=3,451) circa February 2015, using descriptive analysis, and explored how concern related to demographics and self- reported cooking ability using linear regression. Overall, high school students were neutral in their concern, although Food and Nutrition students specifically were significantly less concerned (p=0.002) than high school students overall. University undergraduates were moderately unconcerned about food allergies. Concern was highest in younger students, decreasing between 13-18 years of age, and plateauing between 19-23 years. Among students aged 13-18 years, concern was higher among those who worked or volunteered in a daycare, and who had previously taken a food preparation course. Among students aged 19-23 years, concern was higher among females and those with less advanced cooking abilities. Concern was significantly correlated with perceiving food allergies as a personal threat. This study offers a first exploration of perceived risk of food allergies among this demographic, and can guide future, more rigorous assessments.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/2051916</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1155/2017/2051916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy (Cairo)\20170511-MajowiczSE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy (Cairo)\20170511-MajowiczSE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Majowicz SE</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/2051916</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Casale,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida, Tampa, Fla.</style></auth-address><titles><title><style face="normal" font="Arial">Biologics and biomarkers for asthma, urticaria, and nasal polyposis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1421" start="1411">1411-1421</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Point-of-care</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Many patients with allergic disorders continue to have uncontrolled symptoms despite new and better pharmacologic options. Novel biologic agents that target specific and critical pathophysiologic pathways have been developed to better manage these patients. The utility of biologic agents for the management of allergic diseases has been facilitated by recent advances in better characterizing patients, including identification of relevant biomarkers that predict clinical responsiveness. This has led to the ability to phenotype and endotype patients, allowing for a more rational approach to picking a specific biologic agent for a specific patient. In this review I focus on point-of-care biomarkers that enhance the usefulness of biologics to manage uncontrolled asthma, urticaria, and nasal polyposis. I discuss biologic agents already approved for the management of allergic and respiratory disorders and biologics currently in development or recently abandoned because of a lack of efficacy or intolerable side effects. The successes and failures of biologics in clinical trials have facilitated our ability to better understand which molecules and pathways are most important in the pathogenesis of allergic diseases and in the development of symptoms and impairment in individual patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477720">PM:28477720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-1411-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-1411-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Casale TB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feng,J.</style></author><author><style face="normal" font="Arial"> Luo,J.</style></author><author><style face="normal" font="Arial"> Mack,M.R.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Zhang,F.</style></author><author><style face="normal" font="Arial"> Wang,G.</style></author><author><style face="normal" font="Arial"> Gong,X.</style></author><author><style face="normal" font="Arial"> Cai,T.</style></author><author><style face="normal" font="Arial"> Mei,Z.</style></author><author><style face="normal" font="Arial"> Kim,B.S.</style></author><author><style face="normal" font="Arial"> Yin,S.</style></author><author><style face="normal" font="Arial"> Hu,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, The Center for the Study of Itch, Washington University School of Medicine, St. Louis, MO, USA</style></auth-address><titles><title><style face="normal" font="Arial">The antimicrobial peptide hBD2 promotes itch through Toll-like receptor 4 signaling in mice</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="888" start="885">885-888</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-Like Receptor 4</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="Arial">The psoriasis biomarker hBD2 produces a robust scratching response in a TLR4-dependent manner in mice. TRPV1 is a downstream mediator of hBD2-induced itch. These findings suggest that hBD2 might act as an endogenous pruritogen in psoriatic itch</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28442325">PM:28442325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170426-FengJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170426-FengJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170426, Feng J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Veilleux,M.S.</style></author><author><style face="normal" font="Arial"> Shear,N.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hotel-Dieu de Levis Hospital and Laval University, Department of Medicine, Division of Dermatology, Quebec City, Quebec</style></auth-address><titles><title><style face="normal" font="Arial">Biologics in patients with skin diseases</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1430" start="1423">1423-1430</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hidradenitis Suppurativa</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Melanoma</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pemphigus</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Biologic agents are important therapeutic options for treating multiple moderate-to-severe cutaneous diseases. Monoclonal antibodies already in use or under investigation are targeted for psoriasis, atopic dermatitis, melanoma, hidradenitis suppurativa, and pemphigus vulgaris</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477721">PM:28477721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-1423-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-1423-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Veilleux MS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chipps,B.E.</style></author><author><style face="normal" font="Arial"> Lanier,B.</style></author><author><style face="normal" font="Arial"> Milgrom,H.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Hedlin,G.</style></author><author><style face="normal" font="Arial"> Szefler,S.J.</style></author><author><style face="normal" font="Arial"> Kattan,M.</style></author><author><style face="normal" font="Arial"> Kianifard,F.</style></author><author><style face="normal" font="Arial"> Ortiz,B.</style></author><author><style face="normal" font="Arial"> Haselkorn,T.</style></author><author><style face="normal" font="Arial"> Iqbal,A.</style></author><author><style face="normal" font="Arial"> Rosen,K.</style></author><author><style face="normal" font="Arial"> Trzaskoma,B.</style></author><author><style face="normal" font="Arial"> Busse,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Capital Allergy and Respiratory Disease Center, Sacramento, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="1444" start="1431">1431-1444</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> moderate-to-severe persistent allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Asthma is one of the most common chronic diseases of childhood. Allergen sensitization and high frequencies of comorbid allergic diseases are characteristic of severe asthma in children. Omalizumab, an anti-IgE mAb, is the first targeted biologic therapeutic approved for the treatment of moderate-to-severe persistent allergic asthma (AA) that remains uncontrolled despite high-dose inhaled corticosteroids plus other controller medications. Since its initial licensing for use in adults and adolescents 12 years of age and older, the clinical efficacy, safety, and tolerability of omalizumab have been demonstrated in several published clinical trials in children aged 6 to less than 12 years with moderate-to-severe AA. These studies supported the approval of the pediatric indication (use in children aged >/=6 years) by the European Medicines Agency in 2009 and the US Food and Drug Administration in 2016. After this most recent change in licensing, we review the outcomes from clinical trials in children with persistent AA receiving omalizumab therapy and observational studies from the past 7 years of clinical experience in Europe. Data sources were identified by using PubMed in 2016. Guidelines and management recommendations and materials from the recent US Food and Drug Administration's Pediatric Advisory Committee meeting are also reviewed</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - France -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477722">PM:28477722</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-1431-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-139-1431-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Chipps BE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stukus,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH. Electronic address: david.stukus@nationwidechildrens.org</style></auth-address><titles><title><style face="normal" font="Arial">Peanut-free schools: What does it really mean, and are they necessary?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="392" start="391">391-392</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170429IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28454741">PM:28454741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170429-StukusDR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170429-StukusDR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170429, Stukus DR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sorensen,M.</style></author><author><style face="normal" font="Arial"> Kuehn,A.</style></author><author><style face="normal" font="Arial"> Mills,E.N.C.</style></author><author><style face="normal" font="Arial"> Costello,C.A.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Smabrekke,L.</style></author><author><style face="normal" font="Arial"> Primicerio,R.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Klingenberg,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric and Adolescent medicine, University Hospital of North Norway, Tromso, Norway; Paediatric Research group, Institute of clinical medicine, University of Tromso, The Arctic University of Norway. Electronic address: martin.sorensen@unn.noDepartment of Infection and Immunity, Luxembourg Institute of Health, Luxembourg</style></auth-address><titles><title><style face="normal" font="Arial">Cross-reactivity in Fish Allergy: A Double-Blind Placebo-Controlled Food Challenge Trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arctic</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Fish species</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE testing</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">One third of fish-allergic patients tolerate at least one fish species. Specific IgE testing can identify most patients with fish allergy and reduce the need of oral challenges in the diagnostic work-up</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Luxembourg -CO - United Kingdom -CO - Norway -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479332">PM:28479332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-SorensenM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-SorensenM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Sorensen M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,M.</style></author><author><style face="normal" font="Arial"> Yang,I.V.</style></author><author><style face="normal" font="Arial"> Davidson,E.J.</style></author><author><style face="normal" font="Arial"> Joetham,A.</style></author><author><style face="normal" font="Arial"> Takeda,K.</style></author><author><style face="normal" font="Arial"> O'Connor,B.P.</style></author><author><style face="normal" font="Arial"> Gelfand,E.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045</style></auth-address><titles><title><style face="normal" font="Arial">Forkhead Box Protein 3 (FoxP3) Demethylation is Associated with Tolerance Induction in Peanut-Induced Intestinal Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> forkhead box protein 3</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Induction of tolerance</style></keyword><keyword><style face="normal" font="Arial"> Jejunum</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> peanut-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg suppression</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Regulatory T cells (Tregs) play an essential role in the maintenance of immune homeostasis in allergic diseases. OBJECTIVES: To define the mechanisms underlying induction of tolerance to peanut protein and prevention of the development of peanut allergy. METHODS: High or low doses of peanut extract (PE) were administered to pups every day for 2 weeks prior to peanut sensitization and challenge. Following challenge, symptoms, Treg numbers, FoxP3, Th2, Th17 cytokine and TGFbeta expression in mesenteric lymph node (MLN) CD4+ T cells and in jejunum were monitored. Treg suppressive activity and FoxP3 methylation in MLN CD4+ T cells were assayed. RESULTS: Feeding high but not low doses of peanut prior to sensitization induced tolerance as demonstrated by prevention of diarrhea and peanut-specific IgE responses, increases in the percentage of CD4+CD25+FoxP3+ cells in MLN, and FoxP3 mRNA and protein expression in CD4+ cells from MLN or jejunum. Feeding high doses of peanut prior to sensitization decreased percentages of CD3+CD4+IL13+ cells and CD3+CD4+IL17+ cells in MLN and decreased IL13, IL17A, and increased TGFbeta mRNA expression in the jejunum; numbers of CD103+ DC in MLN were significantly increased. Treg suppression was shown to be antigen specific. FoxP3 methylation was increased in PE sensitized and challenged mice, whereas in tolerized mice, levels were significantly reduced. CONCLUSIONS: Feeding high doses of peanut to pups induced tolerance to peanut protein. FoxP3 demethylation was associated with tolerance induction, indicating that Tregs play an important role in the regulation of peanut sensitivity and maintenance of immune homeostasis</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479331">PM:28479331</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-WangM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-WangM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Wang M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Joulia,R.</style></author><author><style face="normal" font="Arial"> Mailhol,C.</style></author><author><style face="normal" font="Arial"> Valitutti,S.</style></author><author><style face="normal" font="Arial"> Didier,A.</style></author><author><style face="normal" font="Arial"> Espinosa,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inserm, U1043, Toulouse, F-31300, France; Universite de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France</style></auth-address><titles><title><style face="normal" font="Arial">Direct monitoring of basophil degranulation by using avidin-based probes</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Avidin</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">We show that fluorescent avidin binds to basophil cell surface upon degranulation and can be used to set up a new basophil activation test (BAT). This new assay provides results comparable to those provided by the CD63 exposure-based BAT, but has the advantage to directly monitor granule exteriorization</style></abstract><notes><style face="normal" font="Arial">DA - 20170423IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433691">PM:28433691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170423-JouliaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170423-JouliaR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, Joulia R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Golden,D.B.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Johns Hopkins University, Baltimore, Md.</style></auth-address><titles><title><style face="normal" font="Arial">Rush Venom Immunotherapy: Ready for Prime Time?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="805" start="804">804-805</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483322">PM:28483322</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-804-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-804-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Golden DB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garvey,A.A.</style></author><author><style face="normal" font="Arial"> O'Sullivan,D.</style></author><author><style face="normal" font="Arial"> Hourihane,J.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatrics and Child Health, University College, Cork, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Home-based induction of sustained unresponsiveness in children with mild reactions to high doses of peanut</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28460846">PM:28460846</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170502-GarveyAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170502-GarveyAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Garvey AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ledford,D.K.</style></author><author><style face="normal" font="Arial"> Akin,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida, Tampa, Fla. Electronic address: dledford@health.usf.eduDepartment of Medicine, Brigham and Women's Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="Arial">Tryptase Increase without Mastocytosis or Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="869">869-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.12.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483325">PM:28483325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-869.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-869.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Ledford DK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.12.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hjort,C.</style></author><author><style face="normal" font="Arial"> Schiotz,P.O.</style></author><author><style face="normal" font="Arial"> Ohlin,M.</style></author><author><style face="normal" font="Arial"> Wurtzen,P.A.</style></author><author><style face="normal" font="Arial"> Christensen,L.H.</style></author><author><style face="normal" font="Arial"> Hoffmann,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">The number and affinity of productive IgE pairs determine allergen activation of mast cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">IgE composition (number and concentration of IgE pairs, IgE clonality, and IgE affinity) determines number of mast cells reacting and allergen threshold for activation and may dictate the threshold allergen dose and severity of allergy symptoms in the individual allergic patient</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479333">PM:28479333</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-HjortC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-HjortC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Hjort C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Johansson,E.K.</style></author><author><style face="normal" font="Arial"> Bergstrom,A.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Lind,T.</style></author><author><style face="normal" font="Arial"> Soderhall,C.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Ballardini,N.</style></author><author><style face="normal" font="Arial"> Wahlgren,C.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, SE-17177 Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">IgE Sensitization in Relation to Preschool Eczema and Filaggrin Mutation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> BAMSE</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Filaggrin mutation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food and aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> mutation analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eczema (atopic dermatitis) is associated with an increased risk of having IgE antibodies. IgE sensitization may occur through an impaired skin barrier. Filaggrin (FLG) mutation is associated with eczema, and possibly also with IgE sensitization. OBJECTIVE: To explore the longitudinal relation between preschool eczema and/or FLG mutation and IgE sensitization in childhood. METHODS: A total of 3201 children from the BAMSE birth cohort recruited from the general population were included. Regular parental questionnaires identified children with eczema. Blood samples were collected at 4, 8, and 16 years for analysis of specific IgE. FLG mutation analysis was performed on 1890 of the children. RESULTS: Preschool eczema was associated with IgE sensitization to both food and aeroallergens up to age 16 (overall adjOR 2.30; 95%CI: 2.00-2.66). This association was even stronger among children with persistent preschool eczema. FLG mutation was associated with IgE sensitization to peanut at age 4 years (adjOR 1.88; 95% CI: 1.03-3.44), but not to other allergens up to age 16 years. FLG mutation and preschool eczema were not effect modifiers for the association between IgE sensitization and preschool eczema or FLG mutation, respectively. Sensitized children with preschool eczema were characterized by polysensitization, but no other specific IgE sensitization patterns were found. CONCLUSIONS: Preschool eczema is associated with IgE sensitization, to both food and aeroallergens, up to 16 years of age. FLG mutation is associated with IgE sensitization to peanut, but not to other allergens. Sensitized children with preceding preschool eczema are more often polysensitized</style></abstract><notes><style face="normal" font="Arial">DA - 20170430IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456621">PM:28456621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170430-JohanssonEK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170430-JohanssonEK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170430, Johansson EK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reddy,A.</style></author><author><style face="normal" font="Arial"> Greenberger,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy &amp; Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pa.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Bronchopulmonary Aspergillosis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="867" start="866">866-867</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="05/13/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2016.08.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483324">PM:28483324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-866-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-866-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Reddy A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2016.08.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,Y.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Su,H.</style></author><author><style face="normal" font="Arial"> Wen,H.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Yao,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, 210042, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="891" start="888">888-891</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479326">PM:28479326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-HanY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-HanY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Han Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burton,O.T.</style></author><author><style face="normal" font="Arial"> Tamayo,J.M.</style></author><author><style face="normal" font="Arial"> Stranks,A.J.</style></author><author><style face="normal" font="Arial"> Koleoglou,K.J.</style></author><author><style face="normal" font="Arial"> Oettgen,H.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Boston Children's Hospital, Boston, MA, 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-specific IgG antibodies signaling via FcgammaRIIb promote food tolerance</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food tolerance</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food-allergic subjects produce high-titer IgE antibodies that bind to mast cells via FcepsilonRI and trigger immediate hypersensitivity reactions upon antigen encounter. Food-specific IgG antibodies arise in the setting of naturally resolving food allergy and accompany the acquisition of food allergen unresponsiveness in oral immunotherapy (OIT). OBJECTIVE: In this study, we sought to delineate the effects of IgG and its inhibitory Fc receptor, FcgammaRIIb, on both de novo allergen sensitization in naive animals and on established immune responses in the setting of pre-existing food allergy. METHODS: Allergen-specific IgG was administered to mice undergoing sensitization and desensitization to the model food allergen, ovalbumin (OVA). Cellular and molecular mechanisms were interrogated using mast cell- and FcgammaRIIb-deficient mice. The requirement for FcgammaRII in IgG-mediated inhibition of human mast cells was investigated using a neutralizing antibody. RESULTS: Administration of specific IgG to food allergy-prone IL4raF709 mice during initial food exposure prevented the development of IgE antibodies, T helper (Th) 2 responses, and anaphylactic responses upon challenge. When given as an adjunct to oral desensitization in mice with established IgE-mediated hypersensitivity, IgG facilitated tolerance restoration, favoring the expansion of Foxp3+ regulatory T cells (Treg) along with suppression of existing Th2 and IgE responses. IgG and FcgammaRIIb suppresses the adaptive allergic responses via effects on mast cell function. CONCLUSION: These findings suggest that allergen-specific IgG antibodies can act to induce and sustain immunological tolerance to foods</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479335">PM:28479335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-BurtonOT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-BurtonOT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Burton OT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakamura,T.</style></author><author><style face="normal" font="Arial"> Fujiwara,Y.</style></author><author><style face="normal" font="Arial"> Yamada,R.</style></author><author><style face="normal" font="Arial"> Fujii,W.</style></author><author><style face="normal" font="Arial"> Hamabata,T.</style></author><author><style face="normal" font="Arial"> Lee,M.Y.</style></author><author><style face="normal" font="Arial"> Maeda,S.</style></author><author><style face="normal" font="Arial"> Aritake,K.</style></author><author><style face="normal" font="Arial"> Roers,A.</style></author><author><style face="normal" font="Arial"> Sessa,W.C.</style></author><author><style face="normal" font="Arial"> Nakamura,M.</style></author><author><style face="normal" font="Arial"> Urade,Y.</style></author><author><style face="normal" font="Arial"> Murata,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Animal Radiology, Graduate School of Agriculture and Life Sciences, University of Tokyo, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Mast cell-derived prostaglandin D2 attenuates anaphylactic reactions in mice</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="632" start="630">630-632</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457595">PM:28457595</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170501-NakamuraT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170501-NakamuraT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Nakamura T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Homann,A.</style></author><author><style face="normal" font="Arial"> Schramm,G.</style></author><author><style face="normal" font="Arial"> Jappe,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical and Molecular Allergology, Priority Research Area Asthma &amp; Allergy, Airway Research Center North (ARCN), Member of the German Centre for Lung Research (DZL), Research Center Borstel, Borstel, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Glycans and Glycan-specific IgE in Clinical and Molecular Allergology - Sensitization, Diagnostics and Clinical Symptoms</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="368" start="356">356-368</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> allergy therapy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasite infection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">Glycan-specific IgE antibodies are cross-reacting with highly similar or even identical carbohydrate structures on a variety of different natural allergens, the so-called cross-reactive carbohydrate determinants (CCDs). In clinical practice, CCDs often interfere with the specificity of in vitro allergy diagnostics, thus impairing allergy therapy decisions for individual patients. Strikingly, these IgE antibodies directed against CCD often do not cause clinically relevant allergy symptoms. Opposed to that, the IgE-binding glycan allergen galactose-alpha-(1,3)-galactose (alpha-Gal) is associated with IgE-mediated delayed anaphylaxis in meat allergy. The reason for this discrepancy is not known. The discovery of alpha-Gal stimulated new discussions and investigations regarding the relevance of anti-glycan IgE for allergic diseases. In this review, the impact of glycans and glycan-specific IgE on sensitization to allergens and allergy diagnosis is described. As parasite infections elicit a similar immunological environment as allergic diseases, the association of glycan-specific antibodies against parasite glycoproteins with glycan structures on allergens are discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479330">PM:28479330</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-HomannA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170508-HomannA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Homann A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,S.</style></author><author><style face="normal" font="Arial"> Morita,H.</style></author><author><style face="normal" font="Arial"> Ruckert,B.</style></author><author><style face="normal" font="Arial"> Boonpiyathad,T.</style></author><author><style face="normal" font="Arial"> Neumann,A.</style></author><author><style face="normal" font="Arial"> Akdis,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Type 3 innate lymphoid cells induce proliferation of CD94+ NK cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Australia</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> NK cells</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170423IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Australia -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433689">PM:28433689</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170423-LiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170423-LiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170423, Li S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cook,K.A.</style></author><author><style face="normal" font="Arial"> Ford,C.M.</style></author><author><style face="normal" font="Arial"> Leyvas,E.A.</style></author><author><style face="normal" font="Arial"> Waalen,J.</style></author><author><style face="normal" font="Arial"> White,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Scripps Clinic, Division of Allergy, Asthma and Immunology, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">Half of systemic reactions to allergen immunotherapy are delayed, majority require treatment with epinephrine</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1417" start="1415">1415-1417</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170429IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28454684">PM:28454684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170429-CookKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170429-CookKA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170429, Cook KA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kitzmuller,C.</style></author><author><style face="normal" font="Arial"> Kalser,J.</style></author><author><style face="normal" font="Arial"> Mutschlechner,S.</style></author><author><style face="normal" font="Arial"> Hauser,M.</style></author><author><style face="normal" font="Arial"> Zlabinger,G.J.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Fusion Proteins of Flagellin and the Major Birch Pollen Allergen Bet v 1 show Enhanced Immunogenicity, Reduced Allergenicity and Intrinsic Adjuvanticity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> aluminium hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> CD40</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> fusion proteins</style></keyword><keyword><style face="normal" font="Arial"> Hek293 Cells</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition ELISA</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Fusion Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recombinant fusion proteins of flagellin and antigens have been demonstrated to induce strong innate and adaptive immune responses. Such fusion proteins may enhance the efficacy of allergen-specific immunotherapy (AIT). OBJECTIVE: To characterize different fusion proteins of flagellin and the major birch pollen allergen Bet v 1 for suitability as allergy vaccines. METHODS: A truncated version of flagellin (NtCFlg) was genetically fused to the N- or C-terminus of Bet v 1. TLR5-binding was assessed with HEK293 cells expressing TLR5. Up-regulation of CD40, CD80, CD83, and CD86 on monocyte-derived dendritic cells (mdDC) from allergic patients was analyzed by flow cytometry. The T cell-stimulatory capacity of the fusion proteins was assessed with naive and Bet v 1-specific T cells. IgE-binding was tested in inhibition ELISA and basophil activation tests (BAT). Mice were immunized with the fusion proteins in the absence and presence of aluminium hydroxide (alum). Cellular and antibody responses were monitored. Murine antibodies were tested for blocking capacity in BAT. RESULTS: Both fusion proteins matured mdDC via TLR5. Compared to Bet v 1 the fusion proteins showed stronger T cell-stimulatory and reduced IgE-binding capacity and induced murine Bet v 1-specific antibodies in the absence of alum. However, only antibodies induced by immunization with NtCFlg fused to the C-terminus of Bet v 1 inhibited the binding of patients IgE antibodies to Bet v 1. CONCLUSION: Bet v 1-flagellin fusion proteins show enhanced immunogenicity, reduced allergenicity and intrinsic adjuvanticity and thus, represent promising vaccines for birch pollen AIT. However, the sequential order of allergen and adjuvant within a fusion protein determines its immunological characteristics</style></abstract><notes><style face="normal" font="Arial">DA - 20170430IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456624">PM:28456624</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170430-KitzmullerC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170430-KitzmullerC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170430, Kitzmuller C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mehr,S.</style></author><author><style face="normal" font="Arial"> Frith,K.</style></author><author><style face="normal" font="Arial"> Barnes,E.H.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Children's Hospital at Westmead, Sydney, NSW</style></auth-address><titles><title><style face="normal" font="Arial">Food protein induced enterocolitis syndrome in Australia: A population based study 2012-2014</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food groups</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Siblings</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="4" Year="2017">2017/4/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food protein induced enterocolitis syndrome (FPIES) is a non-IgE mediated gastrointestinal allergic disorder. Large population based FPIES studies are lacking. OBJECTIVE: To determine the incidence and clinical characteristics of FPIES in Australian infants METHODS: An Australia wide survey (2012-2014) was undertaken via the Australian Paediatric Surveillance Unit, with monthly notification of new cases of acute FPIES in infants aged &lt;24 months by 1400 participating Paediatricians. RESULTS: 230 infants with FPIES were identified. The incidence of FPIES in Australian infants (&lt;24 months) was 15.4/100,000/year. Median age of first episode, diagnosis and notification were 5, 7 and 10 months respectively. There was no gender predilection. 7% of infants had siblings with a history of FPIES and 5% reacted during exclusive breastfeeding. 68% had a single food trigger (20% two, 12% three or more food triggers). The most common FPIES triggers were rice (45%), cow's milk (33%) and egg (12%). 51% of infants reacted on their first known exposure. Infants with FPIES to multiple versus single food groups were younger at initial episode (4.6 vs. 5.8 months, P=0.001) and more frequently had fruit and/or vegetable FPIES (66% vs. 21%, p&lt;0.0001). Infants exclusively breastfed for more than 4 months had a trend to lower rates of FPIES to multiple food groups (23% vs. 36%, P=0.06). 64% of infants with multiple FPIES which included cow's milk FPIES had co-associated solid food FPIES. 42% of infants with fish-FPIES had reacted to other food groups. CONCLUSIONS: FPIES is not rare, with an estimated incidence of 15.4/100,000/year. Rice is the most common food trigger in Australia. Factors associated with multiple-FPIES included early onset disease and FPIES to fruits and/or vegetables</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28427879">PM:28427879</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170421-MehrS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170421-MehrS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Mehr S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al Saif,F.</style></author><author><style face="normal" font="Arial"> Jouen,F.</style></author><author><style face="normal" font="Arial"> Hebert,V.</style></author><author><style face="normal" font="Arial"> Chiavelli,H.</style></author><author><style face="normal" font="Arial"> Darwish,B.</style></author><author><style face="normal" font="Arial"> Duvert-Lehembre,S.</style></author><author><style face="normal" font="Arial"> Joly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, INSERM U1234, Rouen University Hospital, University of Rouen, France</style></auth-address><titles><title><style face="normal" font="Arial">Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="562" start="560">560-562</pages><volume><style face="normal" font="Arial">76</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> autoantigen</style></keyword><keyword><style face="normal" font="Arial"> Autoantigens</style></keyword><keyword><style face="normal" font="Arial"> BP180</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Complement C3</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fluorescent Antibody Technique,Direct</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> NC16A</style></keyword><keyword><style face="normal" font="Arial"> Non-Fibrillar Collagens</style></keyword><keyword><style face="normal" font="Arial"> Pemphigoid Gestationis</style></keyword><keyword><style face="normal" font="Arial"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy Complications</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170218IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - LetterPT - Multicenter StudyRN - 0 (Autoantibodies)RN - 0 (Autoantigens)RN - 0 (Complement C3)RN - 0 (Immunoglobulin G)RN - 0 (Non-Fibrillar Collagens)RN - 0 (collagen type XVII)RN - Pruritic urticarial papules plaques of pregnancySB - IMCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2016.09.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28212762">PM:28212762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\2017-76-560-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\2017-76-560-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170218, Al Saif F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2016.09.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nachef,Z.</style></author><author><style face="normal" font="Arial"> Krishnan,A.</style></author><author><style face="normal" font="Arial"> Mashtare,T.</style></author><author><style face="normal" font="Arial"> Zhuang,T.</style></author><author><style face="normal" font="Arial"> Mador,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Internal Medicine-Division of Pulmonary and Critical Care Medicine , The State University of New York at Buffalo-School of Medicine , Buffalo , NY , USA</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Buffalo</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="Arial"> Peak Expiratory Flow Rate</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The purpose of this study is to examine the comparative efficacy of Omalizumab (OMA) and Mepolizumab (Mepo) in the treatment of severe asthma by performing a network meta-analysis. METHOD: Data Sources: A systematic review of the literature was performed through four databases from their inception to February 2016. STUDY SELECTIONS: Randomized control trials and cohort studies were considered if they addressed the individual efficacy of OMA and Mepo in the treatment of asthma that was not well controlled on inhaled corticosteroids (ICSs) with or without other agents. RESULTS: OMA was significantly better than Mepo in improving the Asthma Quality of Life Questionnaire with a mean difference of 0.38 and a confidence interval of (0.21-0.55), p &lt; 0.0001, without reaching the minimal clinically important difference of 0.5. No significant difference was seen in Asthma Control Questionnaire, forced expiratory volume in second 1 (FEV1), and Peak Expiratory Flow Rate (PEFR) improvement from baseline. Both medications were successful in reducing the calculated annualized rates of asthma exacerbations (AEs) vs placebo by approximately 50%. The heterogeneity score for the different comparisons were elevated except for the PEFR. CONCLUSION: When compared indirectly via a network meta-analysis, the efficacy of OMA and Mepo was similar in the treatment of asthma that was not well controlled on at least high-dose ICS. The high heterogeneity observed and the different selection criteria for the use of the two drugs do not permit us to make any definitive recommendations for the preferential use of OMA vs Mepo in the patient populations studied. However, the current data do not suggest any major differences in efficacy</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2017.1306548</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28459601">PM:28459601</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170501-NachefZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170501-NachefZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Nachef Z</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2017.1306548</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kampe,M.</style></author><author><style face="normal" font="Arial"> Vosough,M.</style></author><author><style face="normal" font="Arial"> Malinovschi,A.</style></author><author><style face="normal" font="Arial"> Alimohammadi,M.</style></author><author><style face="normal" font="Arial"> Alving,K.</style></author><author><style face="normal" font="Arial"> Forsberg,B.</style></author><author><style face="normal" font="Arial"> Lotvall,J.</style></author><author><style face="normal" font="Arial"> Middelveld,R.</style></author><author><style face="normal" font="Arial"> Dahlen,B.</style></author><author><style face="normal" font="Arial"> Janson,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Medical Sciences: Respiratory , Allergy and Sleep Research, Uppsala University , Uppsala , Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Upper airway and skin symptoms in allergic and non-allergic asthma: results from the Swedish GA2LEN study</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic and non-allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parental allergy</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic and non-allergic asthma are viewed as separate entities, despite sharing similarities. The aims of this study were to determine differences in symptoms from the upper airways and the skin in allergic and non-allergic asthma. The secondary aims were to identify childhood risk factors and to compare quality of life in the two asthma groups. METHODS: This cohort (age 17-76 years) consisted of 575 subjects with allergic or non-allergic asthma and 219 controls. The participants participated in an interview, spirometry, exhaled nitric oxide (NO), skin prick test and responded to the Mini Asthma Quality of Life Questionnaire. RESULTS: Self-reported allergic rhinitis was significantly more common in both allergic and non-allergic asthma (82.3% and 40.7%) compared with the controls. The prevalence of chronic rhinosinusitis (CRS) was similar in both asthma groups. Eczema was significantly more common in both asthmatic groups (72.3% and 59.8%) than controls (47.0%) (p &lt; 0.001 and p = 0.012). Severe respiratory infection in childhood and parental allergy were risk factors for both allergic and non-allergic asthma. Quality of life was significantly lower in non-allergic than allergic asthma (p = 0.01). CONCLUSION: Concomitant symptoms from the upper airways and the skin were significantly more common in both allergic and non-allergic asthma. This indicates that non-allergic asthma has a systemic component with similarities to what is found in allergic asthma. There were similarities in the childhood risk factor pattern between the two types of asthma but asthma-related quality of life was lower in the non-allergic asthma group</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2017.1326132</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463525">PM:28463525</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170502-KampeM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170502-KampeM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Kampe M</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2017.1326132</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adatia,A.</style></author><author><style face="normal" font="Arial"> Clarke,A.E.</style></author><author><style face="normal" font="Arial"> Yanishevsky,Y.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Alberta, Edmonton</style></auth-address><titles><title><style face="normal" font="Arial">Sesame allergy: current perspectives</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="151" start="141">141-151</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental exposure</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Middle East</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Sesame is an important global allergen affecting ~0.1% of the North American population. It is a major cause of anaphylaxis in the Middle East and is the third most common food allergen in Israel. We conducted a systematic review of original articles published in the last 10 years regarding the diagnosis and management of sesame allergy. Skin prick testing appears to be a useful predictor of sesame allergy in infants, although data are less consistent in older children and adults. The diagnostic capacity of serum-specific immunoglobulin E is poor, especially in studies that used oral food challenges to confirm the diagnosis. Double-blind, placebo-controlled food challenge thus remains the diagnostic gold standard for sesame allergy. The cornerstone of sesame allergy management is allergen avoidance, though accidental exposures are common and patients must be prepared to treat the consequent reactions with epinephrine. Novel diagnostic and treatment options such as component-resolved diagnostics, basophil activation testing, and oral immunotherapy are under development but are not ready for mainstream clinical application</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S113612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28490893">PM:28490893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-141-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-141-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Adatia A</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S113612</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goh,K.J.</style></author><author><style face="normal" font="Arial"> Yii,A.C.A.</style></author><author><style face="normal" font="Arial"> Lapperre,T.S.</style></author><author><style face="normal" font="Arial"> Chan,A.K.</style></author><author><style face="normal" font="Arial"> Chew,F.T.</style></author><author><style face="normal" font="Arial"> Chotirmall,S.H.</style></author><author><style face="normal" font="Arial"> Koh,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory and Critical Care Medicine, Singapore General Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to Aspergillus species is associated with frequent exacerbations in severe asthma</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="140" start="131">131-140</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Severe asthma is a largely heterogeneous disease with varying phenotypic profiles. The relationship between specific allergen sensitization and asthma severity, particularly in Asia, remains unclear. We aim to study the prevalence of specific allergen sensitization patterns and investigate their association with outcomes in a severe asthma cohort in an Asian setting. METHODS: We conducted a cross-sectional study of patients receiving step 4 or 5 Global Initiative for Asthma treatment. Univariate and multivariate analyses were performed to assess the association between sensitization to a specific identifiable allergen by skin prick test (SPT) and uncontrolled asthma (defined in our study as the use of >/=2 steroid bursts or hospitalization in the past year, a history of near-fatal asthma or evidence of airflow obstruction on spirometry). RESULTS: Two hundred and six severe asthma patients (mean age 45+/-17 years, 99 [48.1%] male) were evaluated. Of them, 78.2% had a positive SPT to one or more allergens. The most common allergen to which patients were sensitized was house dust mites (Blomia tropicalis, Dermatophagoides pteronyssinus and Dermatophagoides farinae). Also, 11.7% were sensitized to Aspergillus species. On multivariate analysis, Aspergillus sensitization was associated with uncontrolled asthma (odds ratio 6.07, 95% confidence interval 1.80-20.51). In particular, Aspergillus sensitization was independently associated with the use of >/=2 steroid bursts in the past year (odds ratio 3.05, 95% confidence interval 1.04-8.95). No similar associations of uncontrolled asthma with sensitization to any other allergens were found. CONCLUSION: High allergen, specifically Aspergillus sensitization was observed in the Asian population with severe asthma by SPT. Aspergillus sensitization was specifically associated with frequent exacerbations and a greater corticosteroid requirement. An improved understanding of the severe asthma with Aspergillus sensitization phenotype is warranted, which is likely a subgroup of severe asthma with fungal sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S130459</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28461762">PM:28461762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-131-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-131-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Goh KJ</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S130459</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dosanjh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Center, Rady Childrens Hospital, San Diego, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Egg introduction: differential allergic responses</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="110" start="109">109-110</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Whole egg</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The use of egg protein preparations in clinical trials to reduce the incidence of egg allergy among infants includes a number of preparations of egg. These include whole egg, egg white protein, and egg yolk preparations. The study of the differential immune responses to these allergenic proteins in comparison is suggested as a future research area of investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20170424IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S129580</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28435301">PM:28435301</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-109-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-109-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170424, Dosanjh A</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S129580</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Davies,A.M.</style></author><author><style face="normal" font="Arial"> Allan,E.G.</style></author><author><style face="normal" font="Arial"> Keeble,A.H.</style></author><author><style face="normal" font="Arial"> Delgado,J.</style></author><author><style face="normal" font="Arial"> Cossins,B.P.</style></author><author><style face="normal" font="Arial"> Mitropoulou,A.N.</style></author><author><style face="normal" font="Arial"> Pang,M.O.Y.</style></author><author><style face="normal" font="Arial"> Ceska,T.</style></author><author><style face="normal" font="Arial"> Beavil,A.J.</style></author><author><style face="normal" font="Arial"> Craggs,G.</style></author><author><style face="normal" font="Arial"> Westwood,M.</style></author><author><style face="normal" font="Arial"> Henry,A.J.</style></author><author><style face="normal" font="Arial"> McDonnell,J.M.</style></author><author><style face="normal" font="Arial"> Sutton,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">King's College London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Biol Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Biol Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin E and its interactions with receptors FcRI and CD23 play a central role in allergic disease. Omalizumab, a clinically-approved therapeutic antibody, inhibits the interaction between IgE and FcRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells and antigen-presenting cells. We solved the crystal structure of the complex between an omalizumab-derived Fab and IgE-Fc, with one Fab bound to each C3 domain. Free IgE-Fc adopts an acutely bent structure, but in the complex it is only partially bent, with large-scale conformational changes in the C3 domains that inhibit the interaction with FcRI. CD23 binding is inhibited sterically due to overlapping binding sites on each C3 domain. Studies of omalizumab Fab binding in solution demonstrate the allosteric basis for FcRI inhibition and, together with the structure, reveal how omalizumab may accelerate dissociation of receptor-bound IgE from FcRI, exploiting the intrinsic flexibility and allosteric potential of IgE</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 1083-351X (Electronic)IS - 0021-9258 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1074/jbc.M117.776476</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28438838">PM:28438838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biol Chem\20170425-DaviesAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biol Chem\20170425-DaviesAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Davies AM</style></custom2><misc3><style face="normal" font="Arial">10.1074/jbc.M117.776476</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vega,J.</style></author><author><style face="normal" font="Arial"> Vega,J.M.</style></author><author><style face="normal" font="Arial"> Garcia-Ortiz,J.C.</style></author><author><style face="normal" font="Arial"> Sanchez-Velicia,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Seccion de Dermatologia, Hospital Universitario Rio Hortega, Valladolid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Diagnostic utility of dermoscopy in cutaneous reactions to Thaumetopoea pityocampa</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="e77" start="e76">e76-e77</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animals</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="Arial"> Dermoscopy</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Moths</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20150903IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - LetterSB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.13318</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26333805">PM:26333805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\2016-30-e76-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\2016-30-e76-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150903, Vega J</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.13318</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Quintieri,L.</style></author><author><style face="normal" font="Arial"> Monaci,L.</style></author><author><style face="normal" font="Arial"> Baruzzi,F.</style></author><author><style face="normal" font="Arial"> Giuffrida,M.G.</style></author><author><style face="normal" font="Arial"> de Candia,S.</style></author><author><style face="normal" font="Arial"> Caputo,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Reduction of whey protein concentrate antigenicity by using a combined enzymatic digestion and ultrafiltration approach</style></title><secondary-title><style face="normal" font="Arial">J Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci Technol</style></full-title></periodical><pages end="1916" start="1910">1910-1916</pages><volume><style face="normal" font="Arial">54</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic digestion</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Food</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Papain</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Pepsin digestion</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein concentrate</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Ultrafiltration</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> Whey protein concentrate</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0975-8402</style></isbn><abstract><style face="normal" font="Arial">The global interest in saving food resources is leading to recycle wasted-food materials to extract useful nutrients. In dairy industry, the recycling of whey proteins determines their utilization in the healthy-addressed foods, which, however, can cause immunological responses in allergic subjects. In this work, a whey protein concentrate (WPC) was alternatively hydrolyzed with pepsin, papain, trypsin and rennin in order to attenuate or abolish the +¦-lactoglobulin (BLG) antigenicity. The electrophoretic profiles of both pepsin and papain WPC hydrolysates proved the disappearance of the BLG band, even though a slight antigenicity was still found by ELISA. Pepsin hydrolysates, filtered through a 10-kDa cut-off membrane, did not produce immunological response. A deeper investigation carried out on pepsin digested and ultrafiltered samples by LC</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôMS/MS showed the disappearance of the immunoreactive BLG-fragment IVTQMKGLDIQKVAGTW. The remaining peptides, partially overlapped to major IgE binding epitopes, were not able to give immunoreactivity response. The combined WPC pepsin digestion with ultrafiltration confirmed to be a user-friendly strategy to reduce markedly the WPC antigenicity. The improvement of this two-steps process could be used to produce novel hypoallergenic infant food formulas</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13197-017-2625-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28720947">PM:28720947</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci Technol\20170511-QuintieriL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci Technol\20170511-QuintieriL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Quintieri L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13197-017-2625-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Belmar,N.A.</style></author><author><style face="normal" font="Arial"> Chan,S.W.</style></author><author><style face="normal" font="Arial"> Fox,M.I.</style></author><author><style face="normal" font="Arial"> Samayoa,J.A.</style></author><author><style face="normal" font="Arial"> Stickler,M.M.</style></author><author><style face="normal" font="Arial"> Tran,N.N.</style></author><author><style face="normal" font="Arial"> Akamatsu,Y.</style></author><author><style face="normal" font="Arial"> Hollenbaugh,D.</style></author><author><style face="normal" font="Arial"> Harding,F.A.</style></author><author><style face="normal" font="Arial"> Alvarez,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063</style></auth-address><titles><title><style face="normal" font="Arial">Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Biotherapeutics</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="Arial">Recent advances in immuno-oncology have shown that the immune system can be activated to induce long-term, durable antitumor responses. For immuno-oncology drug development, immune activation is often explored using rat Abs in immunocompetent mouse models. Although these models can be used to show efficacy, antidrug immune responses to experimental protein-based therapeutics can arise. Immunogenicity of surrogate Abs may therefore represent an important obstacle to the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic models. A recent publication has shown that anti-glucocorticoid-induced TNFR family-related protein agonistic Ab DTA-1 (rat or murinized IgG2a) can induce the development of anaphylaxis in C57BL/6 mice upon repeated i.p. dosing because of an anti-idiotypic anti-drug Ab immune response. This study was undertaken to address the impact of the immunogenicity derived from the Fc and variable domains. To this end, chimerized (rat V domains/mouse constant regions) and murinized (95% mouse sequence) DTA-1-based surrogate Abs with a murine IgG2c H chain isotype were created. Chimerization and murinization of DTA-1 did not affect receptor binding and glucocorticoid-induced TNFR family-related protein-induced T cell agonistic properties. Similar in vivo antitumor efficacy and intratumoral CD8+/regulatory T cells were also observed. Finally, treatment of C57BL/6 mice with the chimerized and murinized DTA-1 Abs on a C57BL/6-matched IgG2c isotype resulted in reduced development and severity of anaphylaxis as measured by decline of body temperature, behavioral effects, serum IL-4, IgE, and anti-drug Ab levels. These results suggest that careful murinization and selection of a strain-matched H chain isotype are critical to generate ideal surrogate Abs for testing immuno-oncology mechanisms in vivo</style></abstract><notes><style face="normal" font="Arial">DA - 20170427IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601512</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28446565">PM:28446565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170427-BelmarNA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170427-BelmarNA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170427, Belmar NA</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601512</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blanchard,C.</style></author><author><style face="normal" font="Arial"> Simon,D.</style></author><author><style face="normal" font="Arial"> Schoepfer,A.</style></author><author><style face="normal" font="Arial"> Straumann,A.</style></author><author><style face="normal" font="Arial"> Simon,H.U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nestle Research Center, Lausanne, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic esophagitis: unclear roles of IgE and eosinophils</style></title><secondary-title><style face="normal" font="Arial">J Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Intern Med</style></full-title></periodical><pages end="457" start="448">448-457</pages><volume><style face="normal" font="Arial">281</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> heritability</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the oesophagus. Recognized as a distinct entity only two decades ago, the emergence of the disease along with the availability of new technologies has rapidly opened new research avenues and outlined the main features of the pathogenesis of EoE. Yet, each advance in our understanding of the disease has raised new questions about the previous consensus. Currently, new subsets of the disease challenge our diagnostic criteria. For instance, it was believed that EoE did not respond to proton pump inhibitor (PPI) therapy; however, it has now been shown that a substantial proportion of EoE patients indeed respond to PPIs. In addition, a new subset of patients not even presenting eosinophil infiltrates in the oesophagus has also been described. Moreover, approaches for better understanding the heritability of the disease bring into question the dogma of predominant genetic involvement. Furthermore, the specificity and sensitivity of allergy testing for targeted food avoidance is highly controversial, and the production of specific antibodies in EoE now includes IgG4 in addition to IgE. In conclusion, EoE is perceived as 'a moving target' and the aim of this review was to summarize the current understanding of EoE pathogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 1365-2796 (Electronic)IS - 0954-6820 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/joim.12568</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425585">PM:28425585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Intern Med\2017-281-448-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Intern Med\2017-281-448-57.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Blanchard C</style></custom2><misc3><style face="normal" font="Arial">10.1111/joim.12568</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stave,G.M.</style></author><author><style face="normal" font="Arial"> Lee,E.H.</style></author><author><style face="normal" font="Arial"> Darcey,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Occupational and Environmental Medicine, Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina</style></auth-address><titles><title><style face="normal" font="Arial">Laboratory Animal Bite Anaphylaxis-A National Survey: Part 1: Case Series and Review of the Literature</style></title><secondary-title><style face="normal" font="Arial">J Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Occup Environ Med</style></full-title></periodical><pages end="738" start="728">728-738</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animal Welfare</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Rodents</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: This study documents previously unreported cases of laboratory animal bite anaphylaxis in animal laboratory facilities in the United States. METHODS: An online survey was e-mailed to designated institutional officials at laboratory animal facilities identified by the National Institutes of Health Office of Laboratory Animal Welfare. RESULTS: One hundred ninety eight organizations responded and 15 organizations indicated that workers had experienced anaphylaxis following an animal bite. Case report forms were completed by nine of these institutions for 14 cases, 13 for rodent bites, and one involving a needlestick from a horse. In half of the cases involving rodents, there was no prior history of animal allergy. All workers had uncomplicated recoveries. Treatment, testing, and work restrictions varied across cases. CONCLUSIONS: While uncommon, anaphylaxis from laboratory animal bites occurs more frequently than suggested by the literature</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1536-5948 (Electronic)IS - 1076-2752 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/JOM.0000000000001005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28796663">PM:28796663</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Occup Environ Med\20170421-StaveGM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Occup Environ Med\20170421-StaveGM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Stave GM</style></custom2><misc3><style face="normal" font="Arial">10.1097/JOM.0000000000001005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ergun,O.</style></author><author><style face="normal" font="Arial"> Tahir,E.</style></author><author><style face="normal" font="Arial"> Kuscu,O.</style></author><author><style face="normal" font="Arial"> Ozgen,B.</style></author><author><style face="normal" font="Arial"> Yilmaz,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">General Practitioner Otorhinolaryngologist, Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Hacettepe University, Ankara, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Acute Invasive Fungal Rhinosinusitis: Presentation of 19 Cases, Review of the Literature, and a New Classification System</style></title><secondary-title><style face="normal" font="Arial">J Oral Maxillofac Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Oral Maxillofac Surg</style></full-title></periodical><pages end="767.e8" start="767">767-767.e8</pages><volume><style face="normal" font="Arial">75</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Disease</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal Agents</style></keyword><keyword><style face="normal" font="Arial"> antifungals</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Glucose</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Contrast Media</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Debridement</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic Imaging</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Hematologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immunocompromised Host</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Neutropenia</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Type 2 diabetes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The aim of this study was to determine the correlation between acute invasive fungal rhinosinusitis (AIFRS) and underlying diseases, micro-organisms, presenting symptoms, extent of disease, radiologic findings, and outcomes and propose a new classification system. MATERIALS AND METHODS: The data of 19 AIFRS cases were analyzed retrospectively. Magnetic resonance imaging and computed tomography were performed in all patients preoperatively. All patients underwent at least 1 surgical debridement. RESULTS: Hematologic diseases were the most common (52%) underlying diseases. Patients with type 2 diabetes and those with multiple etiologies causing immunosuppression had the lowest survival. Aspergillus and Mucoraceae species were isolated in 9 patients but were not associated with poor prognosis. Headache and nasal discharge or crusting were the most common presenting symptoms. Premaxillary involvement was significantly correlated with poor prognosis (P = .001). Unilateral involvement was correlated with poor prognosis, although this finding was not significant (P = .111). The overall mortality rate was 61.2%. Patients with neutropenia that was corrected had 80% survival (P = .014). Cessation of corticosteroids and regulating blood glucose levels in patients with immunosuppression from corticosteroid use resulted in 75% survival. CONCLUSION: There is no single curative treatment for AIFRS. For a favorable prognosis, underlying conditions must be treated in addition to surgical debridement and antifungals</style></abstract><notes><style face="normal" font="Arial">DA - 20161205IS - 1531-5053 (Electronic)IS - 0278-2391 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Antifungal Agents)RN - 0 (Contrast Media)SB - AIMSB - DSB - IMCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.joms.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27918884">PM:27918884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Oral Maxillofac Surg\2017-75-767-e8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Oral Maxillofac Surg\2017-75-767-e8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161205, Ergun O</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.joms.2016.11.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Flaherty,M.G.</style></author><author><style face="normal" font="Arial"> Kaplan,S.J.</style></author><author><style face="normal" font="Arial"> Jerath,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 University of North Carolina, Chapel Hill, NC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis of Life-Threatening Alpha-Gal Food Allergy Appears to Be Patient Driven</style></title><secondary-title><style face="normal" font="Arial">J Prim Care Community Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Prim Care Community Health</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> urgent care</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Patients exhibiting life-threatening symptoms associated with the alpha-gal food allergy (delayed urticaria or anaphylaxis due to mammalian meat) are frequently undiagnosed, causing unnecessary emergency department (ED) and health care visits, and extensive pain and suffering. This study aimed to determine the path to diagnosis experienced by alpha-gal patients. METHODS: Semistructured interviews were conducted from March to June 2016 with a chronological systematic sample of approximately 10% of patients diagnosed with alpha-gal and treated by the University of North Carolina Allergy and Immunology Clinic (n = 28). Main outcome measures included average length of time between first symptoms' appearance and diagnosis, number and type of health care encounters en route to diagnosis, and typical symptom severity. RESULTS: Six interviewees (21%) were diagnosed within a year of experiencing symptoms, of the remaining 22, mean time to diagnosis was 7.1 years. In over 100 medical encounters (including 28 ED visits and 2 urgent care) the correct diagnosis or effective diagnosing referral occurred less than 10% of the time. Seventy-one percent (20/28) described their first symptoms as severe. More patients found the allergist specializing in this condition on their own (n = 12; 43%) than those who were formally diagnosed or received referrals (n = 10; 36%) through the health care system. CONCLUSIONS: The medical community is challenged to stay abreast of emerging and newly uncovered illnesses through traditional medical literature communication channels. Presently, patients more often discover a diagnosis of alpha-gal allergy by using information resources on their own than by presenting to the ED with anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170427IS - 2150-1327 (Electronic)IS - 2150-1319 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/2150131917705714</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28447914">PM:28447914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Prim Care Community Health\20170427-FlahertyMG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Prim Care Community Health\20170427-FlahertyMG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170427, Flaherty MG</style></custom2><misc3><style face="normal" font="Arial">10.1177/2150131917705714</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Erban,T.</style></author><author><style face="normal" font="Arial"> Harant,K.</style></author><author><style face="normal" font="Arial"> Hubert,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Crop Research Institute, Drnovska 507/73, Prague 6-Ruzyne, Czechia.</style></auth-address><titles><title><style face="normal" font="Arial">Detailed two-dimensional gel proteomic mapping of the feces of the house dust mite Dermatophagoides pteronyssinus and comparison with D. farinae: Reduced trypsin protease content in D. pteronyssinus and different isoforms</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Chymotrypsin</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Der f 3</style></keyword><keyword><style face="normal" font="Arial"> Der f 6</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 3</style></keyword><keyword><style face="normal" font="Arial"> Der p 6</style></keyword><keyword><style face="normal" font="Arial"> Der p 9</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Ubiquitin</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="Arial">Major domestic mite allergens are present in feces. We present a detailed 2D-E-MS/MS proteomic analysis of the Dermatophagoides pteronyssinus feces. Precise cultivation yielded a pure fecal extract. We detected differences in fecal allergens/digestive enzymes between D. pteronyssinus and D. farinae using 2D-E fingerprinting, including unique information on species-specific protease isoforms. Proteomic analysis was performed by 2D-E coupled with MALDI-TOF/TOF identification. The species-specific differences in the fecal extracts of the mites were attributed to trypsin-like proteases known as group 3 allergens. In D. farinae, Der f 3 exhibited high abundance with a pI similar (acidic) to that of the cysteine protease Der f 1 and the chymotrypsin protease Der f 6, whereas in D. pteronyssinus, Der p 3 was rarely detected and exhibited low abundance only at basic pI. Moreover, Der p 9 was detected at a pI of ~ 10, in contrast to Der p 1 and Der p 6, suggesting different compartmentalization in the body. Overall, in D. pteronyssinus feces, allergens of groups 1, 2, 6, and 15 were quantitatively similar to those of D. farinae with the exception of the group 3 and 9 allergens. This work provides novel insights into mite-defecated proteins/digestive enzymes, which are important allergens. SIGNIFICANCE: Millions of people are affected by allergy and asthma, and their number is growing. In homes, the major triggers of allergy and asthma are the house dust mites Dermatophagoides farinae and D. pteronyssinus, and a clear understanding of the development of diseases caused by these mites is needed. The major sources of mite allergens are their feces, which are deposited in the environment and are easily inhaled as part of aeroplankton. However, descriptions of and comparisons between the major fecal allergens of these two mites are lacking. This study shows that similar group 1 (cysteine protease), 2 (NPC2 family), 6 (chymotrypsin) and 15 (chitinase-like) allergens are present in the feces of these two mite species, as determined by 2D-E mapping, whereas group 3 (trypsin) and 9 (collagenolytic protease) allergens in the feces of the two species are different. The results provide unique MS/MS mapped fingerprints of mite species-specific isoforms in feces. The presence of ubiquitin in mite feces suggests that these proteins participate in the post-translational modification of fecal proteins. The findings are essential for understanding differences between D. farinae and D. pteronyssinus with respect to immunoreactivity, protease activation mechanisms, association with microbes, and food utilization</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - engPT - Journal ArticleCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2017.04.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28442447">PM:28442447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170426-ErbanT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170426-ErbanT.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170426-ErbanTmmc2.xlsxC:\A&amp;H HMW Papers\J Proteomics\20170426-ErbanTmmc3.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170426-ErbanTmmc2.xlsxF:\A&amp;H HMW Papers\J Proteomics\20170426-ErbanTmmc3.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170426, Erban T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2017.04.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perez-Riverol,A.</style></author><author><style face="normal" font="Arial"> Dos Santos-Pinto,J.R.A.</style></author><author><style face="normal" font="Arial"> Lasa,A.M.</style></author><author><style face="normal" font="Arial"> Palma,M.S.</style></author><author><style face="normal" font="Arial"> Brochetto-Braga,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Biologia Molecular de Artropodes-LBMA-IBRC-UNESP (Univ Estadual Paulista), Av. 24-A, n degrees 1515, CEP 13506-900, Bela Vista, Rio Claro, SP, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Wasp venomic: Unravelling the toxins arsenal of Polybia paulista venom and its potential pharmaceutical applications</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bioactive compounds</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Biotechnological applications</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">Polybia paulista (Hymenoptera: Vespidae) is a neotropical social wasp from southeast Brazil. As most social Hymenoptera, venom from P. paulista comprises a complex mixture of bioactive toxins ranging from low molecular weight compounds to peptides and proteins. Several efforts have been made to elucidate the molecular composition of the P. paulista venom. Data derived from proteomic, peptidomic and allergomic analyses has enhanced our understanding of the whole envenoming process caused by the insect sting. The combined use of bioinformatics, -omics- and molecular biology tools have allowed the identification, characterization, in vitro synthesis and recombinant expression of several wasp venom toxins. Some of these P. paulista - derived bioactive compounds have been evaluated for the rational design of antivenoms and the improvement of allergy specific diagnosis and immunotherapy. Molecular characterization of crude venom extract has enabled the description and isolation of novel toxins with potential biotechnological applications. Here, we review the different approaches that have been used to unravel the venom composition of P. paulista. We also describe the main groups of P. paulista - venom toxins currently identified and analyze their potential in the development of component-resolved diagnosis of allergy, and in the rational design of antivenoms and novel bioactive drugs</style></abstract><notes><style face="normal" font="Arial">DA - 20170424IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2017.04.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28435107">PM:28435107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170424-PerezRiverolA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170424-PerezRiverolA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170424, Perez-Riverol A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2017.04.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,Y.</style></author><author><style face="normal" font="Arial"> Liu,H.</style></author><author><style face="normal" font="Arial"> Tu,M.</style></author><author><style face="normal" font="Arial"> Qiao,M.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author><author><style face="normal" font="Arial"> Du,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Food Science and Technology, National Engineering Research Center of Seafood, Dalian Polytechnic University, Dalian, 116034, China</style></auth-address><titles><title><style face="normal" font="Arial">Mass spectrometry analysis and in silico prediction of allergenicity of peptides in tryptic hydrolysates of the proteins from Ruditapes philippinarum</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> bioactive peptides</style></keyword><keyword><style face="normal" font="Arial"> Bivalve</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cytoskeleton</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> tryptic hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> UPLC</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The Ruditapes philippinarum is nutrient-rich and widely-distributed, but little attentions had been paid on the identification and characterization of bioactive peptides in the bivalve. In this study, we evaluated the peptides of the Ruditapes philippinarum enzymolysised by trypsin using a combination of UPLC separation and a ESI-Q-TOF-MS/MS spectrometer, followed by data processing, sequence-similarity database searching. The potential allergenicity of the peptides was assessed in silico. RESULT: The enzymolysis was performed under conditions as following, E:S 3:100 (w/w), pH 9.0, 45 degrees C for 4 h. After separation and detection, a Swiss-Prot database and a Ruditapes philippinarum sequence database were used, totally 966 unique peptides were identified by non-error tolerant database searching, 173 peptides matched 55 precursor proteins were highly conserved cytoskeleton protein. The rest 793 peptides were identified from the Ruditapes philippinarum sequence database. Results showed that 510 peptides were labeled as allergens and 31 peptides were potential allergens, 425 peptides were predicted to be non-allergens. CONCLUSION: The abundant peptide information would contribute to further studying the structure and potential function of the Ruditapes philippinarum. And further vitro studies would be performed in order to demonstrate and ensure correct production of the hydrolysates if used in food industry of the Ruditapes philippinarum</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8389</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425100">PM:28425100</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170420-YuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170420-YuY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Yu Y</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8389</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,C.</style></author><author><style face="normal" font="Arial"> Huang,R.</style></author><author><style face="normal" font="Arial"> Yao,R.</style></author><author><style face="normal" font="Arial"> Yang,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Xiangya Hospital of Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China</style></auth-address><titles><title><style face="normal" font="Arial">The Immunotherapeutic Role of Bacterial Lysates in a Mouse Model of Asthma</style></title><secondary-title><style face="normal" font="Arial">Lung</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lung</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bacterial lysate</style></keyword><keyword><style face="normal" font="Arial"> Bacterial lysates</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Recurrent respiratory tract infections</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Recurrent respiratory tract infections in young children, especially viral infections, are the major cause of acute asthmatic exacerbations and contribute to development of asthma. Bacterial extracts have been used to improve the immune defenses of the respiratory tract. However, seldom studies have examined the effect of bacterial lysates on childhood asthma. In this study, we examined whether bacterial lysates (OM-85) will improve symptoms of asthmatic mice via modulation of the immune response. METHODS: Asthmatic mice models were established with OVA challenge and treated with oral administration of Broncho-Vaxom (OM-85). Next, infiltrations of inflammatory cells including eosinophil and neutrophils were examined. Pulmonary tissues in asthmatic mice models were analyzed by hematoxylin and eosin (HE) staining. The levels of Th1/Th2-typed cytokines in bronchoalveolar lavage fluid (BALF) of asthmatic mice models were examined by enzyme-linked immunosorbent assay. RESULTS: Compared to control group, we found significant reduction of airway wall thickness, luminal stenosis, and mucus plug formation in asthmatic mice models after oral administration of OM-85. The infiltrations of eosinophil were also significantly decreased in BALF in asthmatic mice models. Oral administration of OM-85 was shown to suppress Th2-type cytokine levels. CONCLUSION: Our findings provide evidence that oral administration of OM-85 is capable of attenuating airway inflammation in asthmatic mice models. Oral administration of OM-85 may have a positive impact in terms of asthma severity</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1432-1750 (Electronic)IS - 0341-2040 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s00408-017-0003-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474108">PM:28474108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lung\20170505-LiuC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lung\20170505-LiuC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Liu C</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s00408-017-0003-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kasumagic-Halilovic,E.</style></author><author><style face="normal" font="Arial"> Beslic,N.</style></author><author><style face="normal" font="Arial"> Ovcina-Kurtovic,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, University Clinical Center Sarajevo, Bosnia and HerzegovinaDepartment of Nuclear Medicine and Endocrinology, University Clinical Center Sarajevo, Bosnia and HerzegovinaDepartment of Dermatology and Venereology, University Clinical Center Sarajevo, Bosnia and Herzegovina</style></auth-address><titles><title><style face="normal" font="Arial">Thyroid Autoimmunity in Patients with Chronic Urticaria</style></title><secondary-title><style face="normal" font="Arial">Med Arch</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Arch</style></full-title></periodical><pages end="31" start="29">29-31</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endocrinology</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nuclear medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thyroglobulin</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Hormones</style></keyword><keyword><style face="normal" font="Arial"> Thyroxine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: chronic urticaria (CU) is a skin disorder characterized by transient, pruritic wheals persisting for longer than 6 weeks. The etiopathogenesis of the disease is still unclear, but there is evidence that autoimmunity and endocrine dysfunction may be involved. AIM: the aim of this study was to determine whether chronic urticaria is statistically associated with thyroid autoimmunity. PATIENTS AND METHODS: in a prospective case-control study, we compared the frequency of thyroid auto-antibodies (thyroglobulin antibody, anti-Tg and thyroid peroxidase antibody, anti-TPO) in 70 patients with chronic urticaria and in 70 healthy volunteers. Thyroid auto-antibodies and thyroid hormones (thyroxine (T4), triiodthyronine (T3) and thyroid stimulating hormone (TSH) were measured in all subjects. RESULTS: thyroid functional abnormalities were found in 8 (11.43%) patients. Anti-Tg and anti-TPO were positive in 16 (23%) and 21 (30%) patients, respectively. In control group, only one subject (1.42%) had abnormalities in thyroid hormonal status, and two subjects (2.86%) had positive thyroid auto-antibodies. Compared with the control group, the frequency of both anti-Tg and anti-TPO was significantly higher in those with chronic urticaria (P &lt; 0.05). CONCLUSION: this study shows a significant association between chronic urticaria and thyroid autoimmunity, and that tests to detect thyroid auto-antibodies are relevant in patients with chronic urticaria</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 0350-199X (Print)IS - 0350-199X (Linking)LA - engPT - Journal ArticleCO - Bosnia and Herzegovina -</style></notes><work-type><style face="normal" font="Arial">10.5455/medarh.2017.71.29-31</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428670">PM:28428670</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Arch\2017-71-29-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Arch\2017-71-29-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Kasumagic-Halilovic E</style></custom2><misc3><style face="normal" font="Arial">10.5455/medarh.2017.71.29-31</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Michailopoulos,P.</style></author><author><style face="normal" font="Arial"> Almaliotis,D.</style></author><author><style face="normal" font="Arial"> Georgiadou,I.</style></author><author><style face="normal" font="Arial"> Papakosta,D.</style></author><author><style face="normal" font="Arial"> Gougoulias,K.</style></author><author><style face="normal" font="Arial"> Giouleka,P.</style></author><author><style face="normal" font="Arial"> Gioulekas,D.</style></author><author><style face="normal" font="Arial"> Siempis,T.</style></author><author><style face="normal" font="Arial"> Karampatakis,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary Department, 424 General Military Hospital of Thessaloniki, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Conjunctivitis in Patients with Respiratory Allergic Symptoms; a Retrospective Study in Greece</style></title><secondary-title><style face="normal" font="Arial">Med Hypothesis Discov Innov Ophthalmol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Med Hypothesis Discov Innov Ophthalmol</style></abbr-1></periodical><pages end="9" start="3">3-9</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Here, we report on the prevalence of allergic conjunctivitis and positive skin prick test (SPT) results in relation to respiratory allergic conditions among patients with symptoms of allergies at a respiratory outpatient clinic. A questionnaire survey of symptoms (i.e., asthma-like, rhinitis, and conjunctivitis symptoms) involving 1522 patients was carried out. The responses of 1242 patients indicated that they had allergic conjunctivitis, asthma, rhinitis, or a combination of these conditions, and 869 of these patients underwent SPTs that assessed responses to 40 allergens. Allergic conjunctivitis was found to be very common (40%, 497 out of 1242 patients) among those with symptoms of allergies. Conjunctivitis was slightly more common among women, while rhinitis was more common among men. Patients with both conjunctivitis and rhinitis were more likely to undergo SPTs, and they had a higher rate of positive SPTs. The coexistence of two or more comorbidities increased the risk of having an immunoglobulin E (IgE)-mediated allergy (based on the SPT results) compared to having each of the conditions alone. In conclusion, allergic conjunctivitis can occur either alone or with asthma and/or rhinitis. It is not always accompanied by rhinitis, but the coexistence of these conditions was the strongest indicator of IgE-mediated allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 2322-4436 (Print)IS - 2322-3219 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428968">PM:28428968</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Hypothesis Discov Innov Ophthalmol\2017-6-3-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Hypothesis Discov Innov Ophthalmol\2017-6-3-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Michailopoulos P</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gilbert,J.D.</style></author><author><style face="normal" font="Arial"> Grabowski,M.</style></author><author><style face="normal" font="Arial"> Byard,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Forensic Science SA, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Intravenous administration of cannabis and lethal anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Med Sci Law</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Sci Law</style></full-title></periodical><pages end="94" start="91">91-94</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Autopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> Cannabis</style></keyword><keyword><style face="normal" font="Arial"> Cannabis sativa</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Opiate</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Cannabis allergy appears to be increasing. A 33-year-old woman is reported who collapsed and died shortly after injecting herself with a cannabis solution prepared by pouring boiling water onto plant material. There were no significant findings at autopsy, except for a single recent venepuncture wound in the left cubital fossa. Toxicological examination of the blood revealed low levels of methylamphetamine and amphetamine with tetrahydrocannabinol (Delta9-THC) and 11-nor-9-carboxy-Delta9-THC, and no opiates. The syringe used by the decedent contained Delta9-THC. Serum tryptase levels were markedly elevated (>200 microg/L; N &lt; 12 microg/L). This finding coupled with the sudden collapse after injecting an aqueous extract of cannabis indicated a likely anaphylactic or anaphylactoid reaction to the extract. Cannabis allergy may occur following handling, inhalation, swallowing or injecting Cannabis sativa plants or their products. The possibility of an allergic reaction should therefore be considered at autopsy in deaths where there has been recent contact with cannabis</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 2042-1818 (Electronic)IS - 0025-8024 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1177/0025802417699343</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28438101">PM:28438101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Sci Law\2017-57-91-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Sci Law\2017-57-91-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Gilbert JD</style></custom2><misc3><style face="normal" font="Arial">10.1177/0025802417699343</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vidal-Quist,J.C.</style></author><author><style face="normal" font="Arial"> Ortego,F.</style></author><author><style face="normal" font="Arial"> Rombauts,S.</style></author><author><style face="normal" font="Arial"> Castanera,P.</style></author><author><style face="normal" font="Arial"> Hernandez-Crespo,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Insect-Plant Interaction, Department of Environmental Biology, Centro de Investigaciones Biologicas (CSIC), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Dietary shifts have consequences for the repertoire of allergens produced by the European house dust mite</style></title><secondary-title><style face="normal" font="Arial">Med Vet Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Vet Entomol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen composition</style></keyword><keyword><style face="normal" font="Arial"> Allergen genes</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Culture Media</style></keyword><keyword><style face="normal" font="Arial"> Culture medium</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Digestive Physiology</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immunodetection</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pyroglyphidae</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="Arial">Products manufactured from mass-cultured house dust mites, currently commercialized for the diagnosis and immunotherapy of allergy, are heterogeneous in terms of allergen composition and thus present concerns to regulatory authorities. The most abundant species, Dermatophagoides pteronyssinus (Trouessart) (Astigmata: Pyroglyphidae), produces 19 allergenic proteins. Many of these are putatively involved in mite digestive physiology and metabolism. This study aimed to evaluate the effects of mite-rearing media on allergen production. Mites were adapted to feed on culture media supplemented with proteins, lipids, carbohydrates or beard shavings, and collected to quantify major allergens (Der p 1 and 2) by immunodetection, transcription of allergen genes by real-time quantitative polymerase chain reaction, and allergen-related enzymatic activities. All culture media significantly affected the content of major allergens. Modification of macronutrients in the diet produced minor effects on the transcription of allergen genes, but significantly altered mite allergen-related activities. The most remarkable impacts were detected in mites feeding on beard shavings and were reflected in reductions in the content of major allergens, alterations in the transcription of nine allergen genes, and changes in eight allergen-related activities. These results demonstrate the importance of culture media to the quality and consistency of mite extracts used for pharmaceuticals, and highlight the need to further elucidate allergen production by mites in the laboratory and in domestic environments</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1365-2915 (Electronic)IS - 0269-283X (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/mve.12234</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28429373">PM:28429373</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Vet Entomol\20170421-VidalQuistJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Vet Entomol\20170421-VidalQuistJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Vidal-Quist JC</style></custom2><misc3><style face="normal" font="Arial">10.1111/mve.12234</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Radke,T.J.</style></author><author><style face="normal" font="Arial"> Brown,L.G.</style></author><author><style face="normal" font="Arial"> Faw,B.</style></author><author><style face="normal" font="Arial"> Hedeen,N.</style></author><author><style face="normal" font="Arial"> Matis,B.</style></author><author><style face="normal" font="Arial"> Perez,P.</style></author><author><style face="normal" font="Arial"> Viveiros,B.</style></author><author><style face="normal" font="Arial"> Ripley,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Restaurant Food Allergy Practices - Six Selected Sites, United States, 2014</style></title><secondary-title><style face="normal" font="Arial">MMWR Morb Mortal Wkly Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">MMWR Morb Mortal Wkly Rep</style></full-title></periodical><pages end="407" start="404">404-407</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Forum</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> restaurant</style></keyword><keyword><style face="normal" font="Arial"> Restaurants</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="Arial">Food allergies affect an estimated 15 million persons in the United States (1), and are responsible for approximately 30,000 emergency department visits and 150-200 deaths each year (2). Nearly half of reported fatal food allergy reactions over a 13-year period were caused by food from a restaurant or other food service establishment (3). To ascertain the prevalence of food allergy training, training topics, and practices related to food allergies, CDC's Environmental Health Specialists Network (EHS-Net), a collaborative forum of federal agencies and state and local health departments with six sites, interviewed personnel at 278 restaurants. Fewer than half of the 277 restaurant managers (44.4%), 211 food workers (40.8%), and 156 servers (33.3%) interviewed reported receiving food allergy training. Among those who reported receiving training, topics commonly included the major food allergens and what to do if a customer has a food allergy. Although most restaurants had ingredient lists for at least some menu items, few had separate equipment or areas designated for the preparation of allergen-free food. Restaurants can reduce the risk for allergic reactions among patrons by providing food allergy training for personnel and ingredient lists for all menu items and by dedicating equipment and areas specifically for preparing allergen-free food</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 1545-861X (Electronic)IS - 0149-2195 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.15585/mmwr.mm6615a2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28426639">PM:28426639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\MMWR Morb Mortal Wkly Rep\2017-66-404-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\MMWR Morb Mortal Wkly Rep\2017-66-404-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Radke TJ</style></custom2><misc3><style face="normal" font="Arial">10.15585/mmwr.mm6615a2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,M.</style></author><author><style face="normal" font="Arial"> Wan,J.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Zhang,D.</style></author><author><style face="normal" font="Arial"> Peng,J.</style></author><author><style face="normal" font="Arial"> Qi,C.</style></author><author><style face="normal" font="Arial"> Guo,Q.</style></author><author><style face="normal" font="Arial"> Xia,S.</style></author><author><style face="normal" font="Arial"> Su,Z.</style></author><author><style face="normal" font="Arial"> Wang,S.</style></author><author><style face="normal" font="Arial"> Xu,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Simultaneously increased expression of glucocorticoidinduced tumor necrosis factor receptor and its ligand contributes to increased interleukin5/13producing group 2 innate lymphocytes in murine asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="4299" start="4291">4291-4299</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> ST2</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="Arial">Glucocorticoidinduced tumor necrosis factor receptor (GITR) is expressed at high levels on CD4+CD25+ regulatory T cells (Tregs). Following activation by its ligand (GITRL), GITR influences the activity of effector T cells and Tregs and participates in the development of numerous autoimmune and inflammatory diseases, including asthma. However, the GITR/GITRL expression level in lung tissue and its influence on group 2 innate lymphocytes (ILC2s) in asthma remains unclear. The present study detected the number of ILC2s and the expression levels of GITR and GITRL in the lung tissues of asthmatic mice by flow cytometry analysis, immunofluorescence staining and reverse transcription quantitative polymerase chain reaction. The results demonstrated that the number of ILC2s and the expression levels of ILC2associated molecules (interleukin33 receptor ST2, RAR related orphan receptor A and inducible T cell costimulator) were increased in the lung tissues of asthmatic mice. The upregulated ILC2s were accompanied by an increased number of GITRpositive cells in the spleen and lung tissues, and additionally an increased level of GITRL mRNA in lung tissue in asthma. In addition, increased mRNA expression levels of interleukin (IL)5 and IL13 were observed in the asthmatic lung, and there was a significant, positive correlation between the mRNA levels of GITR/GITRL and ILC2associated molecules. Therefore, GITRL treatment may increase the number of ILC2s and/or GITRpositive cells in lung tissue. These results indicated that the activity of GITRexpressing ILC2s may be enhanced via interaction of GITRL and GITR, which may contribute to pathogenesis of asthma. These findings present potential therapeutic targets for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6500</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28440511">PM:28440511</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-15-4291-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-15-4291-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Zhang M</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6500</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Forkuo,G.S.</style></author><author><style face="normal" font="Arial"> Nieman,A.N.</style></author><author><style face="normal" font="Arial"> Yuan,N.Y.</style></author><author><style face="normal" font="Arial"> Kodali,R.</style></author><author><style face="normal" font="Arial"> Yu,O.B.</style></author><author><style face="normal" font="Arial"> Zahn,N.M.</style></author><author><style face="normal" font="Arial"> Jahan,R.</style></author><author><style face="normal" font="Arial"> Li,G.</style></author><author><style face="normal" font="Arial"> Stephen,M.R.</style></author><author><style face="normal" font="Arial"> Guthrie,M.L.</style></author><author><style face="normal" font="Arial"> Poe,M.M.</style></author><author><style face="normal" font="Arial"> Hartzler,B.D.</style></author><author><style face="normal" font="Arial"> Harris,T.W.</style></author><author><style face="normal" font="Arial"> Yocum,G.T.</style></author><author><style face="normal" font="Arial"> Emala,C.W.</style></author><author><style face="normal" font="Arial"> Steeber,D.A.</style></author><author><style face="normal" font="Arial"> Stafford,D.C.</style></author><author><style face="normal" font="Arial"> Cook,J.M.</style></author><author><style face="normal" font="Arial"> Arnold,L.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABAA Receptor Modulators</style></title><secondary-title><style face="normal" font="Arial">Mol Pharm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Pharm</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">We describe pharmacokinetic and pharmacodynamic properties of two novel oral drug candidates for asthma. Phenolic alpha4beta3gamma2 GABAAR selective compound 1 and acidic alpha5beta3gamma2 selective GABAAR positive allosteric modulator compound 2 relaxed airway smooth muscle ex vivo and attenuated airway hyperresponsiveness (AHR) in a murine model of asthma. Importantly, compound 2 relaxed acetylcholine contracted human tracheal airway smooth muscle strips. Oral treatment of compound 1 and 2 decreased eosinophils in bronchoalveolar lavage fluid in ovalbumin sensitized and challenged mice, thus exhibiting anti-inflammatory properties. Additionally, compound 1 reduced the number of lung CD4+ T lymphocytes and directly modulated their transmembrane currents by acting on GABAARs. Excellent pharmacokinetic properties were observed, including long plasma half-life (up to 15 hours), oral availability, and extremely low brain distribution. In conclusion, we report the selective targeting of GABAARs expressed outside the brain and demonstrate reduction of AHR and airway inflammation with two novel orally available GABAAR ligands</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 1543-8392 (Electronic)IS - 1543-8384 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.molpharmaceut.7b00183</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28440659">PM:28440659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Pharm\20170425-ForkuoGS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Pharm\20170425-ForkuoGS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Forkuo GS</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.molpharmaceut.7b00183</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhan,X.</style></author><author><style face="normal" font="Arial"> Xi,Y.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Zhao,J.</style></author><author><style face="normal" font="Arial"> Wei,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Life Sciences. Anhui Normal University. Wuhu, Anhui. China. Department of Medical Parasitology. Wannan Medical College. Wuhu, Anhui. China.</style></auth-address><titles><title><style face="normal" font="Arial">Composition and diversity of acaroids mites (Acari: Astigmata) community in the stored rhizomatic traditional Chinese medicinal materials</style></title><secondary-title><style face="normal" font="Arial">Nutr Hosp</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutr Hosp</style></full-title></periodical><pages end="459" start="454">454-459</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acari</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Herbs</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus putrescentiae</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the species and breeding density of ac a roid mites in the stored rhizomatic traditional Chinese medicinal materials in Anhui province, China, in order to supply evidences for control and prevention of such species. METHODS: The stored traditional Chinese medicinal materials of root-stock origins were collected in 30 herb stores and warehouses in 17 cities across Anhui province. Mites were collected by using Tullgren funnel and directicopy, and identified under microscopy. RESULTS: Twenty-two species of acaroid mites, belonging to 15 genera under 5 families, were identified from the total 47 stored samples, in which Tyrophagus putrescentiae, Acarus farinae, Carpoglyphus lactis, and Cologlyplus berlesei were predominant. CONCLUSION: Breeding density of acaroid mites was high in the stored rhizomatic traditional Chinese medicinal materials in Anhui province. This indicates that the traditional Chinese medicinal herbs of root-stock origins in storage are seriously contaminated by the acaroid mites, and such infestation should be positively controlled to reduce the potential harm to public health</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1699-5198 (Electronic)IS - 0212-1611 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.20960/nh.1164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28421804">PM:28421804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutr Hosp\2017-34-454-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutr Hosp\2017-34-454-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Zhan X</style></custom2><misc3><style face="normal" font="Arial">10.20960/nh.1164</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turlea,M.</style></author><author><style face="normal" font="Arial"> Cioca,D.P.</style></author><author><style face="normal" font="Arial"> Marza,F.</style></author><author><style face="normal" font="Arial"> Turlea,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Spitalul Municipal Arad, Sectia Oftalmologie</style></auth-address><titles><title><style face="normal" font="Arial">[Lacrimal assessment of lg E in cases with allergic conjunctivitis]</style></title><secondary-title><style face="normal" font="Arial">Oftalmologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oftalmologia</style></full-title></periodical><pages end="100" start="96">96-100</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2012 Tears</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis,Allergic</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lacrimal Apparatus</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Ocular allergy</style></keyword><keyword><style face="normal" font="Arial"> Ocular symptoms</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tear</style></keyword><keyword><style face="normal" font="Arial"> Tears</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2009">2009</year></dates><abstract><style face="normal" font="Arial">PURPOSE: To present the study regarding Ig E tears dosation in cases with allergic conjunctivitis. METHOD: The Ig E tear dosation was done on two study groups--group A with 124 patients presenting allergic conjunctivitis symptoms (58 with seasonal allergic conjunctivitis, 43 with atopic allergic ocular symptoms, 23 treated with olopatadina 0.1% for 10 days) and compare group B consisting of 40 healthy patients (no local or general allergic symptoms) evaluated in the the Ophthalmology Clinic Arad between 2002-2008. The biological material used in the study was that of tears samples. For the determination of Ig E we used ELISA method, HUMAN IMUNO IG E QUANTITATION (Bethyl Laboratoires, Montgomery, TX) test. RESULTS: Significant statistic high levels of IgE concentration were observed in study group A in patients with allergic seasonal conjunctivitis (331.11 +/- 125.22 ng/ml) and patients with atopic terrain (177.18 +/- 56.70) compared to group B (67.25 +/- 8.89 ng/ml) with healthy patients. In the study group with allergic seasonal conjunctivitis there have been significant diminished IgE levels (71.70 +/- 9.94) after treatment. CONCLUSION: The method of IgE tears dosation proved to be efficient in establishing the ethiology of ocular allergies and in the screening of new cases with allergic conjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20100405IS - 1220-0875 (Print)IS - 1220-0875 (Linking)LA - rumPT - English AbstractPT - Journal ArticleRN - 0 (Biomarkers)RN - 37341-29-0 (Immunoglobulin E)SB - IMCO - Romania -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="20361659">PM:20361659</url></web-urls></urls><custom2><style face="normal" font="Arial">20100405, Turlea M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mateos-Hernandez,L.</style></author><author><style face="normal" font="Arial"> Villar,M.</style></author><author><style face="normal" font="Arial"> Moral,A.</style></author><author><style face="normal" font="Arial"> Rodriguez,C.G.</style></author><author><style face="normal" font="Arial"> Arias,T.A.</style></author><author><style face="normal" font="Arial"> de la Osa,V.</style></author><author><style face="normal" font="Arial"> Brito,F.F.</style></author><author><style face="normal" font="Arial"> Fernandez de Mera,I.</style></author><author><style face="normal" font="Arial"> Alberdi,P.</style></author><author><style face="normal" font="Arial"> Ruiz-Fons,F.</style></author><author><style face="normal" font="Arial"> Cabezas-Cruz,A.</style></author><author><style face="normal" font="Arial"> Estrada-Pena,A.</style></author><author><style face="normal" font="Arial"> de la Fuente,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">SaBio, Instituto de Investigacion de Recursos Cinegeticos, IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Tick-host conflict: immunoglobulin E antibodies to tick proteins in patients with anaphylaxis to tick bite</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="20644" start="20630">20630-20644</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">13</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="Arial">Tick-borne infectious diseases and allergies are a growing problem worldwide. Tick bite allergy has been associated with the direct effect of immunoglobulin E (IgE) response to tick salivary antigens, or secondary to the induction of allergy to red meat consumption through IgE antibodies against the carbohydrate alpha-Gal (Gal alpha 1-3Gal beta 1-(3)4GlcNAc-R). However, despite the growing burden of this pathology, the proteins associated with anaphylaxis to tick bite have not been characterized. To address this question, a comparative proteomics approach was used to characterize tick proteins producing an IgE antibody response in a healthy individual with record of tick bites, which had not resulted in any allergic reactions, and two patients with anaphylactic reactions to Rhipicephalus bursa or Hyalomma marginatum tick bites. Both patients and the healthy individual were red meat tolerant. The results supported a patient-specific IgE antibody response to tick species responsible for the anaphylaxis to tick bite. Both patients and the healthy individual serologically recognized tick proteins with and without alpha-Gal modifications, with proteins differentially recognized by patients but not control sera. These proteins could be used as potential antigens for diagnostics, treatment and prevention of tick bite-induced allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Czech Republic -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.15243</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28423486">PM:28423486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\2017-8-20630-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\2017-8-20630-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Mateos-Hernandez L</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.15243</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gu,Z.W.</style></author><author><style face="normal" font="Arial"> Wang,Y.X.</style></author><author><style face="normal" font="Arial"> Cao,Z.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, China Medical University Affiliated Shengjing Hospital, Shenyang, Liaoning, China</style></auth-address><titles><title><style face="normal" font="Arial">Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2 and Th17 responses and upregulating the Treg response</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="22369" start="22361">22361-22369</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">14</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-17</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse model of AR</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> Th17 response</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) has long been considered to predominantly involve the actions of Th2 cells, with relatively small contributions from Th1 cells. In recent years, the discovery of Th17 and regulatory T (Treg) cells has rendered the Th1/Th2 balance paradigm more complex and expanded our understanding of the pathogenesis of AR. IL-17, a key cytokine produced by Th17 cells, is known to induce allergen-specific Th2 cell activation, eosinophil and neutrophil accumulation, and serum IgE production in asthma; all of these features may play important roles in AR. To the best of our knowledge, only a few studies have assessed the feasibility of using IL-17 antagonists to treat AR. Thus, the principal objectives of the present study were, first, to determine the status of Th17 and Treg cells in the nasal mucosa of a mouse model of AR, and, second, to investigate the effects of IL-17 on such cells and the therapeutic efficacy of anti-IL-17 antibodies (Abs) in the context of AR. Anti-IL-17 Abs were given intranasally during the re-challenge of BALB/c mice with ovalbumin (OVA)-induced AR. We measured the numbers of nasal rubbing motions and sneezes, eosinophil and neutrophil levels, Th1, Th2, Th17, and Treg parameters in the nasal mucosa. Anti-IL-17 Abs markedly reduced the number of nasal rubbing motions and sneezes, decreased eosinophil and neutrophil infiltration, reduced Th2 and Th17 responses, and increased the Treg response. Anti-IL-17 Ab treatment protects against AR. These results will improve our understanding of AR pathogenesis and may lead to the development of novel therapeutic approaches for management of the condition</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.15652</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28423590">PM:28423590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\2017-8-22361-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\2017-8-22361-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Gu ZW</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.15652</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,Q.</style></author><author><style face="normal" font="Arial"> Li,F.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Ma,J.</style></author><author><style face="normal" font="Arial"> Sheng,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Child and Adolescent Healthcare, MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200092, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Upregulation of calprotectin in mild IgE-mediated ovalbumin hypersensitivity</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> calprotectin</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="4" Year="2017">2017/4/8</year></dates><abstract><style face="normal" font="Arial">Calprotectin, also known as S100A8/A9, has been linked to gut inflammation caused by IgE-mediated food hypersensitivities, but the pathophysiologic abnormalities it causes remain to be determined. We created a mild food hypersensitivity model through oral gavage of ovalbumin in Norway brown rats without using immune adjuvant. Changes in the levels of calprotectin and inflammation-associated cytokines were then observed over time. We found that fecal calprotectin as well as jejunal and liver TLR4, TNF-alpha, NF-kappaB, IL-1beta, and IL-6 were upregulated in hypersensitive rats. Additionally, the influence of calprotectin on CD4+ T and dendritic cells was observed by co-culturing CD4+ T cells with dendritic cells, which revealed a shift toward increased Th2 T cells in calprotectin-treated cultures. These results suggest that calprotectin, along with other inflammatory factors, promotes the inflammation seen in mild food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.16954</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28454097">PM:28454097</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170428-ZhuQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170428-ZhuQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Zhu Q</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.16954</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodpai,R.</style></author><author><style face="normal" font="Arial"> Intapan,P.M.</style></author><author><style face="normal" font="Arial"> Thanchomnang,T.</style></author><author><style face="normal" font="Arial"> Sanpool,O.</style></author><author><style face="normal" font="Arial"> Janwan,P.</style></author><author><style face="normal" font="Arial"> Laummaunwai,P.</style></author><author><style face="normal" font="Arial"> Wongkham,C.</style></author><author><style face="normal" font="Arial"> Insawang,T.</style></author><author><style face="normal" font="Arial"> Maleewong,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Identification of antigenic proteins in Strongyloides stercoralis by proteomic analysis</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Cell Division</style></keyword><keyword><style face="normal" font="Arial"> cell signaling</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunoproteomics</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides</style></keyword><keyword><style face="normal" font="Arial"> Strongyloides stercoralis</style></keyword><keyword><style face="normal" font="Arial"> Strongyloidiasis</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Transportation</style></keyword><keyword><style face="normal" font="Arial"> Two dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1432-1955</style></isbn><abstract><style face="normal" font="Arial">Strongyloides stercoralis is an intestinal helminth that infects people worldwide. Hyperinfection or disseminated human strongyloidiasis can involve vital organs, leading to lethal outcomes. We analyzed immunoproteomics of antigenic spots, derived from S. stercoralis third-stage larvae and reacted with human strongyloidiasis sera, by two-dimensional gel electrophoresis and immunoblotting. Of 26 excised antigenic spots analyzed by liquid chromatography</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôelectrospray ionization</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôtandem mass spectrometry, 20 proteins were identified. Most proteins were associated with enzymes involved in the metabolic process, energy generation, and oxidation</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôreduction. The proteins relate to promotion of worm development, cell division, cell signaling and transportation, and regulation of muscular contraction. Identification of antigenic proteins shows promise in helping to discover potential diagnostic protein markers or vaccine candidates for S. stercoralis infection</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-017-5443-9</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00436-017-5443-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20170510-RodpaiR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20170510-RodpaiR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Rodpai R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-017-5443-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nam,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Physician's recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Patient Prefer Adherence</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Patient Prefer Adherence</style></full-title></periodical><pages end="387" start="381">381-387</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Education</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rush immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy (AIT) is currently the only immune-modifying treatment for allergic disease. The clinical efficacy of AIT for the treatment of allergic rhinitis and bronchial asthma is well documented. However, many factors including inconvenience, cost, side effects, and adherence influence the initiation and persistence of AIT, and patients lack knowledge and have misconceptions about the treatment. OBJECTIVE: We evaluated the knowledge, attitude, and satisfaction of patients who received AIT. METHODS: We conducted a retrospective analysis of medical records of 167 patients who received AIT, and compared the clinical characteristics between conventional immunotherapy (CIT) and rush immunotherapy (RIT). Ninety-nine patients completed a questionnaire survey. RESULTS: Of the total 167 patients, 65.9% (n=110) were treated with CIT and 34.1% (n=57) with RIT. More than half of the patients (68.7%) initiated AIT according to their physician's recommendation. Frequent hospital visits were the main barrier for persistence of AIT. RIT patients were younger and started AIT earlier than CIT patients. The majority (77%) of patients who received AIT were satisfied, with no significant difference between CIT and RIT groups. RIT and fewer allergens used in AIT were related with preference for AIT to pharmacotherapy. The longer duration of AIT was associated with higher treatment satisfaction. CONCLUSION: A majority of patients initiated AIT by the physician's recommendation and were satisfied with treatment regardless of CIT or RIT schedule. Adequate patient education and a strict patient-physician relationship in early AIT period could improve the effectiveness and compliance of AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 1177-889X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.2147/PPA.S118368</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28424541">PM:28424541</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Patient Prefer Adherence\2017-11-381-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Patient Prefer Adherence\2017-11-381-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Nam YH</style></custom2><misc3><style face="normal" font="Arial">10.2147/PPA.S118368</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kannan,J.A.</style></author><author><style face="normal" font="Arial"> Brokamp,C.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> LeMasters,G.K.</style></author><author><style face="normal" font="Arial"> Hershey,G.K.K.</style></author><author><style face="normal" font="Arial"> Villareal,M.S.</style></author><author><style face="normal" font="Arial"> Lockey,J.E.</style></author><author><style face="normal" font="Arial"> Ryan,P.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio</style></auth-address><titles><title><style face="normal" font="Arial">Parental Snoring and Environmental Pollutants, but Not Aeroallergen Sensitization, Are Associated with Childhood Snoring in a Birth Cohort</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="38" start="31">31-38</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Environmental Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> paternal</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Sleep Disorders</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Snoring</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> tobacco smoke</style></keyword><keyword><style face="normal" font="Arial"> traffic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">The objective of this study was to determine whether atopy and other clinical and environmental variables predict the risk of childhood habitual snoring (HS) in a birth cohort born to atopic parents. Participants completed clinical evaluations and questionnaires at ages 1-4 and age 7. HS was defined as snoring >/=3 nights/week. Traffic-related air pollution (TRAP) exposure was estimated using land-use regression. The association between early (&lt;/=age 4) and current (age 7) allergic disease, environmental exposures, and snoring at age 7 was examined using adjusted logistic regression. Of the 609 children analyzed the prevalence of HS at age 7 was 21%. Early tobacco smoke exposure [environmental tobacco smoke (ETS)] [odds ratio (OR) 1.79, 95% CI (confidence interval) 1.12-2.84], rhinitis (OR 1.74, 95% CI 1.06-2.92), wheezing (OR 1.63, 95% CI 1.05-2.53), maternal HS (OR 2.08, 95% CI 1.36-3.18), and paternal HS (OR 1.83, 95% CI 1.14-3.00) were significantly associated with HS at age 7. Current TRAP (OR 1.93, 95% CI 1.13-3.26), respiratory infections (OR 1.16, 95% 1.03-1.35), maternal HS (OR 2.86, 95% CI 1.69-4.84), and paternal HS (OR 3.01, 95% CI 1.82-5.09) were significantly associated with HS at age 7. To our knowledge, this is the largest birth cohort examining longitudinal predictors of snoring in children born to atopic parents. Parental HS was the only variable consistently associated with childhood HS from ages 1 to 7. Early rhinitis, early ETS exposure, and concurrent traffic pollution exposure increased the risk of HS at age 7, while aeroallergen sensitization did not. Children with these characteristics should be considered for screening of sleep disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 2151-321X (Print)IS - 2151-321X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2016.0681</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28465864">PM:28465864</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-31-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-31-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Kannan JA</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2016.0681</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmer,D.J.</style></author><author><style face="normal" font="Arial"> Prescott,S.L.</style></author><author><style face="normal" font="Arial"> Perkin,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Paediatrics and Child Health, The University of Western Australia, Perth, WA, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Early introduction of food reduces food allergy - Pro and Con</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="221" start="214">214-221</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161231IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12692</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28039897">PM:28039897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-214-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-214-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161231, Palmer DJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12692</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Polloni,L.</style></author><author><style face="normal" font="Arial"> Schiff,S.</style></author><author><style face="normal" font="Arial"> Ferruzza,E.</style></author><author><style face="normal" font="Arial"> Lazzarotto,F.</style></author><author><style face="normal" font="Arial"> Bonaguro,R.</style></author><author><style face="normal" font="Arial"> Toniolo,A.</style></author><author><style face="normal" font="Arial"> Celegato,N.</style></author><author><style face="normal" font="Arial"> Antonella,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Referral Centre for Food Allergy Diagnosis and Treatment, Veneto Region, Department of Women and Child Health, Padua University Hospital, Padua, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy and attitudes to close interpersonal relationships: an exploratory study on attachment</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="463" start="458">458-463</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is a common immunological disease that includes potentially fatal reactions. It impacts considerably on patients' social life including close interpersonal relationships. Attachment theory provides a theoretical framework to evaluate the quality of close interpersonal relationships in chronic disorders. Attachment insecurity, mainly characterized by attachment avoidance, has been found in a variety of health conditions, but still needs to be investigated in food allergy. The study aimed to investigate attachment, as attitude to close interpersonal relationships, among food-allergic young patients, compared to healthy controls. METHODS: This is a cross-sectional study involving patients suffering from IgE-mediated food allergy sequentially recruited and matched to healthy controls for age and gender. The Attachment Style Questionnaire (ASQ) was used to assess five factors and two attachment dimensions (Anxiety-Avoidance). Associations with anaphylaxis and adrenaline prescription were explored among patients. RESULTS: 174 participants were assessed (female=45%; Mean age=17.51; SD=4.26). Food-allergic patients reported significantly higher levels of Discomfort with closeness (p&lt;0.05), Relationships as secondary (p&lt;0.05) and Attachment Avoidance (p&lt;0.0001) compared to controls. CONCLUSIONS: Clinicians should be aware of implications of insecure attachment for health and illness. They should support patients in limiting social impairment finding a balance between safety and psychological wellbeing. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12732</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28480615">PM:28480615</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170508-PolloniL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170508-PolloniL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Polloni L</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12732</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kutlug,S.</style></author><author><style face="normal" font="Arial"> Kilic,M.</style></author><author><style face="normal" font="Arial"> Bilgici,B.</style></author><author><style face="normal" font="Arial"> Paksu,S.</style></author><author><style face="normal" font="Arial"> Yildiran,A.</style></author><author><style face="normal" font="Arial"> Sancak,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Pediatric Immunology and Allergy, Ondokuz Mayis Univesity, Samsun, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">An evaluation of vitamin D levels in children with seasonal allergic rhinitis during pollen season</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="451" start="446">446-451</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Serum vitamin D levels have not been studied in children with seasonal allergic rhinitis (SAR). The aim of this study was to evaluate the vitamin D levels of children with SAR and to compare them to levels in healthy children during pollen season. METHODS: This study was conducted in 100 children with SAR and 100 healthy controls. Clinical and laboratory evaluations and vitamin D analyses of all the participants were performed between the months of April and July. Pollen sensitization was detected in the patient group using a skin prick test. 25(OH)D3 levels were compared between the patient and control groups. Associations among the patient 25(OH)D3 levels and their demographic, clinical, and laboratory characteristics were analyzed. RESULTS: Overall, 72% of the patients were male, the median age was 12.35 years (range: 6-17.8 years), and the median body mass index value was 19.15 (range: 13.6-27.8). There were no differences between the patients and healthy controls in terms of gender, age, or body mass index. The mean levels of 25(OH)D3 (20.78 +/- 6) in patients were higher than those of the controls (17.92 +/- 4). In the patient group, no associations were found among 25(OH)D3 levels, demographic characteristics, atopy test results, atopy history, severity of rhinitis, and the total four-symptoms score (all p > 0.05). CONCLUSIONS: During pollen season, children with SAR may have higher vitamin D levels than healthy controls. The presence of asthma and/or atopic dermatitis in addition to SAR did not change this result. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12728</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28452068">PM:28452068</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170428-KutlugS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170428-KutlugS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Kutlug S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12728</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van der Valk,J.P.</style></author><author><style face="normal" font="Arial"> Vergouwe,Y.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Steyerberg,E.W.</style></author><author><style face="normal" font="Arial"> Reitsma,M.</style></author><author><style face="normal" font="Arial"> Wichers,H.J.</style></author><author><style face="normal" font="Arial"> Savelkoul,H.F.J.</style></author><author><style face="normal" font="Arial"> Vlieg-Boerstra,B.</style></author><author><style face="normal" font="Arial"> de Groot,H.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.J.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Allergology, Erasmus MC, Rotterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Prediction of cashew nut allergy in sensitised children</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="490" start="487">487-490</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic parameters</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">As an alternative to the costly, time-consuming and possibly stressful double-blind, placebo-controlled challenge (DBPCFC) test, a model to predict the risk of cashew nut allergy was studied incorporating patient characteristics, standard diagnostic parameters (specific IgE (sIgE) and Skin Prick Test (SPT)) as well as component resolved diagnosis (CRD This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12726</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28423473">PM:28423473</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170419-vanderValkJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170419-vanderValkJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, van der Valk JP</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12726</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loo,E.X.L.</style></author><author><style face="normal" font="Arial"> Sim,J.Z.T.</style></author><author><style face="normal" font="Arial"> Toh,J.Y.</style></author><author><style face="normal" font="Arial"> Goh,A.</style></author><author><style face="normal" font="Arial"> Teoh,O.H.</style></author><author><style face="normal" font="Arial"> Chan,Y.H.</style></author><author><style face="normal" font="Arial"> Saw,S.M.</style></author><author><style face="normal" font="Arial"> Kwek,K.</style></author><author><style face="normal" font="Arial"> Tan,K.H.</style></author><author><style face="normal" font="Arial"> Gluckman,P.D.</style></author><author><style face="normal" font="Arial"> Godfrey,K.M.</style></author><author><style face="normal" font="Arial"> van Bever,H.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Chong,Y.S.</style></author><author><style face="normal" font="Arial"> Chong,M.F.</style></author><author><style face="normal" font="Arial"> Shek,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Relation of infant dietary patterns to allergic outcomes in early childhood</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="495" start="490">490-495</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental influence</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">Allergic disorders result from the complex interplay between genetic predisposition and environmental influences. According to the Developmental Origins of Health and Disease hypothesis, environmental pressures at critical or early periods of development can evoke persisting changes in gene regulation and expression (1), affecting disease development. Infant nutrition is a major environmental influence in early life as the immature gut is exposed to a variety of food proteins. However, results from studies examining the early introduction of allergenic food and allergic outcomes have been conflicting. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Singapore -CO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12727</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28452075">PM:28452075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170428-LooEX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170428-LooEX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, LooEX</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12727</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pneumology and Immunology, Charite Universitatsmedizin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Early introduction of food reduces food allergy - Does it?</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="213" start="212">212-213</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170424IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - EditorialCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12713</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28436111">PM:28436111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-212-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-212-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170424, Beyer K</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12713</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Esfahani,A.</style></author><author><style face="normal" font="Arial"> Chamlin,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, IllinoisDivision of Dermatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="Arial">Garlic Dermatitis on the Neck of an Infant Treated for Nasal Congestion</style></title><secondary-title><style face="normal" font="Arial">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Dermatol</style></full-title></periodical><pages end="e213" start="e212">e212-e213</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allium</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Garlic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health benefit</style></keyword><keyword><style face="normal" font="Arial"> Health benefits</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">The health benefits of garlic (Allium sativum) as a naturopathic remedy have been well documented, but topical application of garlic has been linked to allergic and irritant contact dermatitis. We present a case of severe irritant contact dermatitis due to application of a fresh garlic necklace to the neck of infant for treatment of nasal congestion</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pde.13147</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425131">PM:28425131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Dermatol\20170420-EsfahaniA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Dermatol\20170420-EsfahaniA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Esfahani A</style></custom2><misc3><style face="normal" font="Arial">10.1111/pde.13147</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van der Lee,S.</style></author><author><style face="normal" font="Arial"> Kemmeren,J.M.</style></author><author><style face="normal" font="Arial"> de Rond,L.G.H.</style></author><author><style face="normal" font="Arial"> Ozturk,K.</style></author><author><style face="normal" font="Arial"> Westerhof,A.</style></author><author><style face="normal" font="Arial"> de Melker,H.E.</style></author><author><style face="normal" font="Arial"> Sanders,E.A.M.</style></author><author><style face="normal" font="Arial"> Berbers,G.A.M.</style></author><author><style face="normal" font="Arial"> van der Maas,N.A.T.</style></author><author><style face="normal" font="Arial"> Rumke,H.C.</style></author><author><style face="normal" font="Arial"> Buisman,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1.Centre for Infectious Disease Control, National institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands 2.Department of Peadiatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands 3.Netherlands Pharmacovigilance Centre Lareb, 's Hertogenbosch, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Elevated Immune Response Among Children 4 Years Of Age With Pronounced Local Adverse Events After The Fifth Dtap Vaccination</style></title><secondary-title><style face="normal" font="Arial">Pediatr Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Infect Dis</style></full-title></periodical><pages end="e229" start="e223">e223-e229</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Diphtheria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunization Schedule</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> Pertussis Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Tetanus</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In the Netherlands, acellular pertussis vaccines replaced the more reactogenic whole-cell pertussis vaccines. This replacement in the primary immunization schedule of infants coincided with a significant increase in pronounced local adverse events (AEs) in 4 years old children shortly after the administration of a fifth diphtheria, tetanus, acellular pertussis and inactivated polio (DTaP-IPV) vaccine. The objective of this study was to investigate possible differences in vaccine antigen-specific immune responses between children with and without a pronounced local AE after the fifth DTaP-IPV vaccination. METHODS: Blood was sampled in two groups of four year olds: a case group reporting pronounced local swelling and/or erythema up to extensive limb swelling at the injection site (n=30) and a control group (n=30). PBMCs were stimulated with individual vaccine antigens. Plasma antigen-specific IgG, IgG-subclass and total IgE concentrations, and T-cell cytokine (IFN-gamma, IL-13, IL-17 and IL-10) production by stimulated PBMCs were determined by multiplex bead-based-fluorescent multiplex immunoassays. RESULTS: In children with AEs, significantly higher total IgE and vaccine antigen-specific IgG and IgG4 responses as well as levels of the Th2 cytokine IL-13 were found after pertussis, tetanus and diphtheria stimulation compared with controls. CONCLUSIONS: Children with pronounced local reactions show higher humoral and cellular immune responses. Acellular vaccines are known to skew towards more Th2 responses. The pronounced local AEs may be associated with more Th2-skewing after the fifth DTaP-IPV vaccination, but other biologic factors may also impact the occurrence of these pronounced local reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1532-0987 (Electronic)IS - 0891-3668 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1097/INF.0000000000001620</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28430750">PM:28430750</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Infect Dis\20170421-vanderLeeS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Infect Dis\20170421-vanderLeeS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, van der Lee S</style></custom2><misc3><style face="normal" font="Arial">10.1097/INF.0000000000001620</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kimura,M.</style></author><author><style face="normal" font="Arial"> Shimomura,M.</style></author><author><style face="normal" font="Arial"> Morishita,H.</style></author><author><style face="normal" font="Arial"> Meguro,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Shizuoka Children's Hospital, Shizuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Prognosis of infantile food protein-induced enterocolitis syndrome in Japan</style></title><secondary-title><style face="normal" font="Arial">Pediatr Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Int</style></full-title></periodical><pages end="860" start="855">855-860</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although the serum C-reactive protein (CRP) level and the percentage of eosinophils in peripheral blood (Eo) are increased at onset in infants with food protein-induced enterocolitis syndrome (FPIES), the relationship of these laboratory findings with the prognosis is presently unknown. METHODS: Correlations of the serum CRP levels and Eo at onset with the prognosis was analyzed in 32 patients with FPIES caused by cow's milk (CM). RESULTS: The rate of tolerance acquisition was 18.8, 56.3, 87.5, and 96.9% at the ages of 6, 12, 24, and 36 months, respectively. The serum CRP level increased in 50% of subjects at onset (median 0.21 mg/dL, range &lt;0.20-18.2 mg/dL) and Eo elevated in 71.9% of subjects at onset (7.1%, 1.0-50.5%). The time of tolerance acquisition showed a significant positive correlation with the serum CRP level at onset (r=0.45, p&lt;0.01), while it had a significant negative correlation with Eo at onset (r=-0.36, p&lt;0.05). Although CM-specific IgE antibody (sIgE) was positive in 9 of 32 FPIES patients at onset (median 0.93, range 0.38-18.9 kU/L), it decreased thereafter. CM-sIgE at onset did not correlate significantly with the prognosis (r=0.22, p>0.05). CONCLUSIONS: These results suggest that the serum CRP level is not only an indicator of the activity of intestinal inflammation, but also a useful parameter of poor prognosis in patients with FPIES. By contrast, eosinophilia at onset could be used as a maker of good prognosis, suggesting to have some beneficial effects in pathophysiology of FPIES. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170422IS - 1442-200X (Electronic)IS - 1328-8067 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/ped.13305</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28432705">PM:28432705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Int\20170422-KimuraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Int\20170422-KimuraM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170422, Kimura M</style></custom2><misc3><style face="normal" font="Arial">10.1111/ped.13305</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inam,A.</style></author><author><style face="normal" font="Arial"> Shahzad,M.</style></author><author><style face="normal" font="Arial"> Shabbir,A.</style></author><author><style face="normal" font="Arial"> Shahid,H.</style></author><author><style face="normal" font="Arial"> Shahid,K.</style></author><author><style face="normal" font="Arial"> Javeed,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Carica papaya ameliorates allergic asthma via down regulation of IL-4, IL-5, eotaxin, TNF-+¦, NF--©B, and iNOS levels</style></title><secondary-title><style face="normal" font="Arial">Phytomedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Phytomedicine</style></full-title></periodical><pages end="7" start="1">1-7</pages><volume><style face="normal" font="Arial">32</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abbreviations: Carica papaya leaves (CPL)</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Bronchoaveolar lavage fluid (BALF)</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Differential leukocyte count (DLC)</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Discovery</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inducible nitric oxide synthase (iNOS)</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4 (IL-4)</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5 (IL-5)</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocyte Count</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nuclear factor-kappaB (NF--©B)</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin (OVA)</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> papaya</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T helper cells (Th)</style></keyword><keyword><style face="normal" font="Arial"> Th2-type immunity</style></keyword><keyword><style face="normal" font="Arial"> TNF-+¦</style></keyword><keyword><style face="normal" font="Arial"> Total leukocyte count (TLC)</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor necrosis factor-+¦ (TNF-+¦,)</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0944-7113</style></isbn><abstract><style face="normal" font="Arial">Background Natural products have a prime importance as an essential source for new drug discovery. Carica papaya leaves (CPL) have been used to treat inflammation in traditional system of medicine. Aim/hypothesis Current study evaluates the anti-inflammatory and immunomodulatory effects of CPL extract using mouse model of ovalbumin- (OVA) induced allergic asthma. Methods All the mice were intraperitoneally sensitized and subsequently given intranasal challenge with OVA except the control group. Group-III and -IV were treated for seven consecutive days with CPL extract and methylprednisolone (MP), respectively. At the end of study, histopathological examination of the lungs was performed and inflammatory cell counts were done in blood as well as bronchoalveolar lavage fluid (BALF). The mRNA expression levels of IL-4, IL-5, eotaxin, TNF-+¦, NF--©B, and iNOS were measured using reverse transcription polymerase chain reaction (RT-PCR). Results Results showed significant attenuation of lung infiltration of inflammatory cells, alveolar thickening, and goblet cell hyperplasia after treatment with CPL extract. We also found significant suppression of total and differential leukocyte counts in both blood and BALF samples of CPL extract treated group. CPL extract also alleviated the expression levels of IL-4, IL-5, eotaxin, TNF-+¦, NF--©B, and iNOS. Similarly, treatment with MP, used as a reference drug, also significantly ameliorated all the pro-inflammatory markers. Conclusion Current study shows that CPL extract possesses anti-inflammatory effect in mouse model of allergic airway inflammation by down-regulating IL-4, IL-5, eotaxin, TNF-+¦, NF--©B, and iNOS expression levels</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Pakistan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.phymed.2017.04.009</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.phymed.2017.04.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Phytomedicine\20170511-InamA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Phytomedicine\20170511-InamA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Inam A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.phymed.2017.04.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sebastiani,L.</style></author><author><style face="normal" font="Arial"> Busconi,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Recent developments in olive (Olea europaea L.) genetics and genomics: applications in taxonomy, varietal identification, traceability and breeding</style></title><secondary-title><style face="normal" font="Arial">Plant Cell Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Cell Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Applications</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Taxonomy</style></keyword><keyword><style face="normal" font="Arial"> Traceability</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1432-203X</style></isbn><abstract><style face="normal" font="Arial">The latest results in DNA markers application and genomic studies in olive</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00299-017-2145-9</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00299-017-2145-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Cell Rep\20170511-SebastianiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Cell Rep\20170511-SebastianiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Sebastiani L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00299-017-2145-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kallieri,M.</style></author><author><style face="normal" font="Arial"> Papaioannou,A.I.</style></author><author><style face="normal" font="Arial"> Papathanasiou,E.</style></author><author><style face="normal" font="Arial"> Ntontsi,P.</style></author><author><style face="normal" font="Arial"> Papiris,S.</style></author><author><style face="normal" font="Arial"> Loukides,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a 2nd Respiratory Medicine Department, "Attikon" University Hospital, Athens Medical School , National and Kapodistrian University of Athens , Greece</style></auth-address><titles><title><style face="normal" font="Arial">Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study</style></title><secondary-title><style face="normal" font="Arial">Postgrad Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postgrad Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody, used for the treatment of severe refractory allergic asthma. However, not all patients with IgE levels within the limits of administration, respond to treatment. The aim of the present study, was to determine clinical and inflammatory characteristics that could predict response to omalizumab. METHODS: We studied retrospectively patients treated with omalizumab as per GINA guidelines in one asthma tertiary referral center. Demographic and functional characteristics, level of asthma control, fractional exhaled nitric oxide, blood and eosinophils and IgE level, induced sputum cell count, eosinophil cationic protein and Interleukin-13 in sputum supernatant were recorded. All measurements were performed before starting treatment with omalizumab. Response to treatment was evaluated according to the physician's global evaluation of treatment effectiveness. Patients were characterized as early responders when improvement was achieved within 16 weeks and as late responders when improvement was achieved between 16 and 32 weeks. Patients who did not show any improvement after 32 weeks of therapy were considered as non-responders. RESULTS: Forty-one patients treated with omalizumab were included in the study. 28 (68.3%) patients were characterized as responders while 13 patients (31.7%) were considered as non-responders. Among responders, 25 (89%) were early responders and 3 (n=11%) were late responders. Responders were characterized by lower baseline FEV1 and FEV1/FVC and higher IL-13 levels in induced sputum supernatant compared to non-responders. Late responders had higher serum IgE levels, shorter disease duration and higher number of blood eosinophils. Finally, using ROC curve analysis, the best predictors of response to omalizumab were FEV1 (AUC=0.718) and IL-13 in sputum supernatant (AUC=0.709). CONCLUSION: Lower baseline FEV1 and higher IL-13 levels in induced sputum supernatant were predictors of response to omalizumab. Patients with higher baseline serum IgE levels, shorter disease duration and higher blood eosinophils may experience a late response and might benefit from a more prolonged treatment before being characterized as non-responders</style></abstract><notes><style face="normal" font="Arial">DA - 20170421IS - 1941-9260 (Electronic)IS - 0032-5481 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1080/00325481.2017.1321945</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28427296">PM:28427296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postgrad Med\20170421-KallieriM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postgrad Med\20170421-KallieriM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170421, Kallieri M</style></custom2><misc3><style face="normal" font="Arial">10.1080/00325481.2017.1321945</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marinheiro,R.</style></author><author><style face="normal" font="Arial"> Amador,P.</style></author><author><style face="normal" font="Arial"> Semedo,F.</style></author><author><style face="normal" font="Arial"> Sa,C.</style></author><author><style face="normal" font="Arial"> Duarte,T.</style></author><author><style face="normal" font="Arial"> Goncalves,S.</style></author><author><style face="normal" font="Arial"> Seixo,F.</style></author><author><style face="normal" font="Arial"> Caria,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servico de Cardiologia, Centro Hospitalar de Setubal, Setubal, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">In-hospital acute myocardial infarction: A case of type II Kounis syndrome</style></title><secondary-title><style face="normal" font="Arial">Rev Port Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Cardiol</style></full-title></periodical><pages end="" start="391">391-</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Coronary Angiography</style></keyword><keyword><style face="normal" font="Arial"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="Arial"> Coronary Vasospasm</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exanthema</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">Kounis syndrome (KS) is the coincidental occurrence of acute coronary syndrome (ACS) and anaphylactic or allergic insult. It results from mast cell degranulation with subsequent release of numerous inflammatory mediators, leading to coronary vasospasm or atheromatous plaque rupture. Diagnosis is clinical and based on the temporal relationship between the two events. Despite the growing number of reported cases, especially in southern Europe, the lack of awareness of this association may lead to under-reporting in Portugal. Recognition of KS, even if retrospective, has clinical implications since individual atopy must be investigated and desensitization measures should be employed, if possible, to prevent future events. We report the case of a 70-year-old man who was admitted to hospital because of generalized exanthema and itching and onset of chest pain while under observation. Coronary angiography confirmed coronary artery disease and ACS and he was diagnosed as having type II KS</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 2174-2030 (Electronic)IS - 0870-2551 (Linking)LA - engLA - porPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.repc.2016.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449974">PM:28449974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Cardiol\20170428-MarinheiroR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Cardiol\20170428-MarinheiroR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Marinheiro R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.repc.2016.07.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pettersson,H.</style></author><author><style face="normal" font="Arial"> Zarnegar,B.</style></author><author><style face="normal" font="Arial"> Westin,A.</style></author><author><style face="normal" font="Arial"> Persson,V.</style></author><author><style face="normal" font="Arial"> Peuckert,C.</style></author><author><style face="normal" font="Arial"> Jonsson,J.</style></author><author><style face="normal" font="Arial"> Hallgren,J.</style></author><author><style face="normal" font="Arial"> Kullander,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neuroscience, Uppsala University, Box 593, 751 24, Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">SLC10A4 regulates IgE-mediated mast cell degranulation in vitro and mast cell-mediated reactions in vivo</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="1085">1085-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell protease</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Passive cutaneous anaphylaxis reaction</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">Mast cells act as sensors in innate immunity and as effector cells in adaptive immune reactions. Here we demonstrate that SLC10A4, also referred to as the vesicular aminergic-associated transporter, VAAT, modifies mast cell degranulation. Strikingly, Slc10a4 -/- bone marrow-derived mast cells (BMMCs) had a significant reduction in the release of granule-associated mediators in response to IgE/antigen-mediated activation, whereas the in vitro development of mast cells, the storage of the granule-associated enzyme mouse mast cell protease 6 (mMCP-6), and the release of prostaglandin D2 and IL-6 were normal. Slc10a4-deficient mice had a strongly reduced passive cutaneous anaphylaxis reaction and a less intense itching behaviour in response to the mast cell degranulator 48/80. Live imaging of the IgE/antigen-mediated activation showed decreased degranulation and that ATP was retained to a higher degree in mast cell granules lacking SLC10A4. Furthermore, ATP was reduced by two thirds in Slc10a4 -/- BMMCs supernatants in response to IgE/antigen. We speculate that SLC10A4 affects the amount of granule-associated ATP upon IgE/antigen-induced mast cell activation, which affect the release of granule-associated mast cell mediators. In summary, SLC10A4 acts as a regulator of degranulation in vitro and of mast cell-related reactions in vivo</style></abstract><notes><style face="normal" font="Arial">DA - 20170425IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-01121-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28439090">PM:28439090</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-1085.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-1085.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170425, Pettersson H</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-01121-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sun,L.</style></author><author><style face="normal" font="Arial"> Ren,X.</style></author><author><style face="normal" font="Arial"> Wang,I.C.</style></author><author><style face="normal" font="Arial"> Pradhan,A.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Flood,H.M.</style></author><author><style face="normal" font="Arial"> Han,B.</style></author><author><style face="normal" font="Arial"> Whitsett,J.A.</style></author><author><style face="normal" font="Arial"> Kalin,T.V.</style></author><author><style face="normal" font="Arial"> Kalinichenko,V.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China</style></auth-address><titles><title><style face="normal" font="Arial">The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice</style></title><secondary-title><style face="normal" font="Arial">Sci Signal</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Signal</style></full-title></periodical><pages end="" start="eaai8583">eaai8583-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">475</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Compliance</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="Arial">Goblet cell metaplasia and excessive mucus secretion associated with asthma, cystic fibrosis, and chronic obstructive pulmonary disease contribute to morbidity and mortality worldwide. We performed a high-throughput screen to identify small molecules targeting a transcriptional network critical for the differentiation of goblet cells in response to allergens. We identified RCM-1, a nontoxic small molecule that inhibited goblet cell metaplasia and excessive mucus production in mice after exposure to allergens. RCM-1 blocked the nuclear localization and increased the proteasomal degradation of Forkhead box M1 (FOXM1), a transcription factor critical for the differentiation of goblet cells from airway progenitor cells. RCM-1 reduced airway resistance, increased lung compliance, and decreased proinflammatory cytokine production in mice exposed to the house dust mite and interleukin-13 (IL-13), which triggers goblet cell metaplasia. In cultured airway epithelial cells and in mice, RCM-1 reduced IL-13 and STAT6 (signal transducer and activator of transcription 6) signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3, which are key transcriptional regulators of goblet cell differentiation. These results suggest that RCM-1 is an inhibitor of goblet cell metaplasia and IL-13 signaling, providing a new therapeutic candidate to treat patients with asthma and other chronic airway diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1937-9145 (Electronic)IS - 1945-0877 (Linking)LA - engPT - Journal ArticleCO - China -CO - Taiwan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1126/scisignal.aai8583</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28420758">PM:28420758</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Signal\2017-10-eaai8583.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Signal\2017-10-eaai8583.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170419, Sun L</style></custom2><misc3><style face="normal" font="Arial">10.1126/scisignal.aai8583</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yaffe,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Science Signaling, AAAS, Washington, DC 20005, USA; David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA</style></auth-address><titles><title><style face="normal" font="Arial">Highlight: A new way to block the development of asthma from dust mites</style></title><secondary-title><style face="normal" font="Arial">Sci Signal</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Signal</style></full-title></periodical><pages end="" start="eaan3693">eaan3693-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">475</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="Arial">Targeting a transcription factor, generally considered to be "nondruggable," may help to prevent asthma from developing.Asthma, an inflammatory airway disease with a typical onset in childhood, is increasingly being diagnosed in inner city populations. Exposure to airborne allergens from decaying house dust mites is thought to be a major contributor to asthma development. In this issue of Science Signaling, Sun et al. identified a small molecule inhibitor of FOXM1, a transcription factor that controls critical cellular changes associated with asthma development, and a member of a broad class of molecules generally considered "undruggable." The drug-named RCM-1 after Robert Costa, the late scientist who identified the human FOXM1 gene-markedly reduced cytokine production in the lungs, suppressed airway mucus accumulation, and markedly ameliorated both the lung tissue changes and invasion of inflammatory cells into the peribronchial space seen in mice exposed to extracts of house dust mites or interleukin-13, a proinflammatory cytokine that is central to the pathogenesis of asthma. The drug, or optimized versions of it, may be of direct benefit to patients in the early stages of asthma, and the work provides clear evidence that targeting of "nondruggable" targets such as transcription factors is both possible and promising.</style></abstract><notes><style face="normal" font="Arial">DA - 20170419IS - 1937-9145 (Electronic)IS - 1945-0877 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1126/scisignal.aan3693</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28420752">PM:28420752</url></web-urls><pdf-urls><url ppv-ref="no">pdf</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170419, Yaffe M</style></custom2><misc3><style face="normal" font="Arial">10.1126/scisignal.aan3693</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Metz,M.</style></author><author><style face="normal" font="Arial"> Staubach,P.</style></author><author><style face="normal" font="Arial"> Bauer,A.</style></author><author><style face="normal" font="Arial"> Brehler,R.</style></author><author><style face="normal" font="Arial"> Gericke,J.</style></author><author><style face="normal" font="Arial"> Kangas,M.</style></author><author><style face="normal" font="Arial"> Ashton-Chess,J.</style></author><author><style face="normal" font="Arial"> Jarvis,P.</style></author><author><style face="normal" font="Arial"> Georgiou,P.</style></author><author><style face="normal" font="Arial"> Canvin,J.</style></author><author><style face="normal" font="Arial"> Hillenbrand,R.</style></author><author><style face="normal" font="Arial"> Erpenbeck,V.J.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Charite - Universitatsmedizin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcepsilonRI-positive cells in the skin</style></title><secondary-title><style face="normal" font="Arial">Theranostics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Theranostics</style></abbr-1></periodical><pages end="1276" start="1266">1266-1276</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omalizumab on levels of high affinity IgE receptor-positive (FcepsilonRI+) and IgE-positive (IgE+) dermal cells and blood basophils. Treatment efficacy and safety were also assessed. Study design. In a double-blind study, CSU patients aged 1875 years were randomized to receive 300 mg omalizumab (n=20) or placebo (n=10) subcutaneously every 4 weeks for 12 weeks. Changes in disease activity were assessed by use of the weekly Urticaria Activity Score (UAS7). Circulating IgE levels, basophil numbers and levels of expression of FcepsilonRI+ and IgE+ cells in the skin and in blood basophils were determined. Results. Patients receiving omalizumab showed a significantly greater decrease in UAS7 compared with patients receiving placebo. At Week 12 the mean difference in UAS7 between treatment groups was -14.82 (p=0.0027), consistent with previous studies. Total IgE levels in serum were increased after omalizumab treatment and remained elevated up to Week 12. Free IgE levels decreased after omalizumab treatment. Mean levels of FcepsilonRI+ skin cells in patients treated with omalizumab 300 mg were decreased at Week 12 compared with baseline in the dermis of both non-lesional and lesional skin, reaching levels comparable with those seen in healthy volunteers (HVs). There were no statistically significant changes in mean FcvarepsilonRI+ cell levels in the placebo group. Similar results were seen for changes in IgE+ cells, although the changes were not statistically significant. The level of peripheral blood basophils increased immediately after treatment start and returned to Baseline values after the follow-up period. The levels of FcepsilonRI and IgE expression on peripheral blood basophils were rapidly reduced by omalizumab treatment up to Week 12. Conclusions. Treatment with omalizumab resulted in rapid clinical benefits in patients with CSU. Treatment with omalizumab was associated with reduction in FcvarepsilonRI+ and IgE+ basophils and intradermal cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170424IS - 1838-7640 (Electronic)IS - 1838-7640 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.7150/thno.18304</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28435464">PM:28435464</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Theranostics\2017-7-1266-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Theranostics\2017-7-1266-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170424, Metz M</style></custom2><misc3><style face="normal" font="Arial">10.7150/thno.18304</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aspevik,T.</style></author><author><style face="normal" font="Arial"> Oterhals,A.</style></author><author><style face="normal" font="Arial"> Ronning,S.B.</style></author><author><style face="normal" font="Arial"> Altintzoglou,T.</style></author><author><style face="normal" font="Arial"> Wubshet,S.G.</style></author><author><style face="normal" font="Arial"> Gildberg,A.</style></author><author><style face="normal" font="Arial"> Afseth,N.K.</style></author><author><style face="normal" font="Arial"> Whitaker,R.D.</style></author><author><style face="normal" font="Arial"> Lindberg,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nofima AS, P.B. 1425 Oasen, 5828, Bergen, Norway</style></auth-address><titles><title><style face="normal" font="Arial">Valorization of Proteins from Co- and By-Products from the Fish and Meat Industry</style></title><secondary-title><style face="normal" font="Arial">Top Curr Chem (J)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Top Curr Chem (J)</style></abbr-1></periodical><pages end="" start="53">53-</pages><volume><style face="normal" font="Arial">375</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Aquaculture</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Feathers</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fisheries</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> Livestock</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> Viscera</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Large volumes of protein-rich residual raw materials, such as heads, bones, carcasses, blood, skin, viscera, hooves and feathers, are created as a result of processing of animals from fisheries, aquaculture, livestock and poultry sectors. These residuals contain proteins and other essential nutrients with potentially bioactive properties, eligible for recycling and upgrading for higher-value products, e.g. for human, pet food and feed purposes. Here, we aim to cover all the important aspects of achieving optimal utilization of proteins in such residual raw materials, identifying those eligible for human consumption as co-products and for feed applications as by-products. Strict legislation regulates the utilization of various animal-based co- and by-products, representing a major hurdle if not addressed properly. Thorough understanding and optimization of all parts of the production chain, including conservation and processing, are important prerequisites for successful upgrading and industrial implementation of such products. This review includes industrially applied technologies such as freezing/cooling, acid preservation, salting, rendering and protein hydrolysis. In this regard, it is important to achieve stable production and quality through all the steps in the manufacturing chain, preferably supported by at- or online quality control points in the actual processing step. If aiming for the human market, knowledge of consumer trends and awareness are important for production and successful introduction of new products and ingredients</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 2365-0869 (Print)IS - 2364-8961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.1007/s41061-017-0143-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28466455">PM:28466455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Top Curr Chem (J)\2017-375-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Top Curr Chem (J)\2017-375-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Aspevik T</style></custom2><misc3><style face="normal" font="Arial">10.1007/s41061-017-0143-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Unal,E.S.</style></author><author><style face="normal" font="Arial"> Gul,U.</style></author><author><style face="normal" font="Arial"> Dursun,A.B.</style></author><author><style face="normal" font="Arial"> Oner,E.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Yenimahalle Training and Research Hospital, Yildirim Beyazit University, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Prediction of atopy via total immunoglobulin E levels andskin prick tests in patients with psoriasis</style></title><secondary-title><style face="normal" font="Arial">Turk J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Turk J Med Sci</style></full-title></periodical><pages end="582" start="577">577-582</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/AIM: Although the etiopathogeneses of psoriasis and atopy appear to be different, psoriasis has been found to be associated with atopy and atopic dermatitis. In this study, we aimed to determine the role of atopy by examining the medical history and clinical and laboratory findings of patients with psoriasis. MATERIALS AND METHODS: Patients with psoriasis, asthma patients, and healthy volunteers were included in the study. Serum total immunoglobulin E (IgE) levels were obtained, and prick tests were administered to all groups. RESULTS: Psoriatic patients demonstrated percentages of atopy history (21.3%) that were higher than those of the healthy subjects (15.7%). The median total IgE level in psoriatic patients was found to be statistically higher than that in the healthy control group (P > 0.05). With respect to mite positivity, there were statistically significant differences in the psoriatic (P &lt; 0.05) and asthmatic groups (P &lt; 0.001) when compared to the healthy control group. CONCLUSION: Our study is the first to use skin prick tests with psoriatic patients. Skin prick test sensitivity to mites increased in psoriatic patients, and we believe that this finding may be useful in protecting psoriatic patients from activation of psoriasis and in determining the appropriate treatment approach</style></abstract><notes><style face="normal" font="Arial">DA - 20170420IS - 1300-0144 (Print)IS - 1300-0144 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.3906/sag-1601-133</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425249">PM:28425249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Turk J Med Sci\2017-47-577-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Turk J Med Sci\2017-47-577-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170420, Unal ES</style></custom2><misc3><style face="normal" font="Arial">10.3906/sag-1601-133</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Fernandez-Caldas,E.</style></author><author><style face="normal" font="Arial"> Thomas,W.R.</style></author><author><style face="normal" font="Arial"> Chapman,M.D.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Caraballo,L.</style></author><author><style face="normal" font="Arial"> Acevedo,N.</style></author><author><style face="normal" font="Arial"> Chew,F.T.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Behrooz,L.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Pascal,D.</style></author><author><style face="normal" font="Arial"> Rosario,N.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author><author><style face="normal" font="Arial"> Geller,M.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Barnes,C.S.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author><author><style face="normal" font="Arial"> Benjaponpitak,S.</style></author><author><style face="normal" font="Arial"> Capriles-Hulett,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Department, Centro Medico Docente La Trinidad, Caracas, Venezuela</style></auth-address><titles><title><style face="normal" font="Arial">International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="14">14-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> International consensus</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Since mite allergens are the most relevant inducers of allergic diseases worldwide, resulting in significant morbidity and increased burden on health services, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), formed by the American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI), the European Academy of Allergy and Clinical Immunology (EAACI), and the World Allergy Organization (WAO), has proposed to issue an International Consensus (ICON) on the clinical consequences of mite hypersensitivity. The objectives of this document are to highlight aspects of mite biology that are clinically relevant, to update the current knowledge on mite allergens, routes of sensitization, the genetics of IgE responses to mites, the epidemiologic aspects of mite hypersensitivity, the clinical pictures induced by mites, the diagnosis, specific immunotherapeutic approaches, and prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Venezuela -CO - United States -CO - Australia -CO - Singapore -CO - Colombia -CO - Spain -CO - Netherlands -CO - France -CO - Brazil -CO - Japan -CO - Austria -CO - United KIngdom -CO - Italy -CO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0145-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28451053">PM:28451053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Sanchez-Borges M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0145-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Starchenka,S.</style></author><author><style face="normal" font="Arial"> Bell,A.J.</style></author><author><style face="normal" font="Arial"> Mwange,J.</style></author><author><style face="normal" font="Arial"> Skinner,M.A.</style></author><author><style face="normal" font="Arial"> Heath,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Therapeutics, Ltd, Dominion Way, Worthing, BN14 8SA UK</style></auth-address><titles><title><style face="normal" font="Arial">Molecular fingerprinting of complex grass allergoids: size assessments reveal new insights in epitope repertoires and functional capacities</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Lol p 1</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAF</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Size distribution</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Structural analysis</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Subcutaneous allergen immunotherapy (SCIT) is a well-documented treatment for allergic disease which involves injections of native allergen or modified (allergoid) extracts. The use of allergoid vaccines is a growing sector of the allergy immunotherapy market, associated with shorter-course therapy. The aim of this study was the structural and immunological characterisation of group 1 (Lol p 1) IgG-binding epitopes within a complex mix grass allergoid formulation containing rye grass. METHODS: HP-SEC was used to resolve a mix grass allergoid preparation of high molecular weight into several distinct fractions with defined molecular weight and elution profiles. Allergen verification of the HP-SEC allergoid fractions was confirmed by mass spectrometry analysis. IgE and IgG immunoreactivity of the allergoid preparations was explored and Lol p 1 specific IgG-binding epitopes mapped by SPOT synthesis technology (PepSpot) with structural analysis based on a Lol p 1 homology model. RESULTS: Grass specific IgE reactivity of the mix grass modified extract (allergoid) was diminished in comparison with the mix grass native extract. A difference in IgG profiles was observed between an intact mix grass allergoid preparation and HP-SEC allergoid fractions, which indicated enhancement of accessible reactive IgG epitopes across size distribution profiles of the mix grass allergoid formulation. Detailed analysis of the epitope specificity showed retention of six Lol p 1 IgG-binding epitopes in the mix grass modified extract. CONCLUSION: The structural and immunological changes which take place following the grass allergen modification process was further unravelled revealing distinct IgG immunological profiles. All epitopes were mapped on the solvent exposed area of Lol p 1 homology model accessible for IgG binding. One of the epitopes was identified as an 'immunodominant' Lol p 1 IgG-binding epitope (62-IFKDGRGCGSCFEIK-76) and classified as a novel epitope. The results from this study support the concept that modification allows shorter-course therapy options as a result of providing an IgG epitope repertoire important for efficacy. Additionally, the work paves the way to help further develop methods for standardising allergoid platforms</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0146-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28451054">PM:28451054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-17.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Starchenka S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0146-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cosmi,L.</style></author><author><style face="normal" font="Arial"> Annunziato,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universita degli Studi di Firenze Scuola di Scienze della Salute Umana, 60222, Firenze, Toscana, Italy</style></auth-address><titles><title><style face="normal" font="Arial">ILC2 are the Earliest Recruiters of Eosinophils in Lungs of Allergic Asthmatic Patients</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="668" start="666">666-668</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201704-0799ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28475847">PM:28475847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20170505-CosmiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20170505-CosmiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Cosmi L</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201704-0799ED</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kusza,S.</style></author><author><style face="normal" font="Arial"> Ilie,D.E.</style></author><author><style face="normal" font="Arial"> Sauer,M.</style></author><author><style face="normal" font="Arial"> Sauer,I.W.</style></author><author><style face="normal" font="Arial"> Gavojdian,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research and Development Station for Sheep and Goats Caransebes, Academy for Agricultural and Forestry Sciences, 325400, Caransebes, Romania</style></auth-address><titles><title><style face="normal" font="Arial">Preliminary report on beta-casein gene Met183QVal183 polymorphism in Romanian indigenous Zackel sheep breeds</style></title><secondary-title><style face="normal" font="Arial">Acta Biochim Pol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Biochim Pol</style></full-title></periodical><pages end="341" start="339">339-341</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Forestry</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Genetic polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Goats</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Hair Follicle</style></keyword><keyword><style face="normal" font="Arial"> Homozygote</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Sheep milk</style></keyword><keyword><style face="normal" font="Arial"> TaqMan</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">Genetic polymorphisms of the milk protein genes are important because of their effects on quantitative traits and technological properties of milk manufacturing. In the present study we identified the polymorphism of the beta-casein gene in two local sheep breeds (Racka n=98 and Turcana n=111) in Romania. The most studied variants at the ovine beta-casein (CSN2) locus are: A and G variants. Genomic DNA was extracted from hair follicles and beta-casein genotypes were determined by the rapid TaqMan (Applied Biosystems, USA) genotyping assay. Homozygote genotypes GG were not detected in any of the studied breeds. In both, the Racka and Turcana breeds, the A variant had a much higher frequency, 0.98% and 0.97%, respectively. In the current study, the fast DNA tests for genotyping ovine CSN2 were successfully optimized, however, further samples and correlations of genomic results with milk characteristics and production data are needed for the development of future selection schemes of the Romanian indigenous sheep breeds, with the ultimate purpose to produce low allergen level sheep milk and derived dairy products</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1734-154X (Electronic)IS - 0001-527X (Linking)LA - engPT - Journal ArticleCO - Romania -</style></notes><work-type><style face="normal" font="Arial">10.18388/abp.2016_1437</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28510613">PM:28510613</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Biochim Pol\20170516-KuszaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Biochim Pol\20170516-KuszaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Kusza S</style></custom2><misc3><style face="normal" font="Arial">10.18388/abp.2016_1437</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez-Jimenez,P.</style></author><author><style face="normal" font="Arial"> Chicharro,P.</style></author><author><style face="normal" font="Arial"> Perez-Plaza,A.</style></author><author><style face="normal" font="Arial"> de Argila,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Dermatologia, Hospital Universitario de La Princesa, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="Arial">Response to Omalizumab in Solar Urticaria: Report of 3 Cases</style></title><secondary-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phototherapy</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sunlight</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H1 antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. The third experienced no improvement and developed a mild local reaction to the injected medication. We conclude that omalizumab may offer a potentially safe, useful alternative for patients with solar urticaria who do not respond to conventional therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ad.2016.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457471">PM:28457471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Actas Dermosifiliogr\20170501-RodriguezJimenezP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Actas Dermosifiliogr\20170501-RodriguezJimenezP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Rodriguez-Jimenez P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ad.2016.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ribeiro,H.</style></author><author><style face="normal" font="Arial"> Abreu,I.</style></author><author><style face="normal" font="Arial"> Cunha,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Olive crop-yield forecasting based on airborne pollen in a region where the olive groves acreage and crop system changed drastically</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Olive trees are one of the most economically important perennial crops in Portugal. During the last decade, the Alentejo olive-growing region has suffered a significantly change in the crop production system, with the regional pollen index (RPI) and olive fruit production registering a significant growth. The aim of this study was to ascertain the utility of this highly variable production and pollen data in crop forecasting modeling. Airborne pollen was sampled using a Cour-type trap from 1999 to 2015. A linear regression model fitted with the regional pollen index as the independent variable showed an accuracy of 87% in estimating olives fruit production in Alentejo. However, the average deviation between observed and modeled production was 32% with half of the tested years presenting deviations between 36 and 66%. The low accuracy of this model is a consequence of the great overall variation and significant upward trend observed in both the production and the RPI dataset that conceal the true association between these variables. In order to overcome this problem, a detrend procedure was applied to both time series to remove the trend observed. The regression model fitted with the fruit production and the RPI detrended data showed a lowest forecasting accuracy of 63% but the average deviation between observed and modeled production decrease to 14% with a maximum deviation value of 33%. This procedure allows focusing the analysis on the production fluctuations related to the biological response of the trees rather than with the changes in the production system</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9483-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9483-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170520-RibeiroH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170520-RibeiroH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Ribeiro H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9483-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ota,Y.</style></author><author><style face="normal" font="Arial"> Ishikawa,F.</style></author><author><style face="normal" font="Arial"> Sato,T.</style></author><author><style face="normal" font="Arial"> Hiruta,N.</style></author><author><style face="normal" font="Arial"> Kitamura,M.</style></author><author><style face="normal" font="Arial"> Yokota,H.</style></author><author><style face="normal" font="Arial"> Ikemiyagi,Y.</style></author><author><style face="normal" font="Arial"> Bujo,H.</style></author><author><style face="normal" font="Arial"> Fujiwara,M.</style></author><author><style face="normal" font="Arial"> Suzuki,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Toho University Sakura Medical Center, Chiba, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">A case of refractory chronic rhinosinusitis with anti-desmoglein 3 IgG4 autoantibody</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170519IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.04.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28522276">PM:28522276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170519-OtaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170519-OtaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170519, Ota Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.04.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhami,S.</style></author><author><style face="normal" font="Arial"> Nurmatov,U.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Khan,T.</style></author><author><style face="normal" font="Arial"> Asaria,M.</style></author><author><style face="normal" font="Arial"> Zaman,H.</style></author><author><style face="normal" font="Arial"> Agarwal,A.</style></author><author><style face="normal" font="Arial"> Netuveli,G.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Calderon,M.</style></author><author><style face="normal" font="Arial"> Cingi,C.</style></author><author><style face="normal" font="Arial"> Durham,S.</style></author><author><style face="normal" font="Arial"> Van Wijk,R.G.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Hamelmann,E.</style></author><author><style face="normal" font="Arial"> Hellings,P.</style></author><author><style face="normal" font="Arial"> Jacobsen,L.</style></author><author><style face="normal" font="Arial"> Knol,E.</style></author><author><style face="normal" font="Arial"> Linnemann,D.L.</style></author><author><style face="normal" font="Arial"> Lin,S.</style></author><author><style face="normal" font="Arial"> Maggina,P.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Elberink,H.O.</style></author><author><style face="normal" font="Arial"> Pajno,G.</style></author><author><style face="normal" font="Arial"> Panwankar,R.</style></author><author><style face="normal" font="Arial"> Pastorello,E.</style></author><author><style face="normal" font="Arial"> Penagos,M.</style></author><author><style face="normal" font="Arial"> Pitsios,C.</style></author><author><style face="normal" font="Arial"> Rotiroti,G.</style></author><author><style face="normal" font="Arial"> Timmermans,F.</style></author><author><style face="normal" font="Arial"> Tsilochristou,O.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.</style></author><author><style face="normal" font="Arial"> Wilkinson,J.</style></author><author><style face="normal" font="Arial"> Williams,A.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Evidence-Based Health Care Ltd, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical recommendations</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis. In order to inform the development of clinical recommendations, we undertook a systematic review to assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis METHODS: We searched 15 international biomedical databases for published, in progress and unpublished evidence. Studies were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using established instruments. Our primary outcomes of interest were symptom, medication and combined symptom and medication scores. Secondary outcomes of interest included cost-effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using random-effects meta-analyses. RESULTS: We identified 5932 studies of which 160 studies satisfied our eligibility criteria. There was a substantial body of evidence demonstrating significant reductions in standardized mean differences (SMD) of symptom (SMD -0.53, 95%CI -0.63, -0.42), medication (SMD -0.37, 95%CI -0.49, -0.26) and combined symptom and medication (SMD -0.49, 95%CI -0.69, -0.30) scores whilst on treatment that were robust to pre-specified sensitivity analyses. There was in comparison a more modest body of evidence on effectiveness post-discontinuation of AIT, this suggesting a benefit in relation to symptom scores. CONCLUSIONS: AIT is effective in improving symptom, medication and combined symptom and medication scores in patients with allergic rhinoconjunctivitis whilst on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom .CO - Italy -CO - Malaysia -CO - Germany -CO - China -CO - Belgium -CO - Netherlands -CO - Greece -CO - United States -CO - Mexico -CO - Denmark -CO - Spain -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28493631">PM:28493631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170511-DhamiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170511-DhamiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Dhami S</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13208</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paganin,F.</style></author><author><style face="normal" font="Arial"> Mangiapan,G.</style></author><author><style face="normal" font="Arial"> Proust,A.</style></author><author><style face="normal" font="Arial"> Prudhomme,A.</style></author><author><style face="normal" font="Arial"> Attia,J.</style></author><author><style face="normal" font="Arial"> Marchand-Adam,S.</style></author><author><style face="normal" font="Arial"> Pellet,F.</style></author><author><style face="normal" font="Arial"> Milhe,F.</style></author><author><style face="normal" font="Arial"> Melloni,B.</style></author><author><style face="normal" font="Arial"> Bernady,A.</style></author><author><style face="normal" font="Arial"> Raspaud,C.</style></author><author><style face="normal" font="Arial"> Nocent,C.</style></author><author><style face="normal" font="Arial"> Berger,P.</style></author><author><style face="normal" font="Arial"> Guilleminault,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">INSERM U 600. UMR 6212, Universite de la Mediterranee, Marseille, France</style></auth-address><titles><title><style face="normal" font="Arial">Lung function parameters in omalizumab responder patients: an interesting tool?</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> forced vital capacity</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Residual Volume</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Omalizumab, an anti-IgE antibody, is used to treat patients with severe allergic asthma. The evolution of lung function parameters over time and the difference between omalizumab responder and non-responder patients remain inconclusive. The objective of this real-life study was to compare the changes in FEV1 of omalizumab responders and non-responders at 6 months. METHODS: A multicenter analysis was performed in 10 secondary and tertiary institutions. Lung function parameters (forced vital capacity (FVC), pre- and post-bronchodilator FEV1, residual volume (RV) and total lung capacity (TLC) were determined at baseline and at 6 months. Omalizumab response was assessed at the 6-month visit. In the omalizumab responder patients, lung function parameters were also obtained at 12, 18 and 24 months. RESULTS: Mean pre-bronchodilator FEV1 showed improvement in responders at 6 months, while a decrease was observed in non-responders (+0.2 +/- 0.4L and -0.1 +/- 0.4L respectively, p&lt;0.01). After an improvement at 6 months, pre- and post-bronchodilator FEV1 remained stable at 12, 18 and 24 months. The FEV1/FVC remained unchanged over time, but the proportion of patients with an FEV1/FVC ratio &lt; 0.7 decreased at 6, 12, 18 and 24 months (55.2%, 54.0%, 54.0% and 44.8%, respectively, p&lt;0.05). Mean RV values decreased at 6 months but increased at 12 months and 24 months (p&lt;0.05). RV/TLC ratio decreased at 6 months and remained unchanged at 24 months. CONCLUSION: After omalizumab initiation, FEV1 improved at 6 months in responder patients and then remained stable for 2 years. RV and RV/TLC improved at 6 months. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28517027">PM:28517027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\201705178-PaganinF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\201705178-PaganinF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Paganin F</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13202</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carsin,A.</style></author><author><style face="normal" font="Arial"> Romain,T.</style></author><author><style face="normal" font="Arial"> Ranque,S.</style></author><author><style face="normal" font="Arial"> Reynaud-Gaubert,M.</style></author><author><style face="normal" font="Arial"> Dubus,J.C.</style></author><author><style face="normal" font="Arial"> Mege,J.L.</style></author><author><style face="normal" font="Arial"> Vitte,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Aix-Marseille Univ, APHM Assistance Publique Hopitaux de Marseille, Hopital Timone Enfants, Pneumo-pediatrie, Centre de Ressources et de Competences en Mucoviscidose, Marseille, France</style></auth-address><titles><title><style face="normal" font="Arial">Aspergillus fumigatus in cystic fibrosis: an update on immune interactions and molecular diagnostics in ABPA</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enfant</style></keyword><keyword><style face="normal" font="Arial"> Enfants</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Host-Pathogen Interactions</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Mucoviscidose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> respiratory failure</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">A wide spectrum of pathological conditions may result from the interaction of Aspergillus fumigatus and the immune system of its human host. Allergic bronchopulmonary aspergillosis is one of the most severe Aspergillus fumigatus-related diseases due to possible evolution towards pleuropulmonary fibrosis and respiratory failure. Allergic bronchopulmonary aspergillosis occurs almost exclusively in cystic fibrosis or asthmatic patients. An estimated 8 to 10% of cystic fibrosis patients experience this condition. The diagnosis of allergic bronchopulmonary aspergillosis relies on criteria first established in 1977. Progress in the understanding of host-pathogen interactions in Aspergillus fumigatus and cystic fibrosis patients and the ongoing validation of novel laboratory tools concur to update and improve the diagnosis of allergic bronchopulmonary aspergillosis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170517IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13204</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28513848">PM:28513848</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170517-CarsinA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170517-CarsinA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170517, Carsin A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13204</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grzanka,A.</style></author><author><style face="normal" font="Arial"> Damasiewicz-Bodzek,A.</style></author><author><style face="normal" font="Arial"> Kasperska-Zajac,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Diseases, Dermatology and Allergology, School of Medicine with Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="Arial">The relationship between circulating concentrations of interleukin 17 and C reactive protein in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="25">25-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-17</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Up-regulation of interleukin 17 (IL-17) family cytokines and acute phase response have been observed in patients with chronic spontaneous urticaria (CSU). It has been demonstrated that IL-17 stimulates C-reactive protein (CRP) expression. AIM: To determine relationship between circulating concentrations of IL-17 and CRP in CSU. METHODS: Concentrations of IL-17 in plasma and CRP in serum were measured in patients with CSU of varying severity and in the healthy subjects. RESULTS: IL-17 and CRP concentrations were significantly higher in CSU patients as compared to the healthy subjects. In addition, there were significant differences in IL-17 and CRP concentrations between CSU patients with mild, moderate-severe symptoms and the healthy subjects. CRP did not correlate significantly with IL-17. CONCLUSIONS: Increased circulating IL-17 concentration may represent an independent index of systemic inflammatory response in CSU, which is not related to increased CRP concentration</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0197-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28491102">PM:28491102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Grzanka A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0197-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,H.J.</style></author><author><style face="normal" font="Arial"> Kim,E.J.</style></author><author><style face="normal" font="Arial"> Yoon,D.</style></author><author><style face="normal" font="Arial"> Lee,J.K.</style></author><author><style face="normal" font="Arial"> Chang,W.S.</style></author><author><style face="normal" font="Arial"> Lim,Y.M.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author><author><style face="normal" font="Arial"> Lee,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of Self-reported Allergic Diseases and IgE Levels: A 2010 KNHANES Analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="339" start="329">329-339</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Blattella germanica</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The prevalence of allergic diseases is known to be associated with both demographic and environmental factors. Herein, we aimed to determine significant factors associated with the prevalence of allergic diseases and with total immunoglobulin E (tIgE) and specific immunoglobulin E (sIgE) levels in Korea. METHODS: We analyzed unweighted data collected by the 2010 Korea National Health and Nutrition Examination Survey for 2,342 subjects who underwent serum tests for tIgE and sIgE to Dermatophagoides farinae, dog, and Blattella germanica, representing a sample of 16,003,645 citizens, by considering the sample weight and stratification. RESULTS: The overall prevalence of self-reported allergic diseases was 37.6%. The prevalence rates of allergic rhinitis and atopic dermatitis decreased with age, whereas the asthma prevalence was not affected by the age of the subjects. When analyzed according to the type of allergic diseases, the prevalence of self-reported allergic disease was significantly associated with various factors (e.g. age, occupation, living in urban areas, and depression). The tIgE level decreased with age, but later increased. Elevation of tIgE was significantly associated with male sex, type of occupation, obesity, and smoking status. However, the risk factors for the increased sIgE levels to each allergen were quite different. Sensitization to D. farinae was more likely in young subjects, whereas the prevalence of sensitization to B. germanica was significantly higher in subjects with male sex, residing in a house (houses), and with glucose intolerance. Finally, young age and the smoking status were significantly associated with sensitization to dog. CONCLUSIONS: Various demographic and environmental factors were significantly associated with the prevalence of self-reported allergic diseases and the levels of tIgE and sIgE to D. farinae, B. germanica, and dog in Korea</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.4.329</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497920">PM:28497920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-329-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-329-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Park HJ</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.4.329</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okada,Y.</style></author><author><style face="normal" font="Arial"> Yamashita,T.</style></author><author><style face="normal" font="Arial"> Kumagai,H.</style></author><author><style face="normal" font="Arial"> Morikawa,Y.</style></author><author><style face="normal" font="Arial"> Akasawa,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of General Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Accurate Determination of Childhood Food Allergy Prevalence and Correction of Unnecessary Avoidance</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="328" start="322">322-328</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood food allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Because the true prevalence of food allergy (FA), as based on the results of an oral food challenge test (OFC), is unknown, it is likely that children with suspected FA unnecessarily eliminate potentially causative foods. This study aimed to identify the prevalence of FA and to determine the proportion of children who unnecessarily eliminate food. METHODS: To identify children with FA, a primary survey was conducted via a questionnaire with all children aged 0-18 years in Niijima village (remote islands of Japan). In the secondary survey, a detailed medical interview was conducted by doctors with children who currently did not eat some foods. The third survey involved serum food-specific immunoglobulin E (IgE) tests and an OFC for children with suspected FA. RESULTS: Of 376 enrolled children, 374 (99.5%) completed the questionnaire. Some foods were eliminated by 18.6% and 13.0% of all children and those >/=6 years old, respectively. The target population for the secondary survey included 69 children who all completed the medical interview. The target population for the third survey consisted of 35 children, of whom 26 (74.3%) underwent the blood test. An OFC was performed 35 times with 20 children. As a result, the prevalence of FA was 4.9% in children of all ages and 4.7% in those >/=6 years old. Moreover, 55.0% children were able to cease eliminating food intake. CONCLUSIONS: It is possible that a considerable number of children unnecessarily eliminate food because of suspected FA</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.4.322</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497919">PM:28497919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-322-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-322-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Okada Y</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.4.322</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,Y.S.</style></author><author><style face="normal" font="Arial"> Han,K.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Kim,N.I.</style></author><author><style face="normal" font="Arial"> Roh,J.Y.</style></author><author><style face="normal" font="Arial"> Seo,S.J.</style></author><author><style face="normal" font="Arial"> Song,H.J.</style></author><author><style face="normal" font="Arial"> Lee,M.G.</style></author><author><style face="normal" font="Arial"> Choi,J.H.</style></author><author><style face="normal" font="Arial"> Park,Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Increased Risk of Chronic Spontaneous Urticaria in Patients With Autoimmune Thyroid Diseases: A Nationwide, Population-based Study</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="377" start="373">373-377</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hashimoto's thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Diseases</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">There was no previous population-based study on the comparison of the risk of chronic spontaneous urticaria (CSU) between autoimmune thyroid diseases (AITD) and age- and gender-matched controls. The primary objective of this study was to evaluate the risk of CSU after diagnosis of AITD using national registry data from Korea. The secondary objective was to evaluate other risk factors of CSU. Based on the disease code diagnoses in 2003-2005, we composed an AITD group (n=3,659) and an age- and gender-matched control group (n=18,295). Each patient was tracked for whether CSU occurs or not until 2013. After adjusting for demographic differences and comorbidities, patients with AITD had a significantly higher rate of CSU compared to the control group (hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.25-1.70; P&lt;0.001). Among the AITD patients, the adjusted HR for CSU was higher in patients with Hashimoto's thyroiditis (HR, 1.50) than in those with Grave's disease (HR, 1.33), although the difference was not statistically significant (P=0.368). Analysis of CSU patients associated with AITD showed that female patients had a significantly higher risk of CSU compared to male ones (HR, 1.34; P=0.001) and that those with allergic rhinitis (HR, 1.51; P&lt;0.001), atopic dermatitis (HR, 2.44; P&lt;0.001), and asthma (HR, 1.50; P&lt;0.001) had a significantly higher risk of CSU compared to patients without respective diseases. Our results demonstrated that AITD could be significantly associated with an increased risk of CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.4.373</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497925">PM:28497925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-373-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-373-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Kim YS</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.4.373</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Menzella,F.</style></author><author><style face="normal" font="Arial"> Galeone,C.</style></author><author><style face="normal" font="Arial"> Formisano,D.</style></author><author><style face="normal" font="Arial"> Castagnetti,C.</style></author><author><style face="normal" font="Arial"> Ruggiero,P.</style></author><author><style face="normal" font="Arial"> Simonazzi,A.</style></author><author><style face="normal" font="Arial"> Zucchi,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cardio-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Real-life Efficacy of Omalizumab After 9 Years of Follow-up</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="372" start="368">368-372</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Juniper</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and long-acting beta2-agonists in patients with suboptimal control of severe asthma. Patients with severe asthma will typically require chronic treatment, although due to the limited amount of data available there are still some concerns about the safety and efficacy of long-term therapy with omalizumab. Herein, in an extension of a previous 4-year study, we report disease-related outcomes of 8 patients with severe persistent allergic asthma who have been followed for a total of 9 years in a real-life setting. Both quality of life (QoL) (evaluated using the Juniper Asthma-Related QoL Questionnaire [AQLQ]) and forced expiratory volume in 1 second (FEV1) showed sustained improvement at 9 years. The median values of AQLQ and FEV1 at 4 years were 5.5 and 82.0% compared to 5.9 and 85.5%, respectively, at 9 years, which were all significantly increased from baseline. After 9 years, the mean annual number of severe exacerbations was 0.63 compared to 5 at baseline. There also appeared to be a trend toward use of a lower dose of ICS at longer follow-up times. After 9 years, there were no safety concerns for continued use of omalizumab, and no asthma-related hospitalizations or emergency department visits were documented over the last 5 years. The present analysis is the longest reported clinical follow-up of omalizumab. Long-term maintenance treatment with omalizumab for up to 9 years is associated with continued benefits in reducing symptoms, exacerbations, and medication burden without any safety concerns</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.4.368</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497924">PM:28497924</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-368-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-368-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Menzella F</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.4.368</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,D.J.</style></author><author><style face="normal" font="Arial"> Shim,M.H.</style></author><author><style face="normal" font="Arial"> Lee,N.</style></author><author><style face="normal" font="Arial"> Yoo,Y.</style></author><author><style face="normal" font="Arial"> Choung,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Korea University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="367" start="360">360-367</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-1</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> trafficking</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Loss</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Although the role of eosinophils in eosinophilic gastroenteritis (EGE) is not fully understood, they are believed to be a principal effector cell. Previous studies have demonstrated that eotaxin and its specific receptor, cysteine-cysteine chemokine receptor-3 (CCR3), play a central role in eosinophil trafficking into the gastrointestinal (GI) tract. Thus, we examined the targeting of CCR3 as a potential therapeutic intervention for EGE in a mouse model. METHODS: Eight- to 10-week-old BALB/c mice were intraperitoneally sensitized and intragastrically challenged with ovalbumin (OVA). Different groups of mice were administered either an anti-CCR3 antibody or a control IgG by intraperitoneal injection 1 hour before each OVA challenge. Eosinophilic inflammation in the intestinal mucosa, mucosal injury, and severity of diarrhea were compared between different groups at 1 hour after final OVA challenge. RESULTS: Anti-CCR3 antibody reduced the number of eosinophils in peripheral blood and intestinal mucosa, but not in bone marrow. This reduction was associated with restoration of reduced villous crypt ratio, increased intestinal epithelial cell proliferation, and weight loss induced by OVA challenge. However, Anti-CCR3 antibody had no effect on the level of OVA specific immunoglobulin E (IgE) and the expression of critical chemokines or cytokines in eosinophil trafficking into the GI tract, such as eotaxin-1, interleukin (IL)-5, and IL-13. CONCLUSIONS: Anti-CCR3 antibody significantly reduced the severity of eosinophilic inflammation, mucosal injury, and diarrhea in a mouse model of food allergen-induced GI eosinophilic inflammation. CCR3 may be a novel therapeutic target for treatment of EGE and other GI eosinophil-mediated diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.4.360</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497923">PM:28497923</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-360-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-360-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Song DJ</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.4.360</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kowal,K.</style></author><author><style face="normal" font="Arial"> Bielecki,P.</style></author><author><style face="normal" font="Arial"> DuBuske,I.V.</style></author><author><style face="normal" font="Arial"> DuBuske,L.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">In vitro impact of anti-immunoglobulin E monoclonal antibodies, including omalizumab on whole blood basophil histamine release: Assessment of direct induction of basophil histamine release and evaluation of modulation of allergen-induced basophil histamine release</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="215" start="204">204-215</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil histamine release</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine content</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin 3</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-3</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> QGE031</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">AIM: The aim of this study was to evaluate the potential of anti-immunoglobulin E (IgE) and/or anti-IgE-IgE immune complexes to release histamine from peripheral blood basophils. In addition, a potential modulating effect of anti-IgE-IgE complexes on allergen-induced peripheral blood basophil histamine release was evaluated. METHODS: Whole blood basophil histamine release (WBB-HR) tests done by using glass-fiber-based microtiter plates were performed in 62 patients with allergic rhinitis and/or asthma sensitized to perennial allergens. Evaluation of the direct effects of monoclonal anti-IgEs, including E25, E27, and QGE031, on WBB-HR, and the indirect effects of anti-IgE-serum IgE complexes on spontaneous and allergen-induced WBB-HR were conducted. The tests were performed with and without pretreatment of the basophils with interleukin 3, and the results were expressed as the fraction of total histamine content released. RESULTS: There was no difference between WBB-HR induced by any of the studied anti-IgE antibodies and that induced by isotype antibodies for all blood samples assessed, which, for each patient, was significantly less than that induced by positive anti-IgE control antibodies. Similarly, no effect of any of the studied anti-IgE-IgE complexes on spontaneous or allergen-induced WBB-HR could be demonstrated. CONCLUSION: There was no evidence that humanized, monoclonal anti-IgE antibodies E25 (omalizumab), E27, or QGE031 directly or indirectly induced histamine release from peripheral blood basophils</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441991">PM:28441991</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-204-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-204-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170426, Kowal K</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shroba,J.</style></author><author><style face="normal" font="Arial"> Barnes,C.</style></author><author><style face="normal" font="Arial"> Nanda,M.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author><author><style face="normal" font="Arial"> Ciaccio,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Ara h2 levels in dust from homes of individuals with peanut allergy and individuals with peanut tolerance</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="196" start="192">192-196</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Ara h2</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> peanut consumption</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Approximately 1% of the U.S. population has a peanut allergy. Previous studies that measured peanut protein in house dust support the hypothesis that household peanut consumption may lead to clinical sensitization through transdermal exposure. OBJECTIVE: The aim of this pilot study was to characterize Ara h2 levels in house dust from homes with and without individuals with peanut allergy. METHODS: Household dust was obtained from homes with an individual with peanut allergy and from homes with no individual with peanut allergy. Ara h2 levels were determined by using a monoclonal antibody-based immunoassay with a level of determination of 150 ng per gram of dust. Peanut consumption information was obtained by questionnaire. RESULTS: A total of 85 dust samples were collected: 38 from homes with a individual with peanut allergy and 47 from control homes. The median Ara h2 level in homes with an individual with peanut allergy was 1236 ng/g (interquartile range [IQR], 256-1342 ng/g), whereas the median Ara h2 level in homes without an individual with peanut allergy was 650 ng/g (IQR, 163-2201 ng/g). Ara h2 levels in dust from homes of individuals with peanut allergy were not significantly lower than in dust from control homes. Of the homes with an individual with peanut allergy, 15 reported complete avoidance of peanut in the home (39%). Ara h2 levels in homes that completely avoided peanuts were not significantly lower than Ara h2 levels in homes that did not restrict peanuts (p = 0.531). CONCLUSION: Although families may restrict peanuts and peanut products in the home, there was still detectable Ara h2 levels found in homes. Each subject's definition of restriction may vary, there seemed to be peanut protein entering the home, although the protein origin is not known. Possibilities include cross-reactivity with another antigen or transport into the home on some vector. Further investigation of hypotheses regarding cross-reactivity and environmental exposure to Ara h2 is necessary</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441989">PM:28441989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-192-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-192-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170426, Shroba J</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Willits,E.K.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author><author><style face="normal" font="Arial"> Jin,J.</style></author><author><style face="normal" font="Arial"> Patel,B.</style></author><author><style face="normal" font="Arial"> Motosue,M.</style></author><author><style face="normal" font="Arial"> Bhagia,A.</style></author><author><style face="normal" font="Arial"> Almasri,J.</style></author><author><style face="normal" font="Arial"> Erwin,P.J.</style></author><author><style face="normal" font="Arial"> Kumar,S.</style></author><author><style face="normal" font="Arial"> Joshi,A.Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Vitamin D and food allergies in children: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="e28" start="e21">e21-e28</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441999">PM:28441999</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-e21-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-e21-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170426, Willits EK</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">El-Zein,M.</style></author><author><style face="normal" font="Arial"> Conus,F.</style></author><author><style face="normal" font="Arial"> Benedetti,A.</style></author><author><style face="normal" font="Arial"> Menzies,D.</style></author><author><style face="normal" font="Arial"> Parent,M.E.</style></author><author><style face="normal" font="Arial"> Rousseau,M.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Association between Bacillus Calmette-Guerin (BCG) Vaccination and Childhood Asthma in the Quebec Birth Cohort on Immunity and Health</style></title><secondary-title><style face="normal" font="Arial">Am J Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Epidemiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administrative data</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">We estimated the association between Bacillus-Calmette Guerin (BCG) vaccination and childhood asthma in a birth cohort using administrative databases, and determined the impact of adjusting for potential confounders collected from a subset of subjects. Multiple data sources were used: 1) administrative data for 76,623 subjects (stage 1) in the Quebec Birth Cohort on Immunity and Health (1974-1994) including BCG vaccination, perinatal and sociodemographic characteristics, and use of health services for asthma; and 2) self-reported asthma risk factors collected in 2012 by telephone interviews with 1,643 subjects (stage 2) using a balanced two-stage sampling design. We estimated odds ratios and 95% confidence intervals for asthma using logistic regression and correcting for the known sampling fractions from stage 1 to stage 2, overall and sex-stratified. In total, 35,612 subjects (46.5%) were BCG vaccinated and 5,870 (7.7%) had asthma. The final odds ratio, integrating results from both stages of sampling, was 0.95 (95% confidence interval: 0.87, 1.04). Results did not differ according to sex; (P for interaction = 0.327). In the largest study ever conducted on this topic, and using the best possible comprehensive adjustment for confounders, no association was found between BCG vaccination and asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170504IS - 1476-6256 (Electronic)IS - 0002-9262 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/aje/kwx088</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28472373">PM:28472373</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Epidemiol\20170504-ElZeinM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Epidemiol\20170504-ElZeinM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170504, El-Zein M</style></custom2><misc3><style face="normal" font="Arial">10.1093/aje/kwx088</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hawley,B.</style></author><author><style face="normal" font="Arial"> Cummings,K.J.</style></author><author><style face="normal" font="Arial"> Mohammed,M.</style></author><author><style face="normal" font="Arial"> Dimmock,A.E.</style></author><author><style face="normal" font="Arial"> Bascom,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Health Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia</style></auth-address><titles><title><style face="normal" font="Arial">Allergic sinusitis and severe asthma caused by occupational exposure to locust bean gum: Case report</style></title><secondary-title><style face="normal" font="Arial">Am J Ind Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Ind Med</style></full-title></periodical><pages end="663" start="658">658-663</pages><volume><style face="normal" font="Arial">60</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> West Virginia</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work-related symptom</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">We present a case that highlights the difficulties with diagnosis and the dangers of occupational allergic sinusitis and asthma left unrecognized. We describe the case history of a man who experienced work-related symptoms 1 year after beginning work as a cheesemaker at a creamery, and whose respiratory symptoms progressively worsened over 16 years before an occupational cause of his asthma was identified. His initial discrete episodes of sinusitis and acute bronchitis evolved into persistent asthma of increasing severity with exacerbations requiring repeated emergency room treatment. The case described in our report emphasizes the importance of clinician diagnosis of OA, and subsequent removal from exposure, such that asthma severity does not progress to near-fatal or fatal asthma in the sensitized worker. As demonstrated by this case report, identification of an occupational cause of asthma relies on a high degree of suspicion and excellent detective work by the clinician</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1097-0274 (Electronic)IS - 0271-3586 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1002/ajim.22725</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497854">PM:28497854</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Ind Med\20170512-HawleyB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Ind Med\20170512-HawleyB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Hawley B</style></custom2><misc3><style face="normal" font="Arial">10.1002/ajim.22725</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,T.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Miller,M.</style></author><author><style face="normal" font="Arial"> Cao,L.</style></author><author><style face="normal" font="Arial"> Zhao,J.</style></author><author><style face="normal" font="Arial"> Wu,J.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Li,S.</style></author><author><style face="normal" font="Arial"> Zou,M.</style></author><author><style face="normal" font="Arial"> Xu,J.</style></author><author><style face="normal" font="Arial"> Broide,D.H.</style></author><author><style face="normal" font="Arial"> Dong,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Qilu hospital of Shandong University</style></auth-address><titles><title><style face="normal" font="Arial">Autophagy Plays a Role in FSTL1-induced EMT and Airway Remodeling in Asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L40" start="L27">L27-L40</pages><volume><style face="normal" font="Arial">313</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> E-cadherin</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial-mesenchymal transition</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> refractory asthma</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> Transmission electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic disease related to airway hyper-responsiveness and airway remodeling. Airway remodeling is the important reason of refractory asthma and is associated with differentiation of airway epithelia into myofibroblasts via epithelial-mesenchymal transition (EMT) to increase the process of subepithelial fibrosis. There is growing evidence that autophagy modulates remodeling. However, the underlying molecular mechanisms of these effects are still unclear. In this study, we hypothesized that Follistatin-like 1(FSTL1) promotes EMT and airway remodeling by intensifying autophagy. Using transmission electron microscopy (TEM), double membrane autophagosomes were detected in the airways of patients and mice. More autophagosomes were in asthmatic patients and OVA-challenged mice compared to healthy control. The expression of FSTL1 and Beclin1 were upregulated in the airways of asthmatic patients and OVA-challenged mice, accompany with airway EMT and remodeling. In OVA-challenged Fstl1+/- mice, the degree of airway remodeling and autophagy were decreased compared to control mice. The effects of FSTL1 on autophagy and EMT were also tested in 16HBE cells in vitro. Additionally, inhibition of autophagy by using LY294002 and siRNA-ATG5 reduced the FSTL1-induced EMT in 16HBE cells as measured by E-cadherin, N-cadherin and vimentin expression. In line herewith, administration of LY294002 reduced the expression of autophagy, EMT and airway remodeling markers in FSTL1-challenged WT mice. Taken together, our study suggests that FSTL1 may induce EMT and airway remodeling by activating autophagy. These findings may provide novel avenues for therapeutic research targeting the autophagy and FSTL1 pathway which may be beneficial to patients with refractory asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00510.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28473327">PM:28473327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\2017-313-L27-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\2017-313-L27-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Liu T</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00510.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gregory,D.J.</style></author><author><style face="normal" font="Arial"> Kobzik,L.</style></author><author><style face="normal" font="Arial"> Yang,Z.</style></author><author><style face="normal" font="Arial"> McGuire,C.C.</style></author><author><style face="normal" font="Arial"> Fedulov,A.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Harvard T.H.Chan School of Public Health</style></auth-address><titles><title><style face="normal" font="Arial">Transgenerational transmission of asthma risk after exposure to environmental particles during pregnancy</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L405" start="L395">L395-L405</pages><volume><style face="normal" font="Arial">313</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> asthma susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Diesel</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust</style></keyword><keyword><style face="normal" font="Arial"> diesel exhaust particle</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust particles</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Maternal Exposure</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Suspensions</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Exposure to environmental particles during pregnancy increases asthma susceptibility of the offspring. We tested the hypothesis that this transmission continues to F2 and F3 generations and occurs via epigenetic mechanisms. We compared allergic susceptibility of three generations of BALB/c offspring after a single maternal exposure during pregnancy to diesel exhaust particles or concentrated urban air particles. After pregnant dams received intranasal instillations of particle suspensions or control, their F1, F2 and F3 offspring were tested in a low-dose ovalbumin protocol for allergy sensitivity. We found that the elevated asthmatic susceptibility after maternal exposure to particles during pregnancy persists into F2 and, with lesser magnitude, into F3 generations. This was evident from elevated eosinophil counts in bronchoalveolar lavage fluid (BAL), histopathologic changes of allergic airway disease, and increased BAL levels of IL-5 and IL-13. We have previously shown that dendritic cells (DCs) can mediate transmission of risk upon adoptive transfer. We therefore used an enhanced reduced representation bisulfite sequencing protocol to quantify DNA methylation in DCs from each generation. Distinct methylation changes were identified in F1, F2 and F3 DCs. The subset of altered loci shared across the 3 generations were not linked to known allergy genes or pathways, but included a number of genes linked to chromatin modification, suggesting potential interaction with other epigenetic mechanisms (e.g. histone modifications).The data indicate that pregnancy airway exposure to DEP triggers a transgenerationally transmitted asthma susceptibility and suggests a mechanistic role for epigenetic alterations in DCs in this process</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00035.2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28495853">PM:28495853</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\2017-313-L395-405.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\2017-313-L395-405.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Gregory DJ</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00035.2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yocum,G.T.</style></author><author><style face="normal" font="Arial"> Turner,D.L.</style></author><author><style face="normal" font="Arial"> Danielsson,J.</style></author><author><style face="normal" font="Arial"> Barajas,M.B.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Xu,D.</style></author><author><style face="normal" font="Arial"> Harrison,N.</style></author><author><style face="normal" font="Arial"> Homanics,G.E.</style></author><author><style face="normal" font="Arial"> Farber,D.L.</style></author><author><style face="normal" font="Arial"> Emala,C.W.,Sr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Columbia University</style></auth-address><titles><title><style face="normal" font="Arial">GABAA Receptor alpha4 Subunit Knockout Enhances Lung Inflammation and Airway Reactivity in a Murine Asthma Model</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L415" start="L406">L406-L415</pages><volume><style face="normal" font="Arial">313</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway reactivity</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Anesthetics</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CD62L</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> gamma-Aminobutyric Acid</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Relaxation</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">Emerging evidence indicates that hypnotic anesthetics affect immune function. Many anesthetics potentiate gamma-aminobutyric acid A receptor (GABAAR) activation, and these receptors are expressed on multiple subtypes of immune cells, providing a potential mechanistic link. Like immune cells, airway smooth muscle (ASM) cells also express GABAARs, particularly isoforms containing alpha4 subunits, and activation of these receptors leads to ASM relaxation. We sought to determine if GABAAR signaling modulates the ASM contractile and inflammatory phenotype of a murine allergic asthma model utilizing GABAAR alpha4 subunit global knockout (KO; Gabra40/0) mice. Wild type (WT) and Gabra4 KO mice were sensitized with house dust mite (HDM) antigen or exposed to phosphate buffered saline (PBS) intranasally 5 days/week for 3 weeks. Ex vivo tracheal rings from HDM-sensitized WT and Gabra4 KO mice exhibited similar magnitudes of acetylcholine-induced contractile force and isoproterenol-induced relaxation (p=n.s.; n=4). In contrast, in vivo airway resistance (flexiVent) was significantly increased in Gabra4 KO mice (p&lt;0.05, n=8). Moreover, the Gabra4 KO mice demonstrated increased eosinophilic lung infiltration (p&lt;0.05; n=4), and increased markers of lung T cell activation/memory (CD62L low, CD44 high; p&lt;0.01, n=4). In vitro, Gabra4 KO CD4+ cells produced increased cytokines and exhibited increased proliferation after stimulation of the T cell receptor as compared to WT CD4+ cells. These data suggest that the GABAAR alpha4 subunit plays a role in immune cell function during allergic lung sensitization. Thus, GABAAR alpha4 subunit-specific agonists have the therapeutic potential to treat asthma via two mechanisms: direct ASM relaxation and inhibition of airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00107.2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28473323">PM:28473323</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170505-YocumGT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170505-YocumGT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Yocum GT</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00107.2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,C.X.</style></author><author><style face="normal" font="Arial"> Singh,A.</style></author><author><style face="normal" font="Arial"> Kim,Y.W.</style></author><author><style face="normal" font="Arial"> Conway,E.M.</style></author><author><style face="normal" font="Arial"> Carlsten,C.</style></author><author><style face="normal" font="Arial"> Tebbutt,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of British Columbia, 8166, Medicine, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis of Western Red Cedar Asthma Using a Blood-based Gene Expression Biomarker Panel</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="1617" start="1615">1615-1617</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> transcriptomics</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword><keyword><style face="normal" font="Arial"> Wood</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="Arial">Western red cedar asthma is the most common form of occupational asthma in the Pacific Northwest region of North America and is caused by a low molecular weight molecule, plicatic acid, found in western red cedar wood. In the present study, peripheral whole blood transcriptomics was used to identify biomarker panels that distinguish asthmatic individuals who are sensitive to plicatic acid from asthmatic individuals who are not sensitive to plicatic acid. These findings suggest that blood may be used as a resource to diagnose western red cedar asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201608-1740LE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463537">PM:28463537</url></web-urls><pdf-urls><url ppv-ref="no">Scott.Tebbutt@hli.ubc.ca</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170502, Yang CX</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201608-1740LE</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guo,Z.Q.</style></author><author><style face="normal" font="Arial"> Dong,W.Y.</style></author><author><style face="normal" font="Arial"> Xu,J.</style></author><author><style face="normal" font="Arial"> Hong,Z.C.</style></author><author><style face="normal" font="Arial"> Zhao,R.W.</style></author><author><style face="normal" font="Arial"> Deng,C.R.</style></author><author><style face="normal" font="Arial"> Zhuang,G.S.</style></author><author><style face="normal" font="Arial"> Zhang,R.X.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">T-helper type 1-T-helper type 2 shift and nasal remodeling after fine particulate matter exposure in a rat model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="155" start="148">148-155</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exposure to fine particulate matter (particulate matter &lt;/=2.5 mum [PM2.5]) increases the risk of allergic rhinitis (AR), but the underlying mechanisms remains unclear. Thus, we investigated the roles of T-helper (Th)1-Th2 cytokines and nasal remodeling after ambient PM2.5 exposure in a rat model of AR. METHODS: Female Sprague-Dawley rats were randomized into six groups: a negative control group, a group of healthy rats exposed to 3000 mug/m3 PM2.5, an ovalbumin (OVA) induced AR model, and three PM2.5-exacerbated AR groups exposed to three different concentrations (200, 1000, and 3000 mug/m3) of PM2.5 for 30 days via inhalation. Nasal symptoms, levels of Th1-Th2 cytokines, the degree of eosinophilia in nasal lavage fluid (NLF), and the messenger RNA (mRNA) expressions of transcription factors GATA-3 and T-bet in the nasal mucosa were measured in each individual rat. Hyperplasia of globet cells and collagen deposition were examined by histology. RESULTS: PM2.5 significantly increased the number of sneezes and nasal rubs in rats with AR. PM2.5 also significantly decreased interferon gamma and increased interleukin (IL) 4 and IL-13 expressions as well as the number of eosinophils in NLF. The mRNA expression of GATA-3 in the nasal mucosa of rats with AR was upregulated by PM2.5, whereas T-bet was significantly downregulated. Statistically significant differences in OVA-specific serum immunoglobulin E, goblet cell hyperplasia, collagen deposition, and transforming growth factor beta 1 levels were observed between the PM2.5-exacerbated AR groups and the AR model group. CONCLUSION: Analysis of our data indicated that an increase in the immune response with Th2 polarization and the development of nasal remodeling may be the immunotoxic mechanisms behind the exacerbation of AR after exposure to PM2.5</style></abstract><notes><style face="normal" font="Arial">DA - 20170412IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2017.31.4437</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401852">PM:28401852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-148-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-148-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170412, Guo ZQ</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2017.31.4437</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,J.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Zheng,Y.</style></author><author><style face="normal" font="Arial"> Lai,X.</style></author><author><style face="normal" font="Arial"> Westermann-Clark,E.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author><author><style face="normal" font="Arial"> Kong,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Specific immunoglobulin E and immunoglobulin G4 toward major allergens of house-dust mite during allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="160" start="156">156-160</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Delta</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgG4</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Specific immunoglobulin E (sIgE) and sIgG4 to house-dust mite (HDM) major allergens during allergen immunotherapy (AIT) and their clinical relevance remain unclear. OBJECTIVE: To investigate the variation of sIgE and sIgG4 to HDM major allergens and the correlation with clinical responses during AIT in patients with allergic rhinitis. METHODS: Thirty-nine patients with HDM allergy were divided into the AIT group (taking immunotherapy) and the control group (medication only use). The AIT group was subdivided into negative clinical responses to AIT (nAIT) group and positive clinical responses to AIT (pAIT) group according to symptom relief and subjective evaluation. sIgE and sIgG4 to Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farinae (Df), and their group 1 and group 2 major allergens (Dp1, Df1, Dp2, and Df2) were measured before AIT, at 6 months, and at 1 year after starting AIT. RESULTS: Dp2, Df, and Df2 sIgE values decreased significantly in the pAIT group versus the nAIT group after 1 year of AIT (median values of delta change were Dp2, -10.09 versus 5.89 kU/L, p = 0.001; median values of Df were -9.69 versus 17.54 kU/L, p = 0.004; median values of Df2 were -11.06 versus 20.08 kU/L, p = 0.013). There was a robust increase in the sIgG4 values to Dp, Df, and their major allergens in both the pAIT and the nAIT groups overall after 1 year of treatment. CONCLUSION: Patients with a positive response to AIT showed a significant reduction of HDM group 2 sIgEs compared with those with a negative response to AIT, which indicated that a decrease in group 2 sIgEs could be a marker that reflected AIT clinical efficacy</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2017.31.4434</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28490399">PM:28490399</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-156-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-156-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Chen J</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2017.31.4434</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McGrath,K.</style></author><author><style face="normal" font="Arial"> Stein,B.</style></author><author><style face="normal" font="Arial"> Kalhagen,L.</style></author><author><style face="normal" font="Arial"> Leighton,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Medicine, Northwestern University, Chicago, Illinois.</style></auth-address><titles><title><style face="normal" font="Arial">Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="86" start="85">85-86</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> imatinib</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.04.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499700">PM:28499700</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170513-McGrathK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170513-McGrathK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, McGrath K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.04.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Akin,O.</style></author><author><style face="normal" font="Arial"> Arslan,M.</style></author><author><style face="normal" font="Arial"> Haymana,C.</style></author><author><style face="normal" font="Arial"> Karabulut,E.</style></author><author><style face="normal" font="Arial"> Hacihamdioglu,B.</style></author><author><style face="normal" font="Arial"> Yavuz,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Endocrinology, Gulhane Education and Research Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Association of neck circumference and pulmonary function in children</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="30" start="27">27-30</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endocrinology</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> forced vital capacity</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function test</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory function</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> waist circumference</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Childhood obesity leads to many complications including impaired respiratory function. There are various anthropometric parameters related to obesity. OBJECTIVE: To investigate the correlation between anthropometric indices and pulmonary function test results in children without asthma. METHODS: Children without any respiratory disorders were enrolled in this study. Anthropometric measurements, such as height, weight, neck circumference (NC), and waist circumference, were obtained from the enrollees and body mass index was calculated. Afterward, pulmonary function tests were performed using spirometry. RESULTS: A total of 178 children (106 boys, 59.5%) with a mean age of 9.7 years were included the study. NC was above the 90th percentile in 65 children. Importantly, pulmonary parameters, such as forced expiratory volume during the first second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC), were lower in subjects with a large NC. Similarly, waist circumference was above the 90th percentile in 67 children, and FEV1/FVC was significantly lower in children with a large waist circumference. Moreover, there was a statistically significant negative correlation among FEV1, FEV1/FVC, and body mass index SD score. Also, multivariable linear regression analysis showed that an NC above the 90th percentile was associated with lower FEV1 and FEV1/FVC values. CONCLUSION: We identified NC as a novel anthropometric index that is strongly correlated with respiratory functions in children. Therefore, close monitoring of respiratory symptoms, particularly in children with obesity and a large NC, could help with early and prompt determination of respiratory complications of obesity</style></abstract><notes><style face="normal" font="Arial">DA - 20170521IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.04.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28527867">PM:28527867</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170521-AkinO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170521-AkinO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170521, Akin O</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.04.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cabana,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Epidemiology and Biostatistics and Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Hydrolyzed Formula in Allergy Prevention</style></title><secondary-title><style face="normal" font="Arial">Ann Nutr Metab</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Nutr Metab</style></full-title></periodical><pages end="45" start="38">38-45</pages><volume><style face="normal" font="Arial">70 Suppl 2</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early intervention</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Policy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> hydrolyzed formula</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> Infant formulas</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">Asthma, eczema, food allergy, and allergic rhinitis are some of the most common pediatric, chronic conditions in the world. Breastfeeding is the optimal way to feed all infants. For those infants who are exposed to infant formula, some studies suggest that certain partially hydrolyzed or extensively hydrolyzed formulas may decrease the risk of allergic disease compared to nonhydrolyzed formulas for children with a family history of atopic disease. Overall, there is some evidence to suggest that partially hydrolyzed whey formulas and extensively hydrolyzed casein formulas may decrease the risk of developing eczema for infants at high risk of allergic disease. The evidence for a preventive effect of hydrolyzed formulas on allergic rhinitis, food allergy, and asthma is inconsistent and insufficient. Finally, the qualitative changes to the peptides by the method of hydrolysis, not just the degree of protein hydrolysis, may have a large influence on the preventive effect of a particular infant formula for the potential risk of allergic disease. As a result, it may be difficult to generalize findings from clinical studies using a specific infant formula to other infant formulas from different manufacturers using different methods of hydrolysis. Further clinical studies are needed to help clinicians identify which infants may benefit from early intervention, as well as which specific hydrolyzed formulas are best suited to decrease the risk of future allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1421-9697 (Electronic)IS - 0250-6807 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000460269</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28521324">PM:28521324</url></web-urls></urls><custom2><style face="normal" font="Arial">20170518, Cabana MD</style></custom2><misc3><style face="normal" font="Arial">10.1159/000460269</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">West,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, Pediatrics, Umea University, Umea, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Introduction of Complementary Foods to Infants</style></title><secondary-title><style face="normal" font="Arial">Ann Nutr Metab</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Nutr Metab</style></full-title></periodical><pages end="54" start="47">47-54</pages><volume><style face="normal" font="Arial">70 Suppl 2</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> complementary foods</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Multiple foods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> peanut consumption</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">While earlier food allergy prevention strategies implemented avoidance of allergenic foods in infancy, the current paradigm is shifting from avoidance to controlled exposure. This review focuses on the outcome of recent randomized controlled trials, which have examined the early introduction of allergenic foods for allergy prevention, and discusses the implementation of results in clinical practice. In infants at high risk of allergic disease, there is now direct evidence that regular early peanut consumption will reduce the prevalence of peanut allergy, compared to avoidance. Many international infant feeding guidelines already recommend complementary foods, including allergenic foods, to be introduced from 4 to 6 months of age irrespective of family history risk. Interim guidelines from 10 International Pediatric Allergy Associations state that healthcare providers should recommend the introduction of peanut-containing products into the diets of infants at high risk of allergic disease in countries where peanut allergy is prevalent. Direct translation of the results obtained from a cohort of high-risk infants to the general population has proved difficult, and issues regarding feasibility, safety, and cost-effectiveness have been raised. Five randomized placebo-controlled trials have assessed the effects of early egg exposure in infancy with varying results. In a recent comprehensive meta-analysis, there was moderate-certainty evidence that early versus late introduction of egg was associated with a reduced egg allergy risk. Although promising, optimal timing, doses, and if the feeding regimen should be stratified according to infant allergy risk remain to be determined. The single study that assessed introduction of multiple foods from 3 months whilst breastfeeding compared with exclusive breastfeeding until 6 months of age showed no reduction in food allergy prevalence. Future research should aim at optimizing infant feeding regimens and support a tolerogenic gastrointestinal microenvironment during the period of food allergen introduction</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1421-9697 (Electronic)IS - 0250-6807 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1159/000457928</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28521316">PM:28521316</url></web-urls></urls><custom2><style face="normal" font="Arial">20170518, West C</style></custom2><misc3><style face="normal" font="Arial">10.1159/000457928</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Chatchatee,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, Kravis Children's Hospital, New York, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms of Tolerance Induction</style></title><secondary-title><style face="normal" font="Arial">Ann Nutr Metab</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Nutr Metab</style></full-title></periodical><pages end="24" start="7">7-24</pages><volume><style face="normal" font="Arial">70 Suppl 2</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy guidelines</style></keyword><keyword><style face="normal" font="Arial"> food immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Induction of tolerance</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> NIAID</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">Food allergy results from failure in oral tolerance that usually occurs in infancy or early childhood. Exposure to peanut and hen's egg via the inflamed and disrupted epithelial barrier in children with severe atopic dermatitis is a risk factor for the development of allergy to these foods and supports the hypothesis that epicutaneous exposure in the absence of oral feeding is an important pathway of allergic IgE sensitization in infants. In recent years, the collective evidence has pointed toward the protective effect of an early feeding with peanut and egg in children with eczema, taking advantage of the pathways underlying oral tolerance to counteract epicutaneous exposure. An addendum to the NIAID food allergy guidelines recommends introduction of peanut into the diet of 4- to 6-month-old infants with severe eczema or egg allergy as an effective strategy to prevent peanut allergy. Strategies aimed at restoring the skin barrier are currently explored as an alternative approach of prevention of eczema and allergic sensitization. Manipulation of the diet via supplementation with probiotics and prebiotics to restore the healthy gut microbiota represents another potential pathway to induction of tolerance in the gut. Oral, epicutaneous, and sublingual routes of food immunotherapy are promising and induce desensitization in the majority of the treated subjects with food allergy but are not proven to restore permanent oral tolerance. Rigorous multicenter randomized clinical trials are necessary to elucidate the optimal timing, dose, duration, as well as the preventive and therapeutic effects of these diverse approaches</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1421-9697 (Electronic)IS - 0250-6807 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000457915</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28521317">PM:28521317</url></web-urls></urls><custom2><style face="normal" font="Arial">20170518, Nowak-Wegrzyn A</style></custom2><misc3><style face="normal" font="Arial">10.1159/000457915</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oddy,W.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Breastfeeding, Childhood Asthma, and Allergic Disease</style></title><secondary-title><style face="normal" font="Arial">Ann Nutr Metab</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Nutr Metab</style></full-title></periodical><pages end="36" start="26">26-36</pages><volume><style face="normal" font="Arial">70 Suppl 2</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> complementary foods</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health benefit</style></keyword><keyword><style face="normal" font="Arial"> Health benefits</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune maturation</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> TA</style></keyword><keyword><style face="normal" font="Arial"> Tasmania</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">The worldwide prevalence of childhood asthma has been increasing considerably, and the protection afforded by breastfeeding in its development has been the subject of controversy for more than 80 years. Previous systematic reviews have generally found a protective effect of breastfeeding on allergic outcomes, although many studies have methodological limitations. Although breastfeeding is protective against lower respiratory tract infection during infancy, such protection has not been demonstrated for asthma in all studies. Breastfeeding has health benefits for the mother and child. Exclusive breastfeeding for the first 6 months of an infant's life, with continued breastfeeding for up to 2 years or longer, is recognized as the "gold" standard for infant feeding because human milk is uniquely suited to the human infant, and its nutritional content and bioactivity promote a healthy development. There is increasing concern that the practice of delaying complementary foods until 6 months may exacerbate the risk of allergic disease. Breast milk contains immunological components that protect against infections and allergic disease in infancy. The composition of human breast milk is complex, containing factors that interact with the infant immune system and intestinal milieu including allergens, cytokines, immunoglobulins, polyunsaturated fatty acids, and chemokines. Transforming growth factor beta is a cytokine in human milk involved in maintaining intestinal homeostasis, inflammation regulation, and oral tolerance development. Modern day society, with increased standards of hygiene, has changed the gut flora of Western infants, potentially impacting the risk of developing immune-mediated diseases including allergic disease and asthma. Microbial diversity is intrinsic to healthy immune maturation and function. Compared to breastfed infants, formula-fed infants had lower bacterial diversity and an altered intestinal microbiota in the first few weeks of life associated with an increased risk of eczema and asthma. Favorable gut colonization through continued breastfeeding may promote tolerance as well as protection when complementary feeding is initiated</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1421-9697 (Electronic)IS - 0250-6807 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1159/000457920</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28521318">PM:28521318</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170518, Oddy WH</style></custom2><misc3><style face="normal" font="Arial">10.1159/000457920</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Janahi,I.A.</style></author><author><style face="normal" font="Arial"> Rehman,A.</style></author><author><style face="normal" font="Arial"> Al-Naimi,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Pediatrics, Weill Cornell Medical College-Qtar, Doha, Qatar</style></auth-address><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis</style></title><secondary-title><style face="normal" font="Arial">Ann Thorac Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Thorac Med</style></full-title></periodical><pages end="82" start="74">74-82</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> and ABPA</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal Agents</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hyphae</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Qatar</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder that often occurs in patients with asthma or cystic fibrosis (CF) and is characterized by a hypersensitivity response to the allergens of the fungus Aspergillus fumigatus. In patients with CF, growth of A. fumigatus hyphae within the bronchial lumen triggers an immunoglobulin E (IgE)-mediated hypersensitivity response that results in airway inflammation, bronchospasm, and bronchiectasis. In most published studies, the prevalence of ABPA is about 8.9% in patients with CF. Since the clinical features of this condition overlap significantly with that of CF, ABPA is challenging to diagnose and remains underdiagnosed in many patients. Diagnosis of ABPA in CF patients should be sought in those with evidence of clinical and radiologic deterioration that is not attributable to another etiology, a markedly elevated total serum IgE level (while off steroid therapy) and evidence of A. fumigatus sensitization. Management of ABPA involves the use of systemic steroids to reduce inflammation and modulate the immune response. In patients who do not respond to steroids or cannot tolerate them, antifungal agents should be used to reduce the burden of A. fumigatus allergens. Recent studies suggest that omalizumab may be an effective option to reduce the frequency of ABPA exacerbations in patients with CF. Further randomized controlled trials are needed to better establish the efficacy of omalizumab in managing patients with CF and ABPA</style></abstract><notes><style face="normal" font="Arial">DA - 20170504IS - 1817-1737 (Print)IS - 1998-3557 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Qatar -</style></notes><work-type><style face="normal" font="Arial">10.4103/atm.ATM_231_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28469716">PM:28469716</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Thorac Med\2017-12-74-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Thorac Med\2017-12-74-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170504, Janahi IA</style></custom2><misc3><style face="normal" font="Arial">10.4103/atm.ATM_231_16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nagaraj,C.</style></author><author><style face="normal" font="Arial"> Haitchi,H.M.</style></author><author><style face="normal" font="Arial"> Heinemann,A.</style></author><author><style face="normal" font="Arial"> Howarth,P.</style></author><author><style face="normal" font="Arial"> Olschewski,A.</style></author><author><style face="normal" font="Arial"> Marsh,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ludwig Boltzmann Institute for Lung Vascular Research , Stiftingtalstrasse 24 , Graz, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Increased expression of p22phox mediates airway hyperresponsiveness in an experimental model of asthma</style></title><secondary-title><style face="normal" font="Arial">Antioxid Redox Signal</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Antioxid Redox Signal</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">AIM: Chronic airway diseases such as asthma are associated with increased production of reactive oxygen species (ROS) and oxidative stress. Endogenous NADPH oxidases are a major source of superoxide in lung, but their underlying role in asthma pathology is poorly understood. We sought to characterize the involvement of NADPH oxidase in allergic asthma by studying the role of CYBA (p22phox) in human asthma and murine house dust mite (HDM)-induced allergic airway inflammation. RESULTS: Increased expression and localisation of p22-PHOX was observed in biopsies of asthmatic patients. HDM treated wild-type mice possessed elevated p22phox expression, corresponded with elevated superoxide production. p22phox knockout (KO) mice did not induce superoxide and were protected against HDM-induced goblet cell hyperplasia and mucus production and HDM-induced airway-hyperreactivity (AHR). IL-13 induced tracheal hyperreactivity and Signal transducer and activator of transcription (STAT)6 phosphorylation was attenuated in the absence of p22phox or catalase pretreatment. INNOVATION: Our study identifies increased expression of p22phox in lungs of asthmatic patients and in experimental model. The induced AHR and mucus hypersecretion is result of an increased ROS from the p22phox dependent NADPH oxidase, which in turn activates STAT6 for the pathological feature of Asthma. CONCLUSIONS: Together with the increased p22phox expression in lungs of asthmatic patients, these findings demonstrate a crucial role of p22phox dependent NADPH oxidase for the development of mucus hypersecretion and AHR in HDM-induced model of asthma. This suggests inhibition of functional NADPH oxidase by selective interference of p22phox might hold promising therapeutic strategy for the management of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1557-7716 (Electronic)IS - 1523-0864 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1089/ars.2016.6863</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28510479">PM:28510479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Antioxid Redox Signal\20170516-NagarajC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Antioxid Redox Signal\20170516-NagarajC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Nagaraj C</style></custom2><misc3><style face="normal" font="Arial">10.1089/ars.2016.6863</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korczak-Kowalska,G.</style></author><author><style face="normal" font="Arial"> Stelmaszczyk-Emmel,A.</style></author><author><style face="normal" font="Arial"> Bocian,K.</style></author><author><style face="normal" font="Arial"> Kiernozek,E.</style></author><author><style face="normal" font="Arial"> Drela,N.</style></author><author><style face="normal" font="Arial"> Domagala-Kulawik,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Faculty of Biology, University of Warsaw, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Expanding Diversity and Common Goal of Regulatory T and B Cells. II: In Allergy, Malignancy, and Transplantation</style></title><secondary-title><style face="normal" font="Arial">Arch Immunol Ther Exp (Warsz)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Immunol Ther Exp (Warsz)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Breg</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> organ transplantation</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">Regulation of immune response was found to play an important role in the course of many diseases such as autoimmune diseases, allergy, malignancy, organ transplantation. The studies on immune regulation focus on the role of regulatory cells (Tregs, Bregs, regulatory myeloid cells) in these disorders. The number and function of Tregs may serve as a marker of disease activity. As in allergy, the depletion of Tregs is observed and the results of allergen-specific immunotherapy could be measured by an increase in the population of IL-10+ regulatory cells. On the basis of the knowledge of anti-cancer immune response regulation, new directions in therapy of tumors are introduced. As the proportion of regulatory cells is increased in the course of neoplasm, the therapeutic action is directed at their inhibition. The depletion of Tregs may be also achieved by an anti-check-point blockade, anti-CD25 agents, and inhibition of regulatory cell recruitment to the tumor site by affecting chemokine pathways. However, the possible favorable role of Tregs in cancer development is considered and the plasticity of immune regulation should be taken into account. The new promising direction of the treatment based on regulatory cells is the prevention of transplant rejection. A different way of production and implementation of classic Tregs as well as other cell types such as double-negative cells, Bregs, CD4+ Tr1 cells are tested in ongoing trials. On the basis of the results of current studies, we could show in this review the significance of therapies based on regulatory cells in different disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170504IS - 1661-4917 (Electronic)IS - 0004-069X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00005-017-0471-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28470464">PM:28470464</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Immunol Ther Exp (Warsz)\20170504-KorczakKowalskaG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Immunol Ther Exp (Warsz)\20170504-KorczakKowalskaG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170504, Korczak-Kowalska G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00005-017-0471-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,S.C.</style></author><author><style face="normal" font="Arial"> Chou,H.C.</style></author><author><style face="normal" font="Arial"> Chiang,B.L.</style></author><author><style face="normal" font="Arial"> Chen,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">CTGF upregulation correlates with MMP-9 level in airway remodeling in a murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Arch Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Med Sci</style></full-title></periodical><pages end="676" start="670">670-676</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> CTGF</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hypertrophy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Connective tissue growth factor (CTGF) mediates hypertrophy, proliferation, and extracellular matrix synthesis. Matrix metalloproteinase (MMP) plays a role in airway extracellular matrix remodeling. The correlation between CTGF and MMP in airway remodeling of asthma was unknown. This study investigated lung CTGF expression and its correlation with MMP and airway structural changes in a murine model of asthma. MATERIAL AND METHODS: Female BALB/c mice were sensitized and challenged by intraperitoneal injections and intranasal phosphate-buffered saline (PBS) or ovalbumin (OVA). Airway responsiveness and serum OVA-specific IgE were measured. Airway structural changes were quantified by morphometric analysis. Differential cell counts and MMP-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 were evaluated in bronchoalveolar lavage fluid (BALF). Lung CTGF was determined by Western blot. RESULTS: Serum OVA-specific IgE level and airway responsiveness in enhanced pause (Penh) is significantly higher in sensitized mice challenged with OVA compared to PBS-challenged mice. MMP-2, MMP-9, and TIMP-1 in BALF were significantly higher in OVA mice. Airway structural changes of animals' lungs with OVA challenge showed increased thickness of the smooth muscle layer and numbers of Goblet cells and inflammatory cells and eosinophils near airways and perivascular areas. Lung CTGF expression significantly increased in OVA-challenged mice. CTGF expressions positively correlated with MMP-9 (r = 0.677, p &lt; 0.05), TIMP-1 (r = 0.574, p &lt; 0.05) and thickness of the smooth muscle layer (r = 0.499, p &lt; 0.05). CONCLUSIONS: This study indicates that CTGF upregulation correlates with MMP-9, probably involved in the pathogenesis of airway remodeling of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1734-1922 (Print)IS - 1734-1922 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.5114/aoms.2016.60371</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28507585">PM:28507585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Med Sci\2017-13-670-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Med Sci\2017-13-670-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Lin SC</style></custom2><misc3><style face="normal" font="Arial">10.5114/aoms.2016.60371</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sole,D.</style></author><author><style face="normal" font="Arial"> Aranda,C.S.</style></author><author><style face="normal" font="Arial"> Wandalsen,G.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Escola Paulista de Medicina, Federal University of Sao Paulo, Rua dos Otonis</style></auth-address><titles><title><style face="normal" font="Arial">Asthma: epidemiology of disease control in Latin America - short review</style></title><secondary-title><style face="normal" font="Arial">Asthma Res Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Res Pract</style></full-title></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="Arial">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Latin America</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment guidelines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is reported as one of the most common chronic diseases in childhood, impairing the quality of life of patients and their families and incurring high costs to the healthcare system and society. Despite the development of new drugs and the availability of international treatment guidelines, asthma is still poorly controlled, especially in Latin America. Original and review articles on asthma control or epidemiology with high levels of evidence have been selected for analysis among those published in PubMed referenced journals during the last 20 years, using the following keywords: "asthma control" combined with "Latin America", " epidemiology", "prevalence", "burden", "mortality", "treatment and unmet needs", "children", "adolescents", and "infants". There was a high prevalence and severity of asthma during the period analyzed, especially in children and adolescents. Wheezing in infants was a significant reason for seeking medical care in Latin American health centers. Moreover, the frequent use of quick-relief bronchodilators and oral corticosteroids by these patients indicates the lack of a policy for providing better care for asthmatic patients, as well as poor asthma control. Among adults, studies document poor treatment and control of the disease, as revealed by low adherence to routine anti-inflammatory medications and high rates of emergency care visits and hospitalization. In conclusion, although rare, studies on asthma control in Latin America repeatedly show that patients are inadequately controlled and frequently overestimate their degree of asthma control according to the criteria used by international asthma treatment guidelines. Additional education for doctors and patients is essential for adequate control of this illness, and therefore also for reduction of the individual and social burden of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 2054-7064 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40733-017-0032-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28507765">PM:28507765</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Res Pract\2017-3-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Res Pract\2017-3-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Sole D</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40733-017-0032-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maseda,Y.</style></author><author><style face="normal" font="Arial"> Ohori,J.</style></author><author><style face="normal" font="Arial"> Tanaka,N.</style></author><author><style face="normal" font="Arial"> Nagano,H.</style></author><author><style face="normal" font="Arial"> Miyashita,K.</style></author><author><style face="normal" font="Arial"> Kurono,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Mucosal and systemic immune response to sublingual or intranasal immunization with phosphorylcholine</style></title><secondary-title><style face="normal" font="Arial">Auris Nasus Larynx</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Auris Nasus Larynx</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Haemophilus</style></keyword><keyword><style face="normal" font="Arial"> Haemophilus influenzae</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Hemocyanin</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> KLH</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylcholine</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus pneumoniae</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Type I allergy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Phosphorylcholine (PC) is a structural component of a wide variety of pathogens including Streptococcus pneumoniae and Haemophilus influenzae. Here, the immune response in mice to PC immunization via the sublingual (SL) route versus the intranasal (IN) route was investigated in terms of efficacy and safety. METHODS: BALB/c mice were immunized with PC-keyhole limpet hemocyanin (KLH) plus cholera toxin (CT) or CT alone via the IN or SL route. The immune response generated was studied in terms of PC-specific antibody titers, interferon (IFN)-gamma and interleukin (IL)-4 production by CD4+ T cells, and cross-reactivity of PC-specific immunoglobulin (Ig)-A antibodies in nasal washes against S. pneumoniae and non-typeable H. influenzae. RESULTS: SL and IN immunization with PC-KLH plus CT resulted in a marked increase in the levels of PC-specific, mucosal IgA and serum IgM, IgG, and IgA antibodies. Additionally, SL immunization elicited significantly higher levels of PC-specific IgG2a subclass antibodies and IFN-gamma in serum. On the other hand, IN immunization with CT alone remarkably increased the total IgE level in serum compared with SL and IN immunization with PC-KLH plus CT. PC-specific IgA antibodies in nasal wash samples reacted to most strains of S. pneumoniae and non-typeable H. influenzae. CONCLUSION: SL immunization is as effective as IN immunization to induce PC-specific immune responses and more effective than IN immunization to reduce the production of IgE and to prevent the sensitization to allergen causing type I allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1879-1476 (Electronic)IS - 0385-8146 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anl.2017.04.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28478921">PM:28478921</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Auris Nasus Larynx\20170508-MasedaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Auris Nasus Larynx\20170508-MasedaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Maseda Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anl.2017.04.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mas,S.</style></author><author><style face="normal" font="Arial"> Oeo-Santos,C.</style></author><author><style face="normal" font="Arial"> Cuesta-Herranz,J.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Colas,C.</style></author><author><style face="normal" font="Arial"> Fernandez,J.</style></author><author><style face="normal" font="Arial"> Barber,D.</style></author><author><style face="normal" font="Arial"> Rodriguez,R.</style></author><author><style face="normal" font="Arial"> de los Rios,V.</style></author><author><style face="normal" font="Arial"> Barderas,R.</style></author><author><style face="normal" font="Arial"> Villalba,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dpto. Bioquimica y Biologia Molecular I, Universidad Complutense de Madrid, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">A relevant IgE-reactive 28kDa protein identified from Salsola kali pollen extract by proteomics is a natural degradation product of an integral 47kDa polygalaturonase</style></title><secondary-title><style face="normal" font="Arial">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochim Biophys Acta</style></full-title></periodical><pages end="1076" start="1067">1067-1076</pages><volume><style face="normal" font="Arial">1865</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> fraxinus excelsior</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> oleaceae</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Polygalacturonase</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Salsola</style></keyword><keyword><style face="normal" font="Arial"> Salsola kali</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">A highly prevalent IgE-binding protein band of 28kDa is observed when Salsola kali pollen extract is incubated with individual sera from Amaranthaceae pollen sensitized patients. By an immunoproteomic analysis of S. kali pollen extract, we identified this protein band as an allergenic polygalacturonase enzyme. The allergen, named Sal k 6, exhibits a pI of 7.14 and a molecular mass of 39,554.2Da. It presents similarities to Platanaceae, Poaceae, and Cupressaceae allergenic polygalacturonases. cDNA-encoding sequence was subcloned into the pET41b vector and produced in bacteria as a His-tag fusion recombinant protein. The far-UV CD spectrum determined that rSal k 6 was folded. Immunostaining of the S. kali pollen protein extract with a rSal k 6-specific pAb and LC-MS/MS proteomic analyses confirmed the co-existence of the 28kDa band together with an allergenic band of about 47kDa in the pollen extract. Therefore, the 28kDa was assigned as a natural degradation product of the 47kDa integral polygalacturonase. The IgE-binding inhibition to S. kali pollen extract using rSal k 6 as inhibitor showed that signals directed to both protein bands of 28 and 47kDa were completely abrogated. The average prevalence of rSal k 6 among the three populations analyzed was 30%, with values correlating well with the levels of grains/m3 of Amaranthaceae pollen. Sal k 6 shares IgE epitopes with Oleaceae members (Fraxinus excelsior, Olea europaea and Syringa vulgaris), with IgE-inhibition values ranging from 20% to 60%, respectively. No IgE-inhibition was observed with plant-derived food extracts</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbapap.2017.05.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502749">PM:28502749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\20170515-MasS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\20170515-MasS.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\20170515-MasS.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\20170515-MasS.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170515, Mas S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbapap.2017.05.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shakeri,F.</style></author><author><style face="normal" font="Arial"> Boskabady,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Neurogenetic Inflammation Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Anti-inflammatory, antioxidant, and immunomodulatory effects of curcumin in ovalbumin-sensitized rat</style></title><secondary-title><style face="normal" font="Arial">Biofactors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biofactors</style></full-title></periodical><pages end="576" start="567">567-576</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Curcumin</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> PLA2</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anti-inflammatory and antioxidant properties of curcumin have been shown. In this study, anti-inflammatory, antioxidant, and immunomodulatory effects of curcumin in sensitized rat were evaluated. METHODS: Six groups of rats including control (C), ovalbumin-sensitized (as a rat model of asthma, S), S groups treated with curcumin (Cu 0.15, 0.30, and 0.60 mg/mL), and 1.25 mug/mL dexamethasone (S + D) were studied. Curcumin and dexamethasone were given in animals' drinking water during sensitization period. Total and differential WBC count, PLA2, TP, IFN-gamma, IL-4, IgE, oxidant, and antioxidant biomarker levels in bronchoalveolar lavage fluid (BALF) were examined. RESULTS: Total WBC, neutrophil and eosinophil counts, levels of PLA2, TP, IgE, IL-4, NO2 , NO3 , and MDA in BALF were increased but lymphocyte percentage, SOD, CAT, thiol, and IFN-gamma levels and IFN-gamma/IL-4 ratio decreased in S animals compared to controls (P &lt; 0.001 for all cases). Treatment with all concentrations of curcumin significantly improved total WBC, PLA2, TP, IgE, IL-4, IFN-gamma, IFN-gamma/IL-4 ratio, SOD, thiol, NO2 , and NO3 compared to S group (P &lt; 0.01 to P &lt; 0.001). Two higher concentrations of curcumin significantly decreased neutrophil and eosinophil counts and MDA level but increased IFN-gamma, CAT and lymphocyte values compared to S group (P &lt; 0.001 for all cases). Dexamethasone treatment also significantly improved most of the measured parameters (P &lt; 0.05 to P &lt; 0.001) but it did not change IL-4 and IFN-gamma levels and IFN-gamma/IL-4 ratio. CONCLUSION: Anti-inflammatory, antioxidant, and immunomodulatory effects of curcumin with more specific immunomodulatory effect on Th1/Th2 balance compared to dexamethasone in sensitized rats was shown. (c) 2017 BioFactors, 2017</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1872-8081 (Electronic)IS - 0951-6433 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1002/biof.1364</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509396">PM:28509396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biofactors\2017-43-567-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biofactors\2017-43-567-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Shakeri F</style></custom2><misc3><style face="normal" font="Arial">10.1002/biof.1364</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Awad,K.</style></author><author><style face="normal" font="Arial"> Abushouk,A.I.</style></author><author><style face="normal" font="Arial"> AbdelKarim,A.H.</style></author><author><style face="normal" font="Arial"> Mohammed,M.</style></author><author><style face="normal" font="Arial"> Negida,A.</style></author><author><style face="normal" font="Arial"> Shalash,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Research Group of Egypt, Cairo, Egypt; Faculty of Medicine, Zagazig University, Zagazig, Egypt</style></auth-address><titles><title><style face="normal" font="Arial">Bee venom for the treatment of Parkinson's disease: How far is it possible?</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="302" start="295">295-302</pages><volume><style face="normal" font="Arial">91</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Alternative Medicine</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dopamine</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">Parkinson's disease (PD) is the second most common neurodegenerative disease, characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta leading to depletion of striatal dopamine and motor symptoms as bradykinesia, resting tremors, rigidity, and postural instability. Current therapeutic strategies for PD are mainly symptomatic and may cause motor complications, such as motor fluctuations and dyskinesia. Therefore, alternative medicine may offer an effective adjuvant treatment for PD. Bee venom therapy (BVT) has long been used as a traditional therapy for several conditions, such as rheumatoid arthritis, asthma, and skin diseases. Experimental and clinical studies showed that BVT could be an effective adjuvant treatment for PD. Several mechanisms were suggested for these findings including the ability of BVT to attenuate neuroinflammation, inhibit apoptosis of dopaminergic neurons, protect against glutamate-induced neurotoxicity, and restore normal dopamine levels in the nigrostriatal pathway. In this article, we reviewed and summarized the literature regarding the potential of BVT for the treatment of PD</style></abstract><notes><style face="normal" font="Arial">DA - 20170506IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.04.065</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477460">PM:28477460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-91-295-302.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-91-295-302.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170506, Awad K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.04.065</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bui,T.T.</style></author><author><style face="normal" font="Arial"> Piao,C.H.</style></author><author><style face="normal" font="Arial"> Song,C.H.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author><author><style face="normal" font="Arial"> Chai,O.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy, Chonbuk National University Medical School, Jeonju 54896, Jeonbuk, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Bupleurum chinense extract ameliorates an OVA-induced murine allergic asthma through the reduction of the Th2 and Th17 cytokines production by inactivation of NFkappaB pathway</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="1095" start="1085">1085-1095</pages><volume><style face="normal" font="Arial">91</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Cytoplasm</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">Bupleurum chinense belongs to the Bupleurum spp. family that has been used in traditional herbal medicine for over thousand years. It has been reported to have anti-inflammatory, anti-oxidant, hepato-protective, antipyretic, analgesic, anti-fibrotic and immunomodulatory effect. However, the effect of B. Chinense on allergic asthma remains unclear. This study investigated the immunomodulatory effects of B. Chinense extracts (BCE) on airway inflammation in asthmatic mice model. In the ovalbumin (OVA)-induced allergic asthma model, we evaluated the number of total cells, differential inflammatory cells and the production of proinflammatory cytokines in bronchoalveolar lavage fluid (BALF) and lung homogenate as well as histological structure. The levels of NFkappaB p65, IkappaBalpha, p-NFkappaB p65, p-IkappaBalpha and the total immunoglobulin (Ig) E, anti-OVA IgE, anti-OVA IgG were also examined. The oral administration of 200mg/kg BCE inhibited the accumulation of inflammatory cells especially eosinophils in BALF. Also, BCE regulated the imbalance of Th1, Th2 and Th17-related production, with attenuated the expression of GATA3, IL-1beta, IL-4, IL-5, IL-6, TNF-alpha and RORgammat, IL-17A in BALF and lung homogenate, meanwhile, up-regulated the secretion of INF-gamma in lung homogenate. The levels of IgE, anti-OVA IgE, anti-OVA IgG1 and anti-OVA IgG2a were also suppressed by BCE treatment in serum. Futhermore, BCE inhibited the proinflammatory cytokines via inactivation of NFkappaB p65 phosphorylation and IkappaBalpha degradation in cytoplasm. The histological analysis showed that the infiltration of inflammatory cells, mucus hypersecretion and collagen fi ber deposits were ameliorated in BCE treated mice. In addition, BCE induced the functional differentiation of naive CD4+ T cells forward to Th1 and Tr1 through producing INF-gamma and IL-10. These results suggest that BCE may have therapeutic potential for treating allergic asthma through inhibiting Th2/Th17 cytokines production by inactivation of NFkappaB pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.04.133</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28531919">PM:28531919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-91-1085-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-91-1085-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Bui TT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.04.133</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Devis,D.L.</style></author><author><style face="normal" font="Arial"> Davies,J.M.</style></author><author><style face="normal" font="Arial"> Zhang,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Molecular features of grass allergens and development of biotechnological approaches for allergy prevention</style></title><secondary-title><style face="normal" font="Arial">Biotechnol Adv</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biotechnol Adv</style></full-title></periodical><pages end="556" start="545">545-556</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen evolution</style></keyword><keyword><style face="normal" font="Arial"> Allergen function</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plant</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Barley</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Engineering</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grain allergen</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant allergen</style></keyword><keyword><style face="normal" font="Arial"> plant allergens</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> Transgenic grass</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plants</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0734-9750</style></isbn><abstract><style face="normal" font="Arial">Allergic diseases are characterized by elevated allergen-specific IgE and excessive inflammatory cell responses. Among the reported plant allergens, grass pollen and grain allergens, derived from agriculturally important members of the Poaceae family such as rice, wheat and barley, are the most dominant and difficult to prevent. Although many allergen homologs have been predicted from species such as wheat and timothy grass, fundamental aspects such as the evolution and function of plant pollen allergens remain largely unclear. With the development of genetic engineering and genomics, more primary sequences, functions and structures of plant allergens have been uncovered, and molecular component-based allergen-specific immunotherapies are being developed. In this review, we aim to provide an update on (i) the distribution and importance of pollen and grain allergens of the Poaceae family, (ii) the origin and evolution, and functional aspects of plant pollen allergens, (iii) developments of allergen-specific immunotherapy for pollen allergy using biotechnology and (iv) development of less allergenic plants using gene engineering techniques. We also discuss future trends in revealing fundamental aspects of grass pollen allergens and possible biotechnological approaches to reduce the amount of pollen allergens in grasses</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biotechadv.2017.05.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.biotechadv.2017.05.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biotechnol Adv\20170523-DevisDL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biotechnol Adv\20170523-DevisDL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Devis DL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biotechadv.2017.05.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Traidl-Hoffmann,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Lehrstuhl fur Umweltmedizin, UNIKA-T, Technische Universitat Munchen, Neusasser Strasse 47, 86156, Augsburg, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Allergy - an environmental disease]</style></title><secondary-title><style face="normal" font="Arial">Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</style></full-title></periodical><pages end="591" start="584">584-591</pages><volume><style face="normal" font="Arial">60</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Microstructure</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="Arial">The increase in allergies is a phenomenon that is being observed in all fast-developing countries. For a long time, science has taken as a starting point that solely a genetic predisposition is a precondition for the development of an allergy. Today, knowledge of environmental factors that can alter genes or the transcription of genes in the cells, has improved. Epidemiological studies have meanwhile identified several environmental factors that have a protective or supporting effect on allergy development. The environmental microbiome has recently gained central interest. A common theme in most of the studies is diversity: reduced diversity is correlated with enhanced risk for chronic inflammatory diseases and allergy.It is now of great interest for research to further analyze such environment-gene and/or environment-human interactions on all levels - from organs to cells to small and microstructures such as genes. For immunologists, it is specifically about understanding the influencing factors and effector pathways of allergens, and to apply thereby obtained insights in the follow-up for the ultimate goal of allergy research - prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 1437-1588 (Electronic)IS - 1436-9990 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00103-017-2547-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28466132">PM:28466132</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz\20170503-TraidlHoffmannC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz\20170503-TraidlHoffmannC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Traidl-Hoffmann C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00103-017-2547-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yan,X.</style></author><author><style face="normal" font="Arial"> Zhang,A.</style></author><author><style face="normal" font="Arial"> Yu,L.</style></author><author><style face="normal" font="Arial"> Chen,C.</style></author><author><style face="normal" font="Arial"> Cui,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Acupuncture, Moxibustion and Tuina, Gansu University of Chinese Medicine, Lanzhou 730000, China</style></auth-address><titles><title><style face="normal" font="Arial">Differential Expression of Serum Proteins in Rats with Allergic Asthma: A Study Based on the Nanoliter Two-Dimensional Liquid Chromatography Technique</style></title><secondary-title><style face="normal" font="Arial">Can Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Can Respir J</style></full-title></periodical><pages end="" start="8015703">8015703-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acupuncture</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Differential expression</style></keyword><keyword><style face="normal" font="Arial"> Differential protein</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Tuina</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective. To investigate the pathogenesis of allergic asthma via the nanoliter two-dimensional liquid chromatography (nano-2D-LC) technique. Method. 24 Wistar rats were randomized into 3 groups: the blank-control group (A), the restrained group (B), and the asthma model group (C). The nanoliter two-dimensional liquid chromatography (nano-2D-LC) technique was used to study the differential protein expressions of the serum in asthmatic rats. Results. Compared with the restrained group, the data from the asthma model group displayed a distinctive peak, that is, peak number 13 (94.731 min). The data also displayed three missing peaks in the asthma group, that is, peak number 1 (77.489 min), peak number 2 (78.418 min), and peak number 5 (80.533 min), suggesting that the corresponding peptides might be related to the pathogenesis of asthma. Compared with the blank-control group, the restrained group showed 4 new peaks, that is, peak number 2 (78.418 min), peak number 4 (79.398 min), peak number 5 (80.533 min), and peak number 7 (81.824 min). The restrained group also displayed a missing peak, that is, peak number 3 (78.804 min), indicating that those 5 polypeptides might be related to the binding-induced stress stimuli. Conclusion. The study suggests that the pathogenesis of allergic asthma is closely related to abnormal levels of proteins; however, future animal experiments should identify the specific protein expressions caused by stress factors</style></abstract><notes><style face="normal" font="Arial">DA - 20170510IS - 1916-7245 (Electronic)IS - 1198-2241 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/8015703</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28487623">PM:28487623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Can Respir J\2017-2017-8015703.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Can Respir J\2017-2017-8015703.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Yan X</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/8015703</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Karagiannis,S.N.</style></author><author><style face="normal" font="Arial"> Josephs,D.H.</style></author><author><style face="normal" font="Arial"> Bax,H.J.</style></author><author><style face="normal" font="Arial"> Spicer,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer</style></title><secondary-title><style face="normal" font="Arial">Cancer Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Cancer Res</style></abbr-1></periodical><pages end="2783" start="2779">2779-2783</pages><volume><style face="normal" font="Arial">77</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> folate</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophage Activation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">IgG monoclonal antibodies have made significant contributions to cancer therapy, but suffer from several limitations that restrict their effectiveness in unleashing host immune system components against tumors. The development of monoclonal antibodies of an alternative class, namely IgE, may offer enhanced immune surveillance and superior effector cell potency against cancer cells. In our recent article, we elaborate our proof-of-concept studies of a mouse/human chimeric IgE antibody (MOv18 IgE), which is specific for the cancer-associated antigen folate receptor alpha. We demonstrate superior antitumor efficacy for IgE compared with an otherwise identical IgG in a syngeneic immunocompetent animal, and we identify TNFalpha/MCP-1 signaling as an IgE-mediated mechanism of monocyte and macrophage activation and recruitment to tumors. These findings draw parallels with powerful macrophage-activating functions employed by IgE against parasites, rather than allergic IgE mechanisms. The potential clinical application of IgE-derived drugs in clinical oncology is clear if the antitumor activity of MOv18 IgE in these preclinical experiments can be replicated in patients. In particular, different IgE antibodies with specificity for many other antigens already validated as targets for IgG suggest a wide potential for development of a novel class of antibody therapy. Cancer Res; 77(11); 1-5. (c)2017 AACR</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 1538-7445 (Electronic)IS - 0008-5472 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1158/0008-5472.CAN-17-0428</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526770">PM:28526770</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cancer Res\20170520-KaragiannisSN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cancer Res\20170520-KaragiannisSN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Karagiannis SN</style></custom2><misc3><style face="normal" font="Arial">10.1158/0008-5472.CAN-17-0428</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahmed,S.</style></author><author><style face="normal" font="Arial"> Truong,L.D.</style></author><author><style face="normal" font="Arial"> Workeneh,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Baylor College of Medicine, One Baylor Plaza, 6620 Maine, Ste 11C, Houston, TX, 77030, USAThe Houston Methodist Hospital, 6565 Fannin Street, Suite M227, Houston, TX, 77030, USABaylor College of Medicine, One Baylor Plaza, 6620 Maine, Ste 11C, Houston, TX, 77030, USA. bworkene@bcm.edu</style></auth-address><titles><title><style face="normal" font="Arial">Fraternal twins with job's syndrome and immune complex nephritis</style></title><secondary-title><style face="normal" font="Arial">CEN Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">CEN Case Rep</style></full-title></periodical><pages end="66" start="61">61-66</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antigen</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Glomerulonephritis</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Job's Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Nephritis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> twin</style></keyword><keyword><style face="normal" font="Arial"> Twins</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">Job's syndrome or autosomal dominant hyperimmunoglobulin E syndrome (Hyper-IgE) is a rare disorder that results from a STAT3 gene mutation, which results in the absence of T-helper 17 (Th17) cells and manifests as a severe immunodeficiency. Affected individuals suffer recurrent soft tissue and pulmonary infections among other manifestations, and the spectrum of the disease is still being characterized. We describe 2 sisters with Job's syndrome each with variable expressivity. However, both patients developed proteinuric kidney disease and had biopsies confirming the presence of immune complex glomerulonephritis with staining for immunoglobulins and complement components. Previous reports link Job's syndrome and the development of systemic lupus erythematosus (SLE), but proliferative immune complex glomerulonephritis has not been described. We speculate that continual internal and external antigen exposure may induce an autoimmune process similar to SLE, which in turn may account for the immune complex disease in the kidney</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 2192-4449 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13730-015-0191-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509165">PM:28509165</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\CEN Case Rep\2016-5-61-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\CEN Case Rep\2016-5-61-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Ahmed S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13730-015-0191-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zimmer,J.</style></author><author><style face="normal" font="Arial"> Doring,S.</style></author><author><style face="normal" font="Arial"> Strecker,D.</style></author><author><style face="normal" font="Arial"> Trosemeier,J.H.</style></author><author><style face="normal" font="Arial"> Hanschmann,K.M.</style></author><author><style face="normal" font="Arial"> Fuhrer,F.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Kaul,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Minor allergen patterns in birch pollen allergen products - A question of pollen?</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1091" start="1079">1079-1091</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergen pattern</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 4</style></keyword><keyword><style face="normal" font="Arial"> Bet v 6</style></keyword><keyword><style face="normal" font="Arial"> Bet v 7</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Contrary to the scientific differentiation between major and minor allergens, the regulatory framework controlling allergen products in the EU distinguishes relevant and non-relevant allergens. Given the lack of knowledge on their clinical relevance, minor allergens are usually not controlled by allergen product specifications. Especially in birch pollen (BP) allergen products, minor allergens are commonly disregarded. OBJECTIVES: To quantify three minor allergens in BP allergen products from different manufacturers and to assess the influence of the utilized BP on minor allergen patterns. METHODS: Besides common quality parameters like Bet v 1 content, Bet v 4, Bet v 6 and Bet v 7 were quantified in 70 BP allergen product batches from six manufacturers, using ELISA systems developed in-house. Batch-to-batch variability was checked for agreement with a variability margin of 50-200% from mean of the given batches for individual allergen content. Subsequently, minor allergen patterns were generated via multidimensional scaling and related to information on the pollen lots used in production of the respective product batches. RESULTS: Like the already established Bet v 4 ELISA, the ELISA systems for quantification of Bet v 6 and Bet v 7 were successfully validated. Differences in minor allergen content between products as well as batch-to-batch consistency were observed. Correlations between minor and major allergen content were low to moderate. 20% of batches exceeded the variability margin for at least one minor allergen. Interestingly, these fluctuations could not in all cases be linked to the use of certain BP lots. CONCLUSIONS &amp; CLINICAL RELEVANCE: The impact of the observed minor allergen variability on safety and efficacy of BP allergen products can currently not be estimated. As the described differences could only in few cases be related to the used pollen lots, it is evident that additional factors influence minor allergens in BP allergen products. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12955</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28493312">PM:28493312</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170511-ZimmerJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170511-ZimmerJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Zimmer J</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12955</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ziyab,A.H.</style></author><author><style face="normal" font="Arial"> Ewart,S.</style></author><author><style face="normal" font="Arial"> Lockett,G.A.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Arshad,H.</style></author><author><style face="normal" font="Arial"> Holloway,J.W.</style></author><author><style face="normal" font="Arial"> Karmaus,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Community Medicine and Behavioral Sciences, Faculty of Medicine, Kuwait University, Kuwait</style></auth-address><titles><title><style face="normal" font="Arial">Expression of the filaggrin gene in umbilical cord blood predicts eczema risk in infancy: a birth cohort study</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1192" start="1185">1185-1192</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> community medicine</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> filaggrin gene</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Poisson</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Umbilical Cord</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="5" Year="2017">2017/5/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Filaggrin gene (FLG) expression, particularly in the skin, has been linked to the development of the skin barrier and is associated with eczema risk. However, knowledge as to whether FLG expression in umbilical cord blood (UCB) is associated with eczema development and prediction is lacking. OBJECTIVE: This study sought to assess whether FLG expression in UCB associates with and predicts the development of eczema in infancy. METHODS: Infants enrolled in a birth cohort study (n = 94) were assessed for eczema at ages 3-, 6-, and 12-months. Five probes measuring FLG transcripts expression in UCB were available from genome-wide gene expression profiling. FLG genetic variants R501X, 2282del4, and S3247X were genotyped. Associations were assessed using Poisson regression with robust variance estimation. Area under the curve (AUC), describing the discriminatory/predictive performance of fitted models, was estimated from logistic regression. RESULTS: Increased level of FLG expression measured by probe A_24_P51322 was associated with reduced risk of eczema during the first year of life (RR = 0.60, 95% CI: 0.38-0.95). In contrast, increased level of FLG antisense transcripts measured by probe A_21_P0014075 was associated with increased risk of eczema (RR = 2.02, 95% CI: 1.10-3.72). In prediction models including FLG expression, FLG genetic variants, and sex, discrimination between children who will and will not develop eczema at 3-months of age was high (AUC: 0.91, 95% CI: 0.84-0.98). CONCLUSIONS AND CLINICAL RELEVANCE: This study demonstrated, for the first time, that FLG expression in UCB is associated with eczema development in infancy. Moreover, our analysis provided prediction models that were capable of discriminating, to a great extent, between those who will and will not develop eczema in infancy. Therefore, early identification of infants at increased risk of developing eczema is possible and such high-risk newborns may benefit from early stratification and intervention. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170514IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Kuwait -CO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12956</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502108">PM:28502108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170514-ZiyabAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170514-ZiyabAH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170514, Ziyab AH</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12956</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sousa,A.R.</style></author><author><style face="normal" font="Arial"> Marshall,R.P.</style></author><author><style face="normal" font="Arial"> Warnock,L.C.</style></author><author><style face="normal" font="Arial"> Bolton,S.</style></author><author><style face="normal" font="Arial"> Hastie,A.</style></author><author><style face="normal" font="Arial"> Symon,F.</style></author><author><style face="normal" font="Arial"> Hargadon,B.</style></author><author><style face="normal" font="Arial"> Marshall,H.</style></author><author><style face="normal" font="Arial"> Richardson,M.</style></author><author><style face="normal" font="Arial"> Brightling,C.E.</style></author><author><style face="normal" font="Arial"> Haldar,P.</style></author><author><style face="normal" font="Arial"> Milone,R.</style></author><author><style face="normal" font="Arial"> Chalk,P.</style></author><author><style face="normal" font="Arial"> Williamson,R.</style></author><author><style face="normal" font="Arial"> Panettieri,R.,Jr.</style></author><author><style face="normal" font="Arial"> Knowles,R.</style></author><author><style face="normal" font="Arial"> Bleecker,E.R.</style></author><author><style face="normal" font="Arial"> Wardlaw,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">GlaxoSmithKline Stevenage, UK</style></auth-address><titles><title><style face="normal" font="Arial">Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="899" start="890">890-899</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> CCL2</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PC20</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients with severe asthma appear relatively corticosteroid resistant. Corticosteroid responsiveness is closely related to the degree of eosinophilic airway inflammation. The extent to which eosinophilic airway inflammation in severe asthma responds to treatment with systemic corticosteroids is not clear. OBJECTIVE: To relate the physiological and inflammatory response to systemic corticosteroids in asthma to disease severity and the baseline extent of eosinophilic inflammation. METHODS: Patients with mild/moderate and severe asthma were investigated before and after two-weeks of oral prednisolone (Clintrials. gov NCT00331058 and NCT00327197). We pooled the results from 2 studies with common protocols. The US study contained 2 independent centres and the UK 1 independent centre. The effect of oral corticosteroids on FEV1 , Pc20, airway inflammation and serum cytokines were investigated. Baseline measurements were compared with healthy subjects. RESULTS: 32 mild/moderate asthmatics, 50 severe asthmatics and 35 healthy subjects took part. At baseline both groups of asthmatics had a lower FEV1 and Pc20 and increased eosinophilic inflammation compared to healthy subjects. The severe group had a lower FEV1 and more eosinophilic inflammation compared to mild/moderate asthmatics. Oral prednisolone caused a similar degree of suppression of eosinophilic inflammation in all compartments in both groups of asthmatics. There were small improvements in FEV1 and Pc20 for both mild/ moderate and severe asthmatics with a correlation between the baseline eosinophilic inflammation and the change in FEV1 . There was a ~50% reduction in the serum concentration of CXCL10 (IP-10), CCL22 (MDC), CCL17 (TARC), CCL-2 (MCP-1) and CCL-13 (MCP-4) in both asthma groups after oral corticosteroids. CONCLUSIONS AND CLINICAL RELEVANCE: Disease severity does not influence the response to systemic corticosteroids. The study does not therefore support the concept that severe asthma is associated with corticosteroid resistance. Only baseline eosinophilic inflammation was associated with the physiological response to corticosteroids, confirming the importance of measuring eosinophilic inflammation to guide corticosteroid use. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12954</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28493293">PM:28493293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170511-SousaAR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170511-SousaAR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Sousa AR</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12954</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Langier,S.</style></author><author><style face="normal" font="Arial"> Benor,S.</style></author><author><style face="normal" font="Arial"> Kadar,L.</style></author><author><style face="normal" font="Arial"> Shani,N.</style></author><author><style face="normal" font="Arial"> Etkin,S.</style></author><author><style face="normal" font="Arial"> Stark,M.</style></author><author><style face="normal" font="Arial"> Bondar,E.</style></author><author><style face="normal" font="Arial"> Aizic,A.</style></author><author><style face="normal" font="Arial"> Kivity,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology Unit, Tel Aviv University, Tel Aviv, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Aging leads to impaired epicutaneous sensitization that causes attenuated allergy and pulmonary inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Pharmacol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Pharmacol Physiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory sensitization</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">Aging is associated with altered decreased barrier function in the skin, which can lead to different types of immunoglobulin E (IgE)-mediated sensitization to environmental allergens. Yet, allergen-specific respiratory sensitization among the elderly is not well described. The aim of this study was to investigate the effect of aging on allergic pulmonary inflammation induced by epicutaneous sensitization of mechanically irritated skin in mice. For this purpose, 6-week-, 6-month-, and 18-month-old female BALB/c mice, underwent epicutaneous sensitization with ovalbumin (OVA) or PBS, followed by an inhaled OVA challenge. Blood OVA-specific IgE levels measured after epicutaneous sensitization, as well as, bronchial alveolar lavage fluids (BALF) leucocyte, eosinophil, and cytokine levels measured after OVA inhalation challenge were similar among the 6-week-old (young) and 6-month-old (adult) groups. However, significantly decreased levels of systemic OVA-IgE, and BALF leukocyte, eosinophil and T helper cell type 2 cytokine levels, were measured after OVA inhalation challenge in elderly (18-month-old) mice compared to the other groups of mice. In addition, interleukin-10 (IL-10), a regulatory suppressor cytokine, was more abundant in the BALF of the elderly group after epicutaneous sensitization and inhalation challenge. Our results suggest that elderly mice have a reduced allergic response to induced sensitization with OVA, possibly regulated by increased IL-10 levels. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 1440-1681 (Electronic)IS - 0305-1870 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/1440-1681.12778</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28466565">PM:28466565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Pharmacol Physiol\20170503-LangierS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Pharmacol Physiol\20170503-LangierS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Langier S</style></custom2><misc3><style face="normal" font="Arial">10.1111/1440-1681.12778</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hiremath,G.</style></author><author><style face="normal" font="Arial"> Gupta,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Assistant Professor of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, TN</style></auth-address><titles><title><style face="normal" font="Arial">Promising Modalities to Identify and Monitor Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> biomaterials</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagogastroduodenoscopy</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is an allergen-mediated condition characterized by symptoms of esophageal dysfunction and histological evidence of intense eosinophilic inflammation involving the esophagus in absence of overlapping conditions such as gastroesophageal reflux disease. Since the initial description as a distinct entity about two decades ago, there has been a remarkable rise in the recognition of this clinico-pathologic entity. Current approach to diagnose and monitor EoE requires repeated esophagogastroduodenoscopies (EGDs), with associated sedation/anesthesia, to visualize mucosal abnormalities, and to obtain multiple biopsies for histologic assessment and to evaluate treatment response. Frequent EGDs with multiple biopsies can increase the risk of procedural complications, place significant financial burden on families, and escalate healthcare costs. In addition, this burdensome approach may contribute towards delayed diagnosis and sub-optimal monitoring thereby increasing the likelihood of complications such as esophageal narrowing and stricture formation which may require escalation of care including endoscopic interventions. Clinical progression and complications associated with EoE can be attenuated through early identification and optimal management. Therefore, developing reliable, safe, less cumbersome and cost-effective modalities for early diagnosis and effective monitoring of EoE is an area of active research. These efforts have been substantially supported by development of new biomaterials, analytical methodologies and application of novel concepts. Herein, we summarize modalities which have shown promise to advance diagnosis and monitoring of EoE and could improve the care of affected individuals and advance the field</style></abstract><notes><style face="normal" font="Arial">DA - 20170514IS - 1542-7714 (Electronic)IS - 1542-3565 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cgh.2017.05.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28501533">PM:28501533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Gastroenterol Hepatol\20170514-HiremathG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Gastroenterol Hepatol\20170514-HiremathG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170514, Hiremath G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cgh.2017.05.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Bilsen,J.H.M.</style></author><author><style face="normal" font="Arial"> Sienkiewicz-Szlapka,E.</style></author><author><style face="normal" font="Arial"> Lozano-Ojalvo,D.</style></author><author><style face="normal" font="Arial"> Willemsen,L.E.M.</style></author><author><style face="normal" font="Arial"> Antunes,C.M.</style></author><author><style face="normal" font="Arial"> Molina,E.</style></author><author><style face="normal" font="Arial"> Smit,J.J.</style></author><author><style face="normal" font="Arial"> Wroblewska,B.</style></author><author><style face="normal" font="Arial"> Wichers,H.J.</style></author><author><style face="normal" font="Arial"> Knol,E.F.</style></author><author><style face="normal" font="Arial"> Ladics,G.S.</style></author><author><style face="normal" font="Arial"> Pieters,R.H.H.</style></author><author><style face="normal" font="Arial"> Denery-Papini,S.</style></author><author><style face="normal" font="Arial"> Vissers,Y.M.</style></author><author><style face="normal" font="Arial"> Bavaro,S.L.</style></author><author><style face="normal" font="Arial"> Larre,C.</style></author><author><style face="normal" font="Arial"> Verhoeckx,K.C.M.</style></author><author><style face="normal" font="Arial"> Roggen,E.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">TNO, PO Box 360, 3700 AJ Zeist, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Application of the adverse outcome pathway (AOP) concept to structure the available in vivo and in vitro mechanistic data for allergic sensitization to food proteins</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="13">13-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Respiratory sensitization</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The introduction of whole new foods in a population may lead to sensitization and food allergy. This constitutes a potential public health problem and a challenge to risk assessors and managers as the existing understanding of the pathophysiological processes and the currently available biological tools for prediction of the risk for food allergy development and the severity of the reaction are not sufficient. There is a substantial body of in vivo and in vitro data describing molecular and cellular events potentially involved in food sensitization. However, these events have not been organized in a sequence of related events that is plausible to result in sensitization, and useful to challenge current hypotheses. The aim of this manuscript was to collect and structure the current mechanistic understanding of sensitization induction to food proteins by applying the concept of adverse outcome pathway (AOP). MAIN BODY: The proposed AOP for food sensitization is based on information on molecular and cellular mechanisms and pathways evidenced to be involved in sensitization by food and food proteins and uses the AOPs for chemical skin sensitization and respiratory sensitization induction as templates. Available mechanistic data on protein respiratory sensitization were included to fill out gaps in the understanding of how proteins may affect cells, cell-cell interactions and tissue homeostasis. Analysis revealed several key events (KE) and biomarkers that may have potential use in testing and assessment of proteins for their sensitizing potential. CONCLUSION: The application of the AOP concept to structure mechanistic in vivo and in vitro knowledge has made it possible to identify a number of methods, each addressing a specific KE, that provide information about the food allergenic potential of new proteins. When applied in the context of an integrated strategy these methods may reduce, if not replace, current animal testing approaches. The proposed AOP will be shared at the www.aopwiki.org platform to expand the mechanistic data, improve the confidence in each of the proposed KE and key event relations (KERs), and allow for the identification of new, or refinement of established KE and KERs</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -CO - Poland -CO - Spain -CO - Portugal -CO - United States -CO - France -CO - Italy -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0152-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28507730">PM:28507730</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, van Bilsen JH</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0152-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elliott,J.</style></author><author><style face="normal" font="Arial"> Kelly,S.E.</style></author><author><style face="normal" font="Arial"> Johnston,A.</style></author><author><style face="normal" font="Arial"> Skidmore,B.</style></author><author><style face="normal" font="Arial"> Gomes,T.</style></author><author><style face="normal" font="Arial"> Wells,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Affiliations: School of Epidemiology, Public Health and Preventive Medicine (Elliott, Kelly, Wells), University of Ottawa; Cardiovascular Research Methods Centre (Elliott, Kelly, Johnston, Wells), University of Ottawa Heart Institute</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review</style></title><secondary-title><style face="normal" font="Arial">CMAJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">CMAJ Open</style></abbr-1></periodical><pages end="E385" start="E373">E373-E385</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis and asthma are important public health concerns, yet there is no consensus about the benefits and harms of allergen-specific immunotherapy to treat these conditions. We performed an umbrella review of systematic reviews summarizing the current evidence for the benefits and harms of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). METHODS: We searched MEDLINE, Embase, the Cochrane Library and the grey literature from Jan. 1, 2010 to Nov. 20, 2016 for systematic reviews of randomized controlled trials or prospectively controlled studies involving children or adults with allergic rhinitis or asthma. Outcomes were summarized narratively (benefits: total combined symptom-medication score, symptom score, medication score, disease-specific quality of life, adherence; harms: anaphylaxis, death, local and systemic reactions). RESULTS: Twenty-three systematic reviews were included. SCIT and SLIT were more effective than placebo for most outcomes. SCIT was better than SLIT at improving medication and symptom scores, with no differences in quality of life; however, data were limited for this comparison. Anaphylaxis and death were infrequently reported. Few reviews assessed benefits or harms among children. INTERPRETATION: Allergen immunotherapy appears to be effective among patients with allergic rhinitis and asthma. The safety of allergen immunotherapy is not conclusively established, although death and anaphylaxis appear to be rare. PROSPERO no.: CRD42015024590</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2291-0026 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.9778/cmajo.20160066</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28495938">PM:28495938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\CMAJ Open\2017-5-E373-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\CMAJ Open\2017-5-E373-85.pdf</url></text-urls><related-urls><url ppv-ref="no">suppl. segnalati ma non scaricabili</url></related-urls></urls><custom2><style face="normal" font="Arial">20170512, Elliott J</style></custom2><misc3><style face="normal" font="Arial">10.9778/cmajo.20160066</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tomsitz,D.</style></author><author><style face="normal" font="Arial"> Brockow,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Biederstein, Technische Universitat Munchen, Biedersteiner Strasse 29, 80802, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Component Resolved Diagnosis in Hymenoptera Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Api m 10</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Honey</style></keyword><keyword><style face="normal" font="Arial"> honey bee</style></keyword><keyword><style face="normal" font="Arial"> honey bee venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera allergy</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> Ves v 5</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Hymenoptera anaphylaxis is one of the leading causes of severe allergic reactions and can be fatal. Venom-specific immunotherapy (VIT) can prevent a life-threatening reaction; however, confirmation of an allergy to a Hymenoptera venom is a prerequisite before starting such a treatment. Component resolved diagnostics (CRD) have helped to better identify the responsible allergen. RECENT FINDINGS: Many new insect venom allergens have been identified within the last few years. Commercially available recombinant allergens offer new diagnostic tools for detecting sensitivity to insect venoms. Additional added sensitivity to nearly 95% was introduced by spiking yellow jacket venom (YJV) extract with Ves v 5. The further value of CRD for sensitivity in YJV and honey bee venom (HBV) allergy is more controversially discussed. Recombinant allergens devoid of cross-reactive carbohydrate determinants often help to identify the culprit venom in patients with double sensitivity to YJV and HBV. CRD identified a group of patients with predominant Api m 10 sensitization, which may be less well protected by VIT, as some treatment extracts are lacking this allergen. The diagnostic gap of previously undetected Hymenoptera allergy has been decreased via production of recombinant allergens. Knowledge of analogies in interspecies proteins and cross-reactive carbohydrate determinants is necessary to distinguish relevant from irrelevant sensitizations</style></abstract><notes><style face="normal" font="Arial">DA - 20170514IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0707-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28501976">PM:28501976</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170514, Tomsitz D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0707-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Polk,B.I.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Allergy/Immunology, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO, 64108, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Patient-Centered Outcomes in Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Activities of Daily Living</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Food allergy prevalence is increasing very rapidly, causing a significant disease burden. The threat of severe allergic reactions occurring unexpectedly and in settings that are not equipped to recognize and treat anaphylaxis is a constant source of worry for individuals and families with food allergies. Inadequate knowledge and understanding in the community significantly impairs the overall quality of life of these individuals and families. Additionally, families face challenges in finding and affording appropriate allergen-free foods. RECENT FINDINGS: Advancements have been made in understanding the impact of food allergies on patient-centered outcomes such as quality of life and economic impact, and attempts have been made to develop tools to assess patient-centered variables. Innovative national and regional initiatives are helping to spread awareness of the disease condition and to create resources, including access to allergen-free foods. While there is a growing momentum toward recognition of food allergic disorders as a condition that profoundly impacts activities of daily living, greater effort needs to be expounded to develop validated tools and interventions that can adequately address these issues</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial"> 10.1007/s11882-017-0708-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28516366">PM:28516366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Polk BI</style></custom2><misc3><style face="normal" font="Arial"> 10.1007/s11882-017-0708-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shaker,M.S.</style></author><author><style face="normal" font="Arial"> Schwartz,J.</style></author><author><style face="normal" font="Arial"> Ferguson,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aChildren's Hospital at Dartmouth, Lebanon bThe Geisel School of Medicine, Hanover, New Hampshire cWhite River Junction VA Medical Center, White River Junction, Vermont dSeton Hill University, Greensburg Pennsylvania, USA</style></auth-address><titles><title><style face="normal" font="Arial">An update on the impact of food allergy on anxiety and quality of life</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pediatr</style></full-title></periodical><pages end="502" start="497">497-502</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Counseling</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mitigation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vermont</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="13" Month="5" Year="2017">2017/5/13</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Food allergies have become more common, and management involves dietary avoidance that can impair quality of life. Patients and families must manage the daily risk of anaphylaxis at each meal. The purpose of this review is to describe the impact of food allergies on quality of life and to provide an update on new developments in food allergy management, particularly peanut allergy. RECENT FINDINGS: Food allergy requires careful avoidance of common and ubiquitous dietary allergens. Living with food allergy is associated with annual economic costs in excess of $4000 per child, in addition to risks of anxiety and depressive symptoms. An expert panel sponsored by the 2017 National Institute of Allergy and Infectious Diseases published addendum guidelines for the prevention of peanut allergy, which suggest three separate approaches to peanut protein introduction for infants at various levels of risk. SUMMARY: Clinicians must be aware of underappreciated burdens faced by children and families with food allergies. Management involves a partnership between primary and specialty care. Mitigation strategies to improve quality of life for patients include efforts to avoid overdiagnosis in synergy with balanced counseling about the risks of food allergies. Experimental food allergen desensitization can improve quality of life but remains investigational at this time. For patients with significant anxiety, interdisciplinary management involving professional counseling may be helpful. Risk stratification and early introduction of peanut protein can help prevent the development of peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1531-698X (Electronic)IS - 1040-8703 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOP.0000000000000509</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509782">PM:28509782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pediatr\20170516-ShakerMS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pediatr\20170516-ShakerMS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Shaker MS</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOP.0000000000000509</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Switlyk,S.A.</style></author><author><style face="normal" font="Arial"> Taylor,A.L.</style></author><author><style face="normal" font="Arial"> Gaertner,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Private practice, Sarasota, Florida, USADepartment of Dermatology, University of Florida, Gainesville, USA</style></auth-address><titles><title><style face="normal" font="Arial">Severe refractory atopic dermatitis with elevated serum IgE treated with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cutis</style></full-title></periodical><pages end="E8" start="E6">E6-E8</pages><volume><style face="normal" font="Arial">99</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Private Practice</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28492605">PM:28492605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cutis\2017-99-E6-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cutis\2017-99-E6-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Switlyk SA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,K.</style></author><author><style face="normal" font="Arial"> Xu,W.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Leng,Y.</style></author><author><style face="normal" font="Arial"> Wu,W.</style></author><author><style face="normal" font="Arial"> Peng,X.</style></author><author><style face="normal" font="Arial"> Liang,Y.</style></author><author><style face="normal" font="Arial"> Li,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Establishment of a novel quantum dots-encoded microbead-based flow cytometric method for quantification of soluble FcepsilonRIalpha in serum</style></title><secondary-title><style face="normal" font="Arial">Cytometry A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cytometry A</style></full-title></periodical><pages end="693" start="686">686-693</pages><volume><style face="normal" font="Arial">91</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptance</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Emulsification</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantum Dots</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="Arial">The soluble form of the transmembrane glycoprotein, FcepsilonRIalpha which corresponds to the high-affinity receptor for IgE, is found in serum. Growing evidence suggests the pathogenic role of IgE and FcepsilonRI in systemic lupus erythematosus (SLE). The goal of this study is to develop a sensitive and standardized cytometric assay for quantification of sFcepsilonRIalpha. A membrane emulsification technique was utilized to incorporate CuInS2 /ZnS quantum dots and Fe3 O4 nanoparticles into poly (styrene-co-maleic anhydride) microbeads. The beads were then carboxylated and coated with capture antibody monoclonal anti-human FcepsilonRIalpha. This antibody binds to FcepsilonRIalpha but does not block the binding of FcepsilonRIalpha to IgE. After incubation with standards or serum samples, the microbeads were incubated with excessive native human IgE, followed by incubation with Phycoerythrin (PE) conjugated anti-human IgE. The resulting quantum dot microbeads were gated, and sFcepsilonRIalpha quantification was analyzed based on PE fluorescence intensity. The method exhibited good linearity (R2 > 0.99), and the limit of detection was established at 0.29 ng/mL with the dynamic range of up to 200 ng/mL. The precision of the assay validated by intra- and inter-assay variability met the acceptance criteria with the mean recovery falling within 80-110% of the theoretical concentration and a corresponding CV &lt; 20%. We tested 149 serum samples which 89 were from SLE patients and 60 were from healthy volunteers. For the first time, we detected an increased sFcepsilonRIalpha level in the serum of SLE patients, which was confirmed by a commercial ELISA kit. Compared to ELISA, this novel method is more sensitive and efficient. It allows for the simple comparative analysis of sFcepsilonRIalpha levels in health and disease. (c) 2017 International Society for Advancement of Cytometry</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1552-4930 (Electronic)IS - 1552-4922 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/cyto.a.23128</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28505391">PM:28505391</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytometry A\20170515-LinK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytometry A\20170515-LinK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Lin K</style></custom2><misc3><style face="normal" font="Arial">10.1002/cyto.a.23128</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simpson,E.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Oregon Health and Science University, Portland, OR, USA. simpsone@ohsu.edu</style></auth-address><titles><title><style face="normal" font="Arial">Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials</style></title><secondary-title><style face="normal" font="Arial">Dermatol Ther (Heidelb)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dermatol Ther (Heidelb)</style></full-title></periodical><pages end="248" start="243">243-248</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oregon</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="5" Year="2017">2017/5/13</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Patients with moderate-to-severe atopic dermatitis (AD) report a multidimensional disease burden that includes impaired health-related quality-of-life (HRQoL). Changes in overall health status and specific dimensions that contribute to HRQoL were evaluated in adults with moderate-to-severe AD who participated in phase 3 clinical trials of dupilumab, which is a fully human monoclonal antibody that inhibits signaling of cytokines IL-4 and IL-13. METHODS: Two dupilumab phase 3 clinical trials of identical design included the 5-dimension 3-level EuroQol (EQ-5D) as a measure of HRQoL. EQ-5D data from the two trials were pooled in an analysis that, using analysis of covariance, compared subcutaneous dupilumab 300 mg once weekly (qw) or every 2 weeks (q2w) versus placebo for EQ-5D utility score change from baseline overall and for clinical responders. The proportions of patients who reported different levels of problems on the individual dimension of the EQ-5D were also compared by treatment group. RESULTS: Patients (n = 1379) were 57.9% male with a mean (SD) age of 38.3 (14.3) years; baseline EQ-5D utility scores ranged from 0.611 to 0.629 across treatment groups. EQ-5D least squares mean change from baseline at week 16 was 0.031 with placebo, and was significantly greater with dupilumab qw (0.207) and q2w (0.210) (both P &lt; 0.0001), which exceeded the minimal clinically important difference and resulted in scores that approached population norms. Changes from baseline among patients who achieved AD clinical response were greater than changes among the total population. Improvements were driven by the individual EQ-5D dimensions with the greatest burden at baseline (i.e., pain/discomfort, anxiety/depression and usual activities). CONCLUSION: In adults with moderate-to-severe AD, dupilumab resulted in improvements in HRQoL that were statistically significant relative to placebo and were clinically meaningful. FUNDING: Sanofi and Regeneron Pharmaceuticals, Inc. TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT02277743 and NCT02277769, EudraCT Numbers 2014-001198-15 and 2014-002619-40</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 2193-8210 (Print)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13555-017-0181-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28503712">PM:28503712</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dermatol Ther (Heidelb)\20170515-SimpsonEL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dermatol Ther (Heidelb)\20170515-SimpsonEL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Simpson EL</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13555-017-0181-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adis Medical Writers</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Individualize treatment for vernal keratoconjunctivitis based on clinical features and personal preferences</style></title><secondary-title><style face="normal" font="Arial">Drugs Ther Perspect</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs Ther Perspect</style></full-title></periodical><pages end="276" start="272">272-276</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> immunomodulators</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Tacrolimus</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1179-1977</style></isbn><abstract><style face="normal" font="Arial">Due to the lack of clarity regarding the pathogenesis of vernal keratoconjunctivitis, the treatment of this condition is challenging. The therapeutic regimen should be selected from among the many options (e.g. oral and/or topical mast-cell stabilizers, antihistamines, corticosteroids, and immunomodulators) based on the clinical features of the disease, personal preferences of the patient and clinical experience of the prescriber. Moderate-to-severe vernal keratoconjunctivitis may require topical corticosteroid treatment during the acute phase, followed by topical ciclosporin or tacrolimus for long-term management</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40267-017-0405-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40267-017-0405-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs Ther Perspect\2017-33-272-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs Ther Perspect\2017-33-272-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Adis Medical Writers</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40267-017-0405-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ramadan,R.A.</style></author><author><style face="normal" font="Arial"> Morad,E.A.</style></author><author><style face="normal" font="Arial"> El-Shabrawy,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Microbiology &amp; Immunology,Faculty of Medicine, Zagazig University, Zagazig, Egypt</style></auth-address><titles><title><style face="normal" font="Arial">T Regulatory Cells Response to Allergen Specific Immunotherapy in Patients with Allergic Airway Diseases: A Prospective Study</style></title><secondary-title><style face="normal" font="Arial">Egypt J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Egypt J Immunol</style></full-title></periodical><pages end="63" start="51">51-63</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inverse correlation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> self-antigens</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Forkhead box P3 (FoxP3) T regulatory (Treg) cells modulate the immune system by blocking other types of T-cells. They maintain tolerance to self-antigens and help in inducing tolerance to foreign antigens. A deregulation of FoxP3 Tregs seems to play an important role in allergic disorders. The aim of this work was to study the response of FoxP3 Treg cells and their FoxP3 expression in patients, attending the Allergy Unit and the Chest Outpatient Clinic, Faculty of Medicine, Zagazig University, with allergic airway diseases, before and 1 year after receiving subcutaneous allergen specific immunotherapy (SIT). This prospective study was carried out on 25 patients with allergic airway diseases, confirmed by positive skin test, and that showed clinical improvement one year after SIT. All cases were subjected to total immunoglobulin E quantitation by ELISA. FoxP3 Treg cells frequency and FoxP3 relative fluorescence intensity, as an indicator of Tregs function, were assessed by flowcytometry. The results were compared before and after SIT. Twenty five age and sex matched apparently healthy volunteers were enrolled as controls. Our findings demonstrated that in comparison to the control group, the count of FoxP3 T regulatory cells was higher; however, the function was lower among the enrolled patients (P= 0.007 and P&lt; 0.001, respectively). When FoxP3 Tregs were compared in the patients before and one year after SIT, it was found that both the count and FoxP3 expression showed statistically significant increase (P&lt; 0.001). An inverse correlation was found between FoxP3 Tregs count and FoxP3 expression. It is concluded that patients with allergic airway diseases have increased number of FoxP3 Treg cells but with defective function. SIT plays a role in increasing the number of FoxP3 Tregs and improving their suppressive function, which leads to control of airway inflammation and thus clinical improvement</style></abstract><notes><style face="normal" font="Arial">DA - 20170514IS - 1110-4902 (Print)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502133">PM:28502133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Egypt J Immunol\2016-23-51-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Egypt J Immunol\2016-23-51-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170514, Ramadan RA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">El-Sayed,Z.A:</style></author><author><style face="normal" font="Arial"> Radwan,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy-immunology glossary</style></title><secondary-title><style face="normal" font="Arial">Egypt J Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Egypt J Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="32">32-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Egypt</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Egypt -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.jespai.org/ulogs/paperindex.php?paperID=253&amp;topicid=1&amp;issueid=29</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Egypt J Pediatr Allergy Immunol\2017-15-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Egypt J Pediatr Allergy Immunol\2017-15-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, El-Sayed ZA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larrea-Baca,I.</style></author><author><style face="normal" font="Arial"> Gurpegui-Resano,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergologia, Ambulatorio Conde Oliveto, Servicio Navarro de Salud (Osasunbidea), Pamplona, Espana.</style></auth-address><titles><title><style face="normal" font="Arial">Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life</style></title><secondary-title><style face="normal" font="Arial">Enferm Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Enferm Clin</style></full-title></periodical><pages end="368" start="361">361-368</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SF36</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Evaluation of the impact on the quality of life (QOL) relating to health in patients with chronic urticaria (CSU) treated with omalizumab. METHOD: Longitudinal descriptive observational study of quality of life based on18 patients with chronic urticaria >/=12 years treated with omalizumab. Changes in QOL examined at 1 month (T1), at 6 months (T6) and 12 months (T12), by: Visual Analogical Scale (UAS), specific urticaria QOL questionnaire (CU-Q2oL), general health questionnaire (SF-36) and activity of urticaria questionnaire (Score UAS7). RESULTS: The most disabling symptoms for patients were: pruritus (61.1%); decrease in health and physical activity (55.5%), wheals, swelling and nervousness (50%); depression and shame of marks (38.89%); side effects to drugs (33.33%); sleepiness and tiredness (27.78%); work (22.22%); "choosing clothes and pain" 16.67% and social relations (11.11%). Statistically significant differences were observed in T1, T6 and T12. In T1, UAS -4.72 (p=.001); CU-Q2oL -16.38 (p&lt;.001); SF-36 15.44 (p=.006); UAS7 wheals -7.27 (p=.001), UAS7 pruritus -8.72 (p=.003). In T6, UAS -4.26 (p=.001); CU-Q2oL -18.94 (p&lt;.001); SF-36 15.41 (p&lt;.001); UAS7 wheals -7.41 (p=.001), UAS7 pruritus -7.11 (p=.001). In T12 UAS -9.61 (p=.004); CU-Q2oL -21.38 (p=.01); SF-36 17.53 (p=.04); UAS7 wheals -8.23 (p=.004), UAS7 pruritus -10.69 (p=.004). CONCLUSIONS: There was a very good response in T1, which was maintained in T6 and T12. Patients with chronic urticaria treated with omalizumab presented good results with a reduction of CUE activity and improvement of their QOL</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1579-2013 (Electronic)IS - 1130-8621 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.enfcli.2017.03.01</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457893">PM:28457893</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170501, Larrea-Baca I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.enfcli.2017.03.01</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stickley,A.</style></author><author><style face="normal" font="Arial"> Sheng Ng,C.F.</style></author><author><style face="normal" font="Arial"> Konishi,S.</style></author><author><style face="normal" font="Arial"> Koyanagi,A.</style></author><author><style face="normal" font="Arial"> Watanabe,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Stockholm Center for Health and Social Change (SCOHOST), Sodertorn University, Huddinge 141 89, Sweden.</style></auth-address><titles><title><style face="normal" font="Arial">Airborne pollen and suicide mortality in Tokyo, 2001-2011</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="140" start="134">134-140</pages><volume><style face="normal" font="Arial">155</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Labour</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Social Change</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Suicide</style></keyword><keyword><style face="normal" font="Arial"> Sulfur</style></keyword><keyword><style face="normal" font="Arial"> Sulfur Dioxide</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Prior research has indicated that pollen might be linked to suicide mortality although the few studies that have been undertaken to date have produced conflicting findings and been limited to Western settings. This study examined the association between the level of airborne pollen and suicide mortality in Tokyo, Japan in the period from 2001 to 2011. The daily number of suicide deaths was obtained from the Japanese Ministry of Health, Labour and Welfare, with pollen data being obtained from the Tokyo Metropolitan Institute of Public Health. A time-stratified case-crossover study was performed to examine the association between different levels of pollen concentration and suicide mortality. During the study period there were 5185 male and 2332 female suicides in the pollen season (February to April). For men there was no association between airborne pollen and suicide mortality. For women, compared to when there was no airborne pollen, the same-day (lag 0) pollen level of 30 to &lt;100 grains per cm2 was associated with an approximately 50% increase in the odds for suicide (e.g. 30 to &lt;50 grains per cm2: odds ratio 1.574, 95% confidence interval 1.076-2.303, p=0.020). The estimates remained fairly stable after adjusting for air pollutants and after varying the cut-points that defined the pollen levels. Our results indicate that pollen is associated with female suicide mortality in Tokyo</style></abstract><notes><style face="normal" font="Arial">DA - 20170220IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleRN - 0 (Air Pollutants)RN - 0 (Allergens)RN - 0 (Particulate Matter)RN - 0UZA3422Q4 (Sulfur Dioxide)RN - 66H7ZZK23N (Ozone)RN - S7G510RUBH (Nitrogen Dioxide)SB - IMCO - Sweden -CO - Japan -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2017.02.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219016">PM:28219016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-155-134-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-155-134-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170220, Stickley A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2017.02.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tammaro,A.</style></author><author><style face="normal" font="Arial"> Romano,I.</style></author><author><style face="normal" font="Arial"> Parisella,F.R.</style></author><author><style face="normal" font="Arial"> De Marco,G.</style></author><author><style face="normal" font="Arial"> Persechino,F.</style></author><author><style face="normal" font="Arial"> Trimarchi,I.</style></author><author><style face="normal" font="Arial"> Persechino,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">UOC Dermatology, NESMOS Department, Faculty of Medicine and Psycology, Sapienza University of Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Successful of subcutaneous and oral hyposensitizing therapy in 30 patients</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="137" start="135">135-137</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic drug</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic drugs</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> rast</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Background. Pharmacotherapy and immunotherapy are the main treatment modalities for respiratory allergy. The aim of this paper has been to evaluate the efficacy and tolerability of subcutaneous and sublingual immunotherapy in association in allergic patients, and to demonstrate that the patients who have performed a second oral vaccination cycle after 4-5 years from the first subcutaneous treatment, derive benefits that may last for years. This is due to immune system's plasticity. Methods. The study was conducted in 30 allergic patients which had previously executed a full cycle of classical subcutaneous immunotherapy, with a partial remission of symptoms. After 4-5 years, they were subjected to sublingual immunotherapy for the same allergen, improving the results obtained. Results. All the patients reported a decrease or absence of clinical symptoms, a reduction in the use of anti-allergic drugs, and lower values of PRIST and RAST after the treatment. Conclusions. The results of this clinical study confirm the improvement of results when subcutaneous and sublingual immunotherapy are associated</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497677">PM:28497677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-135-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-135-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Tammaro A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Disappearance of severe oral allergy syndrome following omalizumab treatment</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="144" start="143">143-144</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">The first case of disappearance of apple-induced oral allergy syndrome in a birch pollen-allergic patient following omalizumab treatment is reported. This observation in a case of type 2 food allergy suggests that omalizumab is potentially an effective preventive treatment for patients with severe, type 1 food allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497679">PM:28497679</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-143-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-143-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Asero R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roger,R.A.</style></author><author><style face="normal" font="Arial"> Ibero,I.M.</style></author><author><style face="normal" font="Arial"> Carrillo,D.T.</style></author><author><style face="normal" font="Arial"> Lopez,A.R.</style></author><author><style face="normal" font="Arial"> Sanchez,M.V.</style></author><author><style face="normal" font="Arial"> Alvarez,N.J.</style></author><author><style face="normal" font="Arial"> Cancelliere,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Perceived efficacy and satisfaction of patients with subcutaneous hypoallergenic high-dose house dust mite extract</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="105" start="100">100-105</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">The efficacy and safety of subcutaneous immunotherapy with modified, high-dose, major allergen house dust mite extract is widely supported by double-blind, placebo-controlled studies. However, little is known regarding patient-perceived efficacy and satisfaction. An observational, retrospective, multicentre study in patients treated with Acaroid(R) was conducted to assess the efficacy and degree of satisfaction of the patients after the first six months of treatment with it. All the clinical study procedures were performed according to the routine clinical practice. This study demonstrates that Acaroid(R) is effective and well tolerated. The patients' condition demonstrated a clear and marked improvement in the first 6 months after treatment initiation. Patients treated with Acaroid(R) were very satisfied, with a correlation to improvement in patient-perceived symptoms and the administration of treatment by a healthcare professional</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497671">PM:28497671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-100-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-100-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Roger RA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Keller,F.A.</style></author><author><style face="normal" font="Arial"> Oselka,S.R.</style></author><author><style face="normal" font="Arial"> Carvalho,M.M.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Escola Paulista de Medicina-Federal University of Sao Paulo, SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Body Mass Index and skin reactivity to histamine and Dermatophagoides pteronyssinus in children and adolescents followed in a pediatric allergy service</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="113" start="110">110-113</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Status</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin reactivity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> Wheezing infants</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Rationale. Recent data suggest that the nutritional status assessed by body mass index (BMI) is positively associated with skin reactivity to histamine in children. Objective. To study the relation between BMI and skin reactivity to histamine and Dermatophagoides pteronyssinus in allergic children and adolescents. Methods. The medical charts of patients attended in our outpatient clinic between 2013 and 2014 (n = 972) were evaluated. Only patients with asthma, allergic rhinitis or wheezing infants sensitized to at least one aeroallergen were selected: a total of 626 patients (6 months to 19 year-olds; 60.1% male) were enrolled. Weight (kg), height (m), BMI (weight/height2), and the mean diameter of the wheals induced by histamine (10 mg/ml) and Dermatophagoides pteronyssinus in skin prick tests (SPT) were obtained. Skin index (SI; ratio of allergen-induced wheal diameter and corresponding histamine diameter) was also analyzed. Results. All patients had shown a mean wheal diameter of histamine greater than 1 mm. There was no increased skin reactivity to histamine with increasing BMI Z score (ZBMI). However, a significant correlation between BMI and the mean wheal of histamine was observed in patients &lt; -1 ZBMI. Similar results were observed with Dermatophagoides pteronyssinus, (even considering the SI). Conclusions. We did not document interference of nutritional status (ZBMI) on the skin reactivity to histamine or Dermatophagoiodes pteronyssinus in atopic patients. Further investigation is required</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497673">PM:28497673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-110-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-110-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Keller FA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silva,D.</style></author><author><style face="normal" font="Arial"> Pereira,A.M.</style></author><author><style face="normal" font="Arial"> Santos,N.</style></author><author><style face="normal" font="Arial"> Amaral,L.</style></author><author><style face="normal" font="Arial"> Delgado,L.</style></author><author><style face="normal" font="Arial"> Oude Elberink,J.N.</style></author><author><style face="normal" font="Arial"> Coimbra,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servico de Imunoalergologia, Centro Hospitalar de Sao Joao E.P.E., Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">The Vespid Allergy Quality of Life Questionnaire - cultural adaptation and translation to Portuguese</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="121" start="114">114-121</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera allergy</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">A cross-cultural translation of the Vespid Allergy Quality of Life Questionnaire (VQLQ) to the Portuguese population (VQLQ-P) was performed, assessing its applicability in wasp and in non-beekeeper bee venom allergic patients. Additionally, we evaluated a Visual Analogue Scale (VAS) to estimate hymenoptera allergy interference with daily life. Methods. Cross-cultural translation was performed according to recommendations. The final VQLQ-P version, the Expectation of Outcome questionnaire (EoQ), EQ-5D and VAS were applied to wasp (n = 19) and non-beekeeper bee venom allergic patients (n = 30). Results. VQLQ-P significantly correlated with EoQ, (r = 0.76, p &lt; 0.01), EQ-5D (usual activities and anxiety / depression dimensions) and VAS, with a good internal consistency (Cronbach alpha = 0.88) in wasp allergic individuals. VQLQ-P and EoQ correlation was also high (r = 0.67, p &lt; 0.01) in bee allergy. Conclusion. The VQLQ-P is a valuable tool to evaluate quality of life impairment in Portuguese hymenoptera venom allergic individuals</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497674">PM:28497674</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-114-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-114-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Silva D</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gamba,P.</style></author><author><style face="normal" font="Arial"> Lombardi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head and Neck Surgery, Poliambulanza Foundation Hospital, Brescia, ItalyDepartmental Unit of Allergology, Clinical Immunology and Pneumology, Poliambulanza Foundation Hospital, Brescia, Italy. Phone: +39 030 35 18 555 E-mail: carlo.lombardi@poliambulanza.it</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophil fungal rhinosinusitis caused by Fusarium infection secondary to odontogenic maxillary sinus disease: when collaboration between otolaryngologist and allergologist leads to the correct diagnosis and therapy</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="142" start="138">138-142</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Dental implants</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fusarium</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> maxillary</style></keyword><keyword><style face="normal" font="Arial"> Maxillary Sinus</style></keyword><keyword><style face="normal" font="Arial"> Maxillary Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Rhinitis and sinusitis usually coexist and are concurrent in most individuals; thus, the correct terminology is now "rhinosinusitis". On the basis of numerous causative factors, often co-existing in the same patient, the diagnosis of rhinosinusitis is also made by a wide variety of practitioners (allergologists, otolaryngologists, pulmonologists, primary care physicians, paediatricians, and many others). Approximately 5-15% of the population suffers from chronic rhinosinusitis, and in 10-12% of them, it is of dental origin. The treatment of odontogenic maxillary sinus disease is directed to the management of the rhinosinusitis and of the odontogenic source. The widespread use of dental implants and reconstructive procedures for dental implant placement has led to new types of complication, as in this case report, due to chronic eosinophilic rhinosinusitis secondary to Fusarium infection in the maxillary sinus. The patient was initially evaluated by the allergologist, and subsequently successfully treated by the otolaryngologist with Functional Endoscopic Sinus Surgery. The advantages of endoscopic sinus surgery include more accurate visualization, no external incision, reduced soft tissue dissection, and reduced hospital stay. Chronic maxillary sinusitis of dental origin is a common disease that requires treatment of the sinusitis as well as of the odontogenic source</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497678">PM:28497678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-138-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-138-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Gamba P</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">AlQahtani,A.</style></author><author><style face="normal" font="Arial"> Alshaikh,N.</style></author><author><style face="normal" font="Arial"> Alzarei,A.</style></author><author><style face="normal" font="Arial"> Musleh,A.</style></author><author><style face="normal" font="Arial"> Alamri,A.</style></author><author><style face="normal" font="Arial"> AlQahtani,A.</style></author><author><style face="normal" font="Arial"> Alfawwaz,F.</style></author><author><style face="normal" font="Arial"> Alshammari,F.</style></author><author><style face="normal" font="Arial"> Aloulah,M.</style></author><author><style face="normal" font="Arial"> Marglani,O.</style></author><author><style face="normal" font="Arial"> Alsaleh,S.</style></author><author><style face="normal" font="Arial"> Alandejani,T.</style></author><author><style face="normal" font="Arial"> Mokarbesh,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology Head and Neck Surgery, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</style></auth-address><titles><title><style face="normal" font="Arial">Contralateral sinus involvement of surgically treated unilateral allergic fungal rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Irrigation</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="5" Year="2017">2017/5/13</year></dates><abstract><style face="normal" font="Arial">Recurrence of allergic fungal rhinosinusitis (AFRS) is well recognized. However, there is scarcity in the literature describing involvement of the non-diseased sinuses. We aimed to evaluate the recurrence forms of unilateral AFRS as well as to study the possible predictor factors of developing the disease in the contralateral side. Patients with exclusive unilateral AFRS from (2010 to 2015) were enrolled in multi-institutional case-control study. All patients were evaluated after endoscopic sinus surgery for recurrence. Patient's records were reviewed for demographics, medical treatment, and clinical, radiological, and surgical data. A total of 68 patients were identified. Delayed contralateral involvement after the initial surgery was found in 30.8% with mean duration of recurrence 16.9 months. A significant association was found with the presence of pre-operative contralateral symptoms and signs of inflammation (OR 3.49, 95% CI 1.19-10.22, p value 0.02). Post-operative use of budesonide irrigation was associated with less contralateral involvement (OR 0.11, 95% CI 0.01-0.87, p value 0.01). Association of other variables like: comorbidities, perioperative use of systemic steroid, radiological signs, extent of surgery, additional surgery to the contralateral side, and post-operative use of systemic steroids did not show statistical significance. Involvement of the contralateral sinuses in 30% of unilateral AFRS cases is considered significant. The non-diseased sinuses should be involved in the routine endoscopic examination and post-operative treatment. Further studies are necessary to investigate the possibility of prophylactic surgical intervention of the non-diseased sinuses</style></abstract><notes><style face="normal" font="Arial">DA - 20170514IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4604-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28501959">PM:28501959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170514-AlQahtaniA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170514-AlQahtaniA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170514, AlQahtani A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4604-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sagit,M.</style></author><author><style face="normal" font="Arial"> Polat,H.</style></author><author><style face="normal" font="Arial"> Gurgen,S.G.</style></author><author><style face="normal" font="Arial"> Berk,E.</style></author><author><style face="normal" font="Arial"> Guler,S.</style></author><author><style face="normal" font="Arial"> Yasar,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of ENT, Kayseri Egitim ve Arastirma Hastanesi KBB Klinigi, Sanayi Mah. Ataturk Bulvari Hastane Cad. No: 78, 38010, Kayseri, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Effectiveness of quercetin in an experimental rat model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Quercetin</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> Turbinates</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> VIP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">We aimed to investigate whether quercetin had a therapeutic effect in an experimental rat model of allergic rhinitis. The study was conducted with 35 rats, which were randomly assigned into 4 groups: group 1 (n = 5), sham group; group 2 (quercetin group, n = 10) received 80 mg/kg day quercetin; group 3 (steroid group, n = 10) received steroid (mometasone furoate); and group 4 (control group, n = 10), received ovalbumin alone. Rats were sensitized by administration of ovalbumin on alternate days over 14 days via an intraperitoneal route. On day 15, in addition to ovalbumin via an intranasal route, quercetin and steroid were given over 7 days to the corresponding groups. All rats were then sacrificed and nasal turbinates were evaluated histopathologically, and serum total IgE and ovalbumin (OVA)-specific IgE values were measured before and after treatment. A significant increase in OVA-specific IgE values was detected in all groups except sham group. A significant increase was detected in post-treatment total IgE levels in the control group, while no significant change was detected in the sham, quercetin, and intranasal steroid groups. On histopathological evaluation, it was observed that findings of allergic rhinitis were suppressed in the quercetin group when compared to the control group. In immunohistochemical evaluation, it was detected that COX-2 and VIP expressions were weaker in the quercetin group compared to the control group. Based on these findings, we conclude that quercetin was effective in allergic rhinitis induced by ovalbumin in rats both histopathologically and serologically</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4602-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28493194">PM:28493194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170511-SagitM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170511-SagitM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Sagit M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4602-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> Chavannes,N.H.</style></author><author><style face="normal" font="Arial"> Guldemond,N.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MACVIA-France (Contre les Maladies Chroniques pour un Vieillissement Actif en France) European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Realising the potential of mHealth to improve asthma and allergy care: how to shape the future</style></title><secondary-title><style face="normal" font="Arial">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Respir J</style></full-title></periodical><pages end="" start="1700447">1700447-</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - EditorialCO - France -CO - Netherlands -CO - Finland -CO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1183/13993003.00447-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28461306">PM:28461306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Respir J\2017-49-1700447.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Respir J\2017-49-1700447.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1183/13993003.00447-2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kwak,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Economic Development, Jobs, Transport and Resources, 5 Ring Road, Bundoora, VIC, 3186, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Keys for the morphological identification of the Australian paralysis ticks (Acari: Ixodidae), with scanning electron micrographs</style></title><secondary-title><style face="normal" font="Arial">Exp Appl Acarol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Appl Acarol</style></full-title></periodical><pages end="101" start="93">93-101</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acari</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Ixodes</style></keyword><keyword><style face="normal" font="Arial"> Ixodidae</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Paralysis</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Ticks</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">The Australian paralysis ticks (Ixodes: Sternalixodes) are of considerable medical and veterinary importance within Australia. This is because of their ability to cause paralysis but also their capacity to transmit pathogens and induce allergic reactions. The available keys for the identification of the group (Ixodes holocyclus Neumann, Ixodes cornuatus Roberts, and Ixodes hirsti Hassall) are ambiguous and contain errors, making accurate identification of the group difficult. Illustrations of varying quality and accuracy of these species have been published in the past; however, they have never been collectively treated using scanning electron microscopy (SEM). Female Australian paralysis ticks are here examined using SEM, and the first pictorial key for this group is presented along with an accurate text key</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1572-9702 (Electronic)IS - 0168-8162 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10493-017-0133-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497302">PM:28497302</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Appl Acarol\20170512-KwakML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Appl Acarol\20170512-KwakML.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Kwak ML</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10493-017-0133-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kepil,O.S.</style></author><author><style face="normal" font="Arial"> Bavbek,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Chest Diseases, Division of Allergy and Immunology , Izmir Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital , Izmir , Turkeyb Division of Immunology and Allergy, Department of Chest Diseases , Ankara University School of Medicine , Ankara , Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Prospects for new and emerging therapeutics in severe asthma: the role of biologics</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Respir Med</style></full-title></periodical><pages end="512" start="505">505-512</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> refractory asthma</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Asthma is a common and heterogeneous disease. While current conventional therapies are effective in the majority of the patients, a significant subgroup remain uncontrolled despite these treatments. Different biological agents are currently approved or undergoing development for treatment of asthma, including anti-IgE, anti-interleukin (IL)-5, anti-IL-13, anti-IL-4 and anti-thymic stromal lymphopoietin agents. This review will focus on the currently available evidence regarding the new and emerging biological agents in severe asthma. Areas covered: A non-systematic review of the available English-language literature regarding severe asthma and biological agents was performed. We summarized and discussed the current evidence about the use of new and emerging biological agents in severe asthma. Expert commentary: Because of the heterogeneity of response to therapy in refractory asthma it is of utmost importance to correctly estimate patient outcomes before starting biological therapy to make patient selection more effective. Currently, the decision of which biologic to initiate in patients with uncontrolled severe asthma should be made based on the atopic status, blood eosinophil and total IgE levels, exacerbation history, safety profile, cost, frequency and route of administration</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1080/17476348.2017.1326821</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28464704">PM:28464704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Respir Med\20170503-KepilOS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Respir Med\20170503-KepilOS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Kepil OS</style></custom2><misc3><style face="normal" font="Arial">10.1080/17476348.2017.1326821</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gupta,R.K.</style></author><author><style face="normal" font="Arial"> Raghav,A.</style></author><author><style face="normal" font="Arial"> Sharma,A.</style></author><author><style face="normal" font="Arial"> GUPTA,K.</style></author><author><style face="normal" font="Arial"> Neelabh</style></author><author><style face="normal" font="Arial"> Mandal,P.</style></author><author><style face="normal" font="Arial"> Tripathi,A.</style></author><author><style face="normal" font="Arial"> Ansari,I.A.</style></author><author><style face="normal" font="Arial"> Das,M.</style></author><author><style face="normal" font="Arial"> Dwivedi,P.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Glycation of clinically relevant chickpea allergen attenuates its allergic immune response in Balb/c mice</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="256" start="244">244-256</pages><volume><style face="normal" font="Arial">235</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic mediators</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chickpea</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="11" Year="2017">2017/11/15</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">Glycation of food allergens may alter their immunological behaviour. We sought to investigate the impact of glycation on the allergenicity of a food protein. Herein, a chickpea protein (</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëê26 kDa) was purified and characterized as lectin. Further, glycation of this purified protein was carried out. Thereafter, allergic behaviour of this glycated protein was compared with its native form, using various allergic parameters in Balb/c mice. The reduced allergenicity of glycated protein was observed as lesser allergic phenotypes, reduced serum immunoglobulins and allergic mediators, lower mast cells and eosinophil counts, lower protein expressions of Th2 cytokines and associated transcription factors. In addition, more Th1 and less Th2 cytokine production in exposed splenocyte, were evident in the glycated protein treated mice as compared to its native protein treatment. Thus, glycation of the chickpea allergen attenuated the sensitizing potential and allergic responses in Balb/c mice significantly and could also be clinically beneficial</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.05.056</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodchem.2017.05.056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-235-244-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-235-244-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Gupra RK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.05.056</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Himly,M.</style></author><author><style face="normal" font="Arial"> Mills-Goodlet,R.</style></author><author><style face="normal" font="Arial"> Geppert,M.</style></author><author><style face="normal" font="Arial"> Duschl,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Nanomaterials in the Context of Type 2 Immune Responses-Fears and Potentials</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="471">471-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Detoxification</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> engineered nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> multifunctional</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wound Healing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The type 2 immune response is an adaptive immune program involved in defense against parasites, detoxification, and wound healing, but is predominantly known for its pathophysiological effects, manifesting as allergic disease. Engineered nanoparticles (NPs) are non-self entities that, to our knowledge, do not stimulate detrimental type 2 responses directly, but have the potential to modulate ongoing reactions in various ways, including the delivery of substances aiming at providing a therapeutic benefit. We review, here, the state of knowledge concerning the interaction of NPs with type 2 immune responses and highlight their potential as a multifunctional platform for therapeutic intervention</style></abstract><notes><style face="normal" font="Arial">DA - 20170510IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Austria -CO - Brazil -CO - Poland -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00471</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28487697">PM:28487697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-471.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-471.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Himly M</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00471</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Diny,N.L.</style></author><author><style face="normal" font="Arial"> Rose,N.R.</style></author><author><style face="normal" font="Arial"> Cihakova,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophils in Autoimmune Diseases</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="484">484-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Bowel Diseases</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> molecular microbiology</style></keyword><keyword><style face="normal" font="Arial"> multifunctional</style></keyword><keyword><style face="normal" font="Arial"> Neuromyelitis Optica</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infections</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Eosinophils are multifunctional granulocytes that contribute to initiation and modulation of inflammation. Their role in asthma and parasitic infections has long been recognized. Growing evidence now reveals a role for eosinophils in autoimmune diseases. In this review, we summarize the function of eosinophils in inflammatory bowel diseases, neuromyelitis optica, bullous pemphigoid, autoimmune myocarditis, primary biliary cirrhosis, eosinophilic granulomatosis with polyangiitis, and other autoimmune diseases. Clinical studies, eosinophil-targeted therapies, and experimental models have contributed to our understanding of the regulation and function of eosinophils in these diseases. By examining the role of eosinophils in autoimmune diseases of different organs, we can identify common pathogenic mechanisms. These include degranulation of cytotoxic granule proteins, induction of antibody-dependent cell-mediated cytotoxicity, release of proteases degrading extracellular matrix, immune modulation through cytokines, antigen presentation, and prothrombotic functions. The association of eosinophilic diseases with autoimmune diseases is also examined, showing a possible increase in autoimmune diseases in patients with eosinophilic esophagitis, hypereosinophilic syndrome, and non-allergic asthma. Finally, we summarize key future research needs</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00484</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28496445">PM:28496445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-484.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-484.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Diny NL</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00484</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Castro-Rodriguez,J.A.</style></author><author><style face="normal" font="Arial"> Garcia-Marcos,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pulmonology, Division of Pediatrics, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, ChilePediatric Allergy and Pulmonology Units, "Virgen de la Arrixaca" University Children's Hospital, IMIB-Arrixaca Bio-health Research Institute, University of Murcia, Murcia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">What Are the Effects of a Mediterranean Diet on Allergies and Asthma in Children?</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="72">72-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">This review updates the relationship between the adherence to Mediterranean diet (MedDiet) assessed by questionnaire and asthma, allergic rhinitis, or atopic eczema in childhood. It deals with the effect of MedDiet in children on asthma/wheeze, allergic rhinitis, and atopic dermatitis/eczema, and also with the effect of MedDiet consumption by the mother during pregnancy on the inception of asthma/wheeze and allergic diseases in the offspring. Adherence to MedDiet by children themselves seems to have a protective effect on asthma/wheezing symptoms after adjustment for confounders, although the effect is doubtful on lung function and bronchial hyperresponsiveness. By contrast, the vast majority of the studies showed no significant effect of MedDiet on preventing atopic eczema, rhinitis, or atopy. Finally, studies on adherence to MedDiet by the mother during pregnancy showed some protective effect on asthma/wheeze symptoms in the offspring only during the first year of life, but not afterward. Very few studies have shown a protective effect on wheezing, current sneeze, and atopy, and none on eczema. Randomized control trials on the effect of the adherence to MedDiet to prevent (by maternal consumption during pregnancy) or improve (by child consumption) the clinical control of asthma/wheezing, allergic rhinitis, or atopic dermatitis are needed</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Chile -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28484688">PM:28484688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Castro-Rodriguez JA</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guibas,G.V.</style></author><author><style face="normal" font="Arial"> Mathioudakis,A.G.</style></author><author><style face="normal" font="Arial"> Tsoumani,M.</style></author><author><style face="normal" font="Arial"> Tsabouri,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Infection, Immunity and Respiratory Medicine, University Hospital of South Manchester, University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Relationship of Allergy with Asthma: There Are More Than the Allergy "Eggs" in the Asthma "Basket"</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="92">92-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> multifaceted</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma and allergy share a similar and very close course, especially through childhood. Considerable research effort has been put in untangling these associations; however, it is now becoming obvious that this is an exceedingly difficult task. In fact, each research breakthrough further perplexes this picture, as we are steadily moving toward the era of personalized medicine and we begin to appreciate that what we thought to be a single disease, asthma, is in fact an accumulation of distinct entities. In the context of this "syndrome," which is characterized by several, as of yet poorly defined endotypes and phenotypes, the question of the link of "asthma" with allergy probably becomes non-relevant. In this review, we will revisit this question while putting the emphasis on the multifaceted nature of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28503545">PM:28503545</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Guibas GV</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00092</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsabouri,S.</style></author><author><style face="normal" font="Arial"> Mavroudi,A.</style></author><author><style face="normal" font="Arial"> Feketea,G.</style></author><author><style face="normal" font="Arial"> Guibas,G.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Child Health Department, University of Ioannina School of Medicine, Ioannina, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="82">82-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">This review presents up-to-date understanding of immunotherapy in the treatment of children with allergic asthma. The principal types of allergen immunotherapy (AIT) are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both of them are indicated for patients with allergic rhinitis and/or asthma, who have evidence of clinically relevant allergen-specific IgE, and significant symptoms despite reasonable avoidance measures and/or maximal medical therapy. Studies have shown a significant decrease in asthma symptom scores and in the use of rescue medication, and a preventive effect on asthma onset. Although the safety profile of SLIT appears to be better than SCIT, the results of some studies and meta-analyses suggest that the efficacy of SCIT is better and that SCIT has an earlier onset than SLIT in children with allergic asthma. Severe, not controlled asthma, and medical error were the most frequent causes of SCIT-induced adverse events</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28484690">PM:28484690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Tsabouri S</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00082</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abramidze,T.</style></author><author><style face="normal" font="Arial"> Gotua,M.</style></author><author><style face="normal" font="Arial"> Chikhelidze,N.</style></author><author><style face="normal" font="Arial"> Cheishvili,T.</style></author><author><style face="normal" font="Arial"> Gamkrelidze,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Allergy and Immunology Research, Tbilisi; Institute of Botany, Ilia State University, Tbilisi, Georgia</style></auth-address><titles><title><style face="normal" font="Arial">PLANT AEROALLERGENS IN TWO MAJOR CITIES OF GEORGIA</style></title><secondary-title><style face="normal" font="Arial">Georgian Med News</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Georgian Med News</style></full-title></periodical><pages end="80" start="75">75-80</pages><number><style face="normal" font="Arial">264</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Aerobiological parameters</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Alder</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alnus</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Ash</style></keyword><keyword><style face="normal" font="Arial"> Beech</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chestnut</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Corylus</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Fagus</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Gramineae</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hazel</style></keyword><keyword><style face="normal" font="Arial"> hornbeam</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> mulberry</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">Pollen allergy is caused by a hypersensitivity reaction mainly of the respiratory tract and eye conjunctivae to pollen grains. The number of people allergic to plant aeroallergens has substantially increased in big cities and industrial areas. The monitoring of aerobiological parameters is of paramount importance for the characterization of allergenic risks. The aims of presented study were as follows: to profile the plant aeroallergens in two major cities of Georgia, to compare the character of pollination curves, to determine the dates of beginning of pollen seasons and their duration in particular cities. Two Burkard 7-day samplers were located in cities: Tbilisi, with climate transitional from humid subtropical to relatively mild continental and Kutaisi, with humid subtropical with a well-defined on-shore/monsoonal flow. Pollen counts were expressed as a daily mean value in number of pollen grains/spores per m3 of air. Data was obtained in 2016 year. The main tree pollen types for both centers were: Alnus (Alder), Betula (Birch), Carpinus (Hornbeam), Castanae (Chestnut), Corylus (Hazel), Cupressaceae (Cypress), Fagus (Beech), Fraxinus (Ash), Juglans (Walnut), Morus (Mulberry), Pinus (Pine), Platanus (Plane Tree), Quercus (Oak), Salix (Willow), Tilia (Lime), and Ulmus (Elm Tree). Comparison analysis had shown that the pollination season of the most trees began earlier in Kutaisi. As an example, the beginning of pollination was about 10-15 days earlier for Corylus and Alnus. The difference in pollen count of particular taxa was observed as well. It was much higher in Kutaisi for Corylus, Alnus and Cupressaceae and significantly higher in Tbilisi for Platanus and Pinus. Main grass pollen was Gramineae (Grasses): the pollination started a little bit earlier in Kutaisi, but the pollen count was generally higher in Tbilisi. The features of pollen seasonal distribution and amount were revealed also for the weeds (mainly Ambrosia (Ragweed) and Artemiasia (Mugwort)). The differences noted in pollen count between two major cities of Georgia may be due to a different composition of local flora and the influence of weather</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1512-0112 (Print)IS - 1512-0112 (Linking)LA - engPT - Journal ArticleCO - Georgia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28480855">PM:28480855</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Georgian Med News\2017-264-75-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Georgian Med News\2017-264-75-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Abramidze T</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Melamed,I.</style></author><author><style face="normal" font="Arial"> Robinson,L.</style></author><author><style face="normal" font="Arial"> Heffron,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Benefit of Montelukast in Atopic Dermatitis Induced by Food Allergies</style></title><secondary-title><style face="normal" font="Arial">Glob J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Glob J Allergy</style></full-title></periodical><pages end="018" start="013">013-018</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cetirizine</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hydrocortisone</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> nerve growth factor</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rast</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: Cysteinyl leukotriene levels are elevated in patients with atopic dermatitis, which canlead to eosinophilic infi ltration of the gastrointestinal tract.Objective: We examined the role that montelukast (a leukotriene receptor antagonist) might play inimproving symptoms of atopic dermatitis induced by food allergies.Methods: We conducted a randomized, double-blind, placebo-controlled, parallel group study in20 children, aged 1 to 8 years, with 4 study visits every 3 weeks for 9 weeks. Primary inclusion criteriaconsisted of: 1) positive reactivity to food (indicated by skin or RAST test); 2) 10-25 % body area affectedwith atopic dermatitis; and 3) gastrointestinal symptoms. Liquid cetirizine and 1% hydrocortisone creamwere both given as rescue medications for atopic dermatitis fl are-ups. Pruritis and atopic dermatitis fl areupscores were used to collect clinical data. Laboratory values for nerve growth factor were evaluatedpre- and post-treatment.Results: Our main endpoints were the effects of montelukast on the clinical presentation of atopicdermatitis. When comparing the treatment group to placebo, we noted a signifi cant reduction in thepruritis score (p=0.002); a trend toward a reduction in the use of rescue medication (cetirizine: p=0.056;hydrocortisone cream: p=0.056); and a reduction in the level of nerve growth factor; mean values:placebo=3.06 to montelukast=2.59.Conclusion: The infl ammatory pathway triggered by food allergies that may lead to atopic dermatitiscan be modulated with montelukast. Furthermore, nerve growth factor may play a role in the pathogenesisof atopic dermatitis and montelukast may modify this pathway.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Roboto-Regular">10.17352/2455-8141.000018</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.17352/2455-8141.000018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Glob J Allergy\2017-3-013-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Glob J Allergy\2017-3-013-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Melamed I</style></custom2><misc3><style face="normal" font="Roboto-Regular">10.17352/2455-8141.000018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,T.H.</style></author><author><style face="normal" font="Arial"> Ho,H.K.</style></author><author><style face="normal" font="Arial"> Leung,T.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Centre, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong</style></auth-address><titles><title><style face="normal" font="Arial">Genetically modified foods and allergy</style></title><secondary-title><style face="normal" font="Arial">Hong Kong Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hong Kong Med J</style></full-title></periodical><pages end="295" start="291">291-295</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Technology</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetically modified crops</style></keyword><keyword><style face="normal" font="Arial"> genetically modified food</style></keyword><keyword><style face="normal" font="Arial"> Genetically modified foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Mandatory labelling</style></keyword><keyword><style face="normal" font="Arial"> Marketing</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">2015 marked the 25th anniversary of the commercial use and availability of genetically modified crops. The area of planted biotech crops cultivated globally occupies a cumulative two billion hectares, equivalent to twice the land size of China or the United States. Foods derived from genetically modified plants are widely consumed in many countries and genetically modified soybean protein is extensively used in processed foods throughout the industrialised countries. Genetically modified food technology offers a possible solution to meet current and future challenges in food and medicine. Yet there is a strong undercurrent of anxiety that genetically modified foods are unsafe for human consumption, sometimes fuelled by criticisms based on little or no firm evidence. This has resulted in some countries turning away food destined for famine relief because of the perceived health risks of genetically modified foods. The major concerns include their possible allergenicity and toxicity despite the vigorous testing of genetically modified foods prior to marketing approval. It is imperative that scientists engage the public in a constructive evidence-based dialogue to address these concerns. At the same time, improved validated ways to test the safety of new foods should be developed. A post-launch strategy should be established routinely to allay concerns. Mandatory labelling of genetically modified ingredients should be adopted for the sake of transparency. Such ingredient listing and information facilitate tracing and recall if required</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1024-2708 (Print)IS - 1024-2708 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.12809/hkmj166189</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28473652">PM:28473652</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hong Kong Med J\20170505-LeeTH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hong Kong Med J\20170505-LeeTH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Lee TH</style></custom2><misc3><style face="normal" font="Arial">10.12809/hkmj166189</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liwski,R.S.</style></author><author><style face="normal" font="Arial"> Greenshields,A.L.</style></author><author><style face="normal" font="Arial"> Murphey,C.</style></author><author><style face="normal" font="Arial"> Bray,R.A.</style></author><author><style face="normal" font="Arial"> Gebel,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Dalhousie University, Halifax, Nova Scotia, B3H 1V8, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">It's about time: The development and validation of a rapid optimized single antigen bead (ROB) assay protocol for LABScreen</style></title><secondary-title><style face="normal" font="Arial">Hum Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Immunol</style></full-title></periodical><pages end="499" start="489">489-499</pages><volume><style face="normal" font="Arial">78</style></volume><number><style face="normal" font="Arial">7-8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody Specificity</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Centrifugation</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nova Scotia</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">The LABScreen single antigen bead assay (SAB) is a method widely used for the identification and monitoring of human leukocyte antigen (HLA) antibodies in patients pre-and post-transplant. While accurate testing of patient samples is key for optimal patient care, time can also be important, especially during deceased donor workups or post-transplant assessments. Here we describe the development and validation of the Rapid Optimized SAB (ROB) protocol, a modified version of the One Lambda LABScreen SAB (OLSAB) procedure, which reduces assay time from 85 to 25 min (>70% reduction) without impacting assay quality or sensitivity. Optimization steps included shortened centrifugation cycles and reduced serum and secondary antibody incubation times in combination with increased secondary antibody concentration. Linear regression analysis of baseline median fluorescence intensity (MFI) values showed excellent correlation between the ROB and OLSAB protocols (r2 >0.98) for both class I and class II antibodies in 58 sera tested in two HLA laboratories. Importantly, the ROB protocol demonstrated a trend towards improved inter-laboratory MFI concordance when compared to the OLSAB procedure (r2=0.9816 vs 0.9451), especially for HLA antibody specificities in the 500-2,000 MFI range (r2 =0.7824 vs 0.6313). Implementation of the ROB protocol will expedite HLA antibody testing and may improve reproducibility of the SAB assay</style></abstract><notes><style face="normal" font="Arial">DA - 20170514IS - 1879-1166 (Electronic)IS - 0198-8859 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.humimm.2017.05.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28501500">PM:28501500</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Immunol\20170514-LiwskiRS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Immunol\20170514-LiwskiRS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170514, Liwski RS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.humimm.2017.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blank,S.</style></author><author><style face="normal" font="Arial"> Etzold,S.</style></author><author><style face="normal" font="Arial"> Darsow,U.</style></author><author><style face="normal" font="Arial"> Schiener,M.</style></author><author><style face="normal" font="Arial"> Eberlein,B.</style></author><author><style face="normal" font="Arial"> Russkamp,D.</style></author><author><style face="normal" font="Arial"> Wolf,S.</style></author><author><style face="normal" font="Arial"> Graessel,A.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL) , Ingolstadter Landstrasse 1, D-85764 Munich , Germany</style></auth-address><titles><title><style face="normal" font="Arial">Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen composition</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and environment</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Api m 1</style></keyword><keyword><style face="normal" font="Arial"> Api m 10</style></keyword><keyword><style face="normal" font="Arial"> Api m 2</style></keyword><keyword><style face="normal" font="Arial"> Api m 3</style></keyword><keyword><style face="normal" font="Arial"> Api m 5</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Honeybee venom</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy is the only curative treatment for honeybee venom (HBV) allergy, which is able to protect against further anaphylactic sting reactions. Recent analyses on a molecular level have demonstrated that HBV represents a complex allergen source that contains more relevant major allergens than formerly anticipated. Moreover, allergic patients show very diverse sensitization profiles with the different allergens. HBV-specific immunotherapy is conducted with HBV extracts which are derived from pure venom. The allergen content of these therapeutic extracts might differ due to natural variations of the source material or different down-stream processing strategies of the manufacturers. Since variations of the allergen content of therapeutic HBV extracts might be associated with therapeutic failure, we adressed the component-resolved allergen composition of different therapeutic grade HBV extracts which are approved for immunotherapy in numerous countries. The extracts were analyzed for their content of the major allergens Api m 1, Api m 2, Api m 3, Api m 5 and Api m 10. Using allergen-specific antibodies we were able to demonstrate the underrepresentation of relevant major allergens such as Api m 3, Api m 5 and Api m 10 in particular therapeutic extracts. Taken together, standardization of therapeutic extracts by determination of the total allergenic potency might imply the intrinsic pitfall of losing information about particular major allergens. Moreover, the variable allergen composition of different therapeutic HBV extracts might have an impact on therapy outcome and the clinical management of HBV-allergic patients with specific IgE to particular allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Luxembourg -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1323603</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28494206">PM:28494206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170511-BlankS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170511-BlankS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Blank S</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1323603</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bozek,A.</style></author><author><style face="normal" font="Arial"> Pyrkosz,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Clinical Department of Internal Disease , Dermatology and Allergology, Medical University of Silesia , Katowice , Poland</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy of mold allergy: a review</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Mold allergy</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">Mold allergies are common, mainly target the respiratory tract and present as allergic rhinitis and/or bronchial asthma. Molds include a large group of different allergens that induce all types of allergic reactions. Allergen specific immunotherapies (AITs) to molds are common; however, at the present time, they are limited to Alternaria. This review presents not only the benefits but also the problems with such types of AIT based on the literature and our experience</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1314404</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28481693">PM:28481693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170508-BozekA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170508-BozekA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Bozek A</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1314404</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kummola,L.</style></author><author><style face="normal" font="Arial"> Ortutay,Z.</style></author><author><style face="normal" font="Arial"> Vahatupa,M.</style></author><author><style face="normal" font="Arial"> Prince,S.</style></author><author><style face="normal" font="Arial"> Uusitalo-Jarvinen,H.</style></author><author><style face="normal" font="Arial"> Jarvinen,T.A.H.</style></author><author><style face="normal" font="Arial"> Junttila,I.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland</style></auth-address><titles><title><style face="normal" font="Arial">R-Ras deficiency does not affect papain-induced IgE production in mice</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="288" start="280">280-288</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: R-Ras GTPase has recently been implicated in the regulation of immune functions, particularly in dendritic cell (DC) maturation, immune synapse formation, and subsequent T cell responses. METHODS: Here, we investigated the role of R-Ras in allergen-induced immune response (type 2 immune response) in Rras deficient (R-Ras KO) and wild type (WT) mice. RESULTS: Initially, we found that the number of conventional DC's in the lymph nodes (LNs) was reduced in R-Ras KO mice. The expression of co-stimulatory CD80 and CD86 molecules on these cells was also reduced on DC's from the R-Ras KO mice. However, there was no difference in papain-induced immune response between the R-Ras WT and KO as measured by serum IgE levels after the immunization. Interestingly, neither the DC number nor co-stimulatory molecule expression was different between WT and R-Ras KO animals after the immunization. CONCLUSIONS: Taken together, despite having reduced number of conventional DC's in the R-Ras KO mice and low expression of CD80 on DC's, the R-Ras KO mice are capable of mounting papain-induced IgE responses comparable to that of the WT mice. To our knowledge, this is the first report addressing potential differences in in vivo allergen responses regulated by the R-Ras GTPase</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.168</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497586">PM:28497586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\20170512-KummolaL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\20170512-KummolaL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Kummola L</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.168</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanden,C.</style></author><author><style face="normal" font="Arial"> Mori,M.</style></author><author><style face="normal" font="Arial"> Jogdand,P.</style></author><author><style face="normal" font="Arial"> Jonsson,J.</style></author><author><style face="normal" font="Arial"> Krishnan,R.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Erjefalt,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Airway Inflammation, Department of Experimental Medical Science, Lund University, Lund, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Broad Th2 neutralization and anti-inflammatory action of pentosan polysulfate sodium in experimental allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Heparin</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Mucus hyper-secretion</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> SPR</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Th2 cytokines like interleukin-4, -5, and -13 are regarded as important drivers of the immunopathology underlying allergic rhinitis (AR) and asthma. The present study explores the capacity of pentosan polysulfate sodium (PPS), a semi-synthetic heparin-like macromolecular carbohydrate, to bind Th2 cytokines and exert biological neutralization in vitro, as well as anti-inflammatory actions in vivo. METHODOLOGY: The capacity of PPS to bind recombinant Th2 cytokines was tested with surface plasmon resonance (SPR) technology and biological Th2 neutralization was assessed by Th2-dependent proliferation assays. The in vivo anti-inflammatory action of PPS was studied using a validated Guinea-pig model of AR. RESULTS: Binding studies revealed a strong and specific binding of PPS to IL-4, IL-5, and IL-13 with IC values suggesting as stronger cytokine binding than for heparin. Cytokine binding translated to a biological neutralization as PPS dose dependently inhibited Th2-dependent cell proliferation. Topical administration of PPS 30 min prior to nasal allergen challenge of sensitized animals significantly reduced late phase plasma extravasation, luminal influx of eosinophils, neutrophils, and total lavage leukocytes. Similar, albeit not statistically secured, effects were found for tissue leukocytes and mucus hyper-secretion. The anti-inflammatory effects of PPS compared favorably with established topical nasal steroid treatment. CONCLUSION: This study points out PPS as a potent Th2 cytokine-binding molecule with biological neutralization capacity and broad anti-inflammatory effects in vivo. As such PPS fulfills the role as a potential candidate molecule for the treatment of AR and further studies of clinical efficacy seems highly warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Australia -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497614">PM:28497614</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\20170512-SandenC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\20170512-SandenC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Sanden C</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.164</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Faroldi,G.</style></author><author><style face="normal" font="Arial"> Ronnberg,E.</style></author><author><style face="normal" font="Arial"> Grujic,M.</style></author><author><style face="normal" font="Arial"> Pejler,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Inhibition of the BET family of epigenetic reader proteins: A novel principle for modulating gene expression in IgE-activated mast cells</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="150" start="141">141-150</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Histones</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated response</style></keyword><keyword><style face="normal" font="Arial"> IL-3</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lysine</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The BET family of bromodomain-containing proteins constitute epigenetic readers that bind to acetylated lysine residues of core histones, thereby translating epigenetic histone marks to effects on gene expression. BET inhibitors are currently emerging as promising therapeutic agents for treatment of various pathological conditions. Here, we explored the potential of using BET inhibition to modulate IgE-mediated responses in mast cells. METHODS: We assessed the effects of BET inhibitors PFI-1, I-BET151, and I-BET762 on responses downstream of mast cell activation through IgE receptor cross-linking. RESULTS: BET inhibitors were neither toxic for mast cells (at doses up to 20 muM), nor did they prevent IgE-mediated mast cell degranulation. However, we found that BET inhibition, in particular by I-BET151, suppressed IL-6 gene expression and IL-6 protein release in response to IgE-mediated mast cell activation. This was observed in both bone marrow-derived mast cells (BMMCs) and in mature peritoneal-cell derived mast cells. Further analysis showed that BET inhibition also suppressed the expression of a number of additional genes of those that were upregulated by IgE receptor cross-linking, including IL-3, IL-7R, CCR1, and ADAMTS9. However, BET inhibition was selective, i.e., several genes that were upregulated by IgE receptor cross-linking were not affected by BET inhibitors. CONCLUSIONS: These findings suggest that BET inhibition can interfere with the upregulated expression of selected genes in mast cells activated by IgE receptor cross-linking. Further, our findings introduce the concept of utilizing epigenetic mechanisms for modulating mast cell function in the context of IgE-driven disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.150</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474499">PM:28474499</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\2017-5-141-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\2017-5-141-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Garcia-Faroldi G</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.150</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahler,V.</style></author><author><style face="normal" font="Arial"> Klein,C.</style></author><author><style face="normal" font="Arial"> Sager,A.</style></author><author><style face="normal" font="Arial"> Zimmermann,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hautklinik Universitatsklinikum Erlangen, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">House dust mite-specific immunotherapy with two licensed vaccines: Outcome under clinical routine conditions</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="140" start="132">132-140</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptance</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: House dust mite (HDM) allergens are major causes for the development of allergic diseases. A disease modifying effect and clinical benefit of allergen immunotherapy (AIT) has been demonstrated in a number of clinical trials. Clinical trials, however, are carried out in selected populations under specific conditions based on inclusion and exclusion criteria and may not represent the entire patient population from medical practice. Objective of this study conducted in patients with HDM allergy was to systematically collect information about the benefit of AIT under clinical routine conditions. METHODS: In this prospective, multi-center non-interventional study, 220 patients (117 adults, 103 children) with HDM allergy receiving subcutaneous AIT with Depigoid(R) were monitored for 2 years. Organ-specific key symptoms, health-related quality of life (QoL), and the use of concomitant anti-allergic medication were assessed at baseline and after 12 and 24 months. Effectiveness and tolerability of the AIT was assessed by physicians and patients. Occurrence of adverse events (AEs) was continuously monitored. RESULTS: Two hundred and nineteen patients (116 adults, 103 children) were evaluated. A major improvement of the total symptom-score was observed after 24 (12) months in 76% (72%) and 80% (79%) of adults and children, respectively, accompanied by a reduction in concomitant anti-allergic medication and a pronounced improvement in QoL. The effectiveness and tolerability of the AIT was estimated as very good/good by 80-90% of physicians and patients. AEs were observed in 4/117 adults (3.4%) and in 7/103 children (6.8%). Serious AEs were reported in three adults and one child: A grade-II anaphylactic reaction (one adult) controlled by oral antihistamines (no hospitalization) classified as "definitely," three others as not (2) or possibly (1) drug-related. CONCLUSIONS: The data collected from 220 patients confirm the efficacy, tolerability/safety, and acceptance of AIT with Depigoid(R) in adults and children with HDM allergy under routine clinical conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474505">PM:28474505</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\2017-5-132-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\2017-5-132-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Mahler V</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.141</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Do,D.C.</style></author><author><style face="normal" font="Arial"> Yang,S.</style></author><author><style face="normal" font="Arial"> Yao,X.</style></author><author><style face="normal" font="Arial"> Hamilton,R.G.</style></author><author><style face="normal" font="Arial"> Schroeder,J.T.</style></author><author><style face="normal" font="Arial"> Gao,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</style></auth-address><titles><title><style face="normal" font="Arial">N-glycan in cockroach allergen regulates human basophil function</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bla g 2</style></keyword><keyword><style face="normal" font="Arial"> C-type lectin receptor</style></keyword><keyword><style face="normal" font="Arial"> C-type lectin receptors</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> CLR</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> DC-SIGN</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Galactose</style></keyword><keyword><style face="normal" font="Arial"> Glucosamine</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human basophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> MALDI TOF mass spectrometry</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF</style></keyword><keyword><style face="normal" font="Arial"> Mannose</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Cockroach allergen exposure elicits cockroach sensitization and poses an increased risk for asthma. However, the major components in cockroach allergen and the mechanisms underlying the induction of cockroach allergen-induced allergy and asthma remain largely elusive. We sought to examine the role of cockroach-associated glycan in regulating human basophil function. METHODS: N-linked glycans from naturally purified cockroach allergen Bla g 2 were characterized by MALDI-TOF mass spectrometry. Binding of cockroach allergen to serum IgE from cockroach allergic subjects was determined by solid-phase binding immunoassays. Role of cockroach associated glycan in histamine release and IL-4 production from human basophils was examined. Expression of C-type lectin receptors (CLRs) and their role in mediating glycan-uptake in the basophils was also investigated. RESULTS: MALDI-TOF mass spectrometric analysis of N-glycan from Bla g 2 showed complex hybrid-types of glycans that terminated with mannose, galactose, and/or N-acetyl glucosamine (GlcNAc). Deglycosylated Bla g 2 showed reduced binding to IgE and was less capable of inducing histamine release from human basophils. In contrast, N-glycan derived from Bla g 2 significantly inhibited histamine release and IL-4 production from basophils passively sensitized with serum from cockroach allergic subjects. An analysis of CLRs revealed the expression of DC-SIGN and DCIR, but not MRC1 and dectin-1, in human basophils. Neutralizing antibody to DCIR, but not DC-SIGN, significantly inhibited Bla g 2 uptake by human basophils. A dose-dependent bindings of cockroach allergen to DCIR was also observed. CONCLUSIONS: These observations indicate a previously unrecognized role for cockroach allergen-associated glycans in allergen-induced immune reactions, and DCIR may play a role in mediating the regulation of glycan on basophil function</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.145</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474843">PM:28474843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\20170505-DoDC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\20170505-DoDC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Do DC</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.145</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shimokawa,C.</style></author><author><style face="normal" font="Arial"> Kanaya,T.</style></author><author><style face="normal" font="Arial"> Hachisuka,M.</style></author><author><style face="normal" font="Arial"> Ishiwata,K.</style></author><author><style face="normal" font="Arial"> Hisaeda,H.</style></author><author><style face="normal" font="Arial"> Kurashima,Y.</style></author><author><style face="normal" font="Arial"> Kiyono,H.</style></author><author><style face="normal" font="Arial"> Yoshimoto,T.</style></author><author><style face="normal" font="Arial"> Kaisho,T.</style></author><author><style face="normal" font="Arial"> Ohno,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences, Kanagawa 230-0045, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Mast Cells Are Crucial for Induction of Group 2 Innate Lymphoid Cells and Clearance of Helminth Infections</style></title><secondary-title><style face="normal" font="Arial">Immunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunity</style></full-title></periodical><pages end="874" start="863">863-874</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Ecosystem</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">Mast cells are important for eradication of intestinal nematodes; however, their precise mechanisms of action have remained elusive, especially in the early phase of infection. We found that Spi-B-deficient mice had increased numbers of mast cells and rapidly expelled the Heligmosomoides polygyrus (Hp) nematode. This was accompanied by induction of interleukin-13 (IL-13)-producing group 2 innate lymphoid cells (ILC2) and goblet cell hyperplasia. Immediately after Hp infection, mast cells were rapidly activated to produce IL-33 in response to ATP released from apoptotic intestinal epithelial cells. In vivo inhibition of the P2X7 ATP receptor rendered the Spi-B-deficient mice susceptible to Hp, concomitant with elimination of mast cell activation and IL-13-producing ILC2 induction. These results uncover a previously unknown role for mast cells in innate immunity in that activation of mast cells by ATP orchestrates the development of a protective type 2 immune response, in part by producing IL-33, which contributes to ILC2 activation</style></abstract><notes><style face="normal" font="Arial">DA - 20170517IS - 1097-4180 (Electronic)IS - 1074-7613 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.immuni.2017.04.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28514691">PM:28514691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunity\2017-46-863-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunity\2017-46-863-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170517, Shimokawa C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.immuni.2017.04.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shalaby,K.H.</style></author><author><style face="normal" font="Arial"> Al-Heialy,S.</style></author><author><style face="normal" font="Arial"> Tsuchiya,K.</style></author><author><style face="normal" font="Arial"> Farahnak,S.</style></author><author><style face="normal" font="Arial"> McGovern,T.K.</style></author><author><style face="normal" font="Arial"> Risse,P.A.</style></author><author><style face="normal" font="Arial"> Suh,W.K.</style></author><author><style face="normal" font="Arial"> Qureshi,S.T.</style></author><author><style face="normal" font="Arial"> Martin,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Meakins-Christie Laboratories, Department of Medicine, McGill University and McGill University Health Centre Research Institute, Montreal, Canada</style></auth-address><titles><title><style face="normal" font="Arial">The TLR4-TRIF pathway can protect against the development of experimental allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="149" start="138">138-149</pages><volume><style face="normal" font="Arial">152</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interferon-beta</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> Toll</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="5" Year="2017">2017/5/14</year></dates><abstract><style face="normal" font="Arial">The Toll-like Receptor (TLR) adaptor proteins Myeloid Differentiating Factor 88 (MyD88) and Toll, interleukin-1 Receptor and Resistance protein (TIR) domain-containing adaptor inducing interferon-beta (TRIF) comprise the two principal limbs of the TLR signaling network. We studied the role of these adaptors in the TLR4-dependent inhibition of allergic airway disease and induction of CD4+ICOS+ T cells by nasal application of Protollin , a mucosal adjuvant composed of TLR2 and 4 agonists. Wild-type (wt), Trif -/- or Myd88 -/- mice were sensitized to birch pollen extract (BPEx), then received intranasal Protollin followed by consecutive BPEx challenges. Protollin's protection against allergic airway disease was TRIF-dependent and MyD88-independent. TRIF-deficiency diminished the CD4+ICOS+ T cell subsets in the lymph nodes draining the nasal mucosa, as well as their recruitment to the lungs. Overall, TRIF-deficiency reduced the proportion of cervical lymph node and lung CD4+ICOS+Foxp3- cells, in particular. Adoptive transfer of cervical lymph node cells supported a role for Protollin-induced CD4+ICOS+ cells in the TRIF-dependent inhibition of AHR. Thus, our data demonstrate that stimulation of the TLR4-TRIF pathway can protect against the development of allergic airway disease and that a TRIF-dependent adjuvant effect on CD4+ICOS+ T cell responses may be a contributing mechanism. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170514IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12755</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502093">PM:28502093</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20170514-ShalabyKH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20170514-ShalabyKH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170514, Shalaby KH</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12755</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qu,S.Y.</style></author><author><style face="normal" font="Arial"> He,Y.L.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Wu,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary and Critical Care Medicine, Fourth Military Medical University, Xi'an, China</style></auth-address><titles><title><style face="normal" font="Arial">Transcription factor RBP-J-mediated signaling regulates Basophil's immunoregulatory function in mouse asthma model</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="124" start="115">115-124</pages><volume><style face="normal" font="Arial">152</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperactivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> Notch signaling</style></keyword><keyword><style face="normal" font="Arial"> OX40L</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Basophils (BAs) play an important role in the promotion of aberrant Th2 immune response in asthma. It is not only the effective cell, but also modulates initiation of Th2 immune responses. We earlier demonstrated that Notch signaling regulates the biological function of BAs in vitro. However, whether this pathway plays the same role in vivo is not clear. The purpose of the present study was to investigate the effect of Notch signaling on BA's function in the regulation of allergic airway inflammation in a murine model of asthma. Bone marrow BAs were prepared by BM cell culture in the presence of rIL-3 (300 pg/mL) for 7 days, followed by isolation of the CD49b+ microbeads. The recombination signal binding protein J (RBP-J-/- ) BAs were co-cultured with T cells, and the supernatant and the T cell subtypes were examined. The results indicated disruption of the capacity of BAs for antigen presentation alongside an upregulation of the immunoregulatory function. This was possibly due to the low expression of OX40L in the RBP-J-/- BAs. BAs were adoptively transferred to OVA-sensitized recipient mice, to establish an asthma model. Lung pathology, cytokine profiles of BALF, airway hyperactivity, and the absolute number of Th1/Th2 cells in lungs were determined. Overall, our results indicate that the RBP-J-mediated Notch signaling is critical for BA-dependent immunoregulation. Deficiency of RBP-J influences the immunoregulatory function of BAs, which include activation of T-cells and their differentiation into Th cell subtypes. Notch signaling pathway is a potential therapeutic target for BA-based immunotherapy against asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12753</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28493549">PM:28493549</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20170511-QuSY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20170511-QuSY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Qu SY</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12753</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sharma,S.</style></author><author><style face="normal" font="Arial"> Rasal,V.P.</style></author><author><style face="normal" font="Arial"> Patil,P.A.</style></author><author><style face="normal" font="Arial"> Joshi,R.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, KLE University, College of Pharmacy, Belgaum, Karnataka, India</style></auth-address><titles><title><style face="normal" font="Arial">Effect of Angelica glauca essential oil on allergic airway changes induced by histamine and ovalbumin in experimental animals</style></title><secondary-title><style face="normal" font="Arial">Indian J Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Pharmacol</style></full-title></periodical><pages end="59" start="55">55-59</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Apiaceae</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Angelica glauca Edgew (Apiaceae) is used in traditional medicine for treatment of several diseases including bronchial asthma. The present investigation was aimed to evaluate broncho-relaxant activity of A. glauca essential oil in histamine and ovalbumin (OVA)-induced broncho constriction in experimental animals. MATERIALS AND METHODS: Airway was induced using histamine aerosol in guinea pigs (n = 24) and OVA aerosol in albino mice (n = 24). The number of inflammatory cells, namely, absolute eosinophils count in blood, total immunoglobulin E (IgE) in serum, eosinophils, and neutrophils in bronchoalveolar lavage fluid (BALF) and histopathological examination of lung tissues were investigated in A. glauca oil and dexamethasone-treated groups. A. glauca oil 200 muL/kg was given orally, and dexamethasone 2 mg/kg was given intraperitoneal. Both the treatments were repeated daily for 7 days. Results were analyzed by one-way ANOVA, and P &lt;/= 0.05 was considered statistically significant. RESULTS: Treatment with A. glauca essential oil significantly (P &lt; 0.001) increased the time of preconvulsive dyspnea in histamine-induced guinea pigs. Oral treatment of A. glauca oil significantly (P &lt; 0.001) decreased absolute blood eosinophil count (from 325 +/- 3.69 to 200 +/- 3.05 cells/mm3), serum level of IgE (from 6.10 +/- 0.05 to 0.70 +/- 0.08 IU/L), and the number of eosinophils (from 11.0% +/-1.41% to 3.0% +/-0.51%), neutrophils (from 13.0% +/-1.12% to 5.0% +/-1.39%) in BALF. Histopathological changes observed in lungs of untreated group were marked suppressed by treatment with A. glauca oil. CONCLUSION: The essential oil of A. glauca has bronchorelaxation in both histamine and OVA-induced bronchoconstriction in animals. The traditional use of A. glauca against asthma could be attributed to its bronchodilator property as observed in the present study</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1998-3751 (Electronic)IS - 0253-7613 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0253-7613.201019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28458423">PM:28458423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Pharmacol\2017-49-55-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Pharmacol\2017-49-55-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Sharma S</style></custom2><misc3><style face="normal" font="Arial">10.4103/0253-7613.201019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bachsais,N.</style></author><author><style face="normal" font="Arial"> Boussag-Abib,L.</style></author><author><style face="normal" font="Arial"> Laraba-Djebari,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Biological Sciences, Laboratory of Cellular and Molecular Biology, USTHB, BP 32, El Alia, Bab Ezzouar, 16111, Algiers, Algeria</style></auth-address><titles><title><style face="normal" font="Arial">Safety and efficiency of active immunization with detoxified antigen against scorpion venom: side effect evaluation</style></title><secondary-title><style face="normal" font="Arial">Inflamm Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflamm Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Algeria</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> vascular permeability</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The efficiency and safety of vaccine are the most important properties, however, as any medication, it can induce side effects. This prophylactic therapy could be used to prevent the lethal and pathophysiological effects induced after scorpion envenomation. METHODS: In this study, detoxified venom associated to alum adjuvant (V*alum) is used as a vaccine against scorpion venom for immunization of mice. We evaluate the safety and the inflammatory response of this vaccine. We also investigated the protective effect of this formulation against the toxicity of native Androctonus australis hector venom. RESULTS: Results showed no adverse events occurred after immunization of animals. This active immunization of animals did not cause change in vascular permeability, no edema formation in the studied organs. Furthermore, there are no IgE production in sera, nor change in the morphology of the mast cells in skin tissues. However, low inflammatory response triggered by activating the recruitment of eosinophils associated to IL-4 and IL-5 release was observed. All immunized animals are protected from the toxic effects of native venom until 6 LD50 and to 7 LD50 after the second challenge. CONCLUSION: This safe vaccine preparation seems to induce a long-term protection without any risk of deleterious inflammatory response</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1420-908X (Electronic)IS - 1023-3830 (Linking)LA - engPT - Journal ArticleCO - Algeria -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00011-017-1055-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28516208">PM:28516208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflamm Res\20170518-BachsaisN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflamm Res\20170518-BachsaisN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Bachsais N</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00011-017-1055-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jiang,X.</style></author><author><style face="normal" font="Arial"> Fang,L.</style></author><author><style face="normal" font="Arial"> Wu,H.</style></author><author><style face="normal" font="Arial"> Mei,X.</style></author><author><style face="normal" font="Arial"> He,F.</style></author><author><style face="normal" font="Arial"> Ding,P.</style></author><author><style face="normal" font="Arial"> Liu,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022, China</style></auth-address><titles><title><style face="normal" font="Arial">TLR2 Regulates Allergic Airway Inflammation and Autophagy Through PI3K/Akt Signaling Pathway</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> pattern recognition</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TLRs</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 2</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">Toll-like receptors (TLRs) are innate pattern recognition receptors that play a critical role in allergic inflammation, yet their contribution to autophagy in asthma remains poorly defined. Here, we investigate the role of Toll-like receptor 2 (TLR2) in phosphoinositide 3-kinases/protein kinase B (PI3K/Akt) pathway-mediated autophagy in ovalbumin-induced airway inflammation in mice. Wild-type (WT) and TLR2-knockout (TLR2-/-) C57BL/6 mice were ovalbumin-sensitized and ovalbumin-challenged. In ovalbumin-challenged WT mice, enhanced expression of TLR2 in lung tissue, remarkable inflammatory cell infiltrates, goblet cell hyperplasia, and increased mucus production were observed. The number of inflammatory cells and interleukin-13 (IL-13) levels increased, while interferon-gamma (IFN-gamma) levels decreased in bronchoalveolar lavage fluid. Expression of PI3K, phospho-Akt, Beclin-1 and LC3-II was enhanced significantly. These changes were mitigated dose-dependently in 3-methyl adenine-treated mice. In contrast, similar but weaker changes were found in ovalbumin-challenged TLR2-/- mice, and the changes were not significantly attenuated by 3-methyl adenine treatment. These results indicate that TLR2 confers a pivotal role in allergic airway inflammation via regulating the PI3K/Akt signaling pathway-related autophagy in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-017-0581-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28493079">PM:28493079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20170511-JiangX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20170511-JiangX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Jiang X</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-017-0581-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gellrich,D.</style></author><author><style face="normal" font="Arial"> Eder,K.</style></author><author><style face="normal" font="Arial"> San Nicolo,M.</style></author><author><style face="normal" font="Arial"> Berghaus,A.</style></author><author><style face="normal" font="Arial"> Groger,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-Universitat Munchen, Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">The Clinical Impact of Bet v 6 in Birch Pollen-Sensitized Patients</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="43" start="34">34-43</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 6</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bet v 6, a minor birch pollen allergen, is commercially available for allergen-specific IgE antibody testing. However, there is hardly any literature on the clinical impact of Bet v 6. The aim of the present study was to analyze if testing specific IgE against Bet v 6 can add valuable benefit to the standard diagnostics of birch pollen-sensitized patients, especially in patients with unknown sensitization-eliciting allergens. METHODS: Birch pollen-sensitized patients with missing IgE reactivity against Bet v 1, 2, and 4 were tested for specific IgE antibodies against Bet v 6. For comparison, an equal number of randomly selected patients with birch pollen sensitization, regardless of their individual sensitization patterns, were tested for specific anti-Bet v 6. RESULTS: Of 57 cases with missing reactivity against the standard birch pollen allergens, 2 patients were positive for Bet v 6. In the representative sample, 3 patients showed specific IgE against Bet v 6 - resulting in a total prevalence of 5%. None of the Bet v 6-positive patients showed allergic symptoms after exposure to birch pollen or an oral allergy syndrome. An increased prevalence of asthma and a higher degree of sensitization were the only distinctive clinical features in Bet v 6-positive patients. CONCLUSIONS: Among birch pollen-sensitized patients, the prevalence of specific IgE against Bet v 6 is low. Further, sensitization to Bet v 6, which shows characteristics of a panallergen, remains clinically silent. Therefore, determination of anti-Bet v 6 is not considered useful in the clinical routine</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000470843</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28494455">PM:28494455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-34-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-34-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Gellrich D</style></custom2><misc3><style face="normal" font="Arial">10.1159/000470843</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hirschl,S.</style></author><author><style face="normal" font="Arial"> Ralser,C.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Gangitano,A.</style></author><author><style face="normal" font="Arial"> Huber,S.</style></author><author><style face="normal" font="Arial"> Ebner,C.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Wolf,M.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Griesbeck,C.</style></author><author><style face="normal" font="Arial"> Wallner,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biotechnology and Food Engineering, MCI Management Center Innsbruck, Innsbruck, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Expression and Characterization of Functional Recombinant Bet v 1.0101 in the Chloroplast of Chlamydomonas reinhardtii</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="50" start="44">44-50</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptance</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Affinity chromatography</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1.0101</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> Sonication</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy (AIT) still plays a minor role in the treatment of allergic diseases. To improve the acceptance of AIT by allergic patients, the treatment has to become more convenient and efficacious. One possibility is the oral application of allergens or derivatives thereof. Therefore, we sought to produce a recombinant allergen in the green alga Chlamydomonas reinhardtii as a novel production platform. METHODS: The major birch pollen allergen Bet v 1 was selected as candidate molecule, and a codon-optimized gene was synthesized and stably integrated into the microalga C. reinhardtii FUD50. Positive transformants were identified by PCR, cultured, and thereafter cells were disrupted by sonication. Bet v 1 was purified from algal total soluble protein (TSP) by affinity chromatography and characterized physicochemically as well as immunologically. RESULTS: All transformants showed expression of the allergen with yields between 0.01 and 0.04% of TSP. Algal-derived Bet v 1 displayed similar secondary structure elements as the Escherichia coli-produced reference allergen. Moreover, Bet v 1 produced in C. reinhardtii showed binding comparable to human IgE as well as murine Bet v 1-specific IgG. CONCLUSION: We could successfully produce recombinant Bet v 1 in C. reinhardtii. As microalgae are classified as GRAS (generally recognized as safe), the pilot study supports the development of novel allergy treatment concepts such as the oral administration of allergen-containing algal extracts for therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000471852</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28494467">PM:28494467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-44-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-44-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Hirschl S</style></custom2><misc3><style face="normal" font="Arial">10.1159/000471852</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thiriou,D.</style></author><author><style face="normal" font="Arial"> Morianos,I.</style></author><author><style face="normal" font="Arial"> Xanthou,G.</style></author><author><style face="normal" font="Arial"> Samitas,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">2(nd) Respiratory Medicine Dept., Athens Chest Hospital "Sotiria", Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Innate immunity as the orchestrator of allergic airway inflammation and resolution in asthma</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="54" start="43">43-54</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial peptides</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> tissue repair</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="Arial">The respiratory system is constantly in direct contact with the environment and, has therefore, developed strong innate and adaptive immune responses to combat pathogens. Unlike adaptive immunity which is mounted later in the course of the immune response and is naive at the outset, innate immunity provides the first line of defense against microbial agents, while also promoting resolution of inflammation. In the airways, innate immune effector cells mainly consist of eosinophils, neutrophils, mast cells, basophils, macrophages/monocytes, dendritic cells and innate lymphoid cells, which attack pathogens directly or indirectly through the release of inflammatory cytokines and antimicrobial peptides, and coordinate T and B cell-mediated adaptive immunity. Airway epithelial cells are also critically involved in shaping both the innate and adaptive arms of the immune response. Chronic allergic airway inflammation and linked asthmatic disease is often considered a result of aberrant activation of type 2 T helper cells (Th2) towards innocuous environmental allergens; however, innate immune cells are increasingly recognized as key players responsible for the initiation and the perpetuation of allergic responses. Moreover, innate cells participate in immune response regulation through the release of anti-inflammatory mediators, and guide tissue repair and the maintenance of airway homeostasis. The scope of this review is to outline existing knowledge on innate immune responses involved in allergic airway inflammation, highlight current gaps in our understanding of the underlying molecular and cellular mechanisms and discuss the potential use of innate effector cells in new therapeutic avenues</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.04.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463786">PM:28463786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-48-43-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-48-43-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Thiriou D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.04.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,T.Y.</style></author><author><style face="normal" font="Arial"> Zhou,Q.L.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Shang,Y.X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Shikonin alleviates allergic airway remodeling by inhibiting the ERK-NF-kappaB signaling pathway</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="179" start="169">169-179</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> extracellular signal-regulated kinase</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Platelet-Derived Growth Factor</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="Arial">Shikonin is a naphthoquinone extracted from the root of Lithospermum erythrorhizon, and has been reported to suppress allergic airway inflammation in mice. However, the underlying mechanisms are unclear and need to be further elucidated. In this study, shikonin (0.5, 2 or 4mg/kg) was given intraperitoneally to ovalbumin (OVA)-challenged BALB/c mice. We found that the pathological airway remodeling of asthmatic mice was alleviated by shikonin, and the infiltrated inflammatory cells and collagen deposition in their lungs were reduced. Furthermore, the abnormal activation of extracellular signal-regulated kinase (ERK)/nuclear factor-kappaB (NF-kappaB) pathway and the elevation of matrix metalloproteinase 9 (MMP9) in the lung of asthmatic mice were suppressed by shikonin. The inactivation of NF-kappaB by shikonin was at least in part via inhibiting IkappaBalpha activation. In vitro, the treatment of shikonin inhibited the platelet-derived growth factor (PDGF)-induced proliferation of primary airway smooth muscle cells (ASMCs), and induced a G0/G1 arrest in these cells. In addition, ASMCs exposed to PDGF acquired an enhanced migratory ability, and the activities of MMP9 and matrix metalloproteinase 2 (MMP2) and expression of MMP9 of these cells were significantly up-regulated. These PDGF-induced alterations were also inhibited by shikonin. The inhibitory effects of shikonin on the proliferation and migration of ASMCs were comparable to pyrrolidinedithiocarbamate (PDTC), an inhibitor of NF-kappaB pathway. In conclusion, the present study sheds lights on how shikonin alleviates allergic airway remodeling</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.05.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28521243">PM:28521243</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-48-169-79.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-48-169-79.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Wang TY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.05.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salari,F.</style></author><author><style face="normal" font="Arial"> Vahedi,F.</style></author><author><style face="normal" font="Arial"> Varasteh,A.R.</style></author><author><style face="normal" font="Arial"> Ketabdar,H.</style></author><author><style face="normal" font="Arial"> Chamani,J.</style></author><author><style face="normal" font="Arial"> Sankian,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.</style></auth-address><titles><title><style face="normal" font="Arial">Enhanced sublingual immunotherapy by TAT-fused recombinant allergen in a murine rhinitis model</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="125" start="118">118-125</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Che a 3</style></keyword><keyword><style face="normal" font="Arial"> Chenopodium album</style></keyword><keyword><style face="normal" font="Arial"> Chenopodium album pollen</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual administration</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Allergen-specific sublingual immunotherapy (SLIT) is well known as an effective and non-invasive route to induce allergy desensitization. The goal of this study was to investigate whether a TAT-fused recombinant allergen could enhance SLIT efficacy. BALB/c mice sensitized to the main allergen (Che a 3) of Chenopodium album pollen were treated sublingually either with rChe a 3 (100mug/dose) or rTAT-Che a 3 (100mug/dose), two times per week for eight weeks. SLIT with rTAT-Che a 3 led to significantly greater allergen-specific IgG2a than rChe a 3; however, neither rTAT-Che a 3 nor rChe a 3 affected allergen-specific IgE or IgG1 antibody levels. In addition, interleukin 4 (IL-4) levels in re-stimulated splenocytes from the rTAT-Che a 3 mice were significantly lower than in those from the rChe a 3 mice, while interferon-gamma (IFN-gamma) was significantly greater in the rChe a 3 mice than in the rTAT-Che a 3 mice. Furthermore, sublingual administration of rTAT-Che a 3 induced significantly greater TGF-beta secretion in re-stimulated splenocytes than administration of rChe a 3. Accordingly, SLIT with rTAT-Che a 3 led to significantly greater expression of TGF-beta- and Foxp3-specific mRNAs in the splenocytes than in those from the rChe a 3 mice. Our findings demonstrate that TAT-fused rChe a 3 suppressed the allergic response through preferential enhancement of systemic regulatory T-cell (Treg)-mediated immunity responses, likely by facilitating allergen capture and presentation by sublingual Langerhans-like dendritic cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170514IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - Iran -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.04.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28501765">PM:28501765</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-48-118-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-48-118-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170514, Salari F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.04.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Osborne,N.J.</style></author><author><style face="normal" font="Arial"> Alcock,I.</style></author><author><style face="normal" font="Arial"> Wheeler,B.W.</style></author><author><style face="normal" font="Arial"> Hajat,S.</style></author><author><style face="normal" font="Arial"> Sarran,C.</style></author><author><style face="normal" font="Arial"> Clewlow,Y.</style></author><author><style face="normal" font="Arial"> McInnes,R.N.</style></author><author><style face="normal" font="Arial"> Hemming,D.</style></author><author><style face="normal" font="Arial"> White,M.</style></author><author><style face="normal" font="Arial"> Vardoulakis,S.</style></author><author><style face="normal" font="Arial"> Fleming,L.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">European Centre for Environment and Human Health, University of Exeter Medical School, Truro, Cornwall, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Pollen exposure and hospitalization due to asthma exacerbations: daily time series in a European city</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthma hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">Exposure to pollen can contribute to increased hospital admissions for asthma exacerbation. This study applied an ecological time series analysis to examine associations between atmospheric concentrations of different pollen types and the risk of hospitalization for asthma in London from 2005 to 2011. The analysis examined short-term associations between daily pollen counts and hospital admissions in the presence of seasonal and long-term patterns, and allowed for time lags between exposure and admission. Models were adjusted for temperature, precipitation, humidity, day of week, and air pollutants. Analyses revealed an association between daily counts (continuous) of grass pollen and adult hospital admissions for asthma in London, with a 4-5-day lag. When grass pollen concentrations were categorized into Met Office pollen 'alert' levels, 'very high' days (vs. 'low') were associated with increased admissions 2-5 days later, peaking at an incidence rate ratio of 1.46 (95%, CI 1.20-1.78) at 3 days. Increased admissions were also associated with 'high' versus 'low' pollen days at a 3-day lag. Results from tree pollen models were inconclusive and likely to have been affected by the shorter pollen seasons and consequent limited number of observation days with higher tree pollen concentrations. Future reductions in asthma hospitalizations may be achieved by better understanding of environmental risks, informing improved alert systems and supporting patients to take preventive measures</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-017-1369-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28500390">PM:28500390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\20170513-OsborneNJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\20170513-OsborneNJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Osborne NJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-017-1369-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mori,F.</style></author><author><style face="normal" font="Arial"> Cianferoni,A.</style></author><author><style face="normal" font="Arial"> Brambilla,A.</style></author><author><style face="normal" font="Arial"> Barni,S.</style></author><author><style face="normal" font="Arial"> Sarti,L.</style></author><author><style face="normal" font="Arial"> Pucci,N.</style></author><author><style face="normal" font="Arial"> de Martino,M.</style></author><author><style face="normal" font="Arial"> Novembre,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Allergy Unit, Department of Pediatric, Anna Meyer Children's University Hospital, Florence, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Side effects and their impact on the success of milk oral immunotherapy (OIT) in children</style></title><secondary-title><style face="normal" font="Arial">Int J Immunopathol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Immunopathol Pharmacol</style></full-title></periodical><pages end="187" start="182">182-187</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">Oral immunotherapy (OIT) has been introduced as a new immune-modulating treatment under investigation for food allergies. The aim of our study was to evaluate the success of OIT in a cohort of children with milk allergy. These children underwent OIT in a clinical practice and were followed for up to ten years. The secondary endpoint was to describe the main adverse events during OIT and compare them to those reported in the literature. Eighty-two milk-allergic children started OIT. According to the OIT endpoint reached after one year, all of the children enrolled in the study were divided into four groups: complete desensitization; partial desensitization; step down; and stop groups. Any adverse events that occurred during OIT were also recorded. Of the 82 patients, eight were recruited in the last months of 2010 so they were still ongoing at the end of the study. For that reason, they were excluded from the analysis. The majority (73%) of the 74 children evaluated (51 boys, 23 girls; median age, 7 years; age range, 2-18 years; specific serum IgE for cow's milk, 36 KUA/L [range, 3-100 KUA/L]; milk SPT wheal diameter, 7 mm [range, 2-15 mm]) reached complete (58.1%) or partial (14.9%) desensitization, 9.4% were subjected to step down. The remaining 17.6% of the children discontinued OIT because of the occurrence of chronic gastroenteric (GE) symptoms (46.1%) or acute asthma (15.3%) following milk intake. In agreement with the literature, we found that chronic GE symptoms was the main reason for OIT discontinuation. OIT represents a valid tool for the treatment of food allergies in children; however, the risk of potential adverse reactions, both IgE- and non-IgE-mediated, should be discussed with parents prior to the initiation of OIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 2058-7384 (Electronic)IS - 0394-6320 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/0394632017697986</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28466667">PM:28466667</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Immunopathol Pharmacol\20170503-MoriF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Immunopathol Pharmacol\20170503-MoriF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Mori F</style></custom2><misc3><style face="normal" font="Arial">10.1177/0394632017697986</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dinardi,R.R.</style></author><author><style face="normal" font="Arial"> de Andrade,C.R.</style></author><author><style face="normal" font="Arial"> da Cunha,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Pulmonology Unit, University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of the external nasal dilator on adolescent athletes with and without allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="134" start="127">127-134</pages><volume><style face="normal" font="Arial">97</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> athlete</style></keyword><keyword><style face="normal" font="Arial"> Athletes</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exertion</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal resistance</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: The ability to effectively breathe through the nose is an important component of physical exercise. The goal of this study is to evaluate the effect of the external nasal dilator (END) on healthy adolescent athletes and those with allergic rhinitis. METHODS: Clinical trial, double-blind, crossover, in which we evaluated healthy adolescent athletes with allergic rhinitis, using experimental and placebo ENDs, submitted to a maximum cardio-respiratory test in randomized order. Predicted values for peak nasal inspiratory flow (PNIF%) and nasal resistance (NR) were obtained, and the rating of perceived exertion (RPE) was also assessed after the race test. RESULTS: 65 adolescents participated in the study, 30 of whom had allergic rhinitis. The use of experimental ENDs demonstrated a statistically significant improvement in peak nasal inspiratory flow values (predicted %), nasal resistance, maximal oxygen uptake value (VO2Max.) and rating of perceived exertion, both in the healthy group and the one with allergic rhinitis. CONCLUSION: Results suggested that END reduces nasal resistance, improves maximal oxygen uptake and rating of perceived exertion after a maximum cardio-respiratory test on healthy adolescents and those with allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1872-8464 (Electronic)IS - 0165-5876 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijporl.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483221">PM:28483221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-97-127-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-97-127-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Dinardi RR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijporl.2017.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arrais,M.</style></author><author><style face="normal" font="Arial"> Lulua,O.</style></author><author><style face="normal" font="Arial"> Quifica,F.</style></author><author><style face="normal" font="Arial"> Rosado-Pinto,J.</style></author><author><style face="normal" font="Arial"> Gama,J.M.R.</style></author><author><style face="normal" font="Arial"> Taborda-Barata,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Military Hospital, Luanda, Angola</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of asthma and allergies in 13-14-year-old adolescents from Luanda, Angola</style></title><secondary-title><style face="normal" font="Arial">Int J Tuberc Lung Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Tuberc Lung Dis</style></full-title></periodical><pages end="712" start="705">705-712</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Conditioning</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control measures</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paracetamol</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Public school</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">SETTING: The few epidemiological studies on asthma and allergic diseases performed in Africa have shown that the prevalence of these diseases is high or increasing. No such studies have been performed in Angola. OBJECTIVE: To determine the prevalence of asthma and other allergic diseases in Angolan adolescents. DESIGN: This was a descriptive, observational, cross-sectional study in the province of Luanda, Angola, using the International Study of Asthma and Allergies in Childhood study methodology in adolescents aged 13 and 14 years. Twenty-three (12%) public schools were randomly selected. Data were analysed using the Statistical Package for the Social Sciences version 22.0 software. RESULTS: A total of 3128 adolescents were included. The prevalence of asthma (wheezing in the previous 12 months) was 13.4%. The prevalence of rhinitis (sneezing, runny or blocked nose in the previous 12 months) was 27% and that of eczema (itchy skin lesions in the previous 12 months) was 20%; both were more prevalent in girls. Rhinitis was associated with a greater number of episodes of night cough in adolescents with asthma. Rhinitis and eczema, a split-type air conditioning system, and frequent intake (more than once per month) of paracetamol were associated with a higher risk of having asthma. CONCLUSION: Asthma and related allergic diseases are a public health problem in adolescents from Luanda. Preventive and control measures should be implemented</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1815-7920 (Electronic)IS - 1027-3719 (Linking)LA - engPT - Journal ArticleCO - Angola -CO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.5588/ijtld.16.0530</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28482967">PM:28482967</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Tuberc Lung Dis\2017-21-705-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Tuberc Lung Dis\2017-21-705-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Arrais M</style></custom2><misc3><style face="normal" font="Arial">10.5588/ijtld.16.0530</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kurtul,B.E.</style></author><author><style face="normal" font="Arial"> Kabatas,E.U.</style></author><author><style face="normal" font="Arial"> Boybeyi,S.D.</style></author><author><style face="normal" font="Arial"> Caglar,A.A.</style></author><author><style face="normal" font="Arial"> Ozer,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Ankara, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Increased red cell distribution width levels in children with seasonal allergic conjunctivitis</style></title><secondary-title><style face="normal" font="Arial">Int Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Ophthalmol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Seasonal allergic conjunctivitis (SAC) is an inflammatory disease of the conjunctiva. Red cell distribution width (RDW) is a widely accepted inflammatory marker. We aimed to investigate whether RDW level is associated with the development of SAC in pediatric population. METHODS: The present study consisted of 90 subjects (45 children with SAC and 45 age- and sex-matched healthy children). The demographic findings, complete blood count parameters including RDW and laboratory parameters, were evaluated. RESULTS: The mean RDW levels were significantly higher in children with SAC compared to the control group (14.02 +/- 0.82 vs. 13.26 +/- 0.64%, respectively, p &lt; 0.001). In receiver operating characteristic analysis, the area under the curve for RDW for predicting SAC was 0.786, and a RDW value of 13.45 or higher predicted SAC with a sensitivity of 75.6% and specificity of 65%. CONCLUSION: Our study suggests that elevated RDW levels are significantly associated with SAC in pediatric population, which may imply a possible role of increased inflammatory status and oxidative stress in the pathogenesis of SAC</style></abstract><notes><style face="normal" font="Arial">DA - 20170519IS - 1573-2630 (Electronic)IS - 0165-5701 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10792-017-0563-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28523524">PM:28523524</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Ophthalmol\20170519-KurtulBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Ophthalmol\20170519-KurtulBE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170519, Kurtul BE</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10792-017-0563-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schumacher,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Arizona College of Medicine, Tucson, Arizona, USA</style></auth-address><titles><title><style face="normal" font="Arial">Thunderstorm asthma</style></title><secondary-title><style face="normal" font="Arial">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Intern Med J</style></full-title></periodical><pages end="607" start="605">605-607</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Arizona</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> thunderstorm</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - engPT - LetterCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1111/imj.13411</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28503885">PM:28503885</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med J\2017-47-605-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med J\2017-47-605-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Schumacher MJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/imj.13411</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hew,M.</style></author><author><style face="normal" font="Arial"> Sutherland,M.</style></author><author><style face="normal" font="Arial"> Thien,F.</style></author><author><style face="normal" font="Arial"> O'Hehir,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy, Asthma and Clinical Immunology, The Alfred Hospital, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">The Melbourne thunderstorm asthma event: can we avert another strike?</style></title><secondary-title><style face="normal" font="Arial">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Intern Med J</style></full-title></periodical><pages end="487" start="485">485-487</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> thunderstorm</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - engPT - EditorialCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/imj.13413</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28503876">PM:28503876</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med J\2017-47-485-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med J\2017-47-485-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Hew M</style></custom2><misc3><style face="normal" font="Arial">10.1111/imj.13413</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mainente,F.</style></author><author><style face="normal" font="Arial"> Fratea,C.</style></author><author><style face="normal" font="Arial"> Simonato,B.</style></author><author><style face="normal" font="Arial"> Zoccatelli,G.</style></author><author><style face="normal" font="Arial"> Rizzi,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Food Allergy Risk Management in the EU Labelling Legislation</style></title><secondary-title><style face="normal" font="Arial">J Agric Environ Ethics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Agric Environ Ethics</style></full-title></periodical><pages end="285" start="275">275-285</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Beverages</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food labelling</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> United Nations</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-322X</style></isbn><abstract><style face="normal" font="Arial">Food allergy represents an increasing public health issue, and a large number of food control authorities have provided regulations aimed to minimize the risk of allergic reaction for sensitized consumers. The Food and Agriculture Organization of the United Nations together with the World Health Organization established the Codex Alimentarius Commission whose main goal is to protect the consumers</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ health. To purse this task the Commission listed the foods and ingredients causing the most severe allergic reactions that should be labelled. It has been reported that some cases of specific foods hypersensitivity display a different prevalence among different Countries. Thus, the European Union drew up a list of mandatory allergens (that must be labelled) longer than that provided by Codex Alimentarius. As a consequence of the complexity of the legal phraseology of the European Union (EU) and/or European Community (EC) the Regulations and/or Directives were differently translated in all EC/EU official languages determining possible misinterpretations of the legislation. Moreover, food labelling regulations were also established with the goal to promote the consumers</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ conscious choice about what they eat. Starting from the case of the fermented beverages, we analysed the European legislative scenario concerning the allergen labelling of the last fifteen years, highlighting that mistranslations, misinterpretations and lack of information in the EU Regulations might lead to health and ethical issues</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10806-017-9668-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10806-017-9668-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Environ Ethics\20170521-MainenteF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Environ Ethics\20170521-MainenteF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170521, Mainente F</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10806-017-9668-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pablos-Tanarro,A.</style></author><author><style face="normal" font="Arial"> Lozano-Ojalvo,D.</style></author><author><style face="normal" font="Arial"> Martinez-Blanco,M.</style></author><author><style face="normal" font="Arial"> Lopez-Fandino,R.</style></author><author><style face="normal" font="Arial"> Molina,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">SENSITIZING AND ELICITING CAPACITY OF EGG WHITE PROTEINS IN BALB/C MICE AS AFFECTED BY PROCESSING</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg white proteins</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> heated egg</style></keyword><keyword><style face="normal" font="Arial"> high pressure</style></keyword><keyword><style face="normal" font="Arial"> High-pressure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Oral sensitization</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Denaturation</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">This study assesses to what extent technological processes that lead to different degrees of denaturation of egg white proteins affect their allergenicity. We focused on heat (80 masculineC, 10 min) and high pressure (400 MPa and 37 masculineC, 10 min) treatments and used a BALB/c mouse model of food allergy. Oral sensitization to egg white using cholera toxin as adjuvant induced the production of IgE and IgG1 isotypes and led to severe clinical signs following challenge with the allergen. Extensive protein denaturation caused by heat treatment increased its ability to induce Th1 responses and reduced both its sensitizing and eliciting capacity. Heated egg white stimulated the production of IgE over IgG1 antibodies directed, at least in part, towards new epitopes exposed as a result of heat treatment. Conversely, partial denaturation caused by high pressure treatment increased the ability of egg white to stimulate Th2 responses and its allergenic potential</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b00953</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28467846">PM:28467846</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170503-PablosTanarroA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170503-PablosTanarroA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Pablos-Tanarro A</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b00953</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wong,P.H.</style></author><author><style face="normal" font="Arial"> Quinn,J.M.</style></author><author><style face="normal" font="Arial"> Gomez,R.A.</style></author><author><style face="normal" font="Arial"> Webb,C.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Wilford Hall Ambulatory Surgical Center, Lackland Air Force Base, San Antonio, Tex.</style></auth-address><titles><title><style face="normal" font="Arial">Systemic reactions to immunotherapy during mountain cedar season: implications for seasonal dose adjustment</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1439" start="1438">1438-1439</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499782">PM:28499782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1438-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1438-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Wong PH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schulten,V.</style></author><author><style face="normal" font="Arial"> Tripple,V.</style></author><author><style face="normal" font="Arial"> Seumois,G.</style></author><author><style face="normal" font="Arial"> Qian,Y.</style></author><author><style face="normal" font="Arial"> Scheuermann,R.H.</style></author><author><style face="normal" font="Arial"> Fu,Z.</style></author><author><style face="normal" font="Arial"> Locci,M.</style></author><author><style face="normal" font="Arial"> Rosales,S.</style></author><author><style face="normal" font="Arial"> Vijayanand,P.</style></author><author><style face="normal" font="Arial"> Sette,A.</style></author><author><style face="normal" font="Arial"> Alam,R.</style></author><author><style face="normal" font="Arial"> Crotty,S.</style></author><author><style face="normal" font="Arial"> Peters,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">La Jolla Institute for Allergy &amp; Immunology, La Jolla, CA 9203, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Follicular T cells</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germinal Center</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">Follicular helper T cells (Tfh cells) are a CD4 T cell subset essential for germinal center formation and B cell responses, although their role in allergy and allergen-specific immunotherapy (AIT) is unclear. Here, we show that AIT-treated patients have a higher ratio of regulatory Tfh cells (Tfr) to follicular T cells (Tfh) and hypothesize an IL-2 dependent mechanism</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506846">PM:28506846</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170516-SchultenV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170516-SchultenV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Schulten V</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Peters,R.L.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author><author><style face="normal" font="Arial"> Gurrin,L.C.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Wake,M.</style></author><author><style face="normal" font="Arial"> Ponsonby,A.L.</style></author><author><style face="normal" font="Arial"> Tang,M.L.K.</style></author><author><style face="normal" font="Arial"> Lowe,A.J.</style></author><author><style face="normal" font="Arial"> Matheson,M.</style></author><author><style face="normal" font="Arial"> Dwyer,T.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Murdoch Childrens Research Institute, Parkville, Australia</style></auth-address><titles><title><style face="normal" font="Arial">The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="153" start="145">145-153</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> one year old children</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The HealthNuts study previously reported interim prevalence data showing the highest prevalence of challenge-confirmed food allergy in infants internationally. However, population-derived prevalence data on challenge-confirmed food allergy and other allergic diseases in preschool-aged children remain sparse. OBJECTIVE: This study aimed to report the updated prevalence of food allergy at age 1 year from the whole cohort, and to report the prevalence of food allergy, asthma, eczema, and allergic rhinitis at age 4 years. METHODS: HealthNuts is a population-based cohort study with baseline recruitment of 5276 one-year-old children who underwent skin prick test (SPT) to 4 food allergens and those with detectable SPT results had formal food challenges. At age 4 years, parents completed a questionnaire (81.3% completed) and those who previously attended the HealthNuts clinic at age 1 year or reported symptoms of a new food allergy were invited for an assessment that included SPT and oral food challenges. Data on asthma, eczema, and allergic rhinitis were captured by validated International Study of Asthma and Allergies in Childhood questionnaires. RESULTS: The prevalence of challenge-confirmed food allergy at age 1 and 4 years was 11.0% and 3.8%, respectively. At age 4 years, peanut allergy prevalence was 1.9% (95% CI, 1.6% to 2.3%), egg allergy was 1.2% (95% CI, 0.9% to 1.6%), and sesame allergy was 0.4% (95% CI, 0.3% to 0.6%). Late-onset peanut allergy at age 4 years was rare (0.2%). The prevalence of current asthma was 10.8% (95% CI, 9.7% to 12.1%), current eczema was 16.0% (95% CI, 14.7% to 17.4%), and current allergic rhinitis was 8.3% (95% CI, 7.2% to 9.4%). Forty percent to 50% of this population-based cohort experienced symptoms of an allergic disease in the first 4 years of their life. CONCLUSIONS: Although the prevalence of food allergy decreased between age 1 year and age 4 years in this population-based cohort, the prevalence of any allergic disease among 4-year-old children in Melbourne, Australia, is remarkably high</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - New Zealand -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28514997">PM:28514997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170518-PetersRL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170518-PetersRL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Peters RL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,D.D.</style></author><author><style face="normal" font="Arial"> Antoni,C.</style></author><author><style face="normal" font="Arial"> Freedman,S.J.</style></author><author><style face="normal" font="Arial"> Levesque,M.C.</style></author><author><style face="normal" font="Arial"> Sundy,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Novartis, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="Arial">Phase 2 to Phase 3 Clinical Trial Transitions: Reasons for Success and Failure in Immunologic Diseases</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="687" start="685">685-687</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Switzerland -CO- United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506849">PM:28506849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170516-PatelDD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170516-PatelDD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Patel DD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gold,D.R.</style></author><author><style face="normal" font="Arial"> Adamkiewicz,G.</style></author><author><style face="normal" font="Arial"> Arshad,S.H.</style></author><author><style face="normal" font="Arial"> Celedon,J.C.</style></author><author><style face="normal" font="Arial"> Chapman,M.D.</style></author><author><style face="normal" font="Arial"> Chew,G.L.</style></author><author><style face="normal" font="Arial"> Cook,D.N.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author><author><style face="normal" font="Arial"> Gehring,U.</style></author><author><style face="normal" font="Arial"> Gern,J.E.</style></author><author><style face="normal" font="Arial"> Johnson,C.C.</style></author><author><style face="normal" font="Arial"> Kennedy,S.</style></author><author><style face="normal" font="Arial"> Koutrakis,P.</style></author><author><style face="normal" font="Arial"> Leaderer,B.</style></author><author><style face="normal" font="Arial"> Mitchell,H.</style></author><author><style face="normal" font="Arial"> Litonjua,A.A.</style></author><author><style face="normal" font="Arial"> Mueller,G.A.</style></author><author><style face="normal" font="Arial"> O'Connor,G.T.</style></author><author><style face="normal" font="Arial"> Ownby,D.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author><author><style face="normal" font="Arial"> Persky,V.</style></author><author><style face="normal" font="Arial"> Perzanowski,M.S.</style></author><author><style face="normal" font="Arial"> Ramsey,C.D.</style></author><author><style face="normal" font="Arial"> Salo,P.M.</style></author><author><style face="normal" font="Arial"> Schwaninger,J.M.</style></author><author><style face="normal" font="Arial"> Sordillo,J.E.</style></author><author><style face="normal" font="Arial"> Spira,A.</style></author><author><style face="normal" font="Arial"> Suglia,S.F.</style></author><author><style face="normal" font="Arial"> Togias,A.</style></author><author><style face="normal" font="Arial"> Zeldin,D.C.</style></author><author><style face="normal" font="Arial"> Matsui,E.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School; Department of Environmental Health, Harvard T.H. Chan School of Public Health; Boston, MA.</style></auth-address><titles><title><style face="normal" font="Arial">NIAID, NIEHS, NHLBI, MCAN Workshop Report: The Indoor Environment and Childhood Asthma: Implications for Home Environmental Intervention in Asthma Prevention and Management</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> asthma prevention</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Environmental intervention</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> exposure reduction</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> indoor exposure</style></keyword><keyword><style face="normal" font="Arial"> indoor exposures</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> NIAID</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">Environmental exposures have been recognized as critical in the initiation and exacerbation of asthma, one of the most common chronic childhood diseases. The National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), National Heart, Lung, and Blood Institute (NHLBI), and Merck Childhood Asthma Network (MCAN) sponsored a joint workshop to discuss the current state of the science with respect to the indoor environment and its effects on the development and morbidity of childhood asthma. The workshop included U.S. and international experts with backgrounds in allergy/allergens, immunology, asthma, environmental health, environmental exposures and pollutants, epidemiology, public health, and bioinformatics. Workshop participants provided new insights into the biologic properties of indoor exposures, indoor exposure assessment and exposure reduction techniques. This informed a primary focus of the workshop-- to critically review trials and research relevant to the prevention or control of asthma through environmental intervention. The participants identified important limitations and gaps in the scientific methodologies and knowledge, and proposed and prioritized areas for future research. The group reviewed socioeconomic and structural challenges to changing environmental exposure and offered recommendations for creative study design to overcome these challenges in trials to improve asthma management. The recommendations of this workshop can serve as guidance for future research in the study of the indoor environment and on environmental interventions as they pertain to the prevention and management of asthma and airway allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Netherlands -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502823">PM:28502823</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170515-GoldDR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170515-GoldDR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Gold DR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hemmer,W.</style></author><author><style face="normal" font="Arial"> Altmann,F.</style></author><author><style face="normal" font="Arial"> Holzweber,F.</style></author><author><style face="normal" font="Arial"> Gruber,C.</style></author><author><style face="normal" font="Arial"> Wantke,F.</style></author><author><style face="normal" font="Arial"> Wohrl,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">FAZ- Floridsdorf Allergy Center, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">ImmunoCAP cellulose displays cross-reactive carbohydrate (CCD) epitopes and can cause false-positive test results in patients with high anti-CCD IgE antibody levels</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bromelain</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> Cellulose</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Streptavidin</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Cross-reactive carbohydrate determinants (CCDs) in plants and insect venoms are a common cause of irrelevant positive test results during in-vitro allergy diagnosis. We observed that some CCD-positive sera show non-specific IgE-binding even with CCD-free recombinant allergens when using the Phadia ImmunoCAP platform. OBJECTIVE: We investigated if cellulose used as allergen carrier in the ImmunoCAP harbors residual N-glycans causing non-specific background-binding in CCD-positive sera. METHODS: IgE binding to six samples of blank ImmunoCAPs coupled with either streptavidin (SA-CAP 1-2) or non-allergenic maltose-binding protein (MBP-CAP 1-4) and to a panel of four recombinant allergens was compared in CCD-positive sera before and after inhibition with a CCD inhibitor (MUXF-HSA). RESULTS: Out of 52 CCD-positive sera (bromelain 1.01-59.6 kUa/L) tested on SA-CAP-1, 35 (67%) showed IgE-binding greater than 0.35 kUa/L (0.41-4.22 kUa/L). Among those with anti-CCD IgE levels >7.0 kUa/L, 90% (26/29) were positive. IgE-binding to SA-CAP-1 correlated with IgE-binding to bromelain (r=0.68) and was completely abolished by serum pre-incubation with the CCD inhibitor (n=15). Binding scores with SA-CAP-2 and MBP-CAPs 1-4 were generally lower but strongly correlated with SA-CAP-1 and bromelain. IgE reactivity of 10 CCD-positive sera (14.0-52.5 kUa/L) with the recombinant allergens rPhl p12, rFel d1, rAra h2, and rPru p3 was positive to at least one allergen in 8/10 (0.36-1.63 kUa/L) and borderline in 2/10 (0.21-0.25 kUa/L). Binding correlated with antibody binding to bromelain (r=0.61) and to all blank ImmunoCAPs (r>0.90) and could be completely blocked by the CCD inhibitor. Overall, mean background-binding to cellulose CCDs corresponded to 2-3% of the reactivity seen with bromelain. CONCLUSIONS: Cellulose used as a solid phase allergen carrier may contain varying amounts of CCDs sufficient to cause false-positive test results up to 2 kUa/L with non-glycosylated recombinant allergens in patients with high levels of anti-CCD IgE antibodies</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506851">PM:28506851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170516-HemmerW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170516-HemmerW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Hemmer W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smith,P.K.</style></author><author><style face="normal" font="Arial"> Masilamani,M.</style></author><author><style face="normal" font="Arial"> Li,X.M.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Griffith University, Southport, Queensland, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers To: Additional effects of dietary advanced glycation end products)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="320" start="319">319-320</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170522IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28528928">PM:28528928</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170522-SmithPK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170522-SmithPK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Smith PK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miller,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mission: Allergy, Inc, Hawleyville, Conn, and the Department of Pediatrics, New York Medical College, Valhalla, NY.</style></auth-address><titles><title><style face="normal" font="Arial">Additional effects of dietary advanced glycation end products</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="319">319-</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170522IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28528927">PM:28528927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170522-MillerJD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170522-MillerJD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Miller JD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Turner,M.C.</style></author><author><style face="normal" font="Arial"> Karagiannis,S.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inst. of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna; The Interuniversity Messerli Research Institute, Univ. of Veterinary Medicine Vienna, Medical University Vienna, University Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">AllergoOncology: IgE- and IgG4- mediated immune mechanisms linking Allergy with Cancer and their translational implications</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> AllergoOncology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Austria -CO - Spain -CO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526623">PM:28526623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170520-JensenJarolimE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170520-JensenJarolimE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Jensen-Jarolim E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Cardell,L.O.</style></author><author><style face="normal" font="Arial"> Fernandez de Rojas,D.H.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Allergy and Clinical Immunology, Imperial College London - NHLI, Royal Brompton Hospital, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: time for a change?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="52" start="41">41-52</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> severity criteria</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">Guidelines on the treatment of asthma, allergic rhinitis (AR) and allergen immunotherapy (AIT) lack recommendations for house dust mite (HDM) allergy. An expert panel reviewed current guidelines in the light of new data, to assess whether guidelines could be improved. Most guidelines and key position papers did not provide specific recommendations on treatment of allergic asthma (AA) caused by HDM allergy, although some included AIT as a treatment option for AA in general. Around half of the guidelines stated that AIT with HDM extract was an effective treatment for AR, with several indicating sublingual immunotherapy (SLIT) as an option. This heterogeneity is caused by quality issues affecting studies of AIT with perennial allergens in AA and AR, including use of different diagnosis and severity criteria, lack of consistent scoring or grading systems for primary and safety outcomes, and lack of consensus on treatment parameters. There is a need for well-designed clinical trials to serve as a basis for guideline recommendations. Although results from recent studies strengthen the evidence base for the efficacy and safety of SLIT in HDM AA and AR, their impact on subsequent guideline updates will depend on the methodology and evidence model used by each guideline</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - France -CO - Italy -CO - Sweden -CO - Spain -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.01.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526624">PM:28526624</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170520-CalderonMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170520-CalderonMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Calderon MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.01.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heine,G.</style></author><author><style face="normal" font="Arial"> Hollstein,T.</style></author><author><style face="normal" font="Arial"> Treptow,S.</style></author><author><style face="normal" font="Arial"> Radbruch,A.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Charite-Universitatsmedizin Berlin, Klinik fur Dermatologie und Allergologie, Allergie-Centrum-Charite, Charite Platz 1, D-10117 Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">9-cis retinoic acid modulates the type I allergic immune response</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> activation marker</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISpot</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin A</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Vitamin A is a potent regulator of adaptive immunity. The impact of the endogenous metabolite 9-cis retinoic acid (9cRA) on allergic sensitization is unknown. OBJECTIVE: To investigate whether and to what extent 9cRA modulates the humoral immune response. METHODS: BALB/c mice were sensitized and challenged with ovalbumin (OVA). 9cRA was applied repeatedly together with the antigen. Immunoglobulin production and cellular analysis were performed by ELISA, ELISPOTs and flow-cytometry. Human CD19+ B cells were activated in vitro in the presence or absence of 9cRA and activation markers, proliferation and secreted Ig were analyzed by flow-cytometry and ELISA. RESULTS: 9cRA applied together with repeated OVA challenges transiently increased specific serum IgA, IgE and IgG1 serum levels (2.0-8.9-fold). After OVA recall, specific IgE concentrations were reduced by a mean of 57% after adding 9cRA, while IgA was strongly induced (20-fold) and IgG1 remained unchanged. Correspondingly, less specific IgE- and more IgA secreting cells resided in the spleen in the 9cRA groups. Additionally, 9cRA promoted the migration of specific B cells to the mesenteric, but not the draining lymph nodes. In purified stimulated human B cells, 9cRA markedly reduced IgE production and enhanced IgA production. B cell activation was modulated by 9cRA reducing the expression of CD86 and promoting IL-10. CONCLUSIONS: Our data indicate that 9cRA modulates the allergic immune response by reducing the IgE response but promoting the IgA response. Thus, 9cRA can modulate the allergic immune response towards a non-IgE condition</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526622">PM:28526622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170520-HeineG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170520-HeineG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Heine G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hernandez-Ojeda,A.</style></author><author><style face="normal" font="Arial"> Rojas,N.</style></author><author><style face="normal" font="Arial"> Barriga,F.</style></author><author><style face="normal" font="Arial"> Wietstruck,M.A.</style></author><author><style face="normal" font="Arial"> Morales,P.S.</style></author><author><style face="normal" font="Arial"> Borzutzky,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile</style></auth-address><titles><title><style face="normal" font="Arial">Incidence and risk factors of food allergy after umbilical cord blood transplantation in children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> Umbilical Cord</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170521IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28527904">PM:28527904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170521-Hernandez-OjedaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170521-Hernandez-OjedaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170521, Hernandez-Ojeda A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jayaraman,D.</style></author><author><style face="normal" font="Arial"> Bratton,D.L.</style></author><author><style face="normal" font="Arial"> Harbeck,R.J.</style></author><author><style face="normal" font="Arial"> Wolf,M.</style></author><author><style face="normal" font="Arial"> Rabinovitch,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Pediatrics, National Jewish Health, Denver, Colo</style></auth-address><titles><title><style face="normal" font="Arial">A case of recurrent facial angioedema associated with elevated tree pollen counts</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1772" start="1771">1771-1772</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506423">PM:28506423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1771-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1771-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Jayaraman D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tsuang,A.</style></author><author><style face="normal" font="Arial"> Demain,H.</style></author><author><style face="normal" font="Arial"> Patrick,K.</style></author><author><style face="normal" font="Arial"> Pistiner,M.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Epinephrine use and training in schools for food-induced anaphylaxis among non-nursing staff</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1420" start="1418">1418-1420</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine use</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506422">PM:28506422</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1418-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1418-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Tsuang A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jover,C.V.</style></author><author><style face="normal" font="Arial"> Rodriguez,P.R.</style></author><author><style face="normal" font="Arial"> Domenech,W.J.</style></author><author><style face="normal" font="Arial"> Duran,G.R.</style></author><author><style face="normal" font="Arial"> Garcia Teruel,M.J.</style></author><author><style face="normal" font="Arial"> Santes,G.J.</style></author><author><style face="normal" font="Arial"> Bartolome,Z.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, General University Hospital of Elda, Alicante, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Seminal plasma hypersensitivity: Clinical and histopathologic features in a multipara woman</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1770" start="1768">1768-1770</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499776">PM:28499776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1768-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1768-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Jover CV</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schoos,A.M.</style></author><author><style face="normal" font="Arial"> Bonnelykke,K.</style></author><author><style face="normal" font="Arial"> Chawes,B.L.</style></author><author><style face="normal" font="Arial"> Stokholm,J.</style></author><author><style face="normal" font="Arial"> Bisgaard,H.</style></author><author><style face="normal" font="Arial"> Kristensen,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Precision allergy: Separate allergies to male and female dogs</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499775">PM:28499775</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170513-SchoosAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170513-SchoosAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Schoos AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Netting,M.J.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author><author><style face="normal" font="Arial"> Beck,K.M.</style></author><author><style face="normal" font="Arial"> McWilliam,V.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Tang,M.L.K.</style></author><author><style face="normal" font="Arial"> Ponsonby,A.L.</style></author><author><style face="normal" font="Arial"> Prescott,S.L.</style></author><author><style face="normal" font="Arial"> Vale,S.</style></author><author><style face="normal" font="Arial"> Loh,R.K.S.</style></author><author><style face="normal" font="Arial"> Makrides,M.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">South Australian Healthy and Medical Research Institute, Adelaide, South Australia, Australia; Discipline of Paediatrics, University of Adelaide, Adelaide, South Australia, Australia</style></auth-address><titles><title><style face="normal" font="Arial">An Australian Consensus on Infant Feeding Guidelines to Prevent Food Allergy: Outcomes From the Australian Infant Feeding Summit</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> South Australia</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Infant feeding in the first postnatal year of life has an important role in an infant's risk of developing food allergy. Consumer infant feeding advice is diverse and lacks consistency. AIM: The Australian Infant Feeding Summit was held with the aim of achieving national consensus on the wording of guidelines for infant feeding and allergy prevention. METHODS: Two meetings were hosted by the Centre for Food and Allergy Research, the Australasian Society of Clinical Immunology and Allergy, and the Australian National Allergy Strategy. The first meeting of 30 allergy researchers, clinicians, and consumers assessed the evidence. The second consensus meeting involved 46 expert stakeholders including state and federal health care agencies, consumers, and experts in allergy, infant feeding, and population health. RESULTS: Partner stakeholders agreed on consensus wording for infant feeding advice: CONCLUSIONS: Consensus was achieved in a context in which there is a high prevalence of food allergy. Guidelines for other countries are being updated. Provision of consistent wording related to infant feeding to reduce food allergy risk will ensure clear consumer advice</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499774">PM:28499774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170513-NettingMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170513-NettingMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Netting MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sato,M.</style></author><author><style face="normal" font="Arial"> Shoda,T.</style></author><author><style face="normal" font="Arial"> Shimizu,H.</style></author><author><style face="normal" font="Arial"> Orihara,K.</style></author><author><style face="normal" font="Arial"> Futamura,K.</style></author><author><style face="normal" font="Arial"> Matsuda,A.</style></author><author><style face="normal" font="Arial"> Yamada,Y.</style></author><author><style face="normal" font="Arial"> Irie,R.</style></author><author><style face="normal" font="Arial"> Yoshioka,T.</style></author><author><style face="normal" font="Arial"> Shimizu,T.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author><author><style face="normal" font="Arial"> Nomura,I.</style></author><author><style face="normal" font="Arial"> Matsumoto,K.</style></author><author><style face="normal" font="Arial"> Arai,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan; Department of Pediatrics, Juntendo University Graduate School of Medicine, Tokyo, JapanDepartment of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Gene Expression Patterns in Distinct Endoscopic Findings for Eosinophilic Gastritis in Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1649" start="1639">1639-1649</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastritis</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-3</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Gastritis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> ontology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic gastritis (EG) is clinicopathologically characterized by both marked gastric eosinophilia and clinical symptoms. The endoscopic findings in EG vary among patients, leading to clinical confusion. However, little is known about the relationship between precise endoscopic findings and the pathophysiological process responsible for EG. OBJECTIVE: We aimed to elucidate whether the gross endoscopic findings of EG can be classified into distinct gene expression profiles. METHODS: We enrolled pediatric patients who underwent gastrointestinal endoscopy for clinical symptoms suggestive of eosinophilic gastrointestinal disorder between 2011 and 2016. EG was diagnosed when gastric eosinophilia was greater than or equal to 30 eosinophils/hpf. The gene expression profiles of gastric biopsies were assessed using microarray technology. RESULTS: Patients with EG and control subjects (n = 8, each) were examined. On the microarray, 1,999 genes were differentially expressed between EG and the controls (>/=2-fold difference, adjusted P value &lt; .05), including significant upregulation of eotaxin-3 (C-C chemokine ligand 26). The endoscopic findings of patients with EG fell roughly into 2 types, namely, ulcerative and nodular lesions. Despite identifying distinct patterns of gene expression, most differentially regulated genes overlapped between the 2 endoscopic finding types. Several gene ontology terms were enriched in the substantially overlapped genes, but not in each of the distinct genes. CONCLUSIONS: Our results strongly indicate that ulcerative and nodular lesions are a single disease, EG, or a variation thereof, in spite of morphological differences. Our findings may contribute to a better understanding of the pathogenesis of EG, as well as to more accurate diagnosis of this disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526277">PM:28526277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1639-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1639-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Sato M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gothe,F.</style></author><author><style face="normal" font="Arial"> Kappler,M.</style></author><author><style face="normal" font="Arial"> Griese,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dr von Haunersches Kinderspital, University of Munich, German Center for Lung Research (DZL), Munich, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Increasing Total Serum IgE, Allergic Bronchopulmonary Aspergillosis, and Lung Function in Cystic Fibrosis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disorder contributing to lung disease in cystic fibrosis (CF) and challenging to diagnose. OBJECTIVE: This study analyzed the predictive value of increasing total IgE (t-IgE) levels in a CF cohort alongside with clinical and serologic data. METHODS: A total of 387 children and young adults were followed from 2000 to 2006 and retrospectively classified into 6 groups. Patients with t-IgE levels &lt; 95th percentile and without specific Aspergillus fumigatus (Af)-IgE were classified as "Naive," those with Af-specific IgE (Af-sIgE) as "Sensitized." Patients with elevated t-IgE at entrance and Af-sIgE were labeled "Former ABPA," and those without, as "High t-IgE." Patients whose t-IgE values started normal and exceeded the 95th percentile during the study were labeled either "ABPA at risk" if Af-sIgE-positive or "Rising t-IgE" if not. Courses of t-IgE over time were divided into episodes with increasing IgE (DeltaIgE) and related to pulmonary outcome. RESULTS: A total of 125 patients were classified Naive (32%), 64 Sensitized (17%), 49 ABPA at risk (13%), 32 Rising t-IgE (8%), 102 Former ABPA (26%), and 15 High t-IgE (4%). A total of 874 DeltaIgE episodes were accompanied by forced expiratory volume in 1 second (FEV1) declines (r = -0.21, P &lt; .0001). Steroid treatment of severest DeltaIgE episodes resulted in improved long-term pulmonary outcomes (P &lt; .01). This FEV1 preservation effect was only detectable if t-IgE levels at least doubled within 3 months and exceeded the 95th age-specific percentile (P &lt; .05). CONCLUSIONS: DeltaIgE obtained from the course of t-IgE levels may be helpful in diagnosing treatment requiring ABPA and predicts the effect of systemic steroid treatment on pulmonary outcome</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526275">PM:28526275</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170520-GotheF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170520-GotheF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Gothe F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bachert,C.</style></author><author><style face="normal" font="Arial"> Gevaert,P.</style></author><author><style face="normal" font="Arial"> Hellings,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Upper Airways Research Laboratory, Ghent University, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1516" start="1512">1512-1516</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biotherapeutics</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis without nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-4 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal endoscopy</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Running</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">In western countries, 85% of chronic rhinosinusitis with nasal polyp disease reveals a type 2 inflammatory pattern with expression of IL-4, -5, and -13 as well as increased concentrations of IgE, whereas chronic rhinosinusitis without nasal polyps merely expresses these biomarkers. The degree of type 2 inflammation furthermore is associated with disease severity, asthma comorbidity, and recurrence of disease after surgery. Therefore, these biomarkers also form the targets for innovative therapeutic approaches such as monoclonal antibodies directed against IgE, IL-5, and IL-4 receptor alpha, blocking the activity of IL-4 and -13. Having demonstrated efficacy in severe asthma, the antibodies have been tested in proof-of-concept studies in patients with nasal polyposis with or without asthma, and have demonstrated their potential to reduce nasal and sinus nasal polyp burden monitored by nasal endoscopy and computed tomography scanning, and to improve typical symptoms. No biomarkers have been identified to select subjects for therapy, to predict response to a specific drug, or to monitor treatment success, which is best documented by nasal polyp score and symptoms. Phase 3 studies are currently in preparation or running, which aim to demonstrate efficacy in larger patient populations and to achieve registration for the indication nasal polyps</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Belgium -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526278">PM:28526278</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1512-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1512-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Bachert C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cook,K.A.</style></author><author><style face="normal" font="Arial"> Kelso,J.M.</style></author><author><style face="normal" font="Arial"> White,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Scripps Clinic, Division of Allergy, Asthma and Immunology, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">Increased risk of systemic reactions extends beyond completion of rush immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1775" start="1773">1773-1775</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rush immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506424">PM:28506424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1773-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1773-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Cook KA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uong,P.</style></author><author><style face="normal" font="Arial"> Curran-Everett,D.</style></author><author><style face="normal" font="Arial"> Leung,D.Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, National Jewish Health, Denver, Colo</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus colonization is associated with increased inhaled corticosteroid requirements in patients with atopic dermatitis and asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1783" start="1782">1782-1783</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526276">PM:28526276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1782-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1782-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Uong P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ye,L.</style></author><author><style face="normal" font="Arial"> Song,D.</style></author><author><style face="normal" font="Arial"> Jin,M.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic roles of telocytes in OVA-induced acute asthma in mice</style></title><secondary-title><style face="normal" font="Arial">J Cell Mol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cell Mol Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">Telocytes (TCs) newly discovered as the mesenchyme-derived interstitial cells were found to have supportive effects on mesenchymal stem cells (MSCs). The present study aimed at investigating effects of TCs or TCs gathered with MSCs on experimental airway inflammation and hyper-responsiveness. The TCs were isolated from the lung tissue of the female BALB/c mice. The ovalbumin (OVA)-induced asthma model was established. TCs (1 x 106 /2 x 106 ) and/or MSCs (1 x 106 ) were injected through mice tail vein for consecutive three days before OVA excited the mice. This study at first demonstrated that the transplantation of TCs could improve allergen-induced asthma by obviously inhibiting airway inflammation and airway hyper-responsiveness preclinically, with the down-regulation of Th2-related cytokine IL-4, transcription factor GATA-3 and Th2 cell differentiation, while up-regulation of Th1-related cytokine IFN-gamma, transcription factor T-bet and Th1 cells proliferation in asthma, just like MSCs. Co-transplantation of TCs with MSCs showed better therapeutic effects on experimental asthma, even though the therapeutic effects of TCs alone were similar to those of MSCs alone. TCs and the combination of TCs with MSCs could improve the airway inflammation and airway hyper-responsiveness and can be a new alternative for asthma therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170519IS - 1582-4934 (Electronic)IS - 1582-1838 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/jcmm.13199</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28524369">PM:28524369</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cell Mol Med\20170519-YeL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cell Mol Med\20170519-YeL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170519, Ye L</style></custom2><misc3><style face="normal" font="Arial">10.1111/jcmm.13199</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lv,Y.</style></author><author><style face="normal" font="Arial"> Fu,J.</style></author><author><style face="normal" font="Arial"> Shi,X.</style></author><author><style face="normal" font="Arial"> Yang,Z.</style></author><author><style face="normal" font="Arial"> Han,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Pharmacy, Xi'an Jiaotong University, 76# Yanta West Road, Xi'an, 710061, China</style></auth-address><titles><title><style face="normal" font="Arial">Screening allergic components of Yejuhua injection using LAD2 cell membrane chromatography model online with high performance liquid chromatography-ion trap-time of flight-mass spectrum system</style></title><secondary-title><style face="normal" font="Arial">J Chromatogr B Analyt Technol Biomed Life Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Chromatogr B Analyt Technol Biomed Life Sci</style></full-title></periodical><pages end="124" start="119">119-124</pages><volume><style face="normal" font="Arial">1055-1056</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic component</style></keyword><keyword><style face="normal" font="Arial"> allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Cell Membrane</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> histamine release assay</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> TCM</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">Yejuhua (YJH) injection is a traditional Chinese medicine (TCM) injection and has a widely application in clinical practice. However, adverse drug reactions (ADRs) caused by YJH injection, majorly manifested as allergic reactions, have been reported. Hence, Effective and practical method for allergen screening and identification is needed. In this work, a LAD2/CMC model coupled online with HPLC-IT-TOF-MS system was developed to screen, analyze, and identify the allergenic components of YJH injection. A fraction was retained on the LAD2/CMC column, and identified as linarin (LN). Histamine release assay was performed by the multiple reaction monitoring (MRM) method of UPLC-ESI-MS/MS. Results showed that YJH injection and LN were in accord with their allergic effects by increasing histamine release. In conclusion, the LAD2/CMC-HPLC-IT-TOF-MS system developed in this study could be used to screen allergenic components in complex systems</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1873-376X (Electronic)IS - 1570-0232 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jchromb.2017.04.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463725">PM:28463725</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Chromatogr B Analyt Technol Biomed Life Sci\2017-1055_1056-119-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Chromatogr B Analyt Technol Biomed Life Sci\2017-1055_1056-119-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Lv Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jchromb.2017.04.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jain,C.</style></author><author><style face="normal" font="Arial"> DAS,S.</style></author><author><style face="normal" font="Arial"> Ramachandran,V.G.</style></author><author><style face="normal" font="Arial"> Saha,R.</style></author><author><style face="normal" font="Arial"> Bhattacharya,S.N.</style></author><author><style face="normal" font="Arial"> Dar,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Senior Resident, Department of Microbiology, UCMS and GTB Hospital, Delhi, India</style></auth-address><titles><title><style face="normal" font="Arial">Malassezia Yeast and Cytokine Gene Polymorphism in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Clin Diagn Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Diagn Res</style></full-title></periodical><pages end="DC05" start="DC01">DC01-DC05</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal culture</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> senior</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Atopic Dermatitis (AD) is a recurrent chronic condition associated with microorganism and their interaction with the susceptible host. Malassezia yeast is a known commensal which is thought to provoke the recurrent episodes of symptoms in atopic dermatitis patients. Malassezia immunomodulatory properties along with defective skin barrier in such host, results in disease manifestation. Here, we studied Single Nucleotide Polymorphism (SNP) in IL10 and IFN gamma genes of the host and its relation with susceptibility to Malassezia infection. AIM: To isolate Malassezia yeast from AD patients and compare the genetic susceptibility of the host by correlating the cytokine gene polymorphism with the control subjects. MATERIALS AND METHODS: Study was conducted from January 2012 to January 2013. It was a prospective observational study done in Department of Microbiology and Department of Dermatology and Venereology in University College of Medical Sciences and GTB Hospital, Delhi. Sample size comprised of 38 cases each of AD. Skin scrapings were used for fungal culture on Sabouraud Dextrose Agar (SDA) and Modified Dixon Agar (MDA) and isolated were identified as per conventional phenotypic methods. Genomic DNA was extracted from blood samples collected from all study subjects. Cytokine genotyping was carried out by Amplification Refractory Mutations System- Polymerase Chain Reaction (ARMS-PCR) with sequence specific primers. Three SNPs (IL10-1082A/G; IL10-819/592C/T; IFN-gamma+874A/T) in two cytokine genes were assessed in all the patients and healthy controls. STATISTICAL ANALYSIS: Chi-Square Test or Fisher's-Exact Test and Bonferroni's correction. RESULTS: In AD group, Malassezia yeasts were cultured in 24 out of 38 samples and thus the identification rate was 63.1 percent as compared to healthy group, 52.6 percent (20/38). Significant difference in allele, or genotype distribution were observed in IL10-819/592C/T and IFN-gamma+874A/T gene polymorphism in AD group. CONCLUSION: Higher isolation rate in cases as compared to control group highlights the implication of Malassezia in AD. Association between specific cytokine gene polymorphism and clinical outcome was found to be significant in study group. The result of cytokine gene polymorphism in the present study demonstrated susceptibility of host to Malassezia infection</style></abstract><notes><style face="normal" font="Arial">DA - 20170517IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.7860/JCDR/2017/23948.9474</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28511379">PM:28511379</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-DC01-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-DC01-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170517, Jain C</style></custom2><misc3><style face="normal" font="Arial">10.7860/JCDR/2017/23948.9474</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mendonca,L.O.</style></author><author><style face="normal" font="Arial"> Malle,L.</style></author><author><style face="normal" font="Arial"> Donovan,F.X.</style></author><author><style face="normal" font="Arial"> Chandrasekharappa,S.C.</style></author><author><style face="normal" font="Arial"> Montealegre Sanchez,G.A.</style></author><author><style face="normal" font="Arial"> Garg,M.</style></author><author><style face="normal" font="Arial"> Tedgard,U.</style></author><author><style face="normal" font="Arial"> Castells,M.</style></author><author><style face="normal" font="Arial"> Saini,S.S.</style></author><author><style face="normal" font="Arial"> Dutta,S.</style></author><author><style face="normal" font="Arial"> Goldbach-Mansky,R.</style></author><author><style face="normal" font="Arial"> Suri,D.</style></author><author><style face="normal" font="Arial"> Jesus,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Immunology and Allergy Department, HC-FMUSP, Sao Paulo, SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN</style></title><secondary-title><style face="normal" font="Arial">J Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anakinra</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exons</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic analysis</style></keyword><keyword><style face="normal" font="Arial"> Genetic Screening</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Deficiency of interleukin-1 receptor antagonist (DIRA) is a rare life-threatening autoinflammatory disease caused by autosomal recessive mutations in IL1RN. DIRA presents clinically with early onset generalized pustulosis, multifocal osteomyelitis, and elevation of acute phase reactants. We evaluated and treated an antibiotic-unresponsive patient with presumed DIRA with recombinant IL-1Ra (anakinra). The patient developed anaphylaxis to anakinra and was subsequently desensitized. METHODS: Genetic analysis of IL1RN was undertaken and treatment with anakinra was initiated. RESULTS: A 5-month-old Indian girl born to healthy non-consanguineous parents presented at the third week of life with irritability, sterile multifocal osteomyelitis including ribs and clavicles, a mild pustular rash, and elevated acute phase reactants. SNP array of the patient's genomic DNA revealed a previously unrecognized homozygous deletion of approximately 22.5 Kb. PCR and Sanger sequencing of the borders of the deleted area allowed identification of the breakpoints of the deletion, thus confirming a homozygous 22,216 bp deletion that spans the first four exons of IL1RN. Due to a clinical suspicion of DIRA, anakinra was initiated which resulted in an anaphylactic reaction that triggered desensitization with subsequent marked and sustained clinical and laboratory improvement. CONCLUSION: We report a novel DIRA-causing homozygous deletion affecting IL1RN in an Indian patient. The mutation likely is a founder mutation; the design of breakpoint-specific primers will enable genetic screening in Indian patients suspected of DIRA. The patient developed anaphylaxis to anakinra, was desensitized, and is in clinical remission on continued treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1573-2592 (Electronic)IS - 0271-9142 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - United States -CO - Sweden -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10875-017-0399-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28503715">PM:28503715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Immunol\20170515-MendoncaLO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Immunol\20170515-MendoncaLO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Mendonca LO</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10875-017-0399-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kimura,H.</style></author><author><style face="normal" font="Arial"> Inami,M.</style></author><author><style face="normal" font="Arial"> Hamaguchi,Y.</style></author><author><style face="normal" font="Arial"> Takehara,K.</style></author><author><style face="normal" font="Arial"> Akimoto,S.</style></author><author><style face="normal" font="Arial"> Yokooji,T.</style></author><author><style face="normal" font="Arial"> Matsuo,H.</style></author><author><style face="normal" font="Arial"> Matsushita,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Food-dependent exercise-induced anaphylaxis due to shrimp associated with 43 kDa, a new antigen</style></title><secondary-title><style face="normal" font="Arial">J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food-dependent exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170504IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/1346-8138.13890</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28470776">PM:28470776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol\20170504-KimuraH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol\20170504-KimuraH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170504, Kimura H</style></custom2><misc3><style face="normal" font="Arial">10.1111/1346-8138.13890</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kochling,H.</style></author><author><style face="normal" font="Arial"> Schaper,K.</style></author><author><style face="normal" font="Arial"> Wilzopolski,J.</style></author><author><style face="normal" font="Arial"> Gutzmer,R.</style></author><author><style face="normal" font="Arial"> Werfel,T.</style></author><author><style face="normal" font="Arial"> Baumer,W.</style></author><author><style face="normal" font="Arial"> Kietzmann,M.</style></author><author><style face="normal" font="Arial"> Rossbach,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Veterinary Medicine Hannover, Institute for Pharmacology, Toxicology and Pharmacy, Hannover, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Combined treatment with H1 and H4 receptor antagonists reduces inflammation in a mouse model of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> H4 receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Histamine 4 receptor (H4R) antagonists are considered as new therapeutics for the treatment of atopic dermatitis (AD) and first clinical trials have already shown promising results. Histamine 1 receptor (H1R) antagonists are traditionally used to treat AD although the evidence for the efficacy is weak. The combined blockade of both, H1R and H4R, might provide synergistic anti-inflammatory. OBJECTIVE: The study was performed to test the anti-inflammatory potential of a combined treatment with an H1R and an H4R antagonist in a mouse AD model. METHODS: The development of ovalbumin-induced AD-like skin lesions was analysed mice treated with the H1R inverse agonist mepyramine, the H4R antagonist JNJ-39758979 or a combination of both. RESULTS: Mice treated with mepyramine plus JNJ-39758979 showed less severe skin lesions, with a diminished influx of inflammatory cells, a reduced epidermal thickening and a lower level of IL-33 in lesional skin. Scratching behaviour was ameliorated in mice treated with the combination. Moreover, total numbers of skin-draining lymph node cells and splenocytes were significantly reduced. Both substances given alone did not elicit this strong anti-inflammatory effect. CONCLUSION: H1R and H4R antagonists provide synergistic anti-inflammatory effects in a mouse model of AD. The combined therapy with H1R and H4R antagonists might represent a new strategy for the treatment of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2017.04.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28495120">PM:28495120</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20170512-KochlingH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20170512-KochlingH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Kochling H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2017.04.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Seyfarth,F.</style></author><author><style face="normal" font="Arial"> Miguel,D.</style></author><author><style face="normal" font="Arial"> Schliemann,S.</style></author><author><style face="normal" font="Arial"> Hipler,U.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Jena University Hospital, Jena, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Diagnostic precision of component-resolved vs. extract-based in vitro diagnosis of hymenoptera venom allergy: effects on clinical management</style></title><secondary-title><style face="normal" font="Arial">J Dtsch Dermatol Ges</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dtsch Dermatol Ges</style></abbr-1></periodical><pages end="515" start="507">507-515</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Api m 1</style></keyword><keyword><style face="normal" font="Arial"> Api m 4</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pol d 5</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Ves v 1</style></keyword><keyword><style face="normal" font="Arial"> Ves v 5</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The measurement of specific IgE (sIgE) antibodies plays a key role in the diagnosis of honeybee and wasp venom allergy. In recent years, component-resolved diagnosis (CRD) has been introduced, which allows for the measurement of sIgE antibodies against Api m 1, Ves v 1, Ves v 5, and Pol d 5, as well as cross-reactive carbohydrate determinants (CCDs). These tests are intended to help determine the clinical relevance of any given sensitization, especially in patients with dual sensitization. PATIENTS AND METHODS: Specific IgE antibody levels were measured in 143 patients with bee and/or wasp venom allergy using the extract-based ImmunoCAP(R) allergens i1 and i3 as well as the ImmunoCAP(R) allergen components i208-211 and O214 (Api m 1, Ves v 1, Ves v 5, Pol d 5, CCDs). In patients with dual sensitization, inhibition testing was also performed. In a subgroup of the study population, sIgE to Api m 1, Api m 4, Pol d 5, and Ves v 5 were determined using the ISAC(R) allergy microarray (n = 44). RESULTS: The sensitivity of Ves v 5 in patients with isolated wasp venom allergy was 78.5 %; in combination with Ves v 1, that figure increased to 92.3 %. The sensitivity of Api m 1 in individuals with isolated bee venom allergy was 25 %. CRD and inhibition testing in individuals with dual sensitization showed divergent results. CRD using the ISAC(R) allergy microarray showed marked differences, especially with regard to Api m 1 and CCDs. CONCLUSION: Component-resolved tests are a valuable addition to the diagnostic spectrum as long as they are used in combination with established procedures. Apart from Ves v 5, measuring IgE antibodies to Ves v 1 should always be included in the diagnostic workup</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1610-0387 (Electronic)IS - 1610-0379 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/ddg.13240</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28485877">PM:28485877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dtsch Dermatol Ges\2017-15-507-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dtsch Dermatol Ges\2017-15-507-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Seyfarth F</style></custom2><misc3><style face="normal" font="Arial">10.1111/ddg.13240</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saporta,D.</style></author><author><style face="normal" font="Arial"> Hurst,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Private Practice, Associates in ENT &amp; Allergy, Elizabeth, NJ, USATufts University, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Increased Sensitization to Mold Allergens Measured by Intradermal Skin Testing following Hurricanes</style></title><secondary-title><style face="normal" font="Arial">J Environ Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Environ Public Health</style></full-title></periodical><pages end="" start="2793820">2793820-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Private Practice</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective. To report on changes in sensitivity to mold allergens determined by changes in intradermal skin testing reactivity, after exposure to two severe hurricanes. Methods. A random, retrospective allergy charts review divided into 2 groups of 100 patients each: Group A, patients tested between 2003 and 2010 prior to hurricanes, and Group B, patients tested in 2014 and 2015 following hurricanes. Reactivity to eighteen molds was determined by intradermal skin testing. Test results, age, and respiratory symptoms were recorded. Chi-square test determined reactivity/sensitivity differences between groups. Results. Posthurricane patients had 34.6 times more positive results (p &lt; 0.0001) at weaker dilutions, all tested molds were found to be more reactive, and 95% had at least one positive test versus only 62% before the hurricanes (p &lt; 0.0001); average mold reactivity was 55% versus 16% while 17% of patients reacted to the entire panel versus none before the hurricanes (p &lt; 0.0001). The posthurricane population was younger (p &lt; 0.001) and included more patients with asthma or lower respiratory symptoms (p &lt; 0.05). Conclusion. Reactivity and sensitization to mold allergens increased compared to patients before the hurricanes. This supports climatologists' hypothesis that environmental changes resulting from hurricanes can be a health risk as reflected in increased allergic sensitivities and symptoms and has significant implications for physicians treating patients from affected areas</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1687-9813 (Electronic)IS - 1687-9805 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/2793820</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28491100">PM:28491100</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Environ Public Health\2017-2017-2793820.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Environ Public Health\2017-2017-2793820.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Saporta D</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/2793820</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yoo,H.</style></author><author><style face="normal" font="Arial"> Kang,M.</style></author><author><style face="normal" font="Arial"> Pyo,S.</style></author><author><style face="normal" font="Arial"> Chae,H.S.</style></author><author><style face="normal" font="Arial"> Ryu,K.H.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Chin,Y.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Korea</style></auth-address><titles><title><style face="normal" font="Arial">SKI3301, a purified herbal extract from Sophora tonkinensis, inhibited airway inflammation and bronchospasm in allergic asthma animal models in vivo</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiserum</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Leguminosae</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Roots</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thromboxane</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Sophora tonkinensis (Leguminosae, ST) is a traditional herbal plant in Korea and China. Its roots and rhizomes have been used to dissipate heat, to clear toxic material and to treat acute pharyngolaryngeal infections and sore throats. AIM OF STUDY: In this study, we tried to investigate the anti-inflammatory and anti-asthmatic effects of a purified extract (SKI3301) from Sophora tonkinensis using in vitro enzyme assay models and ovalbumin (OVA)-induced asthma animal models. MATERIALS AND METHODS: The effect of SKI3301 on pro-inflammatory enzymes such as 5-lipoxygenase, phosphodiesterase 3 &amp; 4, and thromboxane synthase was assayed in vitro. BALB/c mice were sensitized with OVA/Alum ip injection and nebulized with OVA to induce airway inflammation. Bronchoalveolar lavage (BAL) fluid was collected and analyzed for leukocytes infiltration and IL-5 production along with lung histopathology. Guinea pigs passively sensitized with anti-OVA antiserum were used to investigate the effect of SKI3301 on bronchospasm in vitro and in vivo. RESULTS: SKI3301 potently inhibited the activities of 5-lipoxygenase, phosphodiesterase 3 &amp; 4, and thromboxane synthase. Orally administered SKI3301 attenuated the total leukocytes and eosinophil infiltration and IL-5 level in BAL fluids. Histopathological changes associated with lung inflammation were also reduced by SKI3301. SKI3301 inhibited OVA-induced contraction of isolated trachea from sensitized guinea pigs. SKI3301 also protected OVA-induced bronchoconstriction in the sensitized guinea pigs. Maackiain, one of 3 major components of SKI3301, was effective in inhibiting 5-lipoxygenase and OVA-induced airway inflammation. CONCLUSION: In this study, SKI3301 potently inhibited pro-inflammatory enzymes and attenuated OVA-induced bronchospasm in animal model of allergic asthma. These results suggest that SKI3301 may have therapeutic potential for allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.05.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506902">PM:28506902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20170516-YooH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20170516-YooH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Yoo H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.05.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aurich,S.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Leipzig</style></auth-address><titles><title><style face="normal" font="Arial">TNF receptor-associated periodic syndrome (TRAPS) mimicking chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> antibiotic treatment</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypothyroidism</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgA Deficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Marfan Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="5" Year="2017">2017/5/13</year></dates><abstract><style face="normal" font="Arial">Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare (about one per million) autosomal dominant autoinflammatory disease being typically characterized by recurrent fever episodes accompanied by variable gastrointestinal, musculoskeletal, neurological, lymphoid, urogenital and skin symptoms (table 1) [1-3]. We report on a 21 year old non atopic male with prediagnosed IgA deficiency, Marfan syndrome and hypothyroidism who first presented in our university allergy centre with three year history of antihistamine resistant, only slightly itching urticarial rash being accompanied by fatigue. Histology showed superficial perivascular lymphocytic dermatitis with eosinophils and intravascular neutrophil granulocytes. Routine laboratory parameters were within normal range but due to persistently elevated antistreptolysin-titers, without any focal infection detectable, he unsuccessfully received antibiotic treatment. Urticarial rash was only improved by recurrent cycles of systemic methylprednisolone. Under the diagnosis of chronic spontaneous urticaria (CSU) we then treated him with omalizumab subcutaneously (300-600mg once monthly). Symptoms initially seemed to improve during summer time but therapy was stopped after 18 months due to complete recurrence of urticarial rash and persistence of fatigue. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14327</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28500690">PM:28500690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170513-AurichS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170513-AurichS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Aurich S</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14327</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Church,M.K.</style></author><author><style face="normal" font="Arial"> Labeaga,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Allergy Centre Charite, Charite Universitatsmedizin, Berlin, GermanyFAES Farma, S.A. Medical Department, Bilbao, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Bilastine</style></keyword><keyword><style face="normal" font="Arial"> Blood-Brain Barrier</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Difficult-to-treat</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">This review set out to examine published papers detailing the efficacy of bilastine in skin models and urticaria to assess whether it meets the optimal profile for updosing in urticaria, i.e. strong clinical efficacy and freedom from unwanted side effects, particularly sedation. Bilastine is a highly effective H1 -antihistamine even when used at the basic dose of 20 mg daily. Its facilitated uptake after oral dosage gives it a rapid onset and long duration of action. In both wheal and flare studies and in urticaria updosing four fold showed increased effectiveness. With respect to somnolence, bilastine is a substrate for P-glycoprotein, a membrane pump which prevents it crossing the blood-brain barrier. Consequently, bilastine is a practically 'non-sedating' H1 -antihistamine. In conclusion, the excellent profile of bilastine in both efficacy and safety make it the ideal H1 -antihistamine for updosing the daily dose fourfold in difficult-to-treat urticaria as recommended by the EAACI/GALEN/EDF/WAO guideline for the management of urticaria. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14305</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28467671">PM:28467671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170503-ChurchMK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170503-ChurchMK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Church MK</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14305</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">To,K.K.W.</style></author><author><style face="normal" font="Arial"> Yip,C.C.Y.</style></author><author><style face="normal" font="Arial"> Yuen,K.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory for Emerging Infectious Diseases, Hong Kong Special Administrative Region; Carol Yu Centre for Infection, Hong Kong Special Administrative Region</style></auth-address><titles><title><style face="normal" font="Arial">Rhinovirus - From bench to bedside</style></title><secondary-title><style face="normal" font="Arial">J Formos Med Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Formos Med Assoc</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Common Cold</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> lower respiratory tract infections</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Multiplex PCR</style></keyword><keyword><style face="normal" font="Arial"> Multiplex-PCR</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Rhinoviruses</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">Rhinovirus has been neglected in the past because it was generally perceived as a respiratory virus only capable of causing mild common cold. Contemporary epidemiological studies using molecular assays have shown that rhinovirus is frequently detected in adult and pediatric patients with upper or lower respiratory tract infections. Severe pulmonary and extrapulmonary complications are increasingly recognized. Contrary to popular belief, some rhinoviruses can actually replicate well at 37 degrees C and infect the lower airway in humans. The increasing availability of multiplex PCR panels allows rapid detection of rhinovirus and provides the opportunity for timely treatment and early recognition of outbreaks. Recent advances in the understanding of host factors for viral attachment and replication, and the host immunological response in both asthmatic and non-asthmatic individuals, have provided important insights into rhinovirus infection which are crucial in the development of antiviral treatment. The identification of novel drugs has been accelerated by repurposing clinically-approved drugs. As humoral antibodies induced by past exposure and vaccine antigen of a particular serotype cannot provide full coverage for all rhinovirus serotypes, novel vaccination strategies are required for inducing protective response against all rhinoviruses</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 0929-6646 (Print)IS - 0929-6646 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jfma.2017.04.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28495415">PM:28495415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Formos Med Assoc\20170512-ToKK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Formos Med Assoc\20170512-ToKK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, To KK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jfma.2017.04.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chan,T.K.</style></author><author><style face="normal" font="Arial"> Tan,W.S.D.</style></author><author><style face="normal" font="Arial"> Peh,H.Y.</style></author><author><style face="normal" font="Arial"> Wong,W.S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore 117600</style></auth-address><titles><title><style face="normal" font="Arial">Aeroallergens Induce Reactive Oxygen Species Production and DNA Damage and Dampen Antioxidant Responses in Bronchial Epithelial Cells</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Damage</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> nitrosative stress</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">Exposure to environmental allergens is a major risk factor for asthma development. Allergens possess proteolytic activity that is capable of disrupting the airway epithelium. Although there is increasing evidence pointing to asthma as an epithelial disease, the underlying mechanism that drives asthma has not been fully elucidated. In this study, we investigated the direct DNA damage potential of aeroallergens on human bronchial epithelial cells and elucidated the mechanisms mediating the damage. Human bronchial epithelial cells, BEAS-2B, directly exposed to house dust mites (HDM) resulted in enhanced DNA damage, as measured by the CometChip and the staining of DNA double-strand break marker, gammaH2AX. HDM stimulated cellular reactive oxygen species production, increased mitochondrial oxidative stress, and promoted nitrosative stress. Notably, expression of nuclear factor erythroid 2-related factor 2-dependent antioxidant genes was reduced immediately after HDM exposure, suggesting that HDM altered antioxidant responses. HDM exposure also reduced cell proliferation and induced cell death. Importantly, HDM-induced DNA damage can be prevented by the antioxidants glutathione and catalase, suggesting that HDM-induced reactive oxygen and nitrogen species can be neutralized by antioxidants. Mechanistic studies revealed that HDM-induced cellular injury is NADPH oxidase (NOX)-dependent, and apocynin, a NOX inhibitor, protected cells from double-strand breaks induced by HDM. Our results show that direct exposure of bronchial epithelial cells to HDM leads to the production of reactive oxygen and nitrogen species that damage DNA and induce cytotoxicity. Antioxidants and NOX inhibitors can prevent HDM-induced DNA damage, revealing a novel role for antioxidants and NOX inhibitors in mitigating allergic airway disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170520IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1600657</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526682">PM:28526682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170520-ChanTK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170520-ChanTK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170520, Chan TK</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1600657</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klassen,C.</style></author><author><style face="normal" font="Arial"> Karabinskaya,A.</style></author><author><style face="normal" font="Arial"> Dejager,L.</style></author><author><style face="normal" font="Arial"> Vettorazzi,S.</style></author><author><style face="normal" font="Arial"> Van Moorleghem,J.</style></author><author><style face="normal" font="Arial"> Luhder,F.</style></author><author><style face="normal" font="Arial"> Meijsing,S.H.</style></author><author><style face="normal" font="Arial"> Tuckermann,J.P.</style></author><author><style face="normal" font="Arial"> Bohnenberger,H.</style></author><author><style face="normal" font="Arial"> Libert,C.</style></author><author><style face="normal" font="Arial"> Reichardt,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Cellular and Molecular Immunology, University Medical Center Gottingen, 37073 Gottingen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Airway Epithelial Cells Are Crucial Targets of Glucocorticoids in a Mouse Model of Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Dimerization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> target cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">Although glucocorticoids (GCs) are a mainstay in the clinical management of asthma, the target cells that mediate their therapeutic effects are unknown. Contrary to our expectation, we found that GC receptor (GR) expression in immune cells was dispensable for successful therapy of allergic airway inflammation (AAI) with dexamethasone. Instead, GC treatment was compromised in mice expressing a defective GR in the nonhematopoietic compartment or selectively lacking the GR in airway epithelial cells. Further, we found that an intact GR dimerization interface was a prerequisite for the suppression of AAI and airway hyperresponsiveness by GCs. Our observation that the ability of dexamethasone to modulate gene expression in airway epithelial cells coincided with its potency to resolve AAI supports a crucial role for transcriptional regulation by the GR in this cell type. Taken together, we identified an unknown mode of GC action in the treatment of allergic asthma that might help to develop more specific therapies in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601691</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28515280">PM:28515280</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170518-KlassenC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170518-KlassenC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Klassen C</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601691</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fassbender,S.</style></author><author><style face="normal" font="Arial"> Opitz,F.V.</style></author><author><style face="normal" font="Arial"> Johnen,S.</style></author><author><style face="normal" font="Arial"> Forster,I.</style></author><author><style face="normal" font="Arial"> Weighardt,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology and Environment, LIMES Institute of the University of Bonn, Bonn, Germany</style></auth-address><titles><title><style face="normal" font="Arial">MyD88 Contributes to Staphylococcal Enterotoxin B-Triggered Atopic Dermatitis-Like Skin Inlflammation in Mice</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="1804" start="1802">1802-1804</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.04.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457911">PM:28457911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-1802-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-1802-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Fassbender S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.04.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,K.E.</style></author><author><style face="normal" font="Arial"> Jung,M.J.</style></author><author><style face="normal" font="Arial"> Houh,Y.</style></author><author><style face="normal" font="Arial"> Kim,T.S.</style></author><author><style face="normal" font="Arial"> Lee,W.J.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Bang,S.I.</style></author><author><style face="normal" font="Arial"> Kim,C.H.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Park,H.J.</style></author><author><style face="normal" font="Arial"> Cho,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cosmetic Sciences, Sookmyung Women's University, Chungpa-Dong 2-Ka, Yongsan-ku, Seoul 04310, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Erdr1 attenuates Dermatophagoides farina body extract-induced atopic dermatitis in NC/Nga mice</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.04.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457912">PM:28457912</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\20170501-KimKE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\20170501-KimKE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Kim KE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.04.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sung,M.</style></author><author><style face="normal" font="Arial"> Kim,S.W.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Lim,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, CHA Gumi Medical Center, CHA University School of Medicine, Gumi, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Regional Difference of Causative Pollen in Children with Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Korean Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Korean Med Sci</style></full-title></periodical><pages end="932" start="926">926-932</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alder</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">The aim of this study was to investigate role of common pollen in Korean school-aged children with allergic rhinitis (AR) in 5 provinces (Incheon Metropolitan City-Gyeonggi Province, Chungcheongbuk-do, Gwangju Metropolitan City, Busan Metropolitan City, and Jeju Special Self-Governing Province), using a questionnaire and skin prick test, and to assess the differences among the residential regions. Among the enrolled 14,678 total children, 1,641 (22.0%) had AR. The sensitization rate to pollen (38.7%) was the second highest among examined allergens and significant differences were in the sensitization rates to trees, weeds, and grasses among the 5 provinces (P &lt; 0.05). The sensitization to trees (25.2%) was the highest common among the pollen types and significant differences also were observed in the sensitization rates to alder, birch, Japanese cedar, oak, and elm among the 5 provinces. The sensitization rate to weeds (19.9%) was the second highest and significant differences were observed in the sensitization rate to Japanese hop, mugwort, and ragweed among the 5 provinces. The sensitization rate to house dust mite was 86.8%, the highest among examined allergens and that to Dermatophagoides farinae exhibited regional differences (P = 0.003) but not to D. farinae (P = 0.584). The sensitization rate to mold (13.5%) was the highest in Jeju and lowest in Busan, and a statistically significant difference was detected among the 5 provinces. These results support that examined pollen allergens are strongly associated with residential region due to regional causative pollen differences among children with AR within Korea to investigate the main pollen allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1598-6357 (Electronic)IS - 1011-8934 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3346/jkms.2017.32.6.926</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28480649">PM:28480649</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Korean Med Sci\2017-32-926-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Korean Med Sci\2017-32-926-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Sung M</style></custom2><misc3><style face="normal" font="Arial">10.3346/jkms.2017.32.6.926</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Kivit,S.</style></author><author><style face="normal" font="Arial"> Kostadinova,A.I.</style></author><author><style face="normal" font="Arial"> Kerperien,J.</style></author><author><style face="normal" font="Arial"> Morgan,M.E.</style></author><author><style face="normal" font="Arial"> Muruzabal,V.A.</style></author><author><style face="normal" font="Arial"> Hofman,G.A.</style></author><author><style face="normal" font="Arial"> Knippels,L.M.J.</style></author><author><style face="normal" font="Arial"> Kraneveld,A.D.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Willemsen,L.E.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Dietary, nondigestible oligosaccharides and Bifidobacterium breve M-16V suppress allergic inflammation in intestine via targeting dendritic cell maturation</style></title><secondary-title><style face="normal" font="Arial">J Leukoc Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Leukoc Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> activation marker</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium breve</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CpG DNA</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> galectin-9</style></keyword><keyword><style face="normal" font="Arial"> HT29 Cells</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Dietary intervention with short-chain galacto-oligosaccharides (scGOS), long-chain fructo-oligosaccharides (lcFOS) and Bifidobacterium breve M-16V (Bb) (GF/Bb) suppresses food allergic symptoms in mice, potentially via intestinal epithelial cell (IEC)-derived galectin-9. Furthermore, in vitro studies showed galacto- and fructo-oligosaccharides (GF) to enhance the immunomodulatory capacity of a TLR9 ligand representing bacterial CpG DNA when exposed to IEC. In this study, we investigated whether GF/Bb modulates dendritic cells (DCs) and subsequent Th2 and regulatory T cell (Treg) frequency in the small intestinal lamina propria (SI-LP). BALB/c mice were fed GF/Bb during oral OVA sensitization. DC and T cell phenotype were determined in SI-LP mononuclear cells using flow cytometry. Murine bone marrow-derived DCs (BMDCs) were exposed to recombinant galectin-9 or human monocyte-derived DCs (moDCs) and were cultured in IEC-conditioned medium from GF and TLR9 ligand-exposed HT-29 cells. GF/Bb reduced allergic symptoms and enhanced serum galectin-9 levels, while suppressing activation, restoring phagocytic capacity, and normalizing CD103 expression of SI-LP DCs of OVA-allergic mice. In vitro, galectin-9 suppressed LPS-induced activation markers and cytokine secretion by BMDCs, and IEC-conditioned medium suppressed moDC activation in a galectin-9-dependent manner. Besides suppression of SI-LP DC activation, dietary GF/Bb also lowered the frequency of activated Th2 cells, while enhancing Treg in the SI-LP of OVA-allergic mice compared to the control diet. Dietary intervention with GF/Bb enhances galectin-9 and suppresses allergic symptoms of OVA-allergic mice in association with reduced intestinal DC and Th2 activation and increased Treg frequency in these mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1938-3673 (Electronic)IS - 0741-5400 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1189/jlb.3A0516-236R</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28495789">PM:28495789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Leukoc Biol\20170512-deKivitS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Leukoc Biol\20170512-deKivitS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, de Kivit S</style></custom2><misc3><style face="normal" font="Arial">10.1189/jlb.3A0516-236R</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bastl,K.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Kmenta,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research group Aerobiology and pollen information, Department of Oto-Rhino-Laryngology, Medical University of Vienna, Wien, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of Pollen Apps Forecasts: The Need for Quality Control in an eHealth Service</style></title><secondary-title><style face="normal" font="Arial">J Med Internet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Internet Res</style></full-title></periodical><pages end="" start="e152">e152-</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen load</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pollen forecasts are highly valuable for allergen avoidance and thus raising the quality of life of persons concerned by pollen allergies. They are considered as valuable free services for the public. Careful scientific evaluation of pollen forecasts in terms of accurateness and reliability has not been available till date. OBJECTIVE: The aim of this study was to analyze 9 mobile apps, which deliver pollen information and pollen forecasts, with a focus on their accurateness regarding the prediction of the pollen load in the grass pollen season 2016 to assess their usefulness for pollen allergy sufferers. METHODS: The following number of apps was evaluated for each location: 3 apps for Vienna (Austria), 4 apps for Berlin (Germany), and 1 app each for Basel (Switzerland) and London (United Kingdom). All mobile apps were freely available. Today's grass pollen forecast was compared throughout the defined grass pollen season at each respective location with measured grass pollen concentrations. Hit rates were calculated for the exact performance and for a tolerance in a range of +/-2 and +/-4 pollen per cubic meter. RESULTS: In general, for most apps, hit rates score around 50% (6 apps). It was found that 1 app showed better results, whereas 3 apps performed less well. Hit rates increased when calculated with tolerances for most apps. In contrast, the forecast for the "readiness to flower" for grasses was performed at a sufficiently accurate level, although only two apps provided such a forecast. The last of those forecasts coincided with the first moderate grass pollen load on the predicted day or 3 days after and performed even from about a month before well within the range of 3 days. Advertisement was present in 3 of the 9 analyzed apps, whereas an imprint mentioning institutions with experience in pollen forecasting was present in only three other apps. CONCLUSIONS: The quality of pollen forecasts is in need of improvement, and quality control for pollen forecasts is recommended to avoid potential harm to pollen allergy sufferers due to inadequate forecasts. The inclusion of information on reliability of provided forecasts and a similar handling regarding probabilistic weather forecasts should be considered</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1438-8871 (Electronic)IS - 1438-8871 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.2196/jmir.7426</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483740">PM:28483740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Internet Res\2017-19-e152.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Internet Res\2017-19-e152.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Bastl K</style></custom2><misc3><style face="normal" font="Arial">10.2196/jmir.7426</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chmielewska,A.</style></author><author><style face="normal" font="Arial"> Piescik-Lech,M.</style></author><author><style face="normal" font="Arial"> Shamir,R.</style></author><author><style face="normal" font="Arial"> Szajewska,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, Umea University, Umea, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Systematic review: Early infant feeding practices and the risk of wheat allergy</style></title><secondary-title><style face="normal" font="Arial">J Paediatr Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Paediatr Child Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">AIM: Wheat is a common allergen. Early feeding practices (breastfeeding, potentially allergenic foods) might affect the risk of allergy. To systematically evaluate the association between early feeding practices and the risk of wheat allergy and sensitisation. METHODS: Five databases were searched for studies of any design up to July 2015. RESULTS: We included seven studies (five observational, low to moderate quality, two randomised controlled trials (RCTs), high quality). The results come from observational studies unless stated otherwise. Longer breastfeeding was associated with wheat allergy (two studies, n = 1847) and sensitisation (one study, n = 3781). Evidence for exclusive breastfeeding was contradictory; longer exclusive breastfeeding was associated with either lower (one study, n = 408) or higher (one study, n = 3781) risk of wheat sensitisation. Breastfeeding at gluten introduction did not affect the risk of wheat allergy (two studies, n = 2581). Introducing cereal >/=7 months of age increased the risk of wheat allergy (one study, n = 1612), but results from an RCT (n = 1303) showed no effect. Early introduction of gluten was associated with a reduced risk of wheat sensitisation up to 5 years in one observational study (n = 3781) but not in RCTs (n = 1303). CONCLUSIONS: Based on limited evidence, the influence of breastfeeding and an early exposure to gluten on the risk of wheat allergy remain uncertain. There is no evidence supporting breastfeeding at gluten introduction as modifying the risk. Early introduction of gluten might reduce the risk of sensitisation, but currently, no evidence exists that it affects the risk of wheat allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170517IS - 1440-1754 (Electronic)IS - 1034-4810 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Poland -CO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/jpc.13562</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28514046">PM:28514046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Paediatr Child Health\20170517-ChmielewskaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Paediatr Child Health\20170517-ChmielewskaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170517, Chmielewska A</style></custom2><misc3><style face="normal" font="Arial">10.1111/jpc.13562</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsui,K.</style></author><author><style face="normal" font="Arial"> Tachioka,K.</style></author><author><style face="normal" font="Arial"> Onodera,K.</style></author><author><style face="normal" font="Arial"> Ikeda,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbial Science and Host Defense, Meiji Pharmaceutical University, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Topical Application of Josamycin Inhibits Development of Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice</style></title><secondary-title><style face="normal" font="Arial">J Pharm Pharm Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Pharm Pharm Sci</style></abbr-1></periodical><pages end="47" start="38">38-47</pages><volume><style face="normal" font="Arial">20</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Betamethasone</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Langerhans Cells</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> macrolide</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients with atopic dermatitis (AD) have superficial skin colonization by Staphylococcus aureus and an increased number of T helper type 2 (Th2) cells in their peripheral blood. Our previous study showed that josamycin, a macrolide antibiotic, had excellent bactericidal activity against S. aureus strains isolated from AD patients and simultaneously inhibited Th1 and Th2 cell development mediated by Langerhans cells. The purpose of the present study was to evaluate the effect of topical application of josamycin on AD-like skin lesions in NC/Nga mice. METHODS: Josamycin (0.1%) was topically administered to NC/Nga mice with AD-like skin lesions induced by 2, 4, 6-trinitrochlorobenzene (TNCB). The therapeutic effects of josamycin were assessed by measurement of the skin severity scores, histological changes in the lesioned skin, serum levels of total IgE, and expression of interferon (IFN)-gamma and interleukin (IL)-4 in lymph nodes and skin lesions. RESULTS: Topical treatment with josamycin significantly suppressed the increase in the skin severity score in NC/Nga mice. This suppressive effect was equal to that of betamethasone, and was associated with a decrease in the density of cellular infiltration into the dermis, the mast cell count in the dermis and the serum IgE level. Furthermore, topical application of josamycin reduced the expression of IFN-gamma and IL-4 in auricular lymph node cells and the skin lesions. CONCLUSION: The present results show that topical application of josamycin inhibits the development of AD-like skin lesions in NC/Nga mice. This suggests that topical application of josamycin to AD lesions colonized by S. aureus would be beneficial for control of AD by acting on superficially located S. aureus and by inhibiting the development of Th1 and Th2 cells.This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1482-1826 (Electronic)IS - 1482-1826 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.18433/J3GW3D</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28459659">PM:28459659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharm Pharm Sci\2017-20-38-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharm Pharm Sci\2017-20-38-47.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Matsui K</style></custom2><misc3><style face="normal" font="Arial">10.18433/J3GW3D</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,G.</style></author><author><style face="normal" font="Arial"> Lee,S.H.</style></author><author><style face="normal" font="Arial"> Oh,D.S.</style></author><author><style face="normal" font="Arial"> Kim,Y.U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The K-herb Research Center, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Melatonin inhibits neuronal dysfunction-associated with neuroinflammation by atopic psychological stress in NC/Nga atopic-like mouse models</style></title><secondary-title><style face="normal" font="Arial">J Pineal Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pineal Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Corticotropin-Releasing Hormone</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> melatonin</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword></keywords><dates><year Day="13" Month="5" Year="2017">2017/5/13</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD), also known as atopic eczema, is chronic pruritic skin disease. AD can increase psychological stress as well, increasing glucocorticoid release and exacerbating the associated symptoms. Chronic glucocorticoid elevation disturbs neuroendocrine signaling, and can induce neuroinflammation, neurotoxicity, and cognitive impairment; however, it is unclear if AD-related psychological stress elevates glucocorticoids enough to cause neuronal damage. Therefore, we assessed the effects of AD-induced stress in a mouse AD model. AD-related psychological stress increased astroglial and microglial activation, neuroinflammatory cytokine expression, and markers of neuronal loss. Notably, melatonin administration inhibited the development of skin lesions, scratching behavior, and serum IgE levels in the model mice, and additionally caused a significant reduction in corticotropin-releasing hormone responsiveness, and a significant reduction in neuronal damage. Finally, we produced similar results in a corticosterone-induced AD-like skin model. This is the first study to demonstrate that AD-related psychological stress increases neuroendocrine dysfunction, exacerbates neuroinflammation, and potentially accelerates other neurodegenerative disease states. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 1600-079X (Electronic)IS - 0742-3098 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1111/jpi.12420</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28500766">PM:28500766</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pineal Res\20170513-ParkG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pineal Res\20170513-ParkG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Park G</style></custom2><misc3><style face="normal" font="Arial">10.1111/jpi.12420</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arena,S.</style></author><author><style face="normal" font="Arial"> D'Ambrosio,C.</style></author><author><style face="normal" font="Arial"> Vitale,M.</style></author><author><style face="normal" font="Arial"> Mazzeo,F.</style></author><author><style face="normal" font="Arial"> Mamone,G.</style></author><author><style face="normal" font="Arial"> Di Stasio,L.</style></author><author><style face="normal" font="Arial"> Maccaferri,M.</style></author><author><style face="normal" font="Arial"> Curci,P.L.</style></author><author><style face="normal" font="Arial"> Sonnante,G.</style></author><author><style face="normal" font="Arial"> Zambrano,N.</style></author><author><style face="normal" font="Arial"> Scaloni,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Proteomics &amp; Mass Spectrometry Laboratory, ISPAAM, National Research Council, 80147 Naples, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Differential representation of albumins and globulins during grain development in durum wheat and its possible functional consequences</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Biological significance</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Bread</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Durum wheat</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Endosperm</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> globulins</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> hardness</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Pasta</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seed proteins</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Triticum</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">Durum wheat (Triticum turgidum ssp. durum (Desf.) Husn.) is an economically important crop used for the production of semolina, which is the basis of pasta and other food products. Its grains provide proteins and starch for human consumption. Grain development is a key process in wheat physiology; it is highly affected by a number of enzymes that control the metabolic processes governing accumulation of starch and storage proteins and ultimately grain weight. Most of these enzymes are present in the albumin/globulin grain fraction, which represents about a quarter of total seed proteins. With the aim to describe the dynamic profile of the albumin/globulin fraction during durum wheat grain development, we performed a proteomic analysis of this subproteome using a two-dimensional differential gel electrophoresis (2D-DIGE)-based approach and compared six developmental stages. A total of 285 differentially (237 over- and 48 under-) represented spots was identified by nanoLC-ESI-LIT-MS/MS, which were associated with 217 non-redundant Triticum sequence entries. Quantitative protein dynamics demonstrated that carbon metabolism, energy, protein destination/storage, disease/defense and cell growth/division functional categories were highly affected during grain development, concomitantly with progressive grain size increase and starch/protein reserve accumulation. Bioinformatic interaction prediction revealed a complex network of differentially represented proteins mainly centered at enzymes involved in carbon and protein metabolism. A description of 18 proteins associated with wheat flour human allergies was also obtained; these components showed augmented levels at the last developmental stages. By providing a comprehensive understanding of the molecular basis of durum wheat grain development, yield and quality formation, this study provides the foundation and reveals potential biomarkers for further investigations of durum wheat breeding and semolina quality. BIOLOGICAL SIGNIFICANCE: A 2D-DIGE-based comparative analysis of the albumin/globulin fraction from durum wheat caryopses at six developmental stages was performed to describe the dynamic subproteomic changes associated with grain development. Quantitative variations of 217 differentially proteins demonstrated that highly affected are the functional categories of carbon metabolism, energy, protein destination/storage, disease/defense and cell growth/division, which displayed a general over-representation, consistently with concomitant occurrence of grain size increase and starch/protein reserve accumulation. Bioinformatics revealed a complex protein network centered mainly at enzymes involved in carbon and protein metabolism. Differentially represented proteins and corresponding functional categories highly resembled those previously identified as variable in developing bread wheat grain. This suggests that the main differences in kernel hardness between durum and bread wheat probably do not depend on proteomic changes in corresponding albumins/globulins, but on other specific factors affecting the interaction between the starch granules and the endosperm protein matrix in the kernel</style></abstract><notes><style face="normal" font="Arial">DA - 20170507IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2017.05.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28478307">PM:28478307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170507-ArenaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170507-ArenaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170507, Arena S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2017.05.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Czubinski,J.</style></author><author><style face="normal" font="Arial"> Montowska,M.</style></author><author><style face="normal" font="Arial"> Pospiech,E.</style></author><author><style face="normal" font="Arial"> Lampart-Szczapa,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry and Food Analysis, Poznan University of Life Sciences, 28 Wojska Polskiego, 60-637, Poznan, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Proteomic analysis of Lupinus angustifolius (var. Zeus and Bojar) and Lupinus luteus (var. Lord and Parys) seed proteins and their hydrolysates</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2-DE</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic digestion</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Analysis</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gels</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vitro digestion</style></keyword><keyword><style face="normal" font="Arial"> Lupin</style></keyword><keyword><style face="normal" font="Arial"> Lupinus</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seed proteins</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Two dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Proteins enzymatic digestion is a very complex process, during which some components are degraded, while others remain in an unchanged form. Moreover, the enzymatic hydrolysis is one of the most popular methods used to reduce the allergenicity of food proteins. In this study, the efficiency of enzymatic hydrolysis of lupin seeds proteins was assessed by proteomic analysis performed by two-dimensional gel electrophoresis (2-DE) coupled with mass spectrometry identification. Two digestion systems were used, namely, oriented digestion carried out by trypsin and the model in vitro digestion mimicking conditions present in the gastrointestinal tract. RESULTS: The comparisons of 2-DE maps of proteins isolated form different lupin seeds species revealed that the differences in proteins expression were observed mainly in the central parts of gels, i.e., in the molecular weight range from 20 to 70 kDa, and the pH range 5-7. A total number of 27 differentially expressed proteins spots were successfully identified by mass spectrometry analysis. An important reduction in the number of proteins spots on 2-DE maps was observed when trypsin, and the in vitro digestion model were applied. The protein spot insensitive to digestion in both hydrolysis systems was identified as beta-conglutin. CONCLUSIONS: The results provide insight into the nature of the digestion process that may take place after lupin seed proteins intake and highlight the important fact that some of the proteins are insensitive to digestive enzymes activity. Moreover, evaluation of digestion activity of trypsin towards lupin seed proteins may be used for the development of specific processes of hypoallergenic food production</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8436</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28516510">PM:28516510</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170518-CzubinskiJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170518-CzubinskiJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Czubinski J</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8436</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guzek,D.</style></author><author><style face="normal" font="Arial"> Glabska,D.</style></author><author><style face="normal" font="Arial"> Brodowska,M.</style></author><author><style face="normal" font="Arial"> Godziszewska,J.</style></author><author><style face="normal" font="Arial"> Gorska-Horczyczak,E.</style></author><author><style face="normal" font="Arial"> Pogorzelska,E.</style></author><author><style face="normal" font="Arial"> Wojtasik-Kalinowska,I.</style></author><author><style face="normal" font="Arial"> Wierzbicka,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Organization and Consumption Economics, Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences</style></auth-address><titles><title><style face="normal" font="Arial">The sensory quality of allergen-controlled, fat-reduced, salt-reduced pork-ostrich sausages during storage</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> acceptance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> colour</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumer acceptability</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Meat Products</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Physical properties</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sensory quality</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Spices</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Texture</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: New meat products tailored to consumers' health should be characterised by reduced sodium, fat and cholesterol content and other health-promoting benefits. However, the food sector's greatest challenge is allergen-free production. Consumers are not willing to compromise the sensory quality of meat products for health. The aim of the study was to analyse the influence of the storage time on the physical properties and consumer acceptance of allergen-controlled, fat-reduced, salt-reduced pork-ostrich sausages. The object of the study were pork-ostrich sausages produced according to a new patented technology, which focused on eliminating cross-contamination on-line in the plant, eliminating cross-contamination after preparation and eliminating spices with high allergy potential. The production was focused on fat (ca. 50%) and salt (ca. 30%) levels reduction. RESULTS: No changes in the sausage's texture parameters were observed during storage time, however, some changes in colour were observed. There were no significant differences in sensory consumer acceptability of pork-ostrich sausage after 14 days of storage, thus it may be stated that the instrumentally assessed differences in colour did not influence consumer acceptance. CONCLUSION: The applied fat and NaCl reduction in the pork-ostrich sausages contributed to higher consumer ratings and was not correlated with saltiness acceptability</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8421</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28485500">PM:28485500</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170509-GuzekD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170509-GuzekD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Guzek D</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8421</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hara,A.</style></author><author><style face="normal" font="Arial"> Iwasa,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Faculty of Science, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395.</style></auth-address><titles><title><style face="normal" font="Arial">When is allergen immunotherapy effective?</style></title><secondary-title><style face="normal" font="Arial">J Theor Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Theor Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy is used to treat allergic symptoms such as rhinitis and itchy eyes in Japanese patients with cedar pollen allergy (JCPA). Administration of small amounts of pollen over several years may suppress severe allergic symptoms when these patients are later exposed to large amounts of pollen in the environment. Herein, we developed a simple mathematical model to identify conditions in which allergen immunotherapy is effective. We considered the dynamics of type 2 T helper cells (Th2) and regulatory T cells (Treg), both of which differentiate from naive T cells. Therapy was considered successful under the following three conditions: (1) Without therapy patients develop allergic symptoms upon exposure to environmental pollen, (2) with therapy patients do not develop symptoms upon exposure, and (3) patients do not develop allergic symptoms to the therapy itself. We defined scores for therapeutic success and identified ranges of parameters in which allergen immunotherapy is likely to be successful. Treg cells have a longer lifespan than Th2 cells, allowing accumulation over many years. In accordance, therapy with linear dose increases (rather than constant doses) reduced the risk of allergies to the therapy itself, and led to stronger accumulation of resistance to pollen exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1095-8541 (Electronic)IS - 0022-5193 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jtbi.2017.04.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483565">PM:28483565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Theor Biol\20170509-HaraA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Theor Biol\20170509-HaraA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Hara A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jtbi.2017.04.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Castaneda,A.R.</style></author><author><style face="normal" font="Arial"> Bein,K.J.</style></author><author><style face="normal" font="Arial"> Smiley-Jewell,S.</style></author><author><style face="normal" font="Arial"> Pinkerton,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Center for Health and the Environment , University of California , Davis , California , USA</style></auth-address><titles><title><style face="normal" font="Arial">Fine Particulate Matter (PM2.5) Enhances Allergic Sensitization in BALB/c Mice</style></title><secondary-title><style face="normal" font="Arial">J Toxicol Environ Health A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Toxicol Environ Health A</style></full-title></periodical><pages end="207" start="197">197-207</pages><volume><style face="normal" font="Arial">80</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heme</style></keyword><keyword><style face="normal" font="Arial"> heme oxygenase 1</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Ambient particulate matter (PM), a component of air pollution, exacerbates airway inflammation and hyperreactivity in asthmatic patients. Studies showed that PM possesses adjuvant-like properties that enhance the allergic inflammatory response; however, the mechanism (or mechanisms) by which PM enhances the allergic response remains to be determined. The aim of this study was to assess how exposure to fine PM collected from Sacramento, CA, shapes the allergic airway immune response in BALB/c mice undergoing sensitization and challenge with ovalbumin (OVA). Eight-week-old BALB/c male mice were sensitized/challenged with phosphate-buffered saline (PBS/PBS; n = 6), PM/PBS (n = 6), OVA/OVA (n = 6), or OVA + PM/OVA (n = 6). Lung tissue, bronchoalveolar lavage fluid (BALF), and plasma were analyzed for cellular inflammation, cytokines, immunoglobulin E, and heme oxygenase-1 (HO-1) expression. Mice in the OVA + PM/OVA group displayed significantly increased airway inflammation compared to OVA/OVA animals. Total cells, macrophages, and eosinophils recovered in BALF were significantly elevated in the OVA + PM/OVA compared to OVA/OVA group. Histopathological grading indicated that OVA + PM/OVA treatment induced significant inflammation compared to OVA/OVA. Both immunoglobulin (Ig) E and tumor necrosis factor (TNF) alpha levels were significantly increased in OVA/OVA and OVA + PM /OVA groups compared to PBS/PBS control. The number of HO-1 positive alveolar macrophages was significantly elevated in lungs of mice treated with OVA + PM /OVA compared to OVA/OVA. Our findings suggest that fine PM enhances allergic inflammatory response in pulmonary tissue through mechanisms involving increased oxidative stress</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 1528-7394 (Print)IS - 0098-4108 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/15287394.2016.1222920</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28494199">PM:28494199</url></web-urls></urls><custom2><style face="normal" font="Arial">20170511, Castaneda AR</style></custom2><misc3><style face="normal" font="Arial">10.1080/15287394.2016.1222920</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Z.</style></author><author><style face="normal" font="Arial"> Zheng,W.</style></author><author><style face="normal" font="Arial"> Xie,H.</style></author><author><style face="normal" font="Arial"> Chai,R.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> He,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Guta District, Jinzhou, 121001, Liaoning, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Up-regulated expression of substance P in CD8+ T cells and NK1R on monocytes of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Transl Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Transl Med</style></full-title></periodical><pages end="" start="93">93-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin E2</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Large numbers of CD8+ T cells were observed in atopic dermatitis (AD) skin, and monocytes from AD patients showed increased prostaglandin E2 production. However, little is known about the expression of substance P (SP) and its receptor NK1R in blood leukocytes of patients with AD. OBJECTIVE: To explore the expression of SP and NK1R in leukocytes of AD and the influence of allergens on SP and NK1R expression. METHODS: The expression levels of SP and NK1R in patients with AD were examined by flow cytometry, ELISA and a mouse AD model. RESULTS: The plasma SP level was 4.9-fold higher in patients with AD than in HC subjects. Both the percentage of SP expression in the population and mean fluorescence intensity (MFI) of SP expression were elevated in CD8+ T cells in the blood of AD patients. However, both the CD14+NK1R+ population and MFI of NK1R expression on CD14+ cells were enhanced in the blood of AD patients. Allergens ASWE, HDME and PPE failed to up-regulate SP expression in CD8+ T cells. However, allergens ASWE and HDME both enhanced NK1R expression on CD14+ blood leukocytes regardless of AD or HC subjects. OVA-sensitized AD mice showed an elevated proportion and MFI of SP-expressing CD8+ T cells in the blood, which agrees with the SP expression situation in human AD blood. Injection of SP into mouse skin did not up-regulate NK1R expression on monocytes. CONCLUSIONS: An elevated plasma SP level, up-regulated expression of SP and NK1R indicate that the SP/NK1R complex is important in the development of AD. Therefore, SP and NK1R antagonist or blocker agents may help to treat patients with AD. Trial registration Registration number: ChiCTR-BOC-16010279; Registration date: Dec., 28, 2016; retrospectively registered</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1479-5876 (Electronic)IS - 1479-5876 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12967-017-1196-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28460633">PM:28460633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Transl Med\2017-15-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Transl Med\2017-15-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Zhang Z</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12967-017-1196-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Haas,N.L.</style></author><author><style face="normal" font="Arial"> Haas,M.R.C.</style></author><author><style face="normal" font="Arial"> Gregory,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Michigan, Department of Emergency Medicine, 1500 E. Medical Center Drive, B1-380 Taubman Center, SPC 5305 Ann Arbor, MI 48109-5305, USA</style></auth-address><titles><title><style face="normal" font="Arial">A case report of anaphylaxis to Typhoid Vaccine Live Oral Ty21a (Vivotif)</style></title><secondary-title><style face="normal" font="Arial">J Travel Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Travel Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">Typhoid Vaccine Live Oral Ty21a (Vivotif) is typically well tolerated, and adverse events are infrequent and mild. To the best of the authors' knowledge, only one prior anaphylactic reaction has previously been reported. We present a case of anaphylaxis related to Vivotif, in which a 66-year-old male with no medical comorbidities developed anaphylaxis following the third of a four-dose course (in the absence of concomitant vaccination administration), which consisted of tongue swelling, difficulty breathing, abdominal discomfort and rash. He was managed with epinephrine, corticosteroids and antihistamines</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1708-8305 (Electronic)IS - 1195-1982 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/jtm/tax022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28498925">PM:28498925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Travel Med\20170512-HaasNL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Travel Med\20170512-HaasNL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Haas NL</style></custom2><misc3><style face="normal" font="Arial">10.1093/jtm/tax022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Canning,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">No Abstract Available</style></auth-address><titles><title><style face="normal" font="Arial">Re: Low Prevalence of Latex Allergy in Children with Spinal Dysraphism in Non-Latex-Free Environment</style></title><secondary-title><style face="normal" font="Arial">J Urol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Urol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0022-5347</style></isbn><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.juro.2017.05.048</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.juro.2017.05.048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Urol\20170524-CanningDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Urol\20170524-CanningDA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170524, Canning DA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.juro.2017.05.048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Conejero,L.</style></author><author><style face="normal" font="Arial"> Khouili,S.C.</style></author><author><style face="normal" font="Arial"> Martinez-Cano,S.</style></author><author><style face="normal" font="Arial"> Izquierdo,H.M.</style></author><author><style face="normal" font="Arial"> Brandi,P.</style></author><author><style face="normal" font="Arial"> Sancho,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lung CD103+ dendritic cells restrain allergic airway inflammation through IL-12 production</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="e90420">e90420-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CD103+ dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> Th1 immunity</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> Th17 response</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">DCs are necessary and sufficient for induction of allergic airway inflammation. CD11b+ DCs direct the underlying Th2 immunity, but debate surrounds the function of CD103+ DCs in lung immunity and asthma after an allergic challenge. We challenged Batf3-/- mice, which lacked lung CD103+ DCs, with the relevant allergen house dust mite (HDM) as a model to ascertain their role in asthma. We show that acute and chronic HDM exposure leads to defective Th1 immunity in Batf3-deficient mice. In addition, chronic HDM challenge in Batf3-/- mice results in increased Th2 and Th17 immune responses and exacerbated airway inflammation. Mechanistically, Batf3 absence does not affect induction of Treg or IL-10 production by lung CD4+ T cells following acute HDM challenge. Batf3-dependent CD103+ migratory DCs are the main source of IL-12p40 in the mediastinal lymph node DC compartment in the steady state. Moreover, CD103+ DCs selectively increase their IL-12p40 production upon HDM administration. In vivo IL-12 treatment reverts exacerbated allergic airway inflammation upon chronic HDM challenge in Batf3-/- mice, restraining Th2 and Th17 responses without triggering Th1 immunity. These results suggest a protective role for lung CD103+ DCs to HDM allergic airway inflammation through the production of IL-12</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 2379-3708 (Electronic)IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.90420</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28515363">PM:28515363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2017-2-e90420.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2017-2-e90420.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Conejero L</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.90420</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oriss,T.B.</style></author><author><style face="normal" font="Arial"> Raundhal,M.</style></author><author><style face="normal" font="Arial"> Morse,C.</style></author><author><style face="normal" font="Arial"> Huff,R.E.</style></author><author><style face="normal" font="Arial"> DAS,S.</style></author><author><style face="normal" font="Arial"> Hannum,R.</style></author><author><style face="normal" font="Arial"> Gauthier,M.C.</style></author><author><style face="normal" font="Arial"> Scholl,K.L.</style></author><author><style face="normal" font="Arial"> Chakraborty,K.</style></author><author><style face="normal" font="Arial"> Nouraie,S.M.</style></author><author><style face="normal" font="Arial"> Wenzel,S.E.</style></author><author><style face="normal" font="Arial"> Ray,P.</style></author><author><style face="normal" font="Arial"> Ray,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="e91019">e91019-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human T cells</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">Severe asthma (SA) is a significant problem both clinically and economically, given its poor response to corticosteroids (CS). We recently reported a complex type 1-dominated (IFN-gamma-dominated) immune response in more than 50% of severe asthmatics despite high-dose CS treatment. Also, IFN-gamma was found to be critical for increased airway hyperreactivity (AHR) in our model of SA. The transcription factor IRF5 expressed in M1 macrophages can induce a Th1/Th17 response in cocultured human T cells. Here we show markedly higher expression of IRF5 in bronchoalveolar lavage (BAL) cells of severe asthmatics as compared with that in cells from milder asthmatics or healthy controls. Using our SA mouse model, we demonstrate that lack of IRF5 in lymph node migratory DCs severely limits their ability to stimulate the generation of IFN-gamma- and IL-17-producing CD4+ T cells and IRF5-/- mice subjected to the SA model displayed significantly lower IFN-gamma and IL-17 responses, albeit showing a reciprocal increase in Th2 response. However, the absence of IRF5 rendered the mice responsive to CS with suppression of the heightened Th2 response. These data support the notion that IRF5 inhibition in combination with CS may be a viable approach to manage disease in a subset of severe asthmatics</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 2379-3708 (Electronic)IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.91019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28515358">PM:28515358</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2017-2-e91019.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2017-2-e91019.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Oriss TB</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.91019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tamborini,A.</style></author><author><style face="normal" font="Arial"> Robertson,E.</style></author><author><style face="normal" font="Arial"> Talbot,J.J.</style></author><author><style face="normal" font="Arial"> Barrs,V.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">VRCC, Laindon, UK</style></auth-address><titles><title><style face="normal" font="Arial">Sinonasal aspergillosis in a British Shorthair cat in the UK</style></title><secondary-title><style face="normal" font="Arial">JFMS Open Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JFMS Open Rep</style></full-title></periodical><pages end="" start="2055116916653775">2055116916653775-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Debridement</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Epistaxis</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal culture</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Hyphae</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> posaconazole</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> Turbinates</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2016">2016/1</year></dates><abstract><style face="normal" font="Arial">Case summary A 13-year-old, castrated male, British Shorthair cat presented for investigation of chronic, intermittent, bilateral epistaxis and stertor. CT revealed severe asymmetric bilateral intranasal involvement with extensive turbinate lysis, increased soft tissue attenuation and lysis of the sphenopalatine bone and cribriform plate. On retroflexed pharyngoscopy, a plaque-like mass occluded the choanae. Rostral rhinoscopic examination revealed extensive loss of nasal turbinates, necrotic tissue and mucosal fungal plaques in the left nasal cavity. The right nasal cavity was less severely affected. The nasal cavities were debrided extensively of plaques and necrotic tissue. Aspergillus fumigatus was isolated on fungal culture, and species identity was confirmed using comparative sequence analysis of the partial beta-tubulin gene. On histopathology of nasal biopsies, there was ulcerative lymphoplasmacytic and neutrophilic rhinitis, and fungal hyphae were identified on nasal mucosa, consistent with a non-invasive mycosis. The cat was treated with oral itraconazole after endoscopic debridement, but signs relapsed 4.5 months from diagnosis. Residual left nasal fungal plaques were again debrided endoscopically and oral posaconazole was administered for 6 months. Fourteen months from diagnosis, the cat remains clinically well with mild intermittent left nasal discharge secondary to atrophic rhinitis. Relevance and novel information This is the first case of rhinoscopically confirmed sinonasal aspergillosis to be diagnosed in a cat in the UK. Endoscopic confirmation of resolution of infection is useful in cases where mild nasal discharge persists after treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 2055-1169 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1177/2055116916653775</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28491427">PM:28491427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JFMS Open Rep\2016-2-2055116916653775.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JFMS Open Rep\2016-2-2055116916653775.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Tamborini A</style></custom2><misc3><style face="normal" font="Arial">10.1177/2055116916653775</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aramaki,E.</style></author><author><style face="normal" font="Arial"> Shikata,S.</style></author><author><style face="normal" font="Arial"> Ayaya,S.</style></author><author><style face="normal" font="Arial"> Kumagaya,S.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Social Computing Lab, Graduate School of Information Science, Nara Institute of Science and Technology, Ikoma, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Crowdsourced Identification of Possible Allergy-Associated Factors: Automated Hypothesis Generation and Validation Using Crowdsourcing Services</style></title><secondary-title><style face="normal" font="Arial">JMIR Res Protoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JMIR Res Protoc</style></full-title></periodical><pages end="" start="e83">e83-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Information Science</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hypothesis generation is an essential task for clinical research, and it can require years of research experience to formulate a meaningful hypothesis. Recent studies have endeavored to apply crowdsourcing to generate novel hypotheses for research. In this study, we apply crowdsourcing to explore previously unknown allergy-associated factors. OBJECTIVE: In this study, we aimed to collect and test hypotheses of unknown allergy-associated factors using a crowdsourcing service. METHODS: Using a series of questionnaires, we asked crowdsourcing participants to provide hypotheses on associated factors for seven different allergies, and validated the candidate hypotheses with odds ratios calculated for each associated factor. We repeated this abductive validation process to identify a set of reliable hypotheses. RESULTS: We obtained two primary findings: (1) crowdsourcing showed that 8 of the 13 known hypothesized allergy risks were statically significant; and (2) among the total of 157 hypotheses generated by the crowdsourcing service, 75 hypotheses were statistically significant allergy-associated factors, comprising the 8 known risks and 53 previously unknown allergy-associated factors. These findings suggest that there are still many topics to be examined in future allergy studies. CONCLUSIONS: Crowdsourcing generated new hypotheses on allergy-associated factors. In the near future, clinical trials should be conducted to validate the hypotheses generated in this study</style></abstract><notes><style face="normal" font="Arial">DA - 20170517IS - 1929-0748 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2196/resprot.5851</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28512079">PM:28512079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JMIR Res Protoc\2017-6-e83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JMIR Res Protoc\2017-6-e83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170517, Aramaki E</style></custom2><misc3><style face="normal" font="Arial">10.2196/resprot.5851</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84498</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">IgE-mediated food allergies in children: prevalence, triggers, and management</style></title><secondary-title><style face="normal" font="Arial">Korean J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Korean J Pediatr</style></full-title></periodical><pages end="105" start="99">99-105</pages><volume><style face="normal" font="Arial">60</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine use</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Handling</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Geography</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Food allergy (FA) is a serious health problem, and severe FA such as food-induced anaphylaxis can often be life threatening. The incidence of FA has been increasing especially in children. They usually develop early in life and affect up to 10% of children. The 2 most common food allergens worldwide are milk and eggs, while the third one varies depending on the countries: peanuts in the United States and Switzerland, wheat in Germany and Japan, tree nuts in Spain, sesame in Israel, and walnuts in Korea. These common food allergens are different and difficult to identify because of differing study methodologies, population, geography, age, and dietary exposure patterns. The current management of FA relies on the strict avoidance of culprit allergens, the prompt treatment of allergic reactions, including epinephrine use for food-induced anaphylaxis, monitoring, and education to prevent further reactions. Newer approaches for tolerance induction to FA and FA immunotherapy have been under investigation but are not yet ready for real-world application. Thus, consistent and systematic education of patients, caregivers, and food-handling people is of primary importance for the management and prevention of FA reactions. This review assesses and compares IgE-mediated FA in children in Korea and other countries, with a focus on summarizing the prevalence, common triggers, and management of FA</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1738-1061 (Print)IS - 1738-1061 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3345/kjp.2017.60.4.99</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28461822">PM:28461822</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Pediatr\2017-60-99-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Pediatr\2017-60-99-105.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Lee S</style></custom2><misc3><style face="normal" font="Arial">10.3345/kjp.2017.60.4.99</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blauvelt,A.</style></author><author><style face="normal" font="Arial"> de Bruin-Weller,M.</style></author><author><style face="normal" font="Arial"> Gooderham,M.</style></author><author><style face="normal" font="Arial"> Cather,J.C.</style></author><author><style face="normal" font="Arial"> Weisman,J.</style></author><author><style face="normal" font="Arial"> Pariser,D.</style></author><author><style face="normal" font="Arial"> Simpson,E.L.</style></author><author><style face="normal" font="Arial"> Papp,K.A.</style></author><author><style face="normal" font="Arial"> Hong,H.C.</style></author><author><style face="normal" font="Arial"> Rubel,D.</style></author><author><style face="normal" font="Arial"> Foley,P.</style></author><author><style face="normal" font="Arial"> Prens,E.</style></author><author><style face="normal" font="Arial"> Griffiths,C.E.M.</style></author><author><style face="normal" font="Arial"> Etoh,T.</style></author><author><style face="normal" font="Arial"> Pinto,P.H.</style></author><author><style face="normal" font="Arial"> Pujol,R.M.</style></author><author><style face="normal" font="Arial"> Szepietowski,J.C.</style></author><author><style face="normal" font="Arial"> Ettler,K.</style></author><author><style face="normal" font="Arial"> Kemeny,L.</style></author><author><style face="normal" font="Arial"> Zhu,X.</style></author><author><style face="normal" font="Arial"> Akinlade,B.</style></author><author><style face="normal" font="Arial"> Hultsch,T.</style></author><author><style face="normal" font="Arial"> Mastey,V.</style></author><author><style face="normal" font="Arial"> Gadkari,A.</style></author><author><style face="normal" font="Arial"> Eckert,L.</style></author><author><style face="normal" font="Arial"> Amin,N.</style></author><author><style face="normal" font="Arial"> Graham,N.M.H.</style></author><author><style face="normal" font="Arial"> Pirozzi,G.</style></author><author><style face="normal" font="Arial"> Stahl,N.</style></author><author><style face="normal" font="Arial"> Yancopoulos,G.D.</style></author><author><style face="normal" font="Arial"> Shumel,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Oregon Medical Research Center, Portland, OR, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asia-Pacific</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Calcineurin</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oregon</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> topical calcineurin inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dupilumab (an anti-interleukin-4-receptor-alpha monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis. We aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-severe atopic dermatitis. METHODS: In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS), adults with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids were enrolled at 161 hospitals, clinics, and academic institutions in 14 countries in Europe, Asia-Pacific, and North America. Patients were randomly assigned (3:1:3) to subcutaneous dupilumab 300 mg once weekly (qw), dupilumab 300 mg every 2 weeks (q2w), or placebo via a central interactive voice/web response system, stratified by severity and global region. All three groups were given concomitant topical corticosteroids with or without topical calcineurin inhibitors where inadvisable for topical corticosteroids. Topical corticosteroids could be tapered, stopped, or restarted on the basis of disease activity. Coprimary endpoints were patients (%) achieving Investigator's Global Assessment (IGA) 0/1 and 2-point or higher improvement from baseline, and Eczema Area and Severity Index 75% improvement from baseline (EASI-75) at week 16. Week 16 efficacy and week 52 safety analyses included all randomised patients; week 52 efficacy included patients who completed treatment by US regulatory submission cutoff. This study is registered with ClinicalTrials.gov, NCT02260986. FINDINGS: Between Oct 3, 2014, and July 31, 2015, 740 patients were enrolled: 319 were randomly assigned to dupilumab qw plus topical corticosteroids, 106 to dupilumab q2w plus topical corticosteroids, and 315 to placebo plus topical corticosteroids. 623 (270, 89, and 264, respectively) were evaluable for week 52 efficacy. At week 16, more patients who received dupilumab plus topical corticosteroids achieved the coprimary endpoints of IGA 0/1 (39% [125 patients] who received dupilumab plus topical corticosteroids qw and 39% [41 patients] who received dupilumab q2w plus topical corticosteroids vs 12% [39 patients] who received placebo plus topical corticosteroids; p&lt;0.0001) and EASI-75 (64% [204] and 69% [73] vs 23% [73]; p&lt;0.0001). Week 52 results were similar. Adverse events were reported in 261 (83%) patients who received dupilumab qw plus topical corticosteroids, 97 (88%) patients who received dupilumab q2w, and 266 (84%) patients who received placebo, and serious adverse events in nine (3%), four (4%), and 16 (5%) patients, respectively. No significant dupilumab-induced laboratory abnormalities were noted. Injection-site reactions and conjunctivitis were more common in patients treated with dupilumab plus topical corticosteroids-treated patients than in patients treated with placebo plus topical corticosteroids. INTERPRETATION: Dupilumab added to standard topical corticosteroid treatment for 1 year improved atopic dermatitis signs and symptoms, with acceptable safety. FUNDING: Sanofi and Regeneron Pharmaceuticals Inc</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Netherlands -CO - Canada -CO - Australia -CO - United Kingdom -CO - Japan -CO - Spain -CO - Poland -CO - Czech Republic -CO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(17)31191-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28478972">PM:28478972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20170508-BlauveltA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20170508-BlauveltA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Blauvelt A</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(17)31191-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Strowd,L.C.</style></author><author><style face="normal" font="Arial"> Feldman,S.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27104, USA</style></auth-address><titles><title><style face="normal" font="Arial">Dupilumab for atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(17)31192-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28478973">PM:28478973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20170508-StrowdLC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20170508-StrowdLC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Strowd LC</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(17)31192-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bardin,P.G.</style></author><author><style face="normal" font="Arial"> Price,D.</style></author><author><style face="normal" font="Arial"> Chanez,P.</style></author><author><style face="normal" font="Arial"> Humbert,M.</style></author><author><style face="normal" font="Arial"> Bourdin,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Monash Lung and Sleep, Monash Hospital and University, Clayton, VIC, Australia; Hudson Institute of Medical Research, Melbourne, Clayton, VIC, AustraliaObservational and Pragmatic Research Institute, Singapore; Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UKUMR INSERM 1067, CNRS 7333, Marseille, France Aix-Marseille Universite, Marseille, France; APHM Assistance Publique Hopitaux de Marseille, Clinique des bronches, de l'allergie et du Sommeil, Hopital Nord, Marseille, FranceService de Pneumologie, Assistance Publique-Hopitaux de Paris, Hopital Bicetre, University Paris-Sud, Orsay, France; Universite Paris-Saclay, INSERM U999, Le Kremlin-Bicetre, FranceDepartement de Pneumologie et Addictologie-Hopital Arnaud de Villeneuve-Montpellier, France; PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France. Electronic address: a-bourdin@chu-montpellier.fr</style></auth-address><titles><title><style face="normal" font="Arial">Managing asthma in the era of biological therapies</style></title><secondary-title><style face="normal" font="Arial">Lancet Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Respir Med</style></full-title></periodical><pages end="378" start="376">376-378</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> Clinique</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United Kingdom -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2213-2600(17)30124-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463176">PM:28463176</url></web-urls><pdf-urls><url ppv-ref="no">a-bourdin@chu-montpellier.fr</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Bardin PG</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2213-2600(17)30124-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84502</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choi,J.H.</style></author><author><style face="normal" font="Arial"> Hwang,S.H.</style></author><author><style face="normal" font="Arial"> Suh,J.D.</style></author><author><style face="normal" font="Arial"> Kim,J.K.</style></author><author><style face="normal" font="Arial"> Hong,S.C.</style></author><author><style face="normal" font="Arial"> Lim,Y.C.</style></author><author><style face="normal" font="Arial"> Kim,S.N.</style></author><author><style face="normal" font="Arial"> Cho,J.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Menopausal hormone therapy may increase non-allergic rhinitis among postmenopausal women: Results from the Korea National Health and Nutrition Examination Survey (2010</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2012)</style></title><secondary-title><style face="normal" font="Arial">Maturitas</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Maturitas</style></abbr-1></periodical><pages end="49" start="46">46-49</pages><volume><style face="normal" font="Arial">102</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Menopausal hormone therapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Postmenopausal</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> waist circumference</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0378-5122</style></isbn><abstract><style face="normal" font="Arial">Objectives To investigate the association between menopausal hormone therapy (MHT) and chronic rhinitis. Methods The data used in this study were derived from the Korea National Health and Nutrition Examination Survey. The analysis included 2,967 postmenopausal women under 70 years of age, and with no missing data. The questionnaires about MHT, current life habits, reproductive history, and rhinitis were reviewed. The levels of total IgE and specific IgE for Dermatophagoides farinae, cockroaches, and dogs were measured, using approximately 10% of all samples. We compared women who were users of MHT and non-users of MHT. We also compared women with and without chronic rhinitis. Results Of 2,967 women matching the study criteria, 567 were MHT users. The proportion of general rhinitis symptoms was greater among MHT users (24.5%) than among MHT non-users (18.9%, p = 0.003). The proportion of cases of rhinorrhea or posterior nasal drip was also greater among MHT users (6.3% vs. 4.3%, p = 0.042), while there were no differences between the two groups in the proportion of cases of nasal obstruction. There were no differences in total IgE and specific IgE levels between the two groups. MHT was used by 23.4% of women with chronic rhinitis and 18.0% of women without chronic rhinitis. Age, waist circumference, and body mass index were also increased among women without chronic rhinitis compared with those with chronic rhinitis. Conclusions MHT may cause non-allergic rhinitis in postmenopausal women. Age and obesity may also affect the occurrence of non-allergic rhinitis in postmenopausal women</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.maturitas.2017.05.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.maturitas.2017.05.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Maturitas\2017-102-46-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Maturitas\2017-102-46-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Choi JH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.maturitas.2017.05.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis and insect stings and bites</style></title><secondary-title><style face="normal" font="Arial">Med Lett Drugs Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Lett Drugs Ther</style></full-title></periodical><pages end="e82" start="e79">e79-e82</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">1520</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1523-2859 (Electronic)IS - 0025-732X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463951">PM:28463951</url></web-urls></urls><custom2><style face="normal" font="Arial">20170502, no authors</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barac,A.</style></author><author><style face="normal" font="Arial"> Stevanovic,G.</style></author><author><style face="normal" font="Arial"> Pekmezovic,M.</style></author><author><style face="normal" font="Arial"> Rakocevic,Z.</style></author><author><style face="normal" font="Arial"> Stosovic,R.</style></author><author><style face="normal" font="Arial"> Erovic,B.</style></author><author><style face="normal" font="Arial"> Tomic Spiric,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia</style></auth-address><titles><title><style face="normal" font="Arial">Study toward resolving the controversy over the definition of allergic fungal rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Med Mycol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Mycol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="5" Year="2017">2017/5/6</year></dates><abstract><style face="normal" font="Arial">Dysbiosis of the microbiome on the airway mucosa leads to the development of chronic inflammatory and allergic disorders. The aim of this study was to consider the potential diagnostic criteria for allergic fungal rhinosinusitis (AFRS) and nonallergic fungal rhinosinusitis (FRS), and the role of fungal presence in an environment for the development of AFRS. In this study, 136 patients were divided into two groups: patients with positive specific immunoglobulin E (sIgE) and fungal finding (AFRS group), and patients with negative sIgE and positive fungal finding (FRS group). The study design included: anamnesis data, sIgE, eosinophil count and skin-prick test, rhinology and computerized tomography (CT) observation and mycological finding. Our results showed: (i) the prevalence in Serbia is: AFRS 1.3%, FRS 2.8%; (ii) 30.4% patients with sIgE+ had more often severe and recurrent chronic rhinosinusitis (CRS) (P = .005) and the presence of polyps (P = .025); (iii) 46.4% patients with sIgE+ had positive fungi on the sinonasal mucosa and were considered as AFRS; (iv) patients with AFRS had more frequent asthma (P = .024) and chronicity of CRS >10 years (P = .000). The persistent fungal presence and prolonged duration of CRS could be a silent threat for the progression of inflammation and development of FRS. Lavage with hypertonic-NaCl should be included in the everyday hygiene routine in an effort to decrease fungal load and antigenic exposure. The presence of allergological parameters and better response to corticosteroid therapy in AFRS patients should be considered as crucial diagnostic criteria for AFRS</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1460-2709 (Electronic)IS - 1369-3786 (Linking)LA - engPT - Journal ArticleCO - Serbia -CO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1093/mmy/myx032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28482010">PM:28482010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Mycol\20170508-BaracA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Mycol\20170508-BaracA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Barac A</style></custom2><misc3><style face="normal" font="Arial">10.1093/mmy/myx032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tarhini,A.A.</style></author><author><style face="normal" font="Arial"> Moschos,S.J.</style></author><author><style face="normal" font="Arial"> Lin,Y.</style></author><author><style face="normal" font="Arial"> Lin,H.M.</style></author><author><style face="normal" font="Arial"> Sander,C.</style></author><author><style face="normal" font="Arial"> Yin,Y.</style></author><author><style face="normal" font="Arial"> Venhaus,R.</style></author><author><style face="normal" font="Arial"> Gajewski,T.F.</style></author><author><style face="normal" font="Arial"> Kirkwood,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDepartment of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania bLudwig Institute for Cancer Research Ltd, New York, New York</style></auth-address><titles><title><style face="normal" font="Arial">Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-alpha2b in patients with metastatic melanoma</style></title><secondary-title><style face="normal" font="Arial">Melanoma Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Melanoma Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Chills</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Melanoma</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Tachycardia</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="Arial">This study evaluated the safety and clinical benefit of ecromeximab (KW2871) combined with high-dose interferon-alpha2b (HDI) in patients with metastatic melanoma. We also carried out pharmacokinetic and immune monitoring studies of this combination. This was an open-label, phase 1/2 study of ecromeximab plus HDI in patients with measurable metastatic melanoma. Eligible patients received ecromeximab-HDI combination therapy: ecromeximab administered intravenously once every 2 weeks and HDI at a dose of 20 million units (MU)/m administered intravenously for 5 consecutive days per week for the first 4 weeks (induction phase) and then at 10 MU/m subcutaneously thrice weekly through week 14 (maintenance phase). Patients were treated with combination therapy until disease progression or limiting toxicity. Three dose-escalation cohorts (5, 10, and 20 mg/m) of ecromeximab were planned. Thirty-six evaluable patients were enrolled including six in each of cohorts 1 and 2, and 24 in cohort 3. Median progression-free survival was 2.53 months [95% confidence interval (CI):1.93-3.83] and it was 1.93 months (95% CI: 1.00-3.80) in cohort 3. The median overall survival was 10.28 months (95% CI: 6.93-16.77) and 7.78 months (95% CI: 6.03-13.97) in cohort 3. There was no significant difference in progression-free survival or overall survival by BRAF mutation status. The response rate was 5.6% (95% CI: 0.68-18.7), with two patients showing an objective response (one complete response and one partial response), and the clinical benefit rate was 78% (95% CI: 61-90). Stable disease as best response was observed in 26 (72%) patients including five in each of cohorts 1 and 2, and 16 in cohort 3. Treatment-emergent adverse events considered related to ecromeximab treatment occurred in four (66.7%) patients in cohort 1, five (83.3%) patients in cohort 2, and seven (29.2%) patients in cohort 3. Among TEAEs with a maximum severity of grade 3 or 4, those that occurred only in cohort 3 were related to pain, electrolyte imbalance, blood cell decreases, and allergic reaction. Safety and efficacies considered related to ecromeximab occurred in cohort 3 and included grade 3 hypersensitivity [one (4.2%)] and grade 2 hypotension [one (4.2%)]. Regimen-limiting toxicities occurred in two (8.3%) patients in cohort 3: hypersensitivity (with hypertension, supraventricular tachycardia, bronchospasm, chills, and dyspnea) and hypotension. One patient out of 31 examined showed a low-level transient positivity for human antichimeric antibodies against ecromeximab. Pharmacokinetic measurements by enzyme-linked immunosorbent assay determined that administration of HDI does not influence serum levels of ecromeximab at 5, 10, and 20 mg/m dose levels. Ecromeximab in combination with HDI was generally well tolerated in patients with metastatic melanoma and has shown low immunogenicity. However, the clinical activity was limited, suggesting that future development of this combination should be deprioritized and that other combinations, such as with immune checkpoint inhibitors, should be considered</style></abstract><notes><style face="normal" font="Arial">DA - 20170510IS - 1473-5636 (Electronic)IS - 0960-8931 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/CMR.0000000000000353</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28489678">PM:28489678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Melanoma Res\20170510-TarhiniAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Melanoma Res\20170510-TarhiniAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170510, Tarhini AA</style></custom2><misc3><style face="normal" font="Arial">10.1097/CMR.0000000000000353</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arefieva,A.S.</style></author><author><style face="normal" font="Arial"> Smoldovskaya,O.V.</style></author><author><style face="normal" font="Arial"> Tikhonov,A.A.</style></author><author><style face="normal" font="Arial"> Rubina,A.Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy and autoimmunity: Molecular diagnostics, therapy, and presumable pathogenesis</style></title><secondary-title><style face="normal" font="Arial">Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Biol</style></full-title></periodical><pages end="204" start="194">194-204</pages><volume><style face="normal" font="Arial">51</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> autoantigen</style></keyword><keyword><style face="normal" font="Arial"> Autoantigens</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1608-3245</style></isbn><abstract><style face="normal" font="Arial">Allergic and autoimmune diseases represent immunopathological reactions of an organism to antigens. Despite that the allergy is a result of exaggerated immune response to foreign antigens (allergens) and autoimmune diseases are characterized by the pathological response to internal antigens (autoantigens), the underlying mechanisms of these diseases are probably common. Thus, both types of diseases represent variations in the hypersensitivity reaction. A large percentage of both the adult and pediatric population is in need of early diagnostics of these pathologies of the immune system. Considering the diversity of antibodies produced in allergic and autoimmune disease and the difficulties accompanying clinical diagnosing, molecular diagnostics of these pathological processes should be carried out in several stages, including screening and confirmatory studies. In this review, we summarize the available data on the molecular diagnostics and therapy of allergic and autoimmune diseases and discuss the basic similarities and differences in the mechanisms of their development</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1134/S0026893317020030</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1134/S0026893317020030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Biol\2017-51-194-204.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Biol\2017-51-194-204.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170521, Arefieva AS</style></custom2><misc3><style face="normal" font="Arial">10.1134/S0026893317020030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Su,L.</style></author><author><style face="normal" font="Arial"> Shi,L.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Huang,L.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Nie,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Pharmacy, Second Military Medical University, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Metabolic profiling of asthma in mice and the interventional effects of SPA using liquid chromatography and Q-TOF mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">Mol Biosyst</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Biosyst</style></full-title></periodical><pages end="1181" start="1172">1172-1181</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid Metabolism</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory lung disease that leads to 250 000 deaths annually. There is a need to better understand asthma by identifying new pathogenic molecules. We conducted a liquid-chromatography time-of-flight mass spectrometry (LC-Q-TOF-MS)-based metabolomics study to test for asthma and investigate the interventional mechanisms of surfactant protein A (SPA) in OVA-induced asthma mice. The results revealed that asthma disturbed 32 metabolites in 9 metabolic pathways. After SPA treatment, the metabolomics profile found in asthma was significantly reversed, shifting much closer to that of the control group, indicating that SPA has therapeutic effects against asthma. Metabolomic pathway analysis by the ingenuity pathway analysis demonstrated that several pathways including fatty acid metabolism, lipid metabolism, and purine metabolism were significantly altered in asthma. This study offers new methodologies for the understanding of asthma and the mechanisms of SPA in treating asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1742-2051 (Electronic)IS - 1742-2051 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1039/c7mb00025a</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463380">PM:28463380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Biosyst\2017-13-1172-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Biosyst\2017-13-1172-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Su L</style></custom2><misc3><style face="normal" font="Arial">10.1039/c7mb00025a</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Broekman,H.C.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author><author><style face="normal" font="Arial"> de Jong,G.</style></author><author><style face="normal" font="Arial"> Gaspari,M.</style></author><author><style face="normal" font="Arial"> den Hartog Jager,C.F.</style></author><author><style face="normal" font="Arial"> Houben,G.F.</style></author><author><style face="normal" font="Arial"> Verhoeckx,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Medical Center Utrecht, Utrecht, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Is mealworm or shrimp allergy indicative for food allergy to insects?</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Edible insects</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food security</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Security</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Waxes</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">SCOPE: The growing world population is a key driver for the exploration of sustainable protein sources to ensure food security. Mealworm and other insects are promising candidates. Previously we found that shrimp allergic patients are at risk for mealworm allergy, and that mealworm can induce a primary allergy 3.This study set out to investigate the allergenic potential of edible insects, suggested for human consumption by agencies such as WHO/FAO, in both the shrimp (potentially cross-reactive) and primary mealworm allergic population. The following insects were studied: mealworm, house cricket, giant mealworm, lesser mealworm, African grasshopper, large wax moth and black soldier fly. METHODS AND RESULTS: 15 shrimp (mealworm sensitized or allergic) patients and four primary mealworm allergic subjects, who participated in previous studies, were included. All shrimp allergic patients were sensitized to multiple insects with similar response profiles for all insects tested. Primary mealworm allergic patients, showed IgE binding to proteins from only a few insects on immunoblot, although basophil activation test was positive for all tested insects. CONCLUSION: Shrimp allergic patients are most likely at risk of food allergy to mealworm and other insects. Primary mealworm allergy does not mean subjects are likely to react to all insects. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201601061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28500661">PM:28500661</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170513-BroekmanHC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170513-BroekmanHC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Broekman HC</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201601061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sim,D.W.</style></author><author><style face="normal" font="Arial"> Lee,J.S.</style></author><author><style face="normal" font="Arial"> Park,K.H.</style></author><author><style face="normal" font="Arial"> Jeong,K.Y.</style></author><author><style face="normal" font="Arial"> Ye,Y.M.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Accurate assessment of alpha-gal syndrome using Cetuximab and Bovine Thyroglobulin-specific IgE</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Porcine serum albumin</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Streptavidin</style></keyword><keyword><style face="normal" font="Arial"> streptavidin CAP</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Thyroglobulin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">SCOPE: IgE against galactose-alpha-1,3-galactose (alpha-Gal) cause alpha-gal syndrome. Bovine thyroglobulin (BTG) and cetuximab share this epitope. We aimed to determine the utility of specific IgE (sIgE) against cetuximab as compared to BTG for diagnosing alpha-gal syndrome. METHODS AND RESULTS: Twelve patients with alpha-gal syndrome, 11 patients with immediate beef or pork allergy, 18 asymptomatic individuals with meat sensitivity, and 10 non-atopic subjects were enrolled. We checked the levels of sIgE against BTG and cetuximab using the streptavidin CAP assay. Additionally, IgE reactivity to BTG and cetuximab was assessed by immunoblotting. All alpha-gal syndrome patients had a high concentration of sIgE against BTG, and cetuximab. In contrast to alpha-gal syndrome, patients with immediate allergic reactions to meat consumption and those with asymptomatic sensitization had significantly lower concentration of BTG and cetuximab sIgE, and a high prevalence of sIgE against bovine or porcine serum albumin. Although the concentration of sIgE against alpha-gal was lower in individuals with asymptomatic sensitization, IgE immunoblotting showed the presence of sIgE against alpha-Gal in this group. CONCLUSION: Differentiation of alpha-gal syndrome from patients with immediate allergy to meat consumption or asymptomatic sensitization requires quantification of cetuximab- or BTG-induced sIgE via detection of IgE for alpha-gal. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201601046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497612">PM:28497612</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170512-SimDW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170512-SimDW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Sim DW</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201601046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chotirmall,S.H.</style></author><author><style face="normal" font="Arial"> Martin-Gomez,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.</style></auth-address><titles><title><style face="normal" font="Arial">Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal treatment</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">Bronchiectasis is a chronic irreversible airway abnormality associated with infectious agents that either cause or superinfect the airways. While the role of bacteria is well studied, much remains to be determined about fungi in both cystic fibrosis- and non-cystic fibrosis-related bronchiectasis. The airway is constantly exposed to inhaled ambient moulds of which Aspergillus represent the most ubiquitous. In a normal healthy host, this situation is of little consequence. The presence of anatomical or immunological abnormalities such as those in bronchiectasis leads to a range of fungal-related pathologies from asymptomatic airway colonization to fungal sensitization, allergic bronchopulmonary aspergillosis or chronic pulmonary aspergillosis. These entities are difficult to recognize, diagnose and treat due in part to a lack of validated biomarkers. Our true understanding of the complex relationships that regulate fungal-host interactions is still in its infancy and, several questions remain. This includes if fungal epidemiology in bronchiectasis is uniform across countries, and to what extent immunopathological mechanisms-related to fungal airway infections-occurs in different disease states. Specific triggers to allergic or infectious responses to Aspergillus require further exploration. How transition occurs between allergic and invasive phenotypes and their respective biomarkers is also important. Whether anti-fungal treatment is warranted in all cases and what the optimal management strategy is, particularly when treatment should commence and its expected duration remains unclear. Further research is clearly necessary and should be prioritized to better understand the clinical effects and impact of Aspergillus in the setting of bronchiectasis</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Singapore -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-017-0143-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28516246">PM:28516246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20170518-ChotirmallSH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20170518-ChotirmallSH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Chotirmall SH</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-017-0143-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ramirez-Garcia,A.</style></author><author><style face="normal" font="Arial"> Pellon,A.</style></author><author><style face="normal" font="Arial"> Buldain,I.</style></author><author><style face="normal" font="Arial"> Antoran,A.</style></author><author><style face="normal" font="Arial"> Arbizu-Delgado,A.</style></author><author><style face="normal" font="Arial"> Guruceaga,X.</style></author><author><style face="normal" font="Arial"> Rementeria,A.</style></author><author><style face="normal" font="Arial"> Hernando,F.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fungal and Bacterial Biomics Research Group, Department of Immunology, Microbiology and Parasitology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940, Leioa, Bizkaia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Proteomics as a Tool to Identify New Targets Against Aspergillus and Scedosporium in the Context of Cystic Fibrosis</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asp f 13</style></keyword><keyword><style face="normal" font="Arial"> Asp f 2</style></keyword><keyword><style face="normal" font="Arial"> Asp f 3</style></keyword><keyword><style face="normal" font="Arial"> Asp f 5</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus nidulans</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus niger</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> beta-Glucosidase</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Cell wall proteins</style></keyword><keyword><style face="normal" font="Arial"> Chitinase</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> cytochrome P450</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Filamentous fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Glutaminase</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heat shock protein</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteinase</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Thioredoxin</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">Cystic fibrosis (CF) is a genetic disorder that increases the risk of suffering microbial, including fungal, infections. In this paper, proteomics-based information was collated relating to secreted and cell wall proteins with potential medical applications from the most common filamentous fungi in CF, i.e., Aspergillus and Scedosporium/Lomentospora species. Among the Aspergillus fumigatus secreted allergens, beta-1,3-endoglucanase, the alkaline protease 1 (Alp1/oryzin), Asp f 2, Asp f 13/15, chitinase, chitosanase, dipeptidyl-peptidase V (DppV), the metalloprotease Asp f 5, mitogillin/Asp f 1, and thioredoxin reductase receive a special mention. In addition, the antigens beta-glucosidase 1, catalase, glucan endo-1,3-beta-glucosidase EglC, beta-1,3-glucanosyltransferases Gel1 and Gel2, and glutaminase A were also identified in secretomes of other Aspergillus species associated with CF: Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, and Aspergillus terreus. Regarding cell wall proteins, cytochrome P450 and eEF-3 were proposed as diagnostic targets, and alkaline protease 2 (Alp2), Asp f 3 (putative peroxiredoxin pmp20), probable glycosidases Asp f 9/Crf1 and Crf2, GPI-anchored protein Ecm33, beta-1,3-glucanosyltransferase Gel4, conidial hydrophobin Hyp1/RodA, and secreted aspartyl protease Pep2 as protective vaccines in A. fumigatus. On the other hand, for Scedosporium/Lomentospora species, the heat shock protein Hsp70 stands out as a relevant secreted and cell wall antigen. Additionally, the secreted aspartyl proteinase and an ortholog of Asp f 13, as well as the cell wall endo-1,3-beta-D-glucosidase and 1,3-beta-glucanosyl transferase, were also found to be significant proteins. In conclusion, proteins mentioned in this review may be promising candidates for developing innovative diagnostic and therapeutic tools for fungal infections in CF patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-017-0139-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28484941">PM:28484941</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20170509-RamirezGarciaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20170509-RamirezGarciaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Ramirez-Garcia A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-017-0139-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cahill,K.N.</style></author><author><style face="normal" font="Arial"> Katz,H.R.</style></author><author><style face="normal" font="Arial"> Cui,J.</style></author><author><style face="normal" font="Arial"> Lai,J.</style></author><author><style face="normal" font="Arial"> Kazani,S.</style></author><author><style face="normal" font="Arial"> Crosby-Thompson,A.</style></author><author><style face="normal" font="Arial"> Garofalo,D.</style></author><author><style face="normal" font="Arial"> Castro,M.</style></author><author><style face="normal" font="Arial"> Jarjour,N.</style></author><author><style face="normal" font="Arial"> Dimango,E.</style></author><author><style face="normal" font="Arial"> Erzurum,S.</style></author><author><style face="normal" font="Arial"> Trevor,J.L.</style></author><author><style face="normal" font="Arial"> Shenoy,K.</style></author><author><style face="normal" font="Arial"> Chinchilli,V.M.</style></author><author><style face="normal" font="Arial"> Wechsler,M.E.</style></author><author><style face="normal" font="Arial"> Laidlaw,T.M.</style></author><author><style face="normal" font="Arial"> Boyce,J.A.</style></author><author><style face="normal" font="Arial"> Israel,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Brigham and Women's Hospital, Harvard Medical School, Boston</style></auth-address><titles><title><style face="normal" font="Arial">KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="1920" start="1911">1911-1920</pages><volume><style face="normal" font="Arial">376</style></volume><number><style face="normal" font="Arial">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Bronchoscopy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> imatinib</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methacholine PC20</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PC20</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> refractory asthma</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Stem Cell Factor</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mast cells are present in the airways of patients who have severe asthma despite glucocorticoid treatment; these cells are associated with disease characteristics including poor quality of life and inadequate asthma control. Stem cell factor and its receptor, KIT, are central to mast-cell homeostasis. We conducted a proof-of-principle trial to evaluate the effect of imatinib, a KIT inhibitor, on airway hyperresponsiveness, a physiological marker of severe asthma, as well as on airway mast-cell numbers and activation in patients with severe asthma. METHODS: We conducted a randomized, double-blind, placebo-controlled, 24-week trial of imatinib in patients with poorly controlled severe asthma who had airway hyperresponsiveness despite receiving maximal medical therapy. The primary end point was the change in airway hyperresponsiveness, measured as the concentration of methacholine required to decrease the forced expiratory volume in 1 second by 20% (PC20). Patients also underwent bronchoscopy. RESULTS: Among the 62 patients who underwent randomization, imatinib treatment reduced airway hyperresponsiveness to a greater extent than did placebo. At 6 months, the methacholine PC20 increased by a mean (+/-SD) of 1.73+/-0.60 doubling doses in the imatinib group, as compared with 1.07+/-0.60 doubling doses in the placebo group (P=0.048). Imatinib also reduced levels of serum tryptase, a marker of mast-cell activation, to a greater extent than did placebo (decrease of 2.02+/-2.32 vs. 0.56+/-1.39 ng per milliliter, P=0.02). Airway mast-cell counts declined in both groups. Muscle cramps and hypophosphatemia were more common in the imatinib group than in the placebo group. CONCLUSIONS: In patients with severe asthma, imatinib decreased airway hyperresponsiveness, mast-cell counts, and tryptase release. These results suggest that KIT-dependent processes and mast cells contribute to the pathobiologic basis of severe asthma. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01097694 .)</style></abstract><notes><style face="normal" font="Arial">DA - 20170517IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticlePT - Research Support, N.I.H., ExtramuralCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa1613125</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28514613">PM:28514613</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-376-1911-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-376-1911-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170517, Cahill KN</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa1613125</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galli,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Departments of Pathology and of Microbiology and Immunology and the Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA</style></auth-address><titles><title><style face="normal" font="Arial">Mast Cells and KIT as Potential Therapeutic Targets in Severe Asthma</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="1984" start="1983">1983-1984</pages><volume><style face="normal" font="Arial">376</style></volume><number><style face="normal" font="Arial">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> c-kit</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proto-Oncogene Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proto-Oncogene Proteins c-kit</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170517IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - EditorialPT - CommentRN - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMe1702653</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28514622">PM:28514622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-376-1983-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-376-1983-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170517, Galli SJ</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMe1702653</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Toussaint,M.</style></author><author><style face="normal" font="Arial"> Jackson,D.J.</style></author><author><style face="normal" font="Arial"> Swieboda,D.</style></author><author><style face="normal" font="Arial"> Guedan,A.</style></author><author><style face="normal" font="Arial"> Tsourouktsoglou,T.D.</style></author><author><style face="normal" font="Arial"> Ching,Y.M.</style></author><author><style face="normal" font="Arial"> Radermecker,C.</style></author><author><style face="normal" font="Arial"> Makrinioti,H.</style></author><author><style face="normal" font="Arial"> Aniscenko,J.</style></author><author><style face="normal" font="Arial"> Edwards,M.R.</style></author><author><style face="normal" font="Arial"> Solari,R.</style></author><author><style face="normal" font="Arial"> Farnir,F.</style></author><author><style face="normal" font="Arial"> Papayannopoulos,V.</style></author><author><style face="normal" font="Arial"> Bureau,F.</style></author><author><style face="normal" font="Arial"> Marichal,T.</style></author><author><style face="normal" font="Arial"> Johnston,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Airway Disease Infection Section, National Heart and Lung Institute (NHLI), Imperial College London, London</style></auth-address><titles><title><style face="normal" font="Arial">Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation</style></title><secondary-title><style face="normal" font="Arial">Nat Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> neutrophil extracellular trap</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viral infection</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">Respiratory viral infections represent the most common cause of allergic asthma exacerbations. Amplification of the type-2 immune response is strongly implicated in asthma exacerbation, but how virus infection boosts type-2 responses is poorly understood. We report a significant correlation between the release of host double-stranded DNA (dsDNA) following rhinovirus infection and the exacerbation of type-2 allergic inflammation in humans. In a mouse model of allergic airway hypersensitivity, we show that rhinovirus infection triggers dsDNA release associated with the formation of neutrophil extracellular traps (NETs), known as NETosis. We further demonstrate that inhibiting NETosis by blocking neutrophil elastase or by degrading NETs with DNase protects mice from type-2 immunopathology. Furthermore, the injection of mouse genomic DNA alone is sufficient to recapitulate many features of rhinovirus-induced type-2 immune responses and asthma pathology. Thus, NETosis and its associated extracellular dsDNA contribute to the pathogenesis and may represent potential therapeutic targets of rhinovirus-induced asthma exacerbations</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1546-170X (Electronic)IS - 1078-8956 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1038/nm.4332</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28459437">PM:28459437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Med\20170501-ToussaintM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Med\20170501-ToussaintM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Toussaint M</style></custom2><misc3><style face="normal" font="Arial">10.1038/nm.4332</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reynolds,L.A.</style></author><author><style face="normal" font="Arial"> Finlay,B.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Michael Smith Laboratories, University of British Columbia, 2185 East Mall, Vancouver, British Columbia V6T 1Z4, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Early life factors that affect allergy development</style></title><secondary-title><style face="normal" font="Arial">Nat Rev Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nat Rev Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="Arial">The incidence of allergic disease continues to rise in industrialized countries. The rapid increase in the incidence of allergic disease throughout the past half century suggests that recently altered environmental factors are driving allergy development. Accumulating evidence suggests that environmental experiences that occur during the first months of life can influence the risk of allergic sensitization. In this Review, we present the evidence relating to specific early life exposures that affect future allergy development, and discuss how these exposures may promote either tolerance or allergic sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1474-1741 (Electronic)IS - 1474-1733 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1038/nri.2017.39</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28504257">PM:28504257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Rev Immunol\20170515-ReynoldsLA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Rev Immunol\20170515-ReynoldsLA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Reynolds LA</style></custom2><misc3><style face="normal" font="Arial">10.1038/nri.2017.39</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bouten,H.</style></author><author><style face="normal" font="Arial"> Nijsten,T.E.</style></author><author><style face="normal" font="Arial"> Noordhoek,H.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Erasmus MC, Rotterdam</style></auth-address><titles><title><style face="normal" font="Arial">Cutaneous ulcerating nodules after many years of immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Ned Tijdschr Geneeskd</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ned Tijdschr Geneeskd</style></full-title></periodical><pages end="" start="A9554">A9554-</pages><volume><style face="normal" font="Arial">160</style></volume><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants,Immunologic</style></keyword><keyword><style face="normal" font="Arial"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> aluminium hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemically induced</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Foreign bodies</style></keyword><keyword><style face="normal" font="Arial"> Foreign body</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Injections,Intradermal</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis,Allergic,Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Ulcer</style></keyword><keyword><style face="normal" font="Arial"> Vaccin</style></keyword><keyword><style face="normal" font="Arial"> Vaccins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">A 40-year-old female patient was referred to the department of Dermatology with subcutaneous nodules and ulcers years after starting with immunotherapy injections (Purethal) for hay fever. The skin reaction appeared to be due to aluminium hydroxide, which is used as an adjuvant to many injections and vaccins. Aluminium hydroxide can cause delayed granulomatous contact dermatitis or foreign body reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20160210IS - 1876-8784 (Electronic)IS - 0028-2162 (Linking)LA - dutPT - Case ReportsPT - Journal ArticleRN - 0 (Adjuvants, Immunologic)RN - 5QB0T2IUN0 (Aluminum Hydroxide)SB - IMCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26860748">PM:26860748</url></web-urls><pdf-urls><url ppv-ref="no">h.bouten@erasmusmc.nl</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20160210, Bouten H</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,J.</style></author><author><style face="normal" font="Arial"> Xu,H.</style></author><author><style face="normal" font="Arial"> Liang,X.</style></author><author><style face="normal" font="Arial"> Lv,S.</style></author><author><style face="normal" font="Arial"> Lin,B.</style></author><author><style face="normal" font="Arial"> Jia,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Radiotherapy, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Allergic conditions are not associated with the risk of non-Hodgkin's lymphoma or Hodgkin's lymphoma: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Onco Targets Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Onco Targets Ther</style></full-title></periodical><pages end="2198" start="2189">2189-2198</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> radiotherapy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We aimed to systematically evaluate the association between allergic conditions and the risk of Hodgkin's lymphoma (HL) and non-HL (NHL). Systematic literature searches in PubMed and Embase were conducted up to October 2015 to identify eligible studies. Either a fixed-effects model or a random-effects model was adopted to estimate overall odds ratios (ORs) according to heterogeneity across studies. Subgroup and publication bias analyses were applied. A total of 24 case-control studies and 13 cohort studies (conducted from 1987 to 2015) were included in the analysis of the risk of NHL. History of any allergic condition was inversely associated with the risk of NHL in case-control studies (OR =0.83, 95% CI 0.76-0.91), while the reduction in the risk of NHL was not observed in cohort studies (OR =1.18, 95% CI 0.98-1.42). Significant association with the risk of NHL was found for asthma, hay fever, food allergy, allergic rhinitis, and hives. In the pooled analysis of the risk of HL, 12 studies (two were cohort studies) were included. The pooled OR was 0.96 (95% CI 0.84-1.09) for case-control studies and 1.46 (95% CI 0.63-3.38) for cohort studies. For specific allergic condition, we observed a reduced risk of HL in individuals with hay fever and food allergy. In conclusion, history of any allergic condition was not significantly associated with the risk of NHL or HL. Several specific allergic conditions, including asthma, hay fever, food allergy, and allergic rhinitis, might be associated with a reduced risk of NHL, while individuals with hay fever or food allergy may have a reduced risk of HL</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1178-6930 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.2147/OTT.S128849</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28458562">PM:28458562</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Onco Targets Ther\2017-10-2189-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Onco Targets Ther\2017-10-2189-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Yang J</style></custom2><misc3><style face="normal" font="Arial">10.2147/OTT.S128849</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ye,L.</style></author><author><style face="normal" font="Arial"> Mou,Y.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Jin,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Affiliated Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of microRNA-19b on airway remodeling, airway inflammation and degree of oxidative stress by targeting TSLP through the Stat3 signaling pathway in a mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Methane</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="Arial">This study explored the effects of microRNA-19b (miR-19b) on airway remodeling, airway inflammation, and degree of oxidative stress in a mouse model of asthma. Bioinformatics analyses and dual luciferase reporter gene assays revealed that thymic stromal lymphopoietin (TSLP) is a direct target of miR-19b. An asthma model was established via ovalbumin (OVA) sensitization and challenge in 72 female BALB/c mice. Mice were then assigned to saline, OVA-sensitized, saline+miR-19b mimics, saline+anti-TSLP, OVA-sensitized+miR-19b mimics, OVA-sensitized+mimics scramble, OVA-sensitized+anti-TSLP, and OVA-sensitized+IgG2a groups. Pathological morphology changes were detected through hematoxylin/eosin, Masson, and periodic acid-Schiff staining. miR-19b was downregulated while TSLP and Stat3 were upregulated in the OVA-sensitized group compared with the saline group. Bronchoalveolar lavage fluid samples from OVA-sensitized mice showed increased total protein, IL-4, IL-5 and IL-6 levels, numbers of inflammatory cells, eosinophils, neutrophils, mononuclear macrophages and lymphocytes, and eosinophil% compared to controls. Lung tissues from sensitized mice exhibited decreased superoxide dismutase activity and increased methane dicarboxylic aldehyde levels. The effects of OVA sensitization were reversed in the OVA-sensitized+miR-19b mimics and OVA-sensitized+anti-TSLP groups. These findings suggest miR-19b reduces airway remodeling, airway inflammation, and degree of oxidative stress by inhibiting Stat3 signaling through TSLP downregulation in a mouse asthma model</style></abstract><notes><style face="normal" font="Arial">DA - 20170504IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.17258</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28472780">PM:28472780</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170504-YeL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170504-YeL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170504, Ye L</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.17258</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jacobs,S.E.</style></author><author><style face="normal" font="Arial"> Saez-Lacy,D.</style></author><author><style face="normal" font="Arial"> Wynkoop,W.</style></author><author><style face="normal" font="Arial"> Walsh,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Infectious Diseases, Weill Cornell Medicine, New York, New York</style></auth-address><titles><title><style face="normal" font="Arial">Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature</style></title><secondary-title><style face="normal" font="Arial">Open Forum Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Open Forum Infect Dis</style></full-title></periodical><pages end="" start="ofx040">ofx040-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Isavuconazole is a new triazole that is approved for primary therapy of invasive aspergillosis. We provide the first report of a patient with allergic bronchopulmonary aspergillosis (ABPA) who was successfully treated with isavuconazole with marked improvement and minimal adverse effects. We further review the literature on antifungal management of ABPA</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 2328-8957 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/ofid/ofx040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28491888">PM:28491888</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Open Forum Infect Dis\2017-4-ofx040.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Open Forum Infect Dis\2017-4-ofx040.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Jacobs SE</style></custom2><misc3><style face="normal" font="Arial">10.1093/ofid/ofx040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fernandes,R.S.</style></author><author><style face="normal" font="Arial"> Barbosa,T.C.</style></author><author><style face="normal" font="Arial"> Barbosa,M.M.F.</style></author><author><style face="normal" font="Arial"> Miyasato,P.A.</style></author><author><style face="normal" font="Arial"> Nakano,E.</style></author><author><style face="normal" font="Arial"> Leite,L.C.C.</style></author><author><style face="normal" font="Arial"> Farias,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil, 1500, Sao Paulo, SP, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Stage and tissue expression patterns of Schistosoma mansoni venom allergen-like proteins SmVAL 4, 13, 16 and 24</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="223">223-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergen-like protein</style></keyword><keyword><style face="normal" font="Arial"> Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene family</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hybridization</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> In Situ Hybridization</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Parasitism</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Penetration</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma mansoni</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin penetration</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> Transformation</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Schistosoma mansoni venom allergen-like protein (SmVAL) is a gene family composed of 29 members divided into group 1 encoding proteins potentially secreted, and group 2 encoding intracellular components. Some members were found to be upregulated in the transition of germ ball - cercariae - day 3 schistosomula, suggesting that group 1 SmVAL proteins are associated with the invasion of the human host, although their functions are not completely established. Recently, we have described the localization of SmVAL7 (group 1) and SmVAL6 (group 2) transcripts in the oesophageal gland and in the oral and ventral suckers of adult parasites, respectively. The expression patterns of the two genes suggest that SmVAL7 protein plays a role in the blood-feeding process while SmVAL6 is associated with the parasite attachment and movement in the vasculature. In this way, searching for additional secreted SmVAL proteins that could be involved in key processes from skin penetration to the beginning of blood-feeding, we investigated the tissue localization of SmVAL4, 13, 16 and 24 by whole-mount in situ hybridization (WISH). RESULTS: We report here the localization of group 1 SmVAL4 and 24 transcripts in the pre-acetabular glands of developing germ balls. Time course experiments of in vitro cultured schistosomula after cercariae transformation demonstrated that SmVAL4 protein is secreted during the first 3 h of in vitro culture, correlating with the emptying of acetabular glands as documented by confocal microscopy. In addition, the localization of SmVAL13 transcripts in adult male anterior oesophageal gland suggests that the respective protein may be involved in the first steps of the blood-feeding process. SmVAL16 was localized close to the neural ganglia and requires further investigation. CONCLUSIONS: Our findings demonstrate that SmVAL proteins have localizations that place them in strategic positions to be considered as potential vaccine candidates as some members are exposed to interaction with the immune system and may participate in key processes of mammalian invasion and parasitism establishment</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-017-2144-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28482920">PM:28482920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2017-10-223.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2017-10-223.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Fernades RS</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-017-2144-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Parande,S.S.</style></author><author><style face="normal" font="Arial"> Ebrahimby,A.</style></author><author><style face="normal" font="Arial"> Dousty,A.</style></author><author><style face="normal" font="Arial"> Maleki,M.</style></author><author><style face="normal" font="Arial"> Movassaghi,A.</style></author><author><style face="normal" font="Arial"> Borji,H.</style></author><author><style face="normal" font="Arial"> Haghparast,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, P. O. Box: 91775-1793, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Somatic extracts of Marshallagia marshalli downregulate the Th2 associated immune responses in ovalbumin-induced airway inflammation in BALB/c mice</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="233">233-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recently the role of gastrointestinal nematodes in modulating the immune responses in inflammatory and immune-mediated conditions such as allergy and autoimmune diseases has been introduced. This is mainly due to the suppressive effects of somatic and excretory secretory (ES) products of nematodes on the immune responses. In this study, we evaluated the immunomodulatory potentials of somatic products of Marshallagia marshalli, a gastrointestinal nematodes of sheep, to suppress the immune-mediated responses in a murine model of allergic airway inflammation. BALB/c mice were intraperitoneally (IP) sensitized with ovalbumin (OVA)/Alum and then challenged with 1% OVA. Somatic products of M. marshalli were administered during each sensitization. The effects of somatic products on development of allergic airway inflammation were evaluated by analyzing inflammatory cells recruitment, histopathological changes, cytokines production (IL-4, IL-13, IL-10, TGF-beta) and serum antibody titers (IgG1, IgG2a). RESULTS: Somatic products of M. marshalli were able to suppress the induction of allergic airway inflammation in mice. Modulation of Th2 type responses (IL-4, IL-13, IgG1) via upregulations of IL-10 and TGF-beta production was observed after injection of somatic products of M. marshalli. In addition, inflammatory cells infiltration and pathological disorders were significantly diminished following administration of somatic products. CONCLUSIONS: Our data raised the possibility that helminths could be a potential therapeutic candidate to alleviate the inflammatory conditions in allergic asthma. According to these results, we concluded that M. marshalli may contain immune-modulatory molecules that attenuate allergic airway inflammation via induction of regulatory cytokines. Further investigations are required to identify molecules that might have potentials for development of novel therapeutic targets</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-017-2159-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28494800">PM:28494800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2017-10-233.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2017-10-233.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Parande SS</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-017-2159-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mattiucci,S.</style></author><author><style face="normal" font="Arial"> Colantoni,A.</style></author><author><style face="normal" font="Arial"> Crisafi,B.</style></author><author><style face="normal" font="Arial"> Mori-Ubaldini,F.</style></author><author><style face="normal" font="Arial"> Caponi,L.</style></author><author><style face="normal" font="Arial"> Fazii,P.</style></author><author><style face="normal" font="Arial"> Nascetti,G.</style></author><author><style face="normal" font="Arial"> Bruschi,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Infectious Diseases, Section of Parasitology, "Sapienza - University of Rome", and "Umberto I" University Hospital, P. le Aldo Moro, 5, 00185, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">IgE sensitization to Anisakis pegreffii in Italy: comparison of two methods for the diagnosis of allergic anisakiasis</style></title><secondary-title><style face="normal" font="Arial">Parasite Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasite Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis allergy</style></keyword><keyword><style face="normal" font="Arial"> Anisakis pegreffii</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> EPS</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">IgE sensitization to Anisakis pegreffii in Italian subjects suffering from gastro-allergic anisakiasis (GAA) (N= 5), or showing chronic urticaria (CU+) after fish consumption (N= 100), was investigated. A control group (N= 5) was also included. IgE response was analyzed by immunoblotting (WB) assay, using both excretory/secretory products (ESPs) and crude extract (CE) of A. pegreffii larvae. The results were compared with those achieved by the conventional immunological method for Anisakis allergy (i.e. immunoCAP). Among the 110 subjects, 28 showed IgE positivity with both WB and iCAP methods; 13 proved IgE reactivity, in WB assay, to EPS antigens of A. pegreffii, here provisionally indicated as Ani s 1-like, Ani s 7-like, Ani s 13-like; only 15 sera have shown IgE-WB reaction to Ani s 7-like and Ani s 13-like. iCAP and WB exhibited a high concordance value (k=1.00) when iCAP value was &lt;0.35 (negative result) and >50.0 (positive result). In the sera samples recorded as positive to Anisakis allergy, Ani s 1-like was responsible for 46.4% of the sensitivity, while Ani s 7-like and Ani s 13-like for 100%. They could be considered as major antigens in the diagnosis of allergic anisakiasis caused by A. pegreffii. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170505IS - 1365-3024 (Electronic)IS - 0141-9838 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pim.12440</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28475216">PM:28475216</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasite Immunol\20170505-MattiucciS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasite Immunol\20170505-MattiucciS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170505, Mattiucci S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pim.12440</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pezzi,M.</style></author><author><style face="normal" font="Arial"> Leis,M.</style></author><author><style face="normal" font="Arial"> Chicca,M.</style></author><author><style face="normal" font="Arial"> Roy,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Life Sciences and Biotechnology, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Gamasoidosis by the special lineage L1 of Dermanyssus gallinae (Acarina: Dermanyssidae): A case of heavy infestation in a public place in Italy</style></title><secondary-title><style face="normal" font="Arial">Parasitol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acari</style></keyword><keyword><style face="normal" font="Arial"> Acarina</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cytochrome C</style></keyword><keyword><style face="normal" font="Arial"> Dermanyssus gallinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA sequencing</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gamasoidosis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Pigeons</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">Among Gamasina (Acari: Mesostigmata) mites, some dermanyssoid species are known to cause gamasoidosis, a human dermatitis characterized by papulosquamous eruptions and urticarian lesions. We describe a case of mite infestation which occurred in public conference halls in Ferrara (Italy), affecting four people who attended the place and showed signs of gamasoidosis. The mites were collected and characterized using scanning electron microscopy, light microscopy and mitochondrial DNA sequencing (Cytochrome c oxidase subunit I partial CDS). Based on morphological and molecular data, the species responsible for the infestation was identified as the special lineage L1 of the poultry red mite, Dermanyssus gallinae (De Geer) (Acarina: Dermanissydae), a cryptic species known to be associated with pigeons. Rock doves, Columba livia Gmelin (Columbiformes: Columbidae) were roosting on the top of the public building, thus the mites probably gained access to the halls through small window openings. The present case report is the first one providing morpho-molecular identification of a D. gallinae cryptic species responsible of gamasoidosis in Italy</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1873-0329 (Electronic)IS - 1383-5769 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.parint.2017.05.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483708">PM:28483708</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Int\20170505-PezziM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Int\20170505-PezziM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Pezzi M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.parint.2017.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abe,N.</style></author><author><style face="normal" font="Arial"> Teramoto,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Osaka City Institute of Public Health and Environmental Sciences, 8-34 Tojo-cho, Tennoji-ku, Osaka, 543-0026, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Anisakis haemoglobin is a main antigen inducing strong and prolonged immunoreactions in rats</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis pegreffii</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Haemoglobin</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Pseudoterranova</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Anisakis simplex larvae are well known to cause gastrointestinal and allergic manifestations after ingestion of parasitized raw or undercooked seafood. The antibody recognition dynamics against the components of Anisakis larval antigen after primary and re-infection with Anisakis live larvae remain unclear. For this study, immunoblot analyses of serum IgG, IgE, and IgM against Anisakis larval somatic extract were performed in rats that had been orally inoculated with A. simplex live larvae. Multiple antigen fractions were recognized after primary infection. Their reaction was enhanced after re-infection. Antibody recognition was observed for 12 weeks after re-infection. The fraction of approximately 35 kDa contained a main antigen that induced strong and prolonged immunoreactions in IgG and IgE. The antibody reaction to this fraction appeared to be enhanced after inoculation of larval homogenates. This fraction was heat tolerant with boiling for 30 min. The fraction was spotted by immunoblotting after two-dimensional electrophoresis and was identified as Anisakis haemoglobin (Ani s 13) using mass spectrometry analysis. The amino acid sequences of haemoglobin mRNAs from two A. simplex sensu stricto and one Anisakis pegreffii were identified by RACE-PCR. They differed from those of two isolates of Pseudoterranova decipiens and A. pegreffii. Results of this study show that Anisakis haemoglobin, which is known to be a major allergen of A. simplex, induces strong and prolonged immunoreaction in rats. This report is the first to show the amino acid sequence variation of Anisakis haemoglobin mRNA between A. simplex sensu stricto and A. pegreffii</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1432-1955 (Electronic)IS - 0932-0113 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-017-5475-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497226">PM:28497226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20170512-AbeN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20170512-AbeN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Abe N</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-017-5475-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84525</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lowe,A.J.</style></author><author><style face="normal" font="Arial"> Angelica,B.</style></author><author><style face="normal" font="Arial"> Su,J.</style></author><author><style face="normal" font="Arial"> Lodge,C.J.</style></author><author><style face="normal" font="Arial"> Hill,D.J.</style></author><author><style face="normal" font="Arial"> Erbas,B.</style></author><author><style face="normal" font="Arial"> Bennett,C.M.</style></author><author><style face="normal" font="Arial"> Gurrin,L.C.</style></author><author><style face="normal" font="Arial"> Axelrad,C.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Vic., Australia</style></auth-address><titles><title><style face="normal" font="Arial">Age at onset and persistence of eczema are related to subsequent risk of asthma and hay fever from birth to 18 years of age</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="390" start="384">384-390</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Age of Onset</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> toddler</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Few studies have simultaneously addressed the importance of age of onset and persistence of eczema for the subsequent development of asthma and hay fever, particularly into early adulthood. METHODS: A high-risk birth cohort was recruited comprising 620 infants, who were then followed up frequently until 2 years of age, annually from age 3 to 7, then at 12 and 18 years, to document any episodes of eczema, current asthma, and hay fever. The generalized estimation equation technique was used to examine asthma and hay fever outcomes at 6 (n = 325), 12 (n = 248) and 18 (n = 240) years, when there was consistency of associations across the follow-ups. RESULTS: Very early-onset persistent (onset &lt;6 months, still present from 2 to 5 years) eczema was related to current asthma (adjusted OR = 3.2 [95% CI = 1.7-6.1]), as was very early-onset remitting eczema (onset &lt;6 months but not present from 2-5 years, OR = 2.7, 95% CI = 1.0-7.2) and early-onset persistent eczema (onset from 6-24 months, OR = 2.3, 95% CI = 1.2-4.7). Late-onset eczema (commenced from 2-5 years) was associated with increased risk of asthma at 12 years (OR = 3.0, 95% CI=1.1-8.2) but not at age 6 years. Only very early-onset persistent eczema was associated with increased risk of hay fever (aOR = 2.4, 95% CI = 1.4-4.1). CONCLUSION AND CLINICAL RELEVANCE: Eczema which commences in early infancy and persists into toddler years is strongly associated with asthma, and to a lesser extent hay fever, in high-risk children. If these associations are causal, prevention of early-life eczema might reduce the risk of respiratory allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170316IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12714</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28301056">PM:28301056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-384-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\2017-28-384-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170316, Lowe AJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12714</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Watkins,R.D.</style></author><author><style face="normal" font="Arial"> Zawahir,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Gastroenterology &amp; Nutrition, University of Maryland, 22 South Greene Street, N5W68, Baltimore, MD 21201, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Celiac Disease and Nonceliac Gluten Sensitivity</style></title><secondary-title><style face="normal" font="Arial">Pediatr Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Clin North Am</style></full-title></periodical><pages end="576" start="563">563-576</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free diet</style></keyword><keyword><style face="normal" font="Arial"> Gluten-related disorders</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Gluten-related disorders include celiac disease (CD), wheat allergy, and nonceliac gluten sensitivity. CD is an autoimmune enteropathy caused by damage to small intestinal mucosa when gluten is ingested in genetically susceptible individuals. Currently, the only available treatment of CD is gluten-free diet. Several potential treatments are being researched. Wheat allergy is a hypersensitivity reaction caused by IgE-mediated and/or non-IgE-mediated immune response, and can involve the gastrointestinal tract, skin, or respiratory tract. Nonceliac gluten sensitivity is one of a variety of immunologic, morphologic, or symptomatic manifestations precipitated by ingestion of gluten in individuals in whom CD and wheat allergy are excluded</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1557-8240 (Electronic)IS - 0031-3955 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pcl.2017.01.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502438">PM:28502438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Clin North Am\2017-64-563-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Clin North Am\2017-64-563-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Watkins RD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pcl.2017.01.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fahey,L.M.</style></author><author><style face="normal" font="Arial"> Liacouras,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, 7NW, Philadelphia, PA 19104, USA</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Gastrointestinal Disorders</style></title><secondary-title><style face="normal" font="Arial">Pediatr Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Clin North Am</style></full-title></periodical><pages end="485" start="475">475-485</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disorders</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis (EoE) is an atopic disease that is characterized by an isolated infiltration of eosinophils into the epithelium of the esophagus and is triggered by specific allergens. Patients should undergo an upper endoscopy with biopsy after 6 to 8 weeks of treatment with a proton pump inhibitor in order to make the diagnosis of EoE. Eosinophilic gastroenteritis is a pathologic eosinophilic infiltration of any portion of the gastrointestinal tract, and eosinophilic proctocolitis is an eosinophilic infiltration in the colon alone</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1557-8240 (Electronic)IS - 0031-3955 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pcl.2017.01.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502433">PM:28502433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Clin North Am\2017-64-475-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Clin North Am\2017-64-475-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Fahey LM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pcl.2017.01.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84528</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaczmarski,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Therapeutic use of hypoallergenic formulas formulas in cow's milk allergy, and multiply food allergy in developmental age</style></title><secondary-title><style face="normal" font="Arial">Pediatr Polska</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Polska</style></full-title></periodical><pages end="484" start="475">475-484</pages><volume><style face="normal" font="Arial">92</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid-based formulas</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Developmental age</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> eHF</style></keyword><keyword><style face="normal" font="Arial"> Extensively hydrolysed formulas</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Multiple food allergies</style></keyword><keyword><style face="normal" font="Arial"> Multiply food allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0031-3939</style></isbn><abstract><style face="normal" font="Arial">Cow's milk protein allergy (CMPA) may affect between 2,0</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô3,0 percent of infants and young children. Milk proteins may induce allergic reactions and are responsible for a variety of clinical symptoms, involving mainly the skin, gastrointestinal and respiratory tracts. The general symptoms such as anaphylaxis are rarely occurring. These CMPA symptoms are easily missed in primary care settings; therefore, the proper knowledge on clinical symptoms, accurate diagnosis and management are desirable. This paper discusses mostly the aspects of treatment of CMA, paying attention to two types of special milk formulas; extensively hydrolysed casein or whey proteins of cow milk (eHF) or elementary formula (amino acids formula; AAF). In AA formula, milk proteins fraction has been replaced with synthetic aminoacids and such formulas are used for the treatment of severe form of cow's milk allergy as well as of multiple food allergies in children</style></abstract><notes><style face="normal" font="Arial">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pepo.2017.05.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.pepo.2017.05.004</url></web-urls><pdf-urls><url ppv-ref="no">elamagott@gmail.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170523, Kaczmarski M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pepo.2017.05.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Manousaki,D.</style></author><author><style face="normal" font="Arial"> Paternoster,L.</style></author><author><style face="normal" font="Arial"> Standl,M.</style></author><author><style face="normal" font="Arial"> Moffatt,M.F.</style></author><author><style face="normal" font="Arial"> Farrall,M.</style></author><author><style face="normal" font="Arial"> Bouzigon,E.</style></author><author><style face="normal" font="Arial"> Strachan,D.P.</style></author><author><style face="normal" font="Arial"> Demenais,F.</style></author><author><style face="normal" font="Arial"> Lathrop,M.</style></author><author><style face="normal" font="Arial"> Cookson,W.O.C.M.</style></author><author><style face="normal" font="Arial"> Richards,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Clinical Epidemiology, Department of Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D levels and susceptibility to asthma, elevated immunoglobulin E levels, and atopic dermatitis: A Mendelian randomization study</style></title><secondary-title><style face="normal" font="Arial">PLoS Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PLoS Med</style></full-title></periodical><pages end="" start="e1002294">e1002294-</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alleles</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Biobank</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Effect size</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mendelian Randomization</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Public health importance</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> reverse causation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Sunlight</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Low circulating vitamin D levels have been associated with risk of asthma, atopic dermatitis, and elevated total immunoglobulin E (IgE). These epidemiological associations, if true, would have public health importance, since vitamin D insufficiency is common and correctable. METHODS AND FINDINGS: We aimed to test whether genetically lowered vitamin D levels were associated with risk of asthma, atopic dermatitis, or elevated serum IgE levels, using Mendelian randomization (MR) methodology to control bias owing to confounding and reverse causation. The study employed data from the UK Biobank resource and from the SUNLIGHT, GABRIEL and EAGLE eczema consortia. Using four single-nucleotide polymorphisms (SNPs) strongly associated with 25-hydroxyvitamin D (25OHD) levels in 33,996 individuals, we conducted MR studies to estimate the effect of lowered 25OHD on the risk of asthma (n = 146,761), childhood onset asthma (n = 15,008), atopic dermatitis (n = 40,835), and elevated IgE level (n = 12,853) and tested MR assumptions in sensitivity analyses. None of the four 25OHD-lowering alleles were associated with asthma, atopic dermatitis, or elevated IgE levels (p >/= 0.2). The MR odds ratio per standard deviation decrease in log-transformed 25OHD was 1.03 (95% confidence interval [CI] 0.90-1.19, p = 0.63) for asthma, 0.95 (95% CI 0.69-1.31, p = 0.76) for childhood-onset asthma, and 1.12 (95% CI 0.92-1.37, p = 0.27) for atopic dermatitis, and the effect size on log-transformed IgE levels was -0.40 (95% CI -1.65 to 0.85, p = 0.54). These results persisted in sensitivity analyses assessing population stratification and pleiotropy and vitamin D synthesis and metabolism pathways. The main limitations of this study are that the findings do not exclude an association between the studied outcomes and 1,25-dihydoxyvitamin D, the active form of vitamin D, the study was underpowered to detect effects smaller than an OR of 1.33 for childhood asthma, and the analyses were restricted to white populations of European ancestry. This research has been conducted using the UK Biobank Resource and data from the SUNLIGHT, GABRIEL and EAGLE Eczema consortia. CONCLUSIONS: In this study, we found no evidence that genetically determined reduction in 25OHD levels conferred an increased risk of asthma, atopic dermatitis, or elevated total serum IgE, suggesting that efforts to increase vitamin D are unlikely to reduce risks of atopic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1549-1676 (Electronic)IS - 1549-1277 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United Kingdom -CO - Germany -CO - France -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pmed.1002294</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28486474">PM:28486474</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS Med\2017-14-e1002294.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS Med\2017-14-e1002294.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Manousaki D</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pmed.1002294</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kiss,T.</style></author><author><style face="normal" font="Arial"> Szabo,A.</style></author><author><style face="normal" font="Arial"> Oszlanczi,G.</style></author><author><style face="normal" font="Arial"> Lukacs,A.</style></author><author><style face="normal" font="Arial"> Timar,Z.</style></author><author><style face="normal" font="Arial"> Tiszlavicz,L.</style></author><author><style face="normal" font="Arial"> Csupor,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Szeged, Faculty of Pharmacy, Department of Pharmacognosy, Szeged, Hungary</style></auth-address><titles><title><style face="normal" font="Arial">Repeated-dose toxicity of common ragweed on rats</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0176818">e0176818-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Common ragweed</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive species</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Ambrosia artemisiifolia L. is an invasive species with highly allergenic pollens. Ragweed originates from North America, but it also occurs and is spreading in Europe, causing seasonal allergic rhinitis for millions of people. Recently, the herb of A. artemisiifolia has gained popularity as medicinal plant and food. The effects of its long-term intake are unknown; there are no toxicological data to support the safe use of this plant. The aim of our study was to assess the repeated dose toxicity of A. artemisiifolia on animals. Ragweed puree was administered in low dose (500 mg/kg b. w.) and high dose (1000 mg/kg b. w.) to male Wistar rats according to 407 OECD Guidelines for the Testing of Chemicals. Clinical symptoms, various blood chemical parameters, body weight and organ weights of the rats were measured. Reduced liver function enzymes (AST, ALT), reduced triglyceride level in the low dose and increased carbamide level in the high dose group were observed. The weight of the liver relative to body weight was significantly reduced in both groups, while the brain weight relative to body weight was significantly elevated in both groups. According to our results, the repeated use of ragweed resulted in toxic effects in rats and these results question the safety of long-term human consumption of common ragweed</style></abstract><notes><style face="normal" font="Arial">DA - 20170504IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0176818</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28472131">PM:28472131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0176818.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0176818.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S2_File.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S3_File.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S4_File.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S5_File.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S6_File.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S7_File.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S2_File.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S3_File.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S4_File.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S5_File.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S6_File.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176818-S7_File.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170504, Kiss T</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0176818</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Acevedo,N.</style></author><author><style face="normal" font="Arial"> Ezer,S.</style></author><author><style face="normal" font="Arial"> Kebede,M.S.</style></author><author><style face="normal" font="Arial"> Gaertner,V.D.</style></author><author><style face="normal" font="Arial"> Soderhall,C.</style></author><author><style face="normal" font="Arial"> D'Amato,M.</style></author><author><style face="normal" font="Arial"> Kabesch,M.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Kere,J.</style></author><author><style face="normal" font="Arial"> Pulkkinen,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Science and Education, Karolinska Institutet, and Sachs' Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Neuropeptide S (NPS) variants modify the signaling and risk effects of NPS Receptor 1 (NPSR1) variants in asthma</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0176568">e0176568-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma risk</style></keyword><keyword><style face="normal" font="Arial"> BAMSE</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> epistasis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic association</style></keyword><keyword><style face="normal" font="Arial"> Genetic Association Studies</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Single nucleotide polymorphisms (SNPs) close to the gain-of-function substitution, Asn(107)Ile (rs324981, A>T), in Neuropeptide S Receptor 1 (NPSR1) have been associated with asthma. Furthermore, a functional SNP (rs4751440, G>C) in Neuropeptide S (NPS) encodes a Val(6)Leu substitution on the mature peptide that results in reduced bioactivity. We sought to examine the effects of different combinations of these NPS and NPSR1 variants on downstream signaling and genetic risk of asthma. In transfected cells, the magnitude of NPSR1-induced activation of cAMP/PKA signal transduction pathways and downstream gene expression was dependent on the combination of the NPS and NPSR1 variants with NPS-Val(6)/NPSR1-Ile(107) resulting in strongest and NPS-Leu(6)/NPSR1-Asn(107) in weakest effects, respectively. One or two copies of the NPS-Leu(6) (rs4751440) were associated with physician-diagnosed childhood asthma (OR: 0.67, 95%CI 0.49-0.92, p = 0.01) and together with two other linked NPS variants (rs1931704 and rs10830123) formed a protective haplotype (p = 0.008) in the Swedish birth cohort BAMSE (2033 children). NPS rs10830123 showed epistasis with NPSR1 rs324981 encoding Asn(107)Ile (p = 0.009) in BAMSE and with the linked NPSR1 rs17199659 (p = 0.005) in the German MAGIC/ISAAC II cohort (1454 children). In conclusion, NPS variants modify asthma risk and should be considered in genetic association studies of NPSR1 with asthma and other complex diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Finland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0176568</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463995">PM:28463995</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0176568.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0176568.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176568-S2_Table.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176568-S4_Table.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176568-S2_Table.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0176568-S4_Table.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170502, Acevedo N</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0176568</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qiu,Z.</style></author><author><style face="normal" font="Arial"> Zhou,J.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Qin,X.</style></author><author><style face="normal" font="Arial"> Dai,Y.</style></author><author><style face="normal" font="Arial"> Ke,Y.</style></author><author><style face="normal" font="Arial"> Chen,Z.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Ying,S.</style></author><author><style face="normal" font="Arial"> Shen,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</style></auth-address><titles><title><style face="normal" font="Arial">Deletion of Shp2 in bronchial epithelial cells impairs IL-25 production in vitro, but has minor influence on asthmatic inflammation in vivo</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0177334">e0177334-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Shp2 played an important role in cigarette-smoke-mediated inflammation, surfactant homeostasis and asthmatic airway remodeling. However, whether shp2 plays a key role in epithelium-associated allergic reaction is still unknown. In this study, LPS and OVA were observed to induce the production of IL-25 in bronchial epithelial cells in vitro via the activation of MAPK p38 and JNK. Furthermore, blockage of Shp2 by its specific inhibitor PHPS1 or by siRNA-mediated depletion was found to reduce the production of IL-25 in epithelial cells as well as the up-regulated LPS-triggered activation of JNK but not p38. To confirm the role of intra-bronchial epithelial Shp2 in OVA-induced allergic reaction, we generated CC10-rtTA/(tetO)7-Cre/Shp2f/f mice, where Shp2 was conditionally knocked out in bronchial epithelial cells. Surprisingly, specific deletion of Shp2 in bronchial epithelial cells showed a mild but insignificant effect on the expressions of epithelium-derived cytokines as well as TH2 and TH17 polarization following allergen-induced murine airway inflammation. Collectively, our data suggested that deletion of Shp2 impaired IL-25 production in bronchial epithelial cells in vitro, but might yet have minor influence on OVA-induced allergic reaction in vivo</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0177334</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28481957">PM:28481957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0177334.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0177334.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Qiu Z</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0177334</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Obel,K.B.</style></author><author><style face="normal" font="Arial"> Ntumba,K.J.M.</style></author><author><style face="normal" font="Arial"> Kalambayi,K.P.</style></author><author><style face="normal" font="Arial"> Zalagile,A.P.</style></author><author><style face="normal" font="Arial"> Kinkodi,K.D.</style></author><author><style face="normal" font="Arial"> Munogolo,K.Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence and determinants of asthma in adults in Kinshasa</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0176875">e0176875-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Congo</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Sub-Saharan Africa</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban environment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Epidemiological data on asthma among adults in sub-Saharan Africa are sparse. OBJECTIVE: To determine the prevalence of and factors associated with asthma among adults in Kinshasa. METHODS: A previously validated asthma questionnaire was administered to an adult population aged >/=18 years in urban and peri-urban suburbs of Kinshasa. A random stratified multi-stage sampling plan was used to select the study participants. Logistic regression was used to identify factors associated with asthma. RESULTS: The mean age of respondents was 36.7 (SD 15.36) years, 75% lived in an urban environment, and 57% were women. The prevalence of asthma-ever was 6.9% (95% CI: 5.4-8.4). Among asthmatic patients, intermittent asthma was estimated at 75.7% and severe asthma at 9.3%. Family atopy (OR: 3.97; 95% CI: 2.42-6.50; p&lt;0.001), and the presence of a cat in the house (OR: 1.82; 95% CI: 1.01-3.28; p = 0.045) were associated with self-reported asthma. CONCLUSION: Asthma is relatively frequent in adults in Kinshasa, a prevalence similar to those reported elsewhere in Africa. Family atopy and the presence of a cat in the house could be the most common determinants to be confirmed with national survey in order to design guidelines for the control of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170502IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Congo -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0176875</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28464036">PM:28464036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0176875.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0176875.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170502, Obel KB</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0176875</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Virchow,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">New horizons in allergen-specific immunotherapy in allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Pneumologe</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pneumologe</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1613-6055</style></isbn><abstract><style face="normal" font="Arial">National and international guidelines have been very cautious in their recommendations regarding allergen immunotherapy (AIT) in asthma. AIT has only been recommended for patients with mild disease, good asthma control, and a clear link between (typically seasonal) allergen exposure und asthma symptoms. However, current studies demonstrated that AIT can also be safe and effective in patients with not well-controlled asthma and perennial allergies (such as house dust mite allergy). Thus, there are new horizons in AIT suggesting that AIT could represent a sustained disease-modifying intervention in patients with not well-controlled asthma.</style></abstract><notes><style face="normal" font="Arial">LA - GERCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10405-017-0116-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10405-017-0116-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pneumologe\20170522-VirchowJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pneumologe\20170522-VirchowJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Virchow JC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10405-017-0116-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sardecka,I.</style></author><author><style face="normal" font="Arial"> Krogulska,A.</style></author><author><style face="normal" font="Arial"> Toporowska-Kowalska,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Allergology, Gastroenterology and Nutrition, 3 Chair of Paediatrics, Medical University of Lodz, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">The influence of dietary immunomodulatory factors on development of food allergy in children</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="96" start="89">89-96</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">In the last few years many studies have been conducted on the role of dietary and environmental factors in the prevention of allergic diseases among children. Many studies have shown that the diet of pregnant women and children in their early postnatal life, rich in antioxidants, vitamin D, and fatty acids is beneficial as it reduces the risk of allergy in their future life. Moreover, there are many reports about the main role of gut microbiota and probiotics in the allergy prevention, what can indicate new ways of procedures in allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - POland -</style></notes><work-type><style face="normal" font="Arial">10.5114/pdia.2016.63955</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28507485">PM:28507485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-89-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-89-96.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Sardecka I</style></custom2><misc3><style face="normal" font="Arial">10.5114/pdia.2016.63955</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kolaczek,A.</style></author><author><style face="normal" font="Arial"> Skorupa,D.</style></author><author><style face="normal" font="Arial"> Antczak-Marczak,M.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Kupczyk,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Safety and efficacy of venom immunotherapy: a real life study</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="167" start="159">159-167</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> beekeeping</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Venom immunotherapy (VIT) is recommended as the first-line treatment for patients allergic to Hymenoptera venom. AIM: To analyze the safety and efficacy of VIT in a real life setting. MATERIAL AND METHODS: One hundred and eighty patients undergoing VIT were studied to evaluate the safety, efficacy, incidence and nature of symptoms after field stings and adverse reactions to VIT. RESULTS: Significantly more patients were allergic to wasp than bee venom (146 vs. 34, p &lt; 0.0001). Early and late side effects were more common during the maintenance (48 patients, 26.7%) than during the induction of VIT (32 patients, 17.8%), were more frequent in patients allergic to bees, and were not associated with angiotensin convertase inhibitors (ACEi) or beta-adrenergic antagonists use. Systemic reactions were observed in 4 individuals on wasp VIT (2.7%) and in 6 patients allergic to bees (17.65%). The VIT was efficacious as most patients reported no reactions (50%) or reported only mild local reactions (43.75%) to field stings. The decrease in sIgE at completion of VIT correlated with the dose of vaccine received (r = 0.53, p = 0.004). Beekeeping (RR = 29.54, p &lt; 0.0001) and female sex (RR = 1.27, p = 0.033) were associated with a higher risk of venom allergy. CONCLUSIONS: Venom immunotherapy is highly efficacious and safe as most of the adverse events during the induction and maintenance phase are mild and local. Side effects of VIT are more common in subjects on bee VIT. Beekeeping and female sex are associated with a higher risk of allergy to Hymenoptera venom</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2017.67082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28507496">PM:28507496</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-159-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-159-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170516, Kolaczek A</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2017.67082</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tacquard,C.</style></author><author><style face="normal" font="Arial"> Chassard,D.</style></author><author><style face="normal" font="Arial"> Stenger,R.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Malinovsky,J.M.</style></author><author><style face="normal" font="Arial"> Mertes,P.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis during labor or caesarean delivery: What the anaesthetists must know</style></title><secondary-title><style face="normal" font="Arial">Pratic Anesth Reanim</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pratic Anesth Reanim</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergie</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Curares</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Grossesse</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Labor</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Neuromuscular blocking agents</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parturiente</style></keyword><keyword><style face="normal" font="Arial"> Placenta</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1279-7960</style></isbn><abstract><style face="normal" font="Arial">Reasons for anaphylactic reactions are the same than that documented in a general population at the beginning of pregnancy but they change then after, latex and antibiotics being mostly implicated during delivery as well as oxytocics and sulprostone. During anaphylactic shock, the decrease in venous return is worsened by uterine compression of the vena cavae and placenta hypoperfusions may induce fetal distress. The treatment is based on the administration of epinephrine and vascular filling. Emergency C-section is required for delivery except if vaginal delivery can be rapidly performed. The diagnosis is supported by plasma tryptase concentration measurement histamine concentration being of no value in pregnant women. Etiologic research is to be performed after 4</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô6 weeks. When latex or anaesthetic agent allergy is suspected during pregnancy, it must be confirmed before delivery. A cutaneous provocative test may be done when a local anaesthetic allergy is suspected or evoked. No premedication can prevent anaphylaxis</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pratan.2017.04.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.pratan.2017.04.004</url></web-urls><pdf-urls><url ppv-ref="no">paul-michel.mertes@chru-strasbourg.fr</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170521, Tacquard C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pratan.2017.04.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lundblad,L.K.A.</style></author><author><style face="normal" font="Arial"> Gulec,N.</style></author><author><style face="normal" font="Arial"> Poynter,M.E.</style></author><author><style face="normal" font="Arial"> DeVault,V.L.</style></author><author><style face="normal" font="Arial"> Dienz,O.</style></author><author><style face="normal" font="Arial"> Boyson,J.E.</style></author><author><style face="normal" font="Arial"> Daphtary,N.</style></author><author><style face="normal" font="Arial"> Aliyeva,M.</style></author><author><style face="normal" font="Arial"> Ather,J.L.</style></author><author><style face="normal" font="Arial"> Scheuplein,F.</style></author><author><style face="normal" font="Arial"> Schaub,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Vermont, Dept. of Medicine, USA.</style></auth-address><titles><title><style face="normal" font="Arial">The role of iNKT cells on the phenotypes of allergic airways in a mouse model</style></title><secondary-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Airways hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vermont</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">iNKT cells and mast cells have both been implicated in the syndrome of allergic asthma through their activation-induced release of Th2 type cytokines and secretion of histamine and other mediators, respectively, which can promote airways hyperresponsiveness (AHR) to agents such as methacholine. However, a mechanistic link between iNKT cells and mast cell recruitment or activation has never been explored. Our objective was to determine whether iNKT cells are necessary for the recruitment of mast cells and if iNKT cells can influence the acute allergen induced bronchoconstriction (AIB) caused by mast cell mediator release. To do so, we pharmacologically eliminated iNKT cells using a specific antibody (NKT-14) and examined its impact on airway inflammation and physiological phenotype. In mice treated with NKT-14, the elimination of iNKT cells was sufficient to prevent AHR and pulmonary eosinophilic inflammation elicited by administration of the iNKT cell agonist, alphaGalCer. In mice treated with NKT-14 and then sensitized and challenged with house dust mite extract (HDM), eliminating the iNKT cells significantly reduced both AHR and AIB but did not affect pulmonary inflammation, the mast cell population, nor the release of the mast cell mediators mast cell protease-1 and prostaglandin D2. We conclude that while iNKT cells contribute to the phenotype of allergic airways disease through the manifestation of AIB and AHR, their presence is not required for mast cell recruitment and activation, or to generate the characteristic inflammatory response subsequent to allergen challenge</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pupt.2017.05.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483562">PM:28483562</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170509-LundbladLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170509-LundbladLK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Lundblad LK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pupt.2017.05.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Riaguas Almenara,A.</style></author><author><style face="normal" font="Arial"> Montesa,L.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Radiodiagnostico, Hospital Miguel Servet, Zaragoza, Espana.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylactic shock secondary to ruptured hydatid cyst of liver into the pleural cavity</style></title><secondary-title><style face="normal" font="Arial">Radiologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Radiologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Zaragoza</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1578-178X (Electronic)IS - 0033-8338 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rx.2017.04.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28495459">PM:28495459</url></web-urls><pdf-urls><url ppv-ref="no">anariaguas@hotmail.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170512, Riaguas Almenara A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rx.2017.04.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ikari,T.</style></author><author><style face="normal" font="Arial"> Nagai,K.</style></author><author><style face="normal" font="Arial"> Ohe,M.</style></author><author><style face="normal" font="Arial"> Harada,T.</style></author><author><style face="normal" font="Arial"> Akiyama,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Center for Respiratory Diseases, JCHO Hokkaido Hospital, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Multiple cavities with halo sign in a case of invasive pulmonary aspergillosis during therapy for drug-induced hypersensitivity syndrome</style></title><secondary-title><style face="normal" font="Arial">Respir Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med Case Rep</style></full-title></periodical><pages end="128" start="124">124-128</pages><volume><style face="normal" font="Arial">21</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal Agents</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> herpes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A 67-year-old female with rheumatoid arthritis and asthma-chronic obstructive pulmonary disease overlap syndrome was admitted for drug-induced hypersensitivity syndrome (DIHS) caused by salazosulfapyridine. Human herpes virus 6 (HHV-6) variant B was strongly positive on peripheral blood. Multiple cavities with ground grass opacities rapidly emerged predominantly in the upper and middle lobes. She was diagnosed with invasive pulmonary aspergillosis (IPA), and was treated successfully with antifungal agents. Therapeutic systemic corticosteroids, emphysematous change in the lungs, and the worsening of the patient's general condition due to DIHS were considered major contributing factor leading to IPA. HHV-6 reactivation could have an effect on clinical course of IPA. Cavities with halo sign would provide an early clue to IPA in non-neutropenic and immunosuppressive patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 2213-0071 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmcr.2017.04.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28480161">PM:28480161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med Case Rep\2017-21-124-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med Case Rep\2017-21-124-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Ikari T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmcr.2017.04.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kermenli,T.</style></author><author><style face="normal" font="Arial"> Yalcinoz,K.</style></author><author><style face="normal" font="Arial"> Polat,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Elbistan State Hospital, Thoracic Surgery Clinic, Kahramanmaras, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Intrathoracic multiple recurrence and bilateral endobronchial rupture of cyst hydatid disease; the rare cause of anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Respir Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med Case Rep</style></full-title></periodical><pages end="115" start="113">113-115</pages><volume><style face="normal" font="Arial">21</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 2213-0071 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmcr.2017.04.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28458996">PM:28458996</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med Case Rep\2017-21-113-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med Case Rep\2017-21-113-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Kermenli T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmcr.2017.04.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bedolla-Barajas,M.</style></author><author><style face="normal" font="Arial"> Torres-Alvarez,N.E.</style></author><author><style face="normal" font="Arial"> Contreras-Gonzalez,U.</style></author><author><style face="normal" font="Arial"> Hernandez-Colin,D.</style></author><author><style face="normal" font="Arial"> Bedolla-Pulido,T.I.</style></author><author><style face="normal" font="Arial"> Robles-Figueroa,M.</style></author><author><style face="normal" font="Arial"> Morales-Romero,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Servicio de Alergia e Inmunologia Clinica. Guadalajara, Jalisco, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">[High prevalence of food sensitization among adults with allergic diseases who live in the Guadalajara metropolitan area]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="75" start="66">66-75</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of food sensitization in adults shows differences owing to geographic, regional and cultural circumstances. OBJECTIVE: To identify the prevalence and factors associated with food sensitization in adults with allergic diseases. METHODS: Cross-sectional study, where medical records of adult patients with any allergic disease and who tested positive to airborne allergens on at least one skin test were reviewed. Age, sex, underlying allergic disease and skin test result were recorded. Statistical analyses included food sensitization prevalence with the corresponding 95 % confidence intervals (CI), as well as a multivariate analysis to determine associated factors. RESULTS: We included 258 patients with a mean of 36 years of age; 75 % were of the female sex. The most common underlying condition was allergic rhinitis (59 %). The prevalence of food sensitization was 37 % (95 % CI, 31.5-43.3) and it did not vary significantly according to sex or allergic disease in question. The most sensitizing food was soybeans (44.8 %), and associated factors were sensitization to cat dander (OR = 1.8; 95 % CI, 1.03-3.2) and 5 or more positive skin tests (OR = 4.3, 95 % CI 2.3-8.1). CONCLUSION: The prevalence of food sensitization in people with allergic disease was 40 %. Further studies are required to determine its prevalence in the general population</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188714">PM:28188714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-66-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-66-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Bedolla-Barajas M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rojas-Mendez,I.C.</style></author><author><style face="normal" font="Arial"> Arana-Munoz,O.</style></author><author><style face="normal" font="Arial"> Lopez-Garcia,A.I.</style></author><author><style face="normal" font="Arial"> Rivero-Yeverino,D.</style></author><author><style face="normal" font="Arial"> Caballero-Lopez,C.G.</style></author><author><style face="normal" font="Arial"> Papaqui-Tapia,S.</style></author><author><style face="normal" font="Arial"> Camero-Martinez,H.</style></author><author><style face="normal" font="Arial"> Vazquez-Rojas,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Benemerita Universidad Autonoma de Puebla, Hospital Universitario de Puebla, Servicio de Alergia e Inmunologia Clinica Puebla, Puebla, Mexico.</style></auth-address><titles><title><style face="normal" font="Arial">[Skin reactivity frequency to aeroallergens in patients with clinical symptoms of allergic disease]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="12" start="7">7-12</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lolium</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin reactivity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic diseases diagnosis must be based on adequate allergological anamnesis and an immunological sensitization test; the most sensitive and specific is the skin prick test. OBJECTIVE: To determine the frequency of skin reactivity to aeroallergens, by age groups, in patients of the Department of Allergy and Clinical Immunology of the Hospital Universitario de Puebla, in Mexico. METHODS: A cross-sectional study was conducted that included patients aged 2 to 64 years with symptoms suggestive of allergic disease, in which skin prick tests with aeroallergens were performed; the diagnostic criteria were those of international guidelines. Frequencies, percentages and dispersion measures were calculated. RESULTS: Of 173 patients, 63 % were females. Mean age was 22.3 years. The frequency of skin reactivity for Quercus sp. was 12.72 %, for Periplaneta americana, 9.83 %, for Dermatophagoides farinae, 9.25 %, for Cynodon dactylon, 8.09 %, for Blatella germanica, 8.09 %, for Holcus halepensis, 6.94 %, for Dermatophagoides pteronyssinus, 6.36 %, for Schinus molle, 5.78 %, for Fraxinus uhdei, 5.20 %, for Lolium perenne, 5.20 %, for Ambrosia eliator, 5.20 % and for Artemisa tridentata, 4.62 %. CONCLUSION: Although Dermatophagoides are the most frequently reported aeroallergens, the most common aeroallergen in this study was pollen, probably owing to geographical and environmental factors, although this was not observed in the analysis by age groups</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188708">PM:28188708</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-7-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-7-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Rojas.Memdez IC</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Molina-Veloso,A.</style></author><author><style face="normal" font="Arial"> Borrego-Alonso,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Archivo Nacional de la Republica de Cuba, Laboratorio de Conservacion Preventiva. La Habana, Cuba.</style></auth-address><titles><title><style face="normal" font="Arial">[Viable allergenic fungi in a documentary deposit of the National Archive of Cuba]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="51" start="40">40-51</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Air sampling</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Cuba</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> Indoor environments</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Intense and persistent exposure to indoor-air biological agents has been associated with the appearance of allergic diseases. Archives and libraries Indoor environments in tropical countries are an important reservoir of fungal propagules. OBJECTIVE: To evaluate the degree of air pollution with allergenic fungi in a repository of frequently-manipulated documents. METHODS: Air sampling was performed by two methods: active (biocollector) and passive (sedimentation plate). Fungi were taxonomically identified, and spores were measured to determine their penetrability in the human respiratory tract, and its impact on episodes of allergy. RESULTS: In terms of concentration and diversity, the local environment behaved as a fungal propagule reservoir, which showed that there is significant health risk for the staff that manipulates the documents. Some spores were shown to be able to reach the lower respiratory tract when inhaled, which increases their allergenic and pathogenic potential. Aspergillus, Cladosporium, Penicillium and Alternaria, which are referred to as highly allergenic fungi, were prevalent. CONCLUSION: Aerobiological studies are a valuable tool for the treatment of patients with allergy to fungi and other disorders they produce</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Cuba -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188712">PM:28188712</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-40-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-40-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Molina-Veloso A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzales-Gonzalez,V.A.</style></author><author><style face="normal" font="Arial"> Diaz-Flores,A.M.</style></author><author><style face="normal" font="Arial"> Fernandez-Zelaya,K.Z.</style></author><author><style face="normal" font="Arial"> Rivera-Reyes,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidad Nacional Autonoma de Honduras. Tegucigalpa, Francisco Morazan, Honduras.</style></auth-address><titles><title><style face="normal" font="Arial">[Prevalence of sensitization to inhalant allergens in the immunology department from Hospital de Especialidades Pediatricas Maria, Honduras, 2016]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="33" start="24">24-33</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic diseases are a public health problem; estimates indicate that between 30% and 40% of the world population is affected by some allergy. Knowing the prevalence of allergen sensitization allows for adequate diagnoses and treatments to be offered. In Honduras there are no studies available in pediatric patients. OBJECTIVE: The purpose of this research was to identify the most common types of sensitization in children and their correlation with the most common allergic diseases in patients on immunotherapy at the Maria Hospital of Pediatric Specialties. METHODS: Cross-sectional, descriptive, retrospective study in which medical records and databases of patients on allergic immunotherapy at the Maria Hospital of Pediatric Specialties were reviewed between January 2015 and June 2016. RESULTS: 215 children on immunotherapy were assessed; ages ranged from 3 to 18 years, with a mean of 10.8 years. Aeroallergen-positive epicutaneous tests were identified in 73.02%. The most common aeroallergens were Dermatophagoides farinae and Dermatophagoides pteronyssinus mix (96.74%), American cockroach 37.21%, and Aspergillus fumigatus and Homodenderum cladosporioides (16.28%). CONCLUSION: House dust mites and American cockroach were the most common causes of sensitization in patients on immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Honduras -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188710">PM:28188710</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-24-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-24-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Gonzales-Gonzalez VA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Molina-Saenz,M.M.</style></author><author><style face="normal" font="Arial"> Villa-Arango,A.M.</style></author><author><style face="normal" font="Arial"> Cardona-Villa,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidad de Antioquia, IPS Universitaria, Servicio Alergologia Clinica. Grupo de Alergologia Clinica y Experimental. Medellin, Colombia.</style></auth-address><titles><title><style face="normal" font="Arial">[Safety of subcutaneous immunotherapy with tyrosine-adsorbed house dust mite extracts in patients with allergic disease]</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="65" start="52">52-65</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In spite of allergen-specific immunotherapy (SIT) multiple benefits, its use is restricted in some countries owing to concerns about severe adverse reactions. OBJECTIVE: To evaluate systemic adverse reactions in patients with atopic dermatitis, allergic asthma, allergic rhinitis and allergic conjunctivitis who received subcutaneous immunotherapy with tyrosine-adsorbed Dermatophagoides and Glycyphagoides dust mites extracts. METHODS: Retrospective study of the 2010-2015-period that included 773 patients diagnosed with IgE-mediated diseases, where the safety of allergen-specific immunotherapy was described according to the World Organization of Allergy subcutaneous immunotherapy-induced systemic reactions classification system. RESULTS: 79.7 % of patients had rhinitis, 54.9 % asthma, 34.5 % conjunctivitis and 16.4 % atopic dermatitis. Out of 12,546 tyrosine-adsorbed extract doses, 45 systemic reactions were recorded: 12 were grade 1 (30 %), 27 grade 2 (67.5 %) and 1 was grade 3 (2.5 %); the reaction rate was 0.35 per 100 administered injections, for an incidence rate of 5.8 %. No fatal reactions occurred. CONCLUSION: The frequency of systemic reactions with subcutaneous immunotherapy with Dermatophagoides farinae, Dermatophagoides pteronyssinus and Blomia tropicalis tyrosine-adsorbed extracts was similar to that reported with other extracts</style></abstract><notes><style face="normal" font="Arial">DA - 20170211IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188713">PM:28188713</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-52-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-52-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Molina-Saenz MM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baiz,N.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Chastang,J.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Earlier than early exposure to allergenic food and prevention of allergic sensitization in young children</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="402" start="400">400-402</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Grossesse</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Peanut intake</style></keyword><keyword><style face="normal" font="Arial"> Preconception</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Sensibilisation allergique</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.029</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.02.029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170522-BaizN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170522-BaizN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, BaizN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adou,A.H.</style></author><author><style face="normal" font="Arial"> Siransy,L.</style></author><author><style face="normal" font="Arial"> Yeboah,R.</style></author><author><style face="normal" font="Arial"> Kouacou,A.P.</style></author><author><style face="normal" font="Arial"> N'guessan,K.</style></author><author><style face="normal" font="Arial"> Dasse,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergenic sensitivity to coffee and tea in atopic sickle-cell patients</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="363" start="356">356-363</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthme</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic sickle-cell disease</style></keyword><keyword><style face="normal" font="Arial"> Coffee</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food sensitization</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> NSAID</style></keyword><keyword><style face="normal" font="Arial"> NSAIDs</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Rhinite</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sickle cell disease</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Introduction Allergic diseases are a real public health issue. Dass+® et al. estimate that 15% of patients with atopic sickle-cell disease present post-NSAID respiratory manifestations, with 5% being related to NSAIDs and 10% possibly associated with other allergens. In the course of this survey, we sought to investigate the remaining 10% for food sensitization to coffee and tea, which are frequent consumer products in the context of our study. Patients and methods This was a 10-month prospective, descriptive, analytical study. We enrolled 150 patients with atopic sickle-cell disease having no previous history of food allergy to coffee and/or to tea in an allergological survey that included questioning and prick-tests to commercial extracts and to native coffee and tea. Results The average age of our population was 18.53 years. A total of 16.67% of patients presented coffee sensitization and 20% were sensitized to tea. A total of 3.33% of the population were bi-sensitized to both allergens. Fifteen patients presented asthma and 145 had rhinitis. Coffee sensitization was not a factor in the severity of either asthma or rhinitis (odds ratio = 0). However, there was a risk, though low, of sensitization to tea with regard to the severity of rhinitis (odds ratio = 1.3). Conclusion This study revealed high sensitization affecting the course of rhinitis in our population, allowing us to further investigate the general trophallergenic profile</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Ivory Coast -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.148</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.02.148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170522-AdouAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170522-AdouAH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170521, Adou AH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.148</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guilleminault,L.</style></author><author><style face="normal" font="Arial"> Viala-Gastan,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de pneumologie, centre hospitalier regional universitaire Sud Reunion/GHSR, BP 350, 97448 Saint-Pierre cedex, France</style></auth-address><titles><title><style face="normal" font="Arial">Blomia tropicalis: A house dust mite in the tropics</style></title><secondary-title><style face="normal" font="Arial">Rev Mal Respir</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Mal Respir</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="05/27/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Blo t 5</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> South America</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage mite</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Blomia tropicalis is a mite that belongs to the superfamily of Glycyphagidae. Initially described as a storage mite, it is now considered as a house dust mite of tropical and sub-tropical areas. STATE OF THE ART: Sensitization to this mite is very common in South America and Southeast Asia. Epidemiological studies have also found sensitization to this mite in Africa and Central America. Blo t 5 is the major allergen of B. tropicalis. Co-sensitization to other house dust mites such as Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f) is very common. Cross-reactivity has been described but recombinant allergens revealed by molecular biology techniques do not explain this cross-reactivity. Sensitization to B. tropicalis seems to begin at the age of 36 months, the incidence increases until adulthood, and decreases from the age of 50. The involvement of B. tropicalis in allergic rhinitis and asthma is well described. It is also implicated in other allergic diseases. Few studies have assessed the therapeutic strategies available against this mite but immunotherapy is widely used. PERSPECTIVES: Studies are needed to better understand the role of B. tropicalis in human diseases and to develop specific treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1776-2588 (Electronic)IS - 0761-8425 (Linking)LA - frePT - English AbstractPT - Journal ArticlePT - ReviewCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmr.2016.10.877</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502519">PM:28502519</url></web-urls><pdf-urls><url ppv-ref="no">laurent.guilleminault@chu-reunion.fr</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170515, Guilleminault L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmr.2016.10.877</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kong Cardoso,B.</style></author><author><style face="normal" font="Arial"> Semedo,F.</style></author><author><style face="normal" font="Arial"> Tomaz,E.R.</style></author><author><style face="normal" font="Arial"> Pires,A.P.</style></author><author><style face="normal" font="Arial"> Inacio,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Positive prick test to parietaria: What´s the meaning?</style></title><secondary-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></full-title></periodical><pages end="217" start="211">211-217</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> Parietaria pollen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> predictive model</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background: In most cases a positive prick test (PT) to parietaria goes along with positive PT to other pollens. On the other hand, a significant percentage of this patients don´t presenta rPar j2 specific IgE, which is currently considered as a marker to parietaria allergy. Objective: To define predictive criteria for allergy to parietaria pollen in patients with a positive PT to this pollen. Methods: We collected the medical records, PT results and rPar j 2 specific IgE levels of 64 patients with a positive PT to parietaria - wheal with mean diameter equal or larger then 3mm. Using the CHAID algorithm (Qui-squared Automatic Interaction Detection) we were able to create a classification tree of parietaria allergy (considering "true allergy" the positivity of specific IgE to rPar j 2). Results: In our study group, 36 were female and mean age was 25.0±15,0; 70.3% had a positive PT to dust mites, 84.4 % to grass pollen, 84.4% to olive tree pollen and 62.5% to "other pollens" (non grass nor olive tree pollen). Predictive factors identified by the best model were the ratio between mean diameters of histamine and parietaria PT wheals, the patient gender and the result of the PT to "other pollens". Therefore, patients with a PT wheal to parietaria larger than histamine that were female hada rPar j 2 positive in 100% of the cases. In the other hand, a PTwheal to parietaria equal or smaller to histamine followed by a positive PT to "other pollens" were related to a 95.5% probability of negative rPar j 2IgE. The computed tree estimated risks were: re-substitution 0.16 (standard error 0.04) and cross-validation 0.19 (standard error 0.05). Conclusion: Basic allergological patient evaluation allowedto create a predictive model of parietaria pollen allergy with a reasonable performance</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000400003&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2016-24-211-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2016-24-211-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170521, Kong Cardoso B</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smith-Norowitz,T.A.</style></author><author><style face="normal" font="Arial"> Weaver,D.</style></author><author><style face="normal" font="Arial"> Chorny,V.</style></author><author><style face="normal" font="Arial"> Norowitz,Y.M.</style></author><author><style face="normal" font="Arial"> Lent,D.</style></author><author><style face="normal" font="Arial"> Hammerschlag,M.R.</style></author><author><style face="normal" font="Arial"> Joks,R.</style></author><author><style face="normal" font="Arial"> Kohlhoff,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Infectious Diseases, State University of New York Downstate Medical Center, Brooklyn, New York, 11203</style></auth-address><titles><title><style face="normal" font="Arial">Chlamydia pneumoniae induces Interferon gamma responses in peripheral blood mononuclear cells in children with allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Scand J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Scand J Immunol</style></full-title></periodical><pages end="64" start="59">59-64</pages><volume><style face="normal" font="Arial">86</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chlamydia</style></keyword><keyword><style face="normal" font="Arial"> Chlamydia pneumoniae</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="Arial">Respiratory infections caused by Chlamydia pneumoniae have been associated with exacerbations of asthma. Cell mediated immunity (CMI) is critical for maintaining immunity. We compared Interferon (IFN)-gamma responses in C. pneumoniae-infected peripheral blood mononuclear cells (PBMC) in pediatric patients +/- asthma. Presence of C. pneumoniae was tested from asthma patients (N=17) and non-asthmatic controls (N=16) (PCR). PBMC were infected for 1 hr +/- C. pneumoniae AR-39 (MOI = 0.1), and cultured for 48 hrs. IFN-gamma levels were measured in supernatants (ELISA). C. pneumoniae-IgG antibodies in serum were determined (MIF). All subjects tested negative for C. pneumoniae (PCR). C. pneumoniae-induced IFN-gamma production in vitro was more prevalent in asthma compared with non-asthma; levels of IFN-gamma were higher in asthma compared with non-asthma (P= 0.003). There was no association between recent respiratory infection and positive IFN-gamma responses. These data show that C. pneumoniae modulates IFN-gamma responses in patients with asthma, even in absence of active infection. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1365-3083 (Electronic)IS - 0300-9475 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/sji.12561</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28480606">PM:28480606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Scand J Immunol\20170508-SmithNorowitzTA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Scand J Immunol\20170508-SmithNorowitzTA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, Smith Norowitz TA</style></custom2><misc3><style face="normal" font="Arial">10.1111/sji.12561</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jo,C.H.</style></author><author><style face="normal" font="Arial"> Son,J.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Oda,T.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Lee,M.R.</style></author><author><style face="normal" font="Arial"> Sato,M.</style></author><author><style face="normal" font="Arial"> Kim,H.T.</style></author><author><style face="normal" font="Arial"> Unzai,S.</style></author><author><style face="normal" font="Arial"> Park,S.Y.</style></author><author><style face="normal" font="Arial"> Hwang,K.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Biotechnology, College of Life Sciences &amp; Biotechnology, Korea University, Seoul, 136-701, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Structural insights into a 20.8-kDa tegumental-allergen-like (TAL) protein from Clonorchis sinensis</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="1764">1764-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Ca2+-binding</style></keyword><keyword><style face="normal" font="Arial"> Calmodulin</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clonorchiasis</style></keyword><keyword><style face="normal" font="Arial"> Clonorchis sinensis</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics Simulation</style></keyword><keyword><style face="normal" font="Arial"> Molecular dynamics simulations</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Survival of Clonorchis sinensis, a cause of human clonorchiasis, requires tegument proteins, which are localized to the tegumental outer surface membrane. These proteins play an important role in a host response and parasite survival. Thus, these proteins are interesting molecular targets for vaccine and drug development. Here, we have determined two crystal structures of the calmodulin like domain (amino acid [aa] positions 1-81) and dynein light chain (DLC)-like domain (aa 83-177) of a 20.8-kDa tegumental-allergen-like protein from Clonorchis sinensis (CsTAL3). The calmodulin like domain has two Ca2+-binding sites (named CB1 and CB2), but Ca2+ binds to only one site, CB1. The DLC-like domain has a dimeric conformation; the interface is formed mainly by hydrogen bonds between the main chain atoms. In addition, we have determined full-length structure of CsTAL3 in solution and showed the conformational change of CsTAL3 induced by Ca2+ ion binding using small-angle X-ray scattering analysis and molecular dynamics simulations. The Ca2+-bound form has a more extended conformation than the Ca2+-free from does. These structural and biochemical analyses will advance the understanding of the biology of this liver fluke and may contribute to our understanding of the molecular mechanism of calcium-responsive and tegumental-allergen-like proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-02044-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28496122">PM:28496122</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-1764.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-1764.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Jo CH</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-02044-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jiao,D.</style></author><author><style face="normal" font="Arial"> Wong,C.K.</style></author><author><style face="normal" font="Arial"> Tsang,M.S.</style></author><author><style face="normal" font="Arial"> Chu,I.M.</style></author><author><style face="normal" font="Arial"> Liu,D.</style></author><author><style face="normal" font="Arial"> Zhu,J.</style></author><author><style face="normal" font="Arial"> Chu,M.</style></author><author><style face="normal" font="Arial"> Lam,C.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong, China</style></auth-address><titles><title><style face="normal" font="Arial">Activation of Eosinophils Interacting with Bronchial Epithelial Cells by Antimicrobial Peptide LL-37: Implications in Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="1848">1848-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> CD18</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> CXCL8</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> extracellular signal-regulated kinase</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intercellular Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">The role of antimicrobial peptide LL-37 in asthma exacerbation is unclear. Microbial infection, which is the most common inducer of asthma exacerbation, is accompanied by elevated LL-37. The present study found that co-culture of eosinophils and bronchial epithelial cell line BEAS-2B significantly enhanced intercellular adhesion molecule-1 on both cells and CD18 expression on eosinophils upon LL-37 stimulation. IL-6, CXCL8 and CCL4 were substantially released in co-culture in the presence of LL-37. LL-37 triggered the activation of eosinophils interacting with BEAS-2B cells in a P2X purinoceptor 7/epidermal growth factor receptor-dependent manner. Eosinophils and BEAS-2B cells differentially contribute to the expression of cytokines/chemokines in co-culture, while soluble mediators were sufficient to mediate the intercellular interactions. Intracellular p38-mitogen-activated protein kinase, extracellular signal-regulated kinase and NF-kappaB signaling pathways were essential for LL-37-mediated activation of eosinophils and BEAS-2B cells. By using the ovalbumin-induced asthmatic model, intranasal administration of mCRAMP (mouse ortholog of LL-37) in combination with ovalbumin during the allergen challenge stage significantly enhanced airway hyperresponsiveness and airway inflammation in sensitized mice, thereby implicating a deteriorating role of LL-37 in allergic asthma. This study provides evidence of LL-37 in triggering asthma exacerbation via the activation of eosinophils interacting with bronchial epithelial cells in inflammatory airway</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -CO - Macao -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-02085-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28500314">PM:28500314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-1848.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-1848.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Jiao D</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-02085-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chiu,C.Y.</style></author><author><style face="normal" font="Arial"> Chan,Y.L.</style></author><author><style face="normal" font="Arial"> Tsai,Y.S.</style></author><author><style face="normal" font="Arial"> Chen,S.A.</style></author><author><style face="normal" font="Arial"> Wang,C.J.</style></author><author><style face="normal" font="Arial"> Chen,K.F.</style></author><author><style face="normal" font="Arial"> Chung,I.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Chang Gung Memorial Hospital at Keelung, and Chang Gung University, Taoyuan, Taiwan.</style></auth-address><titles><title><style face="normal" font="Arial">Airway Microbial Diversity is Inversely Associated with Mite-Sensitized Rhinitis and Asthma in Early Childhood</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="1820">1820-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> Abundance</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="Arial">Microbiota plays an important role in regulating immune responses associated with atopic diseases. We sought to evaluate relationships among airway microbiota, serum IgE levels, allergic sensitization and their relevance to rhinitis and asthma. Microbial characterization was performed using Illumina-based 16S rRNA gene sequencing of 87 throat swabs collected from children with asthma (n = 32) and rhinitis (n = 23), and from healthy controls (n = 32). Data analysis was performed using QIIME (Quantitative Insights Into Microbial Ecology) v1.8. Significantly higher abundance of Proteobacteria was found in children with rhinitis than in the healthy controls (20.1% vs. 16.1%, P = 0.009). Bacterial species richness (Chao1 index) and diversity (Shannon index) were significantly reduced in children with mite sensitization but not in those with food or IgE sensitization. Compared with healthy children without mite sensitization, the mite-sensitized children with rhinitis and asthma showed significantly lower Chao1 and Shannon indices. Moraxella and Leptotrichia species were significantly found in the interaction of mite sensitization with rhinitis and asthma respectively. Airway microbial diversity appears to be inversely associated with sensitization to house dust mites. A modulation between airway dysbiosis and responses to allergens may potentially cause susceptibility to rhinitis and asthma in early childhood</style></abstract><notes><style face="normal" font="Arial">DA - 20170513IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-02067-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28500319">PM:28500319</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-1820.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-1820.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170513, Chiu CY</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-02067-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fu,L.</style></author><author><style face="normal" font="Arial"> Peng,J.</style></author><author><style face="normal" font="Arial"> Zhao,S.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Su,X.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Safety Key Laboratory of Zhejiang Province, School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, 310018, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Lactic acid bacteria-specific induction of CD4+Foxp3+T cells ameliorates shrimp tropomyosin-induced allergic response in mice via suppression of mTOR signaling</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="1987">1987-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">The beneficial effects of probiotics have been described in allergic sensitization and diseases; however, many questions remain unanswered, such as characteristics of the most effective strains in modulation of allergic responses and how orally administered probiotics affect the systemic immune system. In the present work, oral administration of five lactic acid bacteria strains showed variable effects on protection against the allergic reaction in a mouse model of food allergy to shrimp tropomyosin (ST). The most effective anti-allergic strain, Bacillus coagulans 09.712 (Bc), greatly improved epithelial barrier function and increased lymphocytes proliferation. Moreover, Bc suppresses ST sensitization by altering Th1/Th2/Treg balance as a result of strong induction of CD4+Foxp3+Tregs in combination with IL-10 producing. Bc-specific induction of CD4+Foxp3+ Tregs also suppresses Th17 pro-inflammatory response in this mouse model. Finally, the intake of Bc suppresses mTOR activation and thus the phosphorylation of downstream factors. Inhibition of mTOR signaling by Bc further results in FOXP3 up-regulation and GATA-3 down-regulation, which, in turn, facilitate to control Th2-predominant and Th17 pro-inflammatory responses caused by ST. Our work provides further characterization of the anti-allergic effects of probiotic LAB strains, and identifies new targets for preventive and curative treatment of food allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170517IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-02260-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28512288">PM:28512288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-1987.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-1987.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170517, Fu L</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-02260-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pham,D.L.</style></author><author><style face="normal" font="Arial"> Lim,K.M.</style></author><author><style face="normal" font="Arial"> Joo,K.M.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author><author><style face="normal" font="Arial"> Leung,D.Y.M.</style></author><author><style face="normal" font="Arial"> Ye,Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="1318">1318-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cornea</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Forearm</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Stratum corneum</style></keyword><keyword><style face="normal" font="Arial"> TEWL</style></keyword><keyword><style face="normal" font="Arial"> transepidermal water loss</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="Arial">Increased filaggrin expression was found to be correlated with severity scores in chronic spontaneous urticaria (CSU); however, the role of filaggrin breakdown products (FBPs) in CSU has not been studied. We collected stratum corneum (SC) specimens from the volar forearms of 10 CSU patients, 10 AD patients, and 10 healthy normal controls (NCs) and measured contents of FBPs (pyrrolidone carboxylic acid [PCA] and urocanic acid [UCA]) using UPLC-MS/MS, transepidermal water loss (TEWL) and epidermal pH. Compared to NCs, cis-UCA level was increased in CSU lesions (P &lt; 0.05) and decreased in AD lesions (P &lt; 0.01). The cis-to-trans-UCA ratio in SC specimens from CSU patients was significantly greater than those from AD and NC subjects. AD lesions had lower FBP and PCA contents compared to NC skin (both P &lt; 0.001), and higher TEWL and pH compared to CSU lesions. Moreover, cis-UCA, but not trans-UCA, enhanced the IgE-mediated basophil activation, as well as IgE- and calcium-mediated degranulation of LAD-2 cells, in a dose-dependent manner. These findings suggest that increased cis-to-trans UCA ratio in the epidermis is a distinct feature of CSU, which could enhance mast cell degranulation. Modulation of cis-UCA may be a potential target for skin diseases associated with IgE-mediated mast cell degranulation</style></abstract><notes><style face="normal" font="Arial">DA - 20170503IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-01487-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28465560">PM:28465560</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-1318.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-1318.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170503, Pham DL</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-01487-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ribeiro,H.</style></author><author><style face="normal" font="Arial"> Costa,C.</style></author><author><style face="normal" font="Arial"> Abreu,I.</style></author><author><style face="normal" font="Arial"> Esteves da Silva,J.C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Earth Sciences Institute, Pole of the Faculty of Sciences, University of Porto, R. Campo Alegre 687, 4169-007 Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of O3 and NO2 atmospheric pollutants on Platanus x acerifolia pollen: Immunochemical and spectroscopic analysis</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="297" start="291">291-297</pages><volume><style face="normal" font="Arial">599-600</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> FTIR</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pla a 1</style></keyword><keyword><style face="normal" font="Arial"> Pla a 2</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen wall</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharides</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">In the present study, the effects of two important oxidizing atmospheric pollutants (O3 and NO2) on the allergenic properties and chemical composition of Platanus x acerifolia pollen were studied. Pollen samples were subjected to O3 and/or NO2 under in vitro conditions for 6h at atmospheric concentration levels (O3: 0.061ppm; NO2: 0.025ppm and the mixture of O3 and NO2: 0.060 and 0.031ppm respectively). Immunoblotting (using Pla a 1 and Pla a 2 antibodies), infrared and X-ray photoelectron spectroscopy techniques were used. Immunochemical analysis showed that pollen allergenicity changes were different according to the pollutant tested (gas or mixture of gasses) and that the same pollutant gas may interact in a different manner with each specific allergen. The spectroscopy results showed modifications in the FTIR spectral features of bands assigned to proteins, lipids, and polysaccharides of the pollen exposed to the pollutants, as well as in the XPS spectra high-resolution components C 1s, N 1s, and O 1s. This indicates that while airborne, the pollen wall suffers further modifications of its components induced by air pollution, which can compromise the pollen function</style></abstract><notes><style face="normal" font="Arial">DA - 20170506IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.04.206</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477486">PM:28477486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2017-599_600-291-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2017-599_600-291-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170506, Ribeiro H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.04.206</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McInnes,R.N.</style></author><author><style face="normal" font="Arial"> Hemming,D.</style></author><author><style face="normal" font="Arial"> Burgess,P.</style></author><author><style face="normal" font="Arial"> Lyndsay,D.</style></author><author><style face="normal" font="Arial"> Osborne,N.J.</style></author><author><style face="normal" font="Arial"> Skjoth,C.A.</style></author><author><style face="normal" font="Arial"> Thomas,S.</style></author><author><style face="normal" font="Arial"> Vardoulakis,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Met Office Hadley Centre, FitzRoy Road, Exeter, EX1 3PB, UK</style></auth-address><titles><title><style face="normal" font="Arial">Mapping allergenic pollen vegetation in UK to study environmental exposure and human health</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="499" start="483">483-499</pages><volume><style face="normal" font="Arial">599-600</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Alder</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic taxa</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alnus</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Ash</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Corylus</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Flower</style></keyword><keyword><style face="normal" font="Arial"> Flowers</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Hazel</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plantago</style></keyword><keyword><style face="normal" font="Arial"> Plantain</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen emission model</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Rumex</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urtica</style></keyword><keyword><style face="normal" font="Arial"> Vegetation</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="Arial">Allergenic pollen is produced by the flowers of a number of trees, grasses and weeds found throughout the UK. Exposure to such pollen grains can exacerbate pollen-related asthma and allergenic conditions such as allergic rhinitis (hay fever). Maps showing the location of these allergenic taxa have many applications: they can be used to provide advice on risk assessments; combined with health data to inform research on health impacts such as respiratory hospital admissions; combined with weather data to improve pollen forecasting systems; or as inputs to pollen emission models. In this study we present 1km resolution maps of 12 taxa of trees, grass and weeds found in the UK. We have selected the main species recorded by the UK pollen network. The taxa mapped in this study were: Alnus (alder), Fraxinus (ash), Betula (birch), Corylus (hazel), Quercus (oak), Pinus (pine) and Salix (willow), Poaceae (grass), Artemisia (mugwort), Plantago (plantain), Rumex (dock, sorrels) and Urtica (nettle). We also focus on one high population centre and present maps showing local level detail around the city of London. Our results show the different geographical distributions of the 12 taxa of trees, weeds and grass, which can be used to study plants in the UK associated with allergy and allergic asthma. These maps have been produced in order to study environmental exposure and human health, although there are many possible applications. This novel method not only provides maps of many different plant types, but also at high resolution across regions of the UK, and we uniquely present 12 key plant taxa using a consistent methodology. To consider the impact on human health due to exposure of the pollen grains, it is important to consider the timing of pollen release, and its dispersal, as well as the effect on air quality, which is also discussed here</style></abstract><notes><style face="normal" font="Arial">DA - 20170508IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Gulliver">10.1016/j.scitotenv.2017.04.136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28482306">PM:28482306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2017-599_600-483-99.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2017-599_600-483-99.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170508, McInnes RN</style></custom2><misc3><style face="normal" font="Gulliver">10.1016/j.scitotenv.2017.04.136</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,F.C.</style></author><author><style face="normal" font="Arial"> Chiou,H.J.</style></author><author><style face="normal" font="Arial"> Kuo,C.F.</style></author><author><style face="normal" font="Arial"> Chung,T.T.</style></author><author><style face="normal" font="Arial"> Yu,H.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Epidemiology of Anaphylactic Shock and Its Related Mortality in Hospital Patients in Taiwan: A Nationwide Population-Based Study</style></title><secondary-title><style face="normal" font="Arial">Shock</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Shock</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cause of Death</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Food-induced anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inpatients</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Anaphylactic shock is potentially life-threatening. However, there is a paucity of data about its incidence and associated mortality, particularly in Asian populations. We aimed to investigate the epidemiology of anaphylactic shock and its related mortality after the hospitalization of patients in the general population of Taiwan. The National Health Insurance Research Database was used to identify patients with anaphylactic shock and estimate its incidence for inpatients sampled from 2005 to 2012. The pattern of anaphylactic shock and anaphylactic shock-related mortality rate was also examined. Of 22,080,199 patients who were admitted to hospitals from 2005 to 2012, there were 2289 incident cases of anaphylactic shock and 2219 people were included. Incidence of hospitalizations due to anaphylactic shock ranged from 12.71 to 13.23 per million of the population between 2005 and 2012. The incidence of anaphylactic shock in our study was substantially lower than other western countries, including the United States. There were 24 deaths due to drug-induced anaphylactic shock among the hospitalizations; overall mortality rate was 1.08%. Eighteen (0.81%) patients died within 30 days; 22 (0.99%) died within two months following the anaphylactic shock. The highest incidence occurred in patients aged 70-79 years. Conversely, food-induced anaphylactic shock was not influenced by age. In conclusion, drug-induced anaphylactic shock was a major cause of deaths due to anaphylactic shock in hospitalized patients. Most cases of anaphylactic shock occurred in the older population, and the mortality rate was lower in females than in males, though the difference was not significant</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1540-0514 (Electronic)IS - 1073-2322 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1097/SHK.0000000000000899</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28498295">PM:28498295</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Shock\20170512-LiuFC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Shock\20170512-LiuFC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Liu FC</style></custom2><misc3><style face="normal" font="Arial">10.1097/SHK.0000000000000899</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,D.D.</style></author><author><style face="normal" font="Arial"> Muskaj,I.</style></author><author><style face="normal" font="Arial"> Savage,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="Arial">Platelet proteins cause basophil histamine release through an immunoglobulin-dependent mechanism</style></title><secondary-title><style face="normal" font="Arial">Transfusion</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfusion</style></full-title></periodical><pages end="1716" start="1709">1709-1716</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil histamine release</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mitochondria</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A general understanding of allergic transfusion reaction mechanisms remains elusive. Multiple mechanisms have been proposed, but none have been compared experimentally. STUDY DESIGN AND METHODS: We used histamine release (HR) from healthy human donor basophils to model allergic transfusion reactions. Platelet component supernatant (plasma), platelet lysate, and manipulated platelet lysates (dialyzed, delipidated, trypsinized, mild heat-inactivated, and ultracentrifuged) were used to characterize allergic stimuli. Immunoglobulin-dependent mechanisms were investigated through cell surface immunoglobulin depletion and ibrutinib signaling inhibition. HR induced by platelet mitochondria was compared with HR by platelet lysate with or without DNase treatment. RESULTS: Robust, dose-responsive HR to platelet lysate was observed in two of eight nulliparous, never-transfused, healthy donors. No HR was observed with plasma. Among manipulated platelet lysates, only trypsin treatment significantly reduced HR (39% reduction; p = 0.008). HR in response to platelet lysate significantly decreased with either cell surface immunoglobulin depletion or ibrutinib pretreatment. Platelet mitochondria induced minimal basophil HR, and DNase treatment did not inhibit platelet lysate-induced HR. CONCLUSION: Type I immediate hypersensitivity to platelet proteins may be an allergic transfusion reaction mechanism. Prior sensitization to human proteins is not required for basophil responses to platelet proteins. Further study into the relative contributions of hypersensitivity to platelet versus plasma proteins in transfusion is warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20170504IS - 1537-2995 (Electronic)IS - 0041-1132 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/trf.14126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28470742">PM:28470742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfusion\20170504-LeeDD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfusion\20170504-LeeDD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170504, Lee DD</style></custom2><misc3><style face="normal" font="Arial">10.1111/trf.14126</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zeytun,E.</style></author><author><style face="normal" font="Arial"> Dogan,S.</style></author><author><style face="normal" font="Arial"> Ozcicek,F.</style></author><author><style face="normal" font="Arial"> Unver,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Erzincan University Faculty of Arts and Sciences, Erzincan, Turkey. erhanzeytun24@gmail.com</style></auth-address><titles><title><style face="normal" font="Arial">Sensitivity to House Dust Mites Allergens in Patients with Allergic Asthma in Erzincan Province, Turkey</style></title><secondary-title><style face="normal" font="Arial">Turkiye Parazitol Derg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Turkiye Parazitol Derg</style></full-title></periodical><pages end="41" start="34">34-41</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the sensitivity of allergic asthma (AA) patients to house dust mites (HDM) by conducting skin tests, measuring total and specific IgE antibodies to Dermatophagoides pteronyssinus and D. farinae mites, and examining HDM fauna in patients' homes. METHODS: The study included 25 patients with AA and 31 healthy controls, who were challenged with Der p and Der f allergens; serum levels of allergen-specific lgE and total IgE were measured. Dust samples were collected from the homes of all participants, and mite species and the number of mites per gram of dust were investigated. RESULTS: D. pteronyssinus was found in the homes of 94.7% patients with positive Der p reactions in the skin test (p&lt;0.001). D. farinae was found in the homes of 22.2% patients with positive Der f reactions in the skin test (p>0.05). D. pteronyssinus-specific IgE was detected in 75% patients in whose homes D. pteronyssinus was also found, while D. farinae-specific IgE was detected in 16.6% patients in whose homes D. farinae was also found. CONCLUSION: A part of AA patients residing in Erzincan are sensitive to HDM allergens, and high numbers of mites leading to allergic sensitization are found in their homes</style></abstract><notes><style face="normal" font="Arial">DA - 20170509IS - 2146-3077 (Electronic)IS - 1300-6320 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5152/tpd.2017.5059</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483732">PM:28483732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Turkiye Parazitol Derg\2017-41-34-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Turkiye Parazitol Derg\2017-41-34-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170509, Zeytun E</style></custom2><misc3><style face="normal" font="Arial">10.5152/tpd.2017.5059</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84562</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mrdan,S.</style></author><author><style face="normal" font="Arial"> Ljubojevic,M.</style></author><author><style face="normal" font="Arial"> Orlovic,S.</style></author><author><style face="normal" font="Arial"> Cukanovic,J.</style></author><author><style face="normal" font="Arial"> Dulic,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Poisonous and allergenic plant species in preschool's and primary school's yards in the city of Novi Sad</style></title><secondary-title><style face="normal" font="Arial">Urban Forestry Urban Green</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Urban Forestry Urban Green</style></full-title></periodical><pages end="119" start="112">112-119</pages><volume><style face="normal" font="Arial">25</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Acer</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plant</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plants</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Juniperus</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poisonous plants</style></keyword><keyword><style face="normal" font="Arial"> Populus</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschools</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary schools</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> School-age children</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Taxus</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><isbn><style face="normal" font="Arial">1618-8667</style></isbn><abstract><style face="normal" font="Arial">Presence of the poisonous and allergenic plant species was observed in 8 primary schools and 6 preschools in Novi Sad, Serbia. The aim of this research was to determine the extent to which pre-school and school-age children are exposed to harmful plant species and also to gain insight does the present landscaping take into account the appropriateness in the use of certain ornamental species in arranging preschool's and school's greenery. In the analyzed locations 22 poisonous plant species were noticed, mainly belonging to genera Thuja, Symphoricarpos, Cotoneaster, Juniperus, Berberis and Taxus, represented with 367 specimens. Along with poisonous, 21 allergenic plant species mainly belonging to genera Acer, Tilia, Betula, Populus, Platanus, Celtis, Aesculus, Thuja, Ulmus, Robinia and Quercus, represented with 675 specimens, were determined. The calculated allergenic index grouped most of the investigated species into strongly allergenic (calculated A.I. = 7) due to their prolonged phenantesic period, high abundance and possible cross-reactivity with other species noticed in the greenery. Establishment and enhancement of the collaboration between schools and experts from relevant institutions would result in the removal of the very most allergenic and poisonous landscape plants and ultimately toxic-free and allergy-friendly school yards. Gradual removal might temper the public reluctance to this measurement, but finally only joint efforts and complete abandonment of pointed species can convert unhealthy school yards into ones that are safe and allergy-friendly</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Serbia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ufug.2017.05.007</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ufug.2017.05.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Urban Forestry Urban Green\2017-25-112-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Urban Forestry Urban Green\2017-25-112-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Mrdan S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ufug.2017.05.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Scholz,F.M.</style></author><author><style face="normal" font="Arial"> Burrows,A.K.</style></author><author><style face="normal" font="Arial"> Griffin,C.E.</style></author><author><style face="normal" font="Arial"> Muse,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Animal Dermatology Clinic, Perth Veterinary Specialists, 305 Selby Street North, Osborne Park, WA, 6017, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Determination of threshold concentrations of plant pollens in intradermal testing using fluorescein in clinically healthy nonallergic cats</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="351">351-</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bermuda</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescein</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Intradermal testing</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Tree pollens</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="14" Month="5" Year="2017">2017/5/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Currently the same allergen concentrations for canine intradermal testing (IDT) are recommended for feline IDT. Feline skin reactions are subtle and more difficult to read than canine reactions. This difference may be due to suboptimal allergen concentrations used for IDT in cats. HYPOTHESIS/OBJECTIVES: To determine the irritant threshold concentration (ITC) of 16 pollen allergens using serial dilutions of allergen and intravenous fluorescein. The hypothesis tested was that feline IDT currently is performed at suboptimal allergen concentrations for pollens. ANIMALS: Twenty privately owned healthy clinically nonallergic cats. METHODS: IDT was performed in duplicate using 16 pollen allergens (weeds, grasses and trees) at a dilution of 8000 PNU/mL. Two blinded investigators graded the test reactions independently using subjective and objective criteria. Intravenous fluorescein was then administered and the test reactions were re-evaluated. IDT was repeated for any allergen that was positive, using serial dilutions of allergen at a concentration of 6000 and 4000 PNU/mL. RESULTS: The ITC for 2 of 16 of the allergens was determined. The ITC of Cynodon dactylon (Bermuda grass) and Schinus spp. (Peppercorn) was determined to be between 6000 and 8000 PNU/mL. The ITC of all other allergens tested in this study was >8000 PNU/mL. CONCLUSIONS AND CLINICAL IMPORTANCE: This study confirms that suboptimal allergen concentrations currently are used for feline IDT as the ITC is >8000 PNU/mL for 14 of 16 of the grass, weed and tree pollens evaluated. The ITC of Cynodon dactylon and Schinus spp. was determined to be between 6000 and 8000 PNU/mL</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12320</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28503777">PM:28503777</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170515-ScholzFM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170515-ScholzFM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170515, Scholz FM</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12320</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Lockey,R.F.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Greenberger,P.A.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author><author><style face="normal" font="Arial"> El-Gamal,Y.</style></author><author><style face="normal" font="Arial"> Fineman,S.</style></author><author><style face="normal" font="Arial"> Geller,M.</style></author><author><style face="normal" font="Arial"> Gonzalez-Estrada,A.</style></author><author><style face="normal" font="Arial"> Tanno,L.</style></author><author><style face="normal" font="Arial"> Thong,B.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Department, Centro Medico Docente La Trinidad, Caracas, Venezuela</style></auth-address><titles><title><style face="normal" font="Arial">In-flight allergic emergencies</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="15">15-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air travel</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic emergencies</style></keyword><keyword><style face="normal" font="Arial"> allergic emergency</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Travel</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic and hypersensitivity reactions such as anaphylaxis and asthma exacerbations may occur during air travel. Although the exact incidence of in-flight asthma and allergic emergencies is not known, we have concerns that this subject has not received the attention it warrants. There is a need to provide passengers at risk and airlines with the necessary measures to prevent and manage these emergencies. A review of the epidemiology, management and approaches to prevention of allergic and asthma emergencies during air travel is presented with the goal of increasing awareness about these important, potentially preventable medical events</style></abstract><notes><style face="normal" font="Arial">DA - 20170512IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Venezuela -CO - Spain -CO - Germany -CO - United States -CO - United Kingdom -CO - Japan -CO - Egypt -CO - Brazil -CO - France -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0148-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28496564">PM:28496564</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170512, Sanchez-Borges M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0148-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fang,S.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Zhu,X.</style></author><author><style face="normal" font="Arial"> Yie,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Child Health, Zhengzhou Children's Hospital, Zhengzhou 450053, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Lactobacillus rhamnosus GG improves symptoms and its mechnism in mice with ovalbumin-induced food allergy]</style></title><secondary-title><style face="normal" font="Arial">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</style></full-title></periodical><pages end="600" start="597">597-600</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bacteroides</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Intestines</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus rhamnosus</style></keyword><keyword><style face="normal" font="Arial"> LGG</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Objective To investigate the effect of Lactobacillus rhamnosus GG (LGG) on peripheral blood IL-4/IFN-gamma in mice with ovalbumin-induced food allergy. Methods The mice with food allergy were divided into 3 groups (n=10 in each group): food allergy model group, low-dose LGG group (1x108 CFU/mL, 200 muL/d) and high-dose LGG group (1x109 CFU/mL, 200 muL/d). The healthy mice (n=10) served as a control group. Mice in the LGG groups were given LGG for consecutive 22 days after modeling. The control mice and the food allergy model mice were given normal saline instead of LGG. At day 23, the allergic score, body mass, thymus index, spleen index were recorded and calculated; the expressions of IgE, IL-4 and IFN-gamma in peripheral blood were detected by ELISA; the pathological changes of small intestines were observed by HE staining and fecal flora were examined by bacterial culture. Results The thymus and spleen indexes had no significant differences within the 4 groups. Compared with the control group, IL-4, allergic score, E.coli and bacteroides increased, and IFN-gamma, IFN-gamma/IL-4, IgE, body mass, Bifidobacterium and Lactobacillus decreased in the mice with food allergy. Compared with the mice with food allergy, IL-4, allergic score, E.coli and Bacteroides decreased significantly, and IFN-gamma, IFN-gamma/IL-4, IgE, body mass, Bifidobacterium and Lactobacillus significantly increased in the LGG groups in a dose-dependent manner. In the food allergy model group, some edematous and necrotic epithelial cells were found in intestinal mucosa. Compared with the food allergy model group, the intestinal mucosa was integrated and the intestinal cells appeared ordered in the LGG groups. Conclusion LGG can remarkably improve the symptoms of ovalbumin-induced food allergy probably by decreasing IL-4/IFN-gamma ratio</style></abstract><notes><style face="normal" font="Arial">DA - 20170515IS - 1007-8738 (Print)IS - 1007-8738 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502295">PM:28502295</url></web-urls></urls><custom2><style face="normal" font="Arial">20170515, Fang S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kashiwakura,J.I.</style></author><author><style face="normal" font="Arial"> Ando,T.</style></author><author><style face="normal" font="Arial"> Kawakami,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory for Allergic Disease, RIKEN Center for Integrative Medical Sciences</style></auth-address><titles><title><style face="normal" font="Arial">Role of Histamine-releasing Factor in Allergic Inflammatory Reactions</style></title><secondary-title><style face="normal" font="Arial">Yakugaku Zasshi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yakugaku Zasshi</style></full-title></periodical><pages end="521" start="517">517-521</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FAb</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> glutathione S transferase</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> histamine-releasing factor</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serotonin</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> target cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Mast cells are effector cells in immunoglobulin E (IgE)-mediated immediate hypersensitivity and allergic diseases such as asthma and food allergy. Mast cells are activated by the aggregation of the IgE-bound high-affinity IgE receptor FcepsilonRI with multivalent antigen. Activated mast cells secrete proinflammatory mediators such as histamine, serotonin, and proteases and produce cytokines and chemokines. However, it has been reported that mast cells are activated by crosslinking of FcepsilonRI with monomeric IgE in the absence of antigen. We have recently demonstrated that histamine-releasing factor (HRF) is involved in IgE-mediated mast cell activation both in vitro and in vivo. HRF binds to a subset of IgE and IgG molecules [HRF-reactive antibodies (Abs)]. The Fab, but not Fc, portions of the IgE and IgG molecules are HRF-binding sites, and the N-terminal 19-residue (N19) and H3 portions of HRF are HRF-reactive Ab-binding sites. We observed that both N19 and H3 tagged with glutathione S transferase (GST) (GST-N19 and GST-H3) can inhibit the interaction between HRF and HRF-reactive Abs. Using acute- and late-phase passive cutaneous anaphylaxis mouse models, it was shown that HRF initiates mast cell activation through HRF-reactive, but not HRF-nonreactive, IgE in vivo. Antigen-induced passive cutaneous anaphylaxis was inhibited by pretreatment with GST-N19 and GST-H3. We demonstrated that pretreatment with GST-N19 before antigen challenge inhibited antigen-induced mast cell-dependent airway inflammation. In addition, GST-N19 partially inhibited Aspergillus fumigatus extract-induced IgE-dependent airway inflammation. However, GST-N19 did not inhibit T cell-dependent airway inflammation. These results suggest that mast cells are target cells for HRF to initiate IgE- and mast cell-dependent airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170501IS - 1347-5231 (Electronic)IS - 0031-6903 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1248/yakushi.16-00239-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28458281">PM:28458281</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yakugaku Zasshi\2017-137-517-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yakugaku Zasshi\2017-137-517-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170501, Kashiwakura JI</style></custom2><misc3><style face="normal" font="Arial">10.1248/yakushi.16-00239-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84567</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,X.L.</style></author><author><style face="normal" font="Arial"> Zheng,C.Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, 306th Clinical College of People's Liberation Army, Anhui Medical University, Hefei 230032, China. zcz3066@126.com</style></auth-address><titles><title><style face="normal" font="Arial">[Effects of adipose-derived stem cells and non-methylated CpG-oligodeoxynucleotides on peripheral blood CD4+CD25+ regulatory T cells in young mice with food allergy]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="595" start="590">590-595</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+ Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Jejunum</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the effects of adipose-derived stem cells (ADSC) and non-methylated CpG-oligodeoxynucleotides (CpG-ODN) on the expression of peripheral blood CD4+CD25+ regulatory T (Treg) cells in young mice with food allergy, as well as their immune intervention effects. METHODS: A total of 40 female BALB/c mice were randomly divided into control group, allergic group, ADSC treatment group, and CpG-ODN treatment group, with 10 mice in each group. A mouse model of food allergy was established by intraperitoneal injection and intragastric administration of ovalbumin (OVA) for sensitization and challenge. The mice in the control group were treated with normal saline at the same dose; the mice in the ADSC treatment group were given intraperitoneal injection of ADSC (1x106 cells for each mouse) before and after OVA challenge, and those in the CpG-ODN treatment group were given intraperitoneal injection of non-methylated CpG-ODN solution (40 mug for each mouse) at 1 hour before challenge by gavage. The allergic symptom scores were determined for each group after model establishment. ELISA was used to measure the serum level of OVA-IgE. Flow cytometry was used to measure the percentage of peripheral blood CD4+CD25+ Treg cells. Hematoxylin and eosin staining was used for the pathological analysis of the jejunum. RESULTS: The allergic group had significantly higher allergic symptom scores and serum level of OVA-IgE than the control group (P&lt;0.05). There were no significant differences in the allergic symptom score and the serum level of OVA-IgE between the ADSC treatment group and the CpG-ODN treatment group (P>0.05), but these two groups had significantly lower allergic symptom scores and serum level of OVA-IgE than the allergic group and significantly higher allergic symptom scores and serum level of OVA-IgE than the control group (P&lt;0.01). The allergic group had a significantly lower percentage of peripheral blood CD4+CD25+ Treg cells than the control group (P&lt;0.05). The ADSC treatment group and the CpG-ODN treatment group had a significantly higher percentage of peripheral blood CD4+CD25+ Treg cells than the allergic group (P&lt;0.05); there were no significant differences between these two groups or between them and the control group (P>0.05). Pathological results showed structural damage and edema in the jejunal villi, a large number of eosinophils, and lymphocyte infiltration in the allergic group, while the ADSC treatment group and the CpG-ODN treatment group had less structural damage and edema in the jejunal villi, a lower number of eosinophils, and less lymphocyte infiltration. CONCLUSIONS: ADSC and non-methylated CpG-ODN have a certain effect in the treatment of food allergy and can increase the percentage of peripheral blood CD4+CD25+ Treg cells and reduce the level of OVA-IgE. They may be associated with the induction of immune tolerance and these two treatment have comparable effects. Detailed mechanisms of action still need further investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20170516IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2017.05.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506355">PM:28506355</url></web-urls></urls><custom2><style face="normal" font="Arial">20170516, Chen XL</style></custom2><misc3><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2017.05.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Costa,C.</style></author><author><style face="normal" font="Arial"> Goncalo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servico de Imunoalergologia. Hospital de Santa Maria. Centro Hospitalar Lisboa Norte. Lisboa. Portugal.; Clinica Universitaria de Imunoalergologia. Faculdade de Medicina. Universidade de Lisboa. Lisboa. PortugalServico de Dermatologia. Centro Hospitalar e Universitario de Coimbra. Coimbra. Portugal. Clinica de Dermatologia. Faculdade de Medicina. Universidade de Coimbra</style></auth-address><titles><title><style face="normal" font="Arial">[Letter to the Editor. Urticaria in the Emergency Room: Recommendations for Diagnostic and Therapeutic Approach]</style></title><secondary-title><style face="normal" font="Arial">Acta Med Port</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Med Port</style></full-title></periodical><pages end="349" start="347">347-349</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1646-0758 (Electronic)IS - 0870-399X (Linking)LA - porPT - LetterPT - CommentCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.20344/amp.8597</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28555564">PM:28555564</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Med Port\2017-30-347-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Med Port\2017-30-347-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Costa C</style></custom2><misc3><style face="normal" font="Arial">10.20344/amp.8597</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lesonen,A.S.</style></author><author><style face="normal" font="Arial"> Vinogradova,I.A.</style></author><author><style face="normal" font="Arial"> Loskutova,E.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Petrozavodsk State University, Petrozavodsk, 185910, Russian Federation; kuzmanna@mail.ru</style></auth-address><titles><title><style face="normal" font="Arial">The presence of anti-allergic antihistamines for consumers in older age groups</style></title><secondary-title><style face="normal" font="Arial">Adv Gerontol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Adv Gerontol</style></abbr-1></periodical><pages end="142" start="138">138-142</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The work investigated the availability of the antihistamines for consumers aged 45 years and older. The main factors reducing accessibility: self-healing, low frequency of references to the doctor if you have allergic reactions, failure to comply with medical appointments, low level of awareness about the use and side effects</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1561-9125 (Print)IS - 1561-9125 (Linking)LA - rusPT - English AbstractPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28557404">PM:28557404</url></web-urls><pdf-urls><url ppv-ref="no">kuzmanna@mail.ru</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170530, Lesonen AS</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gibbons,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Localized Heat Urticaria from 95-GHz Millimeter Waves</style></title><secondary-title><style face="normal" font="Arial">Aerosp Med Hum Perform</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Aerosp Med Hum Perform</style></full-title></periodical><pages end="588" start="586">586-588</pages><volume><style face="normal" font="Arial">88</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> physical urticaria</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin Temperature</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Local heat urticaria is a physical urticaria caused by the environmental stimulus of heat. Typically, the resultant lesion, a wheal, is pruritic (itches) and is sometimes accompanied by a burning sensation. It is a self-limited phenomenon that resolves after 1.5-2 h. The prevalence of local heat urticaria in the general population has been estimated as 1 in 200,000 persons. CASE REPORT: The subject, a 39-yr-old active duty man, participated in a test of a 95-GHz energy beam designed to heat the skin. He had delayed presentation of raised, erythematous, nonpruritic, nonpainful areas at five of the exposure sites where the skin temperature exceeded 54 degrees C. All wheals resolved within 2 h of the exposures.Gibbons JA. Localized heat urticaria from 95-GHz millimeter waves. Aerosp Med Hum Perform. 2017; 88(6):586-588</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 2375-6314 (Print)IS - 2375-6314 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3357/AMHP.4707.2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28539148">PM:28539148</url></web-urls></urls><custom2><style face="normal" font="Arial">20170525, Gibbons JA</style></custom2><misc3><style face="normal" font="Arial">10.3357/AMHP.4707.2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tammaro,A.</style></author><author><style face="normal" font="Arial"> Romano,I.</style></author><author><style face="normal" font="Arial"> Persechino,F.</style></author><author><style face="normal" font="Arial"> Parisella,F.R.</style></author><author><style face="normal" font="Arial"> Trimarchi,I.</style></author><author><style face="normal" font="Arial"> Persechino,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Unit*, NESMOS Department, S. Andrea Hospital, University of Rome "Sapienza", Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Plasticity of immune system vs. memory therapy IST</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="486" start="482">482-486</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pharmacotherapy and immunotherapy are the main treatments for allergic diseases to inhalants. OBJECTIVE: This study investigates whether to repeat short cycles of immunotherapy after 3 or 5 years the from interruption of the first therapeutic cycle, lasting 3-4 years, to maintain immune memory in individuals subjected to IST. METHODS AND RESULTS: We have compared two groups, one of 452 patients who, after the first treatment for 3-4 years of IST, performed a cycle of four months after three and 10 years from the suspension, and a second group of 126 individuals who have performed only the IST treatment for 3-4 years. The best results were obtained in the first group. CONCLUSIONS: These results are due to the immune system's plasticity, a very important concept in clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20170527IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.01.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28549766">PM:28549766</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170527-TammaroA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170527-TammaroA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170527, Tammaro A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.01.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turk,M.</style></author><author><style face="normal" font="Arial"> Yilmaz,I.</style></author><author><style face="normal" font="Arial"> Bahcecioglu,S.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Retreatment</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous data have shown the high efficacy of omalizumab in chronic spontaneous urticaria (CSU). However, factors that may be effective on the response to therapy, relapse rates after drug discontinuation, and efficacy of retreatment remain unclear. This study aimed to determine the efficacy of omalizumab in CSU refractory to conventional therapy, to identify possible factors affecting treatment response and relapse, and also to evaluate the efficacy of retreatment on relapsed disease. METHODS: The data of CSU patients treated with 300 mg/month omalizumab for at least 3 months were retrospectively analyzed. In order to evaluate the efficacy of treatment and retreatment, baseline and follow-up concomitant medication score (CMS) and urticaria activity score (UAS) were calculated. Possible factors affecting treatment response and relapse were identified. RESULTS: Twenty-five patients were included. The median duration of omalizumab therapy was 6 (6-12) months. Of the patients with baseline UAS 6 (5.5-6) and CMS 13 (10-15), 8 (32%) had complete response (UAS = 0) and 2 (8%) were non-responders after 3 months of therapy. None of the complete responders were positive for IgG-anti-TPO. After discontinuation of omalizumab therapy, 11 (61%) patients experienced relapse and 10 of them received retreatment with omalizumab. Half of the patients had complete response, and half had partial response (UAS = 1-4) after retreatment. No treatment related adverse events were documented. CONCLUSIONS: Omalizumab has high efficacy in both the treatment and retreatment of CSU; however, relapse rates after discontinuation are high. Autoimmune markers may be helpful in predicting treatment response and relapse</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.05.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28566225">PM:28566225</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170601-TurkM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170601-TurkM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Turk M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.05.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gon,Y.</style></author><author><style face="normal" font="Arial"> Shikano,S.</style></author><author><style face="normal" font="Arial"> Maruoka,S.</style></author><author><style face="normal" font="Arial"> Mizumura,K.</style></author><author><style face="normal" font="Arial"> Kozu,Y.</style></author><author><style face="normal" font="Arial"> Kuroda,K.</style></author><author><style face="normal" font="Arial"> Tsuboi,E.</style></author><author><style face="normal" font="Arial"> Takeshita,I.</style></author><author><style face="normal" font="Arial"> Kishi,H.</style></author><author><style face="normal" font="Arial"> Nomura,Y.</style></author><author><style face="normal" font="Arial"> Oshima,T.</style></author><author><style face="normal" font="Arial"> Hashimoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">CpG oligodeoxynucleotides enhance airway epithelial barrier integrity</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="S49" start="S47">S47-S49</pages><volume><style face="normal" font="Arial">66S</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.05.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550967">PM:28550967</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170528-GonY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170528-GonY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Gon Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.05.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ito,T.</style></author><author><style face="normal" font="Arial"> Hirose,K.</style></author><author><style face="normal" font="Arial"> Norimoto,A.</style></author><author><style face="normal" font="Arial"> Saku,A.</style></author><author><style face="normal" font="Arial"> Nakajima,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Dectin-1 plays a critical role in HDM-induced PGE2 production in macrophages</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="S46" start="S44">S44-S46</pages><volume><style face="normal" font="Arial">66S</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> PGE2</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="5" Year="2017">2017/5/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.05.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532701">PM:28532701</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170523-ItoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170523-ItoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Ito T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oguma,T.</style></author><author><style face="normal" font="Arial"> Taniguchi,M.</style></author><author><style face="normal" font="Arial"> Shimoda,T.</style></author><author><style face="normal" font="Arial"> Kamei,K.</style></author><author><style face="normal" font="Arial"> Matsuse,H.</style></author><author><style face="normal" font="Arial"> Hebisawa,A.</style></author><author><style face="normal" font="Arial"> Takayanagi,N.</style></author><author><style face="normal" font="Arial"> Konno,S.</style></author><author><style face="normal" font="Arial"> Fukunaga,K.</style></author><author><style face="normal" font="Arial"> Harada,K.</style></author><author><style face="normal" font="Arial"> Tanaka,J.</style></author><author><style face="normal" font="Arial"> Tomomatsu,K.</style></author><author><style face="normal" font="Arial"> Asano,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Schizophyllum</style></keyword><keyword><style face="normal" font="Arial"> Schizophyllum commune</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is an allergic pulmonary disease characterized by a hypersensitivity reaction to Aspergillus species colonizing the airways. The clinical characteristics of ABPA may differ depending on genetic and environmental background. We performed a nationwide survey to determine the clinical characteristics of ABPA in Japan. METHODS: In 2013, a questionnaire on physician-diagnosed ABPA/allergic bronchopulmonary mycosis was sent to 903 medical centers specializing in respiratory or allergic diseases. Cases fulfilling the following criteria were categorized as possible ABPA-central bronchiectasis (ABPA-CB): 1) presence of specific serum immunoglobulin E (IgE) antibodies or a positive skin reaction to Aspergillus, and 2) bronchiectasis or mucoid impaction in the central bronchi. RESULTS: Of 499 physician-diagnosed cases reported by 132 clinical centers, 358 cases met the criteria for possible ABPA-CB. Median age of ABPA-CB onset was 57 (interquartile range, 44-68) years; later-onset disease, developing >/=50 years of age, accounted for 66% of the cases and was associated with female sex, delayed onset of asthma, and lower levels of serum IgE. A third of the patients (120 patients, 34%) exhibited low levels of serum total IgE (&lt;1000 IU/mL). Aspergillus species were isolated from sputum in 126/213 cases (59%), and Schizophyllum commune was identified in 12 (6%) patients. During the course of the treatment, ABPA recurred in 169 (48%) cases. CONCLUSIONS: This nationwide survey identified several unique clinical characteristics of ABPA in Japan, such as late-onset, relatively lower serum IgE levels, and frequent recurrences/flares</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.04.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28546015">PM:28546015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170526-OgumaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170526-OgumaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Oguma T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.04.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nair,P.M.</style></author><author><style face="normal" font="Arial"> Starkey,M.R.</style></author><author><style face="normal" font="Arial"> Haw,T.J.</style></author><author><style face="normal" font="Arial"> Liu,G.</style></author><author><style face="normal" font="Arial"> Horvat,J.C.</style></author><author><style face="normal" font="Arial"> Morris,J.C.</style></author><author><style face="normal" font="Arial"> Verrills,N.M.</style></author><author><style face="normal" font="Arial"> Clark,A.R.</style></author><author><style face="normal" font="Arial"> Ammit,A.J.</style></author><author><style face="normal" font="Arial"> Hansbro,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Priority Research Centres for Healthy Lungs, Grow up Well and Cancer Research, Innovation and Translation, University of Newcastle &amp; Hunter Medical Research Institute, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ubiquitin</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is an allergic airway disease (AAD) caused by aberrant immune responses to allergens. Protein phosphatase-2A (PP2A) is an abundant serine/threonine phosphatase with anti-inflammatory activity. The ubiquitin proteasome system (UPS) controls many cellular processes, including the initiation of inflammatory responses by protein degradation. We assessed if enhancing PP2A activity with Fingolimod (FTY720) or 2-amino-4-(4-(heptyloxy) phenyl)-2-methylbutan-1-ol (AAL(S) ), or inhibiting proteasome activity with Bortezomib (BORT) could suppress experimental AAD. METHODS: Acute AAD was induced in C57BL/6 mice by intraperitoneal sensitisation with ovalbumin (OVA) in combination with intranasal (i.n) exposure to OVA. Chronic AAD was induced in mice with prolonged i.n exposure to crude house dust mite (HDM) extract. Mice were treated with vehicle, FTY720, AAL(S) , BORT or AAL(S) +BORT and hallmark features of AAD assessed. RESULTS: AAL(S) reduced the severity of acute AAD by suppressing tissue eosinophils and inflammation, mucus secreting cell (MSC) numbers, type-2 associated cytokines (Interleukin (IL)-33, thymic stromal lymphopoietin, IL-5 and IL-13), serum immunoglobulin (Ig)E, and airway hyper-responsiveness (AHR). FTY720 only suppressed tissue inflammation and IgE. BORT reduced bronchoalveolar lavage fluid (BALF) and tissue eosinophils and inflammation, IL-5, IL-13, and AHR. Combined treatment with AAL(S) +BORT had complementary effects and suppressed BALF and tissue eosinophils and inflammation, MSC numbers, reduced the production of type-2 cytokines and AHR. AAL(S) , BORT and AAL(S) +BORT also reduced airway remodelling in chronic AAD. CONCLUSION: These findings highlight the potential of combination therapies that enhance PP2A and inhibit proteasome activity as novel therapeutic strategies for asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13212</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543283">PM:28543283</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170525-NairPM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170525-NairPM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Nair PM</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13212</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rigbi,N.E.</style></author><author><style face="normal" font="Arial"> Goldberg,M.R.</style></author><author><style face="normal" font="Arial"> Levy,M.B.</style></author><author><style face="normal" font="Arial"> Nachshon,L.</style></author><author><style face="normal" font="Arial"> Golobov,K.</style></author><author><style face="normal" font="Arial"> Elizur,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Assaf Harofeh Medical Center, Zerifin, Sackler School of Medicine, Tel Aviv University, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Changes in patient quality of life during oral immunotherapy for food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Quality of life is (QOL) impaired in patients with food allergy and improves following oral immunotherapy (OIT). However, the treatment itself is prolonged and demanding. We examined changes in patient QOL during OIT for food allergy. METHODS: The FAQLQ-PF was administered to children aged 4-12 years undergoing OIT for milk, peanut or egg allergy, at the beginning and after 4 months of treatment. Patients were categorized as improved, unchanged, or diminished FAQLQ-PF (>0.5 point decrease, a change of &lt;/=0.5 points, or >0.5 increase, respectively) and compared. Food-allergic patients not undergoing OIT served as controls. RESULTS: The Food Anxiety, Social and Dietary limitation and total FAQLQ-PF scores improved significantly during the study period (p=0.001, p=0.018 and p=0.01, respectively) in treated but not in control patients, while the Emotional Impact did not. The change in the FAQLQ-PF was independent of the maximal tolerated dose at baseline or following four months of treatment, the pace of dose-increase or of number or severity of reactions experienced. The total FAQLQ-PF score was inversely associated with the score at baseline on multi-variate analysis (regression coefficient = -0.56, p&lt;0.001). That was driven primarily by improvement in QOL scores in patients with high score (worse QOL) at baseline. Some patients with low FAQLQ-PF score (better QOL) at baseline, deteriorated. CONCLUSIONS: QOL of patients with food allergy improves in some but deteriorates in others during OIT. Patients with impaired QOL at baseline, improve significantly despite the treatment-burden. Some patients with better QOL at baseline, might deteriorate during OIT. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13211</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28542911">PM:28542911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170525-RigbiNE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170525-RigbiNE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Rigbi NE</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13211</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maurer,M.</style></author><author><style face="normal" font="Arial"> Abuzakouk,M.</style></author><author><style face="normal" font="Arial"> Berard,F.</style></author><author><style face="normal" font="Arial"> Canonica,W.</style></author><author><style face="normal" font="Arial"> Oude Elberink,H.</style></author><author><style face="normal" font="Arial"> Gimenez-Arnau,A.</style></author><author><style face="normal" font="Arial"> Grattan,C.</style></author><author><style face="normal" font="Arial"> Hollis,K.</style></author><author><style face="normal" font="Arial"> Knulst,A.</style></author><author><style face="normal" font="Arial"> Lacour,J.P.</style></author><author><style face="normal" font="Arial"> Lynde,C.</style></author><author><style face="normal" font="Arial"> Marsland,A.</style></author><author><style face="normal" font="Arial"> McBride,D.</style></author><author><style face="normal" font="Arial"> Nakonechna,A.</style></author><author><style face="normal" font="Arial"> Ortiz de Frutos,J.</style></author><author><style face="normal" font="Arial"> Proctor,C.</style></author><author><style face="normal" font="Arial"> Sussman,G.</style></author><author><style face="normal" font="Arial"> Sweeney,C.</style></author><author><style face="normal" font="Arial"> Tian,H.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author><author><style face="normal" font="Arial"> Wolin,D.</style></author><author><style face="normal" font="Arial"> Balp,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Charite - Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">The Burden of Chronic Spontaneous Urticaria Is Substantial: Real-World Evidence From ASSURE-CSU</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Difficult-to-treat</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Arab Emirates</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat, and frustrating for patients and physicians. Real-world evidence for the burden of CSU is limited. The objective of this study was to document disease duration, treatment history, and disease activity, as well as impact on health-related quality of life (HRQoL) and work among patients with inadequately controlled CSU, and to describe its humanistic, societal, and economic burden. METHODS: This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for >/=12 months despite treatment. Demographics, disease characteristics, and health care resources in the previous 12 months were collected from medical records. Patient-reported data on urticaria and angioedema symptoms, HRQoL, and work productivity and activity impairment were collected from a survey and a diary. RESULTS: Almost 50% of patients had moderate-to-severe disease activity as reported by Urticaria Activity Score. Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively. CSU markedly interfered with sleep and daily activities. Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL. More than 20% of patients reported >/=1 hour per week of missed work; productivity impairment was 27%. These effects increased with greater disease activity. Significant health care resources and costs were incurred to treat CSU. CONCLUSIONS: CSU has considerable humanistic and economic impacts. Patients with greater disease activity and with angioedema experience greater HRQoL impairments. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United Arab Emirates -CO - France -CO - Italy -CO - Netherlands -CO - Spain -CO - United Kingdom -CO - France -CO - Canada -CO - United States -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13209</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543019">PM:28543019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170525-MaurerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170525-MaurerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Maurer M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13209</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhami,S.</style></author><author><style face="normal" font="Arial"> Kakourou,A.</style></author><author><style face="normal" font="Arial"> Asamoah,F.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Marek,J.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Bonini,M.</style></author><author><style face="normal" font="Arial"> Cavkaytar,O.</style></author><author><style face="normal" font="Arial"> Flood,B.</style></author><author><style face="normal" font="Arial"> Gajdanowicz,P.</style></author><author><style face="normal" font="Arial"> Izuhara,K.</style></author><author><style face="normal" font="Arial"> Kalayci,O.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Palomares,O.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Smolinska,S.</style></author><author><style face="normal" font="Arial"> Sokolowska,M.</style></author><author><style face="normal" font="Arial"> Asaria,M.</style></author><author><style face="normal" font="Arial"> Netuveli,G.</style></author><author><style face="normal" font="Arial"> Zaman,H.</style></author><author><style face="normal" font="Arial"> Akhlaq,A.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Evidence-Based Health Care Ltd, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: To inform the development of the European Academy of Allergy and Clinical Immunonology's (EAACI) Guidelines on Allergen Immunotherapy (AIT) for allergic asthma, we assessed the evidence on the effectiveness, cost-effectiveness and safety of AIT. METHODS: We performed a systematic review, which involved searching nine databases. Studies were screened against pre-defined eligibility criteria and critically appraised using established instruments. Data were synthesized using random-effects meta-analyses. RESULTS: 98 studies satisfied the inclusion criteria. Short-term symptom scores were reduced with a standardized mean difference (SMD) of -1.11 (95%CI -1.66, -0.56). This was robust to a pre-specified sensitivity analyses, but there was evidence suggestive of publication bias. Short-term medication scores were reduced SMD -1.21 (95%CI -1.87, -0.54), again with evidence of potential publication bias. There was no reduction in short-term combined medication and symptom scores SMD 0.17 (95%CI -0.23, 0.58), but one study showed a beneficial long-term effect. For secondary outcomes subcutaneous immunotherapy (SCIT) improved quality of life and decreased allergen specific airways hyperreactivity (AHR) but this was not the case for sub-lingual immunotherapy (SLIT). There were no consistent effects on asthma control, exacerbations, lung function, and non-specific AHR. AIT resulted in a modest increased risk of adverse events (AEs). Although relatively uncommon, systemic AEs were more frequent with SCIT; however no fatalities were reported. The limited evidence on cost-effectiveness was mainly available for sublingual immunotherapy (SLIT) and this suggested that SLIT is likely to be cost-effective. CONCLUSIONS: AIT can achieve substantial reductions in short-term symptom and medication scores in allergic asthma. It was however associated with a modest increased risk of systemic and local AEs. More data are needed in relation to secondary outcomes, longer-term effectiveness and cost-effectiveness. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - Greece -CO - Romania -CO - Germany -CO - Poland -CO - Italy -CO - Switzerland -CO - Turkey -CO - Japan -CO - Spain -CO - Pakistan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543086">PM:28543086</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170525-DhamiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170525-DhamiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Dhami S</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13208</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84580</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oropeza,A.R.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Broesby-Olsen,S.</style></author><author><style face="normal" font="Arial"> Kristensen,T.</style></author><author><style face="normal" font="Arial"> Moller,M.B.</style></author><author><style face="normal" font="Arial"> Vestergaard,H.</style></author><author><style face="normal" font="Arial"> Kjaer,H.F.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Lassen,A.</style></author><author><style face="normal" font="Arial"> Mortz,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Patterns of anaphylaxis after diagnostic work-up: a follow-up study of 226 patients with suspected anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Co-factors</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Most published studies on anaphylaxis are retrospective or register based. Data on subsequent diagnostic work-up are sparse. We aimed to characterize patients seen with suspected anaphylaxis at the emergency care setting (ECS), after subsequent diagnostic work-up at our Allergy Center (AC). METHODS: Prospective study including patients from the ECS, Odense University Hospital, during May 2013-April 2014. Possible anaphylaxis cases were daily identified based on a broad search profile including history and symptoms in patient records, diagnostic codes and pharmacological treatments. At the AC, all patients were evaluated according to international guidelines. RESULTS: Among 226 patients with suspected anaphylaxis, the diagnosis was confirmed in 124 (54.9%) after diagnostic work-up; 118 of the 124 fulfilled WAO/EAACI criteria of anaphylaxis at the ECS, while 6 were found among 46 patient with clinical suspicion but not fulfilling the WAO/EAACI criteria at the ECS. The estimated incidence rate of anaphylaxis was 26 cases per 100,000 person years and the one year period prevalence was 0.04%. The most common elicitor was drugs (41.1%) followed by venom (27.4%) and food (20.6%). In 13 patients (10.5%) no elicitor could be identified. Mastocytosis was diagnosed in 7.7% of adult patients and was significantly associated with severe anaphylaxis. Atopic diseases were significantly associated only with food-induced anaphylaxis. Co-factors were present in 58.1% and were significantly associated with severe anaphylaxis. CONCLUSION: A broad search profile in the ECS and subsequent diagnostic work-up is important for identification and classification of patients with anaphylaxis. Evaluation of co-morbidities and co-factors are important. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13207</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543193">PM:28543193</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170525-OropezaAR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170525-OropezaAR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Oropeza AR</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13207</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Mozo,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Botany, Ecology and Plant Physiology, University of Cordoba, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Poaceae pollen as the leading aeroallergen worldwide: a review</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> pan-allergen</style></keyword><keyword><style face="normal" font="Arial"> Pan-allergens</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant phenology</style></keyword><keyword><style face="normal" font="Arial"> Plant Physiology</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Subfamily</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">The Poaceae family comprises over 12,000 wind-pollinated species which release large amounts of pollen into the atmosphere. Poaceae pollen is currently regarded as the leading airborne biological pollutant and the chief cause of pollen-allergy worldwide. Sensitization rates vary by country, and those variations are reviewed here. Grass pollen allergens are grouped according to their protein structure and function. In Poaceae, although species belonging to different sub-families are characterized by distinct allergen subsets, there is a considerable degree of cross-reactivity between many species. Cross-reactivity between grass-pollen protein and fresh fruit pan-allergens is associated with the appearance of food allergies. The additional influence of urban pollution may prompt a more severe immunological response. The timing and the intensity of the pollen season is governed by species genetics, but plant phenology is also influenced by climate; as a result, climate changes may affect airborne pollen concentrations. This paper reviews the findings of worldwide research which has highlighted the major impact of climate change on plant phenology and also on the prevalence and severity of allergic disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13210</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543717">PM:28543717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170525-GarciaMozoH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170525-GarciaMozoH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Garcia-Mozo H</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13210</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tschannen,M.P.</style></author><author><style face="normal" font="Arial"> Gluck,U.</style></author><author><style face="normal" font="Arial"> Bircher,A.J.</style></author><author><style face="normal" font="Arial"> Heijnen,I.</style></author><author><style face="normal" font="Arial"> Pletscher,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Suva (Swiss National Accident Insurance Fund), Division of Occupational Medicine, Lucerne, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Thaumatin and gum arabic allergy in chewing gum factory workers</style></title><secondary-title><style face="normal" font="Arial">Am J Ind Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Ind Med</style></full-title></periodical><pages end="669" start="664">664-669</pages><volume><style face="normal" font="Arial">60</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Gum Arabic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> thaumatin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">Thaumatin is a sweetener and flavor modifier commonly used in the food industry. Likewise, gum arabic is widely used as a food stabilizer and thickening agent. We report here that a powder mixture composed of 10% thaumatin and 90% gum arabic led to allergic symptoms in the upper airways in occupationally exposed individuals: four of eight workers of a chewing gum factory exposed to this powder mixture had pronounced rhinitis. A positive skin prick test result for pure thaumatin was obtained in all four individuals with rhinitis of whom two also had a positive skin prick test result for pure gum arabic and gum arabic-specific IgE. Subsitution of a powdered thaumatin with a liquid form reduced symptoms among the rhinitic workers. Although gum arabic is a well-known potential allergen, we were unable to find prior documentation of allergic symptoms to thaumatin when it is used in the food industry</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1097-0274 (Electronic)IS - 0271-3586 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1002/ajim.22729</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543634">PM:28543634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Ind Med\20170525-TschannenMP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Ind Med\20170525-TschannenMP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Tschannen MP</style></custom2><misc3><style face="normal" font="Arial">10.1002/ajim.22729</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ma,L.</style></author><author><style face="normal" font="Arial"> Xiao,X.</style></author><author><style face="normal" font="Arial"> Ma,Y.</style></author><author><style face="normal" font="Arial"> Wu,H.</style></author><author><style face="normal" font="Arial"> Qiu,S.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The State Key Laboratory of Respiratory Disease for Allergy at Shengzhen University, School of Medicine, Shenzhen UniversityShenzhen 518116, China</style></auth-address><titles><title><style face="normal" font="Arial">Effect of activation of Toll-like receptor 7 in the inhibition of allergic asthma on a mouse model</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="2152" start="2143">2143-2152</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Targeting Toll-like receptor 7 (TLR7) is known to have a potential therapeutic effect on experimental allergic asthma, but the exact mechanism is incompletely understood. To investigate the potential therapeutic effect of TLR7 agonist (TLR7a) a new versatile TLR7 agonist conjugated to Der f 1 was synthesized and evaluated in vivo here. It was confirmed that the course of airway hyperresponsiveness (AHR) and eosinophilia of the TLR7a vaccine-treated mice were limited. Levels of specific IgG1, IgG2a and IgE antibodies of these mice were changed obviously compared with that of the model mice. The expression of T helper 2 cytokine, interleukin (IL)-4, production in bronchoalveolar lavage fluid (BALF) and splenocytes were significantly decreased, while the levels of IFN-gamma, IL-12 and IL-10 were increased after the treatment of TLR7a vaccine. In addition, Muc5 expression and goblet cells were significantly decreased in the lung tissue of asthma model mice treated with TLR7a plus Der f 1. These results suggest that the TLR7a-Der f 1 vaccine exhibits interesting therapeutic potency in suppressing allergic asthma and could be used a new agent in the treatment of allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170531LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28559967">PM:28559967</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2017-9-2143-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2017-9-2143-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Ma L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84584</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dai,R.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Cai,S.</style></author><author><style face="normal" font="Arial"> Zheng,C.</style></author><author><style face="normal" font="Arial"> Zhou,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Shanghai General Hospital, Shanghai Jiaotong UniversityShanghai 200080, China</style></auth-address><titles><title><style face="normal" font="Arial">Delivery of adipose-derived mesenchymal stem cells attenuates airway responsiveness and inflammation in a mouse model of ovalbumin-induced asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="2428" start="2421">2421-2428</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Adipose-derived mesenchymal stem cells (ADMSCs) possess immunomodulation property, yet their therapeutic potential in asthma is unclear. This study aimed to explore the effects of ADMSCs on airway hyperresponsiveness and inflammation in ovalbumin (OVA)-induced asthma models. The underlying mechanism(s) was also examined. BALB/c mice were sensitized with OVA on days 0, 7, and 14, followed by 8-week OVA challenge from day 22. ADMSCs were injected via tail vein on day 21. Animals were measured for airway responsiveness, lung pathology, IgE and cytokine levels in serum, cell composition in bronchoalveolar lavage fluid (BALF), gene expression in the lung, and regulatory T cells (Tregs). We found that delivery of ADMSCs decreased airway responsiveness and eosinophil counts in BALF and reduced infiltration of inflammatory cells and number of mucus-expressing goblet cells in the lung in OVA-challenged mice. OVA-evoked elevation of serum IgE levels and alteration of cytokine production in serum and BALF was significantly prevented by ADMSCs. In addition, administration of ADMSCs impaired the regulation of lung IL-10, Foxp3, IL-17, and RORgamma expression by OVA challenge and restored the percentage of CD4+CD25+Foxp3+ Tregs in the spleen. In conclusion, ADMSCs confer protection against OVA-induced airway hyperresponsiveness and inflammation, which is associated with induction of Tregs and restoration of immune homeostasis. These findings suggest that ADMSCs may have therapeutic implications for allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170531LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28559992">PM:28559992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2017-9-2421-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2017-9-2421-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Dai R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pollard,S.L.</style></author><author><style face="normal" font="Arial"> Lima,J.J.</style></author><author><style face="normal" font="Arial"> Mougey,E.</style></author><author><style face="normal" font="Arial"> Romero,K.</style></author><author><style face="normal" font="Arial"> Tarazona-Meza,C.</style></author><author><style face="normal" font="Arial"> Tomaino,K.</style></author><author><style face="normal" font="Arial"> Guzman,G.M.</style></author><author><style face="normal" font="Arial"> Hansel,N.N.</style></author><author><style face="normal" font="Arial"> Checkley,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Free 25(OH)D concentrations are associated with atopy and lung function in children with asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="41" start="37">37-41</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> forced vital capacity</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Peru</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Evidence suggests free mono-hydroxyvitamin D (25[OH]D) concentrations are more strongly linked to certain outcomes than total concentrations; however, no studies have examined the relation between free 25(OH)D and respiratory or allergic disease. OBJECTIVE: To examine associations between total and free 25(OH)D concentrations and asthma outcomes. METHODS: We quantified total and free 25(OH)D concentrations in 137 Peruvian children with asthma and 152 children without asthma and examined associations with asthma outcomes. RESULTS: Mean age +/- SD was 13 +/- 2.5 years, and 50.2% were boys. Mean total and measured free 25(OH)D concentrations were 29 +/- 9.5 ng/mL and 5.0 +/- 1.3 pg/mL, respectively. Lower free but not total 25(OH)D concentrations were significantly associated with atopy in all children (total, odds ratio [OR] 1.3 per 10-ng/mL decrease, 95% confidence interval [CI] 0.95-1.7, P = .12; vs free, OR 1.3 per 1-pg/mL decrease, 95% CI 1.0-1.6, P = .02) and children with asthma (total, OR 1.1 per 10-ng/mL decrease, 95% CI 0.75-1.7, P = .57; vs free, OR 1.6 per 1-pg/mL decrease, 95% CI 1.0-2.5, P = .04). Free but not total 25(OH)D levels were significantly associated with pre-bronchodilator forced expiratory volume in 1 second (total, 0.11 L, -0.12 to 0.34, P = .34; vs free, 0.20 L, 0.021-0.39, P = .03) and forced vital capacity (total, 0.13 L, -0.12 to 0.37, P = .31; vs free, 0.22 L, 0.026-0.42, P = .03) Z-scores in children with asthma. CONCLUSION: Atopy, forced expiratory volume in 1 second, and forced vital capacity were more strongly linked to free than to total 25(OH)D concentrations, suggesting the free form might be more relevant in modulating allergic disease risk and pulmonary function in children with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Peru -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.04.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28533007">PM:28533007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170523-PollardSL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170523-PollardSL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Pollard SL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.04.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ukleja-Sokolowska,N.</style></author><author><style face="normal" font="Arial"> Gawronska-Ukleja,E.</style></author><author><style face="normal" font="Arial"> Zbikowska-Gotz,M.</style></author><author><style face="normal" font="Arial"> Socha,E.</style></author><author><style face="normal" font="Arial"> Lis,K.</style></author><author><style face="normal" font="Arial"> Sokolowski,L.</style></author><author><style face="normal" font="Arial"> Bartuzi,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, L. Rydygier Collegium Medicum, Bydgoszcz, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Association of of IgE Can f 2 and dyspnea in pet allergic patients</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="88" start="86">86-88</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Can f 2</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.04.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28554705">PM:28554705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170530-UklejaSokolowskaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170530-UklejaSokolowskaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Ukleja-Sokolowska N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.04.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Seol,J.E.</style></author><author><style face="normal" font="Arial"> Kim,D.H.</style></author><author><style face="normal" font="Arial"> Park,S.H.</style></author><author><style face="normal" font="Arial"> Kang,J.N.</style></author><author><style face="normal" font="Arial"> Sung,H.S.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Aquagenic Urticaria Diagnosed by the Water Provocation Test and the Results of Histopathologic Examination</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="345" start="341">341-345</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Barrier cream</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phototherapy</style></keyword><keyword><style face="normal" font="Arial"> physical urticaria</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">An 18-year-old male visited our department complaining of recurrent episodes of an itchy rash after hand washing, showering/bathing, drinking water, and getting rain-soaked. He was diagnosed with aquagenic urticaria after a water provocation test and histopathologic examination. Five months of antihistamine treatment successfully prevented further wheal formation. Aquagenic urticaria is a very unusual form of physical urticaria caused by contact with water. It manifests as pruritic small wheals surrounded by erythema within 30 minutes of exposure. The condition can be diagnosed by a water provocation test. Systemic antihistamines are the first-line treatment, with anticholinergics, phototherapy, or barrier cream used alternatively or additionally. Four cases of aquagenic urticaria have been reported in Korea, but no histopathologic evaluation was reported in the English or Korean literature. Herein, we provide both a case report of aquagenic urticaria diagnosed by the water provocation test and histopathologic examination results for this patient</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2017.29.3.341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28566914">PM:28566914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2017-29-341-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2017-29-341-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Seol JE</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2017.29.3.341</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arumugam,G.</style></author><author><style face="normal" font="Arial"> Sreeramulu,B.</style></author><author><style face="normal" font="Arial"> Paulchamy,R.</style></author><author><style face="normal" font="Arial"> Thangavel,S.</style></author><author><style face="normal" font="Arial"> Sundaram,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Zoology, University of Madras, Chennai, India</style></auth-address><titles><title><style face="normal" font="Arial">Purification and functional characterization of lectin with phenoloxidase activity from the hemolymph of cockroach, Periplaneta americana</style></title><secondary-title><style face="normal" font="Arial">Arch Insect Biochem Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Insect Biochem Physiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Copper</style></keyword><keyword><style face="normal" font="Arial"> Dopamine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erythrocytes</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Fucose</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Hemagglutination</style></keyword><keyword><style face="normal" font="Arial"> Hemagglutinins</style></keyword><keyword><style face="normal" font="Arial"> Hemocyanin</style></keyword><keyword><style face="normal" font="Arial"> Hemolymph</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Invertebrates</style></keyword><keyword><style face="normal" font="Arial"> Ion Exchange</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Salmonella</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="Arial">Lectins also identified as hemagglutinins are multivalent proteins and on account of their fine sugar-binding specificity play an important role in immune system of invertebrates. The present study was carried out on the hemolymph lectin of cockroach, Periplaneta americana with appropriate screening and purification to understand its molecular as well as functional nature. The lectin from the hemolymph was purified using ion-exchange chromatography. The approximate molecular weight of purified lectin was 340 kDa as determined by FPLC analysis. Rabbit erythrocytes were highly agglutinated with purified lectin from the hemolymph of P. americana. The hemagglutination activity (HA) of lectin was specifically inhibited by fucose. Glycoproteins also inhibited the HA activity of lectin. The amino acid sequences of the purified lectin revealed homology with amino acid sequences of allergen proteins from P. americana. Purified lectin showed the highest phenoloxidase activity against dopamine. The activators such as exogenous proteases and LPS from Escherichia coli and Salmonella minnesota significantly enhanced the PO activity of the purified lectin. Besides, the presence of copper and hemocyanin conserved domain in the purified lectin provided a new facet that insects belonging to the ancient clade such as cockroaches retained some traces of evolutionary resemblance in possessing lectin of ancient origin</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1520-6327 (Electronic)IS - 0739-4462 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1002/arch.21390</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28557066">PM:28557066</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Insect Biochem Physiol\20170530-ArumugamG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Insect Biochem Physiol\20170530-ArumugamG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Arumugam G</style></custom2><misc3><style face="normal" font="Arial">10.1002/arch.21390</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wakayama,N.</style></author><author><style face="normal" font="Arial"> Matsune,S.</style></author><author><style face="normal" font="Arial"> Okubo,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Nippon Medical School Musashikosugi Hospital, 1-396, Kosugimachi, Nakahara-ku Kawasaki-shi, Kanagawa Prefecture 211-0063, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Delayed type of allergic skin reaction to Candida albicans in eosinophilic rhinosinusitis cases</style></title><secondary-title><style face="normal" font="Arial">Auris Nasus Larynx</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Auris Nasus Larynx</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candida albicans</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Intradermal testing</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Eosinophilic chronic rhinosinusitis (ECRS) is frequently complicated by asthma, and recognized as refractory and persistent rhinosinusitis. However, the detailed pathophysiology of ECRS has not been elucidated yet. In this study, we investigated the association between recurrent ECRS and intradermal testing to multi-antigens including Candida albicans. METHODS: The subjects were 49 cases of bilateral chronic rhinosinusitis including 24 ECRS cases. They underwent endoscopic sinus surgery and submitted to pathological examination. Prior to surgery, peripheral blood eosinophil count, total and antigen-specific IgE levels (11 categories), and intradermal tests (5 categories) were carried out in all patients. These patients were followed-up for longer than 3 months. We compared the results of preoperative and postoperative clinical examination data between ECRS and non-ECRS (NECRS) cases. RESULTS: Positive reaction of the delayed type of intradermal testing to C. albicans was significantly more often observed in ECRS than NECRS cases. (P&lt;0.01) Additionally, these positive reaction cases exhibited significantly higher recurrence of nasal polyps and symptoms of ECRS (P&lt;0.05). CONCLUSION: These results suggest the involvement of (Coombs) type IV allergic reaction to C. albicans in the pathophysiology of ECRS</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1879-1476 (Electronic)IS - 0385-8146 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anl.2017.05.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552275">PM:28552275</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Auris Nasus Larynx\20170529-WakayamaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Auris Nasus Larynx\20170529-WakayamaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Wakayama N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anl.2017.05.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Villaverde,R.R.</style></author><author><style face="normal" font="Arial"> Rodriguez,A.B.</style></author><author><style face="normal" font="Arial"> Cano,D.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Beyond Urticaria: Schnitzler Syndrome</style></title><secondary-title><style face="normal" font="Arial">Balkan Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Balkan Med J</style></full-title></periodical><pages end="479" start="478">478-479</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Schnitzler Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 2146-3131 (Electronic)IS - 2146-3123 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.4274/balkanmedj.2017.0259</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552842">PM:28552842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Balkan Med J\2017-34-478-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Balkan Med J\2017-34-478-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Villaverde RR</style></custom2><misc3><style face="normal" font="Arial">10.4274/balkanmedj.2017.0259</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,Y.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Hou,Y.</style></author><author><style face="normal" font="Arial"> Huang,H.H.L.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Sun,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, Health Science Center, Xi'an Jiaotong University, China</style></auth-address><titles><title><style face="normal" font="Arial">The human mast cell line-1 cell membrane chromatography coupled with HPLC-ESI-MS/MS method for screening potentical anaphylactic components from chuanxinlian injection</style></title><secondary-title><style face="normal" font="Arial">Biomed Chromatogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Chromatogr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Cell Membrane</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="Arial">Chuanxinlian injection is a traditional Chinese medicine injection widely used in China to treat sore throat, cough, and dysentery. While, the high occurrence of severe adverse reactions had been reported in clinical practice in recent years. In the present study, a human mast cell line-1 cell membrane chromatography coupled with HPLC-ESI-MS/MS method was established to screen and identify potentical anaphylactic components in chuanxinlian injection, and the dehydroandrographolide was identified as a potential anaphylactic component. In vitro anaphylactic assay showed that intracellular Ca2+ concentration clearly increased under dehydroandrographolide (100 muM) treatment, beta-Hexosaminidase and histamine release in human mast cell line-1 cells were both markedly enhanced with increased concentrations of dehydroandrographolide, confirming the anaphylactic activity of dehydroandrographolide. The application for chuanxinlian injection in this study suggested that the developed human mast cell line-1 cell membrane chromatography coupled with HPLC-ESI-MS/MS system may be effective and rapid for screening the potentical anaphylactic components from complex samples</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1099-0801 (Electronic)IS - 0269-3879 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/bmc.4015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28556951">PM:28556951</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Chromatogr\20170530-LinY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Chromatogr\20170530-LinY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Lin Y</style></custom2><misc3><style face="normal" font="Arial">10.1002/bmc.4015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Y.L.</style></author><author><style face="normal" font="Arial"> Chen,C.L.</style></author><author><style face="normal" font="Arial"> Chen,C.M.</style></author><author><style face="normal" font="Arial"> Ko,W.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Hesperetin-5,7,3'-O-triacetate suppresses airway hyperresponsiveness in ovalbumin-sensitized and challenged mice without reversing xylazine/ketamine-induced anesthesia in normal mice</style></title><secondary-title><style face="normal" font="Arial">BMC Pharmacol Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMC Pharmacol Toxicol</style></abbr-1></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PDE4 inhibitor</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Therapy</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> Vehicles</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We recently reported that hesperetin-5,7,3'-O-triacetate (HTA) dually inhibited phosphodiesterase (PDE)3/4 with a therapeutic ratio of 20.8. The application and development of PDE4 inhibitors for treating asthma or COPD are limited by their side effects, such as nausea, vomiting and gastric hypersecretion. PDE4 inhibitors were reported to reverse xylazine/ketamine-induced anesthesia in rats and triggered vomiting in ferrets. Thus the reversing effect of HTA on xylazine/ketamine-induced anesthesia in mice was studied to assess emetic effect of HTA. The aim of this study was to prove the therapeutic effect of HTA without vomiting effect at an effective dose for treating COPD. METHODS: Ten female BALB/c mice in each group were sensitized by ovalbumin (OVA) on days 0 and 14. On day 21, these mice were emphasized the sensitization by Freund's complete adjuvant. Mice were challenged by 1% OVA nebulization on days 28, 29, and 30. Airway hyperresponsiveness (AHR) was assessed on day 32 in each group, using the FlexiVent system to determine airway resistance (RL) and lung dynamic compliance (Cdyn) in anesthetized ovalbumin (OVA)-sensitized and challenged mice. Each group was orally administered HTA (10 ~ 100 mumol/kg), roflumilast (1 and 5 mg/kg) or vehicles (controls) 2 h before and 6 and 24 h after OVA provocation. For comparison, sham-treated mice were challenged with saline instead of 1% OVA. The ability to reverse xylazine/ketamine-induced anesthesia by HTA or roflumilast for 3 h was determined in normal mice. We used roflumilast, a selective PDE4 inhibitor and bronchodilator for severe COPD approved by the US Food and Drug Administration, as a reference drug. RESULTS: In the results, HTA (100 mumol/kg, p.o.) or roflumilast (5 mg/kg, p.o.) significantly suppressed all RL values of MCh at 0.78 ~ 25 mg/mL and enhanced Cdyn values of MCh at 3.125 ~ 25 mg/mL compared to OVA-sensitized and -challenged control mice. Orally administered 1, 3 or 10 mg/kg roflumilast, but not 30 or 100 mumol/kg HTA, significantly reversed xylazine/ketamine-induced anesthesia. CONCLUSIONS: In contrast to roflumilast, HTA may ameliorate COPD but induce few side effects of nausea, vomiting and gastric hypersecretion at an effective dose for treating COPD, because HTA did not reverse xylazine/ketamine-induced anesthesia in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 2050-6511 (Electronic)IS - 2050-6511 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40360-017-0146-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28558784">PM:28558784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Pharmacol Toxicol\2017-18-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Pharmacol Toxicol\2017-18-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Yang YL</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40360-017-0146-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84593</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferkh,K.E.</style></author><author><style face="normal" font="Arial"> Nwaru,B.I.</style></author><author><style face="normal" font="Arial"> Griffiths,C.</style></author><author><style face="normal" font="Arial"> Patel,A.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma UK Centre for Applied Research, Centre for Medical Informatics, Usher Institute for Population Health Sciences, The University of Edinburgh, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="Arial">Healthcare costs of asthma comorbidities: a systematic review protocol</style></title><secondary-title><style face="normal" font="Arial">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ Open</style></full-title></periodical><pages end="" start="e015102">e015102-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> complementary medicine</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> ethics</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evaluation Studies</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Informatics</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Asthma is associated with many comorbid conditions that have the potential to impact on its management, control and outcomes. These comorbid conditions have the potential to impact on healthcare expenditure. We plan to undertake a systematic review to synthesise the evidence on the healthcare costs associated with asthma comorbidity. METHODS AND ANALYSIS: We will systematically search the following electronic databases between January 2000 and January 2017: National Health Service (NHS) Economic Evaluation Database, Google Scholar, Allied and Complementary Medicine Database (AMED), Global Health, PsychINFO, Medline, Embase, Institute for Scientific Information Web of Science and Cumulative Index to Nursing and Allied Health Literature. We will search the references in the identified studies for additional potential papers. Additional literature will be identified by contacting experts in the field and through searching of registers of ongoing studies. The review will include cost-effectiveness and economic modelling/evaluation studies and analytical observational epidemiology studies that have investigated the healthcare costs of asthma comorbidity. Two reviewers will independently screen studies and extract relevant data from included studies. Methodological quality of epidemiological studies will be assessed using the Effective Public Health Practice Project tool, while that of economic evaluation studies will be assessed using the Drummond checklist. This protocol has been published in International Prospective Register of Systematic Reviews (PROSPERO) database (No. CRD42016051005). ETHICS AND DISSEMINATION: As there are no primary data collected, formal NHS ethical review is not necessary. The findings of this systematic review will be disseminated in a peer-reviewed journal and presented at relevant conferences. PROSPEROREGISTRATION NUMBER: CRD42016051005</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmjopen-2016-015102</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28566366">PM:28566366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2017-7-e015102.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Open\2017-7-e015102.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Ferkh KE</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmjopen-2016-015102</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84594</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nissen,F.</style></author><author><style face="normal" font="Arial"> Quint,J.K.</style></author><author><style face="normal" font="Arial"> Wilkinson,S.</style></author><author><style face="normal" font="Arial"> Mullerova,H.</style></author><author><style face="normal" font="Arial"> Smeeth,L.</style></author><author><style face="normal" font="Arial"> Douglas,I.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Validation of asthma recording in electronic health records: protocol for a systematic review</style></title><secondary-title><style face="normal" font="Arial">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ Open</style></full-title></periodical><pages end="" start="e014694">e014694-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Health Records</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> ethics</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Records</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a common, heterogeneous disease with significant morbidity and mortality worldwide. It can be difficult to define in epidemiological studies using electronic health records as the diagnosis is based on non-specific respiratory symptoms and spirometry, neither of which are routinely registered. Electronic health records can nonetheless be valuable to study the epidemiology, management, healthcare use and control of asthma. For health databases to be useful sources of information, asthma diagnoses should ideally be validated. The primary objectives are to provide an overview of the methods used to validate asthma diagnoses in electronic health records and summarise the results of the validation studies. METHODS: EMBASE and MEDLINE will be systematically searched for appropriate search terms. The searches will cover all studies in these databases up to October 2016 with no start date and will yield studies that have validated algorithms or codes for the diagnosis of asthma in electronic health records. At least one test validation measure (sensitivity, specificity, positive predictive value, negative predictive value or other) is necessary for inclusion. In addition, we require the validated algorithms to be compared with an external golden standard, such as a manual review, a questionnaire or an independent second database. We will summarise key data including author, year of publication, country, time period, date, data source, population, case characteristics, clinical events, algorithms, gold standard and validation statistics in a uniform table. ETHICS AND DISSEMINATION: This study is a synthesis of previously published studies and, therefore, no ethical approval is required. The results will be submitted to a peer-reviewed journal for publication. Results from this systematic review can be used to study outcome research on asthma and can be used to identify case definitions for asthma. PROSPERO REGISTRATION NUMBER: CRD42016041798</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmjopen-2016-014694</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28554919">PM:28554919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2017-7-e014694.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Open\2017-7-e014694.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Nissen F</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmjopen-2016-014694</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Torres-Arroyo,A.</style></author><author><style face="normal" font="Arial"> Ruiz-Lara,A.</style></author><author><style face="normal" font="Arial"> Castillo-Villanueva,A.</style></author><author><style face="normal" font="Arial"> Mendez-Cruz,S.T.</style></author><author><style face="normal" font="Arial"> Espinosa-Padilla,S.E.</style></author><author><style face="normal" font="Arial"> Espinosa-Rosales,F.J.</style></author><author><style face="normal" font="Arial"> Zarate-Mondragon,F.</style></author><author><style face="normal" font="Arial"> Cervantes-Bustamante,R.</style></author><author><style face="normal" font="Arial"> Bosch-Canto,V.</style></author><author><style face="normal" font="Arial"> Vizzuett-Lopez,I.</style></author><author><style face="normal" font="Arial"> Ordaz-Favila,J.C.</style></author><author><style face="normal" font="Arial"> Oria-Hernandez,J.</style></author><author><style face="normal" font="Arial"> Reyes-Vivas,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Proteomics: a tool to develop novel diagnostic methods and unravel molecular mechanisms of pediatric diseases</style></title><secondary-title><style face="normal" font="Arial">Bol Med Hosp Infant Mexico</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bol Med Hosp Infant Mexico</style></full-title></periodical><pages end="240" start="233">233-240</pages><volume><style face="normal" font="Arial">74</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Blindness</style></keyword><keyword><style face="normal" font="Arial"> Cataract</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood cataract</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> cow milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> Developing Countries</style></keyword><keyword><style face="normal" font="Arial"> developing country</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1665-1146</style></isbn><abstract><style face="normal" font="Arial">Proteomics is the study of the expression of changes and post-translational modifications (PTM) of proteins along a metabolic condition either normal or pathological. In the field of health, proteomics allows obtaining valuable data for treatment, diagnosis or pathophysiological mechanisms of different illnesses. To illustrate the aforementioned, we describe two projects currently being performed at the Instituto Nacional de Pediatr+¡a: The immuno-proteomic study of cow milk allergy and the Proteomic study of childhood cataract. Cow's milk proteins (CMP) are the first antigens to which infants are exposed and generate allergy in some of them. In Mexico, the incidence of CMP allergy has been estimated at 5-7%. Clinical manifestations include both gastrointestinal and extra-gastrointestinal symptoms, making its diagnosis extremely difficult. An inappropriate diagnosis affects the development and growth of children. The goals of the study are to identify the main immune-reactive CMP in Mexican pediatric population and to design more accurate diagnostic tools for this disease. Childhood cataract is a major ocular disease representing one of the main causes of blindness in infants; in developing countries, this disease promotes up to 27% of cases related to visual loss. From this group, it has been estimated that close to 60% of children do not survive beyond two years after vision lost. PTM have been pointed out as the main cause of protein precipitation at the crystalline and, consequently, clouding of this tissue. The study of childhood cataract represents an outstanding opportunity to identify the PTM associated to the cataract-genesis process</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bmhimx.2017.03.009</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.bmhimx.2017.03.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Bol Med Hosp Infant Mexico\20170601-TorresArroyoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Bol Med Hosp Infant Mexico\20170601-TorresArroyoA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Torres-Arroyo A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bmhimx.2017.03.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,E.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine, Cheonan, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Pruritic Urticarial Papules and Plaques of Pregnancy Occurring Postpartum Treated with Intramuscular Injection of Autologous Whole Blood</style></title><secondary-title><style face="normal" font="Arial">Case Rep Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Rep Dermatol</style></full-title></periodical><pages end="156" start="151">151-156</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Fetus</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Pruritic urticarial papules and plaques of pregnancy (PUPPP) is one of the most common diseases associated with pregnancy. In most cases, the skin lesions develop in the third trimester of primigravidas. There are no systemic alterations seen in PUPPP; however, most patients report severe pruritus. A 34-year-old woman presented 1 week postpartum with typical clinical features of PUPPP. The patient showed good response to intramuscular injection of autologous whole blood with no adverse effects to the patient or her baby. Presentation of PUPPP in the postpartum period is rare. Conservative management with topical corticosteroids and oral antihistamines is commonly used to relieve pruritus. In severe cases, skin lesions and symptoms are controlled with a brief course of systemic corticosteroids. Investigation of new treatment options has been limited by patient concerns about the negative effects of medication on the fetus or breastfeeding. Intramuscular injection of autologous whole blood could be an alternative treatment option for PUPPP, especially for women who worry about the use of medications during pregnancy or breastfeeding</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1662-6567 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1159/000473874</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28559815">PM:28559815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Dermatol\2017-9-151-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Dermatol\2017-9-151-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Kim EH</style></custom2><misc3><style face="normal" font="Arial">10.1159/000473874</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jung,K.H.</style></author><author><style face="normal" font="Arial"> Lovinsky-Desir,S.</style></author><author><style face="normal" font="Arial"> Yan,B.</style></author><author><style face="normal" font="Arial"> Torrone,D.</style></author><author><style face="normal" font="Arial"> Lawrence,J.</style></author><author><style face="normal" font="Arial"> Jezioro,J.R.</style></author><author><style face="normal" font="Arial"> Perzanowski,M.</style></author><author><style face="normal" font="Arial"> Perera,F.P.</style></author><author><style face="normal" font="Arial"> Chillrud,S.N.</style></author><author><style face="normal" font="Arial"> Miller,R.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of personal exposure to black carbon on changes in allergic asthma gene methylation measured 5-ádays later in urban children: importance of allergic sensitization</style></title><secondary-title><style face="normal" font="Arial">Clin Epigenetics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Epigenetics</style></full-title></periodical><pages end="" start="61">61-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic regulation</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> seroatopy</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1868-7083</style></isbn><abstract><style face="normal" font="Arial">Asthma gene DNA methylation may underlie the effects of air pollution on airway inflammation. However, the temporality and individual susceptibility to environmental epigenetic regulation of asthma has not been fully elucidated. Our objective was to determine the timeline of black carbon (BC) exposure, measured by personal sampling, on DNA methylation of allergic asthma genes 5-ádays later to capture usual weather variations and differences related to changes in behavior and activities. We also sought to determine how methylation may vary by seroatopy and cockroach sensitization and by elevated fractional exhaled nitric oxide (FeNO)</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13148-017-0361-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s13148-017-0361-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Epigenetics\2017-9-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Epigenetics\2017-9-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170602, Jung KH</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13148-017-0361-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ashley,S.E.</style></author><author><style face="normal" font="Arial"> Tan,H.T.</style></author><author><style face="normal" font="Arial"> Peters,R.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Vuillermin,P.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Tang,M.L.K.</style></author><author><style face="normal" font="Arial"> Koplin,J.</style></author><author><style face="normal" font="Arial"> Lowe,A.</style></author><author><style face="normal" font="Arial"> Ponsonby,A.L.</style></author><author><style face="normal" font="Arial"> Molloy,J.</style></author><author><style face="normal" font="Arial"> Matheson,M.C.</style></author><author><style face="normal" font="Arial"> Saffery,R.</style></author><author><style face="normal" font="Arial"> Ellis,J.A.</style></author><author><style face="normal" font="Arial"> Martino,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Murdoch Childrens Research Institute, Royal Children's Hospital, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Genetic variation at the Th2 immune gene IL13 is associated with IgE-mediated paediatric food allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1037" start="1032">1032-1037</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food sensitization</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Genetic polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Genetic Variation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Linkage Disequilibrium</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergies pose a considerable world-wide public health burden with incidence as high as one in ten in 12-month-old infants. Few food allergy genetic risk variants have yet been identified. The Th2 immune gene IL13 is a highly plausible genetic candidate as it is central to the initiation of IgE class switching in B cells. OBJECTIVE: Here, we sought to investigate whether genetic polymorphisms at IL13 are associated with the development of challenge-proven IgE-mediated food allergy. METHOD: We genotyped nine IL13 "tag" single nucleotide polymorphisms (tag SNPs) in 367 challenge-proven food allergic cases, 199 food-sensitized tolerant cases and 156 non-food allergic controls from the HealthNuts study. 12-month-old infants were phenotyped using open oral food challenges. SNPs were tested using Cochran-Mantel-Haenszel test adjusted for ancestry strata. A replication study was conducted in an independent, co-located sample of four paediatric cohorts consisting of 203 food allergic cases and 330 non-food allergic controls. Replication sample phenotypes were defined by clinical history of reactivity, 95% PPV or challenge, and IL13 genotyping was performed. RESULTS: IL13 rs1295686 was associated with challenge-proven food allergy in the discovery sample (P=.003; OR=1.75; CI=1.20-2.53). This association was also detected in the replication sample (P=.03, OR=1.37, CI=1.03-1.82) and further supported by a meta-analysis (P=.0006, OR=1.50). However, we cannot rule out an association with food sensitization. Carriage of the rs1295686 variant A allele was also associated with elevated total plasma IgE. CONCLUSIONS AND CLINICAL RELAVANCE: We show for the first time, in two independent cohorts, that IL13 polymorphism rs1295686 (in complete linkage disequilibrium with functional variant rs20541) is associated with challenge-proven food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12942</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544327">PM:28544327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170525-AshleySE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170525-AshleySE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Ashley SE</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12942</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,X.W.</style></author><author><style face="normal" font="Arial"> Wang,J.J.</style></author><author><style face="normal" font="Arial"> Gutowska-Owsiak,D.</style></author><author><style face="normal" font="Arial"> Salimi,M.</style></author><author><style face="normal" font="Arial"> Selvakumar,T.A.</style></author><author><style face="normal" font="Arial"> Gwela,A.</style></author><author><style face="normal" font="Arial"> Chen,L.Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.J.</style></author><author><style face="normal" font="Arial"> Giannoulatou,E.</style></author><author><style face="normal" font="Arial"> Ogg,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Military Stomatology, Department of Oral Medicine, School of Stomatology, The Fourth Military Medical University, Xi'an Shaanxi Province, China</style></auth-address><titles><title><style face="normal" font="Arial">Deficiency of filaggrin regulates endogenous cysteine protease activity, leading to impaired skin barrier function</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="631" start="622">622-631</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Claudin-1</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> cysteine proteases</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> E-cadherin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> filaggrin gene</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> impaired barrier function</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> occludin</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier function</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disorder, characterized by skin barrier defects and enhanced allergen priming. Null mutations in the filaggrin gene (FLG) are strongly associated with moderate to severe AD, but the pathways linking barrier dysfunction and cutaneous inflammation are still largely unknown. AIM: To assess alteration of endogenous cysteine protease activity in FLG-deficient keratinocytes, and to determine whether the alteration in cysteine protease activity affects epidermal barrier function and associated gene and protein expression. METHODS: We established a stable FLG knockdown cell line, and reconstructed epidermal equivalents in vitro. Barrier function of the reconstructed epidermis, the barrier-associated genes and proteins, and the activity of endogenous cysteine proteases were tested. Inhibitors of cysteine proteases were used to further evaluate the role of endogenous cysteine proteases in epidermal barrier function. RESULTS: FLG knockdown induced impaired epidermal barrier function. Microarray, western blotting and fluorescence staining showed reduced expression of K10, ZO-1, E-cadherin, claudin-1 and occludin in FLG knockdown keratinocytes. Compared with cysteine protease activity in control cells, protease activity was dramatically enhanced in FLG knockdown keratinocytes. Furthermore, administration of cysteine protease inhibitors significantly recovered expression of K10 and tight junction proteins, and the barrier defect induced by FLG deficiency. CONCLUSIONS: This is the first observation of elevated endogenous cysteine protease activity in FLG-deficient keratinocytes, which may play an important role in impaired barrier function in AD skin. Modulation of cysteine protease activity might be a novel therapeutic approach for AD treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - China -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.13113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28556377">PM:28556377</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20170530-WangXW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20170530-WangXW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Wang XW</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.13113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Y.P.</style></author><author><style face="normal" font="Arial"> Maimaiti,Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Wang,L.L.</style></author><author><style face="normal" font="Arial"> Tan,G.P.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China</style></auth-address><titles><title><style face="normal" font="Arial">[Changing analysis of allergic rhinitis inhalant allergen spectrum in Xinjiang region]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="360" start="355">355-360</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Ethnic Groups</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="5" Year="2017">2017/5/7</year></dates><abstract><style face="normal" font="Arial">Objective: To investigate the aeroallergen spectrum in allergic rhinitis in Xinjiang area and analyze its relating factors. Methods: Skin prick test was carried out in 480 cases with allergic rhinitis using 20 inhaled allergens. The major change in recent years with allergic rhinitis and allergen distribution was compared.SPSS 17.0 software was used to analyze the data. Results: Among 480 cases, 406 showed positive reaction. The most common allergens found in patients were chenopodium (61.6%) and mugwort (44.1%), followed by willow(37.7%), maple(37.7%), poplar(30.3%), house dust mite(30.3%), plantain(29.8%), acacia(25.9%), dust mite maple(25.4%), and so on. The rate of positive reaction to only one allergen was 9.6%, of which 21 were mite allergens. The positiverate to allergensin male and female were 84.2% and 85.1%, the distribution of allergens in both sexes did not differ(chi(2)=0.001, P=0.978). The positiverate to allergens in patients aged 21 to 35 years old was 88.6%, in patients aged 36 to 54 years old was 78.4%, the difference was statistically significant(chi(2)=0.258, P&lt;0.01). The positive rate to allergens in Kazakhs was slightly higher than that in other ethnic groups (91.7%). The positive rates to allergens in the Han, Uygur and other ethnic groups were 84.8%, 86.4% and 63.3% respectively, the difference was statistically significant(chi(2)=9.779, P=0.044). Seventy-five point four percent of all allergen-positive patients(306 cases) combined with asthma. Conclusions: The major allergen with allergic rhinitis is chenopodium. Among them, Kazakh allergic positive rate is higher than other ethnic groups</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.05.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28558454">PM:28558454</url></web-urls></urls><custom2><style face="normal" font="Arial">20170531, Yang YP</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.05.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Navarro,A.M.</style></author><author><style face="normal" font="Arial"> Delgado,J.</style></author><author><style face="normal" font="Arial"> Munoz-Cano,R.M.</style></author><author><style face="normal" font="Arial"> Dordal,M.T.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">UGC of Allergy, Hospital El Tomillar , Carretera Alcala - Dos Hermanas km 6, 41700 Dos Hermanas, Seville Spain</style></auth-address><titles><title><style face="normal" font="Arial">Allergic respiratory disease (ARD), setting forth the basics: proposals of an expert consensus report</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="16">16-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Delphi Technique</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Severity of the disease</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The variability of symptoms observed in patients with respiratory allergy often hampers classification based on the criteria proposed in guidelines on rhinitis and asthma. OBJECTIVES: We assessed specific aspects of allergic respiratory disease (ARD) that are not explicitly addressed in the guidelines in order to issue specific recommendations and thus optimize clinical practice. METHODS: Using the Delphi technique, 40 Spanish allergists were surveyed to reach consensus on 71 items related to ARD. RESULTS: Consensus was achieved for 95.7% of the items. These included the following: the clinical manifestations of ARD are heterogeneous and individual airborne allergens can be related to specific clinical profiles; the optimal approach in patients with ARD is based on the global assessment of rhinoconjunctivitis and asthma; aeroallergens are largely responsible for the clinical features and severity of the disease; and clinical expression is associated with the period of environmental exposure to the allergen. Pharmacological treatment of ARD is often based on the intensity of symptoms recorded during previous allergen exposures and cannot always be administered following a step-up approach, as recommended in clinical practice guidelines. Allergen immunotherapy (AIT) is the only option for overall treatment of respiratory symptoms using an etiological approach. AIT can modify the prognosis of ARD and should therefore be considered a valuable first-line treatment. CONCLUSIONS: The present study highlights gaps in current asthma and rhinitis guidelines and addresses specific aspects of ARD, such as global assessment of both asthma and rhinitis or the specific role of variable allergen exposure in the clinical expression of the disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0150-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28533901">PM:28533901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Navarro AM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0150-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhami,S.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Fernandez Rivas,M.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Evidence-Based Health Care Ltd, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="Arial">Quality indicators for the acute and long-term management of anaphylaxis: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="15">15-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guideline implementation</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The quality of acute and long-term anaphylaxis management is variable and this contributes to the poor outcomes experienced by many patients. Clinical practice guidelines have the potential to improve outcomes, but implementing guideline recommendations in routine practice is challenging. Quality indicators have the potential to support guideline implementation efforts. OBJECTIVE: To identify quality indicators to support the acute and long-term management of anaphylaxis. METHODS: We conducted a systematic review of the literature that involved searching Medline, EMBASE and CINAHL databases for peer-reviewed published literature for the period 1 January 2005-31 December 2015. Additionally we searched Google for grey and unpublished literature. The identified indicators were descriptively summarized against the most recent international anaphylaxis guidelines (i.e. those produced by the European Academy of Allergy and Clinical Immunology) and critically evaluated using the Agency for Healthcare Research and Quality's criteria for indicator development. RESULTS: Our searches revealed 830 publications, from which we identified five sources for 54 indicators addressing both acute (n = 27) and long-term (n = 27) management of anaphylaxis. The majority of indicators were developed through expert consensus with relatively few of these having been formally piloted or tested to demonstrate that they could discriminate between variations in practice and/or that they were sensitive to change. CONCLUSIONS: There is a need for a comprehensive set of quality indicators for anaphylaxis management. We have however identified some indicators for the acute and long-term management of anaphylaxis that could with relatively little additional work support efforts to translate guideline recommendations into clinical care</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - Italy -CO - Denmark -CO - Spain -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0151-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28546858">PM:28546858</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Dhami S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0151-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farahnik,B.</style></author><author><style face="normal" font="Arial"> Beroukhim,K.</style></author><author><style face="normal" font="Arial"> Nakamura,M.</style></author><author><style face="normal" font="Arial"> Abrouk,M.</style></author><author><style face="normal" font="Arial"> Zhu,T.H.</style></author><author><style face="normal" font="Arial"> Singh,R.</style></author><author><style face="normal" font="Arial"> Lee,K.</style></author><author><style face="normal" font="Arial"> Bhutani,T.</style></author><author><style face="normal" font="Arial"> Koo,J.</style></author><author><style face="normal" font="Arial"> Liao,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Vermont College of Medicine, Burlington, Vermont.</style></auth-address><titles><title><style face="normal" font="Arial">Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report</style></title><secondary-title><style face="normal" font="Arial">Dermatol Online J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dermatol Online J</style></full-title></periodical><pages end="" start="9">9-</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> topical steroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vermont</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a common inflammatory dermatosis characterized by pruritus, erythema, induration, and lichenification. Current treatment options for generalized atopic dermatitis are limited and have potentially serious adverse effects, especially in patients with severe, chronic AD who frequently require systemic anti-inflammatory agents. Apremilast, an oral phosphodiesterase-4 inhibitor, was FDA approved in September 2014 for the treatment of moderate-to-severe plaque psoriasis. However, its upstream anti-inflammatory effects, ease of use as an oral agent, and mild side-effect profile make it an interesting treatment option for AD as well. Herein, we present a patient with a life-long history of AD recalcitrant to topical steroids and cyclosporine who attained subjective and objective improvement in pruritus and erythema after 10-week treatment with apremilast</style></abstract><notes><style face="normal" font="Arial">DA - 20170524IS - 1087-2108 (Electronic)IS - 1087-2108 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28537861">PM:28537861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dermatol Online J\2017-23-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dermatol Online J\2017-23-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170524, Farahnik B</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'erme,A.M.</style></author><author><style face="normal" font="Arial"> Romanelli,M.</style></author><author><style face="normal" font="Arial"> Chiricozzi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Unit, Livorno Hospital, Livorno</style></auth-address><titles><title><style face="normal" font="Arial">Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy</style></title><secondary-title><style face="normal" font="Arial">Drug Des Devel Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drug Des Devel Ther</style></full-title></periodical><pages end="1480" start="1473">1473-1480</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-4 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor alpha subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1177-8881 (Electronic)IS - 1177-8881 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2147/DDDT.S113192</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28553077">PM:28553077</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drug Des Devel Ther\2017-11-1473-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drug Des Devel Ther\2017-11-1473-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, D'Erme AM</style></custom2><misc3><style face="normal" font="Arial">10.2147/DDDT.S113192</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shirley,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Springer, Mairangi Bay 0754, Private Bag 65901, Auckland, New Zealand.</style></auth-address><titles><title><style face="normal" font="Arial">Dupilumab: First Global Approval</style></title><secondary-title><style face="normal" font="Arial">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs</style></full-title></periodical><pages end="1121" start="1115">1115-1121</pages><volume><style face="normal" font="Arial">77</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">Dupilumab (Dupixent(R)) is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor alpha (IL-4Ralpha) subunit. Dupilumab inhibits the signalling of the type 2 cytokines IL-4 and IL-13 and was co-developed by Regeneron Pharmaceuticals and Sanofi as a potential therapeutic agent for the treatment of atopic or allergic diseases. In March 2017 dupilumab received its first global approval, in the USA, for use in the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab is in preregistration for this indication in the EU. In addition, dupilumab is currently under phase III development across the world for the treatment of asthma and nasal polyposis as well as for atopic dermatitis in paediatric patients. The agent has also entered phase II development in the USA for the treatment of eosinophilic oesophagitis. This article summarizes the milestones in the development of dupilumab leading to this first approval for the treatment of moderate-to-severe atopic dermatitis in adults</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 1179-1950 (Electronic)IS - 0012-6667 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40265-017-0768-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28547386">PM:28547386</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs\20170526-ShirleyM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs\20170526-ShirleyM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Shirley M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40265-017-0768-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schafer,U.</style></author><author><style face="normal" font="Arial"> Kienle-Gogolok,A.</style></author><author><style face="normal" font="Arial"> Hadler,M.</style></author><author><style face="normal" font="Arial"> Karagiannis,E.</style></author><author><style face="normal" font="Arial"> Schnitzer,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergiezentrum Sachsen, Dresden, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Treatment Satisfaction During Sublingual Immunotherapy with a Five-Grass Pollen Tablet for Allergic Rhinoconjunctivitis: A Prospective, Non-Interventional Study</style></title><secondary-title><style face="normal" font="Arial">Drugs Real World Outcomes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Drugs Real World Outcomes</style></abbr-1></periodical><pages end="117" start="109">109-117</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ocular symptoms</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patient adherence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sublingual immunotherapy (SLIT) is a safe/well-tolerated alternative to allergen injection immunotherapy for allergic rhinoconjunctivitis (ARC). Patient adherence is essential and patient-related outcome measures including treatment satisfaction are informative/indicative of adherence. OBJECTIVE: The aim was to assess treatment satisfaction with five-grass pollen tablet SLIT under real-life conditions. METHODS: Treatment satisfaction among adults taking SLIT with a five-grass pollen tablet for grass pollen-related ARC was assessed with QUARTIS, a self-report questionnaire dedicated to the management of patients treated with SLIT for ARC. This 1-year prospective, non-interventional, post-authorization study was conducted in Germany between 2008 and 2010. RESULTS: Of the 327 patients treated with the five-grass pollen tablet, 253 completed the QUARTIS questionnaire before and during (at least one item) treatment and were included in this analysis. Between the baseline and the treatment season, significant improvements were documented in nasal and ocular symptoms, and in the impact of allergy on everyday life. At the end of the first treatment period, patients had an improved opinion of the ease of SLIT intake and a significantly improved perception of SLIT. Compliance, overall satisfaction and motivation to continue SLIT the following year were good. Physicians' assessments showed reduced symptoms and a reduced need for symptomatic medication throughout the study. SLIT was also well tolerated. CONCLUSION: Under real-life conditions, five-grass pollen tablet treatment was associated with a good level of treatment satisfaction, good symptom control, a reduced need for symptomatic medication, and favourable tolerability. These facets impacted favourably on patient functioning, disposition towards this medication, and adherence</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 2199-1154 (Print)IS - 2198-9788 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40801-017-0109-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540507">PM:28540507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs Real World Outcomes\20170525-SchaferU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs Real World Outcomes\20170525-SchaferU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Schafer U</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40801-017-0109-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawasaki,T.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author><author><style face="normal" font="Arial"> Miyata,H.</style></author><author><style face="normal" font="Arial"> Akira,S.</style></author><author><style face="normal" font="Arial"> Kawai,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Molecular Immunobiology, Graduate School of Biological Sciences, Nara Institute of Science and Technology (NAIST), Nara, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Deletion of PIKfyve alters alveolar macrophage populations and exacerbates allergic inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">EMBO J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMBO J</style></full-title></periodical><pages end="1718" start="1707">1707-1718</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">Alveolar macrophages (AMs) are specialized tissue-resident macrophages that orchestrate the immune responses to inhaled pathogens and maintain organ homeostasis of the lung. Dysregulation of AMs is associated with allergic inflammation and asthma. Here, we examined the role of a phosphoinositide kinase PIKfyve in AM development and function. Mice with conditionally deleted PIKfyve in macrophages have altered AM populations. PIKfyve deficiency results in a loss of AKT activation in response to GM-CSF, a cytokine critical for AM development. Upon exposure to house dust mite extract, mutant mice display severe lung inflammation and allergic asthma accompanied by infiltration of eosinophils and lymphoid cells. Moreover, they have defects in production of retinoic acid and fail to support incorporation of Foxp3+ Treg cells in the lung, resulting in exacerbation of lung inflammation. Thus, PIKfyve plays a role in preventing excessive lung inflammation through regulating AM function</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1460-2075 (Electronic)IS - 0261-4189 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.15252/embj.201695528</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28533230">PM:28533230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMBO J\20170523-KawasakiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMBO J\20170523-KawasakiT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Kawasaki T</style></custom2><misc3><style face="normal" font="Arial">10.15252/embj.201695528</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Falcon-Rodriguez,C.I.</style></author><author><style face="normal" font="Arial"> De Vizcaya-Ruiz,A.</style></author><author><style face="normal" font="Arial"> Rosas-Perez,I.A.</style></author><author><style face="normal" font="Arial"> Osornio-Vargas,A.R.</style></author><author><style face="normal" font="Arial"> Segura-Medina,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Posgrado en Ciencias Biologicas, Universidad Nacional Autonoma de Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Inhalation of concentrated PM2.5 from Mexico City acts as an adjuvant in a guinea pig model of allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Environ Pollut</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Pollut</style></full-title></periodical><pages end="483" start="474">474-483</pages><volume><style face="normal" font="Arial">228</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hydrocarbons</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mexico City</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="Arial">Exposure to Particulate Matter (PM) could function as an adjuvant depending on the city of origin in mice allergic asthma models. Therefore, our aim was to determine whether inhalation of fine particles (PM2.5) from Mexico City could act as an adjuvant inducing allergic sensitization and/or worsening the asthmatic response in guinea pig, as a suitable model of human asthma. Experimental groups were Non-Sensitized (NS group), sensitized with Ovalbumin (OVA) plus Aluminum hydroxide (Al(OH)3) as adjuvant (S + Adj group), and sensitized (OVA) without adjuvant (S group). All the animals were exposed to Filtered Air (FA) or concentrated PM2.5 (5 h/daily/3 days), employing an aerosol concentrator system, PM2.5 composition was characterized. Lung function was evaluated by barometric plethysmography (Penh index). Inflammatory cells present in bronchoalveolar lavage were counted as well as OVA-specific IgG1 and IgE were determined by ELISA assay. Our results showed in sensitized animals without Al(OH)3, that the PM2.5 exposure (609 +/- 12.73 mug/m3) acted as an adjuvant, triggering OVA-specific IgG1 and IgE concentration. Penh index increased approximately 9-fold after OVA challenge in adjuvant-sensitized animals as well as in S + PM2.5 group ( approximately 6-fold), meanwhile NS + FA and S + FA lacked response. S + Adj + PM2.5 group showed an increase significantly of eosinophils and neutrophils in bronchoalveolar lavage. PM2.5 composition was made up of inorganic elements and Polycyclic Aromatic Hydrocarbons, as well as endotoxins and beta-glucan, all these components could act as adjuvant. Our study demonstrated that acute inhalation of PM2.5 acted as an adjuvant, similar to the aluminum hydroxide effect, triggering allergic asthma in a guinea pig model. Furthermore, in sensitized animals with aluminum hydroxide an enhancing influence of PM2.5 exposure was observed as specific-hyperresponsiveness to OVA challenge (quickly response) and eosinophilic and neutrophilic airway inflammation. Fine particles from Mexico City is a complex mix, which play a significant role as adjuvant in allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1873-6424 (Electronic)IS - 0269-7491 (Linking)LA - engPT - Journal ArticleCO - Mexico -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envpol.2017.05.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570992">PM:28570992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Pollut\2017-228-474-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Pollut\2017-228-474-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Falcon-Rodriguez CI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envpol.2017.05.050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Czubinski,J.</style></author><author><style face="normal" font="Arial"> Montowska,M.</style></author><author><style face="normal" font="Arial"> Springer,E.</style></author><author><style face="normal" font="Arial"> Pospiech,E.</style></author><author><style face="normal" font="Arial"> Lampart-Szczapa,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immunoreactivity changes during lupin seed storage proteins digestion</style></title><secondary-title><style face="normal" font="Arial">Eur Food Res Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Food Res Technol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid composition</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Lupin</style></keyword><keyword><style face="normal" font="Arial"> Lupinus</style></keyword><keyword><style face="normal" font="Arial"> Manufacture</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seed proteins</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1438-2385</style></isbn><abstract><style face="normal" font="Arial">Lupin seeds are already widely used as an ingredient in different food products. Their attractiveness is related mainly to their high protein content that is characterised by a favourable amino acid composition, as well as the desired technological properties. However, with the increase of lupin seeds usage in food manufacture, their potential allergic properties have been demonstrated. The aim of this work was to study the immunoreactivity changes taking place during the enzymatic hydrolysis of the major seed proteins of narrow-leafed (Lupinus angustifolius, varieties Zeus and Bojar) and yellow (L. luteus, var. Lord and Parys) lupin species. Two digestion systems were used, namely the in vitro model simulating digestion taking place in digestive track, and specific hydrolysis carried out by trypsin. The obtained hydrolysates were analysed by means of one-dimensional electrophoresis, and their immunoreactivity was assessed with the use of a sera pool from patients with lupin-specific IgE. An important reduction in allergenicity of lupin seed proteins was observed when trypsin digestion was applied. The digestion in the in vitro model revealed the possibility of formation of neoallergens which were identified on the basis of mass spectrometry results as +¦-conglutin fraction</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00217-017-2910-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00217-017-2910-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Food Res Technol\20170604-CzubinskiJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Food Res Technol\20170604-CzubinskiJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170604, Czubinski J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00217-017-2910-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Clothier,H.J.</style></author><author><style face="normal" font="Arial"> Crawford,N.</style></author><author><style face="normal" font="Arial"> Russell,M.A.</style></author><author><style face="normal" font="Arial"> Buttery,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">SAEFVIC, Murdoch Childrens Research Institute, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia</style></title><secondary-title><style face="normal" font="Arial">Euro Surveill</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Euro Surveill</style></full-title></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunisation</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza vaccination</style></keyword><keyword><style face="normal" font="Arial"> Influenza Vaccine</style></keyword><keyword><style face="normal" font="Arial"> influenza vaccines</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">Australia was alerted to a possible increase in allergy-related adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC's initial investigation and upon conclusion of the 2015 influenza vaccination programme, to define the signal event and implications for vaccine programmes. Allergy-related AEFI were defined as anaphylaxis, angioedema, urticaria or generalised allergic reaction. Investigations compared 2015 TIV AEFI reports to previous years as proportions and reporting risk (RR) per 100,000, stratified by influenza vaccine brand. The initial investigation showed an increased proportion of allergy-related AEFI compared with 2014 (25% vs 12%), predominantly in adults, with insufficient clinical severity to alter the programme risk-benefit. While overall TIV AEFI RR in 2015 was similar to previous years (RR: 1.07, 95% confidence interval (CI): 0.88-1.29), we identified a near-doubling RR for allergy-related AEFI in 2015 (RR: 1.78, 95% CI: 1.14-- 2.80) from 2011 to 2014 with no difference by vaccine brand or severity increase identified. This increase in generalised allergy-related AEFI, across all used vaccine brands, supports evidence of variable reactogenicity arising from influenza vaccine strain variations. This investigation underlines the importance of effective seasonal influenza vaccine pharmacovigilance</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1560-7917 (Electronic)IS - 1025-496X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.2807/1560-7917.ES.2017.22.20.30535</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552101">PM:28552101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Euro Surveill\2017-22-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Euro Surveill\2017-22-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Clothier HJ</style></custom2><misc3><style face="normal" font="Arial">10.2807/1560-7917.ES.2017.22.20.30535</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zheng,F.</style></author><author><style face="normal" font="Arial"> Copotoiu,R.</style></author><author><style face="normal" font="Arial"> Tacquard,C.</style></author><author><style face="normal" font="Arial"> Demoulin,B.</style></author><author><style face="normal" font="Arial"> Malinovsky,J.M.</style></author><author><style face="normal" font="Arial"> Levy,B.</style></author><author><style face="normal" font="Arial"> Longrois,D.</style></author><author><style face="normal" font="Arial"> Barthel,G.</style></author><author><style face="normal" font="Arial"> Mertes,P.M.</style></author><author><style face="normal" font="Arial"> Marchal,F.</style></author><author><style face="normal" font="Arial"> Demoulin-Alexikova,S.</style></author><author><style face="normal" font="Arial"> Collange,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Anesthesiology , Zhongnan Hospital of Wuhan University , Wuhan , Hubei , China</style></auth-address><titles><title><style face="normal" font="Arial">Epinephrine but not vasopressin attenuates the airway response to anaphylactic shock in rats</style></title><secondary-title><style face="normal" font="Arial">Exp Lung Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Lung Res</style></full-title></periodical><pages end="166" start="158">158-166</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">airflow</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> respiratory resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The two life-threatening signs of anaphylactic shock (AS) are severe arterial hypotension and bronchospasm. Guidelines recommend epinephrine as first-line treatment. Arginine vasopressin (AVP) has been proposed as an alternative if epinephrine does not correct arterial hypotension. These two drugs may have beneficial, neutral or deleterious effects on airflow either directly or by modifying factors that regulate vasodilatation and/or edema in the bronchial wall. AIM OF THE STUDY: To compare the effects of epinephrine and AVP on airflow and airway leakage in a rat model of AS. MATERIALS AND METHODS: Thirty-two ovalbumin-sensitized rats were randomized into four groups: control (CON), AS without treatment (OVA), AS treated with epinephrine (EPI), and AS treated with AVP (AVP). Mean arterial pressure (MAP), respiratory resistance and elastance and microvascular leakage in the airways were measured. RESULTS: All OVA rats died within 20 minutes following ovalbumin injection. Ovalbumin induced severe arterial hypotension and airway obstruction (221 +/- 36 hPa.s.L-1 vs. vehicle 52 +/- 8 hPa.s.L-1; p &lt; 0.0001) associated with microvascular leakage distributed throughout the trachea, bronchi and intra-pulmonary airways. EPI and AVP extended survival time; EPI restored a higher level of MAP than AVP. Airway obstruction was attenuated by epinephrine (146 +/- 19 hPa.s.L-1; p &lt; 0.0001), but not by AVP (235 +/- 58 hPa.s.L-1; p = 0.42). CONCLUSIONS: Epinephrine was superior to AVP for alleviating the airway response in a rat model of AS. When bronchospasm and severe arterial hypotension are present during AS, epinephrine should be the drug of choice</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1521-0499 (Electronic)IS - 0190-2148 (Linking)LA - engPT - Journal ArticleCO - China -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1080/01902148.2017.1323981</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28541755">PM:28541755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Lung Res\20170525-ZhengF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Lung Res\20170525-ZhengF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Zheng F</style></custom2><misc3><style face="normal" font="Arial">10.1080/01902148.2017.1323981</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Z.</style></author><author><style face="normal" font="Arial"> Tao,Z.Z.</style></author><author><style face="normal" font="Arial"> Zhou,X.H.</style></author><author><style face="normal" font="Arial"> Wu,T.T.</style></author><author><style face="normal" font="Arial"> Ye,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430072, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Immunosuppressive effect of sinomenine in an allergic rhinitis mouse model</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="2410" start="2405">2405-2410</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) is a chronic allergic airway disease that has become a significant global public health issue. Sinomenine (SN), a natural phytochemical found in Sinomenium acutum, showed anti-inflammatory and immunosuppressive effect in previous studies. In order to explore the role of SN in the treatment of AR, mice were sensitized and challenged by ovalbumin (OVA) to establish an AR mouse model. SN was administered to AR mice orally, and compared with dexamethasone treatment as a positive control. Nasal symptoms and histopathological changes were used to evaluate the effect of SN treatment in the AR mice model. In addition, the levels of anti-OVA specific IgE and various cytokines in the serum were measured by enzyme-linked immunosorbent assay, while the levels of transforming growth factor-beta (TGF-beta) in the mucosa were also detected by western blot analysis and reverse transcription-quantitative polymerase chain reaction. AR mice that received SN treatment had reduced symptom scores and milder eosinophil infiltration. The serum levels of anti-OVA specific IgE and interleukin-4 significantly decreased following SN treatment. Furthermore, TGF-beta expression levels in the serum and nasal mucosa tissue in AR mice increased when compared with those in AR mice without treatment. In conclusion, SN treatment alleviated the symptoms of AR in mice and had an immunosuppressive effect on AR, which may result from the upregulation of TGF-beta</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4237</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28565855">PM:28565855</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-13-2405-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-13-2405-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Chen Z</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4237</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhami,S.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Edinburgh , UK</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis: epidemiology, aetiology and relevance for the clinic</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="895" start="889">889-895</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long term care</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Long-Term Care</style></keyword><keyword><style face="normal" font="Arial"> long-term outcome</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="Arial">Introduction Anaphylaxis is responsible for considerable morbidity and it may in some cases prove fatal. Areas covered This review summarises the findings from recent studies on the epidemiology and aetiology of anaphylaxis and draws on the insights from this work and recent international guidelines to consider the implications for clinical care. Acute management of anaphylaxis is centred on early recognition, treatment with adrenaline (epinephrine) and other essential life-support measures. The importance of longer-term care of patients with a history of or at risk of anaphylaxis are also considered with a view to minimising the risk of further reactions and decreasing the severity and impact of these reactions. Tailored individual anaphylaxis management plans should be a routine component of this longer-term care with provision of adrenaline auto-injectors to those at risk of further episodes of anaphylaxis. More generally, there is a need to ensure that there are standard protocols in place to ensure that risks of triggering anaphylaxis are minimised and appropriate acute and long-term care are provided if reactions occur. Expert commentary It is important to be aware that anaphylaxis may occur in patients of any age, sex or ethnicity. Early recognition and prompt treatment with adrenaline are potentially life-saving. Careful assessment of risk and appropriate long-term management are key to improving long-term outcomes in those at risk of repeat episodes of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1334552</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28562113">PM:28562113</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-889-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\2017-13-889-95.pdf</url></text-urls><image-urls><url ppv-ref="no">pdfpdf -no</url></image-urls></urls><custom2><style face="normal" font="Arial">20170531, Dhami S</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1334552</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Senti,G.</style></author><author><style face="normal" font="Arial"> Kundig,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Center , Wiesbaden , Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy in allergic rhinitis: Current use and future trends</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> CpG motifs</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> virus-like particle</style></keyword><keyword><style face="normal" font="Arial"> Virus-like particles</style></keyword><keyword><style face="normal" font="Arial"> viruslike particles</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Type-1 allergies are among the most chronic common diseases of humans. Allergen immunotherapy (AIT) is the only causative and disease-modifying treatment option besides allergen avoidance. Severe systemic adverse allergic reactions may be induced by every AIT treatment. Different approaches have been used to provide safer AIT preparations to lower or even totally overcome this risk. Areas covered: A structured literature recherche in Medline and Pubmed under inclusion of national and international guidelines and Cochrane meta-analyses has been performed aiming at reviewing clinical use of such approaches in AIT. New allergen preparations may include allergoids, recombinant allergens (recA) and modified recombinant allergens (recA) in subcutaneous as well as in mucosal immunotherapies (application e.g. using bronchial, nasal, oral and sublingual application) with sublingual being the established mucosal application route and new ways of application like intralymphatic and epicutaneous immunotherapy. Expert Commentary: Immune-modifying agents like Virus-like particles and CpG-motifs, adjuvants like MPL and aluminiumhydroxide are evaluated and found to increase and direct the immunological response towards immunological tolerance. New forms of allergen extracts can improve safety and efficacy of AIT and may change our way of performing allergen immunotherapy in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Germany -CO - France -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1333423</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532268">PM:28532268</url></web-urls><pdf-urls><url ppv-ref="no">Ludger.Klimek@allergiezentrum.org</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1333423</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kowalewicz-Kulbat,M.</style></author><author><style face="normal" font="Arial"> Locht,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology , University of Lodz , Lodz , Poland</style></auth-address><titles><title><style face="normal" font="Arial">BCG and protection against inflammatory and auto-immune diseases</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Vaccines</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Vaccines</style></full-title></periodical><pages end="10" start="1">1-10</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> BCG Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Bladder</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intervention Studies</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Bacillus Calmette-Guerin (BCG) is the only available vaccine against tuberculosis. Although its protective efficacy against pulmonary tuberculosis is still under debate, it provides protection against other mycobacterial diseases. BCG is also an effective therapy against superficial bladder cancer and potentially decreases overall childhood mortality. Areas covered: The purpose of this paper is to provide a state-of-the-art summary of the beneficial effects of BCG in inflammatory and auto-immune diseases. As a strong inducer of Th1 type immunity, BCG has been reported to protect against atopic conditions, such as allergic asthma, a Th2-driven disorder. Its protective effect has been well documented in mice, but still awaits definitive evidence in humans. Similarly, murine studies have shown a protective effect of BCG against auto-immune diseases, such as multiple sclerosis and insulin-dependent diabetes, but studies in humans have come to conflicting conclusions. Expert commentary: Studies in mice have shown a beneficial effect of the BCG vaccine against allergic asthma, multiple sclerosis and diabetes. However, the understanding of its mechanism is still fragmentary and requires further in depth research. Some observational or intervention studies in humans have also suggested a beneficial effect, but definitive evidence for this requires confirmation in carefully conducted prospective studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1744-8395 (Electronic)IS - 1476-0584 (Linking)LA - engPT - Journal ArticleCO - Poland -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1080/14760584.2017.1333906</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532186">PM:28532186</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Vaccines\2017-16-1-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Vaccines\2017-16-1-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Kowalewicz-Kulbat M</style></custom2><misc3><style face="normal" font="Arial">10.1080/14760584.2017.1333906</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barrios,J.</style></author><author><style face="normal" font="Arial"> Patel,K.R.</style></author><author><style face="normal" font="Arial"> Aven,L.</style></author><author><style face="normal" font="Arial"> Achey,R.</style></author><author><style face="normal" font="Arial"> Minns,M.S.</style></author><author><style face="normal" font="Arial"> Lee,Y.</style></author><author><style face="normal" font="Arial"> Trinkaus-Randall,V.E.</style></author><author><style face="normal" font="Arial"> Ai,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">Early life allergen-induced mucus overproduction requires augmented neural stimulation of pulmonary neuroendocrine cell secretion</style></title><secondary-title><style face="normal" font="Arial">FASEB J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">FASEB J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GABA</style></keyword><keyword><style face="normal" font="Arial"> hyperactivity</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innervation</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucin</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> neurotrophin</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="Arial">Pulmonary neuroendocrine cells (PNECs) are the only innervated airway epithelial cells. To what extent neural innervation regulates PNEC secretion and function is unknown. Here, we discover that neurotrophin 4 (NT4) plays an essential role in mucus overproduction after early life allergen exposure by orchestrating PNEC innervation and secretion of GABA. We found that PNECs were the only cellular source of GABA in airways. In addition, PNECs expressed NT4 as a target-derived mechanism underlying PNEC innervation during development. Early life allergen exposure elevated the level of NT4 and caused PNEC hyperinnervation and nodose neuron hyperactivity. Associated with aberrant PNEC innervation, the authors discovered that GABA hypersecretion was required for the induction of mucin Muc5ac expression. In contrast, NT4-/- mice were protected from allergen-induced mucus overproduction and changes along the nerve-PNEC axis without any defects in inflammation. Last, GABA installation restored mucus overproduction in NT4-/- mice after early life allergen exposure. Together, our findings provide the first evidence for NT4-dependent neural regulation of PNEC secretion of GABA in a neonatal disease model. Targeting the nerve-PNEC axis may be a valid treatment strategy for mucus overproduction in airway diseases, such as childhood asthma.-Barrios, J., Patel, K. R., Aven, L., Achey, R., Minns, M. S., Lee, Y., Trinkaus-Randall, V. E., Ai, X. Early life allergen-induced mucus overproduction requires augmented neural stimulation of pulmonary neuroendocrine cell secretion</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1530-6860 (Electronic)IS - 0892-6638 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1096/fj.201700115R</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28566470">PM:28566470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FASEB J\20170601-BarriosJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FASEB J\20170601-BarriosJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Barrios J</style></custom2><misc3><style face="normal" font="Arial">10.1096/fj.201700115R</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84617</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Pei,Y.</style></author><author><style face="normal" font="Arial"> Li,Q.</style></author><author><style face="normal" font="Arial"> Sun,Y.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Zhi,Y.</style></author><author><style face="normal" font="Arial"> Deng,R.</style></author><author><style face="normal" font="Arial"> Hou,Y.</style></author><author><style face="normal" font="Arial"> Hu,X.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Establishment of a Lateral Flow Colloidal Gold Immunoassay Strip for the Rapid Detection of Soybean Allergen +¦-Conglycinin</style></title><secondary-title><style face="normal" font="Arial">Food Anal Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Anal Methods</style></full-title></periodical><pages end="2435" start="2429">2429-2435</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> cross-reactions</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crossreactions</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> Scanner</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> soybean allergens</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergy</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1936-976X</style></isbn><abstract><style face="normal" font="Arial">A rapid lateral flow colloidal gold immunoassay strip was established in a sandwich format with the colloidal gold-labelled mouse anti-+¦-conglycinin monoclonal antibody (mAb) and the rabbit anti-+¦-conglycinin polyclonal antibody (pAb) in order to specifically identify a soybean allergen, +¦-conglycinin. Soybean and soy derivatives have become ubiquitous in many vegetarian and meat-based food products, and as a result, dietary avoidance has become difficult. Therefore, soybean avoidance is challenging for individuals with soybean allergy. In our study, the selected mAb showed high affinity to the target and no cross-reactivity with other soybean allergens. Based on the sandwich immunoassay principle, the rabbit pAb was applied in the test line with high titre. The assay could be accomplished within 10-ámin without sophisticated procedures. The limit of detection of the test strip was calculated at 1.66-ámg/kg in powdered milk using an optical density scanner that measures relative optical density. The assay showed high specificity for +¦-conglycinin, with no cross-reactions with other food allergens. The efficacy of the lateral flow test strip to detect +¦-conglycinin in powdered milk samples ranged between 80.8 and 89.2% with relative standard deviations of less than 7.2%. Therefore, the test strip is useful as a rapid and reliable detection method for +¦-conglycinin in powdered milk. In addition, this assay is suitable for monitoring +¦-conglycinin in other processed foods when samples are appropriately extracted</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12161-017-0800-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s12161-017-0800-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Anal Methods\2017-10-2429-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Anal Methods\2017-10-2429-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170603, Wang Y</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12161-017-0800-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zheng,S.</style></author><author><style face="normal" font="Arial"> Qin,G.</style></author><author><style face="normal" font="Arial"> Tian,H.</style></author><author><style face="normal" font="Arial"> Zhang,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Animal Husbandry and Veterinary Medicine, Shenyang Agricultural University, 120 Dongling Road, Shenyang, Liaoning 110866, PR China.</style></auth-address><titles><title><style face="normal" font="Arial">Three-dimensional structure of Gly m 5 (beta-conglycinin) plays an important role in its stability and overall allergenicity</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="388" start="381">381-388</pages><volume><style face="normal" font="Arial">234</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animal Husbandry</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil histamine release</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Gly m 5</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vitro digestion</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monomer</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Piglets</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="Arial">To date, there is insufficient knowledge regarding the relationship of the allegenicity and the three-dimensional structure of Gly m 5 (beta-conglycinin), a major allergen in soybean. In the present study, allergen Gly m 5 was demonstrated to generate three major digestion-resistant fragments when it was subjected to in vitro digestion. The largest fragment corresponded to the main body of the monomer and two smaller fragments corresponded to the main bodies of two modules of the monomer. Two major protease cleavage sites were located in the regions near to the connection between two modules. Coincidentally, the major digestion-resistant fragments were demonstrated to contain intact IgE epitopes and be capable to induce basophil histamine release in Gly m 5 sensitised piglets, indicating that the three-dimensional structure of Gly m 5 afforded the molecule some protection from complete degradation into small peptides and amino acids, and contributed to its overall allergenicity</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.05.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28551251">PM:28551251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-234-381-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-234-381-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Zheng S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.05.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rzychon,M.</style></author><author><style face="normal" font="Arial"> Brohee,M.</style></author><author><style face="normal" font="Arial"> Cordeiro,F.</style></author><author><style face="normal" font="Arial"> Haraszi,R.</style></author><author><style face="normal" font="Arial"> Ulberth,F.</style></author><author><style face="normal" font="Arial"> O'Connor,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Retieseweg 111, Geel 2440, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">The feasibility of harmonizing gluten ELISA measurements</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="154" start="144">144-154</pages><volume><style face="normal" font="Arial">234</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Belgium</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Calibrator</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Reference materials</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Selectivity</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="Arial">Many publications have highlighted that routine ELISA methods do not give rise to equivalent gluten content measurement results. In this study, we assess this variation between results and its likely impact on the enforcement of the EU gluten-free legislation. This study systematically examines the feasibility of harmonizing gluten ELISA assays by the introduction of: a common extraction procedure; a common calibrator, such as a pure gluten extract and an incurred matrix material. The comparability of measurements is limited by a weak correlation between kit results caused by differences in the selectivity of the methods. This lack of correlation produces bias that cannot be corrected by using reference materials alone. The use of a common calibrator reduced the between-assay variability to some extent, but variation due to differences in selectivity of the assays was unaffected. Consensus on robust markers and their conversion to "gluten content" are required</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.04.092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28551218">PM:28551218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-234-144-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-234-144-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Rzychon M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.04.092</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Benede,S.</style></author><author><style face="normal" font="Arial"> Garrido-Arandia,M.</style></author><author><style face="normal" font="Arial"> Martin-Pedraza,L.</style></author><author><style face="normal" font="Arial"> Bueno,C.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Villalba,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dpto. Bioquimica y Biologia Molecular I, Universidad Complutense de Madrid, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Multifactorial Modulation of Food-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="552">552-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Cross-link</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> filaggrin gene</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intracellular signaling</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumins</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandins</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Prevalence of food-induced anaphylaxis increases progressively and occurs in an unpredictable manner, seriously affecting the quality of life of patients. Intrinsic factors including age, physiological, and genetic features of the patient as well as extrinsic factors such as the intake of drugs and exposure to environmental agents modulate this disorder. It has been proven that diseases, such as mastocytosis, defects in HLA, or filaggrin genes, increase the risk of severe allergic episodes. Certain allergen families such as storage proteins, lipid transfer proteins, or parvalbumins have also been linked to anaphylaxis. Environmental factors such as inhaled allergens or sensitization through the skin can exacerbate or trigger acute anaphylaxis. Moreover, the effect of dietary habits such as the early introduction of certain foods in the diet, and the advantage of the breastfeeding remain as yet unresolved. Interaction of allergens with the intestinal cell barrier together with a set of effector cells represents the primary pathways of food-induced anaphylaxis. After an antigen cross-links the IgEs on the membrane of effector cells, a complex intracellular signaling cascade is initiated, which leads cells to release preformed mediators stored in their granules that are responsible for the acute symptoms of anaphylaxis. Afterward, they can also rapidly synthesize lipid compounds such as prostaglandins or leukotrienes. Cytokines or chemokines are also released, leading to the recruitment and activation of immune cells in the inflammatory microenvironment. Multiple factors that affect food-induced anaphylaxis are discussed in this review, paying special attention to dietary habits and environmental and genetic conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00552</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28559894">PM:28559894</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-552.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-552.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Benede S</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00552</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Escribese,M.M.</style></author><author><style face="normal" font="Arial"> Rosace,D.</style></author><author><style face="normal" font="Arial"> Chivato,T.</style></author><author><style face="normal" font="Arial"> Fernandez,T.D.</style></author><author><style face="normal" font="Arial"> Corbi,A.L.</style></author><author><style face="normal" font="Arial"> Barber,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine, IMMA Applied Molecular Medicine Institute, CEU San Pablo University, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Alternative Anaphylactic Routes: The Potential Role of Macrophages</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="515">515-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is an acute, life-threatening, multisystem syndrome resulting from the sudden release of mediators from effector cells. There are two potential pathways for anaphylaxis. The first one, IgE-dependent anaphylaxis, is induced by antigen (Ag) cross-linking of Ag-specific IgE bound to the high-affinity IgE receptor (FcepsilonRI) on mast cells and basophils. The second one, IgG-dependent anaphylaxis is induced by Ag cross-linking of Ag-specific IgG bound to IgG receptors (FcgammaRI, FcgammaRIIA, FcgammaRIIB, FcgammaRIIC, and FcgammaRIIIA) on macrophages, neutrophils, and basophils. Macrophages exhibit a huge functional plasticity and are capable of exerting their scavenging, bactericidal, and regulatory functions under a wide variety of tissue conditions. Herein, we will review their potential role in the triggering and development of anaphylaxis. Thereby, macrophages, among other immune cells, play a role in both anaphylactic pathways (1) by responding to anaphylactic mediators secreted by mast cells after specific IgE cross-linking or (2) by acting as effector cells in the anaphylactic response mediated by IgG. In this review, we will go over the cellular and molecular mechanisms that take place in the above-mentioned anaphylactic pathways and will discuss the clinical implications in human allergic reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00515</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28533777">PM:28533777</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-515.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-515.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Escribese MM</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00515</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foong,R.X.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author><author><style face="normal" font="Arial"> Fox,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma, Allergy and Lung Biology, Department of Paediatric Allergy, King's College London, Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Asthma, Food Allergy, and How They Relate to Each Other</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="89">89-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The association between atopic diseases is well known, and previous research has shown that having one atopic disease can predispose to having another. The link between asthma and food allergy has been well researched, but the exact relationship between the two atopic conditions is not fully understood. Food allergic infants are at increased risk for the development of asthma and are at risk of food-induced asthmatic episodes and also anaphylaxis. Having a diagnosis of both food allergy and asthma has also been shown to have an effect on the severity of a patient's disease including being at greater risk of severe asthmatic episodes. Therefore, understanding the relationship between these two conditions in order to treat and manage these children safely is crucial to clinicians</style></abstract><notes><style face="normal" font="Arial">DA - 20170524IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00089</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28536690">PM:28536690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-89.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-89.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170524, Foong RX</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00089</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cipriani,F.</style></author><author><style face="normal" font="Arial"> Calamelli,E.</style></author><author><style face="normal" font="Arial"> Ricci,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Unit, S. Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Allergen Avoidance in Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="103">103-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is the most frequent disease among the chronic respiratory disorders in pediatric age with an important social impact. In the last years, many efforts have been made to identify effective preventive approaches to get a better control of symptoms and to obtain the best future outcomes for the patients. In patients with allergic asthma triggered by the exposure to indoor allergens, the avoidance is the first intervention to prevent the appearance or the worsening of bronchial symptoms. This review article summarized the most recent evidence from literature about the efficacy of specific control interventions for the most important allergens. Even if a wide spectrum of interventions has been suggested and may help to reduce exposure to trigger allergy for sensitized patients suffering from respiratory allergy, evidence supporting the efficacy of these approaches is still weak and subject of controversy. However, the exposure control to specific airborne allergens is still widely recommended and may be effective as part of a holistic approach to reduce the severity of allergic respiratory symptoms in sensitized individuals</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00103</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540285">PM:28540285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-103.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Cipriani F</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00103</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rangel,A.H.N.</style></author><author><style face="normal" font="Arial"> Zaros,L.G.</style></author><author><style face="normal" font="Arial"> Lima,T.C.</style></author><author><style face="normal" font="Arial"> Borba,L.H.F.</style></author><author><style face="normal" font="Arial"> Novaes,L.P.</style></author><author><style face="normal" font="Arial"> Mota,L.F.M.</style></author><author><style face="normal" font="Arial"> Silva,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculdade de Ciencias Agrarias e Veterinarias, Universidade Estadual Paulista, Jaboticabal, SP, Brasil</style></auth-address><titles><title><style face="normal" font="Arial">Polymorphism in the Beta Casein Gene and analysis of milk characteristicsin Gir and Guzera dairy cattle</style></title><secondary-title><style face="normal" font="Arial">Genet Mol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Genet Mol Res</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allele frequency</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analysis of Variance</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cattle</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA extraction</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Hair Follicle</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">Several human health problems have been related to the allergenic constitution of bovine milk due to the body's immune reaction to milk proteins. It is necessary find solutions to minimize the occurrence of such reactions, given the importance of milk as a source of animal protein. The aim of this study was to evaluate the allelic frequency of the CSN2 gene and to evaluate differences in the characteristics of Gir and Guzera bovine milk. One hundred and fifty-six cows were used (68 Gir and 88 Guzera) from the Felipe Camarao Experimental Station herd of the Agricultural Research Corporation of RN (EMPARN). DNA extractions were carried out from hair follicles of the animals; the gene was then amplified and sequenced in an ABI 3100 automatic sequencer. The obtained sequences were submitted to analysis using the Geneious 5.6.5(R) program. Data were submitted to analysis of variance and to the Tukey-Kramer test at 5% probability and cluster analyses by main components were performed. Allele frequencies were 98 and 97% for the A2 allele and 0.96 and 0.93% for the genotype A2A2 for Gir and Guzera, respectively. Gir and Guzera animals showed differences in protein, lactose, and non-fat dry extract levels. Although correlations between milk yield and the production and some milk components are moderate, increases in milk yield are always greater than the increase in constituent yield. In addition, even though Guzera animals have a higher percentage of protein, lactose, and non-fat dry extract, milk from Zebu breeds is an alternative for individuals sensitive to beta-casein protein</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 1676-5680 (Electronic)IS - 1676-5680 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.4238/gmr16029592</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28549202">PM:28549202</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Genet Mol Res\20170526-RangelAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Genet Mol Res\20170526-RangelAH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Rangel AH</style></custom2><misc3><style face="normal" font="Arial">10.4238/gmr16029592</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nadim,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clalit Health Organization, Israel</style></auth-address><titles><title><style face="normal" font="Arial">[RED HERRING COMPLAINTS IN AN EIGHTEEN YEARS OLD FEMALE WITH A HYDATID CYST OF THE LUNG]</style></title><secondary-title><style face="normal" font="Arial">Harefuah</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Harefuah</style></full-title></periodical><pages end="667" start="665">665-667</pages><volume><style face="normal" font="Arial">155</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adolescence</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> Chills</style></keyword><keyword><style face="normal" font="Arial"> Cysts</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hemoptysis</style></keyword><keyword><style face="normal" font="Arial"> herring</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Brain and eye hydatid cysts are early symptomatic, as opposed to those developing in other organs, including lungs, where they remain asymptomatic through adolescence, even to adulthood, due to their slow growth. Hence, discovering that patients have lung hydatid cyst occurs, frequently, during random chest imaging. Up to thirty percent of pulmonary echinococcal cysts may rupture spontaneously, after chest or abdominal trauma. The main lung hydatidosis complaints, such as dyspnea and chest pain, are caused by the reduction of the functional area of the lung, expectoration of the tapeworm cystoides into the bronchial tree, or by compression of surrounding structures. When a hydatid cyst ruptures and its contents are poured into the pleural cavity or into the bronchi, the patient's condition will worsen deeply with severe hemoptysis, fever and chills, or anaphylactic shock. Therefore, treatment must be performed early upon the disclosure of these ominous findings. Our case report emphasizes that even if a cyst in the lung is symptomatic, it is frequently not diagnosed early, or might be completely missed by experienced clinicians. Moreso, when symptoms which are not recognized in the medical literature, such as symptoms of pulmonary hydatidic disease, exist as a "red herring" which blind the clinician from seeing the primary disease. Delay in diagnosis could also ostensibly occur due to physician's adherence to previous medical history, as he would think that a serious complaint, such as shortness of breath, is associated with health problems in the past, although, actually it is a result of a different diagnosis: a hydatid lung cyst</style></abstract><notes><style face="normal" font="Arial">DA - 20170522IS - 0017-7768 (Print)IS - 0017-7768 (Linking)LA - hebPT - English AbstractPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28530073">PM:28530073</url></web-urls></urls><custom2><style face="normal" font="Arial">20170522, Nadim N</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Wicht-Langhammer,S.</style></author><author><style face="normal" font="Arial"> von Bernus,L.</style></author><author><style face="normal" font="Arial"> Thorn,C.</style></author><author><style face="normal" font="Arial"> Cazan,D.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Hormann,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zentrum fur Rhinologie und Allergologie Wiesbaden, An den Quellen 10, 65183, Wiesbaden, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Anaphylactic reactions to vaccines : Chicken egg allergy and the influenza H1N1 vaccination]</style></title><secondary-title><style face="normal" font="Arial">HNO</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">HNO</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenalin</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Contraindication</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Cortisone</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza vaccination</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic reactions to influenza vaccinations are a well-known phenomenon; however, only a few published statistics give information on the risks. Patients with a chicken egg allergy must be particularly carefully handled during an influenza epidemic where vaccines produced using embryonated chicken eggs are primarily employed. METHODS: A selective literature review and analysis of the problem of allergic reactions to vaccinations was performed. RESULTS: The two most common relative contraindications among patients to be vaccinated are the presence of an egg allergy and a previous anaphylactic reaction to vaccination. These patients have a significantly increased risk of sustaining an adverse reaction. These high-risk patients should therefore only be vaccinated on the basis of thorough assessment of medical history, and then only with caution. The emergency routine must include sufficient precautionary measures, in case an anaphylactic reaction occurs. CONCLUSION: Current guidelines for the treatment of anaphylactic reactions are to be observed. Immediate treatment of the first symptoms of an anaphylactic reaction-i.v. administration of adrenalin, antihistamines, cortisone, and in some cases betamimetics-can usually prevent anaphylactic shock. Alternatively, a graded vaccination ("split protocol") and overnight surveillance can be considered in this group of patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1433-0458 (Electronic)IS - 0017-6192 (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00106-017-0363-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540396">PM:28540396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\HNO\20170525-KlimekL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\HNO\20170525-KlimekL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00106-017-0363-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sukenikova,L.</style></author><author><style face="normal" font="Arial"> Cerny,V.</style></author><author><style face="normal" font="Arial"> Novotna,O.</style></author><author><style face="normal" font="Arial"> Petraskova,P.</style></author><author><style face="normal" font="Arial"> Borakova,K.</style></author><author><style face="normal" font="Arial"> Kolarova,L.</style></author><author><style face="normal" font="Arial"> Prokesova,L.</style></author><author><style face="normal" font="Arial"> Hrdy,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic</style></auth-address><titles><title><style face="normal" font="Arial">Different capacity of in vitro generated myeloid dendritic cells of newborns of healthy and allergic mothers to respond to probiotic strain E. coli O83:K24:H31</style></title><secondary-title><style face="normal" font="Arial">Immunol Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Lett</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> activation marker</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> myeloid dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="Arial">Allergic diseases belong to one of the most common diseases with steadily increasing incidence even among young children. There is an urgent need to identify a prognostic marker pointing to increased risk of allergy development enabling early preventive measures introduction. It has been shown that administration of selected probiotic strains or mixtures could prevent allergy development. In our study, we have tested the capacity of probiotic strain Escherichia coli O83:K24:H31 (E. coli O83) to promote dendritic cell (DC) maturation and polarisation of immune responses. Increased presence of activation marker CD83 was observed on DC stimulated by E. coli O83 and DC of newborns of allergic mothers have significantly more increased cell surface presence of CD83 in comparison to children of healthy mothers. Increased gene expression and secretion of IL-10 was detected in DC stimulated with E. coli O83 being higher in DC of newborns of healthy mothers in comparison to allergic ones. Generally, increased presence of intracellular cytokines (IL-4, IL-13, IFN-gamma, IL-17A, IL-22, IL-10) was detected in CD4+ T cells cocultured with DC of children of allergic mothers in comparison to healthy ones. E. coli O83 primed DC significantly increased IL-10 and IL-17A in CD4 T cells of newborns of healthy mothers in comparison to the levels detected in CD4 T cells cocultured with control non-stimulated DC. We can conclude E. coli O83 induces dendritic cell maturation and IL-10 production in DC. Newborns of allergic mothers have generally increased reactivity of both DC and CD4 T cells which together with decreased capacity of DC of newborns of allergic mothers to produce IL-10 could support inappropriate immune responses development after allergen encounter</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1879-0542 (Electronic)IS - 0165-2478 (Linking)LA - engPT - Journal ArticleCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imlet.2017.05.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28554713">PM:28554713</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Lett\20170530-SukenikovaL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Lett\20170530-SukenikovaL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Sukenikova L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imlet.2017.05.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shargorodsky,J.</style></author><author><style face="normal" font="Arial"> Garcia-Esquinas,E.</style></author><author><style face="normal" font="Arial"> Umanskiy,R.</style></author><author><style face="normal" font="Arial"> Navas-Acien,A.</style></author><author><style face="normal" font="Arial"> Lin,S.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Coastal Ear Nose and Throat, Neptune, NJ</style></auth-address><titles><title><style face="normal" font="Arial">Household pet exposure, allergic sensitization, and rhinitis in the U.S. population</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="651" start="645">645-651</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> dog dander</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> pet exposure</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The effect of animal dander exposure on allergic sensitization may be age-dependent. A comparison between the association of the levels of exposure to pet allergen with rhinitis symptoms and allergic sensitization in children and adults is yet to be performed in the U.S. POPULATION: METHODS: Cross-sectional study of 3034 adults (age, 20 to 85 years) and 2104 children (age, 6 to 19 years) in the National Health and Nutrition Examination Survey, 2005-2006. Samples of household dust were collected to measure the amounts of indoor allergens in the participants' homes. Self-reported rhinitis was based on symptoms during the past 12 months, and allergen sensitization was defined as a positive response to any of the 19 specific immunoglobulin E (IgE) antigens tested. RESULTS: Higher levels of exposure to dog dander were associated with a higher prevalence of any allergic sensitization in adults (prevalence ratio [PR] 1.19; 95% confidence interval [CI], 1.01 to 1.39), but a lower prevalence in children (PR 0.84; 95% CI, 0.73 to 0.096), p-interaction by age group 0.02. Cat exposure was associated with an increased prevalence of rhinitis symptoms in adults (PR for the 3rd vs lowest tertile of cat dander concentrations: 1.14; 95% CI, 1.05 to 1.23) but not in children (PR for the 3rd vs lowest tertile of cat dander IgE concentrations: 0.86; 95% CI, 0.70 to 1.07), p-interaction 0.01. CONCLUSION: Allergic sensitization and symptomatic response to pet dander exposure may vary based on age. Further studies are necessary to assess the mechanisms for these apparent differences</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21929</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544629">PM:28544629</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170525-ShargorodskyJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170525-ShargorodskyJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Shargorodsky J</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21929</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Di Lorenzo,G.</style></author><author><style face="normal" font="Arial"> Leto-Barone,M.S.</style></author><author><style face="normal" font="Arial"> L Piana,S.</style></author><author><style face="normal" font="Arial"> Plaia,A.</style></author><author><style face="normal" font="Arial"> Di Bona,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento BioMedico di Medicina Interna e Specialistica (Di.Bi.M.I.S.), Universita degli Studi di Palermo, Scuola di Medicina e Chirurgia, Palermo, Italy</style></auth-address><titles><title><style face="normal" font="Arial">The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="669" start="660">660-669</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although the preventive efficacy of allergen immunotherapy (AIT) in the onset of new allergen sensitizations has been asserted by many reviews, position papers, and consensus conferences, the evidence available is from only 3 studies. The objective of this work was a systematic review to evaluate the preventive efficacy of AIT in the onset of new allergen sensitizations. The end-point was the risk difference (RD) in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. METHODS: Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (until November 30th, 2016) were done. Random-effects and fixed-effects model meta-analyses were performed. Randomized controlled trials or observational studies comparing children treated with AIT with house dust mite (HDM) to subjects who did not receive AIT, with a long-term observation period (at least 3 years including treatment and follow-up) have been included. RESULTS: Eight studies totaling 721 children (390 treated with AIT and 331 with pharmacotherapy) met the inclusion criteria. The risk of bias was high. Low evidence supports the conclusion that AIT prevents the onset of new allergen sensitizations, with 3 of 8 studies reporting a reduction in the onset of new sensitizations in patients treated with AIT vs pharmacotherapy. Our meta-analysis found no difference between AIT and pharmacotherapy, with high heterogeneity (RD, -0.10; 95% confidence interval [CI], -0.31 to 0.11; p = 0.32; I2 = 91.4%). CONCLUSION: The data of this systematic review do not support a preventive effect in the onset of new allergen sensitizations, in children treated with AIT in comparison with those treated with pharmacotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21946</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544523">PM:28544523</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170525-DiLorenzoG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170525-DiLorenzoG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Di Lorenzo G</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21946</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shin,J.H.</style></author><author><style face="normal" font="Arial"> Lee,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDepartment of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">How does the pattern of aeroallergen sensitization change over time across all ages?</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="659" start="652">652-659</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Identification of aeroallergen sensitization is important for diagnosis and management of allergic diseases. Immunoglobulin E (IgE) sensitization status is known to change over time. However, few studies have explored changes in sensitization patterns across all age groups. The aim of the present study was to evaluate the changing patterns of in vitro IgE sensitization tests in allergic rhinitis patients across all age groups. METHODS: We recruited all patients who were diagnosed as having rhinitis and who underwent in vitro IgE sensitization testing from 2007 to 2016. Of these, we included 138 who underwent repeat testing. We analyzed epidemiological data and allergen sensitization patterns. RESULTS: Of all patients, 56.5% of exhibited changes in allergen sensitization patterns. The allergens to which all age groups were sensitive were most commonly mites, with the exception of patients aged 40 to 59 years. The age group in which "new sensitization," composed of those with "newly developed sensitization" and "sensitization to more allergens," was most frequent was the 2 to 12 years old group, followed by the 20 to 39 years old group. The age group in which "desensitization," composed of those with "negative conversion" and "desensitization to fewer allergens," was most prevalent was the 20 to 39 years old group followed by the 13 to 19 years old group. Grass pollen was the most common newly-sensitized allergen and also the most common desensitized allergen. CONCLUSION: IgE sensitization to aeroallergens can change in individuals with allergy. These changes may be different according to the patient's age. If rhinitis symptoms or treatment efficacy changes, repeat IgE sensitization testing is needed to find changes in allergen sensitization patterns</style></abstract><notes><style face="normal" font="Arial">DA - 20170518IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21942.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28518538">PM:28518538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170518-ShinJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170518-ShinJH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170518, Shin JH</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21942.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84631</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choi,J.E.</style></author><author><style face="normal" font="Arial"> Kim,K.R.</style></author><author><style face="normal" font="Arial"> Noh,Y.</style></author><author><style face="normal" font="Arial"> Chung,W.H.</style></author><author><style face="normal" font="Arial"> Cho,Y.S.</style></author><author><style face="normal" font="Arial"> Chung,S.K.</style></author><author><style face="normal" font="Arial"> Dhong,H.J.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Intranasal distribution and clearance of thermoreversible gel in an animal model</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="711" start="705">705-711</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug delivery</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescein</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Poloxamer 407 (P407) has been investigated for an intranasal drug delivery system. However, there is little known about the distribution and clearance of intranasally applied P407. The purpose of this study was to evaluate the distribution and clearance time of P407 in an animal model. METHODS: Five male pigs were administered the experimental solution (18% of P407 with 0.01% of fluorescein) and the control solution (normal saline with 0.01% of fluorescein) into their right and left nasal cavity, respectively. For quantitative analysis, endoscopic images of each nasal cavity were taken immediately and at 10, 20, 30, and 60 minutes after intranasal administration. RESULTS: The experimental group showed a significantly wider distribution of fluorescein than the control group at 10, 20, and 30 minutes. The experimental group also showed a significantly higher mean intensity of fluorescein than the control group at 10, 20, and 30 minutes. The mean intensity in the control group was significantly decreased during 30 minutes but the mean intensity in the experimental group was significantly decreased during 60 minutes. CONCLUSION: A substantial amount of P407 remained in the nasal cavity for at least 30 minutes post-application</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21944</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544659">PM:28544659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170525-ChoiJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170525-ChoiJE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Choi JE</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21944</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84632</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morikawa,T.</style></author><author><style face="normal" font="Arial"> Fukuoka,A.</style></author><author><style face="normal" font="Arial"> Matsushita,K.</style></author><author><style face="normal" font="Arial"> Yasuda,K.</style></author><author><style face="normal" font="Arial"> Iwasaki,N.</style></author><author><style face="normal" font="Arial"> Akasaki,S.</style></author><author><style face="normal" font="Arial"> Fujieda,S.</style></author><author><style face="normal" font="Arial"> Yoshimoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Allergic Diseases, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Activation of group 2 innate lymphoid cells exacerbates and confers corticosteroid-resistance to mouse nasal type 2 inflammation</style></title><secondary-title><style face="normal" font="Arial">Int Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunol</style></full-title></periodical><pages end="233" start="221">221-233</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal inflammation</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Papain</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">Both Th2 cells and group 2 innate lymphoid cells (ILC2s) contribute to allergic diseases. However, their exact role and relationship in nasal allergic disorders is unclear. In this study, we investigated the cooperation of Th2 cells and ILC2s in a mouse model of nasal allergic disorder. To differentially activate Th2 cells and/or ILC2s in nasal mucosa, mice were intranasally administered ovalbumin (OVA) antigen, papain, an ILC2-activator, or both for 2 weeks. Epithelial thickness and number of eosinophils in the nasal mucosa were evaluated at 24 hours after the final challenge. Intranasal administration of OVA and papain preferentially activated Th2 cells and ILC2s, respectively, in the nose. Both OVA and papain increased the nasal epithelial thickness and number of eosinophils, and their coadministration significantly enhanced the symptoms. Although T/B-cell-deficient mice showed severely decreased nasal symptoms induced by OVA or OVA-plus-papain, the mice still showed slight papain-induced nasal symptoms. In ILC2-deficient mice, OVA-plus-papain-induced nasal symptoms were suppressed to the same level as OVA-alone. Similarly, IL-33- and ST2-deficient mice showed decreased OVA-plus-papain-induced nasal symptoms. IL-5 induced eosinophilia only, but IL-13 contributed to both nasal epithelial thickening and eosinophilia induced by OVA-plus-papain. Dexamethasone ameliorated OVA-alone-induced nasal epithelial thickening. However, OVA-plus-papain-induced nasal epithelial thickening was only partially controlled by dexamethasone. These results demonstrate that IL-33/ST2-pathway-mediated ILC2 activation exacerbated Th2-cell-induced nasal inflammation by producing IL-13. Although Th2-cell-alone-induced nasal inflammation was controlled by corticosteroid treatment, the activation of ILC2s conferred treatment resistance. Therefore, ILC2s and its activators could be therapeutic targets for treatment-refractory nasal allergic disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1460-2377 (Electronic)IS - 0953-8178 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1093/intimm/dxx030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28541554">PM:28541554</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunol\20170525-MorikawaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunol\20170525-MorikawaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Morikawa T</style></custom2><misc3><style face="normal" font="Arial">10.1093/intimm/dxx030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wijerathne,C.U.B.</style></author><author><style face="normal" font="Arial"> Seo,C.S.</style></author><author><style face="normal" font="Arial"> Song,J.W.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author><author><style face="normal" font="Arial"> Moon,O.S.</style></author><author><style face="normal" font="Arial"> Won,Y.S.</style></author><author><style face="normal" font="Arial"> Kwon,H.J.</style></author><author><style face="normal" font="Arial"> Son,H.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Isoimperatorin attenuates airway inflammation and mucus hypersecretion in an ovalbumin-induced murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="76" start="67">67-76</pages><volume><style face="normal" font="Arial">49</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">Isoimperatorin (IMP), an active natural furocoumarin, has numerous pharmacologic effects, including anti-inflammatory, analgesic, antispasmodic, and anticancer activities. This study aimed to evaluate the preventive activity of IMP in an ovalbumin (OVA)-induced murine model of asthma and to investigate its possible molecular mechanisms. Female BALB/c mice were sensitized on days 0 and 14 via intraperitoneal injection of 20mug OVA. On days 21-23 after the initial sensitization, the mice received an airway challenge with OVA (1% w/v in PBS) for 1h; meanwhile, IMP (10 or 30mg/kg once daily) was administered by gavage on days 18-23. Our results revealed that IMP significantly lowered the productions of interleukin (IL)-4, IL-5, IL-13, eotaxin, and immunoglobulin (Ig)E in bronchoalveolar lavage fluid (BALF), plasma, or lung tissues. Histological studies showed that IMP inhibited OVA-induced inflammatory cell infiltration and mucus production in the respiratory tract. In addition, pretreatment with IMP suppressed the activation of p38 mitogen-activated protein kinase (p38 MAPK), extracellular-signal-regulated kinases 1/2 (ERK1/2), and nuclear factor-kappaB (NF-kappaB). Together, these results suggest that IMP effectively inhibits airway inflammation and mucus hypersecretion by downregulating the levels of Th2 cytokines and inhibiting NF-kappaB and MAPK pathways</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.05.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28551494">PM:28551494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-49-67-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-49-67-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Wijerathne CU</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.05.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fu,M.</style></author><author><style face="normal" font="Arial"> Fu,S.</style></author><author><style face="normal" font="Arial"> Ni,S.</style></author><author><style face="normal" font="Arial"> Zou,L.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Hong,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, School of Pharmacy, Jilin University, Changchun 130021, China</style></auth-address><titles><title><style face="normal" font="Arial">Anti-inflammatory effect of epigallocatechin gallate in a mouse model of ovalbumin-induced allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="108" start="102">102-108</pages><volume><style face="normal" font="Arial">49</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase-2</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="5" Year="2017">2017/5/27</year></dates><abstract><style face="normal" font="Arial">Currently, a variety of studies have demonstrated that green tea has anti-allergic properties, and the major polyphenolic compound, epigallocatechin gallate (EGCG), plays a significant role. Some research indicates that EGCG reduces the production and expression of allergy-related substances. Therefore, EGCG has a potential effect of reducing allergic rhinitis (AR). In this study, the effect of EGCG on allergic rhinitis in an ovalbumin (OVA)-induced mouse model was investigated. After administration of EGCG, the number of sneezes and the occurrence of nasal rubbing were significantly decreased, the concentrations of immunoglobulin E (IgE) and histamine were suppressed in AR mouse serum, the levels of interleukin (IL)-1beta, IL-4, and IL-6 were reduced in AR mice nasal lavage fluid (NLF), and the nasal mucosa mRNA and protein expression of cyclooxygenase 2 (COX-2), IL-1beta, IL-4, and IL-6 were inhibited. The data indicate that EGCG has a beneficial effect of reducing allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.05.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28558302">PM:28558302</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-49-102-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-49-102-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Fu M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.05.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nogami,K.</style></author><author><style face="normal" font="Arial"> Shima,M.</style></author><author><style face="normal" font="Arial"> Fukutake,K.</style></author><author><style face="normal" font="Arial"> Fujii,T.</style></author><author><style face="normal" font="Arial"> Taki,M.</style></author><author><style face="normal" font="Arial"> Matsushita,T.</style></author><author><style face="normal" font="Arial"> Higasa,S.</style></author><author><style face="normal" font="Arial"> Sato,T.</style></author><author><style face="normal" font="Arial"> Sakai,M.</style></author><author><style face="normal" font="Arial"> Arai,M.</style></author><author><style face="normal" font="Arial"> Uchikawa,H.</style></author><author><style face="normal" font="Arial"> Engl,W.</style></author><author><style face="normal" font="Arial"> Abbuehl,B.</style></author><author><style face="normal" font="Arial"> Konkle,B.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Nara Medical University, Kashihara, Japan. r</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations</style></title><secondary-title><style face="normal" font="Arial">Int J Hematol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Hematol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Factor Viii</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hemophilia A</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene</style></keyword><keyword><style face="normal" font="Arial"> Polyethylene glycol</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prophylactic treatment</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="Arial">Rurioctocog alfa pegol (BAX 855) is a novel third-generation recombinant factor VIII whose active ingredient is chemically modified with polyethylene glycol. A global multicenter phase 2/3 study of the product in 137 patients (including 11 patients from Japan) with severe hemophilia A aged 12-65 years, reported an extended half-life and a good tolerability profile, as well as a significantly lower annualized bleeding rate in the prophylactic treatment arm than in the on-demand treatment arm. Using descriptive statistics, a post hoc analysis was performed to compare the pharmacokinetics, safety, and efficacy profiles of the product in the Japanese subpopulation and the overall population. Extended half-life was demonstrated in the Japanese subpopulation. The mean [standard deviation (SD)] annualized bleeding rates in the prophylactic treatment arm were 3.7 (4.7) for the overall population (n = 120) and 4.0 (3.4) for the Japanese subpopulation (n = 11). The proportion of bleeds reported as excellent or good was 94.9% (149/157) in the overall population, whereas that in the Japanese subpopulation was 92.3% (12/13). No FVIII inhibition or anaphylactic reaction was reported in the Japanese subpopulation. The post hoc comparisons demonstrated similar pharmacokinetic, safety, and efficacy profiles between the overall population and the Japanese subpopulation</style></abstract><notes><style face="normal" font="Arial">DA - 20170527IS - 1865-3774 (Electronic)IS - 0925-5710 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Austria -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12185-017-2265-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550352">PM:28550352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Hematol\20170527-NogamiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Hematol\20170527-NogamiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170527, Nogami K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12185-017-2265-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84636</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chevigne,A.</style></author><author><style face="normal" font="Arial"> Campizi,V.</style></author><author><style face="normal" font="Arial"> Szpakowska,M.</style></author><author><style face="normal" font="Arial"> Bourry,D.</style></author><author><style face="normal" font="Arial"> Dumez,M.E.</style></author><author><style face="normal" font="Arial"> Martins,J.C.</style></author><author><style face="normal" font="Arial"> Matagne,A.</style></author><author><style face="normal" font="Arial"> Galleni,M.</style></author><author><style face="normal" font="Arial"> Jacquet,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Macromolecules Biologiques, Centre for Protein Engineering, University of Liege, B-4000 Liege, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">The Lys-Asp-Tyr Triad within the Mite Allergen Der p 1 Propeptide Is a Critical Structural Element for the pH-Dependent Initiation of the Protease Maturation</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1087">E1087-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Engineering</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="5" Year="2017">2017/5/20</year></dates><abstract><style face="normal" font="Arial">The major house dust mite allergen, Der p 1, is a papain-like cysteine protease expressed as an inactive precursor, proDer p 1, carrying an N-terminal propeptide with a unique structure. The maturation of the zymogen into an enzymatically-active form of Der p 1 is a multistep autocatalytic process initiated under acidic conditions through conformational changes of the propeptide, leading to the loss of its inhibitory ability and its subsequent gradual cleavage. The aims of this study were to characterize the residues present in the Der p 1 propeptide involved in the initiation of the zymogen maturation process, but also to assess the impact of acidic pH on the propeptide structure, the activity of Der p 1 and the fate of the propeptide. Using various complementary enzymatic and structural approaches, we demonstrated that a structural triad K17p-D51p-Y19p within the N-terminal domain of the propeptide is essential for its stabilization and the sensing of pH changes. Particularly, the protonation of D51p under acidic conditions unfolds the propeptide through disruption of the K17p-D51p salt bridge, reduces its inhibition capacity and unmasks the buried residues K17p and Y19p constituting the first maturation cleavage site of the zymogen. Our results also evidenced that this triad acts in a cooperative manner with other propeptide pH-responsive elements, including residues E56p and E80p, to promote the propeptide unfolding and/or to facilitate its proteolysis. Furthermore, we showed that acidic conditions modify Der p 1 proteolytic specificity and confirmed that the formation of the first intermediate represents the limiting step of the in vitro Der p 1 maturation process. Altogether, our results provide new insights into the early events of the mechanism of proDer p 1 maturation and identify a unique structural triad acting as a stabilizing and a pH-sensing regulatory element</style></abstract><notes><style face="normal" font="Arial">DA - 20170522IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Luxembourg -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18051087</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28531096">PM:28531096</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1087.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1087.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Chevigne A</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18051087</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Van Rijt,L.S.</style></author><author><style face="normal" font="Arial"> Utsch,L.</style></author><author><style face="normal" font="Arial"> Lutter,R.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Oxidative Stress: Promoter of Allergic Sensitization to Protease Allergens?</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1112">E1112-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergens</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Tight Junctions</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">Allergies arise from aberrant T helper type 2 responses to allergens. Several respiratory allergens possess proteolytic activity, which has been recognized to act as an adjuvant for the development of a Th2 response. Allergen source-derived proteases can activate the protease-activated receptor-2, have specific effects on immune cells by cleaving cell membrane-bound regulatory molecules, and can disrupt tight junctions. The protease activity can induce a non-allergen-specific inflammatory response in the airways, which will set the stage for an allergen-specific Th2 response. In this review, we will discuss the evidence for the induction of oxidative stress as an underlying mechanism in Th2 sensitization to proteolytic allergens. We will discuss recent data linking the proteolytic activity of an allergen to its potential to induce oxidative stress and how this can facilitate allergic sensitization. Based on experimental data, we propose that a less proficient anti-oxidant response to allergen-induced oxidative stress contributes to the susceptibility to allergic sensitization. Besides the effect of oxidative stress on the immune response, we will also discuss how oxidative stress can increase the immunogenicity of an allergen by chemical modification</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18061112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28545251">PM:28545251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1112.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1112.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, van Rijt LS</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18061112</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kohn,J.B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">What Is Oral Allergy Syndrome?</style></title><secondary-title><style face="normal" font="Arial">J Acad Nutr Diet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Acad Nutr Diet</style></full-title></periodical><pages end="" start="988">988-</pages><volume><style face="normal" font="Arial">117</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 2212-2672 (Print)IS - 2212-2672 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jand.2017.03.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550892">PM:28550892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Acad Nutr Diet\2017-117-988.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Acad Nutr Diet\2017-117-988.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Kohn JB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jand.2017.03.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eggleston,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Professor Emeritus of Pediatrics, Johns Hopkins University School of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Cockroach Allergy and Urban Asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="390" start="389">389-390</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170522IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28528788">PM:28528788</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170522-EgglestonPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170522-EgglestonPA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Eggleston PA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gobl,C.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> Najafi,N.</style></author><author><style face="normal" font="Arial"> Schrank,E.</style></author><author><style face="normal" font="Arial"> Madl,T.</style></author><author><style face="normal" font="Arial"> Kosol,S.</style></author><author><style face="normal" font="Arial"> Madritsch,C.</style></author><author><style face="normal" font="Arial"> Dorofeeva,Y.</style></author><author><style face="normal" font="Arial"> Flicker,S.</style></author><author><style face="normal" font="Arial"> Thalhamer,J.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Zangger,K.</style></author><author><style face="normal" font="Arial"> Tjandra,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Chemistry/Organic and Bioorganic Chemistry, University of Graz, Graz, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Flexible IgE epitope containing domains of Phl p 5 cause high allergenic activity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Cross-link</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Phl p 5</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">This is the first study determining the three-dimensional structure of Phl p 5a which reveals a novel mechanism for high allergenic activity based on flexibly connected IgE-reactive domains which cross-link effector cell-bound IgE more efficiently than isolated rigid globular proteins. These findings may also form a basis for specific immunotherapy strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532654">PM:28532654</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170523-GoblC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170523-GoblC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Gobl C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teufelberger,A.R.</style></author><author><style face="normal" font="Arial"> Nordengrun,M.</style></author><author><style face="normal" font="Arial"> Braun,H.</style></author><author><style face="normal" font="Arial"> Maes,T.</style></author><author><style face="normal" font="Arial"> De Grove,K.</style></author><author><style face="normal" font="Arial"> Holtappels,G.</style></author><author><style face="normal" font="Arial"> O'Brien,C.</style></author><author><style face="normal" font="Arial"> Provoost,S.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author><author><style face="normal" font="Arial"> Goncalves,A.</style></author><author><style face="normal" font="Arial"> Beyaert,R.</style></author><author><style face="normal" font="Arial"> Declercq,W.</style></author><author><style face="normal" font="Arial"> Vandenabeele,P.</style></author><author><style face="normal" font="Arial"> Krysko,D.V.</style></author><author><style face="normal" font="Arial"> Broker,B.M.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Krysko,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">The IL-33/ST2 axis is crucial in type 2 airway responses induced by the Staphylococcus aureus protease SplD</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immune system</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> soluble ST2</style></keyword><keyword><style face="normal" font="Arial"> ST2</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic airway inflammatory diseases such as chronic rhinosinusitis with nasal polyps and asthma showed increased nasal Staphylococcus aureus (S. aureus) colonization. Serine protease like protein D (SplD) and other closely related proteases secreted by S. aureus have recently been identified as inducers of allergic asthma in humans and mice but their mechanism of action is largely unknown. OBJECTIVE: We investigated the role of recombinant SplD in driving Th2-biased responses and IgE formation in a murine model of allergic asthma. METHODS: Allergic asthma was induced in C57BL/6 J wild type mice, TLR4 knockout mice (TLR4-/-) and Rag2 knockout mice (Rag2-/-) by repeated intratracheal applications of SplD. Inflammatory parameters in the airways were assessed by flow cytometry, ELISA, Luminex and immunohistochemistry. Serum SplD-specific IgE levels were analysed by ELISA. RESULTS: We observed that repeated intratracheal exposure to SplD led to IL-33 and eotaxin production, eosinophilia, bronchial hyperreactivity and goblet cell hyperplasia in the airways. Blocking the IL-33 activity using a soluble ST2 receptor (sST2) significantly decreased the numbers of eosinophils, IL-13+ILC2s, IL-13+CD4+ T cells, and IL-5 and IL-13 production by lymph node cells but had no effect on IgE production. SplD-induced airway inflammation and IgE production were largely dependent on the presence of the functional adaptive immune system and independent of TLR4 signalling. CONCLUSION: The S. aureus-derived protein SplD is a potent allergen of S. aureus and induces a Th2-biased inflammatory response in the airways in an IL-33-dependent, but TRL4-independent manner. sST2 could be an efficient strategy to interfere with SplD-induced Th2 inflammation, but does not prevent the allergic sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532656">PM:28532656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170523-TeufelbergerAR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170523-TeufelbergerAR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Teufelberger AR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turkeltaub,P.C.</style></author><author><style face="normal" font="Arial"> Cheon,J.</style></author><author><style face="normal" font="Arial"> Friedmann,E.</style></author><author><style face="normal" font="Arial"> Lockey,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Independent Scientist, Bethesda, Md.</style></auth-address><titles><title><style face="normal" font="Arial">The Influence of Asthma and/or Hay Fever on Pregnancy: Data from the 1995 National Survey of Family Growth</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1690" start="1679">1679-1690</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Low birth weight</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy Outcome</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is associated with adverse pregnancy outcomes. At the same time there is a worldwide increase in asthma and hay fever. OBJECTIVE: This study addresses whether asthma and/or hay fever adversely influence pregnancy outcomes. METHODS: Data from the 1995 National Survey of Family Growth that include a history of diagnosed asthma, hay fever, and adverse pregnancy outcomes in 10,847 women representative of the US population aged 15 to 44 years were analyzed. RESULTS: Women with the allergic phenotypes asthma and hay fever and hay fever only had no significant increase in adverse pregnancy outcomes (spontaneous pregnancy loss, preterm birth, infant low birth weight), whereas women with the nonatopic phenotype asthma only (without hay fever) did. The study did not evaluate endotypes. CONCLUSIONS: This study provides new data that the allergic phenotypes, asthma and hay fever and hay fever only, are compatible with healthy pregnancy, whereas the nonatopic asthma phenotype, asthma only, adversely impacts pregnancy</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - South KOrea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550983">PM:28550983</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1679-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1679-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Turkeltaub PC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sato,S.</style></author><author><style face="normal" font="Arial"> Yamamoto,M.</style></author><author><style face="normal" font="Arial"> Yanagida,N.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author><author><style face="normal" font="Arial"> Imai,T.</style></author><author><style face="normal" font="Arial"> Nagao,M.</style></author><author><style face="normal" font="Arial"> Borres,M.P.</style></author><author><style face="normal" font="Arial"> Moverare,R.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Jug r 1 sensitization is important in walnut-allergic children and youth</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1786" start="1784">1784-1786</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Jug r 1</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552380">PM:28552380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1784-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1784-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Sato S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sinert,R.</style></author><author><style face="normal" font="Arial"> Levy,P.</style></author><author><style face="normal" font="Arial"> Bernstein,J.A.</style></author><author><style face="normal" font="Arial"> Body,R.</style></author><author><style face="normal" font="Arial"> Sivilotti,M.L.A.</style></author><author><style face="normal" font="Arial"> Moellman,J.</style></author><author><style face="normal" font="Arial"> Schranz,J.</style></author><author><style face="normal" font="Arial"> Baptista,J.</style></author><author><style face="normal" font="Arial"> Kimura,A.</style></author><author><style face="normal" font="Arial"> Nothaft,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, SUNY Downstate Medical Center/Kings County Hospital Medical Center, Brooklyn, NY.</style></auth-address><titles><title><style face="normal" font="Arial">Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1409" start="1402">1402-1409</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACE-I</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Angiotensin-converting enzyme inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Bradykinin</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Icatibant</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Upper airway angioedema is a rare, unpredictable, and at times life-threatening adverse effect of angiotensin-converting enzyme inhibitors (ACE-Is) with no existing effective pharmacologic treatment. Icatibant is a bradykinin B2 receptor antagonist that may be beneficial in patients with ACE-I-induced angioedema. OBJECTIVE: We aimed to evaluate the efficacy of icatibant in subjects with ACE-I-induced angioedema. METHODS: At 31 centers in 4 countries, adults on ACE-Is who presented within 12 hours of the onset of at least moderately severe angioedema were randomized 1:1 to icatibant 30 mg or placebo administered subcutaneously. The primary efficacy end point was time to meeting discharge criteria after study drug administration, based on the severity of airway symptoms assessed hourly by a blinded physician using clinical ratings across 4 domains. RESULTS: A total of 121 subjects were randomized (icatibant, n = 61; placebo, n = 60); 118 received treatment a median of 7.8 hours from symptom onset. We observed no difference in time to meeting discharge criteria between groups (median, 4.0 hours in each group; P = .63). There also was no difference in time to onset of symptom relief (median, icatibant, 2.0 hours; placebo, 1.6 hours; P = .57) or any other secondary end point. Similar findings were noted in prespecified and post hoc subgroup analyses stratified by symptom severity, time interval to treatment, age, and other clinical covariates. No new safety signals were detected. CONCLUSIONS: Icatibant was no more efficacious than placebo in at least moderately severe ACE-I-induced angioedema of the upper airway</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552382">PM:28552382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170529-SinertR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170529-SinertR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Sinert R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Coop,C.A.</style></author><author><style face="normal" font="Arial"> Schapira,R.S.</style></author><author><style face="normal" font="Arial"> Freeman,T.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center, San Antonio, Tex</style></auth-address><titles><title><style face="normal" font="Arial">Are ACE Inhibitors and Beta-blockers Dangerous in Patients at Risk for Anaphylaxis?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1211" start="1207">1207-1211</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">ACE</style></keyword><keyword><style face="normal" font="Arial"> ACE inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Beta-blockers</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Radiocontrast media</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">The objective of this article is to review the available studies regarding angiotensin converting enzyme (ACE) inhibitors and beta-blockers and their effect on patients at risk for anaphylaxis. A literature search was conducted in PUBMED to identify peer-reviewed articles using the following keywords: anaphylaxis, ACE inhibitor, beta-blocker, food allergy, radiocontrast media, venom allergy, skin testing, and immunotherapy. Some studies show an increased risk of anaphylaxis in patients who are taking ACE inhibitors and beta-blockers, whereas others studies do not show an increased risk. For venom immunotherapy, there are more data supporting the concomitant use of beta-blockers and ACE inhibitors in the build-up and maintenance phases. Most of the medical literature is limited to case reports and retrospective data. Prospective controlled trials are needed on this important topic. For those patients at risk of anaphylaxis who lack cardiovascular disease, it is recommended to avoid beta-blockers and possibly ACE inhibitors. However, for those patients with cardiovascular disease, beta-blockers and ACE inhibitors have been shown to increase life expectancy. Consideration should be given for the concomitant use of these medications while patients are receiving venom immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552379">PM:28552379</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1207-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1207-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Coop CA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,P.H.</style></author><author><style face="normal" font="Arial"> Ue,K.L.</style></author><author><style face="normal" font="Arial"> Wagner,A.</style></author><author><style face="normal" font="Arial"> Rutkowski,R.</style></author><author><style face="normal" font="Arial"> Rutkowski,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong KongDepartment of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United KingdomDepartment of Allergy, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomDepartment of Respiratory Diagnostics, Medical University of Bialystok, Bialystok, PolandDepartment of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. Electronic address: chris.rutkowski@gstt.nhs.uk</style></auth-address><titles><title><style face="normal" font="Arial">Opioid Hypersensitivity: Predictors of Allergy and Role of Drug Provocation Testing</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: True IgE-mediated hypersensitivity to opioids is rare and many reactions are due to direct mast cell degranulation. Opioid drug provocation testing (DPT) is the gold standard for diagnosis but is underutilized. OBJECTIVE: The objective of this study was to evaluate the clinical characteristics and predictors of opioid hypersensitivity, as well as outcomes of opioid DPT. METHODS: Patients referred for opioid DPT over the past 9 years were studied. Patient characteristics, indications for opioid use, symptoms of index reaction, and outcomes of DPT were analyzed. Association analysis was performed to study variables associated with a diagnosis of opioid hypersensitivity. RESULTS: Of the total of 98 patients referred with suspected opioid hypersensitivity, 15 (15%) were diagnosed with opioid allergy. Angioedema (odds ratio [OR]: 5.66; 95% confidence interval [CI]: 1.49-21.47; P = .011) and hypotension (OR: 5.00; 95% CI: 1.15-21.70; P = .032) were significantly more frequent in opioid allergic patients than those with a negative DPT. Patients who received opioids during anesthesia were significantly more likely to be opioid allergic (OR: 6.74; 95% CI: 2.05-22.13; P = .001). In contrast, a negative association was identified with patients who received opioids for analgesia (OR: 0.27; 95% CI: 0.08-0.86; P = .008). CONCLUSIONS: Only 15% of our cohort were diagnosed with opioid allergy, emphasizing the importance of DPT in preventing erroneous overdiagnosis. Patients with a history of angioedema or hypotension as their index reaction were significantly more likely to be opioid allergic. DPT are safe when performed by experienced clinicians after risk stratification and using individualized protocols</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -CO - Hong Kong -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.03.035.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550985">PM:28550985</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170528-LiPH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170528-LiPH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Li PH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.03.035.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mitsui,M.</style></author><author><style face="normal" font="Arial"> Shoda,T.</style></author><author><style face="normal" font="Arial"> Natsume,O.</style></author><author><style face="normal" font="Arial"> Nomura,I.</style></author><author><style face="normal" font="Arial"> Narita,M.</style></author><author><style face="normal" font="Arial"> Fukuda,A.</style></author><author><style face="normal" font="Arial"> Sakamoto,S.</style></author><author><style face="normal" font="Arial"> Kasahara,M.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Factors Associated with Development of Food Allergy in Young Children after Liver Transplantation: A Retrospective Analysis of 10 Years' Experience</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1706" start="1698">1698-1706</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Liver transplant</style></keyword><keyword><style face="normal" font="Arial"> Liver Transplantation</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> organ transplantation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although development of food allergy after liver transplantation is most commonly described in young children, little is known about identification of young liver-transplant recipients who are at risk of food allergy. OBJECTIVE: This study aimed to identify the types of food allergy and the risk factors for the development of food allergy after liver transplantation. METHODS: This was a retrospective analysis of pediatric liver transplant recipients in our organ transplantation center during 2005-2015. Relevant data of all patients who underwent liver transplantation were extracted from the center's database and the medical records. Differences in patients' characteristics were evaluated for associations between food allergy and potential risk factors. Logistic regression models were used to calculate adjusted odds ratios. RESULTS: We obtained the data of 206 patients under 36 months of age, 42 (20.4%) of whom developed food allergy after liver transplantation. The allergy was IgE-mediated-only in 30 (71.4%) and non-IgE-mediated-only in 10 (23.8%). Multivariate analysis found eczema at liver transplantation to be a significant risk factor (adjusted odds ratio [aOR] 2.41, 95% confidence interval [CI] 1.14-4.77, P &lt; .05). Eczema increased the risk of developing IgE-mediated food allergy after liver transplantation (aOR 3.13, 95% CI 1.41-6.93, P &lt; .01), whereas no significant association was observed with non-IgE-mediated food allergy. CONCLUSIONS: We identified eczema at liver transplantation as a significant risk factor for the development of IgE-mediated food allergy after liver transplantation, but not non-IgE-mediated food allergy. Our findings may contribute to a better understanding of the susceptible subgroup requiring special caution and to the establishment of effective strategies for prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550984">PM:28550984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1698-706.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1698-706.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Mitsui M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barbosa,A.C.</style></author><author><style face="normal" font="Arial"> Castro,F.M.</style></author><author><style face="normal" font="Arial"> Meireles,P.R.</style></author><author><style face="normal" font="Arial"> Arruda,L.K.</style></author><author><style face="normal" font="Arial"> Cardoso,S.R.</style></author><author><style face="normal" font="Arial"> Kalil,J.</style></author><author><style face="normal" font="Arial"> Yang,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical Immunology and Allergy, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Esophagitis: Latent Disease in Patients with Anaphylactic Reaction to Cow's Milk</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor-responsive esophageal eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy and eosinophilic esophagitis are a substantial and evolving public health issue. Clinicians should know the relationship between these diseases and how one may predispose to the other. This can help minimize misdiagnosis. OBJECTIVE: The objective of this study was to assess esophageal eosinophilia and eosinophilic esophagitis frequency in patients with persistent cow's milk allergy and anaphylaxis manifestations. METHODS: Patients with persistent cow's milk allergy with anaphylaxis manifestations were enrolled from 2012 through 2016 at the Sao Paulo University Hospital, Brazil. All of them were submitted to endoscopy despite the presence or absence of gastrointestinal symptoms. Demographics data, atopic comorbidities, medication use, endoscopic findings, and esophageal eosinophilia frequency were evaluated. RESULTS: Eighty-nine patients were selected. The median age was 8 years. It was observed that 34 of 89 patients (38.2%; 95% confidence interval [CI]: 28.14%-49.16%) presented with esophageal eosinophilia. Five patients (7.1%) presented proton pump inhibitor-responsive esophageal eosinophilia, and 10 patients (14.2%) presented eosinophilic esophagitis. We found that 29.4% were asymptomatic patients, 23.5% had nonspecific symptoms, 23.5% had persistent typical symptoms, and 23.5% had intermittent typical symptoms. There was an association with inflammatory endoscopy findings in 21 patients (61.7%). CONCLUSIONS: This description demands scientific attention because it is the highest frequency of esophageal eosinophilia yet described in a group of patients with cow's milk allergy presenting with anaphylaxis. Eosinophilic esophagitis is a condition that can coexist "silently" with an IgE-mediated food allergy and is most often underestimated and underdiagnosed</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28566137">PM:28566137</url></web-urls><pdf-urls><url ppv-ref="no">adriana.marcia.barbosa@gmail.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170601, Barbosa AC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Prince,B.T.</style></author><author><style face="normal" font="Arial"> Devonshire,A.L.</style></author><author><style face="normal" font="Arial"> Erickson,K.A.</style></author><author><style face="normal" font="Arial"> Bergerson,J.</style></author><author><style face="normal" font="Arial"> Fuleihan,D.</style></author><author><style face="normal" font="Arial"> Szychlinski,C.</style></author><author><style face="normal" font="Arial"> Schleimer,R.P.</style></author><author><style face="normal" font="Arial"> Bryce,P.J.</style></author><author><style face="normal" font="Arial"> Singh,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Allergy and Immunology, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="Arial">Regulatory T Cell Populations in Children Are Affected by Age and Food Allergy Diagnosis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> CCR6</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">Young food allergic children have decreased regulatory T cell (Treg) percentages. Only Tregs from healthy controls demonstrated age-related increases in their expression of the gut-associated chemokine receptor CCR6, which may be important in maintaining oral tolerance to foods and preventing the development of allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170527IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28549988">PM:28549988</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170527-PrinceBT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170527-PrinceBT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170527, Prince BT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van Hage,M.</style></author><author><style face="normal" font="Arial"> Hamsten,C.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="Arial">ImmunoCAP Assays: pros and cons in allergology</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE assays</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> singleplex</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">Allergen-specific IgE measurements together with the clinical history are the cornerstones of allergy diagnosis. During the past decades not only characterization and standardization of allergen extracts have improved but also assay technology. Here we discuss the uses, advantages, misinterpretations and limitations of ImmunoCAP IgE assays (Thermo Fisher Scientific/Phadia, Uppsala, Sweden) in the field of allergology. They can be performed as singleplex (ImmunoCAP) and since a decade also as multiplex (ISAC). The major benefit of ImmunoCAP is the obtained quantified allergen-specific IgE antibody level and the lack of interference from allergen-specific IgG antibodies. However, ImmunoCAP allergen extract are limited to the composition of the extract. The introduction of allergen molecules has had major impact on the analytical specificity and allergy diagnosis. They are utilized in both singleplex ImmunoCAP and multiplex ImmunoCAP ISAC assays. The major advantage of ISAC is the comprehensive IgE pattern obtained with a minute amount of serum. The shortcomings are its semiquantitative measurements, lower analytical sensitivity and cost per assay. With respect to assay performance ImmunoCAP allergen extracts are good screening tools, but allergen molecules dissect the IgE response on a molecular level and put allergy research on the map of precision medicine</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Sweden -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552762">PM:28552762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170529-vanHageM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170529-vanHageM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, van Hage M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamid,F.</style></author><author><style face="normal" font="Arial"> Versteeg,S.A.</style></author><author><style face="normal" font="Arial"> Wiria,A.E.</style></author><author><style face="normal" font="Arial"> Wammes,L.J.</style></author><author><style face="normal" font="Arial"> Wahyuni,S.</style></author><author><style face="normal" font="Arial"> Supali,T.</style></author><author><style face="normal" font="Arial"> Sartono,E.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Yazdanbakhsh,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia</style></auth-address><titles><title><style face="normal" font="Arial">Molecular diagnostics and lack of clinical allergy in helminth-endemic areas in Indonesia</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen microarray</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indonesia</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">Allergen microarray characterization of sensitization to common allergen sources in a helminth-endemic area of Indonesia shows that helminth induced cross-reactivity to cross-reactive carbohydrate determinants (CCD), and not primary sensitization to their major allergens, is the dominant feature</style></abstract><notes><style face="normal" font="Arial">DA - 20170528IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Indonesia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550987">PM:28550987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170528-HamidF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170528-HamidF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170528, Hamid F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,K.H.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Lee,S.C.</style></author><author><style face="normal" font="Arial"> Son,Y.W.</style></author><author><style face="normal" font="Arial"> Sim,D.W.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of the ImmunoCAP Assay and AdvanSure AlloScreen Advanced Multiplex Specific IgE Detection Assay</style></title><secondary-title><style face="normal" font="Arial">Yonsei Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yonsei Med J</style></full-title></periodical><pages end="792" start="786">786-792</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> dog dander</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Simultaneous detection</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The AdvanSure AlloScreen assay is an advanced multiplex test that allows for simultaneous detection of specific IgE (sIgE) against multiple allergens. For precise identification of causative allergens in allergic patients, we compared this new multiplex sIgE assay with the ImmunoCAP assay, which is currently the gold-standard method for sIgE detection. MATERIALS AND METHODS: Serum samples from 218 Korean allergic disease patients were used to compare the ImmunoCAP and AlloScreen assays with respect to the following 13 allergens: Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat and dog dander, Alternaria, birch, oak, ragweed, mugwort, rye grass, and food allergens (egg white, cow's milk, peanuts). RESULTS: A total of 957 paired tests using the 13 allergens were compared. The total agreement ratio ranged from 0.74 (oak) to 0.97 (Alternaria). With respect to class association analyses, the gamma index ranged from 0.819 (rye grass) to 0.990 (Alternaria). The intra-class correlation coefficients for house dust mites, cat and dog dander, Alternaria, birch, ragweed, egg white, cow's milk, and peanut sIgE titers were >0.8. CONCLUSION: The AlloScreen and ImmunoCAP assays exhibited similar diagnostic performance. However, due to methodological differences between the two systems, careful interpretation of their results is needed in clinical applications</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1976-2437 (Electronic)IS - 0513-5796 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3349/ymj.2017.58.4.786</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540992">PM:28540992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yonsei Med J\2017-58-786-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yonsei Med J\2017-58-786-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Park KH</style></custom2><misc3><style face="normal" font="Arial">10.3349/ymj.2017.58.4.786</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khodoun,M.V.</style></author><author><style face="normal" font="Arial"> Tomar,S.</style></author><author><style face="normal" font="Arial"> Tocker,J.E.</style></author><author><style face="normal" font="Arial"> Wang,Y.H.</style></author><author><style face="normal" font="Arial"> Finkelman,F.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267</style></auth-address><titles><title><style face="normal" font="Arial">Prevention of food allergy development and suppression of established food allergy by neutralization of TSLP, IL-25 and IL-33</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Triglycerides</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy (FA) is an increasing problem that has no approved treatment. The pro-Th2 cytokines, IL-25, IL-33 and TSLP, are associated with FA and monoclonal antibodies (mAbs) to these cytokines are reported to suppress murine FA development. OBJECTIVE: Determine whether anti-pro-Th2 cytokine mAbs can block both FA maintenance and induction. METHODS: IgE-mediated FA was induced in BALB/c mice by oral gavage (o.g.) with medium chain triglycerides plus egg white (MCT/EW) and was characterized by increased numbers of lamina propria Th2 cells, mast cells shock, and eosinophils, shock (hypothermia), mast cell degranulation (increased serum MMCP1), increased serum IgG1 anti-EW and IgE, and increased IL-4 and IL-13 secretion following MCT/EW challenge. To suppress FA development, mice were injected with anti-IL-25, IL-33R, and/or TSLP monoclonal antibodies prior to the initial o. g. with MCT/EW; to suppress established FA, treatment with the same mAbs was initiated after FA development. RESULTS: Injection of a mAb to IL-25, IL-33R, or TSLP strongly inhibited FA development. No single mAb to a pro-Th2 cytokine could suppress established FA and optimal FA suppression required treatment with a cocktail of all three anti-pro-Th2 mAbs. Treatment with the three mAb cocktail during initial MCT/EW immunization induced EW tolerance. CONCLUSION: All of the pro-Th2 cytokines are required to induce our model of FA, while any pro-Th2 cytokine can maintain established FA. Pro-Th2 cytokines prevent oral tolerance. Combined treatment with antagonists to all three pro-Th2 cytokines or with an inhibitor of pro-Th2 cytokine production may be able to suppress established human FA</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.02.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552763">PM:28552763</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170529-KhodounMV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170529-KhodounMV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Khodoun MV</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.02.046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenberg,J.</style></author><author><style face="normal" font="Arial"> Prushinskaya,O.</style></author><author><style face="normal" font="Arial"> Harris,J.D.</style></author><author><style face="normal" font="Arial"> Guidetti-Myers,G.</style></author><author><style face="normal" font="Arial"> Steiding,J.</style></author><author><style face="normal" font="Arial"> Sawicki,G.S.</style></author><author><style face="normal" font="Arial"> Gaffin,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory Diseases , Boston Children's Hospital , Boston , MA , USA</style></auth-address><titles><title><style face="normal" font="Arial">Utilization of a patient-centered asthma passport tool in a subspecialty clinic</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma action plan</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Medical Record</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Workflow</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Despite available and effective tools for asthma self-assessment (Asthma Control Test, ACT) and self-management (Asthma Action Plan, AAP), they are underutilized in outpatient specialty clinics. We evaluated the impact of a patient-centered checklist, the Asthma Passport, on improving ACT and AAP utilization in clinic. METHODS: This was a randomized, interventional quality-improvement project in which the Asthma Passport was distributed to 120 pediatric asthma patients over the duration of 16 weeks. The passport's checklist consisted of tasks to be completed by the patient/family, including completion of the ACT and AAP. We compared rates of completion of the ACT and AAP for those who received the passport versus the control group, and assessed patient/caregiver and provider satisfaction. RESULTS: Based on electronic medical record data from 222 participants, the ACT completion rate was not significantly different between the passport and control groups, however, the AAP completion rate was significantly greater than control (30.0% vs. 17.7%, p = 0.04). When per-protocol analysis was limited to groups who completed and returned their passports, ACT and AAP completion rates were significantly greater than control (73.8% vs. 44.1% (p = 0.002) and 35.7% vs. 17.7% (p = 0.04), respectively). Nearly all participants reported high satisfaction with care, and surveyed providers viewed the passport favorably. CONCLUSIONS: A patient-centered checklist significantly improved the completion rate of the AAP. For patient's who completed and returned the asthma passport, the ACT completion rate was also improved. Participants and providers reported high satisfaction with the checklist, suggesting that it can effectively promote asthma self-management and self-assessment without burdening clinicians or clinic workflow</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2017.1323916</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28548904">PM:28548904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170526-GreenbergJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170526-GreenbergJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Greenberg J</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2017.1323916</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meli,A.P.</style></author><author><style face="normal" font="Arial"> Fontes,G.</style></author><author><style face="normal" font="Arial"> Leung,S.C.</style></author><author><style face="normal" font="Arial"> King,I.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology and Immunology, Microbiome and Disease Tolerance Centre, McGill University, Montreal, Quebec H3A 2B4, Canada</style></auth-address><titles><title><style face="normal" font="Arial">T Follicular Helper Cell-Derived IL-4 Is Required for IgE Production during Intestinal Helminth Infection</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germinal Center</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Parasitic helminth</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">IgE production plays a crucial role in protective as well as pathogenic type 2 immune responses. Although the cytokine IL-4 is required for the development of IgE-producing plasma cells, the source of IL-4 and cellular requirements for optimal IgE responses remain unclear. Recent evidence suggests that T follicular helper (Tfh) cells are the primary producer of IL-4 in the reactive lymph node during type 2 immune responses. As Tfh cells are also required for the development of plasmablasts derived from germinal center and extrafollicular sources, we hypothesized that this cell subset is essential for the IgE plasmablast response. In this study, we show that during intestinal helminth infection, IL-4 derived from Tfh cells is required for IgE class switching and plasmablast formation. Notably, early IgE class switching did not require germinal center formation. Additionally, Tfh cell-derived IL-4 was required to maintain the Th2 response in the mesenteric lymph nodes of infected mice. Collectively, our results indicate that IL-4-producing Tfh cells are central orchestrators of the type 2 immune response in the reactive lymph nodes during parasitic helminth infection</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1700141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28533444">PM:28533444</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170523-MeliAP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170523-MeliAP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Meli AP</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1700141</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Spuls,P.I.</style></author><author><style face="normal" font="Arial"> Gerbens,L.A.A.</style></author><author><style face="normal" font="Arial"> Apfelbacher,C.J.</style></author><author><style face="normal" font="Arial"> Wall,D.</style></author><author><style face="normal" font="Arial"> Arents,B.W.M.</style></author><author><style face="normal" font="Arial"> Barbarot,S.</style></author><author><style face="normal" font="Arial"> Roberts,A.</style></author><author><style face="normal" font="Arial"> Deleuran,M.</style></author><author><style face="normal" font="Arial"> Middelkamp-Hup,M.A.</style></author><author><style face="normal" font="Arial"> Vestergaard,C.</style></author><author><style face="normal" font="Arial"> Weidinger,S.</style></author><author><style face="normal" font="Arial"> Schmitt,J.</style></author><author><style face="normal" font="Arial"> Irvine,A.D.</style></author><author><style face="normal" font="Arial"> Flohr,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">The international TREatment of ATopic eczema (TREAT) Registry Taskforce: an initiative to harmonise data collection across national atopic eczema photo- and systemic therapy registries</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="2016" start="2014">2014-2016</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="5" Year="2017">2017/5/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Germany -CO - Ireland -CO - France -CO - United KIngdom -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.05.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28558913">PM:28558913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-2014-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2017-137-2014-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Spuls PI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.05.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Omri,M.</style></author><author><style face="normal" font="Arial"> Kraiem,H.</style></author><author><style face="normal" font="Arial"> Mejri,O.</style></author><author><style face="normal" font="Arial"> Naija,M.</style></author><author><style face="normal" font="Arial"> Chebili,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine Ibn El Jazzar of Sousse, Sousse, Tunisia</style></auth-address><titles><title><style face="normal" font="Arial">Management of Kounis syndrome: two case reports</style></title><secondary-title><style face="normal" font="Arial">J Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Case Rep</style></full-title></periodical><pages end="" start="145">145-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Kounis syndrome corresponds to the occurrence of myocardial injury following an allergic insult. This syndrome is infrequent, and is not well known. In consequence, it is usually misdiagnosed leading to inappropriate treatment. The current literature is limited to case studies and there are no international recommendations concerning this topic. CASE PRESENTATION: We discussed, through two case reports, the clinical presentation and the management of a 60-year-old North African man and a 45-year-old North African man presenting with chest pain suggesting acute coronary syndrome following anaphylactic reaction. Triggering factors were a drug in the first case and herbal dermal exposure in the second. A clinical examination and electrocardiogram revealed anaphylactic reaction associated with myocardial infarction. Appropriate management of these two life-threatening conditions allowed an improvement in our patients' condition and their transfer to specialized units. CONCLUSIONS: Although Kounis syndrome is a rare phenomenon, physicians should be aware of its physiopathological mechanisms in order to treat it appropriately. The difficulty lies in the fact that the treatment of either of the two associated entities may worsen the other injury</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1752-1947 (Electronic)IS - 1752-1947 (Linking)LA - engPT - Journal ArticleCO - Tunisia -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13256-017-1310-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532437">PM:28532437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Case Rep\2017-11-145.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Case Rep\2017-11-145.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Omri M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13256-017-1310-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suzuki,C.</style></author><author><style face="normal" font="Arial"> Lopes da Silva,N.</style></author><author><style face="normal" font="Arial"> Kumar,P.</style></author><author><style face="normal" font="Arial"> Pathak,P.</style></author><author><style face="normal" font="Arial"> Ong,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Novartis Biociencias S.A. , Sao Paulo , Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Cost effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting</style></title><secondary-title><style face="normal" font="Arial">J Med Econ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Econ</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Resource utilization</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Omalizumab add-on to standard-of-care therapy has proven to be efficacious in severe asthma patients for whom exacerbations cannot be controlled otherwise. Moreover, evidence from different healthcare settings suggests reduced healthcare resource utilization with omalizumab. Based on these findings, we aimed to assess the cost effectiveness of the addition of omalizumab to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. METHODS: A previously published Markov model was adapted using Brazil-specific unit costs to compare the costs and outcomes of the addition of omalizumab to standard-of-care therapy versus standard-of-care therapy alone. Model inputs were largely based on the eXpeRience study. Costs and health outcomes were calculated for lifetime-years and were annually discounted at 5%. Both one-way and probabilistic sensitivity analyses were performed. RESULTS: An additional cost of R$280,400 for 5.20 additional quality-adjusted life-years was estimated with the addition of omalizumab to standard-of-care therapy, resulting in an incremental cost-effectiveness ratio of R$53,890. One-way sensitivity analysis indicated that discount rates, standard-of-care therapy exacerbation rates, and exacerbation-related mortality rates had the largest impact on incremental cost-effectiveness ratios. LIMITATIONS: Assumptions of lifetime treatment adherence and rate of future exacerbations independent of previous events might affect the findings. Lack of Brazilian patients in the eXpeRience study may affect the findings, although sample size and baseline characteristics suggest that the modelled population closely resembles Brazilian severe allergic asthma patients. CONCLUSION: Results indicate that omalizumab as an add-on therapy is more cost-effective than standard-of-care therapy alone for Brazilian patients with uncontrolled severe allergic asthma, based on the World Health Organization's cost-effectiveness threshold of up to 3 times the gross domestic product</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1941-837X (Electronic)IS - 1369-6998 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - India -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1080/13696998.2017.1333513</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532191">PM:28532191</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Econ\20170523-SuzukiC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Econ\20170523-SuzukiC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Suzuki C</style></custom2><misc3><style face="normal" font="Arial">10.1080/13696998.2017.1333513</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maeta,A.</style></author><author><style face="normal" font="Arial"> Sakamoto,Y.</style></author><author><style face="normal" font="Arial"> Yuki,S.</style></author><author><style face="normal" font="Arial"> Takahashi,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Science and Nutrition, School of Human Environmental Sciences, Mukogawa Women's University</style></auth-address><titles><title><style face="normal" font="Arial">Intake of Diet Including 1% Ovomucoid for 4 Weeks Induces Oral Desensitization in Ovomucoid-Specific Allergic Mouse Model</style></title><secondary-title><style face="normal" font="Arial">J Nutr Sci Vitaminol (Tokyo)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Nutr Sci Vitaminol (Tokyo)</style></full-title></periodical><pages end="110" start="104">104-110</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular permeability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We propose a new oral immunotherapy (OIT) method that includes a small amount of a food allergen in the diet. However, it is not clear whether this method will induce oral desensitization and immune tolerance. Therefore, we investigated the therapeutic effectiveness using a 1% food allergen diet in an allergic mouse model. C3H/HeJ mice were sensitized to ovomucoid (OM) in alum four times at 12-d intervals. Sensitized mice were divided into two groups: the OIT group (19% casein diet with 1% OM) and the non-treated group (20% casein diet without OM). The non-sensitized mice served as the non-allergy group. The OIT treatment was performed for 4 wk. To assess desensitization and immune tolerance, we performed oral and intraperitoneal OM challenges, assessed vascular permeability of the dorsal skin, and measured allergic biomarkers. The OIT group exhibited significantly lower oral symptom scores and vascular permeability than the non-treated group, but the two groups did not differ in intraperitoneal allergy symptom scores. Furthermore, the OIT group had significantly higher OM-specific IgA levels in their plasma than the non-treated group. However, the plasma levels of OM-specific IgE, IgG1, and IgG2a were not significantly different between the OIT and the non-treated groups. These results suggest that the proposed OIT using an OM-supplemented diet may induce desensitization, but not immune tolerance, in an OM allergic mouse model</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1881-7742 (Electronic)IS - 0301-4800 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3177/jnsv.63.10</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552874">PM:28552874</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Nutr Sci Vitaminol (Tokyo)\2017-63-104-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Nutr Sci Vitaminol (Tokyo)\2017-63-104-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Maeta A</style></custom2><misc3><style face="normal" font="Arial">10.3177/jnsv.63.10</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ochiai,M.</style></author><author><style face="normal" font="Arial"> Misaki,K.</style></author><author><style face="normal" font="Arial"> Takeuchi,T.</style></author><author><style face="normal" font="Arial"> Narumi,R.</style></author><author><style face="normal" font="Arial"> Azuma,Y.</style></author><author><style face="normal" font="Arial"> Matsuo,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Veterinary Medicine, Kitasato University</style></auth-address><titles><title><style face="normal" font="Arial">Egg White Hydrolysate Can Be a Low-Allergenic Food Material to Suppress Ectopic Fat Accumulation in Rats Fed an Equicaloric Diet</style></title><secondary-title><style face="normal" font="Arial">J Nutr Sci Vitaminol (Tokyo)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Nutr Sci Vitaminol (Tokyo)</style></full-title></periodical><pages end="119" start="111">111-119</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> Adipose tissue</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Alkaline Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Hypertriglyceridemia</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscles</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Egg white (EW) is known as a nutritional protein but can induce allergic reactions in humans. We investigated the dietary effects of EW and its hydrolysate (EWH), which contains less allergen, on body fat accumulation in Wistar rats fed an equicaloric high-fat and high-sucrose diet for 8 wk (Exp A). The pair-feeding of EW and equicaloric-feeding of EWH increased fecal fat excretion and suppressed lipid accumulation in the liver and muscles but not in the abdominal adipose tissues, carcass, or total body. Dietary EWH also suppressed the serum glucose level and alkaline phosphatase activity. Further, we showed a higher dispersibility of EW and EWH in physicochemical assay (Exp B). Next, we investigated the suppressive effects of a single administration of EW and EWH on lipid-induced hypertriglyceridemia and small intestinal meal transit in ddY mice (Exp C). However, a single administration of EW or EWH did not suppress the lipid-induced hypertriglyceridemia nor did it delay the rate of small intestinal transit. These findings indicated that dietary EW and EWH reduce hepatic and muscular (ectopic) fat accumulation mainly by suppressing fat absorption and supplying fat to the liver and muscles. Therefore, the low-allergenic EWH can be effective for the prevention of high-fat-diet-induced obesity</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1881-7742 (Electronic)IS - 0301-4800 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3177/jnsv.63.111</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552875">PM:28552875</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Nutr Sci Vitaminol (Tokyo)\2017-63-111-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Nutr Sci Vitaminol (Tokyo)\2017-63-111-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Ochiai M</style></custom2><misc3><style face="normal" font="Arial">10.3177/jnsv.63.111</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sieczkowska-Golub,J.</style></author><author><style face="normal" font="Arial"> Meglicka,M.</style></author><author><style face="normal" font="Arial"> Plocek,A.</style></author><author><style face="normal" font="Arial"> Banaszkiewicz,A.</style></author><author><style face="normal" font="Arial"> Jarzebicka,D.</style></author><author><style face="normal" font="Arial"> Toporowska-Kowalska,E.</style></author><author><style face="normal" font="Arial"> Gawronska,A.</style></author><author><style face="normal" font="Arial"> Oracz,G.</style></author><author><style face="normal" font="Arial"> Kierkus,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children's Memorial Health Institute, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Induction Therapy With Biosimilar Infliximab in Children With Crohn's Disease</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: In most European countries, an infliximab biosimilar (CT-P13) is currently in common use. In vitro and in vivo studies have proved a high similarity between CT-P13 and the reference infliximab. CT-P13 was licensed for use in patients with Crohn's diseases (CD) based on the extrapolation of data from preclinical studies and clinical trials in rheumatology indications. The aim of this study was to assess the similarity between CT-P13 and the originator infliximab in induction therapy in CD paediatric patients. METHODS: Thirty-six CD paediatric patients from three Polish academic centres who started biological therapy with CT-P13 were enrolled in this prospective, observational study. Patients received three induction doses (5 mg/kg) of CT-P13 at weeks 0, 2, 6. Assessment was performed before the first infusion and at week 14. RESULTS: Overall 34/36 (94.4%) patients completed induction therapy with CT-P13. A clinical response or remission after three initial doses was achieved in 31/36 (86%) and 24/36 (67%) of patients, respectively. Clinically and statistically significant decreases in Paediatric Crohn's Disease Activity Index, C-reactive protein and erythrocyte sedimentation rate were observed in the responders group. An allergic reaction during infusion, which led to treatment discontinuation, was observed in one case. CONCLUSION: Induction therapy with CT-P13 in children with CD is effective. The profile appears similar to that reported for the reference infliximab. No unexpected adverse events occurred</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001643</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28542043">PM:28542043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20170525-SieczkowskaGolubJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20170525-SieczkowskaGolubJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Sieczkowska-Golub J</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001643</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saha,B.</style></author><author><style face="normal" font="Arial"> Pandey,N.</style></author><author><style face="normal" font="Arial"> Bhattacharya,S.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Plant Biology, Bose Institute, 93/1 Acharya Prafulla Chandra Road, Kolkata 700009, India</style></auth-address><titles><title><style face="normal" font="Arial">Charting novel allergens from date palm pollen (Phoenix sylvestris) using homology driven proteomics</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylation</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> beta-Galactosidase</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Coconut</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> de novo sequencing</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Glycan moieties</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kolkata</style></keyword><keyword><style face="normal" font="Arial"> Methionine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Two dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> Workflow</style></keyword></keywords><dates><year Day="20" Month="5" Year="2017">2017/5/20</year></dates><abstract><style face="normal" font="Arial">Pollen grains from Phoenix sylvestris (date palm), a commonly cultivated tree in India has been found to cause severe allergic diseases in an increasing percentage of hypersensitive individuals. To unearth its allergenic components, pollen protein were profiled by two-dimensional gel electrophoresis followed by immunoblotting with date palm pollen sensitive patient sera. Allergens were identified by MALDI-TOF/TOF employing a layered proteomic approach combining conventional database dependent search and manual de novo sequencing followed by homology-based search as Phoenix sylvestris is unsequenced. Derivatization of tryptic peptides by acetylation has been demonstrated to differentiate the 'b' from the 'y' ions facilitating efficient de novo sequencing. Ten allergenic proteins were identified, out of which six showed homology with known allergens while others were reported for the first time. Amongst these, isoflavone reductase, beta-conglycinin, S-adenosyl methionine synthase, 1, 4 glucan synthase and beta-galactosidase were commonly reported as allergens from coconut pollen and presumably responsible for cross-reactivity. One of the allergens had IgE binding epitope recognized by its glycan moiety. The allergenic potency of date palm pollen has been demonstrated using in vitro tests. The identified allergens can be used to develop vaccines for immunotherapy against date palm pollen allergy. THE SIGNIFICANCE OF THE STUDY: Identification of allergenic proteins from sources harboring them is essential in developing therapeutic interventions. This is the first comprehensive study on the identification of allergens from Phoenix sylvestris (date palm) pollen, one of the major aeroallergens in India using a proteomic approach. Proteomic methods are being increasingly used to identify allergens. However, since many of these proteins arise from species which are un-sequenced, it becomes difficult to interpret those using conventional proteomics. Date palm being an unsequenced species, the IgE-reactive proteins have been identified using a stratified proteomic workflow incorporating manual de novo sequencing and homology-based proteomics. This study also gives an insight into the presence of glycan nature of the IgE binding epitopes. Five proteins have been found to be common with coconut pollen allergens and presumably responsible for cross-reactivity. These can be used in diagnostics to differentiate patient cohorts allergic to both coconut and date palm pollen from true date palm pollen allergic subjects. This would also determine better specific immunotherapy regimes between the two cohorts. The allergens identified herein have potential towards vaccine development in date palm pollen allergy as well as in enriching the existing catalogue of allergenic proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170524IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2017.05.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28535932">PM:28535932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170524-SahaB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170524-SahaB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170524, Saha B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2017.05.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hashemi,H.</style></author><author><style face="normal" font="Arial"> Mohebbi,M.</style></author><author><style face="normal" font="Arial"> Mehravaran,S.</style></author><author><style face="normal" font="Arial"> Mazloumi,M.</style></author><author><style face="normal" font="Arial"> Jahanbani-Ardakani,H.</style></author><author><style face="normal" font="Arial"> Abtahi,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities</style></title><secondary-title><style face="normal" font="Arial">J Res Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Res Med Sci</style></full-title></periodical><pages end="" start="53">53-</pages><volume><style face="normal" font="Arial">22</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abscess</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cellular immunity</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Keratoconus</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Strabismus</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The hyperimmunoglobulin E syndromes (HIESs) are very rare immunodeficiency syndromes with multisystem involvement, including immune system, skeleton, connective tissue, and dentition. HIES are characterized by the classic triad of high serum levels of immunoglobulin E (IgE), recurrent staphylococcal cold skin abscess, and recurrent pneumonia with pneumatocele formation. Most cases of HIES are sporadic although can be inherited as autosomal dominant and autosomal recessive traits. A fundamental immunologic defect in HIES is not clearly elucidated but abnormal neutrophil chemotaxis due to decreased production or secretion of interferon gamma has main role in the immunopathogenesis of syndrome, also distorted Th1/Th2 cytokine profile toward a Th2 bias contributes to the impaired cellular immunity and a specific pattern of infection susceptibility as well as atopic-allergic constitution of syndrome. The ophthalmic manifestations of this disorder include conjunctivitis, keratitis, spontaneous corneal perforation, recurrent giant chalazia, extensive xanthelasma, tumors of the eyelid, strabismus, and bilateral keratoconus. The diagnosis of HIES is inconclusive, dependent on the evolution of a constellation of complex multisystemic symptoms and signs which develop over the years. Until time, no treatment modality is curative for basic defect in HIES, in terms of cytokines/chemokines derangement. Of note, bone marrow transplant and a monoclonal anti-IgE (omalizumab) are hoped to be successful treatment in future</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1735-1995 (Print)IS - 1735-1995 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Iran -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4103/jrms.JRMS_1050_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28567072">PM:28567072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Res Med Sci\2017-22-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Res Med Sci\2017-22-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Hashemi H</style></custom2><misc3><style face="normal" font="Arial">10.4103/jrms.JRMS_1050_16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al-Kouba,J.</style></author><author><style face="normal" font="Arial"> Wilkinson,A.N.</style></author><author><style face="normal" font="Arial"> Starkey,M.R.</style></author><author><style face="normal" font="Arial"> Rudraraju,R.</style></author><author><style face="normal" font="Arial"> Werder,R.B.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Law,S.C.</style></author><author><style face="normal" font="Arial"> Horvat,J.C.</style></author><author><style face="normal" font="Arial"> Brooks,J.F.</style></author><author><style face="normal" font="Arial"> Hill,G.R.</style></author><author><style face="normal" font="Arial"> Davies,J.M.</style></author><author><style face="normal" font="Arial"> Phipps,S.</style></author><author><style face="normal" font="Arial"> Hansbro,P.M.</style></author><author><style face="normal" font="Arial"> Steptoe,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The University of Queensland Diamantina Institute, University of Queensland, Brisbane, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-encoding bone marrow transfer inactivates allergic T cell responses, alleviating airway inflammation</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="85742">85742-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="6" Year="2017">2017/6/2</year></dates><abstract><style face="normal" font="Arial">Memory Th2 cell responses underlie the development and perpetuation of allergic diseases. Because these states result from immune dysregulation, established Th2 cell responses represent a significant challenge for conventional immunotherapies. New approaches that overcome the detrimental effects of immune dysregulation are required. We tested whether memory Th2 cell responses were silenced using a therapeutic approach where allergen expression in DCs is transferred to sensitized recipients using BM cells as a vector for therapeutic gene transfer. Development of allergen-specific Th2 responses and allergen-induced airway inflammation was blocked by expression of allergen in DCs. Adoptive transfer studies showed that Th2 responses were inactivated by a combination of deletion and induction of T cell unresponsiveness. Transfer of BM encoding allergen expression targeted to DCs terminated, in an allergen-specific manner, Th2 responses in sensitized recipients. Importantly, when preexisting airway inflammation was present, there was effective silencing of Th2 cell responses, airway inflammation was alleviated, and airway hyperreactivity was reversed. The effectiveness of DC-targeted allergen expression to terminate established Th2 responses in sensitized animals indicates that exploiting cell-intrinsic T cell tolerance pathways could lead to development of highly effective immunotherapies</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 2379-3708 (Electronic)IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.85742</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570267">PM:28570267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\2017-2-85742.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\2017-2-85742.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Al-Kouba J</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.85742</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferguson,G.T.</style></author><author><style face="normal" font="Arial"> Fitzgerald,J.M.</style></author><author><style face="normal" font="Arial"> Bleecker,E.R.</style></author><author><style face="normal" font="Arial"> Laviolette,M.</style></author><author><style face="normal" font="Arial"> Bernstein,D.</style></author><author><style face="normal" font="Arial"> LaForce,C.</style></author><author><style face="normal" font="Arial"> Mansfield,L.</style></author><author><style face="normal" font="Arial"> Barker,P.</style></author><author><style face="normal" font="Arial"> Wu,Y.</style></author><author><style face="normal" font="Arial"> Jison,M.</style></author><author><style face="normal" font="Arial"> Goldman,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial</style></title><secondary-title><style face="normal" font="Arial">Lancet Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Respir Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> reversibility</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Suicide</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Benralizumab is a humanised, anti-interleukin 5 receptor alpha monoclonal antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma. The objective of this trial was to assess the safety and efficacy of benralizumab for patients with mild to moderate, persistent asthma. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients aged 18-75 years, weighing at least 40 kg, and with a postbronchodilator reversibility in forced expiratory volume in 1 s (FEV1) of at least 12% at screening, from 52 clinical research centres in six countries. Patients must have been receiving either low- to medium-dosage inhaled corticosteroids (ICS) or low-dosage ICS plus long-acting beta2 agonist fixed-combination therapy at screening, had a morning prebronchodilator FEV1 of more than 50% to 90% predicted at screening, and had one or more of the following symptoms within the 7 days before randomisation: a daytime or night-time asthma symptom score of at least 1 for at least 2 days, rescue short-acting beta2 agonist use for at least 2 days, or night-time awakenings due to asthma for at least one night. We converted patients' ICS treatments to 180 mug or 200 mug budesonide dry powder inhaler twice daily for the entire duration of the study using the approved dosages in the patients' respective countries and randomly allocated them (1:1; stratified by blood eosinophil count [&lt;300 cells per muL vs >/=300 cells per muL] and region [USA vs the rest of the world]) with an interactive web-based voice response system to receive subcutaneous placebo or benralizumab 30 mg injections every 4 weeks for 12 weeks. All patients and investigators involved in patient treatment or clinical assessment and those assessing outcomes were masked to treatment allocation. The primary endpoint was change from baseline prebronchodilator FEV1 at week 12. Efficacy analyses used an intention to treat approach. This trial is registered with ClinicalTrials.gov, number NCT02322775. FINDINGS: Between Feb 2, 2015, and April 24, 2015, we enrolled 351 patients, with 211 (60%) randomly assigned (105 [50%] to placebo and 106 [50%] to benralizumab). Benralizumab resulted in an 80 mL (95% CI 0-150; p=0.04) greater improvement (least-squares mean difference) in prebronchodilator FEV1 after 12 weeks than did placebo (placebo group: 2246 mL [SD 768] at baseline vs 2261 mL [796] at week 12, change from baseline of 0 mL; benralizumab group: 2248 mL [606] vs 2310 mL [670], 70 mL). 44 (42%) patients in the benralizumab group had adverse events compared with 49 (47%) in the placebo group. The most common adverse events for both groups were nasopharyngitis (eight [8%] patients in each group) and upper respiratory tract infections (five [5%] patients in each group). Serious adverse events occurred in two (2%) patients each in the benralizumab (pancytopenia and a suicide attempt, both considered unrelated to treatment) and placebo (cervix carcinoma and colon adenoma) groups. INTERPRETATION: This study suggests that active and modifiable disease processes might be ongoing in patients with mild to moderate, persistent asthma receiving ICS. Although the lung function improvement observed does not warrant use of benralizumab in this population because it did not reach the minimum clinically important difference of 10%, further studies to assess this finding should be considered. FUNDING: AstraZeneca</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2213-2600(17)30190-X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28545978">PM:28545978</url></web-urls><pdf-urls><url ppv-ref="no">garytferguson@msn.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Ferguson GT</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2213-2600(17)30190-X</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gao,P.</style></author><author><style face="normal" font="Arial"> Su,Z.</style></author><author><style face="normal" font="Arial"> Lv,X.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun, China</style></auth-address><titles><title><style face="normal" font="Arial">Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent</style></title><secondary-title><style face="normal" font="Arial">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mediators Inflamm</style></full-title></periodical><pages end="" start="5931865">5931865-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Interleukin- (IL-) 35 is a member of the IL-12 cytokine family and a heterodimeric protein formed by Epstein-Barr-induced gene 3 (EBI3) and IL-12p35. Emerging evidence shows that IL-35 is a key player in the regulation of cellular communication, differentiation, and inflammation. Altered IL-35 expression has been found in disease conditions such as cancer, rheumatoid arthritis, and, more recently, asthma. In cancer, IL-35 is involved in the regulation of tumorigenesis, cancer progression, and metastasis. In rheumatoid arthritis, IL-35 acts as a negative regulator of inflammation. Similarly, IL-35 also appears to suppress allergic inflammation in asthma. In an in vivo murine model of asthma, transfer of adenovirus-mediated IL-35 markedly reduced the degree of airway hyperresponsiveness (AHR) and inflammatory cell infiltration. Many studies have shown the involvement of IL-35 in a number of aspects of allergic inflammation, such as eosinophil and neutrophil recruitment as well as inhibition of inflammatory mediators of the Th2 subtype. However, the exact molecular mechanisms underlying the role of IL-35 in human asthma have yet to be fully elucidated. This review describes the current evidence regarding the role of IL-35 in the pathophysiology of asthma and evaluates the potential of IL-35 as a biomarker for airway inflammation and a therapeutic target for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/5931865</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28553015">PM:28553015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mediators Inflamm\2017-2017-5931865.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mediators Inflamm\2017-2017-5931865.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170529, Gao P</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/5931865</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84667</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Antwi,A.O.</style></author><author><style face="normal" font="Arial"> Obiri,D.D.</style></author><author><style face="normal" font="Arial"> Osafo,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science &amp; Technology (KNUST), Kumasi, Ghana</style></auth-address><titles><title><style face="normal" font="Arial">Stigmasterol Modulates Allergic Airway Inflammation in Guinea Pig Model of Ovalbumin-Induced Asthma</style></title><secondary-title><style face="normal" font="Arial">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mediators Inflamm</style></full-title></periodical><pages end="" start="2953930">2953930-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Ghana</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vascular Cell Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We explored the potential benefits of stigmasterol in the treatment of asthma, an airway disorder characterized by immune pathophysiology and with an ever-increasing worldwide prevalence. We assessed the modulatory effect of the intraperitoneal administration of stigmasterol on experimentally induced airway inflammation in guinea pigs. The effect of stigmasterol on inflammatory cell proliferation, oxidative stress, lung histopathology, and remodeling was investigated. The results showed significant suppressive effects on ovalbumin-induced airway inflammatory damage. Stigmasterol at 10-100 mg/kg reduced proliferation of eosinophils, lymphocytes, and monocytes while reducing peribronchiolar, perivascular, and alveolar infiltration of inflammatory cells. Histopathology revealed stigmasterol maintained lung architecture and reversed collagen deposition, an index of lung remodeling. Overexpression of serum vascular cell adhesion molecule-1 (VCAM-1) and ovalbumin-specific immunoglobulin E (OVA sIgE) elicited by ovalbumin sensitization and challenge was significantly controlled with stigmasterol. Taken together, stigmasterol possessed significant antiasthmatic properties and had suppressive effects on key features of allergen-induced asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - engPT - Journal ArticleCO - Ghana -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/2953930</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28555089">PM:28555089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mediators Inflamm\2017-2017-2953930.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mediators Inflamm\2017-2017-2953930.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Antwi AO</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/2953930</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mao,D.</style></author><author><style face="normal" font="Arial"> Tang,R.</style></author><author><style face="normal" font="Arial"> Wu,R.</style></author><author><style face="normal" font="Arial"> Hu,H.</style></author><author><style face="normal" font="Arial"> Sun,L.J.</style></author><author><style face="normal" font="Arial"> Zhu,H.</style></author><author><style face="normal" font="Arial"> Bai,X.</style></author><author><style face="normal" font="Arial"> Han,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aRespiratory Department, Chinese PLA General Hospital bDepartment of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College cDepartment of Respiratory Medicine, Peking University Third Hospital, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence trends in the characteristics of patients with allergic asthma in Beijing, 1994 to 2014</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e7077">e7077-</pages><volume><style face="normal" font="Arial">96</style></volume><number><style face="normal" font="Arial">22</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonists</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Theophylline</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">This study aimed to determine the clinical profiles and prevalence trends during 1994 to 2014 among patients with allergic asthma (AA), which is a clinical phenotype of asthma.We retrospectively analyzed the characteristics of 319 patients who were diagnosed with AA between March 1, 1994 and February 28, 2014 at 3 Beijing centers.The patients included 155 males and 164 females, and the mean age was 50.86 +/- 15.27 years (range 13-86 years). The proportions of asthma attacks in summer and autumn were 60.7% (1994-1999), 61.8% (1999-2004), 56.4% (2004-2009), and 33.1% (2009-2014). The most frequently used medication at home was theophylline (27.9%), which was followed by inhaled corticosteroids (20.38%), inhaled corticosteroids/long-acting beta-2-agonists (10.66%), and leukotriene receptor antagonists (9.4%). The elderly group had the highest rates of summer and autumn attacks, multiple hospitalizations, reduced pulmonary function, smoking history, and positive allergen tests. The middle-aged group had the lowest rates of summer and autumn attacks, and multiple hospitalizations. The youngest group had the lowest rates of reduced pulmonary function, smoking history, and positive allergen tests. The top 5 allergens were dust (9.1%), mites (8.8%), seafood (8.2%), pollen (6.3%), and animal fur (6%). Women were significantly more likely to have a positive allergen test (93 women vs 68 men).The present study revealed the characteristics of Chinese patients with AA, and allergen-specific differences in sex and age during 1994 to 2014. The use of therapeutic drugs at home remains insufficient</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000007077</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28562576">PM:28562576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2017-96-e7077.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2017-96-e7077.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Mao D</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000007077</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Espineira,M.</style></author><author><style face="normal" font="Arial"> Santaclara,F.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ANFACO-CECOPESCA, Carretera Colegio Universitario, NO 16, 36310, Vigo, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Fast Real-Time PCR Method for Detection of Soy in Foods</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="181" start="173">173-181</pages><volume><style face="normal" font="Arial">1620</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Automation</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emulsification</style></keyword><keyword><style face="normal" font="Arial"> Fast real-time PCR</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Security</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> TaqMan</style></keyword><keyword><style face="normal" font="Arial"> TaqMan real-time PCR</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Soy is used as an additive in the manufacturing of diverse products, because of their ability of emulsification, water and fat absorption, contributing to the consistency of food products. Moreover, soy is recognized as a potential allergen, so its presence should be indicated in all the food products.These issues highlight the need for techniques that allow the detection of soy in foods. This work describes a real-time PCR method for the detection of soy in a wide range of foodstuffs. The main features of this technique are its reliability and sensitivity, allowing the detection of trace amounts of soybean in processed products. TaqMan real-time PCR is one of the simplest and fastest molecular biology techniques, with a high potential for automation. Therefore, it is one of the techniques most used for screening a variety of substances.The methodology herein described is of great value in issues regarding the presence of soy protein in processed products, especially in verifying labeling and security regulations to protect consumer's rights</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-7060-5_12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540708">PM:28540708</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1620-173-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1620-173-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Espineira M</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-7060-5_12</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84670</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santaclara,F.J.</style></author><author><style face="normal" font="Arial"> Espineira,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ANFACO-CECOPESCA, Carretera Colegio Universitario, N masculine 16, 36310, Vigo, SpainANFACO-CECOPESCA, Carretera Colegio Universitario, N masculine 16, 36310, Vigo, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Fast Real-Time PCR for the Detection of Crustacean Allergens in Foods</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="171" start="163">163-171</pages><volume><style face="normal" font="Arial">1620</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> Crabs</style></keyword><keyword><style face="normal" font="Arial"> Crayfish</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustacean allergen</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fast real-time PCR</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food security</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Prawn</style></keyword><keyword><style face="normal" font="Arial"> Prawns</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Security</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimps</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Crustaceans are one of the most common allergens causing severe food reaction. Hypersensitivity reactions associated with seafood intake are one of the most common food allergies in adults. Crustaceans including shrimps, prawns, crabs, lobster, and crayfish are a common cause of anaphylaxis or hypersensitivity, with shrimps and crabs being the most common causes of allergy. Symptoms occur most often when food or cooking water are ingested.These food allergens are a health problem, and they have become very important; as evidenced by the existence of several regulations that establish that labeling must be present regarding these allergens to warn consumers.The methodology herein exposed allows the detection of crustaceans in any type of product, including those where very aggressive treatments of temperature and pressure are used during the manufacturing process.The main features of this method are its high sensitivity and specificity, and reduced analysis time of real-time PCR (40 min). This assay is a potential tool in issues related to the labeling of products and food security to protect the allergic consumer</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-7060-5_11</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540707">PM:28540707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1620-163-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1620-163-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Santaclara FJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-7060-5_11</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84671</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Magnaval,J.F.</style></author><author><style face="normal" font="Arial"> Laurent,G.</style></author><author><style face="normal" font="Arial"> Gaudre,N.</style></author><author><style face="normal" font="Arial"> Fillaux,J.</style></author><author><style face="normal" font="Arial"> Berry,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Parasitology, Faculty of Medicine, Toulouse University, 37 allees Jules-Guesde, Toulouse, France</style></auth-address><titles><title><style face="normal" font="Arial">A diagnostic protocol designed for determining allergic causes in patients with blood eosinophilia</style></title><secondary-title><style face="normal" font="Arial">Mil Med Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mil Med Res</style></full-title></periodical><pages end="" start="15">15-</pages><volume><style face="normal" font="Arial">4</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Blood eosinophilia is a common laboratory abnormality, and its characterization frequently represents a quandary for primary care physicians. Consequently, in France, specialists and particularly hematologists, often must investigate patients who present with blood eosinophilia that often, but not always, occurs because of allergic causes. Both the Departments of Hematology and Parasitology at Toulouse University Hospitals established a collaboration to rule out allergic causes of eosinophilia, particularly helminthiases, prior to initiating more sophisticated investigations. METHODS: Since 2004, the authors employed the same protocol to investigate eosinophilic outpatients who attended the clinic of Parasitology at Toulouse University Hospitals, and they reported the performance of this diagnostic procedure that was designed to be rapid (no hospitalization required) and only moderately expensive. RESULTS: A total of 406 patients who presented with blood eosinophilia greater than 0.5 (x109, giga cells per litter, G/L) had an allergic etiology in 350 (86.2%) cases. Among the remaining 56 subjects, 17 did not undergo a follow-up and 39 were referred to another specialized department, mostly Hematology. However, only 21 patients attended then were subsequently investigated. Non-allergic causes of eosinophilia, including 3 cases of the lymphoid variant of hypereosinophilic syndrome and 2 cases of myeloproliferative disorder, were identified in 14 patients, whereas 7 remained diagnosed as having idiopathic eosinophilia. CONCLUSION: This study underlines the need to investigate patients presenting with even moderate blood eosinophilia. The work-up that was employed appears to be efficient and versatile and may be used by any medical specialist, such as in hematology, infectious disease, or internal medicine departments, who needs to investigate eosinophilic patients and should initially rule out any etiology of allergic eosinophilia</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 2054-9369 (Electronic)IS - 2054-9369 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40779-017-0124-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28546866">PM:28546866</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mil Med Res\2017-4-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mil Med Res\2017-4-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Magnaval JF</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40779-017-0124-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ngu,L.H.</style></author><author><style face="normal" font="Arial"> Ong,P.W.</style></author><author><style face="normal" font="Arial"> Leong,H.Y.</style></author><author><style face="normal" font="Arial"> Chew,H.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genetics Department, Hospital Kuala Lumpur, Malaysia</style></auth-address><titles><title><style face="normal" font="Arial">Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II</style></title><secondary-title><style face="normal" font="Arial">Mol Genet Metab Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Genet Metab Rep</style></full-title></periodical><pages end="32" start="28">28-32</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Age of Onset</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anti-ids</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cause of Death</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Mucopolysaccharidosis</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> respiratory failure</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Mucopolysaccharidosis (MPS) II or Hunter syndrome is a chronic, progressive, multi-systemic illness associated with significant morbidity and early mortality. Available evidence in Asian populations shows that Hunter syndrome has a mean age of onset of 2 to 5 years and a life expectancy of 13 years in more severely affected individuals, with respiratory failure reported as the leading cause of death. Enzyme replacement therapy (ERT) with idursulfase (Elaprase, Shire Pharmaceuticals) and idursulfase beta (Hunterase, Green Cross Corp) are the only approved treatment for patients with MPS II. While these agents have the same amino acids, they have different glycosylation patterns because they are produced in different cell lines via different manufacturing processes. In previous studies, the beneficial effects of idursulfase beta have been confirmed in patients up to 35 years of age, without serious treatment-related safety concerns. The major drawbacks associated with ERT include the potential development of serious infusion-related anaphylactic reactions and up to 50% of treated patients develop anti-IDS antibodies. Here we report the case of a 13-year-old Malaysian patient with attenuated MPS II who developed troublesome infusion-associated reactions while receiving idursulfase treatment but tolerated and responded favorably to idursulfase beta</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 2214-4269 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ymgmr.2017.05.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540187">PM:28540187</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Genet Metab Rep\2017-12-28-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Genet Metab Rep\2017-12-28-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Ngu LH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ymgmr.2017.05.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nair,P.</style></author><author><style face="normal" font="Arial"> Wenzel,S.</style></author><author><style face="normal" font="Arial"> Rabe,K.F.</style></author><author><style face="normal" font="Arial"> Bourdin,A.</style></author><author><style face="normal" font="Arial"> Lugogo,N.L.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Barker,P.</style></author><author><style face="normal" font="Arial"> Sproule,S.</style></author><author><style face="normal" font="Arial"> Ponnarambil,S.</style></author><author><style face="normal" font="Arial"> Goldman,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Dosing regimens</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">Background Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia. Methods In a 28-week randomized, controlled trial, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or every 8 weeks [with the first three doses administered every 4 weeks]) versus placebo on the reduction in the oral glucocorticoid dose while asthma control was maintained in adult patients with severe asthma. The primary end point was the percentage change in the oral glucocorticoid dose from baseline to week 28. Annual asthma exacerbation rates, lung function, symptoms, and safety were assessed. Results Of 369 patients enrolled, 220 underwent randomization and started receiving benralizumab or placebo. The two benralizumab dosing regimens significantly reduced the median final oral glucocorticoid doses from baseline by 75%, as compared with a reduction of 25% in the oral glucocorticoid doses in the placebo group (P&lt;0.001 for both comparisons). The odds of a reduction in the oral glucocorticoid dose were more than 4 times as high with benralizumab as with placebo. Among the secondary outcomes, benralizumab administered every 4 weeks resulted in an annual exacerbation rate that was 55% lower than the rate with placebo (marginal rate, 0.83 vs. 1.83, P=0.003), and benralizumab administered every 8 weeks resulted in an annual exacerbation rate that was 70% lower than the rate with placebo (marginal rate, 0.54 vs. 1.83, P&lt;0.001). At 28 weeks, there was no significant effect of either benralizumab regimen on the forced expiratory volume in 1 second (FEV1), as compared with placebo. The effects on various measures of asthma symptoms were mixed, with some showing significant changes in favor of benralizumab and others not showing significant changes. Frequencies of adverse events were similar between each benralizumab group and the placebo group. Conclusions Benralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. These effects occurred without a sustained effect on the FEV1. (Funded by AstraZeneca; ZONDA ClinicalTrials.gov number, NCT02075255 .)</style></abstract><notes><style face="normal" font="Arial">DA - 20170522IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Germany -CO - Poland -CO - United Kingdom -CO - France -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa1703501</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28530840">PM:28530840</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\20170522-NairP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\20170522-NairP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Nair P</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa1703501</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bal,S.M.</style></author><author><style face="normal" font="Arial"> Bernink,J.H.</style></author><author><style face="normal" font="Arial"> Nagasawa,M.</style></author><author><style face="normal" font="Arial"> Groot,J.</style></author><author><style face="normal" font="Arial"> Shikhagaie,M.M.</style></author><author><style face="normal" font="Arial"> Golebski,K.</style></author><author><style face="normal" font="Arial"> van Drunen,C.M.</style></author><author><style face="normal" font="Arial"> Lutter,R.</style></author><author><style face="normal" font="Arial"> Jonkers,R.E.</style></author><author><style face="normal" font="Arial"> Hombrink,P.</style></author><author><style face="normal" font="Arial"> Bruchard,M.</style></author><author><style face="normal" font="Arial"> Villaudy,J.</style></author><author><style face="normal" font="Arial"> Munneke,J.M.</style></author><author><style face="normal" font="Arial"> Fokkens,W.</style></author><author><style face="normal" font="Arial"> Erjefalt,J.S.</style></author><author><style face="normal" font="Arial"> Spits,H.</style></author><author><style face="normal" font="Arial"> Ros,X.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cell Biology and Histology, Academic Medical Center, Amsterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs</style></title><secondary-title><style face="normal" font="Arial">Nat Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Immunol</style></full-title></periodical><pages end="645" start="636">636-645</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cell Plasticity</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cells,Cultured</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunity,Innate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-12</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1beta</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice,Scid</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Disease,Chronic Obstructive</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> Th1-Th2 Balance</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="Arial">Group 2 innate lymphoid cells (ILC2s) secrete type 2 cytokines, which protect against parasites but can also contribute to a variety of inflammatory airway diseases. We report here that interleukin 1beta (IL-1beta) directly activated human ILC2s and that IL-12 induced the conversion of these activated ILC2s into interferon-gamma (IFN-gamma)-producing ILC1s, which was reversed by IL-4. The plasticity of ILCs was manifested in diseased tissues of patients with severe chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP), which displayed IL-12 or IL-4 signatures and the accumulation of ILC1s or ILC2s, respectively. Eosinophils were a major cellular source of IL-4, which revealed cross-talk between IL-5-producing ILC2s and IL-4-producing eosinophils. We propose that IL-12 and IL-4 govern ILC2 functional identity and that their imbalance results in the perpetuation of type 1 or type 2 inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20160520IS - 1529-2916 (Electronic)IS - 1529-2908 (Linking)LA - engPT - Journal ArticleRN - 0 (Interleukin-1beta)RN - 187348-17-0 (Interleukin-12)RN - 207137-56-2 (Interleukin-4)RN - 82115-62-6 (Interferon-gamma)SB - IMCO - Netherlands -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1038/ni.3444</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27111145">PM:27111145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Immunol\2016-17-636-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Immunol\2016-17-636-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160520, Bal SM</style></custom2><misc3><style face="normal" font="Arial">10.1038/ni.3444</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,Z.</style></author><author><style face="normal" font="Arial"> Dai,L.L.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Jia,L.Q.</style></author><author><style face="normal" font="Arial"> Jing,X.G.</style></author><author><style face="normal" font="Arial"> Li,P.F.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> An,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory and Critical Care Medicine, Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">MicroRNA-145 down-regulates mucin 5AC to alleviate airway remodeling and targets EGFR to inhibit cytokine expression</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> EGFR</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor receptor</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Mucin</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">This study aims to explore how microRNA-145 (miR-145) affects airway remodeling and cytokine expression by targeting epidermal growth factor receptor (EGFR) to regulate mucin 5AC (MUC5AC).Mice alveolar epithelial cells (AECs) were divided into a control, blank, miR-145 mimics, mimic control, miR-145 inhibitors, inhibitor control, si-EGFR and miR-145 inhibitors + si-EGFR group. Asthma mice models with airway remodeling were induced with an Ovalbumin (OVA) solution and randomly divided into a normal, asthma, asthma + miR-145 mimics, asthma + miR-145 mimic control, asthma + si-EGFR or asthma + si-EGFR NC group. Airway remodeling degree and histomorphology was measured using hematoxylin-eosin (HE), Masson and periodic acid-Schiff (PAS) staining. Flow cytometry was used to detect Th2 and Th17 cells in peripheral blood, ELISA was used to measure inflammatory factors. qRT-PCR and western blotting was adapted to detect the expressions of EGFR and the relevant cytokines that are regulated by miR-145.The control, miR-145 mimics and si-EGFR groups showed a higher expression of miR-145 and a lower expression of EGFR and cytokines than the blank, mimic control, inhibitor control and miR-145 inhibitor + si-EGFR groups. Mice in the asthma + miR-145 mimics and asthma + si-EGFR groups showed lower WAt/Pbm, WAi/Pbm and WAm/Pbm, less inflammatory cells, less airway modeling and alleviated goblet cell hyperplasia and mucus obstruction than the asthma group. Furthermore, the expressions of EGFR and cytokines of transfected cells and lung tissues were negatively related to those of miR-145. MiR-145 can down-regulate MUC5AC by negatively targeting EGFR and thereby relieving airway remodeling</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.17933</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28564633">PM:28564633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170531-ChengZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170531-ChengZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Cheng Z</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.17933</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sacco,C.</style></author><author><style face="normal" font="Arial"> Perna,S.</style></author><author><style face="normal" font="Arial"> Vicari,D.</style></author><author><style face="normal" font="Arial"> Alfo,M.</style></author><author><style face="normal" font="Arial"> Bauer,C.P.</style></author><author><style face="normal" font="Arial"> Hoffman,U.</style></author><author><style face="normal" font="Arial"> Forster,J.</style></author><author><style face="normal" font="Arial"> Zepp,F.</style></author><author><style face="normal" font="Arial"> Schuster,A.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Pneumology &amp; Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Growth curves of "normal" serum total IgE levels throughout childhood: a quantile analysis in a birth cohort</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="534" start="525">525-534</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> enzyme immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous studies of serum total IgE (t-IgE) were not able to discriminate well enough atopic from non-atopic subjects, i.e. with or without serum-specific IgE antibodies to allergens. OBJECTIVES: To model growth curves of the total IgE levels in children without atopic sensitization (hereafter defined as "normal" t-IgE levels) and to test their usefulness in predicting atopic sensitization. METHODS: The German Multicentre Allergy Study (MAS), a birth cohort with 1314 recruited newborns, began in 1990 and examined the participants until age 20y. Total and specific IgE (t-IgE, s-IgE) were analysed with a fluorescent enzyme immunoassay ImmunoCAP (TFS, Sweden) at ages 1,2,3,5,6,7,10,13 and 20 years. Participants were classified as "never atopic" if all their available serum samples had negative response (cut-off: &lt;0.35 kUA /l) for s-IgE to the 9 common foodborne and airborne allergenic extracts (milk, egg, soy, wheat, house dust mite, cat, dog, birch and grass) tested in the MAS birth cohort. By contrast, participants were defined as atopic if they had , for at least at one available serum sample, s-IgE >/= 0.35 kUA /l to at least one allergenic extract tested. The evolution of t-IgE levels in the "never atopic" children was described by growth curves, estimated by exploiting a quantile regression model. A "reference" percentile, based on the t-IgE value measured at age 5y, was assigned to each child with no IgE sensitization at that age. Upward deviations from the own "reference" quantile of t-IgE in atopic and "never atopic" children were calculated and a ROC analysis was used to identify the best cut-off point for predicting atopic sensitization. RESULTS: Overall, 1113 of 1314 children were included in this analysis. Of these, 469 were "never atopic" and 644 atopic. Quantile trajectories of t-IgE levels in "never atopic" subjects were stable from 5y of age, increased to a plateau at age 10-13y, and decreased slightly afterwards. The onset of atopic s-IgE responses was characterized by an upward deviation of serum t-IgE levels from their "reference" trajectory. T-IgE quantiles predicted the onset of atopy with high efficiency (AUC >80%). ROC analysis showed that deviations from the t-IgE level "reference" quantile above 0.32, 0.41, 0.42, 0.30 and 0.58 kU/l (log-units) at 6,7,10,13 and 20 years of age, respectively, predicted an atopic sensitization. CONCLUSIONS: The growth curves of "normal" serum t-IgE concentrations were estimated in "never atopic" children; for each individual who was non-atopic at 5ys of age a "reference" quantile was identified that represented the individual's "normal" level of t-IgE production. Upward deviations of observed t-IgE levels from the own "reference" quantile, from 6ys to 20ys of age, predicted at each year the occurrence of atopic sensitization. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12738</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544337">PM:28544337</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170525-SaccoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170525-SaccoC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Sacco C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12738</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mori,S.</style></author><author><style face="normal" font="Arial"> Tsumagari,S.</style></author><author><style face="normal" font="Arial"> Kurihara,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Kanagawa Children's Medical Center, Yokohama, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A case of a 7-year-old girl with late-onset anaphylaxis to fermented soybeans</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="502" start="501">501-502</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Food</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Natto</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergy</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> Traditional food</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">Fermented soybean (natto) is a traditional food in Japan. Because natto is rich in vitamin K2, it affects both thrombolysis and bone metabolism and has been widely marketed throughout the world as a health food. Most people with a soybean allergy can safely consume fermented soybean products such as miso (soybean paste), soy sauce, and natto because the fermentation process weakens the immunoreactivity of the soybean protein.1 Nevertheless, there had been several reports of natto-induced late-onset anaphylaxis in adults.2,3 The characteristic feature of late-onset anaphylaxis is its occurrence up to half a day after ingestion of the allergen, even though it is an IgE-mediated allergic reaction. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12736</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544003">PM:28544003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170525-MoriS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170525-MoriS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Mori S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12736</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Occasi,F.</style></author><author><style face="normal" font="Arial"> Duse,M.</style></author><author><style face="normal" font="Arial"> Nebbioso,M.</style></author><author><style face="normal" font="Arial"> Castro,G.</style></author><author><style face="normal" font="Arial"> Fraia,M.D.</style></author><author><style face="normal" font="Arial"> Capata,G.</style></author><author><style face="normal" font="Arial"> Lollobrigida,V.</style></author><author><style face="normal" font="Arial"> Zicari,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">"Sapienza" University of Rome, Department of Pediatrics, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Vernal keratoconjunctivitis treated with Omalizumab: A case series</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="505" start="503">503-505</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">We report the cases of 4 children affected by Vernal keratoconjunctivitis (VKC) treated with Omalizumab with resolution of ocular signs and symptoms. Vernal keratoconjunctivitis (VKC) is a chronic conjunctivitis, not responding to topical antihistamines and frequently misdiagnosed and mistreated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12737</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543949">PM:28543949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170525-OccasiF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170525-OccasiF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Occasi F</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12737</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tran,M.M.</style></author><author><style face="normal" font="Arial"> Lefebvre,D.L.</style></author><author><style face="normal" font="Arial"> Dai,D.</style></author><author><style face="normal" font="Arial"> Dharma,C.</style></author><author><style face="normal" font="Arial"> Subbarao,P.</style></author><author><style face="normal" font="Arial"> Lou,W.</style></author><author><style face="normal" font="Arial"> Azad,M.B.</style></author><author><style face="normal" font="Arial"> Becker,A.B.</style></author><author><style face="normal" font="Arial"> Mandhane,P.J.</style></author><author><style face="normal" font="Arial"> Turvey,S.E.</style></author><author><style face="normal" font="Arial"> Sears,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, McMaster University, Hamilton, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Timing of food introduction and development of food sensitization in a prospective birth cohort</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="477" start="471">471-477</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food sensitization</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> latent class analysis</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The effect of infant feeding practices on the development of food allergy remains controversial. We examined the relationship between timing and patterns of food introduction and sensitization to foods at age 1 year in the Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort study. METHODS: Nutrition questionnaire data prospectively collected at age 3, 6, 12, 18 and 24 months were used to determine timing of introduction of cow's milk products, egg and peanut. At age 1 year, infants underwent skin prick testing to cow's milk, egg white and peanut. Logistic regression models were fitted to assess the impact of timing of food exposures on sensitization outcomes, and latent class analysis was used to study patterns of food introduction within the cohort. RESULTS: Among 2124 children with sufficient data, delaying introduction of cow's milk products, egg and peanut beyond the first year of life significantly increased the odds of sensitization to that food (cow's milk adjOR 3.69, 95% CI 1.37-9.08; egg adjOR 1.89, 95% CI 1.25-2.80; peanut adjOR 1.76, 95% CI 1.07-3.01). Latent class analysis produced a three-class model: early, usual and delayed introduction. A pattern of delayed introduction, characterized by avoidance of egg and peanut during the first year of life, increased the odds of sensitization to any of the three tested foods (adjOR 1.78, 95% CI 1.26-2.49). CONCLUSIONS: Avoidance of potentially allergenic foods during the first year of life significantly increased the odds of sensitization to the corresponding foods. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28557044">PM:28557044</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170530-TranMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170530-TranMM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Tran MM</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12739</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elizur,A.</style></author><author><style face="normal" font="Arial"> Bollyky,J.B.</style></author><author><style face="normal" font="Arial"> Block,W.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Immunology and Rheumatology</style></auth-address><titles><title><style face="normal" font="Arial">Elimination diet and the development of multiple tree-nut allergies</style></title><secondary-title><style face="normal" font="Arial">Pediatr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Res</style></full-title></periodical><pages end="677" start="671">671-677</pages><volume><style face="normal" font="Arial">82</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nut allergy</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUNDDespite its high prevalence, relatively little is known about the characteristics of patients with multiple tree-nuts allergies.METHODSPatients (n=60, aged 4-15 years), recruited for a multiple food (tree-nuts, peanut, milk, egg, soy, sesame and wheat) oral immunotherapy (OIT) study, filled a questionnaire on their initial allergy evaluation. Medical records were reviewed. At OIT enrollment (median interval, 7.5 years), patients underwent oral food challenges (OFC) to foods still eliminated.RESULTSThere was significantly less evidence for eliminating tree-nuts compared to other foods, as reflected by lower rate of acute reaction to the offending food, either as the trigger for initial allergy evaluation (5.9% for tree-nuts vs. 20-40% for other foods, respectively P&lt;0.001), or later in life (14.5% vs. 38-75%, respectively P=0.001), and a higher rate of negative SPT/sIgE at initial diagnosis (25 vs. &lt;10%, P&lt;0.001). SPT/sIgE increased significantly from past initial levels to present for tree-nuts (P&lt;0.001) and peanut (P=0.001) but not for other foods, and most OFCs performed at present were positive.CONCLUSIONSTree-nuts are often eliminated from the diet of multiple food-allergic patients, despite low probability for allergy. Sensitization and allergy to most tree-nuts exist years later suggesting it developed during the period of elimination.Pediatric Research accepted article preview online, 26 May 2017. doi:10.1038/pr.2017.127</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 1530-0447 (Electronic)IS - 0031-3998 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/pr.2017.127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28549059">PM:28549059</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Res\20170526-ElizurA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Res\20170526-ElizurA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Elizur A</style></custom2><misc3><style face="normal" font="Arial">10.1038/pr.2017.127</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deverriere,G.</style></author><author><style face="normal" font="Arial"> Lemee,L.</style></author><author><style face="normal" font="Arial"> Grange,S.</style></author><author><style face="normal" font="Arial"> Boyer,S.</style></author><author><style face="normal" font="Arial"> Picard,C.</style></author><author><style face="normal" font="Arial"> Fischer,A.</style></author><author><style face="normal" font="Arial"> Marguet,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatric Respiratory and Allergy Diseases</style></auth-address><titles><title><style face="normal" font="Arial">Life-Threatening Pneumopathy and U urealyticum in a STAT3-deficient Hyper-IgE Syndrome Patient</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20160845">e20160845-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Haemophilus</style></keyword><keyword><style face="normal" font="Arial"> Haemophilus influenzae</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mycoplasma</style></keyword><keyword><style face="normal" font="Arial"> Mycoplasma pneumoniae</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T helper 17 cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> ureaplasma</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="Arial">A deficiency in signal transducer and activator of transcription 3 (STAT3) is responsible for autosomal dominant hyperimmunoglobulin E syndrome, an immunodeficiency syndrome causing Staphylococcus aureus, Streptococcus pneumonia, Haemophilus influenzae, and, rarely, Pseudomonas aeruginosa and Aspergillus sp infections. Currently, intracellular pathogens are not targeted in the management of severe infections. The pathophysiologic mechanism of hyperimmunoglobulin E syndrome immunodeficiency has recently been linked to a disorder in the T helper 17 pathway and disruption of the interleukin -23/interleukin-17 axis. We report an unusual case of severe pleuropneumopathy by Ureaplasma urealyticum in a teenage girl with STAT3-deficient hyperimmunoglobulin E syndrome (STAT3 HIES). A previous case of severe lung infection by Mycoplasma pneumoniae has already been described in a STAT3-deficient patient, but U urealyticum has never been reported in patients with STAT3 HIES. After a review of the literature, it seems that the specific immunodeficiency pathway of STAT3 HIES exposes STAT3 HIES patients to Ureaplasma lung infections because the pathophysiology of STAT3 HIES and Ureaplasma is based on STAT3 and T helper 17 cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2016-0845</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28562253">PM:28562253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\2016-139-e20160845.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\2016-139-e20160845.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Deverriere G</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2016-0845</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farbman,K.S.</style></author><author><style face="normal" font="Arial"> Michelson,K.A.</style></author><author><style face="normal" font="Arial"> Neuman,M.I.</style></author><author><style face="normal" font="Arial"> Dribin,T.E.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> Stack,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Divisions of Emergency Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Reducing Hospitalization Rates for Children With Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20164114">e20164114-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Adoption</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVES: Most children with anaphylaxis in the emergency department (ED) are hospitalized. Opportunities exist to safely reduce the hospitalization rate for children with anaphylaxis by decreasing unnecessary hospitalizations. A quality improvement (QI) intervention was conducted to improve care and reduce hospitalization rates for children with anaphylaxis. METHODS: We used the Model for Improvement and began with development and implementation in 2011 of a locally developed evidence-based guideline based on national recommendations for the management of anaphylaxis. Guideline adoption and adherence were supported by interval reminders and feedback to providers. Patients from 2008 to 2014 diagnosed with anaphylaxis were identified, and statistical process control methods were used to evaluate change in hospitalization rates over time. The balancing measure was any return visit to the ED within 72 hours. To control for secular trends, hospitalization rates for anaphylaxis at 34 US children's hospitals over the same time period were analyzed. RESULTS: Over the study period, there were 1169 visits for children with anaphylaxis, of which 731 (62%) occurred after the QI implementation. The proportion of children hospitalized decreased from 54% to 36%, with no increase in the 72-hour ED revisit rate. The hospitalization rate across 34 other US pediatric hospitals remained static at 52% over the study period. CONCLUSIONS: We safely reduced unnecessary hospitalizations for children with anaphylaxis and sustained the change over 3 years by using a QI initiative that included evidence-based guideline development and implementation, reinforced by provider reminders and structured feedback</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2016-4114</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28562277">PM:28562277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\2016-139-e20164114.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\2016-139-e20164114.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Farbman KS</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2016-4114</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Rotrosen,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology, Department of Pediatrics</style></auth-address><titles><title><style face="normal" font="Arial">The Benefits of New Guidelines to Prevent Peanut Allergy</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20164293">e20164293-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2016-4293</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28562280">PM:28562280</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\2016-139-e20164293.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\2016-139-e20164293.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Sicherer SH</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2016-4293</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cabana,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatrics and Epidemiology and Biostatistics, and Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, California</style></auth-address><titles><title><style face="normal" font="Arial">Corticosteroids and Asthma: Too Much or Too Little?</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20170598">e20170598-</pages><volume><style face="normal" font="Arial">139</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Policy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2017-0598</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28557773">PM:28557773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\2016-139-e20170598.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\2016-139-e20170598.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Cabana MD</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2017-0598</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,P.</style></author><author><style face="normal" font="Arial"> Xu,Z.</style></author><author><style face="normal" font="Arial"> Cui,Z.</style></author><author><style face="normal" font="Arial"> Zhang,Z.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Ethylene production by Alternaria alternata and its association with virulence on inoculated grape berries</style></title><secondary-title><style face="normal" font="Arial">Phytoparasitica</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Phytoparasitica</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Ethylene</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Germination</style></keyword><keyword><style face="normal" font="Arial"> Grape</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Methionine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Virulence</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1876-7184</style></isbn><abstract><style face="normal" font="Arial">Ethylene has been shown to promote spore germination and hyphal growth in the phytopathogenic fungus Alternaria alternata. However, little is known about the ethylene biosynthetic pathway in this fungus. In the present study, the ethylene biosynthetic pathway in A. alternata was investigated to explore ethylene-associated virulence of this fungus. The strain A0 of A. alternata did not produce ethylene on basal medium with different possible precursors or intermediates for ethylene biosynthesis (glutamate, aspartate, 2-oxoglutarate and 1-aminocyclopropano </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1-carboxylic acid). However, ethylene production was observed when methionine was added as a precursor to the medium and was further promoted by continuous light illumination. Furthermore, addition of 2-keto-4-methylthiobutyric acid (KMBA) promoted ethylene production in the absence of methionine, indicating that the KMBA pathway was mainly responsible for ethylene biosynthesis in this fungus. The strain A0 was inoculated into grape berries to examine the effect of ethylene production on its virulence (as assessed by lesion formation at the inoculation site). The results indicated that higher ethylene production caused larger lesion formation. Similar results were also obtained when isolates of A. alternata, obtained from infected grapes, were inoculated. Thus, the present study thus demonstrated that A. alternata produces ethylene via the KMBA pathway and utilizes it for enhanced virulence expression during infection</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12600-017-0594-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s12600-017-0594-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Phytoparasitica\20170606-ZhuP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Phytoparasitica\20170606-ZhuP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Zhu P</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12600-017-0594-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Habibi,P.</style></author><author><style face="normal" font="Arial"> Prado,G.S.</style></author><author><style face="normal" font="Arial"> Pelegrini,P.B.</style></author><author><style face="normal" font="Arial"> Hefferon,K.L.</style></author><author><style face="normal" font="Arial"> Soccol,C.R.</style></author><author><style face="normal" font="Arial"> Grossi-de-Sa,M.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Optimization of inside and outside factors to improve recombinant protein yield in plant</style></title><secondary-title><style face="normal" font="Arial">Plant Cell Tiss Organ Cult</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Cell Tiss Organ Cult</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Attention</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Carrot</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-5044</style></isbn><abstract><style face="normal" font="Arial">The use of plant systems as factories for recombinant protein production became a prominent alternative for pharmaceutical industries due to their high potential for protein accumulation. In the last decades, the application of plants for protein production has gained more attention, as plants represent an economic strategy that leads to high levels of purified and active proteins for the pharmaceutical sector. Currently, FDA approval of the first generation of recombinant proteins produced in carrot cells, taliglucerase alfa, demonstrated that plant cells have a significant capacity to express complex proteins for therapeutic use. Although plant systems still have technical and economic barriers that require improvements in future years, the optimization of upstream and downstream components affecting protein accumulation is considered a key feature in the development of new pharmaceutical proteins. Therefore, an improvement of critical features, including transcription, translation and post-translational modifications, in plant cells could make plant systems a safe and economical alternative for biopharmaceutical production. Hence, in this review, the most recent advances influencing the upstream and downstream processes involved in recombinant protein accumulation in plant cells are described. We also discuss how plant systems are becoming the benchmark for the production of several biopharmaceuticals</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11240-017-1240-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s11240-017-1240-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Cell Tiss Organ Cult\20170606-HabibiP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Cell Tiss Organ Cult\20170606-HabibiP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Habibi P</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11240-017-1240-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anturaniemi,J.</style></author><author><style face="normal" font="Arial"> Uusitalo,L.</style></author><author><style face="normal" font="Arial"> Hielm-Bjorkman,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Veterinary Medicine, Department of Equine and Small Animal Medicine, University of Helsinki, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Environmental and phenotype-related risk factors for owner-reported allergic/atopic skin symptoms and for canine atopic dermatitis verified by veterinarian in a Finnish dog population</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0178771">e0178771-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Causality</style></keyword><keyword><style face="normal" font="Arial"> colour</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinarian</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The aim of this cross-sectional study was to observe whether environmental factors and phenotypic traits are associated with owner-reported skin problems and with veterinary diagnosed canine atopic dermatitis (CAD). Data were collected using the validated online DOGRISK questionnaire. Out of the data that the questionnaire provides for analysis, focus was first turned towards addressing questions regarding 'Atopy/allergy (skin symptoms)' using a total of 8643 dogs: 1585 dogs with owner-reported allergic/atopic skin symptoms and 7058 dogs without. A subsequent analysis compared dogs with veterinary-verified CAD (n = 322) as a case group against the 7058 dogs without owner-reported skin symptoms. The association between 21 factors related to the environment, canine phenotypes and breed groups within both populations were analysed using univariable and multivariable logistic regression. The environmental factors that showed a significant inverse association with the risk of owner-reported allergic/atopic skin symptoms were as following: whether the dog was living in a detached house, whether there were other dogs in the household, and whether the dog was born in the current household. Having over 50% white colour in the coat and living in an extremely clean household were significantly associated with an increased risk of owner-reported allergic/atopic skin symptoms. The five breeds demonstrating the highest proportion of owner-reported allergic/atopic skin symptoms were West Highland white terrier, Boxer, English bulldog, Dalmatian and French bulldog. The Federation Cynologique Internationale dog breed groups 3 (Terriers) and 6 (Scent hounds and related breeds) showed a significantly higher risk for owner-reported allergic/atopic skin symptoms than mixed breed dogs. In the second population, the inverse association was observed between the risk of CAD and the presence of other dogs in the household, and whether the dog had been born in the current household. The results indicate that some environmental factors and canine phenotypes are associated with CAD and owner-reported skin symptoms, but they still do not prove causality</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0178771</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570617">PM:28570617</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0178771.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0178771.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Anturaniemi J</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0178771</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aguilar-Pimentel,A.</style></author><author><style face="normal" font="Arial"> Graessel,A.</style></author><author><style face="normal" font="Arial"> Alessandrini,F.</style></author><author><style face="normal" font="Arial"> Fuchs,H.</style></author><author><style face="normal" font="Arial"> Gailus-Durner,V.</style></author><author><style face="normal" font="Arial"> Hrabe de Angelis,M.</style></author><author><style face="normal" font="Arial"> Russkamp,D.</style></author><author><style face="normal" font="Arial"> Chaker,A.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Blank,S.</style></author><author><style face="normal" font="Arial"> Gutermuth,J.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Center Munich, Neuherberg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0178563">e0178563-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyallergies</style></keyword><keyword><style face="normal" font="Arial"> Polyallergy</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific immunotherapy (AIT) is the only curative treatment for type-1 allergies, but sometimes shows limited therapeutic response as well as local and systemic side effects. Limited control of local inflammation and patient symptoms hampers its widespread use in severe allergic asthma. OBJECTIVE: Our aim was to evaluate whether AIT is more effective in suppression of local inflammation if performed under the umbrella of short-term non-specific immunomodulation using a small molecule inhibitor of JAK pathways. METHODS: In C57BL/6J mice, a model of ovalbumin (OVA)-induced allergic airway inflammation and allergen-specific immunotherapy was combined with the administration of Tofacitinib (TOFA, a FDA-approved JAK inhibitor) from 48 hours prior to 48 hours after therapeutic OVA-injection. The effect of TOFA on human FOXP3+CD4+ T cells was studied in vitro. RESULTS: AIT combined with short-term TOFA administration was significantly more effective in suppressing total cell and eosinophil infiltration into the lung, local cytokine production including IL-1beta and CXCL1 and showed a trend for the reduction of IL-4, IL-13, TNF-alpha and IL-6 compared to AIT alone. Furthermore, TOFA co-administration significantly reduced systemic IL-6, IL-1beta and OVA-specific IgE levels and induced IgG1 to the same extent as AIT alone. Additionally, TOFA enhanced the induction of human FOXP3+CD4+ T cells. CONCLUSIONS: This proof of concept study shows that JAK inhibition did not inhibit tolerance induction, but improved experimental AIT at the level of local inflammation. The improved control of local inflammation might extend the use of AIT in more severe conditions such as polyallergy, asthma and high-risk patients suffering from mastocytosis or anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Luxembourg -CO - Denmark -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0178563</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570653">PM:28570653</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0178563.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0178563.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Aguilar-Pimentel A</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0178563</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teixeira,A.D.D.</style></author><author><style face="normal" font="Arial"> Games,P.D.</style></author><author><style face="normal" font="Arial"> Katz,B.B.</style></author><author><style face="normal" font="Arial"> Tomich,J.M.</style></author><author><style face="normal" font="Arial"> Zanuncio,J.C.</style></author><author><style face="normal" font="Arial"> Serrao,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of General Biology, Universidade Federal de Vicosa, Vicosa, Minas Gerais, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Proteomic analysis in the Dufour's gland of Africanized Apis mellifera workers (Hymenoptera: Apidae)</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0177415">e0177415-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Apis mellifera</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cell Communication</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Detoxification</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Exocrine Glands</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid Metabolism</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The colony of eusocial bee Apis mellifera has a reproductive queen and sterile workers performing tasks such as brood care and foraging. Chemical communication plays a crucial role in the maintenance of sociability in bees with many compounds released by the exocrine glands. The Dufour's gland is a non-paired gland associated with the sting apparatus with important functions in the communication between members of the colony, releasing volatile chemicals that influence workers roles and tasks. However, the protein content in this gland is not well studied. This study identified differentially expressed proteins in the Dufour's glands of nurse and forager workers of A. mellifera through 2D-gel electrophoresis and mass spectrometry. A total of 131 spots showed different expression between nurse and forager bees, and 28 proteins were identified. The identified proteins were categorized into different functions groups including protein, carbohydrate, energy and lipid metabolisms, cytoskeleton-associated proteins, detoxification, homeostasis, cell communication, constitutive and allergen. This study provides new insights of the protein content in the Dufour's gland contributing to a more complete understanding of the biological functions of this gland in honeybees</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0177415</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28542566">PM:28542566</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0177415.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0177415.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Teixeira AD</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0177415</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,R.</style></author><author><style face="normal" font="Arial"> Gu,X.</style></author><author><style face="normal" font="Arial"> Lai,W.</style></author><author><style face="normal" font="Arial"> Peng,X.</style></author><author><style face="normal" font="Arial"> Yang,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, College of Veterinary Medicine, Sichuan Agricultural University, Wenjiang, China</style></auth-address><titles><title><style face="normal" font="Arial">Transcriptome-microRNA analysis of Sarcoptes scabiei and host immune response</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0177733">e0177733-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential expression</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sarcoptes scabiei</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Scabies is a parasitic disease, caused by the mite Sarcoptes scabiei, and is considered one of the top 50 epidemic diseases and one the most common human skin disease, worldwide. Allergic dermatitis, including an intense itch, is a common symptom, however diagnosis is difficult and there is currently no effective vaccine. The goal of this study was to examine the immune interaction mechanism of both S. scabiei and infected hosts. mRNA-seq and microRNA-seq were conducted on the S. scabiei mite and on infected and uninfected hosts. We focused on differential expression of unigenes and microRNAs, as well as the real targets of unigenes in enriched immune signaling pathways. S. scabiei enhanced host immune function and decreased metabolism after infection, while the immune response of the host inhibited S. scabiei proliferation and metabolism signaling pathways. Differentially expressed unigenes of S. scabiei were enriched in the JAK-STAT signaling pathway and the Toll-like receptor signaling pathway. The differential expression analysis indicated that microRNAs of S. scabiei and hosts have major roles in regulating immune interactions between parasites and hosts</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0177733</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28542251">PM:28542251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0177733.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0177733.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, He R</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0177733</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carr,W.W.</style></author><author><style face="normal" font="Arial"> Yawn,B.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Physician, Allergy &amp; Asthma Associates of Southern California, A Medical Group , Southern California Research , Mission Viejo , CA</style></auth-address><titles><title><style face="normal" font="Arial">Management of allergic rhinitis in the era of effective over-the-counter treatments</style></title><secondary-title><style face="normal" font="Arial">Postgrad Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postgrad Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> decongestants</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Sprays</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment guidelines</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) may be regarded as a trivial issue unworthy of the doctor's time, and with the availability of many different over-the-counter (OTC) treatments, up to two thirds of patients self-manage AR before seeking medical care. Yet, AR can have a significant impact on health-related quality of life and is associated with a greater detriment to work productivity than other chronic diseases such as diabetes and hypertension. For many patients, the impact on quality of life is greater than suggested by reported symptoms and should also be a focus of treatment. Although many patients can effectively manage AR symptoms independently, a significant percentage will need direction from a physician to obtain optimal results. The availability of several different classes of treatment-including decongestants, sedating and non-sedating antihistamines, and more recently intranasal corticosteroids (INS)-has increased the complexity of self-management, leaving patients confused about the best approach to treatment. Treatment guidelines universally classify INS as the most effective medical agents available for use in the OTC and primary care settings. Many patients are unaware that INS are available OTC and that they are more effective than other therapies. Patients may have negative perceptions about the safety of INS and may have experienced unpleasant taste, scent, and feel with nasal sprays. Unless a patient volunteers the information, healthcare professionals (HCPs) may be unaware that the patient has significant AR and is using one or more OTC AR therapies. To address this gap in communication, HCPs must be proactive in identifying, assessing, and advising patients with AR, including best strategies to assess allergen trigger symptoms, which treatments are appropriate, and when and how to use them. Proper use of delivery devices is especially important. This article reviews the primary care management of AR in the context of the availability of effective OTC medicines</style></abstract><notes><style face="normal" font="Arial">DA - 20170523IS - 1941-9260 (Electronic)IS - 0032-5481 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/00325481.2017.1333384</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532204">PM:28532204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postgrad Med\20170523-CarrWW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postgrad Med\20170523-CarrWW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170523, Carr WW</style></custom2><misc3><style face="normal" font="Arial">10.1080/00325481.2017.1333384</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dournes,G.</style></author><author><style face="normal" font="Arial"> Berger,P.</style></author><author><style face="normal" font="Arial"> Refait,J.</style></author><author><style face="normal" font="Arial"> Macey,J.</style></author><author><style face="normal" font="Arial"> Bui,S.</style></author><author><style face="normal" font="Arial"> Delhaes,L.</style></author><author><style face="normal" font="Arial"> Montaudon,M.</style></author><author><style face="normal" font="Arial"> Corneloup,O.</style></author><author><style face="normal" font="Arial"> Chateil,J.F.</style></author><author><style face="normal" font="Arial"> Marthan,R.</style></author><author><style face="normal" font="Arial"> Fayon,M.</style></author><author><style face="normal" font="Arial"> Laurent,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Center for Cardiothoracic Research of Bordeaux, University of Bordeaux, Bordeaux, France</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: MR Imaging of Airway Mucus Contrasts as a Tool for Diagnosis</style></title><secondary-title><style face="normal" font="Arial">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Radiology</style></full-title></periodical><pages end="" start="162350">162350-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ethics</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Informed Consent</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="Arial">Purpose To assess the diagnostic accuracy of mucus contrast characterization by using magnetic resonance (MR) imaging to discriminate allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF). Materials and Methods The study was approved by the local Ethics Committee, and all patients or their parents gave written informed consent. One hundred ten consecutive patients with CF were screened between January 2014 and July 2015. All patients underwent a non-contrast material-enhanced MR protocol that included routine T1-weighted and T2-weighted sequences. The presence of mucus with both high T1 and low T2 signal intensities and the so-called inverted mucoid impaction signal (IMIS) sign was qualitatively and quantitatively assessed by two physicians who were blinded to all other data. The reference standard for a diagnosis of ABPA was the criteria of the Cystic Fibrosis Foundation Consensus Conference. ABPA status was followed up for 1 year. Reproducibility was assessed by using the kappa test, correlation was assessed by using the Spearman coefficient, and diagnostic accuracy was assessed by calculating the sensitivity and specificity of IMIS. Results One hundred eight patients with CF were included (mean age, 20 years +/- 11 [standard deviation]; range, 6-53 years): 18 patients with ABPA and 90 patients without ABPA. At the lobar level, inter- and intrareader reproducibility were very good (kappa > 0.90). IMIS had 94% sensitivity (95% confidence interval [CI]: 73%, 99%) and 100% specificity (95% CI: 96%, 100%) for the diagnosis of ABPA. A complete resolution of IMIS was observed in patients with ABPA after 3 months of specific treatment that was significantly correlated with decrease in total immunoglobulin E level (rho = 0.47; P = .04). Conclusion The IMIS sign was both specific and sensitive for the diagnosis of ABPA in CF. Allergic fungal inflammation appears to induce characteristic modifications of mucus contrasts that are assessable by using a noninvasive, contrast material-free, and radiation-free method. (c) RSNA, 2017 Online supplemental material is available for this article</style></abstract><notes><style face="normal" font="Arial">DA - 20170522IS - 1527-1315 (Electronic)IS - 0033-8419 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1148/radiol.2017162350</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28530849">PM:28530849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Radiology\2017-162350.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Radiology\2017-162350.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Dournes G</style></custom2><misc3><style face="normal" font="Arial">10.1148/radiol.2017162350</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nahas,R.</style></author><author><style face="normal" font="Arial"> Green,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A change reaction? Patient safety risks of a hybrid system for allergy documentation</style></title><secondary-title><style face="normal" font="Arial">Res Social Admin Pharm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Res Social Admin Pharm</style></full-title></periodical><pages end="e35" start="e34">e34-e35</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Patient safety</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year><pub-dates><date Day="0" Month="8" Year="2017">2017/8</date></pub-dates></dates><isbn><style face="normal" font="Arial">1551-7411</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.sapharm.2017.04.040</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.sapharm.2017.04.040</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Res Social Admin Pharm\2017-13-e34-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Res Social Admin Pharm\2017-13-e34-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170610, Nahas R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.sapharm.2017.04.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dong,H.M.</style></author><author><style face="normal" font="Arial"> Le,Y.Q.</style></author><author><style face="normal" font="Arial"> Wang,Y.H.</style></author><author><style face="normal" font="Arial"> Zhao,H.J.</style></author><author><style face="normal" font="Arial"> Huang,C.W.</style></author><author><style face="normal" font="Arial"> Hu,Y.H.</style></author><author><style face="normal" font="Arial"> Luo,L.S.</style></author><author><style face="normal" font="Arial"> Wan,X.</style></author><author><style face="normal" font="Arial"> Wei,Y.L.</style></author><author><style face="normal" font="Arial"> Chu,Z.Q.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Cai,S.X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, NanFang Hospital, Southern Medical University, Guangzhou, 510515, China</style></auth-address><titles><title><style face="normal" font="Arial">Extracellular heat shock protein 90alpha mediates HDM-induced bronchial epithelial barrier dysfunction by activating RhoA/MLC signaling</style></title><secondary-title><style face="normal" font="Arial">Respir Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Res</style></full-title></periodical><pages end="" start="111">111-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> beta Catenin</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> E-cadherin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heat shock protein</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> Myosin light chain</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> RhoA</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TEER</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The disruption and hyperpermeability of bronchial epithelial barrier are closely related to the pathogenesis of asthma. House dust mite (HDM), one of the most important allergens, could increase the airway epithelial permeability. Heat shock protein (Hsp) 90alpha is also implicated in the lung endothelial barrier dysfunction by disrupting RhoA signaling. However, the effect of extracellular Hsp90alpha (eHsp90alpha) on the bronchial epithelial barrier disruption induced by HDM has never been reported. METHODS: To investigate the involvement of eHsp90alpha in the bronchial epithelial barrier disruption induced by HDM, normal human bronchial epithelial cell line 16HBE14o- (16HBE) cells were treated by HDM, human recombinant (hr) Hsp90alpha and hrHsp90beta respectively and pretreated by1G6-D7, a specific anti-secreted Hsp90alpha monoclonal antibody (mAb). Hsp90alpha-silencing cells were also constructed. To further evaluate the role of RhoA signaling in this process, cells were pretreated by inhibitors of Rho kinase, GSK429286A and Y27632 2HCl. Transepithelial electrical resistance (TEER) and FITC-dextran flux (FITC-DX) were examined as the epithelial barrier function. Expression and localization of adherens junctional proteins E-cadherin and beta-catenin were evaluated by western blotting and immunofluorescence respectively. The level of eHsp90alpha was investigated by concentration and purification of condition media. RhoA activity was determined by using a Rho G-LISA(R) RhoA activation assay kitTM biochem kit, and the phosphorylation of myosin light chain (MLC), the downstream signal molecule of RhoA, was assessed by western blotting. RESULTS: The epithelial barrier disruption and the loss of adherens junctional proteins E-cadherin and beta-catenin in cytomembrane were observed in HDM-treated 16HBE cells, paralleled with the increase of eHsp90alpha secretion. All of which were rescued in Hsp90alpha-silencing cells or by pretreating 16HBE cells with 1G6-D7. Also, 1G6-D7 suppressed RhoA activity and MLC phosphorylation induced by HDM. Furthermore, inhibitors of Rho kinase prevented and restored the airway barrier disruption. Consistently, it was hrHsp90alpha instead of hrHsp90beta that promoted barrier dysfunction and activated RhoA/MLC signaling in 16HBE cells. CONCLUSIONS: The eHsp90alpha mediates HDM-induced human bronchial epithelial barrier dysfunction by activating RhoA/MLC signaling, suggesting that eHsp90alpha is a potential therapeutic target for treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12931-017-0593-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28558721">PM:28558721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2017-18-111.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2017-18-111.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Dong HM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12931-017-0593-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Endo,Y.</style></author><author><style face="normal" font="Arial"> Shirai,T.</style></author><author><style face="normal" font="Arial"> Saigusa,M.</style></author><author><style face="normal" font="Arial"> Mochizuki,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine Shizuoka General Hospital Shizuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Severe acute asthma caused by Chlamydophila pneumoniae infection</style></title><secondary-title><style face="normal" font="Arial">Respirol Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respirol Case Rep</style></full-title></periodical><pages end="" start="e00239">e00239-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Aminophylline</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chlamydophila pneumoniae</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Levofloxacin</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Asthma exacerbation is associated with respiratory infections, including those by viruses and atypical bacteria. We herein report a case of severe acute asthma in an adult caused by Chlamydophila pneumoniae (C. pneumoniae) infection. A 39-year-old woman without a history of asthma reported to the emergency department with progressive worsening of cough, shortness of breath, and wheezing with low oxygen saturation. A computed tomography (CT) scan revealed patchy ground-glass opacity and bronchial wall thickening. She was treated with systemic corticosteroids, inhaled short-acting beta2 agonists, aminophylline, doripenem, and levofloxacin. Through successful treatment in the intensive care unit (ICU), her condition and the chest X-ray and CT findings improved. Chlamydophila pneumoniae infection was confirmed by elevated paired serum C. pneumoniae-specific IgA antibodies. Chlamydophila pneumoniae infection is an important cause of severe acute asthma. On CT, findings typical of C. pneumoniae pneumonia were noted</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 2051-3380 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1002/rcr2.239</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28560041">PM:28560041</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respirol Case Rep\2017-5-e00239.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respirol Case Rep\2017-5-e00239.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Endo Y</style></custom2><misc3><style face="normal" font="Arial">10.1002/rcr2.239</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxie en France : fréquence, caractéristiques et besoins non satisfaits</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxie</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> epinephrine auto-injectors</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Pressing</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Background Ascertaining how anaphylaxis is diagnosed, and treated nationally and globally is an important preliminary step towards the development of worldwide strategic action plans in order to identify and solve key issues. In order to estimate the degree of awareness of anaphylaxis and evaluate the standards of care for the management of anaphylaxis, in this study we sought to assess the lifetime prevalence of anaphylaxis in France from general adult population as well as to gather on the characteristics of the reactions and its impact in quality of life and management. Methods A prospective web-based survey was launched via Internet to a non-randomized, cross-sectional, convenience sample of French adult general population. The questions were related to the awareness regarding anaphylaxis and its management. Only fully completed questionnaires have been considered eligible for analysis. Results From a total of 8003 responses, 56% of the French population surveyed mentioned being aware of the term </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£anaphylaxis</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ and 8% reported history of anaphylaxis. Respiratory manifestations associated with angioedema have been described by 34%, gastrointestinal symptoms by 17% and cognitive manifestations by 14%. However, the majority of cases (69%) have been treated in outpatients</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ settings and only 43% have been referred to an allergist for further investigations. From those 130 patients (1.6%) who received auto-injectable adrenaline medical prescription, only 15% keep this device available for immediate use. Conclusion The results of this pioneer study defining the rate of anaphylaxis, characteristics, and attitudes regarding anaphylaxis among a representative portion of the French population flag an urgent and pressing need for improved public health initiatives regarding anaphylaxis recognition and treatment, which may be managed in the forthcoming years due to implementation of national and international actions</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.02.242</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.02.242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170608-TannoLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170608-TannoLK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170608, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.02.242</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pitsios,C.</style></author><author><style face="normal" font="Arial"> Lefoussis,C.</style></author><author><style face="normal" font="Arial"> Dimitriou,A.</style></author><author><style face="normal" font="Arial"> Giannakopoulos,D.</style></author><author><style face="normal" font="Arial"> Ergazakis,M.</style></author><author><style face="normal" font="Arial"> Vartholomaios,S.</style></author><author><style face="normal" font="Arial"> Kouri,M.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Kompoti,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergen immunotherapy is safe during pollen season. Results of a 10-year, real-life prospective study</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="307" start="302">302-307</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cyprus</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Effets secondaires</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> olive pollen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Objective Although systemic reactions (SRs) due to allergen immunotherapy (AIT) are rare, preventing them is a major concern for allergologists. Natural exposure during pollen season is a controversial risk factor, so some centers reduce AIT's maintenance dose in-season. The aim of this study was to examine whether administering the maintenance dose of subcutaneous AIT (SCIT) during pollen season, without adjustment, is safe. Patients and methods Initially, a retrospective pilot study was conducted, that included thirty-four monosensitized patients treated with perennial SCIT without in-season dose adjustment during maintenance. Pollen counts were monitored with a Burkard trap, to validate the pollen season. Two SRs were registered; one during and the other out of season, showing no seasonal effect on SCIT's safety. A ten-year-long, prospective study using the same SCIT protocol, followed the pilot one. Seventy-eight monosensitized patients, allergic to Grasses or Parietaria or Olive pollen, completed this study, while 28 monosensitized mite-allergic patients served as a control group. Only standardized depot solutions were used. Results A total of 2910 pollen-extracts maintenance-dose injections were administered. Four SRs (Grade 1 or 2, WAO Classification) were registered; 2/1210 during pollen season and 2/1700 off-season. One (Grade 4) reaction, out of 880 mite extract injections, was registered. The presence of SRs did not correlate with any AIT brand. Conclusion In our study population pollen season does not seem to be a risk factor for SRs for monosensitized allergic patients. SRs due to pollen AIT presented with a similar frequency as with mite AIT</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Cyprus -CO - Greece -CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.01.008</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.01.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170608-PitsiosC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170608-PitsiosC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170608, Pitsios C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.01.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tchabi,F.L.</style></author><author><style face="normal" font="Arial"> Tossou,G.M.</style></author><author><style face="normal" font="Arial"> Akoegninou,A.</style></author><author><style face="normal" font="Arial"> Trigo,M.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Aeropalynological study of the town of Abomey-Calavi (Benin) during the long rainy season</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="316" start="308">308-316</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abomey-Calavi</style></keyword><keyword><style face="normal" font="Arial"> Acacia</style></keyword><keyword><style face="normal" font="Arial"> aeropalynology</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Benin</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Hirst-type device</style></keyword><keyword><style face="normal" font="Arial"> Meteorological factor</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">The pollen content of the atmosphere in the city of Abomey-Calavi was analysed during the rainy season. A Hirst-type device was used to collect the particles. The daily mean captured was 35 grains of pollen and 12 spores per cubic meter of air belonging to 32 types and 7 families. The dominant taxa were: Acacia auriculuformis (34.54%), Poaceae (30.59%), C.-áindicum (7.61%) and E.-águineensis (2.38%). The correlation between pollen data and weather conditions was positive for the amount of pollen grains, temperature and wind speed, but negative for pollen grains and rainfall</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Spain -CO - Benin -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.03.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.03.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170608-TchabiFL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170608-TchabiFL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160608, Tchabi FL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.03.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Godet,C.</style></author><author><style face="normal" font="Arial"> Couturaud,F.</style></author><author><style face="normal" font="Arial"> Ragot,S.</style></author><author><style face="normal" font="Arial"> Laurent,F.</style></author><author><style face="normal" font="Arial"> Brun,A.L.</style></author><author><style face="normal" font="Arial"> Bergeron,A.</style></author><author><style face="normal" font="Arial"> Cadranel,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de maladies infectieuses et de medecine interne, CHU de Poitiers, 2, rue de la Miletrie, 86021 Poitiers cedex, France.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis: Evaluation of a maintenance therapy with nebulized Ambisome(R)</style></title><secondary-title><style face="normal" font="Arial">Rev Mal Respir</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Mal Respir</style></full-title></periodical><pages end="587" start="581">581-587</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aerosols</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Amphotericin B</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal treatment</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug interaction</style></keyword><keyword><style face="normal" font="Arial"> Drug Interactions</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> single-blind</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) affects 3-13% of patients with asthma. Its natural history includes possibly life-threatening exacerbations and evolution towards fixed obstructive ventilatory disorders or even irreversible lung fibrosis lesions. ABPA prognosis is directly associated with exacerbation control and the main objective of the treatment is to decrease their frequency and duration. Recommendations regarding dosage and duration of treatment are not very precise. The currently used combination of itraconazole and corticosteroid therapy has many limitations. The interests of a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) are to heighten antifungal lung tissue concentration, to circumvent drug interactions and decrease the potential toxicity of systemic antifungal treatments. Finally, this association leads to improved eradication of Aspergillus, thereby limiting the risk of side effects and the emergence of treatment-resistant Aspergillus strains. METHODS: This is a phase II, multicentre, randomized, single blind, controlled therapeutic study, with the objective of comparing the potential benefit on exacerbation control of a maintenance therapy by LAmB nebulization. The main objective of the study is to compare the incidence of severe clinical exacerbations in ABPA treatment, between a maintenance treatment strategy with nebulized LAmB and a conventional strategy without antifungal maintenance therapy. EXPECTED RESULTS: The results will guide practitioners in the management of ABPA treatments and help to define the place of aerosols of LAmB on "evidence base medicine" criteria</style></abstract><notes><style face="normal" font="Arial">DA - 20170529IS - 1776-2588 (Electronic)IS - 0761-8425 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmr.2017.04.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552257">PM:28552257</url></web-urls><pdf-urls><url ppv-ref="no">c.godet@chu-poitiers.fr</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170529, Godet C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmr.2017.04.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Radhakrishnan,R.C.</style></author><author><style face="normal" font="Arial"> Basu,G.</style></author><author><style face="normal" font="Arial"> George,R.E.</style></author><author><style face="normal" font="Arial"> Parmar,H.</style></author><author><style face="normal" font="Arial"> Tamilarasi,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India</style></auth-address><titles><title><style face="normal" font="Arial">Rituximab-induced urticarial dermatitis during the treatment of membranous nephropathy</style></title><secondary-title><style face="normal" font="Arial">Saudi J Kidney Dis Transpl</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Saudi J Kidney Dis Transpl</style></full-title></periodical><pages end="660" start="657">657-660</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Rituximab is a monoclonal antibody directed against B cells and is being increasingly used for various renal indications. Acute dermatologic manifestations such as urticaria are well known to occur during rituximab infusion. Here, we report the case of a 53- year-old female who was treated with rituximab for membranous nephropathy and developed an exanthematous rash, which progressed with a further dose of rituximab and was diagnosed as urticarial dermatitis. A review of literature showed that urticarial dermatitis following rituximab therapy has been seldom reported and identification of this complication is very important to avoid giving further doses and thus, increasing the severity of lesions</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 1319-2442 (Print)IS - 1319-2442 (Linking)LA - engPT - Case ReportsCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/1319-2442.206462</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540910">PM:28540910</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Saudi J Kidney Dis Transpl\2017-28-657-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Saudi J Kidney Dis Transpl\2017-28-657-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Radhakrishnan RC</style></custom2><misc3><style face="normal" font="Arial">10.4103/1319-2442.206462</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jordakieva,G.</style></author><author><style face="normal" font="Arial"> Kundi,M.</style></author><author><style face="normal" font="Arial"> Lemell,P.</style></author><author><style face="normal" font="Arial"> Zieglmayer,R.</style></author><author><style face="normal" font="Arial"> Zieglmayer,P.</style></author><author><style face="normal" font="Arial"> Godnic-Cvar,J.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="2555">2555-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erythrocytes</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Hematocrit</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="Arial">House dust mite (HDM) allergy is a predominant cause for perennial allergic rhinitis (AR) in Europe. We recently reported that circulating erythrocyte numbers decrease after airway allergen challenge in a murine asthma model and in grass-pollen sensitized AR subjects. Consequently, we aimed to evaluate these findings in HDM sensitized AR subjects and the influence of preceding allergen immunotherapy. Seventy-seven (age 26.8 +/- 7.3 years; 54.5% female) HDM-allergic rhinitis subjects previously enrolled in a randomized, monocentric sublingual immunotherapy (SLIT) trial at the Vienna Challenge Chamber (VCC) were included. Subjects had either received placebo (n = 22), low-dose HDM (n = 29) or high-dose HDM specific sublingual immunotherapy (n = 26) daily for 24 weeks. Blood sampling was performed before and after 6 hours of HDM allergen exposure. Overall, specific airway allergen challenge resulted in a significant decrease in circulating erythrocytes and hematocrit (p &lt; 0.001), and elevation of leukocytes (p &lt; 0.001), particularly segmented neutrophils (p &lt; 0.001). Gender had no significant effect on the observed changes in circulating blood cells. Erythrocytes decreased and neutrophil counts increased significantly after airway allergen challenge regardless of preceding immunotherapy. These findings imply a rapid systemic mobilization of neutrophils occurring within immediate type hypersensitivity response upon a specific allergen challenge, which is possibly inversely linked with the erythrocyte numbers</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-02321-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28566688">PM:28566688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-2555.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-2555.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Jordakieva G</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-02321-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simpson,J.</style></author><author><style face="normal" font="Arial"> Lynch,J.P.</style></author><author><style face="normal" font="Arial"> Loh,Z.</style></author><author><style face="normal" font="Arial"> Zhang,V.</style></author><author><style face="normal" font="Arial"> Werder,R.B.</style></author><author><style face="normal" font="Arial"> Spann,K.</style></author><author><style face="normal" font="Arial"> Phipps,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Biomedical Sciences, The University of Queensland, Queensland, 4072, Australia</style></auth-address><titles><title><style face="normal" font="Arial">The Absence of Interferon-beta Promotor Stimulator-1 (IPS-1) Predisposes to Bronchiolitis and Asthma-like Pathology in Response to Pneumoviral Infection in Mice</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="2353">2353-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Bronchiolitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interferon-beta</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">Respiratory syncytial virus (RSV)-bronchiolitis is a major cause of infant morbidity and mortality and a risk factor for subsequent asthma. We showed previously that toll-like receptor (TLR)7 in plasmacytoid dendritic cells (pDCs) is critical for protection against bronchiolitis and asthma in mice infected with pneumonia virus of mice (PVM), the mouse homolog of RSV. This lack of redundancy was unexpected as interferon-beta promotor stimulator-1 (IPS-1) signalling, downstream of RIG-I-like receptor (RLR) and not TLR7 activation, contributes to host defence in hRSV-inoculated adult mice. To further clarify the role of IPS-1 signalling, we inoculated IPS-1-/- and WT mice with PVM in early-life, and again in later-life, to model the association between bronchiolitis and asthma. IPS-1 deficiency predisposed to severe PVM bronchiolitis, characterised by neutrophilic inflammation and necroptotic airway epithelial cell death, high mobility group box 1 (HMGB1) and IL-33 release, and downstream type-2 inflammation. Secondary infection induced an eosinophilic asthma-like pathophysiology in IPS-1-/- but not WT mice. Mechanistically, we identified that IPS-1 is necessary for pDC recruitment, IFN-alpha production and viral control. Our findings suggest that TLR7 and RLR signalling work collaboratively to optimally control the host response to pneumovirus infection thereby protecting against viral bronchiolitis and subsequent asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170525IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-02564-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28539639">PM:28539639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-2353.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-2353.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170525, Simpson J</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-02564-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krishnareddy,S.</style></author><author><style face="normal" font="Arial"> Stier,K.</style></author><author><style face="normal" font="Arial"> Recanati,M.</style></author><author><style face="normal" font="Arial"> Lebwohl,B.</style></author><author><style face="normal" font="Arial"> Green,P.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Celiac Disease Center at Columbia University, Columbia University, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Commercially available glutenases: a potential hazard in coeliac disease</style></title><secondary-title><style face="normal" font="Arial">Therap Adv Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Therap Adv Gastroenterol</style></full-title></periodical><pages end="481" start="473">473-481</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Coeliac disease</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> dietary supplement</style></keyword><keyword><style face="normal" font="Arial"> Dietary Supplements</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free diet</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Lipase</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical therapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> papaya</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peptidase</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The only treatment for celiac disease (CD) is a gluten-free diet (GFD). However, there is interest among patients in a medical therapy to replace or help with a GFD. Therapies include gluten-degrading enzymes (glutenases). There are glutenases available marketed as dietary supplements that have not been demonstrated to digest the toxic epitopes of gluten. METHODS: We investigated the contents, claims, and disclaimers of glutenase products and assessed patient interest using Google AdWords to obtain Google search frequencies. RESULTS: Among 14 glutenase product, all contained proteases, eight contained X-prolyl exopeptidase dipeptidyl peptidase IV, two did not state the protease contents, and eight failed to specify the name or origin of all proteases. Eleven contained carbohydrases and lipases and three probiotics. One declared wheat and milk as allergens, two contained herbal products (type not stated) and one Carica papaya. Thirteen claimed to degrade immunogenic gluten fragments, four claimed to help alleviate gastrointestinal symptoms associated with eating gluten. Disclaimers included not being evaluated by the US Food and Drug Administration and products not intended to diagnose, treat, cure, or prevent any disease. On Google AdWords, the search frequency for the product names and the search terms was 3173 searches per month. CONCLUSIONS: The names of these products make implicit claims that appear to be supported by the claims on the labels and websites for which there is no scientific basis. Google search data suggest great interest and therefore possible use by patients with CD. There needs to be greater oversight of these 'drugs'</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1756-283X (Print)IS - 1756-283X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/1756283X17690991</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28567117">PM:28567117</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Therap Adv Gastroenterol\2017-10-473-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Therap Adv Gastroenterol\2017-10-473-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Krishnareddy S</style></custom2><misc3><style face="normal" font="Arial">10.1177/1756283X17690991</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Crowley,C.M.</style></author><author><style face="normal" font="Arial"> Fontaine,J.H.</style></author><author><style face="normal" font="Arial"> Gerriets,J.E.</style></author><author><style face="normal" font="Arial"> Schelegle,E.S.</style></author><author><style face="normal" font="Arial"> Hyde,D.M.</style></author><author><style face="normal" font="Arial"> Miller,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">California National Primate Research Center, University of California, Davis, United States</style></auth-address><titles><title><style face="normal" font="Arial">Early life allergen and air pollutant exposures alter longitudinal blood immune profiles in infant rhesus monkeys</style></title><secondary-title><style face="normal" font="Arial">Toxicol Appl Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicol Appl Pharmacol</style></full-title></periodical><pages end="69" start="60">60-69</pages><volume><style face="normal" font="Arial">328</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cell Count</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Monkeys</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhesus Monkeys</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="Arial">Early life is a critical period for the progressive establishment of immunity in response to environmental stimuli; the impact of airborne challenges on this process is not well defined. In a longitudinal fashion, we determined the effect of episodic house dust mite (HDM) aerosol and ozone inhalation, both separately and combined, on peripheral blood immune cell phenotypes and cytokine expression from 4 to 25weeks of age in an infant rhesus monkey model of childhood development. Immune profiles in peripheral blood were compared with lung lavage at 25weeks of age. Independent of exposure, peripheral blood cell counts fluctuated with chronologic age of animals, while IFNgamma and IL-4 mRNA levels increased over time in a linear fashion. At 12weeks of age, total WBC, lymphocyte numbers, FoxP3 mRNA and IL-12 mRNA were dramatically reduced relative to earlier time points, but increased to a steady state with age. Exposure effects were observed for monocyte numbers, as well as CCR3, FoxP3, and IL-12 mRNA levels in peripheral blood. Significant differences in cell surface marker and cytokine expression were detected following in vitro HDM or PMA/ionomycin stimulation of PBMC isolated from animals exposed to either HDM or ozone. Lavage revealed a mixed immune phenotype of FoxP3, IFNgamma and eosinophilia in association with combined HDM plus ozone exposure, which was not observed in blood. Collectively, our findings show that airborne challenges during postnatal development elicit measureable cell and cytokine changes in peripheral blood over time, but exposure-induced immune profiles are not mirrored in the lung</style></abstract><notes><style face="normal" font="Arial">DA - 20170522IS - 1096-0333 (Electronic)IS - 0041-008X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.taap.2017.05.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28529118">PM:28529118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol Appl Pharmacol\2017-328-60-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol Appl Pharmacol\2017-328-60-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170522, Crowley CM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.taap.2017.05.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,T.</style></author><author><style face="normal" font="Arial"> Chan,S.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author><author><style face="normal" font="Arial"> Cro,S.</style></author><author><style face="normal" font="Arial"> Cornelius,V.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK</style></auth-address><titles><title><style face="normal" font="Arial">The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan</style></title><secondary-title><style face="normal" font="Arial">Trials</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Trials</style></full-title></periodical><pages end="" start="231">231-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> objective SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and safety of omalizumab for children with severe atopic eczema. This article describes the detailed statistical analysis plan for the ADAPT as an update to the published protocol and is submitted prior to knowing all outcomes. METHOD AND DESIGN: The ADAPT is a randomised, double-blind, placebo-controlled trial with a primary objective to determine whether anti-IgE reduces eczema severity as assessed by the validated eczema score (objective SCORAD) after 24 weeks of treatment in children with severe eczema. This articles outline the overall analysis principles including considerations on sample definition in each analysis, missing data, and adjusted covariates. Comparability and representativeness of the randomised groups, primary and sensitivity analyses of the primary and secondary outcomes as well as subgroup analysis are described. RESULTS: This prespecified statistical analysis plan has been developed to comply with international guidelines which will increase the transparency of the data analysis for the ADAPT. TRIAL REGISTRATION: ISRCTN, identifier: ISRCTN15090567 . Registered on 3 December 2014; EU Clinical Trials Register, EudraCT Number: 2010-020841-29 . Registered on 14 May 2010. The first participant was enrolled on 15 January 2015</style></abstract><notes><style face="normal" font="Arial">DA - 20170524IS - 1745-6215 (Electronic)IS - 1745-6215 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13063-017-1976-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28535776">PM:28535776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trials\2017-18-231.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trials\2017-18-231.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170524, Chen T</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13063-017-1976-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gomez,R.M.</style></author><author><style face="normal" font="Arial"> Jares,E.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Baiardini,I.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Sanchez Borges,M.</style></author><author><style face="normal" font="Arial"> Kaplan,A.P.</style></author><author><style face="normal" font="Arial"> Baena-Cagnani,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fundacion Ayre at Instituto Medico Alas, Sarmiento 771, 330-31, 4400 Salta, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Why a registry of Chronic Urticaria (CUR) is needed</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="16">16-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Chronic urticaria (CU) has a major effect on patients' quality of life. While there have been progressive advances regarding its pathogenesis and treatment, much remains to be done. Registries of other chronic non-communicable diseases have shown many benefits, such as additional basic knowledge and management approaches to diabetes mellitus. Standards of care as well as diagnostic approaches can be elaborated and compared from different sites, using validated instruments. Registries in allergic diseases are also becoming well recognized, and the first registry on CU, accessible from SLaai's webpage, includes parameters for identification, evaluation and management. In our vision, informatics strategies have the potential to improve care for chronic illnesses such as CU. The registry represents a valid instrument from which to obtain a sufficient sample size for epidemiological studies and/or clinical research planning, including feasibility and potential enrollment. It can also provide invaluable data for adapting guidelines to local populations, as well as diagnostic approaches and cost-effective interventions in the context of organizational efforts to improve patient care</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Argentina -CO - Italy -CO - Venezuela -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0147-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28546849">PM:28546849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Gomez RM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0147-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cherrez,A.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author><author><style face="normal" font="Arial"> Calderon,J.C.</style></author><author><style face="normal" font="Arial"> Simancas-Racines,D.</style></author><author><style face="normal" font="Arial"> Cherrez Ojeda,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiralab Research Group, Respiralab, Guayaquil, Ecuador</style></auth-address><titles><title><style face="normal" font="Arial">Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="21">21-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> disparities</style></keyword><keyword><style face="normal" font="Arial"> disparity</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Latin America</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The current EAACI/GA2LEN/EDF/WAO guideline for urticaria provide specific recommendations for the diagnostic workup and treatment of patients with chronic spontaneous urticaria (CsU). This study explored if physicians in Ecuador know these recommendations and implement them in their actual clinical practice for CsU. METHODS: We investigated physicians who treat CsU patients in a cross-sectional study using a standardized questionnaire. Descriptive statistics were employed, adjusted logistic regression was performed to assess the link of guideline knowledge and use of therapy. RESULTS: Seven hundred forty surveys were collected and analyzed. The mean age of physicians was 42.3 (+/-12.5) years. Most of the participants (65.1%) were general physicians (GP), 13.7% were pediatricians, 11.0% internists, 6.8% dermatologists or allergists (D/A). Only 18.8% knew the EAACI/GA2LEN/EDF/WAO guideline. 44.5% of GPs searched for CsU etiology in contrast to 90% of D/A. Most common diagnostic test was total serum IgE (83.5%). Most common first line symptomatic treatment was oral corticoids (46.3%), followed by second generation antihistamines (sgAHs, 36.8%). A/D prescribed more sgAHs (regular doses) (74.1 vs 28.6% of GP) (p &lt; 0.05). Experience with omalizumab was reported only by 3.5%, of physicians, and higher rates among who were familiar with the guideline. CONCLUSION: This study shows that the knowledge of guideline recommendations in physicians who treat urticaria patients in Ecuador is low. The diagnostic workup and treatment of CsU patients are largely not in line with guideline recommendations in real life practice settings. We were able to compare results between German and Ecuadorian physicians and found that Ecuadorian physicians have lower awareness of the current guideline (33 vs 18%). Only one-third of physicians reported using regular doses of sgAHs as the first line treatment. Also, only 12.9% of physicians use sgAHs in higher doses and physicians still use fgAHs, particularly pediatricians (42.9%). Our results suggest that disparities in knowledge between physicians from different countries could influence the management of CsU. Knowledge of the guidelines is linked to better choices of treatments. Awareness of guidelines needs to be promoted for better management of chronic urticaria</style></abstract><notes><style face="normal" font="Arial">DA - 20170526IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Ecuador -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0150-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28546850">PM:28546850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170526, Cherrez A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0150-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mehrdana,F.</style></author><author><style face="normal" font="Arial"> Buchmann,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Aquatic Pathobiology, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1870, Frederiksberg C, Denmark. foojan@sund.ku.dkLaboratory of Aquatic Pathobiology, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1870, Frederiksberg C, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Excretory/secretory products of anisakid nematodes: biological and pathological roles</style></title><secondary-title><style face="normal" font="Arial">Acta Vet Scand</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Vet Scand</style></full-title></periodical><pages end="" start="42">42-</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Anisakid</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody production</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Birds</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Invertebrates</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Penetration</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pseudoterranova</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vertebrates</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="Arial">Parasites from the family Anisakidae are widely distributed in marine fish populations worldwide and mainly nematodes of the three genera Anisakis, Pseudoterranova and Contracaecum have attracted attention due to their pathogenicity in humans. Their life cycles include invertebrates and fish as intermediate or transport hosts and mammals or birds as final hosts. Human consumption of raw or underprocessed seafood containing third stage larvae of anisakid parasites may elicit a gastrointestinal disease (anisakidosis) and allergic responses. Excretory and secretory (ES) compounds produced by the parasites are assumed to be key players in clinical manifestation of the disease in humans, but the molecules are likely to play a general biological role in invertebrates and lower vertebrates as well. ES products have several functions during infection, e.g. penetration of host tissues and evasion of host immune responses, but are at the same time known to elicit immune responses (including antibody production) both in fish and mammals. ES proteins from anisakid nematodes, in particular Anisakis simplex, are currently applied for diagnostic purposes but recent evidence suggests that they also may have a therapeutic potential in immune-related diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170624IS - 1751-0147 (Electronic)IS - 0044-605X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13028-017-0310-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28645306">PM:28645306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Vet Scand\2017-19-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Vet Scand\2017-19-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170624, Mehrdana F</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13028-017-0310-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lu,L.</style></author><author><style face="normal" font="Arial"> Arizmendi,N.</style></author><author><style face="normal" font="Arial"> Kulka,M.</style></author><author><style face="normal" font="Arial"> Unsworth,L.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">DICE 13-390, Department of Chemical and Materials Engineering, University of Alberta, 9211-116 Street NW, Edmonton, AB, T6G 1H9, Canada</style></auth-address><titles><title><style face="normal" font="Arial">The Spontaneous Adhesion of BMMC onto Self-Assembled Peptide Nanoscaffold without Activation Inhibits Its IgE-Mediated Degranulation</style></title><secondary-title><style face="normal" font="Arial">Adv Healthc Mater</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Healthc Mater</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> biomaterials</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Diffusion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="Arial">Mast cells play a distinct role in the innate immune response. Engineered microenvironments for the express purpose of influencing mast cell activity will provide a novel means of designing biomaterials, as well as a means to systematically investigate mast cell biology in a 3D setting. Here, the effect of nanoscaffolds composed of self-assembling peptides, namely (RADA)4 , on bone-marrow-derived murine mast cell (BMMC) activity is reported. Unlike most studies that stimulate mast cells to induce adhesion, this results show that BMMCs spontaneously adhere to the artificial nanoscaffold without initiating their activation. It is observed that the classical immunoglobulin (IgE) antigen-mediated degranulation of adhered BMMC is inhibited by the nanoscaffold, while non-IgE (A23187)-induced degranulation is unaffected. The inhibition of IgE-antigen-mediated degranulation is likely a result of inhibited molecular diffusion within the matrix; antigen diffusion, IgE-FcepsilonRI complex shuttling, and/or formation of multiple IgE-FcepsilonRI clusters may be physically hindered in the presence of the polyvalent nanofiber network. Moreover, the IgE/antigen-induced inflammatory cytokine tumor necrosis factor alpha release from adherent BMMCs is significantly reduced likely due to interaction with the nanofiber matrix. This work is considered the first step in quantifying mast cell activity in artificial matrices composed of self-assembling peptides</style></abstract><notes><style face="normal" font="Arial">DA - 20170630IS - 2192-2659 (Electronic)IS - 2192-2640 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1002/adhm.201700334</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28665558">PM:28665558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Healthc Mater\20170630-LuL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Healthc Mater\20170630-LuL.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Healthc Mater\20170630-LuL.mp4</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Healthc Mater\20170630-LuL.mp4</url></image-urls></urls><custom2><style face="normal" font="Arial">20170630, Lu L</style></custom2><misc3><style face="normal" font="Arial">10.1002/adhm.201700334</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Muller-Germann,I.</style></author><author><style face="normal" font="Arial"> Pickersgill,D.A.</style></author><author><style face="normal" font="Arial"> Paulsen,H.</style></author><author><style face="normal" font="Arial"> Alberternst,B.</style></author><author><style face="normal" font="Arial"> Poschl,U.</style></author><author><style face="normal" font="Arial"> Frohlich-Nowoisky,J.</style></author><author><style face="normal" font="Arial"> Despres,V.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergenic Asteraceae in air particulate matter: quantitative DNA analysis of mugwort and ragweed</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Artemisia vulgaris</style></keyword><keyword><style face="normal" font="Arial"> Asteraceae</style></keyword><keyword><style face="normal" font="Arial"> Atmospheric aerosol</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Central Europe</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA analysis</style></keyword><keyword><style face="normal" font="Arial"> DNA quantification</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Habitat</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Mugwort (Artemisia vulgaris) and ragweed (Ambrosia artemisiifolia) are highly allergenic Asteraceae. They often cause pollen allergies in late summer and fall. While mugwort is native to Europe, ragweed reached Europe as a neophyte from North America about 150-áyears ago and continued spreading ever since. To understand possible relationships between the spread of ragweed, its abundance in air, and to judge possible health risks for the public, we quantified ragweed DNA in inhalable fine as well as in coarse air particulate matter. Mugwort was chosen for comparison, as it is closely related to ragweed and grows in similar, though mainly not identical, habitats but is native to Germany. The DNA quantification was performed on atmospheric aerosol samples collected over a period of 5-áyears in central Europe. The DNA concentrations were highest during the characteristic pollination periods but varied greatly between different years. In the inhalable fine particle fraction, ragweed exceeds the mugwort DNA concentration fivefold, while the coarse particle fraction, bearing intact pollen grains, contains more mugwort than ragweed DNA. The higher allergenic potential of ragweed might be linked to the humidity or long-range transport-induced bursting of ragweed pollen into smaller allergenic particles, which may reach the lower airways and cause more intense allergic reactions. Airborne ragweed DNA was detected also outside the local pollination periods, which can be explained by atmospheric long-range transport. Back-trajectory analyses indicate that the air masses containing ragweed DNA during winter had originated in regions with milder climate and large ragweed populations (Southern France, Carpathian Basin)</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9485-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9485-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170626-MullerGermannI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170626-MullerGermannI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170626, Muller-Germann I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9485-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tamura,M.</style></author><author><style face="normal" font="Arial"> Matsui,K.</style></author><author><style face="normal" font="Arial"> Kobayashi,Y.</style></author><author><style face="normal" font="Arial"> Ogita,C.</style></author><author><style face="normal" font="Arial"> Tsuboi,K.</style></author><author><style face="normal" font="Arial"> Kusakabe,M.</style></author><author><style face="normal" font="Arial"> Azuma,K.</style></author><author><style face="normal" font="Arial"> Abe,T.</style></author><author><style face="normal" font="Arial"> Yoshikawa,T.</style></author><author><style face="normal" font="Arial"> Sekiguchi,M.</style></author><author><style face="normal" font="Arial"> Azuma,N.</style></author><author><style face="normal" font="Arial"> Kitano,M.</style></author><author><style face="normal" font="Arial"> Sano,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A case of eel collagen allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword></keywords><dates><year Day="2" Month="6" Year="2017">2017/6/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.04.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583315">PM:28583315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170626-MullerGermannI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170626-MullerGermannI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Tamura M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.04.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,M.H.</style></author><author><style face="normal" font="Arial"> Cho,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South KoreaDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea. Electronic address: mineyang81@ewha.ac.krDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Different clinical features of anaphylaxis according to cause and risk factors for severe reactions</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Contributing factors</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Drug treatment</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syncope</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis is a life-threatening allergic reaction. Several studies reported different anaphylactic reactions according to the causative substances. However, a comparison of anaphylaxis for each cause has not been done. This study was conducted to identify common causes of anaphylaxis, characteristics of anaphylactic reaction for each cause and to analyze the factors related to the severity of the reaction. METHODS: Medical records of patients who visited the emergency room of Ewha Womans University Mokdong Hospital from March 2003 to April 2016 and diagnosed with anaphylactic shock were retrospectively reviewed. We compared the clinical features of anaphylaxis according to the cause. In addition, the severity of anaphylaxis was analyzed and contributing factors for severe anaphylaxis were reviewed. RESULTS: A total of 199 patients with anaphylaxis were analyzed. Food was the most common cause (49.7%), followed by drug reaction (36.2%), bee venom (10.1%), and unknown cause (4.0%). Cardiovascular symptoms of syncope and hypotension were more common in drug-induced anaphylaxis. The incidence of severe anaphylaxis was the highest in anaphylaxis due to drugs (54.2%). Urticaria and other skin symptoms were significantly more common in food-induced anaphylaxis. Risk factors for severe anaphylaxis included older age, male, and drug-induced one. Epinephrine treatment of anaphylaxis was done for 69.7% and 56.9% of patients with food-induced and drug-induced anaphylaxis, respectively. CONCLUSIONS: More severe anaphylaxis developed with drug treatment and in males. Low rate of epinephrine prescription was also observed. Male patients with drug induced anaphylaxis should be paid more attention</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.05.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28602247">PM:28602247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170612-KimSY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170612-KimSY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Kim SY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.05.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maruoka,S.</style></author><author><style face="normal" font="Arial"> Gon,Y.</style></author><author><style face="normal" font="Arial"> Mizumura,K.</style></author><author><style face="normal" font="Arial"> Okamoto,S.</style></author><author><style face="normal" font="Arial"> Tsuya,K.</style></author><author><style face="normal" font="Arial"> Shikano,S.</style></author><author><style face="normal" font="Arial"> Soda,K.</style></author><author><style face="normal" font="Arial"> Naguro,I.</style></author><author><style face="normal" font="Arial"> Ichijo,H.</style></author><author><style face="normal" font="Arial"> Hashimoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Involvement of apoptosis signal-regulating kinase-1 in house dust mite-induced allergic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="S52" start="S50">S50-S52</pages><volume><style face="normal" font="Arial">66S</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.05.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624251">PM:28624251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170618-MaruokaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170618-MaruokaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, Maruoka S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.05.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rauber,M.M.</style></author><author><style face="normal" font="Arial"> Pickert,J.</style></author><author><style face="normal" font="Arial"> Holiangu,L.</style></author><author><style face="normal" font="Arial"> Mobs,C.</style></author><author><style face="normal" font="Arial"> Pfutzner,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical &amp; Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="6" Year="2017">2017/6/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic urticaria (CU) is a frequent skin disease characterized by relapsing appearance of pruritic hives. While clinical symptoms are due to the release of histamine by cutaneous mast cells, the underlying pathophysiology is still unknown. However, previous studies indicate that basophils might be of relevance. Besides, the occurrence of autoantibodies against IgE or its receptor, FcepsilonRI, and the therapeutic efficacy of anti-IgE antibodies imply that IgE-mediated mechanisms also play an important role in CU. METHODS: Reactivity of CU patients' peripheral blood basophils (n=60) to specific anti-FcepsilonRI and IgE-independent fMLP stimulation was determined by basophil activation test in comparison to patients suffering from IgE-mediated allergic rhinitis (n=10) and healthy controls (n=10). In addition, immunoglobulin receptor (FcepsilonRI, FcgammaRII) expression and surface bound antibodies (IgE, IgG) were quantified on basophils. Furthermore, the autoreactive capacity of CU sera was evaluated and urticaria-related symptoms were assessed by both UCT and CU-Q2 oL. RESULTS: Stimulating CU patients' basophils via FcepsilonRI, we identified three distinct immunological phenotypes. One subgroup of patients' basophils reacted to FcepsilonRI stimulation, whereas the others had anti-FcepsilonRI non-reactive basophils. Among the latter a subgroup with pronounced basopenia was identified. Of note, this group was characterized by augmented serum-induced basophil activation, increased levels of autoantibodies against thyroid peroxidase and also exhibited the strongest disease impact on their quality of life. CONCLUSIONS: CU patients can be categorized into three immunological subgroups based on their basophil reactivity and frequency. These phenotypes are associated with different clinical characteristics, pointing to basophils as important players in CU pathophysiology. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13215</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28585360">PM:28585360</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170606-RauberMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170606-RauberMM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Rauber MM</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13215</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Trischler,J.</style></author><author><style face="normal" font="Arial"> Lieb,A.</style></author><author><style face="normal" font="Arial"> Arnold,M.</style></author><author><style face="normal" font="Arial"> Schulze,J.</style></author><author><style face="normal" font="Arial"> Rosewich,M.</style></author><author><style face="normal" font="Arial"> Schubert,R.</style></author><author><style face="normal" font="Arial"> Bottoli,I.</style></author><author><style face="normal" font="Arial"> Zielen,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital, Division of Allergology, Pulmonology and Cystic fibrosis, University Hospital Frankfurt, Frankfurt am Main, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab effectively protects against early- and late allergic responses in asthma after 4 weeks</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="6" Year="2017">2017/6/5</year></dates><abstract><style face="normal" font="Arial">Omalizumab is licensed for therapy in severe allergic asthma with an effect demonstrated after 8 weeks or longer treatment. Since new applications for omalizumab demand precise knowledge of the onset of effects, the objective of this study was to determine the time course of the early (EAR) and late allergic reaction (LAR). Ten patients (IgE >300 IU/mL and &lt;700 IU/mL) with a significant response to allergen challenge were treated with omalizumab according to the approved dosing table. Bronchial allergen provocations (BAP) were repeated at week 1, 2, 4 and 8. EAR was significantly reduced after 4 weeks (DeltaFEV1 28 vs. 11%; p&lt;0.001), eNO (86 vs. 53ppb; p&lt;0.05) and basophil activation after 2 weeks (CD63 expression 79 vs. 32%, p&lt;0.05) and LAR already after 1 week (DeltaFEV1 26 vs. 13%, p&lt;0.05). These results demonstrate the onset of protective effects earlier than previously determined, potentially improving seasonal utilization and combination with immunotherapy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170605IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13217</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28581121">PM:28581121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170605-TrischlerJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170605-TrischlerJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170605, Trischler J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13217</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zielen,S.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Richter,H.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department for Children and Adolescents, Division of Allergology, Pulmonology and Cystic fibrosis, Goethe University Hospital, Frankfurt, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma progression</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy immunotherapy (AIT) is the only treatment for allergic rhinitis (AR) and/or allergic asthma (AA) with long-term efficacy. However, there are few real-life data on the progression of AR and/or AA in patients receiving AIT. OBJECTIVES: To assess the real-world, long-term efficacy of grass-pollen sublingual immunotherapy (SLIT) tablets in AR and their impact on asthma onset and progression. METHODS: In a retrospective analysis of a German longitudinal prescription database, AR patients treated with grass pollen SLIT tablets were compared with a control group not having received AIT. Multiple regression was used to compare changes over time in rescue symptomatic AR medication use after treatment cessation, asthma medication use, and the time to asthma onset in the two groups. RESULTS: After applying all selection criteria, 2851 SLIT and 71275 Control patients were selected for the study.After treatment cessation, AR medication use was 18.8 percentage points lower (after adjustment for covariates, and relative to the pre-treatment period) in SLIT tablet group than in the non AIT group (p&lt;0.001). Asthma onset was less frequent in SLIT tablet group than in non AIT group (odds ratio: 0.696, p=0.002), and time to asthma was significantly longer (hazard ratio: 0.523; p=0.003). After SLIT cessation, asthma medication use fell by an additional 16.7 percentage points (relative to the pre-treatment period) in the SLIT tablet group vs. the non AIT group (p=0.004). CONCLUSIONS: Real-world treatment of AR patients with grass pollen SLIT tablets was associated with slower AR progression, less frequent asthma onset and slower asthma progression This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13213</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28561266">PM:28561266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170531-ZielenS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170531-ZielenS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Zielen S</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13213</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silverberg,J.I.</style></author><author><style face="normal" font="Arial"> Thyssen,J.P.</style></author><author><style face="normal" font="Arial"> Paller,A.S.</style></author><author><style face="normal" font="Arial"> Drucker,A.</style></author><author><style face="normal" font="Arial"> Wollenberg,A.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author><author><style face="normal" font="Arial"> Todd,G.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Bieber,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="Arial">What's in a name?: Atopic dermatitis or atopic eczema, but not eczema alone</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Writing</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The ideal nomenclature of atopic dermatitis or atopic eczema (AD/AE) has long been contested. It is becoming increasingly clear that the disparate nomenclature of this disease may have important deleterious ramifications for clinical care, research and drug development. OBJECTIVE: To reach consensus among an international group of experts in AD/AE on the nomenclature for AD/AE. METHODS: A 3-question survey was sent to the councilors and associates of the International Eczema Council. Consensus was reached with at least 90% response and more than 90% agreement on nomenclature. RESULTS: Seventy-one of 77 (92.2%) IEC councilors and associates responded to the survey. Consensus was reached on the preference for the atopic prefix, i.e. AD or AE (69 of 71 [97.2%]). However, consensus was not reached preference of AD (40 [58.0%]) or AE (30 [43,5%]). Sixty-three respondents (88.7%) and 55 (77.5%) felt that the terms AD and AE were acceptable, whereas only 11 (15.5%) felt that eczema was acceptable. CONCLUSIONS: Use of the atopic prefix, i.e. either AE or AD, is recommended. Whereas, use of the term eczema is not recommended. We encourage physicians in all specialties and in every country to shift their own use of terminology to AD or AE in writing, presentations and discussions with patients and other health care personnel as a first step. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Denmark -CO - Germany -CO - South Korea -CO - Japan -CO - South Africa -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13225</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28605026">PM:28605026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170612-SilverbergJI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170612-SilverbergJI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Silverberg JI</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13225</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lexmond,W.S.</style></author><author><style face="normal" font="Arial"> Goettel,J.A.</style></author><author><style face="normal" font="Arial"> Sallis,B.F.</style></author><author><style face="normal" font="Arial"> McCann,K.</style></author><author><style face="normal" font="Arial"> Rings,E.H.H.M.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Nurko,S.</style></author><author><style face="normal" font="Arial"> Snapper,S.B.</style></author><author><style face="normal" font="Arial"> Fiebiger,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">Spontaneous food allergy in Was-/- mice occurs independent of FcepsilonRI-mediated mast cell activation</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic diarrhea</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Experimental animal model</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human food</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> ISAC microarray</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="6" Year="2017">2017/6/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergies are a growing health problem and the development of therapies that prevent disease onset is limited by the lack of adjuvant-free experimental animal models. We compared allergic sensitization in patients with food allergy or Wiskott-Aldrich syndrome (WAS) and defined whether spontaneous disease in Was-/- mice recapitulates the pathology of a conventional disease model and/or human food allergy. METHODS: Comparative ImmunoCAP ISAC microarray was performed in patients with food allergy or WAS. Spontaneous food allergy in Was-/- mice was compared to an adjuvant-based model in wild-type mice (WT-OVA/alum). Intestinal and systemic anaphylaxis was assessed and the role of the high affinity IgE Fc receptor (FcepsilonRI) in allergic sensitization was evaluated using Was-/- Fcer1a-/- mice. RESULTS: Polysensitization to food was detected in both WAS and food allergic patients which was recapitulated in the Was-/- model. Oral administration of OVA in Was-/- mice induced low titers of OVA-specific IgE compared to the WT-OVA/alum model. Irrespectively, 79% of Was-/- mice developed allergic diarrhea following oral OVA challenge. Systemic anaphylaxis occurred in Was-/- mice (95%) with a mortality rate >50%. Spontaneous sensitization and intestinal allergy occurred independent of FcepsilonRI expression on mast cells and basophils. CONCLUSIONS: Was-/- mice provide a model of food allergy with the advantage of mimicking polysensitization and low food-antigen IgE titers as observed in humans with clinical food allergy. This model will facilitate studies on aberrant immune responses during spontaneous disease development. Our results imply that therapeutic targeting of the IgE/FcepsilonRI activation cascade will not affect sensitization to food. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170610IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Netherlands -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13219</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28600891">PM:28600891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170610-LexmondWS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170610-LexmondWS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170610, Lexmond WS</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13219</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84719</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fux,M.</style></author><author><style face="normal" font="Arial"> von Garnier,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Institute of Clinicla Chemistry, Inselspital, Bern University Hospital, University of Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Sputum Basophils and Asthma Diagnosis: Dawn of a New Era?</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1439" start="1437">1437-1439</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="Arial">More than 40 years ago, Kimura et al. discovered that basophils are enriched in sputum samples of asthma patients (1). Since then, various scientific approaches have attempted to elucidate the role of basophils in the pathophysiology of asthma. The scarcity of basophils and technical limitations of earlier studies have made it difficult to increase our understanding how basophils affect the disease course in asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170531IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - EditorialCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13214</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28561329">PM:28561329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170531-FuxM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170531-FuxM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170531, Fux M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13214</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wong,B.N.</style></author><author><style face="normal" font="Arial"> Vadas,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Medicine, St. Michael's Hospital, Toronto, CanadaDivision of Allergy and Clinical Immunology, Department of Medicine, St. Michael's Hospital, Toronto, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Angioedema suppressed by a combination of anti-histamine and leukotriene modifier</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="28">28-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cetirizine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> ethics</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene modifier</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Lip</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Angioedema without co-existent urticaria is due to a limited number of causes, including hereditary and acquired C1 esterase inhibitor deficiency, drug-induced angioedema or idiopathic histaminergic or non-histaminergic angioedema. We describe a cohort of patients with recurrent angioedema whose clinical features and response to medications are distinct from the causes above. METHODS: Patients were accrued retrospectively from an academic allergy practice between 2007 and 2014. After institutional research ethics board approval, patients' charts were reviewed and demographic, clinical and laboratory data were extracted. RESULTS: A total of 11 patients were recruited. The mean age at presentation was 54.9 years (range 19-70 years) and 6 of 11 were male. The mean number of episodes per year was 18.7 (range 2-60) and mean duration of episodes was 22.4 h (range 4-96). About half of episodes (52%) began overnight. Areas of involvement were lips (73%), tongue (64%), eyelids (18%), feet (36%) and hands (27%). None of the patients had low C3, C4, or CH50; none had significantly positive ANA; C1 esterase inhibitor level and function and C1q were normal in all patients tested. In these 11 patients, complete suppression of recurrences by the combination of cetirizine 20 mg daily and montelukast 10 mg daily was reported by 9 (82%) of patients; whereas 2 (18%) of patients had a partial response to this combination of medications. CONCLUSIONS: Herein, we report a form of angioedema without urticaria, mediated by a combination of histamine and leukotrienes. Clinical, demographic and therapeutic characteristics differentiate this from other recognized causes of angioedema</style></abstract><notes><style face="normal" font="Arial">DA - 20170615IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0201-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28616043">PM:28616043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Wong BN</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0201-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sandhu,M.</style></author><author><style face="normal" font="Arial"> Casselman,J.</style></author><author><style face="normal" font="Arial"> Peppers,B.</style></author><author><style face="normal" font="Arial"> Tcheurekdjian,H.</style></author><author><style face="normal" font="Arial"> Hostoffer,R.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Type 1 Kounis syndrome in a patient with idiopathic anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="104" start="103">103-104</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">Anaphylactic insults that cause cardiovascular signs and symptoms have been defined as Kounis syndrome, which has been associated with specific triggered anaphylactic reactions. Kounis syndrome has not been described in patients with no evidence of coronary artery disease (type I Kounis) in a scenario of idiopathic anaphylaxis. We reported a case of a 65-year-old white woman with no evidence of coronary artery disease who experienced two myocardial infarctions on separate occasions attributable to idiopathic anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2017.8.0198</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583235">PM:28583235</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2017-8-103-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2017-8-103-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Sandhu M</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2017.8.0198</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferastraoaru,D.</style></author><author><style face="normal" font="Arial"> Shtessel,M.</style></author><author><style face="normal" font="Arial"> Lobell,E.</style></author><author><style face="normal" font="Arial"> Hudes,G.</style></author><author><style face="normal" font="Arial"> Rosenstreich,D.</style></author><author><style face="normal" font="Arial"> de Vos,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Diagnosing environmental allergies: Comparison of skin-prick, intradermal, and serum specific immunoglobulin E testing</style></title><secondary-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Rhinol (Providence)</style></full-title></periodical><pages end="62" start="53">53-62</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental allergies</style></keyword><keyword><style face="normal" font="Arial"> environmental allergy</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> skin-prick testing</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergists commonly perform intradermal skin testing (IDST) after negative skin-prick testing (SPT) to comprehensively diagnose environmental allergic sensitization. However, with the availability of modern methods to detect serum-specific immunoglobulin E (ssIgE), it is unclear if ssIgE testing could substitute for IDST. OBJECTIVE: To determine the efficacy of ssIgE testing and IDST when added to SPT in diagnosing environmental allergic sensitizations. METHODS: SPT, IDST, and ssIgE testing to nine common environmental allergens were analyzed in 75 patients with oculonasal symptoms who presented to our allergy clinics in the Bronx, New York, between January 2014 and May 2015. RESULTS: A total of 651 SPT and 499 ssIgE tests were independently performed and revealed 162 (25%) and 127 (25%) sensitizations, respectively. When SPT results were negative, IDST results revealed 108 of 452 additional sensitizations (24%). In contrast, when SPT results were negative, ssIgE test results only revealed 9% additional sensitizations. When both SPT and IDST results were negative, ssIgE testing only detected 3% of additional sensitizations, and ssIgE levels were typically low in these cases (median, 1.25 kU/L; range, 0.357-4.47 kU/L). When both SPT and ssIgE test results were negative, IDST results detected 15% additional sensitizations. CONCLUSION: IDST detected more additional environmental sensitizations compared with ssIgE testing. IDST, therefore, may be useful when the SPT and/or ssIgE testing results were negative, but the exposure history indicated relevant allergic sensitization. Serology added only a little more information if both SPT and IDST results were negative but may be useful in combination with SPT if IDST cannot be performed</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/ar.2017.8.0194</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583228">PM:28583228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2017-8-53-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Rhinol (Providence)\2017-8-53-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Ferastraoaru D</style></custom2><misc3><style face="normal" font="Arial">10.2500/ar.2017.8.0194</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Su,X.M.</style></author><author><style face="normal" font="Arial"> Ren,Y.</style></author><author><style face="normal" font="Arial"> Li,M.L.</style></author><author><style face="normal" font="Arial"> Zhao,X.</style></author><author><style face="normal" font="Arial"> Kang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Respiratory Disease, the First Affiliated Hospital of China Medical University, Shenyang 110001, China</style></auth-address><titles><title><style face="normal" font="Arial">[Therapeutic effects of Tubastatin A Hcl on airway inflammation in acute mice asthma model]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Yi Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Yi Xue Za Zhi</style></full-title></periodical><pages end="1892" start="1888">1888-1892</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">24</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway reactivity</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">Objective: To investigated the therapeutic effects of Tubastatin A Hcl, a selective HDAC6 inhibitor, on airway inflammation in acute mice bronchial asthma (asthma) model. Methods: A total of 48 BALB/C mice were randomly divided into control group, asthma group, dexamethasone group and Tubastatin A Hcl group with 12 mice in each group. Then the airway hyperresponsiveness was assessed in each group; total cell number, different cell number, levels of Interleukin (IL)-4, IL-5 and Interferon-gamma (IFN-gamma) in the bronchoalveolar lavage fluid (BALF) were detected; the lung tissues of each group were stained with HE to observe the inflammatory cells infiltration. AB-PAS was used to observe the goblet cell metaplasia in tracheal epithelium. Masson staining was used to observe the collagen deposition in lung tissue. Results: The airway reactivity in Tubastatin A Hcl group was significantly lower than that in asthma group [(4.18+/-0.94) vs (6.02+/-0.47), P&lt;0.05]; in the Tubastatin A Hcl group, the total inflammatory cells [(57.0+/-5.7)x10(4)/ml vs (87.0+/-5.6)x10(4)/ml], eosinophil cells [(6.8+/-1.7)x10(4)/ml vs (12.3+/-3.5)x10(4)/ml] and levels of IL-4 [(19.3+/-2.7) vs (26.2+/-3.2)ng/ml] in BALF were obviously lower than those of asthma group (all P&lt;0.05); IL-5 in Tubastatin A Hcl group was lower and IFN-gamma was higher than that of asthma group, while there were no significant differences (both P>0.05). The degree of inflammatory cells infiltrations around the airway and vascular, number of inflammatory cells [(9.80+/-2.42) vs (20.67+/-7.53)], score of inflammation [(2.20+/-0.70) vs (3.60+/-0.68) points, ], and percentage of goblet cell metaplasia [(50.46+/-5.03)% vs (71.06+/-5.38)%] in the lung tissue of Tubastatin A Hcl group were lower than that of asthma group (all P&lt;0.05). Although collagen deposition in the lung tissue of Tubastatin A Hcl group was lower than asthma group, there were no significant differences (P>0.05). However, all of the above results in the dexamethasone group were slightly better than Tubastatin A Hcl group, which had no significant differences (P>0.05). Conclusion: Tubastatin A Hcl can effectively alleviate the level of airway inflammation in acute asthma, but its anti-inflammatory effect is limited, which is not as significant as dexamethasone</style></abstract><notes><style face="normal" font="Arial">DA - 20170626IS - 0376-2491 (Print)IS - 0376-2491 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.0376-2491.2017.24.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28648015">PM:28648015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Zhonghua Yi Xue Za Zhi\2017-97-1888-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Zhonghua Yi Xue Za Zhi\2017-97-1888-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170626, Su XM</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.0376-2491.2017.24.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rojas-Perez-Ezquerra,P.</style></author><author><style face="normal" font="Arial"> Noguerado-Mellado,B.</style></author><author><style face="normal" font="Arial"> Morales-Cabeza,C.</style></author><author><style face="normal" font="Arial"> Zambrano,I.G.</style></author><author><style face="normal" font="Arial"> Datino,R.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department. Hospital General Universitario Gregorio Maranon Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Atrial fibrilation in anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Am J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Med</style></full-title></periodical><pages end="1116" start="1114">1114-1116</pages><volume><style face="normal" font="Arial">130</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> Arrhythmia</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Atrial Fibrillation</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cause of Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Heart Rate</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The relationship between anaphylaxis and cardiovascular events has been reported in the past. While skin and respiratory symptoms are usually the most common and the first to appear, cardiovascular complications play a key role and represent the leading cause of death in anaphylaxis. METHODS: We report 3 episodes of atrial fibrillation triggered by anaphylaxis. Allergy and cardiology studies were performed. In both patients, the etiological agent was identified: Anisakis simplex hypersensitivity and food allergy. RESULTS: and Conclusions: Heart is the source and target of chemical mediators released during an allergic reaction. In the heart, there are plenty of mast cells, and are predominantly located around the coronary adventitia and in close contact with small vessels in the muscle wall. The release of mediators can influence ventricular function, heart rate and coronary artery tone. Anaphylaxis can trigger any kind of arrhythmia. In these cases, the very interesting point of discussion was: which should be first, treating anaphylaxis or cardiac events? The other controversial point was the use of epinephrine, the first line of treatment for anaphylaxis. Recommendations about epinephrine in cardiac patients during an anaphylactic event, is still a mayor dilemma. We emphasize the importance of the priority of establishing protocols between cardiologist and allergist in treatment of cardiac complications during anaphylaxis and we warn about the correct diagnosis of arrhythmias in anaphylaxis, in order to treat them as soon as possible, to prevent other consequences and complications</style></abstract><notes><style face="normal" font="Arial">DA - 20170611IS - 1555-7162 (Electronic)IS - 0002-9343 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.amjmed.2017.05.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601540">PM:28601540</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Med\20170611-RojasPerezEzquerraP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Med\20170611-RojasPerezEzquerraP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Rojas-Perez-Ezquerra P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.amjmed.2017.05.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Movassagh,H.</style></author><author><style face="normal" font="Arial"> Shan,L.</style></author><author><style face="normal" font="Arial"> Duke-Cohan,J.S.</style></author><author><style face="normal" font="Arial"> Halayko,A.J.</style></author><author><style face="normal" font="Arial"> Uzonna,J.E.</style></author><author><style face="normal" font="Arial"> Gounni,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Semaphorin 3E Alleviates Hallmarks of House Dust Mite-Induced Allergic Airway Disease</style></title><secondary-title><style face="normal" font="Arial">Am J Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Pathol</style></full-title></periodical><pages end="1576" start="1566">1566-1576</pages><volume><style face="normal" font="Arial">187</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> cell migration</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Semaphorins are an essential family of guidance cues ubiquitously expressed in various organs, which play diverse developmental, homeostatic, and pathological roles. Semaphorin 3E (Sema3E), initially identified as a neuronal chemorepellent, is involved in the regulation of cell migration, proliferation, and angiogenesis. However, expression and function of Sema3E in allergic asthma has not been extensively investigated. We determined the expression of Sema3E in the airways and its effect on airway inflammation, hyperresponsiveness, and remodeling as pathological features of allergic asthma provoked by house dust mite in vivo. Our data indicate that exposure to house dust mite markedly reduces Sema3E expression in mouse airways. More important, replenishment of Sema3E by intranasal administration of exogenous Sema3E protects mice from allergic asthma by reducing eosinophilic inflammation, serum IgE level, and T helper cell 2/T helper cell 17 cytokine response. The regulatory effect of Sema3E on cytokine response was sustained on allergen recall response in the lymph nodes and spleen. Furthermore, goblet cell hyperplasia, collagen deposition, and airway hyperresponsiveness were significantly diminished on Sema3E treatment. The inhibitory effect of Sema3E was associated with a reduction of pulmonary CD11b+ conventional dendritic cells and regulation of CD4+ T-cell cytokine response. Collectively, our data represent a novel approach to treating allergic asthma via regulation of immune response to house dust mite</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 1525-2191 (Electronic)IS - 0002-9440 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ajpath.2017.03.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634005">PM:28634005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Pathol\2017-187-1566-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Pathol\2017-187-1566-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Movassagh H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ajpath.2017.03.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,X.M.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Gu,W.</style></author><author><style face="normal" font="Arial"> Guo,Y.J.</style></author><author><style face="normal" font="Arial"> Cheng,Y.</style></author><author><style face="normal" font="Arial"> Peng,J.</style></author><author><style face="normal" font="Arial"> Guo,X.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Impaired TNF/TNFR2 signaling enhances Th2 and Th17 polarization and aggravates allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L601" start="L592">L592-L601</pages><volume><style face="normal" font="Arial">313</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">CD4+T cell differentiation plays an important role in allergic airway diseases. Tumor necrosis factor receptor 2 (TNFR2) has been shown to regulate CD4+T lymphocyte differentiation, but its role in allergic airway inflammation is not clear. Here we investigated the role of TNFR2 in allergic airway inflammation. Mouse model was generated by immunization with OVA and intranasal administration of TNFR2 antibody. Airway inflammation and CD4+T cell differentiation were measured in vivo and in vitro. Inhibited TNFR2 signaling aggravated airway inflammation and increased the expression of inflammatory cytokines (IL-4, IL-5, IL-17, and TNF-alpha) in serum and bronchoalveolar lavage fluid (BALF). Impaired TNFR2 signaling promoted Th2 and Th17 polarization but inhibited Th1 and CD4+CD25+ T cells differentiation in vivo. Furthermore, TNFR2 signaling inhibition promoted Th2 and Th17 polarization in vitro, which may through the activation of TNF receptor-associated factor 2 (TRAF2) and nuclear factor (NF)-kappaB signaling. Therefore, our findings indicate that impaired TNF/TNFR2 signaling enhances Th2 and Th17 polarization and aggravates allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170616IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00409.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28619762">PM:28619762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170616-LiXM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170616-LiXM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170616, Li XM</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00409.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,M.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Zhou,W.</style></author><author><style face="normal" font="Arial"> Bai,Y.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Peking Union Medical College Hospital, Respiratory Diseases, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Critical Role of IRAK-M in Regulating Antigen-induced Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="Arial">Asthma is an airway epithelium disorder involving allergic lung inflammation. IRAK-M is a negative regulator of Toll-like receptor (TLR) signaling on airway epithelial cells and macrophages and known to limit overproduction of cytokines during the inflammatory process. However, the direct role of IRAK-M on asthma pathogenesis is unclear. In the present study, we found significant elevation of IRAK-M expression in mouse lungs following ovalbumin (OVA) exposure. Compared to wild type (WT) mice, IRAK-M knockout (KO) mice responded to OVA challenge with significantly worse infiltration of airway inflammatory cells, greater airway responsiveness, higher proinflammatory cytokine levels in lung homogenates, and more prominent Th2 and Th17 deviation. OVA exposure also induced higher activities of dendritic cells (DCs) and macrophages from IRAK-M KO mouse lungs. Furthermore, adoptive transfer of either IRAK-M KO bone marrow derived-DCs or -macrophages into WT mice aggravated OVA-induced airway inflammation. In vitro experiments showed that IRAK-M KO naive CD4+ T cells were more prone to differentiate to Th17, but not Tregs. Consistently, activation of IkappaBzeta was significantly increased in absence of IRAK-M to facilitate Th17 polarization. These findings suggest that IRAK-M plays a crucial role in the regulation of allergic airway inflammation through modifying the function of airway epithelia, DCs, macrophages and differentiation of naive CD4+ T cell. Modulation of IRAK-M may provide a novel target to control asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170630IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2016-0370OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28665693">PM:28665693</url></web-urls><pdf-urls><url ppv-ref="no">gjinming@yahoo.com</url><url ppv-ref="no">200510020227tom@163.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170630, Zhang M</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2016-0370OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Esquivel,A.</style></author><author><style face="normal" font="Arial"> Busse,W.W.</style></author><author><style face="normal" font="Arial"> Calatroni,A.</style></author><author><style face="normal" font="Arial"> Togias,A.G.</style></author><author><style face="normal" font="Arial"> Grindle,K.G.</style></author><author><style face="normal" font="Arial"> Bochkov,Y.A.</style></author><author><style face="normal" font="Arial"> Gruchalla,R.S.</style></author><author><style face="normal" font="Arial"> Kattan,M.</style></author><author><style face="normal" font="Arial"> Kercsmar,C.M.</style></author><author><style face="normal" font="Arial"> Khurana,H.G.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> LeBeau,P.</style></author><author><style face="normal" font="Arial"> Liu,A.H.</style></author><author><style face="normal" font="Arial"> Szefler,S.J.</style></author><author><style face="normal" font="Arial"> Teach,S.J.</style></author><author><style face="normal" font="Arial"> West,J.B.</style></author><author><style face="normal" font="Arial"> Wildfire,J.</style></author><author><style face="normal" font="Arial"> Pongracic,J.A.</style></author><author><style face="normal" font="Arial"> Gern,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Wisconsin Madison, 5228, Madison, Wisconsin, United States</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Omalizumab on Rhinovirus Infections, Illnesses and Exacerbations of Asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="992" start="985">985-992</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poisson</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Rhinoviruses</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> shedding</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> virology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal. OBJECTIVE: To test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus illnesses in children with allergic asthma. METHODS: The Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE) was a study of children with allergic asthma (6-17 years, n=478) from low-income census tracts in 8 U.S. cities, and we analyzed virology for the groups randomized to treatment with guidelines-based asthma care (n=89) or add-on omalizumab (n=259). Weekly nasal mucus samples were analyzed for rhinoviruses, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during the fall seasons of 2012 or 2013. Adjusted illness rates (illnesses per sample) by treatment arm were calculated using a Poisson regression. MEASUREMENTS AND MAIN RESULTS: Rhinoviruses were detected in 97/171 (57%) exacerbation samples and 2,150/5,959 (36%) non-exacerbation samples (OR=2.32, p&lt;0.001). Exacerbations were significantly associated with detection of rhinovirus-C (OR=2.85, p&lt;0.001) and rhinovirus-A (OR=2.92, p&lt;0.001), and to a lesser extent, rhinovirus-B (OR=1.98, p=0.019). Omalizumab decreased the duration of RV infection (11.2 days vs 12.4 days, p=0.03), and reduced peak rhinovirus shedding by 0.4 log units (95% CI -0.77, -0.02, p=0.04). Finally, omalizumab decreased the frequency of rhinovirus illnesses (Risk Ratio [RR] 0.64, 95% CI 0.49-0.84). CONCLUSIONS: In children with allergic asthma, treatment with omalizumab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses. These findings provide direct evidence that blocking IgE decreases susceptibility to RV infections and illness. Clinical trial registration available at www.clinicaltrials.gov, ID NCT0143040</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201701-0120OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28608756">PM:28608756</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-985-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-985-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Esquivel A</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201701-0120OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oliveria,J.P.</style></author><author><style face="normal" font="Arial"> Salter,B.M.</style></author><author><style face="normal" font="Arial"> Maclean,J.</style></author><author><style face="normal" font="Arial"> Kotwal,S.</style></author><author><style face="normal" font="Arial"> Smith,A.</style></author><author><style face="normal" font="Arial"> Harris,J.M.</style></author><author><style face="normal" font="Arial"> Scheerens,H.</style></author><author><style face="normal" font="Arial"> Sehmi,R.</style></author><author><style face="normal" font="Arial"> Gauvreau,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 McMaster University Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Increased IgE+ B Cells in Sputum, but Not Blood, Bone Marrow, or Tonsils, after Inhaled Allergen Challenge in Subjects with Asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="109" start="107">107-109</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Tonsil</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170630IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201611-2274LE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28665197">PM:28665197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-107-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-107-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170630, Oliveria JP</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201611-2274LE</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salter,B.</style></author><author><style face="normal" font="Arial"> Sehmi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Medicine McMaster University Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Epstein-Barr Virus-induced Gene 2 and Leukocyte Airway Recruitment in Response to Allergen Challenge</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="1544" start="1543">1543-1544</pages><volume><style face="normal" font="Arial">195</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170615IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201701-0096ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28617082">PM:28617082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-1543-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-195-1543-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Salter B</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201701-0096ED</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saglani,S.</style></author><author><style face="normal" font="Arial"> Bush,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Royal Brompton Hospital, Respiratory Paediatrics, London, United Kingdom of Great Britain and Northern Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Asthma Attacks in Children: Does Blocking IgE Reduce Rhinoviral Infections?</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="942" start="941">941-942</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Great Britain</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170622IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201706-1165ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28640649">PM:28640649</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-941-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-941-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170622, Saglani S</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201706-1165ED</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Skoczowski,A.</style></author><author><style face="normal" font="Arial"> Obtulowicz,K.</style></author><author><style face="normal" font="Arial"> Czarnobilska,E.</style></author><author><style face="normal" font="Arial"> Dyga,W.</style></author><author><style face="normal" font="Arial"> Mazur,M.</style></author><author><style face="normal" font="Arial"> Stawoska,I.</style></author><author><style face="normal" font="Arial"> Waga,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biology, Pedagogical University of Cracow, Krakow, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Antibody reactivity in patients with IgE-mediated wheat allergy to various subunits and fractions of gluten and non-gluten proteins from omega-gliadin-free wheat genotypes</style></title><secondary-title><style face="normal" font="Arial">Ann Agric Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Agric Environ Med</style></full-title></periodical><pages end="236" start="229">229-236</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chemiluminescence</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten intolerance</style></keyword><keyword><style face="normal" font="Arial"> glutenin</style></keyword><keyword><style face="normal" font="Arial"> Glutenin subunits</style></keyword><keyword><style face="normal" font="Arial"> Hybrids</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunodetection</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword><keyword><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="Arial">Introduction and objective[/b]. Gluten proteins (gliadins and glutenins) are polymorphic wheat storage proteins of allergenic properties. Significant differences in chemical composition between both protein groups allow to expect highly specific immunological response of individual subunits and fractions in reactions with IgE sera of people allergic to wheat. The aim of these studies was to identify and characterize the most allergenic gluten proteins (GP) and nongluten proteins (NGP) occurred in two closely related wheat hybrid genotypes. [b]Materials and method.[/b] 3xC and 3xN wheat hybrids, which differ strongly in regard of gliadin composition, were analyzed. Seven people manifesting different symptoms of wheat allergy donated sera for the experiment. The technique of immunoblotting after SDS-PAGE was used for identification of allergenic subunits and fractions among GP and NGP. Immunologically active protein bands were visualized by chemiluminescence. [b]Results[/b]. Great variation of immunodetection spectra was observed. Results of immunoblotting showed LMW glutenins to be of highest, gliadins of medium, while NGP of lowest allergenicity for selected patients. The 43-kDa and 47-kDa LMW glutenin subunits, 40-kDa and 43-kDa gamma-gliadin fractions and 49-kDa NGP can be considered as the most immunoreactive among all protein bands [b]separated by SDS-PAGE. CONCLUSION: [/b] The observed differentiation of immunodetection spectra allows to model highly specific IgE-binding profiles of allergenic wheat proteins attributed to individual patients with symptoms of gluten intolerance. Highly immunoreactive subunits and fractions among GP and NGP were identified. The observed immunoreactivity of 49 kDa NGP is worth to emphasize, as it has never been reported as wheat allergenic protein before</style></abstract><notes><style face="normal" font="Arial">DA - 20170630IS - 1898-2263 (Electronic)IS - 1232-1966 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5604/12321966.1233572</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28664699">PM:28664699</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Agric Environ Med\2017-24-229-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Agric Environ Med\2017-24-229-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170630, Skoczowski A</style></custom2><misc3><style face="normal" font="Arial">10.5604/12321966.1233572</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Plunkett,G.</style></author><author><style face="normal" font="Arial"> Jacobson,R.S.</style></author><author><style face="normal" font="Arial"> Golden,D.B.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ALK-Abello Inc, Round Rock, Texas</style></auth-address><titles><title><style face="normal" font="Arial">Hymenoptera venoms used to produce allergen extracts</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="654" start="649">649-654</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venoms</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mixing</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To review the methods and materials used for collection, purification, commercial production, and clinical application of Hymenoptera venoms. DATA SOURCES: Most of the sources for this review are the experience and expertise of the authors. Published reports and review articles on Hymenoptera venom collection and production were identified through database searches (PubMed). STUDY SELECTIONS: Studies describing the methods for Hymenoptera venom collection and production were selected for review. RESULTS: Meticulous methods for identification and collection of the insects are required. Collection and purification of the venoms from the insects are based on validated methods and result in a commercial extract that is standardized for the major allergenic proteins required for accurate diagnosis and safe and effective treatment of patients allergic to insect sting. The steps required for mixing, purifying, testing, and standardizing the products are described. CONCLUSION: Hymenoptera venom extracts were developed using many new methods for the collection, purification, and commercial production of the unique materials required for this product. Clinical applications for diagnosis and treatment are affected by the integrity and stability of the allergens after processing and purification</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.05.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583258">PM:28583258</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-649-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-649-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Plunkett G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.05.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahdavinia,M.</style></author><author><style face="normal" font="Arial"> Rasmussen,H.E.</style></author><author><style face="normal" font="Arial"> Engen,P.</style></author><author><style face="normal" font="Arial"> Van den Berg,J.P.</style></author><author><style face="normal" font="Arial"> Davis,E.</style></author><author><style face="normal" font="Arial"> Engen,K.</style></author><author><style face="normal" font="Arial"> Green,S.J.</style></author><author><style face="normal" font="Arial"> Naqib,A.</style></author><author><style face="normal" font="Arial"> Botha,M.</style></author><author><style face="normal" font="Arial"> Gray,C.</style></author><author><style face="normal" font="Arial"> Lunjani,N.</style></author><author><style face="normal" font="Arial"> Hlela,C.</style></author><author><style face="normal" font="Arial"> Basera,W.</style></author><author><style face="normal" font="Arial"> Hobane,L.</style></author><author><style face="normal" font="Arial"> Watkins,A.</style></author><author><style face="normal" font="Arial"> Tobin,M.C.</style></author><author><style face="normal" font="Arial"> Landay,A.</style></author><author><style face="normal" font="Arial"> Keshavarzian,A.</style></author><author><style face="normal" font="Arial"> Levin,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology and Microbiology, Allergy/Immunology Section, Rush University Medical Center, Chicago</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis and food sensitization in South African toddlers: Role of fiber and gut microbiota</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="743" start="742">742-743</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food sensitization</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> toddler</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.04.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583264">PM:28583264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-742-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-742-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Mahdavinia M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.04.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,S.S.</style></author><author><style face="normal" font="Arial"> Johnson,J.A.</style></author><author><style face="normal" font="Arial"> Peppers,B.</style></author><author><style face="normal" font="Arial"> Tcheurekdjian,H.</style></author><author><style face="normal" font="Arial"> Hostoffer,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Hospitals Regional Hospitals, Internal Medicine Residency Program, Richmond Heights, Ohio.</style></auth-address><titles><title><style face="normal" font="Arial">A case of green tea (Camellia sinensis) imbibement causing possible anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="748" start="747">747-748</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.04.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583266">PM:28583266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-747-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-747-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Wu SS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.04.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de la Varga,M.R.</style></author><author><style face="normal" font="Arial"> Gutierrez Fernandez,D.</style></author><author><style face="normal" font="Arial"> Anez,G.A.</style></author><author><style face="normal" font="Arial"> Foncubierta,F.A.</style></author><author><style face="normal" font="Arial"> Andres Garcia,J.A.</style></author><author><style face="normal" font="Arial"> Medina Varo,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unidad de Investigacion, Area de investigacion clinica en Inmunologia y Reumatologia, Hospital Universitario Puerta del Mar, Cadiz, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Use of the basophil activation test in monitoring clinical tolerance after desensitization to brentuximab vedotin</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="747" start="745">745-747</pages><volume><style face="normal" font="Arial">118</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> brentuximab vedotin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical tolerance</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.04.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583265">PM:28583265</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-745-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-118-745-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, de la Varga MR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.04.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rokosz,M.</style></author><author><style face="normal" font="Arial"> Bauer,C.</style></author><author><style face="normal" font="Arial"> Schroeder,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Creighton University School of Medicine, Omaha, Nebraska.</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic esophagitis induced by aeroallergen sublingual immunotherapy in an enteral feeding tube-dependent pediatric patient</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="89" start="88">88-89</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nebraska</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170605IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.05.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28578907">PM:28578907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-88-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-88-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170605, Rokosz M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.05.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schou Nielsen,J.</style></author><author><style face="normal" font="Arial"> Meteran,H.</style></author><author><style face="normal" font="Arial"> Ulrik,C.S.</style></author><author><style face="normal" font="Arial"> Porsbjerg,C.</style></author><author><style face="normal" font="Arial"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Natural history of skin prick test reactivity: A 20-year prospective study of a random population sample of children and adolescents</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="188" start="184">184-188</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> puberty</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic reactions to airborne allergens may have important consequences for affected individuals and are believed to be unstable through life, although evidence from longitudinal studies is limited. OBJECTIVE: To assess changes in skin prick reactivity during 20 years in a random population sample of children and adolescents in relation to symptoms of rhinitis. METHODS: A total of 983 individuals, aged 7 to 17 years, were randomly selected in 1986 and invited to 4 examinations during a 20-year period. During each examination, a skin prick test was performed using common local aeroallergens (ie, birch, grass, mugwort, horse, dog, cat, house dust mite [Dermatophagoides pteronyssinus and Dermatophagoides farinae] and 2 molds [Alternaria iridis and Cladosporium herbarum]). RESULTS: The prevalence of allergy to any tested allergen peaked at the ages of 13 to 23 years. Rates of sensitization were variable. In the group of individuals tested more than once (n = 592), 16% developed sensitization during the study period and 9% became desensitized. In the group of individuals tested at all 4 examinations (n = 148), 34% developed sensitization and 22% became desensitized. In the group who developed sensitization, 55% had rhinitis, 17% had asthma, and 70% had eczema. In the group who became desensitized, 30% had rhinitis, 10% had asthma, and 50% had eczema. CONCLUSION: This 20-year prospective study found that sensitization is common, but its prevalence in individuals is also variable over time. Furthermore, through puberty and early adulthood a large number of individuals develop sensitization and a smaller number become desensitized. In addition, we found that symptoms of rhinitis rarely preceded sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170610IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.05.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599992">PM:28599992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170610-SchouNielsenJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170610-SchouNielsenJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170610, Schou Nielsen J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dong,H.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Yao,S.</style></author><author><style face="normal" font="Arial"> Liang,B.</style></author><author><style face="normal" font="Arial"> Long,Y.</style></author><author><style face="normal" font="Arial"> Xie,Y.</style></author><author><style face="normal" font="Arial"> Mai,J.</style></author><author><style face="normal" font="Arial"> Gong,S.</style></author><author><style face="normal" font="Arial"> Zhou,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510120, China</style></auth-address><titles><title><style face="normal" font="Arial">The recombinant fusion protein of cholera toxin B and neutrophil-activating protein expressed on Bacillus subtilis spore surface suppresses allergic inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">Appl Microbiol Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Microbiol Biotechnol</style></full-title></periodical><pages end="5829" start="5819">5819-5829</pages><volume><style face="normal" font="Arial">101</style></volume><number><style face="normal" font="Arial">14</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> Bacillus subtilis</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> CTB</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">The neutrophil-activating protein of Helicobacter pylori (HP-NAP) has been identified as a modulator with anti-Th2 inflammation activity, and cholera toxin B (CTB) is a mucosal adjuvant that can also induce antigen tolerance. In this study, we constructed a CTB-NAP fusion protein on the surface of Bacillus subtilis spore and evaluate the efficiency of oral administration of the recombinant CTB-NAP spores in preventing asthma in mice. Oral administration of recombinant CTB or CTB-NAP spores significantly decreased serum ovalbumin (OVA)-specific IgE (p &lt; 0.001) and increased fecal IgA (p &lt; 0.01) compared to the treatment with non-recombinant spores. Oral administration of recombinant CTB or CTB-NAP spores induced IL-10 and IFN-gamma expression and reduced IL-4 levels in bronchoalveolar lavage fluid (BALF). Moreover, CTB and CTB-NAP spores reduced the eosinophils in BALF and inflammatory cell infiltration in the lungs. Furthermore, CD4+CD25+Foxp3+ Tregs in splenocytes were significantly increased in mice treated with recombinant CTB or CTB-NAP spores. The number of CD4+CD25+Foxp3+ Tregs caused by CTB-NAP was higher than that by CTB alone. Our study indicated that B. subtilis spores with surface expression of subunit CTB or CTB-NAP could inhibit OVA-induced allergic inflammation in mice. The attenuated inflammation was attributed to the induction of CD4+CD25+Foxp3+ Tregs and IgA. Moreover, the fusion protein CTB-NAP demonstrated a better efficiency than CTB alone in inhibiting the inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1432-0614 (Electronic)IS - 0175-7598 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00253-017-8370-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28608279">PM:28608279</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Microbiol Biotechnol\20170613-DongH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Microbiol Biotechnol\20170613-DongH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Dong H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00253-017-8370-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,J.</style></author><author><style face="normal" font="Arial"> Jia,S.</style></author><author><style face="normal" font="Arial"> Xie,P.</style></author><author><style face="normal" font="Arial"> Arenas,G.A.</style></author><author><style face="normal" font="Arial"> Galiano,R.D.</style></author><author><style face="normal" font="Arial"> Hong,S.J.</style></author><author><style face="normal" font="Arial"> Mustoe,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Burns, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, GD, 510080, China</style></auth-address><titles><title><style face="normal" font="Arial">Topical application of Dermatophagoides farinae or oxazolone induces symptoms of atopic dermatitis in the rabbit ear</style></title><secondary-title><style face="normal" font="Arial">Arch Dermatol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dermatol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Burns</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hapten</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Keratin</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxazolone</style></keyword><keyword><style face="normal" font="Arial"> PCNA</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disease characterized by hyperproliferation and abnormal differentiation of the epidermis, and dermal infiltration of inflammatory cells. Appropriate animal models that recapitulate human AD and allow the analysis of disease processes in a reliable manner are essential to the study of AD. In this study, we established two AD models in rabbits by applying an allergen, Dermatophagoides farinae (Der f), or a hapten, oxazolone (OXZ). Application of the allergen or hapten induced a rapid onset and a chronically sustained AD-like skin lesion. The clinical symptoms, which include skin erythema, scaling, papula and edema, of AD-like rabbit skin were similar to those in human AD. Histological analysis showed that allergen- or hapten-treated rabbit skin showed increased epidermal thickening and inflammatory cell infiltration. Furthermore, PCNA and keratin 10 (K10) staining revealed excessive proliferation and insufficient differentiation of the epidermis in the rabbit AD-like skin. Western blot analysis showed decreased expression of thymic stromal lymphopoietin (TSLP), an AD cytokine, in the rabbit AD-like skin. Our results suggest that the allergen- or hapten-induced rabbit AD models have pathological features of human AD-like symptoms and will be useful for evaluating both pathogenic mechanisms and potential therapeutic agents for human AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1432-069X (Electronic)IS - 0340-3696 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00403-017-1758-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667471">PM:28667471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dermatol Res\20170701-ZhaoJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dermatol Res\20170701-ZhaoJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Zhao J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00403-017-1758-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pollard,S.L.</style></author><author><style face="normal" font="Arial"> Lima,J.J.</style></author><author><style face="normal" font="Arial"> Romero,K.</style></author><author><style face="normal" font="Arial"> Tarazona-Meza,C.</style></author><author><style face="normal" font="Arial"> Mougey,E.</style></author><author><style face="normal" font="Arial"> Tomaino,K.</style></author><author><style face="normal" font="Arial"> Malpartida-Guzman,G.</style></author><author><style face="normal" font="Arial"> Hansel,N.N.</style></author><author><style face="normal" font="Arial"> Checkley,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, 1800 Orleans Ave, Suite 9121, Baltimore, USA</style></auth-address><titles><title><style face="normal" font="Arial">Associations between serum 25(OH)D concentrations and prevalent asthma among children living in communities with differing levels of urbanization: a cross-sectional study</style></title><secondary-title><style face="normal" font="Arial">Asthma Res Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Res Pract</style></full-title></periodical><pages end="" start="5">5-</pages><volume><style face="normal" font="Arial">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urbanization</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Prior evidence suggests that vitamin D deficiency may increase the risk of asthma and atopy and impair pulmonary function in children. METHODS: In this cross-sectional analysis nested in a case-control study, we analyzed serum 25(OH)D concentrations in 413 children with asthma and 471 children without asthma living in two geographically adjacent study communities (Pampas and Villa El Salvador). We measured total and antigen-specific IgE levels, pulmonary function, asthma control, and exhaled nitric oxide. RESULTS: Mean 25(OH)D concentrations were 25.2 ng/mL (SD 10.1) in children with asthma and 26.1 ng/mL (SD 13.7) in children without asthma (p = 0.28). Vitamin D deficiency (25(OH)D &lt; 20 ng/ml) was more common in Pampas than in Villa El Salvador (52.7% vs. 10.5%; p &lt; 0.001). In the overall study population, a 10 ng/ml decrease in serum 25(OH)D concentrations was not significantly associated with odds of asthma (OR 1.09, 95% CI: 0.94 to 1.25). However, vitamin D deficiency was associated with a 1.6-fold increase in odds of asthma in the overall cohort (95% CI: 1.14 to 2.25). After stratifying by site, a 10 ng/mL decrease in serum 25(OH)D concentrations was associated with 18% higher odds of having asthma in Pampas (OR = 1.18, 95% CI 1.02 to 1.38), whereas there was no significant association between 25(OH)D concentrations and asthma in Villa El Salvador (OR = 0.95, 95% CI 0.87 to 1.05). Combined data from these geographically adjacent populations suggests a possible threshold for the relationship between 25(OH)D levels and asthma at approximately 27.5 ng/ml. Serum 25(OH)D concentrations were not clearly associated with asthma control, total serum IgE, atopy, or airway inflammation. CONCLUSION: Serum 25(OH)D concentrations were inversely associated with asthma in one study community with a high prevalence of deficiency. Studies are needed to investigate a possible threshold 25(OH)D concentration after which higher vitamin D levels show no further benefit for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 2054-7064 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40733-017-0033-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28588900">PM:28588900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Res Pract\2017-3-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Res Pract\2017-3-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Pollard SL</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40733-017-0033-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heyl,K.A.</style></author><author><style face="normal" font="Arial"> Karsten,C.M.</style></author><author><style face="normal" font="Arial"> Slevogt,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Septomics Research Center, Jena University Hospital, Albert-Einstein-Str. 10, D-07745 Jena, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Galectin-3 binds highly galactosylated IgG1 and is crucial for the IgG1 complex mediated inhibition of C5aReceptor induced immune responses</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="90" start="86">86-90</pages><volume><style face="normal" font="Arial">479</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animals</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Antibody Complex</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> Blotting,Western</style></keyword><keyword><style face="normal" font="Arial"> Cell Movement</style></keyword><keyword><style face="normal" font="Arial"> Cells,Cultured</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis</style></keyword><keyword><style face="normal" font="Arial"> Chemotaxis,Leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Cross-link</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Galactose</style></keyword><keyword><style face="normal" font="Arial"> Galectin 3</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> Lectins,C-Type</style></keyword><keyword><style face="normal" font="Arial"> Mediator Complex</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice,Inbred C57BL</style></keyword><keyword><style face="normal" font="Arial"> Mice,Knockout</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptor,Anaphylatoxin C5a</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Receptors,IgG</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="Arial">Changes in the glycosylation of immunoglobulins have been shown to modulate immune homeostasis and disease pathology. In this sense it has been shown that highly galactosylated but not agalactosylated IgG1 immune complexes (ICs) inhibit C5aR-mediated pro-inflammatory immune responses via the assembly of FcgammaRIIB-Dectin-1 receptor complexes. In this study we demonstrated that Galectin-3, a galactose-binding lectin that is known to cross-link proteins on cell-surfaces via binding their N-glycans, bound to highly-galactosylated, but not agalactosylated IgG1. Further, Galectin-3 was essential for the IC-mediated inhibition of C5a-induced neutrophil chemotaxis in vitro. Taken together our results indicate that Galectin-3 mediates the interaction of ICs with the FcgammaRIIB-Dectin-1 receptor complex for delivering immunoregulatory signals to inhibit C5aR-mediated immune responses</style></abstract><notes><style face="normal" font="Arial">DA - 20160925IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleRN - 0 (Antigen-Antibody Complex)RN - 0 (Fcgr2b protein, mouse)RN - 0 (Galectin 3)RN - 0 (Immunoglobulin G)RN - 0 (Lectins, C-Type)RN - 0 (Mediator Complex)RN - 0 (Receptor, Anaphylatoxin C5a)RN - 0 (Receptors, IgG)RN - 0 (dectin 1)RN - X2RN3Q8DNE (Galactose)SB - IMCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2016.09.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27620493">PM:27620493</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\2016-479-86-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\2016-479-86-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160925, Heyl KA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2016.09.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakayama,T.</style></author><author><style face="normal" font="Arial"> Yamazaki,T.</style></author><author><style face="normal" font="Arial"> Yo,A.</style></author><author><style face="normal" font="Arial"> Tone,K.</style></author><author><style face="normal" font="Arial"> Mahdi,Alshahni M.</style></author><author><style face="normal" font="Arial"> Fujisaki,R.</style></author><author><style face="normal" font="Arial"> Makimura,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical Laboratory Medicine, Graduate School of Medical Care and Technology</style></auth-address><titles><title><style face="normal" font="Arial">Detection of Fungi from an Indoor Environment using Loop-mediated Isothermal Amplification (LAMP) Method</style></title><secondary-title><style face="normal" font="Arial">Biocontrol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biocontrol Sci</style></full-title></periodical><pages end="104" start="97">97-104</pages><volume><style face="normal" font="Arial">22</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Ascomycota</style></keyword><keyword><style face="normal" font="Arial"> Basidiomycota</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candida albicans</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical laboratory</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcus</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcus neoformans</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> Indoor environments</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mucor</style></keyword><keyword><style face="normal" font="Arial"> Mucorales</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Loop-mediated isothermal amplification (LAMP) is a useful DNA detection method with high specificity and sensitivity. The LAMP reaction is carried out within a short time at a constant temperature without the need for thermal cycling. We developed a LAMP primer set for detecting a wide range of fungi by aligning the sequences of the large subunit ribosomal RNA gene of Candida albicans (Ascomycota), Cryptococcus neoformans (Basidiomycota), and Mucor racemosus (Mucorales). The threshold of C. albicans rDNA as template with our LAMP primer set was in the range of 10-100 copies per a reaction. In this study, we evaluated the correlation between colony forming units (CFU) and LAMP detection rate using the LAMP method for environmental fungi. The LAMP method should be a useful means of detecting fungi in indoor environments, disaster areas, or even in confined manned spacecraft to prevent allergies or infections caused by fungi</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 1884-0205 (Electronic)IS - 1342-4815 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.4265/bio.22.97</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28659561">PM:28659561</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biocontrol Sci\2017-22-97-104.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biocontrol Sci\2017-22-97-104.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Nakayama T</style></custom2><misc3><style face="normal" font="Arial">10.4265/bio.22.97</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,D.E.</style></author><author><style face="normal" font="Arial"> Lee,Y.</style></author><author><style face="normal" font="Arial"> Kim,M.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Jon,S.</style></author><author><style face="normal" font="Arial"> Lee,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biomedical Science and Engineering Interdisciplinary Program, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon, 34141, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Biomaterials</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomaterials</style></full-title></periodical><pages end="44" start="37">37-44</pages><volume><style face="normal" font="Arial">140</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bilirubin</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nanomedicine</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">Although asthma, a chronic inflammatory airway disease, is relatively well-managed by inhaled corticosteroids, the side effects associated with the long-term use of these agents precipitate the need for alternative therapeutic options based on differing modes of action. Bilirubin, a potent endogenous antioxidant, and anti-inflammatory molecule have been shown to ameliorate asthmatic symptoms; however, its clinical translation has been limited owing to its water insolubility and associated potential toxicity. Here we report the first application of bilirubin-based nanoparticles (BRNPs) as a nanomedicine for the treatment of allergic lung inflammatory disease. BRNPs were prepared directly from self-assembly of PEGylated bilirubin in aqueous solution and had a hydrodynamic diameter of approximately 100 nm. Because allergen-specific type 2 T-helper (Th2) cells play a key role in the pathogenesis and progression of allergic asthma, the effects of BRNPs on Th2 immune responses were investigated both in vivo and in vitro. BRNPs after intravenous injection (i.v.) showed much higher serum concentration and a longer circulation time of bilirubin than the intraperitoneal injection (i.p.) of BRNPs or unconjugated bilirubin (UCB). The anti-asthmatic effects of BRNPs were assessed in a mouse model of allergen-induced asthma. Compared with UCB, treatment with BRNPs suppressed the symptoms of experimental allergic asthma and dramatically ameliorated Th2-related allergic lung inflammation. Consistent with these results, BRNPs caused a reduction of Th2 cell populations and the expression of related cytokines by antibody-stimulated CD4+ T cells in vitro. Therefore, our results establish BRNPs as an important immunomodulatory agent that may be useful as a therapeutic for allergic lung inflammatory disease and other immune-mediated disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1878-5905 (Electronic)IS - 0142-9612 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biomaterials.2017.06.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624706">PM:28624706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomaterials\2017-140-37-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomaterials\2017-140-37-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, Kim DE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biomaterials.2017.06.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bioinformatics and Medical Informatics Research Center, San Diego State University, 5500 Campanile Dr., 92182 San Diego, CA USA.</style></auth-address><titles><title><style face="normal" font="Arial">Inflammasomes, the cardinal pathology mediators are activated by pathogens, allergens and mutagens: A critical review with focus on NLRP3</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="825" start="819">819-825</pages><volume><style face="normal" font="Arial">92</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Caspase 1</style></keyword><keyword><style face="normal" font="Arial"> caspase-1</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> cysteine proteases</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Inflammasomes</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Informatics</style></keyword><keyword><style face="normal" font="Arial"> Multiprotein Complexes</style></keyword><keyword><style face="normal" font="Arial"> Mutagens</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> PAMP</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="Arial">Inflammation is a pivotal defense system of body. Unfortunately, when homeostasis falters, the same inflammatory mechanism acts as a double-edged sword, and turns offensive, paving the path for a broad array of pathologies. A multi-protein complex termed as inflammasome perceives the PAMPs (pathogen associated molecular patterns) and DAMPs (danger associated molecular patterns), executing immune responses. This activation predominantly encompasses the elaboration of effector cytokines IL-1beta, IL-18, and the cysteine proteases (caspase 1 and 11). Extensive study on an inflammasome NLRP3 has revealed its role in the onset and progression of pathogenic, metabolic, autoimmune, neural, and geriatric diseases. In this regard, this inflammasome's immune activation mechanisms and inhibition strategies have been discussed. Through this rigorous literature analysis, the superficial diversity between pathogens/allergens and mutagens, and NLRP3 activity towards them has been emphasized. Though there is a scope for inhibition of aberrant inflammasomes, including that of NLRP3, given their complexity and unpredictability, prevention of their activation by lifestyle correction has been suggested</style></abstract><notes><style face="normal" font="Arial">DA - 20170609IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.05.126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599247">PM:28599247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-92-819-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-92-819-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170609, Patel S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.05.126</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amouzadeh,T.M.</style></author><author><style face="normal" font="Arial"> Shamsipur,M.</style></author><author><style face="normal" font="Arial"> Saber,R.</style></author><author><style face="normal" font="Arial"> Sarkar,S.</style></author><author><style face="normal" font="Arial"> Ebrahimi,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Center for Science and Technology in Medicine, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">A high sensitive visible light-driven photoelectrochemical aptasensor for shrimp allergen tropomyosin detection using graphitic carbon nitride-TiO2 nanocomposite</style></title><secondary-title><style face="normal" font="Arial">Biosens Bioelectron</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biosens Bioelectron</style></abbr-1></periodical><pages end="118" start="113">113-118</pages><volume><style face="normal" font="Arial">98</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Ascorbic Acid</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Glutaraldehyde</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Polyethyleneimine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Selectivity</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergen</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Titanium</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">Herein, for the first time a visible-light-driven photoelectrochemical (PEC) aptasensor for shrimp tropomyosin determination was fabricated by using graphitic carbon nitride (g-C3N4) and titanium dioxide (TiO2) as photoactive nanomaterials, ascorbic acid (AA) as electron donor and ruthenium (III) hexaammine (Ru(NH3)63+) as signal enhancer. The surface of an ITO electrode was first modified with g-C3N4, TiO2, and polyethyleneimine (PEI) and then the amine terminal aptamerTROP probe was attached to PEI by the use of glutaraldehyde (GA) as cross-linker. After that, Ru(NH3)63+ was adsorbed on aptamer to enhance the photocurrent signal. The principle of proposed PEC aptasensor is based on the formation of a selective complex between tropomyosin and immobilized aptamerTROP probe on the surface of ITO/g-C3N4-TiO2/PEI/aptamerTROP-Ru(NH3)6+3. After the incubation of tropomyosin with TROP aptamer probe, the photocurrent signal decreased due to releasing adsorbed Ru(NH3)63+ on aptamer and preventing AA from scavenging photogenerated holes to the photoactive modified electrode. Under the optimized conditions, the fabricated PEC aptasensor was used for the determination of shrimp tropomyosin in the concentration range of 1-400ngmL-1 with a limit of detection of 0.23ngmL-1. The proposed PEC aptasensor exhibited high selectivity, sensitivity, and good stability</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1873-4235 (Electronic)IS - 0956-5663 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bios.2017.06.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667837">PM:28667837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biosens Bioelectron\2017-98-113-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biosens Bioelectron\2017-98-113-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Amouzadeh TM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bios.2017.06.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mulvey,J.J.</style></author><author><style face="normal" font="Arial"> Magro,C.</style></author><author><style face="normal" font="Arial"> Chadburn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">New York Presbyterian Hospital, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy</style></title><secondary-title><style face="normal" font="Arial">Blood Cells Mol Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Blood Cells Mol Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylatoxins</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> C3a</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndromes</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="Arial">The anaphylatoxins produced by an unbridled complement cascade in atypical hemolytic uremic syndrome (aHUS) can alter the leukocyte environment in tissues and peripheral blood, causing clinically significant eosinophilia. While the membrane attack complex and C5a anaphlatoxin can be suppressed with anti-C5 biologics, the production of C3a is still capable of driving a destructive hypereosinophilic syndrome in spite of anticomplement therapy. The side-effects of glucocorticoids in treating hypereosinophilic syndrome limit their therapeutic index in long-term treatment and this behooves the use of alternative strategies. While use of the anti-IL-5 antibody, mepolizumab, has been reported for treatment of primary hypereosinophilic syndromes off-label, its usage in the setting of complement-driven thrombotic microangiopathy has not been attempted. We report mepolizumab's rapid resolution of a glucocorticoid-resistant hypereosinophilic syndrome that caused multi-organ dysfunction in a patient with a complex immune diathesis. The patient's long standing TTP/aHUS disease activity, shown to have direct correlation with his eosinophil count, improved with anti-IL-5 therapy, suggesting a reciprocal enhancement between the conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170626IS - 1096-0961 (Electronic)IS - 1079-9796 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bcmd.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28648630">PM:28648630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Blood Cells Mol Dis\20170626-MulveyJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Blood Cells Mol Dis\20170626-MulveyJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170626, Mulvey JJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bcmd.2017.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qian,L.J.</style></author><author><style face="normal" font="Arial"> Kang,S.M.</style></author><author><style face="normal" font="Arial"> Xie,J.L.</style></author><author><style face="normal" font="Arial"> Huang,L.</style></author><author><style face="normal" font="Arial"> Wen,Q.</style></author><author><style face="normal" font="Arial"> Fan,Y.Y.</style></author><author><style face="normal" font="Arial"> Lu,L.J.</style></author><author><style face="normal" font="Arial"> Jiang,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Gulou District, Nanjing, Jiangsu, 210009, China</style></auth-address><titles><title><style face="normal" font="Arial">Early-life gut microbial colonization shapes Th1/Th2 balance in asthma model in BALB/c mice</style></title><secondary-title><style face="normal" font="Arial">BMC Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Microbiol</style></full-title></periodical><pages end="" start="135">135-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> intestinal flora</style></keyword><keyword><style face="normal" font="Arial"> intestinal microflora</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> microflora</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We aimed to investigate the effect of early-life diverse microbial exposures on gut microbial colonization in an OVA-induced asthma model in BALB/c mice. METHODS: BALB/c mice were divided into 4 groups: A, offsprings were kept in a SPF environment during fetal, lactation, and childhood periods; B, offsprings were kept in the SPF environment during fetal and lactation periods, and kept in the general environment during childhood; C, offsprings were kept in the SPF environment only during fetal period, and then kept in the general environment; and D, offsprings were kept in the general environment during whole periods. The diversity of intestinal flora was analyzed using denaturing gradient gel electrophoresis. Mice were sensitized with OVA to establish an animal model of asthma. Then asthma-related inflammatory cytokines and histological analysis were performed. RESULTS: The diversity of intestinal microflora in group D was significantly higher than groups A, B and C at three days and three weeks after birth, and the diversity of intestinal microflora in groups C and D were significantly higher than groups A and B at five weeks after birth. The pathologic scores of OVA-induced asthmatic mice in group D were significantly lower than group A, and serum IFN-gamma levels and the IFN-gamma/IL-4 ratio in group D were significantly higher than group A. CONCLUSIONS: Exposure to diverse microbial environments in early life affects gut microbial colonization in BALB/c mice. The diversity of the intestinal flora in early life may prevent airway inflammation in asthma via regulating the Th1/Th2 balance</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1471-2180 (Electronic)IS - 1471-2180 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12866-017-1044-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28623898">PM:28623898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Microbiol\2017-17-135.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Microbiol\2017-17-135.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, Qian LJ</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12866-017-1044-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Finding a Path to Safety in Food Allergy: Assessment of the Global Burden, Causes, Prevention, Management, and Public Policy.</style></title><secondary-title><style face="normal" font="Arial">Books</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Books</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="06/25/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Public Policy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="30" Month="11" Year="2016">2016/11/30</year></dates><abstract><style face="normal" font="Arial">Over the past 20 years, public concerns have grown in response to the apparent rising prevalence of food allergy and related atopic conditions, such as eczema. Although evidence on the true prevalence of food allergy is complicated by insufficient or inconsistent data and studies with variable methodologies, many health care experts who care for patients agree that a real increase in food allergy has occurred and that it is unlikely to be due simply to an increase in awareness and better tools for diagnosis. Many stakeholders are concerned about these increases, including the general public, policy makers, regulatory agencies, the food industry, scientists, clinicians, and especially families of children and young people suffering from food allergy. At the present time, however, despite a mounting body of data on the prevalence, health consequences, and associated costs of food allergy, this chronic disease has not garnered the level of societal attention that it warrants. Moreover, for patients and families at risk, recommendations and guidelines have not been clear about preventing exposure or the onset of reactions or for managing this disease. Finding a Path to Safety in Food Allergy examines critical issues related to food allergy, including the prevalence and severity of food allergy and its impact on affected individuals, families, and communities; and current understanding of food allergy as a disease, and in diagnostics, treatments, prevention, and public policy. This report seeks to: clarify the nature of the disease, its causes, and its current management; highlight gaps in knowledge; encourage the implementation of management tools at many levels and among many stakeholders; and delineate a roadmap to safety for those who have, or are at risk of developing, food allergy, as well as for others in society who are responsible for public health</style></abstract><notes><style face="normal" font="Arial">DA - 20170614LA - engPT - ReviewPT - Book</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28609025">PM:28609025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Books\Finding a Path to Safety in Food Allergy.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Books\Finding a Path to Safety in Food Allergy.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170626, no authors</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lowe,A.J.</style></author><author><style face="normal" font="Arial"> Su,J.C.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Cranswick,N.</style></author><author><style face="normal" font="Arial"> Robertson,C.F.</style></author><author><style face="normal" font="Arial"> Forster,D.</style></author><author><style face="normal" font="Arial"> Varigos,G.</style></author><author><style face="normal" font="Arial"> Hamilton,S.</style></author><author><style face="normal" font="Arial"> Kennedy,R.</style></author><author><style face="normal" font="Arial"> Axelrad,C.</style></author><author><style face="normal" font="Arial"> Tang,M.L.K.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Lung Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, 3010</style></auth-address><titles><title><style face="normal" font="Arial">A randomised trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: The PEBBLES Pilot Study</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emollients</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="Arial">It is hypothesised that the impaired skin barrier in atopic dermatitis (AD) allows the immune system to be exposed to environmental allergens, resulting in sensitisation and allergic disease[1]. Two small trials recently found that routine use of emollients reduced the incidence of AD during the active treatment period by approximately half [2, 3]. It remains unknown if prophylactic use of emollients can prevent the development of AD beyond the treatment period (as opposed to simply delay its onset) or if this reduction in AD leads to a reduced risk of allergic sensitisation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170622IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15747</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28639306">PM:28639306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170622-LoweAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170622-LoweAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170622, Lowe AJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15747</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,N.H.</style></author><author><style face="normal" font="Arial"> Ferretti,M.</style></author><author><style face="normal" font="Arial"> Phillips,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Urology, New York Medical College, Valhalla, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Hyper IgE Syndrome and Renal Cell Carcinoma</style></title><secondary-title><style face="normal" font="Arial">Case Rep Urol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Case Rep Urol</style></abbr-1></periodical><pages end="" start="7083451">7083451-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urology</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Hyper IgE Syndrome (HIES) is an immunodeficiency disorder characterized by increased serum levels of IgE, eczema, and recurrent cutaneous and pulmonary infections. In this report, we present, to our knowledge, the first documented case of renal cell carcinoma (RCC) found in a patient with HIES. The patient received infectious disease clearance prior to obtaining a partial nephrectomy which revealed clear cell histology. Both HIES and RCC have an immunological basis for their pathophysiology and may involve common pathways. Further studies may provide insight into any possible link and clinicians should be mindful of immunocompromised patients who present with risk factors for genitourinary malignancy</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 2090-696X (Print)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/7083451</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28607797">PM:28607797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Urol\2017-2017-7083451.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Urol\2017-2017-7083451.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Patel NH</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/7083451</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,C.M.</style></author><author><style face="normal" font="Arial"> Chang,C.B.</style></author><author><style face="normal" font="Arial"> Chan,M.W.</style></author><author><style face="normal" font="Arial"> Wen,Z.H.</style></author><author><style face="normal" font="Arial"> Wu,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan 60002, China</style></auth-address><titles><title><style face="normal" font="Arial">Dust mite allergen-specific immunotherapy increases IL4 DNA methylation and induces Der p-specific T cell tolerance in children with allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Cell Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Mol Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Hypertrophy</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (allergen-SIT) is a highly effective treatment for children with allergic asthma (AA), an immune-mediated chronic disease leading to bronchial muscle hypertrophy and airway obstruction in response to specific allergens. T helper cells and secreted cytokines play important roles in the pathogenesis of asthma, and epigenetic modulation controls genes important for T cell development and cytokine expression. This study evaluated T helper cell-secreted cytokines and DNA methylation patterns in children treated with Dermatophagoides pteronyssinus (Der p) allergen-SIT. Our results showed that after Der p challenge, peripheral blood mononuclear cells (PBMCs) from the SIT group, compared with the non-SIT AA group, produced lower levels of IL-4, IL-5 and IL-2. The SIT group, compared with the AA group, exhibited decreased sensitivity to the Der p allergen, concurrent with IL-4 down-modulation due to increased promoter DNA methylation, as estimated in PBMCs. Our results showed that SIT decreased IL-4 and IL-5, and inhibited T cell proliferation, by inhibiting IL-2 production after the specific allergen challenge. These results suggest that decreased IL-2 production and increased IL-4 cytokine promoter methylation is a potential mechanism of Der p-specific allergen desensitization immunotherapy.Cellular &amp;Molecular Immunology advance online publication, 12 June 2017; doi:10.1038/cmi.2017.26</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 2042-0226 (Electronic)IS - 1672-7681 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1038/cmi.2017.26</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28603280">PM:28603280</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Mol Immunol\20170612-WangCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Mol Immunol\20170612-WangCM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Wang CM</style></custom2><misc3><style face="normal" font="Arial">10.1038/cmi.2017.26</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xiao,L.</style></author><author><style face="normal" font="Arial"> Jiang,L.</style></author><author><style face="normal" font="Arial"> Hu,Q.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">MicroRNA-133b Ameliorates Allergic Inflammation and Symptom in Murine Model of Allergic Rhinitis by Targeting Nlrp3</style></title><secondary-title><style face="normal" font="Arial">Cell Physiol Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Physiol Biochem</style></full-title></periodical><pages end="912" start="901">901-912</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Caspase 1</style></keyword><keyword><style face="normal" font="Arial"> caspase-1</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="26" Month="6" Year="2017">2017/6/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Emerging evidences indicate that post-transcriptional regulation by microRNAs is critical in allergic rhinitis (AR) pathogenesis. MircroRNA-133b (miR-133b) was recently suggested as a potential predictor of AR. However, the in vivo effect of miR-133b on AR is unclear. METHODS: AR model was established in BALB/c mice by intraperitoneal sensitization and intranasal challenge with ovalbumin (OVA). MiR-133b agomir was then intranasally administrated to mice after OVA challenge for another 7 days. The symptom of nasal rubbing and sneezing were recorded after the last OVA challenge. Nasal mucosa tissues and serum were collected. MiR-133b expression, serum OVA-specific immunoglobulin E (IgE) concentration, proinflammatory cytokines (TNF-alpha, IL-4, IL-5, IL-10 and IFN-gamma) levels, and Nlrp3 inflammasome activation were measured by RT-PCR, ELISA, western blotting or immunohistochemistry, respectively. Histopathologic changes were evaluated using hematoxylin and eosin and Sirius red staining. The luciferase activity and protein expression of Nlrp3 were also determined. RESULTS: MiR-133b expression was significantly decreased in nasal mucosa of AR mice, which was restored by nasal administration with miR-133b agomir. Upregulation of miR-133b markedly reduced the concentration of OVA-specific IgE, the frequencies of nasal rubbing and sneezing, and the levels of cytokines (TNF-alpha, IL-4, IL-5 and IFN-gamma). Levels of IL-4, IL-5, IL-10 and IFN-gamma produced by cervical lymph node cells were significantly lowered in miR-133b agomir-treated mice. Moreover, miR-133b also appeared to strongly attenuate pathological alterations and eosinophils and mast cells infiltration in nasal mucosa. Notably, we demonstrated for the first time that miR-133b negatively regulated Nlrp3 expression through binding with the 3' untranslated region of Nlrp3. Consequently, infection of miR-133b in nasal mucosa remarkably suppressed the Nlrp3 inflammasome activation, as evidenced by reduced Nlrp3, Caspase-1, ASC, IL-18 and IL-1 expressions. CONCLUSION: MiR-133b alleviates allergic symptom in AR mice by inhibition of Nlrp3 inflammasome-meditated inflammation. These findings provide us an insight into the potential role of miR-133b in relation to AR treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 1421-9778 (Electronic)IS - 1015-8987 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1159/000478645</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28662502">PM:28662502</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Physiol Biochem\2017-43-901-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Physiol Biochem\2017-43-901-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Xiao L</style></custom2><misc3><style face="normal" font="Arial">10.1159/000478645</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heinzelmann,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Journalist science + technology</style></auth-address><titles><title><style face="normal" font="Arial">The Innovation from Innsbruck: Plant-based Allergen Recombinantly Produced in Green Alga</style></title><secondary-title><style face="normal" font="Arial">Chimia (Aarau)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chimia (Aarau)</style></full-title></periodical><pages end="820" start="818">818-820</pages><volume><style face="normal" font="Arial">70</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="30" Month="11" Year="2016">2016/11/30</year></dates><abstract><style face="normal" font="Arial">An innovation in biotechnology: for the first time, researchers from MCI Innsbruck and the University of Salzburg have manufactured and purified a plant-based allergen in a green alga and opened the door to a specific immunotherapy against allergies. Their vision: to replace the unpleasant injection with oral administration, as its production is both simple and cost-effective</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 0009-4293 (Print)IS - 0009-4293 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.2533/chimia.2016.818</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28661347">PM:28661347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chimia (Aarau)\2016-70-818-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chimia (Aarau)\2016-70-818-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Heinzelmann E</style></custom2><misc3><style face="normal" font="Arial">10.2533/chimia.2016.818</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Muldoon,E.G.</style></author><author><style face="normal" font="Arial"> Strek,M.E.</style></author><author><style face="normal" font="Arial"> Patterson,K.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic and Noninvasive Infectious Pulmonary Aspergillosis Syndromes</style></title><secondary-title><style face="normal" font="Arial">Clin Chest Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chest Med</style></full-title></periodical><pages end="534" start="521">521-534</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic fungal infection of lung</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0272-5231</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ccm.2017.04.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797493">PM:28797493</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Chest Med\2017-38-521-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Chest Med\2017-38-521-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Muldoon EG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ccm.2017.04.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tordesillas,L.</style></author><author><style face="normal" font="Arial"> Cubells-Baeza,N.</style></author><author><style face="normal" font="Arial"> Gomez-Casado,C.</style></author><author><style face="normal" font="Arial"> Berin,C.</style></author><author><style face="normal" font="Arial"> Esteban,V.</style></author><author><style face="normal" font="Arial"> Barcik,W.</style></author><author><style face="normal" font="Arial"> O'Mahony,L.</style></author><author><style face="normal" font="Arial"> Ramirez,C.</style></author><author><style face="normal" font="Arial"> Pacios,L.F.</style></author><author><style face="normal" font="Arial"> Garrido-Arandia,M.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Icahn School of Medicine at Mount Sinai, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms underlying induction of allergic sensitization by Pru p 3</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> CD1d</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Plant food allergen</style></keyword><keyword><style face="normal" font="Arial"> Plant food allergens</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recently, the nature of the lipid-ligand of Pru p 3, one of the most common plant food allergens in Southern Europe, has been identified as a derivative of the alkaloid camptothecin bound to phytosphingosine. However, the origin of its immunological activity is still unknown. OBJECTIVE: We sought to evaluate the role of the Pru p 3 lipid- ligand in the immunogenic activity of Pru p 3. METHODS: In vitro cultures of different cell types (monocyte-derived dendritic cells (moDCs), PBMCs and epithelial and iNKT-hybridoma cell lines) have been used to determine the immunological capacity of the ligand, by measuring cell proliferation, maturation markers and cytokine production. To study the capacity of the lipid-ligand to promote sensitization to Pru p 3 in vivo, a mouse model of anaphylaxis to peach has been produced and changes in the humoral and basophil responses have been analyzed. RESULTS: The lipid-ligand of Pru p 3 induced maturation of moDCsc and proliferation of PBMCs. Its immunological activity resided in the phytosphingosine tail of the ligand. The adjuvant activity of the ligand was also confirmed in vivo, where the complex of Pru p 3-ligand induced higher levels of IgE than Pru p 3 alone. The immunological capacity of the Pru p 3 ligand was mediated by CD1d, as maturation of moDCs was inhibited by anti-CD1d antibodies and Pru p 3-ligand co-localized with CD1d on epithelial cells. Finally, Pru p 3-ligand presented by CD1d was able to interact with iNKTs. CONCLUSIONS &amp; CLINICAL RELEVANCE: The Pru p 3 lipid-ligand could act as an adjuvant to promote sensitization to Pru p 3, through its recognition by CD1d receptors. This intrinsic adjuvant activity of the accompanying lipid cargo could be a general essential feature of the mechanism underlying the phenomenon of allergenicity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170615IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Spain -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12962</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28618148">PM:28618148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170615-TordesillasL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170615-TordesillasL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Tordesillas L</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12962</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Backman,H.</style></author><author><style face="normal" font="Arial"> Raisanen,P.</style></author><author><style face="normal" font="Arial"> Hedman,L.</style></author><author><style face="normal" font="Arial"> Stridsman,C.</style></author><author><style face="normal" font="Arial"> Andersson,M.</style></author><author><style face="normal" font="Arial"> Lindberg,A.</style></author><author><style face="normal" font="Arial"> Lundback,B.</style></author><author><style face="normal" font="Arial"> Ronmark,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Clinical Medicine, Division of Occupational and Environmental Medicine/the OLIN unit, Umea University, Umea, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016 - results from three population surveys</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> OLIN</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: During the latter half of the 20th century the prevalence of asthma and many other allergic diseases has increased. Information on asthma prevalence trends after 2010, especially regarding studies separating allergic asthma from non-allergic asthma is lacking. OBJECTIVE: The aim was to estimate prevalence trends of current asthma, both allergic and non-allergic, from 1996 to 2016. METHODS: Three cross-sectional samples from the same area of Sweden, 20-69 years, participated in surveys with the same questionnaire in 1996 (n=7104 participants, 85% response rate), 2006 (n=6165, 77%) and 2016 (n=5466, 53%), respectively. Allergic rhino-conjunctivitis was used as a marker for allergic sensitization in order to define allergic asthma. RESULTS: The prevalence of current asthma increased from 8.4% (95%CI 7.8-9.0) in 1996 to 9.9% (95%CI 9.2-10.6) in 2006 and 10.9% (95%CI 10.1-11.7) in 2016 (p=&lt;0.001). Allergic asthma increased from 5.0% (95%CI 4.5-5.5) in 1996 to 6.0% (95%CI 5.4-6.6) in 2006 and further to 7.3% (95%CI 6.6-8.0) in 2016 (p&lt;0.001), while the prevalence of non-allergic asthma remained stable around 3.4-3.8%. The increase in current asthma was most pronounced among women and among the middle-aged. Physician-diagnosed asthma, asthma medication use, and allergic rhino-conjunctivitis also increased significantly, while the prevalence of symptoms common in asthma such as wheeze and attacks of shortness of breath decreased slightly or was stable. The prevalence of current smoking decreased from 27.4% in 1996 to 12.3% in 2016. CONCLUSIONS &amp; CLINICAL RELEVANCE: The prevalence of allergic asthma increased from 1996 to 2006 and further to 2016, while the prevalence of non-allergic asthma remained on a stable prevalence level. The prevalence of symptoms common in asthma decreased slightly or was stable despite a substantial decrease in the prevalence of current smoking. Clinicians should be aware that the previously observed increase in prevalence of allergic asthma is still ongoing. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12963</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28608416">PM:28608416</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170613-BackmanH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170613-BackmanH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Backman H</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12963</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UKNIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UKThe David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK</style></auth-address><titles><title><style face="normal" font="Arial">Nut allergy guideline</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="709" start="708">708-709</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170602IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12950</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28574656">PM:28574656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-708-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-708-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170602, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12950</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moon,I.J.</style></author><author><style face="normal" font="Arial"> Chang,S.E.</style></author><author><style face="normal" font="Arial"> Kim,S.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">First case of anaphylaxis after botulinum toxin type A injection</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Botulinum Toxin Type A</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscles</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">Botulinum toxin type A (BTA) (also known as onabotulinum toxin A) injection is widely used in the field of cosmetic dermatology. Although a few adverse events related to intramuscular BTA injection have been reported, no life-threatening adverse reaction has been documented to date. We report a case of anaphylaxis induced by intramuscular BTA injection into the masseter muscles of a 35-year-old woman. She had previously received injections of the identical BTA product into the same muscles without incident. However, during the reported procedure, symptoms suggestive of angio-oedema and anaphylaxis developed about 5 min after BTA injection. Intramuscular epinephrine was used to manage the reaction. Following this, the patient was found to have an elevated total serum IgE level. We could not perform testing with BTA because of the risk of triggering another episode of anaphylaxis; however, intradermal tests using the identical sterile saline and patch test using the topical anaesthetic cream both showed negative results, thus we strongly suspect BTA as being the cause of anaphylaxis in this case</style></abstract><notes><style face="normal" font="Arial">DA - 20170622IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.13108</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28639343">PM:28639343</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20170622-MoonIJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20170622-MoonIJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170622, Moon IJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.13108</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pinto Gouveia,M.</style></author><author><style face="normal" font="Arial"> Gameiro,A.</style></author><author><style face="normal" font="Arial"> Pinho,A.</style></author><author><style face="normal" font="Arial"> Goncalo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Department, Coimbra University Hospital Centre, Coimbra, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Long-term management of chronic spontaneous urticaria with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Anti-H1</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inducible urticaria</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed pressure</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="25" Month="6" Year="2017">2017/6/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Clinical trials have shown the efficacy of omalizumabs efficacy in refractory chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), but real-life management strategies are lacking. AIM: To assess the long-term efficacy and safety of omalizumab, and to identify predictive factors and optimum dosage regimens. METHODS: This was a prospective study of 13 patients (11 women, 2 men) with severe CSU [weekly urticaria activity score (UAS7) > 28] resistant to anti-H1 antihistamines. Patients were started on omalizumab 150 mg subcutaneously every 4 weeks. Dose and interval between administrations were adjusted according to clinical response (189 administrations; treatment duration range 2-38 months). RESULTS: Mean UAS7 was 36.3 +/- 5.4. Of the 13 patients, all had experienced angio-oedema, while in addition, 7 had delayed pressure urticaria (DPU) and 1 had solar urticaria (SU). After omalizumab treatment, 4 (30.8%) of the 13 patients had complete response (CR), and the remaining 8 (61.5%) had partial response. CR was achieved with a dose of 150 mg every 4 (n = 2 patients) or 5 (n = 2) weeks. One of these patients remained disease-free after stopping treatment. Partial responses were achieved with 150 mg every 4 weeks (n = 4) and with 300 mg (n = 4) at intervals of 5 weeks (n = 1), 4 weeks (n = 2) or 3 weeks (n = 1). Only one patient (7.7%) did not show significant improvement, despite a dose of 300 mg every 4 weeks. There were no significant differences in epidemiological, clinical and laboratory data between the different response groups. Only two adverse events were observed: one was mild headache and the other was severe angio-oedema and aggravation of urticaria within 6 h of omalizumab administration. CONCLUSION: Omalizumab dose and interval between administrations could be individualized for long-term management of CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20170626IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.13173</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28649751">PM:28649751</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20170626-PintoGouveiaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20170626-PintoGouveiaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170626, Pinto Gouveia M</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.13173</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food Allergies and Intolerances</style></title><secondary-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Gastroenterol Hepatol</style></full-title></periodical><pages end="" start="A24">A24-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1542-3565</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cgh.2017.05.028</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.cgh.2017.05.028</url></web-urls></urls><custom2><style face="normal" font="Arial">20170703, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cgh.2017.05.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferlito,C.</style></author><author><style face="normal" font="Arial"> Barnaba,V.</style></author><author><style face="normal" font="Arial"> Abrignani,S.</style></author><author><style face="normal" font="Arial"> Bombaci,M.</style></author><author><style face="normal" font="Arial"> Sette,A.</style></author><author><style face="normal" font="Arial"> Sidney,J.</style></author><author><style face="normal" font="Arial"> Biselli,R.</style></author><author><style face="normal" font="Arial"> Tomao,E.</style></author><author><style face="normal" font="Arial"> Cattaruzza,M.S.</style></author><author><style face="normal" font="Arial"> Germano,V.</style></author><author><style face="normal" font="Arial"> Biondo,M.I.</style></author><author><style face="normal" font="Arial"> Salerno,G.</style></author><author><style face="normal" font="Arial"> Lulli,P.</style></author><author><style face="normal" font="Arial"> Caporuscio,S.</style></author><author><style face="normal" font="Arial"> Diamanti,A.P.</style></author><author><style face="normal" font="Arial"> Falco,M.</style></author><author><style face="normal" font="Arial"> Biselli,V.</style></author><author><style face="normal" font="Arial"> Cardelli,P.</style></author><author><style face="normal" font="Arial"> Autore,A.</style></author><author><style face="normal" font="Arial"> Lucertini,E.</style></author><author><style face="normal" font="Arial"> De Cesare,D.P.</style></author><author><style face="normal" font="Arial"> Peragallo,M.S.</style></author><author><style face="normal" font="Arial"> Lista,F.</style></author><author><style face="normal" font="Arial"> Martire,C.</style></author><author><style face="normal" font="Arial"> Salemi,S.</style></author><author><style face="normal" font="Arial"> Nisini,R.</style></author><author><style face="normal" font="Arial"> D'Amelio,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sapienza Universita di Roma, Azienda Ospedaliera S. Andrea, Roma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Lack of evidence for post-vaccine onset of autoimmune/lymphoproliferative disorders, during a nine-month follow-up in multiply vaccinated Italian military</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="66" start="60">60-66</pages><volume><style face="normal" font="Arial">181</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Mass Media</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray Analysis</style></keyword><keyword><style face="normal" font="Arial"> Military Personnel</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">Anecdotal case reports, amplified by mass media and internet-based opinion groups, have recently indicated vaccinations as possibly responsible for autoimmunity/lymphoproliferation development. Multiply vaccinated Italian military personnel (group 1, operating in Italy, group 2, operating in Lebanon) were followed-up for nine months to monitor possible post-vaccine autoimmunity/lymphoproliferation onset. No serious adverse event was noticed in both groups. Multivariate analysis of intergroup differences only showed a significant association between lymphocyte increase and tetanus/diphtheria vaccine administration. A significant post-vaccine decrease in autoantibody positivity was observed. Autoantibodies were also studied by microarray analysis of self-proteins in subjects exposed to >/=4 concurrent vaccinations, without observing significant difference among baseline and one and nine months post-vaccine. Moreover, HLA-A2 subjects have been analyzed for the possible CD8T-cell response to apoptotic self-epitopes, without observing significant difference between baseline and one month post-vaccine. Multiple vaccinations in young adults are safe and not associated to autoimmunity/lymphoproliferation onset during a nine-month-long follow-up</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2017.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28625884">PM:28625884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\2017-181-60-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\2017-181-60-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Ferlito C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2017.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vasileiou,E.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Butler,C.</style></author><author><style face="normal" font="Arial"> El Ferkh,K.</style></author><author><style face="normal" font="Arial"> von Wissmann,B.</style></author><author><style face="normal" font="Arial"> McMenamin,J.</style></author><author><style face="normal" font="Arial"> Ritchie,L.</style></author><author><style face="normal" font="Arial"> Schwarze,J.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Johnston,S.L.</style></author><author><style face="normal" font="Arial"> Tian,L.</style></author><author><style face="normal" font="Arial"> Simpson,C.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, Scotland, UK</style></auth-address><titles><title><style face="normal" font="Arial">Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Infect Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza vaccination</style></keyword><keyword><style face="normal" font="Arial"> Influenza Vaccine</style></keyword><keyword><style face="normal" font="Arial"> influenza vaccines</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> live vaccine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Scotland</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="Arial">There is uncertainty about the effectiveness of influenza vaccination in people with asthma and its impact on asthma outcomes, which may contribute to the sub-optimal vaccination rates in people with asthma. This systematic review and meta-analysis involved searching 12 international databases for randomized controlled trials (RCTs) and high quality quasi-experimental and epidemiological studies (1970 to 2016). The risk of bias was low for three included RCTs. The quality of three included observational studies was moderate. The quality of evidence was very low for all study outcomes. Pooled vaccine effectiveness in 1,825 people with asthma from two test-negative design case-control studies was 45% (95% CI 31 to 56) for laboratory-confirmed influenza. Pooled efficacy of live vaccines in reducing influenza was 81% (95% CI 33 to 94). Live vaccine reduced febrile illness by 72% (95% CI 20 to 90). Influenza vaccine prevented 59-78% of asthma attacks leading to emergency visits and/or hospitalizations. For people with asthma influenza vaccination may be effective in both reducing influenza infection and asthma attacks</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1537-6591 (Electronic)IS - 1058-4838 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1093/cid/cix524</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28591866">PM:28591866</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Infect Dis\20170607-VasileiouE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Infect Dis\20170607-VasileiouE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Vasileiou E</style></custom2><misc3><style face="normal" font="Arial">10.1093/cid/cix524</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martignago,I.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Ridolo,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medicine and Surgery Department, University of Parma, via Gramsci n.14, 43126 Parma, ItalyASST Pini/CTO, Cardiac/Pulmonary Rehabilitation, Milan, ItalyMedicine and Surgery Department, University of Parma, via Gramsci n.14, 43126 Parma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="13">13-</pages><volume><style face="normal" font="Arial">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera sting</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Subcutaneous route</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy (AIT) is the only treatment that works on the causes of allergy. Available AIT nowadays are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for allergic rhinitis and asthma, while for allergy to Hymenoptera venom only subcutaneous route is recommended. A bulk of trials and meta-analyses demonstrated that efficacy and safety of AIT in decreasing allergic clinical symptoms and use of rescue medications, while its preventive capacity is yet under investigation. The most important of these effects is the prevention of potentially fatal anaphylactic reactions to Hymenoptera stings by venom immunotherapy (VIT). A certain number of studies thus far available showed that AIT, in both forms, is able to prevent the progress of allergic rhinitis into asthma and the development of new sensitizations. These effects should be related to the mechanisms of action of AIT. In fact, it has been demonstrated that both SCIT and SLIT are able to modify the allergen presentation by dendritic cells, with result in modification of the phenotype of allergen-specific T cells, switching from the typical of allergic inflammation Th2-type response to a Th1-type one. Also allergen-specific T regulatory (Treg) cells play a pivotal role by producing suppressive cytokines, such as IL-10 and TGF-beta. However, the only plain evidence of a preventive effect concerns VIT, while the other outcomes need to be furtherly investigated</style></abstract><notes><style face="normal" font="Arial">DA - 20170622IS - 1476-7961 (Print)IS - 1476-7961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-017-0070-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28638279">PM:28638279</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170622, Martignago I</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-017-0070-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rudd,P.A.</style></author><author><style face="normal" font="Arial"> Thomas,B.J.</style></author><author><style face="normal" font="Arial"> Zaid,A.</style></author><author><style face="normal" font="Arial"> Macdonald,M.</style></author><author><style face="normal" font="Arial"> Kan,O.</style></author><author><style face="normal" font="Arial"> Rolph,M.S.</style></author><author><style face="normal" font="Arial"> Soorneedi,A.R.</style></author><author><style face="normal" font="Arial"> Bardin,P.G.</style></author><author><style face="normal" font="Arial"> Mahalingam,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Glycomics, Griffith University, Gold Coast Campus, QLD, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Role of human metapneumovirus and respiratory syncytial virus in asthma exacerbations: where are we now?</style></title><secondary-title><style face="normal" font="Arial">Clin Sci (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Sci (Lond)</style></full-title></periodical><pages end="1721" start="1713">1713-1721</pages><volume><style face="normal" font="Arial">131</style></volume><number><style face="normal" font="Arial">14</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute exacerbations</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human metapneumovirus</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="Arial">Since its discovery in 2001, human metapneumovirus (hMPV) has been identified as an important cause of respiratory tract infection in young children, second only to the closely related respiratory syncytial virus (RSV). Clinical evidence suggests that hMPV is associated with acute exacerbations of asthma in both children and adults, and may play a role in initiating asthma development in children. Animal models have demonstrated that airway hyperresponsiveness (AHR) and inflammation are triggered following hMPV infection, and hMPV is able to persist in vivo by inhibiting innate immune responses and causing aberrant adaptive responses. In this review, we discuss the prevalence of hMPV infection in pediatric and adult populations and its potential role in asthma exacerbation. We also review recent advances made in animal models to determine immune responses following hMPV infection, and compare to what is known about RSV</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1470-8736 (Electronic)IS - 0143-5221 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1042/CS20160011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667069">PM:28667069</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Sci (Lond)\2017-131-1713-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Sci (Lond)\2017-131-1713-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Rudd PA</style></custom2><misc3><style face="normal" font="Arial">10.1042/CS20160011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Russell,R.J.</style></author><author><style face="normal" font="Arial"> Brightling,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infection, Immunity and Inflammation, Institute for Lung Health, Glenfield Hospital, University of Leicester, LE3 9QP, U.K</style></auth-address><titles><title><style face="normal" font="Arial">Pathogenesis of asthma: implications for precision medicine</style></title><secondary-title><style face="normal" font="Arial">Clin Sci (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Sci (Lond)</style></full-title></periodical><pages end="1735" start="1723">1723-1735</pages><volume><style face="normal" font="Arial">131</style></volume><number><style face="normal" font="Arial">14</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> multifaceted</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="Arial">The pathogenesis of asthma is complex and multi-faceted. Asthma patients have a diverse range of underlying dominant disease processes and pathways despite apparent similarities in clinical expression. Here, we present the current understanding of asthma pathogenesis. We discuss airway inflammation (both T2HIGH and T2LOW), airway hyperresponsiveness (AHR) and airways remodelling as four key factors in asthma pathogenesis, and also outline other contributory factors such as genetics and co-morbidities. Response to current asthma therapies also varies greatly, which is probably related to the inter-patient differences in pathogenesis. Here, we also summarize how our developing understanding of detailed pathological processes potentially translates into the targeted treatment options we require for optimal asthma management in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1470-8736 (Electronic)IS - 0143-5221 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1042/CS20160253</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667070">PM:28667070</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Sci (Lond)\2017-131-1723-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Sci (Lond)\2017-131-1723-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Russell RJ</style></custom2><misc3><style face="normal" font="Arial">10.1042/CS20160253</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Luo,W.Y.</style></author><author><style face="normal" font="Arial"> Xu,Z.M.</style></author><author><style face="normal" font="Arial"> Hong,L.</style></author><author><style face="normal" font="Arial"> Wu,Q.Y.</style></author><author><style face="normal" font="Arial"> Zhang,Y.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cardiovascular Intensive Care Unit, Shanghai Children's Medical Center, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Nutritional outcomes in infants with food allergy after cardiac surgery</style></title><secondary-title><style face="normal" font="Arial">Congenit Heart Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Congenit Heart Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutritional Status</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is a rapidly growing public health concern because of its increasing prevalence, as well as life-threatening potential. There is limited knowledge on the nutritional status for the pediatric congenital heart disease (CHD) patients with food allergy. OBJECTIVE: This study investigated both clinical and nutritional outcomes according to the CHD infants with food allergy. METHODS: Forty CHD infants with food allergy and 39 controls were recruited in Shanghai, China. The height and weight for age and weight for height were converted to z-scores to evaluate their effects on nutritional status before and after CHD operation. RESULTS: Cow's milk showed the most frequently sensitized food allergen. The WHZ in the >/=2 allergen group was different before operation and after operation (P = .040). The number of sensitized food allergens significantly correlated with the WHZ (r = -0.431, P = .001), WAZ (r = -0.465, P = .000), and HAZ (r = -0.287, P = .025). Infection and NT-BNP showing negative correlation with WHZ and WAZ of infants with food allergy. CONCLUSIONS: The increased number of sensitized food allergens is associated with negative effects on both short-term and long-term nutritional status in infants with CHD. Therefore, the meticulous and continuous evaluation and management of both growth and nutritional status should be considered in CHD patients with a high number of sensitized food allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170609IS - 1747-0803 (Electronic)IS - 1747-079X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/chd.12489</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28598588">PM:28598588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Congenit Heart Dis\20170609-LuoWY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Congenit Heart Dis\20170609-LuoWY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170609, Luo WY</style></custom2><misc3><style face="normal" font="Arial">10.1111/chd.12489</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tolouie,H.</style></author><author><style face="normal" font="Arial"> Hashemi,M.</style></author><author><style face="normal" font="Arial"> Mohammadifar,M.A.</style></author><author><style face="normal" font="Arial"> Ghomi,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Food Science and Technology , Shahid Beheshti University of Medical Science , Tehran , Iran</style></auth-address><titles><title><style face="normal" font="Arial">Cold Atmospheric Plasma Manipulation of Proteins in Food Systems</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Cold plasma</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Physico-chemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> Protein structures</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">Plasma processing has been getting a lot of attention in recent applications as a novel, eco-friendly, and highly efficient approach. Cold plasma has mostly been used to reduce microbial counts in foodstuff and biological materials, as well as in different levels of packaging, particularly in cases where there is thermal sensitivity. As it is a very recent application, the impact of cold plasma treatment has been studied on the protein structures of food and pharmaceutical systems, as well as in the packaging industry. Proteins, as a food constituent, play a remarkable role in the techno-functional characteristics of processed foods and/or the physico-chemical properties of protein-based films. At the same time, some proteins are responsible for reduction in quality and nutritional value, and/or causing allergic reactions in the human body. This study is a review of the influences of different types of plasma on the conformation and function of proteins with food origin, especially enzymes and allergens, as well as protein-made packaging films. In enzyme manipulation with plasma, deactivation has been reported to be either partial or complete. In addition, an activity increase has been observed in some cases. These variations are caused by the effect of different active species of plasma on the enzyme structure and its function. The level and type of variations in the functional properties of food proteins, purified proteins in food, and plasma-treated protein films are affected by a number of control factors, including treatment power, time, and gas type, as well as the nature of the substance and the treatment environment</style></abstract><notes><style face="normal" font="Arial">DA - 20170614IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - Iran -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2017.1335689</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28613926">PM:28613926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\20170614-TolouieH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\20170614-TolouieH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170614, Tolouie H</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2017.1335689</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bartuzi,Z.</style></author><author><style face="normal" font="Arial"> Cocco,R.R.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Contribution of Molecular Allergen Analysis in Diagnosis of Milk Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="46">46-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Caseins</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Cow milk proteins</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> heated milk</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergen</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: We sought to describe the available evidence supporting the utilization of the molecular allergen analysis (MAA) for diagnosis and management of cow milk protein allergy (CMPA). RECENT FINDINGS: Cow milk proteins are among the most common food allergens in IgE- and non-IgE-mediated food allergic disorders in children. Most individuals with CMPA are sensitized to both caseins and whey proteins. Caseins are more resistant to high temperatures compared to whey proteins. MAA is not superior to the conventional diagnostic tests based on the whole allergen extracts for diagnosis of CMPA. However, MAA can be useful in diagnosing tolerance to extensively heated milk proteins in baked foods. Children with CMPA and high levels of casein IgE are less likely to tolerate baked milk compared to children with low levels of casein IgE. Specific IgE-binding patterns to casein and betalactoglobulin peptides may predict the natural course of CMPA and differentiate subjects who are more likely to develop CMPA at a younger age versus those with a more persistent CMPA. Specific IgE-binding patterns to casein and beta-lactoglobulin peptides may also predict response to milk OITand identify patientsmost likely to benefit fromOIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170609IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - POland -CO - Brazil -CO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0716-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28597347">PM:28597347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170609, Bartuzi Z</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0716-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nanagas,V.C.</style></author><author><style face="normal" font="Arial"> Baldwin,J.L.</style></author><author><style face="normal" font="Arial"> Karamched,K.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA</style></auth-address><titles><title><style face="normal" font="Arial">Hidden Causes of Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="44">44-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: This study aimed to review important hidden causes of anaphylaxis in ingestants, non-ingestants, and uncommon settings. RECENT FINDINGS: Multiple new and elusive causes of anaphylaxis have been described over the past 35 years. Further research is required to identify the epidemiology, pathophysiology, and clinical impact of these hidden causes. Although these culprits should be considered in the appropriate clinical scenarios, many remain exceedingly rare</style></abstract><notes><style face="normal" font="Arial">DA - 20170603IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0713-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28577270">PM:28577270</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170603, Nanagas VC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0713-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goldman,M.</style></author><author><style face="normal" font="Arial"> Hirsch,I.</style></author><author><style face="normal" font="Arial"> Zangrilli,J.G.</style></author><author><style face="normal" font="Arial"> Newbold,P.</style></author><author><style face="normal" font="Arial"> Xu,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">AstraZeneca , Gaithersburg , MD , USA</style></auth-address><titles><title><style face="normal" font="Arial">The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies</style></title><secondary-title><style face="normal" font="Arial">Curr Med Res Opin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Res Opin</style></full-title></periodical><pages end="1613" start="1605">1605-1613</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Benralizumab, an anti-eosinophilic monoclonal antibody, in combination with high-dosage inhaled corticosteroids and long-acting beta2-agonists (ICS/LABA) significantly reduced asthma exacerbations, improved lung function, and reduced symptoms for patients with severe, uncontrolled asthma with blood eosinophil counts >/=300 cells/microL in the Phase III SIROCCO and CALIMA studies. To understand the efficacy and safety of benralizumab for patients with eosinophil-driven disease with blood eosinophil counts lower than 300 cells/microL, we evaluated the effect of applying an eosinophil cutoff of >/=150 cells/microL. METHODS: Adult patients with uncontrolled asthma despite high-dosage ICS/LABA +/- additional asthma controller(s) received subcutaneous benralizumab 30 mg every 8 weeks (Q8W; first three doses every 4 weeks) or placebo for 48 (SIROCCO) or 56 (CALIMA) weeks. Efficacy measures including annual exacerbation rate, prebronchodilator FEV1, and total asthma symptom score were analyzed by baseline blood eosinophil counts >/=150 vs. &lt;150 cells/microL. RESULTS: Benralizumab reduced asthma exacerbation rates by 42% in SIROCCO (rate ratio: 0.58; 95% CI: 0.46-0.74; p&lt;0.001; n = 325) and 36% in CALIMA (rate ratio: 0.64; 95% CI: 0.50-0.81; p&lt;0.001; n = 300) vs. placebo (n = 306, 315) for patients with blood eosinophil counts >/=150 cells/microL. Benralizumab increased prebronchodilator FEV1 (both studies, p&lt;/=0.002) and improved total asthma symptom score in SIROCCO (p = 0.009) at end of treatment vs. placebo for patients with blood eosinophil counts >/=150 cells/microL. The overall adverse events frequency was similar between treatment groups and eosinophil count cohorts. CONCLUSION: These results support the efficacy and safety of benralizumab for patients with severe asthma and blood eosinophil counts >/=150 cells/microL</style></abstract><notes><style face="normal" font="Arial">DA - 20170623IS - 1473-4877 (Electronic)IS - 0300-7995 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/03007995.2017.1347091</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28644104">PM:28644104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Med Res Opin\20170623-GoldmanH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Med Res Opin\20170623-GoldmanH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170623, Goldman H</style></custom2><misc3><style face="normal" font="Arial">10.1080/03007995.2017.1347091</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hon,K.L.E.L.</style></author><author><style face="normal" font="Arial"> Tsang,K.Y.C.</style></author><author><style face="normal" font="Arial"> Leung,T.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Chinese University of Hong Kong, 6/F, Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong SAR. China</style></auth-address><titles><title><style face="normal" font="Arial">Relevance of cat and dog sensitization by skin prick testing in childhood eczema and asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Pediatr Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Pediatr Rev</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood eczema</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> dog dander</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food sensitization</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin sensitization</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Household animal dander has been implicated as aeroallergen in childhood atopic diseases. Many parents seek healthcare advice if household pet keeping may be detrimental in atopic eczema (AE) and atopies. AIM: We investigated if skin sensitization by cat/dog dander was associated with disease severity and quality of life in children with AE. METHODS: Demographics, skin prick test (SPT) results, disease severity (Nottingham eczema severity score NESS), Children Dermatology Life Quality Index (CDLQI), blood IgE and eosinophil counts of a cohort of AE patients were reviewed. RESULTS: 325 AE patients followed at a pediatric dermatology clinic were evaluated. Personal history of asthma was lowest (20%) in the dog-dander-positive-group but highest (61%) in both-cat-and-dog-dander-positive group (p=0.007). Unlike dust mite or food sensitization, the incidence of cat or dog sensitization was low. Binomial logistic regression ascertained that cat-dander sensitization was associated with increasing age (adjusted odds ratio [aOR], 1.056; 95% Confidence Interval [CI], 1.006 to 1.109; p=0.029), dust-mite sensitization (aOR, 4.625; 95% CI, 1.444 to 14.815; p=0.010), food-allergen sensitization (aOR, 2.330; 95% CI, 1.259 to 4.310; p=0.007) and keeping-cat-ever (aOR, 7.325; 95% CI, 1.193 to 44.971; p=0.032); whereas dog-dander sensitization was associated with dust-mite sensitization (aOR, 9.091; 95% CI, 1.148 to 71.980; p=0.037), food-allergen sensitization (aOR, 3.568; 95% CI, 1.341 to 9.492; p=0.011) and keeping-dog-ever (aOR, 6.809; 95% CI, 2.179 to 21.281; p=0.001). However, neither cat nor dog sensitization were associated with asthma, allergic rhinitis, parental or sibling atopic status, disease severity or quality of life. CONCLUSION: Physicians should advise parents that there is no direct correlation between AE severity, quality of life, asthma or allergic rhinitis with skin sensitization to cats or dogs. Sensitized patients especially those with concomitant asthma and severe symptoms may consider non-furry alternatives if they plan to have a pet. Highly sensitized individuals, especially those with asthma co-morbidity, may have to remove their pet for a trial period to determine if symptoms improve</style></abstract><notes><style face="normal" font="Arial">DA - 20170623IS - 1875-6336 (Electronic)IS - 1573-3963 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.2174/1573396313666170615085018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28641549">PM:28641549</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170623, Hon KL</style></custom2><misc3><style face="normal" font="Arial">10.2174/1573396313666170615085018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patil,S.U.</style></author><author><style face="normal" font="Arial"> Calatroni,A.</style></author><author><style face="normal" font="Arial"> Schneider,M.</style></author><author><style face="normal" font="Arial"> Steinbrecher,J.</style></author><author><style face="normal" font="Arial"> Smith,N.</style></author><author><style face="normal" font="Arial"> Washburn,C.</style></author><author><style face="normal" font="Arial"> Ma,A.</style></author><author><style face="normal" font="Arial"> Shreffler,W.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="Arial">Data-driven programmatic approach to analysis of basophil activation tests</style></title><secondary-title><style face="normal" font="Arial">Cytometry B Clin Cytom</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cytometry B Clin Cytom</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Labor</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> quality measures</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Conventional data analysis of flow cytometry-based basophil activation testing requires repetitive, labor-intensive analysis that hampers efforts to standardize testing for clinical applications. Using an open-source platform, we developed and implemented a programmatic approach to the analysis of the basophil activation test (BAT) by flow cytometry. METHODS: Using the BUHLMANN FlowCAST(R) assay, peripheral blood from peanut allergic patients undergoing oral immunotherapy was incubated with peanut allergens (Arah1, Arah2, Arah6, whole peanut extract) and stained with fluorescent antibodies to CCR3 and CD63 for the development of a data-driven programmatic analysis using Bioconductor and R. Basophil identification using clustering and classification was validated using manually gated comparisons in an experimental subset. Reproducibility of CD63 upregulation set on unstimulated or anti-FcERI stimulated basophils was compared. RESULTS: BAT analysis of 294 experiments was successful in 91.5% using the above approach, with a total of 7,166 individual basophil activation tests from 269 experiments. We estimate this represents a net saving of 1340 minutes of labor by a skilled operator. Medium-based gating correlated to respective manual gating more closely than anti-FcERI based gating (R=0.96 vs. R=0.84, p&lt;0.001). Only 2% of the basophil activation results were significantly different from manual gating. Quality measures of the experiments and other measures of basophil activation were also provided by the analysis. CONCLUSIONS: We present a novel data-driven flow cytometric platform for the analysis of clinical basophil activation testing, providing a high throughput objective approach to basophil activation analysis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170615IS - 1552-4957 (Electronic)IS - 1552-4949 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1002/cyto.b.21537</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28618453">PM:28618453</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytometry B Clin Cytom\20170615-PatilSU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytometry B Clin Cytom\20170615-PatilSU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Patil SU</style></custom2><misc3><style face="normal" font="Arial">10.1002/cyto.b.21537</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hanifin,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Oregon Health &amp; Science University, 3303 Bond Avenue, Portland, OR 97239, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Adult-Onset Atopic Dermatitis: Fact or Fancy?</style></title><secondary-title><style face="normal" font="Arial">Dermatol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dermatol Clin</style></full-title></periodical><pages end="302" start="299">299-302</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Adult-onset atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood eczema</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oregon</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis therapy can be a challenge in many cases. Persistence into adulthood often reflects the more severe cases and such patients have the added problems of hand eczema and thick nummular lesions that resist topical medications. Within this group are patients labeled as having adult-onset atopic dermatitis, a designation that is hard to define and probably represents those whose childhood eczema was simply forgotten. Management is difficult for most adult cases and should not be diverted by questionable labels</style></abstract><notes><style face="normal" font="Arial">DA - 20170604IS - 1558-0520 (Electronic)IS - 0733-8635 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.det.2017.02.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28577799">PM:28577799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann N Y Acad Sci\2017-35-299-302.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann N Y Acad Sci\2017-35-299-302.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170604, Hanifin JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.det.2017.02.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guvenc,I.A.</style></author><author><style face="normal" font="Arial"> Acar,M.</style></author><author><style face="normal" font="Arial"> Muluk,N.B.</style></author><author><style face="normal" font="Arial"> Kucukcan,N.E.</style></author><author><style face="normal" font="Arial"> Cingi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ENT Department, Cigli Regional Training Hospital, Izmir, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Is there an association between migraine and allergic rhinitis?</style></title><secondary-title><style face="normal" font="Arial">Ear Nose Throat J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ear Nose Throat J</style></full-title></periodical><pages end="E23" start="E18">E18-E23</pages><volume><style face="normal" font="Arial">96</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Herbs</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE assays</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> inferior turbinate</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Neural Pathways</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Tree pollens</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">We conducted a prospective study to evaluate nasal signs and symptoms and to perform allergen-specific immunoglobulin E (IgE) testing to investigate the relationship between migraine and allergic rhinitis. Our study group consisted of 40 patients diagnosed with migraine-22 men and 18 women, aged 21 to 38 years (mean: 25.7). We compared their findings with a control group of 40 healthy adults-15 men and 25 women, aged 19 to 36 years (mean: 25.1). Allergen-specific IgE measurements were obtained with six groups of allergens: fungi, grass pollens, tree pollens, wild herbs, house dust mite 1, and house dust mite 2. We found no significant difference between the migraine patients and the controls in the incidence of nasal signs and symptoms (i.e., discharge, congestion, itching, and sneezing) or inferior turbinate signs (i.e., color and edema). According to the IgE assays, 14 migraine patients (35.0%) were sensitized to one or more allergens, compared with 11 of the controls (27.5%); the difference was not statistically significant. Sensitization was highest for the grass pollens panel in both groups. Even though we did not find an association between migraine and allergic rhinitis, the recent literature supports a correlation between migraine and atopy. The two conditions share common neural pathways and common mediators, and they can be linked statistically in patients and their families. A pathophysiologic association between the two conditions seems more likely than an etiologic association. In this regard, future efforts could be focused on the determination of atopy in migraine patients and the therapeutic implications of this diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 1942-7522 (Electronic)IS - 0145-5613 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28636737">PM:28636737</url></web-urls><related-urls><url ppv-ref="no">presto - MedLine</url></related-urls></urls><custom2><style face="normal" font="Arial">20170621, Guvenc IA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bernard,A.</style></author><author><style face="normal" font="Arial"> Sardella,A.</style></author><author><style face="normal" font="Arial"> Voisin,C.</style></author><author><style face="normal" font="Arial"> Dumont,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Louvain Centre for Toxicology and Applied Pharmacology, Institute of Experimental and Clinical Research (IREC), Catholic University of Louvain, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Nasal epithelium injury by chlorination products and other stressors predicts persistent sensitization to aeroallergens in young schoolchildren</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="152" start="145">145-152</pages><volume><style face="normal" font="Arial">158</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Bleach</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> CC16</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urea</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic sensitization during childhood is a dynamic process with a substantial rate of remission. Factors influencing this process are largely unknown. METHODS: We conducted a two-year prospective study among 121 schoolchildren (mean age, 5.8 years; 64 boys). We measured urea, club cell protein (CC16), beta2-microglobulin and albumin in nasal lavage fluid (NALF) and IgE to cat, pollen or house dust mite (HDM) in nasal mucosa fluid. RESULTS: Odds of persistent sensitization to any aeroallergen increased across baseline ascending tertiles of urea-adjusted beta2-microglobulin or albumin and descending tertiles of albumin- or beta2-microglobulin-adjusted CC16 (P-trend = 0.006, 0.02, 0.044 and 0.006, respectively). Persistent HDM sensitization also increased with baseline descending tertiles of raw or urea-adjusted CC16 (both P-trend = 0.007). Such strong associations were not observed with new-onset or remitted sensitization to any aeroallergen or with raw NALF concentrations of urea, albumin or beta2-microglobulin. At baseline, house cleaning with bleach and chlorinated pool attendance emerged among the strongest and most consistent determinants of NALF biomarkers, being both associated with higher urea and lower CC16 in NALF. CONCLUSION: In young children, a defective nasal epithelium attributable to immaturity or stressors such as chlorination products is predictive of more persistent aeroallergen sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2017.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28628840">PM:28628840</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-158-145-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-158-145-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Bernard A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2017.06.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.L.</style></author><author><style face="normal" font="Arial"> Gao,W.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Anhui Provincial Hospital, No. 17, Lujiang Road, Hefei, 230001, Anhui Province, China</style></auth-address><titles><title><style face="normal" font="Arial">Concentration-dependent effects of PM2.5 mass on expressions of adhesion molecules and inflammatory cytokines in nasal mucosa of rats with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white blood cell</style></keyword></keywords><dates><year Day="2" Month="6" Year="2017">2017/6/2</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) represents a clinical health issue affecting approximately 500 million people worldwide. This study aimed to explore the effects of airborne fine particulate matter (PM2.5) on the nasal mucosa of rats with AR. Seventy-five healthy male SD rats were included and randomly divided into the normal, model, low-concentration, middle-concentration, and high-concentration groups (15 rats each group). AR rat models were established using sensitized mixture and were stimulated using different concentrations of PM2.5. Sneeze and nose-scratching events were observed. Automatic hematology analyzer was utilized to count white blood cells (WBCs). The serum IgE, ICAM-1, and VCAM-1 expressions, eosinophil (EOS) infiltration, and IFN-gamma, IL-4, IL-5, IL-33, and TSLP expressions were detected by ELISA, HE staining, and qRT-PCR. Greater numbers of WBCs, increased IgE level, elevated levels of ICAM-1, VCAM-1, EOS, IFN-gamma, IL-4, IL-5, IL-33, and TSLP in the model, low-concentration, middle-concentration, and high-concentration groups than the normal group. The same trend also exhibited in rats of the middle-concentration and high-concentration groups than that of the model and low-concentration groups. Comparisons between normal rats and AR rats indicated that AR rats exhibit remarkably higher cytokine expression levels of IFN-gamma, IL-4, IL-5, TSLP, and IL-33. The study revealed that as stimulation is triggered by PM2.5, AR rats result in increased levels of adhesion molecules and inflammatory cytokine expressions in a concentration-dependent manner. Analyses of PM2.5 as well as, its effects on AR are crucial in the continued drive for both prevention and management of the disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170603IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4606-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28577221">PM:28577221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170603-WangYL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170603-WangYL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170603, Wang YL</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4606-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,K.J.</style></author><author><style face="normal" font="Arial"> Zhou,M.L.</style></author><author><style face="normal" font="Arial"> Xu,Y.Y.</style></author><author><style face="normal" font="Arial"> Zhou,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, #79 Qingchun Road, Hangzhou, 310003, Zhejiang, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">The role of local allergy in the nasal inflammation</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Detection methods</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> Nasal allergen provocation testing</style></keyword><keyword><style face="normal" font="Arial"> Nasal inflammation</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="Arial">Local allergic inflammation (LAI) is recognized recently. 'entopy' was used to define LAI, which was positively correlated with allergen provocation testing, local sIgE up-regulation, inflammatory mediator secretion, and a lack of systemic allergy. The study of LAI is in its infancy and focuses mainly on the respiratory system. It is closely related to nasal inflammation and plays important roles in patients with nonallergic rhinitis (NAR), nonallergic chronic sinusitis with nasal polyps (CRSwNP), and nonallergic fungal rhinosinusitis (NAFRS). Based on studies using nasal allergen provocation testing, 40-57% of patients with NAR exhibited positive results and could be diagnosed as local allergic rhinitis. Total IgE and common airborne allergen-sIgE were up-regulated in eosinophilic CRSwNP patients compared to noneosinophilic CRSwNP patients and healthy controls, possibly due to local allergic inflammation. Some researchers also found that the level of local sIgE was increased in patients with NAFRS; they suggested that local allergic inflammation occurs in NAFRS. Studies of LAI will increase our understanding of nasal inflammation and help to establish novel treatments. However, the diagnosis of local allergic inflammation is complex due to the lack of convenient detection methods. The relationship between local allergic inflammation and systemic allergic inflammation is unclear, and an appropriate treatment for local allergic inflammation is required</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4640-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28625008">PM:28625008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170618-ChengKJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170618-ChengKJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, Cheng KJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4640-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Glatstein,M.</style></author><author><style face="normal" font="Arial"> Adir,D.</style></author><author><style face="normal" font="Arial"> Galil,B.</style></author><author><style face="normal" font="Arial"> Scolnik,D.</style></author><author><style face="normal" font="Arial"> Rimon,A.</style></author><author><style face="normal" font="Arial"> Pivko-Levy,D.</style></author><author><style face="normal" font="Arial"> Hoyte,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDepartment of Pediatrics, Division of Pediatric Emergency Medicine, Dana-Dwek Children Hospital, University of Tel Aviv bThe Steinhardt Museum of Natural History, Israel National Center for Biodiversity Studies, Tel Aviv University, Tel Aviv, Israel cDenver Health and Hospital Authority, Rocky Mountain Poison and Drug Center, Denver, Colorado, USA dDepartment of Pediatrics, Divisions of Pediatric Emergency Medicine and Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Pediatric jellyfish envenomation in the Mediterranean Sea</style></title><secondary-title><style face="normal" font="Arial">Eur J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdomen</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Burns</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cellulitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chills</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health hazards</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> jellyfish</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean Sea</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Opiate</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spasm</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tachycardia</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Several species of jellyfish native to the western Indian Ocean have entered the Mediterranean Sea through the Suez Canal. Since the late 1980s, each summer Rhopilema nomadica forms swarms as long as 100 km in the southeastern Levant and since the millennium aggregations of additional nonnative jellyfish have been sighted. The aim of this study was to evaluate children seen in the emergency department after jellyfish envenomations and to establish patterns of toxicity associated with this organism. METHODS: A retrospective chart review was performed of all children presenting after jellyfish envenomations to the pediatric emergency department during the jellyfish swarming seasons (June-August) between 2010 and 2015. Extracted data included age, location of envenomation, pain scores, local and systemic manifestations, treatment provided in the emergency department and hospital, and disposition. RESULTS: Forty-one patients fulfilled the inclusion criteria; their ages ranged from 1 to 16 years and the median age was 9.4 years. Clinical manifestations were evident in all patients. Pain, present in 100% of patients, and an erythematous, whip-like, linear rash present in 87.8%, were the most common manifestations. The majority of 'burns' associated with jellyfish stings were first and second degree. The upper limb was affected in 34% and the lower limb was affected in 61% of cases. One patient suffered a sting to the abdomen and three patients suffered a sting to the face. Treatment in the emergency department included pain control, with nonsteroidal anti-inflammatory drugs and opiates, and antihistamines and topical corticosteroids in some cases. Nearly 49% of patients were seen during the summer of 2015 alone and seven patients in this group needed hospitalization. Reasons for hospitalization included systemic symptoms such as fever, chills, tachycardia, and muscle spasms. Two patients developed severe cellulitis, one patient had an anaphylactic reaction, and one was admitted to the ICU after suffering an anaphylactic reaction to a sting sustained while surfing. CONCLUSION: The prevalence of the jellyfish swarms and the severity of clinical manifestations because of their envenomations suggest that it should be considered as a health hazard in the Mediterranean Sea. We call for public health authorities in affected countries to initiate a health hazards database, familiarize medical and healthcare staff with the clinical syndromes, train medical and healthcare staff` in appropriate treatment, and initiate and continue public awareness campaigns</style></abstract><notes><style face="normal" font="Arial">DA - 20170622IS - 1473-5695 (Electronic)IS - 0969-9546 (Linking)LA - engPT - Journal ArticleCO - Israel -CO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1097/MEJ.0000000000000479</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28639958">PM:28639958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Emerg Med\20170622-GlatsteinM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Emerg Med\20170622-GlatsteinM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170622, Glatstein M</style></custom2><misc3><style face="normal" font="Arial">10.1097/MEJ.0000000000000479</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,C.N.</style></author><author><style face="normal" font="Arial"> Lee,Y.L.</style></author><author><style face="normal" font="Arial"> Lin,Y.P.</style></author><author><style face="normal" font="Arial"> Chung,W.H.</style></author><author><style face="normal" font="Arial"> Tzeng,Y.M.</style></author><author><style face="normal" font="Arial"> Lee,C.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Basic Medical Science, College of Medicine, China Medical University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Ovatodiolide suppresses allergic airway inflammation and hyperresponsiveness in a murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">Asthma, a complex pulmonary allergic disease, major therapy is applied of drugs to control the disease, but quickly recur after the drugs are stopped. In patients with severe asthma may show steroid resistance and would benefit from the development of novel therapeutic drugs. Ovatodiolide, a unique macrocyclic diterpenoid isolated from Anisomeles indica, showed therapeutic potential for the treatment of allergic asthma. As a model of allergic inflammation, we used ovalbumin (OVA)-immunized mice, which displayed T helper cell type 2 (TH2) cytokine expression in bronchoalveolar lavage fluid (BALF), as well as airway inflammation and hyperresponsiveness (AHR). The results showed that ovatodiolide suppressed TH2 activation, including cell proliferation and production of the TH2 related cytokines, interleukin (IL)-4, IL-5, IL-13, IL-33, eosinophil chemotactic protein (eotaxin), and also reduced airway hyperresponsiveness. In this study, ovatodiolide inhibited allergic asthma through downregulation of TH2 responses in a murine model of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.06.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28666799">PM:28666799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20170701-WangCN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20170701-WangCN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Wang CN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.06.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Occelli,A.</style></author><author><style face="normal" font="Arial"> Soize,S.</style></author><author><style face="normal" font="Arial"> Ranc,C.</style></author><author><style face="normal" font="Arial"> Giovannini-Chami,L.</style></author><author><style face="normal" font="Arial"> Bailly,C.</style></author><author><style face="normal" font="Arial"> Leloutre,B.</style></author><author><style face="normal" font="Arial"> Boyer,C.</style></author><author><style face="normal" font="Arial"> Baque-Juston,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Bronchocele density in cystic fibrosis as an indicator of allergic broncho-pulmonary aspergillosis: A preliminary study</style></title><secondary-title><style face="normal" font="Arial">Eur J Radiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Radiol</style></full-title></periodical><pages end="199" start="195">195-199</pages><volume><style face="normal" font="Arial">93</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic broncho-pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Chest computed tomography scan</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> CT scan</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> High-attenuation mucus</style></keyword><keyword><style face="normal" font="Arial"> Hyperdense bronchocele</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><isbn><style face="normal" font="Arial">0720-048X</style></isbn><abstract><style face="normal" font="Arial">Objective Allergic broncho-pulmonary aspergillosis (ABPA) is a severe and under-diagnosed complication of cystic fibrosis (CF). The aim of the study was to determine whether the mucus content of bronchoceles in cystic fibrosis complicated with ABPA reveals a higher density than the mucus content of non-ABPA cystic fibrosis. Materials and methods We studied retrospectively 43 computed tomography scans (CT scans) of a pediatric population of cystic fibrosis patients. We measured the mucus attenuation in Hounsfield Units (HU) of all bronchoceles &amp;gt;5 mm in diameter. Results We found bronchoceles &amp;gt;5 mm in 13/43 patients. 5/13 patients had a positive diagnosis of ABPA. The median HU value of bronchoceles was higher in patients with than without ABPA [98 HU (26</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô135) vs 28 HU (10</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô36); P = 0,02]. Moreover, all patients with a bronchocele density &amp;gt;36HU were ABPA positive. Conclusions CF complicated with ABPA shows higher attenuation bronchoceles on CT scans of the chest. Systematic density measurements of bronchoceles could help to raise the difficult diagnosis of ABPA in patients suffering from cystic fibrosis. Larger series could confirm a threshold in HU which could become a new imaging criterion for the diagnosis of ABPA</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejrad.2017.05.047</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ejrad.2017.05.047</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Radiol\2017-93-195-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Radiol\2017-93-195-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Occelli A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejrad.2017.05.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,Q.</style></author><author><style face="normal" font="Arial"> Yang,C.Y.</style></author><author><style face="normal" font="Arial"> Guo,B.Y.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Liaocheng People's Hospital, Liaocheng, Shandong, China.</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of mechanism of PM2.5 and house dust mite antigen Der p1 in attack stage of child asthma</style></title><secondary-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></full-title></periodical><pages end="2462" start="2458">2458-2462</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: We analyzed the influence of PM2.5 and house dust mite antigen Der p1 on the treatment of child asthma attack. PATIENTS AND METHODS: A total of 96 children with asthma attack were included into the study. The patients were randomly divided into the PM2.5 group, the house dust mite antigen group, the synergistic group and the control group (n= 24 in each group). RESULTS: The PM2.5 concentration in the PM2.5 group was twice higher than standard level (&lt;/= the average value of PM2.5 in local air). All cases were given with same treatment, and the treatment effects were compared and analyzed. It was found that the asthma control rate in the control group was significantly higher than that in the PM2.5 group and the house dust mite antigen group, and the synergistic group was the lowest. The control time in the synergistic group was significantly longest, followed by the PM2.5 group and the house dust mite antigen group, and the control group was significantly short (p&lt;0.05). After the intervention, the FVC, FEV1, and PEF levels were all increased. Those in control group were significantly higher than those of PM2.5 group and Dermatophagoides pteronyssinus group. Indicators in the collaborative group were the lowest. Differences were statistically significant (p&lt;0.05). The differences in the PM2.5 group and Dermatophagoides pteronyssinus group were not statistically significant. The contents of serum IL-25, TSLP, and malondialdehyde after treatment of the control group significantly lowered while the other three groups showed a significant higher (p&lt;0.05). CONCLUSIONS: The PM2.5 and house dust mite antigen Der p1 can influence the treating effects of child asthma attack by an inflammatory reaction and oxidative stress</style></abstract><notes><style face="normal" font="Arial">DA - 20170615IS - 2284-0729 (Electronic)IS - 1128-3602 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28617540">PM:28617540</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Rev Med Pharmacol Sci\2017-21-2458-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Rev Med Pharmacol Sci\2017-21-2458-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Cheng Q</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,G.</style></author><author><style face="normal" font="Arial"> Duan,X.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author><author><style face="normal" font="Arial"> Chen,P.</style></author><author><style face="normal" font="Arial"> Yu,J.</style></author><author><style face="normal" font="Arial"> Zheng,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Chinese Materia Medica, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650500, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Immunoregulatory effects of the traditional Dai prescription Yajieshaba on food allergic mice</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="3182" start="3175">3175-3182</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-21</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Loratadine</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">The Dai prescription Yajieshaba is widely used in Traditional Dai Medicine to treat food allergies and intolerance. However, information on the active chemical ingredients, effects and mechanisms of action of Yajieshaba is limited. The present study aimed to elucidate the effects and underlying mechanisms of Yajieshaba in the treatment of food allergies. Liquid chromatography with a diode array detector was used to measure the levels of palmatine and berberine, the active ingredients of Yajieshaba. A food allergy model was established in female BALB/c mice by three injections of ovalbumin (OVA) at 0, 48, and 96 h. OVA-sensitized mice recieved no treatments (control), Yajieshaba, loratadine, palmatine or berberine. The scratching frequency, serum immunoglobulin (Ig)G, IgE, interleukin (IL)-4, IL-10, IL-17, IL-21, interferon-gamma and tumor necrosis factor-alpha levels were assessed at 50 and 98 h. The percentage of regulatory T cells (Tregs) was evaluated by flow cytometry at 98 h. The scratching frequency induced by OVA was significantly suppressed in mice treated with loratadine, palmatine, berberine or 3.50 and 4.70 g/kg Yajieshaba. The frequency of CD4+CD25+Treg in the spleen increased from 6.80% in mice in the control group to 12.50% in mice treated with 4.70 g/kg body weight Yajieshaba. Mice treated with palmatine or 4.70 g/kg body weight Yajieshaba had increased forkhead box p3 expression compared with those in the control group. Treatment with Yajieshaba decreased the scratching frequency and increased CD4+CD25+Foxp3+ Treg frequency in the spleen. This indicated that symptoms of allergic reaction were alleviated following Yajieshaba treatment. Palmatine was identified as one of the major active components of Yajieshaba. The present study identified the possible mechanism through which Yajieshaba treatment may alleviate food allergy symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4442</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587391">PM:28587391</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-13-3175-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-13-3175-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Zhang G</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4442</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Royce,S.G.</style></author><author><style face="normal" font="Arial"> Rele,S.</style></author><author><style face="normal" font="Arial"> Broughton,B.R.S.</style></author><author><style face="normal" font="Arial"> Kelly,K.</style></author><author><style face="normal" font="Arial"> Samuel,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fibrosis Laboratory, Monash University, Clayton, Victoria, Australia;</style></auth-address><titles><title><style face="normal" font="Arial">Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease</style></title><secondary-title><style face="normal" font="Arial">FASEB J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">FASEB J</style></full-title></periodical><pages end="4178" start="4168">4168-4178</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic airways disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="Arial">Structural changes known as airway remodeling (AWR) characterize chronic/severe asthma and contribute to lung dysfunction. Thus, we assessed the in vivo efficacy of induced pluripotent stem cell and mesenchymoangioblast-derived mesenchymal stem cells (MCA-MSCs) on AWR in a murine model of chronic allergic airways disease (AAD)/asthma. Female Balb/c mice were subjected to a 9-wk model of ovalbumin (OVA)-induced chronic AAD and treated intravenously or intranasally with MCA-MSCs from weeks 9 to11. Changes in airway inflammation (AI), AWR, and airway hyperresponsiveness (AHR) were assessed. OVA-injured mice presented with AI, goblet cell metaplasia, epithelial thickening, increased airway TGF-beta1 levels, subepithelial myofibroblast and collagen accumulation, total lung collagen concentration, and AHR (all P &lt; 0.001 vs. uninjured control group). Apart from epithelial thickness, all other parameters measured were significantly, although not totally, decreased by intravenous delivery of MCA-MSCs to OVA-injured mice. In comparison, intranasal delivery of MCA-MSCs to OVA-injured mice significantly decreased all parameters measured (all P &lt; 0.05 vs. OVA group) and, most notably, normalized aberrant airway TGF-beta1 levels, airway/lung fibrosis, and AHR to values measured in uninjured animals. MCA-MSCs also increased collagen-degrading gelatinase levels. Hence, direct delivery of MCA-MSCs offers great therapeutic benefit for the AWR and AHR associated with chronic AAD.-Royce, S. G., Rele, S., Broughton, B. R. S., Kelly, K., Samuel, C. S. Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1530-6860 (Electronic)IS - 0892-6638 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1096/fj.201700178R</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28626025">PM:28626025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FASEB J\20170619-RoyceSG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FASEB J\20170619-RoyceSG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Royce SG</style></custom2><misc3><style face="normal" font="Arial">10.1096/fj.201700178R</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,K.R.</style></author><author><style face="normal" font="Arial"> Bai,Y.</style></author><author><style face="normal" font="Arial"> Trieu,K.G.</style></author><author><style face="normal" font="Arial"> Barrios,J.</style></author><author><style face="normal" font="Arial"> Ai,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">Targeting acetylcholine receptor M3 prevents the progression of airway hyperreactivity in a mouse model of childhood asthma</style></title><secondary-title><style face="normal" font="Arial">FASEB J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">FASEB J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylcholine</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early intervention</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">Asthma often progresses into adulthood from early-life episodes of adverse environmental exposures. However, how the injury to developing lungs contributes to the pathophysiology of persistent asthma remains poorly understood. In this study, we identified an age-related mechanism along the cholinergic nerve-airway smooth muscle (ASM) axis that underlies prolonged airway hyperreactivity (AHR) in mice. We showed that ASM continued to mature until approximately 3 wk after birth. Coinciding with postnatal ASM maturation, there was a critical time window for the development of ASM hypercontractility after cholinergic stimulation. We found that allergen exposure in neonatal mice, but not in adult mice, elevated the level and activity of cholinergic nerves (termed neuroplasticity). We demonstrated that cholinergic neuroplasticity is necessary for the induction of persistent AHR after neonatal exposure during rescue assays in mice deficient in neuroplasticity. In addition, early intervention with cholinergic receptor muscarinic (ChRM)-3 blocker reversed the progression of AHR in the neonatal exposure model, whereas beta2-adrenoceptor agonists had no such effect. Together, our findings demonstrate a functional relationship between cholinergic neuroplasticity and ASM contractile phenotypes that operates uniquely in early life to induce persistent AHR after allergen exposure. Targeting ChRM3 may have disease-modifying benefits in childhood asthma.-Patel, K. R., Bai, Y., Trieu, K. G., Barrios, J., Ai, X. Targeting acetylcholine receptor M3 prevents the progression of airway hyperreactivity in a mouse model of childhood asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170616IS - 1530-6860 (Electronic)IS - 0892-6638 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1096/fj.201700186R</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28619712">PM:28619712</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FASEB J\20170616-PatelKR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FASEB J\20170616-PatelKR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170616, Patel KR</style></custom2><misc3><style face="normal" font="Arial">10.1096/fj.201700186R</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohammadi,M.</style></author><author><style face="normal" font="Arial"> Mokhtarian,K.</style></author><author><style face="normal" font="Arial"> Kardar,G.A.</style></author><author><style face="normal" font="Arial"> Farrokhi,S.</style></author><author><style face="normal" font="Arial"> Sadroddiny,E.</style></author><author><style face="normal" font="Arial"> Khorramizadeh,M.R.</style></author><author><style face="normal" font="Arial"> Falak,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Expression of recombinant parvalbumin from wolf-herring fish and determination of its IgE-binding capability</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="585" start="573">573-585</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Carp</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumins</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">In this study, we produced the recombinant form of parvalbumin from wolf-herring fish and determined its IgE reactivity. Parvalbumin cDNA was sub-cloned into pET28 and expressed in Escherichia coli BL-21. The immunoreactivities of the recombinant and native parvalbumins were compared, and the effect of calcium binding was determined by sera from 25 fish-allergic patients. ELISA and Western blotting confirmed similar IgE-reactivities of the recombinant and native proteins and confirmed that this phenomenon is highly dependent on calcium binding. The recombinant protein was 94.5% similar to carp parvalbumin (Cyp c1). Approximately 72% of patients reacted strongly with recombinant parvalbumin, 80% of them reacted with the native form and only 56% showed IgE reactivity with crude extract. Because the IgE-binding capacity of recombinant wolf-herring parvalbumin is retained and is highly similar to Cyp c1, the wild and hypoallergenic forms of this allergen could be used for diagnosis and immunotherapy of fish allergy, respectively</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1306493</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1306493</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-573-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-573-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Mohammadi M</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1306493</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chung,J.H.</style></author><author><style face="normal" font="Arial"> Kong,J.N.</style></author><author><style face="normal" font="Arial"> Choi,H.E.</style></author><author><style face="normal" font="Arial"> Kong,K.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Antioxidant, anti-inflammatory, and anti-allergic activities of the sweet-tasting protein brazzein</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antibacterial</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Beverages</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> Brazzein</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase-2</style></keyword><keyword><style face="normal" font="Arial"> defensin</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Functional sweetener</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> sugar substitutes</style></keyword><keyword><style face="normal" font="Arial"> Sweet tasting protein</style></keyword><keyword><style face="normal" font="Arial"> Sweet-tasting protein</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">Sweet-tasting proteins may be useful as low-calorie sugar substitutes in foods, beverages, and medicines. Brazzein is an attractive sweetener because of its high sweetness, sugar-like taste, and good stability at high temperature and wide pH ranges. To investigate the bioactivities of brazzein, the antibacterial, antifungal, antioxidant, anti-inflammatory, and anti-allergic activities were determined in vitro. Brazzein showed no antibacterial and antifungal activities, although it showed approximately 45% or greater similarity to defensin, which has antimicrobial effects, and drosomycin, which is used as an antifungal agent. However, brazzein exhibited strong antioxidant effects, showing ABTS radical scavenging activity (IC50 = 12.55 ++M) and DPPH activity (IC50 &amp;gt; 30 ++M). Brazzein also showed anti-inflammatory activity and anti-allergic activity in a +¦-hexosaminidase assay (IC50 &amp;gt; 15 ++M) and cyclooxygenase-2 inhibition assay (IC50 = 12.62 ++M), respectively. These results suggest that brazzein has antioxidant, anti-inflammatory, and anti-allergic activities and considerable potential as a functional sweetener</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.06.084</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodchem.2017.06.084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\20170609-ChungJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\20170609-ChungJH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170609, Chung JH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.06.084</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Duan,L.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Ma,P.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Xu,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Environment and Health (Huazhong University of Science and Technology), Ministry of Education &amp; Ministry of Environmental Protection, Wuhan, 430030, China</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin E antagonizes ozone-induced asthma exacerbation in Balb/c mice through the Nrf2 pathway</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="56" start="47">47-56</pages><volume><style face="normal" font="Arial">107</style></volume><number><style face="normal" font="Arial">Pt A</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin E</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">Millions of people are regularly exposed to ozone, a gas known to contribute significantly to worsening the symptoms of patients with asthma. However, the mechanisms underlying these ozone exacerbation effects are not fully understood. In this study, we examined the exacerbation effect of ozone in OVA-induced asthma mice and tried to demonstrate the protective mechanism of vitamin E (VE). An asthma mouse model was established, and used to identify the exacerbating effects of ozone by assessing cytokine and serum immunoglobulin concentrations, airway leukocyte infiltration, histopathological changes in lung tissues, and airway hyper-responsiveness. We then determined the amount of reactive oxygen species (ROS) accumulated, the extent to which VE induced ROS elimination, and examined the antagonistic effects of VE on the ozone-induced exacerbating effects. This study showed that 1-ppm ozone exposure could exacerbate OVA-induced asthma in mice. More importantly we found that ozone induced oxidative stress in asthmatic airways may lead to the inhibition of Nuclear factor-erythroid 2-related factor 2 (Nrf2), and may subsequently induce even more exaggerated oxidative stress associated with asthma exacerbation. Through VE induced Nrf2 activation and the subsequent increase in Nrf2 target protein expression, this study suggests a novel mechanism for alleviating ozone exacerbated asthma symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2017.06.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624471">PM:28624471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2017-107-47-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2017-107-47-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, Duan L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2017.06.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Di Stasio,L.</style></author><author><style face="normal" font="Arial"> Picariello,G.</style></author><author><style face="normal" font="Arial"> Mongiello,M.</style></author><author><style face="normal" font="Arial"> Nocerino,R.</style></author><author><style face="normal" font="Arial"> Canani,R.B.</style></author><author><style face="normal" font="Arial"> Bavaro,S.</style></author><author><style face="normal" font="Arial"> Monaci,L.</style></author><author><style face="normal" font="Arial"> Ferranti,P.</style></author><author><style face="normal" font="Arial"> Mamone,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Food Sciences, CNR, Avellino, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Peanut digestome: Identification of digestion resistant IgE binding peptides</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="98" start="88">88-98</pages><volume><style face="normal" font="Arial">107</style></volume><number><style face="normal" font="Arial">Pt A</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 3</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestibility models</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Digestive tract</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal digestion</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> RP-HPLC</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="Arial">Stability to proteolytic degradation in the digestive tract is considered a general feature shared by most food allergens. Current digestibility models exclusively utilize purified allergen proteins, neglecting the relevant effects of matrix that occur for foodstuff systems. In the present study, we investigated digestion stability of the major peanut allergens directly in the natural matrix using an in vitro static model that simulates the gastrointestinal digestion including the oral, gastric, duodenal and intestinal (brush border membrane enzymes) phases. Immunogenicity was evaluated by Western Blot using N=8 pooled sera of peanut allergic pediatric subjects. Immunoreactive, large-sized and fragments of Ara h 2, Ara h 6 and Ara h 3 survived hydrolysis as assessed by SDS-PAGE. Smaller resistant peptides mainly arising from Ara h 3 and also Ara h 1 were detected and further identified by LC-high resolution-MS/MS. RP-HPLC purification followed by dot-blot analysis and MS/MS-based identification demonstrated that stable IgE-binding peptides derived from Ara h 3. These results provide a more realistic picture of the potentially allergenic determinants of peanuts that survived the human digestion, taking into account the role of the food matrix, which may significantly affect gastrointestinal breakdown of peanut allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2017.06.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634114">PM:28634114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2017-107-88-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2017-107-88-98.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2017-107-88-98mmc2.xlsxF:\A&amp;H HMW Papers\Food Chem Toxicol\2017-107-88-98mmc2.xlsx</url></related-urls><image-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2017-107-88-98mmc3.xlsxF:\A&amp;H HMW Papers\Food Chem Toxicol\2017-107-88-98mmc3.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20160621, Di Stasio L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2017.06.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Javed,B.</style></author><author><style face="normal" font="Arial"> Padfield,P.</style></author><author><style face="normal" font="Arial"> Sperrin,M.</style></author><author><style face="normal" font="Arial"> Simpson,A.</style></author><author><style face="normal" font="Arial"> Mills,E.N.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Manchester Institute of Biotechnology, Manchester M17DN, UK</style></auth-address><titles><title><style face="normal" font="Arial">A protocol for a systematic review to identify allergenic tree nuts and the molecules responsible for their allergenic properties</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="416" start="411">411-416</pages><volume><style face="normal" font="Arial">106</style></volume><number><style face="normal" font="Arial">Pt A</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Detection methods</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food label</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="5" Month="6" Year="2017">2017/6/5</year></dates><abstract><style face="normal" font="Arial">Food regulations require that tree nuts and derived ingredients are included on food labels in order to help individuals with IgE-mediated allergies to avoid them. However, there is no consensus regarding which tree nut species should be included in this definition and specified on food labels. Allergen detection methods used for monitoring foods target allergen molecules, but it not clear which are the most relevant molecules to choose. A modified population-exposure-comparators-outcome (PECO) approach has been developed to systematically review the evidence regarding (1) which allergenic tree nuts should be included in food allergen labelling lists and (2) which are the clinically relevant allergens which should be used as analytical targets. A search strategy and criteria against which the evidence will be evaluated have been developed. The resulting evidence will be used to rank tree nuts with regards their ability to cause IgE-mediated allergies, and allergen molecules regarding their capacity to elicit an allergic reaction. The results of the systematic review will enable risk assessors and managers to identify tree nut species that should be included in food allergen labelling lists and ensure analytical methods for determination of allergens in foods are targeting appropriate molecules</style></abstract><notes><style face="normal" font="Arial">DA - 20170609IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2017.06.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28595954">PM:28595954</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2017-106-411-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2017-106-411-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170609, Javed B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2017.06.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blom,W.M.</style></author><author><style face="normal" font="Arial"> Kruizinga,A.G.</style></author><author><style face="normal" font="Arial"> Rubingh,C.M.</style></author><author><style face="normal" font="Arial"> Remington,B.C.</style></author><author><style face="normal" font="Arial"> Crevel,R.W.R.</style></author><author><style face="normal" font="Arial"> Houben,G.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Netherlands Organisation for Applied Scientific Research TNO, Zeist, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Assessing food allergy risks from residual peanut protein in highly refined vegetable oil</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="313" start="306">306-313</pages><volume><style face="normal" font="Arial">106</style></volume><number><style face="normal" font="Arial">Pt A</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross contact</style></keyword><keyword><style face="normal" font="Arial"> Cross-contact</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Oils</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut oil</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanut proteins</style></keyword><keyword><style face="normal" font="Arial"> precautionary labelling</style></keyword><keyword><style face="normal" font="Arial"> Probabilistic risk assessment</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetable oil</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="Arial">Refined vegetable oils including refined peanut oil are widely used in foods. Due to shared production processes, refined non-peanut vegetable oils can contain residual peanut proteins. We estimated the predicted number of allergic reactions to residual peanut proteins using probabilistic risk assessment applied to several scenarios involving food products made with vegetable oils. Variables considered were: a) the estimated production scale of refined peanut oil, b) estimated cross-contact between refined vegetable oils during production, c) the proportion of fat in representative food products and d) the peanut protein concentration in refined peanut oil. For all products examined the predicted risk of objective allergic reactions in peanut-allergic users of the food products was extremely low. The number of predicted reactions ranged depending on the model from a high of 3 per 1000 eating occasions (Weibull) to no reactions (LogNormal). Significantly, all reactions were predicted for allergen intakes well below the amounts reported for the most sensitive individual described in the clinical literature. We conclude that the health risk from cross-contact between vegetable oils and refined peanut oil is negligible. None of the food products would warrant precautionary labelling for peanut according to the VITAL(R) programme of the Allergen Bureau</style></abstract><notes><style face="normal" font="Arial">DA - 20170604IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2017.05.072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28578104">PM:28578104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2017-106-306-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2017-106-306-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170604, Blom WM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2017.05.072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bogahawaththa,D.</style></author><author><style face="normal" font="Arial"> Chandrapala,J.</style></author><author><style face="normal" font="Arial"> Vasiljevic,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Thermal denaturation of bovine immunoglobulin G and its association with other whey proteins</style></title><secondary-title><style face="normal" font="Arial">Food Hydrocolloid</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Hydrocolloid</style></full-title></periodical><pages end="357" start="350">350-357</pages><volume><style face="normal" font="Arial">72</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> Covalent-complex</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> thermal effect</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><isbn><style face="normal" font="Arial">0268-005X</style></isbn><abstract><style face="normal" font="Arial">Thermal denaturation of bovine immunoglobulin G (IgG) was studied alone and in the presence of major whey proteins. The two heating regimes studied provided the simulated thermal effect compared to high-temperature short-time (HTST, 72-á-¦C/15s) and ultra-high temperature (UHT, 100-á-¦C/30s equivalent to 140-¦C/5s in terms of denaturation of +¦-lactoglobulin) conditions. Simulated HTST conditions least impacted on the secondary structure of IgG and other whey proteins when they were present either alone or in mixtures of whey proteins. The heating at 100-á-¦C for 30s caused formation of covalent-complexes of IgG alone, as well as in the mixtures, mainly through thiol-disulfide reactions. Under 100-á-¦C/30s treatment, bovine serum albumin (BSA) did not interact with IgG through thiol-disulfide reactions in a binary mixture of proteins (IgG and BSA). +¦-Lactalbumin (ALA) appeared to preferentially lead denaturation of whey proteins over +¦-lactoglobulin (BLG), in a protein mixture (BLG, ALA, IgG, and BSA), suggesting a possible catalytic role by BSA and/or IgG on ALA, while native whey contains another component that can inhibit this effect. The presence of other whey proteins did not contribute to thermal stability of IgG at 100-á-¦C</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodhyd.2017.06.017</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodhyd.2017.06.017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Hydrocolloid\2017-72-350-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Hydrocolloid\2017-72-350-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Bogahawaththa D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodhyd.2017.06.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferreira,S.S.</style></author><author><style face="normal" font="Arial"> Nunes,F.P.B.</style></author><author><style face="normal" font="Arial"> Casagrande,F.B.</style></author><author><style face="normal" font="Arial"> Martins,J.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunoendocrinology, Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences of University Sao Paulo (FCF/USP), Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Insulin Modulates Cytokine Release, Collagen and Mucus Secretion in Lung Remodeling of Allergic Diabetic Mice</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="633">633-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Glucose</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> cell migration</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Protamine</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The role of insulin in lung remodeling in a model of asthma in healthy and diabetic mice was evaluated. MATERIAL AND METHODS: Diabetic male BALB/c mice (alloxan, 50 mg/kg, intravenous) and controls were sensitized by subcutaneous (s.c.) injection of ovalbumin (OA, 20 microg) in aluminum hydroxide (Al(OH)3, 2 mg) 10 days after the alloxan injection and received the same dose 12 days later. Six days after the last sensitization, animals were nebulized with OA solution for 7 days. The first set of diabetic and control mice received 2 and 1 IU, respectively, of s.c. neutral protamine Hagedorn (NPH) insulin and were analyzed 8 h later. The second set of diabetic and control mice received 2 and 1 IU, respectively, of insulin 12 h before the OA challenge and half doses of insulin 2 h before each the seven OA challenges. Twenty-four hours after the last challenge, the following analyses were performed: (a) quantification of the cells in the bronchoalveolar lavage fluid (BALF), the white cell count, and blood glucose; (b) morphological analysis of lung tissues by hematoxylin and eosin staining; (c) quantification of collagen deposition in lung tissues and mucus by morphometric analysis of histological sections stained with Masson's trichrome and periodic acid-Schiff (PAS), respectively; and (d) quantification of the cytokine concentrations (IL-4, IL-5, and IL-13) in the BALF supernatant. RESULTS: Compared to controls, diabetic mice had significantly reduced inflammatory cells (81%) in the BALF, no eosinophils in the BALF and peripheral blood and reduced collagen deposition and mucus in the lungs. BALF concentrations of IL-4 (48%) and IL-5 (31%) decreased and IL-13 was absent. A single dose of insulin restored peripheral blood eosinophils and BALF mononuclear cells but not BALF eosinophils, collagen deposition, and mucus levels. However, multiple doses of insulin restored both total cells and eosinophils in the BALF and peripheral blood, BALF cytokines, and collagen deposition and mucus secretion into the lungs. CONCLUSION: The results suggest that insulin modulates the production/release of cytokines, cell migration, deposition of collagen, and mucus secretion in lung remodeling of a mouse model of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170626IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00633</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28649241">PM:28649241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-633.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-633.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170626, Ferreira SS</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00633</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,Q.</style></author><author><style face="normal" font="Arial"> Chu,Z.</style></author><author><style face="normal" font="Arial"> Zhu,L.</style></author><author><style face="normal" font="Arial"> Yang,T.</style></author><author><style face="normal" font="Arial"> Wang,P.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Zhang,F.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Ding,W.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">2-Deoxy-d-Glucose Treatment Decreases Anti-inflammatory M2 Macrophage Polarization in Mice with Tumor and Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="637">637-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cell Death</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Chitin</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glycolysis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophage polarization</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">As important effector cells in inflammation, macrophages can be functionally polarized into either inflammatory M1 or alternatively activated anti-inflammatory M2 phenotype depending on surroundings. The key roles of glycolysis in M1 macrophage polarization have been well defined. However, the relationship between glycolysis and M2 polarized macrophages is still poorly understood. Here, we report that 2-deoxy-d-glucose (2-DG), an inhibitor of the glycolytic pathway, markedly inhibited the expressions of Arg, Ym-1, Fizz1, and CD206 molecules, the hall-markers for M2 macrophages, during macrophages were stimulated with interleukin 4. The impacted M2 macrophage polarization by 2-DG is not due to cell death but caused by the impaired cellular glycolysis. Molecular mechanism studies indicate that the effect of 2-DG on M2 polarized macrophages relies on AMPK-Hif-1alpha-dependent pathways. Importantly, 2-DG treatment significantly decreases anti-inflammatory M2 macrophage polarization and prevents disease progression in a series of mouse models with chitin administration, tumor, and allergic airway inflammation. Thus, the identification of the master role of glycolysis in M2 macrophage polarization offers potential molecular targets for M2 macrophages-mediated diseases. 2-DG therapy may have beneficial effects in patients with tumors or allergic airway inflammation by its negative regulation on M2 macrophage polarization</style></abstract><notes><style face="normal" font="Arial">DA - 20170616IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00637</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28620389">PM:28620389</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-637.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-637.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170616, Zhao Q</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00637</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rao,S.P.</style></author><author><style face="normal" font="Arial"> Ge,X.N.</style></author><author><style face="normal" font="Arial"> Sriramarao,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States</style></auth-address><titles><title><style face="normal" font="Arial">Regulation of Eosinophil Recruitment and Activation by Galectins in Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Med (Lausanne)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Med (Lausanne)</style></full-title></periodical><pages end="" start="68">68-</pages><volume><style face="normal" font="Arial">4</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Galectin 1</style></keyword><keyword><style face="normal" font="Arial"> Galectin 3</style></keyword><keyword><style face="normal" font="Arial"> Galectins</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> growth factors</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> trafficking</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Eosinophils are differentiated granulocytes that are recruited from the bone marrow to sites of inflammation via the vascular system. Allergic asthma is characterized by the presence of large numbers of eosinophils in the lungs and airways. Due to their capacity to rapidly release inflammatory mediators such as cytokines, chemokines, growth factors, and cytotoxic granule proteins upon stimulation, eosinophils play a critical role in pro-inflammatory processes in allergen-exposed lungs. Identifying key players and understanding the molecular mechanisms directing eosinophil trafficking and recruitment to inflamed airways is a key to developing therapeutic strategies to limit their influx. Recent studies have brought to light the important role of glycans and glycan binding proteins in regulating recruitment of eosinophils. In addition to the role of previously identified eosinophil- and endothelial-expressed adhesion molecules in mediating eosinophil trafficking and recruitment to the inflamed airways, studies have also indicated a role for galectins (galectin-3) in this process. Galectins are mammalian lectins expressed by various cell types including eosinophils. Intracellularly, they can regulate biological processes such as cell motility. Extracellularly, galectins interact with beta-galactosides in cell surface-expressed glycans to regulate cellular responses like production of inflammatory mediators, cell adhesion, migration, and apoptosis. Eosinophils express galectins intracellularly or on the cell surface where they interact with cell surface glycoconjugate receptors. Depending on the type (galectin-1, -3, etc.) and location (extracellular or intracellular, endogenous or exogenously delivered), galectins differentially regulate eosinophil recruitment, activation, and apoptosis and thus exert a pro- or anti-inflammatory outcome. Here, we have reviewed information pertaining to galectins (galectin-1, -3 -9, and -10) that are expressed by eosinophils themselves and/or other cells that play a role in eosinophil recruitment and function in the context of allergic asthma and their potential use as disease biomarkers or therapeutic targets for immunomodulation</style></abstract><notes><style face="normal" font="Arial">DA - 20170616IS - 2296-858X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3389/fmed.2017.00068</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28620605">PM:28620605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Med (Lausanne)\2017-4-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Med (Lausanne)\2017-4-68.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170616, Rao SP</style></custom2><misc3><style face="normal" font="Arial">10.3389/fmed.2017.00068</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miftahussurur,M.</style></author><author><style face="normal" font="Arial"> Nusi,I.A.</style></author><author><style face="normal" font="Arial"> Graham,D.Y.</style></author><author><style face="normal" font="Arial"> Yamaoka,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Gastroenterology and Hepatology Section, Department of Medicine, Baylor College of MedicineHouston, TX, United States</style></auth-address><titles><title><style face="normal" font="Arial">Helicobacter, Hygiene, Atopy, and Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Microbiol</style></full-title></periodical><pages end="" start="1034">1034-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Gastritis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Indonesia</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> inverse correlation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Peptic Ulcer</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Suggestion</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Ulcer</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The hygiene hypothesis links environmental and microbial exposures in early life to the prevalence of atopy, allergy, and asthma. Helicobacter pylori infection is typically acquired in childhood and acquisition of the infection is associated with poor household hygiene. Some population surveys have shown an inverse association between H. pylori infection and atopy, allergy, and asthma leading to the suggestion that H. pylori infection may be protective against disease; others consider it simply a biomarker for poor household hygiene. We review the relevant surveys, cohort studies, meta-analyses, and studies testing the protective hypothesis. Overall, the results of surveys and cohort studies are inconsistent, whereas meta-analyses show a significant but weak inverse correlation. In contrast, studies directly testing the protection hypothesis in relation to asthma in populations with poor hygiene and low H. pylori prevalence failed to confirm a protective effect. H. pylori is a major cause of human disease including chronic gastritis, peptic ulcer, and gastric malignancies. H. pylori infections most likely serve as a biomarker for poor hygienic conditions in childhood. We conclude that while synergistic interactions between environmental factors in childhood are important determinants of the pathogenesis of atopy, allergy, and asthma; H. pylori is inversely related to good hygiene and thus it's presence serves as a biomarker rather than for a specific prevention role for H. pylori or H. pylori antigens</style></abstract><notes><style face="normal" font="Arial">DA - 20170623IS - 1664-302X (Print)IS - 1664-302X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Japan -CO - Indonesia -</style></notes><work-type><style face="normal" font="Arial">10.3389/fmicb.2017.01034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28642748">PM:28642748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Microbiol\2017-8-1034.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Microbiol\2017-8-1034.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170623, Miftahussurur M</style></custom2><misc3><style face="normal" font="Arial">10.3389/fmicb.2017.01034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Comberiati,P.</style></author><author><style face="normal" font="Arial"> Di Cicco,M.E.</style></author><author><style face="normal" font="Arial"> D'Elios,S.</style></author><author><style face="normal" font="Arial"> Peroni,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, University of Verona, Verona, Italy</style></auth-address><titles><title><style face="normal" font="Arial">How Much Asthma Is Atopic in Children?</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="122">122-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 2296-2360 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00122</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28603709">PM:28603709</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-122.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-122.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Comberiati P</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00122</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caggiano,S.</style></author><author><style face="normal" font="Arial"> Cutrera,R.</style></author><author><style face="normal" font="Arial"> Di Marco,A.</style></author><author><style face="normal" font="Arial"> Turchetta,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Intermediate Care Unit, Pediatric Department, Bambino Gesu Children's Hospital, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Exercise-Induced Bronchospasm and Allergy</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="131">131-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adult asthma</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> exercise-induced bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> exercise-induced bronchospasm</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Hyperventilation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> sport</style></keyword><keyword><style face="normal" font="Arial"> Sports</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Sport is an essential part of childhood, with precious and acknowledged positive health effects but the impact of exercise-induced bronchoconstriction (EIB) significantly reduces participation in physical activity. It is important to recognize EIB, differentiating EIB with or without asthma if the transient narrowing of the airways after exercise is associated with asthmatic symptoms or not, in the way to select the most appropriate treatment among the many treatment options available today. Therapy is prescribed based on symptoms severity but diagnosis of EIB is established by changes in lung function provoked by exercise evaluating by direct and indirect tests. Sometimes, in younger children it is difficult to obtain the registration of difference between the preexercise forced expiratory volume in the first second (FEV1) value and the lowest FEV1 value recorded within 30 min after exercise, defined as the gold standard, but interrupter resistance, in association with spirometry, has been showed to be a valid alternative in preschool age. Atopy is the main risk factor, as demonstrated by epidemiologic data showing that among the estimated pediatric population with EIB up to 40% of them have allergic rhinitis and 30% of these patients may develop adult asthma, according with atopic march. Adopting the right treatment and prevention, selecting sports with no marked hyperventilation and excessive cooling of the airways, children with EIB can be able to take part in physical activity like all others</style></abstract><notes><style face="normal" font="Arial">DA - 20170623IS - 2296-2360 (Print)IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28642859">PM:28642859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-131.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-131.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170623, Caggiano S</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00131</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Macharadze,D.</style></author><author><style face="normal" font="Arial"> Janaeva,H.</style></author><author><style face="normal" font="Arial"> Avilov,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1capital ER, Cyrilliceoples Friendship University of Russia, Moscow; 2Janaeva Ch.A., Medical Center, Urus-Martan, Chechnya (Russia)</style></auth-address><titles><title><style face="normal" font="Arial">[RAGWEED ALLERGY IN THE SOUTH OF RUS</style></title><secondary-title><style face="normal" font="Arial">Georgian Med News</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Georgian Med News</style></full-title></periodical><pages end="99" start="93">93-99</pages><volume><style face="normal" font="Arial">266</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Allergy to ragweed pollen and other weeds is a global problem due to the rapid spread of these grasses around the world. In addition, pollen of short ragweed (Ambrosia, Amb) and mugwort (Artemisia, Art) - one of the main causes of respiratory allergy - seasonal allergic rhinoconjunctivitis (hay fever) with/without bronchial asthma patients living in the South of Russia. Epidemiological studies on the prevalence of Allergy to Amb and Art among patients living in Chechen Republic, absent. Aim - of this retrospective study was to investigate the prevalence of sensitization to weed pollen in patients of Chechnya. We surveyed small a, Cyrillicllergy (skin prick tests with 13 inhalant allergens) from 845 patients aged 4-68 years, in Urus-Martan for the period 2013-2016 yrs. Polisensitization was defined as the presence of positive skin tests to 2 or more extracts of different groups of allergens. ~26% and 21% of patients in the Chechen Republic have an allergy to Amb and Art, respectively. Further studies at the molecular level will help to establish the geographical variation of the sensitization profile to the major component of Amb and Art, which could have clinical significance in the proper selection of specific immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1512-0112 (Print)IS - 1512-0112 (Linking)LA - rusPT - English AbstractPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28628023">PM:28628023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Georgian Med News\2017-266-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Georgian Med News\2017-266-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Macharadze D</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84800</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sepiashvili,R.</style></author><author><style face="normal" font="Arial"> Chikhladze,M.</style></author><author><style face="normal" font="Arial"> Khachapuridze,D.</style></author><author><style face="normal" font="Arial"> Gamkrelidze,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Allergology, Asthma and Clinical Immunology, Georgian Academy of Sciences, Tskaltubo,Georgia</style></auth-address><titles><title><style face="normal" font="Arial">CORRELATION BETWEEN SPIROMETRY DATES AND SPECIAL ALLE</style></title><secondary-title><style face="normal" font="Arial">Georgian Med News</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Georgian Med News</style></full-title></periodical><pages end="88" start="86">86-88</pages><volume><style face="normal" font="Arial">266</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Alder</style></keyword><keyword><style face="normal" font="Arial"> Alle</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchodilatation</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candida albicans</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Festuca</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lolium</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Plantain</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">The study aimed to establish correlation between airway obstruction and specific IgE specificity, managing future treatment in the patients with bronchial asthma, among the population of west Georgia. In the study have been involved 56 patients (among them 24 males and 32 females) of different ages, with diagnostic bronchial asthma (according to GINA recommendation). On the ground of the aim the study included the following steps of allegro-diagnostics: I step - Computerized spirometry by apparatus ,,SPIROLAB 3". II step - To detect allergenization degree, total serum IgE levels, specific IgE and concentration of Phadiatop, using modern automated system - "Immuno CAP 100", were estimated in the patients. III step- future treatment recommendations. All 56 patients were undergone the spirometry measurement. Our results show that of 56 patient 21 (38%) had very severe obstruction by spiromatry: Pretest: FEV 1 - 28%; FEF-45%; FEV1/FVC ratio -55% on average. Post test: significant bronchodilatation was revealed FEV1> +12%( >200 mL) after the inhalation of four puffs of a short - acting beta2 sympathomimetic agent, e.r., 400 microg of salbutamol. In 19 (33%) patients severe bronchoobstruction was established. By spiromometry was revealed: Pre test: FEV 1 - 42%; FEF-55%; FEV1/FVC ratio -67% on average. Post test: significant bronchodilatation was revealed FEV1> +12%( >200 mL) In 14 (25%) patients moderate bronchoobstruction was diagnosed, the spiromatry results were. Pretest: FEV 1 - 52%; FEF-65%; FEV1/FVC ratio - 67% on average. Post test: It was revealed significant bronchodilatation FEV1> +12%( >200 mL). Only in 2 (4%) patients were diagnosed the normal spiromatry. In the patients with bronchial asthma of a specific positivity of specific IgE to the weeds (Wx2) - ambrosia, plantain, clasp/tarragon, atriplex - in 23 (53%) on average; tree dust (Tx9) - alder, lactarius piperatus, nuts, oak, willow - 11 (19%); and cereals (Gx1) - festuca pratensis, lolium temulentum, timoti grass, poa - 9 (16%); Mx2 -Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Candida albicans, Alternaria alternate- 15 (21%) was revealed, only in 5 (9%) patients we cannot established the allergy specific IgE. It was established the correlation between spiromatry dates and special allergen specific IgE in patient with bronchial asthma. The latter is of great importance for providing the effective and safe allegro-specific immunotherapy (ASIT) and successful preventive measures</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1512-0112 (Print)IS - 1512-0112 (Linking)LA - engPT - Journal ArticleCO - Georgia -CO - Russia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28628021">PM:28628021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Georgian Med News\2017-266-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Georgian Med News\2017-266-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Sepiashvili R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84801</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adams-Groom,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Assessment of pollen assemblages on footwear for evidence of pollen deriving from a mock crime scene: a contribution to forensic palynology</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> crime</style></keyword><keyword><style face="normal" font="Arial"> Habitat</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Palynology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">To provide evidence of a link between a crime scene and a suspect, pollen analysis is occasionally employed. However, experimental research linking pollen on footwear to a specific crime scene has been infrequently undertaken such that there are limited references to cite in court. In this blind study, the author had to determine, which of 12 pairs of footwear had walked on a mock scene by comparing their assemblages to those of two scene controls. An additional four control pairs of footwear that had not been worn on or near the scene were also analysed. The pollen data from the footwear was assessed and compared with the scene control samples for: number of taxa, key types, Czekanowski Coefficient and general assemblages. Results indicated that six of the pairs of footwear had walked on the scene and these were, indeed, the ones that actually had done so. The four control pairs were dissimilar in most aspects, particularly key types. This research demonstrates, with some limitations, that evidence of a match between footwear sample and location can be found, even when material from other habitats is present on an exhibit</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2017.1310293</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2017.1310293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\20170611-AdamsGroomB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Grana\20170611-AdamsGroomB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Adams-Groom B</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2017.1310293</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maya Manzano,J.M.</style></author><author><style face="normal" font="Arial"> Fernandez Rodriguez,S.</style></author><author><style face="normal" font="Arial"> Silva Palacios,I.</style></author><author><style face="normal" font="Arial"> Gonzalo Garijo,A.</style></author><author><style face="normal" font="Arial"> Tormo Molina,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison between two adhesives (silicone and petroleum jelly) in Hirst pollen traps in a controlled environment</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Acer</style></keyword><keyword><style face="normal" font="Arial"> Adhesives</style></keyword><keyword><style face="normal" font="Arial"> Aerobiological sampling</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> Petroleum</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen trap</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Rumex</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">Aerobiological sampling through volumetric pollen traps requires the use of an appropriate adhesive, whose selection is a critical factor in these studies. This study compares the differences between two adhesives that have been widely used in aerobiological studies with the aim of providing a persuasive argument for using petroleum jelly as a viable alternative to silicone diluted with the banned substance carbon tetrachloride. The study was performed using Hirst-type pollen traps in an indoor controlled environment to avoid interference attributed to outdoor meteorological parameters. Furthermore, a gravimetric study was conducted simultaneously as a control. Four different pollen types with different pollen sizes and similar flowering seasons were studied (Acer, Platanus, Quercus and Rumex). Differences between pollen traps were minimised by interchanging the drums in each pollen trap every 24-áhours. Gravimetric results showed homogeneous airborne pollen distribution in the study. No statistically significant differences were found between the results for the sample adhesives for Quercus and Platanus, whereas significant differences were observed for Rumex and Acer. In the case of Acer, more pollen grains were recorded using the petroleum jelly, while for Rumex, more pollen grains were recorded with silicone. After this experiment we consider that petroleum jelly can be used as a viable alternative adhesive to the banned silicone diluted with carbon tetrachloride</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2017.1319973</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2017.1319973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\20170611-MayaManzanoJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\20170611-MayaManzanoJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Maya Manzano JM</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2017.1319973</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Newsome,N.</style></author><author><style face="normal" font="Arial"> Adams-Groom,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Seasonal variation in surface soil pollen taxa over 12 months in three English mature woodlands</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="385" start="377">377-385</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> Soil</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="3" Month="9" Year="2017">2017/9/3</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">This study aimed to determine whether or not a seasonal, or even monthly, pattern of pollen accumulation could be found in surface soil. Three mature woodlands in the English Midlands were selected and soil samples were taken from the same area, each month, for 12-ámonths. Pollen types were recorded and compared across the woodlands. Pollen condition was assessed for seasonal differences in Bannam?s woodland. Two of the woodlands (Windmill Naps and Wirehill) had pollen assemblages that were dominated heavily by Quercus pollen but the third (Bannam?s) was more balanced. Each pollen type found was present in almost every month and winter was, for some types, a time of increased pollen. No clear, consistent patterns were visible in the results across the woodlands or for each pollen type. Although some pollen types showed an increase in levels during their flowering season, this was only consistent across all three woodlands for grasses (Poaceae). The condition of the pollen grains remained similar across the 12-ámonths with a small (up to 12%) increase in fresh pollen in May. This study concludes that for damp woodland soil in the English Midlands, a clear, seasonal or monthly pattern cannot be determined</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2016.1276618</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2016.1276618</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\2017-56-377-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Grana\2017-56-377-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Newsome N</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2016.1276618</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cugno,M.</style></author><author><style face="normal" font="Arial"> Mancuso,M.E.</style></author><author><style face="normal" font="Arial"> Tedeschi,A.</style></author><author><style face="normal" font="Arial"> Santagostino,E.</style></author><author><style face="normal" font="Arial"> Lorini,M.</style></author><author><style face="normal" font="Arial"> Carbonelli,V.</style></author><author><style face="normal" font="Arial"> Peyvandi,F.</style></author><author><style face="normal" font="Arial"> Mannucci,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Internal Medicine, Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Milan, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Haemophilia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Haemophilia</style></full-title></periodical><pages end="e353" start="e348">e348-e353</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Complement Activation</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Factor IX</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Haemophilia</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene C4</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Patients with haemophilia B who develop factor IX (FIX) neutralizing antibodies (inhibitors) after FIX infusion are at high risk of hypersensitivity reactions upon FIX re-exposure, but the underlying mechanisms are incompletely understood. AIM: To investigate biomechanisms of FIX hypersensitivity. METHODS: A cellular antigen stimulation test (CAST) was employed to evaluate leukotriene C4 (LTC4) release from basophils stimulated by FIX in three treated children with haemophilia B, one of whom developed FIX inhibitor and experienced anaphylaxis following FIX re-exposure. Anti-FIX IgE and IgG antibodies and markers of complement activation (C5b9, C3d and iC3b) were measured in plasma, the last also after FIX infusion. Ten healthy children served as controls. RESULTS: The patient who developed anti-FIX inhibitors and anaphylaxis had a nonsense mutation in FIX gene (p.Arg298Stop) and, compared to controls, had higher plasma levels of specific anti-FIX IgE (2.285 vs 0.084 OD492 nm ), with marked LTC4 release from his FIX-stimulated basophils (519.8 vs 39.9 pg/mL). Further, he had higher plasma levels of anti-FIX IgG of all the four subclasses (total IgG 1.180 vs 0.120 OD492 nm ) with FIX neutralizing activity (1.5 BU); mild complement activation occurred during FIX-induced anaphylaxis (C5b9 increased from 258.5 to 351.1 ng/mL). The same parameters were normal in the two patients who tolerated FIX infusion. CONCLUSION: In the patient with haemophilia B who experienced anaphylaxis after FIX, but not in the patients with haemophilia B who tolerated FIX, the CAST assay showed FIX-induced LTC4 release, which was associated with high plasma levels of specific anti-FIX IgE and IgG antibodies</style></abstract><notes><style face="normal" font="Arial">DA - 20170608IS - 1365-2516 (Electronic)IS - 1351-8216 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/hae.13282</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28594432">PM:28594432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Haemophilia\20170608-CugnoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Haemophilia\20170608-CugnoM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170608, Cugno M</style></custom2><misc3><style face="normal" font="Arial">10.1111/hae.13282</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Becker,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zentrum fur Rhinologie und Allergologie Wiesbaden, Wiesbaden, Deutschland</style></auth-address><titles><title><style face="normal" font="Arial">[Molecular component-resolved allergy diagnostics in ENT]</style></title><secondary-title><style face="normal" font="Arial">HNO</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">HNO</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Cross Reactions</style></keyword><keyword><style face="normal" font="Arial"> cross-reactions</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">Molecular component-resolved diagnostics (CRD) are, in addition to its research applications, being increasingly used in daily allergological routine. CRD offers improved diagnostic accuracy via a better understanding of the underlying allergen causing symptoms and helps to distinguish between true sensitization and cross reactions in polysensitized patients, thereby providing an approach for individual personalized therapy. Particularly in food allergies and anaphylaxis, CRD can stratify risks for the recurrence of reactions and their severity. The education and extended vocational training of clinical allergologists has to keep pace with the tremendous increase of knowledge in the field of molecular allergology</style></abstract><notes><style face="normal" font="Arial">DA - 20170615IS - 1433-0458 (Electronic)IS - 0017-6192 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00106-017-0372-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28616774">PM:28616774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\HNO\20170615-KlimekL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\HNO\20170615-KlimekL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00106-017-0372-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schiener,M.</style></author><author><style face="normal" font="Arial"> Graessel,A.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.B.</style></author><author><style face="normal" font="Arial"> Blank,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL) , Ingolstadter Landstrasse 1, D-85764 Munich , Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-specific immunotherapy of Hymenoptera venom allergy - also a matter of diagnosis</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen composition</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and environment</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venoms</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">Stings of hymenoptera can induce IgE-mediated hypersensitivity reactions in venom-allergic patients, ranging from local up to severe systemic reactions and even fatal anaphylaxis. Allergic patients' quality of life can be mainly improved by altering their immune response to tolerate the venoms by injecting increasing venom doses over years. This venom-specific immunotherapy is highly effective and well tolerated. However, component-resolved information about the venoms has increased in the last years. This knowledge is not only able to improve diagnostics as basis for an accurate therapy, but was additionally used to create tools which enable the analysis of therapeutic venom extracts on a molecular level. Therefore, during the last decade the detailed knowledge of the allergen composition of hymenoptera venoms has substantially improved diagnosis and therapy of venom allergy. This review focuses on state of the art diagnostic and therapeutic options as well as on novel directions trying to improve therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Luxembourg -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1334745</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28604163">PM:28604163</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170612-SchienerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170612-SchienerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Schiener M</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1334745</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Su,Y.</style></author><author><style face="normal" font="Arial"> Romeu-Bonilla,E.</style></author><author><style face="normal" font="Arial"> Anagnostou,A.</style></author><author><style face="normal" font="Arial"> Fitz-Patrick,D.</style></author><author><style face="normal" font="Arial"> Hearl,W.</style></author><author><style face="normal" font="Arial"> Heiland,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Immunomic Therapeutics, Inc. (ITI) , Rockville , MD USA</style></auth-address><titles><title><style face="normal" font="Arial">Safety and Long-Term Immunological Effects of CryJ2-LAMP Plasmid Vaccine in Japanese Red Cedar Atopic Subjects: A phase I study</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA vaccine</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Hawaii</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Plasmid</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">Japanese Red Cedar (JRC) pollen induced allergy affects one third of Japanese and the development of effective therapies remains an unachieved challenge. We designed a DNA vaccine encoding CryJ2 allergen from the JRC pollen and Lysosomal Associated Membrane Protein 1 (LAMP-1) to treat JRC allergy. These Phase IA and IB trials assessed safety and immunological effects of the investigational CryJ2-LAMP DNA vaccine in both non-sensitive and sensitive Japanese expatriates living in Honolulu, Hawaii. In the Phase IA trial, six JRC non-sensitive subjects and nine JRC and/or Mountain Cedar (MC) sensitive subjects were given four vaccine doses (each 4 mg/1 ml) intramuscularly (IM) at 14-day intervals. Nine JRC and/or MC sensitive subjects were given four doses (2 mg/0.5 ml) IM at 14-day intervals. The safety and functional biomarkers were followed for 132 days. Following this, 17 of 24 sub-jects were recruited into the IB trial and received one booster dose (2 mg/0.5 ml) IM approximately 300 days after the first vaccination dose to which they were randomized in the first phase of the trial. All safety endpoints were met and all subjects tolerated CryJ2-LAMP vaccinations well. At the end of the IA trial, ten out of 12 JRC sensitive and six out of 11 MC sensitive subjects experienced skin test negative conversion, possibly related to the CryJ2-LAMP vaccinations. Collectively, these data suggested that the CryJ2-LAMP DNA vaccine is safe and may be immunologically effective in treating JRC induced allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1329070</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28605294">PM:28605294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170612-SuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170612-SuY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Su Y</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1329070</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moreau,A.</style></author><author><style face="normal" font="Arial"> Anderer,P.</style></author><author><style face="normal" font="Arial"> Ross,M.</style></author><author><style face="normal" font="Arial"> Cerny,A.</style></author><author><style face="normal" font="Arial"> Almazan,T.</style></author><author><style face="normal" font="Arial"> Peterson,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Detection of Nocturnal Scratching Movements in Patients with Atopic Dermatitis Using Accelerometers and Recurrent Neural Networks</style></title><secondary-title><style face="normal" font="Arial">IEEE J Biomed Health Inform</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">IEEE J Biomed Health Inform</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Neural networks</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis is a chronic inflammatory skin condition affecting both children and adults and is associated with pruritus. A method for objectively quantifying nocturnal scratching events could aid in the development of therapies for atopic dermatitis and other pruritic disorders. High-resolution wrist actigraphy (3-D accelerometer sensors sampled at 20 Hz) is a non-invasive method to record movement. This work presents an algorithm to detect nocturnal scratching events based on actigraphy data. The twofold process consists of segmenting the data into "no motion", "single handed motion" and "both handed motion" followed by discriminating motion segments into scratching and other motion using a bi-directional recurrent neural network classifier. The performance was compared against manually scored infrared (IR) video data collected from 24 subjects (6 healthy controls and 18 atopic dermatitis patients) demonstrating an F1 score of 0.68 and a rank correlation of 0.945. The algorithm clearly outperformed a published reference method based on wrist actigraphy (F1 score of 0.09 and a rank correlation of 0.466). The results suggest that scratching movements can be discriminated from other nocturnal movements accurately</style></abstract><notes><style face="normal" font="Arial">DA - 20170614IS - 2168-2208 (Electronic)IS - 2168-2194 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1109/JBHI.2017.2710798</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28613187">PM:28613187</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\IEEE J Biomed Health Inform\20170614-MoreauA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\IEEE J Biomed Health Inform\20170614-MoreauA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170614, Moreau A</style></custom2><misc3><style face="normal" font="Arial">10.1109/JBHI.2017.2710798</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,H.</style></author><author><style face="normal" font="Arial"> Roan,F.</style></author><author><style face="normal" font="Arial"> Ziegler,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Program, Benaroya Research Institute, Seattle, WA, USA</style></auth-address><titles><title><style face="normal" font="Arial">The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines</style></title><secondary-title><style face="normal" font="Arial">Immunol Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Rev</style></full-title></periodical><pages end="130" start="116">116-130</pages><volume><style face="normal" font="Arial">278</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis often precedes the development of other atopic diseases. The atopic march describes this temporal relationship in the natural history of atopic diseases. Although the pathophysiological mechanisms that underlie this relationship are poorly understood, epidemiological and genetic data have suggested that the skin might be an important route of sensitization to allergens. Animal models have begun to elucidate how skin barrier defects can lead to systemic allergen sensitization. Emerging data now suggest that epithelial cell-derived cytokines such as thymic stromal lymphopoietin (TSLP), IL-33, and IL-25 may drive the progression from atopic dermatitis to asthma and food allergy. This review focuses on current concepts of the role of skin barrier defects and epithelial cell-derived cytokines in the initiation and maintenance of allergic inflammation and the atopic march</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/imr.12546</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658558">PM:28658558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Rev\2017-278-116-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Rev\2017-278-116-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Han H</style></custom2><misc3><style face="normal" font="Arial">10.1111/imr.12546</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palomares,O.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author><author><style face="normal" font="Arial"> Martin-Fontecha,M.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells</style></title><secondary-title><style face="normal" font="Arial">Immunol Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Rev</style></full-title></periodical><pages end="236" start="219">219-236</pages><volume><style face="normal" font="Arial">278</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Breg</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Patient adherence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Allergy is a major public health problem with a high socio-economic impact. The number of allergic patients is expected to reach to four billion within two decades when the World's population reaches to 10 billion. Our knowledge on the molecular mechanisms underlying allergic diseases and allergen tolerance induction had significant advances during the last years. Nowadays, it is well accepted that the generation and maintenance of allergen-specific regulatory T cells (Tregs) and regulatory B cells (Bregs) and the involvement of their suppressive cytokines and surface molecules are essential for the induction of allergen tolerance. These mechanisms play essential roles for the restoration of healthy immune responses to allergens in allergen-specific immunotherapy (AIT) and healthy immune response during high-dose antigen exposure in beekeepers and cat owners. AIT remains as the only disease-modifying and curative treatment for allergic diseases and represents a perfect model to investigate the antigen-specific immune responses in humans. A large number of clinical trials demonstrated AIT as an effective treatment in many patients, but it still faces several drawbacks in relation to efficacy, safety, long duration, and patient adherence. Novel strategies to overcome these inconveniences, such as the development of novel adjuvants and alternative routes of administration are being developed. The better understanding of the molecular mechanism governing the generation of Treg and Breg cells during allergen tolerance might well open new avenues for alternative therapeutic interventions in allergic diseases and help better understanding of other immune-tolerance-related diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/imr.12555</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658547">PM:28658547</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Rev\2017-278-219-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Rev\2017-278-219-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Palomares O</style></custom2><misc3><style face="normal" font="Arial">10.1111/imr.12555</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foster,P.S.</style></author><author><style face="normal" font="Arial"> Maltby,S.</style></author><author><style face="normal" font="Arial"> Rosenberg,H.F.</style></author><author><style face="normal" font="Arial"> Tay,H.L.</style></author><author><style face="normal" font="Arial"> Hogan,S.P.</style></author><author><style face="normal" font="Arial"> Collison,A.M.</style></author><author><style face="normal" font="Arial"> Yang,M.</style></author><author><style face="normal" font="Arial"> Kaiko,G.E.</style></author><author><style face="normal" font="Arial"> Hansbro,P.M.</style></author><author><style face="normal" font="Arial"> Kumar,R.K.</style></author><author><style face="normal" font="Arial"> Mattes,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Priority Research Centre for Healthy Lungs, Department of Microbiology and Immunology, School of Biomedical Sciences &amp; Pharmacy, Faculty of Health and Hunter Medical Research Institute, The University of Newcastle, Callaghan, NSW, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Modeling TH 2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma</style></title><secondary-title><style face="normal" font="Arial">Immunol Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Rev</style></full-title></periodical><pages end="40" start="20">20-40</pages><volume><style face="normal" font="Arial">278</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway macrophages</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-1</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">In this review, we highlight experiments conducted in our laboratories that have elucidated functional roles for CD4+ T-helper type-2 lymphocytes (TH 2 cells), their associated cytokines, and eosinophils in the regulation of hallmark features of allergic asthma. Notably, we consider the complexity of type-2 responses and studies that have explored integrated signaling among classical TH 2 cytokines (IL-4, IL-5, and IL-13), which together with CCL11 (eotaxin-1) regulate critical aspects of eosinophil recruitment, allergic inflammation, and airway hyper-responsiveness (AHR). Among our most important findings, we have provided evidence that the initiation of TH 2 responses is regulated by airway epithelial cell-derived factors, including TRAIL and MID1, which promote TH 2 cell development via STAT6-dependent pathways. Further, we highlight studies demonstrating that microRNAs are key regulators of allergic inflammation and potential targets for anti-inflammatory therapy. On the background of TH 2 inflammation, we have demonstrated that innate immune cells (notably, airway macrophages) play essential roles in the generation of steroid-resistant inflammation and AHR secondary to allergen- and pathogen-induced exacerbations. Our work clearly indicates that understanding the diversity and spatiotemporal role of the inflammatory response and its interactions with resident airway cells is critical to advancing knowledge on asthma pathogenesis and the development of new therapeutic approaches</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/imr.12549</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658543">PM:28658543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Rev\2017-278-20-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Rev\2017-278-20-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Foster PS</style></custom2><misc3><style face="normal" font="Arial">10.1111/imr.12549</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kubo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Noda, JapanLaboratory for Cytokine Regulation, Research Center for Integrative Medical Science (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Innate and adaptive type 2 immunity in lung allergic inflammation</style></title><secondary-title><style face="normal" font="Arial">Immunol Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Rev</style></full-title></periodical><pages end="172" start="162">162-172</pages><volume><style face="normal" font="Arial">278</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Allergic inflammation is a type 2 immune disorder classically characterized by high levels of immunoglobulin E (IgE) and the development of Th2 cells. Asthma is a pulmonary allergic inflammatory disease resulting in bronchial hyper-reactivity. Atopic asthma is defined by IgE antibody-mediated mast cell degranulation, while in non-atopic asthma there is no allergen-specific IgE and more involvement of innate immune cells, such as basophils, group 2 innate lymphoid cells (ILC2), and eosinophils. Recently, protease allergens were shown to cause asthmatic responses in the absence of Th2 cells, suggesting that an innate cell network (IL-33/TSLP-basophil-ILC2-IL-5/IL-13 axis) can facilitate the sensitization phase of type 2 inflammatory responses. Recent evidence also indicates that in the chronic phase, these innate immune cells directly or indirectly contribute to the adaptive Th2 cell responses. In this review, we discuss the role of Th2 cytokines (IL-4 and IL-13) and innate immune cells (mast cells, basophils, ILC2s, and dendritic cells) in the cross-talk between innate and adaptive inflammatory responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/imr.12557</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658559">PM:28658559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Rev\2017-278-162-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Rev\2017-278-162-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Kubo M</style></custom2><misc3><style face="normal" font="Arial">10.1111/imr.12557</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deckers,J.</style></author><author><style face="normal" font="Arial"> De Bosscher,K.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Ghent University, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Interplay between barrier epithelial cells and dendritic cells in allergic sensitization through the lung and the skin</style></title><secondary-title><style face="normal" font="Arial">Immunol Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Rev</style></full-title></periodical><pages end="144" start="131">131-144</pages><volume><style face="normal" font="Arial">278</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">The prevalence of asthma is increasing over the years and it has become obvious that a thorough understanding of mechanisms leading to Th2 sensitization and to asthma is urgently needed to provide better ways to treat the disease. This articles reviews the different players involved in the initiation of allergic reactions in the lung and in the skin, and highlights the importance of a crosstalk between antigen-presenting dendritic cells and structural cell-derived signals in this process. Our increasing understanding of these mechanisms indicates that structural cells, such as airway epithelial cells and skin keratinocytes, need to be considered as more than a simple physical barrier since they are very upstream of the entire Th2 cascade and therefore might represent crucial targets for new therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/imr.12542</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658557">PM:28658557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Rev\2017-278-131-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Rev\2017-278-131-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Deckers J</style></custom2><misc3><style face="normal" font="Arial">10.1111/imr.12542</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krishnamurthy,P.</style></author><author><style face="normal" font="Arial"> Da-Silva-Arnold,S.</style></author><author><style face="normal" font="Arial"> Turner,M.J.</style></author><author><style face="normal" font="Arial"> Travers,J.B.</style></author><author><style face="normal" font="Arial"> Kaplan,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, 46202</style></auth-address><titles><title><style face="normal" font="Arial">PARP14 limits severity of allergic skin disease</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disease models</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Ribose</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">Poly-ADP ribose polymerase-14 (PARP14 or ARTD8) was initially identified as a transcriptional co-activator for Stat6, where the presence of IL-4 and activated Stat6 induces the enzymatic activity of PARP14 that promotes Th2 differentiation and allergic airway disease. To further our understanding of PARP14 in allergic disease, we studied the function of PARP14 in allergic inflammation of skin using mice that express constitutively active Stat6 in T cells (Stat6VT) and develop spontaneous inflammation of the skin. We mated Stat6VT mice to Parp14-/- mice and observed that approximately 75% of the Stat6VTxParp14-/- mice develop severe atopic dermatitis (AD)-like lesions, compared to about ~50% of Stat6VT mice, and have increased morbidity compared to Stat6VT mice. Despite this, gene expression in the skin and the cellular infiltrates were only modestly altered by the absence of PARP14. In contrast, we saw significant changes in systemic T cell cytokine production. Moreover, adoptive transfer experiments demonstrated that decreases in IL-4 production reflected a cell intrinsic role for PARP14 in Th2 cytokine control. Thus, our data suggests that although PARP14 has similar effects on T cell cytokine production in several allergic disease models, the outcome of those effects is distinct, depending on the target organ of disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12782</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28653395">PM:28653395</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20170627-KrishnamurthyP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20170627-KrishnamurthyP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Krishnamurthy P</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12782</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rekabi,M.</style></author><author><style face="normal" font="Arial"> Arshi,S.</style></author><author><style face="normal" font="Arial"> Bemanian,M.H.</style></author><author><style face="normal" font="Arial"> Rekabi,V.</style></author><author><style face="normal" font="Arial"> Rajabi,A.</style></author><author><style face="normal" font="Arial"> Fallahpour,M.</style></author><author><style face="normal" font="Arial"> Molatefi,R.</style></author><author><style face="normal" font="Arial"> Shokri,S.</style></author><author><style face="normal" font="Arial"> Eslami,N.</style></author><author><style face="normal" font="Arial"> Ahmadian,J.</style></author><author><style face="normal" font="Arial"> Khoshmirsafa,M.</style></author><author><style face="normal" font="Arial"> Seif,F.</style></author><author><style face="normal" font="Arial"> Mahdaviani,S.A.</style></author><author><style face="normal" font="Arial"> Akbarpour,N.</style></author><author><style face="normal" font="Arial"> Nabavi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis &amp; Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Allergy &amp; Clinical Immunology, Iran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of a new protocol for wheat desensitization in patients with wheat-induced anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Immunotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunotherapy</style></full-title></periodical><pages end="645" start="637">637-645</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-dosing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">AIM: New approaches such as oral immunotherapy (OIT) may be useful in IgE-mediated anaphylaxis to wheat. PATIENTS &amp; METHODS: 12 patients underwent OIT protocol that comprised of two phases: the first with semolina flour and the second with spaghetti. Total and specific wheat IgE were assayed by ELISA before and after OIT and 18 months later. Skin prick tests were also performed. RESULTS: Patients successfully tolerated 50 g of wheat. The median baseline total IgE was decreased after up-dosing phase and decreased after follow-up (p &lt; 0.01). The median baseline wheat-specific IgE was increased after up-dosing and decreased after follow-up (p &lt; 0.001). CONCLUSION: The efficiency and safety of our OIT protocol were shown on wheat allergic patients but further investigation is needed</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1750-7448 (Electronic)IS - 1750-743X (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.2217/imt-2017-0011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28653575">PM:28653575</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunotherapy\2017-9-637-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunotherapy\2017-9-637-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Rekabi M</style></custom2><misc3><style face="normal" font="Arial">10.2217/imt-2017-0011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shashikumar,B.M.</style></author><author><style face="normal" font="Arial"> Harish,M.R.</style></author><author><style face="normal" font="Arial"> Shwetha,B.</style></author><author><style face="normal" font="Arial"> Kavya,M.</style></author><author><style face="normal" font="Arial"> Deepadarshan,K.</style></author><author><style face="normal" font="Arial"> Phani,H.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Mandya Institute of Medical Sciences, Mandya, Karnataka, India</style></auth-address><titles><title><style face="normal" font="Arial">Hypersensitive Reaction to Tattoos: A Growing Menace in Rural India</style></title><secondary-title><style face="normal" font="Arial">Indian J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Dermatol</style></full-title></periodical><pages end="296" start="291">291-296</pages><volume><style face="normal" font="Arial">62</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> Government Regulation</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Informed Consent</style></keyword><keyword><style face="normal" font="Arial"> Ink</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multicolor</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Tattooing</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Increased enthusiasm toward newer fashion trends among rural India along with the lack of government regulation has led to increased tattoo reactions. OBJECTIVE: The objective of this study is to describe various clinical manifestations of hypersensitive reactions to tattoo ink reported at a tertiary care hospital in Mandya district. MATERIALS AND METHODS: An observational study was carried out over a period of 1 year from June 2014 to May 2015 at Mandya Institute of Medical Sciences, Mandya. All the patients reporting with allergic reaction due to tattooing were included in the present study after obtaining informed consent. Transient acute inflammatory reaction, infections, and skin diseases localized on tattooed area were excluded from this study. A detailed history regarding the onset, duration and color used for tattooing were collected. Cutaneous examination and biopsy was to done to know the type of reaction. RESULTS: Fifty cutaneous allergic reactions were diagnosed among 39 patients. Mean age of subjects was 22 years and mean duration before the appearance of lesion was 7 months. Common colors associated with reactions were red (53.9%), black (33.3%), green (5.1%), and multicolor (7.7%). Itching was the predominant symptom. Skin lesions mainly consisted of lichenoid papules and plaques, eczematous lesions, and verrucous lesions. Lichenoid histopathology reaction was the most common tissue allergic reaction. CONCLUSION: Increasing popularity of tattooing among young people has predisposed to parallel increase in adverse reactions. Red pigment is most common cause of allergic reaction in the present study, and lichenoid reaction is the most common reaction</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1998-3611 (Electronic)IS - 0019-5154 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/ijd.IJD_210_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28584372">PM:28584372</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Dermatol\2017-62-291-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Dermatol\2017-62-291-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Shashikumar BM</style></custom2><misc3><style face="normal" font="Arial">10.4103/ijd.IJD_210_16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mathew,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.</style></auth-address><titles><title><style face="normal" font="Arial">Association Between Food Allergy and Childhood Asthma: So Close and Yet So Far!</style></title><secondary-title><style face="normal" font="Arial">Indian J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Pediatr</style></full-title></periodical><pages end="577" start="575">575-577</pages><volume><style face="normal" font="Arial">84</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170623IS - 0973-7693 (Electronic)IS - 0019-5456 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12098-017-2402-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28643163">PM:28643163</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Pediatr\20170623-MathewJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Pediatr\20170623-MathewJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170623, Mathew JL</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12098-017-2402-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rerknimitr,P.</style></author><author><style face="normal" font="Arial"> Otsuka,A.</style></author><author><style face="normal" font="Arial"> Nakashima,C.</style></author><author><style face="normal" font="Arial"> Kabashima,K.i</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus</style></title><secondary-title><style face="normal" font="Arial">Inflamm Regen</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflamm Regen</style></full-title></periodical><pages end="" start="14">14-</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cornea</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> multifaceted</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> pruritogens</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Stratum corneum</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Tight Junctions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1880-8190</style></isbn><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a common chronic skin inflammatory disorder characterized by recurrent eczema accompanied by an intractable itch that leads to an impaired quality of life. Extensive recent studies have shed light on the multifaceted pathogenesis of the disease. The complex interplay among skin barrier deficiency, immunological derangement, and pruritus contributes to the development, progression, and chronicity of the disease. Abnormalities in filaggrin, other stratum corneum constituents, and tight junctions induce and/or promote skin inflammation. This inflammation, in turn, can further deteriorate the barrier function by downregulating a myriad of essential barrier-maintaining molecules. Pruritus in AD, which may be due to hyperinnervation of the epidermis, increases pruritogens, and central sensitization compromises the skin integrity and promotes inflammation. There are unmet needs in the treatment of AD. Based on the detailed evidence available to date, certain disease mechanisms can be chosen as treatment targets. Numerous clinical trials of biological agents are currently being conducted and are expected to provide treatments for patients suffering from AD in the future. This review summarizes the etiopathogenesis of the disease and provides a rationale for choosing the novel targeted therapy that will be available in the future</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s41232-017-0044-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1186/s41232-017-0044-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflamm Regen\2017-37-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflamm Regen\2017-37-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Rerknimitr P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s41232-017-0044-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Epstein,M.M.</style></author><author><style face="normal" font="Arial"> Tilp,C.</style></author><author><style face="normal" font="Arial"> Erb,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">The Use of Mouse Asthma Models to Successfully Discover and Develop Novel Drugs</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="70" start="61">61-70</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Discovery</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic animals</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="Arial">The past 20 years have seen a proliferation of scientific data on the pathophysiology of asthma. Most of these data were generated in mice using tool reagents, gene-deficient or transgenic animals. In contrast, studies on disease pathogenesis in patients are scarce. Previously, a good novel antiasthma target for drug development was one that abrogated asthma in mice when it was knocked out, neutralized or induced asthma when it was overexpressed. This type of approach led to many drug candidates that worked in mice but unfortunately failed in patients, thereby demonstrating that the results of experiments in mice are not always predictive of clinical efficacy. Currently, there is active debate about the use of mouse models in drug discovery. In this review, we summarize the obstacles and challenges faced when using experimental mouse models of asthma in drug discovery. We propose that the initial selection of a novel drug target begins with defining the unmet medical need and specific patient population, followed by a thorough evaluation of available human data, and, only then, well-planned and executed mouse asthma experiments. Using this approach, we argue that mouse models lend support for the target when the models are tailored for the specific asthma patient population, and that targeted, reliable, and predictive mouse models can indeed improve and accelerate the drug discovery process</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000473699</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28586774">PM:28586774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-61-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-61-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Epstein MM</style></custom2><misc3><style face="normal" font="Arial">10.1159/000473699</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsui,T.</style></author><author><style face="normal" font="Arial"> Yamashita,H.</style></author><author><style face="normal" font="Arial"> Mori,M.</style></author><author><style face="normal" font="Arial"> Tanaka,H.</style></author><author><style face="normal" font="Arial"> Inagaki,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University, Gifu, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Eppikajutsuto Protects against Food Allergy Induced by Ovalbumin in a Murine Model</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="83" start="71">71-83</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic diarrhea</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> herbal medicines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Intestines</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Passive anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="6" Year="2017">2017/6/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Currently, there are no efficient medications available for the prevention and treatment of food allergy (FA). Herbal medicines, including traditional Japanese Kampo medicines (TJKMs), are promising therapeutic drugs. METHODS: We screened 18 TJKMs for treatment of FA symptoms in a mouse FA model induced by ovalbumin (OVA). BALB/c mice were sensitized intraperitoneally by an OVA/aluminum hydroxide gel mixture followed by 4 booster doses of oral OVA and FA symptom induction by 50 mg of OVA. TJKMs were orally administered for 28 days from the day of sensitization to the day before FA symptom induction. Evaluated FA symptoms included a decrease in body temperature and allergic diarrhea. Allergic sensitization was determined by plasma OVA-specific IgE levels. Cytokine mRNA levels in mesenteric lymph nodes, plasma mouse mast cell protease-1, and the number of mast cells in the small and large intestines were analyzed. Additionally, the therapeutic effect of the TJKM eppikajutsuto (EJT) on mast cell degranulation was determined in active anaphylaxis and passive cutaneous anaphylaxis models. RESULTS: EJT effectively prevented FA symptoms. Although OVA-specific IgE levels and the intestinal mast cell numbers were not different between the EJT-treated and untreated FA mice, plasma mMcpt1 and IL-4 levels were lower in EJT-treated FA mice than untreated FA mice. EJT could alleviate symptoms in both active and passive anaphylaxis models. CONCLUSION: EJT prevented OVA-induced FA symptoms in a mouse model, suggesting that EJT might exert its therapeutic activity via IL-4 suppression and the inhibition of mucosal mast cell degranulation</style></abstract><notes><style face="normal" font="Arial">DA - 20170604IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000472715</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28578324">PM:28578324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-71-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-71-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170604, Matsui T</style></custom2><misc3><style face="normal" font="Arial">10.1159/000472715</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamada,Y.</style></author><author><style face="normal" font="Arial"> Matsumoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Drug Development Research Laboratories, Kyoto R&amp;amp;D Center, Maruho Co., Ltd., Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="Arial">House Dust Mites Induce Production of Endothelin-1 and Matrix Metalloproteinase-9 in Keratinocytes via Proteinase-Activated Receptor-2 Activation</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="92" start="84">84-92</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAR-2</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Serine protease inhibitor</style></keyword><keyword><style face="normal" font="Arial"> serine proteases</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin barrier dysfunction and abnormal immune response. House dust mites (HDM) are a major source of allergens, some of which have cysteine and serine protease activities. Keratinocytes stimulated by HDM-derived proteases have been suggested to contribute to the pathogenesis of AD by producing various cytokines. However, whether keratinocytes contribute to the induction of pruritus in AD, especially by producing pruritus-related mediators upon stimulation with HDM-derived proteases, has not been fully elucidated. METHODS: We examined whether the production of endothelin-1 (ET-1), matrix metalloproteinase (MMP)-2, and MMP-9 in keratinocytes can be induced by stimulation with Dermatophagoides farinae extracts, and if so, whether pretreatment with a protease inhibitor or proteinase-activated receptor-2 (PAR-2) antagonist affects the production of these mediators in keratinocytes. RESULTS: Although MMP-2 levels were undetectable in the culture supernatants, the production of ET-1 and MMP-9 was increased upon stimulation with HDM extracts in a concentration- and time-dependent manner and suppressed by pretreatment of HDM extracts with serine protease inhibitor, but not with cysteine protease inhibitor. Mite-derived serine proteases also induced ET-1 and MMP-9 production in a concentration- and time-dependent manner. Moreover, pretreatment with a PAR-2 antagonist inhibited the production of ET-1 and MMP-9 in keratinocytes. CONCLUSION: These results suggest that the activation of PAR-2 on keratinocytes by HDM-derived serine proteases induces the production of ET-1 and MMP-9, and may contribute to the induction of pruritus in AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000473700</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28586781">PM:28586781</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-84-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-84-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Yamada Y</style></custom2><misc3><style face="normal" font="Arial">10.1159/000473700</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kennedy,D.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Olfactory loss in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="550" start="549">549-550</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> olfactory loss</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21969</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28591473">PM:28591473</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-549-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\2017-7-549-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Kennedy DW</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21969</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jung,A.Y.</style></author><author><style face="normal" font="Arial"> Heo,M.J.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">WCSL of INtegrated Human Airway-on-a-chip, Department of Otorhinolaryngology, Inha University, Incheon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Glucosamine has an antiallergic effect in mice with allergic asthma and rhinitis</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="769" start="763">763-769</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dietary supplement</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Glucosamine</style></keyword><keyword><style face="normal" font="Arial"> Heme</style></keyword><keyword><style face="normal" font="Arial"> heme oxygenase 1</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Glucosamine (GlcN) is generally used as a dietary supplement because of its antiinflammatory effects. We evaluated the antiallergic effect of GlcN in mice with allergic asthma and rhinitis. METHODS: Thirty-two mice were allocated equally into 4 groups (n = 8). In group A (control), we performed intraperitoneal/intranasal challenge using sterile saline. In group B (asthma/rhinitis), we used ovalbumin for intraperitoneal/intranasal challenge to induce allergic asthma and rhinitis. In groups C and D (GlcN treatment), mice were given 1% and 5% GlcN throughout the period of ovalbumin challenge, respectively. We measured serum total and ovalbumin-specific immunoglobulin E (IgE), cytokine titers (interleukin-1, -4, -5, -6, -10, and -17; tumor necrosis factor-alpha; and interferon-gamma), and the number of inflammatory cells (eosinophils, neutrophils, lymphocytes) in bronchoalveolar lavage (BAL) fluid. We also performed histopathologic examination of the lung and nasal cavity. Finally, we performed real-time polymerase chain reaction for the genes Bcl-2, EC-SOD, VEGF, caspase-3, Bax, COX-2, Hif-1alpha, and heme oxygenase-1. RESULTS: Compared with group B, group D had significant serum total and ovalbumin-specific IgE decreases after GlcN treatment (p &lt; 0.05). Titers for IL-4, IL-5, IL-6, and IL-17 in BAL fluid were significantly decreased in group D (p &lt; 0.05). Eosinophils in BAL fluid were significantly decreased in group D compared with group B (p &lt; 0.05). Groups C and D showed significant improvement of inflammation compared with group B. Group D had significant downregulation of EC-SOD, Bax, Hif-1alpha, and heme oxygenase-1 compared with group B. CONCLUSION: GlcN had a significant antiallergic effect in mice with allergic asthma and rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170530IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21967</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28558148">PM:28558148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170530-JungAY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170530-JungAY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170530, Jung AY</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21967</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Benninger,M.S.</style></author><author><style face="normal" font="Arial"> Strohl,M.</style></author><author><style face="normal" font="Arial"> Holy,C.E.</style></author><author><style face="normal" font="Arial"> Hanick,A.L.</style></author><author><style face="normal" font="Arial"> Bryson,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Cleveland Clinic, Cleveland, OH</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of atopic disease in patients with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="762" start="757">757-762</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The objective of this work was to evaluate prevalence of eosinophilic esophagitis (EoE) in the United States, and analyze prevalence of atopic disease in patients with EoE. The study design was a retrospective administrative database analysis in U.S.-based outpatient settings. METHODS: A retrospective claims analysis in the inpatient and outpatient setting (using MarketScan) was conducted to analyze prevalence of atopic disease diagnoses in patients with EoE in 2012, and timing of those diagnoses vs EoE. RESULTS: From published evidence, prevalence of EoE was estimated at 1 to 5 patients per 10,000 and prevalence of asthma, allergic rhinitis (AR), and atopic dermatitis (AD) concurrent to EoE ranged from 20% to 50%, 50% to 75%, and 2% to 19% cases, respectively. From 2009 and 2013, the estimated prevalence of EoE in MarketScan increased from 2.7 to 5.6 per 10,000 enrollees age 34.5 +/- 18.43 years (mean +/- standard deviation). Age followed a bimodal distribution with peaks at 12 and 41 years. Women accounted for 35.6% cases. Prevalence of asthma, AR, AD, and food allergies up to 12 months post-EoE diagnosis reached 44.7%, 27.1%, 25.2%, and 16.9%, respectively, with 63.5% of all patients suffering from at least 1 of these 4 diseases and 3.0% suffering from all 4. CONCLUSION: The diagnosis of EoE is associated with the diagnoses of asthma, AR, AD, and food allergies. The high prevalence of these conditions in EoE patients further strengthens the hypothesis of a common pathogenesis</style></abstract><notes><style face="normal" font="Arial">DA - 20170614IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21968</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614630">PM:28614630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170614-BenningerMS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170614-BenningerMS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170614, Benninger MS</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21968</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rojo,J.</style></author><author><style face="normal" font="Arial"> Rivero,R.</style></author><author><style face="normal" font="Arial"> Romero-Morte,J.</style></author><author><style face="normal" font="Arial"> Fernandez-Gonzalez,F.</style></author><author><style face="normal" font="Arial"> Perez-Badia,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Environmental Sciences, University of Castilla-La Mancha, 45071, Toledo, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Modeling pollen time series using seasonal-trend decomposition procedure based on LOESS smoothing</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="348" start="335">335-348</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Data Interpretation,Statistical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Flowering phenology</style></keyword><keyword><style face="normal" font="Arial"> Flowers</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Least-Squares Analysis</style></keyword><keyword><style face="normal" font="Arial"> Life cycle</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Models,Theoretical</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant phenology</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Analysis of airborne pollen concentrations provides valuable information on plant phenology and is thus a useful tool in agriculture-for predicting harvests in crops such as the olive and for deciding when to apply phytosanitary treatments-as well as in medicine and the environmental sciences. Variations in airborne pollen concentrations, moreover, are indicators of changing plant life cycles. By modeling pollen time series, we can not only identify the variables influencing pollen levels but also predict future pollen concentrations. In this study, airborne pollen time series were modeled using a seasonal-trend decomposition procedure based on LOcally wEighted Scatterplot Smoothing (LOESS) smoothing (STL). The data series-daily Poaceae pollen concentrations over the period 2006-2014-was broken up into seasonal and residual (stochastic) components. The seasonal component was compared with data on Poaceae flowering phenology obtained by field sampling. Residuals were fitted to a model generated from daily temperature and rainfall values, and daily pollen concentrations, using partial least squares regression (PLSR). This method was then applied to predict daily pollen concentrations for 2014 (independent validation data) using results for the seasonal component of the time series and estimates of the residual component for the period 2006-2013. Correlation between predicted and observed values was r = 0.79 (correlation coefficient) for the pre-peak period (i.e., the period prior to the peak pollen concentration) and r = 0.63 for the post-peak period. Separate analysis of each of the components of the pollen data series enables the sources of variability to be identified more accurately than by analysis of the original non-decomposed data series, and for this reason, this procedure has proved to be a suitable technique for analyzing the main environmental factors influencing airborne pollen concentrations</style></abstract><notes><style face="normal" font="Arial">DA - 20160805IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - engPT - Journal ArticleRN - 0 (Air Pollutants)RN - 0 (Allergens)SB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-016-1215-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27492630">PM:27492630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\2017-61-335-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biometeorol\2017-61-335-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160805, Rojo J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-016-1215-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abdelghany,M.</style></author><author><style face="normal" font="Arial"> Shah,S.</style></author><author><style face="normal" font="Arial"> Subedi,R.</style></author><author><style face="normal" font="Arial"> Kozman,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">In reply: Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome: Mastocytosis and post-mortem diagnosis</style></title><secondary-title><style face="normal" font="Arial">Int J Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Cardiol</style></full-title></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="Arial">242</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic acute coronary syndrome</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> post-mortem</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><isbn><style face="normal" font="Arial">0167-5273</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijcard.2017.04.008</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ijcard.2017.04.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Cardiol\2017-242-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Cardiol\2017-242-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Abdelghany M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijcard.2017.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kounis,N.G.</style></author><author><style face="normal" font="Arial"> Koniari,I.</style></author><author><style face="normal" font="Arial"> Soufras,G.D.</style></author><author><style face="normal" font="Arial"> Patsouras,N.</style></author><author><style face="normal" font="Arial"> Hahalis,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome: Mastocytosis and post-mortem diagnosis</style></title><secondary-title><style face="normal" font="Arial">Int J Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Cardiol</style></full-title></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="Arial">242</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic acute coronary syndrome</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera sting</style></keyword><keyword><style face="normal" font="Arial"> Indolent mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndromes</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> post-mortem</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><isbn><style face="normal" font="Arial">0167-5273</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijcard.2017.02.144</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ijcard.2017.02.144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Cardiol\2017-242-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Cardiol\2017-242-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Kounis NG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijcard.2017.02.144</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Will,B.M.</style></author><author><style face="normal" font="Arial"> Severino,R.</style></author><author><style face="normal" font="Arial"> Johnson,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Georgetown University, School of Biomedical Graduate Education, Washington, DC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Identification of allergens by IgE-specific testing improves outcomes in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Body Surface Area</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: IgE quantitative assaying of allergens (IgEQAA) has long been implemented by allergists in determining patients' reactivities for allergic rhinitis and asthma, two of the three diagnoses in atopic syndrome. This test operates by measuring the patient's IgE response to different allergens and can identify potential triggers for a patient's symptoms. Despite this, IgEQAA has yet to see the same widespread use in the field of dermatology, specifically in the treatment of patients with atopic dermatitis (AD). MATERIALS AND METHODS: The affected body surface area (BSA) at first presentation, IgEQAA classes, and total immunoglobulin E (IgE) concentration were taken retrospectively for 54 patients with AD. RESULTS: Of the 54 patients observed, 41 had an abnormally high total IgE concentration (76%). Additionally, it was observed that nine (17%) of our patients significantly improved after making lifestyle changes. CONCLUSION: Knowledge of the identified specific antigens can guide patients to make lifestyle modifications that may improve disease outcomes. IgEQAA and avoidance of allergens may help some patients with AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.13673</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28631812">PM:28631812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\20170620-WillBM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\20170620-WillBM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Will BM</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.13673</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gabriel,M.F.</style></author><author><style face="normal" font="Arial"> Uriel,N.</style></author><author><style face="normal" font="Arial"> Teifoori,F.</style></author><author><style face="normal" font="Arial"> Postigo,I.</style></author><author><style face="normal" font="Arial"> Sunen,E.</style></author><author><style face="normal" font="Arial"> Martinez,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Microbiology and Parasitology, Faculty of Pharmacy, Laboratory of Parasitology and Allergy, Lascaray Research Centre, University of the Basque Country, Vitoria, Spain</style></auth-address><titles><title><style face="normal" font="Arial">The major Alternaria alternata allergen, Alt a 1: A reliable and specific marker of fungal contamination in citrus fruits</style></title><secondary-title><style face="normal" font="Arial">Int J Food Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Food Microbiol</style></full-title></periodical><pages end="30" start="26">26-30</pages><volume><style face="normal" font="Arial">257</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alt a 1</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular marker</style></keyword><keyword><style face="normal" font="Arial"> orange</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> RNA extraction</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virulence</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="Arial">The ubiquitously present spores of Alternaria alternata can spoil a wide variety of foodstuffs, including a variety of fruits belonging to the Citrus genus. The major allergenic protein of A. alternata, Alt a 1, is a species-specific molecular marker that has been strongly associated with allergenicity and phytopathogenicity of this fungal species. This study aimed to evaluate the potential of the detection of Alt a 1 as a reliable indicator of A. alternata contamination in citrus fruits. To accomplish this aim, sixty oranges were artificially infected with a spore suspension of A. alternata. Internal fruit material was collected at different incubation times (one, two and three weeks after the fungal inoculation) and used for both total RNA extraction and protein extraction. Alt a 1 detection was then performed by polymerase chain reaction (PCR) amplification using Alt a 1 specific primers and by enzyme-linked immunosorbent assay (ELISA). The experimental model presented in this work was effective to simulate the typical Alternaria black rot phenotype and its progression. Although both PCR and ELISA techniques have been successfully carried out for detecting Alt a 1 allergen in A. alternata infected oranges, the PCR method was found to be more sensitive than ELISA. Nevertheless, ELISA results were highly valuable to demonstrate that considerable amounts of Alt a 1 are produced during A. alternata fruit infection process, corroborating the recently proposed hypothesis that this protein plays a role in the pathogenicity and virulence of Alternaria species. Such evidence suggests that the detection of Alt a 1 by PCR-based assay may be used as a specific indicator of the presence of pathogenic and allergenic fungal species, A. alternata, in fruits. This knowledge can be employed to control the fungal infection and mitigate agricultural losses as well as human exposure to A. alternata allergens and toxins</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1879-3460 (Electronic)IS - 0168-1605 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28633053">PM:28633053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Food Microbiol\2017-257-26-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Food Microbiol\2017-257-26-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Gabriel MF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cavallero,S.</style></author><author><style face="normal" font="Arial"> Bruno,A.</style></author><author><style face="normal" font="Arial"> Arletti,E.</style></author><author><style face="normal" font="Arial"> Caffara,M.</style></author><author><style face="normal" font="Arial"> Fioravanti,M.L.</style></author><author><style face="normal" font="Arial"> Costa,A.</style></author><author><style face="normal" font="Arial"> Cammilleri,G.</style></author><author><style face="normal" font="Arial"> Graci,S.</style></author><author><style face="normal" font="Arial"> Ferrantelli,V.</style></author><author><style face="normal" font="Arial"> D'Amelio,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Validation of a commercial kit aimed to the detection of pathogenic anisakid nematodes in fish products</style></title><secondary-title><style face="normal" font="Arial">Int J Food Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Food Microbiol</style></full-title></periodical><pages end="79" start="75">75-79</pages><volume><style face="normal" font="Arial">257</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anisakid</style></keyword><keyword><style face="normal" font="Arial"> Anisakids</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Ascaris</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish Products</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hysterothylacium</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Pseudoterranova</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality assurance</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Squid</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zoonosis</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">Anisakids are parasitic nematodes responsible for a zoonosis that occurs following the ingestion of fish and fish products infected with larvae belonging to the genera Anisakis and Pseudoterranova. Rarely Contracaecum is found in association with gastric/intestinal illness, while Hysterothylacium is commonly considered not pathogenic. Although Real Time PCR assays have been recently used with the aim to detect and quantify these parasites in food products, methods applied did not undergo through extensive validation process, a feature highly desirable or mandatory in the case of testing laboratories accredited for the ISO EN 17025:2005. Here, a comprehensive study has been performed to validate a commercial kit based on multiplex real time PCR for the qualitative detection of Anisakis and Pseudoterranova. Inclusivity/exclusivity trials were carried out on DNA from species of the genera Anisakis, Pseudoterranova, Contracaecum, Hysterothylacium and Ascaris, on fish intentionally contaminated with Anisakis spp. and Pseudoterranova spp. and on marine organisms as fish, crustacean and squid to test the commercial kit on a large sample. The assay gave positive amplification for several Anisakis and Pseudoterranova species, while providing no signal for the members of the remaining genera. Each sample was correctly assigned either to Anisakis or Pseudoterranova, thus indicating that no cross-reaction occurred. The LOD was determined using two independent standard curves. Robustness was assayed by using two different thermocyclers in three distinct laboratories with different operators. The establishment of a validation dossier will permit the use of the commercial kit for the detection of Anisakis and Pseudoterranova DNA in fish and fish products intended for human consumption by public or private laboratories, following the requirements regarding the quality assurance processes described in the ISO EN 17025:2005</style></abstract><notes><style face="normal" font="Arial">DA - 20170624IS - 1879-3460 (Electronic)IS - 0168-1605 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.06.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28646669">PM:28646669</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Food Microbiol\2017-257-75-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Food Microbiol\2017-257-75-9.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Food Microbiol\2017-257-75-9mmc1.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Food Microbiol\2017-257-75-9mmc1.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170624, Cavallero S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.06.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kamalaldin,N.A.</style></author><author><style face="normal" font="Arial"> Sulaiman,S.A.</style></author><author><style face="normal" font="Arial"> Yusop,M.R.</style></author><author><style face="normal" font="Arial"> Yahaya,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Regenerative Medicine Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200 Kepala Batas, Penang, Malaysia</style></auth-address><titles><title><style face="normal" font="Arial">Does Inhalation of Virgin Coconut Oil Accelerate Reversal of Airway Remodelling in an Allergic Model of Asthma?</style></title><secondary-title><style face="normal" font="Arial">Int J Inflam</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Inflam</style></full-title></periodical><pages end="" start="8741851">8741851-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Coconut</style></keyword><keyword><style face="normal" font="Arial"> Coconut oil</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Gas Chromatography-Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Many studies have been done to evaluate the effect of various natural products in controlling asthma symptoms. Virgin coconut oil (VCO) is known to contain active compounds that have beneficial effects on human health and diseases. The objective of this study was to evaluate the effect of VCO inhalation on airway remodelling in a rabbit model of allergic asthma. The effects of VCO inhalation on infiltration of airway inflammatory cells, airway structures, goblet cell hyperplasia, and cell proliferation following ovalbumin induction were evaluated. Allergic asthma was induced by a combination of ovalbumin and alum injection and/or followed by ovalbumin inhalation. The effect of VCO inhalation was then evaluated via the rescue or the preventive route. Percentage of inflammatory cells infiltration, thickness of epithelium and mucosa regions, and the numbers of goblet and proliferative cells were reduced in the rescue group but not in preventive group. Analysis using a gas chromatography-mass spectrometry found that lauric acid and capric acid were among the most abundant fatty acids present in the sample. Significant improvement was observed in rescue route in alleviating the asthma symptoms, which indicates the VCO was able to relieve asthma-related symptoms more than preventing the onset of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 2090-8040 (Print)IS - 2042-0099 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/8741851</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28660089">PM:28660089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Inflam\2017-2017-8741851.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Inflam\2017-2017-8741851.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Kamalaldin NA</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/8741851</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,J.H.</style></author><author><style face="normal" font="Arial"> Jin,M.</style></author><author><style face="normal" font="Arial"> Choi,Y.A.</style></author><author><style face="normal" font="Arial"> Jeong,N.H.</style></author><author><style face="normal" font="Arial"> Park,J.S.</style></author><author><style face="normal" font="Arial"> Shin,T.Y.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CMRI, Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Suppressive effect of an aqueous extract of Diospyros kaki calyx on dust mite extract/2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Med</style></full-title></periodical><pages end="511" start="505">505-511</pages><volume><style face="normal" font="Arial">40</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diospyros</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a common chronic inflammatory skin disease, affecting 10-20% of individuals worldwide. Therefore, the discovery of drugs for treating AD is an attractive subject and important to human health. Diospyros kaki and Diospyros kaki (D. kaki) folium exert beneficial effects on allergic inflammation. However, the effect of D. kaki calyx on AD remains elusive. The present study evaluated the effects of an aqueous extract of D. kaki calyx (AEDKC) on AD-like skin lesions using mouse and keratinocyte models. We used a mouse AD model by the repeated skin exposure of house dust mite extract [Dermatophagoides farinae extract (DFE)] and 2,4-dinitrochlorobenzene (DNCB) to the ears. In addition, to determine the underlying mechanism of its operation, tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma)-activated keratinocytes (HaCaT) were used. Oral administration of AEDKC decreased AD-like skin lesions, as demonstrated by the reduced ear thickness, serum immunoglobulin E (IgE), DFE-specific IgE, IgG2a, histamine level and inflammatory cell infiltration. AEDKC inhibited the expression of pro-inflammatory cytokines and a chemokine via downregulation of nuclear factor-kappaB and signal transducer and activator of transcription 1 in HaCaT cells. On examination of the AD-related factors in vivo and in vitro, it was confirmed that AEDKC decreased AD-like skin lesions. Taken together, the results suggest that AEDKC is a potential drug candidate for the treatment of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1791-244X (Electronic)IS - 1107-3756 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3892/ijmm.2017.3017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28627593">PM:28627593</url></web-urls><pdf-urls><url ppv-ref="no">shkim72@knu.ac.kr</url><url ppv-ref="no">tyshin@woosuk.ac.kr</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Yu JH</style></custom2><misc3><style face="normal" font="Arial">10.3892/ijmm.2017.3017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palomares,O.</style></author><author><style face="normal" font="Arial"> Sanchez-Ramon,S.</style></author><author><style face="normal" font="Arial"> Davila,I.</style></author><author><style face="normal" font="Arial"> Prieto,L.</style></author><author><style face="normal" font="Arial"> Perez De Llano,L.</style></author><author><style face="normal" font="Arial"> Lleonart,M.</style></author><author><style face="normal" font="Arial"> Domingo,C.</style></author><author><style face="normal" font="Arial"> Nieto,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, 28040 Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1328">E1328-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">Asthma is an airway disease characterised by chronic inflammation with intermittent or permanent symptoms including wheezing, shortness of breath, chest tightness, and cough, which vary in terms of their occurrence, frequency, and intensity. The most common associated feature in the airways of patients with asthma is airway inflammation. In recent decades, efforts have been made to characterise the heterogeneous clinical nature of asthma. The interest in improving the definitions of asthma phenotypes and endotypes is growing, although these classifications do not always correlate with prognosis nor are always appropriate therapeutic approaches. Attempts have been made to identify the most relevant molecular and cellular biomarkers underlying the immunopathophysiological mechanisms of the disease. For almost 50 years, immunoglobulin E (IgE) has been identified as a central factor in allergic asthma, due to its allergen-specific nature. Many of the mechanisms of the inflammatory cascade underlying allergic asthma have already been elucidated, and IgE has been shown to play a fundamental role in the triggering, development, and chronicity of the inflammatory responses within the disease. Blocking IgE with monoclonal antibodies such as omalizumab have demonstrated their efficacy, effectiveness, and safety in treating allergic asthma. A better understanding of the multiple contributions of IgE to the inflammatory continuum of asthma could contribute to the development of novel therapeutic strategies for the disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18061328</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28635659">PM:28635659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1328.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1328.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170621, Palomares O</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18061328</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reithofer,M.</style></author><author><style face="normal" font="Arial"> Jahn-Schmid,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna 1090, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Allergens with Protease Activity from House Dust Mites</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1368">E1368-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Type I allergy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">Globally, house dust mites (HDM) are one of the main sources of allergens causing Type I allergy, which has a high risk of progressing into a severe disabling disease manifestation such as allergic asthma. The strong protease activities of a number of these allergens are thought to be involved in several steps of the pathophysiology of this allergic disease. It has been a common notion that protease activity may be one of the properties that confers allergenicity to proteins. In this review we summarize and discuss the roles of the different HDM proteases in the development of Type I allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18071368</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28653989">PM:28653989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1368.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1368.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Reithofer M</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18071368</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jacquet,A.</style></author><author><style face="normal" font="Arial"> Campisi,V.</style></author><author><style face="normal" font="Arial"> Szpakowska,M.</style></author><author><style face="normal" font="Arial"> Dumez,M.E.</style></author><author><style face="normal" font="Arial"> Galleni,M.</style></author><author><style face="normal" font="Arial"> Chevigne,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medicine, Division of Research Affairs, Chulalongkorn University, 10330 Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="Arial">Profiling the Extended Cleavage Specificity of the House Dust Mite Protease Allergens Der p 1, Der p 3 and Der p 6 for the Prediction of New Cell Surface Protein Substrates</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1373">E1373-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cell surface receptors</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 3</style></keyword><keyword><style face="normal" font="Arial"> Der p 6</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAF</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Substrate Specificity</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">House dust mite (HDM) protease allergens, through cleavages of critical surface proteins, drastically influence the initiation of the Th2 type immune responses. However, few human protein substrates for HDM proteases have been identified so far, mainly by applying time-consuming target-specific individual studies. Therefore, the identification of substrate repertoires for HDM proteases would represent an unprecedented key step toward a better understanding of the mechanism of HDM allergic response. In this study, phage display screenings using totally or partially randomized nonameric peptide substrate libraries were performed to characterize the extended substrate specificities (P(5)-P(4)') of the HDM proteases Der p 1, Der p 3 and Der p 6. The bioinformatics interface PoPS (Prediction of Protease Specificity) was then applied to define the proteolytic specificity profile of each protease and to predict new protein substrates within the human cell surface proteome, with a special focus on immune receptors. Specificity profiling showed that the nature of residues in P(1) but also downstream the cleavage sites (P' positions) are important for effective cleavages by all three HDM proteases. Strikingly, Der p 1 and Der p 3 display partially overlapping specificities. Analysis with PoPS interface predicted 50 new targets for the HDM proteases, including 21 cell surface receptors whose extracellular domains are potentially cleaved by Der p 1, Der p 3 and/or Der p 6. Twelve protein substrate candidates were confirmed by phage ELISA (enzyme linked immunosorbent assay). This extensive study of the natural protein substrate specificities of the HDM protease allergens unveils new cell surface target receptors for a better understanding on the role of these proteases in the HDM allergic response and paves the way for the design of specific protease inhibitors for future anti-allergic treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Thailand -CO - Belgium -CO - Luxembourg -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18071373</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28654001">PM:28654001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1373.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1373.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Jacquet A</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18071373</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hofer,H.</style></author><author><style face="normal" font="Arial"> Weidinger,T.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Wolf,M.</style></author><author><style face="normal" font="Arial"> Twaroch,T.E.</style></author><author><style face="normal" font="Arial"> Stolz,F.</style></author><author><style face="normal" font="Arial"> Neubauer,A.</style></author><author><style face="normal" font="Arial"> Dall,E.</style></author><author><style face="normal" font="Arial"> Hammerl,P.</style></author><author><style face="normal" font="Arial"> Jacquet,A.</style></author><author><style face="normal" font="Arial"> Wallner,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg 5020, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Comparing Proteolytic Fingerprints of Antigen-Presenting Cells during Allergen Processing</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1225">E1225-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Centrifugation</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="Arial">Endolysosomal processing has a critical influence on immunogenicity as well as immune polarization of protein antigens. In industrialized countries, allergies affect around 25% of the population. For the rational design of protein-based allergy therapeutics for immunotherapy, a good knowledge of T cell-reactive regions on allergens is required. Thus, we sought to analyze endolysosomal degradation patterns of inhalant allergens. Four major allergens from ragweed, birch, as well as house dust mites were produced as recombinant proteins. Endolysosomal proteases were purified by differential centrifugation from dendritic cells, macrophages, and B cells, and combined with allergens for proteolytic processing. Thereafter, endolysosomal proteolysis was monitored by protein gel electrophoresis and mass spectrometry. We found that the overall proteolytic activity of specific endolysosomal fractions differed substantially, whereas the degradation patterns of the four model allergens obtained with the different proteases were extremely similar. Moreover, previously identified T cell epitopes were assigned to endolysosomal peptides and indeed showed a good overlap with known T cell epitopes for all four candidate allergens. Thus, we propose that the degradome assay can be used as a predictor to determine antigenic peptides as potential T cell epitopes, which will help in the rational design of protein-based allergy vaccine candidates</style></abstract><notes><style face="normal" font="Arial">DA - 20170608IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18061225</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28594355">PM:28594355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1225.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1225.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170608, Hofer H</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18061225</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grutsch,S.</style></author><author><style face="normal" font="Arial"> Fuchs,J.E.</style></author><author><style face="normal" font="Arial"> Ahammer,L.</style></author><author><style face="normal" font="Arial"> Kamenik,A.S.</style></author><author><style face="normal" font="Arial"> Liedl,K.R.</style></author><author><style face="normal" font="Arial"> Tollinger,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Organic Chemistry &amp; Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80/82, A-6020 Innsbruck, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Conformational Flexibility Differentiates Naturally Occurring Bet v 1 Isoforms</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1192">E1192-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1.0101</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1.0102</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics</style></keyword><keyword><style face="normal" font="Arial"> Molecular Dynamics Simulation</style></keyword><keyword><style face="normal" font="Arial"> Molecular dynamics simulations</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Relaxation</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="6" Year="2017">2017/6/3</year></dates><abstract><style face="normal" font="Arial">The protein Bet v 1 represents the main cause for allergic reactions to birch pollen in Europe and North America. Structurally homologous isoforms of Bet v 1 can have different properties regarding allergic sensitization and Th2 polarization, most likely due to differential susceptibility to proteolytic cleavage. Using NMR relaxation experiments and molecular dynamics simulations, we demonstrate that the initial proteolytic cleavage sites in two naturally occurring Bet v 1 isoforms, Bet v 1.0101 (Bet v 1a) and Bet v 1.0102 (Bet v 1d), are conformationally flexible. Inaccessible cleavage sites in helices and strands are highly flexible on the microsecond-millisecond time scale, whereas those located in loops display faster nanosecond-microsecond flexibility. The data consistently show that Bet v 1.0102 is more flexible and conformationally heterogeneous than Bet v 1.0101. Moreover, NMR hydrogen-deuterium exchange measurements reveal that the backbone amides in Bet v 1.0102 are significantly more solvent exposed, in agreement with this isoform's higher susceptibility to proteolytic cleavage. The differential conformational flexibility of Bet v 1 isoforms, along with the transient exposure of inaccessible sites to the protein surface, may be linked to proteolytic susceptibility, representing a potential structure-based rationale for the observed differences in Th2 polarization and allergic sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18061192</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587205">PM:28587205</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1192.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1192.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Grutsch S</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18061192</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hollbacher,B.</style></author><author><style face="normal" font="Arial"> Schmitt,A.O.</style></author><author><style face="normal" font="Arial"> Hofer,H.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Lackner,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Deptartment of Molecular Biology, University of Salzburg, A-5020 Salzburg, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Identification of Proteases and Protease Inhibitors in Allergenic and Non-Allergenic Pollen</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1199">E1199-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Functional annotation</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="5" Month="6" Year="2017">2017/6/5</year></dates><abstract><style face="normal" font="Arial">Pollen is one of the most common causes of allergy worldwide, making the study of their molecular composition crucial for the advancement of allergy research. Despite substantial efforts in this field, it is not yet clear why some plant pollens strongly provoke allergies while others do not. However, proteases and protease inhibitors from allergen sources are known to play an important role in the development of pollen allergies. In this study, we aim to uncover differences in the transcriptional pattern of proteases and protease inhibitors in Betula verrucosa and Pinus sylvestris pollen as models for high and low allergenic potential, respectively. We applied RNA sequencing to Betula verrucosa and Pinus sylvestris pollen. After de-novo assembly we derived general functional profiles of the protein coding transcripts. By utilization of domain based functional annotation we identified potential proteases and protease inhibitors and compared their expression in the two types of pollen. Functional profiles are highly similar between Betula verrucosa and Pinus sylvestris pollen. Both pollen contain proteases and inhibitors from 53 and 7 Pfam families, respectively. Some of the members comprised within those families are implicated in facilitating allergen entry, while others are known allergens themselves. Our work revealed several candidate proteins which, with further investigation, represent exciting new leads in elucidating the process behind allergic sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18061199</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587253">PM:28587253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1199.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1199.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Hollbacher B</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18061199</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Randall,T.A.</style></author><author><style face="normal" font="Arial"> London,R.E.</style></author><author><style face="normal" font="Arial"> Fitzgerald,M.C.</style></author><author><style face="normal" font="Arial"> Mueller,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Integrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Proteases of Dermatophagoides pteronyssinus</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1204">E1204-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Acari</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> cysteine proteases</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 3</style></keyword><keyword><style face="normal" font="Arial"> Der p 6</style></keyword><keyword><style face="normal" font="Arial"> Der p 9</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sarcoptes scabiei</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="Arial">Since the discovery that Der p 1 is a cysteine protease, the role of proteolytic activity in allergic sensitization has been explored. There are many allergens with proteolytic activity; however, exposure from dust mites is not limited to allergens. In this paper, genomic, transcriptomic and proteomic data on Dermatophagoides pteronyssinus (DP) was mined for information regarding the complete degradome of this house dust mite. D. pteronyssinus has more proteases than the closely related Acari, Dermatophagoides farinae (DF) and Sarcoptes scabiei (SS). The group of proteases in D. pteronyssinus is found to be more highly transcribed than the norm for this species. The distribution of protease types is dominated by the cysteine proteases like Der p 1 that account for about half of protease transcription by abundance, and Der p 1 in particular accounts for 22% of the total protease transcripts. In an analysis of protease stability, the group of allergens (Der p 1, Der p 3, Der p 6, and Der p 9) is found to be more stable than the mean. It is also statistically demonstrated that the protease allergens are simultaneously more highly expressed and more stable than the group of D. pteronyssinus proteases being examined, consistent with common assumptions about allergens in general. There are several significant non-allergen outliers from the normal group of proteases with high expression and high stability that should be examined for IgE binding. This paper compiles the first holistic picture of the D. pteronyssinus degradome to which humans may be exposed</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18061204</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587273">PM:28587273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1204.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1204.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Randall TA</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18061204</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">La Mantia,I.</style></author><author><style face="normal" font="Arial"> Andaloro,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Sciences, Surgical and Advanced Technologies, GF Ingrassia, University of Catania - ENT Unit, Santa Marta e Santa Venera Hospital, Acireale, Catania, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Demographics and clinical features predictive of allergic versus non-allergic rhinitis in children aged 6-18 years: A single-center experience of 1535 patients</style></title><secondary-title><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="109" start="103">103-109</pages><volume><style face="normal" font="Arial">98</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absenteeism</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Resource utilization</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic rhinitis (CR) is one of the most common causes accounting for lost-school days, absenteeism and resource utilization in pediatric patients. Distinction between common causes of CR, allergic (AR)and non-allergic rhinitis (NAR), based upon clinical features is critical, especially in primary care settings or facilities with lack of allergen sensitivity testing, as management strategies differ considerably. The current study elucidates clinical factors, particularly facial features associated with AR and NAR using a large cohort. METHODS: In a retrospective cohort analysis of pediatric patients aged 6-18 years, we assessed patient demographics, clinical symptoms, and signs associated with allergic rhinitis using multivariable regression techniques. RESULTS: Overall, 1490 patients (mean age: 10.11 +/- 3.31 years; 48% female; 69% AR and 31% NAR) were included in the study. In multivariable regression analysis, major clinical features associated with AR were: sneezing (OR: 3.53; 95% CI: 2.35-5.32; p &lt; 0.001), rhinorrhea (OR: 1.77; 95% CI: 1.18-2.66; p = 0.006), nasal itching (OR: 17.88; 95% CI: 11.92-26.83; p &lt; 0.001), horizontal nasal crease (OR: 5.09; 95% CI: 1.29-20.01; p = 0.020) and conjunctivitis (OR: 4.66; 95% CI: 3.28-6.62; p &lt; 0.001). On the contrary, we noted presence of Dennie-Morgan fold (OR: 1.67; 95% CI: 1.11-2.56; p = 0.014), moderate to severe persistent or intermittent symptoms to be likely associated with NAR than AR. CONCLUSION: In pediatric patients presenting with symptoms of rhinitis, facial hallmarks serve as an adjunct to sensitivity testing in establishing a diagnosis as well as differentiating between NAR from AR, albeit individualized upon patient history and clinical features</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1872-8464 (Electronic)IS - 0165-5876 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijporl.2017.04.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583485">PM:28583485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-98-103-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pediatr Otorhinolaryngol\2017-98-103-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, La Mantia I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijporl.2017.04.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suda,K.</style></author><author><style face="normal" font="Arial"> Yanai,T.</style></author><author><style face="normal" font="Arial"> Toma,M.</style></author><author><style face="normal" font="Arial"> Aiyoshi,T.</style></author><author><style face="normal" font="Arial"> Sasaki,T.</style></author><author><style face="normal" font="Arial"> Muraji,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Surgery, Ibaraki Children's Hospital, Ibaraki, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Aggressive gastrointestinal food allergy in neonates and its possible relationship to necrotizing enterocolitis</style></title><secondary-title><style face="normal" font="Arial">Int J Surg Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Surg Case Rep</style></full-title></periodical><pages end="178" start="175">175-178</pages><volume><style face="normal" font="Arial">36</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cellular immunity</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Methicillin-Resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> MRSA</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The incidence of gastrointestinal food allergy (FA) in neonates is increasing. Despite this, cases of patients with gastrointestinal FA who develop necrotizing enterocolitis (NEC) requiring laparotomy are extremely rare. PRESENTATION OF CASE: We describe two cases that presented with bloody stool with a probable diagnosis of FA as eosinophils were positive in the stool at onset. Both cases failed conservative treatment. Jejunostomy and ileostomy were performed in both cases due to secondary NEC with underlying acute FA. Post-surgery, raised peripheral blood eosinophil count, presence of cow's milk-specific IgE antibody and positive allergen-specific lymphocyte stimulation test were found. Stoma closure were performed 3 and 1 months later in both cases. Postoperative recovery was uneventful. DISCUSSION: A few reports have not identified risk factors for NEC secondary to FA. Thrombocytopenia and rise in C-reactive protein (CRP) levels 2days after the development of FA may be suggestive of FA with NEC. Methicillin-resistant Staphylococcus aureus (MRSA) was detected in the fecal culture of both patients at the time of the onset of NEC. The toxic antigen produced by MRSA may cause activation of milk-protein-primed T cells and exacerbate FA. CONCLUSION: The decrease of platelet levels and rise in CRP may indicate the development of secondary NEC in patients with FA. Additionally, MRSA detected in the fecal culture also may be a risk factor for NEC through the activation of cellular immunity reaction pathways</style></abstract><notes><style face="normal" font="Arial">DA - 20170610IS - 2210-2612 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijscr.2017.05.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601030">PM:28601030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Surg Case Rep\2017-36-175-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Surg Case Rep\2017-36-175-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170610, Suda K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijscr.2017.05.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hara,Y.</style></author><author><style face="normal" font="Arial"> Shiraishi,A.</style></author><author><style face="normal" font="Arial"> Sakane,Y.</style></author><author><style face="normal" font="Arial"> Takezawa,Y.</style></author><author><style face="normal" font="Arial"> Kamao,T.</style></author><author><style face="normal" font="Arial"> Ohashi,Y.</style></author><author><style face="normal" font="Arial"> Yasunaga,S.</style></author><author><style face="normal" font="Arial"> Sugahara,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology, Ehime University School of Medicine, Shitsukawa, Toon, Ehime, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge</style></title><secondary-title><style face="normal" font="Arial">Invest Ophthalmol Vis Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Invest Ophthalmol Vis Sci</style></full-title></periodical><pages end="2929" start="2922">2922-2929</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nobiletin</style></keyword><keyword><style face="normal" font="Arial"> Ocular surface</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> orange</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yogurt</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">Purpose: To evaluate the effects of mandarin orange yogurt containing nobiletin and beta-lactoglobulin on the allergic conjunctivitis induced by a conjunctival allergen challenge (CAC). Methods: Experiment 1 was performed on 26 asymptomatic patients (age, 25.3 +/- 5.3 years) with proven seasonal allergic conjunctivitis due to cedar pollen. We compared the degree of conjunctivitis induced by CAC before and after ingesting mandarin orange yogurt for 2 weeks. Experiment 2 was a double-blind, placebo-controlled trial performed on 31 patients (age, 32.5 +/- 12.2 years). A diet containing mandarin orange yogurt was compared to a diet containing yogurt lacking the mandarin orange on the conjunctivitis induced by CAC. The temperature of the inferior bulbar conjunctiva was measured before and 20 minutes after the CAC with an ocular surface thermographer (OST). The degree of conjunctival injection and chemosis was graded by slit-lamp biomicroscopy. The changes in the symptoms were evaluated by a questionnaire. Results: In experiment 1, the scores of redness (3.07 +/- 3.03 vs. 1.05 +/- 1.70), chemosis (2.84 +/- 2.27 vs. 0.81 +/- 1.11), itching (4.34 +/- 3.05 vs. 1.39 +/- 2.12), and temperature (0.73 +/- 0.42 degrees C vs. 0.45 +/- 0.43 degrees C) were significantly lower (P &lt; 0.001) after a diet of mandarin orange yogurt for 2 weeks. In experiment 2, the scores of redness (1.03 +/- 0.18 vs. 1.28 +/- 0.52; P = 0.0156), itching (1.93 +/- 1.92 vs. 2.82 +/- 2.21; P = 0.0133), and surface temperature (0.54 +/- 0.21 degrees C vs. 0.31 +/- 0.25 degrees C; P &lt; 0.001) were significantly lower in the mandarin orange yogurt group than in the control yogurt group. Conclusions: Mandarin orange yogurt can be an effective nutritional intervention for allergic conjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170608IS - 1552-5783 (Electronic)IS - 0146-0404 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1167/iovs.16-21206</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28593244">PM:28593244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Invest Ophthalmol Vis Sci\2017-58-2922-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Invest Ophthalmol Vis Sci\2017-58-2922-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170608, Hara Y</style></custom2><misc3><style face="normal" font="Arial">10.1167/iovs.16-21206</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,A.L.</style></author><author><style face="normal" font="Arial"> Sun,Y.Q.</style></author><author><style face="normal" font="Arial"> Du,P.</style></author><author><style face="normal" font="Arial"> Meng,X.C.</style></author><author><style face="normal" font="Arial"> Guo,L.</style></author><author><style face="normal" font="Arial"> Li,S.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key laboratory of Dairy Science, Ministry of Education, College of Food Sciences, Northeast Agriculture University, Xiangfang District, Harbin, Heilongjiang, China</style></auth-address><titles><title><style face="normal" font="Arial">The Effect of Lactobacillus actobacillus Peptidoglycan on Bovine beta-Lactoglobulin-Sensitized Mice via TLR2/NF-kappaB Pathway</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="158" start="147">147-158</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Peptidoglycan</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 2</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Our previous study reported that Lactobacillus acidophilus(L.acidophilus) key laboratory of dairy science (KLDS) 1.0738 had an effective impact on inhibiting beta-lactoglobulin (beta-lg) allergy. This study further investigated the anti-allergic activity of peptidoglycan (PGN) isolated from KLDS 1.0738. This study aimed to assess whether toll-like receptor 2 (TLR2)/NF-kappaB (NF-kappaB) signaling activated by PGN was responsible for reducing allergic inflammation. Our data showed that administration of L. acidophilus PGN inhibited IgE production and improved the Treg/Th17 balance toward a Treg response in a mouse model of beta-lg allergy. In addition, treating different doses L. acidophilus PGN to sensitized mice significantly increased TLR2 levels, along with enhancing NF-kappaB expression, especially in medium and high concentration (p&lt;0.05). Further analysis revealed that the mRNA expression of TLR2 and NF-kappaB were positively correlated with the Foxp3 mRNA expression (p&lt;0.05), but were negatively correlated with the RORgammat mRNA expression in L. acidophilus PGN-treated group compared to allergy group (p&amp;lt;0.05). This study suggests PGN was similar to probiotics in preventing beta-lg allergy through regulating Treg/Th17 imbalance, and activation of TLR2/NF-kappaB signaling may be involved in this process</style></abstract><notes><style face="normal" font="Arial">DA - 20170611IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601055">PM:28601055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-147-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-147-58.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Li AL</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Daneshmandi,S.</style></author><author><style face="normal" font="Arial"> Nourizadeh,M.</style></author><author><style face="normal" font="Arial"> Pourpak,Z.</style></author><author><style face="normal" font="Arial"> Pourfathollah,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Eliciting Th1 Immune Response Using Casein- (Alpha S1) loaded Dendritic Cells</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="168" start="159">159-168</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> GFP</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 immune response</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (AIT) has been recently considered as an alternative approach to ameliorate the symptoms of allergen exposure and improvement the patients' quality of life. Dendritic cells (DC) in the forms of tolerogenic or Th1-induced cells have been investigated in several studies as one of the promising approaches of AIT in allergic diseases. The aim of this study was to evaluate the potency of casein-loaded DCs in eliciting the Th1 immune responses in Balb/c mice as a potential therapeutic approach in allergic condition. Immature bone marrow-derived DCs were loaded with casein (protein or mRNA) or green fluorescent protein (GFP) mRNA. DCs were evaluated based on the expression of specific markers and production of proinflammatory cytokines. Expression of DC markers in all groups was significantly higher than immature DCs, but lower than LPS-activated DCs. Despite an increase in TNF-alpha and IL-12, IL-6 was decreased in casein-DC treatments. Caseinloaded DCs could induce proliferation in lymphocytes and stimulate them to produce higher amounts of IFN-gamma and in some extent IL-10 and TGF-beta, while they could not stimulate IL-4 secretion. Casein-loaded DCs could partially elicit the Th1 responses; this would be a promising approach to use them as an allergic protective way for applying immune cell therapy in cow's milk allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170611IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601056">PM:28601056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-159-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-159-68.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Daneshmandi S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teifoori,F.</style></author><author><style face="normal" font="Arial"> Postigo,I.</style></author><author><style face="normal" font="Arial"> Martinez,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Microbiology, and Parasitology, Faculty of Pharmacy and Laboratory of Parasitology and Allergy, Lascaray Research Centre, University of the Basque Country, Paseo de la Universidad, Vitoria, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Learning from the Molecular Profile of Blattella Germanica Allergens Identified from Allergic Patients in Tehran, Iran</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="170" start="169">169-170</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Blattella germanica</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">No Abstract</style></abstract><notes><style face="normal" font="Arial">DA - 20170611IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601057">PM:28601057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-169-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-169-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Teifoori F</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soleimani-Ahmadi,M.</style></author><author><style face="normal" font="Arial"> Zare,M.</style></author><author><style face="normal" font="Arial"> Abtahi,S.M.</style></author><author><style face="normal" font="Arial"> Khazeni,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Infectious Diseases Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Species Identification and Prevalence of House Dust Mites as Respiratory Allergen in Kindergartens of the Bandar Abbas City</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="139" start="133">133-139</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control measures</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Species identification</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vacuum</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">The aim of this study was to identify the species and prevalence of house dust mites (HDMs) in kindergartens in Bandar Abbas, south of Iran. In this study 10 kindergartens were selected randomly in five areas of Bandar Abbas. Two dust samples were collected from each sampling place with a vacuum cleaner. Mites were isolated and mounted in Hoyer's medium and identified using a morphology-based key. In total, 1758 mites were collected and identified, whichconsisted of five species: Dermatophagoides pteronyssinus (31.06%), D. evansi (23.49%), D. farinae (17.75%), Ornithonyssus bacoti (19.45%), and Cheyletus malaccensis (8.25%). Two main allergenic dust mite species D. pteronyssinus and D. farinae, coinhabited and were collected from all of kindergartens. Results of this study have revealed that D. pteronyssinus is the most prevalent HDMs in Bandar Abbas Kindergartens and all studied areas are contaminated by more than one dust mite Regarding the high prevalence of HDMs in Bandar Abbas kindergartens, implementation of strict control measures is necessary for reduction of mite population and prevention of children respiratory diseases and other allergic disorders in this city</style></abstract><notes><style face="normal" font="Arial">DA - 20170611IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601053">PM:28601053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-133-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-133-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Soleimani-Ahmadi M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zivanovic,M.</style></author><author><style face="normal" font="Arial"> Atanaskovic-Markovic,M.</style></author><author><style face="normal" font="Arial"> Medjo,B.</style></author><author><style face="normal" font="Arial"> Gavrovic-Jankulovic,M.</style></author><author><style face="normal" font="Arial"> Smiljanic,K.</style></author><author><style face="normal" font="Arial"> Tmusic,V.</style></author><author><style face="normal" font="Arial"> Djuric,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Special Hospital "Sokobanja", Sokobanja, Serbia</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of Food Allergy in Children by Skin Prick Tests with Commercial Extracts and Fresh Foods, Specific IgE and, Open Oral Food Challenge-Our Five Years Experience in Food Allergy Work-up</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="132" start="127">127-132</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy workup</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">IgE- mediated food allergy affects 6-8% of children. Our study aimed to define the correlations between the results obtained with skin prick tests (SPTs) using commercial extracts and fresh foods, and the correlations between these result and those obtained with specific IgE (sIgE) and/ or challenge. Children aged from 2 months to 6 years were recruited prospectively. Overall 571 children were positive to one food. In all children we performed SPT using commercial extracts of suspected food and fresh foods and sIgE. If SPT and sIgE test results did not correspond to the history, we performed open oral food challenge. Sensitivity of SPT with commercial extracts for all tested food was poor (3-35%), while sensitivity of fresh food skin prick tests (FFSPT) was excellent (50-100%), and showed correlation with open oral food challenge (p&lt;0.001). Our results suggest that fresh food extracts are more effective in detecting sensitization and with levels of sIgE greater than class 3 could predict clinical reactivity, without the need for potentially hazardous food challenges</style></abstract><notes><style face="normal" font="Arial">DA - 20170611IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Serbia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601052">PM:28601052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-127-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-127-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, ZIvanovic M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farahmand Fard,M.A.</style></author><author><style face="normal" font="Arial"> Khanjani,N.</style></author><author><style face="normal" font="Arial"> Arabi,M.A.</style></author><author><style face="normal" font="Arial"> Ashrafi,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Asthma and Allergic Rhinitis Correlation in Palm Tree Workers of Jahrom City in 2016</style></title><secondary-title><style face="normal" font="Arial">Iran J Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Otorhinolaryngol</style></full-title></periodical><pages end="154" start="147">147-154</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">92</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Employment</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perfume</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Precaution</style></keyword><keyword><style face="normal" font="Arial"> precautions</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Allergic rhinitis and asthma can be related to occupation. The present study aimed to investigate the correlation between asthma or allergic rhinitis and employment in the palm tree gardens of Jahrom, Iran. MATERIALS AND METHODS: This was a cross-sectional study including 50 palm tree garden workers and a control group of 50 office employees. Data collection included demographics, as well as standard International Study of Asthma and Allergies in Childhood (ISAAC) and A New Symptom-Based Questionnaire for Predicting the Presence of Asthma (ASQ) questionnaires. Data were analyzed using SPSS22. Descriptive statistics, chi-square test, t-test, and logistics regression were used to analyze data. RESULTS: The correlation between asthma and occupation was significant ( P=0.046); and asthma prevalence was higher in palm tree garden workers. However, no relationship was observed between age, duration of employment, smoking cigarettes, hookah, or opium addiction with asthma. Furthermore, in this study, no significant relation was observed between the prevalence of asthma and contact with dust, contact with pets' skin and hair, family history of asthma, or the use of perfume and air freshener. The symptoms of allergic rhinitis (including sneezing, runny nose, and blocked nose) were significantly greater in palm tree garden workers (P=0.038). These symptoms in both workers and office employees were higher in spring. CONCLUSION: In our study, allergic rhinitis and asthma were more common in palm tree garden workers than in the general population. According to our study, people working in this occupation should take necessary precautions</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 2251-7251 (Print)IS - 2251-7251 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28589108">PM:28589108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Otorhinolaryngol\2017-29-147-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Otorhinolaryngol\2017-29-147-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Farahmand Fard MA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tipu,H.N.</style></author><author><style face="normal" font="Arial"> Ahmed,D.</style></author><author><style face="normal" font="Arial"> Gardezi,S.A.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Armed Forces Institute of Pathology (AFIP), Rawalpindi, Pakistan</style></auth-address><titles><title><style face="normal" font="Arial">In silico identification of epitopes from house cat and dog proteins as peptide immunotherapy candidates based on human leukocyte antigen binding affinity</style></title><secondary-title><style face="normal" font="Arial">Iran J Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Vet Res</style></full-title></periodical><pages end="59" start="56">56-59</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen nomenclature</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> binding affinity</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> HLA class II</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> IUIS</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> NetMHCII-2.2</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The objective of this descriptive study was to determine Felis domesticus (cat) and Canis familiaris (dog) protein epitopes that bind strongly to selected HLA class II alleles to identify synthetic vaccine candidate epitopes and to identify individuals/populations who are likely to respond to vaccines. FASTA amino acid sequences of experimentally validated allergenic proteins of house cat and dog were identified using International Union of Immunological Societies (IUIS) allergen nomenclature database. NetMHCII 2.2 server was used to determine binding affinities in the form of 1-log 50 k and in nM with commonly found HLA II alleles. Screening of house cat and dog allergenic proteins identified 4 (with 2 isoforms for chain 1 and 3 isoforms for chain 2 for fel d 1) and 6 proteins, respectively. Number of strong binders from each protein against each HLA type was determined as potential candidate for allergen immunotherapy. HLA-DRB1*0101 bound maximum number of epitopes (207 and 275 from house cat and dog, respectively) while HLA-DRB1*0802 bound none. We conclude that HLA specific epitope prediction can help identify synthetic peptide vaccine candidates and predict response as well</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1728-1997 (Print)IS - 2252-0589 (Linking)LA - engPT - Journal ArticleCO - Pakistan -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28588634">PM:28588634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Vet Res\2017-18-56-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Vet Res\2017-18-56-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Tipu HN</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Y.</style></author><author><style face="normal" font="Arial"> Tu,Z.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Sha,X.</style></author><author><style face="normal" font="Arial"> Huang,T.</style></author><author><style face="normal" font="Arial"> Ma,D.</style></author><author><style face="normal" font="Arial"> Pang,J.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The reduction in the IgE-binding ability of beta-lactoglobulin by dynamic high pressure microfluidization coupled with glycation treatment revealed by high resolution mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> DHPM</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Galactose</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> high pressure</style></keyword><keyword><style face="normal" font="Arial"> High-pressure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE Binding Ability</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding ability</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">Our previous study indicated that pretreatment by dynamic high pressure microfluidization (DHPM) and glycation with galactose was a promising method for decreasing the immunoglobulin E (IgE) binding ability of beta-lactoglobulin (beta-LG). In present work, the conformational alteration of beta-LG subjected to DHPM and glycation treatment were investigated in relation to IgE binding ability by Orbitrap mass spectrometry. After DHPM pretreatment, lower IgE binding ability of glycated beta-LG was observed with increasing pressures. Prior to DHPM pretreatment, 11 glycated sites were identified, while the number of glycation sites was increased to 12 after pretreatment. However, there was no significant difference of the glycation sites at the pressures of 50, 100, and 200 MPa, respectively. Average degree of substitution per peptide molecule of beta-LG (DSP) was investigated to assess the degree of glycation for per glycation site. All the samples pretreated by DHPM exhibited higher glycation level than that of without DHPM pretreatment. The shielding effects of epitopes owing to glycation contributed to the reduction of IgE binding capacity. Orbitrap mass spectrometry could provide a comprehensive understanding of the nature of protein glycation</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b00934</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28654282">PM:28654282</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170627-ChenY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170627-ChenY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Chen Y</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b00934</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boukid,F.</style></author><author><style face="normal" font="Arial"> Prandi,B.</style></author><author><style face="normal" font="Arial"> Sforza,S.</style></author><author><style face="normal" font="Arial"> Sayar,R.</style></author><author><style face="normal" font="Arial"> Seo,Y.W.</style></author><author><style face="normal" font="Arial"> Mejri,M.</style></author><author><style face="normal" font="Arial"> Yacoubi,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Understanding the Effects of Genotype, Growing Year and Breeding on Tunisian Durum Wheat Allergenicity (Part 1): The Baker's asthma case</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analysis of Variance</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baker's asthma</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Durum wheat</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> heritability</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein quantification</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="Arial">Baker's asthma is a serious airway disease triggered by wheat proteins CM3 alpha-amylase/trypsin inhibitor. The purpose of the present study was to investigate the impact of genotype and crop year on allergen CM3 alpha-amylase/trypsin inhibitor associated to baker's asthma. A historical series of Tunisian durum wheat (100 accessions), derived from three crop years, was used to compare the amount of CM3 from landraces to advanced cultivars. CM3 protein quantification was assessed after an enzymatic cleavage of the soluble protein extracts on an UPLC/ESI-MS system, using a marker peptide for its quantification. Combined data analysis of variance revealed an important effect of genotype, crop year and their interaction. The CM3 allergenic proteins were found to significantly vary among studied genotypes, as confirmed by genetic variability, coefficient of variance, heritability and genetic advance</style></abstract><notes><style face="normal" font="Arial">DA - 20170623IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Tunisia -CO - Italy -CO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b02040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28644028">PM:28644028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170623-BoukidF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170623-BoukidF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170623, Boukid F</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b02040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Geng,F.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Liu,D.</style></author><author><style face="normal" font="Arial"> Jin,Y.</style></author><author><style face="normal" font="Arial"> Ma,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Coarse Cereal Processing, Ministry of Agriculture, College of Pharmacy and Biological Engineering, Chengdu University , No. 1 Upper Section of Shiling Street, Chengdu 610106, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Identification of N-Glycosites in Chicken Egg White Proteins Using an Omics Strategy</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chymotrypsin</style></keyword><keyword><style face="normal" font="Arial"> Clusterin</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg white proteins</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> Glycopeptides</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Isoelectric Point</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> PNGase F</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">Chicken egg white (CEW) is a perfect source of natural proteins that possesses outstanding functional properties and various bioactivities. The glycosylation structure of CEW proteins plays important roles in their functions, bioactivities, and allergies. The present work attempted to identify N-glycosites of CEW proteins using an omics strategy. CEW proteins were digested with trypsin and chymotrypsin; glycopeptides were enriched and deglycosylated using PNGase F in H218O water, followed by analysis using high-performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS). A total of 71 N-glycosites in 26 CEW glycoproteins were identified. Web-Logo analysis showed that most of the N-glycosites were at N-X-T (55%) and N-X-S (32%). Furthermore, two-dimensional electrophoresis of CEW clusterin demonstrated a series of spots horizontally distributed at 35-37 kDa with an extremely wide isoelectric point range of 4.54-6.68, indicating the heterogeneity of glycosylation of CEW clusterin. These results provided important information for the understanding of the structures, functions, and bioactivities of CEW glycoproteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b01706</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587447">PM:28587447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170627-GengF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170627-GengF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Geng F</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b01706</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hill,R.C.</style></author><author><style face="normal" font="Arial"> Oman,T.J.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Shan,G.</style></author><author><style face="normal" font="Arial"> Schafer,B.</style></author><author><style face="normal" font="Arial"> Herman,R.A.</style></author><author><style face="normal" font="Arial"> Tobias,R.</style></author><author><style face="normal" font="Arial"> Shippar,J.</style></author><author><style face="normal" font="Arial"> Malayappan,B.</style></author><author><style face="normal" font="Arial"> Sheng,L.</style></author><author><style face="normal" font="Arial"> Xu,A.</style></author><author><style face="normal" font="Arial"> Bradshaw,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development, Validation, and Inter-laboratory Evaluation of a Quantitative Multiplexing Method to assess levels of Ten Endogenous Allergens in Soybean Seed and its Application to Field Trials Spanning Three Growing Seasons</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen profile</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Gly m 5</style></keyword><keyword><style face="normal" font="Arial"> Gly m 6</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> soybean allergens</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">As part of the regulatory approval process in Europe, comparison of endogenous soybean allergen levels between genetically engineered (GE) and non-GE plants has been requested. A quantitative multiplex analytical method using tandem mass spectrometry has been developed and validated to measure ten potential soybean allergens from soybean seed. The analytical method was implemented at six laboratories to demonstrate the robustness of the method and further applied to three soybean field studies across multiple growing seasons (including 21 non-GE soybean varieties) to assess the natural variation of allergen levels. The results show environmental factors contribute more than gentic factors to the large variation in allergen abundance (2 to 50-fold between environmental replicates) as well as a large contribution of Gly m 5 and Gly m 6 to the total allergen profile calling into question the scientific rational for measurement of endogenous allergen levels between GE and non-GE varieties in the safety assessment</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b01018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28635260">PM:28635260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170621-HillRC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170621-HillRC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170621, Hill RC</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b01018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boukid,F.</style></author><author><style face="normal" font="Arial"> Prandi,B.</style></author><author><style face="normal" font="Arial"> Sforza,S.</style></author><author><style face="normal" font="Arial"> Sayar,R.</style></author><author><style face="normal" font="Arial"> Seo,Y.W.</style></author><author><style face="normal" font="Arial"> Mejri,M.</style></author><author><style face="normal" font="Arial"> Yacoubi,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Understanding the Effects of Genotype, Growing Year and Breeding on Tunisian Durum Wheat Allergenicity (Part 2): The celiac disease case</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Durum wheat</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic diversity</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Germplasm</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">The aim of this study was to compare immunogenic and toxic gluten peptides related to celiac disease (CD). 100 accessions of genotypes selected during the 20th century in Tunisia were in vitro digested, then analyzed by UPLC/ESI-MS technique using an isotopically labeled internal standard. The first MANOVA confirmed a high variability in the content of immunogenic and toxic peptides reflecting high genetic diversity in the germplasm released during the last century in Tunisia, consistently with PCA and clustering analysis results. Our finding showed also important variability in CD epitopes due to growing season's climate scenarios. Moreover, the second MANOVA revealed significant differences between abandoned and modern cultivars CD-related peptide amounts. Although we could not conclude that there was an augment of allergens in newly selected durum wheat lines compared to abandoned ones, we demonstrated that modern genotypes peptides were less sensitive to climate variation, which is a useful indicator for wheat breeders</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Tunisia -CO - Italy -CO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b02041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28635270">PM:28635270</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170621-BoukidF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170621-BoukidF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170621, Boukid F</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b02041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maazi,H.</style></author><author><style face="normal" font="Arial"> Banie,H.</style></author><author><style face="normal" font="Arial"> Aleman,G.</style></author><author><style face="normal" font="Arial"> Patel,N.</style></author><author><style face="normal" font="Arial"> Wang,B.</style></author><author><style face="normal" font="Arial"> Sankaranarayanan,I.</style></author><author><style face="normal" font="Arial"> Bhargava,V.</style></author><author><style face="normal" font="Arial"> Sato,T.</style></author><author><style face="normal" font="Arial"> Lewis,G.</style></author><author><style face="normal" font="Arial"> Cesaroni,M.</style></author><author><style face="normal" font="Arial"> Karras,J.</style></author><author><style face="normal" font="Arial"> Das,A.</style></author><author><style face="normal" font="Arial"> Soroosh,P.</style></author><author><style face="normal" font="Arial"> Akbari,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, California 90033, USA</style></auth-address><titles><title><style face="normal" font="Arial">Activated Plasmacytoid Dendritic Cells regulate Type 2 Innate Lymphoid Cells-mediated Airway Hyperreactivity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interferon alpha</style></keyword><keyword><style face="normal" font="Arial"> Interferon-alpha</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> molecular microbiology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptome analysis</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic asthma is a prevalent inflammatory disease of the airways caused by dysregulated immune balance in the lungs with incompletely understood pathogenesis. The recently identified type 2 innate lymphoid cells (ILC2s) play significant roles in the pathogenesis of asthma. While ILC2-activating factors have been identified, the mechanisms that suppress ILC2s remain largely unknown. Plasmacytoid dendritic cells, pDCs, are important in antiviral immunity and in maintaining tolerance to inert antigens. OBJECTIVE: To address the role of pDCs in regulating ILC2's function and ILC2-medited airway hyperreactivity (AHR) and lung inflammation. METHODS: We used several mouse models including BDCA-2-DTR transgenic and Interferon alpha receptor-1 deficient mice as well as purified primary ILC2s to reach our objective. We extended and validated our findings to human ILC2s. RESULTS: We show that activation of pDCs through Toll-like receptor-7/8 suppresses ILC2-mediated AHR and airway inflammation and that depletion of pDCs reverses this suppression. We further show that pDCs suppress cytokine production and proliferation rate while increasing the apoptosis rate of ILC2s through the production of interferon alpha. Transcriptome analysis of both human and murine ILC2s confirms the activation of regulatory pathways in ILC2s by interferon alpha. CONCLUSION: Activation of pDCs alleviates AHR and airway inflammation by suppressing ILC2's function and survival. Our findings reveal a novel regulatory pathway in ILC2-mediated pulmonary inflammation with important clinical implications</style></abstract><notes><style face="normal" font="Arial">DA - 20170605IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28579374">PM:28579374</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170605-MaaziH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170605-MaaziH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170605, Maazi H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rudders,S.A.</style></author><author><style face="normal" font="Arial"> Clark,S.</style></author><author><style face="normal" font="Arial"> Camargo,C.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="Arial">Inpatient interventions are infrequent during pediatric hospitalizations for food-induced anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1424" start="1421">1421-1424</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="3" Month="6" Year="2017">2017/6/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587809">PM:28587809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1421-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1421-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Rudders SA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masilamani,M.</style></author><author><style face="normal" font="Arial"> Chang,L.M.</style></author><author><style face="normal" font="Arial"> Kamalakannan,M.</style></author><author><style face="normal" font="Arial"> Schussler,E.</style></author><author><style face="normal" font="Arial"> Rassbach,W.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Jaffe Food Allergy Institute, Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY;</style></auth-address><titles><title><style face="normal" font="Arial">Dietary isoflavone supplementation for food allergy: a pilot study</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1762" start="1760">1760-1762</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="2" Month="6" Year="2017">2017/6/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583480">PM:28583480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1760-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1760-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Masilamani M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brauer,D.L.</style></author><author><style face="normal" font="Arial"> Tse,K.Y.</style></author><author><style face="normal" font="Arial"> Lin,J.C.</style></author><author><style face="normal" font="Arial"> Schatz,M.X.</style></author><author><style face="normal" font="Arial"> Simon,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Scripps Green Hospital, La Jolla, Calif</style></auth-address><titles><title><style face="normal" font="Arial">The Utility of the Reflux Symptom Index for Diagnosis of Laryngopharyngeal Reflux in an Allergy Patient Population</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="138" start="132">132-138</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Drainage</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vocal cord dysfunction</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Laryngopharyngeal reflux (LPR) is associated with asthma, vocal cord dysfunction, cough, postnasal drainage, and throat irritation. The Reflux Symptom Index (RSI) is a clinical tool to predict the presence of LPR, but a threshold RSI score has never been validated for the diagnosis of LPR in an allergic patient population. OBJECTIVE: To identify the optimal threshold RSI score predictive of LPR in an allergy clinic population. METHODS: The 9-question RSI questionnaire was administered to 84 patients in the Kaiser Permanente San Diego Allergy Department. The patient's allergist (who was blinded to the patient's RSI responses) was asked to determine whether the patient had symptoms consistent with LPR. Each subject's RSI score was then compared with a corresponding physician-based diagnosis. After determining the correlation between the subject's RSI score and physician-diagnosed LPR/supraesophageal reflux, a cutoff level above which LPR/supraesophageal reflux would be highly suspected was calculated on the basis of most optimal balance of sensitivity and specificity determined via a receiver-operating curve analysis. RESULTS: Thirty of the 84 patients (36%) were diagnosed with LPR. The mean RSI score for the group without LPR was 18.3 +/- 9.8 (out of 45 possible), while the LPR group's mean was 25.0 +/- 8.3 (P &lt; .01). The optimal RSI score cutoff was determined to be 19. An abbreviated questionnaire was also generated using 6 of the RSI questions found to be significantly different between patients with and without LPR. CONCLUSIONS: An RSI score of 19 appears to represent the best threshold for predicting LPR in an allergy clinic patient population</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606786">PM:28606786</url></web-urls><pdf-urls><url ppv-ref="no">kevin.y.tse@kp.org</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170613, Brauer DL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weinbrand-Goichberg,J.</style></author><author><style face="normal" font="Arial"> Benor,S.</style></author><author><style face="normal" font="Arial"> Rottem,M.</style></author><author><style face="normal" font="Arial"> Shacham,N.</style></author><author><style face="normal" font="Arial"> Mandelberg,A.</style></author><author><style face="normal" font="Arial"> Levine,A.</style></author><author><style face="normal" font="Arial"> Sade,K.</style></author><author><style face="normal" font="Arial"> Kivity,S.</style></author><author><style face="normal" font="Arial"> Dalal,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy Unit, E. Wolfson Medical Center, Holon, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Long-term outcomes following baked milk-containing diet for IgE-mediated milk allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1778" start="1776">1776-1778</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> long-term outcome</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword></keywords><dates><year Day="2" Month="6" Year="2017">2017/6/2</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583481">PM:28583481</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1776-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1776-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Weinbrand-Goichberg J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shaker,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Allergy and Clinical Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, NH.</style></auth-address><titles><title><style face="normal" font="Arial">An Economic Analysis of a Peanut Oral Immunotherapy Study in Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1716" start="1707">1707-1716</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut oral immunotherapy (POIT) decreases the probability of accidental recurrent systemic reactions but reactions from the therapy itself are frequent. OBJECTIVE: The purpose of this economic analysis was to characterize the potential cost-effectiveness of POIT. METHODS: Cohort simulations were used to evaluate the effect of POIT for children with peanut allergy. A POIT with probiotic was used in the base-case simulation and long-term survival was modeled using age-adjusted mortality together with the risk of food allergy-associated mortality. RESULTS: The incremental POIT cost-effectiveness ratio was $2142 per quality-adjusted life-year. A mean number of 12.3 (95% CI, 12.0-12.5) and 2.0 (95% CI, 1.9-2.1) allergic reactions occurred in the POIT and avoidance groups over 20 years of simulation, with 2.3 (95% CI, 2.2-2.3) episodes of anaphylaxis treated with intramuscular epinephrine per subject in the POIT group and 1.1 (95% CI, 1.0-1.2) episodes per subject in the avoidance group. In sensitivity analyses, POIT was associated with lower rates of anaphylaxis than strict avoidance when the annual rate of accidental allergic reactions in the peanut avoidance group exceeded 25%, the annual rate of anaphylaxis in the POIT group dropped below 6%, or the probability of sustained unresponsiveness after 4 years of POIT was 68% or greater. CONCLUSIONS: POIT may be cost-effective in a long-term economic model. However, treated patients may experience a greater rate of peanut-associated allergic reactions and anaphylaxis. The analysis was sensitive to rates of accidental allergic reactions, therapy-associated adverse events, and likelihood of therapy-induced tolerance</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606784">PM:28606784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1707-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1707-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Shaker MS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Williams,S.J.</style></author><author><style face="normal" font="Arial"> Khokhar,A.</style></author><author><style face="normal" font="Arial"> Gharib,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Basic and Clinical Immunology, University of California Irvine, Irvine, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">Successful rapid desensitization to intravenous bevacizumab using a 14-step protocol: case report</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1747" start="1746">1746-1747</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">California</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Rapid desensitization</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606785">PM:28606785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1746-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1746-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Williams SJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Happle,C.</style></author><author><style face="normal" font="Arial"> Jirmo,A.C.</style></author><author><style face="normal" font="Arial"> Meyer-Bahlburg,A.</style></author><author><style face="normal" font="Arial"> Habener,A.</style></author><author><style face="normal" font="Arial"> Hoymann,H.G.</style></author><author><style face="normal" font="Arial"> Hennig,C.</style></author><author><style face="normal" font="Arial"> Skuljec,J.</style></author><author><style face="normal" font="Arial"> Hansen,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany</style></auth-address><titles><title><style face="normal" font="Arial">B cells control maternofetal priming of allergy and tolerance in a murine model of allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amniotic Fluid</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> In utero</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> intrauterine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic asthma is a chronic lung disease resulting from inappropriate immune responses to environmental antigens. Early tolerance induction is an attractive approach for primary prevention of asthma. OBJECTIVE: We analysed the mechanisms of perinatal tolerance induction to allergens with particular focus on the role of B cells in preconceptional and early intrauterine immune priming. METHODS: Wild type (WT) and B cell deficient mice received ovalbumin (OVA) intranasally before mating. Their offspring was analysed in a murine model of allergic airway inflammation. RESULTS: While antigen application before conception protected WT progeny from allergy, it aggravated allergic airway inflammation in B cell deficient offspring. B cell transfer restored protection, demonstrating the crucial role of B cells in perinatal tolerance induction. Effective diaplacentar allergen transfer was detectable in pregnant WT mice but not in pregnant B cell KO dams, and antigen concentrations in WT amniotic fluid were higher than in IgG-free amniotic fluid of B cell deficient dams. Application of OVA/IgG immune complexes (IC) during pregnancy boosted OVA uptake by fetal dendritic cells (DCs). Fetal DCs in humans and mice expressed strikingly higher levels of Fcgamma receptors compared to DCs from adults and were highly efficient in taking up OVA-IC. Moreover, murine fetal DCs effectively primed antigen-specific foxp3+ Tregs after in vitro coincubation with OVA/IgG containing amniotic fluid. CONCLUSION: Our data support a decisive role for B cells and immunoglobulins during in utero tolerance priming. These findings improve the understanding of perinatal immunity and may support the development of effective primary prevention strategies for allergy and asthma in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170611IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601684">PM:28601684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170611-HappleC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170611-HappleC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Happle C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.051</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venkateshaiah,S.U.</style></author><author><style face="normal" font="Arial"> Zhu,X.</style></author><author><style face="normal" font="Arial"> Rajavelu,P.</style></author><author><style face="normal" font="Arial"> Niranjan,R.</style></author><author><style face="normal" font="Arial"> Manohar,M.</style></author><author><style face="normal" font="Arial"> Verma,A.K.</style></author><author><style face="normal" font="Arial"> Lasky,J.A.</style></author><author><style face="normal" font="Arial"> Mishra,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Tulane Eosinophilic Disorders Center (TEDC), Section of Pulmonary Diseases, Tulane University School of Medicine, New Orleans, LA 70112, USA</style></auth-address><titles><title><style face="normal" font="Arial">Regulatory effects of Interleukin (IL)-15 on allergen-induced airway obstruction</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic disorders</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-15</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Airway obstruction is a physiologic feature of asthma and IL-15 may have an important role in the pathogenesis of asthma. OBJECTIVE: We tested the hypothesis that regulation of IL-15 is critical for the preservation of allergen-induced airway hyperresponsiveness (AHR), airway resistance and compliance in response to methacholine. METHODS: Airway inflammation, AHR, resistance and compliance were assessed in IL-15- gene deficient mice and IL-15 overexpressing mice in an allergen-induced murine model of asthma. We assessed eosinophils by anti-MBP immunostaining, goblet cells hyperplasia by PAS staining, and cytokines and chemokine levels by performing qPCR and ELISA analyses. RESULTS: Herein, we made a novel observation that IL-15 deficiency promotes baseline airway resistance in naive mice. Moreover, rIL-15 delivery to the lung downregulates expression of proinflammatory cytokines, and improves allergen-induced AHR, resistance and compliance. These observations were further validated in DOX-inducible CC-10-IL-15 transgenic mice. DOX exposed Aspergillus extract challenged CC-10-IL-15 bitransgenic mice exhibited significantly reduced levels of proinflammatory cytokines (IL-4, IL-5, IL-13) and decreased goblet cell hyperplasia. Airway obstruction including AHR and resistance was diminished in allergen challenged DOX exposed mice compared to non-DOX exposed CC-10-IL-15 bitransgenic mice. Mechanistically, we observed that IL-15-mediated protection of airway obstruction is associated with induced IFN-gamma and IL-10-producing regulatory CD4+CD25+Foxp3+ T cells. Additionally, we found that a human IL-15 agonist (ALT-803) improved airway resistance and compliance in an experimental asthma model. CONCLUSION: We report our novel finding that IL-15 has a potent inhibitory effect on the airway obstruction that occurs in response to environmental allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606589">PM:28606589</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170613-VenkateshaiahSU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170613-VenkateshaiahSU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Venkateshaiah SU</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Clay,C.D.</style></author><author><style face="normal" font="Arial"> Strait,R.T.</style></author><author><style face="normal" font="Arial"> Mahler,A.</style></author><author><style face="normal" font="Arial"> Khodoun,M.V.</style></author><author><style face="normal" font="Arial"> Finkelman,F.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267</style></auth-address><titles><title><style face="normal" font="Arial">Anti-FcgammaRIIB monoclonal antibody suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcgammaRIII</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The inhibitory receptor, FcgammaRIIB, is expressed on human and murine bone marrow-derived cells and limits inflammation by suppressing signaling through stimulatory receptors. OBJECTIVE: Evaluate the effects of K9.361, a mouse IgG2a alloantibody to mouse FcgammaRIIB, on murine anaphylaxis. METHODS: Wild-type and FcgammaR-deficient mice were used to study anaphylaxis, which was induced by injection of 2.4G2 (rat IgG2b mAb that binds both FcgammaRIIB and the stimulatory receptor, FcgammaRIII); by actively immunizing IgE-deficient mice, then challenging with the immunizing Ag; and by passive immunization with IgG or IgE anti-TNP mAb, followed by injection of TNP-ovalbumin. Pretreatment with K9.361 was assessed for ability to influence anaphylaxis. RESULTS: Unexpectedly, K9.361 injection induced mild anaphylaxis, which was both Fcgamma</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624610">PM:28624610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170618-ClayCD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170618-ClayCD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, Clay CD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mukai,K.</style></author><author><style face="normal" font="Arial"> Chinthrajah,R.S.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author><author><style face="normal" font="Arial"> Tsai,M.</style></author><author><style face="normal" font="Arial"> Gaudenzio,N.</style></author><author><style face="normal" font="Arial"> Galli,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA</style></auth-address><titles><title><style face="normal" font="Arial">A new fluorescent-avidin-based method for quantifying basophil activation in whole blood</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">We report herein a simple new fluorescent-avidin-based method to detect activated basophils in the whole blood of normal or allergic subjects, and compare this method to a basophil activation test based on detection of CD63</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606590">PM:28606590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170613-MukaiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170613-MukaiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Mukai K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.052</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kansen,H.M.</style></author><author><style face="normal" font="Arial"> van Erp,F.C.</style></author><author><style face="normal" font="Arial"> Knol,E.F.</style></author><author><style face="normal" font="Arial"> Pontoppidan,B.</style></author><author><style face="normal" font="Arial"> Meijer,Y.</style></author><author><style face="normal" font="Arial"> van der Ent,C.K.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Pulmonology and Allergology, University Medical Centre Utrecht, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers To: Allergy testing in predicting outcome of open food challenge to peanut)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Netherlands -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624347">PM:28624347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170618-KansenHM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170618-KansenHM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, Kansen HM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Acker,W.W.</style></author><author><style face="normal" font="Arial"> Plasek,J.M.</style></author><author><style face="normal" font="Arial"> Blumenthal,K.G.</style></author><author><style face="normal" font="Arial"> Lai,K.H.</style></author><author><style face="normal" font="Arial"> Topaz,M.</style></author><author><style face="normal" font="Arial"> Seger,D.L.</style></author><author><style face="normal" font="Arial"> Goss,F.R.</style></author><author><style face="normal" font="Arial"> Slight,S.P.</style></author><author><style face="normal" font="Arial"> Bates,D.W.</style></author><author><style face="normal" font="Arial"> Zhou,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of General Medicine and Primary Care, Brigham and Women's Hospital, Boston, Mass; Geisinger Commonwealth School of Medicine, Scranton, Pa</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of food allergies and intolerances documented in electronic health records</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Health Records</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Records</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Radioallergosorbent Test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy prevalence is reported to be increasing, but epidemiological data using patients' electronic health records (EHRs) remain sparse. OBJECTIVE: We sought to determine the prevalence of food allergy and intolerance documented in the EHR allergy module. METHODS: Using allergy data from a large health care organization's EHR between 2000 and 2013, we determined the prevalence of food allergy and intolerance by sex, racial/ethnic group, and allergen group. We examined the prevalence of reactions that were potentially IgE-mediated and anaphylactic. Data were validated using radioallergosorbent test and ImmunoCAP results, when available, for patients with reported peanut allergy. RESULTS: Among 2.7 million patients, we identified 97,482 patients (3.6%) with 1 or more food allergies or intolerances (mean, 1.4 +/- 0.1). The prevalence of food allergy and intolerance was higher in females (4.2% vs 2.9%; P &lt; .001) and Asians (4.3% vs 3.6%; P &lt; .001). The most common food allergen groups were shellfish (0.9%), fruit or vegetable (0.7%), dairy (0.5%), and peanut (0.5%). Of the 103,659 identified reactions to foods, 48.1% were potentially IgE-mediated (affecting 50.8% of food allergy or intolerance patients) and 15.9% were anaphylactic. About 20% of patients with reported peanut allergy had a radioallergosorbent test/ImmunoCAP performed, of which 57.3% had an IgE level of grade 3 or higher. CONCLUSIONS: Our findings are consistent with previously validated methods for studying food allergy, suggesting that the EHR's allergy module has the potential to be used for clinical and epidemiological research. The spectrum of severity observed with food allergy highlights the critical need for more allergy evaluations</style></abstract><notes><style face="normal" font="Arial">DA - 20170604IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28577971">PM:28577971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170604-AckerWW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170604-AckerWW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170604, Acker WW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> O'hehir,R.E.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> D'Amato,G.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author><author><style face="normal" font="Arial"> van Eerd,M.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of thunderstorm-induced asthma using Google Trends</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="893" start="891">891-893</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">An asthma outbreak of hospitalizations and deaths was noticed in Australia (November 2016) and in Kuwait (December 2016). This outbreak was clearly demonstrated using Google Trends (GT), a Web-based surveillance tool of interest in clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20170605IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -CO - Australia -CO - Spain -CO - Italy -CO - Germany -CO - Belgium -CO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.04.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28579375">PM:28579375</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170605-BousquetJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170605-BousquetJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170605, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.04.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rajput,S.</style></author><author><style face="normal" font="Arial"> Sharma,V.</style></author><author><style face="normal" font="Arial"> Hughes,S.M.</style></author><author><style face="normal" font="Arial"> Ewing,C.I.</style></author><author><style face="normal" font="Arial"> Arkwright,P.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Manchester, Manchester, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Allergy testing in predicting outcome of open food challenge to peanut</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624349">PM:28624349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170618-RajputS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170618-RajputS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, Rajput S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weber,M.</style></author><author><style face="normal" font="Arial"> Niespodziana,K.</style></author><author><style face="normal" font="Arial"> Linhart,B.</style></author><author><style face="normal" font="Arial"> Neubauer,A.</style></author><author><style face="normal" font="Arial"> Huber,H.</style></author><author><style face="normal" font="Arial"> Henning,R.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170603IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28576673">PM:28576673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170603-WeberM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170603-WeberM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170603, Weber M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choi,C.Y.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Oh,S.</style></author><author><style face="normal" font="Arial"> Lee,H.J.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Park,S.H.</style></author><author><style face="normal" font="Arial"> Kim,H.J.</style></author><author><style face="normal" font="Arial"> Lee,S.J.</style></author><author><style face="normal" font="Arial"> Chun,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 02841, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Anti-inflammatory potential of a heat-killed Lactobacillus strain isolated from Kimchi on house dust mite-induced atopic dermatitis in NC/Nga mice</style></title><secondary-title><style face="normal" font="Arial">J Appl Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Appl Microbiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgG1</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Kimchi</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">AIMS: Atopic dermatitis (AD) is an allergic skin disease driven by the Th2-prone immune response. Therefore, a fundamental approach to restoring the Th1/Th2 balance is needed to treat AD. METHODS AND RESULTS: Eighteen different Lactobacillus strains isolated from Kimchi were screened to identify those that stimulated immune cells to secret Th1-type or Th2-type cytokines. Lactobacillus brevis NS1401 induced the greatest IFN-gamma and IL-12 secretion and the least IL-4 production among the tested Lactobacillus strains. Furthermore, oral administration of heat-killed NS1401 ameliorated the symptoms of dust mite-induced AD in NC/Nga mice by decreasing the serum IgE level and reducing the number of mast cells and eosinophils in lesions. Also, the size and number of cells in the draining lymph nodes of NS1401-administered mice were significantly reduced. In agreement with these results, secretion of a Th1-type cytokine (IFN-gamma) and allergen-specific IgG2a were increased, whereas secretion of Th2-type cytokines (IL-4, IL-5, and IL-10) and allergen-specific IgG1 were decreased upon administration of NS1401 in mice. CONCLUSIONS: Lactobacillus brevis NS1401 alleviates the symptoms of AD by restoring the Th1/Th2 balance through enhancing Th1-prone immunity. SIGNIFICANCE AND IMPACT OF THE STUDY: The immunomodulatory function of Lactobacillus brevis NS1401 may provide effective new therapeutics against AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1365-2672 (Electronic)IS - 1364-5072 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1111/jam.13515</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28632956">PM:28632956</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Appl Microbiol\20170620-ChoiCY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Appl Microbiol\20170620-ChoiCY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Choi CY</style></custom2><misc3><style face="normal" font="Arial">10.1111/jam.13515</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,W.Q.</style></author><author><style face="normal" font="Arial"> Xie,Z.Z.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Zhao,J.H.</style></author><author><style face="normal" font="Arial"> Hu,Q.</style></author><author><style face="normal" font="Arial"> Chen,Y.H.</style></author><author><style face="normal" font="Arial"> Gao,W.Y.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Depatment of Respiratory and Critical, No.2 People's Hospital Of Kunming, Kunming 650204, Yunnan Province, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Influences of PON1 on Airway Inflammation and Remodeling in Bronchial Asthma</style></title><secondary-title><style face="normal" font="Arial">J Cell Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cell Biochem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Colorimetry</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fibroblasts</style></keyword><keyword><style face="normal" font="Arial"> fibronectin</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid peroxidation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Plasmid</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">This study aims to explore the influences of Paraoxonase-1 (PON1) involved in airway inflammation and remodeling in asthma. Mice were divided into control, asthma, asthma + PON1 and asthma + NC groups, and asthma models were established via aerosol inhalation of ovalbumin (OVA). HE, Masson and PAS stains were used to observe airway inflammation and remodeling, Giemsa staining to assess inflammatory cells in bronchoalveolar lavage fluid (BALF), qRT-PCR and western blot to detect PON1 expression, lipid peroxidation and glutathione assays to quantify malondialdehyde (MDA) activity and glutathione peroxidase (GSH) levels, ELISA to determine inflammatory cytokines and immunoglobulin, and colorimetry to detect PON1 activities. Additionally, mice lung macrophages and fibroblasts were transfected with PON1 plasmid in vitro; ELISA and qRT-PCR were performed to understand the effects of PON1 on inflammatory cytokines secreted by lung macrophages, MTT assay for lung fibroblasts proliferation and qRT-PCR and western blot for the expressions of PON1, COL1A1 and fibronectin. After overexpression of PON1, the asthma mice had decreased inflammatory cell infiltration, fibrosis degree, and airway wall thickness; inflammatory cells and inflammatory cytokines in BALF were also reduced, expressions of OVA-IgE and IgG1, and MDA activity were decreased, but the expressions of OVA-IgG2a and INF-gamma and GSH levels were increased. Besides, PON1 significantly inhibited microphage expression of LPS-induced inflammatory cytokines, lung fibroblast proliferation, and COL1A1 and fibronectin expression. Thus, PON1 could relieve airway inflammation and airway remodeling in asthmatic mice and inhibit the secretion of LPS-induced macrophage inflammatory cytokines and the proliferation of lung fibroblasts. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1097-4644 (Electronic)IS - 0730-2312 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/jcb.26242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28657647">PM:28657647</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cell Biochem\20170628-ChenWQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cell Biochem\20170628-ChenWQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Chen WQ</style></custom2><misc3><style face="normal" font="Arial">10.1002/jcb.26242</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mukherjee,S.</style></author><author><style face="normal" font="Arial"> Banerjee,G.</style></author><author><style face="normal" font="Arial"> Das,D.</style></author><author><style face="normal" font="Arial"> Mahapatra,A.B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Junior Resident, Department of Physiology, R G Kar Medical College and Hospital, Kolkata, West Bengal, India</style></auth-address><titles><title><style face="normal" font="Arial">Occurrence of COPD in Patients with Respiratory Allergy: A Clinico-Spirometric Evaluation in a Tertiary Hospital, Kolkata</style></title><secondary-title><style face="normal" font="Arial">J Clin Diagn Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Diagn Res</style></full-title></periodical><pages end="CC13" start="CC11">CC11-CC13</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Kolkata</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Smoking is established as the most important causative factor responsible for Chronic Obstructive Pulmonary Disease (COPD). Occurrence of allergy in COPD patients causes acute exacerbation of this disease, but role of allergy is not established in aetiopathogenesis of COPD. AIM: The present study was aimed at evaluation of occurrence of COPD in patients having symptoms suggestive of respiratory allergy. MATERIALS AND METHODS: An observational cross-sectional study was conducted to evaluate occurrence of COPD in patients having respiratory allergic symptoms by routine spirometric screening. Five hundred and fifty urban patients aged 18-60 years (both gender) ailing from chronic respiratory symptoms like cough, wheeze and Shortness Of Breath (SOB), who were referred from OPDs of RGKMCH, Kolkata, were included in this study. After obtaining detailed clinical profile, patients were divided into two groups: subjects having additional clinical symptoms suggestive of respiratory allergy (n=260) like nasal catarrh, nasal stuffiness and sneezing and subjects with no symptoms suggestive of respiratory allergy (n=290). Thereafter, routine spirometry was carried out following recommendations of ATS/ERS (2005). Patients were then categorized based on FVC, FEV1, FEV1/FVC, FEF25-75 and PEFR percent predicted values. RESULTS: Study revealed that 18.97% of non-allergic population was suffering from COPD whereas only 7.69% of allergic subjects had COPD. This difference was statistically highly significant (p=0.0001). Although there was no significant difference in prevalence of respiratory symptoms between these two groups. CONCLUSION: Present study concludes that patients with respiratory allergy may have coexistent COPD but occurrence of COPD is much less than that in patients with no respiratory allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.7860/JCDR/2017/25643.9841</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658755">PM:28658755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-CC11-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-CC11-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Mukherjee S</style></custom2><misc3><style face="normal" font="Arial">10.7860/JCDR/2017/25643.9841</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iijima,S.</style></author><author><style face="normal" font="Arial"> Kojo,K.</style></author><author><style face="normal" font="Arial"> Takayama,N.</style></author><author><style face="normal" font="Arial"> Hiragun,M.</style></author><author><style face="normal" font="Arial"> Kan,T.</style></author><author><style face="normal" font="Arial"> Hide,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hanamizuki Clinic, Ushiku, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Case of cholinergic urticaria accompanied by anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Blindness</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fexofenadine</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Intradermal Tests</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Lip</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> MGL_1304</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="Arial">Cholinergic urticaria occasionally occurs in combination with anaphylactic symptoms. However, this has not been widely reported. Herein, we report the case of a 14-year-old Japanese male who was diagnosed with cholinergic urticaria accompanied by anaphylaxis. The patient, who was suffering from atopic dermatitis and bronchial asthma, had developed wheals after exercising or bathing, which would have increased his core body temperature, since summer 2014. He experienced two episodes of severe systemic symptoms and wheal development when he took a bath after eating in December 2014 and the following January. His symptoms included wheezing, numbness of the lips, respiratory distress, blindness and fainting. Laboratory tests revealed the following results: serum IgE level, 7060 IU/mL; titers of specific immunoglobulin E antibodies against Malassezia and MGL_1304, 31.70 UA/mL and 112.5 ng/mL, respectively. A histamine release test against human sweat revealed a class 4 response. Skin prick and intradermal tests against autologous sweat produced immediate-type positive reactions. According to these findings, we diagnosed him with the sweat-hypersensitivity type of cholinergic urticaria accompanied by anaphylaxis. He was successfully treated with lafutidine, a histamine H2 receptor antagonist, in combination with fexofenadine. It is important for dermatologists to be aware that cholinergic urticaria can progress to anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170630IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/1346-8138.13951</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28665007">PM:28665007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol\20170630-IijimaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol\20170630-IijimaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170630, Iijima S</style></custom2><misc3><style face="normal" font="Arial">10.1111/1346-8138.13951</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Glocova,I.</style></author><author><style face="normal" font="Arial"> Bruck,J.</style></author><author><style face="normal" font="Arial"> Geisel,J.</style></author><author><style face="normal" font="Arial"> Muller-Hermelink,E.</style></author><author><style face="normal" font="Arial"> Widmaier,K.</style></author><author><style face="normal" font="Arial"> Yazdi,A.S.</style></author><author><style face="normal" font="Arial"> Rocken,M.</style></author><author><style face="normal" font="Arial"> Ghoreschi,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University Medical Center Tubingen, Eberhard Karls University, Liebermeisterstr. 25, D-72076 Tubingen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Induction of skin-pathogenic Th22 cells by epicutaneous allergen exposure</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH22</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease with dysfunction of the skin barrier, an abnormal immune response and frequent allergies to environmental antigens like food antigens. Clinical observations suggest that certain diets can influence the course of AD. OBJECTIVE: Here we compared the phenotype of food allergen-specific T cells activated through skin or gut allergen exposure to transfer skin inflammation into naive recipients upon epicutaenous allergen challenge. METHODS: Ovalbumin (OVA) TCR-transgenic mice were treated epicutaneously with OVA or were fed OVA. CD4+ T cells from skin lymph nodes or mesenteric lymph nodes were transferred into naive BALB/c mice, which were challenged with OVA epicutaneously. Skin inflammation was determined by histological parameters. In addition, we analyzed the phenotype of the immune response in lymphoid tissues and in skin tissue. RESULTS: TCR-transgenic T cells activated through epicutaneous or oral OVA exposure both migrate to skin lymph nodes after adoptive transfer and epicutaenous OVA exposure. AD-like skin inflammation could only be induced by the transfer of epicutaneously primed OVA T cells. Analysis of the immune phenotype demonstrated an IL-22/IL-17A-dominated immune phenotype of skin-pathogenic T cells. CONCLUSION: IL-22 seems to be the critical cytokine for the development of AD and is induced in this model by epicutaneous sensitization with OVA</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdermsci.2017.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28655472">PM:28655472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Sci\20170628-GlocovaI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Sci\20170628-GlocovaI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Glocova I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdermsci.2017.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cha,H.Y.</style></author><author><style face="normal" font="Arial"> Ahn,S.H.</style></author><author><style face="normal" font="Arial"> Cheon,J.H.</style></author><author><style face="normal" font="Arial"> Park,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Korean Pediatrics, Hospital of Korean Medicine, Pusan National University, Geumo-ro 20, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 50612, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Hataedock treatment has preventive therapeutic effects for atopic dermatitis through skin barrier protection in Dermatophagoides farinae-induced NC/Nga mice</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="336" start="327">327-336</pages><volume><style face="normal" font="Arial">206</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> CD40</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Coptis</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Kinase C</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signal transducer and activator of transcription 6</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> STAT-6</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="6" Year="2017">2017/6/3</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Hataedock treatment is traditionally used for the purpose of preventing the future skin disease by feeding herbal extracts to the newborn in traditional Chinese and Korean medicine. AIM OF THE STUDY: This study investigated the preventive therapeutic effects of Hataedock (HTD) treatment for atopic dermatitis (AD) through skin barrier protection in Dermatophagoides farinae-induced NC/Nga mice. MATERIALS AND METHODS: To the HTD treatment group, the extract of Coptis japonica Makino and Glycyrrhiza uralensis Fischer, which analyzed with High Performance Liquid Chromatography (HPLC)-fingerprint for quality consistency, was administered orally to the 3-week-old mice before inducing AD. After that, Dermatophagoides farinae was applied except the control group to induce AD-like skin lesions. We confirmed the effects of HTD on morphological changes, protection of skin barrier, regulation of Th2 differentiation, inflammation regulation and induction of apoptosis through histochemistry, immunohistochemistry, and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. RESULTS: HTD effectively reduced edema, angiogenesis and skin lesion. HTD also increased the levels of liver X receptor (LXR) and filaggrin but decreased the level of protein kinase C (PKC) (p&lt;0.01). The levels of interleukin-4 (IL-4), IL-13, signal transducer and activator of transcription-6 (STAT-6) and Cluster of differentiation 40 (CD40) were significantly reduced in the HTD treated group (p&lt;0.01). HTD also suppressed the mast cell degranulation and the level of the high-affinity IgE receptor (FcvarepsilonRI), substance P, Matrix metalloproteinases-9 (MMP-9) and 5-hydroxytryptamine (5-HT) (p&lt;0.01). The levels of inflammatory factors such as nuclear factor-kappaB (NF-kappaB) p65, phosphorylated IkappaB (p-IkappaB) and inducible nitric oxide synthase (iNOS) were also decreased (p&lt;0.01). Apoptosis of inflammatory cells was also found to increase (p&lt;0.01). CONCLUSION: Our results indicate that HTD effectively regulate the Th2 differentiation, mast cell activation and various inflammatory responses on AD-induced mice through protection of skin barrier. Therefore, HTD may have potential applications for alternative and preventive treatment in the management of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583294">PM:28583294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\2017-206-327-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\2017-206-327-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Cha HY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yen,C.Y.</style></author><author><style face="normal" font="Arial"> Chiang,W.D.</style></author><author><style face="normal" font="Arial"> Liu,S.Y.</style></author><author><style face="normal" font="Arial"> Wang,K.T.</style></author><author><style face="normal" font="Arial"> Liao,E.C.</style></author><author><style face="normal" font="Arial"> Hsieh,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Lithospermum erythrorhizon extract inhibits Der p2-induced inflammatory response through alleviation of thymic stromal lymphopoietin, nuclear factor Kappa B, and inflammasome expression in human bronchial epithelial cells</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="8" start="1">1-8</pages><volume><style face="normal" font="Arial">201</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Angelica</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antigens,Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropod Proteins</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Caspase 1</style></keyword><keyword><style face="normal" font="Arial"> caspase-1</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Cytoskeletal Proteins</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> drug effects</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Inflammasomes</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lithospermum</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> NF-kappa B</style></keyword><keyword><style face="normal" font="Arial"> NOD-like receptor</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Extracts</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> STAT</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> STAT3 Transcription Factor</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Lithospermum erythrorhizon (LE) and Angelica sinensis (AS), widely used in several folk medicine for wound, pus discharge and dermatitis for the history of several hundred years in Asian countries. AIM OF STUDY: To investigate the therapeutic effect of LE and AS on Der p2-induced inflammatory response in human bronchial epithelial (BEAS-2B) cells. METHODS: The effects of Der p2 stimulation on thymic stromal lymphopoietin (TSLP), the nuclear factor kappa B (NF-kappaB) pathway, the inflammasome (specifically, the apoptosis speck-like protein [ASC] and nod-like receptor 3 [NLRP3]), Caspase-1 and the signal transducer and activator of transcription (STAT) 3 pathway were evaluated in the human bronchial epithelial (BEAS-2B) cells. RESULTS: The results indicated that LE, AS, and LE+AS reduced TSLP, I kappa B kinase-alpha, and NLRP3 levels; LE and AS reduced Caspase-1; LE and LE+AS also reduced NF-kappaB p50, NF-kappaB p65, ASC, and STAT3 levels. CONCLUSION: Both LE and AS aqueous extracts exert anti-inflammatory effects in Der p2-stimulated BEAS-2B cells. These effects may involve multiple mechanisms, including the inhibition of TSLP production as well as the suppression of IKKalpha, Caspase-1 and NLRP3; however, additional studies are warranted to elucidate the underlying mechanisms</style></abstract><notes><style face="normal" font="Arial">DA - 20170303IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Anti-Inflammatory Agents)RN - 0 (Antigens, Dermatophagoides)RN - 0 (Arthropod Proteins)RN - 0 (Cytokines)RN - 0 (Cytoskeletal Proteins)RN - 0 (Dermatophagoides pteronyssinus antigen p 2)RN - 0 (Inflammasomes)RN - 0 (NF-kappa B)RN - 0 (PYCARD protein, human)RN - 0 (Plant Extracts)RN - 0 (STAT3 Transcription Factor)RN - 0 (STAT3 protein, human)RN - 0 (thymic stromal lymphopoietin)RN - EC 3.4.22.36 (Caspase 1)SB - IMCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.02.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28254482">PM:28254482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\2017-201-1-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\2017-201-1-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170303, Yen CY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.02.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,J.</style></author><author><style face="normal" font="Arial"> Lv,L.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author><author><style face="normal" font="Arial"> Huo,C.</style></author><author><style face="normal" font="Arial"> Zheng,Z.</style></author><author><style face="normal" font="Arial"> Yin,B.</style></author><author><style face="normal" font="Arial"> Jiang,P.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Gao,Y.</style></author><author><style face="normal" font="Arial"> Xue,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, Xi'an 710069, China</style></auth-address><titles><title><style face="normal" font="Arial">Pulvis Fellis Suis extract attenuates ovalbumin-induced airway inflammation in murine model of asthma</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="41" start="34">34-41</pages><volume><style face="normal" font="Arial">207</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enteritis</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharyngitis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whooping Cough</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Pulvis Fellis Suis (PFS), named with "Zhu Danfen" in China, has been extensively used for the therapy of enteritis, acute pharyngitis, whooping cough and asthma in folk medicine. Although PFS shows anti-inflammatory activities, its effect on airway inflammation in asthma has not been studied. AIM OF THE STUDY: To explore the protective effect of PFS ethanol extract against airway inflammation in asthmatic mice. MATERIALS AND METHODS: Allergic asthma in mice was sensitized and challenged by OVA. Mice were administered in oral with PFS daily at doses of 100, 200 and 400mg/kg on days 21-27. Inflammatory cell counts and classification in bronchoalveolar lavage fluid (BALF) were analysed. Histopathological evaluation of the lung tissue was performed by hematoxylin and eosin (H&amp;E) and periodic acid-schiff (PAS) staining. The IgE level in serum was measured by using enzyme-linked immunoassay (ELISA). ELISA was also used to detect the levels of Th1/Th2 cytokine and eotaxin in BALF. RESULTS: Histological results revealed that PFS could ameliorate OVA-induced histological changes by attenuating inflammatory cell infiltration, mucus hypersecretion and goblet cell hyperplasia in the lung. Treatment with different doses of PFS significantly decreased the elevated inflammatory cell numbers in BALF and IgE production in serum. PFS treatment reduced the production of Th2 cytokine IL-4, IL-5, IL-13, and promoted Th1 cytokine IFN-gamma production in BALF. In addition, PFS also decreased the levels of eotaxin and TNF-alpha in BALF. CONCLUSIONS: These findings suggest that PFS has a markedly anti-inflammatory effect on OVA-induced allergic asthma in mice, and could be a promising protective agent recommended for allergic asthma patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170618IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.06.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624362">PM:28624362</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\2017-207-34-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\2017-207-34-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170618, He J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.06.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jappe,U.</style></author><author><style face="normal" font="Arial"> Kull,S.</style></author><author><style face="normal" font="Arial"> Opitz,A.</style></author><author><style face="normal" font="Arial"> Zabel,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical and Molecular Allergology, Priority Research Area Asthma and Allergy, Research Center Borstel, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis to vanilla ice cream: a near fatal cross reactivity phenomenon</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Ice</style></keyword><keyword><style face="normal" font="Arial"> Ice Cream</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lupine</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">Although lupine is amongst the 17 foods that have to be declared it still has the features of a hidden allergen because those potentially allergic to lupine are not aware of the fact and, therefore, do not take adequate consequences, i.e. avoidance. Lupine occurs as additive in wheat flour, and is used as wheat and soy substitute. The significance of lupine is: a) its potential cross-reactivity with peanut and b) that the allergic reactions are mostly severe.1 This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14445</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28662315">PM:28662315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170629-JappeU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170629-JappeU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Jappe U</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14445</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stingeni,L.</style></author><author><style face="normal" font="Arial"> Bianchi,L.</style></author><author><style face="normal" font="Arial"> Hansel,K.</style></author><author><style face="normal" font="Arial"> Neve,D.</style></author><author><style face="normal" font="Arial"> Foti,C.</style></author><author><style face="normal" font="Arial"> Corazza,M.</style></author><author><style face="normal" font="Arial"> Bini,V.</style></author><author><style face="normal" font="Arial"> Moretta,I.</style></author><author><style face="normal" font="Arial"> Principato,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Clinical, Allergological, and Venereological Dermatology, Department of Medicine, University of Perugia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Dermatitis caused by arthropods in domestic environment: an Italian multicentre study</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Glycyphagus domesticus</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Skin diseases caused by mites and insects living in domestic environments have been rarely systematically studied. OBJECTIVES: To study patients with dermatitis induced by arthropods in domestic environment describing their clinical features, isolating culprit arthropods and relating the clinical features to the parasitological data. METHODS: The study was performed in 105 subjects with clinical and anamnestic data compatible with the differential diagnosis of ectoparasitoses in domestic environments. Clinical data and arthropods findings obtained by indoor dust direct examination were studied. RESULTS: Indoor dust direct examination demonstrated possible arthropods infestation in 98 subjects (93.3%), more frequently mites (56.1%) (mainly Pyemotes ventricosus and Glycyphagus domesticus) than insects (43.9%) (mainly Formicidae and Bethylidae). Strophulus (46.9%) and urticaria-like eruption (36.7%) in upper limbs and trunk with severe extent were prevalent. Itch was mostly severe (66.3%) and continuous (55.1%). Ectoparasitoses occurred frequently with acute course in summer (44.9%) and spring (30.6%). CONCLUSIONS: Possible correlation between clinical and aetiological diagnosis of arthropods ectoparasitoses in domestic environments needs the close cooperation between dermatologist and parasitologist. This is crucial to successfully and definitely resolve skin lesions by eradicating the factors favouring infestation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28653403">PM:28653403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170627-StingeniL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170627-StingeniL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Stingeni L</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14438</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Kim,C.W.</style></author><author><style face="normal" font="Arial"> Choi,J.Y.</style></author><author><style face="normal" font="Arial"> Yu,D.S.</style></author><author><style face="normal" font="Arial"> Kim,J.W.</style></author><author><style face="normal" font="Arial"> Han,K.D.</style></author><author><style face="normal" font="Arial"> Park,Y.G.</style></author><author><style face="normal" font="Arial"> Lee,Y.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, College of Medicine, The Catholic University of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis is inversely associated with hepatitis B antigen positivity: a population-based cohort study</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis B virus</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="6" Year="2017">2017/6/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: No clear association between hepatitis B virus (HBV) infection and atopic dermatitis (AD) has been established. Some studies have reported that subjects with HBV had an increased risk of atopy; other studies reported an inverse association between HBV seropositivity and allergic diseases. OBJECTIVE: We evaluated the association between AD and hepatitis B antigen (HBsAg) positivity using Korean National Health and Nutrition Examination Survey data. METHODS: In total, 14,776 participants aged > 19 years were included in the analysis. Multiple logistic regression analyses were used to evaluate the odds ratio of HBsAg positivity in association with AD and asthma. RESULTS: The prevalence of HBsAg positivity was lower in individuals with AD than in those without AD (mean [SE], 0.7% [0.4] vs. 3.7% [0.2]; P &lt; 0.001). However, HBsAg positivity was not significantly associated with asthma (3.7% [0.2] vs. 2.8% [0.8]; P &lt; 0.001). HBsAg positivity decreased the risk of AD significantly (OR = 0.223; 95% CI = 0.069-0.72). CONCLUSIONS: This study demonstrates an inverse association between AD and HBsAg positivity using a nationwide, population-based, cross-sectional health examination and survey. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170624IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14428</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28646620">PM:28646620</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170624-KimHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170624-KimHY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170624, Kim HY</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14428</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pedersen,R.O.</style></author><author><style face="normal" font="Arial"> Peters,T.</style></author><author><style face="normal" font="Arial"> Panda,R.</style></author><author><style face="normal" font="Arial"> Wehling,P.</style></author><author><style face="normal" font="Arial"> Garber,E.A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Office of Scientific and Professional Development, Office of the Chief Scientist, Office of the Commissioner, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993</style></auth-address><titles><title><style face="normal" font="Arial">Detection and Antigenic Profiling of Undeclared Peanut in Imported Garlic Using an xMAP Multiplex Immunoassay for Food Allergens</style></title><secondary-title><style face="normal" font="Arial">J Food Prot</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Prot</style></full-title></periodical><pages end="1213" start="1204">1204-1213</pages><volume><style face="normal" font="Arial">80</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Garlic</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">A shipment of imported garlic powder was suspected of containing peanut. Samples (subs) collected from the shipment displayed considerable variability in peanut antigenicity when analyzed by enzyme-linked immunosorbent assay (ELISA). This raised questions regarding whether peanut was actually present, the amount present, and the basis for the variability in antigenic content. Analyses that used an xMAP multiplex assay for the detection of peanut and additional food allergens generated responses that were characteristic of peanut. Specifically, the relative intensities of two different peanut-specific antibodies coupled to beads (peanut-37 and -38) and the antigen profiles were identical to garlic controls spiked with peanut. In addition, the xMAP data did not indicate the presence of other allergens. Quantitative analyses indicated an approximately fivefold variation in peanut concentration among different subs. In contrast, within a sub, the apparent peanut concentration appeared constant. Particle size analyses of the garlic powder subs indicated a single distribution profile, with a peak at 380 mum. ELISA analysis of sieve-fractionated garlic powder from one of the subs indicated that slightly less than half of the detectable peanut was smaller than 212 mum, with the remainder almost evenly split between 212 and 300 mum and >300 mum. Modeling to predict possible oral exposure levels of peanut other than those directly measured requires additional research on the physicochemical properties of peanut and garlic, along with information on the production of the garlic powder</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1944-9097 (Electronic)IS - 0362-028X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-485</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28632417">PM:28632417</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Prot\2017-80-1204-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Prot\2017-80-1204-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Pedersen RO</style></custom2><misc3><style face="normal" font="Arial">10.4315/0362-028X.JFP-16-485</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Noble,K.A.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Sathe,S.K.</style></author><author><style face="normal" font="Arial"> Roux,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Biological Science, 319 Stadium Dr., Florida State Univ., Tallahassee, FL 32306-4370, U.S.A</style></auth-address><titles><title><style face="normal" font="Arial">A Cherry Seed-Derived Spice, Mahleb, is Recognized by Anti-Almond Antibodies Including Almond-Allergic Patient IgE</style></title><secondary-title><style face="normal" font="Arial">J Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Almond protein</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Prunus</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="19" Month="6" Year="2017">2017/6/19</year></dates><abstract><style face="normal" font="Arial">There are a number of examples of immunologic cross-reactivity elicited by pollens, fruits, seeds, and nuts of closely related plant species. Such cross-reactivity is of particular concern for patients with food allergies. In this report, we investigated a spice (mahleb) that is prepared from the kernel of the St. Lucie cherry, Prunus mahaleb, for cross-reactivity with almond (Prunus dulcis), using enzyme-linked immunosorbent assay (ELISA) and Western blot. Almond and mahleb are members of the same genus. Cross-reactivity between the mahleb and almond was demonstrated by reaction of cherry and almond kernel protein extracts with antibodies raised against almond proteins. Almond-specific murine monoclonal IgG, rabbit polyclonal IgG, and almond-allergic serum IgE each exhibited cross-reactivity with cherry kernel protein. Because of the demonstrated cross-reactivity between almond and mahleb, these findings should be of special concern to almond-allergic patients and attending medical personnel</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1750-3841 (Electronic)IS - 0022-1147 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/1750-3841.13757</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28627716">PM:28627716</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci\20170619-NobleKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci\20170619-NobleKA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Noble KA</style></custom2><misc3><style face="normal" font="Arial">10.1111/1750-3841.13757</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Z.X.</style></author><author><style face="normal" font="Arial"> Shi,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Allergology, Institute of Immunology; Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.</style></auth-address><titles><title><style face="normal" font="Arial">Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Huazhong Univ Sci Technolog Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Huazhong Univ Sci Technolog Med Sci</style></full-title></periodical><pages end="411" start="407">407-411</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> multiallergen</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">It has always been controversial whether a single allergen performs better than multiple allergens in polysensitized patients during the allergen-specific immunotherapy. This study aimed to examine the clinical efficacy of single-allergen sublingual immunotherapy (SLIT) versus multi-allergen subcutaneous immunotherapy (SCIT) and to discover the change of the biomarker IL-4 after 1-year immunotherapy in polysensitized children aged 6-13 years with allergic rhinitis (AR) induced by house dust mites (HDMs). The AR polysensitized children (n=78) were randomly divided into two groups: SLIT group and SCIT group. Patients in the SLIT group sublingually received a single HDM extract and those in the SCIT group were subcutaneously given multiple-allergen extracts (HDM in combination with other clinically relevant allergen extracts). Before and 1 year after the allergen-specific immunotherapy (ASIT), the total nasal symptom scores (TNSS), total medication scores (TMS) and IL-4 levels in peripheral blood mononuclear cells (PBMCs) were compared respectively between the two groups. The results showed that the TNSS were greatly improved, and the TMS and IL-4 levels were significantly decreased after 1-year ASIT in both groups (SLIT group: P&lt;0.001; SCIT group: P&lt;0.001). There were no significant differences in any outcome measures between the two groups (for TNSS: P>0.05; for TMS: P>0.05; for IL-4 levels: P>0.05). It was concluded that the clinical efficacy of single-allergen SLIT is comparable with that of multi-allergen SCIT in 6-13-year-old children with HDM-induced AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1672-0733 (Print)IS - 1672-0733 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11596-017-1748-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28585143">PM:28585143</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Huazhong Univ Sci Technolog Med Sci\2017-37-407-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Huazhong Univ Sci Technolog Med Sci\2017-37-407-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Wang ZX</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11596-017-1748-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schroeder,J.T.</style></author><author><style face="normal" font="Arial"> Bieneman,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224</style></auth-address><titles><title><style face="normal" font="Arial">Activation of Human Basophils by A549 Lung Epithelial Cells Reveals a Novel IgE-Dependent Response Independent of Allergen</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human basophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-3</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> passive sensitization</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="6" Year="2017">2017/6/26</year></dates><abstract><style face="normal" font="Arial">Evidence for epithelial cell (EC)-derived cytokines (e.g., thymic stromal lymphopoietin [TSLP]) activating human basophils remains controversial. We therefore hypothesize that ECs can directly activate basophils via cell-to-cell interaction. Basophils in medium alone or with IL-3 +/- anti-IgE were coincubated with TSLP, IL-33, or IL-25. Analogous experiments cocultured basophils (1-72 h) directly with EC lines. Supernatants were tested for mediators and cytokines. Abs targeting receptors were tested for neutralizing effects. Lactic acid (pH 3.9) treatment combined with passive sensitization tested the role of IgE. Overall, IL-33 augmented IL-13 secretion from basophils cotreated with IL-3, with minimal effects on histamine and IL-4. Conversely, basophils (but not mast cells) released histamine and marked levels of IL-4/IL-13 (10-fold) when cocultured with A549 EC and IL-3, without exogenous allergen or IgE cross-linking stimuli. The inability to detect IL-33 or TSLP, or to neutralize their activity, suggested a unique mode of basophil activation by A549 EC. Half-maximal rates for histamine (4 h) and IL-4 (5 h) secretion were slower than observed with standard IgE-dependent activation. Ig stripping combined with passive sensitization +/- omalizumab showed a dependency for basophil-bound IgE, substantiated by a requirement for cell-to-cell contact, aggregation, and FcepsilonRI-dependent signaling. A yet unidentified IgE-binding lectin associated with A549 EC is implicated after discovering that LacNAc suppressed basophil activation in cocultures. These findings point to a lectin-dependent activation of basophil requiring IgE but independent of allergen or secreted cytokine. Pending further investigation, we predict this unique mode of activation is linked to inflammatory conditions whereby IgE-dependent activation of basophils occurs despite the absence of any known allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1700055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28652400">PM:28652400</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170627-SchroederJT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170627-SchroederJT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Schroeder JT</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1700055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lund,S.J.</style></author><author><style face="normal" font="Arial"> Portillo,A.</style></author><author><style face="normal" font="Arial"> Cavagnero,K.</style></author><author><style face="normal" font="Arial"> Baum,R.E.</style></author><author><style face="normal" font="Arial"> Naji,L.H.</style></author><author><style face="normal" font="Arial"> Badrani,J.H.</style></author><author><style face="normal" font="Arial"> Mehta,A.</style></author><author><style face="normal" font="Arial"> Croft,M.</style></author><author><style face="normal" font="Arial"> Broide,D.H.</style></author><author><style face="normal" font="Arial"> Doherty,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of California, San Diego, La Jolla</style></auth-address><titles><title><style face="normal" font="Arial">Leukotriene C4 Potentiates IL-33-Induced Group 2 Innate Lymphoid Cell Activation and Lung Inflammation</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene C4</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene E4</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> lipid mediators</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> P2Y12</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="Arial">Asthma is a complex disease that is promoted by dysregulated immunity and the presence of many cytokine and lipid mediators. Despite this, there is a paucity of data demonstrating the combined effects of multiple mediators in asthma pathogenesis. Group 2 innate lymphoid cells (ILC2s) have recently been shown to play important roles in the initiation of allergic inflammation; however, it is unclear whether lipid mediators, such as cysteinyl leukotrienes (CysLTs), which are present in asthma, could further amplify the effects of IL-33 on ILC2 activation and lung inflammation. In this article, we show that airway challenges with the parent CysLT, leukotriene C4 (LTC4), given in combination with low-dose IL-33 to naive wild-type mice, led to synergistic increases in airway Th2 cytokines, eosinophilia, and peribronchial inflammation compared with IL-33 alone. Further, the numbers of proliferating and cytokine-producing lung ILC2s were increased after challenge with both LTC4 and IL-33. Levels of CysLT1R, CysLT2R, and candidate leukotriene E4 receptor P2Y12 mRNAs were increased in ILC2s. The synergistic effect of LTC4 with IL-33 was completely dependent upon CysLT1R, because CysLT1R-/- mice, but not CysLT2R-/- mice, had abrogated responses. Further, CysLTs directly potentiated IL-5 and IL-13 production from purified ILC2s stimulated with IL-33 and resulted in NFAT1 nuclear translocation. Finally, CysLT1R-/- mice had reduced lung eosinophils and ILC2 responses after exposure to the fungal allergen Alternaria alternata Thus, CysLT1R promotes LTC4- and Alternaria-induced ILC2 activation and lung inflammation. These findings suggest that multiple pathways likely exist in asthma to activate ILC2s and propagate inflammatory responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601569</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667163">PM:28667163</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170701-LundSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170701-LundSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Lund SJ</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601569</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,P.S.</style></author><author><style face="normal" font="Arial"> Kearney,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, The University of Alabama at Birmingham, Birmingham, AL 35294</style></auth-address><titles><title><style face="normal" font="Arial">CD36 and Platelet-Activating Factor Receptor Promote House Dust Mite Allergy Development</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Alabama</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen uptake</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylcholine</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> platelet-activating factor</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="Arial">Over 89% of asthmatic children in underdeveloped countries demonstrate sensitivity to house dust mites (HDMs). The allergic response to HDMs is partially mediated by epithelial cell-derived cytokines that activate group 2 innate lymphoid cells, induce migration and activation of dendritic cells, and promote effector differentiation of HDM-specific TH2 cells. However, the contribution of innate receptor engagement on epithelial or dendritic cells by HDMs that ultimately mediates said innate and adaptive allergic responses is poorly understood. We and other investigators have demonstrated that HDMs express phosphorylcholine (PC) moieties. The major PC receptors involved in immune responses include CD36 and platelet-activating factor receptor (PAFR). Because CD36 and PAFR are expressed by epithelial cells and dendritic cells, and expression of these receptors is higher in human asthmatics, we determined whether engagement of CD36 or PAFR on epithelial or dendritic cells contributes to HDM allergy development. Testing bone marrow chimeric mice revealed that CD36 engagement on radioresistant cells and PAFR engagement on radioresistant and radiosensitive cells in the lung promote allergic responses to HDMs. Additionally, passive anti-PC IgM Abs administered intratracheally with HDMs decreased allergen uptake by epithelial cells and APCs in the lungs of C57BL/6 mice but not CD36-/- or PAFR-/- mice. These results show that CD36 and PAFR are important mediators of HDM allergy development and that inhibiting HDM engagement with PC receptors in the lung protects against allergic airway disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1700034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667161">PM:28667161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170701-PatelPS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170701-PatelPS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Patel PS</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1700034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vigl,B.</style></author><author><style face="normal" font="Arial"> Salhat,N.</style></author><author><style face="normal" font="Arial"> Parth,M.</style></author><author><style face="normal" font="Arial"> Pankevych,H.</style></author><author><style face="normal" font="Arial"> Mairhofer,A.</style></author><author><style face="normal" font="Arial"> Bartl,S.</style></author><author><style face="normal" font="Arial"> Smrzka,O.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">AFFiRiS AG, Karl-Farkas-Gasse 22, 1030 Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies</style></title><secondary-title><style face="normal" font="Arial">J Immunol Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Methods</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Ligelizumab</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">Targeting plasma IgE by therapeutic mABs like Omalizumab (Xolair(R)) is current clinical practice for severe allergic conditions or other IgE related diseases like chronic urticaria. As an alternative to soluble IgE targeting, IgE supply can be lowered by targeting the Extracellular Membrane Proximal Domain (EMPD) of the IgE B cell receptor (BCR) present on IgE switched B cells. This ultimately leads to apoptosis of these cells upon IgE BCR crosslinking. Since tools to selectively assess the efficacy of IgE BCR crosslinking by IgE targeting antibodies are limited, a readily quantifiable cell model was developed that allows to specifically address IgE BCR crosslinking activity in vitro. The new cell model allowed for a direct quantitative comparison of anti-EMPD IgE therapeutic prototype antibody 47H4 with anti-IgE(Ce3) directed therapeutic antibody Omalizumab and with a newly selected anti-human EMPD IgE monoclonal antibody, designated mAB 15cl12. Furthermore, a complementing mouse model was developed that allows for in vivo validation of antibodies addressing human EMPD IgE. It carries a targetable humanized EMPD IgE sequence that has been introduced by seamless genomic replacement of the endogenous EMPD encoding sequence. The model allowed to directly compare IgE lowering activity of two anti-human EMPD IgE therapeutic antibodies in vivo. Our tools provide the means for quantitative assessment of IgE BCR crosslinking activity which is increasingly gaining attention with respect to forthcoming second generation anti-IgE clinical candidates such as Ligelizumab or other clinical candidates featuring additional effector functions such as IgE BCR crosslinking activity</style></abstract><notes><style face="normal" font="Arial">DA - 20170625IS - 1872-7905 (Electronic)IS - 0022-1759 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jim.2017.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28647457">PM:28647457</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Methods\20170625-ViglB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Methods\20170625-ViglB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170625, Vigl B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jim.2017.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fleri,W.</style></author><author><style face="normal" font="Arial"> Vaughan,K.</style></author><author><style face="normal" font="Arial"> Salimi,N.</style></author><author><style face="normal" font="Arial"> Vita,R.</style></author><author><style face="normal" font="Arial"> Peters,B.</style></author><author><style face="normal" font="Arial"> Sette,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA</style></auth-address><titles><title><style face="normal" font="Arial">The Immune Epitope Database: How Data Are Entered and Retrieved</style></title><secondary-title><style face="normal" font="Arial">J Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Res</style></full-title></periodical><pages end="" start="5974574">5974574-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> MHC binding</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Primates</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Easy access to a vast collection of experimental data on immune epitopes can greatly facilitate the development of therapeutics and vaccines. The Immune Epitope Database and Analysis Resource (IEDB) was developed to provide such a resource as a free service to the biomedical research community. The IEDB contains epitope and assay information related to infectious diseases, autoimmune diseases, allergic diseases, and transplant/alloantigens for humans, nonhuman primates, mice, and any other species studied. It contains T cell, B cell, MHC binding, and MHC ligand elution experiments. Its data are curated primarily from the published literature and also include direct submissions from researchers involved in epitope discovery. This article describes the process of capturing data from these sources and how the information is organized in the IEDB data. Different approaches for querying the data are then presented, using the home page search interface and the various specialized search interfaces. Specific examples covering diverse applications of interest are given to highlight the power and functionality of the IEDB</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/5974574</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634590">PM:28634590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Res\2017-2017-5974574.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Res\2017-2017-5974574.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170621, Fleri W</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/5974574</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,F.</style></author><author><style face="normal" font="Arial"> Su,X.</style></author><author><style face="normal" font="Arial"> Huang,G.</style></author><author><style face="normal" font="Arial"> Xin,X.F.</style></author><author><style face="normal" font="Arial"> Cao,E.H.</style></author><author><style face="normal" font="Arial"> Shi,Y.</style></author><author><style face="normal" font="Arial"> Song,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China</style></auth-address><titles><title><style face="normal" font="Arial">Adenosine Triphosphate Promotes Allergen-Induced Airway Inflammation and Th17 Cell Polarization in Neutrophilic Asthma</style></title><secondary-title><style face="normal" font="Arial">J Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Res</style></full-title></periodical><pages end="" start="5358647">5358647-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenosine</style></keyword><keyword><style face="normal" font="Arial"> Adenosine Triphosphate</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Apyrase</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-17</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Adenosine triphosphate (ATP) is a key mediator to alert the immune dysfunction by acting on P2 receptors. Here, we found that allergen challenge caused an increase of ATP secretion in a murine model of neutrophilic asthma, which correlated well with neutrophil counts and interleukin-17 production. When ATP signaling was blocked by intratracheal administration of the ATP receptor antagonist suramin before challenge, neutrophilic airway inflammation, airway hyperresponsiveness, and Th17-type responses were reduced significantly. Also, neutrophilic inflammation was abrogated when airway ATP levels were locally neutralized using apyrase. Furthermore, ATP promoted the Th17 polarization of splenic CD4+ T cells from DO11.10 mice in vitro. In addition, ovalbumin (OVA) challenge induced neutrophilic inflammation and Th17 polarization in DO11.10 mice, whereas administration of suramin before challenge alleviated these parameters. Thus, ATP may serve as a marker of neutrophilic asthma, and local blockade of ATP signaling might provide an alternative method to prevent Th17-mediated airway inflammation in neutrophilic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/5358647</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28626774">PM:28626774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Res\2017-2017-5358647.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Res\2017-2017-5358647.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Zhang F</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/5358647</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ikegawa,K.</style></author><author><style face="normal" font="Arial"> Suzuki,S.</style></author><author><style face="normal" font="Arial"> Nomura,H.</style></author><author><style face="normal" font="Arial"> Enokida,T.</style></author><author><style face="normal" font="Arial"> Yamazaki,T.</style></author><author><style face="normal" font="Arial"> Okano,S.</style></author><author><style face="normal" font="Arial"> Endo,K.</style></author><author><style face="normal" font="Arial"> Saito,S.</style></author><author><style face="normal" font="Arial"> Yamaguchi,M.</style></author><author><style face="normal" font="Arial"> Tahara,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Pharmacy, National Cancer Center Hospital East, National Research and Development Agency, Kashiwa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Retrospective analysis of premedication, glucocorticosteroids, and H1-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer</style></title><secondary-title><style face="normal" font="Arial">J Int Med Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Int Med Res</style></full-title></periodical><pages end="" start="300060517713531">300060517713531-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergy</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> glucocorticosteroid</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> H1 receptor</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Head and neck cancer</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">Objectives We evaluated infusion-related reactions associated with cetuximab combination chemotherapy comprising an H1-receptor antagonist plus dexamethasone as anti-allergy premedications for patients with head and neck cancer. Methods We retrospectively evaluated 248 patients who received a cetuximab combination regimen between December 2012 and August 2015. All patients received 5 mg intravenous dichlorpheniramine (H1-receptor antagonist), and dexamethasone (DEX) was adjusted from 6.6 mg to 13.2 mg according to the emetogenic risk. Results We identified 248 subjects, including 13 (5.2%) with infusion-related reactions (grade 1 in five [2.0%], grade 2 in seven [2.8%], and grade 4 in one [0.4%]). The incidence of these reactions in cetuximab combination regimens, each employing an H1-receptor antagonist, using a higher dose of dexamethasone (13.2 mg) was not significantly lower compared with those using 6.6 mg DEX (2.4% vs 8.3%, respectively; p = 0.43). Twelve patients experienced infusion-related reactions associated with the first cetuximab administration, and one reaction occurred after the third administration. Conclusions The incidence of infusion-related reactions was lower compared with those of previous studies. Dexamethasone combined with an H1-receptor antagonist was useful for preventing allergic responses. The incidence of infusion-related reactions was not lower with 13.2 mg dexamethasone, and 6.6 mg DEX prevented infusion-related reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1473-2300 (Electronic)IS - 0300-0605 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1177/0300060517713531</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606015">PM:28606015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Int Med Res\20170613-IkegawaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Int Med Res\20170613-IkegawaK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Ikegawa K</style></custom2><misc3><style face="normal" font="Arial">10.1177/0300060517713531</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rial Prado,M.J.</style></author><author><style face="normal" font="Arial"> Batolome,B.</style></author><author><style face="normal" font="Arial"> Pastor,C.</style></author><author><style face="normal" font="Arial"> Cuesta,J.</style></author><author><style face="normal" font="Arial"> Parra,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy department, Complexo Hospitalario Universitario A Coruna, A Coruna, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Troponin as a Cause of Hypersensitivity to Barnacle</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="195" start="194">194-195</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Troponin</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0159</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570228">PM:28570228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Rial Prado MJ</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0159</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martorell,A.</style></author><author><style face="normal" font="Arial"> Alonso,E.</style></author><author><style face="normal" font="Arial"> Echeverria,L.</style></author><author><style face="normal" font="Arial"> Escudero,C.</style></author><author><style face="normal" font="Arial"> Garcia-Rodriguez,R.</style></author><author><style face="normal" font="Arial"> Blasco,C.</style></author><author><style face="normal" font="Arial"> Bone,J.</style></author><author><style face="normal" font="Arial"> Borja-Segade,J.</style></author><author><style face="normal" font="Arial"> Bracamonte,T.</style></author><author><style face="normal" font="Arial"> Claver,A.</style></author><author><style face="normal" font="Arial"> Corzo,J.L.</style></author><author><style face="normal" font="Arial"> de la Hoz,B.</style></author><author><style face="normal" font="Arial"> Del Olmo,R.</style></author><author><style face="normal" font="Arial"> Dominguez,O.</style></author><author><style face="normal" font="Arial"> Fuentes-Aparicio,V.</style></author><author><style face="normal" font="Arial"> Guallar,I.</style></author><author><style face="normal" font="Arial"> Larramona,H.</style></author><author><style face="normal" font="Arial"> Martin-Munoz,F.</style></author><author><style face="normal" font="Arial"> Matheu,V.</style></author><author><style face="normal" font="Arial"> Michavila,A.</style></author><author><style face="normal" font="Arial"> Ojeda,I.</style></author><author><style face="normal" font="Arial"> Ojeda,P.</style></author><author><style face="normal" font="Arial"> Piquer,M.</style></author><author><style face="normal" font="Arial"> Poza,P.</style></author><author><style face="normal" font="Arial"> Reche,M.</style></author><author><style face="normal" font="Arial"> Rodriguez del Rio,P.</style></author><author><style face="normal" font="Arial"> Rodriguez,M.</style></author><author><style face="normal" font="Arial"> Ruano,F.</style></author><author><style face="normal" font="Arial"> Sanchez-Garcia,S.</style></author><author><style face="normal" font="Arial"> Terrados,S.</style></author><author><style face="normal" font="Arial"> Valdesoiro,L.</style></author><author><style face="normal" font="Arial"> Vazquez-Ortiz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology. University General Hospital. Valencia</style></auth-address><titles><title><style face="normal" font="Arial">Oral immunotherapy for food allergy: a spanish guideline. Egg and Milk Immunotherapy Spanish Guide (items guide). Part II</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Avoidance diet</style></keyword><keyword><style face="normal" font="Arial"> avoidance diets</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Congresses</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Cow s milk and egg are the most frequent causes of food allergy in the first years of life. Treatments such as oral immunotherapy (OIT) have been investigated as an alternative to avoidance diets. No clinical practice guides on the management of OIT with milk and egg are currently available. Objectives: To develop a clinical guide on OIT based on the available scientific evidence and the opinions of experts. METHODS: A review was made of studies published in the period between 1984 and June 2016, Doctoral Theses published in Spain, and summaries of communications at congresses (SEAIC, SEICAP, EAACI, AAAAI), with evaluation of the opinion consensus established by a group of experts pertaining to the scientific societies SEICAP and SEAIC. RESULTS: Recommendations have been established regarding the indications, requirements and practical aspects of the different phases of OIT, as well as special protocols for patients at high risk of suffering adverse reactions. CONCLUSIONS: A clinical practice guide is presented for the management of OIT with milk and egg, based on the opinion consensus of Spanish experts</style></abstract><notes><style face="normal" font="Arial">DA - 20170608IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0178</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28593864">PM:28593864</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\20170608-MartorellA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\20170608-MartorellA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170608, Martorell A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0178</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Basagana,M.</style></author><author><style face="normal" font="Arial"> Luengo,O.</style></author><author><style face="normal" font="Arial"> Labrador,M.</style></author><author><style face="normal" font="Arial"> Garriga,T.</style></author><author><style face="normal" font="Arial"> Mattsson,L.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Component-Resolved Diagnosis of Dog Allergy</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="187" start="185">185-187</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0150</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570224">PM:28570224</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Basagana M</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0150</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asero,R.</style></author><author><style face="normal" font="Arial"> Scala,E.</style></author><author><style face="normal" font="Arial"> Villalta,D.</style></author><author><style face="normal" font="Arial"> Pravettoni,V.</style></author><author><style face="normal" font="Arial"> Arena,A.</style></author><author><style face="normal" font="Arial"> Billeri,L.</style></author><author><style face="normal" font="Arial"> Colombo,G.</style></author><author><style face="normal" font="Arial"> Cortellini,G.</style></author><author><style face="normal" font="Arial"> Cucinelli,F.</style></author><author><style face="normal" font="Arial"> De Cristofaro,M.L.</style></author><author><style face="normal" font="Arial"> Farioli,L.</style></author><author><style face="normal" font="Arial"> Iemoli,E.</style></author><author><style face="normal" font="Arial"> Lodi Rizzini,F.</style></author><author><style face="normal" font="Arial"> Longo,R.</style></author><author><style face="normal" font="Arial"> Losappio,L.</style></author><author><style face="normal" font="Arial"> Macchia,D.</style></author><author><style face="normal" font="Arial"> Maietta,G.</style></author><author><style face="normal" font="Arial"> Minale,P.</style></author><author><style face="normal" font="Arial"> Murzilli,F.</style></author><author><style face="normal" font="Arial"> Nebiolo,F.</style></author><author><style face="normal" font="Arial"> Pastorello,E.A.</style></author><author><style face="normal" font="Arial"> Ventura,M.T.</style></author><author><style face="normal" font="Arial"> Voltolini,S.</style></author><author><style face="normal" font="Arial"> Amato,S.</style></author><author><style face="normal" font="Arial"> Mistrello,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy</style></auth-address><titles><title><style face="normal" font="Arial">Shrimp Allergy: Analysis of Commercially Available Extracts for In Vivo Diagnosis</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="182" start="175">175-182</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pen m 2</style></keyword><keyword><style face="normal" font="Arial"> Pen m 4</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Reactor</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergen</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergy</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Skin prick testing (SPT) with commercial extracts is the first step in the diagnosis of shrimp allergy, although its clinical efficiency is unknown. Objective: To analyze the clinical usefulness of all commercial crustacean extracts available for SPT in Italy. METHODS: We performed a multicenter study of 157 shrimp-allergic patients who underwent SPT with 5 commercial crustacean extracts and with house dust mite (HDM) extract. Commercial extracts were analyzed using SDS-PAGE and compared with a freshly prepared in-house shrimp extract. IgE to Pen a 1/Pen m 1, Pen m 2, and Pen m 4 was determined, and immunoblot analysis was performed on a large number of sera. RESULTS: The skin reactions caused by commercial crustacean extracts were extremely heterogeneous, resulting in 32 clinical profiles, with marked differences in protein content and missing proteins at molecular weights corresponding to those of major shrimp allergens. Only strong Pen a 1/Pen m 1 reactors reacted to both HDM and all 5 commercial extracts in SPT. Most patients, including those who were tropomyosin-negative, reacted to HDM. Patients reacted to a large and variable array of proteins, and IgE reactivity was common at high molecular weights (>50 kDa). CONCLUSIONS: The in vivo diagnosis of shrimp allergy must continue to be based on SPT with fresh material. Shrimp-allergic patients frequently react to a number of ill-defined high-molecular-weight allergens, thus leaving currently available materials for component-resolved diagnosis largely insufficient. Mites and crustaceans probably share several allergens other than tropomyosin</style></abstract><notes><style face="normal" font="Arial">DA - 20161213IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27959286">PM:27959286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-175-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-175-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161213, Asero R</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0127</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kotsiou,O.S.</style></author><author><style face="normal" font="Arial"> Xirogiannis,K.I.</style></author><author><style face="normal" font="Arial"> Gourgoulianis,K.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, BIOPOLIS, Larissa, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Kounis Syndrome: Is it Really a Takotsubo-Like Syndrome?</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="200" start="198">198-200</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Faculty</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0145</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570230">PM:28570230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-198-200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-198-200.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170601, Kotsiou OS</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0145</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sekerel,B.E.</style></author><author><style face="normal" font="Arial"> Seyhun,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pediatric Allergy and Asthma , Hacettepe University Faculty of Medicine , Ankara , Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Expert panel on practice patterns in the management of cow's milk protein allergy and associated economic burden of disease on health service in Turkey</style></title><secondary-title><style face="normal" font="Arial">J Med Econ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Econ</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> direct costs</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> General well-being</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> indirect costs</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="Arial">AIMS: To evaluate practice patterns in the management of cow's milk protein allergy (CMPA) and associated economic burden of disease on health service in Turkey. MATERIALS AND METHODS: This study was based on experts' views on the practice patterns in management of CMPA manifesting with either proctocolitis or eczema symptoms and, thereby, aimed to estimate economic burden of CMPA. Practice patterns were determined via patient flow charts developed by experts using the modified Delphi method for CMPA presented with proctocolitis and eczema. Per patient total 2-year direct medical costs were calculated, including cost items of physician visits, laboratory tests, and treatment. RESULTS: According to the consensus opinion of experts, 2-year total direct medical cost from a payer perspective and societal perspective was calculated to be $US2,116.05 and $US2,435.84, respectively, in an infant with CMPA presenting with proctocolitis symptoms, and $US4,001.65 and $US4,828.90, respectively, in an infant with CMPA presenting with eczema symptoms. Clinical nutrition was the primary cost driver that accounted for 89-92% of 2-year total direct medical costs, while the highest total direct medical cost estimated from a payer perspective and societal perspective was noted for the management of an exclusively formula-fed infant presenting either with proctocolitis ($US3,743.85 and $US4,025.63, respectively) or eczema ($US6,854.10 and $US7,917.30, respectively). The first line use of amino acid based formula (AAF) was associated with total direct cost increment $US1,848.08 and $US3,444.52 in the case of proctocolitis and eczema, respectively. LIMITATIONS: Certain limitations to this study should be considered. First, being focused only on direct costs, the lack of data on indirect costs or intangible costs of illness seems to be a major limitation of the present study, which likely results in a downward bias in the estimates of the economic cost of CMPA. Second, given the limited number of studies concerning epidemiology and practice patterns in CMPA in Turkey, use of expert clinical opinion of the panel members rather than real-life data on practice patterns that were used to identify direct medical costs might raise a concern with the validity and reliability of the data. Also, while this was a three-step study with six experts included in the first stage (developing local guidelines for diagnosis, treatment, and follow-up of infants with CMPA in Turkey) and 410 pediatricians included in the second stage (a cross-sectional questionnaire-survey to determine pediatricians' awareness and practice of CMPA in infants and children), only four members were included in the present Delphi panel, which allows a limited discussion. Third, lack of sensitivity analyses and exclusion of indirect costs and costs related to alterations in quality of life, behavior of infants, and general well-being of infants and their parents from the cost-analysis seems to be another limitation that may have caused under-estimation of relative cost-effectiveness of the formulae. Fourth, calculation of costs per local guidelines rather than real-life practice patterns is another limitation that, otherwise, would extend the knowledge achieved in the current study. Notwithstanding these limitations, the present expert panel provided practice patterns in the management of CMPA and an estimate of the associated costs, depending on the symptom profile at initial admission for the first time in Turkey. CONCLUSIONS: In conclusion, in providing the first health economic data on CMPA in Turkey, the findings revealed that CMPA imposes a substantial burden on the Turkish healthcare system from both a payer perspective and societal perspective, and indicated clinical nutrition as a primary cost driver. Management of infants presenting with eczema, exclusively formula-fed infants, and first line use of AAF were associated with higher estimates for 2-year direct medical costs</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1941-837X (Electronic)IS - 1369-6998 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1080/13696998.2017.1342171</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28602101">PM:28602101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Econ\20170612-SekerelBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Econ\20170612-SekerelBE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Sekerel BE</style></custom2><misc3><style face="normal" font="Arial">10.1080/13696998.2017.1342171</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bui,T.T.</style></author><author><style face="normal" font="Arial"> Piao,C.H.</style></author><author><style face="normal" font="Arial"> Kim,S.M.</style></author><author><style face="normal" font="Arial"> Song,C.H.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author><author><style face="normal" font="Arial"> Chai,O.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Anatomy, Chonbuk National University Medical School , Jeonju, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Citrus tachibana Leaves Ethanol Extract Alleviates Airway Inflammation by the Modulation of Th1/Th2 Imbalance via Inhibiting NF-kappaB Signaling and Histamine Secretion in a Mouse Model of Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">J Med Food</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Food</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory disease of bronchial airway, which is characterized by chronic airway inflammation, airway edema, goblet cell hyperplasia, the aberrant production of the Th2 cytokines, and eosinophil infiltration in the lungs. In this study, the therapeutic effect and the underlying mechanism of Citrus tachibana leaves ethanol extract (CTLE) in the ovalbumin (OVA)-induced allergic asthma and compound 48/80-induced anaphylaxis were investigated. Oral administration of CTLE inhibited OVA-induced asthmatic response by reducing airway inflammation, OVA-specific IgE and IgG1 levels, and increasing OVA-specific IgG2a levels. CTLE restored Th1/Th2 balance through an increase in Th2 cytokines tumor necrosis factor-alpha, interleukin (IL)-4, and IL-6 and decreases in Th1 cytokines interferon-gamma and IL-12. Furthermore, CTLE inhibited the total level of NF-kappaB and the phosphorylation of IkappaB-alpha and NF-kappaB by OVA. In addition, CTLE dose-dependently inhibited compound 48/80-induced anaphylaxis via blocking histamine secretion from mast cells. The anti-inflammatory mechanism of CTLE may involve the modulation of Th1/Th2 imbalance via inhibiting the NF-kappaB signaling and histamine secretion. Taken together, we suggest that CTLE could be used as a therapeutic agent for patients with Th2-mediated or histamine-mediated allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170609IS - 1557-7600 (Electronic)IS - 1096-620X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1089/jmf.2016.3853</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28598706">PM:28598706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Food\20170609-BuiTT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Food\20170609-BuiTT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170609, Bui TT</style></custom2><misc3><style face="normal" font="Arial">10.1089/jmf.2016.3853</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Correa,M.P.</style></author><author><style face="normal" font="Arial"> Andrade,F.E.C.</style></author><author><style face="normal" font="Arial"> Gimenes,A.D.</style></author><author><style face="normal" font="Arial"> Gil,C.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Post-Graduation in Biosciences, UN</style></auth-address><titles><title><style face="normal" font="Arial">Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Mol Med (Berl)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Mol Med (Berl)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic skin inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> extracellular signal-regulated kinase</style></keyword><keyword><style face="normal" font="Arial"> Galectin 1</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell protease</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> systemic treatment</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is caused by both dysregulated immune responses and an impaired skin barrier. Although beta-galactoside-binding protein galectin-1 (Gal-1) has immunomodulatory effects in several inflammatory disorders, therapeutic strategies based on its anti-inflammatory properties have not been explored in AD. Thus, we evaluate pharmacological treatment with Gal-1 in the progression of an ovalbumin (OVA)-induced AD-like skin lesions. The skin of OVA-immunized male BALB/c mice was challenged with drops containing OVA on days 11, 14-18 and 21-24. Additionally, in the last week, a subset of animals was treated intraperitoneally with recombinant Gal-1 (rGal-1) or dexamethasone (Dex). Treatment with rGal-1 decreased the clinical signs of dermatitis in BALB/c mice and diminished local eotaxin and IFN-gamma levels. The treatment also suppressed the infiltration of eosinophils and mast cells, which was verified by reduced expression of mouse mast cell protease 6 (mMCP6) and eosinophil peroxidase (EPX). These localized effects are associated with extracellular signal-regulated kinase (ERK) activation and downregulation of endogenous Gal-1. The inhibition of disease progression induced by rGal-1 was also correlated with reduced plasma IL-17 levels. Our results demonstrate that rGal-1 is an effective treatment for allergic skin inflammation in AD and may impact the development of novel strategies for skin inflammatory diseases. KEY MESSAGES: Pharmacological treatment with rGal-1 reduces clinical signs of atopic dermatitis. Systemic treatment with rGal-1 inhibits eosinophil and mast cell influx in the skin of AD animals. rGal-1 reduced local eotaxin levels and systemic IL-17 levels. The inhibition of disease progression induced by rGal-1 was correlated with upregulation of phosphorylated ERK</style></abstract><notes><style face="normal" font="Arial">DA - 20170630IS - 1432-1440 (Electronic)IS - 0946-2716 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00109-017-1566-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28664215">PM:28664215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Mol Med (Berl)\20170630-CorreaMP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Mol Med (Berl)\20170630-CorreaMP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170630, Correa MP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00109-017-1566-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gocmen,R.</style></author><author><style face="normal" font="Arial"> Acar,N.P.</style></author><author><style face="normal" font="Arial"> Cagdas,D.</style></author><author><style face="normal" font="Arial"> Kurne,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Radiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Progressive multifocal leukoencephalopathy in a patient with lymphoma and presumptive hyper IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">J Neurovirol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Neurovirol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Central Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="Arial">We, herein, report a 23-year-old male with a rare inherited immunodeficiency disease, hyperimmunoglobulin IgE syndrome (HIES), who developed progressive multifocal leukoencephalopathy (PML) and lymphoma simultaneously. Primary immunodeficiency of the patient has remained undiagnosed until adulthood. PML is a severe demyelinating disease of the central nervous system caused by John Cunningham virus. HIES is a rare, inherited immunodeficiency characterized by high serum levels of IgE, recurrent staphylococcal infection, eczema, and hypereosinophilia. PML may accompany primary immunodeficiency syndromes, but the association with HIES is exceedingly rare. We discuss the imaging findings, medical management, and a review of related literature on primary immunodeficiency cases complicating with PML</style></abstract><notes><style face="normal" font="Arial">DA - 20170623IS - 1538-2443 (Electronic)IS - 1355-0284 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13365-017-0536-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28643229">PM:28643229</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Neurovirol\20170623-GocmenR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Neurovirol\20170623-GocmenR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170623, Gocmen R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13365-017-0536-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stave,G.M.</style></author><author><style face="normal" font="Arial"> Lee,E.H.</style></author><author><style face="normal" font="Arial"> Darcey,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Occupational and Environmental Medicine, Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina</style></auth-address><titles><title><style face="normal" font="Arial">Laboratory Animal Bite Anaphylaxis: A National Survey: Part 2: Treatment Protocols</style></title><secondary-title><style face="normal" font="Arial">J Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animal Welfare</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: This study documents current treatment protocols for laboratory animal bite anaphylaxis in the United States. METHODS: An online survey was e-mailed to designated institutional officials at laboratory animal facilities identified by the National Institutes of Health Office of Laboratory Animal Welfare. RESULTS: One hundred eighty-nine organizations responded to the question of whether they had a treatment protocol with 32% indicating that they had a protocol. Having a case of anaphylaxis increased the likelihood of having a protocol (61%). Of those with a protocol, 58% included treatment with injectable epinephrine, if clinically indicated. Among all respondents, only 14% reported keeping injectable epinephrine at the location where animal work is performed. CONCLUSIONS: A minority of responding organizations had protocols in place to address laboratory animal bite anaphylaxis. Organizations with workers at risk should consider implementing a protocol for assessment and treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1536-5948 (Electronic)IS - 1076-2752 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/JOM.0000000000001063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28609353">PM:28609353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Occup Environ Med\20170613-StaveGM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Occup Environ Med\20170613-StaveGM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Stave GM</style></custom2><misc3><style face="normal" font="Arial">10.1097/JOM.0000000000001063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fong,A.T.</style></author><author><style face="normal" font="Arial"> Katelaris,C.H.</style></author><author><style face="normal" font="Arial"> Wainstein,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Bullying and quality of life in children and adolescents with food allergy</style></title><secondary-title><style face="normal" font="Arial">J Paediatr Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Paediatr Child Health</style></full-title></periodical><pages end="635" start="630">630-635</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">Food allergy is an increasing phenomenon in Australia, with most recent reports of food allergy occurring in 1 in 12 children. A number of studies have demonstrated that children and adolescents with food allergies experience a decreased quality of life across a number of domains. More recent evidence suggests that this population also experiences an increased occurrence of bullying compared to similar school-aged children. Some individuals have reported being bullied because of their allergies, whilst others have reported specific allergy-related-bullying, such as being touched with foods that they are allergic to or having their food being intentionally contaminated with an allergen. Where there may be a risk of severe anaphylaxis, this is of great concern. This article reviews the current literature on bullying in populations of children and adolescents with food allergies. Several papers worldwide have investigated this, providing evidence of its occurrence in North America, Canada, Italy and Japan</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1440-1754 (Electronic)IS - 1034-4810 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/jpc.13570</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28608485">PM:28608485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Paediatr Child Health\2017-53-630-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Paediatr Child Health\2017-53-630-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Fong AT</style></custom2><misc3><style face="normal" font="Arial">10.1111/jpc.13570</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Netting,M.J.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Healthy Mothers Babies and Children's Theme, South Australian Health Medical Research Institute, Adelaide, South Australia, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Advice about infant feeding for allergy prevention: A confusing picture for Australian consumers?</style></title><secondary-title><style face="normal" font="Arial">J Paediatr Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Paediatr Child Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Solid food</style></keyword><keyword><style face="normal" font="Arial"> South Australia</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">AIM: Early feeding plays an important role in programming the immune system, particularly the risk of food allergy. There are many infant feeding guides published for consumers available in Australia, with most based on the National Health and Medical Research Council (NHMRC) 2012 Infant Feeding Guidelines for Health Workers and the Australasian Society of Clinical Immunology and Allergy (ASCIA) Infant Feeding Advice for allergy prevention. We sought to compare allergy-specific content of infant feeding educational material written for parents with these two documents. METHODS: Australian websites of children's hospitals, early child health organisations and consumer groups providing information about diet during pregnancy, breastfeeding and early infancy were compared with NHMRC and ASCIA guidelines. RESULTS: Twenty-five sets of infant feeding information were identified. Food allergy was discussed in 18 resources. Recommended length of exclusive breastfeeding and timing of commencing solid foods was consistently around 6 months, with some variation in wording. Advice regarding to include and not delay introduction of common allergens into babies' diets was generally consistent with NHMRC and ASCIA recommendations, however the audit identified some resources that still recommended delayed introduction of common allergens. CONCLUSION: As consumers have access to a plethora of health information it is imperative that information about infant feeding from health-care authorities is simple, evidence-based and consistent to avoid confusion. Use of consensus wording related to infant feeding guidelines to prevent allergies will provide clear messages related to the timing of introduction to solid foods and inclusion of allergens in the early diet</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1440-1754 (Electronic)IS - 1034-4810 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/jpc.13594</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28603870">PM:28603870</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Paediatr Child Health\20170612-NettingMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Paediatr Child Health\20170612-NettingMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Netting MJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/jpc.13594</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goodwin,R.D.</style></author><author><style face="normal" font="Arial"> Rodgin,S.</style></author><author><style face="normal" font="Arial"> Goldman,R.</style></author><author><style face="normal" font="Arial"> Rodriguez,J.</style></author><author><style face="normal" font="Arial"> Devos,G.</style></author><author><style face="normal" font="Arial"> Serebrisky,D.</style></author><author><style face="normal" font="Arial"> Feldman,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Psychology, Queens College and The Graduate Center, The City University of New York, Queens, NY</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy and Anxiety and Depression among Ethnic Minority Children and Their Caregivers</style></title><secondary-title><style face="normal" font="Arial">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> minority children</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="6" Year="2017">2017/6/5</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the relationship between food allergy and symptoms of anxiety and depression among ethnic minority, low socioeconomic status (SES) children and their caregivers. STUDY DESIGN: Pediatric patients ages 4-12 years with and without food allergy and their caregivers were recruited from urban pediatric outpatient clinics. Statistical analyses were used to examine the prevalence of symptoms of anxiety and depression among patients and their caregivers with and without food allergy, adjusting for asthma. RESULTS: Eighty patients ranging from ages 4 to 12 years, with a mean age of 8.1 years, and their caregivers participated in the study. Food allergy was associated with significantly higher t scores on the Multidimensional Anxiety Scale for Children (MASC) Total (P = .007), MASC Humiliation Rejection, (P = .02) and MASC Social Anxiety (P = .02) among pediatric patients, adjusting for asthma. Food allergy was not associated with child depression symptoms, nor was there a significant difference in anxiety or depression symptoms among caregivers of patients with and without food allergy. CONCLUSIONS: Food allergy appears to be associated with increased symptoms of social anxiety and higher levels of anxiety overall, but not depression, in ethnic minority children of lower socioeconomic status. This finding was not due to confounding by asthma. Food allergy was not associated with higher levels of depression or anxiety symptoms among caregivers of pediatric patients with food allergy. Future studies should investigate potential pathways between food allergy and anxiety that may be unique to children in underserved populations, and develop interventions to reduce anxiety in children with food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170609IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jpeds.2017.04.055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28595764">PM:28595764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr\20170609-GoodwinRD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr\20170609-GoodwinRD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170609, Goodwin RD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jpeds.2017.04.055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silva,C.M.</style></author><author><style face="normal" font="Arial"> Silva,S.A.D.</style></author><author><style face="normal" font="Arial"> Antunes,M.M.C.</style></author><author><style face="normal" font="Arial"> Silva,G.A.P.D.</style></author><author><style face="normal" font="Arial"> Sarinho,E.S.C.</style></author><author><style face="normal" font="Arial"> Brandt,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidade Federal de Pernambuco (UFPE), Programa de Pos Graduacao em Saude da Crianca e do Adolescente, Recife, PE, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Do infants with cow's milk protein allergy have inadequate levels of vitamin D?</style></title><secondary-title><style face="normal" font="Arial">J Pediatr (Rio J)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr (Rio J)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To verify whether infants with cow's milk protein allergy (CMPA) have inadequate vitamin D levels. METHODS: This cross-sectional study included 120 children aged 2 years or younger, one group with CMPA and a control group. The children were recruited at the pediatric gastroenterology, allergology, and pediatric outpatient clinics of a university hospital in the Northeast of Brazil. A questionnaire was administered to the caregiver and blood samples were collected for vitamin D quantification. Vitamin D levels &lt;30ng/mL were considered inadequate. Vitamin D level was expressed as mean and standard deviation, and the frequency of the degrees of sufficiency and other variables, as proportions. RESULTS: Infants with CMPA had lower mean vitamin D levels (30.93 vs.35.29ng/mL; p=0.041) and higher deficiency frequency (20.3% vs.8.2; p=0.049) than the healthy controls. Exclusively or predominantly breastfed infants with CMPA had higher frequency of inadequate vitamin D levels (p=0.002). Regardless of sun exposure time, the groups had similar frequencies of inadequate vitamin D levels (p=0.972). CONCLUSIONS: Lower vitamin D levels were found in infants with CMPA, especially those who were exclusively or predominantly breastfed, making these infants a possible risk group for vitamin D deficiency</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1678-4782 (Electronic)IS - 0021-7557 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jped.2017.01.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28628759">PM:28628759</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr (Rio J)\20170619-SilvaCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr (Rio J)\20170619-SilvaCM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Silva CM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jped.2017.01.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harvey,B.M.</style></author><author><style face="normal" font="Arial"> Eussen,S.R.B.M.</style></author><author><style face="normal" font="Arial"> Harthoorn,L.F.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Children's Investigational Research Program, LLC (ChiRP), Bentonville AR, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mineral Intake and Status of Cow's Milk Allergic Infants Consuming an Amino Acid-based Formula</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> complementary foods</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Ferritin</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Magnesium</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Phosphorus</style></keyword><keyword><style face="normal" font="Arial"> Potassium</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">Data on the mineral status of infants with cow's milk allergy (CMA) consuming an amino acid-based formula (AAF) have not been published. The present study aims to assess mineral status of term infants aged 0-8 months diagnosed with CMA receiving an AAF for 16 weeks. Serum concentrations of calcium, phosphorus, chloride, sodium, potassium, magnesium and ferritin were determined in 82 subjects at baseline and in 66 subjects after 16 weeks on AAF using standard methods and evaluated against age-specific reference ranges. Additionally, individual estimated energy and mineral intakes were compared to Adequate Intakes defined by the European Food Safety Authority and the US Institute of Medicine. The results of this study show that the AAF was effective in providing an adequate mineral status in infants with CMA. The vast majority of infants aged 0-6 months (formula only) and aged 6-12 months (formula and complementary foods) had adequate mineral intakes</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001655</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28604516">PM:28604516</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20170612-HarveyBM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20170612-HarveyBM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Harvey BM</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001655</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Woods,D.</style></author><author><style face="normal" font="Arial"> Winchester,K.</style></author><author><style face="normal" font="Arial"> Towerman,A.</style></author><author><style face="normal" font="Arial"> Gettinger,K.</style></author><author><style face="normal" font="Arial"> Carey,C.</style></author><author><style face="normal" font="Arial"> Timmermann,K.</style></author><author><style face="normal" font="Arial"> Langley,R.</style></author><author><style face="normal" font="Arial"> Browne,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Washington University, St. Louis, MO, USA</style></auth-address><titles><title><style face="normal" font="Arial">From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Oncol Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Oncol Nurs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">PEG-aspariginase is a backbone chemotherapy agent in pediatric acute lymphoblastic leukemia and in some non-Hodgkin lymphoma therapies. Nurses lack standardized guidelines for monitoring patients receiving PEG-asparaginase and for educating patients/families about hypersensitivity reaction risks. An electronic search of 6 databases using publication years 2000-2015 and multiple professional organizations and clinical resources was conducted. Evidence sources were reviewed for topic applicability. Each of the final 23 sources was appraised by 2 team members. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) system was used to assign a quality and strength rating for each recommendation. Multiple recommendations were developed: 4 relating to nurse monitoring of patients during and after drug administration, 8 guiding hypersensitivity reaction management, and 4 concerning patient/family educational content. These strong recommendations were based on moderate, low, or very-low-quality evidence. Several recommendations relied on generalized drug hypersensitivity guidelines. Additional research is needed to safely guide PEG-asparaginase monitoring, hypersensitivity reaction management, and patient/family education. Nurses administering PEG-asparaginase play a critical role in the early identification and management of hypersensitivity reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1532-8457 (Electronic)IS - 1043-4542 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/1043454217713455</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28602129">PM:28602129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Oncol Nurs\20170612-WoodsM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Oncol Nurs\20170612-WoodsM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Woods</style></custom2><misc3><style face="normal" font="Arial">10.1177/1043454217713455</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sato,A.</style></author><author><style face="normal" font="Arial"> Ebina,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Pharmacy, Iwaki Meisei University, 5-5-1 Chuodai-Iino, Iwaki, Fukushima, 970-8551, JapanFaculty of Pharmacy, Iwaki Meisei University, 5-5-1 Chuodai-Iino, Iwaki, Fukushima, 970-8551, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A biotinylated peptide, BP21, as a novel potent anti-anaphylactic agent targeting platelet-activating factor</style></title><secondary-title><style face="normal" font="Arial">J Pept Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pept Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Alanine</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Bradykinin</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Consensus Sequence</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAF</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> platelet-activating factor</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serotonin</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tryptophan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular permeability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="6" Year="2017">2017/6/19</year></dates><abstract><style face="normal" font="Arial">Platelet-activating factor (PAF) is an important mediator of anaphylaxis and is therefore an anti-anaphylactic drug target. We recently reported that synthetic N-terminally biotinylated peptides (BP4-BP29) inhibit PAF by directly interacting with PAF and its metabolite/precursor lyso-PAF. In this study, we investigated whether the biotinylated peptides can inhibit anaphylactic reactions in vivo. In mouse models of anaphylaxis, one of the peptides, BP21, markedly and dose-dependently inhibited hypothermia with a maximum dose-response within 30 min after administration, even at doses 20 times lesser than doses of the known PAF antagonist CV-3988. In contrast, the anti-hypothermic effect of BGP21, in which the Tyr-Lys-Asp-Gly sequence in BP21 was modified to a Gly-Gly-Gly-Gly sequence, was less than that of BP21. The alanine scanning and shuffling the amino acid residues of BP4 (Tyr-Lys-Asp-Gly) demonstrated that the Tyr-Lys-Asp-Gly consensus sequence is important for the inhibitory effect of the peptide on hypothermia. BP21 also suppressed vascular permeability during anaphylaxis with a maximum dose-response within 30 min of administration. In a rat model of hind paw oedema, BP21 significantly inhibited the oedema induced by PAF but not that induced by the other pro-inflammatory mediators, such as histamine, serotonin, and bradykinin. Tryptophan fluorescence measurements showed that BP21 interacted with PAF, but not with histamine, serotonin, or bradykinin. In contrast, BGP21 did not interact with PAF. These results suggest that biotinylated peptides, especially BP21, can specifically and markedly inhibit anaphylactic reactions in vivo and that this involves direct interaction of its Tyr-Lys-Asp-Gly region with PAF. Therefore, a biotinylated peptide, BP21, can be used as novel potential anti-anaphylactic drugs targeting PAF. Copyright (c) 2017 European Peptide Society and John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1099-1387 (Electronic)IS - 1075-2617 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1002/psc.3019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28627122">PM:28627122</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pept Sci\20170619-SatoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pept Sci\20170619-SatoA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Sato A</style></custom2><misc3><style face="normal" font="Arial">10.1002/psc.3019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Molina,M.D.</style></author><author><style face="normal" font="Arial"> Muccilli,V.</style></author><author><style face="normal" font="Arial"> Saletti,R.</style></author><author><style face="normal" font="Arial"> Foti,S.</style></author><author><style face="normal" font="Arial"> Masci,S.</style></author><author><style face="normal" font="Arial"> Barro,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Plant Breeding, Institute for Sustainable Agriculture (IAS-CSIC), 14004 Cordoba, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Comparative proteomic analysis of two transgenic low-gliadin wheat lines and non-transgenic wheat control</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2D electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> 2D-electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> beta-Amylase</style></keyword><keyword><style face="normal" font="Arial"> Biological significance</style></keyword><keyword><style face="normal" font="Arial"> Bread</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Coeliac disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Endosperm</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Gliadin content</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> glutenin</style></keyword><keyword><style face="normal" font="Arial"> Glutenin subunits</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grain proteins</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein fraction</style></keyword><keyword><style face="normal" font="Arial"> Protein fractions</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> RNA interference</style></keyword><keyword><style face="normal" font="Arial"> RNAi</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Safety evaluation</style></keyword><keyword><style face="normal" font="Arial"> Serpin</style></keyword><keyword><style face="normal" font="Arial"> Serpins</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Transformation</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic wheat</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergen</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergens</style></keyword><keyword><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">Gluten proteins are major determinants of the bread making quality of wheat, but also of important wheat-related disorders, including coeliac disease (CD), and allergies. We carried out a proteomic study using the total grain proteins from two low-gliadin wheat lines, obtained by RNAi, and the untransformed wild type as reference. The impact of silencing on both target and on non-target proteins was evaluated. Because of the great protein complexity, we performed separate analyses of four kernel protein fractions: gliadins and glutenin subunits, and metabolic and CM-like proteins, by using a classical 2D electrophoresis gel based approach followed by RP-HPLC/nESI-MS/MS. As a result of the strong down-regulation of gliadins, the HMW-GS, metabolic and chloroform/methanol soluble proteins were over-accumulated in the transgenic lines, especially in the line D793, which showed the highest silencing of gliadins. Basing on these data, and considering that metabolic proteins and chloroform/methanol soluble proteins (CM-like), such as the alpha-amylase/trypsin inhibitor family, beta-amylase and serpins, were related to wheat allergens, further in vivo analysis will be needed, especially those related to clinical trials in controlled patients, to determine if these lines could be used for food preparation for celiac or other gluten intolerant groups. BIOLOGICAL SIGNIFICANCE: Several enteropathies and allergies are related to wheat proteins. Biotechnological techniques such as genetic transformation and RNA interference have allowed the silencing of gliadin genes, providing lines with very low gliadin content in the grains. We report a proteomic-based approach to characterize two low-gliadin transgenic wheat lines obtained by RNAi technology. These lines harbor the same silencing fragment, but driven by two different endosperm specific promoters (gamma-gliadin and D-hordein). The comprehensive proteome analysis of these transgenic lines, by combining two-dimensional electrophoresis and RP-HPLC/nESI-MS/MS, provided a large number of spots differentially expressed between the control and the transgenic lines. Hence, the results of this study will facilitate further safety evaluation of these transgenic lines</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2017.06.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28625740">PM:28625740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMD.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMDmmc2.xlsxC:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMDmmc4.xlsxC:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMDmmc5.xlsxC:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMDmmc7.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMDmmc2.xlsxF:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMDmmc4.xlsxF:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMDmmc5.xlsxF:\A&amp;H HMW Papers\J Proteomics\20170619-GarciaMolinaMDmmc7.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170619, Garcia-Molina MD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2017.06.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohammadi,A.</style></author><author><style face="normal" font="Arial"> Hashemi,S.M.</style></author><author><style face="normal" font="Arial"> Abtahi,S.H.</style></author><author><style face="normal" font="Arial"> Lajevardi,S.M.</style></author><author><style face="normal" font="Arial"> Kianipour,S.</style></author><author><style face="normal" font="Arial"> Mohammadi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</style></auth-address><titles><title><style face="normal" font="Arial">An investigation on non-invasive fungal sinusitis; Molecular identification of etiologic agents</style></title><secondary-title><style face="normal" font="Arial">J Res Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Res Med Sci</style></full-title></periodical><pages end="" start="67">67-</pages><volume><style face="normal" font="Arial">22</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candida glabrata</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> fungal allergens</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Mucor</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Penicillium chrysogenum</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Rhizopus</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fungal sinusitis is increasing worldwide in the past two decades. It is divided into two types including invasive and noninvasive. Noninvasive types contain allergic fungal sinusitis (AFS) and fungus ball. AFS is a hypersensitivity reaction to fungal allergens in the mucosa of the sinonasal tract in atopic individuals. The fungus ball is a different type of noninvasive fungal rhinosinusitis which is delineated as an accumulation of debris and fungal elements inside a paranasal sinus. Fungal sinusitis caused by various fungi such as Aspergillus species, Penicillium, Mucor, Rhizopus, and phaeohyphomycetes. The aim of the present study is to identify fungal species isolated from noninvasive fungal sinusitis by molecular methods. MATERIALS AND METHODS: During 2015-2016, a total of 100 suspected patients were examined for fungal sinusitis. Functional endoscopic sinus surgery was performed using the Messerklinger technique. Clinical samples were identified by phenotypic and molecular methods. Polymerase chain reaction (PCR) sequencing of ITS1-5.8S-ITS2 region and PCR-restriction fragment length polymorphism with MspI restriction enzyme was performed for molecular identification of molds and yeasts, respectively. RESULTS: Twenty-seven out of 100 suspected cases (27%) had fungal sinusitis. Nasal congestion (59%) and headache (19%) were the most common clinical signs among patients. Fifteen patients (55.5%) were male and 12 patients (44.5%) were female. Aspergillus flavus was the most prevalent fungal species (26%), followed by Penicillium chrysogenum (18.5%) and Candida glabrata species complex (15%). CONCLUSION: Since clinical manifestations, computed tomography scan, endoscopy, and histopathological findings are very nonspecific in AFS and fungus ball; therefore, molecular investigations are compulsory for precise identification of etiologic agents and appropriate management of these fungal infections</style></abstract><notes><style face="normal" font="Arial">DA - 20170615IS - 1735-1995 (Print)IS - 1735-1995 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.4103/jrms.JRMS_166_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28616054">PM:28616054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Res Med Sci\2017-22-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Res Med Sci\2017-22-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Mohammadi A</style></custom2><misc3><style face="normal" font="Arial">10.4103/jrms.JRMS_166_17</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,S.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Tong,P.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang, 330047, P.R.China</style></auth-address><titles><title><style face="normal" font="Arial">Development of a H2 O2 -sensitive quantum dots-based fluorescent sandwich ELISA for sensitive detection of bovine beta-lactoglobulin by monoclonal antibody</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic residues</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence quenching</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Horseradish Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen Peroxide</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> Infant formulas</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Quantum Dots</style></keyword><keyword><style face="normal" font="Arial"> Quenching</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bovine beta-lactoglobulin (BLG) is the major allergen in cows' milk, and specific epitope play a key role in food allergy. Developing a method specifically bind to IgE epitope is necessary for testing BLG and its allergenic residues. RESULTS: The monoclonal antibody (1G9) specific to IgE linear epitope for BLG was identified as high affinity and specificity. Based on 1G9, a sensitive fluorescent sandwich enzyme-linked immunosorbent assay (sELISA) was successfully developed using catalase-mediated fluorescence quenching of thiolated CdTe quantum dots in the presence of hydrogen peroxide as fluorescent signal output. The fluorescent sELISA showed high sensitivity and specificity, the limit of detection was 0.49 ng mL-1 , which was 16-folds lower than horseradish peroxidase (HRP)-based sELISA. The linear range for BLG detection were 125-4000 ng mL-1 (r2 = 0.9939) and 0.48-62.5 ng mL-1 (r2 = 0.9919). The recoveries and coefficients of variation were 94.25%-109.83% and 4.38%-20.29%, respectively. Allergenic residues were also detected in hydrolyzed infant formulas. The results of fluorescent sELISA showed good performance as HRP-based sELISA and commercial sELISA kit. CONCLUSION: This proposed fluorescent sELISA could be employed to detect BLG and its allergenic residues in food with highly sensitivity, reliability, and recovery</style></abstract><notes><style face="normal" font="Arial">DA - 20170616IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8489</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28620918">PM:28620918</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170616-HeS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170616-HeS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170616, He S</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8489</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hanson,C.G.</style></author><author><style face="normal" font="Arial"> Proctor,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Health Sciences, Oakland University, Rochester, MI, USA</style></auth-address><titles><title><style face="normal" font="Arial">Ethmoid malformation associated with pediatric nasal polyposis and allergic fungal sinusitis</style></title><secondary-title><style face="normal" font="Arial">J Surg Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Surg Case Rep</style></full-title></periodical><pages end="" start="rjx099">rjx099-</pages><volume><style face="normal" font="Arial">2017</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epistaxis</style></keyword><keyword><style face="normal" font="Arial"> ethmoid</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">A 17-year-old female with allergic fungal sinusitis and nasal polyposis presented with epistaxis in the emergency room. On examination, right-sided proptosis and irregular nasal obstruction were observed in the right nasal cavity. CT imaging revealed massive right-sided polyposis and significant ipsilateral malformation with boney architecture preservation of the ethmoidal labyrinth and lamina papyracea. The patient was treated surgically with symptomatic improvement. These findings indicate a unique malformation of the ethmoid while the patient was in development. To the authors' knowledge, this anatomical malformation has not been previously described in the literature. Physicians should implement diagnostic procedures early if nasal polyposis and allergic fungal sinusitis is suspected in pediatric patients, especially with periocular involvement, to mitigate the risk of boney malformations of the sinuses</style></abstract><notes><style face="normal" font="Arial">DA - 20170609IS - 2042-8812 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1093/jscr/rjx099</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28596822">PM:28596822</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Surg Case Rep\2017-2017-rjx099.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Surg Case Rep\2017-2017-rjx099.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170609, Hanson CG</style></custom2><misc3><style face="normal" font="Arial">10.1093/jscr/rjx099</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,L.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Hu,Y.</style></author><author><style face="normal" font="Arial"> Zou,X.</style></author><author><style face="normal" font="Arial"> Yu,B.</style></author><author><style face="normal" font="Arial"> Qi,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergens in red ginseng extract induce the release of mediators associated with anaphylactoid reactions</style></title><secondary-title><style face="normal" font="Arial">J Transl Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Transl Med</style></full-title></periodical><pages end="" start="148">148-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reactions</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Ginsenoside</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> TCM</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> Translational research</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylactoid reactions induced by preparations containing red ginseng have been reported. The aim of this study is to evaluate the allergenicity and screen potential allergens in red ginseng extract thoroughly. METHODS: Red ginseng extract (RGE) and different fractions of RGE were prepared and evaluated by measuring the degranulation and viability of rat basophilic leukemia 2H3 (RBL-2H3) cells. Potential allergens were screened by RBL-2H3 cell extraction and allergenicity verified in RBL-2H3 cells, mouse peritoneal mast cells, Laboratory of Allergic Disease 2 (LAD2) human mast cells and mice, respectively. RESULTS: 80% ethanol extract of red ginseng extract induced mast cell degranulation with less cytotoxicity, but 40% ethanol extract could not. Ginsenoside Rd and 20(S)-Rg3 could induce a significant increase in beta-hexosaminidase release, histamine release and translocation of phosphatidylserine in RBL-2H3 cells. Ginsenoside Rd and 20(S)-Rg3 also increased beta-hexosaminidase release and the intracellular Ca2+ concentration in mouse peritoneal mast cells and LAD2 cells. In addition, histamine levels in serum of mice were elevated dose-dependently. CONCLUSIONS: Ginsenoside Rd and 20(S)-Rg3 are potential allergens that induce the release of mediators associated with anaphylactoid reactions. Our study could guide optimization of methods associated with Rd/20(S)-Rg3-containing preparations and establishment of quality standards for safe application of Traditional Chinese Medicines</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 1479-5876 (Electronic)IS - 1479-5876 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12967-017-1249-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28659175">PM:28659175</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Transl Med\2017-15-148.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Transl Med\2017-15-148.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Wang L</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12967-017-1249-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Luo,W.</style></author><author><style face="normal" font="Arial"> Pan,G.</style></author><author><style face="normal" font="Arial"> Huang,H.</style></author><author><style face="normal" font="Arial"> Zheng,P.</style></author><author><style face="normal" font="Arial"> Wei,N.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Zeng,G.</style></author><author><style face="normal" font="Arial"> Sun,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease; National Clinical Research Center of Respiratory Disease; Guangzhou Institute of Respiratory Diseases; Department of Allergy and Clinical Immunology, First Affiliated Hospital of Guangzhou Medical University</style></auth-address><titles><title><style face="normal" font="Arial">A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma</style></title><secondary-title><style face="normal" font="Arial">J Vis Exp</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Vis Exp</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bermuda</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnostics</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> grass pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Humulus</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="6" Year="2017">2017/6/4</year></dates><abstract><style face="normal" font="Arial">Sensitization to grass pollen imposes a global risk for allergic airway diseases. Although prevention relies on local investigation of the pollen allergens, data on this topic are limited in southern China. Any available data were obtained by self-report questionnaires, skin prick tests, and total or specific IgE tests using crude extracts. For many reasons, these methods are unreliable. Serum sIgE reactivity to Bermuda grass, Timothy grass, and Humulus scandens allergens in a cohort of patients from Greater Guangzhou (southern China's largest city and its outskirts) with allergic rhinitis and/or asthma were examined using a fully-automated immunoassay analyzer as a component-resolved diagnostics (CRD) tool. For the first time, a considerably high prevalence of Bermuda grass sIgE positivity was demonstrated in Chinese southerners with allergic rhinitis and/or asthma. In these patients, a subtle prevalence of sensitization to Timothy grass and Humulus scandens was also noted, which may arise from cross-reactivity, as the latter two are not common in the region. This was also supported by the detection of allergen components. Fully-automated immunoassay analyzers may offer satisfactory consistency between regions, laboratories, and institutions and over time. The automaticity of the instrument may enable a standardized detection that would not have been readily revealed before the advent of CRD. This is a study that uses a CRD approach to investigate sensitization to grass pollen allergens in southern China. It adds to current evidence in the literature. Future studies are needed to validate these findings. However, although CRD is a useful tool, the findings made with the fully-automated immunoassay analyzer should not substitute for other laboratory investigations, clinical evaluations, and physician expertise</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1940-087X (Electronic)IS - 1940-087X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3791/55723</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28605372">PM:28605372</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Vis Exp\20170612-LuoW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Vis Exp\20170612-LuoW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Luo W</style></custom2><misc3><style face="normal" font="Arial">10.3791/55723</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez-Goncer,I.</style></author><author><style face="normal" font="Arial"> Niven,R.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Aspergillosis Centre, University Hospital of South Manchester, M23 9LT Manchester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Successful long-term terbinafine therapy in an asthmatic patient with Aspergillus sensitization and bronchiectasis</style></title><secondary-title><style face="normal" font="Arial">Med Mycol Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Mycol Case Rep</style></full-title></periodical><pages end="33" start="31">31-33</pages><volume><style face="normal" font="Arial">16</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> terbinafine</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> voriconazole</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Severe asthma with fungal sensitization (SAFS) is estimated to affect ~25% of patients with poorly controlled asthma. Tri-azole therapy is effective in only 60-80% and side effects are common. We report a 25 years-old woman with severe asthma, Aspergillus sensitization and marked bronchiectasis that developed a rare Achilles-tendinopathy with both itraconazole and voriconazole. She started a trial with terbinafine as salvage therapy that led to a striking improvement and long-term control of her respiratory disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 2211-7539 (Print)IS - 2211-7539 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mmcr.2017.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28652961">PM:28652961</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Mycol Case Rep\2017-16-31-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Mycol Case Rep\2017-16-31-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Rodriguez-Goncer I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mmcr.2017.04.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Diaz,S.N.</style></author><author><style face="normal" font="Arial"> Arias-Cruz,A.</style></author><author><style face="normal" font="Arial"> Macouzet-Sanchez,C.</style></author><author><style face="normal" font="Arial"> Partida-Ortega,A.B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Impact of air pollution in respiratory allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Med Univ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Univ</style></full-title></periodical><pages end="215" start="212">212-215</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">73</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diesel</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Gasoline</style></keyword><keyword><style face="normal" font="Arial"> Hydrocarbons</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung development</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reactive species</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> traffic</style></keyword><keyword><style face="normal" font="Arial"> Urban air pollution</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1665-5796</style></isbn><abstract><style face="normal" font="Arial">Allergic respiratory disease, which includes allergic rhinoconjunctivitis and asthma, is one of the most common diseases, with a major impact on a patient's quality of life. Air pollution is one of the main factors associated with the development of allergic respiratory disease, it has been shown to impair lung development in children and adolescents. The origins of particulate matter produced from various sources, including those issued by traffic and the burning of fuels such as coal, gasoline and diesel. Diesel emissions represent the majority of the particulate matter in urban air pollution. It has been found that the co-exposure of diesel emissions and airborne allergens increases allergen-specific IgE levels, severity of asthma, inflammation and airway hyper-responsiveness. In vivo and in vitro studies have reported the activation of anti-transcription and pro-inflammatory mediators. Polycyclic aromatic hydrocarbons, metal components or metabolites may increase due to the formation of oxygen reactive species that interact with DNA, producing different types of damage as oxidative damage</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmu.2016.10.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.rmu.2016.10.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Univ\2017-18-212-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Univ\2017-18-212-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170101, Gonzalez-Diaz SN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmu.2016.10.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vogel,M.</style></author><author><style face="normal" font="Arial"> Horn,M.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Clinic of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, CH-3010, Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="Arial">Isolation of Natural Anti-FcepsilonRIalpha Autoantibodies from Healthy Donors</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="22" start="5">5-22</pages><volume><style face="normal" font="Arial">1643</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> autoantigen</style></keyword><keyword><style face="normal" font="Arial"> Autoantigens</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> IVIg</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Natural antibodies are defined as antibodies detected in a healthy individual without active immunization. These antibodies are specific for exoantigens, as well as for autoantigens, mostly without any pathogenic role. Most of the studies conducted with natural (auto-) antibodies have been performed using affinity purified antibodies from individual sera or polyclonal Ig-preparations such as Intravenous Ig (IVIg). For in-depth analysis of such autoantibodies affinity-purified Ig-preparations from healthy individuals are of no use, as they are oligoclonal or polyclonal. Thus, there is a need of human monoclonal autoantibodies. Human monoclonal autoantibodies can be produced from B cells isolated from humans; however, this requires the screening of a large number of antibodies to identify one among them specific to an antigen. Using the phage display technology we generated such autoantibodies against the alpha subunit of the high-affinity IgE receptor (FcepsilonRIalpha). Here we describe the step-by-step protocol for the generation of such libraries and the isolation of autoantibodies by affinity panning</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-7180-0_2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667526">PM:28667526</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1643-5-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1643-5-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Vogel M</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-7180-0_2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ohshita,N.</style></author><author><style face="normal" font="Arial"> Ichimaru,Y.</style></author><author><style face="normal" font="Arial"> Gamoh,S.</style></author><author><style face="normal" font="Arial"> Tsuji,K.</style></author><author><style face="normal" font="Arial"> Kishimoto,N.</style></author><author><style face="normal" font="Arial"> Tsutsumi,Y.M.</style></author><author><style face="normal" font="Arial"> Momota,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, Osaka Dental University, Osaka 540-0008, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Management of infusion reactions associated with cetuximab treatment: A case report</style></title><secondary-title><style face="normal" font="Arial">Mol Clin Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Clin Oncol</style></full-title></periodical><pages end="855" start="853">853-855</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Bradycardia</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic effect</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor receptor</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Radiation</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Cetuximab is a drug targeting the epidermal growth factor receptor, which is indicated for the treatment of unresectable advanced or recurrent head and neck or colorectal cancer. Cetuximab also enhances the cytotoxic effects of radiation in squamous cell carcinoma. The severity of infusion reactions (IR) is categorized from grade 1 to 5; grades 3 and 4 are associated with life-threatening reactions (anaphylaxis), whereas grade 5 indicates death. The incidence of grade 3-4 IR with premedication is reported to be 1.1%. We herein describe a case of a 77-year-old man who developed IR during intravenous administration of cetuximab. The patient developed grade 3-4 anaphylaxis with pruritus, rash and urticaria, followed by hypotension and bradycardia. The timely diagnosis and treatment with intravenous infusion of a vasopressor drug and Ringer's acetate solution proved to be effective. The case presented herein demonstrated an unfeatured aspect of cetuximab-related IR as dermatological reactions over the entire body followed by circulatory collapse</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 2049-9450 (Print)IS - 2049-9450 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3892/mco.2017.1242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28588776">PM:28588776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Clin Oncol\2017-6-853-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Clin Oncol\2017-6-853-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Ohshita N</style></custom2><misc3><style face="normal" font="Arial">10.3892/mco.2017.1242</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Magishi,N.</style></author><author><style face="normal" font="Arial"> Yuikawa,N.</style></author><author><style face="normal" font="Arial"> Kobayashi,M.</style></author><author><style face="normal" font="Arial"> Taniuchi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Laboratory, Higashimaru Shoyu Co., Ltd., Tatsuno, Hyogo 6794167, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Degradation and removal of soybean allergen in Japanese soy sauce</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="2268" start="2264">2264-2268</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic degradation</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Filtration</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> soybean allergens</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">Soy sauce is a traditional fermented seasoning of Japan and is available throughout the world. The two main raw ingredients of soy sauce are soybean and wheat, both of which are established food allergens. The present study examined the degradation and removal of soybean allergens in soy sauce by immunoblotting with antisoybean protein antibody from rabbit and sera from two children with soybean allergy. It was demonstrated that soybean allergens were gradually degraded during the fermentation process, but were not completely degraded in raw soy sauce. During the processes of heattreatment and filtration, the soluble soybean allergens in raw soy sauce were denatured to insoluble allergens by heattreatment and subsequently completely removed from soy sauce by filtration. Therefore, to reduce the allergenicity of soy sauce, heattreatment and filtration are very important processes in addition to the enzymatic degradation during the fermentation of soy sauce</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6815</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656270">PM:28656270</url></web-urls><pdf-urls><url ppv-ref="no">nmagishi@higashimaru.co.jp</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Magishi N</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6815</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,K.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Jiang,R.</style></author><author><style face="normal" font="Arial"> Chen,D.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Xiong,W.</style></author><author><style face="normal" font="Arial"> Li,D.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Yuan,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chongqing Cancer Research Institute, Chongqing 400030, P.R. ChinaLaboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing 400016, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Protective effects of astragaloside IV against ovalbumin-induced allergic rhinitis are mediated by T-box protein expressed in T cells/GATA-3 and forkhead box protein 3/retinoic acid-related orphan nuclear receptor gammat</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="1215" start="1207">1207-1215</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> embryology</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> forkhead box protein 3</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tissue Engineering</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="Arial">3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosyl-cycloastragenol, or Astragaloside IV (AST), is one of the major active ingredients isolated from Astragalus membranaceous with distinct pharmacological effects, and possesses anti-inflammatory, immunoregulatory and antifibrotic properties. However, the effects of AST on allergic rhinitis remain to be elucidated. The present study aimed to examine the effects of AST on immunoglobulin (Ig) Emediated allergic reactions in vivo, by using a mouse model of allergic rhinitis established via repetitive sensitization and intranasal challenge with ovalbumin (OVA). Intragastric administration of AST (25 mg/kg or 50 mg/kg) or dexamethasone (DEX; 3 mg/kg) significantly alleviated the inflammatory response, nasal symptoms and mucosa remodeling, and decreased the serum levels of OVAspecific IgE in allergic mice. Furthermore, treatment with AST or DEX significantly suppressed the mRNA and protein expression levels of the transcription factor GATA3 and retinoic acid receptorrelated orphan nuclear receptor (ROR)gammat in tissue samples isolated from the spleen and nasal mucosa of mice with allergic rhinitis. Conversely, mRNA and protein expression levels of Tbox protein expressed in T cells (Tbet) and forkhead box protein 3 (Foxp3) were upregulated in the spleen and nasal mucosa of mice with allergic rhinitis following treatment with AST or DEX, and spleen protein levels of signal transducer and activator of transcription 3 followed a similar trend. In addition, treatment with AST was associated with fewer adverse events compared with treatment with DEX. The present results suggested that treatment with AST may attenuate OVAinduced allergic rhinitis via regulating the expression of the transcription factors GATA3, RORgammat, Tbet and Foxp3, which commit T helper cells to the Th1 phenotype. Therefore, AST may represent an alternative therapeutic approach for the treatment of patients with allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6685</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28586019">PM:28586019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-1207-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-1207-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Li K</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6685</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qiu,C.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author><author><style face="normal" font="Arial"> Shi,F.</style></author><author><style face="normal" font="Arial"> Fen,M.</style></author><author><style face="normal" font="Arial"> Ren,L.</style></author><author><style face="normal" font="Arial"> Qi,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, The Second Clinical College, Jinan University, Shenzhen, Guangdong 518001, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Silencing of beta1 integrin regulates airway remodeling by regulating the transcription of SOCEassociated genes in asthmatic mice</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="2651" start="2645">2645-2651</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">The incidence of asthma is increasing globally; however, current treatments are only able to cure a certain proportion of patients. There is an urgent need to develop novel therapies. beta1 integrin serves a role in the pathophysiology of asthma through the development of airway remodeling. The aim of the present study was to investigate silencing of the beta1 integrin gene in preclinical models of allergic asthma. BALB/c mice were sensitized with ovalbumin through intraperitoneal injection and repeated aerosolized ovalbumin. A short hairpin RNA of the beta1 integrin gene was designed and transfected into mouse models of asthma in vivo, in order to evaluate whether silencing of the beta1 integrin gene affects airway smooth muscle cell proliferation and inflammation by regulating the mRNA expression of storeoperated Ca2+ entry (SOCE)associated genes. Silencing the beta1 integrin gene may downregulate beta1 integrin mRNA while not statistically decreasing alphasmooth muscle actin gene expression and airway smooth muscle thickness. beta1 integrin silencing was able to downregulate the transcription of SOCEassociated genes to normal levels, including calcium releaseactivated calcium modulator 1 and short transient receptor potential channel member 1, but not stromal interaction molecule 1, in asthma. Silencing of the beta1 integrin gene additionally maintained nuclear factor of activated Tcells cytoplasmic 1 gene expression, and inflammatory cytokines interleukin4 and interferongamma at normal levels. The results of the present study provide evidence to suggest that silencing of the beta1 integrin gene may be of therapeutic benefit for patients with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6863</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656279">PM:28656279</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-2645-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-2645-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Qiu C</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6863</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ni,W.W.</style></author><author><style face="normal" font="Arial"> Wang,L.B.</style></author><author><style face="normal" font="Arial"> Zhou,Y.J.</style></author><author><style face="normal" font="Arial"> Cao,M.D.</style></author><author><style face="normal" font="Arial"> Huang,W.</style></author><author><style face="normal" font="Arial"> Guo,M.</style></author><author><style face="normal" font="Arial"> Ji,C.M.</style></author><author><style face="normal" font="Arial"> Sun,J.L.</style></author><author><style face="normal" font="Arial"> Wei,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Expression, purification and epitope analysis of Pla a 3 allergen from Platanus acerifolia pollen</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="2855" start="2851">2851-2855</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arctic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pla a 3</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">Platanus acerifolia (P. acerifolia) is an important cause of pollinosis in cities. The use of allergen extracts on patients with allergic diseases is the most commonly applied method to attempt to treat pollinosis. Pla a 3, a nonspecific lipid transfer protein, is a major allergen present in P. acerifolia pollen extracts. In the present study, the Pla a 3 gene was subcloned into a pSUMOMut vector using Stu I and Xho I sites and transformed into the Arctic Express (DE3) RP E. coli host strain. The purified Pla a 3 allergen was analyzed by western blotting and the results revealed that the Pla a 3 allergen has the ability to bind IgE in the P. acerifolia pollen of allergic patients' sera. Moreover, the authors predicted the potential B cell epitopes of the Pla a 3 allergen using the DNAStar Protean system, the Bioinformatics Predicted Antigenic Peptides system and the BepiPred 1.0 server. In addition, the T cell epitopes were predicted by the SYFPEITHI database and the NetMHCII2.2 server. As a result, two B cell epitopes (3545 and 8186) and four potential T cell epitopes including 215, 4550, 5561 and 6773 were predicted in the present study. The current results can be used to contribute to allergen immunotherapies and useful in peptidebased vaccine designs of pollen allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6867</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656246">PM:28656246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-2851-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-2851-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Ni WW</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6867</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carlos Ribeiro,J.</style></author><author><style face="normal" font="Arial"> Miguel Cunha,L.</style></author><author><style face="normal" font="Arial"> Sousa-Pinto,B.</style></author><author><style face="normal" font="Arial"> Fonseca,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">LAQV/REQUIMTE, DGAOT, Faculdade de Ciencias da Universidade do Porto, Campus Agrario de Vairao, Vila do Conde, PortugalMEDCCINTEAllergy Unit, CUF Porto Institute &amp; Hospital, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Allergic risks of consuming edible insects: A systematic review</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic risk</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Arginine kinase</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Edible insects</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pan-allergen</style></keyword><keyword><style face="normal" font="Arial"> Pan-allergens</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">The expected future demand for food and animal-derived protein will require environment-friendly novel food sources with high nutritional value. Insects may be one of such novel food sources. However, there needs to be an assessment of the risks associated with their consumption, including allergic risks. Therefore, we performed a systematic review aiming to analyse current data available regarding the allergic risks of consuming insects. We reviewed all reported cases of food allergy to insects, and studied the possibility of cross-reactivity and co-sensitisation between edible insects, crustaceans and house dust mites. We analysed a total of 25 articles - eight assessing the cross-reactivity/co-sensitisation between edible insects, crustaceans and house dust mite; three characterizing allergens in edible insects and 14 case reports, describing case series or prevalence studies of food allergy caused by insects. Cross-reactivity/co-sensitisation between edible insects and crustaceans seems to be clinically relevant, while it is still unknown if co-sensitisation between house dust mites and edible insects can lead to a food allergy. Additionally, more information is also needed about the molecular mechanisms underlying food allergy to insects, although current data suggest that an important role is played by arthropod pan-allergens such as tropomyosin or arginine kinase. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201700030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28654197">PM:28654197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170627-CarlosRibeiroJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170627-CarlosRibeiroJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, CarlosRibeiroJ</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201700030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez,M.J.</style></author><author><style face="normal" font="Arial"> Mascaraque,A.</style></author><author><style face="normal" font="Arial"> Ramos-Soriano,F.J.</style></author><author><style face="normal" font="Arial"> Torres,M.J.</style></author><author><style face="normal" font="Arial"> Perkins,J.R.</style></author><author><style face="normal" font="Arial"> Gomez,F.</style></author><author><style face="normal" font="Arial"> Garrido,M.</style></author><author><style face="normal" font="Arial"> Cubells,N.</style></author><author><style face="normal" font="Arial"> Andreu,D.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Rojo,J.</style></author><author><style face="normal" font="Arial"> Mayorga,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Laboratory, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Pru p 3-Epitope-based sublingual immunotherapy in a murine model for the treatment of peach allergy</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> CpG motifs</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> LTP-syndrome</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Motifs</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergy</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="Arial">SCOPE: Food-specific immunotherapy (SIT) is a promising treatment for LTP-syndrome. We propose a novel sublingual-SIT (SLIT) that combines a Pru p 3 T-cell peptide and an oligodeoxyribonucleotide (ODN) with CpG motifs (ODN-CpG) as adjuvants to induce a specific Th1/Treg response. METHODS AND RESULTS: LTP-peach allergic mice were treated sublingually with a combination of a CpG sequence and mono- or tetravalent systems including a Pru p 3 peptide, D1 (Prup3) or D4 (Prup3). Mice were challenged intraperitoneally with Pru p 3 one/three weeks after SLIT and tolerance was assessed. Mice treated with D1 (Prup3)+CpG were protected from anaphylaxis after Pru p 3 challenge. They showed no change in body temperature, lower levels of Pru p 3-specific IgE and IgG1 antibodies and higher levels of sIgG2a compared to the untreated group. They had fewer IgE and IgG1 secreting cells and more sIgG2a secreting cells. Moreover, a significantly lower number of Pru p 3-specific CD4+ T-cells and a higher number of Treg cells were found, alongside a Th1 cytokine pattern. These changes were maintained for three weeks after stopping treatment. CONCLUSION: D1 Prup3+CpG represents a promising SIT for food allergy. It is easily synthesized and induces protection from anaphylaxis to Pru p 3 that is maintained for at least three weeks. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170606IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201700110</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28586170">PM:28586170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170606-RodriguezMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170606-RodriguezMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170606, Rodriguez MJ</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201700110</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,H.</style></author><author><style face="normal" font="Arial"> Roan,F.</style></author><author><style face="normal" font="Arial"> Johnston,L.K.</style></author><author><style face="normal" font="Arial"> Smith,D.E.</style></author><author><style face="normal" font="Arial"> Bryce,P.J.</style></author><author><style face="normal" font="Arial"> Ziegler,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Program, Benaroya Research Institute, Seattle, Washington, USA</style></auth-address><titles><title><style face="normal" font="Arial">IL-33 promotes gastrointestianl allergy in a TSLP-independent manner</style></title><secondary-title><style face="normal" font="Arial">Mucosal Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mucosal Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) often precedes asthma and food allergy, indicating that epicutaneous sensitization to allergens may be important in the induction of allergic responses at other barrier surfaces. Thymic stromal lymphopoietin (TSLP) and interleukin (IL)-33 are two cytokines that may drive type 2 responses in the skin; both are potential targets in the treatment of allergic diseases. We tested the functional role of IL-33 and the interplay between IL-33 and TSLP in mouse models of atopic march and gastrointestinal (GI) allergy. IL-33-driven allergic disease occurred in a TSLP-independent manner. In contrast, mice lacking IL-33 signaling were protected from onset of allergic diarrhea in TSLP-driven disease. Epithelial-derived IL-33 was important in this model, as specific loss of IL-33 expression in the epithelium attenuated cutaneous inflammation. Notably, the development of diarrhea following sensitization with TLSP plus antigen was ameliorated even when IL-33 was blocked after sensitization. Thus, IL-33 has an important role during early cutaneous inflammation and during challenge. These data reveal critical roles for IL-33 in the "atopic march" that leads from AD to GI allergy.Mucosal Immunology advance online publication, 28 June 2017; doi:10.1038/mi.2017.61</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1935-3456 (Electronic)IS - 1933-0219 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/mi.2017.61</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656964">PM:28656964</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mucosal Immunol\20170628-HanH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mucosal Immunol\20170628-HanH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Han H</style></custom2><misc3><style face="normal" font="Arial">10.1038/mi.2017.61</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamprecht,A.</style></author><author><style face="normal" font="Arial"> Morio,F.</style></author><author><style face="normal" font="Arial"> Bader,O.</style></author><author><style face="normal" font="Arial"> Le Pape,P.</style></author><author><style face="normal" font="Arial"> Steinmann,J.</style></author><author><style face="normal" font="Arial"> Dannaoui,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne, University of Cologne, Goldenfelsstr. 19-21, 50935, Cologne, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Amphotericin B</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal treatment</style></keyword><keyword><style face="normal" font="Arial"> antifungals</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Echinocandins</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Triazoles</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="6" Year="2017">2017/6/26</year></dates><abstract><style face="normal" font="Arial">Aspergillus fumigatus is the most frequent filamentous fungus isolated from respiratory specimens from patients with cystic fibrosis (CF). Triazoles are the most widely used antifungals in the treatment of allergic bronchopulmonary aspergillosis (ABPA) and invasive aspergillosis (IA) in CF patients. Treatment success could be severely compromised by the occurrence of azole-resistant A. fumigatus (ARAf), which is increasingly reported worldwide from both clinical samples and the environment. In previous studies, ARAf has been detected in up to 8% of CF patients. Isolates from CF patients requiring antifungal treatment should therefore be routinely subjected to antifungal susceptibility testing. The optimal treatment of ABPA or IA in CF patients with azole-resistant isolates has not been established; treatment options include liposomal amphotericin B i.v. and/or echinocandins i.v</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticleCO - France .CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-017-0162-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28653258">PM:28653258</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20170627-HamprechtA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20170627-HamprechtA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Hamprecht A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-017-0162-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergenic foods should be introduced earlier in life to cut risks of developing allergies</style></title><secondary-title><style face="normal" font="Arial">Nurs Child Young People</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nurs Child Young People</style></full-title></periodical><pages end="" start="12">12-</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food tolerance</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">A US review into allergenic food tolerance has found that early introduction to specific food types can reduce the risks of allergy development</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 2046-2344 (Electronic)IS - 2046-2336 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.7748/ncyp.29.5.12.s12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28604200">PM:28604200</url></web-urls></urls><custom2><style face="normal" font="Arial">20170612, no authors</style></custom2><misc3><style face="normal" font="Arial">10.7748/ncyp.29.5.12.s12</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aika,S.</style></author><author><style face="normal" font="Arial"> Ito,M.</style></author><author><style face="normal" font="Arial"> Yamamoto,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Nursing, Shimane University, Faculty of Medicine, Matsue, JapanDepartment of Nursing, Kawasaki University of Medical Welfare, Faculty of Medical Welfare, Kurushiki, JapanDepartment of Nursing, Hokkaido University of Science, Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy response capabilities of mothers and related factors</style></title><secondary-title><style face="normal" font="Arial">Nurs Health Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nurs Health Sci</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Emotions</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">A parent's ability to confidently manage a child's food allergy (i.e. food allergy response capability) is considered instrumental toward treating this disorder; however, little is known regarding this measure and associated factors. A questionnaire survey among 280 qualified participants identified the greatest food allergy response capability as "spousal collaboration", followed by "elimination diet capacity", "gathering information from medical professionals", "knowledge about food allergies", and "stress coping". These capabilities were associated with maternal and household health status, food items eliminated and their number, anaphylaxis experience, and type of medical facility used. This measure represented a predictor of maternal quality of life and health status, household health status, and overall life stress (not related to childrearing). Thus, to improve food allergy response capability, multidisciplinary cooperation and support are required from professionals, such as physicians, nurses, nutritionists, and clinical psychologists. Nurses in particular must take an interest in the situations these mothers face and in their emotions; elicit their power to cope with stress; provide knowledge about food allergies; provide individualized, specific information about elimination diets; and conduct interventions to enable spousal cooperation</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 1442-2018 (Electronic)IS - 1441-0745 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/nhs.12351</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28660672">PM:28660672</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nurs Health Sci\20170629-AikaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nurs Health Sci\20170629-AikaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Aika S</style></custom2><misc3><style face="normal" font="Arial">10.1111/nhs.12351</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choudhary,S.</style></author><author><style face="normal" font="Arial"> Murad,S.</style></author><author><style face="normal" font="Arial"> Hayat,M.Q.</style></author><author><style face="normal" font="Arial"> Shakoor,Z.</style></author><author><style face="normal" font="Arial"> Arshad,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan</style></auth-address><titles><title><style face="normal" font="Arial">Identification of IgE- binding pollen protein from Cannabis sativa in pollen-hypersensitive patients from north Pakistan</style></title><secondary-title><style face="normal" font="Arial">Pak J Pharm Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pak J Pharm Sci</style></full-title></periodical><pages end="42" start="37">37-42</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Cannabis</style></keyword><keyword><style face="normal" font="Arial"> Cannabis sativa</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">Cannabis sativa (C.sativa) is well-known for its medicinal, industrial and recreational use. However, allergies in relation to Cannabis sativa (C.sativa) are rarely reported. C. sativa is one of the common weeds found in Pakistan and its pollen grains are common in spring and fall season. Although categorized as an aeroallergen, there are limited number of reports regarding allergenic potential in C. sativa. Therefore, the current study is aimed at exploring the IgE- binding potential among the C. sativa pollen in local pollen allergic patients. Initial screening of C. sativa sensitized individuals was carried out by dot blot from the sera of pollen allergic patients. Proteins from the pollen grains were extracted and resolved on 10% gel. Eight bands were visible on gel however only one protein fragment i.e. of 14KDa size was found to bind to IgE as analyzed through protein gel blot analysis. Strong IgE affinity of a 14 kDa protein fragment from C. sativa pollen extract suggests its allergenic potential. Further study is required to find the exact nature of this protein fragment</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1011-601X (Print)IS - 1011-601X (Linking)LA - engPT - Journal ArticleCO - Pakistan -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28603110">PM:28603110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pak J Pharm Sci\2017-30-37-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pak J Pharm Sci\2017-30-37-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Choudhary S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fernando,D.D.</style></author><author><style face="normal" font="Arial"> Marr,E.J.</style></author><author><style face="normal" font="Arial"> Zakrzewski,M.</style></author><author><style face="normal" font="Arial"> Reynolds,S.L.</style></author><author><style face="normal" font="Arial"> Burgess,S.T.G.</style></author><author><style face="normal" font="Arial"> Fischer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">QIMR Berghofer Medical Research Institute, Infectious Diseases Department, 300 Herston Road, Herston, Brisbane, 4006, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Gene silencing by RNA interference in Sarcoptes scabiei: a molecular tool to identify novel therapeutic targets</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="289">289-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> BLAST</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Drosophila</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Silencing</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> glutathione S transferase</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immersion</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> RNA interference</style></keyword><keyword><style face="normal" font="Arial"> RNAi</style></keyword><keyword><style face="normal" font="Arial"> Sarcoptes scabiei</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sri Lanka</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword></keywords><dates><year Day="10" Month="6" Year="2017">2017/6/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Scabies is one of the most common and widespread parasitic skin infections globally, affecting a large range of mammals including humans, yet the molecular biology of Sarcoptes scabiei is astonishingly understudied. Research has been hampered primarily due to the difficulty of sampling or culturing these obligatory parasitic mites. A further and major impediment to identify and functionally analyse potential therapeutic targets from the recently emerging molecular databases is the lack of appropriate molecular tools. METHODS: We performed standard BLAST based searches of the existing S. scabiei genome databases using sequences of genes described to be involved in RNA interference in Drosophila and the mite model organism Tetranychus urticae. Experimenting with the S. scabiei mu-class glutathione S-transferase (SsGST-mu1) as a candidate gene we explored the feasibility of gene knockdown in S. scabiei by double-stranded RNA-interference (dsRNAi). RESULTS: We provide here an analysis of the existing S. scabiei draft genomes, confirming the presence of a double stranded RNA (dsRNA) - mediated silencing machinery. We report for the first time experimental gene silencing by RNA interference (RNAi) in S. scabiei. Non-invasive immersion of S. scabiei in dsRNA encoding an S. scabiei glutathione S-transferase mu-class 1 enzyme (SsGST-mu1) resulted in a 35% reduction in the transcription of the target gene compared to controls. CONCLUSIONS: A series of experiments identified the optimal conditions allowing systemic experimental RNAi without detrimental side effects on mite viability. This technique can now be used to address the key questions on the fundamental aspects of mite biology and pathogenesis, and to assess the potential therapeutic benefits of silencing S. scabiei target genes</style></abstract><notes><style face="normal" font="Arial">DA - 20170611IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Sri Lanka -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-017-2226-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601087">PM:28601087</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2017-10-289.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2017-10-289.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170611, Fernando DD</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-017-2226-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ludovisi,A.</style></author><author><style face="normal" font="Arial"> Di Felice,G.</style></author><author><style face="normal" font="Arial"> Carballeda-Sangiao,N.</style></author><author><style face="normal" font="Arial"> Barletta,B.</style></author><author><style face="normal" font="Arial"> Butteroni,C.</style></author><author><style face="normal" font="Arial"> Corinti,S.</style></author><author><style face="normal" font="Arial"> Marucci,G.</style></author><author><style face="normal" font="Arial"> Gonzalez-Munoz,M.</style></author><author><style face="normal" font="Arial"> Pozio,E.</style></author><author><style face="normal" font="Arial"> Gomez-Morales,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious Diseases, Istituto Superiore di Sanita, viale Regina Elena 299, 00161, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Allergenic activity of Pseudoterranova decipiens (Nematoda: Anisakidae) in BALB/c mice</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="290">290-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anisakid</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakids</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nematoda</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pseudoterranova</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anisakis simplex is the only fishery-product associated parasite causing clinical allergic responses in humans so far. However, other anisakids, due to the presence of shared or own allergens, could also lead to allergic reactions after sensitization. The aim of this study was to determine if Pseudoterranova decipiens belonging to the family Anisakidae has allergenic activity and is able to induce sensitization after oral administration in a murine (BALB/c mice) model. RESULTS: The ingestion of A. pegreffii proteins by BALB/c mice, which had been previously sensitized by intraperitoneal inoculation with the corresponding live L3 larvae, triggers signs of allergy within 60 min, whereas P. decipiens did to a lesser extent. Beside symptoms, allergic reactions were furtherly supported by the presence of histamine in sera of sensitized mice. Specific IgG1 and IgE responses were detected in sera of all sensitized mice from week four. Specific IgG2a response was detected in sera from mice sensitized to P. decipiens. After polyclonal or specific activation with anti-CD3/anti-CD28 or antigens, respectively, splenocytes from mice infected i.p. with A. pegreffii or P. decipiens larvae showed significantly higher production of IL-10 than naive mice. After stimulation with specific antigens, significantly higher IL-5 and IL-13 amounts were produced by specific antigen stimulated splenocytes than by the naive cells; only P. decipiens proteins induced IFN-. CONCLUSIONS: The overall results suggest that infection with P. decipiens can sensitize mice to react to subsequent oral challenge with anisakid proteins, as described for A. simplex (sensu stricto) and A. pegreffii infections. The results show that anisakid proteins induce a dominant Th2 response, although P. decipiens could also induce a mixed type 1/type 2 pattern</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-017-2231-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606183">PM:28606183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2017-10-290.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2017-10-290.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Ludovisi A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-017-2231-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sastalla,I.</style></author><author><style face="normal" font="Arial"> Williams,K.W.</style></author><author><style face="normal" font="Arial"> Anderson,E.D.</style></author><author><style face="normal" font="Arial"> Myles,I.A.</style></author><author><style face="normal" font="Arial"> Reckhow,J.D.</style></author><author><style face="normal" font="Arial"> Espinoza-Moraga,M.</style></author><author><style face="normal" font="Arial"> Freeman,A.F.</style></author><author><style face="normal" font="Arial"> Datta,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bacterial Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Molecular Typing of Staphylococcus aureus Isolated from Patients with Autosomal Dominant Hyper IgE Syndrome</style></title><secondary-title><style face="normal" font="Arial">Pathogens</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pathogens</style></full-title></periodical><pages end="" start="E23">E23-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Enterotoxins</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Gram-Negative Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Host-Pathogen Interactions</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methicillin resistance</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Molecular Typing</style></keyword><keyword><style face="normal" font="Arial"> Multilocus Sequence Typing</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococci</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virulence</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="Arial">Autosomal dominant hyper IgE syndrome (AD-HIES) is a primary immunodeficiency caused by a loss-of-function mutation in the Signal Transducer and Activator of Transcription 3 (STAT3). This immune disorder is clinically characterized by increased susceptibility to cutaneous and sinopulmonary infections, in particular with Candida and Staphylococcus aureus. It has recently been recognized that the skin microbiome of patients with AD-HIES is altered with an overrepresentation of certain Gram-negative bacteria and Gram-positive staphylococci. However, these alterations have not been characterized at the species- and strain-level. Since S. aureus infections are influenced by strain-specific expression of virulence factors, information on colonizing strain characteristics may provide insights into host-pathogen interactions and help guide management strategies for treatment and prophylaxis. The aim of this study was to determine whether the immunodeficiency of AD-HIES selects for unique strains of colonizing S. aureus. Using multi-locus sequence typing (MLST), protein A (spa) typing, and PCR-based detection of toxin genes, we performed a detailed analysis of the S. aureus isolates (n = 13) found on the skin of twenty-one patients with AD-HIES. We found a low diversity of sequence types, and an abundance of strains that expressed methicillin resistance, Panton-Valentine leukocidin (PVL), and staphylococcal enterotoxins K and Q (SEK, SEQ). Our results indicate that patients with AD-HIES may often carry antibiotic-resistant strains that harbor key virulence factors</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 2076-0817 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/pathogens6020023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587312">PM:28587312</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pathogens\2017-6-E23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pathogens\2017-6-E23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Sastalla I</style></custom2><misc3><style face="normal" font="Arial">10.3390/pathogens6020023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Visitsunthorn,N.</style></author><author><style face="normal" font="Arial"> Kijmassuwan,T.</style></author><author><style face="normal" font="Arial"> Visitsunthorn,K.</style></author><author><style face="normal" font="Arial"> Pacharn,P.</style></author><author><style face="normal" font="Arial"> Jirapongsananuruk,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Characteristics of Allergy to Hymenoptera Stings</style></title><secondary-title><style face="normal" font="Arial">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera sting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inpatients</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Syringes</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Wasps</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The purpose of this study was to evaluate the clinical characteristics of allergy to stings from the Hymenoptera order of insects in a hospital in Thailand. METHODS: A descriptive retrospective analytical study was carried out in inpatients and outpatients suffering from Hymenoptera stings from 2009 to 2013 in Siriraj Hospital. RESULTS: Medical records of 386 patients with an allergy to Hymenoptera stings were evaluated. Anaphylaxis was more common in patients younger than 15 years, who comprised 22.3% of patients in this study. The most common sting type was from wasps (58.3%). Eighty-five percent of patients sought medical treatment less than 24 hours after being stung. A systemic reaction and anaphylaxis were found in 9.9% and 4.4% of subjects, respectively. In 17 patients with anaphylaxis, only 11 patients (64.7%) received an epinephrine (adrenaline) injection as treatment, and only 8 (47.1%) received epinephrine autoinjectors or epinephrine-prefilled syringes to prevent a possible subsequent severe reaction. Significantly more patients younger than 15 years received epinephrine for prevention of an allergic reaction than did those older than 15 years (87.5% vs 11.7%, P &lt; 0.001). Antibiotics were given to 43.0% of patients. CONCLUSIONS: Anaphylaxis from Hymenoptera stings was more common in children than in adults. Only half of the patients visited the emergency room within 1 hour of being stung. Overuse of antibiotics and underuse of epinephrine were found. More information about Hymenoptera stings should be provided to the public, and the use of epinephrine should be encouraged in the case of severe reactions and anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170614IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1097/PEC.0000000000001200</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614101">PM:28614101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Emerg Care\20170614-VisitsunthornN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Emerg Care\20170614-VisitsunthornN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170614, Visitsunthorn N</style></custom2><misc3><style face="normal" font="Arial">10.1097/PEC.0000000000001200</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iannotti,L.L.</style></author><author><style face="normal" font="Arial"> Lutter,C.K.</style></author><author><style face="normal" font="Arial"> Stewart,C.P.</style></author><author><style face="normal" font="Arial"> Gallegos Riofrio,C.A.</style></author><author><style face="normal" font="Arial"> Malo,C.</style></author><author><style face="normal" font="Arial"> Reinhart,G.</style></author><author><style face="normal" font="Arial"> Palacios,A.</style></author><author><style face="normal" font="Arial"> Karp,C.</style></author><author><style face="normal" font="Arial"> Chapnick,M.</style></author><author><style face="normal" font="Arial"> Cox,K.</style></author><author><style face="normal" font="Arial"> Waters,W.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Brown School, Institute for Public Health, Washington University in St Louis, St Louis, Missouri</style></auth-address><titles><title><style face="normal" font="Arial">Eggs in Early Complementary Feeding and Child Growth: A Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20163459">e20163459-</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="07/09/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anthropometry</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth and Development</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Marketing</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Poisson</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eggs are a good source of nutrients for growth and development. We hypothesized that introducing eggs early during complementary feeding would improve child nutrition. METHODS: A randomized controlled trial was conducted in Cotopaxi Province, Ecuador, from March to December 2015. Children ages 6 to 9 months were randomly assigned to treatment (1 egg per day for 6 months [n = 83]) and control (no intervention [n = 80]) groups. Both arms received social marketing messages to encourage participation in the Lulun Project (lulun meaning "egg" in Kichwa). All households were visited once per week to monitor morbidity symptoms, distribute eggs, and monitor egg intakes (for egg group only). Baseline and end point outcome measures included anthropometry, dietary intake frequencies, and morbidity symptoms. RESULTS: Mothers or other caregivers reported no allergic reactions to the eggs. Generalized linear regression modeling showed the egg intervention increased length-for-age z score by 0.63 (95% confidence interval [CI], 0.38-0.88) and weight-for-age z score by 0.61 (95% CI, 0.45-0.77). Log-binomial models with robust Poisson indicated a reduced prevalence of stunting by 47% (prevalence ratio [PR], 0.53; 95% CI, 0.37-0.77) and underweight by 74% (PR, 0.26; 95% CI, 0.10-0.70). Children in the treatment group had higher dietary intakes of eggs (PR, 1.57; 95% CI, 1.28-1.92) and reduced intake of sugar-sweetened foods (PR, 0.71; 95% CI, 0.51-0.97) compared with control. CONCLUSIONS: The findings supported our hypothesis that early introduction of eggs significantly improved growth in young children. Generally accessible to vulnerable groups, eggs have the potential to contribute to global targets to reduce stunting</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Ecuador -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2016-3459</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28588101">PM:28588101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\2016-140-e20163459.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\2016-140-e20163459.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Iannotti LL</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2016-3459</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qiu,S.</style></author><author><style face="normal" font="Arial"> Fan,X.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Dong,P.</style></author><author><style face="normal" font="Arial"> Zhou,W.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author><author><style face="normal" font="Arial"> Guo,F.</style></author><author><style face="normal" font="Arial"> Zheng,Y.</style></author><author><style face="normal" font="Arial"> Yang,J.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of National Health and Family Planning Commission on Parasitic Disease Control and Prevention, Jiangsu Provincial Key Laboratory on Parasite and Vector Control, Jiangsu Institute of Parasitic Diseases and Public Health Research Center of Jiangnan University, Wuxi, Jiangsu, China</style></auth-address><titles><title><style face="normal" font="Arial">Schistosoma japonicum infection downregulates house dust mite-induced allergic airway inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0179565">e0179565-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma japonicum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The "hygiene hypothesis" is a theory try to explain the dramatic increases in the prevalence of autoimmune and allergic diseases over the past two to three decades in developed countries. According to this theory, reduced exposure to parasites and microorganisms in childhood is the main cause for the increased incidences of both T helper 1 (Th1)-mediated autoimmunity and Th2-mediated allergy. In this study, we investigated the impact of Schistosoma japonicum infection on the allergic airway inflammation induced by repeated intracheal inoculations of house dust mites (HDM), which is a Th17 and neutrophils dominant murine asthma model, mimicking severe asthma. We found that S. japonicum infection downregulated airway hyperresponsiveness. The infiltrating cells, Th17 and Th2 effector cytokines in the bronchoalveolar lavage (BAL) fluids and lungs were significantly reduced in the infected mice. Our findings indicated that S. japonicum infection was able to effectively inhibit host's allergic airway inflammation, which may be related to the upregulated Treg cells upon infection. To our knowledge, it is the first study to reveal the impact of S. japonicum infection on house dust mite induced severe asthma. More in depth investigation is need to elucidate the underlying mechanisms</style></abstract><notes><style face="normal" font="Arial">DA - 20170614IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0179565</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614408">PM:28614408</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0179565.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0179565.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170614, Qiu S</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0179565</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alvarez-Simon,D.</style></author><author><style face="normal" font="Arial"> Munoz,X.</style></author><author><style face="normal" font="Arial"> Gomez-Olles,S.</style></author><author><style face="normal" font="Arial"> de Homdedeu,M.</style></author><author><style face="normal" font="Arial"> Untoria,M.D.</style></author><author><style face="normal" font="Arial"> Cruz,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Effects of diesel exhaust particle exposure on a murine model of asthma due to soybean</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0179569">e0179569-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Diesel</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust</style></keyword><keyword><style face="normal" font="Arial"> diesel exhaust particle</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust particles</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> hull</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> soybean allergens</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exposure to soybean allergens has been linked to asthma outbreaks. Exposure to diesel exhaust particles (DEP) has been associated with an increase in the risk of asthma and asthma exacerbation; however, in both cases the underlying mechanisms remain poorly understood, as does the possible interaction between the two entities. OBJECTIVE: To investigate how the combination of soybean allergens and DEP can affect the induction or exacerbation of asthma in a murine model. METHODS: BALB/c mice received intranasal instillations of saline, 3 or 5 mg protein/ml soybean hull extract (SHE), or a combination of one of these three solutions with DEP. Airway hyperresponsiveness (AHR), pulmonary inflammation in bronchoalveolar lavage, total serum immunoglobulin E and histological studies were assessed. RESULTS: A 5 mg protein/ml SHE solution was able by itself to enhance AHR (p = 0.0033), increase eosinophilic inflammation (p = 0.0003), increase levels of IL-4, IL-5, IL-13, IL-17A, IL-17F and CCL20, and reduce levels of IFN-gamma. The combination of 5 mg protein/ml SHE with DEP also produced an increase in AHR and eosinophilic inflammation, but presented a slightly different cytokine profile with higher levels of Th17-related cytokines. However, while the 3 mg protein/ml SHE solution did not induce asthma, co-exposure with DEP resulted in a markedly enhanced AHR (p = 0.002) and eosinophilic inflammation (p = 0.004), with increased levels of IL-5, IL-17F and CCL20 and decreased levels of IFN-gamma. CONCLUSIONS &amp; CLINICAL RELEVANCE: The combination of soybean allergens and DEP is capable of triggering an asthmatic response through a Th17-related mechanism when the soybean allergen concentration is too low to promote a response by itself. DEP monitoring may be a useful addition to allergen monitoring in order to prevent new asthma outbreaks</style></abstract><notes><style face="normal" font="Arial">DA - 20170619IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0179569</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28628664">PM:28628664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0179569.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0179569.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170619, Alvarez-Simon D</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0179569</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,L.</style></author><author><style face="normal" font="Arial"> Hua,L.</style></author><author><style face="normal" font="Arial"> He,Y.</style></author><author><style face="normal" font="Arial"> Bao,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pulmonology, Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Differential effects of formaldehyde exposure on airway inflammation and bronchial hyperresponsiveness in BALB/c and C57BL/6 mice</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0179231">e0179231-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Formaldehyde</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Epidemiological evidence suggests that formaldehyde (FA) exposure may influence the prevalence and severity of allergic asthma. However, the role of genetic background in FA-induced asthma-like responses is poorly understood. In the present study, we investigated the nature and severity of asthma-like responses triggered by exposure to different doses of FA together with or without ovalbumin (OVA) in two genetically different mouse strains-BALB/c and C57BL/6. Both mouse strains were divided into two main groups: the non-sensitized group and the OVA-sensitized group. All the groups were exposed to 0, 0.5 or 3.0 mg/m3 FA for 6 h/day over 25 consecutive days. At 24 h after the final FA exposure, the pulmonary parameters were evaluated. We found that FA exposure induced Th2-type allergic responses in non-sensitized BALB/c and C57BL/6 mice. In addition, FA-induced allergic responses were significantly more prominent in BALB/c mice than in C57BL/6 mice. In sensitized BALB/c mice, however, FA exposure suppressed the development of OVA-induced allergic responses. Exposure to 3.0 mg/m3 FA in sensitized C57BL/6 mice also led to suppressed allergic responses, whereas exposure to 0.5 mg/m3 FA resulted in exacerbated allergic responses to OVA. Our findings suggest that FA exposure can induce differential airway inflammation and bronchial hyperresponsiveness in BALB/c and C57BL/6 mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0179231</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28591193">PM:28591193</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0179231.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0179231.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Li L</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0179231</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lommatzsch,M.</style></author><author><style face="normal" font="Arial"> Geissler,K.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Virchow,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Abteilung fur Pneumologie/Interdisziplinare Internistische Intensivstation, Zentrum fur Innere Medizin, Universitat Rostock</style></auth-address><titles><title><style face="normal" font="Arial">[IgE and Anti-IgE in Asthma: A Chequered History]</style></title><secondary-title><style face="normal" font="Arial">Pneumologie</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pneumologie</style></full-title></periodical><pages end="405" start="398">398-405</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">A long and winding road led to the discovery of immunoglobulin E (IgE) in 1966 and 1967. We are currently on a long and winding road to understand the immunologic basis of the clinical effects of the anti-IgE antibody omalizumab in asthma. It is possible that patients with asthma (as patients with chronic spontaneous urticaria) benefit in different immunologic ways from omalizumab treatment. This article reviews the history of IgE discovery and current concepts of anti-IgE therapy in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170626IS - 1438-8790 (Electronic)IS - 0934-8387 (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1055/s-0043-102070</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28651294">PM:28651294</url></web-urls></urls><custom2><style face="normal" font="Arial">20170626, Lommatzsch M</style></custom2><misc3><style face="normal" font="Arial">10.1055/s-0043-102070</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Siergiejko,Z.</style></author><author><style face="normal" font="Arial"> Siergiejko,G.</style></author><author><style face="normal" font="Arial"> Klukowski,M.</style></author><author><style face="normal" font="Arial"> Swiebocka,E.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Bronchial allergen challenge </style><style face="normal" font="Symbol">-</style><style face="normal" font="Arial"> An old, but still useful tool in research and diagnostics</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="43" start="39">39-43</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> asthmatic reactions</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Bronchial provocation test+éowa kluczowe</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oskrzelowa prowokacja alergenem</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> test prowokacji oskrzeli</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year><pub-dates><date Day="0" Month="3" Year="2017">2017/3</date></pub-dates></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">A bronchial allergen challenge may serve both as a diagnostic as well as investigative procedure. Its usage in the diagnosis of asthma is infrequent due to its time-consuming nature as well as (in our opinion) an unfounded fear for a patient's safety. It is quite useful in the diagnostics of workplace related illnesses. Due to its ability to produce a controlled, long-lasting allergic-inflammatory reaction in the bronchi, this procedure is commonly used in research settings as well as in the assessment of new substances which may potentially have a place in the treatment of asthma, for ex. through the blocking of late asthmatic reactions. Changes stimulated by a bronchial allergen challenge may be evaluated by many methods using different materials, i.e. samples obtained from direct biopsies, bronchoalveolar lavages, exhaled breath condensates, or measured fractional exhaled nitric oxide. This procedure is a seemingly ideal research and diagnostic tool, however, a common protocol for its execution has not yet been accepted. Recent legal regulations have resulted in difficulties obtaining various allergens for challenge tests. Hopefully this is a temporary and minor setback for this very useful and constantly developing procedure</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2017.02.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.02.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2017-4-39-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2017-4-39-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Siergiejko Z</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2017.02.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nucera,E.</style></author><author><style face="normal" font="Arial"> Colagiovanni,A.</style></author><author><style face="normal" font="Arial"> Mezzacappa,S.</style></author><author><style face="normal" font="Arial"> Buonomo,A.</style></author><author><style face="normal" font="Arial"> Aruanno,A.</style></author><author><style face="normal" font="Arial"> Rizzi,A.</style></author><author><style face="normal" font="Arial"> Schiavino,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis by antihistamine containing bovine gelatin: the utility of the basophil activation test in the diagnostic work-up</style></title><secondary-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Dermatol Alergol</style></full-title></periodical><pages end="280" start="279">279-280</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1642-395X</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.5114/ada.2017.67851</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5114/ada.2017.67851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-279-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Dermatol Alergol\2017-34-279-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Nucera E</style></custom2><misc3><style face="normal" font="Arial">10.5114/ada.2017.67851</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jain,A.</style></author><author><style face="normal" font="Arial"> Salunke,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Regional Centre for Biotechnology, Faridabad, 121001, India</style></auth-address><titles><title><style face="normal" font="Arial">Crystal structure of non-specific lipid transfer protein from Solanum melongena</style></title><secondary-title><style face="normal" font="Arial">Proteins</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proteins</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> eggplant</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Non-specific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Nsltp</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant protein</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Solanaceae</style></keyword><keyword><style face="normal" font="Arial"> Structural analysis</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="Arial">Lipids are considered to protect protein allergens from proteolysis and are generally seen to exist in a bound form. One of the well-known plant protein families with bound lipids is non-specific lipid transfer proteins (nsLTPs). Structure-function relationships in the case of the members of non-specific lipid transfer protein family are not clearly understood. As part of exploring the seed proteome, we have analyzed the proteome of a member of Solanaceae family, Solanum melongena (eggplant) and a non-specific lipid transfer protein from S. melongena, SM80.2 was purified, crystallized and the structure was determined at 1.87A resolution. Overall, the tertiary structure is a cluster of alpha-helices forming an internal hydrophobic cavity. Absence of conserved Tyr79, known to govern the plasticity of hydrophobic cavity, and formation of hydrogen bond between Asn79 and Asn36 further reduced the pocket size. Structural analysis of SM80.2 thus gives insight about a new hydrogen bond mediated mechanism followed in closure of the binding pocket. Extra electron densities observed at two different places on the protein surface and not in the cavity could provide interesting physiological relevance. In light of allergenic properties, probably overlapping of epitopic region and ligand binding on surface could be a main reason. This work shows first crystal structure of A-like nsLTP with a close binding pocket and extra density on the surface suggesting a plausible intermediate state during transfer. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170614IS - 1097-0134 (Electronic)IS - 0887-3585 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1002/prot.25335</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612368">PM:28612368</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proteins\20170614-JainA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proteins\20170614-JainA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170614, Jain A</style></custom2><misc3><style face="normal" font="Arial">10.1002/prot.25335</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Franz-Oberdorf,K.</style></author><author><style face="normal" font="Arial"> Langer,A.</style></author><author><style face="normal" font="Arial"> Strasser,R.</style></author><author><style face="normal" font="Arial"> Isono,E.</style></author><author><style face="normal" font="Arial"> Ranftl,Q.L.</style></author><author><style face="normal" font="Arial"> Wunschel,C.</style></author><author><style face="normal" font="Arial"> Schwab,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biotechnology of Natural Products, Technische Universitat Munchen, Freising, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Physical Interaction between the Strawberry Allergen Fra a 1 and an Associated Partner FaAP</style></title><secondary-title><style face="normal" font="Arial">Proteins</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proteins</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apple allergen</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> dimer</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fra a 1</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruit allergens</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Mal d 1</style></keyword><keyword><style face="normal" font="Arial"> monomer</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Strawberry</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">The strawberry fruit allergens Fra a 1.01E, Fra a 1.02 and Fra a 1.03 belong to the group of pathogenesis-related 10 (PR-10) proteins and are homologues of the major birch pollen Bet v 1 and apple allergen Mal d 1. Bet v 1 related proteins are the most extensively studied allergens but their physiological function in planta remains elusive. Since Mal d 1-Associated Protein (MdAP) has been previously identified as interaction partner of Mal d 1 we studied the binding of the orthologous Fra a 1-Associated Protein (FaAP) to Fra a 1.01E/1.02/1.03. As the C-terminal sequence of FaAP showed strong auto-activation activity in yeast two-hybrid analysis a novel time resolved DNA-switching system was successfully applied. Fra a 1.01E, Fra a 1.02 and Fra a 1.03 bind to FaAP with KD of 4.5 +/- 1.1 nM, 15 +/- 3 nM, and 11 +/- 2 nM, respectively. Fra a 1.01E forms a dimer, whereas Fra a 1.02 and Fra a 1.03 bind as monomer. The results imply that PR-10 proteins might be integrated into a protein-interaction network and FaAP binding appears to be essential for the physiological function of the Fra a 1 proteins. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1097-0134 (Electronic)IS - 0887-3585 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/prot.25343</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656626">PM:28656626</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proteins\20170628-FranzOberdorfK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proteins\20170628-FranzOberdorfK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Franz-Oberdorf K</style></custom2><misc3><style face="normal" font="Arial">10.1002/prot.25343</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Candreva,A.M.</style></author><author><style face="normal" font="Arial"> Ferrer-Navarro,M.</style></author><author><style face="normal" font="Arial"> Bronsoms,S.</style></author><author><style face="normal" font="Arial"> Quiroga,A.</style></author><author><style face="normal" font="Arial"> Curciarello,R.</style></author><author><style face="normal" font="Arial"> Cauerhff,A.</style></author><author><style face="normal" font="Arial"> Petruccelli,S.</style></author><author><style face="normal" font="Arial"> Docena,G.H.</style></author><author><style face="normal" font="Arial"> Trejo,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centro de Investigacion y Desarrollo en Criotecnologia de Alimentos (CIDCA), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), La Plata, ArgentinaInstituto de Estudios Inmunologicos y Fisiopatologicos (IIFP), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), La Plata, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Identification of cross-reactive B-cell epitopes between Bos d 9.0101(Bos Taurus) and Gly m 5.0101 (Glycine max) by epitope mapping MALDI-TOF MS</style></title><secondary-title><style face="normal" font="Arial">Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alimentos</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cross allergenicity</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic digestion</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitope Mapping</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gly m 5.0101</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> Glycine max</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunodominant peptide</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic beads</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> RP-HPLC</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy Proteins</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="Arial">Exposure to cow's milk constitutes one of the most common causes of food allergy. In addition, exposure to soy proteins has become relevant in a restricted proportion of milk allergic pediatric patients treated with soy formulae as a dairy substitute, because of the cross-allergenicity described between soy and milk proteins . We have previously identified several cross-reactive allergens between milk and soy that may explain this intolerance. The purpose of the present work was to identify epitopes in the purified alphaS1-casein and the recombinant soy allergen Gly m 5.0101 using an alpha-casein-specific monoclonal antibody (1D5 mAb) by through two different approaches for epitope mapping, to understand cross-reactivity between milk and soy. The 1D5 mAb was immobilized onto magnetic beads, incubated with the peptide mixture previously obtained by enzymatic digestion of the allergens, and the captured peptides were identified by MALDI-TOF MS analysis. On a second approach, the peptide mixture was resolved by RP-HPLC and immunodominant peptides were identified by dot blot with the mAb. Finally, recognized peptides were sequenced by MALDI-TOF MS. This novel MS based approach led us to identify and characterize four peptides on alpha-casein and three peptides on Glym5 with a common core motif. Information obtained from these cross-reactive epitopes allows us to gain valuable insight into the molecular mechanisms of cross-reactivity, to further develop new and more effective vaccines for food allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170623IS - 1615-9861 (Electronic)IS - 1615-9853 (Linking)LA - engPT - Journal ArticleCO - Argentina -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1002/pmic.201700069</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28643898">PM:28643898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proteomics\20170623-CandrevaAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proteomics\20170623-CandrevaAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170623, Candreva AM</style></custom2><misc3><style face="normal" font="Arial">10.1002/pmic.201700069</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silva,G.B.,Jr.</style></author><author><style face="normal" font="Arial"> Vasconcelos,A.G.,Jr.</style></author><author><style face="normal" font="Arial"> Rocha,A.M.T.</style></author><author><style face="normal" font="Arial"> Vasconcelos,V.R.</style></author><author><style face="normal" font="Arial"> Barros,J.Neto</style></author><author><style face="normal" font="Arial"> Fujishima,J.S.</style></author><author><style face="normal" font="Arial"> Ferreira,N.B.</style></author><author><style face="normal" font="Arial"> Barros,E.J.G.</style></author><author><style face="normal" font="Arial"> Daher,E.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidade de Fortaleza, Faculdade de Medicina, Centro de Ciencias da Saude, Fortaleza, Ceara, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Acute kidney injury complicating bee stings - a review</style></title><secondary-title><style face="normal" font="Arial">Rev Inst Med Trop Sao Paulo</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Inst Med Trop Sao Paulo</style></full-title></periodical><pages end="" start="e25">e25-</pages><volume><style face="normal" font="Arial">59</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Kidney Injury</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Apamin</style></keyword><keyword><style face="normal" font="Arial"> Bilirubin</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Creatine Kinase</style></keyword><keyword><style face="normal" font="Arial"> Creatinine</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Dopamine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hemolysis</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Norepinephrine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> poisoning</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhabdomyolysis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">Bee stings can cause severe reactions and have caused many victims in the last years. Allergic reactions can be triggered by a single sting and the greater the number of stings, the worse the prognosis. The poisoning effects can be systemic and can eventually cause death. The poison components are melitin, apamin, peptide 401, phospholipase A2, hyaluronidase, histamine, dopamine, and norepinephrine, with melitin being the main lethal component. Acute kidney injury (AKI) can be observed in patients suffering from bee stings and this is due to multiple factors, such as intravascular hemolysis, rhabdomyolysis, hypotension and direct toxicity of the venom components to the renal tubules. Arterial hypotension plays an important role in this type of AKI, leading to ischemic renal lesion. The most commonly identified biopsy finding in these cases is acute tubular necrosis, which can occur due to both, ischemic injury and the nephrotoxicity of venom components. Hemolysis and rhabdomyolysis reported in many cases in the literature, were demonstrated by elevated serum levels of indirect bilirubin and creatine kinase. The severity of AKI seems to be associated with the number of stings, since creatinine levels were higher, in most cases, when there were more than 1,000 stings. The aim of this study is to present an updated review of AKI associated with bee stings, including the currently advised clinical approach</style></abstract><notes><style face="normal" font="Arial">DA - 20170607IS - 1678-9946 (Electronic)IS - 0036-4665 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1590/S1678-9946201759025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28591253">PM:28591253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Inst Med Trop Sao Paulo\2017-59-e25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Inst Med Trop Sao Paulo\2017-59-e25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170607, Silva GB Jr</style></custom2><misc3><style face="normal" font="Arial">10.1590/S1678-9946201759025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamada,S.</style></author><author><style face="normal" font="Arial"> Kuroe,A.</style></author><author><style face="normal" font="Arial"> Tsukino,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Hikone Municipal Hospital, Hikone, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Does omalizumab impair glucose homeostasis in a patient with severe persistent asthma and type 2 diabetes mellitus?</style></title><secondary-title><style face="normal" font="Arial">Rev Port Pneumol (2006)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Pneumol (2006)</style></full-title></periodical><pages end="304" start="303">303-304</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Type 2 diabetes</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 2173-5115 (Electronic)IS - 0873-2159 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rppnen.2017.05.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28602732">PM:28602732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Pneumol (2006)\20170612-HamadaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Pneumol (2006)\20170612-HamadaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Hamada S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rppnen.2017.05.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Juel,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Plastic Surgery, Aalborg University Hospital, Aalborg, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Tinnitus after administration of sublingual immunotherapy</style></title><secondary-title><style face="normal" font="Arial">SAGE Open Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">SAGE Open Med Case Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/OBJECTIVES: Sublingual immunotherapy was first described in 1986. Since then, its use has been increased as an alternative to subcutaneously administered immunotherapy in the treatment of allergic rhinitis. The most common side effects are of oropharyngeal and gastrointestinal in nature, for example, itching, swelling, irritation, ulceration of the oropharynx and nausea, abdominal pain, diarrhoea, and vomiting. More severe side effects are dominated by systemic and respiratory tract manifestations. RESULTS: In this clinical case, the author reports a right-sided transient tinnitus lasting for 48 h after administration of sublingual immunotherapy for house dust mite in allergic rhinitis. CONCLUSIONS: This case provide important insights for clinical practice, as tinnitus has not been previously reported as a side effect of sublingual immunotherapy with house dust mite allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170616IS - 2050-313X (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1177/2050313X17713150</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28620492">PM:28620492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\SAGE Open Med Case Rep\20170616-JuelJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\SAGE Open Med Case Rep\20170616-JuelJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170616, Juel J</style></custom2><misc3><style face="normal" font="Arial">10.1177/2050313X17713150</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deak,P.E.</style></author><author><style face="normal" font="Arial"> Vrabel,M.R.</style></author><author><style face="normal" font="Arial"> Kiziltepe,T.</style></author><author><style face="normal" font="Arial"> Bilgicer,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN, 46556, USA</style></auth-address><titles><title><style face="normal" font="Arial">Determination of Crucial Immunogenic Epitopes in Major Peanut Allergy Protein, Ara h2, via Novel Nanoallergen Platform</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="3981">3981-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h2</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">Current methods for detection and diagnosis of allergies do not provide epitope specific immunogenic information and hence lack critical information that could aid in the prediction of clinical responses. To address this issue, we developed a nanoparticle based platform, called nanoallergens that enable multivalent display of potential allergy epitopes for determining the immunogenicity of each IgE binding epitope. By synthesizing nanoallergens that present various epitopes from the major peanut allergen, Ara h2, we directly determined the immunogenicity of each epitope, alone and in combination with other epitopes, using patient sera. This information provided insights on which epitopes are most critical for physiological responses to Ara h2 and revealed the importance of both high and low affinity epitopes for allergic responses. We anticipate the nanoallergen platform to be used to provide information regarding allergic reactions and therefore potentially aid in more accurate diagnosis and design of personalized treatment options</style></abstract><notes><style face="normal" font="Arial">DA - 20170622IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-04268-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28638052">PM:28638052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-3981.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-3981.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170622, Deak PE</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-04268-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sjoberg,L.C.</style></author><author><style face="normal" font="Arial"> Nilsson,A.Z.</style></author><author><style face="normal" font="Arial"> Lei,Y.</style></author><author><style face="normal" font="Arial"> Gregory,J.A.</style></author><author><style face="normal" font="Arial"> Adner,M.</style></author><author><style face="normal" font="Arial"> Nilsson,G.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Experimental Asthma and Allergy Research, Institute of Environmental Medicine, Karolinska University Hospital, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Interleukin 33 exacerbates antigen driven airway hyperresponsiveness, inflammation and remodeling in a mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="4219">4219-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell protease</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="6" Year="2017">2017/6/26</year></dates><abstract><style face="normal" font="Arial">Interleukin 33 (IL-33) represents a potential link between the airway epithelium and induction of Th2-type inflammatory responses associated with the development of asthma. This study investigated the potential of IL-33 to exacerbate antigen driven asthma responses. An ovalbumin (OVA) asthma model was used in which sensitized C57BL/6 mice were exposed to IL-33 before each OVA challenge. IL-33 given to sensitized mice acted synergistically with antigen and aggravated airway inflammation, hyperresponsiveness and remodeling compared with mice that were only OVA sensitized and challenged and mice that were only exposed to IL-33. Elevated levels of local and systemic mast cell protease mMCP-1, as well as antigen-specific IgE production, were observed following IL-33 administration to sensitized mice. Similarly, exposing OVA-sensitized mice to IL-33 increased the Th2 cytokine levels, including IL-4, IL-5 and IL-13. Furthermore, IL-33 and OVA administration to OVA-sensitized mice increased ILC2s in the lung, suggesting a role for ILC2s in IL-33-mediated exacerbation of OVA-induced airway responses. Collectively, these findings show that IL-33 aggravates important features of antigen-driven asthma, which may have implications for asthma exacerbations</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-03674-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28652606">PM:28652606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-4219.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-4219.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Sjoberg LC</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-03674-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jatana,S.</style></author><author><style face="normal" font="Arial"> Palmer,B.C.</style></author><author><style face="normal" font="Arial"> Phelan,S.J.</style></author><author><style face="normal" font="Arial"> DeLouise,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Engineering, University of Rochester, Rochester, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunomodulatory Effects of Nanoparticles on Skin Allergy</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="3979">3979-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Engineering</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin allergy</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">In recent years there has been considerable effort to understand the interaction of nanomaterials with the skin. In this study we use an in vivo mouse model of allergic contact dermatitis to investigate how nanoparticles (NPs) may alter allergic responses in skin. We investigate a variety of NPs that vary in size, charge and composition. Results show that small (&lt;200 nm) negative and neutral charged NPs exhibit an immunosuppressive effect but that positively charged NPs do not. Confocal imaging suggests positively charged NPs may penetrate skin to a lesser extent and thereby are less able interact with and alter the local immune responses. Interestingly, negatively charged silica (20 nm) NPs suppress allergic response to two chemically distinct sensitizers; 1-fluoro-2, 4-dinitrobenzene and 2-deoxyurushiol. Skin wiping and NP application time studies suggest that the immunomodulatory mechanism is not due solely to the blocking of sensitizer adduct formation in skin. Results suggest that NPs modulate early immune events that impact mast cell degranulation. Our study shows for the first time the potential to modulate the elicitation phase of the allergic response which depends on the NP charge and composition. These finding can be used to inform the design topical therapeutics to mitigate allergic responses in skin</style></abstract><notes><style face="normal" font="Arial">DA - 20170622IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-03729-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28638049">PM:28638049</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-3979.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-3979.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170622, Jatana S</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-03729-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xie,Y.M.</style></author><author><style face="normal" font="Arial"> Gao,S.</style></author><author><style face="normal" font="Arial"> Wang,L.Y.</style></author><author><style face="normal" font="Arial"> Wang,Z.L.</style></author><author><style face="normal" font="Arial"> Cai,X.T.</style></author><author><style face="normal" font="Arial"> Zhou,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Department of Neurology and Gastroenterology, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Disease of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China</style></auth-address><titles><title><style face="normal" font="Arial">[Clinical Feature in Infants of Breast Feeding Allergy and Its Possible Relation with Gastrointestinal Peptide Change in Breast Milk]</style></title><secondary-title><style face="normal" font="Arial">Sichuan Da Xue Xue Bao Yi Xue Ban</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sichuan Da Xue Xue Bao Yi Xue Ban</style></full-title></periodical><pages end="150" start="147">147-150</pages><volume><style face="normal" font="Arial">48</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth defects</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To investigate clinical features in infants of breast milk allergy(BMA), and the possible relationship with the changes of somatostatin (SST) and motilin (MTL) in breast milk. METHODS: Twenty three cases of pure breast feeding infants with allergic gastroenteritis were collected, while another 23 normal infants with pure breast feeding were enrolled as normal controls. Samples of infant stools and breast milk were collected for the measurement of SST and MTL levels detected by by radioimmunity. RESULTS: The levels of SST and MTL in stool samples (pg/mg) were 32.6+/-8.9, 2.3+/-3.7 in BMA group and 56.2+/-12.7, 21.6+/-4.7 in normal control group, respectively. Those in breast milk (pg/mg) were 236.7+/-28.9, 159.4+/-36.7 in BMA group and 412.6+/-36.7, 216.8+/-59.7 in normal control group, respectively. All the differences were statistically significant ( P&lt;0.05). In BMA infants, the clinical features were 91.3% (20/23) of diarrhea, 86.9% (21/23) of vomiting, 69.6% (16/23) of hematochezia, 95.7% (22/23) of C-reactive protein (CRP) increasing, 87.0% (20/23) of occult blood in stools, 73.9% (17/23) of neutrophil increasing, 39.1% (9/23) of WBC in stools. CONCLUSIONS: For those infants of breast feeding with persisting and repeated gastrointestinal symptoms, allergy for breast milk should be considered. Deficiency of SST and MTL in breast milk may be a possible cause for food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170614IS - 1672-173X (Print)IS - 1672-173X (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612576">PM:28612576</url></web-urls></urls><custom2><style face="normal" font="Arial">20170614, Xie YM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Castro,L.L.</style></author><author><style face="normal" font="Arial"> Xisto,D.G.</style></author><author><style face="normal" font="Arial"> Kitoko,J.Z.</style></author><author><style face="normal" font="Arial"> Cruz,F.F.</style></author><author><style face="normal" font="Arial"> Olsen,P.C.</style></author><author><style face="normal" font="Arial"> Redondo,P.A.G.</style></author><author><style face="normal" font="Arial"> Ferreira,T.P.T.</style></author><author><style face="normal" font="Arial"> Weiss,D.J.</style></author><author><style face="normal" font="Arial"> Martins,M.A.</style></author><author><style face="normal" font="Arial"> Morales,M.M.</style></author><author><style face="normal" font="Arial"> Rocco,P.R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho, 373, Bloco G-014, Ilha do Fundao, 21941-902, Rio de Janeiro, RJ, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Stem Cell Res Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Stem Cell Res Ther</style></full-title></periodical><pages end="" start="151">151-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adipose tissue</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Difficult-to-treat</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> extracellular vesicles</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Mechanics</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mesenchymal Stromal Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Stromal Cells</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> tissue remodeling</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="24" Month="6" Year="2017">2017/6/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a chronic inflammatory disease that can be difficult to treat due to its complex pathophysiology. Most current drugs focus on controlling the inflammatory process, but are unable to revert the changes of tissue remodeling. Human mesenchymal stromal cells (MSCs) are effective at reducing inflammation and tissue remodeling; nevertheless, no study has evaluated the therapeutic effects of extracellular vesicles (EVs) obtained from human adipose tissue-derived MSCs (AD-MSC) on established airway remodeling in experimental allergic asthma. METHODS: C57BL/6 female mice were sensitized and challenged with ovalbumin (OVA). Control (CTRL) animals received saline solution using the same protocol. One day after the last challenge, each group received saline, 105 human AD-MSCs, or EVs (released by 105 AD-MSCs). Seven days after treatment, animals were anesthetized for lung function assessment and subsequently euthanized. Bronchoalveolar lavage fluid (BALF), lungs, thymus, and mediastinal lymph nodes were harvested for analysis of inflammation. Collagen fiber content of airways and lung parenchyma were also evaluated. RESULTS: In OVA animals, AD-MSCs and EVs acted differently on static lung elastance and on BALF regulatory T cells, CD3+CD4+ T cells, and pro-inflammatory mediators (interleukin [IL]-4, IL-5, IL-13, and eotaxin), but similarly reduced eosinophils in lung tissue, collagen fiber content in airways and lung parenchyma, levels of transforming growth factor-beta in lung tissue, and CD3+CD4+ T cell counts in the thymus. No significant changes were observed in total cell count or percentage of CD3+CD4+ T cells in the mediastinal lymph nodes. CONCLUSIONS: In this immunocompetent mouse model of allergic asthma, human AD-MSCs and EVs effectively reduced eosinophil counts in lung tissue and BALF and modulated airway remodeling, but their effects on T cells differed in lung and thymus. EVs may hold promise for asthma; however, further studies are required to elucidate the different mechanisms of action of AD-MSCs versus their EVs</style></abstract><notes><style face="normal" font="Arial">DA - 20170625IS - 1757-6512 (Electronic)IS - 1757-6512 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13287-017-0600-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28646903">PM:28646903</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Stem Cell Res Ther\2017-8-151.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Stem Cell Res Ther\2017-8-151.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170625, de Castro LL</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13287-017-0600-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matyasovszky,I.</style></author><author><style face="normal" font="Arial"> Makra,L..</style></author><author><style face="normal" font="Arial"> Tusnady,G..</style></author><author><style face="normal" font="Arial"> Csepe,Z.</style></author><author><style face="normal" font="Arial"> Nyul,L.G.</style></author><author><style face="normal" font="Arial"> Chapman,D.S.</style></author><author><style face="normal" font="Arial"> Sumeghy,Z.</style></author><author><style face="normal" font="Arial"> Szucs,G..</style></author><author><style face="normal" font="Arial"> Paldy,A.</style></author><author><style face="normal" font="Arial"> Magyar,D.</style></author><author><style face="normal" font="Arial"> Manyoki,G.</style></author><author><style face="normal" font="Arial"> Erostyak,J.</style></author><author><style face="normal" font="Arial"> Bodnar,K.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Deak,A.J.</style></author><author><style face="normal" font="Arial"> Thibaudon,M.</style></author><author><style face="normal" font="Arial"> Albertini,R.</style></author><author><style face="normal" font="Arial"> Bonini,M.</style></author><author><style face="normal" font="Arial"> Sikoparija,B.</style></author><author><style face="normal" font="Arial"> Radisic,P.</style></author><author><style face="normal" font="Arial"> Gehrig,R.</style></author><author><style face="normal" font="Arial"> Rybnicek,O.</style></author><author><style face="normal" font="Arial"> Severova,E.</style></author><author><style face="normal" font="Arial"> Rodinkova,V.</style></author><author><style face="normal" font="Arial"> Prikhodko,A.</style></author><author><style face="normal" font="Arial"> Maleeva,A.</style></author><author><style face="normal" font="Arial"> Stjepanovic,B.</style></author><author><style face="normal" font="Arial"> Ianovici,N.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Seliger,A.K.</style></author><author><style face="normal" font="Arial"> Weryszko-Chmielewska,E.</style></author><author><style face="normal" font="Arial"> Sauliene,I.</style></author><author><style face="normal" font="Arial"> Shalaboda,V.</style></author><author><style face="normal" font="Arial"> Yankova,R.</style></author><author><style face="normal" font="Arial"> Peternel,R.</style></author><author><style face="normal" font="Arial"> Scevkova,J.</style></author><author><style face="normal" font="Arial"> Bullock,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Biogeographical drivers of ragweed pollen concentrations in Europe</style></title><secondary-title><style face="normal" font="Arial">Theor Appl Climatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Theor Appl Climatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Altitude</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Latitude</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Slovakia</style></keyword><keyword><style face="normal" font="Arial"> Slovenia</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Ukraine</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1434-4483</style></isbn><abstract><style face="normal" font="Arial">The drivers of spatial variation in ragweed pollen concentrations, contributing to severe allergic rhinitis and asthma, are poorly quantified. We analysed the spatiotemporal variability in 16-year (1995</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2010) annual total (66 stations) and annual total (2010) (162 stations) ragweed pollen counts and 8 independent variables (start, end and duration of the ragweed pollen season, maximum daily and calendar day of the maximum daily ragweed pollen counts, last frost day in spring, first frost day in fall and duration of the frost-free period) for Europe (16-áyears, 1995</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2010) as a function of geographical coordinates. Then annual total pollen counts, annual daily peak pollen counts and date of this peak were regressed against frost-related variables, daily mean temperatures and daily precipitation amounts. To achieve this, we assembled the largest ragweed pollen data set to date for Europe. The dependence of the annual total ragweed pollen counts and the eight independent variables against geographical coordinates clearly distinguishes the three highly infected areas: the Pannonian Plain, Western Lombardy and the Rh+¦ne-Alpes region. All the eight variables are sensitive to longitude through its temperature dependence. They are also sensitive to altitude, due to the progressively colder climate with increasing altitude. Both annual total pollen counts and the maximum daily pollen counts depend on the start and the duration of the ragweed pollen season. However, no significant changes were detected in either the eight independent variables as a function of increasing latitude. This is probably due to a mixed climate induced by strong geomorphological inhomogeneities in Europe</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Hungary -CO - United Kingdom -CO - Germany -CO - France -CO - Italy -CO - Serbia -CO - Switzerland -CO - Czech Republic -CO - Ukraine -CO - Romania -CO - Russia -CO - Croatia -CO - Austria -CO - Slovenia -CO - Poland -CO - Lithuania -CO - Belarus -CO - Bulgaria -CO - Slovakia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00704-017-2184-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s00704-017-2184-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Theor Appl Climatol\20170703-MatyasovszkyI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Theor Appl Climatol\20170703-MatyasovszkyI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Matyasovszky I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00704-017-2184-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yasui,K.</style></author><author><style face="normal" font="Arial"> Matsuyama,N.</style></author><author><style face="normal" font="Arial"> Okamura-Shiki,I.</style></author><author><style face="normal" font="Arial"> Ikeda,T.</style></author><author><style face="normal" font="Arial"> Ishii,K.</style></author><author><style face="normal" font="Arial"> Furuta,R.A.</style></author><author><style face="normal" font="Arial"> Hirayama,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Japanese Red Cross Kinki Block Blood Center, Osaka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Clinical utility of a passive immune basophil activation test for the analysis of allergic transfusion reactions</style></title><secondary-title><style face="normal" font="Arial">Transfusion</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfusion</style></full-title></periodical><pages end="2095" start="2084">2084-2095</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In previous studies, we demonstrated that the basophil activation test, which is performed using patient blood and the supernatants from transfused blood components, was able to elucidate not only the causative relationship between allergic transfusion reactions and the transfusion but also the mechanisms behind allergic transfusion reactions. However, for a large number of allergic transfusion reactions, patients are in a state of myelosuppression, and the basophil activation test cannot be performed for these patients because there are insufficient numbers of peripheral blood basophils. STUDY DESIGN AND METHODS: To overcome this obstacle, we developed a passive immune basophil activation test, in which patient plasma and residually transfused blood are used as the patient's sources of immunoglobulin E and allergen, respectively, whereas healthy volunteer basophils serve as the responder cell source. The passive immune basophil activation test was performed for two patients who had severe allergic transfusion reactions, using supernatants of the residual platelet concentrates and the patients' own immunoglobulin E. RESULTS: There were no differences in either surface immunoglobulin E or activation in response to allergens between untreated basophils and so-called quasi-basophils, in which immunoglobulin E was replaced by a third party's immunoglobulin E. In these patients, the supernatants of the residual platelet concentrates exclusively activated basophils in response to quasi-basophils onto which the patients' immunoglobulin E, but not a third party's immunoglobulin E, was bound. CONCLUSION: The passive immune basophil activation test may help clarify the causal relationship between allergic transfusion reactions and transfused blood, even when patients experience myelosuppression</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1537-2995 (Electronic)IS - 0041-1132 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/trf.14208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656655">PM:28656655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfusion\20170628-YasuiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfusion\20170628-YasuiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Yasui K</style></custom2><misc3><style face="normal" font="Arial">10.1111/trf.14208</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Henggeler,J.C.</style></author><author><style face="normal" font="Arial"> Verissimo,M.</style></author><author><style face="normal" font="Arial"> Ramos,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Non-coeliac gluten sensitivity: A review of the literature</style></title><secondary-title><style face="normal" font="Arial">Trends Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Trends Food Sci Technol</style></full-title></periodical><pages end="92" start="84">84-92</pages><volume><style face="normal" font="Arial">66</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Coeliac disease</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Extraintestinal</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free diet</style></keyword><keyword><style face="normal" font="Arial"> Gluten-related disorders</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Irritable Bowel Syndrome</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Non-coeliac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><isbn><style face="normal" font="Arial">0924-2244</style></isbn><abstract><style face="normal" font="Arial">Background Non-coeliac gluten sensitivity (NCGS) is an emerging and still poorly defined clinical entity, which is part of the spectrum of gluten-related disorders (along with coeliac disease and wheat allergy) but also closely related to irritable bowel syndrome. It is characterized by a wide array of both gastrointestinal and extra-intestinal symptoms. NCGS was first defined in the 1970s, but has gained critical relevance in recent years. Scope and approach This review covers the existing definitions, documented symptoms and methods of diagnosis, treatment via a gluten-free diet, history, prevalence in the general population and possible mechanisms for NCGS. It also looks into recent studies and their findings. All information is relative to studies published in the last 6 years (2011-present). Key findings and conclusions Despite recent advances in characterising NCGS as a clinical entity and gaining novel insights into its pathogenesis, further studies are needed to better understand its etiology and mechanism and to establish specific biomarkers</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tifs.2017.05.018</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.tifs.2017.05.018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trends Food Sci Technol\2017-66-84-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trends Food Sci Technol\2017-66-84-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Henggeler JC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tifs.2017.05.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Joseph,I.M.</style></author><author><style face="normal" font="Arial"> Kuriakose,C.K.</style></author><author><style face="normal" font="Arial"> Dev,A.V.</style></author><author><style face="normal" font="Arial"> Philip,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 DNB General Medicine Senior Resident, Dr Somervell Memorial CSI Medical College, Karakonam, Thiruvananthapuram, Kerala, India</style></auth-address><titles><title><style face="normal" font="Arial">Low dose versus high dose anti-snake venom therapy in the treatment of haematotoxic snake bite in South India</style></title><secondary-title><style face="normal" font="Arial">Trop Doct</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Trop Doct</style></full-title></periodical><pages end="304" start="300">300-304</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Bite</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> normalisation</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> senior</style></keyword><keyword><style face="normal" font="Arial"> South India</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">Most of the studies on the appropriate dose of anti-snake venom (ASV) are from tertiary hospitals and the guidelines are unclear. Our observational study compared the outcomes of two prevalent treatment regimes for haematotoxic snake bite in a secondary care hospital in South India. The time to normalisation of whole blood clotting time, mortality and complications were not different between the groups. The average dose of ASV required in the low and high dose groups were 106 mL and 246 mL, respectively. Consequently, patients who received low dose ASV incurred approximately 50% less expense. Urticarial rashes were also significantly fewer in the low dose group</style></abstract><notes><style face="normal" font="Arial">DA - 20170608IS - 1758-1133 (Electronic)IS - 0049-4755 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1177/0049475517712804</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28592212">PM:28592212</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trop Doct\20170608-JosephIM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trop Doct\20170608-JosephIM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170608, Joseph IM</style></custom2><misc3><style face="normal" font="Arial">10.1177/0049475517712804</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foust-Wheatcraft,D.A.</style></author><author><style face="normal" font="Arial"> Dell,D.L.</style></author><author><style face="normal" font="Arial"> Rosenkrantz,W.S.</style></author><author><style face="normal" font="Arial"> Griffin,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Animal Dermatology Clinic, 3901 East 82nd Street, Indianapolis, IN, 46240, USA</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of the intradermal irritant threshold concentrations of nine allergens from two different manufacturers in clinically nonallergic dogs in the USA</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bermuda</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Chenopodium album</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mulberry</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Prosopis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Xanthium</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The intradermal irritant threshold concentration for many allergens is unknown. OBJECTIVE: To determine the intradermal irritant threshold concentration (ITC) of nine allergens from two different manufacturers. ANIMALS: Twenty privately owned clinically nonallergic dogs. METHODS: Alternaria, cat dander, Dermatophagoides farinae, Chenopodium album (lamb's quarter), Xanthium strumarium (cocklebur), Prosopis glandulosa (mesquite), Morus alba (white mulberry), Cynodon dactylon (Bermuda grass) and Phleum pretense (Timothy grass) from two manufacturers (ALK; Round Rock, TX, USA and Greer(R) Laboratories; Lenoir, NC, USA) were injected intradermally at two dilutions and at 15 and 30 min evaluated subjectively (1-4) and objectively (horizontal wheal diameter) by two blinded investigators. A subjective score of 3 or 4 by either investigator at either timed reading was considered positive. If both concentrations resulted in positive reactions, two additional dilutions were performed. The ITC was defined as the lowest tested concentration that elicited a positive reaction in >/=10% of animals. RESULTS: The ITCs were Alternaria >2,000 PNU/mL; cat dander 750 PNU/mL (ALK) and 2,000 PNU/mL (Greer(R) ); D. farinae &lt;1:10,000 w/v; C. album &lt;6,000 PNU/mL; X. strumarium &lt;6,000 PNU/mL; P. glandulosa &lt;500 PNU/mL; M. alba &lt;6,000 PNU/mL; C. dactylon &lt;10,000 PNU/mL (ALK) and &lt;6,000 PNU/mL (Greer(R) ); and P. pretense &lt;6,000 PNU/mL. CONCLUSIONS AND CLINICAL SIGNIFICANCE: There were significant differences in subjective scoring and objective measurement between manufacturers for Alternaria, cat dander and P. pretense. Results revealed significant positive correlation between subjective scoring and objective measurement for each time, investigator and manufacturer separately</style></abstract><notes><style face="normal" font="Arial">DA - 20170630IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12464</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28664559">PM:28664559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170630-FoustWheatcraftDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170630-FoustWheatcraftDA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170630, Foust-Wheatcraft DA</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12464</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perecinsky,S.</style></author><author><style face="normal" font="Arial"> Varga,M.</style></author><author><style face="normal" font="Arial"> Petrovicova,J.</style></author><author><style face="normal" font="Arial"> Ragac,O.</style></author><author><style face="normal" font="Arial"> Perecinska,K.</style></author><author><style face="normal" font="Arial"> Jancova,A.</style></author><author><style face="normal" font="Arial"> Murinova,L.</style></author><author><style face="normal" font="Arial"> Bacinsky,T.</style></author><author><style face="normal" font="Arial"> Legath,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Occupational Medicine and Clinical Toxicology, Medical Faculty, Pavol Jozef Safarik University and the L. Pasteur University Hospital, Rastislavova 43, 04190, Kosice, Slovakia.</style></auth-address><titles><title><style face="normal" font="Arial">Different clinical effect of several types of airborne allergens on the severity of bronchial hyperreactivity</style></title><secondary-title><style face="normal" font="Arial">Wien Klin Wochenschr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Wien Klin Wochenschr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PC20</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Slovakia</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic sensitization belongs to the most common risk factors for bronchial asthma. However, in clinical practice, it is not clear whether sensitization against pollen and perennial allergens is differently associated with the severity of bronchial hyperresponsiveness (BHR). AIM: To find out whether patients sensitized to perennial allergens differ in severity of bronchial hyperresponsiveness from patients sensitized to pollen allergens. METHODS: The study includes 109 patients. Based on the results of skin prick tests, patients were divided into three groups: sensitivity to pollen allergens - group A; sensitivity to perennial allergens - group B; sensitivity to both pollen and perennial allergens - group C. Based on the histamine bronchoprovocation test, we compared the values of histamine provocative concentration causing a 20% drop in FEV1 (PC20) among particular groups of patients. Mild bronchial hyperresponsiveness was determined if the value of PC20 was >4 mg/ml, while if the value of PC20 was &lt;4 mg/ml, the bronchial hyperresponsiveness was considered as moderate/severe. RESULTS: A statistically significant difference was found in the degrees of bronchial hyperresponsiveness between the three groups of patients, namely, group A with the patients sensitized only to the pollen allergens, group B comprising patients sensitized to the perennial allergens only, and group C, involving patients sensitized to the combination of both pollen and perennial allergens. The PC20 values were higher among the patients from the group A (7.46 mg/ml) compared to group B (4.25 mg/ml) and C (4.52 mg/ml). The odds ratio for moderate/severe BHR was 5.21 and 5.04 in group B and group C, respectively. CONCLUSION: Severity of bronchial hyperresponsiveness shows differences according to sensitization to particular allergens. Perennial allergens are more often associated with serious forms of bronchial hyperresponsiveness which also have an impact on the severity and prognosis of bronchial asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170608IS - 1613-7671 (Electronic)IS - 0043-5325 (Linking)LA - engPT - Journal ArticleCO - Slovakia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00508-017-1220-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28593388">PM:28593388</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Wien Klin Wochenschr\20170608-PerecinskyS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Wien Klin Wochenschr\20170608-PerecinskyS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170608, Perecinsky S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00508-017-1220-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Netting,M.</style></author><author><style face="normal" font="Arial"> Gold,M.</style></author><author><style face="normal" font="Arial"> Quinn,P.</style></author><author><style face="normal" font="Arial"> El-Merhibi,A.</style></author><author><style face="normal" font="Arial"> Penttila,I.</style></author><author><style face="normal" font="Arial"> Makrides,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Nutrition Research Centre, South Australian Health Medical Research Institute, 72 King William Road, North Adelaide, South Australia 5006 Australia</style></auth-address><titles><title><style face="normal" font="Arial">Randomised controlled trial of a baked egg intervention in young children allergic to raw egg but not baked egg</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="22">22-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> baked egg</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> egg tolerance</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> South Australia</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole egg</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Consumption of baked egg by raw egg allergic children is associated with immune changes suggesting development of tolerance. However, causation has not been tested using a double blind randomized controlled trial (RCT). We aimed to compare clinical and immunological outcomes after baked egg (BE) consumption in young BE tolerant egg allergic children. METHODS: In a double blind RCT, BE tolerant egg allergic children consumed 10 g BE (1.3 g protein) 2 to 3 times per week for 6 months (n = 21 intervention group) or similar egg free baked goods (n = 22 control group) while maintaining an otherwise egg free diet. The final assessment was a raw egg oral food challenge (OFC) 1 month after ceasing the intervention product. Egg specific IgE and IgG4 were assessed at baseline and 7 months. RESULTS: After the intervention there was no difference in raw egg tolerance between groups, (23.5% (4/17) intervention group and 33.3% (6/18) control group). This was independent of age and amount of BE consumed (aOR 0.50 CI 0.11-2.40 p = 0.39). Both groups demonstrated decreased egg specific serum IgE titres and decreased whole egg specific IgE/IgG4 ratios. DISCUSSION: We conducted this trial because inclusion of baked egg protein in the diet of egg allergic children appears to move children towards a more tolerant immune profile. Strengths of our study include design of the blinded intervention, the consistent dosing protocol and the regular monitoring of symptoms and intake. However, the study was limited by small sample size resulting in insufficient power to show statistically significant results. CONCLUSION: Our study suggests that short term, regular consumption of BE by BE tolerant 1 to 5 year old children with IgE mediated raw egg allergy may not induce, accelerate or slow development of tolerance to raw egg in this selected population. Trials with larger sample sizes are required to further test this hypothesis. TRIAL REGISTRATION: The trial was registered on 7th February 2012 with the Australian New Zealand Clinical Trials Registry (ACTRN 12612000173897)</style></abstract><notes><style face="normal" font="Arial">DA - 20170626IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0152-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28649294">PM:28649294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170626, Netting M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0152-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ke,L.Q.</style></author><author><style face="normal" font="Arial"> Wang,F.M.</style></author><author><style face="normal" font="Arial"> Luo,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. luoyunchun501@163.com</style></auth-address><titles><title><style face="normal" font="Arial">[Effects of vasoactive intestinal peptide on airway inflammation and Th17/Treg balance in asthmatic mice]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="704" start="699">699-704</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vasoactive Intestinal Peptide</style></keyword><keyword><style face="normal" font="Arial"> VIP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the effects of vasoactive intestinal peptide (VIP) on the airway inflammation and its regulatory effect on Th17/Treg imbalance in asthmatic mice. METHODS: A total of 30 BALB/c mice were equally and randomly divided into three groups: control, asthma, and VIP. An acute asthmatic mouse model was established by sensitization and challenge with ovalbumin (OVA). The control group received normal saline instead of OVA. Before the challenge with OVA, the VIP group was administered VIP (20 mug/mL) by aerosol inhalation for 30 minutes. The bronchoalveolar lavage fluid (BALF) and the lung tissue were collected from mice. The pathological changes in the lung tissue were observed by hematoxylin and eosin staining. The levels of Th17/Treg-related cytokines in BALF were measured by enzyme-linked immunosorbent assay. The expression of retinoid-related orphan receptor gamma t (RORgammat) and forkhead box P3 (Foxp3) were measured by real-time fluorescence quantitative PCR and immunohistochemistry. RESULTS: The histopathological results showed that the VIP group had milder symptoms of airway inflammation than the asthma group. The level of IL-17 in BALF in the asthma group was significantly higher than that in the control group and the VIP group (P&lt;0.01), but the level of IL-17 in the control group was significantly lower than that in the VIP group (P&lt;0.01). The level of IL-10 in BALF in the asthma group was significantly lower than that in the control group and the VIP group (P&lt;0.01, but the level of IL-10 in the VIP group was significantly higher than that in the control group (P&lt;0.01). The asthma group showed significantly higher expression levels of RORgammat mRNA and protein in the lung tissue and significantly lower expression levels of Foxp3 mRNA and protein than the control group (P&lt;0.01). The VIP group had significantly lower expression levels of RORgammat mRNA and protein in the lung tissue and significantly higher expression levels of Foxp3 mRNA and protein than the asthma group (P&lt;0.05). CONCLUSIONS: The Th17/Treg imbalance may be closely related to the airway inflammation in asthmatic mice. VIP can improve airway inflammation by regulating the Th17/Treg imbalance in asthmatic mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2017.06.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606240">PM:28606240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2017-19-699-704.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Zhongguo Dang Dai Er Ke Za Zhi\2017-19-699-704.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Ke LQ</style></custom2><misc3><style face="normal" font="Arial">10.7499/j.issn.1008-8830.2017.06.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Q.</style></author><author><style face="normal" font="Arial"> Zhan,S.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Su,H.</style></author><author><style face="normal" font="Arial"> Dai,X.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Beng,H.</style></author><author><style face="normal" font="Arial"> Tan,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">Preparation of a Sustained-Release Nebulized Aerosol of R-terbutaline Hydrochloride Liposome and Evaluation of Its Anti-asthmatic Effects via Pulmonary Delivery in Guinea Pigs</style></title><secondary-title><style face="normal" font="Arial">AAPS PharmSciTech</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">AAPS PharmSciTech</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Bronchodilator response</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> liposome</style></keyword><keyword><style face="normal" font="Arial"> Liposomes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Size distribution</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic efficacy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">An aerosolized liposome formulation for the pulmonary delivery of an anti-asthmatic medication was developed. Asthma treatment usually requires frequent administration of medication for a sustained bronchodilator response. Liposomes are known for their sustained drug release capability and thus would be a suitable delivery system for prolonging the therapeutic effect of anti-asthmatic medication. Liposomes prepared by thin film hydration were loaded with a model drug, R-terbutaline hydrochloride(R-TBH), using an ammonium sulfate-induced transmembrane electrochemical gradient. This technique provided an encapsulation efficiency of up to 71.35% and yielded R-TBH liposomes with a particle size of approximately 145 +/- 20 nm. According to stability studies, these R-TBH liposomes should be stored at 4 degrees C before usage. Compared to R-TBH solution, which showed 90.84% release within 8 h, liposomal R-TBH had a cumulative release of 73.53% at 37 degrees C over 192 h. A next generation impactor (NGI) was used to analyze the particle size distribution in the lungs of R-TBH liposome aerosol in vitro at 5 degrees C. The therapeutic efficacy of the nebulized aerosol of the R-TBH liposomes was assessed via pulmonary delivery in guinea pigs. The results showed that, compared to the R-TBH solution group, the R-TBH liposome group had a prolonged anti-asthma effect</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1530-9932 (Electronic)IS - 1530-9932 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1208/s12249-017-0816-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28681333">PM:28681333</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\AAPS PharmSciTech\20170706-LiQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\AAPS PharmSciTech\20170706-LiQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Li Q</style></custom2><misc3><style face="normal" font="Arial">10.1208/s12249-017-0816-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">An,C.</style></author><author><style face="normal" font="Arial"> Woo,C.</style></author><author><style face="normal" font="Arial"> Yamamoto,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Introducing DNA-based methods to compare fungal microbiota and concentrations in indoor, outdoor, and personal air</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne fungi</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> DNA-based methods</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> High throughput sequencing</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Inhalation of airborne fungi is known to cause respiratory illnesses such as allergies. However, the association between exposure and health outcomes remains largely unclear, in part due to lack of knowledge about fungal exposure in daily life. This study aims to introduce DNA-based methods such as high-throughput sequencing (HTS) and quantitative polymerase chain reaction (qPCR) to compare fungal microbiota and concentrations in indoor, outdoor, and personal air. Five sets of concurrent indoor, outdoor, and personal air samples were collected, each with duration of 4-ádays. Sequencing analysis revealed greater species richness in personal than indoor air for four out of the five sets, indicating that people are exposed to outdoor species that are not in indoor air. The personal</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôindoor (P/I) and personal</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôoutdoor (P/O) ratios of total fungi were 1.2 and 0.15, respectively, suggesting that personal exposure to total fungi is better represented by indoor than outdoor concentrations. However, the ratios were taxon dependent, highlighting the complexity of generalizing personal exposure to the diverse kingdom Fungi. These results demonstrate that the HTS/qPCR method is useful for assessing taxon-specific fungal exposure, which might be difficult to achieve effectively using conventional, non-DNA-based techniques</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9490-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9490-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170622-AnC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170622-AnC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170622, An C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9490-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Robichaud,A.</style></author><author><style face="normal" font="Arial"> Comtois,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Statistical modeling, forecasting and time series analysis of birch phenology in Montreal, Canada</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> ENSO</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Ice</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictive model</style></keyword><keyword><style face="normal" font="Arial"> Predictive models</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">The aim of this study was to analyse birch pollen time series observed in Montreal (Canada) in order to understand the link between inter-annual variability of phenology and environmental factors and to build predictive models for the upcoming pollen season. Modeling phenology is challenging, especially in Canada, where phenological observations are rare. Nevertheless, understanding phenology is required for scientific applications (e.g. inputs to numerical models of pollen dispersion) but also to help allergy sufferers to better prepare their medication and avoidance strategies before the start of the pollen season. We used multivariate statistical regression to analyse and predict phenology. The predictors were drawn from a large basin (over 60) of potential environmental predictors including meteorological data and global climatic indices such NAO (North Atlantic Oscillation index) and ENSO/MEI (Multivariate Enso Index). Results of this paper are summarized as follows: (1) an accurate forecast for the upcoming season starting date of the birch pollen season was obtained (showing low bias and total forecast error of about 4-ádays in Montreal), (2) NAO and ENSO/MEI indices were found to be well correlated (i.e. 44% of the variance explained) with birch phenology, (3) a long-term trend of 2.6-ádays per decade (p-á&lt;-á0.1) towards longer season duration was found for the length of the birch pollen season in Montreal. Finally, perturbations of the quasi-biennial cycle of birch were observed in the pollen data during the pollen season following the Great Ice Storm of 1998 which affected south-eastern Canada</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9488-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9488-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170615-RobichaudA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170615-RobichaudA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Robichaud A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9488-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Janati,A.</style></author><author><style face="normal" font="Arial"> Bouziane,H.</style></author><author><style face="normal" font="Arial"> del Mar Trigo,M.</style></author><author><style face="normal" font="Arial"> Kadiri,M.</style></author><author><style face="normal" font="Arial"> Kazzaz,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Poaceae pollen in the atmosphere of Tetouan (NW Morocco): effect of meteorological parameters and forecast of daily pollen concentration</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anthesis</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Main pollen season</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> Meteorological variables</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tetouan</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">The Poaceae pollen season has been characterized in Tetouan during a 7-year period, and the effect of weather conditions on daily concentrations was examined. The forecast models were produced using a stepwise multiple regression analyses. Firstly, three models were constructed to predict daily Poaceae pollen concentrations during the main pollen season, as well as the pre-peak and post-peak periods with data from 2008 to 2012 and tested on data from 2013 and 2014. Secondly, the regression models using leave-one-out cross-validation were produced with data obtained during 2008</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2014 taking into account meteorological parameters and mean pollen concentrations of the same day in other years. The duration of the season ranged from 70-ádays in 2009 to 158-ádays in 2012. The highest amount of Poaceae pollen was detected in spring and the first fortnight of July. The annual sum of airborne Poaceae pollen concentrations varied between 2100 and 6251. The peak of anthesis was recorded in May in six of the other years studied. The regression models accounted for 36.3</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô85.7% of variance in daily Poaceae pollen concentrations. The models fitted best when the mean pollen concentration of the same day in other years was added to meteorological variables, and explained 78.4</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô85.7% of variance of the daily pollen changes. When the year 2014 was used for validating the models, the lowest root-mean-square errors values were found between the observed and estimated data (around 13). The reasonable predictor variables were the mean pollen concentration of the same day in other years, mean temperature, precipitations, and maximum relative humidity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Morocco -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9487-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9487-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170704-JanatiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170704-JanatiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Janati A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9487-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ogorek,R.</style></author><author><style face="normal" font="Arial"> Kozak,B.</style></author><author><style face="normal" font="Arial"> Visnovska,Z.</style></author><author><style face="normal" font="Arial"> Tancinova,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Phenotypic and genotypic diversity of airborne fungal spores in Dem+ñnovsk+í Ice Cave (Low Tatras, Slovakia)</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeromycota</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airborne fungal spore</style></keyword><keyword><style face="normal" font="Arial"> Airborne fungi</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcus</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Ecosystem</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Ice</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Low temperature</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microclimate</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Slovakia</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spore concentration</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">This paper is the first aero-mycological report from Dem+ñnovsk+í Ice Cave. Fungal spores were sampled from the internal and external air of the cave in June, 2014, using the impact method with a microbiological air sampler. Airborne fungi cultured on PDA medium were identified using a combination of classical phenotypic and molecular methods. Altogether, the presence of 18 different fungal spores, belonging to 3 phyla, 9 orders and 14 genera, was detected in the air of the cave. All of them were isolated from the indoor samples, and only 9 were obtained from the outdoor samples. Overall, airborne fungal spores belonging to the genus Cladosporium dominated in this study. However, the spores of Trametes hirsuta were most commonly found in the indoor air samples of the cave and the spores of C. herbarum in the outdoor air samples. On the other hand, the spores of Alternaria abundans, Arthrinium kogelbergense, Cryptococcus curvatus, Discosia sp., Fomes fomentarius, Microdochium seminicola and T. hirsuta were discovered for the first time in the air of natural and artificial underground sites. The external air of the cave contains more culturable airborne fungal spores (755 colony-forming units (CFU) per 1-ám3 of air) than the internal air (from 47 to 273-áCFU in 1-ám3), and these levels of airborne spore concentration do not pose a threat to the health of tourists. Probably, the specific microclimate in the cave, including the constant presence of ice caps and low temperature, as well as the location and surrounding environment, contributes to the unique species composition of aeromycota and their spores in the cave. Thus, aero-mycological monitoring of underground sites seems to be very important for their ecosystems, and it may help reduce the risk of fungal infections in humans and other mammals that may arise in particular due to climate change</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -CO - Slovakia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9491-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10453-017-9491-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170703-OgorekR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170703-OgorekR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Ogorek R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9491-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brehler,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Insects and arachnids as elicitors of toxic and allergic reactions in Germany</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="136" start="129">129-136</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bees</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> Wasps</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Bees and wasps are the main culprits in terms of severe allergic reactions to insects in Germany; venoms from both insects are available for specific immunotherapy (SIT). Therefore, it is important to differentiate reactions to venom from other animals. It is also necessary for the sake of targeted prevention to assign sting reactions of any kind to their causal agents</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0026-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-017-0026-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-129-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-129-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Brehler R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0026-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rueff,F.</style></author><author><style face="normal" font="Arial"> Mastnik,S.</style></author><author><style face="normal" font="Arial"> Oppel,E.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mast cell diseases in patients with insect venom allergy: implications for diagnosis and therapy</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="145" start="137">137-145</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergies</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergy</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndrome</style></keyword><keyword><style face="normal" font="Arial"> Mast cell disease</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Clonal mast cell disease is detected in up to 5% of adult patients with insect venom allergy. Mastocytosis and monoclonal mast cell activation syndrome (MMAS) are considered high-risk diseases in Hymenoptera venom allergy (HVA)</style></abstract><notes><style face="normal" font="Arial">LA- ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0023-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-017-0023-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-137-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-137-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Rueff F</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0023-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dinkel,G.</style></author><author><style face="normal" font="Arial"> Pietschke,K.</style></author><author><style face="normal" font="Arial"> Belge,K.</style></author><author><style face="normal" font="Arial"> Yazdi,A.</style></author><author><style face="normal" font="Arial"> Fischer,J..</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Bee venom allergy: a recent trend among amateur beekeepers</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="121" start="119">119-121</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0018-y</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-017-0018-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-119-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-119-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Dinkel G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0018-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bauer,A.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Dealing with absolute and relative contraindications to specific immunotherapy using Hymenoptera venoms</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="128" start="122">122-128</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACE</style></keyword><keyword><style face="normal" font="Arial"> Acquired Immunodeficiency Syndrome</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Contraindication</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venoms</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Acute infectious disorders, uncontrolled bronchial asthma, severe chronic inflammatory disorders, severe cardiovascular disorders, autoimmune or immunodeficiency disorders, active or progressive cancer, acquired immunodeficiency syndrome (AIDS), treatment initiation during pregnancy, as well as medication with +¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çæblockers and angiotensin-converting enzyme (ACE) inhibitors, among others, are considered either absolute or relative contraindications to specific immunotherapy using Hymenoptera venom (HV-SIT). Some of the contraindications listed above, however, are potential risk factors in the event of anaphylaxis, such that one regularly needs to challenge these contraindications on a-ácase-by-case basis so as not to withhold HV-SIT from patients at particularly high risk</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0024-0</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-017-0024-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-122-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-122-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Bauer A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0024-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,J.L.</style></author><author><style face="normal" font="Arial"> Ning,W.X.</style></author><author><style face="normal" font="Arial"> Li,S.X.</style></author><author><style face="normal" font="Arial"> Xu,Y.C.</style></author><author><style face="normal" font="Arial"> Wu,L.</style></author><author><style face="normal" font="Arial"> Wang,Y.S.</style></author><author><style face="normal" font="Arial"> Xu,X.F.</style></author><author><style face="normal" font="Arial"> Jiang,Y.</style></author><author><style face="normal" font="Arial"> Sheng,Y.J.</style></author><author><style face="normal" font="Arial"> Zhou,Y.L.</style></author><author><style face="normal" font="Arial"> Wang,J.H.</style></author><author><style face="normal" font="Arial"> Tang,L.F.</style></author><author><style face="normal" font="Arial"> Chen,Z.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East China</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hospitalisation</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The aim of the current study is to evaluate the prevalence, severity and possible risk factors of systemic reactions (SRs) to subcutaneous allergen immunotherapy (SCIT) in children and adolescents with asthma in Hangzhou, east China's Zhejiang province. METHODS: From January 2011 to December 2016, this survey analysed the SCIT-related SRs involving 429 patients (265 children and 134 adolescents) affected by allergic asthma. Recorded data included demographics, diagnosis, patient statuses, pulmonary function testing results before and after each injection, allergen dosage, and details of SRs. RESULTS: All patients finished the initial phase and six patients withdrew during the maintenance phase. There were 2.59% (328/12,655) SRs in all injections (3.28% in children and 1.47% in adolescents); 15.62% (67/429) patients experienced SRs (18.49% children and 10.98% adolescents). There were 54.57% SRs of grade 1; 42.37% SRs of grade 2; 3.05% SRs of grade 3; and no grades 4 or grade 5 SRs occurred in patients. Most reactions were mild, and were readily controlled by immediate emergency treatment. There was no need for hospitalisation. The occurrence of SRs was significantly higher in children than that in adolescents (p&lt;0.01). A higher ratio of SRs was found among patients with moderate asthma. CONCLUSION: This retrospective survey showed that properly-conducted SCIT was a safe treatment for children and adolescents with asthma in Hangzhou, East China. Children and patients with moderate asthma may be prone to develop SRs</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.04.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629672">PM:28629672</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170620-LiuJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170620-LiuJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Liu JL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.04.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,J.</style></author><author><style face="normal" font="Arial"> Wei,K.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Dong,W.</style></author><author><style face="normal" font="Arial"> Ma,N.</style></author><author><style face="normal" font="Arial"> Zhu,L.</style></author><author><style face="normal" font="Arial"> Hu,L.P.</style></author><author><style face="normal" font="Arial"> Huang,H.</style></author><author><style face="normal" font="Arial"> Zhu,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, College of Animal Science and Technology, Shandong Agricultural University, Shandong Taian 271018, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Oral immunisation with Taishan Pinus massoniana pollen polysaccharide adjuvant with recombinant Lactococcus lactis-expressing Proteus mirabilis ompA confers optimal protection in mice</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="505" start="496">496-505</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunisation</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lactococcus</style></keyword><keyword><style face="normal" font="Arial"> Lactococcus lactis</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> lymphocyte proliferation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharides</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Proteus</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Recombinant vaccine</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Proteus mirabilis poses a critical burden on the breeding industry, but no efficient vaccine is available for animals. METHOD: A recombinant Lactococcus lactis expressing the ompA of P. mirabilis was used to develop a vaccine. The mucosal and systemic immune responses of the recombinant vaccine were evaluated in mice after oral immunisation. The inhibition on P. mirabilis colonisation of vaccines was also determined. Moreover, Taishan Pinus massoniana pollen polysaccharides (TPPPS) were used as adjuvants to examine the immunomodulatory effects. RESULTS: The pure recombinant L. lactis vaccine significantly induced the production of specific IgA and IgG, IL-2, IL-4, IFN-gamma, and T lymphocyte proliferation, and the immunised mice exhibited significant resistance to P. mirabilis colonisation. Notably, the TPPPS adjuvant vaccines induced higher levels of immune responses than the pure L. lactis. CONCLUSIONS: The L. lactis as a vaccine vehicle combined with TPPPS adjuvant provides a feasible method for preventing P. mirabilis infection</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629671">PM:28629671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170620-ZhouJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170620-ZhouJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Zhou J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.04.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qiao,J.</style></author><author><style face="normal" font="Arial"> Sun,S.</style></author><author><style face="normal" font="Arial"> Yuan,L.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of icariin on asthma mouse model are associated with regulation of prostaglandin D2 level</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> real-time quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We aimed to observe the effect of icariin on an asthma mouse model and explore the potential underlying mechanisms. METHODS: The asthma mouse model was established by ovalbumin (OVA) sensitisation and respiratory syncytial virus (RSV) infection and then treated with icariin. Airway resistance was assessed by whole body plethysmograph. In addition, pathological slides were stained with haematoxylin-eosin, and the peribronchial inflammation was observed microscopically. The concentration of prostaglandin D2 (PGD2) in serum and bronchoalveolar lavage fluid (BALF) was detected by enzyme-linked immuno sorbent assay (ELISA). The relative level of prostaglandin D2 receptor 2 (CRTH2) mRNA was assessed by real-time quantitative PCR. RESULTS: Compared with the icariin-untreated group, there was a significant reduction of Penh in the treated group. Total leucocyte amount and all sorts of leukocytes were lower in the treated group than in the untreated group. HE staining results revealed that a large number of inflammatory cells infiltrated into the peribronchial tissues of untreated group, and the degree of airway inflammation decreased significantly in the treated group. PGD2 in serum and BALF, as well as CRTH2 mRNA level in lung tissues were lower in the treated group than in the untreated group. CONCLUSION: Icariin is a promising therapeutic strategy for asthma, and PGD2 might be a new target for asthma therapy in OVA-induced and RSV-infected asthma model</style></abstract><notes><style face="normal" font="Arial">DA - 20170703IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28669561">PM:28669561</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170703-QiaoJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170703-QiaoJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Qiao J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.02.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alvaro,M.</style></author><author><style face="normal" font="Arial"> Escarrer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Sant Joan de Deu, Esplugues, Universistat de Barcelona, Barcelona, Spain. Clinica Juaneda, Palma de Mallorca, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy in childhood: Are we close to having an effective treatment?</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="315" start="313">313-315</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Palma de Mallorca</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170709IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - EditorialCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28688477">PM:28688477</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2017-45-313-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\2017-45-313-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170709, Alvaro M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martorell,A.</style></author><author><style face="normal" font="Arial"> Alonso,E.</style></author><author><style face="normal" font="Arial"> Echeverria,L.</style></author><author><style face="normal" font="Arial"> Escudero,C.</style></author><author><style face="normal" font="Arial"> Garcia-Rodriguez,R.</style></author><author><style face="normal" font="Arial"> Blasco,C.</style></author><author><style face="normal" font="Arial"> Bone,J.</style></author><author><style face="normal" font="Arial"> Borja-Segade,J.</style></author><author><style face="normal" font="Arial"> Bracamonte,T.</style></author><author><style face="normal" font="Arial"> Claver,A.</style></author><author><style face="normal" font="Arial"> Corzo,J.L.</style></author><author><style face="normal" font="Arial"> de la Hoz,B.</style></author><author><style face="normal" font="Arial"> Del Olmo,R.</style></author><author><style face="normal" font="Arial"> Dominguez,O.</style></author><author><style face="normal" font="Arial"> Fuentes-Aparicio,V.</style></author><author><style face="normal" font="Arial"> Guallar,I.</style></author><author><style face="normal" font="Arial"> Larramona,H.</style></author><author><style face="normal" font="Arial"> Martin-Munoz,F.</style></author><author><style face="normal" font="Arial"> Matheu,V.</style></author><author><style face="normal" font="Arial"> Michavila,A.</style></author><author><style face="normal" font="Arial"> Ojeda,I.</style></author><author><style face="normal" font="Arial"> Ojeda,P.</style></author><author><style face="normal" font="Arial"> Piquer,M.</style></author><author><style face="normal" font="Arial"> Poza,P.</style></author><author><style face="normal" font="Arial"> Reche,M.</style></author><author><style face="normal" font="Arial"> Rio,P.R.D.</style></author><author><style face="normal" font="Arial"> Rodriguez,M.</style></author><author><style face="normal" font="Arial"> Ruano,F.</style></author><author><style face="normal" font="Arial"> Sanchez-Garcia,S.</style></author><author><style face="normal" font="Arial"> Terrados,S.</style></author><author><style face="normal" font="Arial"> Valdesoiro,L.</style></author><author><style face="normal" font="Arial"> Vazquez-Ortiz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, University General Hospital, Valencia, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Oral immunotherapy for food allergy: A Spanish guideline. Egg and milk immunotherapy Spanish guide (ITEMS GUIDE). Part 2: Maintenance phase of cow milk (CM) and egg oral immunotherapy (OIT), special treatment dosing schedules. Models of dosing schedules of OIT with CM and EGG</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="518" start="508">508-518</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Avoidance diet</style></keyword><keyword><style face="normal" font="Arial"> avoidance diets</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Congresses</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> egg oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Cow's milk and egg are the most frequent causes of food allergy in the first years of life. Treatments such as oral immunotherapy (OIT) have been investigated as an alternative to avoidance diets. No clinical practice guides on the management of OIT with milk and egg are currently available. OBJECTIVES: To develop a clinical guide on OIT based on the available scientific evidence and the opinions of experts. METHODS: A review was made of studies published in the period between 1984 and June 2016, Doctoral Theses published in Spain, and summaries of communications at congresses (SEAIC, SEICAP, EAACI, AAAAI), with evaluation of the opinion consensus established by a group of experts pertaining to the scientific societies SEICAP and SEAIC. RESULTS: Recommendations have been established regarding the indications, requirements and practical aspects of the different phases of OIT, as well as special protocols for patients at high risk of suffering adverse reactions. CONCLUSIONS: A clinical practice guide is presented for the management of OIT with milk and egg, based on the opinion consensus of Spanish experts</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.05.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28676231">PM:28676231</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170705-MartorellA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170705-MartorellA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Martorell A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.05.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hiraguchi,Y.</style></author><author><style face="normal" font="Arial"> Tokuda,R.</style></author><author><style face="normal" font="Arial"> Gen,M.</style></author><author><style face="normal" font="Arial"> Shingaki,T.</style></author><author><style face="normal" font="Arial"> Yoshino,S.</style></author><author><style face="normal" font="Arial"> Kumagai,Y.</style></author><author><style face="normal" font="Arial"> Ebishima,Y.</style></author><author><style face="normal" font="Arial"> Hirayama,J.</style></author><author><style face="normal" font="Arial"> Kainuma,K.</style></author><author><style face="normal" font="Arial"> Nagao,M.</style></author><author><style face="normal" font="Arial"> Owa,K.</style></author><author><style face="normal" font="Arial"> Suehiro,Y.</style></author><author><style face="normal" font="Arial"> Fujisawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Clinical Research, Mie National Hospital, Mie, Japan; Center of Allergy and Clinical Immunology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Identification of a novel food allergen in lotus root</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lotus</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170624IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.05.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28645450">PM:28645450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170624-HiraguchiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170624-HiraguchiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170624, Hiraguchi Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.05.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nunomura,S.</style></author><author><style face="normal" font="Arial"> Ra,C.</style></author><author><style face="normal" font="Arial"> Terui,T.</style></author><author><style face="normal" font="Arial"> Okayama,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology Project Team, Nihon University School of Medicine, Tokyo, Japan; Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan; Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Disulfide-linked dimerization of the FcRgamma chain is required for positive and negative regulation of mast cell activation via FcepsilonRI</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="S43" start="S41">S41-S43</pages><volume><style face="normal" font="Arial">66S</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dimerization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.04.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629706">PM:28629706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170620-NunomuraS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170620-NunomuraS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Nunomura S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.04.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kohsaka,T.</style></author><author><style face="normal" font="Arial"> Hiragun,T.</style></author><author><style face="normal" font="Arial"> Ishii,K.</style></author><author><style face="normal" font="Arial"> Hiragun,M.</style></author><author><style face="normal" font="Arial"> Kamegashira,A.</style></author><author><style face="normal" font="Arial"> Hide,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Integrated Health Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Different hypersensitivities against homologous proteins of MGL_1304 in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mala s 8</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MGL_1304</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> Sweat</style></keyword><keyword><style face="normal" font="Arial"> Sweating</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="6" Year="2017">2017/6/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is exacerbated by sweating, and the skin of most patients with AD are resided by Malassezia (M.) fungi. Recently, MGL_1304 produced by Malasseziaglobosa was identified as the major histamine releasing antigen in human sweat. METHODS: The full length cDNA of the counterpart of MGL_1304 in Malasseziarestricta (Mala r 8), was cloned by degenerate PCR and rapid identification of cDNA ends (RACE). Recombinant MGL_1304, and its counterparts, Mala s 8 (produced by Malasseziasympodialis) and Mala r 8 were prepared, and compared in their allergenicities by dot blot analysis and histamine release tests with sera and basophils of patients with AD. RESULTS: The identities between MGL_1304 and Mala s 8, MGL_1304 and Mala r 8, and Mala s 8 and Mala r 8 were 68%, 78%, and 76%, respectively, in protein sequences. Dot blot analysis revealed that the level of IgE binding to Mala s 8 was higher than that of MGL_1304. However, histamine release tests revealed that MGL_1304 and Mala r 8 possessed higher activity than Mala s 8. In addition, the crude lysate of M. globosa showed higher histamine release ability than that of M. sympodialis. CONCLUSIONS: Patients with AD showed hypersensitivities against MGL_1304 and its homologs. However, the allergenicities of the homologs are variable and the histamine release activities may be different from the solid-phase binding activities for IgE. Sweat allergy should be carefully evaluated with biological activities of MGL_1304 and its homologs of other Malassezia fungi residing on the skin</style></abstract><notes><style face="normal" font="Arial">DA - 20170628IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.05.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28655443">PM:28655443</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170628-KohsakaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170628-KohsakaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170628, Kohsaka T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.05.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84977</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hirata,H.</style></author><author><style face="normal" font="Arial"> Yoshida,N.</style></author><author><style face="normal" font="Arial"> Tatewaki,M.</style></author><author><style face="normal" font="Arial"> Shiromori,S.</style></author><author><style face="normal" font="Arial"> Sato,K.</style></author><author><style face="normal" font="Arial"> Wakayama,T.</style></author><author><style face="normal" font="Arial"> Tokita,S.</style></author><author><style face="normal" font="Arial"> Sugiyama,K.</style></author><author><style face="normal" font="Arial"> Arima,M.</style></author><author><style face="normal" font="Arial"> Kurasawa,K.</style></author><author><style face="normal" font="Arial"> Fukuda,T.</style></author><author><style face="normal" font="Arial"> Shima,D.</style></author><author><style face="normal" font="Arial"> Fukushima,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan. Department of Rheumatology, Dokkyo Medical University, Tochigi, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Survey on the proper use of an adrenaline auto-injector in 551 Japanese outdoor workers after Hymenoptera stings</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera sting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28690032">PM:28690032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170710-HirataH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170710-HirataH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Hirata H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.06.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fukuda,K.</style></author><author><style face="normal" font="Arial"> Ishida,W.</style></author><author><style face="normal" font="Arial"> Harada,Y.</style></author><author><style face="normal" font="Arial"> Wakasa,Y.</style></author><author><style face="normal" font="Arial"> Takagi,H.</style></author><author><style face="normal" font="Arial"> Takaiwa,F.</style></author><author><style face="normal" font="Arial"> Fukushima,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of oral immunotherapy with a rice-based edible vaccine containing hypoallergenic Japanese cedar pollen allergens for treatment of established allergic conjunctivitis in mice</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cry j 1</style></keyword><keyword><style face="normal" font="Arial"> Cry j 2</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Edible vaccine</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic rice</style></keyword><keyword><style face="normal" font="Arial"> Transgenic rice seeds</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We have previously shown that prophylactic oral administration of transgenic rice seeds expressing hypoallergenic modified antigens suppressed the development of allergic conjunctivitis induced by Japanese cedar pollen. We have now investigated the efficacy of oral immunotherapy with such transgenic rice for established allergic conjunctivitis in mice. METHODS: BALB/c mice were sensitized with two intraperitoneal injections of Japanese cedar pollen in alum, challenged with pollen in eyedrops, and then fed for 16 days with transgenic rice seeds expressing modified Japanese cedar pollen allergens Cry j 1 and Cry j 2 or with nontransgenic rice seeds as a control. They were then challenged twice with pollen in eyedrops, with clinical signs being evaluated at 15 min after the first challenge and the eyes, blood, spleen, and lymph nodes being isolated at 24 h after the second challenge. RESULTS: The number of eosinophils in the conjunctiva and the clinical score for conjunctivitis were both significantly lower in mice fed the transgenic rice than in those fed nontransgenic rice. Oral vaccination with transgenic rice seeds also resulted in a significant increase in the production of IFN-gamma by splenocytes, whereas it had no effect on the number of CD4+CD25+Foxp3+ regulatory T cells in the spleen or submandibular or mesenteric lymph nodes. CONCLUSIONS: Oral administration of transgenic rice seeds expressing hypoallergenic allergens ameliorated allergic conjunctivitis in the established setting. Such a rice-based edible vaccine is potentially both safe and effective for oral immunotherapy in individuals with allergic conjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28676431">PM:28676431</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170705-FukudaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170705-FukudaK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Fukuda K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Skaaby,T.</style></author><author><style face="normal" font="Arial"> Taylor,A.E.</style></author><author><style face="normal" font="Arial"> Thuesen,B.H.</style></author><author><style face="normal" font="Arial"> Jacobsen,R.K.</style></author><author><style face="normal" font="Arial"> Friedrich,N.</style></author><author><style face="normal" font="Arial"> Mollehave,L.T.</style></author><author><style face="normal" font="Arial"> Hansen,S.</style></author><author><style face="normal" font="Arial"> Larsen,S.C.</style></author><author><style face="normal" font="Arial"> Volker,U.</style></author><author><style face="normal" font="Arial"> Nauck,M.</style></author><author><style face="normal" font="Arial"> Volzke,H.</style></author><author><style face="normal" font="Arial"> Hansen,T.</style></author><author><style face="normal" font="Arial"> Pedersen,O.</style></author><author><style face="normal" font="Arial"> Jorgensen,T.</style></author><author><style face="normal" font="Arial"> Paternoster,L.</style></author><author><style face="normal" font="Arial"> Munafo,M.</style></author><author><style face="normal" font="Arial"> Grarup,N.</style></author><author><style face="normal" font="Arial"> Linneberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Centre for Prevention and Health, Centre for Health, Capital Region of Denmark, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Estimating the causal effect of body mass index on hay fever, asthma, and lung function using Mendelian randomization</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> forced vital capacity</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Mendelian Randomization</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> reverse causation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Observational studies have shown that body mass index (BMI) is positively associated with asthma. However, observational data are prone to confounding and reverse causation. In Mendelian randomization, genetic variants are used as un-confounded markers of exposures to examine causal effects. We examined the causal effect of BMI on asthma, hay fever, allergic sensitization, serum total immunoglobulin E (IgE), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC). METHODS: We included 490,497 participants in the observational and 162,124 participants in the genetic analyses. A genetic risk score (GRS) was created using 26 BMI-associated single nucleotide polymorphisms (SNPs). Results were pooled in meta-analyses and expressed as odds ratios (ORs) or beta-estimates with 95% confidence interval (CI). RESULTS: The GRS was significantly associated with asthma (OR=1.009; 95% CI: 1.004, 1.013), but not with hay fever (OR= 0.998; 95% CI: 0.994, 1.002), or allergic sensitization (OR=0.999; 95% CI: 0.986, 1.012) per BMI-increasing allele. The GRS was significantly associated with decrease in FEV1: beta=-0.0012 (95% CI: -0.0019, -0.0006) and FVC: beta=-0.0022 (95% CI: -0.0031, -0.0014) per BMI-increasing allele. Effect sizes estimated by instrumental variable analyses were OR=1.07 (95% CI: 1.03, 1.10) for asthma, a 9 ml decrease in FEV1 (95% CI: 2.0-15 ml decrease), and a 16 ml decrease in FVC (95% CI: 7.0-24 ml decrease) per 1 kg/m2 higher BMI. CONCLUSIONS: The results support the conclusion that increasing BMI is causally related to higher prevalence of asthma and decreased lung function, but not with hay fever or biomarkers of allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28675761">PM:28675761</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170704-SkaabyT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170704-SkaabyT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Skaaby T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13242</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pfaar,O.</style></author><author><style face="normal" font="Arial"> Lang,S.</style></author><author><style face="normal" font="Arial"> Pieper-Furst,U.</style></author><author><style face="normal" font="Arial"> Astvatsatourov,A.</style></author><author><style face="normal" font="Arial"> Gerich,F.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Kramer,M.F.</style></author><author><style face="normal" font="Arial"> Reydelet,Y.</style></author><author><style face="normal" font="Arial"> Shah-Hosseini,K.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Universitatsmedizin Mannheim, Heidelberg University, Mannheim, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid A</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Preseasonal</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> RQLQ</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A relevant proportion of allergic rhinitis (AR) patients experience recurrent symptoms after successfully completing allergen immunotherapy (AIT). This prospective, controlled, non-interventional study used internationally standardised instruments to determine the clinical effects of a preseasonal, ultra-short-course booster AIT on clinical outcome parameters. METHODS: This two-arm study included patients aged >/=12 years with recurrent grass pollen-induced seasonal AR who had completed a successful course of any grass pollen AIT at least five years before enrolment. Overall, 56 patients received one preseasonal short-course booster AIT using tyrosine-absorbed grass pollen allergoids containing the adjuvant monophosphoryl lipid A (MPL(R) ); 51 control patients received symptomatic medication. The combined symptom and medication score (CSMS) was recorded in the (peak) grass pollen season. Furthermore, concomitant (antiallergic) medication use, the patients'state of health, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) results, and safety/tolerability of the treatment were assessed. RESULTS: The CSMS in the peak grass pollen season was significantly lower in the booster AIT group (Delta=38.4%, P&lt;0.01). Moreover, significantly more patients in this group used no concomitant antiallergic medication throughout the peak grass pollen season. Twice as many patients in the booster AIT group as in the control group reported having a better state of health than in the preceding season. RQLQ results showed significant differences favouring the booster AIT. The booster AIT was generally well tolerated, with only 2 patients reporting mild, grade 1 systemic adverse events. CONCLUSION: Booster AIT using tyrosine-absorbed allergoids containing the adjuvant MPL(R) effectively prevents re-occurrence of symptoms in patients with grass pollen-induced AR. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13240</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28675499">PM:28675499</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170704-PfaarO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170704-PfaarO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Pfaar O</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13240</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jappe,U.</style></author><author><style face="normal" font="Arial"> Minge,S.</style></author><author><style face="normal" font="Arial"> Kreft,B.</style></author><author><style face="normal" font="Arial"> Ludwig,A.</style></author><author><style face="normal" font="Arial"> Przybilla,B.</style></author><author><style face="normal" font="Arial"> Walker,A.</style></author><author><style face="normal" font="Arial"> Varga,R.</style></author><author><style face="normal" font="Arial"> Seidel,P.</style></author><author><style face="normal" font="Arial"> Biedermann,T.</style></author><author><style face="normal" font="Arial"> Anemuller,W.</style></author><author><style face="normal" font="Arial"> Kromminga,A.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author><author><style face="normal" font="Arial"> Merk,H.</style></author><author><style face="normal" font="Arial"> Wagner,N.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Waldmann,I.</style></author><author><style face="normal" font="Arial"> Saloga,J.</style></author><author><style face="normal" font="Arial"> Becker,W.M.</style></author><author><style face="normal" font="Arial"> Goldmann,T.</style></author><author><style face="normal" font="Arial"> Platts-Mills,T.A.</style></author><author><style face="normal" font="Arial"> Homann,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical and Molecular Allergology, Priority Research Area Asthma &amp; Allergy, Research Center Borstel, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Borstel, GermanyInterdisciplinary Allergy Division, Dept. of Internal Medicine, University of Lubeck, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Meat allergy associated with alpha-Gal - Closing diagnostic gaps by anti-alpha-Gal IgE immune profiling</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cetuximab</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glycolipids</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> singleplex</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Thyroglobulin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Glycoproteins and glycolipids of some mammalian species contain the disaccharide galactosyl-alpha-(1,3)-galactose (alpha-Gal). It is known that alpha-Gal is immunogenic in humans and causes glycan-specific IgG and also IgE responses with clinical relevance. alpha-Gal is part of the IgE-reactive monoclonal therapeutic antibody cetuximab and is associated with delayed anaphylaxis to red meat. In this study, different alpha-Gal-containing analytes are examined in singleplex and multiplex assays to resolve individual sensitization patterns with IgE against alpha-Gal. METHODS: Three serum groups, alpha-Gal-associated meat allergy (MA) patients, idiopathic anaphylaxis (IA) patients with suspected meat allergy and non-meat-allergic healthy control individuals (HC), were analyzed via singleplex allergy diagnostics and a newly established immunoblot diagnostic system. The new dot blot detection system resolved individual IgE sensitization profiles for alpha-Gal-containing analytes cetuximab, bovine thyroglobulin and HSA-conjugated alpha-Gal. RESULTS: Singleplex allergy diagnostics using the alpha-Gal-analytes cetuximab and bovine thyroglobulin confirms the history of meat allergy patients in 91% and 88% of the cases, respectively. A novel dot-blot-based assay system for the detection of IgE against alpha-Gal reveals individual IgE sensitization profiles for alpha-Gal-containing analytes. An alpha-Gal-associated IgE cross-reactivity profile (IgE against cetuximab, bovine thyroglobulin and HSA-alpha-Gal) was identified, which is associated with meat allergy. CONCLUSIONS: Detection of individual sensitization patterns with different alpha-Gal-containing analytes provides the basis for an individual allergy diagnosis for alpha-Gal sensitized patients. Higher amounts of alpha-Gal in pork and beef innards compared to muscle meat as indicated by a higher staining intensity are a plausible explanation for the difference in allergic symptom severity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170703IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13238</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670695">PM:28670695</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170703-JappeU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170703-JappeU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Jappe U</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13238</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lawson,K.</style></author><author><style face="normal" font="Arial"> Bahnson,H.T.</style></author><author><style face="normal" font="Arial"> Brittain,E.</style></author><author><style face="normal" font="Arial"> Sever,M.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author><author><style face="normal" font="Arial"> Keet,C.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Fleischer,D.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Stukus,D.</style></author><author><style face="normal" font="Arial"> Gupta,R.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Rho Federal Systems Division, Chapel Hill, NC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Letter of response to Greenhawt et al. 'LEAPing Through the Looking Glass: Secondary Analysis of the Effect of Skin Test Size and Age of Introduction on Peanut Tolerance after Early Peanut Introduction'</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="1271" start="1267">1267-1271</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glass</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - LetterCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28691223">PM:28691223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\2017-72-1267-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\2017-72-1267-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Lawson K</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13127</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larsen,L.F.</style></author><author><style face="normal" font="Arial"> Juel-Berg,N.</style></author><author><style face="normal" font="Arial"> Hansen,K.S.</style></author><author><style face="normal" font="Arial"> Mills,E.N.C.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Poulsen,L.K.</style></author><author><style face="normal" font="Arial"> Jensen,B.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Clinic, Copenhagen University Hospital Gentofte, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">A comparative study on basophil activation test, histamine release assay and passive sensitization histamine release assay in the diagnosis of peanut allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> histamine release assay</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> passive sensitization</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy can be diagnosed using basophil tests. Several methods measuring basophil activation are available. This study aimed at comparing basophil activation test (BAT), histamine release assay (HR) and passive sensitization histamine release assay (passive HR) in the diagnosis of peanut allergy. METHODS: BAT, HR, and passive HR were performed on eleven peanut allergic and fourteen non-allergic subjects. Blood was incubated with peanut extract or anti-IgE and tests performed as follows:</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United Kingdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13243</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686296">PM:28686296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170707-LarsenLF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170707-LarsenLF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Larsen LF</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13243</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yepes-Nunez,J.J.</style></author><author><style face="normal" font="Arial"> Brozek,J.L.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Pawankar,R.</style></author><author><style face="normal" font="Arial"> Cuello-Garcia,C.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Morgano,G.P.</style></author><author><style face="normal" font="Arial"> Agarwal,A.</style></author><author><style face="normal" font="Arial"> Gandhi,S.</style></author><author><style face="normal" font="Arial"> Terracciano,L.</style></author><author><style face="normal" font="Arial"> Schunemann,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Epidemiology &amp; Biostatistics, McMaster University, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D supplementation in primary allergy prevention: systematic review of randomized and non-randomized studies</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: To date, a systematic review of the evidence regarding the association between Vitamin D and allergic diseases development has not yet been undertaken. OBJECTIVE: To review the efficacy and safety of Vitamin D supplementation when compared to no supplementation in pregnant women, breastfeeding women, infants and children for the prevention of allergies. METHODS: Three databases were searched through 30 January 2016 including randomized (RCT) and non-randomized studies (NRS). Two reviewers independently extracted data and assessed the certainty in the body of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Among the 1932 articles identified, one RCT and four NRS were eligible. Very low certainty in the body of evidence across examined studies suggests that Vitamin D supplementation for pregnant women, breastfeeding women and infants may not decrease the risk of developing allergic diseases such as atopic dermatitis (in pregnant women), allergic rhinitis (in pregnant women, and infants), asthma and/or wheezing (in pregnant women, breastfeeding women, and infants), or food allergies (in pregnant women). We found no studies of primary prevention of allergic diseases in children. CONCLUSION: Limited information is available addressing primary prevention of allergic diseases after Vitamin D supplementation and its potential impact remains uncertain. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -CO - Colombia -CO - Vatican City -CO - Japan -CO - Mexico -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13241</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28675776">PM:28675776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170704-YepesNunezJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170704-YepesNunezJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Yepes-Nunez JJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13241</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stoevesandt,J.</style></author><author><style face="normal" font="Arial"> Hosp,C.</style></author><author><style face="normal" font="Arial"> Kerstan,A.</style></author><author><style face="normal" font="Arial"> Trautmann,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Venereology, and Allergology, University Hospital Wurzburg, Josef-Schneider-Strasse 2, 97080 Wurzburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Safety of 100 microg venom immunotherapy rush protocols in children compared to adults</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="32">32-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> sting-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is a paucity of studies examining the safety of venom immunotherapy (VIT) in children. We aimed to assess the incidence of anaphylactic side effects during rush VIT in a cohort of pediatric patients and adult controls. METHODS: 72 consecutive cycles of VIT-buildup in 71 children/adolescents aged 7-17 years were retrospectively evaluated and compared to an adult control group (n = 981) with regard to baseline parameters (sex, causative venom, severity of index sting reaction, results of allergy testing, comorbidities) and the incidence of anaphylactic adverse reactions. RESULTS: Compared to adults, severe index sting-induced anaphylaxis was significantly less common in children (P = .001). Children were more likely to suffer from bee venom allergy (P &lt; .001) and showed higher levels of bee venom-specific IgE (P = .013), but lower serum tryptase concentrations (P = .014). The overall rate of VIT-induced anaphylactic reactions was higher in children than in adults (6.9% vs 2.5%, P = .046 by univariate analysis). In the final binary logistic regression model, however, only bee VIT (P = .039; odds ratio 2.25; confidence interval 1.04-4.87) and 5-day compared to 3-day buildup protocols (P = .011; odds ratio 2.64; confidence interval 1.25-5.57) were associated with an increased risk of treatment-induced anaphylaxis. All pediatric patients finally reached and tolerated the target maintenance dose of 100 microg. CONCLUSIONS: The higher anaphylactic reaction rate observed in pediatric patients may be attributed to a greater prevalence of bee venom allergy. VIT-induced anaphylaxis in children is usually mild and does not affect further updosing and maintenance of VIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0204-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28706538">PM:28706538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Stoevesandt J</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0204-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jeong,K.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Ahn,K.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Min,T.K.</style></author><author><style face="normal" font="Arial"> Pyun,B.Y.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Kim,K.W.</style></author><author><style face="normal" font="Arial"> Sohn,M.H.</style></author><author><style face="normal" font="Arial"> Kim,K.E.</style></author><author><style face="normal" font="Arial"> Jang,G.C.</style></author><author><style face="normal" font="Arial"> Song,T.W.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Jeon,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,Y.J.</style></author><author><style face="normal" font="Arial"> Park,Y.M.</style></author><author><style face="normal" font="Arial"> Yum,H.Y.</style></author><author><style face="normal" font="Arial"> Kim,H.H.</style></author><author><style face="normal" font="Arial"> Kim,W.K.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Age-Based Causes and Clinical Characteristics of Immediate-Type Food Allergy in Korean Children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="430" start="423">423-430</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Korean children</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> pine nut</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimps</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Age-based causes and clinical characteristics of immediate-type food allergy (FA) have not been sufficiently studied. Therefore, we investigated age-dependent clinical profiles of FA in Korean children through an extensive multicenter investigation. METHODS: Using a case report form developed by the authors, a retrospective medical record review was performed of patients (0-18 years old) diagnosed with immediate-type FA between September 2014 and August 2015 in 14 tertiary hospitals in Korea. RESULTS: A total of 1,353 children and adolescents, 93% younger than 7 years, were enrolled in the present study, and 1,661 cases of immediate-type FA were recorded in these patients. The 7 major causative foods were cow's milk (28.1%), hen's eggs (27.6%), wheat (7.9%), walnuts (7.3%), peanuts (5.3%), buckwheat (1.9%), and shrimps (1.9%). Categorizing the patients into 4 age groups revealed that the most common causative food was different for each age group: cow's milk (&lt;2 years), walnuts (2-6 years), walnuts (7-12 years), and buckwheat (13-18 years). The onset time of symptoms was less than 10 minutes in 49%, between 10 and 30 minutes in 17%, and between 30 minutes and 2 hours in 34% of cases. Food-induced anaphylaxis was reported in 506 (30.5%) out of 1,661 cases, and the 7 major causes of food-induced anaphylaxis was cow's milk (27.5%), hen's eggs (21.9%), wheat (11.3%), walnuts (10.5%), peanuts (5.9%), buckwheat (4.2%), and pine nuts (3.0%). The proportion of anaphylaxis was highest in the patients allergic to buckwheat (67.7%), followed by those allergic to pine nuts (57.7%), walnuts (43.8%), wheat (43.5%), and peanuts (34.1%). CONCLUSIONS: The 5 major causative foods of immediate-type FA in Korean children were cow's milk, hen's eggs, wheat, walnuts, and peanuts. The distribution of causative foods was considerably distinctive according to different age groups. Anaphylaxis was reported in 30.5% of immediate-type FA cases</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.5.423</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677356">PM:28677356</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-423-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-423-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Jeong K</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.5.423</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jeong,K.Y.</style></author><author><style face="normal" font="Arial"> Park,K.H.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Monoclonal Antibodies to Recombinant Fag e 3 Buckwheat Allergen and Development of a Two-site ELISA for Its Quantification</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="422" start="417">417-422</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Fag e 3</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vicilin</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Buckwheat is a major cause of anaphylaxis, and Fag e 3 is the key major allergen in buckwheat. However, an immunoassay system for the quantification of Fag e 3 has yet to be developed. METHODS: We developed a 2-site enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies (mAbs) produced against recombinant Fag e 3. We applied this ELISA to quantify native Fag e 3 in total buckwheat extract. RESULTS: Four clones of mAbs were produced, and all recognized vicilin allergens not only from buckwheat, but also from peanut and walnut. However, the ELISA using these antibodies was only able to quantify Fag e 3 in the total extract after addition of 1% sodium dodecyl sulphate (SDS) and heating, which facilitated dissociation of the allergen. The detection limit of the developed 2-site ELISA was 0.8 mug/mL. The measurement of Fag e 3 in the total extract of buckwheat showed that approximately 12% of protein in total buckwheat extract was Fag e 3. CONCLUSIONS: We have developed an ELISA system for the quantification of the group 3 buckwheat allergen, Fag e 3, specifically. This assay will be useful for standardization of buckwheat allergens and monitoring of buckwheat contamination in foods</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.5.417</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677355">PM:28677355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-417-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-417-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Jeong KY</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.5.417</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,M.</style></author><author><style face="normal" font="Arial"> Lee,J.Y.</style></author><author><style face="normal" font="Arial"> Jeon,H.Y.</style></author><author><style face="normal" font="Arial"> Yang,H.K.</style></author><author><style face="normal" font="Arial"> Lee,K.J.</style></author><author><style face="normal" font="Arial"> Han,Y.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Ahn,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of Immediate-Type Food Allergy in Korean Schoolchildren in 2015: A Nationwide, Population-based Study</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="416" start="410">410-416</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Buckwheat</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food groups</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">PURPOSE: This study aimed to determine the prevalence of immediate-type food allergy (FA) among schoolchildren in Korea. METHODS: A nationwide, cross-sectional study was performed in September 2015. A stratified random sample of 50,000 participants was selected from children and adolescents aged 6-7 years (n=17,500), 9-10 years (n=17,500), 12-13 years (n=7,500), and 15-16 years (n=7,500). Parents were asked to complete a questionnaire on the detailed history of immediate-type FA. RESULTS: A total of 32,001 (64.0%) responded to the questionnaire survey, and 29,842 children (59.7%) were analyzed after adjusting for missing data. The number of the cases in each age group was 9,671 (6-7 years), 9,756 (9-10 years), 5,169 (12-13 years), and 5,246 (15-16 years). The prevalence of lifetime perceived FA was 15.82%. The prevalence of current immediate-type FA was 4.06% in total, with 3.15% in 6- to 7-year-olds, 4.51% in 9- to 10-year-olds, 4.01% in 12- to 13-year-olds, and 4.49% in 15- to 16-year-olds. Among individual food items, peanut (0.22%) was the most frequent causative food, followed by hen's egg (0.21%), cow's milk (0.18%), and buckwheat (0.13%). Among the food groups, fruits (1.41%), crustaceans (0.84%), tree nuts (0.32%), and fish (0.32%) were the most common offending foods. The prevalence of food-induced anaphylaxis was 0.97%. The most frequent causative food of anaphylaxis was peanut (0.08%), followed by cow's milk (0.07%), buckwheat (0.06%), and hen's egg (0.06%), while fruits (0.28%), crustaceans (0.18%), tree nuts (0.12%), and fish (0.09%) were the most commonly responsible food groups. CONCLUSIONS: The prevalence of current immediate-type FA and food-induced anaphylaxis in Korean schoolchildren in 2015 was 4.06% and 0.97%, respectively. Peanuts, cow's milk, hen's egg, fruits, crustaceans, and tree nuts are common allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.5.410</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677354">PM:28677354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-410-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-410-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Kim M</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.5.410</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Slawson,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Virginia Health System, Charlottesville, VA, USA</style></auth-address><titles><title><style face="normal" font="Arial">One-Third of Adults with Diagnosed Asthma Can Be Weaned Off All Asthma Medications</style></title><secondary-title><style face="normal" font="Arial">Am Fam Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am Fam Physician</style></full-title></periodical><pages end="" start="586">586-</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170703IS - 1532-0650 (Electronic)IS - 0002-838X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28671383">PM:28671383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am Fam Physician\2017-95-586.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am Fam Physician\2017-95-586.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Slawson D</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rahman,S.</style></author><author><style face="normal" font="Arial"> Walker,D.</style></author><author><style face="normal" font="Arial"> Sultan,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anaesthesia, Royal Free Hospital, Pond Street, London, UKDepartment of Anaesthesia, University College London Hospitals, London, UKDepartment of Anaesthesia, University College London Hospitals, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Medical identification or alert jewellery: an opportunity to save lives or an unreliable hindrance?</style></title><secondary-title><style face="normal" font="Arial">Anaesthesia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anaesthesia</style></full-title></periodical><pages end="1145" start="1139">1139-1145</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaesthesia</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">Medical identification jewellery can convey vital information to emergency responders, but mistakes and ambiguity may lead to misdiagnosis and morbidity. We performed a review of relevant articles retrieved from Pubmed(R) , Embase(R) and Scopus(R) and Google UK Inc. to investigate the commercial availability and issuance of these products. From 84 identified studies, we shortlisted 74 for review. The Google search retrieved 1,090,000 results within 0.57 s (January 2017). We explored 32 websites selling medical alert jewellery in the first five pages of these results. We found that patients themselves are currently responsible for the engraved wording on medical alert jewellery, with no mandatory physician checks. The accuracy and appropriateness of this information may thus vary. In the absence of national guidance in the UK, we suggest that there should be a list of specific indications warranting their use, a requirement for regular review of information, and clarity around the level of physician input into the engraving chosen. We discuss the potential benefits vs. risks of wearing medical alert jewellery and clarify the limitations of medical teams' responsibilities in relation to patients found to be wearing them</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1365-2044 (Electronic)IS - 0003-2409 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/anae.13958</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677832">PM:28677832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anaesthesia\20170705-RahmanS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anaesthesia\20170705-RahmanS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Rahman S</style></custom2><misc3><style face="normal" font="Arial">10.1111/anae.13958</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Medsker,B.H.</style></author><author><style face="normal" font="Arial"> Forno,E.</style></author><author><style face="normal" font="Arial"> Han,Y.Y.</style></author><author><style face="normal" font="Arial"> Acosta-Perez,E.</style></author><author><style face="normal" font="Arial"> Colon-Semidey,A.</style></author><author><style face="normal" font="Arial"> Alvarez,M.</style></author><author><style face="normal" font="Arial"> Alcorn,J.F.</style></author><author><style face="normal" font="Arial"> Canino,G.J.</style></author><author><style face="normal" font="Arial"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Newborn Medicine, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania</style></auth-address><titles><title><style face="normal" font="Arial">Cockroach allergen exposure and plasma cytokines among children in a tropical environment</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="70" start="65">65-70</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody arrays</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> dog dander</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-21</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Puerto Rican</style></keyword><keyword><style face="normal" font="Arial"> Puerto Rico</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> School-age children</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Little is known about the effects of socioeconomic status or cockroach allergen on immune responses in school-age children, particularly in tropical environments. OBJECTIVE: To examine whether cockroach allergen and/or socioeconomic status is associated with plasma cytokine levels in Puerto Rican children. METHODS: This was a cross-sectional study of 532 children (6-14 years old) with (n = 272) and without (n = 260) asthma in San Juan (Puerto Rico). House dust allergens (cockroach [Bla g 2], dust mite [Der p 1], cat dander [Fel d 1], dog dander [Can f 1], and mouse urinary protein [Mus m 1]) were quantified using monoclonal antibody arrays. A panel of 14 cytokines (interleukin [IL]-1beta, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, interferon-gamma, and tumor necrosis factor-alpha) was measured in plasma samples. Low household income was defined as less than $15,000 per year (below the median income for Puerto Rico in 2008-2009). Linear regression was used for the analysis of cockroach allergen and plasma cytokines. RESULTS: In a multivariable analysis adjusting for low income and other allergen levels, cockroach allergen was significantly associated with decreased IL-17A and with increased levels of 8 cytokines (IL-4, IL-10, IL-17F, IL-21, IL-25, IL-31, interferon-gamma, and tumor necrosis factor-alpha). After stratifying this analysis by cockroach allergy (ie, having a cockroach positive immunoglobulin E reaction), our findings remained largely unchanged for children sensitized to cockroach but became weaker and statistically nonsignificant for non-sensitized children. CONCLUSION: Cockroach allergen has broad effects on adaptive immune responses in school-age children in a tropical environment, particularly in those sensitized to cockroach</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.05.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668242">PM:28668242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-65-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-65-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Medsker BH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.05.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baba,S.</style></author><author><style face="normal" font="Arial"> Kondo,K.</style></author><author><style face="normal" font="Arial"> Suzukawa,M.</style></author><author><style face="normal" font="Arial"> Ohta,K.</style></author><author><style face="normal" font="Arial"> Yamasoba,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Distribution, subtype population, and IgE positivity of mast cells in chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="128" start="120">120-128</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> chymase</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell protease</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) has been categorized into 2 subtypes in the Asian population: eosinophilic chronic rhinosinusitis (ECRS; similar to CRSwNP in Western countries) and non-ECRS (characterized by inflammation dominated by T-helper cell type 1). The pathogenesis of CRSwNP and the role of mast cells are poorly understood. OBJECTIVE: To investigate the distribution, phenotypes, and immunoglobulin E (IgE) positivity of mast cells in these 2 subtypes of CRSwNP. METHODS: We collected nasal tissue from patients with CRSwNP and control subjects. The mRNA for mast cell proteases tryptase and chymase was measured using real-time polymerase chain reaction, and the distribution of each type of protease-positive mast cell was examined using immunohistochemistry and immunofluorescence. IgE distribution on mast cells was determined using double-immunofluorescent staining for IgE and tryptase. RESULTS: Expression of tryptase mRNA was significantly increased in nasal polyps from patients with the 2 subtypes of CRSwNP compared with controls. Immunohistochemistry showed increased numbers of tryptase-positive mast cells in the epithelium, glands, and submucosa of ECRS polyps, whereas the number of tryptase- and chymase-positive mast cells was increased in the glands and submucosa of non-ECRS polyps. IgE-positive mast cells were abundant in the epithelial, glandular, and submucosal regions of ECRS polyps but few were detected in non-ECRS polyps. CONCLUSION: The present study demonstrates that the distribution, subtype population, and IgE positivity of mast cells is different between ECRS and non-ECRS nasal polyps. Our results suggest a role for IgE-mediated mast cell activation in the pathogenesis of ECRS</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.05.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634018">PM:28634018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170621-BabaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170621-BabaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170621, Baba S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.05.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia-Granero,D.B.</style></author><author><style face="normal" font="Arial"> Vera,D.G.</style></author><author><style face="normal" font="Arial"> Grande,C.</style></author><author><style face="normal" font="Arial"> Jimenez,R.B.</style></author><author><style face="normal" font="Arial"> Rodriguez,C.F.</style></author><author><style face="normal" font="Arial"> Bobolea,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">AllergyDepartment, Hospital 12 de octubre Institute for Health Research (i + 12), Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Modern challenges of allergic bronchopulmonary aspergillosis diagnosis and management: Finding from a case study with a history of rituximab use</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="94" start="93">93-94</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.05.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668248">PM:28668248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-93-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-93-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Garcia-Granero DB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.05.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sokol,W.N.</style></author><author><style face="normal" font="Arial"> Wunschmann,S.</style></author><author><style face="normal" font="Arial"> Agah,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Allergy, Asthma and Immunology, University of California at Irvine, Irvine, California.</style></auth-address><titles><title><style face="normal" font="Arial">Grasshopper anaphylaxis in patients allergic to dust mite, cockroach, and crustaceans: Is tropomyosin the cause?</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="92" start="91">91-92</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.05.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668247">PM:28668247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-91-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-91-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Sokol WN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.05.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bozek,A.</style></author><author><style face="normal" font="Arial"> Starczewska-Dymek,L.</style></author><author><style face="normal" font="Arial"> Jarzab,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="82" start="77">77-82</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly patients</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prolonged effect of allergen immunotherapy is unknown, especially in older patients. OBJECTIVE: To analyze the 3-year effect of sublingual allergen-specific immunotherapy (SLIT) to house dust mites in elderly patients with allergic rhinitis. METHODS: Forty-seven elderly patients (65.78 +/- 4.89 years old) underwent SLIT to house dust mites and were monitored for 3 years and compared with a placebo group. SLIT was performed with the use of oral Staloral 300 SR Der p and Der f 50/50% extract (Stallergens Greer, London, United Kingdom) or placebo. Symptoms and medication score, represented by the average adjusted symptom score (AAdSS), serum level of immunoglobulin (Ig) G4 to Dermatophagoides pteronyssinus, Dermatophagoides farinae, Der p 1, and Der p 2, and quality of life, were assessed immediately after SLIT and 3 years later. RESULTS: The AAdSS was significantly decreased after SLIT, and the level remained low during the 3 years after SLIT compared with placebo. Serum-specific IgG4 against D pteronyssinus, D farinae, Der p 1, and Der p 2 increased during the SLIT trial in the study group. For the 3 years of observation after SLIT, there were no significant changes of specific IgG4 levels against the analyzed allergens compared with results just after SLIT. Quality of life based on the Rhinoconjunctivitis Quality of Life Questionnaire score was significantly decreased in patients who received SLIT, from 1.48 (95% confidence interval 1.33-1.79) to 0.98 (95% confidence interval 0.67-1.07; P &lt; .05) compared with 0.94 (95% confidence interval 0.55-1.04) 3 years after SLIT. CONCLUSION: The prolonged positive effect after SLIT to house dust mites was observed in elderly patients with allergic rhinitis. Further trials are needed to confirm this effect. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01605760</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.05.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668244">PM:28668244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-77-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-77-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Bozek A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.05.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pesek,R.D.</style></author><author><style face="normal" font="Arial"> Rettiganti,M.</style></author><author><style face="normal" font="Arial"> O'Brien,E.</style></author><author><style face="normal" font="Arial"> Beckwith,S.</style></author><author><style face="normal" font="Arial"> Daniel,C.</style></author><author><style face="normal" font="Arial"> Luo,C.</style></author><author><style face="normal" font="Arial"> Scurlock,A.M.</style></author><author><style face="normal" font="Arial"> Chandler,P.</style></author><author><style face="normal" font="Arial"> Levy,R.A.</style></author><author><style face="normal" font="Arial"> Perry,T.T.</style></author><author><style face="normal" font="Arial"> Kennedy,J.L.</style></author><author><style face="normal" font="Arial"> Chervinskiy,S.</style></author><author><style face="normal" font="Arial"> Vonlanthen,M.</style></author><author><style face="normal" font="Arial"> Casteel,H.</style></author><author><style face="normal" font="Arial"> Fiedorek,S.C.</style></author><author><style face="normal" font="Arial"> Gibbons,T.</style></author><author><style face="normal" font="Arial"> Jones,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Arkansas Children's Hospital and University of Arkansas for Medical Sciences, Little Rock, Arkansas.</style></auth-address><titles><title><style face="normal" font="Arial">Effects of allergen sensitization on response to therapy in children with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="183" start="177">177-183</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arkansas</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental allergies</style></keyword><keyword><style face="normal" font="Arial"> environmental allergy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disorders</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Southeastern United States</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In children with eosinophilic esophagitis (EoE) foods are the most common disease triggers, but environmental allergens are also suspected culprits. OBJECTIVE: To determine the effects of environmental allergen sensitization on response to treatment in children with EoE in the southeastern United States. METHODS: Patients 2 to 18 years old who were referred to the Arkansas Children's Hospital Eosinophilic Gastrointestinal Disorders Clinic from January 2012 to January 2016 were enrolled in a prospective, longitudinal cohort study with collection of demographics, clinical symptoms, medical history, allergy sensitization profiles, and response to treatment over time. Comparisons were made between complete responders (peak esophageal eosinophil count &lt;15 per high-power field [HPF]) and nonresponders (>25 eosinophils per HPF) after treatment with diet elimination alone, swallowed corticosteroids alone, or diet elimination and swallowed corticosteroids. Sensitization patterns to environmental allergens found in the southeastern United States were analyzed for the effect on treatment response. RESULTS: A total of 223 individuals were enrolled. Of these, 182 had environmental allergy profiling and at least one endoscopy while receiving proton pump inhibitor (PPI) therapy. Twenty-nine individuals had PPI-responsive EoE and were excluded from further analysis, leaving 123 individuals with non-PPI-responsive EoE who were further analyzed; 72 (58.5%) were complete responders and 33 (26.8%) were nonresponders. Seventeen individuals (13.8%) were partial responders (>/=1 but &lt;/=25 eosinophils per HPF) and excluded from further analysis. Nonresponders were more likely to be sensitized to perennial allergens (P = .02). There was no significant difference in response based on seasonal allergen sensitization. Individuals with mold or cockroach sensitization were more likely to fail combination diet and swallowed corticosteroid treatment (P = .02 and P = .002). CONCLUSION: Perennial allergen and mold sensitization may lead to nonresponse to EoE treatment in some patients. Additional studies are needed to further understand the effect of environmental allergens on EoE. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01779154</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28676207">PM:28676207</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170705-PesekRD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170705-PesekRD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Pesek RD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kubota,S.</style></author><author><style face="normal" font="Arial"> Nozawa,A.</style></author><author><style face="normal" font="Arial"> Yanai,T.</style></author><author><style face="normal" font="Arial"> Ozasa,K.</style></author><author><style face="normal" font="Arial"> Mori,S.</style></author><author><style face="normal" font="Arial"> Kurihara,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Yokohama Minami Kyousai Hospital</style></auth-address><titles><title><style face="normal" font="Arial">THE CASE OF A 14-YEAR-OLD BOY WHO EXPERIENCED ANAPHYLAXIS DUE TO JELLYFISH (MASTIGIAS PAPUA) INGESTION</style></title><secondary-title><style face="normal" font="Arial">Arerugi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arerugi</style></full-title></periodical><pages end="812" start="809">809-812</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Edible jellyfish</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> jellyfish</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Resuscitation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">We report a case of jellyfish allergy diagnosed via an oral food challenge. A 14-year-old boy had no history of jellyfish stings and had been eating commercially available jellyfish products twice yearly for the past 5-6 years. Five minutes after eating a commercially available boiled jellyfish product (100g), he experienced nausea, wheezing, and erythema and had visited our hospital. We suspected an anaphylactic reaction and treated him with intramuscular adrenaline injection, corticosteroid and antihistamine infusions, volume resuscitation, and salbutamol sulfate inhalation, which resulted in an improvement of the symptoms. One-month later in our hospital, we administered an oral food challenge of the same boiled jellyfish product bought at the same grocery store to the patient. After ingesting 14g of boiled jellyfish, he experienced erythema, wheezing, nausea, and abdominal pain. Several reports have described anaphylaxis caused by the ingestion of jellyfish, but the allergens in jellyfish have not been analyzed. A skin prick test for poly-gamma-glutamic acid (PGA) which is a component of jellyfish stings was negative. This suggests that he was sensitized to some allergen other than PGA via a route different from that of jellyfish sting. Our skin prick test for several kinds of edible jellyfish suggests that allergenicity may be different for different jellyfish</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701647">PM:28701647</url></web-urls></urls><custom2><style face="normal" font="Arial">20170713, Kubota S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suzuki,S.</style></author><author><style face="normal" font="Arial"> Miyata,Y.</style></author><author><style face="normal" font="Arial"> Jinno,M.</style></author><author><style face="normal" font="Arial"> Kishino,Y.</style></author><author><style face="normal" font="Arial"> Homma,T.</style></author><author><style face="normal" font="Arial"> Ota,S.</style></author><author><style face="normal" font="Arial"> Tanaka,A.</style></author><author><style face="normal" font="Arial"> Yokoe,T.</style></author><author><style face="normal" font="Arial"> Ohnishi,T.</style></author><author><style face="normal" font="Arial"> Sagara,H.</style></author><author><style face="normal" font="Arial"> Kurata,N.</style></author><author><style face="normal" font="Arial"> Shimakura,K.</style></author><author><style face="normal" font="Arial"> Kurose,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Division of Allergology and Respiratory Medicine, Showa University School of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">AN ADULT CASE OF ANAPHYLAXIS CAUSED BY ALLERGY TO JELLYFISH</style></title><secondary-title><style face="normal" font="Arial">Arerugi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arerugi</style></full-title></periodical><pages end="808" start="804">804-808</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Diving</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> jellyfish</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Sodium Dodecyl Sulfate</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A 35-year-old female, professional diver, reported nausea, vomiting, and systemic hives 20 to 30 minutes after ingestion of antipasto made with jellyfish. Patient reported prior episodes of swelling after stings from several different creatures, including jelly fish. She also developed a systemic allergic reaction after sting from an unknown creature while diving. On the initial visit to our hospital, serum total IgE level was 545IU/ml. We extracted crude allergen from jellyfish and evaluated allergen specific IgE antibody levels using ELISA. Patient samples showed higher levels of jellyfish-derived allergen specific IgE than healthy control samples. Basophils were isolated from the peripheral blood of patient. Stimulation with jellyfish-derived allergen showed expression of surface antigens on basophils increased in a concentration-dependent manner. Methods using sodium dodecyl sulfate poly acrylamide gel electrophoresis and immunoblotting showed acid-soluble collagen fraction from jellyfish contained above 250kDa weighed protein that may have caused this current event. A provocation test using jellyfish samples was not performed due to risk of anaphylactic shock. The patient was diagnosed with a jellyfish allergy due to IgE mediated anaphylaxis after ingestion. She was asked to refrain from consuming any food containing jellyfish. IgE-mediated food allergy caused by jellyfish is rare worldwide. Collagen was speculated to be an allergen in this study. Additional study to detect specific allergens related to jellyfish allergy would be particularly useful to specify disease phenotypes and individual care in future</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701646">PM:28701646</url></web-urls></urls><custom2><style face="normal" font="Arial">20170713, Suzuki S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>84999</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gotoh,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Nippon Medical School Tama Nagayama Hospital</style></auth-address><titles><title><style face="normal" font="Arial">GUIDE TO ALLERGEN IMMUNOTHERAPY FOR MITE ALLERGY</style></title><secondary-title><style face="normal" font="Arial">Arerugi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arerugi</style></full-title></periodical><pages end="791" start="788">788-791</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701643">PM:28701643</url></web-urls></urls><custom2><style face="normal" font="Arial">20170713, Gotoh M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85000</rec-number><ref-type name="Book, Whole">6</ref-type><contributors><authors><author><style face="normal" font="Arial">AA.VV.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food Engineering: Integrated Approaches</style></title><secondary-title><style face="normal" font="Arial">Books</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Books</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Food Technology</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food Engineering: Integrated Approaches presents an up-to-date review of important food engineering concepts, issues and recent advances in the field. Distinguished food engineers and food scientists from key institutions worldwide have contributed chapters that provide a deep analysis of their particular subjects. At the same time, each topic is framed within the context of a broader more integrated approach, demonstrating its relationship and interconnectedness to other areas. The premise of this work, therefore, is to offer both a comprehensive understanding of food engineering as a whole and a thorough knowledge of individual subjects. This approach appropriately conveys the basic fundamentals, state-of-the-art technology, and applications of the involved disciplines, and further encourages scientific collaboration among researchers. This book is mainly directed to academics, and to undergraduate and postgraduate students in food engineering, food science and food technology. Scholars will find a selection of innovative topics ranging from bubbles in food and transport phenomena in food systems to practical food processing applications at the industrial level. Professionals working in food research centers and food industries may also find this book useful.</style></abstract><notes><style face="normal" font="Arial">LA - ENG</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.springer.com/us/book/9780387754291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Books\Food Engineering Integrated Approaches.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Books\Food Engineering Integrated Approaches.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, AA.VV.</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">AA.VV.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Handbook of Food Proteins</style></title><secondary-title><style face="normal" font="Arial">Books</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Books</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Applications</style></keyword><keyword><style face="normal" font="Arial"> emulsion</style></keyword><keyword><style face="normal" font="Arial"> Emulsions</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gels</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Traditionally a source of nutrition, proteins are also added to foods for their ability to form gels and stabilise emulsions, among other properties. The range of specialised protein ingredients used in foods is increasing. Handbook of food proteins provides an authoritative overview of the characteristics, functionalities and applications of different proteins of importance to the food industry in one convenient volume.</style></abstract><notes><style face="normal" font="Arial">LA - ENG</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.sciencedirect.com/science/book/9781845697587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Books\Handbook of Food Proteins.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Books\Handbook of Food Proteins.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, AA.VV.</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,S.</style></author><author><style face="normal" font="Arial"> Qian,R.</style></author><author><style face="normal" font="Arial"> Wang,S.</style></author><author><style face="normal" font="Arial"> Ye,J.</style></author><author><style face="normal" font="Arial"> Zheng,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China</style></auth-address><titles><title><style face="normal" font="Arial">Identification of IgE and IgG1 specific antigens in Echinococcus granulosus cyst fluid</style></title><secondary-title><style face="normal" font="Arial">Braz J Med Biol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Med Biol Res</style></full-title></periodical><pages end="" start="e6071">e6071-</pages><volume><style face="normal" font="Arial">50</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2-DE</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cystic echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Echinococcus</style></keyword><keyword><style face="normal" font="Arial"> Echinococcus granulosus</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Two dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="Arial">Cystic echinococcosis (CE) is an anthropozoonotic disease with worldwide distribution and is caused by the cestode Echinococcus granulosus. Anaphylactic shock induced by CE rupture is a serious complication especially in patients with hydatid infections, as the resulting leakage of fluid contains highly toxic endogenous antigen. We aimed to isolate and identify the antigens of specific IgE and IgG1 (sIgE and sIgG1) in E. granulosus cyst fluid (EgCF). Crude antigen for EgCF was prepared from E. granulosus-infected sheep liver. Antigens were separated and identified by one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (1D SDS-PAGE), two-dimensional gel electrophoresis (2-DE), and immunoblotting. Results of 1D SDS-PAGE and immunoblotting showed that 40.5 kDa protein was the major antigen of sIgE, and 35.5 kDa protein was the major antigen of sIgG1 in EgCF. Results of 2-DE and immunoblotting showed that main antigens of sIgE in EgCF were four proteins with pI values ranging from 6.5 to 9.0 and a molecular weight of 40.5 kDa. Main antigens of sIgG1 in EgCF were five proteins with pI values ranging from 6.5 to 9.0 and a molecular weight of 35.5 kDa. The antigens identified for sIgE and sIgG1 can provide critical insights into cellular and molecular mechanisms underlying anaphylactic shock induced by CE</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1414-431X (Electronic)IS - 0100-879X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1590/1414-431x20176071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28678921">PM:28678921</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Med Biol Res\2017-50-e6071.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Med Biol Res\2017-50-e6071.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Li S</style></custom2><misc3><style face="normal" font="Arial">10.1590/1414-431x20176071</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ma,H.</style></author><author><style face="normal" font="Arial"> Guo,S.</style></author><author><style face="normal" font="Arial"> Luo,Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> He,J.</style></author><author><style face="normal" font="Arial"> Tang,J.</style></author><author><style face="normal" font="Arial"> Shen,L.</style></author><author><style face="normal" font="Arial"> Song,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Anhui Provincial Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui, China</style></auth-address><titles><title><style face="normal" font="Arial">MicroRNA-20b promotes the accumulation of CD11b+Ly6G+Ly6Clow myeloid-derived suppressor cells in asthmatic mice</style></title><secondary-title><style face="normal" font="Arial">Cent Eur J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cent Eur J Immunol</style></full-title></periodical><pages end="38" start="30">30-38</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">miR-20b is a member of the miR-106a-363 gene cluster, which has been shown to play an important role in a variety of diseases, including cancer, inflammation, and autoimmune diseases. Our previous study indicated that miR-20b has an inhibitory effect on airway inflammation in asthmatic mice, but the exact mechanism is unclear. In this study, we report that the ratio of CD11b+Ly6G+Ly6Clow cells, but not the amount of CD11b+Ly6C+Ly6G- cells, was increased in the lung tissue of asthmatic mice after intranasal instillation with miR-20b mimics, while Th2-type cytokines (interleukin (IL)-4 and IL-13) were significantly decreased in the bronchoalveolar lavage fluid. In addition, the transcription factor CREB regulated the expression of miR-20b. Our findings suggest that miR-20b can induce the accumulation of myeloid-derived suppressor cells in the lungs of asthmatic mice, which may be a mechanism by which miR-20b inhibits airway inflammation in asthmatic mice. Thus, miR-20b may be used as a target for the effective treatment of asthma in the future</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1426-3912 (Print)IS - 1426-3912 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.5114/ceji.2017.67316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28680329">PM:28680329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cent Eur J Immunol\2017-42-30-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cent Eur J Immunol\2017-42-30-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Ma H</style></custom2><misc3><style face="normal" font="Arial">10.5114/ceji.2017.67316</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jang,T.Y.</style></author><author><style face="normal" font="Arial"> Jung,A.Y.</style></author><author><style face="normal" font="Arial"> Kyung,T.S.</style></author><author><style face="normal" font="Arial"> Kim,D.Y.</style></author><author><style face="normal" font="Arial"> Hwang,J.H.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, Inha University College of Medicine, Incheon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Anti-allergic effect of luteolin in mice with allergic asthma and rhinitis</style></title><secondary-title><style face="normal" font="Arial">Cent Eur J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cent Eur J Immunol</style></full-title></periodical><pages end="29" start="24">24-29</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">AIM OF THE STUDY: We aimed to evaluate the anti-allergic effect of luteolin treatment in mice with allergic asthma and rhinitis. MATERIAL AND METHODS: Thirty-two BALB/c mice (n = 8 for each group) were used. Mice in group A (nonallergic group) were exposed to saline, while those in Group B (allergic group) were exposed to ovalbumin (OVA) intraperitoneal (i.p.) injection and intranasal (i.n.) challenge. Null treatment group (Group C) received sterile saline (150 mul) i.p. injection, 30 minutes before each i.n. challenge. Finally, the treatment group (Group D) received luteolin (0.1 mg/kg) by i.p. injection, 30 minutes before each i.n. challenge. We evaluated the number of inflammatory cells including eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage (BAL) fluid, the titers of IL-4, IL-5 and IL-13 in lung homogenate, and we also evaluated histopathologic findings, including infiltration of inflammatory cells into the pulmonary parenchyma and nasal mucosa. RESULTS: After the OVA challenge, the number of eosinophils, neutrophils and lymphocytes in BAL fluid was significantly increased in group B, compared to group A (p &lt; 0.001). Mice in group C had no significant difference (p > 0.05). On the other hand, group D showed a significant decrease in all inflammatory cells compared to group B (p &lt; 0.05). Also, group D showed a significant decrease in IL-4, IL-5 and IL-13 in their lung homogenate compared to groups B and C (p &lt; 0.05). Group D also showed a significant decrease in inflammatory cell infiltration after luteolin treatment (p &lt; 0.05). CONCLUSION: Luteolin had an anti-allergic effect in a murine model of allergic asthma and rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1426-3912 (Print)IS - 1426-3912 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5114/ceji.2017.67315</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28680328">PM:28680328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cent Eur J Immunol\2017-42-24-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cent Eur J Immunol\2017-42-24-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Jang TY</style></custom2><misc3><style face="normal" font="Arial">10.5114/ceji.2017.67315</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santos,A.F.</style></author><author><style face="normal" font="Arial"> Shreffler,W.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Allergy, King's College London/Guy's and St Thomas' Hospital, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Roadmap for the clinical application of the basophil activation test in food allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1124" start="1115">1115-1124</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Standardisation</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">The diagnosis of IgE-mediated food allergy based solely on the clinical history and the documentation of specific IgE to whole allergen extract or single allergens is often ambiguous, requiring oral food challenges (OFC), with the attendant risk and inconvenience to the patient, to confirm the diagnosis of food allergy. This is a considerable proportion of patients assessed in Allergy clinics. The basophil activation test (BAT) has emerged as having superior specificity and comparable sensitivity to diagnose food allergy, when compared with skin prick test and specific IgE. BAT, therefore, may reduce the number of OFC required for accurate diagnosis, particularly positive OFC. BAT can also be used to monitor resolution of food allergy and the clinical response to immunomodulatory treatments. Given the practicalities involved in the performance of BAT, we propose that it be applied for selected cases where the history, skin prick test and/or specific IgE are not definitive for the diagnosis of food allergy. In the cases that the BAT is positive, food allergy is sufficiently confirmed without OFC; in the cases that BAT is negative or the patient has non-responder basophils, OFC may still be indicated. However, broad clinical application of BAT demands further standardisation of the laboratory procedure and of the flow cytometry data analyses, as well as clinical validation of BAT as a diagnostic test for multiple target allergens and confirmation of its feasibility and cost-effectiveness in multiple settings. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170615IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12964</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28618090">PM:28618090</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170615-SantosAF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170615-SantosAF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170615, Santos AF</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12964</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pfaar,O.</style></author><author><style face="normal" font="Arial"> Hohlfeld,J.M.</style></author><author><style face="normal" font="Arial"> Al-Kadah,B.</style></author><author><style face="normal" font="Arial"> Hauswald,B.</style></author><author><style face="normal" font="Arial"> Homey,B.</style></author><author><style face="normal" font="Arial"> Hunzelmann,N.</style></author><author><style face="normal" font="Arial"> Schliemann,S.</style></author><author><style face="normal" font="Arial"> Velling,P.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, Universitatsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Dose-response relationship of a new Timothy grass pollen allergoid in comparison to a 6-grass pollen allergoid</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> Late phase reaction</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> optimal dose</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Preseasonal</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Subcutaneous allergen immunotherapy with grass pollen allergoids has been proven to be effective and safe in the treatment of patients with allergic rhinoconjunctivitis. Based on the extensive cross-reactivity among Pooideae species, it has been suggested that grass pollen extracts could be prepared from a single species, rather than from a multiple species mixture. OBJECTIVE: To find the optimal dose of a Phleum pratense allergoid preparation and compare its efficacy and safety to a 6-grass pollen allergoid preparation. METHODS: In this double-blind, placebo-controlled study (EudraCT: 2011-000674-58), 3 doses of Phleum pratense allergoid (1800 Therapeutic Units (TU), standard dose 6000 TU, and 18000 TU) were compared with placebo and the marketed 6-grass pollen allergoid (6000 TU). In a preseasonal dosing regimen, 102 patients were randomized to 5 treatment groups and received 9 subcutaneous injections. The primary efficacy endpoint was the change in wheal size (late phase reaction, LPR) in response to the intracutaneous testing (ICT) before and after treatment, comparing the active allergoids to placebo. Secondary outcomes were the change in Total Nasal Symptom Score (TNSS) assessed in the allergen exposure chamber (AEC), the changes in Phleum pratense-serum specific IgG4 , and the incidence of adverse events (AEs). RESULTS: All 3 doses of the Phleum pratense and the 6-grass pollen allergoid preparations were significantly superior to placebo for the primary outcome, whereas there were no significant differences in the change in TNSS. Compared to the standard dose, the high dose of Phleum pratense did not produce any additional significant benefit, but showed a slight increase in AEs. Yet this increase in AEs was lower than for the 6-grass pollen preparation. CONCLUSIONS &amp; CLINICAL RELEVANCE: The standard dose of the new Phleum pratense allergoid was comparable to the marketed 6-grass pollen preparation at equal dose for the parameters measured. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12977</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696503">PM:28696503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170711-PfaarO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170711-PfaarO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Pfaar O</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12977</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stiefel,G.</style></author><author><style face="normal" font="Arial"> Anagnostou,K.</style></author><author><style face="normal" font="Arial"> Boyle,R.J.</style></author><author><style face="normal" font="Arial"> Brathwaite,N.</style></author><author><style face="normal" font="Arial"> Ewan,P.</style></author><author><style face="normal" font="Arial"> Fox,A.T.</style></author><author><style face="normal" font="Arial"> Huber,P.</style></author><author><style face="normal" font="Arial"> Luyt,D.</style></author><author><style face="normal" font="Arial"> Till,S.J.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Clark,A.T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">BSACI guideline for the diagnosis and management of peanut and tree nut allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="739" start="719">719-739</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> aetiology</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Macadamia</style></keyword><keyword><style face="normal" font="Arial"> macadamia food allergy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pecan</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen food syndrome</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nut allergy</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><isbn><style face="normal" font="Arial">1365-2222</style></isbn><abstract><style face="normal" font="Arial">Peanut nut and tree nut allergy are characterised by IgE mediated reactions to nut proteins. Nut allergy is a global disease. Limited epidemiological data suggest varying prevalence in different geographical areas. Primary nut allergy affects over 2% of children and 0.5% of adults in the UK. Infants with severe eczema and/or egg allergy have a higher risk of peanut allergy. Primary nut allergy presents most commonly in the first five years of life, often after the first known ingestion with typical rapid onset IgE-mediated symptoms. The clinical diagnosis of primary nut allergy can be made by the combination of a typical clinical presentation and evidence of nut specifc IgE shown by a positive skin prick test (SPT) or specific IgE (sIgE) test. Pollen food syndrome is a distinct disorder, usually mild, with oral/pharyngeal symptoms, in the context of hay fever or pollen sensitisation, which can be triggered by nuts. It can usually be distinguish clinically from primary nut allergy. The magnitude of a SPT or sIgE relates to the probability of clinical allergy, but does not relate to clinical severity. SPT of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ-á8-ámm or sIgE-á</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ-á15-áKU/L to peanut is highly predictive of clinical allergy. Cut off values are not available for tree nuts. Test results must be interpreted in the context of the clinical history. Diagnostic food challenges are usually not necessary but may be used to confirm or refute a conflicting history and test result. As nut allergy is likely to be a long-lived disease, nut avoidance advice is the cornerstone of management. Patients should be provided with a comprehensive management plan including avoidance advice, patient specific emergency medication and an emergency treatment plan and training in administration of emergency medication. Regular re-training is required</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12957</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1111/cea.12957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-719-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-719-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Stiefel G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12957</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cianferoni,A.</style></author><author><style face="normal" font="Arial"> Saltzman,R.</style></author><author><style face="normal" font="Arial"> Saretta,F.</style></author><author><style face="normal" font="Arial"> Barni,S.</style></author><author><style face="normal" font="Arial"> Dudek,E.</style></author><author><style face="normal" font="Arial"> Kelleher,M.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, The Children's Hospital of Philadelphia, PA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Invariant natural killer cells change after an oral allergy desensitization protocol for cow's milk</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food tolerance</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> invariant natural killer T cells</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Killer Cells</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> natural killer cell</style></keyword><keyword><style face="normal" font="Arial"> Natural killer cells</style></keyword><keyword><style face="normal" font="Arial"> Natural killer T cell</style></keyword><keyword><style face="normal" font="Arial"> natural killer T cells</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cow milk (CM) allergy (CMA) affects up to 3% of the pediatric population and recent data suggest that only about 50% will outgrow by age 8. Oral immunotherapy (OIT) is a type of immune-modulating treatment that is able to induce desensitization to food allergens, to increase tolerance threshold, to reduce the risk of anaphylaxis, and to improve the patient's quality of life. The examination of the immunological changes observed during the establishment of food allergy (FA) desensitization in FA patients is a window into the pathogenesis of food allergy and food tolerance development. In this pathway, we have previously found that invariant natural killer T cells (iNKTs) are involved in CM allergy sensitization and now examine their role in OIT. METHODS: In this study, 10 of the 11 children with CM induced anaphylaxis enrolled in a CMA OIT clinical trial and completed the protocol. Peripheral blood iNKTs were quantitatively and qualitatively via flow cytometry characterized ex-vivo and after culture with milk lipids before and after completing the OIT protocol. RESULTS: After completing OIT for CM, children were able to reintroduce CM in their diet. For the first time, we demonstrated that OIT induced a significant increase in the peripheral blood iNKT, as well as their switch from a T helper (Th-2; i.e. IL-4, IL-13) to Th-1 (i.e. IFN-gamma) cytokine profile. CONCLUSIONS AND CLINICAL RELEVANCE: This study confirms the efficacy and safety of CM-OIT as well as the role of iNKT cells in CM allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12975</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28685970">PM:28685970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170707-CianferoniA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170707-CianferoniA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Cianferoni A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12975</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caminati,M.</style></author><author><style face="normal" font="Arial"> Giorgis,V.</style></author><author><style face="normal" font="Arial"> Palterer,B.</style></author><author><style face="normal" font="Arial"> Racca,F.</style></author><author><style face="normal" font="Arial"> Salvottini,C.</style></author><author><style face="normal" font="Arial"> Rossi,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit and Asthma Center, Verona University and General Hospital, Verona, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Allergy and Sexual Behaviours: an Update</style></title><secondary-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Condoms</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cosmetics</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> Semen</style></keyword><keyword><style face="normal" font="Arial"> Seminal fluid</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin allergy</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="26" Month="6" Year="2017">2017/6/26</year></dates><abstract><style face="normal" font="Arial">The exact prevalence of hypersensitivity reactions related to sexual behaviours is not known; however, they heavily impact on the quality of life and of sex life of affected patients. In fact, not only common respiratory and skin allergies, such as asthma, rhinitis, urticaria and atopic dermatitis, but also food and drug allergy have been found to negatively affect the quality of sex life. Allergic diseases impact on the sexual function in both physical and psychological ways, representing one of the main complaints of a considerable proportion of patients. Sexual behaviours may act as the triggers of allergic reactions or as the carriers of allergens. Food and drug allergens can be carried through human organic fluids, like saliva and semen. Latex in condoms and numerous substances in lubricants, spermicides, topical medications and cosmetics can cause allergic reactions or contact dermatitis. Sexual activity itself is also a potential trigger of symptoms in patients affected by respiratory allergies, like honeymoon asthma and rhinitis. In seminal plasma hypersensitivity, seminal fluid proteins are the culprit allergens. The present review aims at summarizing the state of the art about allergy and sexual behaviours. In clinical practice, the influence of common allergic diseases on the sexual quality of life should be taken carefully into account. Sexual behaviours need to be accounted in the differential diagnosis of hypersensitivity reactions, and awareness on those exposure routes should be raised between different specialists and general practitioners</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12016-017-8618-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28653246">PM:28653246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170627-CaminatiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170627-CaminatiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Caminati M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12016-017-8618-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Strinnholm,A.</style></author><author><style face="normal" font="Arial"> Hedman,L.</style></author><author><style face="normal" font="Arial"> Winberg,A.</style></author><author><style face="normal" font="Arial"> Jansson,S.A.</style></author><author><style face="normal" font="Arial"> Lindh,V.</style></author><author><style face="normal" font="Arial"> Ronmark,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Clinical Medicine, Occupational and Environmental Medicine, OLIN Unit, Umea University, 901 87 Umea, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Health Related Quality of Life among schoolchildren aged 12-13 years in relation to food hypersensitivity phenotypes: a population-based study</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lactose Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> OLIN</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: While Health Related Quality of Life has been investigated among children with IgE-mediated food allergy, less is known about quality of life among children with other types of hypersensitivity to food. The aim of this study was to investigate Health Related Quality of Life (HRQL) in children with and without food hypersensitivity. Further, we compared HRQL between children with different phenotypes of food hypersensitivity. METHODS: In a large population-based cohort of schoolchildren in Northern Sweden, the parents of 2612 (96% of invited) completed a questionnaire. All 125 (5%) children who reported complete elimination of milk, egg, fish or wheat due to food hypersensitivity were invited to a clinical examination and 94 children participated. Of these, 75 children also completed a generic (KIDSCREEN-52) and a disease-specific HRQL questionnaire (FAQLQ-TF). Thereafter, these children were categorised into the different phenotypes: current food allergy, outgrown food allergy, and lactose intolerance. Additionally, 209 children with unrestricted diets answered the generic questionnaire. RESULTS: The median score of all KIDSCREEN-52 domains were above the population norm of 50 both in children with and without food hypersensitivity. No significant differences in distribution in generic or disease-specific HRQL were found between children with or without food hypersensitivity. There were no significant differences in HRQL between children with different phenotypes of food hypersensitivity. However, children with current food allergy tended to have the lowest HRQL. Further, poor HRQL defined as >/=75th percentile for the disease specific score was significantly more common in the current food allergy phenotype in the domain Emotional impact and the total FAQLQ, compared to the other phenotypes. CONCLUSIONS: In this population-based study, 12-13 year old children reported good HRQL regardless of having food hypersensitivity or not. However, the children with the current phenotype reported lower HRQL than the other phenotypes</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0156-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28680560">PM:28680560</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Strinnholm A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0156-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elenius,V.</style></author><author><style face="normal" font="Arial"> Lahdesmaki,T.</style></author><author><style face="normal" font="Arial"> Hietala,M.</style></author><author><style face="normal" font="Arial"> Jartti,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Turku University Hospital, Kiinamyllynkatu 4-8, 20520 Turku, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy in a child with de novo KAT6A mutation</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="19">19-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical diagnostics</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Crying combined with miscellaneous gastrointestinal symptoms are typical symptoms of infant with food allergy, but are also common among children with abnormal neurological development. Mutations in KAT6A gene is known to cause a syndrome characterized by developmental delay, hypotonia, cardiac defects, microcephaly, specific facial features and early feeding problems. However, these feeding problems have not earlier been specified. We present the first reported case of a DBPCFC confirmed food allergy in a child with KAT6A mutation whose feeding problems resolved with elimination diet. The present case does not establish proof of cause, but highlights the importance of careful clinical diagnostics despite other possible causes for feeding problems. Recognizing that early feeding problems these patients regularly have might be caused by food allergy is important for outcome and quality of life for these patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170626IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0155-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28649320">PM:28649320</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-19.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170626, Elenius V</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0155-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marki,I.</style></author><author><style face="normal" font="Arial"> Rebeaud,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Abionic SA, Biopole, sect. Esplanade SE-A, Route de la Corniche 3, CH-1066, Epalinges, Switzerland.</style></auth-address><titles><title><style face="normal" font="Arial">Nanotechnologies for In Vitro IgE Testing</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma.Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma.Rep</style></abbr-1></periodical><pages end="" start="50">50-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abionic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Nanotechnology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: This review discusses the recent advances in the development of IgE antibody assays based on nanotechnologies. IgE blood testing is an important part of the diagnostic workup of IgE-mediated hypersentivity. We also address the challenges in moving from an academic proof-of-concept to a product routinely used by allergy experts. RECENT FINDINGS: Several nanotechnologies have been applied to the field of IgE testing: nanoparticles are used either as a support to capture analytes or as a detection tool to enhance the measurement signal. Nanofluidics allows to reduce assay time by enhancing molecular interaction. Nanotechnologies bring forth new methods for in vitro IgE testing. Substantial advantages such as lower sample volume, shorter assay time, simplified procedures, and lower analytic sensitivity, without affecting test precision and accuracy, can be achieved thanks to nanotechnologies</style></abstract><notes><style face="normal" font="Arial">DA - 20170617IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0717-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28623535">PM:28623535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma.Rep\2017-17-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma.Rep\2017-17-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170617, Marki I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0717-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gray,C.L.</style></author><author><style face="normal" font="Arial"> Berry,L.</style></author></authors></contributors><titles><title><style face="normal" font="Roboto-Black">Cranial nerve mischief masquerading as food allergy. Auriculotemporal (Frey's) syndrome in a child with Moebius syndrome.</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="93" start="92">92-93</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/NewsEvents/Gallery</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-92-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-92-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Gray CL</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">O Warner,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The foetal origins of allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="68" start="62">62-68</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Foetus</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human microbiome</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The dramatic increases in allergy and allergic diseases which have occurred over the past half-century havebeen strongly associated with changes in early life events. Changes in lifestyle, which have affected nutrition,allergen and microbial exposures, have been strongly implicated as explanations for changing allergysusceptibility. To what extent these influences affect the foetus during pregnancy rather than the infant postnatallyis uncertain. In all probability there is a sequence of events through pregnancy and early post-natallife which in combination change the outcomes. Successful pregnancy is associated with a Th-2, allergybiasedimmunological environment which results in virtually all neonates having an apparent allergic patternof immune responsiveness. Under normal circumstances this is rapidly down-regulated after birth, most likelyaffected by the evolving human microbiome. Interactions between genetic and environmental variation, bothduring pregnancy and in the first months of the infantfs life, perturb this normal sequence and lead to asustained Th-2-biased allergic response.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/NewsEvents/Gallery</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-62-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-62-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, O Warner J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al Badri,F.M.</style></author><author><style face="normal" font="Arial"> Jeebhay,M.F.</style></author></authors></contributors><titles><title><style face="normal" font="Roboto-Black">Factors associated with serial longitudinal changes in exhaled nitric oxide (FeNO) - A review of the literature   </style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="109" start="98">98-109</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma education</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">It has been well documented that the major hallmarks of asthma are the presence of airway inflammation,variable airway obstruction and airway hyperresponsiveness (AHR). Fractional exhaled nitric oxide (FeNO)is a well-known inflammatory marker which has a potential role in the diagnosis and surveillance of thoseat risk of developing asthma, although its utility in occupational contexts is less clear. This review focuseson identifying the factors associated with longitudinal changes in FeNO in general asthmatic and workingpopulations. The review found that exposure to allergens (common aeroallergens and occupational allergens)or their avoidance, as well as asthma-education programmes (especially those focusing on adherence toinhaled corticosteroid usage) are associated with longitudinal changes in FeNO. Other host-associatedfactors such as baseline lung function (FEV1), atopy status and smoking need further evaluation in order toassess their impact on serial longitudinal changes in FeNO.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/NewsEvents/Gallery</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-98-109.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-98-109.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Al Badri FM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Peter,J.</style></author><author><style face="normal" font="Arial"> Onyango,V.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">When you cannot beat back the mould: chronic mucocutaneous candidiasis</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="121" start="116">116-121</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic mucocutaneous candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> STAT1</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Candida spp are normal human commensal fungi that have co-evolved with human beings over millennia.Normal host immunity with a delicate balance of pro- and anti-inflammatory signals maintains a stable host.fungus relationship. T-cells, particularly intact T-helper 17 cell, neutrophils and the type-1 interferon cytokinenetworks are non-redundant for preventing invasive fungal disease. Self-limiting and/or easily treated mucosalinfections to candida occur in immunocompetent hosts, usually associated with altered mucosal-barrier integrity.In contrast, severe, persistent and recurrent mucosal-candida infections - known as 'chronic mucocutaneouscandidiasisf (CMC) . suggest an underlying immunodeficiency and warrant investigation. To date, more thanten gene defects have been associated with CMC, either alone or in combination with other syndromic featuresand/or infections. In this review, we present the first South African CMC family with a confirmed gain-of-function(GOF) STAT1 mutation. We discuss host fungal immunity to candida, describing the known gene defects andthen outline a clinical approach to the diagnosis, highlighting specific management of issues in the care ofpatients with CMC.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/NewsEvents/Gallery</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-116-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-116-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Peter J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Emanuel,S.</style></author><author><style face="normal" font="Arial"> Hawarden,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Wheat allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="112" start="110">110-112</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/NewsEvents/Gallery</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-110-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-110-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Emanuel S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghiasian,S.A.</style></author><author><style face="normal" font="Arial"> Maghsood,A.H.</style></author><author><style face="normal" font="Arial"> Aghamirian,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Parasitology and Mycology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Aeromycological analysis of allergenic airborne fungi in Qazvin, Iran</style></title><secondary-title><style face="normal" font="Arial">Curr Med Mycol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Mycol</style></full-title></periodical><pages end="9" start="5">5-9</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerosols</style></keyword><keyword><style face="normal" font="Arial"> Agar</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne fungi</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosol</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosols</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health hazards</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhizopus</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND PURPOSE: Airborne fungi are one of the most important agents responsible for triggering allergicreactions such as rhinitis and severe asthma. This study was conducted to analyze and monitor the prevalence and distribution patterns of atmospheric fungal aerosols in the air of Qazvin during winter of 2012. MATERIALS AND METHODS: In the current descriptive study, the incidence and diversity of potentially allergenic airborne fungi were determined using two times sampling interval in 25 different locations of Qazvin city by Petri dish trappingtechnique and exposure of 10- cm diameter plates of Sabouraud's dextrose agar medium plus chloramphenicol to the air. RESULTS: A total of 2867 fungal colonies were counted on 156 Petri dishes. Of the identified 18 microfungi genera,Cladosporium spp. was the most frequently isolated genera representing 30.9% of isolates, followed by 30.9% Penicillium spp. (27.3%), Aspergillus spp %) . (24.5 , Alternaria spp. (3.3%), Rhizopus spp. (3.1%), and other fungal genera. CONCLUSION: The high prevalence, high quantity and variety of allergenic airborne fungi in the air of Qazvin showed that people residing in this area are exposed to health hazards. Furthermore, reduction of exposure to bio-aerosols containing these outdoor fungi is necessary to improve the health of individuals, especially those sensitive to fungal-induced diseases like asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 2423-3439 (Print)IS - 2423-3420 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.18869/acadpub.cmm.2.3.5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28681022">PM:28681022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Med Mycol\2016-2-5-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Med Mycol\2016-2-5-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Ghiasian SA</style></custom2><misc3><style face="normal" font="Arial">10.18869/acadpub.cmm.2.3.5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dominguez-Ortega,J.</style></author><author><style face="normal" font="Arial"> Perez-Camo,I.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">New Eliciting Agents of Occupational Asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="144" start="129">129-144</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Occupational asthma is a type of asthma that arises from exposures in the workplace. There are more than 400 known causes of occupational asthma and the list is growing. New causes of allergic occupational asthma involving high and low molecular weight agents are continuously being reported. Their knowledge is important for physicians and occupational health and safety professionals to maintain a high level of suspicion in exposed workers to these substances. The majority of new causes of allergic occupational asthma between 2011 and mid-2016 were seen with high-molecular-weight agents. Most new cases are observed in food and agro-alimentary industry, but also in the cosmetic industry, and frequently are associated with other IgE-mediated manifestations, especially allergic rhinoconjunctivitis and contact urticaria. Among the low-molecular weight agents, new acrylate and aldehyde compounds have been identified as eliciting agents of occupational asthma, as well as drugs, biocides, and other chemicals recently introduced in industry</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0123-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0123-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-129-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-129-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Dominguez-Ortega J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0123-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Zieglmayer,P.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Current Standards and Improvements in the Use of SLIT Tablets for Allergen Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="289" start="286">286-289</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Refrigeration</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> sublingual tablet</style></keyword><keyword><style face="normal" font="Arial"> Sublingual tablets</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">The clinical use of sublingual allergen immunotherapy (SLIT) can be traced back several decades. Ever since that first use, scientists have sought to develop new ways of application for immunotherapy. SLIT with aqueous formulations was mainly used but has a number of practical limitations, such as the need for refrigeration, poor dosing accuracy, and allergen spreading from the sublingual zone to other enoral and pharyngeal regions. Solid pharmaceutical formulations of allergen extracts in the form of freeze-dried sublingual tablets have been first clinically studied in the 1990s and were followed by DBPC prospective studies from 2006 onwards. Today, there are numerous different products of fast dissolving SLIT tablets for several allergens. Their clinical use and scientific background and evidence are discussed</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Austria -CO - France -CO - Italy -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0133-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0133-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-286-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-286-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0133-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Coman,I.</style></author><author><style face="normal" font="Arial"> Lemiere,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Fractional Exhaled Nitric Oxide (FeNO) in the Screening and Diagnosis Work-Up of Occupational Asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="159" start="145">145-159</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exhaled NO</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">FeNO is a simple non-invasive tool used as a surrogate marker of airway inflammation in the management of asthma. FeNO has been assessed in several populations of workers exposed to high- and low-molecular weight agents. However, there are many confounding factors to consider in the interpretation of FeNO. As such, its use in the investigation of occupational asthma (OA) has yielded inconsistent results. In screening studies of OA to high molecular weight (HMW) agents, an increase of FeNO over time has been associated with the development of bronchial hyperresponsiveness (BHR). When used in the investigation of OA, increases in FeNO show high positive predictive values for a positive specific inhalation challenge (SIC) to HMW agents. Subjects with high specific IgE to their workplace allergens seem to present higher increases in FeNO than subjects without specific IgE to causal agent. Changes in FeNO have less frequently been observed in studies of OA to low molecular weight (LMW) agents than OA to HMW agents, except for isocyanate-induced OA. Cluster analyses of patients exposed to various HMW and LMW agents have documented significant increases of FeNO in clusters of patients with OA to HMW agents, but not LMW. Recent studies have provided useful information for improving our understanding of the pathophysiology of exhaled NO in OA despite the previously reported conflicting results. Future studies are still required to clarify its role in the screening, investigation, and management of OA</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0122-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0122-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-145-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-145-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Coman I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0122-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Raulf,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Component-Resolved and Complementary Tests in the Diagnosis of Occupational Allergy: Advantages and Limitations</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="180" start="171">171-180</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> baker</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> CD203c</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hevea</style></keyword><keyword><style face="normal" font="Arial"> Hevea brasiliensis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergen</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergens</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Enhancing the repertoire of in vitro methods together with the development of recombinant technology in the field of allergy diagnosis brought tremendous advances in understanding allergens, allergic reactions, and patients</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ care. This review is focusing not only on component-resolved diagnosis with occupational allergens, complementary methods, their advantages to improve the in vitro diagnosis for occupational allergy but also their limitations. Up to now, the number of occupational asthma sensitizers characterized on the molecular level and their availability for routine diagnosis is very low. One exception, however, is Hevea brasiliensis latex as an important occupational allergen source. H. brasiliensis latex is an excellent model for the useful application of recombinant single allergens for improvement of routine diagnostics. Despite the many efforts and excellent research in the field of baker</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs asthma to characterize the occupationally relevant allergens the results are highly diverse. No major allergen can be identified and the IgE-sensitization profile of each baker showed great inter-individual variation. Therefore, for routine diagnosis of baker</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs asthma, the assessment of allergen-specific IgE with the whole wheat (and/or rye) flour extract is still recommended. Unfortunately, no wheat allergens relevant for baker</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs asthma are commercially available, although they might help to discriminate between wheat-induced food allergy, grass pollen allergy, and baker</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs asthma. In particular cases with discrepancy between different diagnostic tests, the determination of basophil activation test is a recommended option. Flow cytometry determination of CD63 or CD203c on basophils induced by stimulation with the relevant allergen is a good clinically validated test and also useful for the diagnosis of occupational allergy. It is still necessary to increase the knowledge of occupational allergen molecules and include standardized tools into routine diagnostic. For the future, combination of new diagnostic tools and biomarkers, platforms, and complementary methods in occupational allergy and asthma diagnosis is a promising option. In addition, integration of these possibilities in workplace-related allergy and asthma studies is helpful to understand the complex interaction between work-related exposure, individual susceptibility and health outcome</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0124-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0124-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-171-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-171-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Raulf M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0124-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Folletti,I.</style></author><author><style face="normal" font="Arial"> Paolocci,G.</style></author><author><style face="normal" font="Arial"> Muzi,G.</style></author><author><style face="normal" font="Arial"> Siracusa,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">United Airway Disease in Occupational Allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="170" start="160">160-170</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health care workers</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> Laboratory animals</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Occupational rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Occupations</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tertiary prevention</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">The term </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£united airway disease</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ has been used since 2000 to describe the strong association between asthma and rhinitis. Although this term is not extensively used, it refers to the fact that asthma and rhinitis are frequently associated and share common risk factors, causal agents and mechanisms. Similarly, since 2010 the term occupational united airway disease has been used to describe the strong association between occupational asthma and rhinitis. Rhinitis and occupational rhinitis are less severe diseases but more frequent than asthma and occupational asthma, respectively. Every year several case reports and epidemiological studies enhance the long list of agents responsible for occupational asthma and rhinitis with new agents or occupations. Primary, secondary and tertiary prevention strategies are aimed at reduction of the onset and severity of work-related respiratory diseases. Primary prevention mainly includes avoiding/reducing exposure to known sensitizing/irritant agents. Secondary prevention or early detection should focus on medical surveillance of individuals at risk, health and safety education and training of workers, and recognition of early bronchial/nasal symptoms. Tertiary prevention includes early recognition and diagnosis, appropriate removal from further exposure and pharmacologic treatment. Unfortunately, pharmacologic treatment has seldom been studied in occupational asthma and rhinitis, and it usually refers to the international guidelines of management of asthma and rhinitis aimed to achieve control of the two diseases. For simultaneous treatment of asthma and rhinitis, the anti-IgE monoclonal antibody omalizumab, effective in occupational asthma and rhinitis, is available. Immunotherapy has been shown to be effective in health care workers with occupational asthma due to natural rubber latex, in workers with occupational asthma due to laboratory animals and in baker</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs asthma. A limitation of immunotherapy, however, can be systemic reactions after subcutaneous injections of sometimes non-standardized and non-purified extracts</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0126-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0126-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-160-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-160-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Folletti I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0126-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Esteban-Gorgojo,I.</style></author><author><style face="normal" font="Arial"> Rial,M.J.</style></author><author><style face="normal" font="Arial"> Sastre,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Infrequent Treatments for Occupational Asthma: Immunotherapy and Biological Therapy</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="128" start="118">118-128</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug therapy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> refractory asthma</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Standardized extracts</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Occupational asthma is an important social, health, and economic burden in our society, but its treatment options have not been yet sufficiently explored. Drug therapies do not differ much from ordinary asthma treatments, and avoidance is the main managing option for this condition. However, other therapeutic options like immunotherapy and biological therapies have not been used as in other asthma and rhinitis etiologies. Occupational asthma has different pathomechanisms depending of its triggers, but in immunological IgE-dependent asthma, these therapies can be fairly efficient. Not many immunotherapy studies have been carried out lately on this topic, and its reproducibility might be its biggest disadvantage. Maybe the main existing limitation is the lack of standardized extracts in order to perform this treatment. With no proper extracts, this treatment cannot be implemented, and its tolerance is going to differ depending on the extract used in each specific case. On the other hand, biological treatments are a promising option in the management of severe occupational asthma. Not many studies have been conducted so far in occupational allergy. Nevertheless, these biological treatments are upcoming and evolving therapies, so we expect further studies in a close future, including recently approved therapeutic options such as mepolizumab in eosinophilic refractory asthma. These new treatment possibilities should enhance their use and empower them also in the occupational field</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0125-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0125-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-118-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-118-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Esteban-Gorgojo I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0125-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moscato,G.</style></author><author><style face="normal" font="Arial"> Pala,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Occupational Asthma in the Food Industry</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="200" start="191">191-200</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental intervention</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Flours</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Specific allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Standardized extracts</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Inhalation of food-derived allergens during food processing at the workplace represents a risk for developing occupational asthma (OA) in exposed workers. Cereal flours and seafood are the causal agents most frequently involved. The management of food-derived OA includes timely pharmacologic therapy and environmental interventions aimed to avoid or reduce exposure to the offending agent to increase the probability of recovery. Cessation of exposure is the best option, but when the causative agent cannot be completely avoided reduction of exposure, through modification of food processing, improving ventilation, mechanization, etc. can be considered as an alternative. Quantification of real exposure levels is crucial, and new accurate immunologic and chemical assays able to detect low levels of aerosolized flour and seafood allergens have recently been developed. Recent papers have described intervention strategies effective in reducing airborne allergen exposure in flour and seafood industry, but the long-term health impact of this intervention has still to be defined. Specific allergen immunotherapy (SIT) might be another management option in individuals with IgE-mediated food-induced OA. Both a short- and a long-lasting beneficial effect of SIT with wheat flour in reducing symptoms whilst keeping the patient at work has been shown in bakers</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ asthma, but at present, SIT is not for routine use for bakers</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ asthma due to the lack of commercial standardized extracts. A better identification on a molecular basis of allergens involved in flour and in other IgE-mediated food-derived OA might help in preparing new extracts suitable for immunotherapy. In selected cases of bakers</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ asthma, the monoclonal antibody omalizumab has been effective in reducing symptoms. SIT and omalizumab might represent further management options in IgE-mediated OA in food industry</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0120-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0120-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-191-200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-191-200.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Moscato G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0120-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ozdemir,C.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Precision Medicine in Allergic Disorders</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="285" start="283">283-285</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0132-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0132-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-283-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-283-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Ozdemir C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0132-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chu,C.H.</style></author><author><style face="normal" font="Arial"> Davis,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, University of South Carolina, 6311 Garners Ferry Road, Building #3, Columbia, SC, 29209, USA. Dorn VA Medical Center, Columbia, SC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient</style></title><secondary-title><style face="normal" font="Arial">Drug Saf Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Drug Saf Case Rep</style></abbr-1></periodical><pages end="" start="9">9-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antinuclear antibodies</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis</style></keyword><keyword><style face="normal" font="Arial"> Hepatitis C</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rheumatoid Factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Type 2 diabetes</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">A 62-year-old white woman with a history of hepatitis C and type 2 diabetes mellitus developed urticaria during treatment with ustekinumab for plaque psoriasis. The patient received two 45-mg ustekinumab injections in her first 2 months and then one 45-mg injection every 3 months for her psoriasis. After 10 months, she developed a round red rash on her skin diffusely on her body. She also complained of joint pain in her hands. Rheumatology became involved, and investigations revealed that her antinuclear antibody titer was negative, but her rheumatoid factor, erythrocyte sedimentation rate, and liver function enzymes were elevated. She was diagnosed with urticaria, and ustekinumab was discontinued. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's urticaria and her use of ustekinumab. Ustekinumab was subsequently discontinued, and the patient received a course of Harvoni(R) (Gilead Sciences, Inc., Forest City, California, United States) (ledispasvir/sofosbuvir) with clearance of the hepatitis C virus. The patient is currently receiving another biologic agent, ixekizumab, and reports no complaints, including that of urticaria</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 2199-1162 (Print)IS - 2199-1162 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40800-017-0051-2.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677075">PM:28677075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drug Saf Case Rep\2017-4-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drug Saf Case Rep\2017-4-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Chu CH</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40800-017-0051-2.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Romita,P.</style></author><author><style face="normal" font="Arial"> Mascia,P.</style></author><author><style face="normal" font="Arial"> Calogiuri,G.</style></author><author><style face="normal" font="Arial"> Foti,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Bari. ItalyUniversity of Bari - Department of Biomedical Science and Human Oncology, Dermatological Clinic Bari. Italy</style></auth-address><titles><title><style face="normal" font="Arial">Cold-induced anaphylaxis: the case of a 9-year-old child and review of the literature</style></title><secondary-title><style face="normal" font="Arial">Endocr Metab Immune Disord Drug Targets</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Endocr Metab Immune Disord Drug Targets</style></full-title></periodical><pages end="99" start="96">96-99</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Cold induced urticaria</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency kit</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine injector</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physical urticaria</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: The present review investigated cold-induced anaphylaxis, a potentially life-threatening condition that occurs after exposure to cold stimuli and is characterized by respiratory distress and/or hypotension. Anaphylaxis is rarely associated to cold-induced urticarial (CU), a particular form of physical urticaria that is difficult to diagnose and manage. The incidence of cold-induced urticaria has been estimated at about 0.05%, higher in colder regions and in women; its pathological mechanisms are still unknown. METHODS: The literature was searched via the Medline/PubMed database (http://www.ncbi.nlm.gov/pubmed). RESULTS AND CONCLUSION: Patients affected by CU should be deeply informed about the risk of anaphylaxis and preventive measures. The prevention of CU is based on the avoidance of cold exposure. The most effective treatment is antihistamines symptomatic therapy. Anyway, patients should also carry with them an emergency kit containing corticosteroids, antihistamines and an epinephrine injector. Future studies are necessary to determine the CU pathophysiology so to establish a more targeted management of this important and potentially life-threatening condition</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 2212-3873 (Electronic)IS - 1871-5303 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2174/1871530317666170703122939</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28675997">PM:28675997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Endocr Metab Immune Disord Drug Targets\2017-17-96-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Endocr Metab Immune Disord Drug Targets\2017-17-96-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Romita P</style></custom2><misc3><style face="normal" font="Arial">10.2174/1871530317666170703122939</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roy,S.</style></author><author><style face="normal" font="Arial"> Chakraborty,A.</style></author><author><style face="normal" font="Arial"> Maitra,S.</style></author><author><style face="normal" font="Arial"> Bhattacharya,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Botany, Environmental Biology Laboratory, Visva-Bharati, Santiniketan, West Bengal, Pin-731235, IndiaDepartment of Statistics, Visva-Bharati, Santiniketan, West Bengal, Pin-731235, IndiaAllergy and Asthma Research Centre, 48/7 Purna Das Road, Kolkata, West Bengal, Pin- 700029, IndiaDepartment of Botany, Environmental Biology Laboratory, Visva-Bharati, Santiniketan, West Bengal, Pin-731235, India. kashinathb23@rediffmail.com</style></auth-address><titles><title><style face="normal" font="Arial">Monitoring of airborne fungal spore load in relation to meteorological factors, air pollutants and allergic symptoms in Farakka, an unexplored biozone of eastern India</style></title><secondary-title><style face="normal" font="Arial">Environ Monit Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Monit Assess</style></full-title></periodical><pages end="" start="370">370-</pages><volume><style face="normal" font="Arial">189</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airborne fungal spore</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Kolkata</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meteorological factor</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Factors</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Outdoor environment</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin reactivity</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spore calendar</style></keyword><keyword><style face="normal" font="Arial"> Spore concentration</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">Fungi are important components of atmosphere which play a major role in causing respiratory allergy upon inhalation. An airborne fungal spore survey was carried out in two outdoor environments in Farakka-an unexplored township covering the National Thermal Power Station, West Bengal, India for a period of 2 years (October 2013 to September 2015). A Burkard personal volumetric air sampler was used at 15 days interval to collect the total fungal spore load. A fungal spore calendar has been prepared depicting monthly average spore concentration in the air. The relationships between fungal spore concentration and different climatic factors were analysed statistically. Higher concentration levels of aerospora and pollutants were recorded during winter season. A detailed questionnaire was used to obtain medical history data of 523 local patients visiting the outpatients department of Farakka NTPC (National Thermal Power Station) hospital. A significant positive correlation was found between fungal spore concentration, atmospheric pollutants and allergic manifestation. The dominant fungal spores were isolated, sub-cultured and tested for allergenic potential by skin prick tests (SPTs) among subjects with clinical history of respiratory allergy, which evoked >45.0% skin reactivity upon individuals</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1573-2959 (Electronic)IS - 0167-6369 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10661-017-6044-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28676932">PM:28676932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-370.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-370.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Roy S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10661-017-6044-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mortuaire,G.</style></author><author><style face="normal" font="Arial"> Michel,J.</style></author><author><style face="normal" font="Arial"> Papon,J.F.</style></author><author><style face="normal" font="Arial"> Malard,O.</style></author><author><style face="normal" font="Arial"> Ebbo,D.</style></author><author><style face="normal" font="Arial"> Crampette,L.</style></author><author><style face="normal" font="Arial"> Jankowski,R.</style></author><author><style face="normal" font="Arial"> Coste,A.</style></author><author><style face="normal" font="Arial"> Serrano,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inserm U995, service d'ORL et de chirurgie cervicofaciale, Lille Inflammation Research International Center, universite de Lille, hopital Huriez, CHU de Lille, 59000 Lille, France.</style></auth-address><titles><title><style face="normal" font="Arial">Specific immunotherapy in allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Otorhinolaryngol Head Neck Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur Ann Otorhinolaryngol Head Neck Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Chirurgie</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamines</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T-regulatory lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis is a common condition, with significant impact on quality of life depending on severity and quality of control. Allergen-specific immunotherapy (allergen-SIT) is the only known treatment able to alter the natural course of allergic rhinitis. Although well known to allergologists, it has yet to be fully adopted by the ENT community. This review, based on the most recent meta-analyses and clinical studies, shows that SIT significantly reduces symptoms and medication requirements (nasal corticosteroids, H1-antihistamines) in allergic rhinitis. It can reduce the risk of progression to asthma and, if initiated early enough, of developing new sensitizations. Immunobiological analysis shows an altered inflammatory profile following SIT, with immune tolerance involving T-regulatory lymphocyte induction and IgG production. Sublingual SIT with drops is as effective as subcutaneous SIT and is simpler to use, with less anaphylactic risk. Standardization of trial protocols in terms of treatment response assessment and side effect grading is recommended to improve comparative studies. Sublingual SIT with tablets has recently been introduced, providing a good opportunity for ENT practitioners to adopt the SIT approach in rhinitis triggered by allergy to pollens and, in the near future, to house dust mites</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1879-730X (Electronic)IS - 1879-7296 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anorl.2017.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28684084">PM:28684084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Otorhinolaryngol Head Neck Dis\20170707-MortuaireG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Otorhinolaryngol Head Neck Dis\20170707-MortuaireG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Mortuaire G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anorl.2017.06.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsuda,M.</style></author><author><style face="normal" font="Arial"> Doi,K.</style></author><author><style face="normal" font="Arial"> Tsutsumi,T.</style></author><author><style face="normal" font="Arial"> Fujii,S.</style></author><author><style face="normal" font="Arial"> Kishima,M.</style></author><author><style face="normal" font="Arial"> Nishimura,K.</style></author><author><style face="normal" font="Arial"> Kuroda,I.</style></author><author><style face="normal" font="Arial"> Tanahashi,Y.</style></author><author><style face="normal" font="Arial"> Yuasa,R.</style></author><author><style face="normal" font="Arial"> Kinjo,T.</style></author><author><style face="normal" font="Arial"> Kuramoto,N.</style></author><author><style face="normal" font="Arial"> Mizutani,N.</style></author><author><style face="normal" font="Arial"> Nabe,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Regulation of allergic airway inflammation by adoptive transfer of CD4+ T cells preferentially producing IL-10</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> growth factors</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-21</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic beads</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">Anti-inflammatory pharmacotherapy for asthma has mainly depended on the inhalation of glucocorticoids, which non-specifically suppress immune responses. If the anti-inflammatory cytokine interleukin (IL)-10 can be induced by a specific antigen, asthmatic airway inflammation could be suppressed when individuals are exposed to the antigen. The purpose of this study was to develop cellular immunotherapeutics for atopic diseases using IL-10-producing CD4+ T cells. Spleen cells isolated from ovalbumin (OVA)-sensitized mice were cultured with the antigen, OVA and growth factors, IL-21, IL-27 and TGF-beta for 7 days. After the 7-day culture, the CD4+ T cells were purified using a murine CD4 magnetic beads system. When the induced CD4+ T cells were stimulated by OVA in the presence of antigen-presenting cells, IL-10 was preferentially produced in vitro. When CD4+ T cells were adoptively transferred to OVA-sensitized mice followed by intratracheal OVA challenges, IL-10 was preferentially produced in the serum and bronchoalveolar lavage fluid in vivo. IL-10 production coincided with the inhibition of eosinophilic airway inflammation and epithelial mucus plugging. Most of the IL-10-producing CD4+ T cells were negative for Foxp3 and GATA-3, transcription factors of naturally occurring regulatory T cells and Th2 cells, respectively, but double positive for LAG-3 and CD49b, surface markers of inducible regulatory T cells, Tr1 cells. Collectively, most of the induced IL-10-producing CD4+ T cells could be Tr1 cells, which respond to the antigen to produce IL-10, and effectively suppressed allergic airway inflammation. The induced Tr1 cells may be useful for antigen-specific cellular immunotherapy for atopic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.06.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668505">PM:28668505</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20170702-MatsudaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20170702-MatsudaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Matsuda M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.06.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bao,Z.J.</style></author><author><style face="normal" font="Arial"> Fan,Y.M.</style></author><author><style face="normal" font="Arial"> Cui,Y.F.</style></author><author><style face="normal" font="Arial"> Sheng,Y.F.</style></author><author><style face="normal" font="Arial"> Zhu,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tuberculosis Department of Hangzhou RedCross Hospital, Hangzhou City, Zhejiang, China.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of PM2.5 mediated oxidative stress on the innate immune cellular response of Der p1 treated human bronchial epithelial cells</style></title><secondary-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></full-title></periodical><pages end="2912" start="2907">2907-2912</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the effect of stimulation of Human Bronchial Epithelial Cells (HBEC) by Der p1 and PM2.5 on the expression of innate immune cell factors to find new therapeutic targets for treatment of bronchial asthma. MATERIALS AND METHODS: The Der p1 antigen exposure model in the HEBC line, 16HBE-14o, was established in vitro. PM2.5 at a concentration of 50 microM/cm2, was added to these cells for 0.5 h, 1 h, 2 h and 3 h. Cells were treated with the following reagents for the indicated times: 300 ng/mL Der p1 for 21 h, 50 microM/cm2 PM2.5 for 3 h, 10 mM Nac for 3 h and PM2.5 contamination for 3 h. The experiment was divided into five groups: control (group A), Der p1 exposure group (group B), PM2.5 treated group (group C), PM2.5+Der p1 exposure group (group D), Nac+PM2.5+Der p1 exposure group (group E). ELISA method was adopted to test the expression levels of malondialdehyde, IL-25, IL-33 and thymic stromal lymphopoietin (TSLP), and Real-time RT-PCT was used to measure IL-25, IL-33 and TSLP mRNA. RESULTS: The protein and mRNA levels of malondialdehyde, IL-25, IL-33 and TSLP in group D were significantly higher than those in the other groups, while the protein and mRNA levels of malondialdehyde, IL-25, IL-33 and TSLP in group E were significantly lower than those in group D (p&lt;0.05). CONCLUSIONS: PM2.5 can enhance the Der p1 antigen-induced HBEC innate immune response through the expression of IL-25, IL-33 and TSLP, which may exacerbate the occurrence rate of bronchial asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 2284-0729 (Electronic)IS - 1128-3602 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28682426">PM:28682426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Rev Med Pharmacol Sci\2017-21-2907-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Rev Med Pharmacol Sci\2017-21-2907-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Bao ZJ</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,J.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Wang,W.</style></author><author><style face="normal" font="Arial"> Ouyang,X.</style></author><author><style face="normal" font="Arial"> Zheng,W.</style></author><author><style face="normal" font="Arial"> Wang,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Respiratory, Binzhou People's Hospital, Binzhou, Shandong 256610, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Altered expression of regulatory T and Th17 cells in murine bronchial asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="722" start="714">714-722</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Alteration of the careful balance of the ratio of Th1/Th2 cell subsets impacts immune function and plays an important role in the pathogenesis of asthma. There is little research on the impact of changes on the balance of the regulatory T (Treg)/Th17 subset ratio and its possible repercussions for asthma. This investigation used a murine model of asthma to measure the expression levels of Treg and Th17 cells and the levels of their transcription factors Foxp3 and retinoic acid receptor-related orphan nuclear receptor (ROR)gammat in bronchial asthma while assessing indexes of airway inflammation. Thirty female SPF BALB/c mice were divided into three equally numbered groups: a normal control, an asthma and a dexamethasone treatment group. All the airway inflammation indexes measured were more prominent in the asthma group and less so in the control group. The percentage of the lymphocyte subset CD4+CD25+Foxp3+ cells in the CD4+ cells in the asthma group was significantly lower than that in the normal control group (P&lt;0.01). The percentage of the lymphocyte subset CD4+IL-17+ cells in the CD4+ cells in the asthma group was significantly higher than that in the normal control group (P&lt;0.01). The ratio of CD4+CD25+Foxp3+ cells/CD4+IL-17+ cells in the asthma group decreased compared with that in the normal control group (P&lt;0.01). The expression level of Foxp3 of the mice in the asthma group was significantly lower than that in the control group (P&lt;0.01). The expression intensity of RORgammat in the asthma group was higher than that in the normal control group (P&lt;0.01). Finally, the Foxp3/RORgammat protein expression ratio in the asthma group was significantly lower than that in the normal control group (P&lt;0.01). The Foxp3/RORgammat protein expression ratio and the airway responsiveness were negatively correlated. The average levels of inflammation markers in the dexamethasone group were intermediate between the other groups. During the course of bronchial asthma the unbalanced expression of Treg and Th17 affects mostly the expression of Foxp3/RORgammat, leading to inflammation of the airways. Dexamethasone may inhibit airway inflammation by regulating the balance between Treg and Th17</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4519</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28672989">PM:28672989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-14-714-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-14-714-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Zhu J</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4519</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bruggemann,T.R.</style></author><author><style face="normal" font="Arial"> Fernandes,P.</style></author><author><style face="normal" font="Arial"> Oliveira,L.M.</style></author><author><style face="normal" font="Arial"> Sato,M.N.</style></author><author><style face="normal" font="Arial"> Martins,M.A.</style></author><author><style face="normal" font="Arial"> Arantes-Costa,F.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Experimental Therapeutics LIM20, Department of Medicine, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Cigarette Smoke Increases CD8alpha+ Dendritic Cells in an Ovalbumin-Induced Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="718">718-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cigarette smoke</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposition</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is an allergic lung disease and, when associated to cigarette smoke exposition, some patients show controversial signs about lung function and other inflammatory mediators. Epidemiologic and experimental studies have shown both increasing and decreasing inflammation in lungs of subjects with asthma and exposed to cigarette smoke. Therefore, in this study, we analyzed how cigarette smoke affects pro-inflammatory and anti-inflammatory mediators in a murine model of allergic pulmonary inflammation. We sensitized Balb/c mice to ovalbumin (OVA) with two intraperitoneal injections. After sensitization, the animals were exposed to cigarette smoke twice a day, 30 min per exposition, for 12 consecutive days. In order to drive the cell to the lungs, four aerosol challenges were performed every 48 h with the same allergen of sensitization. OVA sensitization and challenge developed pulmonary Th2 characteristic response with increased airway responsiveness, remodeling, increased levels of IgE, interleukin (IL)-4, and IL-13. Cigarette smoke, unexpectedly, reduced the levels of IL-4 and IL-13 and simultaneously decreased anti-inflammatory cytokines as IL-10 and transforming growth factor (TGF)-beta in sensitized and challenged animals. OVA combined with cigarette smoke exposition decreased the number of eosinophils in bronchoalveolar lavage and increased the number of neutrophils in lung. The combination of cigarette smoke and lung allergy increased recruitment of lymphoid dendritic cells (DCs) into lymph nodes, which may be the leading cause to an increase in number and activation of CD8+ T cells in lungs. In addition, lung allergy and cigarette smoke exposure decreased an important regulatory subtype of DC such as plasmacytoid DC as well as its activation by expression of CD86, PDL2, and ICOSL, and it was sufficient to decrease T regs influx and anti-inflammatory cytokines release such as IL-10 and TGF-beta but not enough to diminish the structural changes. In conclusion, we observed, in this model, that OVA sensitization and challenge combined with cigarette smoke exposure leads to mischaracterization of the Th2 response of asthma by decreasing the number of eosinophils, IL-4, and IL-13 and increasing number of neutrophils, which is related to the increased number of CD8a+ DCs and CD8+ T cells as well as reduction of the regulatory cells and its released cytokines</style></abstract><notes><style face="normal" font="Arial">DA - 20170703IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00718</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670318">PM:28670318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-718.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-718.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Bruggemann TR</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00718</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korinek,M.</style></author><author><style face="normal" font="Arial"> Tsai,Y.H.</style></author><author><style face="normal" font="Arial"> El-Shazly,M.</style></author><author><style face="normal" font="Arial"> Lai,K.H.</style></author><author><style face="normal" font="Arial"> Backlund,A.</style></author><author><style face="normal" font="Arial"> Wu,S.F.</style></author><author><style face="normal" font="Arial"> Lai,W.C.</style></author><author><style face="normal" font="Arial"> Wu,T.Y.</style></author><author><style face="normal" font="Arial"> Chen,S.L.</style></author><author><style face="normal" font="Arial"> Wu,Y.C.</style></author><author><style face="normal" font="Arial"> Cheng,Y.B.</style></author><author><style face="normal" font="Arial"> Hwang,T.L.</style></author><author><style face="normal" font="Arial"> Chen,B.H.</style></author><author><style face="normal" font="Arial"> Chang,F.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical UniversityKaohsiung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Anti-allergic Hydroxy Fatty Acids from Typhonium blumei Explored through ChemGPS-NP</style></title><secondary-title><style face="normal" font="Arial">Front Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pharmacol</style></full-title></periodical><pages end="" start="356">356-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Araceae</style></keyword><keyword><style face="normal" font="Arial"> Bioactive compounds</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Increasing prevalence of allergic diseases with an inadequate variety of treatment drives forward search for new alternative drugs. Fatty acids, abundant in nature, are regarded as important bioactive compounds and powerful nutrients playing an important role in lipid homeostasis and inflammation. Phytochemical study on Typhonium blumei Nicolson and Sivadasan (Araceae), a folk anti-cancer and anti-inflammatory medicine, yielded four oxygenated fatty acids, 12R-hydroxyoctadec-9Z,13E-dienoic acid methyl ester (1) and 10R-hydroxyoctadec-8E,12Z-dienoic acid methyl ester (2), 9R-hydroxy-10E-octadecenoic acid methyl ester (3), and 12R*-hydroxy-10E-octadecenoic acid methyl ester (4). Isolated compounds were identified by spectroscopic methods along with GC-MS analysis. Isolated fatty acids together with a series of saturated, unsaturated and oxygenated fatty acids were evaluated for their anti-inflammatory and anti-allergic activities in vitro. Unsaturated (including docosahexaenoic and eicosapentaenoic acids) as well as hydroxylated unsaturated fatty acids exerted strong anti-inflammatory activity in superoxide anion generation (IC50 2.14-3.73 muM) and elastase release (IC50 1.26-4.57 muM) assays. On the other hand, in the anti-allergic assays, the unsaturated fatty acids were inactive, while hydroxylated fatty acids showed promising inhibitory activity in A2</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 1663-9812 (Print)IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - Taiwan -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.3389/fphar.2017.00356</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28674495">PM:28674495</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pharmacol\2017-8-356.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pharmacol\2017-8-356.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Korinek M</style></custom2><misc3><style face="normal" font="Arial">10.3389/fphar.2017.00356</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iwata,K.</style></author><author><style face="normal" font="Arial"> Watanabe,M.</style></author><author><style face="normal" font="Arial"> Kurai,J.</style></author><author><style face="normal" font="Arial"> Burioka,N.</style></author><author><style face="normal" font="Arial"> Nakamoto,S.</style></author><author><style face="normal" font="Arial"> Hantan,D.</style></author><author><style face="normal" font="Arial"> Shimizu,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Association between transported Asian dust and outdoor fungal concentration during winter in a rural area of western Japan</style></title><secondary-title><style face="normal" font="Arial">Genes Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Genes Environ</style></full-title></periodical><pages end="" start="19">19-</pages><volume><style face="normal" font="Arial">39</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recently, Asian dust (AD) has become a serious health problem and several studies have clearly proven that AD can aggravate asthma. However, it remains unclear as to which components of AD have a strong effect on the asthma exacerbation caused by AD exposure. Outdoor fungi can increase emergency department visits and hospitalization for asthma exacerbation and can aggravate asthma symptoms. Therefore, this study was aimed at investigating the relationship between AD and outdoor fungi and determining the potential of fungi to cause airborne particulate matter (PM)-related inflammatory responses. METHODS: Airborne PM was collected each day from January 26, 2015 to February 27, 2015. Daily levels of outdoor fungi-associated PM were calculated using a culture-based method. Production of cytokines such as interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-alpha was assessed in THP1 cells stimulated by the collected airborne PM each day. RESULTS: Daily levels of AD particles were assessed using Light Detection and Ranging and did not correlate with outdoor fungi (r = -0.17, P = 0.94). There was also no association between outdoor fungi and the daily production of IL-6 (r = 0.16, P = 0.37), IL-8 (r = 0.19, P = 0.30), or TNF-alpha induced by collected PM (r = 0.07, P = 0.70). However, the daily levels of AD particles were significantly associated with IL-6 (r = 0.91, P &lt; 0.0001), IL-8 (r = 0.64, P = 0.0004), and TNF-alpha (r = 0.72, P &lt; 0.0001) production. CONCLUSION: AD did not increase the acute levels of outdoor fungi and outdoor fungi did not affect the cytokine production induced by airborne PM. These results suggest that outdoor fungi do not have any detectable effect on the asthma exacerbation caused by AD exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1880-7046 (Print)IS - 1880-7046 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s41021-017-0079-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28680509">PM:28680509</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Genes Environ\2017-39-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Genes Environ\2017-39-19.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Iwata K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s41021-017-0079-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Imai,A.</style></author><author><style face="normal" font="Arial"> Satoi,K.</style></author><author><style face="normal" font="Arial"> Fujimoto,E.</style></author><author><style face="normal" font="Arial"> Sato,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Inducing maternal inflammation promotes leptin production in offspring but does not improve allergic symptoms in a mouse model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Heliyon</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Heliyon</style></abbr-1></periodical><pages end="" start="e00327">e00327-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adipokines</style></keyword><keyword><style face="normal" font="Arial"> Adipose tissue</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fetus</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> intrauterine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Leptin</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lipopolysaccharides</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal challenge</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><isbn><style face="normal" font="Arial">2405-8440</style></isbn><abstract><style face="normal" font="Arial">Aims The intrauterine environment is considered to affect immunological development in fetus, leading to an increased risk of developing allergy. In particular, maternal lipopolysaccharides (LPS) administration might regulate the development of allergic disease in offspring. Several studies have shown that being obese relates to a higher prevalence of allergic diseases compared to normal weight. The present study explored the effects of inducing maternal inflammation with LPS before pregnancy on body weight, physical composition including body fat, adipokine production, and pathology of allergic rhinitis in offspring. Main methods Female mice received a single intraperitoneal injection of LPS (2 ++g/g BW). After 5 days of LPS administration, female mice were mated with males, and experimental allergic rhinitis was induced in female offspring. Immunization and nasal challenge with ovalbumin (OVA) were performed at 7 and 8 weeks of age. Allergic rhinitis-like symptoms, OVA-specific IgE and adipokines in sera, body weight, fat pad weight, and cytokine production by splenocytes in these 9-week-old offspring. Key findings Maternal LPS administration results in a significant increase in body weight, visceral fat accumulation, and serum leptin concentration, and the dominance of Th1 in Th balance. Nevertheless, there was no statistical difference in OVA-specific IgE titer and allergic-like symptoms between the groups. Significance In conclusion, maternal LPS promoted leptin production and altered Th balance in mice offspring, but not improved allergic symptoms in a mouse model of allergic rhinitis. It might suggest that inflammation during pregnancy plays a role in the adipose tissue function which could diversely influence allergic inflammation in offspring</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.heliyon.2017.e00327</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.heliyon.2017.e00327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Heliyon\2017-3-e00327.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Heliyon\2017-3-e00327.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Imai A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.heliyon.2017.e00327</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inomata,N.</style></author><author><style face="normal" font="Arial"> Miyakawa,M.</style></author><author><style face="normal" font="Arial"> Aihara,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Kanagawa, 236-0004, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Gibberellin-regulated protein in Japanese apricot is an allergen cross-reactive to Pru p 7</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> Bats</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruit allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Informed Consent</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition tests</style></keyword><keyword><style face="normal" font="Arial"> Ion Exchange</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergy</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pru p 7</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Gibberellin-regulated protein (GRP, also known as peamaclein) was recently identified as a new marker allergen related to systemic reactions in peach allergy; however, its role in other fruit allergies is unknown. OBJECTIVE: To investigate the allergenicity of Japanese apricot (JA) GRP and clarify the clinical characteristics of JA allergy patients with GRP sensitization. METHODS: Seven patients (two males, five females, mean age 28.0 years) diagnosed with JA allergy based on relevant clinical history, positive skin test and/or challenge test were enrolled. JA GRP with a molecular weight of 6896.5 Da was purified by ion-exchange column chromatography. We performed enzyme-linked immunosorbent assay (ELISA), IgE-immunoblotting, basophil activating tests (BATs), and skin prick tests (SPTs) with purified JA GRP. To investigate the cross-reactivity between JA GRP and native Pru p 7 (nPru p 7), we performed ELISA inhibition tests. We measured specific IgE levels against apricot, peach, rPru p 1, rPru p 3, and rPru p 4 using ImmunoCAP. RESULTS: ELISA and IgE-immunoblotting using JA GRP showed positive reactions in six (85.7%) and seven (100%) patients, respectively. Five patients who provided informed consent for BATs and SPTs using JA GRP had positive results. In four patients who underwent ELISA inhibition tests using JA GRP and nPru p 7, IgE binding to one GRP inhibited binding to the other. The positivity for specific IgE against apricot, peach, rPru p 1, rPru p 3, and rPru p 4 was 14.3%, 57.1%, 0%, 0%, and 0%, respectively. Patients developed allergic reactions that were frequently accompanied with facial swelling, especially of the eyelids, which was dependent on cofactors, such as exercise. CONCLUSIONS AND CLINICAL RELEVANCE: These results indicated that GRP might be a causative allergen of JA allergy, whose onset frequently requires a cofactor, such as exercise, and might be cross-reactive between JAs and peaches</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.180</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28685994">PM:28685994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\20170707-InomataN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\20170707-InomataN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Inomata N</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.180</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Choi,G.</style></author><author><style face="normal" font="Arial"> Kim,B.S.</style></author><author><style face="normal" font="Arial"> Park,Y.J.</style></author><author><style face="normal" font="Arial"> Shim,I.</style></author><author><style face="normal" font="Arial"> Chung,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Clonal Expansion of Allergen-specific CD4+ T Cell in the Lung in the Absence of Lymph Nodes</style></title><secondary-title><style face="normal" font="Arial">Immune Netw</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immune Netw</style></full-title></periodical><pages end="170" start="163">163-170</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">The expansion of allergen-specific CD4+ T cells is a critical step in inducing airway inflammation during allergic asthma. Such clonal expansion of T cells is initiated through the interaction between allergen-bearing dendritic cells and allergen-specific naive T cells in the draining lymph nodes. Whether such T cell clonal expansion also occurs in the lung, the primary organ encountering inhaled allergens, remains unclear. Compared with wild-type mice, we found similar frequencies of CD4+ T cells in the lung of lymph node-deficient Rorgtgfp/gfp mice after repeated exposure to inhaled allergens. In addition, we observed an evident population of CD4+ T cells that underwent clonal expansion in the lung of allergen-challenged mice treated with an S1P antagonist FTY720 in an in vivo proliferation study with CFSE-labeled OT-II T cells. Moreover, the expansion of allergen-specific CD4+ T cells was significantly enhanced in the lungs of Rorgtgfp/gfp mice in comparison to that of wild-type mice. These results together demonstrate that the clonal expansion of allergen-specific CD4+ T cells occurs in the absence of the lymph nodes, indicating that the lung can act as a primary site of the clonal expansion of CD4+ T cells in response to inhaled allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1598-2629 (Print)IS - 1598-2629 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4110/in.2017.17.3.163</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28680377">PM:28680377</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immune Netw\2017-17-163-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immune Netw\2017-17-163-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Choi G</style></custom2><misc3><style face="normal" font="Arial">10.4110/in.2017.17.3.163</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Del Moral,M.G.</style></author><author><style face="normal" font="Arial"> Martinez-Naves,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cell Biology, Complutense University School of Medicine, Madrid 28040, Spain</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Lipids in Development of Allergic Responses</style></title><secondary-title><style face="normal" font="Arial">Immune Netw</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immune Netw</style></full-title></periodical><pages end="143" start="133">133-143</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Most allergic diseases are caused by activation of Th2 type immune responses resulting in the production of specific IgE against proteins found in normally harmless substances such as pollen, mites, epithelia or food. Allergenic substances are composed, in addition to proteins, of other compounds such as carbohydrates and lipids. Those lipids are able to promote the development of Th2-type responses associated with allergy. There are lipids found in pollen, milk or insect venom that are specifically recognized by CD1 restricted unconventional T lymphocytes, which can promote allergic reactions. Furthermore, a large number of allergens are proteins containing hydrophobic parts that specifically bind lipids that are capable to favor allergenic immune responses. Also, lipids associated to substances like pollen, dander, epithelia or the bacteria can act on cells of the innate system, including dendritic cells, which in turn lead to the differentiation of Th2-type clones. Finally, lipids may also influence the ability of allergens to be exposed to the immune system within the oral, respiratory or intestinal mucosa where allergic response occurs with great frequency</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1598-2629 (Print)IS - 1598-2629 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.4110/in.2017.17.3.133</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28680374">PM:28680374</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immune Netw\2017-17-133-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immune Netw\2017-17-133-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Del Moral MG</style></custom2><misc3><style face="normal" font="Arial">10.4110/in.2017.17.3.133</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saltabayeva,U.</style></author><author><style face="normal" font="Arial"> Garib,V.</style></author><author><style face="normal" font="Arial"> Morenko,M.</style></author><author><style face="normal" font="Arial"> Rosenson,R.</style></author><author><style face="normal" font="Arial"> Ispayeva,Z.</style></author><author><style face="normal" font="Arial"> Gatauova,M.</style></author><author><style face="normal" font="Arial"> Zulus,L.</style></author><author><style face="normal" font="Arial"> Karaulov,A.</style></author><author><style face="normal" font="Arial"> Gastager,F.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">International Network of Universities for Molecular Allergololgy and Immunology, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="98" start="93">93-98</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic testing</style></keyword><keyword><style face="normal" font="Arial"> direct costs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indirect costs</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen molecule-based diagnosis has been suggested to facilitate the identification of disease-causing allergen sources and the prescription of allergen-specific immunotherapy (AIT). The aim of the current study was to compare allergen molecule-based IgE serology with allergen extract-based skin testing for the identification of the disease-causing allergen sources. The study was conducted in an area where patients are exposed to pollen from multiple sources (trees, grasses, and weeds) at the same time to compare the diagnostic efficiency of the 2 forms of diagnosis. METHODS: Patients from Astana, Kazakhstan, who suffered from pollen-induced allergy (n = 95) were subjected to skin prick testing (SPT) with a local panel of tree pollen, grass pollen, and weed pollen allergen extracts and IgE antibodies specific for marker allergen molecules (nArt v 1, nArt v 3, rAmb a 1, rPhl p 1, rPhl p 5, rBet v 1) were measured by ImmunoCAP. Direct and indirect costs for diagnosis based on SPT and marker allergen-based IgE serology as well as direct costs for immunotherapy depending on SPT and serological test results were calculated. RESULTS: The costs for SPT-based diagnosis per patient were lower than the costs for allergen molecule-based IgE serology. However, allergen molecule-based serology was more precise in detecting the disease-causing allergen sources. A lower number of immunotherapy treatments (n = 119) was needed according to molecular diagnosis as compared to extract-based diagnosis (n = 275), which considerably reduced the total costs for diagnosis and for a 3-year treatment from EUR 1,112.30 to 521.77 per patient. CONCLUSIONS: The results from this real-life study show that SPT is less expensive than allergen molecule-based diagnostic testing, but molecular diagnosis allowed more precise prescription of immunotherapy which substantially reduced treatment costs and combined costs for diagnosis and treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Kazakhstan -CO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1159/000477442</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28654920">PM:28654920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-93-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-93-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Saltabayeva U</style></custom2><misc3><style face="normal" font="Arial">10.1159/000477442</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stemeseder,T.</style></author><author><style face="normal" font="Arial"> Klinglmayr,E.</style></author><author><style face="normal" font="Arial"> Moser,S.</style></author><author><style face="normal" font="Arial"> Lang,R.</style></author><author><style face="normal" font="Arial"> Himly,M.</style></author><author><style face="normal" font="Arial"> Oostingh,G.J.</style></author><author><style face="normal" font="Arial"> Zumbach,J.</style></author><author><style face="normal" font="Arial"> Bathke,A.C.</style></author><author><style face="normal" font="Arial"> Hawranek,T.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Influence of Intrinsic and Lifestyle Factors on the Development of IgE Sensitization</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="104" start="99">99-104</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> farming environment</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paternal</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IgE sensitization is a prerequisite for the development of allergic symptoms. The investigation of factors influencing the development of IgE is therefore crucial for understanding the onset of allergic diseases. METHODS: This epidemiological study investigated personal, intrinsic, and lifestyle factors in a nonselected cohort of 501 Austrian adolescents (aged 12-21 years). IgE levels to 112 allergen molecules were analyzed in the serum of participants using the ImmunoCAP ISAC(R). Allergic sensitization, IgE levels to single allergens, and ISAC score sums were correlated with results obtained from a questionnaire. RESULTS: In this adolescent cohort, male participants showed a higher sensitization frequency (56.8%) compared to females (50.9%) and significantly increased IgE levels to profilins. Underweight subjects demonstrated a stronger IgE sensitization. Family size inversely correlated with IgE levels to PR-10 allergens, and predominately paternal allergies were a predictive factor for IgE sensitization in the children. Vaccination, breastfeeding, and delivery mode showed no influence, while a highly protective effect was observed for growing up on a farm. Of all of the investigated lifestyle factors, only smoking significantly influenced the risk for IgE development. Participants with moderate frequencies of colds showed increased sensitization levels. CONCLUSION: A hereditary predisposition and lifestyle factors such as a farming environment, smoking, family size, body weight, or frequency of colds significantly influenced the development of allergen-specific IgE in this cohort of adolescents</style></abstract><notes><style face="normal" font="Arial">DA - 20170627IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1159/000475499</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28654924">PM:28654924</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-99-104.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-99-104.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170627, Stemeseder T</style></custom2><misc3><style face="normal" font="Arial">10.1159/000475499</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maeda,N.</style></author><author><style face="normal" font="Arial"> Yamada,C.</style></author><author><style face="normal" font="Arial"> Takahashi,A.</style></author><author><style face="normal" font="Arial"> Kuroki,K.</style></author><author><style face="normal" font="Arial"> Maenaka,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic application of human leukocyte antigen-G1 improves atopic dermatitis-like skin lesions in mice</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="207" start="202">202-207</pages><volume><style face="normal" font="Arial">50</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Discovery</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Killer Cells</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> natural killer cell</style></keyword><keyword><style face="normal" font="Arial"> Natural killer cells</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">Human leukocyte antigen (HLA)-G is an immune checkpoint molecule that plays critical roles in immune response and in triggering inhibitory signaling to immune cells such as T cells, natural killer cells, and antigen-presenting cells. Thus, the application of HLA-G can be considered for treating immune response-related inflammatory disorders. We have previously reported that treatment with HLA-G1 and HLA-G2 ameliorates the joint swelling associated with collagen-induced arthritis of DBA/1 mice, an animal model for rheumatoid arthritis. In this study, we further investigated the effects of HLA-G1 on atopic dermatitis (AD), the most common inflammatory skin disorder. AD-like lesions were induced with the extract of the house dust mite Dermatophagoides farinae in NC/Nga mice. Continuous administration of HLA-G1 ameliorated the AD-like skin lesions in the mice. Furthermore, production of immunoglobulin E, interleukin (IL)-13, and IL-17A was significantly reduced in HLA-G1-treated mice, suggesting a Th2/Th17-mediated immune-inhibitory function of HLA-G1 in vivo. Our studies shed light on novel therapeutic strategies with recombinant HLA-G proteins for immune reaction-mediated chronic inflammatory disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.06.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28675838">PM:28675838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-50-202-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-50-202-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Maeda N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.06.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">da Cruz Cabral,L.</style></author><author><style face="normal" font="Arial"> Rodriguero,M.</style></author><author><style face="normal" font="Arial"> Stenglein,S.</style></author><author><style face="normal" font="Arial"> Fog Nielsen,K.</style></author><author><style face="normal" font="Arial"> Patriarca,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Characterization of small-spored Alternaria from Argentinean crops through a polyphasic approach</style></title><secondary-title><style face="normal" font="Arial">Int J Food Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Food Microbiol</style></full-title></periodical><pages end="215" start="206">206-215</pages><volume><style face="normal" font="Arial">257</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Endopolygalacturonase gene</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Metabolites profile</style></keyword><keyword><style face="normal" font="Arial"> Polyphasic approach</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0168-1605</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Argentina -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.06.026</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ijfoodmicro.2017.06.026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Food Microbiol\2017-257-206-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Food Microbiol\2017-257-206-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, da Cruz Cabral L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijfoodmicro.2017.06.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moran,G.</style></author><author><style face="normal" font="Arial"> Arevalo,E.</style></author><author><style face="normal" font="Arial"> Barria,M.</style></author><author><style face="normal" font="Arial"> Ortloff,A.</style></author><author><style face="normal" font="Arial"> Folch,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Expression of Toll-Like Receptor 2 (TLR2) and TLR4 in Response to Aspergillus Fumigatus in Murine Models of Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Int J Immunol Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Immunol Immunother</style></full-title></periodical><pages end="" start="015">015-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TLRs</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 2</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">Toll-like receptors (TLRs) constitute a protein family of cellular receptors that mediate the recognition of microbial challenges and the subsequent inflammatory response. The role of these receptors in allergic diseases of airways remains unclear. The objective of this study was to evaluate TLR2 and TLR4 expression in the lung in a murine model of bronchial hypersensitivity to Aspergillus fumigatus. Different groups of 5-month-old mice (Balb/c) were housed in cages containing hay bedding that was contaminated with A. fumigatus and were kept in an isolation room for 16 days to allow for the induction of allergic airway inflammation.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.23937/2378-3672/1410015</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.23937/2378-3672/1410015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Immunol Immunother\2015-2-015.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Immunol Immunother\2015-2-015.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Moran G</style></custom2><misc3><style face="normal" font="Arial">10.23937/2378-3672/1410015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kohli,A.</style></author><author><style face="normal" font="Arial"> Glatz,M.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Fast Updosing of Subcutaneous House Dust Mite Immunotherapy is Well Tolerated by Pediatric Patients</style></title><secondary-title><style face="normal" font="Arial">Int J Immunol Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Immunol Immunother</style></full-title></periodical><pages end="" start="024">024-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cumulative dose</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE serum level</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Data on the safety of a cluster regimen to start a subcutaneous immunotherapy (SCIT) with house dust mite (HDM) extract in pediatric patients are scarce. This study investigates the rate of adverse events (AEs) and the applicability of a cluster regimen for HDM SCIT in pediatric patients, and identifies possible risk factors for the development of AEs. A total of 147 injections with a depot extract (D. pteronyssinus / D. farinae, 50% each) were applied to 21 HDM-sensitized pediatric patients (age 5-18 years) with allergic asthma and/or allergic rhinitis within 2 weeks. Systemic adverse events (AEs) were mild to moderate (rhinitis, nausea or mild asthma), and occurred after 5 injections (3.4%) in three different patients (14.3%). Local AEs occurred in 14 patients (66.7%); 11 of these patients (78.6%) had minor local AEs and only 3 patients (21.4%) had major local AEs of a diameter = 5 cm. All AEs developed within 60 minutes after the last injection. All patients received the full cumulative dose. Patients with local AEs had higher total IgE serum levels than patients without AEs (p = 0.02). In conclusion, the cluster regimen for induction of HDM SCIT is a safe and well tolerated procedure in children.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.23937/2378-3672/1410024</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.23937/2378-3672/1410024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Immunol Immunother\2016-3-024.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Immunol Immunother\2016-3-024.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Kohli A</style></custom2><misc3><style face="normal" font="Arial">10.23937/2378-3672/1410024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McKenna,O.E.</style></author><author><style face="normal" font="Arial"> Posselt,G.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Lackner,P.</style></author><author><style face="normal" font="Arial"> Schmitt,A.O.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author><author><style face="normal" font="Arial"> Wessler,S.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg 5020, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Multi-Approach Analysis for the Identification of Proteases within Birch Pollen</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1433">E1433-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gels</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Metalloproteases</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Threonine</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">Birch pollen allergy is highly prevalent, with up to 100 million reported cases worldwide. Proteases in such allergen sources have been suggested to contribute to primary sensitisation and exacerbation of allergic disorders. Until now the protease content of Betula verrucosa, a birch species endemic to the northern hemisphere has not been studied in detail. Hence, we aim to identify and characterise pollen and bacteria-derived proteases found within birch pollen. The pollen transcriptome was constructed via de novo transcriptome sequencing and analysis of the proteome was achieved via mass spectrometry; a cross-comparison of the two databases was then performed. A total of 42 individual proteases were identified at the proteomic level. Further clustering of proteases into their distinct catalytic classes revealed serine, cysteine, aspartic, threonine, and metallo-proteases. Further to this, protease activity of the pollen was quantified using a fluorescently-labelled casein substrate protease assay, as 0.61 ng/mg of pollen. A large number of bacterial strains were isolated from freshly collected birch pollen and zymographic gels with gelatinase and casein, enabled visualisation of proteolytic activity of the pollen and the collected bacterial strains. We report the successful discovery of pollen and bacteria-derived proteases of Betula verrucosa</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18071433</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677627">PM:28677627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1433.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1433.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, McKenna OE</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18071433</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Di Felice,G.</style></author><author><style face="normal" font="Arial"> Colombo,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Center for Drug Research and Evaluation, Istituto Superiore di Sanita, RomeInstitute of Biomedicine and Molecular Immunology, National Research Council, Palermo, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Nanoparticle-allergen complexes for allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Int J Nanomedicine</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Nanomedicine</style></abbr-1></periodical><pages end="4504" start="4493">4493-4504</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patient Compliance</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1178-2013 (Electronic)IS - 1176-9114 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2147/IJN.S134630</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28684909">PM:28684909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Nanomedicine\2017-12-4493-504.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Nanomedicine\2017-12-4493-504.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Di Felice G</style></custom2><misc3><style face="normal" font="Arial">10.2147/IJN.S134630</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,Y.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Meng,Q.</style></author><author><style face="normal" font="Arial"> Wu,F.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Tang,Y.</style></author><author><style face="normal" font="Arial"> Guan,Y.</style></author><author><style face="normal" font="Arial"> An,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Quantum dots-based lateral flow immunoassay combined with image analysis for semiquantitative detection of IgE antibody to mite</style></title><secondary-title><style face="normal" font="Arial">Int J Nanomedicine</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Nanomedicine</style></abbr-1></periodical><pages end="4812" start="4805">4805-4812</pages><volume><style face="normal" font="Arial">2017</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> image analysis</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> lateral flow immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Semiquantitative and rapid detection of specific IgE (sIgE) with well clinical relevance to house dust mite (HDM) are promising for prevalence rhinitis and asthma patients due to the increasing air pollution. However, the conventional IgE measurement systems are time-consuming, complicated and require special instruments. Herein, we overcome the above limitations of sIgE to HDM detection system by developing a quantum dot nanobeads-based lateral flow immunoassay and an image analysis procedure. The proposed detection system could semiquantitatively measure the IgE in a linear range of 0.2-10 U/mL. Moreover, there is a well correlation between the developed detection system and the clinical symptoms by a comparison study using 56 positive patients' sera and 40 healthy control sera. The proposed detection system is simple, robust and easy-to-use and promising for in home test.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.2147/IJN.S134539</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2147/IJN.S134539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Nanomedicine\2017-2017-4805-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Nanomedicine\2017-2017-4805-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Zhao Y</style></custom2><misc3><style face="normal" font="Arial">10.2147/IJN.S134539</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salih,A.M.</style></author><author><style face="normal" font="Arial"> Kakamad,F.H.</style></author><author><style face="normal" font="Arial"> Hammood,Z.D.</style></author><author><style face="normal" font="Arial"> Yasin,B.</style></author><author><style face="normal" font="Arial"> Ahmed,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medical Sciences, School of Medicine, Department Surgery, University of Sulaimani, Francois Mitterrand Street, Sulaimani, Kurdistan Region, Iraq</style></auth-address><titles><title><style face="normal" font="Arial">Abdominal wall Hydatid cyst: A review a literature with a case report</style></title><secondary-title><style face="normal" font="Arial">Int J Surg Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Surg Case Rep</style></full-title></periodical><pages end="156" start="154">154-156</pages><volume><style face="normal" font="Arial">37</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Iraq</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Hydatid cyst (HC) disease is a serious health problem in endemic areas. It is a parasitic infection that commonly involves liver and lungs while muscular HC is rare. HC of abdominal wall was reported only six times. We reported a 39-year-old male presented with HC of the right loin who was managed surgically with brief literature review. CONCLUSION: HC should be put in the differential diagnosis of the abdominal wall masses. Its pre-operative diagnosis is important to prevent rupture with subsequent anaphylaxis and recurrence. Surgery is the main modality of treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 2210-2612 (Print)IS - 2210-2612 (Linking)LA - engPT - Journal ArticleCO - Iraq -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijscr.2017.06.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28683329">PM:28683329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Surg Case Rep\2017-37-154-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Surg Case Rep\2017-37-154-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Salih AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijscr.2017.06.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gorczynski,R.</style></author><author><style face="normal" font="Arial"> Hoffmann,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Toronto, Toronto, ON, CanadaUBC, Vancouver, BC, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Toward a New Kind of Vaccine: A Logical Extension of the Symmetrical Immune Network Theory</style></title><secondary-title><style face="normal" font="Arial">Interact J Med Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Interact J Med Res</style></full-title></periodical><pages end="" start="e8">e8-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Anti-idiotype antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-idiotypic antibodies</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast cancer</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dextran</style></keyword><keyword><style face="normal" font="Arial"> Dextran Sulfate</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Tetanus</style></keyword><keyword><style face="normal" font="Arial"> Tetanus Toxoid</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The symmetrical immune network theory, developed in 1975, is based on the existence of specific T cell factors and hypothesizes that normal IgG immune responses comprise the production of 2 kinds of antibodies, namely antigen-specific antibodies and anti-idiotypic antibodies. OBJECTIVE: The aim of this study was to confirm the existence of specific T cells factors and to show that immunization of C3H mice with BL/6 skin or using nominal antigen for immunization (Tetanus Toxoid) induced production of antigen-specific (anti-BL/6 or antitetanus) antibodies plus anti-idiotypic antibodies (C3H anti-anti-C3H). Subsequently, we investigated the role of combinations of antigen-specific and anti-idiotype antibodies in a variety of animal models of clinical diseases. METHODS: Antigen-specific antibodies were produced by conventional immunization of mice (eg, with tetanus toxoid or by skin allografting). Subsequent anti-idiotypic antibodies were derived by exhaustive absorption of antigen-specific antibody, with confirmation of anti-idiotypic specificity by binding to relevant target antigen-specific antibodies in an enzyme-linked immunosorbent assay (ELISA). Antigen-specific plus anti-idiotypic antibodies were then used to modulate skin allograft survival, dextran sulfate sodium (DSS)-induced colitis, ovalbumin (OVA)-induced IgE production, and breast cancer growth in mice. RESULTS: Infusions of anti-BL/6 antibodies together with BL/6 anti-anti-BL/6 antibodies specifically suppressed (>85%) an immune response to BL/6 lymphocytes in C3H mice. The two kinds of antibodies with complementary specificity are hypothesized to stimulate 2 populations of T lymphocytes. Coselection of these 2 populations leads to a new stable steady state of the system with diminished reactivity to BL/6 tissue. A combination of anti-C3H and C3H antianti-C3H IgG antibodies down-regulated inflammation in a mouse model of inflammatory bowel disease (>75%) and attenuated anti-IgE production and sensitization to produce IL4 cytokines (>70%) in an OVA-allergy model. Combination of C3H antiBL/6 and BL/6 anti-anti-BL/6 antibodies decreased tumor growth and metastases (>705) in an EMT6 transplantable breast cancer model. CONCLUSIONS: Use of a combination of antigen-specific and anti-idiotypic antibodies has potential as a new class of vaccines</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1929-073X (Print)IS - 1929-073X (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.2196/ijmr.7612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28679488">PM:28679488</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Interact J Med Res\2017-6-e8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Interact J Med Res\2017-6-e8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Gorczynski R</style></custom2><misc3><style face="normal" font="Arial">10.2196/ijmr.7612</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calatroni,A.</style></author><author><style face="normal" font="Arial"> Wildfire,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Rho Federal Systems Division, Chapel Hill, NC.</style></auth-address><titles><title><style face="normal" font="Arial">Graphic Depiction of Bioinformatics Data</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170625IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28647586">PM:28647586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170625-CalatroniA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170625-CalatroniA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170625, Calatroni A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sheehan,W.J.</style></author><author><style face="normal" font="Arial"> Brough,H.A.</style></author><author><style face="normal" font="Arial"> Makinson,K.</style></author><author><style face="normal" font="Arial"> Petty,C.R.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Boston Children's Hospital, Division of Allergy and Immunology, Boston; Harvard Medical School, Boston</style></auth-address><titles><title><style face="normal" font="Arial">Distribution of Peanut Protein in School and Home Environments of Inner-City Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Classroom</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Home environment</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="Arial">Peanut protein was widely detectable in dust samples from school classrooms and cafeterias, with school levels higher than home levels, suggesting that schools may be an important place of exposure to food allergens in the environment</style></abstract><notes><style face="normal" font="Arial">DA - 20170625IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28647585">PM:28647585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170625-SheehanWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170625-SheehanWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170625, Sheehan WJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chitnavis,M.</style></author><author><style face="normal" font="Arial"> Stein,D.J.</style></author><author><style face="normal" font="Arial"> Commins,S.</style></author><author><style face="normal" font="Arial"> Schuyler,A.J.</style></author><author><style face="normal" font="Arial"> Behm,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Va.</style></auth-address><titles><title><style face="normal" font="Arial">First-dose anaphylaxis to infliximab: a case of mammalian meat allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1426" start="1425">1425-1426</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> infliximab</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634101">PM:28634101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170621-ChitnavisM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170621-ChitnavisM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170621, Chitnavis M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Noguerado-Mellado,B.</style></author><author><style face="normal" font="Arial"> Rojas-Perez-Ezquerra,P.</style></author><author><style face="normal" font="Arial"> Saenz de Santa Maria Garcia,M.</style></author><author><style face="normal" font="Arial"> Rodriguez-Macias,G.</style></author><author><style face="normal" font="Arial"> Tornero,P.</style></author><author><style face="normal" font="Arial"> Bartolome,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Gregorio Maranon Health Research Institute, Madrid, Spain. Roxall, R&amp;D Department, Bilbao, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylactic shock due to brentuximab-vendotin confirmed by skin test and in vitro tests</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1429" start="1427">1427-1429</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634100">PM:28634100</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1427-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1427-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170621, Noguerado-Mellado B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wi,C.I.</style></author><author><style face="normal" font="Arial"> Sohn,S.</style></author><author><style face="normal" font="Arial"> Ali,M.</style></author><author><style face="normal" font="Arial"> Krusemark,E.</style></author><author><style face="normal" font="Arial"> Ryu,E.</style></author><author><style face="normal" font="Arial"> Liu,H.</style></author><author><style face="normal" font="Arial"> Juhn,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="Arial">Natural Language Processing for Asthma Ascertainment in Different Practice Settings</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="131" start="126">126-131</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Health Records</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Records</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Natural Language Processing</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We developed and validated NLP-PAC, a natural language processing (NLP) algorithm based on predetermined asthma criteria (PAC) for asthma ascertainment using electronic health records at Mayo Clinic. OBJECTIVE: To adapt NLP-PAC in a different health care setting, Sanford Children Hospital, by assessing its external validity. METHODS: The study was designed as a retrospective cohort study that used a random sample of 2011-2012 Sanford Birth cohort (n = 595). Manual chart review was performed on the cohort for asthma ascertainment on the basis of the PAC. We then used half of the cohort as a training cohort (n = 298) and the other half as a blind test cohort to evaluate the adapted NLP-PAC algorithm. Association of known asthma-related risk factors with the Sanford-NLP algorithm-driven asthma ascertainment was tested. RESULTS: Among the eligible test cohort (n = 297), 160 (53%) were males, 268 (90%) white, and the median age was 2.3 years (range, 1.5-3.1 years). NLP-PAC, after adaptation, and the human abstractor identified 74 (25%) and 72 (24%) subjects, respectively, with 66 subjects identified by both approaches. Sensitivity, specificity, positive predictive value, and negative predictive value for the NLP algorithm in predicting asthma status were 92%, 96%, 89%, and 97%, respectively. The known risk factors for asthma identified by NLP (eg, smoking history) were similar to the ones identified by manual chart review. CONCLUSIONS: Successful implementation of NLP-PAC for asthma ascertainment in 2 different practice settings demonstrates the feasibility of automated asthma ascertainment leveraging electronic health record data with a potential to enable large-scale, multisite asthma studies to improve asthma care and research</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634104">PM:28634104</url></web-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170621, Wi CI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valovirta,E.</style></author><author><style face="normal" font="Arial"> Petersen,T.H.</style></author><author><style face="normal" font="Arial"> Piotrowska,T.</style></author><author><style face="normal" font="Arial"> Laursen,M.K.</style></author><author><style face="normal" font="Arial"> Andersen,J.S.</style></author><author><style face="normal" font="Arial"> Sorensen,H.F.</style></author><author><style face="normal" font="Arial"> Klink,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Lung Disease and Clinical Allergology, Univ of Turku and Terveystalo Allergy Clinic Turku, Finland.</style></auth-address><titles><title><style face="normal" font="Arial">Results from the 5-year SQ grass SLIT-tablet asthma prevention (GAP) trial in children with grass pollen allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevention</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen-specific</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy immunotherapy targets the immunological cause of allergic rhinoconjunctivitis and allergic asthma and has the potential to alter the natural course of allergic disease. OBJECTIVE: The primary objective was to investigate the effect of the SQ grass SLIT-tablet compared to placebo on the risk of developing asthma. METHODS: 812 children (5-12 years), with a clinically relevant history of grass pollen allergic rhinoconjunctivitis and no medical history or signs of asthma, were included in the randomised, double-blind, placebo-controlled trial, comprising 3 years treatment and 2 years follow-up. RESULTS: There was no difference in time to onset of asthma, defined by pre-specified asthma criteria relying on documented reversible impairment of lung function (primary endpoint). Treatment with the SQ grass SLIT-tablet significantly reduced the risk of experiencing asthma symptoms or using asthma medication at the end of trial (odds ratio=0.66, p&lt;0.036), during the 2-year post treatment follow-up, and during the entire 5-year trial period. Also, grass allergic rhinoconjunctivitis symptoms were 22-30% reduced (p&lt;0.005 for all 5 years). At the end of the trial, the use of allergic rhinoconjunctivitis pharmacotherapy was significantly less (27% relative difference to placebo, p&lt;0.001). Total IgE, grass pollen specific IgE, and skin prick test reactivity to grass pollen were all reduced compared to placebo. CONCLUSION: Treatment with the SQ grass SLIT-tablet reduced the risk of experiencing asthma symptoms and using asthma medication, and had a positive, long-term clinical effect on rhinoconjunctivitis symptoms and medication use but did not show an effect on the time to onset of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Poland -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689794">PM:28689794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170710-ValovirtaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170710-ValovirtaE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Valovirta E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yagami,A.</style></author><author><style face="normal" font="Arial"> Aihara,M.</style></author><author><style face="normal" font="Arial"> Ikezawa,Z.</style></author><author><style face="normal" font="Arial"> Hide,M.</style></author><author><style face="normal" font="Arial"> Kishikawa,R.</style></author><author><style face="normal" font="Arial"> Morita,E.</style></author><author><style face="normal" font="Arial"> Chinuki,Y.</style></author><author><style face="normal" font="Arial"> Fukutomi,Y.</style></author><author><style face="normal" font="Arial"> Urisu,A.</style></author><author><style face="normal" font="Arial"> Fukushima,A.</style></author><author><style face="normal" font="Arial"> Itagaki,Y.</style></author><author><style face="normal" font="Arial"> Sugiura,S.I.</style></author><author><style face="normal" font="Arial"> Tanaka,H.</style></author><author><style face="normal" font="Arial"> Teshima,R.</style></author><author><style face="normal" font="Arial"> Kato,Z.</style></author><author><style face="normal" font="Arial"> Noguchi,E.</style></author><author><style face="normal" font="Arial"> Nakamura,M.</style></author><author><style face="normal" font="Arial"> Saito,H.</style></author><author><style face="normal" font="Arial"> Matsunaga,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, Fujita Health University School of Medicine, Aichi, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Outbreak of immediate-type hydrolyzed wheat protein allergy due to a facial soap in Japan</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="881" start="879">879-881</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Hydrolyzed wheat protein</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170621IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.03.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28633942">PM:28633942</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170621-YagamiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170621-YagamiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170621, Yagami A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.03.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guvenir,H.</style></author><author><style face="normal" font="Arial"> Dibek Misirlioglu,E.</style></author><author><style face="normal" font="Arial"> Capanoglu,M.</style></author><author><style face="normal" font="Arial"> Buyuktiryaki,B.</style></author><author><style face="normal" font="Arial"> Unal,O.</style></author><author><style face="normal" font="Arial"> Toyran,M.</style></author><author><style face="normal" font="Arial"> Kocabas,C.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Allergy and Immunology, Ankara Children's Hematology Oncology Training and Research Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1157" start="1156">1156-1157</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.02.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689831">PM:28689831</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1156-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1156-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Guvenir H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.02.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pellerin,L.</style></author><author><style face="normal" font="Arial"> Jenks,J.A.</style></author><author><style face="normal" font="Arial"> Chinthrajah,S.</style></author><author><style face="normal" font="Arial"> Dominguez,T.</style></author><author><style face="normal" font="Arial"> Block,W.</style></author><author><style face="normal" font="Arial"> Zhou,X.</style></author><author><style face="normal" font="Arial"> Noshirvan,A.</style></author><author><style face="normal" font="Arial"> Gregori,S.</style></author><author><style face="normal" font="Arial"> Roncarolo,M.G.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author><author><style face="normal" font="Arial"> Bacchetta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sean N. Parker Center for Allergy and Asthma Research at Stanford University; Division of Pulmonary and Critical Care at Stanford University, Department of Medicine; Division of Stem Cell Transplantation and Regenerative Medicine at Stanford University, Department of Pediatrics, ISCBRM</style></auth-address><titles><title><style face="normal" font="Arial">Peanut-specific Tr1 cells induced in vitro from allergic individuals are functionally impaired</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> Arachis</style></keyword><keyword><style face="normal" font="Arial"> Arachis hypogaea</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> stem cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Tolerogenic dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergy is a life threatening condition which lacks regulatory-approved treatment. T regulatory type 1 (Tr1) cells are potent suppressors of immune responses and can be induced in vivo upon repeated antigen exposure or in vitro using tolerogenic dendritic cells (DC-10). Whether or not oral immunotherapy (OIT) leads to antigen-specific Tr1 cell induction has not been established. OBJECTIVES: To determine whether peanut-specific Tr1 cells can be generated in vitro from peripheral blood of peanut allergic (PA) individuals at baseline or during OIT, and whether they are functional as compared to peanut-specific Tr1 cells induced from healthy controls (HC). METHODS: DC-10 were differentiated in the presence of IL-10 from peripheral blood mononuclear cells of PA individuals and HC pulsed with the main peanut allergens Arachis hypogaea (Ara h) 1 and 2, and used as antigen presenting cells for autologous CD4+T cells (pea-T10). Pea-T10 cells were characterized by the presence of CD49b+LAG3+ Tr1 cells, antigen-specific proliferative responses, and cytokine production. RESULTS: CD49b+LAG3+ Tr1 cells were induced in pea-T10 cells at comparable percentages from HC and PA individuals. Despite their antigen specificity, pea-T10 cells of PA individuals with or without OIT, as compared to those of HC, were not anergic and had high Th2 cytokine production upon peanut-specific restimulation. CONCLUSIONS: Peanut-specific Tr1 cells can be induced from HC and PA individuals, but those from PA individuals are functionally defective independently of the OIT. The unfavorable Tr1/Th2 ratio is discussed as possible cause of PA-Tr1 cell impairment</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689791">PM:28689791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170710-PellerinL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170710-PellerinL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Pellerin L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bachert,C.</style></author><author><style face="normal" font="Arial"> Sousa,A.R.</style></author><author><style face="normal" font="Arial"> Lund,V.J.</style></author><author><style face="normal" font="Arial"> Scadding,G.K.</style></author><author><style face="normal" font="Arial"> Gevaert,P.</style></author><author><style face="normal" font="Arial"> Nasser,S.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Cornet,M.E.</style></author><author><style face="normal" font="Arial"> Kariyawasam,H.H.</style></author><author><style face="normal" font="Arial"> Gilbert,J.</style></author><author><style face="normal" font="Arial"> Austin,D.</style></author><author><style face="normal" font="Arial"> Maxwell,A.C.</style></author><author><style face="normal" font="Arial"> Marshall,R.P.</style></author><author><style face="normal" font="Arial"> Fokkens,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Upper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University and Ghent University Hospital, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Reduced need for surgery in severe nasal polyposis with mepolizumab: randomised trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Smell</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients with eosinophilic nasal polyposis frequently require surgery, and recurrence rates are high. OBJECTIVE: To assess the efficacy and safety of mepolizumab vs placebo for severe bilateral nasal polyposis. METHODS: This randomised, double-blind, placebo-controlled trial recruited patients aged 18-70 years with recurrent nasal polyposis requiring surgery. Patients received intravenous mepolizumab 750 mg or placebo every 4 weeks for a total of six doses, in addition to daily topical corticosteroid treatment. The primary endpoint was the number of patients no longer requiring surgery at Week 25, based on a composite endpoint of endoscopic nasal polyp score and nasal polyposis severity visual analogue scale (VAS) score. Secondary endpoints included change in nasal polyposis severity VAS score, endoscopic nasal polyp score, improvement in individual VAS symptoms (rhinorrhoea, mucus in throat, nasal blockage, and sense of smell), patient-reported outcomes (PRO), and safety. RESULTS: 105 patients received mepolizumab (n=54) or placebo (n=51). A significantly greater proportion of patients in the mepolizumab group compared with the placebo group no longer required surgery at Week 25 (16[30%] vs 5[10%], respectively; P=0.006). There was a significant improvement in nasal polyposis severity VAS score, endoscopic nasal polyp score, all individual VAS symptom scores, and sino-nasal outcome test [SNOT]-22 PRO score in the mepolizumab group compared with placebo. Mepolizumab's safety profile was comparable to placebo. CONCLUSION: In patients with recurrent nasal polyposis on topical corticosteroids who required surgery, mepolizumab treatment led to a greater reduction in the need for surgery and a greater improvement in symptoms than placebo. CLINICAL IMPLICATIONS: Results suggest that mepolizumab treatment has the potential to improve quality of life and reduce surgery-associated burden for patients with severe nasal polyposis</style></abstract><notes><style face="normal" font="Arial">DA - 20170708IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Sweden -CO - United KIngdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687232">PM:28687232</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170708-BachertC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170708-BachertC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170708, Bachert C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Waibel,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Landstuhl Regional Medical Center, Landstuhl, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Group Allergen Immunotherapy Education Improves Patient Knowledge and Staff Satisfaction</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1162" start="1162">1162-1162</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689832">PM:28689832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1162.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1162.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Waibel KH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Albers,F.C.</style></author><author><style face="normal" font="Arial"> Price,R.G.</style></author><author><style face="normal" font="Arial"> Smith,S.G.</style></author><author><style face="normal" font="Arial"> Yancey,S.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Mepolizumab Efficacy in Patients with Severe Eosinophilic Asthma Receiving Different Controller Therapies</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">This post hoc analysis of the MENSA study demonstrates that mepolizumab reduced the annualized exacerbation rate relative to placebo in patients with severe eosinophilic asthma irrespective of the number or type of background controller therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20170708IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687231">PM:28687231</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170708-AlbersFC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170708-AlbersFC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170708, Albers FC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Casas,R.</style></author><author><style face="normal" font="Arial"> Ruiz-Leon,A.M.</style></author><author><style face="normal" font="Arial"> Estruch,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Circulating immune cell activation and diet: A review on human trials</style></title><secondary-title><style face="normal" font="Arial">J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Immunol</style></full-title></periodical><pages end="" start="102">102-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> Atherosclerosis</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> E-Selectin</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> fibrinogen</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Intercellular Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukins</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The World Health Organization (WHO) recognizes that diet plays an important role in the prevention of several low-grade inflammatory diseases such as diabetes, atherosclerosis, metabolic syndrome and obesity. All of these diseases are characterized by elevated concentrations of inflammatory markers in the systemic circulation [e.g: C-reactive protein (CRP), interleukins, fibrinogen and adhesion molecules including E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular adhesion protein-1 (VCAM-1)]. This review focuses on the evidence obtained from epidemiological, dietary intervention and supplementation studies in humans supporting the role of monounsaturated and polyunsaturated fatty acids and other specific components of the diet in the prevention or delay of diabetes, cancer, cardiovascular disease and obesity. Thus, we provide an update of the knowledge of the relationship between diet and the modulation of immune cell activation by different dietary patterns and also highlight the importance of the overall quality and composition of the diet to protect against the previously mentioned disorders.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.15761/JAI.1000102</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.15761/JAI.1000102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Immunol\2017-1-102.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Immunol\2017-1-102.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Casas R</style></custom2><misc3><style face="normal" font="Arial">10.15761/JAI.1000102</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olivier,C.E.</style></author><author><style face="normal" font="Arial"> Pereira Gonçalves dos Santos,R.A.</style></author><author><style face="normal" font="Arial"> Guedes Pinto Argentão,D.</style></author><author><style face="normal" font="Arial"> Dias da Silva,M.</style></author><author><style face="normal" font="Arial"> Patussi dos Santos Lima,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food-dependent drug-induced angioedema: a case report</style></title><secondary-title><style face="normal" font="Arial">J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Immunol</style></full-title></periodical><pages end="" start="101">101-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">angioedema</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.15761/JAI.1000101</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.15761/JAI.1000101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Immunol\2017-1-101.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Immunol\2017-1-101.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Olivier CE</style></custom2><misc3><style face="normal" font="Arial">10.15761/JAI.1000101</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hopp,R.J.</style></author><author><style face="normal" font="Arial"> Donovan,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Eosinophilic Cystitis in a 7-Year-Old-Boy with Eosinophilic Esophagitis, Asthma, Food Allergies, and Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="251">251-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cystitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000251</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-251.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-251.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Hopp RJ</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000251</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hopp,R.J.</style></author><author><style face="normal" font="Arial"> Lewis,E.</style></author><author><style face="normal" font="Arial"> Kunnath,S.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Do Pinworms Cause Eosinophilic Esophagitis?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="247">247-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Enterobius</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophageal biopsy</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Heartburn</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Eosinophils are found in the gastrointestinal tract with the exception of the esophagus. Eosinophilic esophagitis (EE) clinically results in heartburn, abdominal pain and vomiting, and most children with EE are atopic. Diagnosis is supported by esophageal biopsy findings of >15 eosinophil's/hpf. Enterobius vermicularis infection is characteristically mild. However, there are case reports of eosinophilic ileocolitis, gastroenteritis and appendicitis secondary to pinworm infestation, but no case reports of EE associated with pinworm infestation have been reported.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000247</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-247.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-247.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Hopp RJ</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000247</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,X.P.</style></author><author><style face="normal" font="Arial"> Zhang,F.Q.</style></author><author><style face="normal" font="Arial"> Tan,X.S.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Ma,W.X.</style></author><author><style face="normal" font="Arial"> Ou-Yang,H.F.</style></author><author><style face="normal" font="Arial"> Wu,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China</style></auth-address><titles><title><style face="normal" font="Arial">EPO modified MSCs can inhibit asthmatic airway remodeling in an animal model</style></title><secondary-title><style face="normal" font="Arial">J Cell Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cell Biochem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> EPO</style></keyword><keyword><style face="normal" font="Arial"> Erythropoietin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Proliferating Cell Nuclear Antigen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Veins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: There was no effective measures can be obtained at present to reverse or prevent airway remodeling. We investigated the therapeutic effect of Erythropoietin (EPO) gene modified mesenchymal stem cells (MSCs) on asthmatic airway remodeling and the possible underlied molecular mechanisms. METHODS: EPO gene was transfected into MSCs via lentivirus vector. The transfected cells (EPO-MSCs) were identi?ed by ?ow cytometry and the EPO secreting function was detected by PCR and western blot. MSCs or EPO-MSCs were administrated to albumin (OVA)-induced chronic asthmatic mouse model via tail veins. The asthmatic phenotype was analyzed. Number of cells in bronchoalveolar lavage fluid (BALF) was counted using a haemocytometer. Histological ?ndings of airways were evaluated by microscopic examination. The concentrations of interleukin 4(IL-4), interleukin 5(IL-5) and interleukin 13(IL-13) in lung homogenate were determined by ELISA. The activation state of transforming growth factor-beta 1 (TGF-beta1), Transforming growth factor beta-activated kinase 1 (TAK1) and p38 Mitogen Activated Protein Kinase (p38MAPK) signaling was detected by Real-Time PCR and western blotting. RESULTS: EPO-MSCs were successfully constructed. EPO-MSCs showed a more potently suppressive effect on local asthmatic airway in?ammation and the level of IL-4, IL-5 and IL-13 in lung tissue than MSCs. Moreover, the numbers of goblet cells, the thicknesses of smooth muscle layer, collagen density, percentage of proliferating cell nuclear antigen positive (PCNA+ ) mesenchymal cells and von Willebrand factor positive(vWF+ ) vessels were also significantly inhibited by EPO-MSCs. Furthermore, EPO-MSCs could downregulate the expression of TGF-beta1, TAK1 and p38MAPK in lung tissue both in mRNA level and in protein level. CONCLUSION: EPO gene modified MSCs may more efficiently attenuate asthmatic airway remodeling, which maybe related with the downregulation of TGF-beta1-TAK1-p38MAPK pathway activity</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1097-4644 (Electronic)IS - 0730-2312 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/jcb.26268</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686347">PM:28686347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cell Biochem\20170707-HanXP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cell Biochem\20170707-HanXP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Han XP</style></custom2><misc3><style face="normal" font="Arial">10.1002/jcb.26268</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pakran,J.</style></author><author><style face="normal" font="Arial"> AlFalasi,A.A.</style></author><author><style face="normal" font="Arial"> Al Hammadi,A.H.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Flagellate erythema as manifestation of food hypersensitivity</style></title><secondary-title><style face="normal" font="Arial">J Dermatol Dermatolog Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Dermatol Dermatolog Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flagellate erythema</style></keyword><keyword><style face="normal" font="Arial"> Flagellate mushroom dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mushroom dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Mushrooms</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Shiitake dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Shiitake mushroom</style></keyword><keyword><style face="normal" font="Arial"> Shiitake mushroom dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Shiitake Mushrooms</style></keyword><keyword><style face="normal" font="Arial"> United Arab Emirates</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2352-2410</style></isbn><abstract><style face="normal" font="Arial">Food hypersensitivity can present in myriad forms leaving the physician baffled. Here we present a case of flagellate dermatitis in an elderly female with bronchial asthma on omalizumab injections, after ingestion of canned shiitake mushrooms. Knowledge about shiitake mushroom dermatitis is important due to increasing prevalence worldwide because of changing culinary preferences</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Arab Emirates -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdds.2017.05.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jdds.2017.05.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol Dermatolog Surg\20170704-PakranJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol Dermatolog Surg\20170704-PakranJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Pakran J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdds.2017.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ptaschinski,C.</style></author><author><style face="normal" font="Arial"> Hrycaj,S.M.</style></author><author><style face="normal" font="Arial"> Schaller,M.A.</style></author><author><style face="normal" font="Arial"> Wellik,D.M.</style></author><author><style face="normal" font="Arial"> Lukacs,N.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, University of Michigan, Ann Arbor, MI 48109</style></auth-address><titles><title><style face="normal" font="Arial">Hox5 Paralogous Genes Modulate Th2 Cell Function during Chronic Allergic Inflammation via Regulation of Gata3</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="509" start="501">501-509</pages><volume><style face="normal" font="Arial">199</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chimera</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene family</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Jurkat Cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung development</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a significant health burden in western countries, and continues to increase in prevalence. Th2 cells contribute to the development of disease through release of the cytokines IL-4, IL-5, and IL-13, resulting in increased airway eosinophils and mucus hypersecretion. The molecular mechanisms behind the disease pathology remain largely unknown. In this study we investigated a potential regulatory role for the Hox5 gene family, Hoxa5, Hoxb5, and Hoxc5, genes known to be important in lung development within mesenchymal cell populations. We found that Hox5-mutant mice show exacerbated pathology compared with wild-type controls in a chronic allergen model, with an increased Th2 response and exacerbated lung tissue pathology. Bone marrow chimera experiments indicated that the observed enhanced pathology was mediated by immune cell function independent of mesenchymal cell Hox5 family function. Examination of T cells grown in Th2 polarizing conditions showed increased proliferation, enhanced Gata3 expression, and elevated production of IL-4, IL-5, and IL-13 in Hox5-deficient T cells compared with wild-type controls. Overexpression of FLAG-tagged HOX5 proteins in Jurkat cells demonstrated HOX5 binding to the Gata3 locus and decreased Gata3 and IL-4 expression, supporting a role for HOX5 proteins in direct transcriptional control of Th2 development. These results reveal a novel role for Hox5 genes as developmental regulators of Th2 immune cell function that demonstrates a redeployment of mesenchyme-associated developmental genes</style></abstract><notes><style face="normal" font="Arial">DA - 20170603IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601826</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28576978">PM:28576978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2017-199-501-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2017-199-501-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170603, Ptaschinski C</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601826</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,A.J.</style></author><author><style face="normal" font="Arial"> Ro,M.J.</style></author><author><style face="normal" font="Arial"> Cho,K.J.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lipopolysaccharide/TLR4 Stimulates IL-13 Production through a MyD88-BLT2</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôLinked Cascade in Mast Cells, Potentially Contributing to the Allergic Response</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> costimulation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene B4</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> NF-+¦B</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> small interfering RNA</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="Arial">In an experimental asthma model, the activation of TLR4 by bacterial LPS occasionally exacerbates allergic inflammation through the production of Th2 cytokines, and mast cells have been suggested to play a central role in this response. However, the detailed mechanism underlying how LPS/TLR4 stimulates the production of Th2 cytokines, especially IL-13, remains unclear in mast cells. In the current study, we observed that the expression levels of leukotriene B4 receptor-2 (BLT2) and the synthesis of its ligands were highly upregulated in LPS-stimulated bone marrow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôderived mast cells and that BLT2 blockade with small interfering RNA or a pharmacological inhibitor completely abolished IL-13 production, suggesting a mediatory role of the BLT2 ligand</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôBLT2 axis in LPS/TLR4 signaling to IL-13 synthesis in mast cells. Moreover, we demonstrated that MyD88 lies upstream of the BLT2 ligand</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôBLT2 axis and that this MyD88-BLT2 cascade leads to the generation of reactive oxygen species through NADPH oxidase 1 and the subsequent activation of NF-+¦B, thereby mediating IL-13 synthesis. Interestingly, we observed that costimulation of LPS/TLR4 and IgE/Fc+ÁRI caused greatly enhanced IL-13 synthesis in mast cells, and blockading BLT2 abolished these effects. Similarly, in vivo, the IL-13 level was markedly enhanced by LPS administration in an OVA-induced asthma model, and injecting a BLT2 antagonist beforehand clearly attenuated this increase. Together, our findings suggest that a BLT2-linked cascade plays a pivotal role in LPS/TLR4 signaling for IL-13 synthesis in mast cells, thereby potentially exacerbating allergic response. Our findings may provide insight into the mechanisms underlying how bacterial infection worsens allergic inflammation under certain conditions</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1602062</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.4049/jimmunol.1602062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20170712-LeeAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20170712-LeeAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170712, Lee AJ</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1602062</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jang,Y.H.</style></author><author><style face="normal" font="Arial"> Choi,J.K.</style></author><author><style face="normal" font="Arial"> Jin,M.</style></author><author><style face="normal" font="Arial"> Choi,Y.A.</style></author><author><style face="normal" font="Arial"> Ryoo,Z.Y.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author><author><style face="normal" font="Arial"> Park,P.H.</style></author><author><style face="normal" font="Arial"> Kim,S.U.</style></author><author><style face="normal" font="Arial"> Kwon,T.K.</style></author><author><style face="normal" font="Arial"> Jang,M.H.</style></author><author><style face="normal" font="Arial"> Im,S.H.</style></author><author><style face="normal" font="Arial"> Moon,S.Y.</style></author><author><style face="normal" font="Arial"> Lee,W.J.</style></author><author><style face="normal" font="Arial"> Lee,S.J.</style></author><author><style face="normal" font="Arial"> Kim,D.W.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of DermatologyPharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">House Dust Mite Increases pro-Th2 Cytokines, IL-25 and IL-33 via the Activation of TLR1/6 Signaling</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune activation</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TLRs</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="Arial">House dust mite (HDM) has been implicated in the etiology and exacerbation of atopic dermatitis (AD). Diverse factors contribute to HDM allergenicity through the activation of innate immunity. We investigated whether Dermatophagoides farinae extract (DFE) allergens mediate innate immune activation through specific Toll-like receptors (TLRs) in epidermal keratinocytes, DFE-induced murine AD model and human AD lesions. DFE activated the expression of TLR1, TLR6, interleukin (IL)-25, and IL-33 in human primary keratinocytes and HaCaT cells. Knockdown of TLR6 inhibited DFE-induced upregulation of IL-25 or IL-33. In addition, the suppression of TLR1 inhibited the release of IL-33. DFE induced the expression of IL-25 and IL-33 by upregulation of IRAK1, TAK1, IKK, and NF-kappaB pathways. Tlr6-/- mice did not show DFE-induced upregulation of IL-25 and IL-33. Furthermore, DFE-induced upregulation of IL-25 was not induced in Tlr1-/- mice. We also identified upregulated mRNA and protein expression of TLR1, TLR6, IL-25 and IL-33 in human AD skin lesions with high HDM sensitization. We found that DFE-induced activation of TLR1 and TLR6 may cause polarization towards a Th2 immune response via the release of IL-25 and IL-33</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.03.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28684329">PM:28684329</url></web-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Jang YH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.03.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,K.J.</style></author><author><style face="normal" font="Arial"> Xu,Y.Y.</style></author><author><style face="normal" font="Arial"> Zhou,M.L.</style></author><author><style face="normal" font="Arial"> Zhou,S.H.</style></author><author><style face="normal" font="Arial"> Wang,S.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology,First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou,China</style></auth-address><titles><title><style face="normal" font="Arial">Role of local allergic inflammation and Staphylococcus aureus enterotoxins in Chinese patients with chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="Arial">J Laryngol Otol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Laryngol Otol</style></abbr-1></periodical><pages end="713" start="707">707-713</pages><volume><style face="normal" font="Arial">131</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Enterotoxins</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> Superantigens</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the role of local allergic inflammation and Staphylococcus aureus enterotoxins in chronic rhinosinusitis with nasal polyps. METHODS: This study included 36 patients with chronic rhinosinusitis with nasal polyps and 18 controls. Total immunoglobulin E, eosinophil cationic protein, staphylococcal enterotoxin types A and B specific immunoglobulin E, staphylococcal enterotoxin types A and B, and myeloperoxidase levels were determined. RESULTS: Four patients with chronic rhinosinusitis with nasal polyps had a local allergy. All chronic rhinosinusitis with nasal polyps patients tested negative for staphylococcal enterotoxin types A and B specific immunoglobulin E. The chronic rhinosinusitis with nasal polyps group had significantly elevated staphylococcal enterotoxin types A and B levels in the supernatant. Fourteen patients belonged to the eosinophilic chronic rhinosinusitis with nasal polyps group and the others were characterised as having non-eosinophilic chronic rhinosinusitis with nasal polyps. CONCLUSION: Local allergy may play a role in chronic rhinosinusitis with nasal polyps, independent of staphylococcal enterotoxin superantigens. Staphylococcal enterotoxins may be important in the pathogenesis of chronic rhinosinusitis with nasal polyps; however, their roles as superantigens were not confirmed in this study. In Chinese subjects, chronic rhinosinusitis with nasal polyps usually manifests as a neutrophilic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1748-5460 (Electronic)IS - 0022-2151 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1017/S0022215117001335</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28683848">PM:28683848</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Laryngol Otol\2017-131-707-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Laryngol Otol\2017-131-707-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Cheng KJ</style></custom2><misc3><style face="normal" font="Arial">10.1017/S0022215117001335</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tai,H.Y.</style></author><author><style face="normal" font="Arial"> Zhou,J.K.</style></author><author><style face="normal" font="Arial"> Yeh,C.C.</style></author><author><style face="normal" font="Arial"> Tam,M.F.</style></author><author><style face="normal" font="Arial"> Sheu,S.Y.</style></author><author><style face="normal" font="Arial"> Shen,H.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The different modes of binding of the dust mite allergens, Der f 7 and Der p 7, on a monoclonal antibody WH9 contribute to the differential reactivity</style></title><secondary-title><style face="normal" font="Arial">J Microbiol Immunol Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Microbiol Immunol Infect</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Der f 7</style></keyword><keyword><style face="normal" font="Arial"> Der p 7</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Homology modeling</style></keyword><keyword><style face="normal" font="Arial"> Homology modeling and docking</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunoblot inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> MoAb WH9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1684-1182</style></isbn><abstract><style face="normal" font="Arial">Background Der f 7 and Der p 7 are important house dust mite allergens. An IgE-binding inhibition monoclonal antibody WH9 reacts ten folds stronger against Der p 7 than to Der f 7. The purpose of this study is to identify the antigenic determinant(s) and the structural basis of Der f 7 recognize by WH9. Methods WH9-reactive determinant(s) on Der f 7 was identified by immunoblot and immunoblot inhibition. The 3-D binary complex structures of WH9 and the group 7 allergens were simulated with homology modeling and docking methods. Results WH9 reacted with the Der f 7 f9 fragment. Among the five site-directed Der f 7 mutants, WH9 showed reduced immunoblot reactivity against Der f 7 S156A, D159A and P160A mutants. Only the wild-type protein and the Der f 7 I157A and L158A mutants can inhibit significantly the WH9-binding against Der f 7. The structural model of the Der f 7-WH9 complex suggests residues S156 and D159 of Der f 7 can bind to WH9 via potential hydrogen bonds. Conclusion The structure models of Der f 7-WH9 and Der p 7-WH9 complexes revealed that the differential modes of binding of Der p 7 and Der f 7 allergens on WH9 contribute to the differential reactivity of WH9 against the Der f 7 and the Der p 7 mite allergens.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jmii.2016.11.011</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jmii.2016.11.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Microbiol Immunol Infect\20170705-TaiHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Microbiol Immunol Infect\20170705-TaiHY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Tai HY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jmii.2016.11.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jo,W.R.</style></author><author><style face="normal" font="Arial"> Park,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anti-allergic effect of fisetin on IgE-mediated mast cell activation in vitro and on passive cutaneous anaphylaxis (PCA)</style></title><secondary-title><style face="normal" font="Arial">J Nutr Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Nutr Biochem</style></full-title></periodical><pages end="111" start="103">103-111</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fisetin</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> spleen tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Syk kinase</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0955-2863</style></isbn><abstract><style face="normal" font="Arial">Fisetin (3,7,3',4'-tetrahydroxyflavone), a naturally occurring bioactive flavonoid, has been shown to inhibit inflammation. However, little is known about the effect of fisetin on immunoglobulin E (IgE)-mediated allergic responses. In this study, the effect of fisetin on rat basophilic leukemia (RBL-2H3) cell-mediated allergic reactions was investigated. Fisetin inhibited ß-hexosaminidase release, and decreased the level of interleukin-4 (IL-4) and tumor necrosis factor-alpha (TNF-a) mRNA in IgE/antigen (IgE/Ag)-stimulated RBL-2H3 cells. To elucidate the anti-allergic mechanism, we examined the levels of signaling molecules responsible for degranulation and release of inflammatory cytokines. Fisetin decreased the levels of activated spleen tyrosine kinase (Syk), Gab2 proteins, linker of activated T cells (LAT), ERK1/2 in the IgE/Ag stimulated RBL2H3 cells, NF?B and STAT3 proteins activated in the ear tissue of mice with PCA. In addition, fisetin significantly lowered of Fc?RI a-subunit mRNA expression. Consistent with the cellular data, fisetin markedly suppressed RBL-2H3 cell-dependent passive cutaneous anaphylaxis (PCA) in IgE/Ag-sensitized mice. These results suggest that fisetin may have potential as a therapeutic agent for the treatment of allergic diseases.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jnutbio.2017.06.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797929">PM:28797929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Nutr Biochem\20170705-JoWR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Nutr Biochem\20170705-JoWR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Jo WR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jnutbio.2017.06.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Conti,A.</style></author><author><style face="normal" font="Arial"> Burastero,G.</style></author><author><style face="normal" font="Arial"> Suli,C.</style></author><author><style face="normal" font="Arial"> Banerjee,S.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author><author><style face="normal" font="Arial"> Alessio,M.</style></author><author><style face="normal" font="Arial"> Burastero,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Proteome Biochemistry, IR</style></auth-address><titles><title><style face="normal" font="Arial">Identification by serological proteome analysis of paramyosin as prominent allergen in dust mite allergy</style></title><secondary-title><style face="normal" font="Arial">J Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biological significance</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical laboratory</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Der p 11</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Paramyosin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Two dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">Component-resolved diagnosis (CRD) of IgE-mediated hypersensitivities is challenged by the possibility that single patients are sensitized to components not commercially available to the clinical lab. Here, we studied a patient with positive extract-based diagnosis of house dust mite (HDM) allergy based on routine in vivo (prick test) and in vitro (serum specific IgE) tests, whose serum scored negative for IgE to the three recombinant allergens routinely used in CRD (group 1 allergens, group 2 allergens and tropomyosin). By means of serological proteome analysis via two-dimensional gel electrophoresis combined with immunoblotting and mass spectrometry, paramyosin (group 11 allergen: Der f 11 and Der p 11) was identified as the allergen component recognized by serum IgE from this patient in a raw allergen extract. Nine patients (64%) had IgE to Der p 11 in a group of 14 HDM allergic patients. BIOLOGICAL SIGNIFICANCE: Our results add up to previous reports indicating that paramyosin is a clinically relevant HDM allergen and highlight that it can represent, in some patients, the first sensitizing component of this allergen source. This suggests that, at the moment, the use of allergen extract for the purpose of measuring IgE reactivity cannot be replaced by component resolved diagnosis and that group 11 allergens should be included among allergen components routinely tested in the clinical laboratory</style></abstract><notes><style face="normal" font="Arial">DA - 20170708IS - 1876-7737 (Electronic)IS - 1874-3919 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jprot.2017.06.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687424">PM:28687424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteomics\20170708-ContiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteomics\20170708-ContiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170708, Conti A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jprot.2017.06.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lu,G.</style></author><author><style face="normal" font="Arial"> Hollenbach,S.J.</style></author><author><style face="normal" font="Arial"> Baker,D.C.</style></author><author><style face="normal" font="Arial"> Tan,S.</style></author><author><style face="normal" font="Arial"> Hutchaleelaha,A.</style></author><author><style face="normal" font="Arial"> Curnutte,J.T.</style></author><author><style face="normal" font="Arial"> Conley,P.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Portola Pharmaceuticals Inc, South San Francisco, California, USA</style></auth-address><titles><title><style face="normal" font="Arial">Preclinical safety and efficacy of andexanet alfa in animal models</style></title><secondary-title><style face="normal" font="Arial">J Thromb Haemost</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Thromb Haemost</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Diphenhydramine</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Fibrin</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Monkeys</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Andexanet is a recombinant modified form of factor Xa (FXa), designed to bind to and reverse the anticoagulant activity of FXa inhibitors. OBJECTIVES: To evaluate the ability of andexanet to reverse the anticoagulant activity of rivaroxaban, and assess its pharmacokinetics (PK) and toxicity in animal models. METHODS: The effects of andexanet on blood loss, anti-FXa activity, rivaroxaban unbound plasma concentrations, and other coagulation parameters were assessed in a rabbit liver laceration 'treatment' model. Andexanet was administered 10 min after blood loss was initiated. The toxicity of repeated administration of andexanet (up to 60 mg kg-1 day-1 ) was assessed in cynomolgus monkeys. PK parameters were evaluated in rats and monkeys. RESULTS: Excess blood loss due to anticoagulation with rivaroxaban was significantly decreased by a single intravenous bolus administration of andexanet at 35 and 75 mg/rabbit, by 75% and 63%, respectively. This correlated with dose-dependent decreases in the unbound fraction of rivaroxaban, and anti-FXa activity. Co-administration of rivaroxaban had no significant impact on the PK parameters of andexanet. Andexanet (up to 60 mg kg-1 day-1 ) was well tolerated in monkeys, with no accumulation of andexanet or rivaroxaban. There was a single occurrence of anaphylaxis which resolved after treatment with diphenhydramine and epinephrine. There was no histological evidence of prothrombotic activity with high-dose andexanet compared with vehicle control, as measured by clot and fibrin deposition in all major organs. CONCLUSIONS: These data suggest that andexanet is a promising therapy for the reversal of FXa inhibitor-induced anticoagulation, supporting clinical studies in humans. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1538-7836 (Electronic)IS - 1538-7836 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/jth.13768</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28682477">PM:28682477</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Thromb Haemost\20170706-LuG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Thromb Haemost\20170706-LuG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Lu G</style></custom2><misc3><style face="normal" font="Arial">10.1111/jth.13768</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis and Insect Stings and Bites</style></title><secondary-title><style face="normal" font="Arial">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA</style></full-title></periodical><pages end="87" start="86">86-87</pages><volume><style face="normal" font="Arial">318</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170703IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jama.2017.6470</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28672315">PM:28672315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA\2017-318-86-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA\2017-318-86-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1001/jama.2017.6470</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gauthier,M.</style></author><author><style face="normal" font="Arial"> Chakraborty,K.</style></author><author><style face="normal" font="Arial"> Oriss,T.B.</style></author><author><style face="normal" font="Arial"> Raundhal,M.</style></author><author><style face="normal" font="Arial"> DAS,S.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Huff,R.</style></author><author><style face="normal" font="Arial"> Sinha,A.</style></author><author><style face="normal" font="Arial"> Fajt,M.</style></author><author><style face="normal" font="Arial"> Ray,P.</style></author><author><style face="normal" font="Arial"> Wenzel,S.E.</style></author><author><style face="normal" font="Arial"> Ray,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">13</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> CXCR3</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> STAT1</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="Arial">We previously showed that Th1/type 1 inflammation marked by increased IFN-gamma levels in the airways can be appreciated in 50% of patients with severe asthma, despite high dose corticosteroid (CS) treatment. We hypothesized that a downstream target of IFN-gamma, CXCL10, which recruits Th1 cells via the cognate receptor CXCR3, is an important contributor to Th1high asthma and CS unresponsiveness. We show high levels of CXCL10 mRNA closely associated with IFNG levels in the BAL cells of 50% of severe asthmatics and also in the airways of mice subjected to a severe asthma model, both in the context of high-dose CS treatment. The inability of CS to dampen IFNG or CXCL10 expression was not because of impaired nuclear translocation of the glucocorticoid receptor (GR) or its transactivational functions. Rather, in the presence of CS and IFN-gamma, STAT1 and GR were recruited on critical regulatory elements in the endogenous CXCL10 promoter in monocytes, albeit without any abatement of CXCL10 gene expression. High CXCL10 gene expression was also associated with a mast cell signature in both humans and mice, CXCR3 being also expressed by mast cells. These findings suggest that the IFN-gamma-CXCL10 axis plays a central role in persistent type 1 inflammation that may be facilitated by CS therapy through GR-STAT1 cooperation converging on the CXCL10 promoter</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 2379-3708 (Electronic)IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.94580</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28679952">PM:28679952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\20170706-GauthierM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\20170706-GauthierM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Gauthier M</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.94580</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Laforte,V.</style></author><author><style face="normal" font="Arial"> Lo,P.S.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author><author><style face="normal" font="Arial"> Juncker,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, 3801 University St., Montreal, QC, Canada, H3A 2B4</style></auth-address><titles><title><style face="normal" font="Arial">Antibody Colocalization Microarray for Cross-Reactivity-Free Multiplexed Protein Analysis</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="261" start="239">239-261</pages><volume><style face="normal" font="Arial">1619</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Printing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Measuring many proteins at once is of great importance to the idea of personalized medicine, in order to get a snapshot of a person's health status. We describe the antibody colocalization microarray (ACM), a variant of antibody microarrays which avoids reagent-induced cross-reactivity by printing individual detection antibodies atop their corresponding capture antibodies. We discuss experimental parameters that are critical for the success of ACM experiments, namely, the printing positional accuracy needed for the two printing rounds and the need for protecting dried spots during the second printing round. Using small sample volumes (less than 30 muL) and small quantities of reagents, up to 108 different targets can be measured in hundreds of samples with great specificity and sensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-7057-5_19</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28674891">PM:28674891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1619-239-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1619-239-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Laforte V</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-7057-5_19</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fiuza,B.S.D.</style></author><author><style face="normal" font="Arial"> Silva,M.J.</style></author><author><style face="normal" font="Arial"> Alcantara-Neves,N.M.</style></author><author><style face="normal" font="Arial"> Barreto,M.L.</style></author><author><style face="normal" font="Arial"> Costa,R.D.S.</style></author><author><style face="normal" font="Arial"> Figueiredo,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Biorregulacao, Laboratorio de Imunofarmacologia e Biologia Molecular, Universidade Federal da Bahia (ICS), Bahia, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Polymorphisms in DENND1B gene are associated with asthma and atopy phenotypes in Brazilian children</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="41" start="33">33-41</pages><volume><style face="normal" font="Arial">90</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic markers</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Social Change</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">Asthma is a heterogeneous disease associated with a complex basis involving environmental factors and individual variabilities. The DENN Domain Containing 1B (DENND1B) gene has an important role on T cell receptor (TCR) down-regulation on Th2 cells and studies have shown that mutations or loss of this factor can be associated with increased Th2 responses and asthma. The aim of this work is to evaluate the association of polymorphisms in the DENND1B with asthma and allergy markers phenotypes in Brazilian children. Genotyping was performed using a commercial panel from Illumina (2.5 Human Omni bead chip) in 1309 participants of SCAALA (Social Change, Asthma, Allergy in Latin American) program. Logistic regressions for asthma and atopy markers were performed using PLINK software 1.9. The analyzes were adjusted for sex, age, helminth infections and ancestry markers. The DENND1B gene was associated with different phenotypes such as severe asthma and atopic markers (specific IgE production, skin prick test and IL-13 production). Among the 166 SNPs analyzed, 72 were associated with asthma and/or allergy markers. In conclusion, polymorphisms in the DENND1B are significantly associated with development of asthma and atopy and these polymorphisms can influence DENND1B expression and consequently, asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2017.06.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668455">PM:28668455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-90-33-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2017-90-33-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Fiuza BS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2017.06.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ni,W.W.</style></author><author><style face="normal" font="Arial"> Huang,W.</style></author><author><style face="normal" font="Arial"> Wu,D.Q.</style></author><author><style face="normal" font="Arial"> Zhou,Y.J.</style></author><author><style face="normal" font="Arial"> Ji,C.M.</style></author><author><style face="normal" font="Arial"> Cao,M.D.</style></author><author><style face="normal" font="Arial"> Guo,M.</style></author><author><style face="normal" font="Arial"> Sun,J.L.</style></author><author><style face="normal" font="Arial"> Wei,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Expression and purification of a major allergen, Pla a 1, from Platanus acerifolia pollen and the preparation of its monoclonal antibody</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="2892" start="2887">2887-2892</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ascites</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> hybridoma</style></keyword><keyword><style face="normal" font="Arial"> Hybridomas</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pla a 1</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="Arial">Platanus acerifolia pollen is considered an important source of airborne allergens in numerous cities. Pla a 1 is a major allergen from P. acerifolia pollen. The present study aimed to express and purify Pla a 1, and to prepare its monoclonal antibody. In the present study, the Pla a 1 gene was subcloned into a pET28a vector and transformed into the ArcticExpress (DE3) RP Escherichia coli host strain. The purified Pla a 1 was then used to immunize BALB/c mice. When serum detection was positive, spleen cells were isolated from the mice and fused with SP2/0 myeloma cells at a ratio of 10:1. Hybridoma cells were screened by indirect ELISA and limiting dilution. Positive cells were used to induce the formation of antibodycontaining ascites fluid, and the antibodies were purified using protein Aagarose. The results of the present study demonstrated that recombinant Pla a 1 was successfully expressed and purified, and exhibited positive immunoglobulin Ebinding to serum from patients allergic to P. acerifolia. A total of 11 hybridomas that steadily secreted antiPla a 1 antibody were obtained and an immunoblotting analysis indicated that all of these monoclonal antibodies specifically recognized the Pla a 1 protein. These results suggested that specific antiPla a 1 antibodies may be obtained, which can be used for the rapid detection of Pla a 1 allergens and in the preparation of vaccines against P. acerifolia pollen</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.6899</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677761">PM:28677761</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-2887-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-2887-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Ni WW</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.6899</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kiewiet,M.B.G.</style></author><author><style face="normal" font="Arial"> van Esch,B.C.A.M.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Faas,M.M.</style></author><author><style face="normal" font="Arial"> de Vos,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, RB Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Partially hydrolyzed whey proteins prevent clinical symptoms in a cow's milk allergy mouse model and enhance regulatory T and B cell frequencies</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Peyer's Patches</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">SCOPE: Partially hydrolyzed cow's milk proteins are used to prevent cow's milk allergy in children. Here we studied the immunomodulatory mechanisms of partial cow's milk hydrolysates in vivo. METHODS AND RESULTS: Mice were sensitized with whey or partially hydrolyzed whey using cholera toxin. Whey-specific IgE levels were measured to determine sensitization and immune cell populations from spleen, mesenteric lymph nodes and Peyer's patches after oral whey administration were measured by flowcytometry. Whey-specific IgE and IgG1 levels in partial whey hydrolysate sensitized animals were enhanced, but challenge did not induce clinical symptoms. This immunomodulatory effect of partial whey hydrolysate was associated with increased regulatory B and T cells in the spleen, together with a prevention of IgM-IgA class switching in the mesenteric lymph nodes and an increased Th1 and activated Th17 in the Peyer's patches. CONCLUSION: Partial hydrolysate sensitization did not induce whey induced clinical symptoms, even though sensitization was established. Increased regulatory cell populations in the systemic immune system and a prevention of increased total Th1 and activated Th17 in the intestinal immune organs could contribute to the suppression of allergic symptoms. This knowledge is important for a better understanding of the beneficial effects of hydrolysates. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201700340</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28679035">PM:28679035</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170705-KiewietMB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170705-KiewietMB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Kiewiet MB</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201700340</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korte,R.</style></author><author><style face="normal" font="Arial"> Bracker,J.</style></author><author><style face="normal" font="Arial"> Brockmeyer,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Food Chemistry, University of Munster, Munster, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Gastrointestinal digestion of hazelnut allergens on molecular level: Elucidation of degradation kinetics and resistant immunoactive peptides using mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal digestion</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> Label-free</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Structure</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Plant food allergen</style></keyword><keyword><style face="normal" font="Arial"> Plant food allergens</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">SCOPE: Allergy to hazelnut seeds ranks among the most prevalent food allergies in Europe. The aim of this study was to elucidate the gastrointestinal digestion of hazelnut allergens on molecular level. METHODS AND RESULTS: Hazelnut flour was digested in vitro following the Infogest consensus model. For six allergenic proteins, the time-dependent course of digestion was monitored by SDS-PAGE and HPLC-MS/MS, and degradation products were characterized by a bottom-up proteomics approach. Depending on the molecular structure, a specific biochemical fate was observed for each allergen, and degradation kinetics were traced back to the peptide level. 1183 peptides were characterized, including 130 peptides that carry known IgE-binding epitopes and may represent sensitizers for hazelnut allergy. The kinetics of peptide formation and degradation were determined by label free quantification and follow a complex multi-stage mechanism. CONCLUSION: We present a comprehensive survey on the gastrointestinal digestion of a relevant allergenic food on level of the peptidome, including the first systematic characterization and quantification of degradation products. This provides information on the differential resistance of plant food allergens and their structural elements undergoing digestion and forms the basis for a deeper understanding of the molecular principles responsible for sensitization to food allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201700130</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677900">PM:28677900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170705-KorteR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170705-KorteR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Korte R</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201700130</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Loxham,M.</style></author><author><style face="normal" font="Arial"> Smart,D.E.</style></author><author><style face="normal" font="Arial"> Bedke,N.J.</style></author><author><style face="normal" font="Arial"> Smithers,N.P.</style></author><author><style face="normal" font="Arial"> Filippi,I.</style></author><author><style face="normal" font="Arial"> Blume,C.</style></author><author><style face="normal" font="Arial"> Swindle,E.J.</style></author><author><style face="normal" font="Arial"> Tariq,K.</style></author><author><style face="normal" font="Arial"> Howarth,P.H.</style></author><author><style face="normal" font="Arial"> Holgate,S.T.</style></author><author><style face="normal" font="Arial"> Davies,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergenic proteases cleave the chemokine CX3CL1 directly from the surface of airway epithelium and augment the effect of rhinovirus</style></title><secondary-title><style face="normal" font="Arial">Mucosal Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mucosal Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> CX3CL1</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAR-2</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> shedding</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">CX3CL1 has been implicated in allergen-induced airway CD4+ T-lymphocyte recruitment in asthma. As epidemiological evidence supports a viral infection-allergen synergy in asthma exacerbations, we postulated that rhinovirus (RV) infection in the presence of allergen augments epithelial CX3CL1 release. Fully differentiated primary bronchial epithelial cultures were pretreated apically with house dust mite (HDM) extract and infected with rhinovirus-16 (RV16). CX3CL1 was measured by enzyme-linked immunosorbent assay and western blotting, and shedding mechanisms assessed using inhibitors, protease-activated receptor-2 (PAR-2) agonist, and recombinant CX3CL1-expressing HEK293T cells. Basolateral CX3CL1 release was unaffected by HDM but stimulated by RV16; inhibition by fluticasone or GM6001 implicated nuclear factor-kappaB and ADAM (A Disintegrin and Metalloproteinase) sheddases. Conversely, apical CX3CL1 shedding was stimulated by HDM and augmented by RV16. Although fluticasone or GM6001 reduced RV16+HDM-induced apical CX3CL1 release, heat inactivation or cysteine protease inhibition completely blocked CX3CL1 shedding. The HDM effect was via enzymatic cleavage of CX3CL1, not PAR-2 activation, yielding a product mitogenic for smooth muscle cells. Extracts of Alternaria fungus caused similar CX3CL1 shedding. We have identified a novel mechanism whereby allergenic proteases cleave CX3CL1 from the apical epithelial surface to yield a biologically active product. RV16 infection augmented HDM-induced CX3CL1 shedding-this may contribute to synergy between allergen exposure and RV infection in triggering asthma exacerbations and airway remodeling.Mucosal Immunology advance online publication, 5 July 2017; doi:10.1038/mi.2017.63</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 1935-3456 (Electronic)IS - 1933-0219 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/mi.2017.63</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677664">PM:28677664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mucosal Immunol\20170705-LoxhamM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mucosal Immunol\20170705-LoxhamM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Loxham M</style></custom2><misc3><style face="normal" font="Arial">10.1038/mi.2017.63</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ryu,J.H.</style></author><author><style face="normal" font="Arial"> Xie,C.</style></author><author><style face="normal" font="Arial"> Kim,E.J.</style></author><author><style face="normal" font="Arial"> Park,S.H.</style></author><author><style face="normal" font="Arial"> Choi,Y.J.</style></author><author><style face="normal" font="Arial"> Kang,S.S.</style></author><author><style face="normal" font="Arial"> Shin,M.K.</style></author><author><style face="normal" font="Arial"> Kang,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Convergence Medical Science, Gyeongsang National University, Jinju 52727, Korea.</style></auth-address><titles><title><style face="normal" font="Arial">Reduction of Asthmatic Parameters by Sea Hare Hydrolysates in a Mouse Model of Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="E699">E699-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Convergence</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene D4</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">Sea hare has a variety of biological activities. However, little is known regarding the anti-asthmatic effects of sea hare. This study was performed to identify the effect of sea hare hydrolysates (SHH) on an ovalbumin (OVA)-induced allergic asthma model. The experimental asthma model was sensitized and challenged with OVA. We found that a high-dose of SHH (HSHH) significantly inhibited OVA-induced airway inflammation and mucus production around the airway in lung sections, while low- and medium-dose SHH showed an insignificant effect. In addition, HSHH highly reduced OVA-induced production of interleukin-4, -5, -13, leukotriene D4, E4, and histamine in bronchoalveolar lavage fluid. HSHH decreased the histamine-induced increase in the intracellular Ca2+ level and contractions in asthmatic smooth muscle cells. Furthermore, HSHH did not affect the weights of the spleen nor thymus, whereas dexamethasone (DEX), a steroidal anti-inflammatory drug, reduced them. Taken together, these results showed that HSHH reduced asthmatic parameters in a mouse model of allergic asthma, and suggest that SHH could be used as a potential therapeutic agent for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170705IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9070699</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28678189">PM:28678189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9- E699.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9- E699.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170705, Ryu JH</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9070699</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santos,L.</style></author><author><style face="normal" font="Arial"> Vericimo,M.</style></author><author><style face="normal" font="Arial"> Teixeira,G.</style></author><author><style face="normal" font="Arial"> Clemente,S.S.</style></author><author><style face="normal" font="Arial"> Figueiredo,I.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Imunobiologia, Instituto de Biologia, Universidade Federal Fluminense, Niteroi, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Seroreactivity to Anisakis spp. in the perinatal period</style></title><secondary-title><style face="normal" font="Arial">Obstet Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Obstet Med</style></full-title></periodical><pages end="98" start="96">96-98</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: This study had sought to assess the seroreactivity to the fish nematode Anisakis spp. in a puerperal population, as well as to ascertain whether a correlation exists between maternal and cord blood levels. METHODS: Blood samples were obtained from puerperal women and cord blood to measure specific anti-Anisakis antigen IgG and IgE by ELISA. Non-parametric tests were used to compare two or more independent and related samples. RESULTS: Of the 99 maternal serum samples assessed, 21 were positive on ELISA (21.2%). There were no significant differences in the mean ranks of IgG optical density levels between women who ate fish and those who did not (p = 0.456), those who ate raw fish and those who did not (p = 0.479), or between those who had allergic complaints and those who did not (p = 0.431). CONCLUSION: Transplacental passage of antibodies occurred, leading to moderate correlation between maternal and cord blood serum levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1753-495X (Print)IS - 1753-495X (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1177/1753495X16689443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28680472">PM:28680472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Obstet Med\2017-10-96-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Obstet Med\2017-10-96-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Santos L</style></custom2><misc3><style face="normal" font="Arial">10.1177/1753495X16689443</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,R.T.</style></author><author><style face="normal" font="Arial"> Liu,J.Q.</style></author><author><style face="normal" font="Arial"> Lu,H.Y.</style></author><author><style face="normal" font="Arial"> Chen,Y.M.</style></author><author><style face="normal" font="Arial"> Guan,L.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Liu,Z.J.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, The Shanghai Tenth People's Hospital of Tongji University, Shanghai 200072, China</style></auth-address><titles><title><style face="normal" font="Arial">Micro RNA-155 plays a critical role in the initiation of food allergen-related inflammation in the intestine</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="67505" start="67497">67497-67505</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">40</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="Arial">The pathogenesis of food allergy (FA) is to be further investigated. Regulatory B cells (B10 cell) play a critical in the maintenance of the homeostasis in the intestine. Deregulation of B10 cell is associated with immune inflammation. Micro RNA (miR) 155 is involved in affecting immune cell function. This study tests a hypothesis that miR-155 affects the B10 cell function to facilitate the initiation of FA. In this study, BALB/c mice were sensitized to ovalbumin (OVA) to induce FA-like inflammation in the intestine. B cells were isolated from the intestine by magnetic cell sorting. The expression of miR-155 and IL-10 in B cells was assessed by real time RT-PCR. The results showed that mice sensitized to OVA showed FA-like inflammation and lower frequency of B10 cell in the intestine. B cells isolated from the intestine of FA mice showed higher levels of miR-155 and lower levels of IL-10. Although all the three T helper (Th)2 cytokines, including interleukin (IL)-4, IL-5 and IL-13, were higher in the serum, only IL-13 was positively correlated with the levels of miR-155 in the intestinal B cells. Exposure to IL-13 in the culture markedly increased the expression of miR-155 and suppressed the expression of IL-10 in B cells. Blocking miR-155 abolished the IL-13-induced IL-10 suppression in B cells and inhibited FA response in mice. In conclusion, miR-155 plays a critical role in the initiation of FA in mice. Blocking miR-155 has therapeutic potential in the treatment of FA</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.18723</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28978048">PM:28978048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170707-LinRT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170707-LinRT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Lin RT</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.18723</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thostesen,L.M.</style></author><author><style face="normal" font="Arial"> Kjaer,H.F.</style></author><author><style face="normal" font="Arial"> Pihl,G.T.</style></author><author><style face="normal" font="Arial"> Nissen,T.N.</style></author><author><style face="normal" font="Arial"> Birk,N.M.</style></author><author><style face="normal" font="Arial"> Kjaergaard,J.</style></author><author><style face="normal" font="Arial"> Jensen,A.K.G.</style></author><author><style face="normal" font="Arial"> Aaby,P.</style></author><author><style face="normal" font="Arial"> Olesen,A.W.</style></author><author><style face="normal" font="Arial"> Stensballe,L.G.</style></author><author><style face="normal" font="Arial"> Jeppesen,D.L.</style></author><author><style face="normal" font="Arial"> Benn,C.S.</style></author><author><style face="normal" font="Arial"> Kofoed,P.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Kolding Hospital, Skovvangen 2-8, DK-6000</style></auth-address><titles><title><style face="normal" font="Arial">Neonatal BCG has no effect on allergic sensitization and suspected food allergy until 13 months</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="596" start="588">588-596</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Vaccination with Bacillus Calmette-Guerin (BCG) is used in many countries as protection against tuberculosis. Studies have suggested that BCG may also have non-specific effects, reducing non-tuberculosis mortality, morbidity, and atopic manifestations. In this study we evaluated the effect of neonatal BCG vaccination on allergic sensitization and suspected food allergy at 13 months of age. METHODS: The Danish Calmette Study was conducted from 2012-2015 at three Danish hospitals. Within 7 days of birth, the 4262 newborns of 4184 included mothers were randomized 1:1 to BCG or to a no-intervention control group. Exclusion criteria were gestational age &lt;32 weeks, birth weight &lt;1000 g, known immunodeficiency, or no Danish-speaking parent. Follow-up information was collected through telephone interviews at 3 and 13 months of age. Subgroups of participants were offered blood sampling at 13 months of age. RESULTS: By 13 months of age the parents and/or general practitioners of 5.6% (117/2089) of the children in the BCG group and 6.1% (126/2061) of the control group suspected food allergy, resulting in a risk ratio comparing BCG-vaccinated children with control children of 0.91 (95% CI 0.71 to 1.16). Among 1370 blood samples, sensitization (Phadiatop Infant > 0.35 kUA/l) was found in 55/743 (7.4%) children in the BCG group and 50/627 (8.0%) of the control group (risk ratio 0.94 (0.65 to 1.36)). CONCLUSION: In this randomized clinical trial neonatal BCG had no significant effect on suspected food allergy or on sensitization at 13 months of age. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12748</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28660649">PM:28660649</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170629-ThostesenLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170629-ThostesenLM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Thostesen LM</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12748</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Padua,I.</style></author><author><style face="normal" font="Arial"> Moreira,A.</style></author><author><style face="normal" font="Arial"> Padrao,P.</style></author><author><style face="normal" font="Arial"> Moreira,P.</style></author><author><style face="normal" font="Arial"> Barros,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Travelling with food allergy: what to expect from the airlines?</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="598" start="597">597-598</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">Food allergy (FA) has a significant impact on patients and families 'quality of life (1) and, considering that traveling is particularly anxiety provoking for children (2) , many parents prefer to minimize the risk induced by such activities by avoiding them altogether (3) . This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12742</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28632328">PM:28632328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170620-PaduaI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170620-PaduaI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Padua I</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12742</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lagreula,M.</style></author><author><style face="normal" font="Arial"> Chiriac,A.M.</style></author><author><style face="normal" font="Arial"> Leoni,M.C.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Caimmi,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Risk factors for developing food-induced bronchospasm during oral food challenge</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="602" start="598">598-602</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Larynx</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">Prevalence of both asthma and food allergy is increasing in Western Europe (1,2). In France, according to recent surveys, the prevalence of asthma is 9.4% in children and 7% in adults (3). Food allergy proven by oral food challenges (OFC) affects between 1 to 10% of the population (4). Studies have been considering both disorders as comorbidities under the atopic disease concept. Asthmatic children with food allergy have an increased risk for asthma exacerbation and severe asthma, especially when developing anaphylactic reactions (1,5). Each part of the respiratory system (the nose, the larynx, and the lungs) may be involved in food-induced allergic reactions, especially in IgE-mediated allergic reactions, and food allergies play a role in the pathogenesis of respiratory tract symptoms (6). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170620IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12745</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28631334">PM:28631334</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170620-LagreulaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170620-LagreulaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170620, Lagreula M</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12745</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cosme-Blanco,W.</style></author><author><style face="normal" font="Arial"> Lopez,E.</style></author><author><style face="normal" font="Arial"> Morales-Bronner,S.</style></author><author><style face="normal" font="Arial"> Blouin,W.</style></author><author><style face="normal" font="Arial"> Hernandez-Trujillo,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, University of Puerto Rico, Medical Sciences Campus, San Juan, PR, USA</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis to Horses and Epinephrine Use-Increasing Awareness Among Pediatric Patients and Families</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="610" start="608">608-610</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> dog dander</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Puerto Rico</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">Pet allergens follow aeroallergens as a common cause of asthma and rhinitis in children (1,2). Specifically, cat and dog dander are typical triggers of these symptoms(1). However, high percent of patients with severe asthma can be sensitized to other mammals, such as horses and mice(3). This is not limited to occupational or rural areas where exposure to this animal is more prevalent. A high rate of sensitization to horses in people with no known direct exposure who live in urban areas is well documented(4). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - United states -CO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12753</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686311">PM:28686311</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170707-CosmeBiancoW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170707-CosmeBiancoW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Cosme-Bianco W</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12753</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsuoka,T.</style></author><author><style face="normal" font="Arial"> Bernstein,D.I.</style></author><author><style face="normal" font="Arial"> Masuyama,K.</style></author><author><style face="normal" font="Arial"> Nolte,H.</style></author><author><style face="normal" font="Arial"> Okamiya,K.</style></author><author><style face="normal" font="Arial"> Seitzberg,D.</style></author><author><style face="normal" font="Arial"> Nelson,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head &amp; Neck Surgery, Faculty of Medicine, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, Yamanashi, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> interdisciplinary</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> North America</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: House dust mite (HDM) respiratory allergy is a common and burdensome disease in children and adolescents. There are few HDM allergy immunotherapy trials in children with perennial allergic rhinitis. This post hoc analysis used pooled data to evaluate efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in adolescents (12-17 years). METHODS: In 2 double-blind, placebo-controlled trials conducted in North America and Japan, respectively, subjects aged 12+ years with HDM allergic rhinitis were randomized to up to one year of treatment. The primary endpoint in both trials was the average total combined rhinitis score (TCRS) during the last 8 weeks of treatment in the active group compared to placebo. Data from subjects aged 12-17 years were pooled (N=395). RESULTS: In the pooled adolescent subpopulation, average TCRS improved 22% with 12 SQ-HDM versus placebo (absolute treatment difference of 1.04; p&lt;0.01). Rhinitis daily symptom score (DSS), conjunctivitis DSS, and rhinitis daily medication score (DMS) were also significantly improved versus placebo in the pooled adolescent subpopulation (all p&lt;0.05). There were no new safety signals for adolescents. The frequency of adverse events were similar in adolescents and adults with the majority being mild application site related events. CONCLUSIONS: Treatment with 12 SQ-HDM appears to be effective and well-tolerated in adolescents with HDM allergic rhinitis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170629IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12747</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28660739">PM:28660739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170629-MatsuokaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170629-MatsuokaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170629, Matsuoka T</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12747</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lai,F.P.</style></author><author><style face="normal" font="Arial"> Yang,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatrics, National Cheng Kung University Hospital, Medical College, National Cheng Kung University, Taiwan.</style></auth-address><titles><title><style face="normal" font="Arial">The prevalence and characteristics of cow's milk protein allergy in infants and young children with iron deficiency anemia</style></title><secondary-title><style face="normal" font="Arial">Pediatr Neonatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Pediatr Neonatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anemia</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Colonoscopy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Failure to Thrive</style></keyword><keyword><style face="normal" font="Arial"> Ferritin</style></keyword><keyword><style face="normal" font="Arial"> hemorrhagic</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> Hypoalbuminemia</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> iron deficiency anemia</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The clinical presentation of cow's milk protein allergy (CMPA) in children varies. This retrospective study aimed to investigate the prevalence and clinical manifestations of CMPA in young children who visited for evaluation of iron deficiency anemia (IDA). METHODS: Patients aged &lt;4 years who were diagnosed as having IDA (serum ferritin &lt;12 ng/mL) at the National Cheng Kung University Hospital, Taiwan in the period 2005-2015 were reviewed. Their clinical presentations, laboratory data, endoscopy findings, and prognosis were analyzed. RESULTS: Seven of 51 IDA patients (13.7%) had CMPA. The pallor (100%), failure to thrive (43%), and general edema (43%) were the common features. Six (86%) had hypoalbuminemia and four (57%) had positive occult blood in the stool. Of the five patients who underwent skin prick test, four (80%) had positive results. Most of the colonoscopies revealed erosive and hemorrhagic colitis and lymphoid hyperplasia, but none of the biopsies demonstrated eosinophilia in the lamina propria. All of the patients recovered from their IDA within seven months of cow's milk protein elimination and iron supplementation. CONCLUSION: CMPA should be considered in young children with undetermined IDA. Cow's milk protein elimination and iron supplementation help in the recovery</style></abstract><notes><style face="normal" font="Arial">DA - 20170712IS - 2212-1692 (Electronic)IS - 1875-9572 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pedneo.2017.01.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28698024">PM:28698024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Neonatol\20170706-LaiFP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Neonatol\20170706-LaiFP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Lai FP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pedneo.2017.01.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Savi,E.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Boni,E.</style></author><author><style face="normal" font="Arial"> Mauro,M.</style></author><author><style face="normal" font="Arial"> Peveri,S.</style></author><author><style face="normal" font="Arial"> Pravettoni,V.</style></author><author><style face="normal" font="Arial"> Quercia,O.</style></author><author><style face="normal" font="Arial"> Reccardini,F.</style></author><author><style face="normal" font="Arial"> Montagni,M.</style></author><author><style face="normal" font="Arial"> Pessina,L.</style></author><author><style face="normal" font="Arial"> Ridolo,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Dept. Unit, G. Da Saliceto Hospital, AUSL, Piacenza, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0180270">e0180270-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Venom immunotherapy (VIT) is highly effective in preventing allergic reactions to insect stings, but the appropriate venom must be used to achieve clinical protection. In patients with multiple positive results to venoms, molecular allergy diagnostics or CAP-inhibition may identify the causative venom. Concerning allergy to venom from Polistes spp. it has been proposed that only the European species P. dominulus should be used for VIT. However, this recommendation is not present in any international guideline. Using both laboratory and clinical data, we aimed to evaluate the reliability of this proposal. METHODS: We performed an in vitro study using CAP-inhibition to determine sensitization of 19 patients allergic to Polistes venom. The clinical study included 191 patients with positive tests to Polistes treated with VIT, 102 were treated with P. dominulus and 89 were treated with a mix of American Polistes (mAP). RESULTS: The difference in % of inhibition was significant concerning inhibition of P. dominulus sIgE by P. dominulus venom (79.8%) compared with inhibition by mAP venom (64.2%) and not significant concerning the inhibition of mAP sIgE by P. dominulus venom (80.1%) and by mAP venom (73.6%). Instead, the clinical protection from stings was not statistically different between the two kinds of venom. CONCLUSION: The data from CAP inhibition would suggest that the choice of either P. dominulus venom or mAP venom for VIT is appropriate in patients with CAP inhibition higher than 70%, but the clinical data show the same odds of protection from stings using for VIT P. dominulus or mAP venom</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0180270</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686638">PM:28686638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0180270.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0180270.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170707, Savi E</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0180270</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Macglashan,D.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Johns Hopkins Asthma and Allergy Center, Baltimore, MD</style></auth-address><titles><title><style face="normal" font="Arial">FceRI density and spontaneous secretion from human basophils</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0179734">e0179734-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> aggregates</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Buffers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Deuterium</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FceRI</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human basophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptor Aggregation</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Mast cells and basophils depend on aggregation of the high-affinity IgE receptor, FceRI, to initiate secretion. A variety of studies have shown that FceRI densities vary 100 fold among subjects' basophils and it has been speculated that high densities might be responsible for unusual behaviors of the cells, notably sensitivity to certain monomeric IgE antibodies or spontaneous release. These studies experimentally examined the density dependence of spontaneous release and signaling element expression in subjects' basophils with FceRI densities ranging from approximately 6000 to 600,000 per cell. Through the use of numerical simulation, this study examined the expectations for spontaneous receptor aggregation and aggregate persistence at densities of FceRI ranging from 5000 to 500,000. Experimentally, FceRI density was not associated with greater spontaneous histamine release even when secretion was enhanced by the inclusion of deuterium oxide in the buffers. There was also no association of 15 activating or de-activating signaling elements with FceRI density. The numerical simulations demonstrated that at densities of approximately 500,000 receptors, 13% of receptors were involved in transient aggregates at any given moment but that these aggregates rarely persisted for greater than 10 milliseconds. In contrast, a weak linear antigen aggregator, with ligand affinities known to induce secretion, would generate aggregates persisting for an average of approximately 60 milliseconds. These results suggest that although a high density of FceRI likely produces a large number of transient aggregates, these aggregates do not persist long enough to induce signaling that results in secretion and do not induce the cells to alter their expression of several signaling elements known to be important in regulating secretion from human basophils. The results set some boundaries on the aggregation requirements for inducing histamine release from human basophils</style></abstract><notes><style face="normal" font="Arial">DA - 20170703IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0179734</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28671980">PM:28671980</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0179734.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0179734.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0179734.s002.xlsxC:\A&amp;H HMW Papers\PLoS One\2017-12-e0179734.s003.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0179734.s002.xlsxF:\A&amp;H HMW Papers\PLoS One\2017-12-e0179734.s003.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170703, MacGlashan D Jr</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0179734</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silva,S.L.</style></author><author><style face="normal" font="Arial"> Albuquerque,A.</style></author><author><style face="normal" font="Arial"> Amaral,A.J.</style></author><author><style face="normal" font="Arial"> Li,Q.Z.</style></author><author><style face="normal" font="Arial"> Mota,C.</style></author><author><style face="normal" font="Arial"> Cheynier,R.</style></author><author><style face="normal" font="Arial"> Victorino,R.M.M.</style></author><author><style face="normal" font="Arial"> Pereira-Santos,M.C.</style></author><author><style face="normal" font="Arial"> Sousa,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa. Lisboa, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Autoimmunity and allergy control in adults submitted to complete thymectomy early in infancy</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0180385">e0180385-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell depletion</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptor</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Thymectomy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The contribution of the decline in thymic activity for the emergence of autoimmunity is still debatable. Immune-competent adults submitted to complete thymectomy early in life provide a unique model to address this question. We applied here strict criteria to identify adults lacking thymic activity based on sjTREC levels, to exclude thymic rebound and/or ectopic thymuses. In agreement, they featured severe naive CD4 T-cell depletion and contraction of T-cell receptor diversity. Notwithstanding this, there was neither increased incidence of autoimmune disease in comparison with age-matched controls nor significant changes in their IgG/IgA/IgM/IgE autoreactivity profiles, as assessed through extensive arrays. We reasoned that the observed relative preservation of the regulatory T-cell compartment, including maintenance of naive regulatory CD4 T-cells, may contribute to limit the emergence of autoimmunity upon thymectomy. Our findings have implications in other clinical settings with impaired thymic activity, and are particularly relevant to studies of autoimmunity in ageing</style></abstract><notes><style face="normal" font="Arial">DA - 20170707IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Portugal -CO - United States -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0180385</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686710">PM:28686710</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0180385.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0180385.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0180385.S1_Table.xlsC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0180385.S2_Table.xlsC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0180385.S3_Table.xlsC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0180385.S4_Table.xls</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0180385.S1_Table.xlsF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0180385.S2_Table.xlsF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0180385.S3_Table.xlsF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0180385.S4_Table.xls</url></image-urls></urls><custom2><style face="normal" font="Arial">20170707, Silva SL</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0180385</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">John-Schuster,G.</style></author><author><style face="normal" font="Arial"> de Kleijn,S.</style></author><author><style face="normal" font="Arial"> van Wijck,Y.</style></author><author><style face="normal" font="Arial"> Kremer,V.</style></author><author><style face="normal" font="Arial"> Smits,H.H.</style></author><author><style face="normal" font="Arial"> Pieper,M.P.</style></author><author><style face="normal" font="Arial"> Hiemstra,P.S.</style></author><author><style face="normal" font="Arial"> Taube,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Leiden University Medical Center, Albinusdreef 2, 2333, ZA Leiden, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">The effect of tiotropium in combination with olodaterol on house dust mite-induced allergic airway disease</style></title><secondary-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regime</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tiotropium</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">One of the major goals of asthma therapy is to maintain asthma control and prevent acute exacerbations. Long-acting bronchodilators are regularly used for the treatment of asthma patients and in clinical studies the anti-cholinergic tiotropium has recently been shown to reduce exacerbations in patients with asthma. So far it is unclear how tiotropium exerts this effect. For this purpose, we designed an allergen-driven rechallenge model of allergic airway inflammation in mice, to assess the effectiveness of tiotropium and the long-acting beta-2 adrenoceptor agonist olodaterol on allergen-induced exacerbations of airway disease. Female C57BL/6J mice were sensitized intranasally (i.n.) with 1 mug of house dust mite (HDM) extract followed by a challenge regime (5 consecutive days 10 mug HDM extract i.n.) after one week. Mice were exposed to a secondary challenge five weeks after sensitization and were treated i.n. with different concentrations of tiotropium or olodaterol (1, 10 and 100 mug/kg) or a combination thereof (10 mug/kg each) prior to and during the secondary challenge period. Three days after the last challenge, bronchoalveolar lavage (BAL) fluid and lung tissue were collected for flow cytometry and histologic analysis, respectively. Secondary challenge with HDM extract strongly induced allergic airway disease reflected by inflammatory cell infiltration and goblet cell metaplasia. Treatment with tiotropium, but not with olodaterol reduced tissue inflammation and goblet cell metaplasia in a dose-dependent manner. The combination of tiotropium and olodaterol was more effective in significantly reducing tissue inflammation compared to tiotropium treatment alone, and also led to a decrease in BAL cell counts. These data suggest that in a model of relapsing allergic airway disease tiotropium directly prevents exacerbations by reducing inflammation and mucus production in the airways. In addition, the combination of tiotropium and olodaterol exerts synergistic effects</style></abstract><notes><style face="normal" font="Arial">DA - 20170708IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pupt.2017.06.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687462">PM:28687462</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170708-JohnSchusterG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170708-JohnSchusterG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170708, John-Schuster G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pupt.2017.06.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barnig,C.</style></author><author><style face="normal" font="Arial"> Baron-Thurotte,A.</style></author><author><style face="normal" font="Arial"> Barbaud,A.</style></author><author><style face="normal" font="Arial"> Beaudouin,E.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Bonniaud,P.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Didier,A.</style></author><author><style face="normal" font="Arial"> Drouet,M.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author><author><style face="normal" font="Arial"> Lavaud,F.</style></author><author><style face="normal" font="Arial"> Maihol,C.</style></author><author><style face="normal" font="Arial"> Metz-Favre,C.</style></author><author><style face="normal" font="Arial"> Neukirch,C.</style></author><author><style face="normal" font="Arial"> Petit,N.</style></author><author><style face="normal" font="Arial"> Perotin,J.M.</style></author><author><style face="normal" font="Arial"> Ponvert,C.</style></author><author><style face="normal" font="Arial"> Sauvage,C.</style></author><author><style face="normal" font="Arial"> Magnan,A.</style></author><author><style face="normal" font="Arial"> Birnbaum,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Recommandations de la Société Française d'Allergologie. Indications des actes allergologiques en Hôpital de Jour</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">France</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Recommandation</style></keyword><keyword><style face="normal" font="Arial"> Recommandations</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.05.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.05.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170710-BarnigC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170710-BarnigC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Barnig C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.05.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Urquiza-Ramirez,C.I.</style></author><author><style face="normal" font="Arial"> Eliosa-Alvarado,G.A.</style></author><author><style face="normal" font="Arial"> Gonzalez-Flores,S.</style></author><author><style face="normal" font="Arial"> Fernandez de Cordova-Aguirre,J.C.</style></author><author><style face="normal" font="Arial"> Velasco-Medina,A.A.</style></author><author><style face="normal" font="Arial"> Velazquez-Samano,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis in teenager with bronchial asthma</style></title><secondary-title><style face="normal" font="Arial">Rev Med Hosp General Mexico</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Med Hosp General Mexico</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asma</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Aspergilosis broncopulmonar al+®rgica</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronquiectasias</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity mechanisms</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Itraconazole</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mecanismos de hipersensibilidad</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0185-1063</style></isbn><abstract><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by hypersensitivity mechanisms against antigens released by Aspergillus species, colonizing the airways. We present the case of a 16-year-old male with a history of asthma and allergic rhinoconjunctivitis with a history of 15 months of cough with purulent sputum, intermittent fever and dyspnea. Thoracic tomography showed bronchiectasis accompanied by mucus impaction. He was treated with different antibiotics and steroid regimens, without a favorable clinical response. The presence of eosinophilia in the peripheral blood, immunoglobulin E Total, skin tests for Aspergillus positive guided the diagnosis of ABPA. Treatment with prednisone plus itraconazole was started, with remission of symptoms. ABPA should be suspected in patients with asthma with poor response to treatment and alteration in radiologic studies. Treatment includes systemic steroids and avoiding exposure to Aspergillus.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.hgmx.2017.05.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.hgmx.2017.05.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Med Hosp General Mexico\20170706-UrquizaRamirezCI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Med Hosp General Mexico\20170706-UrquizaRamirezCI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Urquiza-Ramirez CI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.hgmx.2017.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mota,A.F.</style></author><author><style face="normal" font="Arial"> Cardoso,B.K.</style></author><author><style face="normal" font="Arial"> Jordao,M.F.</style></author><author><style face="normal" font="Arial"> Tomaz,E.</style></author><author><style face="normal" font="Arial"> Catirra,LO.</style></author><author><style face="normal" font="Arial"> Inacio,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylactic reactions in children admitted to a pediatric emergency department</style></title><secondary-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></full-title></periodical><pages end="49" start="39">39-49</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a systemic acute hypersensitivity reaction, showing a large variation in clinical presentation and severity. Itis a medical emergency requiring an immediate recognition and represents a challenge mainly in younger population. The aimof our study was to evaluate the incidence of anaphylaxis and characterize it in children admitted to a pediatric emergencydepartment during a 5.year period. Revision of 38.978 files of patient with less than 18 years admitted to the pediatricemergency department between 01/01/2010 and 31/12/2014 was performed. From the analyzed data 27 anaphylactic reactionswere identified; 24 children.54 % females, mean age 5,5 years were involved. For 10 of them this was a first episode.The incidence was 69.2/100 000 in 5 years. All children had cutaneous manifestations and 74 % had respiratory, 33 % gastrointestinaland 15 % cardiovascular involvement. In 63% of the reactions food was the eliciting factor, in 11 % hymenopterastings and in 7 % skin care products. The treatment options were in 93 % a first generation antihistaminic, in 89 % corticosteroid,in 70% supplementary oxygen, in 59 % adrenaline, in 44 % inhaled salbutamol and in 27 % normal saline solution,in different combinations. Hospitalization was required in 10 episodes. Eleven children (46 %) were referred to an allergyconsultation. There was no mortality. Anaphylaxis is a rare reason for admission in the emergency department. Food relatedreactions were the most common cause in our study group. Only in 59% of the episodes adrenaline was used, in spite of theguidelines recommend it as first line of treatment, for every anaphylactic reaction. Less than 50% of the children were referredto a specialty consultation, lacking the majority the access to both, a correct diagnostic workup and a personalized emergencyand therapeutic plan.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212017000100003&amp;lng=pt&amp;nrm=iso&amp;tlng=pt</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-39-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-39-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Mota AF</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sangalho,I.</style></author><author><style face="normal" font="Arial"> Pereira Barbosa,M.</style></author><author><style face="normal" font="Arial"> Branco Ferreira,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis - 8 years of hospital admissions in the Immunoallergology Department of Centro Hospitalarde Lisboa Norte</style></title><secondary-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Imunoalergol</style></full-title></periodical><pages end="38" start="27">27-38</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: Anaphylaxis is a very variable entity, sometimes representing a significant diagnostic challenge. The increasing incidence and number of hospitalizations due to anaphylaxis make it a relatively common disease in our reality. Objective:To characterize a population of patients hospitalized in the Allergy Department with the diagnosis of anaphylaxis. Material and methods: In the period 2005.2013,146 patients were admitted to our department with anaphylaxis and received hospital discharge. Of those, only 133 discharge reports were available or contained sufficient data for analysis. Results: Anaphylaxis was more common in females (58 %) and the main causes were drugs, food and provocation tests, corresponding respectively to 49 %, 26 % and 8 % of cases. There were more cases of drug anaphylaxis in winter; food anaphylaxis was more common in spring. Half of the patients didn't mention previous episodes of anaphylaxis. There was a predominance of mucocutaneous(93 %) manifestations, followed by respiratory (71 %) and cardiovascular (32 %) manifestations. Most of the reactions were of moderate severity (57 %). There were more severe cases in drug anaphylaxis, in males, in older patients and in patients without previous episodes. 77 % of cases were observed by Otorhinolaryngology, and of these, 32 % showed ENT changes (with laryngeal involvement in 41 %). 55 % of patients received treatment with epinephrine and in 52 % of cases adrenaline auto.injector was prescribed. Conclusions: Most observations are similar to other published studies. However, the administrationof epinephrine and the prescription of an auto.injectoris higher in this series. In addition, it also denotes a greater contribution of the ENT Department in the evaluation of these patients.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212017000100003&amp;lng=pt&amp;nrm=iso&amp;tlng=pt</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-27-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-27-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Sangalho I</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.</style></author><author><style face="normal" font="Arial"> Jing,Y.</style></author><author><style face="normal" font="Arial"> Qiao,J.</style></author><author><style face="normal" font="Arial"> Luan,B.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Song,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.</style></auth-address><titles><title><style face="normal" font="Arial">Activation of the mTOR signaling pathway is required for asthma onset</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="4532">4532-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma remission</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2-cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="Arial">The mTOR pathway has been implicated in immune functions; however, its role in asthma is not well understood. We found that patients experiencing an asthma attack, when compared with patients in asthma remission, showed significantly elevated serum mTOR pathway activation, increased Th17 cells and IL-4, and decreased Treg cells and IFN-gamma. In patients experiencing asthma, mTOR activation was positively correlated with the loss of Th17/Treg and Th1/Th2 balance. The role of mTOR in asthma was further confirmed using an ovalbumin-induced asthmatic mouse model. The mTOR pathway was activated in asthmatic mice, demonstrated by elevated levels of p-PI3K, p-Akt, p-mTOR, and p-p70S6k, and this activation was significantly reduced by treatment with budenoside or mTOR pathway inhibitors. Moreover, mTOR pathway inhibitor treatment reduced asthmatic markers and reversed the Th17/Treg and Th1/Th2 imbalances in asthmatic mice. Finally, different mTOR pathway inhibitor treatments have different inhibitory effects on signaling molecules in asthmatic mice. In summary, mTOR is activated during asthma onset and suppressed during asthma remission, and inhibiting the mTOR pathway in asthmatic mice alleviates asthmatic markers and restores the balances of Th17/Treg and Th1/Th2 cytokines. These data strongly suggest a critical requirement for mTOR pathway activation in asthma onset, suggesting potential targets for asthma treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-04826-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28674387">PM:28674387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-4532.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-4532.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Zhang Y</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-04826-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Poplutz,M.</style></author><author><style face="normal" font="Arial"> Levikova,M.</style></author><author><style face="normal" font="Arial"> Luscher-Firzlaff,J.</style></author><author><style face="normal" font="Arial"> Lesina,M.</style></author><author><style face="normal" font="Arial"> Algul,H.</style></author><author><style face="normal" font="Arial"> Luscher,B.</style></author><author><style face="normal" font="Arial"> Huber,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biochemistry and Molecular Immunology, Medical School, RWTH Aachen University, Aachen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Endotoxin tolerance in mast cells, its consequences for IgE-mediated signalling, and the effects of BCL3 deficiency</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="4534">4534-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Lysine</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="Arial">Stimulation with lipopolysaccharide (LPS; endotoxin) not only causes rapid production of proinflammatory cytokines, but also induces a state of LPS hypo-responsiveness to a second LPS stimulation (endotoxin tolerance (ET)). Murine bone marrow-derived MCs (BMMCs) and peritoneal MCs (PMCs) developed ET as shown by an abrogated production of Il6/Tnf RNAs and IL-6/TNF-alpha proteins. In naive BMMCs, LPS stimulation induced a transient decline in the trimethylation of lysine 9 of the core histone H3 (H3K9me3), a suppressive chromatin mark, at the Il6/Tnf promoters, which correlated with p50(NFkappaB) and p65(NFkappaB) binding. Both demethylation and NFkappaB binding were abrogated in tolerant cells. In addition, cytosolic NFkappaB activation was suppressed in tolerant BMMCs. Intriguingly, antigen stimulation of naive and tolerant MCs induced comparable production of Il6/Tnf and IL-6/TNF-alpha, although ET also affected antigen-triggered activation of NFkappaB; pharmacological analysis indicated the importance of Ca2+-dependent transcription in this respect. In macrophages, the IkappaB member BCL3 is induced by LPS and known to be involved in ET, which was not corroborated comparing wild-type and Bcl3-deficient BMMCs. Interestingly, Bcl3-deficient PMCs produce markedly increased amounts of IL-6/TNF-alpha after LPS stimulation. Collectively, ET in MCs is BCL3-independent, however, in PMCs, BCL3 negatively regulates immediate LPS-induced cytokine production and quantitatively affects ET</style></abstract><notes><style face="normal" font="Arial">DA - 20170704IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-04890-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28674400">PM:28674400</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-4534.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-4534.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170704, Poplutz M</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-04890-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Byrd,A.L.</style></author><author><style face="normal" font="Arial"> Deming,C.</style></author><author><style face="normal" font="Arial"> Cassidy,S.K.B.</style></author><author><style face="normal" font="Arial"> Harrison,O.J.</style></author><author><style face="normal" font="Arial"> Ng,W.I.</style></author><author><style face="normal" font="Arial"> Conlan,S.</style></author><author><style face="normal" font="Arial"> Belkaid,Y.</style></author><author><style face="normal" font="Arial"> Segre,J.A.</style></author><author><style face="normal" font="Arial"> Kong,H.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Microbial Genomics Section, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA</style></auth-address><titles><title><style face="normal" font="Arial">Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Sci Transl Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Transl Med</style></full-title></periodical><pages end="" start=" eaal4651"> eaal4651-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">397</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus epidermidis</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">The heterogeneous course, severity, and treatment responses among patients with atopic dermatitis (AD; eczema) highlight the complexity of this multifactorial disease. Prior studies have used traditional typing methods on cultivated isolates or sequenced a bacterial marker gene to study the skin microbial communities of AD patients. Shotgun metagenomic sequence analysis provides much greater resolution, elucidating multiple levels of microbial community assembly ranging from kingdom to species and strain-level diversification. We analyzed microbial temporal dynamics from a cohort of pediatric AD patients sampled throughout the disease course. Species-level investigation of AD flares showed greater Staphylococcus aureus predominance in patients with more severe disease and Staphylococcus epidermidis predominance in patients with less severe disease. At the strain level, metagenomic sequencing analyses demonstrated clonal S. aureus strains in more severe patients and heterogeneous S. epidermidis strain communities in all patients. To investigate strain-level biological effects of S. aureus, we topically colonized mice with human strains isolated from AD patients and controls. This cutaneous colonization model demonstrated S. aureus strain-specific differences in eliciting skin inflammation and immune signatures characteristic of AD patients. Specifically, S. aureus isolates from AD patients with more severe flares induced epidermal thickening and expansion of cutaneous T helper 2 (TH2) and TH17 cells. Integrating high-resolution sequencing, culturing, and animal models demonstrated how functional differences of staphylococcal strains may contribute to the complexity of AD disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170706IS - 1946-6242 (Electronic)IS - 1946-6234 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1126/scitranslmed.aal4651</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28679656">PM:28679656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Transl Med\2017-9- eaal4651.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Transl Med\2017-9- eaal4651.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170706, Byrd AL</style></custom2><misc3><style face="normal" font="Arial">10.1126/scitranslmed.aal4651</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oida,K.</style></author><author><style face="normal" font="Arial"> Einhorn,L.</style></author><author><style face="normal" font="Arial"> Herrmann,I.</style></author><author><style face="normal" font="Arial"> Panakova,L.</style></author><author><style face="normal" font="Arial"> Resch,Y.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author><author><style face="normal" font="Arial"> Hofstetter,G.</style></author><author><style face="normal" font="Arial"> Tanaka,A.</style></author><author><style face="normal" font="Arial"> Matsuda,H.</style></author><author><style face="normal" font="Arial"> Jensen-Jarolim,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Veterinaerplatz 1, 1210 Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Innate function of house dust mite allergens: robust enzymatic degradation of extracellular matrix at elevated pH</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="23">23-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic degradation</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Gels</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exposure to the house dust mite Dermatophagoides pteronyssinus (D.p.) increases the risk for developing allergic diseases in humans and their best friends, the dogs. Here, we explored whether this allergenic mite via its enzymes may impact the cutaneous extracellular matrix (ECM), which critically determines epithelial barrier integrity both structurally and functionally. METHODS: Two extracts obtained from either dust-purified or cultured D.p. bodies were used in the present study. To assess the potential impact of D.p. on protein components of the ECM, proteolytic activity of the D.p. extracts were determined by casein and gelatin gel zymography, and their N-acetyl-beta-hexosaminidase activity determined colorimetrically. In addition, IgE-dependent and innate degranulation potential of D.p. was examined in canine MPT-1 mast cells and neurite outgrowth assay using rat pheochromocytoma PC-12 cells. RESULTS: In gel zymography, both extracts digested the substrates casein and gelatin in a dose-dependent manner, especially at alkaline pH, and effective in a wide range of temperatures (30 degrees C-42 degrees C). In particular, a 25-kDa band corresponding to Der p 1, the major D.p. allergen for humans, was found enzymatically active in both casein and gelatin gels regardless of the presence of metal ions and of alkaline conditions. Besides protease activity, N-acetyl-beta-hexosaminidase activity was detected in both extracts, suggesting that D.p. affects the cutaneous ECM through deteriorating both proteins and glycosaminoglycans. While both D.p. extracts induced IgE-dependent mast cell degranulation, much less innate effects on mast- and neuronal cells were observed. CONCLUSIONS: Our data highlight that D.p. is a robust source of several distinct enzymes with protease- and N-acetyl-beta-hexosaminidase activities. In alkaline milieu they can degrade components of the ECM. Therefore, D.p. may contribute to epithelial barrier disruption especially when the skin surface pH is elevated</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0154-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28702111">PM:28702111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Oida K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0154-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dobrovolskaia,M.A.</style></author><author><style face="normal" font="Arial"> Shurin,M.R.</style></author><author><style face="normal" font="Arial"> Kagan,V.E.</style></author><author><style face="normal" font="Arial"> Shvedova,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, NCI at Frederick , Frederick, Maryland 21702, United States</style></auth-address><titles><title><style face="normal" font="Arial">Ins and Outs in Environmental and Occupational Safety Studies of Asthma and Engineered Nanomaterials</style></title><secondary-title><style face="normal" font="Arial">ACS Nano</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ACS Nano</style></full-title></periodical><pages end="7571" start="7565">7565-7571</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Centers for Disease Control</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> indirect costs</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanotechnology</style></keyword><keyword><style face="normal" font="Arial"> Nanotubes</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> Xenobiotics</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">According to the Centers for Disease Control and Prevention, approximately 25 million Americans suffer from asthma. The disease total annual cost is about $56 billion and includes both the direct and indirect costs of medications, hospital stays, missed work, and decreased productivity. Air pollution with xenobiotics, bacterial agents, and industrial nanomaterials, such as carbon nanotubes, contribute to the exacerbation of this condition and are a point of particular attention in environmental toxicology as well as in occupational health and safety research. Mast cell degranulation and activation of Th2 cells triggered either by allergen-specific immunoglobulin E (IgE) or by alternative mechanisms, such as locally produced neurotransmitters, underlie the pathophysiological process of airway constriction during an asthma attack. Other immune and non-immune cell types, including basophils, eosinophils, Th1, Th17, Th9, macrophages, dendritic cells, and smooth muscle cells, are involved in the inflammatory and allergic responses during asthma, which, under chronic conditions, may progress without mast cells, the key trigger of the acute asthma attack. To decipher complex molecular, cellular, and genetic mechanisms, many researchers have attempted to develop in vitro and in vivo models to study asthma. Herein, we summarize the advantages and disadvantages of various models and their applicability to nanoparticle evaluation in asthma research. We further suggest that a framework for both in vitro and in vivo methods should be used to study the impact of engineered nanomaterials on asthma etiology, pathophysiology, and treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170724IS - 1936-086X (Electronic)IS - 1936-0851 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acsnano.7b04916</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28737932">PM:28737932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\ACS Nano\20170724-DobrovolskaiaMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\ACS Nano\20170724-DobrovolskaiaMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170724, Dobrovolskaia MA</style></custom2><misc3><style face="normal" font="Arial">10.1021/acsnano.7b04916</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khorasanizadeh,M.</style></author><author><style face="normal" font="Arial"> Eskian,M.</style></author><author><style face="normal" font="Arial"> Rezaei,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. AND Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma</style></title><secondary-title><style face="normal" font="Arial">Acta Med Iran</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Med Iran</style></full-title></periodical><pages end="353" start="352">352-353</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1735-9694 (Electronic)IS - 0044-6025 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28724278">PM:28724278</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Med Iran\2017-55-352-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Med Iran\2017-55-352-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Khorasanizadeh M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">LeLeiko,N.S.</style></author><author><style face="normal" font="Arial"> Cerezo,C.S.</style></author><author><style face="normal" font="Arial"> Shapiro,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Alpert School of Medicine at Brown University, Providence, RI 02903, USA</style></auth-address><titles><title><style face="normal" font="Arial">New Concepts in Food Allergy: The Pediatric Gastroenterologist's View</style></title><secondary-title><style face="normal" font="Arial">Adv Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Pediatr</style></full-title></periodical><pages end="109" start="87">87-109</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170709IS - 1878-1926 (Electronic)IS - 0065-3101 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.yapd.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28688601">PM:28688601</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Pediatr\2017-64-87-109.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Pediatr\2017-64-87-109.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170709, LeLeiko NS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.yapd.2017.03.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,A.L.</style></author><author><style face="normal" font="Arial"> Song,Z.W.</style></author><author><style face="normal" font="Arial"> Lang,X.L.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Xia,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Seasonal variability in bacterial and fungal diversity and community composition of the near-surface atmosphere in coastal megacity</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Mycobacteria</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant Diseases</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Radiation</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus epidermidis</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Bacteria and fungi are ubiquitous in the near-surface atmosphere where they may impact on the surrounding environment and human health, especially in coastal megacities. However, the diversity, composition, and seasonal variations of these airborne microbes remain limited. This study investigated the airborne microbes of the near-surface atmosphere in coastal megacity Qingdao over one year. It was found that the sample in summer displayed the highest bacterial and fungal diversity, while sample in winter exhibited the lowest bacterial and fungal diversity. Proteobacteria was the dominating bacteria, and Dothideomycetes was the most dominating fungi in the near-surface atmosphere, which took up 53</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô76 and 49</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô78% relative abundance, respectively. However, the bacterial diversity and community composition had significant seasonal variations. These data suggest that a complex set of environmental factors, including landscaping ratio, solar radiation temperature, and marine microorganisms, can affect the composition of airborne microbes in the near-surface atmosphere in coastal megacity. The analysis of the pathogenic microorganisms or opportunistic pathogenic microorganisms existed in the near-surface atmosphere revealed that the relative abundance of pathogenic microorganisms in autumn was the highest. The main pathogenic microorganisms or opportunistic pathogenic microorganisms were Acinetobacter baumannii (accounting for up to 9.93% relative abundance), Staphylococcus epidermidis (accounting for up to 11.26% relative abundance), Mycobacterium smegmatis (accounting for up to 3.68% relative abundance), Xanthomonas oryzae pv. oryzae (accounting for up to 5.36% relative abundance), which may be related to certain human or plant diseases in specific environments or at certain seasons. Therefore, the investigation of airborne microbial communities of near-surface atmosphere in coastal megacities is very important to both the understanding of airborne microbes and public health</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9489-z</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10453-017-9489-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170727-XuAL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170727-XuAL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Xu AL</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9489-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Micheluz,A.</style></author><author><style face="normal" font="Arial"> Manente,S.</style></author><author><style face="normal" font="Arial"> Prigione,V.</style></author><author><style face="normal" font="Arial"> Tigini,V.</style></author><author><style face="normal" font="Arial"> Varese,G.C.</style></author><author><style face="normal" font="Arial"> Ravagnan,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The effects of book disinfection to the airborne microbiological community in a library environment</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Books</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Disinfection</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> Indoor environments</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Penicillium chrysogenum</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">The management of fungal contaminants inside libraries and archives has become a big challenge for librarians, restorers and scientists. Several disinfection treatments have been developed in recent years, using both chemical and physical approaches on book collections and indoor environments. However, there is a lack of knowledge about the temporal efficiency of these cleanings, especially in relation with the preservation environments. The aim of this study was to determine the long-term effect of a chemical disinfection that interested a previous-contaminated book collection inside a University library. The monitoring after 6-ámonths and 1-áyear from the cleaning confirmed any fungal growth on the disinfected books and the reduction of 90% of the airborne fungal load, highlighting anyway the presence of high fungal diversity. Sixty-eight different airborne fungal entities were isolated, in particular Aspergillus vitricola, Bulleromyces albus, Cladosporium cladosporioides, Cladosporium pseudocladosporioides, Cladosporium sphaerospermum, Penicillium brevicompactum, Rodothorula mugillaginosa and Sporodiobolus pararoseus. Several fungal species were sampled from the disinfected books, in particular Aspergillus penicillioides and Penicillium chrysogenum. The presence of these fungi both as airborne and as settled particles highlights the importance to maintain clean the preservation environments in order to prevent further microbial contaminations</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9492-4</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10453-017-9492-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170727-MicheluzA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170727-MicheluzA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Micheluz A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9492-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grinn-Gofron,A.</style></author><author><style face="normal" font="Arial"> Bosiacka,B.</style></author><author><style face="normal" font="Arial"> Bednarz,A.</style></author><author><style face="normal" font="Arial"> Wolski,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A comparative study of hourly and daily relationships between selected meteorological parameters and airborne fungal spore composition</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air sampling</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airborne fungal spore</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore composition</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Meteorological factor</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Factors</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> Meteorological variables</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Redundancy analysis</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Air sampling was conducted in Szczecin (Poland) throughout April</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôSeptember 2013. The final data set included 177 daily and 4248 hourly samples. The total of 21 types of spores, which occurred in a number >10 in the season, were taken into account. The following meteorological parameters were analyzed: air temperature, relative humidity, precipitation and wind speed. Effects of individual weather parameters on hourly and daily concentrations of different fungal spore types were examined using Spearman</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs rank association test, whereas effects of complex of meteorological factors on hourly and daily compositions of spore were assessed using detrended correspondence analysis (DCA) and redundancy analysis (RDA). Airborne fungal spore distribution patterns in relation to meteorological variables were determined by RDA, after DCA results detected a linear structure of the spore data. The RDA results obtained indicated that all the applied variables accounted for 20 and 22% of the total variance in the hourly and daily spore data, respectively. The results of stepwise forward selection of variables revealed all included hourly and daily meteorological variables were statistically significant. The largest amount of the total variance in the spore composition was explained by the air temperature in both cases (16%). Multivariate ordination did not show large differences between the hourly and daily relationships (with exception of wind speed impact), while the differences between simple hourly and daily correlations were more clear. Correlations between daily values of variables were in most cases higher than between hourly values of variables</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9493-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10453-017-9493-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170727-GrinnGofronA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170727-GrinnGofronA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Grinn-Gofron A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9493-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takahashi,Y.</style></author><author><style face="normal" font="Arial"> Kawashima,S.</style></author><author><style face="normal" font="Arial"> Suzuki,Y.</style></author><author><style face="normal" font="Arial"> Ohta,N.</style></author><author><style face="normal" font="Arial"> Kakehata,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Enrichment of airborne Japanese cedar (Cryptomeria japonica) pollen in mountain ranges when passing through a front accompanying temperate low pressure</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria japonica</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Values obtained by the real-time pollen monitors set up at 14 measuring points in the Tohoku region indicate that a large amount of Japanese cedar pollen was dispersed along the western region and northern flank of the Ou Mountain Range when a front accompanying the temperate low pressures passed through the west sea of northern Hokkaido. We are sure that this phenomenon is related to pollen enrichment by mountain ranges. The time at which highest concentrations of pollen grains were observed shifted from the western to the eastern side, in accordance with the path of the front. No pollen was seen after the passage of the cold front</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9494-2</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10453-017-9494-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170727-TakahashiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170727-TakahashiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Takahashi Y</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9494-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruggiero,F.</style></author><author><style face="normal" font="Arial"> Bedini,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Free orbicules of Cupressaceae detected in daily aerobiological samples by optical and confocal microscopy</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> autofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Members of Cupressaceae and Taxaceae are known to release large amounts of highly allergenic pollen grains into the atmosphere, which are responsible for the onset of pollinosis in many countries throughout the world. In addition to pollen grains, their pollen sacs produce orbicules, which are submicron particles reported to carry allergens and which are potentially able to reach much further down the respiratory tract than pollen grains. Previous research has postulated the presence of orbicules in the atmosphere; however, direct observations have not yet been reported. The aim of this research was to provide the first direct evidence that Cupressaceae orbicules are released into the atmosphere by detecting them in daily aerobiological samples. We observed pollen sacs, pollen grains, and orbicules of nine species of Cupressaceae using scanning electron microscope (SEM). We then used a light and confocal microscope, to examine daily aerobiological samples. Under SEM, we measured the orbicule size (0.494</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.777-á-Ám) and detected unknown nanometric particles (130</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô200-ánm). Under the light microscope, aerobiological samples showed clusters of stained dots surrounding the pollen grains of Cupressaceae. Under the confocal microscope, the same clusters were resolved into submicron particles with the same autofluorescence as the pollen grains. These features enabled us to identify them as orbicules. We believe that our findings help to explain the onset of pollinosis and allergic asthma related to Cupressaceae pollen grains in many countries, even before pollen grains are actually detected or after they are no longer observed in aerobiological monitoring samples</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9495-1</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10453-017-9495-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170727-RuggieroF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170727-RuggieroF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Ruggiero F</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9495-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kalmarzi,R.</style></author><author><style face="normal" font="Arial"> Ataee,P.</style></author><author><style face="normal" font="Arial"> Homagostar,G.</style></author><author><style face="normal" font="Arial"> Tagik,M.</style></author><author><style face="normal" font="Arial"> Ghaderi,E.</style></author><author><style face="normal" font="Arial"> Kooti,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cellular &amp; Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of the frequency of food allergens based on skin prick test in children in Kurdistan Province - Iran</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cocoa</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tomatoes</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Food allergy refers to abnormal reactions of the body caused by an immune system response to food. This study was conducted aiming to investigate allergy to food allergens in children with food allergies. MATERIALS AND METHODS: This study was conducted as a cross-sectional one on 304 children aged six months to seven years with food allergies admitted to the tertiary referral hospital in Kurdistan Province - Iran, during 2014-2015. All the patients were examined for skin prick test using 49 allergens. Finally, the obtained data were analysed using SPSS15 and chi-square and t tests. RESULTS: The highest percentage of occurrence of bump reaction (wheal) and redness (flare) was due to the consumption of fish, eggs, tomatoes, and cocoa. Moreover, the lowest rate of wheal and flare was caused by exposure to allergens like latex, tea, malt, and wheat flour. The reaction most created due to the consumption of foods was flare which was higher among under three-year-olds group (p&lt;0.05), and between the sexes, girls showed the most common allergic reactions (p&lt;0.05). CONCLUSION: Since food allergy has a high prevalence in children, it should be considered with great interest. Considering that avoiding food allergens is the first step in the treatment of food allergies, the present study may be a useful guide in this regard</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.02.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28750899">PM:28750899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170728-KalmarziR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170728-KalmarziR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Kalmarzi R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.02.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arakawa,S.</style></author><author><style face="normal" font="Arial"> Suzukawa,M.</style></author><author><style face="normal" font="Arial"> Igarashi,S.</style></author><author><style face="normal" font="Arial"> Matsui,H.</style></author><author><style face="normal" font="Arial"> Yamaguchi,M.</style></author><author><style face="normal" font="Arial"> Nagase,T.</style></author><author><style face="normal" font="Arial"> Ohta,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Hospital Organization, Tokyo National Hospital, Tokyo, Japan; Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Resveratrol inhibits IgE binding and down-regulates intracellular phosphorylation of Syk following IgE aggregation on human basophils</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="S55" start="S53">S53-S55</pages><volume><style face="normal" font="Arial">66S</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregation</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human basophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Resveratrol</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.06.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28716456">PM:28716456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170718-ArakawaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170718-ArakawaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Arakawa S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.06.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asaria,M.</style></author><author><style face="normal" font="Arial"> Dhami,S.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Health Economics, University of York, UK</style></auth-address><titles><title><style face="normal" font="Arial">Health Economic Analysis of Allergen Immunotherapy (AIT) for the Management of Allergic Rhinitis, Asthma, Food Allergy and Venom Allergy: A Systematic Overview</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical recommendations</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modelling</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk groups</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is developing guidelines for allergen immunotherapy (AIT) for the management of allergic rhinitis, allergic asthma, IgE-mediated food allergy and venom allergy. To inform the development of clinical recommendations, we undertook systematic reviews to critically assess evidence on the effectiveness, safety and cost-effectiveness of AIT for these conditions. This paper focusses on synthesizing data and gaps in the evidence on the cost-effectiveness of AIT for these conditions. METHODS: We produced summaries of evidence in each domain and then synthesized findings on health economic data identified from four recent systematic reviews on allergic rhinitis, asthma, food allergy and venom allergy, respectively. The quality of these studies were independently assessed using the Critical Appraisal Skills Programme (CASP) tool for health economic evaluations. RESULTS: 23 studies satisfied our inclusion criteria. Of these, 19 studies investigated the cost-effectiveness of AIT in allergic rhinitis, of which seven were based on data from randomized controlled trials with economic evaluations conducted from a health system perspective. This body of evidence suggested that sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) would be considered cost-effective using the (English) National Institute for Health and Clinical Excellence (NICE) cost-effectiveness threshold of pound20,000/quality adjusted life year (QALY). However, the quality of the studies and the general lack of attention to characterizing uncertainty and handling missing data should be taken into account when interpreting these results. For asthma, there were three eligible studies, all of which had significant methodological limitations; these suggested that SLIT, when used in patients with both asthma and allergic rhinitis, may be cost-effective with an incremental cost-effectiveness ratio (ICER) of pound10,726 per QALY. We found one economic modelling study for venom allergy which, despite being based largely on expert opinion and plausible assumptions, suggested that AIT for bee and wasp venom allergy is only likely to be cost-effective for very high risk groups who may be exposed to multiple exposures to venom/year (e.g., bee keepers). We found no eligible studies investigating the cost-effectiveness of AIT for food allergy. CONCLUSIONS: Overall the evidence to support the cost-effectiveness of AIT is limited and of low methodological quality, but suggests that AIT may be cost-effective for people with allergic rhinitis with or without asthma and in high risk subgroups for venom allergy. We were unable to draw any conclusions on the cost-effectiveness of AIT for food allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - Netherlands -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13254</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28718981">PM:28718981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170718-AsariaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170718-AsariaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Asaria M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13254</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Karatzas,K.</style></author><author><style face="normal" font="Arial"> Riga,M.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Werchan,M.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Environmental Informatics Research Group, Dept. of Mechanical Engineering, Aristotle University, P.O. Box 483, 54124, Thessaloniki, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Computational validation of the recently proposed pollen season definition criteria</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">In a recently published paper (Pfaar et al., 2016), a Task Force of the Immunotherapy and Aerobiology and Pollution Interest Groups of the EAACI suggested specific criteria for the definition of pollen exposure times for three types of pollen events: (a) Pollen Season (PS) start and end, (b) high pollen season (or Peak Pollen Period-PPP) start and end, and (c) high pollen days. Species addressed included Birch, Grasses, Cypress, Olive, and Ragweed. Two important questions arise from the aforementioned definitions: (i) do they lead to a narrow (thus well defined) time interval identifying start and end event dates (robustness of the criteria) and (ii) if slightly altered, will they result to a narrow (thus again well defined) fluctuation of start and end event dates (sensitivity of the criteria)? In an effort to provide with responses to aforementioned questions, we analyzed Poaceae pollen count data coming from Germany (up to 40 pollen monitoring stations, years 2012-2016). The analysis addressed all pollen events for the first question, and focused on the PS and PPP start and end events for the second question. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13255</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28718953">PM:28718953</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170718-KaratzasK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170718-KaratzasK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Karatzas K</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13255</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,L.T.</style></author><author><style face="normal" font="Arial"> Shu,Q.</style></author><author><style face="normal" font="Arial"> Luo,X.Q.</style></author><author><style face="normal" font="Arial"> Liu,Z.Q.</style></author><author><style face="normal" font="Arial"> Qiu,S.Q.</style></author><author><style face="normal" font="Arial"> Liu,J.Q.</style></author><author><style face="normal" font="Arial"> Guo,H.J.</style></author><author><style face="normal" font="Arial"> Li,L.J.</style></author><author><style face="normal" font="Arial"> Li,M.G.</style></author><author><style face="normal" font="Arial"> Liu,D.B.</style></author><author><style face="normal" font="Arial"> Xia,L.X.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Research Center of Allergy &amp; Immunology, Shenzhen University School of Medicine, Shenzhen, 518060, China</style></auth-address><titles><title><style face="normal" font="Arial">Long term effects: Galectin-1 and specific immunotherapy for allergic responses in the intestine</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Galectin 1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND AIMS: Mast cell activation interferes with the effects of allergen-specific immunotherapy (SIT). Galectin-1 (Gal-1) is capable of regulating immune cells' functions. This study tests the hypothesis that administration of Gal-1 promotes and prolongs the efficacy of SIT via suppressing mast cell activation. METHODS: An intestinal allergy mouse model was developed. The co-administration of SIT and Gal-1 on suppression of the allergic responses, prevention of mast cell activation, and generation of antigen-specific regulatory T cells (Treg) in the intestine were observed in sensitized mice. RESULTS: The coadministration of Gal-1 and SIT markedly suppressed the allergic responses in the mouse intestine vs. the use of either SIT alone or Gal-1 alone. The Gal-1 binds to the IgE/FcvarepsilonRI complexes on the surface of mast cells to prevent mast cell activation during SIT. Gal-1 promoted the SIT-generated allergen-specific Tregs in the intestine of sensitized mice. Coadministration of Gal-1 and SIT significantly enhanced the efficacy of immunotherapy in suppressing allergic responses in the intestine, which lasted for at least for 12 months. CONCLUSIONS: Long term effects of specific immunotherapy on intestinal allergy can be achieved with Gal-1/SIT therapy by inhibiting mast cell activation and facilitating Treg development. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13256</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28718965">PM:28718965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170718-YangLT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170718-YangLT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Yang LT</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13256</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">For the Patient: Prevalence and triggers of anaphylactic events in schools</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="" start="328">328-</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668114">PM:28668114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-328.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-328.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, no authors</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fajt,M.L.</style></author><author><style face="normal" font="Arial"> Rosenberg,S.L.</style></author><author><style face="normal" font="Arial"> Yecies,E.</style></author><author><style face="normal" font="Arial"> Traister,R.S.</style></author><author><style face="normal" font="Arial"> Petrov,A.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="316" start="309">309-316</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Rush immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weed pollens</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy (AIT) is an effective treatment option for allergic rhinitis. Although conventional AIT takes 6 months to reach maintenance dosing, rush AIT accelerates the build-up period and reaches the maintenance dose months earlier. However, accelerated schedules of AIT carry an increased risk of systemic reactions (SR). OBJECTIVE: We aimed to describe a novel 1-day, eight-step modified environmental rush immunotherapy (MERIT) protocol, characteristics of the patients who underwent this therapy, and the safety of this procedure. We also compared distinguishing features of those patients with SRs. METHODS: We retrospectively analyzed demographic and clinical data of 362 adult patients seen in an outpatient university allergy clinic, from January 2005 to January 2015, and who underwent MERIT protocol treatment for allergic rhinitis. RESULTS: In a univariate analysis, the factors significantly associated with SR were lower body mass index (BMI); younger age; a higher number of allergens in the extracts; and the presence of cat, dust mite, and certain weed pollens. In a multivariate analysis, cat, dust mite, and mugwort were significantly associated with SRs. Over the 10-year period, 50 patients experienced SRs (13.81%), with a total number of 68 SRs. Only 4.7% of the SRs occurred on the MERIT day. Most SRs occurred >30 minutes and were mild. Our MERIT protocol continuation rate for all the patients was 49.2% and did not seem to be influenced by having an SR versus no SR. CONCLUSION: We present a modified rush AIT protocol that seems to be effective and safe. Most patients tolerated therapy, and only a minority of patients developed SRs, which generally were mild. We identified novel risk factors for SRs that may help determine optimal dosing to decrease the risk of SRs. Ultimately, future studies will be needed to compare the safety of our MERIT protocol with traditional AIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668111">PM:28668111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-309-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-309-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Fajt ML</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4053</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bellanti,J.A.</style></author><author><style face="normal" font="Arial"> Settipane,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The atopic disorders and atopy ... "strange diseases" now better defined!</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="242" start="241">241-242</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4074</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668105">PM:28668105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-241-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-241-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Bellanti JA</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4074</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Casale,T.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Thiens,F.</style></author><author><style face="normal" font="Arial"> Pawankar,R.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Gomez,M.</style></author><author><style face="normal" font="Arial"> Sisul,J.C.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Sublett,J.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A call to arms of specialty societies to review the WHO International Classification of Diseases, Eleventh Revision terms appropriate for the diseases they manage: The example of the Joint Allergy Academies</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="55" start="54">54-55</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668104">PM:28668104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-54-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-54-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,M.</style></author><author><style face="normal" font="Arial"> Kim,Y.M.</style></author><author><style face="normal" font="Arial"> Lee,J.Y.</style></author><author><style face="normal" font="Arial"> Yang,H.K.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Cho,J.</style></author><author><style face="normal" font="Arial"> Ahn,K.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Seasonal variation and monthly patterns of skin symptoms in Korean children with atopic eczema/dermatitis syndrome</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="299" start="294">294-299</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic eczema/dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema/dermatitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Korean children</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There have been controversies about the seasonality in aggravation of atopic eczema/dermatitis syndrome (AEDS) symptoms, although understanding the seasonal patterns of AEDS symptoms is an important step in preventing exacerbation through proactive management. OBJECTIVE: The aim of this study was to evaluate whether there are seasonal variations or monthly patterns of symptoms in children with AEDS. METHODS: A total of 590 children with AEDS (median age, 21 months) were enrolled and were followed up for at least 1 year between August 2012 and March 2015. Daily symptom scores that described the extent of itching, sleep disturbance, erythema, dryness, oozing, and edema were recorded on a scale of 0 to 4. The baseline score for each patient was defined as the 20th percentile of each individual's total score. The symptom score difference of each patient was expressed relative to the baseline level. The seasonal or monthly variation in symptom score differences was analyzed through generalized estimating equation analysis. RESULTS: Based on the AEDS symptom records from 87,879 person-days, the mean symptom score difference from baseline in patients with AEDS increased significantly in spring, autumn, and winter relative to the reference season (summer): by 0.62 (95% confidence interval [CI], 0.44-0.81) in spring, by 0.45 (95% CI, 0.24-0.67) in winter, and by 0.18 (95% CI, 0.02-0.36) in autumn. The mean symptom score difference from baseline increased significantly in January, February, March, April, May, June, October, November, and December relative to the reference month of August. CONCLUSION: Skin symptoms in children with AEDS were worse in spring, winter, and autumn than in summer. In terms of monthly patterns, the skin symptoms were the worst in April</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668109">PM:28668109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-294-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-294-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Kim M</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4055</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">White,M.V.</style></author><author><style face="normal" font="Arial"> Silvia,S.</style></author><author><style face="normal" font="Arial"> Muniz,R.</style></author><author><style face="normal" font="Arial"> Herrem,C.</style></author><author><style face="normal" font="Arial"> Hogue,S.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Prevalence and triggers of anaphylactic events in schools</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="293" start="286">286-293</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Transportation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Prevention and management of anaphylaxis in schools is an area of active interest as allergy and asthma rates in children continue to increase. A greater understanding of the prevalence and characteristics of anaphylaxis can help guide preventive and management strategies both within and outside of the school setting, with the goal of reducing morbidity and mortality. OBJECTIVE: This study was performed to elucidate the epidemiology of and management strategies for anaphylaxis in the school setting. METHODS: A cross-sectional, Web-based survey was administered to schools that participated in an initiative that provides stock epinephrine autoinjectors (EAIs) to qualifying U.S. schools. Representatives from participating schools completed a questionnaire regarding anaphylactic reactions that occurred during the 2014-2015 school year. Weighted analyses were performed to account for differential responses between schools that completed the survey and those that did not. RESULTS: A total of 12,275 of the 45,819 invited schools responded to the survey. The occurrence of one or more anaphylactic events was reported by 1358 schools. Most events (89.8% [1803/2008]) occurred in students. High school students accounted for the largest proportion of anaphylactic reactions among students (40.1% [723/1802]). Food was the most commonly identified anaphylaxis trigger across grade levels, seasons, and geographic regions. The trigger was unknown to the individual who experienced anaphylaxis in 21.8% of the events (436/1998). No known history of allergy or asthma was present in 24.5% (491/2001) and 51.3% (1026/2000) of affected individuals, respectively. Transportation to the hospital or clinic for further treatment and/or management was reported for 72.6% of the individuals with anaphylactic events (1450/1997). Results from the weighted analyses were similar to those of the unweighted analyses. CONCLUSION: Anaphylaxis occurred across grade levels and in individuals with or without known risk factors, which reinforced the need for school preparedness in both management of anaphylaxis and stocking of EAIs</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4066</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668108">PM:28668108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-286-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-286-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, White MV</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4066</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,C.H.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Lee,J.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Association of maternal depression and allergic diseases in Korean children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="308" start="300">300-308</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Korean children</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Marital Status</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">PURPOSE: An association between childhood allergic disease and parental psychological disorders has been reported. However, little is known about the relationship between childhood allergic disease and maternal depression. This study was performed to determine if there is an association between childhood allergic disease and maternal depression. METHODS: Data were acquired from 13,782 subjects (8091 mothers) ages &lt; 18 years who participated in the Korea National Health and Nutrition Examination Surveys, which was conducted from 2007 to 2014. The presence of allergic disease (asthma or atopic dermatitis) and depression was based on self-reported physician diagnosis in the health interview surveys. RESULTS: Logistic regression analyses showed maternal depression was significantly associated with single marital status (separated or divorced, adjusted odds ratio [aOR] 2.204 [95% confidence interval {CI},1.256-3.867]), less than middle school graduated level (aOR 2.959 [95% CI, 1.514-5.781]), middle school graduated educational level (aOR 2.420 [95% CI, 1.355-4.319]), being a current smoker (aOR 2.257 [95% CI, 1.481-3.438]), being an ex-smoker (aOR 2.533 [95% CI, 1.506-4.260]), maternal asthma (aOR 2.786 [95% CI, 1.453-5.344]), and maternal hypertension (aOR 1.942 [95% CI, 1.106-3.408]). Maternal depression was significantly associated with children's asthma (aOR 2.028 [95% CI, 1.234-3.335]) and children's atopic dermatitis (aOR 1.755 [95% CI, 1.183-2.602]). CONCLUSION: The present study showed maternal depression might be a risk factor for the clinical diagnosis of asthma and atopic dermatitis in Korean children</style></abstract><notes><style face="normal" font="Arial">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4059</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668110">PM:28668110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-300-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-300-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170702, Kim CH</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4059</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmiere,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Center of Legal Medicine, Lausanne University Hospital, Lausanne, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Decline in Postmortem Serum Tryptase Levels in Anaphylactic Deaths</style></title><secondary-title><style face="normal" font="Arial">Am J Forensic Med Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Forensic Med Pathol</style></full-title></periodical><pages end="275" start="274">274-275</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1533-404X (Electronic)IS - 0195-7910 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1097/PAF.0000000000000320</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28691949">PM:28691949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Forensic Med Pathol\20170710-PalmiereC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Forensic Med Pathol\20170710-PalmiereC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Palmiere C</style></custom2><misc3><style face="normal" font="Arial">10.1097/PAF.0000000000000320</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klompas,M.</style></author><author><style face="normal" font="Arial"> Cocoros,N.M.</style></author><author><style face="normal" font="Arial"> Menchaca,J.T.</style></author><author><style face="normal" font="Arial"> Erani,D.</style></author><author><style face="normal" font="Arial"> Hafer,E.</style></author><author><style face="normal" font="Arial"> Herrick,B.</style></author><author><style face="normal" font="Arial"> Josephson,M.</style></author><author><style face="normal" font="Arial"> Lee,M.</style></author><author><style face="normal" font="Arial"> Payne Weiss,M.D.</style></author><author><style face="normal" font="Arial"> Zambarano,B.</style></author><author><style face="normal" font="Arial"> Eberhardt,K.R.</style></author><author><style face="normal" font="Arial"> Malenfant,J.</style></author><author><style face="normal" font="Arial"> Nasuti,L.</style></author><author><style face="normal" font="Arial"> Land,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Michael Klompas, Noelle M. Cocoros, John T. Menchaca, and Jessica Malenfant are with the Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA.</style></auth-address><titles><title><style face="normal" font="Arial">State and Local Chronic Disease Surveillance Using Electronic Health Record Systems</style></title><secondary-title><style face="normal" font="Arial">Am J Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Public Health</style></full-title></periodical><pages end="1412" start="1406">1406-1412</pages><volume><style face="normal" font="Arial">107</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Health Records</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Records</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To assess the feasibility of chronic disease surveillance using distributed analysis of electronic health records and to compare results with Behavioral Risk Factor Surveillance System (BRFSS) state and small-area estimates. METHODS: We queried the electronic health records of 3 independent Massachusetts-based practice groups using a distributed analysis tool called MDPHnet to measure the prevalence of diabetes, asthma, smoking, hypertension, and obesity in adults for the state and 13 cities. We adjusted observed rates for age, gender, and race/ethnicity relative to census data and compared them with BRFSS state and small-area estimates. RESULTS: The MDPHnet population under surveillance included 1 073 545 adults (21.8% of the state adult population). MDPHnet and BRFSS state-level estimates were similar: 9.4% versus 9.7% for diabetes, 10.0% versus 12.0% for asthma, 13.5% versus 14.7% for smoking, 26.3% versus 29.6% for hypertension, and 22.8% versus 23.8% for obesity. Correlation coefficients for MDPHnet versus BRFSS small-area estimates ranged from 0.890 for diabetes to 0.646 for obesity. CONCLUSIONS: Chronic disease surveillance using electronic health record data is feasible and generates estimates comparable with BRFSS state and small-area estimates. (Am J Public Health. Published online ahead of print July 20, 2017: e1-e7. doi:10.2105/AJPH.2017.303874)</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1541-0048 (Electronic)IS - 0090-0036 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2105/AJPH.2017.303874</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28727539">PM:28727539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Public Health\2017-107-1406-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Public Health\2017-107-1406-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Klompas M</style></custom2><misc3><style face="normal" font="Arial">10.2105/AJPH.2017.303874</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McKnight,C.G.</style></author><author><style face="normal" font="Arial"> Jude,J.A.</style></author><author><style face="normal" font="Arial"> Zhu,Z.</style></author><author><style face="normal" font="Arial"> Panettieri,R.A.,Jr.</style></author><author><style face="normal" font="Arial"> Finkelman,F.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Cincinnati, Medicine, Cincinnati, Ohio, United States</style></auth-address><titles><title><style face="normal" font="Arial">House Dust Mite-induced Allergic Airway Disease is Independent of IgE and FcvarepsilonRIalpha</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="682" start="674">674-682</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="Arial">IgE contributes to disease exacerbations but not to baseline airway hyperresponsiveness (AHR) in human asthma. In rodent allergic airway disease (AAD), mast cell and IgE dependence for the induction of AHR has only been observed when mice are immunized with a relatively weak allergen without adjuvant. To evaluate the role of IgE in murine AAD that is induced by a potent allergen, we inoculated BALB/c and FVB/N background wild-type, and IgE- or FcepsilonRIalpha-deficient mice intratracheally with large or limiting doses of house dust mite extract (HDM) and evaluated AHR, pulmonary eosinophilia, goblet cell metaplasia, serum IgE, and lung mastocytosis. We found that neither IgE nor FcepsilonRIalpha contributed to AAD, even in mice inoculated with the lowest dose of HDM, which readily induced detectable disease but did not increase serum IgE or pulmonary mast cell levels. In contrast, high doses of HDM strikingly increased serum IgE and pulmonary mast cells, although both AHR and airway mast cell degranulation were equally elevated in wild-type and IgE-deficient mice. Surprisingly, allergen challenge of mice with severe AAD and pulmonary mastocytosis failed to acutely increase airway resistance, lung Newtonian resistance or hysteresis. Overall, this study shows that while mice may not reliably model acute asthma exacerbations, mechanisms that are IgE- and FcepsilonRIalpha-independent are responsible for AHR and airway inflammation when low doses of a potent allergen are inhaled repetitively</style></abstract><notes><style face="normal" font="Arial">DA - 20170712IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2016-0356OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28700253">PM:28700253</url></web-urls><pdf-urls><url ppv-ref="no">finkelfd@ucmail.uc.edu</url><url ppv-ref="no">christopher.mcknight@uc.edu</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170712, McKnight CG</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2016-0356OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Platts-Mills,T.A.E.</style></author><author><style face="normal" font="Arial"> Woodfolk,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Medicine University of Virginia School of Medicine Charlottesville, Virginia</style></auth-address><titles><title><style face="normal" font="Arial">Mite Avoidance as a Logical Treatment for Severe Asthma in Childhood. Why Not?</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="121" start="119">119-121</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201703-0450ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28707970">PM:28707970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-119-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\2017-196-119-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Platts-Mills TA</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201703-0450ED</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guo,Y.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Wang,D.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Hu,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Rhinol Allergy</style></full-title></periodical><pages end="47" start="42">42-47</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: This study was designed to evaluate the efficacy and safety of sublingual immunotherapy (SLIT) with house-dust mite (HDM) extract in Chinese patients with HDM-induced allergic rhinitis (AR). METHODS: A randomized, double-blind, placebo controlled trial was conducted with the outpatients of the Eye, Ear, Nose, and Throat Hospital, Fudan University. Forty-eight patients were eligible for randomization to SLIT with a mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae extract or placebo for 1 year. The primary outcome measures for efficacy were the total nasal symptom score (TNSS) and the individual nasal symptom score. Secondary end points were allergic conjunctivitis scores (ACS) and medication scores (MS). Adverse events (AE) also were monitored. RESULTS: Intragroup analysis demonstrated a significant improvement in the active treatment group for individual nasal symptom score and TNSS (p &lt; 0.05), although no improvement was observed in the placebo group of congestion, sneezing, and itching (p > 0.05). Furthermore, the ACS and MS in the active treatment group also statistically decreased (p &lt; 0.05). In addition, the active treatment had significant effects on relieving nasal symptoms both in adults and children (p &lt; 0.05), and no statistical difference was observed between these two subgroups (p > 0.05). AEs that occurred ranged from mild to moderate, and no severe systematic reactions were observed. CONCLUSION: SLIT with a mixture of HDM extract significantly relieved allergy symptoms and reduced the need for antiallergic drugs, which indicated the superiority of active treatment over placebo for patients with HDM-induced AR. However, due to the limited sample size, the findings need to be further confirmed</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.2500/ajra.2017.31.4447</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28716168">PM:28716168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-42-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Rhinol Allergy\2017-31-42-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Guo Y</style></custom2><misc3><style face="normal" font="Arial">10.2500/ajra.2017.31.4447</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Naz,S.</style></author><author><style face="normal" font="Arial"> Desclozeaux,M.</style></author><author><style face="normal" font="Arial"> Mounsey,K.E.</style></author><author><style face="normal" font="Arial"> Chaudhry,F.R.</style></author><author><style face="normal" font="Arial"> Walton,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Zoology, Faculty of Sciences, Pir Mehr Ali Shah Arid Agriculture University Rawalpindi, Rawalpindi, Pakistan</style></auth-address><titles><title><style face="normal" font="Arial">Characterization of Sarcoptes scabiei Tropomyosin and Paramyosin: Immunoreactive Allergens in Scabies</style></title><secondary-title><style face="normal" font="Arial">Am J Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Trop Med Hyg</style></full-title></periodical><pages end="860" start="851">851-860</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen characterization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> Paramyosin</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Sar s 10</style></keyword><keyword><style face="normal" font="Arial"> Sar s 11</style></keyword><keyword><style face="normal" font="Arial"> Sarcoptes scabiei</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin allergy</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">Scabies is a human skin disease due to the burrowing ectoparasite Sarcoptes scabiei var. hominis resulting in intense itching and inflammation and manifesting as a skin allergy. Because of insufficient mite material and lack of in vitro propagation system for antigen preparation, scabies is a challenging disease to develop serological diagnostics. For allergen characterization, full-length S. scabiei tropomyosin (Sar s 10) was cloned, expressed in pET-15b, and assessed for reactivity with IgE antibodies from human sera. IgE binding was observed to Sar s 10 with sera collected from subjects with ordinary scabies, house dust mite (HDM)-positive and naive subjects and a diagnostic sensitivity of &lt; 30% was observed. S. scabiei paramyosin (Sar s 11) was cloned, and expressed in pET-28a in three overlapping fragments designated Sspara1, Sspara2, and Sspara3. IgE and IgG binding was observed to Sspara2 and Sspara3 antigens with sera collected from ordinary scabies, and HDM-positive subjects, but no binding was observed with sera collected from naive subjects. Sspara2 displayed excellent diagnostic potential with 98% sensitivity and 90% specificity observed for IgE binding and 70% sensitivity for IgG. In contrast, the diagnostic sensitivity of Sspara3 was 84% for IgE binding and 40% for IgG binding. In combination, Sspara2 and Sspara3 provided an IgE sensitivity of 94%. This study shows that IgE binding to Sspara2 and Sspara3 is a highly sensitive method for diagnosis of scabies infestation in clinical practice. The developed enzyme-linked immunosorbent assay helps direct future development of a specific diagnostic tool for scabies</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1476-1645 (Electronic)IS - 0002-9637 (Linking)LA - engPT - Journal ArticleCO - Pakistan -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.4269/ajtmh.16-0976</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722633">PM:28722633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Trop Med Hyg\2017-97-851-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Trop Med Hyg\2017-97-851-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Naz S</style></custom2><misc3><style face="normal" font="Arial">10.4269/ajtmh.16-0976</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vandekerckhove,M.</style></author><author><style face="normal" font="Arial"> Van Droogenbroeck,B.</style></author><author><style face="normal" font="Arial"> de Loose,M.</style></author><author><style face="normal" font="Arial"> Taverniers,I.</style></author><author><style face="normal" font="Arial"> Daeseleire,E.</style></author><author><style face="normal" font="Arial"> Gevaert,P.</style></author><author><style face="normal" font="Arial"> Lapeere,H.</style></author><author><style face="normal" font="Arial"> Van Poucke,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Technology and Food Science Unit, Flanders Research Institute, Institute for Agriculture, Fisheries and Food (ILVO), Burg. Van Gansberghelaan 115, 9820, Merelbeke, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">Development of an LC-MS/MS method for the detection of traces of peanut allergens in chili pepper</style></title><secondary-title><style face="normal" font="Arial">Anal Bioanal Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Bioanal Chem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Detection methods</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Fisheries</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> LC-MS</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> marker peptides</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spices</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="Arial">The recent detection of nuts (including peanut) in spices across the globe has led to enormous recalls of several spices and food products in the last two years. The lack of validated detection methods specific for spices makes it difficult to assess allergen presence at trace levels. Because of the urgent need for confirmation of possible peanut presence in chili peppers, an LC-MS/MS method was optimized and developed for this particular food matrix. Although several studies optimized LC-MS detection strategies specific for peanuts, the presence of complex components in the spices (e.g., phenolic components) makes method optimization and validation necessarily. Focus was laid on validation of the method with real incurred chili peppers (whereby a known amount of peanut is added) at low concentrations, to deal with possible matrix interferences. LC-MS/MS proves to be a good alternative to the currently most applied methods (ELISA and RT-PCR) and can be used as a complementary method of analysis when results are unclear. Peanut marker peptides were selected based on their abundancy in digested incurred chili peppers. The limit of detection was determined to be 24 ppm (mg peanut/kg), a level whereby the risk for potential allergic reactions is zero, considering the typical portion size of spices. The chili pepper powder under investigation proved to contain low levels of peanuts after LC-MS/MS, ELISA, and RT-PCR testing. Graphical abstract Standard curve of the detected peanuts in chili pepper samples using the novel LC-MS/MS method</style></abstract><notes><style face="normal" font="Arial">DA - 20170726IS - 1618-2650 (Electronic)IS - 1618-2642 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00216-017-0506-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28744561">PM:28744561</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Bioanal Chem\20170726-VandekerckhoveM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Bioanal Chem\20170726-VandekerckhoveM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, Vandekerckhove M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00216-017-0506-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bui,T.T.</style></author><author><style face="normal" font="Arial"> Piao,C.H.</style></author><author><style face="normal" font="Arial"> Song,C.H.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author><author><style face="normal" font="Arial"> Chai,O.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy, Chonbuk National University Medical School, Jeonju, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Baicalein, wogonin, and Scutellaria baicalensis ethanol extract alleviate ovalbumin-induced allergic airway inflammation and mast cell-mediated anaphylactic shock by regulation of Th1/Th2 imbalance and histamine release</style></title><secondary-title><style face="normal" font="Arial">Anat Cell Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anat Cell Biol</style></full-title></periodical><pages end="134" start="124">124-134</pages><volume><style face="normal" font="Arial">50</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baicalein</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat peritoneal mast cells</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Asthma is characterized by chronic inflammation, goblet cell hyperplasia, the aberrant production of the Th2 cytokines, and eosinophil infiltration into the lungs. In this study, we examined the effects of baicalein, wogonin, and Scutellaria baicalensis ethanol extract on ovalbumin (OVA)-induced asthma by evaluating Th1/Th2 cytokine levels, histopathologic analysis, and compound 48/80-induced systemic anaphylaxis and mast cell activation, focusing on the histamine release from rat peritoneal mast cells. Baicalein, wogonin, and S. baicalensis ethanol extract also decreased the number of inflammatory cells especially eosinophils and downregulated peribronchial and perivascular inflammation in the lungs of mice challenged by OVA. Baicalein, wogonin, and S. baicalensis ethanol extract significantly reduced the levels of tumor necrosis factor alpha, interleukin (IL)-1beta, IL-4, IL-5 and the production of OVA-specific IgE and IgG1, and upregulated the level of interferon-gamma and OVA-specific IgG2a. In addition, oral administration of baicalein, wogonin, and S. baicalensis ethanol extract inhibited compound 48/80-induced systemic anaphylaxis and plasma histamine release in mice. Moreover, baicalein, wogonin, and S. baicalensis ethanol extract suppressed compound 48/80-induced mast cell degranulation and histamine release from rat peritoneal mast cells. Conclusively, baicalein and wogonin as major flavonoids of S. baicalensis may have therapeutic potential for allergic asthma through modulation of Th1/Th2 cytokine imbalance and histamine release from mast cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 2093-3665 (Print)IS - 2093-3665 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5115/acb.2017.50.2.124</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28713616">PM:28713616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anat Cell Biol\2017-50-124-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anat Cell Biol\2017-50-124-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Bui TT</style></custom2><misc3><style face="normal" font="Arial">10.5115/acb.2017.50.2.124</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abrams,E.M.</style></author><author><style face="normal" font="Arial"> Becker,A.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, Manitoba, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Delayed stinging insect reactions</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170724IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.06.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28736112">PM:28736112</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170724-AbramsEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170724-AbramsEM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170724, Abrams EM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.06.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,P.H.</style></author><author><style face="normal" font="Arial"> Gunawardana,N.</style></author><author><style face="normal" font="Arial"> Thomas,I.</style></author><author><style face="normal" font="Arial"> Ue,K.L.</style></author><author><style face="normal" font="Arial"> Siew,L.</style></author><author><style face="normal" font="Arial"> Watts,T.J.</style></author><author><style face="normal" font="Arial"> Bintcliffe,K.</style></author><author><style face="normal" font="Arial"> Haque,R.</style></author><author><style face="normal" font="Arial"> Rutkowski,K.</style></author><author><style face="normal" font="Arial"> Skypala,I.</style></author><author><style face="normal" font="Arial"> Till,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Sesame allergy in adults: Investigation and outcomes of oral food challenges</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="22" Month="7" Year="2017">2017/7/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170726IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28743426">PM:28743426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170726-LiPH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170726-LiPH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, Li PH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.06.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vignon,G.</style></author><author><style face="normal" font="Arial"> Cognee,A.S.</style></author><author><style face="normal" font="Arial"> Carrere,F.</style></author><author><style face="normal" font="Arial"> Masson,I.</style></author><author><style face="normal" font="Arial"> Borde,F.</style></author><author><style face="normal" font="Arial"> Augereau,P.F.</style></author><author><style face="normal" font="Arial"> Aucher,P.</style></author><author><style face="normal" font="Arial"> Lellouche,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Groupement de cooperation sanitaire de Saintonge, Centres hospitaliers de Saintes et Royan, Vaux-sur-Mer, France</style></auth-address><titles><title><style face="normal" font="Arial">A new case of IgE multiple myeloma with review of literature</style></title><secondary-title><style face="normal" font="Arial">Ann Biol Clin (Paris)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Biol Clin (Paris)</style></full-title></periodical><pages end="444" start="442">442-444</pages><volume><style face="normal" font="Arial">75</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE Myeloma</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Multiple Myeloma</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">IgE myeloma is an extremely rare disease characterized by frequent plasma cell leukemia, little monoclonal-spike on electrophoresis, an high incidence of t(11;14) translocation and a worse survival than those with common myelomas. We report here a new case of IgE myeloma and discuss clinical presentation, biological features and therapeutic option</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1950-6112 (Electronic)IS - 0003-3898 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1684/abc.2017.1263.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28751289">PM:28751289</url></web-urls></urls><custom2><style face="normal" font="Arial">20170728, Vignon G</style></custom2><misc3><style face="normal" font="Arial">10.1684/abc.2017.1263.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Basler,K.</style></author><author><style face="normal" font="Arial"> Galliano,M.F.</style></author><author><style face="normal" font="Arial"> Bergmann,S.</style></author><author><style face="normal" font="Arial"> Rohde,H.</style></author><author><style face="normal" font="Arial"> Wladykowski,E.</style></author><author><style face="normal" font="Arial"> Vidal,Y.S.</style></author><author><style face="normal" font="Arial"> Guiraud,B.</style></author><author><style face="normal" font="Arial"> Houdek,P.</style></author><author><style face="normal" font="Arial"> Schuring,G.</style></author><author><style face="normal" font="Arial"> Volksdorf,T.</style></author><author><style face="normal" font="Arial"> Caruana,A.</style></author><author><style face="normal" font="Arial"> Bessou-Touya,S.</style></author><author><style face="normal" font="Arial"> Schneider,S.W.</style></author><author><style face="normal" font="Arial"> Duplan,H.</style></author><author><style face="normal" font="Arial"> Brandner,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venerology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Biphasic influence of Staphylococcus aureus on human epidermal tight junctions</style></title><secondary-title><style face="normal" font="Arial">Ann N Y Acad Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann N Y Acad Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Infections</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cell Membrane</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Claudin-1</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Membranes</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> occludin</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Tight Junctions</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2017">2017/7/28</year></dates><abstract><style face="normal" font="Arial">Bacterial infections (e.g., with Staphylococcus aureus) are serious problems in skin with a compromised barrier, such as in patients with atopic dermatitis. Previously, it was shown that tight junction (TJ) proteins are influenced by staphylococcal infection, and TJ function is impaired after infection of the keratinocyte cell line HaCaT. However, functional studies in cells or models more similar to human skin are missing. Therefore, we investigated bacterial colonialization and infection with live S. aureus in primary human keratinocytes and reconstructed human epidermis (RHE). We show that short-term inoculation results in increased TJ barrier function-which could not be seen in HaCaT cells-hinting at an early protective effect. This is accompanied by occludin phosphorylation and sustained localization of occludin and claudin-4 at cell membranes. Long-term incubation resulted in decreased presence of claudin-1 and claudin-4 at cell membranes and decreased TJ barrier function. The agr regulon of S. aureus plays a role in the increasing but not in the decreasing effect. Proinflammatory cytokines, which are produced as a result of S. aureus inoculation, influence both phases. In summary, we show here that S. aureus can have short-term promoting effects on the TJ barrier, while in the long term it results in disturbance of TJs</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1749-6632 (Electronic)IS - 0077-8923 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/nyas.13418</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28753223">PM:28753223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann N Y Acad Sci\20170728-BaslerK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann N Y Acad Sci\20170728-BaslerK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Basler K</style></custom2><misc3><style face="normal" font="Arial">10.1111/nyas.13418</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fernand,M.G.</style></author><author><style face="normal" font="Arial"> Roullier,C.</style></author><author><style face="normal" font="Arial"> Guitton,Y.</style></author><author><style face="normal" font="Arial"> Lalande,J.</style></author><author><style face="normal" font="Arial"> Lacoste,S.</style></author><author><style face="normal" font="Arial"> Dupont,J.</style></author><author><style face="normal" font="Arial"> Ruiz,N.</style></author><author><style face="normal" font="Arial"> Pouchus,Y.F.</style></author><author><style face="normal" font="Arial"> Raheriniaina,C.</style></author><author><style face="normal" font="Arial"> Eulalie,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Fungi isolated from Madagascar shrimps - investigation of the Aspergillus niger metabolism by combined LC-MS and NMR metabolomics studies</style></title><secondary-title><style face="normal" font="Arial">Aquaculture</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Aquaculture</style></full-title></periodical><pages end="758" start="750">750-758</pages><volume><style face="normal" font="Arial">479</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus niger</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> LC-MS</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimps</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0044-8486</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Madagascar -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aquaculture.2017.07.015</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.aquaculture.2017.07.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aquaculture\2017-479-750-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aquaculture\2017-479-750-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Fernand MG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aquaculture.2017.07.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Petriz,N.A.</style></author><author><style face="normal" font="Arial"> Parisi,C.A.</style></author><author><style face="normal" font="Arial"> Busaniche,J.N.</style></author><author><style face="normal" font="Arial"> Evangelista,P.</style></author><author><style face="normal" font="Arial"> Mehaudy,R.</style></author><author><style face="normal" font="Arial"> Orsi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Seccion de Alergia Pediatrica, Hospital Italiano de Buenos Aires, Argentina.</style></auth-address><titles><title><style face="normal" font="Arial">Natural history of immunoglobulin E-mediated cow's milk allergy in a population of Argentine children</style></title><secondary-title><style face="normal" font="Arial">Arch Argent Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Argent Pediatr</style></full-title></periodical><pages end="335" start="331">331-335</pages><volume><style face="normal" font="Arial">115</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Cow's milk protein allergy is the most common allergy in pediatrics. Immunoglobulin E (IgE)-mediated cow's milk allergy poses a higher risk for life and a worse prognosis. OBJETIVES: To describe the course of IgE-mediated cow's milk protein allergy and risk factors associated with disease persistence. PATIENTS AND METHODS: This was a descriptive, retrospective study conducted in patients seen at the Division of Pediatric Allergy of Hospital Italiano between June 2006 and June 2012 who had been diagnosed with IgE-mediated cow's milk allergy. RESULTS: Out of the 72 patients with IgE-mediated cow's milk allergy, 39 (54%) were boys. Patients' average age at the time of diagnosis was 5.19 +/- 3.7months old; the most common symptoms were urticaria and vomiting. Rhinitis and asthma were the most commonly observed concomitant atopic diseases. In the study period, 54.5% of patients developed tolerance at an average age of 32 months old. An 8-mm papule in the skin prick test and casein sensitization were associated with disease persistence. CONCLUSION: Overall, 54.5% of patients developed tolerance at 32 months old. A significant association was observed between papule size at the time of diagnosis and casein sensitization and disease persistence</style></abstract><notes><style face="normal" font="Arial">DA - 20170724IS - 1668-3501 (Electronic)IS - 0325-0075 (Linking)LA - engLA - spaPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.5546/aap.2017.eng.331</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28737860">PM:28737860</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Argent Pediatr\2017-115-331-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Argent Pediatr\2017-115-331-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170724, Petriz NA</style></custom2><misc3><style face="normal" font="Arial">10.5546/aap.2017.eng.331</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dalrymple,R.A.</style></author><author><style face="normal" font="Arial"> Makwana,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="Arial">Introduction of allergenic foods from 3 months of age reduces incidence of food allergy in breastfed infants</style></title><secondary-title><style face="normal" font="Arial">Arch Dis Child Educ Pract Ed</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dis Child Educ Pract Ed</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="25" Month="7" Year="2017">2017/7/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170726IS - 1743-0593 (Electronic)IS - 1743-0585 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/archdischild-2016-311809</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28743732">PM:28743732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dis Child Educ Pract Ed\20170726-DalrympleRA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dis Child Educ Pract Ed\20170726-DalrympleRA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, Dalrymple RA</style></custom2><misc3><style face="normal" font="Arial">10.1136/archdischild-2016-311809</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,H.</style></author><author><style face="normal" font="Arial"> Luo,Z.D.</style></author><author><style face="normal" font="Arial"> Tang,X.H.</style></author><author><style face="normal" font="Arial"> Han,J.D.</style></author><author><style face="normal" font="Arial"> Gao,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">Folliculotropic mycosis fungoides associated with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Australas J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Australas J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Mycosis Fungoides</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1440-0960 (Electronic)IS - 0004-8380 (Linking)LA - engPT - LetterCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/ajd.12607</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731507">PM:28731507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Australas J Dermatol\20170721-ZhouH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Australas J Dermatol\20170721-ZhouH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Zhou H</style></custom2><misc3><style face="normal" font="Arial">10.1111/ajd.12607</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Biscola,V.</style></author><author><style face="normal" font="Arial"> de Olmos,A.R.</style></author><author><style face="normal" font="Arial"> Choiset,Y.</style></author><author><style face="normal" font="Arial"> Rabesona,H.</style></author><author><style face="normal" font="Arial"> Garro,M.S.</style></author><author><style face="normal" font="Arial"> Mozzi,F.</style></author><author><style face="normal" font="Arial"> Chobert,J.M.</style></author><author><style face="normal" font="Arial"> Drouet,M.</style></author><author><style face="normal" font="Arial"> Haertle,T.</style></author><author><style face="normal" font="Arial"> Franco,B.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Food Research Center, Department of Food and Experimental Nutrition, Faculty of Pharmaceutical Sciences, University of Sao Paulo, 580 Professor Lineu Prestes 13 B, Sao Paulo, SP 05508-000, Brazil3 Protein Functions and Interactions Research Team, UR 1268 Biopolymeres Interactions Assemblages, INRA, BP 71627, 44316 Nantes Cedex 3, France</style></auth-address><titles><title><style face="normal" font="Arial">Soymilk fermentation by Enterococcus faecalis VB43 leads to reduction in the immunoreactivity of allergenic proteins beta-conglycinin (7S) and glycinin (11S)</style></title><secondary-title><style face="normal" font="Arial">Benef Microbes</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Benef Microbes</style></full-title></periodical><pages end="643" start="635">635-643</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">11S</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enterococcus faecalis</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lactic Acid</style></keyword><keyword><style face="normal" font="Arial"> Lactic acid bacteria</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolytic enzyme</style></keyword><keyword><style face="normal" font="Arial"> Proteolytic enzymes</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> RP-HPLC</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy Proteins</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soymilk</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">Food allergies represent a serious problem affecting human health and soy proteins rank among the most allergenic proteins from food origin. The proteolytic enzymes produced by lactic acid bacteria (LAB) can hydrolyse the major allergens present in soybean, reducing their immunoreactivity. Many studies have reported the ability of LAB to ferment soy-based products; while the majority of them focus on the improvement of the sensory characteristics and functionality of soy proteins, a lack of information about the role of lactic fermentation in the reduction of immunoreactivity of these proteins exists. The aim of the present study was to evaluate the capability of the proteolytic strain Enterococcus faecalis VB43 to hydrolyse the main allergenic proteins present in soymilk and to determine the immunoreactivity of the obtained hydrolysates. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) results of fermented soymilk demonstrated complete hydrolysis of the beta-subunit from beta-conglycinin and the acidic polypeptide from glycinin. Reversed phase high performance liquid chromatography (RP-HPLC) analysis of the peptides released after hydrolysis revealed the appearance of new peptides and the disappearance of non-hydrolysed proteins, indicating extensive hydrolysis of the substrate. Results from competitive enzyme-linked immunosorbent assay (ELISA) tests clearly indicated a reduction in the immunoreactivity (more than one logarithmic unit) in the fermented sample as compared to the non-fermented control. Our results suggest that the soymilk fermented by E. faecalis VB43 may induce lower allergic responses in sensitive individuals. The strain E. faecalis VB43 may be considered as an excellent candidate to efficiently reduce the immunoreactivity of soymilk proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1876-2891 (Electronic)IS - 1876-2883 (Linking)LA - engPT - Journal ArticleCO - France -CO - Argentina -CO - Poland -CO - Iran -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.3920/BM2016.0171</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28726509">PM:28726509</url></web-urls><pdf-urls><url ppv-ref="no">vbiscola@usp.br</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170720, Biscola V</style></custom2><misc3><style face="normal" font="Arial">10.3920/BM2016.0171</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Corthesy,B.</style></author><author><style face="normal" font="Arial"> Bioley,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">R&amp;D Laboratory, Division of Immunology and Allergy, University State Hospital (CHUV), Epalinges, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic intranasal instillation of allergen-loaded microbubbles suppresses experimental allergic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Biomaterials</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomaterials</style></full-title></periodical><pages end="51" start="41">41-51</pages><volume><style face="normal" font="Arial">142</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="Arial">Despite proven efficiency, subcutaneous immunotherapy for aeroallergens is impaired by the duration of the protocol, the repeated injections and potential side-effects associated with the doses of allergen administered. Intranasal delivery of immunotherapeutic agents may overcome several of these drawbacks, provided that an efficient allergen delivery vehicle can be identified. This study evaluates whether intranasally delivered gas-filled microbubble (MB)-associated ovalbumin (OVA), used as a model allergen, can serve as a therapeutic treatment in a mouse model of established allergic asthma. Lung and systemic production of pro-tolerogenic markers, including Foxp3+ CD4 T cells, IL-10, and TGF-beta, as well as the Th1-type cytokine IFN-gamma, was observed after intranasal immunization with OVA-MB. Post-treatment, aerosol-sensitized mice exhibited the same pattern of markers. Moreover, decrease of eosinophils and neutrophils in BALs, lower frequencies of Th2 cytokine- and IL-17-producing CD4 T cells in lungs and reduced specific IgE in BALs and sera after allergen challenge were observed. Concomitantly, lung resistance and mucus production diminished in OVA-MB-treated animals. Thus, therapeutic intranasal administration of OVA-MBs in established experimental allergic asthma allows modulating pathology-associated immune and physiological parameters usually triggered after exposure to the allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1878-5905 (Electronic)IS - 0142-9612 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biomaterials.2017.07.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28727997">PM:28727997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomaterials\2017-142-41-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomaterials\2017-142-41-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Corthesy B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biomaterials.2017.07.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perera,A.L.H.A.</style></author><author><style face="normal" font="Arial"> Perera,B.G.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemistry, Faculty of Science, University of Colombo, 03 Colombo, Sri Lanka</style></auth-address><titles><title><style face="normal" font="Arial">Development of an Economical Method to Reduce the Extractable Latex Protein Levels in Finished Dipped Rubber Products</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="9573021">9573021-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bromelain</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Glove</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex proteins</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Papain</style></keyword><keyword><style face="normal" font="Arial"> papaya</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sri Lanka</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Natural rubber latex (NRL) allergy is caused by the extractable latex proteins in dipped rubber products. It is a major concern for the consumers who are sensitive to the allergenic extractable proteins (EP) in products such as NRL gloves. Objective of this research was to develop an economical method to reduce the EP in finished dipped NRL products. In order to reduce the EP levels, two natural proteases, bromelain from pineapple and papain from papaya, were extracted and partially purified using (NH4)2SO4. According to the newly developed method, different glove samples were treated with a 5% solution of each partially purified enzyme, for 2 hours at 60 degrees C. Residual amounts of in treated samples were quantified using the modified Lowry assay (ASTM D5712-10). Bromelain displayed a 54 (+/-11)% reduction of the EP from the dipped rubber products, whereas it was 58 (+/-8)% with papain. These results clearly indicate that the selected natural proteases, bromelain, and papain contribute significantly towards the reduction of the total EP in finished NRL products. Application of bromelain enzyme for the aforementioned purpose has not been reported up to date, whereas papain has been used to treat raw NRL towards reducing the EP</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 2314-6141 (Electronic)LA - engPT - Journal ArticleCO - Sri Lanka -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/9573021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28706952">PM:28706952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-9573021.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-9573021.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Perera AL</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/9573021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jia,L.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Li,S.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Shen,J.</style></author><author><style face="normal" font="Arial"> Tan,W.</style></author><author><style face="normal" font="Arial"> Wu,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Detection of IL-9 producing T cells in the PBMCs of allergic asthmatic patients</style></title><secondary-title><style face="normal" font="Arial">BMC Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Immunol</style></full-title></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interferon-+¦</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-9</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1471-2172</style></isbn><abstract><style face="normal" font="Arial">Interleukin-9 (IL-9) was reported as an active participant in the pathogenesis of allergic asthma. This study aimed to investigate the major source ofIL-9 and its effect on interferon +¦ (IFN-+¦) and immunoglobulin (Ig) secretion by B cells</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12865-017-0220-1</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s12865-017-0220-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Immunol\2017-18-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Immunol\2017-18-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Jia L</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12865-017-0220-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Begen,F.M.</style></author><author><style face="normal" font="Arial"> Barnett,J.</style></author><author><style face="normal" font="Arial"> Barber,M.</style></author><author><style face="normal" font="Arial"> Payne,R.</style></author><author><style face="normal" font="Arial"> Gowland,M.H.</style></author><author><style face="normal" font="Arial"> Lucas,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Psychology, University of Bath, Claverton Down, Bath, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Parents' and caregivers' experiences and behaviours when eating out with children with a food hypersensitivity</style></title><secondary-title><style face="normal" font="Arial">BMC Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Public Health</style></full-title></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: For parents and caregivers of food hypersensitive (FH) children, accommodating their child's dietary needs when eating out can be a challenging experience. This study explored caregivers' experiences and behaviours when eating out with their FH child in order to gain insights into how they support and prepare their child in negotiating safe eating out experiences. METHODS: A cross-sectional, qualitative design was used. In depth, semi-structured interviews were carried out with 15 caregivers of children with FH. Interviews were analysed using framework analysis. RESULTS: Caregivers reported a number of issues relating to eating out with their FH child, or allowing their child to eat out without their supervision. Through themes of 'family context', 'child-focused concerns', and 'venue issues', caregivers described how they managed these and explained the limitations and sacrifices that FH imposed on their child, themselves, and family members. CONCLUSIONS: Through deeper understanding of the anxieties, negotiations and compromises experienced by caregivers of children with FH when they are eating out, clinicians and support charities can tailor their support to meet the needs of caregivers and children. Support and education provision should focus on providing caregivers of children with FH the tools and strategies to help enable safe eating out experiences</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1471-2458 (Electronic)IS - 1471-2458 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12889-017-4594-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28728569">PM:28728569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Public Health\2017-18-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Public Health\2017-18-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Begen FM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12889-017-4594-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ledingham,J.</style></author><author><style face="normal" font="Arial"> Snowden,N.</style></author><author><style face="normal" font="Arial"> Ide,Z.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Diagnosis and early management of inflammatory arthritis</style></title><secondary-title><style face="normal" font="Arial">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Early treatment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Spine</style></keyword><keyword><style face="normal" font="Arial"> Spondylitis</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="Arial">What you need to knowConsider inflammatory arthritis in anyone with acute or subacute onset of joint pain, early morning stiffness, and soft tissue swellingEarly diagnosis and treatment with disease modifying anti-rheumatic drugs (DMARDS) and corticosteroids improves function and symptomatic and radiographic outcomesPatients need rapid access to specialist advice during flaresPrescription and monitoring of DMARDs can be shared between specialists and non-specialists if pathways and communication are clearSpecialists are best placed to guide changes in DMARDS or steroid treatmentAutoimmune inflammation affects the joints of people with inflammatory arthritis. No definitive cause has been identified, despite extensive research. An environmental trigger in a genetically predisposed individual seems to be the most likely mechanism.1About 80-100 adults in 100</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çë000 develop inflammatory arthritis every year.2 3 Rheumatoid arthritis is the most common inflammatory arthritis, affecting approximately 500</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çë000 people in the UK.4 Spondylo-arthropathies, which include psoriatic arthritis, reactive arthritis, and ankylosing spondylitis, are slightly less common. In ankylosing spondylitis inflammation occurs mainly in the spine, but peripheral arthritis can occur.5 Inflammatory arthritis primarily affects people of working age, and within 10 years of diagnosis around 40% of people with rheumatoid arthritis are unable to work.6Systematic reviews of randomised controlled trials show that early treatment can control symptoms, induce remission, minimise irreparable damage, and protect against the mortality and morbidity associated with inflammatory arthritis, especially cardiovascular. Guidelines7 and quality standards8 from the UK</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs National Institute for Health and Care Excellence recommend early aggressive treatment for rheumatoid arthritis. This approach has been shown to be cost effective,9 and management principles for rheumatoid arthritis are broadly applicable to all forms of inflammatory arthritis. This clinical update, aimed at non specialists, provides information on the diagnosis and early management of inflammatory arthritis.Sources and selection criteriaWe performed a Pubmed search on the </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çª</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmj.j3248</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1136/bmj.j3248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\20170728-LedinghamJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\20170728-LedinghamJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Ledingham J</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmj.j3248</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vella,C.</style></author><author><style face="normal" font="Arial"> Sammut,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Mater Dei Hospital, Msida, MaltaDepartment of Paediatrics, Mater Dei Hospital, Msida, Malta</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis secondary to Parietaria judaica (wall pellitory)</style></title><secondary-title><style face="normal" font="Arial">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Malta</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Parietaria</style></keyword><keyword><style face="normal" font="Arial"> Parietaria judaica</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">Aeroallergens are an unusual cause of anaphylaxis with sparse reports in the literature. We describe a case of suspected anaphylaxis to Parietaria judaica pollen and the difficulties encountered in confirming this diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - Malta -</style></notes><work-type><style face="normal" font="Arial">10.1136/bcr-2017-220309</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28710239">PM:28710239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Case Rep\20170715-VellaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Case Rep\20170715-VellaC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Vella C</style></custom2><misc3><style face="normal" font="Arial">10.1136/bcr-2017-220309</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Munblit,D.</style></author><author><style face="normal" font="Arial"> Treneva,M.</style></author><author><style face="normal" font="Arial"> Korsunskiy,I.</style></author><author><style face="normal" font="Arial"> Asmanov,A.</style></author><author><style face="normal" font="Arial"> Pampura,A.</style></author><author><style face="normal" font="Arial"> Warner,J.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Imperial College London, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">A national survey of Russian physicians' knowledge of diagnosis and management of food-induced anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMJ Open</style></full-title></periodical><pages end="" start="e015901">e015901-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenalin</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Food allergy is an increasing burden worldwide and is a common problem within paediatric populations, affecting 5%-8% of children. Anaphylaxis caused by food proteins is a potentially life-threatening condition and all healthcare practitioners should be aware of its recognition and management. Russia is the largest country in Europe but it is still unknown whether physicians are prepared to diagnose and manage food-induced anaphylaxis effectively. We aimed to examine physicians' knowledge of diagnosis and management of food-induced anaphylaxis. SETTING, POPULATION AND OUTCOMES: A survey was designed and published online at VrachiRF.ru website (for registered Russian-speaking practicing physicians). We obtained information on respondents' clinical settings, experience and specialty. Survey questions were based on a characteristic clinical scenario of anaphylaxis due to food ingestion. Outcome measures consisted of correct answers to the anaphylaxis diagnosis and management questions. RESULTS: From a total of 707 of physicians accessed in the survey, 315 (45%) responded to the clinical scenario. 16 respondents reported training in allergy-immunology and have been excluded from the analysis, leaving the final sample size of 299. Respondents were paediatricians (68%) and other specialties adult physicians (32%). Overall, 100 (33%) of respondents diagnosed anaphylaxis, but only 29% of those making the correct diagnosis administered adrenalin (1:1000) intramuscular. Respondents working in secondary/tertiary clinics diagnosed anaphylaxis significantly more often (p=0.04) when compared with primary care/private practice physicians. This difference was also apparent as the most important influence on responses in the multivariate analysis. CONCLUSIONS: In this national sample of Russian physicians, we found poor knowledge in both anaphylaxis diagnosis and management. Our data show that the chance of being properly diagnosed with anaphylaxis is 33% and being appropriately treated with adrenalin is 10%. These findings highlight lack of anaphylaxis knowledge among Russian physicians, both paediatricians and other specialists and illustrates the urgent need for allergy/anaphylaxis training</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Russia -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1136/bmjopen-2017-015901</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28729318">PM:28729318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Open\2017-7-e015901.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Open\2017-7-e015901.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Munblit D</style></custom2><misc3><style face="normal" font="Arial">10.1136/bmjopen-2017-015901</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamamoto,Y.</style></author><author><style face="normal" font="Arial"> Ano,S.</style></author><author><style face="normal" font="Arial"> Allard,B.</style></author><author><style face="normal" font="Arial"> O'Sullivan,M.</style></author><author><style face="normal" font="Arial"> McGovern,T.K.</style></author><author><style face="normal" font="Arial"> Martin,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Meakins-Christie Laboratories, The Research Institute of McGill University Health Centre and the Department of Medicine, McGill University, Montreal, QC</style></auth-address><titles><title><style face="normal" font="Arial">MK reduces inhaled chlorine triggered AHR and airway inflammation in the mouse</style></title><secondary-title><style face="normal" font="Arial">Br J Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Br J Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Chlorine</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> irritant-induced asthma</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> lipid mediators</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Methylcellulose</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcome measurement</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND PURPOSE: Cysteinyl leukotrienes (CysLTs) are pro-inflammatory lipid mediators that exacerbate disease state in several asthma phenotypes including asthma induced by allergen, virus and exercise. However, the role of CysLTs in irritant-induced airway disease is not well characterized. The purpose of the current study was to investigate the effect of montelukast (MK), a CysLT1R antagonist, on parameters of irritant-induced asthma (IIA) induced by inhalation of chlorine (Cl2 ) in the mouse. EXPERIMENTAL APPROACH: BALB/c mice were exposed to Cl2 (100ppm, for 5 minutes). MK (3mg/kg) or the vehicle 1% methylcellulose (MC) was administered 24 hours and 1 hour prior to Cl2 exposure and 1 hour prior to outcome measurements. Twenty-four hours after exposure, responses to inhaled aerosolized methacholine (MCh), cell composition and an array of cytokines/chemokines in bronchoalveolar lavage (BAL) fluid were measured. Neutralizing antibodies against interleukin (IL)-6 and vascular endothelial growth factor (VEGF) were administered prior to exposures. KEY RESULTS: MK reduced Cl2 -induced airway hyperresponsiveness (AHR) to MCh in the peripheral lung compartment as estimated from dynamic elastance but not in large conducting airways. MK treatment attenuated Cl2 -induced macrophage influx, neutrophilia and eosinophilia in BAL fluid. Cl2 exposure increased vascular endothelial growth factor (VEGF), IL-6, keratinocyte cytokine and macrophage inflammatory protein-1alpha in BAL fluid. MK treatment prevented Cl2 -induced increases in VEGF and IL-6. Anti-IL-6 inhibited Cl2 -induced neutrophilia and reduced AHR. CONCLUSION AND IMPLICATIONS: Findings in the present study demonstrate that MK treatment attenuates Cl2 -induced neutrophilia and AHR. These effects are mediated, in part, via IL-6</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1476-5381 (Electronic)IS - 0007-1188 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/bph.13953</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28718891">PM:28718891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Pharmacol\20170718-HamamotoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Pharmacol\20170718-HamamotoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Hamamoto Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/bph.13953</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,L.L.</style></author><author><style face="normal" font="Arial"> Li,F.H.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Zhang,X.F.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China</style></auth-address><titles><title><style face="normal" font="Arial">Tangeretin has anti-asthmatic effects via regulating PI3K and Notch signaling and modulating Th1/Th2/Th17 cytokine balance in neonatal asthmatic mice</style></title><secondary-title><style face="normal" font="Arial">Braz J Med Biol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Med Biol Res</style></full-title></periodical><pages end="" start="e5991">e5991-</pages><volume><style face="normal" font="Arial">50</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> cell signaling</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Jagged</style></keyword><keyword><style face="normal" font="Arial"> Jagged-1</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Compliance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> Notch signaling</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> phosphoinositide 3-kinase</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> progression of asthma</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2/Th17</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic allergic disease characterized by airway inflammation, airway hyper-responsiveness (AHR), and mucus hypersecretion. T-lymphocytes are involved in the pathogenesis of asthma, mediating airway inflammatory reactions by secreting cytokines. The phosphoinositide 3-kinase (PI3K) and Notch signaling pathways are associated with T cell signaling, proliferation, and differentiation, and are important in the progression of asthma. Thus, compounds that can modulate T cell proliferation and function may be of clinical value. Here, we assessed the effects of tangeretin, a plant-derived flavonoid, in experimental asthma. BALB/c mice at postnatal day (P) 12 were challenged with ovalbumin (OVA). Separate groups of mice (n=18/group) were administered tangeretin at 25 or 50 mg/kg body weight by oral gavage. Dexamethasone was used as a positive control. Tangeretin treatment reduced inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF) and also restored the normal histology of lung tissues. OVA-specific IgE levels in serum and BALF were reduced. AHR, as determined by airway resistance and lung compliance, was normalized. Flow cytometry analyses revealed a reduced Th17 cell population. Tangeretin reduced the levels of Th2 and Th17 cytokines and raised IFN-gamma levels. PI3K signaling was inhibited. The expressions of the Notch 1 receptor and its ligands Jagged 1 and 2 were downregulated by tangeretin. Our findings support the possible use of tangeretin for treating allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170726IS - 1414-431X (Electronic)IS - 0100-879X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1590/1414-431x20175991</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28746467">PM:28746467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Med Biol Res\2017-50-e5991.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Med Biol Res\2017-50-e5991.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, Liu LL</style></custom2><misc3><style face="normal" font="Arial">10.1590/1414-431x20175991</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Osada,T.</style></author><author><style face="normal" font="Arial"> Maeda,M.</style></author><author><style face="normal" font="Arial"> Tanabe,C.</style></author><author><style face="normal" font="Arial"> Furuta,K.</style></author><author><style face="normal" font="Arial"> Vavricka,C.J.</style></author><author><style face="normal" font="Arial"> Sasaki,E.</style></author><author><style face="normal" font="Arial"> Okano,M.</style></author><author><style face="normal" font="Arial"> Kimura,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Ibaraki 300-2611, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Glycoform of a newly identified pollen allergen, Cha o 3, from Chamaecyparis obtusa (Japanese cypress, Hinoki)</style></title><secondary-title><style face="normal" font="Arial">Carbohydr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Carbohydr Res</style></full-title></periodical><pages end="23" start="18">18-23</pages><volume><style face="normal" font="Arial">448</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Cellulase</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Cup a 1</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Cypress pollen</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Jun a 1</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> N-glycosylation</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="Arial">Cha o 3 is a newly found glycosylated allergen from Chamaecyparis obtusa (Japanese cypress) pollen. The deduced amino acid sequence of Cha o 3 indicates that this glycoallergen contains a cellulase domain and a number of putative N-glycosylation sites. However, the structures of N -glycans linked to Cha o 3 remain to be determined. In this study, therefore, we analyzed the glycoform of Cha o 3 and found that this glycoallergen carries exclusively plant complex-type N-glycans; major structures were GlcNAc2Man3Xyl1Fuc1GlcNAc2 (39%), Gal1Fuc1GlcNAc2Man3Xyl1Fuc1GlcNAc2 (14%), and Gal2Fuc2GlcNAc2Man3Xyl1Fuc1GlcNAc2 (25%). The glycoform of Cha o 3 bearing the Lea epitope is similar to those of Cry j1, Jun a 1, or Cup a 1, major glycoallergens in cedar or cypress pollens, and the predominant occurrence of GlcNAc2Man3Xyl1Fuc1GlcNAc2 is a common structural feature of glycoallergens from Cupressaceae pollens</style></abstract><notes><style face="normal" font="Arial">DA - 20170602IS - 1873-426X (Electronic)IS - 0008-6215 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.carres.2017.05.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28575723">PM:28575723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Carbohydr Res\2017-448-18-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Carbohydr Res\2017-448-18-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170602, Osada T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.carres.2017.05.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,S.H.</style></author><author><style face="normal" font="Arial"> Song,Y.H.</style></author><author><style face="normal" font="Arial"> Kim,T.H.</style></author><author><style face="normal" font="Arial"> Kim,S.B.</style></author><author><style face="normal" font="Arial"> Han,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,H.S.</style></author><author><style face="normal" font="Arial"> Oh,S.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Inje University College of Medicine, Goyang, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Acute Pancreatitis and Rhabdomyolysis with Acute Kidney Injury following Multiple Wasp Stings</style></title><secondary-title><style face="normal" font="Arial">Case Rep Nephrol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Case Rep Nephrol</style></abbr-1></periodical><pages end="" start="8596981">8596981-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Kidney Injury</style></keyword><keyword><style face="normal" font="Arial"> Amylase</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lipase</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pancreas</style></keyword><keyword><style face="normal" font="Arial"> Pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Renal Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhabdomyolysis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Toxic reaction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Multiple wasp stings can induce multiple organ dysfunction by toxic reactions. However, acute pancreatitis is a rare manifestation in wasp sting injury. A 74-year-old woman visited the emergency department by anaphylactic shock because of multiple wasp stings. Acute kidney injury, rhabdomyolysis, hepatotoxicity, and coagulopathy were developed next day. Serum amylase and lipase were elevated and an abdominal computed tomography revealed an acute pancreatitis. Urine output was recovered after 16 days of oliguria (below 500 ml/day). Her kidney, liver, and pancreas injury gradually improved after sessions of renal replacement therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 2090-6641 (Print)IS - 2090-665X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/8596981</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28706746">PM:28706746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Nephrol\2017-2017-8596981.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Nephrol\2017-2017-8596981.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Yang SH</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/8596981</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chang,H.Y.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Stanford University School of Medicine, Stanford University, Stanford, CA, USA.</style></auth-address><titles><title><style face="normal" font="Arial">IL-4Ralpha Inhibitor for Atopic Disease</style></title><secondary-title><style face="normal" font="Arial">Cell</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell</style></full-title></periodical><pages end="" start="222">222-</pages><volume><style face="normal" font="Arial">170</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="Arial">Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Ralpha subunit of IL-4 and IL-13 receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema). To view this Bench to Bedside, open or download the PDF</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1097-4172 (Electronic)IS - 0092-8674 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cell.2017.06.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28708993">PM:28708993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell\2017-170-222.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell\2017-170-222.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Chang HY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cell.2017.06.046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caslin,H.L.</style></author><author><style face="normal" font="Arial"> McLeod,J.J.A.</style></author><author><style face="normal" font="Arial"> Spence,A.J.</style></author><author><style face="normal" font="Arial"> Qayum,A.A.</style></author><author><style face="normal" font="Arial"> Kolawole,E.M.</style></author><author><style face="normal" font="Arial"> Taruselli,M.T.</style></author><author><style face="normal" font="Arial"> Paranjape,A.</style></author><author><style face="normal" font="Arial"> Elford,H.L.</style></author><author><style face="normal" font="Arial"> Ryan,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Virginia Commonwealth University, Richmond, VA, 23284, United States</style></auth-address><titles><title><style face="normal" font="Arial">Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cells</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="16" start="10">10-16</pages><volume><style face="normal" font="Arial">319</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> AP1</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Hydroxyurea</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">While IgE is considered the primary mediator of mast cell activation, IL-33 contributes substantially in asthma, allergic rhinitis, and atopic dermatitis. To develop effective treatments for allergic disease, it is important to understand the role of therapeutic agents on IL-33 activation. We examined the effect of Didox (3,4-dihydroxybenzohydroxamic acid), an antioxidant and ribonucleotide reductase (RNR) inhibitor, on IL-33-mediated mast cell activation. Didox suppressed IL-6, IL-13, TNF, and MIP-1alpha (CCL3) production in bone marrow derived mast cells following IL-33 activation. This suppression was observed in different genetic backgrounds and extended to peritoneal mast cells. The antioxidant N-acetylcysteine mimicked the suppression of Didox, albeit at a much higher dose, while the RNR inhibitor hydroxyurea had no effect. Didox substantially suppressed IL-33-mediated NFkappaB and AP-1 transcriptional activities. These results suggest that Didox attenuates IL-33-induced mast cell activation and should be further studied as a potential therapeutic agent for inflammatory diseases involving IL-33</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1090-2163 (Electronic)IS - 0008-8749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2017.04.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28750923">PM:28750923</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20170728-CaslinHL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20170728-CaslinHL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Caslin HL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2017.04.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bezerra,C.F.</style></author><author><style face="normal" font="Arial"> Mota,E.F.</style></author><author><style face="normal" font="Arial"> Silva,A.C.M.</style></author><author><style face="normal" font="Arial"> Tome,A.R.</style></author><author><style face="normal" font="Arial"> Silva,M.Z.R.</style></author><author><style face="normal" font="Arial"> de Brito,D.</style></author><author><style face="normal" font="Arial"> Porfirio,C.T.M.N.</style></author><author><style face="normal" font="Arial"> Oliveira,A.C.</style></author><author><style face="normal" font="Arial"> Lima-Filho,J.V.</style></author><author><style face="normal" font="Arial"> Ramos,M.V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto Federal de Educacao, Ciencia e Tecnologia do Estado do Rio Grande do Norte, Pau dos Ferros, Rio Grande do Norte, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Latex proteins from Calotropis procera: Toxicity and immunological tolerance revisited</style></title><secondary-title><style face="normal" font="Arial">Chem Biol Interact</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chem Biol Interact</style></full-title></periodical><pages end="149" start="138">138-149</pages><volume><style face="normal" font="Arial">274</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Apocynaceae</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological tolerance</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex proteins</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Peritoneum</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Roots</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Survivors</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">Many thousands of plants are disseminated worldwide in traditional and folk medicines based on the belief that their leaves, roots, seeds, bark or secretions, when adequately handled, can treat, alleviate or ameliorate numerous disease symptoms. Calotropis procera (Apocynaceae) is a popular medicinal plant and the claims of this shrub's phytomedicinal properties have been scientifically validated. In this study, further prospects towards the in vivo toxicity and oral immunological tolerance of phytomodulatory proteins isolated from the latex of C. procera are reported. Acute toxicity was determined in mice by oral and intraperitoneal administration of latex proteins (LP) and was followed behavioral, hematological and histological analyses. Oral immunological tolerance to LP was assessed by intraperitoneal immunization in mice that had received LP orally before. Animals given 5000 mg/kg orally exhibited only discrete behavioral alterations and augmentation of monocytes. Death was not notified 14 days after exposure. However, all animals receiving LP 150 mg/kg by i.p. died in 1 h. Death (20%) was documented when LP (75 mg/kg) was given in the peritoneum and signs of harmful effects were observed in the survivors (80%). Oral immunological tolerance was observed in animals previously given LP orally, when they were further immunized/challenged with peritoneal exposure to different doses of LP. This was confirmed by the lowering of IgE and IgG in the serum, IL-4 and IFN-gamma in spleen homogenates and the absence of anaphylaxis signs. It is therefore concluded that LP exhibited quite discrete adverse effects when orally administrated at higher concentrations and this route of administration did not stimulate adverse immunological reactions. Instead it was observed immunological tolerance. The present study contributes very important information concerning the safe use of C. procera as a phytotherapeutic agent</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1872-7786 (Electronic)IS - 0009-2797 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cbi.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709944">PM:28709944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chem Biol Interact\20170715-BezerraCF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chem Biol Interact\20170715-BezerraCF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Bezerra CF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cbi.2017.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zeng,F.J.</style></author><author><style face="normal" font="Arial"> Chen,C.</style></author><author><style face="normal" font="Arial"> Liu,M.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic reactions to antivenom in a patient bitten twice by the same snake within a month: A rare case report and literature review</style></title><secondary-title><style face="normal" font="Arial">Chin J Traumatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Chin J Traumatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-snake venom serum</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin allergy</style></keyword><keyword><style face="normal" font="Arial"> Snake Bites</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1008-1275</style></isbn><abstract><style face="normal" font="Arial">Antivenom is the most effective method currently available for the treatment of poisonous snake bite. Allergic reactions to antivenom have been reported in the past. Here we shared a case of allergic reactions to antivenom in an old male patient who was bitten twice by the same snake (probably same one) at the same biting site within a month whereas the patient did not show any allergic disorder in the first bitten. Envenomations twice in a short period time by the same kind of snake are very rare. Physician should be alert to the occurrence of allergic reactions in treating this type of patients with antivenom. The skin allergy test has a certain value in predicting the allergic response before the second use of antivenom. Desensitization may reduce the incidence of allergic reactions, but this is insufficient. Rather than non-IgE-mediated immediate hypersensitivity, patients receiving the second treatment of antivenom may develop IgE-mediated immediate hypersensitivity. Once happened, the antivenom treatment should be stopped promptly and anti-allergy treatment should be given immediately</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cjtee.2016.12.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988729">PM:28988729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin J Traumatol\20170720-ZengFJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin J Traumatol\20170720-ZengFJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Zeng FJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cjtee.2016.12.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,M.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine,PUMC Hospital,CAMS and PUMC,Beijing 100730,ChinaDepartment of Respiratory Medicine,PUMC Hospital,CAMS and PUMC,Beijing 100730,China</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Analysis of 77 Patients with Allergic Bronchopulmonary Aspergillosis in Peking Union Medical College Hospital</style></title><secondary-title><style face="normal" font="Arial">Chin Med Sci J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chin Med Sci J</style></full-title></periodical><pages end="357" start="352">352-357</pages><volume><style face="normal" font="Arial">39</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diffusion</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung cancer</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="Arial">Objective To summarize the clinical features of allergic bronchopulmonary aspergillosis(ABPA)to facilitate its early diagnosis and treatment. Methods We retrospectively analyzed the clinical data of 77 patients who had been admitted to Peking Union Medical College Hospital from January 1996 to July 2015 with ABPA. Results The average age of these 77 patients(38 men and 39 women)was(41.8+/-18.3)years. The co-morbidities included bronchial asthma(n=74,96%)and pulmonary cystic fibrosis(n=3,4%). The main symptoms and signs of ABPA were chronic cough(100%),sputum production(97%),wheeze(86%),sputum plugs(25%),blood-stained sputum(18%),hemoptysis(9%),chest pain(9%),fever(47%),weight loss(30%),and night sweat(12%). Laboratory tests revealed elevated levels of blood eosinophils absolute count(87%),anti-aspergillus antigen-specific IgE(89%)and specific IgG(57%)as well as a positive result of Aspergillus antigen skin test(88%). Pulmonary function testing showed that the incidences of obstructive ventilation and diffusion dysfunction were 66% and 65%,respectively;in addition,bronchodilatation test showed positive result in 60% of the patients. The most common CT findings were central bronchiectasis(81%),patchy infiltrations(79%),pleural thickening(49%),mediastinal adenopathy(35%),nodular opacities(25%),mucoid impaction(21%),and fleeting infiltrations(35%). In addition,44 cases(58%)were misdiagnosed as tuberculosis,pneumonia,lung abscess,and/or lung cancer autoimmune diseases. Conclusions ABPA can be easily misdiagnosed. ABPA should be carefully considered in patients with asthma or pulmonary cystic fibrosis who also suffer from wheeze,sputum plugs,elevated eosinophils central bronchiectasis,and fleeting infiltrations</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 1001-9294 (Print)IS - 1001-9294 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3881/j.issn.1000-503X.2017.03.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28695805">PM:28695805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin Med Sci J\2017-39-352-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin Med Sci J\2017-39-352-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Zhang M</style></custom2><misc3><style face="normal" font="Arial">10.3881/j.issn.1000-503X.2017.03.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gupta,M.</style></author><author><style face="normal" font="Arial"> Sicherer,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Icahn School of Medicine at Mount Sinai, Department of Pediatrics, Division of Allergy Immunology, Elliot and Roslyn Jaffe Food Allergy Institute, One Gustave L. Levy Place, Box 1198, New York, NY 10029.</style></auth-address><titles><title><style face="normal" font="Arial">Timing of food introduction and atopy prevention</style></title><secondary-title><style face="normal" font="Arial">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Dermatol</style></full-title></periodical><pages end="405" start="398">398-405</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> formula feeding</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">The apparent increase in atopic disease, particularly food allergy, over the past 2 decades has resulted in reconsideration of prevention strategies aimed at the infant's diet. Early advice to have atopy-prone infants delay ingestion of potential food allergens, such as egg, cow's milk, and peanut, was rescinded, as new evidence emerged that did not support these approaches. More recently, randomized controlled trials have provided data to support an opposite strategy, promoting early ingestion of allergens as a means of food allergy prevention. Specifically, new guidelines suggest early ingestion of peanut as a means to prevent peanut allergy. Additional dietary approaches regarding breastfeeding, early introduction of other types of food allergens, formula feeding, dietary nutrients, and probiotics are also under scrutiny as potential preventative strategies. This review focuses on the timing of food introduction as a preventative strategy for food allergy and also discusses other aspects of the infant diet that may provide opportunities for prevention of atopic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clindermatol.2017.03.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709571">PM:28709571</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Dermatol\2017-35-398-405.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Dermatol\2017-35-398-405.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Gupta M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clindermatol.2017.03.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Scadding,G.K.</style></author><author><style face="normal" font="Arial"> Kariyawasam,H.H.</style></author><author><style face="normal" font="Arial"> Scadding,G.</style></author><author><style face="normal" font="Arial"> Mirakian,R.</style></author><author><style face="normal" font="Arial"> Buckley,R.J.</style></author><author><style face="normal" font="Arial"> Dixon,T.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Farooque,S.</style></author><author><style face="normal" font="Arial"> Jones,N.</style></author><author><style face="normal" font="Arial"> Leech,S.</style></author><author><style face="normal" font="Arial"> Nasser,S.M.</style></author><author><style face="normal" font="Arial"> Powell,R.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Rotiroti,G.</style></author><author><style face="normal" font="Arial"> Simpson,A.</style></author><author><style face="normal" font="Arial"> Smith,H.</style></author><author><style face="normal" font="Arial"> Clark,A.T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007)</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="889" start="856">856-889</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> BSACI</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cromoglycate</style></keyword><keyword><style face="normal" font="Arial"> decongestant</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> ipratropium bromide</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> non-allergic,non-infectious rhinitis</style></keyword><keyword><style face="normal" font="Arial"> non-infectious rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Protozoa</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinitis control</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Standards of Care Committee</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><isbn><style face="normal" font="Arial">1365-2222</style></isbn><abstract><style face="normal" font="Arial">This is an updated guideline for the diagnosis and management of allergic and non-allergic rhinitis, first published in 2007. It was produced by the Standards of Care Committee of the British Society of Allergy and Clinical Immunology, using accredited methods. Allergic rhinitis is common and affects 10</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô15% of children and 26% of adults in the UK, it affects quality of life, school and work attendance, and is a risk factor for development of asthma. Allergic rhinitis is diagnosed by history and examination, supported by specific allergy tests. Topical nasal corticosteroids are the treatment of choice for moderate to severe disease. Combination therapy with intranasal corticosteroid plus intranasal antihistamine is more effective than either alone and provides second line treatment for those with rhinitis poorly controlled on monotherapy. Immunotherapy is highly effective when the specific allergen is the responsible driver for the symptoms. Treatment of rhinitis is associated with benefits for asthma. Non-allergic rhinitis also is a risk factor for the development of asthma and may be eosinophilic and steroid-responsive or neurogenic and non- inflammatory. Non-allergic rhinitis may be a presenting complaint for systemic disorders such as granulomatous or eosinophilic polyangiitis, and sarcoidoisis. Infective rhinitis can be caused by viruses, and less commonly by bacteria, fungi and protozoa</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12953</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1111/cea.12953</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-856-89.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-856-89.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, Scadding GK</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12953</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maniscalco,M.</style></author><author><style face="normal" font="Arial"> Motta,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Rehabilitation Unit, ICS Maugeri SPA, IRCCS, 82037, Telese Terme (Benevento), ItalyInstitute of Biomolecular Chemistry, National Research Council, 80078, Pozzuoli (Naples), Italy</style></auth-address><titles><title><style face="normal" font="Arial">Biomarkers in Allergic Asthma: Which Matrix Should We Use?</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1098" start="1097">1097-1098</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="Arial">We have read with great interest the review article by Villasenor et al. [1] on metabolomics strategies for the identification of novel biomarkers associated with specific phenotypes of allergic asthma. The paper also suggests the usefulness of specific biological matrices in the metabolomics approach to respiratory pathologies, indicating preferentially bronchoalveolar lavage fluid (BALF), lung biopsy or sputum for exploratory studies on molecular mechanism of a respiratory disease, and plasma or urine for detecting diagnostic or prognostic biomarkers. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12978</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703932">PM:28703932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-1097-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-1097-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Maniscalco M</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12978</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Deschildre,A.</style></author><author><style face="normal" font="Arial"> Lejeune,S.</style></author><author><style face="normal" font="Arial"> Cap,M.</style></author><author><style face="normal" font="Arial"> Flammarion,S.</style></author><author><style face="normal" font="Arial"> Jouannic,L.</style></author><author><style face="normal" font="Arial"> Amat,F.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CHU Lille, Pediatric Pulmonology and Allergy Department, Hopital Jeanne de Flandre, and Universite Nord de France, F 59000, Lille, France</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy phenotypes: the key to personalized therapy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1137" start="1125">1125-1137</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Co-factors</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="Arial">Food allergies (FAs) are of increasing public health concern and are characterized by a large spectrum of diseases. Their diversity is well known for immunologic pathways (IgE, non-IgE mediated FAs), and natural history. Many other factors and patient characteristics are involved including type of food, exposure route, allergic comorbidities, gender, racial and ethnic backgrounds, co-factors and health conditions. Food allergen components and sensitization profiles are also involved in FA phenotypes. A new approach to chronic disorders based on the identification of phenotypes through extensive knowledge of all the complex components is also applicable to FAs and could lead towards integrative care management. Diagnostic biomarkers for FAs are emerging which also contribute to better care modalities. The aim of this article is to highlight current knowledge regarding the phenotypic diversity of FA. This review will focus on IgE-mediated FAs and how identifying phenotypes may help to better understand the pathophysiological complexity, improve diagnosis and lead to personalized treatment strategies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12984</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28710890">PM:28710890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170716-DeschildreA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170716-DeschildreA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Deschildre A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12984</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Suarez-Farinas,M.</style></author><author><style face="normal" font="Arial"> Estrada,Y.</style></author><author><style face="normal" font="Arial"> Parker,M.L.</style></author><author><style face="normal" font="Arial"> Greenlees,L.</style></author><author><style face="normal" font="Arial"> Stephens,G.</style></author><author><style face="normal" font="Arial"> Krueger,J.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author><author><style face="normal" font="Arial"> Howell,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MedImmune, LLC, Gaithersburg, MD, 20878</style></auth-address><titles><title><style face="normal" font="Arial">Identification of Unique Proteomic Signatures in Allergic and Non-Allergic Skin Disease</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Difficult-to-treat</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD), psoriasis (PS), and contact dermatitis (CD) are common skin diseases, characterized by barrier disruption and systemic inflammation, with unique epidermal signatures and common inflammatory pathways identified by transcriptomic profiling. This study profiled proteomic signatures in serum from subjects with AD, PS, and CD compared with healthy controls (HC). OBJECTIVE: Identify unique proteomic signatures to distinguish between inflammatory diseases with similar epidermal disruption and overlapping epithelial inflammation. METHODS: Sera from 20 subjects with moderate to severe AD, 10 subjects with CD, 12 subjects with moderate to severe PS, 10 subjects with both AD and CD, and 10 HC with no history of skin disease was analyzed using high throughput proteomic analysis that detects expression of 1129 protein targets. Protein expression was compared between disease and HC, and across diseases for statistical significance (fold change >/=1.5 and false discovery rate &lt;/=0.05), to identify unique proteomic signatures for each disease. RESULTS: Complement C5A anaphylatoxin (C5A), lipopolysaccharide binding protein (LBP), C-reactive protein (CRP), ILT-4, C-C motif ligand 18 (PARC), and sialic acid-binding Ig-like lectin 14 (SIG14) were significantly modulated in all three diseases compared with HC. We identified unique signatures for AD (Immunoglobulin E (IgE), thymus- and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC)), CD (10 proteins), and PS (kynureninase (KYNU)). Proteomic profiling in subjects with both AD and CD identified additional dysregulated proteins compared with subjects with either condition alone, indicating an exacerbated inflammation reaction. CONCLUSIONS AND CLINICAL RELEVANCE: Unique sera proteomic signatures may distinguish between inflammatory skin diseases despite similar epidermal barrier disruption and epithelial inflammation. This may provide insight into disease pathogenesis, diagnosis and therapeutic intervention in difficult-to-treat subjects. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12979</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703865">PM:28703865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170713-WangJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170713-WangJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12979</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Clinica San Carlo, Paderno Dugnano (MI), Milan, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="669" start="667">667-669</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> D-dimer</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">Chronic spontaneous urticaria (CSU) is a condition presenting as the spontaneous occurrence of itchy weals with or without angio-oedema for > 6 weeks. A patient with severe chronic spontaneous urticaria who developed resistance to omalizumab is described. The patient's D-dimer plasma levels strictly paralleled the disease activity despite the administration of anti-IgE therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.13181</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28691309">PM:28691309</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\2017-42-667-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\2017-42-667-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Asero R</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.13181</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chieosilapatham,P.</style></author><author><style face="normal" font="Arial"> Ogawa,H.</style></author><author><style face="normal" font="Arial"> Niyonsaba,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Current insights into the role of human beta-defensins in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial activity</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial peptides</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> beta-Defensins</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune dysregulation</style></keyword><keyword><style face="normal" font="Arial"> immunomodulators</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">Antimicrobial peptides or host defense peptides are small molecules that display both antimicrobial activities and complex immunomodulatory functions to protect against various diseases. Among these peptides, the human beta-defensins (hBDs) are primarily localized in epithelial surfaces, including those of the skin, where they contribute to protective barriers. In atopic dermatitis skin lesions, altered skin barrier and immune dysregulation are believed to be responsible for reduced hBD synthesis. Impaired hBD expression in the skin is reportedly the leading cause of increased susceptibility to bacterial and viral infection in patients with atopic dermatitis. Although hBDs have considerable beneficial effects as antimicrobial agents and immunomodulators and may clinically ameliorate atopic dermatitis, recent evidence has also suggested the negative effects of hBDs in atopic dermatitis development. In the current review, we provide an overview of the regulation of hBDs and their role in the pathogenesis of atopic dermatitis. The efforts to utilize these molecules in clinical applications are also described. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1365-2249 (Electronic)IS - 0009-9104 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/cei.13013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28708318">PM:28708318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Immunol\20170714-ChieosilapathamP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Immunol\20170714-ChieosilapathamP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Chieosilapatham P</style></custom2><misc3><style face="normal" font="Arial">10.1111/cei.13013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teixeira,R.N.</style></author><author><style face="normal" font="Arial"> Leite,G.D.S.</style></author><author><style face="normal" font="Arial"> Bonini,M.</style></author><author><style face="normal" font="Arial"> Gorjao,R.</style></author><author><style face="normal" font="Arial"> Agondi,R.C.</style></author><author><style face="normal" font="Arial"> Kokron,C.M.</style></author><author><style face="normal" font="Arial"> Carvalho,C.R.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physical Therapy, University of Sao Paulo School of Medicine, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Atopy in Elite Endurance Athletes</style></title><secondary-title><style face="normal" font="Arial">Clin J Sport Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin J Sport Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> athlete</style></keyword><keyword><style face="normal" font="Arial"> Athletes</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To assess the frequency of atopy (specific IgE levels), to evaluate the allergic symptoms using the Allergy Questionnaire for Athletes (AQUA), and to determine whether atopy is associated with allergic symptoms in elite endurance athletes. DESIGN: Cross-sectional study. SETTING: Assessments were performed at Hospital das Clinicas-Sao Paulo University Medical School. PARTICIPANTS: Fifty-nine elite endurance athletes (triathletes and runners). MAIN OUTCOME MEASURES: Allergic symptoms were assessed by a validated self-report AQUA questionnaire and atopy by specific IgE level. RESULTS: The frequency of atopy (specific IgE to at least one inhalant allergen) and allergic symptoms was 57.6% and 54.2%, respectively. In addition, no association was observed between atopy and allergic symptoms. CONCLUSIONS: A possible implication from our results is that atopy screening in elite athletes should be performed using AQUA questionnaire and measuring specific IgE simultaneously</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1536-3724 (Electronic)IS - 1050-642X (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1097/JSM.0000000000000444</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28708708">PM:28708708</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin J Sport Med\20170714-TeixeiraRN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin J Sport Med\20170714-TeixeiraRN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Teixeira RN</style></custom2><misc3><style face="normal" font="Arial">10.1097/JSM.0000000000000444</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sherbenou,D.W.</style></author><author><style face="normal" font="Arial"> Mark,T.M.</style></author><author><style face="normal" font="Arial"> Forsberg,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Hematology, University of Colorado Anschutz Medical Campus, Aurora, CO.</style></auth-address><titles><title><style face="normal" font="Arial">Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future</style></title><secondary-title><style face="normal" font="Arial">Clin Lymphoma Myeloma Leuk</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Lymphoma Myeloma Leuk</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Multiple Myeloma</style></keyword><keyword><style face="normal" font="Arial"> natural killer cell</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="Arial">In 2015, 2 monoclonal antibodies were approved for the treatment of relapsed or refractory multiple myeloma (RRMM), elotuzumab and daratumumab. Elotuzumab is a monoclonal IgG-kappa antibody directed against SLAMF7 (signaling lymphocytic activation molecule F7), a cell surface receptor involved in natural killer cell activation. Daratumumab is a monoclonal IgG-kappa antibody that binds to CD38, a transmembrane protein found on the surface of myeloma cells and responsible for cellular adhesion and ectoenzymatic activity. Both elotuzumab and daratumumab act through recruitment of the immune system to enhance cellular cytotoxicity directed against myeloma cells. Elotuzumab requires lenalidomide and dexamethasone combined to enhance progression-free survival in patients with RRMM, and daratumumab has both single-agent and combination activity with either lenalidomide or the proteasome inhibitor bortezomib in RRMM. The adverse effect profile of both agents mainly consists of allergic-type infusion reactions. Other considerations for monoclonal antibody use in the treatment of MM include the potential for interference in serum protein electrophoresis testing and cross-reactivity of daratumumab with CD38 present on red blood cells. In the present report, we discussed the clinical development of daratumumab and elotuzumab and newer immunologic approaches to the treatment of MM</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 2152-2669 (Electronic)IS - 2152-2669 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clml.2017.06.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734795">PM:28734795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Lymphoma Myeloma Leuk\20170723-SherbenouDW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Lymphoma Myeloma Leuk\20170723-SherbenouDW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Sherbenou DW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clml.2017.06.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Knoedler,T.G.</style></author><author><style face="normal" font="Arial"> Minutillo,G.T.</style></author><author><style face="normal" font="Arial"> Steele,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Tulane University School of Medicine, New Orleans, LA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Knee Pain in a Boy With Hyper IgE Type 1 Syndrome (Job Variant)</style></title><secondary-title><style face="normal" font="Arial">Clin Pediatr (Phila)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Pediatr (Phila)</style></abbr-1></periodical><pages end="884" start="882">882-884</pages><volume><style face="normal" font="Arial">56</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Knee</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1938-2707 (Electronic)IS - 0009-9228 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/0009922817715951</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28720031">PM:28720031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Pediatr (Phila)\2017-56-882-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Pediatr (Phila)\2017-56-882-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Knoedler TG</style></custom2><misc3><style face="normal" font="Arial">10.1177/0009922817715951</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chomchai,S.</style></author><author><style face="normal" font="Arial"> Chomchai,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Faculty of Medicine Siriraj Hospital , Mahidol University , Bangkok , Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Histamine poisoning from insect consumption: an outbreak investigation from Thailand</style></title><secondary-title><style face="normal" font="Arial">Clin Toxicol (Phila)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Toxicol (Phila)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flushing</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frog</style></keyword><keyword><style face="normal" font="Arial"> Frogs</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine poisoning</style></keyword><keyword><style face="normal" font="Arial"> Histidine</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> poisoning</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Insect consumption is a common practice in the Asian culture and all over the world. We are reporting an outbreak investigation of histamine poisoning from ingestion of fried insects. METHODS: On 24 July 2014, a group of students at a seminar presented to Angthong Provincial Hospital, Thailand, with pruritic rash after ingesting snacks consisting of fried insects from a vendor. We initiated an outbreak investigation with retrospective cohort design and collected samples of remaining foods for analyses. Attack rates, relative risks and their confidence intervals (CI) were calculated. RESULTS: Out of 227 students, 28 developed illnesses that were consistent with our case definition which included, flushing, pruritus, urticarial rashes, headache, nausea, vomiting, diarrhea, dyspnea and bronchospasm. Two children were hospitalized for progressive bronchospasm overnight without serious complications. The types of food ingested included a lunch that was provided at the seminar for all students and snacks that 41 students bought from the only vendor in the vicinity. The snacks included fried grasshoppers, silkworm pupae, common green frogs, bamboo borers, crickets and meat balls. The attack rates were highest (82.6 and 85.0%) among students who ingested fried grasshoppers and silkworm pupae and lowest (4.4 and 5.3%) among those who did not ingest them, with relative risk of 18.7 (95% CI 9.6-36.4) for grasshoppers and 16.0 (95% CI 8.8-29.3) for silkworm pupae. Histamine concentrations in the fried grasshoppers and silkworm pupae were 9.73 and 7.66 mg/100g, respectively. DISCUSSION AND CONCLUSION: Through epidemiological analysis and laboratory confirmation, we have illustrated that histamine poisoning can occur from ingestion of fried insects. We postulate that histidine, which is present in high concentration in grasshoppers and silkworm pupae, is decarboxylated by bacteria to histamine, a heat stable toxin. The ingestion of histamine is responsible for the clinical pictures being reported</style></abstract><notes><style face="normal" font="Arial">DA - 20170727IS - 1556-9519 (Electronic)IS - 1556-3650 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1080/15563650.2017.1349320</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28748745">PM:28748745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Toxicol (Phila)\20170727-ChomchaiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Toxicol (Phila)\20170727-ChomchaiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Chomchai S</style></custom2><misc3><style face="normal" font="Arial">10.1080/15563650.2017.1349320</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sheikh,A.</style></author><author><style face="normal" font="Arial"> Sheikh,Z.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Dhami,S.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">National clinical practice guidelines for food allergy and anaphylaxis: an international assessment</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="23">23-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2045-7022</style></isbn><abstract><style face="normal" font="Arial">Clinical practice guidelines are important tools to promote evidence-based clinical care, but not all countries have the capacity or infrastructure to develop these in-house. The European Academy of Allergy and Clinical Immunology has recently developed guidelines for the prevention, diagnosis and management of food allergy and the management of anaphylaxis. In order to inform dissemination, adaptation and implementation plans, we sought to identify countries that have/do not have national guidelines for food allergy and anaphylaxis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0161-z</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s13601-017-0161-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-23.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Sheikh A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0161-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alessandri,C.</style></author><author><style face="normal" font="Arial"> Ferrara,R.</style></author><author><style face="normal" font="Arial"> Bernardi,M.L.</style></author><author><style face="normal" font="Arial"> Zennaro,D.</style></author><author><style face="normal" font="Arial"> Tuppo,L.</style></author><author><style face="normal" font="Arial"> Giangrieco,I.</style></author><author><style face="normal" font="Arial"> Tamburrini,M.</style></author><author><style face="normal" font="Arial"> Mari,A.</style></author><author><style face="normal" font="Arial"> Ciardiello,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Istituto di Bioscienze e Biorisorse - IBBR-CNR, Naples, ItalyAllergy Data Laboratories s.c., Latina, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosing allergic sensitizations in the third millennium: why clinicians should know allergen molecule structures</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="21">21-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Diagnostic tests to detect allergic sensitization were introduced at the end of the nineteenth century but only in the late 1990s did the advent of molecular allergology revolutionize the approach to the allergic patient. Personalized Medicine, a medical procedure that separates patients into different groups with different medical decisions, practices and interventions has sanctioned this change. In fact, in the last few years molecular allergology and the observation that not every patient has the same allergic profile, even when allergic to the same allergenic source, has originated the concept "one size does not fit all". This new approach requires the identification of still unknown allergens, but also the more detailed investigation of those already known. In depth studies of the structure-function relationships in allergenic molecules can reveal the structural determinants involved in the IgE-binding. Then, the knowledge of the epitope profile of each allergen and of the environmental/experimental conditions affecting the exposure of IgE-binding epitopes can provide important contributions to the understanding of cross-reaction processes and to the improvement of diagnosis, immunotherapy and the overall patient treatment. The evolution of diagnostic systems cannot ignore these new needs in this field</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy7 -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0158-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28725346">PM:28725346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Alessandri C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0158-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kreijkamp-Kaspers,S.</style></author><author><style face="normal" font="Arial"> Hawke,K.</style></author><author><style face="normal" font="Arial"> Guo,L.</style></author><author><style face="normal" font="Arial"> Kerin,G.</style></author><author><style face="normal" font="Arial"> Bell-Syer,S.E.</style></author><author><style face="normal" font="Arial"> Magin,P.</style></author><author><style face="normal" font="Arial"> Bell-Syer,S.V.</style></author><author><style face="normal" font="Arial"> van Driel,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building 16/910, Royal Brisbane &amp; Women's Hospital Complex, Brisbane, Herston, Queensland, Australia, 4029</style></auth-address><titles><title><style face="normal" font="Arial">Oral antifungal medication for toenail onychomycosis</style></title><secondary-title><style face="normal" font="Arial">Cochrane Database Syst Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cochrane Database Syst Rev</style></full-title></periodical><pages end="" start="CD010031">CD010031-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal treatment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Azoles</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> Onychomycosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Physical properties</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> terbinafine</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fungal infection of the toenails, also called onychomycosis, is a common problem that causes damage to the nail's structure and physical appearance. For those severely affected, it can interfere with normal daily activities. Treatment is taken orally or applied topically; however, traditionally topical treatments have low success rates due to the nail's physical properties. Oral treatments also appear to have shorter treatment times and better cure rates. Our review will assist those needing to make an evidence-based choice for treatment. OBJECTIVES: To assess the effects of oral antifungal treatments for toenail onychomycosis. SEARCH METHODS: We searched the following databases up to October 2016: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of included and excluded studies for further references to relevant randomised controlled trials (RCTs). We sought to identify unpublished and ongoing trials by correspondence with authors and by contacting relevant pharmaceutical companies. SELECTION CRITERIA: RCTs comparing oral antifungal treatment to placebo or another oral antifungal treatment in participants with toenail onychomycosis, confirmed by one or more positive cultures, direct microscopy of fungal elements, or histological examination of the nail. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 48 studies involving 10,200 participants. Half the studies took place in more than one centre and were conducted in outpatient dermatology settings. The participants mainly had subungual fungal infection of the toenails. Study duration ranged from 4 months to 2 years.We assessed one study as being at low risk of bias in all domains and 18 studies as being at high risk of bias in at least one domain. The most common high-risk domain was 'blinding of personnel and participants'.We found high-quality evidence that terbinafine is more effective than placebo for achieving clinical cure (risk ratio (RR) 6.00, 95% confidence interval (CI) 3.96 to 9.08, 8 studies, 1006 participants) and mycological cure (RR 4.53, 95% CI 2.47 to 8.33, 8 studies, 1006 participants). Adverse events amongst terbinafine-treated participants included gastrointestinal symptoms, infections, and headache, but there was probably no significant difference in their risk between the groups (RR 1.13, 95% CI 0.87 to 1.47, 4 studies, 399 participants, moderate-quality evidence).There was high-quality evidence that azoles were more effective than placebo for achieving clinical cure (RR 22.18, 95% CI 12.63 to 38.95, 9 studies, 3440 participants) and mycological cure (RR 5.86, 95% CI 3.23 to 10.62, 9 studies, 3440 participants). There were slightly more adverse events in the azole group (the most common being headache, flu-like symptoms, and nausea), but the difference was probably not significant (RR 1.04, 95% CI 0.97 to 1.12; 9 studies, 3441 participants, moderate-quality evidence).Terbinafine and azoles may lower the recurrence rate when compared, individually, to placebo (RR 0.05, 95% CI 0.01 to 0.38, 1 study, 35 participants; RR 0.55, 95% CI 0.29 to 1.07, 1 study, 26 participants, respectively; both low-quality evidence).There is moderate-quality evidence that terbinafine was probably more effective than azoles for achieving clinical cure (RR 0.82, 95% CI 0.72 to 0.95, 15 studies, 2168 participants) and mycological cure (RR 0.77, 95% CI 0.68 to 0.88, 17 studies, 2544 participants). There was probably no difference in the risk of adverse events (RR 1.00, 95% CI 0.86 to 1.17; 9 studies, 1762 participants, moderate-quality evidence) between the two groups, and there may be no difference in recurrence rate (RR 1.11, 95% CI 0.68 to 1.79, 5 studies, 282 participants, low-quality evidence). Common adverse events in both groups included headache, viral infection, and nausea.Moderate-quality evidence shows that azoles and griseofulvin probably had similar efficacy for achieving clinical cure (RR 0.94, 95% CI 0.45 to 1.96, 5 studies, 222 participants) and mycological cure (RR 0.87, 95% CI 0.50 to 1.51, 5 studies, 222 participants). However, the risk of adverse events was probably higher in the griseofulvin group (RR 2.41, 95% CI 1.56 to 3.73, 2 studies, 143 participants, moderate-quality evidence), with the most common being gastrointestinal disturbance and allergic reaction (in griseofulvin-treated participants) along with nausea and vomiting (in azole-treated participants). Very low-quality evidence means we are uncertain about this comparison's impact on recurrence rate (RR 4.00, 0.26 to 61.76, 1 study, 7 participants).There is low-quality evidence that terbinafine may be more effective than griseofulvin in terms of clinical cure (RR 0.32, 95% CI 0.14 to 0.72, 4 studies, 270 participants) and mycological cure (RR 0.64, 95% CI 0.46 to 0.90, 5 studies, 465 participants), and griseofulvin was associated with a higher risk of adverse events, although this was based on low-quality evidence (RR 2.09, 95% CI 1.15 to 3.82, 2 studies, 100 participants). Common adverse events included headache and stomach problems (in griseofulvin-treated participants) as well as taste loss and nausea (in terbinafine-treated participants). No studies addressed recurrence rate for this comparison.No study addressed quality of life. AUTHORS' CONCLUSIONS: We found high-quality evidence that compared to placebo, terbinafine and azoles are effective treatments for the mycological and clinical cure of onychomycosis, with moderate-quality evidence of excess harm. However, terbinafine probably leads to better cure rates than azoles with the same risk of adverse events (moderate-quality evidence).Azole and griseofulvin were shown to probably have a similar effect on cure, but more adverse events appeared to occur with the latter (moderate-quality evidence). Terbinafine may improve cure and be associated with fewer adverse effects when compared to griseofulvin (low-quality evidence).Only four comparisons assessed recurrence rate: low-quality evidence found that terbinafine or azoles may lower the recurrence rate when compared to placebo, but there may be no difference between them.Only a limited number of studies reported adverse events, and the severity of the events was not taken into account.Overall, the quality of the evidence varied widely from high to very low depending on the outcome and comparison. The main reasons to downgrade evidence were limitations in study design, such as unclear allocation concealment and randomisation as well as lack of blinding</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1469-493X (Electronic)IS - 1361-6137 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1002/14651858.CD010031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28707751">PM:28707751</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cochrane Database Syst Rev\2017-7-CD010031.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cochrane Database Syst Rev\2017-7-CD010031.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Kreijkamp-Kaspers S</style></custom2><misc3><style face="normal" font="Arial">10.1002/14651858.CD010031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Plagova,A.</style></author><author><style face="normal" font="Arial"> Nykamp,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Recognition and Management of Anaphylaxis in Older Adults</style></title><secondary-title><style face="normal" font="Arial">Consult Pharm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Consult Pharm</style></full-title></periodical><pages end="405" start="398">398-405</pages><volume><style face="normal" font="Arial">32</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Contraindication</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Practice parameters</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To discuss medications that cause anaphylaxis in older adults and its treatment, with a focus on epinephrine. DATA SOURCE: A search of PubMed using the terms "anaphylaxis," "drug-induced anaphylaxis," "epinephrine autoinjectable," "anaphylaxis diagnosis," "anaphylaxis treatment," and "epinephrine cost" was performed. English-language articles from January 2000 to August 2016 appearing in these searches were reviewed. STUDY SELECTION/DATA EXTRACTION: Relevant review articles, consensus statements, practice parameters, task force recommendations, and original articles were assessed for recognition and treatment of drug-induced anaphylaxis. DATA SYNTHESIS: Anaphylaxis is a serious allergic reaction that occurs with food, insect stings, latex, radio contrast agents, and medications. Medications that are commonly used by older adults can cause anaphylaxis. Epinephrine remains the first-line treatment option and does not have any contraindications. CONCLUSION: Early recognition of drug-induced anaphylaxis symptoms is critical and medication should be administered immediately to prevent cardiac arrest. Additionally, health care providers can provide others with education on administration of epinephrine auto-injectable agents, availability of alternative options, and patient-assistance programs to lower the cost of epinephrine agents</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 0888-5109 (Print)IS - 0888-5109 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4140/TCP.n.2017.398</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701251">PM:28701251</url></web-urls></urls><custom2><style face="normal" font="Arial">20170713, Plagova A</style></custom2><misc3><style face="normal" font="Arial">10.4140/TCP.n.2017.398</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Allen-Ramey,F.</style></author><author><style face="normal" font="Arial"> Mao,J.</style></author><author><style face="normal" font="Arial"> Blauer-Peterson,C.</style></author><author><style face="normal" font="Arial"> Rock,M.</style></author><author><style face="normal" font="Arial"> Nathan,R.</style></author><author><style face="normal" font="Arial"> Halpern,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Merck &amp; Co., Inc., Global Health Outcomes, Center for Observational and Real-world Evidence , West Point , PA</style></auth-address><titles><title><style face="normal" font="Arial">Healthcare costs for allergic rhinitis patients on allergy immunotherapy: a retrospective observational study</style></title><secondary-title><style face="normal" font="Arial">Curr Med Res Opin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Res Opin</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Propensity score</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Resource utilization</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Subcutaneous immunotherapy (SCIT) for allergic rhinitis (AR) has been shown to control symptoms for up to several years following treatment discontinuation, but the effect of SCIT on healthcare costs for commercially insured patients is unknown. The objective of this study was to compare healthcare costs and resource utilization for patients with AR who received SCIT compared with those who discontinued SCIT shortly after initiation. METHODS: This retrospective cohort study evaluated medical and pharmacy claims from the Optum Research Database from January 2009 through February 2014 for adults and pediatric patients with >7 (continuers) vs &lt;/=7 (discontinuers) injection visits for SCIT within 60 days of initiation. RESULTS: After 1:1 propensity score matching, each cohort included 6,710 patients. Continuers were less likely than discontinuers to use oral corticosteroids (27.7% vs 29.6%, P = 0.018), or to have >/=1 respiratory-related emergency room visit (5.4% vs 6.5%, P = 0.008) and >/=1 inpatient stay (1.1% vs 1.7%; P = 0.002). Continuers were more likely than discontinuers to have >/=1 AR-related office (98.8% vs 94.6%, P&lt;0.001) or outpatient visit (2.4% vs 1.7%, P = 0.002). Continuers had greater mean total AR-related costs than discontinuers ($1,918 vs $646, P&lt;0.001). Unadjusted mean total respiratory-related costs were lower for continuers than discontinuers, although the difference was not statistically significant ($1,589 vs $1,785, P = 0.077); when adjusted with a generalized linear model, these costs were significantly lower among continuers (P&lt;0.001). CONCLUSIONS: Continued SCIT use is associated with decreased emergency room visits and inpatient stays, decreased oral corticosteroid use, and lower respiratory-related costs, compared with early discontinuation</style></abstract><notes><style face="normal" font="Arial">DA - 20170724IS - 1473-4877 (Electronic)IS - 0300-7995 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/03007995.2017.1359517</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28737480">PM:28737480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Med Res Opin\20170724-AllenRameyF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Med Res Opin\20170724-AllenRameyF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170724, Allen-Ramey F</style></custom2><misc3><style face="normal" font="Arial">10.1080/03007995.2017.1359517</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schroer,B.</style></author><author><style face="normal" font="Arial"> Bjelac,J.</style></author><author><style face="normal" font="Arial"> Leonard,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDepartment of Pediatrics, Division of Pediatric Allergy and Immunology bDepartment of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA</style></auth-address><titles><title><style face="normal" font="Arial">What is new in managing patients with food allergy? Almost everything</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pediatr</style></full-title></periodical><pages end="583" start="578">578-583</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: This review aims to describe current concepts in managing patients with food allergy. There have been many recent advances in the management of patients with IgE-mediated reactions to food, including diagnosis, prevention, management, and ongoing research in the field. Food allergy is increasing in prevalence and may be life threatening. This review aims to highlight changes in recommended practice when diagnosing and managing patients with food allergy. RECENT FINDINGS: Early introduction of highly allergenic foods, particularly peanut, has been shown to decrease the risk for development of food allergy in patients who are at elevated risk. Avoidance of foods without a clinical history of food allergy may increase the risk of subsequent allergy. Epinephrine remains the first line therapy for anaphylaxis, and patients and families need to be instructed on indications and technique for use. Promising research is ongoing in areas of immunotherapy to food allergens. SUMMARY: Food allergy is a potentially life-threatening condition that may persist throughout adulthood. Practitioners should be aware of changes to recommendations for the diagnosis, prevention, and management of patients with food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1531-698X (Electronic)IS - 1040-8703 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOP.0000000000000534</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28719388">PM:28719388</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pediatr\20170718-SchroerB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pediatr\20170718-SchroerB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Schroer B</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOP.0000000000000534</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roxbury,C.R.</style></author><author><style face="normal" font="Arial"> Lin,S.Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Update on Allergen Immunotherapy for Allergic Rhinitis: Drops, Tablets, or Shots?</style></title><secondary-title><style face="normal" font="Arial">Curr Otorhinolaryngol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Otorhinolaryngol Rep</style></full-title></periodical><pages end="186" start="181">181-186</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> ILIT</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2167-583X</style></isbn><abstract><style face="normal" font="Arial">Allergen immunotherapy (AIT) is the only disease-modifying treatment available for allergic rhinitis (AR). Dosing considerations, efficacy, and safety of subcutaneous (SCIT), sublingual (SLIT), and intralymphatic (ILIT) immunotherapy are discussed</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40136-017-0159-z</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40136-017-0159-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Otorhinolaryngol Rep\20170723-RoxburyCR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Otorhinolaryngol Rep\20170723-RoxburyCR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Roxbury CR</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40136-017-0159-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,H.</style></author><author><style face="normal" font="Arial"> Zhu,Z.</style></author><author><style face="normal" font="Arial"> Huang,W.</style></author><author><style face="normal" font="Arial"> Cheng,X.</style></author><author><style face="normal" font="Arial"> He,J.</style></author><author><style face="normal" font="Arial"> Xiong,C.</style></author><author><style face="normal" font="Arial"> Han,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Dermatology , the First Affiliated Hospital of Guangzhou Medical College , Guangzhou 510120 , P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Common and Uncommon Adverse Cutaneous Reactions to Erlotinib: A Study of 20 Chinese Patients with Cancer</style></title><secondary-title><style face="normal" font="Arial">Cutan Ocul Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cutan Ocul Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor receptor</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung cancer</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Pigmentation</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> topical steroids</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is used for treating non-small cell lung cancers. It is frequently known to cause skin toxicities. Systemic toxicities and anaphylactic cutaneous reactions have been rarely mentioned. Adverse cutaneous reactions were reported in 20 patients, including 6 cases of anaphylactic dermatitis, 12 cases of acneiform rash, 9 cases of xerosis, 5 cases of nail changes, and 4 cases of hair changes. One case of anaphylactic dermatitis manifested as erythema with swelling on the face and neck, and others as erosive and scaly erythema on the fold of skin, or red macules, papules, plaques, and pigmentation on the whole body. Clinical details indicated anaphylactic reactions, including a high percentage of eosinophils in the peripheral blood, eosinophilic infiltration in the dermis layer, and good response to antihistamines and topical steroids. Systemic toxicities accompanied by cutaneous reactions occurred in five patients including one case of anaphylactic dermatitis and four cases of acneiform rash. Elevated hepatic enzymes were observed among all the patients with grade 3 or 4 acneiform rashes. One patient with anaphylactic dermatitis and one with acneiform rash discontinued erlotinib administration due to severe lesions, high fever, or severe elevation of hepatic enzymes</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1556-9535 (Electronic)IS - 1556-9527 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/15569527.2017.1355316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28707485">PM:28707485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cutan Ocul Toxicol\20170714-ZhuH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cutan Ocul Toxicol\20170714-ZhuH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Zhu H</style></custom2><misc3><style face="normal" font="Arial">10.1080/15569527.2017.1355316</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chessa,M.A.</style></author><author><style face="normal" font="Arial"> Vincenzi,C.</style></author><author><style face="normal" font="Arial"> Leuzzi,M.</style></author><author><style face="normal" font="Arial"> Piraccini,B.M.</style></author><author><style face="normal" font="Arial"> La Placa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Protein Contact Dermatitis to Suet</style></title><secondary-title><style face="normal" font="Arial">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dermatitis</style></full-title></periodical><pages end="289" start="288">288-289</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170614IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1097/DER.0000000000000298.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614108">PM:28614108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dermatitis\2017-28-288-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dermatitis\2017-28-288-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170614, Chessa MA</style></custom2><misc3><style face="normal" font="Arial">10.1097/DER.0000000000000298.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pelaia,G.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author><author><style face="normal" font="Arial"> Matucci,A.</style></author><author><style face="normal" font="Arial"> Paolini,R.</style></author><author><style face="normal" font="Arial"> Triggiani,M.</style></author><author><style face="normal" font="Arial"> Paggiaro,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University Magna Graecia of Catanzaro, Catanzaro</style></auth-address><titles><title><style face="normal" font="Arial">Targeted therapy in severe asthma today: focus on immunoglobulin E</style></title><secondary-title><style face="normal" font="Arial">Drug Des Devel Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drug Des Devel Ther</style></full-title></periodical><pages end="1987" start="1979">1979-1987</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard "one size fits all" approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma (Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) targeted therapy with a specific target in severe allergic asthma. This review summarizes current knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical practice has established omalizumab as a safe and effective targeted therapy for the treatment of patients with severe persistent IgE-mediated allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1177-8881 (Electronic)IS - 1177-8881 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.2147/DDDT.S130743</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28721017">PM:28721017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drug Des Devel Ther\2017-11-1979-1987.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drug Des Devel Ther\2017-11-1979-1987.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Pelaia G</style></custom2><misc3><style face="normal" font="Arial">10.2147/DDDT.S130743</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mansouritorghabeh,H.</style></author><author><style face="normal" font="Arial"> Jabbari-Azad,F.</style></author><author><style face="normal" font="Arial"> Varasteh,A.</style></author><author><style face="normal" font="Arial"> Sankian,M.</style></author><author><style face="normal" font="Arial"> Farid-Hosseini,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ph.D. Student, Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Common solvents for making extraction of allergenic proteins from plants' pollens for prick tests and related factors: a technical review</style></title><secondary-title><style face="normal" font="Arial">Electron Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Electron Physician</style></full-title></periodical><pages end="4446" start="4440">4440-4446</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Buffers</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Solvents</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Type I allergy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Collecting information on influencing factors in developing consistent and high-quality extracts results in accurate diagnosis and effective treatment of type I allergy (IgE mediated). Furthermore, considering that a large number of allergens are currently in practice, any attempt to develop a more effective procedure for preparing extract may be useful. Nowadays, different saline solvents, temperature, incubation time, and PH are being incorporated for preparing allergen extracts. The objective of the current study was to clear and address the commonest of solvent buffers and allied conditions for making extracts of pollens of grasses, trees, and weeds. The literature review was done in Jan 2016 on PubMed and Google Scholar medical search engines without any time limitation. After reading abstracts of 87 articles, finally 37 relevant papers were selected and their full texts were retrieved. In conclusion, 24 full-text papers were recognized appropriate and chosen. The extracted information for papers has been described fully in the text. On the basis of these data, PBS buffer with PH 7.4, temperature of 4 degrees C and with overnight incubation time, may be the optimized condition in order to have a proper extract for carrying out skin prick tests</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 2008-5842 (Print)IS - 2008-5842 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.19082/4440</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28713519">PM:28713519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Electron Physician\2017-9-4440-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Electron Physician\2017-9-4440-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Mansouritorghabeh H</style></custom2><misc3><style face="normal" font="Arial">10.19082/4440</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mao,Y.</style></author><author><style face="normal" font="Arial"> Cernigoj,U.</style></author><author><style face="normal" font="Arial"> Zalokar,V.</style></author><author><style face="normal" font="Arial"> Strancar,A.</style></author><author><style face="normal" font="Arial"> Kulozik,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Technical University of Munich, Chair for Food and Bioprocess Engineering</style></auth-address><titles><title><style face="normal" font="Arial">Production of beta-Lactoglobulin hydrolysates by monolith based immobilized trypsin reactors</style></title><secondary-title><style face="normal" font="Arial">Electrophoresis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Electrophoresis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF/MS</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reactor</style></keyword><keyword><style face="normal" font="Arial"> Slovenia</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">Tryptic hydrolysis of beta-Lactoglobulin (beta-Lg) is attracting more and more attention due to the reduced allergenicity and the functionality of resulting hydrolysates. To produce hydrolysates in an economically viable way, immobilized trypsin reactors (IMTRs), based on polymethacrylate monolith with pore size 2.1 mum (N1) and 6 mum (N2), were developed and used in a flow-through system. IMTRs were characterized in terms of permeability and enzymatic activity during extensive usage. N1 showed twice the activity compared with N2, correlating well with its almost two times higher amount of immobilized trypsin. N2 showed high stability over 18 cycles, as well as over more than 30 weeks during storage. The efficiency of IMTRs on hydrolyzing beta-Lg was compared with free trypsin, and the resulting hydrolysates were analyzed by MALDI-TOF/MS. The final hydrolysis degree by N1 reached 9.68% (86.58% cleavage sites) within 4 h, while only around 6% (53.67% cleavage sites) by 1.5 mg of free trypsin. Peptides analysis showed the different preference between immobilized trypsin and free trypsin. Under the experimental conditions used in this study, the potential cleavage site Lys135 -Phe136 was resistant against the immobilized trypsin in N1. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 1522-2683 (Electronic)IS - 0173-0835 (Linking)LA - engPT - Journal ArticleCO - Slovenia -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/elps.201700188</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28714138">PM:28714138</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Electrophoresis\20170717-MaoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Electrophoresis\20170717-MaoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Mao Y</style></custom2><misc3><style face="normal" font="Arial">10.1002/elps.201700188</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Webb,L.M.</style></author><author><style face="normal" font="Arial"> Lundie,R.J.</style></author><author><style face="normal" font="Arial"> Borger,J.G.</style></author><author><style face="normal" font="Arial"> Brown,S.L.</style></author><author><style face="normal" font="Arial"> Connor,L.M.</style></author><author><style face="normal" font="Arial"> Cartwright,A.N.</style></author><author><style face="normal" font="Arial"> Dougall,A.M.</style></author><author><style face="normal" font="Arial"> Wilbers,R.H.</style></author><author><style face="normal" font="Arial"> Cook,P.C.</style></author><author><style face="normal" font="Arial"> Jackson-Jones,L.H.</style></author><author><style face="normal" font="Arial"> Phythian-Adams,A.T.</style></author><author><style face="normal" font="Arial"> Johansson,C.</style></author><author><style face="normal" font="Arial"> Davis,D.M.</style></author><author><style face="normal" font="Arial"> Dewals,B.G.</style></author><author><style face="normal" font="Arial"> Ronchese,F.</style></author><author><style face="normal" font="Arial"> MacDonald,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="Arial">Type I interferon is required for T helper (Th) 2 induction by dendritic cells</style></title><secondary-title><style face="normal" font="Arial">EMBO J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMBO J</style></full-title></periodical><pages end="2418" start="2404">2404-2418</pages><volume><style face="normal" font="Arial">36</style></volume><number><style face="normal" font="Arial">16</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma mansoni</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> type I IFN</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">Type 2 inflammation is a defining feature of infection with parasitic worms (helminths), as well as being responsible for widespread suffering in allergies. However, the precise mechanisms involved in T helper (Th) 2 polarization by dendritic cells (DCs) are currently unclear. We have identified a previously unrecognized role for type I IFN (IFN-I) in enabling this process. An IFN-I signature was evident in DCs responding to the helminth Schistosoma mansoni or the allergen house dust mite (HDM). Further, IFN-I signaling was required for optimal DC phenotypic activation in response to helminth antigen (Ag), and efficient migration to, and localization with, T cells in the draining lymph node (dLN). Importantly, DCs generated from Ifnar1-/- mice were incapable of initiating Th2 responses in vivo These data demonstrate for the first time that the influence of IFN-I is not limited to antiviral or bacterial settings but also has a central role to play in DC initiation of Th2 responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1460-2075 (Electronic)IS - 0261-4189 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - New Zealand -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.15252/embj.201695345</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28716804">PM:28716804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMBO J\20170718-WebbLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMBO J\20170718-WebbLM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Webb LM</style></custom2><misc3><style face="normal" font="Arial">10.15252/embj.201695345</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Demirel,R.</style></author><author><style face="normal" font="Arial"> Sen,B.</style></author><author><style face="normal" font="Arial"> Kadaifciler,D.</style></author><author><style face="normal" font="Arial"> Yoltas,A.</style></author><author><style face="normal" font="Arial"> Okten,S.</style></author><author><style face="normal" font="Arial"> Ozkale,E.</style></author><author><style face="normal" font="Arial"> Berikten,D.</style></author><author><style face="normal" font="Arial"> Samson,R.A.</style></author><author><style face="normal" font="Arial"> Haliki,U.A.</style></author><author><style face="normal" font="Arial"> YIlmaz,N.</style></author><author><style face="normal" font="Arial"> Abaci,G.O.</style></author><author><style face="normal" font="Arial"> Aydogdu,H.</style></author><author><style face="normal" font="Arial"> Asan,A.</style></author><author><style face="normal" font="Arial"> Kivanc,M.</style></author><author><style face="normal" font="Arial"> Ozdil,S.</style></author><author><style face="normal" font="Arial"> Sakartepe,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Science Department of Biology, Anadolu University, 26470, Eskisehir, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Indoor airborne fungal pollution in newborn units in Turkey</style></title><secondary-title><style face="normal" font="Arial">Environ Monit Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Monit Assess</style></full-title></periodical><pages end="" start="362">362-</pages><volume><style face="normal" font="Arial">189</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne fungi</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Glycerol</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Nosocomial infection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> spore count</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Pathogenic and/or opportunistic fungal species are major causes of nosocomial infections, especially in controlled environments where immunocompromised patients are hospitalized. Indoor fungal contamination in hospital air is associated with a wide range of adverse health effects. Regular determination of fungal spore counts in controlled hospital environments may help reduce the risk of fungal infections. Because infants have inchoate immune systems, they are given immunocompromised patient status. The aim of the present study was to evaluate culturable airborne fungi in the air of hospital newborn units in the Thrace, Marmara, Aegean, and Central Anatolia regions of Turkey. A total of 108 air samples were collected seasonally from newborn units in July 2012, October 2012, January 2013, and April 2013 by using an air sampler and dichloran 18% glycerol agar (DG18) as isolation media. We obtained 2593 fungal colonies comprising 370 fungal isolates representing 109 species of 28 genera, which were identified through multi-loci gene sequencing. Penicillium, Aspergillus, Cladosporium, Talaromyces, and Alternaria were the most abundant genera identified (35.14, 25.40, 17.57, 2.70, and 6.22% of the total, respectively)</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1573-2959 (Electronic)IS - 0167-6369 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10661-017-6051-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667414">PM:28667414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-362.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-362.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170701, Demirel R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10661-017-6051-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pfister,H.</style></author><author><style face="normal" font="Arial"> Morzadec,C.</style></author><author><style face="normal" font="Arial"> Le Cann,P.</style></author><author><style face="normal" font="Arial"> Madec,L.</style></author><author><style face="normal" font="Arial"> Lecureur,V.</style></author><author><style face="normal" font="Arial"> Chouvet,M.</style></author><author><style face="normal" font="Arial"> Jouneau,S.</style></author><author><style face="normal" font="Arial"> Vernhet,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institut technique des gaz et de l'air, Saint-Gregoire, France; UMR Inserm 1085, Institut de Recherche sur la Sante, l'Environnement et le Travail (IRSET), Universite de Rennes 1, 2 avenue du Professeur Leon Bernard, 35043 Rennes, France</style></auth-address><titles><title><style face="normal" font="Arial">Granulometry, microbial composition and biological activity of dusts collected in French dairy farms</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="702" start="691">691-702</pages><volume><style face="normal" font="Arial">158</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bacteroidetes</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial epithelium</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> Firmicutes</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> organic dust</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Size distribution</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Straw</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dairy working increases the prevalence of lower airway respiratory diseases, especially COPD and asthma. Epidemiological studies have reported that chronic inhalation of organic dusts released during specific daily tasks could represent a major risk factor for development of these pathologies in dairy workers. Knowledge on size, nature and biological activity of such organic dusts remain however limited. OBJECTIVE: To compare size distribution, microbial composition and cellular effects of dusts liberated by the spreading of straw bedding in five French dairy farms located in Brittany. RESULTS: Mechanized distribution of straw bedding generated a cloud of inhalable dusts in the five dairy farms' barns. Thoracic particles having a 3-7.5microm size constituted 58.9-68.3% of these dusts. Analyses of thoracic dusts by next generation sequencing showed that the microbial dust composition differed between the five French farms, although Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria represent more than 97.5% of the bacterial phyla detected in each sample. Several bacteria genera comprising of human pathogenic species, such as Pseudomonas, Staphylococcus, Thermoactinomyces or Saccharopolyspora were identified. Cladosporium and Alternaria fungal genera, which are potent environmental determinants of respiratory symptoms, were detected in dusts collected in the five farms and their levels reached 15.5-51.1% and 9-24.7% of assignable fungal sequences in each sample, respectively. Finally, all dust samples significantly and strongly increased the expression of the pro-inflammatory TNF-alpha, IL-1beta, IL-6 and IL-8 cytokines at both mRNA and protein levels in human monocyte-derived macrophages. Their effects were dose-dependent and detectable from 1microg/ml. The intensity of the macrophage responses however differed according to the samples. CONCLUSIONS: Our results strengthen the hypothesis that organic dusts released during the distribution of straw bedding are mainly constituted of thoracic particles which are small enough to deposit on lower bronchial epithelium of dairy farmers and induce inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2017.07.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28735230">PM:28735230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-158-691-702.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-158-691-702.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-158-691-702mmc2.xlsC:\A&amp;H HMW Papers\Environ Res\2017-158-691-702mmc3.xlsC:\A&amp;H HMW Papers\Environ Res\2017-158-691-702mmc4.xlsC:\A&amp;H HMW Papers\Environ Res\2017-158-691-702mmc5.xls</url></related-urls><image-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-158-691-702mmc2.xlsC:\A&amp;H HMW Papers\Environ Res\2017-158-691-702mmc3.xlsC:\A&amp;H HMW Papers\Environ Res\2017-158-691-702mmc4.xlsC:\A&amp;H HMW Papers\Environ Res\2017-158-691-702mmc5.xls</url></image-urls></urls><custom2><style face="normal" font="Arial">20170723, Pfister H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2017.07.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vadala,M.</style></author><author><style face="normal" font="Arial"> Poddighe,D.</style></author><author><style face="normal" font="Arial"> Laurino,C.</style></author><author><style face="normal" font="Arial"> Palmieri,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?</style></title><secondary-title><style face="normal" font="Arial">EPMA J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EPMA J</style></full-title></periodical><pages end="311" start="295">295-311</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Molecular Mimicry</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Purpura</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="Arial"> type 1 diabetes</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1878-5085</style></isbn><abstract><style face="normal" font="Arial">Autoimmune diseases, including multiple sclerosis and type 1 diabetes mellitus, affect about 5% of the worldwide population. In the last decade, reports have accumulated on various autoimmune disorders, such as idiopathic thrombocytopenia purpura, myopericarditis, primary ovarian failure, and systemic lupus erythematosus (SLE), following vaccination. In this review, we discuss the possible underlying mechanisms of autoimmune reactions following vaccinations and review cases of autoimmune diseases that have been correlated with vaccination. Molecular mimicry and bystander activation are reported as possible mechanisms by which vaccines can cause autoimmune reactions. The individuals who might be susceptible to develop these reactions could be especially not only those with previous post-vaccination phenomena and those with allergies but also in individuals who are prone to develop autoimmune diseases, such as those with a family history of autoimmunity or with known autoantibodies, and the genetic predisposed individuals</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13167-017-0101-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29021840">PM:29021840</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EPMA J\20170815-VadalaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EPMA J\20170815-VadalaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Vadala M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13167-017-0101-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calderon,J.</style></author><author><style face="normal" font="Arial"> Cherrez,A.</style></author><author><style face="normal" font="Arial"> Ramon,G.D.</style></author><author><style face="normal" font="Arial"> Lopez Jove,O.</style></author><author><style face="normal" font="Arial"> Baptist,A.</style></author><author><style face="normal" font="Arial"> Matos,E.</style></author><author><style face="normal" font="Arial"> Morfin Maciel,B.</style></author><author><style face="normal" font="Arial"> Calero,E.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Cherrez,S.</style></author><author><style face="normal" font="Arial"> Simancas-Racines,D.</style></author><author><style face="normal" font="Arial"> Cherrez Ojeda,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiralab, Respiralab Research Group, Guayaquil, Ecuador</style></auth-address><titles><title><style face="normal" font="Arial">Information and communication technology use in asthmatic patients: a cross-sectional study in Latin America</style></title><secondary-title><style face="normal" font="Arial">ERJ Open Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ERJ Open Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Diffusion</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Latin America</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peru</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Rapid diffusion, low cost and broad availability of information and communication technologies (ICTs) make them an attractive platform for managing care, communication and interventions in asthma. There is little information in Latin America about usage frequency of ICTs in asthmatic patients. The analysis undertaken consisted of an observational, cross-sectional study that aimed to identify the frequency and type of ICTs most often used by asthmatics. The Spanish version of the Michigan questionnaire was employed in five Latin American countries. Age and educational level was categorised. Logistic regression was performed among these groups concerning the frequency of ICT usage and the level of interest shown in seeking and receiving information about asthma. In total, 673 asthma patients were surveyed. The mean age was 43.44 years. Over two-thirds of the participants were female (68.4%). The most used ICT was the short message service (SMS) (69.9%). SMS and E-mail are useful tools for communicating (i.e. receiving and seeking information) with all asthma patients, irrespective of their age. WhatsApp (61.5%) and Facebook (32.0%) were rated as being the most interesting channels of communication for receiving information. Regression analysis showed that younger asthmatics and asthmatics with higher educational levels were most likely to use almost all forms of ICTs. ICTs are generally an attractive platform for managing care, communication and interventions to improve asthma care. SMS and E-mail were found to be the preferred ICT forms among users. However, social media forms such as WhatsApp and Facebook may also be appropriate for certain types of patient</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 2312-0541 (Print)IS - 2312-0541 (Linking)LA - engPT - Journal ArticleCO - Ecuador -CO - Germany -CO - Argentina -CO - United States -CO - Peru -CO - Mexico -CO - Venezuela -</style></notes><work-type><style face="normal" font="Arial">10.1183/23120541.00005-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28717641">PM:28717641</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\ERJ Open Res\20170718-CalderonJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\ERJ Open Res\20170718-CalderonJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Calderon J</style></custom2><misc3><style face="normal" font="Arial">10.1183/23120541.00005-2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sellitto,A.</style></author><author><style face="normal" font="Arial"> De Fanis,U.</style></author><author><style face="normal" font="Arial"> Balestrieri,A.</style></author><author><style face="normal" font="Arial"> Savoia,A.</style></author><author><style face="normal" font="Arial"> Astarita,C.</style></author><author><style face="normal" font="Arial"> Romano,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Internal Medicine, Allergy and Clinical Immunology, Department of Medical and Surgical Sciences, Second University of Naples School of Medicine, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria: a preliminary report</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="175" start="171">171-175</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Omalizumab has recently obtained indication for chronic spontaneous urticaria both in the US and Europe. However, the mechanism of action of this drug has yet to be fully elucidated. Previous studies have shown elevations in cytokine serum levels in patients with chronic spontaneous urticaria, and it is not known whether omalizumab treatment may affect cytokine serum levels in this condition. Besides, a proportion of chronic spontaneous urticaria patients have concomitant atopy, which may be associated, at least in theory, with prevalence of serum Th2-type cytokines. In this study, serial serum samples from five patients (4 atopic and 1 nonatopic) with chronic spontaneous urticaria were assayed for cytokine concentrations by means of flow-cytometry-based multiplex bead assays, before and during omalizumab treatment. Omalizumab appeared to significantly affect the concentrations of multiple cytokines in a case of severe, long-lasting chronic spontaneous urticaria. Interestingly, IL-22 serum levels were found to progressively increase in three of five patients. Further studies are thus needed in larger patient populations, to conclusively establish whether the mechanism of action of omalizumab in chronic spontaneous urticaria also includes modulation of cytokine synthesis</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.10</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752720">PM:28752720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-171-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-171-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Sellitto A</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.10</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Capriles-Hulet,A.</style></author><author><style face="normal" font="Arial"> Caballero-Fonseca,F.</style></author><author><style face="normal" font="Arial"> Gonzalez-Aveledo,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela. Allergy Service, Clinica El Avila, Caracas, Venezuela.</style></auth-address><titles><title><style face="normal" font="Arial">Justification for IgE as a therapeutic target in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="153" start="148">148-153</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> autoantigen</style></keyword><keyword><style face="normal" font="Arial"> Autoantigens</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> highly cytokinergic IgE</style></keyword><keyword><style face="normal" font="Arial"> histamine releasing factors</style></keyword><keyword><style face="normal" font="Arial"> histamine-releasing factor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Monoclonal anti-IgE antibodies (omalizumab) are able to induce clinically significant benefits in patients with severe chronic spontaneous urticaria (CS). Those results led clinicians and investigators to reconsider a possible pathogenic role not previously supported for IgE and its receptors in this disease, and to investigate additional approaches for understanding its pathogenesis. IgE antibodies to unknown environmental allergens able to trigger chronic urticaria are not generally regarded as the etiologic factor for the disease. Other proposed mechanisms for the production of wheals and angioedema in CSU include IgG autoantibodies and CD4-positive T cells directed to the high-affinity IgE receptor, autoantibodies to IgE itself, IgE autoantibodies directed to thyroid and nuclear autoantigens, highly cytokinergic IgE, and histamine-releasing factors able to bind to IgE and cause mast cell activation. It is expected that a better knowledge on the mechanisms leading to CSU and the clarification of the immunological effects of anti-IgE will provide novel therapies for this frequent condition</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Venezuela -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.02</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752717">PM:28752717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-148-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-148-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Sanchez-Borges M</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.02</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berti,A.</style></author><author><style face="normal" font="Arial"> Yacoub,M.R.</style></author><author><style face="normal" font="Arial"> Stahl Skov,P.</style></author><author><style face="normal" font="Arial"> Falkencrone,S.</style></author><author><style face="normal" font="Arial"> Casati,L.</style></author><author><style face="normal" font="Arial"> Burastero,S.</style></author><author><style face="normal" font="Arial"> Sabbadini,M.G.</style></author><author><style face="normal" font="Arial"> Colombo,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, IRCCS San Raffaele Scientific Institute, Milan, Italy. Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="160" start="154">154-160</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> histamine releasing factors</style></keyword><keyword><style face="normal" font="Arial"> histamine-releasing factor</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Background. Histamine release (HR) test has previously been shown to predict the presence of endogenous histamine-releasing factors in chronic spontaneous urticaria (CSU). Objectives and methods. Twenty CSU patients unresponsive to antihistamine treatment were enrolled in order to evaluate the correlations between HR test results and demographic features, quality of life, disease activity, clinical course, and autologous serum and plasma skin tests (ASST and APST). Results. All patients with positive HR test (9/9, 100%) had a more severe disease activity at onset (urticaria activity score, UAS > 2) when compared to negative HR test patients (5/11; p = 0.04). Quality of life questionnaire's results were not substantially different between HR positive and negative subgroups at baseline (p > 0.05), and results of HR test and ASST/APST did not co-segregate (p > 0.05). After 12 months, patients with a positive HR test had a significant reduction of disease activity (p = 0.003) whereas patients with a negative HR test did not (p > 0.05), leading to disease remission and antihistamine treatment withdrawal in 67% (6/9) of positive HR test patients versus 18% (2/11) of negative HR test patients (p = 0.027). Conclusions. Positive HR test may predict spontaneous CSU remission at 12 months</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752718">PM:28752718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-154-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-154-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Berti A</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.17</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ciprandi,G.</style></author><author><style face="normal" font="Arial"> Scala,E.</style></author><author><style face="normal" font="Arial"> Ariano,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">IRCCS-A.O.U. San Martino-IST, Genova, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Phleum pratense molecular pattern across Italy</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="180" start="176">176-180</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> molecular-based allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Introduction. Phleum pratense (Timothy grass) is the most frequent cause of grass allergy in Europe. Molecular-based allergy diagnostics have been recently introduced in the clinical practice, allowing to define and characterize exactly the sensitization profile. Aim of the study. The present study was aimed to investigate the possible relationships between Graminaceae pollen data and the pattern of IgE reactivity to different allergen components across Italy. Methods. Pollen data, including duration and quantity, were recorded over a 10-year period in 24 Italian centres located along the Italian peninsula. Phl p molecular patterns (Phl p 1, 5, 7, 12) were evaluated in 4 different Italian geographical areas. Results. There were significant differences about pollen count and sensitization prevalence across Italy. Different molecular patterns were defined considering the different Italian locations. Conclusion. This study demonstrates that Phleum pratense sensitization is relevant in Italy, but there are significant geographical variations variations as far as pollen exposure and pattern of IgE reactivity to the considered allergen components are concerned. This information may have clinical relevance in managing patients allergic to grass pollen</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.01</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752721">PM:28752721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-176-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-176-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Ciprandi G</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.01</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arslan Lied,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Clinical Allergy, Department of Occupational Diseases and Section of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.</style></auth-address><titles><title><style face="normal" font="Arial">Red meat allergy induced by tick bites: A Norwegian case report</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="188" start="186">186-188</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Red meat allergy</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Food allergies, especially delayed hypersensitivity reactions, are often challenging for both patients and clinicians. Here, we report the case of a 64-year-old man who had allergic reactions six hours after eating a meal containing red meat. He reported that he had several tick bites in months before the reaction. High serum specific IgE levels of alpha-gal confirmed the diagnosis of alpha-gal allergic reaction with delayed onset after red meat ingestion caused by tick bite</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Norway -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.04</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752723">PM:28752723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-186-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-186-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Arslan Lied G</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.04</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vassilopoulou,E.</style></author><author><style face="normal" font="Arial"> Christoforou,C.</style></author><author><style face="normal" font="Arial"> Andreou,E.</style></author><author><style face="normal" font="Arial"> Heraclides,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Life and Health Sciences, University of Nicosia, Cyprus.</style></auth-address><titles><title><style face="normal" font="Arial">Effects of food allergy on the dietary habits and intake of primary schools' Cypriot children</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="185" start="181">181-185</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cyprus</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Energy Intake</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food groups</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fructose</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary schools</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin E</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Aim. To determine whether food allergy affects overall dietary intake and food choices in Cypriot primary school children. Methods. As part of the first epidemiological study in Cyprus on food allergy in primary school children, two 24-hour recalls (one from a week and one from a weekend day) of twenty-eight food allergic children (21 girls) and thirty healthy children (20 girls) aged 6-11 years old, were analysed and compared regarding their macro- and micronutrient content, food choices and meal distribution. Results. Significant differences between the two subgroups of children were estimated regarding the total energy intake and macronutrients, where food allergic children were found to consume in lower quantities, as well as for calcium, niacin, fiber and vitamin E. Food allergic children were also found to avoid combining foods from the various food groups in their meals, and to prefer specific food products from each category, whereas they consumed higher amounts of sugar and fructose. Conclusion. Food allergy in Cypriot food allergic children impacts on both the quality and quantity of food choices, probably due to lack of nutritional education regarding proper elimination diet and alternative nutrient sources</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Cyprus -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.07</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752722">PM:28752722</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-181-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-181-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Vassilopoulou E</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.07</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Korus,A.</style></author><author><style face="normal" font="Arial"> Gumul,D.</style></author><author><style face="normal" font="Arial"> Krystyjan,M.</style></author><author><style face="normal" font="Arial"> Juszczak,L.</style></author><author><style face="normal" font="Arial"> Korus,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of the quality, nutritional value and antioxidant activity of gluten-free biscuits made from corn-acorn flour or corn-hemp flour composites</style></title><secondary-title><style face="normal" font="Arial">Eur Food Res Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Food Res Technol</style></full-title></periodical><pages end="1438" start="1429">1429-1438</pages><volume><style face="normal" font="Arial">243</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> Dietary Fiber</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Flours</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> hardness</style></keyword><keyword><style face="normal" font="Arial"> Hemp</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensory properties</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1438-2385</style></isbn><abstract><style face="normal" font="Arial">The aim of this study was to evaluate the effect of substituting 20</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô60% of corn flour with acorn or hemp flour on the quality, nutritional, pro-health value, and sensory properties of gluten-free biscuits. Partial replacement of corn flour with the mentioned above flours resulted in a significant reduction of biscuit volume and an increase of their hardness. The biscuits in the experiment were significantly darker than the control ones. Increasing the content of both studied flours resulted in a distinct trend of color variation from yellow toward red-purple. The protein content in biscuits with the addition of acorn flour did not differ significantly in comparison with the control biscuits, whereas biscuits with flour hemp contained 40</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô122% more protein in comparison with the control ones. The total dietary fiber content increased correspondingly with the addition of the investigated flours. The total polyphenols content (TPC) in biscuits with the acorn flour addition increased in the range of 308</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô801% in relation to the control, and the addition of hemp flour increased the TPC in the range of 41</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô143%. It was found that acorn flour contributed to higher growth (an average of 367%) of the antioxidant activity of the biscuits in relation to the control samples than the hemp flour (an average of 114%). The control biscuits obtained the highest sensory score, similarly biscuits with 20 and 40% acorn flour addition. The most favorable replacement should be that not more than a 40% substitute of corn flour with acorn flour</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00217-017-2853-y</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s00217-017-2853-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Food Res Technol\2017-243-1429-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Food Res Technol\2017-243-1429-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Korus A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00217-017-2853-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qian,J.</style></author><author><style face="normal" font="Arial"> Ma,X.</style></author><author><style face="normal" font="Arial"> Xun,Y.</style></author><author><style face="normal" font="Arial"> Pan,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cadres of the respiratory, Beijing Shijitan Hospital, Affiliated to Capital Medical University, Beijing 100038, China</style></auth-address><titles><title><style face="normal" font="Arial">Protective effect of forsythiaside A on OVA-induced asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">Forsythiaside A (FSA), an active constituent isolated from the Chinese medicinal herb Forsythia suspensa, has been known to have anti-inflammatory effect. However, the effect of FSA on allergic airway inflammation remains unclear. The aim of this study was to investigate the effect of FSA on OVA-induced asthma in mice. Mice model of asthma was induced by OVA. OVA-induced airway hyperresponsiveness (AHR) and inflammatory cells in BALF were detected. The production of IgE, IL-4, IL-5, IFN-gamma, and IL-13 were detected by ELISA. The effects of FSA on Nrf2 and NF-kappaB signaling pathways were detected by western blot analysis. The results showed that treatment of FSA significantly attenuated OVA-induced lung histopathological changes. FSA inhibited OVA-induced AHR and inflammatory cells in BALF. OVA-induced IgE, IL-4, IL-5, and IL-13 production were also inhibited by FSA. Western blot analysis showed that treatment of FSA inhibited OVA-induced NF-kappaB activation. Treatment of FSA dose-dependently up-regulated the expression of Nrf2 and HO-1. In addition, we found that FSA up-regulated the expression of Nrf2 and HO-1 both in A549 cells and MS-H cells. Taken together, FSA suppressed inflammatory responses in OVA-induced asthma through activating Nrf2/HO-1 signaling pathway. FSA may be a promising potential preventive agent for asthma treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170722IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.07.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28733217">PM:28733217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20170722-QianJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20170722-QianJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170722, Qian J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.07.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,X.Y.</style></author><author><style face="normal" font="Arial"> Tian,Z.M.</style></author><author><style face="normal" font="Arial"> Ning,H.Y.</style></author><author><style face="normal" font="Arial"> Wang,X.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. allergy2015@126.com</style></auth-address><titles><title><style face="normal" font="Arial">The ambient pollen distribution in Beijing urban area and its relationship with consumption of outpatient anti-allergic prescriptions</style></title><secondary-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Rev Med Pharmacol Sci</style></full-title></periodical><pages end="115" start="108">108-115</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">3 Suppl</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Sprays</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The impact of pollen exposure on allergy medication is poorly characterized. We aim to study the main kind of ambient pollen in Beijing urban area and the correlation with outpatient anti-allergic prescriptions throughout one year in a tertiary hospital. MATERIALS AND METHODS: With a modified volumetric trap, ambient pollens were sampled from January to December 2015. Meanwhile, information on 15 anti-allergic medication prescriptions in outpatient pharmacy was obtained and analyzed by generalized linear model. RESULTS: The total quantity of pollens amounted to 76164 grains in 2015. Two peaks of pollen concentration were observed, which happened from March to April 2015, and from August to September 2015. Consumption of antihistamines, LATRA, nasal sprays, and SABA showed two peaks trend in accordance with pollen distribution (p&lt;0.01). ICS+LABA showed no seasonal peak without a significant correlation with pollen counts (p>0.05). Medication peak was higher in autumn than spring (p&lt;0.01). CONCLUSIONS: The ambient pollen distribution was in accordance with the anti-allergic prescription amount with the two-peak season. The autumn medication peak was higher than spring peak, which clarified that outpatients were more sensitive to autumn pollen compared with spring pollen</style></abstract><notes><style face="normal" font="Arial">DA - 20170726IS - 2284-0729 (Electronic)IS - 1128-3602 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28745780">PM:28745780</url></web-urls><pdf-urls><url ppv-ref="no">allergy2015@126.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170726, Wang XY</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,X.</style></author><author><style face="normal" font="Arial"> Dang,Y.J.</style></author><author><style face="normal" font="Arial"> Wang,G.F.</style></author><author><style face="normal" font="Arial"> Jin,X.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Respiratory Medicine , Huashan Hospital Affiliated to Fudan University , Shanghai , China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Aspergillus fumigatus on glucocorticoid receptor and beta2-adrenergic receptor expression in a rat model of asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Lung Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Lung Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ADRB2</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Steroid-resistant asthma</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TLRs</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Conventional inhaled corticosteroids or beta2-adrenergic receptor agonists do not work well in some asthmatic populations while empirical antifungal therapy has obvious impact on those patients. The study was designed to investigate whether short-term exposure to Aspergillus fumigatus (A. fumigatus) could decrease glucocorticoid receptor (GCR) and beta2-adrenergic receptor (ADRB2) expression in lung tissue of asthmatic rats. MATERIALS AND METHODS: A rat model of chronic asthma was first established by ovalbumin sensitization and challenge. Rats with chronic asthma were then exposed to short-term application of A. fumigatus spores. Airway hyper-responsiveness, eosinophil ratio in bronchoalveolar lavage (BAL) fluid and total IgE in serum were counted in these experimental animals. GCR and ADRB2 expression in the lung were detected and analyzed. Furthermore, the levels of toll-like receptors (TLRs) 2, 3 and 4 in lung tissue were measured. RESULTS: Short-term exposure to A. fumigatus could down-regulate the expression of GCR, aggravate airway hyper-responsiveness and increase the level of TLR2 in rats with asthma. There were no obvious changes in the levels of ADRB2 expression, recruited eosinophils, total IgE, TLR3 and TLR4 after application of A. fumigatus in asthmatic rats. CONCLUSIONS: These findings indicate that A. fumigatus exposure may be involved in glucocorticoids unresponsiveness by down-regulating the expression of GCR in asthmatics. The possibility of A. fumigatus colonization or infection should not be ignored in patients of steroid-resistant asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 1521-0499 (Electronic)IS - 0190-2148 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/01902148.2017.1339142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696809">PM:28696809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Lung Res\20170711-ZhouX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Lung Res\20170711-ZhouX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Zhou X</style></custom2><misc3><style face="normal" font="Arial">10.1080/01902148.2017.1339142</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,H.Y.</style></author><author><style face="normal" font="Arial"> Hur,J.</style></author><author><style face="normal" font="Arial"> Kim,I.K.</style></author><author><style face="normal" font="Arial"> Kang,J.Y.</style></author><author><style face="normal" font="Arial"> Yoon,H.K.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Kwon,S.S.</style></author><author><style face="normal" font="Arial"> Kim,Y.K.</style></author><author><style face="normal" font="Arial"> Rhee,C.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine , The Catholic University of Korea , Gyeonggi-do , Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model</style></title><secondary-title><style face="normal" font="Arial">Exp Lung Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Lung Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary fibrosis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Nintedanib is a multi-tyrosine kinase receptor inhibitor recently approved for treatment of idiopathic pulmonary fibrosis. Although angiogenesis is a key process involved in airway structural changes in patients with bronchial asthma, the effect of nintedanib targeting the angiokinase pathway on airway inflammation and remodeling has not been evaluated. METHODS: We used a 3-month ovalbumin (OVA) challenge mouse model of airway remodeling. Nintedanib was orally administrated during the challenge period, and the effects were examined based on the percentage of airway inflammatory cells, airway hyper-reactivity (AHR), peribronchial goblet cell hyperplasia, total lung collagen and smooth muscle area. The expression of growth factor receptors was analyzed in mice lung tissues. RESULTS: The OVA challenged group showed a significant increase in airway eosinophilic inflammation, elevated Th2 cytokines, AHR, and airway remodeling compared to those in the control group. The airway remodeling process, as evaluated by goblet cell hyperplasia, total lung collagen level, and airway smooth muscle area, was suppressed by nintedanib compared to that by OVA. Nintedanib effectively suppressed the phosphorylation of vascular endothelial growth factor/ platelet derived growth factor subunit2/fibroblast growth factor3 receptors in the mice lung. CONCLUSIONS: Nintedanib effectively ameliorated airway inflammation and remodeling in an OVA-induced chronic asthma model. These results suggest that nintedanib could be a new treatment agent targeting airway remodeling in patients with severe asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 1521-0499 (Electronic)IS - 0190-2148 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1080/01902148.2017.1339141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696800">PM:28696800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Lung Res\20170711-LeeHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Lung Res\20170711-LeeHY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Lee HY</style></custom2><misc3><style face="normal" font="Arial">10.1080/01902148.2017.1339141</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abraham,M.</style></author><author><style face="normal" font="Arial"> Khosroshahi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Medicine, Division of Rheumatology , Emory University School of Medicine , Atlanta , GA , USAa Department of Medicine, Division of Rheumatology , Emory University School of Medicine , Atlanta , GA , USA</style></auth-address><titles><title><style face="normal" font="Arial">Diagnostic and treatment workup for IgG4-related disease</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="875" start="867">867-875</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pancreas</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: IgG4-Related Disease is a newly recognized condition which is increasingly diagnosed by practitioners due to improvement in clinical awareness. Men and women have been found to be affected by this disease in various organs, more commonly with involvement of the salivary and lacrimal glands as well as pancreas and liver. Areas covered: The diagnosis and management of this condition remain challenging as biomarkers and therapies are being investigated. Hallmark features on histology are still the gold standard for confirmation of diagnosis, whereas serum IgG4 level has been shown to be neither necessary nor sufficient for the diagnosis. Glucocorticoids remain the most effective initial management for this condition while there are limited clinical trials on the effectiveness of maintenance therapy. Expert commentary: This review serves as an update on approaches for diagnosis and management of IgG4-RD. Most of the known data in this field comes from retrospective cohort studies and expert consensus guidelines but new ongoing prospective studies, clinical trials and better understanding of the pathogenesis of this condition are promising</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1354698</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701054">PM:28701054</url></web-urls><pdf-urls><url ppv-ref="no">akhosroshahi@emory.edu</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170713, Abraham M</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1354698</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Plundrich,N.</style></author><author><style face="normal" font="Arial"> Lila,M.A.</style></author><author><style face="normal" font="Arial"> Foegeding,E.</style></author><author><style face="normal" font="Arial"> Laster,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Plants for Human Health Institute , North Carolina Research Campus, North Carolina State University, North Carolina, USA</style></auth-address><titles><title><style face="normal" font="Arial">Protein-bound polyphenols create "ghost" band artifacts during chemiluminescence-based antigen detection</style></title><secondary-title><style face="normal" font="Arial">F1000Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">F1000Res</style></full-title></periodical><pages end="" start="254">254-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Artifacts</style></keyword><keyword><style face="normal" font="Arial"> Chemiluminescence</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg white proteins</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Horseradish Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Antigen detection during Western blotting commonly utilizes a horseradish peroxidase-coupled secondary antibody and enhanced chemiluminescent substrate. We utilized this technique to examine the impact of green tea-derived polyphenols on the binding of egg white protein-specific IgE antibodies from allergic human plasma to their cognate antigens. Our experiments unexpectedly showed that green tea-derived polyphenols, when stably complexed with egg white proteins, caused hyperactivation of horseradish peroxidase resulting in the appearance of white "ghost" bands. This study suggests that caution should be taken when evaluating polyphenol-bound proteins by enhanced chemiluminescence Western blotting using horseradish peroxidase and demonstrates that protein-bound polyphenols can be a source of "ghost" band artifacts on Western blots</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 2046-1402 (Print)IS - 2046-1402 (Linking)LA - engPT - Journal ArticleCO - United States -.</style></notes><work-type><style face="normal" font="Arial">10.12688/f1000research.10622.2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28721200">PM:28721200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\F1000Res\2017-6-254.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\F1000Res\2017-6-254.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Plundrich N</style></custom2><misc3><style face="normal" font="Arial">10.12688/f1000research.10622.2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,L.</style></author><author><style face="normal" font="Arial"> Zhang,F.</style></author><author><style face="normal" font="Arial"> Cao,Z.</style></author><author><style face="normal" font="Arial"> Xiao,Y.</style></author><author><style face="normal" font="Arial"> Li,S.</style></author><author><style face="normal" font="Arial"> Yu,B.</style></author><author><style face="normal" font="Arial"> Qi,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Ginsenoside F2 induces the release of mediators associated with Anaphylactoid reactions</style></title><secondary-title><style face="normal" font="Arial">Fitoterapia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Fitoterapia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="Arial"> anaphylactoid reactions</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Ginsenoside</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> PPD</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> structure-allergenicity relationship</style></keyword><keyword><style face="normal" font="Arial"> TCM</style></keyword><keyword><style face="normal" font="Arial"> Translational research</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="Arial">Recently, the allergenicity of ginsenosides, as main active components in ginseng, has attracted much attention. Ginsenoside Rb1 and Rd. have been reported to induce anaphylactoid reaction. In this study, the allergenicity of a series of 20(S)-protopanaxadiol (PPD) type ginsenosides, including Rb1, Rd., F2, Compound K and 20(S)-PPD, was evaluated in rat basophilic leukemia 2H3 (RBL2H3) cells. As a result, 20(S)-PPD had no effect on the mast cell degranulation, but other components showed anaphylactoid potential to different extent. The allergenicity was stronger and stronger according to the order "Rb1, Rd., F2, Compound K". Then, F2 was further verified in RBL-2H3 cells, mouse peritoneal mast cells (MPMCs), Laboratory of Allergic Disease 2 (LAD2) human mast cells in vitro and mice in vivo. Results showed that F2 could induce a significant increase of histamine release and translocation of phosphatidylserine in RBL-2H3 cells. F2 also increased beta-hexosaminidase release and the intracellular Ca2+ concentration of MPMCs and LAD2 cells. In addition, histamine level in serum of mice was elevated dose-dependently. Our study revealed the potential structure-allergenicity relationship of 20(S)-PPD type ginsenosides and first verified the allergenicity of ginsenoside F2. This study could guide the establishment of quality standards for safe application of ginsenoside-containing preparations</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 1873-6971 (Electronic)IS - 0367-326X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fitote.2017.07.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734737">PM:28734737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Fitoterapia\20170723-WangL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Fitoterapia\20170723-WangL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Wang L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fitote.2017.07.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sokolova,R.N.</style></author><author><style face="normal" font="Arial"> Yankova,R.K.</style></author><author><style face="normal" font="Arial"> Abadjieva,T.I.</style></author><author><style face="normal" font="Arial"> Popova,T.A.</style></author><author><style face="normal" font="Arial"> Ivanovska,M.V.</style></author><author><style face="normal" font="Arial"> Murdjeva,M.A.</style></author><author><style face="normal" font="Arial"> Orbetzova,M.M.</style></author><author><style face="normal" font="Arial"> Dermendzhiev,S.M.</style></author><author><style face="normal" font="Arial"> Pavlova,M.V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Association between Type 2 Diabetes, Obesity and Key Immunological Components of IgE-mediated Inflammation</style></title><secondary-title><style face="normal" font="Arial">Folia Med (Plovdiv)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Folia Med (Plovdiv)</style></full-title></periodical><pages end="164" start="159">159-164</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Epidemics</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Glycemic control</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Type 2 diabetes</style></keyword><keyword><style face="normal" font="Arial"> waist circumference</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Changes in lifestyle and obesity in recent decades have brought about a dramatic increase in type 2 diabetes mellitus (DM2) and allergic diseases. Clinical and epidemiological studies associate obesity with epidemics of allergic diseases. The link between obesity and DM2 with immunological components of IgE-mediated allergic inflammation is not yet conclusively established. AIM: To examine the key immunological components of IgE-mediated allergic inflammation in patients with DM2 and their relationship with glycemic control and anthropometric indicators. MATERIALS AND METHODS: Fifty-five patients with DM2 and 32 healthy controls with normal weight and body mass index (BMI) of 18-24.9 kg/m2 were included in the study. Th2-cytokine profile (serum levels of IL-4 and IL-5, pg/ml) and total serum IgE IU/ml were assessed in all participants in the study using ELISA. In patients with DM2, levels of glycated hemoglobin (HbA1c%) in the blood were also measured. RESULTS: Serum levels of IL-4 and IL-5 are significantly higher in patients with DM2 compared to the control group. Serum levels of IL-4 and IL-5 positively correlated with BMI as well as serum levels of IL-4 with waist circumference. Total serum IgE positively correlated with HbA1c. CONCLUSION: Obesity and poor glycemic control in patients with DM2 affect key immunological components of IgE-mediated allergic inflammation and possibly alter the immune response to allergens and antigens</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 0204-8043 (Print)IS - 0204-8043 (Linking)LA - engPT - Journal ArticleCO - Bulgaria -</style></notes><work-type><style face="normal" font="Arial">10.1515/folmed-2017-0021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28704195">PM:28704195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Folia Med (Plovdiv)\2017-59-159-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Folia Med (Plovdiv)\2017-59-159-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Sokolova RN</style></custom2><misc3><style face="normal" font="Arial">10.1515/folmed-2017-0021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohan Kumar,B.V.</style></author><author><style face="normal" font="Arial"> Prasada Rao,U.J.S.</style></author><author><style face="normal" font="Arial"> Prabhasankar,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immunogenicity characterization of hexaploid and tetraploid wheat varieties related to celiac disease and wheat allergy</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="903" start="888">888-903</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Gliadin content</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Hypoimmunogenic</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot assay</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="3" Month="9" Year="2017">2017/9/3</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">Wheat is one of the major cereals consumed throughout the world; there has been a radical increase in the population suffering from many wheat-related disorders. The present study was conducted to screen low immunogenic hexaploid and tetraploid wheat varieties. A total of 34 different wheat varieties were tested for its total protein content, gliadin content and immunoreactivity with immunoglobulins of celiac (IgA) and wheat allergy patients (IgE). The wheat varieties HD-2851 and NIAW-917 (hexaploid) and NIDW-295, UAS-428, PDW-291, MPO-1215 and DDK-1025 (tetraploid) were found to be less immunoreactive varieties for both celiac and wheat allergy patients. The immunoblot assays for IgE reactivity have revealed that gliadin subunits present in all varieties are found to be allergic proteins. The principal component analysis biplot showed that tetraploid wheat varieties are less immunoreactive than hexaploids. The low immunogenic wheat varieties are suitable for plant breeding and preparation of low gluten or hypo-immunogenic productsABSTRACTWheat is one of the major cereals consumed throughout the world; there has been a radical increase in the population suffering from many wheat-related disorders. The present study was conducted to screen low immunogenic hexaploid and tetraploid wheat varieties. A total of 34 different wheat varieties were tested for its total protein content, gliadin content and immunoreactivity with immunoglobulins of celiac (IgA) and wheat allergy patients (IgE). The wheat varieties HD-2851 and NIAW-917 (hexaploid) and NIDW-295, UAS-428, PDW-291, MPO-1215 and DDK-1025 (tetraploid) were found to be less immunoreactive varieties for both celiac and wheat allergy patients. The immunoblot assays for IgE reactivity have revealed that gliadin subunits present in all varieties are found to be allergic proteins. The principal component analysis biplot showed that tetraploid wheat varieties are less immunoreactive than hexaploids. The low immunogenic wheat varieties are suitable for plant breeding and preparation of low gluten or hypo-immunogenic products</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1319342</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1319342</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-888-903.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-888-903.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Mohan Kumar BV</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1319342</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Van Gansbeke,B.</style></author><author><style face="normal" font="Arial"> Beny,G.</style></author><author><style face="normal" font="Arial"> de Loose,M.</style></author><author><style face="normal" font="Arial"> Taverniers,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A TaqMan Real-Time PCR Assay for Apricot (Prunus armeniaca) as an Authenticity Test for Detection of Traces of Persipan in Marzipan</style></title><secondary-title><style face="normal" font="Arial">Food Anal Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Anal Methods</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Almond</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Prunus</style></keyword><keyword><style face="normal" font="Arial"> Prunus persica</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> TaqMan</style></keyword><keyword><style face="normal" font="Arial"> TaqMan real-time PCR</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1936-976X</style></isbn><abstract><style face="normal" font="Arial">Almond (Prunus dulcis), typically used in marzipan, is becoming more valuable by increasing global demand. As a consequence, substitution with cheaper alternatives is a common practice. Marzipan can be adulterated with apricot (Prunus armeniaca) or peach (Prunus persica), because of similar characteristics. Both species are closely related to almond; however, small differences in non-specific lipid transfer protein (LTP), used as target sequence for a qPCR test, can be noticed. In this study, a TaqMan qPCR method for specific detection of apricot in marzipan was developed. After optimization, specificity and sensitivity tests were carried out on real samples and the limit of detection was determined. The TaqMan qPCR method showed high specificity for apricot and was able to detect as low as 1% persipan in marzipan</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12161-017-0964-5</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s12161-017-0964-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Anal Methods\20170727-Van GansbekeB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Anal Methods\20170727-Van GansbekeB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">201707027, Van Gansbeke B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12161-017-0964-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liao,Y.S.</style></author><author><style face="normal" font="Arial"> Kuo,J.H.</style></author><author><style face="normal" font="Arial"> Chen,B.L.</style></author><author><style face="normal" font="Arial"> Tsuei,H.W.</style></author><author><style face="normal" font="Arial"> Lin,C.Y.</style></author><author><style face="normal" font="Arial"> Lin,H.</style></author><author><style face="normal" font="Arial"> Cheng,H.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development and Validation of the Detection Method for Wheat and Barley Glutens Using Mass Spectrometry in Processed Foods</style></title><secondary-title><style face="normal" font="Arial">Food Anal Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Anal Methods</style></full-title></periodical><pages end="2847" start="2839">2839-2847</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Barley</style></keyword><keyword><style face="normal" font="Arial"> barley flour</style></keyword><keyword><style face="normal" font="Arial"> Coeliac disease</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Glutens</style></keyword><keyword><style face="normal" font="Arial"> Hordein</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> marker peptides</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1936-976X</style></isbn><abstract><style face="normal" font="Arial">Currently, the only effective treatment for coeliac disease is a gluten-free (GF) diet to avoid gluten-containing food intake. However, the current enzyme-linked immunosorbent assay (ELISA) method for detecting gluten lacks the ability to precisely detect and quantify gluten in fermented and hydrolyzed foods. The purpose of this study was to use liquid chromatography-tandem mass spectrometry (LC-MS/MS) to develop a robust and stable method for gliadin and hordein detection when assessing food safety. This study successfully extracted hordein from barley flour to use as a reference standard. Liquid chromatography/quadrupole time-of-flight mass spectrometer (LC/Q-TOF/MS) performed an analysis to identify unique marker peptides from gliadin and hordein. For determining the limit of detection of gluten in GF products, gliadin and hordein were spiked into GF products at concentrations of 1</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô100-ámg/kg with isotope-labeled peptides as internal standards (IS). The developed method enabled the detection of 2.5-ámg/kg of wheat and barley gluten in GF products. Finally, compared with the immunochemical method, the ability for the MS-based method to detect and quantify gluten content from fermented and hydrolyzed foods was unaffected and demonstrated the potential to analyze suspected gluten-contaminated foods to assess product safety</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12161-017-0827-0</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s12161-017-0827-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Anal Methods\2017-10-2839-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Anal Methods\2017-10-2839-47.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Liao YS</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12161-017-0827-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chiozzi,R.Z.</style></author><author><style face="normal" font="Arial"> Capriotti,A.L.</style></author><author><style face="normal" font="Arial"> Cavaliere,C.</style></author><author><style face="normal" font="Arial"> La Barbera,G.</style></author><author><style face="normal" font="Arial"> Montone,C.M.</style></author><author><style face="normal" font="Arial"> Piovesana,S.</style></author><author><style face="normal" font="Arial"> Lagana,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Label-Free Shotgun Proteomics Approach to Characterize Muscle Tissue from Farmed and Wild European Sea Bass (Dicentrarchus labrax)</style></title><secondary-title><style face="normal" font="Arial">Food Anal Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Anal Methods</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Bass</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> European sea bass</style></keyword><keyword><style face="normal" font="Arial"> Farmed</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish muscle</style></keyword><keyword><style face="normal" font="Arial"> Fish Products</style></keyword><keyword><style face="normal" font="Arial"> Fishes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food quality</style></keyword><keyword><style face="normal" font="Arial"> Fractionation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Label-free</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Shotgun proteomics</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Workflow</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1936-976X</style></isbn><abstract><style face="normal" font="Arial">Sea bass represents one of the main fish products in the market. Most of it comes from farming and is bred in different conditons with respect to the wild fish. Differences may thus be expected. In this study, a proteomic profile of farmed and wild sea bass samples was performed, employing a fractionation strategy where peptide samples were first separated by 2D chromatography. The peptides were finally analyzed by shotgun proteomics workflow combined to tandem MS. The chosen fractionation approach was successful allowing to greatly improve the fish muscle protein characterization and detect some interesting differences between wild fish and farmed sea bass. Sixty-nine proteins were overexpressed in farmed fish samples, whereas 182 proteins were underexpressed. Some of these proteins could be related to the breeding conditions and the diet with which fishes were fed, thus providing some interesting results for assessing food quality based on a comprehensive proteomic study</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12161-017-0999-7</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s12161-017-0999-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Anal Methods\20170723-ChiozziRZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Anal Methods\20170723-ChiozziRZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Chiozzi RZ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12161-017-0999-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Damodaran,S.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A two-step enzymatic modification method to reduce immuno-reactivity of milk proteins</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="732" start="724">724-732</pages><volume><style face="normal" font="Arial">237</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Immuno-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein cross-linking</style></keyword><keyword><style face="normal" font="Arial"> Protein hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.05.152</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodchem.2017.05.152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-237-724-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-237-724-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Damodaran S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.05.152</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hur,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Animal Science and Technology, Chung-Ang University, 4726 Seodong-daero, Daedeok-myeon, Anseong-si, Gyeonggi-do, 17546, Republic of Korea. Electronic address: hursj@cau.ac.kr</style></auth-address><titles><title><style face="normal" font="Arial">A study on current risk assessments and guidelines on the use of food animal products derived from cloned animals</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="92" start="85">85-92</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">Part A</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Food Supply</style></keyword><keyword><style face="normal" font="Arial"> Genotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword><keyword><style face="normal" font="Arial"> Safety assessments</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">The author widely surveyed and analyzed the food safety issues, ethical issues, permits, and approval of animal products from animals cloned by somatic cell nuclear transfer worldwide. As a result of a 2-year survey, the author found that there is no evidence that meat and milk derived from cloned animals or their progeny pose a risk to food safety in terms of genotoxicity, adverse reproductive effects, or allergic reactions. Most countries have not approved meat and milk derived from cloned animals, and their progeny are entering the food supply. To establish the guidelines, the author suggests four principles of safety assessment for meat and milk derived from cloned animals. The four main principles for safety assessment are similarities of chemical composition, adverse reproductive effects, genotoxicity, and allergic reactions under the influence of meat and milk from cloned animals and noncloned counterparts. This principle means that meat and milk derived from a cloned animal are safe if there are no differences in the four safety assessments of meat and milk between cloned animal's progeny and noncloned counterparts</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2017.07.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28750773">PM:28750773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2017-108-85-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2017-108-85-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Hur SJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2017.07.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rolet-Repecaud,O.</style></author><author><style face="normal" font="Arial"> Arnould,C..</style></author><author><style face="normal" font="Arial"> Gavoye,S.</style></author><author><style face="normal" font="Arial"> Beuvier,E.</style></author><author><style face="normal" font="Arial"> Achilleos,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">An immunoassay to assess lamb and kid rennets authenticity</style></title><secondary-title><style face="normal" font="Arial">Food Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Control</style></full-title></periodical><pages end="255" start="251">251-255</pages><volume><style face="normal" font="Arial">82</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adulteration</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Kid rennet</style></keyword><keyword><style face="normal" font="Arial"> Lamb rennet</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0956-7135</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodcont.2017.07.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodcont.2017.07.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Control\2017-82-251-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Control\2017-82-251-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Rolet-Repecaud O</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodcont.2017.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cunsolo,V.</style></author><author><style face="normal" font="Arial"> Saletti,R.</style></author><author><style face="normal" font="Arial"> Muccilli,V.</style></author><author><style face="normal" font="Arial"> Gallina,S.</style></author><author><style face="normal" font="Arial"> Di Francesco,A.</style></author><author><style face="normal" font="Arial"> Foti,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Proteins and bioactive peptides from donkey milk: The molecular basis for its reduced allergenic properties</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="57" start="41">41-57</pages><volume><style face="normal" font="Arial">99</style></volume><number><style face="normal" font="Arial">Pt 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> bioactive peptides</style></keyword><keyword><style face="normal" font="Arial"> Donkey</style></keyword><keyword><style face="normal" font="Arial"> Donkey milk</style></keyword><keyword><style face="normal" font="Arial"> Donkey milk proteome</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Nutraceutical</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2017.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28784499">PM:28784499</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\20170727-CunsoloV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\20170727-CunsoloV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Cunsolo V</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2017.07.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mohammadi,R.</style></author><author><style face="normal" font="Arial"> Yousefi,M.</style></author><author><style face="normal" font="Arial"> Sarlak,Z.</style></author><author><style face="normal" font="Arial"> Shah,N.P.</style></author><author><style face="normal" font="Arial"> Mortazavian,A.M.</style></author><author><style face="normal" font="Arial"> Sadeghi,E.</style></author><author><style face="normal" font="Arial"> Khajavi,M.Z.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Influence of commercial culture composition and cow milk to soy milk ratio on the biochemical, microbiological, and sensory characteristics of a probiotic fermented composite drink</style></title><secondary-title><style face="normal" font="Arial">Food Sci Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Sci Biotechnol</style></full-title></periodical><pages end="757" start="749">749-757</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus acidophilus</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Sensory evaluation</style></keyword><keyword><style face="normal" font="Arial"> sensory properties</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy Milk</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yogurt</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2092-6456</style></isbn><abstract><style face="normal" font="Arial">In this study, the effects of various ratios of cow milk to soy milk (100:0, 75:25, 50:50, 25:75, and 0:100) and three types of commercial culture composition (ABY-1, MY-720, and YO-Mix 210; all of them containing Lactobacillus acidophilus, Bifidobacterium lactis, and yogurt cultures) on the biochemical, microbiological, and sensory characteristics of a probiotic fermented composite drink during incubation and refrigerated storage were investigated. It was found that the shortest fermentation time, greatest mean pH drop rate, and mean acidity increase rate were related to the 50:50/ABY treatment. 25:75/ABY and 25:75/MY treatments exhibited the highest viability of B. bifidum and/or L. acidophilus at the end of 21-ádays of refrigerated storage. The influence of the type of starter culture composition on the sensory properties of the final products was not significant. Based on microbial and sensory evaluations, using the 50:50 ratio with each type of culture composition was considered as the most suitable treatment</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -.CO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10068-017-0097-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s10068-017-0097-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Sci Biotechnol\2017-26-749-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Sci Biotechnol\2017-26-749-57.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Mohammadi R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10068-017-0097-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Battisti,C.</style></author><author><style face="normal" font="Arial"> Chambefort,A.</style></author><author><style face="normal" font="Arial"> Digaud,O.</style></author><author><style face="normal" font="Arial"> Duplessis,B.</style></author><author><style face="normal" font="Arial"> Perrin,C.</style></author><author><style face="normal" font="Arial"> Volatier,J.L.</style></author><author><style face="normal" font="Arial"> Gauvreau-Beziat,J.</style></author><author><style face="normal" font="Arial"> Menard,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Anses, French Agency for FoodEnvironmental and Occupational Health Safety14, rue Pierre et Marie Curie 94701 Maisons-AlfortFrance</style></auth-address><titles><title><style face="normal" font="Arial">Allergens labeling on French processed foods - an Oqali study</style></title><secondary-title><style face="normal" font="Arial">Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Sci Nutr</style></full-title></periodical><pages end="888" start="881">881-888</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food quality</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> precautionary statement</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">The French Observatory of Food Quality (Oqali) aims at collecting all nutritional data provided on labels of processed foods (nutritional information and composition), at branded products level, in order to follow nutritional labeling changes over time. This study carries out an overview of allergens labeling frequencies by distinguishing allergens used in recipes from those listed on precautionary statements, for the fourteen allergen categories for which labeling is mandatory according to European legislation. 17,309 products were collected, between 2008 and 2012, from 26 food categories. Products were classified per family and type of brand (national brands, retailer brands, entry-level retailer brands, hard discount, and specialized retailer brands). Allergenic ingredients were identified from ingredients lists and precautionary statements. 73% of the 17,309 products studied contained at least one allergen in their ingredients list and 39% had a precautionary statement for one or more allergens. Milk (53%), gluten (41%), and egg (22%) were the most commonly used allergens in ingredients lists. For precautionary statement, nuts (20%), egg (14%), peanut (13%), soybean (12%), and milk (11%) were the most common allergens listed. Precautionary statement was most frequently found among first-price products (hard discount and entry-level retailer brands). National brands seemed to use it less frequently. For all these results, differences depended both on food categories and allergen categories. This study will enable to follow allergens labeling and their use as ingredients over time, particularly by assessing an hypothetical increase in allergens presence in processed food</style></abstract><notes><style face="normal" font="Arial">DA - 20170727IS - 2048-7177 (Print)IS - 2048-7177 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1002/fsn3.471</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28748076">PM:28748076</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Sci Nutr\2017-5-881-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Sci Nutr\2017-5-881-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Battisti C</style></custom2><misc3><style face="normal" font="Arial">10.1002/fsn3.471</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Byard,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Medicine, The University of Adelaide, Level 3 Medical School North Building, Frome Road, Adelaide, South Australia, 5005, Australia. roger.byard@sa.gov.au</style></auth-address><titles><title><style face="normal" font="Arial">Death by food</style></title><secondary-title><style face="normal" font="Arial">Forensic Sci Med Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Forensic Sci Med Pathol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Autopsy</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gastroenteritis</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> poisoning</style></keyword><keyword><style face="normal" font="Arial"> Protozoa</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> South Australia</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="Arial">Although death from food is not an uncommon finding in forensic facilities worldwide, the range of underlying lethal mechanisms and associated conditions that should be sought at the time of autopsy is quite disparate. Deaths may occur from i) infectious agents including bacteria, viruses, protozoa, cestodes, nematodes and prions; ii) natural toxins including amanita toxins, tetrodotoxin, ciguatera and scombroid; iii) anaphylaxis; iv) poisoning; v) mechanical issues around airway and gut obstruction and/or perforation; and vi) miscellaneous causes. Food-related deaths are important in terms of global mortality, and thus autopsies need to be comprehensive with full ancillary testing. Medicolegal matters may involve issues concerning likely exposure to infectious agents, possible foods ingested, the declared content and possible components of food, the significance of toxicological analyses, and aspects of duty of care in cases of cafe coronary syndrome and gastroenteritis while in care</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1556-2891 (Electronic)IS - 1547-769X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12024-017-9899-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28710688">PM:28710688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Forensic Sci Med Pathol\20170715-ByardRW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Forensic Sci Med Pathol\20170715-ByardRW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Byard RW</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12024-017-9899-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-de-Olano,D.</style></author><author><style face="normal" font="Arial"> Alvarez-Twose,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Department, Hospital Universitario Ramon y Cajal, Madrid, SpainInstituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Insights in Anaphylaxis and Clonal Mast Cell Disorders</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="792">792-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> clonal mast cell disorders</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell disorders</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher comparing to the general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might sometimes be difficult to identify which may lead to underdiagnosis, and anaphylaxis is commonly the presenting symptom in these patients. Although the release of mast cell (MC) mediators upon MC activation might present with a wide variety of symptoms, particular clinical features typically characterize MC mediator release episodes in patients with clonal MCD without skin involvement. Final diagnosis requires a bone marrow study, and it is recommended that this should be done in reference centers. In this article, we address the main triggers for anaphylaxis, risk factors, clinical presentation, diagnosis, and management of patients with MC activation syndromes (MCASs), with special emphasis on clonal MCAS [systemic mastocytosis and mono(clonal) MC activations syndromes]</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00792</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28740494">PM:28740494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-792.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-792.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Gonzalez-de-Olano D</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00792</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hou,T.Y.</style></author><author><style face="normal" font="Arial"> Chen,M.R.</style></author><author><style face="normal" font="Arial"> Chou,Y.C.</style></author><author><style face="normal" font="Arial"> Kan,P.C.</style></author><author><style face="normal" font="Arial"> Tsai,Y.T.</style></author><author><style face="normal" font="Arial"> Cha,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Impact of Enhancer of Zeste Homolog 2 on T Helper Cell-Mediated Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="790">790-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Enhancer of zeste homolog 2 (Ezh2) has been shown to play a role in the differentiation of T helper (Th) 1 and 2 cells in mice studies using Ezh2-deficient T cells. However, the results have been inconsistent, and the function of Ezh2 in human Th1 and Th2 cell differentiation and its association with disease remains controversial. We measured the expression of Ezh2 in Th1 and Th2 cells in peripheral blood mononuclear cells after acute challenge with house dust mite using flow cytometry in patients with allergic rhinitis (AR) and controls. The role of Ezh2 was further explored by adding the p38 inhibitor to see if this affected allergen-induced Th1 and Th2 differentiation. The expression of Ezh2 in the Th1 and Th2 cells was significantly lower in the patients than in the controls and was negatively correlated with serum IL-17A levels in the patients. Ex vivo allergen challenge resulted in rapid Th2 cell differentiation, which was negatively associated with the Ezh2 expression in Th2 cells. Inhibiting p38 activity increased the expression of Ezh2 in Th2 cells and reduced the number of differentiated Th2 cells. Our findings suggest that Ezh2 expression is potentially associated with AR development</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00790</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28740493">PM:28740493</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-790.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-790.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Hou TY</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00790</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Coutinho,D.S.</style></author><author><style face="normal" font="Arial"> Anjos-Valotta,E.A.</style></author><author><style face="normal" font="Arial"> do Nascimento,C.V.M.F.</style></author><author><style face="normal" font="Arial"> Pires,A.L.A.</style></author><author><style face="normal" font="Arial"> Napimoga,M.H.</style></author><author><style face="normal" font="Arial"> Carvalho,V.F.</style></author><author><style face="normal" font="Arial"> Torres,R.C.</style></author><author><style face="normal" font="Arial"> E Silva,P.M.</style></author><author><style face="normal" font="Arial"> Martins,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Inflamacao, Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">15-Deoxy-Delta-12,14-Prostaglandin J2 Inhibits Lung Inflammation and Remodeling in Distinct Murine Models of Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="740">740-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">15-deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2) has been described as an anti-inflammatory lipid mediator in several in vitro and in vivo studies, but its effect on allergic pulmonary inflammation remains elusive. The aim of this study was to investigate the therapeutic potential of 15d-PGJ2 based on distinct murine models of allergic asthma triggered by either ovalbumin (OVA) or house dust mite extract (HDM). Characteristics of lung inflammation, airway hyper-reactivity (AHR), mucus exacerbation, and lung remodeling in sensitized A/J mice treated or not with 15d-PGJ2 were assessed. 15d-PGJ2 treatments were carried out systemically or topically given via subcutaneous injection or intranasal instillation, respectively. Analyses were carried out 24 h after the last allergen provocation. Irrespective of the route of administration, 15d-PGJ2 significantly inhibited the peribronchial accumulation of eosinophils and neutrophils, subepithelial fibrosis and also mucus exacerbation caused by either OVA or HDM challenge. The protective effect of 15d-PGJ2 occurred in parallel with inhibition of allergen-induced AHR and lung tissue production of pro-inflammatory cytokines, such as interleukin (IL)-5, IL-13, IL-17, and TNF-alpha. Finally, 15d-PGJ2 was found effective in inhibiting NF-kappaB phosphorylation upon HDM challenge as measured by Western blotting. In conclusion, our findings suggest that 15d-PGJ2 can reduce crucial features of asthma, including AHR, lung inflammation, and remodeling in distinct murine models of the disease. These effects are associated with a decrease in lung tissue generation of pro-inflammatory cytokines by a mechanism related to downregulation of NF-kappaB phosphorylation</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00740</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28713373">PM:28713373</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-740.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-740.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Coutinho DS</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00740</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhvania,P.</style></author><author><style face="normal" font="Arial"> Hoyle,N.S.</style></author><author><style face="normal" font="Arial"> Nadareishvili,L.</style></author><author><style face="normal" font="Arial"> Nizharadze,D.</style></author><author><style face="normal" font="Arial"> Kutateladze,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Eliava Phage Therapy Center, Tbilisi, Georgia</style></auth-address><titles><title><style face="normal" font="Arial">Phage Therapy in a 16-Year-Old Boy with Netherton Syndrome</style></title><secondary-title><style face="normal" font="Arial">Front Med (Lausanne)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Med (Lausanne)</style></full-title></periodical><pages end="" start="94">94-</pages><volume><style face="normal" font="Arial">4</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Infections</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Georgia</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Netherton Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal Infections</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Netherton syndrome (NS) is a rare autosomal recessive disorder, characterized by a classical triad of clinical features, including congenital ichthyosiform erythroderma, trichorrhexis invaginata, and atopic diathesis coupled with frequent bacterial infections (1). The genetic basis for the disease has been recently identified with mutations in gene SPINK5, which is involved in the regulation of formation of skin barriers. We report on a 16-year-old male with all the typical manifestations of NS, including atopic diathesis and ongoing serious staphylococcal infections and allergy to multiple antibiotics whose family sought help at the Eliava Phage Therapy Center when all other treatment options were failing. Treatment with several antistaphylococcal bacteriophage preparations led to significant improvement within 7 days and very substantial changes in his symptoms and quality of life after treatment for 6 months, including return visits to the Eliava Phage Therapy Center after 3 and 6 months of ongoing use of phage at home</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 2296-858X (Print)IS - 2296-858X (Linking)LA - engPT - Journal ArticleCO - Georgia -</style></notes><work-type><style face="normal" font="Arial">10.3389/fmed.2017.00094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28717637">PM:28717637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Med (Lausanne)\2017-4-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Med (Lausanne)\2017-4-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Zhvania P</style></custom2><misc3><style face="normal" font="Arial">10.3389/fmed.2017.00094</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kanagaratham,C.</style></author><author><style face="normal" font="Arial"> Camateros,P.</style></author><author><style face="normal" font="Arial"> Ren,J.</style></author><author><style face="normal" font="Arial"> Sladek,R.</style></author><author><style face="normal" font="Arial"> Vidal,S.M.</style></author><author><style face="normal" font="Arial"> Radzioch,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">McGill University; University of British Columbia</style></auth-address><titles><title><style face="normal" font="Arial">Mouse Chromosome 4 Is Associated with the Baseline and Allergic IgE Phenotypes</style></title><secondary-title><style face="normal" font="Arial">G3 (Bethesda)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">G3 (Bethesda)</style></full-title></periodical><pages end="2564" start="2559">2559-2564</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infections</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">Regulation of IgE concentration in the blood is a complex trait, with high concentrations associated with parasitic infections as well as allergic diseases. A/J strain mice have significantly higher plasma concentrations of IgE both at baseline and after ovalbumin antigen exposure when compared to C57BL/6J strain mice. Our objective was to determine the genomic regions associated with this difference in phenotype. To achieve this, we used a panel of recombinant congenic strains (RCS) derived from A/J and C57BL/6J strains. We measured IgE in the RCS panel at baseline and following allergen exposure. Using marker by marker analysis of the RCS genotype and phenotype data, we identified multiple regions associated with the IgE phenotype. A single region was identified to be associated with baseline IgE level, while multiple regions were associated with the phenotype after allergen exposure. The most significant region was found on Chromosome 4 from 81.46 - 86.17 Mbp. Chromosome 4 substitution strain mice had significantly higher concentration of IgE than their background parental strain mice, C57BL/6J. Our data presents multiple candidate regions associated with plasma IgE concentration at baseline and following allergen exposure, with the most significant one located on Chromosome 4</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 2160-1836 (Electronic)IS - 2160-1836 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1534/g3.117.042739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696925">PM:28696925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\G3 (Bethesda)\20170711-KanagarathamC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\G3 (Bethesda)\20170711-KanagarathamC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Kanagaratham C</style></custom2><misc3><style face="normal" font="Arial">10.1534/g3.117.042739</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Q.</style></author><author><style face="normal" font="Arial"> Si,N.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Zhang,D.</style></author><author><style face="normal" font="Arial"> Wang,R.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Wang,S.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Deng,X.</style></author><author><style face="normal" font="Arial"> Ma,Y.</style></author><author><style face="normal" font="Arial"> Ge,P.</style></author><author><style face="normal" font="Arial"> Zhao,J.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, China 6 Tiantanxili, DongCheng District, Beijing 100050, China</style></auth-address><titles><title><style face="normal" font="Arial">Steroid sulfatase and filaggrin mutations in a boy with severe ichthyosis, elevated serum IgE level and moyamoya syndrome</style></title><secondary-title><style face="normal" font="Arial">Gene</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Gene</style></full-title></periodical><pages end="108" start="103">103-108</pages><volume><style face="normal" font="Arial">628</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> filaggrin gene</style></keyword><keyword><style face="normal" font="Arial"> Filaggrin mutation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Ichthyosis</style></keyword><keyword><style face="normal" font="Arial"> ichthyosis vulgaris</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">X-linked ichthyosis (XLI) is a relatively common, recessive condition caused by mutations in the steroid sulfatase (STS) gene. Common loss-of-function mutations in the filaggrin gene (FLG) cause ichthyosis vulgaris and predispose individuals to atopic eczema. We report a case of a 6-year-old boy who presented with unusually severe XLI, an increased serum immunoglobulin E level (2120IU/ml) and moyamoya angiopathy. Whole-exome sequencing identified a gross deletion encompassing the STS in Xp22.31 and the p.K4022X FLG mutation. The deletion is at least 1.6Mb in size in the proband, based on real-time quantitative polymerase chain reaction results. No other genetic mutations related to ichthyosis, moyamoya or hyper-immunoglobulin E syndrome were detected. Furthermore, his mother's brothers suffered from mild XLI and only had a deletion encompassing the STS. Additionally, his father and older sister suffered from mild ichthyosis vulgaris and had the p.K4022X FLG mutation. We report the first case of XLI with concurrent moyamoya syndrome. Moreover, an IgE-mediated immune response may have triggered the moyamoya signaling cascade in this patient with ichthyosis. Furthermore, our study strengthens the hypothesis that filaggrin defects can synergize with an STS deficiency to exacerbate the ichthyosis phenotype in an ethnically diverse population</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1879-0038 (Electronic)IS - 0378-1119 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.gene.2017.07.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28710038">PM:28710038</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Gene\2017-628-103-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Gene\2017-628-103-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Zhang Q</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.gene.2017.07.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tungtrongchitr,A.</style></author><author><style face="normal" font="Arial"> Jumpasri,J.</style></author><author><style face="normal" font="Arial"> Sookrung,N.</style></author><author><style face="normal" font="Arial"> Visitsunthorn,N.</style></author><author><style face="normal" font="Arial"> Tantilipikorn,P.</style></author><author><style face="normal" font="Arial"> Piboonpocanan,O.</style></author><author><style face="normal" font="Arial"> Indrawattana,N.</style></author><author><style face="normal" font="Arial"> Tungtrongchitr,R.</style></author><author><style face="normal" font="Arial"> Chaicumpa,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Faculty of Medicine, Siriraj Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Alteration of -656(G/T) and -607(C/A) polymorphisms in interleukin-18 (IL-18) gene in house dust mite-sensitive allergic rhinitis patients in Thailand</style></title><secondary-title><style face="normal" font="Arial">Genet Mol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Genet Mol Res</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Variation</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-18</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Membranes</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR-RFLP</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) is an IgE-mediated inflammation of the nasal membranes, which is naturally triggered by aeroallergens. House dust mites (HDM) are the most common inhalant allergens. Interleukin-18 (IL-18) has been established as an essential cytokine that can activate the generation of IgE. This randomized controlled study aimed to identify the possible relationship of the genetic variations in the IL-18 gene with AR in mite-sensitive Thai patients. Study subjects consisted of 150 AR patients and 50 normal participants. Genomic DNA of 30 randomized AR patients and 30 randomized controls were screened by sequencing for the selection of candidate single nucleotide polymorphisms (SNPs), and further analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay for all subjects. The following five SNPs were detected in the IL-18 gene: -656 G/T, -607 C/A, and -137 G/C in promoter 1 and -920 C/T and -373 C/G in promoter 2. The results showed that -656 G/T and -607 C/A SNPs were significantly correlated with IgE levels specific to Dermatophagoides pteronyssinus (Der p) allergen (P = 0.045 and P = 0.045, respectively), and significant differences were observed in the genotype distribution of AR patients when compared with controls [P = 0.044 and P = 0.044, respectively; odds ratios (ORs): 1.941 (95%CI, 1.014-3.715) and 1.941 (95%CI, 1.014-3.715), respectively]. Our findings indicate that the IL-18 alleles, -656T (rs1946519) and -607A (rs1946518), might be associated with the higher production of Der p allergen-specific IgE in mite-sensitive AR patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1676-5680 (Electronic)IS - 1676-5680 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.4238/gmr16039641</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28692122">PM:28692122</url></web-urls><pdf-urls><url ppv-ref="no">anchalee.tun@mahidol.ac.th</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170710, Tungtrongchitr A</style></custom2><misc3><style face="normal" font="Arial">10.4238/gmr16039641</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosendahl,J.</style></author><author><style face="normal" font="Arial"> Fogelholm,M.</style></author><author><style face="normal" font="Arial"> Pelkonen,A.</style></author><author><style face="normal" font="Arial"> Makela,M.J.</style></author><author><style face="normal" font="Arial"> Makitie,O.</style></author><author><style face="normal" font="Arial"> Erkkola,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">A History of Cow's Milk Allergy Is Associated with Lower Vitamin D Status in Schoolchildren</style></title><secondary-title><style face="normal" font="Arial">Horm Res Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Horm Res Paediatr</style></abbr-1></periodical><pages end="250" start="244">244-250</pages><volume><style face="normal" font="Arial">88</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Policy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> validated questionnaire</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/AIMS: Vitamin D insufficiency is common in children. We aimed to evaluate the main determinants of vitamin D status in Finnish school-aged children, including the history of allergic diseases. METHODS: We conducted a cross-sectional study on 171 ten-year-olds where serum 25-hydroxyvitamin D (25[OH]D) levels were measured, and data on food consumption and use of vitamin D supplements were collected. The history of allergic diseases was evaluated with a validated questionnaire. RESULTS: Vitamin D insufficiency (&lt;50 nmol/L) was observed in 16% of the children. In children with a history of cow's milk allergy, the mean 25(OH)D levels were lower than in children without allergy (60.5 +/- 12.6 nmol/L vs. 75.5 +/- 22.3 nmol/L, p = 0.004). Lack of vitamin D supplementation, female gender, non-Caucasian ethnicity, and a history of milk allergy were associated with lower vitamin D status. CONCLUSION: The vitamin D status in our study sample of Finnish schoolchildren was sufficient, which suggests that health policy strategies - such as the recommendation of vitamin D supplementation and the fortification of food products with vitamin D - have been successful in improving vitamin D status in children. Special concern should be given to children with a history of milk allergy to ensure their vitamin D sufficiency</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 1663-2826 (Electronic)IS - 1663-2818 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1159/000478779</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28715821">PM:28715821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Horm Res Paediatr\2017-88-244-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Horm Res Paediatr\2017-88-244-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Rosendahl J</style></custom2><misc3><style face="normal" font="Arial">10.1159/000478779</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Graham,F.</style></author><author><style face="normal" font="Arial"> Tardio,N.</style></author><author><style face="normal" font="Arial"> Paradis,L.</style></author><author><style face="normal" font="Arial"> Des Roches,A.</style></author><author><style face="normal" font="Arial"> Begin,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a CHUM, Hopital Notre-Dame , Montreal , QC , Canada</style></auth-address><titles><title><style face="normal" font="Arial">Update on oral immunotherapy for egg allergy</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease modifying effect</style></keyword><keyword><style face="normal" font="Arial"> disease-modifying effect</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> long-term follow-up</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">Oral immunotherapy (OIT) is an emerging treatment for IgE-mediated egg allergy. In the past decade, a multitude of studies have assessed the potential for egg OIT to induce clinical desensitization. The following review will evaluate the efficacy and safety of this therapy as determined by randomized controlled, non-randomized controlled and uncontrolled trials. Recent studies using reduced allergenic egg products and anti-IgE assisted therapy to improve egg OIT safety will also be discussed. Recent advances in the mechanisms underlying food OIT suggest that certain immune parameters may be helpful in monitoring response to therapy, including egg OIT. Although, egg OIT is consistently shown to be effective with regards to clinical desensitization, fewer studies have looked at persistent tolerance or sustained unresponsiveness. Limited results of long-term follow-up trials suggest that this therapy may have disease-modifying effects. In general, the comparison of studies is complicated by major differences in study designs, OIT protocols and endpoints</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1339844</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696863">PM:28696863</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170711-GrahamF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170711-GrahamF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Graham F</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1339844</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sugita,J.</style></author><author><style face="normal" font="Arial"> Asada,Y.</style></author><author><style face="normal" font="Arial"> Ishida,W.</style></author><author><style face="normal" font="Arial"> Iwamoto,S.</style></author><author><style face="normal" font="Arial"> Sudo,K.</style></author><author><style face="normal" font="Arial"> Suto,H.</style></author><author><style face="normal" font="Arial"> Matsunaga,T.</style></author><author><style face="normal" font="Arial"> Fukuda,K.</style></author><author><style face="normal" font="Arial"> Fukushima,A.</style></author><author><style face="normal" font="Arial"> Yokoi,N.</style></author><author><style face="normal" font="Arial"> Ohno,T.</style></author><author><style face="normal" font="Arial"> Azuma,M.</style></author><author><style face="normal" font="Arial"> Ebihara,N.</style></author><author><style face="normal" font="Arial"> Saito,H.</style></author><author><style face="normal" font="Arial"> Kubo,M.</style></author><author><style face="normal" font="Arial"> Nakae,S.</style></author><author><style face="normal" font="Arial"> Matsuda,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Ocular Atopic Diseases, Department of Ophthalmology, Juntendo University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Contributions of Interleukin-33 and TSLP in a papain-soaked contact lens-induced mouse conjunctival inflammation model</style></title><secondary-title><style face="normal" font="Arial">Immun Inflamm Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immun Inflamm Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact Lenses</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Ocular surface</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> TSLP receptor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Pathological changes of severe chronic allergic conjunctivitis are driven not only via acquired immunity but also via innate immunity. Type 2 immune response-initiating cytokines may play some roles as innate immunity-dependent components of the ocular surface inflammation. To investigate the involvement of type 2 immune response-initiating cytokines in innate immunity-dependent, papain-induced conjunctival inflammation model using IL-25-, IL-33-, and TSLP receptor (TSLPR)-knockout (KO) mice with reference to basophils and ILC2. METHODS: Papain-soaked contact lenses (papain-CLs) were installed in the conjunctival sacs of C57BL/6-IL-25 KO, IL-33 KO, TSLPR KO, Rag2 KO, Bas-TRECK, and wild-type mice and their eyes were sampled at day 5. The eosinophil and basophil infiltration in papain-CL model was evaluated histologically and cytokine expression was examined. To clarify the roles of basophils and ILC2, basophil/ILC2-depletion experiments were carried out. RESULTS: Papain-induced conjunctival inflammation exhibited eosinophil infiltration and upregulation of Th2 cytokine expression. Reduction of eosinophil and basophil infiltration and attenuated Th2 cytokine expression were observed in the papain-CL model using IL-33 KO and TSLPR KO mice. Depletion of basophils or ILC2s in the conjunctivae of the papain-CL model reduced eosinophil infiltration. CONCLUSIONS: Innate immunity-driven type 2 immune responses of the ocular surface are dependent on IL-33, TSLP, basophils, and ILC2. These components may be possible therapeutic targets for refractory allergic keratoconjunctivitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1002/iid3.189</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28730605">PM:28730605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Inflamm Dis\20170721-SugitaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Inflamm Dis\20170721-SugitaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Sugita J</style></custom2><misc3><style face="normal" font="Arial">10.1002/iid3.189</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tordesillas,L.</style></author><author><style face="normal" font="Arial"> Berin,M.C.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10034, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunology of Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Immunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunity</style></full-title></periodical><pages end="50" start="32">32-50</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">Many consider food allergy as the "second wave" of the allergy epidemic following the "first wave" of respiratory allergy, i.e., asthma and allergic rhinitis, plaguing westernized countries, with up to 8% of young children and 2%-3% of adults in the United States now affected by hypersensitivity reactions to various foods. In the past decade, there have been great strides in our understanding of the underlying immunopathogenesis of these disorders, which have led to improved diagnostic techniques, management strategies, and therapeutic approaches. Here we will review the most recent understanding of basic mechanisms underlying IgE-mediated food allergies and novel therapeutic approaches under investigation for both the prevention and treatment of IgE-mediated food allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1097-4180 (Electronic)IS - 1074-7613 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.immuni.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28723552">PM:28723552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunity\2017-47-32-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunity\2017-47-32-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Tordesillas L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.immuni.2017.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shibata,T.</style></author><author><style face="normal" font="Arial"> Ato,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, JapanDepartment of Immunology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A critical role of Gas6/Axl signal in allergic airway responses during RSV vaccine-enhanced disease</style></title><secondary-title><style face="normal" font="Arial">Immunol Cell Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Cell Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-Like Receptor 4</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="Arial">Respiratory syncytial virus (RSV) is a common virus that causes lower respiratory infections across a wide range of ages. A licensed RSV vaccine is not available because vaccination with formalin-inactivated RSV (FI-RSV) and the subsequent RSV infection cause not only insufficient induction of neutralizing antibodies but also severe allergic airway responses, termed FI-RSV vaccine enhanced disease (FI-RSV VED). However, the underlying mechanism has not been identified, although a Th2-biased immune response is known to be a hallmark of this disease. Our previous studies have shown that growth arrest-specific 6 (Gas6)/Axl signaling leads to Th2-biased immune responses during fungus-induced allergic airway inflammation. Here, we show that Gas6/Axl signaling also leads to FI-RSV VED and partially identify the mechanism in mice. Inhibiting Gas6/Axl signaling using Gas6-deficient mice, neutralizing antibodies, and a specific inhibitor of Axl attenuated allergic airway hyperresponsiveness, including airway inflammation, goblet cell hyperplasia, and Th2 cytokine production, in addition to increasing interferon-gamma levels and the production of RSV-neutralizing IgG2a in FI-RSV VED. Gas6 was produced in lymph nodes during immunization with FI-RSV. Lymph node cells derived from immunized mice produced high levels of Gas6 and Th2 cytokines, but not IFN-gamma, after restimulation with RSV. Finally, we found that dendritic cells stimulated with RSV-glycoprotein (G protein) produced Gas6 and that Axl signaling suppressed DC maturation and the induction of IL-12 production by the toll-like receptor 4 agonist RSV-fusion protein. Taken together, these results indicate that RSV-G protein-induced Gas6/Axl signaling causes allergic airway responses during FI-RSV VED.Immunology and Cell Biology accepted article preview online, 19 July 2017. doi:10.1038/icb.2017.61</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1440-1711 (Electronic)IS - 0818-9641 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1038/icb.2017.61</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722020">PM:28722020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Cell Biol\20170719.ShibataT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Cell Biol\20170719.ShibataT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Shibata T</style></custom2><misc3><style face="normal" font="Arial">10.1038/icb.2017.61</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shabankarehfard,E.</style></author><author><style face="normal" font="Arial"> Ostovar,A.</style></author><author><style face="normal" font="Arial"> Farrokhi,S.</style></author><author><style face="normal" font="Arial"> Naeimi,B.</style></author><author><style face="normal" font="Arial"> Zaeri,S.</style></author><author><style face="normal" font="Arial"> Nazmara,S.</style></author><author><style face="normal" font="Arial"> Keshtkar,M.</style></author><author><style face="normal" font="Arial"> Sadeghzadeh,F.</style></author><author><style face="normal" font="Arial"> Dobaradaran,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Environmental Health Engineering , Faculty of Health, Bushehr University of Medical Sciences , Bushehr , Iran</style></auth-address><titles><title><style face="normal" font="Arial">Air- and Dust-Borne Fungi in Indoor and Outdoor Home of Allergic Patients in a Dust-Storm-Affected Area</style></title><secondary-title><style face="normal" font="Arial">Immunol Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Invest</style></full-title></periodical><pages end="589" start="577">577-589</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="7" Year="2017">2017/7/25</year></dates><abstract><style face="normal" font="Arial">Despite the recent increases in fungi-induced allergic diseases, there is no report yet in the region of the Persian Gulf on concentration levels of fungi in relationship with health state. Therefore, our aim was to measure fungi prevalence as well as to evaluate the relationships between air- and dust-borne fungal genera and allergic diseases. A matched case-control study was carried out including 45 allergic cases and 45 age- and gender-matched controls for each individual. Indoor and outdoor dust and indoor air samples were collected from participant homes during May to October 2015. A Quick Take 30 Pump and sterile wet swab were used to determine fungal types and their amounts in the air (CFU/m3) and dust (CFU/100 cm2) samples, respectively. A significant reverse association was found between indoor dust-borne Alternaria and asthma (Odds ratio (OR) = 0.14, 95% CI = 0.02-0.86). Contrarily, increased levels of indoor air-borne Aspegillus fumigatus (OR = 2.00, 95% CI = 0.37-10.55) and Alternaria (OR = 3.00, 95% CI = 0.34-25.83) were correlated with asthma development. Also, correlation analysis showed a significant relation between indoor air-borne Penicillium levels and reactivity to skin prick test in asthmatic patients (p = 0.04). Our findings support the notion that fungal exposures can either cause or prevent the development of allergic diseases. Accordingly, appropriate measures should be taken for a better management of fungi-induced allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1532-4311 (Electronic)IS - 0882-0139 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1080/08820139.2017.1322102</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28742415">PM:28742415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Invest\2017-46-577-89.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Invest\2017-46-577-89.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Shabankarehfard E</style></custom2><misc3><style face="normal" font="Arial">10.1080/08820139.2017.1322102</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kartik,M.</style></author><author><style face="normal" font="Arial"> Kanala,A.</style></author><author><style face="normal" font="Arial"> Sunilnadikuda</style></author><author><style face="normal" font="Arial"> Rao,S.M.</style></author><author><style face="normal" font="Arial"> Prakasham,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Critical Care Medicine, Yashoda Multi-Speciality Hospital, Hyderabad, Telangana, India</style></auth-address><titles><title><style face="normal" font="Arial">Invasive Mediastinal Aspergillosis in Immunocompetent Male with Invasion of Left Atrium and Hilar Structures</style></title><secondary-title><style face="normal" font="Arial">Indian J Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Crit Care Med</style></full-title></periodical><pages end="411" start="408">408-411</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Hyphae</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Opportunistic Infections</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Aspergillus is described as mould characterised by septate hyphae about 2-4mu in diameter, it is ubiquitous in nature and spreads by inhalation of spores. It causes opportunistic infections in almost six forms namely Allergic bronchopulmonary aspergillosis, Aspergillus sinusitis, Cutaneous aspergillosis, Aspergilloma, Chronic pulmonary aspergillosis, Invasive aspergillosis. Invasive aspergillosis of mediastinum in an immunocompetent patient has rarely been reported. We present a case of a young male who had presented with chest pain, cough and breathleness was later diagnosed as fulminant mediastinal aspergillosis. Incisional biopsy with histology report and endotracheal cultures helped in diagnosing mediastinal aspergillosis. Despite initiation of the right antifungal therapy and best supportive measures, patient died of septic shock and multiorgan dysfunction. This case report highlights the need for higher suspicion in such cases of mediastinal masses and early tissue biopsy which can help in reducing mortality</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 0972-5229 (Print)IS - 0972-5229 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/ijccm.IJCCM_18_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701850">PM:28701850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Crit Care Med\2017-21-408-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Crit Care Med\2017-21-408-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Kartik M</style></custom2><misc3><style face="normal" font="Arial">10.4103/ijccm.IJCCM_18_17</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamizan,A.W.</style></author><author><style face="normal" font="Arial"> Rimmer,J.</style></author><author><style face="normal" font="Arial"> Alvarado,R.</style></author><author><style face="normal" font="Arial"> Sewell,W.A.</style></author><author><style face="normal" font="Arial"> Kalish,L.</style></author><author><style face="normal" font="Arial"> Sacks,R.</style></author><author><style face="normal" font="Arial"> Harvey,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Positive allergen reaction in allergic and nonallergic rhinitis: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="877" start="868">868-877</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation test</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen provocation test</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skull</style></keyword><keyword><style face="normal" font="Arial"> Skull Base</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The diagnosis of allergic rhinitis (AR) is based on cutaneous and serological assessment to determine immunoglobulin E (IgE)-mediated disease. However, discrepancies between these tests and nasal provocation exist. Patients diagnosed as non-allergic rhinitis (NAR) but with positive nasal allergen provocation test (NAPT) may represent a local allergic condition or entopy, still suitable to allergy interventions. The objective of this study was to determine the frequency of nasal reactivity toward allergens among AR and NAR patients, and to describe the diagnostic characteristics of NAPT methodologies. METHODS: EMBASE (1947-) and Medline (1946-) were searched until December 8, 2015. A search strategy was used to identify studies on AR or NAR patients subjected to diagnostic local nasal provocation. All studies providing original NAPT data among the AR or NAR population were included. Meta-analysis of proportion data was presented as a weighted probability % (95% confidence interval [CI]). RESULTS: The search yielded 4504 studies and 46 were included. The probability of nasal allergen reactivity for the AR population was 86.3% (95% CI, 84.4 to 88.1) and in NAR was 24.7% (95% CI, 22.3 to 27.2). Reactivity was high with pollen for both AR 97.1% (95% CI, 94.2 to 99.2) and NAR 47.5% (95% CI, 34.8 to 60.4), and lowest with dust for both AR 79.1% (95% CI, 76.4 to 81.6) and NAR 12.2% (95% CI, 9.9 to 14.7). NAPT yielded high positivity when defined by subjective end-points: AR 91.0% (95% CI, 86.6 to 94.8) and NAR 30.2% (95% CI, 22.9 to 37.9); and lower with objective end-points: AR 80.8% (95% CI, 76.8 to 84.5) and NAR 14.1% (95% CI, 11.2 to 17.2). CONCLUSION: Local allergen reactivity is demonstrated in 26.5% of patients previously considered non-allergic. Similarly, AR, when defined by skin-prick test (SPT) or serum specific IgE (sIgE), may lead to 13.7% of patients with inaccurate allergen sensitization or non-allergic etiologies</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21988</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28727909">PM:28727909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170720-HamizanAW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170720-HamizanAW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Hamizan AW</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21988</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yosri,H.</style></author><author><style face="normal" font="Arial"> Elkashef,W.F.</style></author><author><style face="normal" font="Arial"> Said,E.</style></author><author><style face="normal" font="Arial"> Gameil,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pharmacology and Toxicology Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt</style></auth-address><titles><title><style face="normal" font="Arial">Crocin modulates IL-4/IL-13 signaling and ameliorates experimentally induced allergic airway asthma in a murine model</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="312" start="305">305-312</pages><volume><style face="normal" font="Arial">50</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma progression</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lactate Dehydrogenase</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Edema</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a chronic respiratory disease with a prevalent T helper (Th2)-mediated immune reaction. Crocin, the major bioactive constituent of saffron, has been reported in multiple studies to have numerous pharmacological activities, including prominent anti-oxidant activities. In the current study, the anti-asthmatic potential of crocin was evaluated. Adult male Swiss Albino mice were administered 10mg of ovalbumin (OVA) mixed with 1mg of aluminum hydroxide intraperitoneally on days 0 and 7 and were administered crocin (25mg/kg) orally daily for 16days. Asthma progression was associated with significant increase in the lung/body weight index, inflammatory cell counts in bronchoalveolar lavage fluid (BALF), lung total protein content, and serious index of lung permeability, indicating pulmonary edema with accumulation of serous fluids within the lungs. Serum lactate dehydrogenase (LDH) activity and lung malondialdehyde (MDA) content were significantly increased, while lung superoxide dismutase (SOD) activity, reduced glutathione (GSH) levels, and serum and lung catalase activities were significantly decreased. These changes reflect significant pulmonary inflammation with concomitant disturbance of oxidant/antioxidant homeostasis. Moreover, tumor necrosis factor (TNF)-alpha, interleukin (IL)-4, and IL-13 contents in the lung were also significantly high after OVA sensitization. Crocin treatment significantly alleviated the OVA-induced allergic asthma-associated alterations in inflammatory and oxidative stress biomarkers. Crocin enhanced anti-oxidant defenses, reduced the incidence of oxidative stress, and restored pro-inflammatory cytokines to normal levels. Histopathological analysis showed significant lung improvement in crocin-treated mice. In conclusion, crocin showed a significant protective effect against allergic asthma progression, which was associated with down-regulation of inflammatory cytokine expression and restoration of oxidant/antioxidant homeostasis</style></abstract><notes><style face="normal" font="Arial">DA - 20170724IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28738246">PM:28738246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-50-305-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-50-305-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170724, Yosri H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.07.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Humeniuk,P.</style></author><author><style face="normal" font="Arial"> Dubiela,P.</style></author><author><style face="normal" font="Arial"> Hoffmann-Sommergruber,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna 1090, Austria. piotr.humeniuk@meduniwien.ac.atDepartment of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna 1090, Austria. pawel.dubiela@meduniwien.ac.atDepartment of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna 1090, Austria. karin.hoffmann@meduniwien.ac.at</style></auth-address><titles><title><style face="normal" font="Arial">Dendritic Cells and Their Role in Allergy: Uptake, Proteolytic Processing and Presentation of Allergens</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1491">E1491-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">Dendritic cells (DCs) are the most important antigen presenting cells to activate naive T cells, which results in the case of Type 1 allergies in a Type 2 helper T cell (Th2)-driven specific immune response towards allergens. So far, a number of different subsets of specialized DCs in different organs have been identified. In the recent past methods to study the interaction of DCs with allergenic proteins, their different uptake and processing mechanisms followed by the presentation to T cells were developed. The following review aims to summarize the most important characteristics of DC subsets in the context of allergic diseases, and highlights the recent findings. These detailed studies can contribute to a better understanding of the pathomechanisms of allergic diseases and contribute to the identification of key factors to be addressed for therapeutic interventions</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18071491</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696399">PM:28696399</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\20170711-HumeniukP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\20170711-HumeniukP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Humeniuk P</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18071491</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kong,Q.</style></author><author><style face="normal" font="Arial"> Kitaoka,M.</style></author><author><style face="normal" font="Arial"> Wakabayashi,R.</style></author><author><style face="normal" font="Arial"> Kamiya,N.</style></author><author><style face="normal" font="Arial"> Goto,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Applied Chemistry, Kyushu University, 744 Moto-oka, 819-0395, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Transcutaneous immunotherapy of pollinosis using solid-in-oil nanodispersions loaded with T cell epitope peptides</style></title><secondary-title><style face="normal" font="Arial">Int J Pharm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Pharm</style></full-title></periodical><pages end="409" start="401">401-409</pages><volume><style face="normal" font="Arial">529</style></volume><number><style face="normal" font="Arial">1-2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> epitope peptide</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergies</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual administration</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">Pollinosis, a typical seasonal allergy, is a serious public health problem. Limited numbers of patients receive curative immunotherapy instead of symptomatic therapy; however, there are still some concerns about the inconvenience and side effects of subcutaneous injections and sublingual administration caused by immunotherapy. Here, we propose a simple and safe transcutaneous immunotherapy using solid-in-oil (S/O) nanodispersions loaded with vaccine T cell epitope peptides derived from pollen allergen. S/O nanodispersions are oil-based dispersions of antigens coated with hydrophobic surfactants. They have a high potential to deliver biomolecules including peptides or proteins to immune cells in the skin, and to induce an immune response. The result of quantitative and qualitative analysis by in vitro permeation experiments demonstrated the effective permeation of T cell epitope peptides into the skin. Furthermore, in vivo experiments using a pollinosis mouse model indicated that the S/O nanodispersions loaded with T cell epitopes suppressed serum antibody IgE and cytokine production, and alleviated allergic symptoms to a similar therapeutic level to that observed for subcutaneous injection. These results indicate the potential of transcutaneous immunotherapy using S/O nanodispersions for the future treatment of pollinosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1873-3476 (Electronic)IS - 0378-5173 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijpharm.2017.07.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28705615">PM:28705615</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Pharm\20170714-KongQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Pharm\20170714-KongQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Kong Q</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijpharm.2017.07.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Erel,F.</style></author><author><style face="normal" font="Arial"> Sarioglu,N.</style></author><author><style face="normal" font="Arial"> Kose,M.</style></author><author><style face="normal" font="Arial"> Kaymakci,M.</style></author><author><style face="normal" font="Arial"> Gokcen,M.</style></author><author><style face="normal" font="Arial"> Kepekci,A.H.</style></author><author><style face="normal" font="Arial"> Arslan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Faculty of Medicine, Balikesir University, Balikesir, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Intradermal Skin Testing in Allergic Rhinitis and Asthma with Negative Skin Prick Tests</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="197" start="193">193-197</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Taking medical history, physical examination, and performing some in vivo and in vitro tests are necessary for the diagnosis of allergy. Skin prick test (SPT) is considered as the standard method and first-line approach for the detection of allergic sensitization. Although mainly SPT is used for the detection of allergic sensitization, intradermal skin test (IDST) may be necessary, especially in patients with a negative SPT result. IDST is quite safe; however, is nowadays seldom used for detection of inhalant allergy and its value remains controversial. We aimed to investigate whether IDST is useful and necessary in diagnosis of respiratory allergies or not. This study involved 4223 patients with allergic rhinitis (AR) and/or bronchial asthma (BA). SPT results were positive in 2419 patients (57%) and negative in 1804 (43%). IDST was applied to 344 patients with marked allergic symptoms and with negative SPT results. Out of 344 patients, 152 (44%) showed allergic sensitization to IDST. The most commonly encountered allergic response was against the house dust mite (HDM) (32.6%). Allergic response against fungal spores was also relatively high (22%), while the pollen allergy rate (4.3%) was quite low. In BA patients with negative prick test, IDST made a significant contribution to the diagnosis of HDM allergy (p=0.003). To avoid missed diagnosis of AR and BA, particularly regarding the HDM allergy, application of IDST may be beneficial; therefore, IDST should be considered as the next step after SPT for diagnosis of allergy prior to in vitro or provocation tests</style></abstract><notes><style face="normal" font="Arial">DA - 20170722IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732432">PM:28732432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-193-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-193-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170722, Erel F</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ebrahimi,M.</style></author><author><style face="normal" font="Arial"> Gharagozlou,M.</style></author><author><style face="normal" font="Arial"> Mohebbi,A.</style></author><author><style face="normal" font="Arial"> Hafezi,N.</style></author><author><style face="normal" font="Arial"> Azizi,G.</style></author><author><style face="normal" font="Arial"> Movahedi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Neonatal and Children's Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran AND Department of Allergy and Clinical Immunology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, IranDepartment of Allergy and Clinical Immunology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">The Efficacy of Oral Immunotherapy in Patients with Cow's Milk Allergy</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="192" start="183">183-192</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Cow's milk allergy is the most common type of food allergy that decrease the quality of life of patients and their families. The aim of this study was to evaluate the efficacy of oral immunotherapy in patients with cow's milk allergy. 14 patients above 3 years of age with a history of cow's milk allergy confirmed by positive double blind placebo controlled food challenge (DBPCFC) test, presence of serum IgE against cow's milk and positive SPT (skin prick test) were enrolled in this study. During the immunotherapy all patients received increasing amounts of cow's milk during three phases. The type and severity of allergic reactions were recorded after each dose. The serum IgE and SPT were measured at the beginning and at the end of study. Since February 2014 to March 2015, 14 patients with the median age of 4.75 (3.7-7) years were studied. 13 patients (92.9%) completed the build up and maintenance phase successfully and became desensitized to cow's milk. During the build up and maintenance phase, 24 (2.0%) and 11 (0.9%) episodes of allergic reactions occurred, respectively. The median serum IgE level against cow's milk proteins and casein decreased from 39.3 to 10.4 and 7.72 to 2.83 (ku/L), respectively. The median of the difference of the wheal diameter in SPT with the control, decreased from 10 to 6 mm during the immunotherapy protocol. Oral immunotherapy is effective to decrease the frequency and the severity of allergic reactions but due to high rate of allergic reactions and possible anaphylaxis, it must be done under strict supervision of both clinicians and caregivers</style></abstract><notes><style face="normal" font="Arial">DA - 20170722IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732431">PM:28732431</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-183-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-183-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170722, Ebrahimi M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Verstappen,J.</style></author><author><style face="normal" font="Arial"> Mirosa,M.</style></author><author><style face="normal" font="Arial"> Thomson,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Using the Systems-Practice Framework to Understand Food Allergen Management Practices at College Catering Operations: A Qualitative Study</style></title><secondary-title><style face="normal" font="Arial">J Acad Nutr Diet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Acad Nutr Diet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen management</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> Catering</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Focus Groups</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food allergen management</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Foodservice</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The number of individuals with food allergies or intolerances attending catered university residential colleges is increasing, and safe dining options are required to minimize the risk of allergic reactions and food-induced death. OBJECTIVE: This qualitative research study sought to advance professional knowledge of the factors affecting allergen management practices, particularly pertaining to college foodservices. DESIGN: Three catered residential colleges affiliated with a major university in New Zealand were selected as research sites. The study used an ethnographic approach and systems-practice theory as a framework for data collection and organizing results. Data collection techniques included document analyses (3 hours per site), observations (6 to 8 hours per site), focus groups with foodservice workers (30 to 45 minutes per site, n=16), and interviews with foodservice managers (45 to 90 minutes per interview, n=5). Notes and transcripts were coded through the process of thematic analysis using NVivo for Mac software, version 11.1.1, to identify factors affecting allergen management practices. RESULTS: The main factors affecting allergen management practices at college foodservices included information provided by residents about dietary requirements; communication between residents and foodservice staff; systems for allergen management; attitude of foodservice staff; and college size. CONCLUSIONS: Detailed dietary information, effective communication with residents, sufficient resources, clarification of responsibilities, and thorough systems are required for staff to perform safe allergen management practices. Ultimately, successful implementation was predominantly determined by staff attitude. Foodservice managers are advised to identify motivators and address barriers of staff attitudes toward allergen management practices to promote successful implementation</style></abstract><notes><style face="normal" font="Arial">DA - 20170709IS - 2212-2672 (Print)IS - 2212-2672 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jand.2017.05.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28688885">PM:28688885</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Acad Nutr Diet\20170709-VerstappenJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Acad Nutr Diet\20170709-VerstappenJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170709, Verstappen J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jand.2017.05.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jin,T.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Chen,Y.W.</style></author><author><style face="normal" font="Arial"> Guo,F.</style></author><author><style face="normal" font="Arial"> Howard,A.</style></author><author><style face="normal" font="Arial"> Cao,M.J.</style></author><author><style face="normal" font="Arial"> Fu,T.J.</style></author><author><style face="normal" font="Arial"> McHugh,T.H.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">CRYSTAL STRUCTURE OF COCOSIN, A POTENTIAL FOOD ALLERGEN FROM COCONUT (Cocos nucifera)</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">11S</style></keyword><keyword><style face="normal" font="Arial"> 11S globulin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Coconut</style></keyword><keyword><style face="normal" font="Arial"> Cocos</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Crystallization</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genomic DNA</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">Coconut (Cocos nucifera) is an important palm tree. Coconut fruit is widely consumed. The most abundant storage protein in coconut fruit is cocosin (a likely food allergen), which belongs to the 11S globulin family. Cocosin was crystallized near a century ago, but its structure remains unknown. By optimizing crystallization conditions and cryoprotectant solutions, we were able to obtain cocosin crystals that diffracted to 1.85 A. The cocosin gene was cloned from genomic DNA isolated from dry coconut tissue. The protein sequence deduced from the predicted cocosin coding sequence was used to guide model building and structure refinement. The structure of cocosin was determined, for the first time, and it revealed a typical 11S globulin feature of a double layer doughnut-shaped hexamer</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b02252</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28712292">PM:28712292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170717-JinT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170717-JinT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Jin T</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b02252</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hu,M.</style></author><author><style face="normal" font="Arial"> Liu,G.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Pan,T.M.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Sun,L.</style></author><author><style face="normal" font="Arial"> Cao,M.J.</style></author><author><style face="normal" font="Arial"> Liu,G.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cloning, expression, and the effects of processing on sarcoplasmic-calcium-binding protein, an important allergen in mud crab</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> digestion assay</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE titer</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-titer</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> sarcoplasmic</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> SCP</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shellfish allergy</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">Shellfish allergy is a prevalent, long-lasting disorder usually persisting throughout life. However, the allergen information is incomprehensive in crab. This study aimed to identify a novel allergen in crab, show its potential in diagnosis and reduce the allergenicity by food processing. A 21-kDa protein was purified from Scylla paramamosain and confirmed as sarcoplasmic calcium binding protein (SCP) by MALDI-TOF/TOF-MS. Total RNA was isolated from crab muscle and a rapid amplification of cDNA was performed to obtain an ORF of 579 bp that coded for 193 amino acid residues. According to the results of Circular dichroism analysis and ELISA assay, the recombinant SCP (rSCP) expressed in Escherichia coli showed similar physicochemical and immunoreactive properties to native SCP (nSCP). Additionally, the extensive cross reactivity of SCP among different species and the bi-directional IgE cross-reactivity between nSCP and rSCP were detected by iELISA. The allergenicity of rSCP was reduced via Maillard reaction or enzymatic cross-linking reaction, which was confirmed by the results of scanning electron microscopy, dot blot, and digestion assay. A straightforward and reproducible way was developed to obtain high yields of rSCP that maintains structural integrity and full IgE reactivity, which could compensate the low specific IgE-titers of most patient sera for future diagnosis. Furthermore, Maillard reaction and enzymatic cross-linking reaction were effective approaches for the production of hypoallergenic seafood</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b02381</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28692255">PM:28692255</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170710-HuM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170710-HuM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Hu M</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b02381</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gergen,P.J.</style></author><author><style face="normal" font="Arial"> Mitchell,H.E.</style></author><author><style face="normal" font="Arial"> Calatroni,A.</style></author><author><style face="normal" font="Arial"> Sever,M.L.</style></author><author><style face="normal" font="Arial"> Cohn,R.D.</style></author><author><style face="normal" font="Arial"> Salo,P.M.</style></author><author><style face="normal" font="Arial"> Thorne,P.S.</style></author><author><style face="normal" font="Arial"> Zeldin,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Immunology and Transplantation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address: pgergen@niaid.nih.govRho Federal Systems Division, Inc, Chapel Hill, NC</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization and Exposure to Pets: The Effect on Asthma Morbidity in the US Population</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="107" start="101">101-107</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although pets are found in more than 50% of US homes, the effect of pet allergen exposure on asthma morbidity in the US population is not well documented. OBJECTIVE: To determine the effect of dog and cat allergen exposures on asthma morbidity in the US population. METHODS: The National Health and Nutrition Examination Survey is a representative sample of civilian US population. Data on asthma, dog and cat allergen levels in bedroom dust, as well as specific IgE to dog and cat were analyzed for all participants 6 years or older. RESULTS: Pets are common in the United States, with more that 50% of households having a dog or a cat or both. The prevalence of allergic sensitization in the National Health and Nutrition Examination Survey population was similar for dog and cat, with both being approximately 12%. Among those who were sensitized, exposure to elevated levels of pet allergens was associated with an increased prevalence of asthma and asthma attacks. Indeed, 44.2% of the asthma attacks were attributable to exposure to high levels of dog allergen in the bedroom among patients with asthma sensitive to dog and 30.3% were attributable to cat allergen exposure among the comparable cat-sensitive and exposed group. Projecting these results to the US population indicates more than 1 million increased asthma attacks each year for the dog-sensitive and exposed group and more than 500,000 increased asthma attacks for the cat-sensitive and exposed population of patients with asthma. CONCLUSIONS: Exposure to elevated levels of dog and cat allergens among those sensitized individuals with asthma is associated with excess asthma attacks. Reducing pet allergen exposures has the potential for a significant decrease in asthma morbidity</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28694047">PM:28694047</url></web-urls><pdf-urls><url ppv-ref="no">pgergen@niaid.nih.gov</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170711, Gergen PJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Epstein,T.E.</style></author><author><style face="normal" font="Arial"> Tankersley,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Allergy, and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio; Allergy Partners of Central Indiana, Indianapolis, Ind</style></auth-address><titles><title><style face="normal" font="Arial">Are Allergen Immunotherapy Dose Adjustments Needed for Local Reactions, Peaks of Season, or Gaps in Treatment?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1233" start="1227">1227-1233</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709818">PM:28709818</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170715-EpsteinTE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170715-EpsteinTE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Epstein TE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nanda,A.</style></author><author><style face="normal" font="Arial"> Wasan,A.</style></author><author><style face="normal" font="Arial"> Sussman,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma and Allergy Center, Lewisville and Flower Mound, Texas; Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Texas.</style></auth-address><titles><title><style face="normal" font="Arial">Provider Health and Wellness</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1548" start="1543">1543-1548</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic Health Records</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flower</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Records</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Malpractice</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Errors</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> quality of care</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Suicide</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="Arial">Provider health and wellness is a significant issue and can impact patient care, including patient satisfaction, quality of care, medical errors, malpractice risk, as well as provider and office staff turnover and early retirement. Health and wellness encompasses various areas including burnout, depression, divorce, and suicide and affects providers of all specialties and at all levels of training. Providers deal with many everyday stresses, including electronic health records, office politics, insurance and billing issues, dissatisfied patients, and their own personal and family issues. Approximately half of all physicians suffer from burnout, and the rate of burnout among physicians of all specialties is increasing. An important first step in dealing with burnout is recognition and then seeking assistance. Strategies to prevent and treat burnout include increasing provider resiliency as well as implementing practical changes in the everyday practice of medicine. There is currently very little data regarding health and wellness specifically in the field of allergy and immunology, and studies are necessary to determine the prevalence of burnout and related issues in this field. Many medical specialties as well as state and national medical associations have health and wellness committees and other resources, which are essential for providers. Health and wellness programs should be introduced early in a provider's training and continued throughout a provider's career</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734859">PM:28734859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1543-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1543-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Nanda A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hekking,P.W.</style></author><author><style face="normal" font="Arial"> Amelink,M.</style></author><author><style face="normal" font="Arial"> Wener,R.R.</style></author><author><style face="normal" font="Arial"> Bouvy,M.L.</style></author><author><style face="normal" font="Arial"> Bel,E.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Comorbidities in Difficult-to-Control Asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="113" start="108">108-113</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fluticasone</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Difficult-to-control asthma is associated with significant medical and financial burden. Comorbidities are known to contribute to uncontrolled asthma. Better insight into the prevalence, nature, and risk factors of comorbidities may optimize treatment strategies in patients with difficult-to-control asthma and decrease disease burden. OBJECTIVES: The objectives of this study were to assess the prevalence, number, and type of comorbidities in difficult-to-control asthma compared with not-difficult-to-control asthma, and to investigate whether specific patient characteristics are associated with particular comorbidities. METHODS: A total of 5,002 adult patients with a prescription for high-dose (>1,000 mug) fluticasone or oral corticosteroids, extracted from 65 Dutch pharmacy databases, were sent questionnaires about patient characteristics. Of the 2,312 patients who returned the questionnaires, 914 were diagnosed with difficult-to-control asthma. Diagnoses of comorbidities (gastroesophageal reflux, nasal polyps, cardiovascular disease, anxiety/depression, obesity, and diabetes) were based on treatment prescriptions or questionnaires. Associations were assessed using multivariable logistic regression analyses. RESULTS: A total of 92% of patients with difficult-to-control asthma had >/=1 comorbidity. Patients with difficult-to-control asthma had more comorbidities (mean +/- SD comorbidities 2.22 +/- 1.27 vs 1.69 +/- 1.32; P &lt; .01), and a significantly higher prevalence of each comorbidity, compared with patients with not-difficult-to-control asthma, except for diabetes and nasal polyposis. Comorbidities were associated with specific patient characteristics, including older age, female gender, smoking history, and chronic prednisone use. CONCLUSIONS: Almost all patients with difficult-to-control asthma have comorbidities, in particular asthmatic women of older age, former smokers, and asthmatics who are prednisone dependent. Recognition of these typical characteristics can help physicians in the diagnostic workup, so that adequate preventive measures can be taken</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734857">PM:28734857</url></web-urls><pdf-urls><url ppv-ref="no">p.w.hekking@amc.uva.nl</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170723, Hekking PW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sperlich,J.M.</style></author><author><style face="normal" font="Arial"> Grimbacher,B.</style></author><author><style face="normal" font="Arial"> Workman,S.</style></author><author><style face="normal" font="Arial"> Haque,T.</style></author><author><style face="normal" font="Arial"> Seneviratne,S.L.</style></author><author><style face="normal" font="Arial"> Burns,S.O.</style></author><author><style face="normal" font="Arial"> Reiser,V.</style></author><author><style face="normal" font="Arial"> Vach,W.</style></author><author><style face="normal" font="Arial"> Hurst,J.R.</style></author><author><style face="normal" font="Arial"> Lowe,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="168" start="159">159-168</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> common variable immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> CVID</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Multiplex PCR</style></keyword><keyword><style face="normal" font="Arial"> Multiplex-PCR</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> virology</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients with common variable immunodeficiency (CVID) suffer frequent respiratory tract infections despite immunoglobulin replacement and are prescribed significant quantities of antibiotics. The clinical and microbiological nature of these exacerbations, the symptomatic triggers to take antibiotics, and the response to treatment have not been previously investigated. OBJECTIVES: To describe the nature, frequency, treatment, and clinical course of respiratory tract exacerbations in patients with CVID and to describe pathogens isolated during respiratory tract exacerbations. METHODS: We performed a prospective diary card exercise in 69 patients with CVID recruited from a primary immunodeficiency clinic in the United Kingdom, generating 6210 days of symptom data. We collected microbiology (sputum microscopy and culture, atypical bacterial PCR, and mycobacterial culture) and virology (nasopharyngeal swab multiplex PCR) samples from symptomatic patients with CVID. RESULTS: There were 170 symptomatic exacerbations and 76 exacerbations treated by antibiotics. The strongest symptomatic predictors for commencing antibiotics were cough, shortness of breath, and purulent sputum. There was a median delay of 5 days from the onset of symptoms to commencing antibiotics. Episodes characterized by purulent sputum responded more quickly to antibiotics, whereas sore throat and upper respiratory tract symptoms responded less quickly. A pathogenic virus was isolated in 56% of respiratory exacerbations and a potentially pathogenic bacteria in 33%. CONCLUSIONS: Patients with CVID delay and avoid treatment of symptomatic respiratory exacerbations, which could result in structural lung damage. However, viruses are commonly represented and illnesses dominated by upper respiratory tract symptoms respond poorly to antibiotics, suggesting that antibiotic usage could be better targeted</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United KIngdom -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734862">PM:28734862</url></web-urls><pdf-urls><url ppv-ref="no">d.lowe@ucl.ac.uk</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170723, Sperlich JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Joshi,S.</style></author><author><style face="normal" font="Arial"> Khan,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Texas Southwestern Medical Center, Dallas, Texas</style></auth-address><titles><title><style face="normal" font="Arial">The expanding field of biologics in the management of chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1499" start="1489">1489-1499</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">angioedema</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="Arial">Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternative therapies for refractory cases. Largely based on the success of biologics for various diseases, this class of drugs has come to the forefront of medical research. The first and only Food and Drug Administration-approved biologic for the management of CU is omalizumab (humanized anti-IgE mAb). In the past decade, a substantial amount of research has been centered on the mechanism of action, efficacy, dosing, and safety of omalizumab. This review will focus on the data surrounding the management of CU with omalizumab, off-label use of other biologics for CU, and biologics currently under investigation for use in CU. We will also discuss management considerations and areas of interest for future research</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734860">PM:28734860</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1489-99.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1489-99.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Joshi S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Davis,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Health &amp; Engineering Johns Hopkins Bloomberg School of Public Health 615 N. Wolfe St., Baltimore MD 21205.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of home exposure to Staphylococcus aureus on asthma in adolescents</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Enterotoxins</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="Arial">This is the first study to find that environmental Staphylococcus aureus and staphylococcal enterotoxins in a national population of inner-city adolescents with asthma are common and have the potential to drive asthma symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739287">PM:28739287</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170725-DavisMF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170725-DavisMF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Davis MF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,P.</style></author><author><style face="normal" font="Arial"> Su,H.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Hu,X.</style></author><author><style face="normal" font="Arial"> Yang,F.</style></author><author><style face="normal" font="Arial"> Lu,J.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Transplantation Biology Research Division, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Phosphatase Wip1 controls the development of Th9 cells and allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy therapy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic asthma is one of the most common diseases worldwide, resulting in a burden of diseases. No available therapeutic regimens can cure asthma so far. OBJECTIVE: To identify new molecular targets for Th9 cells-mediated allergic airway inflammation. METHODS: Wild-type p53-induced phosphatase 1 (Wip1) gene knockout mice, Wip1 inhibitor-treated mice and ovalbumin (OVA)-induced allergic airway inflammation mouse models were employed to characterize the roles of Wip1 in allergic airway inflammation. The induction of Th cell subsets in vitro, real-time PCR, immunoblots, luciferase assay and ChIP assays were employed to determine the regulatory pathways of Wip1 in Th9 differentiation. RESULTS: We herein demonstrate that Wip1-deficient mice are less prone to allergic airway inflammation as indicated by the decreased pathological alterations in lungs. Short-term treatment of Wip1-specific inhibitor significantly ameliorates allergic inflammation progression. Intriguingly, Wip1 selectively impaired Th9 cell but not Th1, Th2 and Th17 cell differentiation. Biochemical assays show that Wip1 deficiency increases c-Jun/c-Fos activity in a JNK-dependent manner and that c-Jun/c-Fos directly binds to Il-9 promoter and inhibits Il-9 transcription. CONCLUSION: Phosphatase Wip1 controls Th9 cell development through regulating c-Jun/c-Fos activity on Il-9 promoter and is important for the pathogenesis of allergic airway inflammation. These findings shed lights on the previously unrecognized roles of Wip1 in Th9 cell differentiation. The inhibitory effects of a Wip1 inhibitor on the pathogenesis of allergic airway inflammation may have important implications for clinical application of Wip1 inhibitors in allergy therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20170722IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732646">PM:28732646</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170722-WangP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170722-WangP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170722, Wang P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mukherjee,M.</style></author><author><style face="normal" font="Arial"> Bulir,D.C.</style></author><author><style face="normal" font="Arial"> Radford,K.</style></author><author><style face="normal" font="Arial"> Kjarsgaard,M.</style></author><author><style face="normal" font="Arial"> Huang,C.M.</style></author><author><style face="normal" font="Arial"> Jacobsen,E.A.</style></author><author><style face="normal" font="Arial"> Ochkur,S.I.</style></author><author><style face="normal" font="Arial"> Catuneanu,A.</style></author><author><style face="normal" font="Arial"> Lamothe-Kipnes,H.</style></author><author><style face="normal" font="Arial"> Mahony,J.</style></author><author><style face="normal" font="Arial"> Lee,J.J.</style></author><author><style face="normal" font="Arial"> Lacy,P.</style></author><author><style face="normal" font="Arial"> Nair,P.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respirology, McMaster University, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Sputum autoantibodies in severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antinuclear antibodies</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-Cell Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-2</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The persistence of eosinophils in sputum despite high doses of corticosteroids indicates disease severity in asthma. Chronic inflamed airways over time may lose tolerance to immunogenic entities released upon frequent eosinophil degranulation, which further contributes to disease severity and necessitates increase in maintenance corticosteroids. OBJECTIVES: To investigate the possibility of a polyclonal autoimmune event in asthmatic airways, and identify associated clinical and molecular characteristics. METHODS: Presence of autoantibodies against eosinophil peroxidase (EPX) and anti-nuclear antibodies (ANAs) was investigated in eosinophilic asthmatics maintained on high dose corticosteroids and/or prednisone. The ability of sputum immunoglobulins to induce eosinophil degranulation in vitro was assessed. In addition, the associated inflammatory micro-environment in patients with detectable autoantibodies was examined. RESULTS: We report a "polyclonal" autoimmune event occurring in the airways of prednisone-dependent asthmatics with increased eosinophil activity and/or recurrent pulmonary infections, evident by the concomitant presence of sputum anti-EPX and ANAs of the IgG subtype. Extensive cytokine profiling of the sputum revealed a Th2-dominated micro-environment (eotaxin-2, IL-5, IL-18, IL-13), and increased signalling molecules that support the formation of ectopic lymphoid structures (B-cell activating factor, B-cell attracting chemokine-1). Immunoprecipitated sputum immunoglobulins from patients with increased autoantibodies triggered eosinophil degranulation in vitro, with release of extensive histone-rich extracellular-traps; an event unsuppressed by dexamethasone possibly contributing to the steroid-unresponsive nature of these eosinophilic patients. CONCLUSION: This study identifies an "autoimmune" endotype of severe asthma that can be identified by the presence of sputum autoantibodies against EPX and autologous cellular components</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28751233">PM:28751233</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170728-MukherjeeM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170728-MukherjeeM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Mukherjee M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Casale,T.B.</style></author><author><style face="normal" font="Arial"> Cox,L.S.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Golden,D.B.K.</style></author><author><style face="normal" font="Arial"> Bons,B.</style></author><author><style face="normal" font="Arial"> Didier,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy &amp; Immunology, University of South Florida, Tampa, Fla.</style></auth-address><titles><title><style face="normal" font="Arial">Safety Review of 5-Grass Pollen Tablet from Pooled Data of Clinical Trials</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1727" start="1717">1717-1727</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Beta-2 agonists</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> sublingual tablet</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The 5-grass pollen sublingual tablet has been approved for the treatment of grass pollen-induced allergic rhinoconjunctivitis in subjects with or without intermittent asthma. OBJECTIVE: To provide a comprehensive analysis of the safety profile of the 5-grass tablet on the basis of pooled data from 8 clinical trials. METHODS: Subjects (5-65 years old) with medically confirmed grass pollen-induced allergic rhinoconjunctivitis were included in the double-blind studies. Those with intermittent asthma not requiring treatment other than inhaled beta-2 agonists could participate. Randomized subjects received a 5-grass or placebo tablet daily 2 or 4 months preseasonally and coseasonally (5 single-season studies, over 3 years in a long-term study) or outside the season (phase I studies). Adverse events were pooled and analyzed descriptively. RESULTS: Among 2,512 subjects enrolled, 1,514 received the 5-grass tablet. A total of 1,038 adults and 154 pediatric (5-17 years old) subjects were treated with the 300 Index of Reactivity dose (vs 840 and 158 placebo recipients, respectively); 17% had intermittent asthma, and 62% were polysensitized. Adverse reactions (ADRs) reported in more than 10% of actively treated subjects were mild or moderate application-site reactions, for example, oral pruritus 25% (placebo 4%) and throat irritation 21% (placebo 3%). These generally occurred during the first week of treatment and decreased over time. They led to discontinuation in less than 2.5% of subjects. None of the 3 serious ADRs were reports of anaphylaxis. No notable differences were detected in terms of incidence, nature, and severity of ADRs between adult and pediatric populations, nor between subjects with or without asthma. CONCLUSIONS: The pooled analysis in 1,514 subjects from 8 clinical studies demonstrates that the 5-grass pollen sublingual tablet has a similar good safety profile in adult and pediatric patients with or without mild, intermittent asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Germany -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734858">PM:28734858</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1717-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1717-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Casale TB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tham,E.H.</style></author><author><style face="normal" font="Arial"> Lee,B.W.</style></author><author><style face="normal" font="Arial"> Chan,Y.H.</style></author><author><style face="normal" font="Arial"> Loo,E.X.L.</style></author><author><style face="normal" font="Arial"> Toh,J.Y.</style></author><author><style face="normal" font="Arial"> Goh,A.</style></author><author><style face="normal" font="Arial"> Teoh,O.H.</style></author><author><style face="normal" font="Arial"> Yap,F.</style></author><author><style face="normal" font="Arial"> Tan,K.H.</style></author><author><style face="normal" font="Arial"> Godfrey,K.M.</style></author><author><style face="normal" font="Arial"> Chong,M.F.F.</style></author><author><style face="normal" font="Arial"> van Bever,H.P.S.</style></author><author><style face="normal" font="Arial"> Chong,Y.S.</style></author><author><style face="normal" font="Arial"> Shek,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Low Food Allergy Prevalence Despite Delayed Introduction of Allergenic Foods-Data from the GUSTO Cohort</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is mounting evidence that early introduction of allergenic food decreases the risk of food allergy development, especially in high-risk infants with eczema. However, there is a lack of data to suggest whether this association holds true in Asian populations. OBJECTIVE: To investigate the relationship between the timing of introduction of allergenic foods and food allergy outcomes in infants in the Growing Up in Singapore Towards healthy Outcomes (GUSTO) study. METHODS: The GUSTO cohort recruited 1152 mothers of Chinese, Malay, and Indian ethnicity who had singleton, naturally conceived pregnancies and followed their offspring prospectively. Information on demographic characteristics, child health, infant feeding practices, and a convincing history of IgE-mediated food allergy was obtained from interviewer-administered questionnaires at multiple time points. Corroborative skin prick tests to food allergens were performed at 18 and 36 months. RESULTS: Most of the infants were introduced to egg (49.6%), peanut (88.7%), and shellfish (90.2%) after age 10 months. Food allergy prevalence was, however, very low between age 12 and 48 months: egg, 0.35% to 1.8%; peanut allergy, 0.1% to 0.3%; and shellfish, 0.2% to 0.9%. There were no significant associations between the timing of introduction of allergenic foods and the development of food allergy, adjusted for confounders including breast-feeding and eczema. CONCLUSIONS: Food allergy rates in Singapore are low despite delayed introduction of allergenic foods. Early introduction of allergenic foods may thus not be necessary in populations in which overall food allergy prevalence is low, and thus infant feeding recommendations should be carefully tailored to individual populations</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Singapore -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734861">PM:28734861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170723-ThamEH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170723-ThamEH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Tham EH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de Oliveira Filho,J.N.</style></author><author><style face="normal" font="Arial"> Apostolico,J.S.</style></author><author><style face="normal" font="Arial"> Andrade,D.A.G.</style></author><author><style face="normal" font="Arial"> Silva,F.R.D.</style></author><author><style face="normal" font="Arial"> Fernandes,E.R.</style></author><author><style face="normal" font="Arial"> Andersen,M.L.</style></author><author><style face="normal" font="Arial"> Keller,A.C.</style></author><author><style face="normal" font="Arial"> Rosa,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Immunology and Parasitology, Federal University of Sao Paulo (UNIFESP/EPM), Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Sleep deprivation predisposes allergic mice to develop neutrophilic lung inflammation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although different studies associated sleep deprivation with systemic inflammatory changes, the effect of sleep duration on the pathology of allergic chronic diseases is poorly understood. OBJECTIVE: To evaluate the influence of sleep deprivation on allergen-induced pulmonary inflammation. METHODS: Ovalbumin (OVA)-sensitized C57BL/6 mice were exposed to a first set of intranasal OVA challenge under sleep deprivation (SD) or healthy sleep (HS) conditions followed by a second OVA challenge, one week apart. Some groups were subjected to corticoid treatment with dexamethasone. RESULTS: OVA-sensitized SD mice developed a more severe airway inflammation than the HS allergic group. Analysis of lung parenchyma revealed that the inflammation in SD allergic mice was marked by an influx of neutrophils (mainly) and eosinophils and secretion of IL-6, TNF-alpha, and IL-17, in contrast to the eosinophilic inflammation and IL-4 production observed in HS allergic mice. The same cytokine profile was observed in ex vivo culture of cervical lymph nodes cells and splenocytes, indicating that in allergic mice SD favors immune responses towards a pro-inflammatory Th17 profile. This idea is supported by the fact that disruption of IL-17 signaling (IL-17RA-/-) prevented airway neutrophilia in allergic SD mice. Furthermore, SD allergic mice became refractory to corticoid treatment, in contrast to HS allergic group. CONCLUSION: Collectively, our data show that sleep quality participates in the progression of allergen-induced eosinophilic lung inflammation to corticoid refractory neutrophilic manifestation</style></abstract><notes><style face="normal" font="Arial">DA - 20170722IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732645">PM:28732645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170722-deOliveiraFilhoJN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170722-deOliveiraFilhoJN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170722, de Oliveira Filho JN</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hindley,J.P.</style></author><author><style face="normal" font="Arial"> Filep,S.</style></author><author><style face="normal" font="Arial"> Block,D.</style></author><author><style face="normal" font="Arial"> King,E.M.</style></author><author><style face="normal" font="Arial"> Chapman,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">INDOOR Biotechnologies, Cardiff, Wales, UK</style></auth-address><titles><title><style face="normal" font="Arial">Dose of Allergens in a Peanut Snack (Bamba(R)) Associated with Prevention of Peanut Allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">This letter reports the dose of specific allergens (Ara h 1, Ara h 2 and Ara h 6) in the peanut snack (Bamba(R)) that was successfully used to prevent peanut allergy in the Learning Early About Peanut (LEAP) study. The results provide weekly doses of specific allergen that are associated with prevention of peanut allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709966">PM:28709966</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170715-HindleyJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170715-HindleyJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Hindley JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Filep,S.</style></author><author><style face="normal" font="Arial"> Block,D.</style></author><author><style face="normal" font="Arial"> Smith,B.R.E.</style></author><author><style face="normal" font="Arial"> King,E.M.</style></author><author><style face="normal" font="Arial"> Commins,S.</style></author><author><style face="normal" font="Arial"> Kulis,M.</style></author><author><style face="normal" font="Arial"> Vickery,B.P.</style></author><author><style face="normal" font="Arial"> Chapman,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">INDOOR Biotechnologies Inc., Charlottesville, VA</style></auth-address><titles><title><style face="normal" font="Arial">Specific allergen profiles of peanut foods and of diagnostic or therapeutic allergenic products</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen profile</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Butter</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> enzyme immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Flours</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Oils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut butter</style></keyword><keyword><style face="normal" font="Arial"> Peanut oil</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Roasting</style></keyword><keyword><style face="normal" font="Arial"> SRM</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">RATIONALE: 'Generic' immunoassays for peanut cannot discriminate between allergen levels in peanut derived food products or therapeutics. Clinical trials of oral immunotherapy are strengthened by using standardized peanut preparations, with defined doses of major allergens. OBJECTIVE: This paper describes measurement of Ara h 1, Ara h 2 and Ara h 6 in peanut foods and in peanut flour extracts used for allergy diagnosis and oral immunotherapy. METHODS: Monoclonal antibody-based enzyme immunoassays for Ara h 1, Ara h 2 and Ara h 6 were used to compare allergen levels in peanut (n=19) and tree nut (n=16) butter, peanut flour (n=11); oils (n=8); extracts used for diagnosis and oral immunotherapy (n=5); and the National Institute for Standards and Technology Peanut Butter Standard Reference Material(R) 2387. RESULTS: Roasted peanut butters contained 991-21,406mug/g Ara h 1 and exceeded Ara h 2 and Ara h 6 levels by 2-4 fold. Similarly, NIST SRM 2387 contained 11,275mug/g Ara h 1; 2,522mug/g Ara h 2 and 2,036mug/g Ara h 6. In contrast, peanut flours contained 787-14,631mug/g Ara h 2 and exceeded Ara h 1 levels by 2-20 fold. Flour extracts used for oral immunotherapy contained 394-505mug/ml Ara h 1, 1,187-5,270mug/ml Ara h 2 and 1,104-8,092mug/ml Ara h 6. In most cases, specific peanut allergens were not detected in tree nut butters or peanut oils. CONCLUSIONS: The results show marked differences in specific peanut allergen profiles in peanut butter, flour and peanut preparations for clinical use. Roasting may increase Ara h 1 levels in peanut butter. Variability in allergen levels could affect the outcome of clinical trials of peanut oral immunotherapy, especially with respect to Ara h 1. Specific allergen measurements will improve standardization and provide accurate dosing of peanut preparations that are being used for oral immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709968">PM:28709968</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170715-FilepS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170715-FilepS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Filep S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McCormack,K.</style></author><author><style face="normal" font="Arial"> Egan,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Single-step venom allergy testing</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1797" start="1796">1796-1797</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom allergy testing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-2198</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.020</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jaip.2017.05.020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1796-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1796-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, McCormack K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mouraux,S.</style></author><author><style face="normal" font="Arial"> Bernasconi,E.</style></author><author><style face="normal" font="Arial"> Pattaroni,C.</style></author><author><style face="normal" font="Arial"> Koutsokera,A.</style></author><author><style face="normal" font="Arial"> Aubert,J.D.</style></author><author><style face="normal" font="Arial"> Claustre,J.</style></author><author><style face="normal" font="Arial"> Pison,C.</style></author><author><style face="normal" font="Arial"> Royer,P.J.</style></author><author><style face="normal" font="Arial"> Magnan,A.</style></author><author><style face="normal" font="Arial"> Kessler,R.</style></author><author><style face="normal" font="Arial"> Benden,C.</style></author><author><style face="normal" font="Arial"> Soccal,P.M.</style></author><author><style face="normal" font="Arial"> Marsland,B.J.</style></author><author><style face="normal" font="Arial"> Nicod,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de Pneumologie, CHUV, Lausanne, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Corynebacterium</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Transplantation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Platelet-Derived Growth Factor</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> real-time quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Homeostatic turnover of the extracellular matrix conditions the structure and function of the healthy lung. In lung transplantation, long-term management remains limited by Chronic Lung Allograft Dysfunction (CLAD), an umbrella term used for a heterogeneous entity ultimately associated with pathological airway and/or parenchyma remodeling. OBJECTIVE: To assess whether the local cross-talk between the pulmonary microbiota and host cells is a key determinant in the control of lower airway remodeling post-transplantation. METHODS: Microbiota DNA and host total RNA were isolated from 189 bronchoalveolar lavages obtained from 116 patients post-lung transplantation. Expression of a set of 11 genes encoding either matrix components, or factors involved in matrix synthesis or degradation (anabolic and catabolic remodeling, respectively), was quantified by real-time quantitative PCR. Microbiota composition was characterized using 16S ribosomal RNA gene sequencing and culture. RESULTS: We identified four host gene expression profiles, amongst which catabolic remodeling, associated with high expression of metallopeptidase-7, -9, and -12, diverged from anabolic remodeling linked to maximal thrombospondin and platelet-derived growth factor D expression. While catabolic remodeling aligned with a microbiota dominated by pro-inflammatory bacteria (e.g. Staphylococcus, Pseudomonas and Corynebacterium), anabolic remodeling was linked to typical members of the healthy steady state (e.g. Prevotella, Streptococcus and Veillonella). Mechanistic assays provided direct evidence that these bacteria can impact upon host macrophage-fibroblast activation and matrix deposition. CONCLUSION: Host-microbes interplay potentially determines remodeling activities in the transplanted lung highlighting new therapeutic opportunities to ultimately improve long-term lung transplant outcome</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28729000">PM:28729000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170721-MourauxS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170721-MourauxS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Mouraux S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Epp,A.</style></author><author><style face="normal" font="Arial"> Hobusch,J.</style></author><author><style face="normal" font="Arial"> Bartsch,Y.C.</style></author><author><style face="normal" font="Arial"> Petry,J.</style></author><author><style face="normal" font="Arial"> Lilienthal,G.M.</style></author><author><style face="normal" font="Arial"> Koeleman,C.A.M.</style></author><author><style face="normal" font="Arial"> Eschweiler,S.</style></author><author><style face="normal" font="Arial"> Mobs,C.</style></author><author><style face="normal" font="Arial"> Hall,A.</style></author><author><style face="normal" font="Arial"> Morris,S.C.</style></author><author><style face="normal" font="Arial"> Braumann,D.</style></author><author><style face="normal" font="Arial"> Engellenner,C.</style></author><author><style face="normal" font="Arial"> Bitterling,J.</style></author><author><style face="normal" font="Arial"> Rahmoller,J.</style></author><author><style face="normal" font="Arial"> Leliavski,A.</style></author><author><style face="normal" font="Arial"> Thurmann,R.</style></author><author><style face="normal" font="Arial"> Collin,M.</style></author><author><style face="normal" font="Arial"> Moremen,K.W.</style></author><author><style face="normal" font="Arial"> Strait,R.T.</style></author><author><style face="normal" font="Arial"> Blanchard,V.</style></author><author><style face="normal" font="Arial"> Petersen,A.</style></author><author><style face="normal" font="Arial"> Gemoll,T.</style></author><author><style face="normal" font="Arial"> Habermann,J.K.</style></author><author><style face="normal" font="Arial"> Petersen,F.</style></author><author><style face="normal" font="Arial"> Nandy,A.</style></author><author><style face="normal" font="Arial"> Kahlert,H.</style></author><author><style face="normal" font="Arial"> Hertl,M.</style></author><author><style face="normal" font="Arial"> Wuhrer,M.</style></author><author><style face="normal" font="Arial"> Pfutzner,W.</style></author><author><style face="normal" font="Arial"> Jappe,U.</style></author><author><style face="normal" font="Arial"> Finkelman,F.D.</style></author><author><style face="normal" font="Arial"> Ehlers,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratories of Immunology and Antibody Glycan Analysis, Institute for Nutrition Medicine, University of Lubeck &amp; University Medical Center Schleswig Holstein, Lubeck, Germany marc.ehlers@uk-sh.de</style></auth-address><titles><title><style face="normal" font="Arial">Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">In presence of high allergen dosis besides IgE also IgG antibodies can induce allergic reactions, whose severity is dependent on the induced type of IgG Fc glycosylation, what should be considered for new AIT protocols containing new adjuvants</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Netherlands -CO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28728998">PM:28728998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170721-EppA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170721-EppA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Epp A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dubiela,P.</style></author><author><style face="normal" font="Arial"> Aina,R.</style></author><author><style face="normal" font="Arial"> Polak,D.</style></author><author><style face="normal" font="Arial"> Geiselhart,S.</style></author><author><style face="normal" font="Arial"> Humeniuk,P.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Alessandri,S.</style></author><author><style face="normal" font="Arial"> Del Conte,R.</style></author><author><style face="normal" font="Arial"> Cantini,F.</style></author><author><style face="normal" font="Arial"> Borowski,T.</style></author><author><style face="normal" font="Arial"> Bublin,M.</style></author><author><style face="normal" font="Arial"> Hoffmann-Sommergruber,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Enhanced Pru p 3 IgE binding activity by selective free fatty acid-interaction</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergen</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">Upon binding to certain lipids, the major peach allergen, Pru p 3, undergoes conformational changes thus exposing one dominant IgE epitope. This conformational change enhances the allergenicity of Pru p 3</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Italy -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28712832">PM:28712832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170717-DubielaP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170717-DubielaP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Dubiela P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agyemang,A.</style></author><author><style face="normal" font="Arial"> Feuille,E.</style></author><author><style face="normal" font="Arial"> Tang,J.</style></author><author><style face="normal" font="Arial"> Steinwandtner,I.</style></author><author><style face="normal" font="Arial"> Sampson,H.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Outcomes of 84 consecutive open food challenges to extensively heated (baked) milk in the allergy office</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170703IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28669888">PM:28669888</url></web-urls><pdf-urls><url ppv-ref="no">anna.nowak-wegrzyn@mssm.edu</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170703, Agyemang A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author><author><style face="normal" font="Arial"> Koppelman,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Neb.</style></auth-address><titles><title><style face="normal" font="Arial">Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Cookies</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Ice</style></keyword><keyword><style face="normal" font="Arial"> Ice Cream</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nebraska</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> threshold level</style></keyword><keyword><style face="normal" font="Arial"> threshold levels</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut immunotherapy studies are conducted with the aim to decrease the sensitivity of patients to peanut exposure with the outcome evaluated by testing the threshold for allergic response in a double-blind placebo-controlled food challenge. The clinical relevance of increasing this threshold is not well characterized. OBJECTIVE: We aimed to quantify the clinical benefit of an increased threshold for peanut-allergic patients. METHODS: Quantitative risk assessment was performed by matching modeled exposure to peanut protein with individual threshold levels. Exposure was modeled by pairing US consumption data for various food product categories with potential contamination levels of peanut that have been demonstrated to be present on occasion in such food products. Cookies, ice cream, doughnuts/snack cakes, and snack chip mixes were considered in the risk assessment. RESULTS: Increasing the baseline threshold before immunotherapy from 100 mg or less peanut protein to 300 mg peanut protein postimmunotherapy reduces the risk of experiencing an allergic reaction by more than 95% for all 4 food product categories that may contain trace levels of peanut residue. Further increase in the threshold to 1000 mg of peanut protein had an additional quantitative benefit in risk reduction for all patients reacting to 300 mg or less at baseline. CONCLUSIONS: We conclude that achieving thresholds of 300 mg and 1000 mg of peanut protein by peanut immunotherapy is clinically relevant, and that the risk for peanut-allergic patients who have achieved this increased threshold to experience an allergic reaction is reduced in a clinically meaningful way</style></abstract><notes><style face="normal" font="Arial">DA - 20170703IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28669889">PM:28669889</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170703-BaumertJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170703-BaumertJL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170703, Baumert JL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lei,D.</style></author><author><style face="normal" font="Arial"> Akin,C.</style></author><author><style face="normal" font="Arial"> Kovalszki,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, Mass</style></auth-address><titles><title><style face="normal" font="Arial">Management of Mastocytosis in Pregnancy: A Review</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1223" start="1217">1217-1223</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indolent systemic mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="Arial">In this article, the authors present a case of pregnancy complicated by the need for management of indolent systemic mastocytosis. The diagnosis of mastocytosis is reviewed, as well as subtypes of mastocytosis and management options particularly in pregnancy. A table of pregnancy/lactaction categories for common medications used in mastocytosis is presented</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739366">PM:28739366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170725-LeiD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170725-LeiD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Lei D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chiriac,A.M.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Schrijvers,R.</style></author><author><style face="normal" font="Arial"> Bousquet,P.J.</style></author><author><style face="normal" font="Arial"> Mura,T.</style></author><author><style face="normal" font="Arial"> Molinari,N.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Designing Predictive Models for Beta-Lactam Allergy Using the Drug Allergy and Hypersensitivity Database</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="148" start="139">139-148</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="Arial"> beta-Lactams</style></keyword><keyword><style face="normal" font="Arial"> betalactam</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictive model</style></keyword><keyword><style face="normal" font="Arial"> Predictive models</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Beta-lactam antibiotics represent the main cause of allergic reactions to drugs, inducing both immediate and nonimmediate allergies. The diagnosis is well established, usually based on skin tests and drug provocation tests, but cumbersome. OBJECTIVES: To design predictive models for the diagnosis of beta-lactam allergy, based on the clinical history of patients with suspicions of allergic reactions to beta-lactams. METHODS: The study included a retrospective phase, in which records of patients explored for a suspicion of beta-lactam allergy (in the Allergy Unit of the University Hospital of Montpellier between September 1996 and September 2012) were used to construct predictive models based on a logistic regression and decision tree method; a prospective phase, in which we performed an external validation of the chosen models in patients with suspicion of beta-lactam allergy recruited from 3 allergy centers (Montpellier, Nimes, Narbonne) between March and November 2013. Data related to clinical history and allergy evaluation results were retrieved and analyzed. RESULTS: The retrospective and prospective phases included 1991 and 200 patients, respectively, with a different prevalence of confirmed beta-lactam allergy (23.6% vs 31%, P = .02). For the logistic regression method, performances of the models were similar in both samples: sensitivity was 51% (vs 60%), specificity 75% (vs 80%), positive predictive value 40% (vs 57%), and negative predictive value 83% (vs 82%). The decision tree method reached a sensitivity of 29.5% (vs 43.5%), specificity of 96.4% (vs 94.9%), positive predictive value of 71.6% (vs 79.4%), and negative predictive value of 81.6% (vs 81.3%). CONCLUSIONS: Two different independent methods using clinical history predictors were unable to accurately predict beta-lactam allergy and replace a conventional allergy evaluation for suspected beta-lactam allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.04.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739365">PM:28739365</url></web-urls><pdf-urls><url ppv-ref="no">a-chiriac@chu-montpellier.fr</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170725, Chiriac AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.04.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huffaker,M.F.</style></author><author><style face="normal" font="Arial"> McGhee,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Immunology, and Rheumatology, Stanford University, Stanford, Calif; Department of Allergy and Immunology, Lucille Packard Children's Hospital, Palo Alto, Calif.</style></auth-address><titles><title><style face="normal" font="Arial">Four cases of delayed onset systemic reaction to shellfish</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170723IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734856">PM:28734856</url></web-urls><pdf-urls><url ppv-ref="no">michelle.f.huffaker@gmail.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170723, Huffaker MF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maurer,M.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Brehler,R.</style></author><author><style face="normal" font="Arial"> Hillen,U.</style></author><author><style face="normal" font="Arial"> Jakob,T.</style></author><author><style face="normal" font="Arial"> Mahler,V.</style></author><author><style face="normal" font="Arial"> Pfohler,C.</style></author><author><style face="normal" font="Arial"> Staubach,P.</style></author><author><style face="normal" font="Arial"> Treudler,R.</style></author><author><style face="normal" font="Arial"> Wedi,B.</style></author><author><style face="normal" font="Arial"> Magerl,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab Treatment in Chronic Inducible Urticaria: A Systematic Review of Published Evidence</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inducible urticaria</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> cold urticaria</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed pressure</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermographism</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> H1-antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in chronic inducible urticarias (CIndUs), which are frequently H1-antihistamine resistant. OBJECTIVE: We aimed to determine, from the current published literature, the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. METHODS: We performed a PubMed(R) search to identify evidence on omalizumab use in the following nine CIndU subtypes: symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria and aquagenic urticaria. RESULTS: 43 trials, case studies, case reports and analyses were identified. Our review indicates that omalizumab has substantial benefits in various CIndUs. The evidence is strongest for symptomatic dermographism, cold urticaria and solar urticaria. Little/no evidence was available on vibratory angioedema, aquagenic and contact urticaria. Our review supports the rapid onset of action, demonstrated through early symptom control in most cases, sometimes within 24 hours. Many patients gained complete/partial symptom relief and substantially improved quality of life. Adverse events were generally low with omalizumab being well tolerated by most patients including children. CONCLUSIONS: A strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU. More data from randomised controlled studies are warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28751232">PM:28751232</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170728-MaurerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170728-MaurerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Maurer M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mangold,A.R.</style></author><author><style face="normal" font="Arial"> Thompson,A.K.</style></author><author><style face="normal" font="Arial"> Davis,M.D.</style></author><author><style face="normal" font="Arial"> Saulite,I.</style></author><author><style face="normal" font="Arial"> Cozzio,A.</style></author><author><style face="normal" font="Arial"> Guenova,E.</style></author><author><style face="normal" font="Arial"> Hodak,E.</style></author><author><style face="normal" font="Arial"> Amitay-Laish,I.</style></author><author><style face="normal" font="Arial"> Pujol,R.M.</style></author><author><style face="normal" font="Arial"> Pittelkow,M.R.</style></author><author><style face="normal" font="Arial"> Gniadecki,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mayo Clinic, Scottsdale, Arizona.</style></auth-address><titles><title><style face="normal" font="Arial">Early clinical manifestations of Sezary syndrome: A multicenter retrospective cohort study</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Arizona</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mycosis Fungoides</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sezary</style></keyword><keyword><style face="normal" font="Arial"> Sezary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell receptor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Classic Sezary syndrome (SS) is defined by erythroderma, generalized lymphadenopathy, and leukemic blood involvement. Clinical observations suggest that SS begins as a nonerythrodermic disease. OBJECTIVE: To describe the early clinical characteristics of patients with SS. METHODS: A retrospective, multicenter chart review was performed for 263 confirmed cases of SS diagnosed during 1976-2015. RESULTS: Erythroderma was the earliest recorded skin sign of SS in only 25.5% of cases, although most patients (86.3%) eventually developed erythroderma. In patients without erythroderma during their initial visit, the first cutaneous signs of SS were nonspecific dermatitis (49%), atopic dermatitis-like eruption (4.9%), or patches and plaques of mycosis fungoides (10.6%). The mean diagnostic delay was 4.2 years overall, 2.2 years for cases involving erythroderma at the initial presentation, and 5.0 years for cases not involving erythroderma at the initial presentation. LIMITATIONS: This study is retrospective. CONCLUSION: Erythroderma is uncommon as an initial sign of SS. Early SS should be considered in cases of nonerythrodermic dermatitis that is refractory to conventional treatments. In these cases, examination of the blood by PCR for monoclonal T-cell receptor rearrangement and by flow cytometry to identify an expanded or aberrant T-cell population should be considered</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Switzerland -CO - Israel -CO - Spain -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2017.05.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709694">PM:28709694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20170715-MangoldAR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20170715-MangoldAR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Mangold AR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2017.05.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rzymski,P.</style></author><author><style face="normal" font="Arial"> Jaskiewicz,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Microalgal food supplements from the perspective of Polish consumers: patterns of use, adverse events, and beneficial effects</style></title><secondary-title><style face="normal" font="Arial">J Appl Phycol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Appl Phycol</style></full-title></periodical><pages end="1850" start="1841">1841-1850</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Chlorella</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> General well-being</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypothyroidism</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Patterns of use</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-5176</style></isbn><abstract><style face="normal" font="Arial">Microalgal food supplements are becoming increasingly popular due to their promising biological effects and high nutritional value, evidenced in in vitro, in vivo, and human studies. Some products of this kind have, however, raised controversies concerning their safety. At the same time, not much is known about the frequency of adverse events following the use of microalgal supplements, potential factors that may influence them, and general characteristics and behaviours of the consumer group. The present study aimed to fill this gap and surveyed a group of Polish consumers of microalgal products (n-á=-á150) using an online questionnaire. As found, microalgal supplements (Spirulina, Chlorella, and Aphanizomenon) were popular in groups representing lacto-ovo-vegetarianism and veganism and were consumed predominantly for nutritional, immune-boosting, and detoxifying purposes. Their use was rarely discussed with specialists; the Internet constituted the most important source of information regarding these supplements. The most frequently self-reported health-beneficial effects of supplementation included the following: increased immunity, higher vitality, improved hair and skin quality, and better general well-being. Diarrhoea, nausea, abdominal pain, and skin rash were among the most often reported adverse events. Pre-existing medical conditions, namely renal failure and hypothyroidism, but not Hashimoto</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs thyroiditis, were associated with increased occurrence of side effects. Those individuals who had consulted specialists as to the use of supplements reported adverse events significantly less often. A strikingly high frequency of side effects and very low consumer satisfaction were reported by a group of consumers supplementing Aphanizomenon-based products. In summary, the present study highlights that microalgal consumers may benefit from additional warnings of potential side effects and from consulting a qualified health specialist prior to use</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10811-017-1079-5</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10811-017-1079-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Appl Phycol\2017-29-1841-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Appl Phycol\2017-29-1841-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170723, Rzymski P</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10811-017-1079-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shi,J.</style></author><author><style face="normal" font="Arial"> Chen,M.</style></author><author><style face="normal" font="Arial"> Ouyang,L.</style></author><author><style face="normal" font="Arial"> Huang,L.</style></author><author><style face="normal" font="Arial"> Lin,X.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Liang,R.</style></author><author><style face="normal" font="Arial"> Lv,Z.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author><author><style face="normal" font="Arial"> Jiang,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Respiratory Medicine , Sun Yat-Sen Memorial Hospital, Sun Yat-sen University , Guangzhou , China</style></auth-address><titles><title><style face="normal" font="Arial">Airway smooth muscle cells from ovalbumin-sensitized mice show increased proliferative response to TGFbeta1 due to upregulation of Smad3 and TGFbetaRII</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="475" start="467">467-475</pages><volume><style face="normal" font="Arial">54</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> extracellular signal-regulated kinase</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: This study aimed to elucidate the role of Transforming growth factor (TGF)-beta1 signaling in the proliferation of airway smooth muscle cells (ASMCs). BACKGROUND: TGF-beta1 is an important cytokine in airway remodeling in asthma. However, results of studies focusing on the effect of TGFbeta1 on proliferation of ASMCs are controversial. METHODS: An allergic model that mimics airway remodeling in chronic asthma was established and primary ASMCs were cultured. Cell proliferation was detected by viable cell counting and Cell Counting Kit (CCK)-8 analysis. Expression and phosphorylation of Smad3, type 1 TGFbeta receptor (TGFbetaRI), type 2 TGFbeta receptor (TGFbetaRII), extracellular signal-regulated kinase (ERK)-1/2, p38 mitogen-activated protein kinase (MAPK), C-Jun N-terminal kinase (JNK) and AKT were detected by western blot. siRNAs were used to knock down Smad3 and TGFbetaRII. RESULTS: Smad3 and TGFbetaRII were up-regulated in primary ASMCs isolated from ovalbumin (OVA)-sensitized mice as compared with ASMCs isolated from unsensitized control mice, which persisted for at least four passages. TGFbeta1 stimulated proliferation of ASMCs isolated from OVA-sensitized mice, which was inhibited by specific siRNA targeting Smad3 or TGFbetaRII. However ASMCs from control mice showed no proliferative response to TGFbeta1. TGFbeta1-induced proliferation of ASMCs from OVA-sensitized mice was markedly attenuated by PD-98059, a specific ERK1/2 inhibitor. TGFbeta1 induced ERK1/2 phosphorylation within 15 minute, which was partially blocked by specific inhibitor of Smad3 (SIS3). CONCLUSIONS: ASMCs isolated from OVA-sensitized mice showed hyper-proliferation upon TGFbeta1 stimulation. This might have been associated with up-regulated Smad3 and TGFbetaRII and mediated by ERK1/2 downstream to Smad3</style></abstract><notes><style face="normal" font="Arial">DA - 20161201IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1225760</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27905842">PM:27905842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\2017-54-467-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\2017-54-467-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161201, Shi J</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1225760</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Niven,R.M.</style></author><author><style face="normal" font="Arial"> Simmonds,M.R.</style></author><author><style face="normal" font="Arial"> Cangelosi,M.J.</style></author><author><style face="normal" font="Arial"> Tilden,D.P.</style></author><author><style face="normal" font="Arial"> Cottrell,S.</style></author><author><style face="normal" font="Arial"> Shargill,N.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a MAHSC, University of Manchester and University Hospital of South Manchester , Manchester , UK</style></auth-address><titles><title><style face="normal" font="Arial">Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Bronchial thermoplasty (BT) as an add-on therapy for uncontrolled severe asthma is an alternative to biologic therapies like omalizumab (OM). We conducted an indirect treatment comparison (ITC) to appraise comparative effectiveness of BT and OM. METHODS: A systematic literature review identified relevant randomized controlled trials. The ITC followed accepted methodology. RESULTS: The ITC comprised a sham-controlled trial of BT (AIR2) and two placebo-controlled trials of OM (INNOVATE; EXTRA). Comparing the BT post-treatment period to ongoing treatment with OM, showed no significant differences in the rate ratios (RRs) for severe exacerbations (RR of BT versus OM = 0.91 [95% CI: 0.64, 1.30]; p = 0.62) or hospitalizations (RR = 0.57 [95% CI: 0.17, 1.86]; p = 0.53); emergency department visits were significantly reduced by 75% with BT (RR = 0.25 [95% CI: 0.07, 0.91]; p = 0.04); the proportions of patients with clinically meaningful response on the asthma quality-of-life questionnaire were comparable (RR = 1.06 [95% CI: 0.86, 1.34]; p = 0.59). The RR for exacerbations statistically favours OM over the total study period in AIR2 (RR = 1.50 [95% CI: 1.11, 2.02]; p = 0.009) likely reflecting a transient increase in events during the BT peri-treatment period. CONCLUSIONS: The ITC should be interpreted cautiously considering the differences between patient populations in the included trials. However, based on the analysis, BT compares well with a potentially more costly pharmacotherapy for asthma. Clinicians evaluating the relative merits of using these treatments should consider the totality of evidence and patient preferences to make an informed decision</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2017.1337789</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28708944">PM:28708944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170714-NivenRM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170714-NivenRM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Niven RM</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2017.1337789</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Michelet,M.</style></author><author><style face="normal" font="Arial"> Schluckebier,D.</style></author><author><style face="normal" font="Arial"> Petit,L.M.</style></author><author><style face="normal" font="Arial"> Caubet,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Children Hospital, Pediatric Allergology Unit CHU Toulouse, Toulouse, France</style></auth-address><titles><title><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome - a review of the literature with focus on clinical management</style></title><secondary-title><style face="normal" font="Arial">J Asthma Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Asthma Allergy</style></full-title></periodical><pages end="207" start="197">197-207</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dietician</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Failure to Thrive</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal food allergy</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Lethargy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Non-IgE-mediated gastrointestinal food allergies</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Potatoes</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome (FPIES) is a potentially severe presentation of non-IgE-mediated gastrointestinal food allergy (non-IgE-GI-FA) with heterogeneous clinical manifestations. Acute FPIES is typically characterized by profuse vomiting and lethargy, occurring classically 1-4 hours after ingestion of the offending food. When continuously exposed to the incriminated food, a chronic form has been described with persistent vomiting, diarrhea, and/or failure to thrive. Although affecting mainly infants, FPIES has also been described in adults. Although FPIES is actually one of the most actively studied non-IgE-GI-FAs, epidemiologic data are lacking, and estimation of the prevalence is based on a limited number of prospective studies. The exact pathomechanisms of FPIES remain not well defined, but recent data suggest involvement of neutrophils and mast cells, in addition to T cells. There is a wide range of food allergens that can cause FPIES with some geographical variations. The most frequently incriminated foods are cow milk, soy, and grains in Europe and USA. Furthermore, FPIES can be induced by foods usually considered as hypoallergenic, such as chicken, potatoes or rice. The diagnosis relies currently on typical clinical manifestations, resolving after the elimination of the offending food from the infant's/child's diet and/or an oral food challenge (OFC). The prognosis is usually favorable, with the vast majority of the case resolving before 5 years of age. Usually, assessment of tolerance acquisition by OFC is proposed every 12-18 months. Of note, a switch to an IgE-mediated FA is possible and has been suggested to be associated with a more severe phenotype. Avoiding the offending food requires education of the family of the affected child. A multidisciplinary approach including ideally allergists, gastroenterologists, dieticians, specialized nurses, and caregivers is often useful to optimize the management of these patients, that might be difficult</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.2147/JAA.S100379</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28721077">PM:28721077</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-197-207.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma Allergy\2017-10-197-207.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Michelet M</style></custom2><misc3><style face="normal" font="Arial">10.2147/JAA.S100379</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stelmach,R.</style></author><author><style face="normal" font="Arial"> Cruz,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Divisao de Pneumologia, Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo (SP) BrasilCoordenador do Nucleo de Excelencia em Asma, Universidade Federal da Bahia, Salvador (BA) Brasil</style></auth-address><titles><title><style face="normal" font="Arial">The paradox of asthma: neglect, burden, and big data</style></title><secondary-title><style face="normal" font="Arial">J Bras Pneumol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Bras Pneumol</style></full-title></periodical><pages end="160" start="159">159-160</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170726IS - 1806-3756 (Electronic)IS - 1806-3713 (Linking)LA - engLA - porPT - EditorialCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1590/s1806-37562017000300002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28746523">PM:28746523</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Bras Pneumol\2017-43-159-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Bras Pneumol\2017-43-159-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, Stelmach R</style></custom2><misc3><style face="normal" font="Arial">10.1590/s1806-37562017000300002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cardoso,T.A.</style></author><author><style face="normal" font="Arial"> Roncada,C.</style></author><author><style face="normal" font="Arial"> Silva,E.R.D.</style></author><author><style face="normal" font="Arial"> Pinto,L.A.</style></author><author><style face="normal" font="Arial"> Jones,M.H.</style></author><author><style face="normal" font="Arial"> Stein,R.T.</style></author><author><style face="normal" font="Arial"> Pitrez,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">. Centro Infant, Instituto de Pesquisas Biomedicas, Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre (RS) Brasil</style></auth-address><titles><title><style face="normal" font="Arial">The impact of asthma in Brazil: a longitudinal analysis of data from a Brazilian national database system</style></title><secondary-title><style face="normal" font="Arial">J Bras Pneumol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Bras Pneumol</style></full-title></periodical><pages end="168" start="163">163-168</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> indirect costs</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Mais</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">Objective:: To present official longitudinal data on the impact of asthma in Brazil between 2008 and 2013. Methods:: This was a descriptive study of data collected between 2008 and 2013 from an official Brazilian national database, including data on asthma-related number of hospitalizations, mortality, and hospitalization costs. A geographical subanalysis was also performed. Results:: In 2013, 2,047 people died from asthma in Brazil (5 deaths/day), with more than 120,000 asthma-related hospitalizations. During the whole study period, the absolute number of asthma-related deaths and of hospitalizations decreased by 10% and 36%, respectively. However, the in-hospital mortality rate increased by approximately 25% in that period. The geographic subanalysis showed that the northern/northeastern and southeastern regions had the highest asthma-related hospitalization and in-hospital mortality rates, respectively. An analysis of the states representative of the regions of Brazil revealed discrepancies between the numbers of asthma-related hospitalizations and asthma-related in-hospital mortality rates. During the study period, the cost of asthma-related hospitalizations to the public health care system was US$ 170 million. Conclusions:: Although the numbers of asthma-related deaths and hospital admissions in Brazil have been decreasing since 2009, the absolute numbers are still high, resulting in elevated direct and indirect costs for the society. This shows the relevance of the burden of asthma in middle-income countries. Objetivo:: Apresentar dados longitudinais oficiais sobre o impacto da asma no Brasil entre 2008 e 2013. Metodos:: Estudo descritivo de dados extraidos de um banco de dados do governo brasileiro entre 2008 e 2013, no qual foram analisados as hospitalizacoes e obitos por asma, bem como o custo das hospitalizacoes. Foi tambem realizada uma subanalise geografica. Resultados:: Em 2013, 2.047 pessoas morreram de asma no Brasil (5 obitos/dia), com mais de 120.000 hospitalizacoes por asma. Durante o periodo de estudo, o numero absoluto de obitos e hospitalizacoes por asma diminuiu 10% e 36%, respectivamente. No entanto, a taxa de mortalidade hospitalar aumentou aproximadamente 25%. A subanalise geografica mostrou que as regioes Norte/Nordeste e Sudeste apresentaram as maiores taxas de hospitalizacao e mortalidade hospitalar por asma, respectivamente. A analise dos estados representativos de cada regiao mostrou discrepancias entre as hospitalizacoes por asma e as taxas de mortalidade hospitalar por asma. Durante o periodo de estudo, as hospitalizacoes por asma custaram US$ 170 milhoes ao sistema publico de saude. Conclusoes:: Embora os obitos e hospitalizacoes por asma no Brasil estejam diminuindo desde 2009, os numeros absolutos ainda sao altos, com elevados custos diretos e indiretos para a sociedade, o que mostra a relevancia do impacto da asma em paises de renda media</style></abstract><notes><style face="normal" font="Arial">DA - 20170726IS - 1806-3756 (Electronic)IS - 1806-3713 (Linking)LA - engLA - porPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1590/s1806-37562016000000352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28746526">PM:28746526</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Bras Pneumol\2017-43-163-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Bras Pneumol\2017-43-163-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, Cardoso TA</style></custom2><misc3><style face="normal" font="Arial">10.1590/s1806-37562016000000352</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saito,T.</style></author><author><style face="normal" font="Arial"> Iida,S.</style></author><author><style face="normal" font="Arial"> Terao,K.</style></author><author><style face="normal" font="Arial"> Kumagai,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Translational Clinical Research Science and Strategy Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation</style></title><secondary-title><style face="normal" font="Arial">J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="Arial">Nemolizumab is a humanized anti-interleukin-31 receptor A monoclonal antibody for treating atopic dermatitis, and it especially improves pruritus. The objective of the simulation study was to optimize the dose regimen using a flat dose. The serum nemolizumab concentration and pruritus visual analog scale as an efficacy end point were modeled using the population analysis approach in 299 patients with atopic dermatitis who received placebo or doses between 0.1 and 3 mg/kg as a single dose once every 4 weeks or 2 mg/kg once every 8 weeks. A 1-compartment model with first-order absorption was employed as the pharmacokinetic model. An indirect turnover model with an inhibition component was employed as the main part of the pharmacokinetic-pharmacodynamic model. The models well described the observations. Therefore, simulations with several dose regimens were performed to optimize the dose regimen including a flat dose. The simulated area under the concentration-time curve at a steady state around 75 mg in the every-4-week regimen corresponds to that associated with the dose range of 0.5 to 2 mg/kg in the 4-week regimen. The simulated pruritus visual analog scale also showed a similar tendency. These simulation results support dose optimization during the clinical development program of nemolizumab</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 1552-4604 (Electronic)IS - 0091-2700 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1002/jcph.969</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703903">PM:28703903</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Pharmacol\20170713-SaitoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Pharmacol\20170713-SaitoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Saito T</style></custom2><misc3><style face="normal" font="Arial">10.1002/jcph.969</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,L.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Zhao,P.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Agricultural College of Yanbian University, Gongyuan Street, Yanji, Jilin 133002, PR China.</style></auth-address><titles><title><style face="normal" font="Arial">Regulatory effect of baicalin on the imbalance of Th17/Treg responses in mice with allergic asthma</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGY RELEVANCE: Baicalin, a flavonoid compound, was isolated from traditional Chinese medicine Scutellaria baicalensis Georgi. The study aimed to explore the regulatory effect of baicalin on immunological balance of Th17/Treg responses and the possible mechanisms in mice with allergic asthma. MATERIALS AND METHODS: Mice were sensitized and challenged with OVA+LPS by intranasal instillation, and were intragastrically treated with baicalin from days 22 to 36 after sensitization. The organ coefficient of lung was determined. Immunoglobulin E (IgE) level in serum and cytokine IL-17A, IL-6, IL-10 levels in bronchoalveolar lavage fluid (BALF) were measured by ELISA. Histological changes in lung and airway tissues were observed by hematoxylin and eosin (H&amp;E) and periodic acid-Schiff staining (PAS). The expressions of signal transducer and activator of transcription 3 (STAT3) and forkhead box P3 (FOXP3) in lung tissues were evlaulated by immunohistochemistry and western blot methods. RESULTS: Baicalin obviously decreased OVA+LPS-induced organ coefficient of lung, inhibited serum IgE and BALF IL-7A and IL-6 secrection, promoted BALF IL-10 secrection in a dose-dependent manner. Histological studies demonstrated that baicaclin significantly alleviated OVA+LPS-induced inflammatory responses and mucus secretion in lung and airway tissues. Immunohistochemistry and western blot studies showed that baicalin substantially suppressed STAT3 expression and promoted FOXP3 expression in lung tissues of mice. CONCLUSIONS: These findings suggest that baicalin effectively protects against OVA+LPS-induced allergic asthma in mice by regulating the immunological imbalance of Th17/Treg responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709893">PM:28709893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20170715-XuL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20170715-XuL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Xu L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.07.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shin,N.R.</style></author><author><style face="normal" font="Arial"> Ryu,H.W.</style></author><author><style face="normal" font="Arial"> Ko,J.W.</style></author><author><style face="normal" font="Arial"> Park,S.H.</style></author><author><style face="normal" font="Arial"> Yuk,H.J.</style></author><author><style face="normal" font="Arial"> Kim,H.J.</style></author><author><style face="normal" font="Arial"> Kim,J.C.</style></author><author><style face="normal" font="Arial"> Jeong,S.H.</style></author><author><style face="normal" font="Arial"> Shin,I.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Veterinary Medicine (BK21 project team), Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju 500-757, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Artemisia argyi attenuates airway inflammation in ovalbumin-induced asthmatic animals</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Tea</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: Artemisia argyi is a traditional herbal medicine in Korea and commonly called as mugwort. It is traditionally used as food source and tea to control abdominal pain, dysmenorrhoea, uterine haemorrhage, and inflammation. AIM OF THE STUDY: We investigated the effects of A. argyi (TOTAL) and dehydromatricarin A (DA), its active component on ovalbumin (OVA)-induced allergic asthma. MATERIALS AND METHODS: The animals were sensitized on day 0 and 14 by intraperitoneal injection of OVA with aluminum hydroxide. On day 21, 22 and 23 after the initial sensitization, the animals received an airway challenge with OVA for 1h using an ultrasonic nebulizer. TOTAL (50 and 100mg/kg) or DA (10 and 20mg/kg) were administered to mice by oral gavage once daily from day 18 to 23. Airway hyperresponsiveness (AHR) was measured 24h after final OVA challenge. RESULT: TOTAL and DA treated animals reduced inflammatory cell counts, cytokines and AHR in asthmatic animals, which was accompanied with inflammatory cell accumulation and mucus hypersecretion. Furthermore, TOTAL and DA significantly declined Erk phosphorylation and the expression of MMP-9 in asthmatic animals. CONCLUSION: In conclusion, we indicate that Total and DA suppress allergic inflammatory responses caused by OVA challenge. It was considered that A. argyi has a potential for treating allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170724IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.07.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28735728">PM:28735728</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20170724-ShinNR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20170724-ShinNR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170724, Shin NR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.07.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schwerd,T.</style></author><author><style face="normal" font="Arial"> Twigg,S.R.F.</style></author><author><style face="normal" font="Arial"> Aschenbrenner,D.</style></author><author><style face="normal" font="Arial"> Manrique,S.</style></author><author><style face="normal" font="Arial"> Miller,K.A.</style></author><author><style face="normal" font="Arial"> Taylor,I.B.</style></author><author><style face="normal" font="Arial"> Capitani,M.</style></author><author><style face="normal" font="Arial"> McGowan,S.J.</style></author><author><style face="normal" font="Arial"> Sweeney,E.</style></author><author><style face="normal" font="Arial"> Weber,A.</style></author><author><style face="normal" font="Arial"> Chen,L.</style></author><author><style face="normal" font="Arial"> Bowness,P.</style></author><author><style face="normal" font="Arial"> Riordan,A.</style></author><author><style face="normal" font="Arial"> Cant,A.</style></author><author><style face="normal" font="Arial"> Freeman,A.F.</style></author><author><style face="normal" font="Arial"> Milner,J.D.</style></author><author><style face="normal" font="Arial"> Holland,S.M.</style></author><author><style face="normal" font="Arial"> Frede,N.</style></author><author><style face="normal" font="Arial"> Muller,M.</style></author><author><style face="normal" font="Arial"> Schmidt-Arras,D.</style></author><author><style face="normal" font="Arial"> Grimbacher,B.</style></author><author><style face="normal" font="Arial"> Wall,S.A.</style></author><author><style face="normal" font="Arial"> Jones,E.Y.</style></author><author><style face="normal" font="Arial"> Wilkie,A.O.M.</style></author><author><style face="normal" font="Arial"> Uhlig,H.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, England, UK</style></auth-address><titles><title><style face="normal" font="Arial">A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis</style></title><secondary-title><style face="normal" font="Arial">J Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Exp Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine receptor</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-11</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-6</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Oncostatin M</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="Arial">Multiple cytokines, including interleukin 6 (IL-6), IL-11, IL-27, oncostatin M (OSM), and leukemia inhibitory factor (LIF), signal via the common GP130 cytokine receptor subunit. In this study, we describe a patient with a homozygous mutation of IL6ST (encoding GP130 p.N404Y) who presented with recurrent infections, eczema, bronchiectasis, high IgE, eosinophilia, defective B cell memory, and an impaired acute-phase response, as well as skeletal abnormalities including craniosynostosis. The p.N404Y missense substitution is associated with loss of IL-6, IL-11, IL-27, and OSM signaling but a largely intact LIF response. This study identifies a novel immunodeficiency with phenotypic similarities to STAT3 hyper-IgE syndrome caused by loss of function of GP130</style></abstract><notes><style face="normal" font="Arial">DA - 20170727IS - 1540-9538 (Electronic)IS - 0022-1007 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1084/jem.20161810</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28747427">PM:28747427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Exp Med\20170727-SchwerdT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Exp Med\20170727-SchwerdT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, SchwerdT</style></custom2><misc3><style face="normal" font="Arial">10.1084/jem.20161810</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">El-Housseiny,L.</style></author><author><style face="normal" font="Arial"> Ibrahim,M.K.</style></author><author><style face="normal" font="Arial"> Sellinger,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Th2 related markers in milk allergic inflammatory mice model, versus OVA</style></title><secondary-title><style face="normal" font="Arial">J Genet Eng Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Genet Eng Biotechnol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Intranasal challenge</style></keyword><keyword><style face="normal" font="Arial"> Low fat milk</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1687-157X</style></isbn><abstract><style face="normal" font="Arial">Experimental studies on allergic asthma are limited by the high cost of the administrated allergens. In this study we tested the allergic potency of low fat milk as a cheap substitute to the widely used standard allergen, ovalbumin (OVA). BALB/c female mice (4 weeks old) were sensitized intraperitoneally with low fat milk/or OVA followed by intranasal challenge with the two allergens on days 28 and 29. At day 31, serum, bronchoalveolar lavage fluid (BALF), and lungs were harvested. Mice of the low fat milk model showed infiltration of eosinophils, macrophages, lymphocytes, and neutrophils in BALF comparable to that of the OVA model. Both allergic protocols led to the production of similar numbers of Th2 cells and induced comparable expression of Th2 cytokine (IL-13) as evident by real time PCR for IL-13 and GATA3 (Th2 transcription factor) and confirmed by immunofluorescence for Th2 surface markers (T1/ST2). In addition, both mouse models had similar elevated levels of allergen specific antibody, IgG1 and IgE. Notably, HE, PAS, and LUNA stained lung sections from low fat milk treated mice had higher average pathological scores as compared to OVA treated mice. In conclusion, this study suggests that the low fat milk-induced inflammation showed hallmarks of allergic airway inflammatory model such as eosinophilic influx in BALF, increased numbers of Th2 cells, augmented expression of IL-13, elevated levels of circulatory IgG1 and IgE, signs of robust pulmonary inflammation, and most importantly it is a cheap and promising model for studying acute allergic airway inflammation and acute asthma</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Egypt -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jgeb.2017.07.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jgeb.2017.07.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Genet Eng Biotechnol\20170727-ElhousseinyL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Genet Eng Biotechnol\20170727-ElhousseinyL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, El-housseiny L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jgeb.2017.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maslin,K.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Mackenzie,H.</style></author><author><style face="normal" font="Arial"> Vlieg-Boerstra,B.</style></author><author><style face="normal" font="Arial"> Dean,T.</style></author><author><style face="normal" font="Arial"> Sommer,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Health Sciences and Social Work, University of Portsmouth, Portsmouth, UK</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of nutrient intake in adolescents and adults with and without food allergies</style></title><secondary-title><style face="normal" font="Arial">J Hum Nutr Diet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Hum Nutr Diet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> dietary supplement</style></keyword><keyword><style face="normal" font="Arial"> Dietary Supplements</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Energy Intake</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> folate</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nutritional deficiency</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Selenium</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Exclusion diets for the management of food allergy pose a risk of nutritional deficiencies and inadequate growth in children, yet less is known about their effect in adolescents and adults. The present study aimed to compare the dietary intake of adolescents and adults with food allergies with that of a control group. METHODS: A food allergic and a control group were recruited from Portsmouth and the Isle of Wight in the UK. Participants were recruited from a food allergy charity, allergy clinics, a local school and university, and previous research studies. Macro and micronutrient intake data were obtained using a 4-day estimated food diary. Sociodemographic and anthropometric data was collected via a constructed questionnaire. RESULTS: This cross-sectional study included 81 adolescents (48 food allergic and 33 controls) aged 11-18 years and 70 adults aged 19-65 years (23 food allergic and 47 controls). Overall, 19 (22.8%) adolescents and 19 (27.1%) adults took dietary supplements, with no difference according to food allergic status. Adolescents with food allergy had higher intakes of niacin and selenium than adolescents without (P &lt; 0.05). This difference persisted when dietary supplements were removed from the analysis. Adults with food allergies had higher intakes of folate and zinc than those without (P &lt; 0.05); however, this difference did not persist when dietary supplements were removed from the analysis. Across all participants, the intake of several micronutrients was suboptimal. There was no difference in protein or energy intake, or body mass index, according to food allergic status. CONCLUSIONS: The dietary intake of food allergic participants was broadly similar and, in some cases, better than that of control participants. However, suboptimal intakes of several micronutrients were observed across all participants, suggesting poor food choices</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 1365-277X (Electronic)IS - 0952-3871 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Austria -CO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/jhn.12495</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28707418">PM:28707418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Hum Nutr Diet\20170714-MaslinK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Hum Nutr Diet\20170714-MaslinK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Maslin K</style></custom2><misc3><style face="normal" font="Arial">10.1111/jhn.12495</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rubenhagen,R.</style></author><author><style face="normal" font="Arial"> Dangers,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a DST Diagnostische Systeme &amp; Technologien GmbH , 19059 Schwerin , Germany</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of a novel point-of-care test for the rapid semi-quantitative detection of allergen-specific immunoglobulin E</style></title><secondary-title><style face="normal" font="Arial">J Immunoassay Immunochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunoassay Immunochem</style></full-title></periodical><pages end="554" start="538">538-554</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Point-of-care</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen-specific IgE levels in human sera support the diagnosis of allergies. However, commonly used laboratory tests are time consuming. The new point-of-care test FastCheckPOC 20 (FCP20) allows the simultaneous and semi-quantitative evaluation of IgE antibodies for 20 aeroallergens and food allergens. METHODS: Two hundred patients with allergic symptoms were included in a multicenter performance evaluation using both whole blood and plasma or serum samples. FCP20 results were compared with the skin prick test (SPT) and the ImmunoCAP system (Phadia) which was used as reference for specific IgE values. RESULTS: The concordance between FCP20 and ImmunoCAP was 76% for positive results and 80% for negative results over 20 allergens. Overall agreement (accuracy) of FCP20 with the ImmunoCAP was 80% across all 20 allergens. The concordance between FCP20 and SPT over all 20 allergens was 66% for positive results and 71% for negative results. Overall agreement of FCP20 with the SPT was 70%. Semi-quantitative FCP20 results (Levels 1-5) revealed nearly identical values for whole blood and plasma/serum test results. A good concordance was also observed between FCP20 levels and ImmunoCAP classes. CONCLUSIONS: FastCheckPOC 20 is reliable to determine allergen-specific IgE in human whole blood and plasma/serum samples</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1532-4230 (Electronic)IS - 1532-1819 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1080/15321819.2017.1349668</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28692338">PM:28692338</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="Arial">20170710, Rubenhagen R</style></custom2><misc3><style face="normal" font="Arial">10.1080/15321819.2017.1349668</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ramirez,W.</style></author><author><style face="normal" font="Arial"> Bourg,V.</style></author><author><style face="normal" font="Arial"> Torralba,D.</style></author><author><style face="normal" font="Arial"> Facenda,E.</style></author><author><style face="normal" font="Arial"> Tamargo,B.</style></author><author><style face="normal" font="Arial"> Gonzalez,B.O.</style></author><author><style face="normal" font="Arial"> Sierra,G.</style></author><author><style face="normal" font="Arial"> Perez,O.</style></author><author><style face="normal" font="Arial"> Perez-Llano,Y.</style></author><author><style face="normal" font="Arial"> Labrada,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Allergens Department , Centro Nacional de Biopreparados , Bejucal , Mayabeque , Cuba</style></auth-address><titles><title><style face="normal" font="Arial">Safety of a proteoliposome from Neisseria meningitides as adjuvant for a house dust mite allergy vaccine</style></title><secondary-title><style face="normal" font="Arial">J Immunotoxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunotoxicol</style></full-title></periodical><pages end="159" start="152">152-159</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cuba</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neisseria</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> purified allergens</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Safety evaluation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">The proteoliposome (PL) of Neisseria meningitidis serogroup B has been reported as a safe and potent vaccine adjuvant, inducing a TH1-skewed response. The present study describes a pre-clinical safety evaluation of an allergy therapeutic vaccine candidate based on purified allergens from Dermatophagoides siboney house dust mite and PL as adjuvant, both components adsorbed onto aluminum hydroxide gel. Two separate studies of acute toxicity evaluation were performed in mice and rabbits, and two repeat-dose studies were conducted in non-sensitized and allergen-sensitized Balb/c mice, respectively. The study in sensitized mice intends to model a therapeutic setting. Aerosolized allergen challenge was used in both settings to model natural respiratory exposure. In the therapeutic setting, mice were administered with three doses containing 2 mug allergen at weekly intervals [subcutaneous route] and subsequently challenged with aerosolized allergen for 6 consecutive days. Parameters of general toxicity effects were assessed via measures of behavior, body weight, food and water consumption, and macroscopic evaluation of organs. Histological examination of organs and the injection site was performed. Potential immunotoxicity effects at the systemic level were assessed by blood eosinophil counting and serum allergen specific IgE by ELISA The vaccine did not produce general or functional toxic effects of significance, at a dose up to 100 mug allergen per kg body weight. An expected local reaction at the injection site was observed, which could be attributed mostly to the immunological effect of aluminum hydroxide. The models implemented here suggest an acceptable safety profile of this vaccine for testing in clinical trials of allergy immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170712IS - 1547-6901 (Electronic)IS - 1547-691X (Linking)LA - engPT - Journal ArticleCO - Cuba -</style></notes><work-type><style face="normal" font="Arial">10.1080/1547691X.2017.1346007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28697661">PM:28697661</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunotoxicol\2017-14-152-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunotoxicol\2017-14-152-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170712, Ramirez W</style></custom2><misc3><style face="normal" font="Arial">10.1080/1547691X.2017.1346007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kuroda,Y.</style></author><author><style face="normal" font="Arial"> Yuki,T.</style></author><author><style face="normal" font="Arial"> Takahashi,Y.</style></author><author><style face="normal" font="Arial"> Sakaguchi,H.</style></author><author><style face="normal" font="Arial"> Matsunaga,K.</style></author><author><style face="normal" font="Arial"> Itagaki,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Safety Science Research Laboratories , Kao Corporation , Haga-Gun , Japan</style></auth-address><titles><title><style face="normal" font="Arial">Long form of thymic stromal lymphopoietin of keratinocytes is induced by protein allergens</style></title><secondary-title><style face="normal" font="Arial">J Immunotoxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunotoxicol</style></full-title></periodical><pages end="187" start="178">178-187</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> HSA</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> Human serum albumin</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immediate-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> rare allergen</style></keyword><keyword><style face="normal" font="Arial"> Rare allergens</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat gluten</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">A growing body of evidence suggests that epicutaneous sensitization of protein allergens induces immediate-type hypersensitivity (IHS) following induction of Type 2 immune responses in animals and humans. Thymic stromal lymphopoietin (TSLP) derived from keratinocytes is a cytokine that can activate dendritic cells and has been implicated in development of inflammatory Type 2 helper T-cells. However, there is no direct evidence that allergens directly regulate TSLP expression in keratinocytes. This study aimed to evaluate the response of TSLP to protein allergens in cultured human keratinocytes and to identify appropriate endpoints for IHS. The transcription of long-form TSLP (loTSLP) was strongly induced by ovalbumin, wheat gluten (WG), acid-hydrolyzed WG (acid-HWG), and extracts from feces of Dermatophagoides pteronyssinus and D. farina, and trypsin, but not by rare allergens, human serum albumin (HSA), or extracts of mite bodies. In acid-HWG, loTSLP mRNA was significantly augmented by acid hydrolysis of WG for 0.5 h compared to WG. However, prolonged acid hydrolysis attenuated this induction similarly to that reported in previous animal studies. These results suggested that intense loTSLP transcriptional induction was a characteristic of a high-allergenic protein. Additionally, TSLP production was induced by exposure to ovalbumin, WG, and acid-HWG in combination with a trio of cytokines, i.e. interleukin (IL)-4, IL-13, and tumor necrosis factor (TNF)-alpha. However, no TSLP protein was detected following exposure to HSA, even in the presence of these cytokines. With acid-HWG, TSLP protein release was consistent with loTSLP transcription. Thus, intense loTSLP transcriptional induction and TSLP protein expression are each effective indicators that can be used for in vitro screening of IHS</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1547-6901 (Electronic)IS - 1547-691X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/1547691X.2017.1349220</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28720058">PM:28720058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunotoxicol\2017-14-178-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunotoxicol\2017-14-178-87.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Kuroda Y</style></custom2><misc3><style face="normal" font="Arial">10.1080/1547691X.2017.1349220</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jenmalm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical and Experimental Medicine, Unit of Autoimmunity and Immune Regulation, Linkoping University, Linkoping, SwedenInternational Inflammation (in-FLAME) Network of the World Universities Network</style></auth-address><titles><title><style face="normal" font="Arial">The mother-offspring dyad: microbial transmission, immune interactions and allergy development</style></title><secondary-title><style face="normal" font="Arial">J Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Intern Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune development</style></keyword><keyword><style face="normal" font="Arial"> Immune maturation</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In utero</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">The increasing prevalence of allergy in affluent countries may be caused by reduced intensity and diversity of microbial stimulation, resulting in abnormal postnatal immune maturation. Most studies investigating the underlying immunomodulatory mechanisms have focused on postnatal microbial exposure, for example demonstrating that the gut microbiota differs in composition and diversity during the first months of life in children who later do or do not develop allergic disease. However, it is also becoming increasingly evident that the maternal microbial environment during pregnancy is important in childhood immune programming, and the first microbial encounters may occur already in utero. During pregnancy, there is a close immunological interaction between the mother and her offspring, which provides important opportunities for the maternal microbial environment to influence the immune development of the child. In support of this theory, combined pre- and postnatal supplementation seems to be crucial for the preventive effect of probiotics on infant eczema. Here, the influence of microbial and immune interactions within the mother-offspring dyad on childhood allergy development will be discussed. In addition, how perinatal transmission of microbes and immunomodulatory factors from mother to offspring may shape appropriate immune maturation during infancy and beyond, potentially via epigenetic mechanisms, will be examined. Deeper understanding of these interactions between the maternal and offspring microbiome and immunity is needed to identify efficacious preventive measures to combat the allergy epidemic. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1365-2796 (Electronic)IS - 0954-6820 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/joim.12652</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28727206">PM:28727206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Intern Med\20170720-JenmalmMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Intern Med\20170720-JenmalmMC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Jenmalm MC</style></custom2><misc3><style face="normal" font="Arial">10.1111/joim.12652</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">di Cara,G.</style></author><author><style face="normal" font="Arial"> Panfili,E.</style></author><author><style face="normal" font="Arial"> Marseglia,G.L.</style></author><author><style face="normal" font="Arial"> Pacitto,A.</style></author><author><style face="normal" font="Arial"> Salvatori,C.</style></author><author><style face="normal" font="Arial"> Testa,I.</style></author><author><style face="normal" font="Arial"> Fabiano,C.</style></author><author><style face="normal" font="Arial"> Verrotti,A.</style></author><author><style face="normal" font="Arial"> Latini,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universita degli Studi di Perugia, Dipartimento di Scienze Chirurgiche e Biomediche, Perugia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Association Between Pollen Exposure and Nasal Cytokines in Grass Pollen-Allergic Children</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="263" start="261">261-263</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0161</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731413">PM:28731413</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Di Cara G</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0161</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">El-Qutob,D.</style></author><author><style face="normal" font="Arial"> Bartolome,B.</style></author><author><style face="normal" font="Arial"> Cuesta,J.</style></author><author><style face="normal" font="Arial"> Mir,A.</style></author><author><style face="normal" font="Arial"> Alberola,A.</style></author><author><style face="normal" font="Arial"> Pastor-Vargas,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Allergy, University Hospital of La Plana, Vila-Real, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Identification of a Lipid Transfer Protein as a New Allergen From Morus alba Pollen</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="265" start="263">263-265</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731414">PM:28731414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, El-Qutob D</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0162</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia Rodriguez,R.</style></author><author><style face="normal" font="Arial"> Mendez Diaz,Y.</style></author><author><style face="normal" font="Arial"> Moreno Lozano,L.</style></author><author><style face="normal" font="Arial"> Extremera Ortega,A.</style></author><author><style face="normal" font="Arial"> Gomez Torrijos,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital General Universitario de Ciudad Real, Ciudad Real, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic Esophagitis After Egg Oral Immunotherapy in an Adult With Egg-Allergy and Egg-Bird Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="267" start="266">266-267</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> egg oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> egg-bird syndrome</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0163</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731415">PM:28731415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Garcia Rodriguez R</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0163</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mori,F.</style></author><author><style face="normal" font="Arial"> Sarti,L.</style></author><author><style face="normal" font="Arial"> Barni,S.</style></author><author><style face="normal" font="Arial"> Pucci,N.</style></author><author><style face="normal" font="Arial"> Belli,F.</style></author><author><style face="normal" font="Arial"> Stagi,S.</style></author><author><style face="normal" font="Arial"> Novembre,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Department of Pediatrics, Anna Meyer Children's University Hospital, Florence, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Donkey s Milk Is Well Accepted and Tolerated by Infants With Cow s Milk Food Protein-Induced Enterocolitis Syndrome: A Preliminary Study</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="271" start="269">269-271</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Donkey</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731417">PM:28731417</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Mori F</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0167</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martorell,A.</style></author><author><style face="normal" font="Arial"> Alonso,E.</style></author><author><style face="normal" font="Arial"> Echeverria,L.</style></author><author><style face="normal" font="Arial"> Escudero,C.</style></author><author><style face="normal" font="Arial"> Garcia-Rodriguez,R.</style></author><author><style face="normal" font="Arial"> Blasco,C.</style></author><author><style face="normal" font="Arial"> Bone,J.</style></author><author><style face="normal" font="Arial"> Borja-Segade,J.</style></author><author><style face="normal" font="Arial"> Bracamonte,T.</style></author><author><style face="normal" font="Arial"> Claver,A.</style></author><author><style face="normal" font="Arial"> Corzo,J.L.</style></author><author><style face="normal" font="Arial"> de la Hoz,B.</style></author><author><style face="normal" font="Arial"> Del Olmo,R.</style></author><author><style face="normal" font="Arial"> Dominguez,O.</style></author><author><style face="normal" font="Arial"> Fuentes-Aparicio,V.</style></author><author><style face="normal" font="Arial"> Guallar,I.</style></author><author><style face="normal" font="Arial"> Larramona,H.</style></author><author><style face="normal" font="Arial"> Martin-Munoz,F.</style></author><author><style face="normal" font="Arial"> Matheu,V.</style></author><author><style face="normal" font="Arial"> Michavila,A.</style></author><author><style face="normal" font="Arial"> Ojeda,I.</style></author><author><style face="normal" font="Arial"> Ojeda,P.</style></author><author><style face="normal" font="Arial"> Piquer,M.</style></author><author><style face="normal" font="Arial"> Poza,P.</style></author><author><style face="normal" font="Arial"> Reche,M.</style></author><author><style face="normal" font="Arial"> Rodriguez del Rio,P.</style></author><author><style face="normal" font="Arial"> Rodriguez,M.</style></author><author><style face="normal" font="Arial"> Ruano,F.</style></author><author><style face="normal" font="Arial"> Sanchez-Garcia,S.</style></author><author><style face="normal" font="Arial"> Terrados,S.</style></author><author><style face="normal" font="Arial"> Valdesoiro,L.</style></author><author><style face="normal" font="Arial"> Vazquez-Ortiz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, University General Hospital, Valencia, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Oral Immunotherapy for Food Allergy: A Spanish Guideline. Immunotherapy Egg and Milk Spanish Guide (ITEMS Guide). Part I: Cow Milk and Egg Oral Immunotherapy: Introduction, Methodology, Rationale, Current State, Indications, Contraindications, and Oral Immunotherapy Build-up Phase</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="237" start="225">225-237</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Avoidance diet</style></keyword><keyword><style face="normal" font="Arial"> avoidance diets</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Contraindication</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> egg oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Cow milk and egg are the most frequent causes of food allergy in the first years of life. Oral immunotherapy (OIT) has been investigated as an alternative to avoidance diets. No clinical practice guidelines on the management of OIT with milk and egg are currently available. Objectives: To develop clinical guidelines for OIT based on available scientific evidence and the opinions of experts. METHODS: A review was made of studies published between 1984 and June 2016, doctoral theses published in Spain, summaries of communications at scientific meetings (SEAIC, SEICAP, EAACI, and AAAAI), and the consensus of opinion established by a group of experts from the scientific societies SEICAP and SEAIC. RESULTS: Recommendations were established regarding the indications, requirements and practical aspects of the different phases of OIT, as well as special protocols for patients at high risk of adverse reactions. CONCLUSIONS: Clinical practice guidelines based on the consensus reached between Spanish experts are presented for the management of OIT with milk and egg</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0177</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731411">PM:28731411</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-225-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-225-37.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Martorell A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0177</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Azofra,J.</style></author><author><style face="normal" font="Arial"> Echechipia,S.</style></author><author><style face="normal" font="Arial"> Irazabal,B.</style></author><author><style face="normal" font="Arial"> Munoz,D.</style></author><author><style face="normal" font="Arial"> Bernedo,N.</style></author><author><style face="normal" font="Arial"> Garcia,B.E.</style></author><author><style face="normal" font="Arial"> Gastaminza,G.</style></author><author><style face="normal" font="Arial"> Goikoetxea,M.J.</style></author><author><style face="normal" font="Arial"> Joral,A.</style></author><author><style face="normal" font="Arial"> Lasa,E.</style></author><author><style face="normal" font="Arial"> Gamboa,P.</style></author><author><style face="normal" font="Arial"> Diaz,C.</style></author><author><style face="normal" font="Arial"> Beristain,A.</style></author><author><style face="normal" font="Arial"> Quinones,D.</style></author><author><style face="normal" font="Arial"> Bernaola,G.</style></author><author><style face="normal" font="Arial"> Echenagusia,M.A.</style></author><author><style face="normal" font="Arial"> Liarte,I.</style></author><author><style face="normal" font="Arial"> Garcia,E.</style></author><author><style face="normal" font="Arial"> Cuesta,J.</style></author><author><style face="normal" font="Arial"> Martinez,M.D.</style></author><author><style face="normal" font="Arial"> Velasco,M.</style></author><author><style face="normal" font="Arial"> Longo,N.</style></author><author><style face="normal" font="Arial"> Pastor-Vargas,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Seccion de Alergia. Area de Gestion del Pulmon. Hospital Universitario Central de Asturias. Oviedo. Spain</style></auth-address><titles><title><style face="normal" font="Arial">Heterogeneity in allergy to mollusks: a clinical-immunological study in a population from the North of Spain</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="260" start="252">252-260</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Gestion</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170103IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0137</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28045373">PM:28045373</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-252-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-252-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170103, Azofra J</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0137</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tavernier,S.J.</style></author><author><style face="normal" font="Arial"> Vanlangenakker,N.</style></author><author><style face="normal" font="Arial"> Vetters,J.</style></author><author><style face="normal" font="Arial"> Carmeliet,P.</style></author><author><style face="normal" font="Arial"> Janssens,S.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunoregulation and Mucosal Immunology, VIB Center for Inflammation Research, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Opposing regulation and roles for PHD3 in lung dendritic cells and alveolar macrophages</style></title><secondary-title><style face="normal" font="Arial">J Leukoc Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Leukoc Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hypoxia</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immunology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">The prolyl hydroxylase domain-containing enzymes (PHDs) are important metabolic sensors of the cell and its environment, which might be employed to alert cells of the immune system. These enzymes regulate the expression of the hypoxia inducible factor (HIF) isoforms and NF-kappaB, crucial transcription factors controlling cellular metabolism and inflammation. PHD/HIF signaling is activated in the allergic lung and is proposed as a potential druggable pathway. Here, we investigated the regulation and role of the PHD isoforms in CD11c-expressing dendritic cells (DCs) and macrophages (Mvarphi), sensors of the environment and crucial antigen-presenting cells in the pathogenesis of asthma. Although PHD2 and PHD3 were expressed in baseline, stimulation with house dust mite (HDM) allergen, hypoxia, and TLR4 ligands induced the expression of PHD3 in DCs. Conditional deletion or overexpression of PHD3 in CD11chi cells had minor effects on DCs and alveolar Mvarphi biology in steady state. However, when put into competition with wild-type counterparts in mixed chimeric mice, alveolar Mvarphi uniquely required PHD3 for optimal reconstitution of the alveolar space. Using genetic and chemical approaches, we were unable to find a clear role for PHD3 or the other PHD isoforms in DCs in asthma development. These data show cell-specific competitive advantage of PHD3 expression in antigen-presenting cells, but question whether therapeutic manipulation of PHDs in DCs would offer therapeutic benefit in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1938-3673 (Electronic)IS - 0741-5400 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1189/jlb.3A0916-405R</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28716863">PM:28716863</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Leukoc Biol\20170718-TavernierSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Leukoc Biol\20170718-TavernierSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Tavernier SJ</style></custom2><misc3><style face="normal" font="Arial">10.1189/jlb.3A0916-405R</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,Y.T.</style></author><author><style face="normal" font="Arial"> Wu,C.T.</style></author><author><style face="normal" font="Arial"> Sun,H.L.</style></author><author><style face="normal" font="Arial"> Ko,J.L.</style></author><author><style face="normal" font="Arial"> Lue,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.</style></auth-address><titles><title><style face="normal" font="Arial">Fungal immunomodulatory protein-fve could modulate airway remodel through by affect IL17 cytokine</style></title><secondary-title><style face="normal" font="Arial">J Microbiol Immunol Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Microbiol Immunol Infect</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Intranasal challenge</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is one of the most common allergic diseases. Our previous studies have reported that FIP-fve in acute allergic mouse model can reduce inflammation, improve the balance of the Th1/Th2 system. However, the effects of reducing airway remodeling on FIP-fve is still unknown. OBJECTIVE: We hypothesized that orally administrated FIP-fve should be able to reduce airway remodeling in chronic allergic models. METHODS: The chronic asthma animal model was established with 6-8 weeks female Balb/c mice. After intranasal challenges with OVA, the airway inflammation and AHR were determined by a BUXCO system. BALF was analyzed with Liu's stain and ELISA assay. Lung histopathologic changes and Collagen deposition were assayed with H&amp;E, Masson's trichrome and IHC stain. RESULTS: FIP-fve significantly decreased the number of infiltrating inflammatory cells and Th2 cytokines and increased Th1 cytokines in BALF and serum compared with the OVA sensitized mice. FIP-fve had a better effect than corticosteroid could reduce infiltrating cells in lung especially neutrophils and eosinophils. We also found that the oral FIP-fve group suppressed IL-17 and enhanced IL-22 in the serum and BALF. In addition, oral FIP-fve decreased MMP9 expression, collagen expression and airway remodeling in lung tissues. CONCLUSION: FIP-fve had anti-inflammatory effects on OVA-induced airway inflammation and an effect to inhibited Th17 cells to reduced airway remodeling and collagen expression. Moreover, FIP-fve might be a potential alternative therapy for allergic airway diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170715IS - 1995-9133 (Electronic)IS - 1684-1182 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jmii.2017.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709839">PM:28709839</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Microbiol Immunol Infect\20170715-LeeYT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Microbiol Immunol Infect\20170715-LeeYT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170715, Lee YT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jmii.2017.06.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brown,W.</style></author><author><style face="normal" font="Arial"> Schmitz,T.</style></author><author><style face="normal" font="Arial"> Scott,D.M.</style></author><author><style face="normal" font="Arial"> Friesner,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacy Practice, North Dakota State University, Fargo, ND, USA</style></auth-address><titles><title><style face="normal" font="Arial">Is Telehealth Right for Your Practice and Your Patients With Asthma?</style></title><secondary-title><style face="normal" font="Arial">J Patient Exp</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Patient Exp</style></abbr-1></periodical><pages end="49" start="46">46-49</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma education</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> North Dakota</style></keyword><keyword><style face="normal" font="Arial"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Telehealth services are becoming increasingly used to provide care to patients living in rural areas. Little is known about the patient satisfaction with the provision of these services. METHODS: A prospective cohort pilot study was developed to evaluate the use of telehealth for the delivery of asthma education services in the rural, medically underserved community of Oakes, North Dakota. A certified asthma educator used real-time, audio-visual telehealth technology to meet with patients the local community pharmacy. Patients met with the educator monthly for the first three months of the study, and once every three months thereafter. Patient satisfaction was measured using a five item survey. RESULTS: Eighteen patients completed the study (90 percent completion rate). Patient satisfaction scores were relatively high, typically between 4 and 5 on a 5-point scale. CONCLUSIONS: Participants in a rural, medically underserved community found the community pharmacy location and the telehealth technology a convenient means to access a specialty provider for asthma education</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 2374-3735 (Print)IS - 2374-3735 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/2374373516685952</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28725859">PM:28725859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Patient Exp\2017-4-46-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Patient Exp\2017-4-46-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Brown W</style></custom2><misc3><style face="normal" font="Arial">10.1177/2374373516685952</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gatford,K.L.</style></author><author><style face="normal" font="Arial"> Wooldridge,A.L.</style></author><author><style face="normal" font="Arial"> Kind,K.L.</style></author><author><style face="normal" font="Arial"> Bischof,R.</style></author><author><style face="normal" font="Arial"> Clifton,V.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pre-birth origins of allergy and asthma</style></title><secondary-title><style face="normal" font="Arial">J Reprod Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Reprod Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> aetiology</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Developmental programming</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Experimental models</style></keyword><keyword><style face="normal" font="Arial"> folic acid</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intrauterine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> IUGR</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0165-0378</style></isbn><abstract><style face="normal" font="Arial">Allergy is a chronic disease that can develop as early as infancy, suggesting that early life factors are important in its aetiology. Variable associations between size at birth, a crude marker of the fetal environment, and allergy have been reported in humans and require comprehensive review. Associations between birth weight and allergy are however confounded in humans, and we and others have therefore begun exploring the effects of early life events on allergy in experimental models. In particular, we are using ovine models to investigate whether and how a restricted environment before birth protects against allergy, whether methyl donor availability contributes to allergic protection in IUGR, and why maternal asthma during pregnancy is associated with increased risks of allergic disease in children. We found that experimental intrauterine growth restriction (IUGR) in sheep reduced cutaneous responses to antigens in progeny, despite normal or elevated IgE responses. Furthermore, maternal methyl donor supplementation in late pregnancy partially reversed effects of experimental IUGR, consistent with the proposal that epigenetic pathways underlie some but not all effects of IUGR on allergic susceptibility. Ovine experimental allergic asthma with exacerbations reduces relative fetal size in late gestation, with some changes in immune populations in fetal thymus suggestive of increased activation. Maternal allergic asthma in mice also predisposes progeny to allergy development. In conclusion, these findings in experimental models provide direct evidence that a perturbed environment before birth alters immune system development and postnatal function, and provide opportunities to investigate underlying mechanisms and develop and evaluate interventions</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jri.2017.07.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jri.2017.07.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Reprod Immunol\201707-GatfordKL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Reprod Immunol\201707-GatfordKL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Gatford KL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jri.2017.07.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Onuma,M.</style></author><author><style face="normal" font="Arial"> Terada,M.</style></author><author><style face="normal" font="Arial"> Ono,S.</style></author><author><style face="normal" font="Arial"> Murakami,A.</style></author><author><style face="normal" font="Arial"> Ishida,T.</style></author><author><style face="normal" font="Arial"> Sano,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Oosagami Animal Clinic</style></auth-address><titles><title><style face="normal" font="Arial">Incidence of anaphylactic reactions after propofol administration in dogs</style></title><secondary-title><style face="normal" font="Arial">J Vet Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Vet Med Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> emulsion</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean Oil</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="Arial">Propofol is an anesthetic agent suspended in an emulsion system that includes egg yolk lecithin and soybean oil, because of which, there is concern about the use of propofol in patients allergic to these substances. We examined the association between propofol administration and incidence of adverse events in dogs with allergy to egg yolk lecithin and soybean oil. On the basis of the findings of an allergen-specific immunoglobulin E (IgE) test, 14 dogs with high levels (high-IgE group) and 7 dogs with low levels (normal-IgE group) of IgE were selected. Following intravenous administration of propofol, the incidence of anaphylactic reactions and plasma histamine concentrations under general anesthesia maintained with isoflurane throughout surgery were compared between the two groups. The frequency of anaphylactic reactions and plasma histamine concentrations were compared by the chi-square test and Student t-test, respectively. The statistical significance for both tests was set at P&lt;0.05. In the high- and normal-IgE groups, the average frequencies of anaphylactic reactions after propofol administration were 21.4% and 14.3%, and the mean plasma histamine concentrations were 167.9 +/- 94.5 nM and 65.7 +/- 40.3 nM, respectively. Animals of neither groups experienced shock-like symptoms. These results revealed that propofol might be relatively safe, although careful perioperative anesthesia monitoring and standby protocols are required when using propofol in dogs with a history of allergic diseases or high chicken- or soybean-specific IgE levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1347-7439 (Electronic)IS - 0916-7250 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1292/jvms.16-0550</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28717055">PM:28717055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Vet Med Sci\201718-OnumaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Vet Med Sci\201718-OnumaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Onuma M</style></custom2><misc3><style face="normal" font="Arial">10.1292/jvms.16-0550</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ha,J.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Lee,H.</style></author><author><style face="normal" font="Arial"> Choi,Y.</style></author><author><style face="normal" font="Arial"> Oh,H.</style></author><author><style face="normal" font="Arial"> Yoon,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food and Nutrition, Sookmyung Women's University, Seoul 04310, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Identification of Pork Adulteration in Processed Meat Products Using the Developed Mitochondrial DNA-Based Primers</style></title><secondary-title><style face="normal" font="Arial">Korean J Food Sci Anim Resour</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Korean J Food Sci Anim Resour</style></full-title></periodical><pages end="468" start="464">464-468</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adulteration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Cattle</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> ethics</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Meat Products</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> processed meat</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The identification of pork in commercially processed meats is one of the most crucial issues in the food industry because of religious food ethics, medical purposes, and intentional adulteration to decrease production cost. This study therefore aimed to develop a method for the detection of pork adulteration in meat products using primers specific for pig mitochondrial DNA. Mitochondrial DNA sequences for pig, cattle, chicken, and sheep were obtained from GenBank and aligned. The 294-bp mitochondrial DNA D-loop region was selected as the pig target DNA sequence and appropriate primers were designed using the MUSCLE program. To evaluate primer sensitivity, pork-beef-chicken mixtures were prepared as follows: i) 0% pork-50% beef-50% chicken, ii) 1% pork-49.5% beef-49.5% chicken, iii) 2% pork-49% beef-49% chicken, iv) 5% pork-47.5% beef-47.5% chicken, v) 10% pork-45% beef-45% chicken, and vi) 100% pork-0% beef-0% chicken. In addition, a total of 35 commercially packaged products, including patties, nuggets, meatballs, and sausages containing processed chicken, beef, or a mixture of various meats, were purchased from commercial markets. The primers developed in our study were able to detect as little as 1% pork in the heat treated pork-beef-chicken mixtures. Of the 35 processed products, three samples were pork positive despite being labeled as beef or chicken only or as a beef-chicken mix. These results indicate that the developed primers could be used to detect pork adulteration in various processed meat products for application in safeguarding religious food ethics, detecting allergens, and preventing food adulteration</style></abstract><notes><style face="normal" font="Arial">DA - 20170727IS - 1225-8563 (Print)IS - 1225-8563 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5851/kosfa.2017.37.3.464</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28747833">PM:28747833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Korean J Food Sci Anim Resour\2017-37-464-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Korean J Food Sci Anim Resour\2017-37-464-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Ha J</style></custom2><misc3><style face="normal" font="Arial">10.5851/kosfa.2017.37.3.464</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nam,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,H.M.</style></author><author><style face="normal" font="Arial"> Jeong,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">The potential protective role of taurine against experimental allergic inflammation</style></title><secondary-title><style face="normal" font="Arial">Life Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Life Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Caspase 1</style></keyword><keyword><style face="normal" font="Arial"> caspase-1</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">AIMS: Taurine has been widely evaluated as a potential therapeutic agent in chronic inflammatory disorders and various infections. However, the potential role of taurine in regulating allergic inflammatory responses is currently unknown. MATERIALS AND METHODS: The present study was designed to evaluate the in vitro effects of taurine on the levels of thymic stromal lymphopoietin (TSLP) and other pro-inflammatory cytokines and activation of caspase-1 and nuclear factor (NF)-kappaB as well as the phosphorylations of c-Jun N-terminal kinase (JNK) and p38 in phorbol 12-myristate 13-acetate and calcium ionophore A23187 (PMACI)-triggered human mast cell line, HMC-1 cells. Furthermore, we assessed the therapeutic effects of taurine on ovalbumin (OVA)-induced allergic rhinitis (AR) animal models. KEY FINDINGS AND SIGNIFICANCE: Here, the obtained results showed that taurine dose-dependently inhibited the production and mRNA expression of TSLP and pro-inflammatory cytokines in HMC-1 cells exposed to PMACI. Taurine attenuated the phosphorylation of JNK and p38 in activated HMC-1 cells. Moreover, taurine brought a significant inhibition of the activities of NF-kappaB and caspase-1. In an OVA-induced AR animal model, the increased levels of nose rubbing, histamine, immunoglobulin E, TSLP, and interleukin IL-1beta were dramatically reduced by the administration of taurine. In summary, taurine could serve as potential novel remedy of allergic inflammatory disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 1879-0631 (Electronic)IS - 0024-3205 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.lfs.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28694089">PM:28694089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Life Sci\20170711-NamSY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Life Sci\20170711-NamSY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Nam SY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.lfs.2017.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ki,H.H.</style></author><author><style face="normal" font="Arial"> Hwang,S.W.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Kim,D.K.</style></author><author><style face="normal" font="Arial"> Lee,Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Oriental Pharmacy, College of Pharmacy and WonkwangOriental Medicines Research Institute, Wonkwang University, Iksan, Jeonbuk 54538, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">A dichloromethane fraction of Triticum aestivum sprouts reduces allergic immune response through inhibiting Th2 differentiation in ovalbumin immunized mice</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="3541" start="3535">3535-3541</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dietary supplement</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Triticum</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="Arial">Triticum aestivum sprouts are small shoots that germinate from seeds and are consumed as a dietary supplement. The present study aimed to determine whether a dichloromethane fraction isolated from Triticum aestivum sprouts (TDF) suppressed the allergic immune response in ovalbumin (OVA)sensitized mice. In vivo experiments were performed by administering TDF or vehicle to mice during the sensitization and this was immediately followed by an intradermal injection of OVA into the ears. Splenocytes isolated from OVAsensitized mice were pretreated with TDF and rechallenged with OVA for ex vivo evaluation. Results demonstrated that TDF suppressed the inflammatory response in ear tissues and levels of total immunoglobulin (Ig)E and OVAspecific IgE in serum. TDF inhibited the production of interleukin (IL)4 and expression of GATAbinding protein3 (GATA3) transcription factor which regulates the differentiation of naive T helper (Th) cells into Th2 cells in OVAstimulated splenocytes. TDF inhibited Th1associated cytokine interferongamma and IL12 production and downregulated the expression of Th1 specific transcription factor Tbox 21 in OVAstimulated splenocytes. Overall, these results indicated that TDF attenuates OVAinduced allergic immune response by suppressing the production of Th2 specific cytokine IL4, through inhibiting transcription factor GATA3, and suggests that TDF may exhibit the potential to regulate the immune response in allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.7020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28713973">PM:28713973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-3535-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-3535-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Ki HH</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.7020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fu,L.Q.</style></author><author><style face="normal" font="Arial"> Li,Y.L.</style></author><author><style face="normal" font="Arial"> Fu,A.K.</style></author><author><style face="normal" font="Arial"> Wu,Y.P.</style></author><author><style face="normal" font="Arial"> Wang,Y.Y.</style></author><author><style face="normal" font="Arial"> Hu,S.L.</style></author><author><style face="normal" font="Arial"> Li,W.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of Molecular Animal Nutrition and Feed Sciences, College of Animal Science, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="4158" start="4151">4151-4158</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="08/01/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animal Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus metaplasia</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="Arial">Pidotimod is a synthetic dipeptide with biological and immunomodulatory properties. It has been widely used for treatment and prevention of recurrent respiratory infections. However, its impact on the regulation of allergic pulmonary inflammation is still not clear. In the current study, an ovalbumin (OVA)induced allergic asthma model was used to investigate the immunemodulating effects of pidotimod on airway eosinophilia, mucus metaplasia and inflammatory factor expression compared with dexamethasone (positive control). The authors determined that treatment with pidotimod exacerbated pulmonary inflammation as demonstrated by significantly increased eosinophil infiltration, dramatically elevated immunoglobulin E production, and enhanced T helper 2 response. Moreover, treatment failed to attenuate mucus production in lung tissue, and did not reduce OVAinduced high levels of FIZZ1 and Arg1 expression in asthmatic mice. In contrast, administration of dexamethasone was efficient in alleviating allergic airway inflammation in OVAinduced asthmatic mice. These data indicated that pidotimod as an immunotherapeutic agent should be used cautiously and the effectiveness for controlling allergic asthma needs further evaluation and research</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.7046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731127">PM:28731127</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-4151-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-4151-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Fu LQ</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.7046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gamaletsou,M.N.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University Hospital of South Manchester, National Aspergillosis Centre, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection?</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal treatment</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Laryngoscopy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Manometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Ulcer</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: We studied the relationship between GORD and allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), or Aspergillus bronchitis. BACKGROUND: Gastroesophageal reflux disease (GORD) is well known to initiate or exacerbate pulmonary inflammatory conditions, inducing bronchial asthma and chronic obstructive lung disease. METHODS: We reviewed four patients referred with elevated Aspergillus serology markers and marked pulmonary symptoms for ABPA, CPA, and Aspergillus bronchitis, and discussed the underlying pathophysiological relationship with GORD. Data were collected retrospectively from medical records included age, gender, predisposing factors for ABPA, chronic pulmonary aspergillosis, or Aspergillus bronchitis; presence of nocturnal reflux, nausea, epigastric pain, Medical Research Council dyspnea scale score, pH manometry data, endoscopic results (ulcers, Barrett's esophagus), treatment of GORD [proton-pump inhibitors (PPIs), surgical operation]; history of smoking, alcohol consumption; concomitant COPD; serological markers (anti-Aspergillus IgG, anti-Aspergillus IgE), and antifungal treatment. RESULTS: Four patients with GORD were studied; following PPIs administration two achieved clinical improvement. One had ABPA, one CPA, and two had Aspergillus bronchitis; median age was 57 years [range 39-71]; males-to-females ratio was 1:3. Serological markers for aspergillosis were: median total IgE antibodies 573 KIU/L [range 13.1-850], median Aspergillus IgE-specific antibodies 1.2 kAU/L [range &lt;0.4-24.7], and median Aspergillus IgG titers 71 mg/L [range 20-119]. Aspergillus fumigatus grew in one sputum sample. CONCLUSION: Clinicians caring for patients with gastroesophageal reflux disease presenting with elevated Aspergillus IgG or IgE antibodies should maintain a high index of suspicion for this association and proceed to appropriate evaluations, including laryngoscopy and endoscopy, initiating specific PPI-directed therapy when indicated</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-017-0176-y.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28702854">PM:28702854</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20170713-GamaletsouMN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20170713-GamaletsouMN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Gamaletsou MN</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-017-0176-y.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Croote,D.</style></author><author><style face="normal" font="Arial"> Quake,S.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Bioengineering, Stanford University, Stanford, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Food allergen detection by mass spectrometry: the role of systems biology</style></title><secondary-title><style face="normal" font="Arial">NPJ Syst Biol Appl</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">NPJ Syst Biol Appl</style></abbr-1></periodical><pages end="" start="16022">16022-</pages><volume><style face="normal" font="Arial">2</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food allergen detection</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> instrumentation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanut proteins</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteotypic peptide</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> SRM</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Systems Biology</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Workflow</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Food allergy prevalence is rising worldwide, motivating the development of assays that can sensitively and reliably detect trace amounts of allergens in manufactured food. Mass spectrometry (MS) is a promising alternative to commonly employed antibody-based assays owing to its ability to quantify multiple proteins in complex matrices with high sensitivity. In this review, we discuss a targeted MS workflow for the quantitation of allergenic protein in food products that employs selected reaction monitoring (SRM). We highlight the aspects of SRM method development unique to allergen quantitation and identify opportunities for simplifying the process. One promising avenue identified through a comprehensive survey of published MS literature is the use of proteotypic peptides, which are peptides whose presence appears robust to variations in food matrix, sample preparation protocol, and MS instrumentation. We conclude that proteotypic peptides exist for a subset of allergenic milk, egg, and peanut proteins. For less studied allergens such as soy, wheat, fish, shellfish, and tree nuts, we offer guidance and tools for peptide selection and specificity verification as part of an interactive web database, the Allergen Peptide Browser (http://www.AllergenPeptideBrowser.org). With ongoing improvements in MS instrumentation, analysis software, and strategies for targeted quantitation, we expect an increasing role of MS as an analytical tool for ensuring regulatory compliance</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 2056-7189 (Print)IS - 2056-7189 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/npjsba.2016.22</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28725476">PM:28725476</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\NPJ Syst Biol Appl\2016-2-16022.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\NPJ Syst Biol Appl\2016-2-16022.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Croote D</style></custom2><misc3><style face="normal" font="Arial">10.1038/npjsba.2016.22</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lawlis,T.</style></author><author><style face="normal" font="Arial"> Bakonyi,S.</style></author><author><style face="normal" font="Arial"> Williams,L.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Public Health and Nutrition, University of Canberra, Canberra, Australian Capital Territory, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy in schools: The importance of government involvement</style></title><secondary-title><style face="normal" font="Arial">Nutr Diet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nutr Diet</style></abbr-1></periodical><pages end="87" start="82">82-87</pages><volume><style face="normal" font="Arial">74</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Australian Capital Territory</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guideline implementation</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">AIM: Children have the highest rates of food-related allergic reactions. While 85% of children outgrow allergies including cow's milk and eggs by five years of age, allergies to peanuts and seafood continue into adulthood. The school setting poses a high-risk environment for allergen exposure. The aim of the present study was to examine the availability, drivers and communication of school food allergy awareness and management policies/guidelines in one Australian education jurisdiction. METHODS: A cross-sectional study comprising an online survey of principals on school allergy awareness (n = 100) was conducted in public, catholic and independent primary and high schools in an Australian education jurisdiction between August 2011 and November 2012. RESULTS: Sixty-three per cent (17/27) of schools responding to the survey reported using food allergy management guidelines. An average of 13 students per school were reported to have a food allergy with 93% of schools reported having students with at least one food allergy. Parents, not government policy, were identified as primary drivers of food allergy guideline implementation and a third of schools provided anaphylaxis training annually. Communication of food allergy management was limited with only 42 school websites either providing access to policies/guidelines or providing a food allergy statement. CONCLUSIONS: Detailed awareness and management guidelines are integral for schools to adequately manage food-induced allergic reactions, including anaphylaxis, in the school environment. To enable this, national government support through legislation and policy is needed to ensure a consistent, up-to-date and policed approach to food allergy management in the Australian education sector</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1747-0080 (Electronic)IS - 1446-6368 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/1747-0080.12225</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731550">PM:28731550</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutr Diet\2017-74-82-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutr Diet\2017-74-82-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Lawlis T</style></custom2><misc3><style face="normal" font="Arial">10.1111/1747-0080.12225</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vandenplas,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Kidz Health Castle, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">Prevention and Management of Cow's Milk Allergy in Non-Exclusively Breastfed Infants</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="E731">E731-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid formula</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> cow milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">Introduction: The prevention and management of cow milk allergy (CMA) is still debated. Since CMA is much less frequent in breastfed infants, breastfeeding should be stimulated. Method: Literature was searched using databases to find original papers and reviews on this topic. Results: Hydrolysates with a clinical proof of efficacy are recommended in the prevention and treatment of CMA. However, not all meta-analyses conclude that hydrolysates do prevent CMA or other atopic manifestations such as atopic dermatitis. There are pros and cons to consider partially hydrolysed protein as an option for starter infant formula for each non-exclusively breastfed infant. A challenge test is still recommended as the most specific and sensitive diagnostic test, although a positive challenge test does not proof that the immune system is involved. The Cow Milk Symptom Score (CoMiSS) is an awareness tool that enables healthcare professionals to better recognize symptoms related to the ingestion of cow milk, but it still needs validation as diagnostic tool. The current recommended elimination diet is a cow milk based extensive hydrolysate, although rice hydrolysates or soy infant formula can be considered in some cases. About 10 to 15% of infants allergic to cow milk will also react to soy. Mainly because of the higher cost, amino acid based formula is reserved for severe cases. There is no place for infant formula with intact protein from other animals as cross-over allergenicity is high. During recent years, attention focused also on the bifidogenic effect of prebiotics and more recently also on human milk oligosaccharides. A bifidogenic gastrointestinal microbiome may decrease the risk to develop allergic disease. The addition of probiotics and prebiotics to the elimination diet in treatment may enhance the development of tolerance development. Conclusion: Breastfeeding is the best way to feed infants. Cow milk based extensive hydrolysates remain the first option for the treatment of CMA for the majority of patients, while amino acid formulas are reserved for the most severe cases. Rice hydrolysates and soy infant formula are second choice options. Partial hydrolysates with clinical proof of efficacy are recommended in some guidelines in the prevention of CMA and allergic disease in at risk infants, and may be considered as an option as protein source in starter infant formula</style></abstract><notes><style face="normal" font="Arial">DA - 20170712IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9070731</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28698533">PM:28698533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-E731.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-E731.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170712, Vandenplas Y</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9070731</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,Z.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Dai,L.</style></author><author><style face="normal" font="Arial"> Jia,L.</style></author><author><style face="normal" font="Arial"> Jing,X.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Li,P.</style></author><author><style face="normal" font="Arial"> An,L.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory and Critical Care Medicine, Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China</style></auth-address><titles><title><style face="normal" font="Arial">Suppression of microRNA-384 enhances autophagy of airway smooth muscle cells in asthmatic mouse</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="67933" start="67941">67941-67933</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">40</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> progression of asthma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">Injury to airway smooth muscle (ASM) cells hallmarks the pathological progression of asthma, a chronic inflammatory airway disease. MicroRNAs (miRNAs) play essential roles in the development of asthma as well as airway remodeling. Here we studied the involvement of miRNAs in the regulation of autophagic survival of ASM cells and airway disorder. We analyzed autophagy-associated factors LC3 and Beclin-1 by RT-qPCR and protein blotting in purified airway smooth muscle cells from ovalbumin (OVA)-induced asthmatic mice. The biological activity of miRNA targeting Beclin-1 was explored by bioinformatics method and confirmed in a dual luciferase reporter assay. Loss of function experiment was performed via transplantation of miRNA in OVA-induced asthmatic mice. We detected high autophagy levels in ASM cells, which appeared to result from augmentation of Beclin-1 protein, rather than Beclin-1 mRNA, suggesting presence of post-transcriptional control of Beclin-1. Next, miR-384 was figured out to be a Belcin-1-targeting miRNA, which significantly decreased after OVA treatment. Mechanistically, binding of miR-384 to 3'-UTR of Beclin-1 mRNA potently suppressed Beclin-1 protein translation in ASM cells, similar to previous finding in another cell type. In vivo, transplantation of miR-384 significantly attenuated Belcin-1 protein levels in ASM cells, resulting in reduced autophagy of ASM cells and attenuation of asthmatic features by OVA. Together, these data suggest that re-expression of miR-384 may reduce augmentation of Beclin-1-dependent autophagy of ASM cells, as a novel promising treatment for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.18913</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28978085">PM:28978085</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\20170720-ChengZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\20170720-ChengZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Cheng Z</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.18913</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghaffari,J.</style></author><author><style face="normal" font="Arial"> Rokni,G.R.</style></author><author><style face="normal" font="Arial"> Kazeminejad,A.</style></author><author><style face="normal" font="Arial"> Abedi,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Infectious Disease Research Center with Focus on Nosocomial Infection, Bou-Ali Sina Hospital, Mazandaran University of Medical Sciences, Sari, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Association among Thyroid Dysfunction, Asthma, Allergic Rhinitis and Eczema in Children with Alopecia Areata</style></title><secondary-title><style face="normal" font="Arial">Open Access Maced J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Open Access Maced J Med Sci</style></full-title></periodical><pages end="309" start="305">305-309</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Alopecia</style></keyword><keyword><style face="normal" font="Arial"> Alopecia Areata</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nosocomial infection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Alopecia areata is a non-scarring hair loss, which typically starts quickly. Atopy is one of the possible predisposing risk factors for this condition. AIM: This study aimed to evaluate the prevalence of thyroid disease, atopic dermatitis and allergic diseases in children with alopecia areata and compare the results with healthy individuals. METHODS: This case-control study was conducted on 50 patients with alopecia areata, diagnosed by a dermatologist, and 150 healthy individuals as the control group. Participants filled the questionnaires, and necessary tests were performed. RESULTS: In this study, the mean age of the participants was 2.55 +/- 14.26 and 3.19 +/- 11.92 in the case and control groups, respectively. Prevalence of asthma was 22% in the case group and 12.5% in control group (P = 0.109). Also, allergic rhinitis and eczema were observed in 20% and 22% of the subjects of the case group, whereas they were reported to be 8% and 10% in the control group (PV = 0.03 and 0.175, respectively). Moreover, 28% and 8% of the participants in the case and control groups had a family history of atopy and allergic disorders, respectively (P = 0.046). A significant difference was observed between the two groups regarding gender, type of delivery and contact with animals. CONCLUSIONS: According to the results of this study, a significant association was observed between the prevalence of alopecia areata and atopic conditions, such as allergic rhinitis and history of atopic dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170712IS - 1857-9655 (Print)IS - 1857-9655 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.3889/oamjms.2017.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28698747">PM:28698747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Open Access Maced J Med Sci\2017-5-305-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Open Access Maced J Med Sci\2017-5-305-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170712, Ghaffari J</style></custom2><misc3><style face="normal" font="Arial">10.3889/oamjms.2017.050</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Delcombel,R.</style></author><author><style face="normal" font="Arial"> Karembe,H.</style></author><author><style face="normal" font="Arial"> Nare,B.</style></author><author><style face="normal" font="Arial"> Burton,A.</style></author><author><style face="normal" font="Arial"> Liebenberg,J.</style></author><author><style face="normal" font="Arial"> Fourie,J.</style></author><author><style face="normal" font="Arial"> Varloud,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ceva Sante Animale, 10 avenue de la Ballastiere, 33500, Libourne, France</style></auth-address><titles><title><style face="normal" font="Arial">Synergy between dinotefuran and fipronil against the cat flea (Ctenocephalides felis): improved onset of action and residual speed of kill in adult cats</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="341">341-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Alopecia</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Bioassay</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Flea Infestations</style></keyword><keyword><style face="normal" font="Arial"> Fleas</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The cat flea, Ctenocephalides felis felis (C. felis), is a cosmopolitan hematophagous ectoparasite, and is considered to be the most prevalent flea species in both Europe and the USA. Clinical signs frequently associated with flea bites include pruritus, dermatitis and in severe cases even pyodermatitis and alopecia. Ctenocephalides felis is also a vector for several pathogens and is an intermediate host for the cestode Dipylidium caninum. Treatment of cats with a fast-acting pulicide, that is persistently effective in protecting the animal against re-infestation, is therefore imperative to their health. In addition, a rapid onset of activity ("speed of kill") may also reduce the risks of disease transmission and flea allergic dermatitis. The aim of this study was to evaluate the in vitro insecticidal activity and potential synergism between dinotefuran and fipronil against C. felis. A further aim was to evaluate the onset of activity and residual speed of kill of the combination in vivo on cats artificially infested with C. felis. METHODS: In the first study, the insecticidal activity of dinotefuran and fipronil separately and dinotefuran/fipronil (DF) in combination, at a fixed ratio (2:1), was evaluated using an in vitro coated-vial bioassay. In the second study, the onset of activity against existing flea infestations and residual speed of kill of DF against artificial flea infestations on cats was assessed in vivo. Onset of activity against existing flea infestations was assessed in terms of knock-down effect within 2 h post-treatment and onset of speed of kill assessed at 3 h, 6 h and 12 h post-treatment. Residual speed of kill was evaluated 6 h and 48 h after infestation, over a period of six weeks post-treatment. RESULTS: In vitro results revealed that the DF combination was synergistic and more potent against fleas than either compound alone. The combination also proved effective when tested in vivo. Efficacy was > 97% [geometric mean (GM) and arithmetic mean (AM)] at 3 h after treatment, and >/= 99.8% (GM and AM) at 6 h and 12 h post-treatment. At 6 h after flea re-infestations, the efficacy of DF remained >/= 90.8% (GM and AM) for up to 28 days, and at 42 days post-treatment persistent efficacy was still >/= 54.3% (GM and AM). At 48 h after flea re-infestations, DF remained almost fully effective for up to 28 days, with efficacies >/= 99.4% (GM and AM) and was persistently >/= 93.0% (GM and AM) effective for up to 42 days post-treatment. CONCLUSIONS: The combination of dinotefuran and fipronil in a single formulation exhibited strong synergistic insecticidal activity against C. felis in vitro, and also proved effective on artificially infested cats. This activity had a rapid onset that persisted for 6 weeks against re-infestations of C. felis on cats. The rapid curative insecticidal effect was observed as early as 3 h after treatment, and as early as 6 h after re-infestations for up to 6 weeks post-treatment. The insecticidal activity profile of DF makes it an optimal candidate for the protection of cats against flea infestations, and possibly also associated diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleCO - France -CO - United States -CO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-017-2272-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28724438">PM:28724438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2017-10-341.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2017-10-341.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Delcombel R</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-017-2272-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Speciale,A.</style></author><author><style face="normal" font="Arial"> Trombetta,D.</style></author><author><style face="normal" font="Arial"> Saija,A.</style></author><author><style face="normal" font="Arial"> Panebianco,A.</style></author><author><style face="normal" font="Arial"> Giarratana,F.</style></author><author><style face="normal" font="Arial"> Ziino,G.</style></author><author><style face="normal" font="Arial"> Minciullo,P.L.</style></author><author><style face="normal" font="Arial"> Cimino,F.</style></author><author><style face="normal" font="Arial"> Gangemi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Annunziata, 98168, Messina, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Exposure to Anisakis extracts can induce inflammation on in vitro cultured human colonic cells</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACE</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Caco 2 cell</style></keyword><keyword><style face="normal" font="Arial"> Caco-2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish species</style></keyword><keyword><style face="normal" font="Arial"> flesh</style></keyword><keyword><style face="normal" font="Arial"> Freezing</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Intestinal epithelium</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infections</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="Arial">Anisakis spp. is a parasitic nematode whose infective third-stage larvae may be found within the flesh of fish species commonly consumed by humans. Thorough cooking or freezing should render the fish safe for consumption; furthermore, marinating solutions containing biocidal agents might have a significant action against Anisakis larvae. Some studies suggest a relationship between some parasitic infections and development of inflammatory bowel disorders, and Anisakis infection might be a risk factor for stomach or colon cancer. The aim of our study was to investigate if crude extracts (CEs) obtained from Anisakis larvae marinated in a solution with added allyl isothiocyanate (ACE-AITC) and frozen, or from frozen only Anisakis larvae (ACE), can induce an inflammatory effect on in vitro differentiated colonic Caco-2 cells exposed or not to LPS. Caco-2 exposure to the two CEs induced a marked COX-2 expression and potentiated LPS-induced COX-2 overexpression, confirming that substances present in Anisakis larvae can induce an inflammatory response in the intestinal epithelium, possibly also exacerbating the effects of other inflammatory stimuli. ACE induced a marked decrease in caspase-3 activation, while AITC-ACE increased its activation. However, LPS-induced caspase-3 activation appeared lower in cells treated with ACE and with the lower concentration of AITC-ACE. Thus, it is evident that Anisakis CEs may affect various cell pathways crucial not only in the inflammatory process but also in cell growth and death. Thus, CEs obtained from nonviable Anisakis larvae retain or are otherwise provided with noxious properties able to induce a strong inflammation response in intestinal epithelial cells. Furthermore, their influence may persist also following pretreatment with the biocidal agent AITC, indicating that the harmful substances contained in crude extracts from Anisakis larvae are resistant to the thermal or biocidal agent treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 1432-1955 (Electronic)IS - 0932-0113 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-017-5551-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28702801">PM:28702801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20170713-SpecialeA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20170713-SpecialeA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Speciale A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-017-5551-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wuhao,L.</style></author><author><style face="normal" font="Arial"> Ran,C.</style></author><author><style face="normal" font="Arial"> Xujin,H.</style></author><author><style face="normal" font="Arial"> Zhongdao,W.</style></author><author><style face="normal" font="Arial"> Dekumyoy,P.</style></author><author><style face="normal" font="Arial"> Zhiyue,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zhongshan School of Medicine, Sun Yat-sen University, 74 2nd Zhongshan Road, Guangzhou, 510080, China</style></auth-address><titles><title><style face="normal" font="Arial">Parasites and asthma</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasite infection</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory B cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="7" Year="2017">2017/7/8</year></dates><abstract><style face="normal" font="Arial">Nowadays, many studies have found low morbidity of asthma in epidemic areas of parasitic diseases, as shown by the hygiene hypothesis. It is obvious that some parasite infections can prevent asthma and studies have been carried out to clarify the mechanism of the preventive effect and search for the future asthmatic therapies. Previous findings have indicated that this mechanism may be related to the immune response switching from Th1 to Th2 and important cells induced by parasites, including the regulatory T cells, regulatory B cells, dendrite cells, and alternatively activated macrophages. Cytokine IL-10 also plays a nonredundant role in protection against allergic airway inflammation in asthma. This review focuses on the relationship between parasites and asthma, and the potential protection mechanism involved</style></abstract><notes><style face="normal" font="Arial">DA - 20170709IS - 1432-1955 (Electronic)IS - 0932-0113 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-017-5548-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689246">PM:28689246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20170709-WuhaoL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20170709-WuhaoL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170709, Wuhao L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-017-5548-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,L.</style></author><author><style face="normal" font="Arial"> Guo,J.</style></author><author><style face="normal" font="Arial"> Liao,W.</style></author><author><style face="normal" font="Arial"> Ye,P.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Chen,T.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Zhong,N.</style></author><author><style face="normal" font="Arial"> Sun,B.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease, Department of Otolaryngology-Head and Neck Surgery, Laboratory of ENT-HNS Disease, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">Long-term effects of adenotonsillectomy on serum specific immunoglobulin E</style></title><secondary-title><style face="normal" font="Arial">Pediatr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The biased immune reactions of the adenotonsillar tissues are not always reflected by the serum IgE; thus, we hypothesize that the systemic atopic status may not be changed after the adenotonsillectomy (AT) in children. METHODS: Twenty-five with AT and 23 age-matched healthy childrenwere enrolled into this study, followed-up approximately 4 years. Nasal Symptoms Scores (NSS), Quality of Life Scores (QOLS), specific IgE (sIgE), cytokines, and inflammatory cell were documented in all the subjects before and after study. RESULTS: Fourteen patients and 3 healthycontrols had positive serum sIgE levels (>0.35 kU/l) at the study-start that was not changed by the study-end. Two patients and 2 healthy controls with serum sIgE-negativeshowed the Dermatophagoidespteronyssinus sensitization at the study-end. NSS and QOLS showed significant improvement after the surgery in the sIgE-positive patients (P&lt;0.05), whereas no significant changes were found in the sIgE-negative patients (P=1.00). In addition, the serum sIgE-negative patients showed significantly increases in IL4, IL5, and IL10 levels in the serum (P&lt;0.001), although no significant differences were found post-surgery (P=0.667, 0.408, 0.714, respectively). CONCLUSIONS: Our study showed that AT did not affect pediatric atopic status. The systemic atopy may be independent of the tonsillar and adenoid tissues in children.Pediatric Research accepted article preview online, 12 July 2017. doi:10.1038/pr.2017.165</style></abstract><notes><style face="normal" font="Arial">DA - 20170712IS - 1530-0447 (Electronic)IS - 0031-3998 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/pr.2017.165</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28700564">PM:28700564</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Res\20170712-SongL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Res\20170712-SongL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170712, Song L</style></custom2><misc3><style face="normal" font="Arial">10.1038/pr.2017.165</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sicherer,S.H.</style></author><author><style face="normal" font="Arial"> Allen,K.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author><author><style face="normal" font="Arial"> Donovan,S.M.</style></author><author><style face="normal" font="Arial"> Oria,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="Arial">Critical Issues in Food Allergy: A National Academies Consensus Report</style></title><secondary-title><style face="normal" font="Arial">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatrics</style></full-title></periodical><pages end="" start="e20170194">e20170194-</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">The National Academies of Sciences, Engineering, and Medicine convened an expert, ad hoc committee to examine critical issues related to food allergy. The authors of the resulting report, "Finding a Path to Safety in Food Allergy: Assessment of the Global Burden, Causes, Prevention, Management, and Public Policy," evaluated the scientific evidence on the prevalence, diagnosis, prevention, and management of food allergy and made recommendations to bring about a safe environment for those affected. The committee recommended approaches to monitor prevalence, explore risk factors, improve diagnosis, and provide evidence-based health care. Regarding diagnostics, emphasis was placed on utilizing allergy tests judiciously in the context of the medical history because positive test results are not, in isolation, diagnostic. Evidence-based prevention strategies were advised (for example, a strategy to prevent peanut allergy through early dietary introduction). The report encourages improved education of stakeholders for recognizing and managing as well as preventing allergic reactions, including an emphasis on using intramuscular epinephrine promptly to treat anaphylaxis. The report recommends improved food allergen labeling and evaluation of the need for epinephrine autoinjectors with a dosage appropriate for infants. The committee recommended policies and guidelines to prevent and treat food allergic reactions in a various settings and suggested research priorities to address key questions about diagnostics, mechanisms, risk determinants, and management. Identifying safe and effective therapies is the ultimate goal. This article summarizes the key findings from the report and emphasizes recommendations for actions that are applicable to pediatricians and to the American Academy of Pediatrics</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1542/peds.2017-0194</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739655">PM:28739655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatrics\20170725-SichererSH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatrics\20170725-SichererSH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Sicherer SH</style></custom2><misc3><style face="normal" font="Arial">10.1542/peds.2017-0194</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,R.</style></author><author><style face="normal" font="Arial"> Chen,G.</style></author><author><style face="normal" font="Arial"> Huang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Shaanxi Province Key Laboratory of Jujube, College of Life Science, Yan'an University, Yan'an, China</style></auth-address><titles><title><style face="normal" font="Arial">Shot-gun proteome and transcriptome mapping of the jujube floral organ and identification of a pollen-specific S-locus F-box gene</style></title><secondary-title><style face="normal" font="Arial">PeerJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PeerJ</style></full-title></periodical><pages end="" start="e3588">e3588-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aldolase</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Flower</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Flowers</style></keyword><keyword><style face="normal" font="Arial"> Fructose-Bisphosphate Aldolase</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Histones</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Non-specific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> ontology</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Organelles</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen-specific</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Ribosomes</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> transcriptomics</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The flower is a plant reproductive organ that forms part of the fruit produced as the flowering season ends. While the number and identity of proteins expressed in a jujube (Ziziphus jujuba Mill.) flower is currently unknown, integrative proteomic and transcriptomic analyses provide a systematic strategy of characterizing the floral biology of plants. We conducted a shotgun proteomic analysis on jujube flowers by using a filter-aided sample preparation tryptic digestion, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In addition, transcriptomics analyses were performed on HiSeq2000 sequencers. In total, 7,853 proteins were identified accounting for nearly 30% of the 'Junzao' gene models (27,443). Genes identified in proteome generally showed higher RPKM (reads per kilobase per million mapped reads) values than undetected genes. Gene ontology categories showed that ribosomes and intracellular organelles were the most dominant classes and accounted for 17.0% and 14.0% of the proteome mass, respectively. The top-ranking proteins with iBAQ >1010 included non-specific lipid transfer proteins, histones, actin-related proteins, fructose-bisphosphate aldolase, Bet v I type allergens, etc. In addition, we identified one pollen-specificity S-locus F-box-like gene located on the same chromosome as the S-RNase gene. Both of these may activate the behaviour of gametophyte self-incompatibility in jujube. These results reflected the protein profile features of jujube flowers and contributes new information important to the jujube breeding system</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 2167-8359 (Print)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.7717/peerj.3588</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28729959">PM:28729959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PeerJ\2017-5-e3588.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PeerJ\2017-5-e3588.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Chen R</style></custom2><misc3><style face="normal" font="Arial">10.7717/peerj.3588</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,M.J.</style></author><author><style face="normal" font="Arial"> Park,H.R.</style></author><author><style face="normal" font="Arial"> Shin,T.Y.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a CMRI, Department of Pharmacology, School of Medicine , Kyungpook National University , Daegu , Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Diospyros kaki calyx inhibits immediate-type hypersensitivity via the reduction of mast cell activation</style></title><secondary-title><style face="normal" font="Arial">Pharm Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharm Biol</style></full-title></periodical><pages end="1953" start="1946">1946-1953</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Diospyros</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evans Blue</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immediate-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pigmentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">CONTEXT: Diospyros kaki L. (Ebenaceae) fruit is widely distributed in Asia and is known to exert anti-inflammatory and antithrombotic effects. OBJECTIVE: We evaluated the inhibitory effect of aqueous extract of D. kaki calyx (AEDKC) on mast cell-mediated immediate-type hypersensitivity and underlying mechanism of action. MATERIALS AND METHODS: For in vivo, ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) and immunoglobulin (Ig) E-mediated passive cutaneous anaphylaxis (PCA) models were used. In the ASA, AEDKC (1-100 mg/kg) was orally administered 3 times during 14 days. In the PCA, AEDKC was orally treated 1 h before the antigen challenge. The control drug dexamethasone was used to compare the effectiveness of AEDKC. For in vitro, IgE-stimulated RBL-2H3 cells and primary cultured peritoneal mast cells were used to determine the role of AEDKC (0.01-1 mg/mL). RESULTS: Oral administration of AEDKC dose dependently suppressed rectal temperature decrease and increases in serum histamine, total IgE, OVA-specific IgE, and interleukin (IL)-4 in the ASA. In the PCA, AEDKC reduced Evans blue pigmentation. Compared to dexamethasone (10 mg/kg), AEDKC (100 mg/kg) showed similar inhibitory effects in vivo. AEDKC concentration dependently suppressed the release of histamine and beta-hexosaminidase through the reduction of intracellular calcium in mast cells. In addition, AEDKC decreased the expression and secretion of tumour necrosis factor-alpha and IL-4 by the reduction of nuclear factor-kappaB. The inhibitory potential of AEDKC (1 mg/mL) was similar with dexamethasone (10 muM) in vitro. CONCLUSIONS: We suggest that AEDKC may be a potential candidate for the treatment of mast cell-mediated allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1744-5116 (Electronic)IS - 1388-0209 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1080/13880209.2017.1354386</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28724321">PM:28724321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharm Biol\2017-55-1946-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharm Biol\2017-55-1946-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Kim MJ</style></custom2><misc3><style face="normal" font="Arial">10.1080/13880209.2017.1354386</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Prodjinotho,U.F.</style></author><author><style face="normal" font="Arial"> von Horn,C.</style></author><author><style face="normal" font="Arial"> Debrah,A.Y.</style></author><author><style face="normal" font="Arial"> Batsa Debrah,L.</style></author><author><style face="normal" font="Arial"> Albers,A.</style></author><author><style face="normal" font="Arial"> Layland,L.E.</style></author><author><style face="normal" font="Arial"> Hoerauf,A.</style></author><author><style face="normal" font="Arial"> Adjobimey,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital Bonn, Bonn, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Pathological manifestations in lymphatic filariasis correlate with lack of inhibitory properties of IgG4 antibodies on IgE-activated granulocytes</style></title><secondary-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PLoS Negl Trop Dis</style></full-title></periodical><pages end="" start="e0005777">e0005777-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Benin</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Filariasis</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Ghana</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">Helminth parasites are known to be efficient modulators of their host's immune system. To guarantee their own survival, they induce alongside the classical Th2 a strong regulatory response with high levels of anti-inflammatory cytokines and elevated plasma levels of IgG4. This particular antibody was shown in different models to exhibit immunosuppressive properties. How IgG4 affects the etiopathology of lymphatic filariasis (LF) is however not well characterized. Here we investigate the impact of plasma and affinity-purified IgG/IgG4 fractions from endemic normals (EN) and LF infected pathology patients (CP), asymptomatic microfilaraemic (Mf+) and amicrofilaraemic (Mf-) individuals on IgE/IL3 activated granulocytes. The activation and degranulation states were investigated by monitoring the expression of CD63/HLADR and the release of granule contents (neutrophil elastase (NE), eosinophil cationic protein (ECP) and histamine) respectively by flow cytometry and ELISA. We could show that the activation of granulocytes was inhibited in the presence of plasma from EN and Mf+ individuals whereas those of Mf- and CP presented no effect. This inhibitory capacity was impaired upon depletion of IgG in Mf+ individuals but persisted in IgG-depleted plasma from EN, where it strongly correlated with the expression of IgA. In addition, IgA-depleted fractions failed to suppress granulocyte activation. Strikingly, affinity-purified IgG4 antibodies from EN, Mf+ and Mf- individuals bound granulocytes and inhibited activation and the release of ECP, NE and histamine. In contrast, IgG4 from CP could not bind granulocytes and presented no suppressive capacity. Reduction of both the affinity to, and the suppressive properties of anti-inflammatory IgG4 on granulocytes was reached only when FcgammaRI and II were blocked simultaneously. These data indicate that IgG4 antibodies from Mf+, Mf- and EN, in contrast to those of CP, natively exhibit FcgammaRI/II-dependent suppressive properties on granulocytes. Our findings suggest that quantitative and qualitative alterations in IgG4 molecules are associated with the different clinical phenotypes in LF endemic regions</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1935-2735 (Electronic)IS - 1935-2727 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Ghana -CO - Benin -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pntd.0005777</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28742098">PM:28742098</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2017-11-e0005777.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS Negl Trop Dis\2017-11-e0005777.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Prodjinotho UF</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pntd.0005777</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lind,T.</style></author><author><style face="normal" font="Arial"> Ekebom,A.</style></author><author><style face="normal" font="Arial"> Alm,Kubler K.</style></author><author><style face="normal" font="Arial"> Ostensson,P.</style></author><author><style face="normal" font="Arial"> Bellander,T.</style></author><author><style face="normal" font="Arial"> Lohmus,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Environmental Medicine, Karolinska Institutet, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Pollen Season Trends (1973-2013) in Stockholm Area, Sweden</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0166887">e0166887-</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Alder</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Monitoring</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hazel</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Models,Theoretical</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time Factors</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">In the present study, the phenological and quantitative changes in the pollen seasons between 1973 and 2013 in the Stockholm region of Sweden were studied for nine types of pollen (hazel, alder, elm, birch, oak, grass, mugwort, willow and pine). Linear regression models were used to estimate the long term trends in duration, start- and end-dates, peak-values and the yearly accumulated pollen sums of the pollen seasons. The pollen seasons of several arboreal plant species (e.g. birch, oak and pine) were found to start significantly earlier today compared to 41 years earlier, and have an earlier peak-date, while the season of other species seemed largely unaffected. However, the long term trends in the end-dates of pollen seasons differed between arboreal and herbaceous species. For herbaceous species (grass and mugwort), a significant change towards later end-dates was observed and the duration of season was found to have increased. A significant trend towards an earlier end-date was found in the majority of the arboreal plant species (i.e. elm, oak, pine and birch), but the length of the season seemed unaffected. A trend towards an increase in yearly concentrations of pollen was observed for several species; however the reasons for this phenomenon cannot be explained unambiguously by the present study design. The trend of increasing yearly mean air temperatures in the Stockholm area may be the reason to changed phenological patterns of pollen seasons</style></abstract><notes><style face="normal" font="Arial">DA - 20161129IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleRN - 0 (Air Pollutants)RN - 0 (Allergens)SB - IMCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0166887</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27898718">PM:27898718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2016-11-e0166887.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2016-11-e0166887.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161129, Lind T</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0166887</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lai,P.S.</style></author><author><style face="normal" font="Arial"> Allen,J.G.</style></author><author><style face="normal" font="Arial"> Hutchinson,D.S.</style></author><author><style face="normal" font="Arial"> Ajami,N.J.</style></author><author><style face="normal" font="Arial"> Petrosino,J.F.</style></author><author><style face="normal" font="Arial"> Winters,T.</style></author><author><style face="normal" font="Arial"> Hug,C.</style></author><author><style face="normal" font="Arial"> Wartenberg,G.R.</style></author><author><style face="normal" font="Arial"> Vallarino,J.</style></author><author><style face="normal" font="Arial"> Christiani,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Impact of environmental microbiota on human microbiota of workers in academic mouse research facilities: An observational study</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0180969">e0180969-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">16S rDNA</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air sampling</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human microbiome</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbial exposure</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To characterize the microbial environment of workers in academic mouse research facilities using endotoxin, 16S qPCR, and 16S amplicon sequencing. To determine whether the work microbiome contributes to the human microbiome of workers. METHODS: We performed area air sampling from the animal rooms, dirty, middle, and setup cage wash locations in four academic mouse research facilities. 10 workers in the dirty cage wash area underwent personal air sampling as well as repeated collection of nasal, oral, and skin samples before and after the work shift. Environmental samples underwent measurement of endotoxin, mouse allergen, bacteria copy number via 16S qPCR, and microbial identification via 16S rDNA sequencing. 16S rDNA sequencing was also performed on human samples before and after the work shift. SourceTracker was used to identify the contribution of the work microbiome to the human microbiome. RESULTS: Median endotoxin levels ranged from undetectable to 1.0 EU/m3. Significant differences in mouse allergen levels, bacterial copy number, microbial richness, and microbial community structure were identified between animal, dirty, middle, and setup cage wash locations. Endotoxin levels had only a moderate correlation with microbial composition. Location within a facility was a stronger predictor of microbial community composition (R2 = 0.41, p = 0.002) than facility. The contribution of the work microbiome to the pre-shift human microbiome of workers was estimated to be 0.1 +/- 0.1% for the oral microbiome; 3.1 +/- 1.9% for the nasal microbiome; and 3.0 +/- 1.5% for the skin microbiome. CONCLUSIONS: The microbial environment of academic animal care facilities varies significantly by location rather than facility. Endotoxin is not a proxy for assessment of environmental microbial exposures using 16S qPCR or 16S rDNA sequencing. The work microbiome contributes to the composition of the nasal and skin microbiome of workers; the clinical implications of this observation should be further studied</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0180969</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28704437">PM:28704437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0180969.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0180969.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Lai PS</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0180969</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Skappak,C.</style></author><author><style face="normal" font="Arial"> Ilarraza,R.</style></author><author><style face="normal" font="Arial"> Wu,Y.Q.</style></author><author><style face="normal" font="Arial"> Drake,M.G.</style></author><author><style face="normal" font="Arial"> Adamko,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Emergency Medicine, McMaster University, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Virus-induced asthma attack: The importance of allergic inflammation in response to viral antigen in an animal model of asthma</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0181425">e0181425-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway reactivity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Memory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory function</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viruses</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral exposure</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus-induced asthma</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma exacerbation can be a life-threatening condition, and is most often triggered by common respiratory viruses. Poor asthma control and worsening of respiratory function is associated with increased airway inflammation, including eosinophilia. Prevention of asthma exacerbation relies on treatment with corticosteroids, which preferentially inhibit allergic inflammation like eosinophils. Human studies demonstrate that inactivated virus can trigger eosinophil activation in vitro through antigen presentation and memory CD4+ lymphocytes. We hypothesized that animals with immunologic memory to a respiratory virus would also develop airway hyperresponsiveness in response to a UV-inactivated form of the virus if they have pre-existing allergic airway inflammation. Guinea pigs were ovalbumin-sensitized, infected with live parainfluenza virus (PIV), aerosol-challenged with ovalbumin, and then re-inoculated 60 days later with live or UV-inactivated PIV. Some animals were either treated with dexamethasone prior to the second viral exposure. Lymphocytes were isolated from parabronchial lymph nodes to confirm immunologic memory to the virus. Airway reactivity was measured and inflammation was assessed using bronchoalveolar lavage and lung histology. The induction of viral immunologic memory was confirmed in infected animals. Allergen sensitized and challenged animals developed airway hyperreactivity with eosinophilic airway inflammation when re-exposed to UV-inactivated PIV, while non-sensitized animals did not. Airway hyperreactivity in the sensitized animals was inhibited by pre-treatment with dexamethasone. We suggest that the response of allergic inflammation to virus antigen is a significant factor causing asthma exacerbation. We propose that this is one mechanism explaining how corticosteroids prevent virus-induced asthma attack</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0181425</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28742120">PM:28742120</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0181425.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0181425.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Skappak C</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0181425</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goodman,J.E.</style></author><author><style face="normal" font="Arial"> Loftus,C.T.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Zu,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Gradient, Cambridge, Massachusetts, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Impact of respiratory infections, outdoor pollen, and socioeconomic status on associations between air pollutants and pediatric asthma hospital admissions</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0180522">e0180522-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> effect modification</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Meteorological factor</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Factors</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> neighborhood</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> New York City</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric asthma</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> School-age children</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Epidemiology studies have shown that ambient concentrations of ozone and fine particulate matter (PM2.5) are associated with increased emergency department (ED) visits and hospital admissions (HAs) for asthma. OBJECTIVE: Evaluate the impact of outdoor pollen, respiratory infections, and socioeconomic status (SES) on the associations between ambient ozone and PM2.5 and asthma HAs in New York City. METHODS: Daily ozone, PM2.5, meteorological factors, pollen, and hospitalization records during 1999 to 2009 were obtained for New York City residents. Daily counts of HAs for asthma and respiratory infections were calculated for all-age and specific age groups, and for high- and low-SES communities. Generalized additive models were used to examine ambient concentrations of ozone and PM2.5 and asthma HAs, potential confounding effects of outdoor pollen and HAs for respiratory infections, and potential effect modification by neighborhood SES. RESULTS: Both ozone and PM2.5 were statistically significantly associated with increased asthma HAs in children aged 6-18 years (per 10 ppb increase in ozone: RR = 1.0203, 95% CI: 1.0028-1.0382; per 10 mug/m3 increase in PM2.5: RR = 1.0218, 95% CI: 1.0007-1.0434), but not with total asthma HAs, or asthma HAs in other age groups. These associations were stronger for children living in the high-SES areas. Adjustment for respiratory infection HAs at various lags did not result in changes greater than 10% in the risk estimates for either ozone or PM2.5. In contrast, adjustment for outdoor pollen generally attenuated the estimated RRs for both ozone and PM2.5. CONCLUSIONS: Ambient ozone and PM2.5 are associated with asthma HAs in school-age children, and these associations are not modified by SES. HAs for respiratory infections do not appear to be a confounder for observed ozone- and PM2.5-asthma HAs associations, but pollen may be a weak confounder</style></abstract><notes><style face="normal" font="Arial">DA - 20170718IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States .</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0180522</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28719626">PM:28719626</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0180522.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0180522.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170718, Goodman JE</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0180522</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mitlehner,W.</style></author><author><style face="normal" font="Arial"> Mitlehner,H.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Private Medical Practice for Pneumology, Internal Medicine, Allergology, KlappholzData Management/Biostatistics, Berlin</style></auth-address><titles><title><style face="normal" font="Arial">Tolerance Induction of Horse Allergy by Horse Contact with Curly Horses</style></title><secondary-title><style face="normal" font="Arial">Pneumologie</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pneumologie</style></full-title></periodical><pages end="483" start="480">480-483</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">A horse allergic rider completed 60 riding lessons on Curly Horses within six months. This rider has become clinically tolerant to normal horse breeds within this time. This case may indicate that riding and brushing ABCR Curly Horses after 60 riding hours facilitates tolerance induction. Our data indicate that this could be a valid alternative to the common recommendation to strictly avoid horse riding</style></abstract><notes><style face="normal" font="Arial">DA - 20170712IS - 1438-8790 (Electronic)IS - 0934-8387 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1055/s-0043-108137.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701016">PM:28701016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pneumologie\2017-71-480-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pneumologie\2017-71-480-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170712, Mitlehner W</style></custom2><misc3><style face="normal" font="Arial">10.1055/s-0043-108137.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meeusen,E.N.</style></author><author><style face="normal" font="Arial"> Lim,E.</style></author><author><style face="normal" font="Arial"> Mathivanan,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, AustraliaGarvan Institute of Medical Research, St. Vincent's Health, University of New South Wales, Darlinghurst, NSW, AustraliaDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Secreted tumor antigens - immune biomarkers for diagnosis and therapy</style></title><secondary-title><style face="normal" font="Arial">Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antibody secreting cell</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cancer Vaccines</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">With the advent of immunotherapies for cancer, there is growing interest in the identification of tumor antigens. Tumor antigens are self-molecules altered through genetic mutations (neoantigens), protein truncation, protein misfolding or abnormal post translational modifications. To induce an immune response, tumor antigens need to be secreted into the tumor environment and presented to the immune system in the draining lymph nodes, resulting in the generation of tumor-specific effector cells and antibodies. Cytotoxic T cells (CTL) are thought to be responsible for killing of tumor cells, and several recent studies have used MS, combined with exome/transcriptome sequencing and bioinformatics, to identify their cognate peptide ligands on tumor MHC class I molecules. Circulating (serum) antibodies have been more widely used to identify tumor antigens in a range of human cancers, using 2-D western blots, immunoaffinity and microarray technologies. More specific antibody probes have been generated by harvesting antibodies directly from antibody secreting cells (ASC) through in vitro cultures of lymph node cells (ASC-probes) or B cell immortalization. Further identification and characterization of tumor antigens is likely to have important implications for cancer diagnostic and biomarker discovery, immune profiling, and the development of cancer vaccines and targeted immunotherapies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 1615-9861 (Electronic)IS - 1615-9853 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1002/pmic.201600442</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28714192">PM:28714192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proteomics\20170717-MeeusenEN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proteomics\20170717-MeeusenEN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Meeusen EN</style></custom2><misc3><style face="normal" font="Arial">10.1002/pmic.201600442</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singer Brugiolo,A.S.</style></author><author><style face="normal" font="Arial"> Carvalho Gouveia,A.C.</style></author><author><style face="normal" font="Arial"> de Souza Alves,C.C.</style></author><author><style face="normal" font="Arial"> de Castro E Silva,F.M.</style></author><author><style face="normal" font="Arial"> de Oliveira,E.E.</style></author><author><style face="normal" font="Arial"> Paula Ferreira,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">IMUNOCET, Departamento de Parasitologia, Microbiologia e Imunologia, Instituto de Ciencias Biologicas, Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Ferulic acid supresses Th2 immune response and prevents remodeling in ovalbumin-induced pulmonary allergy associated with inhibition of epithelial-derived cytokines</style></title><secondary-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Forum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="Arial">Asthma is characterized by intermittent airway obstruction and chronic inflammation, orchestrated primarily by Th2 cytokines. There is a strong rationale for developing new asthma therapies, since current treatment protocols present side effects and may not be effective in cases of difficult-to-control asthma. The purpose of this study was to evaluate the effect of ferulic acid, a phenolic acid commonly present in plants, in the ovalbumin-induced pulmonary allergy murine model. METHODS: BALB/c mice were sensitized and challenged with ovalbumin, and treatments were provided by gavage. Six groups of mice (n = 6) were studied, labeled as: control, pulmonary allergy, dexamethasone, and 3 receiving ferulic acid (at 25, 50, and 100 mg/kg). Lung tissue, bronchoalveolar lavage fluid and serum were collected for analysis. RESULTS: Ferulic acid treatment inhibited an established allergic Th2-response by decreasing the key features of pulmonary allergy, including lung and airway inflammation, eosinophil infiltration, mucus production and serum levels of OVA-specific IgE. These results were associated with lower levels of CCL20, CCL11 and CCL5 chemokines and IL-4, IL-5, IL-13, TSLP, IL-25 and IL-33 cytokines in lung tissue homogenate. CONCLUSIONS: In this study it was demonstrated for the first time that ferulic acid treatment is able to suppress one of the main features of the airway remodeling, indicated by reduction of mucus production, besides the Th2 pathogenic response on ovalbumin-induced pulmonary allergy. Taken together, results shows that the immunopathological mechanism underlying these effects is linked to a reduction of the epithelial-derived chemokines and cytokines, suggesting that ferulic acid may be useful as a potential therapeutic agent for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170709IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pupt.2017.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689020">PM:28689020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170709-SingerBrugioloAS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170709-SingerBrugioloAS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170709, Singer Brugiolo AS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pupt.2017.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Joshi,R.</style></author><author><style face="normal" font="Arial"> Valdez,D.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Eikenburg,D.C.</style></author><author><style face="normal" font="Arial"> Knoll,B.J.</style></author><author><style face="normal" font="Arial"> Bond,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 3455 Cullen Blvd., Houston, TX 77204-5027, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Effects of beta-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype</style></title><secondary-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> Beta-blockers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Our previous studies suggested certain beta-adrenoceptor blockers (beta-blockers) attenuate the asthma phenotype in ovalbumin driven murine models of asthma. However, the ovalbumin model has been criticized for lack of clinical relevance. METHODS: We tested the non-selective beta-blockers, carvedilol and nadolol, in house dust mite (HDM) driven murine asthma models where drugs were administered both pre- and post-development of the asthma phenotype. We measured inflammation, mucous metaplasia, and airway hyper-responsiveness (AHR). We also measured the effects of the beta-blockers on extracellular-signal regulated kinases (ERK 1/2) phosphorylation in lung homogenates. RESULTS: We show that nadolol, but not carvedilol, attenuated inflammation and mucous metaplasia, and had a moderate effect attenuating AHR. Following HDM exposure, ERK1/2 phosphorylation was elevated, but the level of phosphorylation was unaffected by beta-blockers, suggesting ERK1/2 phosphorylation becomes dissociated from the asthma phenotype. CONCLUSION: Our findings in HDM models administering drugs both pre- and post-development of the asthma phenotype are consistent with previous results using ovalbumin models and show differential effects for nadolol and carvedilol on the asthma phenotype. Lastly, our data suggest that ERK1/2 phosphorylation may be involved in development of the asthma phenotype, but may have a limited role in maintaining the phenotype</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pupt.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28729042">PM:28729042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170721-JoshiR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20170721-JoshiR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Joshi R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pupt.2017.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">TGA improves product labelling for potential allergens</style></title><secondary-title><style face="normal" font="Arial">Reactions Weekly</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Reactions Weekly</style></full-title></periodical><pages end="7" start="7">7-7</pages><volume><style face="normal" font="Arial">1660</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1179-2051</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40278-017-32972-7</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40278-017-32972-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Reactions Weekly\2017-1660-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Reactions Weekly\2017-1660-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40278-017-32972-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goodman,J.E.</style></author><author><style face="normal" font="Arial"> Kennedy,E.M.</style></author><author><style face="normal" font="Arial"> Seeley,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Do individuals with asthma experience airway hyper-responsiveness after exposure to nitrogen dioxide?</style></title><secondary-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biological significance</style></keyword><keyword><style face="normal" font="Arial"> Controlled Human Exposure</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">The current 100 ppb short-term National Ambient Air Quality Standard for NO2, and EPA's determination of a causal association for respiratory effects, are based in part on controlled human exposure studies evaluating airway hyper-responsiveness (AHR). A meta-analysis by Goodman et al. (2009) found increased AHR at 100 ppb NO2 but no clear concentration-response relationship up to 600 ppb, and an overall lack of an AHR effect for studies involving exercise or exposure to allergens. Several factors have been suggested to explain why effects on AHR are observed while people are at rest, but not during exercise or after exposure to allergens. These include an exercise-induced refractory period; partial reversal of bronchospasm from use of forced expiration maneuvers; and greater airway responsiveness of participants exposed to NO2 at rest. We reviewed the scientific evidence to determine whether there is biological support for these factors and found that none sufficiently explained the lack of an effect during exercise or after exposure to allergens. In the absence of either a consistent concentration-response or a plausible explanation for the paradoxical AHR findings, the biological significance of these findings is uncertain and provides equivocal support for NO2 as a causal factor of AHR at these exposure levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.yrtph.2017.07.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28751262">PM:28751262</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20170728-GoodmanJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20170728-GoodmanJE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Goodman JE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.yrtph.2017.07.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ekmay,R.D.</style></author><author><style face="normal" font="Arial"> Coon,C.N.</style></author><author><style face="normal" font="Arial"> Ladics,G.S.</style></author><author><style face="normal" font="Arial"> Herman,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dow AgroSciences LLC, Indianapolis, IN, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Allergenic potential of novel proteins - What can we learn from animal production?</style></title><secondary-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal digestion</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal System</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro digestibility</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein digestibility</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> Swine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">Currently, risk assessment of the allergenic potential of novel proteins relies heavily on evaluating protein digestibility under normal conditions based on the theory that allergens are more resistant to gastrointestinal digestion than non-allergens. There is also proposed guidance for expanded in vitro digestibility assay conditions to include vulnerable sub-populations. One of the underlying rationales for the expanded guidance is that current in vitro assays do not accurately replicate the range of physiological conditions. Animal scientists have long sought to predict protein and amino acid digestibility for precision nutrition. Monogastric production animals, especially swine, have gastrointestinal systems similar to humans, and evaluating potential allergen digestibility in this context may be beneficial. Currently, there is no compelling evidence that the mechanisms sometimes postulated to be associated with allergenic sensitization, e.g. antacid modification of stomach pH, are valid among production animals. Furthermore, examples are provided where non-biologically representative assays are better at predicting protein and amino acid digestibility compared with those designed to mimic in vivo conditions. Greater emphasis should be made to align in vitro assessments with in vivo data</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.yrtph.2017.07.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28751264">PM:28751264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20170728-EkmayRD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20170728-EkmayRD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Ekmay RD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.yrtph.2017.07.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hill,R.C.</style></author><author><style face="normal" font="Arial"> Fast,B.J.</style></author><author><style face="normal" font="Arial"> Herman,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dow AgroSciences LLC, 9330 Zionsville Road, Indianapolis, IN 46268, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Transgenesis affects endogenous soybean allergen levels less than traditional breeding</style></title><secondary-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> GM Crops</style></keyword><keyword><style face="normal" font="Arial"> GM-crops</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean allergen</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="Arial">The regulatory body that oversees the safety assessment of genetically modified (GM) crops in the European Union, the European Food Safety Authority (EFSA), uniquely requires that endogenous allergen levels be quantified as part of the compositional characterization of GM versions of crops, such as soybean, that are considered to be major allergenic foods. The value of this requirement for assessing food safety has been challenged for multiple reasons including negligible risk of altering allergen levels compared with traditional non-GM breeding. Scatter plots comparing the mean endogenous allergen levels in non-GM soybean isoline grain with the respective levels in GM grain or concurrently grown non-GM commercial reference varieties clearly show that transgenesis causes less change compared with traditional breeding. This visual assessment is confirmed by the quantitative fit of the line of identity (y = x) to the datasets. The current science on allergy does not support the requirement for quantifying allergen levels in GM crops to support safety assessment</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.yrtph.2017.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28720347">PM:28720347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20170719-HillRC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Regul Toxicol Pharmacol\20170719-HillRC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Hill RC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.yrtph.2017.07.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abdelaziz,R.</style></author><author><style face="normal" font="Arial"> Boussaid,R.</style></author><author><style face="normal" font="Arial"> El Gueddari,Y.</style></author><author><style face="normal" font="Arial"> Beji,M.</style></author><author><style face="normal" font="Arial"> Kebe,M.</style></author><author><style face="normal" font="Arial"> Douagui,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical profile and management of urticaria in the Maghreb</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Algeria</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical profile</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Maghreb</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria control test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">The aim of the study was to evaluate the profile of and treatment modalities for chronic spontaneous urticaria in the Maghreb. Patients and methods A prospective multicenter, descriptive study conducted in a cohort of 211 chronic urticaria patients aged between 16 and 94 years between September 15 and December 20, 2015, in the 4 countries of the Maghreb. Results The study was carried out in 152 women (72%) and 59 men (28%) of average age of 38 years. The most common symptom was pruritus, which was present in 95% of all patients and in 36% of angioedema patients. Seventy-four percent of patients underwent laboratory tests. Antihistamines were prescribed in 95% of patients, at high dose in 32% of patients. Regarding quality of life as assessed by the Urticaria Control Test (UCT), only 45% of patients had well-controlled disease. Regarding therapeutic control of symptoms, complete remission was observed in 40% of patients, with partial remission in 55% and worsening in 5%. Conclusion Chronic urticaria was characterized in our study by significant clinical symptoms having a significant impact on patients</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ quality of life. Therapeutic management consisted primarily of prescription of antihistamines (95%), with corticosteroids being administered to 44% of patients, contrary to the international recommendations</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Algeria -CO - Morocco -CO - Tunisia -CO - Mauritania -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.04.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.04.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170728-AbdelazizR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170728-AbdelazizR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Abdelaziz R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.04.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Perromat,M.</style></author><author><style face="normal" font="Arial"> Maridet,C.</style></author><author><style face="normal" font="Arial"> Boralevi,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Atopic prurigo - three cases</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopic prurigo</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> nummular eczema</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Prick and patch</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Prurigo</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">In 2002, we described a new clinical entity: atopic prurigo. We present three cases herein. This type of prurigo is more frequent in atopic subjects. It covers the entire body-á</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô-áthough not the face-á</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô-áin the form of multiple vesicular papules that are very itchy and often nodular. These vesicular papules are often grouped in the waist, wrist and ankle regions. The lesions sometimes develop into nummular eczema. The prurigo becomes chronic and resistant to standard treatments, occasionally with severe impairment of patient quality of life. It is related to delayed-type hypersensitivity to house-dust mites, either through direct contact or through inhalation. We used two different types of test: traditional patch-tests and prick-tests under transparent occlusive film, named </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£prick- and patch-tests</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ that are more specific. Read at 30 minutes, then 48-áand 96 hours respectively, they confirm the presence of a delayed-type allergy. Specific immunotherapy, based on clinical and atopic criteria, proved efficient in all three cases within the first few months. We consider atopic prurigo to be a </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£clinical form</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ of atopic dermatitis with delayed hypersensitivity to house-dust mites</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.05.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.05.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170728-PerromatM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170728-PerromatM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Perromat M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.05.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krull,G.</style></author><author><style face="normal" font="Arial"> Gianella,P.</style></author><author><style face="normal" font="Arial"> Soccal,P.M.</style></author><author><style face="normal" font="Arial"> Pralong,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de pneumologie, Departement des specialites de medecine, HUG, 1211 Geneve 14</style></auth-address><titles><title><style face="normal" font="Arial">[Occupational asthma]</style></title><secondary-title><style face="normal" font="Arial">Rev Med Suisse</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Med Suisse</style></full-title></periodical><pages end="1975" start="1972">1972-1975</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">539</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical care</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="Arial">Occupational asthma is the most common occupational respiratory disease. It mainly affects young workers with significant socio-economic consequences. Early recognition improves its prognosis. A rigorous investigative approach while the worker is still exposed at work and appropriate medical care require a multi-disciplinary collaboration. Prevention is the key element in the management of professional asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 1660-9379 (Print)IS - 1660-9379 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696639">PM:28696639</url></web-urls></urls><custom2><style face="normal" font="Arial">20170711, Krull G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gaillard,J.</style></author><author><style face="normal" font="Arial"> Borgeat-Kaeser,A.</style></author><author><style face="normal" font="Arial"> Buss,G.</style></author><author><style face="normal" font="Arial"> Spertini,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service d'immunologie et allergie, CHUV, 1011 Lausanne</style></auth-address><titles><title><style face="normal" font="Arial">[Food-dependent exercise-induced anaphylaxis : a stepwise diagnosis]</style></title><secondary-title><style face="normal" font="Arial">Rev Med Suisse</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Med Suisse</style></full-title></periodical><pages end="738" start="734">734-738</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">557</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alcohol</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergie</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> estrogen</style></keyword><keyword><style face="normal" font="Arial"> Estrogens</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> FDEIA</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food-dependent exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> NSAID</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">Food-dependent exercise-induced anaphylaxis (FDEIA) is a potentially severe food allergy. Physical exercise, NSAID, alcohol, infectious diseases and estrogens are recognized cofactors, able to reduce the amount of allergen needed to achieve a threshold for the induction of anaphylaxis. Various kinds of causative food but only a few responsible proteins have been identified. The best known is wheat omega5-gliadine. An oral food challenge remains the gold standard to prove the diagnosis. Its clinical application remains difficult and includes an allergen challenge, a cofactor challenge and a third step which integrates both of them in a single test. Gluten flour and NSAID + alcohol combination seem more efficient than respectively wheat flour and physical exercise in a provocation test condition</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1660-9379 (Print)IS - 1660-9379 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722361">PM:28722361</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170711, Gaillard J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moi,L.</style></author><author><style face="normal" font="Arial"> Salvade,I.</style></author><author><style face="normal" font="Arial"> Ribi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service d'immunologie et allergie, Departement de medecine, CHUV, 1011 Lausanne</style></auth-address><titles><title><style face="normal" font="Arial">[Allergy to human seminal plasma]</style></title><secondary-title><style face="normal" font="Arial">Rev Med Suisse</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Med Suisse</style></full-title></periodical><pages end="753" start="748">748-753</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">557</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergie</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Condoms</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dyspareunia</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Fertilization</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Prostate</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> unexplained anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vulvovaginitis</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="Arial">Hypersensitivity to human seminal plasma is rare, but probably under-diagnosed. It should be suspected in women with unexplained anaphylaxis, vulvo-vaginitis, pelvic pain and dyspareunia. The diagnosis relies on the clinical presentation, the exclusion of other causes, a positive skin test result to seminal plasma and the detection of IgE directed to allergenic proteins (such as prostate specific antigen). Use of condoms is the best preventive measure. Premedication with antihistamines or anti-inflammatory agents is often unreliable. Some patients may benefit from intra-vaginal or subcutaneous desensitization procedures to seminal plasma, which then require to measures to uphold tolerance. In case of pregnancy wish, artificial insemination or in-vitro fertilization with spermatozoids is an alternative to desensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1660-9379 (Print)IS - 1660-9379 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722364">PM:28722364</url></web-urls></urls><custom2><style face="normal" font="Arial">20170711, Moi L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aguiar,R.</style></author><author><style face="normal" font="Arial"> Fernandes,N.P.</style></author><author><style face="normal" font="Arial"> Lopes,A.</style></author><author><style face="normal" font="Arial"> Lopes,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary aspergillosis treated successfully with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Rev Port Pneumol (2006)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Pneumol (2006)</style></full-title></periodical><pages end="306" start="304">304-306</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170714IS - 2173-5115 (Electronic)IS - 0873-2159 (Linking)LA - engPT - LetterCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rppnen.2017.05.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28705584">PM:28705584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Pneumol (2006)\20170714-AguiarM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Pneumol (2006)\20170714-AguiarM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170714, Aguiar R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rppnen.2017.05.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,L.</style></author><author><style face="normal" font="Arial"> Dai,F.</style></author><author><style face="normal" font="Arial"> Wei,J.J.</style></author><author><style face="normal" font="Arial"> Tang,X.Y.</style></author><author><style face="normal" font="Arial"> Chen,Z.</style></author><author><style face="normal" font="Arial"> Sun,G.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology-Head and Neck Surgery, Huashan Hospital of Fudan University, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergic inflammation is exacerbated by allergen-induced type 2 innate lymphoid cells in a murine model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Rhinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rhinology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> aluminium hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> NALT</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="7" Year="2017">2017/7/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Group 2 innate lymphoid cells (ILC2s) represent a new innate effector leukocyte population that mediates type-2 immune response. However, the contribution of ILC2s to allergic rhinitis (AR) is currently not well defined. OBJECTIVE: To evaluate the potential existence and function of allergen-induced ILC2s in the experimental AR. METHODS: We established a murine model of AR using ovalbumin (OVA) and aluminium hydroxide. The OVA-induced ILC2s were sorted and purified from the mouse nasal-associated lymphoid tissue (NALT). Then, we assessed ILC2s responses to mouse recombinant interleukin (rmIL)-25, anti-IL17RB antibody and CC chemokine ligand (CCL) 25 in the culture. After that, we adoptively transferred the NALT-derived ILC2s alone or plus rmIL-25 or anti-IL17RB antibody to the murine model of AR to investigate their role in the nasal allergic inflammation. RESULTS: We showed that ILC2s could be induced by OVA in the NALT of AR model. They were induced to secrete IL-5 and IL-13 by rmIL-25, and blocking of IL17RB contributed to the decreased production of these cytokines in the culture. We found that CCL25 induced the NALT-derived ILC2s migration through CC chemokine receptor 9 on ILC2s in vitro. Numbers of sneezing and nasal rubbing as well as counts of invasive eosinophils were all enhanced after the adoptive transfer of cultured ILC2s in vitro. The expressions of IL-5, IL-13, IL-25 and CCL25 in the NLF of allergic mice were also increased. CONCLUSION: These findings show that ILC2s play a proinflammatory role in the murine AR model, and also highlight ILC2s as a new target in the future AR therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170709IS - 0300-0729 (Print)IS - 0300-0729 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.4193/Rhin17.065</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689218">PM:28689218</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170709, Lin L</style></custom2><misc3><style face="normal" font="Arial">10.4193/Rhin17.065</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,S.</style></author><author><style face="normal" font="Arial"> Yang,R.</style></author><author><style face="normal" font="Arial"> Wang,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Medicine and Health, Lishui University, 1 Xueyuan Road, Lishui, 323000, Zhejiang Province, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Anti-asthmatic effect of pitavastatin through aerosol inhalation is associated with CD4+ CD25+ Foxp3+ T cells in an asthma mouse model</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="6084">6084-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> statin</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-A) reductase, and studies have shown that statins also have anti-inflammatory and immunomodulatory properties. The purpose of this study was to investigate the anti-asthmatic effects of pitavastatin, a type of statin, in an asthma mouse model. Mice were sensitized and challenged with ovalbumin (OVA) to establish the asthma model. These mice were then treated with inhaled pitavastatin (5 mg/kg) or dexamethasone (2 mg/kg), the latter of which served as a positive control. The results of the study showed that pitavastatin reduced allergen-induced increases in airway resistance and alleviated bronchial tube thickness and goblet cell hyperplasia in lung tissues. In addition, the results showed that pitavastatin inhibited OVA-induced increases in eosinophil counts and total inflammatory cell counts in bronchoalveolar lavage fluid (BALF) and increased the percentage of CD4+ CD25+ Foxp3+ Treg in the BALF of asthmatic mice. IL-4 and IL-17 levels were decreased, whereas IFN-gamma levels were significantly increased in the BALF of pitavastatin-treated mice compared with the BALF of OVA-challenged mice. These results suggest that pitavastatin has potential as a therapy for allergic airway disease and that its effects are associated with its ability to regulate CD4+ CD25+ Foxp3+ T cell counts</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-06476-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28729731">PM:28729731</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-6084.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-6084.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Wu S</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-06476-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pablos,I.</style></author><author><style face="normal" font="Arial"> Eichhorn,S.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Gartner,U.</style></author><author><style face="normal" font="Arial"> Wolf,M.</style></author><author><style face="normal" font="Arial"> Ebner,C.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Arora,N.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Salzburg, Department of Molecular Biology, Division of Allergy and Immunology, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Proteomic profiling of the weed feverfew, a neglected pollen allergen source</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="6049">6049-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Asteraceae</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> cDNA cloning</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feverfew</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Invasive weed</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid-transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pectate lyase</style></keyword><keyword><style face="normal" font="Arial"> Polcalcin</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Standardized extracts</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Thioredoxin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">Feverfew (Parthenium hysterophorus), an invasive weed from the Asteraceae family, has been reported as allergen source. Despite its relevance, knowledge of allergens is restricted to a partial sequence of a hydroxyproline-rich glycoprotein. We aimed to obtain the entire sequence for recombinant production and characterize feverfew pollen using proteomics and immunological assays. Par h 1, a defensin-proline fusion allergen was obtained by cDNA cloning and recombinantly produced in E. coli. Using two complementary proteomic strategies, a total of 258 proteins were identified in feverfew pollen among those 47 proteins belonging to allergenic families. Feverfew sensitized patients' sera from India revealed IgE reactivity with a pectate lyase, PR-1 protein and thioredoxin in immonoblot. In ELISA, recombinant Par h 1 was recognized by 60 and 40% of Austrian and Indian sera, respectively. Inhibition assays demonstrated the presence of IgE cross-reactive Par h 1, pectate lyase, lipid-transfer protein, profilin and polcalcin in feverfew pollen. This study reveals significant data on the allergenic composition of feverfew pollen and makes recombinant Par h 1 available for cross-reactivity studies. Feverfew might become a global player in weed pollen allergy and inclusion of standardized extracts in routine allergy diagnosis is suggested in exposed populations</style></abstract><notes><style face="normal" font="Arial">DA - 20170721IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-06213-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28729676">PM:28729676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-6049.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-6049.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170721, Pablos I</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-06213-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dias,J.T.</style></author><author><style face="normal" font="Arial"> Svedberg,G.</style></author><author><style face="normal" font="Arial"> Nystrand,M.</style></author><author><style face="normal" font="Arial"> Andersson-Svahn,H.</style></author><author><style face="normal" font="Arial"> Gantelius,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Proteomics and Nanobiotechnology, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Rapid signal enhancement method for nanoprobe-based biosensing</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="6837">6837-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen microarray</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> Iron oxide</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray assay</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2017">2017/7/28</year></dates><abstract><style face="normal" font="Arial">The introduction of nanomaterials as detection reagents has enabled improved sensitivity and facilitated detection in a variety of bioanalytical assays. However, high nanoprobe densities are typically needed for colorimetric detection and to circumvent this limitation several enhancement protocols have been reported. Nevertheless, there is currently a lack of universal, enzyme-free and versatile methods that can be readily applied to existing as well as new biosensing strategies. The novel method presented here is shown to enhance the signal of gold nanoparticles enabling visual detection of a spot containing &lt;10 nanoparticles. Detection of Protein G on paper arrays was improved by a 100-fold amplification factor in under five minutes of assay time, using IgG-labelled gold, silver, silica and iron oxide nanoprobes. Furthermore, we show that the presented protocol can be applied to a commercial allergen microarray assay, ImmunoCAP ISAC sIgE 112, attaining a good agreement with fluorescent detection when analysing human clinical samples</style></abstract><notes><style face="normal" font="Arial">DA - 20170729IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Sweden</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-07030-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28754966">PM:28754966</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-6837.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-6837.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170729, Dias JT</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-07030-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Apostolovic,D.</style></author><author><style face="normal" font="Arial"> Krstic,M.</style></author><author><style face="normal" font="Arial"> Mihailovic,J.</style></author><author><style face="normal" font="Arial"> Starkhammar,M.</style></author><author><style face="normal" font="Arial"> Cirkovic Velickovic,T.</style></author><author><style face="normal" font="Arial"> Hamsten,C.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Peptidomics of an in vitro digested alpha-Gal carrying protein revealed IgE-reactive peptides</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="5201">5201-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gastric digestion</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> peptidomics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Red meat allergy</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thyroglobulin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="Arial">The mammalian carbohydrate galactose-alpha1,3-galactose (alpha-Gal) causes a novel form of food allergy, red meat allergy, where patients experience severe allergic reactions several hours after red meat consumption. Here we explored gastric digestion of alpha-Gal glycoproteins using an in vitro model. Bovine thyroglobulin (BTG), a typical alpha-Gal carrying glycoprotein, was digested with pepsin. The resulting peptides were characterised by SDS PAGE, immunoblot and ImmunoCAP using sera from 20 red meat allergic patients. During pepsinolysis of BTG, a wide range of peptide bands was observed of which 14 to 17 kDa peptides remained stable throughout the gastric phase. The presence of the alpha-Gal epitope on the obtained peptides was demonstrated by an anti-alpha-Gal antibody and IgE from red meat allergic patients. The alpha-Gal digests were able to inhibit up to 86% of IgE reactivity to BTG. Importantly, basophil activation test demonstrated that the allergenic activity of BTG was retained after digestion in all four tested patients. Mass spectrometry-based peptidomics revealed that these peptides represent mostly internal and C-terminal parts of the protein, where the most potent IgE-binding alpha-Gal residues were identified at Asn1756, Asn1850 and Asn2231. Thus allergenic alpha-Gal epitopes are stable to pepsinolysis, reinforcing their role as clinically relevant food allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170713IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Serbia -CO - South Korea -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-05355-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701697">PM:28701697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-5201.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-5201.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170713, Apostolovic D</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-05355-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamad,A.</style></author><author><style face="normal" font="Arial"> Burks,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of North Carolina, Chapel Hill, NC Thurston Arthritis Research Center, UNC Chapel Hill 3300 Thurston Building, Chapel Hill, NC 27599, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Oral tolerance and allergy</style></title><secondary-title><style face="normal" font="Arial">Semin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food tolerance</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal immune system</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="Arial">Food allergy prevalence is increasing in the developed world. It's estimated that each year in the US, anaphylaxis to food results in 30,000 emergency room visits and 150 deaths. Over the past few decades, there has been a tremendous effort to better understand the pathogenesis of food allergy and mechanisms of food tolerance. In this article we review the structural of the gastrointestinal immune system and mechanisms of natural tolerance to food. We then review the factors that may result in the IgE mediated hypersensitivity reaction to food allergens resulting in clinical food allergy. Lastly, we provide a brief review of the efforts to induce immune tolerance to patients with food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1096-3618 (Electronic)IS - 1044-5323 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.smim.2017.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739336">PM:28739336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunol\20170725-HamadA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunol\20170725-HamadA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Hamad A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.smim.2017.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nam,S.T.</style></author><author><style face="normal" font="Arial"> Park,Y.H.</style></author><author><style face="normal" font="Arial"> Kim,H.W.</style></author><author><style face="normal" font="Arial"> Kim,H.S.</style></author><author><style face="normal" font="Arial"> Lee,D.</style></author><author><style face="normal" font="Arial"> Lee,M.B.</style></author><author><style face="normal" font="Arial"> Kim,Y.M.</style></author><author><style face="normal" font="Arial"> Choi,W.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, College of Medicine, Konkuk University, Chungju 27478, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Suppression of IgE-mediated mast cell activation and mouse anaphylaxis via inhibition of Syk activation by 8-formyl-7-hydroxy-4-methylcoumarin, 4mu8C</style></title><secondary-title><style face="normal" font="Arial">Toxicol Appl Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicol Appl Pharmacol</style></full-title></periodical><pages end="31" start="25">25-31</pages><volume><style face="normal" font="Arial">332</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic mediators</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> cell signaling</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lyn</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergies</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="Arial">Mast cells trigger IgE-mediated allergic reactions by releasing various allergic mediators. 8-Formyl-7-hydroxy-4-methylcoumarin, also called 4mu8C, was originally known as an inositol-requiring enzyme 1 (IRE1) suppressant, but no study has examined its relationship with mast cells and allergic diseases. Therefore, the purpose of this study was to determine whether 4mu8C is effective in suppressing allergic reactions in mast cells and in IgE-mediated allergic animal model. 4mu8C suppressed the degranulation of IgE-mediated mast cells (IC50=3.2muM) and the production of cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-4 (IL-4) in a dose-dependent manner. 4mu8C also suppressed passive cutaneous anaphylaxis (PCA) in mice (ED50=25.1mg/kg). In an experiment on mast cell signaling pathways stimulated by antigen, the phosphorylation and activation of Syk was decreased by 4mu8C, and phosphorylation of downstream signaling molecules, such as linker for activated T cells (LAT), Akt, and the three MAP kinases, ERK, p38, and JNK, were suppressed. Mechanistic studies showed that 4mu8C inhibited the activity of Lyn and Fyn in vitro. Based on the results of those experiments, the suppressor mechanism of allergic reaction by 4mu8C involved reduced activity of Lyn and Fyn, which is pivotal in an IgE-mediated signaling pathway. In summary, for the first time, this study shows that 4mu8C inhibits Lyn and Fyn, thus suppressing allergic reaction by reducing the degranulation and the production of inflammatory cytokines. This suggests that 4mu8C can be used as a new medicinal candidate to control allergic diseases such as seasonal allergies and atopic dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170724IS - 1096-0333 (Electronic)IS - 0041-008X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.taap.2017.07.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28736076">PM:28736076</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol Appl Pharmacol\20170724-NamST.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol Appl Pharmacol\20170724-NamST.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170724, Nam ST</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.taap.2017.07.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gunasekara,P.</style></author><author><style face="normal" font="Arial"> Handunnetti,S.M.</style></author><author><style face="normal" font="Arial"> Premawansa,S.</style></author><author><style face="normal" font="Arial"> Witharana,E.W.R.A.</style></author><author><style face="normal" font="Arial"> Dasanayake,W.M.D.K.</style></author><author><style face="normal" font="Arial"> Ratnayake,I.P.</style></author><author><style face="normal" font="Arial"> Seneviratne,S.L.</style></author><author><style face="normal" font="Arial"> Dias,R.K.S.</style></author><author><style face="normal" font="Arial"> Premakumara,G.A.S.</style></author><author><style face="normal" font="Arial"> de Silva,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Colombo, Sri Lanka.</style></auth-address><titles><title><style face="normal" font="Arial">IgE cross-reactivity of phospholipase A2 and hyaluronidase of Apis dorsata (Giant Asian Honeybee) and Apis mellifera (Western Honeybee) venom: Possible use of A. mellifera venom for diagnosis of patients allergic to A. dorsata venom</style></title><secondary-title><style face="normal" font="Arial">Toxicon</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicon</style></full-title></periodical><pages end="35" start="27">27-35</pages><volume><style face="normal" font="Arial">137</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Apis mellifera</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> immunoblot inhibition</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> PLA2</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Sri Lanka</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="Arial">Diagnostic and therapeutic reagents are unavailable for anaphylaxis arising from stings by Apis dorsata. Venom profiles and cross-reactivity of A. dorsata and Apis mellifera were compared, to ascertain whether venom of A. mellifera can be used for diagnosis in A. dorsata allergy. Both venom profiles were similar by High Performance Liquid Chromatography and SDS-PAGE. Sera of 29 of 30 (96.7%) patients with anaphylaxis to A. dorsata stings had IgE to the phospholipase-2 (PLA2) doublet (15 and 16 kDa) of A. dorsata venom by immunoblot, compared to 26 of 30 (86.7%) with the PLA2 of A. mellifera and a purified preparation of PLA2. Twelve patients (40%) with severe anaphylaxis had IgE reactivity to a 39 kDa protein band of venom of both species, a third band, identified in immunoblot as hyaluronidase. The cross-reactivity of PLA2 and hyaluronidase of A. dorsata and A. mellifera were further confirmed by immunoblot inhibition results. Twenty five of 30 (83.3%) of our patients had positive venom specific IgE (>0.35 KUA/L) reactivity to Phadia ImmunoCAPs of A. mellifera venom. The observed IgE cross reactivity suggests the possibility of using A. mellifera venom as a diagnostic test for A. dorsata venom allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170717IS - 1879-3150 (Electronic)IS - 0041-0101 (Linking)LA - engPT - Journal ArticleCO - Sri Lanka -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.toxicon.2017.07.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28712914">PM:28712914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicon\20170717-GunasekaraP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicon\20170717-GunasekaraP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170717, Gunasekara P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.toxicon.2017.07.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kouides,P.</style></author><author><style face="normal" font="Arial"> Wawra-Hehenberger,K.</style></author><author><style face="normal" font="Arial"> Sajan,A.</style></author><author><style face="normal" font="Arial"> Mead,H.</style></author><author><style face="normal" font="Arial"> Simon,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Rochester School of Medicine, Rochester, New York</style></auth-address><titles><title><style face="normal" font="Arial">Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data</style></title><secondary-title><style face="normal" font="Arial">Transfusion</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfusion</style></full-title></periodical><pages end="2403" start="2390">2390-2403</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Factor Viii</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hemophilia A</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Haemate-P/Humate-P (Humate-P) is a pasteurized human plasma-derived concentrate containing both Factor VIII and von Willebrand factor for treatment of hemophilia A and von Willebrand disease (VWD). STUDY DESIGN AND METHODS: We analyzed the safety of Humate-P based on more than 33 years of postmarketing pharmacovigilance data, representing an estimated exposure of approximately 25,000 patient-years. The analysis comprises reports of potential adverse drug reactions (ADRs) from all sources, reported as part of routine pharmacovigilance at CSL Behring. ADRs considered clinically relevant or potential risks of Humate-P were identified based on defined and standardized Medical Dictionary for Regulatory Activities queries. Recognizing the limitations of spontaneous reporting, we also reviewed the literature, including clinical trials with mandatory reporting. RESULTS: From 1982 to 2015, a total of 670 postmarketing cases had been reported via pharmacovigilance, for an overall reporting rate of approximately one ADR per 3900 administered standard doses. Of these cases, 343 involved ADRs considered clinically relevant risks (33 thromboembolic complications, 97 inhibitor formation, 110 hypersensitivity or allergic reactions) or potential risks (103 suspected virus transmissions) for Humate-P. Most thromboembolic complications occurred in patients undergoing surgery or with other known risk factors. Inhibitor formation occurred mostly in patients with hemophilia A (24 cases were high titer). Most patients with hypersensitivity or allergic reactions had VWD. None of the reported suspected virus transmission cases were confirmed to be associated with Humate-P. Reported results of company-sponsored studies showed a low incidence of adverse events possibly or probably related to Humate-P. CONCLUSIONS: More than 33 years of pharmacovigilance data continue to support the safety of Humate-P</style></abstract><notes><style face="normal" font="Arial">DA - 20170710IS - 1537-2995 (Electronic)IS - 0041-1132 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/trf.14241</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28691218">PM:28691218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfusion\20170710-KouidesP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfusion\20170710-KouidesP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170710, Kouides P</style></custom2><misc3><style face="normal" font="Arial">10.1111/trf.14241</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ozdemir,O.</style></author><author><style face="normal" font="Arial"> Bozkurt,H.B.</style></author><author><style face="normal" font="Arial"> Elmas,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Pediatric Allergy and Immunology, Sakarya University School of Medicine, Sakarya, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab's role in the treatment of steroid dependent malignant idiopathic anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Turk Pediatri Ars</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Turk Pediatri Ars</style></abbr-1></periodical><pages end="107" start="105">105-107</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomato</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">If an anaphylaxis episode is not caused by an identifiable trigger, it is defined as idiopathic anaphylaxis. Although it is rarely observed, idiopathic anaphylaxis is clinically significant because of its morbidity and fatality risk. No effective treatment has been demonstrated to date. We report a girl aged 16 years who had had malignant idiopathic anaphylaxis since the age of 12 years who was treated successfully with omalizumab. Although she avoided allergic trigger foods such as tomato and seafood, she used to have these attacks twice a week. Attacks were averted by taking 60 mg prednisone. When prednisone was tapered down to 5 mg on every alternate day, the episodes recurred. Later, attacks could not be controlled on &lt;30 mg of prednisone daily. After being steroid-dependent for 4 years, subcutaneous omalizumab 225 mg every two weeks was started. Under omalizumab therapy, the attacks disappeared and prednisone was discontinued</style></abstract><notes><style face="normal" font="Arial">DA - 20170727IS - 1306-0015 (Print)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5152/TurkPediatriArs.2017.2262</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28747843">PM:28747843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Turk Pediatri Ars\20170727-OzdemirO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Turk Pediatri Ars\20170727-OzdemirO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Ozdemir O</style></custom2><misc3><style face="normal" font="Arial">10.5152/TurkPediatriArs.2017.2262</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uzunoglu,K.E.</style></author><author><style face="normal" font="Arial"> Akdemir,C.</style></author><author><style face="normal" font="Arial"> Direkel,S.</style></author><author><style face="normal" font="Arial"> Cebeci Guler,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Giresun University School of Medicine, Giresun, Turkey.ì</style></auth-address><titles><title><style face="normal" font="Arial">The Investigation of the Presence of Mites in Some Served Dry Foodstuffs</style></title><secondary-title><style face="normal" font="Arial">Turkiye Parazitol Derg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Turkiye Parazitol Derg</style></full-title></periodical><pages end="95" start="92">92-95</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Glycyphagus domesticus</style></keyword><keyword><style face="normal" font="Arial"> Habitat</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lepidoglyphus</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage mite</style></keyword><keyword><style face="normal" font="Arial"> storage mites</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus putrescentiae</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Mites are microscopic organisms that lower the quality of life of people who are sensitive to them by causing conditions such as atopic dermatitis, allergic rhinitis, and asthma. These organisms are found in every habitat where humans live. This study was conducted to determine the presence of storage mites in dry food items. METHODS: Various food items were procured 10 times each in 300-gram samples. Mites were extracted with a Berlese funnel apparatus over Erlenmeyer flasks containing 70% alcohol placed at the end of the funnel stems for over 48 h. RESULTS: Of 25 food items examined in the study, only six were contaminated by mites. Species of the mites found were Acarus siro (34.6%), Glycyphagus domesticus (22.8%), Tyrophagus putrescentiae (16.8%), Tyrophagus spp. (7.9%), Rhizoglyphus spp. (1%), Lepidoglyphus destructor (7.9%), Cheylettus malacensis (4%), and Cheylettus spp. (2%). CONCLUSION: Although the results of the study show that the presence of mites in food items sold in open containers at open-air markets or stores was low, we suppose that they can cause important health problems for sensitive people</style></abstract><notes><style face="normal" font="Arial">DA - 20170711IS - 2146-3077 (Electronic)IS - 1300-6320 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5152/tpd.2017.4837</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28695832">PM:28695832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Turkiye Parazitol Derg\2017-41-92-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Turkiye Parazitol Derg\2017-41-92-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170711, Uzunoglu KE</style></custom2><misc3><style face="normal" font="Arial">10.5152/tpd.2017.4837</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nordlund,B.</style></author><author><style face="normal" font="Arial"> Lundholm,C.</style></author><author><style face="normal" font="Arial"> Ullemar,V.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Ortqvist,A.K.</style></author><author><style face="normal" font="Arial"> Almqvist,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Epidemiology and Biostatistics,Karolinska Institutet,Stockholm,Sweden</style></auth-address><titles><title><style face="normal" font="Arial">The STOPPA Twin Study Explains the Exhaled Nitric Oxide and Asthma Link by Genetics and Sensitization</style></title><secondary-title><style face="normal" font="Arial">Twin Res Hum Genet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Twin Res Hum Genet</style></full-title></periodical><pages end="337" start="330">330-337</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> twin</style></keyword><keyword><style face="normal" font="Arial"> Twin studies</style></keyword><keyword><style face="normal" font="Arial"> twin study</style></keyword><keyword><style face="normal" font="Arial"> Twins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The link between asthma and exhaled nitric oxide (FENO) is not completely understood. The aim of this study was to estimate the association between FENO and asthma, taking genetics, sensitization, and inhaled corticosteroids (ICS) into account. METHODS: A total of 681 twins (53% monozygotic [MZ] and 47% dizygotic [DZ]) from the population-based STOPPA study (mean age 12.6 years) were recruited and information on FENO (parts per billion), parental report of current asthma, sensitization to airborne allergens (Phadiatop; IgE >/=0.35 kUA/l), and ICS-treatment was collected. We estimated the association between FENO and asthma, sensitization, and ICS in all twins and within pairs (DZ and MZ) to address shared genetic and environmental factors. Linear regression of log-transformed FENO was used and results presented as exponentiated regression coefficients (exp[beta]), with 95% confidence interval (CI). RESULTS: We found an association between asthma and FENO in all twins, exp(beta) 1.31 [1.11, 1.54]. In within-pairs analysis, the association was stronger within DZ pairs discordant for FENO, exp(beta) 1.50 [1.19, 1.89], compared to MZ pairs, exp(beta) 1.07 [0.84, 1.37], p = .049. There was no difference in FENO in non-sensitized children with asthma, compared to children with neither asthma nor sensitization, exp(beta) 0.89 [0.77, 1.03]. However, increased FENO was associated with sensitization, exp(beta) 1.48 [1.30, 1.69], and with sensitization together with asthma, exp(beta) 1.98 [1.57, 2.51], in all twins and within DZ pairs discordant for FENO, but not in MZ pairs. The FENO asthma association remained in DZ pairs without regular ICS-treatment. CONCLUSIONS: The association between FENO and asthma is explained by genetics and sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1832-4274 (Print)IS - 1832-4274 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1017/thg.2017.35</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28724478">PM:28724478</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Twin Res Hum Genet\2017-20-330-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Twin Res Hum Genet\2017-20-330-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Nordlund B</style></custom2><misc3><style face="normal" font="Arial">10.1017/thg.2017.35</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lane,M.J.</style></author><author><style face="normal" font="Arial"> Pucheu-Haston,C.M.</style></author><author><style face="normal" font="Arial"> Kearney,M.T.</style></author><author><style face="normal" font="Arial"> Woodward,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Veterinary Clinical Sciences, Louisiana State University School of Veterinary Medicine, Skip Bertman Drive, Baton Rouge, LA, 70803, USA</style></auth-address><titles><title><style face="normal" font="Arial">Determination of irritant threshold concentrations of multiple tree, grass, weed and mould allergens for intradermal testing of horses residing in the southern USA</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Ash</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Curvularia</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Intradermal testing</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Kentucky</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> Late phase reaction</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> Louisiana</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> mulberry</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> pecan</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Appropriate allergen threshold concentrations (TCs) for intradermal testing (IDT) have not been established in horses for many pollen and mould allergens. OBJECTIVES: To determine the TCs in non-allergic horses and describe the frequency of late phase reactions for 26 allergens, including trees, grasses, weeds and moulds in horses residing in the southern Unites States. ANIMALS: Twenty four clinically normal horses in the southern United States. METHODS: Threshold concentrations for different allergens were determined using IDT subjective measurements at 30 minutes. Delayed reactions were evaluated at 4 and 24 h. RESULTS: Threshold concentrations (all PNU/mL) were established for eight tree allergens (black willow 1,000, box elder 1,000, live oak 1,000, pecan 2,000, white ash 4,000, red oak 4,000, red mulberry 2,000 and green ash 2,000); two grass allergens (Johnson grass 250 PNU/mL and Kentucky blue grass 500 PNU/mL); two weeds (carelessweed 1,000 PNU/mL, great ragweed 500 PNU/mL) and one mould (Curvularia 8,000 PNU/mL). The TC was not determined due to excessive reactivity at the lowest concentration tested (1,000 PNU/mL) for bahia and perennial rye grass. Eleven other allergens did not meet the criteria to establish a TC when evaluated at 30 min due to lack of positive reactions. Multiple allergens caused positive reactions in >/=10% of horses at 4 h. Reactions at 24 h were rare with the exception of one horse. CONCLUSIONS AND CLINICAL IMPORTANCE: This study identified intradermal TC for multiple pollen and mould allergens in horses. These values may prove useful for optimizing allergen concentrations for IDT of allergic horses</style></abstract><notes><style face="normal" font="Arial">DA - 20170719IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12472</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722254">PM:28722254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170719-LaneMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170719-LaneMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170719, Lane MJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12472</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maina,E.</style></author><author><style face="normal" font="Arial"> Devriendt,B.</style></author><author><style face="normal" font="Arial"> Cox,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Changes in cytokine profiles following treatment with food allergen-specific sublingual immunotherapy in dogs with adverse food reactions</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Induction of tolerance</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukins</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="7" Year="2017">2017/7/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergen-specific sublingual immunotherapy (FA-SLIT) is considered to be a novel, safe and effective approach in dogs with adverse food reactions (AFR). HYPOTHESIS/OBJECTIVES: To investigate changes in key cytokines associated with FA-SLIT. ANIMALS: Eleven dogs with confirmed AFR. METHODS: Participants received either dose escalation of FA-SLIT or placebo over a six month period. Oral food challenge was performed at the beginning and end of the study, along with clinical examinations and collection of skin surface bacterial cytology and blood. Peripheral blood mononuclear cells were stimulated with the culprit food antigen. ELISA methods were used to quantify Interleukin (IL)-10, IFN-gamma, IL-4 and IL-17A in the supernatant of stimulated cells. RESULTS: IL-10 and IFN-gamma levels were significantly increased at the end of the study in the treatment group (T), compared with the placebo group (P), whereas no changes were found in IL-4 levels. IL-17A levels were decreased in both groups (but more profoundly in T). Bacterial scores on the skin were positively correlated with IL-17A and inversely correlated with IL-10 concentrations. Interleukins were not correlated with clinical scores. CONCLUSION AND CLINICAL IMPORTANCE: FA-SLIT may modulate the allergic response toward Th1 and Treg cell phenotypes, and induction of tolerance in dogs with AFR. Therefore, FA-SLIT may be a tool to desensitize dogs with AFR. However, more data on a larger number of cases and a broader panel of cytokines are needed to corroborate these findings, and to elucidate the mechanism of action for responses to FA-SLIT by dogs with AFR</style></abstract><notes><style face="normal" font="Arial">DA - 20170724IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12463</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28736961">PM:28736961</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170724-MainaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170724-MainaE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170724, Maina E</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12463</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aberg,L.</style></author><author><style face="normal" font="Arial"> Varjonen,K.</style></author><author><style face="normal" font="Arial"> Ahman,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Djurakuten i Stor-Stockholm AB, Kungstensgatan 58, 113 29, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Results of allergen-specific immunotherapy in atopic dogs with Malassezia hypersensitivity: a retrospective study of 16 cases</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intradermal test</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hypersensitivity reactions to Malassezia spp have been shown to occur in dogs with atopic dermatitis (AD) and to cause exacerbation of clinical signs. Improvement of clinical signs following use of antifungal medication is seen with both Malassezia overgrowth or Malassezia hypersensitivity (MHS). Subcutaneous immunotherapy (SCIT) is considered a safe and effective treatment for management of canine AD. Adverse effects are considered rare. OBJECTIVES: To report on the use of SCIT with Malassezia extracts in mono-sensitized dogs. ANIMALS: Sixteen client owned dogs diagnosed with MHS and treated with SCIT. METHODS: A retrospective review of medical records of atopic dogs diagnosed with MHS, mono-sensitized for Malassezia allergens on intradermal test and treated with SCIT for more than 10 months. Efficacy was measured by decreasing use of anti-inflammatory and antifungal medication by >/=50% and by decreasing pruritus by >/=50% as assessed by owners, using a pruritus score. RESULTS: Good response to SCIT was seen in nine of 16 cases (56%) with both a reduction in use of anti-inflammatory and antifungal medication as well as a reduction in pruritus scores by >/=50%. No adverse effects were reported. CONCLUSION: Allergen-specific immunotherapy was a safe treatment for dogs with Malassezia hypersensitivity. The efficacy of Malassezia immunotherapy corresponds well to the results of previous studies of immunotherapy with other environmental allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170727IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Case ReportsCO - Sweden -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12475</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28748560">PM:28748560</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170727-AbergL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170727-AbergL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Aberg L</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12475</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soria,I.</style></author><author><style face="normal" font="Arial"> Alvarez,J.</style></author><author><style face="normal" font="Arial"> Manzano,A.I.</style></author><author><style face="normal" font="Arial"> Lopez-Relano,J.</style></author><author><style face="normal" font="Arial"> Cases,B..</style></author><author><style face="normal" font="Arial"> Mas-Fontao,A.</style></author><author><style face="normal" font="Arial"> Canada,F.J.</style></author><author><style face="normal" font="Arial"> Fernandez-Caldas,E.</style></author><author><style face="normal" font="Arial"> Casanovas,M.</style></author><author><style face="normal" font="Arial"> Jimenez-Barbero,J.</style></author><author><style face="normal" font="Arial"> Palomares,O.</style></author><author><style face="normal" font="Arial"> Vinals-Florez,L.M.</style></author><author><style face="normal" font="Arial"> Subiza,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine</style></title><secondary-title><style face="normal" font="Arial">Vet Immunol Immunopathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Vet Immunol Immunopathol</style></abbr-1></periodical><pages end="72" start="65">65-72</pages><volume><style face="normal" font="Arial">190</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen uptake</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood donor</style></keyword><keyword><style face="normal" font="Arial"> Blood Donors</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Glutaraldehyde</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> Nuclear Magnetic Resonance</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Saccharomyces</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0165-2427</style></isbn><abstract><style face="normal" font="Arial">We have recently reported that grass pollen allergoids conjugated with non oxidized mannan of Saccharomyces cerevisae using glutaraldehyde results in a novel hypoallergenic mannan-allergen complex with improved properties for allergen vaccination. Using this approach, human dendritic cells show a better allergen uptake and cytokine profile production (higher IL-10/IL-4 ratio) for therapeutic purposes. Here we aim to address whether a similar approach can be extended to dogs using canine dendritic cells. Six healthy Spanish Greyhound dogs were used as blood donors to obtain canine dendritic cells (DC) derived from peripheral blood monocytes. Allergens from Dermatophagoides farinae mite were polymerized and conjugated with nonoxidized mannan. Nuclear magnetic resonance (NMR), gel electrophoresis (SDS-PAGE), immunoblotting and IgE-ELISA inhibition studies were conducted to evaluate the main characteristics of the allergoid obtained. Mannan-allergen conjugate and controls were assayed in vitro for canine DC uptake and production of IL-4 and IL-10. The results indicate that the conjugation of D. farinae allergens with nonoxidized mannan was feasible using glutaraldehyde. The resulting product was a polymerized structure showing a high molecular weight as detected by NMR and SDS-PAGE analysis. The mannan-allergen conjugate was hypoallergenic with a reduced reactivity with specific dog IgE. An increase in both allergen uptake and IL-10/IL-4 ratio was obtained when canine DCs were incubated with the mannan-allergen conjugate, as compared with the control allergen preparations (unmodified D. farinae allergens and oxidized mannan-allergen conjugate). We conclude that hypoallergenic D. farinae allergens coupled to nonoxidized mannan is a novel allergen preparation suitable for canine allergy immunotherapy targeting dendritic cells</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.vetimm.2017.07.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.vetimm.2017.07.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Immunol Immunopathol\20170728-SoriaI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Immunol Immunopathol\20170728-SoriaI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Soria I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.vetimm.2017.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mateo-Morejon,M.</style></author><author><style face="normal" font="Arial"> Labrada-Rosado,A.</style></author><author><style face="normal" font="Arial"> Torralba-Averoff,D.</style></author><author><style face="normal" font="Arial"> Cruz-Jimenez,R.</style></author><author><style face="normal" font="Arial"> Oliva-Diaz,Y.</style></author><author><style face="normal" font="Arial"> Alvarez-Castello,M.</style></author><author><style face="normal" font="Arial"> Ciria-Martin,A.</style></author><author><style face="normal" font="Arial"> Jimenez-Frandin,M.</style></author><author><style face="normal" font="Arial"> Reyes-Zamora,M.C.</style></author><author><style face="normal" font="Arial"> Castro-Almarales,R.L.</style></author><author><style face="normal" font="Arial"> Tamargo-Garcia,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergen Department, Centro Nacional de Biopreprados, Carretera Beltran Km 1 (1/2), Bejucal, Mayabeque Cuba</style></auth-address><titles><title><style face="normal" font="Arial">Is peanut causing food allergy in Cuba? Preliminary assessment of allergic sensitization and IgE specificity profile to peanut allergens in Cuban allergic patients</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="26">26-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 3</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Arachis</style></keyword><keyword><style face="normal" font="Arial"> Arachis hypogaea</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cuba</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Havana</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MW</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut Agglutinin</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergy is increasing at an alarming pace in developed countries. Peanut (Arachis hypogaea) is a common food in Cuba. Nevertheless, reported values of sensitization and symptom severity are usually low. As our objective, we carried out an evaluation of allergic sensitivity to perform an assessment of allergic sensitization and IgE specificity profile to peanut allergens in Cuban allergic patients. METHODS: The Skin Prick Test (SPT) was performed for each patient, using two glycerinated allergenic extracts, prepared from raw or roasted peanuts. Overall, 316 food allergic patients (159 adults and 157 children) attending allergy services at four hospitals in Havana were included, as well as 303 adult non- allergic volunteers. The IgE binding profile of 26 selected SPT positive patients was further analyzed by immunoblotting. RESULTS: The prevalence of sensitization to peanut was 4.6% in general adult population, whereas in adult food-allergic patients it was 18.6%. Prevalence rates were even greater in food allergic children achieving 25.8%. Sensitization frequencies were apparently greater for roasted, as compared to raw peanuts, although the difference was not significant (p> 0.05, Mc Nemar's). IgE binding was shown mostly by the 15 and 17 kDa bands, tentatively identified as the major allergens Ara h 2 and Ara h 6. The IgG4 binding profile was similar to IgE, although with more prominence of the bands at 37 and 28 KDa, corresponding to an Ara h 3 fragment and Peanut Agglutinin. DISCUSSION: The study estimated a relatively high prevalence of peanut sensitization in population. Data reported here suggest that IgE sensitization in Cuban patients is focused mostly on MW bands corresponding to the major allergens Ara h 6 and Ara h 2. CONCLUSIONS: Sensitization to peanut allergen is indeed relatively frequent in Cuba. The IgE profile is congruent to a sensitization pattern by ingestion of roasted peanuts and is directed to well-known major allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Cuba -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0156-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28725335">PM:28725335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170720, Mateo-Morejon M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0156-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,F.F.</style></author><author><style face="normal" font="Arial"> Yu,S.Q.</style></author><author><style face="normal" font="Arial"> Zhao,C.L.</style></author><author><style face="normal" font="Arial"> Che,N.</style></author><author><style face="normal" font="Arial"> Jin,L.</style></author><author><style face="normal" font="Arial"> Wang,Q.L.</style></author><author><style face="normal" font="Arial"> Ge,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology Head and Neck Surgery, Tongji Hospital, Tongji University, Shanghai 200065, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effect of hydrogen-rich saline on the CD4(+) CD25(+) Foxp3(+) Treg cells of allergic rhinitis guinea pigs model]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="511" start="506">506-511</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Movement</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">Objective: To explore the effect of hydrogen-rich saline on the CD4(+) CD25(+) Foxp3(+) Treg cells in a guinea pig model of allergic rhinitis (AR) and investigate the underling anti-inflammatory mechanism. Methods: Using random number table, eighteen guinea pigs were divided into three groups (control group/AR group/HRS group, n=6 of each group). AR guinea pig model was built with ovalbumin and aluminum. The guinea pigs were injected with hydrogen-rich saline (HRS group) for ten days after sensitation. And control group was injected with equal normal saline at the same time. Number of sneezes, degree of runny nose and nasal rubbing movements were scored. Peripheral blood eosinophil count was recorded. The content of interleukin 10(IL-10) and transforming growth factor beta (TGF-beta) in the serum were detected by enzyme-linked immunosorbent assay (ELISA). Immunohistochemical method was taken to detect IL-10 and TGF-beta in nasal mucosa. The proportion of CD4(+) CD25(+) Foxp3(+) T cells in the CD4(+) T cells of spleen and peripheral blood were determined with flow cytometry. SPSS 17.0 software was used to analyze the data. Results: There was significant difference in symptom scores among them. The scores of AR group preceded control group, and HRS could decrease the scores of AR ((6.29+/-1.79) vs (1.01+/-0.71), (4.50+/-0.84) vs (6.29+/-1.79), F=24.725, all P&lt;0.05). The highest number of eosinophils in the peripheral blood belonged to control group, and the number of eosinophils were dramatically reduced after HRS administration ((0.41+/-0.05)x10(9)/L vs (0.25+/-0.03 )x10(9)/L, (0.32+/-0.03)x10(9)/L vs (0.41+/-0.05)x10(9)/L, F=70.05, all P&lt;0.05). The content of IL-10 and TGF-beta in control group is peak ((86.88+/-17.17) pg/ml, (598.28+/-72.70) pg/ml, respectively), and compared with AR group, HRS also increased the expression of IL-10 and TGF-beta of peripheral blood ((72.54+/-11.75) pg/ml vs (53.49+/-10.07) pg/ml, (530.23+/-57.15) pg/ml vs (482.69+/-65.96) pg/ml, F value was 28.357, 14.128, respectively, all P&lt;0.05). The proportion of CD4(+) CD25(+) Foxp3(+) Treg cells in controls exceeded HRS group and AR group (1.81%+/-0.10%, 1.29%+/-0.74%, respectively), and HRS treatment increased the ratio of CD4(+) CD25(+) Foxp3(+) Treg cells than AR group of peripheral blood ((1.50%+/-0.11%) vs (1.15%+/-0.11%), F=168.96, P&lt;0.05). But there was no significant diferences in splene tissue ((1.01%+/-0.08%) vs (0.98%+/-0.09%), F=97.381, P>0.05). Conclusion: Both the number and the cytokine secretion of CD4(+) CD25(+) Foxp3(+) Treg cells are decreased in AR group, HRS may inhibit inflammatory response and ameliorate AR via improving the number and the cytokine secretion</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28728239">PM:28728239</url></web-urls></urls><custom2><style face="normal" font="Arial">20170720, Xu FF</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,L.</style></author><author><style face="normal" font="Arial"> You,Q.J.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Yang,H.H.</style></author><author><style face="normal" font="Arial"> Fang,H.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China</style></auth-address><titles><title><style face="normal" font="Arial">[Evaluation of efficacy of 1 year after completing the 2-year specific sublingual immunotherapy treatment course in allergic rhinitis]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="500" start="497">497-500</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">Objective: To evaluate the efficacy of treatment at 1 year after completing the 2-year specific sublingual immunotherapy in patients with allergic rhinitis (AR). Methods: A retrospective analysis of 124 patients with AR who were allergic to dust mite and treated in the First Affiliated Hospital of Wenzhou Medical University since 2012 was performed. All patients achieved sublingual immunotherapy (SLIT) for 2 years and had a regular follow-up over 1 year. Efficacy evaluation index such as VAS score, total nasal symptom score and total medication score were compared between the time of SLIT for 2 years, and 1 year after termination of SLIT. Paired t test was used for the comparison of scores. Results: Compared with those before treatment, the VAS score, total nasal symptom score and total medication score at the time of SLIT for 2 years were significantly decreased in all patients with AR [(9.40+/-5.96) vs (24.78+/-6.36), (4.53+/-2.06) vs (9.51+/-2.02), (0.42+/-0.87) vs (3.02+/-0.41), t value was 17.627, 24.600, 5.331, respectively, all P&lt;0.01]. Compared with 2 years SLIT treatment, VAS score and total nasal symptom score were significantly increased than 1 year after termination of immunotherapy [(12.52+/-6.92) vs (9.40+/-5.96), (5.30+/-2.36) vs (4.53+/-2.06), t=5.199, 3.744, respectively, all P&lt;0.01], but the total medication score showed no significant difference [(0.34+/-0.84) vs (0.42+/-0.87), t=-1.043, P>0.05]. Conclusions: The symptoms after 2 years SLIT in patients with AR have been well controlled. One year after the termination of SLIT, there is a certain rebound in symptoms, 2 years SLIT may not be the ideal treatment cycle for AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28728237">PM:28728237</url></web-urls></urls><custom2><style face="normal" font="Arial">20170720, Han L</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shen,X.L.</style></author><author><style face="normal" font="Arial"> Zhao,D.</style></author><author><style face="normal" font="Arial"> Yan,X.H.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Feng,N.Y.</style></author><author><style face="normal" font="Arial"> Wen,W.L.</style></author><author><style face="normal" font="Arial"> Ha,H.Y.</style></author><author><style face="normal" font="Arial"> Yang,Z.C.</style></author><author><style face="normal" font="Arial"> Di,L.L.</style></author><author><style face="normal" font="Arial"> Guo,H.Q.</style></author><author><style face="normal" font="Arial"> Liu,H.T.</style></author><author><style face="normal" font="Arial"> Ma,R.X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology Head and Neck Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, China</style></auth-address><titles><title><style face="normal" font="Arial">[Epidemiological investigation of allergic rhinitis in Ningxia]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></full-title></periodical><pages end="496" start="491">491-496</pages><volume><style face="normal" font="Arial">52</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Policy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Rural Population</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban Population</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="Arial">Objective: To investigate the epidemiological characteristics of allergic rhinitis (AR) in Ningxia and to analyze its related factors. Methods: From March to September of 2013, a multi-stage and cluster sampling method was used to investigate the diagnosis and treatment of AR in Ningxia Area (3 years and above). Guidelines for diagnosis and treatment of allergic rhinitis (2009, Wuyishan) was used as the basis for the diagnosis of adult AR, while Guidelines for diagnosis and treatment of pediatric allergic rhinitis (2010, Chongqing) was used as the basis for children. SPSS 16.0 software was used to complete the statistical analysis. Results: The total number of questionnaires was 6 000, and the number of effective questionnaire was 5 236, the recovery rate was 87.27%. With 684 cases diagnosed of AR, the prevalence of AR in Ningxia was 13.06% (684/5 236), including 13.40% (325/2 425) of males, 12.77% (359/2 811) of females. The difference was not statistically significant (chi(2)=0.456, P>0.05). There was significant difference in the prevalence between Hui and Han [14.35% (452/3 150) vs 11.12% (232/2 086), chi(2)=11.51, P&lt;0.05]. According to ARIA criteria, persistent AR was 27.63% (189/684), intermittent AR was 72.37% (495/684). The month with highest incidence of AR in Ningxia Area was September, accounting for 71.78% (491/684). The prevalence of urban population was 14.54%, with the prevalence of rural population was 11.90%, and the difference was significant between urban and rural residents (chi(2)=7.90, P&lt;0.05). The age group with highest prevalence rate was 21~30 years old. The main inhalation allergens were mugwort (68.42%), weeds (58.48%) and ragweed (55.56%). The main dietary allergens were wheat flour (14.33%), peanut (13.74%) and walnut kernel (11.99%). The most common complication was allergic conjunctivitis [82.02% (561/684)]. Conclusion: The epidemiology of AR in Ningxia Area is preliminarily understood, which will provide the epidemiological evidence for the prevention and treatment of AR and the formulation of public health policy</style></abstract><notes><style face="normal" font="Arial">DA - 20170720IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28728236">PM:28728236</url></web-urls></urls><custom2><style face="normal" font="Arial">20170720, Shen XL</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.1673-0860.2017.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rabe,U.</style></author><author><style face="normal" font="Arial"> Altengarten,J.</style></author><author><style face="normal" font="Arial"> Benke,E.</style></author><author><style face="normal" font="Arial"> Erdmann,A.</style></author><author><style face="normal" font="Arial"> Erdmann,A.P.</style></author><author><style face="normal" font="Arial"> Fiedler,G.</style></author><author><style face="normal" font="Arial"> Hofmann,S.</style></author><author><style face="normal" font="Arial"> Jasch,B.</style></author><author><style face="normal" font="Arial"> Kallien,U.</style></author><author><style face="normal" font="Arial"> Knuppe-Andree,S.</style></author><author><style face="normal" font="Arial"> Ludcke,H.J.</style></author><author><style face="normal" font="Arial"> Lohse,K.</style></author><author><style face="normal" font="Arial"> Piller,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Long-term efficacy of specific subcutaneous, short-term MPL adjuvant immunotherapy over three treatment and three follow-up years, as measured by quality of life</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="154" start="147">147-154</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">Apart from allergen avoidance, specific immunotherapy (SIT) is the only causal treatment for pollen allergy diseases. Its efficacy and tolerability have been demonstrated in numerous studies on adults and children. There are fewer studies, however, evidencing a-álong-term treatment effect and the effect of treatment on patients</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ quality of life (QoL)</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0029-8</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40629-017-0029-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-147-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-147-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Rabe U</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0029-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simoleit,A.</style></author><author><style face="normal" font="Arial"> Werchan,M.</style></author><author><style face="normal" font="Arial"> Werchan,B.</style></author><author><style face="normal" font="Arial"> Mucke,H.G.</style></author><author><style face="normal" font="Arial"> Gauger,U.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Birch, grass, and mugwort pollen concentrations and intradiurnal patterns at two different urban sites in Berlin, Germany</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="164" start="155">155-164</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Intradiurnal patterns</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> mugwort pollen</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">The study investigated the seasonal courses and intradiurnal patterns of birch (Betula), grass (Poaceae), and mugwort (Artemisia) pollen at two sites in the city of Berlin in 2014 and 2015</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0012-4</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40629-017-0012-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-155-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-155-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Simoleit A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0012-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blatner,C.</style></author><author><style face="normal" font="Arial"> Oppel,E.M.</style></author><author><style face="normal" font="Arial"> Wieser,A.</style></author><author><style face="normal" font="Arial"> Herzinger,T.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">No Abstract Available</style></auth-address><titles><title><style face="normal" font="Arial">The small liver fluke (Dicrocoelium dendriticum): an unusual clinical finding in chronic urticaria</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="167" start="165">165-167</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0021-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40629-017-0021-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-165-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-165-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Blatner C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0021-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wiesmuller,G.A.</style></author><author><style face="normal" font="Arial"> Heinzow,B.</style></author><author><style face="normal" font="Arial"> Aurbach,U.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Bufe,A.</style></author><author><style face="normal" font="Arial"> Buzina,W.</style></author><author><style face="normal" font="Arial"> Cornely,O.A.</style></author><author><style face="normal" font="Arial"> Engelhart,S.</style></author><author><style face="normal" font="Arial"> Fischer,G.</style></author><author><style face="normal" font="Arial"> Gabrio,T.</style></author><author><style face="normal" font="Arial"> Heinz,W.</style></author><author><style face="normal" font="Arial"> Herr,C.E.W.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Koberle,M.</style></author><author><style face="normal" font="Arial"> Lichtnecker,H.</style></author><author><style face="normal" font="Arial"> Lob-Corzilius,T.</style></author><author><style face="normal" font="Arial"> Merget,R.</style></author><author><style face="normal" font="Arial"> Mulleneisen,N.</style></author><author><style face="normal" font="Arial"> Nowak,D.</style></author><author><style face="normal" font="Arial"> Rabe,U.</style></author><author><style face="normal" font="Arial"> Raulf,M.</style></author><author><style face="normal" font="Arial"> Seidl,H.P.</style></author><author><style face="normal" font="Arial"> Steiss,J.O.</style></author><author><style face="normal" font="Arial"> Szewszyk,R.</style></author><author><style face="normal" font="Arial"> Thomas,P.</style></author><author><style face="normal" font="Arial"> Valtanen,K.</style></author><author><style face="normal" font="Arial"> Hurrass,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Abridged version of the AWMF guideline for the medical clinical diagnostics of indoor mould exposure</style></title><secondary-title><style face="normal" font="Arial">Allergo J Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergo J Int</style></full-title></periodical><pages end="193" start="168">168-193</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> adaptation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic risk</style></keyword><keyword><style face="normal" font="Arial"> Alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic allergic</style></keyword><keyword><style face="normal" font="Arial"> extrinsic allergic alveolitis</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Hemorrhage</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity pneumonitis</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mood</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Moulds</style></keyword><keyword><style face="normal" font="Arial"> Mucous Membrane</style></keyword><keyword><style face="normal" font="Arial"> Mycose</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> odour</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk groups</style></keyword><keyword><style face="normal" font="Arial"> Sarcoidosis</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Toxic reaction</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2197-0378</style></isbn><abstract><style face="normal" font="Arial">This article is an abridged version of the AWMF mould guideline </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£Medical clinical diagnostics of indoor mould exposure</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ presented in April 2016 by the German Society of Hygiene, Environmental Medicine and Preventive Medicine (Gesellschaft f++r Hygiene, Umweltmedizin und Pr+ñventivmedizin, GHUP), in collaboration with the above-mentioned scientific medical societies, German and Austrian societies, medical associations and experts. Indoor mould growth is a potential health risk, even if a quantitative and/or causal relationship between the occurrence of individual mould species and health problems has yet to be established. Apart from allergic bronchopulmonary aspergillosis (ABPA) and mould-caused mycoses, only sufficient evidence for an association between moisture/mould damage and the following health effects has been established: allergic respiratory disease, asthma (manifestation, progression and exacerbation), allergic rhinitis, hypersensitivity pneumonitis (extrinsic allergic alveolitis), and increased likelihood of respiratory infections/bronchitis. In this context the sensitizing potential of moulds is obviously low compared to other environmental allergens. Recent studies show a comparatively low sensitizing prevalence of 3</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô10% in the general population across Europe. Limited or suspected evidence for an association exist with respect to mucous membrane irritation and atopic eczema (manifestation, progression and exacerbation). Inadequate or insufficient evidence for an association exist for chronic obstructive pulmonary disease, acute idiopathic pulmonary hemorrhage in children, rheumatism/arthritis, sarcoidosis and cancer. The risk of infection posed by moulds regularly occurring indoors is low for healthy persons; most species are in risk group-á1 and a few in risk group-á2 (Aspergillus fumigatus, A.-áflavus) of the German Biological Agents Act (Biostoffverordnung). Only moulds that are potentially able to form toxins can be triggers of toxic reactions. Whether or not toxin formation occurs in individual cases is determined by environmental and growth conditions, above all the substrate. In the case of indoor moisture/mould damage, everyone can be affected by odour effects and/or mood disorders. However, this is not a health hazard. Predisposing factors for odour effects can include genetic and hormonal influences, imprinting, context and adaptation effects. Predisposing factors for mood disorders may include environmental concerns, anxiety, condition, and attribution, as well as various diseases. Risk groups to be protected particularly with regard to an infection risk are persons on immunosuppression according to the classification of the German Commission for Hospital Hygiene and Infection Prevention (Kommission f++r Krankenhaushygiene und Infektionspr+ñvention, KRINKO) at the Robert Koch- Institute (RKI) and persons with cystic fibrosis (mucoviscidosis); with regard to an allergic risk, persons with cystic fibrosis (mucoviscidosis) and patients with bronchial asthma should be protected</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40629-017-0013-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40629-017-0013-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-168-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-168-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Wiesmuller GA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40629-017-0013-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guo,H.</style></author><author><style face="normal" font="Arial"> Zheng,Y.</style></author><author><style face="normal" font="Arial"> Cai,X.</style></author><author><style face="normal" font="Arial"> Yang,H.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Hao,L.</style></author><author><style face="normal" font="Arial"> Jin,Y.</style></author><author><style face="normal" font="Arial"> Yang,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Gastroenterology Unit, Nanjing Children's Hospital Affiliated with Nanjing Medical University, 72 Guangzhou Road, Nanjing, Jiangsu 210008, China</style></auth-address><titles><title><style face="normal" font="Arial">Correlation between serum vitamin D status and immunological changes in children affected by gastrointestinal food allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological changes</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Low vitamin D status is linked to increased incidence of food allergy and intestinal inflammation. Whether vitamin D status is associated with immunological changes in children with gastrointestinal food allergy (GFA) remains unclear. METHODS: Forty-nine GFA children (aged 2-11 years old) were enrolled in this study. Serum 25-hydroxyvitamin D (25OHD) level, total immunoglobulin E (IgE), specific IgE against allergens, circulating regulatory T lymphocytes (Tregs), and blood eosinophil numbers were measured. RESULTS: Levels of serum 25OHD in the GFA children ranged 35.5-156.4nmol/L, with a mean value similar to that of the healthy controls. Compared to those with normal 25OHD (>/=75nmol/L), GFA children with low 25OHD (&lt;75nmol/L) had increased total IgE (84% vs. 54%, P&lt;0.05), persistent blood eosinophilia (56% vs. 25%, P&lt;0.05), and delayed resolution of symptoms after food allergen elimination (odds ratio 3.51, 95% CI 1.00-12.36, P&lt;0.05). Among the GFA children with elevated total IgE, those with low 25OHD had lower circulatory Tregs (8.79+/-2.4% vs. 10.21+/-1.37%, P&lt;0.05), higher total IgE (1197.5+/-1209.8 vs. 418.5+/-304.6kU/L, P&lt;0.05), and persistent eosinophilia (0.61+/-0.52 vs. 0.31+/-0.15x109cells/L, P&lt;0.05) compared to those with normal 25OHD. In addition, serum 25OHD concentrations inversely correlated with total IgE (R=-0.434, P&lt;0.05), and positively with Treg population (R=0.356, P&lt;0.05). CONCLUSION: Low serum vitamin D status correlates with stronger allergic immune response in GFA children</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757197">PM:28757197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170731-GuoH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170731-GuoH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Guo H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.03.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Isik,S.</style></author><author><style face="normal" font="Arial"> Karaman,M.</style></author><author><style face="normal" font="Arial"> Micili,S.C.</style></author><author><style face="normal" font="Arial"> Caglayan-Sozmen,S.</style></author><author><style face="normal" font="Arial"> Bagriyanik,H.A.</style></author><author><style face="normal" font="Arial"> Arikan-Ayyildiz,Z.</style></author><author><style face="normal" font="Arial"> Uzuner,N.</style></author><author><style face="normal" font="Arial"> Karaman,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dokuz Eylul University, Department of Pediatric Allergy and Immunology, Izmir, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Sinomenine ameliorates the airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in a murine model of chronic asthma</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppression</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sinomenine (SIN), an alkaloid isolated from the root of Sinomenium acutum which has a variety of pharmacological effects, including anti-inflammation, immunosuppression and anti-angiogenesis. The present study aimed to evaluate the effects of SIN on airway remodelling, epithelial apoptosis, and T Helper (Th)-2 derived cytokine levels in a murine model of chronic asthma. METHODS: Twenty-two BALB/c mice were divided into four groups; I (control), II (placebo), III, IV. Mice in groups III and IV received the SIN (100mg/kg), and dexamethasone (1mg/kg) respectively. Epithelium thickness, sub-epithelial smooth muscle thickness, number of mast and goblet cells of samples isolated from the lung were measured. Immunohistochemical scorings of the lung tissue for matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor (VEG-F), transforming growth factor-beta (TGF-beta), terminal deoxynucleotidyl transferase-mediated dUTP nick endlabeling (TUNEL) and cysteine-dependent aspartate-specific proteases (caspase)-3 were determined. IL-4, IL-5, IL-13, Nitric oxide in bronchoalveolar lavage fluid (BALF) and ovalbumin-specific immunoglobulin (Ig) E in serum were quantified by standard ELISA protocols. RESULTS: The dose of 100mg/kg SIN treatment provided beneficial effects on all of the histopathological findings of airway remodelling compared to placebo (p&lt;0.05). All cytokine levels in BALF and serum and immunohistochemical scores were significantly lower in 100mg/kg SIN treated group compared to the placebo (p&lt;0.05). CONCLUSIONS: These findings suggested that the dose of 100mg/kg SIN improved all histopathological changes of airway remodelling and its beneficial effects might be related to modulating Th-2 derived cytokines and the inhibition of apoptosis of airway epithelial cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.05.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778746">PM:28778746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170805-IsikS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170805-IsikS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Isik S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.05.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mencia,G.</style></author><author><style face="normal" font="Arial"> El-Qutob,D.</style></author><author><style face="normal" font="Arial"> Pineda,F.</style></author><author><style face="normal" font="Arial"> Castillo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Allergy, Consortium Provincial Hospital, Castellon, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Occupational allergy to Triticum spelta flour</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Triticum</style></keyword></keywords><dates><year Day="29" Month="7" Year="2017">2017/7/29</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28764943">PM:28764943</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170802-ManciaG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170802-ManciaG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Mencia G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Itoh-Nagato,N.</style></author><author><style face="normal" font="Arial"> Inoue,Y.</style></author><author><style face="normal" font="Arial"> Nagao,M.</style></author><author><style face="normal" font="Arial"> Fujisawa,T.</style></author><author><style face="normal" font="Arial"> Shimojo,N.</style></author><author><style face="normal" font="Arial"> Iwata,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Shimoshizu National Hospital, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Desensitization to a whole egg by rush oral immunotherapy improves the quality of life of guardians: A multicenter, randomized, parallel-group, delayed-start design study</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Whole egg</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients with food allergies and their families have a significantly reduced health-related quality of life (QOL). METHODS: We performed a multicenter, randomized, parallel-group, delayed-start design study to clarify the efficacy and safety of rush oral immunotherapy (rOIT) and its impact on the participants' daily life and their guardians (UMIN000003943). Forty-five participants were randomly divided into an early-start group and a late-start group. The early-start group received rOIT for 3 months, while the late-start group continued the egg elimination diet (control). In the next stage, both groups received OIT until all participants had finished 12 months of maintenance OIT. RESULTS: The ratio of the participants in whom an increase of the TD was achieved in the first stage was significantly higher in the early-start group (87.0%), than in the late-start group (22.7%). The QOL of the guardians in the early-start group significantly improved after the first stage (65.2%), in comparison to the late-start group (31.8%). During 12 months of rOIT, the serum ovomucoid-specific IgE levels, the percentage of CD203c+ basophils upon stimulation with egg white, and the wheal size to egg white were decreased, while the serum ovomucoid-specific IgG4 levels were increased. However, approximately 80% of the participants in the early-start group showed an allergic reaction during the first stage of the study, whereas none of the patients in the late-start group experienced an allergic reaction. CONCLUSIONS: rOIT induced desensitization to egg and thus improved the QOL of guardians; however, the participants experienced frequent allergic reactions due to the treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778455">PM:28778455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170805-ItohNagatoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170805-ItohNagatoN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Itoh-Nagato N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yonekura,S.</style></author><author><style face="normal" font="Arial"> Okamoto,Y.</style></author><author><style face="normal" font="Arial"> Sakurai,D.</style></author><author><style face="normal" font="Arial"> Okubo,K.</style></author><author><style face="normal" font="Arial"> Gotoh,M.</style></author><author><style face="normal" font="Arial"> Kaneko,S.</style></author><author><style face="normal" font="Arial"> Konno,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="Arial">An analysis of factors related to the effect of sublingual immunotherapy on Japanese cedar pollen induced allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2017">2017/7/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sublingual immunotherapy (SLIT) can improve the symptoms of allergic rhinitis and modify its natural history; however, its efficacy varies among patients. This study aimed to determine which factors modify the effect of SLIT through post hoc analysis of a previous phase 3 trial of standardized Japanese cedar (JC) pollen extract (CEDARTOLEN(R)). METHODS: The study included 482 patients who had previously completed a phase 3 trial during two seasons. The SLIT and placebo groups each contained 241 subjects. Because pollen dispersal differed in the two seasons, we identified good and poor responders from the SLIT group in the 2nd season. We compared patient baseline characteristics, changes in serum immunoglobulin, and severity of symptoms in the 1st season between good and poor responders, as well as between SLIT and placebo groups. RESULTS: When we compared the baseline characteristics of good and poor responders, a significant difference was observed in body mass index (BMI) such that the patients with BMI >/=25 presented with lower treatment efficacy. No significant difference was observed in correlation with any other factors or treatment-induced alterations of serum immunoglobulin levels. We found that 75.3% of the patients with moderate symptoms and 50.9% of the patients with severe or very severe symptoms in the 1st season met our criteria for good responders in the 2nd season. CONCLUSIONS: BMI might modify the effect of SLIT; however, other factors were not related clearly. The severity of symptoms in the 1st season of treatment does not predict that in the 2nd season</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28760534">PM:28760534</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170801-YonekuraS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170801-YonekuraS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Yonekura S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martins,C.F.</style></author><author><style face="normal" font="Arial"> Morais,K.L.</style></author><author><style face="normal" font="Arial"> Figueroa,P.</style></author><author><style face="normal" font="Arial"> Dias,N.F.</style></author><author><style face="normal" font="Arial"> Valente,N.S.</style></author><author><style face="normal" font="Arial"> Maruta,C.W.</style></author><author><style face="normal" font="Arial"> Criado,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital das Clinicas of the University of Sao Paulo Medical School, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Histopathological and clinical evaluation of chronic spontaneous urticaria patients with neutrophilic and non-neutrophilic cutaneous infiltrate</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="7" Year="2017">2017/7/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic urticaria has an expressive prevalence in general population, especially in adults, and is defined by the presence of intermittent hives for six weeks or longer. Our study aims to characterize the histological patterns of chronic spontaneous urticaria, based on the inflammatory cell infiltrate, and correlate them to laboratory exams. METHODS: It was performed a retrospective analysis of laboratory, histopathology and direct immunofluorescence data of 93 patients with chronic urticaria. For histopathological analysis, cell count was performed in four fields at high magnification (x400) for each specimen. The resulting cell count medians were submitted to statistical analysis and, then, were correlated to laboratorial findings. RESULTS: We found a female predominance (76.34%) of chronic urticaria cases, and an average age of 42.5 years (SD +/- 15). Two histological groups were distinctive: 1) chronic urticaria with predominance of neutrophils or eosinophils - N (%) = 39 (42.4%) - and 2) chronic urticaria with predominance of lymphocytes - N (%) = 53 (57.6%). There was not significant correlation between histological groups and laboratorial tests. Moreover, direct immunofluorescence was positive in 21 (33,87%) from 62 patients. CONCLUSIONS: There is not enough scientific evidence to support neutrophilic urticaria as a solid, separate entity</style></abstract><notes><style face="normal" font="Arial">DA - 20170729IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.06.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28754324">PM:28754324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170729-MartinsCF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170729-MartinsCF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170729, Martins CF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.06.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saeki,M.</style></author><author><style face="normal" font="Arial"> Kaminuma,O.</style></author><author><style face="normal" font="Arial"> Nishimura,T.</style></author><author><style face="normal" font="Arial"> Kitamura,N.</style></author><author><style face="normal" font="Arial"> Mori,A.</style></author><author><style face="normal" font="Arial"> Hiroi,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Th9 cells induce steroid-resistant bronchial hyperresponsiveness in mice</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="S40" start="S35">S35-S40</pages><volume><style face="normal" font="Arial">66S</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-9</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroid-resistant asthma</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Reduced responsiveness to corticosteroid therapy is a major problem for patients with severe asthma. Although Th9 cells, along with Th2 cells, facilitate antigen-induced airway eosinophilia and bronchial hyperresponsiveness (BHR), the sensitivity of Th9 cell-mediated responses to steroid therapy remains unknown. In this study, we investigated the effect of dexamethasone (Dex) on antigen-induced airway inflammation in Th9 cell-transferred mice. METHODS: Ovalbumin (OVA)-specific Th2 and Th9 cells were polarized from the CD4+ T cells of DO11.10/RAG-2-/- mice. BALB/c mice were adoptively transferred with Th2 or Th9 cells and challenged with OVA. Dex treatment was performed twice, at 1 h before and at 24 h after the OVA challenge. Following treatment, the number of inflammatory cells in the bronchoalveolar lavage fluid and the bronchial responsiveness to inhaled methacholine were determined. RESULTS: In both the Th2 and Th9 cell-transferred mice, substantial accumulation of eosinophils in the lungs and BHR were induced by challenge with the specific antigen. In the Th2 cell-transferred mice, these responses were significantly diminished by Dex treatment. In contrast, neither cellular infiltration nor BHR was affected by Dex treatment in the Th9 cell-transferred mice, although the Th9 cells substantially expressed glucocorticoid receptor alpha. Accordingly, antigen-induced interleukin-9 expression in the Th9 cells was attenuated by Dex treatment at least in vitro. Antigen-induced lung infiltration of infused Th2 cells but not Th9 cells was significantly suppressed by Dex. CONCLUSIONS: In contrast to Th2-mediated responses, Th9-mediated airway inflammation was not affected by Dex. Th9 cells might be involved in the developmental mechanisms of steroid-resistant asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170730IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28755856">PM:28755856</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170730-SaekiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170730-SaekiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170730, Saeki M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sturm,G.J.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Mosbech,H.</style></author><author><style face="normal" font="Arial"> Bilo,M.B.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Antolin-Amerigo,D.</style></author><author><style face="normal" font="Arial"> Cichocka-Jarosz,E.</style></author><author><style face="normal" font="Arial"> Gawlik,R.</style></author><author><style face="normal" font="Arial"> Jakob,T.</style></author><author><style face="normal" font="Arial"> Kosnik,M.</style></author><author><style face="normal" font="Arial"> Lange,J.</style></author><author><style face="normal" font="Arial"> Mingomataj,E.</style></author><author><style face="normal" font="Arial"> Mitsias,D.I.</style></author><author><style face="normal" font="Arial"> Ollert,M.</style></author><author><style face="normal" font="Arial"> Oude Elberink,J.N.G.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Pitsios,C.</style></author><author><style face="normal" font="Arial"> Pravettoni,V.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author><author><style face="normal" font="Arial"> Sin,B.A.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Angier,E.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Pajno,G.B.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Ryan,D.</style></author><author><style face="normal" font="Arial"> Spranger,O.</style></author><author><style face="normal" font="Arial"> Van Wijk,R.G.</style></author><author><style face="normal" font="Arial"> Dhami,S.</style></author><author><style face="normal" font="Arial"> Zaman,H.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venerology, Medical University of Graz, Austria</style></auth-address><titles><title><style face="normal" font="Arial">EAACI Guidelines on Allergen Immunotherapy: Hymenoptera venom allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Albania</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical recommendations</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Cyprus</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency kit</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> Slovenia</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> systemic sting reaction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="Arial">Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid or ant sting. Systemic allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate-to-severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1 -antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence-based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta-analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom allergic children and adults to prevent further moderate to severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline auto-injector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170727IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - United Kingdom -CO - Italy -CO - Germany -CO - Turkey -CO - Romania -CO - Denmark -CO - Switzerland -CO - Spain -CO - Poland -CO - Slovenia -CO - Greece -CO - Luxembourg -CO - Albania -CO - Slovenia -CO - Turkey -CO - Romania -CO - Netherlands -CO - Cyprus -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13262</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28748641">PM:28748641</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170727-SturmGJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170727-SturmGJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170727, Sturm GJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13262</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Damle,S.R.</style></author><author><style face="normal" font="Arial"> Martin,R.K.</style></author><author><style face="normal" font="Arial"> Cockburn,C.L.</style></author><author><style face="normal" font="Arial"> Lownik,J.C.</style></author><author><style face="normal" font="Arial"> Carlyon,J.A.</style></author><author><style face="normal" font="Arial"> Smith,A.D.</style></author><author><style face="normal" font="Arial"> Conrad,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia, 23298, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> Notch signaling</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rodentia</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy and allergic asthma are significant health burdens in developed countries and are increasing in prevalence. Dendritic cells (DCs) initiate immune responses to common aeroallergens and ADAM10 has been demonstrated to be important for the development of adaptive responses. This study's objective was to understand the role of ADAM10 on DCs in the development of allergic and anaphylactic responses. METHODS: In this study we used mouse models of allergic airway inflammation (house dust mice and Alternaria alternata) and OVA-induced models of active anaphylaxis to determine the DC-specific function of ADAM10 and Notch signaling. To examine TH 1 and TH 17 immunity infection with Anaplasma phagocytophilum and Citrobacter rodentium were used. RESULTS: Mice, which have ADAM10 deleted from DCs, have dramatic reductions in IgE production and do not develop significant TH 2 immune responses. Further, ADAM10DC-/- mice are resistant to IgE-mediated anaphylaxis. This response is selective for TH 2 immunity as TH 1 and TH 17 immunity are largely unaffected. Notch1, a known ADAM10 substrate, when knocked out of DCs (Notch1DC-/- ) demonstrated a similar reduction in anaphylaxis and IgE. Without ADAM10 and Notch1 signaling, DCs were unable to make cytokines that stimulate TH 2 cells and cytokines. Anaphylaxis and allergic lung inflammation were restored in ADAM10DC-/- with the overexpression of the Notch1-intracellular domain, confirming the role of Notch signaling. CONCLUSIONS: Targeting ADAM10 and Notch1 on DCs represent a novel strategy for modulating TH 2 immune responses and IgE production. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170726IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28745029">PM:28745029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170726-DamleSR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170726-DamleSR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170726, Damle SR</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13261</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dzoro,S.</style></author><author><style face="normal" font="Arial"> Mittermann,I.</style></author><author><style face="normal" font="Arial"> Resch,Y.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author><author><style face="normal" font="Arial"> Nehr,M.</style></author><author><style face="normal" font="Arial"> Hirschl,A.M.</style></author><author><style face="normal" font="Arial"> Wikberg,G.</style></author><author><style face="normal" font="Arial"> Lundeberg,L.</style></author><author><style face="normal" font="Arial"> Johansson,C.</style></author><author><style face="normal" font="Arial"> Scheynius,A.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathophysiology and Allergy Research, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaDepartment of Pathophysiology and Allergy Research, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">House dust mites as potential carriers for IgE sensitisation to bacterial antigens</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen molecule</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin Manifestations</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="7" Year="2017">2017/7/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IgE-reactivity to antigens from gram-positive and negative bacteria is common in patients suffering from respiratory and skin manifestations of allergy, but the routes and mechanisms of sensitisation are not fully understood. The analysis of the genome, transcriptome and microbiome of house dust mites (HDM) has shown that S. aureus and E. coli species are abundant bacteria within the HDM microbiome. Therefore, our aim was to investigate if HDM are carriers of bacterial antigens leading to IgE sensitisation in patients suffering from atopic dermatitis. METHODS: Plasma samples from AD patients (n=179) were analysed for IgE-reactivity to a comprehensive panel of micro-arrayed HDM allergen molecules and to S. aureus and E. coli by IgE immunoblotting. Antibodies specific for S. aureus and E. coli antigens were tested for reactivity to nitrocellulose-blotted extract from purified HDM bodies and the IgE-reactive antigens were detected by IgE-immunoblot inhibition experiments. IgE antibodies directed to bacterial antigens in HDM were quantified by IgE ImmunoCAP inhibition experiments. RESULTS: IgE-reactivity to bacterial antigens was significantly more frequent in AD patients sensitised to HDM than in AD patients without HDM sensitisation. S. aureus and E. coli antigens were detected in immune-blotted HDM extract and the presence of IgE-reactive antigens in HDM was demonstrated by qualitative and quantitative IgE inhibition experiments. CONCLUSION: HDM may serve as carriers of bacteria responsible for the induction of IgE sensitisation to microbial antigens. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13260</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28741705">PM:28741705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170725-DzoroS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170725-DzoroS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Dzoro S</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13260</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonertz,A.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Hoefnagel,M.</style></author><author><style face="normal" font="Arial"> Timon,M.</style></author><author><style face="normal" font="Arial"> Slater,J.</style></author><author><style face="normal" font="Arial"> Rabin,R.</style></author><author><style face="normal" font="Arial"> Bridgewater,J.</style></author><author><style face="normal" font="Arial"> Pini,C.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Akdis,C.</style></author><author><style face="normal" font="Arial"> Goldstein,J.</style></author><author><style face="normal" font="Arial"> Poulsen,L.K.</style></author><author><style face="normal" font="Arial"> van,Ree R.</style></author><author><style face="normal" font="Arial"> Rhyner,C.</style></author><author><style face="normal" font="Arial"> Barber,D.</style></author><author><style face="normal" font="Arial"> Palomares,O.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Pawankar,R.</style></author><author><style face="normal" font="Arial"> Hamerlijnk,D.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Angier,E.</style></author><author><style face="normal" font="Arial"> Casale,T.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Pajno,G.</style></author><author><style face="normal" font="Arial"> Sturm,G.</style></author><author><style face="normal" font="Arial"> Varga,M.E.</style></author><author><style face="normal" font="Arial"> Van Wijk,R.G.</style></author><author><style face="normal" font="Arial"> Bonini,S.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paul-Ehrlich-Institut, Langen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Challenges in the implementation of EAACI Guidelines on Allergen Immunotherapy: A global perspective on the regulation of allergen products</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Marketing</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">Regulatory approaches for allergen immunotherapy (AIT) products and the availability of high quality AIT products are inherently linked to each other. While allergen products are available in many countries across the globe, their regulation is very heterogeneous. First, we describe the regulatory systems applicable for AIT products in the European Union (EU) and in the United States (US). For Europe, a depiction of the different types of relevant procedures, as well as the committees involved is provided and the fundamental role of national agencies of the EU member states in this complex and unique network is highlighted. Furthermore, the regulatory agencies from Australia, Canada, Japan, Russia, and Switzerland provided information on the system implemented in their countries for the regulation of allergen products. While AIT products are commonly classified as biological medicinal products, they are made available by varying types of procedures, most commonly by either obtaining a marketing authorisation or by being distributed as named patient products. Exemptions from marketing authorisations in exceptional cases, as well as import of allergen products from other countries, are additional tools applied by countries to ensure availability of needed AIT products. Several challenges for AIT products are apparent from this analysis and will require further consideration. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -CO - United Kingdom -CO - Netherlands -CO - Spain -CO - United States -CO - Italy -CO - Switzerland -CO - Japan -CO - Romania -CO - Denmark -CO - Poland -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13266</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28771830">PM:28771830</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170803-BonertzA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170803-BonertzA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Bonertz A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13266</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beretta,C.</style></author><author><style face="normal" font="Arial"> Rifflart,C.</style></author><author><style face="normal" font="Arial"> Evrard,G.</style></author><author><style face="normal" font="Arial"> Jamart,J.</style></author><author><style face="normal" font="Arial"> Thimpont,J.</style></author><author><style face="normal" font="Arial"> Vandenplas,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universite catholique de Louvain, Centre Hospitalier Universitaire UCL Namur, Department of Chest Medicine, Yvoir, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of eosinophilic airway inflammation as a contribution to the diagnosis of occupational asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> PC20</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> sputum eosinophils</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ascertaining the presence of asthma through the assessment of nonspecific bronchial hyperresponsiveness (NSBH) is a key step in the diagnosis of occupational asthma (OA). We aimed at investigating whether indices of airway inflammation including fractional exhaled nitric oxide (FeNO) and sputum eosinophils would be useful adjuncts to the measurement of NSBH in diagnosing OA defined as a positive specific inhalation challenge (SIC). METHODS: The study included 240 consecutive subjects with a suspicion of OA who completed a SIC, of whom 133 showed a positive response. The sensitivity, specificity, and predictive values of NSBH, and FeNO, as well as sputum eosinophil counts assessed at baseline of the SIC were determined. RESULTS: A concentration of histamine inducing a 20% decline in FEV1 (PC20 ) &lt;/=16 mg/mL showed a sensitivity of 87% and a specificity of 36%. A FeNO level >/=25 ppb and a sputum eosinophil count >/= 2% provided lower sensitivity rates (47% and 39%, respectively) than the PC20 value. Eight of the 17 subjects without baseline NSBH despite a positive SIC showed a sputum eosinophil count >/=2%, a FeNO level >/=25 ppb or both outcomes. Combining either a PC20 value &lt;/=16mg/mL or a FeNO >/=25 ppb increased the sensitivity to 91%. Using either a PC20 &lt;/=16mg/mL or a sputum eosinophil count >/=1% increased the sensitivity to 94%. CONCLUSION: Adding the assessment of FeNO level and sputum eosinophils to NSBH improves the identification of subjects who may have OA and require further objective testing before excluding the possibility of OA. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13265</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28771844">PM:28771844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170803-BerettaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170803-BerettaC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Beretta C</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13265</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">North,M.L.</style></author><author><style face="normal" font="Arial"> Jones,M.J.</style></author><author><style face="normal" font="Arial"> MacIsaac,J.L.</style></author><author><style face="normal" font="Arial"> Morin,A.M.</style></author><author><style face="normal" font="Arial"> Steacy,L.M.</style></author><author><style face="normal" font="Arial"> Gregor,A.</style></author><author><style face="normal" font="Arial"> Kobor,M.S.</style></author><author><style face="normal" font="Arial"> Ellis,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical &amp; Molecular Sciences and Division of Allergy &amp; Immunology, Department of Medicine, Queen's University, Kingston, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Blood and Nasal Epigenetics Correlate to Allergic Rhinitis Symptom Development in the Environmental Exposure Unit</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> environmental exposure unit</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> Epigenetics</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Mucin</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> pyrosequencing</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="7" Year="2017">2017/7/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Epigenetic alterations may represent new therapeutic targets and/or biomarkers of allergic rhinitis (AR). Our aim was to examine genome-wide epigenetic changes induced by controlled pollen exposure in the Environmental Exposure Unit (EEU). METHODS: 38 AR-sufferers and 8 non-allergic controls were exposed to grass pollen for 3h on two consecutive days. We interrogated DNA methylation at baseline and 3h in peripheral blood mononuclear cells (PBMCs) using the Infinium Methylation 450K array. We corrected for demographics, cell composition, and multiple testing (Benjamini-Hochberg), and verified hits using bisulfite PCR-pyrosequencing and qPCR. To extend these findings to a clinically relevant tissue, we investigated DNA methylation and gene expression of mucin 4 (MUC4), in nasal brushings from a separate validation cohort exposed to birch pollen. RESULTS: In PBMCs of allergic rhinitis participants, 42 sites showed significant DNA methylation changes of 2% or greater. DNA methylation changes in tryptase gamma 1 (TPSG1), schlafen 12 (SLFN12) and MUC4 in response to exposure were validated by pyrosequencing. SLFN12 DNA methylation significantly correlated with symptoms (p&lt;0.05), and baseline DNA methylation pattern was found to be predictive of symptom severity upon grass allergen exposure (p&lt;0.05). Changes in MUC4 DNA methylation in nasal brushings in the validation cohort correlated with drop in peak nasal inspiratory flow (Spearman r = 0.314, p = 0.034), and MUC4 gene expression was significantly increased (p&lt;0.0001). CONCLUSION: This study revealed novel and rapid epigenetic changes upon exposure in a controlled allergen challenge facility, identified baseline epigenetic status as a predictor of symptom severity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170729IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13263</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28755526">PM:28755526</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170729-NorthML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170729-NorthML.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170729, North ML</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13263</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Snelder,S.M.</style></author><author><style face="normal" font="Arial"> Weersink,E.J.M.</style></author><author><style face="normal" font="Arial"> Braunstahl,G.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Franciscus Gasthuis &amp; Vlietland, Kleiweg 500, 3045 PM Rotterdam, The NetherlandsAcademisch Medisch Centrum, Amsterdam, The NetherlandsFranciscus Gasthuis &amp; Vlietland, Kleiweg 500, 3045 PM Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACQ</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician's global evaluation of treatment effectiveness (GETE). A good clinical and validated parameter for treatment response is currently missing. Also, there are no established criteria for identifying patients who will respond to omalizumab based on pre-treatment characteristics. The Dutch National Omalizumab in Asthma Registry was developed in 2011 to better evaluate inclusion criteria and measure treatment response after 4 months. METHODS: This is a "real world" prospectively designed, observational data registry in which the outcomes of patients who received omalizumab between 2012 and 2015 were evaluated. Data were collected from all centers in the Netherlands comprising demographic features, criteria for starting treatment, GETE, FEV1, oral corticosteroid use and ACQ. RESULTS: 65.5% of the 403 patients had a good or excellent response to omalizumab after 16 weeks according to the treating physician GETE. 64.5% fulfilled all the criteria for prescribing omalizumab at baseline. The mean ACQ improved from 2.96 at baseline to 1.83 at 16 weeks (p &lt; 0.001). 75.3% of the responders showed more than 0.5 points improvement in the ACQ. The mean FEV1 increased from 71.58 to 79.06 (p &lt; 0.001). There was no relationship between patients with a FEV1 &lt;80 and >/=80% at baseline and response (p = 0.981). Most of the responders had a considerable improvement of FEV1 either/or ACQ or OCS use (88.3%). While 86.7% of the responders had an improvement of either ACQ or FEV1. 75.4% of the responders had an improvement of ACQ, while 50.4% had an improvement of FEV1. Finally 11.7% of the patients with no improvement of FEV1, ACQ or OCS use were considered to have a good response. CONCLUSIONS: This registry of 403 inadequately controlled severe allergic asthma patients in the Netherlands showed a good or excellent response of 65.5% to omalizumab after 16 weeks, in accordance with previous studies. The assumption that careful registration would lead to higher response rates could not be supported by the data from this registry. Improvement of ACQ appears to be a useful additional assessment tool to measure response in omalizumab treated patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0206-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28769983">PM:28769983</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Snelder SM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0206-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cosme-Blanco,W.</style></author><author><style face="normal" font="Arial"> Arroyo-Flores,E.</style></author><author><style face="normal" font="Arial"> Nazario,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.</style></auth-address><titles><title><style face="normal" font="Arial">Zika virus infection as a trigger of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Puerto Rico</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Puertorico</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778659">PM:28778659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170805-CosmeBiancoW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170805-CosmeBiancoW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Cosme-Bianco W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferastraoaru,D.</style></author><author><style face="normal" font="Arial"> Gross,R.</style></author><author><style face="normal" font="Arial"> Rosenstreich,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine/Allergy and Immunology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.</style></auth-address><titles><title><style face="normal" font="Arial">Increased malignancy incidence in IgE deficient patients not due to concomitant Common Variable Immunodeficiency</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> common variable immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> CVID</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Glass</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Immunoglobulin E (IgE) deficiency (&lt;2.5 kU/L) has unclear clinical significance. Very little is known about the clinical characteristics of IgE deficiency in patients with Common Variable Immunodeficiency (CVID). OBJECTIVE: To evaluate the clinical and laboratory differences between patients with IgE deficiency and those with non-IgE deficiency with and without CVID diagnosis. METHODS: This is a retrospective study of adult patients who had total serum IgE levels measured at our facility from 2010 through 2015. Patients with IgE levels lower than 2.5 kU/L composed the IgE deficiency group. We used Clinical Looking Glass software to identify laboratory results and comorbid conditions including CVID and malignancy. RESULTS: The IgE levels were measured in 2,339 patients and 63 (2.7%) had IgE deficiency. Of those with IgE deficiency, 14 of 63 (22%) had CVID diagnosis compared with only 62 of 2,276 patients (2.7%) with non-IgE deficiency and CVID. A significantly higher rate of prior malignancy was found in patients with IgE deficiency (21 of 63, 33%) compared with those with non-IgE deficiency (197 of 2,276, 8.7%; P = .001; odds ratio 5.51, 95% confidence interval 3.07-9.88). Six of 14 patients with CVID and IgE deficiency (43%) had a prior malignancy diagnosis compared with 8 of 62 patients (13%) with CVID and non-IgE deficiency (P = .009; odds ratio 10.65, 95% confidence interval 1.79-63.19). In addition to the higher rate of malignancy, patients with CVID and IgE deficiency did not have more severe disease than those with CVID and non-IgE deficiency. CONCLUSION: The rate of prior malignancy is significantly higher in patients with IgE deficiency than in those without IgE deficiency. Similarly, patients with CVID and IgE deficiency have a higher frequency of prior malignancy than those with CVID and non-IgE deficiency. However, patients with IgE deficiency have higher frequency of malignancy than patients with normal IgE levels even in the absence of CVID</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778662">PM:28778662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170805-FerastraoaruD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170805-FerastraoaruD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Ferastraoaru D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barton,J.C.</style></author><author><style face="normal" font="Arial"> Barton,J.C.</style></author><author><style face="normal" font="Arial"> Bertoli,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Brookwood Medical Center, Birmingham, Alabama; Southern Iron Disorders Center, Birmingham, Alabama</style></auth-address><titles><title><style face="normal" font="Arial">Hypogammaglobulinemia E in 216 adults with IgG subclass deficiency and respiratory tract infections</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Alabama</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypogammaglobulinemia</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778661">PM:28778661</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170805-BartonJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170805-BartonJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Barton JC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shah,A.</style></author><author><style face="normal" font="Arial"> Kunal,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110 007, IndiaDepartment of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110 007, India</style></auth-address><titles><title><style face="normal" font="Arial">A review of 42 asthmatic children with allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="155" start="148">148-155</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Paranasal Sinuses</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) in children with asthma, not associated with cystic fibrosis, is yet to receive the recognition it deserves. OBJECTIVE: To highlight the presentation of ABPA in children with asthma. METHODS: This retrospective review documents the occurrence of pediatric ABPA over a period of 31 years in one unit. Children with asthma, eosinophilia and infiltrates on chest radiograph were screened for ABPA. In these patients, demonstration of immediate hypersensitivity response against Aspergillus species along with serological profile and pulmonary function testing were done. Bronchography/computed tomography (CT) of the chest demonstrated central bronchiectasis (CB). CT of the paranasal sinuses was done in patients with upper airways symptoms. In those suspected with allergic Aspergillus sinusitis (AAS) consent was sought from the parents for the invasive procedure needed for the diagnosis of AAS. RESULTS: Of the 349 patients with ABPA diagnosed, 42 (12.03%) were in the pediatric age group. The mean age on presentation was 12.9 +/- 4 years with a male preponderance. All patients had asthma and positive intradermal/skin prick test against Aspergillus species. Ring shadows, the most common radiological presentation, were seen in 28 of 42 patients. Bronchography/CT of the chest demonstrated CB, a feature pathognomic of ABPA, in 32 of 42 patients. High attenuation mucus plugs was observed in 7 of 36 patients while ABPA-seropositive was diagnosed in 10 of 42 patients. On imaging, sinusitis was seen in 20 of 30 patients with upper airways symptoms of whom eight had suspected AAS. Three parents consented for surgery, which confirmed the diagnosis. CONCLUSION: This study highlights the need to evaluate asthmatic children for ABPA as also to exclude AAS</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.148</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765819">PM:28765819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-148-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-148-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Shah A</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.148</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,Y.K.</style></author><author><style face="normal" font="Arial"> Koo,S.M.</style></author><author><style face="normal" font="Arial"> Kim,K.</style></author><author><style face="normal" font="Arial"> Uh,S.T.</style></author><author><style face="normal" font="Arial"> Jang,A.</style></author><author><style face="normal" font="Arial"> Park,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory and Allergy Medicine, Soonchunhyang University Seoul Hospital, Seoul 04401, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Increased antioxidant activity after exposure of ozone in murine asthma model</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="170" start="163">163-170</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">4-hydroxy-2-nonenal</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nrf-2</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCNA</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Proliferating Cell Nuclear Antigen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ozone is well known as an important component of ambient air pollutants. Ozone can aggravate respiratory symptoms in patients with bronchial asthma, but, not in healthy person. We hypothesized asthma itself may show different response to ozone compared to nonasthma. OBJECTIVE: This study was performed to evaluate the differences of response to ozone between normal and asthmatic mice model in terms of status of oxidant injury and antioxidant activity. METHODS: Three parts per million of ozone was exposed to ovalbumin (OVA)-induced murine asthma model for 3 hours at 3, 7, 14, 21 days after completion of asthma model. Airway responsiveness to methacholine was measured after completion of asthma model. Bronchoalveolar lavage (BAL), protein extraction from lung for Western blot and immunohistochemistry of 4-hydroxy-2-nonenal (4-HNE), proliferating cell nuclear antigen (PCNA), NF-E2 related factor 2 (Nrf-2), and activity of glutathione were performed at before and each ozone exposure day. RESULTS: Airway hyper-responsiveness and increased eosinophils in BAL fluid were observed in asthma model. In asthma model, the expression of 4-HNE already more increased at baseline (without ozone) compared to those in sham model. This increased expression is more enhanced at 3 days after ozone exposure. The expression of PCNA was significantly increased in OVA-model compared to those in sham model. The expression of Nrf-2 was observed at baseline, and 3 and 7 days after exposure ozone in asthma model, but not in sham model. The activity of glutathione increased significantly after exposure of ozone, but not in sham model. CONCLUSION: Murine asthma model has enhanced oxygen toxicity and antioxidant activity response to ozone</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.163</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765821">PM:28765821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-163-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-163-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Kim YK</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.163</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turk,M.</style></author><author><style face="normal" font="Arial"> Bahcecioglu,S.N.</style></author><author><style face="normal" font="Arial"> Yilmaz,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, 38030 Kayseri, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Is nonhomogeneous expression of tissue mast cells or allergen specific IgEs bound to tissue mast cells possible?</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="181" start="179">179-181</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Skin prick tests (SPTs) are widely used to demonstrate an IgE-mediated hypersensitivity reaction to a specific allergen. However, local allergic conditions cannot be diagnosed with SPTs. Local specific IgE production was only presented before in mucosal tissues. We present a patient with house dust mite sensitization that had variable SPTs results in different body regions</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.179</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765824">PM:28765824</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-179-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-179-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Turk M</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.179</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thong,B.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore 308433, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">Aerobiology in Asian airway allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="120" start="119">119-120</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - EditorialCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.119</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765815">PM:28765815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-119-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-119-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Thong BY</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.119</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,S.T.</style></author><author><style face="normal" font="Arial"> Park,S.H.</style></author><author><style face="normal" font="Arial"> Lee,S.M.</style></author><author><style face="normal" font="Arial"> Lee,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Gachon University Gil Medical Center, Incheon 21565, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Allergen-specific intralymphatic immunotherapy in human and animal studies</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="137" start="131">131-137</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> ILIT</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> intralymphatic immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Clinical trials of intralymphatic immunotherapy (ILIT) have been performed to overcome the limitations of long-term therapy and the local or systemic hypersensitivity reactions in conventional allergen-specific immunotherapy, including subcutaneous or sublingual immunotherapy. Additionally, several animal studies of ILIT have been conducted in the form of translational or veterinary research. We conducted a literature review to examine the treatment efficacy and adverse effects of ILIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765817">PM:28765817</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-131-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-131-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Kim ST</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.131</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">So,H.J.</style></author><author><style face="normal" font="Arial"> Moon,S.J.</style></author><author><style face="normal" font="Arial"> Hwang,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Jang,H.J.</style></author><author><style face="normal" font="Arial"> Jo,J.H.</style></author><author><style face="normal" font="Arial"> Sung,T.J.</style></author><author><style face="normal" font="Arial"> Lim,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Environmental Health Center for Allergic Rhinitis, Inha University Hospital, Incheon 22332, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Characteristics of airborne pollen in Incheon and Seoul (2015-2016)</style></title><secondary-title><style face="normal" font="Arial">Asia Pac Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asia Pac Allergy</style></full-title></periodical><pages end="147" start="138">138-147</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plant</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plants</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Alnus</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Betula</style></keyword><keyword><style face="normal" font="Arial"> Chenopodiaceae</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Gramineae</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humulus</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pollen allergens are one of the main contributors to the development and/or aggravation of allergic rhinitis, allergic conjunctivitis, and asthma. OBJECTIVE: An examination of the airborne pollen in residential areas should be conducted to aid the diagnosis and treatment of allergic diseases. METHODS: Airborne pollen samples were collected from 2 sites in Incheon and 2 in Seoul from 2015 to 2016. RESULTS: The highest monthly concentration of airborne pollen was observed in May and September each year. Pollen from 32 families and 50 genera was identified over the 2 years; of these, Pinus spp. showed the highest pollen concentration (41.6%), followed by Quercus spp. (25.3%), and Humulus spp. (15.3%), the latter of which had the highest concentration among weed pollen. The total pollen concentration was significantly higher in Incheon than in Seoul (p = 0.001 in 2015, p &lt; 0.001 in 2016) and higher in 2016 than in 2015. The concentrations of pollen from weed species (Cupressaceae, Humulus spp., Artemisia spp., Ambrosia spp., and Chenopodiaceae) and grass species (Gramineae) were significantly higher (p &lt; 0.001) than those from tree species. Pollen was distributed from February to November. The first pollen identified in both regions in each year was Alnus spp. Overall, the total concentration of Quercus spp., Betula spp., Humulus spp., Artemisia spp., Ambrosia spp., and Chenopodiaceae pollen increased significantly over the 2 years. CONCLUSION: Region-specific differences exist in the pollen of major allergenic plants. Continuous monitoring of pollen is thus essential for management of pollen-related allergic disorders in each region</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.138</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765818">PM:28765818</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-138-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asia Pac Allergy\2017-7-138-47.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, So HJ</style></custom2><misc3><style face="normal" font="Arial">10.5415/apallergy.2017.7.3.138</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Siripipattanamongkol,N.</style></author><author><style face="normal" font="Arial"> Vichyanond,P.</style></author><author><style face="normal" font="Arial"> Jirapongsananuruk,O.</style></author><author><style face="normal" font="Arial"> Veskitkul,J.</style></author><author><style face="normal" font="Arial"> Visitsunthorn,N.</style></author><author><style face="normal" font="Arial"> Pacharn,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Age of resolution from IgE-mediated wheat allergy</style></title><secondary-title><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="117" start="113">113-117</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: Wheat allergy is common in children. The natural history of wheat allergies varies among different countries.Objective: To study the age of resolution from IgE-mediated wheat allergy and to define the predictors of wheat tolerance.Method: Patients with a history of immediate reactions after wheat ingestion were included in this study. Skin prick tests(SPTs) and measurement of serum-specific IgE (sIgE) to wheat and ƒÖ-5 gliadin was performed. An oral challenge to wheatwas performed to determine wheat tolerance.Results: Fifty-five patients aged between 6 months and 12 years were included in this study. The median age fordevelopment of wheat tolerance was found to be 76 months (range 37.114 months). The proportion of children with wheattolerance was 14.7% by 2 years of age, 27% by 4 years, 45.7% by 5 years and 69% by 9 years of age. An independent predictorfor wheat tolerance was sIgE levels against ƒÖ-5 gliadin of less than 0.35 kAU/L (adjusted hazard ratio 5.7; 95% CI 1.2.26.8).Conclusions: Of the children with IgE-mediated wheat allergy included in this study, 45.7% developed tolerance by 5 yearsof age. The concentration of sIgE for ƒÖ-5 gliadin is helpful for predicting wheat tolerance.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://apjai-journal.org/volume-35-number-2-june-2017/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-113-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-113-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Siripipattanamongkol N</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goodman,J.E.</style></author><author><style face="normal" font="Arial"> Zu,K.</style></author><author><style face="normal" font="Arial"> Loftus,C.T.</style></author><author><style face="normal" font="Arial"> Tao,G.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Lange,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Ambient ozone and asthma hospital admissions in Texas: a time-series analysis</style></title><secondary-title><style face="normal" font="Arial">Asthma Res Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Res Pract</style></full-title></periodical><pages end="" start="6">6-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Ozone</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2054-7064</style></isbn><abstract><style face="normal" font="Arial">Many studies have evaluated associations between asthma emergency department (ED) visits, hospital admissions (HAs), and ambient ozone (O3) across the US, but not in Texas. We investigated the relationship between O3 and asthma HAs, and the potential impacts of outdoor pollen, respiratory infection HAs, and the start of the school year in Texas</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40733-017-0034-1</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s40733-017-0034-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Res Pract\2017-3-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Res Pract\2017-3-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Goodman JE</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40733-017-0034-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cantani,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">In 2532 Children we Report the Developmental Factors Influencing the Development of Atopic Diseases</style></title><secondary-title><style face="normal" font="Arial">Austin J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Austin J Allergy</style></full-title></periodical><pages end="" start="1025">1025-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic asthma and rhinitis, Atopic Dermatitis (AD), urticaria and gastrointestinal allergy, are common diseases of infants and children. It was recently estimated that 14% of children suffer from AD, 8% from food allergy, and 12% from asthma [1,2]. The cumulated incidence of these diseases in adolescents has been estimated between 25-35%, while the prevalence is about 20% [3]. The phenotypic expression of these illnesses varies extensively, being very mild in some cases, severe in many, and even life threatening in others. Specific IgE antibodies to foods and positive challenge tests to a number of food allergens are frequently present in children with these disorders. Cow's Milk (CM) appears to be the most common offending food both in gastrointestinal (vomiting, diarrhea, etc) and in cutaneous manifestations (urticaria and AD). About 0.5-7% of infants suffer from more or less adverse reactions to CM [4]. Babies particularly of atopic parents are at high risk of developing atopic diseases; therefore they are defined as at-risk babies [5-7].</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.26420/austinjallergy.2017.1025</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.26420/austinjallergy.2017.1025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Austin J Allergy\2017-4-1025.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Austin J Allergy\2017-4-1025.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Cantani A</style></custom2><misc3><style face="normal" font="Arial">10.26420/austinjallergy.2017.1025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UKNIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UKThe David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK</style></auth-address><titles><title><style face="normal" font="Arial">A new approach to specific IgE testing, asthma and auto-injectors in schools</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="987" start="986">986-987</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170728IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12982</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28753249">PM:28753249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-986-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-986-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170728, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12982</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kowal,K.</style></author><author><style face="normal" font="Arial"> Gielicz,A.</style></author><author><style face="normal" font="Arial"> Sanak,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology and Internal Medicine and Department of Experimental Allergology, Immunology Medical University of Bialystok, PolandDepartment of Internal Medicine, Jagiellonian University Medical College, Krakow, PolandDepartment of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland</style></auth-address><titles><title><style face="normal" font="Arial">The effect of allergen-induced bronchoconstriction on concentration of 5-oxo-ETE in exhaled breath condensate of house dust mite-allergic patients</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Arachidonic Acid</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Eicosanoids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Late asthmatic response</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Contraction</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> tear</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Arachidonic acid metabolites regulate several aspects of airway function including inflammation, muscle contraction and mucous secretion. OBJECTIVE: The aim of this study was to evaluate concentration of selected 5-lipoxygenase (LOX) and cyclooxygenase (COX)-derived eicosanoids in exhaled breath condensate (EBC) during allergen induced bronchoconstriction. METHODS: The study was performed on 24 allergic rhinitis/asthma patients sensitized to a house dust mite (HDM) Dermatophagoides pteronyssinus (Dp) and 13 healthy controls (HCs). Bronchial challenge with Dp extract was performed only in the allergic patients. Exhaled breath condensate (EBC) samples were collected before (T0 ) and during Dp-induced bronchoconstriction (TEAR ). Eicosanoid concentration was measured using HPLC-tandem mass spectrometry. RESULTS: Significant bronchoconstriction after Dp challenge was demonstrated in 15 patients (Rs) while in 9 patients (NRs) no asthmatic response could be detected. At T0 the most abundant eicosanoids in EBC of HDM-allergic patients were LTB4 and 5-oxo-ETE while in HCs EBC concentration of LTB4 was significantly greater than that of 5-oxo-ETE. Allergen challenge resulted in significant increase in EBC concentration of 5-oxo-ETE, LTD4 and 8-iso-PGE2 only in Rs. At TEAR , the relative change of 5-oxo-ETE concentration in EBC correlated with decrease of peripheral blood eosinophilia (R= -0.774; p=0.0012). Moreover, the relative increase of 5-oxo-ETE in EBC at TEAR significantly correlated with the severity of the subsequent late asthmatic response (R=0.683 p=0.007). CONCLUSION: Our study demonstrates significant up-regulation of 5-oxo-ETE synthesis in HDM-allergic patients and indicates possible involvement of that mediator in the pathogenesis of allergic asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12990</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28763131">PM:28763131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170801-KowalK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170801-KowalK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Kowal K</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12990</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lozano-Ojalvo,D.</style></author><author><style face="normal" font="Arial"> Perez-Rodriguez,L.</style></author><author><style face="normal" font="Arial"> Pablos-Tanarro,A.</style></author><author><style face="normal" font="Arial"> Molina,E.</style></author><author><style face="normal" font="Arial"> Lopez-Fandino,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Investigacion en Ciencias de la Alimentacion (CIAL, CSIC-UAM), Nicolas Cabrera 9, 28049, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Hydrolysed ovalbumin offers more effective preventive and therapeutic protection against egg allergy than the intact protein</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The application of specific immunotherapy to stimulate oral tolerance towards food allergens is hampered by the high frequency of adverse side effects and the excessive duration of the treatments. OBJECTIVE: In this work, a hydrolysate of ovalbumin with pepsin (OP), selected for its low IgE reactivity and Th2-stimulating capacity, was assayed for its ability to prevent and treat allergy to egg white (EW). METHODS: As a first step, the safety of OP, in terms of the absence of sensitizing and eliciting potential, was evaluated in BALB/c mice. Then, its suitability for prophylactic and therapeutic applications was compared with that of the intact allergen, paying attention to the molecular and cellular mechanisms involved in the control of the allergic process. To this aim, IgE, IgG1, IgG2a and IgA levels, allergic reactions, expression of genes related to Th1, Th2, Th17 and Treg responses, dendritic and T cell populations were assessed in intestinal tissues and spleens of EW-allergic mice, either untreated or treated with intact ovalbumin (OVA) or OP. RESULTS: OP was hypoallergenic, lacked sensitizing potential and offered preventive and therapeutic protection against allergy to EW through the induction of Treg cells and the upregulation of TGF-beta, IL-10, IL-17, Foxp3 and RORgammat in intestinal tissues. This restrained the expression of GATA3 and the differentiation of Th2 cells, leading to low cytokine responses following ex vivo spleen cell stimulation. As compared with intact OVA, OP was more effective against sensitization. In addition, in the therapeutic setting, OP provided quicker desensitization that lasted for at least 3 weeks after discontinuation of the therapy. CONCLUSIONS AND CLINICAL RELEVANCE: This study provides evidence for the superior role of hydrolysed, as compared to intact allergens, in the prevention of allergy development and in the promotion of long term desensitization, as well as of intermolecular tolerance. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12989</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28763132">PM:28763132</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170801-LozanoOjalvoD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170801-LozanoOjalvoD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Lozano-Ojalvo D</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12989</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wanandy,T.</style></author><author><style face="normal" font="Arial"> Dwyer,H.E.</style></author><author><style face="normal" font="Arial"> McLean,L.</style></author><author><style face="normal" font="Arial"> Davies,N.W.</style></author><author><style face="normal" font="Arial"> Nichols,D.</style></author><author><style face="normal" font="Arial"> Gueven,N.</style></author><author><style face="normal" font="Arial"> Brown,S.G.A.</style></author><author><style face="normal" font="Arial"> Wiese,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jack Jumper Allergy Program, Royal Hobart Hospital, GPO Box 1061L, Hobart, Tasmania, 7001, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnosis of allergen sensitization and in allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen peptides</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> long-term storage</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MW</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein quantification</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Tasmania</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword></keywords><dates><year Day="30" Month="7" Year="2017">2017/7/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergen immunotherapy uses pharmaceutical preparations derived from naturally occurring source materials, which contain water-soluble allergenic components responsible for allergic reactions. The success of in vivo and in vitro diagnosis in allergen sensitization and allergen immunotherapy largely depends on the quality, composition and uniformity of allergenic materials used to produce the active ingredients, and the formulation employed to prepare finished products. OBJECTIVES: We aimed to examine the factors influencing batch-to-batch consistency of Jack Jumper (Myrmecia pilosula) ant venom (JJAV) in the form of Active Pharmaceutical Ingredient (AI) and informed whether factors such as temperature, artificial light and container materials influence the quality of JJAV AIs. We also aimed to establish handling and storage requirements of JJAV AIs to ensure preservation of allergenic activities during usage in the diagnosis of allergen sensitization and in allergen immunotherapy. METHODS: The quality and consistency of JJAV AIs were analysed using a combination of bicinchoninic acid assay for total protein quantification, HPLC-UV for JJAV allergen peptides quantification, ELISA Inhibition for total allergenic potency, SDS-PAGE, AU-PAGE and Immunoblot for qualitative assessment of JJAV components, and Limulus Amebocyte Lysate assay for the quantification of endotoxin concentration. API-ZYM and Zymogram assays were used to probe the presence of enzymatic activities in JJAV. RESULTS: Pharmaceutical grade JJAV for allergen immunotherapy has good batch-to-batch consistency. Temporary storage at 4 degrees C and light exposure does not affect the quality of JJAV. Exposure to temperature above 40 degrees C degrades high MW allergens in JJAV. Vials containing JJAV must be stored frozen and in upright position during long-term storage. CONCLUSIONS AND CLINICAL RELEVANCE: We have identified factors which can influence the quality and consistency of JJAV AIs and provided a framework for appropriate handling, transporting and storage of JJAV to be used for the diagnosis of allergen sensitization and in AIT. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170730IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12987</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28756642">PM:28756642</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170730-WanandyT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170730-WanandyT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170730, Wanandy T</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12987</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beck,S.</style></author><author><style face="normal" font="Arial"> Huissoon,A.P.</style></author><author><style face="normal" font="Arial"> Baretto,R.L.</style></author><author><style face="normal" font="Arial"> Krishna,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Allergy and Immunology, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Allergy and Immunology, Heart of England NHS Foundation Trust, Birmingham, UKDepartment of Allergy and Immunology, Heart of England NHS Foundation Trust, Birmingham, UKInstitute of Immunology, Immunotherapy, University of Birmingham, UK</style></auth-address><titles><title><style face="normal" font="Arial">A critical analysis of the utility of component tests in the diagnosis of pollen-related peanut and hazelnut allergy in the context of the BSACI guideline</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1224" start="1223">1223-1224</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> BSACI</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut allergy</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Standardisation</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">We congratulate the authors for producing a comprehensive guideline on the diagnosis and management of peanut and tree nut allergy(1) This is likely to improve care via standardisation across the UK NHS Allergy services. Several studies have illustrated the benefit of component resolved diagnostic (CRD) testing by enhancing the accuracy of peanut and hazelnut allergy diagnosis and aiding the process of risk stratification. However, most of these data are derived from studies carried out on children in Europe and USA with little evidence from adults and the British population. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12991</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28763130">PM:28763130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170801-BeckS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170801-BeckS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Beck S</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12991</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foong,R.X.</style></author><author><style face="normal" font="Arial"> Brough,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Asthma, Allergy and Lung Biology, Department of Paediatric Allergy, King's College London and Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, UKInstitute of Child Health, University College of London, London, UKDivision of Asthma, Allergy and Lung Biology, Department of Paediatric Allergy, King's College London and Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">The role of environmental exposure to peanut in the development of clinical allergy to peanut</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Filaggrin mutation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="8" Year="2017">2017/8/5</year></dates><abstract><style face="normal" font="Arial">The presence of peanut allergy has increased over the years and still remains one of the most common causes of food-related anaphylaxis. The way in which peanut sensitization occurs has been explored, such as via maternal consumption in pregnancy, via breast milk and through a disrupted skin barrier. It has previously been shown that environmental exposure to aeroallergens in household dust can be a risk factor for the development of allergic asthma. However, it is likely that the combination of cutaneous sensitisation via a disrupted skin barrier (i.e. children with eczema especially those with filaggrin mutations) and the interaction with environmental peanut exposure influences the development of peanut allergy. This review aims to explore the current evidence of how environmental exposure to peanut affects the development of peanut allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12992</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28779526">PM:28779526</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170805-FoongRX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170805-FoongRX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Foong RX</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12992</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mindaye,S.T.</style></author><author><style face="normal" font="Arial"> Spiric,J.</style></author><author><style face="normal" font="Arial"> David,N.A.</style></author><author><style face="normal" font="Arial"> Rabin,R.L.</style></author><author><style face="normal" font="Arial"> Slater,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunobiochemistry, Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, CBER/FDA, Silver Spring, MD</style></auth-address><titles><title><style face="normal" font="Arial">Accurate quantification of five German cockroach (GCr) allergens in complex extracts using multiple reaction monitoring mass spectrometry (MRM MS)</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absolute quantification</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bla g 1</style></keyword><keyword><style face="normal" font="Arial"> Bla g 2</style></keyword><keyword><style face="normal" font="Arial"> Bla g 4</style></keyword><keyword><style face="normal" font="Arial"> Bla g 5</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> German cockroach</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide Library</style></keyword><keyword><style face="normal" font="Arial"> Peptide Mapping</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="7" Year="2017">2017/7/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: German cockroach (GCr) allergen extracts are complex and heterogeneous products, and methods to better assess their potency and composition are needed for adequate studies of their safety and efficacy. OBJECTIVE AND METHODS: The objective of this study was to develop an assay based on liquid chromatography and multiple reaction monitoring mass spectrometry (LC-MRM MS) for rapid, accurate, and reproducible quantification of five allergens (Bla g 1, Bla g 2, Bla g3, Bla g 4, and Bla g 5) in crude GCr allergen extracts. RESULTS: We first established a comprehensive peptide library of allergens from various commercial extracts as well as recombinant allergens. Peptide mapping was performed using high resolution MS and the peptide library was then used to identify prototypic and quantotypic peptides to proceed with MRM method development. Assay development included a systematic optimization of digestion conditions (buffer, digestion time, and trypsin concentration), chromatographic separation, and MS parameters. Robustness and suitability were assessed following ICH (Q2 (R1)) guidelines. The method is precise (RSD &lt; 10%), linear over a wide range (r > 0.99, 0.01 -1384 fmol/muL), and sensitive (LLOD and LLOQ &lt;1 fmol/muL). Having established the parameters for LC-MRM MS, we quantified allergens from various commercial GCr extracts and showed considerable variability that may impact clinical efficacy. CONCLUSIONS AND CLINICAL RELEVANCE: Our data demonstrate that the LC-MRM MS method is valuable for absolute quantification of allergens in GCr extracts and likely has broader applicability to other complex allergen extracts. Definitive quantification provides a new standard for labeling of allergen extracts, which will inform patient care, enable personalized therapy, and enhance the efficacy of immunotherapy for environmental and food allergies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170730IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12986</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28756650">PM:28756650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170730-MindayeST.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170730-MindayeST.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170730, Mindaye ST</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12986</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asamoah,F.</style></author><author><style face="normal" font="Arial"> Kakourou,A.</style></author><author><style face="normal" font="Arial"> Dhami,S.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Akdis,C.</style></author><author><style face="normal" font="Arial"> Bonini,M.</style></author><author><style face="normal" font="Arial"> Cavkaytar,O.</style></author><author><style face="normal" font="Arial"> Flood,B.</style></author><author><style face="normal" font="Arial"> Izuhara,K.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Kalayci,O.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="25">25-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Preventive Medicine</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is clinical uncertainty about the effectiveness and safety of allergen immunotherapy (AIT) for the treatment of allergic asthma. OBJECTIVES: To undertake a systematic overview of the effectiveness, cost-effectiveness and safety of AIT for the treatment of allergic asthma. METHODS: We searched nine electronic databases from inception to October 31, 2015. Systematic reviews were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical Appraisal Skills Programme quality assessment tool for systematic reviews. Data were descriptively and thematically synthesized. RESULTS: We identified nine eligible systematic reviews; these focused on delivery of AIT through the following routes: subcutaneous (SCIT; n = 3); sublingual (SLIT; n = 4); and both SCIT and SLIT (n = 2). This evidence found that AIT delivered by SCIT and SLIT can improve medication and symptom scores and measures of bronchial hyper-reactivity. The impact on measures of lung function or asthma control was however less clear. We found no systematic review level evidence on the cost-effectiveness of SCIT or SLIT. SLIT had a favorable safety profile when compared to SCIT, particularly in relation to the risk of systemic reactions. CONCLUSIONS: AIT has the potential to achieve reductions in symptom and medication scores, but there is no clear or consistent evidence that measures of lung function can be improved. Bearing in mind the limitations of synthesizing evidence from systematic reviews and the fact that these reviews include mainly dated studies, a systematic review of current primary studies is now needed to update this evidence base, estimate the effectiveness of AIT on asthma outcomes and to investigate the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United KIngdom -CO - Greece -CO - Germany -CO - Romania -CO - Italy -CO - Switzerland -CO - Turkey -CO - Belgium -CO - Japan -CO - Poland</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0160-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775845">PM:28775845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Asamoah F</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0160-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ozturk,E.</style></author><author><style face="normal" font="Arial"> Ozyigit,L.P.</style></author><author><style face="normal" font="Arial"> Ozturk,A.B.</style></author><author><style face="normal" font="Arial"> Akay,M.O.</style></author><author><style face="normal" font="Arial"> Cetiner,M.</style></author><author><style face="normal" font="Arial"> Ferhanoglu,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Rituximab desensitization in three patients with severe rituximab allergy</style></title><secondary-title><style face="normal" font="Arial">Curr Probl Cancer</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Probl Cancer</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy history</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> Burkitt Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> CD20</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical tolerance</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Non-Hodgkin</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç¦s lymphoma</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"></style><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0147-0272</style></isbn><abstract><style face="normal" font="Arial">Rituximab is a chimeric monoclonal antibody that targets CD20 positive B cells and has a positive effect on both overall and progression-free survival in B cell lymphoid malignancies. Combination rituximab with chemotherapy treatment provide survival improvement. Although rituximab is an important treatment option in hematological malignancies, the risk of allergic reactions is high. These reactions are usually IgE-mediated and can be varied in regards of severity from urticaria to anaphylaxis. It is an option to interrupt the treatment and ommit rituximab therapy who had allergic reactions. Drug desensitization is another option and successful results have been reported by applying desensitization to such reactions. Drug desensitization alters the immune response to induce a state of temporary clinical tolerance to the allergic drug by giving gradual increasing of doses of drug at fixed time intervals. Herein we present 3 cases successfully treated with rituximab desensitization. The cases were using rituximab with the diagnosis of Burkitt lymphoma, follicular lymphoma and marginal zone lymphoma, respectively. Two cases had grade 2, one case had grade 3 systemic allergic reaction with rituximab. There was no known allergy history in all three cases. All patients tolerated the desensitization protocol. The subsequent treatments of the patients were also given by desensitization protocol. A total of 12 desensitizations were administered to 3 cases. No severe or life-threating reactions were observed in subsequent applications. To date applying desensitization protocols ensure rituximab treatment safely. Rituximab desensitization can be performed at trained allergy centers and it may be an appropriate option for rituximab allergic patients.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.currproblcancer.2017.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28860080">PM:28860080</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Probl Cancer\20170802-OzturkE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Probl Cancer\20170802-OzturkE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Ozturk E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.currproblcancer.2017.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paul,R.E.</style></author><author><style face="normal" font="Arial"> Sakuntabhai,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Atopic Dermatitis: The Need for a Sub-Saharan Perspective</style></title><secondary-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></full-title></periodical><pages end="64" start="58">58-64</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic diversity</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Malaria</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> Mosquito bites</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Sub-Saharan Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is one of the most common non-infectious diseases in the world. For over two decades there has been considerable mobilisation to create a robust framework to address this global problem (the International Study of Asthma and Allergies in Childhood [ISAAC] consortium). However, information about Sub-Saharan Africa remains sparse, likely reflecting the increased focus placed on infectious diseases. However, this region harbours the greatest environmental and genetic diversity and thus offers enormous potential for understanding the differential environmental impact on human populations predisposed to allergic diseases. Moreover, it is increasingly clear that many pathologies share the same genetic determinants and this spans both non-infectious and infectious diseases. In this review, we discuss the comparative genetics of the allergic diseases and then expand into infectious diseases, notably malaria. We discuss the considerable overlap in the identified genetic determinants of AD and malaria and develop a hypothesis based on the importance of saliva from mosquito bites, arguably the most prevalent allergen in the region. Following the completion of the first phase of the African Genome project, we stress the significance of more focus on allergic diseases in the region, which will certainly generate an abundance of novel insight into the environmental and genetic determinants of allergy and may also contribute to our understanding of arthropod-borne infectious diseases.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://emjreviews.com/therapeutic-area/allergy-immunology/atopic-dermatitis-the-need-for-a-sub-saharan-perspective/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMJ Allergy Immunol\2016-1-58-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMJ Allergy Immunol\2016-1-58-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Paul RE</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Steveling-Klein,E.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergen-Specific Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></full-title></periodical><pages end="87" start="78">78-87</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deviation</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy remains the only causal treatment of allergic disease to date. Its efficacy in symptom reduction was demonstrated in double blind, placebo-controlled studies of allergic rhinoconjunctivitis, allergic asthma, and Hymenoptera venom hypersensitivity, including long-term effects after discontinuation of treatment. In addition, immunotherapy decreases the risk of developing new sensitisations to aeroallergens in monosensitised patients and allergic asthma in patients with mere allergic rhinitis. The mechanism of immunotherapy entails redirection of the T lymphocyte response from a T helper cell Type 2 phenotype in favour of induction of regulatory T cells and/or immune deviation toward a T helper cell Type 1 phenotype, with resulting inhibition of downstream effector pathways and induction of immunoglobulin G-associated blocking antibodies. Two main application forms are used in clinical practice: subcutaneous immunotherapy and sublingual immunotherapy. The advantage of subcutaneous immunotherapy is its proven efficacy over a broad range of indications. Disadvantages are systemic allergic reactions and inconvenience for the patient due to frequent doctor visits. Sublingual immunotherapy has been shown to result in less systemic allergic reactions and may be more convenient due to home application; however, efficacy has only been proven for allergic rhinitis. For clinicians, the adherence to practice guidelines and thorough knowledge of allergen products, application routes, indications, immunomodulatory mechanisms, efficacy, safety, and cost-effectiveness is important for successful treatment and will be addressed in this review article.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://emjreviews.com/therapeutic-area/allergy-immunology/allergen-specific-immunotherapy/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMJ Allergy Immunol\2016-1-78-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMJ Allergy Immunol\2016-1-78-87.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Steveling-Klein EH</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masjedi,R.M.</style></author><author><style face="normal" font="Arial"> Saeedfar,K.</style></author><author><style face="normal" font="Arial"> Masjedi,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Occupational Allergies: A Brief Review</style></title><secondary-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></full-title></periodical><pages end="77" start="70">70-77</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity pneumonitis</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Occupational allergies are groups of work-related disorders that are accompanied by immunologic reaction to workplace allergens and include occupational asthma, rhinitis, hypersensitivity pneumonitis, dermatitis, and anaphylaxis. This mini review presents a brief analysis of the more important aspects of occupational allergic disorders.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://emjreviews.com/therapeutic-area/allergy-immunology/occupational-allergies-a-brief-review/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMJ Allergy Immunol\2016-1-70-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMJ Allergy Immunol\2016-1-70-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Masjedi RM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Timmermans,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Education Is Key! Call for Action!</style></title><secondary-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></full-title></periodical><pages end="72" start="70">70-72</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">education</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://emjreviews.com/therapeutic-area/allergy-immunology/education-is-key-call-for-action/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-70-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-70-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Timmermans F</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anagnostou,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Oral Immunotherapy for Food Allergy: What Have We Achieved So Far?</style></title><secondary-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></full-title></periodical><pages end="99" start="94">94-99</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> multifaceted</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The burden of food allergy is significant, multi-faceted, and well documented. In an effort to improve food-allergic patients' quality of life, there is a continuous effort to provide novel treatment options for food allergy. Food immunotherapy is an exciting area of research that has seen tremendous progress over the last decade. This review examines the current literature and provides insights into key oral immunotherapy studies published so far. Areas requiring further study, the role of food oral immunotherapy, and its potential future applications for patient care are also discussed.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://emjreviews.com/therapeutic-area/allergy-immunology/oral-immunotherapy-for-food-allergy-what-have-we-achieved-so-far/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-94-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-94-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Anagnostou K</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anderson,S.E.</style></author><author><style face="normal" font="Arial"> Long,C.</style></author><author><style face="normal" font="Arial"> Scott Dotson,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Occupational Allergy</style></title><secondary-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></full-title></periodical><pages end="71" start="65">65-71</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Metals</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> plant protein</style></keyword><keyword><style face="normal" font="Arial"> Plant Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> risk management</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword><keyword><style face="normal" font="Arial"> Workplace exposure</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">An estimated 11 million workers in the USA are potentially exposed to agents that can become a cause of allergic diseases such as occupational asthma and allergic contact dermatitis, which can adversely affect health and well-being. Hundreds of chemicals (e.g. metals, epoxy and acrylic resins, rubber additives, and chemical intermediates) and proteins (e.g. natural rubber latex, plant proteins, mould, animal dander) present in virtually every industry have been identified as causes of allergic disease. In general, allergens can be classified as low molecular weight (chemical) allergens and high molecular weight (protein) allergens. These agents are capable of inducing immunological responses that are both immunoglobulin E and non-immunoglobulin E-mediated. Interestingly, the same chemical can induce diverse immune responses in different individuals. As new hazards continue to emerge, it is critical to understand the immunological mechanisms of occupational allergic disease. Specific understanding of these mechanisms has direct implications in hazard identification, hazard communication, and risk assessment. Such efforts will ultimately assist in the development of risk management strategies capable of controlling workplace exposures to allergens to prevent the induction of sensitisation in naïve individuals and inhibit elicitation of allergic responses. The purpose of this short review is to give a brief synopsis of the incidence, agents, mechanisms, and research needs related to occupational allergy.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://emjreviews.com/therapeutic-area/allergy-immunology/occupational-allergy/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-65-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-65-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Anderson SE</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Melioli,G.</style></author><author><style face="normal" font="Arial"> Riccio,A.M.</style></author><author><style face="normal" font="Arial"> Ledda,S.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Use of Emerging Technologies in Allergen Immunotherapy Management</style></title><secondary-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></full-title></periodical><pages end="86" start="81">81-86</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergen microarray</style></keyword><keyword><style face="normal" font="Arial"> Allergen microarrays</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Emerging technologies are profoundly changing the landscape of allergy diagnoses and future allergy treatments. At the single patient level, the introduction of single components and allergen microarrays for allergy diagnoses has significantly modified treatment strategies. In epidemiological terms, the availability of information from large dataset analyses has allowed and, more importantly, will allow for changes in prophylaxis and treatment strategies in many patients. In this report, we describe the different fields where new technologies have had a significant effect on allergy management and identify new scenarios where the combination of data from basic, clinical, and epidemiological research will improve our knowledge of allergy diagnosis and treatment.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://emjreviews.com/therapeutic-area/allergy-immunology/the-use-of-emerging-technologies-in-allergen-immunotherapy-management/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-81-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-81-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Melioli G</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baskara,I.</style></author><author><style face="normal" font="Arial"> Niquet-Leridon,C.</style></author><author><style face="normal" font="Arial"> Anton,P.M.</style></author><author><style face="normal" font="Arial"> Delayre-Orthez,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Neoformed Compounds from the Maillard Reaction in Infant Formulas: A New Risk Factor for Allergy?</style></title><secondary-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EMJ Allergy Immunol</style></full-title></periodical><pages end="93" start="87">87-93</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food contaminants</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Free amino acids</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Formula</style></keyword><keyword><style face="normal" font="Arial"> Infant formulas</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lactose</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Maillard</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Reducing sugars</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Shelf life</style></keyword><keyword><style face="normal" font="Arial"> sugars</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergies, which are T helper cell Type 2 aberrant responses of the immune system to food proteins, are increasing. Environmental factors, including food contaminants, are often mentioned to explain this increase. Heat treatment of food induces the Maillard reaction, a non-enzymatic reaction between reducing sugars and free amino groups of proteins or free amino acids. This leads to the genesis of neoformed compounds, including advanced Maillard reaction products (also called dietary advanced glycation end-products [AGEs]). Infant formulas are very sensitive to the Maillard reaction because of their high content of lactose and proteins and their long shelf life. The dietary AGEs content is particularly high in hydrolysed infant milk. Among dietary AGEs, Ne-carboxymethyllysine is the main form in milk. An increasing number of studies show potentially deleterious effects of dietary AGEs, including inflammation genesis. These effects seem to be in a great part dependent on the receptor of AGEs (RAGE). RAGE is present on immune cells and studies have shown that RAGE is involved in T helper cell priming, proliferation, and differentiation. Moreover, there is increasing evidence that the Maillard reaction enhances the allergenicity of proteins. All these data indicate a potential role of dietary AGEs in allergies. Nevertheless, the impact of dietary AGEs on the immune system favouring the T helper cell Type 2 profile and consequently predisposition to develop allergy is poorly documented and needs further investigation.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://emjreviews.com/therapeutic-area/allergy-immunology/neoformed-compounds-from-the-maillard-reaction-in-infant-formulas-a-new-risk-factor-for-allergy/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-87-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EMJ Allergy Immunol\2017-2-87-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Baskara I</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Flatin,M.C.</style></author><author><style face="normal" font="Arial"> Ade,S.</style></author><author><style face="normal" font="Arial"> Hounkpatin,S.-H.R.</style></author><author><style face="normal" font="Arial"> Ametonou,B.</style></author><author><style face="normal" font="Arial"> Vodouhe,U.B.</style></author><author><style face="normal" font="Arial"> Adjibabi,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Symptoms of allergic rhinitis in Parakou, Benin: Prevalence, severity and associated factors</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Otorhinolaryngol Head Neck Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur Ann Otorhinolaryngol Head Neck Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Associated factors</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic eczema/dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Benin</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parakou</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1879-7296</style></isbn><abstract><style face="normal" font="Arial">AimsAllergic rhinitis (AR) is an extremely common disease. This study aimed to determine the prevalence and severity of AR symptoms and potential associated factors, in Parakou, a city in Benin.Materials and methodsA cross-sectional study was conducted between April and July 2016, involving inhabitants of the city aged between 6 and 65 years. Cluster sampling was carried out. AR symptoms were defined as the simultaneous presence of rhinorrhea, nasal obstruction and sneezing without evidence of respiratory infection. Data were analyzed on EpiData Analysis v2.2.2.183 and then on R.3.2.1.ResultsThree hundred and ninety-five inhabitants were questioned, with a male/female ratio of 1.32, and median age of 19 years. One hundred and forty-one (35.7%) had AR symptoms, 47 (33.3%) had family history of atopy, and 87 (61.7%) had allergic conjunctivitis. The main triggers were house dust (139; 98.5%) and air pollution (111; 78.7%). On multivariate analysis, associated factors were age &lt; 18 years (P &lt; 0.05), exposure to house dust (P &lt; 0.001), and personal history of urticaria (P &lt; 0.001) or allergic conjunctivitis (P &lt; 0.01). Twenty-eight subjects (19.9%) had persistent symptoms. Forty-three (30.5%) had moderate/severe symptoms, associated with age = 18 years (P &lt; 0.01), family history of atopy (P &lt; 0.01), personal history of atopic eczema/dermatitis (P &lt; 0.01), and presence of a dog or cat at home (P = 0.01).ConclusionThe prevalence of AR symptoms in Parakou was high. A non-negligible proportion of symptoms were severe. This disease merits special attention in the city.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Benin -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anorl.2017.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797520">PM:28797520</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Otorhinolaryngol Head Neck Dis\20170804-FlotinMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Otorhinolaryngol Head Neck Dis\20170804-FlotinMC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Flatin MC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anorl.2017.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gujral,N.</style></author><author><style face="normal" font="Arial"> Yoo,H.</style></author><author><style face="normal" font="Arial"> Bamdad,F.</style></author><author><style face="normal" font="Arial"> Suh,J.W.</style></author><author><style face="normal" font="Arial"> Sunwoo,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sensitive double antibody sandwich ELISA for the quantification of phosvitin</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="847" start="834">834-847</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgY</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="9" Year="2017">2017/9/3</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">An effective double antibody sandwich ELISA (DAS-ELISA) method based on monoclonal (mAb) and chicken egg yolk IgY antibodies was developed to determine phosvitin (PV) content in therapeutic and functional products. Leghorn laying hens were immunized with purified PV to produce anti-PV IgY antibody in the egg yolk. High anti-PV IgY titer obtained from the egg yolks collected during 4?10 weeks of the immunization period contained approximately 6.2% of specific anti-PV IgY in total IgY. The PV detection range of the DAS-ELISA and biotinylated DAS-ELISA was 16.8?90 and 7.5?40?ng/mL, respectively. However, biotinylated DAS-ELISA was the better method for PV quantification in terms of accuracy and sensitivity. This highly efficient PV detection method may recuperate the performance of the existing protein assay methods as well as facilitate future research on PV bioactivities and applications</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -CO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1313821</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1313821</url></web-urls><pdf-urls><url ppv-ref="no">hsunwoo@ualberta.ca</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="Arial">20170801, Gujral N</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1313821</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Razavi,A.</style></author><author><style face="normal" font="Arial"> Malhotra,I.</style></author><author><style face="normal" font="Arial"> Ghosh,A.</style></author><author><style face="normal" font="Arial"> Pusztai-Carey,M.</style></author><author><style face="normal" font="Arial"> Marks,J.</style></author><author><style face="normal" font="Arial"> King,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Antibodies as epidemiological markers of genetically modified crop exposure: detection of Cry1Ab-specific IgG</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="788" start="779">779-788</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> Bacillus thuringiensis</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> GM Crops</style></keyword><keyword><style face="normal" font="Arial"> GM-crops</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Kenya</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> New Guinea</style></keyword><keyword><style face="normal" font="Arial"> Papua New Guinea</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="3" Month="9" Year="2017">2017/9/3</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">There has been an increasing concern with the safety of genetically modified (GM) crops. An important modification of GM crops is the expression of Bacillus thuringiensis (Bt) protein, Cry1Ab. Animal exposure to Cry1Ab indicates that the protein is safe, but that it is immunogenic. Whether Cry1Ab is a human immunogen and whether antibody response to this protein can serve as a marker of high exposure to GM crops is unknown. Here we develop an enzyme-linked immunosorbent assay to detect the presence of Cry1Ab-specific IgG in ?100 individuals living in each of three countries that have varied exposure to GM crops (Papua New Guinea (PNG), low exposure; Kenya, moderate exposure; and the USA, high exposure). Cry1Ab-specific IgG antibodies were detected in individuals living in each region (8%, the USA; 3%, PNG; and 2%, Kenya). Thus, individuals develop anti-Cry1Ab antibodies at a frequency that roughly correlates with the exposure to GM crops expressing this protein</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1313200</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1313200</url></web-urls><pdf-urls><url ppv-ref="no">alex.c.razavi@gmail.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="Arial">20170801,zavi A</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1313200</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Silvan,J.M.</style></author><author><style face="normal" font="Arial"> Mingo,E.</style></author><author><style face="normal" font="Arial"> Martinez-Rodriguez,A.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Grape seed extract (GSE) modulates campylobacter pro-inflammatory response in human intestinal epithelial cell lines</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="753" start="739">739-753</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Caco 2 cell</style></keyword><keyword><style face="normal" font="Arial"> Caco-2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Campylobacter</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Grape</style></keyword><keyword><style face="normal" font="Arial"> HT29 Cells</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="9" Year="2017">2017/9/3</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The main aim of this study was to investigate the effect of Grape seed extract (GSE) on Campylobacter induced-cytokine production by human intestinal cell lines. With this purpose, Caco-2 and HT-29 cells were challenged with culture supernatants from several strains of C.-ájejuni and levels of secreted IL-6, IL-8, and MCP-1 were measured. Cytokine production was higher in HT-29 than in Caco-2 cells, showing different levels of secretion depending of the epithelial cells origin. Also, infective isolates coming from campylobacteriosis patients rendered higher levels of pro-inflammatory cytokines. Co-treatment and pre-treatment of HT-29 cells with GSE and C.-ájejuni significantly reduced cytokines production in a dose-dependent manner. These results make this natural product a putative nutritional tool for use in the treatment of campylobacteriosis, which could contribute to improve disease prevention or reduce disease severity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1312292</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1312292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-739-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-739-53.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Silvan JM</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1312292</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kiyota,K.</style></author><author><style face="normal" font="Arial"> Yoshimitsu,M.</style></author><author><style face="normal" font="Arial"> Satsuki-Murakami,T.</style></author><author><style face="normal" font="Arial"> Akutsu,K.</style></author><author><style face="normal" font="Arial"> Kajimura,K.</style></author><author><style face="normal" font="Arial"> Yamano,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Detection of the tomato allergen Sola l 1 and evaluation of its reactivity after heat and papain treatment</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Calibrator</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Papain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Sola l 1</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tomato</style></keyword><keyword><style face="normal" font="Arial"> tomato allergy</style></keyword><keyword><style face="normal" font="Arial"> Tomatoes</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">To detect the tomato allergen profilin (Sola l 1) from fresh tomato and tomato-containing processed foods, we generated a rabbit polyclonal anti-Sola l 1 peptide antibody. An indirect enzyme-linked immunosorbent assay (iELISA) based on the antibody was established for semiquantification of Sola l 1, and standard curves were generated using Sola l 1 homologue recombinant birch profilin (rBet v 2) as a calibrator. The mean concentration of tomato extracts was 25.6?-¦?9.1?-Ág/g, and the concentrations of tomato-containing processed foods ranged from 13.3 to 24.8?-Ág/g. The reactivity of Sola l 1 after heat and papain treatment of tomato extracts was evaluated using competitive iELISA, and the results showed that Sola l 1 reactivity was stable with or without treatment. Our findings suggested that tomato-containing processed foods and fresh tomatoes both contained Sola l 1 and could have the potential to induce allergic symptoms in patients with tomato allergies</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1347914</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1347914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\20170801-KiyotaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\20170801-KiyotaK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Kiyota K</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1347914</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,Y.F.</style></author><author><style face="normal" font="Arial"> Oey,I.</style></author><author><style face="normal" font="Arial"> Bremer,P.</style></author><author><style face="normal" font="Arial"> Silcock,P.</style></author><author><style face="normal" font="Arial"> Carne,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Science, University of Otago, Dunedin, New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">In vitro peptic digestion of ovomucin-depleted egg white affected by pH, temperature and pulsed electric fields</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="174" start="165">165-174</pages><volume><style face="normal" font="Arial">231</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregation</style></keyword><keyword><style face="normal" font="Arial"> Conalbumin</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Hot Temperature</style></keyword><keyword><style face="normal" font="Arial"> Hydrogen-Ion Concentration</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> MALDI-MS</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovomucin</style></keyword><keyword><style face="normal" font="Arial"> ovotransferrin</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein digestibility</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="Arial">The effect of pH (4, 5, 7, and 9) combined with either heat (60, 80 degrees C for 10min) or pulsed electric fields (PEF) (1.4-1.8kV/cm, 260-690kJ/kg) treatments on the in vitro peptic digestion of ovomucin-depleted egg white was investigated. Protein digestibility, unaffected by 60 degrees C heating, was increased by heating at 80 degrees C, which caused protein aggregation and solution turbidity. Compared to ovalbumin and lysozyme, ovotransferrin was more susceptible to pepsinolysis. Susceptibility to pepsinolysis of ovalbumin and lysozyme was markedly enhanced by heating at 80 degrees C, compared to either 60 degrees C heating or PEF processing. MALDI-MS identified proteolytic fragments from ovalbumin and lysozyme, exhibiting varied resistance to pepsinolysis. PEF processing at approximately 690kJ/kg and pH 4 increased protein digestibility to a similar level to that obtained after heating at 80 degrees C, with negligible solution turbidity, showing potential for the production of digestible protein drinks with good consumer visual appeal owing to their clarity</style></abstract><notes><style face="normal" font="Arial">DA - 20170428IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticleRN - 1391-06-6 (Conalbumin)RN - 37281-36-0 (Ovomucin)SB - IMCO - New Zeland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.03.136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449993">PM:28449993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-231-165-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-231-165-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170428, Liu YF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.03.136</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mattison,C.P.</style></author><author><style face="normal" font="Arial"> Malveira Cavalcante,J.</style></author><author><style face="normal" font="Arial"> Izabel Gallao,M.</style></author><author><style face="normal" font="Arial"> Sousa de Brito,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of industrial cashew nut processing on anacardic acid content and allergen recognition by IgE</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="376" start="370">370-376</pages><volume><style face="normal" font="Arial">240</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anacardic acids</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Cashew allergen</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Industrial processing</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein solubility</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">Cashew nuts are important both nutritionally and industrially, but can also cause food allergies in some individuals. The present study aimed to assess the effect(s) of industrial processing on anacardic acids and allergens present in cashew nuts. Sample analyses were performed using liquid chromatography coupled with mass spectrometry, SDS-PAGE and immunoassay. The anacardic acid concentration ranged from 6.2 to 82.6 mg/g during processing, and this variation was attributed to cashew nut shell liquid incorporation during storage and humidification. Dehydrated and selected samples did not significantly differ in anacardic acid content, having values similar to the raw sample. SDS-PAGE and immunoassay analysis with rabbit polyclonal sera and human IgE indicated only minor differences in protein solubility and antibody binding following processing steps. The findings indicate that appreciable amounts of anacardic acid remain in processed nuts, and that changes to cashew allergens during industrial processing may only mildly affect antibody recognition.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.07.146</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28946285">PM:28946285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2018-240-370-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2018-240-370-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Mattison CP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.07.146</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Franz-Oberdorf,K.</style></author><author><style face="normal" font="Arial"> Eberlein,B.</style></author><author><style face="normal" font="Arial"> Edelmann,K.</style></author><author><style face="normal" font="Arial"> Bleicher,P.</style></author><author><style face="normal" font="Arial"> Kurze,E.</style></author><author><style face="normal" font="Arial"> Helm,D.</style></author><author><style face="normal" font="Arial"> Olbricht,Klaus</style></author><author><style face="normal" font="Arial"> Darsow,U.</style></author><author><style face="normal" font="Arial"> Ring,J.</style></author><author><style face="normal" font="Arial"> Schwab,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">White-fruited strawberry genotypes are not per se hypoallergenic</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="756" start="748">748-756</pages><volume><style face="normal" font="Arial">100</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anthocyanin</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophil activation test (BAT)</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1 homolog</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> cv.Yellow Wonder</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Fra a 1</style></keyword><keyword><style face="normal" font="Arial"> Fragaria</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruit ripening</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Ripening</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Strawberry</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">The strawberry fruit Fra a 1-proteins are homologues of the major birch pollen allergen Bet v 1 and have essential biological functions in pigment formation during fruit ripening. Patients affected by allergy against birch pollen tolerated fruits of a naturally occurring white-fruited F. × ananassa genotype, which showed reduced levels of Fra a 1 proteins along with enzymes of the anthocyanin pigment pathway. We evaluated the cross-reactive allergenic potential of a number of naturally occurring white- and red-fruited strawberry varieties to detect genotypes with low allergenic reactivity, whose fruit might be tolerated by patients with mild allergy. Protein extracts of 51 different strawberry varieties (Fragaria × ananassa, F. vesca, and F. nilgerensis) were screened by Western blot analysis with a polyclonal Fra a 1.02 antibody. Besides, activation of basophils of eight atopic patients allergic to birch pollen were studied using Bet v 1a and different concentrations of 15 selected strawberry protein extracts out of the 51 strawberry genotypes. Median percentages of activated basophils stimulated by extracts from white- and red-fruited genotypes ranged from 36 to 84% and 44 to 76%, respectively indicating that white-fruited strawberry are not per se hypoallergenic. Protein extracts from white-fruited F. vesca cv. Yellow Wonder showed the lowest cross-reactivity but high biological variability. The knowledge about the allergenic potential of different strawberry genotypes may help to improve food safety and can serve as starting point for the development of red-fruited hypoallergenic strawberry cultivars.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2017.07.076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28873746">PM:28873746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\20170802-FranzOberdorfK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\20170802-FranzOberdorfK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Franz-Oberdorf K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2017.07.076</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bosco,L.B.</style></author><author><style face="normal" font="Arial"> da Luz Pinto,C.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pollen analysis of Atlantic forest honey from the Vale do Ribeira Region, state of São Paulo, Brazil</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Apis mellifera</style></keyword><keyword><style face="normal" font="Arial"> Asteraceae</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Euphorbiaceae</style></keyword><keyword><style face="normal" font="Arial"> Fabaceae</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Honey</style></keyword><keyword><style face="normal" font="Arial"> Melissopalynology</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="19" Month="6" Year="2017">2017/6/19</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">The pollen contents of 34 Apis mellifera honey samples from the Quilombola Community of Porto Velho (Vale do Ribeira, state of S?o Paulo, Brazil) were studied in order to identify their botanical and geographical origin. A total number of 114 pollen types distributed in 43 families were identified. Fabaceae pollen types were the most diverse (20). Dominant pollen was observed in 27 samples. The dominant type Piper was found in 21 samples and Zanthoxylum, Mikania cordifolia, Cupania oblongifolia, Cecropia, Attalea and Poaceae only in one sample. The quantitative analysis revealed a predominance of very-high pollen concentrations in the samples (Category IV, 35.3%). A second frequency of occurrence analysis revealed 67 pollen types from 26 botanical families from nectariferous species. Fabaceae was also the family with the largest number of nectariferous pollen types (15), followed by Sapindaceae, Asteraceae (six pollen types each), and Euphorbiaceae (five types). Dominant pollen occurred in 19 samples. The main nectariferous sources of pollen in the present study were: Arecaceae (Attalea and Euterpe/Syagrus), Asteraceae (Mikania cordifolia), Fabaceae (Machaerium), Rutaceae (Zanthoxylum), and Sapindaceae (Cupania oblongifolia). The honey was classified as predominantly heterofloral (67.6%). Monofloral honey from Mikania cordifolia, Machaerium, Zanthoxylum, Cupania oblongifolia, Euterpe/Syagrus and Attalea were also identified. The geographical origin demonstrates Apis mellifera using nectariferous sources available from the Atlantic Rainforest in the south and southeast of Brazil, as well as in the brushwood, secondary forest and field plants. This is one of the first works about melissopalynology in the Vale do Ribeira Region</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2017.1319414</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2017.1319414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\20170801-BoscoLB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Grana\20170801-BoscoLB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Bosco LB</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2017.1319414</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lozano-Ojalvo,D.</style></author><author><style face="normal" font="Arial"> Perez-Rodriguez,L.</style></author><author><style face="normal" font="Arial"> Pablos-Tanarro,A.</style></author><author><style face="normal" font="Arial"> Lopez-Fandino,R.</style></author><author><style face="normal" font="Arial"> Molina,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pepsin treatment of whey proteins under high pressure produces hypoallergenic hydrolysates</style></title><secondary-title><style face="normal" font="Arial">Innovat Food Sci Emerg Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Innovat Food Sci Emerg Technol</style></full-title></periodical><pages end="162" start="154">154-162</pages><volume><style face="normal" font="Arial">43</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody production</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> high pressure</style></keyword><keyword><style face="normal" font="Arial"> High-pressure</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell activation</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey protein isolate</style></keyword><keyword><style face="normal" font="Arial"> whey proteins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1466-8564</style></isbn><abstract><style face="normal" font="Arial">BALB/c mice were used to assess the ability of a whey protein hydrolysate obtained by pepsin treatment under high pressure (400 MPa, 37 °C, 30 min, HWP), to induce anaphylaxis, antibody production and cytokine responses in comparison with the whey protein isolate (WP) from which it is derived. HWP did not contain intact allergens and 50% of its peptides ranged between 10 and 3 kDa. Challenge with HWP did not induce clinical signs, body temperature changes or release of mast cell proteinase-1 in mice sensitized to WP. Immunization of mice with HWP did not produce WP-specific antibodies or allergic reactions upon HWP or WP challenge and thus, it can be considered hypoallergenic. However, HWP stimulated Th2 responses in splenocytes from sensitized mice. These characteristics make HWP a good candidate to be used in the management of milk allergy in diagnosed patients or to induce tolerance to whey proteins.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ifset.2017.07.032</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ifset.2017.07.032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Innovat Food Sci Emerg Technol\20170802-LozanoOjalvoD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Innovat Food Sci Emerg Technol\20170802-LozanoOjalvoD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Lozano-Ojalvo D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ifset.2017.07.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hauser,L.J.</style></author><author><style face="normal" font="Arial"> Chandra,R.K.</style></author><author><style face="normal" font="Arial"> Li,P.</style></author><author><style face="normal" font="Arial"> Turner,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University School of Medicine, Nashville, TN</style></auth-address><titles><title><style face="normal" font="Arial">Role of tissue eosinophils in chronic rhinosinusitis-associated olfactory loss</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> CRS</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> ethmoid</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> olfactory loss</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Skull Base</style></keyword><keyword><style face="normal" font="Arial"> Smell</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="7" Year="2017">2017/7/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Olfactory dysfunction is 1 of the hallmark symptoms of chronic rhinosinusitis (CRS). Eosinophilic inflammation has been implicated as a potential causative factor. However, prior studies have been limited by retrospective study designs, concomitant use of systemic corticosteroids, and other confounding factors. METHODS: CRS and healthy non-CRS control subjects undergoing endoscopic sinus or skull-base surgery were prospectively enrolled and completed olfactory testing utilizing the 40-item Smell Identification Test (SIT) immediately prior to surgery. Histopathological evaluation of tissue excised from the ethmoid bulla was performed by a pathologist in a blinded fashion. Disease severity and patient-reported outcomes were measured via the Lund-Mackay computed tomography (CT) grading system and 22-item Sino-Nasal Outcome Test (SNOT-22), respectively. The associations between olfactory function, tissue eosinophilia, and disease severity were analyzed using Spearman rank order correlation and multiple linear regression. RESULTS: Twenty-seven (27) subjects with CRS without nasal polyps (CRSsNP), 32 subjects with CRS with nasal polyps (CRSwNP), and 10 healthy non-CRS controls were enrolled. CRSwNP was associated with higher mean tissue eosinophil counts (71.6 vs 28.1 eosinophils/high-power field [HPF], p &lt; 0.05) and lower age/sex-adjusted SIT scores (-17.4 vs -6.2, p &lt; 0.001) when compared to CRSsNP. SIT scores were strongly negatively correlated with tissue eosinophil counts in CRSwNP (r = -0.60, p = 0.0003), but not CRSsNP (r = 0.16, p = 0.42). The correlation between olfactory function and tissue eosinophilia in CRSwNP persisted after adjusting for disease severity. CONCLUSION: Tissue eosinophilia is associated with olfactory loss in CRSwNP, independent of disease severity. These results suggest a possible role for eosinophils or eosinophil-associated cytokines in CRS-associated olfactory loss</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.21994</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28742240">PM:28742240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170725-HauserLJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170725-HauserLJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Hauser LJ</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.21994</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Akin,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich</style></auth-address><titles><title><style face="normal" font="Arial">Mast cell activation syndromes</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="355" start="349">349-355</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndrome</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndromes</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">Mast cell activation is common and possibly necessary for maintenance of survival. Disordered mast cell activation occurs when mast cells are pathologically overproduced or if their activation is out of proportion to the perceived threat to homeostasis. Mast cell activation syndrome refers to a group of disorders with diverse causes presenting with episodic multisystem symptoms as the result of mast cell mediator release. Despite introduction of diagnostic criteria and some advances in treatment in the last decade, many areas of mast cell activation syndrome are in need of research. This article reviews our current knowledge about the various types of mast cell activation disorders, their treatment, and areas of uncertainty in need of future investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780942">PM:28780942</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-349-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-349-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Akin C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sasaki,M.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Field,M.J.</style></author><author><style face="normal" font="Arial"> Sawyer,S.M.</style></author><author><style face="normal" font="Arial"> McWilliam,V.</style></author><author><style face="normal" font="Arial"> Peters,R.L.</style></author><author><style face="normal" font="Arial"> Gurrin,L.C.</style></author><author><style face="normal" font="Arial"> Vuillermin,P.J.</style></author><author><style face="normal" font="Arial"> Douglass,J.</style></author><author><style face="normal" font="Arial"> Pezic,A.</style></author><author><style face="normal" font="Arial"> Brewerton,M.</style></author><author><style face="normal" font="Arial"> Tang,M.L.K.</style></author><author><style face="normal" font="Arial"> Patton,G.C.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Murdoch Childrens Research Institute, Parkville, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of clinic-defined food allergy in early adolescence: The SchoolNuts study</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> population-based study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Self-reported food allergy</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Rising rates of food-induced anaphylaxis have recently been shown in the adolescent age group, following earlier descriptions of a rise in children younger than 5 years. However, few population-based studies have examined the prevalence of food allergy in adolescence using objective measures such as oral food challenge (OFC). OBJECTIVE: We sought to determine the prevalence of food allergy among a population-based sample of 10- to 14-year-old adolescents using clinical evaluation including OFC to confirm the diagnosis. METHODS: Schools were randomly selected from greater metropolitan Melbourne, Australia. Students aged 10 to 14 years, and their parents, were asked to complete a questionnaire regarding the adolescent's food allergy or food-related reactions. Clinic evaluation, which consisted of skin prick tests and OFC where eligible, was undertaken if students were suspected to have current food allergy from parent response. Among 9816 students assessed, 5016 had complete parent response and clinic evaluation when eligible. An additional 4800 students had student questionnaires only. RESULTS: The prevalence of clinic-defined current food allergy based on history, sensitization data, and OFC results was 4.5% (95% CI, 3.9-5.1), with the most common food triggers being peanut, 2.7% (95% CI, 2.3-3.2), and tree nut, 2.3% (95% CI, 1.9-2.8). Among the additional group of 4800 adolescents who had only self-reported food allergy status available, the prevalence of self-reported current food allergy was 5.5% (95% CI, 4.9-6.2), with peanut, 2.8% (95% CI, 2.3-3.3), and tree nut, 2.3% (95% CI, 1.9-2.8), the most common. CONCLUSIONS: Approximately 1 in 20 10- to 14-year-old school students in Melbourne has current food allergy. This high prevalence suggests that the previously reported rise in food-induced anaphylaxis in this age group may reflect an increasing prevalence of food allergy rather than simply increased reporting of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170730IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28755784">PM:28755784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170730-SasakiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170730-SasakiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170730, Sasaki M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bakshi,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of ENT and Head &amp; Neck Surgery, Mahatma Gandhi Medical College and Research Institute, Pillaiyarkuppam, Pondicherry, India. Electronic address: saty.bakshi@gmail.com</style></auth-address><titles><title><style face="normal" font="Arial">Rhinosporidiosis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1739">1739-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword></keywords><dates><year Day="28" Month="7" Year="2017">2017/7/28</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757369">PM:28757369</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1739.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1739.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Bakshi SS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mercer,R.D.</style></author><author><style face="normal" font="Arial"> Jones,C.J.</style></author><author><style face="normal" font="Arial"> Smith,H.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Primary Care, Brighton &amp; Sussex Medical School, Mayfield House, University of Brighton, Brighton, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Reviewing the Content and Design of Anaphylaxis Management Plans Published in English</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1294" start="1288">1288-1294</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Guidelines recommend that patients at risk of anaphylaxis are given an anaphylaxis management plan (AMP) providing advice on symptom recognition and emergency management. However, the format and content of plans is not standardized. OBJECTIVE: The objective of this study was to review the design and contents of different AMPs available in English. METHODS: A systematic internet search identified AMPs published online. Each plan was analyzed for design and content (including signs and symptoms indicative of anaphylaxis and the actions to be taken). The content was compared with an e-Delphi-derived statement of the key characteristics of an AMP. RESULTS: The systematic search identified 41 plans from 29 different sources. The majority of plans identified were personalized management plans for individuals (78%); the others were designed for institutions. Most AMPs addressed both mild/moderate and severe allergic reactions and had different instructions related to the degree of severity. Thirty-seven individual symptoms were mentioned as indicators of anaphylaxis. Only 55% of plans that recommended the administration of an adrenaline autoinjector gave further instructions on how to do this. Only 17% of plans contained comprehensive instructions on safe patient positioning. CONCLUSIONS: There are a wide variety of AMPs in English available online. Plans are similar in design, but differ in content. None of the currently available plans contain all the desirable components recommended in the literature. Because of the variation between plans, when practitioners select an AMP for their patient, they need to be attentive to the content of the plan and its appropriateness for that individual</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780984">PM:28780984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1288-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1288-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Mervcer RD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hekking,P.P.</style></author><author><style face="normal" font="Arial"> Loza,M.J.</style></author><author><style face="normal" font="Arial"> Pavlidis,S.</style></author><author><style face="normal" font="Arial"> De Meulder,B.</style></author><author><style face="normal" font="Arial"> Lefaudeux,D.</style></author><author><style face="normal" font="Arial"> Baribaud,F.</style></author><author><style face="normal" font="Arial"> Auffray,C.</style></author><author><style face="normal" font="Arial"> Wagener,A.H.</style></author><author><style face="normal" font="Arial"> Brinkman,P.,I</style></author><author><style face="normal" font="Arial"> Lutter,R.,I</style></author><author><style face="normal" font="Arial"> Bansal,A.</style></author><author><style face="normal" font="Arial"> Sousa,A.R.</style></author><author><style face="normal" font="Arial"> Bates,S.</style></author><author><style face="normal" font="Arial"> Pandis,Y.</style></author><author><style face="normal" font="Arial"> Fleming,L.J.</style></author><author><style face="normal" font="Arial"> Shaw,D.E.</style></author><author><style face="normal" font="Arial"> Fowler,S.J.</style></author><author><style face="normal" font="Arial"> Guo,Y.</style></author><author><style face="normal" font="Arial"> Meiser,A.</style></author><author><style face="normal" font="Arial"> Sun,K.</style></author><author><style face="normal" font="Arial"> Corfield,J.</style></author><author><style face="normal" font="Arial"> Howarth,P.</style></author><author><style face="normal" font="Arial"> Bel,E.H.</style></author><author><style face="normal" font="Arial"> Adcock,I.M.</style></author><author><style face="normal" font="Arial"> Chung,K.F.</style></author><author><style face="normal" font="Arial"> Djukanovic,R.</style></author><author><style face="normal" font="Arial"> Sterk,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Medicine, Academic Medical Centre, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Pathway discovery using transcriptomic profiles in adult-onset severe asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced sputum</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PM</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Adult-onset severe asthma is characterized by highly symptomatic disease despite high intensity asthma treatments. Understanding of the underlying pathways of this heterogeneous disease needed for the development of targeted treatments. Gene Set Variation Analysis (GSVA) is a statistical technique to identify gene profiles in heterogeneous samples. OBJECTIVE: To identify gene profiles associated with adult-onset severe asthma. METHODS: This was a cross-sectional, observational study in which adult patients with adult-onset of asthma (defined as starting at >/=18yrs old) as compared to childhood-onset severe asthma (&lt;18 yrs) were selected from the U-BIOPRED cohort. Gene expression was assessed on the total RNA of induced sputum (n=83), nasal brushings (n=41), and endobronchial brushings (n=65) and biopsies (n=47) (Affymetrix HT HG-U133+ PM). GSVA was used to identify differentially enriched pre-defined gene signatures of leukocyte lineage, inflammatory and induced lung injury pathways. RESULTS: Significant differentially enriched gene signatures in patients with adult-onset as compared to childhood-onset severe asthma were identified in nasal brushings (5 signatures), sputum (3 signatures) and endobronchial brushings (6 signatures). Signatures associated with eosinophilic airway inflammation, mast cells and group 3 innate lymphoid cells (ILC3) were more enriched in adult-onset severe asthma, whereas signatures associated with induced lung injury were less enriched in adult-onset severe asthma. CONCLUSIONS: Adult-onset severe asthma is characterized by inflammatory pathways involving eosinophils, mast cells and ILC3s. These pathways could represent useful targets for the treatment of adult-onset severe asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170730IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - France -CO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28756296">PM:28756296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170730-HekkingPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170730-HekkingPP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170730, Hekking PP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ballmer-Weber,B.K.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Department of Dermatology, University Hospital, Zurich, E1Switzerland; Center of Dermatology and Allergology, Luzerner Kantonsspital, Lucerne. Electronic address: barbara.ballmer@luks.chDepartment of Paediatric Pneumology and Immunology, Charite Universitatsmedizin Berlin, University Medical Center, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Methods in Allergy/Immunology: Food Challenges</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nut allergy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="Arial">Since there is no in vitro test, which can accurately predict the clinical relevance of a sensitization to food, the oral food challenge still remains the most reliable procedure to confirm or exclude food allergy and to assess the development of tolerance in children with potentially transient food allergies such as to cow's milk, hen's egg, wheat or soy. Although in the last few years component-resolved diagnostic has improved the food allergy diagnostics, especially in peanut and tree nut allergy, the majority of patients still need to undergo oral food challenge. The following paper will describe in whom and how to perform an oral food challenge as well as its interpretation of the results with a focus on suspected IgE-mediated food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757143">PM:28757143</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170731-BallmerWeberBK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170731-BallmerWeberBK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Ballmer-Weber BK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Senechal,H.</style></author><author><style face="normal" font="Arial"> Santrucek,J.</style></author><author><style face="normal" font="Arial"> Melcova,M.</style></author><author><style face="normal" font="Arial"> Svoboda,P.</style></author><author><style face="normal" font="Arial"> Zidkova,J.</style></author><author><style face="normal" font="Arial"> Charpin,D.</style></author><author><style face="normal" font="Arial"> Guilloux,L.</style></author><author><style face="normal" font="Arial"> Shahali,Y.</style></author><author><style face="normal" font="Arial"> Selva,M.A.</style></author><author><style face="normal" font="Arial"> Couderc,R.</style></author><author><style face="normal" font="Arial"> Aizawa,T.</style></author><author><style face="normal" font="Arial"> Poncet,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Armand Trousseau Children Hospital, AP-HP, Biochemistry department, Allergy &amp; Environment Research team</style></auth-address><titles><title><style face="normal" font="Arial">A new allergen family involved in pollen food associated syndrome: snakin/gibberellin regulated proteins</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> Cupressus</style></keyword><keyword><style face="normal" font="Arial"> cypress</style></keyword><keyword><style face="normal" font="Arial"> Cypress pollen</style></keyword><keyword><style face="normal" font="Arial"> Cypress pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">At least two pollen food associated syndromes were described with cypress pollen allergy involving peach and citrus. Snakin/gibberellin regulated proteins are described herein to be the cross-reactive allergens between Cupressus sempervirens pollen and fruit/vegetables</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -CO - Czech Republic -CO - Iran -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782634">PM:28782634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170807-SenechalH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170807-SenechalH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Senechal H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Castells,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address: mcastells@bwh.harvard.edu</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis and management of anaphylaxis in precision medicine</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="333" start="321">321-333</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chemotherapy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clonal mast cell disorders</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell disorders</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is the most severe and frightening of the allergic reactions, placing patients at high risk and demanding prompt recognition and immediate management by health care providers. Yet because its symptoms imitate those of other diseases, such as asthma and urticaria, current data suggest that its diagnosis is often missed, with underuse of tryptase measurement; its treatment is delayed, with little use of epinephrine; and its underlying cause or causes are poorly investigated. Deaths from anaphylaxis are difficult to investigate because of miscoding. Surprisingly, patients treated with new and powerful chemotherapy agents and humanized mAbs present with nonclassical symptoms of anaphylaxis, and patients may present with unrecognized clonal mast cell disorders with KIT mutations may present as Hymenoptera-induced or idiopathic anaphylaxis. The goal of this review is to recognize the presentations of anaphylaxis with the description of its current phenotypes, to provide new insight and understanding of its mechanisms and causes through its endotypes, and to address its biomarkers for broad clinical use. Ultimately, the aim is to empower allergists and heath care providers with new tools that can help alleviate patients' symptoms, preventing and protecting them against anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780940">PM:28780940</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-321-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-321-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Castells M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reber,L.L.</style></author><author><style face="normal" font="Arial"> Hernandez,J.D.</style></author><author><style face="normal" font="Arial"> Galli,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Paris, France; Institut National de la Sante et de la Recherche Medicale, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">The pathophysiology of anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="348" start="335">335-348</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Arthropods</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect stings</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pasteur</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Reptiles</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a severe systemic hypersensitivity reaction that is rapid in onset; characterized by life-threatening airway, breathing, and/or circulatory problems; and usually associated with skin and mucosal changes. Because it can be triggered in some persons by minute amounts of antigen (eg, certain foods or single insect stings), anaphylaxis can be considered the most aberrant example of an imbalance between the cost and benefit of an immune response. This review will describe current understanding of the immunopathogenesis and pathophysiology of anaphylaxis, focusing on the roles of IgE and IgG antibodies, immune effector cells, and mediators thought to contribute to examples of the disorder. Evidence from studies of anaphylaxis in human subjects will be discussed, as well as insights gained from analyses of animal models, including mice genetically deficient in the antibodies, antibody receptors, effector cells, or mediators implicated in anaphylaxis and mice that have been "humanized" for some of these elements. We also review possible host factors that might influence the occurrence or severity of anaphylaxis. Finally, we will speculate about anaphylaxis from an evolutionary perspective and argue that, in the context of severe envenomation by arthropods or reptiles, anaphylaxis might even provide a survival advantage</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780941">PM:28780941</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-335-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-335-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Reber LL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fitzpatrick,A.M.</style></author><author><style face="normal" font="Arial"> Jackson,D.J.</style></author><author><style face="normal" font="Arial"> Mauger,D.</style></author><author><style face="normal" font="Arial"> Szefler,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Emory University, Atlanta, Ga</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers to: Nonatopic persistent asthma in children, a missed phenotype of asthma?)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780972">PM:28780972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170807-FitzpatrickAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170807-FitzpatrickAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Fitzpatrick AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Longo,G.</style></author><author><style face="normal" font="Arial"> Conversano,E.</style></author><author><style face="normal" font="Arial"> Panontin,E.</style></author><author><style face="normal" font="Arial"> Ventura,G.</style></author><author><style face="normal" font="Arial"> Ventura,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Univerisity of Trieste, Trieste, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Nonatopic persistent asthma in children, a missed phenotype of asthma?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780971">PM:28780971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170807-LongoG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170807-LongoG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Longo G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsui,K.</style></author><author><style face="normal" font="Arial"> Tofukuji,S.</style></author><author><style face="normal" font="Arial"> Ikeda,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lipoteichoic Acid from Staphylococcus aureus Enhances Allergen-Specific IL-5 Production in Patients with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="258">258-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> lipoteichoic acid</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The present study investigated the effects of lipoteichoic acid (LTA) derived from Staphylococcus aureus on production of the allergen-specific T helper type 2 (Th2) cytokine, interleukin (IL)-5, in human peripheral blood mononuclear cells (PBMCs) from patients with atopic dermatitis (AD). LTA dose-dependently enhanced the production of allergen-induced IL-5 in PBMCs from patients with AD, but not in those from healthy individuals. Also, when PBMCs from healthy individuals were cultured in a suboptimal concentration of anti-CD3 monoclonal antibody, which alone did not induce IL-5 production, the presence of LTA in the cultures dose-dependently augmented IL-5 production. These results suggest that Th2 cells of AD patients have already been primed by sensitization with various allergens and respond readily to LTA in the presence of an allergen, thus explaining the role of S. aureus colonization in AD patients.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000258</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000258</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-258.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-258.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Matsui K</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000258</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsui,K.</style></author><author><style face="normal" font="Arial"> Shigehara,K.</style></author><author><style face="normal" font="Arial"> Ikeda,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Peptidoglycan Synergistically Augments Production of Allergic Mediators from Murine Mast Cells in Combination with Muramyldipeptide</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="256">256-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic mediators</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> CXCL10</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peptidoglycan</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by superficial Staphylococcus aureus colonization and an increased number of mast cells in the lesional skin, the immunopathologic features varying according to lesion duration.Objective: The present study was conducted to clarify the effects of S. aureus cell wall components on production of allergic mediators from murine mast cells.Methods: Peptidoglycan (PEG) and/or muramyldipeptide (MDP) were/was used to stimulate murine mast cells, and the resulting culture supernatants were assayed for Th1 and Th2 chemokines and histamine release. Chemokine production was assessed using reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). Histamine release was measured using a competitive ELISA.Results: PEG stimulation induced production of the Th1 chemokine, CXCL10, and the Th2 chemokine, CCL17 by mast cells. Although MDP did not induce production of these chemokines, it synergistically enhanced the PEG-stimulated production of CCL17, but not CXCL10, from the mast cells. Histamine release was also enhanced in the presence of MDP.Conclusion: The present results suggest that, in AD patients, S. aureus colonization may exacerbate acute allergic inflammation through up-regulation of CCL17 production and histamine release from PEG- and MDP-stimulated mast cells.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000256</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000256</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-256.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-256.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Matsui K</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000256</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Giam,Y.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">An Asian Problem, Oligosaccharides in Cow's Milk Formula (CMF) Causing Anaphylaxis in Older Children, 2 Years Above and Prenatal and Post Natal Mothers in Singapore</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="260">260-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cow's milk formula</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000260</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-260.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-260.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Giam YC</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000260</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boni,E.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Makri,E.</style></author><author><style face="normal" font="Arial"> Preziosi,D.</style></author><author><style face="normal" font="Arial"> Mauro,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">When Allergen Immunotherapy Perfectly Meets its Need: A Case Report</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="259">259-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical criteria</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug treatment</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lolium</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Seasonal, pollen-induced allergic rhinitis can be managed by symptomatic drug treatment, but only allergen immunotherapy (AIT) is able to work on the causes of allergy. Usually, the effectiveness of AIT is assessed by clinical criteria, though the ideal outcome is to lose the allergic sensitization to the administered allergen(s).Here we report the case of a patient who after three years of AIT using a grass pollen extract containing Phleum pratense, Dactilys glomerata, Anthoxanthum odoratum, Poa pratensis and Lolium perenne but not Cynodon dactylon, to which the patient was also sensitized, developed a negative response to allergy tests to the administered allergens.After 3 years of SCIT, the patient was free of both nose and lung symptoms during the grass pollen season and had negative results to the pollens included in the extract, while C. dactylon showed a decrease in respect to basal value but not a negative result.The findings from this case show that AIT in optimal circumstances is able to achieve a complete tolerance to the administered allergen demonstrated by the development of negative results to the grass pollens contained in the extract used for the treatment. This confirms the recent definition of AIT as a treatment fulfilling the requirements of precision medicine.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000259</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-259.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-259.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Boni E</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000259</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lasse,M.</style></author><author><style face="normal" font="Arial"> Deb-Choudhury,S.</style></author><author><style face="normal" font="Arial"> Haines,S.</style></author><author><style face="normal" font="Arial"> Larsen,N.</style></author><author><style face="normal" font="Arial"> Gerrard,J.A.</style></author><author><style face="normal" font="Arial"> Dyer,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The impact of pH, salt concentration and heat on digestibility and amino acid modification in egg white protein</style></title><secondary-title><style face="normal" font="Arial">J Food Compost Anal</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Compost Anal</style></full-title></periodical><pages end="48" start="42">42-48</pages><volume><style face="normal" font="Arial">38</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid modification</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Deamidation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degree of hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Dehydration</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Analysis</style></keyword><keyword><style face="normal" font="Arial"> Food composition</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heated egg</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Maillard</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> OPA</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein digestibility</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><isbn><style face="normal" font="Arial">0889-1575</style></isbn><abstract><style face="normal" font="Arial">In this work egg white was used to study the effect of common food processing conditions on in vitro protein digestibility and on the modification of amino acid residues. Egg white was treated at 20 °C and 100 °C, varying pH (2-12), and zero and high-salt concentrations (0 mM, 200 mM). The digestibility assays confirmed previous findings that exposure of egg white to high temperatures increased digestibility markedly. However, the effects of pH and salt concentrations were found to be minimal. Proteomic analysis was utilised to map amino acid modifications, revealing that increased digestibility in heated egg white comes at the cost of a higher degree of amino acid residue-level modification. The predominant modifications were found to be dehydration and deamidation reactions that increased with increasing heat exposure time. The effects of the Maillard reaction on digestibility and amino acid modification were also determined for egg white in the presence of glucose and methylglyoxal. Proteomic assessment clearly revealed a high degree of modification of up to 38% of available arginine residues in the presence of methylglyoxal. An important correlation was therefore established between increased levels of Maillard reaction products and a decrease in the nutritional value of egg white.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jfca.2014.08.007</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jfca.2014.08.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Compost Anal\2015-38-42-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Compost Anal\2015-38-42-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151011, Lasse M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jfca.2014.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rupa,P.</style></author><author><style face="normal" font="Arial"> Schnarr,L.</style></author><author><style face="normal" font="Arial"> Mine,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of heat denaturation of egg white proteins ovalbumin and ovomucoid on CD4+ T cell cytokine production and human mast cell histamine production</style></title><secondary-title><style face="normal" font="Arial">J Funct Foods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Funct Foods</style></full-title></periodical><pages end="34" start="28">28-34</pages><volume><style face="normal" font="Arial">18</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell cytokine</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical tolerance</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg white proteins</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Heat denaturation</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><isbn><style face="normal" font="Arial">1756-4646</style></isbn><abstract><style face="normal" font="Arial">The conformational epitopes of egg glycoproteins ovalbumin (OVA) and ovomucoid (OVM) recognized by IgE antibodies in an allergic response can be denatured at high temperatures. This structural change results in a decreased allergenicity and has earlier been used to induce clinical tolerance for specific oral immunotherapy in allergic patients via consumption of cooked egg products. We investigated the difference in allergic response when consuming heat-treated and native egg proteins by examining the cytokine production of CD4+ T cells and mast cell histamine release. Cultures of mouse CD4+ T cells and dendritic cells were stimulated with native and heat denatured OVA and OVM (HD-OVA and HD-OVM) and various cytokine and histamine concentrations were measured using ELISA. An increased concentration of IL-12, IL-17 and IL-10 and a decreased concentration of IL-4 were detected in both HD-OVA and HD-OVM (p?&lt;?0.05). A decreased concentration of histamine was detected in HD-OVM (p?&lt;?0.05) with human KU812 basophil like cells. Heat denatured egg proteins OVA and OVM demonstrated a skewed type 1 CD4+ T cell cytokine response and inhibited intracellular Ca2+ concentration. This study provides insights into understanding the mechanisms behind induced tolerance of allergic individuals when consuming cooked egg.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jff.2015.06.030</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jff.2015.06.030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Funct Foods\2015-18-28-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Funct Foods\2015-18-28-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161010, Rupa P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jff.2015.06.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,M.</style></author><author><style face="normal" font="Arial"> Ji,W.</style></author><author><style face="normal" font="Arial"> Pan,L.</style></author><author><style face="normal" font="Arial"> Wang,Q.</style></author><author><style face="normal" font="Arial"> Zhou,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of ephedra asarum aconite decoction on Th1/Th2 balance in two animal models of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Trad Chin Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Trad Chin Med Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Ephedra asarum aconite decoction</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2095-7548</style></isbn><abstract><style face="normal" font="Arial">ObjectiveEphedra asarum aconite decoction is used in the clinical treatment of allergic rhinitis. We investigated the effects of ephedra asarum aconite decoction on Th1/Th2 balance in two animal models of allergic rhinitis and in activated T cells in vitro.MethodsAnimal models of simple and compound kidney yang deficiency types of allergic rhinitis were treated with ephedra asarum aconite decoction to observe the efficacy of this Traditional Chinese Medicine formula on allergic symptoms, serum cytokines, and tissue RNA levels. We also cultured and activated T cells from the mouse. After treatment with ephedra asarum aconite decoction, we tested the proliferation and differentiation of T cells.ResultsEphedra asarum aconite decoction relieved allergy symptoms in both types of animal models, and was more effective in the compound kidney yang deficiency model. In addition to its anti-allergic efficacy, ephedra asarum aconite decoction significantly improved the health status of animals in the compound kidney yang deficiency groups, significantly made their bodyweight rising up, and significantly increased the T-bet mRNA/GATA-3 mRNA ratio. Moreover, ephedra asarum aconite decoction promoted the proliferation of activated T cells and inhibited the differentiation to Th2 cells in vitro.ConclusionsEphedra asarum aconite decoction regulates the balance of Th1/Th2 to ameliorate allergic conditions.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jtcms.2017.07.015</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jtcms.2017.07.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Trad Chin Med Sci\20170802-LiuM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Trad Chin Med Sci\20170802-LiuM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Liu M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jtcms.2017.07.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barni,S.</style></author><author><style face="normal" font="Arial"> Mori,F.</style></author><author><style face="normal" font="Arial"> Bortone,B.</style></author><author><style face="normal" font="Arial"> Novembre,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Department of Pediatrics, Anna Meyer Children's University Hospital, Viale Pieraccini 24, 50139, Florence, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Personalized treatment of severe atopic dermatitis in a child: a ten-year follow-up</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="7" Year="2017">2017/7/29</year></dates><abstract><style face="normal" font="Arial">A 4-year-old-boy with a history of persistent rhinitis and milk and/or egg induced anaphylaxis was first referred to our Allergy Unit in 2008 because of severe atopic dermatitis (AD) since the age of one month. The physical examination was remarkable due to lichenified plaques, scaly and excoriated patchy papules (Figure 1). Moreover he complained of persistent generalized itchiness, with sleeping difficulties which greatly affected his quality of life. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170729IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12761</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28755473">PM:28755473</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170729-BarniS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170729-BarniS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170729, Barni S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12761</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nilsson,L.</style></author><author><style face="normal" font="Arial"> Brockow,K.</style></author><author><style face="normal" font="Arial"> Alm,J.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author><author><style face="normal" font="Arial"> Caubet,J.C.</style></author><author><style face="normal" font="Arial"> Gomes,E.</style></author><author><style face="normal" font="Arial"> Jenmalm,M.C.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Netterlid,E.</style></author><author><style face="normal" font="Arial"> Schwarze,J.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Storsaeter,J.</style></author><author><style face="normal" font="Arial"> Skevaki,C.</style></author><author><style face="normal" font="Arial"> Terreehorst,I.</style></author><author><style face="normal" font="Arial"> Zanoni,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Center, University Hospital, Linkoping, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Vaccination and allergy: EAACI position paper, practical aspects</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Precaution</style></keyword><keyword><style face="normal" font="Arial"> precautions</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">Immunization is highly effective in preventing infectious diseases and therefore an indispensable public health measure. Allergic patients deserve access to the same publicly recommended immunizations as nonallergic patients unless risks associated with vaccination outweigh the gains. Whereas the number of reported possible allergic reactions to vaccines is high, confirmed vaccine-triggered allergic reactions are rare. Anaphylaxis following vaccination is rare, affecting less than 1/100,000, but can occur in any patient. Some patient groups, notably those with a previous allergic reaction to a vaccine or its components, are at heightened risk of allergic reaction and require special precautions. Allergic reactions, however, may occur in patients without known risk factors and cannot be predicted by currently available tools. Unwarranted fear and uncertainty can result in incomplete vaccination coverage for children and adults with or without allergy. In addition to concerns about an allergic reaction to the vaccine itself, there is fear that routine childhood immunization may promote the development of allergic sensitization and disease. Thus, although there is no evidence that routine childhood immunization increases the risk of allergy development, such risks need to be discussed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Sweden -CO - Germany -CO - Spain -CO - Switzerland -CO - Portugal -CO - United Kingdom -CO - Netherlands -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12762</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28779496">PM:28779496</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170805-NilssonL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170805-NilssonL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Nilsson L</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12762</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grubczak,K.</style></author><author><style face="normal" font="Arial"> Tomasiak-Lozowska,M.M.</style></author><author><style face="normal" font="Arial"> Klimek,M.</style></author><author><style face="normal" font="Arial"> Eljaszewicz,A.</style></author><author><style face="normal" font="Arial"> Bodzenta-Lukaszyk,A.</style></author><author><style face="normal" font="Arial"> Moniuszko,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Early effects of ultra-rush wasp-venom immunotherapy on the expression of CD25 on CD4+ T cells</style></title><secondary-title><style face="normal" font="Arial">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Allergol</style></full-title></periodical><pages end="80" start="77">77-80</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> CD25</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune therapy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Multicolor</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Specific immune therapy</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2353-3854</style></isbn><abstract><style face="normal" font="Arial">To date, early effects of specific immune therapy on the parameters of adaptive immune responses in hymenoptera venom allergic patients remain unclear. Therefore, in this pilot study, we aimed to evaluate early changes in the levels of CD25 expression within CD4+ T cells occurring in the course of ultra-rush wasp venom immunotherapy. To this end, ten wasp venom-sensitive patients subjected to ultra-rush immune therapy were recruited for the study. CD4+ T cells and CD25 expression were assessed before the start of treatment, 24 h later and on day 120 with the use of monoclonal antibodies directed at CD4, CD25 (IL-2 receptor) by the means of multi-color flow cytometry. We have demonstrated non-significant decrease in the intensity of CD25 expression on the surface of CD4+ T cells at day 1 but not day 120 of specific immune therapy. Our study suggests that putative early immunosuppressive mechanisms of SIT are not related to dramatic changes in the expression of CD25 on CD4+ T cells.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alergo.2017.06.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.06.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2017-4-77-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2017-4-77-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Grubczak K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alergo.2017.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hu,S.</style></author><author><style face="normal" font="Arial"> Qiu,N.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author><author><style face="normal" font="Arial"> Zhao,H.</style></author><author><style face="normal" font="Arial"> Gao,D.</style></author><author><style face="normal" font="Arial"> Song,R.</style></author><author><style face="normal" font="Arial"> Ma,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Research and Development Center for Egg Processing, College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Identification and comparative proteomic study of quail and duck egg white protein using 2-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry analysis</style></title><secondary-title><style face="normal" font="Arial">Poult Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Poult Sci</style></full-title></periodical><pages end="1144" start="1137">1137-1144</pages><volume><style face="normal" font="Arial">95</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2-DE</style></keyword><keyword><style face="normal" font="Arial"> 2-Dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Chickens</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clusterin</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Ducks</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg white proteins</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis,Gel,Two-Dimensional</style></keyword><keyword><style face="normal" font="Arial"> Embryonic Development</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid Binding protein</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> MALDI-TOF</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MS/MS</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovomucoid</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Quail</style></keyword><keyword><style face="normal" font="Arial"> Reproduction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Species Specificity</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry,Mass,Matrix-Assisted Laser Desorption-Ionization</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="Arial">A proteomic study of egg white proteins from 2 major poultry species, namely quail (Coturnix coturnix) and duck (Anas platyrhynchos), was performed with comparison to those of chicken (Gallus gallus) through 2-dimensional polyacrylamide gel electrophoresis (2-DE) analysis. By using matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry (MALDI-TOF MS/MS), 29 protein spots representing 10 different kinds of proteins as well as 17 protein spots designating 9 proteins were successfully identified in quail and duck egg white, respectively. This report suggested a closer relationship between quail and chicken egg white proteome patterns, whereas the duck egg white protein distribution on the 2-DE map was more distinct. In duck egg white, some well-known major proteins, such as ovomucoid, clusterin, extracellular fatty acid-binding protein precursor (ex-FABP), and prostaglandin D2 synthase (PG D2 synthase), were not detected, while two major protein spots identified as "deleted in malignant brain tumors 1" protein (DMBT1) and vitellogenin-2 were found specific to duck in the corresponding range on the 2-DE gel map. These interspecies diversities may be associated with the egg white protein functions in cell defense or regulating/supporting the embryonic development to adapt to the inhabiting environment or reproduction demand during long-term evolution. The findings of this work will give insight into the advantages involved in the application on egg white proteins from various egg sources, which may present novel beneficial properties in the food industry or related to human health</style></abstract><notes><style face="normal" font="Arial">DA - 20160409IS - 0032-5791 (Print)IS - 0032-5791 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Egg Proteins)SB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3382/ps/pew033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26957635">PM:26957635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Poult Sci\2016-95-1137-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Poult Sci\2016-95-1137-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160409, Hu S</style></custom2><misc3><style face="normal" font="Arial">10.3382/ps/pew033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nica-Badea,D.</style></author><author><style face="normal" font="Arial"> Udristioiu,A.</style></author><author><style face="normal" font="Arial"> Andritoiu,C.V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergenicity risk assessment of foods derived from genetically modified crop plants</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biochemical analysis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> genetically modified crops</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> GM Crops</style></keyword><keyword><style face="normal" font="Arial"> GM-crops</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic plant foods</style></keyword><keyword><style face="normal" font="Arial"> Transgenic plants</style></keyword><keyword><style face="normal" font="Arial"> transgenic wheat</style></keyword><keyword><style face="normal" font="Arial"> Transgenic wheat allergy</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">The rapid spread of agro-biotechnological products has aroused a lot of controversy about the benefits, risks and limits of transgenic plants. The harmful effects of edible genetically modified plants can include toxicity or the induction of unwanted immune responses such as an allergic or immune modulation activity. The evaluation of allergenicity is a step in the assessment of the biosecurity of food derived from GM crops. This review article focuses on a topic of current interest: analysis of the allergenic potential of foods derived from genetically modified crops, of institutional assessment strategies, and of techniques for identification of transgenic proteins having allergenic properties. Recent studies show the results in terms of the extent to which transgenic wheat crops (albumin/globulin and the gluten protein) are responsible for asthma and IgE food allergy. Thus, a comprehensive analysis of allergens (allergenomics) is essential not only for assessment of the risks of food plants, but also for the diagnosis of allergic symptoms</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Romania -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.05.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.05.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170805-NicaBadeaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170805-NicaBadeaD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Nica-Badea D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.05.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barre,A.</style></author><author><style face="normal" font="Arial"> Delplanque,A.</style></author><author><style face="normal" font="Arial"> Simplicien,M.</style></author><author><style face="normal" font="Arial"> Benoist,H.</style></author><author><style face="normal" font="Arial"> Rouge,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Is maize a safe food for patients with celiac disease?</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="381" start="375">375-381</pages><volume><style face="normal" font="Arial">57</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Coeliac disease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten intolerance</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> glutenin</style></keyword><keyword><style face="normal" font="Arial"> HLA-DQ2</style></keyword><keyword><style face="normal" font="Arial"> HLA-DQ8</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Immunotoxic peptides</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maize</style></keyword><keyword><style face="normal" font="Arial"> Molecular docking</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peptides immunotoxiques</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Alignment</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat gluten</style></keyword><keyword><style face="normal" font="Arial"> Zein</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Maize has long been recognized as a safe substitute for gluten-containing cereals for patients with severe gluten intolerance or celiac disease. Maize storage proteins consist primarily of zeins, which substantially differ from wheat gluten proteins, gliadins and glutenins. Yet sequence alignments reveal consistent identities and homologies between certain zeins and wheat gluten proteins. Systematic bioinfomatic searching for potential immunotoxic epitopes in all available amino acid sequences from maize storage proteins failed to identify any immunotoxic epitopes likely to provoke the intestinal mucosa erosion currently seen in celiac disease patients. The absence of immunotoxic epitopes in maize storage proteins was further confirmed by an in silico molecular docking approach, using HLA-DQ2 and HLA-DQ8 as templates. None of the suspected maize immunotoxic epitopes could be fully accommodated in the HCM-II basket of HLA-DQ2 and HLA-DQ8 during docking experiments. The results of the in silico approach confirm the absence of immunotoxic epitopes in maize storage proteins and help reinforce its status as a safe food for celiac disease patients. Maize thus deserves to be recognized as a gluten-free cereal with no harmful impact on celiac disease patients</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.06.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.06.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170805-BarreA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170805-BarreA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Barre A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.06.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Poitevin,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Arundo Donax: a homeopathic medicine, allergen, and musical instrument</style></title><secondary-title><style face="normal" font="Arial">Rev Homeopath</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Rev Homeopath</style></abbr-1></periodical><pages end="126" start="122">122-126</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arundo donax</style></keyword><keyword><style face="normal" font="Arial"> Canne de Provence</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Ch+®ilite</style></keyword><keyword><style face="normal" font="Arial"> Cheilitis</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gramin+®es</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Reed</style></keyword><keyword><style face="normal" font="Arial"> Rhinite allergique</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1878-9730</style></isbn><abstract><style face="normal" font="Arial">Arundo donax, a giant graminaceous plant, is a homeopathic medicine prescribed for the treatment of allergic rhinitis. It also presents skin symptomatology. In allergology, the wild cane with which clarinet and saxophone reeds are made, causes skin contact reactions mainly in subjects allergic to grasses pollens. Arundo donax symptomatology is discussed taking into account these allergy data and the composition of the homeopathic strain.</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.revhom.2017.07.022</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.revhom.2017.07.022</url></web-urls></urls><custom2><style face="normal" font="Arial">20170805, Poitevin B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.revhom.2017.07.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Westman,M.</style></author><author><style face="normal" font="Arial"> Asarnoj,A.</style></author><author><style face="normal" font="Arial"> Hamsten,C.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Windows of opportunity for tolerance induction for allergy by studying the evolution of allergic sensitization in birth cohorts</style></title><secondary-title><style face="normal" font="Arial">Semin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen molecule</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> life course</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1044-5323</style></isbn><abstract><style face="normal" font="Arial">Allergic sensitization is a risk factor for developing IgE-mediated allergic diseases, which are a major cause of chronic illness world-wide. The introduction of allergen molecules to the field of allergy diagnostics has allowed dissecting the IgE response on a molecular level to pinpoint the specific disease-causing allergens. Studying birth cohorts is an essential tool for understanding the development and life course of allergy, enabling the possibility to design preventive strategies. Here we review the evolution of sensitization using data from some of the large European birth cohort studies. Differences and similarities between sensitization to food and various sources of inhalant allergens are discussed and allergen molecules of importance in early childhood predicting disease in adolescence are highlighted. Finally, we discuss windows of opportunity where intervention could be considered and address possible preventive strategies.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.smim.2017.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28789818">PM:28789818</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunol\20170802-WestmanM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunol\20170802-WestmanM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Westman M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.smim.2017.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical aspects of oral immunotherapy for the treatment of allergies</style></title><secondary-title><style face="normal" font="Arial">Semin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1044-5323</style></isbn><abstract><style face="normal" font="Arial">Studies on oral immunotherapy (OIT) have been increasing worldwide. Nevertheless, some concerns exist with this treatment. The rate of long-term sustained unresponsiveness is quite low; moreover, the desensitization or sustained unresponsiveness does not equate to tolerance. Furthermore, adverse reactions are frequent. Therefore, safe and feasible methods for long-term therapies are needed. Novel therapies such as low-dose OIT, hypoallergenic products, and OIT in combination with omalizumab are reported as effective for inducing sustained unresponsiveness and may lead to fewer adverse reactions than standard OIT. Increased safety will contribute to feasibility of OIT. Currently, oral food challenge (OFC) with the low target dose has been reported. We may reduce the need for OIT by implementing low-dose OFC. More effective, safe, and feasible OIT strategies are needed.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.smim.2017.07.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780220">PM:28780220</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunol\20170802-YanagidaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunol\20170802-YanagidaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Yanagida N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.smim.2017.07.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moingeon,P.</style></author><author><style face="normal" font="Arial"> Mascarell,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Differences and similarities between sublingual immunotherapy of allergy and oral tolerance</style></title><secondary-title><style face="normal" font="Arial">Semin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Buccal</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Subcutaneous route</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerogenic dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Weed pollens</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1044-5323</style></isbn><abstract><style face="normal" font="Arial">Allergen immunotherapy is the only treatment altering the natural course of IgE-mediated allergies. Whereas the subcutaneous route for immunotherapy (SCIT) has been historically considered as a reference, we discuss herein the relative advantages of the sublingual and oral routes as alternatives to SCIT in order to elicit allergen-specific tolerance. The buccal and gut immune systems are similarly organized to favor immune tolerance to antigens/allergens, due to the presence of tolerogenic dendritic cells and macrophages promoting the differentiation of CD4+ regulatory T cells. Sublingual immunotherapy (SLIT) is now established as a valid treatment option, with clinical efficacy demonstrated in allergic rhinoconjunctivitis (to either grass, tree, weed pollens or mite allergens) and encouraging results obtained in the management of mild/moderate allergic asthma. While still exploratory, oral immunotherapy (OIT) has shown promising results in the desensitization of patients with food allergies. We review at both biological and clinical levels the perspectives currently pursued for those two mucosal routes.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.smim.2017.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28760498">PM:28760498</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunol\20170802-MoingeonP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunol\20170802-MoingeonP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Moingeon P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.smim.2017.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Szajewska,H.</style></author><author><style face="normal" font="Arial"> Horvath,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, The Medical University of Warsaw, Zwirki i Wigury 63A, 02-091 Warsaw, PolandDepartment of Paediatrics, The Medical University of Warsaw, Zwirki i Wigury 63A, 02-091 Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="Arial">A partially hydrolyzed 100% whey formula and the risk of eczema and any allergy: an updated meta-analysis</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="27">27-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cow's milk formula</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> hydrolyzed formula</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recently, the role of using hydrolyzed formula for the prevention of allergic disease has been questioned. However, not all hydrolyzed formulas are equal. The efficacy of each hydrolyzed formula should be established separately. We updated evidence on the effectiveness of using partially hydrolyzed 100% whey formula (pHF), manufactured by a single manufacturer, for reducing the risk of eczema and allergy in healthy infants at high risk for allergy. METHODS: The Cochrane Library, MEDLINE, and EMBASE databases were searched in June 2016 for randomized and quasi-randomized controlled trials (RCTs); additional data were obtained from reviewed articles and the authors of included trials. RESULTS: Thirteen publications reporting on eight RCTs were included. Use of pHF compared to cow's milk formula reduced the risk of eczema and all allergic diseases among children at high risk for allergy. Both intention-to-treat analyses and per-protocol analyses showed that the reduction was statistically significant at some, albeit not all, time points. CONCLUSIONS: There is evidence to consider use of pHF as an option for reducing the risk of any allergic diseases, particularly eczema. However, the certainty of the evidence is low. One characteristic that makes our meta-analysis distinct from other reviews is that it focuses exclusively on only one type of pHF</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0158-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28781718">PM:28781718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Szajewska H</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0158-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,Y.</style></author><author><style face="normal" font="Arial"> Yang,J.H.</style></author><author><style face="normal" font="Arial"> Han,J.P.</style></author><author><style face="normal" font="Arial"> Li,S.</style></author><author><style face="normal" font="Arial"> Yu,Y.Y.</style></author><author><style face="normal" font="Arial"> Fan,Z.Z.</style></author><author><style face="normal" font="Arial"> Cui,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of "three-acupoint and five-needling method" on the expression level of p-ERK 1/2 protein in lung tissue of rats with allergic bronchial asthma</style></title><secondary-title><style face="normal" font="Arial">World J Acupunct Moxibust</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Acupunct Moxibust</style></full-title></periodical><pages end="28" start="23">23-28</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acupuncture</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> immunohistochemical test</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> p-ERK 1/2</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot test</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1003-5257</style></isbn><abstract><style face="normal" font="Arial">Objective To explore the effect of "three-acupoint and five-needling method" on the expression level of p-ERK 1/2 protein in lung tissue of rats with allergic bronchial asthma Methods Forty SPF-grade male SD rats were selected and randomly divided into four groups, including control group (group C), model group (group M), acupuncture group (group A) and blocker group (group PD), with 10 rats in each group. After corresponding intervention was given, cell counting was conducted, and the expression level of p-ERK 1/2 protein in the lung tissue of rats was detected via immunohistochemical method and Western blot method Results The number of leukocyte and eosinophil in the bronchoalveolar lavage fluid of rats in group A and group PD was smaller than that in group M, but larger than that in group C. It was shown based on the immunohistochemical test and Western blot test that the expression level of p-ERK1/2 protein in the lung tissue of rats in group M was higher than that in group C (P&lt;0.05), while the expression level of p-ERK1/2 protein in group A and group PD was lower than that in group M (P&lt;0.05) Conclusion "Three-acupoint and five-needling method" can effectively relieve the inflammatory response of rats with allergic bronchial asthma, and inhibit the expression level of p-ERK 1/2 protein in the lung tissue of rats with asthma. Acupuncture may alleviate the symptom of allergic bronchial asthma through inhibiting the expression level of p-ERK 1/2 protein.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/S1003-5257(17)30114-9</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/S1003-5257(17)30114-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Acupunct Moxibust\20170802-ZhaoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Acupunct Moxibust\20170802-ZhaoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Zhao Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/S1003-5257(17)30114-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,H.Y.</style></author><author><style face="normal" font="Arial"> Huang,C.H.</style></author><author><style face="normal" font="Arial"> Park,J.</style></author><author><style face="normal" font="Arial"> Pathania,D.</style></author><author><style face="normal" font="Arial"> Castro,C.M.</style></author><author><style face="normal" font="Arial"> Fasano,A.</style></author><author><style face="normal" font="Arial"> Weissleder,R.</style></author><author><style face="normal" font="Arial"> Lee,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Integrated Magneto-Chemical Sensor For On-Site Food Allergen Detection</style></title><secondary-title><style face="normal" font="Arial">ACS Nano</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">ACS Nano</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food allergen detection</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> food sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hazelnuts</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> restaurant</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">Adverse food reactions, including food allergies, food sensitivities, and autoimmune reaction (e.g., celiac disease) affect 5-15% of the population and remain a considerable public health problem requiring stringent food avoidance and epinephrine availability for emergency events. Avoiding problematic foods is practically difficult, given current reliance on prepared foods and out-of-home meals. In response, we developed a portable, point-of-use detection technology, termed integrated Exogenous Antigen Testing (iEAT). The system consists of a disposable antigen extraction device coupled with an electronic keychain reader for rapid sensing and communication. We optimized the prototype iEAT system to detect five major food antigens in peanuts, hazelnuts, wheat, milk, and eggs. Antigen extraction and detection with iEAT requires less than 10 min and achieves high detection sensitivities (e.g., 0.1 mg/kg for gluten - lower than regulatory limits of 20 mg/kg). When testing under restaurant conditions, we were able to detect hidden food antigens such as gluten within "gluten-free" food items. The small size and rapid, simple testing of the iEAT system should help not only consumers but also other key stakeholders such as clinicians, food industries and regulators to enhance food safety</style></abstract><notes><style face="normal" font="Arial">DA - 20170809IS - 1936-086X (Electronic)IS - 1936-0851 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acsnano.7b04318</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28792732">PM:28792732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\ACS Nano\20170809-LinHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\ACS Nano\20170809-LinHY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Lin HY</style></custom2><misc3><style face="normal" font="Arial">10.1021/acsnano.7b04318</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kacik,J.</style></author><author><style face="normal" font="Arial"> Wroblewska,B.</style></author><author><style face="normal" font="Arial"> Lewicki,S.</style></author><author><style face="normal" font="Arial"> Zdanowski,R.</style></author><author><style face="normal" font="Arial"> Kalicki,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Pediatric Nephrology and Allergology, Military Institute of Medicine, 128 Szaserow, 04-141, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Serum Diamine Oxidase in Pseudoallergy in the Pediatric Population</style></title><secondary-title><style face="normal" font="Arial">Adv Exp Med Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Exp Med Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> DAO</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> NK cell</style></keyword><keyword><style face="normal" font="Arial"> NK cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">Histamine intolerance (pseudoallergy) is a poorly investigated type of food hypersensitivity. The main enzyme responsible for histamine degradation in the extracellular matrix is diamine oxidase (DAO). Disturbances in the concentration or activity of DAO may lead to the development of clinical signs of allergy. The aim of the present work was to assess the DAO concentration, peripheral blood morphology, lymphocytes phenotyping (CD3+, CD4+, CD8+, CD19+, NK cells, NKT cells, and activated T-cells), and natural regulatory Treg (nTregs) cell population (CD4+, CD25+, CD127low, and FoxP3) in 34 pediatric patients with histamine-dependent syndromes. Patients were divided into two groups: classical allergy and pseudoallergy on the basis of IgE concentration. The investigation was based on the analysis of peripheral blood samples. A significantly lower serum DAO, both total and specific IgE, concentration was found in the pseudoallergy group compared with the allergy group. There were no significant differences in blood morphology or lymphocyte populations. A similar level of nTreg lymphocytes was also found in both groups, although it was lower than that present in healthy individuals. The findings suggest that the serum DAO is responsible for the symptoms of histamine intolerance. Moreover, a general decrease in nTreg cells in comparison with healthy individuals may lead to symptom aggravation</style></abstract><notes><style face="normal" font="Arial">DA - 20170814IS - 0065-2598 (Print)IS - 0065-2598 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/5584_2017_81</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28804811">PM:28804811</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Exp Med Biol\20170814-KacikJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Exp Med Biol\20170814-KacikJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170814, Kacik J</style></custom2><misc3><style face="normal" font="Arial">10.1007/5584_2017_81</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">No Authors</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A serologic study of related and unrelated food allergens in dogs</style></title><secondary-title><style face="normal" font="Arial">Adv Small Anim Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Small Anim Med Surg</style></full-title></periodical><pages end="5" start="4">4-5</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1041-7826</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENG</style></notes><work-type><style face="normal" font="Arial">10.1016/j.asams.2017.07.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.asams.2017.07.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Small Anim Med Surg\2017-30-4-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Small Anim Med Surg\2017-30-4-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, no authors</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.asams.2017.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valle Rodriguez,I.</style></author><author><style face="normal" font="Arial"> Huerta Lopez,J.G.</style></author><author><style face="normal" font="Arial"> Huerta Hernandez,R.E.</style></author></authors></contributors><titles><title><style face="normal" font="Helvetica">Alergia a alimentos </style></title><secondary-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="15" start="5">5-15</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Alimentos</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Food allergy is a condition that has increased in prevalence in recent decades, the symptoms involvesseveral organs and systems, being the skin most commonly affected, the severity of symptoms has awide range, from mild reactions to life threatening events like in anafi laxis, early diagnosis can improvethe quality of patients life since it can be avoided unnecesary restrictive diets. Physiopathology aspects,clinical features and current treatment are described.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/contenido.cgi?IDPUBLICACION=7097</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2017-26-5-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2017-26-5-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170111, Valle Rodriguez I</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez-Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Mendoza-Hernandez,D.A.</style></author></authors></contributors><titles><title><style face="normal" font="Helvetica">Reintroducción de leche a la dieta... ¿cómo?</style></title><secondary-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="4" start="3">3-4</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy to cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> dieta</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergy to cow's milk is the most common food allergy in infants and young children. Most children havea favorable outcome due to development of immunologic tolerance. In this paper we present the mexicanversion of the «milk ladder», as it is a very useful tool for reintroduction of milk and dairy products todiet in children with a partial o complete tolerance. It has shown to be a very practical tool for pediatricpatients at Allergy Department of the National Institute of Pediatrics.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/contenido.cgi?IDPUBLICACION=7097</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2017-26-3-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2017-26-3-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170211, Rodriguez-Gonzalez M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kang,Y.</style></author><author><style face="normal" font="Arial"> Cai,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical School, Kunming University of Science and Technology, Kunming, Yunnan, China</style></auth-address><titles><title><style face="normal" font="Arial">Future prospect of faecal microbiota transplantation as a potential therapy in asthma</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Ecosystem</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Experimental models</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> progression of asthma</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">There is convincing evidence from both human and animal studies suggesting that the gut microbiota plays an important role in regulating immune responses associated with the development of asthma. Certain intestinal microbial strains have been demonstrated to suppress or impair immune responsiveness in asthma experimental models, suggesting that specific species among gut commensal microbiota may play either a morbific or phylactic role in the progression of asthma. Evidence to date suggests that the intestinal microbiota represent fertile targets for prevention or management of asthma. The faecal microbiota transplantation (FMT) is a rather straightforward therapy that manipulates the human gastrointestinal (GI) microbiota, by which a healthy donor microbiota is transferred into an existing but disturbed microbial ecosystem. The FMT may therefore represent a therapeutic approach for asthma treatment in the foreseeable future. At present, FMT therapy for asthma is very limited and should be actively studied. Considerable efforts are needed to increase our knowledge in the field of FMT therapy for asthma. In this review, we aimed to provide several insights into the development of FMT therapy for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170814IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803667">PM:28803667</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170814-KangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20170814-KangY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170814, Kang Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.04.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Engeroff,P.</style></author><author><style face="normal" font="Arial"> Caviezel,F.</style></author><author><style face="normal" font="Arial"> Storni,F.</style></author><author><style face="normal" font="Arial"> Thoms,F.</style></author><author><style face="normal" font="Arial"> Vogel,M.</style></author><author><style face="normal" font="Arial"> Bachmann,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Inselspital, University of Bern, Salihaus 2, 3007, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Allergens displayed on Virus-Like Particles are highly immunogenic but fail to activate human mast cells</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> SPR</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus-like particle</style></keyword><keyword><style face="normal" font="Arial"> Virus-like particles</style></keyword><keyword><style face="normal" font="Arial"> viruslike particles</style></keyword><keyword><style face="normal" font="Arial"> VLPs</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">The goal of allergen-specific immunotherapy is the induction of protective immune responses in the absence of anaphylactic reactions. We have previously shown that Fel d 1, the major cat allergen, displayed in a repetitive fashion on virus-like particles (VLPs) may fulfill these criteria. Specifically, Fel d 1 on VLPs induced strongly increased IgG responses compared to the free allergen in mice while anaphylactic reactions were essentially abolished. Here we extend these findings to human mast cells and offer a mechanistic explanation for the reduced anaphylactic activity. By performing allergen binding studies and cellular activation assays, we demonstrate that the inability of Fel d 1 displayed on VLPs to activate mast cells is based on a biophysical as well as a biochemical mechanism. Firstly, Fel d 1 on VLPs showed a strongly impaired ability to bind to surface-bound IgE as assessed by Surface Plasmon Resonance (SPR) as well as flow cytometry. Secondly, despite residual binding, repetitively displayed allergen on VLPs failed to cause mast cell activation. These findings indicate that repetitively displaying allergens on VLPs increases their immunogenicity while reducing their potential to cause anaphylactic reactions by essentially eliminating IgE-mediated activation of mast cells. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13268</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787769">PM:28787769</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170808-EngeroffP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170808-EngeroffP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Engeroff P</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13268</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,X.</style></author><author><style face="normal" font="Arial"> Tsilochristou,O.</style></author><author><style face="normal" font="Arial"> Perna,S.</style></author><author><style face="normal" font="Arial"> Hofmaier,S.</style></author><author><style face="normal" font="Arial"> Cappella,A.</style></author><author><style face="normal" font="Arial"> Bauer,C.P.</style></author><author><style face="normal" font="Arial"> Hoffman,U.</style></author><author><style face="normal" font="Arial"> Forster,J.</style></author><author><style face="normal" font="Arial"> Zepp,F.</style></author><author><style face="normal" font="Arial"> Schuster,A.</style></author><author><style face="normal" font="Arial"> D'Amelio,R.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Pneumology&amp; Immunology, Charite-Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Evolution of the IgE and IgG repertoire to a comprehensive array of allergen molecules in the first decade of life</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen molecule</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Phl p 5</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In early childhood, the allergen-specific IgG repertoire is mainly directed to animal and vegetable food molecules and infrequently to airborne molecules. It is unknown whether this early pattern is maintained throughout childhood. OBJECTIVE: To investigate the evolution of IgG and IgE responses to a broad panel of allergenic molecules from birth to age 10yrs. METHODS: We examined the sera collected between birth and age 10yrs from participants in the German Multicentre Allergy Study, a birth cohort born in 1990. The IgE (cut-off >/=0.30 ISU) and IgG (cut-off >/=0.10 ISU) responses to 35 genuine allergenic molecules were measured with a multiplex microarray approach (ImmunoCAP ISAC ). RESULTS: IgE responses were mostly directed against a restricted group of airborne molecules, with a sequence and prevalence hierarchy (Phl p 1 > Bet v 1 > Fel d 1 > Phl p 5 > Der p 2 > Der p 1) largely maintained over time. Conversely, the IgG repertoire was much broader, starting with animal foodborne, then spreading to vegetable foodborne and finally to airborne molecules. A strong and persistent IgG response to a given airborne molecule almost invariably preceded or accompanied an IgE response to that molecule. CONCLUSIONS: The evolution of IgG and IgE responses throughout childhood differs widely at population level. IgG responses are mostly directed to animal food allergens while IgE responses are dominated by airborne allergens. However, a strong IgG response almost invariably precedes or accompanies the appearance of IgE to the same molecule in specifically sensitized subjects. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170809IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - China -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13269</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28791748">PM:28791748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170809-HuangX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170809-HuangX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Huang X</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13269</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hawro,T.</style></author><author><style face="normal" font="Arial"> Ohanyan,T.</style></author><author><style face="normal" font="Arial"> Schoepke,N.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Peveling-Oberhag,A.</style></author><author><style face="normal" font="Arial"> Staubach,P.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Allergie-Centrum-Charite, Charite - Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Comparison and Interpretability of the available Urticaria Activity Scores</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="Arial">The urticaria activity score (UAS) is the gold standard for assessing disease activity in patients with chronic spontaneous urticaria (CSU). Two different versions, the UAS7 and UAS7TD , are currently used in clinical trials and routine care. To compare both versions and to obtain data on their interpretability, 130 CSU patients applied both versions and globally rated their disease activity as none, mild, moderate, or severe. UAS7 and UAS7TD values correlated strongly (r=0.90, P&lt;0.001). Interquartile ranges for UAS7 and UAS7TD values for mild, moderate and severe CSU were 11-20 and 10-24, 16-30 and 16-32, and 27-37 and 28-40. UAS7 values were slightly, but significantly lower as compared to UAS7TD values (mean difference: 1.6+/-4.6, P&lt;0.001). This difference was driven by lower wheal subscores (2.1+/-3.5, P&lt;0.001) and was most pronounced in patients with severe CSU (2.5+/-5.6, P&lt;0.01). The UAS7/UAS7TD ratio was 0.96+/-0.21 and did not differ significantly between mild, moderate and severe CSU. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13271</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815631">PM:28815631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170817-HawroT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170817-HawroT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Hawro T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13271</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leger,D.</style></author><author><style face="normal" font="Arial"> Bonnefoy,B.</style></author><author><style face="normal" font="Arial"> Pigearias,B.</style></author><author><style face="normal" font="Arial"> de La Giclais,B.</style></author><author><style face="normal" font="Arial"> Chartier,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universite Paris Descartes, Sorbonne Paris Cite, APHP, Hotel-Dieu, Centre du Sommeil et de la Vigilance, 75004 Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="36">36-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Self-administered questionnaire</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Sleep Disorders</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Snoring</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Vigilance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sleep disorders are often underreported to physicians by patients with allergies. This study aimed to characterize the sleep disorders associated with respiratory allergy to house dust mites (HDM) at the time of initiation of sublingual allergen immunotherapy (SLIT) in routine clinical practice. METHODS: This prospective, cross-sectional, observational study was conducted between November 2014 and March 2015 at 189 French trial sites and included 1750 participants suffering from HDM allergy who were initiating SLIT. Participants aged less than 5 years old and those who had previously started an allergen immunotherapy (AIT) for HDM allergy were not enrolled in the study. Sleep disorders were assessed by self-administered questionnaires: the Epworth Sleepiness Scale (ESS), the Insomnia Severity Index (ISI) and a modified version of the Hotel Dieu-42 (HD-42) sleep disorder questionnaire. Logistic regression models adjusted for obesity, smoking status, asthma control and nasal obstruction were used to study the relationship between allergic rhinitis (AR) classification and sleep disorders/complaints. RESULTS: Of the 1786 participants enrolled, 1750 (907 adults and 843 children) composed the analysis population. The majority of participants (73.5% of adults and 65.8% of children) reported that their sleep disorders had prompted them to consult their physician. The most commonly observed sleep complaints were poor-quality sleep (50.3% of adults and 37.3% of children), snoring (48.1 and 41.4%, respectively) and nocturnal awakening (37.6 and 28.2%, respectively). Difficulties falling asleep were reported by 27.0% of adults and 24.7% of children. Adults and children suffering from severe persistent AR experienced sleep complaints significantly more often than participants with intermittent or mild persistent AR. CONCLUSIONS: This study highlights the high frequency of sleep disorders and their significant impact on patients with AR induced by HDM, in particular when AR is persistent and severe. Consequently, asking allergic patients about the quality of their sleep appears to be important, especially when the patient has persistent and severe AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0208-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814959">PM:28814959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-36.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Leger D</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0208-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hou,Y.C.</style></author><author><style face="normal" font="Arial"> Hu,H.Y.</style></author><author><style face="normal" font="Arial"> Liu,I.L.</style></author><author><style face="normal" font="Arial"> Chang,Y.T.</style></author><author><style face="normal" font="Arial"> Wu,C.Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The risk of autoimmune connective tissue diseases in patients with atopy: A nationwide population-based cohort study</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="389" start="383">383-389</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue</style></keyword><keyword><style face="normal" font="Arial"> Connective Tissue Diseases</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Urbanization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The relationship between autoimmune connective tissue disease (ACTD) and atopy is controversial. OBJECTIVES: To investigate the risks of ACTDs in patients with atopic triad diseases, including atopic dermatitis, allergic rhinitis, and asthma, by using a nationwide data base. METHODS: A cohort of 155,311 patients newly diagnosed with atopic dermatitis, allergic rhinitis, or asthma in 2002-2011 was obtained from the Taiwan National Health Insurance Research Database. An age- and sex-matched control group was selected from the same data base. The association between atopy and ACTD was investigated by using Cox proportional hazards regression analyses. RESULTS: Atopic dermatitis, allergic rhinitis, and asthma were present in 12.1, 78.6, and 26.3%, respectively, of the patients with atopy. The presence of atopic diseases increased the overall risk of ACTDs (incidence rate ratio 1.85 [95% confidence interval {CI}, 1.52-2.25]). The hazard ratio (HR) for ACTDs remained higher after adjusting for age, sex, urbanization level, socioeconomic status, and comorbidities. Individual risks of systemic lupus erythematosus (HR 1.58 [95% CI, 1.06-2.37]), rheumatoid arthritis (HR 1.74 [95% CI, 1.31-2.33]), and Sjogren syndrome (HR 2.49 [95% CI, 1.71-3.63]) were also higher. The coexistence of atopic triad diseases increased the risk of ACTDs from 1.80 (95% CI, 1.48-2.21) for one atopic disease to 3.29 (95% CI, 1.22-8.88) for three atopic diseases. CONCLUSION: The presence of atopic triad diseases is significantly associated with risks of systemic lupus erythematosus, rheumatoid arthritis, and Sjogren syndrome, and their coexistence exacerbates this risk. To our knowledge, this was the first study that reported an increased risk of Sjogren syndrome among patients with atopy</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814359">PM:28814359</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-383-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-383-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Hou YC</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4071</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Buckley,R.D.</style></author><author><style face="normal" font="Arial"> Carr,T.F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Association of aeroallergen sensitization and atopic disease in the Sonoran Desert</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="375" start="370">370-375</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Bermuda</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Expert Panel Report 3</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> skin-prick testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vegetation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Numerous aeroallergens have been associated with the development of asthma, including Alternaria, house-dust mite, and pet dander. Tucson, Arizona, is located in the Sonoran Desert, which has the highest diversity of vegetation of any desert in the world. Given the unique pollen profile in this region, we sought to identify the most common aeroallergens associated with rhinitis and asthma diagnosis in the local adult population. OBJECTIVE: To identify the prevalence of aeroallergen sensitivity in the Tucson adult population and to identify which aeroallergens are associated with a diagnosis of asthma. METHODS: We conducted a retrospective electronic chart review of 226 consecutive adult patients who underwent aeroallergen skin-prick testing for rhinitis at The University of Arizona Adult Allergy and Immunology Clinic over the course of 1 year. All the subjects were tested to a standard panel of tree, grass, weed, mold, house-dust mite, animal dander, cockroach, and feather extracts. Asthma was diagnosed by using the Expert Panel Report 3 guidelines. RESULTS: Skin testing results were most commonly positive to mesquite (54%), Bermuda (48%), palo verde (47%), olive tree (43%), and chenopodium (43%). Compared with the subjects without asthma, those subjects with asthma were more often sensitized to molds (odds ratio [OR] 2.25 [95% confidence interval {CI}, 1.22-4.14]; p = 0.005), including Alternaria alternata (OR 2.58 [95% CI, 1.23-5.39]; p = 0.011), and cat hair and/or pelt (OR 2.13 [95% CI, 1.24-3.69]; p = 0.006). CONCLUSION: Regional pollens contributed significantly to allergic disease in this unique climate. Sensitization to Alternaria and other nonregional aeroallergens were related to asthma, which supported the current practice of testing and treating patients for allergy to both locally significant and ubiquitous aeroallergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4077</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814357">PM:28814357</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-370-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-370-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Buckley RD</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4077</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tian,M.</style></author><author><style face="normal" font="Arial"> Zhou,Y.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Cui,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Der p 1 and Der p 2 specific immunoglobulin E measurement for diagnosis of Dermatophagoides pteronyssinus allergy: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="342" start="333">333-342</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Der p 2 Allergen</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A clinical history of allergic symptoms and a skin-prick test with house-dust mite crude extracts are standard diagnostic procedures for Dermatophagoides pteronyssinus allergy. Specific immunoglobulin E (IgE) responses to Der p 1 and Der p 2 allergens have been used for the diagnosis of D. pteronyssinus allergy; however, evaluation of the diagnostic performance of Der p 1 and Der p 2 specific IgE (sIgE) produced inconsistent findings. We sought to evaluate the diagnostic accuracy of Der p 1 sIgE and Der p 2 sIgE measurement in the diagnosis of D. pteronyssinus allergy by performing a systematic review and meta-analysis of previously published studies. METHODS: Several medical literature electronic data bases were searched for related literature published through August 1, 2016. A bivariate model was used to pool estimates of sensitivity, specificity, diagnostic odds ratio, and area under the summary receiver operating curves as the main diagnostic measures. RESULTS: Eight studies, which involved 1095 patients, were included in our analysis. The pooled estimates of sensitivity, specificity, and diagnostic odds ratio for Der p 1 were 0.84, 0.97, and 166.57, respectively. The combined results for Der p 2 were a sensitivity of 0.87, specificity of 1.00, and a diagnostic odds ratio of 17342.35. The areas under the summary receiver operating curves for Der p 1 sIgE and Der p 2 sIgE were 0.94 and 0.98, respectively. CONCLUSION: Our results supported the use of Der p 1 and Der p 2 sIgE in the diagnosis of D. pteronyssinus allergy. Both displayed good diagnostic performance and would be useful in a clinical setting in the accurate diagnosis of dust mite allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4073</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814355">PM:28814355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-333-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-333-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Tian M</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4073</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alonso,L.L.</style></author><author><style face="normal" font="Arial"> Warrington,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergy, Shellfish</style></title><secondary-title><style face="normal" font="Arial">Allergy, Shellfish</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy, Shellfish</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> scallop</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Shellfish reactions can occur as a result of immune system mediated effects and also through non-immunological processes. It is important to determine the underlying cause for the patient's presentation to best direct therapy and understand management implications. There is a wide array of consumables that falls under the category of shellfish, including crustaceans (such as crab or shrimp) or mollusks (such as clams or scallops), and this adds to the difficulty in dealing with "shellfish" allergies. Not all individuals react to both. One group notes only 14% cross-reactivity between crustacean and mollusk allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170829LA - engPT - ReviewPT - Book ChapterCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846285">PM:28846285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Books\Allergy_Shellfish.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Books\Allergy_Shellfish.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Alonso LL</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aguilera-Aguirre,L.</style></author><author><style face="normal" font="Arial"> Hao,W.</style></author><author><style face="normal" font="Arial"> Pan,L.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Saavedra-Molina,A.</style></author><author><style face="normal" font="Arial"> Bacsi,A.</style></author><author><style face="normal" font="Arial"> Radak,Z.</style></author><author><style face="normal" font="Arial"> Sur,S.</style></author><author><style face="normal" font="Arial"> Brasier,A.R.</style></author><author><style face="normal" font="Arial"> Ba,X.</style></author><author><style face="normal" font="Arial"> Boldogh,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Texas Medical Branch at Galveston</style></auth-address><titles><title><style face="normal" font="Arial">Pollen-induced oxidative DNA damage response regulates miRNAs controlling allergic inflammation</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L1068" start="L1058">L1058-L1068</pages><volume><style face="normal" font="Arial">313</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Differential expression</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Damage</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> Nucleic Acids</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxidative DNA damage</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reactive species</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">A mucosal oxidative burst is a hallmark response to pollen exposure that promotes allergic inflammatory responses. Reactive species constituents of oxidative stress signal via the modification of cellular molecules including nucleic acids. One of the most abundant oxidative genomic base damage is 8-oxo-7,8-dihydroguanine (8-oxoG), which is removed from DNA by 8-oxoguanine DNA glycosylase1 (OGG1). OGG1 in complex with 8-oxoG acts as a GDP-GTP exchange factor and induces acute inflammation; however, the mechanism(s) by which OGG1 signaling regulates allergic airway inflammation is not known. Here, we postulate that the OGG1 signaling pathway differentially altered the levels of small regulatory RNAs and increased the expression of T helper 2 (Th2) cytokines in ragweed pollen extract (RWPE)-challenged lungs. To determine this, the lungs of sensitized mice expressing or lacking OGG1 were challenged with RWPE and/or with OGG1's excision product 8-oxoG. The responses in lungs were assessed by next-generation sequencing, as well as various molecular and histological approaches. The results showed that RWPE challenge induced oxidative burst, damage to DNA and activated OGG1 signaling, resulting in the differential expression of 84 microRNAs, which then exacerbated antigen-driven allergic inflammation and histological changes in the lungs. The exogenous administration of the down-regulated let-7b-p3 mimetic or inhibitors of up-regulated miR23a or miR27a decreased eosinophil recruitment, mucus and collagen production via controlling the expression of IL4, IL5, and IL13. Together, these data demonstrate the roles of OGG1 signaling in the regulation of antigen-driven allergic immune responses via differential expressions of microRNAs upstream of Th2 cytokines and eosinophils</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00141.2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28798252">PM:28798252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170811-AguileraAguirreL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170811-AguileraAguirreL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Aguilera-Aguirre L</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00141.2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Markus,M.A.</style></author><author><style face="normal" font="Arial"> Borowik,S.</style></author><author><style face="normal" font="Arial"> Reichardt,M.</style></author><author><style face="normal" font="Arial"> Tromba,G.</style></author><author><style face="normal" font="Arial"> Alves,F.</style></author><author><style face="normal" font="Arial"> Dullin,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Max-Planck-Institute for Experimental Medicine</style></auth-address><titles><title><style face="normal" font="Arial">X-ray based lung function measurement reveals persistent loss of lung tissue elasticity in mice recovered from allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elasticity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motion</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">Chronic asthma patients experience difficulties even years after the inciting allergen. Although studies in small animal asthma models have enormously advanced progress in uncovering the mechanisms of inception and development of the disease, little is known about the processes involved in the persistence of asthma symptoms in the absence of allergen exposure. Long term asthma mouse models have so far been scarce or not been able to reproduce the findings in patients. Here we used a common ovalbumin induced acute allergic airway inflammation mouse model to study lung function and remodeling after a four months recovery period. We show by x-ray based lung function measurements that the recovered mice continue to show impaired lung function by displaying significant air-trapping compared to controls. High resolution synchrotron phase contrast computed tomography of structural alterations and diaphragm motion analysis suggest that these changes in pulmonary function are due to a pronounced loss in lung elasticity. Histology of lung sections confirmed that this is most likely caused by a decrease in elastic fibers, indicating that remodelling can develop or persist independently of acute inflammation and is closely related to a loss in lung function. Our findings demonstrate that this x-ray based imaging platform has the potential to comprehensively and non-invasively unravel long term effects in preclinical mouse models of AAI and thus benefits our understanding of chronic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00136.2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775094">PM:28775094</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170804-MarkusMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\20170804-MarkusMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Markus MA</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00136.2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xie,S.</style></author><author><style face="normal" font="Arial"> Greenblatt,R.</style></author><author><style face="normal" font="Arial"> Levy,M.Z.</style></author><author><style face="normal" font="Arial"> Himes,B.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USADepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USADepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USADepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Enhancing Electronic Health Record Data with Geospatial Information</style></title><secondary-title><style face="normal" font="Arial">AMIA Jt Summits Transl Sci Proc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">AMIA Jt Summits Transl Sci Proc</style></abbr-1></periodical><pages end="132" start="123">123-132</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicaid</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Electronic Health Record (EHR)-derived data is a valuable resource for research, and efforts are underway to overcome some of its limitations by using data from external sources to gain a fuller picture of patient characteristics, symptoms, and exposures. Our goal was to assess the utility of augmenting EHR data with geocoded patient addresses to identify geospatial variation of disease that is not explained by EHR-derived demographic factors. Using 2011-2014 encounter data from 27,604 University of Pennsylvania Hospital System asthma patients, we identified factors associated with asthma exacerbations: risk was higher in female, black, middle aged to elderly, and obese patients, as well as those with positive smoking history and with Medicare or Medicaid vs. private insurance. Significant geospatial variability of asthma exacerbations was found using generalized additive models, even after adjusting for demographic factors. Our work shows that geospatial data can be used to cost-effectively enhance EHR data</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 2153-4063 (Print)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815121">PM:28815121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\AMIA Jt Summits Transl Sci Proc\2017-2017-123-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\AMIA Jt Summits Transl Sci Proc\2017-2017-123-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Xie S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cho,C.Y.</style></author><author><style face="normal" font="Arial"> Oles,C.</style></author><author><style face="normal" font="Arial"> Nowatzke,W.</style></author><author><style face="normal" font="Arial"> Oliver,K.</style></author><author><style face="normal" font="Arial"> Garber,E.A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Office of Regulatory Science, Center for Food Safety and Applied Nutrition (CFSAN), Food and Drug Administration, 5001 Campus Drive, College Park, MD, 20740, USA</style></auth-address><titles><title><style face="normal" font="Arial">Cross-reactivity profiles of legumes and tree nuts using the xMAP(R) multiplex food allergen detection assay</style></title><secondary-title><style face="normal" font="Arial">Anal Bioanal Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Bioanal Chem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> false positives</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food allergen detection</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> Lectins</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phylogeny</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">The homology between proteins in legumes and tree nuts makes it common for individuals with food allergies to be allergic to multiple legumes and tree nuts. This propensity for allergenic and antigenic cross-reactivity means that commonly employed commercial immunodiagnostic assays (e.g., dipsticks) for the detection of food allergens may not always accurately detect, identify, and quantitate legumes and tree nuts unless additional orthogonal analytical methods or secondary measures of analysis are employed. The xMAP(R) Multiplex Food Allergen Detection Assay (FADA) was used to determine the cross-reactivity patterns and the utility of multi-antibody antigenic profiling to distinguish between legumes and tree nuts. Pure legumes and tree nuts extracted using buffered detergent displayed a high level of cross-reactivity that decreased upon dilution or by using a buffer (UD buffer) designed to increase the stringency of binding conditions and reduce the occurrence of false positives due to plant-derived lectins. Testing for unexpected food allergens or the screening for multiple food allergens often involves not knowing the identity of the allergen present, its concentration, or the degree of modification during processing. As such, the analytical response measured may represent multiple antigens of varying antigenicity (cross-reactivity). This problem of multiple potential analytes is usually unresolved and the focus becomes the primary analyte, the antigen the antibody was raised against, or quantitative interpretation of the content of the analytical sample problematic. The alternative solution offered here to this problem is the use of an antigenic profile as generated by the xMAP FADA using multiple antibodies (bead sets). By comparing the antigenic profile to standards, the allergen may be identified along with an estimate of the concentration present. Cluster analysis of the xMAP FADA data was also performed and agreed with the known phylogeny of the legumes and tree nuts being analyzed. Graphical abstract The use of cluster analysis to compare the multi-antigen profiles of food allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1618-2650 (Electronic)IS - 1618-2642 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00216-017-0528-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801713">PM:28801713</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Bioanal Chem\20170812-ChoCY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Bioanal Chem\20170812-ChoCY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Cho CY</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00216-017-0528-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bai,Y.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Zhang,D.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Zhao,Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences , Beijing 100085, China</style></auth-address><titles><title><style face="normal" font="Arial">Enhancing the Affinity of Anti-Human alpha-Thrombin 15-mer DNA Aptamer and Anti-Immunoglobulin E Aptamer by PolyT Extension</style></title><secondary-title><style face="normal" font="Arial">Anal Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Chem</style></full-title></periodical><pages end="9473" start="9467">9467-9473</pages><volume><style face="normal" font="Arial">89</style></volume><number><style face="normal" font="Arial">17</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Aptamer</style></keyword><keyword><style face="normal" font="Arial"> Aptamers</style></keyword><keyword><style face="normal" font="Arial"> binding affinity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Capillaries</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Tail</style></keyword><keyword><style face="normal" font="Arial"> Thrombin</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="Arial">Aptamer affinity capillary electrophoresis-laser-induced fluorescence (CE-LIF) for protein detection takes advantage of aptamers for their ease of synthesis and labeling, small size, and having many negative charges. Its success relies on the high binding affinity of aptamers. One 15-mer DNA aptamer (5'-GGT TGG TGT GGT TGG-3', Apt15) shows desirable specificity for human alpha-thrombin, an important enzyme with multiple functions in blood. However, Apt15 has weak binding affinity, and the use of Apt15 in affinity CE-LIF analysis remains challenging. Here we reported that extension of Apt15 at the 3'-end with a polyT tail having length of 18 T or longer significantly enhanced its affinity and enabled a well-isolated and stable peak for thrombin-aptamer complex in affinity CE. It was likely that the improvement of binding affinity resulted from double binding, an additional interaction of the polyT tail with thrombin in addition to the Apt15 section binding to thrombin. With dye-labeled Apt15 having a T25 tail, we achieved detection of thrombin at concentrations as low as 0.1 nM by affinity CE-LIF. This aptamer probe specifically bound to human alpha-thrombin, showing negligible affinity for human beta- and gamma-thrombin, which are proteolyzed derivatives of human alpha alpha-thrombin and share similar structure. This strategy of adding a polyT extension also enhanced the binding affinity of anti-immunoglobulin E aptamer in CE-LIF analysis, showing that the affinity enhancement approach is not limited to the thrombin-binding aptamer and has potential for more applications in bioanalysis</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1520-6882 (Electronic)IS - 0003-2700 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.analchem.7b02313</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28763192">PM:28763192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Chem\20170801-BaiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Chem\20170801-BaiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Bai Y</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.analchem.7b02313</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gori,A.</style></author><author><style face="normal" font="Arial"> Cretich,M.</style></author><author><style face="normal" font="Arial"> Vanna,R.</style></author><author><style face="normal" font="Arial"> Sola,L.</style></author><author><style face="normal" font="Arial"> Gagni,P.</style></author><author><style face="normal" font="Arial"> Bruni,G.</style></author><author><style face="normal" font="Arial"> Liprino,M.</style></author><author><style face="normal" font="Arial"> Gramatica,F.</style></author><author><style face="normal" font="Arial"> Burastero,S.</style></author><author><style face="normal" font="Arial"> Chiari,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Consiglio Nazionale delle Ricerche, Istituto di Chimica del Riconoscimento Molecolare (ICRM), Milano, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Multiple epitope presentation and surface density control enabled by chemoselective immobilization lead to enhanced performance in IgE-binding fingerprinting on peptide microarrays</style></title><secondary-title><style face="normal" font="Arial">Anal Chim Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Chim Acta</style></full-title></periodical><pages end="197" start="189">189-197</pages><volume><style face="normal" font="Arial">983</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Alpha-lactalbumin</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biosensor</style></keyword><keyword><style face="normal" font="Arial"> biosensors</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immobilization</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray assay</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide microarray</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> SPR</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">Multiple ligand presentation is a powerful strategy to enhance the affinity of a probe for its corresponding target. A promising application of this concept lies in the analytical field, where surface immobilized probes interact with their corresponding targets in the context of complex biological samples. Here we investigate the effect of multiple epitope presentation (MEP) in the challenging context of IgE-detection in serum samples using peptide microarrays, and evaluate the influence of probes surface density on the assay results. Using the milk allergen alpha-lactalbumin as a model, we have synthesized three immunoreactive epitope sequences in a linear, branched and tandem form and exploited a chemoselective click strategy (CuAAC) for their immobilization on the surface of two biosensors, a microarray and an SPR chip both modified with the same clickable polymeric coating. We first demonstrated that a fine tuning of the surface peptide density plays a crucial role to fully exploit the potential of oriented and multiple peptide display. We then compared the three multiple epitope presentations in a microarray assay using sera samples from milk allergic patients, confirming that a multiple presentation, in particular that of the tandem construct, allows for a more efficient characterization of IgE-binding fingerprints at a statistically significant level. To gain insights on the binding parameters that characterize antibody/epitopes affinity, we selected the most reactive epitope of the series (LAC1) and performed a Surface Plasmon Resonance Imaging (SPRi) analysis comparing different epitope architectures (linear versus branched versus tandem). We demonstrated that the tandem peptide provides an approximately twofold increased binding capacity with respect to the linear and branched peptides, that could be attributed to a lower rate of dissociation (Kd)</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1873-4324 (Electronic)IS - 0003-2670 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aca.2017.06.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811026">PM:28811026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Chim Acta\2017-983-189-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Chim Acta\2017-983-189-97.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Gori A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aca.2017.06.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masaki,K.</style></author><author><style face="normal" font="Arial"> Fukunaga,K.</style></author><author><style face="normal" font="Arial"> Matsusaka,M.</style></author><author><style face="normal" font="Arial"> Kabata,H.</style></author><author><style face="normal" font="Arial"> Tanosaki,T.</style></author><author><style face="normal" font="Arial"> Mochimaru,T.</style></author><author><style face="normal" font="Arial"> Kamatani,T.</style></author><author><style face="normal" font="Arial"> Ohtsuka,K.</style></author><author><style face="normal" font="Arial"> Baba,R.</style></author><author><style face="normal" font="Arial"> Ueda,S.</style></author><author><style face="normal" font="Arial"> Suzuki,Y.</style></author><author><style face="normal" font="Arial"> Sakamaki,F.</style></author><author><style face="normal" font="Arial"> Oyamada,Y.</style></author><author><style face="normal" font="Arial"> Inoue,T.</style></author><author><style face="normal" font="Arial"> Oguma,T.</style></author><author><style face="normal" font="Arial"> Sayama,K.</style></author><author><style face="normal" font="Arial"> Koh,H.</style></author><author><style face="normal" font="Arial"> Nakamura,M.</style></author><author><style face="normal" font="Arial"> Umeda,A.</style></author><author><style face="normal" font="Arial"> Kamei,K.</style></author><author><style face="normal" font="Arial"> Izuhara,K.</style></author><author><style face="normal" font="Arial"> Asano,K.</style></author><author><style face="normal" font="Arial"> Betsuyaku,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Characteristics of severe asthma with fungal sensitization</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> fungal allergens</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Schizophyllum</style></keyword><keyword><style face="normal" font="Arial"> Schizophyllum commune</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trichophyton</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Some patients with severe asthma also have fungal sensitization and are considered to have severe asthma with fungal sensitization. However, there is limited information on the clinical features of SAFS. OBJECTIVE: To investigate the clinical characteristics of severe asthma with fungal sensitization. METHODS: The present study enrolled 124 patients with severe asthma. We evaluated clinical aspects, such as various serum cytokines, fractional exhaled nitric oxide, pulmonary function, and serum immunoglobulin E (IgE). Fungal sensitization was assessed by determining serum levels of IgE specific to fungal allergens (Aspergillus, Alternaria, Candida, Cladosporium, Penicillium, and Trichophyton species and Schizophyllum commune). The protocol was registered at a clinical trial registry (www.umin.ac.jp/ctr/index-j.htm; UMIN 000002980). RESULTS: Thirty-six patients (29%) showed sensitization to at least 1 fungal allergen. The most common species were Candida (16%), Aspergillus (11%), and Trichophyton (11%). The rate of early-onset asthma (&lt;16 years of age) was higher in patients with fungal sensitization than in those without fungal sensitization (45% vs 25%; P = .02). Interleukin-33 levels were higher in patients with fungal sensitization than in those without fungal sensitization. Of patients with atopic asthma, Asthma Control Test scores were worse in patients with multiple fungal sensitizations than in patients with a single fungal sensitization or those without fungal sensitization. CONCLUSION: Severe asthma with fungal sensitization is characterized by early onset of disease and high serum levels of interleukin-33. Multiple fungal sensitizations are associated with poor asthma control. TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR; www.umin.ac.jp/ctr/index-j.htm): UMIN 000002980</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801088">PM:28801088</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170812-MasakiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170812-MasakiK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Masaki K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tankersley,M.S.</style></author><author><style face="normal" font="Arial"> Cox,L.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Tennessee Health Science Center, Memphis, Tennessee.</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy and systemic reactions</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="195">195-</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.04.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801021">PM:28801021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-195.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-195.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Tankersley MS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.04.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ramesh,M.</style></author><author><style face="normal" font="Arial"> Lieberman,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Montefiore Medical Center, Bronx, New YorkThe University of Tennessee Health Science Center, Memphis, Tennessee.</style></auth-address><titles><title><style face="normal" font="Arial">Adult-onset food allergies</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="119" start="111">111-119</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.05.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801016">PM:28801016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-111-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-111-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Ramesh M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.05.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">David,N.A.</style></author><author><style face="normal" font="Arial"> Penumarti,A.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Slater,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Food allergen extracts to diagnose food-induced allergic diseases: How they are made</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="107" start="101">101-107</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Defatting</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> Government Agencies</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Manufacture</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Sterilization</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To review the manufacturing procedures of food allergen extracts and applicable regulatory requirements from government agencies, potential approaches to standardization, and clinical application of these products. The effects of thermal processing on allergenicity of common food allergens are also considered. DATA SOURCES: A broad literature review was conducted on the natural history of food allergy, the manufacture of allergen extracts, and the allergenicity of heated food. Regulations, guidance documents, and pharmacopoeias related to food allergen extracts from the United States and Europe were also reviewed. STUDY SELECTIONS: Authoritative and peer-reviewed research articles relevant to the topic were chosen for review. Selected regulations and guidance documents are current and relevant to food allergen extracts. RESULTS: Preparation of a food allergen extract may require careful selection and identification of source materials, grinding, defatting, extraction, clarification, sterilization, and product testing. Although extractions for all products licensed in the United States are performed using raw source materials, many foods are not consumed in their raw form. Heating foods may change their allergenicity, and doing so before extraction may change their allergenicity and the composition of the final product. CONCLUSION: The manufacture of food allergen extracts requires many considerations to achieve the maximal quality of the final product. Allergen extracts for a select number of foods may be inconsistent between manufacturers or unreliable in a clinical setting, indicating a potential area for future improvement</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801015">PM:28801015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-101-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-101-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, David NA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jang,Y.H.</style></author><author><style face="normal" font="Arial"> Sim,H.B.</style></author><author><style face="normal" font="Arial"> Moon,S.Y.</style></author><author><style face="normal" font="Arial"> Lee,W.J.</style></author><author><style face="normal" font="Arial"> Lee,S.J.</style></author><author><style face="normal" font="Arial"> Jin,M.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Kim,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Kyungpook National University School of Medicine, Daegu, Korea</style></auth-address><titles><title><style face="normal" font="Arial">House Dust Mite Sensitization Is Inversely Associated with Plasma 25-Hydroxyvitamin D3 Levels in Patients with Severe Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="406" start="400">400-406</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody titer</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The relationship between atopic dermatitis (AD) and low vitamin D levels has been studied. Emerging evidence has implicated vitamin D as a critical regulator of immunity, playing a role in both the innate and cell-mediated immune systems. However, the effect of vitamin D on house dust mite (HDM) sensitization in patients with AD has not been established. OBJECTIVE: We investigated the association between vitamin D levels and HDM sensitization according to AD severity. METHODS: In total, 80 patients (43 men and 37 women) with AD were included. We classified AD severity using Rajka and Langeland scores. Laboratory tests included serum 25-hydroxyvitamin D3, total immunoglobulin E (IgE), and specific IgE antibody titer against Dermatophagoides farinae and D. pteronyssinus. RESULTS: There were no differences in vitamin D levels between the mild or moderate AD and severe AD groups. In the severe AD group, high HDM sensitization group had lower serum vitamin D levels compared to low HDM sensitization group with statistical significance. In addition, a significant negative correlation was found between vitamin D levels and HDM sensitization in the severe AD group. CONCLUSION: Our results demonstrate that low vitamin D levels may link to high HDM sensitization in patients with the severe AD. Further elucidation of the role of vitamin D in HDM sensitization may hold profound implications for the prevention and treatment of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2017.29.4.400</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28761286">PM:28761286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2017-29-400-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2017-29-400-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Jang YH</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2017.29.4.400</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mortuaire,G.</style></author><author><style face="normal" font="Arial"> Michel,J.</style></author><author><style face="normal" font="Arial"> Papon,J.F.</style></author><author><style face="normal" font="Arial"> Malard,O.</style></author><author><style face="normal" font="Arial"> Ebbo,D.</style></author><author><style face="normal" font="Arial"> Crampette,L.</style></author><author><style face="normal" font="Arial"> Jankowski,R.</style></author><author><style face="normal" font="Arial"> Coste,A.</style></author><author><style face="normal" font="Arial"> Serrano,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">L'immunotherapie antiallergenique dans la rhinite allergique</style></title><secondary-title><style face="normal" font="Arial">Ann Fr Otorhinolaryngol Pathol Cerv</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Fr Otorhinolaryngol Pathol Cerv</style></full-title></periodical><pages end="253" start="247">247-253</pages><volume><style face="normal" font="Arial">134</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Acarien</style></keyword><keyword><style face="normal" font="Arial"> Acariens</style></keyword><keyword><style face="normal" font="Arial"> Allergie</style></keyword><keyword><style face="normal" font="Arial"> allergique</style></keyword><keyword><style face="normal" font="Arial"> Allergologue</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Antihistaminiques</style></keyword><keyword><style face="normal" font="Arial"> Asthme</style></keyword><keyword><style face="normal" font="Arial"> EST</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapie</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> ORL</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Rhinite</style></keyword><keyword><style face="normal" font="Arial"> Rhinite allergique</style></keyword><keyword><style face="normal" font="Arial"> Risque</style></keyword><keyword><style face="normal" font="Arial"> sensibilisation</style></keyword><keyword><style face="normal" font="Arial"> Standardisation</style></keyword><keyword><style face="normal" font="Arial"> Traitement</style></keyword><keyword><style face="normal" font="Arial"> Voie sublinguale</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><isbn><style face="normal" font="Arial">1879-7261</style></isbn><abstract><style face="normal" font="Arial">La rhinite allergique (RA) est une pathologie fréquente dont la sévérité ou le mauvais contrôle peut aboutir à une altération significative de la qualité de vie des patients. L'immunothérapie antiallergénique (ITA) constitue à l'heure actuelle le seul traitement étiologique susceptible de modifier l'histoire naturelle de la maladie allergique. Bien connue des allergologues, cette option thérapeutique est encore insuffisamment maîtrisée par les ORL. Cette mise au point basée sur les méta-analyses et les essais les plus récents souligne l'efficacité de l'ITA sur l'amélioration des symptômes de la RA et sur la réduction de la consommation des traitements médicaux (corticoïdes, antihistaminiques). L'ITA serait aussi susceptible de réduire le risque d'apparition d'un asthme et de nouvelles sensibilisations lorsqu'elle est introduite suffisamment précocement. Les analyses immunobiologiques montrent bien une modification du profil inflammatoire après ITA en faveur d'une immunotolérance impliquant les lymphocytes T régulateurs et la production d'IgG. La voie sublinguale en gouttes apporte des résultats comparables à ceux de la voie sous-cutanée tout en proposant une utilisation plus simple réduisant le risque anaphylactique. Une standardisation des protocoles d'étude en termes de mesure de l'effet thérapeutique et de gradation des effets indésirables est néanmoins nécessaire pour améliorer les études comparatives. Les formes sublinguales en comprimés plus récemment introduites constituent une réelle opportunité pour ouvrir le champ de l'ITA aux ORL dans la RA pollinique et prochainement la RA aux acariens.</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aforl.2017.02.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.aforl.2017.02.005</url></web-urls><pdf-urls><url ppv-ref="no">geoffrey.mortuaire@chru-lille.fr</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170820, Mortuaire G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aforl.2017.02.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oppliger,A.</style></author><author><style face="normal" font="Arial"> Barresi,F.</style></author><author><style face="normal" font="Arial"> Maggi,M.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Huaux,F.</style></author><author><style face="normal" font="Arial"> Hotz,P.</style></author><author><style face="normal" font="Arial"> Dressel,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Work and Health, University of Lausanne, CH-1011 Lausanne, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Association of Endotoxin and Allergens with Respiratory and Skin Symptoms: A Descriptive Study in Laboratory Animal Workers</style></title><secondary-title><style face="normal" font="Arial">Ann Work Expo Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Work Expo Health</style></abbr-1></periodical><pages end="835" start="822">822-835</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritants</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mouse allergen</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">Background: In laboratory animal work, allergens are classically considered to play a prominent role in generation of respiratory and skin symptoms. However, recent development may have changed working conditions and require an updating of preventive measures. Objective: In workers exposed to a range of animals besides laboratory mice and rats the relative role of endotoxin, irritants, and allergens in symptom generation was assessed for updating preventative measures and health surveillance. Methods: Eligible workers were recruited from university units in which exposure to rats and/or mice, occurrence of respiratory and/or skin symptoms, and/or a history of animal bites had been reported. Exposure to endotoxin and rat and mouse allergen was assessed (71 half-day personal samples). 'Symptomatic' was defined by work-related ocular, nasal, respiratory, or skin symptoms. A concentration of specific IgE against rat or mouse (e87 and e88) >/=0.35 kU/l defined sensitization. Sensitivity analyses examined the effect of alternative exposure indicators and definitions of 'sensitized' and 'symptomatic'. Results: From 302 eligible workers, 177 participated. There were 121 and 41 workers in the asymptomatic and non-sensitized and symptomatic but non-sensitized group, respectively. Eight subjects were symptomatic and sensitized. Six sensitized subjects were asymptomatic. One participant could not be assigned to a subgroup. Airborne endotoxin and allergen concentrations were mostly below 20 EU m-3 or the detection limit, respectively. Clinical history showed that irritants and sensitizers other than mouse/rat allergen or endotoxin were a major cause of symptoms. Results were sensitive to the selected exposure indicator and the definition of 'symptomatic'. Conclusions: Health surveillance programs need to be adapted to include a larger range of allergens and pay more attention to irritants</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 2398-7316 (Electronic)IS - 2398-7308 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1093/annweh/wxx048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28810679">PM:28810679</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170816, Oppliger A</style></custom2><misc3><style face="normal" font="Arial">10.1093/annweh/wxx048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arpitha,A.</style></author><author><style face="normal" font="Arial"> Sebastin,S.M.</style></author><author><style face="normal" font="Arial"> Rohit,A.C.</style></author><author><style face="normal" font="Arial"> Girish,K.S.</style></author><author><style face="normal" font="Arial"> Vinod,D.</style></author><author><style face="normal" font="Arial"> Aparna,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">DOS in Biotechnology, University of Mysore, Manasagangotri, Mysore, 570 006, IndiaDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, SE-171 77, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Inhibition of Snake Venom Metalloproteinase by beta-Lactoglobulin Peptide from Buffalo (Bubalus bubalis) Colostrum</style></title><secondary-title><style face="normal" font="Arial">Appl Biochem Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Biochem Biotechnol</style></full-title></periodical><pages end="1432" start="1415">1415-1432</pages><volume><style face="normal" font="Arial">182</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> bioactive peptides</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Buffalo</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Colostrum</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Hemorrhage</style></keyword><keyword><style face="normal" font="Arial"> hemorrhagic</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> Molecular docking</style></keyword><keyword><style face="normal" font="Arial"> molecular interactions</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> proteolytic activity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">Bioactive peptide research has experienced considerable therapeutic interest owing to varied physiological functions, efficacy in excretion, and tolerability of peptides. Colostrum is a rich natural source of bioactive peptides with many properties elucidated such as anti-thrombotic, anti-hypertensive, opioid, immunomodulatory, etc. In this study, a variant peptide derived from beta-lactoglobulin from buffalo colostrum was evaluated for the anti-ophidian property by targeting snake venom metalloproteinases. These are responsible for rapid local tissue damages that develop after snakebite such as edema, hemorrhage, myonecrosis, and extracellular matrix degradation. The peptide identified by LC-MS/MS effectively neutralized hemorrhagic activity of the Echis carinatus venom in a dose-dependent manner. Histological examinations revealed that the peptide mitigated basement membrane degradation and accumulation of inflammatory leucocytes at the venom-injected site. Inhibition of proteolytic activity was evidenced in both casein and gelatin zymograms. Also, inhibition of fibrinolytic and fibrinogenolytic activities was seen. The UV-visible spectral study implicated Zn2+ chelation, which was further confirmed by molecular docking and dynamic studies by assessing molecular interactions, thus implicating the probable mechanism for inhibition of venom-induced proteolytic and hemorrhagic activities. The present investigation establishes newer vista for the BLG-col peptide with anti-ophidian efficacy as a promising candidate for therapeutic interventions</style></abstract><notes><style face="normal" font="Arial">DA - 20170203IS - 1559-0291 (Electronic)IS - 0273-2289 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12010-017-2407-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28155167">PM:28155167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Biochem Biotechnol\2017-182-1415-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Biochem Biotechnol\2017-182-1415-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170203, Arpitha A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12010-017-2407-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barrionuevo,L.</style></author><author><style face="normal" font="Arial"> Ramon,G.D.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Pollen allergic is present in the winter? What pollens formed pollen cloud ?</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="67" start="66">66-67</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2012">2012</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - SPA -CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NTQ5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2012-43-66-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2012-43-66-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20120410, Barrionuevo L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Parisi,C.A.</style></author><author><style face="normal" font="Arial"> Bozzola,M.</style></author><author><style face="normal" font="Arial"> De Gennaro,M.</style></author><author><style face="normal" font="Arial"> Maspero,J.F.</style></author><author><style face="normal" font="Arial"> Lopez,K.</style></author><author><style face="normal" font="Arial"> Aguero,C.</style></author><author><style face="normal" font="Arial"> Gervasoni,M.E.</style></author><author><style face="normal" font="Arial"> Sarragquigne,P.</style></author><author><style face="normal" font="Arial"> Garcia,M.</style></author><author><style face="normal" font="Arial"> Benhabib,O.</style></author><author><style face="normal" font="Arial"> Munoz,E.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Egg allergy in pediatrics. Pediatric Committee document of the Argentina Association of Allergy and Clinical Immunology</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="55" start="41">41-55</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adoption</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth and Development</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2012">2012</year></dates><abstract><style face="normal" font="Arial">Eggs are a source of low cost high biological value protein and complex B vitamins important for the child's nutrition. Culturallyit is one of the staples of our diet and because of this, egg allergy is one of the most common food allergies in childhood and has itsgreatest impact on preschool children. These children represent a vulnerable population because they are at an important stage intheir growth and development and the treatment of this condition generates the adoption of restrictive diets that may impact negativelyon their health and quality of life. This impact is given in part by the ubiquity of their proteins that largely restrict the dietand generates risks of allergic reactions that increase as the child grows and earns greater independence.Given the importance of this issue the Pediatrics Committee conducted an updated review to provide useful tools to manage thiscondition.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NTQ3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2012-43-0041-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2012-43-0041-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20120410, Parisi CA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pendino,P.</style></author><author><style face="normal" font="Arial"> Aguero,C.</style></author><author><style face="normal" font="Arial"> Cavagnero,P.</style></author><author><style face="normal" font="Arial"> Lopez,K.</style></author><author><style face="normal" font="Arial"> Kriunis,I.</style></author><author><style face="normal" font="Arial"> Molinas,J.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Prevalence of allergic sensitization to anemophile pollens in a pediatric population from Granadero Baigorria, Argentina</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="89" start="85">85-89</pages><volume><style face="normal" font="Arial">44</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> fraxinus excelsior</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reactivity</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Sorghum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weeds</style></keyword></keywords><dates><year Day="0" Month="0" Year="2013">2013</year></dates><abstract><style face="normal" font="Arial">Background. Pollens are considered as major source of allergic rhinoconjuntivitisand asthma around the world. However, in pediatric population limitedevidence about its role is available.Aim. To determine the prevalence of skin reactivity to pollens (trees, grassesand weeds) in pediatric patients with diagnosis of allergic rhinitis from GranaderoBaigorria, Argentina.Material and method. A cross-sectional study that evaluated 280 patientsof both sexes from 1 to 10 years of age with diagnosis of persistent allergicrhinitis according to ARIA guidelines. Prick tests were performed to all patientsusing commercial extracts of common pollens in our area (Diater Laboratories,Buenos Aires, Argentina). Seventy patients were included for each group.Skin tests were also carried out on 20 healthy children per group randomlychosen from the same study population as control group.Results. From 280 patients tested, 29 (10.3%) had positive skin tests to at least oneextract of pollen. Grasses account for 47.3% (17 positive). Trees account for 44.4%from total positive prick test (16 positive). Weeds were responsible for 8.3 % (3 positive).Ligustrum lucidum was 10 times positive (27.7%) followed by Cynodon dactylonin 7 (19.4%), Poa annua in 3 (8.3%), Sorghum vulgare in 3 (8.3%), Platanus acerifolia in3 (8.3%), Fraxinus excelsior in 3 (8.3%), Morus alba in 3 (8.3%), Ambrosia elatior in 3(8.3%), and Zea mayz in 1 (2.7%). No patient less than two years was positive.Conclusion. Our study shows that from 280 rhinitis allergic patients, 10.3 %were sensitive to pollens. Trees and grasses were responsible for 91.7 % of totalsensitization. Grasses were the most allergenic pollens. Ligustrum lucidumwas the single most allergenic pollen followed by Cynodon dactylon. Sensitivenessrate to pollens increases with age.Based on these results and previous studies, we could suggest that patientswith allergic rhinitis whose symptoms begin or worse in spring or summershould be tested with pollens.</style></abstract><notes><style face="normal" font="Arial">LA - SPA CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NTI4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2013-44-85-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2013-44-85-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20130720, Pendino P</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gaviot,S.</style></author><author><style face="normal" font="Arial"> Bossio,M.B.</style></author><author><style face="normal" font="Arial"> Daraio,M.C.</style></author><author><style face="normal" font="Arial"> Kahn,A.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Seafood allergy: diagnostic value of skin tests</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="32" start="30">30-32</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Seafood allergy</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2014">2014</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - SPA CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NTIy</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2014-45-30-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2014-45-30-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20140220, Gaviot S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Giacaman,M.M.</style></author><author><style face="normal" font="Arial"> Lopez,C.A.</style></author><author><style face="normal" font="Arial"> Guzman,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Exercise-induced anaphylaxis: a review</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="11" start="7">7-11</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2014">2014</year></dates><abstract><style face="normal" font="Arial">During the last years, there has been an increased incidence of a particulartype of anaphylaxis that only manifests with some kind of physical activityand is known as exercise-induced anaphylaxis. Described for the firsttime in 1979 and defined as a form of physical allergy induced by exercise,alone or associated with other triggers, characterized by a severe reactionwhich appears very suddenly. There is also a subset of patients thatonly presents symptoms if the exercise is carried out within a few hoursof eating. This condition is called exercise-induced anaphylaxis and food intake.The pathogenesis of the exercise-induced anaphylaxis is not fully clear,but several theories have been postulated to explain the final release ofvasoactive mediators. Clinical manifestations do not differ significantly fromother anaphylaxis and can range from cutaneous to airway involvement,anaphylactic shock an even death of the patient. The diagnosis of this diseaseis mainly based in a detailed history in search of all possible predisposingagents, immediate sensitization testing, and challenge tests of exercise, foodor drugs if applicable. The mainstay of treatment is to avoid the triggers,along with the acute management of anaphylaxis.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Chile -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NTE4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2014-45-7-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2014-45-7-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20140220, Giacaman MM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garcia Pavon Osorio,S.</style></author><author><style face="normal" font="Arial"> Cortes Morales,G.</style></author><author><style face="normal" font="Arial"> Hernandez Alvarado,A.M.</style></author><author><style face="normal" font="Arial"> Murillo Najera,F.J.</style></author><author><style face="normal" font="Arial"> Sosa Vazquez,M.</style></author><author><style face="normal" font="Arial"> Mendez Rodriguez,M.L.</style></author><author><style face="normal" font="Arial"> Murata,C.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Usefulness of skin tests and other laboratory tests in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="29" start="23">23-29</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2014">2014</year></dates><abstract><style face="normal" font="Arial">Background. There are different diagnosis tests in the approach of a patient sufferingfrom allergic rhinitis; these have pros and cons, allergists should requestthem considering symptoms and cost-benefit.Objectives. Determine diagnosis utility from total IgE, eosinophils in nasal mucus,eosinophils-cells and skin prick test to identify allergy patients.Materials and methods. We mesured total IgE, eosinophils in nasal mucus, eosinophils-cells and skin prick test in 400 patients with allergic rhinitis and 57 withno allergic rinitis. We described sex, age, total IgE y eosinophils-cells, the positivefrequency and stadistic significance, diagnostic value, correlation and concordanceof different diagnosis tests.Results. Total IgE (p&lt;0.001) and eosinophils in nasal mucus (p=0.005) showedsignificant difference, however both test showed low sensibility. The skin pricktests have more sensibility and specificity than others diagnosis tests, the greaterconcordance was between skin prick test and total IgE. The correlation betweenthree test and skin prick test was low. Total IgE showed greater correlation0.20 (p&lt;0.001) than other test.Conclusions. Total IgE, eosinophils in nasal mucus, eosinophils-cells should notroutilnely because have of its low sensibility and concordance.</style></abstract><notes><style face="normal" font="Arial">LA - SPA CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NTIx</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2014-45-23-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2014-45-23-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20140220, Garcia Pavon Osorio S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bozzola,M.</style></author><author><style face="normal" font="Arial"> Marchetti,P.</style></author><author><style face="normal" font="Arial"> Cosentino,M.</style></author><author><style face="normal" font="Arial"> Corti,M.</style></author><author><style face="normal" font="Arial"> Petriz,N.</style></author><author><style face="normal" font="Arial"> Parisi,C.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Cows milk allergy. An assesment of its spontaneous resolution through double blind placebo controlled challenges.</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="48" start="44">44-48</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> DRACMA</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">Introduction: cow´s milk allergy (cma) is a global health issue. a proper diagnosisand follow up become essential. double blind placebo controlled challenges(dbpcc) is the gold standard for this purpose. this paper describes clinicalevolution and characteristics of cma, as well as variables that may modifythe affection course.methods &amp; material: a group of patients, with a previous diagnosis ofcma by open challenges, has been studied and its results cataloged accordingto dracma guidelines. tests with hemodynamic changes or clinicalsymptoms were considered as positives, while those with no clinicalreaction were considered as negatives. variables involved were: ageof symptoms starting, age of dbpcc performing, gender and cma clinicalmanifestations.results: 106 patients has been studied (50 male, 56 female), with a median ageof 5,31 mo (range 5 - 48 mo) at the starting symptoms, and a median age of23,14 mo (range 5 mo - 5 y) at the performing of dbpcc. 13 tests were negative.as regards to the different immune mechanisms, 55 were ige dependent(8 negative), and 51 were mediated by mixed/cellular (5 negative). patientswere divided into two groups: with gastrointestinal symptoms (n=45)and with no gastrointestinal symptoms (n=61). they showed 6 and 7 negativeresults, respectively. all groups were similar. male gender, and anaphylaxisdiagnosis turned out to be risk factors not to resolve cma (p=0,0125 andp=0,002 respectively).conclusions: cma resolution is independent of the immune mechanisms involvedor the age of its symptoms starting. cma is solved spontaneously towardsthe age of two in 87% of the cases. male gender, and anaphylaxis may becomerisk factors not to resolve cma.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=Mg==</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-44-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-44-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150610, Bozzola M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boudet,R.V.</style></author><author><style face="normal" font="Arial"> Copioli,J.C.</style></author><author><style face="normal" font="Arial"> Damilano,G.</style></author><author><style face="normal" font="Arial"> Muino,J.C.</style></author><author><style face="normal" font="Arial"> Gerez,N.</style></author><author><style face="normal" font="Arial"> Chaig,M.R.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Influence of the type of feeding in the development of cow's milk allergy. Factors involved in the process by which the disease is acquired</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="26" start="20">20-26</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy history</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cigarette smoke</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Young infants</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">Background: The results of the research on the natural history of allergy tocow's milk allergy (CMA) still have not provided a clear picture and consistentthat in practice helps the attending physician. Objective: to identify the factorsinvolved in the development of the disease in young infants, in order to determinespecifi c profi les and predictive clinical indexes. Setting: Río Cuarto, Córdoba,Argentina. Design: observacional and retrospective analysis. Population:91 children with a diagnosis of CMA and 91 controls, of both sexes, underthe age of 6 years. Methods: analysis of selected factors of the clinical histories,their relationship with the individual diagnosis (test X2, Odds Ratios, differencesin average) and their combined impact on the probability of being CMA todetermine profi les (multiple correspondence analysis and logistic regression).Elaboration of 3 predictive indices based on: individual Odds Ratios, correspondingto the logistic regression and the identifi cation of greater and smallercriteria, with its respective evaluation of effectiveness diagnoses (predictivesensitivity, specifi city, values and ROC curve). Results: we found that the ageof onset of symptoms, the type of feeding received until the 3rd month of life,exposure to cigarette smoke, the maternal allergy history and the type of clinicalmanifestations with that begins the CMA, are factors that most likely havean impact on its development. Conclusion: the utility of these profi les and predictiveclinics indexes lies in an early identifi cation of patients at risk of CMA.</style></abstract><notes><style face="normal" font="Arial">LA - SPA CO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=Mzg=</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-20-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-20-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150210, Boudet RV</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez Santos,O.</style></author><author><style face="normal" font="Arial"> Murillo,R.C.</style></author><author><style face="normal" font="Arial"> Laurrabaquio Miranda,A.M.</style></author><author><style face="normal" font="Arial"> Cruz Suarez,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Efficacy and safety of immunotherapy with mite extract in patients with allergic rhinoconjuctivitis and asthma</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="19" start="15">15-19</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> controlled clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Cuba</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> RQLQ</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">To evaluate the effi cacy and safety of subcutaneous immunotherapy (SCIT) adouble-blind placebo controlled clinical trial was performed with mite extractsin 154 patient's 18-years elders, with allergic rhinoconjunctivitis and/or bronchialasthma. The SCIT was administered in an increased dosage phase for a 13week period followed by a maintenance phase with monthly injections. Dilutedsolution injections were given as placebo. Effi cacy was evaluated according toquality of life, medication use, and frequency of crisis. Rhinoconjunctivitis qualityof life questionnaire (RQLQ) and asthma quality of life questionnaire (AQLQ)were applied. Safety was measured according to local and systemic adverseevents. 136 patients completed the study (77 with SCIT and 59 with placebo).In both groups there was an increase in the score of quality of life questionnaires,score was higher in SCIT (p = 0.010). Medication use declined in bothrhinitis and asthma in the SCIT group as in the placebo group with no signifi -cant difference between them (p=0,083). The frequency of rhinoconjunctivitisand asthma crisis decreased in the study group, with a greater reduction in thetreatment group (p=0.027). Slight local and systemic reactions were reportedin SCIT, none in the placebo group, p=0.0003. The results indicate that subcutaneousimmunotherapy with mites is effective and safe in patients with allergicrhinoconjunctivitis and asthma.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Cuba -CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=MzY=</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-15-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-15-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150210, Rodriguez Santos O</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Serra,H.M.</style></author><author><style face="normal" font="Arial"> Santo,S.</style></author><author><style face="normal" font="Arial"> Pereira,M.I.</style></author><author><style face="normal" font="Arial"> Romero,P.</style></author><author><style face="normal" font="Arial"> Cassinerio,A.</style></author><author><style face="normal" font="Arial"> Varela,T.</style></author><author><style face="normal" font="Arial"> Romero,O.</style></author><author><style face="normal" font="Arial"> Orellana,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Total and </style><style face="italic" font="GillSansStd-LightItalic">Dermatophagoides pteronyssinus </style><style face="normal" font="GillSansStd-Light">specific IgE and salivary IgA and leukocyte populations in atopic and nonatopic children with asthma and/or rhinitis</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="105" start="95">95-105</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD8</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> globulins</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Igd</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Informed Consent</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> rast</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Saliva</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">Purpose. To perform an immunologically investigation in children with respiratoryproblems of asthma and/or rhinitis (atopic or non atopic) in order to get a better understanding of the immune system imbalance in these patients. Materials and methods. 47 children of both sexes, aged between 6 and 15 years,who were attended for respiratory diseases at the Division of Allergy and Immunology at Children's Hospital de la Santísima Trinidad from Córdoba city werestudied. According to information obtained on clinical history, physical examination and prick tests they were divided into two groups: Atopics (n=25) and non-atopic (n=22). After parents signed informed consent and children over 7years assent to participate in the research work, samples of blood and saliva were taken to determine immune globulins concentrations and specific activitiesas well as to study leukocyte populations and lymphocytes subpopulations.Results. As expected, levels of total serum IgE and the relative percentages ofblood eosinophils were significantly higher in the group of atopic (A) childrenwith regard to non¬atopic (NA) children. The study of specific serum IgE for Dermatophagoides pteronissynus only showed positive results in the A group,and positive correlations between the levels of total and specific IgE, as well asprick and RAST values. Serum IgG and IgA levels showed no significant differencesbetween both groups. Total salivary IgA concentrations were significantly higher in the group of NA children than in the group of A patients. Surprisingly,when specific salivary IgA for D. pteronyssinus was studied, the opposite wasobserved: Atopic patients have nearly twice specific salivary IgA for this allergenthan the NA children.In the study of T cells subpopulations (CD3, CD4 and CD8), no significant differences between groups were observed. The subpopulations of CD27-B cells andCD27+ B cells were similar in both groups (roughly 80% and 20%, respectively).In both groups, approximately 50% of CD27+ B cells expressed IgD and the remaining50% were IgD-. However, atopic children had less than half B cells expressinghigh density of CD27 molecule (CD27+++) with respect to the NAchildren (p=0.044).Conclusion: Among the immunological parameters investigated, we found significantdifferences between A and NA children in the concentrations of total andspecific IgE and salivary IgA to the allergen, and in a subpopulation of CD27+++B cells. These findings are debated in the discussion of the manuscript.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NDM=</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-95-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-95-105.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150910, Serra HM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guzman,M.A.</style></author><author><style face="normal" font="Arial"> Jiusan,L.M.</style></author><author><style face="normal" font="Arial"> Salgado,N.E.</style></author><author><style face="normal" font="Arial"> Tagle,M.T.</style></author><author><style face="normal" font="Arial"> Suarez,T.M.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Allergen characterization of lupine and its potential importance in food allergy: review article</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="14" start="8">8-14</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen characterization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> lentil</style></keyword><keyword><style face="normal" font="Arial"> Lupine</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Pea</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peas</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">Lupine belongs to the leguminous family, along with peanut, peas, chickpeasand lentils. Lupine fl our has been widely used in some countries for its nutritionaland functional properties, outstanding among them its great proteic value,appropriate proportion of fi ber and carbohydrate content, and its low percentageof fat, thus it has been named by some as the "new soy bean". As itsconsumption has increased, there has also been a raise in the report of adversereactions, such as food allergy, that range from oral allergy syndrome to anaphylaxis.The most relevant clinical cross-reaction occurs with peanut and almondconsumption. Now days there are few studies on general and on atopicpopulation regarding lupine sensitization, furthermore, we hardly know its allergens.The lack of brand identifi cation of lupine in foods is a relevant fact thatmakes even more diffi cult to have a realistic knowledge of this emerging foodallergen and its role in the production of food allergies.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Chile -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=MzU=</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-8-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-8-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150210, Guzman MA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Baillieau,F.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Immunoglobulin E: review and update their role in health and disease</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="66" start="54">54-66</pages><volume><style face="normal" font="Arial">46</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="Arial">The elevation of the values of immunoglobulin e (ige) levels, causing the clinicalsuspicion of an allergic disease, is one of the parameters taken into accountto certify their diagnosis. thus, many doctors only refer patients to an allergistwhen in a routine examination; they observed ige above normal values regardlessif there are symptoms that suggested a mechanism of hypersensitivity.while it is recognized its importance in the pathogenesis of allergic reaction,there are other mechanisms that can mediate this type of reaction. this workattempts to deepen the structural, functional and regulation of ige features, demonstratingthe relevance of their dosage in different allergic diseases allegedlypathogenesis, leading medical thought to immuno-allergic diseases without elevatedige, suspecting a possible physiological role in the absence of disease.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=MTM=</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-54-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2015-46-54-66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20150610, Baillieau F</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Laurrabaquio,A.M.</style></author><author><style face="normal" font="Arial"> Rodriguez Santos,O.</style></author><author><style face="normal" font="Arial"> Olea Zapata,R.</style></author><author><style face="normal" font="Arial"> Celio Murillo,R.</style></author><author><style face="normal" font="Arial"> Rojas Galarza,R.A.</style></author><author><style face="normal" font="Arial"> Gonzalez Saravia,C.A.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Food allergy in an exclusively breastfed infant</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="125" start="121">121-125</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Colic</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cuba</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Hypoallergenic diet</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk powder</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Peru</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">The term food allergy refers to adverse events caused by immunologic mechanism.Food allergy may appear at any stage of life, it is a condition that generallymanifests itself in the baby's excessive crying, colic, vomiting, diarrhea accompaniedby blood and skin eczema. The objective of the research is to demonstrateawareness infant to food allergens received in the mother's womb andthrough the exclusive breastfeeding. The methodology was a case report thatwas suspended exclusive breastfeeding and milk powder was introduced intohypoallergenic Puramino. The total IgE was 1.136 kU/L and allergen specific IgEvalues for milk, egg and peanut higher than 100 kU/L and wheat: 24. 4 kU/L. Itis concluded that cow's milk, egg, peanuts and wheat can sensitize the child duringpregnancy and through the womb. The use of a hypoallergenic diet duringthe infant can reverse the process.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -CO - Cuba -CO - Peru -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NTgz</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2016-47-121-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2016-47-121-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Laurrabaquio AM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Birri,M.</style></author><author><style face="normal" font="Arial"> Nuncira,T.</style></author><author><style face="normal" font="Arial"> Dib,M.</style></author><author><style face="normal" font="Arial"> Serra,M.T.</style></author><author><style face="normal" font="Arial"> Agnese,M.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Sensitizen by aeroalergens study with special focus on polinosis as sensitizen factor</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="62" start="57">57-62</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background. Allergies are important in Public Health, among the different typesPollen sensitivity, as hypersensitivity to pollen, are pathologies affecting part ofthe population. Objective. To appreciate the importance of the Pollen sensitivityproblem in our region and to relate them to Rhinitis, Asthma, IgE values, andother allergies. Setting. Allergy and Immunology Service (AAIS) of the HospitalNacional de Clinicas (HNC), in Cordoba city, Central Region of the country.Design. A Cross-sectional study was developed. This is a descriptive study ofusefulness for the healthcare administrator because it allows estimating the diseaseburden significance on the population. It lets to know the sickness Prevalence(P). Population. Clinical Histories (CH) of the patients that attended theAAIS, located in Cordoba city were analyzed. Methods. CH of the patients thatattended the AAIS during the years 2008 and 2009 and that the Prick Test wascarried out, were processed by using the 2000 Epi-Info Program, 3.3.2. version.Statistically, Chi-square and Confidence Interval were calculated. Results.The Prevalence of Pollen sensitivity was 51.96%. From the total sample, 24.24%was monosensitized patients. Among them, 12.5% were monosensitized to pollens.The rest of the sample (75.76%) were poly-sensitized, from these, 65.33%were sensitized to pollens.Conclusion. Analyzing the obtained Prevalence emerges that Pollen sensitivityrepresent a problematic that affect more than a half of the studied population.Also it was observed that the pathology presented a comorbidity associatedto other types of allergy produced by mites or fungus, among others, forthe majority of the patients.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NDY5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2016-47-57-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2016-47-57-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160610, Birri M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Spagnolo,S.</style></author><author><style face="normal" font="Arial"> Deriugin,A.</style></author><author><style face="normal" font="Arial"> Carignano,C.</style></author><author><style face="normal" font="Arial"> Murray,M.G.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Study of the prevalence of allergic diseases refered by two groups of population in the City of Bahia Blanca</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="13" start="6">6-13</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="Arial">Background. The natural biological pollution can cause or exacerbate allergies.A continuous monitoring of pollen grains is performed in Bahía Blanca city since1994. However, due to the lack of systematic information of these allergicdiseases it is unknown whether there is or not a relationship between pollutioneffects and disease prevalence in the local population.Objective. Determine the prevalence of allergic diseases and its associatedsymptoms in two groups of people in Bahía Blanca's city.Location. Bahía Blanca's city hall and National University of the South.Design. Cross-sectional study, implementing a survey and taking a representativesample of each group.Population. Municipal employees and university population.Method. It was elaborated an ad hoc survey, including questions from the ISAACquestionnaire. The R software was used for all the analysis, in order to performa logistic regression analysis. The odds ratio and its corresponding p value(CI95% and 2% error) were used in order to analyze the diseases index.Results. The 22.72% of the interviewed mentioned to suffer some diagnosedallergic disease. The 53.13% of those who showed symptoms denied sufferingfrom any disease. Statistically significant association was observed betweenconjunctivitis and own pets (OR=2.5; p=0.02); and between SIR and the presenceof damp walls (OR=1.8; p&lt;0.05). The logistic regression analysis showedan association between allergic disease and family history of the same disease(p=3.97 e-16) and between asthma or SIA and smoking habits (p=0.0002).Conclusions. The prevalence found for each allergic disease and its investigatedsymptoms agreed with those previously found in other local studies. There wasa high sub-diagnosis manifested in reference to associated symptoms.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=Mzg2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2016-47-6-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2016-47-6-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160210, Spagnolo S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Laurrabaquio,A.M.</style></author><author><style face="normal" font="Arial"> Olea Zapata,R.</style></author><author><style face="normal" font="Arial"> Rodriguez Santos,O.</style></author><author><style face="normal" font="Arial"> Celio Murillo,R.</style></author><author><style face="normal" font="Arial"> Gonzales Saravia,C.A.</style></author><author><style face="normal" font="Arial"> Rojas Galarza,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="GillSansStd-Light">Efficacy and safety of immunotherapy in food allergy</style></title><secondary-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Alerg Inmunol Clin</style></full-title></periodical><pages end="117" start="112">112-117</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chymotrypsin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Cuba</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Microwave</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peru</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Security</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The treatment of food allergy is to educate the patient to avoid ingestion and, when it is not possible, to use, among other procedures, the immunotherapy with the offending food. The objective of this review is to present evidence on efficacy and safety of immunotherapy in food allergy and recommended for implementation pathways. It was accessed databases with describer's immunotherapy, food allergy, pathways, desensitization, efficacy and safety. The OIT from microwave hot milk was effective with good safety profile in children with CM. Chymotrypsin inhibits the formation of âLg and is a new candidate for oral immunotherapy CM. The OIT with milk and omalizumab has shown significant improvement in security measures, but not in the efficacy results.OIT in children with egg allergy develop tolerance decreasing the risk of allergic reactions. It has also increased tolerance uncooked egg. In peanut allergy desensitization induced OIT in children and resulted in a significant increase intolerance with good safety profile. The co-administration of probiotic Lactobacillusrhamnosus with peanut OIT was effective in inducing immune unresponsivenessand sustained changes. It is concluded that the OIT can be an effective and safe for allergy to milk, egg and peanut route. Protocols show different results in efficacy and safety so more clinical trials are required.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Peru -CO - Cuba -CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.archivos.org.ar/contenido/art.php?recordID=NTgx</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2016-47-112-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Alerg Inmunol Clin\2016-47-112-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160910, Laurrabaquio AM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iwasaki,N.</style></author><author><style face="normal" font="Arial"> Yoshimoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Graduate School of Medicine, Osaka City UniversityDepartment of Immunology, Hyogo College of Medicine</style></auth-address><titles><title><style face="normal" font="Arial">Endotoxins induce IgE-independent nasal hypersensitivity.</style></title><secondary-title><style face="normal" font="Arial">Arerugi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arerugi</style></full-title></periodical><pages end="944" start="936">936-944</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cities</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Endotoxins</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170821IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.15036/arerugi.66.936</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28824035">PM:28824035</url></web-urls></urls><custom2><style face="normal" font="Arial">20170821, Iwasaki N</style></custom2><misc3><style face="normal" font="Arial">10.15036/arerugi.66.936</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calabrese,L.H.</style></author><author><style face="normal" font="Arial"> Kavanaugh,A.</style></author><author><style face="normal" font="Arial"> Yeo,A.E.</style></author><author><style face="normal" font="Arial"> Lipsky,P.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cleveland Clinic, Department of Rheumatic &amp; Immunologic Diseases, Cleveland, OH, 44195, USA</style></auth-address><titles><title><style face="normal" font="Arial">Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout</style></title><secondary-title><style face="normal" font="Arial">Arthritis Res Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arthritis Res Ther</style></full-title></periodical><pages end="" start="191">191-</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gout</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Uric Acid</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: To assess frequency and distribution of infusion reactions (IRs) in responders and nonresponders in randomized clinical trials (RCTs) of intravenous pegloticase and the utility of the National Institute of Allergy and Infectious Disease/Food and Allergy and Anaphylaxis Network (NIAID/FAAN) criteria for identifying anaphylaxis in subjects experiencing IRs. METHODS: IRs from two RCTs of pegloticase were evaluated and categorized as anaphylaxis, hypersensitivity, or other. Serum levels of tryptase and total hemolytic complement (CH50) were evaluated at the time of all IRs. Frequency of IRs by each category was evaluated in all subjects, responders or nonresponders to pegloticase. RESULTS: There were 113 IRs in 1695 infusions. Of the 113 IRs, 6 met criteria for anaphylaxis, 53 had one feature of anaphylaxis and were designated as "hypersensitivity", and 54 had no features and were designated "other". In subjects receiving pegloticase every 2 weeks (Q2w), a total of 852 infusions were administered and the IR frequency was 0.5% in responders and 9.7% in nonresponders. In subjects receiving pegloticase every 4 weeks (Q4w), a total of 846 infusions were given and the IR frequency was 2.6% in responders and 12.2% in nonresponders. There were no differences among the three categories of IRs with regard to clinical course or biochemical evidence of immune activation determined by CH50 or tryptase levels. CONCLUSION: IRs mostly occurred in nonresponders. NIAID/FAAN criteria for anaphylaxis did not identify pegloticase-related IRs as having a higher frequency of immune activation or a more severe course. The results are consistent with the conclusion that discontinuance of pegloticase if uric acid rises to >6 mg/dL will decrease the frequency of IRs</style></abstract><notes><style face="normal" font="Arial">DA - 20170818IS - 1478-6362 (Electronic)IS - 1478-6354 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13075-017-1396-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28818095">PM:28818095</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arthritis Res Ther\2017-19-191.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arthritis Res Ther\2017-19-191.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170818, Calabrese LH</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13075-017-1396-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dore,K.A.</style></author><author><style face="normal" font="Arial"> Davies,A.M.</style></author><author><style face="normal" font="Arial"> Drinkwater,N.</style></author><author><style face="normal" font="Arial"> Beavil,A.J.</style></author><author><style face="normal" font="Arial"> McDonnell,J.M.</style></author><author><style face="normal" font="Arial"> Sutton,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">King's College London, Randall Division of Cell and Molecular Biophysics, New Hunt's House, London SE1 1UL, United Kingdom; Medical Research Council &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Thermal sensitivity and flexibility of the Cepsilon3 domains in immunoglobulin E</style></title><secondary-title><style face="normal" font="Arial">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochim Biophys Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic mechanism</style></keyword><keyword><style face="normal" font="Arial"> Allergic mechanisms</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> dimer</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin E (IgE) is the antibody that plays a central role in the mechanisms of allergic diseases such as asthma. Interactions with its receptors, FcepsilonRI on mast cells and CD23 on B cells, are mediated by the Fc region, a dimer of the Cepsilon2, Cepsilon3 and Cepsilon4 domains. A sub-fragment lacking the Cepsilon2 domains, Fcepsilon3-4, also binds to both receptors, although receptor binding almost exclusively involves the Cepsilon3 domains. This domain also contains the N-linked glycosylation site conserved in other isotypes. We report here the crystal structures of IgE-Fc and Fcepsilon3-4 at the highest resolutions yet determined, 1.75A and 2.0A respectively, revealing unprecedented detail regarding the carbohydrate and its interactions with protein domains. Analysis of the crystallographic B factors of these, together with all earlier IgE-Fc and Fcepsilon3-4 structures, shows that the Cepsilon3 domains exhibit the greatest intrinsic flexibility and quaternary structural variation within IgE-Fc. Intriguingly, both well-ordered carbohydrate and disordered polypeptide can be seen within the same Cepsilon3 domains. A simplified method for comparing the quaternary structures of the Cepsilon3 domains in free and receptor-bound IgE-Fc structures is presented, which clearly delineates the FcepsilonRI and CD23 bound states. Importantly, differential scanning fluorimetric analysis of IgE-Fc and Fcepsilon3-4 identifies Cepsilon3 as the domain most susceptible to thermally-induced unfolding, and responsible for the characteristically low melting temperature of IgE</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbapap.2017.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28844738">PM:28844738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\20170828-DoreKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\20170828-DoreKA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Dore KA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbapap.2017.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Trampert,D.C.</style></author><author><style face="normal" font="Arial"> Hubers,L.M.</style></author><author><style face="normal" font="Arial"> van de Graaf,S.F.J.</style></author><author><style face="normal" font="Arial"> Beuers,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology &amp; Hepatology, Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease</style></title><secondary-title><style face="normal" font="Arial">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochim Biophys Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergen specific IgG4</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgG4</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholangitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Melanoma</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Pemphigus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">The pathophysiology of immunoglobulin G4-related disease (IgG4-RD) and its most common manifestations, IgG4-associated (sclerosing) cholangitis and autoimmune pancreatitis, remains largely unknown, but IgG4 is presumably involved. IgG4 is a promiscuous antibody, which could be directly pathogenic, fulfill a protective role, or could just be a fortuitous marker of an aberrant inflammatory response. IgG4 antibodies possess exclusive structural and functional characteristics suggesting anti-inflammatory and tolerance-inducing effects. By studying the role of IgG4 in other inflammatory conditions, namely hypersensitivity and allergies, autoimmune and immune-mediated diseases, infections and malignancies, new insights can be obtained increasing our understanding of the role of IgG4 antibodies in IgG4-RD. Beekeepers, animal laboratory workers and individuals undergoing allergen immunotherapy possess high serum levels of allergen-specific IgG4, which exhibit immunosuppressive functions, protecting the individual from anaphylactic reactions. In autoimmune/immune-mediated diseases, such as pemphigus vulgaris, pemphigus foliaceus and MuSK-myasthenia gravis, IgG4 autoantibodies are pathogenic. Regarding malignancies such as melanoma and cholangiocarcinoma or helminthic infections, IgG4 antibodies inhibit clearance of tumor cells or the invader, respectively. Translating these findings to IgG4-RD, IgG4 alone can implement pathogenic effects and structural damage, but may also function as a protective antibody dampening the more harmful effects of IgG1 when directed against the same epitopes. This article is part of a Special Issue entitled: Cholangiocytes in Health and Disease edited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbadis.2017.07.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782655">PM:28782655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\20170807-TrampertDC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\20170807-TrampertDC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Trampert DC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbadis.2017.07.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Karhu,T.</style></author><author><style face="normal" font="Arial"> Akiyama,K.</style></author><author><style face="normal" font="Arial"> Vuolteenaho,O.</style></author><author><style face="normal" font="Arial"> Bergmann,U.</style></author><author><style face="normal" font="Arial"> Naito,T.</style></author><author><style face="normal" font="Arial"> Tatemoto,K.</style></author><author><style face="normal" font="Arial"> Herzig,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Unit of Biomedicine, University of Oulu, Oulu, Finland; Biocenter Oulu, University of Oulu, Oulu, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Mast cell degranulation via MRGPRX2 by isolated human albumin fragments</style></title><secondary-title><style face="normal" font="Arial">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochim Biophys Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> synthetic peptides</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mast cells are important modulators of the human immune system via their release of several inflammatory mediators and proteases. The release can be activated by different pathways: the classical immunoglobulin E-dependent pathway and by the non-immunological immunoglobulin E-independent pathway. MAS-related G protein-coupled receptor X2 (MRGPRX2) is expressed in mast cells and it is one of the endogenous receptor responsible for the IgE-independent activation of human mast cell. The MRGPRX2 is classified as orphan receptor and unlike most GPCRs, the MRGPRX2 recognizes a wide range of basic molecules. Thus, there still might be several unknown ligands for the receptor. METHODS: MRGPRX2 activating peptides were isolated from human plasma using consecutive HPLC purification steps. The isolation process was monitored with MRGPRX2 transfected HEK 293 cells. The isolated peptides were sequenced by MS and synthetized. The synthetic peptides were used to determine degranulation of the LAD 2 mast cell line by measuring beta-hexosaminidase release. RESULTS: Three endogenous MRGPRX2 activating peptides were isolated from human plasma. These peptides are identified as fragments of albumin. The isolated fragments activate MRGPRX2 and degranulate MRGPRX2 expressing human mast cell line LAD 2 in dose-dependent manner. CONCLUSIONS: The isolated basic peptides generated from human albumin are able to degranulate mast cells via the MRGPRX2. General significance These endogenous albumin fragments, cleaved from albumin by mast cell secreted proteases, provide a possible pathway for self-perpetuating mast cell dependent inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Japan -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbagen.2017.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28844982">PM:28844982</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\20170828-KarhuT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\20170828-KarhuT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Karhu T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbagen.2017.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Y.</style></author><author><style face="normal" font="Arial"> Yin,X.</style></author><author><style face="normal" font="Arial"> Yi,J.</style></author><author><style face="normal" font="Arial"> Peng,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Ophthalmology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">MiR-146a overexpression effectively improves experimental allergic conjunctivitis through regulating CD4+CD25-T cells</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="943" start="937">937-943</pages><volume><style face="normal" font="Arial">94</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> miR-146a</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To study the mechanism of miR-146a in the regulation of allergic conjunctivitis (AC) through CD4+CD25-T cells. METHODS: BALB/c mice were sensitized with ragweed pollen (RW) and alum, and then challenged with RW. Eosinophil infiltration was determined using Giemsa assay. ELISA assay was performed to examine the level of antigen-specific IgE in the serum and cytokine levels in splenocytes. The expression of miR-146a was measured by qRT-PCR. Flow cytometric analysis was used to analyze the percentage of CD4+CD25-T cells and Tregs. RESULTS: In this study, we found that miR-146a overexpression could effectively improve the symptoms of AC in mouse models. Moreover, in vitro experiments, the proliferation of splenocytes was controlled and the expression of IL-5 and IL-13 was also decreased after transfected with miR-146a mimic. In addition, the inhibitory effect of Tregs on Tcons was affected by the change of miR-146a content in Tcons and had a positive correlation effect. When the content of miR-146a in Tregs changed, the inhibition was not affected. In addition, when inhibited miR-146a, NF-kappaB signaling pathway was activated, and the expression of IL-5 and IL-13 in Tcons increased. While after added Bay (NF-kappaB blocker), the NF-kappaB activity was decreased, and the expression of IL-5 and IL-13 in Tcons also reduced. CONCLUSION: MiR-146a decreased in Tcons was contributed to the development of AC through regulating the inhibitory effect of Tregs on Tcons and NF-kappaB signaling pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.07.157</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28810531">PM:28810531</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-94-937-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-94-937-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Yang Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.07.157</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mukherjee,A.A.</style></author><author><style face="normal" font="Arial"> Kandhare,A.D.</style></author><author><style face="normal" font="Arial"> Rojatkar,S.R.</style></author><author><style face="normal" font="Arial"> Bodhankar,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Paud Road, Pune, 411 038, India</style></auth-address><titles><title><style face="normal" font="Arial">Ameliorative effects of Artemisia pallens in a murine model of ovalbumin-induced allergic asthma via modulation of biochemical perturbations</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="889" start="880">880-889</pages><volume><style face="normal" font="Arial">94</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Nrf-2</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Asthma is a chronic, heterogeneous airway disorder characterized by airway inflammatory and remodeling. Artemisia pallens has been reported to possess antioxidant, anti-inflammatory and Anti-allergic potential. OBJECTIVE: To evaluate the anti-asthmatic effects of methanolic extract of Artemisia pallens (APME) against ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) in rats. MATERIALS AND METHOD: AHR was induced in male Sprague-Dawley rats (180-200g) by intraperitoneal (i.p.) injection of OVA and boosted with an identical OVA solution (s.c.) on day 7. Rats were either treated orally with vehicle (10mg/kg), montelukast (10mg/kg) or APME (100, 200 and 400mg/kg) for next 28days. At the end treatments, various biochemical, molecular (RT-PCR and ELISA analysis) and histological parameters were evaluated. RESULTS: APME (200 and 400mg/kg) significantly attenuated (p&lt;0.05) OVA-induced alteration in lung functions measured by Whole-body plethysmography. Increased Bronchoalveolar Lavage (BAL) fluid differential cell count, as well as total protein and albumin in BAL fluid and lungs, was significantly decreased (p&lt;0.05) by APME. It also significantly attenuated (p&lt;0.05) elevated lung oxido-nitrosative stress, myeloperoxidase, and serum IgE levels. OVA-induced down-regulation in lung Nrf2 and upregulation in TNF-alpha, IL-1beta, IL-4, IL-6, TGF-beta mRNA expression was significantly attenuated (p&lt;0.05) by APME (200 and 400mg/kg) treatment. Histopathological analysis of lung tissue showed that APME treatment reduced OVA-induced inflammatory influx and fibrosis. CONCLUSION: Artemisia pallens simultaneously orchestrate plethora of mechanisms viz. modulations of IgE, TGF-beta, TNF-alpha, IL's and Nrf-2 levels to exhibit its anti-asthmatic potential in OVA-induced AHR in rats</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28810518">PM:28810518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-94-880-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-94-880-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Mukherjee AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.08.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahammer,L.</style></author><author><style face="normal" font="Arial"> Grutsch,S.</style></author><author><style face="normal" font="Arial"> Wallner,M.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Tollinger,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Organic Chemistry, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria</style></auth-address><titles><title><style face="normal" font="Arial">NMR resonance assignments of a hypoallergenic isoform of the major birch pollen allergen Bet v 1</style></title><secondary-title><style face="normal" font="Arial">Biomol NMR Assign</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomol NMR Assign</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1.0101</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1.0102</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Relaxation</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="8" Year="2017">2017/8/14</year></dates><abstract><style face="normal" font="Arial">In Northern America and Europe a great number of people are suffering from birch pollen allergy and pollen related food allergies. The trigger for these immunological reactions is the 17.5 kDa major birch pollen allergen Bet v 1, which belongs to the family of PR-10 (pathogenesis-related) proteins. In nature, Bet v 1 occurs as a mixture of various isoforms that possess different immunological properties despite their high sequence identities. Bet v 1.0102 (Bet v 1d), which is investigated here, is a hypoallergenic isoform of Bet v 1 and a potential candidate for allergen-specific immunotherapy. We assigned the backbone and side chain 1H, 13C and 15N resonances of this protein and predicted its secondary structure. The NMR-chemical shift data indicate that Bet v 1.0102 is composed of three alpha-helices and a seven stranded beta-sheet, in agreement with the known structure of the hyperallergenic isoform Bet v 1.0101 (Bet v 1a). Our resonance assignments create the foundation for detailed characterization of the dynamic properties of Bet v 1 isoforms by NMR relaxation measurements</style></abstract><notes><style face="normal" font="Arial">DA - 20170815IS - 1874-270X (Electronic)IS - 1874-270X (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12104-017-9754-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28808910">PM:28808910</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomol NMR Assign\20170815-AhammerL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomol NMR Assign\20170815-AhammerL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170815, Ahammer L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12104-017-9754-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hiraide,E.</style></author><author><style face="normal" font="Arial"> Morinaga,M.</style></author><author><style face="normal" font="Arial"> Hidaka,H.</style></author><author><style face="normal" font="Arial"> Yamada,S.</style></author><author><style face="normal" font="Arial"> Takeyama,J.</style></author><author><style face="normal" font="Arial"> Kitamura,N.</style></author><author><style face="normal" font="Arial"> Kaminuma,O.</style></author><author><style face="normal" font="Arial"> Hiroi,T.</style></author><author><style face="normal" font="Arial"> Du,W.</style></author><author><style face="normal" font="Arial"> Ohashi-Doi,K.</style></author><author><style face="normal" font="Arial"> Nakajima-Adachi,H.</style></author><author><style face="normal" font="Arial"> Hachimura,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Research Center for Food Safety, Graduate School of Agricultural and Life Sciences , The University of Tokyo , Tokyo , Japan</style></auth-address><titles><title><style face="normal" font="Arial">Oral administration of ovalbumin after sensitization attenuates symptoms in a mouse model of food allergic enteropathy</style></title><secondary-title><style face="normal" font="Arial">Biosci Biotechnol Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biosci Biotechnol Biochem</style></full-title></periodical><pages end="1972" start="1967">1967-1972</pages><volume><style face="normal" font="Arial">81</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Loss</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="Arial">Oral immunotherapy (OIT) is a promising treatment of food allergy. To administer an appropriate oral dose of an allergenic component as OIT to individuals sensitized with a food allergen may prevent inducing food allergic inflammation in them. So we attempted to establish a mouse model to evaluate efficacy for oral administration of food allergen after sensitization. In BALB/c mice sensitized by injecting ovalbumin (OVA) with alum twice, OVA was administered before inducing inflammation by feeding the mice with egg white (EW) diet. Severe inflammatory responses, such as enteropathy, weight loss, IL-4 production, and increase of IgE antibody levels, were suppressed by administration with 4 mg of OVA 7 times before feeding EW diet. OVA administration alone induced a slight Th2 response, but no symptoms. The current study demonstrated that severe food allergic enteropathy could be prevented by pre-administration with appropriate dose of OVA to sensitized mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1347-6947 (Electronic)IS - 0916-8451 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/09168451.2017.1361806</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28812470">PM:28812470</url></web-urls><pdf-urls><url ppv-ref="no">ahachi@mail.ecc.u-tokyo.ac.jp</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170816, Hiraide E</style></custom2><misc3><style face="normal" font="Arial">10.1080/09168451.2017.1361806</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,L.</style></author><author><style face="normal" font="Arial"> Xu,J.</style></author><author><style face="normal" font="Arial"> Chu,X.</style></author><author><style face="normal" font="Arial"> Ju,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Yuhuangding Hospital, Yangtai, China</style></auth-address><titles><title><style face="normal" font="Arial">Micro RNA-98 interferes with Thrombospondin 1 expression in peripheral B cells of patients with asthma</style></title><secondary-title><style face="normal" font="Arial">Biosci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biosci Rep</style></full-title></periodical><pages end="" start="BSR20170149">BSR20170149-</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="Arial">Thrombospondin 1 (TSP1)-producing B cells are an important immune regulatory cell fraction in the body, which are compromised in a number of immune diseases. Micro RNAs (miR) are involved in the immune regulation. This study aims to elucidate the mechanism by which miR-98 interferes with the expression of TSP1 in B cells of the peripheral blood system. In this study, peripheral blood samples were collected from patients with allergic asthma. The B cells were isolated from the blood samples to be analyzed for the expression of miR-98 and TSP1. The results showed that the levels of miR-98 were higher, the levels of TSP1 were lower, in B cells isolated from the peripheral blood in patients with asthma. A negative correlation was identified between the data of miR-98 and TSP1 in B cells. Exposure to T helper (Th)2 cytokine, interleukin (IL)-13, increased the expression of miR-98 and suppressed the expression of TSP1 in peripheral B cells, which was abolished by knocking down the miR-98 gene. In conclusion, miR-98 can suppress the expression of TSP1 in the peripheral B cells of patients with allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1573-4935 (Electronic)IS - 0144-8463 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1042/BSR20170149</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28760845">PM:28760845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biosci Rep\2017-37-BSR20170149.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biosci Rep\2017-37-BSR20170149.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Chen L</style></custom2><misc3><style face="normal" font="Arial">10.1042/BSR20170149</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rathinam,M.</style></author><author><style face="normal" font="Arial"> Singh,S.</style></author><author><style face="normal" font="Arial"> Pattanayak,D.</style></author><author><style face="normal" font="Arial"> Sreevathsa,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">ICAR-National Research Centre on Plant Biotechnology, LBS Centre, Pusa Campus, New Delhi, 110012, India</style></auth-address><titles><title><style face="normal" font="Arial">Comprehensive in silico allergenicity assessment of novel protein engineered chimeric Cry proteins for safe deployment in crops</style></title><secondary-title><style face="normal" font="Arial">BMC Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Biotechnol</style></full-title></periodical><pages end="" start="64">64-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Chimeric Proteins</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat stability</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Physico-chemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Engineering</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Unintended effects</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Development of chimeric Cry toxins by protein engineering of known and validated proteins is imperative for enhancing the efficacy and broadening the insecticidal spectrum of these genes. Expression of novel Cry proteins in food crops has however created apprehensions with respect to the safety aspects. To clarify this, premarket evaluation consisting of an array of analyses to evaluate the unintended effects is a prerequisite to provide safety assurance to the consumers. Additionally, series of bioinformatic tools as in silico aids are being used to evaluate the likely allergenic reaction of the proteins based on sequence and epitope similarity with known allergens. RESULTS: In the present study, chimeric Cry toxins developed through protein engineering were evaluated for allergenic potential using various in silico algorithms. Major emphasis was on the validation of allergenic potential on three aspects of paramount significance viz., sequence-based homology between allergenic proteins, validation of conformational epitopes towards identification of food allergens and physico-chemical properties of amino acids. Additionally, in vitro analysis pertaining to heat stability of two of the eight chimeric proteins and pepsin digestibility further demonstrated the non-allergenic potential of these chimeric toxins. CONCLUSIONS: The study revealed for the first time an all-encompassing evaluation that the recombinant Cry proteins did not show any potential similarity with any known allergens with respect to the parameters generally considered for a protein to be designated as an allergen. These novel chimeric proteins hence can be considered safe to be introgressed into plants</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1472-6750 (Electronic)IS - 1472-6750 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12896-017-0384-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28768539">PM:28768539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Biotechnol\2017-17-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Biotechnol\2017-17-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Rathinam M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12896-017-0384-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tang,X.</style></author><author><style face="normal" font="Arial"> Nian,H.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author><author><style face="normal" font="Arial"> Shi,H.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Liu,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Beijing Key Lab of TCM Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, No.10 Xitoutiao, Youanmenwai, Fengtai District, Beijing, 100069, China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of the combined extracts of Herba Epimedii and Fructus Ligustrilucidi on airway remodeling in the asthmatic rats with the treatment of budesonide</style></title><secondary-title><style face="normal" font="Arial">BMC Complement Altern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMC Complement Altern Med</style></abbr-1></periodical><pages end="" start="380">380-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> airflow limitation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Perfusion</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Smad</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> TCM</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is characterized by chronic airway inflammation, leading to structura1 changes in the airway, collectively termed airway remodeling. Airway remodeling is thought to contribute to airway hyper responsiveness and irreversible airflow limitation. The combination of Herba Epimedii (HE) and Fructus Ligustri Lucidi (FLL) decoction and the systemic administration of glucocorticoids (GC) had a synergistic inhibitory action on airway inflammation in the asthmatic model rats. However, the effects of the combination on airway remodeling have not been studied and compared. In the present study, we investigated the effects of the co-administration of combined extracts of HE and FLL with inhaled GC (budesonide) on airway remodeling in the rat asthmatic model induced by ovalbumin (OVA). METHODS: Male Sprague-Dawley rats were sensitized to intraperitoneal OVA followed by repetitive OVA challenge for 7 weeks. Treatments included extracts of HE and FLL (Extracts for short, 100 mg/kg by gastric perfusion), budesonide (1 mg budesonide suspension in 50 ml sterile physiological saline, 3 rats in an ultrasonic nebulizer by nebulized inhabation with a flow of 1.6 ml/min for 30 min), and co-administration of extracts of HE and FLL with budesonide (Co-administration for short) for 4 weeks. Lung histomorphometry and bronchoalveolar lavage fluid (BALF) cell count were assessed 24 h after the final OVA challenge. Levels of interleukin (IL)-4, IL-5 and IgE were measured by ELISA. Expressions of Collagen I and Collagen III were tested by immunohistology. Expressions of transforming growth factor (TGF) -beta1, TGF-beta2 and Smads mRNA were measured by quantitative real-time PCR. RESULTS: Extracts, budesonide and Co-administration significantly reduced allergen-induced increases in the serum levels of IL-4, IL-5 and IgE, the number of eosinophils in BALF, goblet cell hyperplasia, Collagen III integral optical density (IOD) and the mRNA expression of TGF-beta2 and Smad2. Extracts and Co-administration could depress the IOD level of Collagen I and the positive area of Collagen I and Collagen III. Budesonide and Co-administration significantly alleviated the thickening of airway wall. Only Co-administration significantly decreased collagen deposition according to the morphometry of Masson's-stained lung sections, the thickening of airway smooth muscle layer, the number of lymphocytes in BALF and the mRNA expression of TGF-beta1 and Smad3, and this was associated with a significant increase in levels of Smad7 mRNA. CONCLUSIONS: The findings suggested that the combination of budesonide and the herbal extracts had a better synergistic effect on airway remodeling in OVA-reduced asthma rats than the single use of budesonide</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 1472-6882 (Electronic)IS - 1472-6882 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12906-017-1891-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28764781">PM:28764781</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Complement Altern Med\2017-17-380.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Complement Altern Med\2017-17-380.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Tang X</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12906-017-1891-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mattiucci,S.</style></author><author><style face="normal" font="Arial"> Paoletti,M.</style></author><author><style face="normal" font="Arial"> Colantoni,A.</style></author><author><style face="normal" font="Arial"> Carbone,A.</style></author><author><style face="normal" font="Arial"> Gaeta,R.</style></author><author><style face="normal" font="Arial"> Proietti,A.</style></author><author><style face="normal" font="Arial"> Frattaroli,S.</style></author><author><style face="normal" font="Arial"> Fazii,P.</style></author><author><style face="normal" font="Arial"> Bruschi,F.</style></author><author><style face="normal" font="Arial"> Nascetti,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health and Infectious Diseases, Section of Parasitology, "Sapienza University of Rome" and "Umberto I" Teaching Hospital, P.le Aldo Moro, 5, 00185, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Invasive anisakiasis by the parasite Anisakis pegreffii (Nematoda: Anisakidae): diagnosis by real-time PCR hydrolysis probe system and immunoblotting assay</style></title><secondary-title><style face="normal" font="Arial">BMC Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Infect Dis</style></full-title></periodical><pages end="" start="530">530-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis pegreffii</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA sequencing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fish-borne</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Granuloma</style></keyword><keyword><style face="normal" font="Arial"> granulomas</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Intestinal biopsy</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mtDNA</style></keyword><keyword><style face="normal" font="Arial"> Nematoda</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> Teaching</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zoonosis</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anisakiasis is a fish-borne zoonosis caused by Anisakis spp. larvae. One challenging issue in the diagnosis of anisakiasis is the molecular detection of the etiological agent even at very low quantity, such as in gastric or intestinal biopsy and granulomas. Aims of this study were: 1) to identify three new cases of invasive anisakiasis, by a species-specific Real-time PCR probe assay; 2) to detect immune response of the patients against the pathogen. METHODS: Parasite DNA was extracted from parasites removed in the three patients. The identification of larvae removed at gastric and intestinal level from two patients was first obtained by sequence analysis of mtDNA cox2 and EF1 alpha-1 of nDNA genes. This was not possible in the third patient, because of the very low DNA quantity obtained from a single one histological section of a surgically removed granuloma. Real-time PCR species-specific hydrolysis probe system, based on mtDNA cox2 gene, was performed on parasites tissue of the three cases. IgE, IgG4 and IgG immune response against antigens A. pegreffii by Immunoblotting assay was also studied. RESULTS: According to the mtDNA cox2 and the EF1 alpha - 1 nDNA sequence analysis, the larvae from stomach and intestine of two patients were assigned to A. pegreffii. The Real-time PCR primers/probe system, showed a fluorescent signal at 510 nm for A. pegreffii, in all the three cases. In Immunoblotting assay, patient CC1 showed IgE, IgG4 reactivity against Ani s 13-like and Ani s 7-like; patient CC2 revealed only IgG reactivity against Ani s 13-like and Ani s 7-like; while, the third patient showed IgE and IgG reactivity against Ani s 13-like, Ani s 7-like and Ani s 1-like. CONCLUSION: The Real-time PCR assay, a more sensitive method than direct DNA sequencing for the accurate and rapid identification of etiological agent of human anisakiasis, was successfully assessed for the first time. The study also highlights the importance to use both molecular and immunological tools in the diagnosis of human anisakiasis, in order to increase our knowledge about the pathological findings and immune response related to the infection by zoonotic species of the genus Anisakis</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 1471-2334 (Electronic)IS - 1471-2334 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12879-017-2633-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28764637">PM:28764637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Infect Dis\2017-17-530.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Infect Dis\2017-17-530.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Mattiucci S</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12879-017-2633-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olivry,T.</style></author><author><style face="normal" font="Arial"> Bexley,J.</style></author><author><style face="normal" font="Arial"> Mougeot,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.Avacta Animal Health, Leeds, Wetherby, UKRoyal Canin, Aimargues, France</style></auth-address><titles><title><style face="normal" font="Arial">Extensive protein hydrolyzation is indispensable to prevent IgE-mediated poultry allergen recognition in dogs and cats</style></title><secondary-title><style face="normal" font="Arial">BMC Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Vet Res</style></full-title></periodical><pages end="" start="251">251-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Beef</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Chicken meat</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Feathers</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The central premise for the commercialization of diets with hydrolyzed ingredients is that the small-sized digested peptides would be unable to crosslink allergen-specific IgE at the surface of tissue mast cells and induce their degranulation. Evidence for the validity of this concept to diagnose food allergies in dogs and cats is limited, however. Our objectives were to study the recognition of standard and variably hydrolyzed poultry extracts by sera from dogs and cats with elevated chicken-specific serum IgE. RESULTS: Forty sera from dogs and 40 from cats with undetectable, low, medium or high serum levels of chicken-specific IgE were tested by ELISA on plates coated with the positive controls chicken, duck and turkey meat extracts and the negative controls beef meat (dogs) or wheat (cats). Plates were also coated with a non-hydrolyzed chicken meal, and mildly- or extensively-hydrolyzed poultry feather extracts. The frequencies of dogs with positive IgE against the various extracts were: chicken meat: 100%, duck and turkey meats: 97%, beef meat: 3%, non-hydrolyzed chicken meal: 73%, mildly-hydrolyzed poultry feathers: 37% and extensively-hydrolyzed poultry feathers: 0%. For cats, these respective percentages were (with wheat replacing beef as a negative control): 100, 84, 97, 7, 7, 0 and 0%. To detect any allergenic cross-reactivity between poultry meat-based and feather hydrolysate-derived extracts, an IgE ELISA inhibition was also done. Ten canine sera with the highest level of anti-poultry IgE in the previous experiment were incubated overnight with a previously optimized 50 mug amount of each of the extracts used above. We performed ELISA on plates coated with chicken, duck or turkey meats with or without inhibitors. The median inhibition percentages after incubation with the non-hydrolyzed chicken meal were ~22%, with the mildly-hydrolyzed poultry feathers: 14-22%, and those with the extensively-hydrolyzed poultry feathers: 5 to 10%; the last inhibition level was similar to that of the beef meat negative control. CONCLUSIONS: Altogether, these results suggest that an extensive-but not partial-hydrolyzation of the poultry feather extract is necessary to prevent the recognition of allergenic epitopes by poultry-specific IgE</style></abstract><notes><style face="normal" font="Arial">DA - 20170818IS - 1746-6148 (Electronic)IS - 1746-6148 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12917-017-1183-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28818076">PM:28818076</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Vet Res\2017-13-251.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Vet Res\2017-13-251.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170818, Olivry T</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12917-017-1183-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85498</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Samuel,R.J.</style></author><author><style face="normal" font="Arial"> Reynolds,N.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, U.K</style></auth-address><titles><title><style face="normal" font="Arial">Ustekinumab for severe atopic dermatitis: an important negative study</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="341" start="339">339-341</pages><volume><style face="normal" font="Arial">177</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15712</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833005">PM:28833005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\2017-177-339-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\2017-177-339-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Samuel RJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15712</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vieira,M.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Teste de provocação nasal com alérgenos inalantes: da pesquisa para a prática clínica</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="122" start="120">120-122</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Brazil</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Helvetica">10.5935/2526-5393.20170015</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-120-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-120-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Vieira MD</style></custom2><misc3><style face="normal" font="Helvetica">10.5935/2526-5393.20170015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foes Bianchini Garcia,J.</style></author><author><style face="normal" font="Arial"> Silveira Barsotti,N.</style></author><author><style face="normal" font="Arial"> Kokron,C.M.</style></author><author><style face="normal" font="Arial"> Kalil,J.</style></author><author><style face="normal" font="Arial"> Giavina-Bianchi,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Interleukin 2 as adjuvant treatment in a patient with idiopathic CD4 lymphocytopenia and disseminated tuberculosis</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="113" start="109">109-113</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD8</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cerebrospinal fluid</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Fluconazole</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-2</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mycobacteria</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Onychomycosis</style></keyword><keyword><style face="normal" font="Arial"> Opportunistic Infections</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Stroke</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Idiopathic CD4 T lymphocytopenia (ICL) is a rare and severeimmunodeficiency disorder characterized by an unexplaineddecrease of absolute CD4 T-lymphocyte cell counts, which isassociated with opportunistic infections. There are few casereports in the literature describing the use of interleukin 2 (IL2)as a therapeutic option in ICL-associated opportunistic infections.We report the benefits of adding IL2 to the standard treatmentin a patient with ICL and opportunistic infections. A 38-year-oldmale patient was admitted with ischemic stroke due to infectiousvasculitis. Cerebrospinal fluid analysis revealed neutrophilicmeningitis. Culture and PCR were positive for Mycobacteriumtuberculosis. Chest CT was compatible with pulmonary tuberculosis.The patient also presented oral candidiasis, onychomycosis, andseborrheic dermatitis. Blood cell count revealed lymphocytopenia.Standardized treatment for disseminated tuberculosis (RIPEtherapy) and fluconazole were initiated and maintained at homeafter the patient's discharge. After five months of follow-up, thepatient was referred to a clinical immunologist, due to the absenceof significant clinical improvement, with multiple hospitalizationsover the follow-up period. Immunological assessment showedCD4 T cell counts consistently below 100 cells/mm3, and thediagnosis of ICL was confirmed (unexplained lymphocytopeniawith less than 300 cells/mm3 or less than 20% of CD4+ T cellson more than one occasion at least 2 months apart). The patientalso presented rare episodes of B cell lymphocytopenia andhypogammaglobulinemia, treated with gammaglobulin. As anadjuvant treatment, subcutaneous IL2 was added to the standardtreatment. So far the patient underwent five consecutive cycles ofIL2, showing clinical improvement and increased CD4 T cell counts,reaching a maximum value of 401 cells/mm3. CD8, B and naturalkiller cells also increased. New cerebrospinal fluid analyses werenormal, and new Mycobacterium tuberculosis culture and PCR were negative. Our patient had opportunistic infections associatedwith ICL and presented favorable laboratory and clinical outcomesafter the association of IL2 to the standard treatment. This casereport supports the use of IL2 as a safe and potentially effectiveadjuvant treatment for ICL-associated opportunistic infections. Thecase highlights the importance of immunological assessment andfollow-up of patients with suspected immunodeficiency.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170013</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-109-113.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-109-113.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Foes Bianchini Garcia J</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kfouri,R.A.</style></author><author><style face="normal" font="Arial"> Cunha,J.</style></author><author><style face="normal" font="Arial"> Sarinho,E.C.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author><author><style face="normal" font="Arial"> da Fonseca Lima,J.</style></author><author><style face="normal" font="Arial"> Cocco,R.R.</style></author><author><style face="normal" font="Arial"> Fernandes,F.R.</style></author><author><style face="normal" font="Arial"> Marinho,A.K.</style></author><author><style face="normal" font="Arial"> Silva,L.R.</style></author><author><style face="normal" font="Arial"> Rubini,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Rotavirus vaccine: safety and food allergy - Position paper of the Brazilian Societies of Allergy and Immunology (ASBAI), Immunizations (SBIm), and Pediatrics (SBP)</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="54" start="49">49-54</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rotavirus</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Despite the widespread use of vaccines in public immunizationprograms worldwide, rotavirus remains the primary cause ofdiarrhea in children. In Brazil, the monovalent vaccine wasintroduced in the National Immunization Program (ProgramaNacional de Imunizações - PNI) in 2006, and its safety is welldocumented in different studies carried out both before and afterlicensing. Even though there is no association between the use ofrotavirus vaccine and the development of cow's milk protein allergy(CMPA), some pediatricians and family members fear that thevaccine may be somehow related to the emergence or outbreakof this hypersensitivity reaction. This article reviews safety dataavailable for this vaccine and addresses the immunological aspectsof hypersensitivity reactions. The findings demonstrate that there isno causal link between the rotavirus vaccine and CMPA, reinforcingthe position and recommendations of national and internationalagencies as well as of scientific societies.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-49-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-49-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Kfouri RA</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garro,L.S.</style></author><author><style face="normal" font="Arial"> Vivolo Aun,M.</style></author><author><style face="normal" font="Arial"> Motta,A.A.</style></author><author><style face="normal" font="Arial"> Kalil,J.</style></author><author><style face="normal" font="Arial"> Giavina-Bianchi,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Specific IgE, IgG4, and IgA in latex allergy</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="108" start="99">99-108</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: Latex allergy is considered a global health problembecause it is associated with life-threatening reactions. The mainobjective of this study was to identify clinical and laboratory factorsassociated with sensitization and allergy to latex, assessing theconcentrations of latex-specific IgE, IgG4, and IgA. Methods:This was an observational study of a cohort of 400 children andadolescents with neural tube closure defect. Patients underwent aclinical interview and had their blood drawn for the measurement ofserum levels of latex-specific IgE, IgG4, and IgA. The prevalencerates of sensitization and allergy to latex were calculated, andclinical and laboratory variables were analyzed. Results: Theprevalence rates of sensitization and allergy to latex in patientswith neural tube closure defects were 33.2 and 12.2%, respectively.Cutaneous manifestations of latex allergy were the most commonones (79.6%), but anaphylaxis was observed in 4.75% of thepatients. Clinical and surgical factors associated with latex allergywere identified, and a symptom scoring system was developed asa screening tool. A latex-specific IgE concentration . 0.77 kUA/Lshowed good accuracy to differentiate between asymptomaticsensitization and allergy. The measurement of specific IgE torecombinant allergens also showed good accuracy in the diagnosisof allergy. Conclusions: Higher concentrations of latex-specificIgE and Hevb5, lower concentrations of latex-specific IgG4, and asymptom score . 40% were associated with latex allergy.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170012</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-99-108.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-99-108.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Garro LS</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vivolo Aun,N.</style></author><author><style face="normal" font="Arial"> Saraiva-Romanholo,B.M.</style></author><author><style face="normal" font="Arial"> de Almeida,F.M.</style></author><author><style face="normal" font="Arial"> Bruggemann,T.R.</style></author><author><style face="normal" font="Arial"> Lee Ho,P.</style></author><author><style face="normal" font="Arial"> Kalil,J.</style></author><author><style face="normal" font="Arial"> de Arruda Martins,M.</style></author><author><style face="normal" font="Arial"> Magalhaes Arantes-Costa,F.</style></author><author><style face="normal" font="Arial"> Giavina-Bianchi,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Bordetella pertussis vaccine reduces specific IgE, inflammation, and remodeling in an animal model of respiratory allergy caused by house dust mites</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="86" start="75">75-86</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bordetella pertussis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Diphtheria-Tetanus Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Intranasal challenge</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pertussis Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: Adjuvant therapies, such as the use of bacteriallipopolysaccharides, have been evaluated as tools to improvethe effectiveness of allergen-specific immunotherapy. Bordetellapertussis vaccine (Pw) has been shown to have a protective rolein asthma models induced by ovalbumin. Conversely, its role inallergy to dust mites is unknown. We evaluated the effects ofdiphtheria-tetanus-pertussis vaccine (DTPw) in a murine model ofrespiratory allergy induced by Dermatophagoides pteronyssinus(Derp). Methods: Over a 30-day protocol, BALB/c mice wereimmunized subcutaneously with saline or Derp, alone or combinedwith diphtheria-tetanus vaccine (DT) or DTPw (days 0, 7, and 14).Then, they were subjected to intranasal challenge with saline orDerp daily (days 22 to 28), and sacrificed on day 29. We evaluatedserum specific immunoglobulins, bronchoalveolar lavage (BAL)cellularity, lower airway remodeling, density of polymorphonuclearleukocytes (PMN), and acidic mucus area in the nasal epithelium.Results: Animals sensitized to Derp produced high levels ofspecific immunoglobulins, showed increased PMN density andacidic mucus in the nasal mucosa, and elevated BAL cellularityand remodeling. Vaccines led to the reduction of IgE levels, withthe Derp-DTPw group showing similar results to those of the salinegroups. Vaccinated groups showed reduced BAL cellularity andairway remodeling, with more expressive results in the Derp-DTPwgroup compared to Derp-DT. DT and DTPw vaccines inhibited PMNinfiltration in nasal mucosa, and DTPw modulated the productionof acidic nasal mucus. Conclusions: DTPw vaccine decreasedserum specific IgE, nasal and pulmonary inflammation, and lowerairway remodeling.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Helvetica">10/01/2017, aceito em: 15/02/2017</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10/01/2017, aceito em: 15/02/2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-75-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-75-86.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Vivolo Aun M</style></custom2><misc3><style face="normal" font="Helvetica">10/01/2017, aceito em: 15/02/2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,J.</style></author><author><style face="normal" font="Arial"> Adler,F.R.</style></author><author><style face="normal" font="Arial"> Kim,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory and Allergy Medicine, Internal Medicine, College of Medicine, Soonchunhyang University, Soonchunhyang University Bucheon Hospital Jomaruro 170, Wonmigu, Bucheon, Gyeonggido, 14584, Korea. junehyuk@schmc.ac.krDepartment of Biology, University of Utah, 155 South 1400 East, Salt Lake City, UT, 84112-0090, USA.</style></auth-address><titles><title><style face="normal" font="Arial">A Mathematical Model for the Macrophage Response to Respiratory Viral Infection in Normal and Asthmatic Conditions</style></title><secondary-title><style face="normal" font="Arial">Bull Math Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bull Math Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viral infection</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Utah</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> Viral Load</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="Arial">Respiratory viral infections are common in the general population and one of the most important causes of asthma aggravation and exacerbation. Despite many studies, it is not well understood how viral infections cause more severe symptoms and exacerbations in asthmatics. We develop a mathematical model of two types of macrophages that play complementary roles in fighting viral infection: classically [Formula: see text]-[Formula: see text] and alternatively activated macrophages [Formula: see text]-[Formula: see text]. [Formula: see text]-[Formula: see text] destroy infected cells and tissues to remove viruses, while [Formula: see text]-[Formula: see text] repair damaged tissues. We show that a higher viral load or longer duration of infection provokes a stronger immune response from the macrophage system. By adjusting the parameters, we model the differences in response to respiratory viral infection in normal and asthmatic subjects and show how this skews the system toward a response that generates more severe symptoms in asthmatic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170725IS - 1522-9602 (Electronic)IS - 0092-8240 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11538-017-0315-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28741104">PM:28741104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Bull Math Biol\20170725-LeeJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Bull Math Biol\20170725-LeeJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170725, Lee J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11538-017-0315-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Van Hemelrijck,M.</style></author><author><style face="normal" font="Arial"> Karagiannis,S.N.</style></author><author><style face="normal" font="Arial"> Rohrmann,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Cancer Studies, King's College London, Translational Oncology and Urology Research (TOUR), London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?</style></title><secondary-title><style face="normal" font="Arial">Cancer Immunol Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cancer Immunol Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prostate</style></keyword><keyword><style face="normal" font="Arial"> Prostate cancer</style></keyword><keyword><style face="normal" font="Arial"> prostate-specific antigen</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urology</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopy has been investigated as a potential risk factor for prostate cancer. IgE antibodies may be major players in protective responses against tumours, through engendering antigen presentation and enhancing adaptive immune responses targeted towards a specific allergen, but potentially also against tumour-associated antigens such as prostate-specific antigen (PSA). We therefore cross-sectionally investigated associations between circulating levels of PSA and IgE in the National Health and Nutrition Examination Survey 2005-2006. METHODS: We focused on all men aged 40+ years with measurements for PSA and IgE, and no previous diagnosis of prostate cancer (n = 1312). We estimated the association between total and specific IgE concentration and levels of PSA with logistic regression models, adjusted for age, ethnicity/race, education, smoking status, body mass index (BMI), physical activity status, and history of asthma. RESULTS: Both total IgE and the sum of specific IgE were inversely associated with the risk of having PSA levels >/=10 ng/mL, though most findings were not statistically significant. The odds ratios for the second and third tertile of total IgE as compared to the first were 0.21 (95% CI 0.06-0.72) and 0.42 (0.08-2.31). The odds ratio for sum of abnormal specific IgE measurements was 0.77 (0.44-1.34). CONCLUSION: Despite statistical insignificance, the observed trend warrants further research given the increasing evidence of the role of atopy and IgE antibodies in protective responses against tumours. A lifecourse approach of measuring IgE, specific subtypes, and other markers of the humoral immune system (i.e. IgG) could shed more light on its potential anti-cancer characteristics</style></abstract><notes><style face="normal" font="Arial">DA - 20170810IS - 1432-0851 (Electronic)IS - 0340-7004 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00262-017-2048-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28795218">PM:28795218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cancer Immunol Immunother\20170810-VanHemelrijckM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cancer Immunol Immunother\20170810-VanHemelrijckM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170810, Van Hemelrijck M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00262-017-2048-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ly,D.</style></author><author><style face="normal" font="Arial"> Zhu,C.Q.</style></author><author><style face="normal" font="Arial"> Cabanero,M.</style></author><author><style face="normal" font="Arial"> Tsao,M.S.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Toronto General Research Institute, University Health Network</style></auth-address><titles><title><style face="normal" font="Arial">Role for high-affinity IgE receptor in prognosis of lung adenocarcinoma patients</style></title><secondary-title><style face="normal" font="Arial">Cancer Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cancer Immunol Res</style></full-title></periodical><pages end="829" start="821">821-829</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenocarcinoma</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung cancer</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">Cancer development and biology is influenced by the host immune system. Emerging data indicate that the context of immune cell infiltrates may contribute to cancer prognosis. However, the types of infiltrating immune cells that are critical for cancer development remain controversial. In attempts to gain insights into the immune networks that regulate and/or predict tumor progression, gene expression analysis was conducted on microarray datasets of resected tumor samples from 128 early-stage non-small cell lung cancer (NSCLC) adenocarcinoma patients. By limiting analysis to immune-related genes, we identified a 9-gene signature using MAximizing R Square Algorithm (MARSA) that selected for the greatest separation between favorable and adverse prognostic patient subgroups. The prognostic value of this 9-gene signature was validated in ten additional independently published microarray datasets of lung adenocarcinoma (n = 1097, overall survival hazard ratio (HR), 2.05, 95% confidence interval 1.64 to 2.56, P &lt; 0.0001) and was found to be an independent prognostic indicator relative to tumor stage (overall survival hazard ratio (HR), 2.09, 95% confidence interval 1.65 to 2.66, P &lt; 0.0001). Network analysis reveal that genes associated with Fcepsilon complex (FCER1, MS4A2) formed the largest and most significant pathway of the signature. Using immunohistochemistry, we validated that MS4A2, the beta subunit of the IgE receptor expressed on mast cells, is a favorable prognostic indicator and show that MS4A2 gene expression is an independent prognostic marker for early-stage lung cancer patient survival</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 2326-6074 (Electronic)IS - 2326-6066 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1158/2326-6066.CIR-16-0392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775209">PM:28775209</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cancer Immunol Res\20170804-LyD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cancer Immunol Res\20170804-LyD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Ly D</style></custom2><misc3><style face="normal" font="Arial">10.1158/2326-6066.CIR-16-0392</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Luca,A.</style></author><author><style face="normal" font="Arial"> Pariano,M.</style></author><author><style face="normal" font="Arial"> Cellini,B.</style></author><author><style face="normal" font="Arial"> Costantini,C.</style></author><author><style face="normal" font="Arial"> Villella,V.R.</style></author><author><style face="normal" font="Arial"> Jose,S.S.</style></author><author><style face="normal" font="Arial"> Palmieri,M.</style></author><author><style face="normal" font="Arial"> Borghi,M.</style></author><author><style face="normal" font="Arial"> Galosi,C.</style></author><author><style face="normal" font="Arial"> Paolicelli,G.</style></author><author><style face="normal" font="Arial"> Maiuri,L.</style></author><author><style face="normal" font="Arial"> Fric,J.</style></author><author><style face="normal" font="Arial"> Zelante,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Medicine, University of Perugia, 06132 Perugia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">The IL-17F/IL-17RC Axis Promotes Respiratory Allergy in the Proximal Airways</style></title><secondary-title><style face="normal" font="Arial">Cell Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Rep</style></full-title></periodical><pages end="1680" start="1667">1667-1680</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-17</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> upper respiratory</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">The interleukin 17 (IL-17) cytokine and receptor family is central to antimicrobial resistance and inflammation in the lung. Mice lacking IL-17A, IL-17F, or the IL-17RA subunit were compared with wild-type mice for susceptibility to airway inflammation in models of infection and allergy. Signaling through IL-17RA was required for efficient microbial clearance and prevention of allergy; in the absence of IL-17RA, signaling through IL-17RC on epithelial cells, predominantly by IL-17F, significantly exacerbated lower airway Aspergillus or Pseudomonas infection and allergic airway inflammation. In contrast, following infection with the upper respiratory pathogen Staphylococcus aureus, the IL-17F/IL-17RC axis mediated protection. Thus, IL-17A and IL-17F exert distinct biological effects during pulmonary infection; the IL-17F/IL-17RC signaling axis has the potential to significantly worsen pathogen-associated inflammation of the lower respiratory tract in particular, and should be investigated further as a therapeutic target for treating pathological inflammation in the lung</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 2211-1247 (Electronic)LA - engPT - Journal ArticleCO - Italy -CO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.celrep.2017.07.063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28813677">PM:28813677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Rep\2017-20-1667-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Rep\2017-20-1667-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, De Luca A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.celrep.2017.07.063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">LoVerde,D.</style></author><author><style face="normal" font="Arial"> Iweala,O.I.</style></author><author><style face="normal" font="Arial"> Eginli,A.</style></author><author><style face="normal" font="Arial"> Krishnaswamy,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary, Critical Care, Allergy and Immunology, Department of Medicine, Wake Forest University School of Medicine and Wake Forest Baptist Medical Center, Winston-Salem, NC.</style></auth-address><titles><title><style face="normal" font="Arial">Contemporary Reviews in Critical Care Medicine: Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Cardiovascular System</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic testing</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tachycardia</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a systemic, life threatening disorder triggered by mediators released by mast cells and basophils activated via allergic (IgE-mediated) or non-allergic (non-IgE-mediated) mechanisms. It is a rapidly evolving, multisystem process involving the integumentary, pulmonary, gastrointestinal and cardiovascular systems. Anaphylaxis and angioedema are serious disorders that can lead to fatal airway obstruction and culminate in cardiorespiratory arrest resulting in hypoxemia and/or shock. Often, these disorders can be appropriately managed in an outpatient setting. However, these conditions can be severe enough to warrant evaluation of the patient in the emergency department and in some cases, hospitalization and management in an intensive care unit (ICU). Recent reports suggest that underdiagnosis and undertreatment of anaphylaxis are common. Several new syndromes have been described recently including bird-egg, pork-cat, delayed allergy to mammalian meat and a diverse group of mast cell activation disorders. Conditions such as postural orthostatic tachycardia syndrome (POTS), Carcinoid syndrome, Munchausen's stridor and factitious anaphylaxis can present similarly and need to be included in the differential diagnosis. Anaphylaxis is a clinical diagnosis but plasma tryptase and urinary histamine levels are often elevated, allowing diagnostic confirmation. However, diagnostic testing should not delay treatment as results may not be immediately available. The sine qua non of treatment is avoidance of any known triggers and epinephrine, which should never be delayed if this disorder is suspected. Secondary treatments include fluids, bronchodilators, antihistamines and glucocorticoids. Patients with cardiopulmonary arrest, airway or vascular compromise require mechanical ventilation, vasopressors and other advanced life support in the ICU</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.chest.2017.07.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800865">PM:28800865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chest\20170812-LoVerdeD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chest\20170812-LoVerdeD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, LoVerde D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.chest.2017.07.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tangye,S.G.</style></author><author><style face="normal" font="Arial"> Forbes,L.R.</style></author><author><style face="normal" font="Arial"> Leiding,J.</style></author><author><style face="normal" font="Arial"> Preece,K.</style></author><author><style face="normal" font="Arial"> Kumar,A.R.</style></author><author><style face="normal" font="Arial"> Gambineri,E.</style></author><author><style face="normal" font="Arial"> Milner,J.D.</style></author><author><style face="normal" font="Arial"> Cooper,M.A.</style></author><author><style face="normal" font="Arial"> Seppanen,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Division, Garvan Institute of Medical Research Darlinghurst, New South Wales Australia</style></auth-address><titles><title><style face="normal" font="Arial">Low IgE Is Insufficiently Sensitive to Guide Genetic Testing of STAT3 Gain-of-Function Mutations</style></title><secondary-title><style face="normal" font="Arial">Clin Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chem</style></full-title></periodical><pages end="1540" start="1539">1539-1540</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Australia</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic testing</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Rare disease</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170701IS - 1530-8561 (Electronic)IS - 0009-9147 (Linking)LA - engPT - LetterCO - Australia -CO - United States -CO - Italy -CO - New Zealand -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1373/clinchem.2017.273458</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28667185">PM:28667185</url></web-urls><pdf-urls><url ppv-ref="no">mikko.seppanen@hus.fi</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170701, Tangye SG</style></custom2><misc3><style face="normal" font="Arial">10.1373/clinchem.2017.273458</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soto-Ramirez,N.</style></author><author><style face="normal" font="Arial"> Kar,S.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author><author><style face="normal" font="Arial"> Karmaus,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Social Work, University of South Carolina, Columbia, SC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Infant feeding patterns and eczema in children in the first 6 years of life</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> formula feeding</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hispanic</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> paternal</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Modes of infant feeding such as direct and indirect breastfeeding, and formula feeding, and their combinations may play a role in child health. OBJECTIVE: The aim was to investigate which feeding patterns in the first six months pose risks for eczema/skin allergy in children up to 6 years compared to direct breastfeeding for at least 3 months. METHODS: The Infant Feeding Practices Study II in the United States and its 6-year follow-up provided data on feeding modes in infancy and doctor's diagnosed eczema/skin allergy in the first 6 years of life (1,387 infants), based on parental reports. Different feeding patterns were identified. Log-linear models were used to estimate prevalence ratios (PRs) of feeding patterns for doctor's diagnosed eczema/skin allergy in the first 6 years of life, adjusting for confounders. RESULTS: Compared to 'direct breastfeeding for at least 3 months' (DBF3m), the combination of direct feeding at the breast (DBF), pumping and feeding breast milk (BM), and formula (FF) in the first months' (DBF/BM/FF) showed a statistically significant higher risk for eczema/skin allergy in the first 6 years of life (PR= 1.46), adjusting for confounders. DBF combined with BM for the first 3 months followed by mixed feeding also had an increased risk (PR=1.26), though not statistically significant. Formula feeding introduced since birth had no effect on eczema. Among the confounders, paternal eczema and race/ethnicity (Hispanic vs White) were associated with a higher risk of eczema/skin allergy. CONCLUSIONS &amp; CLINICAL RELEVANCE: Mixed infant feeding may carry a higher risk of eczema/skin allergy compared to direct feeding at the breast. The recent epidemic of pumping and feeding in the United States and the use of mixed infant feeding modes requires additional studies to provide appropriate and renewed assessments of the risks of feeding modes for the future development of allergies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12998</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815821">PM:28815821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170817-SotoRamirezN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170817-SotoRamirezN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Soto-Ramirez N</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12998</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stretz,E.</style></author><author><style face="normal" font="Arial"> Oppel,E.M.</style></author><author><style face="normal" font="Arial"> Helen-Caroline,R.</style></author><author><style face="normal" font="Arial"> Chatelain,R.</style></author><author><style face="normal" font="Arial"> Mastnik,S.</style></author><author><style face="normal" font="Arial"> Przybilla,B.</style></author><author><style face="normal" font="Arial"> Rueff,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinikum der Universitat Munchen, Klinik und Poliklinik fur Dermatologie und Allergologie, Munchen, Bayern, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Overcoming severe adverse reactions to venom immunotherapy by using anti-IgE antibodies in combination with a high maintenance dose</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergies</style></keyword><keyword><style face="normal" font="Arial"> insect venom allergy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An omalizumab treatment and a high maintenance venom dose may both help to prevent recurrent systemic allergic reactions (SAR) to venom immunotherapy (VIT). The effectiveness of this combination therapy, however, is unclear. OBJECTIVE: We wanted to explore the possibility whether a temporary treatment with the anti-IgE antibody omalizumab, combined with a VIT using an elevated maintenance dose of >100 mug venom may establish a permanent tolerance of maintenance VIT. METHODS: For this retrospective case series, we scoured our institutional data base for patients who had had an insect venom allergy, and in whom it had not been possible to continue VIT because of repeated unstoppable SAR during maintenance VIT. Patients were divided into those who had received the combination therapy (omalizumab group), and those who had not received omalizumab because its costs could not be covered (controls). Guided by the total IgE level and by body weight, omalizumab had been given subcutaneously 5, 3 and 1 week before VIT had been restarted. Three to six months after an elevated maintenance dose (</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12997</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28802075">PM:28802075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170812-StretzE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170812-StretzE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Stretz E</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12997</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kyburz,A.</style></author><author><style face="normal" font="Arial"> Urban,S.</style></author><author><style face="normal" font="Arial"> Altobelli,A.</style></author><author><style face="normal" font="Arial"> Floess,S.</style></author><author><style face="normal" font="Arial"> Huehn,J.</style></author><author><style face="normal" font="Arial"> Cover,T.L.</style></author><author><style face="normal" font="Arial"> Muller,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Helicobacter pylori and its secreted immunomodulator VacA protect against anaphylaxis in experimental models of food allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> bacterial lysate</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Experimental models</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunomodulators</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell protease</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Prophylactic treatment</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy is an increasingly common health problem in Western populations. Epidemiological studies have suggested both positive and negative associations between food allergy and infection with the gastric bacterium Helicobacter pylori. OBJECTIVE: The objective of this work was to investigate whether experimental infection with H. pylori, or prophylactic treatment with H. pylori-derived immunomodulatory molecules, affects the onset and severity of food allergy, either positively or negatively. METHODS: We infected neonatal C57BL/6 or C3H mice with H. pylori or treated animals with H. pylori components (bacterial lysate or the immunomodulator VacA) and subsequently subjected them to four different protocols for food allergy induction, using either ovalbumin or peanut extract as allergens for sensitization and challenge. Readouts included anaphylaxis scoring, quantification of allergen-specific serum IgE and IgG1 and of the mast cell protease MCPT1, as well as splenic T-helper-2 cell-derived cytokine production. Mesenteric lymph node CD4+ FoxP3+ regulatory T-cells were subjected to flow cytometric quantification and sorting followed by qRT-PCR, and to DNA methylation analyses of the Treg-specific demethylated region (TSDR) within the FOXP3 locus. RESULTS: Mice that had been infected with H. pylori or treated with H. pylori-derived immunomodulators showed reduced anaphylaxis upon allergen sensitization and challenge, irrespective of the allergen used. Most of the immunologic assays confirmed a protective effect of H. pylori. CD4+ FoxP3+ T-cells were more abundant in protected mice and exhibited a stable Treg phenotype characterized by FOXP3 TSDR demethylation. CONCLUSIONS AND CLINICAL RELEVANCE: H. pylori confers protection against the anaphylaxis associated with ovalbumin and peanut allergy and affects the epigenome of T-cells, thereby promoting stable Treg differentiation and functionality. Prophylactic treatment with H. pylori-derived immunomodulators appears to be a promising strategy for food allergy prevention. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12996</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28802077">PM:28802077</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170812-KyburzA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170812-KyburzA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Kyburz A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12996</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,N.</style></author><author><style face="normal" font="Arial"> McKell,M.</style></author><author><style face="normal" font="Arial"> Dang,A.</style></author><author><style face="normal" font="Arial"> Yamani,A.</style></author><author><style face="normal" font="Arial"> Waggoner,L.</style></author><author><style face="normal" font="Arial"> Vanoni,S.</style></author><author><style face="normal" font="Arial"> Noah,T.</style></author><author><style face="normal" font="Arial"> Wu,D.</style></author><author><style face="normal" font="Arial"> Kordowski,A.</style></author><author><style face="normal" font="Arial"> Kohl,J.</style></author><author><style face="normal" font="Arial"> Hoebe,K.</style></author><author><style face="normal" font="Arial"> Divanovic,S.</style></author><author><style face="normal" font="Arial"> Hogan,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229</style></auth-address><titles><title><style face="normal" font="Arial">Lipopolysaccharide suppresses IgE-mast cell mediated reactions</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Infections</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="8" Year="2017">2017/8/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Clinical and experimental analyses have identified a central role for IgE/FcepsilonRI/mast cells in promoting IgE-mediated anaphylaxis. Recent data from human studies suggest that bacterial infections can alter susceptibility to anaphylaxis. OBJECTIVE: We examined the effect of LPS exposure on the induction of IgE-mast cell-(MC) mediated reactions in mice. METHODS: C57BL/6 WT, TLR-4-/- and IL10-/- mice were exposed to LPS and serum cytokines (TNF and IL-10) were measured. Mice were subsequently treated with anti-IgE and the symptoms of passive IgE-mediated anaphylaxis, MC activation, Ca2+ -mobilization and expression of FcepsilonRI on peritoneal MCs were quantitated. RESULTS: We show that LPS exposure of C57BL/6 WT mice constrains IgE-MC mediated reactions. LPS-induced suppression of IgE-MC mediated responses was TLR-4-dependent and associated with increased systemic IL-10 levels, decreased surface expression of FcepsilonRI on MCs and loss of sensitivity to IgE activation. Notably, LPS-induced desensitization of MCs was short-term with MC sensitivity to IgE reconstituted within 48 hours which was associated with recapitulation of FcepsilonRI expression on the MCs. Mechanistic analyses revealed a requirement for IL-10 in LPS-mediated decrease in MC FcepsilonRI surface expression. CONCLUSIONS &amp; CLINICAL RELEVANCE: Collectively, these studies suggest that LPS-induced IL-10 promotes the down regulation of MC surface FcepsilonRI expression and leads to desensitization of mice to IgE-mediated reactions. These studies indicate that targeting of the LPS-TLR-4-IL-10-pathway maybe used as a therapeutic approach to prevent adverse IgE-mediated reactions. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833704">PM:28833704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170823-WangN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170823-WangN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Wang N</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Taye,B.</style></author><author><style face="normal" font="Arial"> Enquselassie,F.</style></author><author><style face="normal" font="Arial"> Tsegaye,A.</style></author><author><style face="normal" font="Arial"> Amberbir,A.</style></author><author><style face="normal" font="Arial"> Medhin,G.</style></author><author><style face="normal" font="Arial"> Fogarty,A.</style></author><author><style face="normal" font="Arial"> Robinson,K.</style></author><author><style face="normal" font="Arial"> Davey,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Colgate University, Department of Biology, Hamilton, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Association between infection with H. pylori and atopy in young Ethiopian Children: a longitudinal study</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Ethiopia</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter</style></keyword><keyword><style face="normal" font="Arial"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Epidemiological evidence from developed countries indicates that Helicobacter pylori infection correlates with a reduced risk of atopy and allergic disorders, however limited data are available from low-income countries. OBJECTIVE: We examined associations between H. pylori infection in early childhood and atopy and reported allergic disorders at the age of 6.5 years in an Ethiopian birth cohort. METHODS: A total of 856 children (85.1% of the 1006 original singletons in a population-based birth cohort) were followed up at age six and half years. An interviewer-led questionnaire administered to mothers provided information on demographic and lifestyle variables. Questions on allergic disease symptoms were based on the International Study of Asthma and Allergies in Children (ISAAC) core allergy and environmental questionnaire. Serum samples were analysed for total IgE levels and anti-H. pylori cytotoxin associated gene A (CagA) IgG antibody using commercially available ELISA kits. Stool samples were analysed for H. pylori antigen using a rapid immunochromatographic test. The independent effects of H. pylori infection (measured at age 3, 5 and 6.5 years) on prevalence and incidence of atopy and reported allergic disorders (measured at age 6.5 years) were determined using multiple logistic regression. RESULTS: In cross-sectional analysis, current H. pylori infection at age 6.5 years was inversely, though not significantly, related to prevalence of atopy and 'any allergic condition' at age 6.5 years. However detection of H. pylori infection at any point up to age 6.5 years was associated with a significantly reduced odds of both atopy and 'any allergic condition' (adjusted OR AOR, 95% CI, 0.54; 0.32 to 0.92, p=0.02, and 0.31; 0.10 to 0.94, p=0.04, respectively). In longitudinal analyses, H. pylori infection at age 3 was inversely associated with incidence of atopy (AOR, 95% CI, 0.49; 0.27 to 0.89, p=0.02). Furthermore, among H. pylori infected children, those with a CagA+ strain had a more pronounced reduction in odds of atopy (AOR=0.35 vs. 0.63 for CagA+ vs. CagA-) and this reduction reached borderline significance. CONCLUSION: These data are consistent with the hypothesis that early exposure to H. pylori is inversely associated with atopy and allergic conditions. A possible modest protective association against atopy was observed in those infected with a more virulent CagA+ strain of H. pylori. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Ethiopia -CO - Malawi -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12995</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787771">PM:28787771</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170808-TayeB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170808-TayeB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Taye B</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12995</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Simoneti,C.S.</style></author><author><style face="normal" font="Arial"> Ferraz,E.</style></author><author><style face="normal" font="Arial"> de Menezes,M.B.</style></author><author><style face="normal" font="Arial"> Bagatin,E.</style></author><author><style face="normal" font="Arial"> Arruda,L.K.</style></author><author><style face="normal" font="Arial"> Vianna,E.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Allergic sensitization to laboratory animals is more associated with asthma, rhinitis and skin symptoms than sensitization to common allergens</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial challenge test</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> Laboratory animal allergy</style></keyword><keyword><style face="normal" font="Arial"> Laboratory animals</style></keyword><keyword><style face="normal" font="Arial"> Mannitol</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Poisson</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Rodents</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Workers exposed to laboratory animals have a high risk of developing laboratory animal allergy (LAA). Atopy seems to be the main risk factor for LAA. We hypothesized that occupational sensitization is a better predictor for the development of asthma, rhinitis and bronchial hyperresponsiveness than common sensitization. OBJECTIVE: To investigate the association between occupational sensitization to laboratory animals and clinical outcomes. METHODS: This was a cross-sectional study performed at two universities on students and employees dealing with small rodents. The subjects were allocated in groups: non-sensitized, common sensitization or occupational sensitization, according to the results of the skin prick test (SPT). All subjects answered a questionnaire about animal exposures, symptoms, allergic diseases, and underwent spirometry and bronchial challenge test with mannitol. Multivariate analysis was performed by using Poisson regression to estimate the prevalence ratio (PR). RESULTS: Data from 453 volunteers were analyzed. Non-sensitized group comprised 237 subjects; common sensitization group, 142 subjects; and occupational sensitization group, 74 subjects. Occupational sensitization was associated with greater risk for all outcomes studied. When the common sensitization group was reference, skin symptoms had PR of 1.36; 95% confidence interval (CI): 1.01-1.85; wheezing had PR of 1.75; CI 95%: 1.21-2.53; rhinitis had PR of 1.25; 95%: 1.11-1.40; nocturnal dyspnea had PR of 2.40; 95% CI: 1.31-4.40; bronchial hyperresponsiveness had PR of 2.47; 95% CI: 1.50-4.09; and confirmed asthma had PR of 2.65; 95% CI: 1.45-4.85. In addition, the overlap of asthma, rhinitis and skin symptoms in a same subject was significantly more prevalent in the occupational sensitization group, 16.2% versus 4.9% in the common sensitization group. CONCLUSION AND CLINICAL RELEVANCE: Occupational sensitization is associated with allergic symptoms and respiratory diseases. SPT with occupational allergens along with other parameters may contribute to detection of risk for allergic and respiratory diseases associated with exposure to laboratory animals. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12994</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787776">PM:28787776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170808-SimonetiCS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170808-SimonetiCS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Simoneti</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12994</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,D.J.</style></author><author><style face="normal" font="Arial"> Chung,Y.J.</style></author><author><style face="normal" font="Arial"> Yang,Y.J.</style></author><author><style face="normal" font="Arial"> Mo,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Dankook University College of Medicine, Cheonan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">The Impact of Allergic Rhinitis on Symptom Improvement in Pediatric Patients After Adenotonsillectomy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Exp Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mouth</style></keyword><keyword><style face="normal" font="Arial"> Mouth Breathing</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergen simultaneous test</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Snoring</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tonsil</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">Objectives: It is well known that allergic rhinitis (AR) has positive association with adenotonsillectomy. However, the impact of AR on symptom improvement after adenotonsillectomy is not well documented. Hence, we aimed to evaluate the effect of AR on the symptom improvement after adenotonsillectomy between AR and nonallergic patients. Methods: A retrospective analysis was performed on 250 pediatric patients younger than 10 years old who received adenotonsillectomy from June 2009 to June 2014 in a tertiary referral hospital. All patients underwent skin prick test or multiple allergen simultaneous test (MAST) before surgery and classified into AR group and control group. Obstructive and rhinitis symptoms including snoring, mouth breathing, nasal obstruction, rhinorrhea, itching, and sneezing were evaluated before and 1 year after surgery using questionnaire and telephone survey. Results: AR group was 131 and control group was 119, showing higher prevalence (52.4%) of AR among adenotonsillectomized patients. Both groups showed dramatic improvement of symptoms such as snoring and mouth breathing after surgery (all P&lt;0.05). However, AR group showed significantly less improvement than control group in snoring, mouth breathing, nasal obstruction, and rhinorrhea (all P&lt;0.05). Multivariate analysis showed that preoperative mouth breathing and snoring were dependent on tonsil grade and postoperative symptoms were mainly dependent on presence of AR. Nasal obstruction was dependent on tonsil grade and presence of AR preoperatively and presence of AR postoperatively. These suggest the importance of AR as a risk factor for mouth breathing, snoring, and nasal obstruction. Conclusion: AR has positive association with adenotonsillectomy and not only allergic symptoms but also obstructive symptoms such as snoring and mouth breathing improved less in AR group than control group. Hence, patients with AR should be monitored for long-term basis and more carefully after adenotonsillectomy</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 1976-8710 (Print)IS - 1976-8710 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.21053/ceo.2017.00500.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28758381">PM:28758381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Otorhinolaryngol\20170731-LeeDJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Otorhinolaryngol\20170731-LeeDJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Lee DJ</style></custom2><misc3><style face="normal" font="Arial">10.21053/ceo.2017.00500.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,T.H.</style></author><author><style face="normal" font="Arial"> Chang,H.S.</style></author><author><style face="normal" font="Arial"> Bae,D.J.</style></author><author><style face="normal" font="Arial"> Song,H.J.</style></author><author><style face="normal" font="Arial"> Kim,M.S.</style></author><author><style face="normal" font="Arial"> Park,J.S.</style></author><author><style face="normal" font="Arial"> Jun,J.A.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Uh,S.T.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Park,C.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Role of S100A9 in the development of neutrophilic inflammation in asthmatics and in a murine model</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Calgranulin B</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Danger signal</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> IFN-+¦</style></keyword><keyword><style face="normal" font="Arial"> IL-1+¦</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> S100A9</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1521-6616</style></isbn><abstract><style face="normal" font="Arial">S100A9 is an endogenous danger signal that promotes and exacerbates the neutrophilic inflammatory response. To investigate the role of S100A9 in neutrophilic asthma, S100A9 levels were measured in sputum from 101 steroid-na+»ve asthmatics using an ELISA kit and the levels were significantly correlated with percentages of neutrophils in sputum. Intranasal administration of recombinant S100A9 markedly increased neutrophil numbers at 8 h and 24 h later with concomitant elevation of IL-1+¦, IL-17, and IFN-+¦ levels. Treatment with an anti-S100A9 antibody restored the increased numbers of neutrophils and the increased airway resistance in OVA/CFA mice toward the levels of sham-treated mice. Concomitantly, the S100A9 and neutrophil elastase double positive cells were markedly reduced with attenuation of IL-1+¦, IL-17, and IFN-+¦ levels by the treatment with the anti-S100A9 antibody. Our data support a role of S100A9 to initiate and amplify the neutrophilic inflammation in asthma, possibly via inducing IL-1+¦, IL-17 and IFN-+¦</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2017.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28847516">PM:28847516</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20170830-LeeTH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\20170830-LeeTH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Lee TH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2017.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aslanian-Kalkhoran,L.</style></author><author><style face="normal" font="Arial"> Elieh-Ali-Komi,D.</style></author><author><style face="normal" font="Arial"> Sadeghi-Shabestari,M.</style></author><author><style face="normal" font="Arial"> Shanebandi,D.</style></author><author><style face="normal" font="Arial"> Babaloo,Z.</style></author><author><style face="normal" font="Arial"> Razavi,A.</style></author><author><style face="normal" font="Arial"> Sadigh-Eteghad,S.</style></author><author><style face="normal" font="Arial"> Kazemi,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Investigation of Fc Receptor-Like 3 (FCRL-3) Gene Polymorphism (rs7528684) with Susceptibility to Allergic Asthma in Iranian North-Western Azeri Population</style></title><secondary-title><style face="normal" font="Arial">Clin Lab</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Lab</style></full-title></periodical><pages end="1305" start="1301">1301-1305</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alleles</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ethnic Groups</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> TaqMan</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is a clinical setting in which multiple cellular and molecular mechanisms are involved. Additionally, increasing genetic studies have provided evidence that single nucleotide polymorphisms (SNPs) in asthma relevant genes confer susceptibility to the disease. Fc receptor-like (FCRL) 3, a transmembrane molecule basically involved in B-cell signaling, mediates immune-disorders including allergy. Aim of study was to investigate the possible association of rs7528684 SNP in FCRL3 gene with a predisposition to allergic asthma in Iranian North-western Azeri population. METHODS: The frequency of genotypes and alleles of rs7528684 SNP in the FCRL3 gene was determined using the TaqMan genotyping method in 191 asthmatic patients and 186 healthy controls. RESULTS: The most frequent genotype in patients and control groups were CT (n = 81, 42.4%) and TT (n = 76, 40.9%), respectively. Statistical analysis showed no significant difference in genotype frequency (p = 0.81) and also in frequency of C and T alleles (p = 0.52) between two groups. CONCLUSIONS: Our results revealed no association between the rs7528684 SNP with susceptibility to allergic asthma in the included population. More studies in different ethnic groups will result in more valid conclusions</style></abstract><notes><style face="normal" font="Arial">DA - 20170809IS - 1433-6510 (Print)IS - 1433-6510 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.7754/Clin.Lab.2017.170126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28792713">PM:28792713</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Lab\2017-63-1301-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Lab\2017-63-1301-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Aslanian-Kalkhoran L</style></custom2><misc3><style face="normal" font="Arial">10.7754/Clin.Lab.2017.170126</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Massaro,I.</style></author><author><style face="normal" font="Arial"> Rossi,O.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Lombardi,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cell Therapy and Transfusion Medicine, Azienda Ospedaliero Universitaria Careggi, Florence, Largo Brambilla 1, 50134 Florence, Italy</style></auth-address><titles><title><style face="normal" font="Arial">A survey on the perception of allergy specialists about the reimbursed grass pollen tablets for seasonal allergic rhinitis in Italy</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="15">15-</pages><volume><style face="normal" font="Arial">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asma</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sublingual immunotherapy (SLIT) is a feasible option to classical subcutaneous immunotherapy to treat respiratory allergy and is increasingly prescribed in Europe. However, the lack of reimbursement may limit its prescription. In 2015, the 5-grass pollen tablets was authorized by the European Medicine Agency to treat grass-pollen induced rhinitis and was approved in Italy for full reimbursement. We evaluated the opinions of allergy specialists after the availability of the reimbursed 5-grass pollen tablets. METHODS: A multiple choice questionnaire composed by six questions was used to assess the specialists opinion. The questionnaire was uploaded on the free access online platform SurveyMonkey. The link to access the platform was sent to all members of the Societa Italiana di Asma, Allergologia e Immunologia Clinica (SIAAIC). The access to the questionnaire was anonymous. At survey ending, the access was closed and data were downloaded directly from SurveyMonkey website. RESULTS: The questionnaire was filled by 70 allergists. The majority of allergists felt as most important the concept of SLIT as a drug, the content of allergen extract mirroring the natural exposure, the pre-coseasonal schedule as the most patient's oriented, the very good profile of tolerability and safety, the importance of the build-up phase, and the importance of checking the patient after starting immunotherapy. CONCLUSIONS: The opinions of the Italian allergy specialists about the reimbursed 5-grass-pollen tablets are very positive and make likely an appropriate prescription of SLIT for grass-pollen induced rhinitis in the next years</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 1476-7961 (Print)IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-017-0071-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814941">PM:28814941</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Massaro I</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-017-0071-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aguirre-Valencia,D.</style></author><author><style face="normal" font="Arial"> Posso-Osorio,I.</style></author><author><style face="normal" font="Arial"> Bravo,J.C.</style></author><author><style face="normal" font="Arial"> Bonilla-Abadia,F.</style></author><author><style face="normal" font="Arial"> Tobon,G.J.</style></author><author><style face="normal" font="Arial"> Canas,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">GIRAT: Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional, Fundacion Valle del Lili and Univesidad Icesi, Cali, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)</style></title><secondary-title><style face="normal" font="Arial">Clin Rheumatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rheumatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cyclophosphamide</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasmapheresis</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="Arial">Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome (CSS), is a small vessel vasculitis associated with eosinophilia and asthma. Clinical manifestations commonly seen in patients presenting with EGPA range from upper airway and lung involvement to neurological, cardiac, cutaneous, and renal manifestations. Treatment for severe presentations includes steroids, cyclophosphamide, plasmapheresis, and recently, rituximab. Rituximab is associated with a good response in the treatment of vasculitis, but a variable response for the control of allergic symptoms. Here, we report a 16-year-old female patient with severe EGPA (gastrointestinal and cutaneous vasculitis, rhinitis and asthma) refractory to conventional treatment. She was treated with rituximab, which enabled rapid control of the vasculitis component of the disease, but there was no response to rhinitis and asthma. Additionally, she developed severe bronchospasm during rituximab infusion. Sequential rituximab and omalizumab were initiated, leading to remission of all manifestations of vasculitis, rhinitis, and asthma, in addition to bronchospasm related to rituximab infusion</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1434-9949 (Electronic)IS - 0770-3198 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10067-017-3780-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28762062">PM:28762062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rheumatol\20170801-AguirreValenciaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rheumatol\20170801-AguirreValenciaD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Aguirre-Valencia D</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10067-017-3780-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Birk,A.O.</style></author><author><style face="normal" font="Arial"> Andersen,J.S.</style></author><author><style face="normal" font="Arial"> Villesen,H.H.</style></author><author><style face="normal" font="Arial"> Steffensen,M.A.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Global Pharmacovigilance and Clinical Development, ALK, Horsholm, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Tolerability of the SQ Tree SLIT Tablet in Adults</style></title><secondary-title><style face="normal" font="Arial">Clin Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Foreign bodies</style></keyword><keyword><style face="normal" font="Arial"> Foreign body</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mouth</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Sensation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The tree pollen sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) is being developed for the treatment of tree pollen induced allergic rhinitis with or without conjunctivitis. The objective of this Phase I trial was to investigate the tolerability and acceptable dose range of the SQ tree SLIT-tablet in adults with allergic rhinoconjunctivitis. METHODS: The trial was a randomized, double-blind, placebo-controlled, dose escalation Phase I trial that included 70 adults (aged 19-61 years) with birch pollen-induced rhinoconjunctivitis with or without mild to moderate asthma. The trial included 6 different dosage groups that were randomized 3:1 to active treatment or placebo once daily for 28 days. Adverse events (AEs) were coded in the Medical Dictionary for Regulatory Activities by medically qualified personnel. Immunologic assessments included IgE and IgE-blocking factor. FINDINGS: Most (96%) reported AEs were mild, and only 5 severe events (0.2%) were reported. The most frequently reported investigational medicinal product-related AEs were oral pruritus, ear pruritus, mouth edema, sensation of foreign body, throat irritation, pharyngolaryngeal pain, dry throat, tongue blistering, eye pruritus, and headache. The trial included doses ranging from 1 to 24 development units (DU), and the mean number of investigational medicinal product-related AEs per participant was highest in the 24 DU group. The 12 and 24 DU doses induced statistically significant changes from baseline compared with placebo in birch specific IgE and IgE-blocking factor. IMPLICATIONS: The trial found that doses up to 12 DU of the SQ tree SLIT tablet have a tolerability profile suitable for at-home administration. An immunomodulatory effect was found for all doses included in the trial, and doses up to 12 DU were thus chosen for further clinical development of the SQ tree SLIT tablet. EudraCT identifier: 2007-003234-42</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 1879-114X (Electronic)IS - 0149-2918 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clinthera.2017.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28844318">PM:28844318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Ther\20170828-BirkAO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Ther\20170828-BirkAO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Birk AO</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clinthera.2017.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nurmatov,U.</style></author><author><style face="normal" font="Arial"> Dhami,S.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Calderon,M.</style></author><author><style face="normal" font="Arial"> Cingi,C.</style></author><author><style face="normal" font="Arial"> Durham,S.</style></author><author><style face="normal" font="Arial"> Van Wijk,R.G.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Hamelmann,E.</style></author><author><style face="normal" font="Arial"> Hellings,P.</style></author><author><style face="normal" font="Arial"> Jacobsen,L.</style></author><author><style face="normal" font="Arial"> Knol,E.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Lin,S.Y.</style></author><author><style face="normal" font="Arial"> Maggina,V.</style></author><author><style face="normal" font="Arial"> Oude-Elberink,H.</style></author><author><style face="normal" font="Arial"> Pajno,G.</style></author><author><style face="normal" font="Arial"> Panwankar,R.</style></author><author><style face="normal" font="Arial"> Pastorello,E.</style></author><author><style face="normal" font="Arial"> Pitsios,C.</style></author><author><style face="normal" font="Arial"> Rotiroti,G.</style></author><author><style face="normal" font="Arial"> Timmermans,F.</style></author><author><style face="normal" font="Arial"> Tsilochristou,O.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> Wilkinson,J.</style></author><author><style face="normal" font="Arial"> Williams,A.</style></author><author><style face="normal" font="Arial"> Worm,M.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Population Medicine, School of Medicine, Cardiff University, Wales, UK</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="24">24-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cost Savings</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cyprus</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for ARC. METHODS: We undertook a systematic overview, which involved searching nine international biomedical databases from inception to October 31, 2015. Studies were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist for systematic reviews. Data were descriptively synthesized. RESULTS: Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT and SLIT. CONCLUSIONS: We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews</style></abstract><notes><style face="normal" font="Arial">DA - 20170810IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United KIngdom -CO - Italy -CO - Germany -CO - Austria -CO - Spain -CO - Turkey -CO - Denmark -CO - Belgium -CO - Netherlands -CO - Mexico -CO - United States -CO - Greece -CO - Japan -CO - Cyprus -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0159-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28794855">PM:28794855</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-15-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-15-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170810, Nurmatov U</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0159-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,S.</style></author><author><style face="normal" font="Arial"> Rani,A.</style></author><author><style face="normal" font="Arial"> Goyal,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Bioinformatics and Medical Informatics Research Center, San Diego State University, San Diego 92182, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Insights into the immune manipulation mechanisms of pollen allergens by protein domain profiling</style></title><secondary-title><style face="normal" font="Arial">Comput Biol Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Comput Biol Chem</style></full-title></periodical><pages end="39" start="31">31-39</pages><volume><style face="normal" font="Arial">70</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroach allergens</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Expansin</style></keyword><keyword><style face="normal" font="Arial"> Hiv</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Informatics</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Motifs</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Pectin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Polygalacturonase</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword></keywords><dates><year Day="29" Month="7" Year="2017">2017/7/29</year></dates><abstract><style face="normal" font="Arial">Plant pollens are airborne allergens, as their inhalation causes immune activation, leading to rhinitis, conjunctivitis, sinusitis and oral allergy syndrome. A myriad of pollen proteins belonging to profilin, expansin, polygalacturonase, glucan endoglucosidase, pectin esterase, and lipid transfer protein class have been identified. In the present in silico study, the protein domains of fifteen pollen sequences were extracted from the UniProt database and submitted to the interactive web tool SMART (Simple Modular Architecture Research Tool), for finding the protein domain profiles. Analysis of the data based on custom-made scripts revealed the conservation of pathogenic domains such as OmpH, PROF, PreSET, Bet_v_1, Cpl-7 and GAS2. Further, the retention of critical domains like CHASE2, Galanin, Dak2, DALR_1, HAMP, PWI, EFh, Excalibur, CT, PbH1, HELICc, and Kelch in pollen proteins, much like cockroach allergens and lethal viruses (such as HIV, HCV, Ebola, Dengue and Zika) was observed. Based on the shared motifs in proteins of taxonomicall-ydispersed organisms, it can be hypothesized that allergens and pathogens manipulate the human immune system in a similar manner. Allergens, being inanimate, cannot replicate in human body, and are neutralized by immune system. But, when the allergens are unremitting, the immune system becomes persistently hyper-sensitized, creating an inflammatory milieu. This study is expected to contribute to the understanding of pollen allergenicity and pathogenicity</style></abstract><notes><style face="normal" font="Arial">DA - 20170806IS - 1476-928X (Electronic)IS - 1476-9271 (Linking)LA - engPT - Journal ArticleCO - United States -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.compbiolchem.2017.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780227">PM:28780227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Comput Biol Chem\2017-70-31-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Comput Biol Chem\2017-70-31-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170806, Patel S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.compbiolchem.2017.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85525</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Helaskoski,E.</style></author><author><style face="normal" font="Arial"> Suojalehto,H.</style></author><author><style face="normal" font="Arial"> Kuuliala,O.</style></author><author><style face="normal" font="Arial"> Aalto-Korte,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Occupational Medicine, Finnish Institute of Occupational Health, 00251, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Occupational contact urticaria and protein contact dermatitis: causes and concomitant airway diseases</style></title><secondary-title><style face="normal" font="Arial">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anhydrides</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Occupational rhinitis</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rubber</style></keyword><keyword><style face="normal" font="Arial"> rubber latex</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Contact urticaria (CU) and protein contact dermatitis (PCD) are mainly induced by an immediate, IgE-mediated immunological mechanism. Immediate sensitization is also linked to asthma and/or allergic rhinitis. OBJECTIVES: To report causes of work-induced CU and PCD, and to evaluate the occurrence of concomitant airway diseases. METHODS: We retrospectively reviewed the patient files of cases diagnosed with CU or PCD at the Finnish Institute of Occupational Health during 1995-2011. We obtained data on occupation, exposures, clinical and immunological test results, and diagnosed occupational skin and respiratory diseases. RESULTS: Altogether, 291 cases of occupational CU or PCD were diagnosed during the study period. The most common causes were flour, cow dander, natural rubber latex, and acid anhydrides. Concomitant occupational asthma caused by the same agent as the skin disease was detected in 60 patients (21%), and occupational rhinitis was detected in 111 patients (38%). CONCLUSIONS: Almost half of the patients (46%) with occupational CU and PCD had concomitant occupational airway disease. Patients with CU/PCD should always be asked about respiratory symptoms, and preventive measures at the workplace should include protection of both the skin and the airways</style></abstract><notes><style face="normal" font="Arial">DA - 20170810IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cod.12856</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28795430">PM:28795430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\20170810-HelaskoskiE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\20170810-HelaskoskiE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170810, Helaskoski E</style></custom2><misc3><style face="normal" font="Arial">10.1111/cod.12856</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cabanillas,B.</style></author><author><style face="normal" font="Arial"> Novak,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Dermatology and Allergy , University of Bonn Medical Center , Sigmund-Freud-Str., 25, 53127 Bonn , Germany</style></auth-address><titles><title><style face="normal" font="Arial">Effects of daily food processing on allergenicity</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Baking</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Frying</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Microwave</style></keyword><keyword><style face="normal" font="Arial"> microwave heating</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Non-thermal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Physico-chemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Pressure cooking</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Processing treatment</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Roasting</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatment</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatments</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="Arial">Daily food processing has the potential to alter the allergenicity of foods due to modification of the physico-chemical properties of proteins. The degree of such modifications depends on factors such as processing conditions, type of food considered, allergenic content, etc. The impact of daily food processing like boiling, roasting, frying or baking on food allergenicity have been extensively studied. The influence of other thermal treatments such as microwave heating or pressure cooking on allergenicity has also been analyzed. Non-thermal treatment such as peeling impacts on the allergenic content of certain foods such as fruits. In this review, we give an updated overview of the effects of daily processing treatments on the allergenicity of a wide variety of foods. The different variables that contribute to the modification of food allergenicity due to processing are also reviewed and discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2017.1356264</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28799792">PM:28799792</url></web-urls><pdf-urls><url ppv-ref="no">natalija.novak@ukbonn.de</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170811, Cabanillas B</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2017.1356264</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jappe,U.</style></author><author><style face="normal" font="Arial"> Schwager,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical and Molecular Allergology, Priority Research Area Asthma &amp; Allergy, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Research Center Borstel, Parkallee 35, 23845, Borstel, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Relevance of Lipophilic Allergens in Food Allergy Diagnosis</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="61">61-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: The purpose of this review is to provide available data on a new class of allergens, the oleosins, and their diagnostic value. There is evidence that allergen extracts used for in vivo as well as in vitro diagnostic tests do not contain oleosins because these proteins are lipophilic and nearly insoluble in saline or aqueous solutions. So far, only oleosins of peanut, sesame and hazelnut have been registered as allergens. Reports on IgE-binding tests performed with oleosins of different species with sera from allergic patients show that IgE specific for oleosins are associated with severe allergic reactions which is why they should be part of the diagnostic tests in the future. RECENT FINDINGS: Recent findings showed that oleosins purified from in shell-roasted peanuts revealed a higher IgE-binding capacity when compared to raw ones. Naturally purified as well as recombinantly produced peanut oleosins can be used in basophil activation test. The synopsis of all reports on different thermal processing of several oleosin sources and the respective data obtained with patients sera investigated via immunoblot and basophil activation test points to the recommendation that-if naturally purified oleosins are used, they should mostly be obtained from roasted food allergen sources. For immunoblot and basophil activation test, both, naturally purified oleosins as well as recombinant modified oleosins are valuable diagnostic tools</style></abstract><notes><style face="normal" font="Arial">DA - 20170810IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0731-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28795292">PM:28795292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170810, Jappe U</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0731-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85528</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,H.D.</style></author><author><style face="normal" font="Arial"> Chambliss,J.M.</style></author><author><style face="normal" font="Arial"> Gupta,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA</style></auth-address><titles><title><style face="normal" font="Arial">Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="63">63-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Recombinant vaccine</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="Arial">Allergy immunotherapy (AIT) is the only disease-modifying therapy for the treatment of allergic diseases. Although its efficacy and utility are well-established, the potential for serious adverse events, cumbersome and lengthy treatment protocols, and variability of natural allergen preparations have limited its widespread application. Recent advances in recombinant technology have opened new avenues for the development of AIT vaccines. The purpose of this review is to highlight recent evidence on the use of novel recombinant vaccines and review the mechanisms, efficacy, safety, and limitations of AIT. Emerging evidence suggests that recombinant vaccines may provide a viable treatment alternative that improves on the limitations of natural extract therapy while maintaining efficacy</style></abstract><notes><style face="normal" font="Arial">DA - 20170819IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0727-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28822054">PM:28822054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-17-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170819, Patel HD</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0727-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singh,S.</style></author><author><style face="normal" font="Arial"> Kumar,N.</style></author><author><style face="normal" font="Arial"> Dwiwedi,P.</style></author><author><style face="normal" font="Arial"> Charan,J.</style></author><author><style face="normal" font="Arial"> Kaur,R.</style></author><author><style face="normal" font="Arial"> Sidhu,P.</style></author><author><style face="normal" font="Arial"> Chugh,V.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, AIIMS, Jodhpur, Rajasthan. IndiaAIIMS-Jodhpur, Rajasthan. India</style></auth-address><titles><title><style face="normal" font="Arial">Monoclonal Antibodies: A Review</style></title><secondary-title><style face="normal" font="Arial">Curr Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast cancer</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Lymphoma</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Transformation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">Over the last three decades, monoclonal antibodies (MAbs) have made a striking transformation from scienti fi c tools to powerful human therapeutics. Muromonab CD3 a murine MAb, was first FDA approved therapeutic MAb for prevention of kidney transplant rejection. Since its approval in 1986, there has been decline in the further application and approvals until the late 1990s when the first chimeric Mab, Rituximab was approved for the treatment of low grade B cell lymphoma in 1997. With the approval by licensing authorities of chimeric, followed by humanized and then fully human monoclonal antibodies, rate of approval and monoclonal antibodies available in the market for the treatment of various diseases has increased dramatically. As of March 2017, FDA has approved approximately 60 therapeutic MAbs with much more currently under evaluation in various phases of clinical trials. MAbs are approved for the treatment of a diseases belonging to various system like cardiovascular, respiratory, hematology, kidney, immunology and oncology. Mab are approved for the treatment of orphan diseases or indications such as paroxysmal nocturnal hemoglobinuria as well as cancers and multiple sclerosis where hundreds of patients are treated and even diseases such as breast cancer, asthma and rheumatoid arthritis where millions are being treated. This review focuses briefly on types, molecular targets, mechanism of actions and therapeutic indications of FDA approved MAb products that are currently on the market</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 2212-3938 (Electronic)IS - 1574-8847 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.2174/1574884712666170809124728</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28799485">PM:28799485</url></web-urls></urls><custom2><style face="normal" font="Arial">20170811, Singh S</style></custom2><misc3><style face="normal" font="Arial">10.2174/1574884712666170809124728</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smukalla,S.M.</style></author><author><style face="normal" font="Arial"> Dimitrova,I.</style></author><author><style face="normal" font="Arial"> Feintuch,J.M.</style></author><author><style face="normal" font="Arial"> Khan,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Dysphagia in the Elderly</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Gastroenterol</style></full-title></periodical><pages end="396" start="382">382-396</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dilation</style></keyword><keyword><style face="normal" font="Arial"> Dysphagia</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly patients</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food avoidance</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Manometry</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1534-309X</style></isbn><abstract><style face="normal" font="Arial">Dysphagia is a common problem in the elderly population with an especially high prevalence in hospitalized and institutionalized patients. If inadequately addressed, dysphagia leads to significant morbidity and contributes to decreased quality of life. Dysphagia can be categorized as emanating from either an oropharyngeal or esophageal process. A disproportionate number of elderly patients suffer from oropharyngeal dysphagia with a multifactorial etiology. Historically, treatment options have been limited and included mostly supportive care with a focus on dietary modification, food avoidance, and swallow rehabilitation. Nascent technologies such as the functional luminal imaging probe (FLIP) and advances in esophageal manometry are improving our understanding of the pathophysiology of oropharyngeal dysphagia. Recent developments in the treatment of specific causes of oropharyngeal dysphagia, including endoscopic balloon dilations for upper esophageal sphincter (UES) dysfunction, show promise and are expected to enhance with further research. Esophageal dysphagia is also common in the elderly and more commonly due to an identifiable cause. The full breadth of treatment options is frequently unavailable to elderly patients due to comorbidities and overall functional status. However, the increasing availability of less invasive solutions to specific esophageal pathologies has augmented the number of treatment options available to this population, where an individualized approach to patient care is paramount. This review focuses on the evaluation and management of dysphagia in the elderly and delineates how standard and novel therapeutics are contributing to more nuanced and personalized management</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11938-017-0144-0</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s11938-017-0144-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Gastroenterol\2017-15-382-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Gastroenterol\2017-15-382-96.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, SMukalla SM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11938-017-0144-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Capecchi,R.</style></author><author><style face="normal" font="Arial"> Italiani,P.</style></author><author><style face="normal" font="Arial"> Puxeddu,I.</style></author><author><style face="normal" font="Arial"> Pratesi,F.</style></author><author><style face="normal" font="Arial"> Tavoni,A.</style></author><author><style face="normal" font="Arial"> Boraschi,D.</style></author><author><style face="normal" font="Arial"> Migliorini,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">IL-1 family cytokines and receptors in IgG4-related disease</style></title><secondary-title><style face="normal" font="Arial">Cytokine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cytokine</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood donor</style></keyword><keyword><style face="normal" font="Arial"> Blood Donors</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-1</style></keyword><keyword><style face="normal" font="Arial"> IL-1 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pancreas</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/AIM: The IgG4-related disease (IgG4-RD) is a fibroinflammatory condition that can affect almost any organ, often associated with eosinophilia and increased levels of IgE and IgG4. Overexpression in tissues of Th2-related cytokines but also of IFN-gamma has been reported. Given the major role of Il-1 family cytokines in inducing and regulating inflammation, and the paucity of data so far available in IgG-RD, we performed a comprehensive analysis of IL-18, related IL-1 family cytokines and soluble receptors in these patients. PATIENTS AND METHODS: Fifteen patients fulfilling the criteria for the diagnosis of IgG4-RD and 80 blood donors as control were recruited. Cytokines of the IL-1 family (IL-1alpha, IL-1beta, IL-33, IL-18), soluble receptors (sIL-1R1, sIL-1R2, sIL-1R3, ST2/sIL-1R4) and antagonists (IL-1Ra, IL-18 binding protein -IL-18BP-) were measured in sera by multiarray ELISA assay. Free IL-18 was calculated as the amount of IL-18 not inhibited by IL-18BP. RESULTS: Half of the patients had a multiorgan disease, mainly affecting retroperitoneum, lymph nodes and pancreas. sIL-1R1 (p=0.0001), sIL-1R2 (p=0.0024), ST2/sIL-1R4 (p=0.002) were significantly increased in IgG4-RD sera compared with healthy controls; sIL-R3 was significantly lower in patients vs controls (p=0,0006). CONCLUSIONS: The increased levels of the soluble forms of the two IL-1 receptors IL-1R1 and IL-1R2 suggest the need to dampen IL-1-mediated inflammation at the tissue level. Elevated circulating ST2/sIL-1R4 levels may represent the marker of an ongoing protective mechanism, but their contribution to organ damage cannot be excluded. On the whole, the data suggest a tight control of IL-1 family cytokines signalling in IgG4-RD</style></abstract><notes><style face="normal" font="Arial">DA - 20170821IS - 1096-0023 (Electronic)IS - 1043-4666 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cyto.2017.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28823915">PM:28823915</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytokine\20170821-CapecchiR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytokine\20170821-CapecchiR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170821, Capecchi R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cyto.2017.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Budrewicz,S.</style></author><author><style face="normal" font="Arial"> Banaszczak,M.</style></author><author><style face="normal" font="Arial"> Piotrowski,J.</style></author><author><style face="normal" font="Arial"> Czerwinska,M.</style></author><author><style face="normal" font="Arial"> Stachowska,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry and Human Nutrition, Pomeranian Medical University in Szczecin, Szczecin, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Allergens and food additives, including potentially harmful ones, present in food products that are preferred by children and adolescents</style></title><secondary-title><style face="normal" font="Arial">Dev Period Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Dev Period Med</style></full-title></periodical><pages end="138" start="131">131-138</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> Ammonium Sulfate</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Additives</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food Preferences</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> inverse correlation</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Non celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Non-celiac gluten sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Sulfates</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The proper development of a child is linked with proper nutrition, including nutritional habits which are formed from childhood. THE AIM OF THE STUDY: The aim of the study was to establish a list of the most popular food products among children and to develop a register of potentially dangerous substances on a Facebook website. MATERIALS AND METHODS: A website was created on Facebook. The participants provided lists of favorite dishes or products. RESULTS: The study involved 264 participants. An inverse correlation was observed with reference to the age of the subjects and the occurrence of sugar syrup in their diet (R=-0.20; p&lt;0.001), glucose-fructose (R= -0.18; p&lt; 0.004), and glucose (R=-0.13; p&lt; 0.039) syrups. The most common potential food allergens are: gluten (R=0.28; p&lt;0.001), eggs (R=0.28; p&lt;0.001), and wheat (R=0.25; p&lt;0.001). The main substances added to food that are present in a child's diet that increase proportionally with reference to the child's age are: salicylates (R=0.37; p&lt;0.001), iron and ammonium sulfates (R=0.21; p&lt;0.001). CONCLUSION: The choices of favorite products are related to age and sex. Products containing gluten, the consumption of which increases with age, carry a risk of undiagnosed celiac disease and non-celiac gluten sensitivity in people with a genetic predisposition. Facebook has fulfilled its role as an effective tool for gathering information about the food preferences of children and adolescents</style></abstract><notes><style face="normal" font="Arial">DA - 20170810IS - 1428-345X (Print)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28796984">PM:28796984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dev Period Med\2017-21-131-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dev Period Med\2017-21-131-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170810, Budrewicz S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanino,T.</style></author><author><style face="normal" font="Arial"> Bando,T.</style></author><author><style face="normal" font="Arial"> Komada,A.</style></author><author><style face="normal" font="Arial"> Nojiri,Y.</style></author><author><style face="normal" font="Arial"> Okada,Y.</style></author><author><style face="normal" font="Arial"> Ueda,Y.</style></author><author><style face="normal" font="Arial"> Sakurai,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tokushima Bunri University</style></auth-address><titles><title><style face="normal" font="Arial">Differential Nitric Oxide-Derived Protein Modifications of Flavin-Containing Monooxygenases in Type 1 Allergic Mice</style></title><secondary-title><style face="normal" font="Arial">Drug Metab Dispos</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drug Metab Dispos</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microsomes</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="Arial">Flavin-containing monooxygenases (FMOs) are major mammalian non-cytochrome P450 oxidative enzymes. T Helper2 cell-activated allergic diseases produce excess levels of nitric oxide (NO) that modify the functions of proteins. However, it remains unclear whether allergy-induced NO affects the pharmacokinetics of drugs metabolized by FMOs. This study investigated alterations of hepatic microsomal FMO1 and FMO3 activities in type 1 allergic mice, and further examined the interaction of FMO1 and FMO3 with allergy-induced NO. Imipramine (IMP; FMO1 substrate) N oxidation activity was not altered in allergic mice with high serum NO and immunoglobulin E levels. At 7 days after primary sensitization (PS7) or secondary sensitization (SS7), benzydamine (BDZ; FMO1 and FMO3 substrate) N oxygenation was significantly decreased to 70% of individual controls. The expression levels of FMO1 and FMO3 proteins were not significantly changed in the sensitized mice. Hepatic inducible NO synthase (iNOS) mRNA level increased 5-fold and 15-fold in PS7 and SS7 mice, respectively, and hepatic tumor necrosis factor-alpha levels were greatly enhanced. When a selective iNOS inhibitor was injected into allergic mice, serum NO levels and BDZ N-oxygenation activity returned to control levels. NO directly suppressed BDZ N-oxygenation, which was likely related to FMO3-dependent metabolism in comparison with IMP N-oxidation. In hepatic microsomes from PS7 and SS7 mice, the suppression of BDZ N-oxygenation was restored by ascorbate. Therefore, type 1 allergic mice had differentially suppressed FMO3-dependent BDZ N-oxygenation. The suppression of FMO3 metabolism related to reversible S-nitrosyl modifications of iNOS-derived NO. NO is expected to alter</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1521-009X (Electronic)IS - 0090-9556 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1124/dmd.117.076570</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28760731">PM:28760731</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drug Metab Dispos\20170801-TaninoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drug Metab Dispos\20170801-TaninoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Tanino T</style></custom2><misc3><style face="normal" font="Arial">10.1124/dmd.117.076570</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Young,J.W.S.</style></author><author><style face="normal" font="Arial"> Shear,N.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Toronto, Toronto, ON, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Cutaneous Drug Reactions in the Elderly</style></title><secondary-title><style face="normal" font="Arial">Drugs Aging</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs Aging</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse drug reactions</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="Arial">Cutaneous adverse drug reactions comprise a significant proportion of all adverse drug reactions. They may mimic other dermatologic or systemic illnesses and may cause significant morbidity or mortality. Seven morphologic groups encompass the most commonly encountered cutaneous drug reaction syndromes: exanthematous (maculopapular), dermatitic/eczematous, urticarial, pustular, blistering, purpuric, and erythrodermic. Drug reactions may have significant downstream consequences for the older individual</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1179-1969 (Electronic)IS - 1170-229X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40266-017-0483-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801750">PM:28801750</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs Aging\20170812-YoungJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs Aging\20170812-YoungJW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Young JW</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40266-017-0483-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mine,K.</style></author><author><style face="normal" font="Arial"> Hirakawa,K.</style></author><author><style face="normal" font="Arial"> Kondo,S.</style></author><author><style face="normal" font="Arial"> Minami,M.</style></author><author><style face="normal" font="Arial"> Okada,A.</style></author><author><style face="normal" font="Arial"> Tsutsu,N.</style></author><author><style face="normal" font="Arial"> Yokogawa,Y.</style></author><author><style face="normal" font="Arial"> Hibio,Y.</style></author><author><style face="normal" font="Arial"> Kojima,F.</style></author><author><style face="normal" font="Arial"> Fujimoto,S.</style></author><author><style face="normal" font="Arial"> Kurisaki,H.</style></author><author><style face="normal" font="Arial"> Anzai,K.</style></author><author><style face="normal" font="Arial"> Yoshikai,Y.</style></author><author><style face="normal" font="Arial"> Nagafuchi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Subtyping of Type 1 Diabetes as Classified by Anti-GAD Antibody, IgE Levels, and Tyrosine kinase 2 (TYK2) Promoter Variant in the Japanese</style></title><secondary-title><style face="normal" font="Arial">EBioMedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">EBioMedicine</style></full-title></periodical><pages end="51" start="46">46-51</pages><volume><style face="normal" font="Arial">23</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Design</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> Th1/Th2 balance</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TYK2</style></keyword><keyword><style face="normal" font="Arial"> type 1 diabetes</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Type 1 diabetes (T1D) is known to be caused by Th1 cell-dependent autoimmunity. Recently, we reported that TYK2 promoter variant serves as a putative virus-induced diabetes susceptibility gene associated with deteriorated interferon-dependent antiviral response. TYK2 is also related to HIES, that is, Th2 cell-dependent. Therefore, TYK2 promoter variant may be also associated with the pathogenesis of T1D, modulating Th1/Th2 balance. RESEARCH DESIGN AND METHODS: We assessed the association between anti- GAD Ab, IgE levels, and TYK2 promoter variant among 313 T1D patients, 184 T2D patients, and 264 YH controls in the Japanese. RESULTS: T1D patients had elevated IgE (median, 56.7U/ml; p&lt;0.0001) compared with T2D patients (22.5U/ml) and controls (43.3U/ml). Contrary to our expectations, there was no correlation between TYK2 promoter variant and IgE levels. We found that T1D could be subtyped as four groups based on anti-GAD Ab and IgE profile: Subtype 1, anti-GAD Ab positive and non-elevated IgE (47.0%); Subtype 2, anti-GAD Ab negative and non-elevated IgE (35.1%); Subtype 3, anti-GAD Ab positive and elevated IgE (10.9%); and Subtype 4, anti-GAD Ab negative and elevated IgE (7.0%). In Subtype 2, a significantly higher incidence was observed in T1D cases carrying the TYK2 promoter variant (OR, 2.60; 95%CI, 1.03-6.97; p=0.032), and also showing a flu-like syndrome at diabetes onset (OR, 2.34; 95%CI, 1.27-4.35; p=0.003). INTERPRETATION: Anti-GAD Ab and IgE profiling helps classifying T1D into four groups that recognize variable pathogenic bases of T1D</style></abstract><notes><style face="normal" font="Arial">DA - 20170822IS - 2352-3964 (Electronic)IS - 2352-3964 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ebiom.2017.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826655">PM:28826655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\EBioMedicine\20170822-MineK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\EBioMedicine\20170822-MineK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170822, Mine K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ebiom.2017.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al-Soqeer,A.A.</style></author><author><style face="normal" font="Arial"> Alsubaie,Q.D.</style></author><author><style face="normal" font="Arial"> Motawei,M.I.</style></author><author><style face="normal" font="Arial"> Mousa,H.M.</style></author><author><style face="normal" font="Arial"> Abdel-Salam,A.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Isolation and identification of allergens and biogenic amines of Prosopis juliflora genotypes</style></title><secondary-title><style face="normal" font="Arial">Electron J Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Electron J Biotechnol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic proteins</style></keyword><keyword><style face="normal" font="Arial"> Amines</style></keyword><keyword><style face="normal" font="Arial"> Bioamine</style></keyword><keyword><style face="normal" font="Arial"> Biogenic Amines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Prosopis</style></keyword><keyword><style face="normal" font="Arial"> Prosopis juliflora</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spermine</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Tyramine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0717-3458</style></isbn><abstract><style face="normal" font="Arial">Background Prosopis, or mesquite (Prosopis juliflora (Sw.) DC.) was introduced in Saudi Arabia for several decades, and heavily used in streets, roadsides and parks plantation. It shows a great adaptation to the prevailing climatic conditions such as high temperature, severe drought and salinity, and spread naturally in many parts of the Kingdom. This research was carried out to isolate allergic proteins and biogenic amines from pollen gains of P. juliflora genotypes that exist in Saudi Arabia from two regions (Al-Qassim and Eastern regions). Results The results showed that eighteen different allergic proteins have been detected in Prosopis juliflora genotypes with molecular weight ranging from 14 to 97 KDa. Moreover, Prosopis juliflora genotypes from the two studied regions contained eight biogenic amines, Histamine, Tyramine, Tryptamine, B-Phenylthylamine, Butricine, Codapherine, Spermidine, and Speramine. All genotypes from Al-Qassim region were found to contain all eight amines. While in Eastern region, histamine did not exist in three genotypes, spermine was not found in six genotypes, and spermidine was not recorded in three genotypes. Genotypes B23, E20 and E21 had the lowest biogenic amine. Conclusions All identified proteins from mesquite trees from both Regions (Eastern and Al-Qassim) are allergic for patients sensitive to pollen grains. Bioamines, other than histamine and tyramine, were recorded in varied concentrations from genotype to another</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Saudi Arabia -CO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejbt.2017.08.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ejbt.2017.08.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Electron J Biotechnol\20170830-AlSoqeerAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Electron J Biotechnol\20170830-AlSoqeerAA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Al-Soqeer AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejbt.2017.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bayliss,H.R.</style></author><author><style face="normal" font="Arial"> Schindler,S.</style></author><author><style face="normal" font="Arial"> Adam,M.</style></author><author><style face="normal" font="Arial"> Essl,F.</style></author><author><style face="normal" font="Arial"> Rabitsch,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evidence for changes in the occurrence, frequency or severity of human health impacts resulting from exposure to alien species in Europe: a systematic map</style></title><secondary-title><style face="normal" font="Arial">Environ Evid</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Evid</style></full-title></periodical><pages end="" start="21">21-</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Alien species</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2047-2382</style></isbn><abstract><style face="normal" font="Arial">Alien species are frequently considered a serious environmental threat but negative impacts on human health through injury, allergy, or as vectors of disease sometimes have the most dire consequences for human livelihoods. Climate change and the increasing magnitude and frequency of introductions of species across geographic barriers as a result of international trade are likely to change their establishment, spread, abundance, physiology or phenology, potentially also altering their human health impacts. Yet despite receiving increasing attention in the scientific literature, there have been few attempts to quantify recent changes in human health impacts. Here we report the findings from a systematic map of the literature identifying evidence of any change in the occurrence, frequency or severity of impacts of alien species on human health in Europe over the last 25-áyears</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13750-017-0100-4</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s13750-017-0100-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Evid\2017-6-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Evid\2017-6-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Bayliss HR</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13750-017-0100-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lambert,K.A.</style></author><author><style face="normal" font="Arial"> Bowatte,G.</style></author><author><style face="normal" font="Arial"> Tham,R.</style></author><author><style face="normal" font="Arial"> Lodge,C.</style></author><author><style face="normal" font="Arial"> Prendergast,L.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Erbas,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Psychology and Public Health, La Trobe University, Melbourne, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Residential greenness and allergic respiratory diseases in children and adolescents - A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Res</style></full-title></periodical><pages end="221" start="212">212-221</pages><volume><style face="normal" font="Arial">159</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> aetiology</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Vegetation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The aetiology of allergic respiratory disease in children is not yet fully understood. Environmental factors are believed to play a major part. The amount of green vegetation surrounding the home (residential greenness) has been recently identified as a potentially important exposure OBJECTIVES: Our goal was to provide a systematic review and quantitative summary of the evidence regarding the relationship between residential greenness and allergic respiratory diseases in children. METHODS: Peer-reviewed literature published prior to 1 March 2017 was systematically searched using nine electronic databases. Meta-analyses were conducted if at least three studies published risk estimates for the same outcome and exposure measures. RESULTS: We included 11 articles across broad outcomes of asthma and allergic rhinitis. Reported effects were inconsistent with varying measures to define residential greenness. Only limited meta-analysis could be conducted, with the pooled odds ratios for asthma (OR 1.01 95%CI 0.93, 1.09; I2 68.1%) and allergic rhinitis (OR 0.99 95%CI 0.87, 1.12; I2 72.9%) being significantly heterogeneous. CONCLUSIONS: Inconsistencies between the studies were too large to accurately assess the association between residential greenness and allergic respiratory disease. A standardised global measure of greenness which accounts for seasonal variation at a specific relevant buffer size is needed to create a more cohesive body of evidence and for future examination of the effect of residential greenness on allergic respiratory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170813IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.envres.2017.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803150">PM:28803150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Res\2017-159-212-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Res\2017-159-212-21.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170813, Lambert KA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.envres.2017.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,H.C.</style></author><author><style face="normal" font="Arial"> Lim,J.Y.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Jang,Y.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Development of a mouse model of eosinophilic chronic rhinosinusitis with nasal polyp by nasal instillation of an Aspergillus protease and ovalbumin</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> macrophage inflammatory protein 2</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1434-4726</style></isbn><abstract><style face="normal" font="Arial">One subtype of chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by the development of a T-helper type 2 (Th2) response and eosinophilic infiltration. Here, we aimed to establish an eosinophilic CRSwNP murine model, which would be essential to understand the underlying pathogenesis and establish a treatment strategy. C57BL/6 mice were challenged intranasally with a mixture of an Aspergillus oryzae-derived protease (AP) and ovalbumin (OVA) for 6, 8, or 12 consecutive weeks (12 mice/group); control mice received the same volume of phosphate-buffered saline for 12-áweeks (n-á=-á12). Sinonasal samples were evaluated histologically, and interleukin (IL)-4, IL-5, IL-13, eotaxin, keratinocyte chemoattractant, and macrophage inflammatory protein-2 mRNA levels in sinonasal mucosa were measured by real-time PCR. Protein levels of Th2 cytokines, INF-+¦, IL-17A, and chemokines in nasal lavage fluid, and total serum IgE were measured by ELISA. Greater eosinophil infiltration in the subepithelial layer was observed in the challenged groups, compared with the control group. Polypoid mucosal lesions were predominantly observed in the 12-week group, which also exhibited mucosal thickening on micro-CT scans. The IL-4, IL-5, and IL-13 mRNA and protein levels were elevated in the sinonasal mucosa and nasal lavage fluid. INF-+¦ and IL-17A were undetectable or not elevated relative to the control group levels. In contrast, eotaxin levels were particularly elevated in the sinonasal mucosa and nasal lavage fluid in the 12-week group. In conclusion, intranasal AP and OVA exposure successfully induced Th2-specific CRSwNP in a murine model</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4717-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28828551">PM:28828551</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170821-KimHC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20170821-KimHC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170821, Kim HC</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4717-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Santis,M.A.</style></author><author><style face="normal" font="Arial"> Giuliani,M.M.</style></author><author><style face="normal" font="Arial"> Giuzio,L.</style></author><author><style face="normal" font="Arial"> De Vita,P.</style></author><author><style face="normal" font="Arial"> Lovegrove,A.</style></author><author><style face="normal" font="Arial"> Shewry,P.R.</style></author><author><style face="normal" font="Arial"> Flagella,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dipartimento di Scienze Agrarie, degli Alimenti e dell'Ambiente, Universita degli Studi di Foggia, Via Napoli 25 - 71122, Foggia, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Differences in gluten protein composition between old and modern durum wheat genotypes in relation to 20th century breeding in Italy</style></title><secondary-title><style face="normal" font="Arial">Eur J Agron</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Agron</style></abbr-1></periodical><pages end="29" start="19">19-29</pages><volume><style face="normal" font="Arial">87</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Coeliac disease</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Differential expression</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Durum wheat</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten index</style></keyword><keyword><style face="normal" font="Arial"> glutenin</style></keyword><keyword><style face="normal" font="Arial"> Glutenin subunits</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Omega-5-gliadin</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein composition</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tri a 19</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat gluten</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">The impact of breeding on grain yields of wheat varieties released during the 20th century has been extensively studied, whereas less information is available on the changes in gluten quality associated with effects on the amount and composition of glutenins and gliadins. In order to explore the effects of breeding during the 20th century on gluten quality of durum wheat for processing and health we have compared a set of old and modern Italian genotypes grown under Mediterranean conditions. The better technological performance observed for the modern varieties was found to be due not only to the introgression of superior alleles of high (HMW-GS) and low molecular weight (LMW-GS) glutenin subunits encoded at Glu-B1 and Glu-B3 loci, but also to differential expression of specific storage proteins. In particular, the higher gluten index observed in modern genotypes was correlated with an increased glutenin/gliadin ratio and the expression of B-type LMW-GS which was, on average, two times higher in the modern than in the old group of durum wheat genotypes. By contrast, no significant differences were found between old and modern durum wheat genotypes in relation to the expression of alpha-type and gamma-type gliadins which are major fractions that trigger coeliac disease (CD) in susceptible individuals. Furthermore, a drastic decrease was observed in the expression of omega-type gliadins in the modern genotypes, mainly omega-5 gliadin (also known as Tri a 19) which is a major allergen in wheat dependent exercise induced anaphylaxis (WDEIA). Immunological and 2DE SDS-PAGE analyses indicated that these differences could be related either to a general down-regulation or to differences in numbers of isoforms. Lower rainfall during grain filling period was related to overall higher expression of HMW-GS and omega-gliadins. In conclusion, breeding activity carried out in Italy during the 20th century appears to have improved durum wheat gluten quality, both in relation to technological performance and allergenic potential</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1161-0301 (Print)IS - 1161-0301 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.eja.2017.04.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28769550">PM:28769550</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Agron\2017-87-19-29.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Agron\2017-87-19-29.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, De Santis MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.eja.2017.04.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kao,D.</style></author><author><style face="normal" font="Arial"> Lux,A.</style></author><author><style face="normal" font="Arial"> Schaffert,A.</style></author><author><style face="normal" font="Arial"> Lang,R.</style></author><author><style face="normal" font="Arial"> Altmann,F.</style></author><author><style face="normal" font="Arial"> Nimmerjahn,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chair of Genetics, Department of Biology, University of Erlangen-Nuremberg, Erwin-Rommel-Str. 3, 91058, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">IgG subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice</style></title><secondary-title><style face="normal" font="Arial">Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fc receptors</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glycosylation</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> tryptic digest</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin G (IgG) glycosylation can modulate antibody effector functions. Depending on the precise composition of the sugar moiety attached to individual IgG glycovariants either pro- or anti-inflammatory effector pathways can be initiated via differential binding to type I or type II Fc-receptors. However, an in depth understanding of how individual IgG subclasses are glycosylated during the steady state and how their glycosylation pattern changes during vaccination is missing. To monitor IgG subclass glycosylation during the steady state and upon vaccination of mice with different T cell dependent and independent antigens, tryptic digests of serum and antigen specific IgG preparations were analysed by reversed phase-liquid chromatography-mass spectrometry. We show that there is a remarkable difference with respect to how individual IgG subclasses are glycosylated during the steady state. More importantly, upon T cell dependent and independent vaccinations, individual antigen specific IgG subclasses reacted differently with respect to changes in individual glycoforms, suggesting that the IgG subclass itself is a major determinant of restricting or allowing alterations in specific IgG glycovariants. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1002/eji.201747208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28771702">PM:28771702</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20170803-KaoD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Immunol\20170803-KaoD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Kao D</style></custom2><misc3><style face="normal" font="Arial">10.1002/eji.201747208</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lim,S.</style></author><author><style face="normal" font="Arial"> Ho,S.J.</style></author><author><style face="normal" font="Arial"> Koo,J.H.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author><author><style face="normal" font="Arial"> Choi,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">dNP2-ctCTLA-4 inhibits German cockroach extract-induced allergic airway inflammation and hyper-responsiveness via inhibition of Th2 responses</style></title><secondary-title><style face="normal" font="Arial">Exp Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Exp Mol Med</style></abbr-1></periodical><pages end="" start="e362">e362-</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Bronchi</style></keyword><keyword><style face="normal" font="Arial"> Cell permeable peptide</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> German cockroach</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Household allergens</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">German cockroaches are major household allergens that can trigger allergic airway inflammatory diseases with sensitive T-cell responses. Although the use of immune modulatory biologics, such as antibodies, to mediate allergic responses has recently been examined, only systemic administration is available because of the size limitations on intranasal administration. Here we utilized a cell-permeable peptide, dNP2, to deliver the cytoplasmic domain of cytotoxic T-lymphocyte antigen-4 (ctCTLA-4) through the airway epithelium to modulate Th2 responses in a German cockroach extract (GCE)-induced allergic airway inflammation model. The intranasal delivery efficiency of the dNP2-dTomato protein to the lungs was higher in GCE-induced asthmatic lung parenchymal cells compared to the sham cells. Intranasal administration of the dNP2-ctCTLA-4 protein inhibited airway hyper-responsiveness and reduced airway inflammation and remodeling, including goblet cell metaplasia and collagen deposition around the bronchi. The number of infiltrated cells, including eosinophils, and the levels of IL-4, IL-5, IL-13 and IFN-gamma in the lungs were significantly reduced, presumably owing to inhibition of Th2 differentiation. However, intranasal administration of CTLA4-Ig did not inhibit airway inflammation. These results collectively suggest that dNP2-ctCTLA-4 is an efficient intranasally applicable candidate biologic for treating allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 2092-6413 (Electronic)IS - 1226-3613 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1038/emm.2017.107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775364">PM:28775364</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Mol Med\2017-49-e362.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Mol Med\2017-49-e362.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Lim S</style></custom2><misc3><style face="normal" font="Arial">10.1038/emm.2017.107</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez-Fernandez,J.</style></author><author><style face="normal" font="Arial"> Rivas,L.</style></author><author><style face="normal" font="Arial"> Luque-Ortega,J.R.</style></author><author><style face="normal" font="Arial"> Nunez-Ramirez,R.</style></author><author><style face="normal" font="Arial"> Campioli,P.</style></author><author><style face="normal" font="Arial"> Garate,T.</style></author><author><style face="normal" font="Arial"> Perteguer,M.J.</style></author><author><style face="normal" font="Arial"> Daschner,A.</style></author><author><style face="normal" font="Arial"> Cuellar,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Parasitologia, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Recombinant vs native Anisakis haemoglobin (Ani s 13): Its appraisal as a new gold standard for the diagnosis of allergy</style></title><secondary-title><style face="normal" font="Arial">Exp Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Parasitol</style></full-title></periodical><pages end="129" start="119">119-129</pages><volume><style face="normal" font="Arial">181</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Ani s 1</style></keyword><keyword><style face="normal" font="Arial"> Ani s 7</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Ascaris</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Haemoglobin</style></keyword><keyword><style face="normal" font="Arial"> Heme</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Periodate</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> tetramer</style></keyword><keyword><style face="normal" font="Arial"> Ultracentrifugation</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="8" Year="2017">2017/8/14</year></dates><abstract><style face="normal" font="Arial">Recombinant allergens are currently the best option for serodiagnosis of human anisakiasis in terms of sensitivity and specificity. However, previous reports showed high rates of anisakiasis patients who were negative to Ani s 7 and especially to Ani s 1. Recently, Anisakis haemoglobin was described as a major allergen (Ani s 13). Although Ani s 13 belongs to a conserved protein family, it seems not to be a cross-reacting antigen because of the absence of IgE recognition against Ascaris haemoglobin in Anisakis patients. The aim of this study is to develop a more sensitive and specific diagnosis tool for Anisakis based on the recently discovered allergen Ani s 13. We obtained and purified recombinant Anisakis haemoglobin (rAni s 13) and the native form (nAni s 13). The recognition of both recombinant and native haemoglobins by anti-haemoglobin IgE from patients' sera was assessed by indirect ELISA and immunoblotting using 43 Anisakis sensitised patients and 44 non-Anisakis sensitised patients. Native Ani s 13 was also treated with periodate to study if oxidation of glycans destroys antibody binding. Furthermore, it was structurally characterised by negative staining electron microscopy and analytical ultracentrifugation. Recombinant Ani s 13 was only recognised by four patients with gastro-allergic anisakiasis (GAA) and immunoblotting analyses showed no bands. However, nAni s 13 was detected by 72.1% of Anisakis sensitised patients measured by indirect ELISA. Particularly, 18 (90%) out of 20 GAA patients were positive. Tetramers and octamers were the most abundant homomers of nAni s 13 but octamers had higher content of bound heme. None of the non-Anisakis sensitised patients were positive. Combined use of purified native form of Ani s 13 with current gold standards would improve the sensitivity and specificity for diagnosing anisakiasis</style></abstract><notes><style face="normal" font="Arial">DA - 20170818IS - 1090-2449 (Electronic)IS - 0014-4894 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.exppara.2017.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28818650">PM:28818650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Parasitol\2017-181-119-29.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Parasitol\2017-181-119-29.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170818, Gonzalez-Fernandez J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.exppara.2017.08.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,M.W.</style></author><author><style face="normal" font="Arial"> Liu,R.</style></author><author><style face="normal" font="Arial"> Wu,H.Y.</style></author><author><style face="normal" font="Arial"> Chen,M.</style></author><author><style face="normal" font="Arial"> Dong,M.N.</style></author><author><style face="normal" font="Arial"> Huang,Y.Q.</style></author><author><style face="normal" font="Arial"> Zhang,C.H.</style></author><author><style face="normal" font="Arial"> Wang,Y.Z.</style></author><author><style face="normal" font="Arial"> Xia,J.</style></author><author><style face="normal" font="Arial"> Shi,Y.</style></author><author><style face="normal" font="Arial"> Xie,F.M.</style></author><author><style face="normal" font="Arial"> Luo,H.</style></author><author><style face="normal" font="Arial"> Zhao,X.Y.</style></author><author><style face="normal" font="Arial"> Wei,W.</style></author><author><style face="normal" font="Arial"> Su,M.X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency, The First Hospital Affiliated to Kunming Medical University, Kunming, Yunnan 650032, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Atorvastatin has a protective effect in a mouse model of bronchial asthma through regulating tissue transglutaminase and triggering receptor expressed on myeloid cells-1 expression</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="930" start="917">917-930</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Atorvastatin</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> metalloproteinase</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> statin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">Airway remodeling in asthma contributes to airway hyperreactivity, loss of lung function and persistent symptoms. Current therapies do not adequately treat the structural airway changes associated with asthma. Statin drugs have improved respiratory health and their therapeutic potential in asthma has been tested in clinical trials. However, the mechanism of action of statins in this context has remained elusive. The present study hypothesized that atorvastatin treatment of ovalbumin-exposed mice attenuates early features of airway remodeling via a mevalonate-dependent mechanism. BALB/c mice were sensitized with ovalbumin and atorvastatin was delivered via oral gavage prior to each ovalbumin exposure. Reverse transcription-semi-quantitative polymerase chain reaction (RT-semi-qPCR), ELISA and western blot analysis were used to assess the expression of a number of relevant genes, including tissue transglutaminase (tTG), triggering receptor expressed on myeloid cells (TREM)-1, nuclear factor erythroid 2-related factor (Nrf) 2, hypoxia-inducible factor (HIF)-1alpha, transforming growth factor (TGF)-beta1, matrix metalloproteinase (MMP)-9 and tissue inhibitors of metalloproteinases (TIMP)-1 in lung tissue. alpha-Smooth muscle actin (alpha-SMA) activity was measured by immunohistochemistry. Airway hyperresponsiveness, lung collagen deposition, airway wall area, airway smooth muscle thickness and lung pathology were also assessed. Atorvastatin treatment led to downregulation of tTG and TREM-1 expression in lung tissue after ovalbumin sensitization, blocked the activity of MMP-9, vascular endothelial growth factor, nuclear factor-kappaB p65, alpha-SMA, HIF-alpha and TGF-beta1 and up-regulated Nrf2 expression. Furthermore, the number of lymphocytes and eosinophils in the atorvastatin group was significantly lower than that in the control group. In addition, airway hyperresponsiveness, lung collagen deposition, airway wall area, airway smooth muscle thickness and pathological changes in the lung were significantly decreased in the atorvastatin group, and tumor necrosis factor-alpha, interleukin (IL)-8, IL-13 and IL-17 in serum were significantly decreased. Histological results demonstrated the attenuating effect of atorvastatin on ovalbumin-induced airway remodeling in asthma. In conclusion, the present study indicated that atorvastatin significantly alleviated ovalbumin-induced airway remodeling in asthma by downregulating tTG and TREM-1 expression. The marked protective effects of atorvastatin suggest its therapeutic potential in ovalbumin-induced airway remodeling in asthma treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4576</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28810543">PM:28810543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-14-917-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-14-917-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Liu MW</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4576</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nie,H.</style></author><author><style face="normal" font="Arial"> Wang,A.</style></author><author><style face="normal" font="Arial"> He,Q.</style></author><author><style face="normal" font="Arial"> Yang,Q.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Zhang,G.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Ding,X.</style></author><author><style face="normal" font="Arial"> Yu,H.</style></author><author><style face="normal" font="Arial"> Hu,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Phenotypic switch in lung interstitial macrophage polarization in an ovalbumin-induced mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="1292" start="1284">1284-1292</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> alternative activation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Arginase</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophage polarization</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin-induced mouse model</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">Macrophage phenotype and function varies according to their polarized state, which in turn is dependent on microenvironmental stimuli. Under normal physiological conditions, lung interstitial macrophages that express interleukin (IL)-10 are considered to serve regulatory roles in the prevention of allergic reactions in the airways. However, the phenotypic profile of lung interstitial macrophages during the pathophysiology of asthma remains unknown. In the current study, the phenotypic characteristics of lung interstitial macrophages were investigated in an ovalbumin (OVA)-induced mouse model of asthma. The patterns of surface markers chemokine ligand and interleukin, and the metabolic enzyme activity of lung interstitial macrophages were investigated using flow cytometry analysis, reverse transcription-quantitative polymerase chain reaction, western blot analysis, and ELISA. It was observed that lung interstitial macrophages derived from OVA-induced asthmatic mice expressed phenotypic markers associated with alternatively activated macrophages (M2), including cluster of differentiation-206, transglutaminase 2, arginase (Arg) 1 and chemokine ligand (CCL)17/CCL22/CCL24 secretion. The M2 macrophages also exhibited increased levels of Arg1 activity and reduced levels of IL-10 expression, relative to macrophages derived from control mice. However, when evaluating the expression of markers associated with classically activated (M1) macrophages, namely inducible nitric oxide synthase and IL-12, it was observed that levels of M1 markers in the interstitial macrophages from asthmatic mice did not differ significantly to those in controls. Collectively, these data suggest that lung interstitial macrophages undergo a phenotypic switch from a regulatory macrophage phenotype under normal conditions to an alternative activation state in OVA-induced asthmatic mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4699</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28810589">PM:28810589</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-14-1284-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-14-1284-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Nie H</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4699</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Levsen,A.</style></author><author><style face="normal" font="Arial"> Cipriani,P.</style></author><author><style face="normal" font="Arial"> Mattiucci,S.</style></author><author><style face="normal" font="Arial"> Gay,M.</style></author><author><style face="normal" font="Arial"> Hastie,L.C.</style></author><author><style face="normal" font="Arial"> Mackenzie,K.</style></author><author><style face="normal" font="Arial"> Pierce,G.J.</style></author><author><style face="normal" font="Arial"> Svanevik,C.S.</style></author><author><style face="normal" font="Arial"> Hojgaard,D.P.</style></author><author><style face="normal" font="Arial"> Nascetti,G.</style></author><author><style face="normal" font="Arial"> Gonzalez,A.F.</style></author><author><style face="normal" font="Arial"> Pascual,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anisakis species composition and infection characteristics in Atlantic mackerel, Scomber scombrus, from major European fishing grounds </style><style face="normal" font="Symbol">-</style><style face="normal" font="Arial"> reflecting changing fish host distribution and migration pattern</style></title><secondary-title><style face="normal" font="Arial">Fish Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Fish Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish species</style></keyword><keyword><style face="normal" font="Arial"> Fishing ground</style></keyword><keyword><style face="normal" font="Arial"> fishing grounds</style></keyword><keyword><style face="normal" font="Arial"> flesh</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Ice</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Larva</style></keyword><keyword><style face="normal" font="Arial"> Mackerel</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean Sea</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> North Sea</style></keyword><keyword><style face="normal" font="Arial"> Northeast Atlantic</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Population structure</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Scomber scombrus</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Species identification</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> zoonotic Anisakis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0165-7836</style></isbn><abstract><style face="normal" font="Arial">Atlantic mackerel (Scomber scombrus) ranks among the most valuable fish species in Europe. The NE Atlantic mackerel population is considered to comprise three main stocks (southern, western and North Sea), with variable proportions of these three intermixing at the northerly feeding grounds. The southern and western mackerel stocks have moved over the past 4</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô5 years further north- and westward. Consequently, large-scale mackerel fishing and processing have become thriving industries in Iceland and the Faroe Islands in just a few years. The mackerel population structure in the Mediterranean Sea is less well known but seems to comprise at least one, more or less isolated, spawning component. Although mackerel is an important food resource, systematic and concerted epidemiological surveys of Anisakis species in Atlantic mackerel from European fishing grounds have been lacking. As part of the EU FP7 PARASITE project (GA no. 312068), occurrence and specific identity of Anisakis spp. from 1801 mackerel from Northeast Atlantic and Mediterranean waters was investigated. In general, mackerel caught at the Atlantic fishing grounds exhibited markedly higher Anisakis spp. infection levels than fish from the Mediterranean localities. Mackerel caught off NW Spain and Portugal (ICES VIIIc, IXa) showed highest overall and muscular prevalence, reaching 87% and 52%, respectively, which differed significantly from all other Atlantic samples. Lowest overall Anisakis spp. prevalence and abundance was recorded in mackerel from Faroe Isles waters, while lowest muscular infection levels were found in the samples from the North Sea. Genetic nematode species identification showed that A. simplex (sensu stricto) is the dominating species in mackerel from the Atlantic areas, while A. pegreffii dominated in the samples from the Mediterranean Sea. The latter species showed generally low prevalence and intensity in the flesh, not exceeding 6% and one larva, respectively. While A. simplex (s. s.) and A. pegreffii seem to co-occur in mackerel from off NW Spain and Portugal, several A. pegreffii were also recorded in mackerel from the North- and Norwegian Seas. These findings imply that the actual mackerel started their feeding migration in waters south to the British Isles, which include parts of the sympatric area of the two sibling species. Thus, A. pegreffii could prove a useful supplementary marker to track migration routes of the different mackerel stock components in NE Atlantic waters</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Norway -CO - Italy -CO - France -CO - United Kingdom -CO - Portugal -CO - Spain -CO - Faroe Islands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fishres.2017.07.030</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.fishres.2017.07.030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Fish Res\20170823-LevsenA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Fish Res\20170823-LevsenA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Levsen A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fishres.2017.07.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mejrhit,N.</style></author><author><style face="normal" font="Arial"> Azdad,O.</style></author><author><style face="normal" font="Arial"> Aarab,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of the IgE reactivity of common pandora parvalbumin in a Moroccan population and action of heating and enzymatic treatments</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic digestion</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic treatment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The aim of this study was to evaluate the immunoglobulin E (IgE) sensitivity to common pandora (Pagellus erythrinus) parvalbumin (CPP) in a Moroccan population from the Fez region, and then to study the effect of temperature and enzymatic digestion on the allergenicity of CPP. This work was conducted with a questionnaire completed by a sera-bank, obtained from 500 patients recruited from Fez hospitals. Their sera were analyzed for specific IgE against CPP. Evaluation of specific IgE showed that 11.8% of patients present higher values (>150?IU/ml). Further indirect ELISA and dot-blot results indicated that CPP showed a decrease in the binding of anti-IgE under heating with an average diminution of 41.9%, while pepsin hydrolysis reduced IgE recognition by 22.9%. These results demonstrate that this population was sensitive to CPP and the sensitivity could be reduced by heating and pepsin hydrolysis with an action higher with temperature than enzymatic digestion processing</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Morocco -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1360256</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1360256</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\20170828-MejrhitN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\20170828-MejrhitN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Mejrhit N</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1360256</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,J.</style></author><author><style face="normal" font="Arial"> Xiang,Q.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Ding,T.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Zhai,Y.</style></author><author><style face="normal" font="Arial"> Bai,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Food and Biological Engineering, Zhengzhou University of Light Industry, Zhengzhou 450001, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Inactivation of soybean trypsin inhibitor by dielectric-barrier discharge (DBD) plasma</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="522" start="515">515-522</pages><volume><style face="normal" font="Arial">232</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> anti-nutritional</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Hydrophobicity</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Soy Milk</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> soybean trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Soybeans</style></keyword><keyword><style face="normal" font="Arial"> Soymilk</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Trypsin Inhibitor,Kunitz Soybean</style></keyword><keyword><style face="normal" font="Arial"> Trypsin Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="Arial">Soybean trypsin inhibitor (STI) is considered as one of the most important anti-nutritional factors in soybeans. The objective of this study was to investigate the impacts and underling mechanisms of dielectric-barrier discharge (DBD) plasma on STI activities. The results shown that DBD plasma treatment significantly induced the inactivation of STI in soymilk and Kunitz-type trypsin inhibitor from soybean (SKTI) in a model system. After exposure to DBD plasma at 51.4W for 21min, the STI activities of soymilk were reduced by 86.1%. Affter being treated by DBD plasma, the intrinsic fluorescence and surface hydrophobicity of SKTI were significantly decreased, while the sulfhydryl contents were increased. It is assumed that DBD plasma-induced conformational changes and oxidative modification might contribute to the inactivation of SKTI. In summary, DBD plasma technology is a potential alternative to heat treatment for the inactivation of anti-nutritional substances in food legumes</style></abstract><notes><style face="normal" font="Arial">DA - 20170511IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Trypsin Inhibitors)RN - 9088-41-9 (Trypsin Inhibitor, Kunitz Soybean)RN - EC 3.4.21.4 (Trypsin)SB - IMCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.03.167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28490106">PM:28490106</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2017-232-515-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2017-232-515-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170511, Li J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.03.167</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jin,Y.</style></author><author><style face="normal" font="Arial"> Goodman,R.E.</style></author><author><style face="normal" font="Arial"> Tetteh,A.O.</style></author><author><style face="normal" font="Arial"> Lu,M.</style></author><author><style face="normal" font="Arial"> Tripathi,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Bioinformatics analysis to assess potential risks of allergenicity and toxicity of HRAP and PFLP proteins in genetically modified bananas resistant to Xanthomonas wilt disease</style></title><secondary-title><style face="normal" font="Arial">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Chem Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Banana</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Capsicum</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food security</style></keyword><keyword><style face="normal" font="Arial"> Genetically modified (GM) bananas</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> HRAP</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Kenya</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> PFLP</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Security</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Uganda</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0278-6915</style></isbn><abstract><style face="normal" font="Arial">Banana Xanthomonas wilt (BXW) disease threatens banana production and food security throughout East Africa. Natural resistance is lacking among common cultivars. Genetically modified (GM) bananas resistant to BXW disease were developed by inserting the hypersensitive response-assisting protein (Hrap) or/and the plant ferredoxin-like protein (Pflp) gene(s) from sweet pepper (Capsicum annuum). Several of these GM banana events showed 100% resistance to BXW disease under field conditions in Uganda. The current study evaluated the potential allergenicity and toxicity of the expressed proteins HRAP and PFLP based on evaluation of published information on the history of safe use of the natural source of the proteins as well as established bioinformatics sequence comparison methods to known allergens (www.AllergenOnline.org and NCBI Protein) and toxins (NCBI Protein). The results did not identify potential risks of allergy and toxicity to either HRAP or PFLP proteins expressed in the GM bananas that might suggest potential health risks to humans. We recognize that additional tests including stability of these proteins in pepsin assay, nutrient analysis and possibly an acute rodent toxicity assay may be required by national regulatory authorities</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -CO - Kenya -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fct.2017.08.024</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.fct.2017.08.024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\20170823-JinY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\20170823-JinY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Jin Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fct.2017.08.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mfueni,E.</style></author><author><style face="normal" font="Arial"> Gama,A.P.</style></author><author><style face="normal" font="Arial"> Kabambe,P.</style></author><author><style face="normal" font="Arial"> Chimbaza,M.</style></author><author><style face="normal" font="Arial"> Matita,G.</style></author><author><style face="normal" font="Arial"> Matumba,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food allergen labeling in developing countries: Insights based on current allergen labeling practices in Malawi</style></title><secondary-title><style face="normal" font="Arial">Food Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Control</style></full-title></periodical><pages end="267" start="263">263-267</pages><volume><style face="normal" font="Arial">84</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergen regulation</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic consumer</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Developing Countries</style></keyword><keyword><style face="normal" font="Arial"> developing country</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Sub-Saharan Africa</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><isbn><style face="normal" font="Arial">0956-7135</style></isbn><abstract><style face="normal" font="Arial">Food allergen labeling is an important tool in minimizing the risk of exposure to foods allergens and the resultant adverse effects for individuals with food allergies. Unlike in the industrialized countries, there have been very few studies that have scrutinized food allergen labels and analyzed the robustness of food allergen regulation in developing countries. In the present study, food allergen labeling of 105 supermarket food products in Malawi were evaluated. Furthermore, Malawi</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs allergen labeling regulation was compared with Codex general standard on labeling, and regulations in force in the E.U, U.S, and Republic of South Africa. About 54.3% of the surveyed products carried the special allergen declaration in addition to the declaration on the list of ingredients, 23.8% used special emphasis (bolding, italic, contrasting color and enlarged font) when declaring allergens on the ingredient list, and 28.6% used precautionary allergen labeling (PAL). Notably, none of the surveyed locally manufactured products had any of these features. However, all the surveyed products complied with the allergen labeling requirements stipulated in Malawi General Standard for Labeling of Prepacked Foods implying that the Malawi standard is not protective enough. Moreover, Malawi</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs allergen labeling regulation was found to be the least demanding. Although this study is based on data from Malawi, trends and implications for standards development may be applicable to other developing countries especially those in Sub-Saharan Africa</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Malawi -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodcont.2017.08.007</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodcont.2017.08.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Control\2018-84-263-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Control\2018-84-263-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170822, Mfueni E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodcont.2017.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Production of wheat gluten hydrolyzates by enzymatic process at high pressure</style></title><secondary-title><style face="normal" font="Arial">Food Sci Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Sci Biotechnol</style></full-title></periodical><pages end="1593" start="1587">1587-1593</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Alcalase</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Degree of hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Free amino acids</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> high pressure</style></keyword><keyword><style face="normal" font="Arial"> High-pressure</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat gluten</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2092-6456</style></isbn><abstract><style face="normal" font="Arial">A novel process for producing wheat gluten enzyme hydrolyzates (WGEHs) was developed, using combinations of Flavourzyme 500MG, Alcalase 2.4L, Protamex, and Marugoto E at the high pressure of 300-áMPa, and the resultant hydrolyzates were analyzed for electrophoretic and hydrolytic properties. It was found that multiple-enzyme treatments increased the proportion of the electrophoretic bands less than 5-ákDa in the hydrolyzates greatly both at ambient pressure and 300-áMPa compared with one-enzyme hydrolysis. The contents of total soluble solids in the WGEHs increased considerably up to 89.75% according to the increase in the number of enzymes used at 300-áMPa compared with 79.37% found for the ambient-pressure hydrolysis. These characteristics together with the contents of soluble nitrogen and free amino acids clearly indicated that the high-pressure enzymatic process of this study is an efficient method for obtaining WGEHs with increased degree of hydrolysis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10068-017-0152-9</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10068-017-0152-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Sci Biotechnol\20170823-KimN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Sci Biotechnol\20170823-KimN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Kim N</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10068-017-0152-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Belluco,S.</style></author><author><style face="normal" font="Arial"> Halloran,A.</style></author><author><style face="normal" font="Arial"> Ricci,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">New protein sources and food legislation: the case of edible insects and EU law</style></title><secondary-title><style face="normal" font="Arial">Food Sec</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Sec</style></full-title></periodical><pages end="814" start="803">803-814</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Edible insects</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> New food</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword><keyword><style face="normal" font="Arial"> Safety assessments</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1876-4525</style></isbn><abstract><style face="normal" font="Arial">Growing global food demand has generated a greater interest in the consumption of new and diversified protein sources. Novel foodstuffs represent a challenge for food law as they need proper safety assessments before obtaining market permission. The case of edible insects and European law is a good representation of this issue because a selection of food grade insect species may be available on the European market in the coming years. However, European legislation does not explicitly address edible insects. Consequently, this has left a grey area, allowing different interpretations of the legislation among Member States. The aim of this paper is to analyse the challenge of the safe management of edible insects in the context of the current legal framework. The current Novel Food legislation, as well as the forthcoming version of the legislation, will be analysed and discussed in relation to edible insects. Particular attention will be paid to the evolution of legislation and to the experiences of both EU and non-EU countries. In recent years, a number of different stakeholders have supported the legalization of edible insect consumption in Europe, but market permission is just the first step towards a new framework for a novel food in a regulatory context. Once admitted, edible insects require proper rules to assure consumers and stakeholders of their benefits and safety. This overview highlights the need to develop clearer legislation to govern the future production and consumption of new food in Europe, provide guarantees to producers, and achieve consumer protection</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12571-017-0704-0</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s12571-017-0704-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Sec\2017-9-803-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Sec\2017-9-803-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Belluco S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12571-017-0704-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tiscoski,N.R.</style></author><author><style face="normal" font="Arial"> Valente,B.M.</style></author><author><style face="normal" font="Arial"> de Souza Muniz,V.</style></author><author><style face="normal" font="Arial"> de Arantes,A.C.</style></author><author><style face="normal" font="Arial"> Martins,M.A.</style></author><author><style face="normal" font="Arial"> de Brito,G.L.</style></author><author><style face="normal" font="Arial"> Sabbadini,N.J.</style></author><author><style face="normal" font="Arial"> Farias,B.C.</style></author><author><style face="normal" font="Arial"> Lanzetti,M.</style></author><author><style face="normal" font="Arial"> Valenca,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Federal University of Rio de Janeiro , Institute of Biomedical Sciences , Rio de Janeiro , Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Pharmacological modulation of reactive oxygen species (ROS) improves the airway hyperresponsiveness by shifting the Th1 response in allergic inflammation induced by ovalbumin</style></title><secondary-title><style face="normal" font="Arial">Free Radic Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Free Radic Res</style></full-title></periodical><pages end="722" start="708">708-722</pages><volume><style face="normal" font="Arial">51</style></volume><number><style face="normal" font="Arial">7-8</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">airflow</style></keyword><keyword><style face="normal" font="Arial"> airflow limitation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allopurinol</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Detoxification</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> EPO</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> TBARS</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">Asthma is an allergic inflammation driven by the Th2 immune response with release of such cytokines as IL-4 and IL-13, which contribute to the airflow limitations and airway hyperresponsiveness (AHR). The involvement of oxidative stress in this process is well-established, but the specific role of the superoxide anion and nitric oxide in asthma are poorly understood. Thus, the aim of this study was to investigate the mechanisms underlying the superoxide anion/nitric oxide production and detoxification in a murine asthma model. BALB/c male mice were sensitized and challenged with ovalbumin (OVA). Pretreatments with either apocynin (14 mg/kg) or allopurinol (25 mg/kg) (superoxide anion synthesis inhibitors), aminoguanidine (50 mg/kg) (nitric oxide synthesis inhibitor) or diethyldithiocarbamate (100 mg/kg) (superoxide dismutase inhibitor) were performed 1 h before the challenge. Our data showed that apocynin and allopurinol ameliorated AHR and reduced eosinophil peroxidase, as well as IL-4 and IL-13 levels. Apocynin also abrogated leukocyte peribronchiolar infiltrate and increased IL-1beta secretion. Aminoguanidine preserved lung function and shifted the Th2 to the Th1 response with a reduction of IL-4 and IL-13 and increase in IL-1beta production. Diethyldithiocarbamate prevented neither allergen-induced AHR nor EPO generation. All treatments protected against oxidative damage observed by a reduction in TBARS levels. Taken together, these results suggest that AHR in an asthma model can be avoided by the down-regulation of superoxide anion and nitric oxide synthesis in a mechanism that is independent of a redox response. This down-regulation is also associated with a transition in the typical immunological Th2 response toward the Th1 profile</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 1029-2470 (Electronic)IS - 1029-2470 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1080/10715762.2017.1364377</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28776450">PM:28776450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Free Radic Res\20170804-TiscoskiNR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Free Radic Res\20170804-TiscoskiNR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Tiscoski NR</style></custom2><misc3><style face="normal" font="Arial">10.1080/10715762.2017.1364377</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ahmed,N.</style></author><author><style face="normal" font="Arial"> French,T.</style></author><author><style face="normal" font="Arial"> Rausch,S.</style></author><author><style face="normal" font="Arial"> Kuhl,A.</style></author><author><style face="normal" font="Arial"> Hemminger,K.</style></author><author><style face="normal" font="Arial"> Dunay,I.R.</style></author><author><style face="normal" font="Arial"> Steinfelder,S.</style></author><author><style face="normal" font="Arial"> Hartmann,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Veterinary Medicine, Institute of Immunology, Freie Universitat BerlinBerlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Toxoplasma Co-infection Prevents Th2 Differentiation and Leads to a Helminth-Specific Th1 Response</style></title><secondary-title><style face="normal" font="Arial">Front Cell Infect Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Cell Infect Microbiol</style></full-title></periodical><pages end="" start="341">341-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> co-infection</style></keyword><keyword><style face="normal" font="Arial"> Coinfection</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fecundity</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematode Infections</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 immune response</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 immune response</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Toxoplasma</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Nematode infections, in particular gastrointestinal nematodes, are widespread and co-infections with other parasites and pathogens are frequently encountered in humans and animals. To decipher the immunological effects of a widespread protozoan infection on the anti-helminth immune response we studied a co-infection with the enteric nematode Heligmosomoides polygyrus in mice previously infected with Toxoplasma gondii. Protective immune responses against nematodes are dependent on parasite-specific Th2 responses associated with IL-4, IL-5, IL-13, IgE, and IgG1 antibodies. In contrast, Toxoplasma gondii infection elicits a strong and protective Th1 immune response characterized by IFN-gamma, IL-12, and IgG2a antibodies. Co-infected animals displayed significantly higher worm fecundity although worm burden remained unchanged. In line with this, the Th2 response to H. polygyrus in co-infected animals showed a profound reduction of IL-4, IL-5, IL-13, and GATA-3 expressing T cells. Co-infection also resulted in the lack of eosinophilia and reduced expression of the Th2 effector molecule RELM-beta in intestinal tissue. In contrast, the Th1 response to the protozoan parasite was not diminished and parasitemia of T. gondii was unaffected by concurrent helminth infection. Importantly, H. polygyrus specific restimulation of splenocytes revealed H. polygyrus-reactive CD4+ T cells that produce a significant amount of IFN-gamma in co-infected animals. This was not observed in animals infected with the nematode alone. Increased levels of H. polygyrus-specific IgG2a antibodies in co-infected mice mirrored this finding. This study suggests that polarization rather than priming of naive CD4+ T cells is disturbed in mice previously infected with T. gondii. In conclusion, a previous T. gondii infection limits a helminth-specific Th2 immune response while promoting a shift toward a Th1-type immune response</style></abstract><notes><style face="normal" font="Arial">DA - 20170809IS - 2235-2988 (Electronic)IS - 2235-2988 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3389/fcimb.2017.00341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28791259">PM:28791259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Cell Infect Microbiol\2017-7-341.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Cell Infect Microbiol\2017-7-341.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Ahmed N</style></custom2><misc3><style face="normal" font="Arial">10.3389/fcimb.2017.00341</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Poulsen,L.K.</style></author><author><style face="normal" font="Arial"> Jensen,B.M.</style></author><author><style face="normal" font="Arial"> Esteban,V.</style></author><author><style face="normal" font="Arial"> Garvey,L.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Clinic, Copenhagen University Hospital at Gentofte, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Beyond IgE-When Do IgE-Crosslinking and Effector Cell Activation Lead to Clinical Anaphylaxis?</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="871">871-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitizations</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell activation syndrome</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis in humans is inherently difficult to study due to the acuteness of symptoms and the lack of biomarkers serving as risk predictors. Most cases are related to IgE sensitizations to foods, insect venoms, and drugs with mastocytosis patients forming a smaller risk group. However, identifying the relatively small fraction of persons at risk has been exceedingly difficult. In this review, we propose to describe anaphylaxis in a broader context than defined by IgE sensitization alone. Exposure to a trigger, such as an allergen, may lead to anaphylaxis, but in particular, the internal dose sensed by the immune system needs to be established. Moreover, intrinsic patient factors as well as the specific circumstances of the exposure, i.e., the extrinsic factors, need to be thoroughly accounted for. More controversially, other triggers of anaphylaxis, such as increased sensitivity to or reduced catabolism of histamine ("histamine intolerance") or mast cell activation syndrome also named mast cell activation disorder have been suggested, but still with very limited epidemiological evidence that a significant proportion of the observed reactions are caused by these alleged conditions. Thus, when all conditions are considered, it seems as if IgE-mediated reactions are responsible for the vast majority of anaphylactic conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00871</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848540">PM:28848540</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-871.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-871.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Poulsen LK</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00871</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guilarte,M.</style></author><author><style face="normal" font="Arial"> Sala-Cunill,A.</style></author><author><style face="normal" font="Arial"> Luengo,O.</style></author><author><style face="normal" font="Arial"> Labrador-Horrillo,M.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Section, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">The Mast Cell, Contact, and Coagulation System Connection in Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="846">846-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bradykinin</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Experimental models</style></keyword><keyword><style face="normal" font="Arial"> factor XII</style></keyword><keyword><style face="normal" font="Arial"> fibrinogen</style></keyword><keyword><style face="normal" font="Arial"> Fibrinolysis</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Heparin</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mast cells/basophils</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Plasmin</style></keyword><keyword><style face="normal" font="Arial"> Plasminogen</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is the most severe form of allergic reaction, resulting from the effect of mediators and chemotactic substances released by activated cells. Mast cells and basophils are considered key players in IgE-mediated human anaphylaxis. Beyond IgE-mediated activation of mast cells/basophils, further mechanisms are involved in the occurrence of anaphylaxis. New insights into the potential relevance of pathways other than mast cell and basophil degranulation have been unraveled, such as the activation of the contact and the coagulation systems. Mast cell heparin released upon activation provides negatively charged surfaces for factor XII (FXII) binding and auto-activation. Activated FXII, the initiating serine protease in both the contact and the intrinsic coagulation system, activates factor XI and prekallikrein, respectively. FXII-mediated bradykinin (BK) formation has been proven in the human plasma of anaphylactic patients as well as in experimental models of anaphylaxis. Moreover, the severity of anaphylaxis is correlated with the increase in plasma heparin, BK formation and the intensity of contact system activation. FXII also activates plasminogen in the fibrinolysis system. Mast cell tryptase has been shown to participate in fibrinolysis through plasmin activation and by facilitating the degradation of fibrinogen. Some usual clinical manifestations in anaphylaxis, such as angioedema or hypotension, or other less common, such as metrorrhagia, may be explained by the direct effect of the activation of the coagulation and contact system driven by mast cell mediators</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00846</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28798744">PM:28798744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-346.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-346.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Guilarte M</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00846</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sastre,B.</style></author><author><style face="normal" font="Arial"> Canas,J.A.</style></author><author><style face="normal" font="Arial"> Rodrigo-Munoz,J.M.</style></author><author><style face="normal" font="Arial"> del Pozo,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunoallergy, Department of Immunology, IIS-Fundacion Jimenez Diaz, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Novel Modulators of Asthma and Allergy: Exosomes and MicroRNAs</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="826">826-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exosomes</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nucleic Acids</style></keyword><keyword><style face="normal" font="Arial"> Nucleotides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Intercellular communication is crucial to the immune system response. In the recent years, the discovery of exosomes has changed the way immune response orchestration was understood. Exosomes are able to operate as independent units that act as mediators in both physiological and pathological conditions. These structures contain proteins, lipidic mediators, and nucleic acids and notoriously include microRNAs (miRNAs). miRNAs are short RNA sequences (around 19-22 nucleotides) with a high phylogenetic conservation and can partially or totally regulate multiple mRNAs, inhibiting protein synthesis. In respiratory diseases such as asthma and allergic sensitization, exosomes released by several cell types and their specific content perform crucial functions in the development and continuation of the pathogenic mechanisms. Released exosomes and miRNAs inside them have been found in different types of clinical samples, such as bronchoalveolar lavage fluids and sputum supernatants, providing new data about the environmental factors and mediators that participate in the inflammatory responses that lead to the exacerbation of asthma. In this review, we summarize our current knowledge of the role of exosomes and miRNAs in asthma and allergic sensitization, paying attention to the functions that both exosomes and miRNAs are described to perform through the literature. We review the effect of exosomes and miRNAs in cells implicated in asthma pathology and the genes and pathways that they modify in them, depicting how their behavior is altered in disease status. We also describe their possible repercussion in asthma diagnosis through their possible role as biomarkers. Therefore, both exosomes and miRNAs can be viewed as potential tools to be added to the arsenal of therapeutics to treat this disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00826</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28785260">PM:28785260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-826.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-826.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Sastre B</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00826</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valtonen,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Clinical Diagnosis of the Dampness and Mold Hypersensitivity Syndrome: Review of the Literature and Suggested Diagnostic Criteria</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="951">951-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">assessment</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chemical sensitivity</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical criteria</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> dampness</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Multiple Chemical Sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sick Building Syndrome</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A great variety of non-specific symptoms may occur in patients living or working in moisture-damaged buildings. In the beginning, these symptoms are usually reversible, mild, and present irritation of mucosa and increased morbidity due to respiratory tract infections and asthma-like symptoms. Later, the disease may become chronic and a patient is referred to a doctor where the assessment of dampness and mold hypersensitivity syndrome (DMHS) often presents diagnostic challenges. Currently, unanimously accepted laboratory tests are not yet available. Therefore, the diagnosis of DMHS is clinical and is based on the patient's history and careful examination. In this publication, I reviewed contemporary knowledge on clinical presentations, laboratory methods, and clinical assessment of DMHS. From the literature, I have not found any proposed diagnostic clinical criteria. Therefore, I propose five clinical criteria to diagnose DMHS: (1) the history of mold exposure in water-damaged buildings, (2) increased morbidity to due infections, (3) sick building syndrome, (4) multiple chemical sensitivity, and (5) enhanced scent sensitivity. If all the five criteria are met, the patient has a very probable DMHS. To resolve the current problems in assigning correct DMHS diagnosis, we also need novel assays to estimate potential risks of developing DMHS</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00951</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848553">PM:28848553</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-951.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-951.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Valtonen V</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00951</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galdiero,M.R.</style></author><author><style face="normal" font="Arial"> Varricchi,G.</style></author><author><style face="normal" font="Arial"> Seaf,M.</style></author><author><style face="normal" font="Arial"> Marone,G.</style></author><author><style face="normal" font="Arial"> Levi-Schaffer,F.</style></author><author><style face="normal" font="Arial"> Marone,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Translational Medical Sciences (DiSMeT), Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer</style></title><secondary-title><style face="normal" font="Arial">Front Med (Lausanne)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Med (Lausanne)</style></full-title></periodical><pages end="" start="103">103-</pages><volume><style face="normal" font="Arial">4</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adipose tissue</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> growth factors</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotrienes</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> nerve growth factor</style></keyword><keyword><style face="normal" font="Arial"> PAF</style></keyword><keyword><style face="normal" font="Arial"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="Arial"> platelet-activating factor</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Stem Cell Factor</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Uterus</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Human mast cells (MCs) and eosinophils were first described and named by Paul Ehrlich. These cells have distinct myeloid progenitors and differ morphologically, ultrastructurally, immunologically, biochemically, and pharmacologically. However, MCs and eosinophils play a pivotal role in several allergic disorders. In addition, these cells are involved in autoimmune disorders, cardiovascular diseases, and cancer. MCs are distributed throughout all normal human tissues, whereas eosinophils are present only in gastrointestinal tract, secondary lymphoid tissues, and adipose tissue, thymus, mammary gland, and uterus. However, in allergic disorders, MCs and eosinophils can form the "allergic effector unit." Moreover, in several tumors, MCs and eosinophils can be found in close proximity. Therefore, it is likely that MCs have the capacity to modulate eosinophil functions and vice versa. For example, interleukin 5, stem cell factor, histamine, platelet-activating factor (PAF), prostaglandin D2 (PGD2), cysteinyl leukotrienes, and vascular endothelial growth factors (VEGFs), produced by activated MCs, can modulate eosinophil functions through the engagement of specific receptors. In contrast, eosinophil cationic proteins such as eosinophil cationic protein and major basic protein (MBP), nerve growth factor, and VEGFs released by activated eosinophils can modulate MC functions. These bidirectional interactions between MCs and eosinophils might be relevant not only in allergic diseases but also in several inflammatory and neoplastic disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170809IS - 2296-858X (Print)IS - 2296-858X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.3389/fmed.2017.00103</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28791287">PM:28791287</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Med (Lausanne)\2017-4-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Med (Lausanne)\2017-4-103.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Galdiero MR</style></custom2><misc3><style face="normal" font="Arial">10.3389/fmed.2017.00103</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moustaki,M.</style></author><author><style face="normal" font="Arial"> Loukou,I.</style></author><author><style face="normal" font="Arial"> Tsabouri,S.</style></author><author><style face="normal" font="Arial"> Douros,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cystic Fibrosis Unit, "Aghia Sophia" Children's Hospital, Athens, Greece</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Sensitization to Allergen in Asthma Prediction and Prevention</style></title><secondary-title><style face="normal" font="Arial">Front Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pediatr</style></full-title></periodical><pages end="" start="166">166-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Secondary prevention</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The burden of asthma in childhood is considerable worldwide, although some populations are much more affected than others. Many attempts have been made by different investigators to identify the factors that could predict asthma development or persistence in childhood. In this review, the relation between atopic sensitization as an indicator of allergy and asthma in childhood will be discussed. Cross sectional studies, carried out in different countries, failed to show any firm correlation between asthma and atopic sensitization. Birth cohort mainly of infants at high risk for asthma and case-control studies showed that atopic sensitization was a risk factor for current asthma in children older than 6 years. In general, clear relations are observed mostly in affluent Western countries, whereas in less affluent countries, the picture is more heterogeneous. For the prediction of asthma development or persistence in school age children, other prerequisites should also be fulfilled such as family history of asthma and wheezing episodes at preschool age. Despite the conductance of different studies regarding the potential role of allergen avoidance for the primary prevention of childhood asthma, it does not seem that this approach is of benefit for primary prevention purposes. However, the identification of children at risk for asthma is of benefit as these subjects could be provided with the best management practices and with the appropriate secondary prevention measures</style></abstract><notes><style face="normal" font="Arial">DA - 20170821IS - 2296-2360 (Print)IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.3389/fped.2017.00166</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28824890">PM:28824890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pediatr\2017-5-166.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pediatr\2017-5-166.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170821, Moustaki M</style></custom2><misc3><style face="normal" font="Arial">10.3389/fped.2017.00166</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kianmehr,M.</style></author><author><style face="normal" font="Arial"> Haghmorad,D.</style></author><author><style face="normal" font="Arial"> Nosratabadi,R.</style></author><author><style face="normal" font="Arial"> Rezaei,A.</style></author><author><style face="normal" font="Arial"> Alavinezhad,A.</style></author><author><style face="normal" font="Arial"> Boskabady,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Neurogeneeic Inflammation Research Centre, Mashhad University of Medical SciencesMashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">The Effect of Zataria multiflora on Th1/Th2 and Th17/T Regulatory in a Mouse Model of Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Pharmacol</style></full-title></periodical><pages end="" start="458">458-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zataria multiflora</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory disease with no definite treatment and more research is needed to overcome this condition. The aim of this study was to investigate the effect of the extract of Zataria multiflora (Z. multiflora) as a medicinal plant on cytokine genes expression in an experimental mouse model of asthma. Adult mice were randomly divided into the following groups: control (C), untreated asthma (A), asthmatic groups treated with dexamethasone (D) and Z. multiflora extract (200, 400, and 800 mug/mL; Z1, Z2, and Z3, respectively), (for groups C, A, and D n = 5 and for groups Z1, Z2, and Z3 n = 6). For induction of the mouse model of asthma, animals were sensitized with intraperitoneal injection and inhalation of ovalbumin (OVA). The number of T helper (Th) subtype cells (using flow cytometry) and the levels of IFN-gamma, FOXP3, IL-4, TGF-beta, IL-17 gene expression (by real time PCR) were assessed in mice splenocytes. The observed changes in spleen cells of group A compared to group C were increased number of Th2 and Th17 cells, enhancement of gene expression of IL-4, IL-17, and TGF-beta (p &lt; 0.001 for all cases), reduction of Th1 cells and Th1/Th2 ratio (p &lt; 0.001 for both cases) and decrease in gene expression of IFN-gamma, FOXP3 and IFN-gamma/IL-4 ratio (p &lt; 0.01 for IFN-gamma and p &lt; 0.001 for other cases). The observed changes in spleen cells of treated compared to untreated A group were enhancement of Treg cells and Th1/Th2 ratio (p &lt; 0.001 for both cases), increase in IFN-gamma (p &lt; 0.05) and FOXP3 (p &lt; 0.001) gene expression and IFN-gamma/IL-4 ratio (p &lt; 0.01) as well as reduction of Th2 and Th17 cells (p &lt; 0.01 to p &lt; 0.001), decrease gene expression of IL-4, IL-17, and TGF-beta (p &lt; 0.05 to p &lt; 0.001). The findings showed that the extract of Z. multiflora decreased pro-inflammatory cytokines in asthma (IL-4 and IL-17 and TGF-beta) but increased anti-inflammatory cytokines (IFN-gamma) gene expression and the number of Treg (FOXP3) in splenocytes of asthmatic mice which may indicate the specific therapeutic effect of the plant extract in allergy, autoimmunity, and infectious diseases via potentiating Th1 and suppressing Th2 and Th17 cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170821IS - 1663-9812 (Print)IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.3389/fphar.2017.00458</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28824424">PM:28824424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Pharmacol\2017-8-458.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Pharmacol\2017-8-458.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170821, Kianmehr M</style></custom2><misc3><style face="normal" font="Arial">10.3389/fphar.2017.00458</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Waldron,R.</style></author><author><style face="normal" font="Arial"> McGowan,J.</style></author><author><style face="normal" font="Arial"> Gordon,N.</style></author><author><style face="normal" font="Arial"> McCarthy,C.</style></author><author><style face="normal" font="Arial"> Mitchell,E.B.</style></author><author><style face="normal" font="Arial"> Doyle,S.</style></author><author><style face="normal" font="Arial"> Fitzpatrick,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Maynooth University, Maynooth, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Draft Genome Sequence of Dermatophagoides pteronyssinus, the European House Dust Mite</style></title><secondary-title><style face="normal" font="Arial">Genome Announc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Genome Announc</style></abbr-1></periodical><pages end="" start=" e00789-17"> e00789-17-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">32</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">Dermatophagoides pteronyssinus is the European dust mite and a major source of human allergens. Here, we present the first draft genome sequence of the mite, as well as the ab initio gene prediction and functional analyses that will facilitate comparative genomic analyses with other mite species</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 2169-8287 (Print)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1128/genomeA.00789-17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28798186">PM:28798186</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Genome Announc\2017-5- e00789-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Genome Announc\2017-5- e00789-17.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Waldron R</style></custom2><misc3><style face="normal" font="Arial">10.1128/genomeA.00789-17</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hill,R.C.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Schafer,B.W.</style></author><author><style face="normal" font="Arial"> Gampala,S.S.</style></author><author><style face="normal" font="Arial"> Herman,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Dow AgroSciences LLC , 9330 Zionsville Road, Indianapolis , Indiana 46268 , United States</style></auth-address><titles><title><style face="normal" font="Arial">Measurement of Lipid Transfer Proteins in Genetically Engineered Maize using Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS)</style></title><secondary-title><style face="normal" font="Arial">GM Crops Food</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">GM Crops Food</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Geography</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Hybrids</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Maize</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zea m 14</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="Arial">Endogenous allergenicity evaluation is a required part of the risk assessment for genetically engineered (GE) crops. Although maize is not considered a major allergenic food, a lipid transfer protein (Zea m 14) in maize grain has been identified as a potential IgE-mediated food allergen. Currently, the relationship between allergen exposure and risk of sensitization is not well understood. Hence, reliable quantitative methods are useful for determining the natural range and variability of allergen levels across multiple geographies and genetic backgrounds. A LC-MS/MS analytical method was developed and validated in our laboratory to quantify Zea m 14 in grain from two GE maize hybrids and twenty non-GE maize hybrids. The measured Zea m 14 levels in GE maize grain and conventional non-GE maize grain ranged from 146.87 to 574.93 ng/mg across sixteen field sites located in the United States and Argentina. The method accurately quantified endogenous Zea m 14 from maize grain and results show Zea m 14 levels in the GE maize varieties were within the natural variation observed in traditionally bred non-GE maize</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 2164-5701 (Electronic)IS - 2164-5698 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645698.2017.1349602</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28758829">PM:28758829</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\GM Crops Food\20170731-HillRC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\GM Crops Food\20170731-HillRC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Hill RC</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645698.2017.1349602</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jauhonen,H.M.</style></author><author><style face="normal" font="Arial"> Laihia,J.</style></author><author><style face="normal" font="Arial"> Oksala,O.</style></author><author><style face="normal" font="Arial"> Viiri,J.</style></author><author><style face="normal" font="Arial"> Sironen,R.</style></author><author><style face="normal" font="Arial"> Alajuuma,P.</style></author><author><style face="normal" font="Arial"> Kaarniranta,K.</style></author><author><style face="normal" font="Arial"> Leino,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland.</style></auth-address><titles><title><style face="normal" font="Arial">Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model</style></title><secondary-title><style face="normal" font="Arial">Graefes Arch Clin Exp Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Graefes Arch Clin Exp Ophthalmol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug treatment</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Evans Blue</style></keyword><keyword><style face="normal" font="Arial"> Experimental models</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Irritation</style></keyword><keyword><style face="normal" font="Arial"> Ketotifen</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Ocular allergy</style></keyword><keyword><style face="normal" font="Arial"> Ocular surface</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Our purpose was to investigate the effect of locally administered cis-urocanic (cis-UCA) in two experimental models of allergic conjunctivitis. METHODS: The compound 48/80 (C48/80)-induced ocular irritation model (IgE-independent) and the ovalbumin (OA)-induced ocular allergy model (IgE-mediated) were used to test and compare the effect of cis-UCA on dexamethasone, ketotifen and olopatadine. In the C48/80 model, clinical severity scoring from photographs, immunohistochemical analysis of nuclear Ki-67 antigen to quantify actively proliferating epithelial cells and of caspase-3 enzyme to identify apoptotic activity in the conjunctival tissue were used. In the OA model, an Evans Blue stain concentration of conjunctival tissue was used to evaluate vascular leakage due to allergic reaction. RESULTS: The cis-UCA was well tolerated and effective in both the IgE-independent and -mediated rat models. Treatment with C48/80 caused conjunctival hyperaemia, which was significantly inhibited by ketotifen at the 6 h time point (p = 0.014) and by dexamethasone and cis-UCA 0.5% at 12 (p = 0.004) and 24 (p = 0.004) hour time points. In a comparison between the active drug treatments, only ketotifen showed a significant difference (p = 0.023) to cis-UCA treatment at the 1 h time point, otherwise there were no statistically significant differences between the active drugs. Ketotifen, dexamethasone and cis-UCA 0.5% significantly inhibited the C48/80-induced nuclear accumulation of Ki-67, without differences between the active treatment groups. In the OA model, cis-UCA 0.5% did not inhibit the vascular leakage of conjunctiva, whereas cis-UCA 2.5% of was at least equally effective compared to olopatadine, abolishing the allergic vascular leakage response almost completely. CONCLUSIONS: The present findings in the two AC models suggest that cis-UCA might have anti-allergic potency both in immediate and delayed-type allergic reactions in the eye</style></abstract><notes><style face="normal" font="Arial">DA - 20170825IS - 1435-702X (Electronic)IS - 0721-832X (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00417-017-3781-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28840310">PM:28840310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Graefes Arch Clin Exp Ophthalmol\20170825-JauhonenHM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Graefes Arch Clin Exp Ophthalmol\20170825-JauhonenHM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170825, Jauhonen HM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00417-017-3781-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,T.H.</style></author><author><style face="normal" font="Arial"> Wu,Y.Y.</style></author><author><style face="normal" font="Arial"> Chan,J.K.</style></author><author><style face="normal" font="Arial"> Ho,H.K.</style></author><author><style face="normal" font="Arial"> Li,P.H.</style></author><author><style face="normal" font="Arial"> Rosa Duque,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Centre, Hong Kong Sanatorium &amp; Hospital, Happy Valley, Hong Kong</style></auth-address><titles><title><style face="normal" font="Arial">Immunoglobulin G testing in the diagnosis of food allergy and intolerance</style></title><secondary-title><style face="normal" font="Arial">Hong Kong Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hong Kong Med J</style></full-title></periodical><pages end="420" start="419">419-420</pages><volume><style face="normal" font="Arial">23</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 1024-2708 (Print)IS - 1024-2708 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.12809/hkmj176310</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775227">PM:28775227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hong Kong Med J\2017-23-419-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hong Kong Med J\2017-23-419-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Lee TH</style></custom2><misc3><style face="normal" font="Arial">10.12809/hkmj176310</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,M.</style></author><author><style face="normal" font="Arial"> Land,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a University of California , San Diegob Kaiser Permanente San Diego</style></auth-address><titles><title><style face="normal" font="Arial">The Current State of Food Allergy Therapeutics</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> FDA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="Arial">The prevalence of IgE mediated food allergy is an increasing public health concern. The current standard of treatment is strict avoidance of the offending food(s). There are no FDA approved treatments for food allergy. This review will provide an overview of strategies currently under investigation for the treatment of food allergy. The main focus of research has been directed at various forms of immunotherapy, including oral, sublingual and epicutaneous delivery routes. While oral immunotherapy (OIT) has shown the greatest promise for efficacy in terms of amount of protein that can be ingested, it has also demonstrated less tolerability and a less favorable safety profile as compared to sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT), which offers the least protection but has the best safety and tolerability profile. Investigation is also underway for modified antigens that may be used for immunotherapy and for adjuncts that may help facilitate immunotherapy, including biologics such as anti-IgE therapy, and also probiotics. There are also a number of preclinical concepts that are being evaluated to manipulate the antigens and/or the immune system that may one day be translatable to patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1359363</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846472">PM:28846472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170828-ChenM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170828-ChenM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Chen M</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1359363</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gamazo,C.</style></author><author><style face="normal" font="Arial"> Amelio,D.</style></author><author><style face="normal" font="Arial"> Gastaminza,G.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author><author><style face="normal" font="Arial"> Irache,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Dept. Microbiology, Instituto de Investigacion Sanitaria de Navarra (Idisna), University of Navarra - C/Irunlarrea, 1; 31</style></auth-address><titles><title><style face="normal" font="Arial">Adjuvants for allergy immunotherapeutics</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="21" Month="8" Year="2017">2017/8/21</year></dates><abstract><style face="normal" font="Arial">Allergic diseases are reaching epidemic proportions in developed countries. In particular, food allergy is increasing in prevalence and severity, thus becoming an important socioeconomic burden. Numerous cell types and cell populations, which form an intricate and balanced network, are involved in an immune response. This balance is occasionally disturbed, leading to the onset of different diseases, such as allergic diseases. Antihistamines and corticosteroids provide some degree of relief from the symptoms of allergic conditions. However, the only treatment that can revert the disease is immunotherapy. Nevertheless, specific immunotherapy has at least two major drawbacks: it is time-consuming, and it can produce local and even systemic allergic side effects. Immunotherapy's potential goes beyond our current knowledge of the immune response; nevertheless, we can still design strategies to reach a safer immune modulation for treating allergies. This review deals with the use of adjuvants to reduce the undesirable side effects associated with specific allergen immunotherapy. For example, nanoparticles used as immunoadjuvants are offering promising results in preclinical assays</style></abstract><notes><style face="normal" font="Arial">DA - 20170821IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1348447</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28825867">PM:28825867</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170821-GamazoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170821-GamazoC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170821, Gamazo C</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1348447</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,L.</style></author><author><style face="normal" font="Arial"> Zhou,S.</style></author><author><style face="normal" font="Arial"> Qi,Q.</style></author><author><style face="normal" font="Arial"> Chi,Y.</style></author><author><style face="normal" font="Arial"> Zhu,J.</style></author><author><style face="normal" font="Arial"> Xu,Z.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Hoellwarth,J.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Su,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Lab of Reproductive Medicine, Department of Pathogen Biology and Immunology, Jiangsu Province Key Laboratory of Pathogen Biology, Nanjing Medical University, 101 Longmian Avenue, Jiangning District, Nanjing, Jiangsu, 211166, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">The regulation of regulation: IL-10 increases CD4+ CD25+ regulatory T cells but impairs their immunosuppressive activity in murine models with schistosomiasis japonica or asthma</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma</style></keyword><keyword><style face="normal" font="Arial"> Schistosoma japonicum</style></keyword><keyword><style face="normal" font="Arial"> Schistosomiasis</style></keyword><keyword><style face="normal" font="Arial"> Schistosomiasis japonica</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg induction</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="Arial">CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) play an important role in maintaining immune homeostasis. Interleukin 10 (IL-10), a cytokine with anti-inflammatory capacities, also has a critical role in controlling immune responses. In addition, it is well known that production of IL-10 is one of suppression mechanisms by Tregs. However, the action of IL-10 on Tregs themselves remains insufficiently understood. In this study, by using a Schistosoma japonicum (S. japonicum)-infected murine model, we show that the elevated IL-10 contributed to Treg induction but impaired their immunosuppressive function. Our investigations further suggest that this may relate to up-regulating serum TGF-beta level but decreasing membrane-bound TGF-beta (mTGF-beta) of Tregs by IL-10 during S. japonicum infection. In addition, similar IL-10-mediated regulation on Tregs was also confirmed in the murine model of asthma. In general, our findings identify a previously unrecognized opposite regulation of IL-10 on Tregs and provide a deep insight into the precise regulation in immune responses. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12813</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28799262">PM:28799262</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20170811-HeL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20170811-HeL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, He L</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12813</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shorter,C.</style></author><author><style face="normal" font="Arial"> Crane,J.</style></author><author><style face="normal" font="Arial"> Pierse,N.</style></author><author><style face="normal" font="Arial"> Barnes,P.</style></author><author><style face="normal" font="Arial"> Kang,J.</style></author><author><style face="normal" font="Arial"> Wickens,K.</style></author><author><style face="normal" font="Arial"> Douwes,J.</style></author><author><style face="normal" font="Arial"> Stanley,T.</style></author><author><style face="normal" font="Arial"> Taubel,M.</style></author><author><style face="normal" font="Arial"> Hyvarinen,A.</style></author><author><style face="normal" font="Arial"> Howden-Chapman,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Wellington Asthma Research Group, Department of Medicine, University of Otago, Wellington, PO Box 7343, Wellington South, New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">Indoor visible mold and mold odour are associated with new-onset childhood wheeze in a dose dependent manner</style></title><secondary-title><style face="normal" font="Arial">Indoor Air</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indoor Air</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood wheeze</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> dampness</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor mold</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> moisture</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> odour</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">Evidence is accumulating that indoor dampness and mold are associated with the development of asthma. The underlying mechanisms remain unknown. New Zealand has high rates of both asthma and indoor mold and is ideally placed to investigate this. We conducted an incident case control study involving 150 children with new-onset wheeze, aged between 1 and 7 years, each matched to two control children with no history of wheezing. Each participant's home was assessed for moisture damage, condensation and mold growth by researchers, an independent building assessor and parents. Repeated measures of temperature and humidity were made and electrostatic dust cloths were used to collect airborne microbes. Cloths were analysed using qPCR. Children were skin prick tested for aeroallergens to establish atopy. Strong positive associations were found between observations of visible mold and new-onset wheezing in children (adjusted odds ratios ranged between 1.30 - 3.56; P&lt;/=0.05). Visible mold and mold odor were consistently associated with new-onset wheezing in a dose-dependent manner. Measurements of qPCR microbial levels, temperature and humidity were not associated with new-onset wheezing. No association was found between atopic status and mold, which suggests a non-allergic association between mold exposure and new-onset wheeze. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 1600-0668 (Electronic)IS - 0905-6947 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/ina.12413</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28779500">PM:28779500</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indoor Air\20170805-ShorterC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indoor Air\20170805-ShorterC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170805, Shorter C</style></custom2><misc3><style face="normal" font="Arial">10.1111/ina.12413</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weng,C.</style></author><author><style face="normal" font="Arial"> Chong,L.</style></author><author><style face="normal" font="Arial"> Jia,X.</style></author><author><style face="normal" font="Arial"> Zheng,R.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Zhu,T.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Allergy and Immunology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Xueyuan West Road 109, Wenzhou, Zhejiang, 325027, China163.com</style></auth-address><titles><title><style face="normal" font="Arial">Anti-Dll4 Antibody Inhibits the Differentiation of Th17 Cells in Asthmatic Mice</style></title><secondary-title><style face="normal" font="Arial">Inflammation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflammation</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">T helper 17 (Th17) cells play an important role in allergic asthma, and the Notch ligand Delta-like ligand (Dll)4 has been reported to direct the differentiation of Th17 cells. In this study, experimental animals were divided into five groups (control group, asthma group, physiological saline group, anti-Dll4 antibody group, and immunoglobulin G group). The study aimed to explore the effect of anti-Dll4 antibody on the differentiation of Th17 cell in asthmatic mice. Dll4 protein expressions were performed by immunohistochemical imaging. The proportion of Th17 cells in mouse spleen-isolated CD4+ T cells were measured by flow cytometry. The protein expression of Th17 transcription factor retinoid-related orphan nuclear receptor (RORgammat) was detected by Western blotting. Interleukin (IL)-17 levels in serum were measured by enzyme-linked immunosorbent assay (ELISA). The study found that the expression of Dll4 in lung tissue from the asthma group significantly increased compared with the anti-Dll4 antibody group. The ratio of Th17 cells in CD4+ T cells was significantly downregulated, and the protein expression of RORgammat in spleen significantly reduced in the anti-Dll4 antibody group compared with the asthma group. Moreover, the IL-17 level in serum from the anti-Dll4 antibody group significantly reduced compared with the asthma group. These results suggested that anti-Dll4 antibody could inhibit the differentiation of Th17 cells in asthmatic mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10753-017-0638-x.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28812183">PM:28812183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20170816-WengC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20170816-WengC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Weng C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10753-017-0638-x.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Krajewska-Wojtys,A.</style></author><author><style face="normal" font="Arial"> Jarzab,J.</style></author><author><style face="normal" font="Arial"> Zawadzinska,K.</style></author><author><style face="normal" font="Arial"> Pyrkosz,K.</style></author><author><style face="normal" font="Arial"> Bozek,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Department of Internal Diseases, Dermatology, and Allergology, Medical University of Silesia, Zabrze, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Local Allergic Rhinitis in Adult Patients with Chronic Nasal Symptoms</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="170" start="165">165-170</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cat allergen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergies</style></keyword><keyword><style face="normal" font="Arial"> Nasal allergy</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="Arial"> nasal specific IgE</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Local allergic rhinitis (LAR) remains an underdiagnosed condition characterized by the local production of IgE antibodies during the natural exposure to aeroallergens. The prevalence of LAR in adult patients with a previous diagnosis of non-AR was assessed. MATERIAL AND METHODS: Eighty-four patients with perennial nasal allergy symptoms but a negative skin prick test and specific IgE antibodies against common inhalant allergens were included in the study. Nasal provocation tests were performed with the inhalant allergens Dermatophagoides pteronyssinus, Alternaria, and cat allergen, followed by the detection of nasal-specific IgE antibodies in the lavage during the challenge. RESULTS: LAR was confirmed in 21 (25%) study patients. In the remaining 63 (75%) patients, non-AR was diagnosed. In addition, LAR was found following exposure to D. pteronyssinus in 19 (22.6%) patients, Alternaria in 3 (3.6%) patients, and the cat allergen in 1 (1.2%) patient. In 2 patients, concomitant allergies to D. pteronyssinus and Alternaria were observed. CONCLUSION: LAR can be a form of chronic perennial rhinitis that has previously been considered to be non-AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1159/000478656</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787729">PM:28787729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-165-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-165-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Krajewska-Wojtys A</style></custom2><misc3><style face="normal" font="Arial">10.1159/000478656</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dogruel,D.</style></author><author><style face="normal" font="Arial"> Bingol,G.</style></author><author><style face="normal" font="Arial"> Altintas,D.U.</style></author><author><style face="normal" font="Arial"> Seydaoglu,G.</style></author><author><style face="normal" font="Arial"> Erkan,A.</style></author><author><style face="normal" font="Arial"> Yilmaz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Allergy and Immunology, Cukurova University Faculty of Medicine, Adana, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">The Trend of Change of Allergic Diseases over the Years: Three Repeated Surveys from 1994 to 2014</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="182" start="178">178-182</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary schools</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although it is known that there has been an increase in asthma and allergic diseases among school-aged children, results vary between countries. The aim of this study was to examine trends in the prevalence of these diseases in the city of Adana (south Turkey) over the last 20 years based on the results of 3 cross-sectional studies. METHODS: Three cross-sectional surveys were performed 10 years apart in south Turkey. Here, we compare the surveys conducted among children between the ages of 6 and 14 years from 1994, 2004, and 2014. The participants were randomly chosen among children attending participating primary schools in Adana. The questionnaire in the first survey contained almost the same questions as the ISAAC. In the 2 latter surveys, we used the ISAAC questionnaire to investigate the prevalence of asthma and other allergic diseases. RESULTS: A total of 2,334 children in 1994, 3,728 children in 2004, and 3,209 children in 2014 were included in the final analysis. The results showed a statistically significant increase in the prevalence of physician-diagnosed allergic diseases across the years, respectively: asthma (5, 4.6, and 8.9%), allergic rhinitis (8.8, 11.4, and 15.6%), and atopic dermatitis (5, 9.9, and 7%). In contrast, the prevalence of parent-reported current wheeze (16.2, 13.2%) decreased in the last 10 years. CONCLUSIONS: Our findings were consistent with the increased prevalence of childhood asthma and other allergic diseases. However, this pattern did not occur in respiratory symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1159/000477726</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787739">PM:28787739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-178-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-178-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Dogruel D</style></custom2><misc3><style face="normal" font="Arial">10.1159/000477726</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Scala,E.</style></author><author><style face="normal" font="Arial"> Abeni,D.</style></author><author><style face="normal" font="Arial"> Cecchi,L.</style></author><author><style face="normal" font="Arial"> Guerra,E.C.</style></author><author><style face="normal" font="Arial"> Locanto,M.</style></author><author><style face="normal" font="Arial"> Pirrotta,L.</style></author><author><style face="normal" font="Arial"> Giani,M.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, IDI-IRCCS, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Molecular Recognition Profiles and Clinical Patterns of PR-10 Sensitization in a Birch-Free Mediterranean Area</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="146" start="138">138-146</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Act d 8</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aln g 1</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Api g 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 8</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cor a 1.0101</style></keyword><keyword><style face="normal" font="Arial"> Cor a 1.0401</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Gly m 4</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Mal d 1</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray Analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pru p 1</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The order Fagales represents an important cause of tree-pollen allergy in northern countries. We investigated the IgE recognition profiles, mutual relationships, and association with clinical symptoms of a panel of allergens belonging to the PR-10 family, the main proteins responsible for Fagales allergy (Act d 8, Aln g 1, Api g 1, Ara h 8, Bet v 1, Cor a 1.0101, Cor a 1.0401, Gly m 4, Mal d 1, and Pru p 1). METHODS: A total of 526 PR-10-reactive subjects living in central and southern Italy were studied by ImmunoCAP-ISAC-112 microarray analysis. RESULTS: Overall, Bet v 1 reactivity was the most commonly (74%) observed among PR-10 proteins, but Cor a 1.0101 was the most prevalent in participants aged &lt;6 years, and between 15 and 65 years. Overall, 26% of the PR-10-reactive persons were Bet v 1 negative, whilst 93.6% of the PR-10 polyreactive individuals were Bet v 1 positive. Among the 10 PR-10s evaluated, 100 combinations were recorded. The strongest association was observed between molecules with the highest sequence identities (Bet v 1 and Cor a 1.0101, Cor a 1.0401 or Aln g 1; Mal d 1 and Pru p 1). Bet v 1-, Cor a 1.0101-, and Aln g 1-specific IgE recognition was associated with respiratory symptoms, whilst Ara h 8, Cor a 1.0401, Gly m 4, Mal d 1, and Pru p 1 were selectively linked to an oral allergic syndrome. CONCLUSIONS: Testing IgE reactivity to a panel of PR-10s in a birch-free area discloses peculiar relationships between clinical phenotypes and sensitization profiles, allowing the identification of novel cluster patterns</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1159/000477565</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787736">PM:28787736</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-138-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-138-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Scala E</style></custom2><misc3><style face="normal" font="Arial">10.1159/000477565</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gil,F.</style></author><author><style face="normal" font="Arial"> Amezqueta,A.</style></author><author><style face="normal" font="Arial"> Martinez,D.</style></author><author><style face="normal" font="Arial"> Aznal,E.</style></author><author><style face="normal" font="Arial"> Etayo,V.</style></author><author><style face="normal" font="Arial"> Dura,T.</style></author><author><style face="normal" font="Arial"> Sanchez-Valverde,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Estella Hospital, Estella, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Association between Caesarean Delivery and Isolated Doses of Formula Feeding in Cow Milk Allergy</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="152" start="147">147-152</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> cow milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> formula feeding</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prematurity</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cow milk allergy (CMA) is the most common food allergy in breastfed infants. The aim of this study is to verify whether certain perinatal factors may influence the development of CMA immunoglobulin E (IgE)+. METHODS: A retrospective, observational study of case and control groups was carried out. Information was collected of patients with CMA IgE+ from our department during the years 1990-2013. Patients of the same age and sex were recruited for the control group. Information on the following variables was collected: sex, age, pregnancy tolerance, duration of pregnancy, type of delivery, isolated doses of formula feeding in hospital (FFH), duration of breastfeeding, and family history of allergy (defined as >/=1 first-degree family member with allergic disease). Statistical analysis was performed using multivariate logistic regression techniques. RESULTS: A total of 211 cases were included in this study. Multivariate analysis showed an influence of duration of breastfeeding, FFH to be a risk factor (OR 4.94; 95% CI 2.68-9.08), especially in caesarean delivery (OR 11.82; 95% CI 2.64-47.50), and prematurity (OR 0.29; 95% CI 0.09-0.92) to be a protective factor. CONCLUSIONS: Perinatal factors play a key role in the development of CMA IgE+, with an influence of breastfeeding duration, FFH and caesarean delivery as risk factors and prematurity as a protective factor. While family history had no important role, environmental factors were more decisive</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - spain -</style></notes><work-type><style face="normal" font="Arial">10.1159/000477725</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787733">PM:28787733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-147-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-147-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Gil F</style></custom2><misc3><style face="normal" font="Arial">10.1159/000477725</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Q.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Chen,B.</style></author><author><style face="normal" font="Arial"> Zhuo,Q.</style></author><author><style face="normal" font="Arial"> Bao,C.</style></author><author><style face="normal" font="Arial"> Lin,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Propofol inhibits NF-kappaB activation to ameliorate airway inflammation in ovalbumin (OVA)-induced allergic asthma mice</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="164" start="158">158-164</pages><volume><style face="normal" font="Arial">51</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="Arial">Propofol, one of the most commonly used intravenous anesthetic agents, has been reported to have anti-inflammatory property. However, the anti-allergic inflammation effect of propofol and its underlying molecular mechanisms have not been elucidated. In the present study, we aim to investigate the roles of NF-kB activation in propofol anti-asthma effect on OVA-induced allergic airway inflammation in mice. In a standard experimental asthma model, Balb/c mice were sensitized with ovalbumin, treated with propofol (50,100,150mg/kg) or a vehicle control 1h before OVA challenge. Blood samples, bronchoalveolar lavage fluid (BALF) and lung tissues were harvested after measurement of airway hyperresponsiveness. Results revealed that propofol not only significantly inhibit airway hyperresponsiveness, but also inhibited the production of Th2 cytokines, NO, Ova-specific IgE and eotaxin. Histological studies indicated that propofol significantly attenuated OVA-induced inflammatory cell infiltration in the peribronchial areas and mucus hypersecretion. Meanwhile, our results indicated that propofol was found to inhibit NF-kB activation in OVA-Induced mice. Furthermore, propofol significantly reduced the TNF-alpha-induced NF-kB activation in A549 cells. In conclusion, our study suggested that propofol effectively reduced allergic airway inflammation by inhibiting NF-kB activation and could thus be used as a therapy for allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170826IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.08.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28843179">PM:28843179</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-51-158-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-51-158-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Zhang Q</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.08.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Navares,R.</style></author><author><style face="normal" font="Arial"> Aznarte,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Superior Technical School of Computer Engineering, UNED, Juan del Rosal, 16, 28040, Madrid, SpainDepartment of Artificial Intelligence, UNED, Juan del Rosal, 16, 28040, Madrid, Spain. jlaznarte@dia.uned.es</style></auth-address><titles><title><style face="normal" font="Arial">Predicting the Poaceae pollen season: six month-ahead forecasting and identification of relevant features</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="656" start="647">647-656</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Artificial Intelligence</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Intelligence</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Models,Theoretical</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Random forest</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">In this paper, we approach the problem of predicting the concentrations of Poaceae pollen which define the main pollination season in the city of Madrid. A classification-based approach, based on a computational intelligence model (random forests), is applied to forecast the dates in which risk concentration levels are to be observed. Unlike previous works, the proposal extends the range of forecasting horizons up to 6 months ahead. Furthermore, the proposed model allows to determine the most influential factors for each horizon, making no assumptions about the significance of the weather features. The performace of the proposed model proves it as a successful tool for allergy patients in preventing and minimizing the exposure to risky pollen concentrations and for researchers to gain a deeper insight on the factors driving the pollination season</style></abstract><notes><style face="normal" font="Arial">DA - 20160917IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)SB - IMCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-016-1242-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27633563">PM:27633563</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\2017-61-647-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biometeorol\2017-61-647-56.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160917, Navares R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-016-1242-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beggs,P.J.</style></author><author><style face="normal" font="Arial"> Sikoparija,B.</style></author><author><style face="normal" font="Arial"> Smith,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, 2109, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Aerobiology in the International Journal of Biometeorology, 1957-2017</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="58" start="51">51-58</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">S1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Biological particles</style></keyword><keyword><style face="normal" font="Arial"> Biometeorology</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Forecasting</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Knowledge gaps</style></keyword><keyword><style face="normal" font="Arial"> Modelling</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="Arial">Aerobiology and biometeorology are related fields. Here we provide a broad review of aerobiology articles published in the International Journal of Biometeorology (IJB) over the past 60 years. We consider how the quantity of such work has varied over this period as well as which regions and countries have been the focus of such work, and where there is a relative paucity. We then focus on a number of highlights and themes in this research, including aerobiology and climate change and aerobiological modelling and forecasting. While much of the article focusses on airborne pollen research, we also discuss the extent to which other airborne organic particles such as fungal spores and bacteria have been the focus of research published in IJB. Also considered are knowledge gaps and research needs and priorities with respect to the field of aerobiology. While the IJB has been one of the main platforms for presenting aerobiological research over recent decades, the article highlights the need for the field of aerobiology to embrace new sampling technologies such as spectral analysis and next-generation sequencing to identify and quantify airborne biological particles</style></abstract><notes><style face="normal" font="Arial">DA - 20170613IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - engPT - EditorialCO - Australia -CO - Serbia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-017-1374-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28607999">PM:28607999</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\2017-61S-51-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biometeorol\2017-61S-51-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170613, Beggs PJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-017-1374-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85580</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wildner,S.</style></author><author><style face="normal" font="Arial"> Elsasser,B.</style></author><author><style face="normal" font="Arial"> Stemeseder,T.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Soh,W.T.</style></author><author><style face="normal" font="Arial"> Villalba,M.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Brandstetter,H.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg 5020, Austria. sabrina.wildner@sbg.ac.at</style></auth-address><titles><title><style face="normal" font="Arial">Endolysosomal Degradation of Allergenic Ole e 1-Like Proteins: Analysis of Proteolytic Cleavage Sites Revealing T Cell Epitope-Containing Peptides</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E1780">E1780-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Che a 1</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Fra e 1</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Histocompatibility</style></keyword><keyword><style face="normal" font="Arial"> Immunogenic properties</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> In silico analysis</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Ole e</style></keyword><keyword><style face="normal" font="Arial"> Ole e 1</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phl p 11</style></keyword><keyword><style face="normal" font="Arial"> Pla l 1</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Sal k 5</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="Arial">Knowledge of the susceptibility of proteins to endolysosomal proteases provides valuable information on immunogenicity. Though Ole e 1-like proteins are considered relevant allergens, little is known about their immunogenic properties and T cell epitopes. Thus, six representative molecules, i.e., Ole e 1, Fra e 1, Sal k 5, Che a 1, Phl p 11 and Pla l 1, were investigated. Endolysosomal degradation and peptide generation were simulated using microsomal fractions of JAWS II dendritic cells. Kinetics and peptide patterns were evaluated by gel electrophoresis and mass spectrometry. In silico MHC (major histocompatibility complex) class II binding prediction was performed with ProPred. Cleavage sites were assigned to the primary and secondary structure, and in silico docking experiments between the protease cathepsin S and Ole e 1 were performed. Different kinetics during endolysosomal degradation were observed while similar peptide profiles especially at the C-termini were detected. Typically, the identified peptide clusters comprised the previously-reported T cell epitopes of Ole e 1, consistent with an in silico analysis of the T cell epitopes. The results emphasize the importance of the fold on allergen processing, as also reflected by conserved cleavage sites located within the large flexible loop. In silico docking and mass spectrometry results suggest that one of the first Ole e 1 cleavages might occur at positions 107-108. Our results provided kinetic and structural information on endolysosomal processing of Ole e 1-like proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18081780</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28812992">PM:28812992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1780.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E1780.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Wildner S</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18081780</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,H.T.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author><author><style face="normal" font="Arial"> Huang,S.C.</style></author><author><style face="normal" font="Arial"> Yu,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Tao-Yuan, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Unsuspected human immunodeficiency virus infection presenting as immunoglobulin G4-related lymphadenopathy: a case report</style></title><secondary-title><style face="normal" font="Arial">Int J STD AIDS</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J STD AIDS</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germinal Center</style></keyword><keyword><style face="normal" font="Arial"> Hiv</style></keyword><keyword><style face="normal" font="Arial"> HIV infection</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G4</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is an immune-mediated condition characterized by infiltration of the involved organs by IgG4-bearing plasma cells. The prevalence of autoimmune diseases, associated with or occurring in patients with human immunodeficiency virus (HIV) infection, has been increasing. We describe a 58-year-old man with an undiagnosed HIV infection, which presented as chronic cervical lymphadenopathy with an elevated serum IgG4 and a very high IgE. Histologically, lymph nodes showed expanded sinusoids and burnt-out germinal centers with increased plasmacytic infiltration and collagen fiber deposition. The absolute number of IgG4+ plasma cells and the IgG4+/IgG+ plasma cell ratio was increased. The lymph nodes were enlarged and clinically the patient improved after steroid treatment. Nine months later, he was diagnosed with acquired immune deficiency syndrome, following presentation with a cavitary left lung lesion. Immunohistochemical studies on the previously resected lymph node revealed complete absence of CD4+ T-lymphocytes and increased CD8+ T-lymphocytes. The pathologic findings met the criteria of both HIV infection and IgG4-related lymphadenopathy. Our case demonstrates that further investigations for underlying HIV infection in a case of IgG4-RD are critical, especially when extremely elevated IgE is concomitantly present</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1758-1052 (Electronic)IS - 0956-4624 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1177/0956462417722479</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28768471">PM:28768471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J STD AIDS\20170803-YuHT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J STD AIDS\20170803-YuHT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Yu HT</style></custom2><misc3><style face="normal" font="Arial">10.1177/0956462417722479</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arej,N.</style></author><author><style face="normal" font="Arial"> Irani,C.</style></author><author><style face="normal" font="Arial"> Abdelmassih,Y.</style></author><author><style face="normal" font="Arial"> Slim,E.</style></author><author><style face="normal" font="Arial"> Antoun,J.</style></author><author><style face="normal" font="Arial"> Bejjani,R.</style></author><author><style face="normal" font="Arial"> Schakal,A.</style></author><author><style face="normal" font="Arial"> Waked,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of allergic sensitization in Lebanese patients with allergic conjunctivitis</style></title><secondary-title><style face="normal" font="Arial">Int Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Ophthalmol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-2630</style></isbn><abstract><style face="normal" font="Arial">To describe the profile of patients with allergic conjunctivitis (AC) regarding their demographics, symptomatology and specific allergen sensitization, in a Lebanese tertiary hospital</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Lebanon -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10792-017-0696-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28831678">PM:28831678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Ophthalmol\20170823-ArejN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Ophthalmol\20170823-ArejN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Arej N</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10792-017-0696-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85584</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moghtaderi,M.</style></author><author><style face="normal" font="Arial"> Torab Jahromi,M.</style></author><author><style face="normal" font="Arial"> Farjadian,S.</style></author><author><style face="normal" font="Arial"> Ghassemi,P.</style></author><author><style face="normal" font="Arial"> Hosseini Teshnizi,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Decreased Sensitization to Aeroallergens among Southwestern Iranian Male Farmers</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="312" start="307">307-312</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> Farmers,Lung function,Mite,Pollen,Skin test,Workplace</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> work-related symptom</style></keyword><keyword><style face="normal" font="Arial"> working environment</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">Farmers are usually exposed to various inhaled allergens like pollens, mites, molds, and animal dander in their working environment which may lead to allergic rhinitis, asthma and urticaria. The purpose of this study was to identify sensitization to various aeroallergens in farmers and their occupational allergy symptoms. This cross sectional study included 103 male farmers and 100 non-farmer healthy controls. The work-related symptoms of farmers were recorded with a questionnaire. Spirometry and skin prick tests with 15 commercial allergen extracts were performed in both farmers and controls. The rate of sensitization to at least one of the applied aeroallergens was 47.6% in farmers compared to 65% in the control group (OR=0.48; CI 95%, 1.08 to 2.07) according to skin prick tests, after adjusting for age. Occupational allergy symptoms were reported by 54.3% farmers. Mean FEV 1 /FVC was significantly lower in farmers than in controls ( p &amp;lt;0.001). The results of this study showed that farmers had no increased risk of sensitization to aeroallergens. Sensitization to pollens was more prevalent than to mites among the farmers in our study and smoking was an important predisposing factor in farmers who suffered from occupational allergy symptoms</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/1013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-307-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-307-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Moghtaderi M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mortaz,E.</style></author><author><style face="normal" font="Arial"> Adcock,I.M.</style></author><author><style face="normal" font="Arial"> Jamaati,H.</style></author><author><style face="normal" font="Arial"> Khosravi,A.</style></author><author><style face="normal" font="Arial"> Movassaghi,M.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Alavi Mogadam,M.</style></author><author><style face="normal" font="Arial"> Redegeld,F..</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immunoglobulin Free Light Chains in the Pathogenesis of Lung Disorders</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="288" start="282">282-288</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma,Chronic obstructive lungs disease (COPD),Free light chain,Hypersensitivity pneumonitis (HP),Idiopathic pulmonary fibrosis (IPF),Lung cancer</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity pneumonitis</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pancreas</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">Inflammation is an important component of numerous cancers and chronic diseases and many inflammatory mediators have been shown to have potential prognostic roles. Tumor-infiltrating mast cells can promote tumor growth and angiogenesis, but the mechanism of mast cell activation is unclear. Early studies have shown that immunoglobulin free light chains (FLC) can trigger mast cell activation in an antigen-specific manner. Increased expression of FLC is observed within the stroma of many human cancers including those of breast, colon, lung, pancreas, kidney, and skin. These overexpressed FLCs are co-localized to areas of mast cell infiltration. Importantly, FLC expression is associated with basal-like cancers with an aggressive phenotype. Moreover, FLC is expressed in areas of inflammatory cell infiltration and its expression is significantly associated with poor clinical outcome. In addition, serum and bronchoalveolar fluid FLC concentrations are increased in patients with idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) compared to control subjects. In this review, we provide an update on the role of FLC in the pathogenesis of several lung disorders and indicate how this may contribute to new therapeutic opportunities. -á -á</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -CO - Netherlands -CO - United Kingdom -CO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/1082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-282-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-282-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Mortaz E</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zare,A.</style></author><author><style face="normal" font="Arial"> Pourfathollah,A.A.</style></author><author><style face="normal" font="Arial"> Pourpak,Z.</style></author><author><style face="normal" font="Arial"> Szebeni,J.</style></author><author><style face="normal" font="Arial"> Ghaffari,S.M.R.</style></author><author><style face="normal" font="Arial"> Kardar,G.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Peptide-based Vaccines Derived from Fc+ÁRI Beta Subunit Can Reduce Allergic Response in Mice Model</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="297" start="289">289-297</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic component</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergy,FceRI beta-subunit,Peptide-based vaccine</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Fc+ÁRI</style></keyword><keyword><style face="normal" font="Arial"> FceRI</style></keyword><keyword><style face="normal" font="Arial"> Hemocyanin</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide vaccines</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic vaccines</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">Current therapeutic approaches in allergic diseases especially asthma generally focus on using immunological strategies. According to the importance of FceRI in controlling allergic response we used two extracellular regions of Fc epsilon receptor I (FceRI) beta subunit peptides to design two peptide-based vaccines. Probably these peptides vaccines by triggering the immune response to FceRI can reduce the allergic symptoms through blocking the IgE specific receptor. Two extracellular parts of FceRI beta subunit were made by peptide synthesizer and conjugated with keyhole limpet Hemocyanin. These conjugated peptides were used and evaluated as therapeutic vaccines in allergic airway inflammation mouse model. Total IgE and anti ovalbumin specific IgE were measured in mice serum and compared in vaccinated and unvaccinated allergic mice. Histamine, prostaglandin D2 (PGD2), IL-4 and IL-13 were measured in bronchoalveolar lavage (BAL) fluid of vaccinated allergic mice versus unvaccinated and histopathologic examination were performed in studied groups. After vaccination of mice with each of the peptide vaccines the specific antibodies titer increased significantly in vaccinated groups versus unvaccinated. In histopathologic study, lavage eosinophil percentage and peribronchial inflammation in lung sections of vaccinated groups was decreased ( p &amp;lt;0.05) . Also the allergic components including total IgE, anti ovalbumin specific IgE, histamine, PGD2, IL-4, and IL-13 showed substantial decline in vaccinated allergic mice. -áThus targeting the extracellular regions of FceRI beta subunit by peptide-based vaccines and induction of specific antibodies against them can reduce allergic responses in allergic mice model. -á-á</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-289-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-289-97.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Zare A</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shokouhi Shoormasti,R.</style></author><author><style face="normal" font="Arial"> Pourpak,Z.</style></author><author><style face="normal" font="Arial"> Fazlollahi,M.R.</style></author><author><style face="normal" font="Arial"> Shabani,A.</style></author><author><style face="normal" font="Arial"> Kazemnejad,A.</style></author><author><style face="normal" font="Arial"> Ebadi,Z.</style></author><author><style face="normal" font="Arial"> Tayebi,B.</style></author><author><style face="normal" font="Arial"> Darabi,B.</style></author><author><style face="normal" font="Arial"> Movahedi,M.</style></author><author><style face="normal" font="Arial"> Mahdaviani,S.A.</style></author><author><style face="normal" font="Arial"> Moin,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Determination of the Most Common Indoor and Outdoor Allergens in 602 Patients with Allergic Symptoms Using Specific IgE Local Panel</style></title><secondary-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Allergy Asthma Immunol</style></full-title></periodical><pages end="306" start="298">298-306</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergens,Epidemiology,IgE-mediated hypersensitivities,Specific IgE,Sensitization</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bermuda</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">Aeroallergens play an important role in developing allergic diseases. The aim of this study was to determine the outdoor and indoor sensitization using a specific regional panel of aeroallergens in allergic patients. All patients with allergic symptoms referred to Immunology, Asthma and Allergy Research Institute (IAARI) in Tehran, Iran from December 2010 to July 2013 entered this cross sectional study. We evaluated serum samples for specific IgE against 20 selected aeroallergens provided by a specific panel (RIDA Allergy Screen test, IAARI panel). A p value less than 0.05 was considered as significant. The patients (n=602) were 49.8 % male and 50.2% female. The median age was 9 years. Positive specific IgE at least to one allergen was 53.2%. The percentages of patients with only outdoor or indoor sensitization were 37.5 and 19.7%, respectively. Moreover, 42.8% showed sensitization to both indoor and outdoor aeroallergens. The most common outdoor aeroallergens in decreasing order were plane tree (32.8%), Bermuda grass (32.2%), timothy grass (30.6%), saltwort (28.4%). The percentage of specific IgE to indoor allergens including mold and mite were 23.8 % and 22.2%, respectively. There was a statistically significant relationship between specific IgE to timothy grass and mold allergens between two genders ( p= 0.04 and p =0.02, respectively).The results of this study shows that outdoor aeroallergens can be considered as the most common causes of allergic symptoms in our allergic patients</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/1130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-298-306.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-298-306.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Shokouhi Shoormasti R</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Badr,G.</style></author><author><style face="normal" font="Arial"> Ramadan,N.K.</style></author><author><style face="normal" font="Arial"> Sayed,L.H.</style></author><author><style face="normal" font="Arial"> Badr,B.M.</style></author><author><style face="normal" font="Arial"> Omar,H.M.</style></author><author><style face="normal" font="Arial"> Selamoglu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zoology Department, Faculty of Science, Assiut University, 71516 Assiut, Egypt</style></auth-address><titles><title><style face="normal" font="Arial">Why whey? Camel whey protein as a new dietary approach to the management of free radicals and for the treatment of different health disorders</style></title><secondary-title><style face="normal" font="Arial">Iran J Basic Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Iran J Basic Med Sci</style></full-title></periodical><pages end="349" start="338">338-349</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibacterial</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Free Radicals</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactalbumin</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> Lactoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Lactoperoxidase</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> Wound Healing</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">The balance between free radicals and antioxidants is an important factor for maintaining health and slowing disease progression. The use of antioxidants, particularly natural antioxidants, has become an important strategy for dealing with this cause of widespread diseases. Natural antioxidants have been used as therapeutic tools against many diseases because they are safe, effective, and inexpensive and are among the most commonly used adjuvants in the treatment of several diseases. Camel whey protein (CWP) is considered a strong natural antioxidant because it decreases oxidative stress, enhances immune system function, and increases glutathione levels. The structure of CWP is very similar to that of other types of whey protein from different types of milk. CWP contains many components, such as lactoferrin (LF), lactalbumin, lactoglobulins, lactoperoxidase, and lysozyme, and is rich in immunoglobulins. However, in contrast to other WPs, CWP lacks beta-lactoglobulin, the main cause of milk allergies in children. The components of CWP have many beneficial effects, including stimulation of both innate and adaptive immunity and anti-inflammatory, anticancer, antibacterial, and antiviral activities. Recently, it has been shown that CWP and its unique components can facilitate the treatment of impaired diabetic wound healing. However, the molecular mechanisms underlying the protective effects of CWP in human and other animal disorders are not fully understood. Therefore, the current review presents a concise summary of the scientific evidence of the beneficial effects of CWP to support its therapeutic use in disease treatment and nutritional intervention</style></abstract><notes><style face="normal" font="Arial">DA - 20170814IS - 2008-3866 (Print)IS - 2008-3866 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Egypt -CO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.22038/IJBMS.2017.8573</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28804604">PM:28804604</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Basic Med Sci\2017-20-338-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Basic Med Sci\2017-20-338-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170814, Badr G</style></custom2><misc3><style face="normal" font="Arial">10.22038/IJBMS.2017.8573</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,W.</style></author><author><style face="normal" font="Arial"> Tu,Z.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Xu,S.</style></author><author><style face="normal" font="Arial"> Niu,C.</style></author><author><style face="normal" font="Arial"> Yao,H.</style></author><author><style face="normal" font="Arial"> Kaltashov,I.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mechanism of the reduction in the IgG and IgE binding of beta-lactoglobulin induced by ultrasound pretreatment combined with dry-state glycation: a study using conventional spectrometry and high resolution mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Fourier transform ion cyclotron resonance mass spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> Hydrophobicity</style></keyword><keyword><style face="normal" font="Arial"> hyposensitization</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE Binding Ability</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Mannose</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Solutions</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ultrasound</style></keyword><keyword><style face="normal" font="Arial"> Ultrasound pretreatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="Arial">Bovine beta-lactoglobulin (beta-Lg) is one of major allergens in cow's milk. Previous study showed that ultrasound treatment induced the conformational changes of beta-Lg and promoted the glycation in aqueous solutions, which is, however, less efficient compared with dry-state. In this work, the effect of ultrasound pretreatment combined with dry-state glycation on the IgG and IgE binding of beta-Lg was studied. Dry-state glycation with mannose after ultrasound pretreatment at 0-600 W significantly reduced the IgG and IgE binding of beta-Lg, with the lowest values observed at 400 W. The decrease in the IgG and IgE binding of beta-Lg was attributed to the increase in glycation extent and the changes of secondary and tertiary structure, which reflected in the increase of UV absorbance, alpha-helix and beta-sheet contents as well as the decrease of intrinsic fluorescence intensity, surface hydrophobicity, beta-turn and random coil contents. Moreover, ultrasound pretreatment promoted the reduction of IgG and IgE binding abilities by improving glycation, reflecting in the increase of the glycation sites and the degree of substitution per peptide (DSP) value determined by Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS). Ultrasound pretreatment at 400 W showed the most significantly enhanced glycation extent. Besides, the results suggested FTICR-MS could provide insights into the glycation at molecular level, which was conducive to the understanding of the mechanism of the reduction in the IgG and IgE binding of beta-Lg. Therefore, ultrasound pretreatment combined with dry-state glycation may be a promising method for beta-Lg hyposensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b02842</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800703">PM:28800703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170812-YangW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170812-YangW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Yang W</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b02842</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,T.</style></author><author><style face="normal" font="Arial"> Hu,X.C.</style></author><author><style face="normal" font="Arial"> Cai,Z.P.</style></author><author><style face="normal" font="Arial"> Voglmeir,J.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Glycomics and Glycan Bioengineering Research Center, College of Food Science and Technology, Nanjing Agricultural University , Nanjing, Jiangsu 210014, China</style></auth-address><titles><title><style face="normal" font="Arial">Qualitative and Quantitative Analysis of Carbohydrate Modification on Glycoproteins from Seeds of Ginkgo biloba</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> CCD</style></keyword><keyword><style face="normal" font="Arial"> CCDs</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> geographic variation</style></keyword><keyword><style face="normal" font="Arial"> Ginkgo biloba</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> glycans</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> N-glycan</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> UPLC</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="8" Year="2017">2017/8/21</year></dates><abstract><style face="normal" font="Arial">Recent progress in the relationship between carbohydrate cross-reactive determinants (CCDs) and allergic response highlights the importance of carbohydrate moieties in the innate immune system. Previous research pointed out that the protein allergen in Ginkgo biloba seeds is glycosylated, and the oligosaccharides conjugated to these proteins might also contribute to the allergy. The aim of this study was to analyze carbohydrate moieties, especially N-linked glycans, of glycoproteins from Ginkgo seeds originating from different places for detailed structures, to enable further research on the role played by N-glycans in Ginkgo-caused allergy. Results of monosaccharide composition and immunoblotting assays indicated the existence of N-glycans. Detailed structural elucidation of the N-glycans was further carried out by means of hydrophilic interaction ultraperformance liquid chromatography (HILIC-UPLC) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). In total, 14 out of 16 structures detected by UPLC were confirmed by MALDI-TOF-MS and tandem mass spectrometry, among which complex-type N-glycans bearing Lewis A determinants and high-mannose-type N-glycans were identified from Ginkgo seeds for the first time. Precise quantification of N-glycans was performed by use of an external standard, and both the absolute amount of each N-glycan and the percentage of different types of N-glycan showed significant diversity among the samples without any pattern of geographic variation</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b01690</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800704">PM:28800704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170812-WangT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170812-WangT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Wang T</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b01690</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lieberman,P.L.</style></author><author><style face="normal" font="Arial"> Jones,I.</style></author><author><style face="normal" font="Arial"> Rajwanshi,R.</style></author><author><style face="normal" font="Arial"> Rosen,K.</style></author><author><style face="normal" font="Arial"> Umetsu,D.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Internal Medicine and Pediatrics, Division of Allergy and Immunology, University of Tennessee College of Medicine, 6139 Chapelle Circle West, Memphis TN 38120 USA.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797731">PM:28797731</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170811-LiebermanPL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170811-LiebermanPL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Lieberman PL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wen,T.</style></author><author><style face="normal" font="Arial"> Kuhl,J.</style></author><author><style face="normal" font="Arial"> Putnam,P.</style></author><author><style face="normal" font="Arial"> Mukkada,V.</style></author><author><style face="normal" font="Arial"> Farrell,M.</style></author><author><style face="normal" font="Arial"> Kaul,A.</style></author><author><style face="normal" font="Arial"> Cole,C.</style></author><author><style face="normal" font="Arial"> Rothenberg,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology</style></auth-address><titles><title><style face="normal" font="Arial">A flow cytometry-based diagnosis of eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170822IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826772">PM:28826772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170822-WenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170822-WenT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170822, Wen T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85593</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Heeringa,J.J.</style></author><author><style face="normal" font="Arial"> Karim,A.F.</style></author><author><style face="normal" font="Arial"> van Laar,J.A.M.</style></author><author><style face="normal" font="Arial"> Verdijk,R.M.</style></author><author><style face="normal" font="Arial"> Paridaens,D.</style></author><author><style face="normal" font="Arial"> van Hagen,P.M.</style></author><author><style face="normal" font="Arial"> van Zelm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Expansion of blood IgG4+ Bcells, Th2 and Tregulatory cells in IgG4-related disease</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> activation marker</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> BLAST</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chemokine receptor</style></keyword><keyword><style face="normal" font="Arial"> Chemokine receptors</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory B cell</style></keyword><keyword><style face="normal" font="Arial"> memory B cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sarcoidosis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="8" Year="2017">2017/8/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition affecting various organs and has a diverse clinical presentation. Fibrosis and accumulation of IgG4+ plasma cells in tissue are hallmarks of the disease and IgG4-RD is associated with elevated IgG4 serum levels. However, disease pathogenesis is still unclear and these cellular and molecular parameters are neither sensitive nor specific for diagnosis of IgG4-RD. OBJECTIVE: We here sought to develop a flowcytometric gating strategy to reliably identify blood IgG4+ B-cells to study their cellular and molecular characteristics and investigate their contribution in disease pathogenesis. METHODS: Sixteen patients with histologically confirmed IgG4-RD, 11 patients with sarcoidosis and 30 healthy individuals were included for 11-color flowcytometric analysis of peripheral blood for IgG4-expressing B cells and T-helper (Th) subsets. In addition, detailed analysis of activation markers and chemokine receptors was performed on IgG4-expressing B cells and IgG4 transcripts were analyzed for somatic hypermutations. RESULTS: Cellular and molecular analyses revealed increased numbers of blood IgG4+ memory B-cells in patients with IgG4-RD. These cells showed reduced expression of CD27 and CXCR5 and increased signs of antibody maturation. Furthermore, IgG4-RD patients, but not patients with sarcoidosis, had increased numbers of circulating plasma blasts and CD21low B-cells, as well as Th2 and regulatory T-cells, indicating of a common disease pathogenesis in IgG4-RD. CONCLUSION: These results provide new insights into the dysregulated IgG4 response in patients with IgG4-RD. A specific "peripheral lymphocyte signature" observed in patients with IgG4-RD, could support diagnosis and treatment monitoring</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28830675">PM:28830675</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170823-HeeringaJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170823-HeeringaJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Heeringa JJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85594</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Spergel,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jaffe Food Allergy Institute, Department of Pediatrics, Division of Allergy and Immunology, Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="Arial">FPIES: not so rare after all!</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797735">PM:28797735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170811-NowakWegrzynA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170811-NowakWegrzynA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Nowak-Wegrzyn A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mazokopakis,E.E.</style></author><author><style face="normal" font="Arial"> Liontiris,M.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Naval Hospital of Crete , Chania, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Commentary: Health Concerns of Brazil Nut Consumption</style></title><secondary-title><style face="normal" font="Arial">J Altern Complement Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Altern Complement Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aflatoxin</style></keyword><keyword><style face="normal" font="Arial"> Aflatoxins</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Bertholletia excelsa</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> brazil nut</style></keyword><keyword><style face="normal" font="Arial"> Brazil Nuts</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Selenium</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroid Diseases</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Type 2 diabetes</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Gain</style></keyword></keywords><dates><year Day="14" Month="8" Year="2017">2017/8/14</year></dates><abstract><style face="normal" font="Arial">Brazil nuts are the fruit of the enormous tropical tree Bertholletia excelsa that are produced in and exported from the territory of the Amazon. As a natural rich source of selenium (Se), the consumption of Brazil nuts is often suggested as therapeutic among patients with autoimmune thyroid diseases. In this review, the current knowledge regarding the main health concerns of Brazil nut consumption, such as Se toxicity, Se-induced type 2 diabetes mellitus, weight gain, radioactivity, aflatoxins, and allergic reactions, is presented and discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20170814IS - 1557-7708 (Electronic)IS - 1075-5535 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1089/acm.2017.0159</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28805450">PM:28805450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Altern Complement Med\20170814-MazokopakisEE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Altern Complement Med\20170814-MazokopakisEE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170814, Mazokopakis EE</style></custom2><misc3><style face="normal" font="Arial">10.1089/acm.2017.0159</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wan,J.</style></author><author><style face="normal" font="Arial"> Mitra,N.</style></author><author><style face="normal" font="Arial"> Hoffstad,O.J.</style></author><author><style face="normal" font="Arial"> Gelfand,J.M.</style></author><author><style face="normal" font="Arial"> Yan,A.C.</style></author><author><style face="normal" font="Arial"> Margolis,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.</style></auth-address><titles><title><style face="normal" font="Arial">Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: A cohort study</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> incident asthma</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="8" Year="2017">2017/8/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis is associated with other allergic conditions, but variations in this "atopic march" are poorly understood. OBJECTIVE: To determine the impact of the age of atopic dermatitis onset on the risk for asthma and seasonal allergies. METHODS: A cohort study was performed using the Pediatric Eczema Elective Registry, which is an observational cohort of subjects with pediatric onset atopic dermatitis. RESULTS: In total, 3966 children were included, and 73% reported atopic dermatitis onset before age 2 years. At baseline, subjects with atopic dermatitis onset at ages 3 to 7 or 8 to 17 years had significantly lower rates of seasonal allergies and asthma than those with onset before age 2. During follow-up, the adjusted relative risks for incident seasonal allergies were 0.82 (95% confidence interval, 0.72-0.91) and 0.64 (95% CI confidence interval, 0.47-0.83) in the 3- to 7- and 8- to 17-years-old at onset groups compared with the age 2 years or younger at onset group. The adjusted risk for incident asthma was not significantly different between the older onset groups and the earliest onset group. LIMITATIONS: Misclassification bias may arise from using self-reported onset age data. CONCLUSIONS: The timing of atopic dermatitis onset may explain part of the variation in the atopic march. These findings may improve future risk stratification of patients for treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170818IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2017.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28818439">PM:28818439</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20170818-WanJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20170818-WanJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170818, Wan J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2017.06.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mutz,M.L.</style></author><author><style face="normal" font="Arial"> Boudreaux,B.B.</style></author><author><style face="normal" font="Arial"> Royal,A.</style></author><author><style face="normal" font="Arial"> Merchant,S.</style></author><author><style face="normal" font="Arial"> Pucheu-Haston,C.</style></author><author><style face="normal" font="Arial"> Griffith,E.H.</style></author><author><style face="normal" font="Arial"> Gieger,T.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cytologic comparison of the percentage of mast cells in lymph node aspirate samples from clinically normal dogs versus dogs with allergic dermatologic disease and dogs with cutaneous mast cell tumors</style></title><secondary-title><style face="normal" font="Arial">J Am Vet Med Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Vet Med Assoc</style></full-title></periodical><pages end="428" start="421">421-428</pages><volume><style face="normal" font="Arial">251</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE To compare percentages of mast cells in lymph node (LN) aspirate samples from clinically normal dogs, dogs with allergic dermatologic disease (ADD), and dogs with cutaneous mast cell tumors (MCTs). DESIGN Prospective cross-sectional study. ANIMALS 20 healthy dogs (group 1), 20 dogs with ADD (group 2), and 20 dogs with an MCT on the head or limbs (group 3). PROCEDURES LN aspirate samples were obtained from easily accessible LNs in group 1, affected skin regions in group 2, and the likely draining LN or LNs of the MCT in group 3; the percentage of mast cells was manually determined for each LN. For group 3, LNs were cytologically categorized with a modified version of a published metastasis categorization scheme. RESULTS Median (range) percentage of mast cells in aspirate samples was 0% (0% to 0.1%) for group 1, 0.05% (0% to 0.55%) for group 2, and 0.4% (0% to 77.4%) for group 3. In group 3, 16 LNs (13 dogs) were palpably normal in size; 6 of these had evidence of possible or certain metastasis. Seven LNs (7 dogs) in group 3 were palpably enlarged, and 5 of these had evidence of certain metastasis. CONCLUSIONS AND CLINICAL RELEVANCE This study provided evidence to support the use of a uniform cytologic grading system to further define nodal metastasis in dogs with MCTs as well as estimates of the percentage of mast cells in LN aspirate samples for healthy dogs and dogs with ADD. Palpably normal LNs in dogs with cutaneous MCT may contain metastasis</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1943-569X (Electronic)IS - 0003-1488 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2460/javma.251.4.421</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28763275">PM:28763275</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Vet Med Assoc\2017-251-421-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Vet Med Assoc\2017-251-421-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Mutz ML</style></custom2><misc3><style face="normal" font="Arial">10.2460/javma.251.4.421</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhu,X.</style></author><author><style face="normal" font="Arial"> Wang,W.</style></author><author><style face="normal" font="Arial"> Shen,J.</style></author><author><style face="normal" font="Arial"> Xu,X.</style></author><author><style face="normal" font="Arial"> Zhou,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nanjing Agricultural University, College of Sciences, Nanjing 210095, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Influence of Gamma Irradiation on Porcine Serum Albumin Structural Properties and Allergenicity</style></title><secondary-title><style face="normal" font="Arial">J AOAC Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J AOAC Int</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> conformational changes</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gamma irradiation</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> irradiated</style></keyword><keyword><style face="normal" font="Arial"> irradiation</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Porcine serum albumin</style></keyword><keyword><style face="normal" font="Arial"> Pork</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Structural properties</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="Arial">Pork provides an ideal source of food energy; however, pork can elicit an allergic reaction, and porcine serumalbumin (PSA) has been identified as a major allergen. This study examined the impact of gamma irradiation on the allergenicity and structural qualities of PSA; the PSA solution was gamma-irradiated at 1, 2, 4, 6, and 8 kGy. Allergenicity was investigated by immunoblotting and competitive indirect ELISA using serum from patients who are allergic to pork, and conformational changes in irradiated PSA were measured by circular dichroism, sulfhydryl group detection, and fluorescence emission spectra. The secondary and tertiary structures of gamma-irradiated PSA were altered, and the allergenicity of PSA was lowered by boosting the amount of irradiation. In addition, there is high correlation between depletion in the &amp;#945;-helix and immunoglobulin E-binding capability of PSA. The results show a new possibility in using gamma irradiation to reduce the allergenicity of pork products</style></abstract><notes><style face="normal" font="Arial">DA - 20170819IS - 1060-3271 (Print)IS - 1060-3271 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.5740/jaoacint.17-0160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28821308">PM:28821308</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170819, Zhu X</style></custom2><misc3><style face="normal" font="Arial">10.5740/jaoacint.17-0160</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Celebi,S.Z.</style></author><author><style face="normal" font="Arial"> Aydin,O.</style></author><author><style face="normal" font="Arial"> Misirligil,Z.</style></author><author><style face="normal" font="Arial"> Mungan,D.</style></author><author><style face="normal" font="Arial"> Demirel,Y.S.</style></author><author><style face="normal" font="Arial"> Celik,G.E.</style></author><author><style face="normal" font="Arial"> Sin,B.A.</style></author><author><style face="normal" font="Arial"> Bavbek,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Ankara University, School of Medicine , Department of Chest Diseases, Division of Immunologyand Allergy</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab in non-allergic asthma: A report of 13 cases</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function test</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There are limited data regarding the effectiveness of omalizumab in patients with non-allergic asthma. OBJECTIVE: To evaluate the clinical and functional effectiveness of omalizumab in patients with non-allergic asthma. METHODS: The study was a single-center, retrospective chart review of patients with non-allergic asthma who were treated with add-on omalizumab between February 2014 and March 2016. After omalizumab was started, data of the Asthma Control Test(ACT), pulmonary function test, and daily oral corticosteroid(OCS) dosage were collected at baseline, 16 weeks, 1 year, 2 and 3 years (if available). The number of exacerbations/hospitalizations were collected 1 year prior to and 6 months/1 year after omalizumab. To calculate the total daily dosage of OCS in milligrams, data for 6 months/1 year prior and after omalizumab treatment were recorded. RESULTS: Thirteen patients were included. After omalizumab, the mean ACT was significantly increased at 16 weeks (n = 13,p = 0.002), 1 year (n = 7,p = 0.006) and 2 years (n = 5,p = 0.006). The mean daily oral corticosteroid dose was significantly decreased at 16 weeks (n = 13,p = 0.001), 1 year (n = 7,p = 0.006), and 2 years (n = 5,p = 0.04). The mean number of exacerbations and hospitalizations were decreased at the 6th month (n = 13; p = 0.001,p = 0.005) and 1st year (n = 7; p = 0.01,p = 0.02). The mean total quantity of OCS decreased 42% from 1.4 g to 0.8 g in the six-month period prior to and post-omalizumab treatment (n = 6,p = 0.02) and decreased 76% from 3.8 g to 0.9 g at one year in the pre vs. post-omalizumab treatment comparison (n = 7,p = 0.01). Six (46.2%) patients responded perfectly and seven (53.8%) partially responded to treatment. CONCLUSION: Omalizumab can be effective in non-atopic severe asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2017.1362427</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800272">PM:28800272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170811-CelebiSZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170811-CelebiSZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Celebi SZ</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2017.1362427</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rastogi,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Ayurvedic College and Hospital, Lucknow, India.</style></auth-address><titles><title><style face="normal" font="Arial">Urticarial rashes following guggulu intake: A case report</style></title><secondary-title><style face="normal" font="Arial">J Ayurveda Integr Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ayurveda Integr Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Case Report</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> pharmacodynamics</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="Arial">Ayurvedic drugs are anecdotally considered safe and are sparingly reported for adversity upon their usage. Reporting adversity however helps understanding the drug pharmacodynamics in a given case and prompts for its safe future application. The patient here has reported urticarial rashes upon use of an Ayurvedic guggulu preparation. The observations were repeated upon the repeated use of the drug. These symptoms were compelling enough to look for a rescue medicine and to withdraw the primary medicine. Guggulu is known for its gastrointestinal and hepatic adversities in some cases. Its skin adversities are however lesser known. This case presents an opportunity to consider urticarial rashes also as possible adversity to guggulu in some cases</style></abstract><notes><style face="normal" font="Arial">DA - 20170822IS - 0975-9476 (Print)IS - 0975-9476 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaim.2017.04.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826837">PM:28826837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ayurveda Integr Med\20170822-RastogiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ayurveda Integr Med\20170822-RastogiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170822, Rastogi S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaim.2017.04.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reddy,V.B.</style></author><author><style face="normal" font="Arial"> Lerner,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Massachusetts General Hospital and Harvard Medical School, United States</style></auth-address><titles><title><style face="normal" font="Arial">Activation of mas-related G-protein coupled receptors by the house dust mite cysteine protease Der p1 provides a new mechanism linking allergy and inflammation</style></title><secondary-title><style face="normal" font="Arial">J Biol Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Biol Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and inflammation</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Cysteine protease</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mutagenesis</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> serine proteases</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="Arial">Cysteine and serine proteases function via protease-activated (PARs) and mas-related G-protein coupled receptors (Mrgprs) to contribute to allergy and inflammation. Der p1 is a cysteine protease and major allergen from the house dust mite and is associated with allergic rhinitis and allergic asthma. Der p1 activates PAR2 and induces the release of the pro-inflammatory cytokine IL-6 from cells. However, the possibility that Der p1 acts on Mrgprs has not been considered. We report here that ratiometric calcium imaging reveals that Der p1 activates the human receptor MRGPRX1 and the mouse homolog MrgprC11, implicated previously in itch. Der p1 cleavage of N-terminal receptor peptides followed by site-directed mutagenesis of the cleavage sites links receptor activation to specific amino acid residues. Der p1 also induced the release of IL-6 from heterologous cells expressing MRGPRX1. In summary, activation of Mrgprs by the allergen Der p1 may contribute to inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1083-351X (Electronic)IS - 0021-9258 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1074/jbc.M117.787887</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28768771">PM:28768771</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biol Chem\20170803-ReddyVB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biol Chem\20170803-ReddyVB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Reddy VB</style></custom2><misc3><style face="normal" font="Arial">10.1074/jbc.M117.787887</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aprodu,I.</style></author><author><style face="normal" font="Arial"> Patrascu,L.</style></author><author><style face="normal" font="Arial"> Banu,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Impact of neutrase and transglutaminase treatment on the antigenicity of soy and wheat proteins</style></title><secondary-title><style face="normal" font="Arial">J Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Biotechnol</style></full-title></periodical><pages end="" start="S65">S65-</pages><volume><style face="normal" font="Arial">256</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> aggregates</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bakery</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein aggregate</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy protein isolate</style></keyword><keyword><style face="normal" font="Arial"> Soy Proteins</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0168-1656</style></isbn><abstract><style face="normal" font="Arial">The effect of exogenous enzymes on antigenic character of soy and wheat proteins was investigated. ELISA tests (RIDASCREEN®Gliadin and RIDASCREEN®FAST SOYA) were used to detect gliadin and soy proteins after incubating the vital gluten and soy protein isolate with neutrase or transglutaminase for 30 min at 50 °C. The residual antigenicity was determined as percentage of allergen protein recognized by specific antibodies in respect to the untreated samples. Hydrolysis with neutrase resulted in almost complete elimination of the antigenic properties of soy and wheat proteins, indicating high affinity of the enzyme for the structural epitopes. The cross-linking reaction catalyzed by transglutaminase resulted in 95% reduction of the residual antigenicity of soy protein, and over 75% in case of gluten. The conformational epitopes might be altered because of involvement of exposed amino acids in cross-linking reactions, or blocked within the protein aggregates. These results suggest the possibility of reducing the antigenicity of two of the most important proteins responsible for allergenic reaction worldwide, by employing the neutrase or transglutaminase treatment at levels recommended for bakery applications.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Romania -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jbiotec.2017.06.1021</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jbiotec.2017.06.1021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biotechnol\2017-256-S65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biotechnol\2017-256-S65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Aprodu I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jbiotec.2017.06.1021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arora,M.</style></author><author><style face="normal" font="Arial"> Bagi,P.</style></author><author><style face="normal" font="Arial"> Strongin,A.</style></author><author><style face="normal" font="Arial"> Heimall,J.</style></author><author><style face="normal" font="Arial"> Zhao,X.</style></author><author><style face="normal" font="Arial"> Lawrence,M.G.</style></author><author><style face="normal" font="Arial"> Trivedi,A.</style></author><author><style face="normal" font="Arial"> Henderson,C.</style></author><author><style face="normal" font="Arial"> Hsu,A.</style></author><author><style face="normal" font="Arial"> Quezado,M.</style></author><author><style face="normal" font="Arial"> Kleiner,D.E.</style></author><author><style face="normal" font="Arial"> Venkatesan,A.M.</style></author><author><style face="normal" font="Arial"> Holland,S.M.</style></author><author><style face="normal" font="Arial"> Freeman,A.F.</style></author><author><style face="normal" font="Arial"> Heller,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD, USA</style></auth-address><titles><title><style face="normal" font="Arial">Gastrointestinal Manifestations of STAT3-Deficient Hyper-IgE Syndrome</style></title><secondary-title><style face="normal" font="Arial">J Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dilation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysphagia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagogastroduodenoscopy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="Arial"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> GERD</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> STAT</style></keyword><keyword><style face="normal" font="Arial"> STAT-3</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> strictures</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="8" Year="2017">2017/8/13</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: STAT 3 deficiency (autosomal dominant hyper immunoglobulin E syndrome (AD-HIES)) is a primary immunodeficiency disorder with multi-organ involvement caused by dominant negative signal transducer and activator of transcription gene 3 (STAT3) mutations. We sought to describe the gastrointestinal (GI) manifestations of this disease. METHODS: Seventy subjects aged five to 60 years with a molecular diagnosis of AD-HIES were evaluated at the National Institutes of Health (NIH). Data collection involved a GI symptom questionnaire and retrospective chart review. RESULTS: In our cohort of 70 subjects, we found that 60% had GI symptoms (42/70). The most common manifestations were gastroesophageal reflux disease (GERD) observed in 41%, dysphagia in 31%, and abdominal pain in 24%. The most serious complications were food impaction in 13% and colonic perforation in 6%. Diffuse esophageal wall thickening in 74%, solid stool in the right colon in 50% (12/24), and hiatal hernia in 26% were the most prevalent radiologic findings. Esophagogastroduodenoscopy (EGD) demonstrated esophageal tortuosity in 35% (8/23), esophageal ulceration in 17% (4/23), esophageal strictures requiring dilation in 9% (2/23), and gastric ulceration in 17% (4/23). Esophageal eosinophilic infiltration was an unexpected histologic finding seen in 65% (11/17). CONCLUSION: The majority of AD-HIES subjects develop GI manifestations as part of their disease. Most notable are the symptoms and radiologic findings of GI dysmotility, as well as significant eosinophilic infiltration, concerning for a secondary eosinophilic esophagitis. These findings suggest that the STAT3 pathway may be implicated in a new mechanism for the pathogenesis of several GI disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170813IS - 1573-2592 (Electronic)IS - 0271-9142 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10875-017-0429-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803389">PM:28803389</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Immunol\20170813-AroraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Immunol\20170813-AroraM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170813, Arora M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10875-017-0429-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Whitehead,G.S.</style></author><author><style face="normal" font="Arial"> Thomas,S.Y.</style></author><author><style face="normal" font="Arial"> Shalaby,K.H.</style></author><author><style face="normal" font="Arial"> Nakano,K.</style></author><author><style face="normal" font="Arial"> Moran,T.P.</style></author><author><style face="normal" font="Arial"> Ward,J.M.</style></author><author><style face="normal" font="Arial"> Flake,G.P.</style></author><author><style face="normal" font="Arial"> Nakano,H.</style></author><author><style face="normal" font="Arial"> Cook,D.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunity, Inflammation and Disease Laboratory</style></auth-address><titles><title><style face="normal" font="Arial">TNF is required for TLR ligand-mediated but not protease-mediated allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">J Clin Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Invest</style></full-title></periodical><pages end="3326" start="3313">3313-3326</pages><volume><style face="normal" font="Arial">127</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="Arial">Asthma is associated with exposure to a wide variety of allergens and adjuvants. The extent to which overlap exists between the cellular and molecular mechanisms triggered by these various agents is poorly understood, but it might explain the differential responsiveness of patients to specific therapies. In particular, it is unclear why some, but not all, patients benefit from blockade of TNF. Here, we characterized signaling pathways triggered by distinct types of adjuvants during allergic sensitization. Mice sensitized to an innocuous protein using TLR ligands or house dust extracts as adjuvants developed mixed eosinophilic and neutrophilic airway inflammation and airway hyperresponsiveness (AHR) following allergen challenge, whereas mice sensitized using proteases as adjuvants developed predominantly eosinophilic inflammation and AHR. TLR ligands, but not proteases, induced TNF during allergic sensitization. TNF signaled through airway epithelial cells to reprogram them and promote Th2, but not Th17, development in lymph nodes. TNF was also required during the allergen challenge phase for neutrophilic and eosinophilic inflammation. In contrast, TNF was dispensable for allergic airway disease in a protease-mediated model of asthma. These findings might help to explain why TNF blockade improves lung function in only some patients with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 1558-8238 (Electronic)IS - 0021-9738 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1172/JCI90890</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28758900">PM:28758900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Invest\20170731-WhiteheadGS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Invest\20170731-WhiteheadGS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Whitehead GS</style></custom2><misc3><style face="normal" font="Arial">10.1172/JCI90890</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nam,K.W.</style></author><author><style face="normal" font="Arial"> Choo,I.</style></author><author><style face="normal" font="Arial"> Chang,J.Y.</style></author><author><style face="normal" font="Arial"> Jung,S.</style></author><author><style face="normal" font="Arial"> Kim,B.J.</style></author><author><style face="normal" font="Arial"> Han,M.K.</style></author><author><style face="normal" font="Arial"> Bae,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis after Idarucizumab Infusion</style></title><secondary-title><style face="normal" font="Arial">J Clin Neurol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Clin Neurol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1738-6586 (Print)IS - 1738-6586 (Linking)LA - engPT - Case ReportsPT - LetterCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28831791">PM:28831791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Neurol\20170823-NamKW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Neurol\20170823-NamKW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Nam KW</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beck,S.C.</style></author><author><style face="normal" font="Arial"> Huissoon,A.P.</style></author><author><style face="normal" font="Arial"> Collins,D.</style></author><author><style face="normal" font="Arial"> Richter,A.G.</style></author><author><style face="normal" font="Arial"> Krishna,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="Arial">The concordance between component tests and clinical history in British adults with suspected pollen-food syndrome to peanut and hazelnut</style></title><secondary-title><style face="normal" font="Arial">J Clin Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Pathol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Pollen food syndrome</style></keyword><keyword><style face="normal" font="Arial"> Pollen-food syndrome</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="8" Year="2017">2017/8/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mild oropharyngeal symptoms to peanut/hazelnut occur in ~30% of patients with pollen-food syndrome (PFS). Component tests are considered a useful adjunct to the diagnosis and may help differentiate PFS from those at a risk of anaphylaxis due to storage protein/lipid transfer protein (LTP) sensitisation. AIMS: To assess concordance between component tests and clinical history in suspected PFS to peanut/hazelnut in a specialist clinic. METHODS: Adult patients were classified into PFS (group 1, n=69) and PFS with mild systemic symptoms (group 2, n=45) based on clinical history. Specific IgE (sIgE) of a per thousand yen0.35aeuro per thousandkUA/L was considered positive as per manufacturersaeuro recommendation. Kappa (I masculine) inter-rater agreement was calculated for concordance between clinical classification and test profiles. RESULTS: Group 1 hazelnut: 85% monosensitised to Cor a1, 12% to storage protein/s or LTP and 3% negative to all components. Group 1 peanut: 41% monosensitised to Ara h8, 44% to storage protein/s or A+/-LTP and 15% negative to all components. Group 2 hazelnut: 67% monosensitised to Cor a1, 16% sensitised to storage protein/s and 17% negative to all components. Group 2 peanut: 19% monosensitised to Ara h8, 62% sensitised to storage protein/s and/or LTP and 19% negative to all components.SIgE to Ara h8 and Cor a1 were greater in group 1 versus group 2: (median (IQR) kUA/L; hazelnut: 12.1 (7.8-25.2) vs 2.4 (0.36-6.3), p&lt;0.001; peanut: 2.4 (0.10-21.1) vs 0.3 (0-3), p&lt;0.01)). CONCLUSION: Concordance between component tests and clinical history for adults with PFS was good for hazelnut (I masculine=0.63) but poor for peanut (I masculine=a^'0.12). Food challenges are warranted in discordant cases for an accurate diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20170806IS - 1472-4146 (Electronic)IS - 0021-9746 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/jclinpath-2017-204573</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780515">PM:28780515</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Pathol\20170806-BeckSC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Pathol\20170806-BeckSC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170806, Beck SC</style></custom2><misc3><style face="normal" font="Arial">10.1136/jclinpath-2017-204573</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shakya,A.K.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author><author><style face="normal" font="Arial"> Gill,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA</style></auth-address><titles><title><style face="normal" font="Arial">Cutaneous vaccination with coated microneedles prevents development of airway allergy</style></title><secondary-title><style face="normal" font="Arial">J Control Release</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Control Release</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual route</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">Allergy cases are increasing worldwide. Currently allergies are treated after their appearance in patients. However, now there is effort to make a preventive vaccine against allergies. The rationale is to target patient populations that are already sensitized to allergens but have yet to develop severe forms of the allergic disease, or who are susceptible to allergy development but have not yet developed them. Subcutaneous injections and the sublingual route have been used as the primary mode of preventive vaccine delivery. However, injections are painful, especially considering that they have to be given repeatedly to infants or young children. The sublingual route is hard to use since infants can't be trained to hold the vaccine under their tongue. In the present study, we demonstrate a microneedle (MN)-based cutaneous preventive allergy treatment against ovalbumin (Ova)-induced airway allergy in mice. Insertion of MNs coated with Ova as a model allergen and CpG oligonucleotide as an adjuvant (MNs-CIT) into the skin significantly induced Ova specific systemic immune response. This response was similar to that induced by hypodermic-needle-based delivery of Ova using the clinically-approved subcutaneous immunotherapy (SCIT) route. MNs-CIT upregulated Ova-specific Th2 cytokines (IL-4, IL-5 &amp; IL-13) and anti-inflammatory cytokines (IL-10) in the bronchoalveolar fluid, and IL-2 and IFN-gamma cytokines in restimulated splenocyte cultures. Absence of mucus deposition inside the bronchiole wall and low stiffness around the lung bronchioles after Ova-allergen challenge further confirmed the protective role of MNs-CIT. Overall, MNs-CIT represents a novel minimally invasive cutaneous immunotherapy to prevent the progression of Ova induced airway allergy in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170819IS - 1873-4995 (Electronic)IS - 0168-3659 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jconrel.2017.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28821461">PM:28821461</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Control Release\20170819-ShakyaAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Control Release\20170819-ShakyaAK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170819, Shakya AK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jconrel.2017.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jankowski,M.</style></author><author><style face="normal" font="Arial"> Kodyra,E.</style></author><author><style face="normal" font="Arial"> Kaszubowska,J.</style></author><author><style face="normal" font="Arial"> Czajkowski,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nicolaus Copernicus University in Torun, Faculty of Medicine, Chair of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Bydgoszcz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Characterization of patients with suspected hypersensitivity to cervico-vaginal fluid</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Tests</style></keyword><keyword><style face="normal" font="Arial"> Internet</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Post-coital</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Sexually Transmitted Diseases</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Transmitted diseases</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic reaction to seminal plasma was described decades ago. In USA only tens of thousands women are estimated to be affected. Not only seminal plasma, but also cervico-vaginal fluid contains sex-restricted antigens, yet allergy to cervicovaginal fluid has never been reported in medical literature. We came to a suspicion that because immunologic tests required to prove such a diagnosis, allergy to cervicovaginal fluid has never been reported yet it is not uncommon. OBJECTIVE: The objective of this study was to use an Internet-based questionnaire to characterize the population of men with suspected hypersensitivity to cervico-vaginal fluid. METHODS: A questionnaire designed to cover localized and systemic symptoms of hypersensitivity reaction was made available via the Internet. Respondents with post-coital adverse reactions were invited to participate. Only respondents who presented with at least two symptoms suggestive to hypersensitivity to seminal plasma or cervicovaginal fluid and were negative for STI and known hypersensitivity reactions such as latex allergy were a subject for further analysis. Board-certified dermatologists were surveyed for seeing bona fide cases of cervicovaginal fluid hypersensitivity. RESULTS: We have identified 52 cases of suspected hypersensitivity to CVF. Both localized and systemic types of hypersensitivity were identified. A substantial number of dermatologists admitted to witnessing cases of hypersensitivity to CVF CONCLUSION: Based on data from affected individuals as well as the opinions of dermatologists worldwide we believe that allergic reaction to cervicovaginal fluid is at least as common as seminal plasma allergy. However, remains unreported due to technical difficulties in diagnosis and dermatologists' disbelief in its actual existence. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170824IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14550</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28837242">PM:28837242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170824-JankowskiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170824-JankowskiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Jankowski M</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14550</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Q.</style></author><author><style face="normal" font="Arial"> Zhong,H.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Zhai,Z.</style></author><author><style face="normal" font="Arial"> Zhou,Z.</style></author><author><style face="normal" font="Arial"> Song,Z.</style></author><author><style face="normal" font="Arial"> Hao,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, China</style></auth-address><titles><title><style face="normal" font="Arial">Different Expression Patterns of Plasma Th1-, Th2-, Th17-, and Th22-Related Cytokines Correlate with Serum Autoreactivity and Allergen Sensitivity in Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Clinical features and basophil activation levels correlate with serum autoreactivity and allergen sensitivity in patients with chronic spontaneous urticaria (CSU). OBJECTIVES: To explore the relationship of the expression patterns of plasma T-helper cell (Th) 1, Th2, Th17, and Th22-related cytokines with the serum autoreactivity and the allergen sensitivity in CSU. METHOD: Twenty related cytokines were measured and analysed in 60 CSU patients, 15 acute urticaria patients, 10 patients with atopic dermatitis (AD), and 15 healthy persons, respectively. Autologous serum skin testing (ASST) and skin prick testing (SPT) were performed to detect autoreactivity and allergy sensitivity, respectively. The protein-protein interaction of cytokines and the molecular pathways were analysed by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and KyotoEncyclopedia of Genes and Genomes (KEGG database), respectively. RESULTS: Th1/Th2 and Th17 related cytokines were significantly elevated and correlated with disease activity in CSU than in healthy controls. Interleukin (IL)-6, IL-10, and IL-13 were significantly higher in acute urticaria than in CSU patients. Granulocyte/macrophage colony-stimulating factor (GM-CSF), IL-10 and IL-17 were significantly higher in ASST + than in</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - China -CO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14541</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846158">PM:28846158</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170828-ChenQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170828-ChenQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Chen Q</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14541</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Treudler,R.</style></author><author><style face="normal" font="Arial"> Zeynalova,S.</style></author><author><style face="normal" font="Arial"> Walther,F.</style></author><author><style face="normal" font="Arial"> Engel,C.</style></author><author><style face="normal" font="Arial"> Simon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Venerology and Allergology, Universitat Leipzig</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis is associated with autoimmune but not with cardiovascular comorbidities in a random sample of the general population in Leipzig, Germany</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Life Style</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) was recently reported to be associated with multiple non-atopic comorbidities [1-4], especially of autoimmune or cardiovascular type. This co-occurrence was related to several immune mechanism of AD being shared with other immune-mediated diseases [2], as well as to chronic inflammation and life style factors [5]. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14495</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28758257">PM:28758257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170731-TreudlerR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170731-TreudlerR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Treudler R</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14495</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shalom,G.</style></author><author><style face="normal" font="Arial"> Magen,E.</style></author><author><style face="normal" font="Arial"> Babaev,M.</style></author><author><style face="normal" font="Arial"> Tiosano,S.</style></author><author><style face="normal" font="Arial"> Vardy,D.A.</style></author><author><style face="normal" font="Arial"> Linder,D.</style></author><author><style face="normal" font="Arial"> Horev,A.</style></author><author><style face="normal" font="Arial"> Saadia,A.</style></author><author><style face="normal" font="Arial"> Comaneshter,D.</style></author><author><style face="normal" font="Arial"> gmon-Levin,N.</style></author><author><style face="normal" font="Arial"> Cohen,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, Soroka Medical Center, Beer-Sheva, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Urticaria and the Metabolic Syndrome: a Cross-sectional Community-based Study of 11,261 Patients</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> community-based</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gout</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Emerging evidence suggests that chronic urticaria (CU) is associated with chronic, low grade, inflammatory process. OBJECTIVE: To evaluate the association between CU and metabolic syndrome and its components in a large community-based medical database. METHODS: A cross-sectional study of CU patients and matched controls was performed. CU was defined as eight urticaria diagnoses (with each two diagnoses registered within a period of six weeks) from 2002 to 2012. Data regarding the prevalence of metabolic syndrome, its components, and possible complications were collected. RESULTS: The study included 11,261 patients with CU and 67,216 controls. In a univariate analysis, CU was significantly associated with higher body mass index (BMI) and a higher prevalence of obesity, diabetes, hyperlipidemia, hypertension, metabolic syndrome, chronic renal failure, and gout. Multivariate analysis demonstrated a significant association between CU and metabolic syndrome (OR = 1.12, 95% CI 1.1-1.2, p &lt; 0.001) and its components- obesity (OR = 1.2, 95% CI 1.1-1.3, p &lt; 0.001), diabetes (OR = 1.08, 95% CI 1.01-1.15, p = 0.001), hyperlipidemia (OR = 1.2, 95% CI 1.1-1.2, p &lt; 0.001), and hypertension (OR = 1.1, 95% CI 1.1-1.2, p &lt; 0.001). CONCLUSIONS: CU patients may have one or more undiagnosed components of metabolic syndrome despite their young age. Thus, appropriate targeted screening is advised. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14548</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846167">PM:28846167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170828-ShalomG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170828-ShalomG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Shalom G</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14548</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nobs,S.P.</style></author><author><style face="normal" font="Arial"> Natali,S.</style></author><author><style face="normal" font="Arial"> Pohlmeier,L.</style></author><author><style face="normal" font="Arial"> Okreglicka,K.</style></author><author><style face="normal" font="Arial"> Schneider,C.</style></author><author><style face="normal" font="Arial"> Kurrer,M.</style></author><author><style face="normal" font="Arial"> Sallusto,F.</style></author><author><style face="normal" font="Arial"> Kopf,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Molecular Biomedicine, Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">PPARgamma in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation</style></title><secondary-title><style face="normal" font="Arial">J Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Exp Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inflammatory diseases</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">Type-2 immune responses are well-established drivers of chronic inflammatory diseases, such as asthma, and represent a large burden on public health systems. The transcription factor PPARgamma is known to promote M2-macrophage and alveolar macrophage development. Here, we report that PPARgamma plays a key role in both T cells and dendritic cells (DCs) for development of type-2 immune responses. It is predominantly expressed in mouse Th2 cells in vitro and in vivo as well as human Th2 cells from allergic patients. Using conditional knockouts, we show that PPARgamma signaling in T cells, although largely dispensable for IL-4 induction, is critical for IL-33-driven Th2 effector function in type-2 allergic airway responses. Furthermore, we demonstrate that IL-4 and IL-33 promote up-regulation of PPARgamma in lung-resident CD11b+ DCs, which enhances migration to draining lymph nodes and Th2 priming capacity. Thus, we uncover a surprising proinflammatory role for PPARgamma and establish it as a novel, important mediator of DC-T cell interactions in type-2 immunity</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1540-9538 (Electronic)IS - 0022-1007 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1084/jem.20162069</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28798029">PM:28798029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Exp Med\20170811-NobsSP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Exp Med\20170811-NobsSP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Nobs SP</style></custom2><misc3><style face="normal" font="Arial">10.1084/jem.20162069</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ito,T.</style></author><author><style face="normal" font="Arial"> Hirose,K.</style></author><author><style face="normal" font="Arial"> Saku,A.</style></author><author><style face="normal" font="Arial"> Kono,K.</style></author><author><style face="normal" font="Arial"> Takatori,H.</style></author><author><style face="normal" font="Arial"> Tamachi,T.</style></author><author><style face="normal" font="Arial"> Goto,Y.</style></author><author><style face="normal" font="Arial"> Renauld,J.C.</style></author><author><style face="normal" font="Arial"> Kiyono,H.</style></author><author><style face="normal" font="Arial"> Nakajima,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="Arial">IL-22 induces Reg3gamma and inhibits allergic inflammation in house dust mite-induced asthma models</style></title><secondary-title><style face="normal" font="Arial">J Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Exp Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">Previous studies have shown that IL-22, one of the Th17 cell-related cytokines, plays multiple roles in regulating allergic airway inflammation caused by antigen-specific Th2 cells; however, the underlying mechanism remains unclear. Here, we show that allergic airway inflammation and Th2 and Th17 cytokine production upon intratracheal administration of house dust mite (HDM) extract, a representative allergen, were exacerbated in IL-22-deficient mice. We also found that IL-22 induces Reg3gamma production from lung epithelial cells through STAT3 activation and that neutralization of Reg3gamma significantly exacerbates HDM-induced eosinophilic airway inflammation and Th2 cytokine induction. Moreover, exostatin-like 3 (EXTL3), a functional Reg3gamma binding protein, is expressed in lung epithelial cells, and intratracheal administration of recombinant Reg3gamma suppresses HDM-induced thymic stromal lymphopoietin and IL-33 expression and accumulation of type 2 innate lymphoid cells in the lung. Collectively, these results suggest that IL-22 induces Reg3gamma production from lung epithelial cells and inhibits the development of HDM-induced allergic airway inflammation, possibly by inhibiting cytokine production from lung epithelial cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1540-9538 (Electronic)IS - 0022-1007 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1084/jem.20162108</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811323">PM:28811323</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Exp Med\20170816-ItoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Exp Med\20170816-ItoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Ito T</style></custom2><misc3><style face="normal" font="Arial">10.1084/jem.20162108</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chhabra,G.S.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Su,M.</style></author><author><style face="normal" font="Arial"> Venkatachalam,M.</style></author><author><style face="normal" font="Arial"> Roux,K.H.</style></author><author><style face="normal" font="Arial"> Sathe,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Nutrition, Food &amp; Exercise Sciences, Florida State Univ., Tallahassee, Fla., 32306-1490, U.S.A</style></auth-address><titles><title><style face="normal" font="Arial">Effects of the Maillard Reaction on the Immunoreactivity of Amandin in Food Matrices</style></title><secondary-title><style face="normal" font="Arial">J Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Almond detection</style></keyword><keyword><style face="normal" font="Arial"> Almonds</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Maillard</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="Arial">Amandin is the major storage protein and allergen in almond seeds. Foods, containing almonds, subjected to thermal processing typically experience Maillard browning reaction. The resulting destruction of amino groups, protein glycation, and/or denaturation may alter amandin immunoreactivity. Amandin immunoreactivity of variously processed almond containing foods was therefore the focus of the current investigation. Commercial and laboratory prepared foods, including those likely to have been subjected to Maillard browning, were objectively assessed by determining Hunter L* , a* , b* values. The L* values for the tested samples were in the range of 31.75 to 85.28 consistent with Maillard browning. Three murine monoclonal antibodies, 4C10, 4F10, and 2A3, were used to determine the immunoreactivity of the targeted samples using immunoassays (ELISA, Western blot, dot blot). The tested foods did not exhibit cross-reactivity indicating that the immunoassays were amandin specific. For sandwich ELISAs, ratio (R) of sample immunoreactivity to reference immunoreactivity was calculated. The ranges of R values were 0.67 to 15.19 (4C10), 1.00 to 11.83 (4F10), and 0.77 to 23.30 (2A3). The results of dot blot and Western blot were consistent with those of ELISAs. Results of these investigations demonstrate that amandin is a stable marker protein for almond detection regardless of the degree of amandin denaturation and/or destruction as a consequence of Maillard reaction encountered under the tested processing conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1750-3841 (Electronic)IS - 0022-1147 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/1750-3841.13839</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833127">PM:28833127</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci\20170823-ChhabraGS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci\20170823-ChhabraGS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Chhabra GS</style></custom2><misc3><style face="normal" font="Arial">10.1111/1750-3841.13839</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fontenelle,G.</style></author><author><style face="normal" font="Arial"> Knoff,M.</style></author><author><style face="normal" font="Arial"> Vericimo,M.A.</style></author><author><style face="normal" font="Arial"> Sao Clemente,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pos-Graduacao de Higiene Veterinaria e Processamento Tecnologico de Produtos de Origem Animal,Faculdade de Medicina Veterinaria,Universidade Federal Fluminense,Niteroi,RJ,Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Epicutaneous sensitization with nematode antigens of fish parasites results in the production of specific IgG and IgE</style></title><secondary-title><style face="normal" font="Arial">J Helminthol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Helminthol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> aluminium hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="Arial">Fish consumption plays an important role in the human diet. Hoplias malabaricus, trahira, is a freshwater fish widely appreciated in several Brazilian states and it is frequently infected by Contracaecum multipapillatum third-instar larvae (L3). The aim of the present study was to evaluate the allergenic potential of the C. multipapillatum L3 crude extract (CECM). BALB/c mice were immunized intraperitoneally (ip) with 10 or 50 mug CECM associated with 2 mg of aluminium hydroxide on days 0, 14 and 48. The determination of specific IgG and IgE antibody levels was done after immunization, and the late immunity was evaluated by the intradermal reaction in the ear pavilion. Epicutaneous sensitization was performed in the dorsal region, with antigenic exposure via a Finn-type chamber, containing 100 mug of chicken ovum albumin (OVA) or 100 mug CECM. After the exposures, the specific antibody levels were determined. In the ip immunization, there was a gradual increase in IgG antibody levels, independent of CECM concentration. In relation to IgE production, it was transitory, and immunization with 10 mug was more efficient than that of 50 mug. The same result was observed in the cellular hypersensitivity reaction. In the case of antigen exposure by the epicutaneous route, it was verified that only CECM was able to induce detectable levels of specific IgG and IgE antibodies. In the present study it was demonstrated that both intraperitoneal immunization and epicutaneous contact with C. multipapillatum larval antigens are potentially capable of inducing allergic sensitization in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1475-2697 (Electronic)IS - 0022-149X (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1017/S0022149X17000633</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780914">PM:28780914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Helminthol\20170807-FontenelleG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Helminthol\20170807-FontenelleG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Fontenelle G</style></custom2><misc3><style face="normal" font="Arial">10.1017/S0022149X17000633</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Keselman,A.</style></author><author><style face="normal" font="Arial"> Fang,X.</style></author><author><style face="normal" font="Arial"> White,P.B.</style></author><author><style face="normal" font="Arial"> Heller,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205</style></auth-address><titles><title><style face="normal" font="Arial">Estrogen Signaling Contributes to Sex Differences in Macrophage Polarization during Asthma</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="1583" start="1573">1573-1583</pages><volume><style face="normal" font="Arial">199</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> estrogen</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophage polarization</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sex hormones</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Allergic asthma is a chronic Th2 inflammation in the lungs that constricts the airways and presents as coughing and wheezing. Asthma mostly affects boys in childhood and women in adulthood, suggesting that shifts in sex hormones alter the course of the disease. Alveolar macrophages have emerged as major mediators of allergic lung inflammation in animal models as well as humans. Whether sex differences exist in macrophage polarization and the molecular mechanism(s) that drive differential responses are not well understood. We found that IL-4-stimulated bone marrow-derived and alveolar macrophages from female mice exhibited greater expression of M2 genes in vitro and after allergen challenge in vivo. Alveolar macrophages from female mice exhibited greater expression of the IL-4Ralpha and estrogen receptor (ER) alpha compared with macrophages from male mice following allergen challenge. An ERalpha-specific agonist enhanced IL-4-induced M2 gene expression in macrophages from both sexes, but more so in macrophages from female mice. Furthermore, IL-4-stimulated macrophages from female mice exhibited more transcriptionally active histone modifications at M2 gene promoters than did macrophages from male mice. We found that supplementation of estrogen into ovariectomized female mice enhanced M2 polarization in vivo upon challenge with allergen and that macrophage-specific deletion of ERalpha impaired this M2 polarization. The effects of estrogen are long-lasting; bone marrow-derived macrophages from ovariectomized mice implanted with estrogen exhibited enhanced IL-4-induced M2 gene expression compared with macrophages from placebo-implanted littermates. Taken together, our findings suggest that estrogen enhances IL-4-induced M2 gene expression and thereby contributes to sex differences observed in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601975</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28760880">PM:28760880</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2017-199-1573-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2017-199-1573-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Keselman A</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601975</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85617</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lew,D.B.</style></author><author><style face="normal" font="Arial"> Michael,C.F.</style></author><author><style face="normal" font="Arial"> Overbeck,T.</style></author><author><style face="normal" font="Arial"> Robinson,W.S.</style></author><author><style face="normal" font="Arial"> Rohman,E.L.</style></author><author><style face="normal" font="Arial"> Lehman,J.M.</style></author><author><style face="normal" font="Arial"> Patel,J.K.</style></author><author><style face="normal" font="Arial"> Eiseman,B.</style></author><author><style face="normal" font="Arial"> LeMessurier,K.S.</style></author><author><style face="normal" font="Arial"> Samarasinghe,A.E.</style></author><author><style face="normal" font="Arial"> Gaber,M.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Tennessee Health Science Center (UTHSC) and Children's Foundation Research Institute, Le Bonheur Children's Hospital, Memphis, TN, USA</style></auth-address><titles><title><style face="normal" font="Arial">Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models</style></title><secondary-title><style face="normal" font="Arial">J Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Res</style></full-title></periodical><pages end="" start="3432701">3432701-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergen uptake</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fel d 1</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mannose</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Saccharomyces</style></keyword><keyword><style face="normal" font="Arial"> Saccharomyces cerevisiae</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">One of the unmet needs for asthma management is a new therapeutic agent with both anti-inflammatory and anti-smooth muscle (ASM) remodeling effects. The mannose receptor (MR) family plays an important role in allergen uptake and processing of major allergens Der p 1 and Fel d 1. We have previously reported that ASM cells express a mannose receptor (ASM-MR) and that mannan derived from Saccharomyces cerevisiae (SC-MN) inhibits mannosyl-rich lysosomal hydrolase-induced bovine ASM cell proliferation. Using a humanized transgenic mouse strain (huASM-MRC2) expressing the human MRC2 receptor in a SM tissue-specific manner, we have demonstrated that ASM hyperplasia/hypertrophy can occur as early as 15 days after allergen challenge in this mouse model and this phenomenon is preventable with SC-MN treatment. This proof-of-concept study would facilitate future development of a potential asthma therapeutic agent with dual function of anti-inflammatory and anti-smooth muscle remodeling effects</style></abstract><notes><style face="normal" font="Arial">DA - 20170824IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/3432701</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28835901">PM:28835901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Res\2017-2017-3432701.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Res\2017-2017-3432701.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Lew DB</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/3432701</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ren,M.</style></author><author><style face="normal" font="Arial"> Tang,Q.</style></author><author><style face="normal" font="Arial"> Chen,F.</style></author><author><style face="normal" font="Arial"> Xing,X.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Tan,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China</style></auth-address><titles><title><style face="normal" font="Arial">Mahuang Fuzi Xixin Decoction Attenuates Th1 and Th2 Responses in the Treatment of Ovalbumin-Induced Allergic Inflammation in a Rat Model of Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Immunol Res</style></full-title></periodical><pages end="" start="8254324">8254324-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> STAT-6</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) is one of the most common allergic diseases, which adversely affect patients' quality of life. Mahuang Fuzi Xixin decoction (MFXD) has been widely used to treat AR in clinics in Asian countries. This study investigated the effect and possible therapeutic mechanisms of MFXD in the treatment of AR. A Wistar rat model of ovalbumin- (OVA-) induced AR was established and then treated with three doses of MFXD; AR symptoms, serum total immunoglobulin E, histamine, histopathological features, and release and expression of factors related to type 1 helper T (Th1) and type 2 helper T (Th2) responses were analyzed. Our study demonstrated that MFXD has a good therapeutic effect on OVA-induced allergic inflammation in an AR rat model as manifested in reduced frequencies of sneezing and nasal scratching and in reduced serum levels of total IgE and HIS. In addition, MFXD regulates imbalance in Th1/Th2 cells caused by AR by simultaneously attenuating Th1 and Th2 responses, such as by reducing the serum levels of IFN-gamma and IL-4 and mRNA expression levels of IFN-gamma, IL-4, GATA-3, and STAT-6. This study provided valuable information on the immunoregulatory effect of MFXD for the treatment of AR in future clinical studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/8254324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28785597">PM:28785597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol Res\2017-2017-8254324.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol Res\2017-2017-8254324.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Ren M</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/8254324</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Meylan,P.</style></author><author><style face="normal" font="Arial"> Lang,C.</style></author><author><style face="normal" font="Arial"> Mermoud,S.</style></author><author><style face="normal" font="Arial"> Johannsen,A.</style></author><author><style face="normal" font="Arial"> Norrenberg,S.</style></author><author><style face="normal" font="Arial"> Hohl,D.</style></author><author><style face="normal" font="Arial"> Vial,Y.</style></author><author><style face="normal" font="Arial"> Prod'hom,G.</style></author><author><style face="normal" font="Arial"> Greub,G.</style></author><author><style face="normal" font="Arial"> Kypriotou,M.</style></author><author><style face="normal" font="Arial"> Christen-Zaech,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology &amp; Venereology</style></auth-address><titles><title><style face="normal" font="Arial">Skin Colonization by Staphylococcus Aureus Precedes the Clinical Diagnosis of Atopic Dermatitis in Infancy</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="2504" start="2497">2497-2504</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective birth cohort study</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) has a well-established association with skin colonization or infection by Staphylococcus aureus, which can exacerbate the disease. However, a causal relationship between specific changes in skin colonization during the first years of life and AD development still remains unclear. In this prospective birth cohort study, we aimed to characterize the association between skin colonization and AD development in 149 Caucasian infants with or without a family history of atopy. We assessed infants clinically and collected axillary and antecubital fossa skin swabs for culture-based analysis, at birth and at seven time points over the first two years of life. We found that at age three months, S. aureus was more prevalent on the skin of infants who developed AD later on. S. aureus prevalence was increased on infants' skin at the time of AD onset and also two months before it, when compared to age-matched unaffected infants. Furthermore, at AD onset, infants testing positive for S. aureus were younger than uncolonized subjects. In conclusion, our results suggest that specific changes in early-life skin colonization may actively contribute to clinical AD onset in infancy</style></abstract><notes><style face="normal" font="Arial">DA - 20170826IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.07.834</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28842320">PM:28842320</url></web-urls><pdf-urls><url ppv-ref="no">stephanie.christen@chuv.ch</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170826, Meylan P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.07.834</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Narukonda,S.</style></author><author><style face="normal" font="Arial"> Vinod,N.R.</style></author><author><style face="normal" font="Arial"> Joshi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Conemaugh Memorial Medical Center, Johnstown, PA, USA</style></auth-address><titles><title><style face="normal" font="Arial">A Case of Pulmonary Vein Thrombosis Associated With Treatment of Omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Investig Med High Impact Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Med High Impact Case Rep</style></full-title></periodical><pages end="" start="2324709617724176">2324709617724176-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atrial Fibrillation</style></keyword><keyword><style face="normal" font="Arial"> Catheter</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Myxoma</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Thrombosis</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Pulmonary vein thrombosis (PVT) is a challenging diagnosis and has been described in association with or as a complication of pulmonary tumors, lung surgeries, atrial myxoma, and after radiofrequency catheter ablation for atrial fibrillation. There are not many reported cases of PVT associated with medication use. We present a case of a 53-year-old male with a history of severe persistent asthma on omalizumab, who presented with shortness of breath and was found to have PVT on computed tomography scan of the chest. The hypercoagulable workup was normal, and the patient did not have a history of malignancy or pulmonary surgeries. Currently, available data suggest an association between omalizumab use and increased risk of arterial thrombotic events. However, on a literature search, we could not find any reported cases of PVT with omalizumab treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 2324-7096 (Print)IS - 2324-7096 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1177/2324709617724176</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815189">PM:28815189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Med High Impact Case Rep\2017-5-2324709617724176.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Med High Impact Case Rep\2017-5-2324709617724176.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Narukonda S</style></custom2><misc3><style face="normal" font="Arial">10.1177/2324709617724176</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,H.</style></author><author><style face="normal" font="Arial"> Sun,H.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious Diseases,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,P R China</style></auth-address><titles><title><style face="normal" font="Arial">MicroRNA let-7a up-regulates OPN expression in a mouse model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Laryngol Otol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Laryngol Otol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukins</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the effect of microRNA let-7a on OPN expression in a mouse model of allergic rhinitis. METHODS: Thirty-two mature female C57BL/6 mice were randomly divided into four groups, with eight mice in each group: microRNA let-7a, microRNA control, OVA and phosphate-buffered saline groups. The microRNA let-7a, microRNA control and OVA groups were sensitised with OVA to establish a mouse model of allergic rhinitis. Nose-scratching events were counted. Nasal mucosa was used to evaluate histological changes of goblet cell hyperplasia. Interleukins 5 and 13 were detected. Interferon-gamma levels in the nasal lavage fluid were assayed with enzyme-linked immunosorbent assay. OPN expression was estimated with polymerase chain reaction. RESULTS: Compared with microRNA control mice, microRNA let-7a treated mice had a significantly increased number of nose-scratching events, nasal mucosal eosinophilia and goblet cell hyperplasia (p 0.05). In addition, microRNA let-7a treated mice had significantly enhanced OPN expression in nasal mucosa (p &lt; 0.05). CONCLUSION: MicroRNA let-7a can promote allergic rhinitis development partly by regulating OPN expression</style></abstract><notes><style face="normal" font="Arial">DA - 20170815IS - 1748-5460 (Electronic)IS - 0022-2151 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1017/S002221511700175X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28807083">PM:28807083</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Laryngol Otol\20170815-YuH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Laryngol Otol\20170815-YuH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170815, Yu H</style></custom2><misc3><style face="normal" font="Arial">10.1017/S002221511700175X</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaneko,K.</style></author><author><style face="normal" font="Arial"> McDowell,A.</style></author><author><style face="normal" font="Arial"> Ishii,Y.</style></author><author><style face="normal" font="Arial"> Hook,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a School of Pharmacy, University of Otago , Dunedin 9054 , New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">Characterization and evaluation of stabilized particulate formulations as therapeutic oral vaccines for allergy</style></title><secondary-title><style face="normal" font="Arial">J Liposome Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Liposome Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> liposome</style></keyword><keyword><style face="normal" font="Arial"> Liposomes</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> PLGA</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="8" Year="2017">2017/8/21</year></dates><abstract><style face="normal" font="Arial">Allergic conditions affect more than a quarter of the population in developed countries, but currently available treatments focus more on symptom relief than treating the underlying atopic condition. alpha-galactosylceramide (alpha-GalCer) is a potent immunomodulating compound that has been shown to have a regulatory effect when delivered systemically in nanoparticles. Parenteral delivery is not preferred for chronic conditions such as allergy, therefore the aim of this study was to determine if a regulatory response could be induced through oral administration in a model of atopy through incorporation of alpha-GalCer into stable particulate formulations (cationic liposomes, polymerized liposomes and poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs)). The formulations showed only minor changes in particle size, polydispersity index and retention of the model antigen ovalbumin (OVA) during incubation in simulated gastrointestinal (GI) conditions. Oral delivery of alpha-GalCer in cationic liposomes could induce immunostimulating effects systemically, as seen through increases in serum IgG antibody levels, whereas delivery of alpha-GalCer in polymerized liposomes and PLGA NPs induced local cytokine changes in the mesenteric lymph nodes (MLNs). The generated responses did not exhibit tolerogenic traits which could be useful for immunoregulation, but the responses generated varied between formulations and suggests that further characterization and optimization could lead to the desired immune response</style></abstract><notes><style face="normal" font="Arial">DA - 20170822IS - 1532-2394 (Electronic)IS - 0898-2104 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/08982104.2017.1370472</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826286">PM:28826286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Liposome Res\20170822-KanekoK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Liposome Res\20170822-KanekoK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170822, Kaneko K</style></custom2><misc3><style face="normal" font="Arial">10.1080/08982104.2017.1370472</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hudson,T.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Director, Occupational and Employee Health, University of California Los Angeles, Health System and Campus, California</style></auth-address><titles><title><style face="normal" font="Arial">Lab Animal Bite Anaphylaxis: Underappreciated, Serious; Not Rare; Needs More Attention</style></title><secondary-title><style face="normal" font="Arial">J Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Occup Environ Med</style></full-title></periodical><pages end="" start="727">727-</pages><volume><style face="normal" font="Arial">59</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170810IS - 1536-5948 (Electronic)IS - 1076-2752 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/JOM.0000000000001103</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28796662">PM:28796662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Occup Environ Med\2017-59-727.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Occup Environ Med\2017-59-727.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170810, Hudson TW</style></custom2><misc3><style face="normal" font="Arial">10.1097/JOM.0000000000001103</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Spiric,J.</style></author><author><style face="normal" font="Arial"> Schulenborg,T.</style></author><author><style face="normal" font="Arial"> Schwaben,L.</style></author><author><style face="normal" font="Arial"> Engin,A.M.</style></author><author><style face="normal" font="Arial"> Karas,M.</style></author><author><style face="normal" font="Arial"> Reuter,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A model for quality control of allergen products with mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">J Proteome Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteome Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Isoallergens</style></keyword><keyword><style face="normal" font="Arial"> Label-free</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="Arial">Birch pollen allergy is diagnosed and treated with aqueous extracts from birch pollen, which contain a mixture of allergens and non-allergenic proteins, including large numbers of closely related sequence variants, so-called iso-allergens of the major allergen, Bet v 1. The quality of therapeutic and diagnostic allergen products largely depends on the allergen and iso-allergen composition. Several biochemical methods are currently applied to detect and quantify allergens and to record protein profiles without differentiating between iso-allergens. Mass spectrometry (MS) may entirely replace these technologies, as it allows sequence specific identification and quantification of proteins and protein profiles including sequence variants in one run. However, protein inference problem still hampers the automatic assignment of peptide sequences to proteins; consequently, impeding the quantification of sequence variants. Therefore, the aim of the study was to set up semi-targeted analyses of label-free MS data that allows unambiguous identification and quantification of birch pollen allergens and non-allergenic proteins. We combined data independent acquisition with manual assignment of predefined target sequences for quantification of iso-allergens and automatic quantification of other allergens and non-allergenic proteins. The quantitative data for birch pollen allergens and sequence variants of Bet v 1 were further confirmed by multiple reaction monitoring</style></abstract><notes><style face="normal" font="Arial">DA - 20170819IS - 1535-3907 (Electronic)IS - 1535-3893 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jproteome.7b00490</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28821210">PM:28821210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteome Res\20170819-SpiricJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteome Res\20170819-SpiricJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170819, Spiric J</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jproteome.7b00490</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Y.</style></author><author><style face="normal" font="Arial"> Mattison,C.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">USDA-ARS, Southern Regional Research Center, FPSQ, 1100 Robert E Lee Blvd, New Orleans, LA, 70124, USAUSDA-ARS, Southern Regional Research Center, FPSQ, 1100 Robert E Lee Blvd, New Orleans, LA, 70124, USA</style></auth-address><titles><title><style face="normal" font="Arial">Polyphenol-Rich Pomegranate Juice Reduces IgE Binding to Cashew Nut Allergens</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Cashew allergen</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Grape</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Juice</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Particle Size</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenols</style></keyword><keyword><style face="normal" font="Arial"> Pomegranate</style></keyword><keyword><style face="normal" font="Arial"> Pomegranate juice</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="26" Month="8" Year="2017">2017/8/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy negatively impacts quality of life and can be life-threatening. Cashew nuts can cause severe reactions in very small amounts, and they are included in a group of foods most commonly responsible for causing food allergy. Polyphenols and polyphenol rich juices have been demonstrated to complex with peanut allergens. Here, the interaction between cashew nut allergens and polyphenol rich juices is evaluated biochemically and immunologically. RESULTS: Various juices, including pomegranate (POM), blueberry (BB), and concord grape (CG) juices, were evaluated for polyphenol content and formation of polyphenol-cashew allergen complexes. Among the various juices studied, POM juice showed a greater capacity to form complexes with cashew proteins. Dynamic light scattering (DLS) demonstrated a sharp increase in cashew protein extract particle size to around 3580 nm, and fewer cashew proteins were resolved by electrophoresis after treatment with POM juice. Immunoassays demonstrated reduced IgG and IgE binding to cashew allergens due to allergen precipitation by POM juice. These observations support the formation of complexes between polyphenol and cashew proteins that can prevent antibody recognition of cashew allergens through allergen precipitation. CONCLUSION: POM juice treatment of cashew extract effectively reduces antibody binding through allergen precipitation, and these findings could be applied to the development of less allergenic cashew nut products and oral immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170826IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8639</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28842925">PM:28842925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170826-LiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170826-LiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Li Y</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8639</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">de la Cruz,S.</style></author><author><style face="normal" font="Arial"> Madrid,R.</style></author><author><style face="normal" font="Arial"> Garcia,A.</style></author><author><style face="normal" font="Arial"> Alcocer,M.</style></author><author><style face="normal" font="Arial"> Martin,R.</style></author><author><style face="normal" font="Arial"> Gonzalez,I.</style></author><author><style face="normal" font="Arial"> Garcia,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Nutricion, Bromatologia y Tecnologia de los Alimentos, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Identification and characterization of the proteins bound by specific phage-displayed recombinant antibodies (scFv) obtained against Brazil nut and almond extracts</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">11S</style></keyword><keyword><style face="normal" font="Arial"> 11S globulin</style></keyword><keyword><style face="normal" font="Arial"> 11S globulins</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> Alimentos</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Almond</style></keyword><keyword><style face="normal" font="Arial"> Almond allergen</style></keyword><keyword><style face="normal" font="Arial"> Almond protein</style></keyword><keyword><style face="normal" font="Arial"> Almonds</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ber e 2</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> brazil nut</style></keyword><keyword><style face="normal" font="Arial"> Brazil Nuts</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> conformational epitopes</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food labelling</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> globulins</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phage Display</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Pru du 6</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant antibody</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scFv</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Almonds and Brazil nuts are widely consumed allergenic nuts whose presence must be declared according to food labelling regulations. Their detection in food products has been recently achieved by ELISA methods with recombinant antibodies (scFv) isolated against complete Brazil nut and almond protein extracts. The screening of phage-scFv libraries against complete protein extracts confers a series of advantages over the use of purified proteins, as recombinant proteins might alter their native folding. However, using this strategy, the nature of the target detected by phage-displayed antibodies remains unknown, and requires further research to identify whether they are nut allergens or other molecules present in the extract, but not related to their allergenic potential. RESULTS: Electrophoretic, chromatographic, immunological and spectrometric techniques revealed that the Brazil nut (BE95) and almond (PD1F6 and PD2C9) specific phage-scFvs detected conformational epitopes of the Brazil nut and almond 11S globulins, recognized by WHO/IUIS as Ber e 2 and Pru du 6 major allergens. Circular dichroism data indicated that severe heat treatment would entail loss of epitope structure, disabling scFv for target detection. CONCLUSIONS: The presence of important Brazil nut and almond allergens (Ber e 2 and Pru du 6) in foodstuffs can be determined by using phage-display antibodies BE95, PD1F6 and PD2C9 as affinity probes in ELISA</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8640</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846130">PM:28846130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20170828-delaCruzS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20170828-delaCruzS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, de la Cruz S</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8640</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Takano,H.</style></author><author><style face="normal" font="Arial"> Inoue,K.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Environmental Health Division, Department of Environmental Engineering, Graduate School of Engineering, Kyoto University, Kyoto Daigaku Katsura, Nishikyo-ku, Kyoto-shi, Kyoto 615-8540, JapanSchool of Nursing, University of Shizuoka, 52-1 Yada, Suruga, Shizuoka 422-8526, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Environmental pollution and allergies</style></title><secondary-title><style face="normal" font="Arial">J Toxicol Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Toxicol Pathol</style></full-title></periodical><pages end="199" start="193">193-199</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Asian sand dust</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diesel</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust</style></keyword><keyword><style face="normal" font="Arial"> diesel exhaust particle</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust particles</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Environmental Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Environmental Pollution</style></keyword><keyword><style face="normal" font="Arial"> Esters</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sanitation</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Environmental changes are thought to be the main factor in the rapid increase and worsening of allergic diseases. While there have been significant changes in many environmental factors, including in environments such as residential, health and sanitation, food, and water/soil/atmospheric environments, the root of each of these changes is likely an increase in chemical substances. In fact, various environmental pollutants, such as air pollutants and chemical substances, have been shown to worsen various allergies in experimental studies. For example, diesel exhaust particles (DEPs), which are an agglomeration of particles and a wide array of chemical substances, aggravate asthma, primarily due to the principle organic chemical components of DEPs. In addition, environmental chemicals such as phthalate esters, which are commonly used as plasticizers in plastic products, also aggravate atopic dermatitis. It has also become evident that extremely small nanomaterials and Asian sand dust particles can enhance allergic inflammation. While the underlying mechanisms that cause such aggravation are becoming clearer at the cellular and molecular levels, methods to easily and quickly evaluate (screen) the ever-increasing amount of environmental pollutants for exacerbating effects on allergies are also under development. To eliminate and control allergic diseases, medical measures are necessary, but it is also essential to tackle this issue by ameliorating environmental changes</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 0914-9198 (Print)IS - 0914-9198 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1293/tox.2017-0028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28798526">PM:28798526</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Toxicol Pathol\2017-30-193-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Toxicol Pathol\2017-30-193-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Takano H</style></custom2><misc3><style face="normal" font="Arial">10.1293/tox.2017-0028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hsiao,K.C.</style></author><author><style face="normal" font="Arial"> Ponsonby,A.L.</style></author><author><style face="normal" font="Arial"> Axelrad,C.</style></author><author><style face="normal" font="Arial"> Pitkin,S.</style></author><author><style face="normal" font="Arial"> Tang,M.L.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial</style></title><secondary-title><style face="normal" font="Arial">Lancet Child Adolesc Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Child Adolesc Health</style></full-title></periodical><pages end="105" start="97">97-105</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desensitisation</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> long-term outcome</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut intake</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgG4</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2352-4642</style></isbn><abstract><style face="normal" font="Arial">BackgroundOral immunotherapy has attracted much interest as a potential treatment for food allergy, yet little is known about its long-term effects. We aimed to assess long-term outcomes in participants who completed a randomised, double-blind, placebo-controlled trial of combined probiotic and peanut oral immunotherapy (PPOIT), which was previously shown to induce desensitisation and 2-week sustained unresponsiveness.MethodsAll participants who completed the PPOIT randomised trial were eligible to participate in this follow-up study 4 years after treatment cessation. Peanut intake and adverse reactions to peanut in the 4 years after treatment cessation were systematically documented with a structured questionnaire administered by allergy nurses. Additionally, participants were invited to undergo peanut skin prick tests, measurement of peanut sIgE and sIgG4 concentrations, and double-blind placebo-controlled peanut challenge to assess 8-week sustained unresponsiveness.Findings48 (86%) of 56 eligible participants were enrolled in the follow-up study. Mean time since stopping treatment was 4·2 years in both PPOIT (SD 0·6) and placebo (SD 0·7) participants. Participants from the PPOIT group were significantly more likely than those from the placebo group to have continued eating peanut (16 [67%] of 24 vs one [4%] of 24; absolute difference 63% [95% CI 42-83], p=0·001; number needed to treat 1·6 [95% CI 1·2-2·4]). Four PPOIT-treated participants and six placebo participants reported allergic reactions to peanut after intentional or accidental intake since stopping treatment, but none had anaphylaxis. PPOIT-treated participants had smaller wheals in peanut skin prick test (mean 8·1 mm [SD 7·7] vs 13·3 mm [7·6]; absolute difference -5·2 mm [95% CI -10·3 to 0·0]; age-adjusted and sex-adjusted p=0·035) and significantly higher peanut sIgG4:sIgE ratios than placebo participants (geometric mean 67·3 [95% CI 10·3-440·0] vs 5·2 [1·2-21·8]; p=0·031). Seven (58%) of 12 participants from the PPOIT group attained 8-week sustained unresponsiveness, compared with one (7%) of 15 participants from the placebo group (absolute difference 52% [95% CI 21-82), p=0·012; number needed to treat 1·9 [95% CI 1·2-4·8]).InterpretationPPOIT provides long-lasting clinical benefit and persistent suppression of the allergic immune response to peanut.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2352-4642(17)30041-X</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/S2352-4642(17)30041-X</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet Child Adolesc Health\2017-1-97-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet Child Adolesc Health\2017-1-97-105.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Hsiao KC</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2352-4642(17)30041-X</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Greenhawt,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Probiotic and peanut oral immunotherapy: a breakthrough for allergy treatment</style></title><secondary-title><style face="normal" font="Arial">Lancet Child Adolesc Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Child Adolesc Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2352-4642</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2352-4642(17)30042-1</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/S2352-4642(17)30042-1</url></web-urls><pdf-urls><url ppv-ref="no">matthew.greenhawt@childrenscolorado.org</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Greenhawt MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2352-4642(17)30042-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jung,C.G.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Ban,G.Y.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author><author><style face="normal" font="Arial"> Shin,Y.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence and Clinical Characteristics of Local Allergic Rhinitis to House Dust Mites</style></title><secondary-title><style face="normal" font="Arial">Yonsei Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yonsei Med J</style></full-title></periodical><pages end="1050" start="1047">1047-1050</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal provocation test</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Non-allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> nonallergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Local allergic rhinitis (LAR) is a localized nasal allergic response in the absence of systemic atopy. The aim of this study was to evaluate the prevalence and clinical characteristics of LAR in Korean rhinitis patients compared to allergic rhinitis (AR) and non-allergic rhinitis (NAR). A total of 304 rhinitis patients were enrolled from November 2014 to March 2016. A skin prick test, serum total and specific immunoglobulin E, and a nasal provocation test (NPT) with house dust mite (HDM) were performed on all patients. Subjects also documented changes in rhinitis symptoms before and after NPT. Seventy-four patients with nasal hyper-reactivity and 80 patients with subclinical allergy were excluded. AR was diagnosed in 69 (46.0%) patients, NAR in 75 (50.0%) patients, and LAR to HDM in 6 (4.0%) patients. The average medication score and disease duration of each group were 14.5 points and 77.6 months in AR, 12.1 point and 51.1 months in NAR, and 17.7 point and 106.0 months in LAR, respectively. There were no significant differences in the baseline nasal symptom score of the three groups. However, after NPT with HDM, the score of rhinitis, itching, and obstructive were 4.83+/-1.47 vs. 1.95+/-2.53, 3.00+/-2.10 vs. 1.45+/-2.06, and 5.50+/-1.38 vs. 2.57+/-2.84 in LAR and NAR, respectively (p&lt;0.05). LAR patients had longer duration of disease and tended to be older and have higher medication score than other rhinitis patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170809IS - 1976-2437 (Electronic)IS - 0513-5796 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3349/ymj.2017.58.5.1047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28792152">PM:28792152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yonsei Med J\2017-58-1047-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yonsei Med J\2017-58-1047-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Jung CG</style></custom2><misc3><style face="normal" font="Arial">10.3349/ymj.2017.58.5.1047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85631</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zamfir,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mass Spectrometry Laboratory, National Institute for Research and Development in Electrochemistry and Condensed Matter, Plautius Andronescu Str.1, 300224, Timisoara, Romania. alina.zamfir@uav.ro</style></auth-address><titles><title><style face="normal" font="Arial">Microfluidics-Mass Spectrometry of Protein-Carbohydrate Interactions: Applications to the Development of Therapeutics and Biomarker Discovery</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="128" start="109">109-128</pages><volume><style face="normal" font="Arial">1647</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> binding affinity</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The functional interactions of carbohydrates and their protein receptors are the basis of biological events critical to the evolution of pathological states. Hence, for the past years, such interactions have become the focus of research for the development of therapeutics and discovery of novel glycan biomarkers based on their binding affinity. Due to the high sensitivity, throughput, reproducibility, and capability to ionize minor species in heterogeneous mixtures, microfluidics-mass spectrometry (MS) has recently emerged as a method of choice in protein-glycan interactomics. In this chapter, a straightforward microfluidics-based MS methodology for the assessment of protein-glycan interactions is presented. The general protocol encompasses: (1) submission of the interacting partners to a binding assay under conditions mimicking the in vivo environment; and (2) screening of the reaction products and their structural characterization by fully automated chip-nanoelectrospray (nanoESI) MS and multistage MS. The first section of the chapter is devoted to describing a method that enables the study of protein-oligosaccharide interactions by chip-nanoESI quadrupole time-of-flight (QTOF) MS and top-down complex analysis by collision-induced dissociation (CID). This section provides the protocol for the determination of the complex formed by standard beta-lactoglobulin (BLG) with maltohexaose (Glc6) and recommends as a concrete application the study of the interaction between BLG extracted from human milk with Glc6, considered a ligand able to reduce the allergenicity of this protein. The second part is dedicated to presenting the protocols for the binding assay followed by chip-nanoESI ion trap (ITMS) and electron transfer dissociation (ETD) in combination with CID for protein-ganglioside interactions, using as an example the B subunit of cholera toxin (Ctb5) in interaction with comercially available GM1 species. The methodology described may be successfully applied to native ganglioside mixtures from human brain, in particular for discovery of biomarkers on the basis of their binding affinity</style></abstract><notes><style face="normal" font="Arial">DA - 20170815IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Romania -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-7201-2_7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28808998">PM:28808998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1647-109-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1647-109-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170815, Zamfir AD</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-7201-2_7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85632</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yu,S.</style></author><author><style face="normal" font="Arial"> Han,B.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Zhuang,W.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Zhang,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Tongji Hospital, Tongji University, Shanghai 200065, China.</style></auth-address><titles><title><style face="normal" font="Arial">Derp1-modified dendritic cells attenuate allergic inflammation by regulating the development of T helper type1(Th1)/Th2 cells and regulatory T cells in a murine model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="181" start="172">172-181</pages><volume><style face="normal" font="Arial">90</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD11b</style></keyword><keyword><style face="normal" font="Arial"> CD4+CD25+FoxP3+</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">The CD4+CD25+Foxp3+ regulatory T cells (Tregs) are known to regulate Th2-induced allergic rhinitis (AR). In this study, we evaluated the efficacy of Derp1-modified dendritic cells (DCs) in AR immunotherapy. Derp1 was synthesized and transfected into DCs to generate Derp1-modified DCs. Phenotypes of Derp1-modified DCs were analyzed with flow cytometry using antibodies against DC markers CD11c, CD11b, CD59, CD103 and Toll-like receptor 1(TLR1). Four groups of subject mice were formed; the controls were treated with immature DCs, while the AR mice models were sensitized with Derp1(AR) and treated with DCs(DC-AR) or Derp1-modified DCs (Derp1DC-AR). The frequency of sneezing and scratching, eosinophil cell count, and Th1/Th2 ratio in the spleen were measured for all groups. The percentage of CD4+CD25+Foxp3+ Tregs in peripheral blood mononuclear cells was measured using flow cytometry; serum IgE, IgG1, and histamine were measured using enzyme-linked immunosorbent assay; expression levels of transcription factors T-bet, GATA3, Foxp3+ and IL-10 were analyzed using reverse transcription-polymerase chain reaction, and Western blot used in analyzed expression of Foxp3+ and IL-10 in nasal mucosa. Treatment with Derp1-modified DCs ameliorated the allergic response. The Derp1DC-AR group had significantly lower eosinophil cell count and the IgE, IgG1, and histamine levels than the AR and DC-AR groups, and higher mRNA levels of Th1 transcription factors T-bet, IL-10 and Foxp3 in nasal mucosa than DC-AR mice, but Th2 transcription factors GATA3 mRNA expression level has the opposite results. Furthermore, the Th1/Th2 ratio and percentage of CD4+CD25+Foxp3+ Tregs was significantly lower in the AR group (p&lt;0.05), but higher in the Derp1DC-AR group than in the control group (p&lt;0.01). Thus, the Derp1-modified DCs increased the percentage of CD4+CD25+Foxp3+Tregs and influenced the balance of Th1/Th2, showing an immunotherapeutic effect against AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2017.07.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28802126">PM:28802126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2017-90-172-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2017-90-172-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Yu S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2017.07.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,Y.</style></author><author><style face="normal" font="Arial"> Feng,G.Z.</style></author><author><style face="normal" font="Arial"> Du,Q.</style></author><author><style face="normal" font="Arial"> Jin,X.X.</style></author><author><style face="normal" font="Arial"> Du,X.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory, The Central Hospital of Maanshan, Maanshan, Anhui 243000, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Fine particulate matter aggravates allergic airway inflammation through thymic stromal lymphopoietin activation in mice</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="4207" start="4201">4201-4207</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Steroid-resistant asthma</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="Arial">Fine particulate matter (PM2.5) has been linked to exacerbation of allergic airway inflammation in mice. However, the mechanism underlying exposure to PM2.5 and subsequent and adverse effects remains to be fully elucidated. Therefore, the present study aimed to investigate the effects of PM2.5 by different levels on airway inflammation in mouse models of in allergic and steroidresistant asthma. BALB/c mice were nasally instilled with PBS (control) or 10, 31.6 or 100 microg PM2.5, and randomly assigned into nine groups. The acute asthma model was previously induced to investigate the change of inflammatory cells in bronchoalveolar lavage fluid (BALF). Histopathological changes of the lung were assessed, in addition to levels of interleukin (IL)4 and IL13 in BALF and immunoglobulin Ein serum. Thymic stromal lymphopoietin (TSLP) proteinexpression levels were assessed by western blotting. The present study demonstrated that medium and highdose PM2.5 is linked to acute exacerbation of allergic airway inflammation in mice. In conclusion, the pathological mechanisms of PM2.5 may be associated with allergic/steroidresistant airway inflammation, Tcell helper (Th)1/Th2 cytokine production and upregulation of TSLP expression in a murine model of allergic and steroid-resistant asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.7089</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765890">PM:28765890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-4201-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-4201-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Liu Y</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.7089</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dunn,N.</style></author><author><style face="normal" font="Arial"> Juto,A.</style></author><author><style face="normal" font="Arial"> Ryner,M.</style></author><author><style face="normal" font="Arial"> Manouchehrinia,A.</style></author><author><style face="normal" font="Arial"> Piccoli,L.</style></author><author><style face="normal" font="Arial"> Fink,K.</style></author><author><style face="normal" font="Arial"> Piehl,F.</style></author><author><style face="normal" font="Arial"> Fogdell-Hahn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden / Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies</style></title><secondary-title><style face="normal" font="Arial">Mult Scler</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mult Scler</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> anti-CD20</style></keyword><keyword><style face="normal" font="Arial"> Anti-drug antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cell depletion</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Rituximab is a chimeric monoclonal anti-CD20 B-cell-depleting antibody increasingly used off-label in multiple sclerosis (MS). The clinical relevance of anti-drug antibodies (ADAs) against rituximab in MS is unknown. OBJECTIVE: To determine frequency of ADA in relation to B-cell counts, allergic reactions and clinical efficacy in a large cohort of MS-treated patients. METHODS: Cross-sectional study with collection of serum samples from 339 MS patients immediately before a scheduled rituximab infusion. ADAs were detected using an in-house-validated electrochemiluminescent immunoassay and a commercial enzyme-linked immunosorbent assay (ELISA) to compare methods. Data on patient demographics and clinical outcomes were retrieved from the Swedish MS Registry and patient records. RESULTS: ADAs were detected in 37% of relapsing-remitting MS and 26% in progressive forms of MS. Presence of ADAs decreased with increasing number of rituximab infusions. There was a significant association between both presence and titres of ADAs and incomplete B-cell depletion, but not with infusion/adverse reactions or clinical outcomes at the group level. Only five patients terminated rituximab during follow-up, four of which were ADA positive. CONCLUSION: Rituximab treatment is associated with a high degree of ADAs, which correlates with efficacy of B-cell depletion; however, the clinical relevance of ADAs remains uncertain</style></abstract><notes><style face="normal" font="Arial">DA - 20170801IS - 1477-0970 (Electronic)IS - 1352-4585 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1177/1352458517720044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28762877">PM:28762877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mult Scler\20170801-DunnN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mult Scler\20170801-DunnN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170801, Dunn N</style></custom2><misc3><style face="normal" font="Arial">10.1177/1352458517720044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brandt,C.</style></author><author><style face="normal" font="Arial"> Roehmel,J.</style></author><author><style face="normal" font="Arial"> Rickerts,V.</style></author><author><style face="normal" font="Arial"> Melichar,V.</style></author><author><style face="normal" font="Arial"> Niemann,N.</style></author><author><style face="normal" font="Arial"> Schwarz,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pneumology and Immunology, Cystic Fibrosis Center, Charite-Universitatsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Aspergillus Bronchitis in Patients with Cystic Fibrosis</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> antibiotic treatment</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal treatment</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal culture</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> minority</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="Arial">Aspergillus fumigatus frequently colonizes the airways of patients with cystic fibrosis (CF) and may cause various severe infections, such as bronchitis. Serological data, sputum dependent markers and longitudinal data of treated cases of Aspergillus bronchitis were evaluated for further description of this infection. This study, which comprises three substudies, aimed to analyze epidemiological data of Aspergillus in CF and the entity of Aspergillus bronchitis. In a first step, data of the German Cystic Fibrosis Registry were used to evaluate the frequency of Aspergillus colonization in patients with CF (n = 2599). Then a retrospective analysis of 10 cases of Aspergillus bronchitis was performed to evaluate longitudinal data for lung function and clinical presentation parameters: sputum production, cough and physical capacity. Finally, a prospective cohort study (n = 22) was conducted to investigate serological markers for Aspergillus bronchitis: total serum IgE, specific serum IgE, specific serum IgG, as well as sputum galactomannan, real-time PCR detection of Aspergillus DNA in sputum and fungal cultures. Analysis of the German CF registry revealed an Aspergillus colonization rate of 32.5% among the 2599 patients. A retrospective data analysis of 10 treated cases revealed the clinical course of Aspergillus bronchitis, including repeated positive sputum culture findings for A. fumigatus, no antibiotic treatment response, total serum IgE levels &lt;200 kU/l, no observation of new pulmonary infiltrates and appropriate antifungal treatment response. Antifungal treatment durations of 4 +/- 1.6 (2-6) weeks significantly reduced cough (P = 0.0067), sputum production (P &lt; 0.0001) and lung function measures (P = 0.0358) but not physical capacity (P = 0.0794). From this retrospective study, a prevalence of 1.6% was calculated. In addition, two cases of Aspergillus bronchitis were identified in the prospective cohort study according to immunological, molecular and microbiological parameters. A prevalence of 9% was assessed. Aspergillus bronchitis appears to occur in a minority of colonized CF patients. Antifungal treatment may reduce respiratory symptoms and restore lung function</style></abstract><notes><style face="normal" font="Arial">DA - 20170818IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-017-0190-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28819878">PM:28819878</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20170818-BrandtC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20170818-BrandtC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170818, Brandt C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-017-0190-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85636</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beierwaltes,P.</style></author><author><style face="normal" font="Arial"> Schoessler,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Assistant Professor, Nursing, Minnesota State University, MankatoDirector of Education, Allergy &amp; Asthma Network</style></auth-address><titles><title><style face="normal" font="Arial">Latex Safe at School: A Student-Centered Approach</style></title><secondary-title><style face="normal" font="Arial">NASN Sch Nurse</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">NASN Sch Nurse</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sound</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">Providing a safe environment for students at risk for anaphylaxis from a latex allergy requires care coordination and collaboration of all members of the school community. Strategies for allergy management include educating the school community, identifying potential exposure to latex, preparing to respond in an emergency, and creating a plan for the future. With the student at the center of sound planning, the school can provide a secure and healthy environment</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 1942-6038 (Electronic)IS - 1942-602X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/1942602X17715495</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28777679">PM:28777679</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\NASN Sch Nurse\20170804-BeierwaltesP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\NASN Sch Nurse\20170804-BeierwaltesP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Beierwaltes P</style></custom2><misc3><style face="normal" font="Arial">10.1177/1942602X17715495</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qin,L.</style></author><author><style face="normal" font="Arial"> Lan,Y.</style></author><author><style face="normal" font="Arial"> Sun,J.</style></author><author><style face="normal" font="Arial"> Zhang,B.</style></author><author><style face="normal" font="Arial"> Xie,P.</style></author><author><style face="normal" font="Arial"> Zheng,J.</style></author><author><style face="normal" font="Arial"> Ma,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China</style></auth-address><titles><title><style face="normal" font="Arial">A Chinese herbal medicine (Modified Guomin Decoction) Influences the differentiation of CD4+ T-cell subsets in OVA-induced asthmatic mice</style></title><secondary-title><style face="normal" font="Arial">Neuro Endocrinol Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Neuro Endocrinol Lett</style></full-title></periodical><pages end="198" start="187">187-198</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow cytometric</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> herbal medicine</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="2" Month="7" Year="2017">2017/7/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Modified Guomin Decoction (MGD) is an effective Chinese herbal medicine for treatment of various allergic diseases, especially allergic asthma. Its water decoction is conventionally used for treatment of allergic bronchitis in China. Up to date, the underlying mechanisms of this herbal combination have not been fully investigated yet. METHODS: In the in vivo study, the mice were treated with Chicken egg ovalbumin (OVA) and aluminum hydroxide gel as the classic allergic asthma animal model. After treatment with MGD, the lung tissues were examined by Histological assessment. The flow cytometric analysis was used to classify the CD4+ T-cell subsets. RT-PCR, Real time fluorescence quota PCR and Western blotting were used to analyze the gene expression of IL-4, IL-5, IFN-gamma T-bet/GAIA-3 and Foxp3 in lung tissues. RESULTS: MGD significantly reduced ovalbumin-specific IgE production in mouse serum and suppressed inflammatory cell infiltration, thus, improved the asthma symptoms. The mechanistic studies indicated that MGD treatment mainly modified the differentiation of CD4+ T-cell subsets and improved their functions. These included that MGD enhanced the proportion of Th1-cell, reduced Th2-cell subsets to CD4+ cell and balanced Treg/Th17 cell populations in the asthmatic mice spleen tissues. For Th1-cells, MGD upregulated the gene expression of their cytokine IFN-gamma and its transcription factor T-bet while it downregulated the gene expression of their cytokines of IL-4 and IL-5. For Th2-cells, MGD mainly downregulated its transcription factor GATA-3 in lung tissues of asthmatic mice. MGD suppressed the Th17-cell subsets in CD4+ cells and upregulated the expression of Foxp3, a specific transcription factor of Treg-cell</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 0172-780X (Print)IS - 0172-780X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759187">PM:28759187</url></web-urls></urls><custom2><style face="normal" font="Arial">20170731, Qin L</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Messina,M.</style></author><author><style face="normal" font="Arial"> Rogero,M.M.</style></author><author><style face="normal" font="Arial"> Fisberg,M.</style></author><author><style face="normal" font="Arial"> Waitzberg,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nutrition Matters, Inc., Pittsfield, Massachusets, United States. Department of Nutrition, School of Public Health, University of Sao Paulo, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Health impact of childhood and adolescent soy consumption</style></title><secondary-title><style face="normal" font="Arial">Nutr Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutr Rev</style></full-title></periodical><pages end="515" start="500">500-515</pages><volume><style face="normal" font="Arial">75</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast cancer</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> estrogen</style></keyword><keyword><style face="normal" font="Arial"> Estrogens</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Isoflavones</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy allergy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soyfood</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">Soyfoods have been intensely researched, primarily because they provide such abundant amounts of isoflavones. Isoflavones are classified as both plant estrogens and selective estrogen receptor modulators. Evidence suggests that these soybean constituents are protective against a number of chronic diseases, but they are not without controversy. In fact, because soyfoods contain such large amounts of isoflavones, concerns have arisen that these foods may cause untoward effects in some individuals. There is particular interest in understanding the effects of isoflavones in young people. Relatively few studies involving children have been conducted, and many of those that have are small in size. While the data are limited, evidence suggests that soy does not exert adverse hormonal effects in children or affect pubertal development. On the other hand, there is intriguing evidence indicating that when soy is consumed during childhood and/or adolescence, risk of developing breast cancer is markedly reduced. Relatively few children are allergic to soy protein, and most of those who initially are outgrow their soy allergy by 10 years of age. The totality of the available evidence indicates that soyfoods can be healthful additions to the diets of children, but more research is required to allow definitive conclusions to be made</style></abstract><notes><style face="normal" font="Arial">DA - 20170825IS - 1753-4887 (Electronic)IS - 0029-6643 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1093/nutrit/nux016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28838083">PM:28838083</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutr Rev\2017-75-500-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutr Rev\2017-75-500-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170825, Messina M</style></custom2><misc3><style face="normal" font="Arial">10.1093/nutrit/nux016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Munblit,D.</style></author><author><style face="normal" font="Arial"> Peroni,D.G.</style></author><author><style face="normal" font="Arial"> Boix-Amoros,A.</style></author><author><style face="normal" font="Arial"> Hsu,P.S.</style></author><author><style face="normal" font="Arial"> Land,B.V.</style></author><author><style face="normal" font="Arial"> Gay,M.C.L.</style></author><author><style face="normal" font="Arial"> Kolotilina,A.</style></author><author><style face="normal" font="Arial"> Skevaki,C.</style></author><author><style face="normal" font="Arial"> Boyle,R.J.</style></author><author><style face="normal" font="Arial"> Collado,M.C.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Geddes,D.T.</style></author><author><style face="normal" font="Arial"> Nanan,R.</style></author><author><style face="normal" font="Arial"> Slupsky,C.</style></author><author><style face="normal" font="Arial"> Wegienka,G.</style></author><author><style face="normal" font="Arial"> Kozyrskyj,A.L.</style></author><author><style face="normal" font="Arial"> Warner,J.O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Imperial College London, London W2 1NY, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Human Milk and Allergic Diseases: An Unsolved Puzzle</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="E894">E894-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human milk</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk composition</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword></keywords><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="Arial">There is conflicting evidence on the protective role of breastfeeding in relation to the development of allergic sensitisation and allergic disease. Studies vary in methodology and definition of outcomes, which lead to considerable heterogeneity. Human milk composition varies both within and between individuals, which may partially explain conflicting data. It is known that human milk composition is very complex and contains variable levels of immune active molecules, oligosaccharides, metabolites, vitamins and other nutrients and microbial content. Existing evidence suggests that modulation of human breast milk composition has potential for preventing allergic diseases in early life. In this review, we discuss associations between breastfeeding/human milk composition and allergy development</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United KIngdom -CO - Russia -CO - Spain -CO - Australia -CO - United States -CO - Netherlands -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9080894</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28817095">PM:28817095</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-E894.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-E894.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Munblit D</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9080894</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Haroun-Diaz,E.</style></author><author><style face="normal" font="Arial"> Azofra,J.</style></author><author><style face="normal" font="Arial"> Gonzalez-Mancebo,E.</style></author><author><style face="normal" font="Arial"> De Las Heras,M.</style></author><author><style face="normal" font="Arial"> Pastor-Vargas,C.</style></author><author><style face="normal" font="Arial"> Esteban,V.</style></author><author><style face="normal" font="Arial"> Villalba,M.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Cuesta-Herranz,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Fundacion IIS-Fundacion Jimenez Diaz, 28040 Madrid, UAM, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Nut Allergy in Two Different Areas of Spain: Differences in Clinical and Molecular Pattern</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="E909">E909-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen pattern</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> LTP</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="8" Year="2017">2017/8/21</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Different clinical and molecular patterns of food allergy have been reported in different areas of the world. The aim of the study is to evaluate differences in allergen patterns among nut-allergic patients in two different areas of Spain. MATERIAL AND METHODS: A total of 77 patients with nut allergy from two different regions of Spain (Madrid and Asturias) were evaluated. RESULTS: Hazelnut, peanut, and walnut were the three most frequent nuts eliciting allergy in both regions, but in a different order. Patients from Madrid experienced systemic reactions more often than patients from Asturias (73.5% Madrid vs. 50.0%, p &lt; 0.05). The percentage of sensitizations to LTP (Lipid Transfer Protein) was higher than Bet v 1 (p &lt; 0.05) in the Madrid area. The percentage of sensitizations in Asturias area was similar to LTP than Bet v 1 (Pru p 3 46.4%, Bet v 1 42.9%, ns). Bet v 1 was the predominant allergen involved among hazelnut-allergic patients (56.2%), while LTP was more common in peanut-allergic patients (61.5%). CONCLUSION: Walnut, hazelnut, and peanut were the most frequent nuts eliciting allergy in Spain. Despite this, important differences in molecular pattern were appreciated not only between both regions, but also among nut-allergic patients in Asturias. The different molecular pattern was linked to the frequency of systemic symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170821IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9080909</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28825657">PM:28825657</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-E909.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-E909.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170821, Haroun-Diaz E</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9080909</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mazzocchi,A.</style></author><author><style face="normal" font="Arial"> Venter,C.</style></author><author><style face="normal" font="Arial"> Maslin,K.</style></author><author><style face="normal" font="Arial"> Agostoni,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Intermediate Care Unit, Fondazione IRCCS Ospedale Ca' Granda-Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy. alessandra.mazzocchi@unimi.itSection of Allergy and Immunology, Children's Hospital Colorado, University of Colorado, Aurora, CO 80045, USA.</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Nutritional Aspects in Food Allergy: Prevention and Management</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="E850">E850-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Avoidance diet</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="Arial">The prevalence of food allergy in childhood appears to be increasing in both developed and transitional countries. The aim of this paper is to review and summarise key findings in the prevention and management of food allergy, focusing on the role of dietary components and nutritional habits in the development and optimal functioning of the immune system. Essential fatty acids, zinc and vitamin D are likely to enhance the anti-inflammatory and antioxidative barrier and promote immunologic tolerance. Additionally, nutritional components such as pre- and probiotics represent a novel research approach in the attempt to induce a tolerogenic immune environment. For all these reasons, the traditional avoidance diet has been, in recent years, completely reconsidered. New findings on the protective effect of an increased diversity of food introduced in the first year of life on allergic diseases are consistent with the hypothesis that exposure to a variety of food antigens during early life might play a role in the development of immune tolerance. Accordingly, therapeutic (and even preventive) interventions should be planned on an individual basis</style></abstract><notes><style face="normal" font="Arial">DA - 20170809IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - United Kingdom -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9080850</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28792480">PM:28792480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-E850.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-E850.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Mazzocchi A</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9080850</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nguyen,A.N.</style></author><author><style face="normal" font="Arial"> Elbert,N.J.</style></author><author><style face="normal" font="Arial"> Pasmans,S.G.M.A.</style></author><author><style face="normal" font="Arial"> Kiefte-de Jong,J.C.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author><author><style face="normal" font="Arial"> Moll,H.A.</style></author><author><style face="normal" font="Arial"> Jaddoe,V.W.V.</style></author><author><style face="normal" font="Arial"> De Jongste,J.C.</style></author><author><style face="normal" font="Arial"> Franco,O.H.</style></author><author><style face="normal" font="Arial"> Duijts,L.</style></author><author><style face="normal" font="Arial"> Voortman,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Epidemiology, Erasmus MC, University Medical Center, 3000 CA Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Diet Quality throughout Early Life in Relation to Allergic Sensitization and Atopic Diseases in Childhood</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="E841">E841-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="8" Year="2017">2017/8/5</year></dates><abstract><style face="normal" font="Arial">Early-life nutrition is an important modifiable determinant in the development of a child's immune system, and may thereby influence the risk of allergic sensitization and atopic diseases. However, associations between overall dietary patterns and atopic diseases in childhood remain unclear. We examined associations of diet quality in early life with allergic sensitization, self-reported physician-diagnosed inhalant and food allergies, eczema, and asthma among 5225 children participating in a population-based cohort in the Netherlands. Diet was assessed during pregnancy, infancy, and childhood using validated food-frequency questionnaires. We calculated food-based diet quality scores (0-10 or 0-15), reflecting adherence to dietary guidelines. At age 10 years, allergic sensitization was assessed with skin prick tests. Information on physician-diagnosed inhalant and food allergies, eczema, and asthma was obtained with questionnaires. We observed no associations between diet quality during pregnancy and allergic sensitization (odds ratio (OR) = 1.05 per point in the diet score, 95% confidence interval (CI): 0.99, 1.13), allergies (0.96, 95% CI: 0.88, 1.04), eczema (0.99, 95% CI: 0.93, 1.06), or asthma (0.93, 95% CI: 0.85, 1.03) in childhood. Also, diet quality in infancy or childhood were not associated with atopic outcomes in childhood. Our findings do not support our hypothesis that a healthy dietary pattern in early life is associated with a lower risk of allergic sensitization or atopic diseases in childhood</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9080841</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28783056">PM:28783056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-E841.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-E841.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Nguyen AN</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9080841</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teodorowicz,M.</style></author><author><style face="normal" font="Arial"> van Neerven,J.</style></author><author><style face="normal" font="Arial"> Savelkoul,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Cell Biology and Immunology Group, Wageningen University &amp; Research, 6708 WD Wageningen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Food Processing: The Influence of the Maillard Reaction on Immunogenicity and Allergenicity of Food Proteins</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="E835">E835-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Maillard</style></keyword><keyword><style face="normal" font="Arial"> Maillard Reaction</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Smell</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> sugars</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">The majority of foods that are consumed in our developed society have been processed. Processing promotes a non-enzymatic reaction between proteins and sugars, the Maillard reaction (MR). Maillard reaction products (MRPs) contribute to the taste, smell and color of many food products, and thus influence consumers' choices. However, in recent years, MRPs have been linked to the increasing prevalence of diet- and inflammation-related non-communicable diseases including food allergy. Although during the last years a better understanding of immunogenicity of MRPs has been achieved, still only little is known about the structural/chemical characteristics predisposing MRPs to interact with antigen presenting cells (APCs). This report provides a comprehensive review of recent studies on the influence of the Maillard reaction on the immunogenicity and allergenicity of food proteins</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9080835</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28777346">PM:28777346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9-E835.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9-E835.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Teodorowicz M</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9080835</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elholm,G.</style></author><author><style face="normal" font="Arial"> Schlunssen,V.</style></author><author><style face="normal" font="Arial"> Doekes,G.</style></author><author><style face="normal" font="Arial"> Basinas,I.</style></author><author><style face="normal" font="Arial"> Bolund,A.C.S.</style></author><author><style face="normal" font="Arial"> Hjort,C.</style></author><author><style face="normal" font="Arial"> Gronager,P.M.</style></author><author><style face="normal" font="Arial"> Omland,O.</style></author><author><style face="normal" font="Arial"> Sigsgaard,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health, Section for Environment, Occupation and Health, Aarhus University, Danish Ramazzini Center, Aarhus, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">High exposure to endotoxin in farming is associated with less new-onset pollen sensitisation</style></title><secondary-title><style face="normal" font="Arial">Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> farm exposure</style></keyword><keyword><style face="normal" font="Arial"> Farmers</style></keyword><keyword><style face="normal" font="Arial"> farming</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Little is known about risk factors for new onset and loss of atopic sensitisation in adulthood. The aim is to examine the longitudinal effect of quantitatively assessed endotoxin exposures on changes in specific allergen sensitisation in young adults. METHODS: The cohort consisted of 1113 young Danish farmers and rural controls, with a mean age of 19 years at baseline. Sensitisation to birch pollen, grass pollen, cat dander and house dust mite was measured by specific IgE levels in serum samples from baseline and at 15 years' follow-up. Changes in sensitisation were analysed in relation to cumulative endotoxin exposure during follow-up, considering early life farm exposure. RESULTS: Endotoxin exposure during follow-up was significantly associated with less new onset of specifically grass and birch pollen sensitisation. For the highest versus lowest quartile of cumulative endotoxin exposure, the OR for new-onset IgE sensitisation was 0.35 (0.13-0.91) for birch and 0.14 (0.05-0.50) for grass. On the other hand, loss of pollen sensitisation showed a positive, although mostly non-significant, association with increased levels of endotoxin exposure. Endotoxin exposure was not associated with significant changes in cat dander and house dust mite sensitisation. CONCLUSIONS: High exposure to endotoxin during young adulthood appears to protect against new onset of pollen sensitisation, independent of childhood farm exposure</style></abstract><notes><style face="normal" font="Arial">DA - 20170824IS - 1470-7926 (Electronic)IS - 1351-0711 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/oemed-2017-104384</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28835393">PM:28835393</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Occup Environ Med\20170824-ElholmG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Occup Environ Med\20170824-ElholmG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Elholm G</style></custom2><misc3><style face="normal" font="Arial">10.1136/oemed-2017-104384</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Crosaz,O.</style></author><author><style face="normal" font="Arial"> Bonati,S.</style></author><author><style face="normal" font="Arial"> Briand,A.</style></author><author><style face="normal" font="Arial"> Chapelle,E.</style></author><author><style face="normal" font="Arial"> Cochet-Faivre,N.</style></author><author><style face="normal" font="Arial"> Ka,D.</style></author><author><style face="normal" font="Arial"> rmon-Hadjaje,C.</style></author><author><style face="normal" font="Arial"> Varloud,M.</style></author><author><style face="normal" font="Arial"> Guillot,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Mycology and Dermatology, CHUVA, Ecole nationale veterinaire d'Alfort, UPE, 7 avenue du General de Gaulle, 94704, Maisons-Alfort, France  jacques.guillot@vet-alfort.fr</style></auth-address><titles><title><style face="normal" font="Arial">Usefulness of a topical combination of dinotefuran and pyriproxyfen for long-term control of clinical signs of allergic dermatitis in privately-owned cats in Ile-de-France region</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="392">392-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Ecole</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Fleas</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The present study assessed the activity of a combination of dinotefuran and pyriproxyfen (Vectra(R) Felis) for long-term control (3 months) of allergic dermatitis (AD) in privately-owned cats under common household conditions in Ile-de-France region. METHODS: This was an open pre-treatment vs post-treatment study. Twenty-eight client-owned cats with clinical signs of AD were enrolled in the study. They received topical application of the combination of dinotefuran and pyriproxyfen on days 0, 28, 56 and 84. Two parameters (clinical signs and pruritus severity) were used to assess the animals' condition on days 0, 28 and 84. Fleas were counted if they were observed. RESULTS: Of the 28 cats initially enrolled, 26 were presented on day 28 and 20 for the final evaluation on day 84. A significant improvement in clinical signs and pruritus was observed in cats for which fleas and/or flea feces were detected on day 0. Globally, the post-treatment AD clinical scores on days 28 and 84 were different from that of the pre-treatment on day 0, with a reduction of 30% and 71%, respectively. For cats with fleas and/or flea feces, the reduction on days 28 and 84 was 33% and 85%, respectively. The improvement of clinical signs and pruritus was not significant in cats with no visible fleas and no flea feces at the beginning of the trial (n = 8). CONCLUSIONS: The present study indicated that the treatment with a combination of dinotefuran and pyriproxyfen should be considered as useful in controlling fleas on cats without additional environmental treatment and useful for long-term control of clinical signs and pruritus in allergic cats</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-017-2335-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28830567">PM:28830567</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2017-10-392.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2017-10-392.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Crosaz O</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-017-2335-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bhat,S.A.</style></author><author><style face="normal" font="Arial"> Mounsey,K.E.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Walton,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inflammation &amp; Healing Research Cluster, School of Health and Sport Sciences, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Locked Bag 4, Maroochydore DC, QLD, 4558, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Host immune responses to the itch mite, Sarcoptes scabiei, in humans</style></title><secondary-title><style face="normal" font="Arial">Parasit Vectors</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasit Vectors</style></full-title></periodical><pages end="" start="385">385-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Infections</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sarcoptes scabiei</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> sport</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">Scabies is a parasitic disease due to infestation of skin by the burrowing mite Sarcoptes scabiei. Scabies is a major public health problem and endemic in resource poor communities worldwide affecting over 100 million people. Associated bacterial infections cause substantial morbidity, and in severe cases can lead to renal and cardiac diseases. Mite infestation of the skin causes localised cutaneous inflammation, pruritus, skin lesions, and allergic and inflammatory responses are mounted by the host against the mite and its products. Our current understanding of the immune and inflammatory responses associated with the clinical manifestations in scabies is far outweighed by the significant global impact of the disease. This review aims to provide a better understanding of human immune responses to S. scabiei in ordinary and crusted scabies phenotypes</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1756-3305 (Electronic)IS - 1756-3305 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13071-017-2320-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797273">PM:28797273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasit Vectors\2017-10-385.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasit Vectors\2017-10-385.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Bhat SA</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13071-017-2320-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Finlay,C.M.</style></author><author><style face="normal" font="Arial"> Stefanska,A.M.</style></author><author><style face="normal" font="Arial"> Coleman,M.M.</style></author><author><style face="normal" font="Arial"> Jahns,H.</style></author><author><style face="normal" font="Arial"> Cassidy,J.P.</style></author><author><style face="normal" font="Arial"> McLoughlin,R.M.</style></author><author><style face="normal" font="Arial"> Mills,K.H.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Secreted products of Fasciola hepatica inhibit the induction of T cell responses that mediate allergy</style></title><secondary-title><style face="normal" font="Arial">Parasite Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasite Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Fasciola</style></keyword><keyword><style face="normal" font="Arial"> Fasciola hepatica</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="Arial">There is evidence from epidemiology studies of a negative association between infection with helminth parasites and the development of allergy and asthma. Here we demonstrate that the excretory/secretory products of the helminth Fasciola hepatica (FHES) protected mice against ovalbumin (OVA)-induced allergic asthma when administered at time of allergen sensitisation. FHES reduced the accumulation of mucus, eosinophils and lymphocytes into the airways of allergen-challenged mice. Furthermore, FHES treatment suppressed Th2 responses in the airways. Interestingly, systemic administration of FHES at allergen challenge had no effect on airway inflammation, demonstrating that alum-induced Th2 response are set following initial allergen sensitisation. Our findings highlight the immunomodulatory potential of molecules secreted by F. hepatica. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170817IS - 1365-3024 (Electronic)IS - 0141-9838 (Linking)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1111/pim.12460</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815724">PM:28815724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasite Immunol\20170817-FinlayCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasite Immunol\20170817-FinlayCM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170817, Finlay CM</style></custom2><misc3><style face="normal" font="Arial">10.1111/pim.12460</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cole,D.</style></author><author><style face="normal" font="Arial"> Weiss,D.</style></author><author><style face="normal" font="Arial"> Kohser,K.L.</style></author><author><style face="normal" font="Arial"> Jones,C.</style></author><author><style face="normal" font="Arial"> Kassam-Adams,N.</style></author><author><style face="normal" font="Arial"> Brown-Whitehorn,T.</style></author><author><style face="normal" font="Arial"> Lewis,M.O.</style></author><author><style face="normal" font="Arial"> Devine,P.M.</style></author><author><style face="normal" font="Arial"> Marsac,M.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Cellie Coping Kit for Children with Food Allergy: A Pilot Study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="44" start="39">39-44</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> Adherence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> learning outcomes</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year><pub-dates><date Day="26" Month="8" Year="2017">2017/8/26</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">The prevalence of pediatric food allergies has increased in children by 50% from 1997 to 2011, affecting 1 in 13 children in the United States. Food allergies can have short- and long-term emotional and physical consequences, which may result in challenges for both children and caregivers. Currently, to our knowledge, there are no low-cost, easily available, evidence-based psychosocial resources for children with food allergies and their families. The Cellie Coping Kit for Food Allergies was created to address this need. This study examined the acceptability and feasibility of the Cellie Coping Kit as an intervention and explored the learning outcomes associated with the kit. Twenty-five children (between ages 7 and 13 with 1 or more food allergies) and their caregivers were recruited from an outpatient clinic while participating in an oral food challenge. Children and caregivers were introduced to the Cellie Coping Kit following their food challenge. Four weeks later, follow-up assessments were completed to evaluate participants' impressions of the intervention. The results suggest that children and caregivers found the Cellie Coping Kit acceptable and feasible. Most (80%-100%) participants thought the intervention materials were trustworthy, found the kit easy to use, liked the appearance of the kit, and would recommend the intervention to others. Approximately 65% of children and 60% of caregivers reported learning from the Cellie Coping Kit. The Cellie Coping Kit for Children with Food Allergies was generally well received by children with food allergies and their families. The Cellie Coping Kit can be used to help facilitate dialog between children and caregivers about food allergy-related issues. While results are promising, additional research (especially in younger children and those newly diagnosed) is needed to determine if the intervention is achieving targeted goals (ie, coping behaviors and improved adherence to medical recommendations).</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2016.0698</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1089/ped.2016.0698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-39-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-39-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Cole D</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2016.0698</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Moreno,M.V.</style></author><author><style face="normal" font="Arial"> Caparros,E.</style></author><author><style face="normal" font="Arial"> Fernandez,J.</style></author><author><style face="normal" font="Arial"> Gonzalez-Delgado,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dpto. Medicina Clinica, Universidad Miguel Hernandez, San Juan, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Immunologic study of two fruit-induced FPIES cases</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dehydration</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">FPIES is a severe non-IgE-mediated food hypersensitivity that typically occurs within the first months of life characterized by profuse vomiting and diarrhea, with progression to dehydration and shock in some patients (1). Normally, it is caused by cow's milk and/or soy but in the last years many other foods have been implicated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12769</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28786506">PM:28786506</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170808-MorenoMV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170808-MorenoMV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Moreno MV</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12769</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Schryver,S.</style></author><author><style face="normal" font="Arial"> Clarke,A.</style></author><author><style face="normal" font="Arial"> La Vieille,S.</style></author><author><style face="normal" font="Arial"> Eisman,H.</style></author><author><style face="normal" font="Arial"> Morris,J.</style></author><author><style face="normal" font="Arial"> Lim,R.</style></author><author><style face="normal" font="Arial"> Gravel,J.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Center, Montreal, QC</style></auth-address><titles><title><style face="normal" font="Arial">Food-induced anaphylaxis to a known food allergen in children often occurs despite adult supervision</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency department visits</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food Labeling</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">Food-related allergic reactions are the leading cause of anaphylaxis and emergency department visits and hospital admissions for food-induced anaphylaxis in children are increasing. Strict avoidance of food allergens is the main strategy in prevention of food-induced anaphylaxis and there are continuous efforts to educate patients and caregivers and to ensure proper food-labeling. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12770</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28786498">PM:28786498</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170808-DeSchryverS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170808-DeSchryverS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, De Schryver S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12770</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yilmaz,I.</style></author><author><style face="normal" font="Arial"> Caglar,A.S.</style></author><author><style face="normal" font="Arial"> Kardas,F.</style></author><author><style face="normal" font="Arial"> Karaca,Z.</style></author><author><style face="normal" font="Arial"> Yenigun,S.</style></author><author><style face="normal" font="Arial"> Tutar,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Successful Desensitization in a Patient with Hypersensitivity Reaction to Laronidase</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="66" start="64">64-66</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Replacement Therapy</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Mucopolysaccharidosis</style></keyword><keyword><style face="normal" font="Arial"> Mucopolysaccharidosis I</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year><pub-dates><date Day="26" Month="8" Year="2017">2017/8/26</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">Mucopolysaccharidosis I (MPS I) is a rare, recessively inherited, lysosomal storage disorder caused by deficiency of the enzyme a-L-iduronidase. Scheie syndrome is the least severe form of MPS I. Patients can be diagnosed in the adolescent age group. Enzyme replacement therapy with laronidase is the best treatment option in Scheie syndrome and is generally well tolerated by patients. Anaphylaxis and other immediate hypersensitvity reactions to laronidase are very rare. Immediate hypersensitivity reaction to laronidase and successful desensitization with laronidase have only been described in 2 pediatric patients. We herein report the first case of a severe immediate hypersensitivity reaction to laronidase in an adult patient with MPS-I disease, who was successfully treated with a laronidase desensitization protocol.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2016.0706</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1089/ped.2016.0706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-64-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-64-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Yilmaz I</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2016.0706</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ferreira,H.</style></author><author><style face="normal" font="Arial"> Alves,M.</style></author><author><style face="normal" font="Arial"> Pineda,F.</style></author><author><style face="normal" font="Arial"> Ferreira,C.</style></author><author><style face="normal" font="Arial"> Silva,A.</style></author><author><style face="normal" font="Arial"> Costa,A.</style></author><author><style face="normal" font="Arial"> Matos,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cross-Reactivity Between Molds and Mushrooms</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="128" start="126">126-128</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> Mushrooms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Type I allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year><pub-dates><date Day="26" Month="8" Year="2017">2017/8/26</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">Fungi are considered one of the most common allergens responsible for type I allergies. This allergic response can be triggered by inhalation of mold spores, skin contact, or ingestion of mushrooms. There are some case reports in the literature advocating an association between sensitization to mold spores and systemic reactions caused by ingestion of mushrooms. However, this association is scarce and not completely explored. The authors report a case of a 12-year-old girl, with symptoms compatible with allergic rhinitis not previously studied, who developed an anaphylatic reaction after ingestion of mushrooms (Macrolepiota procera). The skin prick test revealed sensitivity to Cladosporium herbarum and the prick-to-prick test with the Parasol mushroom (M. procera) was positive, which highlighted the possibility of cross-reactivity between molds and mushrooms, hypothesis that was suggested by Western blot and inhibition test.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Portugal -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2017.0746</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1089/ped.2017.0746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-126-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-126-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Ferreira H</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2017.0746</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lin,C.</style></author><author><style face="normal" font="Arial"> Lee,I.T.</style></author><author><style face="normal" font="Arial"> Sampath,V.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author><author><style face="normal" font="Arial"> Dekruyff,R.H.</style></author><author><style face="normal" font="Arial"> Schneider,L.C.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Combining anti-IgE with oral immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">accidental exposure</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="Arial">Food allergy is a significant medical problem that affects up to 8% of children in developed countries. At present, there are no curative therapies available in routine practice and management of food allergy involves strict allergen avoidance, education, and prompt treatment upon accidental exposure. Oral immunotherapy (OIT) is an efficacious experimental approach to food allergy and has been shown to provide a substantial benefit in terms of allergen desensitization. However, OIT is associated with high rates of allergic reactions, and the period of protection offered by OIT appears to be limited and highly variable. Recurrence of allergen sensitivity after a period of treatment discontinuation is commonly observed. With the aim of of overcoming these limitations of OIT, several trials have studied omalizumab (anti-IgE monoclonal antibody) as an adjuvant treatment for patients undergoing OIT. Results from these trials have shown that the addition of omalizumab to OIT leads to a significant decrease in the frequency and severity of reactions, which allows for an increase in the threshold of tolerance to food allergens. This review provides a summary of the current literature and addresses some of the key questions that remain regarding the use of omalizumab in conjunction with OIT. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12767</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782296">PM:28782296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170807-LinC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170807-LinC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Lin C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12767</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fan,H.</style></author><author><style face="normal" font="Arial"> Huang,L.</style></author><author><style face="normal" font="Arial"> Jin,Y.</style></author><author><style face="normal" font="Arial"> Chen,C.</style></author><author><style face="normal" font="Arial"> Lu,G.</style></author><author><style face="normal" font="Arial"> Zhang,D.</style></author><author><style face="normal" font="Arial"> Jiang,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Study of Penicillium marneffei Infection in Pediatric Patients Without Human Immunodeficiency Virus Infection in China</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="59" start="53">53-59</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD8</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hepatomegaly</style></keyword><keyword><style face="normal" font="Arial"> Hiv</style></keyword><keyword><style face="normal" font="Arial"> HIV infection</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Multiple Organ Failure</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Phagocytosis</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Splenomegaly</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year><pub-dates><date Day="26" Month="8" Year="2017">2017/8/26</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">To date, Penicillium marneffei infection has mainly been reported in adults infected with human immunodeficiency virus (HIV); only a limited number of cases have been reported in children. The aim of the article is to study the clinical and laboratory characteristics of P. marneffei in pediatric patients without HIV infection. In this study, the medical records of 10 pediatric patients with P. marneffei infection at Guangzhou Women and Children's Medical Center were evaluated from May 2011 to November 2015. The duration of symptoms before admission ranged from 8 days to 1 month. Fever was found in all 10 patients. Hepatomegaly and splenomegaly were found in 9/10 and 8/10 patients, respectively. Two patients presented with skin lesions. The main life-threatening complications during hospitalization included hemophagocytic syndrome (8/10), acute respiratory distress syndrome (8/10), disseminated intravascular coagulation (DIC) (7/10), and septic shock (6/10). Two of the 10 patients had underlying immunodeficiencies characterized by an absence of IgG and decreased CD4 and CD8 cell counts, respectively. Phagocytosis in the bone marrow was observed in four patients. Eight patients had abnormal chest radiographs. Only two patients showed remission after treatment. The others died of multiple organ failure and DIC on days 1-17 of hospitalization. Our analysis suggests that P. marneffei infection is a severe disease causing high mortality even in infants and children without HIV. Pediatric clinicians should be vigilant in identifying this disease to ensure an early diagnosis and good prognosis. A systematic approach to immunological evaluations in pediatric patients with the disease is required. Further research is necessary to explore the pathogenesis of and appropriate therapy for this infection.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2016.0722</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1089/ped.2016.0722</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-53-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-53-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, fan H</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2016.0722</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Woicka-Kolejwa,K.</style></author><author><style face="normal" font="Arial"> Mazurek,H.</style></author><author><style face="normal" font="Arial"> Pawlowska-Iwanicka,K.</style></author><author><style face="normal" font="Arial"> Stelmach,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Hypersensitivity Pneumonitis in an 11-Year-Old Boy</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇöA Case Report</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="63" start="60">60-63</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Case Report</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity pneumonitis</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year><pub-dates><date Day="26" Month="8" Year="2017">2017/8/26</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2016.0695</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1089/ped.2016.0695</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-60-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-60-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Woicka-Kolejwa K</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2016.0695</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Maslin,K.</style></author><author><style face="normal" font="Arial"> Grundy,J.</style></author><author><style face="normal" font="Arial"> Glasbey,G.</style></author><author><style face="normal" font="Arial"> Dean,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Health Sciences and Social Work, University of Portsmouth, UK</style></auth-address><titles><title><style face="normal" font="Arial">Should lip dosing be reconsidered when performing open food challenges?</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Lip</style></keyword><keyword><style face="normal" font="Arial"> Mouth</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="Arial">A lip dose or labial food challenge (LFC) is a simple, easy to perform method of diagnosis that could potentially be a convenient alternative to conducting an oral food challenge in children (1). Rance and Dutau (1) published a paper on LFC in 1997 demonstrating their clinical utility, according to the technique described by Moneret-Vautrin et al. (2). This involved a drop of the allergen being placed on the lower lip and left for 10 seconds to two minutes, with the mouth slightly opened. However, in the study by Rance et al. (1), children with positive LFC did not continue to have an oral food challenge (OFC). A subsequent study by Cantani et al.(3) concluded that the LFC should not replace the OFC, but be used at the first step in a food challenge, particularly where there is a risk of anaphylaxis (4). LFCs are not currently included in international food challenge guidelines (5) (7). Here we present data from lip dose reactions in the Food Allergy and Intolerance (FAIR) study from the Isle of Wight in the United Kingdom (UK), with the aim of demonstrating the predictive value of LFCs for diagnosis of food allergy, compared to OFCs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12765</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782200">PM:28782200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170807-VenterC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170807-VenterC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12765</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ruggieri,S.</style></author><author><style face="normal" font="Arial"> Drago,G.</style></author><author><style face="normal" font="Arial"> Longo,V.</style></author><author><style face="normal" font="Arial"> Colombo,P.</style></author><author><style face="normal" font="Arial"> Balzan,M.</style></author><author><style face="normal" font="Arial"> Bilocca,D.</style></author><author><style face="normal" font="Arial"> Zammit,C.</style></author><author><style face="normal" font="Arial"> Montefort,S.</style></author><author><style face="normal" font="Arial"> Scaccianoce,G.</style></author><author><style face="normal" font="Arial"> Cuttitta,G.</style></author><author><style face="normal" font="Arial"> Viegi,G.</style></author><author><style face="normal" font="Arial"> Cibella,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Research Council of Italy, Institute of Biomedicine and Molecular Immunology, Palermo, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to dust mite defines different phenotypes of asthma: a multicenter study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aging</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air quality</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotypes</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE analyse</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor air quality</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Malta</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Indoor allergens are risk factors for asthma: thus, the characterization of indoor air quality is important for studying environment-health relationships in children. In particular, Dermatophagoides pteronyssinus is the dominant allergen for asthma. We cross-sectionally investigated the relationships among respiratory symptoms and function, airway inflammation, allergen sensitization and indoor allergen concentration. METHODS: One hundred thirty two children aging 10-14 years and living in a Southern Mediterranean area were evaluated by parental questionnaires. Spirometry, exhaled nitric oxide (FeNO), skin prick tests, total and specific serum IgE analyses were performed along with the evaluation of home dust samples for the content in Der p 1 allergen. Three clusters were created on the basis of the presence/absence of wheeze in the last 12 months (Wh12m) and Der p 1 specific IgE level. RESULTS: Cluster 1 (Wh12m+/high Der p 1 IgE) presented higher FeNO and poorer pulmonary function (lower FEV1 and FEF25-75% ), while its symptom score was not different from Cluster 2 (Wh12m+/low Der p 1 IgE). Cluster 3 (Wh12m-/low IgE) showed the lowest FeNO values and pulmonary function similar to Cluster 2. Within Cluster 1, both Der p 1 specific IgE and FeNO were positively correlated to dust Der p 1. CONCLUSIONS: Similar asthma phenotypes may occur in children despite differences in their atopic state. In atopic children, sensitizing allergens in the indoor environment may increase airway inflammation worsening pulmonary function. Moreover, environmental exposures may contribute to the development of asthma-like symptoms also in absence of atopic sensitization, thus contributing to asthma overdiagnosis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Malta -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12768</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28783215">PM:28783215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170807-RuggieriS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170807-RuggieriS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Ruggieri S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12768</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kamath,S.D.</style></author><author><style face="normal" font="Arial"> Johnston,E.B.</style></author><author><style face="normal" font="Arial"> Iyer,S.</style></author><author><style face="normal" font="Arial"> Schaeffer,P.M.</style></author><author><style face="normal" font="Arial"> Koplin,J.</style></author><author><style face="normal" font="Arial"> Allen,K.</style></author><author><style face="normal" font="Arial"> Lopata,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia</style></auth-address><titles><title><style face="normal" font="Arial">IgE reactivity to shrimp allergens in infants and their cross-reactivity to house dust mite</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> false negative</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> pan-allergen</style></keyword><keyword><style face="normal" font="Arial"> Pan-allergens</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shellfish allergy</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp allergen</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="Arial">The rise in shellfish allergy incidence, accompanying an increase in consumption and exposure to shellfish allergens, has become a serious problem worldwide. Precise diagnosis of shellfish allergy poses a challenge due to the diversity of consumed species, and immunological cross-reactivity to similar invertebrate pan-allergens. Moreover, variable concentrations of major and minor allergens in diagnostic preparations often result in false-negative results. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12764</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782222">PM:28782222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170807-KamathSD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170807-KamathSD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Kamath SD</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12764</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kotaniemi-Syrjanen,A.</style></author><author><style face="normal" font="Arial"> Csonka,P.</style></author><author><style face="normal" font="Arial"> Pelkonen,A.S.</style></author><author><style face="normal" font="Arial"> Makela,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Likelihood of Immediate Food Challenge Reactions Varies by Age, History, Allergens, and Levels of Sensitization</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="52" start="45">45-52</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adrenalin</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> skin reactions</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year><pub-dates><date Day="26" Month="8" Year="2017">2017/8/26</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">The diagnosis of food allergy is challenging due to different immunologic mechanisms and diversity of symptoms. An open or double-blinded oral food challenge (OFC) was performed on 391 children (aged 0.2-16.9 years) with suspected cow's milk (n?=?266) or wheat allergy (n?=?125) to characterize immediate, delayed, and transient symptoms, and to evaluate the role of earlier food-related symptoms and immunoglobulin E (IgE)-mediated sensitization for the OFC outcome. The OFC resulted in an immediate positive reaction in 38% (n?=?148) and a delayed positive reaction in 21% (n?=?81) of the 391 children. Transient reactions, the majority of which were localized skin reactions, were seen in almost third (n?=?50) of the patients with a negative OFC result (n?=?162/391). Immediate localized skin reactions were more common during the milk challenge (p?=?0.010), whereas immediate lower respiratory tract symptoms (p?=?0.001) were more common during the wheat challenge. Although 14% (n?=?21) of those with an immediate reaction received i.m. adrenalin as a treatment of the reaction, there were no life-threatening events. Multivariate analyses revealed that independent risk factors for the immediate OFC outcome were earlier moderate-to-severe immediate food-related reactions, marked IgE-mediated sensitization to the suspected food, and in case of wheat, age &lt;12 months. The accuracy of OFCs can be enhanced without increasing the risk of serious allergic reactions by taking into account earlier food-related symptoms and the level of IgE-mediated sensitization, by refining our knowledge of transient non-specific reactions, and by applying standardized OFC protocols with over-one-day challenges.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2016.0679</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1089/ped.2016.0679</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-45-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-45-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170826, Kotaniemi-Syrjanen A</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2016.0679</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kloos,R.Q.H.</style></author><author><style face="normal" font="Arial"> Uyl-de Groot,C.A.</style></author><author><style face="normal" font="Arial"> van Litsenburg,R.R.L.</style></author><author><style face="normal" font="Arial"> Kaspers,G.J.L.</style></author><author><style face="normal" font="Arial"> Pieters,R.</style></author><author><style face="normal" font="Arial"> van der Sluis,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Oncology and Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia</style></title><secondary-title><style face="normal" font="Arial">Pediatr Blood Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Blood Cancer</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute lymphoblastic leukemia</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asparaginase</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Monitoring</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erwinia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Therapeutic drug monitoring (TDM) of asparaginase is necessary to respond to variability in asparaginase activity levels, detect silent inactivation, and distinguish between real allergies and allergic-like reactions with and without asparaginase neutralization, respectively. In this study, the costs of an individualized and fixed asparaginase dosing schedule were compared. PROCEDURE: Patients, treated according to the Dutch Childhood Oncology Group ALL-11 protocol (individualized PEGasparaginase treatment, starting dose: 1,500 IU/m2 ) or ALL-10 protocol (native Escherichia coli asparaginase followed by 2,500 IU/m2 PEGasparaginase), were included. To focus on TDM of PEGasparaginase, the costs were also calculated excluding patients treated with Erwinia asparaginase and compared to a hypothetical protocol with a fixed dose of 1,500 IU/m2 PEGasparaginase. Direct asparaginase-related medical costs, including costs for asparaginase use (calculated with the absolute dose), TDM, laboratory tests, daycare treatment, and outpatient clinic visits, were calculated. RESULTS: Eighty-three ALL-10 patients and 51 ALL-11 patients were included. The asparaginase-related costs were 30.8% lower in ALL-11 than in ALL-10 ($29,048 vs. $41,960). The ALL-11 costs of nonallergic patients were 20.4% lower, when using TDM, than the hypothetical protocol with a fixed dose of 1,500 IU/m2 ($13,178 vs. $16,551). TDM accounted for 12.4% of the costs. Including asparaginase waste, TDM in ALL-11 will be cost saving if three doses can be prepared out of one vial compared to a fixed dose of 1,500 IU/m2 . CONCLUSIONS: TDM of asparaginase is cost saving if calculated with the absolute asparaginase dose and will be if the waste is minimalized by preparing multiple doses out of one vial</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 1545-5017 (Electronic)IS - 1545-5009 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1002/pbc.26651</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766887">PM:28766887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Blood Cancer\20170802-KloosRQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Blood Cancer\20170802-KloosRQ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Kloos RQ</style></custom2><misc3><style face="normal" font="Arial">10.1002/pbc.26651</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nagaoka,K.</style></author><author><style face="normal" font="Arial"> Ito,T.</style></author><author><style face="normal" font="Arial"> Ogino,K.</style></author><author><style face="normal" font="Arial"> Eguchi,E.</style></author><author><style face="normal" font="Arial"> Fujikura,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Human lactoferrin induces asthmatic symptoms in NC/Nga mice</style></title><secondary-title><style face="normal" font="Arial">Physiol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Physiol Rep</style></full-title></periodical><pages end="" start="e13365">e13365-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Aluminum</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Arginase</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchus</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-1</style></keyword><keyword><style face="normal" font="Arial"> eotaxin-2</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">Lactoferrin in commercial supplements is known to exert anti-viral and anti-allergic effects. However, this is the first study to evaluate the induction of allergic airway inflammation in NC/Nga mice. Human lactoferrin was administered intraperitoneally with aluminum oxide for sensitization. Five days later, lactoferrin was inoculated intranasally for 5 days, and then on the 12th day, the single inoculation of lactoferrin intranasally was performed as a challenge. On the 13th day, airway hypersensitivity was assessed (AHR), a bronchoalveolar fluid (BALF) cell analysis was conducted, serum IgE and serum lactoferrin-specific IgG and IgE levels as well as the mRNA expression levels of cytokines and chemokines in the lung were measured, and a histopathological analysis of the lung was performed. Human lactoferrin increased AHR, the number of eosinophils in BALF, serum lactoferrin-specific IgG levels, and the mRNA levels of IL-13, eotaxin 1, and eotaxin 2. Moreover, the accumulation of inflammatory cells around the bronchus and the immunohistochemical localization of arginase I and human lactoferrin were detected. Collectively, these results indicate that human lactoferrin induced allergic airway inflammation in mice. Therefore, the commercial use of human lactoferrin in supplements warrants more intensive study</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 2051-817X (Electronic)IS - 2051-817X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.14814/phy2.13365</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28774951">PM:28774951</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Physiol Rep\2017-5-e13365.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Physiol Rep\2017-5-e13365.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Nagaoka K</style></custom2><misc3><style face="normal" font="Arial">10.14814/phy2.13365</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lim,J.H.</style></author><author><style face="normal" font="Arial"> Kim,J.Y.</style></author><author><style face="normal" font="Arial"> Han,D.H.</style></author><author><style face="normal" font="Arial"> Lee,C.H.</style></author><author><style face="normal" font="Arial"> Hong,S.N.</style></author><author><style face="normal" font="Arial"> Wee,J.H.</style></author><author><style face="normal" font="Arial"> Park,S.K.</style></author><author><style face="normal" font="Arial"> Rhee,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0182295">e0182295-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper responsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchial hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> bronchial provocation</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> long-term follow-up</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> poly-sensitization</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The aim of this study is to identify the effects of sublingual immunotherapy (SLIT) on immunologic parameters and bronchial-hyper-responsiveness in children with allergic rhinitis to house-dust mite (HDM), through long-term follow-up cohort. METHODS: Among the Allergic Rhinitis Cohort Study for Kids, pediatric patients who visited the hospital for rhinitis symptoms and proven allergy to HDM through skin prick test were studied. In this cohort, 37 patients received SLIT more than 3-years (SLIT group), and 184 patients received only pharmacologic therapy (non-SLIT group) were included in this study. The results of skin prick test, eosinophil percent and count, total immunoglobulin E (IgE), and bronchial provocation test at initial and 3-year followed-up were compared in the two groups. RESULTS: After 3 year follow-up, only the serum eosinophil percent decreased more significantly in SLIT group than that in the non-SLIT group. New-sensitization rate other than HDM between SLIT and non-SLIT group did not show any significant differences. The distribution of sensitized allergen other than HDM showed increasing tendency after 3 years in both groups. Older age and a small number of sensitized allergen affected the improvement of bronchial hyper-responsiveness regardless of SLIT. CONCLUSION: HDM SLIT in allergic rhinitis children for 3 years in Korea does not affect prevention of new sensitization and poly-sensitization rate increment, and improvement of bronchial hyper-responsiveness</style></abstract><notes><style face="normal" font="Arial">DA - 20170814IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0182295</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28806766">PM:28806766</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0182295.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0182295.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170814, Lim JH</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0182295</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rider,S.D.,Jr.</style></author><author><style face="normal" font="Arial"> Morgan,M.S.</style></author><author><style face="normal" font="Arial"> Arlian,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biological Sciences, Wright State University, Dayton, Ohio, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Allergen homologs in the Euroglyphus maynei draft genome</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0183535">e0183535-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sarcoptes scabiei</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Euroglyphus maynei is a house dust mite commonly found in homes worldwide and is the source of allergens that sensitize and induce allergic reactions in humans. It is the source of species-specific allergens as well as allergens that are cross-reactive with the allergens from house dust mites Dermatophagoides farinae and D. pteronyssinus, and the ectoparasitic scabies mite Sarcoptes scabiei. The genomics, proteomics and molecular biology of E. maynei and its allergens have not been as extensively investigated as those of D. farinae, D. pteronyssinus, and S. scabiei where natural and recombinant allergens from these species have been characterized. Until now, little was known about the genome of E. maynei and it allergens but this information will be important for producing recombinant allergens for diagnostic and therapeutic purposes and for understanding the allergic response mechanism by immune effector cells that mediate the allergic reaction. We sequenced and assembled the 59 Mb E. maynei genome to aid the identification of homologs for known allergenic proteins. The predicted proteome shared orthologs with D. farinae and S. scabiei, and included proteins with homology to more than 30 different groups of allergens. However, the majority of allergen candidates could not be assigned as clear orthologs to known mite allergens. The genomic sequence data, predicted proteome, and allergen homologs identified from E. maynei provide insight into the relationships among astigmatid mites and their allergens, which should allow for the development of improved diagnostics and immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170822IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0183535</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28829832">PM:28829832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0183535.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0183535.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0183535S1_Table.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0183535S2_Table.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0183535S1_Table.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0183535S2_Table.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170822, Rider SD Jr</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0183535</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,L.</style></author><author><style face="normal" font="Arial"> Zhao,L.</style></author><author><style face="normal" font="Arial"> Zhang,B.</style></author><author><style face="normal" font="Arial"> Robotham,J.M.</style></author><author><style face="normal" font="Arial"> Roux,K.H.</style></author><author><style face="normal" font="Arial"> Tang,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Health Sciences, Anhui University, Hefei, Anhui, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Identification of a common Ara h 3 epitope recognized by both the capture and the detection monoclonal antibodies in an ELISA detection kit</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0182935">e0182935-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Alanine</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ara h 3</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition ELISA</style></keyword><keyword><style face="normal" font="Arial"> Isoelectric Focusing</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergy to peanuts has become a common and severe problem, especially in westernized countries. In this study, we evaluated the target and epitope specificity of the capture and detection mouse monoclonal antibodies (mAbs) used in a commercial peanut allergen detection platform. We first identified the target of these antibodies as Ara h 3 and then used an overlapping peptide array of Ara h 3 to determine the antibody-binding epitopes. Further amino acids critical for the binding via alanine substitutions at individual amino acid residues within the epitope were mapped. Finally, inhibition ELISA and inhibition immunoblotting using a recombinant Ara h 3 protein were performed to confirm these results. Surprisingly, the capture and detection mAbs showed identical binding characteristics and were presumed to represent two isolates of the same clone, a notion supported by both isoelectric focusing electrophoresis and Liquid chromatography-mass spectrometry experiments. The simultaneous binding of a pair of identical mAbs to an individual allergen such as Ara h3 is attributed to the multivalency of the analyte and has implications for developing diagnostic assays for additional multimeric allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0182935</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800361">PM:28800361</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0182935.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0182935.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Zhao L</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0182935</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Castillo,D.S.</style></author><author><style face="normal" font="Arial"> Cassola,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Investigaciones Biotecnologicas-Instituto Tecnologico de Chascomus (IIB-INTECH), Universidad Nacional de San Martin (UNSAM)-Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), San Martin, Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Novel sensitive monoclonal antibody based competitive enzyme-linked immunosorbent assay for the detection of raw and processed bovine beta-casein</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0182447">e0182447-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Caseins</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood food allergy</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Competitive ELISA</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Goat milk</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> hybridoma</style></keyword><keyword><style face="normal" font="Arial"> Indirect competitive</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Cow milk protein allergy (CMPA) is the most common childhood food allergy, which can sometimes persist or can newly develop in adulthood with severe symptoms. CMPA's treatment is complete dietary avoidance of milk proteins. To achieve this task, patients have to be aware of milk proteins found as "hidden allergens" in food commodities. In regard to milk proteins, it has been reported that allergenicity of caseins remains unaffected upon heat treatment. For these reasons, we aimed to obtain monoclonal antibodies (mAbs) against native and denatured beta-casein, one of the most abundant and antigenic caseins, in order to develop an indirect competitive ELISA (icELISA) to detect and quantify traces of this milk allergen in raw and processed foodstuffs. We developed two specific hybridoma clones, 1H3 and 6A12, which recognized beta-casein in its denatured and native conformations by indirect ELISA (iELISA). Cross-reaction analysis by Western blot and iELISA indicated that these mAbs specifically recognized beta-casein from bovine and goat milk extracts, while they did not cross-react with proteins present in other food matrixes. These highly specific mAbs enabled the development of sensitive, reliable and reproducible icELISAs to detect and quantify this milk protein allergen in food commodities. The extraction of beta-casein from foodstuff was efficiently carried out at 60 degrees C for 15 minutes, using an extraction buffer containing 1% SDS. The present study establishes a valid 1H3 based-icELISA, which allows the detection and quantification -0.29 ppm and 0.80 ppm, respectively- of small amounts of beta-casein in raw and processed foods. Furthermore, we were able to detect milk contamination in incurred food samples with the same sensitivity as a commercial sandwich ELISA thus showing that this icELISA constitutes a reliable analytical method for control strategies in food industry and allergy prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0182447</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759641">PM:28759641</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0182447.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0182447.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Castillo DS</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0182447</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Srivastava,S.</style></author><author><style face="normal" font="Arial"> Li,Z.</style></author><author><style face="normal" font="Arial"> Skolnik,E.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Nephrology, New York University Langone Medical Center, New York, New York, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Phosphatidlyinositol-3-kinase C2 beta (PI3KC2beta) is a potential new target to treat IgE mediated disease</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0183474">e0183474-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Ca2+ influx</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> K+</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Cross linking of the IgE receptor (FcepsilonRI) on mast cells plays a critical role in IgE-dependent allergy including allergic rhinitis, asthma, anaphylaxis, and delayed type hypersensitivity reactions. The Ca2+ activated K+ channel, KCa3.1, plays a critical role in IgE-stimulated Ca2+ entry and degranulation in mast cells by helping to maintain a negative membrane potential, which provides an electrochemical gradient to drive Ca2+ influx. Of the 3 classes of PI3K, the class II PI3Ks are the least studied and little is known about the roles for class II PI3Ks in vivo in the context of the whole organism under normal and pathological conditions. Studying bone marrow derived mast cells (BMMC) isolated from PI3KC2beta-/- mice, we now show that the class II PI3KC2beta is critical for FcepsilonRI stimulated KCa3.1 channel activation and the subsequent activation of mast cells. We found FcepsilonRI-stimulated Ca2+ entry, cytokine production, and degranulation are decreased in BMMC isolated from PI3KC2beta-/- mice. In addition, PI3KC2beta-/- mice are markedly resistant to both passive cutaneous and passive systemic anaphylaxis. These findings identify PI3KC2beta as a new pharmacologic target to treat IgE-mediated disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170818IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0183474</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28820911">PM:28820911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0183474.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0183474.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170818, Srivastava S</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0183474</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85667</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rockendorf,N.</style></author><author><style face="normal" font="Arial"> Meckelein,B.</style></author><author><style face="normal" font="Arial"> Scherf,K.A.</style></author><author><style face="normal" font="Arial"> Schalk,K.</style></author><author><style face="normal" font="Arial"> Koehler,P.</style></author><author><style face="normal" font="Arial"> Frey,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Mucosal Immunology &amp; Diagnostics, Priority Area Asthma and Allergy, Research Center Borstel, Borstel, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Identification of novel antibody-reactive detection sites for comprehensive gluten monitoring</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0181566">e0181566-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Barley</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> gliadins</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free</style></keyword><keyword><style face="normal" font="Arial"> Gluten-free diet</style></keyword><keyword><style face="normal" font="Arial"> glutenin</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Motifs</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immunology</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat gluten</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Certain cereals like wheat, rye or barley contain gluten, a protein mixture that can trigger celiac disease (CD). To make gluten-free diets available for affected individuals the gluten content of foodstuff must be monitored. For this purpose, antibody-based assays exist which rely on the recognition of certain linear gluten sequence motifs. Yet, not all CD-active gluten constituents and fragments formed during food processing/fermentation may be covered by those tests. In this study, we therefore assayed the coverage of reportedly CD-active gluten components by currently available detection antibodies and determined the antibody-inducing capacity of wheat gluten constituents in order to provide novel diagnostic targets for comprehensive gluten quantitation. Immunizations of outbred mice with purified gliadins and glutenins were conducted and the linear target recognition profile of the sera was recorded using synthetic peptide arrays that covered the sequence space of gluten constituents present in those preparations. The resulting murine immunorecognition profile of gluten demonstrated that further linear binding sites beyond those recognized by the monoclonal antibodies alpha20, R5 and G12 exist and may be exploitable as diagnostic targets. We conclude that the safety of foodstuffs for CD patients can be further improved by complementing current tests with antibodies directed against additional CD-active gluten components. Currently unrepresented linear gluten detection sites in glutenins and alpha-gliadins suggest sequences QQQYPS, PQQSFP, QPGQGQQG and QQPPFS as novel targets for antibody generation</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0181566</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759621">PM:28759621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0181566.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0181566.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Rockendorf N</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0181566</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mattison,C.P.</style></author><author><style face="normal" font="Arial"> Khurana,T.</style></author><author><style face="normal" font="Arial"> Tarver,M.R.</style></author><author><style face="normal" font="Arial"> Florane,C.B.</style></author><author><style face="normal" font="Arial"> Grimm,C.C.</style></author><author><style face="normal" font="Arial"> Pakala,S.B.</style></author><author><style face="normal" font="Arial"> Cottone,C.B.</style></author><author><style face="normal" font="Arial"> Riegel,C.</style></author><author><style face="normal" font="Arial"> Bren-Mattison,Y.</style></author><author><style face="normal" font="Arial"> Slater,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Southern Regional Research Center, Agricultural Research Service, United States Department of Agriculture, New Orleans, Louisiana, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Cross-reaction between Formosan termite (Coptotermes formosanus) proteins and cockroach allergens</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0182260">e0182260-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen characterization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Arginine kinase</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Bla g 5</style></keyword><keyword><style face="normal" font="Arial"> Bla g 7</style></keyword><keyword><style face="normal" font="Arial"> BLAST</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroach allergens</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Expressed sequence tag</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hemocyanin</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Louisiana</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Per a 10</style></keyword><keyword><style face="normal" font="Arial"> Per a 9</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> scFv</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Cockroach allergens can lead to serious allergy and asthma symptoms. Termites are evolutionarily related to cockroaches, cohabitate in human dwellings, and represent an increasing pest problem in the United States. The Formosan subterranean termite (Coptotermes formosanus) is one of the most common species in the southern United States. Several assays were used to determine if C. formosanus termite proteins cross-react with cockroach allergens. Expressed sequence tag and genomic sequencing results were searched for homology to cockroach allergens using BLAST 2.2.21 software. Whole termite extracts were analyzed by mass-spectrometry, immunoassay with IgG and scFv antibodies to cockroach allergens, and human IgE from serum samples of cockroach allergic patients. Expressed sequence tag and genomic sequencing results indicate greater than 60% similarity between predicted termite proteins and German and American cockroach allergens, including Bla g 2/Per a 2, Bla g 3/Per a 3, Bla g 5, Bla g 6/Per a 6, Bla g 7/Per a 7, Bla g 8, Per a 9, and Per a 10. Peptides from whole termite extract were matched to those of the tropomyosin (Bla g 7), arginine kinase (Per a 9), and myosin (Bla g 8) cockroach allergens by mass-spectrometry. Immunoblot and ELISA testing revealed cross-reaction between several proteins with IgG and IgE antibodies to cockroach allergens. Several termite proteins, including the hemocyanin and tropomyosin orthologs of Blag 3 and Bla g 7, were shown to crossreact with cockroach allergens. This work presents support for the hypothesis that termite proteins may act as allergens and the findings could be applied to future allergen characterization, epitope analysis, and clinical studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170802IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0182260</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28767688">PM:28767688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0182260.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0182260.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170802, Mattison CP</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0182260</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oshikata,C.</style></author><author><style face="normal" font="Arial"> Watanabe,M.</style></author><author><style face="normal" font="Arial"> Saito,A.</style></author><author><style face="normal" font="Arial"> Ishida,M.</style></author><author><style face="normal" font="Arial"> Kobayashi,S.</style></author><author><style face="normal" font="Arial"> Konuma,R.</style></author><author><style face="normal" font="Arial"> Kamata,Y.</style></author><author><style face="normal" font="Arial"> Terajima,J.</style></author><author><style face="normal" font="Arial"> Cho,J.</style></author><author><style face="normal" font="Arial"> Yanai,M.</style></author><author><style face="normal" font="Arial"> Tsurikisawa,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1National Hospital Organization Saitama National Hospital,Department of Respirology,Wako,Saitama,Japan</style></auth-address><titles><title><style face="normal" font="Arial">Allergic Bronchopulmonary Mycosis due to Exposure to Eurotium herbariorum after the Great East Japan Earthquake</style></title><secondary-title><style face="normal" font="Arial">Prehosp Disaster Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Prehosp Disaster Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary mycosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor mold</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Natural Disasters</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Indoor mold levels typically increase after natural disasters, flooding, and water damage. Eurotium herbariorum is the sexual stage of Aspergillus glaucus. Case Presentation A 66-year-old, Japanese male, ex-smoker had been diagnosed with bronchial asthma when he was five years old; he achieved remission at the age of 13 years. He was displaced from his home during the Great East Japan Earthquake on March 11, 2011 and moved to temporary housing in Miyagi Prefecture in June 2011. He experienced the first episode of chest tightness, coughing, and wheezing in February 2012, when he again was diagnosed as having bronchial asthma. Mycofloral surveillance detected high counts of Eurotium in the air of his bedroom, kitchen, and living room, with a maximal fungal count of 163,200 colony-forming units per cubic meter (CFU/m3). Although Cladosporium and Penicillium typically predominate in the indoor air of residential dwellings, only low levels of these organisms were present in the patient's home. Morphologic identification confirmed the isolates as E. herbariorum. The patient had positive reactions to E. herbariorum in skin prick testing and the presence of antigen-specific precipitating antibodies to E. herbariorum. Computed tomography of the chest in August 2013 revealed central bronchiectasis and bronchial wall thickening. The patient experienced late reactions after provocation testing with E. herbariorum. CONCLUSION: This report presents the rare case of a patient who developed allergic bronchopulmonary mycosis (ABPM) due to exposure to E. herbariorum during temporary housing after the Great East Japan Earthquake. Oshikata C , Watanabe M , Saito A , Ishida M , Kobayashi S , Konuma R , Kamata Y , Terajima J , Cho J , Yanai M , Tsurikisawa N . Allergic bronchopulmonary mycosis due to exposure to eurotium herbariorum after the Great East Japan Earthquake</style></abstract><notes><style face="normal" font="Arial">DA - 20170815IS - 1945-1938 (Electronic)IS - 1049-023X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1017/S1049023X17006914</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28807087">PM:28807087</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Prehosp Disaster Med\20170815-OshikataC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Prehosp Disaster Med\20170815-OshikataC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170815, Oshikata C</style></custom2><misc3><style face="normal" font="Arial">10.1017/S1049023X17006914</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85670</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zierau,L.</style></author><author><style face="normal" font="Arial"> Walsted,E.S.</style></author><author><style face="normal" font="Arial"> Thomsen,S.F.</style></author><author><style face="normal" font="Arial"> Backer,V.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Response to omalizumab in patients with severe allergic asthma: A real-life study</style></title><secondary-title><style face="normal" font="Arial">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med</style></full-title></periodical><pages end="113" start="109">109-113</pages><volume><style face="normal" font="Arial">131</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> GETE</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0954-6111</style></isbn><abstract><style face="normal" font="Arial">Introduction Omalizumab is a humanized monoclonal anti-IgE antibody, which is widely used for patients with severe uncontrolled asthma. Treatment with omalizumab is known to decrease the number of exacerbations and GETE score (Global Evaluation of Treatment Effectiveness) - but little is known about which patients benefit the most. Moreover, the time to discontinuation of the treatment with omalizumab has yet to be investigated. In this real-life study on a Danish population we explore these important issues Method In a retrospective real-life study, 54 patients treated with omalizumab at a specialized outpatient asthma clinic were included. Change in GETE score, time to discontinuation of treatment and associated risk factors were analysed. Results As a result of omalizumab treatment, most patients improved in GETE score from poor/worsening to excellent. Women were treated for a median time of 31 months (95% CI: 4.6-57.4) and approximately 50% of patients discontinued treatment after 500 days whilst, for men, 50% discontinued treatment after 1500 days. Eosinophil count above 300 cells/µL at treatment initiation was positively related to the discontinuation of omalizumab (HR 4.3 95%CI (1.22-15.28) p = 0.023). Conclusion In conclusion, female gender and an eosinophil count above 300 cells/µL may predict a better treatment response, leading to a shorter treatment time than the current guideline recommendation of maximum 48 months. Additionally, the GETE score improves with omalizumab. More real-life studies are needed to determine which patients will benefit the most from the treatment.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmed.2017.08.011</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.rmed.2017.08.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2017-131-109-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2017-131-109-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Zierau L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmed.2017.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85671</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">One voice for anaphylaxis in France: The vision of the centre of reference in rare diseases</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxie</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Classification Internationale des Maladies</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Rare disease</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">In October 2016, the French Minister of Health launched a call for new Centers of Reference in Rare Diseases (CRRD). In order to support quality clinical practice, prevention and research for patients presenting severe anaphylaxis, together with 15 French public health institutions (Competence Centers in Rare Diseases-CCRD), we submitted a proposal named ANAFIL. French data suggest that fewer than 30,000 people are affected by severe anaphylaxis, with 9.2 per 100,000 person-years based on data from the University Hospital of Montpellier. Cumulative incidence is an inadequate measurement here, since the reaction is no longer active once the episode is resolved and one patient can present different episodes of anaphylactic reactions. Covering 7 of 12 administrative regions in France, all 16 centres making up the ANAFIL network are linked to academic activities, supported by medical and patient associations. Given that anaphylaxis is considered a public health issue by the global allergy community, the ANAFIL proposal provides a key window of opportunity for the construction of a solid academic French consortium that will redress implementation gaps in the field.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -CO - France -</style></notes><work-type><style face="normal" font="Arial">https://doi.org/10.1016/j.reval.2017.06.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.06.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170824-TannoLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170824-TannoLK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Tanno LK</style></custom2><misc3><style face="normal" font="Arial">https://doi.org/10.1016/j.reval.2017.06.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hayashizaki,K.</style></author><author><style face="normal" font="Arial"> Kimura,M.Y.</style></author><author><style face="normal" font="Arial"> Tokoyoda,K.</style></author><author><style face="normal" font="Arial"> Hosokawa,H.</style></author><author><style face="normal" font="Arial"> Shinoda,K.</style></author><author><style face="normal" font="Arial"> Hirahara,K.</style></author><author><style face="normal" font="Arial"> Ichikawa,T.</style></author><author><style face="normal" font="Arial"> Onodera,A.</style></author><author><style face="normal" font="Arial"> Hanazawa,A.</style></author><author><style face="normal" font="Arial"> Iwamura,C.</style></author><author><style face="normal" font="Arial"> Kakuta,J.</style></author><author><style face="normal" font="Arial"> Muramoto,K.</style></author><author><style face="normal" font="Arial"> Motohashi,S.</style></author><author><style face="normal" font="Arial"> Tumes,D.J.</style></author><author><style face="normal" font="Arial"> Iinuma,T.</style></author><author><style face="normal" font="Arial"> Yamamoto,H.</style></author><author><style face="normal" font="Arial"> Ikehara,Y.</style></author><author><style face="normal" font="Arial"> Okamoto,Y.</style></author><author><style face="normal" font="Arial"> Nakayama,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Myosin light chains 9 and 12 are functional ligands for CD69 that regulate airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Sci Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Sci Immunol</style></abbr-1></periodical><pages end="" start="eaaf9154">eaaf9154-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Vessels</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> Myosin light chain</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T helper 2 cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="9" Year="2016">2016/9/16</year></dates><abstract><style face="normal" font="Arial">Recent decades have witnessed a rapid worldwide increase in chronic inflammatory disorders such as asthma. CD4+ T helper 2 cells play critical roles in the pathogenesis of allergic airway inflammation, and CD69 expression on activated CD4 T cells is required to induce allergic inflammation in tissues. However, how CD69 mechanistically controls allergic inflammation remains poorly defined. In lymphoid tissues, CD69 regulates cellular retention through inhibition of S1P1 expression and requires no specific ligands to function. In contrast, we show herein that myosin light chain (Myl) 9 and Myl12 are new functional ligands for CD69. Blockade of CD69-Myl9/12 interaction ameliorates allergic airway inflammation in ovalbumin-induced and house dust mite-induced mouse models of asthma. Within the inflamed mouse airways, we found that the expression of Myl9/12 was increased and that platelet-derived Myl9/12 localized to the luminal surface of blood vessels and formed intravascular net-like structures. Analysis of nasal polyps of eosinophilic chronic rhinosinusitis patients revealed that Myl9/12 expression was increased in inflammatory lesions and was distributed within net-like structures in the intravascular space. In addition, we detected Myl9/12 in perivascular spaces where many CD69+ cells were positioned within Myl9/12 structures. Thus, CD69-Myl9/12 interaction is a key event in the recruitment of activated CD69+ T cells to inflamed tissues and could be a therapeutic target for intractable airway inflammatory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 2470-9468 (Electronic)IS - 2470-9468 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Germany -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1126/sciimmunol.aaf9154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28783682">PM:28783682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Immunol\2016-1-eaaf9154.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Immunol\2016-1-eaaf9154.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Hayashizaki K</style></custom2><misc3><style face="normal" font="Arial">10.1126/sciimmunol.aaf9154</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Henrickson,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Allergy Immunology Division, the Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104, USA.</style></auth-address><titles><title><style face="normal" font="Arial">IgE running interference for rhinovirus?</style></title><secondary-title><style face="normal" font="Arial">Sci Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Sci Immunol</style></abbr-1></periodical><pages end="" start="eaao3115">eaao3115-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">14</style></number><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Running</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">Anti-IgE treatment in pediatric allergic asthmatics reduces rates of symptomatic rhinovirus infection</style></abstract><notes><style face="normal" font="Arial">DA - 20170805IS - 2470-9468 (Electronic)IS - 2470-9468 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1126/sciimmunol.aao3115</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778907">PM:28778907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Immunol\2017-2-eaaao3115.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Immunol\2017-2-eaaao3115.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Henrickson SE</style></custom2><misc3><style face="normal" font="Arial">10.1126/sciimmunol.aao3115</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,T.</style></author><author><style face="normal" font="Arial"> Tibbitt,C.A.</style></author><author><style face="normal" font="Arial"> Feng,X.</style></author><author><style face="normal" font="Arial"> Stark,J.M.</style></author><author><style face="normal" font="Arial"> Rohrbeck,L.</style></author><author><style face="normal" font="Arial"> Rausch,L.</style></author><author><style face="normal" font="Arial"> Sedimbi,S.K.</style></author><author><style face="normal" font="Arial"> Karlsson,M.C.I.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Karlsson Hedestam,G.B.</style></author><author><style face="normal" font="Arial"> Hendriks,R.W.</style></author><author><style face="normal" font="Arial"> Chambers,B.J.</style></author><author><style face="normal" font="Arial"> Nylen,S.</style></author><author><style face="normal" font="Arial"> Coquet,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm 171 77, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">PPAR-gamma promotes type 2 immune responses in allergy and nematode infection</style></title><secondary-title><style face="normal" font="Arial">Sci Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Sci Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status date="09/02/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Adipose tissue</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> PPAR gamma</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="Arial">A hallmark of immunity to worm infections and many allergies is a strong type 2 immune response. This is characterized by the production of cytokines interleukin-5 (IL-5) and IL-13 by adaptive T helper 2 (TH2) cells and/or type 2 innate lymphoid cells. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) is typically regarded as an anti-inflammatory factor. We report that TH2 cells express high levels of PPAR-gamma in response to the allergen house dust mite and after infection with the parasite Heligmosomoides polygyrus Mice lacking PPAR-gamma in T cells failed to effectively differentiate into IL-5- and IL-13-secreting cells and, hence, did not develop TH2 cell-associated pathologies, including goblet cell metaplasia and eosinophilia, in response to allergen challenge. Furthermore, these mice could not mount protective immune responses to nematode infection. In addition, mice lacking PPAR-gamma in T cells had greatly reduced frequencies of TH2 cells in visceral adipose tissue. Mechanistically, PPAR-gamma appeared to promote the expression of the IL-33 receptor on the surface of TH2 cells. These results pinpoint PPAR-gamma as a factor that drives type 2 responses in allergy, worm infection, and visceral adipose tissue</style></abstract><notes><style face="normal" font="Arial">DA - 20170807IS - 2470-9468 (Electronic)IS - 2470-9468 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1126/sciimmunol.aal5196</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28783701">PM:28783701</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Immunol\20170807-ChenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Immunol\20170807-ChenT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170807, Chen T</style></custom2><misc3><style face="normal" font="Arial">10.1126/sciimmunol.aal5196</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sonesson,A.</style></author><author><style face="normal" font="Arial"> Przybyszewska,K.</style></author><author><style face="normal" font="Arial"> Eriksson,S.</style></author><author><style face="normal" font="Arial"> Morgelin,M.</style></author><author><style face="normal" font="Arial"> Kjellstrom,S.</style></author><author><style face="normal" font="Arial"> Davies,J.</style></author><author><style face="normal" font="Arial"> Potempa,J.</style></author><author><style face="normal" font="Arial"> Schmidtchen,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology and Venereology, Department of Clinical Sciences Lund, Lund University, BMC, Tornavagen 10, SE-22184, Lund, Sweden.</style></auth-address><titles><title><style face="normal" font="Arial">Identification of bacterial biofilm and the Staphylococcus aureus derived protease, staphopain, on the skin surface of patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="8689">8689-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Biofilms</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptide fragment</style></keyword><keyword><style face="normal" font="Arial"> Peptide Fragments</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by an impaired epidermal barrier, dysregulation of innate and adaptive immunity, and a high susceptibility to bacterial colonization and infection. In the present study, bacterial biofilm was visualized by electron microscopy at the surface of AD skin. Correspondingly, Staphylococcus aureus (S. aureus) isolates from lesional skin of patients with AD, produced a substantial amount of biofilm in vitro. S. aureus biofilms showed less susceptibility to killing by the antimicrobial peptide LL-37 when compared with results obtained using planktonic cells. Confocal microscopy analysis showed that LL-37 binds to the S. aureus biofilms. Immuno-gold staining of S. aureus biofilm of AD skin detected the S. aureus derived protease staphopain adjacent to the bacteria. In vitro, staphopain B degraded LL-37 into shorter peptide fragments. Further, LL-37 significantly inhibited S. aureus biofilm formation, but no such effects were observed for the degradation products. The data presented here provide novel information on staphopains present in S. aureus biofilms in vivo, and illustrate the complex interplay between biofilm and LL-37 in skin of AD patients, possibly leading to a disturbed host defense, which facilitates bacterial persistence</style></abstract><notes><style face="normal" font="Arial">DA - 20170819IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Poland -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-08046-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28821865">PM:28821865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-8689.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-8689.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170819, Sonesson A</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-08046-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,H.</style></author><author><style face="normal" font="Arial"> Lin,J.</style></author><author><style face="normal" font="Arial"> Zeng,L.</style></author><author><style face="normal" font="Arial"> Ouyang,C.</style></author><author><style face="normal" font="Arial"> Ran,P.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy &amp; Immunology, Shenzhen University School of Medicine, Shenzhen, China</style></auth-address><titles><title><style face="normal" font="Arial">Der f 31, a novel allergen from Dermatophagoides farinae, activates epithelial cells and enhances lung-resident group 2 innate lymphoid cells</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="8519">8519-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 2</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="Arial">Airway epithelial cell-derived thymic stromal lymphopoietin (TSLP) and IL-33 can enhance lung-resident group 2 innate lymphoid cells (ILC2s), and they play an important role in the development of allergic diseases. This study tests the hypothesis that Der f 31 (Dermatophagoides farinae-31), an allergen, modulates airway epithelial cell functions and increases the frequency of lung ILC2s. Our previous research identified cofilin (Der f 31) as a novel allergen. In this study, we found that recombinant Der f 31 (r-Der f 31) upregulated the expression of co-stimulatory molecules in DCs and promoted Th2-skewed polarization. The levels of TSLP and IL-33 in epithelial cells were upregulated by r-Der f 31 via the activation of Toll-like receptor 2. Furthermore, in in vivo studies, r-Der f 31 induced eosinophil-like airway allergy and increased the number of lung-resident ILC2s. In summary, Der f 31 can modulate the functions of airway epithelial cells and increase levels of lung-resident ILC2s</style></abstract><notes><style face="normal" font="Arial">DA - 20170818IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-04878-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28819104">PM:28819104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-8519.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-8519.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170818, Wang H</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-04878-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fujimoto,Y.</style></author><author><style face="normal" font="Arial"> Hasegawa,S.</style></author><author><style face="normal" font="Arial"> Matsushige,T.</style></author><author><style face="normal" font="Arial"> Wakiguchi,H.</style></author><author><style face="normal" font="Arial"> Nakamura,T.</style></author><author><style face="normal" font="Arial"> Hasegawa,H.</style></author><author><style face="normal" font="Arial"> Nakajima,N.</style></author><author><style face="normal" font="Arial"> Ainai,A.</style></author><author><style face="normal" font="Arial"> Oga,A.</style></author><author><style face="normal" font="Arial"> Itoh,H.</style></author><author><style face="normal" font="Arial"> Shirabe,K.</style></author><author><style face="normal" font="Arial"> Toda,S.</style></author><author><style face="normal" font="Arial"> Atsuta,R.</style></author><author><style face="normal" font="Arial"> Morishima,T.</style></author><author><style face="normal" font="Arial"> Ohga,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Pulmonary inflammation and cytokine dynamics of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during A(H1N1)pdm09 influenza infection</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="9128">9128-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> Distress</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Virus Replication</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">Asthmatic patients present more rapid progression of respiratory distress after A(H1N1)pdm09 influenza infection than after seasonal infection. Here, we sought to clarify the pathophysiology of early deterioration in asthmatic patients after A(H1N1)pdm09 infection. Cytokine levels and virus titres in bronchoalveolar lavage fluid from mice with and without asthma after A(H1N1)pdm09 or seasonal H1N1 infection were examined. In asthma/A(H1N1)pdm09 mice, IL-6 and TNF-alpha levels peaked at 3 days post-infection and were higher than those in all other groups. IFN-gamma levels in asthma/A(H1N1)pdm09 mice at 3 days post-infection were higher than in all other mice at any time point, whereas at 7 days post-infection, the levels were lowest in asthma/A(H1N1)pdm09 mice. Virus titres in asthma/A(H1N1)pdm09 mice were highest at 3 days post-infection, and decreased by 7 days post-infection, although the levels at this time point were still higher than that in any other group. Histopathological examination showed more inflammatory cell infiltration and lung tissue destruction in the asthma/A(H1N1)pdm09 group than in any other group. The distinct cytokine profiles in A(H1N1)pdm09-infected asthmatic mice indicated excessive inflammation and virus replication within a few days after infection. Thus, bronchial asthma could be a more exacerbating factor for pandemic influenza infection than for seasonal influenza infection</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-08030-w</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28831046">PM:28831046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-9128.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-9128.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Fujimoto Y</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-08030-w</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Serrano-Candelas,E.</style></author><author><style face="normal" font="Arial"> Martinez-Aranguren,R.</style></author><author><style face="normal" font="Arial"> Vega,O.</style></author><author><style face="normal" font="Arial"> Gastaminza,G.</style></author><author><style face="normal" font="Arial"> Bartra,J.</style></author><author><style face="normal" font="Arial"> Audicana,M.T.</style></author><author><style face="normal" font="Arial"> Nunez-Cordoba,J.M.</style></author><author><style face="normal" font="Arial"> Algorta,J.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author><author><style face="normal" font="Arial"> Martin,M.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biochemistry Unit, Faculty of Medicine, University of Barcelona, Casanova 143, Barcelona, 08036, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="8985">8985-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Anti-IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="21" Month="8" Year="2017">2017/8/21</year></dates><abstract><style face="normal" font="Arial">Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb's mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional mechanisms of action. In this study, we sought to investigate the ability of OmAb to inhibit mast cell and basophil degranulation induced by sera from CSU patients. For this purpose, we performed a comparison between the in vitro incubation of sera from CSU patients treated with OmAb and the in vivo administration of OmAb in a clinical trial. We found that OmAb added in vitro to sera from CSU patients did not modify the ability of the sera to induce cell degranulation. Similarly, the sera from patients treated with OmAb in the context of the clinical trial who had a good clinical outcome maintained the capacity to activate mast cells and basophils. Thus, we conclude that the beneficial activity of OmAb does not correlate with the ability of patient sera to induce cell degranulation</style></abstract><notes><style face="normal" font="Arial">DA - 20170822IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-09361-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28827590">PM:28827590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-8985.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-8985.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170822, Serrano-Candelas E</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-09361-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,S.</style></author><author><style face="normal" font="Arial"> Sun,L.</style></author><author><style face="normal" font="Arial"> He,F.</style></author><author><style face="normal" font="Arial"> Che,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">Anti-allergic activity of glycyrrhizic acid on IgE-mediated allergic reaction by regulation of allergy-related immune cells</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="7222">7222-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Ca2+ influx</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cell-based immunological assay</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vascular permeability</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="Arial">Glycyrrhizic acid (GA), the major bioactive triterpene glycoside of glycyrrhiza, has been shown to possess a wide range of pharmacological properties, including anti-inflammatory and anti-viral properties. However, few studies have examined the anti-allergic activity and exact mechanism of action of GA. In the present work, the anti-allergic activity and possible mechanisms of action of GA on an immunoglobulin (Ig) E-mediated allergic reaction has been studied using three models of allergic reaction in vivo and in vitro. Active systemic allergic reaction in Balb/c mice showed that GA can suppress the increased level of IL-4 to restore the immune balance of TH1/TH2 cells in a dose-dependent manner. Additionally, GA attenuated significantly the B cells producing allergen-specific IgE and IgG1 partly because of the low levels of TH2 cytokines. Both passive cutaneous anaphylaxis in vivo and an RBL-2H3 cell-based immunological assay in vitro indicated that GA acted as a "mast cell stabilizer", as it inhibited mast cell degranulation and decreased vascular permeability by inhibiting the expression of Orai1, STIM1 and TRPC1, which blocked extracellular Ca2+ influxes. The current study suggests that GA may serve as an effective anti-allergic agent derived from food for the prevention and treatment of IgE-mediated allergic reaction</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-07833-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775294">PM:28775294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-7222.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-7222.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Han S</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-07833-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liao,W.</style></author><author><style face="normal" font="Arial"> Zhou,L.</style></author><author><style face="normal" font="Arial"> Zhao,X.</style></author><author><style face="normal" font="Arial"> Song,L.</style></author><author><style face="normal" font="Arial"> Lu,Y.</style></author><author><style face="normal" font="Arial"> Zhong,N.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Sun,B.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease, Department of Otolaryngology-Head and Neck Surgery, Guangzhou, 510120, China</style></auth-address><titles><title><style face="normal" font="Arial">Thermoneutral housing temperature regulates T-regulatory cell function and inhibits ovabumin-induced asthma development in mice</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="7123">7123-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="Arial">The change in ambient temperature is one of the risk factors for the aggravation of bronchial asthma (BA). Yet, whether the ambient temperature influences the immune functions associated with allergic asthma remains unknown. In this study, we treated asthmatic mice with standard temperature (ST, 20 degrees C) or thermoneutral temperature (TT, 30 degrees C). The results showed that the airway inflammatory cell counts in bronchoalveolar lavage fluid (BALF) and airway hyperresponsiveness (AHR) were significantly reduced in the mice treated with TT as compared with the mice treated with ST. The imbalance of Th1/Th2 response in the lung was improved following housing the mice at TT. In addition, the pulmonary Treg cells were increased in asthmatic mice after TT treatment. The temperature stress (29 degrees C and 41 degrees C) drove naive CD4T cells towards Th2 cells. Our data demonstrate that the change of ambient temperature was a risk factor to aggravate experimental asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-07471-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28769099">PM:28769099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-7123.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-7123.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Liao W</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-07471-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bax,H.J.</style></author><author><style face="normal" font="Arial"> Bowen,H.</style></author><author><style face="normal" font="Arial"> Beavil,R.L.</style></author><author><style face="normal" font="Arial"> Chung,R.</style></author><author><style face="normal" font="Arial"> Ward,M.</style></author><author><style face="normal" font="Arial"> Davies,A.M.</style></author><author><style face="normal" font="Arial"> Dodev,T.S.</style></author><author><style face="normal" font="Arial"> McDonnell,J.M.</style></author><author><style face="normal" font="Arial"> Beavil,A.J.</style></author><author><style face="normal" font="Arial"> Sutton,B.J.</style></author><author><style face="normal" font="Arial"> Gould,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Randall Division of Cell and Molecular Biophysics, King's College London, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="Arial">IgE Trimers Drive SPE-7 Cytokinergic Activity</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="8164">8164-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Biophysics</style></keyword><keyword><style face="normal" font="Arial"> Cell surface receptors</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> Cross-link</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monomer</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> trimer</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">Degranulation of mast cells and basophils, with release of agents of the allergic response, ensues when multivalent antigens bind to and cross-link the cells' receptor-bound IgE antibodies. A widely used commercial monoclonal IgE antibody, SPE-7 IgE from Sigma, was found to possess the radically anomalous property, termed "cytokinergic", of inducing basophil degranulation without the intervention of an antigen. We show here that the IgE monomer, freed of protein contaminants, is devoid of this activity, and that the source of the anomaly is a trace impurity, identified as a dissociation-resistant IgE trimer. Possible models for the formation of IgE trimers and the manner in which they cross-link cell surface receptors are suggested herein</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-08212-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811536">PM:28811536</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-8164.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-8164.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Bax HJ</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-08212-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Niu,R.</style></author><author><style face="normal" font="Arial"> Xiao,X.</style></author><author><style face="normal" font="Arial"> Liu,B.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Zhong,Y.</style></author><author><style face="normal" font="Arial"> Ma,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, 410008, P.R. ChinaDepartment of Otolaryngology Head and Neck Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410008, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Inhibition of airway inflammation in a cockroach allergen model of asthma by agonists of miRNA-33b</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="7409">7409-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="Arial">MicroRNAs (miRNAs) play powerful roles in immune function by regulating target genes that mediate cell behavior. It is well known that mast cells have essential effector and immune regulatory functions in IgE-associated allergic disorders and in innate and adaptive immune responses. However, the role of miRNAs in mediating mast cell functions and the relevant mechanisms require further exploration. The roles of miR-33b in airway inflammation and mast cell functions are still unknown. To examine the role of miR-33b in mouse mast cells in cockroach allergen-induced asthma, we developed a lentiviral system for miRNA-33b overexpression to examine whether miRNA-33b mediates airway inflammation by regulating mast cell function and to evaluate the underlying mechanism. The results showed that miR-33b inhibited cockroach allergen-induced asthma in vivo: in particular, it inhibited TH2 cytokine production. In addition, we found that in cells in which miRNA-33b had been transfected, mast cell degranulation was inhibited through suppression of the calcium release and IgE/FcepsilonRI pathway. Our study provides new insight into the roles of miR-33b in asthma and mast cell biology and identifies novel mechanisms that may contribute to mast cell-related pathological conditions in airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170808IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-07882-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28785038">PM:28785038</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-7409.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-7409.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170808, Niu R</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-07882-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lou,H.</style></author><author><style face="normal" font="Arial"> Ma,S.</style></author><author><style face="normal" font="Arial"> Zhao,Y.</style></author><author><style face="normal" font="Arial"> Cao,F.</style></author><author><style face="normal" font="Arial"> He,F.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization patterns and minimum screening panels for aeroallergens in self-reported allergic rhinitis in China</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="9286">9286-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Hazel</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Multiple sensitization</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="Arial">Optimization of skin prick test (SPT) panels, especially in view of significant differences in sensitizations patterns within different geographical areas, is an unmet need within China. Our aim was to assess the patterns and clinical relevance of aeroallergen sensitizations in allergic rhinitis (AR) and define the minimal battery of SPT allergens, classified according to the Koppen-Geiger climate map. Overall, 7148 subjects with self-reported AR completed a standard questionnaire and were assessed for sensitization to relevant allergens by SPT. 6340 (88.7%) patients had at least one positive skin prick reaction, and demonstrated unique sensitization patterns by stratification with age, gender, and geographic region. Sensitization to house dust mites (HDM) was highest in south China, whereas the three most prevalent aeroallergens were mugwort, ragweed and dandelion pollen in north-west China. Higher sensitization rates and multiple sensitizations were associated with AR comorbidities. Eight allergens (Der f, mugwort, Blatella, hazel, goosefoot, Penicillium notatum, animal dander and Der p) allowed identification >96% of sensitized subjects in central China. Differences in optimal panels were observed between regions, with five to six allergens being sufficient for north-east, north-west and south China. These SPT panels may provide a cost-effective tool for screening sensitized patients in China</style></abstract><notes><style face="normal" font="Arial">DA - 20170825IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -CO - France -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-10111-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28839248">PM:28839248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-9286.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-9286.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170825, Lou H</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-10111-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Coombs,K.</style></author><author><style face="normal" font="Arial"> Taft,D.</style></author><author><style face="normal" font="Arial"> Ward,D.V.</style></author><author><style face="normal" font="Arial"> Green,B.J.</style></author><author><style face="normal" font="Arial"> Chew,G.L.</style></author><author><style face="normal" font="Arial"> Shamsaei,B.</style></author><author><style face="normal" font="Arial"> Meller,J.</style></author><author><style face="normal" font="Arial"> Indugula,R.</style></author><author><style face="normal" font="Arial"> Reponen,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Cincinnati, Department of Environmental Health, P.O. Box 670056, Cincinnati, OH, USA</style></auth-address><titles><title><style face="normal" font="Arial">Variability of indoor fungal microbiome of green and non-green low-income homes in Cincinnati, Ohio</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="218" start="212">212-218</pages><volume><style face="normal" font="Arial">610-611</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air sampling</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> renovation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">"Green" housing is designed to use low-impact materials, increase energy efficiency and improve occupant health. However, little is known about the indoor mycobiome of green homes. The current study is a subset of a multicenter study that aims to investigate the indoor environment of green homes and the respiratory health of asthmatic children. In the current study, the mycobiome in air, bed dust and floor dust was compared between green (study site) and non-green (control site), low-income homes in Cincinnati, Ohio. The samples were collected at baseline (within four months following renovation), and 12months after the baseline at the study site. Parallel sample collection was conducted in non-green control homes. Air samples were collected by PM2.5 samplers over 5-days. Bed and floor dust samples were vacuumed after the air sampling was completed. The DNA sample extracts were analyzed using ITS amplicon sequencing. Analysis indicated that there was no clear trend in the fungal communities between green and non-green homes. Instead, fungal community differences were greatest between sample types - air, bed, and floor. Microbial communities also changed substantially between sampling intervals in both green and non-green homes for all sample types, potentially indicating that there was very little stability in the mycobiomes. Research gaps remain regarding how indoor mycobiome fluctuates over time. Longer follow-up periods might elucidate the effect of green renovation on microbial load in buildings</style></abstract><notes><style face="normal" font="Arial">DA - 20170813IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.07.274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803198">PM:28803198</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2017-610_611-212-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2017-610_611-212-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170813, Coombs K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.07.274</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miyashita,C.</style></author><author><style face="normal" font="Arial"> Bamai,Y.A.</style></author><author><style face="normal" font="Arial"> Araki,A.</style></author><author><style face="normal" font="Arial"> Itoh,S.</style></author><author><style face="normal" font="Arial"> Minatoya,M.</style></author><author><style face="normal" font="Arial"> Kobayashi,S.</style></author><author><style face="normal" font="Arial"> Kajiwara,J.</style></author><author><style face="normal" font="Arial"> Hori,T.</style></author><author><style face="normal" font="Arial"> Kishi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Environmental and Health Sciences, Hokkaido University, Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Prenatal exposure to dioxin-like compounds is associated with decreased cord blood IgE and increased risk of wheezing in children aged up to 7years: The Hokkaido study</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="199" start="191">191-199</pages><volume><style face="normal" font="Arial">610-611</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cord Blood</style></keyword><keyword><style face="normal" font="Arial"> cord blood IgE</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune development</style></keyword><keyword><style face="normal" font="Arial"> immune function</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> In utero</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: In utero exposure to dioxin-like compounds (DLCs) may cause imbalance of immune development in early infancy. However, there are few epidemiological studies into the effects of in utero exposure to DLCs on allergies and infections during childhood. This study evaluates associations between concentrations of maternal DLCs and cord blood immunoglobulin (Ig) E, as well as allergies and infections during childhood. METHOD: We recruited 514 pregnant women in a maternity hospital in Sapporo, Japan, and measured concentrations of DLCs in 426 maternal blood samples using high-resolution gas chromatography/high-resolution mass spectrometry. We examined the relationship between concentrations of maternal DLCs and cord blood IgE at birth (n=239), as well as for allergies and infections in children at 3.5 (n=327) and 7 (n=264) years, using regression analysis adjusted for confounding variables. RESULTS: We found a positive association between maternal DLC concentrations and frequency of wheezing in children aged up to 7years [odds ratio (OR); 7.81 (95% confidence interval (CI), 1.42 to 42.9)]. At 3.5years, boys showed inverse associations between maternal DLC concentrations and cord blood IgE [partial regression coefficient; -0.87 (95% CI), -1.68 to -0.06], and frequency of wheezing [OR; 0.03 (95% CI), 0.00 to 0.94] but girls did not. DISCUSSION: As one reason for the significant association observed at 7 but absent at 3.5years, we suggest that allergic symptoms are more obvious in older children due to matured immune function. CONCLUSION: The findings suggest that prenatal exposure to DLCs may modify offspring immune responses and result in increased risk of allergy among children of school age</style></abstract><notes><style face="normal" font="Arial">DA - 20170813IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.07.248</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803196">PM:28803196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2017-610_611-191-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2017-610_611-191-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170813, Miyashita C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.07.248</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sinclair,C.</style></author><author><style face="normal" font="Arial"> Bommakanti,G.</style></author><author><style face="normal" font="Arial"> Gardinassi,L.</style></author><author><style face="normal" font="Arial"> Loebbermann,J.</style></author><author><style face="normal" font="Arial"> Johnson,M.J.</style></author><author><style face="normal" font="Arial"> Hakimpour,P.</style></author><author><style face="normal" font="Arial"> Hagan,T.</style></author><author><style face="normal" font="Arial"> Benitez,L.</style></author><author><style face="normal" font="Arial"> Todor,A.</style></author><author><style face="normal" font="Arial"> Machiah,D.</style></author><author><style face="normal" font="Arial"> Oriss,T.</style></author><author><style face="normal" font="Arial"> Ray,A.</style></author><author><style face="normal" font="Arial"> Bosinger,S.</style></author><author><style face="normal" font="Arial"> Ravindran,R.</style></author><author><style face="normal" font="Arial"> Li,S.</style></author><author><style face="normal" font="Arial"> Pulendran,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Emory Vaccine Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329, USA</style></auth-address><titles><title><style face="normal" font="Arial">mTOR regulates metabolic adaptation of APCs in the lung and controls the outcome of allergic inflammation</style></title><secondary-title><style face="normal" font="Arial">Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Science</style></full-title></periodical><pages end="1021" start="1014">1014-1021</pages><volume><style face="normal" font="Arial">357</style></volume><number><style face="normal" font="Arial">6355</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="Arial">Antigen-presenting cells (APCs) occupy diverse anatomical tissues, but their tissue-restricted homeostasis remains poorly understood. Here, working in mouse models of inflammation, we found that mTOR-dependent metabolic adaptation was required at discrete locations. mTOR was dispensable for DC homeostasis in secondary lymphoid tissues but necessary to regulate cellular metabolism and accumulation of CD103+ DCs and alveolar macrophages in lung. Moreover, while numbers of mTOR-deficient lung CD11b+ DCs were not changed, they were metabolically reprogrammed to skew allergic inflammation from eosinophilic Th2 to neutrophilic Th17 polarity. The mechanism for this change was independent of translational control but dependent on inflammatory DC, which produced IL-23 and increased fatty acid oxidation. mTOR therefore mediates metabolic adaptation of APCs in distinct tissues, influencing the immunological character of allergic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170811IS - 1095-9203 (Electronic)IS - 0036-8075 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1126/science.aaj2155</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28798047">PM:28798047</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Science\20170811-SinclairC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Science\20170811-SinclairC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170811, Sinclair C</style></custom2><misc3><style face="normal" font="Arial">10.1126/science.aaj2155</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Smole,U.</style></author><author><style face="normal" font="Arial"> Schabussova,I.</style></author><author><style face="normal" font="Arial"> Pickl,W.F.</style></author><author><style face="normal" font="Arial"> Wiedermann,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Immunology, Center for Pathophysiology, Infectiology, and Immunology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Murine models for mucosal tolerance in allergy</style></title><secondary-title><style face="normal" font="Arial">Semin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="Arial">Immunity is established by a fine balance to discriminate between self and non-self. In addition, mucosal surfaces have the unique ability to establish and maintain a state of tolerance also against non-self constituents such as those represented by the large numbers of commensals populating mucosal surfaces and food-derived or air-borne antigens. Recent years have seen a dramatic expansion in our understanding of the basic mechanisms and the involved cellular and molecular players orchestrating mucosal tolerance. As a direct outgrowth, promising prophylactic and therapeutic models for mucosal tolerance induction against usually innocuous antigens (derived from food and aeroallergen sources) have been developed. A major theme in the past years was the introduction of improved formulations and novel adjuvants into such allergy vaccines. This review article describes basic mechanisms of mucosal tolerance induction and contrasts the peculiarities but also the interdependence of the gut and respiratory tract associated lymphoid tissues in that context. Particular emphasis is put on delineating the current prophylactic and therapeutic strategies to study and improve mucosal tolerance induction in allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170815IS - 1096-3618 (Electronic)IS - 1044-5323 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.smim.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28807539">PM:28807539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunol\20170815-SmoleU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunol\20170815-SmoleU.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170815, Smole U</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.smim.2017.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Daems,D.</style></author><author><style face="normal" font="Arial"> Peeters,B.</style></author><author><style face="normal" font="Arial"> Delport,F.</style></author><author><style face="normal" font="Arial"> Remans,T.</style></author><author><style face="normal" font="Arial"> Lammertyn,J.</style></author><author><style face="normal" font="Arial"> Spasic,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">KU Leuven-University of Leuven, BIOSYST-MeBioS, Willem de Croylaan 42, B-3001 Leuven, Belgium.</style></auth-address><titles><title><style face="normal" font="Arial">Identification and Quantification of Celery Allergens Using Fiber Optic Surface Plasmon Resonance PCR</style></title><secondary-title><style face="normal" font="Arial">Sensors (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sensors (Basel)</style></full-title></periodical><pages end="" start="E1754">E1754-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Apium graveolens</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bioassay</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Celery</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food quality</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> hybridization</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Mannitol</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality and safety</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface Plasmon Resonance</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="Arial">Accurate identification and quantification of allergens is key in healthcare, biotechnology and food quality and safety. Celery (Apium graveolens) is one of the most important elicitors of food allergic reactions in Europe. Currently, the golden standards to identify, quantify and discriminate celery in a biological sample are immunoassays and two-step molecular detection assays in which quantitative PCR (qPCR) is followed by a high-resolution melting analysis (HRM). In order to provide a DNA-based, rapid and simple detection method suitable for one-step quantification, a fiber optic PCR melting assay (FO-PCR-MA) was developed to determine different concentrations of celery DNA (1 pM-0.1 fM). The presented method is based on the hybridization and melting of DNA-coated gold nanoparticles to the FO sensor surface in the presence of the target gene (mannitol dehydrogenase, Mtd). The concept was not only able to reveal the presence of celery DNA, but also allowed for the cycle-to-cycle quantification of the target sequence through melting analysis. Furthermore, the developed bioassay was benchmarked against qPCR followed by HRM, showing excellent agreement (R(2) = 0.96). In conclusion, this innovative and sensitive diagnostic test could further improve food quality control and thus have a large impact on allergen induced healthcare problems</style></abstract><notes><style face="normal" font="Arial">DA - 20170731IS - 1424-8220 (Electronic)IS - 1424-8220 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.3390/s17081754</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28758965">PM:28758965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sensors (Basel)\2017-17-E1754.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sensors (Basel)\2017-17-E1754.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170731, Daems D</style></custom2><misc3><style face="normal" font="Arial">10.3390/s17081754</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alahi,M.E.E.</style></author><author><style face="normal" font="Arial"> Mukhopadhyay,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Engineering, Macquarie University, Sydney, NSW 2109, Australia.</style></auth-address><titles><title><style face="normal" font="Arial">Detection Methodologies for Pathogen and Toxins: A Review</style></title><secondary-title><style face="normal" font="Arial">Sensors (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sensors (Basel)</style></full-title></periodical><pages end="" start="E1885">E1885-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Beverages</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Fertilizers</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food quality</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Pesticides</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality and safety</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="Arial">Pathogen and toxin-contaminated foods and beverages are a major source of illnesses, even death, and have a significant economic impact worldwide. Human health is always under a potential threat, including from biological warfare, due to these dangerous pathogens. The agricultural and food production chain consists of many steps such as harvesting, handling, processing, packaging, storage, distribution, preparation, and consumption. Each step is susceptible to threats of environmental contamination or failure to safeguard the processes. The production process can be controlled in the food and agricultural sector, where smart sensors can play a major role, ensuring greater food quality and safety by low cost, fast, reliable, and profitable methods of detection. Techniques for the detection of pathogens and toxins may vary in cost, size, and specificity, speed of response, sensitivity, and precision. Smart sensors can detect, analyse and quantify at molecular levels contents of different biological origin and ensure quality of foods against spiking with pesticides, fertilizers, dioxin, modified organisms, anti-nutrients, allergens, drugs and so on. This paper reviews different methodologies to detect pathogens and toxins in foods and beverages</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1424-8220 (Electronic)IS - 1424-8220 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.3390/s17081885</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28813028">PM:28813028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sensors (Basel)\2017-17-E1885.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sensors (Basel)\2017-17-E1885.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Alahi ME</style></custom2><misc3><style face="normal" font="Arial">10.3390/s17081885</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patil,G.</style></author><author><style face="normal" font="Arial"> Mian,R.</style></author><author><style face="normal" font="Arial"> Vuong,T.</style></author><author><style face="normal" font="Arial"> Pantalone,V.</style></author><author><style face="normal" font="Arial"> Song,Q.</style></author><author><style face="normal" font="Arial"> Chen,P.</style></author><author><style face="normal" font="Arial"> Shannon,G.J.</style></author><author><style face="normal" font="Arial"> Carter,T.C.</style></author><author><style face="normal" font="Arial"> Nguyen,H.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Plant Sciences, University of Missouri, Columbia, MO, 65211, USA</style></auth-address><titles><title><style face="normal" font="Arial">Molecular mapping and genomics of soybean seed protein: a review and perspective for the future</style></title><secondary-title><style face="normal" font="Arial">Theor Appl Genet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Theor Appl Genet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Amino acid</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Breeding</style></keyword><keyword><style face="normal" font="Arial"> Chromosomes</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association studies</style></keyword><keyword><style face="normal" font="Arial"> Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Knowledge gaps</style></keyword><keyword><style face="normal" font="Arial"> Livestock</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> Nutritional quality</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Quantitative Trait Loci</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed development</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seed storage</style></keyword><keyword><style face="normal" font="Arial"> Seed storage protein</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Soybean meal</style></keyword><keyword><style face="normal" font="Arial"> Soybean protein</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Sucrose</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="Arial">KEY MESSAGE: Genetic improvement of soybean protein meal is a complex process because of negative correlation with oil, yield, and temperature. This review describes the progress in mapping and genomics, identifies knowledge gaps, and highlights the need of integrated approaches. Meal protein derived from soybean [Glycine max (L) Merr.] seed is the primary source of protein in poultry and livestock feed. Protein is a key factor that determines the nutritional and economical value of soybean. Genetic improvement of soybean seed protein content is highly desirable, and major quantitative trait loci (QTL) for soybean protein have been detected and repeatedly mapped on chromosomes (Chr.) 20 (LG-I), and 15 (LG-E). However, practical breeding progress is challenging because of seed protein content's negative genetic correlation with seed yield, other seed components such as oil and sucrose, and interaction with environmental effects such as temperature during seed development. In this review, we discuss rate-limiting factors related to soybean protein content and nutritional quality, and potential control factors regulating seed storage protein. In addition, we describe advances in next-generation sequencing technologies for precise detection of natural variants and their integration with conventional and high-throughput genotyping technologies. A syntenic analysis of QTL on Chr. 15 and 20 was performed. Finally, we discuss comprehensive approaches for integrating protein and amino acid QTL, genome-wide association studies, whole-genome resequencing, and transcriptome data to accelerate identification of genomic hot spots for allele introgression and soybean meal protein improvement</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1432-2242 (Electronic)IS - 0040-5752 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00122-017-2955-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801731">PM:28801731</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Theor Appl Genet\20170812-PatilG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Theor Appl Genet\20170812-PatilG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Patil G</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00122-017-2955-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ma,T.T.</style></author><author><style face="normal" font="Arial"> Zhuang,Y.</style></author><author><style face="normal" font="Arial"> Gong,H.Y.</style></author><author><style face="normal" font="Arial"> Yii,A.C.</style></author><author><style face="normal" font="Arial"> Wang,X.Y.</style></author><author><style face="normal" font="Arial"> Shi,H.Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Beijing Shijitan Hospital, Capital Medical University</style></auth-address><titles><title><style face="normal" font="Arial">Predictive value of respiratory symptoms for the diagnosis of pollen-induced seasonal asthma among children and adults in Inner Mongolia</style></title><secondary-title><style face="normal" font="Arial">Ther Clin Risk Manag</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ther Clin Risk Manag</style></full-title></periodical><pages end="974" start="967">967-974</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> airflow limitation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Lung function tests</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal asthma</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The diagnosis of asthma is made on the basis of variable respiratory symptoms and supported by objective evidence of variable airflow limitation. However, spirometry and bronchoprovocation tests may not be routinely available in resource-scarce settings or in the context of large-scale epidemiological studies. There is a gap in knowledge about the predictive value of respiratory symptoms for the diagnosis of pollen-induced asthma. OBJECTIVE: The aim of this study was to investigate the predictive value of self-reported respiratory symptoms for diagnosing pollen-induced asthma. PATIENTS AND METHODS: We recruited 1,161 patients with respiratory symptoms who presented to the respiratory medicine outpatient clinic of two central hospitals in Inner Mongolia during the pollen season of July-September 2015. All patients were interviewed by a respiratory physician and completed a questionnaire survey, lung function tests and skin prick tests for common inhaled allergens. RESULTS: A total of 392 patients (33.8%) were diagnosed with asthma and 292 (25.2%, 160 adults, 132 children) with pollen-induced asthma. Respiratory symptoms of cough, wheezing, dyspnea, chest pain and nocturnal awakenings due to breathlessness were all associated with increased odds of being diagnosed with pollen-induced asthma, with cough being the most common symptom in both adults and children, giving a sensitivity of 90.6% in adults and 88.6% in children. Wheezing was the most specific symptom (78% and 89.5% in adults and children, respectively) compared to other symptoms. Overall, the positive predictive value of respiratory symptoms was poor for diagnosing pollen-induced asthma, with the exception of wheezing in children which had a high positive predictive value of 72.7%. CONCLUSION: Cough was the predominant symptom in adults and children with pollen-induced asthma. Wheezing was a reliable predictor of pollen-induced asthma in children. In adults, respiratory symptoms were not sufficiently reliable for diagnosing pollen-induced asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1176-6336 (Print)IS - 1176-6336 (Linking)LA - engPT - Journal ArticleCO - China -CO - Singapore -</style></notes><work-type><style face="normal" font="Arial">10.2147/TCRM.S138355</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28831262">PM:28831262</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ther Clin Risk Manag\2017-13-967-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ther Clin Risk Manag\2017-13-967-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Ma TT</style></custom2><misc3><style face="normal" font="Arial">10.2147/TCRM.S138355</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De-Simone,S.G.</style></author><author><style face="normal" font="Arial"> Souza,A.L.A.</style></author><author><style face="normal" font="Arial"> Aguiar,A.S.</style></author><author><style face="normal" font="Arial"> Melgarejo,A.R.</style></author><author><style face="normal" font="Arial"> Provance,D.W.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">FIOCRUZ, Center of Technological Development in Health (CDTS)/National Institute of Science and Technology for Innovation on Neglected Diseases (INCT-IDN), Rio of Janeiro, RJ, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Development of an elisa for the diagnosis of reactive IgE antibodies anti-therapeutic horse sera</style></title><secondary-title><style face="normal" font="Arial">Toxicon</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicon</style></full-title></periodical><pages end="42" start="37">37-42</pages><volume><style face="normal" font="Arial">138</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgG3</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> patient management</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Population Surveillance</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="Arial">Hypersensitive diseases that involve IgE reactivity are important concern of public, especially those encompassing the potential pathogenesis from the administration of horse serum-based therapeutics such as antivenoms. A method for the definitive diagnosis of reactive IgE is important for identifying allergic patients to control severe collateral effects during planned and emergency application of immunotherapies when the allergy source cannot be avoided for treatment. To date, no tests have been developed to accompany the wide range of antivenoms produced from horse sera. The aim of this was to develop a cost-effective ELISA of high sensitivity and specificity to detect circulating patient IgE that binds horse IgG3, the most prevalent antibody class in passive antibody therapies. Horse IgG3 was purified in a single step on jacalin-Sepharose and absorbed to standard ELISA plates as the capture molecule for reactive human IgE. The direct performance evaluation with allergenic and non-allergenic patient, together with competitive peptides assays, showed high sensitivity and specificity to detect human IgE that recognized horse IgG3. The analytical sensitivity and ED50 were calculated to be 0.01 mug mL-1 and 0.052 mug mL-1, respectively. The intra- and inter-assay coefficient of variation ranged from 3.3 to 11.1% and 4.0-8.0%, respectively. The horse IgG3-based ELISA assay can detect reactive allergenic IgE at picomolar concentrations. The coefficient of variation suggests that it can be easily standardized between laboratories, provide rapid and can be applied to population surveillance. Patient management during treatment for envenomation would be greatly improved by a robust and reliable diagnostic test for preexisting allergies to mitigate life-threating consequences of hypersensitivity</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1879-3150 (Electronic)IS - 0041-0101 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.toxicon.2017.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811248">PM:28811248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicon\2017-138-37-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicon\2017-138-37-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, De-Simone SG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.toxicon.2017.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bazon,M.L.</style></author><author><style face="normal" font="Arial"> Perez-Riverol,A.</style></author><author><style face="normal" font="Arial"> Dos Santos-Pinto,J.R.A.</style></author><author><style face="normal" font="Arial"> Fernandes,L.G.R.</style></author><author><style face="normal" font="Arial"> Lasa,A.M.</style></author><author><style face="normal" font="Arial"> Justo-Jacomini,D.L.</style></author><author><style face="normal" font="Arial"> Palma,M.S.</style></author><author><style face="normal" font="Arial"> Zollner,R.L.</style></author><author><style face="normal" font="Arial"> Brochetto-Braga,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Biologia Molecular de Artropodes-LBMA-IB-RC-UNESP, Univ Estadual Paulista, Av. 24-A, n degrees 1515, Bela Vista, Rio Claro, SP CEP 13506-900, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Heterologous Expression, Purification and Immunoreactivity of the Antigen 5 from Polybia paulista Wasp Venom</style></title><secondary-title><style face="normal" font="Arial">Toxins (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxins (Basel)</style></full-title></periodical><pages end="" start="E259">E259-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Accidents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunodetection</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Ion Exchange</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pichia</style></keyword><keyword><style face="normal" font="Arial"> Poly p 5</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword><keyword><style face="normal" font="Arial"> Wasp Venoms</style></keyword></keywords><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="Arial">Polybia paulista (Hymenoptera: Vespidae) is responsible for a high number of sting accidents and anaphylaxis events in Southeast Brazil, Argentina and Paraguay. The specific detection of allergy to the venom of this wasp is often hampered by the lack of recombinant allergens currently available for molecular diagnosis. Antigen 5 (~23 kDa) from P. paulista venom (Poly p 5) is a highly abundant and glycosylated allergenic protein that could be used for development of component-resolved diagnosis (CRD). Here, we describe the cloning and heterologous expression of the antigen 5 (rPoly p 5) from P. paulista venom using the eukaryotic system Pichia pastoris. The expression as a secreted protein yielded high levels of soluble rPoly p 5. The recombinant allergen was further purified to homogeneity (99%) using a two-step chromatographic procedure. Simultaneously, the native form of the allergen (nPoly p 5) was purified from the wasp venom by Ion exchange chromatography. The rPoly p 5 and nPoly p 5 were then submitted to a comparative analysis of IgE-mediated immunodetection using sera from patients previously diagnosed with sensitization to wasp venoms. Both rPoly p 5 and nPoly p 5 were recognized by specific IgE (sIgE) in the sera of the allergic individuals. The high levels of identity found between nPoly p 5 and rPoly p 5 by the alignment of its primary sequences as well as by 3-D models support the results obtained in the immunoblot. Overall, we showed that P. pastoris is a suitable system for production of soluble rPoly p 5 and that the recombinant allergen represents a potential candidate for molecular diagnosis of P.paulista venom allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170824IS - 2072-6651 (Electronic)IS - 2072-6651 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.3390/toxins9090259</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28837089">PM:28837089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxins (Basel)\2017-9-E259.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxins (Basel)\2017-9-E259.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170824, Bazon ML</style></custom2><misc3><style face="normal" font="Arial">10.3390/toxins9090259</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galli,S.J.</style></author><author><style face="normal" font="Arial"> Starkl,P.</style></author><author><style face="normal" font="Arial"> Marichal,T.</style></author><author><style face="normal" font="Arial"> Tsai,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">STANFORD, CALIFORNIA</style></auth-address><titles><title><style face="normal" font="Arial">Mast Cells and IgE can Enhance Survival During Innate and Acquired Host Responses to Venoms</style></title><secondary-title><style face="normal" font="Arial">Trans Am Clin Climatol Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Trans Am Clin Climatol Assoc</style></full-title></periodical><pages end="221" start="193">193-221</pages><volume><style face="normal" font="Arial">128</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Snakes</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Mast cells and immunoglobulin E (IgE) antibodies are thought to promote health by contributing to host responses to certain parasites, but other beneficial functions have remained obscure. Venoms provoke innate inflammatory responses and pathology reflecting the activities of the contained toxins. Venoms also can induce allergic sensitization and development of venom-specific IgE antibodies, which can predispose some subjects to exhibit anaphylaxis upon subsequent exposure to the relevant venom. We found that innate functions of mast cells, including degradation of venom toxins by mast cell-derived proteases, enhanced survival in mice injected with venoms from the honeybee, two species of scorpion, three species of poisonous snakes, or the Gila monster. We also found that mice injected with sub-lethal amounts of honeybee or Russell's viper venom exhibited enhanced survival after subsequent challenge with potentially lethal amounts of that venom, and that IgE antibodies, FcepsilonRI, and probably mast cells contributed to such acquired resistance</style></abstract><notes><style face="normal" font="Arial">DA - 20170809IS - 0065-7778 (Print)IS - 0065-7778 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28790503">PM:28790503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trans Am Clin Climatol Assoc\2017-128-193-221.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trans Am Clin Climatol Assoc\2017-128-193-221.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170809, Galli SJ</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oray,N.C.</style></author><author><style face="normal" font="Arial"> Bayram,B.</style></author><author><style face="normal" font="Arial"> Altintas,E.</style></author><author><style face="normal" font="Arial"> Sivrikaya,S.</style></author><author><style face="normal" font="Arial"> Savran,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Severe allergic reaction to human insulin in the patient with diabetic ketoacidosis</style></title><secondary-title><style face="normal" font="Arial">Turk J Emerg Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Turk J Emerg Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Diabetic ketoacidosis</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Insulin aspart</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regular insulin</style></keyword><keyword><style face="normal" font="Arial"> Resuscitation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2452-2473</style></isbn><abstract><style face="normal" font="Arial">Diabetic ketoacidosis (DKA) is an acute and major life-threatening complication of diabetes mellitus. Fluid resuscitation, insulin therapy, and electrolyte replacement are essential for DKA treatment. Rarely, life threatening allergic reactions might develop in a patient treated with insulin. If anaphylaxis develops after insulin, the DKA treatment options are restricted. A limited number of case reports have been reported in patients with severe anaphylactic reactions to human insulin who were then treated with synthetic insulin analogues. We present a case of a 45-year-old male patient with allergic reactions to human insulin. The patient was successfully treated with insulin aspart and hemodialysis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tjem.2017.07.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.tjem.2017.07.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Turk J Emerg Med\20170823-OrayNC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Turk J Emerg Med\20170823-OrayNC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Oray NC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tjem.2017.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sehgal,N.</style></author><author><style face="normal" font="Arial"> Priyadarshi,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Radiology, The Mission Hospital, Durgapur, West Bengal, IndiaDepartment of Urology, The Mission Hospital, Durgapur, West Bengal, India</style></auth-address><titles><title><style face="normal" font="Arial">Beware! A simple renal cyst could be a hydatid cyst</style></title><secondary-title><style face="normal" font="Arial">Urol Ann</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Urol Ann</style></abbr-1></periodical><pages end="284" start="281">281-284</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Cysts</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kidney</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> surgical treatment</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urology</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Kidney is one of the most common sites for the cyst formation in the body, and the management of simple cysts is required entirely for its symptoms and complications. Surgical decortication is an established treatment for a large and symptomatic simple renal cyst. On the other hand, hydatid cysts of the kidney are usually multiloculated complex or calcified cysts and are quite rare. Their surgical treatment also differs and requires complete excision with pericystectomy or partial/complete nephrectomy depending upon residual functional parenchyma, using extreme caution to avoid spillage, recurrence or development of severe anaphylactic shock. A simple cyst harboring a hydatid cyst is highly uncommon and quite dangerous; as if not diagnosed preoperatively, it can create huge trouble for both the patient and the operating surgeon which happened in the present case</style></abstract><notes><style face="normal" font="Arial">DA - 20170810IS - 0974-7796 (Print)IS - 0974-7796 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/0974-7796.210028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28794599">PM:28794599</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Urol Ann\2017-9-281-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Urol Ann\2017-9-281-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170810, Sehgal N</style></custom2><misc3><style face="normal" font="Arial">10.4103/0974-7796.210028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schlaud,M.</style></author><author><style face="normal" font="Arial"> Schmitz,R.</style></author><author><style face="normal" font="Arial"> Poethko-Muller,C.</style></author><author><style face="normal" font="Arial"> Kuhnert,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Robert Koch Institute, Dept. of Epidemiology and Health Monitoring, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Vaccinations in the first year of life and risk of atopic disease - Results from the KiGGS study</style></title><secondary-title><style face="normal" font="Arial">Vaccine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vaccine</style></full-title></periodical><pages end="5162" start="5156">5156-5162</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">38</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunisation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The study focused on the question of whether and - if so - to what direction and extent immunisations in the 1st year may be associated with the risk of being diagnosed with atopic diseases after the 1st year of life. METHODS: Data from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS, 2003-2006) were analysed. For analyses of potential associations between vaccination status and risk of hay fever, atopic dermatitis or asthma, sample sizes of 15254, 14297, and 15262, respectively, were available. RESULTS: Children with a sufficient TDPHiHeP vaccination at the end of the 1st year of life had a lower risk of being diagnosed with hay fever after the 1st year of life (adjusted prevalence ratio 0.85, 95% confidence interval 0.76-0.96). Analyses for associations between TDPHiHeP vaccination and risk of atopic dermatitis or asthma, or between age at onset of vaccination or of the number of antigens vaccinated in the 1st year of life and risk of atopic disease failed to yield statistical significance. CONCLUSIONS: Our results provide no evidence that immunisations in the 1st year of life may increase the risk of atopic disease. If any association exists at all, our results may be interpreted as weakly supportive of the hypothesis that immunisations may slightly decrease the risk of atopy in later life</style></abstract><notes><style face="normal" font="Arial">DA - 20170812IS - 1873-2518 (Electronic)IS - 0264-410X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.vaccine.2017.07.111</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801155">PM:28801155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vaccine\20170812-SchlaudM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vaccine\20170812-SchlaudM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170812, Schlaud M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.vaccine.2017.07.111</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marshall,S.</style></author><author><style face="normal" font="Arial"> Fleming,A.</style></author><author><style face="normal" font="Arial"> Moore,A.C.</style></author><author><style face="normal" font="Arial"> Sahm,L.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Pharmacy, University College Cork, Cork, Ireland.</style></auth-address><titles><title><style face="normal" font="Arial">Acceptability of microneedle-patch vaccines: A qualitative analysis of the opinions of parents</style></title><secondary-title><style face="normal" font="Arial">Vaccine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vaccine</style></full-title></periodical><pages end="4904" start="4896">4896-4904</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">37</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> acceptance</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Decision Making</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> Focus Groups</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary schools</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Design</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Vaccines incorporated into microneedle-based patch platforms offer advantages over conventional hypodermic injections. However, the success and clinical utility of these platforms will depend on its acceptance among stakeholders. Minimal focus has been placed on determining parents' acceptability of microneedle-patch vaccines intended for paediatric use. This qualitative study probes the perceived acceptability of microneedle technology for paediatric vaccination in a parent population. RESEARCH DESIGN AND METHODOLOGY: Focus groups (n=6) were convened through purposive sampling of Cork city primary schools. Discussions were audio-recorded, transcribed verbatim, anonymised, independently verified and analysed by thematic analysis, with constant comparison method applied throughout. RESULTS: The opinions of 32 parents were included. All participants declared that their children were fully vaccinated. Five core themes were identified and defined as: (i) concern, (ii) suitability for paediatric use, (iii) potential for parental administration, (iv) the role of the healthcare professional and (v) special populations. Drivers for acceptance include; concerns with current vaccines and vaccination programmes; attributes of microneedle-patch (reduced pain, bleeding, fear and increased convenience) and endorsement by a healthcare professional. Barriers to acceptance include; lack of familiarity, concerns regarding feasibility and suitability in paediatrics, allergic potential, inability to confirm delivery and potential reduction in vaccine coverage. CONCLUSION: This is the first study to explore parental acceptance of microneedle-patch vaccines. Capturing the opinions of parents, the ultimate decision makers in paediatric vaccination, is crucial in the understanding of the eventual uptake of microneedle technology and therefore adds to literature currently available. This study has revealed that even "vaccine-acceptors"; parents who agree with, or do not question vaccination, will question the safety and efficacy of this novel method. Participants in this study remained tentative. However, the study has also revealed that endorsement by healthcare professionals could reduce this tentativeness, thereby identifying the role of healthcare professionals in disseminating information and providing support to parents. An increased awareness of developments in microneedle technology is needed to permit informed decision-making by parents</style></abstract><notes><style face="normal" font="Arial">DA - 20170806IS - 1873-2518 (Electronic)IS - 0264-410X (Linking)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.vaccine.2017.07.083</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780122">PM:28780122</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vaccine\20170806-MarshallS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vaccine\20170806-MarshallS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170806, Marshall S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.vaccine.2017.07.083</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roitel,O.</style></author><author><style face="normal" font="Arial"> Bonnard,L.</style></author><author><style face="normal" font="Arial"> Stella,A.</style></author><author><style face="normal" font="Arial"> Schiltz,O.</style></author><author><style face="normal" font="Arial"> Maurice,D.</style></author><author><style face="normal" font="Arial"> Douchin,G.</style></author><author><style face="normal" font="Arial"> Jacquenet,S.</style></author><author><style face="normal" font="Arial"> Favrot,C.</style></author><author><style face="normal" font="Arial"> Bihain,B.E.</style></author><author><style face="normal" font="Arial"> Couturier,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genclis SA, 15 rue du Bois de la Champelle, Vandoeuvre-les-Nancy, 54500, France</style></auth-address><titles><title><style face="normal" font="Arial">Detection of IgE-reactive proteins in hydrolysed dog foods</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Glutelin</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> IgE-immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Commercial hydrolysed diets are used for the diagnosis of food allergy in dogs. The cleaved parent proteins are presumed to be too small to elicit an allergic response by reacting with allergen-specific immunoglobin E (IgE). OBJECTIVES: To evaluate three commercial hydrolysed dog diets for proteins. ANIMALS: Sera were collected from dogs with suspected food allergy. METHODS: Two batches of each hydrolysed diet were examined by electrophoresis and visualized by Coomassie blue, silver nitrate staining and IgE immunoblotting. RESULTS: From two to five proteins, ranging from 21 to 67 kDa, were detected in all three diets evaluated. Circulating IgE antibodies targeting these proteins were detected by immunoblotting of dog sera. Six different carbohydrate proteins were identified by mass spectrometry; maize/potato granule-bound starch synthase-1, soybean glycinin, soybean beta-conglycinin alpha chain, potato aspartic protease inhibitor, rice glutelin type B1 and soybean sucrose-binding protein. Four of these proteins have been described as allergens in humans. CONCLUSIONS: Some commercial hydrolysed diets contain carbohydrate proteins. Some dogs have circulating IgE antibodies targeting these proteins. The clinical significance of these findings is unknown</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - France -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12473</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28770578">PM:28770578</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170803-RoitelO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170803-RoitelO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Roitel O</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12473</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawano,K.</style></author><author><style face="normal" font="Arial"> Mizuno,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Primo Animal Hospital Tokyo Animal Allergy Medical Center (AAMC), 1-28-7 Shakujiimachi, Nerima-Ku, Tokyo, 177-0041, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> canine atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Der f 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Dermatophagoides farinae is a major and common environmental house dust mite involved in canine atopic dermatitis (CAD). A formulation of recombinant protein Der f 2 is available in Japan for immunotherapy in dogs. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy of a recombinant allergen based on Der f 2-pullulan for the treatment of cAD. METHODS: Dogs (n = 15) with atopic dermatitis were administered Der f 2 conjugated with pullulan (-P). Two dogs were eliminated because of death unrelated to the treatment during the study. The remaining 13 cases were included in the analysis. Clinical signs were evaluated with the Canine Atopic Dermatitis Lesion Index (CADLI) and pruritus levels were evaluated from 0 to 10 with a pruritus Visual Analog Scale (PVAS). RESULTS: The mean +/- standard deviation (SD) of CADLI [before allergen-specific immunotherapy (pre-ASIT) 21.9 +/- 9.7; 60 days post-ASIT 9.8 +/- 8.4 and 120 days post-ASIT 9.7 +/- 8.2] and the mean +/- SD of PVAS [pre-ASIT 7.2 +/- 1.2; post-ASIT (60 days) 2.6 +/- 2.2 and post-ASIT (120 days) 3.1 +/- 2.5] significantly decreased after treatment (Dunnett's test, P &lt; 0.05). Furthermore, the total doses of oral glucocorticoids in the two months pre-ASIT significantly decreased in comparison with two months post-ASIT (123 +/- 72.6 mg vs. 70.0 +/- 84.3 mg; Dunnett's test, P &lt; 0.05). CONCLUSIONS AND CLINICAL IMPORTANCE: The results indicate the effectiveness of Der f 2-P recombinant protein in the treatment of dogs with CAD and testing positive to D. farinae</style></abstract><notes><style face="normal" font="Arial">DA - 20170804IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12470</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28776792">PM:28776792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170804-KawanoK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170804-KawanoK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170804, Kawano K</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12470</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grigoryan,G.</style></author><author><style face="normal" font="Arial"> Weinman,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">"My face is swollen.": A case report of a woman with superior vena cava syndrome presenting as an allergic reaction</style></title><secondary-title><style face="normal" font="Arial">Visual J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Visual J Emerg Med</style></full-title></periodical><pages end="62" start="61">61-62</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Superior vena vaca syndrome</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2405-4690</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.visj.2017.06.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.visj.2017.06.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Visual J Emerg Med\2017-9-61-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Visual J Emerg Med\2017-9-61-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Grigoryan G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.visj.2017.06.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamamoto-Hanada,K.</style></author><author><style face="normal" font="Arial"> Yang,L.</style></author><author><style face="normal" font="Arial"> Ishitsuka,K.</style></author><author><style face="normal" font="Arial"> Ayabe,T.</style></author><author><style face="normal" font="Arial"> Mezawa,H.</style></author><author><style face="normal" font="Arial"> Konishi,M.</style></author><author><style face="normal" font="Arial"> Shoda,T.</style></author><author><style face="normal" font="Arial"> Matsumoto,K.</style></author><author><style face="normal" font="Arial"> Saito,H.</style></author><author><style face="normal" font="Arial"> Ohya,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Support Center for the Japan Environment and Children's Study, National Center for Child Health and Development, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Allergic profiles of mothers and fathers in the Japan Environment and Children's Study (JECS): a nationwide birth cohort study</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="24">24-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antigen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fathers</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> First trimester</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> paternal</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Self-administered questionnaire</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The Japan Environment and Children's Study (JECS) is a nationwide, multicenter, prospective birth cohort investigation launched by the Ministry of Environment in Japan. The purpose of the JECS is to evaluate the influence of prenatal and postnatal exposures to environmental factors on the postnatal health of the children. In this study, we evaluated the allergic characteristics of parents within the JECS cohort. METHODS: This study covered a wide geographical area and encompassed 15 regional centers. We obtained information regarding doctor diagnosed allergic diseases by using maternal and/or paternal self-administered questionnaires during the first trimester of pregnancy. Blood samples were also obtained from mothers and/or fathers to detect serum IgE concentrations. RESULTS: The prevalences of asthma, allergic rhinitis (hay fever), atopic dermatitis, and food allergy were 10.9, 36.0, 15.7 and 4.8%, respectively, among 99,013 mothers; these prevalences among 49,991 fathers were 10.8, 30.3, 11.2 and 3.3%, respectively. Any positive antigen-specific IgE sensitization was found in 73.9% of mothers. The most abundant antigen sensitization in mothers was to Japanese cedar (55.6%), followed by Der p 1 (48%); only 1.0% of mothers were sensitized to egg white. CONCLUSIONS: This is the first epidemiological report on allergic disorders and allergen sensitization of parents during pregnancy among the Japanese general population</style></abstract><notes><style face="normal" font="Arial">DA - 20170816IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0157-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811862">PM:28811862</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170816, Yamamoto-Hanada K</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0157-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamashiro,K.</style></author><author><style face="normal" font="Arial"> Ogata,F.</style></author><author><style face="normal" font="Arial"> Kawasaki,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health, Faculty of Pharmacy, Kindai University</style></auth-address><titles><title><style face="normal" font="Arial">Relationship between Hay Fever and Mineral Concentration in the Hair, Lifestyle or Aging</style></title><secondary-title><style face="normal" font="Arial">Yakugaku Zasshi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Yakugaku Zasshi</style></full-title></periodical><pages end="1040" start="1035">1035-1040</pages><volume><style face="normal" font="Arial">137</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Cadmium</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Chromium</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Minerals</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Selenium</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">It is important to ingest just proportions of minerals to prevent disease, but these minerals are also secreted into the hair. Meanwhile, the number of hay fever patients in Japan is increasing, causing an increase in national medical expenses. In this study, we investigated the relationship between hay fever and mineral concentrations in hair to obtain findings on the risk of developing pollen allergies. A questionnaire survey was conducted for 275 men and 977 women on their lifestyle habits and ten kinds of mineral concentrations present in their hair were measured with subsequent analysis using nominal logistic regression analysis. The results indicated that half the patients in each age group had hay fever, with no significant difference between hay fever and aging, exercise habits, sleep and dietary rhythms. On the other hand, there was a significant difference between hay fever and mineral concentrations in the hair, and in men with hay fever, iron (odds ratio: 0.55, p&lt;0.05) was low, while in women calcium (odds ratio: 0.67, p&lt;0.05), chromium (odds ratio: 0.46, p&lt;0.001), cadmium (odds ratio: 0.68, p&lt;0.01) were low and selenium (odds ratio: 1.78, p&lt;0.01) was high. These results, suggest that measurements mineral concentrations in hair are indicators of hay fever risk</style></abstract><notes><style face="normal" font="Arial">DA - 20170803IS - 1347-5231 (Electronic)IS - 0031-6903 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1248/yakushi.17-00078</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28768942">PM:28768942</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yakugaku Zasshi\2017-137-1035-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yakugaku Zasshi\2017-137-1035-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170803, Yamashiro K</style></custom2><misc3><style face="normal" font="Arial">10.1248/yakushi.17-00078</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leontidou,K.</style></author><author><style face="normal" font="Arial"> Vernesi,C.</style></author><author><style face="normal" font="Arial"> De Groeve,J.</style></author><author><style face="normal" font="Arial"> Cristofolini,F.</style></author><author><style face="normal" font="Arial"> Vokou,D.</style></author><author><style face="normal" font="Arial"> Cristofori,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">DNA metabarcoding of airborne pollen: new protocols for improved taxonomic identification of environmental samples</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Chloroplast DNA</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA extraction</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Metabarcoding is a promising DNA-based method for identifying airborne pollen from environmental samples with advantages over microscopic methods. Sample preparation and DNA extraction are of fundamental importance for obtaining an optimal DNA yield. Currently, there is no standard procedure for these steps, especially for gravimetric pollen samplers. Therefore, the aim of this study was to develop protocols for processing environmental samples for pollen DNA extraction and for metabarcoding analysis and to assess the efficacy of these protocols for the taxonomic assignment of airborne pollen collected by gravimetric (Tauber trap) and volumetric (Hirst-type trap) samplers. Protocols were tested across an increasing complexity of samples, from pure single-species pollen to environmental multi-species samples. A short fragment (about 150 base pairs) of the chloroplast trnL gene was amplified using universal primers for plants. After PCR amplification, amplicons were Sanger-sequenced and taxonomic assignment was accomplished by comparison with a custom-made reference database including chloroplast DNA sequences from most of the anemophilous taxa occurring in the study area (Trentino, northern Italy), representing 46 plant families. Using the classical morphological pollen analysis as a benchmark, we show that DNA metabarcoding is efficient and applicable even in complex samples, provided that protocols for sample preparation, DNA extraction, and metabarcoding analysis are carefully optimized</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -CO - Grrece -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9497-z</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10453-017-9497-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20170904-LeontidouK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20170904-LeontidouK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Leontidou K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9497-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">West,C.E.</style></author><author><style face="normal" font="Arial"> Dzidic,M.</style></author><author><style face="normal" font="Arial"> Prescott,S.L.</style></author><author><style face="normal" font="Arial"> Jenmalm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Sciences, Pediatrics, Umea University, Umea, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Bugging allergy; role of pre-, pro- and synbiotics in allergy prevention</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> allergy risk</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Biodiversity</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune development</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Social Behavior</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> synbiotics</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">Large-scale biodiversity loss and complex changes in social behaviors are altering human microbial ecology. This is increasingly implicated in the global rise in inflammatory diseases, most notably the "allergy epidemic" in very early life. Colonization of human ecological niches, particularly the gastrointestinal tract, is critical for normal local and systemic immune development and regulation. Disturbances in composition, diversity and timing of microbial colonization have been associated with increased allergy risk, indicating the importance of strategies to restore a dysbiotic gut microbiota in the primary prevention of allergic diseases, including the administration of probiotics, prebiotics and synbiotics. Here, we summarize and discuss findings of randomized clinical trials that have examined the effects of these microbiome-related strategies on short and long-term allergy preventative effects - including new guidelines from the World Allergy Organization which now recommend probiotics and prebiotics for allergy prevention under certain conditions. The relatively low quality evidence, limited comparative studies and large heterogeneity between studies, have collectively hampered recommendations on specific probiotic strains, specific timing and specific conditions for the most effective preventive management. At the same time the risk of using available products is low. While further research is needed before specific practice guidelines on supplement probiotics and prebiotics, it is equally important that the underlying dietary and lifestyle factors of dysbiosis are addressed at both the individual and societal levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170903IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Sweden -CO - Spain -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865967">PM:28865967</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170903-WestCE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170903-WestCE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, West CE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Burguete-Cabanas,M.T.</style></author><author><style face="normal" font="Arial"> Fajardo-Ramirez,O.R.</style></author><author><style face="normal" font="Arial"> Yesaki,R.</style></author><author><style face="normal" font="Arial"> Estrada-Maganas,R.</style></author><author><style face="normal" font="Arial"> Salazar-Meza,S.</style></author><author><style face="normal" font="Arial"> Rios-Chavez,O.</style></author><author><style face="normal" font="Arial"> Meester,I.</style></author><author><style face="normal" font="Arial"> Salas-Alanis,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Tecnologico de Monterrey, Centro Medico Zambrano Hellion, San Pedro Garza Garcia, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab for hypersensitive reaction to seminal plasma: A case report</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Case Report</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170819IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO- Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.07.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28821383">PM:28821383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170819-BurgueteCabanasMT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170819-BurgueteCabanasMT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170819, Burguete-Cabanas MT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.07.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Minami,T.</style></author><author><style face="normal" font="Arial"> Fukutomi,Y.</style></author><author><style face="normal" font="Arial"> Sekiya,K.</style></author><author><style face="normal" font="Arial"> Akasawa,A.</style></author><author><style face="normal" font="Arial"> Taniguchi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Hand eczema as a risk factor for food allergy among occupational kitchen workers</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An increasing number of studies in children is highlighting the importance of transdermal routes of exposure to food allergens through damaged skin in the pathogenesis of food allergies. However, data on this in adults are limited. A few case-series studies has documented development of food allergy among kitchen workers with hand eczema after direct contact exposure to foods. METHODS: To explore the significance of hand eczema as a risk factor for food allergies in adults at the epidemiological level, we performed a cross-sectional web-based questionnaire survey on kitchen workers whose exposures were classed as occupational (cooks and food handlers, n = 1592) or non-occupational (housewives, n = 1915). Logistic regression was used to explore the association between the presence/severity of hand eczema and the risk of food allergy after adjustment for potential confounders. RESULTS: Current hand eczema and current diagnosed food allergy were more common among occupational kitchen workers (OKW) than among non-occupational kitchen workers (NOKW) (32.3%-vs-29.9% and 9.9%-vs-3.8%, respectively). Current hand eczema was significantly associated with increased risk of current diagnosed food allergy in OKW (adjusted odds ratio 2.4, 95% CI 1.6-3.7). Those with more severe hand eczema were more likely to suffer from allergic symptoms for foods, and diagnosed food allergy. CONCLUSIONS: This study illustrates a significant public health problem in the adult population, documenting a major impact of hand eczema on the ongoing adult food allergy epidemic</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28874315">PM:28874315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170906-MinamiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170906-MinamiT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Minami T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Koh,H.Y.</style></author><author><style face="normal" font="Arial"> Cho,E.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,W.K.</style></author><author><style face="normal" font="Arial"> Park,Y.M.</style></author><author><style face="normal" font="Arial"> Kim,J.</style></author><author><style face="normal" font="Arial"> Ahn,K.</style></author><author><style face="normal" font="Arial"> Lee,S.W.</style></author><author><style face="normal" font="Arial"> Kim,M.A.</style></author><author><style face="normal" font="Arial"> Hahm,M.I.</style></author><author><style face="normal" font="Arial"> Chae,Y.</style></author><author><style face="normal" font="Arial"> Lee,K.J.</style></author><author><style face="normal" font="Arial"> Kwon,H.J.</style></author><author><style face="normal" font="Arial"> Han,M.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CHA University School of Medicine, Seongnam, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Exposure amount and timing of solar irradiation during pregnancy and the risk of sensitization in children</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> irradiation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Maternal Exposure</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Solar irradiation affects sensitization to aeroallergens and the prevalence of allergic diseases. Little is known, however, about how the time and amount of solar irradiation during pregnancy affects such risks in children. We aimed to find out how solar irradiation during pregnancy affects sensitization to aero-allergens and the prevalence of allergic diseases in children. METHODS: This population-based cross-sectional study involved 7301 aged 6 years and aged 12 years children. Maternal exposure to solar irradiation during pregnancy was evaluated using data from weather stations closest to each child's birthplace. Monthly average solar irradiation during the second and third trimesters was calculated with rank by quartiles. Risks of allergic sensitization and allergic disease were estimated. RESULTS: Relative to the first (lowest) quartile, the adjusted odds ratio (aOR) for allergic sensitization in the fourth (highest) quartile was lowest within solar irradiation during pregnancy months 5-6 (aOR = 0.823, 95% CI 0.720-0.942, p &lt; 0.05). During months 9-10, the aOR for allergic sensitization for the fourth was higher than the first quartile of solar irradiation (aOR = 1.167, 95% CI 1.022-1.333, p &lt; 0.05). Similar results were observed when solar irradiation was analyzed as a continuous variable during months 5 (aOR = 0.975, 95% CI 0.962-0.989, p &lt; 0.001) and month 9 (aOR = 1.018, 95% CI 1.004-1.031, p = 0.003). Increased solar irradiation during months 7-8 increased the risk of asthma (aOR = 1.309, 95% CI 1.024-1.674, p = 0.032). CONCLUSIONS: Maternal exposure to solar irradiation during the second trimester of pregnancy associated with reduced aeroallergen sensitization, whereas solar irradiation during the third trimester was related to increased sensitization to aeroallergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28882557">PM:28882557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170908-KohHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170908-KohHY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Koh HY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Omokawa,A.</style></author><author><style face="normal" font="Arial"> Ueki,S.</style></author><author><style face="normal" font="Arial"> Kikuchi,Y.</style></author><author><style face="normal" font="Arial"> Takeda,M.</style></author><author><style face="normal" font="Arial"> Asano,M.</style></author><author><style face="normal" font="Arial"> Sato,K.</style></author><author><style face="normal" font="Arial"> Sano,M.</style></author><author><style face="normal" font="Arial"> Ito,H.</style></author><author><style face="normal" font="Arial"> Hirokawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Mucus plugging in allergic bronchopulmonary aspergillosis: Implication of the eosinophil DNA traps</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical laboratory</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170909IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886913">PM:28886913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170909-OmokawaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170909-OmokawaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170909, Omokawa A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,X.</style></author><author><style face="normal" font="Arial"> Kanegasaki,S.</style></author><author><style face="normal" font="Arial"> Jin,F.</style></author><author><style face="normal" font="Arial"> Deng,Y.</style></author><author><style face="normal" font="Arial"> Kim,J.R.</style></author><author><style face="normal" font="Arial"> Chang,H.W.</style></author><author><style face="normal" font="Arial"> Tsuchiya,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy, Yeungnam University, 280 Daehak-ro, Gyeongsan, Gyeongbuk, 712-749, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Simultaneous induction of HSP70 expression, and degranulation, in IgE/Ag-stimulated or extracellular HSP70-stimulated mast cells (129/200)</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Eicosanoids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lyn</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> spleen tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In mast cells, induction of HSP70 expression during antigen stimulation has not been reported. METHODS: Mouse bone marrow derived mast cells (BMMC) were stimulated with IgE/Ag or HSP70. Induction of HSP70 expression, and signaling protein phosphorylation, were evaluated by immunoblotting. RESULTS: HSP70 expression is induced in BMMC at an early stage of IgE/Ag-dependent stimulation, some of which is released from the cells in a granule-associated form. Induction of HSP70 expression was also observed with an IgE/Ag-stimulated human basophilic cell line, indicating that the phenomenon is not restricted to mouse BMMC. The induction of HSP70 expression, and its release, followed a similar time course to that of degranulation. Released HSP70 seems to be responsible for degranulation and production of eicosanoids, at least in part, since a neutralizing anti-HSP70 antibody mitigated these activities, and since exogenous HSP70 not only induced immediate degranulation followed by autocrine HSP70 expression but also enhanced degranulation in IgE/Ag stimulated BMMC. Extracellular HSP70 was found to induce phosphorylation of Linker for activation of T cells (LAT) and a series of downstream signaling molecules in BMMC. We further found that Fyn, Lyn and spleen tyrosine kinase (Syk), which are known to concern LAT phosphorylation in IgE/Ag stimulated BMMC, were not phosphorylated in HSP70-stimulated BMMC, whereas lymphocyte-specific-protein tyrosine kinase (Lck) was phosphorylated. CONCLUSION: FcepsilonRI stimulation in BMMC and basophils induces HSP70 expression and its release. Extracellular HSP70 induces degranulation and mediator release via phosphorylation of LAT. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13296</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28857181">PM:28857181</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170831-LiX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170831-LiX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Li X</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13296</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ryan,D.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Angier,E.</style></author><author><style face="normal" font="Arial"> Kristiansen,M.</style></author><author><style face="normal" font="Arial"> Zaman,H.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author><author><style face="normal" font="Arial"> Vidal,C.</style></author><author><style face="normal" font="Arial"> Warner,A.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Halken,S.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Pajno,G.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Sturm,G.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Medical School Doorway 3, Teviot Place Edinburgh, EH8 9AG, UK</style></auth-address><titles><title><style face="normal" font="Arial">Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Management</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The European Academy of Allergy and Clinical Immunology (EAACI) has produced Guidelines on Allergen Immunotherapy (AIT). We sought to gauge the preparedness of primary care to participate in the delivery of AIT in Europe. METHODS: We undertook a mixed-methods, situational analysis. This involved a purposeful literature search, and two surveys: one to primary care clinicians and the other to a wider group of stakeholders across Europe. RESULTS: The 10 papers identified all pointed out gaps or deficiencies in allergy care provision in primary care. The surveys also highlighted similar concerns, particularly in relation to concerns about lack of knowledge, skills, infrastructural weaknesses, reimbursement policies and communication with specialists as barriers to evidence-based care. Almost all countries (92%) reported the availability of AIT. In spite of that, only 28% and 44% of the countries reported the availability of guidelines for primary care physicians and specialists, respectively. Agreed pathways between specialists and primary care physicians were reported as existing in 32-48% of countries. Reimbursement appeared to be an important barrier as AIT was only fully reimbursed in 32% of countries. Additionally, 44% of respondents considered accessibility to AIT and 36% stating patient costs were barriers. CONCLUSIONS: Successful working with primary care providers is essential to scaling-up AIT provision in Europe, but to achieve this the identified barriers must be overcome. Development of primary care interpretation of guidelines to aid patient selection, establishment of disease management pathways and collaboration with specialist groups are required as a matter of urgency. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13264CO - United Kingdom -CO - Netherlands -CO - Denmark -CO - Spain -CO - Romania -CO - Italy -CO - Germany -CO - Austria -</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850687">PM:28850687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170829-RyanD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170829-RyanD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Ryan D</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13264CO - United Kingdom -CO - Netherlands -CO - Denmark -CO - Spain -CO - Romania -CO - Italy -CO - Germany -CO - Austria -</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rondon,C.</style></author><author><style face="normal" font="Arial"> Campo,P.</style></author><author><style face="normal" font="Arial"> Eguiluz,G.I.</style></author><author><style face="normal" font="Arial"> Plaza,C.</style></author><author><style face="normal" font="Arial"> Bogas,G.</style></author><author><style face="normal" font="Arial"> Galindo,P.</style></author><author><style face="normal" font="Arial"> Mayorga,C.</style></author><author><style face="normal" font="Arial"> Torres,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Local allergic rhinitis is an independent rhinitis phenotype: The results of a 10-years follow-up study</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> allergen provocation test</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Local allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen provocation</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen provocation test</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick-test</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The knowledge about the natural history of local allergic rhinitis (LAR) is limited. One unmeet question is to demonstrate whether LAR should be considered the first step in the development of allergic rhinitis (AR) or an independent phenotype. The aim of this study was to prospectively evaluate the natural history of a population with LAR, the potential conversion to AR with systemic atopy, and the development of asthma during 10 years. METHODS: This is the second phase of a 10 year follow-up study of a cohort of 176 patients with LAR of recent onset and 115 age- and sex-matched healthy controls prospectively evaluated from 2005 to 2016. Clinical-demographic questionnaire, spirometry, skin prick-test, and specific-IgE were evaluated yearly. Nasal allergen provocation tests (NAPT) with D. pteronyssinus, Alternaria alternata, Olea europaea, and grass pollen were performed at baseline, and after 5 and 10 years. RESULTS: After 10 years LAR patients experienced a significant and clinically relevant worsening of the rhinitis, with increase of emergency assistance, development of asthma, loss of allergen tolerance, and impairment of the quality of life. This worsening became significant after 5 years and progressed throughout 10 years. A similar rate of development of AR with systemic atopy was detected in patients and controls (9.7% vs 7.8%, Log-rank p=0.623). In 5 patients conversion to systemic atopy occurred >10 years (3%). CONCLUSIONS: LAR is a well-differentiated clinical entity with a low rate of development of systemic atopy, a natural evolution towards worsening and a risk factor for suffering asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13272</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833265">PM:28833265</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170823-RondonC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170823-RondonC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Rondon C</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13272</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Trendelenburg,V.</style></author><author><style face="normal" font="Arial"> Tschirner,S.</style></author><author><style face="normal" font="Arial"> Niggemann,B.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pneumology and Immunology, Charite Universitatsmedizin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Hen's egg allergen in house and bed dust is significantly increased after hen's egg consumption - a pilot study</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><abstract><style face="normal" font="Arial">Environmental exposure to food allergens may be a risk factor for cutaneous sensitization. Previous studies could detect peanut allergen in house dust. In this pilot study, we wanted to investigate whether hen's egg allergen is detectable in house dust collected from different household areas and whether levels are increased after intentional hen's egg consumption. Hen's egg protein levels of dust samples were measured using ELISA. In 8/8 households, hen's egg was detectable in dust samples of eating area and bed. 48 hours after intentional hen's egg consumption, hen's egg protein levels were significantly increased in both. Still, further research is necessary to investigate whether hen's egg allergen in house and bed dust plays a role in sensitization via skin. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170902IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13303</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865141">PM:28865141</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170902-TrendelenburgV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170902-TrendelenburgV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Trendelenburg V</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13303</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Casale,T.B.</style></author><author><style face="normal" font="Arial"> Chipps,B.E.</style></author><author><style face="normal" font="Arial"> Rosen,K.</style></author><author><style face="normal" font="Arial"> Trzaskoma,B.</style></author><author><style face="normal" font="Arial"> Haselkorn,T.</style></author><author><style face="normal" font="Arial"> Omachi,T.A.</style></author><author><style face="normal" font="Arial"> Greenberg,S.</style></author><author><style face="normal" font="Arial"> Hanania,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, University of South Florida, Tampa, Florida</style></auth-address><titles><title><style face="normal" font="Arial">Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthma hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Beclomethasone</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficacy study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recent efficacy studies of asthma biologics have included highly enriched patient populations. Using a similar approach, we examined factors that predict response to omalizumab to facilitate selection of patients most likely to derive the greatest clinical benefit from therapy. METHODS: Data from two phase III clinical trials of omalizumab in patients with allergic asthma were examined. Differences in rates of asthma exacerbations between omalizumab and placebo groups during the 16-week inhaled corticosteroid (ICS) dose-stable phase were evaluated with respect to baseline blood eosinophil counts (eosinophils &lt;300/muL [low] vs >/=300/muL [high]) and baseline markers of asthma severity (emergency asthma treatment in prior year, asthma hospitalization in prior year, forced expiratory volume in 1 second [FEV1 ; FEV1 &lt;65% vs >/=65% predicted], inhaled beclomethasone dipropionate dose [&lt;600 vs >/=600 mug/day], long-acting beta-agonist [LABA] use [yes/no]). RESULTS: Adults/adolescents (N = 1071) were randomized to receive either omalizumab (n = 542) or placebo (n = 529). In the 16-week ICS dose-stable phase, rates of exacerbations requiring >/=3 days of systemic corticosteroid treatment were 0.066 and 0.147 with omalizumab and placebo, respectively, representing a relative rate reduction in omalizumab-treated patients of 55% (95% CI, 32-70%; P = 0.002). For patients with eosinophils >/=300/muL or with more severe asthma, this rate reduction was significantly more pronounced. CONCLUSION: In patients with allergic asthma, baseline blood eosinophil levels and/or clinical markers of asthma severity predict response to omalizumab. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13302</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28859263">PM:28859263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170831-CasaleTB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170831-CasaleTB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Casale TB</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13302</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,G.</style></author><author><style face="normal" font="Arial"> Cheng,B.H.</style></author><author><style face="normal" font="Arial"> Yang,S.B.</style></author><author><style face="normal" font="Arial"> Liu,Z.Q.</style></author><author><style face="normal" font="Arial"> Qiu,S.Q.</style></author><author><style face="normal" font="Arial"> Yang,L.T.</style></author><author><style face="normal" font="Arial"> Xie,R.D.</style></author><author><style face="normal" font="Arial"> Geng,X.R.</style></author><author><style face="normal" font="Arial"> Li,M.G.</style></author><author><style face="normal" font="Arial"> Gao,L.</style></author><author><style face="normal" font="Arial"> Liu,Z.G.</style></author><author><style face="normal" font="Arial"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Affiliated, ENT Hospital and the Research Center of Allergy &amp; Immunology, Shenzhen University School of Medicine, Shenzhen, 518060, China</style></auth-address><titles><title><style face="normal" font="Arial">Targeting histone-acetyltransferase Tip60 inhibits intestinal allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergy</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The over production of IgE plays a critical role in the pathogenesis of allergy; the mechanism is unclear. Histone acetyltransferase (HAT) activities are required in gene transcription of a large number of molecules in the immune system of the body. OBJECTIVES: This study tests a hypothesis that HAT Tat-interactive protein 60 (Tip60) plays an important role in the initiation of IgE-mediated allergy. METHODS: The effects of Tip60 on regulating IgE expression were assessed with B cells. An intestinal allergy mouse model was developed to assess the role of Tip60 in the induction of IgE-mediated allergic inflammation. RESULTS: High levels of Tip60 were observed in the peripheral B cells of patients with FA. Tip60 was required in the expression of IgE and IgG1 in B cells by inducing the chromatin remolding at the gene locus, in which histone acetylation, signal transducer and activator of transcription 6 (STAT6) and nuclear factor-kappaB at the locus of Iepsilon promoter were markedly increased. Blocking Tip60 significantly attenuated the allergic inflammation in the mouse intestinal mucosa. CONCLUSIONS: Tip60 plays an important role in the induction of IgE in B cells. Blocking Tip60 inhibits the allergic inflammation in the intestine, suggesting Tip60 inhibitor may be a potential anti-allergy drug. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13304</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28871603">PM:28871603</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170905-YangG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170905-YangG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Yang G</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13304</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Waidyatillake,N.T.</style></author><author><style face="normal" font="Arial"> Dharmage,S.C.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Lodge,C.J.</style></author><author><style face="normal" font="Arial"> Simpson,J.A.</style></author><author><style face="normal" font="Arial"> Bowatte,G.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Lowe,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Lung Health Unit Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health The University of Melbourne, Melbourne, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Association of Breast Milk Fatty Acids and Allergic Disease Outcomes - a Systematic Review</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> aetiology</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Colostrum</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Dietary poly unsaturated fatty acids (PUFA) have immune regulatory properties. Breast milk is rich in PUFA, and it has been hypothesised that these PUFAs may be important in the aetiology of allergic diseases. Despite a growing body of evidence, the associations between breast milk PUFA and allergic disease have not previously been systematically reviewed. METHODS: The search was performed in PubMed and EMBASE databases using breastfeeding, fatty acid and allergic disease terms. Two authors were involved in selecting papers for review according to the inclusion criteria and extracting information on study characteristics and measures of association. Only studies that reported numeric associations between concentration of breast-milk fatty acids and allergic disease outcomes were included. RESULTS: A total of 18 papers met the inclusion criteria, reporting results from 15 study populations. The majority were cohort studies (n=11), with data from only two case control and two cross sectional studies. Sample size varied between 30 and 352 participants and follow-up time of the cohorts varied between three months and 14 years. Nine studies reported on eczema, seven on sensitisation and only five reported on asthma/wheeze. There was heterogeneity among studies in terms of presenting the association between PUFA and allergy, therefore estimates could not be pooled. Only a few studies observed associations between n-3 and n-6 PUFAs and allergic disease, and the magnitude of this effect varied greatly. CONCLUSIONS: There is insufficient evidence to suggest that colostrum or breast milk poly unsaturated fatty acids influence the risk of childhood allergic diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13300</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28869762">PM:28869762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170904-WaidyatillakeNT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170904-WaidyatillakeNT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Waidyatillake NT</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13300</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'Argenio,V.</style></author><author><style face="normal" font="Arial"> Del Monaco,V.</style></author><author><style face="normal" font="Arial"> Paparo,L.</style></author><author><style face="normal" font="Arial"> De Palma,F.D.E.</style></author><author><style face="normal" font="Arial"> Nocerino,R.</style></author><author><style face="normal" font="Arial"> D'Alessio,F.</style></author><author><style face="normal" font="Arial"> Visconte,F.</style></author><author><style face="normal" font="Arial"> Discepolo,V.</style></author><author><style face="normal" font="Arial"> Del Vecchio,L.</style></author><author><style face="normal" font="Arial"> Salvatore,F.</style></author><author><style face="normal" font="Arial"> Berni,Canani R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CEINGE-Biotecnologie Avanzate s.c.ar.l. Naples, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Altered miR-193a-5p expression in children with cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cow's milk allergy (CMA) is one of the most common food allergies in children. Epigenetic mechanisms have been suggested to play a role in CMA pathogenesis. We shown that DNA methylation of Th1/Th2 cytokine genes and FoxP3 affects CMA disease course. Preliminary evidence suggest that also the miRNome could be implicated in the pathogenesis of allergy. Main study outcome was to comparatively evaluate miRNome in children with CMA and in healthy controls. METHODS: Peripheral blood mononuclear cells were obtained from children aged 4-18 months: 10 CMA patients, 9 CMA patients who outgrew CMA, and 11 healthy controls. Small RNA libraries were sequenced using a next-generation sequencing-based approach. Functional assessment of IL-4 expression was also performed. RESULTS: Among the miRNAs differently expressed, 2 were up-regulated and 14 were down-regulated in children with active CMA compared to healthy controls. miR-193a-5p resulted the most down-regulated miRNA in children with active CMA compared to healthy controls. The predicted targets of miR-193a-5p resulted up-regulated in CMA patients compared to healthy controls. Peripheral blood CD4+ T cells transfected with a miR193a-5 inhibitor showed a significant up-regulation of IL-4 mRNA and its protein expression. Children who outgrew CMA showed miRNA-193a-5p level, and its related targets expression, similar to that observed in healthy controls. CONCLUSIONS: Our results suggest that miR-193a-5p is a post-transcriptional regulator of IL-4 expression and could have a role in IgE-mediated CMA. This miRNA could be a novel diagnostic and therapeutic target for this common form of food allergy in childhood. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13299</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28857182">PM:28857182</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170831-DArgenioV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170831-DArgenioV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, D'Argenio V</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13299</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Iinuma,T.</style></author><author><style face="normal" font="Arial"> Okamoto,Y.</style></author><author><style face="normal" font="Arial"> Morimoto,Y.</style></author><author><style face="normal" font="Arial"> Arai,T.</style></author><author><style face="normal" font="Arial"> Sakurai,T.</style></author><author><style face="normal" font="Arial"> Yonekura,S.</style></author><author><style face="normal" font="Arial"> Sakurai,D.</style></author><author><style face="normal" font="Arial"> Hirahara,K.</style></author><author><style face="normal" font="Arial"> Nakayama,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Pathogenicity of memory Th2 cells is linked to stage of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> ST2</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) consists of three developmental stages that are based on the presence/absence of antigen-specific IgE and symptoms. The pathogenic Th2 (Tpath2) cells constitute a population of Th2 cells with additional potentially pathogenic characteristics. We examined the relationship between Tpath2 cells and the stages of allergic rhinitis by focusing on ST2, which is an IL-33 receptor. METHODS: Patients with Japanese cedar pollen-induced AR (JCP-AR) and healthy volunteers were divided into "non-sensitized," "asymptomatic sensitized (AS)," and "JCP-AR" groups. We analyzed the ST2 expression and the Th2 function of cultured CD4+ T cells. Next, we observed the progress of patients in the AS stage around the time of seasonal pollen dispersal, with the characteristics of Th2 cells. RESULTS: The ST2 expression of T cells was only upregulated in the AR group. The production of IL-4 and IL-13 was found in CD4+ T cells obtained from AS by stimulation with JCP, but reactivity to IL-33 was not observed. Although IL-33 did not induce the elevation of IL-4 production in the JCP-AR group, IL-33 substantially increased the production of IL-5 and IL-13 in comparison to antigen stimulation alone. In newly afflicted patients, the increased expression of ST2 and elevated reactivity to IL-33 was observed, even before the pollen dispersal season. CONCLUSIONS: Our study demonstrated that the pathogenicity of memory Th2 cells is linked to sensitization and the stage of allergic rhinitis. Therefore, Tpath2 cells may provide useful insights into the mechanism of the onset and progression of allergic rhinitis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13295</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28857184">PM:28857184</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170831-IinumaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170831-IinumaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Iinuma T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13295</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85719</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Babina,M.</style></author><author><style face="normal" font="Arial"> Guhl,S.</style></author><author><style face="normal" font="Arial"> Artuc,M.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Allergy Center Charite, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergic FcepsilonRI- and pseudo-allergic MRGPRX2-triggered mast cell activation routes are independent and inversely regulated by SCF</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">While allergic mast cell (MC) degranulation occurs by FcepsilonRI-aggregation and varies in strength among subjects, the analogous pseudo-allergic route was recently uncovered to proceed via MRGPRX2. Here, we examine inter-individual variability in skin MC responses to FcepsilonRI-triggering versus those evoked by MRGPRX2. While population-based variability is comparable between the routes, FcepsilonRI- and MRGPRX2-stimulated pathways are completely independent from each other, and responsiveness to one has therefore no predictive value for the other. Conversely, degranulation triggered by compound 48/80 is highly correlated to the process elicited by Substance P. MRGPRX2 mRNA shows pronounced population-based variability (coefficient of variation 102.9%). Surprisingly, SCF as the MC-supportive mediator par excellence potently inhibits pseudo-allergic degranulation, while it simultaneously promotes allergic stimulation via FcepsilonRI. We conclude that SCF can have selective MC-dampening functions. Clinically, the data imply that subjects highly reactive in one pathway are not automatically hyper-responsive in terms of the alternative route. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13301</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28859248">PM:28859248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170831-BabinaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170831-BabinaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Babina M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13301</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mochimaru,T.</style></author><author><style face="normal" font="Arial"> Fukunaga,K.</style></author><author><style face="normal" font="Arial"> Miyata,J.</style></author><author><style face="normal" font="Arial"> Matsusaka,M.</style></author><author><style face="normal" font="Arial"> Masaki,K.</style></author><author><style face="normal" font="Arial"> Kabata,H.</style></author><author><style face="normal" font="Arial"> Ueda,S.</style></author><author><style face="normal" font="Arial"> Suzuki,Y.</style></author><author><style face="normal" font="Arial"> Goto,T.</style></author><author><style face="normal" font="Arial"> Urabe,D.</style></author><author><style face="normal" font="Arial"> Inoue,M.</style></author><author><style face="normal" font="Arial"> Isobe,Y.</style></author><author><style face="normal" font="Arial"> Arita,M.</style></author><author><style face="normal" font="Arial"> Betsuyaku,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">12-OH-17,18-epoxyeicosatetraenoic acid alleviates eosinophilic airway inflammation in murine lungs</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Arachidonic Acid</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> lipid mediators</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Asthma is characterized by airway inflammation and obstruction with eosinophil infiltration into the airway. Arachidonic acid, an omega-6 fatty acid, is metabolized into cysteinyl leukotriene with pro-inflammatory properties for allergic inflammation, whereas the omega-3 fatty acid eicosapentaenoic acid (EPA) and its downstream metabolites are known to have anti-inflammatory effects. In this study, we investigated the mechanism underlying the counter-regulatory roles of EPA in inflamed lungs. METHODS: Male C57BL6 mice were sensitized and challenged by OVA. After EPA treatment, we evaluated the cell count of BALF, mRNA expressions in the lungs by q-PCR, and the amounts of lipid mediators by Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based lipidomics. We investigated the effect of the metabolite of EPA in vivo and vitro study. RESULTS: EPA treatment reduced accumulation of eosinophils in the airway and decreased mRNA expression of selected inflammatory mediators in the lung. Lipidomics clarified the metabolomic profile in the lungs. Among EPA-derived metabolites, 12-hydroxy-17,18-epoxyeicosatetraenoic acid (12-OH-17,18-EpETE) was identified as one of the major biosynthesized molecules; the production of this molecule was amplified by EPA administration and allergic inflammation. Intravenous administration of 12-OH-17,18-EpETE attenuated airway eosinophilic inflammation through downregulation of C-C chemokine motif 11 (CCL11) mRNA expression in the lungs. In vitro, this molecule also inhibited the release of CCL11 from human airway epithelial cells stimulated with interleukin-4. CONCLUSION: These results demonstrated that EPA alleviated airway eosinophilic inflammation through its conversion into bioactive metabolites. Additionally, our results suggest that 12-OH-17,18-EpETE is a potential therapeutic target for the management of asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28857178">PM:28857178</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170831-MochimaruT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170831-MochimaruT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Mochimaru T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13297</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lima,H.</style></author><author><style face="normal" font="Arial"> Gooderham,M.</style></author><author><style face="normal" font="Arial"> Dutz,J.</style></author><author><style face="normal" font="Arial"> Lynde,C.</style></author><author><style face="normal" font="Arial"> Chapdelaine,H.</style></author><author><style face="normal" font="Arial"> Ellis,A.</style></author><author><style face="normal" font="Arial"> Gilbert,M.</style></author><author><style face="normal" font="Arial"> Ho,V.</style></author><author><style face="normal" font="Arial"> Papp,K.</style></author><author><style face="normal" font="Arial"> Poulin,Y.</style></author><author><style face="normal" font="Arial"> Sussman,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, Department of Medicine, McMaster University, HSC-3U8, 1280 Main St. West, Hamilton, ON L8S 4K1 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> CIU</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging. However, with the advent of proven therapies and validated instruments for measuring disease activity, the concept of treat-to-target (T2T) can be successfully applied to CSU. Herein, we propose a potential PRO therapeutic target and suggest a T2T approach for the management of patients with CSU. METHODS: Principles and recommendations for a treat-to-target approach in CSU (T2T/CSU) were developed by a Canadian task force, consisting of dermatologists, immunologists, and allergists. The task force formulated recommendations for therapeutic targets in CSU on the basis of a systematic literature review and expert opinion. RESULTS: The key features of these T2T/CSU recommendations are the use of a PRO as the principal target, with symptom control as measured by Urticaria Activity Score 7 (UAS7 &lt;/= 6), targeting symptom remission (UAS7 = 0). CONCLUSION: Treatment targets such as UAS7 &lt;/= 6 and UAS7 = 0 provide a benchmark for success in the care of patients with CSU, and will permit the evaluation of a PRO-based T2T approach in the care of these patients and the effect of this approach on improved patient care as seen in other chronic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0210-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28852410">PM:28852410</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Lima H</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0210-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gon,Y.</style></author><author><style face="normal" font="Arial"> Ito,R.</style></author><author><style face="normal" font="Arial"> Maruoka,S.</style></author><author><style face="normal" font="Arial"> Mizumura,K.</style></author><author><style face="normal" font="Arial"> Kozu,Y.</style></author><author><style face="normal" font="Arial"> Hiranuma,H.</style></author><author><style face="normal" font="Arial"> Iida,Y.</style></author><author><style face="normal" font="Arial"> Shikano,S.</style></author><author><style face="normal" font="Arial"> Hashimoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory Medicine, Nihon University School of Medicine, 30-1 Ohyaguchi-Kamicho, Itabashiku, Tokyo 173-8610 Japan</style></auth-address><titles><title><style face="normal" font="Arial">Serum free IgE guided dose reduction of omalizumab: a case report</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for severe asthma patients who are allergic to perennial allergens. The effects of omalizumab for severe asthma therapy have been validated in multiple clinical studies. However, the long-term effects of omalizumab on IgE production and possibility of resetting of administration dose of omalizumab remain unknown. CASE PRESENTATION: The serum total and free IgE levels were measured over time in a 63-year-old female patient with allergic asthma who was administered 375 mg omalizumab biweekly for 36 months. Her symptoms did not worsen and clinical course remained favorable after reducing the dose to 375 mg per month. The serum free IgE levels temporarily increased following a dose reduction of omalizumab. The serum free IgE trough level temporarily increased at 4 weeks after capable to reduce the dosage; however, thereafter, the serum free IgE level decreased to desired levels (below 30 ng/mL). CONCLUSIONS: The present case shows the possibility of reducing the dose following the long-term use of omalizumab. Considering the high medical cost of omalizumab, the dose reduction may be a viable option. It may be useful to measure the serum free IgE level to appropriately identify patients in whom the dose can be reduced, and to carefully monitor the clinical course</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0211-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28861109">PM:28861109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-39.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Gon Y</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0211-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jorge,A.</style></author><author><style face="normal" font="Arial"> Soares,E.</style></author><author><style face="normal" font="Arial"> Sarinho,E.</style></author><author><style face="normal" font="Arial"> Lorente,F.</style></author><author><style face="normal" font="Arial"> Gama,J.</style></author><author><style face="normal" font="Arial"> Taborda-Barata,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">CICS-Health Sciences Research Centre, University of Beira Interior, Avenida Infante D. Henrique, Covilha, 6200-506 Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence and clinical features of adverse food reactions in Portuguese children</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="40">40-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Probable food allergy</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of adverse food reactions (AFR) has been increasing in the western world. Clinical manifestations are diversified and it may not be possible to clinically discriminate between IgE and non-IgE mediated AFR. In Portugal, the prevalence of AFR and food allergies in children is not known. Thus, the objectives of this study were to determine the prevalence of AFR in central Portugal. METHODS: Point prevalence study in 3-11 year-old schoolchildren from Central Portugal. Food-related questionnaires, skin prick tests (SPT) with foods and determination of food-specific IgE levels were performed. RESULTS: Of 4045 schoolchildren, 2474 (61.2%) accepted to be included in the study. Global prevalence of AFR was 7.1% (95% CI 6.2-8.1), based upon the initial questionnaire, 4.6% (95% CI 3.9-5.5), based upon a confirmatory questionnaire and the prevalence of probable food allergy (IgE-associated AFR: positive history + positive SPT and/or positive specific IgE) was 1.4% (95% CI 0.9-1.9). Most frequently implicated foods were fresh fruits, fish and egg. A first episode at an earlier age, mucocutaneous and anaphylactic reactions were more frequent in IgE-associated AFR. CONCLUSIONS: The prevalence of probable food allergy in 3-11 year old Portuguese children from central Portugal is low and parents over-report its frequency. Most frequently implicated foods were fresh fruit and fish. Immediate type, polysymptomatic, and more severe reactions may commence at an earlier age and be more frequent in IgE-associated than in non-IgE associated reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0212-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28878810">PM:28878810</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Jorge A</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0212-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camateros,P.</style></author><author><style face="normal" font="Arial"> Kanagaratham,C.</style></author><author><style face="normal" font="Arial"> Najdekr,L.</style></author><author><style face="normal" font="Arial"> Holub,D.</style></author><author><style face="normal" font="Arial"> Vrbkova,J.</style></author><author><style face="normal" font="Arial"> Cote,L.</style></author><author><style face="normal" font="Arial"> Fournier,J.</style></author><author><style face="normal" font="Arial"> Gourdon,J.</style></author><author><style face="normal" font="Arial"> Creery,D.</style></author><author><style face="normal" font="Arial"> Olivenstein,R.</style></author><author><style face="normal" font="Arial"> Kopriva,F.</style></author><author><style face="normal" font="Arial"> Adam,T.</style></author><author><style face="normal" font="Arial"> Friedecky,D.</style></author><author><style face="normal" font="Arial"> Dzubak,P.</style></author><author><style face="normal" font="Arial"> Hajduch,M.</style></author><author><style face="normal" font="Arial"> Radzioch,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">McGill University Health Center, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="Arial">TLR 7/8 Ligand, S28463, Suppresses Ascaris Suum Induced Allergic Asthma in Nonhuman Primates</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="65" start="55">55-65</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Ascaris</style></keyword><keyword><style face="normal" font="Arial"> Ascaris suum</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cells</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Primates</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> Toll</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> white blood cell</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">S28463, a ligand for Toll like receptor 7/8, has been shown to have anti-inflammatory properties in rodent models of allergic asthma. The principle goal of this study was to assess whether these anti-inflammatory effects can also be observed in a nonhuman primate (NHP) model of allergic asthma. NHPs were sensitized then challenged with natural allergen, Ascaris suum extract, then treated with S28463 orally prior to each allergen challenge. The protective effect of S28463 in NHPs was assessed by measuring various asthma related phenotypes. We also characterized the metabolomic and proteomic signatures of the lung environment and plasma to identify markers associated with the disease and treatment. Our data demonstrates that clinically relevant parameters, such as wheal and flare response, blood IgE levels, recruitment of white blood cells to the bronchoalveolar space, and lung responsiveness are decreased in the S28463 treated allergic NHPs compared to non-treated allergic NHPs. Furthermore, we also identified markers that can distinguish allergic, from non-allergic or allergic and drug treated NHPs, such as metabolites phosphocreatine and glutathione in the plasma and BALF, respectively; and inflammatory cytokines IL-5 and IL-13 in the BALF. Our preclinical study demonstrates that S28463 has potential as a treatment for allergic asthma in primate species closely related to humans. Combined with our previous findings, we demonstrate that S28463 is effective in different models of asthma and in different species, and has the anti-inflammatory properties clinically relevant for the treatment of allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2017-0184OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850259">PM:28850259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Cell Mol Biol\2018-58-55-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Cell Mol Biol\2018-58-55-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Camateros P</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2017-0184OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lortie,K.</style></author><author><style face="normal" font="Arial"> Maheux,C.</style></author><author><style face="normal" font="Arial"> Gendron,D.</style></author><author><style face="normal" font="Arial"> Langlois,A.</style></author><author><style face="normal" font="Arial"> Beaulieu,M.J.</style></author><author><style face="normal" font="Arial"> Marsolais,D.</style></author><author><style face="normal" font="Arial"> Bosse,Y.</style></author><author><style face="normal" font="Arial"> Blanchet,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">IUCPQ Research Center, Respirology, Quebec, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="Arial">CD34 Differentially Regulates Contractile and Non-contractile Elements of Airway Reactivity</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway reactivity</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Airway hyperresponsiveness (AHR), a major hallmark of asthma, results from alterations of contractile and non-contractile elements of airway reactivity. CD34 is a sialomucin expressed on various cells involved in asthma, such as eosinophils and airway smooth muscle (ASM) precursors, highlighting its potential influence in AHR. OBJECTIVE: To study the role of CD34 in the regulation of contractile and non-contractile elements of AHR. METHODS: AHR was induced by chronic exposure to House Dust Mite antigen (HDM). To assess the role of CD34 on contractile elements of AHR, airway reactivity and ASM contractility to methacholine were measured. To assess CD34's role in regulating non-contractile elements of AHR, a chimeric mouse model was used to determine the impact of CD34 expression on inflammatory vs. micro-environmental cells in AHR development. Extracellular matrix production, mucus production and mast cell degranulation were also measured. RESULTS: While wild type (wt) mice developed AHR in response to HDM, a loss of airway reactivity was observed in Cd34-/- mice 24h after the last exposure to HDM compared to naive controls. This was reversed when airway reactivity was measured one week after the last HDM exposure. Additionally, mast cell degranulation and mucus production were altered in the absence of CD34 expression. Importantly, simultaneous expression of CD34 on cells originating from the hematopoietic compartment or the microenvironment is needed for the phenotype expression. CONCLUSION: These results provide evidence that CD34 is required for AHR and airway reactivity maintenance in the early days following an inflammatory episode in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2017-0008OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850257">PM:28850257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Cell Mol Biol\20170829-LortieK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Cell Mol Biol\20170829-LortieK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Lortie K</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2017-0008OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Madigan,L.A.</style></author><author><style face="normal" font="Arial"> Wong,G.S.</style></author><author><style face="normal" font="Arial"> Gordon,E.M.</style></author><author><style face="normal" font="Arial"> Chen,W.S.</style></author><author><style face="normal" font="Arial"> Balenga,N.</style></author><author><style face="normal" font="Arial"> Koziol-White,C.J.</style></author><author><style face="normal" font="Arial"> Panettieri,R.A.,Jr.</style></author><author><style face="normal" font="Arial"> Levine,S.J.</style></author><author><style face="normal" font="Arial"> Druey,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Institute of Allergy and Infectious Diseases, 35037, Bethesda, Maryland, United States</style></auth-address><titles><title><style face="normal" font="Arial">RGS4 Overexpression in Lung Attenuates Airway Hyper-responsiveness in Mice</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="98" start="89">89-98</pages><volume><style face="normal" font="Arial">58</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial epithelium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">A cardinal feature of asthma is airway hyper-responsiveness (AHR) to spasmogens, many of which activate G protein-coupled receptors (GPCRs) on airway smooth muscle (ASM) cells. Asthma subtypes associated with allergy are characterized by eosinophilic inflammation in the lung due to the type 2 immune response to allergens and proinflammatory mediators that promote AHR. The degree to which intrinsic abnormalities of ASM contribute to this phenotype remains unknown. The Regulators of G protein signaling (RGS proteins) are a large group of intracellular proteins that inhibit GPCR signaling pathways. RGS2 and RGS5-deficient mice develop AHR spontaneously. Although RGS4 is upregulated in ASM from patients with severe asthma, the effects of increased RGS4 expression on AHR in vivo are unknown. Here we examined the impact of forced RGS4 overexpression in lung on AHR using transgenic (Tg) mice. Tg RGS4 was expressed in bronchial epithelium and airway smooth muscle (ASM) in vivo, and protein expression in lung was increased at least four-fold compared to that in WT mice. Lung slices from Tg mice contracted less in response to the m3 muscarinic receptor agonist methacholine (MCh) compared to WT although airway resistance in live, unchallenged mice was similar in both strains. Tg mice were partially protected from AHR induced by fungal allergen challenge due to weakened contraction signaling in ASM and reduced type 2 cytokine (IL-5, 13) levels in Tg mice compared to WT. These results provide support for the hypothesis that increasing RGS4 expression and/or function could be a viable therapeutic strategy for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2017-0109OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853915">PM:28853915</url></web-urls><pdf-urls><url ppv-ref="no">laura.madigan22@gmail.com</url><url ppv-ref="no">kdruey@niaid.nih.gov</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="Arial">20170830, Madigan LA</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2017-0109OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kelly,E.A.</style></author><author><style face="normal" font="Arial"> Esnault,S.</style></author><author><style face="normal" font="Arial"> Liu,L.Y.</style></author><author><style face="normal" font="Arial"> Evans,M.D.</style></author><author><style face="normal" font="Arial"> Johansson,M.W.</style></author><author><style face="normal" font="Arial"> Mathur,S.</style></author><author><style face="normal" font="Arial"> Mosher,D.F.</style></author><author><style face="normal" font="Arial"> Denlinger,L.C.</style></author><author><style face="normal" font="Arial"> Jarjour,N.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Wisconsin Madison, Medicine-Allergy, Pulmonary and Critical Care Medicine, Madison, Wisconsin, United States</style></auth-address><titles><title><style face="normal" font="Arial">Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype in Asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> activation marker</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin 3</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-3</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> segmental allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Mepolizumab, an interleukin-5 blocking antibody, reduces exacerbations in severe eosinophilic asthma patients. Mepolizumab arrests eosinophil maturation; however, the functional phenotype of eosinophils that persist in the blood and airway after administration of interleukin-5 neutralizing antibodies has not been reported. OBJECTIVE: To determine the effect of anti-IL-5 antibody on the numbers and phenotypes of allergen-induced circulating and airway eosinophils. METHODS: Airway inflammation was elicited in mild allergic asthma participants by segmental allergen challenge before and one month after a single intravenous 750 milligram dose of mepolizumab. Eosinophils were examined in blood, bronchoalveolar lavage, and endobronchial biopsies forty-eight hours after challenge. MEASUREMENTS AND MAIN RESULTS: Segmental challenge without mepolizumab induced a rise in circulating eosinophils, bronchoalveolar lavage eosinophilia, and eosinophil peroxidase deposition in bronchial mucosa. Interleukin-5 neutralization before allergen challenge abolished the allergen-induced rise in circulating eosinophils and expression of interleukin-3 receptor; whereas, airway eosinophilia and eosinophil peroxidase deposition were blunted but not eliminated. Before mepolizumab treatment, bronchoalveolar lavage eosinophils had more surface interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors, CD69, CD44, and CD23 and decreased interleukin-5 and eotaxin receptors than blood eosinophils. This activation phenotype indicated by bronchoalveolar lavage eosinophil surface markers, as well as the release of eosinophil peroxidase by eosinophils in the bronchial mucosa was maintained after mepolizumab. CONCLUSIONS: Mepolizumab reduced airway eosinophil numbers, but had limited effect on airway eosinophil activation markers suggesting these cells retain functionality. This observation may explain why interleukin-5 neutralization reduces but does not completely eradicate asthma exacerbations. Clinical trial registration available at www.clinicaltrials.gov, ID NCT00802438</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201611-2234OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28862877">PM:28862877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20170901-KellyEA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20170901-KellyEA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Kelly EA</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201611-2234OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Busse,P.J.</style></author><author><style face="normal" font="Arial"> Gernez,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Icahn School of Medicine, Mount Sinai, New York, New York.</style></auth-address><titles><title><style face="normal" font="Arial">Clinical and biological response to rituximab treatment in 3 patients with acquired C1-inhibitor deficiency</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> C1 inhibitor</style></keyword><keyword><style face="normal" font="Arial"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="Arial"> C1-inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866304">PM:28866304</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170903-BussePJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170903-BussePJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Busse PJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nguyen,T.M.N.</style></author><author><style face="normal" font="Arial"> Lomunova,M.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author><author><style face="normal" font="Arial"> Shon,D.H.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Hwang,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anti-allergic effects of Rosae multiflorae fructus via inhibition of T cell proliferation and the mast cell function</style></title><secondary-title><style face="normal" font="Arial">Appl Biol Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Appl Biol Chem</style></full-title></periodical><pages end="402" start="391">391-402</pages><volume><style face="normal" font="Arial">60</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2468-0842</style></isbn><abstract><style face="normal" font="Arial">Anti-allergic effects of the hot water extract of Rosae multiflorae fructus (Rosae extract), which has long been used in oriental medicine for treatment of various diseases, were explored with a chicken ovalbumin (cOVA)-induced mouse model of food allergy. Compared to the sham mice to show severe allergic symptoms (i.e., anaphylaxis, diarrhea and decrease in the body temperature) following oral cOVA challenge, the Rosae extract-treated mice showed a marked improvement in those symptoms. Histology data demonstrated that Rosae extract treatment resulted in a amelioration in the intestinal inflammatory lesion and a reduction in the numbers of mast cells and eosinophils in the small intestine. Studies using DO11.10 TCR transgenic T cells indicated that Rosae extract had an activity to subdue the antigen-specific T cell activation/proliferation in vivo and thereby to lower the level of Th2 cytokine production by T cells during the antigen-specific immune response. Moreover, passive systemic anaphylaxis study showed that the extract also had an activity to inhibit the mast cells function in vivo, i.e., release of granules triggered by specific IgE-antigen interaction. Altogether, the results from this study not only imply a potential clinical application of Rosae extract in prevention and treatment of food allergy but also clearly elucidate the immunoregulatory mechanisms of Rosae extract underlying its anti-allergic effect</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13765-017-0292-x</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s13765-017-0292-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Appl Biol Chem\2017-60-391-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Appl Biol Chem\2017-60-391-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Nguyen TM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13765-017-0292-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kiykim,A.</style></author><author><style face="normal" font="Arial"> Yuce,E.G.</style></author><author><style face="normal" font="Arial"> Baris,E.</style></author><author><style face="normal" font="Arial"> Nain,E.</style></author><author><style face="normal" font="Arial"> Keles,S.</style></author><author><style face="normal" font="Arial"> Akturk,H.</style></author><author><style face="normal" font="Arial"> Bakir,M.</style></author><author><style face="normal" font="Arial"> Ozen,A.</style></author><author><style face="normal" font="Arial"> Baris,S.</style></author><author><style face="normal" font="Arial"> Karakoc Aydiner,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Can Atopic Diseases be Differentiated from Hyper IgE Syndrome by Serum IgE and Blood Eosinophil Levels?</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="81" start="73">73-81</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic granulomatous disease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistent food allergy</style></keyword><keyword><style face="normal" font="Arial"> PID</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: High serum IgE and eosinophil counts are laboratoryfeatures of severe atopic dermatitis (AD), persistent food allergies andsevere allergic asthma as well as some primary immune deficiencies(PID), especially hyperIgE syndrome (HIES). Our objective wasto define cut-off values to discriminate atopic diseases and HIESby comparing serum IgE, eosinophil levels, allergen sensitizationsamong patients with AD, IgE-mediated food allergy, allergic asthmaand/or rhinitis, chronic granulomatous disease and HIES.Materials and Methods: A total of 315 patients were enrolled intothe study. We evaluated serum IgE (IU/L) and eosinophil (/mm3)values, allergen sensitizations and the age range of patients. ROCcurve analysis was performed in order to define an optimal cut-offvalue for serum IgE levels and blood eosinophil counts.Results: The median levels of serum IgE and eosinophils were 2542(min:1, max:55400) and 1000 (min:0, max:37880), respectively inthe PID group. In the atopy group, the median serum IgE was 265(min:4, max:7122), and median eosinophil count was 400 (min:0,max:6050). Serum IgE and blood eosinophil levels were significantlyhigher in PID patients compared to those with atopic diseases(p&lt;0.001 and p&lt;0.001, respectively). IgE was statistically higher in thefood allergy group compared to only house dust mite sensitized and/or grass co-sensitized patients (p=0.008 and p=0.01, respectively).If the IgE cut-off values for HIES are considered to be equal to 2000 IU/l, the sensitivity accounted for 74% and the specificity for 96%(PPV:74%, NPV:96%). When serum IgE=5000 IU/l was consideredas the cut-off, the sensitivity decreased to 56% in contrast to thespecificity increasing to 99% (PPV:91%, NPV:94%). Similarly, foreosinophils=1500/mm3, the sensitivity was %51 and the specificity96% (PPV:61%, NPV:93%) and for eosinophils=2500/mm3, thesensitivity was 41% while the specificity was 98% (PPV:76%, NPV:92%) to discriminate HIES from atopic diseases.Conclusion: It is possible to discriminate atopic diseases from HIESwhen the cut-off values are used are 2500 IU/l for IgE and 1500/mm3 for eosinophils with ROC curve analysis. An atopic disease isthe most likely underlying condition below these values. Moreover,patients with serum IgE higher than 5000 IU/l and/or bloodeosinophils higher than 2500/mm3 should be managed as HIESunless otherwise proven.</style></abstract><notes><style face="normal" font="Arial">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="Humnst777 BT">10.21911/aai.13</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.13</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-73-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-73-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Kiykim,A.</style></custom2><misc3><style face="normal" font="Humnst777 BT">10.21911/aai.13</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yilmaz,I.</style></author><author><style face="normal" font="Arial"> Mungan,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A Baker with Asthma and Wheat Flour Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Asthma Allergy Immunol</style></full-title></periodical><pages end="110" start="107">107-110</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> baker</style></keyword><keyword><style face="normal" font="Arial"> Baker's asthma</style></keyword><keyword><style face="normal" font="Arial"> Bakers</style></keyword><keyword><style face="normal" font="Arial"> Bakery</style></keyword><keyword><style face="normal" font="Arial"> Bread</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat flour</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Patients with wheat flour food allergy and with baker's asthma arenot sensitised to wheat pollen, despite the fact that they share somecommon allergens. In the same way, asthmatic bakers tolerate theingestion of bread. The difference in sensitisation routes (inhalationversus ingestion) and allergenic source (wheat flour versus processedwheat foodstuffs) could explain this fact, although some wheatallergens, like a-amylase inhibitors, lipid transfer proteins andgliadin are implicated in both types of allergy. We report the case ofa 45-year-old male who worked in a bakery for 30 years as a baker.He was confirmed to have occupational asthma, rhinitis and foodallergy due to wheat flour.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.21911/aai.5021</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.5021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-107-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asthma Allergy Immunol\2017-15-107-10.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Yilmaz I</style></custom2><misc3><style face="normal" font="Arial">10.21911/aai.5021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,Y.E.</style></author><author><style face="normal" font="Arial"> Cho,N.</style></author><author><style face="normal" font="Arial"> Cheon,S.</style></author><author><style face="normal" font="Arial"> Kim,K.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry, Chungnam National University, Daejeon, 34134, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Bortezomib, a proteasome inhibitor, alleviates atopic dermatitis by increasing claudin 1 protein expression</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Claudin-1</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Tight Junctions</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic inflammatory skin disease. Many studies investigating AD pathogenesis and its therapy have been conducted but none have been successful. One of the causes of AD is dysfunction of tight junctions through reduction of claudin 1 expression in the epidermal barrier of the skin. In the present study, we investigated the role of bortezomib (BTZ) in the restoration of the reduced expression of claudin 1. Immunoblot and immunofluorescence analyses revealed that BTZ increased the protein expression level of claudin 1 in the human keratinocyte cell line HaCaT, thereby forming paracellular barriers. Furthermore, repeated application of BTZ alleviated atopic symptoms on the backs and ears of DNCB-induced AD mice, and led to the formation of normal tight junctions in the epidermal barrier of 2, 4-dinitrochlorobenzene (DNCB)-induced mice skin. Taken together, these results demonstrate that BTZ-induced claudin 1 expression may be a valuable therapeutic approach for AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2017.08.120</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28859979">PM:28859979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170901-KimYE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170901-KimYE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Kim YE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2017.08.120</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nimpong,J.A.</style></author><author><style face="normal" font="Arial"> Gebregziabher,W.</style></author><author><style face="normal" font="Arial"> Singh,U.P.</style></author><author><style face="normal" font="Arial"> Nagarkatti,P.</style></author><author><style face="normal" font="Arial"> Nagarkatti,M.</style></author><author><style face="normal" font="Arial"> Hodge,J.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Fan,D.</style></author><author><style face="normal" font="Arial"> Ai,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Chemistry and Environmental Health Science, Benedict College, 1600 Harden Street, Columbia, SC, United States</style></auth-address><titles><title><style face="normal" font="Arial">Deficiency of KLF4 compromises the lung function in an acute mouse model of allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Res Commun</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma development</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Up-Regulation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory disease of the airways and the mechanisms are not fully understood. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of monocytes, granulocyte and myeloid cells at early stage of differentiation. They possess phenotypic plasticity and regulate airway inflammation. We recently reported that Kruppel-like factor 4 (KLF4) regulates MDSC differentiation into fibrocytes, emerging effectors in chronic inflammation. However, the role of KLF4 in asthma is not known. Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine and a key initiator of allergic airway inflammation. Given the fact that TSLP promotes Th2 cytokine production that increases MDSC differentiation into fibrocytes, we postulate that KLF4 regulates asthma in a TSLP-dependent manner. In this study, we utilized a model of allergic asthma with ovalbumin challenge (OVA). We found that upon OVA treatment the wild type mice had increased MDSC infiltration into the lung, up-regulation of KLF4 and TSLP gene expression, and higher levels of Th2 cytokines including IL4 and IL13. Consistently, lack of KLF4 expression in monocytes and lung epithelial cells resulted in decreased TSLP expression and lower levels of Th2 cytokines in mice, and fibrocyte generation was compromised. KLF4 deficiency in these cells also led to decreased airway hyperresponsiveness (AHR), a cardinal feature of asthma, as assessed by whole body plethysmography. Moreover, lung fibrosis as measured by trichome staining was attenuated and the population of CD45 + COL1A1+ fibrocytes was diminished in this setting. Together, our results suggest that KLF4 regulates asthma development in a</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrc.2017.08.146</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28867182">PM:28867182</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170904-NimpongJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Res Commun\20170904-NimpongJA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Nimpong JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrc.2017.08.146</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vakharia,P.P.</style></author><author><style face="normal" font="Arial"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA</style></auth-address><titles><title><style face="normal" font="Arial">Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential</style></title><secondary-title><style face="normal" font="Arial">BioDrugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BioDrugs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Factors</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressants</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a complex and heterogeneous inflammatory skin disorder with a profound symptom and lesional burden. Moderate-to-severe AD is particularly challenging to manage, as topical treatments are often inadequate and the systemic immunosuppressants are limited by concerns of toxicity and tolerability. Recent AD research has elucidated the mechanisms and immunologic factors involved in AD pathogenesis. These breakthroughs have led to the development of multiple therapeutic monoclonal antibodies that are directed against specific immunologic targets. This review provides an overview on the pathogenesis of AD as well as the rationale for the targets of various monoclonal antibodies. Additionally, this review explores the efficacy and safety of use for various monoclonal antibodies in the management of AD, as well as the potential role of these agents in the treatment of AD</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 1179-190X (Electronic)IS - 1173-8804 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40259-017-0241-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853008">PM:28853008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BioDrugs\20170830-VakhariaPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BioDrugs\20170830-VakhariaPP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Vakharia PP</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40259-017-0241-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Youm,J.</style></author><author><style face="normal" font="Arial"> Lee,H.</style></author><author><style face="normal" font="Arial"> Chang,H.B.</style></author><author><style face="normal" font="Arial"> Jeon,J.</style></author><author><style face="normal" font="Arial"> Yoon,M.H.</style></author><author><style face="normal" font="Arial"> Woo,J.Y.</style></author><author><style face="normal" font="Arial"> Choi,M.S.</style></author><author><style face="normal" font="Arial"> Hwang,Y.</style></author><author><style face="normal" font="Arial"> Seong,S.</style></author><author><style face="normal" font="Arial"> Na,K.</style></author><author><style face="normal" font="Arial"> Yoon,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Institute, Dong-Wha Pharmaceutical Company</style></auth-address><titles><title><style face="normal" font="Arial">Justicia procumbens Extract (DW2008) Selectively Suppresses Th2 Cytokines in Splenocytes and Ameliorates Ovalbumin-Induced Airway Inflammation in a Mouse Model of Asthma</style></title><secondary-title><style face="normal" font="Arial">Biol Pharm Bull</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biol Pharm Bull</style></full-title></periodical><pages end="1422" start="1416">1416-1422</pages><volume><style face="normal" font="Arial">40</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">DW2008 is an anhydrous ethanol extract of Justicia procumbens produced by Dong-Wha Pharmaceutical, Inc., Co. as a candidate anti-asthmatic drug. In this study, DW2008 selectively reduced T helper 2 (Th2) cytokines in mouse splenocytes and ameliorated ovalbumin-induced airway inflammation by downregulating pulmonary infiltration of differential inflammatory cells and Th2 cytokines more than a decoction or ethanol extract of J. procumbens did in a mouse asthma model. DW2008 also significantly inhibited airway hyperresponsiveness and reduced the thickness of the airway epithelium. HPLC analysis showed that the major peaks (justicidin A and B) of DW2008 were higher than those of the other extracts. Justicidin A and B significantly suppressed Th2 cytokine levels in mouse spleen cells and exhibited a protective effect in ovalbumin-induced airway inflammation. Our findings indicate that DW2008 effectively inhibits allergic airway inflammatory reactions and airway hyperresponsiveness in a mouse model of asthma, suggesting its potential as an anti-asthmatic agent</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 1347-5215 (Electronic)IS - 0918-6158 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1248/bpb.b17-00179</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28867724">PM:28867724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biol Pharm Bull\2017-40-1416-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biol Pharm Bull\2017-40-1416-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Youm J</style></custom2><misc3><style face="normal" font="Arial">10.1248/bpb.b17-00179</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stenberg,H.</style></author><author><style face="normal" font="Arial"> Wadelius,E.</style></author><author><style face="normal" font="Arial"> Moitra,S.</style></author><author><style face="normal" font="Arial"> Aberg,I.</style></author><author><style face="normal" font="Arial"> Ankerst,J.</style></author><author><style face="normal" font="Arial"> Diamant,Z.</style></author><author><style face="normal" font="Arial"> Bjermer,L.</style></author><author><style face="normal" font="Arial"> Tufvesson,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Respiratory Medicine and Allergology, Department of Clinical Sciences , Lund University , 221 84 Lund , Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Club cell protein (CC16) in plasma, bronchial brushes, BAL and urine following an inhaled allergen challenge in allergic asthmatics</style></title><secondary-title><style face="normal" font="Arial">Biomarkers</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomarkers</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoscopy</style></keyword><keyword><style face="normal" font="Arial"> CC16</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Mannitol</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Club cell protein (CC16) is a pneumoprotein secreted by epithelial club cells. CC16 possesses anti-inflammatory properties and is a potential biomarker for airway epithelial damage. We studied the effect of inhaled allergen on pulmonary and systemic CC16 levels. METHODS: Thirty-four subjects with allergic asthma underwent an inhaled allergen challenge. Bronchoscopy with bronchoalveolar lavage (BAL) and brushings was performed before and 24 h after the challenge. CC16 was quantified in BAL and CC16 positive cells and CC16 mRNA in bronchial brushings. CC16 was measured in plasma and urine before and repeatedly after the challenge. Thirty subjects performed a mannitol inhalation challenge prior to the allergen challenge. RESULTS: Compared to baseline, CC16 in plasma was significantly increased in all subjects 0-1 h after the allergen challenge, while CC16 in BAL was only increased in subjects without a late allergic response. Levels of CC16 in plasma and in the alveolar fraction of BAL correlated significantly after the challenge. There was no increase in urinary levels of CC16 post-challenge. Mannitol responsiveness was greater in subjects with lower baseline levels of CC16 in plasma. CONCLUSION: The increase in plasma CC16 following inhaled allergen supports the notion of CC16 as a biomarker of epithelial dysfunction</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 1366-5804 (Electronic)IS - 1354-750X (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1080/1354750X.2017.1375559</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28862880">PM:28862880</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomarkers\20170901-StenbergH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomarkers\20170901-StenbergH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Stenberg H</style></custom2><misc3><style face="normal" font="Arial">10.1080/1354750X.2017.1375559</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feng,Y.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Wang,F.</style></author><author><style face="normal" font="Arial"> Liu,R.</style></author><author><style face="normal" font="Arial"> Chen,L.</style></author><author><style face="normal" font="Arial"> Wu,S.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Chen,M.</style></author><author><style face="normal" font="Arial"> Rao,Y.Q.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The Prevalence of Ocular Allergy and Comorbidities in Chinese School Children in Shanghai</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="7190987">7190987-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ocular allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective. To investigate the prevalence and features of ocular allergy (OA) and comorbidities among school children in Shanghai, China. Methods. This was a population-based cross-sectional study. Each participant completed an ISAAC-based questionnaire. The prevalence of OA symptoms, allergic rhinitis (AR) asthma, atopic dermatitis (AD), and sensitization to mites, pollen, and food was analyzed. Results. A total of 724 and 942 completed questionnaires from the 7-9-year-old (young group) and the 12-14-year-old (teen group) groups were analyzed, respectively. The overall prevalence of OA symptoms was 28%. However, more young students (10.6%) reported mild to severe daily life interference caused by OA than the teens (5.7%). The young group had higher prevalence of diagnosed allergic conjunctivitis (10.2%). The overall prevalence of AR symptom, diagnosed asthma, and diagnosed AD was 40.4%, 11.6%, and 16.7%, respectively. Young children had higher prevalence of diagnosed AR and AD than the teens. There were gender associated differences in the prevalence of AR and asthma among young children, but not among the teens. The comorbidities associated with OA was also analyzed. Sensitization to mites, food, and pollen was associated with higher prevalence of allergic conditions. Conclusions. OA together with other allergic conditions affected a significant number of children in Shanghai.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/7190987</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1155/2017/7190987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-7190987.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-7190987.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Feng Y</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/7190987</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mueller,R.S.</style></author><author><style face="normal" font="Arial"> Olivry,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medizinische Kleintierklinik, Centre for Clinical Veterinary Medicine, LMU Munich, Veterinaerstrasse 13, 80539, Munich, Germany. rmueller@lmu.deDepartment of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Drive, Raleigh, NC, 27607, USA</style></auth-address><titles><title><style face="normal" font="Arial">Critically appraised topic on adverse food reactions of companion animals (4): can we diagnose adverse food reactions in dogs and cats with in vivo or in vitro tests?</style></title><secondary-title><style face="normal" font="Arial">BMC Vet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">BMC Vet Res</style></full-title></periodical><pages end="" start="275">275-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro tests</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Intradermal testing</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> lymphocyte proliferation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The gold standard to diagnose adverse food reactions (AFRs) in the dog and cat is currently an elimination diet with subsequent provocation trials. However, those trials are inconvenient and client compliance can be low. Our objective was to systematically review the literature to evaluate in vivo and in vitro tests used to diagnose AFR in small animals. RESULTS: We searched three databases (CAB Abstracts, MEDLINE and Web of Science) for pertinent references on September 16, 2016. Among 71, 544 and 41 articles found in the CAB Abstract, MEDLINE and Web of Science databases, respectively, we selected 22 articles and abstracts from conference proceedings that reported data usable for evaluation of tests for AFR. Serum tests for food-specific IgE and IgG, intradermal testing with food antigens, lymphocyte proliferation tests, fecal food-specific IgE, patch, gastroscopic, and colonoscopic testing were evaluated. CONCLUSIONS: Testing for serum food-specific IgE and IgG showed low repeatability and, in dogs, a highly variable accuracy. In cats, the accuracy of testing for food-specific IgE was low. Lymphocyte proliferation tests were more frequently positive and more accurate in animals with AFR, but, as they are more difficult to perform, they remain currently a research tool. All other reported tests were only evaluated by individual studies with small numbers of animals. Negative patch test reactions have a very high negative predictability in dogs and could enable a choice of ingredients for the elimination diet in selected patients. Gastroscopic and colonoscopic testing as well as food-specific fecal IgE or food-specific serum IgG measurements appear less useful. Currently, the best diagnostic procedure to identify AFRs in small animals remains an elimination diet with subsequent provocation trials</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1746-6148 (Electronic)IS - 1746-6148 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12917-017-1142-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28854915">PM:28854915</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Vet Res\2017-13-275.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Vet Res\2017-13-275.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Mueller RS</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12917-017-1142-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Westerveld,D.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Glover,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, University of Florida, Gainesville, Florida, USADivision of Gastroenterology, Hepatology and Nutrition, College of Medicine, University of Florida, Gainesville, Florida, USA</style></auth-address><titles><title><style face="normal" font="Arial">Oesophageal mastocytosis: eosinophilic oesophagitis without eosinophils?</style></title><secondary-title><style face="normal" font="Arial">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cetirizine</style></keyword><keyword><style face="normal" font="Arial"> Chest Pain</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Manometry</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> montelukast</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Oesophagitis</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="Arial">A 59-year-old male with a history of lifelong asthma, allergic rhinitis and hypercholesterolaemia presented to the emergency department for management of severe substernal chest pain with radiating pain to his left arm, nausea and diaphoresis. Physical examination was unrevealing and a cardiac workup including cardiac enzymes, ECG, chest radiographs were negative for an underlying ischaemic event. A subsequent gastrointestinal workup including oesophageal manometry and oesophagogastroduodenoscopy revealed elevated lower oesophageal pressures and histopathology suggestive of mast cell proliferation, respectively. These findings were suggestive of oesophageal mastocytosis. Treatment with omeprazole-sodium bicarbonate, cetirizine, montelukast and oral budesonide promptly ameliorated his symptoms which have not recurred</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1136/bcr-2017-221276</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28851715">PM:28851715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Case Rep\20170830-WesterveldD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Case Rep\20170830-WesterveldD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Westerveld D</style></custom2><misc3><style face="normal" font="Arial">10.1136/bcr-2017-221276</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Freire,P.C.</style></author><author><style face="normal" font="Arial"> Munoz,C.H.</style></author><author><style face="normal" font="Arial"> Stingl,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">IgE auto-reactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Blister</style></keyword><keyword><style face="normal" font="Arial"> BP180</style></keyword><keyword><style face="normal" font="Arial"> BP230</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> IgE autoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Bullous pemphigoid (BP) is an autoimmune disease characterised by tense blisters that are usually preceded by urticarial eruptions. Affected patients exhibit IgG and/or IgE auto-antibodies against BP180 and/or BP230. Their relative importance in disease pathogenesis has not been fully elucidated. OBJECTIVES: The aim of this study was to better characterise circulating and tissue-resident IgE in BP patients at the serological, structural and functional level. METHODS: Sera (n=19) and skin (n=33) from BP patients were analysed via ELISA and immunofluorescence, respectively. RESULTS: Results obtained show that BP patients exhibit elevated IgE levels in the serum and in the skin. Within the latter, it is very rarely and only sparsely found along the basement membrane zone (BMZ), but is prominently present on mast cells and eosinophils. At least a portion of these IgE antibodies are BP-specific, as evidenced by serum ELISA and by the co-localization of BP180 and FcepsilonRI-bound IgE on mast cells and/or eosinophils. An important role of these immune reactants can be implied by our additional finding that cross-linking of IgE, derived from BP sera, on FcepsilonRI-expressing rat basophils with BP180 results in robust degranulation of these cells. CONCLUSION: We propose the existence of a disease pathway alternative to IgG and complement that may well be responsible for some of the clinical features of this autoimmune disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15924</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28868796">PM:28868796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170904-FreirePC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170904-FreirePC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Freire PC</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15924</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,Z.</style></author><author><style face="normal" font="Arial"> Zeng,B.</style></author><author><style face="normal" font="Arial"> Wang,C.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Huang,P.</style></author><author><style face="normal" font="Arial"> Pan,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, The Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province 410005, China</style></auth-address><titles><title><style face="normal" font="Arial">MicroRNA-124 alleviates chronic skin inflammation in atopic eczema via suppressing innate immune responses in keratinocytes</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="60" start="53">53-60</pages><volume><style face="normal" font="Arial">319</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="Arial">Chronic skin inflammation in atopic eczema is associated with elevated expression of proinflammatory genes and activation of innate immune responses in keratinocytes. MicroRNAs (miRNAs) are short, single-stranded RNA molecules that silence genes via the degradation of target mRNAs or inhibition of translation. Recent studies have demonstrated that miR-124 is associated with regulation of inflammation factors in several diseases. The aim of this study was to investigate the role of miR-124 in skin inflammation of atopic eczema. We showed that miR-124 expression is decreased in chronic lesional skin of patients with atopic eczema, and could be strongly inhibited by IFN-gamma and TNF-alpha. Through Western blot, real-time PCR and luciferase assays, we revealed that miR-124 inhibited the expression of p65, a member of NF-kappaB family which can regulate many factors involved in the immune response and inflammatory reactions, through direct targeting. Further, upon IFN-gamma or TNF-alpha stimulation, IL8, CCL5 and CCL8 showed to be significantly upregulated by IFN-gamma or TNF-alpha, downregulated by miR-124; the promotive effect of IFN-gamma and TNF-alpha could be partially reversed by miR-124. The levels of IL8, CCL5 and CCL8 could be significantly downregulated by p65 knockdown, upregulated by miR-124 inhibition; the suppressive effect of p65 knockdown could be partially reversed by miR-124. Moreover, contrary to miR-124, p65, IL8, CCL5 and CCL8 mRNA expression was upregulated in chronic lesional skin of patients with atopic eczema, and all inversely correlated with miR-124. Taken together, our data demonstrate that miR-124 controls NF-kappaB-dependent inflammatory responses in keratinocytes and chronic skin inflammation in atopic eczema; rescuing miR-124 expression presents a promising strategy for atopic eczema treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1090-2163 (Electronic)IS - 0008-8749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2017.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28847568">PM:28847568</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20170829-YangZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20170829-YangZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Yang Z</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2017.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gon,Y.</style></author><author><style face="normal" font="Arial"> Maruoka,S.</style></author><author><style face="normal" font="Arial"> Inoue,T.</style></author><author><style face="normal" font="Arial"> Kuroda,K.</style></author><author><style face="normal" font="Arial"> Yamagishi,K.</style></author><author><style face="normal" font="Arial"> Kozu,Y.</style></author><author><style face="normal" font="Arial"> Shikano,S.</style></author><author><style face="normal" font="Arial"> Soda,K.</style></author><author><style face="normal" font="Arial"> Lotvall,J.</style></author><author><style face="normal" font="Arial"> Hashimoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kmicho, Itabashi-ku, Tokyo, 173-8610, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Selective release of miRNAs via extracellular vesicles is associated with house dust mite allergen-induced airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> extracellular vesicles</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: MicroRNAs (miRNAs) may facilitate cell-to-cell communication via extracellular vesicles (EVs). The biological roles of miRNAs in EVs on allergic airway inflammation is unclear. METHODS: Airway secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF) of control and house dust mite (HDM) allergen-exposed HDM-sensitized mice. The expression of miRNAs in AEVs or miRNAs and mRNAs in lung tissue was analyzed using miRNA microarray. RESULTS: The amount of AEV increased 8.9-fold in BALF from HDM-exposed mice compared with that from sham-control mice. HDM exposure resulted in significant changes in the expression of 139 miRNAs in EVs and 175 miRNAs in lung tissues, with 54 miRNAs being common in both samples. Expression changes of these 54 miRNAs between miRNAs in AEVs and lung tissues after HDM exposure were inversely correlated. Computational analysis revealed that 31 genes, including IL-13 and IL-5Ra, are putative targets of the miRNAs upregulated in AEVs but downregulated in lung tissues after HDM exposure. The amount of AEV in BALF after HDM exposure was diminished by treatment with the sphingomyelinase inhibitor GW4869. The treatment with GW4869 also decreased Th2 cytokines and eosinophil counts in BALFs and reduced eosinophil accumulation in airway walls and mucosa. CONCLUSION: These results indicate that selective sorting of miRNA including Th2 inhibitory miRNAs into AEVs and increase release to the airway after HDM exposure would be involve in the pathogenesis of allergic airway inflammation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28859242">PM:28859242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170831-GonY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170831-GonY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Gon Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Food challenges, the risks and benefits</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1107" start="1106">1106-1107</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.12999</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28856837">PM:28856837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-1106-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-1106-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.12999</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tao,B.</style></author><author><style face="normal" font="Arial"> Morris,S.</style></author><author><style face="normal" font="Arial"> Grzeskowiak,L.</style></author><author><style face="normal" font="Arial"> Smith,W.</style></author><author><style face="normal" font="Arial"> Forsyth,K.</style></author><author><style face="normal" font="Arial"> Chataway,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics and Child Health, Flinders University of South Australia, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Sequential hypoallergenic boiled peanut and roasted peanut oral immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Inhibition ELISA</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> South Australia</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell reactivity</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Up-dosing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="Arial">Oral immunotherapy (OIT) using roasted peanut flour can effectively desensitize peanut-allergic children [1] but is considered not to be ready for clinical practice [2] due to high rates (>/=45%) of adverse events (AEs) [3] [4]. This necessitates medically supervised up-dosing in hospital and limits the number of patients that can be treated. In 2001 Beyer et. al proposed that the prevalence of peanut allergy in China was lower than that of the Western world because peanuts consumed in China were boiled, not roasted [5]. They demonstrated that boiling peanuts for 20 minutes reduced IgE binding in vitro when compared to roasted peanut. We have subsequently shown that extended boiling progressively reduced peanut IgE binding to 12.5% at 2 hours and to 5.3% at 12 hours compared to raw peanut while still retaining T cell reactivity [6]. Further, Inhibition ELISAs demonstrated that boiled peanuts have restricted ability (2-h ~70%, 12-h ~50%) to block the binding of patient IgE to raw peanut [6] suggesting boiled peanuts possess an incomplete repertoire of epitopes. This indicates that boiled peanuts alone are unlikely to expose a patient to the full spectrum of peanut epitopes and will therefore require a roasted peanut phase following the initial boiled peanut therapy. We hypothesize that AEs can be reduced by commencing OIT with hypoallergenic boiled peanut. Here we describe a pilot study that aims to characterize the incidence of AEs and successful desensitization in mild/moderate peanut allergic children using hypoallergenic 2-hour boiled peanut prior to roasted peanut OIT. Due to the home-based up-dosing procedure, a cautious approach was adopted which excluded severely allergic children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28873242">PM:28873242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170905-TaoB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170905-TaoB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Tao B</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asady,A.</style></author><author><style face="normal" font="Arial"> Ruft,J.</style></author><author><style face="normal" font="Arial"> Ellrich,A.</style></author><author><style face="normal" font="Arial"> Hawro,T.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Altrichter,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Charite - Universitatsmedizin Berlin, Department of Dermatology and Allergology, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Cholinergic urticaria patients of different age groups have distinct features</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword><keyword><style face="normal" font="Arial"> young adults</style></keyword></keywords><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cholinergic Urticaria (CholU) is a common skin disease characterized by the development of pinpoint sized wheals and severe itch upon physical exercise. Little is known about the epidemiology of CholU. CholU can occur at any age and has the highest prevalence among young adults. As of now, it is unclear if patients of different age show differences in the clinical manifestation of CholU, duration of disease, comorbidities or response to treatment. METHODS: Here, we analysed the demographic data and clinical characteristics including disease duration and comorbidities of 200 CholU patients, 12 to 76 years of age. RESULTS: We identified two distinct types of CholU, one with early onset (EO, 71%) and one with late onset (LO, 29%). EO and LO CholU patients markedly differ in key characteristics: EO patients, who had a disease onset before the age of 36, showed no gender preponderance, and had a significantly higher rate of concomitant atopic dermatitis (16.9 vs. 5.2%; p= 0.028) and higher IgE-Levels (295.5 vs. 267.1 IU/ml; p= 0.020) as compared to LO patients, who were mainly female (69%), had a shorter duration of disease (33.3 vs. 63.7 months; p= 0.005), a higher rate of concomitant other forms of urticaria (48.3 vs. 33.1%; p=0.044), and a higher rate of psychiatric comorbidities (12.1 vs 1.4%; p= 0.001).. CONCLUSION: There are two subtypes of CholU patients with different gender ratios, disease duration, and comorbidities. These findings suggest that two distinct underlying pathogenetic pathways are relevant in these two subgroups of CholU patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28873238">PM:28873238</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170905-AsadyA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170905-AsadyA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Asady A</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amat,F.</style></author><author><style face="normal" font="Arial"> Kouche,C.</style></author><author><style face="normal" font="Arial"> Gaspard,W.</style></author><author><style face="normal" font="Arial"> Lemoine,A.</style></author><author><style face="normal" font="Arial"> Guiddir,T.</style></author><author><style face="normal" font="Arial"> Lambert,N.</style></author><author><style face="normal" font="Arial"> Zakariya,M.</style></author><author><style face="normal" font="Arial"> Ridray,C.</style></author><author><style face="normal" font="Arial"> Nemni,A.</style></author><author><style face="normal" font="Arial"> Saint-Pierre,P.</style></author><author><style face="normal" font="Arial"> Couderc,R.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology-Centre de l'Asthme et des Allergies, Hopital d'Enfants Armand Trousseau, Assistance Publique-Hopitaux de Paris, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Is a slow-progression baked-milk protocol of oral immunotherapy always a safe option for children with cow's milk allergy? A randomized controlled trial</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin-E mediated-cow's milk allergy (IgE-CMA) is the one of the most frequent IgE mediated-food allergy in children in industrialized countries and may cause life- threatening anaphylaxis. The natural history of CM IgE mediated food allergy is favorable for most children. However, the clinical outcome of CMA seems worse than previously described, with less chance of recovery after the age of 31 . This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28875570">PM:28875570</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170906-AmatF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170906-AmatF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Amat F</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Venter,C.</style></author><author><style face="normal" font="Arial"> Brown,T.</style></author><author><style face="normal" font="Arial"> Meyer,R.</style></author><author><style face="normal" font="Arial"> Walsh,J.</style></author><author><style face="normal" font="Arial"> Shah,N.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Chen,T.X.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Heine,R.G.</style></author><author><style face="normal" font="Arial"> Levin,M.</style></author><author><style face="normal" font="Arial"> Vieira,M.C.</style></author><author><style face="normal" font="Arial"> Fox,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Allergy and Immunology, University of Colorado Denver School of Medicine, Children's Hospital Colorado , Box B518, 13123 East 16th Avenue, Anschutz Medical Campus, Aurora, CO 80045 USA</style></auth-address><titles><title><style face="normal" font="Arial">Better recognition, diagnosis and management of non-IgE-mediated cow's milk allergy in infancy: iMAP-an international interpretation of the MAP (Milk Allergy in Primary Care) guideline</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="26">26-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Americas</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Cow's milk allergy (CMA) is one of the most common presentations of food allergy seen in early childhood. It is also one of the most complex food allergies, being implicated in IgE-mediated food allergy as well as diverse manifestations of non-IgE-mediated food allergy. For example, gastrointestinal CMA may present as food protein induced enteropathy, enterocolitis or proctocolitis. Concerns regarding the early and timely diagnosis of CMA have been highlighted over the years. In response to these, guideline papers from the United Kingdom (UK), Australia, Europe, the Americas and the World Allergy Organisation have been published. The UK guideline, 'Diagnosis and management of non-IgE-mediated cow's milk allergy in infancy-a UK primary care practical guide' was published in this journal in 2013. This Milk Allergy in Primary Care (MAP) guideline outlines in simple algorithmic form, both the varying presentations of cow's milk allergy and also focuses on the practical management of the most common presentation, namely mild-to-moderate non-IgE-mediated allergy. Based on the international uptake of the MAP guideline, it became clear that there was a need for practical guidance beyond the UK. Consequently, this paper presents an international interpretation of the MAP guideline to help practitioners in primary care settings around the world. It incorporates further published UK guidance, feedback from UK healthcare professionals and affected families and, importantly, also international guidance and expertise</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - United States -CO - China -CO - Australia -CO - South Africa -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0162-y.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28852472">PM:28852472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Venter C</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0162-y.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berbegal,L.</style></author><author><style face="normal" font="Arial"> DeLeon,F.J.</style></author><author><style face="normal" font="Arial"> Gonzalez,I.</style></author><author><style face="normal" font="Arial"> Silvestre,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Department, Hospital Marina Salud, 03700, Denia, Alicante, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Protein contact dermatitis caused by chicken meat in bird-egg syndrome</style></title><secondary-title><style face="normal" font="Arial">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Contact Dermatitis</style></full-title></periodical><pages end="254" start="253">253-254</pages><volume><style face="normal" font="Arial">77</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Bird-egg syndrome</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Chicken meat</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/cod.12805</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872207">PM:28872207</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2017-77-253-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2017-77-253-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Berbegal L</style></custom2><misc3><style face="normal" font="Arial">10.1111/cod.12805</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amoah,A.S.</style></author><author><style face="normal" font="Arial"> Boakye,D.A.</style></author><author><style face="normal" font="Arial"> Yazdanbakhsh,M.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Influence of Parasitic Worm Infections on Allergy Diagnosis in Sub-Saharan Africa</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="65">65-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Ghana</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> rural area</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sub-Saharan Africa</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T helper 2 cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Epidemiological studies from Sub-Saharan Africa indicate that allergies are on the rise in this region especially in urban compared to rural areas. This increase has been linked to improved hygiene, lifestyle changes, and lower exposure to pathogens in childhood. Reduced exposure to parasitic worm (helminth) infections and allergy outcomes has been the focus of a number of population studies over the years. Paradoxically, there are parallels in the immune responses to helminths and to allergies. Both conditions are associated with elevated levels of immunoglobulin E, high numbers of T helper 2 cells, eosinophils, and mast cells. These immune parallels have meant that the diagnosis of allergies in parts of the world where helminths are endemic can be hampered. The aim of this review is to examine observations from population studies conducted in Sub-Saharan Africa that demonstrate how helminth infections influence the parameters used to diagnose allergy outcomes in this region. We explore specifically how helminth infections hinder the in vitro diagnosis of allergic sensitization, influence the clinical manifestations of allergy, and also the effect of anthelmintic treatment on allergy outcomes. Advancing our understanding of how helminths influence allergy diagnosis is imperative for the development of improved tools to assess, diagnose, and treat allergic disorders in both helminth-endemic and non-endemic countries worldwide</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -CO - Ghana -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0733-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28861721">PM:28861721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-10-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-10-65.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Amoah AS</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0733-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hilger,C.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Kuehn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354, Esch-sur-Alzette, Luxembourg. christiane.hilger@lih.luImmunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, SwedenDepartment of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354, Esch-sur-Alzette, Luxembourg</style></auth-address><titles><title><style face="normal" font="Arial">Diagnosis of Allergy to Mammals and Fish: Cross-Reactive vs. Specific Markers</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="64">64-</pages><volume><style face="normal" font="Arial">17</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> aldolase</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic molecules</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enolase</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> lipocalin</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> panallergen</style></keyword><keyword><style face="normal" font="Arial"> Panallergens</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumins</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Allergen extracts are still widely used in allergy diagnosis as they are regarded as sensitive screening tools despite the fact that they may lack some minor allergens. Another drawback of extracts is their low specificity, which is due to the presence of cross-reactive allergens. Progress in allergen identification has disclosed a number of allergenic molecules of homologous sequence and structure which are present in different animal species. This review summarizes recent advances in mammalian and fish allergen identification and focuses on their clinical relevance. RECENT FINDINGS: Serum albumins and parvalbumins are well-known animal panallergens. More recently several members of the lipocalin family were found to be cross-reactive between furry animals whereas in fish, additional allergens, enolase, aldolase and collagen, were found to be important and cross-reactive allergens. New epidemiological studies have analysed the prevalence and clinical relevance of mammalian and fish components. Primary sensitization can be distinguished from cross-sensitization by using marker allergens. Although substantial progress has been made in allergen identification, only few markers are commercially available for routine clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20170823IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Luxembourg -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11882-017-0732-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28831729">PM:28831729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-10-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Asthma Rep\2017-10-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170823, Hilger C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11882-017-0732-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guttman-Yassky,E.</style></author><author><style face="normal" font="Arial"> Krueger,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Icahn School of Medicine at the Mount Sinai Medical Center, New York, NY, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="73" start="68">68-73</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arrays</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell polarity</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 axis</style></keyword><keyword><style face="normal" font="Arial"> TH22</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Psoriasis and atopic dermatitis (AD) are common T-cell mediated inflammatory diseases of the skin that can be treated by specific cytokine antagonists or more broad immunosuppressive drugs. The diseases are similar in that epidermal keratinocytes respond to T-cell derived cytokines by altering growth and differentiation responses, accounting for major parts of the overall disease phenotype. When studied across European-American populations, psoriasis and AD display differing T-cell polarity and different arrays of cytokines. Psoriasis is a disease largely driven by Th17 T-cells and associated IL-17 activation, while AD has a strong Th2 component associated with IL-4 and IL-13 over-production, and both diseases have activation of Th22 T-cells and Th1 pathways with increased IL-22 and IFNgamma production, respectively. AD is a disease frequently associated with increased IgE production and overt allergies or asthma, most likely due to increased Th2 activation, which is largely lacking in psoriasis. Hence, psoriasis and AD can be viewed as distinct diseases with differing clinical, tissue, and molecular disease phenotypes, but this view does not account for specific subtypes of AD, including Asian-origin, intrinsic, and pediatric AD, that have a prominent IL-17 component and also tissue patterning that overlaps with distinctive psoriasis histopathology. Hence, when considering the range of AD phenotypes, a case can be made that psoriasis and AD exist across a spectrum where polar T-cell axes can be variably present and create some overlapping disease characteristics. Today, approximately 90% of psoriasis patients have extremely controlled disease by targeting the IL-23/Th17 T-cell axis with IL-23 or IL-17-targeting antibodies. An outstanding question is whether targeting a single cytokine axis in AD, for example, Th2 axis, will lead to disease suppression in the majority of patients and across all subtypes, including those with higher IL-17 expression, or whether it is necessary to personalize therapies and target multiple T-cell axes to attain similar disease improvement to psoriasis</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2017.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28869867">PM:28869867</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-68-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-68-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Guttman-Yassky E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2017.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asaumi,T.</style></author><author><style face="normal" font="Arial"> Manabe,T.</style></author><author><style face="normal" font="Arial"> Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Wheat-Dependent Exercise-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="302" start="291">291-302</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-histamines</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> NSAID</style></keyword><keyword><style face="normal" font="Arial"> NSAIDs</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> Prophylactic treatment</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Provocation tests</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Wheat-dependent exercise-induced anaphylaxis (WDEIA) is presently gaining attention. Patients with WDEIA experience allergic symptoms when they exercise following wheat consumption. Some patients may be advised to restrict wheat consumption or exercise because of repeated allergic symptoms without adequate diagnosis or examination. Japanese guidelines recommend that WDEIA should be diagnosed using provocation tests with wheat and exercise. After wheat consumption, patients exercise using a treadmill or an ergometer during provocation tests. Once WDEIA is diagnosed, patients should not consume wheat before physical activity. Exercise is allowed at least 4-áh after wheat intake. They may consume wheat if they do not exercise after wheat consumption, and they may exercise without consuming wheat before exercising. All WDEIA patients should be instructed regarding use of adrenaline auto-injector and should carry one with them. Some patients may respond to prophylactic treatment with anti-histamines. However, there is no established drug for preventing WDEIA; moreover, there is inadequate evidence for routine administration of these prophylactic drugs. Cofactors like nonsteroidal anti-inflammatory drugs (NSAIDs) may directly modulate immune reactions and could exacerbate the condition. Hence, patients should avoid these cofactors. The emergency treatment of WDEIA does not differ from that of immediate-type food allergy or anaphylaxis. Exercise should be stopped when patients show food allergy symptoms. When patients show anaphylactic reactions, adrenaline should be quickly administered. Indications for adrenaline auto-injector use are severe symptoms like persistent coughing, breathing with wheeze, persistent abdominal pain, and confusion. However, there is no evidence that anti-histamines and corticosteroids have lifesaving effects. Consequently, it is important that adrenaline auto-injector is used in an appropriate setting and that the patient is transferred to a hospital immediately. The mechanisms of WDEIA development are unknown. Further research is needed to clarify the mechanisms involved so that it can be treated</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0135-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0135-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-291-302.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-291-302.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Asaumi T</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0135-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fischer,J.</style></author><author><style face="normal" font="Arial"> Hilger,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Alpha-Gal Syndrome: Clinical Presentation, New Concepts, and Unmet Needs</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="311" start="303">303-311</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">For decades, carbohydrate determinants were seen as cross-reactive structures without clinical impact. The discovery of specific IgE to the carbohydrate galactose-+¦-1,3-galactose, called +¦-gal, changed our perspective on the allergenic potential of carbohydrate determinants. +¦-Gal is present in tissues of non-primate mammals and, upon ingestion, can provoke a delayed form of allergic reaction in sensitized patients. We are faced with a new and unique entity of allergy with high clinical relevance in food allergy and anaphylaxis to drugs derived from mammalian products. Tick bites are assumed to constitute the primary sensitization source to +¦-gal. To address the complexity of this disease, the term +¦-gal syndrome has been suggested</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -CO - Luxembourg -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0134-4</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0134-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-303-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-303-11.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Fischer J</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0134-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jarocka-Cyrta,E.</style></author><author><style face="normal" font="Arial"> Valverde-Monge,M.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Management of Food Protein-Induced Enterocolitis Syndrome (FPIES): Current Approach and Future Needs</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="394" start="383">383-394</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk</style></keyword><keyword><style face="normal" font="Arial"> Dehydration</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Failure to Thrive</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Lethargy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> oat</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Weight Loss</style></keyword><keyword><style face="normal" font="Arial"></style><style face="normal" font="Arial"> Young infants</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE, cell-mediated food allergic gastrointestinal disorder triggered by ingestion of food proteins (cow milk, soy, rice, oat, egg, and others). The acute FPIES begins approximately 1</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô4-áh after food ingestion with profuse, repetitive emesis that is accompanied by lethargy and pallor and may be followed later by diarrhea; 15% will require hospitalization because of hypotension and hemodynamic instability due to severe dehydration. A chronic FPIES is less frequent and develops from few days to 4-áweeks after the offending food has been introduced and fed daily. Chronic FPIES presents with intermittent emesis, bloody diarrhea, dehydration, weight loss, and failure to thrive and has been only reported in young infants fed with cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk and soy-based formulas. Acute FPIES to seafood has been reported in older children and in adults. The majority of patients react to a single food; however, FPIES can be triggered by more than one food, especially between cow milk/soy and rice/oats</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0141-5</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0141-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-383-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-383-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Jarocka-Cyrta E</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0141-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Konstantinou,G.N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Safety and Efficacy Balance of Baked Milk and Egg Oral Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Treat Options Allergy</style></full-title></periodical><pages end="382" start="370">370-382</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> Cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> egg allergens</style></keyword><keyword><style face="normal" font="Arial"> egg oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heated egg</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> matrix effect</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatment</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"></style><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2196-3053</style></isbn><abstract><style face="normal" font="Arial">Purpose of review There is a subgroup of individuals with egg or cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk (CM) allergy that can tolerate heated egg or CM. Thermal processing has been shown to affect antigen allergenicity either directly by denaturation of significant epitopes, or indirectly by synergistically altering their susceptibility to the digestion process under specific pH conditions. CM and egg proteins have heat labile molecules that become hypoallergenic after thermal treatment. The allergenicity may be further reduced when the CM and egg allergens are interacting with wheat proteins, and in particular gluten, in an interplay that teleologically affects solubility and therefore bioavailability. This phenomenon is known as the food matrix effect. By exploiting these observations, it has been suggested that diets containing extensively heated CM and egg might comprise an oral immunotherapeutic approach that could alter the expected natural allergy resolution or immunomodulate to tolerance the cases with persistent allergy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40521-017-0143-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0143-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-370-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-370-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Konstantinou GN</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40521-017-0143-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagibashi,T.</style></author><author><style face="normal" font="Arial"> Satoh,M.</style></author><author><style face="normal" font="Arial"> Nagai,Y.</style></author><author><style face="normal" font="Arial"> Koike,M.</style></author><author><style face="normal" font="Arial"> Takatsu,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Toyama Prefectural Institute of Pharmaceutical Research, 17-1 Nakataikouyama, Imizu City, Toyama 939-0363, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5</style></title><secondary-title><style face="normal" font="Arial">Cytokine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cytokine</style></full-title></periodical><pages end="70" start="59">59-70</pages><volume><style face="normal" font="Arial">98</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antibody secreting cell</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Bowel Diseases</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Motifs</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T helper 2 cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> target cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">T helper 2 cells produce a number of cytokines including inteleukin (IL)-5, IL-4 and IL-13. Group 2 innate lymphoid cells (ILC2s) also produce IL-5 under sterile conditions. IL-5 is interdigitating homodimeric glycoprotein and a member of the four alpha helical bundle motifs conserved among hematopoietic cytokines. IL-5 exerts its effects on target cells via IL-5 receptor (IL-5R), composed of an IL-5R alpha and betac subunit. The membrane proximal proline-rich motif of the cytoplasmic domain of both IL-5R alpha and betac subunits is essential for IL-5 signal transduction. Although IL-5 was initially identified by its ability to support the growth and terminal differentiation of mouse B cells into antibody-secreting cells, recombinant IL-5 exerts pleiotropic activities on various target cells. For example, IL-5 is now recognized as the major maturation and differentiation factor for eosinophils in mice and humans. Overexpression of IL-5 in mouse significantly increases eosinophil numbers and antibody levels in vivo, while mice lacking a functional gene for IL-5 or IL-5R display developmental and functional impairments in B cell and eosinophil lineages. In mice, the role of the IL-5/IL-5R system in the production and secretion of Immunoglobulin (Ig) M and IgA in mucosal tissues has been reported. Although eosinophils protect against invading pathogens including virus, bacteria and helminthes, they are also involved in the pathogenesis of various diseases, such as food allergy, asthma, and inflammatory bowel diseases. The recent expansion in our understanding in the context of IL-5 and IL-5-producing ILC2s in eosinophil activation and the pathogenesis of eosinophil-dependent inflammatory diseases has led to advances in therapeutic options. A new therapy currently under invetigarion in clinical trials uses humanized monoclonal antibodies against IL-5 or the IL-5R. In this review, we summarize our current understanding of the functions of IL-5 and its receptor, the innate regulation of IL-5-producing cells, and therapeutic potential of anti-IL-5 and anti-eosinophil (IL-5R) antibodies</style></abstract><notes><style face="normal" font="Arial">DA - 20170902IS - 1096-0023 (Electronic)IS - 1043-4666 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cyto.2016.11.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28863833">PM:28863833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytokine\2017-98-59-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytokine\2017-98-59-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Yanagibashi T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cyto.2016.11.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cox,J.</style></author><author><style face="normal" font="Arial"> Indugula,R.</style></author><author><style face="normal" font="Arial"> Vesper,S.</style></author><author><style face="normal" font="Arial"> Zhu,Z.</style></author><author><style face="normal" font="Arial"> Jandarov,R.</style></author><author><style face="normal" font="Arial"> Reponen,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Health University of Cincinnati, P.O. Box 670056, Cincinnati, OH 45267-0056, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of indoor air sampling and dust collection methods for fungal exposure assessment using quantitative PCR</style></title><secondary-title><style face="normal" font="Arial">Environ Sci Process Impacts</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Sci Process Impacts</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Air sampling</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> bedrooms</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Epicoccum</style></keyword><keyword><style face="normal" font="Arial"> ERMI</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> Indoor environments</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outdoor environment</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">Evaluating fungal contamination indoors is complicated because of the many different sampling methods utilized. In this study, fungal contamination was evaluated using five sampling methods and four matrices for results. The five sampling methods were a 48 hour indoor air sample collected with a Button inhalable aerosol sampler and four types of dust samples: a vacuumed floor dust sample, newly settled dust collected for four weeks onto two types of electrostatic dust cloths (EDCs) in trays, and a wipe sample of dust from above floor surfaces. The samples were obtained in the bedrooms of asthmatic children (n = 14). Quantitative polymerase chain reaction (qPCR) was used to analyze the dust and air samples for the 36 fungal species that make up the Environmental Relative Moldiness Index (ERMI). The results from the samples were compared by four matrices: total concentration of fungal cells, concentration of fungal species associated with indoor environments, concentration of fungal species associated with outdoor environments, and ERMI values (or ERMI-like values for air samples). The ERMI values for the dust samples and the ERMI-like values for the 48 hour air samples were not significantly different. The total cell concentrations of the 36 species obtained with the four dust collection methods correlated significantly (r = 0.64-0.79, p &lt; 0.05), with the exception of the vacuumed floor dust and newly settled dust. In addition, fungal cell concentrations of indoor associated species correlated well between all four dust sampling methods (r = 0.68-0.86, p &lt; 0.01). No correlation was found between the fungal concentrations in the air and dust samples primarily because of differences in concentrations of Cladosporium cladosporioides Type 1 and Epicoccum nigrum. A representative type of dust sample and a 48 hour air sample might both provide useful information about fungal exposures</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 2050-7895 (Electronic)IS - 2050-7887 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1039/c7em00257b</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28858343">PM:28858343</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Sci Process Impacts\20170831-CoxJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Sci Process Impacts\20170831-CoxJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Cox J</style></custom2><misc3><style face="normal" font="Arial">10.1039/c7em00257b</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dispenza,M.C.</style></author><author><style face="normal" font="Arial"> Regan,J.A.</style></author><author><style face="normal" font="Arial"> Bochner,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Division of Allergy and Immunology , Northwestern University , Chicago , USA</style></auth-address><titles><title><style face="normal" font="Arial">Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bruton's tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170822IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1370374</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28829205">PM:28829205</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Expert Rev Clin Immunol\20170822-DispenzaMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Expert Rev Clin Immunol\20170822-DispenzaMC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170822, Dispenza MC</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1370374</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mattiucci,S.</style></author><author><style face="normal" font="Arial"> Giulietti,L.</style></author><author><style face="normal" font="Arial"> Paoletti,M.</style></author><author><style face="normal" font="Arial"> Cipriani,P.</style></author><author><style face="normal" font="Arial"> Gay,M.</style></author><author><style face="normal" font="Arial"> Levsen,A.</style></author><author><style face="normal" font="Arial"> Klapper,R.</style></author><author><style face="normal" font="Arial"> Karl,H.</style></author><author><style face="normal" font="Arial"> Bao,M.</style></author><author><style face="normal" font="Arial"> Pierce,G.J.</style></author><author><style face="normal" font="Arial"> Nascetti,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Population genetic structure of the parasite Anisakis simplex (s. s.) collected in Clupea harengus L. from North East Atlantic fishing grounds</style></title><secondary-title><style face="normal" font="Arial">Fish Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Fish Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis simplex</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atlantic Ocean</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fishing ground</style></keyword><keyword><style face="normal" font="Arial"> fishing grounds</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic analysis</style></keyword><keyword><style face="normal" font="Arial"> Genetic marker</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> herring</style></keyword><keyword><style face="normal" font="Arial"> Herring stocks</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> mtDNA</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> North East Atlantic Ocean</style></keyword><keyword><style face="normal" font="Arial"> North Sea</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Population genetics</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stock identification</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Structure analysis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0165-7836</style></isbn><abstract><style face="normal" font="Arial">The Atlantic herring is a schooling, pelagic species that inhabits both sides of the North Atlantic Ocean. Herring stock identification is usually based on several approaches, including fish meristic characters, population genetic analysis and the use of parasite species composition. A total of 654 Anisakis spp. larvae collected from herring of four fishing grounds in the Norwegian Sea, Baltic Sea, North Sea, and the English Channel off the French coast, was identified to species level using diagnostic allozymes and sequence analysis of EF1 +¦</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1 nDNA and the mtDNA cox2 genes. Population genetic differentiation of Anisakis simplex (s. s.) among the different fishing areas was estimated, at the intraspecific level, on the basis of mtDNA cox2 sequences analysis. Spatial comparison based on molecular variance analysis and Fst values was performed for the collected specimens (among regions). Haplotype network construction showed relevant differences in haplotype frequencies between samples of A. simplex (s. s.) from the different geographical areas. Results indicate a genetic sub-structuring of A. simplex (s. s.) obtained from herring in different areas, with the population from the Norwegian Sea being the most differentiated one, and with North Sea and Baltic Sea populations being most similar. The population genetic structure of A. simplex (s. s.) was in accordance with the herring population genetic structure throughout the host</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs geographical range in the NE Atlantic. Results suggest that mtDNA cox2 is a suitable genetic marker for A. simplex (s. s.) population genetic structure analysis and a valuable tool to elucidate the herring stock structure in the NE Atlantic Ocean</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -CO - France -CO - Norway -CO - Germany -CO - United Kingdom -CO - Spain -CO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.fishres.2017.08.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.fishres.2017.08.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Fish Res\20170901-MattiucciS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Fish Res\20170901-MattiucciS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Mattiucci S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.fishres.2017.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ma,S.</style></author><author><style face="normal" font="Arial"> Wang,R.</style></author><author><style face="normal" font="Arial"> Nie,L.</style></author><author><style face="normal" font="Arial"> Yin,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Pollen-food allergy syndrome in China</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen components</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer proteins</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen-food allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">Little is known about pollen-food allergy syndrome (PFS) in China. To investigate the clinical characteristics, as well as sensitization patterns, of PFS in China. Clinical parameters and serum Immunoglobulin E (IgE) responses to prevalent pollens, plant foods and corresponding allergen components were evaluated. The top three most common pollen-associated allergenic foods were peach, apple and pear. Fifty-nine percent of the patients with PFS were allergic to peach. Sixty-one percent of PFS patients developed systemic reactions with or without oral cavity discomfort upon ingestion of the culprit food. Positive IgE responses to nonspecific lipid transfer proteins occurred in 69.9% of PFS patients, which was in accordance with the high prevalence of systemic reactions. Peach was the most common allergenic food in PFS patients. Patients with PFS in China showed an LTP-dominant sensitization profile and usually presented systemic reactions upon consumption of the allergenic foods</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1372372</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1372372</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\20170901-MaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\20170901-MaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Ma S</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1372372</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cuadrado,C.</style></author><author><style face="normal" font="Arial"> Cheng,H.</style></author><author><style face="normal" font="Arial"> Sanchiz,A.</style></author><author><style face="normal" font="Arial"> Ballesteros,I.</style></author><author><style face="normal" font="Arial"> Easson,M.</style></author><author><style face="normal" font="Arial"> Grimm,C.C.</style></author><author><style face="normal" font="Arial"> Dieguez,M.C.</style></author><author><style face="normal" font="Arial"> Linacero,R.</style></author><author><style face="normal" font="Arial"> Burbano,C.</style></author><author><style face="normal" font="Arial"> Maleki,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Influence of enzymatic hydrolysis on the allergenic reactivity of processed cashew and pistachio</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="379" start="372">372-379</pages><volume><style face="normal" font="Arial">241</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> allergenic potency</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Binding Properties</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Cashew allergen</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic digestion</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic treatment</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Pressure processing</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein structure</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Sonication</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> Thermal treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">Cashew and pistachio allergies are considered a serious health problem. Previous studies have shown that thermal processing, pressurization and enzymatic hydrolysis may reduce the allergenic properties of food by changing the protein structure. This study assesses the allergenic properties of cashew and pistachio after thermal treatment (boiling and autoclaving), with or without pressure (autoclaving), and multiple enzymatic treatments under sonication, by SDS-PAGE, western blot and ELISA, with serum IgE of allergic individuals, and mass spectroscopy. Autoclaving and enzymatic hydrolysis under sonication separately induced a measurable reduction in the IgE binding properties of pastes made from treated cashew and pistachio nuts. These treatments were more effective with pistachio allergens. However, heat combined with enzymatic digestion was necessary to markedly lower IgE binding to cashew allergens. The findings identify highly effective simultaneous processing conditions to reduce or even abolish the allergenic potency of cashew and pistachio</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.08.120</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958542">PM:28958542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\20170904-CuadradoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\20170904-CuadradoC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Cuadrado C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.08.120</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Glusac,J.</style></author><author><style face="normal" font="Arial"> Isaschar-Ovdat,S.</style></author><author><style face="normal" font="Arial"> Kukavica,B.</style></author><author><style face="normal" font="Arial"> Fishman,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Oil-in-water emulsions stabilized by tyrosinase-crosslinked potato protein</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="415" start="407">407-415</pages><volume><style face="normal" font="Arial">100</style></volume><number><style face="normal" font="Arial">Pt 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Droplet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> emulsion</style></keyword><keyword><style face="normal" font="Arial"> Emulsions</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Microstructure</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Olive</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shear</style></keyword><keyword><style face="normal" font="Arial"> shear stress</style></keyword><keyword><style face="normal" font="Arial"> Size distribution</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Viscosity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">Potato protein (PP) holds great promise as a non-allergenic food ingredient with high nutritional value. Attempts to modulate its functional properties by crosslinking have not been reported to date. The effect of tyrosinase-mediated crosslinking of PP on the properties of o/w emulsions was studied in the present work. Among the various PPs, protease inhibitors were efficiently crosslinked by the enzyme as determined by SDS-PAGE analysis. Concentrated emulsions comprising 40% olive oil and 6.1% PP (w/w) were fabricated by a shear stress homogenizer. The PP-stabilized emulsions were evaluated after one and 4h of incubation with tyrosinase. Emulsions were characterized by their droplet size distribution, rheological behavior, creaming resistance and microstructure. The crosslinked emulsion had a self-standing elastic gel-like structure after 1h of incubation. Unlike the Newtonian non-crosslinked emulsion, the crosslinked emulsion exhibited a shear-thinning behavior with a 20-fold increase in viscosity. The longer incubation time coupled with shaking at 250rpm for up to 4h resulted in the disruption of the droplets structure and led to a 2-fold decrease in viscosity, compared to the 1-hour crosslinked emulsion. Droplet size distribution showed formation of large particles in the crosslinked emulsion. Microscopy imaging demonstrated formation of aggregated and dense emulsion droplets network, which also contributed to the emulsion gel-like behavior. In the case of the non-crosslinked emulsion, severe flocculation and coalescence was observed, regardless of incubation time. The results suggest that tyrosinase crosslinking is a useful method to modulate the properties of PP-based food formulations</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 1873-7145 (Electronic)IS - 0963-9969 (Linking)LA - engPT - Journal ArticleCO - Israel -CO - Bosnia and Herzegovina -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2017.07.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28873703">PM:28873703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\2017-100-407-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\2017-100-407-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Glusac J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2017.07.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Su,M.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Roux,K.H.</style></author><author><style face="normal" font="Arial"> Gradziel,T.M.</style></author><author><style face="normal" font="Arial"> Sathe,S.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of processing and storage on almond (Prunus dulcis L.) amandin immunoreactivity</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="95" start="87">87-95</pages><volume><style face="normal" font="Arial">100</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Almond</style></keyword><keyword><style face="normal" font="Arial"> Almond detection</style></keyword><keyword><style face="normal" font="Arial"> Almond protein</style></keyword><keyword><style face="normal" font="Arial"> Almonds</style></keyword><keyword><style face="normal" font="Arial"> Amandin</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Flours</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Prunus</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Roasting</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Sucrose</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">A murine monoclonal antibody (mAb)-based enzyme-linked immunosorbent assay (ELISA) was used to assess amandin immunoreactivity in processed and long-term stored almonds. The results demonstrated that amandin immunoreactivity is stable in variously processed almond seeds. Using the ELISA, amandin immunoreactivity could be detected in commercial whole raw and processed (blanched, sliced, dry roasted, and indicated combinations thereof) almond seeds stored for eleven years and eight months, defatted almond seed flours from several almond varieties/hybrids and their borate saline buffer-solubilized protein extracts stored for ten years and seven months, and several almond varieties grown in different California counties (full fat flours and their defatted flour counterparts). Roasting Nonpareil whole full fat almond seeds, full fat flour, and defatted flour at 170-¦C for 20min each with 2, 5, 10, and 20% w/w corn syrup or sucrose did not prevent amandin detection by ELISA. Similarly, amandin detection in select food matrices spiked with Nonpareil almond protein extract was not inhibited. In conclusion, amandin is a stable target protein for almond detection under the tested processing and storage conditions</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2017.06.061</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodres.2017.06.061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\2017-100-87-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\2017-100-87-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Su M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2017.06.061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rahnama,H.</style></author><author><style face="normal" font="Arial"> Nikmard,M.</style></author><author><style face="normal" font="Arial"> Abolhasani,M.</style></author><author><style face="normal" font="Arial"> Osfoori,R.</style></author><author><style face="normal" font="Arial"> Sanjarian,F.</style></author><author><style face="normal" font="Arial"> Habashi,Ali A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immune analysis of cry1Ab-genetically modified potato by in-silico analysis and animal model</style></title><secondary-title><style face="normal" font="Arial">Food Sci Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Sci Biotechnol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth rate</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin A</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> In silico analysis</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-6</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Solanum tuberosum</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2092-6456</style></isbn><abstract><style face="normal" font="Arial">The safety of feeding transgenic potato (Solanum tuberosum), resistant to the potato tuber moth, to Wistar rats was examined from an immunological perspective. The genetically modified potato (GMP) was harbouring cry1Ab and nptII genes as target and selectable marker genes, respectively. In-silico analysis reconfirmed that Cry1Ab and NPTII protein sequences have no significant homology to known toxins or known allergens. The Wistar rats were fed a diet containing 20% GMP or its parental control, non-GMP (NGMP), for 90-ádays. The consumption of GMP food did not affect the growth rate, food intake, food efficiency, and general health status of the rats. There were no significant differences in the serum concentrations of immunoglobulin A (IgA), IgG, IgM, interleukin 6 (IL-6), and IFN-+¦ between GMP and NGMP-fed rats. Based on such data, it is concluded that the transgenic potato had no adverse effect on immunity functions of Wistar rats</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10068-017-0181-4</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10068-017-0181-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Sci Biotechnol\20170904-RahnamaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Sci Biotechnol\20170904-RahnamaH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Rahnama H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10068-017-0181-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vitte,J.</style></author><author><style face="normal" font="Arial"> Ranque,S.</style></author><author><style face="normal" font="Arial"> Carsin,A.</style></author><author><style face="normal" font="Arial"> Gomez,C.</style></author><author><style face="normal" font="Arial"> Romain,T.</style></author><author><style face="normal" font="Arial"> Cassagne,C.</style></author><author><style face="normal" font="Arial"> Gouitaa,M.</style></author><author><style face="normal" font="Arial"> Baravalle-Einaudi,M.</style></author><author><style face="normal" font="Arial"> Bel,N.S.</style></author><author><style face="normal" font="Arial"> Reynaud-Gaubert,M.</style></author><author><style face="normal" font="Arial"> Dubus,J.C.</style></author><author><style face="normal" font="Arial"> Mege,J.L.</style></author><author><style face="normal" font="Arial"> Gaudart,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Aix-Marseille Univ, APHM Assistance Publique Hopitaux de Marseille, Hopital de La Conception, Laboratoire d'Immunologie, Marseille, France</style></auth-address><titles><title><style face="normal" font="Arial">Multivariate Analysis As a Support for Diagnostic Flowcharts in Allergic Bronchopulmonary Aspergillosis: A Proof-of-Concept Study</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="1019">1019-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic algorithm</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Molecular-based allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Molecular-based allergy diagnosis yields multiple biomarker datasets. The classical diagnostic score for allergic bronchopulmonary aspergillosis (ABPA), a severe disease usually occurring in asthmatic patients and people with cystic fibrosis, comprises succinct immunological criteria formulated in 1977: total IgE, anti-Aspergillus fumigatus (Af) IgE, anti-Af "precipitins," and anti-Af IgG. Progress achieved over the last four decades led to multiple IgE and IgG(4) Af biomarkers available with quantitative, standardized, molecular-level reports. These newly available biomarkers have not been included in the current diagnostic criteria, either individually or in algorithms, despite persistent underdiagnosis of ABPA. Large numbers of individual biomarkers may hinder their use in clinical practice. Conversely, multivariate analysis using new tools may bring about a better chance of less diagnostic mistakes. We report here a proof-of-concept work consisting of a three-step multivariate analysis of Af IgE, IgG, and IgG4 biomarkers through a combination of principal component analysis, hierarchical ascendant classification, and classification and regression tree multivariate analysis. The resulting diagnostic algorithms might show the way for novel criteria and improved diagnostic efficiency in Af-sensitized patients at risk for ABPA</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.01019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28878778">PM:28878778</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1019.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1019.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Vitte J</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.01019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vroman,H.</style></author><author><style face="normal" font="Arial"> Hendriks,R.W.</style></author><author><style face="normal" font="Arial"> Kool,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Dendritic Cell Subsets in Asthma: Impaired Tolerance or Exaggerated Inflammation?</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="941">941-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> functional properties</style></keyword><keyword><style face="normal" font="Arial"> functional property</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Ontogeny</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid DCs</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic mice</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is a prevalent chronic heterogeneous inflammatory disease of the airways, leading to reversible airway obstruction, in which various inflammatory responses can be observed. Mild to moderate asthma patients often present with a Th2-mediated eosinophilic inflammation whereas in severe asthma patients, a Th17-associated neutrophilic or combined Th2 and Th17-mediated eosinophilic/neutrophilic inflammation is observed. The differentiation of these effector Th2 and Th17-cells is induced by allergen-exposed dendritic cells (DCs) that migrate toward the lung draining lymph node. The DC lineage comprises conventional DCs (cDCs) and plasmacytoid DCs (pDCs), of which the cDC lineage consists of type 1 cDCs (cDC1s) and cDC2s. During inflammation, also monocytes can differentiate into so-called monocyte-derived DCs (moDCs). These DC subsets differ both in ontogeny, localization, and in their functional properties. New identification tools and the availability of transgenic mice targeting specific DC subsets enable the investigation of how these different DC subsets contribute to or suppress asthma pathogenesis. In this review, we will discuss mechanisms used by different DC subsets to elicit or hamper the pathogenesis of both Th2-mediated eosinophilic asthma and more severe Th17-mediated neutrophilic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.00941</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848549">PM:28848549</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-941.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-941.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Vroman H</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.00941</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Warners,M.J.</style></author><author><style face="normal" font="Arial"> Terreehorst,I.</style></author><author><style face="normal" font="Arial"> van den Wijngaard,R.M.</style></author><author><style face="normal" font="Arial"> Akkerdaas,J.</style></author><author><style face="normal" font="Arial"> van Esch,B.C.A.M.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Versteeg,S.A.</style></author><author><style face="normal" font="Arial"> Smout,A.J.P.M.</style></author><author><style face="normal" font="Arial"> Bredenoord,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology &amp; Hepatology, Academic Medical Center, Amsterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Abnormal Responses to Local Esophageal Food Allergen Injections in Adult Patients with Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="Arial">Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Gastroenterology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Blanching</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Skin tests and measurement of serum levels of immunoglobulin E do not accurately identify foods for elimination from the diets of patients with eosinophilic esophagitis (EoE). We investigated whether an esophageal prick test (EPT), in which the esophageal mucosa is challenged by local injection of allergen extracts, could identify individuals with esophageal sensitization. During endoscopy 6 allergens were injected in the esophagus of 8 patients with EoE and 3 patients without EoE (controls). A second endoscopy was performed after 24 hrs to evaluate delayed responses. Five of the 8 patients with EoE had evidence for an acute response (luminal obstruction and mucosal blanching); 2 other patients had a delayed wheal or flare reaction. No responses were observed in controls. We conclude that esophageal mucosal food allergen injections induce acute and/or delayed responses in patients with EoE but not controls. The EPT deserves further exploration because it might guide elimination diets</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1528-0012 (Electronic)IS - 0016-5085 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1053/j.gastro.2017.08.062</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870530">PM:28870530</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Gastroenterology\20170905-WarnersMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Gastroenterology\20170905-WarnersMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Warners MJ</style></custom2><misc3><style face="normal" font="Arial">10.1053/j.gastro.2017.08.062</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Adeniyi,T.A.</style></author><author><style face="normal" font="Arial"> Adeonipekun,P.A.</style></author><author><style face="normal" font="Arial"> Olowokudejo,J.D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Annual Records of Airborne Pollen of Poaceae in Five Areas in Lagos, Nigeria</style></title><secondary-title><style face="normal" font="Arial">Grana</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Grana</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Forecast</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Nigeria</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0017-3134</style></isbn><abstract><style face="normal" font="Arial">Poaceae pollen grains are known to be highly allergenic and they are potential causes of allergic respiratory diseases. In order to investigate the incidence of airborne Poaceae, and contribute to current trends in the development of aeropalynology/allergy studies in Nigeria, five highly populated locations in Central Lagos State, Surulere, Ebute-Metta, University of Lagos, Bariga and Gbagada, were sampled. Gravimetric aerosamples were collected monthly from January 2013 to December 2014. The lowest count in 2013 was recorded in the Ebute-Metta area (179), while the highest in 2013 was recorded in Gbagada (564). In 2014, the Surulere area (282) had the lowest count while Bariga (671) had the highest. The locations have similar monthly pollen distribution pattern but different peak months. Generally, Poaceae pollen counts were lowest in the months of June and July. These are therefore the safest months for Poaceae pollen hypersensitive individuals in the study areas. Relative humidity was the most important meteorological parameter with significant correlations in Ebute-Metta and Bariga locations. Results from this work will form the basis for a forecast service required to inform and educate the general public and allergy sufferers about Poaceae pollen distribution in Lagos State</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Nigeria -</style></notes><work-type><style face="normal" font="Arial">10.1080/00173134.2017.1356865</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/00173134.2017.1356865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Grana\20170901-AdeniyiTA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Grana\20170901-AdeniyiTA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901\, Adeniyi TA</style></custom2><misc3><style face="normal" font="Arial">10.1080/00173134.2017.1356865</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,L.</style></author><author><style face="normal" font="Arial"> Zhu,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Allergy , Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology , China</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy of House Dust Mite Allergy</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergen standardization</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> standardization</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">House dust mite (HDM) is a predominant source of indoor aeroallergen worldwide, which induces allergic diseases including allergic rhinoconjunctivitis, allergic asthma, atopic eczema and other allergic skin diseases. Allergen specific immunotherapy (AIT) is the only potential disease-modifying treatment for HDM allergic subjects. However, AIT remains underused due to no universally accepted allergen standardization and a shortage of rigorous clinical studies to confirm safety and efficacy. With the effort of doctors and researchers in allergy field, efficacy, safety, standardization and strategy of AIT are being continuously developed. This review presents the updated research based on recently published trials and meta-analyses</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1364823</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853977">PM:28853977</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170830-YangL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170830-YangL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Yang L</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1364823</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Su,Y.</style></author><author><style face="normal" font="Arial"> Romeu-Bonilla,E.</style></author><author><style face="normal" font="Arial"> Heiland,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Immunomic Therapeutics, Inc. (ITI) , Rockville , MD USA</style></auth-address><titles><title><style face="normal" font="Arial">Next generation immunotherapy for tree pollen allergies</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA vaccine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">Tree pollen induced allergies are one of the major medical and public health burdens in the industrialized world. Allergen-Specific Immunotherapy (AIT) through subcutaneous injection or sublingual delivery is the only approved therapy with curative potential to pollen induced allergies. AIT often is associated with severe side effects and requires long-term treatment. Safer, more effective and convenient allergen specific immunotherapies remain an unmet need. In this review article, we discuss the current progress in applying protein and peptide-based approaches and DNA vaccines to the clinical challenges posed by tree pollen allergies through the lens of preclinical animal models and clinical trials, with an emphasis on the birch and Japanese red cedar pollen induced allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1367882</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853984">PM:28853984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170830-SuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170830-SuY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Su Y</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1367882</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,K.H.</style></author><author><style face="normal" font="Arial"> Song,Y.</style></author><author><style face="normal" font="Arial"> O'Sullivan,M.</style></author><author><style face="normal" font="Arial"> Pereira,G.</style></author><author><style face="normal" font="Arial"> Loh,R.</style></author><author><style face="normal" font="Arial"> Zhang,G.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Public Health, Curtin University of Technology, Bentley WA, Australia</style></auth-address><titles><title><style face="normal" font="Arial">The Implications of DNA Methylation on Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="192" start="183">183-192</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene-environment</style></keyword><keyword><style face="normal" font="Arial"> gene-environment interaction</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Loci</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune development</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">Food allergy is a major clinical and public health concern worldwide. The risk factors are well defined, however, the mechanisms by which they affect immune development remain largely unknown, and unfortunately the effective treatment or prevention of food allergy is still being researched. Recent studies show that the genes that are critical for the development of food allergy are regulated through DNA methylation. Environmental factors can affect host DNA methylation status and subsequently predispose people to food allergy. DNA methylation is therefore an important mediator of gene-environment interactions in food allergy and key to understanding the mechanisms underlying the allergic development. Indeed, the modification and identification of the methylation levels of specific genetic loci have gained increasing attention for therapeutic and diagnostic application in combating food allergy. In this review, we summarize and discuss the recent developments of DNA methylation in food allergy, including the pathogenesis, therapy, and diagnosis. This review will also summarize and discuss the environmental factors that affect DNA methylation levels in food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1159/000479513.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848217">PM:28848217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-183-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-183-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Lee KH</style></custom2><misc3><style face="normal" font="Arial">10.1159/000479513.</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Wu,Y.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Huang,X.</style></author><author><style face="normal" font="Arial"> Zhu,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</style></auth-address><titles><title><style face="normal" font="Arial">Eight Aeroallergen Skin Extracts May Be the Optimal Panel for Allergic Rhinitis Patients in Central China</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="198" start="193">193-198</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Artemisia</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cryptomeria</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Humulus</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of allergic rhinitis (AR) is increasing rapidly in Central China. The skin prick test (SPT) is the standard tool with which to determine the allergen sensitization status in AR patients. Changes in allergen sensitization patterns have been observed within countries and regions due to geographical and seasonal variations. OBJECTIVE: The aim of this study was to evaluate the profile of SPT reactivity to different aeroallergens in AR patients and to suggest a minimal panel of allergens to detect sensitized patients in Central China. METHODS: From January 2015 to December 2016, patients who presented to Tongji Hospital with suspected AR were tested with the same panel of 19 aeroallergens. The results of SPT were analyzed to determine the minimum test battery panel necessary to cover 99% of the cases of SPT sensitization in different age subgroups. RESULTS: A total of 2,416 patients (male:female ratio 1.2:1) were enrolled in our study with an average age of 22.0 years. The overall rate of sensitization to any allergen was 79.0%, and 64.3% of the subjects were monosensitized. The highest sensitized rate was found in the subgroup aged 14-18 years (92.0%), followed by the subgroups of 6-14 years (86.4%), >18 years (75.6%), and &lt;/=6 years (74.9%). The most common sensitization was to Dermatophagoides farinae (71.1%). Testing with 8 allergens (D. pteronyssinus, D. farinae, Platanus, Artemisia, Cryptomeria, Blatella germanica, Humulus, and Alternaria) was sufficient to identify over 99% of the sensitized patients. CONCLUSION: An SPT panel covering 8 allergen extracts was able to detect almost all sensitized patients suffering from AR symptoms in Central China</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1159/000479429</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848100">PM:28848100</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-193-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-193-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.1159/000479429</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marco-Martin,G.</style></author><author><style face="normal" font="Arial"> La Rotta,H.A.</style></author><author><style face="normal" font="Arial"> Vazquez de la Torre,M.</style></author><author><style face="normal" font="Arial"> Higaki,Y.</style></author><author><style face="normal" font="Arial"> Zubeldia,J.M.</style></author><author><style face="normal" font="Arial"> Baeza,M.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Differences in the Anaphylactic Response between C3H/HeOuJ and BALB/c Mice</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="212" start="204">204-212</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis is a severe and potentially lethal allergic reaction whose incidence is increasing. Murine models can elucidate the underlying mechanisms and pave the way for appropriate therapeutic options. However, differences in strains and protocols hamper comparisons of data between researchers. We performed a parallel study of clinical and immune responses with 2 strains of mice, BALB/c and C3H/HeOuJ, in an allergen-induced systemic anaphylaxis protocol. Both strains have been widely used in allergy models, although they have not been compared in an intraperitoneal systemic model. METHODS: Groups of 5-week-old female BALB/c and C3H/HeOuJ mice were intraperitoneally sensitized with peanut in the presence of adjuvants. Specific immunoglobulin (sIg) G1, sIgG2a, sIgE, total IgE, histamine release, and specific stimulated splenocyte cytokines, interleukin (IL)-4, IL-5, IL-10, IL-12, IL-13, and interferon (IFN)-gamma, were assessed. At week 6, mice were intraperitoneally challenged with peanut. Anaphylaxis was evaluated by recognition of clinical symptoms and changes in body temperature. RESULTS: All peanut-sensitized mice induced sIg and developed anaphylactic symptoms upon challenge. Nonetheless, the C3H/HeOuJ strain demonstrated earlier and persistently higher sIgG1 and sIgG2a production, elevated sIgE, and more severe clinical symptoms and histamine release than the BALB/c strain. In contrast, BALB/c exhibited higher release of IL-4, IL-5, IL-10, IL-13, and IFN-gamma. CONCLUSIONS: Both models are suitable for studying anaphylaxis. Consequently, they could be used in research on the pathogenesis and therapy of anaphylaxis. However, according to the type of study performed, differences in the specific clinical, humoral, and cellular responses to antigens have to be considered</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1159/000478983</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850948">PM:28850948</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-204-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-204-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Marco-Martin G</style></custom2><misc3><style face="normal" font="Arial">10.1159/000478983</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okano,H.</style></author><author><style face="normal" font="Arial"> Fujimura,T.</style></author><author><style face="normal" font="Arial"> Fukuoka,N.</style></author><author><style face="normal" font="Arial"> Hayashi,T.</style></author><author><style face="normal" font="Arial"> Nishikawa,K.</style></author><author><style face="normal" font="Arial"> Ono,K.</style></author><author><style face="normal" font="Arial"> Kawamoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hiroshima Research Center for Healthy Aging (HiHA), Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, Higashi-Hiroshima, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Plasma Cluster Ions Reduce the IgE-Binding Capacity of House Dust Mite Allergens under a Simulated Indoor Environmental Condition</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="203" start="199">199-203</pages><volume><style face="normal" font="Arial">173</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aging</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Japanese cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: A high level of house dust mite (HDM) allergens in a living environment is a risk factor for both sensitization to these allergens and asthmatic attacks. We previously showed that plasma cluster ions (PCIs) impaired the IgE-binding capacity of atomized crude allergens prepared from Japanese cedar pollen and fungus under experimental conditions. OBJECTIVE: We evaluated the capacity of PCIs to impair the IgE-binding capacity of airborne HDM allergens under a simulated indoor environmental condition. METHODS: For the determination of the effects of PCIs on HDM allergens under an experimental condition, HDM extract was atomized as aqueous mist into a cylindrical experimental apparatus filled with PCIs. For the evaluation of the effects of PCIs under a simulated natural indoor environmental condition, dried HDM allergens were floated as airborne particles in an acryl cubic apparatus in the presence of PCIs. The IgE-binding capacities of the PCI- and sham-treated HDM allergens were analyzed by an ELISA. RESULTS: The IgE-binding capacity of the HDM allergens was significantly impaired after PCI treatment compared to that after sham treatment under both experimental and simulated environmental conditions. The ELISA results demonstrated that the IgE-binding capacities of HDM allergens after PCI treatment showed 68 and 74% reductions compared to those after sham treatment under the experimental and simulated environmental conditions, respectively. CONCLUSIONS: PCIs have the capacity to impair the IgE-binding capacity of airborne HDM allergens in a simulated environmental condition</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000477724</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848159">PM:28848159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-199-203.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-173-199-203.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Okano H</style></custom2><misc3><style face="normal" font="Arial">10.1159/000477724</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakano,T.</style></author><author><style face="normal" font="Arial"> Hsu,L.W.</style></author><author><style face="normal" font="Arial"> Lai,C.Y.</style></author><author><style face="normal" font="Arial"> Takaoka,Y.</style></author><author><style face="normal" font="Arial"> Inomata,M.</style></author><author><style face="normal" font="Arial"> Kitano,S.</style></author><author><style face="normal" font="Arial"> Chen,C.L.</style></author><author><style face="normal" font="Arial"> Goto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic potential of alpha-lipoic acid derivative, sodium zinc histidine dithiooctanamide, in a mouse model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> BLAST</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Concanavalin A</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Histidine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-17</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oxidative stress is involved in various diseases, including allergies. Several studies have pointed to the preventive and therapeutic potential of antioxidants in allergic disorders. However, little is known about the immunomodulatory effects of antioxidants in type I hypersensitivity. In this study we aimed to explore the impact of a water-soluble antioxidant and alpha-lipoic acid derivative, sodium zinc histidine dithiooctanamide (DHL-HisZn), on mast-cell- and T-cell-mediated allergic and immune responses both in vitro and in vivo. METHODS: The therapeutic impact of DHL-HisZn on mast-cell-mediated type I hypersensitivity was evaluated by a mast-cell degranulation assay using bone marrow-derived mast cells and by a mouse model of ovalbumin (OVA)-induced allergic rhinitis. The effect of DHL-HisZn on the proportion of regulatory T cells (Tregs) was evaluated using flow cytometry. RESULTS: During the course of OVA-induced allergic rhinitis in mice, serum nitrate was elevated, suggesting the involvement of oxidative stress in allergic responses. DHL-HisZn not only suppressed mast-cell degranulation but also ameliorated OVA-induced nasal hypersensitivity, with significant suppression of serum nitrate. DHL-HisZn treatment significantly suppressed OVA-specific immunoglobulin E (IgE) but enhanced OVA-specific IgG2a in OVA-sensitized and nasal-challenged mice. Furthermore, DHL-HisZn treatment suppressed interleukin-17 production in OVA-stimulated splenocytes. Finally, we demonstrated the induction of Tregs by DHL-HisZn in concanavalin A blasts. CONCLUSIONS: These findings suggest that DHL-HisZn may regulate mast-cell-, T-helper 2 (Th2)-, and Th17-mediated allergic and immune responses by induction of Tregs</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - Taiwan -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.22008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28863235">PM:28863235</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170901-NakanoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20170901-NakanoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Nakano T</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.22008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cho,S.M.</style></author><author><style face="normal" font="Arial"> Kim,M.E.</style></author><author><style face="normal" font="Arial"> Kwon,B.</style></author><author><style face="normal" font="Arial"> Nahm,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Immunomodulatory effects induced by intramuscular administration of autologous total immunoglobulin G in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="6" start="1">1-6</pages><volume><style face="normal" font="Arial">52</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood donor</style></keyword><keyword><style face="normal" font="Arial"> Blood Donors</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Der f 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Polyvalent human immunoglobulin G (IgG) preparations produced from the plasma pools of healthy blood donors have been used for the treatment of various autoimmune diseases and allergic diseases because of their anti-inflammatory and immunomodulatory effects. We hypothesized that intramuscular administration of autologous total IgG would induce immunomodulatory effects in patients with allergic diseases, based on the clinical efficacy of autologous blood therapy in patients with atopic dermatitis (AD). METHODS: Sixteen adult AD patients with IgE-mediated sensitization to the house dust mite (Dermatophagoides farinae) received intramuscular injections of 50 mg autologous total IgG twice a week for 4 weeks. The serum levels of IgE, IgG, and IgG4 antibodies to the recombinant group 2 major allergen of Dermatophagoides farinae (Der f 2) and serum levels of interleukin (IL)-10, IL-4, IL-12, and interferon gamma (IFN-gamma) were measured by enzyme-linked immunosorbent assay at baseline and at weeks 4, 8, and 12. RESULTS: The serum level of IgE antibodies to Der f 2 was significantly decreased at 12 weeks compared with baseline (p&lt;0.005). The serum levels of IgG and IgG4 antibodies to Der f 2 were significantly increased at 4, 8, and 12 weeks compared with baseline (p&lt;0.05). The serum levels of IL-10 and IFN-gamma were significantly increased at 4, 8, and 12 weeks compared with baseline (p&lt;0.05). There were no significant differences in the serum levels of IL-4 or IL-12 before and after intramuscular administrations of autologous total IgG (p>0.05). CONCLUSION: Intramuscular administration of autologous total IgG induced anti-allergic immunomodulatory effects in AD patients. Further studies are required to evaluate the detailed immunological mechanism underlying these effects</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.08.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846886">PM:28846886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-52-1-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-52-1-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Cho SM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.08.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sadeghian,T.</style></author><author><style face="normal" font="Arial"> Tavaf,Z.</style></author><author><style face="normal" font="Arial"> Oryan,A.</style></author><author><style face="normal" font="Arial"> Shokouhi,R.</style></author><author><style face="normal" font="Arial"> Pourpak,Z.</style></author><author><style face="normal" font="Arial"> Moosavi-Movahedi,A.A.</style></author><author><style face="normal" font="Arial"> Yousefi,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Protein Chemistry Laboratory (PCL), Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Structure, Chaperone-Like Activity and Allergenicity Profile of Bovine Caseins Upon Peroxynitrite Modification: New Evidences Underlying Mastitis Pathomechanisms</style></title><secondary-title><style face="normal" font="Arial">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biol Macromol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Ascorbic Acid</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine casein</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Caseins</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> nitrotyrosine</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="8" Year="2017">2017/8/26</year></dates><abstract><style face="normal" font="Arial">Mastitis, an inflammatory reaction frequently develops in response to intra-mammary bacterial infection, may induce the generation of peroxynitrite (PON) which is a highly potent reactive oxygen and nitrogen species. Caseins as the intrinsically unfolded proteins seem feasible substrates to react with PON. Therefore, in the current study, structural and functional aspects of both beta-casein (beta-CN) and whole casein fraction (WCF) were evaluated after PON modification, using a variety of techniques. Modification of the bovine caseins with PON results in an important enhancement in the carbonyl, nitrotryptophan, nitrotyrosine and dityrosine content of these proteins. The results of fluorescence and far UV-CD assessments suggested significant structural alteration of caseins upon PON-modification. The chaperone-like activity of beta-casein was significantly altered after PON modification. The results of scanning electron microscopy suggest that bovine caseins display unique morphological features after treatment with PON. Also, the PON-modified caseins preserved their allergenicity profile and displayed partial resistance against digestion by the pancreatic proteases. Ascorbic acid, an important antioxidant component of milk, was also capable to significantly prevent the PON-induced structural damages in bovine milk caseins. In conclusion, our results suggest that PON may have significant role in the structural and functional alteration of milk caseins. Also, the PON-induced structural damaging effects of caseins might be effectively prevented by a sufficient level of milk antioxidant components particularly by ascorbic acid</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.08.120</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28851643">PM:28851643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biol Macromol\20170830-SadeghianT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biol Macromol\20170830-SadeghianT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Sadeghian T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.08.120</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hu,J.</style></author><author><style face="normal" font="Arial"> Li,N.</style></author><author><style face="normal" font="Arial"> Lv,Y.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Xie,J.</style></author><author><style face="normal" font="Arial"> Zhang,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Civil Engineering, Hunan University, Changsha 410082, China.</style></auth-address><titles><title><style face="normal" font="Arial">Investigation on Indoor Air Pollution and Childhood Allergies in Households in Six Chinese Cities by Subjective Survey and Field Measurements</style></title><secondary-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Environ Res Public Health</style></full-title></periodical><pages end="" start=" E979"> E979-</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood allergy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> disparities</style></keyword><keyword><style face="normal" font="Arial"> disparity</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> indoor air</style></keyword><keyword><style face="normal" font="Arial"> Indoor air pollution</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">Greater attention is currently being paid to the relationship between indoor environment and childhood allergies, however, the lack of reliable data and the disparity among different areas hinders reliable assessment of the relationship. This study focuses on the effect of indoor pollution on Chinese schoolchildren and the relationship between specific household and health problems suffered. The epidemiological questionnaire survey and the field measurement of the indoor thermal environment and primary air pollutants including CO(2), fine particulate matter (PM2.5), chemical pollutants and fungi were performed in six Chinese cities. A total of 912 questionnaires were eligible for statistical analyses and sixty houses with schoolchildren aged 9-12 were selected for field investigation. Compared with Chinese national standards, inappropriate indoor relative humidity (&lt;30% or >70%), CO(2) concentration exceeding 1000 ppm and high PM2.5 levels were found in some monitored houses. Di(2-ethylhexyl) phthalate (DEHP) and dibutyl phthalate (DBP) were the most frequently detected semi-volatile organic compounds (SVOCs) in house dust. Cladosporium, Aspergillus and Penicillium were detected in both indoor air and house dust. This study indicates that a thermal environment with CO(2) exceeding 1000 ppm, DEHP and DBP exceeding 1000 mug/g, and high level of PM2.5, Cladosporium, Aspergillus and Penicillium increases the risk of children's allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijerph14090979</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850091">PM:28850091</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Environ Res Public Health\20170829-HuJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Environ Res Public Health\20170829-HuJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Hu J</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijerph14090979</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanaka,M.</style></author><author><style face="normal" font="Arial"> Suzuku,M.</style></author><author><style face="normal" font="Arial"> Takei,Y.</style></author><author><style face="normal" font="Arial"> Okamoto,T.</style></author><author><style face="normal" font="Arial"> Watanabe,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cirsium maritimum Makino Inhibits the Antigen/IgE-mediated Allergic Response In Vitro and In Vivo</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flower</style></keyword><keyword><style face="normal" font="Arial"> Flowers</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> NMR</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">We investigated whether Cirsium maritimum Makino (CMM) can inhibit IgE-mediated allergic response in rat basophilic leukemia (RBL-2H3) cells, and passive cutaneous anaphylaxis (PCA) in BALB/c mice. In vitro, the ethyl acetate extract of CMM (ECMM) significantly inhibited beta-hexosaminidase release and decreased intracellular Ca2+ levels in RBL-2H3 cells. Moreover, ECMM leaves more strongly suppressed the release of beta-hexosaminidase than ECMM flowers. ECMM leaves also significantly suppressed the PCA reaction in the murine model. HPLC, and 1H and 13C NMR indicated that cirsimaritin, a flavonoid, was concentrated in active fractions of the extract. Our findings suggest that ECMM leaves have a potential regulatory effect on allergic reactions that may be mediated by mast cells. Furthermore, cirsimaritin may be the active anti-allergic component in CMM</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b03322</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28876919">PM:28876919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170906-TanakaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170906-TanakaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Tanaka M</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b03322</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Golden,D.B.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, Md.</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis: Recognizing Risk and Targeting Treatment</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1226" start="1224">1224-1226</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888251">PM:28888251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1224-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1224-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Golden DB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kelly,K.J.</style></author><author><style face="normal" font="Arial"> Sussman,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC.</style></auth-address><titles><title><style face="normal" font="Arial">Latex Allergy: Where Are We Now and How Did We Get There?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1216" start="1212">1212-1216</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> government</style></keyword><keyword><style face="normal" font="Arial"> Government Agencies</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Policy</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Latex allergy emerged as an epidemic of anaphylaxis, occupational asthma, and clinical dilemmas in the 1980s. A systematic recognition, investigation, discovery, epidemiology, and prevention strategy followed. International attention and collaborations of investigators, government agencies, manufacturing, and health policy resulted in near elimination of a global epidemic. This article summarizes nearly 4 decades of work in control of this epidemic and focuses attention on future problems that still require resolution</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888250">PM:28888250</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1212-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1212-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Kelly KJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Basu,T.</style></author><author><style face="normal" font="Arial"> Seyedmousavi,S.</style></author><author><style face="normal" font="Arial"> Sugui,J.A.</style></author><author><style face="normal" font="Arial"> Balenga,N.</style></author><author><style face="normal" font="Arial"> Zhao,M.</style></author><author><style face="normal" font="Arial"> Kwon Chung,K.J.</style></author><author><style face="normal" font="Arial"> Biardel,S.</style></author><author><style face="normal" font="Arial"> Laviolette,M.</style></author><author><style face="normal" font="Arial"> Druey,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Molecular Signal Transduction Section, Laboratory of Allergic DiseasesMolecular Microbiology Section, Laboratory of Clinical Infectious Diseases, NIAID/NIH, Bethesda, Maryland USA</style></auth-address><titles><title><style face="normal" font="Arial">Aspergillus fumigatus alkaline protease 1 (Alp1/Asp f13) in the airways correlates with asthma severity</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> molecular microbiology</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="Arial">A fungal protease (Alp1/Asp f13) from Aspergillus fumigatus was detected in the airways of subjects with asthma but not controls, which correlated strongly with disease severity, respiratory dysfunction, and steroid use</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28882610">PM:28882610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170908-BasuT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170908-BasuT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Basu T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Buka,R.J.</style></author><author><style face="normal" font="Arial"> Knibb,R.C.</style></author><author><style face="normal" font="Arial"> Crossman,R.J.</style></author><author><style face="normal" font="Arial"> Melchior,C.L.</style></author><author><style face="normal" font="Arial"> Huissoon,A.P.</style></author><author><style face="normal" font="Arial"> Hackett,S.</style></author><author><style face="normal" font="Arial"> Dorrian,S.</style></author><author><style face="normal" font="Arial"> Cooke,M.W.</style></author><author><style face="normal" font="Arial"> Krishna,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Heart of England NHS Foundation Trust, Birmingham, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis and Clinical Utility of Real-World Measurement of Acute Serum Tryptase in UK Emergency Departments</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1287" start="1280">1280-1287</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: British guidelines recommend that serial acute serum tryptase measurements be checked in all adults and a subset of children presenting with anaphylaxis. This is the first study reporting the clinical utility of acute serum tryptase in a "real-world" emergency department (ED) setting following the publication of the World Allergy Organization (WAO) criteria for anaphylaxis. OBJECTIVES: To (1) assess sensitivity, specificity, and positive and negative predictive values (PPV, NPV) of acute serum tryptase in anaphylaxis; (b) determine factors associated with higher acute serum tryptase levels; and (c) audit compliance of acute serum tryptase measurement in the ED. METHODS: The methods used were retrospective electronic search for ED admissions to 3 acute care hospitals in Birmingham, UK, with anaphylaxis in 2012 using wide search terms followed by scrutiny of electronic clinical records and application of the WAO diagnostic criteria for anaphylaxis. Patients with an acute serum tryptase measurement were included in the analysis. RESULTS: Acute serum tryptase level was measured in 141 of 426 (33.1%) cases. Mean time from the onset of symptoms to the measurement of acute serum tryptase level was 4 hours 42 minutes (SD +/- 05:03 hours) and no patients had serial measurements conforming to British guidelines. Acute serum tryptase level of more than 12.4 ng/mL (75th centile) was associated with a sensitivity, specificity, PPV, and NPV of 28%, 88%, 0.93, and 0.17, respectively. Multiple regression analysis showed that male sex (odds ratio, 2.66; P = .003) and hypotension (odds ratio, 7.08; P = .001) predicted higher acute serum tryptase level. CONCLUSIONS: An acute serum tryptase level of more than 12.4 ng/mL in an ED setting carries high PPV and specificity, but poor sensitivity and NPV</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888252">PM:28888252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1280-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1280-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Buka RJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,S.</style></author><author><style face="normal" font="Arial"> Peterson,A.</style></author><author><style face="normal" font="Arial"> Lohse,C.M.</style></author><author><style face="normal" font="Arial"> Hess,E.P.</style></author><author><style face="normal" font="Arial"> Campbell,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, the University of Iowa Carver College of Medicine, Iowa City, Iowa.</style></auth-address><titles><title><style face="normal" font="Arial">Further Evaluation of Factors That May Predict Biphasic Reactions in Emergency Department Anaphylaxis Patients</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1301" start="1295">1295-1301</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Biphasic reactions</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine use</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Iowa</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis is a systemic allergic reaction that is commonly treated in the emergency department (ED). The risk of a biphasic reaction is the rationale for observation. OBJECTIVE: To derive a prediction rule to stratify ED anaphylaxis patients at risk of a biphasic reaction. METHODS: We conducted an observational study of a cohort of patients presenting to an academic ED with signs and symptoms of anaphylaxis. We collected clinical data on biphasic reactions meeting National Institutes of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network diagnostic criteria. Logistic regression analyses were conducted to identify predictors of biphasic reactions, and odds ratios (ORs) with 95% CIs are reported. The predictive ability of the model features is summarized using the area under a receiver operating characteristics curve, or AUC. Internally validated AUCs were obtained using bootstrap resampling. RESULTS: We identified 872 anaphylaxis-related visits. Thirty-six (4.1%) visits resulted in biphasic reactions. Multivariable analysis showed that prior anaphylaxis (OR, 2.74; 95% CI, 1.33-5.63), unknown inciting trigger (OR, 2.40; 95% CI, 1.14-4.99), and first epinephrine administration more than 60 minutes after symptom onset (OR, 2.29; 95% CI, 1.09-4.79) were statistically significantly associated with biphasic reactions. The AUC of this model was 0.70 (95% CI, 0.61-0.79), with an internally validated AUC of 0.67 (95% CI, 0.59-0.76). The P value from the goodness-of-fit test was .91. CONCLUSIONS: Our study demonstrated a 4.1% rate of biphasic reactions and found that prior anaphylaxis, unknown inciting trigger, and delayed epinephrine use were risk factors for biphasic reactions</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888253">PM:28888253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1295-301.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1295-301.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Lee S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nanda,A.</style></author><author><style face="normal" font="Arial"> Wasan,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma and Allergy Center, Lewisville and Flower Mound, Texas; Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Texas.</style></auth-address><titles><title><style face="normal" font="Arial">Actually Calling and Talking with Your Patient</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1473">1473-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flower</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888258">PM:28888258</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1473.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1473.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Nanda A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reddy,A.</style></author><author><style face="normal" font="Arial"> Greenberger,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy &amp; Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Allergy &amp; Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers To: Is treatment of serological ABPA similar to that of ABPA with bronchiectasis?)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1475">1475-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888260">PM:28888260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1475.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1475.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Reddy A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sehgal,I.S.</style></author><author><style face="normal" font="Arial"> Agarwal,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India</style></auth-address><titles><title><style face="normal" font="Arial">Is treatment of serological ABPA similar to that of ABPA with bronchiectasis?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1474">1474-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - LetterCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888259">PM:28888259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1474.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1474.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Sehgal IS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alqurashi,W.</style></author><author><style face="normal" font="Arial"> Ellis,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Emergency Medicine, Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Do Corticosteroids Prevent Biphasic Anaphylaxis?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1205" start="1194">1194-1205</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Biphasic anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a severe hypersensitivity reaction that is rapid in onset and can result in death. The pattern of an anaphylactic reaction can be uniphasic (or monophasic), biphasic (also called delayed or late phase), or refractory in nature. The most widely cited definition of biphasic anaphylaxis is a recurrence of anaphylactic symptoms after initial resolution despite no further exposure to the trigger. Corticosteroids are thought by some to prevent the development of biphasic symptoms and, therefore, commonly used in the emergency treatment of anaphylaxis but this has not been systemtically analyzed. In this review, Ovid MEDLINE, Ovid EMBASE, Web of Science, and Scopus were searched for articles using "anaphylaxis" combined with the key terms "biphasic" and/or "corticosteroids" and/or "epinephrine." A total of 31 appropriate studies were identified. Biphasic anaphylactic reactions are more likely to occur in moderate to severe anaphylaxis or when anaphylaxis is not treated with timely epinephrine. Because of the potential detrimental adverse effects of corticosteroids and lack of compelling evidence demonstrating an effective role in reducing anaphylaxis severity or preventing biphasic anaphylaxis, we do not advocate for their routine use in anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888249">PM:28888249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1194-205.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1194-205.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Alqurashi W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Raveendran,R.</style></author><author><style face="normal" font="Arial"> Khan,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, The Ohio State University Wexner Medical Center, Columbus, Ohio.</style></auth-address><titles><title><style face="normal" font="Arial">Gelatin Anaphylaxis During Surgery: A Rare Cause of Perioperative Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1467" start="1466">1466-1467</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Ohio</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888257">PM:28888257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1466-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1466-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Raveendran R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leung,T.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong.</style></auth-address><titles><title><style face="normal" font="Arial">In-season Dosage Adjustment for Pollen Subcutaneous Immunotherapy: The Controversy Continues</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1441" start="1440">1440-1441</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Chinese</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888254">PM:28888254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1440-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1440-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Leung TF</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reddy,A.P.</style></author><author><style face="normal" font="Arial"> Kelso,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy/Immunology, Children's Hospital of Philadelphia, Philadelphia, Pa.</style></auth-address><titles><title><style face="normal" font="Arial">Vaccine Reactions</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1464" start="1463">1463-1464</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888256">PM:28888256</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1463-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1463-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Reddy AP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schulke,S.</style></author><author><style face="normal" font="Arial"> Fiedler,A.H.</style></author><author><style face="normal" font="Arial"> Junker,A.C.</style></author><author><style face="normal" font="Arial"> Flaczyk,A.</style></author><author><style face="normal" font="Arial"> Wolfheimer,S.</style></author><author><style face="normal" font="Arial"> Wangorsch,A.</style></author><author><style face="normal" font="Arial"> Heinz,A.</style></author><author><style face="normal" font="Arial"> Beckert,H.</style></author><author><style face="normal" font="Arial"> Nagl,B.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Toda,M.</style></author><author><style face="normal" font="Arial"> Scheurer,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Molecular Allergology, Paul-Ehrlich-Institut, Langen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Critical role of mammalian target of rapamycin for IL-10 dendritic cell induction by a flagellin A conjugate in preventing allergic sensitization</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> fusion proteins</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune modulation</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Listeria monocytogenes</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> myeloid dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> proinflammatory and anti-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> rapamycin</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fusion proteins incorporating the Toll-like receptor 5 ligand flagellin are currently undergoing clinical trials as vaccine candidates for many diseases. OBJECTIVE: We studied the mechanisms of immune modulation by a flagellin:allergen fusion protein containing the Toll-like receptor 5 ligand flagellin A from Listeria monocytogenes and the birch pollen allergen Bet v 1 (recombinant flagellin A [rFlaA]:Betv1). METHODS: BALB/c mice were vaccinated with rFlaA:Betv1 in an experimental Bet v 1 sensitization model. Myeloid dendritic cells (mDCs) were differentiated from mouse bone marrow, and PBMCs were isolated from subjects with birch pollen allergy. Cells were stimulated with equimolar amounts of rFlaA, rBet v 1, rFlaA plus rBet v 1, or the rFlaA:Betv1 conjugate and analyzed for cell activation, cytokine secretion, and metabolic state. RESULTS: rFlaA:Betv1 displayed strong immune-modulating properties both in vivo and in vitro, as characterized by secretion of both proinflammatory and anti-inflammatory cytokines from murine mDCs and PBMCs from patients with birch allergy. rFlaA:Betv1 suppressed TH2 responses from Bet v 1-specific CD4+ T cells and prevented allergic sensitization in a mouse allergy model. Aggregation of rFlaA:Betv1 resulted in stronger protein uptake accompanied by an increased resistance to microsomal digestion. Remarkably, rFlaA:Betv1 induced activation of mammalian target of rapamycin, which increased the metabolic activity of the stimulated mDCs. rFlaA:Betv1-mediated IL-10 secretion, but not proinflammatory cytokine secretion, was inhibited by rapamycin in mDCs. CONCLUSION: These results provide evidence that mammalian target of rapamycin is a key player involved in prevention of TH2 responses by flagellin A conjugate vaccines</style></abstract><notes><style face="normal" font="Arial">DA - 20170909IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886863">PM:28886863</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170909-SchulkeS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170909-SchulkeS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170909, Schulke S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paller,A.S.</style></author><author><style face="normal" font="Arial"> Kabashima,K.</style></author><author><style face="normal" font="Arial"> Bieber,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="Arial">Therapeutic pipeline for atopic dermatitis: End of the drought?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="643" start="633">633-643</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressants</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Janus kinase</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PDE4 inhibitor</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TH2 lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic immunosuppressants. The pipeline of more targeted topical and systemic therapies is expanding based on our growing understanding of the mechanism for AD and is particularly focused on suppressing the skewed immune activation. Most agents are in phase 2 clinical trials. Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available in late 2016 in the United States for mild-to-moderate AD, with other PDE4 inhibitors, an agonist of the aryl hydrocarbon receptor, Janus kinase inhibitors, and commensal organisms also in trials for topical application. The first highly effective mAb for AD, dupilumab, targets the IL-4/IL-13 receptor and was approved in early 2017 in the United States for moderate-to-severe adult AD. Other biologics similarly inhibit TH2 cytokines (thymic stromal lymphopoietin, IL-4, IL-5, IL-13, and the itch-specific cytokine IL-31 and their receptors) or TH22/TH17 cytokines, levels of which are increased in lesional skin. Orally administered small-molecule inhibitors that suppress inflammation (targeting chemoattractant receptor-homologous molecules expressed on TH2 lymphocytes, PDE4, the histamine 4 receptor, and Janus kinase) or specifically itching (eg, NK1R inhibitors) are also being studied. Comparing biomarkers with individual responses to experimental agents will help to determine subphenotypes within AD that predict prognosis and treatment responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170909IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28887947">PM:28887947</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-633-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-633-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170909, Paller AS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Waserman,S.</style></author><author><style face="normal" font="Arial"> Avilla,E.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author><author><style face="normal" font="Arial"> Rosenfield,L.</style></author><author><style face="normal" font="Arial"> Adcock,A.B.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Epinephrine Autoinjectors: New Data, New Problems</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1191" start="1180">1180-1191</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">acute allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Adherence</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> CAMP</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjectors</style></keyword><keyword><style face="normal" font="Arial"> Functionality</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Epinephrine is the first-line treatment for anaphylaxis. Despite this, there have been identified gaps in the management of anaphylaxis including infrequent or delayed use of epinephrine for acute allergic reactions, as well as inadequate epinephrine autoinjector (EAI) training, and prescription rates of these devices for patients at risk. This paper reviews new data, and new problems in recently published literature on EAIs. A database search was conducted for publications between January 2015 and February 2017 using keywords related to EAIs including their functionality and features, carriage, prescription rates, barriers, and side effects. Eligibility criteria included patients at risk for anaphylaxis, caregivers, and health care professionals. Experimental studies and observational studies were included. Of 1,737 potentially relevant articles, 19 were used for analysis. These articles addressed specific aspects of an EAI, including (1) information on features and functionality; (2) prescriptions; (3) training on their use; and (4) carriage and use at the time of reaction by patients, schools, camps, emergency departments, and paramedics. Our review highlights that existing gaps in anaphylaxis management remain unaddressed. Patient needs are largely unmet, and very few studies are being designed to clarify and instill best practice, and to determine how to increase adherence to existing anaphylaxis guidelines through integrated knowledge translation strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888248">PM:28888248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1180-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1180-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Waserman S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turner,P.J.</style></author><author><style face="normal" font="Arial"> Jerschow,E.</style></author><author><style face="normal" font="Arial"> Umasunthar,T.</style></author><author><style face="normal" font="Arial"> Lin,R.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author><author><style face="normal" font="Arial"> Boyle,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Allergy, Imperial College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Fatal Anaphylaxis: Mortality Rate and Risk Factors</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1178" start="1169">1169-1178</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> admissions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="Arial"> betalactam</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Fatal Outcome</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Hospital admissions</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Middle Age</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Posture</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam antibiotics, general anesthetic agents, and radiocontrast injections the commonest triggers. Fatal food anaphylaxis most commonly occurs during the second and third decades. Delayed epinephrine administration is a risk factor; common triggers are nuts, seafood, and in children, milk. For fatal venom anaphylaxis, risk factors include middle age, male sex, white race, cardiovascular disease, and possibly mastocytosis; insect triggers vary by region. Upright posture is a feature of fatal anaphylaxis to both food and venom. The rarity of fatal anaphylaxis and the significant quality of life impact of allergic conditions suggest that quality of life impairment should be a key consideration when making treatment decisions in patients at risk for anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888247">PM:28888247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1169-78.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1169-78.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Turner PJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagida,N.</style></author><author><style face="normal" font="Arial"> Minoura,T.</style></author><author><style face="normal" font="Arial"> Kitaoka,S.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Sagamihara National Hospital, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="Arial">A three-level stepwise oral food challenge for egg, milk, and wheat allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28847653">PM:28847653</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170829-YanagidaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170829-YanagidaN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Yanagida N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wilson,J.M.</style></author><author><style face="normal" font="Arial"> Workman,L.</style></author><author><style face="normal" font="Arial"> Schuyler,A.J.</style></author><author><style face="normal" font="Arial"> Rifas-Shiman,S.L.</style></author><author><style face="normal" font="Arial"> McGowan,E.C.</style></author><author><style face="normal" font="Arial"> Oken,E.</style></author><author><style face="normal" font="Arial"> Gold,D.R.</style></author><author><style face="normal" font="Arial"> Hamilton,R.G.</style></author><author><style face="normal" font="Arial"> Platts-Mills,T.A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, University of Virginia, Charlottesville, VA</style></auth-address><titles><title><style face="normal" font="Arial">Allergen sensitization in a birth cohort at mid-childhood: focus on food component IgE and IgG4 responses</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut components</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">Among 616 eight year old children in an unselected birth cohort the authors found strikingly different IgG4/IgE ratios to milk and peanut components. This finding was additionally related to discordant results between an extract and microchip component IgE assay</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28867458">PM:28867458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170904-WilsonJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170904-WilsonJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Wilson JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jonstam,K.</style></author><author><style face="normal" font="Arial"> Westman,M.</style></author><author><style face="normal" font="Arial"> Holtappels,G.</style></author><author><style face="normal" font="Arial"> Holweg,C.T.J.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Serum periostin, IgE and SE-IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Belgium</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Chronic rhinosinusitis with nasal polyps</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal Polyps</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Polyps</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Belgium -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870464">PM:28870464</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-JonstamK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-JonstamK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Jonstam K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bartnikas,L.M.</style></author><author><style face="normal" font="Arial"> Young,M.C.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Boston Children's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="Arial">Reply (Refers to: Epinephrine use as a measure of successful food allergy management)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine use</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28844497">PM:28844497</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170828-BartnikasLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170828-BartnikasLM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Bartnikas LM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85800</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asero,R.</style></author><author><style face="normal" font="Arial"> Marzano,A.V.</style></author><author><style face="normal" font="Arial"> Ferrucci,S.</style></author><author><style face="normal" font="Arial"> Cugno,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1742" start="1740">1740-1742</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">D-dimer</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170903IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866106">PM:28866106</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1740-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1740-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Asero R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85801</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Teague,W.G.</style></author><author><style face="normal" font="Arial"> Phillips,B.R.</style></author><author><style face="normal" font="Arial"> Fahy,J.V.</style></author><author><style face="normal" font="Arial"> Wenzel,S.E.</style></author><author><style face="normal" font="Arial"> Fitzpatrick,A.M.</style></author><author><style face="normal" font="Arial"> Moore,W.C.</style></author><author><style face="normal" font="Arial"> Hastie,A.T.</style></author><author><style face="normal" font="Arial"> Bleecker,E.R.</style></author><author><style face="normal" font="Arial"> Meyers,D.A.</style></author><author><style face="normal" font="Arial"> Peters,S.P.</style></author><author><style face="normal" font="Arial"> Castro,M.</style></author><author><style face="normal" font="Arial"> Coverstone,A.M.</style></author><author><style face="normal" font="Arial"> Bacharier,L.B.</style></author><author><style face="normal" font="Arial"> Ly,N.P.</style></author><author><style face="normal" font="Arial"> Peters,M.C.</style></author><author><style face="normal" font="Arial"> Denlinger,L.C.</style></author><author><style face="normal" font="Arial"> Ramratnam,S.</style></author><author><style face="normal" font="Arial"> Sorkness,R.L.</style></author><author><style face="normal" font="Arial"> Gaston,B.M.</style></author><author><style face="normal" font="Arial"> Erzurum,S.C.</style></author><author><style face="normal" font="Arial"> Comhair,S.A.A.</style></author><author><style face="normal" font="Arial"> Myers,R.E.</style></author><author><style face="normal" font="Arial"> Zein,J.</style></author><author><style face="normal" font="Arial"> DeBoer,M.D.</style></author><author><style face="normal" font="Arial"> Irani,A.M.</style></author><author><style face="normal" font="Arial"> Israel,E.</style></author><author><style face="normal" font="Arial"> Levy,B.</style></author><author><style face="normal" font="Arial"> Cardet,J.C.</style></author><author><style face="normal" font="Arial"> Phipatanakul,W.</style></author><author><style face="normal" font="Arial"> Gaffin,J.M.</style></author><author><style face="normal" font="Arial"> Holguin,F.</style></author><author><style face="normal" font="Arial"> Fajt,M.L.</style></author><author><style face="normal" font="Arial"> Aujla,S.J.</style></author><author><style face="normal" font="Arial"> Mauger,D.T.</style></author><author><style face="normal" font="Arial"> Jarjour,N.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Virginia School of Medicine, Charlottesville, Va.</style></auth-address><titles><title><style face="normal" font="Arial">Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> airflow limitation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The effect of age on asthma severity is poorly understood. OBJECTIVES: The objective of this study was to compare the baseline features of severe and nonsevere asthma in the Severe Asthma Research Program (SARP) III cohort, and examine in cross section the effects of age on those features. METHODS: SARP III is a National Institutes of Health/National Heart Lung Blood Institute multisite 3-year cohort study conducted to investigate mechanisms of severe asthma. The sample included 188 children (111 severe, 77 nonsevere) and 526 adults (313 severe, 213 nonsevere) characterized for demographic features, symptoms, health care utilization, lung function, and inflammatory markers compared by age and severity. RESULTS: Compared with children with nonsevere asthma, children with severe asthma had more symptoms and more historical exacerbations, but no difference in body weight, post-bronchodilator lung function, or inflammatory markers. After childhood, and increasing with age, the cohort had a higher proportion of women, less allergen sensitization, and overall fewer blood eosinophils. Enrollment of participants with severe asthma was highest in middle-aged adults, who were older, more obese, with greater airflow limitation and higher blood eosinophils, but less allergen sensitization than adults with nonsevere asthma. CONCLUSIONS: The phenotypic features of asthma differ by severity and with advancing age. With advancing age, patients with severe asthma are more obese, have greater airflow limitation, less allergen sensitization, and variable type 2 inflammation. Novel mechanisms besides type 2 inflammatory pathways may inform the severe asthma phenotype with advancing age</style></abstract><notes><style face="normal" font="Arial">DA - 20170903IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.05.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866107">PM:28866107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170903-TeagueWG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170903-TeagueWG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Teague WG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.05.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gill,M.A.</style></author><author><style face="normal" font="Arial"> Liu,A.H.</style></author><author><style face="normal" font="Arial"> Calatroni,A.</style></author><author><style face="normal" font="Arial"> Krouse,R.Z.</style></author><author><style face="normal" font="Arial"> Shao,B.</style></author><author><style face="normal" font="Arial"> Schiltz,A.</style></author><author><style face="normal" font="Arial"> Gern,J.E.</style></author><author><style face="normal" font="Arial"> Togias,A.</style></author><author><style face="normal" font="Arial"> Busse,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pediatrics and Immunology, University of Texas Southwestern Medical Center, Dallas</style></auth-address><titles><title><style face="normal" font="Arial">Enhanced Plasmacytoid Dendritic Cell Antiviral Responses After Omalizumab</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> plasmacytoid dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopy and viral respiratory infections synergistically promote asthma exacerbations. IgE cross-linking inhibits critical viral-induced IFNalpha responses of plasmacytoid dendritic cells (pDCs), which can be deficient in allergic asthma. OBJECTIVE: To determine whether reducing IgE in vivo with omalizumab treatment increases pDC antiviral IFNalpha responses in inner city children with asthma. METHODS: PBMCs and pDCs isolated from children with exacerbation-prone asthma before and during omalizumab treatment were stimulated ex vivo with rhinovirus and influenza in the presence or absence of IgE cross-linking. IFNalpha was measured in supernatants and mRNA of IFNalpha pathway genes determined by qRT-PCR in cell pellets. FcepsilonRIalpha protein and mRNA expression were measured in unstimulated cells by flow cytometry and qRT-PCR respectively. Changes in these outcomes and associations with clinical outcomes were analyzed and statistical modeling utilized to identify risk factors for asthma exacerbations. RESULTS: Omalizumab treatment increased rhinovirus and influenza-induced PBMC and rhinovirus-induced pDC IFNalpha responses in the presence of IgE cross-linking, and reduced pDC surface FcepsilonRIalpha expression. Omalizumab-induced reductions in pDC FcepsilonRIalpha were significantly associated with lower asthma exacerbation rate during the outcome period and correlated with increases in PBMC IFNalpha responses. PBMC FcepsilonRIalpha mRNA measured upon study entry significantly improved an existing model of exacerbation prediction. CONCLUSIONS: These findings indicate that omalizumab treatment augments pDC IFNalpha responses and attenuates pDC FcepsilonRIalpha protein expression, and provide evidence that these effects are related. These results support a potential mechanism underlying clinical observations that allergic sensitization is associated with increased susceptibility to virus-induced exacerbations of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870461">PM:28870461</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-GillMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-GillMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Gill MA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ertas,R.</style></author><author><style face="normal" font="Arial"> Ozyurt,K.</style></author><author><style face="normal" font="Arial"> Ozlu,E.</style></author><author><style face="normal" font="Arial"> Ulas,Y.</style></author><author><style face="normal" font="Arial"> Avci,A.</style></author><author><style face="normal" font="Arial"> Atasoy,M.</style></author><author><style face="normal" font="Arial"> Hawro,T.</style></author><author><style face="normal" font="Arial"> Maure,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Saglik Bilimleri University, Kayseri Education and Research Hospital Dermatology Clinic, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Elevated IgE levels are linked to faster relapse in omalizumab-discontinued chronic spontaneous urticaria patients</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Turkey -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870460">PM:28870460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-ErtasR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-ErtasR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Ertas R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wopereis,H.</style></author><author><style face="normal" font="Arial"> Sim,K.</style></author><author><style face="normal" font="Arial"> Shaw,A.</style></author><author><style face="normal" font="Arial"> Warner,J.O.</style></author><author><style face="normal" font="Arial"> Knol,J.</style></author><author><style face="normal" font="Arial"> Kroll,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Danone Nutricia Research, Utrecht, the Netherlands; Laboratory of Microbiology, Wageningen University, Wageningen, the Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Intestinal Microbiota in Infants at High-risk for Allergy: Effects of Prebiotics and Role in Eczema Development</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cow's milk formula</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterobacteriaceae</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Non-digestible oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The development of gut microbiota in infancy is important in the maturation of the immune system. Deviations in colonization patterns have been associated with allergic manifestations (e.g. eczema), but exact microbiome dysfunctions underlying allergies remain unclear. We studied the gut microbiota of 138 infants at increased risk of developing allergy, participating in a clinical trial investigating the effectiveness of a partially hydrolyzed protein formula supplemented with non-digestible oligosaccharides (pHF-OS) on the prevention of eczema. OBJECTIVE: The effects of the interventions and breastfeeding on fecal microbiota were investigated. Additionally, we aimed to identify microbial patterns associated with the onset of eczema. METHODS: Bacterial taxonomic compositions in the first 26 weeks of life were analyzed using 16S rRNA-gene sequencing. Additionally, fecal pH and microbial metabolites were measured. RESULTS: Fecal microbial composition, metabolites and pH of infants receiving pHF-OS was closer to breastfed infants than to infants receiving standard cow's milk formula. Infants developing eczema by 18 months showed temporal differences that were marked by decreased relative abundances of Parabacteroides and Enterobacteriaceae at 4 weeks, and decreased relative abundances of lactate-utilizing bacteria producing butyrate at 26 weeks, namely Eubacterium and Anaerostipes spp., supported by increased lactate and decreased butyrate levels. CONCLUSIONS: We showed that a pHF with specific prebiotics modulated the gut microbiota closer to that of breastfed infants. Additionally, we identified a potential link between the microbial activity and onset of eczema, which may reflect a suboptimal implementation of gut microbiota at specific developmental stages in infants at high-risk for allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170903IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.05.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866384">PM:28866384</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170903-WopereisH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170903-WopereisH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Wopereis H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.05.054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kinaciyan,T.</style></author><author><style face="normal" font="Arial"> Nagl,B.</style></author><author><style face="normal" font="Arial"> Faustmann,S.</style></author><author><style face="normal" font="Arial"> Frommlet,F.</style></author><author><style face="normal" font="Arial"> Kopp,S.</style></author><author><style face="normal" font="Arial"> Wolkersdorfer,M.</style></author><author><style face="normal" font="Arial"> Wohrl,S.</style></author><author><style face="normal" font="Arial"> Bastl,K.</style></author><author><style face="normal" font="Arial"> Huber,H.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases (DIAID)</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apple allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cross reaction</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Mal d 1</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> recombinant food allergen</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Birch pollen-related apple allergy is among the most prevalent food allergies in adolescent/adult individuals and mainly results from sensitization to the major birch pollen allergen Bet v 1 and subsequent cross-reaction with the apple protein Mal d 1. However, specific immunotherapy with birch pollen has inconsistent effects on apple allergy. OBJECTIVE: To compare the safety and efficacy of sublingual immunotherapy (SLIT) with two formulations containing either recombinant (r) Mal d 1 or Bet v 1 on birch pollen-related apple allergy. METHODS: Sixty participants with birch pollen-related apple allergy were randomized to daily sublingual application of placebo (n=20), 25 mug of rMal d 1 (n=20) or rBet v 1 (n=20) for 16 weeks. Adverse events were regularly recorded. Sublingual challenges with standardized doses of rMal d 1, skin prick testing with recombinant allergens and measurements of allergen-specific IgE and IgG4 antibodies were performed before and after treatment. RESULTS: Both formulations caused comparable, mainly local adverse events. No systemic reactions occurred. Compared to the placebo and the rBet v 1-treated group SLIT with rMal d 1 reduced rMal d 1-induced oral symptoms (P=0.001 and P=0.038), accompanied by longitudinally reduced rMal d 1-specific cutaneous reactions (P=0.022) and enhanced IgG4/IgE ratios (P=0.012). SLIT with rBet v 1 neither improved the clinical reactivity to rMal d 1 nor enhanced rMal d 1-specific IgG4/IgE ratios. Participants receiving placebo showed no allergen-specific changes. CONCLUSION: Sublingual treatment with a recombinant food allergen was safe and clinically effective as determined by standardized challenges. We present a promising approach for the effective treatment of birch pollen-related apple allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870463">PM:28870463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-KinaciyanT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-KinaciyanT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Kinaciyan T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Markevych,I.</style></author><author><style face="normal" font="Arial"> Standl,M.</style></author><author><style face="normal" font="Arial"> Lehmann,I.</style></author><author><style face="normal" font="Arial"> Von Berg,A.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Inner City Clinic, University Hospital of Munich (LMU), Munich, Germany; Institute of Epidemiology I, Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Food diversity during the first year of life and allergic diseases until 15 years</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food diversity</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inner city</style></keyword><keyword><style face="normal" font="Arial"> inner-city</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Higher food diversity during the first year of life appears to decrease the risk of allergic sensitization to aeroallergens up to 15 years only among children with early skin symptoms in German birth cohort</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870462">PM:28870462</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-MarkevychI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170905-MarkevychI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Markevych I</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kurtaj,A.</style></author><author><style face="normal" font="Arial"> Hillebrand,C.</style></author><author><style face="normal" font="Arial"> Fichtinger,G.</style></author><author><style face="normal" font="Arial"> Hattinger,E.</style></author><author><style face="normal" font="Arial"> Lietzenmayer,M.</style></author><author><style face="normal" font="Arial"> Machado,Y.</style></author><author><style face="normal" font="Arial"> Scheiblhofer,S.</style></author><author><style face="normal" font="Arial"> Stoecklinger,A.</style></author><author><style face="normal" font="Arial"> Thalhamer,T.</style></author><author><style face="normal" font="Arial"> Suessner,S.</style></author><author><style face="normal" font="Arial"> Danzer,M.</style></author><author><style face="normal" font="Arial"> Keplinger,S.</style></author><author><style face="normal" font="Arial"> Weinberger,J.</style></author><author><style face="normal" font="Arial"> Schaller,S.</style></author><author><style face="normal" font="Arial"> Winkler,S.</style></author><author><style face="normal" font="Arial"> Gabriel,C.</style></author><author><style face="normal" font="Arial"> Thalhamer,J.</style></author><author><style face="normal" font="Arial"> Weiss,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Natural protective immunity against grass pollen allergy is maintained by a diverse spectrum of response types</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Protective immunity</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">Naturally acquired immunity against allergens utilizes a broad spectrum of response types besides T regulatory cells. Therapeutic concepts should not be limited to T regulatory cell induction, but take advantage of the diversity found in natural responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28867457">PM:28867457</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170904-KurtajA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170904-KurtajA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Kurtaj A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ford,L.S.</style></author><author><style face="normal" font="Arial"> Tyquin,B.K.</style></author><author><style face="normal" font="Arial"> Treloar,M.J.</style></author><author><style face="normal" font="Arial"> Kakakios,A.M.</style></author><author><style face="normal" font="Arial"> Campbell,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Immunology, Children's Hospital at Westmead, Sydney, Australia; NSW Anaphylaxis Education Program, Children's Hospital at Westmead, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Epinephrine use as a measure of successful food allergy management</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis education</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Education program</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine use</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170828IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28844496">PM:28844496</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170828-FordLS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170828-FordLS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170828, Ford LS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Walters,A.M.</style></author><author><style face="normal" font="Arial"> O'Brien,M.A.</style></author><author><style face="normal" font="Arial"> Selmic,L.E.</style></author><author><style face="normal" font="Arial"> McMichael,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison of clinical findings between dogs with suspected anaphylaxis and dogs with confirmed sepsis</style></title><secondary-title><style face="normal" font="Arial">J Am Vet Med Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Vet Med Assoc</style></full-title></periodical><pages end="688" start="681">681-688</pages><volume><style face="normal" font="Arial">251</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">abnormalities</style></keyword><keyword><style face="normal" font="Arial"> Alanine</style></keyword><keyword><style face="normal" font="Arial"> Alkaline Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Biochemical analysis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Globulin</style></keyword><keyword><style face="normal" font="Arial"> globulins</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Intestines</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Lethargy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Sepsis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE To compare clinical signs, laboratory test results, and imaging findings between dogs with suspected anaphylaxis and dogs with sepsis. DESIGN Retrospective case-case study. ANIMALS 10 dogs with suspected anaphylaxis and 22 dogs with confirmed sepsis that met the criteria for systemic inflammatory response syndrome. PROCEDURES Medical records for dogs in each group were reviewed and data extracted regarding signalment; reason for hospital admission; physical examination findings; results of CBC, serum biochemical analysis, coagulation testing, cytologic examination, and microbial culture; and imaging reports. RESULTS All dogs in the anaphylaxis group fulfilled the criteria for systemic inflammatory response syndrome. Dogs in both groups had gastrointestinal signs, lethargy, mentation change, and bleeding abnormalities. Dogs with suspected anaphylaxis had a significantly higher eosinophil count and serum alanine aminotransferase activity and lower blood pH than dogs with sepsis. Dogs with sepsis had a significantly higher band neutrophil count, serum globulins concentration, and serum alkaline phosphatase activity and lower serum glucose concentration. Dogs in both groups had intracavitary free fluid and ultrasonographic findings of thickened intestines, gas or fluid-filled intestines, and a thickened gallbladder wall. CONCLUSIONS AND CLINICAL RELEVANCE Clinical signs, laboratory values, and imaging findings may be similar in dogs with sepsis or anaphylaxis. Given the marked difference in prognosis and treatment, early differentiation is important. Anaphylaxis should be considered if a septic nidus cannot be identified, and supportive care should be considered for such patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1943-569X (Electronic)IS - 0003-1488 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2460/javma.251.6.681</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28857707">PM:28857707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Vet Med Assoc\2017-251-681-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Vet Med Assoc\2017-251-681-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Walters AM</style></custom2><misc3><style face="normal" font="Arial">10.2460/javma.251.6.681</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Seo,C.</style></author><author><style face="normal" font="Arial"> Hwang,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author><author><style face="normal" font="Arial"> Kim,Y.</style></author><author><style face="normal" font="Arial"> Shin,T.H.</style></author><author><style face="normal" font="Arial"> Lee,G.</style></author><author><style face="normal" font="Arial"> Son,Y.J.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Yee,S.T.</style></author><author><style face="normal" font="Arial"> Park,A.K.</style></author><author><style face="normal" font="Arial"> Paik,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Metabolomic study for monitoring of biomarkers in mouse plasma with asthma by gas chromatography-mass spectrometry</style></title><secondary-title><style face="normal" font="Arial">J Chromatogr B Analyt Technol Biomed Life Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Chromatogr B Analyt Technol Biomed Life Sci</style></full-title></periodical><pages end="162" start="156">156-162</pages><volume><style face="normal" font="Arial">1063</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Energy Metabolism</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Gas Chromatography-Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Linoleic Acid</style></keyword><keyword><style face="normal" font="Arial"> Linoleic Acids</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Methionine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> multifaceted</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> Palmitic Acid</style></keyword><keyword><style face="normal" font="Arial"> Partial least squares discriminant analysis</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">Asthma is a multifaceted chronic disease caused by an alteration of various genetic and environmental factors that is increasing in incidence worldwide. However, the biochemical mechanisms regarding asthma are not completely understood. Thus, we performed of metabolomic study for understanding of the biochemical events by monitoring of altered metabolism and biomarkers in asthma. In mice plasma, 27 amino acids(AAs), 24 fatty acids(FAs) and 17 organic acids(OAs) were determined by ethoxycarbonyl(EOC)/methoxime(MO)/tert-butyldimethylsilyl(TBDMS) derivatives with GC-MS. Their percentage composition normalized to the corresponding mean levels of control group. They then plotted as star symbol patterns for visual monitoring of altered metabolism, which were characteristic and readily distinguishable in control and asthma groups. The Mann-Whitney test revealed 25 metabolites, including eight AAs, nine FAs and eight OAs, which were significantly different (p&lt;0.05), and orthogonal partial least-squares-discriminant analysis revealed a clear separation of the two groups. In classification analysis, palmitic acid and methionine were the main metabolites for discrimination between asthma and the control followed by pipecolic, lactic, alpha-ketoglutaric, and linoleic acids for high classification accuracy as potential biomarkers. These explain the metabolic disturbance in asthma for AAs and FAs including intermediate OAs related to the energy metabolism in the TCA cycle</style></abstract><notes><style face="normal" font="Arial">DA - 20170902IS - 1873-376X (Electronic)IS - 1570-0232 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jchromb.2017.08.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865332">PM:28865332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Chromatogr B Analyt Technol Biomed Life Sci\2017-1063-156-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Chromatogr B Analyt Technol Biomed Life Sci\2017-1063-156-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Seo C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jchromb.2017.08.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,K.</style></author><author><style face="normal" font="Arial"> Lee,E.</style></author><author><style face="normal" font="Arial"> Park,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of the associations between immunoglobulin E levels and the number of natural teeth</style></title><secondary-title><style face="normal" font="Arial">J Formos Med Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Formos Med Assoc</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biostatistics</style></keyword><keyword><style face="normal" font="Arial"> Body Mass Index</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metabolic Diseases</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> systemic disease</style></keyword><keyword><style face="normal" font="Arial"> Systemic diseases</style></keyword><keyword><style face="normal" font="Arial"> Tooth</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/PURPOSE: The purpose of the study was to evaluate the association between the number of natural teeth and the total serum immunoglobulin E (IgE), allergen-specific IgE against Dermatophagoides farina, allergen-specific IgE against cockroaches, or allergen-specific IgE against dogs with nationally representative data using the Korean National Health and Nutrition Examination Survey (KNHANES). METHODS: This study involved a cross-sectional analysis using KNHANES data from 2010. A total of 1916 participants were eligible for this study. Multiple regression analyses were used to evaluate the risk of tooth loss in relation to IgE levels. The model was adjusted for age, sex, body mass index, smoking habits, drinking habits, exercise habits, vitamin D levels, metabolic syndrome, allergic rhinitis, asthma, atopic dermatitis, and tooth-brushing frequency. RESULTS: The number of natural teeth of the first quartile to the fourth quartile of total serum IgE were 25.9 +/- 0.2, 25.9 +/- 0.2, 25.1 +/- 0.2, and 25.4 +/- 0.2, respectively, showing an inverse association (P &lt; 0.05). The number of natural teeth of the first quartile to the fourth quartile of allergen-specific IgE against Dermatophagoides farina and allergen-specific IgE against dogs farina both showed an inverse association with statistical significance (P &lt; 0.05). CONCLUSIONS: This study clearly showed the inverse association between total serum IgE and number of natural teeth after adjustments, especially regarding participants without systemic diseases, including diabetes mellitus, hypertension, metabolic diseases, and obesity</style></abstract><notes><style face="normal" font="Arial">DA - 20170902IS - 0929-6646 (Print)IS - 0929-6646 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jfma.2017.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28863873">PM:28863873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Formos Med Assoc\20170902-HanK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Formos Med Assoc\20170902-HanK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Han K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jfma.2017.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ngatu,N.R.</style></author><author><style face="normal" font="Arial"> Tanaka,M.</style></author><author><style face="normal" font="Arial"> Ikeda,M.</style></author><author><style face="normal" font="Arial"> Inoue,M.</style></author><author><style face="normal" font="Arial"> Kanbara,S.</style></author><author><style face="normal" font="Arial"> Nojima,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate School of Health Sciences and Nursing, University of Kochi, Kochi 781-8515, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Sujiaonori-Derived Algal Biomaterials Inhibit Allergic Reaction in Allergen-Sensitized RBL-2H3 Cell Line and Improve Skin Health in Humans</style></title><secondary-title><style face="normal" font="Arial">J Funct Biomater</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Funct Biomater</style></abbr-1></periodical><pages end="" start="E37">E37-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> adiponectin</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Bioactive compounds</style></keyword><keyword><style face="normal" font="Arial"> biomaterials</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Corn</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Longevity</style></keyword><keyword><style face="normal" font="Arial"> Metabolic Disorders</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> Omega-3 fatty acids</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharides</style></keyword><keyword><style face="normal" font="Arial"> Powders</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spinach</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> TEWL</style></keyword><keyword><style face="normal" font="Arial"> transepidermal water loss</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">Sujiaonori, a river alga growing in the Kochi prefecture, Japan, contains several bioactive compounds such as sulfated polysaccharides (ulvans), omega-3 fatty acids, and vitamins. Dietary intake of this alga-based supplement has been reported to increase circulatory adiponectin, a salutary hormone that is reported to be associated with healthy longevity and prevents a number of cardiovascular and metabolic disorders. This report highlights the anti-allergic and skin health enhancing effects of Sujiaonori-derived ulvan (Tosalvan) and supplement, respectively. RBL-2H3 cell line was used to investigate the anti-allergic effect of algal SP through the evaluation of beta-hexosaminidase activity. Algal sulfated polysaccharides or SP (Tosalvan, Yoshino SP) were extracted from powders of dried alga samples provided by local food manufacturers. Report on the effect of daily dietary intake of Sujiaonori-based supplement on skin health is part of a four-week clinical investigation that, in comparison with a supplement made of 70% corn starch powder and 30% spinach powder mixture (twice 3 g daily), explore the beneficial effects of Sujiaonori algal biomaterial (SBM; 3 g taken twice daily) on cardiovascular, gastrointestinal and skin health in a sample of Japanese women. Transepidermal water loss (TEWL) was the skin health marker used in this study and was measured with the use of a corneometer. Significant reduction of beta-hexosaminidase activity was observed in Tosalvan and Yoshino SP-treated cells (vs. control; p &lt; 0.05), whereas dietary intake of SBM markedly reduced TEWL level after four weeks of supplementation, as compared to baseline TEWL (p &lt; 0.001). Additionally, SBM improved TEWL better than the control product (p &lt; 0.001). Findings contained in this report suggest that Sujiaonori-derived Tosalvan and Yoshino SP have anti-allergic potential and that the dietary intake of SBM has a beneficial effect on skin health</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 2079-4983 (Print)IS - 2079-4983 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3390/jfb8030037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850069">PM:28850069</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Funct Biomater\2017-8-E37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Funct Biomater\2017-8-E37.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Ngatu NR</style></custom2><misc3><style face="normal" font="Arial">10.3390/jfb8030037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Goldstein,B.D.</style></author><author><style face="normal" font="Arial"> Lauer,M.E.</style></author><author><style face="normal" font="Arial"> Caplan,A.I.</style></author><author><style face="normal" font="Arial"> Bonfield,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Pulmonology, Rainbow Babies and Children's Hospital, University Hospitals Cleveland Medical Center, Cleveland, OH USA</style></auth-address><titles><title><style face="normal" font="Arial">Chronic asthma and Mesenchymal stem cells: Hyaluronan and airway remodeling</style></title><secondary-title><style face="normal" font="Arial">J Inflamm (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Inflamm (Lond)</style></full-title></periodical><pages end="" start="18">18-</pages><volume><style face="normal" font="Arial">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyaluronan</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> TaqMan</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous studies have demonstrated that ovalbumin sensitization promotes chronic asthma phenotype in murine asthma model. Human mesenchymal stem cells (hMSCs) are multipotent cells in vitro that have been shown to decrease inflammation and can reverse airway remodeling when infused into an in vivo chronic asthma model. However, the mechanism by which hMSCs reverse remodeling is still unclear. In this study, we hypothesized that hMSCs influence remodeling by decreasing extracellular matrix (ECM) deposition, more specifically by decreasing collagen I, collagen III, and hyaluronan synthesis. METHODS: Chronic asthma phenotype was produced in an in vitro model with 3 T3 murine airway fibroblast cells by stimulating with GM-CSF. Collagen I and collagen III gene expression was investigated using RT-PCR and Taqman techniques. Hyaluronan was evaluated using FACE and Western Blots. The chronic asthma phenotype was produced in vivo in murine model using sensitization with ovalbumin with and without hMSC infusion therapy. ECM deposition (specifically trichrome staining, soluble and insoluble collagen deposition, and hyaluronan production) was evaluated. Image quantification was used to monitor trichrome staining changes. RESULTS: GM-CSF which induced collagen I and collagen III production was down-regulated with hMSC using co-culture. In the in vivo model, Ovalbumin induced enhanced ECM deposition, soluble and insoluble collagen production, and lung elastance. hMSC infusions decreased ECM deposition as evidenced by decreases in soluble and insoluble collagen production. CONCLUSION: hMSCs participate in improved outcomes of remodeling by reversing excess collagen deposition and changing hyaluronan levels</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 1476-9255 (Print)IS - 1476-9255 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12950-017-0165-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28860944">PM:28860944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Inflamm (Lond)\2017-4-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Inflamm (Lond)\2017-4-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Goldstein BD</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12950-017-0165-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ariens,L.F.</style></author><author><style face="normal" font="Arial"> Schussler-Raymakers,F.M.</style></author><author><style face="normal" font="Arial"> Frima,C.</style></author><author><style face="normal" font="Arial"> Flinterman,A.</style></author><author><style face="normal" font="Arial"> Hamminga,E.</style></author><author><style face="normal" font="Arial"> Arents,B.W.</style></author><author><style face="normal" font="Arial"> Bruijnzeel-Koomen,C.A.</style></author><author><style face="normal" font="Arial"> De Bruin-Weller,M.S.</style></author><author><style face="normal" font="Arial"> van Os-Medendorp,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Barriers and Facilitators to eHealth Use in Daily Practice: Perspectives of Patients and Professionals in Dermatology</style></title><secondary-title><style face="normal" font="Arial">J Med Internet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Internet Res</style></full-title></periodical><pages end="" start="e300">e300-</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adoption</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Security</style></keyword><keyword><style face="normal" font="Arial"> self-management</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The number of eHealth interventions in the management of chronic diseases such as atopic dermatitis (AD) is growing. Despite promising results, the implementation and use of these interventions is limited. OBJECTIVES: This study aimed to assess opinions of the most important stakeholders influencing the implementation and use of eHealth services in daily dermatology practice. METHODS: The perspectives of health care professionals and patients towards the implementation and use of eHealth services in daily practice were assessed by using a mixed method design. A cross-sectional survey based on the eHealth implementation toolkit (eHit) was conducted to explore factors influencing the adoption of eHealth interventions offering the possibility of e-consultations, Web-based monitoring, and Web-based self-management training among dermatologists and dermatology nurses. The perspectives of patients with atopic dermatitis (AD) regarding the use of eHealth services were discussed in an online focus group. RESULTS: Health care professionals (n=99) and patients (n=9) acknowledged the value of eHealth services and were willing to use these digital tools in daily dermatology practice. Key identified barriers (statements with &lt;50% of the participants scoring totally agree or agree) in the implementation and adoption of eHealth interventions included concerns about the availability (12/99, 12%) and allocation (14/99, 14%) of resources, financial aspects (26/99, 26%), reliability, security, and confidentially of the intervention itself (29/99, 29%), and the lack of education and training (6/99, 6%). CONCLUSIONS: Health care professionals and patients acknowledge the benefits arising from the implementation and use of eHealth services in daily dermatology practice. However, some important barriers were identified that might be useful in addressing the implementation strategy in order to enhance the implementation success of eHealth interventions in dermatology</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 1438-8871 (Electronic)IS - 1438-8871 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.2196/jmir.7512</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28874336">PM:28874336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Internet Res\2017-19-e300.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Internet Res\2017-19-e300.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Ariens LF</style></custom2><misc3><style face="normal" font="Arial">10.2196/jmir.7512</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosenberg,A.S.</style></author><author><style face="normal" font="Arial"> Sauna,Z.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Immunology, Division of Biotechnology Product Review and Research 3, Office of Biotechnology Products, Center for Drugs Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immunogenicity assessment during the development of protein therapeutics</style></title><secondary-title><style face="normal" font="Arial">J Pharm Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pharm Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Here we provide a critical review of the state of the art with respect to non-clinical assessments of immunogenicity for therapeutic proteins. KEY FINDINGS: The number of studies on immunogenicity published annually has more than doubled in the last 5 years. The science and technology, which have reached a critical mass, provide multiple of non-clinical approaches (computational, in vitro, ex vivo and animal models) to first predict and then to modify or eliminate T-cell or B-cell epitopes via de-immunization strategies. We discuss how these may be used in the context of drug development in assigning the immunogenicity risk of new and marketed therapeutic proteins. SUMMARY: Protein therapeutics represents a large share of the pharma market and provide medical interventions for some of the most complex and intractable diseases. Immunogenicity (the development of antibodies to therapeutic proteins) is an important concern for both the safety and efficacy of protein therapeutics as immune responses may neutralize the activity of life-saving and highly effective protein therapeutics and induce hypersensitivity responses including anaphylaxis. The non-clinical computational tools and experimental technologies that offer a comprehensive and increasingly accurate estimation of immunogenic potential are surveyed here. This critical review also discusses technologies which are promising but are not as yet ready for routine use</style></abstract><notes><style face="normal" font="Arial">DA - 20170905IS - 2042-7158 (Electronic)IS - 0022-3573 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/jphp.12810</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872677">PM:28872677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharm Pharmacol\20170905-RosenbergAS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharm Pharmacol\20170905-RosenbergAS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170905, Rosenberg AS</style></custom2><misc3><style face="normal" font="Arial">10.1111/jphp.12810</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sun,R.W.</style></author><author><style face="normal" font="Arial"> Bonilla-Velez,J.</style></author><author><style face="normal" font="Arial"> Pesek,R.D.</style></author><author><style face="normal" font="Arial"> Johnson,A.B.</style></author><author><style face="normal" font="Arial"> Cleves,M.A.</style></author><author><style face="normal" font="Arial"> Richter,G.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic esophagitis in children under the age of 5 years: Clinical characteristics</style></title><secondary-title><style face="normal" font="Arial">Laryngoscope</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Laryngoscope</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Arkansas</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> constipation</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Dysphagia</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> reflux</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Outcome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Whites</style></keyword></keywords><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES/HYPOTHESIS: To delineate clinical characteristics and treatment outcomes of eosinophilic esophagitis (EoE) in the youngest of children. STUDY DESIGN: Retrospective chart review. METHODS: A 7-year retrospective chart review of children with clinicopathologic diagnosis of EoE was performed with specific analysis of patients under 5 years old. EoE was defined as the presence of symptoms of esophageal dysfunction with pathologically proven eosinophilic inflammation (>/=15 eosinophils per high-power field [EOS/HPF]) unresponsive to reflux therapy. Patient parameters and clinical results were systematically reviewed. RESULTS: Of 558 children diagnosed with EoE, 127 (22.8%) were younger than 5 years old (mean age 2.5 years). This subgroup presented with reflux symptoms (90.1%), vomiting (86.2%), diarrhea (55.3%), liquid dysphagia (52.0%), and constipation (50.0%), whereas food impaction (1.6%) was rare. Liquid dysphagia was present at all ages but significantly more common in younger children (P = .0101). The most common food and environmental allergens were egg whites (39.7%), cow's milk (36.5%), peanuts (34.9%), animal dander (15.1%), and weed pollen (11.1%). Patients were managed with antireflux medication (100%), elimination diet (83.5%), and steroid medication (68.5%). After treatment, 86% of parents reported symptom improvement. Mean reduction of EOS in pos-treatment biopsy was 33.5 EOS/HPF (P &lt; .0001), and 67 patients showed histologic resolution of EoE (56.8%, P &lt; .0001). CONCLUSIONS: Approximately one-quarter of children with EoE present under 5 years of age with multiple esophageal symptoms, comorbidities, and allergen-sensitization profiles. These patients demonstrate substantial clinicohistologic improvement following therapy. LEVEL OF EVIDENCE: 4 Laryngoscope, 2017</style></abstract><notes><style face="normal" font="Arial">DA - 20170902IS - 1531-4995 (Electronic)IS - 0023-852X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/lary.26838</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865084">PM:28865084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Laryngoscope\20170902-SunRW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Laryngoscope\20170902-SunRW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Sun RW</style></custom2><misc3><style face="normal" font="Arial">10.1002/lary.26838</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Montowska,M.</style></author><author><style face="normal" font="Arial"> Fornal,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Detection of peptide markers of soy, milk and egg white allergenic proteins in poultry products by LC-Q-TOF-MS/MS</style></title><secondary-title><style face="normal" font="Arial">LWT - Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">LWT - Food Sci Technol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">additives</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg white protein</style></keyword><keyword><style face="normal" font="Arial"> Egg white proteins</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food authenticity</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> glycinin</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Meat product</style></keyword><keyword><style face="normal" font="Arial"> Meat Products</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Nano-LC-Q-TOF-MS/MS</style></keyword><keyword><style face="normal" font="Arial"> Non-meat protein</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> ovotransferrin</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Poultry</style></keyword><keyword><style face="normal" font="Arial"> processed meat</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Roasting</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Texture</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0023-6438</style></isbn><abstract><style face="normal" font="Arial">Soy, milk and egg white proteins are commonly added to meat products. Proteins of non-meat origin, are applied to improve the water-binding capacity of meat and the texture of the product, as well as for economic reasons as meat substitutes. Detection of low amounts of these proteins is relevant to food safety and human health due to their high allergenicity. In this study, we demonstrate that a nano-LC-Q-TOF-MS/MS method can be used to reliably detect non-meat proteins derived from functional protein additives in various commercial poultry meat products (sausages, frankfurters, p+ót+®s). A large number of heat-stable peptide markers, unique to soy (43 peptides), milk (9 peptides) and egg white (12 peptides), were detected. The source of the peptides were main allergenic proteins, namely soy glycinin and +¦-conglycinin, milk +¦-S1-casein and the whey protein +¦-lactoglobulin, as well as egg white ovotransferrin and lysozyme C. These proteins appeared to be relatively resistant to technological operations used in meat processing including roasting and sterilisation. The mass spectrometry method presented, enables reliable monitoring of the presence of allergenic proteins in severely processed meat products, providing a valuable alternative to PCR and ELISA tests</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.lwt.2017.08.091</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.lwt.2017.08.091</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\LWT - Food Sci Technol\20170901-MontowskaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\LWT - Food Sci Technol\20170901-MontowskaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Montowska M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.lwt.2017.08.091</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Raouafi,A.</style></author><author><style face="normal" font="Arial"> Rabti,A.</style></author><author><style face="normal" font="Arial"> Raouafi,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A printed SWCNT electrode modified with polycatechol and lysozyme for capacitive detection of +¦-lactalbumin</style></title><secondary-title><style face="normal" font="Arial">Microchim Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Microchim Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">blood</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> Breast cancer</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> Electrochemical Sensor</style></keyword><keyword><style face="normal" font="Arial"> Electrodes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immobilization</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Tunisia</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1436-5073</style></isbn><abstract><style face="normal" font="Arial">The authors describe an electrochemical sensor for the breast cancer marker +¦-lactalbumin (+¦LA). It is based on the use of printed single-walled carbon nanotube (SWCNT) electrodes that were modified with polycatechol. Impedance-derived electrochemical capacitance spectroscopy (ECS) is applied for detection at an applied potential of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ0.14-áV vs. Ag/AgCl reference electrode. The electrode was prepared in a two-step process. First, a dispersion of SWCNTs was drop-cast onto the surface of a poly(ethylene terephthalate) substrate to act as the working electrode. Next, catechol was electrochemically polymerized on the SWCNTs, prior to the immobilization of lysozyme. The strong interaction between lysozyme and +¦LA induced changes in the redox capacitance which are detected by ECS. The latter shows the device to be capable of detecting +¦LA in the 20 to 80-áng-ÀmL</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1 concentration range. The limit of detection is 9.7-áng-ÀmL</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1 at an S/N ratio of 3. The device was used to detect +¦LA in human blood serum with good recovery results</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Tunisia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00604-017-2481-z</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s00604-017-2481-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microchim Acta\20170901-RaouafiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microchim Acta\20170901-RaouafiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Raouafi A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00604-017-2481-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sferrazza Papa,G.F.</style></author><author><style face="normal" font="Arial"> Milanese,M.</style></author><author><style face="normal" font="Arial"> Facchini,F.M.</style></author><author><style face="normal" font="Arial"> Baiardini,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy - giuseppe.sferrazza@unimi.itCasa di Cura del Policlinico, Department of Neurorehabilitation Sciences, Milan, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Role and challenges of severe asthma services: insights from the UK registry</style></title><secondary-title><style face="normal" font="Arial">Minerva Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Minerva Med</style></abbr-1></periodical><pages end="17" start="13">13-17</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">3 Suppl 1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> ASST</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Severe bronchial asthma affects at least 5% of the asthmatic population and remains a clinical challenge. Data from the UK National Registry for Severe Asthma suggest that dedicated centers may improve asthma control, quality of life, reduce healthcare use and oral steroid burden. A multidisciplinary approach through complete lung function evaluation, optimization of adherence to treatment and immunological characterization are key issues to improve patients' care. In this paper, we provide an overview of the challenges of managing patients with severe asthma and the role of dedicated services</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 1827-1669 (Electronic)IS - 0026-4806 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.23736/S0026-4806.17.05323-X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28862416">PM:28862416</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Minerva Med\2017-108-13-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Minerva Med\2017-108-13-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Sferrazza Papa GF</style></custom2><misc3><style face="normal" font="Arial">10.23736/S0026-4806.17.05323-X</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schwarz,C.</style></author><author><style face="normal" font="Arial"> Brandt,C.</style></author><author><style face="normal" font="Arial"> Whitaker,P.</style></author><author><style face="normal" font="Arial"> Sutharsan,S.</style></author><author><style face="normal" font="Arial"> Skopnik,H.</style></author><author><style face="normal" font="Arial"> Gartner,S.</style></author><author><style face="normal" font="Arial"> Smazny,C.</style></author><author><style face="normal" font="Arial"> Rohmel,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. carsten.schwarz@charite.deCharite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, GermanyLeeds Teaching Hospitals NHS Trust, Leeds, UKUniversitatsklinikum Essen, Essen, GermanyKlinikum Worms, Worms, GermanyHospital Vall d'Hebron, Barcelona, SpainKlinikum der Johann Wolfgang Goethe-Universitat Frankfurt, Frankfurt, GermanyCharite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Invasive Pulmonary Fungal Infections in Cystic Fibrosis</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> antibiotic treatment</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal drug</style></keyword><keyword><style face="normal" font="Arial"> Antifungal treatment</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Caregivers</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Efficacy study</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Mycose</style></keyword><keyword><style face="normal" font="Arial"> Mycoses</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Teaching</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Failure</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> worms</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Invasive pulmonary mycosis is after allergic bronchopulmonary aspergillosis (ABPA) a frequent and severe complication of CF lung disease. Among CF caregivers, there is an insecurity when and how to treat infections of the lung parenchyma caused by different fungi in patients with CF. This case series provides a multicenter experience on diagnostic, manifestation, and treatment of non-ABPA cases of pulmonary. Non-ABPA cases of pulmonary mycoses in patients with CF have been collected from the CF Centers in Berlin, Essen, Worms, Frankfurt (Germany), Leeds (UK), and Barcelona (Spain). Non-ABPA was defined as total serum IgE level &lt;500 kU/L. Scedosporium and Lomentospora species seem to be more virulent in patients with CF and have been successfully treated with triple antifungal drug regimens in several cases. Rare fungi including yeasts can have pathogenic potential in CF. In this series, antibiotic treatment failure was the main indicator for the initiation of antifungal treatment. For an early and effective treatment of pulmonary mycoses in CF, the identification of biomarkers and of risk factors beyond antibiotic treatment failure is crucial and urgently needed. Furthermore, treatment efficacy studies are necessary for the different causative agents of these infections</style></abstract><notes><style face="normal" font="Arial">DA - 20170902IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-017-0199-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28864921">PM:28864921</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20170902-SchwarzC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20170902-SchwarzC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Schwarz C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-017-0199-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bel,E.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Department of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Amsterdam</style></auth-address><titles><title><style face="normal" font="Arial">Moving Upstream - Anti-TSLP in Persistent Uncontrolled Asthma</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="991" start="989">989-991</pages><volume><style face="normal" font="Arial">377</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - EditorialPT - CommentCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMe1709519</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28877024">PM:28877024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-377-989-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-377-989-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Bel EH</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMe1709519</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Israel,E.</style></author><author><style face="normal" font="Arial"> Reddel,H.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Pulmonary and Critical Care Medicine Division-Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (E.I.); and the Clinical Management Group and Centre for Research Excellence in Severe Asthma, Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.)From the Pulmonary and Critical Care Medicine Division-Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (E.I.); and the Clinical Management Group and Centre for Research Excellence in Severe Asthma, Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.)</style></auth-address><titles><title><style face="normal" font="Arial">Severe and Difficult-to-Treat Asthma in Adults</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="976" start="965">965-976</pages><volume><style face="normal" font="Arial">377</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Difficult-to-treat</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMra1608969</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28877019">PM:28877019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-377-965-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-377-965-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Israel E</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMra1608969</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Corren,J.</style></author><author><style face="normal" font="Arial"> Parnes,J.R.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Mo,M.</style></author><author><style face="normal" font="Arial"> Roseti,S.L.</style></author><author><style face="normal" font="Arial"> Griffiths,J.M.</style></author><author><style face="normal" font="Arial"> van der Merwe,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles</style></auth-address><titles><title><style face="normal" font="Arial">Tezepelumab in Adults with Uncontrolled Asthma</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="946" start="936">936-946</pages><volume><style face="normal" font="Arial">377</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids. METHODS: In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezepelumab at three dose levels with placebo over a 52-week treatment period. The primary end point was the annualized rate of asthma exacerbations (events per patient-year) at week 52. RESULTS: The use of tezepelumab at a dose of 70 mg every 4 weeks (low dose; 145 patients), 210 mg every 4 weeks (medium dose; 145 patients), or 280 mg every 2 weeks (high dose; 146 patients) resulted in annualized asthma exacerbation rates at week 52 of 0.26, 0.19, and 0.22, respectively, as compared with 0.67 in the placebo group (148 patients). Thus, exacerbation rates in the respective tezepelumab groups were lower by 61%, 71%, and 66% than the rate in the placebo group (P&lt;0.001 for all comparisons). Similar results were observed in patients regardless of blood eosinophil counts at enrollment. The prebronchodilator forced expiratory volume in 1 second at week 52 was higher in all tezepelumab groups than in the placebo group (difference, 0.12 liters with the low dose [P=0.01], 0.11 liters with the medium dose [P=0.02], and 0.15 liters with the high dose [P=0.002]). A total of 2 patients in the medium-dose group, 3 in the high-dose group, and 1 in the placebo group discontinued the trial regimen because of adverse events. CONCLUSIONS: Among patients treated with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab had lower rates of clinically significant asthma exacerbations than those who received placebo, independent of baseline blood eosinophil counts. (Funded by MedImmune [a member of the AstraZeneca Group] and Amgen; PATHWAY ClinicalTrials.gov number, NCT02054130 .)</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMoa1704064</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28877011">PM:28877011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-377-936-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-377-936-46.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Corren J</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMoa1704064</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klose,C.S.N.</style></author><author><style face="normal" font="Arial"> Mahlakoiv,T.</style></author><author><style face="normal" font="Arial"> Moeller,J.B.</style></author><author><style face="normal" font="Arial"> Rankin,L.C.</style></author><author><style face="normal" font="Arial"> Flamar,A.L.</style></author><author><style face="normal" font="Arial"> Kabata,H.</style></author><author><style face="normal" font="Arial"> Monticelli,L.A.</style></author><author><style face="normal" font="Arial"> Moriyama,S.</style></author><author><style face="normal" font="Arial"> Putzel,G.G.</style></author><author><style face="normal" font="Arial"> Rakhilin,N.</style></author><author><style face="normal" font="Arial"> Shen,X.</style></author><author><style face="normal" font="Arial"> Kostenis,E.</style></author><author><style face="normal" font="Arial"> Konig,G.M.</style></author><author><style face="normal" font="Arial"> Senda,T.</style></author><author><style face="normal" font="Arial"> Carpenter,D.</style></author><author><style face="normal" font="Arial"> Farber,D.L.</style></author><author><style face="normal" font="Arial"> Artis,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jill Roberts Institute for Research in Inflammatory Bowel Disease, Joan and Sanford I. Weill Department of Medicine, Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, New York 10021, USA</style></auth-address><titles><title><style face="normal" font="Arial">The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation</style></title><secondary-title><style face="normal" font="Arial">Nature</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nature</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine milieu</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> gene-deficient mice</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Nippostrongylus</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> tissue repair</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">The type 2 cytokines interleukin (IL)-4, IL-5, IL-9 and IL-13 have important roles in stimulating innate and adaptive immune responses that are required for resistance to helminth infection, promotion of allergic inflammation, metabolic homeostasis and tissue repair. Group 2 innate lymphoid cells (ILC2s) produce type 2 cytokines, and although advances have been made in understanding the cytokine milieu that promotes ILC2 responses, how ILC2 responses are regulated by other stimuli remains poorly understood. Here we demonstrate that ILC2s in the mouse gastrointestinal tract co-localize with cholinergic neurons that express the neuropeptide neuromedin U (NMU). In contrast to other haematopoietic cells, ILC2s selectively express the NMU receptor 1 (NMUR1). In vitro stimulation of ILC2s with NMU induced rapid cell activation, proliferation, and secretion of the type 2 cytokines IL-5, IL-9 and IL-13 that was dependent on cell-intrinsic expression of NMUR1 and Galphaq protein. In vivo administration of NMU triggered potent type 2 cytokine responses characterized by ILC2 activation, proliferation and eosinophil recruitment that was associated with accelerated expulsion of the gastrointestinal nematode Nippostrongylus brasiliensis or induction of lung inflammation. Conversely, worm burden was higher in Nmur1-/- mice than in control mice. Furthermore, use of gene-deficient mice and adoptive cell transfer experiments revealed that ILC2s were necessary and sufficient to mount NMU-elicited type 2 cytokine responses. Together, these data indicate that the NMU-NMUR1 neuronal signalling circuit provides a selective mechanism through which the enteric nervous system and innate immune system integrate to promote rapid type 2 cytokine responses that can induce anti-microbial, inflammatory and tissue-protective type 2 responses at mucosal sites</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 1476-4687 (Electronic)IS - 0028-0836 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1038/nature23676</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28869965">PM:28869965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nature\20170904-KloseCS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nature\20170904-KloseCS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Klose CS</style></custom2><misc3><style face="normal" font="Arial">10.1038/nature23676</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brick,T.</style></author><author><style face="normal" font="Arial"> Ege,M.</style></author><author><style face="normal" font="Arial"> Boeren,S.</style></author><author><style face="normal" font="Arial"> Bock,A.</style></author><author><style face="normal" font="Arial"> von Mutius,E.</style></author><author><style face="normal" font="Arial"> Vervoort,J.</style></author><author><style face="normal" font="Arial"> Hettinga,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dr. von Hauner Children's Hospital, Ludwig Maximilians University Munich, Lindwurm Str. 4, 80337 Munich, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of Processing Intensity on Immunologically Active Bovine Milk Serum Proteins</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cluster Analysis</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> filter</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat treatment</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> Lactoperoxidase</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> pasteurization</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Raw milk</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infection</style></keyword><keyword><style face="normal" font="Arial"> Respiratory infections</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shelf life</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">Consumption of raw cow's milk instead of industrially processed milk has been reported to protect children from developing asthma, allergies, and respiratory infections. Several heat-sensitive milk serum proteins have been implied in this effect though unbiased assessment of milk proteins in general is missing. The aim of this study was to compare the native milk serum proteome between raw cow's milk and various industrially applied processing methods, i.e., homogenization, fat separation, pasteurization, ultra-heat treatment (UHT), treatment for extended shelf-life (ESL), and conventional boiling. Each processing method was applied to the same three pools of raw milk. Levels of detectable proteins were quantified by liquid chromatography/tandem mass spectrometry following filter aided sample preparation. In total, 364 milk serum proteins were identified. The 140 proteins detectable in 66% of all samples were entered in a hierarchical cluster analysis. The resulting proteomics pattern separated mainly as high (boiling, UHT, ESL) versus no/low heat treatment (raw, skimmed, pasteurized). Comparing these two groups revealed 23 individual proteins significantly reduced by heating, e.g., lactoferrin (log2-fold change = -0.37, p = 0.004), lactoperoxidase (log2-fold change = -0.33, p = 0.001), and lactadherin (log2-fold change = -0.22, p = 0.020). The abundance of these heat sensitive proteins found in higher quantity in native cow's milk compared to heat treated milk, renders them potential candidates for protection from asthma, allergies, and respiratory infections</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9090963</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28858242">PM:28858242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\20170831-BrickT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\20170831-BrickT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Brick T</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9090963</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nakazawa,Y.</style></author><author><style face="normal" font="Arial"> Oka,M.</style></author><author><style face="normal" font="Arial"> Takehana,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo105-8512, 105-8512, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals</style></title><secondary-title><style face="normal" font="Arial">Open Med (Wars)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Open Med (Wars)</style></abbr-1></periodical><pages end="238" start="231">231-238</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic drug</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic drugs</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Conjunctiva</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eye-drops</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hyperemia</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Ketotifen</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> tear</style></keyword><keyword><style face="normal" font="Arial"> Tears</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergic conjunctivitis (AC), which is characterized by ocular itching, hyperemia, and edema, deteriorates quality of life. In this study, effects of anti-allergic drugs were evaluated by assessing eye-scratching behavior, the number of eosinophils in conjunctiva epithelial tissues, and concentrations of chemical mediators in the tears of the guinea pig model of ovalbumin (OA)-induced AC. METHODOLOGY: On day 0, 3-week-old guinea pigs were sensitized by OA subconjunctival injections. On days 15, 17, and 19, OA solution was administered. Anti-allergic eye drops were administered 5 and 15 min before the final OA challenge on day 19. Scratching behavior within 1 h after OA exposure was studied. Eosinophils in the conjunctiva were stained with Giemsa reagent. Histamine and substance P (SP) concentrations in tears were measured using ELISA. RESULTS: Subconjunctivally injected guinea pigs were observed for clinical symptoms. Scratching responses significantly reduced with ketotifen or olopatadine treatment. Eosinophil numbers reduced in animals treated with ketotifen, levocabastine, or tranilast. Histamine and/or SP concentrations in tears were inhibited by some of these anti-allergic drugs. CONCLUSIONS: It is important to assess the anti-allergic AC drugs objectively because there are several of these drugs currently available. This model allows for an objective evaluation of anti-allergic drugs for AC</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 2391-5463 (Print)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1515/med-2017-0034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848937">PM:28848937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Open Med (Wars)\2017-12-231-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Open Med (Wars)\2017-12-231-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Nakazawa Y</style></custom2><misc3><style face="normal" font="Arial">10.1515/med-2017-0034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodgin,S.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*OD, MAc, FAAO Veterans Administration Medical Center, Boston, Massachusetts; Private Practice, Wayland, Massachusetts; and Adjunct Faculty, New England College of Optometry, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="Arial">Food-Induced Red Eye</style></title><secondary-title><style face="normal" font="Arial">Optom Vis Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Optom Vis Sci</style></full-title></periodical><pages end="780" start="775">775-780</pages><volume><style face="normal" font="Arial">94</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Aged,80 and over</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis,Allergic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> England</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Eyes</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hyperemia</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> New England</style></keyword><keyword><style face="normal" font="Arial"> Private Practice</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">PURPOSE: This article addresses the etiology of red eyes and a novel case of food-induced red eye. CASE REPORT: An 82-year-old white male patient reported 50 years of episodes of severe unilateral bulbar injection in either eye following ingestion of certain foods. Thinned scleras in this particular patient made the injection in his eyes more observable. Photodocumentation of this reaction after he ingested these foods is shown. CONCLUSIONS: It is hypothesized that this is a new explanation for an intermittent, unilateral, self-limited red eye-a food-induced red eye</style></abstract><notes><style face="normal" font="Arial">DA - 20170612IS - 1538-9235 (Electronic)IS - 1040-5488 (Linking)LA - engPT - Case ReportsPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/OPX.0000000000001088</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28604572">PM:28604572</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Optom Vis Sci\2017-94-775-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Optom Vis Sci\2017-94-775-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170612, Rodgin SG</style></custom2><misc3><style face="normal" font="Arial">10.1097/OPX.0000000000001088</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lei,X.Y.</style></author><author><style face="normal" font="Arial"> Wang,Q.J.</style></author><author><style face="normal" font="Arial"> Wang,J.W.</style></author><author><style face="normal" font="Arial"> Zheng,L.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cloning and characterization of an expansin gene AbEXP from Achyranthes bidentata</style></title><secondary-title><style face="normal" font="Arial">Plant Growth Regul</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Growth Regul</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abiotic stress</style></keyword><keyword><style face="normal" font="Arial"> Acids</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cloning</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Expansin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Nucleotides</style></keyword><keyword><style face="normal" font="Arial"> nutrient deficiencies</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Roots</style></keyword><keyword><style face="normal" font="Arial"> Seedling</style></keyword><keyword><style face="normal" font="Arial"> Seedlings</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-5087</style></isbn><abstract><style face="normal" font="Arial">Achyranthes bidentata, a traditional perennial medicine herb in China, contains a rich source of important pharmaceutically active phytoecdysteroids including 20-hydroxyecdysone (20E). The growth of A. bidentata plants and 20E production are suppressed under abiotic stress condition. Expansins are plant cell wall-loosening proteins to play important roles in different environment stresses. In this study, we tried to clone an expansin gene (designed as AbEXP) from A. bidentata and characterize its transcriptional response to abiotic stresses (salt stress and nutrient deficiency). The cDNA of AbEXP contained 1584 nucleotides with a complete opening reading frame of 786 nucleotides to encode a peptide of 261 amino acids. The expression of the gene was detected in stems, roots or leaves, and was relatively abundant in stems. The expression levels of AbEXP under the salinity stress (25-ámM NaCl) were increased 51.7-folds in roots but decreased in stems significantly. P and K deficiency enhanced the expression of AbEXP in roots and stems, but down-regulated the levels in leaves compared with control conditions. Under N deficiency AbEXP expression levels in roots and leaves were down-regulated by 9.95-fold and 4.58-fold, respectively. The expression level in roots was 43.9-fold of the control level under Fe deficiency while no significant changes of the expression were detected in stems and leaves. Although the growth of A. bidentata seedlings was inhibited under both the salinity stress and nutrient deficiency, 20E content in roots was enhanced significantly under N and P deficiency. These results demonstrate that AbEXP could be involved in the responses to abiotic stresses and manipulation of the gene expression of AbEXP could promote growth and 20E production of A. bidentata</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10725-017-0313-0</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10725-017-0313-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Growth Regul\20170901-LeiXY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Growth Regul\20170901-LeiXY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Lei XY</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10725-017-0313-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Paris,R.</style></author><author><style face="normal" font="Arial"> Pagliarani,G.</style></author><author><style face="normal" font="Arial"> Savazzini,F.</style></author><author><style face="normal" font="Arial"> Aloisi,I.</style></author><author><style face="normal" font="Arial"> Iorio,R..</style></author><author><style face="normal" font="Arial"> Tartarini,S.</style></author><author><style face="normal" font="Arial"> Ricci,G.</style></author><author><style face="normal" font="Arial"> Del Duca,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparative analysis of allergen genes and pro-inflammatory factors in pollen and fruit of apple varieties</style></title><secondary-title><style face="normal" font="Arial">Plant Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Sci</style></full-title></periodical><pages end="68" start="57">57-68</pages><volume><style face="normal" font="Arial">264</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen genes</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apple allergen</style></keyword><keyword><style face="normal" font="Arial"> Apple allergy</style></keyword><keyword><style face="normal" font="Arial"> apple cultivars</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene family</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> Hypoallergenicity</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Mal d 1</style></keyword><keyword><style face="normal" font="Arial"> Mal d 1 genes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> PLA2</style></keyword><keyword><style face="normal" font="Arial"> plant breeding</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Transglutaminase</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0168-9452</style></isbn><abstract><style face="normal" font="Arial">Allergy to freshly consumed apple fruits is often associated to pollinosis and manifested as oral allergy syndrome (OAS). The allergenic properties of apple varieties differ greatly, spanning from low allergenic to high allergenic varieties. The knowledge of the genetic determinants for allergenicity has been of great interest in scientific community for several years, but the molecular mechanisms involved are still little understood. Here, factors putatively involved in allergenicity were investigated at biochemical and molecular level in pollen and in fruits of apple varieties differing in their allergenic potential. Among putative sensitizing factors, transglutaminase (TGase) and phospholipase A2 (PLA2) were considered together with reactive oxygen species (ROS) and known apple allergen genes, with particular attention devoted to the Mal d 1 gene family, the most important one in sensitization. We found that the expression of some allergen genes and the activities of TGase, PLA2 and ROS producing enzyme are lower in the hypo-allergenic variety </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÿDurello di Forl+¼</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ in comparison with the high-allergenic genotypes </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÿGala</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ and </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÿFlorina</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ. These results highlight correlations among allergen expressions, enzymatic activities and apple cultivars; these data underline the possibility that some of them could be used in the future as markers for allergenicity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.plantsci.2017.08.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.plantsci.2017.08.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Sci\20170901-ParisR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Sci\20170901-ParisR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Paris R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.plantsci.2017.08.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bhutani,M.</style></author><author><style face="normal" font="Arial"> Yang,W.H.</style></author><author><style face="normal" font="Arial"> Hebert,J.</style></author><author><style face="normal" font="Arial"> de Takacsy,F.</style></author><author><style face="normal" font="Arial"> Stril,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Alberta, Edmonton, Alberta, Canada</style></auth-address><titles><title><style face="normal" font="Arial">The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0183869">e0183869-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACQ</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prednisone</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Omalizumab is a non-steroidal medication indicated for the treatment of poorly controlled moderate-to-severe allergic asthmatics. This observational study examines the "real world" effectiveness of omalizumab in this population. METHODS: This is a one year open-label observational study that compared clinical outcomes including total oral corticosteroid use, exacerbation history, measures of quality of life and inflammation in patients with moderate-to-severe allergic asthma, who were prescribed omalizumab as part of their treatment with the year prior to therapy. RESULTS: A total of 99 patients were enrolled at 25 sites in Canada. During the study period, the mean total annual OCS dose was reduced from 2301.5 mg (prednisone equivalents) in the year prior to omalizumab to 1130.0 mg (p&lt;0.0001). There was a 71% reduction in asthma exacerbations and 56% of patients on omalizumab remained exacerbation free when compared to the year prior to study entry. Associated with this was reduced health care utilization. There were significant improvements in the Asthma Control Questionnaire (ACQ) and Asthma Quality of Life questionnaire (AQLQ) Patients with an elevated FeNO at baseline showed a better response to treatment. No new safety issues were identified during the study period. CONCLUSION: Our study demonstrates that in "real world" clinical practice, after initiating omalizumab, there is a reduction in total OCS use and exacerbation frequency in patients with moderate-to-severe allergic asthma. Patients on treatment reported improved asthma control and quality of life. FeNO may be a useful biomarker to identify patients who may benefit with omalizumab treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0183869</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28859150">PM:28859150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0183869.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0183869.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Bhutani M</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0183869</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kudo,F.</style></author><author><style face="normal" font="Arial"> Ohta,H.</style></author><author><style face="normal" font="Arial"> Nagai,Y.</style></author><author><style face="normal" font="Arial"> Minegishi,K.</style></author><author><style face="normal" font="Arial"> Koyama,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A young immunocompetent patient with spontaneous Aspergillus empyema who developed severe eosinophilia</style></title><secondary-title><style face="normal" font="Arial">Respir Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Med Case Rep</style></full-title></periodical><pages end="223" start="220">220-223</pages><volume><style face="normal" font="Arial">22</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal drug</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> empyema</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Pleural Effusion</style></keyword><keyword><style face="normal" font="Arial"> Pneumothorax</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Thorax</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-0071</style></isbn><abstract><style face="normal" font="Arial">Aspergillus empyema is usually reported as a complication of surgical procedures, and spontaneous cases are quite rare. Here, we describe the case of a 16-year-old man who suddenly developed dyspnea despite previously being healthy. Chest computed tomography showed multiple mass-containing cavity lesions, pneumothorax, and pleural effusion in the left thorax. Within 2 weeks, Aspergillus fumigatus grew from his pleural effusion, thus he was diagnosed with Aspergillus empyema. He also developed severe eosinophilia after admission, and was treated with anti-fungal drugs. Although there are many factors that can cause eosinophilia, we suspect that infection with Aspergillus fumigatus was the major cause of the eosinophilia in this patient. The lack of bronchial symptoms and lesions were not consistent with a diagnosis of allergic bronchopulmonary aspergillosis. As far as we know, this is the first case of spontaneous Aspergillus empyema resulting in severe eosinophilia</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmcr.2017.08.022</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.rmcr.2017.08.022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med Case Rep\2017-22-220-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med Case Rep\2017-22-220-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Kudo F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmcr.2017.08.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amat,F.</style></author><author><style face="normal" font="Arial"> Bourgoin-Heck,M.</style></author><author><style face="normal" font="Arial"> Lambert,N.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Oral immunotherapy: Raw or baked milk?</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Raw milk</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Avoidance is currently the only accepted form of management for children with cow's milk allergy. Oral immunotherapy has emerged as a promising alternative but carries the potential risk of anaphylactic adverse reaction. Baked milk seems to be safer than raw milk in most cases. However, severe adverse events continue to pose a real threat even in oral immunotherapy programs using baked milk. While many patients undergo successful oral immunotherapy without major safety issues, this is not the case for all patients. The benefits of oral immunotherapy with baked milk in speeding up recovery in children with a severe phenotype of cow's milk allergy should be carefully evaluated at specialized centers equipped to manage highly sensitive patients</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.013</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-AmatF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-AmatF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Amat F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomas,H.</style></author><author><style face="normal" font="Arial"> Beaudouin,E.</style></author><author><style face="normal" font="Arial"> Nguyen,V.M.</style></author><author><style face="normal" font="Arial"> Picaud,J.</style></author><author><style face="normal" font="Arial"> Renaudin,J.M.</style></author><author><style face="normal" font="Arial"> Jacquenet,S.</style></author><author><style face="normal" font="Arial"> Barbaud,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mammals food anaphylaxis's cases from the French allergy vigilance network</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Alcohol</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy Vigilance Network</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxie</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Exertion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Physical Exertion</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> Tiques</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vigilance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Since 2009, cases of food-related anaphylaxis caused by mammalian meat and stemming from IgE antibodies specific to alpha-galactose have been identified, first in the United States then in Australia and several European states. However, there is little epidemiological data enabling these reactions to be classified as food allergies. The aim of this study is to determine the frequency of anaphylaxis caused by reaction to +¦-gal residue within the sphere of food allergy (FA) in France, to identify the symptoms, to analyze the results of diagnostic tests, and to check for the presence of cofactors. We studied 19 adult cases of anaphylaxis stemming from mammalian meat consumption and confirmed by the presence of IgE to +¦-Gal and reported in a questionnaire to identify food-related anaphylaxis by members of the Allergy Vigilance Network covering France and French-speaking Belgium from September 2008 to December 2015. The diagnostic assessment comprised assay of specific anti-+¦-Gal IgE, skin tests, and tests for IgE antibodies specific to meat. The presence of cofactors such as alcohol, physical exertion and medication, as well as exposure to tick bites, was also checked. Mammalian meat anaphylaxis stemming from +¦-galactose constituted 2.8% of FA in this period and occurred 2</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô12 hours after ingestion of the offending food, which in most cases was offal. In 47% of the cases studied, the reaction was preceded by a tick bite. In 12 (63.2%) of cases, cofactors were present, with alcohol consumption in 26.3% of subjects and physical exertion in 21.0%</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.007</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-ThomasH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-ThomasH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Thomas H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sabouraud-Leclerc,D.</style></author><author><style face="normal" font="Arial"> Bradatan,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">PR10 proteins are not always benign: Four paediatric cases</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Betulaceae</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Cross reaction</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Kiwi</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Herein, we report 4-ácases of paediatric anaphylaxis shock involving PR10-áproteins (hazelnut, kiwi and soya), which cast doubts on the standard notion of benign allergic reactions to PR10. Such anaphylactic reactions are always enhanced by cofactors (effort, infection, stress, etc.) or by large quantities of absorbed allergen</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.06.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.06.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-SabouraudLeclercD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-SabouraudLeclercD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Sabouraud-Leclerc D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.06.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jacquenet,S.</style></author><author><style face="normal" font="Arial"> Richard,C.</style></author><author><style face="normal" font="Arial"> Hofmann,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Goji berry food allergy: Current state of knowledge</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Goji</style></keyword><keyword><style face="normal" font="Arial"> Goji berries</style></keyword><keyword><style face="normal" font="Arial"> Goji berry</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Marketing</style></keyword><keyword><style face="normal" font="Arial"> Nutritional composition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sulfites</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Wolfberry</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Because of their special nutritional composition and considerable marketing efforts, superfruits now enjoy a very positive image in terms of healthy foods. But are these products safe for allergy sufferers? This review focuses on one of these superfruits, the goji berry, for which cases of food allergy have recently been reported. The literature review shows that the goji berry is an allergenic source capable of triggering an immediate IgE-mediated reaction which results in most cases from cross-reactivity with pollen or latex</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-JacquenetS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-JacquenetS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Jacquenet S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Essari,L.A.</style></author><author><style face="normal" font="Arial"> Delmas,C.</style></author><author><style face="normal" font="Arial"> Guenard,L.</style></author><author><style face="normal" font="Arial"> Khayath,N.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic asthma to peppermint essential oil: An under-known allergy?</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Bronchoprovocation</style></keyword><keyword><style face="normal" font="Arial"> Candy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Essential oil</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Menthol</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> non-IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Oils</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peppermint</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Terpenes</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Background Peppermint (Mentha piperita) essential oil consists mainly of menthol (terpenes family). There have been a few reports of menthol-induced asthma, involving both IgE-mediated and non-IgE-mediated hypersensitivity. Herein we describe a case of IgE-mediated allergic asthma following ingestion of peppermint essential oil. Patients and methods A 43-year-old female patient with a history of asthma and allergic rhinitis to grass pollens and nasal polyposis surgery who used essential oils from various plants presented asthma attacks on using a toothpaste containing menthol, after eating peppermint candies, and after ingesting peppermint essential oil and throat lozenges. The symptoms abated following administration of bronchodilators. The peppermint essential oil skin test was positive and controls were negative. Five minutes after ingesting a sugar lump containing two drops of peppermint essential oil, her FEV1-áfell from 88-á% of the predicted value to 64-á%. Normal values were restored within 1 hour of bronchodilator therapy. Conclusion We describe a case of IgE-mediated allergic asthma to peppermint essential oil with sensitization being most likely due to menthol. Essential oils can cause veritable allergic asthma and should thus be included in the environment questionnaire given to asthma patients</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.010</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-EssariLA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-EssariLA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Essari LA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Renaudin,J.M.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Fatal food-induced anaphylaxis: Analysis of French data</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergy Vigilance Network</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Death Certificates</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Groundnut</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Data about anaphylaxis mortality are limited and occasionally conflicting. Our aim was to collect and analyze cases of fatal food-induced anaphylaxis in France. Methods Data were obtained from: (1) the CepiDC unit (National Mortality Center) to collect fatal anaphylaxis cases (1979</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2011) through death certificates using ICD9/10 codes related to anaphylaxis; (2) the Allergy-Vigilance network based on voluntary declarations to collect patterns of fatal anaphylaxis cases (2002</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2017). Results (1) CepiDc data: of 1603 fatal anaphylaxis cases (1564 in adults; 39 in children aged &amp;lt; 19 yrs), 8 (male, n = 6) were food-induced. Food was the least frequent cause (0.6%) of fatal anaphylaxis. Iatrogenic causes accounted for 63% of cases and insect venom for 14% (no specific cause: 23%). Seven cases were recorded in persons aged &amp;lt; 32 yrs and 2 in children (mean age: 24.6 yrs [SD: 6.2]). The small number of food-induced fatalities ruled out statistical analysis of the mortality rate; (2) Allergy-Vigilance network data: in 1862 food anaphylaxis cases, 16 deaths (male, n = 10; 63%) were recorded (10 occurred in France). Eleven (69%) fatalities involved children aged </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëñ 18 yrs (mean age: 23.5 yrs [SD: 5.2]). The main food allergens were: groundnuts (n = 6), tree nuts (n = 3), and goat/sheep's milk (n = 2). Eleven (69%) persons died after exposure to a previously known food allergen and 9 (56%) had a history of asthma. Conclusion The number of food-related fatal anaphylaxis cases is low but may be underestimated. Food-induced fatalities occur chiefly in young patients and in males</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.08.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Pouessel G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hofmann,B.</style></author><author><style face="normal" font="Arial"> Richard,C.</style></author><author><style face="normal" font="Arial"> Moneret-Vautrin,D.A.</style></author><author><style face="normal" font="Arial"> Jacquenet,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Goji berry food allergy: A French case report</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Goji</style></keyword><keyword><style face="normal" font="Arial"> Goji berries</style></keyword><keyword><style face="normal" font="Arial"> Goji berry</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Eating foods not commonly found in our traditional diet can occasionally reveal their allergenic potential. Herein, we report the first case in France of allergy to goji berries as attested by skin prick and immunoblot tests. This case is particularly interesting, since it occurred after the initial ingestion of berries, suggesting the existence of cross-reactivity with other plant substances in this female patient, who was also presenting pollen allergies</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-HofmannB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-HofmannB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Hofmann B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Le Pabic,F.</style></author><author><style face="normal" font="Arial"> Castelain,C.</style></author><author><style face="normal" font="Arial"> Pouessel,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Role of therapeutic education and proposals for improving implementation of the individualized care project for allergy</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Individualized care project</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> stakeholders</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic education</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">The individualized care project for food allergies is intended to facilitate its integration into schools. Many stakeholders are involved in its implementation and application in real life. By supplementing the training of the various professionals concerned, the therapeutic education of the child with food allergies, of his family, and of the school and extracurricular staff, should enable him to be successfully integrated into a school setting</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.014</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-LePabicF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-LePabicF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Le Pabic F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klingebiel,C.</style></author><author><style face="normal" font="Arial"> Poisson,A.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Ehrenberg,A.</style></author><author><style face="normal" font="Arial"> Ostling,J.</style></author><author><style face="normal" font="Arial"> Liabeuf,V.</style></author><author><style face="normal" font="Arial"> Agabriel,C.</style></author><author><style face="normal" font="Arial"> Birnbaum,J.</style></author><author><style face="normal" font="Arial"> Porri,F.</style></author><author><style face="normal" font="Arial"> Arif-Lusson,R.</style></author><author><style face="normal" font="Arial"> Gouitaa,M.</style></author><author><style face="normal" font="Arial"> Aferiat-Derome,A.</style></author><author><style face="normal" font="Arial"> Charpin,D.</style></author><author><style face="normal" font="Arial"> Sofalvi,T.</style></author><author><style face="normal" font="Arial"> Cabon-Boudard,I.</style></author><author><style face="normal" font="Arial"> Massabie-Bouchat,Y.P.</style></author><author><style face="normal" font="Arial"> Soler,C.</style></author><author><style face="normal" font="Arial"> Cleach,I.</style></author><author><style face="normal" font="Arial"> Mege,J.L.</style></author><author><style face="normal" font="Arial"> Vitte,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Peamaclein Pru p 7: Epidemiology, clinical implications and place in the molecular diagnosis of peach allergy in the Mediterranean region of FrancePeamaclein Pru p 7: Epidemiology, clinical implications and place in the molecular diagnosis of peach allergy in the Mediterranean region of France</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> cross-reactive carbohydrate determinant</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactive carbohydrate determinants</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergen of peach</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean Region</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergen</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Molecular profile of peach</style></keyword><keyword><style face="normal" font="Arial"> nonspecific lipid transfer protein</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Peach allergen</style></keyword><keyword><style face="normal" font="Arial"> Peach allergy</style></keyword><keyword><style face="normal" font="Arial"> Peach anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Peamaclein</style></keyword><keyword><style face="normal" font="Arial"> PR-10</style></keyword><keyword><style face="normal" font="Arial"> PR10</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Pru p 1</style></keyword><keyword><style face="normal" font="Arial"> Pru p 3</style></keyword><keyword><style face="normal" font="Arial"> Pru p 4</style></keyword><keyword><style face="normal" font="Arial"> Pru p 7</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Molecular-based allergy diagnostic kits using standard IgE reagents such as peach extract, Pru p 1 (PR-10), Pru p 3 (non-specific lipid transfer protein), Pru p 4 (profilin), and cross-reactive carbohydrate determinants, are unable to identify the offending allergen in certain patients with peach allergy in Southern France, despite positive skin tests and a convincing clinical history. The constant and high positivity of the basophil activation test with peach extract in such patients suggests the involvement of a molecular peach allergen not included in existing in vitro diagnostic kits. Herein we report that peamaclein (Pru p 7) is a major allergen in peach-allergic patients in the Mediterranean (Marseille) region and we describe the epidemiological, clinical and laboratory characteristics associated with this novel allergen</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-KlingebielC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-KlingebielC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Klingebiel C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Drouet,M.</style></author><author><style face="normal" font="Arial"> Lavigne,C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Difficult immunotherapy in a mastocytosis patient allergic to wasp venomDifficult immunotherapy in a mastocytosis patient allergic to wasp venom</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory test</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">It is well known that immunotherapy involving hymenoptera venom causes adverse allergic effects in patients with mastocytosis. Herein, we discuss the case of a 30-year-old male patient allergic to wasp venom who had previously presented severe anaphylaxis with serious neurological sequelae. The laboratory tests confirmed that the patient had systemic mastocytosis. The indication of immunotherapy was retained in view of the potentially life-threatening nature of any further bites. The patient's tolerance of immunotherapy was not good and we present the methods adopted to remedy this and, ultimately, to successfully undertake immunotherapy</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.012</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-DrouetM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-DrouetM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Drouet M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Apoil,P.A.</style></author><author><style face="normal" font="Arial"> Yacouba,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergies in Sahelian Africa</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extract</style></keyword><keyword><style face="normal" font="Arial"> Allergenic extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthme</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Carbohydrates</style></keyword><keyword><style face="normal" font="Arial"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic distance</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE assays</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> MUXF3</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particulate matter</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Sahel</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assay</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE assays</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> Vehicles</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Within the next thirty years, the Sahelian countries will have more than 200 million inhabitants, nearly 50 million of whom will be living in the urban areas of their nations</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ capitals. In these cities, particulate matter produced by vehicles and cooking combines with the fine dust brought from the Sahara by the Harmattan wind between November and May, causing increased mortality from infectious and cardiovascular diseases, as well as a rise in symptoms of respiratory allergy. The wide variety of pollens from tropical grasses and their genetic distance from European or North American grass species render the available diagnostic tests practically useless. Conversely, sensitization to mites can be explored using standard allergenic extracts. Helminth infestation and insect bites lead to the production of IgE directed against carbohydrates epitopes. These anti-carbohydrate IgEs (directed against MMXF3, MUXF3 and +¦-galactose) produce false positive results in specific IgE assays in which glycosylated protein extracts are used. This false positivity is present for legumes and mammalian dander, even in the absence of allergic symptoms in the patients being tested. The use of non-glycosylated allergenic components could facilitate the identification of truly sensitized and allergic subjects. However, the contribution of recombinant allergens to diagnosis in African patients requires further confirmation by means of clinical and laboratory studies</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -CO - Mali -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.009</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-ApoilPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-ApoilPA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Apoil PA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sarre,M.E.</style></author><author><style face="normal" font="Arial"> Lavigne,C.</style></author><author><style face="normal" font="Arial"> Beauvillain,C.</style></author><author><style face="normal" font="Arial"> Renier,G.</style></author><author><style face="normal" font="Arial"> Drouet,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis caused by mosquito allergy in systemic mastocytosis: A causal relationship</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergie au moustique</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxie</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Mastocytose syst+®mique</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> Mosquito allergy</style></keyword><keyword><style face="normal" font="Arial"> Mosquito bites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rare disease</style></keyword><keyword><style face="normal" font="Arial"> Rare Diseases</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Anaphylaxis to the mosquito is rare. We report 4 cases of patients with severe anaphylactic reaction after mosquito bites. These 4 patients have systemic mastocytosis. This combination of 2 rare diseases does not seem to be the result of chance and we recommend in case of anaphylaxis to the mosquito to carry out an assay of serum tryptase intercritical and in case of elevation to address the patient to our colleagues internists to search for a mastocytosis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-SarreME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-SarreME.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Sarre ME</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eigenmann,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The clinical variety of cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk-induced proctocolitis</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Cow's milk allergy is frequently suspected in children aged under two years. Nevertheless, IgE- and non-IgE-mediated cow's milk allergy is in fact demonstrated in fewer than 5% of infants. It is thus essential to seek a clear and accurate diagnosis. In addition, the clinical outcome of cow's milk allergy is generally favorable and regular reassessment of the diagnosis is mandatory to reduce the likelihood of unnecessary elimination diets as far as possible</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.08.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-EigenmannP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20170903-EigenmannP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Eigenmann P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leru,P.M.</style></author><author><style face="normal" font="Arial"> Eftimie,A.M.</style></author><author><style face="normal" font="Arial"> Thibaudon,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">...</style></auth-address><titles><title><style face="normal" font="Arial">First Allergenic Pollen Monitoring in Bucharest and Results of Three Years Collaboration with European Aerobiology Specialists</style></title><secondary-title><style face="normal" font="Arial">Rom J Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Rom J Intern Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plant</style></keyword><keyword><style face="normal" font="Arial"> Allergenic plants</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollen trap</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> reseau</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Respiratory allergies induced by allergenic plants pollen represent an important public health problem with increasing prevalence and severity. Aerobiologic study of allergenic pollens is performed in many countries on regular basis and correlated with health data from allergists in the frame of national aerobiology networks. Romania has no aerobiology network and pollen measurements have been done between 1999-2012 in West region only. In the frame of COST Action called Sustainable management of Ambrosia Artemisiifolia in Europe (SMARTER FA 1203), three years collaboration with Reseau National de Surveillance Aerobiologique (RNSA) from France and the first pollen monitoring center in Bucharest were established. The aim of this paper is to present results of first pollen monitoring in Bucharest, activities of Romanian SMARTER group and collaboration with European aerobiology specialists. MATERIAL AND METHOD: We used a Hirst-type pollen trap placed on the roof of Research Center from Colentina Clinical Hospital and the pollen monitoring method based on European Aeroallergen Network (EAN) standardized requirements. Monthly results during the pollen seasons 2</style></abstract><notes><style face="normal" font="Arial">DA - 20170902IS - 1220-4749 (Print)IS - 1220-4749 (Linking)LA - engPT - Journal ArticleCO - Romania -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1515/rjim-2017-0033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865233">PM:28865233</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rom J Intern Med\20170902-LeruPM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rom J Intern Med\20170902-LeruPM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Leru PM</style></custom2><misc3><style face="normal" font="Arial">10.1515/rjim-2017-0033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Levin,M.E.</style></author><author><style face="normal" font="Arial"> Blackhurst,D.M.</style></author><author><style face="normal" font="Arial"> Kirstein,F.</style></author><author><style face="normal" font="Arial"> Kok,D.</style></author><author><style face="normal" font="Arial"> Van der Watt,G.F.</style></author><author><style face="normal" font="Arial"> Marais,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergology, Department of Paediatrics, Faculty of Health Sciences, University of Cape Town, South Africa.</style></auth-address><titles><title><style face="normal" font="Arial">Residual allergenicity of amino acid-based and extensively hydrolysed cow's milk formulas</style></title><secondary-title><style face="normal" font="Arial">S Afr Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">S Afr Med J</style></full-title></periodical><pages end="767" start="763">763-767</pages><volume><style face="normal" font="Arial">107</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid-based formulas</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cow's milk formula</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> extensively hydrolysed formula</style></keyword><keyword><style face="normal" font="Arial"> Extensively hydrolysed formulas</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> hydrolysed cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Hypoallergenicity</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergens</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Oligopeptides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Criteria for labelling infant feeds as suitable for the dietary management of cow's milk protein allergy (CMPA) rely on proving the hypoallergenicity of such feeds or clinical studies showing that the feeds are tolerated by 90% of children with proven CMPA. South African (SA) labelling legislation does not indicate what testing is necessary to prove hypoallergenicity. OBJECTIVES: To evaluate all extensively hydrolysed cow's milk formulas and amino acid-based formulas available in SA for residual allergen content, protein size and amino-acid content. RESULTS: All amino-acid and extensively hydrolysed formulas were found to be similar in composition, with no residual cow's milk allergens detectable by enzyme-linked immunosorbent assay. Furthermore, proteins were absent and only small molecules in the size range of amino acids and possibly of very small oligopeptides were detected. CONCLUSIONS: These findings indicate that the formulas are extremely likely to be compliant with the definition of hypoallergenicity as tolerance in 90% of proven sufferers from cow's milk allergy. The formulas may therefore be labelled as suitable for the dietary management of infants with CMPA</style></abstract><notes><style face="normal" font="Arial">DA - 20170906IS - 0256-9574 (Print)LA - engPT - Journal ArticleCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.7196/SAMJ.2017.v107i9.12137</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28875884">PM:28875884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\S Afr Med J\2017-107-763-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\S Afr Med J\2017-107-763-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170906, Levin ME</style></custom2><misc3><style face="normal" font="Arial">10.7196/SAMJ.2017.v107i9.12137</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ouyang,Y.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Zhang,D.</style></author><author><style face="normal" font="Arial"> Fan,E.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology Head and Neck Surgery and department of Allergy, Beijing TongRen Hospital, Affiliated to the Capital University of Medical Science, Beijing, 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">A model to predict the incidence of allergic rhinitis based on meteorological factors</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="10006">10006-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meteorological conditions</style></keyword><keyword><style face="normal" font="Arial"> Meteorological factor</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Factors</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictive model</style></keyword><keyword><style face="normal" font="Arial"> Predictive models</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time series</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">Meteorological factors have been shown to affect the physiology, distribution, and amounts of inhaled allergens. The aim of this study was to develop a model to predict the trends for onset of allergic rhinitis (AR) patients. A total of 10,914 consecutive AR outpatients were assessed for the number of daily patient visits over a period of 4 years. Meteorological data were used to assess the relationship between meteorological factors and AR incidence by time-series data and regression analysis. Predictive models for incidence of AR were established in pollen-, dust mite- and mould-sensitive groups of patients, and the predictive performances of meteorological factors on the incidence of AR were estimated using root mean squared errors (RMSEs). The incidence of pollen-, dust mites- and mould-sensitive AR patients was significantly correlated with minimum temperature, vapour pressure, and sea-level pressure, respectively. The correlation between comprehensive meteorological parametric (CMP) and incidence of AR was higher than the correlation between the individual meteorological parameters and AR incidence. CMP had higher performance than individual meteorological parameters for predicting the incidence of AR patients. These findings suggest that the incidence of pollen-, dust mites- and mould-sensitive AR can be predicted employing models based on prevailing meteorological conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-10721-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28855645">PM:28855645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-10006.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-10006.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Ouyang Y</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-10721-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">El-Hashim,A.Z.</style></author><author><style face="normal" font="Arial"> Khajah,M.A.</style></author><author><style face="normal" font="Arial"> Renno,W.M.</style></author><author><style face="normal" font="Arial"> Babyson,R.S.</style></author><author><style face="normal" font="Arial"> Uddin,M.</style></author><author><style face="normal" font="Arial"> Benter,I.F.</style></author><author><style face="normal" font="Arial"> Ezeamuzie,C.</style></author><author><style face="normal" font="Arial"> Akhtar,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology &amp; Therapeutics, Faculty of Pharmacy, Kuwait City, Kuwait.</style></auth-address><titles><title><style face="normal" font="Arial">Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3Kdelta/Akt and NFkappaB induction in a murine asthma model</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="9919">9919-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cyprus</style></keyword><keyword><style face="normal" font="Arial"> EGFR</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor</style></keyword><keyword><style face="normal" font="Arial"> epidermal growth factor receptor</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Src</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">The molecular mechanisms underlying asthma pathogenesis are poorly characterized. In this study, we investigated (1) whether Src mediates epidermal growth factor receptor (EGFR) transactivation; (2) if ERK1/2, PI3Kdelta/Akt and NF-kappaB are signaling effectors downstream of Src/EGFR activation; and (3) if upstream inhibition of Src/EGFR is more effective in downregulating the allergic inflammation than selective inhibition of downstream signaling pathways. Allergic inflammation resulted in increased phosphorylation of EGFR, Akt, ERK1/2 and IkappaB in the lung tissues from ovalbumin (OVA)-challenged BALB/c mice. Treatment with inhibitors of Src (SU6656) or EGFR (AG1478) reduced EGFR phosphorylation and downstream signaling which resulted in the inhibition of the OVA-induced inflammatory cell influx in bronchoalveolar lavage fluid (BALF), perivascular and peribronchial inflammation, fibrosis, goblet cell hyper/metaplasia and airway hyper-responsiveness. Treatment with pathway-selective inhibitors for ERK1/2 (PD89059) and PI3Kdelta/Akt (IC-87114) respectively, or an inhibitor of NF-kappaB (BAY11-7085) also reduced the OVA-induced asthmatic phenotype but to a lesser extent compared to Src/EGFR inhibition. Thus, Src via EGFR transactivation and subsequent downstream activation of multiple pathways regulates the allergic airway inflammatory response. Furthermore, a broader upstream inhibition of Src/EGFR offers an attractive therapeutic alternative in the treatment of asthma relative to selectively targeting the individual downstream signaling effectors</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Kuwait -CO - Sweden -CO - Cyprus -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-09349-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28855674">PM:28855674</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-9919.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-9919.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, El-Hashim AZ</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-09349-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Panda,L.</style></author><author><style face="normal" font="Arial"> Gheware,A.</style></author><author><style face="normal" font="Arial"> Rehman,R.</style></author><author><style face="normal" font="Arial"> Yadav,M.K.</style></author><author><style face="normal" font="Arial"> Jayaraj,B.S.</style></author><author><style face="normal" font="Arial"> Madhunapantula,S.V.</style></author><author><style face="normal" font="Arial"> Mahesh,P.A.</style></author><author><style face="normal" font="Arial"> Ghosh,B.</style></author><author><style face="normal" font="Arial"> Agrawal,A.</style></author><author><style face="normal" font="Arial"> Mabalirajan,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Molecular pathobiology of respiratory diseases, Council of Scientific &amp; Industrial Research (CSIR)-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110007, India</style></auth-address><titles><title><style face="normal" font="Arial">Linoleic acid metabolite leads to steroid resistant asthma features partially through NF-kappaB</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="9565">9565-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial epithelium</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Experimental models</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Linoleic Acid</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">Studies have highlighted the role of nutritional and metabolic modulators in asthma pathobiology. Steroid resistance is an important clinical problem in asthma but lacks good experimental models. Linoleic acid, a polyunsaturated fatty acid, has been linked to asthma and glucocorticoid sensitivity. Its 12/15-lipoxygenase metabolite, 13-S-hydroxyoctadecadienoic acid (HODE) induces mitochondrial dysfunction, with severe airway obstruction and neutrophilic airway inflammation. Here we show that HODE administration leads to steroid unresponsiveness in an otherwise steroid responsive model of allergic airway inflammation (AAI). HODE treatment to allergic mice further increased airway hyperresponsiveness and goblet metaplasia. Treatment with dexamethasone was associated with increased neutrophilic inflammation in HODE treated allergic mice; unlike control allergic mice that showed resolution of inflammation. HODE induced loss of steroid sensitivity was associated with increased p-NFkB in mice and reduced GR-alpha transcript levels in cultured human bronchial epithelia. In summary, HODE modifies typical AAI to recapitulate many of the phenotypic features seen in severe steroid unresponsive asthma. We speculate that since HODE is a natural metabolite, it may be relevant to the increased asthma severity and steroid insensitivity in patients who are obese or consume high fat diets. Further characterization of HODE induced steroid insensitivity may clarify the mechanisms</style></abstract><notes><style face="normal" font="Arial">DA - 20170830IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-09869-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28851976">PM:28851976</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-9565.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-9565.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170830, Panda L</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-09869-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zeng,G.</style></author><author><style face="normal" font="Arial"> Luo,W.</style></author><author><style face="normal" font="Arial"> Wu,Z.</style></author><author><style face="normal" font="Arial"> Li,L.</style></author><author><style face="normal" font="Arial"> Zheng,P.</style></author><author><style face="normal" font="Arial"> Huang,H.</style></author><author><style face="normal" font="Arial"> Wei,N.</style></author><author><style face="normal" font="Arial"> Luo,J.</style></author><author><style face="normal" font="Arial"> Sun,B.</style></author><author><style face="normal" font="Arial"> Liu,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Respiratory Disease, Guangzhou, 510120, Guangdong, China</style></auth-address><titles><title><style face="normal" font="Arial">A cross-sectional observational study on allergen-specific IgE positivity in a southeast coastal versus a southwest inland region of China</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="9593">9593-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> Crabs</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimps</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">Few studies addressed trans-regional differences in allergen sensitization between areas within a similar latitudinal range but with distinct geomorphological features. We investigated specific IgE (sIgE) positivity to common allergens in populations from two southern China provinces. Using a uniformed protocol, serum samples were collected from 2778 subjects with suspected atopy in coastal Guangdong and inland Yunnan. The overall prevalence of sIgE positivity were 57.8% (95% CI: 56.0%, 59.6%) from Guangdong vs 60.9% (95% CI: 59.1%, 62.7%) from Yunnan. House dust mite (d1) was the most common allergen in both regions. Among d1-sensitized subjects, only 35.7% (208/583) in Guangdong and 22.9% (147/642) in Yunnan tested positive for d1 alone. Among those poly-sensitized d1-positive subjects, cockroach was the most common co-sensitizing aeroallergen. 41.9% of the d1-sensitized Guangdong subjects showed high-class sIgE reactivity (>/=class 4), in contrast to a very low percentage of such reactivity in Yunnan. However, 36.3% of d1-sensitized subjects in Yunnan were concomitantly positive for tree pollen mix. Surprisingly, Yunnan subjects showed high prevalence of sIgE positivity for crabs and shrimps, either by overall or by age-group analysis, compared with their Guangdong counterparts (both P &lt; 0.05). These findings may add to data about local allergies in China and worldwide</style></abstract><notes><style face="normal" font="Arial">DA - 20170831IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-10109-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28855606">PM:28855606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-9593.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-9593.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170831, Zeng G</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-10109-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Romero-Morte,J.</style></author><author><style face="normal" font="Arial"> Rojo,J.</style></author><author><style face="normal" font="Arial"> Rivero,R.</style></author><author><style face="normal" font="Arial"> Fernandez-Gonzalez,F.</style></author><author><style face="normal" font="Arial"> Perez-Badia,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Environmental Sciences (Botany), University of Castilla-La Mancha, E-45071 Toledo, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Standardised index for measuring atmospheric grass-pollen emission</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="191" start="180">180-191</pages><volume><style face="normal" font="Arial">612</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Botany</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Dactylis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Flowering phenology</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Iberian Peninsula</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lolium</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen production</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="8" Year="2017">2017/8/26</year></dates><abstract><style face="normal" font="Arial">Grass pollen is the main cause of pollen allergy in Europe, and-given its marked allergenic potential and elevated airborne concentrations-constitutes a major public health risk. This study sought to identify the grass species triggering allergies during the highest-risk periods, and to measure the contribution of each species to airborne grass pollen concentrations. This type of research is particularly useful with a view to optimising the prevention and diagnosis of pollen allergies and developing the most effective immunological treatments. To that end, a total of 28 species potentially responsible for allergies were analysed. In order to assess the potential contribution of these species to overall airborne pollen concentrations, an index was designed (Pollen Contribution Index) based on the following parameters for each species: flowering phenology, pollen grain size (polar and equatorial axes), abundance of the species in the area and pollen production. The species contributing most to airborne pollen concentrations were, in order: Dactylis glomerata subsp. hispanica, Lolium rigidum, Trisetum paniceum and Arrhenatherum album. These species all shared certain features: small grain size (and thus greater buoyancy in air), high pollen production and considerable abundance. This Index was applied to a case study in a Mediterranean-climate area of the central Iberian Peninsula, but could equally be applied to other areas and other allergenic pollens. Findings showed that a small number of species were responsible for most airborne grass pollen</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.08.139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850837">PM:28850837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2017-612-180-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2017-612-180-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Romero-Morte J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.08.139</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lang-Yona,N.</style></author><author><style face="normal" font="Arial"> Kunert,A.T.</style></author><author><style face="normal" font="Arial"> Vogel,L.</style></author><author><style face="normal" font="Arial"> Kampf,C.J.</style></author><author><style face="normal" font="Arial"> Bellinghausen,I.</style></author><author><style face="normal" font="Arial"> Saloga,J.</style></author><author><style face="normal" font="Arial"> Schink,A.</style></author><author><style face="normal" font="Arial"> Ziegler,K.</style></author><author><style face="normal" font="Arial"> Lucas,K.</style></author><author><style face="normal" font="Arial"> Schuppan,D.</style></author><author><style face="normal" font="Arial"> Poschl,U.</style></author><author><style face="normal" font="Arial"> Weber,B.</style></author><author><style face="normal" font="Arial"> Frohlich-Nowoisky,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Max Planck Institute for Chemistry, Multiphase Chemistry Department, Mainz, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Fresh water, marine and terrestrial cyanobacteria display distinct allergen characteristics</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="774" start="767">767-774</pages><volume><style face="normal" font="Arial">612</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Biofuels</style></keyword><keyword><style face="normal" font="Arial"> Biomass</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cyanobacteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fresh Water</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health hazards</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> Immunoblot</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Phycocyanin</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">During the last decades, global cyanobacteria biomass increased due to climate change as well as industrial usage for production of biofuels and food supplements. Thus, there is a need for thorough characterization of their potential health risks, including allergenicity. We therefore aimed to identify and characterize similarities in allergenic potential of cyanobacteria originating from the major ecological environments. Different cyanobacterial taxa were tested for immunoreactivity with IgE from allergic donors and non-allergic controls using immunoblot and ELISA. Moreover, mediator release from human FcepsilonR1-transfected rat basophilic leukemia (RBL) cells was measured, allowing in situ examination of the allergenic reaction. Phycocyanin content and IgE-binding potential were determined and inhibition assays performed to evaluate similarities in IgE-binding epitopes. Mass spectrometry analysis identified IgE-reactive bands ranging between 10 and 160kDa as phycobiliprotein compounds. Levels of cyanobacterial antigen-specific IgE in plasma of allergic donors and mediator release from sensitized RBL cells were significantly higher compared to non-allergic controls (p&lt;0.01). Inhibition studies indicated cross-reactivity between IgE-binding proteins from fresh water cyanobacteria and phycocyanin standard. We further addressed IgE-binding characteristics of marine water and soil-originated cyanobacteria. Altogether, our data suggest that the intensive use and the strong increase in cyanobacterial abundance due to climate change call for increasing awareness and further monitoring of their potential health hazards</style></abstract><notes><style face="normal" font="Arial">DA - 20170903IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.08.069</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866404">PM:28866404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2017-612-767-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2017-612-767-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Lang-Yona N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.08.069</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mittal,S.</style></author><author><style face="normal" font="Arial"> Bjornevik,K.</style></author><author><style face="normal" font="Arial"> Im,D.S.</style></author><author><style face="normal" font="Arial"> Flierl,A.</style></author><author><style face="normal" font="Arial"> Dong,X.</style></author><author><style face="normal" font="Arial"> Locascio,J.J.</style></author><author><style face="normal" font="Arial"> Abo,K.M.</style></author><author><style face="normal" font="Arial"> Long,E.</style></author><author><style face="normal" font="Arial"> Jin,M.</style></author><author><style face="normal" font="Arial"> Xu,B.</style></author><author><style face="normal" font="Arial"> Xiang,Y.K.</style></author><author><style face="normal" font="Arial"> Rochet,J.C.</style></author><author><style face="normal" font="Arial"> Engeland,A.</style></author><author><style face="normal" font="Arial"> Rizzu,P.</style></author><author><style face="normal" font="Arial"> Heutink,P.</style></author><author><style face="normal" font="Arial"> Bartels,T.</style></author><author><style face="normal" font="Arial"> Selkoe,D.J.</style></author><author><style face="normal" font="Arial"> Caldarone,B.J.</style></author><author><style face="normal" font="Arial"> Glicksman,M.A.</style></author><author><style face="normal" font="Arial"> Khurana,V.</style></author><author><style face="normal" font="Arial"> Schule,B.</style></author><author><style face="normal" font="Arial"> Park,D.S.</style></author><author><style face="normal" font="Arial"> Riise,T.</style></author><author><style face="normal" font="Arial"> Scherzer,C.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Neurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA</style></auth-address><titles><title><style face="normal" font="Arial">beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease</style></title><secondary-title><style face="normal" font="Arial">Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Science</style></full-title></periodical><pages end="898" start="891">891-898</pages><volume><style face="normal" font="Arial">357</style></volume><number><style face="normal" font="Arial">6354</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylation</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Ligands</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lysine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Copy number mutations implicate excess production of alpha-synuclein as a possibly causative factor in Parkinson's disease (PD). Using an unbiased screen targeting endogenous gene expression, we discovered that the beta2-adrenoreceptor (beta2AR) is a regulator of the alpha-synuclein gene (SNCA). beta2AR ligands modulate SNCA transcription through histone 3 lysine 27 acetylation of its promoter and enhancers. Over 11 years of follow-up in 4 million Norwegians, the beta2AR agonist salbutamol, a brain-penetrant asthma medication, was associated with reduced risk of developing PD (rate ratio, 0.66; 95% confidence interval, 0.58 to 0.76). Conversely, a beta2AR antagonist correlated with increased risk. beta2AR activation protected model mice and patient-derived cells. Thus, beta2AR is linked to transcription of alpha-synuclein and risk of PD in a ligand-specific fashion and constitutes a potential target for therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20170901IS - 1095-9203 (Electronic)IS - 0036-8075 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Norway -CO - Canada -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1126/science.aaf3934</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28860381">PM:28860381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Science\2017-357-891-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Science\2017-357-891-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170901, Mittal S</style></custom2><misc3><style face="normal" font="Arial">10.1126/science.aaf3934</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Freeland,D.M.H.</style></author><author><style face="normal" font="Arial"> Manohar,M.</style></author><author><style face="normal" font="Arial"> Andorf,S.</style></author><author><style face="normal" font="Arial"> Hobson,B.D.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA 94305, USA</style></auth-address><titles><title><style face="normal" font="Arial">Oral immunotherapy for food allergy</style></title><secondary-title><style face="normal" font="Arial">Semin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> allergen dose</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">Food allergy is a pathological, potentially deadly cascade of immune responses to molecules or molecular fragments that are normally innocuous when encountered in foods, such as milk, egg, or peanut. As the incidence and prevalence of food allergy rise, the standard of care is poised to advance beyond food allergen avoidance coupled with injectable epinephrine treatment of allergen-induced systemic reactions. Recent studies provide evidence that oral immunotherapy may effectively redirect the atopic immune responses of food allergy patients as they ingest small but gradually increasing allergen doses over many months, eliciting safer immune responses to these antigens. Research into the molecular and cellular bases of pathological and therapeutic immune responses, and into the possibilities for their safe and effective modulation, is generating tremendous interest in basic and clinical immunology. We synthesize developments, innovations, and key challenges in our understanding of the immune mechanisms associated with atopy and oral immunotherapy for food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170903IS - 1096-3618 (Electronic)IS - 1044-5323 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.smim.2017.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865877">PM:28865877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunol\20170903-FreelandDM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunol\20170903-FreelandDM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170903, Freeland DM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.smim.2017.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fontaine,M.J.</style></author><author><style face="normal" font="Arial"> Shih,H.</style></author><author><style face="normal" font="Arial"> Schubert,R.</style></author><author><style face="normal" font="Arial"> Wong,W.</style></author><author><style face="normal" font="Arial"> Andrews,J.</style></author><author><style face="normal" font="Arial"> Jeng,M.</style></author><author><style face="normal" font="Arial"> Tirouvanziam,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland</style></auth-address><titles><title><style face="normal" font="Arial">Leukocyte and plasma activation profiles in chronically transfused patients with a history of allergic reactions</style></title><secondary-title><style face="normal" font="Arial">Transfusion</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfusion</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Luminex assay</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Rantes</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic transfusion reactions are drawbacks to the benefits of transfusion. Classically, allergic transfusion reactions depend on histamine release from mast cells or basophils, but other leukocyte subsets may also be important. Thus, we propose to better define the exact leukocyte subsets involved in allergic transfusion reactions. STUDY DESIGN AND METHODS: The overall objective of the current study was to compare the activation of specific peripheral blood leukocyte subsets (monocytes, neutrophils, eosinophils, and basophils) in a cohort of 13 patients who received chronic transfusions and had a history of allergic transfusion reactions compared with a control group of patients who received chronic transfusions and had no history of allergic transfusion reactions. Leukocyte subsets were analyzed by flow cytometry at baseline and after red blood cell transfusion, and cytokine levels in platelet-free plasma collected at the same time points were measured by Luminex assay. RESULTS: Flow cytometry and cytokine profiles before and after transfusion did not differ significantly between patients who did and did not have a history of allergic transfusion reactions (p > 0.05). However, post-transfusion samples from both groups showed a decrease in CD63 expression in basophils, monocytes, and eosinophils and a decrease in CD45 expression in all leukocyte subsets compared with pretransfusion samples. Interleukin 10 levels increased after transfusion in the group with a history of allergic transfusion reactions (p = 0.0469), and RANTES (regulated upon activation, normal T-cell expressed and secreted) was significantly decreased post-transfusion in all patients (p = 0.0122). CONCLUSION: None of the leukocyte subsets from patients who had a history of allergic transfusion reactions significantly increased in activation either before or after transfusion. All leukocyte subsets from patients who did and did not have a history of allergic transfusion reactions decreased in their activation profile upon transfusion challenge</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 1537-2995 (Electronic)IS - 0041-1132 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/trf.14275</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28880378">PM:28880378</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfusion\20170907-FontaineMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfusion\20170907-FontaineMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Fontaine MJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/trf.14275</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palmu,S.</style></author><author><style face="normal" font="Arial"> Heikkila,P.</style></author><author><style face="normal" font="Arial"> Uski,V.</style></author><author><style face="normal" font="Arial"> Niitty,S.</style></author><author><style face="normal" font="Arial"> Kurikka,S.</style></author><author><style face="normal" font="Arial"> Korppi,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Child Health Research Tampere University and University Hospital, Tampere, Finland</style></auth-address><titles><title><style face="normal" font="Arial">National allergy programme had little impact on parent-reported food allergies in children aged 6-7 years</style></title><secondary-title><style face="normal" font="Arial">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Acta Paediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergies in children</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Avoidance diet</style></keyword><keyword><style face="normal" font="Arial"> avoidance diets</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nurses</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">AIM: The ten-year Finnish national allergy programme was launched in 2008 to lessen the disease and psychological burden of allergy. This study assessed the prevalence of parent-reported food allergies requiring avoidance diets at primary school in children aged six and seven years. METHODS: The cohort comprised 1,937 children (51% boys) who started primary school in Tampere, Finland in August 2016. School health nurses charted parent-reported, doctor-diagnosed food allergies requiring avoidance diets as part of the routine health examination. RESULTS: We found that 127 (6.6%) children had parent-reported, doctor-diagnosed allergies to at least one food and 37 (1.9%) were allergic to basic foods, namely cows' milk, wheat and one other grain. All required an avoidance diet. The figure did not differ significantly from the 2.7% and 2.5% found by studies of this age group in 2009 and 2013, respectively. Allergies to fresh fruit and vegetables decreased from 5.8% in 2009 to 3.6% in 2016. CONCLUSION: We studied the national allergy programme that started in 2008 and found that there was a non-significant overall decrease in the number of children aged 6-7 on avoidance diets for allergies between 2009-2016. The only allergies that showed signficiant decreases were fresh fruit and vegetables. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/apa.14083</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28925556">PM:28925556</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Paediatr\20170919-PalmuS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Paediatr\20170919-PalmuS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Palmu S</style></custom2><misc3><style face="normal" font="Arial">10.1111/apa.14083</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gon,Y.</style></author><author><style face="normal" font="Arial"> Ito,R.</style></author><author><style face="normal" font="Arial"> Maruoka,S.</style></author><author><style face="normal" font="Arial"> Mizumura,K.</style></author><author><style face="normal" font="Arial"> Kozu,Y.</style></author><author><style face="normal" font="Arial"> Hiranuma,H.</style></author><author><style face="normal" font="Arial"> Iida,Y.</style></author><author><style face="normal" font="Arial"> Hikichi,M.</style></author><author><style face="normal" font="Arial"> Shikano,S.</style></author><author><style face="normal" font="Arial"> Hashimoto,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year><pub-dates><date Day="21" Month="9" Year="2017">2017/9/21</date></pub-dates></dates><publisher><style face="normal" font="Arial">Elsevier</style></publisher><isbn><style face="normal" font="Arial">1323-8930</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.08.003</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alit.2017.08.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170920-GonY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170920-GonY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Gon Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Igarashi,A.</style></author><author><style face="normal" font="Arial"> Ebihara,Y.</style></author><author><style face="normal" font="Arial"> Kumagai,T.</style></author><author><style face="normal" font="Arial"> Hirai,H.</style></author><author><style face="normal" font="Arial"> Nagata,K.</style></author><author><style face="normal" font="Arial"> Tsuji,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Advanced Technology and Development, BML, Inc., Saitama, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Mast cells derived from human induced pluripotent stem cells are useful for allergen tests</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> induced pluripotent stem cells</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pluripotent Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Several methods have been developed to detect allergen-specific IgE in sera. The passive IgE sensitization assay using human IgE receptor-expressing rat cell line RBL-2H3 is a powerful tool to detect biologically active allergen-specific IgE in serum samples. However, one disadvantage is that RBL-2H3 cells are vulnerable to high concentrations of human sera. Only a few human cultured cell lines are easily applicable to the passive IgE sensitization assay. However, the use of human induced pluripotent stem cells (iPSCs) to generate human mast cells (MCs) has not yet been reported. METHODS: The nuclear factor-kappa B (NF-kappaB)-responsive luciferase reporter gene was stably introduced into a human iPSC line 201B7, and the transfectants were induced to differentiate into MCs (iPSC-MCs). The iPSC-MCs were sensitized overnight with sera from subjects who were allergic to cedar pollen, ragweed pollen, mites, or house dust, and then stimulated with an extract of corresponding allergens. Activation of iPSC-MCs was evaluated by beta-hexosaminidase release, histamine release, or luciferase intensity. RESULTS: iPSCs-MCs stably expressed high-affinity IgE receptor and functionally responded to various allergens when sensitized with human sera from relevant allergic subjects. This passive IgE sensitization system, which we termed the induced mast cell activation test (iMAT), worked well even with undiluted human sera. CONCLUSIONS: iMAT may serve as a novel determining system for IgE/allergens in the clinical and research settings</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28919488">PM:28919488</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20160918-IgarashiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20160918-IgarashiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Igarashi A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cardona,V.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Dreborg,S.</style></author><author><style face="normal" font="Arial"> Fusun,K.A.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Popov,T.A.</style></author><author><style face="normal" font="Arial"> Hoffmann,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Current practice of allergy diagnosis and the potential impact of regulation in Europe</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">In the European Union (EU), the regulatory framework regarding diagnostic allergen extracts is currently in the process of being implemented at the national level. Due to these regulations, the initial and periodic renewal expenses for the registration of diagnostic allergen extracts may render extract production unprofitable. Consequently, many extracts may be at risk of removal from the market. The current survey, which was conducted by a task force of the European Academy of Allergy and Clinical Immunology, aimed to assess the current practice of allergy diagnosis in Europe. This survey revealed that skin tests continue to be the main diagnostic procedure and are used as the first option in almost 2/3 of all types of allergic diseases and in 90% of individuals suffering from respiratory allergies. Therefore, there is a need to ensure the availability of high-quality allergen extracts to maintain the common diagnostic procedures used by EU professionals. To reach this goal, it is necessary to align efforts and establish active partnerships between manufacturers, relevant scientific societies, consumer organizations and authorities to maintain the availability of these diagnostic tools. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - France -CO - Sweden -CO - Turkey -CO - Germany -CO - Italy -CO - Bulgaria -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13306</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28905404">PM:28905404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170914-CardonaV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170914-CardonaV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Cardona V</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13306</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kruse,R.L.</style></author><author><style face="normal" font="Arial"> Vanijcharoenkarn,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Scientist Training Program, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030Division of Allergy &amp; Immunology, Department of Pediatrics, Emory University School of Medicine, 2015 Uppergate Drive, Atlanta, GA 30322</style></auth-address><titles><title><style face="normal" font="Arial">Drug Repurposing to treat Asthma and Allergic Disorders: Progress and Prospects</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologic medications</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Training program</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">Allergy and atopic asthma have continued to become more prevalent in modern society despite the advent of new treatments, representing a major global health problem. Common medications such as antihistamines and steroids may have undesirable long-term side effects and lack efficacy in some resistant patients. Biologic medications are increasingly given to treat resistant patients, but they can represent high costs, complex dosing and management, and are not widely available around the world. The field needs new, cheap and convenient treatment options in order to bring better symptom relief to patients. Beyond continued research and development of new drugs, a focus on drug repurposing could alleviate this problem by repositioning effective and safe small molecule drugs from other fields of medicine and applying them toward the treatment of asthma and allergy. Herein, preclinical models, case reports, and clinical trials of drug repurposing efficacy in allergic disease are reviewed. Novel drugs are also proposed for repositioning based on their mechanism of action to treat asthma and allergy. Overall, drug repurposing could become increasingly important as a way of advancing allergy and atopic asthma treatment, filling a need in treatment for patients today. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13305</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28880396">PM:28880396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170907-KruseRL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170907-KruseRL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Kruse RL</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13305</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bousquet,J.</style></author><author><style face="normal" font="Arial"> Arnavielhe,S.</style></author><author><style face="normal" font="Arial"> Bedbrook,A.</style></author><author><style face="normal" font="Arial"> Fonseca,J.</style></author><author><style face="normal" font="Arial"> Morais,Almeida M.</style></author><author><style face="normal" font="Arial"> Todo Bom,A.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Caimmi,D.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Devillier,P.</style></author><author><style face="normal" font="Arial"> Siroux,V.</style></author><author><style face="normal" font="Arial"> Menditto,E.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Stellato,C.</style></author><author><style face="normal" font="Arial"> Ventura,M.T.</style></author><author><style face="normal" font="Arial"> Cruz,A.A.</style></author><author><style face="normal" font="Arial"> Serpa,F.S.</style></author><author><style face="normal" font="Arial"> da Silva,J.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Rodriguez Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Cabanas,M.T.B.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author><author><style face="normal" font="Arial"> Shamai,S.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Bewick,M.</style></author><author><style face="normal" font="Arial"> Price,D.</style></author><author><style face="normal" font="Arial"> Ryan,D.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Valovirta,E.</style></author><author><style face="normal" font="Arial"> Fokkens,W.J.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Eller,E.</style></author><author><style face="normal" font="Arial"> Bosnic-Anticevich,S.</style></author><author><style face="normal" font="Arial"> O'hehir,R.E.</style></author><author><style face="normal" font="Arial"> Tomazic,P.V.</style></author><author><style face="normal" font="Arial"> Yorgancioglu,A.</style></author><author><style face="normal" font="Arial"> Gemicioglu,B.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author><author><style face="normal" font="Arial"> Kull,I.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> van Eerd,M.</style></author><author><style face="normal" font="Arial"> De Vries,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">The ARIA score of allergic rhinitis using mobile technology correlates with quality-of-life: The MASK study</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> healthy ageing</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinitis control</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">Mobile technology has been used to appraise allergic rhinitis control but more data are needed. In order to better assess the importance of mobile technologies in rhinitis control, the ARIA (Allergic Rhinitis and its Impact on Asthma) score ranging from 0 to 4 of the Allergy Diary was compared with EQ-5D (EuroQuol) and WPAI-AS (Work Productivity and Activity Impairment in allergy) in 1,288 users in 18 countries. This study showed that quality-of-life data (EQ-5D visual analogue scale and WPA-IS Question 9) are similar in users without rhinitis and in those with mild rhinitis (scores 0-2). Users with a score of 3 or 4 had a significant impairment in quality-of-life questionnaires. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - France -CO - Portugal -CO - Italy -CO - Brazil -CO - Mexico -CO - Germany -CO - United Kingdom -CO - Finland -CO - Spain -CO - Poland -CO - Netherlands -CO - Denmark -CO - Australia -CO - Austria -CO - Turkey -CO - Belgium -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13307</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28906011">PM:28906011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170914-BousquetJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170914-BousquetJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Bousquet J</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13307</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vakharia,P.P.</style></author><author><style face="normal" font="Arial"> Chopra,R.</style></author><author><style face="normal" font="Arial"> Sacotte,R.</style></author><author><style face="normal" font="Arial"> Patel,N.</style></author><author><style face="normal" font="Arial"> Immaneni,S.</style></author><author><style face="normal" font="Arial"> White,T.</style></author><author><style face="normal" font="Arial"> Kantor,R.</style></author><author><style face="normal" font="Arial"> Hsu,D.Y.</style></author><author><style face="normal" font="Arial"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Feinberg School of Medicine at, Northwestern University, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="Arial">Validation of patient-reported global severity of atopic dermatitis in adults</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> BSA</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is associated with a heterogeneous presentation and clinical course. There is a lack of simple and validated severity assessments that are feasible for clinical practice and epidemiological research. OBJECTIVES: We sought to validate patient-reported global AD severity in adults. METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n=265). RESULTS: At baseline and follow-up, patient-reported global AD severity significantly correlated with oSCORAD (Spearman rho=0.56 and 0.49), SCORAD (0.64 and 0.56), EASI (0.56 and 0.50), BSA (0.52 and 0.45), NRS-itch (0.60 and 0.53), POEM (0.50 and 0.48), and DLQI (0.50 and 0.49) (P&lt;0.0001 for all). Patient-reported moderate and severe AD vs. mild AD were associated with significantly higher oSCORAD, SCORAD, EASI, BSA, NRS-itch, POEM and DLQI (P&lt;0.0001 for all). There was moderate concordance between patient-reported AD severity (mild, moderate and severe) and previously developed severity strata for oSCORAD (kappa=0.39), SCORAD (kappa=0.47), EASI (kappa=0.37), NRS-itch (kappa=0.49), POEM (kappa=0.37), and DLQI (kappa=0.40). Among patients with severe disease at baseline, those who reported mild or moderate disease on follow-up had significantly greater absolute reductions of oSCORAD (-23.4/-9.7/-1.8), SCORAD (-33.0/-13.2/-2.3), EASI (-17.1/-9.8/-3.2), BSA (-46%/-15%/-4%), NRS-itch (-5/-2/0), POEM (-5/-2/0), and DLQI (-8/-6/-1) than those who continued to report severe disease (Kruskal-Wallis, P&lt;/=0.0003 for all). CONCLUSIONS: Patient-reported AD severity appears to be sufficiently valid for assessing AD severity in the clinical and epidemiological setting. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13309</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28905999">PM:28905999</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170914-VakhariaPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170914-VakhariaPP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Vakharia PP</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13309</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wedman,P.A.</style></author><author><style face="normal" font="Arial"> Aladhami,A.</style></author><author><style face="normal" font="Arial"> Chumanevich,A.P.</style></author><author><style face="normal" font="Arial"> Fuseler,J.W.</style></author><author><style face="normal" font="Arial"> Oskeritzian,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, USA</style></auth-address><titles><title><style face="normal" font="Arial">Mast cells and sphingosine-1-phosphate underlie prelesional remodeling in a mouse model of eczema</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Iraq</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Sphingosine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic skin inflammation that affects children and adults worldwide, but its pathogenesis remains ill-understood. We show that a single application of OVA to mouse skin initiates remodeling and cellular infiltration of the hypodermis measured by a newly developed computer-aided method. Importantly, we demonstrate that skin mast cell (MC) activation and local sphingosine-1-phosphate (S1P) are significantly augmented after OVA treatment in mice. Deficiency in sphingosine kinase (SphK)1, the S1P-producing enzyme, or in MC, remarkably mitigates all signs of OVA-mediated remodeling and MC activation. Furthermore, skin S1P levels remain unchanged in MC-deficient mice exposed to OVA. LPS-free OVA does not recapitulate any of the precursor signs of AD, supporting a triggering contribution of LPS in AD that, per se, suffice to activate local MC and elevate skin S1P. We describe MC and S1P as novel pathogenic effectors that initiate remodeling in AD prior to any skin lesions and reveal the significance of LPS in OVA used in most studies, thus mimicking natural antigen (Ag) exposure. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Iraq -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13310</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28905998">PM:28905998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170914-WedmanPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170914-WedmanPA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Wedman PA</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13310</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zdziarski,P.</style></author><author><style face="normal" font="Arial"> Gamian,A.</style></author><author><style face="normal" font="Arial"> Majda,J.</style></author><author><style face="normal" font="Arial"> Korzeniowska-Kowal,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Immunology, Lower Silesian Center for Cellular Transplantation, POBox 1818, 50-385 Wroclaw-46, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="41">41-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> common variable immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Early and late phase reaction</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin replacement therapy</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Intravenous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Laryngeal Edema</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> Late phase reaction</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulations</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rheumatoid Factor</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIg</style></keyword><keyword><style face="normal" font="Arial"> Self Administration</style></keyword><keyword><style face="normal" font="Arial"> self-administration</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> Type I allergy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic, especially anaphylactic, reactions during immunoglobulin replacement therapy are rare, but their pathophysiology and classification remain ambiguous. Recent findings show positive results of skin tests with commercially available immunoglobulins, but target antigens and responsible compounds of the tested immunoglobulins have not been strictly identified. CASE DESCRIPTION AND FINDINGS: Four adult patients with recently diagnosed common variable immunodeficiency qualified for standard subcutaneous immunoglobulin replacement therapy regimen. They had no history of receiving immunoglobulins, blood or blood product transfusions. Edema, confluent wheals and erythema were observed at the site of subcutaneous immunoglobulin infusion: typical early and late phase reaction. A transient increase in various passively transferred IgG and IgE antibodies was responsible for misleading positive outcome of the serological testing for active humoral response such as type I allergy, anti-Rh, isohemagglutinins and rheumatoid factor (RF). Although the clinical presentation was very unusual and severe, the retrospective analysis showed no isohemagglutinins, RF and IgE in the patients' serum before but it was positive after the infusion (median IgE = 18 IU/ml, RF = 8 IU/ml). Type I allergic reaction (laryngeal edema, rhinoconjuctivitis) came out at +14 days of replacement therapy when the patient visited countryside. In the second patient anaphylactic reaction was observed 5 days after ScIg administration, and only when the patient consumed peanuts. Therefore, IgE concentration was measured retrospectively in a series of commercial preparations used in the initial subcutaneous immunoglobulin replacement therapy that caused the adverse event (AE) and it was determined between 138 and 232 IU/ml (kU/l), i.e. 690-2100 IU per g of protein. Specific IgE was within a wide range from 198 (mix of food) to 2809 kUA/l (mix of grass) but many of the tested allergen-specific IgE were class 2 or 3 (i.e. 0.71-17.5 kUA/l). CONCLUSIONS: The case resembles passive cutaneous anaphylaxis and Prausnitz-Kustner reaction but clinical significance of the classical phenomena has not yet been described. This observation indicates that anaphylactic reactions during immunoglobulin replacement therapy may result from IgE or pathological IgG content. Such IgE presence was sporadically reported (34.5-105 IU/ml, i.e. 862.5-1450 IU/g of protein) in intravenous immunoglobulins that are used and monitored by healthcare professionals. In clinical practice the definition of adverse events is inadequate since individual batches of immunoglobulins come with different specificity therefore, they should be classified as transfusion products (not bioequivalents). Such new approach implies establishing (1) new control methods and strategies to ensure introduction of the safety regulations for subcutaneous home self-administration of immunoglobulins as well as (2) guidelines for the prevention of anaphylaxis in patients receiving immunoglobulins (for example peanut)</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0213-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28924447">PM:28924447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Zdziarski P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0213-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaplan,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="482" start="477">477-482</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Pressure</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Dapsone</style></keyword><keyword><style face="normal" font="Arial"> Diphenhydramine</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Hydroxyzine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene Antagonists</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Sulfasalazine</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">The treatment of chronic spontaneous urticaria begins with antihistamines; however, the dose required typically exceeds that recommended for allergic rhinitis. Second-generation, relatively non-sedating H(1)-receptor blockers are typically employed up to 4 times a day. First-generation antihistamines, such as hydroxyzine or diphenhydramine (Atarax or Benadryl), were employed similarly in the past. Should high-dose antihistamines fail to control symptoms (at least 50%), omalizumab at 300 mg/month is the next step. This is effective in 70% of antihistamine-refractory patients. H(2)-receptor blockers and leukotriene antagonists are no longer recommended; they add little and the literature does not support significant efficacy. For those patients who are unresponsive to both antihistamines and omalizumab, cyclosporine is recommended next. This is similarly effective in 65%-70% of patients; however, care is needed regarding possible side-effects on blood pressure and renal function. Corticosteroids should not be employed chronically due to cumulative toxicity that is dose and time dependent. Brief courses of steroid e.g., 3-10 days can be employed for severe exacerbations, but should be an infrequent occurrence. Finally, other agents, such as dapsone or sulfasalazine, can be tried for those patients unresponsive to antihistamines, omalizumab, and cyclosporine</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.6.477</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913986">PM:28913986</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-477-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-477-82.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Kaplan AP</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.6.477</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kang,M.G.</style></author><author><style face="normal" font="Arial"> Kim,M.Y.</style></author><author><style face="normal" font="Arial"> Song,W.J.</style></author><author><style face="normal" font="Arial"> Kim,S.</style></author><author><style face="normal" font="Arial"> Jo,E.J.</style></author><author><style face="normal" font="Arial"> Lee,S.E.</style></author><author><style face="normal" font="Arial"> Kwon,J.W.</style></author><author><style face="normal" font="Arial"> Lee,S.M.</style></author><author><style face="normal" font="Arial"> Park,C.S.</style></author><author><style face="normal" font="Arial"> Park,H.K.</style></author><author><style face="normal" font="Arial"> Park,H.W.</style></author><author><style face="normal" font="Arial"> Chang,Y.S.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Lee,Y.M.</style></author><author><style face="normal" font="Arial"> Jee,Y.K.</style></author><author><style face="normal" font="Arial"> Lee,J.M.</style></author><author><style face="normal" font="Arial"> Choi,I.S.</style></author><author><style face="normal" font="Arial"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Patterns of Inhalant Allergen Sensitization and Geographical Variation in Korean Adults: A Multicenter Retrospective Study</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="508" start="499">499-508</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Alder</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Beech</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Hazel</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Trichophyton</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Inhalant allergen sensitization is one of the major factors involved in the pathogenesis of allergic respiratory diseases. However, the sensitization is determined by interactions between genetic and environmental factors. Thus, testing panels of inhalant allergens may differ among geographical areas. Here we aimed to determine 10 common inhalant allergens in Korean adult patients with suspected respiratory allergies and to examine the variation between different geographical locations. METHODS: A total of 28,954 patient records were retrieved for retrospective analysis, from 12 referral allergy clinics located in 9 different areas. Inclusion criteria were Korean adults (>/=18 years old) who underwent the inhalant allergen skin prick test for suspected history of respiratory allergy. The primary outcome was inhalant allergen skin prick response. Demographic and clinical information were also collected. Positive skin prick responses to allergens were defined as allergen-to-histamine wheal ratio >/=1. Based on skin test results, the most prevalent aeroallergens were determined. RESULTS: The overall prevalence of allergic sensitization was 45.3%. Dermatophagoides farinae and Dermatophagoides pteronyssinus were the most commonly sensitized allergens. Other common inhalant allergens were cat epithelium (8.1%), birch (7.7%), mugwort (6.9%), alder (6.7%), hazel (6.7%), beech (6.7%), oak (6.6%), and Tyrophagus putres (6.2%), in decreasing order frequency. These 10 inhalant allergens explained 90% of inhalant allergen sensitization in the study participants. However, distinct patterns of the 10 inhalant sensitization were observed in patients living in Chungnam and Jeju. American cockroach, Gernam cockroach, and Trichophyton metagrophytes were unique in Chungnam. Orchard, Japanese cedar, and Velvet were unique in Jeju. CONCLUSIONS: The present analysis suggests a panel of 10 most common inhalant allergens in Korean adult patients with suspected respiratory allergies, which explained 90% of inhalant allergen sensitization. This panel can be utilized as a practical and convenient tool for primary practice and epidemiological surveys of respiratory allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.6.499</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913989">PM:28913989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-499-508.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-499-508.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Kang MG</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.6.499</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bae,J.S.</style></author><author><style face="normal" font="Arial"> Kim,E.H.</style></author><author><style face="normal" font="Arial"> Kim,J.H.</style></author><author><style face="normal" font="Arial"> Mo,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Premedical Course, Dankook University College of Medicine, Cheonan, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Mouse Model of IL-17-Dominant Rhinitis Using Polyinosinic-Polycytidylic Acid</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="549" start="540">540-549</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Confocal microscopy</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Killer Cells</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> natural killer cell</style></keyword><keyword><style face="normal" font="Arial"> Natural killer cells</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">Interleukin (IL)-17 plays an important role in rhinitis and the level thereof correlates with the severity of disease. However, no mouse model for IL-17-dominant rhinitis has yet been developed. Our objective was to establish a mouse model of IL-17-dominant rhinitis via intranasal application of polyinosinic-polycytidylic acid (abbreviated as Poly(I:C)). Mice were divided into 6 groups (n=8 for each group); 1) 1 negative control group, 2) 1 positive control group (OVA/alum model), 3) 2 Poly(I:C) groups (10 or 100 mug), and 4) 2 OVA/Poly(I:C) groups (10 or 100 mug). The positive control group was treated with the conventional OVA/alum protocol. In the Poly(I:C) and OVA/Poly(I:C) groups, phosphate-buffered saline or an OVA solution plus Poly(I:C) were administered. The OVA/Poly(I:C) groups exhibited significantly greater neutrophil infiltration and increased IL-17/interferon gamma expression compared with the other groups. However, the levels of total immunoglobulin E (IgE), OVA-specific IgE, eosinophil infiltration, IL-4, IL-5, IL-6, and IL-10 were significantly lower in the OVA/Poly(I:C) groups than in mice subjected to conventional Th2-dominant OVA/alum treatment (the positive control group). IL-17 and neutrophil measurement, chemokine (C-X-C motif) ligand 1 immunohistochemistry, and confocal microscopy revealed increased numbers of IL-17-secreting cells in the nasal mucosa of the OVA/Poly(I:C) groups, which included natural killer cells, CD4 T cells, and neutrophils. In conclusion, we developed a mouse model of IL-17-dominant rhinitis using OVA together with Poly(I:C). This model will be useful in research on neutrophil- or IL-17-dominant rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.6.540</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913994">PM:28913994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-540-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-540-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Bae JS</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.6.540</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,S.H.</style></author><author><style face="normal" font="Arial"> Ban,G.Y.</style></author><author><style face="normal" font="Arial"> Jeong,K.</style></author><author><style face="normal" font="Arial"> Shin,Y.S.</style></author><author><style face="normal" font="Arial"> Park,H.S.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Ye,Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="Arial">A Retrospective Study of Korean Adults With Food Allergy: Differences in Phenotypes and Causes</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="539" start="534">534-539</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Increasing in prevalence, food allergy (FA) is becoming an important public health concern. In Korean adults, however, clinical phenotypes and causes of FA have not been studied. We aimed to study common causative allergens and clinical manifestations of FA in Korean adults. METHODS: This study was conducted as a retrospective review of medical records for 95 patients (>/=19 years old) diagnosed with FA from September 2014 to August 2015 at a single university hospital. RESULTS: In the 95 patients, 181 FA events were recorded. The mean age of first onset of FA symptoms was 34.7+/-15.8 years. The most frequent causative food was seafood (34.8%); shrimp and crab allergies ranked highest, regardless of age and sex. Among all FA events, there were 47 (26.0%) cases of anaphylaxis and 26 (14.4%) cases of oral allergy syndrome (OAS). Seafood (51.1%) was the most frequent cause of anaphylaxis, followed by grains (14.9%). Most OAS cases were associated with fruits (95.7%). The frequency of fruit-induced FA was significantly higher in males than in females (23.0% vs 8.4%, P=0.011). While no cases of vegetables-induced FA were noted in younger individuals (19 to 30 years), vegetables accounted for 20.5% of FA symptoms in older subjects (>/=51 years, P&lt;0.001). Allergic rhinitis (44.2%) and drug allergy (20.0%) were major comorbidities associated with FA. Overall, 29 FA events had cofactors, of which 10 were combined with exercise. CONCLUSIONS: The major causes of FA in Korean adults were crustacean, fruits, and grains. Interestingly, the clinical manifestations of FA and demographics varied according to type of food allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.6.534</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913993">PM:28913993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-534-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-534-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Lee SH</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.6.534</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Byeon,J.H.</style></author><author><style face="normal" font="Arial"> Ri,S.</style></author><author><style face="normal" font="Arial"> Amarsaikhan,O.</style></author><author><style face="normal" font="Arial"> Kim,E.</style></author><author><style face="normal" font="Arial"> Ahn,S.H.</style></author><author><style face="normal" font="Arial"> Choi,I.S.</style></author><author><style face="normal" font="Arial"> Kim,H.J.</style></author><author><style face="normal" font="Arial"> Seo,S.</style></author><author><style face="normal" font="Arial"> Yoon,W.</style></author><author><style face="normal" font="Arial"> Yoo,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Korea University College of Medicine, Anam Hospital, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Association Between Sensitization to Mold and Impaired Pulmonary Function in Children With Asthma</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Immunol Res</style></full-title></periodical><pages end="516" start="509">509-516</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> airflow limitation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostic criteria</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methacholine challenge</style></keyword><keyword><style face="normal" font="Arial"> methacholine PC20</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> PC20</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Recent data indicate that sensitization to mold contributes to the severity and persistence of asthma. In this study, we investigated the relationships between sensitization to mold and lung function parameters in children with asthma. METHODS: We retrospectively reviewed clinical data from 551 asthmatic subjects. We selected subjects who met clinical diagnostic criteria of asthma. Their spirometry, methacholine challenge tests, and measurements of blood eosinophils, serum IgE, eosinophil cationic protein (ECP) and fractional exhaled nitric oxide (FeNO) results were included. Skin prick testing (SPT) results with 13 common aeroallergens in Korea including house dust mites, animal dander, pollen, cockroach and mold were reviewed. Subjects were divided into 3 groups according to their SPT results. Subjects who showed no positive result to any aeroallergen were designated as group 1 (non-sensitized). Group 2 represented subjects who were sensitized to aeroallergens other than mold (other allergen-sensitized) and group 3 included subjects who were sensitized to mold allergens (mold-sensitized). RESULTS: Among the 551 asthmatic subjects, 67 (12.2%) were sensitized to mold and 366 (66.4%) were sensitized to other aeroallergens. The log mean IgE levels were higher in groups 2 (5.96+/-1.14 IU/mL) and 3 (5.81+/-0.97 IU/mL) compared to group 1 (3.88+/-1.68 IU/mL). Blood eosinophils, ECP and FeNO concentrations were significantly higher in groups 2 and 3, but no significant difference was found between the 2 groups. The mean FEV1 value was significantly lower in group 3 (86.9+/-12.1%pred) than in groups 2 (92.0+/-14.8%pred) and 1 (93.4+/-15.4%pred). The log mean methacholine PC20 was significantly lower in group 3 (0.08+/-1.91 mg/mL) than in groups 2 (1.31+/-1.69 mg/mL) and 1 (2.29+/-1.66 mg/mL). CONCLUSIONS: We observed a differential association between mold and other aeroallergen sensitization, and severity of asthma. Sensitization to mold is associated with lower lung function and increased airway hyper-responsiveness in children with asthma. Mold sensitization could be an important factor determining asthma severity particularly airflow limitation in children</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4168/aair.2017.9.6.509</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913990">PM:28913990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-509-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Immunol Res\2017-9-509-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Byeon JH</style></custom2><misc3><style face="normal" font="Arial">10.4168/aair.2017.9.6.509</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kounis,N.G.</style></author><author><style face="normal" font="Arial"> Koniari,I.</style></author><author><style face="normal" font="Arial"> Soufras,G.</style></author><author><style face="normal" font="Arial"> Koutsogiannis,N.</style></author><author><style face="normal" font="Arial"> Velissaris,D.</style></author><author><style face="normal" font="Arial"> Patsouras,N.</style></author><author><style face="normal" font="Arial"> Hahalis,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Cardiology, University of Patras Medical School, Patras, Rion, Achaia, Greece.</style></auth-address><titles><title><style face="normal" font="Arial">Targeted temperature management in Kounis syndrome following cardiac arrest with anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1532-8171 (Electronic)IS - 0735-6757 (Linking)LA - engPT - LetterCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ajem.2017.08.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28882329">PM:28882329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Emerg Med\20170908-KounisNG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Emerg Med\20170908-KounisNG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Kounis NG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ajem.2017.08.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,Q.</style></author><author><style face="normal" font="Arial"> Liu,L.</style></author><author><style face="normal" font="Arial"> Yang,Q.</style></author><author><style face="normal" font="Arial"> Wang,A.</style></author><author><style face="normal" font="Arial"> Chen,S.</style></author><author><style face="normal" font="Arial"> Li,R.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author><author><style face="normal" font="Arial"> Zhang,G.</style></author><author><style face="normal" font="Arial"> Ding,X.</style></author><author><style face="normal" font="Arial"> Yu,H.</style></author><author><style face="normal" font="Arial"> Hu,S.</style></author><author><style face="normal" font="Arial"> Nie,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Renmin Hospital of Wuhan University</style></auth-address><titles><title><style face="normal" font="Arial">Invariant natural killer T cells promote immunogenic maturation of lung dendritic cells in mouse models of asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L990" start="L973">L973-L990</pages><volume><style face="normal" font="Arial">313</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> alternative activation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> invariant natural killer T cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Natural killer T cell</style></keyword><keyword><style face="normal" font="Arial"> natural killer T cells</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">Our previous study showed that invariant natural killer T (iNKT) cells might act as an adjuvant to promote Th2 inflammatory responses in an OVA-induced mouse model of allergic asthma, but the mechanism remains unknown. To clarify the underlying mechanism through which iNKT cells promote Th2 inflammatory responses, we investigated the modulatory influence of iNKT cells on phenotypic and functional maturation of lung dendritic cells (LDCs) using iNKT cell-knockout mice, specific iNKT cell activation, co-culture experiments, and adoptive transfer of iNKT cells in mouse models of asthma. Our data showed that iNKT cell deficiency could downregulate surface maturation markers and proinflammatory cytokine secretion of LDCs from a mouse model of asthma. However, elevated activation of iNKT cells by alpha-Galactosylceramide and adoptive transfer of iNKT cells could upregulate surface maturation markers and proinflammatory cytokine secretion of LDCs from mouse models of asthma. Meanwhile, iNKT cells significantly influenced the function of LDCs, markedly enhancing Th2 responses in vivo and in vitro. In addition, iNKT cell can induce LDCs expression of CD206 and RELM-alpha, reflecting alternative activation of LDCs in a mouse model of asthma. alpha-Galactosylceramide treatment significantly enhanced expression of CD40L of lung iNKT cells from a mouse model of asthma, and the co-culture experiment of LDCs with iNKT cells showed the blockade of CD40L strongly suppressed surface maturation markers and proinflammatory cytokine production by LDCs. Our data suggest that iNKT cells can promote immunogenic maturation of LDCs to enhance Th2 responses in mouse models of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1152/ajplung.00340.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28912381">PM:28912381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\2017-313-L973-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Physiol Lung Cell Mol Physiol\2017-313-L973-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, He Q</style></custom2><misc3><style face="normal" font="Arial">10.1152/ajplung.00340.2016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Qaseem,A.S.</style></author><author><style face="normal" font="Arial"> Singh,I.</style></author><author><style face="normal" font="Arial"> Pathan,A.A.</style></author><author><style face="normal" font="Arial"> Layhadi,J.A.</style></author><author><style face="normal" font="Arial"> Parkin,R.</style></author><author><style face="normal" font="Arial"> Alexandra,F.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Kishore,U.</style></author><author><style face="normal" font="Arial"> Shamji,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Brunel University, 3890, Uxbridge, Middlesex, United Kingdom of Great Britain and Northern Ireland</style></auth-address><titles><title><style face="normal" font="Arial">A Recombinant Fragment of Human Surfactant Protein D Suppresses Basophil Activation, Th2 and B Cell Responses in Grass Pollen-induced Allergic Inflammation</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="1534" start="1526">1526-1534</pages><volume><style face="normal" font="Arial">196</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> CD203c</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Cell Culture</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DAO</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Great Britain</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE synthesis</style></keyword><keyword><style face="normal" font="Arial"> IgE-facilitated allergen binding</style></keyword><keyword><style face="normal" font="Arial"> IL-21</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> Lectin</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> surfactant</style></keyword><keyword><style face="normal" font="Arial"> surfactant protein D</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="Arial">RATIONALE: rfhSP-D has been shown to suppress house dust mite and Aspergillus fumigatus-induced allergic inflammation in murine models. OBJECTIVES: We sought to elucidate the effect of rfhSP-D on FcepsilonRI and CD23-mediated grass pollen induced allergic inflammatory responses. METHODS: rfhSP-D, containing homotrimeric neck and lectin domains, was expressed in Escherichia coli BL21 (lambdaDE3) pLysS. PBMCs and sera were obtained from grass pollen allergic individuals (n=27). The effect of rfhSP-D on basophil activation and histamine release was measured by flow cytometry. IgE-facilitated allergen binding and presentation was assessed by flow cytometry. Th2 cytokines were measured in cell culture supernatants. The effect of rfhSP-D on IgE production by B cells when stimulated with CD40L, IL-4 and IL-21 was also determined. RESULTS: rfhSP-D bound to Phleum pratense in a dose- and calcium-dependent manner. Allergen-induced basophil responsiveness and histamine release was inhibited in the presence of rfhSP-D, as measured by CD63, CD203c (P=0.0086,P=0.04205), and intracellular-labelled DAO (P=0.0003,P=0.0148). The binding of allergen-IgE complexes to B cells was reduced by 51%(P=0.002) in the presence of rfhSP-D. This decrease was concomitant with reduction in CD23 expression on B cells (P&lt;0.001). rfhSP-D suppressed allergen-driven CD27-CD4+CRTH2+ T cell proliferation (P&lt;0.01), IL-4 and IL-5 levels (all,P&lt;0.01). Moreover, rfhSP-D inhibited CD40L/IL-4 and IL-21-mediated IgE production(77.12%; P=0.02) by B cells. CONCLUSION: For the first time, we show that rfhSP-D inhibited allergen-induced basophil responses at a single cell, level and suppressed CD23-mediated facilitated allergen presentation and Th2 cytokine production. In addition, rfhSP-D inhibited IgE synthesis by B cells, which is also a novel observation</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201611-2232PP</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28915062">PM:28915062</url></web-urls><pdf-urls><url ppv-ref="no">asqaseem@gmail.com</url><url ppv-ref="no">m.shamji@imperial.ac.uk</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170915, Qaseem AS</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201611-2232PP</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carr,T.F.</style></author><author><style face="normal" font="Arial"> Zeki,A.A.</style></author><author><style face="normal" font="Arial"> Kraft,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Arizona College of Medicine, Internal Medicine, Tucson, Arizona, United States</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic and Non-Eosinophilic Asthma</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="37" start="22">22-37</pages><volume><style face="normal" font="Arial">197</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary mycosis</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exercise-induced asthma</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Irritant</style></keyword><keyword><style face="normal" font="Arial"> Irritants</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Obesity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">Asthma can be subdivided into eosinophilic or non-eosinophilic phenotypes based on the inflammatory cellular patterns seen in sputum, blood, and airway tissue compartments. However, this level of stratification does not always produce robust clinical phenotypes as there is considerable overlap across these phenotypes when viewed from the perspective of "eosinophilia". Multiple proposed subphenotypes of asthma have instead been described within both the eosinophilic and non-eosinophilic groups. An endotype is the mechanism driving a subphenotype including those associated with eosinophilia such as early-onset allergic asthma, with and without obesity, aspirin sensitive asthma and late-onset eosinophilic asthma, allergic bronchopulmonary mycosis, and exercise-induced asthma. Conversely, subphenotypes of asthma not associated with eosinophilia include those of obesity-induced asthma, asthma with fixed airflow obstruction and minimal inflammation (paucigranulocytic), neutrophilic asthma, and asthma associated with smoking, pollution, infection, or other respiratory irritants. Each of these subphenotypes may have one or more endotype or mechanism driving their clinical presentation. We review the known mechanisms that define each endotype and that lead to the clinical presentation of the known eosinophilic and non-eosinophilic subphenotypes. This approach yields important information regarding potential preventative or therapeutic interventions in these patients with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201611-2232PP</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28910134">PM:28910134</url></web-urls><pdf-urls><url ppv-ref="no">mkraft@deptofmed.arizona.edu</url><url ppv-ref="no">aazeki@ucdavis.edu</url><url ppv-ref="no">tcarr@deptofmed.arizona.edu</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170914, Carr TF</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201611-2232PP</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Prado,I.C.</style></author><author><style face="normal" font="Arial"> Souza,A.L.A.</style></author><author><style face="normal" font="Arial"> Provance-Jr,D.W.</style></author><author><style face="normal" font="Arial"> Cassella,R.J.</style></author><author><style face="normal" font="Arial"> De-Simone,S.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">FIOCRUZ, Center for Technological Development in Health (CDTS)/National Institute of Science and Technology on Innovation in Neglected Population Diseases (INCT-IDPN) FIOCRUZ, Rio de Janeiro, RJ, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Ultrasensitive and rapid immuno-detection of human IgE anti-therapeutic horse sera using an electrochemical immunosensor</style></title><secondary-title><style face="normal" font="Arial">Anal Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Anal Biochem</style></full-title></periodical><pages end="19" start="13">13-19</pages><volume><style face="normal" font="Arial">538</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Carbon</style></keyword><keyword><style face="normal" font="Arial"> Chitosan</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electrodes</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glutaraldehyde</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG3</style></keyword><keyword><style face="normal" font="Arial"> Immunodetection</style></keyword><keyword><style face="normal" font="Arial"> Immunosensor</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">Antivenom allergy disease mediated by patient IgE is an important public health care concern. To improve detection of hypersensitive individuals prior to passive antibody therapy, an amperometric immunosensor was developed to detect reactive human IgE. Whole horse IgG3 (hoIgG3) was immobilized onto the surface of carbon or gold screen-printed electrodes through a cross-linking solution of glutaraldehyde on a chitosan film. Sera from persons with a known allergic response to hoIgG3 or non-allergic individuals was applied to the sensor. Bound human IgE (humIgE) was detected by an anti-humIgE antibody through a quantitative amperometric determination by tracking via the electrochemical reduction of the quinone generated from the hydroquinone with the application of a potential of 25 mV. The optimal immunosensor configuration detected reactive humIgE at a dilution of 1:1800 of the human sera that represent a detection limit of 0.5 pg/mL. Stability testing demonstrated that through 20 cycles of a scan, the specificity and performance remained robust. The new immunosensor successfully detected humIgE antibodies reactive against hoIgG3, which could allow the diagnosis of potential allergenic patients needing therapeutic antivenom preparations from a horse</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1096-0309 (Electronic)IS - 0003-2697 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ab.2017.09.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28919435">PM:28919435</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Anal Biochem\2017-538-13-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Anal Biochem\2017-538-13-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Prado IC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ab.2017.09.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Scott-Taylor,T.H.</style></author><author><style face="normal" font="Arial"> Axinia,S.C.</style></author><author><style face="normal" font="Arial"> Strobel,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Life Sciences and Computing, London Metropolitan University, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="Arial">Lymphoproliferative responses to dendritic cell presentation of sensitizing allergens in atopic children with multiple allergies</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="283" start="274">274-283</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD25</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fluorescein</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergies</style></keyword><keyword><style face="normal" font="Arial"> Multiple allergy</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Thymidine</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peripheral blood mononuclear cells (PBMCs) proliferate inconsistently, rendering current lymphoproliferation assays unreliable in diagnosis. OBJECTIVE: To investigate the utility and nature of proliferation responses in allergy by comparison of the standard lymphoproliferation with a new dendritic cell (DC) stimulated assay. METHODS: Monocyte-derived DCs were pulsed with allergens and incubated with autologous T cells for 7 days. DC-stimulated and standard PBMC proliferation responses to 3 common dietary allergens in children with allergy and without atopy were measured by incorporation of tritiated thymidine and reduction of carboxyl fluorescein succinimidyl ester staining. RESULTS: The DC presentation of sensitizing allergens induced significantly higher proliferative responses than PBMC stimulation (P = .04) and greater distinction between normal and allergic responses. DC-induced stimulation indices of children without sensitivity and those with allergy were significantly different with all 3 foods (P &lt; .001). All children with allergy presented with peanut allergy and 12 of 14 (86%) beta-lactoglobulin-pulsed DC preparations proliferated more than 3.3-fold above un-pulsed cells, but 8 of 18 children (44%) with ovalbumin egg allergy showed proliferation below this level. The stimulation index of DC tritiated thymidine incorporation correlated closely with carboxyl fluorescein succinimidyl ester reduction (P &lt; .001). Sensitivity of detection of peanut, milk, or egg allergy was 100%, 85.7%, or 55.6% and specificity was 60%, 88.9%, or 86.7%, respectively. DC-stimulated T cells expressed increased levels of CD45 RO and CD25 and most produced interferon-gamma. DC-stimulated proliferation correlated with total immunoglobulin E and peanut antigen-stimulated proliferation correlated with peanut specific immunoglobulin E (P = .03). CONCLUSION: The DC-induced lymphoproliferation had higher sensitivity, specificity, and reproducibility than the standard assay and caused increased memory and activated T-cell proliferation in children with food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.06.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890022">PM:28890022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-274-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-274-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Scott-Taylor TH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.06.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dunn,S.E.</style></author><author><style face="normal" font="Arial"> Vicini,J.L.</style></author><author><style face="normal" font="Arial"> Glenn,K.C.</style></author><author><style face="normal" font="Arial"> Fleischer,D.M.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical Sciences and Outreach Lead, Monsanto Company, St Louis, Missouri; Division of Emergency Medicine, Washington University, St Louis, Missouri</style></auth-address><titles><title><style face="normal" font="Arial">The allergenicity of genetically modified foods from genetically engineered crops: A narrative and systematic review</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="222" start="214">214-222</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> genetically modified food</style></keyword><keyword><style face="normal" font="Arial"> Genetically modified foods</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890018">PM:28890018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-214-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-214-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Dunn SE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Esteban,C.A.</style></author><author><style face="normal" font="Arial"> Everhart,R.S.</style></author><author><style face="normal" font="Arial"> Kopel,S.J.</style></author><author><style face="normal" font="Arial"> Klein,R.B.</style></author><author><style face="normal" font="Arial"> Koinis-Mitchell,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Division of Allergy and Immunology, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic sensitization and objective measures of sleep in urban school-aged children with asthma</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="245" start="238">238-245</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">African American</style></keyword><keyword><style face="normal" font="Arial"> African Americans</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Ethnic Groups</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Latino</style></keyword><keyword><style face="normal" font="Arial"> Latinos</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Public school</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Rhode Island</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic sensitization is associated with increased child asthma morbidity and decreased pulmonary function. Nocturnal symptoms and/or awakenings typically are measured by self-report from diary data, whereas objective assessments of sleep in child asthma studies are lacking. OBJECTIVE: To investigate the association between increased allergic sensitization (number of positive allergy test results measured by skin prick test or specific immunoglobulin E) and sleep outcomes (sleep efficiency, sleep duration, and mean number of awakenings measured by actigraphy) in urban schoolchildren with persistent asthma. METHODS: One hundred ninety-six children with persistent asthma (7-9 years old) attending public school in 1 of 4 large urban school districts completed allergy testing during a study clinic visit. Forced expiratory volume in 1 second was monitored at home using a handheld spirometer. Sleep outcomes were measured with a wrist Actiwatch during a 1-month period in the fall and winter seasons. RESULTS: Number of positive allergy test results significantly predicted mean sleep efficiency (P = .02), such that children with more positive test results experienced less efficient sleep. Number of positive allergy test results significantly predicted mean number of night awakenings (P = .05), such that children with more positive allergy test results experienced more night awakenings. Variability in forced expiratory volume in 1 second was a significant moderator in the association between number of positive allergy test results and variability in sleep efficiency (P = .04). Racial and ethnic differences in allergic sensitization and sleep outcomes were found between African Americans and Latinos. CONCLUSION: More positive allergy test results were associated with poorer sleep outcomes measured objectively in this sample of urban children. Implications for environmental control interventions and asthma treatments in different racial and ethnic groups are discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.06.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890019">PM:28890019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-238-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-238-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Esteban CA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.06.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Compton,J.</style></author><author><style face="normal" font="Arial"> Fanning,J.B.</style></author><author><style face="normal" font="Arial"> Nickels,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Center for Biomedical Ethics and Society, Vanderbilt University Medical Center, Nashville, Tennessee.</style></auth-address><titles><title><style face="normal" font="Arial">Genetically modified products and food allergy: Beliefs, evidence, and opportunity</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="199" start="198">198-199</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ethics</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890014">PM:28890014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-198-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-198-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Compton J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Curin,M.</style></author><author><style face="normal" font="Arial"> Garib,V.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="209" start="201">201-209</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> allergy vaccine</style></keyword><keyword><style face="normal" font="Arial"> Allergy vaccines</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Carrier Proteins</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> fusion proteins</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> purified allergens</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Fusion Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> synthetic peptides</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To review the current knowledge regarding recombinant and purified allergens and allergen-derived peptides. DATA SOURCES: PubMed, homepages relevant to the topic, and the National Institutes of Health clinical trial database were searched. STUDY SELECTIONS: The literature was screened for studies describing purified and recombinant allergens and allergen-derived peptides. Studies relevant to the topic were included in this review. RESULTS: Advantages and drawbacks of pure and defined recombinant allergens and peptides over allergen extracts in the context of allergy research, diagnosis, and allergen immunotherapy are discussed. We describe how these molecules are manufactured, which products are currently available on the market, and what the regulative issues are. We furthermore provide an overview of clinical studies with vaccines based on recombinant allergens and synthetic peptides. The possibility of prophylactic vaccination based on recombinant fusion proteins consisting of viral carrier proteins and allergen-derived peptides without allergenic activity are also discussed. CONCLUSION: During the last 25 years more than several hundred allergen sequences were determined, which led to a production of recombinant allergens that mimic biochemically and immunologically their natural counterparts. Especially in Europe, recombinant allergens are increasingly replacing allergen extracts in diagnosis of allergy. Despite many challenges, such as high cost of clinical trials and regulative issues, allergy vaccines based on recombinant allergens and peptides are being developed and will likely soon be available on the market</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2016.11.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890016">PM:28890016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-201-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-201-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Curin M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2016.11.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Motosue,M.</style></author><author><style face="normal" font="Arial"> Bellolio,M.F.</style></author><author><style face="normal" font="Arial"> Van Houten,H.K.</style></author><author><style face="normal" font="Arial"> Shah,N.D.</style></author><author><style face="normal" font="Arial"> Campbell,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota</style></auth-address><titles><title><style face="normal" font="Arial">Predictors of epinephrine dispensing and allergy follow-up after emergency department visit for anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Concordance</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: National guidelines recommend that patients with anaphylaxis be prescribed an epinephrine auto-injector (EAI) and referred to an allergy/immunology (A/I) specialist. OBJECTIVE: To evaluate guideline concordance and identify predictors of EAI dispensing and A/I follow-up in patients with anaphylaxis treated in the emergency department (ED). METHODS: We identified patients seen in the ED for anaphylaxis from 2010 through 2014 from an administrative claims database using an expanded International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code algorithm. RESULTS: Of 7,790 patients identified, 46.5% had an EAI dispensed and 28.8% had A/I follow-up within 1 year after discharge. On multivariable analysis, those 65 years or older (odds ratio [OR] 0.35, 95% confidence interval [CI] 0.30-0.41) and with a medication trigger (OR 0.24, 95% CI 0.21-0.28) had a lower likelihood of EAI dispensing. Those younger than 5 years (OR 2.67, 95% CI 2.15-3.32) and with food (OR 1.40, 95% CI 1.24-1.59) or venom (OR 4.48, 95% CI 3.51-5.72) triggers had a higher likelihood of EAI dispensing. Similarly, for A/I follow-up, the likelihood was lower for age 65 years or older (OR 0.46, 95% CI 0.39-0.54) and medication trigger (OR 0.66, 95% CI 0.56-0.78) and higher for age younger than 5 years (OR 3.15, 95% CI 2.63-3.77) and food trigger (OR 1.39, 95% CI 1.22-1.58). CONCLUSION: Overall, 46.5% of patients with anaphylaxis in the ED had EAI dispensing and 28.8% had A/I follow-up. Patient age and triggers were associated with likelihood of EAI dispensing and A/I follow-up. Post-ED visit anaphylaxis management can be improved, with the potential to decrease future morbidity and mortality risk</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28916424">PM:28916424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170916-MotosueM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170916-MotosueM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Motosue M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dinakarpandian,D.</style></author><author><style face="normal" font="Arial"> Dinakar,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Missouri, Kansas City, Missouri; Stanford University, Palo Alto, CaliforniaStanford University, Palo Alto, California.</style></auth-address><titles><title><style face="normal" font="Arial">Evaluating proteins for potential allergenicity using bioinformatic approaches</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="198" start="197">197-198</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Kansas</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.06.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890013">PM:28890013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-197-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-197-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Dinakarpandian D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.06.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feuille,E.</style></author><author><style face="normal" font="Arial"> Menon,N.R.</style></author><author><style face="normal" font="Arial"> Huang,F.</style></author><author><style face="normal" font="Arial"> Greenhawt,M.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="Arial">Knowledge of food protein-induced enterocolitis syndrome among general pediatricians</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="292" start="291">291-292</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890023">PM:28890023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-291-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-291-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Feuille E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Akuete,K.</style></author><author><style face="normal" font="Arial"> Guffey,D.</style></author><author><style face="normal" font="Arial"> Israelsen,R.B.</style></author><author><style face="normal" font="Arial"> Broyles,J.M.</style></author><author><style face="normal" font="Arial"> Higgins,L.J.</style></author><author><style face="normal" font="Arial"> Green,T.D.</style></author><author><style face="normal" font="Arial"> Naimi,D.R.</style></author><author><style face="normal" font="Arial"> MacGinnitie,A.J.</style></author><author><style face="normal" font="Arial"> Vitalpur,G.</style></author><author><style face="normal" font="Arial"> Minard,C.G.</style></author><author><style face="normal" font="Arial"> Davis,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology, Allergy, and Rheumatology Section, Texas Children's Hospital, Houston, Texas; Department of Pediatrics, Baylor College of Medicine, Houston, Texas</style></auth-address><titles><title><style face="normal" font="Arial">Multicenter prevalence of anaphylaxis in clinic-based oral food challenges</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although previous single-center studies report the rate of anaphylaxis for oral food challenges (OFCs) as 9% to 11%, little is known regarding the epidemiology of clinical OFCs across multiple centers in the United States. OBJECTIVE: To examine the epidemiology, symptoms, and treatment of clinical low-risk OFCs in the nonresearch setting. METHODS: Data were obtained from 2008 to 2013 through a physician survey in 5 food allergy centers geographically distributed across the United States. Allergic reaction rates and the association of reaction rates with year, hospital, and demographics were determined using a linear mixed model. Meta-analysis was used to pool the proportion of reactions and anaphylaxis with inverse-variance weights using a random-effects model with exact confidence intervals (CIs). RESULTS: A total of 6,377 OFCs were performed, and the pooled estimate of anaphylaxis was 2% (95% CI, 1%-3%). The rate of allergic reactions was 14% (95% CI, 13%-16%) and was consistent during the study period (P = .40). Reaction rates ranged from 13% to 33%. Males reacted 16% more frequently than females (95% CI, 4%-37.5%; P = .04). Foods challenged in 2013 varied geographically, with peanut as the most challenged food in the Northeast, Midwest, and West and egg as the most challenged in the South. CONCLUSION: As the largest national survey of allergic reactions of clinical open OFCs in a nonresearch setting in the United States, this study found that performing clinical nonresearch open low-risk OFCs results in few allergic reactions, with 86% of challenges resulting in no reactions and 98% without anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890356">PM:28890356</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170911-AkueteK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170911-AkueteK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Akuete K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valcour,A.</style></author><author><style face="normal" font="Arial"> Jones,J.E.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Borres,M.P.</style></author><author><style face="normal" font="Arial"> Hamilton,R.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory Corporation of America, Burlington, North Carolina.</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization profiles to peanut allergens across the United States</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="266" start="262">262-266</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 8</style></keyword><keyword><style face="normal" font="Arial"> Ara h 9</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis-related protein</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis-related protein 10</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Peanut components</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Measurement of IgE antibody to peanut components can aid in the prediction of allergic responses the food. OBJECTIVE: To investigate the association between patient demographics (age, location) and allergic sensitization to peanut components across the United States. METHODS: Serum samples from 12,155 individuals with peanut extract specific IgE levels of 0.35 kUA/L or higher were analyzed for IgE antibodies to Ara h 1, 2, 3, 8, and 9 by ImmunoCAP. RESULTS: Among this population of peanut sensitized individuals, 79.1% of children (&lt;3 years old) were sensitized to one or more peanut storage proteins (Ara h 1, 2, and/or 3), in contrast to 64.2% of adolescents (12-15 years old) and 22.1% of adults (>20 years old). Although sensitization was more prevalent to Ara h 2 than to the other storage proteins, a sizable fraction of patients were sensitized to Ara h 1 and/or 3 but not to Ara h 2 (eg, 13% of children &lt;3 years old). Moreover, 9.6% of children, 10.2% of adolescents, and 10.5% of adults were sensitized to Ara h 9, whereas 2.4% of children, 49.4% of adolescents, and 42.9% of adults produced IgE to Ara h 8 (pathogenesis-related protein 10). Sensitization to Ara h 8 alone was markedly higher in the Northeastern United States relative to other regions of the country. CONCLUSION: We conclude that sensitization to individual peanut components is highly dependent on age and geographic location. Given that a severe allergic reaction to peanut is unlikely in individuals with isolated sensitization to Ara h 8, a sizable fraction of patients, in particular adolescents and adults, may be at lower risk than anticipated based only on demonstration of sensitization to whole peanut extract</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.06.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890021">PM:28890021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-262-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-262-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Valcour A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.06.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Harmelin,Y.</style></author><author><style face="normal" font="Arial"> Hubiche,T.</style></author><author><style face="normal" font="Arial"> Pharaon,M.</style></author><author><style face="normal" font="Arial"> Del Giudice,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de dermatologie-infectiologie, hopital de Frejus-Saint-Raphael, 240, avenue de Saint-Lambert, 83600 Frejus, France</style></auth-address><titles><title><style face="normal" font="Arial">Three cases of scombroid poisoning</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> flesh</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Poisoning</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gram-Negative Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histidine</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Nausea</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> poisoning</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Scombroid poisoning</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tuna</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Scombroid poisoning is a poorly known type of food poisoning due to the presence of histamine in spoiled fish of the Scombridae family. We report 3 cases of scombroid poisoning seen at the Frejus-Saint-Raphael hospital in the Var region. OBSERVATIONS: Within around thirty minutes of eating a meal containing tuna, three patients presented varied symptoms: malaise, itchy rash, headache, and for two of them, nausea. The diagnosis of scombroid poisoning was based on the circumstances in which the clinical signs appeared and on the signs themselves. The patients were given antihistamines and one injection of intravenous corticosteroids, and symptoms regressed rapidly within a few hours. DISCUSSION: The symptoms of scombroid poisoning appear within a few minutes after eating fish of the Scombridae family and related species. The first symptoms are cutaneous, with flush, pruritus, and erythema of the face and trunk having an urticarial appearance, together with faintness. Gastrointestinal symptoms include nausea, vomiting, abdominal cramps and occasionally diarrhea. Symptoms subside within a few hours. Histamine is present in the flesh of these fish due to decarboxylation of histidine through the action of Gram-negative bacteria whose development is enhanced by heat and sun. Scombroid poisoning is one of the most common types of poisoning caused by eating fish but it is underdiagnosed by dermatologists. The diagnosis is made by measuring histamine levels in the incriminated fish or in the patient's plasma</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 0151-9638 (Print)IS - 0151-9638 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.annder.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28923570">PM:28923570</url></web-urls><pdf-urls><url ppv-ref="no">del-giudice-p@chi-fsr.fr</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170919, Harmelin Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.annder.2017.07.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rivero,A.</style></author><author><style face="normal" font="Arial"> Liang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Kaiser Permanente, Oakland, California, USA1 Kaiser Permanente, Oakland, California, USA</style></auth-address><titles><title><style face="normal" font="Arial">Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis</style></title><secondary-title><style face="normal" font="Arial">Ann Otol Rhinol Laryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Otol Rhinol Laryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal polyp</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To determine the role of biologic therapy on sinonasal symptoms and objective outcomes in chronic rhinosinusitis with nasal polyposis (CRSwNP). METHODS: PubMed, OVID MEDLINE, and Cochrane Central were reviewed from 2000 to 2015. Inclusion criteria included English-language studies containing original data on biologic therapy in CRSwNP patients with reported outcome measures. Two investigators independently reviewed all manuscripts and performed quality assessment and quantitative meta-analysis using validated tools. RESULTS: Of 495 abstracts identified, 7 studies fulfilled eligibility: 4 randomized control trials (RCT), 1 case-control, and 2 case series. Outcome measures included nasal polyp score (NPS,6), computer tomography score (5), and symptom scores (5). Meta-analysis was performed on 5 studies: Anti-IL5 therapy (mepolizumab/reslizumab) and anti-IgE therapy (omalizumab) demonstrated a standard mean difference of NPS improvement of -0.66 (95% CI, -1.24 to -0.08) and -0.75 (95% CI, -1.93 to 0.44), respectively, between biologic therapy and placebo. Quality assessment indicated a low to moderate risk of bias for the RCTs. CONCLUSION: Biologic therapies may prove beneficial in the treatment of recalcitrant nasal polyposis in select populations. In meta-analysis, anti-IL5 therapy demonstrates a reduction in nasal polyp score. Anti-IgE therapy reduces nasal polyp score in patients with severe comorbid asthma. Additional high-level evidence is needed to assess clinical efficacy</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1943-572X (Electronic)IS - 0003-4894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/0003489417731782</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28918644">PM:28918644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Otol Rhinol Laryngol\20170918-RiveroA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Otol Rhinol Laryngol\20170918-RiveroA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Rivero A</style></custom2><misc3><style face="normal" font="Arial">10.1177/0003489417731782</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanaka,Y.</style></author><author><style face="normal" font="Arial"> Sugihara,M.</style></author><author><style face="normal" font="Arial"> Tsumagari,S.</style></author><author><style face="normal" font="Arial"> Takamatsu,N.</style></author><author><style face="normal" font="Arial"> Kurihara,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Kanagawa Children's Medical Center</style></auth-address><titles><title><style face="normal" font="Arial">Food-dependent exercise-induced anaphylaxis due to ingestion of mikan (Citrus unshiu)</style></title><secondary-title><style face="normal" font="Arial">Arerugi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arerugi</style></full-title></periodical><pages end="1015" start="1011">1011-1015</pages><volume><style face="normal" font="Arial">66</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-dependent exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> orange</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">A 12-year-old girl was referred to our hospital owing to repeated anaphylactic reactions induced by exercise after meals. Food-dependent exercise-induced anaphylaxis (FDEIAn) was suspected. However, sequential tests of typical foods, including egg, milk, soy, and wheat, in combination with exercise, were all negative.The results of the skin prick test (SPT) for Citrus unshiu and specific IgE test for orange and grapefruit were positive. Although no symptoms were noted after an exercise challenge combined with the ingestion of only Citrus unshiu, an anaphylactic reaction was induced by additional acetyl-salicylic acid. From these results, she was diagnosed with FDEIAn due to the ingestion of Citrus unshiu. Because the SPT results for other citrus fruits (including orange, grapefruit, lemon, yuzu, sudachi, ponkan, and iyokan) were all positive, it was suggested that these fruits demonstrate cross-reactivity with each other. Since the girl eliminated citrus fruits from her diet, she has not developed any anaphylactic symptoms. Citrus fruits are not known to cause FDEIAn, but the findings of this case suggest that it is necessary to recognize them as a causative allergen of FDEIAn</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.15036/arerugi.66.1011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28904280">PM:28904280</url></web-urls></urls><custom2><style face="normal" font="Arial">20170914, Tanaka Y</style></custom2><misc3><style face="normal" font="Arial">10.15036/arerugi.66.1011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liang,X.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Chen,W.</style></author><author><style face="normal" font="Arial"> Ma,X.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Nagao,N.</style></author><author><style face="normal" font="Arial"> Weng,W.</style></author><author><style face="normal" font="Arial"> Huang,J.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Bioreactor Engineering &amp; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology,130 Meilong Road, Shanghai 200237, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Inhibition of airway remodeling and inflammation by isoforskolin in PDGF-induced rat ASMCs and OVA-induced rat asthma model</style></title><secondary-title><style face="normal" font="Arial">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Pharmacother</style></full-title></periodical><pages end="286" start="275">275-286</pages><volume><style face="normal" font="Arial">95</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Cytoskeleton</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Design</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-1beta</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Phenol</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta1</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="8" Year="2017">2017/8/26</year></dates><abstract><style face="normal" font="Arial">Isoforskolin (ISOF) has been reported to play an important role in many illnesses including respiratory, cardiovascular and ophthalmologic diseases. In our study, we aimed to investigate how ISOF regulates airway remodeling and inflammation in asthma. Based on SO2-stimulated mouse cough model, we assessed the role of ISOF in cough and secretion of phlegm. Afterwards, platelet derived growth factor (PDGF)-induced primary rat airway smooth muscle cell (ASMC) model and ovalbumin (OVA)-induced rat asthma model were used to continue our following research. Our results showed that ISOF could prolong the cough latent period, reduce the cough times in two minutes, and increase the excretion of red phenol, which suggested the antitussive and expectorant effects of ISOF. Besides, ISOF pretreatment reversed the hypotonicity and cytoskeleton remodeling in PDGF-induced ASMCs, and reduced mucus hypersecretion and collagen overdeposition in OVA-induced rat asthma model, which indicated its inhibition on airway remodeling in vitro and in vivo. Moreover, ISOF reduced the invasion of inflammatory cells into bronchoalveolar lavage fluid (BALF) and lungs, which revealed its inhibitory role in airway inflammation. The down-regulation of transforming growth factor beta1 (TGF-beta1) and interleukin-1beta (IL-1beta) upon ISOF treatment might be responsible for its anti-remodeling and anti-inflammation roles. In conclusion, ISOF can reduce cough and sputum, as well as inhibit airway remodeling and inflammation by regulating the expression of TGF-beta1 and IL-1beta. These data indicate the potency of ISOF in treating asthma and also provide insights into the development of new anti-asthma agent</style></abstract><notes><style face="normal" font="Arial">DA - 20170829IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - China -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biopha.2017.08.063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850927">PM:28850927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Pharmacother\2017-95-275-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Pharmacother\2017-95-275-86.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170829, Liang X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biopha.2017.08.063</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yi,S.J.</style></author><author><style face="normal" font="Arial"> Shon,C.</style></author><author><style face="normal" font="Arial"> Min,K.D.</style></author><author><style face="normal" font="Arial"> Kim,H.C.</style></author><author><style face="normal" font="Arial"> Leem,J.H.</style></author><author><style face="normal" font="Arial"> Kwon,H.J.</style></author><author><style face="normal" font="Arial"> Hong,S.</style></author><author><style face="normal" font="Arial"> Kim,K.S.</style></author><author><style face="normal" font="Arial"> Kim,S.Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Association between Exposure to Traffic-Related Air Pollution and Prevalence of Allergic Diseases in Children, Seoul, Korea</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="4216107">4216107-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollution</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Pollution</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Although there has been suggestive evidence of the association between TRAP and ADs, findings remained inconsistent possibly due to limited population. We investigated the association between TRAP and ADs in a large population of children with rich spatial coverage and expanded age span in Seoul, Korea. TRAP exposures were estimated by categorized proximity to the nearest major road (=150, 150-300, 300-500, and >500?m) and density of major roads within 300 meters from children's residences. We estimated the association between two TRAP exposures and three ADs using generalized mixed model after adjusting for individual characteristics. We also investigated whether the association varied by household and regional socioeconomic status. We found associations of atopic eczema with road density [OR = 1.08; 95% CI = 1.01-1.15] and road proximity [1.15, 1.01-1.32; 1.17, 1.03-1.34; and 1.16, 1.01-1.34 for =150, 150-300, and 300-500?m, resp., compared to >500?m]. There was no association with asthma and allergic rhinitis. Effect estimates were generally the highest in the low socioeconomic region. Children living in areas surrounded by large and busy roads were likely to be at greater risks for atopic eczema, with increased vulnerability when living in deprived areas.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/4216107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057259">PM:29057259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-4216107.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-4216107.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Yi SJ</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/4216107</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,W.K.</style></author><author><style face="normal" font="Arial"> Lee,K.S.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author><author><style face="normal" font="Arial"> Sung,M.</style></author><author><style face="normal" font="Arial"> Lee,S.J.</style></author><author><style face="normal" font="Arial"> Jee,H.M.</style></author><author><style face="normal" font="Arial"> Sheen,Y.H.</style></author><author><style face="normal" font="Arial"> Han,M.Y.</style></author><author><style face="normal" font="Arial"> Jung,Y.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Home Remodeling and Food Allergy Interact Synergistically to Increase the Risk of Atopic Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="3793679">3793679-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Purpose. The purpose of this study was to investigate the effects of home remodeling and food allergy (FA) on the development of atopic dermatitis (AD) in children. Methods. The Modified International Study of Asthma and Allergies in Childhood questionnaire was used to survey 4,111 children recruited from 3 kindergartens and 6 elementary schools from Seongnam, Korea. Participants' parents agreed for them to participate in physical examinations, skin prick tests, and blood tests. Results. Home remodeling in the past 12 months (adjusted odds ratio [aOR] 3.40, ), lifetime diagnosis of FA (aOR 3.95, ), parental history of AD (aOR 2.67, ), and FA (aOR 2.35, ) were independent risk factors for lifetime diagnosis of AD ever. When history of home remodeling and FA were combined, the risk for moderate-to-severe AD by scoring atopic dermatitis (SCORAD) score increased (aOR, 7.19, , P for interaction = 0.034). Conclusion. Home remodeling, lifetime diagnosis of FA, parental history of AD, and parental history of FA were independent risk factors for AD. In addition, we observed a synergistic interaction between home remodeling and FA in the risk of moderate-to-severe AD.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/3793679</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1155/2017/3793679</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-3793679.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-3793679.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Lee WK</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/3793679</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Franco-Arellano,B.</style></author><author><style face="normal" font="Arial"> Bernstein,J.T.</style></author><author><style face="normal" font="Arial"> Norsen,S.</style></author><author><style face="normal" font="Arial"> Schermel,A.</style></author><author><style face="normal" font="Arial"> L'abbe,M.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Assessing nutrition and other claims on food labels: a repeated cross-sectional analysis of the Canadian food supply</style></title><secondary-title><style face="normal" font="Arial">BMC Nutrition</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMC Nutrition</style></abbr-1></periodical><pages end="" start="74">74-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food label</style></keyword><keyword><style face="normal" font="Arial"> Food Supply</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Nutrient content</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2055-0928</style></isbn><abstract><style face="normal" font="Arial">In 2010, nutrition claims were investigated in Canadian foods; however, many nutrition and other claims have been introduced since then. This study aimed to determine: i) the proportion of foods carrying claims in 2013, ii) the types and prevalence of nutrition claims (nutrient content claims, health claims, general health claims) and other claims displayed on labels in 2013, iii) and trends in use of nutrition claims between 2010 and 2013</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40795-017-0192-9</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s40795-017-0192-9</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Nutrition\2017-3-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Nutrition\2017-3-74.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Franco-Arellano B</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40795-017-0192-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cross,B.</style></author><author><style face="normal" font="Arial"> Choudhury,T.R.</style></author><author><style face="normal" font="Arial"> Hindle,M.</style></author><author><style face="normal" font="Arial"> Galasko,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Medical student, Blackpool Victoria Hospital, Blackpool, UK</style></auth-address><titles><title><style face="normal" font="Arial">Wasp sting induced STEMI with complete coronary artery occlusion: a case of Kounis syndrome</style></title><secondary-title><style face="normal" font="Arial">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Amines</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera sting</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword><keyword><style face="normal" font="Arial"> wasp venom</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">A 45-year-old previously healthy man with minimal coronary artery disease on imaging presented with an acute MI after sustaining a wasp sting following previous non-eventful exposures throughout his life. This is the first case of Kounis syndrome with optical coherence tomography imaging and proven IgE wasp venom hypersensitivity. The Hymenoptera venom is composed of allergenic proteins and vasoactive amines which are responsible for venom toxicity. This patient also has a history of atopy giving a predisposition for developing IgE-mediated allergic reactions. Hymenoptera stings can be severe in atopic individuals and anaphylaxis may ensue. However, it is a rare cause of myocardial infarction (MI) (Kounis syndrome). Multiple wasp stings in the past may have contributed to sensitisation. Kounis syndrome is a rare clinical manifestation which should remain in the minds of physicians, especially with younger patients with no history of ischaemic heart disease or few risk factors</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1136/bcr-2017-221256</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28882939">PM:28882939</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Case Rep\20170908-CrossB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Case Rep\20170908-CrossB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Cross B</style></custom2><misc3><style face="normal" font="Arial">10.1136/bcr-2017-221256</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shalom,G.</style></author><author><style face="normal" font="Arial"> Magen,E.</style></author><author><style face="normal" font="Arial"> Babaev,M.</style></author><author><style face="normal" font="Arial"> Horev,A.</style></author><author><style face="normal" font="Arial"> Freud,T.</style></author><author><style face="normal" font="Arial"> Ben Yakov,G.</style></author><author><style face="normal" font="Arial"> Comaneshter,D.</style></author><author><style face="normal" font="Arial"> Vardy,D.A.</style></author><author><style face="normal" font="Arial"> Cohen,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology, Soroka Medical Center, Beer-Sheva, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Urticaria and Irritable Bowel Syndrome: a Cross-Sectional Study of 11,271 Patients</style></title><secondary-title><style face="normal" font="Arial">Br J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Br J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Irritable Bowel Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">The human body interacts with the environment mainly through three major tissues: the lungs, skin, and gastrointestinal (GI) tract. In each one, an intensive nervous network is present, conjugated with abundant mast cells (MC). While MC-mediated disorders in airways and the skin are extensively discussed, MC-mediated disorders of the GI tract remain relatively uncommon. Since the GI tract is one of the three main environment-interacting tissues, it is reasonable that MC-mediated disorders of the GI may have the same weight and impact as asthma or chronic urticaria (CU). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/bjd.15997</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28906546">PM:28906546</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Dermatol\20170914-ShalomG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Dermatol\20170914-ShalomG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Shalom G</style></custom2><misc3><style face="normal" font="Arial">10.1111/bjd.15997</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singh,R.</style></author><author><style face="normal" font="Arial"> Perks,W.V.</style></author><author><style face="normal" font="Arial"> Twohig,J.P.</style></author><author><style face="normal" font="Arial"> Kidd,E.J.</style></author><author><style face="normal" font="Arial"> Broadley,K.</style></author><author><style face="normal" font="Arial"> Farrow,S.N.</style></author><author><style face="normal" font="Arial"> Williams,A.S.</style></author><author><style face="normal" font="Arial"> Taylor,P.R.</style></author><author><style face="normal" font="Arial"> Wang,E.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Death Receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="70" start="62">62-70</pages><volume><style face="normal" font="Arial">310</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0008-8749</style></isbn><abstract><style face="normal" font="Arial">The Death Receptor 3 (DR3)/Tumour Necrosis Factor-like cytokine 1A (TL1A) axis stimulates effector T cells and type 2 innate lymphocytes (ILC2) that trigger cytokine release and drive disease pathology in several inflammatory and autoimmune diseases, including murine models of acute allergic lung inflammation (ALI). The aim of this study was to elucidate the role of DR3 in chronic ALI compared to acute ALI, using mice genetically deficient in the DR3 gene (DR3ko). Results showed DR3 expression in the lungs of wild-type mice was up-regulated following induction of acute ALI and this increased expression was maintained in chronic disease. DR3ko mice were resistant to cellular accumulation within the alveolar passages in acute, but not chronic ALI. However, DR3ko mice displayed reduced immuno-histopathology and goblet cell hyperplasia; hallmarks of the asthmatic phenotype; in chronic, but not acute ALI. These data suggest DR3 is a potential therapeutic target, involved in temporally distinct aspects of ALI progression and pathogenesis.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2017.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28942944">PM:28942944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20170920-SinghR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20170920-SinghR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Singh R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2017.09.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,P.</style></author><author><style face="normal" font="Arial"> Cao,L.</style></author><author><style face="normal" font="Arial"> Han,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">E.N.T. Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun 130021, Jilin, China</style></auth-address><titles><title><style face="normal" font="Arial">Angiotensin-converting enzyme (ACE) I/D polymorphism is a risk factor of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Cell Mol Biol (Noisy-le-grand)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Mol Biol (Noisy-le-grand)</style></full-title></periodical><pages end="50" start="48">48-50</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACE</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="Arial">Some previous studies and meta-analysis investigated the association between ACE I/D polymorphism and allergic rhinitis risk. However, the results were conflicting. This meta-analysis, therefore, was performed to evaluate the association between ACE I/D polymorphism and allergic rhinitis risk. Online electronic databases (PubMed and EMBASE) were searched. The strength was evaluated by calculating the OR and 95% CI. Five studies were finally included in this meta-analysis. These studies included 681 cases and 629 controls. ACE I/D polymorphism was significantly associated with allergic rhinitis risk (OR = 1.17; 95% CI 1.07 - 1.29; P = 0.001). In the subgroup analysis of race, Asians showed the increased allergic rhinitis risk (OR = 1.15; 95% CI 1.02 - 1.30; P = 0.03). In a stratified analysis by age, adults with ACE I/D polymorphism showed the increased allergic rhinitis risk (OR = 1.16; 95% CI 1.04 - 1.29; P = 0.006). However, children did not have the significantly increased allergic rhinitis risk (OR = 1.24; 95% CI 0.99 - 1.56; P = 0.06). In conclusion, this meta-analysis indicated that ACE I/D polymorphism was significantly associated with allergic rhinitis risk</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1165-158X (Electronic)IS - 0145-5680 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.14715/cmb/2017.63.8.11</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886328">PM:28886328</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170908, Li P</style></custom2><misc3><style face="normal" font="Arial">10.14715/cmb/2017.63.8.11</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,Y.</style></author><author><style face="normal" font="Arial"> Yang,A.</style></author><author><style face="normal" font="Arial"> Tu,P.</style></author><author><style face="normal" font="Arial"> Hu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, No.11 North Third Ring Road, Chaoyang District, Beijing, 100029 China</style></auth-address><titles><title><style face="normal" font="Arial">Anti-tumor effects of the American cockroach, Periplaneta americana</style></title><secondary-title><style face="normal" font="Arial">Chin Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Chin Med</style></full-title></periodical><pages end="" start="26">26-</pages><volume><style face="normal" font="Arial">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIDS</style></keyword><keyword><style face="normal" font="Arial"> American cockroach</style></keyword><keyword><style face="normal" font="Arial"> angiogenesis</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cell Cycle</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Resistance</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TCM</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Since the incidence of cancer has been on the rise due to increasing exposure to various carcinogenic factors in recent years, cancer has gradually become the first killer to the health of human beings. A growing attention has been paid to anti-cancer effects of traditional Chinese medicine (TCM) with low toxicity and good efficacy. As a kind of TCM, Periplaneta americana (P. americana) has a good effect on clinical application, and its anti-tumor effects has been increasingly well studied. In this review, the research progress on the anti-tumor effects of P. americana was summarized. The main mechanisms of its anti-tumor effects include suppression of tumor cell growth, induction of cell cycle arrest and tumor cell apoptosis, inhibition of angiogenesis, enhancement of immunity, and reversal of tumor drug resistance. This review aims to provide an overview of the research on anti-tumor effects of P. americana and aids in its further application as an anti-tumor drug</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1749-8546 (Print)IS - 1749-8546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13020-017-0149-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28919922">PM:28919922</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chin Med\2017-12-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chin Med\2017-12-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Zhao Y</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13020-017-0149-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cohen,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University of California San Diego, La Jolla, CA, USA</style></auth-address><titles><title><style face="normal" font="Arial">Scabies masquerading as bullous pemphigoid: scabies surrepticius</style></title><secondary-title><style face="normal" font="Arial">Clin Cosmet Investig Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Cosmet Investig Dermatol</style></full-title></periodical><pages end="324" start="317">317-324</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Blister</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fingers</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mineral Oil</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Sarcoptes scabiei</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> Scalp</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Scabies, a parasitic infestation caused by the mite Sarcoptes scabiei, is diagnosed by observing either the mite, its ova, or its excrement. The mite tracts, known as burrows and a characteristic presentation of the pruritic condition, are typically found on the web spaces between the fingers. Other cutaneous lesions include excoriated papules, pustules, and vesicles. However, atypical clinical variants of scabies, such as bullous, crusted, hidden, incognito, nodular, and scalp forms of the parasitic infestation, mimic the morphologic features of other non-parasitic dermatoses. A 76-year-old man presented with pruritic blisters and urticarial plaques that demonstrated not only pathology changes, but direct immunofluorescence also showed findings of bullous pemphigoid. His condition improved, but did not resolve, with topical corticosteroid cream for the management of the primary autoimmune blistering disorder. When other family members subsequently developed scabies, the correct diagnosis for his condition, bullous scabies, was established by demonstrating mites, ova, and scybala on a mineral oil preparation from a skin scraping of a newly appearing burrow. Bullous scabies can masquerade not only clinically, but also both pathologically and immunologically as bullous pemphigoid. Scabies serrupticius is introduced as a unifying term to designate all of the non-classic presentations of S. scabiei mite infestation</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1178-7015 (Print)IS - 1178-7015 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.2147/CCID.S145494</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28883737">PM:28883737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Cosmet Investig Dermatol\2017-10-317-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Cosmet Investig Dermatol\2017-10-317-24.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Cohen PR</style></custom2><misc3><style face="normal" font="Arial">10.2147/CCID.S145494</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caimmi,D.</style></author><author><style face="normal" font="Arial"> Baiz,N.</style></author><author><style face="normal" font="Arial"> Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Arnavielhe,S.</style></author><author><style face="normal" font="Arial"> Murray,R.</style></author><author><style face="normal" font="Arial"> Bedbrook,A.A.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> De Vries,G.</style></author><author><style face="normal" font="Arial"> Fokkens,W.J.</style></author><author><style face="normal" font="Arial"> Fonseca,J.</style></author><author><style face="normal" font="Arial"> Haahtela,T.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Kuna,P.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> Samolinski,B.</style></author><author><style face="normal" font="Arial"> Tomazic,P.V.</style></author><author><style face="normal" font="Arial"> Valiulis,A.</style></author><author><style face="normal" font="Arial"> van Eerd,M.</style></author><author><style face="normal" font="Arial"> Wickman,M.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit, Departement de Pneumologie et Addictologie, Hopital Arnaud de Villeneuve, CHRU de Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinitis control</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Screens</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Visual Analogue Scale (VAS) is a validated tool to assess control in allergic rhinitis patients. OBJECTIVE: The aim of the present study was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) on smartphones screens to evaluate allergic rhinitis symptoms and disease control. METHODS: Each user filled 4 different VAS measuring overall, nasal, ocular and asthma symptoms at least once. Following COSMIN guidelines, we evaluated internal consistency, (Cronbach's alpha-coefficient and test-retest), reliability (intraclass correlation coefficients), sensitivity and acceptability, of the MASK-Rhinitis VAS. RESULTS: Between August 1st , 2015 and July 31st , 2016, the app was used 14,612 times in 15 countries. 1,225 users used it more than once, during the evaluated period. The tool resulted to be statistically satisfactory, showing excellent internal consistency (Cronbach's test >0.84, test-retest >0.7), reliability (>0.9) and acceptability. In addition, the tool had a good sensitivity when users (n=521) answered the VAS twice in less than three hours. CONCLUSIONS &amp; CLINICAL RELEVANCE: The MASK-rhinitis VAS is a reliable and valid tool to assess allergic control on smartphone screens, at the population level. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - France .CO - Ireland -CO - Germany -CO - Netherlands -CO - Portugal -CO - Finland -CO - Poland -CO - Spain -CO - Greece -CO - Austria -CO - Belgium -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886234">PM:28886234</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170908-CaimmiD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170908-CaimmiD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Caimmi D</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Blankestijn,M.A.</style></author><author><style face="normal" font="Arial"> Otten,H.G.</style></author><author><style face="normal" font="Arial"> Suer,W.</style></author><author><style face="normal" font="Arial"> Weimann,A.</style></author><author><style face="normal" font="Arial"> Knol,E.F.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Specific IgE to peanut 2S albumin Ara h 7 has a discriminative ability comparable to Ara h 2 and 6</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">2S albumin</style></keyword><keyword><style face="normal" font="Arial"> 2S Albumins</style></keyword><keyword><style face="normal" font="Arial"> albumin</style></keyword><keyword><style face="normal" font="Arial"> Albumins</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> Ara h 7</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cosensitization</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food challenge outcome</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mono-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> Storage proteins</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Little is known on the clinical relevance of peanut 2S albumin Ara h 7. OBJECTIVE: To investigate the discriminative ability of Ara h 7 in peanut allergy and assess the role of cross-reactivity between Ara h 2, 6 and Ara h 7 isoforms. METHODS: Sensitization to recombinant peanut storage proteins Ara h 1, 2, 3, 6 and 7 was assessed using a line blot in sera from 40 peanut tolerant and 40 peanut allergic patients, based on food challenge outcome. A dose-dependent ELISA inhibition experiment was performed with recombinant Ara h 2, 6 and Ara h 7 isoforms. RESULTS: For Ara h 7.0201 an area under the ROC curve was found of 0.83, comparable to Ara h 2 (AUC 0.81) and Ara h 6 (AUC 0.85). Ara h 7 intensity values strongly correlated with those from Ara h 2 and 6 (rs =0.81). Of all patients sensitized to 2S albumins Ara h 2, 6 or 7, the majority was co-sensitized to all three (n=24, 68%), although mono-sensitization to either 2S albumin was also observed in selected patients (Ara h 2: n=6, 17%; Ara h 6: n=2, 6%; Ara h 7: n=2, 6%). Binding to Ara h 7.0101 could be strongly inhibited by Ara h 7.0201, but not the other way around. CONCLUSIONS &amp; CLINICAL RELEVANCE: Specific IgE against Ara h 7.0201 has a predictive ability for peanut allergy similar to Ara h 2 and 6, and possesses unique IgE epitopes as well as epitopes shared between the other Ara h 7 isoform and Ara h 2 and 6. While co-sensitization to all three 2S albumins is most common, mono-sensitization to either Ara h 2, 6 or 7 occurs in selected patients, leading to a risk of misdiagnosis when testing for a single 2S albumin. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28906044">PM:28906044</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170914-BlankestijnMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170914-BlankestijnMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Blankestijn MA</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salamon,P.</style></author><author><style face="normal" font="Arial"> Shefler,I.</style></author><author><style face="normal" font="Arial"> Moshkovits,I.</style></author><author><style face="normal" font="Arial"> Munitz,A.</style></author><author><style face="normal" font="Arial"> Klotzman,D.H.</style></author><author><style face="normal" font="Arial"> Mekori,Y.A.</style></author><author><style face="normal" font="Arial"> Hershko,A.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Allergy and Clinical Immunology, The Herbert Mast Cell Disorders Center, Meir Medical Center, Kfar Saba, Israel</style></auth-address><titles><title><style face="normal" font="Arial">IL-33 and IgE stimulate mast cell production of IL-2 and regulatory T cells expansion in allergic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Incubation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell disorders</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Oxazolone</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We have previously shown that mast cells (MCs) suppress chronic allergic dermatitis in mice. The underlying mechanism involves MC-derived IL-2, which supports regulatory T cell (Treg) response at the site of inflammation. However, it is not clear what are the factors that drive MCs to produce IL-2. OBJECTIVE: To understand the mechanisms that lead to IL-2 production from MCs in chronic allergic dermatitis. METHODS: Isolated murine bone marrow derived-MCs (BMMCs) were incubated with various stimulators and IL-2 production was assessed by RT-PCR and ELISA. The response of signaling pathways was evaluated by MAPK inhibitors and Western blot analysis. The effect of MC-IL2 on Tregs was studied by incubation of splenic T cells with conditioned media obtained from activated BMMCs. Dermatitis was elicited by repeated exposures of mouse ears to oxazolone. MCs in mouse and human skin samples were evaluated by immunostaining. RESULTS: BMMCs released IL-2 in response to IL-33, and IL-2 production was further enhanced by concomitant FcepsilonRI activation. The effect of IL-33 was mediated by activation of the MAPKs family members. IL-2 in conditioned media from IL-33 and IgE-stimulated BMMCs led to considerable expansion of Tregs in vitro. IL-33 levels were elevated in oxazolone-challenged ears along with increased numbers of IL-2 expressing MCs. Human skin with chronic inflammation also contained IL-2 expressing MCs that co-localized with IL-33 staining in the dermis. CONCLUSIONS: IL-33, in collaboration with IgE, is critical for MC-IL-2 production in allergic skin disease thus leading to Treg stimulation and suppression of allergic dermatitis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892206">PM:28892206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170911-SalamonP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170911-SalamonP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Salamon P</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13027</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Motomura,C.</style></author><author><style face="normal" font="Arial"> Matsuzaki,H.</style></author><author><style face="normal" font="Arial"> Ono,R.</style></author><author><style face="normal" font="Arial"> Iwata,M.</style></author><author><style face="normal" font="Arial"> Okabe,K.</style></author><author><style face="normal" font="Arial"> Akamine,Y.</style></author><author><style face="normal" font="Arial"> Wakatsuki,M.</style></author><author><style face="normal" font="Arial"> Murakami,Y.</style></author><author><style face="normal" font="Arial"> Taba,N.</style></author><author><style face="normal" font="Arial"> Odajima,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, National Hospital Organization Fukuoka Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Aspirin is an Enhancing Factor for Food-dependent Exercise-induced Anaphylaxis in Children</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> FDEIA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-dependent exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> physical activity</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Students</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">Food-dependent exercise-induced anaphylaxis (FDEIA) is typified by the onset of anaphylaxis during or soon after exercise preceded by the ingestion of a causal food. In Japan, a questionnaire-based prevalence study of 76,247 junior high-school students revealed an FDEIA prevalence of 0.017%. 1 Physical activity is beneficial for children, with positive outcomes pertaining to both mental and physical well-being. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892197">PM:28892197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170911-MotomuraC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170911-MotomuraC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Motomura C</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Massaad,M.J.</style></author><author><style face="normal" font="Arial"> Cangemi,B.</style></author><author><style face="normal" font="Arial"> Al-Herz,W.</style></author><author><style face="normal" font="Arial"> Lefranc,G.</style></author><author><style face="normal" font="Arial"> Freeman,A.</style></author><author><style face="normal" font="Arial"> Baxi,S.</style></author><author><style face="normal" font="Arial"> Keles,S.</style></author><author><style face="normal" font="Arial"> Metin,A.</style></author><author><style face="normal" font="Arial"> Dasouki,M.</style></author><author><style face="normal" font="Arial"> Sobh,A.</style></author><author><style face="normal" font="Arial"> Kanariou,M.</style></author><author><style face="normal" font="Arial"> Al-Sukaiti,N.</style></author><author><style face="normal" font="Arial"> Ozen,A.</style></author><author><style face="normal" font="Arial"> Ochs,H.</style></author><author><style face="normal" font="Arial"> Chatila,T.A.</style></author><author><style face="normal" font="Arial"> Manis,J.P.</style></author><author><style face="normal" font="Arial"> Geha,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA</style></auth-address><titles><title><style face="normal" font="Arial">DOCK8 and STAT3 dependent inhibition of IgE isotype switching by TLR9 ligation in human B cells</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> DOCK8</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> isotype switching</style></keyword><keyword><style face="normal" font="Arial"> Kuwait</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - LetterCO - United States -CO - Kuwait -CO - France -CO - Turkey -CO - Egypt -CO - Greece -CO - Oman -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2017.08.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28882618">PM:28882618</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20170908-MassaadMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\20170908-MassaadMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Massaad MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2017.08.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhong,H.</style></author><author><style face="normal" font="Arial"> Fan,X.L.</style></author><author><style face="normal" font="Arial"> Yu,Q.N.</style></author><author><style face="normal" font="Arial"> Qin,Z.L.</style></author><author><style face="normal" font="Arial"> Chen,D.</style></author><author><style face="normal" font="Arial"> Xu,R.</style></author><author><style face="normal" font="Arial"> Chen,D.H.</style></author><author><style face="normal" font="Arial"> Lin,Z.B.</style></author><author><style face="normal" font="Arial"> Wen,W.</style></author><author><style face="normal" font="Arial"> Fu,Q.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China</style></auth-address><titles><title><style face="normal" font="Arial">Increased innate type 2 immune response in house dust mite-allergic patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PBMCs</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">Group 2 innate lymphoid cells (ILC2s) are essential in initiating and driving allergic immune responses. However, there were inconsistent findings of the ILC2 levels in allergic rhinitis (AR) patients. This study investigated the ILC2 levels in the peripheral blood of house dust mite (HDM)-allergic AR patients and their ability to secrete type 2 cytokines. The levels of ILC2s with phenotypic ILC2 characteristics were increased in the HDM-AR patients. The AR patients' symptom score and IL-13 levels were positively associated with the ILC2s in HDM-AR patients. The epithelial cytokine stimulation induced dramatic production of IL-5 and IL-13 in PBMCs of AR patients. We successfully sorted ILC2s from AR patients and identified their ability of type 2 cytokines production. The number of ILC2s increased in the HDM-AR patients and ILC2s produced the amount of TH2 cytokines in the presence of epithelial cytokines, which suggested the important role of ILC2 in AR patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170917IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2017.09.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28917723">PM:28917723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20170917-ZhongH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\20170917-ZhongH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170917, Zhong H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2017.09.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,J.</style></author><author><style face="normal" font="Arial"> Lee,K.S.</style></author><author><style face="normal" font="Arial"> Kim,B.Y.</style></author><author><style face="normal" font="Arial"> Choi,Y.S.</style></author><author><style face="normal" font="Arial"> Yoon,H.J.</style></author><author><style face="normal" font="Arial"> Jia,J.</style></author><author><style face="normal" font="Arial"> Jin,B.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Natural Resources and Life Science, Dong-A University, Busan 604-714, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Anti-fibrinolytic and anti-microbial activities of a serine protease inhibitor from honeybee (Apis cerana) venom</style></title><secondary-title><style face="normal" font="Arial">Comp Biochem Physiol C Toxicol Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Comp Biochem Physiol C Toxicol Pharmacol</style></abbr-1></periodical><pages end="18" start="11">11-18</pages><volume><style face="normal" font="Arial">201</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Antimicrobial activity</style></keyword><keyword><style face="normal" font="Arial"> Api m 6</style></keyword><keyword><style face="normal" font="Arial"> Apis mellifera</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chymotrypsin</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Fibrin</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Gram-Negative Bacteria</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect cells</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Plasmin</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Serine protease inhibitor</style></keyword><keyword><style face="normal" font="Arial"> serine proteases</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Thrombin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">Bee venom contains a variety of peptide constituents, including low-molecular-weight protease inhibitors. While the putative low-molecular-weight serine protease inhibitor Api m 6 containing a trypsin inhibitor-like cysteine-rich domain was identified from honeybee (Apis mellifera) venom, no anti-fibrinolytic or anti-microbial roles for this inhibitor have been elucidated. In this study, we identified an Asiatic honeybee (A. cerana) venom serine protease inhibitor (AcVSPI) that was shown to act as a microbial serine protease inhibitor and plasmin inhibitor. AcVSPI was found to consist of a trypsin inhibitor-like domain that displays ten cysteine residues. Interestingly, the AcVSPI peptide sequence exhibited high similarity to the putative low-molecular-weight serine protease inhibitor Api m 6, which suggests that AcVSPI is an allergen Api m 6-like peptide. Recombinant AcVSPI was expressed in baculovirus-infected insect cells, and it demonstrated inhibitory activity against trypsin, but not chymotrypsin. Additionally, AcVSPI has inhibitory effects against plasmin and microbial serine proteases; however, it does not have any detectable inhibitory effects on thrombin or elastase. Consistent with these inhibitory effects, AcVSPI inhibited the plasmin-mediated degradation of fibrin to fibrin degradation products. AcVSPI also bound to bacterial and fungal surfaces and exhibited anti-microbial activity against fungi as well as gram-positive and gram-negative bacteria. These findings demonstrate the anti-fibrinolytic and anti-microbial roles of AcVSPI as a serine protease inhibitor</style></abstract><notes><style face="normal" font="Arial">DA - 20170917IS - 1532-0456 (Print)IS - 1532-0456 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cbpc.2017.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28917645">PM:28917645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Comp Biochem Physiol C Toxicol Pharmacol\2017-201-11-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Comp Biochem Physiol C Toxicol Pharmacol\2017-201-11-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170917, Yang J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cbpc.2017.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tourani,M.</style></author><author><style face="normal" font="Arial"> Karkhah,A.</style></author><author><style face="normal" font="Arial"> Najafi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Development of an epitope-based vaccine inhibiting immune cells rolling and migration against atherosclerosis using in silico approaches</style></title><secondary-title><style face="normal" font="Arial">Comput Biol Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Comput Biol Chem</style></full-title></periodical><pages end="163" start="156">156-163</pages><volume><style face="normal" font="Arial">70</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Atherosclerosis</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> CTB</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> linkage</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipids</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Tetanus</style></keyword><keyword><style face="normal" font="Arial"> Tetanus Toxin</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">Atherosclerosis is a chronic inflammatory disease characterized by formation of pro-oxidative lipids in large and medium-sized vessels. Over the years, many treatments and drugs have entered the market to improve atherosclerosis and autoantigen-mediated active immunization is currently considered as a beneficial method. Therefore, this study was conducted to design a novel epitope-based vaccine against atherosclerosis employing CD99, CD81 and CD99L2 antigens. In this way, structural vaccinology approaches were used to design a novel multi-epitope vaccine against atherosclerosis. Six epitopes were predicted from CD99, CD81 and CD99L2 proteins. In addition, helper epitopes selected from Tetanus toxin fragment C (TTFrC)ion were applied to induce CD4+ helper T lymphocytes (HTLs) responses. Moreover, cholera toxin B (CTB) was employed as an adjuvant. Finally, EAAAK AND GPGPG sequences as linkers were considered to make a linkage between favorite peptide sequences. A multi-epitope construction was designed based on the predicted epitopes which was 270 residues in length. Further immunoinformatic analyses were carried out to assess physicochemical properties, secondary and tertiary structures, stability, intrinsic protein disorder, solubility, and allergenicity of this chimeric protein. Based on the obtained results, a soluble, and non-allergic protein with a molecular weight of 28.7kDa was designed. Further analyses revealed that the chimeric protein is a stable protein and the predicted epitopes indicated strong potential to induce B-cell and T-cell mediated immune response. Our immunoinformatic analyses revealed that the modeled multi-epitope vaccine had appropriate properties,which can properly stimulate the immune responses of both T and B cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1476-928X (Electronic)IS - 1476-9271 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.compbiolchem.2017.08.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886485">PM:28886485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Comput Biol Chem\2017-70-156-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Comput Biol Chem\2017-70-156-63.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Tourani M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.compbiolchem.2017.08.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Costa,J.</style></author><author><style face="normal" font="Arial"> Silva,I.</style></author><author><style face="normal" font="Arial"> Vicente,A.A.</style></author><author><style face="normal" font="Arial"> Oliveira,M.B.P.P.</style></author><author><style face="normal" font="Arial"> Mafra,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a REQUIMTE-LAQV, Faculdade de Farmacia , Universidade do Porto, Rua de Jorge Viterbo Ferreira , 228, 4050-313 Porto, Portugal</style></auth-address><titles><title><style face="normal" font="Arial">Pistachio nut allergy: an updated overview</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen risk assessment</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> DNA-based methods</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health benefit</style></keyword><keyword><style face="normal" font="Arial"> Health benefits</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated reactions</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Pis v 1</style></keyword><keyword><style face="normal" font="Arial"> Pis v 2</style></keyword><keyword><style face="normal" font="Arial"> Pis v 3</style></keyword><keyword><style face="normal" font="Arial"> Pis v 4</style></keyword><keyword><style face="normal" font="Arial"> Pis v 5</style></keyword><keyword><style face="normal" font="Arial"> Pistachio</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">Pistachio nut (Pistacia vera) is highly appreciated for its organoleptic characteristics and potential health benefits. However, this tree nut is also responsible for triggering moderate to severe IgE-mediated reactions in allergic individuals. Currently, pistachio nut allergy has gained some special attention, mainly due to its intrinsic relation with cashew nut allergy. Like for other nuts, the prevalence of pistachio nut allergy seems to be increasing at a global scale. Until now, there are five allergenic proteins officially listed for pistachio nut (Pis v 1, Pis v 2, Pis v 3, Pis v 4 and Pis v 5). Relevant data on their biochemical classification has become available, enabling establishing a correlation with the respective clinical symptoms. The establishment of an effective allergen risk assessment is a key issue for the food industry, policy makers and regulatory agencies. Thus, the availability of fast, specific and sensitive methods to detect trace amounts of allergens in processed foods is crucial. In the specific case of pistachio nut, there are some protein- and DNA-based methods for its detection/quantification in foods, which can aid to verify label information. Accordingly, all relevant research advances on this topic were summarised, updated and critically discussed in this review</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2017.1379947</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28925724">PM:28925724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\20170919-CostaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\20170919-CostaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Costa J</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2017.1379947</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turcanu,V.</style></author><author><style face="normal" font="Arial"> Brough,H.A.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author><author><style face="normal" font="Arial"> Foong,R.X.</style></author><author><style face="normal" font="Arial"> Marrs,T.</style></author><author><style face="normal" font="Arial"> Santos,A.F.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatric Allergy, King's College London, Guy's &amp; St Thomas' NHS Foundation Trust, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Immune mechanisms of food allergy and its prevention by early intervention</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="98" start="92">92-98</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> early intervention</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Learning</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">The environmental factors driving the increase in food allergies are unclear and possibly involve dual exposure to allergens, microbiome-driven effects or other mechanisms. Until they can be better understood, early intervention aiming at establishing oral tolerance provides an effective way to decrease the window-of-risk when children may develop allergic sensitisation to foods due to the absence of a protective immune response. Thus, the recent LEAP (Learning Early About Peanut allergy) and LEAP-On studies achieved a high level of peanut allergy prevention by early introduction of peanuts in the infants diet and conveyed more information regarding the evolution of IgE and IgG4 antibody responses to food antigens over time</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2017.08.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892729">PM:28892729</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-92-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-92-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Turcanu V</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2017.08.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boyd,S.D.</style></author><author><style face="normal" font="Arial"> Hoh,R.A.</style></author><author><style face="normal" font="Arial"> Nadeau,K.C.</style></author><author><style face="normal" font="Arial"> Galli,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pathology, Stanford, CA 94305, USA; Departments of the Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA 94305, USA</style></auth-address><titles><title><style face="normal" font="Arial">Immune monitoring for precision medicine in allergy and asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="91" start="82">82-91</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">'Precision Medicine' embodies the analyses of extensive data collected from patients and their environments to identify and apply patient-specific prophylactic strategies and medical treatments to improve clinical outcomes and healthcare cost-effectiveness. Many new methods have been developed for evaluating the activity of the human immune system. Such 'immune monitoring' approaches are now being used in studies of allergy and asthma in the hope of identifying better correlates of disease status, predictors of therapeutic outcomes, and potential side-effects of treatment. Together with analyses of family histories, genetic and other biometric data, and measurements of exposures to environmental and other risk factors for developing or exacerbating disease, immune monitoring approaches promise to enable 'Precision Medicine' for allergic diseases and asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2017.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889067">PM:28889067</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-82-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-82-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Boyd SD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2017.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Van De Veen,W.</style></author><author><style face="normal" font="Arial"> Wirz,O.F.</style></author><author><style face="normal" font="Arial"> Globinska,A.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270 Davos, Switzerland;</style></auth-address><titles><title><style face="normal" font="Arial">Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="81" start="74">74-81</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody isotypes</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Beekeepers</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (AIT) has been used for more than 100 years as a clinical tolerance-inducing and immune tolerance-inducing therapy for allergic diseases and represents a potentially curative method of treatment. AIT functions through multiple mechanisms including early desensitization of basophils and mast cells, regulating T-cell and B-cell responses, changing antibody isotypes, and decreasing activation, mediator release and affected tissue migration of eosinophils, basophils, and mast cells. Similar molecular and cellular mechanisms have been observed in subcutaneous AIT, sublingual AIT and peptide immunotherapy as well as natural tolerance to high doses of allergen exposure in beekeepers and cat owners</style></abstract><notes><style face="normal" font="Arial">DA - 20170909IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Switzerland -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2017.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888176">PM:28888176</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-74-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-74-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170909, van de Veen W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2017.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barcik,W.</style></author><author><style face="normal" font="Arial"> Wawrzyniak,M.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> O'Mahony,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Immune regulation by histamine and histamine-secreting bacteria</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Curr Opin Immunol</style></abbr-1></periodical><pages end="113" start="108">108-113</pages><volume><style face="normal" font="Arial">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Differential expression</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="Arial">Histamine is a biogenic amine with extensive effects on many immune cell types. Histamine and its four receptors (H1R-H4R) represent a complex system of immunoregulation with distinct effects dependent on receptor subtypes and their differential expression. In addition to mammalian cells, bacteria can also secrete histamine and the influence of microbiota-derived histamine on host immunological processes is only beginning to be described. However, it is clear that histamine-secreting microbes are present within the human gut microbiota and their levels are increased in asthma patients. Additional studies are required to fully understand the complex regulatory interactions between histamine and the host immune response to everyday microbial and environmental challenges</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.coi.2017.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28923468">PM:28923468</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-108-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Immunol\2017-48-108-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Barcik W</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.coi.2017.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,Y.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aMurdoch Childrens Research Institute, Parkville bDepartment of Paediatrics, University of Melbourne cDepartment of Allergy and Immunology, Royal Children's Hospital, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Dietary intervention for preventing food allergy in children</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg allergy</style></keyword><keyword><style face="normal" font="Arial"> Egg-allergy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> high-risk infants</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant feeding</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intervention trial</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: In the past decade, food allergy has been increasingly recognized as an important public health issue. The role of maternal and infant diet in the development of food allergy has been a major focus of research throughout this period. Recently, research in this area has moved from observational studies to intervention trials, and the findings from these trials have started to influence infant feeding guidelines. In this article, we review recent studies of dietary interventions for preventing food allergy, summarize current knowledge and discuss future research directions. RECENT FINDINGS: The latest result from an intervention trial shows that introduction of peanut in the first year of life reduces the risk of peanut allergy in high-risk infants. A systematic review and meta-analysis of intervention trials also suggests a protective effect of egg introduction from around 4 to 6 months of age for reducing the risk of egg allergy, with most studies conducted in high-risk infants. Despite several intervention trials involving modifications to the maternal diet, the effect of maternal diet during pregnancy and lactation in preventing food allergy remains unclear. SUMMARY: Earlier introduction of allergenic foods is a promising intervention to reduce the risk of some food allergies in high-risk infants. Further work is needed to improve knowledge of how to prevent food allergy in the general population</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1531-698X (Electronic)IS - 1040-8703 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOP.0000000000000552</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28914636">PM:28914636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pediatr\20170915-WangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pediatr\20170915-WangY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Wang Y</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOP.0000000000000552</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Diogo,G.R.</style></author><author><style face="normal" font="Arial"> Sparrow,A.</style></author><author><style face="normal" font="Arial"> Paul,M.J.</style></author><author><style face="normal" font="Arial"> Copland,A.</style></author><author><style face="normal" font="Arial"> Hart,P.J.</style></author><author><style face="normal" font="Arial"> Stelter,S.</style></author><author><style face="normal" font="Arial"> van Dolleweerd,C.</style></author><author><style face="normal" font="Arial"> Drake,P.M.W.</style></author><author><style face="normal" font="Arial"> Macallan,D.C.</style></author><author><style face="normal" font="Arial"> Reljic,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, SW17 0RE London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Murine IL-4Delta2 splice variant down-regulates IL-4 activities independently of IL-4Ralpha binding and STAT-6 phosphorylation</style></title><secondary-title><style face="normal" font="Arial">Cytokine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cytokine</style></full-title></periodical><pages end="162" start="154">154-162</pages><volume><style face="normal" font="Arial">99</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE synthesis</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> STAT-6</style></keyword><keyword><style face="normal" font="Arial"> STAT6</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">IL-4 is a pleiotropic cytokine that is highly Th2 polarizing. The ratio of IL-4 and its splice variant IL-4Delta2 observed in human health and disease suggests a role for both isoforms. In the present study, the biological function of murine IL-4Delta2 and the potential mechanism of action were studied. We report for the first time the generation of a functional, recombinant murine IL-4Delta2 form which is suggestive of its possible biological role in this species. Recombinant murine IL-4Delta2 inhibited IL-4 mediated cellular processes in macrophages and lymphocytes. Specifically, (i) it reversed IL-4 mediated inhibition of IFN-gamma induced nitric oxide release by macrophages, (ii) inhibited IL-4 mediated induction of T cell proliferation, and (iii) prevented IL-4 stimulation of IgE synthesis by B cells. However, IL-4Delta2 did not compete with IL-4 for IL-4Ralpha binding and did not interfere with the downstream STAT-6 phosphorylation in T cells, suggesting an alternative mechanism for its antagonism of specific IL4-driven effects. These findings suggest that the mouse is a suitable experimental model for studies of the biology of IL-4 and its alternative splice variant</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 1096-0023 (Electronic)IS - 1043-4666 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cyto.2017.09.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28917204">PM:28917204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytokine\2017-99-154-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytokine\2017-99-154-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Diogo GR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cyto.2017.09.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gouveia,A.C.C.</style></author><author><style face="normal" font="Arial"> Braga,F.G.</style></author><author><style face="normal" font="Arial"> Mota,M.</style></author><author><style face="normal" font="Arial"> Silva,F.M.C.</style></author><author><style face="normal" font="Arial"> Brugiolo,A.S.S.</style></author><author><style face="normal" font="Arial"> Oliveira,E.E.</style></author><author><style face="normal" font="Arial"> Ayupe,M.C.</style></author><author><style face="normal" font="Arial"> Teixeira,H.C.</style></author><author><style face="normal" font="Arial"> Ferreira,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, Microbiology, and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Enhanced expression of PD-L1 and IFN-gamma on dendritic cells is associated with BCG-induced Th2 inhibition</style></title><secondary-title><style face="normal" font="Arial">Cytokine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cytokine</style></full-title></periodical><pages end="172" start="163">163-172</pages><volume><style face="normal" font="Arial">99</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> EPO</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Forum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mycobacteria</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium</style></keyword><keyword><style face="normal" font="Arial"> Mycobacterium bovis</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">Accumulating evidence indicates that the exposure to Mycobacterium bovis bacillus Calmette-Guerin (BCG) prevents the development of allergy and the airway dendritic cells (DCs) may be involved in this protective effect. However, studies to better characterize the specific interactions between BCG and DCs and their role in this mycobacteria-mediated Th2 cell suppression are still ongoing. This study aimed to evaluate the effect of the neonatal BCG vaccination in the innate immune response in a mouse model of ovalbumin (OVA)-induced airway inflammation. BCG treated neonatal BALB/c mice were sensitized and challenged with aerosolized OVA. Twenty-four hours after the last challenge, samples were collected for analysis. The intranasal BCG treatment inhibited the allergic Th2-response by decreasing the allergen-induced eosinophilic inflammation, EPO activity, CCL11, IL-25, TSLP, IL-4 and IL-5 lung levels, and serum levels of IgE. Mycobacteria treatment increased lung levels of IL-10 and TGF-beta, and the TLR2 and TLR4 expressions by pulmonary CD11c+CD103+CD8alpha+ DCs. Additionally an enhanced expression of PD-L1 was observed besides an increased production of IFN-gamma by these cells. These results indicated that neonatal BCG vaccination inhibits key features of allergic airway inflammation, probably by promoting T regulatory immune response via an enhanced expression of TLR2, TLR4 and PD-L1 on DCs</style></abstract><notes><style face="normal" font="Arial">DA - 20170917IS - 1096-0023 (Electronic)IS - 1043-4666 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cyto.2017.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28917991">PM:28917991</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytokine\2017-99-163-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytokine\2017-99-163-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170917, Gouveia AC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cyto.2017.09.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al-Salama,Z.T.</style></author><author><style face="normal" font="Arial"> Scott,L.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Springer, Private Bag 65901, Mairangi BaY, Auckland, 0754, New Zealand.</style></auth-address><titles><title><style face="normal" font="Arial">Lonoctocog Alfa: A Review in Haemophilia A</style></title><secondary-title><style face="normal" font="Arial">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Factor Viii</style></keyword><keyword><style face="normal" font="Arial"> Haemophilia</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">Lonoctocog alfa (rVIII-SingleChain; Afstyla(R)) is a novel single-chain recombinant factor VIII (FVIII) molecule, with a truncated B-domain and the heavy and light chains covalently linked to form a stable and homogenous drug that binds with high affinity to von Willebrand factor (VWF). Intravenous lonoctocog alfa is approved for the prophylaxis and treatment of bleeding in patients with haemophilia A in several countries worldwide. In two pivotal, multicentre trials, lonoctocog alfa was effective in the treatment of bleeding episodes and as prophylaxis, including for perioperative management in adults, adolescents and children. In terms of haemostatic efficacy in controlling bleeding episodes, overall treatment and investigator-assessed success rates were high across all age groups, with the majority of these bleeds controlled with a single injection of lonoctocog alfa. Low median spontaneous, overall and traumatic annualized bleeding rates were evident with prophylactic lonoctocog alfa regimens in both trials. Lonoctocog alfa was generally well-tolerated, with very low rates of injection-site reactions. No previously treated patient experienced an anaphylactic reaction or developed an inhibitor. In conclusion, lonoctocog alfa is an effective and generally well-tolerated alternative to conventional FVIII products for the treatment and prophylaxis of bleeding, including in the surgical setting, in adults, adolescents and children with haemophilia A</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1179-1950 (Electronic)IS - 0012-6667 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40265-017-0815-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28900904">PM:28900904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs\20170913-AlSalamaZT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs\20170913-AlSalamaZT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Al-Salama ZT</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40265-017-0815-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vena,G.A.</style></author><author><style face="normal" font="Arial"> Cassano,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology and Venereology Private Practice, Bari and Barletta, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">The link between chronic spontaneous urticaria and metabolic syndrome</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="212" start="208">208-212</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Private Practice</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Metabolic syndrome (MS) is a cluster of risk factors for cardiovascular disease and is considered a chronic low-level systemic inflammatory condition. Recent preliminary findings have shown an increased prevalence of MS among patients with chronic urticaria (CU) as compared to controls, with a particularly higher prevalence detected in patients with uncontrolled CU. Chronic spontaneous urticaria (CSU) appears to share some pathomechanisms with MS, including a pro-inflammatory state, increased oxidative stress, alterations in adipokine profile and activation of the coagulation system. Further studies are needed to assess the association of MS and its components with CU/CSU and to obtain more precise information regarding epidemiological aspects, clinical significance and implications. The aim of this review is to present the most relevant literature data on the link between CU/CSU and MS</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28884987">PM:28884987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-208-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-208-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Vena GA</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.12</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bonyadi,M.R.</style></author><author><style face="normal" font="Arial"> Hassanzadeh,D.</style></author><author><style face="normal" font="Arial"> Seyfizadeh,N.</style></author><author><style face="normal" font="Arial"> Borzoueisileh,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology Research Center, Faculty of medicine, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of allergen-specific IgE by immunoblotting method in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="219" start="213">213-219</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal allergen</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE serum level</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immune therapy</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Background and Objectives. Stimulating the immune system by exposure to various allergens to produce specific IgE has a significant role in the pathogenesis of atopic dermatitis. Identifying disease-causing allergens, prevention of exposure to those allergens, and immunotherapy will play an important role in the treatment of Atopic Disease. The purpose of this study was to determine the common allergens of northwest of Iran in patients with atopic dermatitis that are resistant to treatment. Materials and methods. In this descriptive-analytical study, serum levels of total IgE and frequency of specific IgE were measured by Immunoblotting against 20 common allergens in 150 cases of patients with atopic dermatitis, attending to dermatology and asthma and allergy clinics from 2010 to 2011. The control group consisted of individuals who had been clinically healthy. Results. In the 90% of patients that were included in this study, total IgE levels were higher than in healthy people with mean serum levels of total IgE 227.51 +/- 103 IU/ml. 136 patients (90.6%) had specific IgE for at least one allergen. The frequency of positive allergens among the patients who were included in this study were 53.34%, 26.8%, and 19.56% respectively in plants and fungus allergens group, animal allergens group and food allergens group. After avoiding of the allergens (which they had been sensitized to), 60% of patients were cured with immune therapy, and total IgE serum levels in the control group were not increased. Conclusion. Identifying the abundant allergens such as cultivated rye, Timothy grass, house dust mite, birch, cat, horse, potato, dog, egg white, cow milk, in order to advise patients to avoid them or to do immunotherapy and desensitization, is useful in this area</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.06</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28884988">PM:28884988</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-213-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-213-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Bonyadi MR</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.06</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Castilano,A.</style></author><author><style face="normal" font="Arial"> Watti,H.</style></author><author><style face="normal" font="Arial"> Abdulbaki,A.</style></author><author><style face="normal" font="Arial"> Modi,K.</style></author><author><style face="normal" font="Arial"> Bocchini,J.A.,Jr.</style></author><author><style face="normal" font="Arial"> Bahna,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy/Immunology Section, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA</style></auth-address><titles><title><style face="normal" font="Arial">Acute cardiac disease in a patient with hyper-IgE syndrome</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="234" start="231">231-234</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Catheterization</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> heart failure</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunologist</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressants</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Intravenous immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Louisiana</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Resuscitation</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> stem cell transplantation</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tachycardia</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Troponin</style></keyword><keyword><style face="normal" font="Arial"> Troponin I</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">We describe the case of a 24-year-old male with hyper-IgE syndrome (HIES) which was diagnosed at 4 years of age and died from a very rare cardiac complication. He had typical clinical and laboratory manifestations of HIES, including total serum IgE as high as > 100,000 IU/mL. Stem cell transplantation was not available. During the 20-year follow-up, he suffered numerous various infections of the skin and deep organs, partial lung resection, as well as multiple bone fractures. At age 24, he developed acute decompensated heart failure associated with elevated serum troponin I and brain natriuretic protein. Two-dimensional echocardiogram revealed global hypokinesis of the left ventricle with estimated ejection fraction 20-25%, and catheterization revealed ectasia of multiple coronary arteries. Endomyocardial biopsy showed lymphocytic myocarditis, focal necrosis, mild fibrosis, and myxoid degeneration, but cultures were negative. The patient improved on corticosteroid therapy and was discharged on heart failure therapy and external defibrillator. Six weeks later, he developed supraventricular tachycardia and persistent global hypokinesis and was treated with amiodarone. A trial of intravenous immunoglobulin was initiated and was repeated as outpatient every four weeks for four times. However, his cardiac function did not improve and he developed severe hypotension and pulseless electrical activity arrest. Resuscitation was unsuccessful. To the best of our knowledge, this is the first reported case of HIES complicated with lymphocytic myocarditis. Both immunologists and cardiologists need to be aware of such a complication and practice caution in using immunosuppressants when the patient's immune status is markedly compromised</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.13</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28884991">PM:28884991</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-231-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-231-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Castilano A</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.13</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liyanage,C.K.</style></author><author><style face="normal" font="Arial"> Galappatthy,P.</style></author><author><style face="normal" font="Arial"> Seneviratne,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Faculty of Medicine, University of Colombo, Sri Lanka</style></auth-address><titles><title><style face="normal" font="Arial">Corticosteroids in management of anaphylaxis; a systematic review of evidence</style></title><secondary-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="207" start="196">196-207</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> controlled clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Controlled Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled clinical trials</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sri Lanka</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">As anaphylaxis is a medical emergency, there are no randomized controlled clinical trials on its emergency management. Therefore, current guidelines are mostly based on data from observational studies, animal and laboratory studies. Although epinephrine is the mainstay of recommended treatment, corticosteroids are also frequently used. This review evaluates the evidence on the use of corticosteroids in emergency management of anaphylaxis from published human and animal or laboratories studies. Thirty original research papers were found with 22 human studies and eight animal or laboratory studies. The average rate of corticosteroid use in emergency treatment was 67.99% (range 48% to 100%). Corticosteroids appear to reduce the length of hospital stay, but did not reduce revisits to the emergency department. There was no consensus on whether corticosteroids reduce biphasic anaphylactic reactions. None of the human studies had sufficient data to compare the response to treatment in different treatment groups (i.e. corticosteroids, epinephrine, antihistamines). Animal studies demonstrated that corticosteroids act through multiple mechanisms. These modulate gene expression, with effects becoming evident 4 to 24 hours after administration. A much quicker response has been detected within 5 to 30 minutes, through blockade of signal activation of glucocorticoid receptors independent of their genomic effects. Therefore, we conclude that there is no compelling evidence to support or oppose the use of corticosteroid in emergency treatment of anaphylaxis. However, based on the available data, it appears to be beneficial and there was no evidence of adverse outcomes related to the use of corticosteroids in emergency treatment of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Sri Lanka -</style></notes><work-type><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.15</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28884986">PM:28884986</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-196-207.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Ann Allergy Clin Immunol\2017-49-196-207.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Liyanage CK</style></custom2><misc3><style face="normal" font="Arial">10.23822/EurAnnACI.1764-1489.15</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kounelli,M.L.</style></author><author><style face="normal" font="Arial"> Kalogianni,D.P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A sensitive DNA-based fluorometric method for milk authenticity of dairy products based on spectrally distinct microspheres</style></title><secondary-title><style face="normal" font="Arial">Eur Food Res Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Food Res Technol</style></full-title></periodical><pages end="1781" start="1773">1773-1781</pages><volume><style face="normal" font="Arial">243</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adulteration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> detectability</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA isolation</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Goat milk</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hybridization</style></keyword><keyword><style face="normal" font="Arial"> Hybrids</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microspheres</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Oligonucleotide Probes</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sheep</style></keyword><keyword><style face="normal" font="Arial"> Sheep milk</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1438-2385</style></isbn><abstract><style face="normal" font="Arial">Milk authenticity of dairy products is of great demand in order to protect consumers from fraudulent products and health risk. Milk-based products produced by goat and sheep milk are located at the top of the list of healthy dairy products, earning the increasing interest of consumers. As a result, these products are extremely vulnerable to adulteration with milk of lower added and nutritional value for profit. In addition, adulterant milks, such as bovine milk, have been accused to cause allergic reactions, especially to sensitive human groups. For these reasons, there is a great need for sensitive and robust analytical methods for milk adulteration detection. This work focused on the development of a DNA-based analytical method based on hybridization assay on spectrally distinct microspheres for adulteration detection of goat and sheep dairy products with bovine milk. The method includes (a) DNA isolation from dairy products, (b) amplification of DNA sequences specific to each animal species and (c) hybridization assay on the surface of distinct microspheres. The identification of the animal origin is accomplished by species-specific oligonucleotide probes coupled to the microspheres and the hybrids formed are detected by a streptavidin</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôphycoerythrin conjugate. The microspheres are finally analyzed by flow cytometry. The fluorescence emitted by the reporter molecule phycoerythrin is proportional to the concentration of the DNA content in the sample. As low as 0.01% bovine milk in goat milk and 0.05% in sheep milk was able to be detected by the proposed method. The method offers very good detectability, sensitivity and reproducibility</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Greece -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00217-017-2882-6</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s00217-017-2882-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Food Res Technol\2017-243-1773-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Food Res Technol\2017-243-1773-81.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Kounelli ML</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00217-017-2882-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Braun,C.</style></author><author><style face="normal" font="Arial"> Ewert,J.</style></author><author><style face="normal" font="Arial"> Stressler,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Characterization of cross-linked enzyme aggregates (CLEAs) of the fusion protein FUS-PepN_PepX and their application for milk protein hydrolysis</style></title><secondary-title><style face="normal" font="Arial">Eur Food Res Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Food Res Technol</style></full-title></periodical><pages end="1828" start="1815">1815-1828</pages><volume><style face="normal" font="Arial">243</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregates</style></keyword><keyword><style face="normal" font="Arial"> aminopeptidase</style></keyword><keyword><style face="normal" font="Arial"> Bitterness</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Casein hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Degree of hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Exopeptidases</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Peptidase</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Protein Hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Protein hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reactor</style></keyword><keyword><style face="normal" font="Arial"> Solubility</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1438-2385</style></isbn><abstract><style face="normal" font="Arial">The use of general and specific exopeptidases is of great interest for the hydrolysis of food proteins. Protein hydrolysates with a high degree of hydrolysis and, therefore, a reduced bitterness and improved antioxidative capacity can be produced due to the synergistic specificities of the general aminopeptidase PepN and the proline-specific peptidase PepX. These two activities were previously combined in a fusion protein and the latter showed both specific activities. However, due to its solubility an application of the fusion protein in continuous processes will be complicated in the future. Therefore, the aim of this study was the production, characterization and use of cross-linked enzyme aggregates (CLEAs) from the fusion protein (FUS-PepN_PepX CLEAs). The FUS-PepN_PepX CLEAs produced had activity for both specific enzymes. The biochemical characteristics determined (e.g., pH and temperature optima, environmental conditions) showed that the CLEAs are suitable for application in a complex matrix, such as food protein hydrolysates. The relative degree of hydrolysis of a prehydrolyzed casein solution was increased by 100% and the hydrolysate obtained showed a strong antioxidative capacity (ABTS-IC50 value: 7.85-á-Ág-ámL</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1). The stability against NaCl and the possibility of using ethanol as a microbial hurdle as well as the size of the FUS-PepN_PepX CLEAs seem promising for an application in an enzyme membrane reactor in the future. In summary, using these CLEAs, casein hydrolysates with a high degree of hydrolysis, a potentially reduced bitterness and high antioxidative capacity can be produced</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00217-017-2885-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s00217-017-2885-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Food Res Technol\2017-243-1815-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Food Res Technol\2017-243-1815-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Braun C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00217-017-2885-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Robinson,D.S.</style></author><author><style face="normal" font="Arial"> Kariyawasam,H.H.</style></author><author><style face="normal" font="Arial"> Heaney,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Severe Asthma Service, Respiratory Medicine, UCLH NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Phase three studies of biologics for severe asthma: could do better?</style></title><secondary-title><style face="normal" font="Arial">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">50</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1183/13993003.01108-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28899938">PM:28899938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Respir J\20170913-RobinsonDS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Respir J\20170913-RobinsonDS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Robinson DS</style></custom2><misc3><style face="normal" font="Arial">10.1183/13993003.01108-2017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Szegedi,K.</style></author><author><style face="normal" font="Arial"> van Lier,A.</style></author><author><style face="normal" font="Arial"> Res,P.C.</style></author><author><style face="normal" font="Arial"> Chielie,S.</style></author><author><style face="normal" font="Arial"> Bos,J.D.</style></author><author><style face="normal" font="Arial"> Kezic,S.</style></author><author><style face="normal" font="Arial"> Middelkamp-Hup,M.A.</style></author><author><style face="normal" font="Arial"> Luiten,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology Academic Medical Center, University of Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">House Dust Mite allergens Der f and Der p induce IL-31 production by blood derived T cells from Atopic Dermatitis patients</style></title><secondary-title><style face="normal" font="Arial">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170909IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/exd.13438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28887844">PM:28887844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Dermatol\20170909-SzegediK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Dermatol\20170909-SzegediK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170909, Szegedi K</style></custom2><misc3><style face="normal" font="Arial">10.1111/exd.13438</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tang,V.H.</style></author><author><style face="normal" font="Arial"> Stewart,G.A.</style></author><author><style face="normal" font="Arial"> Chang,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Marshall Centre for Infectious Diseases Research and TrainingSchool of Biomedical SciencesThe University of Western AustraliaCrawleyWAAustralia</style></auth-address><titles><title><style face="normal" font="Arial">Dermatophagoides pteronyssinus lytFM encoding an NlpC/P60 endopeptidase is also present in mite-associated bacteria that express LytFM variants</style></title><secondary-title><style face="normal" font="Arial">FEBS Open Bio</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">FEBS Open Bio</style></abbr-1></periodical><pages end="1280" start="1267">1267-1280</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Encoding</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Gram-Positive Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Peptidoglycan</style></keyword><keyword><style face="normal" font="Arial"> Phylogenetic analysis</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Homology</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">The bodies and faecal pellets of the house dust mite (HDM), Dermatophagoides pteronyssinus, are the source of many allergenic and nonallergenic proteins. One of these, the 14-kDa bacteriolytic enzyme LytFM, originally isolated from the spent HDM growth medium, may contribute to bacteriolytic activity previously detected by zymography at 14 kDa in the culture supernatants of some bacterial species isolated from surface-sterilised HDM. Based on previously reported findings of lateral gene transfer between microbes and their eukaryotic hosts, we investigated the presence of lytFM in the genomes of nine Gram-positive bacteria from surface-sterilised HDM, and the expression by these isolates of LytFM and its variants LytFM1/LytFM2. The lytFM gene was detected by PCR in the genomes of three of the isolates: Bacillus licheniformis strain 1, B. licheniformis strain 2 and Staphylococcus aureus. Expression of the variant LytFM1 was detected in culture supernatants of these bacteria by mass spectrometry (MS) and ELISA, and the bacterial LytFM proteins were shown by zymography to be able to hydrolyse peptidoglycan. Our previous reports of LytFM homologues in other mite species and their phylogenetic analysis had suggested that they originated from a common mite ancestor. The phylogenetic analysis reported herein and the detection of other D. pteronyssinus proteins by MS in the culture supernatants of the three isolates that secreted LytFM1 further support the hypothesis of lateral gene transfer to the bacterial endosymbionts from their HDM host. The complete sequence homology observed between the genes amplified from the microbes and those in their eukaryotic host indicated that the lateral gene transfer was an event that occurred recently</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 2211-5463 (Print)IS - 2211-5463 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1002/2211-5463.12263</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28904857">PM:28904857</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FEBS Open Bio\2017-7-1267-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FEBS Open Bio\2017-7-1267-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Tang VH</style></custom2><misc3><style face="normal" font="Arial">10.1002/2211-5463.12263</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tanaka,M.</style></author><author><style face="normal" font="Arial"> Korenori,Y.</style></author><author><style face="normal" font="Arial"> Washio,M.</style></author><author><style face="normal" font="Arial"> Kobayashi,T.</style></author><author><style face="normal" font="Arial"> Momoda,R.</style></author><author><style face="normal" font="Arial"> Kiyohara,C.</style></author><author><style face="normal" font="Arial"> Kuroda,A.</style></author><author><style face="normal" font="Arial"> Saito,Y.</style></author><author><style face="normal" font="Arial"> Sonomoto,K.</style></author><author><style face="normal" font="Arial"> Nakayama,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Microbial Technology, Division of Applied Molecular Microbiology and Biomass Chemistry, Faculty of Agriculture, Graduate school, Kyushu University, Fukuoka 812-8581, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood</style></title><secondary-title><style face="normal" font="Arial">FEMS Microbiol Ecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">FEMS Microbiol Ecol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Biomass</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood allergy</style></keyword><keyword><style face="normal" font="Arial"> Childhood food allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clostridia</style></keyword><keyword><style face="normal" font="Arial"> Clostridium</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterobacteriaceae</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Leuconostoc</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> molecular microbiology</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weaning</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">Bacterial colonization in infancy is considered crucial for the development of the immune system. Recently, there has been a drastic increase in childhood allergies in Japan. Therefore, we conducted a prospective study with 56 infants on the relationship between gut microbiota in the first year of life and the development of allergies during the first 3 years. In the lactation period, organic acid producers such as Leuconostoc, Weissella and Veillonella tended to be underrepresented in subjects who developed food allergies (FA, n = 14) within the first two years. In the weaning period, children in the FA group were highly colonized by unclassified Enterobacteriaceae and two Clostridium species closely related to Clostridium paraputrificum and C. tertium, and the whole tree phylogenetic diversity index was significantly lower in the FA group. All of these differences in the weaning period were statistically significant, even after adjusting for potential confounding factors. A higher abundance of unclassified Enterobacteriaceae was also found in the other allergic group (n = 15), whereas the two Clostridium species were highly specific to the FA group. The mode of action of these Clostridium species in childhood food allergies remains unknown, warranting further investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1574-6941 (Electronic)IS - 0168-6496 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1093/femsec/fix099</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28903469">PM:28903469</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FEMS Microbiol Ecol\20170914-TanakaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FEMS Microbiol Ecol\20170914-TanakaM.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\FEMS Microbiol Ecol\20170914-TanakaM.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\FEMS Microbiol Ecol\20170914-TanakaM.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170914, Tanaka M</style></custom2><misc3><style face="normal" font="Arial">10.1093/femsec/fix099</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Celakovska,J.</style></author><author><style face="normal" font="Arial"> Bukac,J.</style></author><author><style face="normal" font="Arial"> Ettler,K.</style></author><author><style face="normal" font="Arial"> Ettlerova,K.</style></author><author><style face="normal" font="Arial"> Krcmova,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Atopic dermatitis in adolescents and adults </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô the evaluation of association with other allergic diseases and parameters</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="948" start="933">933-948</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food intolerance</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergy</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> SCORAD</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword></keywords><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">There is a lack of reports focusing on the course of atopic dermatitis (AD) with respect to its evolution and association with other allergic diseases and parameters. This study gives the review of results concerning the evaluation of different parameters in patients suffering from AD older than 14 years of age. This study evaluates the occurrence of food allergy, food intolerance, inhalant allergy, occurrence of asthma bronchiale, allergic rhinitis, peripheral blood eosinophilia, family history of atopy, onset of AD and the severity of AD according to the SCORAD index</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1320358</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1320358</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-933-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-933-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Celakovska J</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1320358</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cheng,S.</style></author><author><style face="normal" font="Arial"> Yang,Y.</style></author><author><style face="normal" font="Arial"> Ni,X.</style></author><author><style face="normal" font="Arial"> Peng,J.</style></author><author><style face="normal" font="Arial"> Lai,W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Fluorescent microspheres lateral flow assay for sensitive detection of the milk allergen casein</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="1028" start="1017">1017-1028</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Lateral flow assay</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Microspheres</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">Casein is a type of allergen that may elicit an allergic response in some people. This study developed a competitive lateral flow assay by using fluorescent microspheres (FMs) as label to rapidly and quantitatively detect casein in milk. The limit of detection (LOD) of casein in defatted milk was 100?ng/mL with a good linear range from 100 to 10,000?ng/mL. The average recoveries for intra- and inter-assay ranged from 89.03% to 93.47% and 87.69% to 92.73%, respectively, with corresponding coefficient of variance (CV) of 5.2?7.8% and 6.2?8.5%. The LOD and the CV of FMs lateral flow assay (FMs-LFA) were lower than those of the colloidal gold lateral flow assay used to quantitatively detect casein. Based on the results of enzyme linked immunosorbent assay, our conclusion is that FMs-LFA can be potentially used in the food industry</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1325841</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1325841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1017-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1017-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Cheng S</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1325841</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mejrhit,N.</style></author><author><style face="normal" font="Arial"> Azdad,O.</style></author><author><style face="normal" font="Arial"> El Kabbaoui,M.</style></author><author><style face="normal" font="Arial"> Ouahidi,I.</style></author><author><style face="normal" font="Arial"> Tazi,A.</style></author><author><style face="normal" font="Arial"> Aarab,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sensitivity of Moroccans to sardine parvalbumin and effect of heating and enzymatic treatments</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="1373" start="1362">1362-1373</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic digestion</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic treatment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The aim of this study was to evaluate the IgE sensitivity to sardine parvalbumin (SP) in a Moroccan population from Fez region, and then to study the effect of temperature and enzymatic digestion on the allergenicity of SP. This work was conducted with a questionnaire completed by a sera-bank, obtained from 1008 patients recruited from Fez Hospitals. Their sera were analyzed for specific IgE against SP. From the questionnaire, 8.1% reported adverse reactions to fish and shellfish, where sardine was the most common species causing adverse reactions in patients. Evaluation of specific IgE showed that 7.8% of patients present higher values. Further indirect ELISA and dot-blot results indicated that SP, a major fish allergen, showed a reduction in the human IgE binding under heating and pepsin hydrolysis. These results demonstrate that this population was sensitive to SP and the sensitivity could be reduced by heating and more where it was digested by pepsin</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Morocco -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1343804</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1343804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1362-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1362-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Mejrhit N</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1343804</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Petrasova,M.</style></author><author><style face="normal" font="Arial"> Pospiech,M.</style></author><author><style face="normal" font="Arial"> Tremlova,B.</style></author><author><style face="normal" font="Arial"> Tauferova,A.</style></author><author><style face="normal" font="Arial"> Marcincak,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison of immunofluorescence method with histochemical and ELISA methods focusing on wheat protein detection in meat products</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="1104" start="1094">1094-1104</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gliadin</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Meat product</style></keyword><keyword><style face="normal" font="Arial"> Meat Products</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Screening test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">Gliadin is a major allergen causing allergies occurring also in meat products. Since wheat protein is used as a meat substitute to reduce cost of meat products. Sensitive consumers of these products are really threatened by food allergies in different allergic reaction. The objective of the study was to compare the histochemical, immunochemical (ALERT gliadin screening test) and immunofluorescence methods for the detection of wheat protein in model meat samples and meat products. The limit of detection for the ALERT gliadin screening test was 10???104?mg?kg?1 of addition, while the histochemical method demonstrated concentration of wheat protein already from 10???103?mg?kg?1, and the immunofluorescence method from the concentration of 20?mg?kg?1. Comparison of the methods using McNemar?s test shows a statistically highly significant difference (p?=?.01) between the immunofluorescence method and ELISA and a statistically highly significant difference (p?=?.01) between the immunofluorescence and histochemical methods</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1328661</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1328661</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1094-1104.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1094-1104.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Petrasova M</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1328661</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fang,J.</style></author><author><style face="normal" font="Arial"> Martinez,Y.</style></author><author><style face="normal" font="Arial"> Deng,C.</style></author><author><style face="normal" font="Arial"> Zhu,D.</style></author><author><style face="normal" font="Arial"> Peng,H.</style></author><author><style face="normal" font="Arial"> Jiang,H.</style></author><author><style face="normal" font="Arial"> Li,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effects of dietary enzymolysis products of wheat gluten on the growth performance, serum biochemical, immune, and antioxidant status of broilers</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="1167" start="1155">1155-1167</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Alkaline Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant capacity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Urea Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Chickens</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cuba</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urea</style></keyword><keyword><style face="normal" font="Arial"> Uric Acid</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat gluten</style></keyword></keywords><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">This study is aimed at determining the effects of dietary enzymolysis products of wheat gluten on the growth performance, organ weights, serum and intestinal antioxidant indices, serum biochemical indicators, and immunoglobulins of broiler chickens. The treatments consisted of a basal control diet, 2% of wheat gluten, and 1%, 2%, 3%, and 4% of enzymolysis products of wheat gluten. The inclusion of up to 4% of enzymolysis products of wheat gluten improved body weight and average daily gain. At 21 days, serum superoxide dismutase (T-SOD) had increased in the 2% of wheat gluten treatment (P?&lt;?.05). At 42 days, both serum T-SOD and blood urea nitrogen had increased while uric acid had decreased (P?&lt;?.05) in 2% enzymolysis products of wheat gluten treatment. These results showed that dietary inclusion of 2% enzymolysis products of wheat gluten can have beneficial effects on the growth performance and intestinal antioxidant activities of broiler chickens.Abbreviations: ADG: average daily gain; ADFI: average daily feed intake; AKP: alkaline phosphatase; BUN: blood urea nitrogen; BW: body weight; F/G: feed efficiency; GSH-Px: glutathione peroxidase; MDA: malondialdehyde; T-AOC: total antioxidant capacity; T-SOD: superoxide dismutase; CAT: catalase</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Cuba -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1332009</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1332009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1155-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1155-67.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Fang J</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1332009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,N.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Pan,L.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Dual-labelled immunoassay with goldmag nanoparticles and quantum dots for quantification of casein in milk</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="1115" start="1105">1105-1115</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> Milk allergens</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Quantum Dots</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">A dual-labelled immunoassay using goldmag nanoparticles (GMNPs) and CdTe quantum dots (QDs) was applied for the quantification of casein in milk. In this method, anti-casein monoclonal antibody bound to GMNPs was used as capture probe, and the anti-casein polyclonal antibody, labelled with CdTe QDs, was employed as detection probe. This dual-labelled immunoassay was optimized and applied in the testing of casein content of three brands of commercial milks. The results showed a good linear tendency between casein concentrations and fluorescent intensities in the range of 4.617?289.9?ng/mL, and the half inhibition concentration (IC50) was 36.59?ng/mL. Besides, the recovery rates of this developed immunoassay were in accordance with those in traditional enzyme-linked immunosorbent assay for rapid detection of casein content in commercial milks. It suggested that this dual-labelled immunoassay was reliable, and could provide important theoretical value and practical significance in the identification and quantification of milk allergens</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1328662</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1328662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1105-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1105-15.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Xu N</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1328662</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mejrhit,N.</style></author><author><style face="normal" font="Arial"> Azdad,O.</style></author><author><style face="normal" font="Arial"> Chda,A.</style></author><author><style face="normal" font="Arial"> El Kabbaoui,M.</style></author><author><style face="normal" font="Arial"> Bousfiha,A.</style></author><author><style face="normal" font="Arial"> Bencheikh,R.</style></author><author><style face="normal" font="Arial"> Tazi,A.</style></author><author><style face="normal" font="Arial"> Aarab,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of the sensitivity of Moroccans to shrimp tropomyosin and effect of heating and enzymatic treatments</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="980" start="969">969-980</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic digestion</style></keyword><keyword><style face="normal" font="Arial"> Enzymatic treatment</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Indirect Elisa</style></keyword><keyword><style face="normal" font="Arial"> indirect-ELISA</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimp tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">The aim of this work was to evaluate the IgE-sensitivity to shrimp tropomyosin (ST) in a Moroccan population from Fez region, and then to study the effect of temperature and enzymatic digestion on the allergenicity of ST. This work was conducted with a questionnaire completed by a sera-bank, obtained from 500 patients recruited from Fez Hospitals. Their sera were analyzed for specific IgE-sensitivity to ST. From questionnaire, 9.8% reported allergy to fish and shellfish where shrimp was one of the most common species causing allergy in patients. Evaluation of specific IgE showed that 10.2% of patients present higher values. Further indirect ELISA and Dot-blot results indicated that ST showed a decrease in the human IgE binding under heating or pepsin hydrolysis. These results demonstrate that this population was sensitive to ST and the sensitivity could be reduced by heating and more where it was digested by pepsin</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Morocco -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1323187</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1323187</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-969-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-969-80.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Mejrhit N</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1323187</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xu,N.</style></author><author><style face="normal" font="Arial"> Pan,L.</style></author><author><style face="normal" font="Arial"> Yu,C.</style></author><author><style face="normal" font="Arial"> Wei,X.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Goldmag-based enzyme-linked immunosorbent assay for determination of +¦-lactalbumin in milk</style></title><secondary-title><style face="normal" font="Arial">Food Agric Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Agric Immunol</style></full-title></periodical><pages end="1225" start="1211">1211-1225</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cell Fusion</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> hybridoma</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><publisher><style face="normal" font="Arial">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="Arial">0954-0105</style></isbn><abstract><style face="normal" font="Arial">In this work, a goldmag-based enzyme-linked immunosorbent assay was developed for determination of +¦-lactalbumin (+¦-LA) in milk. The magnetic nanoparticle functionalized with polyetherimide was synthesized by one-pot method and coated with two layers of gold nanoparticles on the surface to synthesize goldmag nanoparticles. Anti-+¦-LA monoclonal antibody, prepared by hybridoma cell lines via cell fusion, was then bound to this goldmag nanoparticle to develop a capture nanoprobe. The results showed that this developed immunoassay had a good linear range of 2.33?127.1?ng/mL with IC50 of 17.2?ng/mL. Besides, recovery rates for +¦-LA in four commercial milks were from 86.7% to 109.8%. The coefficients of variation in intra-assay and inter-assay were 3.9?6.8% and 5.5?9.8%, separately, which could meet the requirements to quantify +¦-LA content in milk. This goldmag-based immunoassay might have considerable potentials in the detection of food allergies</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/09540105.2017.1332013</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/09540105.2017.1332013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1211-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Agric Immunol\2017-28-1211-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Xu N</style></custom2><misc3><style face="normal" font="Arial">10.1080/09540105.2017.1332013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ortiz,J.C.</style></author><author><style face="normal" font="Arial"> Galan-Malo,P.</style></author><author><style face="normal" font="Arial"> Garcia-Galvez,M.</style></author><author><style face="normal" font="Arial"> Mateos,A.</style></author><author><style face="normal" font="Arial"> Ortiz-Ramos,M.</style></author><author><style face="normal" font="Arial"> Razquin,P.</style></author><author><style face="normal" font="Arial"> Mata,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Survey on the occurrence of allergens on food-contact surfaces from school canteen kitchens</style></title><secondary-title><style face="normal" font="Arial">Food Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Control</style></full-title></periodical><pages end="454" start="449">449-454</pages><volume><style face="normal" font="Arial">84</style></volume><number><style face="normal" font="Arial">Supplement C</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Catering</style></keyword><keyword><style face="normal" font="Arial"> Cleaning procedures</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross contact</style></keyword><keyword><style face="normal" font="Arial"> Cross-contact</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Hidden allergens</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Manipulation</style></keyword><keyword><style face="normal" font="Arial"> Meals</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> restaurant</style></keyword><keyword><style face="normal" font="Arial"> Restaurants</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> School canteen</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surfaces control</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="Arial">0956-7135</style></isbn><abstract><style face="normal" font="Arial">According to Regulation (EU) 1169/2011, restaurants and catering services have to manage the risk of food allergens in the products they offer. One of the sources of hidden allergens in food could come from the cross-contact with surfaces or utensils. In order to gain knowledge about the current situation in such kind of establishments, the occurrence of 3 main allergen residues (milk, egg and gluten) has been evaluated in food-contact surfaces from 50 school canteens during a period of two academic years (2014</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2016). The study included not only food-contact surfaces of general use but also surfaces for exclusive use in meals free of specific allergens. These food-contact surfaces were selected and analyzed in situ by using a rapid LFIA test during the visits to kitchens. Leftover sample was sent to a laboratory where an ELISA test was performed to confirm results. Out of 621 analyzed surfaces (213 samples for milk and egg and 195 samples for gluten) none of them were found to content milk with the rapid tests. However, the presence of egg and gluten was detected in 15 and 45% of the food-contact surfaces, respectively. The results obtained with ELISA showed also a low occurrence for milk (6%) but higher for egg (24%) and gluten (57%). It has to be highlighted that for some specific food-contact surfaces the occurrence reached up to 40%. These results indicate that the current cleaning procedures as well as the subsequent manipulation of surfaces are not enough suitable for the control of allergen residues in canteens. Besides, the presence of allergens in food-contact surfaces of exclusive-use to prepare allergen-free meals implies that cross-contaminations might happen, thus increasing the risk of hidden allergens in the final product</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodcont.2017.09.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodcont.2017.09.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Control\2018-84SC-449-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Control\2018-84SC-449-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Ortiz JC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodcont.2017.09.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Z.</style></author><author><style face="normal" font="Arial"> Zhang,R.</style></author><author><style face="normal" font="Arial"> McClements,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Food Science, University of Massachusetts Amherst, Amherst, MA 01003, USA</style></auth-address><titles><title><style face="normal" font="Arial">Control of protein digestion under simulated gastrointestinal conditions using biopolymer microgels</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="94" start="86">86-94</pages><volume><style face="normal" font="Arial">100</style></volume><number><style face="normal" font="Arial">Pt 2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregation</style></keyword><keyword><style face="normal" font="Arial"> alginate</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Denaturation</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> extrusion</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Heat denaturation</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hunger</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Ions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Denaturation</style></keyword><keyword><style face="normal" font="Arial"> protein digestion</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Satiation</style></keyword><keyword><style face="normal" font="Arial"> Satiety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Stomach</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword><keyword><style face="normal" font="Arial"> whey protein isolate</style></keyword><keyword><style face="normal" font="Arial"> WPI</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">Controlling the rate and extent of protein digestion within different regions of the human gastrointestinal tract (GIT) is important for regulating hormonal responses (such as hunger, satiety, and satiation) and immune responses (such as allergenicity). In this study, hydrogel beads (biopolymer microgels) were fabricated by injecting a solution of anionic alginate molecules into a solution of cationic calcium ions using a vibrating extrusion device. A model food protein (whey protein isolate, WPI) was mixed with the alginate solution prior to bead formation. The impact of thermal processing (80 degrees C, 15min) of the WPI before or after microgel formation was examined to determine the impact of protein denaturation and aggregation on encapsulation efficiency and retention. Heat-denaturation of the protein prior to microgel formation led to the highest encapsulation efficiency and retention, which was attributed to the formation of a cold-set protein gel inside the beads. Simulated GIT studies indicated that protein encapsulation in the microgels retarded its digestion in the stomach (around 3.7% digested), but not in the small intestine (around 19.6% digested). The denatured and native proteins were digested differently in different GIT regions: denatured protein digested faster in the stomach (around 11% digested), whereas native protein digested faster in the small intestine (around 41% digested). These results could provide valuable information for the design of microgel-based delivery systems to regulate protein digestion and peptide release in the GIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 1873-7145 (Electronic)IS - 0963-9969 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2017.08.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888462">PM:28888462</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\2017-100-86-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\2017-100-86-94.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Zhang Z</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2017.08.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abbring,S.</style></author><author><style face="normal" font="Arial"> Verheijden,K.A.T.</style></author><author><style face="normal" font="Arial"> Diks,M.A.P.</style></author><author><style face="normal" font="Arial"> Leusink-Muis,A.</style></author><author><style face="normal" font="Arial"> Hols,G.</style></author><author><style face="normal" font="Arial"> Baars,T.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> van Esch,B.C.A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Raw Cow's Milk Prevents the Development of Airway Inflammation in a Murine House Dust Mite-Induced Asthma Model</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="1045">1045-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Raw milk</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Epidemiological studies show an inverse relation between raw cow's milk consumption and the development of asthma. This protective effect seems to be abolished by milk processing. However, evidence for a causal relationship is lacking, and direct comparisons between raw and processed milk are hardly studied. Therefore, this study investigated the preventive capacity of raw and heated raw milk on the development of house dust mite (HDM)-induced allergic asthma in mice. Six- to seven-week-old male BALB/c mice were intranasally (i.n.) sensitized with 1 microg HDM or PBS on day 0, followed by an i.n. challenge with 10 microg HDM or PBS on days 7-11. In addition, mice were fed 0.5 mL raw cow's milk, heated raw cow's milk, or PBS three times a week throughout the study, starting 1 day before sensitization. On day 14, airway hyperresponsiveness (AHR) in response to increasing doses of methacholine was measured to assess lung function. Bronchoalveolar lavage fluid (BALF) and lungs were furthermore collected to study the extent of airway inflammation. Raw milk prevented both HDM-induced AHR and pulmonary eosinophilic inflammation, whereas heated raw milk did not. Both milk types suppressed the Th2-polarizing chemokine CCL17 in lung homogenates and reduced lung Th2 and Th17 cell frequency. IL-4 and IL-13 production after ex vivo restimulation of lung T cells with HDM was also reduced by both milk types. However, local IL-5 and IL-13 concentrations were only suppressed by raw milk. These findings support the asthma-protective capacity of raw cow's milk and show the importance of reduced local type 2 cytokine levels. Heated raw milk did not show an asthma-protective effect, which indicates the involvement of heat-sensitive components. Besides causal evidence, this study provides the basis for further mechanistic studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170912IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.01045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28894452">PM:28894452</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1045.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-1045.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170912, Abbring S</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.01045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Laffont,S.</style></author><author><style face="normal" font="Arial"> Blanquart,E.</style></author><author><style face="normal" font="Arial"> Guery,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre de Physiopathologie de Toulouse Purpan (CPTP), Universite de Toulouse, INSERM, CNRS, UPS, Toulouse, France</style></auth-address><titles><title><style face="normal" font="Arial">Sex Differences in Asthma: A Key Role of Androgen-Signaling in Group 2 Innate Lymphoid Cells</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="1069">1069-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> parasitic infections</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> puberty</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sex hormones</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Infectious diseases, autoimmune diseases, and also allergy differentially affect women and men. In general, women develop strongest immune responses and thus the proportion of infected individuals and the severity of many viral, bacterial, or parasitic infections are increased in men. However, heightened immunity in women makes them more susceptible than men to autoimmunity and allergy. While sex differences in immunity are well documented, little is known about the cellular and molecular mechanisms underlying these immunological differences, particularly in allergic asthma. Asthma is a chronic inflammation of the airways mediated by exacerbated type 2 immune responses. Sex differences have been reported in the incidence, prevalence, and severity of asthma. While during childhood, males are more susceptible to asthma than females, there is a switch at the onset of puberty as for many other allergic diseases. This decrease of asthma incidence around puberty in males suggests that hormonal mediators could play a protective role in the susceptibility to allergic responses in male. Group 2 innate lymphoid cells (ILC2s) have recently emerged as critical players in the initiation of allergic responses, but also in the resolution of parasitic infection, through their capacity to rapidly and potently produce type 2 cytokines. This review will cover the current understanding of the impact of sex-linked factors in allergic inflammation, with a particular focus on the role of sex hormones on the development and function of tissue-resident ILC2s</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.01069</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28912783">PM:28912783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1069.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-1069.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Laffont S</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.01069</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chua,H.H.</style></author><author><style face="normal" font="Arial"> Chou,H.C.</style></author><author><style face="normal" font="Arial"> Tung,Y.L.</style></author><author><style face="normal" font="Arial"> Chiang,B.L.</style></author><author><style face="normal" font="Arial"> Liao,C.C.</style></author><author><style face="normal" font="Arial"> Liu,H.H.</style></author><author><style face="normal" font="Arial"> Ni,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, Taipei 10041, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Intestinal Dysbiosis Featuring Abundance of Ruminococcus gnavus Associates With Allergic Diseases in Infants</style></title><secondary-title><style face="normal" font="Arial">Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Gastroenterology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> intestinal microbiota</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> twin</style></keyword><keyword><style face="normal" font="Arial"> Twins</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND &amp; AIMS: Dysbiosis of the intestinal microbiota has been associated with development of allergies in infants. However, it is not clear what microbes might contribute to this process. We investigated what microbe(s) might be involved in analyses of infant twins and mice. METHODS: We studied fecal specimens prospectively in a twin cohort (n=30) and age-matched singletons (n=14) born at National Taiwan University Children's Hospital, Taipei, Taiwan, from April 2011 to March 2013. Clinical parameters (gestational age, birth body weight, mode of delivery and feeding, immunizations and medical events) were recorded. Fecal samples were collected beginning immediately after birth and for 1 year; the children were followed until 3 years of age and allergic symptoms (repetitive and continuous for at least 6 months) were noted. A skin prick test was used to ascertain atopy. Bacterial communities in fecal samples were profiled by 16S rRNA-based PCR-temporal temperature gradient gel electrophoresis and next generation sequencing. BALB/c mice without and with ovalbumin sensitization/challenge were infected with candidate bacteria by oral gauge intra-gastric intubation. Fecal, serum, lung, and colon tissue samples were collected from mice and analyzed for mechanisms of allergy development. RESULTS: During the investigation period, 20 children (45.5%) developed allergic diseases, including respiratory (allergic rhinitis and asthma) and skin (atopic dermatitis and eczema) allergies. Lachnospiraceae were detected at significantly higher frequency in allergic infants than non-allergic infants (P&lt;.004); the high fecal count of Lachnospiraceae in allergic subjects appeared at 2 months of age and persisted until 12 months of age. The enrichment of Lachnospiraceae in allergic infants was attributed to the overgrowth of Ruminococcus gnavus, which tended to have a low frequency in non-allergic subjects (P=.0004). Increased R gnavus was observed before the onset of allergic manifestations, and associated with respiratory allergies (P&lt;.002) or respiratory allergies coexistent with atopic eczema (P&lt;.001). In mice, endogenous R gnavus grew rapidly following sensitization and challenge with ovalbumin. Mice gavaged with purified R gnavus developed airway hyper-responsiveness and had histologic evidence of airway inflammation (asthma). Expansion of R gnavus in mice stimulated secretion of cytokines (interleukin 25 (IL25), IL33, and thymic stromal lymphopoietin) by colon tissues, which activated type-2 innate lymphoid cells and dendritic cells to promote differentiation of T-helper (Th)2 cells and production of their cytokines (IL4, IL5, and IL13). This led to infiltration of the colon and lung parenchyma by eosinophils and mast cells. CONCLUSIONS: In a study of a twin cohort (some infants with, some without allergies), we associated development of allergies, particularly respiratory allergies, with increased fecal abundance of R gnavus. Mice fed R gnavus developed airway inflammation, characterized by expansion of Th2 cells in the colon and lung, and infiltration of colon and lung parenchyma by eosinophils and mast cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1528-0012 (Electronic)IS - 0016-5085 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1053/j.gastro.2017.09.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28912020">PM:28912020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Gastroenterology\20170915-ChuaHH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Gastroenterology\20170915-ChuaHH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Chua HH</style></custom2><misc3><style face="normal" font="Arial">10.1053/j.gastro.2017.09.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author><author><style face="normal" font="Arial"> Chaker,A.M.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zentrum fur Rhinologie und Allergologie, An den Quellen 10, 65183, Wiesbaden, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Costs of allergic diseases and saving potential by allergen-specific immunotherapy : A personal assessment]</style></title><secondary-title><style face="normal" font="Arial">HNO</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">HNO</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> rescue medication</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The burden of allergic diseases is of particular relevance for the economy and the social welfare and health insurance framework. Allergic rhinitis (AR) has a life-time prevalence of approximately 30% and is one of the most common chronic diseases with considerable socioeconomic impact thus leading to substantial direct, indirect and intangible costs. This article explores the common hypothesis that allergen-specific immunotherapy (ASIT) saves national economic expenses in the long term in comparison to other standard symptomatic treatment or no therapy. METHODS: We conducted a selective search and analysis of the literature in PubMed and Medline including otherwise listed publications in German. Using a predefined model and data extrapolation over 9 years for data from different sources and short-term clinical studies we further discuss the problems and difficulties in analyzing heterogeneous datasets. RESULTS: Using a health-economic model with currently available and accepted variables ASIT proves to be cost-effective in comparison to symptomatic treatment in allergic rhinitis; however, numerous parameters from other models have to be controlled, such as adherence to therapy and therapy discontinuation, heterogeneous costs for different treatment modalities, effect sizes with respect to symptoms including cross-influences with symptomatic rescue medication, duration of efficacy after treatment discontinuation and asthma protection. DISCUSSION: The personal appraisal of the authors demonstrates not only the current knowledge but also the problems in health economical evaluation of ASIT in allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1433-0458 (Electronic)IS - 0017-6192 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00106-017-0410-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28900663">PM:28900663</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\HNO\20170913-KlimekL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\HNO\20170913-KlimekL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00106-017-0410-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pacharn,P.</style></author><author><style face="normal" font="Arial"> Vichyanond,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Pediatrics , Division of Allergy and Immunology , Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok , Thailand b Samitivej Allergy Institute (SAI), Samitivej Thonburi Hospital , Bangkok , Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy for IgE-mediated wheat allergy</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">Among various routes of immunotherapy for food allergy, oral immunotherapy (OIT) appears to have a promising result due to its ability to modify abnormal immunologic mechanism of IgE-mediated food allergy. Other methods for immunomodulation such as sublingual (SLIT) or epicutaneous (EPIT) immunotherapy which carry lower rates of systemic reactions, may have less efficacy. Wheat has recently been recognized as a more common cause of food-induced anaphylaxis than previously recognized, especially among young children, around the world. In wheat allergic patients, avoidance recommended as standard recommendation is not easy to follow, because wheat has been used as a common constituents in various kinds of consumed foods in every day's life. Therefore, wheat OIT may be considered as an alternative treatments for those in which wheat avoidance is not sufficient to avert frequent events of anaphylaxis resulting from inadvertent exposure to small amount of wheat among this population. Currently, only few clinical trials about wheat OIT are available. In this review, we discuss available protocols of wheat OIT, initial starting dose, maintenance dose, and the strategies to minimize the side effects during the treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170912IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1356499</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895784">PM:28895784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170912-PacharnP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170912-PacharnP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170912, Pacharn P</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1356499</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doorley,L.A.</style></author><author><style face="normal" font="Arial"> LeMessurier,K.S.</style></author><author><style face="normal" font="Arial"> Iverson,A.R.</style></author><author><style face="normal" font="Arial"> Palipane,M.</style></author><author><style face="normal" font="Arial"> Samarasinghe,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN 38103, United States; Children's Foundation Research Institute, Memphis, TN 38103, United States</style></auth-address><titles><title><style face="normal" font="Arial">Humoral immune responses during asthma and influenza co-morbidity in mice</style></title><secondary-title><style face="normal" font="Arial">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunobiology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airways</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> humoral immunity</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza A Virus</style></keyword><keyword><style face="normal" font="Arial"> Influenza virus</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viral infection</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Tennessee</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral clearance</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">Humoral immunity serve dual functions of direct pathogen neutralization and enhancement of leukocyte function. Antibody classes are determined by antigen triggers, and the resulting antibodies can contribute to disease pathogenesis and host defense. Although asthma and influenza are immunologically distinct diseases, since we have found that allergic asthma exacerbation promotes antiviral host responses to influenza A virus, we hypothesized that humoral immunity may contribute to allergic host protection during influenza. C57BL/6J mice sensitized and challenged with Aspergillus fumigatus (or not) were infected with pandemic influenza A/CA/04/2009 virus. Negative control groups included naive mice, and mice with only 'asthma' or influenza. Concentrations of antibodies were quantified by ELISA, and in situ localization of IgA- and IgE-positive cells in the lungs was determined by immunohistochemistry. The number and phenotype of B cells in spleens and mediastinal lymph nodes were determined by flow cytometry at predetermined timepoints after virus infection until viral clearance. Mucosal and systemic antibodies remained elevated in mice with asthma and influenza with prominent production of IgE and IgA compared to influenza-only controls. B cell expansion was prominent in the mediastinal lymph nodes of allergic mice during influenza where most cells produced IgG1 and IgA. Although allergy-skewed B cell responses dominated in mice with allergic airways inflammation during influenza virus infection, virus-specific antibodies were also induced. Future studies are required to identify the mechanisms involved with B cell activation and function in allergic hosts facing respiratory viral infections</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1878-3279 (Electronic)IS - 0171-2985 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imbio.2017.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889999">PM:28889999</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunobiology\20170911-DoorleyLA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunobiology\20170911-DoorleyLA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Doorley LA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imbio.2017.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Reshma,A.</style></author><author><style face="normal" font="Arial"> Baranwal,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Advanced Pediatric Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India</style></auth-address><titles><title><style face="normal" font="Arial">Child with Allergies or Allergic Reactions</style></title><secondary-title><style face="normal" font="Arial">Indian J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Chromones</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Life Style</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">Incidence of allergic disorders in children has increased significantly over time due to environmental and life-style changes. These include allergic rhinitis, atopic dermatitis, allergic conjunctivitis, food allergies, bronchial asthma, drug allergies, insect bites and anaphylaxis; most being IgE-mediated type 1 hypersensitivity reactions to common environmental and food antigens. Although most of them are self-limiting, they may adversely affect the quality of life and sometimes become life-threatening as well. These conditions are more likely to get underestimated, or over-diagnosed as recurrent infections. Hence a careful history and physical examination by attending pediatrician are necessary to differentiate it from infections. Diagnostic tests have limited value in identifying the inciting allergen. Management includes avoidance of the inciting allergens (if known), combined with symptomatic relief provided by a combination of pharmacological agents, e.g., antihistamines, anticholinergics, chromones, leukotriene-modifying agents, topical and systemic steroids. Further, specialist consultation needs to be sought, for children with recurrent or persistent symptoms. The scope of this manuscript does not include bronchial asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 0973-7693 (Electronic)IS - 0019-5456 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12098-017-2436-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890990">PM:28890990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Pediatr\20170911-ReshmaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Pediatr\20170911-ReshmaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Reshma A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12098-017-2436-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galvao,J.G.F.M.</style></author><author><style face="normal" font="Arial"> Cavalcante-Silva,L.H.A.</style></author><author><style face="normal" font="Arial"> Carvalho,D.C.M.</style></author><author><style face="normal" font="Arial"> Ferreira,L.K.D.P.</style></author><author><style face="normal" font="Arial"> Monteiro,T.M.</style></author><author><style face="normal" font="Arial"> Alves,A.F.</style></author><author><style face="normal" font="Arial"> Ferreira,L.A.M.P.</style></author><author><style face="normal" font="Arial"> Gadelha,F.A.A.F.</style></author><author><style face="normal" font="Arial"> Piuvezam,M.R.</style></author><author><style face="normal" font="Arial"> Rodrigues-Mascarenhas,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraiba (UFPB), Joao Pessoa, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Ouabain attenuates ovalbumin-induced airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Inflamm Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inflamm Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> cell migration</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> granulocyte</style></keyword><keyword><style face="normal" font="Arial"> Granulocytes</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">PURPOSE: Ouabain, an Na+/K+-ATPase inhibitor hormone, presents immunomodulatory actions, including anti-inflammatory effect on acute inflammation models. METHODS: In the present study, the effect of ouabain in a model of allergic airway inflammation induced by ovalbumin (OVA) was assessed. RESULTS: Initially, it was observed that ouabain treatment inhibited cellular migration induced by OVA on bronchoalveolar lavage fluid (BALF), mostly granulocytes, without modulating macrophage migration. In addition, it was observed, by flow cytometry, that ouabain reduces CD3high lymphocytes cells on BALF. Furthermore, treatment with ouabain decreased IL-4 and IL-13 levels on BALF. Ouabain also promoted pulmonary histological alterations, including decreased cell migration into peribronchiolar and perivascular areas, and reduced mucus production in bronchioles regions observed through hematoxylin-eosin (HE) and by periodic acid-Schiff stain, respectively. Allergic airway inflammation is characterized by high OVA-specific IgE serum titer. This parameter was also reduced by the treatment with ouabain. CONCLUSIONS: Therefore, our data demonstrate that ouabain negatively modulates allergic airway inflammation induced by OVA</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1420-908X (Electronic)IS - 1023-3830 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00011-017-1092-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28905075">PM:28905075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflamm Res\20170914-GalvaoJG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflamm Res\20170914-GalvaoJG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Galvao JG</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00011-017-1092-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bui,T.T.</style></author><author><style face="normal" font="Arial"> Piao,C.H.</style></author><author><style face="normal" font="Arial"> Song,C.H.</style></author><author><style face="normal" font="Arial"> Chai,O.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy, Chonbuk National University Medical School, Jeonju 54907, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Skullcapflavone II attenuates ovalbumin-induced allergic rhinitis through the blocking of Th2 cytokine production and mast cell histamine release</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="84" start="77">77-84</pages><volume><style face="normal" font="Arial">52</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Drainage</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Cavity</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis is a common heterogeneous chronic upper airway disorder and is an IgE-mediated inflammation characterized by one or more nasal symptoms such as sneezing, itching, nasal discharge, rhinorrhea, post nasal drainage and nasal blockage. In the present study, the effects of skullcapflavone II (SCFII) on upper airway inflammation, Th2 cytokines, and NF-kappaB signaling in an ovalbumin (OVA)-induced allergic rhinitis (AR) murine model in vivo were investigated. OVA-induced AR mice increased nasal symptoms, eosinophils and mast cells infiltration into nasal cavity, OVA-specific IgE/IgG1 and histamine in serum, Th2 cytokines including IL-13 and GATA3, and NF-kappaB signaling in NALF and lung homogenate. Interestingly, treatment of SCFII reduced the levels of OVA-specific IgE/IgG1 and histamine in serum, of Th2 cytokines and of NF-kappaB signaling in the NALF and the lung homogenate, and histopathological changes in the nasal tissue and the lung. Also, dexamethasone suppressed such increases. The results of this study suggested that SCFII may ameliorate allergic inflammation of upper airway in AR mice model by blocking the Th2 cytokine production, the NF-kappaB signal pathway and the mast cell histamine release. Taken together, we suggest that SCFII may be used as a therapeutic agent for patients with Th2-mediated or mast cell-mediated allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.08.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886581">PM:28886581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-52-77-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-52-77-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Bui TT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.08.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Flonard,M.</style></author><author><style face="normal" font="Arial"> Lo,E.</style></author><author><style face="normal" font="Arial"> Levetin,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biological Science, The University of Tulsa, Tulsa, OK, 74104, USA</style></auth-address><titles><title><style face="normal" font="Arial">Increasing Juniperus virginiana L. pollen in the Tulsa atmosphere: long-term trends, variability, and influence of meteorological conditions</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cupressaceae</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grassland</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Juniperus</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Meteorological conditions</style></keyword><keyword><style face="normal" font="Arial"> Meteorological variables</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Oklahoma</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="Arial">In the Tulsa area, the Cupressaceae is largely represented by eastern red cedar (Juniperus virginiana L.). The encroachment of this species into the grasslands of Oklahoma has been well documented, and it is believed this trend will continue. The pollen is known to be allergenic and is a major component of the Tulsa atmosphere in February and March. This study examined airborne Cupressaceae pollen data from 1987 to 2016 to determine long-term trends, pollen seasonal variability, and influence of meteorological variables on airborne pollen concentrations. Pollen was collected through means of a Burkard sampler and analyzed with microscopy. Daily pollen concentrations and yearly pollen metrics showed a high degree of variability. In addition, there were significant increases over time in the seasonal pollen index and in peak concentrations. These increases parallel the increasing population of J. virginiana in the region. Pollen data were split into pre- and post-peak categories for statistical analyses, which revealed significant differences in correlations of the two datasets when analyzed with meteorological conditions. While temperature and dew point, among others were significant in both datasets, other factors, like relative humidity, were significant only in one dataset. Analyses using wind direction showed that southerly and southwestern winds contributed to increased pollen concentrations. This study confirms that J. virginiana pollen has become an increasing risk for individuals sensitive to this pollen and emphasizes the need for long-term aerobiological monitoring in other areas</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-017-1444-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28917013">PM:28917013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\20170916-FlonardM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biometeorol\20170916-FlonardM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Flonard M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-017-1444-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Talaei,Z.</style></author><author><style face="normal" font="Arial"> Sheikhbahaei,S.</style></author><author><style face="normal" font="Arial"> Ostadi,V.</style></author><author><style face="normal" font="Arial"> Ganjalikhani,H.M.</style></author><author><style face="normal" font="Arial"> Meidani,M.</style></author><author><style face="normal" font="Arial"> Naghshineh,E.</style></author><author><style face="normal" font="Arial"> Yaran,M.</style></author><author><style face="normal" font="Arial"> Emami,N.A.</style></author><author><style face="normal" font="Arial"> Sherkat,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?</style></title><secondary-title><style face="normal" font="Arial">Int J Fertil Steril</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Fertil Steril</style></abbr-1></periodical><pages end="141" start="134">134-141</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Candida</style></keyword><keyword><style face="normal" font="Arial"> Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic mucocutaneous candidiasis</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> fungal infections</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> lymphocyte proliferation</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Membranes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> PID</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Primary immunodeficiency diseases</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vagina</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">Background: Recurrent vulvovaginal candidiasis (RVVC) is a common cause of morbidity affecting millions of women worldwide. Patients with RVVC are thought to have an underlying immunologic defect. This study has been established to evaluate cell-mediated immunity defect in response to candida antigen in RVVC cases. MATERIALS AND METHODS: Our cross-sectional study was performed in 3 groups of RVVC patients (cases), healthy individuals (control I) and known cases of chronic mucocutaneous candidiasis (CMC) (control II). Patients who met the inclusion criteria of RVVC were selected consecutively and were allocated in the case group. Peripheral blood mononuclear cells were isolated and labeled with CFSE and proliferation rate was measured in exposure to candida antigen via flow cytometry. RESULTS: T lymphocyte proliferation in response to candida was significantly lower in RVVC cases (n=24) and CMC patients (n=7) compared to healthy individuals (n=20, &lt;0.001), but no statistically significant difference was seen between cases and control II group (P>0.05). Family history of primary immunodeficiency diseases (PID) differed significantly among groups (P=0.01), RVVC patients has family history of PID more than control I (29.2 vs. 0%, P=0.008) but not statistically different from CMC patients (29.2 vs. 42.9%, P>0.05). Prevalence of atopy was greater in RVVC cases compared to healthy individuals (41.3 vs. 15%, P=0.054). Lymphoproliferative activity and vaginal symptoms were significantly different among RVVC cases with and without allergy (P=0.01, P=0.02). CONCLUSION: Our findings revealed that T cells do not actively proliferate in response to Candida antigen in some RVVC cases. So it is concluded that patients with cell-mediated immunity defect are more susceptible to recurrent fungal infections of vulva and vagina. Nonetheless, some other cases of RVVC showed normal function of T cells. Further evaluations showed that these patients suffer from atopy. It is hypothesized that higher frequency of VVC in patients with history of atopy might be due to allergic response in mucocutaneous membranes rather than a functional impairment in immune system components</style></abstract><notes><style face="normal" font="Arial">DA - 20170904IS - 2008-076X (Print)IS - 2008-0778 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.22074/ijfs.2017.4883</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28868834">PM:28868834</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Fertil Steril\2017-11-134-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Fertil Steril\2017-11-134-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170904, Talaei Z</style></custom2><misc3><style face="normal" font="Arial">10.22074/ijfs.2017.4883</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weber,A.</style></author><author><style face="normal" font="Arial"> Fuchs,N.</style></author><author><style face="normal" font="Arial"> Kutzora,S.</style></author><author><style face="normal" font="Arial"> Hendrowarsito,L.</style></author><author><style face="normal" font="Arial"> Nennstiel-Ratzel,U.</style></author><author><style face="normal" font="Arial"> von Mutius,E.</style></author><author><style face="normal" font="Arial"> Herr,C.</style></author><author><style face="normal" font="Arial"> Kolb,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Exploring the associations between parent-reported biological indoor environment and airway-related symptoms and allergic diseases in children</style></title><secondary-title><style face="normal" font="Arial">Int J Hyg Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Hyg Environ Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Biological indoor factor</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Crowding</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor environment</style></keyword><keyword><style face="normal" font="Arial"> indoor exposure</style></keyword><keyword><style face="normal" font="Arial"> indoor exposures</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1438-4639</style></isbn><abstract><style face="normal" font="Arial">Objectives Asthma and allergic rhinitis are diseases which require special attention in childhood. Risk factors for these diseases are manifold and include environmental factors. Previous studies have shown associations between indoor mould and respiratory diseases in children. Besides indoor mould, organic waste storage, potted plants, pets and crowding could influence the microbial indoor environment at home and influence the respiratory health of children. Our aim was therefore to explore the associations of these factors with airway-related symptoms and respiratory diseases in pre-schoolers. Methods In this cross-sectional study we evaluated data based on parent-questionnaires regarding the health of their children from the 2014/2015 Health Monitoring Units (GME) in Bavaria. Bivariate and multivariate odds ratios (OR) with 95% confidence intervals (95%-CI) were calculated with logistic regression to explore associations between exposures (visible mould, organic waste storage, potted plants, pets and crowding) and outcome variables (docto+òs diagnosed allergic rhinitis with symptoms in the last 12 months, docto+òs diagnosed asthma with symptoms in the last 12 months, 12 month prevalence of symptoms such as dry cough at night without a cold, wheeze, wheeze attacks and allergic rhinitis symptoms). Results We analysed data from 4732 children (response rate 56.7%) with a mean age of 5.3 years. Visible mould was present in 4.7% of all households and associated with docto+òs diagnosed asthma with symptoms in the last 12 months [aOR2 2.16 (95%-CI 1.01</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô4.63)], wheeze in the last 12 months [aOR2 1.60 (95%-CI 1.0</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2.50)] and allergic rhinitis symptoms in the last 12 months [aOR2 1.75 (95%-CI 1.07</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2.87)]. Crowding was associated with dry cough at night without a cold in the last 12 months [aOR2 1.71 (95%-CI 1.42</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2.05). The other indoor factors showed no association with respiratory health of the children. Conclusion Our results, in line with previous studies, showed positive associations between visible mould at home and airway-related symptoms and allergic diseases in children irrespective of the effect of the other considered indoor exposures. Despite the low prevalence of mould exposure in our study population, our results suggest intervention should be taken for those who do have visible mould exposure at home</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijheh.2017.09.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941773">PM:28941773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Hyg Environ Health\20170920-WeberA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Hyg Environ Health\20170920-WeberA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Weber A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijheh.2017.09.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Castellanos,J.A.</style></author><author><style face="normal" font="Arial"> Tangua,A.R.</style></author><author><style face="normal" font="Arial"> Salazar,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Morfologia, Facultad de Salud, Universidad del Valle, Cali, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Anisakidae nematodes isolated from the flathead grey mullet fish (Mugil cephalus) of Buenaventura, Colombia</style></title><secondary-title><style face="normal" font="Arial">Int J Parasitol Parasites Wildl</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Int J Parasitol Parasites Wildl</style></abbr-1></periodical><pages end="270" start="265">265-270</pages><volume><style face="normal" font="Arial">6</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anisakiasis</style></keyword><keyword><style face="normal" font="Arial"> Anisakid</style></keyword><keyword><style face="normal" font="Arial"> Anisakidae</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> parasitic infection</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Pseudoterranova</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taxonomy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">Anisakiasis is a parasitic infection caused by larval stages of nematodes of the genus Anisakis, Pseudoterranova and Contracaecum, of the Anisakidae family. The lifecycle of these nematodes develops in aquatic organisms and their final hosts are marine mammals. However, humans can act as accidental hosts and become infected with infective stage larvae (L3) by consuming raw or undercooked fish or shellfish carrying the parasite. Of this group of parasites, the genus Anisakis is the most studied: its presence in humans is associated with non-specific gastrointestinal symptoms or allergic responses that can trigger anaphylactic shock. The lack of studies in anisakiasis and Anisakis in Colombia has resulted in this infection being little-known by medical practitioners and therefore potentially underreported. The objective of this study was to identify anisakid nematodes in the flathead grey mullet fish (Mugil cephalus), caught by artisanal fishing methods and commercialized in Buenaventura. Morphological identification was carried out by classical taxonomy complemented by microscopy study using the histochemical technique Hematoxylin-Eosin. Nematodes of the genus Anisakis were found in the host M. cephalus. The Prevalence of Anisakis larvae in flathead grey mullet fish was 33%. The findings confirm the presence of Anisakis sp. in fish for human consumption in the Colombian Pacific region, a justification for further investigation into a possible emerging disease in this country</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 2213-2244 (Print)IS - 2213-2244 (Linking)LA - engPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijppaw.2017.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913166">PM:28913166</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Parasitol Parasites Wildl\2017-6-265-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Parasitol Parasites Wildl\2017-6-265-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Castellanos JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijppaw.2017.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Merdji,H.</style></author><author><style face="normal" font="Arial"> Clere-Jehl,R.</style></author><author><style face="normal" font="Arial"> Monnier,A.</style></author><author><style face="normal" font="Arial"> Meziani,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hopitaux Universitaires de Strasbourg, Strasbourg, France.</style></auth-address><titles><title><style face="normal" font="Arial">Yellow urticaria following plasma transfusion</style></title><secondary-title><style face="normal" font="Arial">Intensive Care Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Intensive Care Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170912IS - 1432-1238 (Electronic)IS - 0342-4642 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00134-017-4931-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28894877">PM:28894877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intensive Care Med\20170912-MerdjiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intensive Care Med\20170912-MerdjiH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170912, Merdji H</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00134-017-4931-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,Y.S.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Ahn,H.S.</style></author><author><style face="normal" font="Arial"> Sohn,T.S.</style></author><author><style face="normal" font="Arial"> Song,J.Y.</style></author><author><style face="normal" font="Arial"> Lee,Y.B.</style></author><author><style face="normal" font="Arial"> Lee,D.H.</style></author><author><style face="normal" font="Arial"> Lee,J.I.</style></author><author><style face="normal" font="Arial"> Jeong,S.C.</style></author><author><style face="normal" font="Arial"> Chae,H.S.</style></author><author><style face="normal" font="Arial"> Han,K.</style></author><author><style face="normal" font="Arial"> Yeo,C.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Epidemiology Study Cluster of Uijeongbu St. Mary's Hospital, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea</style></auth-address><titles><title><style face="normal" font="Arial">The Association between Tobacco Smoke and Serum Immunoglobulin E Levels in Korean Adults</style></title><secondary-title><style face="normal" font="Arial">Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Intern Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> cockroach allergen</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> tobacco smoke</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">Objective Smoking is common in patients with allergic diseases. The aim of this study was to evaluate the cross-sectional association between the current smoking status and total and specific Immunoglobulin E (IgE) levels in Korean adults. Methods Data were obtained from the 2010 Korean National Health and Nutrition Examination Survey, a national cross-sectional study. We analyzed the data of subjects whose smoking status and serum IgE levels were of acceptable quality. Results A total of 1,963 subjects (1,118 never smokers, 340 ex-smokers, and 505 current smokers) were included. The total IgE levels and specific IgE levels to house dust mite Dermatophagoides farinae (Df), cockroach, and dog allergens in never smokers were significantly (p&lt;0.0001) lower than in ex-smokers or current smokers. After adjusting for other variables, current smokers independently had significantly higher levels of total IgE and cockroach-specific IgE than ex-smokers or never smokers. The proportions of subjects with total IgE >/=150 kU/L and specific IgE >/=0.35 kU/L to Df-specific IgE were significantly (p value for trend &lt;0.05) increased in ex-smokers and current smokers. The total IgE levels and IgE levels specific to Df, cockroaches, and dogs significantly (p value for trend &lt;0.05) and proportionally increased with increasing numbers of cigarettes smoked daily. Conclusion Smoking was associated with elevated total IgE levels and IgE levels specific to Df, cockroach, and dog allergens in a cumulative, dose-dependent manner. Furthermore, current smoking status was an independent risk factor for elevated total IgE levels and IgE levels specific to cockroach allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1349-7235 (Electronic)IS - 0918-2918 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.2169/internalmedicine.8737-16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28883244">PM:28883244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med\20170908-KimYS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med\20170908-KimYS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Kim YS</style></custom2><misc3><style face="normal" font="Arial">10.2169/internalmedicine.8737-16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jiang,J.Z.</style></author><author><style face="normal" font="Arial"> Ye,J.</style></author><author><style face="normal" font="Arial"> Jin,G.Y.</style></author><author><style face="normal" font="Arial"> Piao,H.M.</style></author><author><style face="normal" font="Arial"> Cui,H.</style></author><author><style face="normal" font="Arial"> Zheng,M.Y.</style></author><author><style face="normal" font="Arial"> Yang,J.S.</style></author><author><style face="normal" font="Arial"> Che,N.</style></author><author><style face="normal" font="Arial"> Choi,Y.H.</style></author><author><style face="normal" font="Arial"> Li,L.C.</style></author><author><style face="normal" font="Arial"> Yan,G.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy, Histology and Embryology, Medical College of Yanbian University , Yanji 133002, Jilin, China</style></auth-address><titles><title><style face="normal" font="Arial">Asiaticoside Mitigates the Allergic Inflammation by Abrogating the Degranulation of Mast Cells</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> embryology</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lyn</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nrf2</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat peritoneal mast cells</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">The effects of asiaticoside (AS) on allergic responses mediated by mast cells were investigated. AS showed no obvious cytotoxicity on RPMCs (rat peritoneal mast cells). AS reduced the intracellular calcium in RPMCs and deprived the histamine release and degranulation. AS also decreased the generation of antigen-induced tumor necrosis factor alpha, interleukin (IL)-4, IL-8, and IL-1beta in RBL-2H3 cells sensitized by IgE. The suppression of AS on pro-inflammatory cytokines was related with the activation of the intracellular FcepsilonRI and the inhibition of the nuclear factor-kappaB signaling pathway. In addition, AS disabled the phosphorylation of antigen-induced Syk, Lyn, Gab2, and PLCgamma1, thus suppressing the downstream Akt phosphorylation and MAPKs pathways. It also increased HO-1 and Nrf2 expression time dependently. In summary, we demonstrate that AS suppresses the allergic inflammation mediated by mast cells and this effect might be mediated by FcepsilonRI-dependent signaling pathways</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - China -CO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b01590</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28891650">PM:28891650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20170911-JiangJZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20170911-JiangJZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Jiang JZ</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b01590</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carroll,D.J.</style></author><author><style face="normal" font="Arial"> O'Sullivan,J.A.</style></author><author><style face="normal" font="Arial"> Nix,D.B.</style></author><author><style face="normal" font="Arial"> Cao,Y.</style></author><author><style face="normal" font="Arial"> Tiemeyer,M.</style></author><author><style face="normal" font="Arial"> Bochner,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Allergy-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL</style></auth-address><titles><title><style face="normal" font="Arial">Siglec-8 is an activating receptor mediating beta2 integrin-dependent function in human eosinophils</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> glycan</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> inhibitory receptors</style></keyword><keyword><style face="normal" font="Arial"> integrin</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nadph Oxidase</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Kinases</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Siglec</style></keyword><keyword><style face="normal" font="Arial"> Siglec-8</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Subfamily</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> Western blot analysis</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Siglec-8 is a CD33 subfamily cell surface receptor that is selectively expressed on human eosinophils. Following cytokine-priming, Siglec-8 mAb or glycan ligand binding causes eosinophil apoptosis associated with reactive oxygen species (ROS) production. Most CD33-related Siglecs function as inhibitory receptors, but the ability of Siglec-8 to stimulate eosinophil ROS production and apoptosis suggests that Siglec-8 may instead function as an activating receptor. OBJECTIVE: To determine the role of IL-5 priming and to identify the signaling molecules involved in Siglec-8 function for human eosinophils. METHODS: We used a mAb and/or a multimeric synthetic sulfated sialoglycan ligand recognizing Siglec-8, in combination with integrin blocking antibodies, pharmacological inhibitors, phosphoproteomics and western blot analysis, to define the necessity of various proteins involved in Siglec-8 function for human eosinophils. RESULTS: Cytokine priming was required to elicit the unanticipated finding that Siglec-8 engagement promotes rapid beta2-integrin dependent eosinophil adhesion. Also novel was the finding that this adhesion was necessary for subsequent ROS production and apoptosis. Siglec-8-mediated ROS was generated via NADPH oxidase activation, because pretreatment of eosinophils with catalase (an extracellular superoxide scavenger) or NSC23766 (a Rac GTPase inhibitor) completely inhibited Siglec-8 mediated eosinophil apoptosis. Finally, engagement of Siglec-8 on IL-5 primed eosinophils resulted in increased phosphorylation of Akt, p38 and JNK1 that was also beta2-integrin dependent; pharmacologic inhibition of these kinases completely prevented Siglec-8-mediated eosinophil apoptosis. CONCLUSIONS: These data demonstrate that Siglec-8 uniquely functions as an activating receptor on IL-5 primed eosinophils via a novel pathway involving regulation of beta2-integrin-dependent adhesion, NADPH oxidase and a subset of protein kinases</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888781">PM:28888781</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170910-CarrollDJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170910-CarrollDJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Carroll DJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vroman,H.</style></author><author><style face="normal" font="Arial"> Bergen,I.M.</style></author><author><style face="normal" font="Arial"> van Hulst,J.A.C.</style></author><author><style face="normal" font="Arial"> van Nimwegen,M.</style></author><author><style face="normal" font="Arial"> van Uden,D.</style></author><author><style face="normal" font="Arial"> Schuijs,M.J.</style></author><author><style face="normal" font="Arial"> Pillai,S.Y.</style></author><author><style face="normal" font="Arial"> van Loo,G.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Hendriks,R.W.</style></author><author><style face="normal" font="Arial"> Kool,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">TNFAIP3 levels in lung dendritic cells instruct Th2 or Th17 cell differentiation in eosinophilic or neutrophilic asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental triggers</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It is currently unknown, why allergen exposure or environmental triggers in mild to moderate asthma patients results in Th2-mediated eosinophilic inflammation, whereas severe asthma patients often present with Th17-mediated neutrophilic inflammation. The activation state of dendritic cells (DCs) is crucial for both Th2 and Th17-cell differentiation, and is mediated through NF-kappaB activation. Ablation of TNFAIP3, one of the crucial negative regulators of NF-kappaB activation in myeloid cells and DCs was shown to control DC activation. OBJECTIVE: In this study we investigated the precise role of TNFAIP3 in myeloid cells for the development of Th2 and Th17-cell mediated asthma. METHODS: We exposed mice with conditional deletion of the Tnfaip3 gene in either myeloid cells (using the LysM promotor) or specifically in DCs (using the Cd11c promotor) to acute and chronic house dust mite (HDM)-driven asthma models. RESULTS: We demonstrated that reduced Tnfaip3 gene expression in DCs in either Tnfaip3CD11c or Tnfaip3LysM mice dose-dependently controlled development of Th17-mediated neutrophilic severe asthma in both acute and chronic HDM-driven models, whereas wildtype mice developed a purely Th2-mediated eosinophilic inflammation. TNFAIP3-deficient DCs induced HDM-specific Th17-cell differentiation, through increased expression of Th17-instructing cytokines, IL-1ss, IL-6 and IL-23, whereas HDM-specific Th2-cell differentiation was hampered by the increased IL-12 and IL-6 production. CONCLUSIONS: These data show that the extent of TNFAIP3 expression in DCs controls Th2/Th17-cell differentiation. This implies that reducing DC activation could be a new pharmacological intervention to treat severe asthma patients that present with a Th17-mediated neutrophilic inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888782">PM:28888782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170910-VromanH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170910-VromanH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Vroman H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wypych,T.P.</style></author><author><style face="normal" font="Arial"> Marzi,R.</style></author><author><style face="normal" font="Arial"> Wu,G.F.</style></author><author><style face="normal" font="Arial"> Lanzavecchia,A.</style></author><author><style face="normal" font="Arial"> Sallusto,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Research in Biomedicine, Universita della Svizzera Italiana, Bellinzona, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Role of B cells in T helper cell responses in a mouse model of asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody production</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cell depletion</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Lineage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell activation</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> Th17 response</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The importance of B lymphocytes to present antigens for antibody production is well documented. In contrast, very little is known about their capacity to influence CD4+ T cell activation during primary or secondary response to allergens. OBJECTIVE: Using mouse models of asthma, we investigated the role of B cells as antigen presenting cells in propagation and initiation of T helper cell responses. METHODS: Mice were immunized via intranasal route with house dust mite extract (HDM) derived from Dermatophagoides pteronyssinus. To investigate the importance of B cells in maintenance of allergic response, B cells were depleted in HDM-sensitized animals. To investigate the role of B cells in T cell priming, B cells were depleted before HDM sensitization; furthermore, HDM sensitization was performed in mice with MHC-II expression restricted to the B cell lineage. RESULTS: We found that B cells serve as potent antigen presenting cells ex-vivo and restimulate in vivo-primed HDM-specific T helper cells. HDM antigens were taken up by B cells independently of the B cell receptor specificity, indicating that HDM uptake and antigen presentation to CD4+ T cells is not restricted to rare B cells carrying HDM-specific B cell receptors. B cell depletion before HDM challenge in HDM-sensitized mice resulted in a dramatic reduction of allergic response, indicating the role of B cells in amplification of Th2 responses. In contrast, HDM sensitization of mice in which MHC-II expression was restricted to B cells revealed the inability of these cells to initiate Th2 responses, but highlighted their unexpected role in priming Th1 and Th17 responses. CONCLUSION: Collectively, these data reveal new mechanisms leading to initiation and exacerbation of allergic response that may have implications for designing new therapeutic strategies to combat house dust mite allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889953">PM:28889953</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170911-WypychTP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170911-WypychTP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Wypych TP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,J.</style></author><author><style face="normal" font="Arial"> Miller,M.</style></author><author><style face="normal" font="Arial"> Unno,H.</style></author><author><style face="normal" font="Arial"> Rosenthal,P.</style></author><author><style face="normal" font="Arial"> Sanderson,M.</style></author><author><style face="normal" font="Arial"> Broide,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pulmonary Diseases, State Key Laboratory of Biotherapy, and Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, PCR</style></auth-address><titles><title><style face="normal" font="Arial">Ormdl3 Upregulates Airway Smooth Muscle Proliferation, Contraction, and Ca2+ Oscillations in Asthma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Biotherapy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> blood supply</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> calcium flux</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> ORMDL3</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sarcoplasmic</style></keyword><keyword><style face="normal" font="Arial"> Sarcoplasmic Reticulum</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Airway hyperresponsiveness (AHR) is a major feature of asthma attributed predominantly to an extrinsic immune/inflammatory response increasing airway smooth muscle (ASM) contractility. OBJECTIVE: We investigated whether increased ASM expression of ORMDL3, a gene on chromosome 17q21 highly linked to asthma, induced increased ASM proliferation and contractility in vitro, as well as influenced airway contractility and calcium flux in ASM in precision cut lung slices from WT and hORMDL3Zp3-Cre mice (which express increased levels of human ORMDL3). METHODS: Levels of ASM proliferation and contraction were assessed in ASM cells transfected with ORMDL3 in vitro. In addition, airway contractility and calcium oscillations were quantitated in ASM cells in precision cut lung slices derived from naive WT and naive hORMDL3Zp3-Cre mice which do not have a blood supply. RESULTS: Increased ASM expression of ORMDL3 in vitro resulted in increased ASM proliferation and contractility. Precision cut lung slices derived from naive hORMDL3Zp3-Cre mice which do not have airway inflammation exhibit increased airway contractility with increased calcium oscillations in ASM cells. Increased ASM ORMDL3 increases ASM sarcoplasmic reticulum Ca2+ ATPase 2b (SERCA2b) which increases ASM proliferation and contractility. CONCLUSION: Overall, these studies provide evidence that an intrinsic increase in ORMDL3 in ASM can induce increased ASM proliferation and contractility which may contribute to increased AHR in the absence of airway inflammation in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889952">PM:28889952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170911-ChenJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170911-ChenJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Chen J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,J.K.</style></author><author><style face="normal" font="Arial"> Har,D.</style></author><author><style face="normal" font="Arial"> Brown,L.S.</style></author><author><style face="normal" font="Arial"> Khan,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Division of Allergy &amp; Immunology, University of Texas Southwestern Medical Center, Dallas, Tex</style></auth-address><titles><title><style face="normal" font="Arial">Recurrence of Chronic Urticaria: Incidence and Associated Factors</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alternative agent</style></keyword><keyword><style face="normal" font="Arial"> Alternative agents</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Associated factors</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressants</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). OBJECTIVES: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. METHODS: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed. RCU was defined as CU recurring at least 6 months after cessation of controller therapy and resolution of prior CU symptoms. Charts were reviewed for symptom resolution and recurrence, subtypes of CU (idiopathic, physical, and urticarial vasculitis), and medication usage (first-line agents, alternative agents, and steroid dependence). RESULTS: Forty-five of 341 patients (13%) had RCU. The recurrence group had a higher frequency of alternative agent use at 57.8% (n = 26) compared with the nonrecurrence group at 34.8% (n = 103), which was statistically significant (P &lt; .01). The rate of steroid dependence was similar in both groups (13.3% in the recurrence group vs 14.5%) and not statistically significant. Individuals exposed to anti-inflammatory agents, immunosuppressants, and omalizumab had a significantly higher relative risk of recurrence compared with those who only used first-line agents (relative risk [RR] 2.32, P &lt; .01; RR 2.69, P &lt; .01; and RR 2.18, P = .05, respectively). CONCLUSIONS: RCU occurs in approximately 13% of patients with CU in our clinic population. Alternative agent use and antihistamine refractoriness appear to place patients at increased risk for recurrence compared with first-line agent use alone</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888844">PM:28888844</url></web-urls><pdf-urls><url ppv-ref="no">dave.khan@utsouthwestern.edu</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170910, Kim JK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hunter,H.</style></author><author><style face="normal" font="Arial"> Wong,T.</style></author><author><style face="normal" font="Arial"> Winstanley,A.</style></author><author><style face="normal" font="Arial"> Till,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Nutrition and Dietetics, Guy's and St Thomas' NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophilic esophagitis linked to pollen food syndrome</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Dietetics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen food syndrome</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888845">PM:28888845</url></web-urls><pdf-urls><url ppv-ref="no">stephen.till@kcl.ac.uk</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170910, Hunter H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kulthanan,K.</style></author><author><style face="normal" font="Arial"> Chaweekulrat,P.</style></author><author><style face="normal" font="Arial"> Komoltri,C.</style></author><author><style face="normal" font="Arial"> Hunnangkul,S.</style></author><author><style face="normal" font="Arial"> Tuchinda,P.</style></author><author><style face="normal" font="Arial"> Chularojanamontri,L.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine A</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Despite widely recommended usage of cyclosporine A (CsA) in chronic spontaneous urticaria (CSU), there is no meta-analysis concerning its efficacy and safety. OBJECTIVE: To meta-analyze and review the efficacy and safety of CsA in CSU. METHODS: Efficacy was assessed by the relative change in urticaria activity score at 4 weeks and response rates at 4, 8, and 12 weeks. Safety was assessed by analyzing the number of patients with 1 or more adverse event. RESULTS: Eighteen studies (909 participants) including 2 randomized controlled trials were included, with 125, 363, and 266 patients with CSU receiving very low (&lt;2 mg/kg/d), low (from 2 to&lt; 4 mg/kg/d), and moderate (4-5 mg/kg/d) doses of CsA, respectively. After 4 weeks, the mean relative change in urticaria activity score of CsA-treated patients was -17.89, whereas that of controls was -2.3. The overall response rate to CsA treatment with low to moderate doses at 4, 8, and 12 weeks was 54%, 66%, and 73%, respectively. No studies of very low-dose CsA evaluated response rates at 4, 8, and 12 weeks. Among patients treated with very low, low, and moderate doses of CsA, 6%, 23%, and 57% experienced 1 or more adverse event, respectively. CONCLUSIONS: Given the limited number and quality of studies, our results should be interpreted with caution. CsA is effective at low to moderate doses. Adverse events appear to be dose dependent and occur in more than half the patients treated with moderate doses of CsA. We suggest that the appropriate dosage of CsA for CSU may range from 1 to 5 mg/kg/d, and 3 mg/kg/d is a reasonable starting dose for most patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Thailand -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28916431">PM:28916431</url></web-urls><pdf-urls><url ppv-ref="no">papapitt@gmail.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170916, Kulthanan K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Robbins,K.A.</style></author><author><style face="normal" font="Arial"> Ackerman,O.R.</style></author><author><style face="normal" font="Arial"> Carter,C.A.</style></author><author><style face="normal" font="Arial"> Uygungil,B.</style></author><author><style face="normal" font="Arial"> Sprunger,A.</style></author><author><style face="normal" font="Arial"> Sharma,H.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Children's National Health System, Washington, DC.</style></auth-address><titles><title><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome to peanut with early introduction: a clinical dilemma</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888843">PM:28888843</url></web-urls><pdf-urls><url ppv-ref="no">karobbins@childrensnational.org</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170910, Robbins KA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Parpaleix,A.</style></author><author><style face="normal" font="Arial"> Boyer,L.</style></author><author><style face="normal" font="Arial"> Wiedemann,A.</style></author><author><style face="normal" font="Arial"> Lacabaratz,C.</style></author><author><style face="normal" font="Arial"> Margarit,L.</style></author><author><style face="normal" font="Arial"> Enouf,V.</style></author><author><style face="normal" font="Arial"> Le Corvoisier,P.</style></author><author><style face="normal" font="Arial"> Lino,A.</style></author><author><style face="normal" font="Arial"> Covali-Noroc,A.</style></author><author><style face="normal" font="Arial"> Housset,B.</style></author><author><style face="normal" font="Arial"> Chouaid,C.</style></author><author><style face="normal" font="Arial"> Maitre,B.</style></author><author><style face="normal" font="Arial"> Levy,Y.</style></author><author><style face="normal" font="Arial"> Lelievre,J.D.</style></author><author><style face="normal" font="Arial"> Adnot,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">INSERM U955 Institut Mondor de Recherche Biomedicale and Universite Paris Est (UPEC), DHU A-TVB, Creteil, F-94010, France</style></auth-address><titles><title><style face="normal" font="Arial">Impaired Humoral and Cellular Immune Responses to Influenza Vaccination in COPD Patient</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">COPD</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> EST</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza vaccination</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889955">PM:28889955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170911-ParpaleixA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170911-ParpaleixA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Parpaleix A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xie,G.</style></author><author><style face="normal" font="Arial"> Yang,H.</style></author><author><style face="normal" font="Arial"> Peng,X.</style></author><author><style face="normal" font="Arial"> Lin,L.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Lin,K.</style></author><author><style face="normal" font="Arial"> Cui,Z.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Xiao,H.</style></author><author><style face="normal" font="Arial"> Liang,Y.</style></author><author><style face="normal" font="Arial"> Li,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University</style></auth-address><titles><title><style face="normal" font="Arial">Mast cell exosomes can suppress allergic reactions by binding to IgE</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exosomes</style></keyword><keyword><style face="normal" font="Arial"> Free IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">Neutralizing free IgE would appear to be an important strategy for the treatment of allergic diseases. This article explores a novel anti-IgE agent</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28916187">PM:28916187</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-XieG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-XieG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Xie G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gunawardana,N.C.</style></author><author><style face="normal" font="Arial"> Zhao,Q.</style></author><author><style face="normal" font="Arial"> Carayannopoulos,L.N.</style></author><author><style face="normal" font="Arial"> Tsai,K.</style></author><author><style face="normal" font="Arial"> Malkov,V.A.</style></author><author><style face="normal" font="Arial"> Selverian,D.</style></author><author><style face="normal" font="Arial"> Clarke,G.</style></author><author><style face="normal" font="Arial"> Mant,T.</style></author><author><style face="normal" font="Arial"> Butts,B.</style></author><author><style face="normal" font="Arial"> Lund,K.</style></author><author><style face="normal" font="Arial"> Hansel,T.T.</style></author><author><style face="normal" font="Arial"> Nolte,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Imperial Clinical Respiratory Research Unit (ICRRU), St. Mary's Hospital, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">The effects of house dust mite sublingual immunotherapy (SLIT)-tablet effects on immunological biomarkers and nasal allergen challenge symptoms</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Blocking factor</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">SQ HDM SLIT-tablet significantly increased serum HDM-specific IgG4 and IgE blocking factor, and significantly decreased early phase nasal symptoms after nasal allergen challenge. No significant effects on cytokines or gene expression in nasal mucosa were observed</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28911971">PM:28911971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170915-GunawardanaNC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170915-GunawardanaNC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Gunawardana NC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pitt,T.J.</style></author><author><style face="normal" font="Arial"> Becker,A.B.</style></author><author><style face="normal" font="Arial"> Chan-Yeung,M.</style></author><author><style face="normal" font="Arial"> Chan,E.S.</style></author><author><style face="normal" font="Arial"> Watson,W.T.A.</style></author><author><style face="normal" font="Arial"> Chooniedass,R.</style></author><author><style face="normal" font="Arial"> Azad,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Humber River Hospital, Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Reduced risk of peanut sensitization following exposure through breast-feeding and early peanut introduction</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intervention Studies</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> maternal atopy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ontario</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> peanut consumption</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary Prevention</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recent trials have shown that avoiding peanuts during infancy increases the risk of peanut allergy; however, these studies did not address maternal peanut consumption. OBJECTIVE: We sought to investigate the relationship between maternal peanut consumption while breast-feeding, timing of direct peanut introduction, and peanut sensitization at age 7 years. METHODS: Secondary analysis of a nested cohort within the 1995 Canadian Asthma Primary Prevention Study intervention study was performed. Breast-feeding and maternal and infant peanut consumption were captured by repeated questionnaires during infancy. Skin prick testing for peanut sensitization was performed at age 7 years. RESULTS: Overall, 58.2% of mothers consumed peanuts while breast-feeding and 22.5% directly introduced peanuts to their infant by 12 months. At 7 years, 9.4% of children were sensitized to peanuts. The lowest incidence (1.7%) was observed among children whose mothers consumed peanuts while breast-feeding and directly introduced peanuts before 12 months. Incidence was significantly higher (P &lt; .05) if mothers consumed peanuts while breast-feeding but delayed introducing peanuts to their infant beyond 12 months (15.1%), or if mothers avoided peanuts themselves but directly introduced peanuts by 12 months (17.6%). Interaction analyses controlling for study group and maternal atopy confirmed that maternal peanut consumption while breast-feeding and infant peanut consumption by 12 months were protective in combination, whereas either exposure in isolation was associated with an increased risk of sensitization (P interaction = .003). CONCLUSIONS: In this secondary analysis, maternal peanut consumption while breast-feeding paired with direct introduction of peanuts in the first year of life was associated with the lowest risk of peanut sensitization, compared with all other combinations of maternal and infant peanut consumption</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28916221">PM:28916221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-PittTJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-PittTJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Pitt TJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Leib,N.</style></author><author><style face="normal" font="Arial"> Herrmann,N.</style></author><author><style face="normal" font="Arial"> Koch,S.</style></author><author><style face="normal" font="Arial"> Stroisch,T.J.</style></author><author><style face="normal" font="Arial"> Schnautz,S.</style></author><author><style face="normal" font="Arial"> Wilms,H.</style></author><author><style face="normal" font="Arial"> Bieber,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Christine Kuhne-Center for Allergy Research and Education, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany</style></auth-address><titles><title><style face="normal" font="Arial">miRNA-155 mediates down-regulation of the high-affinity receptor for IgE via Toll-like receptor signaling</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">miRNA-155 contributes to the inflammatory process in AD by regulating the expression of the high-affinity receptor for IgE (FcepsilonRI) via its transcription factor PU.1. miRNA-155 may represent an interesting new target in AD therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889954">PM:28889954</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170911-LeibN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170911-LeibN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Leib N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abolhassani,H.</style></author><author><style face="normal" font="Arial"> Chou,J.</style></author><author><style face="normal" font="Arial"> Bainter,W.</style></author><author><style face="normal" font="Arial"> Platt,C.</style></author><author><style face="normal" font="Arial"> Tavassoli,M.</style></author><author><style face="normal" font="Arial"> Momen,T.</style></author><author><style face="normal" font="Arial"> Tavakol,M.</style></author><author><style face="normal" font="Arial"> Eslamian,M.H.</style></author><author><style face="normal" font="Arial"> Gharagozlou,M.</style></author><author><style face="normal" font="Arial"> Movahedi,M.</style></author><author><style face="normal" font="Arial"> Ghadami,M.</style></author><author><style face="normal" font="Arial"> Hamidieh,A.A.</style></author><author><style face="normal" font="Arial"> Azizi,G.</style></author><author><style face="normal" font="Arial"> Yazdani,R.</style></author><author><style face="normal" font="Arial"> Afarideh,M.</style></author><author><style face="normal" font="Arial"> Ghajar,A.</style></author><author><style face="normal" font="Arial"> Havaei,A.</style></author><author><style face="normal" font="Arial"> Chavoushzadeh,Z.</style></author><author><style face="normal" font="Arial"> Mahdaviani,S.A.</style></author><author><style face="normal" font="Arial"> Cheraghi,T.</style></author><author><style face="normal" font="Arial"> Behniafard,N.</style></author><author><style face="normal" font="Arial"> Amin,R.</style></author><author><style face="normal" font="Arial"> Aleyasin,S.</style></author><author><style face="normal" font="Arial"> Faridhosseini,R.</style></author><author><style face="normal" font="Arial"> Jabbari-Azad,F.</style></author><author><style face="normal" font="Arial"> Nabavi,M.</style></author><author><style face="normal" font="Arial"> Bemanian,M.H.</style></author><author><style face="normal" font="Arial"> Arshi,S.</style></author><author><style face="normal" font="Arial"> Molatefi,R.</style></author><author><style face="normal" font="Arial"> Sherkat,R.</style></author><author><style face="normal" font="Arial"> Mansouri,M.</style></author><author><style face="normal" font="Arial"> Mesdaghi,M.</style></author><author><style face="normal" font="Arial"> Babaie,D.</style></author><author><style face="normal" font="Arial"> Mohammadzadeh,I.</style></author><author><style face="normal" font="Arial"> Ghaffari,J.</style></author><author><style face="normal" font="Arial"> Shafiei,A.</style></author><author><style face="normal" font="Arial"> Kalantari,N.</style></author><author><style face="normal" font="Arial"> Ahanchian,H.</style></author><author><style face="normal" font="Arial"> Khoshkhui,M.</style></author><author><style face="normal" font="Arial"> Soheili,H.</style></author><author><style face="normal" font="Arial"> Dabbaghzadeh,A.</style></author><author><style face="normal" font="Arial"> Shirkani,A.</style></author><author><style face="normal" font="Arial"> Kalmarzi,R.N.</style></author><author><style face="normal" font="Arial"> Mortazavi,S.H.</style></author><author><style face="normal" font="Arial"> Tafaroji,J.</style></author><author><style face="normal" font="Arial"> Khalili,A.</style></author><author><style face="normal" font="Arial"> Mohammadi,J.</style></author><author><style face="normal" font="Arial"> Negahdari,B.</style></author><author><style face="normal" font="Arial"> Joghataei,M.T.</style></author><author><style face="normal" font="Arial"> Al-Ramadi,B.K.</style></author><author><style face="normal" font="Arial"> Picard,C.</style></author><author><style face="normal" font="Arial"> Parvaneh,N.</style></author><author><style face="normal" font="Arial"> Rezaei,N.</style></author><author><style face="normal" font="Arial"> Chatila,T.</style></author><author><style face="normal" font="Arial"> Massaad,M.J.</style></author><author><style face="normal" font="Arial"> Keles,S.</style></author><author><style face="normal" font="Arial"> Hammarstrom,L.</style></author><author><style face="normal" font="Arial"> Geha,R.S.</style></author><author><style face="normal" font="Arial"> Aghamohammadi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Clinical, Immunological and Genetic Spectrum of 696 Patients with Combined Immunode fi ciency</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Repair</style></keyword><keyword><style face="normal" font="Arial"> DNA sequencing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Middle East</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United Arab Emirates</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Combined immunodeficiencies (CIDs) are diseases of defective adaptive immunity with diverse clinical phenotypes. Although CIDs are more prevalent in the Middle East than Western countries, the resources for genetic diagnosis are limited. OBJECTIVES: This study aims to characterize the categories of CID patients in Iran clinically and genetically. METHODS: Clinical and laboratory data were obtained from 696 patients with CIDs. Patients were subdivided into those with syndromic (344 patients) and non-syndromic CIDs (352 patients). Targeted DNA sequencing was performed on 243 patients (34.9%). RESULTS: The overall diagnostic yield of the 243 sequenced patients was 77.8% (189 patients). The clinical diagnosis of HIES (p&lt;0.001), onset of disease > 5y (p=0.02), and the absence of multiple affected family members (p=0.04), were significantly more frequent in the patients without a genetic diagnosis. An autosomal recessive disease was found in 62.9% of patients, reflecting the high rate of consanguinity in this cohort. Mutations impairing VDJ recombination and DNA repair were the most common underlying causes of CIDs. However, in patients with syndromic CIDs, autosomal recessive mutations in ATM, autosomal dominant mutations in STAT3 and microdeletions in 22q11.21 were the most commonly affected genomic loci. Patients with syndromic CIDs had a significantly lower five-year survival rate rather than those with non-syndromic CIDs. CONCLUSIONS: This study provides proof of principle for the application of targeted next-generation sequencing panels in countries with limited diagnostic resources. The impact of genetic diagnosis on clinical care requires continued improvements in therapeutic resources for these patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Iran -CO - Sweden -CO - United States -CO - France -CO - United Arab Emirates -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.06.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28916186">PM:28916186</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-AbolhassaniH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-AbolhassaniH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Abolhassani H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.06.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,X.</style></author><author><style face="normal" font="Arial"> Michaeloudes,C.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Wiegman,C.H.</style></author><author><style face="normal" font="Arial"> Adcock,I.M.</style></author><author><style face="normal" font="Arial"> Lian,Q.</style></author><author><style face="normal" font="Arial"> Mak,J.C.W.</style></author><author><style face="normal" font="Arial"> Bhavsar,P.K.</style></author><author><style face="normal" font="Arial"> Chung,K.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Heart and Lung Institute, Imperial College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Cigarette smoke</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> Lung Diseases</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oxidative stress-induced mitochondrial dysfunction may contribute to inflammation and remodeling in chronic obstructive pulmonary disease (COPD). Mesenchymal stem cells (MSCs) protect against lung damage in animal models of COPD. It is unknown whether these effects occur through attenuating mitochondrial dysfunction in airway cells. OBJECTIVE: To examine the effect of induced-pluripotent stem cell-derived MSCs (iPSC-MSCs) on oxidative stress-induce mitochondrial dysfunction in human airway smooth muscle cells (ASMCs) in vitro and in mouse lungs in vivo. METHODS: ASMCs were co-cultured with iPSC-MSCs in the presence of cigarette smoke medium (CSM), and mitochondrial reactive oxygen species (ROS), mitochondrial membrane potential (DeltaPsim) and apoptosis were measured. Conditioned media from iPSC-MSCs and trans-well co-cultures were used to detect any paracrine effects. The effect of systemic injection of iPSC-MSCs on airway inflammation and hyper-responsiveness in ozone-exposed mice was also investigated. RESULTS: Co-culture of iPSC-MSCs with ASMCs attenuated CSM-induced mitochondrial ROS, apoptosis and DeltaPsim loss in ASMCs. iPSC-MSC-conditioned media or trans-well co-cultures with iPSC-MSCs reduced CSM-induced mitochondrial ROS but not DeltaPsim or apoptosis in ASMCs. Mitochondrial transfer from iPSC-MSCs to ASMCs was observed after direct co-culture and was enhanced by CSM. iPSC-MSCs attenuated ozone-induced mitochondrial dysfunction, airway hyper-responsiveness and inflammation in mouse lungs. CONCLUSION: iPSC-MSCs offered protection against oxidative stress-induced mitochondrial dysfunction in human ASMCs and in mouse lungs, whilst reducing airway inflammation and hyper-responsiveness. These effects are, at least partly, dependent on cell-cell contact that allows for mitochondrial transfer, and paracrine regulation. Therefore, iPSC-MSCs show promise as a therapy for oxidative stress-dependent lung diseases such as COPD</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28911970">PM:28911970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170915-LiX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170915-LiX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Li X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gendrin,C.</style></author><author><style face="normal" font="Arial"> Shubin,N.J.</style></author><author><style face="normal" font="Arial"> Boldenow,E.</style></author><author><style face="normal" font="Arial"> Merillat,S.</style></author><author><style face="normal" font="Arial"> Clauson,M.</style></author><author><style face="normal" font="Arial"> Power,D.</style></author><author><style face="normal" font="Arial"> Doran,K.S.</style></author><author><style face="normal" font="Arial"> Abrink,M.</style></author><author><style face="normal" font="Arial"> Pejler,G.</style></author><author><style face="normal" font="Arial"> Rajagopal,L.</style></author><author><style face="normal" font="Arial"> Piliponsky,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Infectious Diseases, University of Washington, Seattle, Washington, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Mast Cell Chymase Decreases The Severity Of Group B Streptococcus Infections</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Infections</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chymase</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="Arial"> fibronectin</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Gram-Positive Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Labor</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell protease</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Streptococcus</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Group B Streptococcus (GBS) or Streptococcus agalactiae are ss-hemolytic, Gram-positive bacteria that colonize the lower genital tract of women and are frequently associated with infections during pregnancy. Innate immune defenses are critical for controlling GBS dissemination and systemic infection. Mast cells are resident sentinel cells that come into contact with pathogens early during colonization and infection. OBJECTIVE: We aimed to investigate the contribution of chymase to systemic GBS infection and rates of preterm birth. METHODS: Pharmacological and genetic approaches using mice deficient in mast cell protease (MCPT)4, the mouse functional homolog of human chymase, were employed. RESULTS: Our studies show that, in response to GBS, mast cells release a protease with chymotrypsin-like cleavage specificity. Additionally, increased GBS systemic infection and preterm births were observed in MCPT4-deficient mice vs. MCPT4 sufficient mice. We further observed that proteolytic cleavage of the host extracellular matrix protein fibronectin by peritoneal cell-derived mast cell (PCMC) lysates diminished GBS adherence. Consistent with this observation, the increase in GBS dissemination and preterm births observed in MCPT4-deficient mice was abolished when GBS were deficient in expression of the fibronectin binding protein, SfbA. CONCLUSIONS: Taken together, our results suggest that the protective effect of MCPT4 against GBS dissemination and preterm labor can in part be attributed to MCPT4-mediated proteolysis of fibronectin. Our studies reveal a novel role of mast cells in defense against bacterial infections</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28916188">PM:28916188</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-GendrinC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-GendrinC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Gendrin C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martinez,C.H.</style></author><author><style face="normal" font="Arial"> Li,S.X.</style></author><author><style face="normal" font="Arial"> Hirzel,A.J.</style></author><author><style face="normal" font="Arial"> Stolberg,V.R.</style></author><author><style face="normal" font="Arial"> Alexis,N.E.</style></author><author><style face="normal" font="Arial"> Barr,R.G.</style></author><author><style face="normal" font="Arial"> Bleecker,E.R.</style></author><author><style face="normal" font="Arial"> Carretta,E.E.</style></author><author><style face="normal" font="Arial"> Christenson,S.A.</style></author><author><style face="normal" font="Arial"> Cooper,C.B.</style></author><author><style face="normal" font="Arial"> Couper,D.J.</style></author><author><style face="normal" font="Arial"> Doerschuk,C.M.</style></author><author><style face="normal" font="Arial"> Han,M.K.</style></author><author><style face="normal" font="Arial"> Hansel,N.N.</style></author><author><style face="normal" font="Arial"> Hastie,A.T.</style></author><author><style face="normal" font="Arial"> Hoffman,E.A.</style></author><author><style face="normal" font="Arial"> Kaner,R.J.</style></author><author><style face="normal" font="Arial"> Martinez,F.J.</style></author><author><style face="normal" font="Arial"> Meyers,D.A.</style></author><author><style face="normal" font="Arial"> O'Neal,W.K.</style></author><author><style face="normal" font="Arial"> Paine,R.,III</style></author><author><style face="normal" font="Arial"> Putcha,N.</style></author><author><style face="normal" font="Arial"> Rennard,S.I.</style></author><author><style face="normal" font="Arial"> Woodruff,P.G.</style></author><author><style face="normal" font="Arial"> Zeidler,M.</style></author><author><style face="normal" font="Arial"> Curtis,J.L.</style></author><author><style face="normal" font="Arial"> Freeman,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Michigan, Ann Arbor, MI</style></auth-address><titles><title><style face="normal" font="Arial">Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ANN</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">Active smoking in stable COPD subjects significantly increased eosinophil accumulation in the distal airspaces, but not in sputum or peripheral blood. Our findings support the need to investigate this cell-type as a potential driver of COPD symptomatology and progression</style></abstract><notes><style face="normal" font="Arial">DA - 20170916IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28916185">PM:28916185</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-MartinezCH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20170916-MartinezCH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170916, Martinez CH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Turi,K.N.</style></author><author><style face="normal" font="Arial"> Gebretsadik,T.</style></author><author><style face="normal" font="Arial"> Lee,R.L.</style></author><author><style face="normal" font="Arial"> Hartert,T.V.</style></author><author><style face="normal" font="Arial"> Evans,A.M.</style></author><author><style face="normal" font="Arial"> Stone,C.</style></author><author><style face="normal" font="Arial"> Sicignano,N.M.</style></author><author><style face="normal" font="Arial"> Wu,A.C.</style></author><author><style face="normal" font="Arial"> Iribarren,C.</style></author><author><style face="normal" font="Arial"> Butler,M.G.</style></author><author><style face="normal" font="Arial"> Mitchel,E.</style></author><author><style face="normal" font="Arial"> Morrow,J.</style></author><author><style face="normal" font="Arial"> Larkin,E.K.</style></author><author><style face="normal" font="Arial"> Wu,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Medicine , Vanderbilt University Medical Center , Nashville , TN , USA</style></auth-address><titles><title><style face="normal" font="Arial">Seasonal patterns of Asthma medication fills among diverse populations of the United States</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma morbidity</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonists</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> medication adherence</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Reliever</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal asthma</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Nonadherence to controller and overuse of reliever asthma medications are associated with exacerbations. We aimed to determine patterns of seasonal asthma medication use and to identify time period(s) during which interventions to improve medication adherence could reduce asthma morbidity. METHODS: We conducted a retrospective cohort study of asthmatics 4-50 years of age and enrolled in three diverse health insurance plans. Seasonal patterns of medications were reported by monthly prescription fill rates per 1000 individuals with asthma from 1998 to 2013, and stratified by healthcare plan, sex, and age. RESULTS: There was a distinct and consistent seasonal fill pattern for all asthma medications. The lowest fill rate was observed in the month of July. Fills increased in the autumn and remained high throughout the winter and spring. Compared with the month of May with high medication fills, July represented a relative decrease of fills ranging from 13% (rate ratio, RR: 0.87, 95% confidence interval, 95%CI: 0.72-1.04) for the combination of inhaled corticosteroids (ICS) + long acting beta agonists (LABA) to 45% (RR: 0.55, 95%CI: 0.49-0.61) for oral corticosteroids. Such a seasonal pattern was observed each year across the 16-year study period, among healthcare plans, sexes, and ages. LABA containing control medication (ICS+LABA and LABA) fill rates were more prevalent in older asthmatics, while leukotriene receptor antagonists were more prevalent in the younger population. CONCLUSIONS: A seasonal pattern of asthma medication fill rates likely represents a reactive response to a loss of disease control and increased symptoms. Adherence to and consistent use of asthma medications among individuals who use medications in reaction to seasonal exacerbations might be a key component in reducing the risk of asthma exacerbations</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2017.1362426</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881155">PM:28881155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170907-TuriKN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170907-TuriKN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Turi KN</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2017.1362426</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,H.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Wang,L.</style></author><author><style face="normal" font="Arial"> Xie,H.</style></author><author><style face="normal" font="Arial"> Chen,L.</style></author><author><style face="normal" font="Arial"> He,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Translational Medicine Institute, Shenyang Medical College, Shenyang, Liaoning, China</style></auth-address><titles><title><style face="normal" font="Arial">Role of IL-18 in atopic asthma is determined by balance of IL-18/IL-18BP/IL-18R</style></title><secondary-title><style face="normal" font="Arial">J Cell Mol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cell Mol Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">It is recognized that IL-18 is related to development of asthma, but role of IL-18 in asthma remains controversial and confusing. This is largely due to lack of information on expression of IL-18 binding protein (BP) and IL-18 receptor (R) in asthma. In this study, we found that plasma levels of IL-18 and IL-18BP were elevated in asthma. The ratio between plasma concentrations of IL-18 and IL-18BP was 1:12.8 in asthma patients. We demonstrated that 13-fold more monocytes, 17.5-fold more neutrophils and 4.1-fold more B cells express IL-18BP than IL-18 in asthmatic blood, suggesting that there is excessive amount of IL-18BP to abolish actions of IL-18 in asthma. We also discovered that more IL-18R+ monocytes, neutrophils and B cells are located in asthmatic blood. Once injected, IL-18 eliminated IL-18R+ monocytes in blood, but up-regulated expression of IL-18R in lung macrophages of OVA-sensitized mice. Our data clearly indicate that the role of IL-18 in asthma is very likely to be determined by balance of IL-18/IL-18BP/IL-18R expression in inflammatory cells. Therefore, IL-18R blocking or IL-18BP activity enhancing therapies may be useful for treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1582-4934 (Electronic)IS - 1582-1838 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/jcmm.13323</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28922563">PM:28922563</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cell Mol Med\20170918-ZhangH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cell Mol Med\20170918-ZhangH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Zhang H</style></custom2><misc3><style face="normal" font="Arial">10.1111/jcmm.13323</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singh,A.K.</style></author><author><style face="normal" font="Arial"> Gupta,P.</style></author><author><style face="normal" font="Arial"> Verma,N.</style></author><author><style face="normal" font="Arial"> Khare,V.</style></author><author><style face="normal" font="Arial"> Ahamad,A.</style></author><author><style face="normal" font="Arial"> Verma,V.</style></author><author><style face="normal" font="Arial"> Agarwal,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Associate Professor, Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India</style></auth-address><titles><title><style face="normal" font="Arial">Fungal Rhinosinusitis: Microbiological and Histopathological Perspective</style></title><secondary-title><style face="normal" font="Arial">J Clin Diagn Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Diagn Res</style></full-title></periodical><pages end="DC12" start="DC10">DC10-DC12</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: On the basis of histopathology Fungal Rhinosinusitis (FRS) is categorized into non-invasive (allergic fungal rhinosinusitis, fungal ball) and invasive (acute invasive, chronic invasive and granulomatous invasive fungal sinusitis). This differentiation helps to decide the treatment. Role of latest molecular methods such as PCR and conventional methods such as KOH microscopy and culture also needs to be evaluated. Therefore, in this study we planned to categorise fungal rhinosinusitis on the basis of histopathology and compare it with other methods such as PCR, culture and KOH microscopy. AIM: To analyse fungal rhinosinusitis cases by both histopathologically and microbiologically. MATERIALS AND METHODS: A total of 76 clinically suspected fungal rhinosinusitis cases were included in the study. The tissue of suspected cases were processed and examined by KOH microscopy, histopathologically, culture and PCR. Histopathological examination was done by PAS, GMS and H&amp;E stain. RESULTS: FRS was diagnosed in 37 (48.68%) cases out of 76 clinically suspected cases of FRS. In which 17 (22.3%) cases were positive by direct microscopy, 21 (27.6%) by culture, 27 (35.5%) by PCR and 14 (18.42%) by histopathology. Approximately 14 cases of FRS were classified according to histopathology; 10 (71.3%) as non-invasive FRS. Out of these 10, 9 (64.2%) were classified as AFRS and 1 (7.14%) as fungal ball. Only 4 cases (28.5%) were diagnosed with invasive FRS. Out of these 4 cases, 2 (14.2%) were of chronic invasive fungal rhinosinusitis, 1 (7.14%) was of granulomatous invasive fungal rhinosinusitis and 1 (7.14%) was of acute fulminant invasive fungal rhinosinusitis. Allergic Fungal Rhinosinusitis (AFRS) is the most common type of FRS. Aspergillus flavus was found to be the most common fungi causing FRS. CONCLUSION: Diagnosis should not be based on the single method. It should be done by both histopathological and microbiological methods, especially for those cases which are difficult to diagnose</style></abstract><notes><style face="normal" font="Arial">DA - 20170912IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.7860/JCDR/2017/25842.10167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892889">PM:28892889</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-DC10-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-DC10-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170912, Singh AK</style></custom2><misc3><style face="normal" font="Arial">10.7860/JCDR/2017/25842.10167</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Machado,Y.</style></author><author><style face="normal" font="Arial"> Duinkerken,S.</style></author><author><style face="normal" font="Arial"> Hoepflinger,V.</style></author><author><style face="normal" font="Arial"> Mayr,M.</style></author><author><style face="normal" font="Arial"> Korotchenko,E.</style></author><author><style face="normal" font="Arial"> Kurtaj,A.</style></author><author><style face="normal" font="Arial"> Pablos,I.</style></author><author><style face="normal" font="Arial"> Steiner,M.</style></author><author><style face="normal" font="Arial"> Stoecklinger,A.</style></author><author><style face="normal" font="Arial"> Lubbers,J.</style></author><author><style face="normal" font="Arial"> Schmid,M.</style></author><author><style face="normal" font="Arial"> Ritter,U.</style></author><author><style face="normal" font="Arial"> Scheiblhofer,S.</style></author><author><style face="normal" font="Arial"> Ablinger,M.</style></author><author><style face="normal" font="Arial"> Wally,V.</style></author><author><style face="normal" font="Arial"> Hochmann,S.</style></author><author><style face="normal" font="Arial"> Raninger,A.M.</style></author><author><style face="normal" font="Arial"> Strunk,D.</style></author><author><style face="normal" font="Arial"> van Kooyk,Y.</style></author><author><style face="normal" font="Arial"> Thalhamer,J.</style></author><author><style face="normal" font="Arial"> Weiss,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Synergistic effects of dendritic cell targeting and laser-microporation on enhancing epicutaneous skin vaccination efficacy</style></title><secondary-title><style face="normal" font="Arial">J Control Release</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Control Release</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunization</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Langerhans Cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> Periodate</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">Due to its unique immunological properties, the skin is an attractive target tissue for allergen-specific immunotherapy. In our current work, we combined a dendritic cell targeting approach with epicutaneous immunization using an ablative fractional laser to generate defined micropores in the upper layers of the skin. By coupling the major birch pollen allergen Bet v 1 to mannan from S. cerevisiae via mild periodate oxidation we generated hypoallergenic Bet-mannan neoglycoconjugates, which efficiently targeted CD14+ dendritic cells and Langerhans cells in human skin explants. Mannan conjugation resulted in sustained release from the skin and retention in secondary lymphoid organs, whereas unconjugated antigen showed fast renal clearance. In a mouse model, Bet-mannan neoglycoconjugates applied via laser-microporated skin synergistically elicited potent humoral and cellular immune responses, superior to intradermal injection. The induced antibody responses displayed IgE-blocking capacity, highlighting the therapeutic potential of the approach. Moreover, application via micropores, but not by intradermal injection, resulted in a mixed TH1/TH17-biased immune response. Our data clearly show that applying mannan-neoglycoconjugates to an organ rich in dendritic cells using laser-microporation is superior to intradermal injection. Due to their low IgE binding capacity and biodegradability, mannan neoglycoconjugates therefore represent an attractive formulation for allergen-specific epicutaneous immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1873-4995 (Electronic)IS - 0168-3659 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Germany -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jconrel.2017.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28919557">PM:28919557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Control Release\20170918-MachadoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Control Release\20170918-MachadoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Machado Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jconrel.2017.09.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,S.Y.</style></author><author><style face="normal" font="Arial"> Oh,I.B.</style></author><author><style face="normal" font="Arial"> Choi,K.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Comparison of IgE induction in mice by pollens from three pine tree species</style></title><secondary-title><style face="normal" font="Arial">J Ecol Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Ecol Environ</style></full-title></periodical><pages end="" start="33">33-</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Pine</style></keyword><keyword><style face="normal" font="Arial"> Pinus</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2288-1220</style></isbn><abstract><style face="normal" font="Arial">Over the years, pine pollens have been excluded as an allergen due to its relatively large size, low protein content, and waxy hydrophobic layer, despite their abundance. However, recent studies suggest the possibilities of pine pollens being allergens, and it has been reported that allergy symptoms were highly prevalent in areas with considerably large pine forests and high possibility of exposure to the pollen. Therefore, we conducted a comparative analysis of the allergenicities of the pollens from the dominant species of Korean pines, red pine (Pinus densiflora), black pine (Pinus thunbergii), and pitch pine (Pinus rigida), in mice</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1186/s41610-017-0052-1</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s41610-017-0052-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ecol Environ\2017-41-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ecol Environ\2017-41-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Kim SY</style></custom2><misc3><style face="normal" font="Arial">10.1186/s41610-017-0052-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Balp,M.M.</style></author><author><style face="normal" font="Arial"> Khalil,S.</style></author><author><style face="normal" font="Arial"> Tian,H.</style></author><author><style face="normal" font="Arial"> Gabriel,S.</style></author><author><style face="normal" font="Arial"> Vietri,J.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Novartis Pharma AG, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Burden of chronic urticaria relative to psoriasis in five European countries</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> resource use</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Quantification of burden of chronic spontaneous urticaria (CSU) versus psoriasis (PsO) is limited. OBJECTIVE: To evaluate the burden associated with CSU versus PsO of all severities (overall PsO), mild and moderate/severe PsO. METHODS: his retrospective cross-sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain, and the United Kingdom. Outcomes included mental and physical component summary scores (MCS and PCS) calculated from the Short-Form (SF)-36v2 or SF-12v2, SF-6D health utility scores, self-reported psychological complaints (anxiety, depression, and sleep difficulties), work productivity and activity impairment, and self-reported health care resource utilisation. Bivariate and multivariate analyses for each outcome and comparative group were conducted. RESULTS: This analysis included 769 CU and 7857 PsO (26.9% moderate/severe) patients. Following adjustment for covariates, CU patients showed a greater health-related quality of life (HRQoL) impairment versus overall PsO (MCS:-2.4, PCS:-1.6, SF-6D:-0.03; all p&lt; 0.001). CU patients showed a higher risk of anxiety, depression, and sleep difficulties (odds ratio [OR]: 1.63, 1.34, and 1.56, respectively; all P&lt; 0.01) and greater healthcare resource use versus overall PsO. The overall activity impairment was significantly greater in CU patients than in overall PsO patients (P=0.001) while the impact on work was not-significantly different. The results vs. moderate/severe PsO group showed no significant differences on all outcomes. CONCLUSION: Burden of illness in CU is higher than PsO of all severities but similar to that observed in moderate/severe PsO. Both diseases have a similar negative impact on work productivity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170912IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14584</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28898460">PM:28898460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170912-BalpMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170912-BalpMM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170912, Balp MM</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14584</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maurer,M.</style></author><author><style face="normal" font="Arial"> Altrichter,S.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Church,M.K.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Benefit from Reslizumab Treatment in a Patient with Chronic Spontaneous Urticaria and Cold Urticaria</style></title><secondary-title><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Eur Acad Dermatol Venereol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic inducible urticaria</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> cold urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">Chronic urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CIndU) including cold urticaria (ColdU) [1]. While antihistamines and omalizumab are effective treatments for both CSU and ColdU [2], many patients show insufficient response to either or both of these treatments [3], and additional and better therapies are needed [4]. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/jdv.14594</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28924988">PM:28924988</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170919-MaurerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20170919-MaurerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Maurer M</style></custom2><misc3><style face="normal" font="Arial">10.1111/jdv.14594</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gupta,R.S.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Kao,L.M.</style></author><author><style face="normal" font="Arial"> Schuster,E.</style></author><author><style face="normal" font="Arial"> Smith,B.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Ann &amp; Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Chicago, Illinois 60611</style></auth-address><titles><title><style face="normal" font="Arial">Economic Factors Impacting Food Allergen Management: Perspectives from the Food Industry</style></title><secondary-title><style face="normal" font="Arial">J Food Prot</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Prot</style></full-title></periodical><pages end="1725" start="1719">1719-1725</pages><volume><style face="normal" font="Arial">80</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen control</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergen management</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> ANN</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Cross contact</style></keyword><keyword><style face="normal" font="Arial"> Cross-contact</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Food allergen management</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">Food allergies affect up to 8% of children in the United States and may occasionally lead to severe life-threatening reactions. Because there is currently no cure for food allergies, strict avoidance of the allergen-containing foods is the only means of preventing an allergic reaction. Consumers rely on food manufacturers to reliably track and declare the presence of food allergens in products. Over the past 10 to 20 years, the food industry has increasingly adopted allergen control approaches in its processing facilities. However, the major industry costs related to food allergen management have not been fully described. The objective of this study was to characterize the factors that contribute to the economic impact of food allergen control practices on the food industry. A focus group (n = 100) was conducted with food industry professionals to identify key areas of cost for food allergen management. A survey based on the domains identified was then developed and disseminated to a convenience sample (n = 50) of quality control food industry specialists with knowledge of their company's food allergen management practices. Nearly all companies (92%) produced food products containing one or more of the top eight allergenic foods recognized by the U.S. Food and Drug Administration or sesame seeds. Cleaning procedures, employee training, and the potential for a recall due to allergen cross-contact were most frequently rated as the important factors in food allergen management. Recalls due to food allergen cross-contact, cleaning procedures, equipment and premises design, and employee training were ranked as the greatest allergen management expenses. Although 96% of companies had a food allergen control plan in place, nearly half (42%) had at least one food allergen-related recall within the past 5 years. The industry appears to endorse a willingness to unify precautionary allergen labeling to communicate a clear message more effectively to consumers</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 1944-9097 (Electronic)IS - 0362-028X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4315/0362-028X.JFP-17-060</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28906157">PM:28906157</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto - 6 mesi</url></related-urls></urls><custom2><style face="normal" font="Arial">20170914, Gupta RS</style></custom2><misc3><style face="normal" font="Arial">10.4315/0362-028X.JFP-17-060</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Koh,B.</style></author><author><style face="normal" font="Arial"> Hufford,M.M.</style></author><author><style face="normal" font="Arial"> Sun,X.</style></author><author><style face="normal" font="Arial"> Kaplan,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202</style></auth-address><titles><title><style face="normal" font="Arial">Etv5 Regulates IL-10 Production in Th Cells</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="2171" start="2165">2165-2171</pages><volume><style face="normal" font="Arial">198</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antigens,Fungal</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Basic-Leucine Zipper Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cells,Cultured</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> DNA-Binding Proteins</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Indiana</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice,Knockout</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> Th cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Transcription Factors</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">IL-10 is an immunoregulatory cytokine that has broad effects across the immune system. In Th cell subsets, Th2 cells produce considerable amounts of IL-10. The transcription factors that regulate IL-10 production in Th2 cells are still incompletely described. In this study, we demonstrate that the ETS family transcription factor ETS variant (Etv)5 regulates IL-10 production in Th2 cells. T cell-specific Etv5-deficient and littermate control mice demonstrated that IL-10 production and gene expression were significantly decreased in the absence of Etv5. In an Aspergillus fumigatus extract-induced inflammation model, IL-10-producing CD4+ T cells in bronchoalveolar lavage and lung were significantly decreased in mice that lacked Etv5 in T cells, compared with control mice. We showed that Etv5 directly binds to the Il10 locus conserved noncoding sequence 3 site and that it activates gene expression in a luciferase reporter assay and following retroviral transduction. Etv5 deficiency did not affect the expression of other transcription factors known to be important for expression of IL-10, including Jun family members, GATA3, E4BP4, and IFN regulatory factor 4. However, in the absence of Etv5, binding of these transcription factors to the Il10 locus was dramatically reduced. Ectopic Etv5 expression in Th2 cells that lack Etv5 restored IL-10 production and the binding of IL-10-inducing transcription factors including E4BP4, IFN regulatory factor 4, and GATA3. Taken together, we conclude that Etv5 plays a crucial role in regulating IL-10 production in Th2 cells by facilitating the binding of IL-10-inducing transcription factors at the Il10 locus</style></abstract><notes><style face="normal" font="Arial">DA - 20170119IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Antigens, Fungal)RN - 0 (Basic-Leucine Zipper Transcription Factors)RN - 0 (DNA-Binding Proteins)RN - 0 (Etv5 protein, mouse)RN - 0 (Nfil3 protein, mouse)RN - 0 (Transcription Factors)RN - 130068-27-8 (Interleukin-10)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1600801</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100679">PM:28100679</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\2017-198-2165-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\2017-198-2165-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170119, Koh B</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1600801</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85977</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chowdhary,A.</style></author><author><style face="normal" font="Arial"> Sharma,C.</style></author><author><style face="normal" font="Arial"> Meis,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, India</style></auth-address><titles><title><style face="normal" font="Arial">Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment</style></title><secondary-title><style face="normal" font="Arial">J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Infect Dis</style></full-title></periodical><pages end="S444" start="S436">S436-S444</pages><volume><style face="normal" font="Arial">216</style></volume><number><style face="normal" font="Arial">suppl_3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus flavus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus infection</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchitis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Prophylaxis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Triazoles</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="15" Month="8" Year="2017">2017/8/15</year></dates><abstract><style face="normal" font="Arial">Aspergillus fumigatus remains the most common species in all pulmonary syndromes, followed by Aspergillus flavus which is a common cause of allergic rhinosinusitis, postoperative aspergillosis and fungal keratitis. The manifestations of Aspergillus infections include invasive aspergillosis, chronic pulmonary aspergillosis and bronchitis. Allergic manifestations of inhaled Aspergillus include allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Triazoles are the mainstay of therapy against Aspergillus infections for treatment and prophylaxis. Lately, increased azole resistance in A. fumigatus has become a significant challenge in effective management of aspergillosis. Earlier studies have brought to light the contribution of non-cyp51 mutations along with alterations in cyp51A gene resulting in azole-resistant phenotypes of A. fumigatus. This review highlights the magnitude of azole-resistant aspergillosis and resistance mechanisms implicated in the development of azole-resistant A. fumigatus and address the therapeutic options available</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1537-6613 (Electronic)IS - 0022-1899 (Linking)LA - engPT - Journal ArticleCO - India -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1093/infdis/jix210</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28911045">PM:28911045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Infect Dis\2017-216S3-436-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Infect Dis\2017-216S3-436-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Chowdhary A</style></custom2><misc3><style face="normal" font="Arial">10.1093/infdis/jix210</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Speakman,S.</style></author><author><style face="normal" font="Arial"> Kool,B.</style></author><author><style face="normal" font="Arial"> Sinclair,J.</style></author><author><style face="normal" font="Arial"> Fitzharris,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">Paediatric food-induced anaphylaxis hospital presentations in New Zealand</style></title><secondary-title><style face="normal" font="Arial">J Paediatr Child Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Paediatr Child Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">AIM: Globally, rates of paediatric food-induced anaphylaxis (FIA) are increasing. Little data is available regarding the epidemiology of FIA among New Zealand (NZ) children. This study investigated the incidence of paediatric (0-14 years) FIA hospital presentations in NZ over a 10-year period. METHODS: Ministry of Health public hospital discharge data from 2006 to 2015 were analysed using FIA-related International Classification of Diseases codes (T78.0 - anaphylactic shock due to adverse food reaction and T78.2 - anaphylactic shock unspecified and free text qualifier) to identify acute hospital presentations. RESULTS: The overall annualised FIA hospital presentation rate was 16.2 per 100 000 children. Subgroup analysis indicated a significantly higher rate in males (19.1/100 000) than in females (13.1/100 000), and among children aged less than 2 years of age (50.5/100 000) compared with older children. Rates among Asian and Pacific children were higher than Maori and NZ European children. In 67.7% of cases, a single specific allergen was suggested by the information provided; among these cases, nuts (48%), specifically peanuts (26%), were the most commonly reported allergen, followed by cow's milk (21%). Time trend analysis showed a 2.8-fold increase in the overall annualised rate for the 10-year period. CONCLUSION: These findings are consistent with other international studies indicating increasing rates of FIA in children. These data will provide information for a review of NZ paediatric allergy services to ensure current international standards with regard to the equitable delivery of timely, appropriate and accessible care are being met. Reasons for differences by gender, age and ethnicity require further investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1440-1754 (Electronic)IS - 1034-4810 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1111/jpc.13705</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28885749">PM:28885749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Paediatr Child Health\20170908-SpeakmanS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Paediatr Child Health\20170908-SpeakmanS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Speakman S</style></custom2><misc3><style face="normal" font="Arial">10.1111/jpc.13705</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Helin,N.</style></author><author><style face="normal" font="Arial"> Kolho,K.L.</style></author><author><style face="normal" font="Arial"> Qvist,E.</style></author><author><style face="normal" font="Arial"> Makela,M.</style></author><author><style face="normal" font="Arial"> Merras-Salmio,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*HUS Porvoo Hospital, department of pediatrics, Porvoo, Finland and University of Helsinki daggerHelsinki University Children's Hospital and University of Helsinki, Finland double daggerMedical Director Pikkujatti lasten ja nuorten laakariasema Oy, Helsinki, Finland section signHelsinki University Hospital, Department of Allergology and University of Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Gastrointestinal Symptoms of Food Challenge-Proven Non-Ige Cow's Milk Allergy are Dissipated by Early School Age</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Parenting</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="9" Year="2017">2017/9/16</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To evaluate the current well-being and dietary restrictions in children six years after food challenge confirmed diagnosis of non-IgE cow's milk protein allergy, compared to peers with gastrointestinal symptoms but negative food challenge. To evaluate the diagnostic process retrospectively. METHODS: Internet-based survey for mothers whose children underwent six years ago the double-blind, placebo-controlled food challenge for cow's milk because of gastrointestinal symptoms causing suspicion of non-IgE cow's milk protein allergy. Concurrent dietary restrictions, overall well-being, medical history and retrospective views on the food challenge were queried using a study-specific questionnaire, the Quality of life using PedsQL general score and parental stress with the Parenting Stress Index questionnaire. RESULTS: Mothers of 42 children (23 girls), median age of 6.7 years (range 5.7-8.6), participated in the survey, the response rate was 70%. All children now consumed cow's milk protein. The only food restrictions reported were empirical lactose-free diets in seven children (17%). One-third of the children in both groups were currently reported to have eating-related issues such as picky eating. Quality of life was good and present parenting stress was average in both groups. The majority of the mothers (87%) felt positive or neutral about the food challenge performed in infancy. CONCLUSIONS: The non-IgE cow's milk allergy with gastrointestinal symptoms diagnosed in infancy was a transient condition with good outcome. At an early school age, nearly all children have a good quality of life and a regular diet. The use of the double-blind, placebo-controlled food challenge was well-endorsed</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001737</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28922259">PM:28922259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20170918-HelinN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20170918-HelinN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Helin N</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001737</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sasihuseyinoglu,A.S.</style></author><author><style face="normal" font="Arial"> Yilmaz,M.</style></author><author><style face="normal" font="Arial"> Altintas,D.U.</style></author><author><style face="normal" font="Arial"> Dogruel,D.</style></author><author><style face="normal" font="Arial"> Serbes,M.</style></author><author><style face="normal" font="Arial"> Uguz,A.H.</style></author><author><style face="normal" font="Arial"> Kiroglu,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of *Pediatric Allergy and Immunology daggerPathology double daggerENT Department, School of Medicine, Cukurova University, Adana, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Squamous Cell Carcinoma With Hyper-IgE Syndrome: A Case Report</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Hematol Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Hematol Oncol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> Carcinoma</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> ear infections</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Middle ear</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Hyper-immunoglobulin E syndrome (HIES) is a rare primary immunodeficiency disease characterized by recurrent infections and elevated levels of serum immunoglobulin E, usually over 2000 IU/mL. Recurrent and chronic infection of the epidermis and squamous epithelium may also be a cause of squamous cell carcinoma (SCC). SCC is rare with HIES. CASE REPORT: A 17-year-old male patient who was diagnosed as HIES was admitted with purulent right ear discharge. The patient had a history of eczema starting from the age of 7 months and a history of recurrent middle ear infection starting from the age of 5. Biopsy specimens were taken from the lesion in the external auditory canal, and the lesion was reported as SCC. CONSLUSION: Patients with autosomal recessive HIES are at an increased risk for infections and malignancies. SCC should be considered in the differential diagnosis of the patients presenting with recurrent middle ear infections and immunodeficiency</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1536-3678 (Electronic)IS - 1077-4114 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPH.0000000000000954</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28902078">PM:28902078</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Hematol Oncol\20170913-SasihuseyinogluAS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Hematol Oncol\20170913-SasihuseyinogluAS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Sasihuseyinoglu AS</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPH.0000000000000954</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ankersmit,H.J.</style></author><author><style face="normal" font="Arial"> Copic,D.</style></author><author><style face="normal" font="Arial"> Simader,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">When meat allergy meets cardiac surgery: A driver for humanized bioprosthesis</style></title><secondary-title><style face="normal" font="Arial">J Thorac Cardiovasc Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Thorac Cardiovasc Surg</style></full-title></periodical><pages end="1327" start="1326">1326-1327</pages><volume><style face="normal" font="Arial">154</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bioprosthesis</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0022-5223</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jtcvs.2017.05.041</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jtcvs.2017.05.041</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Thorac Cardiovasc Surg\2017-154-1326-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Thorac Cardiovasc Surg\2017-154-1326-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Ankersmit HJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jtcvs.2017.05.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hawkins,R.B.</style></author><author><style face="normal" font="Arial"> Ghanta,R.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mammalian meat allergy and advances in bioprosthetic valve technology</style></title><secondary-title><style face="normal" font="Arial">J Thorac Cardiovasc Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Thorac Cardiovasc Surg</style></full-title></periodical><pages end="1328" start="1327">1327-1328</pages><volume><style face="normal" font="Arial">154</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> Mammalian meat</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0022-5223</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jtcvs.2017.05.075</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jtcvs.2017.05.075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Thorac Cardiovasc Surg\2017-154-1327-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Thorac Cardiovasc Surg\2017-154-1327-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Hawkins RB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jtcvs.2017.05.075</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lanz,S.</style></author><author><style face="normal" font="Arial"> Brunner,A.</style></author><author><style face="normal" font="Arial"> Graubner,C.</style></author><author><style face="normal" font="Arial"> Marti,E.</style></author><author><style face="normal" font="Arial"> Gerber,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Swiss Institute of Equine Medicine, University of Bern and Agroscope, Berne, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Insect Bite Hypersensitivity in Horses is Associated with Airway Hyperreactivity</style></title><secondary-title><style face="normal" font="Arial">J Vet Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Vet Intern Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway reactivity</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> equine</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IBH</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insect bite hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Partial Pressure</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Genetic and epidemiologic evidence suggests that in horses, as in other species, different manifestations of hypersensitivity may occur together. HYPOTHESIS: Horses affected with insect bite hypersensitivity (IBH) show airway hyperreactivity (AH) to inhaled histamine, even in the absence of overt clinical signs of equine asthma (EA). ANIMALS: Twenty-two healthy controls (group C), 24 horses suffering from IBH alone (group IBH), and 23 horses suffering from IBH and EA (group IBH/EA). METHODS: The clinical histories were assessed using 2 standardized questionnaires, the Horse Owner Assessed Respiratory Signs Index (HOARSI), and IBH scoring. Horses were classified as EA-affected if their HOARSI was >1 and as IBH-affected if IBH score was >0. Confounding disorders were excluded by clinical examination. The arterial partial pressure of oxygen (PaO2 ) was measured and flowmetric plethysmography used to assess airway reactivity to increasing doses of inhaled histamine. RESULTS: The median histamine provocation concentration (PC) when flow values increased by 35% (PC35) was significantly higher in group C (5.94 [1.11-26.33] mg/mL) compared to group IBH (2.95 [0.23-10.13] mg/mL) and group IBH/EA (2.03 [0.43-10.94] mg/mL; P &lt; 0.01). The PC50 and PC75 showed very similar differences between groups. Furthermore, PaO2 was significantly lower in group IBH (84 +/- 8 mmHg) and group IBH/EA (78 +/- 11 mmHg) compared to group C (89 +/- 6 mmHg; P &lt; 0.01). CONCLUSIONS AND CLINICAL IMPORTANCE: IBH is associated with AH and decreased PaO2 , even in the absence of overt respiratory clinical signs</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1939-1676 (Electronic)IS - 0891-6640 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/jvim.14819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28921663">PM:28921663</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Vet Intern Med\20170918-LanzS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Vet Intern Med\20170918-LanzS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Lanz S</style></custom2><misc3><style face="normal" font="Arial">10.1111/jvim.14819</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gaurav,R.</style></author><author><style face="normal" font="Arial"> Varasteh,J.T.</style></author><author><style face="normal" font="Arial"> Weaver,M.R.</style></author><author><style face="normal" font="Arial"> Jacobson,S.R.</style></author><author><style face="normal" font="Arial"> Hernandez-Lagunas,L.</style></author><author><style face="normal" font="Arial"> Liu,Q.</style></author><author><style face="normal" font="Arial"> Nozik-Grayck,E.</style></author><author><style face="normal" font="Arial"> Chu,H.W.</style></author><author><style face="normal" font="Arial"> Alam,R.</style></author><author><style face="normal" font="Arial"> Nordestgaard,B.G.</style></author><author><style face="normal" font="Arial"> Kobylecki,C.J.</style></author><author><style face="normal" font="Arial"> Afzal,S.</style></author><author><style face="normal" font="Arial"> Chupp,G.L.</style></author><author><style face="normal" font="Arial"> Bowler,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, National Jewish Health, Denver, Colorado, USA</style></auth-address><titles><title><style face="normal" font="Arial">The R213G polymorphism in SOD3 protects against allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JCI Insight</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">17</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">Oxidative stress is important in the pathogenesis of allergic asthma. Extracellular superoxide dismutase (EC-SOD; SOD3) is the major antioxidant in lungs, but its role in allergic asthma is unknown. Here we report that asthmatics have increased SOD3 transcript levels in sputum and that a single nucleotide polymorphism (SNP) in SOD3 (R213G; rs1799895) changes lung distribution of EC-SOD, and decreases likelihood of asthma-related symptoms. Knockin mice analogous to the human R213G SNP had lower airway hyperresponsiveness, inflammation, and mucus hypersecretion with decreased interleukin-33 (IL-33) in bronchoalveolar lavage fluid and reduced type II innate lymphoid cells (ILC2s) in lungs. SOD mimetic (Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin) attenuated Alternaria-induced expression of IL-33 and IL-8 release in BEAS-2B cells. These results suggest that R213G SNP potentially benefits its carriers by resulting in high EC-SOD in airway-lining fluid, which ameliorates allergic airway inflammation by dampening the innate immune response, including IL-33/ST2-mediated changes in ILC2s</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 2379-3708 (Electronic)IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1172/jci.insight.95072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28878123">PM:28878123</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JCI Insight\20170907-GauravR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JCI Insight\20170907-GauravR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Gaurav R</style></custom2><misc3><style face="normal" font="Arial">10.1172/jci.insight.95072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kleinert,S.</style></author><author><style face="normal" font="Arial"> Horton,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Lancet, London EC2Y 5AS, UKThe Lancet, London EC2Y 5AS, UK</style></auth-address><titles><title><style face="normal" font="Arial">After asthma: airways diseases need a new name and a revolution</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(17)32205-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28911917">PM:28911917</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20170915-KleinertS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20170915-KleinertS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Kleinert S</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(17)32205-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Camargo,C.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, and Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Transformational thinking about asthma</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(17)32126-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28911916">PM:28911916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20170915-CamargoJAJr.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20170915-CamargoJAJr.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Camargo JA Jr</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(17)32126-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pavord,I.D.</style></author><author><style face="normal" font="Arial"> Beasley,R.</style></author><author><style face="normal" font="Arial"> Agusti,A.</style></author><author><style face="normal" font="Arial"> Anderson,G.P.</style></author><author><style face="normal" font="Arial"> Bel,E.</style></author><author><style face="normal" font="Arial"> Brusselle,G.</style></author><author><style face="normal" font="Arial"> Cullinan,P.</style></author><author><style face="normal" font="Arial"> Custovic,A.</style></author><author><style face="normal" font="Arial"> Ducharme,F.M.</style></author><author><style face="normal" font="Arial"> Fahy,J.V.</style></author><author><style face="normal" font="Arial"> Frey,U.</style></author><author><style face="normal" font="Arial"> Gibson,P.</style></author><author><style face="normal" font="Arial"> Heaney,L.G.</style></author><author><style face="normal" font="Arial"> Holt,P.G.</style></author><author><style face="normal" font="Arial"> Humbert,M.</style></author><author><style face="normal" font="Arial"> Lloyd,C.M.</style></author><author><style face="normal" font="Arial"> Marks,G.</style></author><author><style face="normal" font="Arial"> Martinez,F.D.</style></author><author><style face="normal" font="Arial"> Sly,P.D.</style></author><author><style face="normal" font="Arial"> von,Mutius E.</style></author><author><style face="normal" font="Arial"> Wenzel,S.</style></author><author><style face="normal" font="Arial"> Zar,H.J.</style></author><author><style face="normal" font="Arial"> Bush,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Medicine Unit, Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of Oxford, UK.</style></auth-address><titles><title><style face="normal" font="Arial">After asthma: redefining airways diseases</style></title><secondary-title><style face="normal" font="Arial">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Airways disease</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - New Zealand -CO - Spain -CO - Australia -CO - Netherlands -CO - Canada -CO - United States -CO - Switzerland -CO - France -CO - Germany -CO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.1016/S0140-6736(17)30879-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28911920">PM:28911920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet\20170915-PavordID.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet\20170915-PavordID.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Pavord ID</style></custom2><misc3><style face="normal" font="Arial">10.1016/S0140-6736(17)30879-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fitzgerald,J.M.</style></author><author><style face="normal" font="Arial"> Bleecker,E.R.</style></author><author><style face="normal" font="Arial"> Menzies-Gow,A.</style></author><author><style face="normal" font="Arial"> Zangrilli,J.G.</style></author><author><style face="normal" font="Arial"> Hirsch,I.</style></author><author><style face="normal" font="Arial"> Metcalfe,P.</style></author><author><style face="normal" font="Arial"> Newbold,P.</style></author><author><style face="normal" font="Arial"> Goldman,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">The Lung Centre, Vancouver General Hospital, UBC Institute for Heart and Lung Health, Gordon and Leslie Diamond Health Care, Vancouver, BC, Canada.</style></auth-address><titles><title><style face="normal" font="Arial">Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies</style></title><secondary-title><style face="normal" font="Arial">Lancet Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lancet Respir Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> pooled analysis</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor alpha monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma. We further explored the efficacy of benralizumab for patients with different baseline blood eosinophil thresholds and exacerbation histories. METHODS: This study is a pooled analysis of the results from the randomised, double-blind, placebo-controlled SIROCCO (NCT01928771) and CALIMA (NCT01914757) phase 3 studies. In these studies, patients with severe, uncontrolled asthma were randomly assigned (1:1:1) to receive subcutaneous benralizumab 30 mg, either every 4 weeks or every 8 weeks (with first three doses given every 4 weeks), or placebo every 4 weeks. The primary endpoint was annual exacerbation rate (AER) ratio versus placebo, analysed by baseline eosinophil counts (>/=0, >/=150, >/=300, or >/=450 cells per muL) and by number of exacerbations (two vs three or more) during the year before enrolment. The analyses were done in accordance with the intention-to-treat principle. FINDINGS: Of 2295 patients, 756 received benralizumab every 4 weeks, 762 received benralizumab every 8 weeks, and 777 patients received placebo. AER among patients with baseline blood eosinophil counts of at least 0 cells per muL was 1.16 (95% CI 1.05-1.28) in patients who received placebo versus 0.75 (0.66-0.84) in patients who received benralizumab every 8 weeks (rate ratio 0.64, 0.55-0.75; p&lt;0.0001). In patients who received benralizumab every 4 weeks who had eosinophil counts of 0 or more cells per muL, AER was 0.73 (0.65-0.82); rate ratio versus placebo was 0.63 (0.54-0.74; p&lt;0.0001). The extent to which exacerbation rates were reduced increased with increasing blood eosinophil thresholds and with greater exacerbation history in patients in the 4-weekly and 8-weekly benralizumab groups. Greater improvements in AER were seen with benralizumab compared with placebo for patients with a combination of high blood eosinophil thresholds and a history of more frequent exacerbations. INTERPRETATION: These results will help to guide clinicians when they are deciding whether to use benralizumab to treat patients with severe, uncontrolled, eosinophilic asthma. FUNDING: AstraZeneca</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/S2213-2600(17)30344-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28919200">PM:28919200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lancet Respir Med\20170918-FitzGeraldJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lancet Respir Med\20170918-FitzGeraldJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, FitzGerald JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/S2213-2600(17)30344-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lindstrom,S.J.</style></author><author><style face="normal" font="Arial"> Silver,J.D.</style></author><author><style face="normal" font="Arial"> Sutherland,M.F.</style></author><author><style face="normal" font="Arial"> Treloar,A.B.</style></author><author><style face="normal" font="Arial"> Newbigin,E.</style></author><author><style face="normal" font="Arial"> McDonald,C.F.</style></author><author><style face="normal" font="Arial"> Douglass,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Austin Health, Melbourne</style></auth-address><titles><title><style face="normal" font="Arial">Thunderstorm asthma outbreak of November 2016: a natural disaster requiring planning</style></title><secondary-title><style face="normal" font="Arial">Med J Aust</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med J Aust</style></full-title></periodical><pages end="237" start="235">235-237</pages><volume><style face="normal" font="Arial">207</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> thunderstorm</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1326-5377 (Electronic)IS - 0025-729X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28899321">PM:28899321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med J Aust\2017-207-235-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med J Aust\2017-207-235-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Lindstrom SJ</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pang,K.A.</style></author><author><style face="normal" font="Arial"> Pang,K.P.</style></author><author><style face="normal" font="Arial"> Pang,E.B.</style></author><author><style face="normal" font="Arial"> Tan,Y.N.</style></author><author><style face="normal" font="Arial"> Chan,Y.H.</style></author><author><style face="normal" font="Arial"> Siow,J.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asia Sleep Centre, Singapore.</style></auth-address><titles><title><style face="normal" font="Arial">Food allergy and allergic rhinitis in 435 asian patients - A descriptive review</style></title><secondary-title><style face="normal" font="Arial">Med J Malaysia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med J Malaysia</style></full-title></periodical><pages end="220" start="215">215-220</pages><volume><style face="normal" font="Arial">72</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Soya bean</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To describe the prevalence of food allergy in Asian patients with allergic rhinitis. STUDY DESIGN: A non-randomized prospectively collected patients over a three year period, with complaints of nose congestion, rhinorrhea and/or nasal discharge. RESULTS: There were 435 patients enrolled, 213 children and 222 adults. The children group had a high prevalence of allergen specific IgE to Dermatophagoides pteryonysinus (70%), Dermatophagoides farina (69%), and Blomia tropicalis (55%); followed by dogs (32%), cats (19%) and cockroaches (19%). In the children food allergy category, the top three allergens were egg white (54%), milk (31%) and soya bean (13%). The adult group had results of Dermatophagoides pteryonysinus (71%), Dermatophagoides farina (72%), and Blomia tropicalis (59%); the adult food allergy category, the top 3 allergens were egg white (13%), milk (6%) and soya bean (5%). There was a statistically significant difference in the child and adult group for Dust, D. pteryonysinus, D. farina, B.tropicalis, egg white, wheat, gluten and soya bean. In the age specific child groups, there was an increased in egg food allergy levels, with a peak at the age of five-nine years old and decreasing thereafter (p=0.04). In the children group, the mean Total Nasal Symptom Score (TNSS) was 10.3 (range of 7 to 13); the adult group was similar, with a mean TNSS of 9.8 (range 5 to 12). CONCLUSION: The prevalence of food allergy in paediatric patients with allergic rhinitis is fairly high and should be considered when treating these children</style></abstract><notes><style face="normal" font="Arial">DA - 20170910IS - 0300-5283 (Print)IS - 0300-5283 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889132">PM:28889132</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med J Malaysia\2017-72-215-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med J Malaysia\2017-72-215-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170910, Pang KA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,D.W.</style></author><author><style face="normal" font="Arial"> Kim,D.K.</style></author><author><style face="normal" font="Arial"> Eun,K.M.</style></author><author><style face="normal" font="Arial"> Bae,J.S.</style></author><author><style face="normal" font="Arial"> Chung,Y.J.</style></author><author><style face="normal" font="Arial"> Xu,J.</style></author><author><style face="normal" font="Arial"> Kim,Y.M.</style></author><author><style face="normal" font="Arial"> Mo,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology-Head and Neck Surgery, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">IL-25 Could Be Involved in the Development of Allergic Rhinitis Sensitized to House Dust Mite</style></title><secondary-title><style face="normal" font="Arial">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mediators Inflamm</style></full-title></periodical><pages end="" start="3908049">3908049-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND PURPOSE: When house dust mite (HDM), a common allergen, comes into the mucosal membrane, it may stimulate innate immunity. However, the precise role of interleukin- (IL-) 25 in the development of HDM-induced nasal allergic inflammation is still unclear. Therefore, we investigated the role of IL-25 in allergic rhinitis (AR) patients sensitized to HDM. METHODS: To confirm the production of IL-25 in human nasal epithelial cells (HNECs), we stimulated HNECs. IL-25 expression in the nasal mucosa from control, non-AR (NAR) patients, and HDM-sensitized AR patients was assessed using immunohistochemistry, and quantitative reverse transcription PCR. Correlations between IL-25 and other inflammatory markers were explored. RESULTS: An in vitro study showed significantly elevated concentrations of IL-25 in the HNEC samples with highest doses of HDM. Nasal tissues from AR patients sensitized to HDM showed significantly higher IL-25 expression, compared to those from the control or NAR patients. Moreover, the expression of IL-25 in nasal tissues from AR patients sensitized to HDM was positively associated with Th2 markers, such as ECP and GATA3. CONCLUSIONS: IL-25 expression increased with high-dose HDM stimulation and was related to Th2 markers. Therefore, IL-25 neutralization might offer a new strategy for treating patients with HDM-sensitized AR</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/3908049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28912627">PM:28912627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mediators Inflamm\2017-2017-3908049.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mediators Inflamm\2017-2017-3908049.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Kim DW</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/3908049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mishra,A.</style></author><author><style face="normal" font="Arial"> Arora,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology Section, CSIR-Institute of Genomics and Integrative Biology, Room 509, Delhi University Campus, Mall Road, Delhi, 110007, India</style></auth-address><titles><title><style face="normal" font="Arial">Allergenicity Assessment of Transgenic Wheat Lines In Silico</style></title><secondary-title><style face="normal" font="Arial">Methods Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Methods Mol Biol</style></full-title></periodical><pages end="111" start="97">97-111</pages><volume><style face="normal" font="Arial">1679</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Engineering</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> GM</style></keyword><keyword><style face="normal" font="Arial"> GM Crops</style></keyword><keyword><style face="normal" font="Arial"> GM-crops</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> in silico tools</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Homology</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Texture</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> transgene</style></keyword><keyword><style face="normal" font="Arial"> Transgenes</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> transgenic wheat</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Agriculture biotechnology is a promising tool for developing varieties with enhanced quality and quantity. Transgenic proteins expressed by genetically modified (GM) food crops improve crop characteristics like nutritional value, taste, and texture, and endow plants with resistance against fungus, pests, and insects. Despite such potential benefits, there are concerns regarding possible adverse effects of GM crops on human health, animals and the environment. Among the proposed guidelines for GM food safety testing-the weight-of-evidence approach proposed by the Codex Alimentarius Commission (ALINORM 03/34A) is the most recent. Till date, several transgenic wheat lines have been developed and research is underway for further improvement. However, GM wheat is not being grown or consumed in any part of the world. In the present study, in silico tools were employed for safety testing of eight transgenes used for the development of transgenic wheat lines. Among the genes studied, none of them shared sequence homology with the reported allergens and may be safe for use in genetic engineering. In conclusion, gene selection for developing transgenic wheat lines should be done with utmost care to ensure its safety for feed and fodder</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/978-1-4939-7337-8_6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913796">PM:28913796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Methods Mol Biol\2017-1679-97-111.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Methods Mol Biol\2017-1679-97-111.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Mishra A</style></custom2><misc3><style face="normal" font="Arial">10.1007/978-1-4939-7337-8_6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Welchering,N.</style></author><author><style face="normal" font="Arial"> von Mutius,E.</style></author><author><style face="normal" font="Arial"> Fuchs,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Padiatrische Pneumologie und Allergologie, Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital der LMU Munchen, Lindwurmstr. 4, D-80337, Munchen, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Anaphylaxis caused by hymenoptera stings - Importance of instructions and training for emergency treatment by non medical personnel]</style></title><secondary-title><style face="normal" font="Arial">MMW Fortschr Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">MMW Fortschr Med</style></full-title></periodical><pages end="46" start="43">43-46</pages><volume><style face="normal" font="Arial">159</style></volume><number><style face="normal" font="Arial">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergologie</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Emergency Treatment</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera sting</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Pneumologie</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1438-3276 (Print)IS - 1438-3276 (Linking)LA - gerPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s15006-017-0009-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28924704">PM:28924704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\MMW Fortschr Med\2017-159-43-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\MMW Fortschr Med\2017-159-43-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Welchering N</style></custom2><misc3><style face="normal" font="Arial">10.1007/s15006-017-0009-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zuo,J.</style></author><author><style face="normal" font="Arial"> Lei,M.</style></author><author><style face="normal" font="Arial"> Wen,M.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Institute, School of Medicine, University of South China, Hengyang, Hunan 421001, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Overexpression of ATP5b promotes cell proliferation in asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="6952" start="6946">6946-6952</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">airflow</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Culture Media</style></keyword><keyword><style face="normal" font="Arial"> Culture medium</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Developed Countries</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic disease</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">Asthma is a complicated systemic disease of the airways, which is characterized by variable symptoms, including bronchial hyperresponsive-ness, inflammation and airflow obstruction. The prevalence of asthma has increased 23fold over recent decades in developed countries; however, the molecular mechanism of asthma remains unclear. In the current study, the expression of recombinant protein Dermatophagoides farinaeI (Derf I) was induced by isopropyl betaD1thiogalactoside (IPTG) and purified using NiNTA. Derf I, an important antigen of asthma, was used to establish the animal model of asthma. Airway hyperresponsiveness was mea-sured using unrestrained wholebody plethysmography with a fourchamber system. Immunoglobulin (Ig)E, IgG and IgG2a were analyzed using indirect enzymelinked immunosorbent assay (ELISA). Proteomic technology was applied to detect the difference between the normal lung tissue and asthma lung tissue samples of the asthma model. Cytokines in bronchoalveolar lavage fluid and the splenocyte culture medium were measured by ELISA and reverse transcriptionquantitative polymerase chain reaction (RTqPCR) was performed to detect the mRNA expression of ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide (ATP5b). In addition, cell growth of arterial smooth muscle cells (ASMCs) was evaluated by MTT assay. In the current study, Derf I was successfully used to construct the animal model of asthma. Out of 23 proteins that exhibit 3fold upregulation or downregulation, ATP5b was chosen for further investigation. The data indicated that ATP5b was overexpressed in the asthma lung tissue when compared with the normal lung tissue. However, when ATP5b was knocked down, cell growth decreased. Therefore, overexpressed ATP5b leads to airway smooth muscle cell (ASMC) proliferation and finally to ASM thickening. Thus, to the best of our knowledge, this is the first study to report that the expression level of ATP5b was markedly increased in lung tissue samples of an asthma model compared with the tissue samples from normal lungs, which promoted ASMC proliferation and contributed to airway remodeling</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.7413</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28901394">PM:28901394</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-6946-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-6946-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Zuo J</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.7413</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hou,M.</style></author><author><style face="normal" font="Arial"> Li,W.</style></author><author><style face="normal" font="Arial"> Xie,Z.</style></author><author><style face="normal" font="Arial"> Ai,J.</style></author><author><style face="normal" font="Arial"> Sun,B.</style></author><author><style face="normal" font="Arial"> Tan,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of OtolaryngologyHead Neck Surgery, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Effects of anticholinergic agent on miRNA profiles and transcriptomes in a murine model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Differentially expressed gene</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Ipratropium</style></keyword><keyword><style face="normal" font="Arial"> ipratropium bromide</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray Analysis</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Subfamily</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="Arial">Anticholinergic agent, ipratropium bromide (IB) ameliorates symptoms of allergic rhinitis (AR) using neuroimmunologic mechanisms. However, the underlying molecular mechanism remains largely unclear. In the present study, 27 mice with AR induced by ovalbumin were randomly allocated to one of three groups: Model group, model group with IB treatment for 2 weeks, and model group with IB treatment for 4 weeks. Allergic symptoms were evaluated according to symptoms scores. Differentially expressed genes [microRNAs (miRNAs) and messenger RNAs (mRNAs)] of nasal mucosa were identified by microarray analysis. The expression levels of candidate genes were measured by reverse transcriptionquantitative polymerase chain reaction (RTqPCR). The data indicates that the symptoms scores in allergic mice were significantly reduced by IB treatment. In the nasal mucosa of allergic mice with IB treatment, 207 mRNAs and 87 miRNAs were differentially expressed, when compared with the sham group. IB treatment significantly downregulated the expression levels of interleukin4Ralpha and prostaglandin D2 synthase, whereas the leukemia inhibitory factor, A20 and nuclear receptor subfamily 4, group A, member 1 expression levels were upregulated. Similarly, the expression levels of mmumiR1243p/5p, 133b5p, 133a3p/5p, 3843p, 181a5p, 378a5p and 30715p were significantly increased. RTqPCR data further validated these mRNA and miRNA expression levels. Thus, IB treatment regulated expression of allergic immuneassociated mRNAs and miRNAs of the nasal mucosa in allergic mice, which may be associated with ameliorated nasal allergic symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.7411</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28901404">PM:28901404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\20170913-HouM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\20170913-HouM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Hou M</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.7411</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sun,M.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Zhao,H.</style></author><author><style face="normal" font="Arial"> Yao,W.</style></author><author><style face="normal" font="Arial"> Yu,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Antiallergic action of bacillus CalmetteGuerin extract in experimental mast cellmediated anaphylactic models</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="6254" start="6248">6248-6254</pages><volume><style face="normal" font="Arial">16</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adenosine</style></keyword><keyword><style face="normal" font="Arial"> Adenosine Monophosphate</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dextran</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="Arial">Allergy is an acquired hypersensitivity reaction of the immune system mediated by IgEinduced mast cell degranulation. In China, bacillus CalmetteGuerin extract (BCGE) has been shown to be clinically effective for regulating immunity, which enhances the resistance of the body to anaphylactic disease, infectious diseases and cancer. However, the mechanisms remain to be fully elucidated. The present study investigated the potential antiallergic effects of BCGE in animal models of mast celldependent anaphylaxis and mechanisms of BCGE in mast cells. Antiallergic actions of BCGE were evaluated in passive cutaneous anaphylaxis, dextran T40induced scratching behavior mouse models, and in ovalbumin (OVA)induced contraction of intestinal tube isolated from OVAsensitized guinea pigs. Direct mast cellstabilizing effects of BCGE were examined in mast cells from the abdominal cavity of OVAsensitized rats. Antiallergic signaling mechanisms of BCGE in mast cells were investigated by detection of cyclic adenosine monophosphate levels and protein kinase A expression in mast cells. It was observed that BCGE prevented OVAinduced cutaneous vascular hyperpermeability, skin itching, elevation in plasma histamine levels and abdominal cavity fluid mast cell degranulation in animal models, in a dosedependent manner. BCGE also suppressed OVAmediated guinea pig intestinal tube contraction in vitro. In addition, BCGE was found to increase the levels of interferongamma, and reduce the levels of interleukin4 and OVAsIg E levels in OVAsensitized rats. BCGE also increased levels of cyclic adenosine monophosphate and the expression of protein kinase A in mast cells separated from the abdominal cavity fluid of OVAsensitized rats. In conclusion, the results suggested that BCGE possesses antiallergic activity by inhibiting IgEinduced mast cell degranulation, providing a foundation for the development of BCGE for the treatment of mast cellmediated allergic disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.7383</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28901381">PM:28901381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\2017-16-6248-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\2017-16-6248-54.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Sun M</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.7383</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mazzucchelli,G.</style></author><author><style face="normal" font="Arial"> Holzhauser,T.</style></author><author><style face="normal" font="Arial"> Cirkovic-Velickovic,T.</style></author><author><style face="normal" font="Arial"> Diaz-Perales,A.</style></author><author><style face="normal" font="Arial"> Molina,E.</style></author><author><style face="normal" font="Arial"> Roncada,P.</style></author><author><style face="normal" font="Arial"> Rodrigues,P.</style></author><author><style face="normal" font="Arial"> Verhoeckx,K.</style></author><author><style face="normal" font="Arial"> Hoffmann-Sommergruber,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Mass Spectrometry - MolSys, Department of Chemistry, University of Liege, Liege, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Current (food) Allergenic Risk Assessment: Is It Fit for Novel Foods? Status Quo and Identification of Gaps</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic consumer</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> genetically modified organism</style></keyword><keyword><style face="normal" font="Arial"> genetically modified organisms</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Marketing</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> novel foods</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serbia</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">Food allergies are recognised as a global health concern. In order to protect allergic consumers from severe symptoms, allergenic risk assessment for well known foods and foods containing genetically modified ingredients was installed. However, population is steadily growing and there is a rising need to provide adequate protein-based foods, including novel sources, not yet used for human consumption. In this context safety issues such as a potential increased allergenic risk need to be assessed before marketing novel food sources. Therefore, the established allergenic risk assessment for genetically modified organisms needs to be re-evaluated for its applicability for risk assessment of novel food proteins. Two different scenarios of allergic sensitization have to be assessed. The first scenario is the presence of already known allergenic structures in novel foods. For this a comparative assessment can be performed and the range of cross-reactivity can be explored, while in the second scenario allergic reactions are observed towards so far novel allergenic structures and no reference material is available. This review summarises the current analytical methods for allergenic risk assessment, highlighting the strengths and limitations of each method and discussing the gaps in this assessment that need to be addressed in the near future. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Belgium -CO - Germany -CO - Serbia -CO - South Korea -CO - Spain -CO - Italy -CO - Portugal -CO - Netherlands -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201700278</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28925060">PM:28925060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170919-MazzucchelliG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170919-MazzucchelliG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Mazzucchelli G</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201700278</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jin,Y.</style></author><author><style face="normal" font="Arial"> He,X.</style></author><author><style face="normal" font="Arial"> Andoh-Kumi,K.</style></author><author><style face="normal" font="Arial"> Fraser,R.Z.</style></author><author><style face="normal" font="Arial"> Lu,M.</style></author><author><style face="normal" font="Arial"> Goodman,R.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Research and Resource Program, Dept. of Food Science &amp; Technology, University of Nebraska-Lincoln, Lincoln, 68508, NE, USA</style></auth-address><titles><title><style face="normal" font="Arial">Evaluating Potential Risks of Food Allergy and Toxicity of Soy Leghemoglobin Expressed in Pichia Pastoris</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Glycine</style></keyword><keyword><style face="normal" font="Arial"> Glycine max</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pepsin</style></keyword><keyword><style face="normal" font="Arial"> Pepsin digestion</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Pichia</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Saccharomyces</style></keyword><keyword><style face="normal" font="Arial"> Saccharomyces cerevisiae</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> Toxins</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">SCOPE: The Soybean (Glycine max) leghemoglobin c2 (LegHb) gene was introduced into Pichia pastoris yeast for sustainable production of a heme-carrying protein, for organoleptic use in plant-based meat. The potential allergenicity and toxicity of LegHb and 17 Pichia host-proteins each representing >/=1% of total protein in production batches were evaluated by literature review, bioinformatics sequence comparisons to known allergens or toxins, and in vitro pepsin digestion. METHODS AND RESULTS: Literature searches found no evidence of allergenicity or toxicity for these proteins. There were no significant sequence matches of LegHb to known allergens or toxins. Eleven Pichia proteins had modest identity matches to minor environmental allergens and thirteen Pichia proteins had significant matches to proteins from toxic sources. Yet the matched allergens and toxins had similar matches to proteins from the commonly consumed yeast Saccharomyces cerevisiae, without evidence of food allergy or toxicity. The demonstrated history of safe use indicates additional tests for allergenicity and toxicity are not needed. The LegHb and Pichia sp. proteins were rapidly digested by pepsin at pH 2. CONCLUSION: These results demonstrate that foods containing recombinant soy LegHb produced in Pichia sp. are unlikely to present an unacceptable risk of allergenicity or toxicity to consumers. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201700297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28921896">PM:28921896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170918-JinX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170918-JinX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Jin X</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201700297</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>85999</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vennemann,A.</style></author><author><style face="normal" font="Arial"> Alessandrini,F.</style></author><author><style face="normal" font="Arial"> Wiemann,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">IBE R&amp;D Institute for Lung Health gGmbH, Mendelstr. 11, 48149 Munster, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Differential Effects of Surface-Functionalized Zirconium Oxide Nanoparticles on Alveolar Macrophages, Rat Lung, and a Mouse Allergy Model</style></title><secondary-title><style face="normal" font="Arial">Nanomaterials (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nanomaterials (Basel)</style></abbr-1></periodical><pages end="" start="280">280-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glucuronidase</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Lactate Dehydrogenase</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">Nanoparticles (NPs) may affect the lung via their chemical composition on the surface. Here, we compared the bioactivity of zirconium oxide (ZrO(2)) NPs coated with either aminopropilsilane (APTS), tetraoxidecanoic acid (TODS), polyethyleneglycol (PGA), or acrylic acid (Acryl). Supernatants from NPs-treated cultured alveolar macrophages (NR8383) tested for lactate dehydrogenase, glucuronidase, tumor necrosis factor alpha, and H(2)O(2) formation revealed dose-dependent effects, with only gradual differences among particles whose gravitational settling and cellular uptake were similar. We selected</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 2079-4991 (Print)IS - 2079-4991 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3390/nano7090280</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28925985">PM:28925985</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nanomaterials (Basel)\2017-7-280.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nanomaterials (Basel)\2017-7-280.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Vennemann A</style></custom2><misc3><style face="normal" font="Arial">10.3390/nano7090280</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86000</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weller,P.F.</style></author><author><style face="normal" font="Arial"> Spencer,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Inflammation, Harvard Medical School, Beth Israel Deaconess Medical Center, CLS 943, 330 Brookline Avenue, Boston, Massachusetts 02215, USADivision of Allergy and Inflammation, Harvard Medical School, Beth Israel Deaconess Medical Center, CLS 943, 330 Brookline Avenue, Boston, Massachusetts 02215, USA</style></auth-address><titles><title><style face="normal" font="Arial">Functions of tissue-resident eosinophils</style></title><secondary-title><style face="normal" font="Arial">Nat Rev Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nat Rev Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and inflammation</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Cytoplasmic Granules</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Tissue Distribution</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">Eosinophils are a prominent cell type in particular host responses such as the response to helminth infection and allergic disease. Their effector functions have been attributed to their capacity to release cationic proteins stored in cytoplasmic granules by degranulation. However, eosinophils are now being recognized for more varied functions in previously underappreciated diverse tissue sites, based on the ability of eosinophils to release cytokines (often preformed) that mediate a broad range of activities into the local environment. In this Review, we consider evolving insights into the tissue distribution of eosinophils and their functional immunobiology, which enable eosinophils to secrete in a selective manner cytokines and other mediators that have diverse, 'non-effector' functions in health and disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1474-1741 (Electronic)IS - 1474-1733 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/nri.2017.95</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28891557">PM:28891557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Rev Immunol\20170911-WellerPF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Rev Immunol\20170911-WellerPF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Weller PF</style></custom2><misc3><style face="normal" font="Arial">10.1038/nri.2017.95</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wallrapp,A.</style></author><author><style face="normal" font="Arial"> Riesenfeld,S.J.</style></author><author><style face="normal" font="Arial"> Burkett,P.R.</style></author><author><style face="normal" font="Arial"> Abdulnour,R.E.</style></author><author><style face="normal" font="Arial"> Nyman,J.</style></author><author><style face="normal" font="Arial"> Dionne,D.</style></author><author><style face="normal" font="Arial"> Hofree,M.</style></author><author><style face="normal" font="Arial"> Cuoco,M.S.</style></author><author><style face="normal" font="Arial"> Rodman,C.</style></author><author><style face="normal" font="Arial"> Farouq,D.</style></author><author><style face="normal" font="Arial"> Haas,B.J.</style></author><author><style face="normal" font="Arial"> Tickle,T.L.</style></author><author><style face="normal" font="Arial"> Trombetta,J.J.</style></author><author><style face="normal" font="Arial"> Baral,P.</style></author><author><style face="normal" font="Arial"> Klose,C.S.N.</style></author><author><style face="normal" font="Arial"> Mahlakoiv,T.</style></author><author><style face="normal" font="Arial"> Artis,D.</style></author><author><style face="normal" font="Arial"> Rozenblatt-Rosen,O.</style></author><author><style face="normal" font="Arial"> Chiu,I.M.</style></author><author><style face="normal" font="Arial"> Levy,B.D.</style></author><author><style face="normal" font="Arial"> Kowalczyk,M.S.</style></author><author><style face="normal" font="Arial"> Regev,A.</style></author><author><style face="normal" font="Arial"> Kuchroo,V.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="Arial">The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation</style></title><secondary-title><style face="normal" font="Arial">Nature</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nature</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunologic Diseases</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Massachusetts</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Neuroimmune</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">Type 2 innate lymphoid cells (ILC2s) both contribute to mucosal homeostasis and initiate pathologic inflammation in allergic asthma. However, the signals that direct ILC2s to promote homeostasis versus inflammation are unclear. To identify such molecular cues, we profiled mouse lung-resident ILCs using single-cell RNA sequencing at steady state and after in vivo stimulation with the alarmin cytokines IL-25 and IL-33. ILC2s were transcriptionally heterogeneous after activation, with subpopulations distinguished by expression of proliferative, homeostatic and effector genes. The neuropeptide receptor Nmur1 was preferentially expressed by ILC2s at steady state and after IL-25 stimulation. Neuromedin U (NMU), the ligand of NMUR1, activated ILC2s in vitro, and in vivo co-administration of NMU with IL-25 strongly amplified allergic inflammation. Loss of NMU-NMUR1 signalling reduced ILC2 frequency and effector function, and altered transcriptional programs following allergen challenge in vivo. Thus, NMUR1 signalling promotes inflammatory ILC2 responses, highlighting the importance of neuro-immune crosstalk in allergic inflammation at mucosal surfaces</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1476-4687 (Electronic)IS - 0028-0836 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/nature24029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28902842">PM:28902842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nature\20170913-WallrappA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nature\20170913-WallrappA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Wallrapp A</style></custom2><misc3><style face="normal" font="Arial">10.1038/nature24029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sherson,D.</style></author><author><style face="normal" font="Arial"> Nielsen,A.D.</style></author><author><style face="normal" font="Arial"> Mortz,C.G.</style></author><author><style face="normal" font="Arial"> Vestergaard,L.</style></author><author><style face="normal" font="Arial"> Brandt,L.P.A.</style></author><author><style face="normal" font="Arial"> Jors,E.</style></author><author><style face="normal" font="Arial"> Baelum,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Occupational and Environmental Medicine, Odense University Hospital, DK-5000 Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Occupational rhinoconjunctivitis caused by the common indoor plant, Hoya compacta</style></title><secondary-title><style face="normal" font="Arial">Occup Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Occup Med (Lond)</style></full-title></periodical><pages end="492" start="490">490-492</pages><volume><style face="normal" font="Arial">67</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acoustic rhinometry</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lettuce</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational physician</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenges</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="Arial">Background: Allergic reactions to the common house plant Hoya compacta (HC) have not previously been described. Aims: To confirm HC as the cause of rhinoconjunctivitis in three horticultural workers. Methods: Greenhouse working conditions were reproduced in our challenge chamber. Results: All three cases developed rhinoconjunctivitis when working with HC plants. A control challenge was performed in two cases with iceberg lettuce causing no symptoms. Nasal volume measured by acoustic rhinometry (AR) fell after all three active challenges, but also after one of the control challenges. Conclusions: Our study confirms that HC may cause occupational rhinoconjunctivitis and asthma through a Type I hypersensitivity reaction. Specific inhalation challenges, nasal nitric oxide measurement and AR may be useful additional tools in supporting such diagnoses for occupational physicians to consider</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1471-8405 (Electronic)IS - 0962-7480 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1093/occmed/kqx095</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28898962">PM:28898962</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Occup Med (Lond)\2017-67-490-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Occup Med (Lond)\2017-67-490-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Sherson D</style></custom2><misc3><style face="normal" font="Arial">10.1093/occmed/kqx095</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sugiura,S.</style></author><author><style face="normal" font="Arial"> Matsui,T.</style></author><author><style face="normal" font="Arial"> Furuta,T.</style></author><author><style face="normal" font="Arial"> Sasaki,K.</style></author><author><style face="normal" font="Arial"> Kando,N.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Aichi Children's Health and Medical Center, Obu, Aichi, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Development of a prediction model for severe wheat allergy</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold dose</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">The purpose of oral food challenges (OFCs) has gradually transformed from a definitive diagnosis of a food allergy to determining the threshold dose of food allergens at the beginning of oral immunotherapy (OIT) or the amount of minimal intake, which has recently come to be considered a better method of managing IgE-mediated food allergy [1][2]. However, OFCs in patients with severe food allergies, defined as low-threshold and severe reactions, carry a risk of triggering anaphylaxis. To predict such severe reactions before OIT, we previously reported prediction models consisting of multiple factors for hen's egg [3] and cow's milk [4] allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12806</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892577">PM:28892577</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170911-SugiuraS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170911-SugiuraS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Sugiura S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12806</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Filipiak-Pittroff,B.</style></author><author><style face="normal" font="Arial"> Koletzko,S.</style></author><author><style face="normal" font="Arial"> Kramer,U.</style></author><author><style face="normal" font="Arial"> Standl,M.</style></author><author><style face="normal" font="Arial"> Bauer,C.P.</style></author><author><style face="normal" font="Arial"> Berdel,D.</style></author><author><style face="normal" font="Arial"> Von Berg,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Marien Hospital Wesel, Department of Pediatrics, Wesel, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Full breastfeeding and allergies from infancy until adolescence in the GINIplus cohort</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">Breastfeeding has major benefits on infant health outcomes and their physical and mental development, but the effect on allergic disease risk remains controversial (1-3). We used the large GINIplus cohort (4) to study short and long term effects of full breastfeeding during the first 4 months compared to formula or mixed feeding on the occurrence of eczema, allergic rhinitis and asthma from birth up to age of 15 years. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12798</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881061">PM:28881061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170907-FilipiakPittroffB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170907-FilipiakPittroffB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Filipiak-Pittroff B</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12798</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eijsvoogel,N.B.</style></author><author><style face="normal" font="Arial"> Hollegien,M.I.</style></author><author><style face="normal" font="Arial"> Bok,L.A.</style></author><author><style face="normal" font="Arial"> Derksen-Lubsen,G.</style></author><author><style face="normal" font="Arial"> Dikken,F.P.J.</style></author><author><style face="normal" font="Arial"> Leenders,A.C.A.P.</style></author><author><style face="normal" font="Arial"> Pijning,A.</style></author><author><style face="normal" font="Arial"> Post,E.D.M.</style></author><author><style face="normal" font="Arial"> Wojciechowski,M.</style></author><author><style face="normal" font="Arial"> Schmitz,R.</style></author><author><style face="normal" font="Arial"> Hilbink,M.</style></author><author><style face="normal" font="Arial"> de Vries,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Jeroen Bosch Hospital, 's-Hertogenbosch</style></auth-address><titles><title><style face="normal" font="Arial">Lower percentage of allergic sensitization in children with Down syndrome</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Down Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">Children with Down syndrome (DS) often suffer from respiratory symptoms like wheezing, cough and dyspnea, especially in their preschool years(1). Healthcare professionals (and parents) often associate these symptoms with allergy or asthma(1-3), and prescribe anti-allergic and anti-asthmatic medication, especially in young DS children(3). Literature shows that allergic sensitization is present in around 27 to 40% of children in western countries(4-7). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Netherlands -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12796</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881053">PM:28881053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170907-EijsvoogelNB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170907-EijsvoogelNB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Eijsvoogel NB</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12796</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Lejeune,S.</style></author><author><style face="normal" font="Arial"> Dupond,M.P.</style></author><author><style face="normal" font="Arial"> Renard,A.</style></author><author><style face="normal" font="Arial"> Fallot,C.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Children's Hospital, 59100, Roubaix, France</style></auth-address><titles><title><style face="normal" font="Arial">Individual healthcare plan for allergic children at school: lessons from a 2015-2016 school year survey</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency action plan</style></keyword><keyword><style face="normal" font="Arial"> emergency kit</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nurseries</style></keyword><keyword><style face="normal" font="Arial"> office</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">The Individual Healthcare Plan (IHP) was implemented in schools in France in 2003 to improve management of allergic children. Our objectives were to assess the practical aspects of IHP (excluding asthma) and allergic reactions occurring at school. METHODS: Prospective study conducted in the North Department (France) during the 2015/2016 school-year. Two questionnaires were developed: one for the school doctors (n=67) and one for the school principals (n=2372). RESULTS: Data from 336 (25%) of the 1325 IHPs (0.24% of children) were collected [mean age: 8 years; food allergy (FA): 94% (peanut=44%, nuts=54%), venom: 4%]. Wide variations in emergency kit (EK) medications were observed: antihistamines (84%), oral corticosteroids (79%), adrenaline auto-injectors (70%), inhaled bronchodilators (65%). 670 (28%) school principals' responses, representing 81% of all IHPs, were analyzed. A total of 1935 EKs were stored (mean: 2.8/school), one or more with adrenaline, by 213 (32%) schools: in the class room (33%), the nursery (14%), or the principal's office (10%). Sixty, mainly mild to moderate allergic reactions (adrenaline injection: 2) occurred in 44 schools (0.09/school/y), in children with previously undocumented allergy in 50%. FA was highly suspected in 92%. CONCLUSION: IHP is mainly implemented for FA. Anaphylaxis remains rare in the school setting and FA is often a suspected cause of reaction. Staff training should be improved. Application of the recommendations regarding the content and accessibility of EK and a widespread emergency action plan are needed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170907IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12795</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881055">PM:28881055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170907-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170907-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170907, Pouessel G</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12795</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Halken,S.</style></author><author><style face="normal" font="Arial"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> Angier,E.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Ryan,D.D.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Geerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author><author><style face="normal" font="Arial"> Pajno,G.B.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Penagos,M.</style></author><author><style face="normal" font="Arial"> Santos,A.F.</style></author><author><style face="normal" font="Arial"> Sturm,G.J.</style></author><author><style face="normal" font="Arial"> Timmermans,F.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Varga,E.M.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Kristiansen,M.</style></author><author><style face="normal" font="Arial"> Dhami,S.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Muraro,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="745" start="728">728-745</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peer Review</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for prevention of i) development of allergic comorbidities in those with established allergic diseases, ii) development of first allergic condition and iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research &amp; Evaluation (AGREE II) framework, which involved a multi-disciplinary expert working group, a systematic review of the underpinning evidence and external peer-review of draft recommendations. Our key recommendation is that a three year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate to severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to two years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than two years post AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease or for prevention of allergic co-morbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease modifying treatment exists but there is an urgent need for more high-quality clinical trials. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -CO - Mexico -CO - United Kingdom -CO - Germany -CO - Romania -CO - Spain -CO - Italy -CO - Netherlands -CO - Poland -CO - Greece -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28902467">PM:28902467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170913-HalkenS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170913-HalkenS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Halken S</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12807</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Namara,B.</style></author><author><style face="normal" font="Arial"> Nash,S.</style></author><author><style face="normal" font="Arial"> Lule,S.A.</style></author><author><style face="normal" font="Arial"> Akurut,H.</style></author><author><style face="normal" font="Arial"> Mpairwe,H.</style></author><author><style face="normal" font="Arial"> Akello,F.</style></author><author><style face="normal" font="Arial"> Tumusiime,J.</style></author><author><style face="normal" font="Arial"> Kizza,M.</style></author><author><style face="normal" font="Arial"> Kabagenyi,J.</style></author><author><style face="normal" font="Arial"> Nkurunungi,G.</style></author><author><style face="normal" font="Arial"> Muhangi,L.</style></author><author><style face="normal" font="Arial"> Webb,E.L.</style></author><author><style face="normal" font="Arial"> Muwanga,M.</style></author><author><style face="normal" font="Arial"> Elliott,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MRC/UVRI Uganda Research Unit, P.O. Box 49, Entebbe, Uganda</style></auth-address><titles><title><style face="normal" font="Arial">Effects of treating helminths during pregnancy and early childhood on risk of allergy-related outcomes: follow up of a randomized controlled trial</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Albendazole</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> helminth infection</style></keyword><keyword><style face="normal" font="Arial"> Helminth infections</style></keyword><keyword><style face="normal" font="Arial"> Helminths</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Income</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Low income</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Praziquantel</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Uganda</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Helminth infections, common in low income countries, may protect against allergy-related disease. Early exposure may be key. In the Entebbe Mother and Baby Study, treating helminths during pregnancy resulted in increased eczema rates in early childhood. We followed the cohort to determine whether this translated to increased asthma rates at school-age. METHODS: This randomized, double-blind, placebo-controlled trial, conducted in Entebbe, Uganda, had three interventions. During pregnancy, women were randomized, simultaneously, to albendazole versus placebo and to praziquantel versus placebo. Their children were independently randomized to quarterly albendazole versus placebo from age 15 months to five years.We here report follow up to age nine years. Primary outcomes at nine years were recent reported wheeze, skin prick test positivity (SPT) to common allergens, and allergen-specific IgE positivity to dust mite or cockroach. Secondary outcomes were doctor-diagnosed asthma and eczema rates between five and nine years, recent eczema, rhinitis, and urticaria at nine years, and SPT and IgE responses to individual allergens. RESULTS: 2507 pregnant women were enrolled; 1215 children were seen at age nine, of whom 1188 are included in this analysis. Reported wheeze was rare at nine years (3.7%) while SPT positivity (25.0%) and IgE positivity (44.1%) were common. There was no evidence of a treatment effect for any of the three interventions on any of the primary outcomes. CONCLUSIONS: Prenatal and early life treatment of helminths, in the absence of change in other exposures, is unlikely to increase the risk of atopic diseases later in childhood in this tropical, low-income setting. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Uganda -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12804</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892575">PM:28892575</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170911-NamaraB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20170911-NamaraB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Namara B</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12804</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tse,S.M.</style></author><author><style face="normal" font="Arial"> Samson,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1Division of Respiratory Medicine, Department of Pediatrics, Sainte-Justine University Hospital Center and University of Montreal, Montreal, QC, Canada. 2Department of Statistics, University of British Columbia, Vancouver, BC, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Time to Asthma-Related Readmission in Children Admitted to the ICU for Asthma</style></title><secondary-title><style face="normal" font="Arial">Pediatr Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Length of Stay</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To compare the time to asthma-related readmissions between children with a previous ICU hospitalization for asthma and those with a non-ICU hospitalization and to explore predictors of time to readmission in children admitted to the ICU. DESIGN: Retrospective cohort study using a pan-Canadian administrative inpatient database from April 1, 2008, to March 31, 2014. SETTING: All adult and pediatric Canadian hospitals. SUBJECTS: Children 2-17 years old with a hospitalization for asthma. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 26,168 children were hospitalized 33,304 times during the study period. The time to readmission was shorter in the ICU group compared with the non-ICU group (median time to readmission 27 mo in ICU vs 35 mo in non-ICU group). Preschool-aged children (hazard ratio, 1.48; 95% CI, 1.02-2.14) and increased length of stay (hazard ratio, 1.63; 95% CI, 1.17-2.27) were associated with a shorter time to readmission. CONCLUSIONS: Children previously admitted to the ICU for asthma had a shorter time to asthma-related readmission, compared with children who did not require intensive care, underlining the importance of targeted long-term postdischarge follow-up of these children. Children of preschool age and who have a lengthier hospital stay are particularly at risk for future morbidity</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1529-7535 (Print)IS - 1529-7535 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1097/PCC.0000000000001336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28922266">PM:28922266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Crit Care Med\20170918-TseSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Crit Care Med\20170918-TseSM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Tse SM</style></custom2><misc3><style face="normal" font="Arial">10.1097/PCC.0000000000001336</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lim,N.R.</style></author><author><style face="normal" font="Arial"> Lohman,M.E.</style></author><author><style face="normal" font="Arial"> Lio,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Elimination Diets in Atopic Dermatitis-A Comprehensive Review</style></title><secondary-title><style face="normal" font="Arial">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Dermatol</style></full-title></periodical><pages end="527" start="516">516-527</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Illinois</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Minerals</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/OBJECTIVES: Diet is a common concern for individuals with atopic dermatitis (AD) and their families. Studies regarding the effect of dietary interventions on AD exist, but many are limited by small size and poor design. Conflicting results present a challenge to clinicians seeking to counsel patients. The aim of the current review is to examine the published literature and generate helpful conclusions for clinicians faced with dietary questions in AD. METHODS: A PubMed search was performed focusing on dietary interventions for AD in children and adults through July 2016. The search was limited to the English language and included studies that evaluated one or more forms of dietary modification for the treatment of AD. Studies of supplementation, such as with vitamins, minerals, or probiotics, were not included, nor were studies on prevention of the development of AD. A total of 43 articles met the inclusion criteria and were included in the final analysis. RESULTS: Trials varied in type, duration, and the AD patient populations studied. Overall, there is some level I evidence to support specific exclusion diets in preselected patients but insufficient evidence for strict elimination diets (diets that are typically limited to six to eight foods). Data supporting other interventions are mixed and based on small, poorly designed studies. CONCLUSIONS: A comprehensive literature review reveals some promising results and several areas in need of further study. More evidence is needed to form a strong foundation for recommendations regarding the utility and role of elimination diets in AD management, but current evidence suggests that strict diet management is not effective in the treatment AD in the vast majority of patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/pde.13244</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28884902">PM:28884902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Dermatol\2017-34-516-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Dermatol\2017-34-516-27.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Lim NR</style></custom2><misc3><style face="normal" font="Arial">10.1111/pde.13244</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Laino,A.</style></author><author><style face="normal" font="Arial"> Lopez-Zavala,A.A.</style></author><author><style face="normal" font="Arial"> Garcia-Orozco,K.D.</style></author><author><style face="normal" font="Arial"> Carrasco-Miranda,J.S.</style></author><author><style face="normal" font="Arial"> Santana,M.</style></author><author><style face="normal" font="Arial"> Stojanoff,V.</style></author><author><style face="normal" font="Arial"> Sotelo-Mundo,R.R.</style></author><author><style face="normal" font="Arial"> Garcia,C.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto de Investigaciones Bioquimicas de La Plata "Dr. Prof. Rodolfo R. Brenner", Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Biochemical and structural characterization of a novel arginine kinase from the spider Polybetes pythagoricus</style></title><secondary-title><style face="normal" font="Arial">PeerJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">PeerJ</style></full-title></periodical><pages end="" start="e3787">e3787-</pages><volume><style face="normal" font="Arial">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Arginine kinase</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Ecosystem</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Energy Metabolism</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Invertebrates</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Nucleotides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Spiders</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Energy buffering systems are key for homeostasis during variations in energy supply. Spiders are the most important predators for insects and therefore key in terrestrial ecosystems. From biomedical interest, spiders are important for their venoms and as a source of potent allergens, such as arginine kinase (AK, EC 2.7.3.3). AK is an enzyme crucial for energy metabolism, keeping the pool of phosphagens in invertebrates, and also an allergen for humans. In this work, we studied AK from the Argentininan spider Polybetes pythagoricus (PpAK), from its complementary DNA to the crystal structure. The PpAK cDNA from muscle was cloned, and it is comprised of 1068 nucleotides that encode a 384-amino acids protein, similar to other invertebrate AKs. The apparent Michaelis-Menten kinetic constant (Km ) was 1.7 mM with a kcat of 75 s-1. Two crystal structures are presented, the apoPvAK and PpAK bound to arginine, both in the open conformation with the active site lid (residues 310-320) completely disordered. The guanidino group binding site in the apo structure appears to be organized to accept the arginine substrate. Finally, these results contribute to knowledge of mechanistic details of the function of arginine kinase</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 2167-8359 (Print)LA - engPT - Journal ArticleCO - Argentina -CO - Mexico -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.7717/peerj.3787</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28924503">PM:28924503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PeerJ\2017-5-e3787.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PeerJ\2017-5-e3787.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Laino A</style></custom2><misc3><style face="normal" font="Arial">10.7717/peerj.3787</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mazzeranghi,F.</style></author><author><style face="normal" font="Arial"> Zanotti,C.</style></author><author><style face="normal" font="Arial"> Di Cerbo,A.</style></author><author><style face="normal" font="Arial"> Verstegen,J.P.</style></author><author><style face="normal" font="Arial"> Cocco,R.</style></author><author><style face="normal" font="Arial"> Guidetti,G.</style></author><author><style face="normal" font="Arial"> Canello,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical efficacy of nutraceutical diet for cats with clinical signs of cutaneus adverse food reaction (CAFR)</style></title><secondary-title><style face="normal" font="Arial">Pol J Vet Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pol J Vet Sci</style></full-title></periodical><pages end="276" start="269">269-276</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adverse food reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous adverse food reactions</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food intolerance</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nutraceutical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> Stomatitis</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="Arial">Food allergies and food intolerances are clinically difficult to discriminate. Most often, along with cutaneous adverse food reactions or CAFR, they are classified as adverse food reactions, whose causes are numerous, including toxic compounds. Eighteen indoor-housed domestic cats with evident clinical symptoms related to CAFR (drooling, back and neck intense itching, neck eczema, chronic conjunctivitis and stomatitis) involving skin lesions were studied. Cytological evaluations of ear, skin and gingival swabs revealed an increased turnover of keratinocytes while the oxytetracycline ELISA determination showed an unexpected high amount of oxytetracycline in all cats at the first visit. All cats were then randomly assigned to receive a standard (SD group) or a nutraceutical diet (ND group) for 60 days. In the ND group a significant reduction of the mean serum concentration of oxytetracycline, pruritus intensity and skin lesion severity (**p&lt;0.01, ***p&lt;0.001, and ***p&lt;0.001, respectively) was observed after 60 days, and associated with a significant improvement in the clinical picture. Although a direct correlation between oxytetracycline presence within cat sera and CAFR-related symptoms has never been described, this study highlights the benefit of a specific nutraceutical diet supplementation in improving clinical symptoms and skin lesions in cats with CARF</style></abstract><notes><style face="normal" font="Arial">DA - 20170902IS - 1505-1773 (Print)IS - 1505-1773 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1515/pjvs-2017-0032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865210">PM:28865210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Vet Sci\2017-20-269-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Vet Sci\2017-20-269-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Mazzeranghi F</style></custom2><misc3><style face="normal" font="Arial">10.1515/pjvs-2017-0032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Doras,C.</style></author><author><style face="normal" font="Arial"> Petak,F.</style></author><author><style face="normal" font="Arial"> Bayat,S.</style></author><author><style face="normal" font="Arial"> Baudat,A.</style></author><author><style face="normal" font="Arial"> von Garnier,C.</style></author><author><style face="normal" font="Arial"> Eigenmann,P.</style></author><author><style face="normal" font="Arial"> Habre,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Anaesthesiological Investigations Unit, University Hospitals of Geneva, Geneva, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">LUNG RESPONSES IN MURINE MODELS OF EXPERIMENTAL ASTHMA: VALUE OF HOUSE DUST MITE OVER OVALBUMIN SENSITIZATION</style></title><secondary-title><style face="normal" font="Arial">Respir Physiol Neurobiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Respir Physiol Neurobiol</style></full-title></periodical><pages end="51" start="43">43-51</pages><volume><style face="normal" font="Arial">247</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modelling</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Natural allergen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">Ovalbumin (OVA) sensitization has limitations in modelling asthma. Thus, we examined the value of allergic sensitization using a purified natural allergen, house dust mite (HDM), over the sensitization performed with OVA. Mice were sham-treated, or sensitized with OVA- or HDM with identical chronology. Airway resistance, tissue damping and elastance were assessed under control conditions and after challenging the animals with methacholine (MCh) and the specific allergen. Inflammatory profile of the bronchoalveolar lavage fluid was characterized and lung histology was performed. While no difference in the lung responsiveness to the specific allergen was noted, hyperresponsiveness to MCh was observed only in the HDM-sensitized animals in the lung peripheral parameters. Lung inflammation differed between the models, but excessive bronchial smooth muscle remodelling occurred only with OVA. In conclusion, we demonstrate that a purified natural allergen offers a more relevant murine model of human allergic asthma by expressing the key features of this chronic inflammatory disease both in the lung function and structure</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 1878-1519 (Electronic)IS - 1569-9048 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Hungary -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.resp.2017.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890402">PM:28890402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Physiol Neurobiol\20170911-DorasC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Physiol Neurobiol\20170911-DorasC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Doras C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.resp.2017.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Benkalfate,N.</style></author><author><style face="normal" font="Arial"> Dirou,S.</style></author><author><style face="normal" font="Arial"> Germaud,P.</style></author><author><style face="normal" font="Arial"> Cavailles,A.</style></author><author><style face="normal" font="Arial"> Pigeanne,T.</style></author><author><style face="normal" font="Arial"> Robert,M.</style></author><author><style face="normal" font="Arial"> Corne,F.</style></author><author><style face="normal" font="Arial"> Cellerin,L.</style></author><author><style face="normal" font="Arial"> Sagan,C.</style></author><author><style face="normal" font="Arial"> Magnan,A.</style></author><author><style face="normal" font="Arial"> Blanc,F.X.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Atélectasie complète dans l'aspergillose bronchopulmonaire allergique : une entité rare à ne pas méconnaître</style></title><secondary-title><style face="normal" font="Arial">Rev Mal Respir</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Mal Respir</style></full-title></periodical><pages end="784" start="783">783-784</pages><volume><style face="normal" font="Arial">34</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergique</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0761-8425</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rmr.2017.07.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.rmr.2017.07.006</url></web-urls><pdf-urls><url ppv-ref="no">stephanie.dirou@chu-nantes.fr</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Benkalfate N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rmr.2017.07.006</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Izquierdo-Dominguez,A.</style></author><author><style face="normal" font="Arial"> Jauregui,I.</style></author><author><style face="normal" font="Arial"> del Cuvillo,A.</style></author><author><style face="normal" font="Arial"> Montoro,J.</style></author><author><style face="normal" font="Arial"> Davila,I.</style></author><author><style face="normal" font="Arial"> Sastre,J.</style></author><author><style face="normal" font="Arial"> Bartra,J.</style></author><author><style face="normal" font="Arial"> Ferrer,M.</style></author><author><style face="normal" font="Arial"> Alobid,I.</style></author><author><style face="normal" font="Arial"> Mullol,J.</style></author><author><style face="normal" font="Arial"> Valero,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Servicio de Alergologia, Consorci Sanitari de Terrassa and Clinica Diagonal, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Allergy rhinitis: similarities and differences between children and adults</style></title><secondary-title><style face="normal" font="Arial">Rhinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rhinology</style></full-title></periodical><pages end="331" start="326">326-331</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> visual analogue scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="9" Month="9" Year="2017">2017/9/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) is a highly prevalent disease worldwide. Although a number of studies have described AR, no studies compared children and adult AR populations. The objective was to compare the AR characteristics between two AR cohorts of children and adults. METHODS: Two AR cohorts (children and adults) from Spain were studied through observational cross-sectional multicentre studies. AR was classified based on classical (allergen exposure), original (o-ARIA), and modified (m-ARIA) ARIA criteria. AR was evaluated by Total 4-Symptoms Score (T4SS), and disease severity by Visual Analogue Scale (VAS, 0-100 mm). AR comorbidities were also evaluated. RESULTS: A total of 5,405 patients (1,275 children, 4,130 adults) were studied. According to symptoms duration, intermittent AR was more frequent in children than in adults. Using o-ARIA severity, more children than adults had moderate/severe AR while, using m-ARIA, more children than adults had severe AR. T4SS was higher in adults than in children. Moreover, VAS was also higher in adults than in children. In addition, asthma atopic dermatitis and conjunctivitis were more associated to children than adults with AR, the frequency of this comorbidities increasing according to higher severity. CONCLUSIONS: AR in children was more intermittent, severe, with less symptoms but with more comorbidities than in adults. These results suggest AR has similarities but also significant differences between children and adults</style></abstract><notes><style face="normal" font="Arial">DA - 20170909IS - 0300-0729 (Print)IS - 0300-0729 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.4193/Rhin17.074</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28887880">PM:28887880</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rhinology\2017-55-326-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rhinology\2017-55-326-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170909, Izquierdo-Dominguez A</style></custom2><misc3><style face="normal" font="Arial">10.4193/Rhin17.074</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schuelke,S.</style></author><author><style face="normal" font="Arial"> Kuttich,K.</style></author><author><style face="normal" font="Arial"> Wolfheimer,S.</style></author><author><style face="normal" font="Arial"> Duschek,N.</style></author><author><style face="normal" font="Arial"> Wangorsch,A.</style></author><author><style face="normal" font="Arial"> Reuter,A.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Pablos,I.</style></author><author><style face="normal" font="Arial"> Gadermaier,G.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Toda,M.</style></author><author><style face="normal" font="Arial"> Scheurer,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section Molecular Allergology, Paul-Ehrlich-Institut, Langen, Hessen, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11782">11782-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status date="09/23/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Art v 1</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Compositae</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Feverfew</style></keyword><keyword><style face="normal" font="Arial"> Fusion protein</style></keyword><keyword><style face="normal" font="Arial"> fusion proteins</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hypoallergen</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic variant</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding capacity</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">Allergies to weed pollen including members of the Compositae family, such as mugwort, ragweed, and feverfew are spreading worldwide. To efficiently treat these newly arising allergies, allergen specific immunotherapy needs to be improved. Therefore, we generated novel vaccine candidates consisting of the TLR5-ligand Flagellin A from Listeria and the major mugwort allergen Art v 1 including either the wild type Art v 1 sequence (rFlaA:Artv1) or a hypoallergenic variant (rFlaA:Artv1hyp) with reduced IgE-binding capacity. Immune modulating capacity of these constructs and respective controls was evaluated in vitro and in vivo. Incorporation of hypoallergenic Art v 1 derivative did not interfere with the resulting fusion proteins' immune stimulatory capacity. Both rFlaA:Artv1 and rFlaA:Artv1hyp induced a prominent, mTOR-dependent, IL-10 secretion from murine dendritic cells, and suppressed allergen-specific TH2-cytokine secretion in vitro and in vivo. Both conjugates retained the capacity to induce rFlaA-specific antibody responses while efficiently inducing production of Art v 1-specific IgG1 and IgG2a antibodies in mice. Interestingly, only the suppression of TH2-cytokine secretion by rFlaA:Artv1 (but not rFlaA:Artv1hyp) was paralleled by a strong secretion of IFN-gamma. In summary, we provided evidence that incorporating hypoallergens into flagellin:allergen fusion proteins is a suitable strategy to further improve these promising vaccine candidates</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-11972-w</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28924222">PM:28924222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11782.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11782.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Schuelke S</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-11972-w</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Campana,R.</style></author><author><style face="normal" font="Arial"> Moritz,K.</style></author><author><style face="normal" font="Arial"> Neubauer,A.</style></author><author><style face="normal" font="Arial"> Huber,H.</style></author><author><style face="normal" font="Arial"> Henning,R.</style></author><author><style face="normal" font="Arial"> Brodie,T.M.</style></author><author><style face="normal" font="Arial"> Kaider,A.</style></author><author><style face="normal" font="Arial"> Sallusto,F.</style></author><author><style face="normal" font="Arial"> Wohrl,S.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, AustriaDivision of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, AustriaBiomay AG, Vienna Competence Center, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11657">11657-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen molecule</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Atopy Patch testing</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">The effects of epicutaneous allergen administration on systemic immune responses in allergic and non-allergic individuals has not been investigated with defined allergen molecules. We studied the effects of epicutaneous administration of rBet v 1 and rBet v 1 fragments on systemic immune responses in allergic and non-allergic subjects. We conducted a clinical trial in which rBet v 1 and two hypoallergenic rBet v 1 fragments were applied epicutaneously by atopy patch testing (APT) to 15 birch pollen (bp) allergic patients suffering from atopic dermatitis, 5 bp-allergic patients suffering from rhinoconjunctivitis only, 5 patients with respiratory allergy without bp allergy and 5 non-allergic individuals. Epicutaneous administration of rBet v 1 and rBet v 1 fragments led to strong and significant increases of allergen-specific T cell proliferation (CLA+ and CCR4+T cell responses) only in bp-allergic patients with a positive APT reaction. There were no relevant changes of Bet v 1-specific IgE and IgG responses. No changes were noted in allergic subjects without bp allergy and in non-allergic subjects. Epicutaneous allergen application boosts specific T cell but not antibody responses mainly in allergic, APT-positive patients suggesting IgE-facilitated allergen presentation as mechanism for its effects on systemic allergen-specific immune responses</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-10278-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28912492">PM:28912492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11657.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11657.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Campana R</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-10278-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Raijmakers,R.P.H.</style></author><author><style face="normal" font="Arial"> Sprenkeler,E.G.G.</style></author><author><style face="normal" font="Arial"> Aleva,F.E.</style></author><author><style face="normal" font="Arial"> Jacobs,C.W.M.</style></author><author><style face="normal" font="Arial"> Kanneganti,T.D.</style></author><author><style face="normal" font="Arial"> Joosten,L.A.B.</style></author><author><style face="normal" font="Arial"> van de Veerdonk,L.</style></author><author><style face="normal" font="Arial"> Gresnigt,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Experimental Internal Medicine and Radboud Center for Infectious diseases (RCI), Radboud University Medical Center, Geert Grooteplein zuid 8, 6525GA, Nijmegen, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Toll-like receptor 2 induced cytotoxic T-lymphocyte-associated protein 4 regulates Aspergillus-induced regulatory T-cells with pro-inflammatory characteristics</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11500">11500-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> CTLA4</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> obstructive</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> regulatory T-cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> Th17 response</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptor 2</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">Patients with cystic fibrosis, chronic obstructive pulmonary disease, severe asthma, pre-existing pulmonary lesions, and severely immunocompromised patients are susceptible to develop infections with the opportunistic pathogenic fungus Aspergillus fumigatus, called aspergillosis. Infections in these patients are associated with persistent pro-inflammatory T-helper (TH)2 and TH17 responses. Regulatory T-cells, natural suppressor cells of the immune system, control pro-inflammatory T-cell responses, but can also contribute to disease by shifting to a pro-inflammatory TH17-like phenotype. Such a shift could play an important role in the detrimental immunopathology that is seen in aspergillosis. Our study demonstrates that Aspergillus fumigatus induces regulatory T-cells with a TH17-like phenotype. We also demonstrate that these regulatory T-cells with a pro-inflammatory TH17-like phenotype can be reprogrammed to their "classical" anti-inflammatory phenotype by activating Toll-like receptor 2 (TLR2), which regulates the induction of cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Similarly, soluble CTLA4 could reverse the pro-inflammatory phenotype of Aspergillus-induced regulatory T-cells. In conclusion, our results suggest a role for regulatory T-cells with a pro-inflammatory TH17-like phenotype in Aspergillus-associated immunopathology, and identifies key players, i.e. TLR2 and CTLA4, involved in this mechanism</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-11738-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28904353">PM:28904353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11500.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11500.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170914, Raijmakers RP</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-11738-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Elaziz,M.A.</style></author><author><style face="normal" font="Arial"> Hemdan,A.M.</style></author><author><style face="normal" font="Arial"> Hassanien,A.</style></author><author><style face="normal" font="Arial"> Oliva,D.</style></author><author><style face="normal" font="Arial"> Xiong,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Computer Science and Technology, Wuhan University of Technology, Wuhan, China.</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of Bioactive Amino Acids from Fish Hydrolysates with a New Bioinformatic Intelligent System Approach</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="10860">10860-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish protein hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Nutritional quality</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein hydrolysate</style></keyword><keyword><style face="normal" font="Arial"> Protein Hydrolysates</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="Arial">The current economics of the fish protein industry demand rapid, accurate and expressive prediction algorithms at every step of protein production especially with the challenge of global climate change. This help to predict and analyze functional and nutritional quality then consequently control food allergies in hyper allergic patients. As, it is quite expensive and time-consuming to know these concentrations by the lab experimental tests, especially to conduct large-scale projects. Therefore, this paper introduced a new intelligent algorithm using adaptive neuro-fuzzy inference system based on whale optimization algorithm. This algorithm is used to predict the concentration levels of bioactive amino acids in fish protein hydrolysates at different times during the year. The whale optimization algorithm is used to determine the optimal parameters in adaptive neuro-fuzzy inference system. The results of proposed algorithm are compared with others and it is indicated the higher performance of the proposed algorithm</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -CO - Egypt -CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-10890-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28883610">PM:28883610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-10860.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-10860.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Elaziz MA</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-10890-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,M.</style></author><author><style face="normal" font="Arial"> Ichinose,T.</style></author><author><style face="normal" font="Arial"> Yoshida,Y.</style></author><author><style face="normal" font="Arial"> Arashidani,K.</style></author><author><style face="normal" font="Arial"> Yoshida,S.</style></author><author><style face="normal" font="Arial"> Takano,H.</style></author><author><style face="normal" font="Arial"> Sun,G.</style></author><author><style face="normal" font="Arial"> Shibamoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Health, School of Public Health, China Medical University, Shenyang, 110122, China.</style></auth-address><titles><title><style face="normal" font="Arial">Urban PM2.5 exacerbates allergic inflammation in the murine lung via a TLR2/TLR4/MyD88-signaling pathway</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11027">11027-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antigen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> gene-deficient mice</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> KC</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">Nevertheless its mechanism has not been well explained yet, PM2.5 is recognized to exacerbate asthma. In the present study, the roles of toll-like receptor (TLR) 2, TLR4 and MyD88, in exacerbation of allergen-induced lung eosinophilia caused by urban PM2.5 was investigated. TLR2-, TLR4-, MyD88-deficient and WT BALB/c mice were intratracheally challenged with PM2.5 +/- ovalbumin (OVA) four times at 2-week intervals. PM2.5 increased neutrophil numbers and KC in bronchoalveolar lavage fluid and caused slight peribronchiolar inflammation in WT mice. However, these changes were attenuated, but not completely suppressed in gene-deficient mice, especially in MyD88-/- mice. In WT mice, PM2.5 + OVA exacerbated OVA-related lung eosinophilia. This exacerbation includes increase of IL-5, IL-13, eotaxin and MCP-3; infiltration of eosinophils into the airway submucosa; proliferation of goblet cells in the airway epithelium; and the production of antigen-specific IgE and IgG1 in serum. All these effects were stronger in TLR2-/- mice than in TLR4-/- mice. In MyD88-/- mice, this pro-inflammatory mediator-inducing ability was considerably weak and lung pathology was negligible. These results suggest that urban PM2.5 may exacerbate allergic inflammation in the murine lung via a TLR2/TLR4/MyD88-signaling pathway. PM2.5-bound trace microbial elements, such as lipopolysaccharide may be a strong candidate for exacerbation of murine lung eosinophilia</style></abstract><notes><style face="normal" font="Arial">DA - 20170909IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -CO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-11471-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28887522">PM:28887522</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11027.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11027.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170909, He M</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-11471-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Priyamvada,H.</style></author><author><style face="normal" font="Arial"> Singh,R.K.</style></author><author><style face="normal" font="Arial"> Akila,M.</style></author><author><style face="normal" font="Arial"> Ravikrishna,R.</style></author><author><style face="normal" font="Arial"> Verma,R.S.</style></author><author><style face="normal" font="Arial"> Gunthe,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">EWRE Division, Department of Civil Engineering, Indian Institute of Technology Madras, Chennai, 600036, India.</style></auth-address><titles><title><style face="normal" font="Arial">Seasonal variation of the dominant allergenic fungal aerosols - One year study from southern Indian region</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11171">11171-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerosols</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne fungi</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosol</style></keyword><keyword><style face="normal" font="Arial"> Bioaerosols</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal allergen</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> PM10</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> quantitative PCR</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Structural features</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">Quantitative estimations of fungal aerosols are important to understand their role in causing respiratory diseases to humans especially in the developing and highly populated countries. In this study we sampled and quantified the three most dominantly found allergenic airborne fungi, Aspergillus fumigatus, Cladosporium cladosporioides, and Alternaria alternata from ambient PM10 samples using the quantitative PCR (qPCR) technique in a southern tropical Indian region, for one full year. Highest concentrations of A. fumigatus and C. cladosporioides were observed during monsoon whereas A. alternata displayed an elevated concentration in winter. The meteorological parameters such as temperature, relative humidity, wind speed, and precipitation exhibited a substantial influence on the atmospheric concentrations of allergenic fungal aerosols. The morphological features of various allergenic fungal spores present in the PM10 were investigated and the spores were found to possess distinct structural features. In a maiden attempt over this region we correlate the ambient fungal concentrations with the epidemiological allergy occurrence to obtain firsthand and preliminary information about the causative fungal allergen to the inhabitants exposed to bioaerosols. Our findings may serve as an important reference to atmospheric scientists, aero-biologists, doctors, and general public</style></abstract><notes><style face="normal" font="Arial">DA - 20170912IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-11727-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28894264">PM:28894264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11171.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11171.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170912, Priyamvada H</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-11727-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yeon,S.M.</style></author><author><style face="normal" font="Arial"> Halim,L.</style></author><author><style face="normal" font="Arial"> Chandele,A.</style></author><author><style face="normal" font="Arial"> Perry,C.J.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Kim,S.U.</style></author><author><style face="normal" font="Arial"> Byun,Y.</style></author><author><style face="normal" font="Arial"> Yuk,S.H.</style></author><author><style face="normal" font="Arial"> Kaech,S.M.</style></author><author><style face="normal" font="Arial"> Jung,Y.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacy, Korea University, Sejong-si, Korea</style></auth-address><titles><title><style face="normal" font="Arial">IL-7 plays a critical role for the homeostasis of allergen-specific memory CD4 T cells in the lung and airways</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11155">11155-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory T cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Recall</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">Memory T cells respond rapidly to repeated antigen exposure and can maintain their population for extended periods through self-renewal. These characteristics of memory T cells have mainly been studied during viral infections, whereas their existence and functions in allergic diseases have been studied incompletely. Since allergic patients can suffer repeated relapses caused by intermittent allergen exposure, we hypothesized that allergen- specific memory Th2 cells are present and the factors necessary for the maintenance of these cells are provided by the lung and airways. Using a murine model of airway inflammation, we found that allergen-specific CD4 T cells survived longer than 70 days in the lung and airways in an IL-7 dependent fashion. These T cells showing homeostatic proliferation were largely found in the mediastinal lymph node (mLN), rather than the airways; however, cells residing in the lung and airways developed recall responses successfully. We also found that CD4 T cells exhibited differential phenotypes in the mLN and in the lung. Altogether, we believe that allergen-specific memory T cells reside and function in the lung and airways, while their numbers are replenished through homeostatic turnover in the mLNs. Furthermore, we determined that IL-7 signaling is important for the homeostasis of these cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170912IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-11492-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28894184">PM:28894184</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11155.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11155.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170912, Yeon SM</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-11492-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salzer,H.J.F.</style></author><author><style face="normal" font="Arial"> Rolling,T.</style></author><author><style face="normal" font="Arial"> Vinnemeier,C.D.</style></author><author><style face="normal" font="Arial"> Tannich,E.</style></author><author><style face="normal" font="Arial"> Schmiedel,S.</style></author><author><style face="normal" font="Arial"> Addo,M.M.</style></author><author><style face="normal" font="Arial"> Cramer,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Infectious Diseases and Tropical Medicine, 1st Department of Internal Medicine, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, DE-20251 Hamburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Helminthic infections in returning travelers and migrants with eosinophilia: Diagnostic value of medical history, eosinophil count and IgE</style></title><secondary-title><style face="normal" font="Arial">Travel Med Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Travel Med Infect Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Tropical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Eosinophilia in travelers and migrants returning from the tropics is often associated with invasive helminthic infections. Total IgE is considered as useful additional diagnostic parameter; however, both parameters are also increased in various other non-helminthic diseases. METHODS: We retrospectively evaluated travelers and migrants seen at our department between September 2007 and May 2014. Patients with an absolute eosinophil count >/=500 cells/mul were considered for further analyses. RESULTS: Among 6618 returned travelers and migrants, 154 (2.3%) had a total eosinophil count >/=500 cells/muL. Of these, 71 patients (46%) were diagnosed with helminthic infection. In an additional 62 patients (40%) with eosinophilia a final diagnosis was found, including non-helminthic infections in 34 patients and non-infectious causes in 28 patients, while in 21 patients (14%) no diagnosis was made. Patients with helminthic infections had higher eosinophil counts than travelers and migrants with other diagnoses (median 981 vs. 710 cells/mul; p = 0.001), while total IgE levels (n = 70; 172 vs. 152 kU/l; p = 0.731) were similar in both groups. CONCLUSION: Eosinophil count but not total IgE levels are associated with helminthic infections in returning travelers and migrants with eosinophilia. Our results do not support the use of total IgE to differentiate helminthic infections from other causes of eosinophilia in this population</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 1873-0442 (Electronic)IS - 1477-8939 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tmaid.2017.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28882532">PM:28882532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Travel Med Infect Dis\20170908-SalzerHJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Travel Med Infect Dis\20170908-SalzerHJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170908, Salzer HJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tmaid.2017.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Woo,E.J.</style></author><author><style face="normal" font="Arial"> Moro,P.L.</style></author><author><style face="normal" font="Arial"> Cano,M.</style></author><author><style face="normal" font="Arial"> Jankosky,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.</style></auth-address><titles><title><style face="normal" font="Arial">Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System</style></title><secondary-title><style face="normal" font="Arial">Vaccine</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vaccine</style></full-title></periodical><pages end="5621" start="5618">5618-5621</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">42</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg Proteins</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Influenza</style></keyword><keyword><style face="normal" font="Arial"> Influenza vaccination</style></keyword><keyword><style face="normal" font="Arial"> Influenza Vaccine</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Spodoptera</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="Arial">On January 16, 2013, the Food and Drug Administration approved recombinant hemagglutinin influenza vaccine (RIV3) (Spodoptera frugiperda cell line; Flublok), which is the first completely egg-free flu vaccine licensed in the United States. To improve our understanding of the safety profile of this vaccine, we reviewed and summarized reports to the Vaccine Adverse Event Reporting System (VAERS) following RIV3. Through June 30, 2016, VAERS received 88 reports. Allergic reactions, including anaphylaxis, were the most common type of adverse event. Based on medical review, 10 cases met the Brighton Collaboration case definition of anaphylaxis, 21 reports described allergic reactions other than anaphylaxis, and 11 reports described signs and symptoms that suggested hypersensitivity. Other adverse events included injection site reactions, fatigue, myalgia, headache, and fever. The occurrence of anaphylaxis and other allergic reactions in some individuals may reflect an underlying predisposition to atopy that may manifest itself after an exposure to any drug or vaccine, and it does not necessarily suggest a causal relationship with the unique constituents that are specific to the vaccine product administered. Further research may elucidate the mechanism of allergic reactions following influenza vaccination: it is possible that egg proteins and influenza hemagglutinin play little or no role. Vaccination remains the single best defense against influenza and its complications. The information summarized here may enable policy makers, health officials, clinicians, and patients to make a more informed decision regarding vaccination strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20170909IS - 1873-2518 (Electronic)IS - 0264-410X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.vaccine.2017.08.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886946">PM:28886946</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vaccine\20170909-WooEJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vaccine\20170909-WooEJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170909, Woo EJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.vaccine.2017.08.047</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sjostrom,Y.</style></author><author><style face="normal" font="Arial"> Mellor,P.</style></author><author><style face="normal" font="Arial"> Bergvall,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Blue Star Animal Hospital, Gjutjarnsgatan 4, Gothenburg, 417 07, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">A novel non-azole topical treatment reduces Malassezia numbers and associated dermatitis: a short term prospective, randomized, blinded and placebocontrolled trial in naturally infected dogs</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal drug</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Malassezia species</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Malassezia yeast overgrowth on the skin is a common and often recurrent cause of dermatitis in dogs; it can be an exacerbating factor of atopic dermatitis. Anti-fungal drugs have been a standard treatment, but there is some concern that resistance may be evolving in a spectrum of Malassezia species. Safe, efficient and easy-to-use alternatives are needed. OBJECTIVES: To assess if a commercially available topical non-azole solution applied to paws affected by Malassezia-associated dermatitis (MAD), could ameliorate Malassezia numbers and associated signs over a short term (14 day) trial. ANIMALS: Eighteen dogs with MAD affecting at least two paws. METHODS: The study design was prospective, randomized, blinded and placebo-controlled, using a split-body protocol. Dogs were treated once daily with the test solution on one paw and placebo on the other. Dogs were examined at days 0 and 14 +/- 3. The primary end-point was Malassezia numbers assessed cytologically. Secondary end-points were clinical scores for lesion severity and pruritus as assessed by a pruritus Visual Analog Scale (PVAS). Owner compliance and adverse effects were assessed. RESULTS: There was a statistically significant reduction in Malassezia numbers and clinical scores for paws treated with the test solution versus placebo. No statistical difference in PVAS was found. CONCLUSION: Daily topical application of the test solution was effective in reducing the Malassezia burden, as well as improving clinical scores in dogs with MAD of the paws. No adverse effects were reported and owners described the product as either "easy" or "very easy" to use</style></abstract><notes><style face="normal" font="Arial">DA - 20170915IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12488</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913896">PM:28913896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170915-SjostromY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170915-SjostromY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170915, Sjostrom Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12488</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Szczepanik,M.P.</style></author><author><style face="normal" font="Arial"> Wilkolek,P.M.</style></author><author><style face="normal" font="Arial"> Adamek,L.R.</style></author><author><style face="normal" font="Arial"> Zajac,M.</style></author><author><style face="normal" font="Arial"> Golynski,M.</style></author><author><style face="normal" font="Arial"> Sitkowski,W.</style></author><author><style face="normal" font="Arial"> Taszkun,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Subdepartment of Clinical Diagnostics and Veterinary Dermatology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Gleboka 30, 20-612, Lublin, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of the correlation between Scoring Feline Allergic Dermatitis and Feline Extent and Severity Index and skin hydration in atopic cats</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cutaneous barrier</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier function</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Thorax</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Evaluation of the severity of clinical signs of cats with allergic skin diseases has used two scoring systems: Scoring Feline Allergic Dermatitis (SCORFAD) and the Feline Extent and Severity Index (FeDESI). The integrity of the cutaneous barrier can also be evaluated by measuring skin hydration. A correlation between the clinical score and skin hydration has been observed in humans and dogs with atopic dermatitis (AD). HYPOTHESIS: To demonstrate a correlation between the clinical score and skin hydration of cats affected with presumed AD. ANIMALS: European short hair cats (n = 18): 11 females and seven males with a confirmed diagnosis of AD. METHODS: SCORFAD and FeDESI scores were calculated and the measurements of skin hydration were assessed from seven body sites using corneometry. The correlation between the SCORFAD and FeDESI systems and skin hydration of each site, and the average skin hydration was calculated. RESULTS: There was a positive correlation between the SCORFAD score and skin hydration for the axilla, thorax and forelimb; for FeDESI and axilla and lumbar sites. There was a negative correlation between the FeDESI and skin hydration for the pinna (r = -0.47). CONCLUSIONS AND CLINICAL IMPORTANCE: Measurements of skin hydration could be a useful tool for the evaluation of allergic cats. There is limited evidence of any useful correlation between clinical scoring systems and measurements of hydration. The pinna may be a suitable region for the assessment of skin barrier function in normal and allergic cats</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12489</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28901591">PM:28901591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20170913-SzczepanikMP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20170913-SzczepanikMP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170913, Szczepanik MP</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12489</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kmenta,M.</style></author><author><style face="normal" font="Arial"> Bastl,K.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Kramer,M.F.</style></author><author><style face="normal" font="Arial"> Heath,M.D.</style></author><author><style face="normal" font="Arial"> Patsi,S.</style></author><author><style face="normal" font="Arial"> Pessi,A.M.</style></author><author><style face="normal" font="Arial"> Saarto,A.</style></author><author><style face="normal" font="Arial"> Werchan,B.</style></author><author><style face="normal" font="Arial"> Werchan,M.</style></author><author><style face="normal" font="Arial"> Zetter,R.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Oto-Rhino-Laryngology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">The grass pollen season 2015: a proof of concept multi-approach study in three different European cities</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dactylis</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Festuca</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen season</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Main pollen season</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Phenology</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen monitoring</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Grasses release the most widespread aeroallergens with considerable sensitization rates, while different species produce several pollen concentration peaks throughout the season. This study analyzed the prevalence of grass species in three different European city areas and compared the flowering period of these species with daily pollen concentrations and the symptom loads of grass pollen allergy sufferers. METHODS: The most prevalent grass species in Vienna (Austria), Berlin (Germany) and Turku (Finland) were studied and examined by use of three different approaches: phenology, pollen monitoring and symptom load evaluation. A mobile pollen exposure chamber was employed to observe reaction patterns of grass pollen allergy sufferers to three common grass species evaluated in this study versus placebo. RESULTS: Common meadow grass (Poa pratensis) and the fescue grass species (Festuca spp.) are important contributors within the grass pollen season. The pollination period of orchard grass (Dactylis glomerata) and false-oat grass (Arrhenatherum elatius) indicated a greater importance in Berlin and Vienna, whereas a broader spectrum of grass species contributed in Turku to the main pollen season. The standardized provocation induced a nasal symptom load, reduction in nasal flow and increased secretion, in contrary to the placebo control group in grass pollen allergic subjects. CONCLUSION: The phenological observations, pollen measurements and symptom data evaluation provided unique insights into the contribution of multiple grass species in different European regions. All investigated grass species in the provocation induced rhinitis symptoms of comparable significance, with some degree of variation in symptom patterns</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Germany -CO - Finland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0163-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28932345">PM:28932345</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Kmenta M</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0163-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Xavier-Elsas,P.</style></author><author><style face="normal" font="Arial"> Ferreira,R.N.</style></author><author><style face="normal" font="Arial"> Gaspar-Elsas,M.I.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pedro Xavier-Elsas, Renato Nunes Ferreira, Department of Immunology, Instituto de Microbiologia Paulo de Goes, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Surgical and immune reconstitution murine models in bone marrow research: Potential for exploring mechanisms in sepsis, trauma and allergy</style></title><secondary-title><style face="normal" font="Arial">World J Exp Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">World J Exp Med</style></abbr-1></periodical><pages end="77" start="58">58-77</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune reconstitution</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Regeneration</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sepsis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="20" Month="8" Year="2017">2017/8/20</year></dates><abstract><style face="normal" font="Arial">Bone marrow, the vital organ which maintains lifelong hemopoiesis, currently receives considerable attention, as a source of multiple cell types which may play important roles in repair at distant sites. This emerging function, distinct from, but closely related to, bone marrow roles in innate immunity and inflammation, has been characterized through a number of strategies. However, the use of surgical models in this endeavour has hitherto been limited. Surgical strategies allow the experimenter to predetermine the site, timing, severity and invasiveness of injury; to add or remove aggravating factors (such as infection and defects in immunity) in controlled ways; and to manipulate the context of repair, including reconstitution with selected immune cell subpopulations. This endows surgical models overall with great potential for exploring bone marrow responses to injury, inflammation and infection, and its roles in repair and regeneration. We review three different murine surgical models, which variously combine trauma with infection, antigenic stimulation, or immune reconstitution, thereby illuminating different aspects of the bone marrow response to systemic injury in sepsis, trauma and allergy. They are: (1) cecal ligation and puncture, a versatile model of polymicrobial sepsis; (2) egg white implant, an intriguing model of eosinophilia induced by a combination of trauma and sensitization to insoluble allergen; and (3) ectopic lung tissue transplantation, which allows us to dissect afferent and efferent mechanisms leading to accumulation of hemopoietic cells in the lungs. These models highlight the gain in analytical power provided by the association of surgical and immunological strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20170911IS - 2220-315X (Print)IS - 2220-315X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5493/wjem.v7.i3.58</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890868">PM:28890868</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Exp Med\2017-7-58-77.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Exp Med\2017-7-58-77.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170911, Xavier-Elsas P</style></custom2><misc3><style face="normal" font="Arial">10.5493/wjem.v7.i3.58</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hou,W.P.</style></author><author><style face="normal" font="Arial"> Wang,Y.J.</style></author><author><style face="normal" font="Arial"> Qiao,L.H.</style></author><author><style face="normal" font="Arial"> Shen,H.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, West Branch of Kaifeng Second People' Hospital, Kaifeng, Henan 475000, China.</style></auth-address><titles><title><style face="normal" font="Arial">[Clinical significance of fractional exhaled nitric oxide combined with in vitro allergen test in identifying children at a high risk of asthma among those with recurrent wheezing]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Dang Dai Er Ke Za Zhi</style></full-title></periodical><pages end="982" start="979">979-982</pages><volume><style face="normal" font="Arial">19</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> Recurrent wheezing</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To investigate the clinical value of combined determination of in vitro allergens and fractional exhaled nitric oxide (FeNO) in indentifying children at a high risk of asthma among those with recurrent wheezing. METHODS: A total of 148 children with recurrent wheezing (0.5-6 years old) were enrolled as study subjects, and 80 healthy children who underwent physical examination were enrolled as the control group. Pharmacia UniCAP immunoassay analyzer was used to measure specific immunoglobulin E (sIgE). Nano Coulomb Nitric Oxide Analyzer was used to measure FeNO. The asthma predictive index (API) was evaluated. RESULTS: The recurrent wheezing group had a significantly higher proportion of children with positive sIgE than the control group [68.9% (102/148) vs 11.3% (9/80); P&lt;0.05]. The recurrent wheezing group also had significantly higher levels and positive rate of FeNO than the control group (P&lt;0.05). The overall positive rate of API in children with wheezing was 32.4%, and the API-positive children had a significantly higher FeNO value than the API-negative children (51+/-6 ppb vs 13+/-5 ppb; P&lt;0.05). The detection rate of API was 40.2% (41/102) in positive-sIgE children and 50.1% (38/73) in FeNO-positive children, and there was no significant difference between these two groups. The children with positive sIgE and FeNO had a significantly higher detection rate of API (81.4%) than those with positive sIgE or FeNO (P&lt;0.05). CONCLUSIONS: Combined determination of FeNO and in vitro allergens is more sensitive in detecting children at a high risk of asthma than FeNO or in vitro allergens determination alone and provides a good method for early identification, diagnosis, and intervention of asthma in children</style></abstract><notes><style face="normal" font="Arial">DA - 20170913IS - 1008-8830 (Print)IS - 1008-8830 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28899467">PM:28899467</url></web-urls></urls><custom2><style face="normal" font="Arial">20170913, Hou WP</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fu,Z.</style></author><author><style face="normal" font="Arial"> Bao,X.H.</style></author><author><style face="normal" font="Arial"> Wu,Y.</style></author><author><style face="normal" font="Arial"> Zhou,J.</style></author><author><style face="normal" font="Arial"> Zhang,Y.H.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Ji,T.Y.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Peking University First Hospital, Beijing 100034, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effectiveness and safety of rituximab for children with autoimmune diseases of the nervous system]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Ke Za Zhi</style></full-title></periodical><pages end="694" start="689">689-694</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases of the Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> CNS</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> IVIg</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Myasthenia Gravis</style></keyword><keyword><style face="normal" font="Arial"> Myoclonus</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Neuromyelitis Optica</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> rituximab</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><abstract><style face="normal" font="Arial">Objective: To assess the effectiveness and safety of rituximab in Chinese children with autoimmune diseases of the nervous system. Method: An ambispective cohort study enrolled patients with refractory and(or) relapse autoimmune diseases of nervous system from June 2010 to June 2016 in Peking University First Hospital.These patients failed to respond to steroids and(or)intravenous immunoglobulin (IVIG) were treated with rituximab and seen for follow-up visits once every 3 months.The effectiveness was assessed by modified Rankin scale (mRs) and the annualized relapse rate.B cell was repeatedly counted after the treatment.Side effects attributed to rituximab were recorded.Paired rank test and chi-square test were used to compare the mRs score and the recurrence rate (time/year) before and after the treatment. Result: A total of 38 patients (15 males and 23 females) with mean age of (6+/-4) years were treated with rituximab.Among those patients, 4 cases were in multiple sclerosis, 5 in neuromyelitis optica, 6 in opsoclonus myoclonus syndrome, 9 in myasthenia gravis, and 14 in autoimmune encephalitis and other nervous system autoimmune diseases.The course of the disease before rituximab treatment was from two months to 7.25 years, with the average of (21+/-19) months.The patients had been followed up for 2-52 months. The mRs score and recurrence rate of 38 patients before receiving rituximab was 3 points (3, 4) and 2.56 (1.80, 4.75) times per year, respectively, while patients after receiving rituximab were mRs score of 0 (0, 2) and had a recurrence rate of 0 (0, 0.17) per year.There was statistical difference before and after treatment (Z=-4.51 and -4.71, P&lt;0.01). Rituximab had a definite benefit in 23 patients, probable benefit in 2 patients, possible benefit in 3 patients, no benefit in one patient, and the disease worsened in 2 patients.Therefore the total effective rate was 74%, except for 6 undetermined cases because of the short follow-up time, and one patient withdrew from the study due to allergic reaction.During the follow-up, only one patient with severe allergy gave up the rituximab treatment. And only one patient was found severe infection with Pneumocystis carinii pneumonia. Conclusion: Rituximab is an effective and safe treatment strategy for patients with refractory and relapse autoimmune diseases of CNS, especially in neuromyelitis optica and myasthenia gravis.The adverse events including infection and allergy during infusion are not common</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 0578-1310 (Print)IS - 0578-1310 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.0578-1310.2017.09.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881516">PM:28881516</url></web-urls></urls><custom2><style face="normal" font="Arial">20170908, Fu Z</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.0578-1310.2017.09.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,Y.F.</style></author><author><style face="normal" font="Arial"> Li,H.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Child Care, Children's Hospital, Chongqing Medical University, Chongqing 400014, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effect of docosahexenoic acid microalgae oil supplementation during pregnancy and lactation on levels of serum polyunsaturated fatty acid and tolerance to ovalbumin in suckling mice]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Ke Za Zhi</style></full-title></periodical><pages end="677" start="672">672-677</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child care</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> HPLC</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Jejunum</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><abstract><style face="normal" font="Arial">Objective: To study the tolerance to ovalbumin (OVA) in suckling mice whose mothers had different doses of docosahexenoic acid (DHA) microalgae oil (DMO) supplementation during pregnancy and lactation. Method: According to different doses of DMO fed to mother mice during pregnancy and lactation, 66 suckling mice were divided into four groups. Suckling mice whose mothers were fed with 0.7% DMO were designated as low dose group (group L) (n=16), 2.1% DMO as middle dose group (group M) (n=16), 3.5% DMO as high dose group (group H) (n=17) and no DMO as control group (n=17). Before exposing to OVA, 8 suckling mice were killed in each group at 21-day-old. Remaining suckling mice were killed at 59-day-old after repeated OVA exposure. The serum polyunsaturated fatty acid (PUFA) levels of suckling mice were analyzed by high performance liquid chromatography (HPLC) at the age of 21- and 59-day.Histological examinations of jejunum were performed by HE staining and the mast cells in jejunum were observed by toluidine blue staining. OVA-IgE in serum, total IgA and OVA-IgA in the feces and IL-4 and IFN-gamma in the supernatants of splenic mononuclear cells (SMC) were measured by ELISA. Real time PCR was performed to identify the gene expression of IL-10, TGF-beta1 mRNA in SMC. Differences among groups were compared by one-way AVOVA and that between each group were compared by LSD. Result: In group M and H, the serum levels of n-3DHA (108+/-29)mug/ml; (102+/-34)mug/ml vs.(40+/-19)mug/ml (F=12.052, P=0.000)and n-3 eicosapentaenoic acid (6.7+/-2.3)mug/ml; (7.7+/-2.0)mug/ml vs. (3.9+/-1.1)mug/ml(F=9.573, P=0.000) were significantly higher than that in control group at the age of 21-day. The serum levels of n-3DHA were higher in group H (17.1+/-2.9)mug/ml than that in control group (5.9+/-3.3) mug/ml after repeated OVA exposure at the age of 59-day (F=10.339, P&lt;0.000). Compared with control group (53+/-12) pg/ml, the levels of IL-4 in SMC in group H (42+/-9)pg/ml were lower (F=2.484, P&lt;0.05). Conclusion: The serum levels of DHA in baby mice, whose mothers was fed with DMO during pregnancy and lactation, were significantly increased till adulthood. However, the effect on tolerance to OVA was limited</style></abstract><notes><style face="normal" font="Arial">DA - 20170908IS - 0578-1310 (Print)IS - 0578-1310 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.0578-1310.2017.09.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881513">PM:28881513</url></web-urls></urls><custom2><style face="normal" font="Arial">20170908, Wu YF</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.0578-1310.2017.09.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ren,N.N.</style></author><author><style face="normal" font="Arial"> Chen,H.J.</style></author><author><style face="normal" font="Arial"> Chen,Q.L.</style></author><author><style face="normal" font="Arial"> Eileen,J.</style></author><author><style face="normal" font="Arial"> An,Y.G.</style></author><author><style face="normal" font="Arial"> Lin,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Guangdong Online Hospital, Guangdong 2nd Provincial People's Hospital, Guangzhou 510317, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effects of human mesenchymal stem cells on airway inflammation in allergic asthma mice and the underlying mechanism]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Yi Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Yi Xue Za Zhi</style></full-title></periodical><pages end="2702" start="2697">2697-2702</pages><volume><style face="normal" font="Arial">97</style></volume><number><style face="normal" font="Arial">34</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> TH17 cells</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Umbilical Cord</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">Objectives: To investigate the effects of human umbilical cord mesenchymal stem cells (hUC-MSCs) on airway inflammation in an ovalbumin (OVA) induced asthma mouse model and the underlying mechanism. Methods: Twenty-four BALB/c mice were randomly divided into four equal groups: normal control group, OVA-induced asthmatic model group, hUC-MSCs treated group (50 mul of hUC-MSCs was transplanted into the trachea of asthmatic mice ) and hUC-MSCs control group (50 mul of hUC-MSCs was transplanted into the trachea of control mice). Human umbilical cord mesenchymal stem cells from umbilical cord of healthy new born babies were used as the source of hUC-MSCs for this study. The asthmatic conditions of the airways and the lungs were assessed by examining: (1) histopathological changes of the airways and the lungs; (2) expression of cytokines IL-6 and TGF-beta mRNA by real-time PCR; (3) total leukocytes and mast cell count in bronchoalveolar lavage fluid (BALF) and number of IL-17-expressing CD4(+) cells (Th17 cells) in the lung tissue using flow cytometry. Results: Typical histopathological changes of asthma were confirmed in the asthmatic model group. These changes included intensive inflammatory cell infiltration around the airways and patchy airway occlusion by hyperviscous mucus. The number of total leukocytes and mast cells in BALF were significantly increased in the asthmatic mice when compared with the control group (P&lt;0.05). Mice in the asthmatic model group had significantly higher percentage of Th17 cells in lung tissues when compared with the control group (2.90% vs 0.76%, P&lt;0.05). In contrast, in the asthmatic mice treated with hUC-MSCs, the inflammatory cell infiltration was significantly reduced compared with asthmatic mice, as observed by significantly lower leukocytes and mast cells in BALF (P&lt;0.05) and significant reduction in the percentage of Th17 cells in the lung of OVA-challenged mice following hUC-MSCs treatment (percentage of Th17 cells: 0.24% vs 2.90%, P&lt;0.05). The expression of mRNA for IL-6 and TGF-beta was significantly suppressed in the hUC-MSCs treatment group (0.23 vs 2.30 and 0.56 vs 6.60, both P&lt;0.01). No asthmatic pathological changes in both normal and hUC-MSCs control groups were observed. Conclusions: hUC-MSCs significantly inhibit the airway inflammation in OVA-induced asthmatic mice. This inhibition is associated with the suppression of Th17 cells and the down-regulation of inflammatory factors such as IL-6 and TGF-beta in the lungs</style></abstract><notes><style face="normal" font="Arial">DA - 20170914IS - 0376-2491 (Print)IS - 0376-2491 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.0376-2491.2017.34.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28910960">PM:28910960</url></web-urls></urls><custom2><style face="normal" font="Arial">20170914, Ren NN</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.0376-2491.2017.34.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Da Silva,P.S.</style></author><author><style face="normal" font="Arial"> Furtado,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Anesthesiology Service, Regional Hospital Alto Vale, Rio do Sul, Santa Catarina, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Methylene Blue to Treat Refractory Latex-Induced Anaphylactic Shock: A Case Report</style></title><secondary-title><style face="normal" font="Arial">A A Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">A A Case Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Methylene Blue</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Perioperative Period</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis occurs in 1/5000-1/20,000 of anesthesia cases and may evolve with shock and cardiovascular collapse in up to 54% of cases. Mortality varies from 3% to 10%. Latex is the second leading cause of anaphylaxis during the perioperative period. We report a case of latex-induced anaphylactic shock refractory to the usual catecholamine treatment that was reversed with the aid of methylene blue. Exaggerated activation of the nitric oxide-cyclic guanosine monophosphate pathway is observed in refractory shock. Methylene blue selectively inhibits this pathway</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 2325-7237 (Electronic)IS - 2325-7237 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1213/XAA.0000000000000630</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28937421">PM:28937421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\A A Case Rep\20170922-DaSilvaPS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\A A Case Rep\20170922-DaSilvaPS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170922, Da Silva PS</style></custom2><misc3><style face="normal" font="Arial">10.1213/XAA.0000000000000630</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singh,R.</style></author><author><style face="normal" font="Arial"> Mal,G.</style></author><author><style face="normal" font="Arial"> Kumar,D.</style></author><author><style face="normal" font="Arial"> Patil,N.V.</style></author><author><style face="normal" font="Arial"> Pathak,K.M.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Camel Milk: An Important Natural Adjuvant</style></title><secondary-title><style face="normal" font="Arial">Agric Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Agric Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptation</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cattle</style></keyword><keyword><style face="normal" font="Arial"> Cheese</style></keyword><keyword><style face="normal" font="Arial"> Copper</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> fat</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> feed</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food processing</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Heat</style></keyword><keyword><style face="normal" font="Arial"> heat stability</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Ice</style></keyword><keyword><style face="normal" font="Arial"> Ice Cream</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Lactoferrin</style></keyword><keyword><style face="normal" font="Arial"> Lactoperoxidase</style></keyword><keyword><style face="normal" font="Arial"> Lysozyme</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical properties</style></keyword><keyword><style face="normal" font="Arial"> Physicochemical property</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Salts</style></keyword><keyword><style face="normal" font="Arial"> Semiarid region</style></keyword><keyword><style face="normal" font="Arial"> Shelf life</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin C</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2249-7218</style></isbn><abstract><style face="normal" font="Arial">One humped camel (Camelus dromedarius) breeds, indigenous to India, have been shown to have good genetic potential to produce milk. Camel milk not only is cost-effective in terms of feed conversion but also has additional advantage of longer lactation period and unique adaptation mechanisms for warm arid and semiarid regions. The key features of camel milk in comparison with other milk are low fat with high content of unsaturated and long-chain fatty acid. The proteins are rich in lactoferrin and lysozymes, but deficient in +¦-lactoglobulin. It has higher percentage of total salts, free calcium, protective proteins and vitamin C, and some of the microminerals, viz iron, copper and zinc. Physicochemical properties of camel milk are also unique and useful for food processing. The shelf life of raw camel milk is 8</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô9-áh, which can be extended up to 18</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô20-áh through activation of camel lactoperoxidase system. Heat stability of camel milk is shown to be highest at pH 6.8, and it ferments relatively slowly compared to the cattle milk. The camel milk is successfully processed for producing a variety of products, such as fermented milk (</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿlassi</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ), soft cheese, flavored milk and </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çÿkulfee</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖ (a kind of ice cream). Camel milk has been traditionally used in different regions of the world as natural adjuvant for managing a variety of human diseases</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40003-017-0284-4</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40003-017-0284-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Agric Res\20171002-SinghR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Agric Res\20171002-SinghR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170902, Singh R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40003-017-0284-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huerta López,J.G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Inmunoterapia con alérgenos. Guía y revisión sistemática. Congreso EAACI (congress 2017) Helsinki Finlandia 17-21 Junio 2017</style></title><secondary-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="40" start="39">39-40</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Congresses</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/contenido.cgi?IDPUBLICACION=7210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2017-26-39-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2017-26-39-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Huerta López JG</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rodriguez Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Mendoza Hernandez,D.A.</style></author><author><style face="normal" font="Arial"> Pedroza Melendez,A.</style></author><author><style face="normal" font="Arial"> Orozco Martinez,M.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Características clínicas de pacientes pediátricos con alergia a látex</style></title><secondary-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="44" start="41">41-44</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Mexico City</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Introduction: Latex allergy remains a signifi cant problem in children with certain risk factors such as early andmultiple surgical interventions as well as atopy. The clinical profi le of mexican children has not been described.Objectives: To describe clinical features of paediatric patients with latex allergy diagnosed at the NationalInstitute of Pediatrics, Mexico City. Material and methods: This is a retrospective, transversal, observationaland descriptive. Results: We included 26 paediatric patients (6 to 18 years old) with latex allergy diagnosisconfi rmed by positive skin prick testing and/or latex-specifi c serum immunoglobulin E > 0.35 KUI/L. We founda gender predominance (male 67%, female 33%). Most of the children had a congenital disease (71%). Allof the children (100%) had a previous history of surgical intervetion and most of these were performed withinthe fi rst twelfe months of age (67%). Most of the patients had been exposed to at least one surgical procedure(80%). Most allergic reactions were mild to moderate (81%). There were 3 cases of anaphylaxis and nofatalities were reported. Most patients had history of atopy and allergic disease (67%). Conclusions: Wedescribed the clinical features and relevant medical history of peadiatric patients with latex allergy.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/contenido.cgi?IDPUBLICACION=7210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2017-26-41-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergia Asma Inmunol Pediatr\2017-26-41-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Rodriguez Gonzalez M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Matsui,T.</style></author><author><style face="normal" font="Arial"> Yamashita,H.</style></author><author><style face="normal" font="Arial"> Saneyasu,K.I.</style></author><author><style face="normal" font="Arial"> Tanaka,H.</style></author><author><style face="normal" font="Arial"> Ito,K.</style></author><author><style face="normal" font="Arial"> Inagaki,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University, Gifu, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Vitamin D deficiency exacerbates sensitization and allergic diarrhea in a murine food allergy model</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D Deficiency</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28935120">PM:28935120</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20170922-MatsuiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20170922-MatsuiT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170922, Matsui T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.08.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thostesen,L.M.</style></author><author><style face="normal" font="Arial"> Kjaergaard,J.</style></author><author><style face="normal" font="Arial"> Pihl,G.T.</style></author><author><style face="normal" font="Arial"> Birk,N.M.</style></author><author><style face="normal" font="Arial"> Nissen,T.N.</style></author><author><style face="normal" font="Arial"> Aaby,P.</style></author><author><style face="normal" font="Arial"> Jensen,A.K.G.</style></author><author><style face="normal" font="Arial"> Olesen,A.W.</style></author><author><style face="normal" font="Arial"> Stensballe,L.G.</style></author><author><style face="normal" font="Arial"> Jeppesen,D.L.</style></author><author><style face="normal" font="Arial"> Benn,C.S.</style></author><author><style face="normal" font="Arial"> Kofoed,P.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatric Department, Kolding Hospital</style></auth-address><titles><title><style face="normal" font="Arial">Neonatal BCG-vaccination and atopic dermatitis before 13 months of age. A randomised clinical trial</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bacillus</style></keyword><keyword><style face="normal" font="Arial"> BCG</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Birth Weight</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Gestational Age</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interviews</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Telephone</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">Studies have suggested that Bacillus Calmette-Guerin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis. The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age &lt;32 weeks, birth weight &lt;1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months. Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR=0.90 (95% confidence intervals 0.80 to 1.00)). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74 to 0.95)) and children without atopic predisposition (RR 1.09 (0.88 to 1.37)) (test of no interaction, p=0.04). Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12 to 76). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28929567">PM:28929567</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170920-ThostesenLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170920-ThostesenLM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Thostesen LM</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13314</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larenas-Linnemann,D.E.S.</style></author><author><style face="normal" font="Arial"> Antolin-Amerigo,D.</style></author><author><style face="normal" font="Arial"> Parisi,C.</style></author><author><style face="normal" font="Arial"> Nakonechna,A.</style></author><author><style face="normal" font="Arial"> Luna-Pech,J.A.</style></author><author><style face="normal" font="Arial"> Wedi,B.</style></author><author><style face="normal" font="Arial"> Davila,I.</style></author><author><style face="normal" font="Arial"> Gomez,M.</style></author><author><style face="normal" font="Arial"> Levin,M.</style></author><author><style face="normal" font="Arial"> Ortega-Martell,J.A.</style></author><author><style face="normal" font="Arial"> Klimek,L.</style></author><author><style face="normal" font="Arial"> Rosario,N.</style></author><author><style face="normal" font="Arial"> Muraro,A.M.</style></author><author><style face="normal" font="Arial"> Agache,I.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Sheikh,A.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hospital Medica Sur, Investigational Unit, Mexicocity, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">National clinical practice guidelines for Allergen Immunotherapy: an international assessment applying AGREE-II</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organizations</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Romania</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Since 1988 numerous allergen immunotherapy guidelines (AIT-GLs) have been developed by national and international organizations to guide physicians in AIT. Even so, AIT is still severely under-used. OBJECTIVE: to evaluate AIT-GLs with AGREE-II, developed in 2010 by McMaster University methodologists to comprehensively evaluate GL-quality. METHODS: Allergist, from different continents, knowledgeable in AIT and AGREE-II trained were selected into the project team. The project received methodologists' guidance. AIT-GLs in any language were sought from 1980-2016; AIT-GLs were AGREE II evaluated by at least 2 team-members, independently; discrepancies were resolved in a second round, by team-discussion or methodologists' consulting. RESULTS: We found 31 AIT-GLs (15 post-2010), ranging from local consensus reports to international position papers (EAACI, AAAAI-ACAAI, WAO). Pre-2010 GLs' scored 1.6-4.6 (23-67%); post-2010 GLs' 2.1-6 (30-86%), on a 7-point Likert-scale. Best evaluated were: German-Austrian-Swiss (6.0), Mexican (5.1) and the AAAAI/ACAAI AIT-GL (4.7). These were also the only 3 GLs that received 'yes' of both evaluators to the item: 'I would recommend this GL for use'. The domains of 'Stakeholder involvement' and 'Rigor of Development' only scored 3/7, and 'Applicability' scored the lowest. Strikingly, newer GLs only scored clearly better in 'Editorial independence' and 'Global evaluation'. CONCLUSIONS: In AIT-GLs there is still a lot of room for improvement, especially in domains crucial for the dissemination. For some GLs, the 'Scientific rigor' domain flawed. When resources are limited, transculturizing a high-quality GL might be preferable over developing a GL from zero. Our study and AGREE-II could help to select the best candidate. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Mexico -CO - Argentina -CO - Spain -CO - United Kingdom -CO - Germany -CO - South Africa -CO - Brazil -CO - Italy -CO - Romania -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940450">PM:28940450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170923-LarenasLinnemannDE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170923-LarenasLinnemannDE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Larenas-Linnemann DE</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13316</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asaduzzaman,M.</style></author><author><style face="normal" font="Arial"> Davidson,C.</style></author><author><style face="normal" font="Arial"> Nahirney,D.</style></author><author><style face="normal" font="Arial"> Fiteih,Y.</style></author><author><style face="normal" font="Arial"> Puttagunta,L.</style></author><author><style face="normal" font="Arial"> Vliagoftis,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, AB, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Protease-Activated Receptor-2 blockade inhibits changes seen in a chronic murine asthma model</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Alberta</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Collagen content</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Proteinase</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">Proteinase-Activated Receptor-2 (PAR2 ) is a G protein-coupled receptor activated by serine proteinases. We have shown that PAR2 activation in the airways is involved in the development of allergic inflammation and airway hyperresponsiveness (AHR) in acute murine models. We hypothesize that functional inhibition of PAR2 prevents allergic inflammation, AHR and airway remodeling in chronic allergic airway inflammation models. We developed a 12 week model of cockroach extract (CE)-mediated AHR, airway inflammation and remodeling in BALB/c. These mice exhibit AHR, increased numbers of eosinophils in bronchoalveolar lavage (BAL) and increased collagen content in the lung tissue compared to saline controls. Administration of an anti-PAR2 antibody, SAM-11, after the initial development of airway inflammation significantly inhibited all these parameters. Our data demonstrate that PAR2 signaling plays a key role in CE-induced AHR and airway inflammation/remodeling and that targeting PAR2 activation may be a successful therapeutic strategy for allergic asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13315</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940559">PM:28940559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170923-AsaduzzamanM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170923-AsaduzzamanM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Asaduzzaman M</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13315</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agrawal,K.</style></author><author><style face="normal" font="Arial"> Arora,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Immunology section, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India</style></auth-address><titles><title><style face="normal" font="Arial">Serine protease allergen favours Th2 responses via PAR-2 and STAT-3 activation in murine model</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine milieu</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> EPO</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Genomics</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PAR-2</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Per a 10</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> STAT-3</style></keyword><keyword><style face="normal" font="Arial"> STAT3</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Protease activity of Per a 10 favours Th2 responses by differential regulation of IL-12p70 and IL-23 cytokine subunits. The present study aims to elucidate the underlying mechanism of differential regulation of IL-12p70 and IL-23. METHODS: PAR-2 activation was blocked in murine model by administering SAM11 before each sensitization. CD11c+ p-STAT3+ cells were measured in lungs by flow cytometry. BMDCs were pre-treated with SAM-11 or isotype control or stattic and stimulated with Per a 10. p-STAT3 levels were measured using Western blot. Transcript levels of IL-12p35, IL12/23p40 and IL-23p19 were measured using RT PCR. Cytokine levels were analysed using ELISA. RESULTS: Protease activity of Per a 10 increases p-STAT3 levels in mice lungs, which gets reduced on PAR-2 blockage. Percentage of p-STAT3+ CD11c+ cells was higher in Per a 10 administered mice and gets reduced upon PAR-2 blockage. IL-12p35 and IL-12p70 levels were higher, IL-23p19 and IL-23 levels were lower in both SAM-11 treated mice and BMDCs indicating a role of PAR-2 mediated signalling. IL-4, TSLP, IL-17A, EPO activity, total cell count and specific IgE and IgG1 levels were lower in SAM-11 administered mice. Inhibiting STAT3 activation via stattic also leads to lower levels of IL-23p19, IL-23 and higher level of IL-12p35. CONCLUSIONS: Per a 10 leads to PAR-2 activation on BMDCs resulting in downstream activation of STAT3 to regulate the balance between IL-12/IL-23 subunits causing a cytokine milieu rich in IL-23 to favour Th2 polarization. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13315</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940472">PM:28940472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170923-AgrawalK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170923-AgrawalK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Agrawal K</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13315</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abrams,E.M.</style></author><author><style face="normal" font="Arial"> Becker,A.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, FE125-685 William Avenue, Winnipeg, MB R3E 0Z2 CanadaDepartment of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, FE125-685 William Avenue, Winnipeg, MB R3E 0Z2 Canada</style></auth-address><titles><title><style face="normal" font="Arial">Oral food challenge outcomes in a pediatric tertiary care center</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="43">43-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical criteria</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food challenge outcome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> tree nuts</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Oral food challenges are the clinical standard for diagnosis of food allergy. Little data exist on predictors of oral challenge failure and reaction severity. METHODS: A retrospective chart review was done on all pediatric patients who had oral food challenges in a tertiary care pediatric allergy clinic from 2008 to 2010. RESULTS: 313 oral challenges were performed, of which the majority were to peanut (105), egg (71), milk (41) and tree nuts (29). There were 104 (33%) oral challenge failures. Children were more likely to fail an oral challenge if they were older (P = .04), had asthma (P = .001) or had atopic dermatitis (P = .03). Risk of challenge failure was significantly different between food allergens, with more failures noted for peanut than for tree nuts, milk or egg (P = .001). Among challenge failures, 19% met criteria for anaphylaxis. Significantly more tree nut and peanut challenges met criteria for anaphylaxis than milk or egg (P &lt; .001). Skin test size and specific IgE level were significantly higher in those who failed oral challenges (P &lt; .001). The highest rate of challenge failure and severity of failure was to cashew, with 63% of cashew challenges reacting, of which 80% met clinical criteria for anaphylaxis. CONCLUSION: The risk of challenge failure differed with type of food studied, with peanut and tree nut having a higher risk of challenge failure and anaphylaxis. Cashew in particular carried a high risk and caution must be exercised when performing these types of oral challenges in children</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0215-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28947906">PM:28947906</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-43.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Abrams EM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0215-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nair,P.M.</style></author><author><style face="normal" font="Arial"> Starkey,M.R.</style></author><author><style face="normal" font="Arial"> Haw,T.J.</style></author><author><style face="normal" font="Arial"> Ruscher,R.</style></author><author><style face="normal" font="Arial"> Liu,G.</style></author><author><style face="normal" font="Arial"> Maradana,M.R.</style></author><author><style face="normal" font="Arial"> Thomas,R.</style></author><author><style face="normal" font="Arial"> O'Sullivan,B.J.</style></author><author><style face="normal" font="Arial"> Hansbro,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Newcastle Hunter Medical Research Institute, 454568, Priority Research Centres for Healthy Lungs and GrowUpWell, New Lambton, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="Arial">RelB-deficient Dendritic Cells Promote the Development of Spontaneous Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Delta</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Histocompatibility</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> myeloid DCs</style></keyword><keyword><style face="normal" font="Arial"> New South Wales</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Remodelling</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> transgene</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wales</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="Arial">RATIONALE: RelB is a member of the NF-kappaB family that is essential for dendritic cell (DC) function and maturation. However, the contribution of RelB to the development of allergic airway inflammation (AAI) is unknown. Here, we identify a pivotal role for RelB in the development of spontaneous AAI, independent of exogenous allergen exposure. METHODS: We assessed AAI in two strains of RelB-deficient (-/-) mice, one with a targeted deletion and another mutant expressing an major histocompatibility complex (MHC) transgene. To determine the importance of RelB in DCs, RelB-sufficient DCs (RelB+/+ or RelB-/-) were adoptively transferred into RelB-/- mice. RESULTS: Both strains had increased pulmonary inflammation compared to their respective wild-type (RelB+/+) and heterozygous (RelB+/-) controls. RelB-/- mice also had increased inflammatory cell influx into the airways, levels of chemokines (CCL2/3/4/5/11/17, CXCL9/10/13) and Th2-associated cytokines (IL-4/5) in lung tissues, serum IgE and airway remodelling (mucus secreting cell numbers (MSCs), collagen deposition and epithelial thickening). Transfer of RelB+/- CD11c+ DCs to RelB-/- mice decreased pulmonary inflammation, with reduced lung chemokine and Th2-associated cytokine (IL-4/5/13/25/33, thymic stromal lymphopoietin) levels, serum IgE, numbers of type 2 innate lymphoid cells, myeloid DCs, gamma delta (gammadelta) T cells and lung Vbeta13 T cells, MSCs, airway collagen deposition and epithelial thickening. CONCLUSION: These data indicate that RelB deficiency may be a key pathway underlying AAI and that DC-encoded RelB is sufficient to restore control</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1165/rcmb.2017-0242OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960101">PM:28960101</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170929, Nair PM</style></custom2><misc3><style face="normal" font="Arial">10.1165/rcmb.2017-0242OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cooper,P.J.</style></author><author><style face="normal" font="Arial"> Chico,M.E.</style></author><author><style face="normal" font="Arial"> Vaca,M.G.</style></author><author><style face="normal" font="Arial"> Sandoval,C.A.</style></author><author><style face="normal" font="Arial"> Loor,S.</style></author><author><style face="normal" font="Arial"> Amorim,L.</style></author><author><style face="normal" font="Arial"> Rodrigues,L.C.</style></author><author><style face="normal" font="Arial"> Barreto,M.L.</style></author><author><style face="normal" font="Arial"> Strachan,D.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">St George's University of London, Infection and Immunity, London, United Kingdom of Great Britain and Northern Ireland</style></auth-address><titles><title><style face="normal" font="Arial">Effect of Early Life Geohelminth Infections on the Development of Wheezing at 5 Years of Age</style></title><secondary-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> childhood wheeze</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> geohelminths</style></keyword><keyword><style face="normal" font="Arial"> Great Britain</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Maternal Exposure</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> neonate</style></keyword><keyword><style face="normal" font="Arial"> neonates</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="28" Month="9" Year="2017">2017/9/28</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Exposures to geohelminths during gestation or early childhood may reduce risk of wheezing illness/asthma and atopy during childhood in tropical regions. OBJECTIVES: To investigate the effect of maternal and early childhood geohelminths on development of wheeze/asthma and atopy during the first 5 years of life. METHODS: Cohort of 2,404 neonates followed to 5 years of age in rural District in coastal Ecuador. Data on wheeze collected by questionnaire and atopy measured by allergen skin prick test reactivity to 9 allergens at 5 years. Stool samples from mothers and children examined for geohelminths by microscopy. MEASUREMENTS AND MAIN RESULTS: 2,090 (86.9%) children were evaluated at 5 years. Geohelminths were observed in 45.5% of mothers and in 34.1% of children by 3 years. Wheeze and asthma were reported for 12.6% and 5.7% of children, respectively, while 14.0% had skin test reactivity at 5 years. Maternal geohelminths were associated with an increased risk of wheeze (adjusted OR 1.41, 95% CI 1.06-1.88) while childhood geohelminths over the first 3 years of life were associated with reduced risk of wheeze (adjusted OR 0.70, 95% CI 0.52-0.96) and asthma (adjusted OR 0.60, 95% CI 0.38-0.94) but not skin prick test reactivity. The effects on wheeze/asthma were greatest with later age of first infection, were observed only in skin test-negative children but were not associated with parasite burden or specific geohelminths. CONCLUSIONS: While maternal exposures to geohelminths may increase childhood wheeze, childhood geohelminths during the first 3 years may provide protection through a non-allergic mechanism</style></abstract><notes><style face="normal" font="Arial">DA - 20170928IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Ecuador -CO - United Kingdom -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1164/rccm.201706-1222OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28957644">PM:28957644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20170928-CooperPJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Respir Crit Care Med\20170928-CooperPJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170928, Cooper PJ</style></custom2><misc3><style face="normal" font="Arial">10.1164/rccm.201706-1222OC</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Palgan,K.</style></author><author><style face="normal" font="Arial"> Bartuzi,Z.</style></author><author><style face="normal" font="Arial"> Chrzaniecka,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology, Clinical Immunology and Internal Diseases, L. Rydygier Collegium Medicum, Bydgoszcz, Poland</style></auth-address><titles><title><style face="normal" font="Arial">ABO blood groups, Rhesus factor, and anaphylactic reactions due to Hymenoptera stings</style></title><secondary-title><style face="normal" font="Arial">Ann Agric Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Agric Environ Med</style></full-title></periodical><pages end="430" start="428">428-430</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood donor</style></keyword><keyword><style face="normal" font="Arial"> Blood Donors</style></keyword><keyword><style face="normal" font="Arial"> Blood Groups</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera sting</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Numerous publications indicate that the prevalence of some infectious, neoplastic and immunological diseases are associated with ABO blood groups. OBJECTIVE: The aim of this study was to verify whether ABO and Rh blood groups are associated with severe anaphylactic reactions after Hymenoptera stings. MATERIAL AND METHODS: A study was undertaken of 71,441 Caucasian subjects living in the same geographic area. The study group included 353 patients with diagnosed systemic anaphylaxis to Hymenoptera venom. Control group included 71,088 healthy blood donors. Frequencies of ABO and Rhesus groups in the study and control groups were compared using univariate and multivariate analyses. RESULTS: No statistically significant interactions were observed between the ABO blood group and anaphylactic reactions to Hymenoptera</style></abstract><notes><style face="normal" font="Arial">DA - 20170928IS - 1898-2263 (Electronic)IS - 1232-1966 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.26444/aaem/74424</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28954484">PM:28954484</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Agric Environ Med\2017-24-428-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Agric Environ Med\2017-24-428-30.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170928, Palgari K</style></custom2><misc3><style face="normal" font="Arial">10.26444/aaem/74424</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanagawa,Y.</style></author><author><style face="normal" font="Arial"> Kondo,A.</style></author><author><style face="normal" font="Arial"> Ishikawa,K.</style></author><author><style face="normal" font="Arial"> Nagasawa,H.</style></author><author><style face="normal" font="Arial"> Takeuchi,I.</style></author><author><style face="normal" font="Arial"> Jitsuiki,K.</style></author><author><style face="normal" font="Arial"> Ohsaka,H.</style></author><author><style face="normal" font="Arial"> Omori,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Acute Critical Care Medicine, Shizuoka Hospital, Juntendo University, Shizuoka, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Kounis syndrome should be excluded when physicians treat patients with anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="392">392-</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958381">PM:28958381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-392.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-119-392.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Yanagawa Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Motosue,M.S.</style></author><author><style face="normal" font="Arial"> Bellolio,M.F.</style></author><author><style face="normal" font="Arial"> Van Houten,H.K.</style></author><author><style face="normal" font="Arial"> Shah,N.D.</style></author><author><style face="normal" font="Arial"> Campbell,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota</style></auth-address><titles><title><style face="normal" font="Arial">Risk factors for severe anaphylaxis in the United States</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="361" start="356">356-361</pages><volume><style face="normal" font="Arial">119</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Claims data</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Minnesota</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk Assessment</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Anaphylaxis is an acute systemic allergic reaction and may be life-threatening. OBJECTIVE: To assess risk factors associated with severe and near-fatal anaphylaxis in a large observational cohort study. METHODS: We analyzed administrative claims data from Medicare Advantage and privately insured enrollees in the United States from 2005 to 2014. Severe anaphylaxis was defined as anaphylaxis resulting in hospital or intensive care unit (ICU) admission, requiring endotracheal intubation, or meeting criteria for near-fatal anaphylaxis. RESULTS: Of 38,695 patients seen in the emergency department for anaphylaxis during the study period, 4,431 (11.5%) required hospitalization, 2,057 (5.3%) were admitted to the ICU, 567 (1.5%) required endotracheal intubation, and 174 (0.45%) were classified as having a near-fatal episode. Multivariable analysis revealed that medication-related anaphylaxis (odds ratio [OR], 1.50; 95% confidence interval [CI], 1.38-1.63; P &lt; .001), age of 65 years or older (OR, 3.15; 95% CI, 2.88-3.44; P &lt; .001), and the presence of cardiac disease (OR, 1.56; 95% CI, 1.50-1.63; P &lt; .001) or lung disease (OR, 1.23; 95% CI, 1.16-1.30; P &lt; .001) were associated with increased odds of severe anaphylaxis requiring any hospital admission, ICU admission, or intubation or being a near-fatal reaction. CONCLUSION: In this large contemporary cohort study, 11.6% of patients had severe anaphylaxis. Age of 65 years or older, medication as a trigger, and presence of comorbid conditions (specifically cardiac and lung disease) were associated with significantly higher odds of severe anaphylaxis. Additional studies examining risk factors for severe anaphylaxis are needed to define risk assessment strategies and establish a framework for management</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.07.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958375">PM:28958375</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-356-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\2017-356-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Motosue MS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.07.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Caminati,M.</style></author><author><style face="normal" font="Arial"> Gatti,D.</style></author><author><style face="normal" font="Arial"> Dama,A.</style></author><author><style face="normal" font="Arial"> Lorenzetti,L.</style></author><author><style face="normal" font="Arial"> Senna,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma Center and Allergy Unit, Verona University and General Hospital, Verona, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Serum periostin during omalizumab therapy in asthma: a tool for patient selection and treatment evaluation</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170924IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941707">PM:28941707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170924-CaminatiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170924-CaminatiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170924, Caminati M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Havstad,S.</style></author><author><style face="normal" font="Arial"> Sitarik,A.R.</style></author><author><style face="normal" font="Arial"> Johnson,C.C.</style></author><author><style face="normal" font="Arial"> Zoratti,E.M.</style></author><author><style face="normal" font="Arial"> Ownby,D.R.</style></author><author><style face="normal" font="Arial"> Levin,A.M.</style></author><author><style face="normal" font="Arial"> Wegienka,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan.</style></auth-address><titles><title><style face="normal" font="Arial">Allergic sensitization in American children of Middle Eastern ethnicity at age 2</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170924IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941706">PM:28941706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170924-HavstadS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20170924-HavstadS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170924, Havstad S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maeno,K.</style></author><author><style face="normal" font="Arial"> Fukuda,S.</style></author><author><style face="normal" font="Arial"> Oguri,T.</style></author><author><style face="normal" font="Arial"> Niimi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Nivolumab-induced asthma in a patient with non-small cell lung cancer</style></title><secondary-title><style face="normal" font="Arial">Ann Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Oncol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung cancer</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1569-8041 (Electronic)IS - 0923-7534 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1093/annonc/mdx455</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28945837">PM:28945837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Oncol\20170925-MaenoK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Oncol\20170925-MaenoK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Maeno K</style></custom2><misc3><style face="normal" font="Arial">10.1093/annonc/mdx455</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valent,P.</style></author><author><style face="normal" font="Arial"> Akin,C.</style></author><author><style face="normal" font="Arial"> Hartmann,K.</style></author><author><style face="normal" font="Arial"> George,T.I.</style></author><author><style face="normal" font="Arial"> Sotlar,K.</style></author><author><style face="normal" font="Arial"> Peter,B.</style></author><author><style face="normal" font="Arial"> Gleixner,K.V.</style></author><author><style face="normal" font="Arial"> Blatt,K.</style></author><author><style face="normal" font="Arial"> Sperr,W.R.</style></author><author><style face="normal" font="Arial"> Manley,P.W.</style></author><author><style face="normal" font="Arial"> Hermine,O.</style></author><author><style face="normal" font="Arial"> Kluin-Nelemans,H.C.</style></author><author><style face="normal" font="Arial"> Arock,M.</style></author><author><style face="normal" font="Arial"> Horny,H.P.</style></author><author><style face="normal" font="Arial"> Reiter,A.</style></author><author><style face="normal" font="Arial"> Gotlib,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Midostaurin: a magic bullet that blocks mast cell expansion and activation</style></title><secondary-title><style face="normal" font="Arial">Ann Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Oncol</style></full-title></periodical><pages end="2376" start="2367">2367-2376</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> KIT D816V</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mutant</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="Arial">Clinically relevant features in patients with systemic mastocytosis (SM) include the cosmetic burden of lesional skin, mediator-related symptoms, and organ damage resulting from mast cell (MC) infiltration in advanced forms of SM. Regardless of the SM variant, expansion of neoplastic MC in the skin and other organs is triggered by mutant forms of KIT, the most prevalent being D816V. Activation of MC with subsequent release of chemical mediators is often caused by IgE-dependent mechanisms in these patients. Midostaurin, also known as PKC412, blocks the kinase activity of wild-type KIT and KIT D816V, counteracts KIT-dependent growth of neoplastic MC, and inhibits IgE-dependent mediator secretion. Based on this activity-profile, the drug has been used for treatment of patients with advanced SM. Indeed, encouraging results have been obtained with the drug in a recent multi-center phase II trial in patients with advanced SM, with an overall response rate of 60% and a substantial decrease in the burden of neoplastic MC in various organs. Moreover, midostaurin improved the overall survival and relapse-free survival in patients with advanced SM compared with historical controls. In addition, midostaurin was found to improve mediator-related symptoms and quality of life, suggesting that the drug may also be useful in patients with indolent SM suffering from mediator-related symptoms resistant to conventional therapies or those with MC activation syndromes. Ongoing and future studies will determine the actual value of midostaurin-induced MC depletion and MC deactivation in these additional indications</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1569-8041 (Electronic)IS - 0923-7534 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Switzerland -CO - France -CO - Netherlands -CO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/annonc/mdx290</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28945834">PM:28945834</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Oncol\2017-28-2367-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Oncol\2017-28-2367-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Valent P</style></custom2><misc3><style face="normal" font="Arial">10.1093/annonc/mdx290</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Weiner,J.J.</style></author><author><style face="normal" font="Arial"> Eudy,A.M.</style></author><author><style face="normal" font="Arial"> Criscione-Schreiber,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Duke University, Department of Medicine, Division of Rheumatology and Immunology</style></auth-address><titles><title><style face="normal" font="Arial">How Well Do Rheumatology Fellows Manage Acute Infusion Reactions? A Pilot Curricular Intervention</style></title><secondary-title><style face="normal" font="Arial">Arthritis Care Res (Hoboken)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arthritis Care Res (Hoboken)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Attitude</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> Curriculum</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Simulation</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Infusible DMARDs are commonly prescribed in rheumatology and other fields. There are no published formal educational curricula rheumatology fellowship programs can use to teach infusion reaction management skills to fellows. We aimed to better understand this educational gap, and implement and assess the effectiveness of an experiential curriculum on acute infusion reaction management. METHODS: We included current rheumatology fellows and recent graduates from five fellowship programs. Using a novel behavioral checklist we assessed fellows' performance managing an infusion reaction in a simulation, followed by a didactic focused on infusion reactions. Pre and post-surveys assessed experiences to determine relevance, as well as attitudes and knowledge. RESULTS: Despite ubiquitous prescribing of infusible biologic DMARDs, >50% of fellows were uncomfortable managing infusion reactions. Only 11% of fellows reported infusion reaction training during fellowship, but 56% reported managing actual patient infusion reactions. In the simulated infusion reaction, fellows managed grade 1 reactions appropriately, but grade 4 reactions poorly, meeting &lt;50% of objectives. All fellows discontinued the infusion in the setting of anaphylaxis, but only 56% administered epinephrine. There was no difference in performance or written knowledge by training year. All fellows felt more prepared to manage infusion reactions post-curriculum and were satisfied with the experience. CONCLUSION: We confirmed an education gap in rheumatology fellowship training regarding infusion reactions, both in knowledge and performance. We developed and implemented a brief experiential curriculum including simulation of a high-risk patient care scenario. This curriculum was well received and is easily exportable to other programs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 2151-4658 (Electronic)IS - 2151-464X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/acr.23417</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941221">PM:28941221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arthritis Care Res (Hoboken)\20170923-WeinerJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arthritis Care Res (Hoboken)\20170923-WeinerJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Weiner JJ</style></custom2><misc3><style face="normal" font="Arial">10.1002/acr.23417</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bando,T.</style></author><author><style face="normal" font="Arial"> Fujita,S.</style></author><author><style face="normal" font="Arial"> Nagano,N.</style></author><author><style face="normal" font="Arial"> Yoshikawa,S.</style></author><author><style face="normal" font="Arial"> Yamanishi,Y.</style></author><author><style face="normal" font="Arial"> Minami,M.</style></author><author><style face="normal" font="Arial"> Karasuyama,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immune Regulation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Differential usage of COX-1 and COX-2 in prostaglandin production by mast cells and basophils</style></title><secondary-title><style face="normal" font="Arial">Biochem Biophys Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Biophys Rep</style></full-title></periodical><pages end="87" start="82">82-87</pages><volume><style face="normal" font="Arial">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> early phase</style></keyword><keyword><style face="normal" font="Arial"> early-phase</style></keyword><keyword><style face="normal" font="Arial"> Eicosanoids</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune regulation</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> lipid mediators</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> PGE2</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> prostaglandin</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time course</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">Basophils have been erroneously considered as minor relatives of mast cells, due to some phenotypic similarity between them. While recent studies have revealed non-redundant roles for basophils in various immune responses, basophil-derived effector molecules, including lipid mediators, remain poorly characterized, compared to mast cell-derived ones. Here we analyzed and compared eicosanoids produced by mouse basophils and mast cells when stimulated with IgE plus allergens. The production of 5-LOX metabolites such as LTB4 and 5-HETE was detected as early as 0.5 h post-stimulation in both cell types, even though their amounts were much smaller in basophils than in mast cells. In contrast, basophils and mast cells showed distinct time course in the production of COX metabolites, including PGD2, PGE2 and 11-HETE. Their production by mast cells was detected at both 0.5 and 6 h post-stimulation while that by basophils was detectable only at 6 h. Of note, mast cells showed 8-9 times higher levels of COX-1 than did basophils at the resting status. In contrast to unaltered COX-1 expression with or without stimulation, COX-2 expression was up-regulated in both cell types upon activation. Importantly, when activated, basophils expressed 4-5 times higher levels of COX-2 than did mast cells. In accordance with these findings, the late-phase production of the COX metabolites by basophils was completely ablated by COX-2 inhibitor whereas the early-phase production by mast cells was blocked by COX-1 but not COX-2 inhibitor. Thus, the production of COX metabolites is differentially regulated by COX-1 and COX-2 in basophils and mast cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170928IS - 2405-5808 (Print)IS - 2405-5808 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbrep.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28955738">PM:28955738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochem Biophys Rep\2017-10-82-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochem Biophys Rep\2017-10-82-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170928, Bando T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbrep.2017.03.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ohkusu-Tsukada,K.</style></author><author><style face="normal" font="Arial"> Tsukada,T.</style></author><author><style face="normal" font="Arial"> Takahashi,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Veterinary Pathology , Nippon Veterinary &amp; Life-science University , Tokyo , Japan</style></auth-address><titles><title><style face="normal" font="Arial">Clonal deletion of T cell repertoires with specific T cell receptor Vbeta chains by two endogenous superantigens in NC/Nga mice</style></title><secondary-title><style face="normal" font="Arial">Biosci Biotechnol Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biosci Biotechnol Biochem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Clonal Deletion</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> Superantigens</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">Superantigens (SAgs) are powerful T-cell stimulatory proteins. Because an atopic dermatitis (AD) model NC/Nga mice had two endogenous SAgs, namely minor lymphocyte-stimulating locus-1a (Mls-1a) and mouse mammary tumor virus (MMTV)(SHN), SAg-responsive T-cells bearing Vbeta5.1, Vbeta6, Vbeta8.1, Vbeta8.2, Vbeta8.3, Vbeta9, and Vbeta11 should be endogenously deleted. Here, we discuss that the endogenous SAgs-expression may be involved in AD-sensitivity in NC/Nga mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 1347-6947 (Electronic)IS - 0916-8451 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/09168451.2017.1374829</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28934904">PM:28934904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biosci Biotechnol Biochem\20170922-OhkusuTsukadaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biosci Biotechnol Biochem\20170922-OhkusuTsukadaK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170922, Ohkusu-Tsukada K</style></custom2><misc3><style face="normal" font="Arial">10.1080/09168451.2017.1374829</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kundumadam,S.</style></author><author><style face="normal" font="Arial"> Reddy,V.</style></author><author><style face="normal" font="Arial"> Mallikethi,R.S.</style></author><author><style face="normal" font="Arial"> Kathi,P.</style></author><author><style face="normal" font="Arial"> Abidov,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Wayne State University School of Medicine, Detroit, MI, USA</style></auth-address><titles><title><style face="normal" font="Arial">An Unusual Case of Recurrent Hypersensitivity Reaction Associated with Kounis-Like Acute Coronary Syndrome</style></title><secondary-title><style face="normal" font="Arial">Case Rep Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Rep Cardiol</style></full-title></periodical><pages end="" start="6421208">6421208-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Arteries</style></keyword><keyword><style face="normal" font="Arial"> Coronary Artery Bypass</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> heart failure</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Kounis</style></keyword><keyword><style face="normal" font="Arial"> Kounis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">There have been multiple reports of allergic reactions associated with acute coronary syndromes. This has been classically described as Kounis syndrome. We present an unusual case of 70-year-old male with multiple prior hypersensitivity reactions and history of coronary artery bypass grafting who presented recurrent episode of severe angioedema and anaphylaxis. He responded to epinephrine but subsequently developed a non-ST elevation myocardial infarction with worsening heart failure. Our case is unique in that, unlike classic Kounis syndrome, the acute coronary event in this case did not present concurrently with the allergic reaction; rather it took nearly 48 hours to present. Subsequent angiogram revealed patent grafts and significant decline in the left ventricular systolic function as compared to his own ECHO a year ago. We postulate that slow mediators of inflammation may play a role in delayed development of acute coronary events with associated LV dysfunction following episodes of angioedema and anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 2090-6404 (Print)IS - 2090-6404 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/6421208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28928989">PM:28928989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Cardiol\2017-2017-6421208.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Cardiol\2017-2017-6421208.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Kundumadam S</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/6421208</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,C.</style></author><author><style face="normal" font="Arial"> Fu,Y.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Kong,Y.</style></author><author><style face="normal" font="Arial"> Li,M.</style></author><author><style face="normal" font="Arial"> Ma,D.</style></author><author><style face="normal" font="Arial"> Zhai,W.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Lin,Y.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author><author><style face="normal" font="Arial"> Ren,F.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Graduate School of Beijing University of Chinese Medicine, Clinical Medical School of Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China</style></auth-address><titles><title><style face="normal" font="Arial">Mesenchymal stromal cells ameliorate acute allergic rhinitis in rats</style></title><secondary-title><style face="normal" font="Arial">Cell Biochem Funct</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Biochem Funct</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mesenchymal Stromal Cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Stromal Cells</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Umbilical Cord</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">Mesenchymal stromal cells (MSCs) have been extensively investigated as a potential antiinflammatory treatment in many inflammatory-related diseases; however, it remains unclear whether MSCs could be used to treat acute allergic rhinitis. A rat model of allergic rhinitis was treated with MSCs. The effect of MSCs on the inflammation of allergic rhinitis was evaluated by sneezing, nose rubbing, the pathology of the nasal mucosa, and the expression of interleukin 4, tumour necrosis factor alpha, and immunoglobulin E in the serum of rats. Also, the population of MSCs isolated from umbilical cords of humans was evaluated to determine if they could inhibit the symptoms and inflammation of acute allergic rhinitis in a rat model. We observed that this population of cells inhibited sneezing, nose rubbing, and changes in the pathology of the nasal mucosa. Intriguingly, we observed that MSCs reduced the expression of interleukin 4, tumour necrosis factor alpha, and immunoglobulin E in the serum. Furthermore, MSCs reduced the expression of histamine and the recruitment of macrophages in the nasal mucosa of allergic rhinitis rats. We reasoned that the effect of MSCs on allergic rhinitis might be through its regulation of the secretion of related cytokines from macrophages during the process of acute allergic rhinitis. This work suggested that MSCs from the umbilical cords of humans could be used as a positive clinical therapy for the human disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1099-0844 (Electronic)IS - 0263-6484 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1002/cbf.3291</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940415">PM:28940415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Biochem Funct\20170923-LiC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Biochem Funct\20170923-LiC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Li C</style></custom2><misc3><style face="normal" font="Arial">10.1002/cbf.3291</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,X.Y.</style></author><author><style face="normal" font="Arial"> Tang,X.Y.</style></author><author><style face="normal" font="Arial"> Ma,L.J.</style></author><author><style face="normal" font="Arial"> Guo,Y.L.</style></author><author><style face="normal" font="Arial"> Li,X.S.</style></author><author><style face="normal" font="Arial"> Zhao,L.M.</style></author><author><style face="normal" font="Arial"> Tian,C.J.</style></author><author><style face="normal" font="Arial"> Cheng,D.J.</style></author><author><style face="normal" font="Arial"> Chen,Z.C.</style></author><author><style face="normal" font="Arial"> Zhang,L.X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, People's Hospital Affiliated to Zhengzhou University, Zhengzhou, China</style></auth-address><titles><title><style face="normal" font="Arial">Schisandrin B down-regulated lncRNA BCYRN1 expression of airway smooth muscle cells by improving miR-150 expression to inhibit the proliferation and migration of ASMC in asthmatic rats</style></title><secondary-title><style face="normal" font="Arial">Cell Prolif</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Cell Prolif</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The mechanism of Schisandrin B on the proliferation and migration of airway smooth muscle cells (ASMCs) in asthmatic rats was explored. METHODS: SD rats were divided into three groups: control (group 1), model (group 2) and model + Schisandrin B (group 3). miR-150 and lncRNA BCYRN1 levels were measured by qRT-PCR. The combination of BCYRN1 and miR-150 was detected by RNA pull down. ASMCs' viability/proliferation/migration were examined by WST-1 assay and 24-well Transwell system. RESULTS: Schisandrin B up-regulated miR-150 expression and down-regulated BCYRN1 expression in sensitized rats. Schisandrin B reversed the expression of miR-150 and BCYRN1 in MV-treated ASMCs. In addition, Schisandrin B inhibited the viability, proliferation and migration of MV-induced ASMCs. We also found miR-150 inhibited BCYRN1 expression which was proved by experiments using ASMCs transfected with miR-150 inhibitor. CONCLUSION: Schisandrin B increased miR-150 expression and decreased BCYRN1, and BCYRN1 expression was inhibited by miR-150, which indicated that Schisandrin B could regulate BCYRN1 through miR-150</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1365-2184 (Electronic)IS - 0960-7722 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1111/cpr.12382</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960519">PM:28960519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Prolif\20170929-ZhangXY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Prolif\20170929-ZhangXY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Zhang XY</style></custom2><misc3><style face="normal" font="Arial">10.1111/cpr.12382</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Anagnostou,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Immunology, Allergy and Rheumatology, Texas Children's Hospital, Feigin Center, 1102 Bates Avenue, Suite 330, MS: BCM320, Houston, TX 77030, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Coconut Allergy Revisited</style></title><secondary-title><style face="normal" font="Arial">Children (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Children (Basel)</style></abbr-1></periodical><pages end="" start="85">85-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Coconut</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="Arial">Despite concerns voiced often by food-allergic patients, allergy to coconut is rare, not directly associated with nut allergy and few cases are reported so far in the literature. We present an interesting case of coconut allergy in a child that was previously tolerant to coconut and regularly exposed via both the skin and gastrointestinal route</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2227-9067 (Print)IS - 2227-9067 (Linking)LA - engPT - Case ReportsCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/children4100085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28961189">PM:28961189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Children (Basel)\2017-4-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Children (Basel)\2017-4-85.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Anagnostou K</style></custom2><misc3><style face="normal" font="Arial">10.3390/children4100085</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hejl,C.</style></author><author><style face="normal" font="Arial"> Mestiri,R.</style></author><author><style face="normal" font="Arial"> Carmoi,T.</style></author><author><style face="normal" font="Arial"> Bugier,S.</style></author><author><style face="normal" font="Arial"> Chianea,D.</style></author><author><style face="normal" font="Arial"> Renard,C.</style></author><author><style face="normal" font="Arial"> Vest,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">IgE monoclonal gammopathy: A case report and literature review</style></title><secondary-title><style face="normal" font="Arial">Clin Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Biochem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gammopathy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> MGUS</style></keyword><keyword><style face="normal" font="Arial"> Multiple Myeloma</style></keyword><keyword><style face="normal" font="Arial"> Myeloma</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0009-9120</style></isbn><abstract><style face="normal" font="Arial">Immunoglobulin E (IgE) gammopathy is a rare disorder, accounting for just 0.1% of all patients with multiple myeloma (MM). Herein, we report a case of IgE monoclonal gammopathy without any biological and clinical symptoms, and we review 63 published cases in the literature. Demographic, biological and clinical presentations and features appear to be similar to those of other subtypes of MM, with a median age of diagnosis of 67 years. There is a slight excess of male patients, and incidence seems to increase with age. The prevalence of renal failure, anaemia and hypercalcaemia at diagnosis was computed to be at 26%, 44% and 18%, respectively, in patients with MM. According to the literature, IgE MM is more aggressive and associated with poorer survival. Nonetheless, cases that are prolonged have also been described</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clinbiochem.2017.09.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941591">PM:28941591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Biochem\20171002-HejlC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Biochem\20171002-HejlC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Hejl C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clinbiochem.2017.09.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kos,S.</style></author><author><style face="normal" font="Arial"> Sanders,R.J.</style></author><author><style face="normal" font="Arial"> Neele,M.</style></author><author><style face="normal" font="Arial"> O'Sullivan,N.</style></author><author><style face="normal" font="Arial"> Ruikes-Mertens,S.</style></author><author><style face="normal" font="Arial"> Phaff,R.A.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Central Laboratory of the Hospital (Maasstad Lab), Department of Clinical Chemistry, Maasstad Hospital, Rotterdam</style></auth-address><titles><title><style face="normal" font="Arial">Preliminary study in specific activity of molecular components in allergy: implications for diagnostics and relationship with disease severity</style></title><secondary-title><style face="normal" font="Arial">Clin Chem Lab Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chem Lab Med</style></full-title></periodical><pages end="e117" start="e113">e113-e117</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Area Under Curve</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child,Preschool</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical chemistry</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="Arial"> Young Adult</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161008IS - 1437-4331 (Electronic)IS - 1434-6621 (Linking)LA - engPT - LetterRN - 0 (Allergens)RN - 0 (Immunoglobulin G)RN - 37341-29-0 (Immunoglobulin E)SB - IMCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1515/cclm-2016-0726</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27718486">PM:27718486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Chem Lab Med\2017-55-e113-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Chem Lab Med\2017-55-e113-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161008, Kos S</style></custom2><misc3><style face="normal" font="Arial">10.1515/cclm-2016-0726</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shaheen,S.O.</style></author><author><style face="normal" font="Arial"> Macdonald-Wallis,C.</style></author><author><style face="normal" font="Arial"> Lawlor,D.A.</style></author><author><style face="normal" font="Arial"> Henderson,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Primary Care and Public Health, Barts and The London, School of Medicine and Dentistry</style></auth-address><titles><title><style face="normal" font="Arial">Haemoglobin concentrations in pregnancy and respiratory and allergic outcomes in childhood: birth cohort study</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disorders</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitisation</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Dentistry</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> forced vital capacity</style></keyword><keyword><style face="normal" font="Arial"> Haemoglobin</style></keyword><keyword><style face="normal" font="Arial"> Hayfever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> iron</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">Background Limited epidemiological evidence suggests that low maternal iron status and anaemia in pregnancy may increase the risk of childhood respiratory and allergic outcomes. Objectives To investigate the relation between maternal haemoglobin concentrations in pregnancy and childhood respiratory and allergic outcomes. Methods In the Avon Longitudinal Study of Parents and Children (ALSPAC) we examined associations of maternal haemoglobin concentrations (g/dL) in pregnancy with hayfever, eczema, wheezing, doctor-diagnosed asthma, allergic sensitisation and total IgE at 7 years, and with lung function at 8-9 years in the offspring, after controlling for potential confounders (N=3234-5335). Results Maternal haemoglobin was not associated with offspring hayfever, eczema, wheezing or asthma. However, the first haemoglobin measurement in pregnancy (&lt;18 weeks' gestation) and the last measurement (>28 weeks' gestation) were negatively associated with allergic sensitisation (adjusted odds ratio (95% CI) per g/dl 0.91 (0.83 to 0.99) and 0.90 (0.83 to 0.98), respectively). The last haemoglobin measurement was also negatively associated with total IgE (adjusted geometric mean ratio 0.94 (0.88 to 0.99)). Anaemia (haemoglobin &lt;11g/dL) in late pregnancy was negatively associated with Forced Vital Capacity (difference in standard deviation score -0.07 (-0.13 to -0.01)). Conclusions and clinical relevance Lower maternal haemoglobin in pregnancy may be a risk factor for allergic sensitisation, elevated IgE and lower FVC in childhood, which may reflect effects of lower prenatal iron status. However, maternal haemoglobin was not associated with risk of childhood asthma or other allergic disorders. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940397">PM:28940397</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170923-ShaheenSO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170923-ShaheenSO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Shaheen SO</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brzoza,Z.</style></author><author><style face="normal" font="Arial"> Grzeszczak,W.</style></author><author><style face="normal" font="Arial"> Trautsolt,W.</style></author><author><style face="normal" font="Arial"> Moczulski,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Inducible T-cell costimulator (ICOS) and CD28 polymorphisms possibly play a role in the pathogenesis of chronic autoreactive urticaria</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> autologous serum skin test</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> haplotype</style></keyword><keyword><style face="normal" font="Arial"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="Arial"> ICOS</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Clinical experience emphasizes the coexistence of chronic spontaneous urticaria (CSU) and autoimmune disturbances. In chromosome 2q33-34, there is a cluster of homologous genes that are considered promising candidate genes for susceptibility to autoimmune diseases. AIM: To examine the possible role of polymorphisms in the genes for CD28 and inducible T-cell costimulator (ICOS) in the background of CSU. METHODS: In total, 149 patients with CSU with positive autologous serum skin test were enrolled in the study. The healthy control (HC) group consisted of 100 healthy volunteers. In all subjects, the CD28 rs2140148 and rs3116496 and the ICOS rs6726035 polymorphisms were analysed. Disease severity was assessed by means of Urticaria Activity Score. RESULTS: We found a statistically significantly lower prevalence of the ICOS rs6726035 TT genotype among patients with CSU compared with HCs. Furthermore, the haplotype rs2140148A, rs3116496T and rs6726035C presented a possible association with CSU. We did not find any association between the examined polymorphisms and either urticaria severity or age of disease onset. CONCLUSIONS: Our results underline the role of autoimmune components in the pathogenesis of chronic autoreactive urticaria, and indicate it as a potentially genetically related disorder</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1111/ced.13212</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940644">PM:28940644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20170923-BrzozaZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20170923-BrzozaZ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Brzoza Z</style></custom2><misc3><style face="normal" font="Arial">10.1111/ced.13212</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lauener,R.</style></author><author><style face="normal" font="Arial"> Eigenmann,P.A.</style></author><author><style face="normal" font="Arial"> Wassenberg,J.</style></author><author><style face="normal" font="Arial"> Jung,A.</style></author><author><style face="normal" font="Arial"> Denery-Papini,S.</style></author><author><style face="normal" font="Arial"> Sjolander,S.</style></author><author><style face="normal" font="Arial"> Pecquet,S.</style></author><author><style face="normal" font="Arial"> Fritsche,R.</style></author><author><style face="normal" font="Arial"> Zuercher,A.</style></author><author><style face="normal" font="Arial"> Wermeille,A.</style></author><author><style face="normal" font="Arial"> Fontanesi,M.</style></author><author><style face="normal" font="Arial"> Mercenier,A.</style></author><author><style face="normal" font="Arial"> Vissers,Y.M.</style></author><author><style face="normal" font="Arial"> Nutten,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">St. Gallen, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Oral Immunotherapy With Partially Hydrolyzed Wheat-Based Cereals: A Pilot Study</style></title><secondary-title><style face="normal" font="Arial">Clin Med Insights Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Med Insights Pediatr</style></abbr-1></periodical><pages end="" start="1179556517730018">1179556517730018-</pages><volume><style face="normal" font="Arial">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> and primary</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">To date, only few studies have assessed oral immunotherapy (OIT) for wheat allergy and often describe severe adverse reactions during therapy. We developed partially hydrolyzed wheat-based cereals (pHC), which were used in a multicenter, open-label, OIT pilot study, in immunoglobulin E-mediated wheat allergy children (NCT01332084). The primary objective of the study was to test whether wheat allergic patients tolerate pHC and primary end point was the presence or not of immediate adverse reactions to pHC during the 1-day initial escalation phase (stepwise increased doses of pHC), with evaluation of the maximum dose tolerated. Of the 9 patients enrolled in the trial, 4 discontinued OIT because of mild to severe reactions at the initial escalation phase. The 5 patients who passed the escalation phase consumed pHC daily for 1 to 6 months. One of these patients withdrew due to noncompliance, whereas the 4 others completed the study and successfully passed the wheat challenge test at the end of the study. About 60% of the adverse events were unrelated to the study product. Our study provides preliminary evidence that pHC is tolerated by a subset of wheat allergic patients. Further studies are warranted to test its efficacy as a potential therapeutic option for wheat allergic patients</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1179-5565 (Print)IS - 1179-5565 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - France -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1177/1179556517730018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959122">PM:28959122</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Med Insights Pediatr\2017-11-1179556517730018.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Med Insights Pediatr\2017-11-1179556517730018.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Lauener R</style></custom2><misc3><style face="normal" font="Arial">10.1177/1179556517730018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chatkin,J.M.</style></author><author><style face="normal" font="Arial"> Zani-Silva,L.</style></author><author><style face="normal" font="Arial"> Ferreira,I.</style></author><author><style face="normal" font="Arial"> Zamel,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Respiratory Diseases, School of Medicine Pontificia Universidade Catolica do Rio Grande do Sul, Av Ipiranga 6680 Room 501, Porto Alegre, 90610-000, Brazil. jmchatkin@pucrs.brDivision of Respiratory Diseases, School of Medicine Pontificia Universidade Catolica do Rio Grande do Sul, Av Ipiranga 6680 Room 501, Porto Alegre, 90610-000, BrazilRespirology Division, McMaster University, 399 Bathurst St, Toronto, ON, M5T2S8, CanadaDepartment of Medicine, Division of Respiratory Diseases, University of Toronto, 399 Bathurst St, Toronto, ON, M5T2S8, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Cannabis-Associated Asthma and Allergies</style></title><secondary-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cannabis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Marijuana</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> second-hand smoke</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">Inhalation of cannabis smoke is its most common use and the pulmonary complications of its use may be the single most common form of drug-induced pulmonary disease worldwide. However, the role of cannabis consumption in asthma patients and allergic clinical situations still remains controversial. To review the evidence of asthma and allergic diseases associated with the use of marijuana, we conducted a search of English, Spanish, and Portuguese medical using the search terms asthma, allergy, marijuana, marihuana, and cannabis. Entries made between January 1970 and March 2017 were retrieved. Several papers have shown the relationship between marijuana use and increase in asthma and other allergic diseases symptoms, as well as the increased frequency of medical visits. This narrative review emphasizes the importance to consider cannabis as a precipitating factor for acute asthma and allergic attacks in clinical practice. Although smoking of marijuana may cause respiratory symptoms, there is a need for more studies to elucidate many aspects in allergic asthma patients, especially considering the long-term use of the drug. These patients should avoid using marijuana and be oriented about individual health risks, possible dangers of second-hand smoke exposure, underage use, safe storage, and the over smoking of marijuana</style></abstract><notes><style face="normal" font="Arial">DA - 20170918IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12016-017-8644-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28921405">PM:28921405</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170918-ChalkinJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170918-ChalkinJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170918, Chalkin JM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12016-017-8644-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wai,C.Y.Y.</style></author><author><style face="normal" font="Arial"> Leung,N.Y.H.</style></author><author><style face="normal" font="Arial"> Leung,P.S.C.</style></author><author><style face="normal" font="Arial"> Chu,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Simon F.S. Li Marine Science Laboratory, School of Life Sciences, The Chinese University of Hong Kong, Room 201A, Science Park Road, Shatin, N.T., Hong Kong, SAR, China</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy of Food Allergy: a Comprehensive Review</style></title><secondary-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Rev Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Employment</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding epitopes</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">Food allergy imposes a severe global health burden, and thus, there is a dire need for safe and effective treatments. Allergen-specific immunotherapy (AIT) is currently the only approach to restore immune tolerance through administrating increasing doses of allergen extracts. Unfortunately, the development of AIT for food allergies has been impeded by the frequent anaphylactic side effects during the course of treatment. The emergence of component-resolved diagnosis has greatly improved our ability to identify causative allergens and revolutionized the design of AIT. Molecular features such as IgE-binding epitopes and T cell epitopes have been elucidated in most major food allergens, inspiring the use of multiple strategies to manipulate the allergens and design safer alternatives to AIT. Although these allergen-modifying approaches are currently restricted to preclinical characterization and animal studies, the employment of these strategies has certainly paved the way for improving the safety of existing AIT. A safe and effective AIT for food allergy is not far beyond reach</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Hong Kong -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12016-017-8647-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28929421">PM:28929421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170920-WaiCY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Rev Allergy Immunol\20170920-WaiCY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Wai CY</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12016-017-8647-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Netts,P.</style></author><author><style face="normal" font="Arial"> Michaelis,L.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Benfield Park Medical Group, Newcastle Upon Tyne, NE6 4QD UK</style></auth-address><titles><title><style face="normal" font="Arial">An interpretation of the new international MAP guideline for the management of Milk Allergy in Primary Care</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> early childhood</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> General practitioner</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> primary care</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">General Practitioners suffer from guideline fatigue. They come fast and furious in many complicated forms. Cow's milk allergy (CMA) is one of the most common presentations of food allergy seen in early childhood presenting to primary and secondary care. The early and accurate diagnosis continues to be highlighted in many countries worldwide. International surveys have found that primary care clinicians would like clearer explanations for the options for the diagnosis of CMA and in so doing a means to increase their understanding of management options for both IgE and Non IgE mediated CMA. In 2013 in response to General Practitioner demands, the UK guideline, 'Diagnosis and management of non-IgE-mediated CMA in infancy-a UK primary care practical guide' was published in this journal. This Milk Allergy in Primary Care (MAP) guideline outlines in simple algorithmic form how to diagnose, manage and refer children with CMA in a primary care setting. Based on the international uptake of the MAP guideline, a global practical guideline International MAP is presented by the Venter and Brown et al to help practitioners in primary care settings. It incorporates further published UK guidance, feedback from UK healthcare professionals and affected families and, importantly, also international guidance and expertise</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0171-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28948011">PM:28948011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Netts P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0171-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boelke,G.</style></author><author><style face="normal" font="Arial"> Berger,U.</style></author><author><style face="normal" font="Arial"> Bergmann,K.C.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Gildemeister,J.</style></author><author><style face="normal" font="Arial"> Jutel,M.</style></author><author><style face="normal" font="Arial"> Pfaar,O.</style></author><author><style face="normal" font="Arial"> Sehlinger,T.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Department of Dermatology and Allergy, Allergy-Center-Charite, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="33">33-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> inverse correlation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Congestion</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The GA2LEN chamber has been developed as a novel mobile allergen exposure chamber (AEC) allowing standardized multicenter trials in allergy. Hitherto, subjective nasal symptom scores have been the most often used outcome parameter, but in standardized modern trials objective parameters are preferred. Despite its practicability, the objective parameter peak nasal inspiratory flow (PNIF) has been rarely used for allergy trials in the setting of allergen exposure chambers. This study aims to evaluate PNIF as an outcome parameter for provocation studies in AECs. METHODS: In a randomized controlled blinded setting subjects suffering from allergic rhinitis were exposed to grass pollen, birch pollen, house dust mite and/or placebo in the GA2LEN chamber. Different allergen concentrations were used to evaluate symptom severities. Patients had to perform PNIF before and every 30 min during a challenge using a portable PNIF meter. RESULTS: 86 subjects participated in 203 challenges, altogether. House dust mite provocations caused the greatest reduction in PNIF values, followed by grass pollen and birch pollen. Provocations with every allergen or pollen concentration led to a significant decrease (p &lt; 0.05) in PNIF compared to baseline. Furthermore, positive correlations were obtained between PNIF and peak expiratory flow, height and weight, and inverse correlations between PNIF and total nasal symptom score, nasal congestion score and visual analog scale of overall subjective symptoms. CONCLUSION: PNIF is a helpful and feasible tool for conducting provocation trials with allergens, especially grass pollen and house dust mite, in an AEC</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Austria -CO - Denmark -CO - France -CO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0169-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28932387">PM:28932387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Boelke G</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0169-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farne,H.A.</style></author><author><style face="normal" font="Arial"> Wilson,A.</style></author><author><style face="normal" font="Arial"> Powell,C.</style></author><author><style face="normal" font="Arial"> Bax,L.</style></author><author><style face="normal" font="Arial"> Milan,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Imperial College, London, UK, W2 1PG</style></auth-address><titles><title><style face="normal" font="Arial">Anti-IL5 therapies for asthma</style></title><secondary-title><style face="normal" font="Arial">Cochrane Database Syst Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cochrane Database Syst Rev</style></full-title></periodical><pages end="" start="CD010834">CD010834-</pages><volume><style face="normal" font="Arial">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ACQ</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> asthma guidelines</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Data Collection</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> List</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> serious adverse events</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: This review is the first update of a previously published review in The Cochrane Library (Issue 7, 2015). Interleukin-5 (IL-5) is the main cytokine involved in the activation of eosinophils, which cause airway inflammation and are a classic feature of asthma. Monoclonal antibodies targeting IL-5 or its receptor (IL-5R) have been developed, with recent studies suggesting that they reduce asthma exacerbations, improve health-related quality of life (HRQoL) and lung function. These are being incorporated into asthma guidelines. OBJECTIVES: To compare the effects of therapies targeting IL-5 signalling (anti-IL-5 or anti-IL-5Ralpha) with placebo on exacerbations, health-related qualify of life (HRQoL) measures, and lung function in adults and children with chronic asthma, and specifically in those with eosinophilic asthma refractory to existing treatments. SEARCH METHODS: We searched the Cochrane Airways Trials Register, clinical trials registries, manufacturers' websites, and reference lists of included studies. The most recent search was March 2017. SELECTION CRITERIA: We included randomised controlled trials comparing mepolizumab, reslizumab and benralizumab versus placebo in adults and children with asthma. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and analysed outcomes using a random-effects model. We used standard methods expected by Cochrane. MAIN RESULTS: Thirteen studies on 6000 participants met the inclusion criteria. Four used mepolizumab, four used reslizumab, and five used benralizumab. One study in benralizumab was terminated early due to sponsor decision and contributed no data. The studies were predominantly on people with severe eosinophilic asthma, which was similarly but variably defined. Eight included children over 12 years but these results were not reported separately. We deemed the risk of bias to be low, with all studies contributing data being of robust methodology. We considered the quality of the evidence for all comparisons to be high overall using the GRADE scheme, with the exception of intravenous mepolizumab because this is not currently a licensed delivery route.All of the anti-IL-5 treatments assessed reduced rates of 'clinically significant' asthma exacerbation (defined by treatment with systemic corticosteroids for three days or more) by approximately half in participants with severe eosinophilic asthma on standard of care (at least medium-dose inhaled corticosteroids (ICS)) with poorly controlled disease (either two or more exacerbations in the preceding year or Asthma Control Questionnaire (ACQ) 1.5 or more). Non-eosinophilic participants treated with benralizumab also showed a significant reduction in exacerbation rates, but no data were available for non-eosinophilic participants, and mepolizumab or reslizumab.We saw modest improvements in validated HRQoL scores with all anti-IL-5 agents in severe eosinophilic asthma. However these did not exceed the minimum clinically important difference for ACQ and Asthma Quality of Life Questionnaire (AQLQ), with St. George's Respiratory Questionnaire (SGRQ) only assessed in two studies. The improvement in HRQoL scores in non-eosinophilic participants treated with benralizumab, the only intervention for which data were available in this subset, was not statistically significant, but the test for subgroup difference was negative.All anti-IL-5 treatments produced a small but statistically significant improvement in mean pre-bronchodilator forced expiratory flow in one second (FEV1) of between 0.08 L and 0.11 L.There were no excess serious adverse events with any anti-IL-5 treatment, and indeed a reduction in favour of mepolizumab that could be due to a beneficial effect on asthma-related serious adverse events. There was no difference compared to placebo in adverse events leading to discontinuation with mepolizumab or reslizumab, but significantly more discontinued benralizumab than placebo, although the absolute numbers were small (36/1599 benralizumab versus 9/998 placebo).Mepolizumab, reslizumab and benralizumab all markedly reduced blood eosinophils, but benralizumab resulted in almost complete depletion, whereas a small number remained with mepolizumab and reslizumab. The implications for efficacy and/or adverse events are unclear. AUTHORS' CONCLUSIONS: Overall our study supports the use of anti-IL-5 treatments as an adjunct to standard of care in people with severe eosinophilic asthma and poor control. These treatments roughly halve the rate of asthma exacerbations in this population. There is limited evidence for improved HRQoL scores and lung function, which may not meet clinically detectable levels. There were no safety concerns regarding mepolizumab or reslizumab, and no excess serious adverse events with benralizumab, although there remains a question over adverse events significant enough to prompt discontinuation.Further research is needed on biomarkers for assessing treatment response, optimal duration and long-term effects of treatment, risk of relapse on withdrawal, non-eosinophilic patients, children (particularly under 12 years), and comparing anti-IL-5 treatments to each other and, in people eligible for both, to anti-immunoglobulin E. For benralizumab, future studies should closely monitor rates of adverse events prompting discontinuation</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 1469-493X (Electronic)IS - 1361-6137 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United KIngdom -</style></notes><work-type><style face="normal" font="Arial">10.1002/14651858.CD010834.pub3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28933516">PM:28933516</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cochrane Database Syst Rev\2017-9-CD010834.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cochrane Database Syst Rev\2017-9-CD010834.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Farne HA</style></custom2><misc3><style face="normal" font="Arial">10.1002/14651858.CD010834.pub3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aalto-Korte,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Occupational Medicine, Finnish Institute of Occupational Health, PO Box 40, 00251 Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">When should the diagnosis 'contact urticaria' be used?</style></title><secondary-title><style face="normal" font="Arial">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact urticaria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Membranes</style></keyword><keyword><style face="normal" font="Arial"> Mucous Membrane</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reaction</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">In the dermatological literature, the term 'contact urticaria syndrome' is often used with patients presenting no symptoms of contact urticaria, but symptoms of adjacent mucous membranes evolving to a systemic allergic reaction. Contact urticaria refers to a wheal and flare reaction following external contact with a causative substance. Its use should be restricted to skin: a skin reaction after direct skin contact</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/cod.12884</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940487">PM:28940487</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\20170923-AaltoKorteK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\20170923-AaltoKorteK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Aalto-Korte K</style></custom2><misc3><style face="normal" font="Arial">10.1111/cod.12884</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mahato,N.</style></author><author><style face="normal" font="Arial"> Sharma,K.</style></author><author><style face="normal" font="Arial"> Koteswararao,R.</style></author><author><style face="normal" font="Arial"> Sinha,M.</style></author><author><style face="normal" font="Arial"> Baral,E.R.</style></author><author><style face="normal" font="Arial"> Cho,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a School of Chemical Engineering, Yeungnam University , Gyeongsan , Republic of Korea -38541</style></auth-address><titles><title><style face="normal" font="Arial">Citrus essential oils: Extraction, authentication and application in food preservation</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibacterial</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Authentication</style></keyword><keyword><style face="normal" font="Arial"> Benzoates</style></keyword><keyword><style face="normal" font="Arial"> Biodegradable</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Citrus</style></keyword><keyword><style face="normal" font="Arial"> citrus essential oils</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Essential oil</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Preservation</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> microencapsulation</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Nitrates</style></keyword><keyword><style face="normal" font="Arial"> Nitrites</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> Oils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Polymers</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword></keywords><dates><year Day="28" Month="9" Year="2017">2017/9/28</year></dates><abstract><style face="normal" font="Arial">Citrus EOs is an economic, eco-friendly and natural alternatives to chemical preservatives and other synthetic antioxidants, such as sodium nitrites, nitrates or benzoates, commonly utilized in food preservation. Citrus based EOs is obtained mainly from the peels of citrus fruits which are largely discarded as wastes and cause environmental problems. The extraction of citrus oils from the waste peels not only saves environment but can be used in various applications including food preservation. The present article presents elaborated viewpoints on the nature and chemical composition of different EOs present in main citrus varieties widely grown across the globe; extraction, characterization and authentication techniques/methods of the citrus EOs; and reviews the recent advances in the application of citrus EOs for the preservation of fruits, vegetables, meat, fish and processed food stuffs. The probable reaction mechanism of the EOs based thin films formation with biodegradable polymers is presented. Other formulation, viz., EOs microencapsulation incorporating biodegradable polymers, nanoemulsion coatings, spray applications and antibacterial action mechanism of the active compounds present in the EOs have been elaborated. Extensive research is required on overcoming the challenges regarding allergies and obtaining safer dosage limits. Shift towards greener technologies indicate optimistic future towards safer utilization of citrus based EOs in food preservation</style></abstract><notes><style face="normal" font="Arial">DA - 20170928IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - India -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2017.1384716</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28956626">PM:28956626</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\20170928-MahatoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\20170928-MahatoN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170928, Mahato N</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2017.1384716</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Levin,M.E.</style></author><author><style face="normal" font="Arial"> Warner,J.O.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The atopic dance.</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="154" start="150">150-154</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">aetiology</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic march</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic march</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergy</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> the allergic march</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The atopic march refers to the disorders that commonly occur together and track with age in a characteristicorder, starting with atopic dermatitis often associated with food allergy, then inhalant allergy contributingto the development of asthma and then rhinitis. The implication of this model of the allergic march is thatthere is a linear progression from one manifestation to another, and a further assumption that there is a singlepredominant mechanism (of 'atopy' which may be defined as the susceptibility to becoming allergic) behind allthe manifestations. New insights from the advent of molecular medicine indicate that many allergic diseasesare better seen as syndromes comprising multiple phenotypes, with different gene/environment interactionsand consequent endotypes. In addition, there are multiple contributing aetiologies to each 'syndrome' andcomplicated interactions between them are better visualised as causal networks, rather than as linear causeand effect. These factors and the variability of progression from one form of atopy to another are at odds withthe concept of the 'atopic march'. We, therefore, suggest that the 'Atopic March' is an outdated concept whichmight be better considered as an 'Atopic Tango'</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2003Mar</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-150-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-150-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Levin ME</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gray,C.</style></author><author><style face="normal" font="Arial"> van Niekerk,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Breastfeeding and allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="149" start="142">142-149</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">There is evidence that allergens can be transmitted via breast milk, albeit in a highly processed form that istolerated by the vast majority of infants. Occasionally, exclusively breast-fed babies can present with signsof allergies, rarely IgE-mediated manifestations, and more commonly delayed type manifestations of thegastrointestinal tract. Allergens transmitted via breast milk can occasionally exacerbate eczema. Blanketelimination of foods during breastfeeding is discouraged and is potentially harmful to both mother andinfant. An assessment by a specialist to determine the exact causative allergens is encouraged. The vastmajority of infants who present with allergies during the breastfeeding period can continue to breastfeed ifthe mother excludes specific foods from her diet.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2003Mar</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-142-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-142-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Gray C</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Holtzhausen,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Under the sea: allergy and envenomation from marine creatures</style></title><secondary-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="160" start="156">156-160</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> jellyfish</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Precaution</style></keyword><keyword><style face="normal" font="Arial"> precautions</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The scope of this article is to provide an overview of the toxic and dangerous marine creatures occurring inSouth African waters and provide some advice regarding the management of symptoms resulting from injury,envenomation or allergic reactions. Three relevant cases are briefly discussed and the reader is reminded ofthe role of marine envenomation in the early scientific investigation of allergy and anaphylaxis. The potentialfor immune-mediated reactions to bluebottles and jellyfish is reviewed and common jellyfish envenomationsyndromes discussed. Precautions are suggested for patients with suspected prior sensitisation.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2003Mar</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-156-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-156-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Holtzhausen J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Falahati,M.</style></author><author><style face="normal" font="Arial"> Ghanbari,S.</style></author><author><style face="normal" font="Arial"> Ebrahimi,M.</style></author><author><style face="normal" font="Arial"> Ghazanfari,M.</style></author><author><style face="normal" font="Arial"> Bazrafshan,F.</style></author><author><style face="normal" font="Arial"> Farahyar,S.</style></author><author><style face="normal" font="Arial"> Falak,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Fractionation and identification of the allergic proteins in Aspergillus species</style></title><secondary-title><style face="normal" font="Arial">Curr Med Mycol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Mycol</style></full-title></periodical><pages end="45" start="37">37-45</pages><volume><style face="normal" font="Arial">2</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> allergic proteins</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ammonia</style></keyword><keyword><style face="normal" font="Arial"> Ammonium Sulfate</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus species</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Centrifugation</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Fractionation</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal Proteins</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Gels</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> Hyphae</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Membranes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Microorganisms</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SDS-PAGE</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> Sodium Dodecyl Sulfate</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spectroscopy</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND PURPOSE: Allergy is an undesired immune response to non-pathogenic agents. However, some opportunistic microorganisms such as fungi can also cause allergy. Among those fungi, hyphae form of Aspergillus strains including A. fumigatus, A. flavus, and A. niger could be mentioned. In this study, we aimed to separate allergic proteins from Aspergillus strains and determine their identity. MATERIALS AND METHODS: Standard species of Aspergillus strains were cultivated in optimized conditions and the mycelium was separated by centrifugation. The fungal cells were lysed through physical methods such as freeze-thawing and grinding to prepare a suitable protein extract. The protein concentration was measured by Bradford method and the electrophoretic pattern of the extract was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were fractionated by ammonium sulfate precipitation and anion exchange chromatography using fast protein liquid chromatography (FPLC) system. The IgE immunoreactivity of the sensitized patients and controls was studied using the fractionated proteins by enzyme-linked immunosorbent assay (ELISA). Following SDS-PAGE, proteins were electrotransferred onto polyvinylidene difluoride (PVDF) membranes and the strips were blotted with allergic patients' and controls' sera. The immunoreactive bands were excised from colloidal coomassie-stained SDS-PAGE gels and studied by mass spectroscopy methods. RESULTS: Among the studied species, A. fumigatus showed stronger IgE reactivity and more IgE reactive protein bands than others did. The proteins with higher molecular weights showed stronger immunoreactivity in Western blotting. Receiver operating characteristic curve analysis demonstrated a correlation between the results of the applied ELISA methods. One of the most prominent IgE-reactive proteins was confirmed to be 45 kDa mycelia catalase. CONCLUSION: Our findings confirmed that high molecular weight proteins might play a major role in allergy and IgE reactivity to Aspergillus species. Moreover, the results showed that precipitation and chromatographic methods are applicable for fractionation of fungal proteins such as mycelial catalase</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2423-3439 (Print)IS - 2423-3420 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.18869/acadpub.cmm.2.4.37</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959794">PM:28959794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Med Mycol\2016-2-37-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Med Mycol\2016-2-37-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Falahati M</style></custom2><misc3><style face="normal" font="Arial">10.18869/acadpub.cmm.2.4.37</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bierme,P.</style></author><author><style face="normal" font="Arial"> Nowak-Wegrzyn,A.</style></author><author><style face="normal" font="Arial"> Caubet,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aDivision of Pediatric Allergy, Department of Pediatrics, University Hospitals of Geneva, Geneva, Switzerland bPediatric Allergy Division, Hopital Femme-Mere-Enfant, Universite de Lyon Est, Lyon, France cDivision of Pediatric Allergy, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA</style></auth-address><titles><title><style face="normal" font="Arial">Non-IgE-mediated gastrointestinal food allergies</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic test</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> EST</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Non-IgE-mediated gastrointestinal food allergies</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> physiopathology</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: We focus on recent advances regarding the epidemiology, physiopathology, diagnosis and managements of non-IgE-mediated gastrointestinal food allergies (non-IgE-GI-FAs), particularly food protein-induced enterocolitis syndrome (FPIES). RECENT FINDINGS: The first international FPIES diagnostic and management guidelines have been recently published. Although FPIES largely remains a diagnosis of exclusion, it may be more prevalent than previously thought. Ondansetron has emerged as a major tool for the treatment of FPIES acute reactions. Recent data also suggest an important role for innate immune cells in FPIES pathogenesis. SUMMARY: Despite major advances in the diagnosis and management of non-IgE-GI-FAs, particularly FPIES, the lack of specific diagnostic tests and biomarkers to guide clinical management remains challenging</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 1531-698X (Electronic)IS - 1040-8703 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - France -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MOP.0000000000000554</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28937509">PM:28937509</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pediatr\20170922-BiermeP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pediatr\20170922-BiermeP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170922, Bierme P</style></custom2><misc3><style face="normal" font="Arial">10.1097/MOP.0000000000000554</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Winston,F.K.</style></author><author><style face="normal" font="Arial"> Yan,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Injury and Research Prevention, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, USASection of Dermatology, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, USA</style></auth-address><titles><title><style face="normal" font="Arial">Wearable health device dermatitis: a case of acrylate-related contact allergy</style></title><secondary-title><style face="normal" font="Arial">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cutis</style></full-title></periodical><pages end="99" start="97">97-99</pages><volume><style face="normal" font="Arial">100</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact allergy</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Housing</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Nickel</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">The popularity of mobile wearable health devices has skyrocketed. Some of these devices are worn on the wrist and have been associated with the development of allergic contact dermatitis. Although nickel has been the suspected culprit in cases reported by the media for consumers, we present a rare report of a patient who developed a localized contact dermatitis that was linked to acrylate allergy on epicutaneous patch testing. We surmise that the source of this acrylate might derive from leaching of this compound from the rechargeable battery housing given its correspondence to where the rash arose</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28961293">PM:28961293</url></web-urls></urls><custom2><style face="normal" font="Arial">20170929, Winston FK</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Verma,A.K.</style></author><author><style face="normal" font="Arial"> Manohar,M.</style></author><author><style face="normal" font="Arial"> Upparahalli Venkateshaiah,S.</style></author><author><style face="normal" font="Arial"> Mishra,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases</style></title><secondary-title><style face="normal" font="Arial">Cytokine Growth Factor Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Cytokine Growth Factor Rev</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> EoE</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Neuropeptides</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vasoactive Intestinal Peptide</style></keyword><keyword><style face="normal" font="Arial"> VIP</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1359-6101</style></isbn><abstract><style face="normal" font="Arial">Worldwide increase incidences of allergic diseases have heightened the interest of clinicians and researchers to understand the role of neuroendocrine cells in the recruitment and activation of inflammatory cells. Several pieces of evidence revealed the association of neuropeptides in the pathogenesis of allergic diseases. Importantly, one such peptide that is secreted by neuronal cells and immune cells exerts a wide spectrum of immunological functions as cytokine/chemokine is termed as Vasoactive Intestinal Peptide (VIP). VIP mediates immunological function through interaction with specific receptors namely VPAC-1, VPAC-2, CRTH2 and PAC1 that are expressed on several immune cells such as eosinophils, mast cells, neutrophils, and lymphocytes; therefore, provide the basis for the action of VIP on the immune system. Additionally, VIP mediated action varies according to target organ depending upon the presence of specific VIP associated receptor, involved immune cells and the microenvironment of the organ. Herein, we present an integrative review of the current understanding on the role of VIP and associated receptors in allergic diseases, the presence of VIP receptors on various immune cells with particular emphasis on the role of VIP in the pathogenesis of allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis. Being crucial signal molecule of the neuroendocrine-immune network, the development of stable VIP analogue and/or antagonist may provide the future therapeutic drug alternative for the better treatment of these allergic diseases. Taken together, our current review summarizes the current understandings of VIP biology and further explore the significance of neuroendocrine cells derived VIP in the recruitment of inflammatory cells in allergic diseases that may be helpful to the investigators for planning the experiments and accordingly predicting new therapeutic strategies for combating allergic diseases. Summarized graphical abstract will help the readers to understand the significance of VIP in allergic diseases</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cytogfr.2017.09.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.cytogfr.2017.09.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cytokine Growth Factor Rev\201711002-VermaAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cytokine Growth Factor Rev\201711002-VermaAK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Verma AK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cytogfr.2017.09.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Domingo,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary Service, Hospital de Sabadell (Corporacio Sanitaria Parc Tauli), Parc Tauli 1, 08208, Sabadell, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Overlapping Effects of New Monoclonal Antibodies for Severe Asthma</style></title><secondary-title><style face="normal" font="Arial">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Drugs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Arm</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic effect</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> European Union</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergens</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="Arial">Among the monoclonal antibodies (mAbs) developed for severe asthma treatment, three have already been marketed. Omalizumab was the first, more than 10 years ago; today, mepolizumab and reslizumab are also available in the European Union and the US. Omalizumab blocks free immunoglobulin E (IgE), mepolizumab and reslizumab block an interleukin (IL-5). In the near future, dupilumab and benralizumab are expected to emerge as two new alternatives. Benralizumab blocks the receptor for IL-5 (IL5-Ralpha) and has a direct cytotoxic effect on eosinophils, and dupilumab blocks the alpha-unit of the heterodimeric receptor for IL-4 and IL-13 (IL-4Ralpha); as a result, dupilumab can block both IL-4 and IL-13. The purpose of this manuscript is to present the pathophysiology of some immunological aspects of severe asthma, describe the adaptive and innate immunity arms as well as their interrelations (stressing the subordination of the adaptive arm to the innate arm), outline the pharmacologic effects of these mAbs, clarify the overlapping effects of the different mAbs, and discuss the differences between mAbs based on their target molecules. Based on the data presented, I propose omalizumab for patients with an allergic phenotype regardless of their peripheral eosinophilic count, and anti-IL-5 as an alternative in allergic patients with blood eosinophilia in which omalizumab has failed; anti-IL5 for patients with an eosinophilic phenotype and omalizumab as an alternative in patients in whom anti-IL5 fails and IgE >/=30 IU/mL (compassionate use). Omalizumab is also proposed for patients with severe chronic asthma allergic to seasonal allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1179-1950 (Electronic)IS - 0012-6667 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40265-017-0810-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28948572">PM:28948572</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drugs\20170926-DomingoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drugs\20170926-DomingoC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Domingo C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40265-017-0810-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Prasad,B.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of ENT, Military Hospital Kirkee, Range Hills, Pune 411020, Maharashtra, India. bipin_rupa@rediffmail.com</style></auth-address><titles><title><style face="normal" font="Arial">Study of factors responsible for recidivism in allergic fungal rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Ear Nose Throat J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ear Nose Throat J</style></full-title></periodical><pages end="E21" start="E18">E18-E21</pages><volume><style face="normal" font="Arial">96</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Education</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Rural</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Patients with allergic fungal rhinosinusitis (AFRS) are typically atopic and immunocompetent. Despite combined modality treatment based on surgery and immunomodulation, the potential for recidivism is well recognized. A study was conducted in a military hospital in India to identify the factors responsible for recidivism in AFRS and to suggest measures to overcome it. Sixty patients with AFRS (42 new cases and 18 cases that required revision surgery) were managed between January 2009 and July 2013. Patients underwent endoscopic, radiologic, and laboratory evaluation for AFRS followed by functional endoscopic sinus surgery. Each patient received oral prednisolone, 1 mg/kg/day, for 1 week preoperatively and 0.5 mg/kg/day for 4 weeks postoperatively. A randomly selected group of 30 patients (group A) received oral prednisolone 0.4 mg/kg/day for the next 4 weeks, tapered to 0.2 mg/kg/day for the next 2 months and to 0.1 mg/kg/day for the last 2 months. The drug was stopped after 6 months. In the remaining 30 patients (group B), oral prednisolone was tapered within 2 months. Topical steroid sprays were advised in all patients. Recidivism was observed in 12 of 42 (28.6%) patients presenting for the first time with AFRS: 9 patients from group B (30%) and 3 patients from group A (10%). Besides inadequate postoperative oral steroid therapy, suboptimal functional endoscopic sinus surgery, noncompliance with intranasal sprays, nonadherence to Kupferberg staging, inadequate follow-up, failure of surgeons to impart health education to patients, and unavailability of ENT consultation in rural belts were found to be factors causing recidivism</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1942-7522 (Electronic)IS - 0145-5613 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28931197">PM:28931197</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170920, Prasad BK</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yue,H.</style></author><author><style face="normal" font="Arial"> Yan,W.</style></author><author><style face="normal" font="Arial"> Ji,X.</style></author><author><style face="normal" font="Arial"> Gao,R.</style></author><author><style face="normal" font="Arial"> Ma,J.</style></author><author><style face="normal" font="Arial"> Rao,Z.</style></author><author><style face="normal" font="Arial"> Li,G.</style></author><author><style face="normal" font="Arial"> Sang,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Environment and Resource, Research Center of Environment and Health, Shanxi University , Taiyuan, Shanxi, People's Republic of China</style></auth-address><titles><title><style face="normal" font="Arial">Maternal Exposure of BALB/c Mice to Indoor NO2 and Allergic Asthma Syndrome in Offspring at Adulthood with Evaluation of DNA Methylation Associated Th2 Polarization</style></title><secondary-title><style face="normal" font="Arial">Environ Health Perspect</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Health Perspect</style></full-title></periodical><pages end="" start="097011">097011-</pages><volume><style face="normal" font="Arial">125</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway disease</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> DNA Methylation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Maternal Exposure</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Fetal stress has been proposed to be associated with diseases in both children and adults. Epidemiological studies suggest that maternal exposure to nitrogen dioxide (NO2) contributes to increased morbidity and mortality of offspring with allergic asthma later in life. OBJECTIVES: We aimed to test whether maternal NO2 exposure causes allergic asthma-related consequences in offspring absent any subsequent lung provocation and whether this exposure enhances the likelihood of developing allergic asthma or the intensity of developed allergic airway disease following postnatal allergic sensitization and challenge. In addition, if such consequences and enhancements occurred, we sought to determine the mechanism(s) of these responses. METHODS: Pregnant BALB/c mice were exposed to either NO2 (2.5 ppm, 5 h/day) or air daily throughout the gestation period. Offspring were sacrificed on postnatal days (PNDs) 1, 7, 14, 21, and 42, and remaining offspring were sensitized by ovalbumin (OVA) injection followed by OVA aerosol challenge during postnatal wk 7-9. We analyzed the lung histopathology, inflammatory cell infiltration, airway hyper-responsiveness (AHR), immune responses, and gene methylation under different treatment conditions. RESULTS: Maternal exposure to NO2 caused a striking increase in inflammatory cell infiltration and the release of type 2 cytokines in the lungs of offspring at PNDs 1 and 7; however, these alterations were reversed during postnatal development. Following OVA sensitization and challenge, the exposure enhanced the levels of allergic asthma-characterized OVA-immunoglobulin (Ig) E, AHR, and airway inflammation in adult offspring. Importantly, differentiation of T-helper (Th) 2 cells and demethylation of the interleukin-4 (IL4) gene occurred during the process. CONCLUSIONS: Maternal exposure to indoor environmental NO2 causes allergic asthma-related consequences in offspring absent any subsequent lung provocation and potentiates the symptoms of allergic asthma in adult offspring following postnatal allergic sensitization and challenge; this response is associated with the Th2-based immune response and DNA methylation of the IL4 gene. https://doi.org/10.1289/EHP685</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 1552-9924 (Electronic)IS - 0091-6765 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1289/EHP685</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28935613">PM:28935613</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Health Perspect\2017-125-097011.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Health Perspect\2017-125-097011.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170922, Yue H</style></custom2><misc3><style face="normal" font="Arial">10.1289/EHP685</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lake,I.R.</style></author><author><style face="normal" font="Arial"> Jones,N.R.</style></author><author><style face="normal" font="Arial"> Agnew,M.</style></author><author><style face="normal" font="Arial"> Goodess,C.M.</style></author><author><style face="normal" font="Arial"> Giorgi,F.</style></author><author><style face="normal" font="Arial"> Hamaoui-Laguel,L.</style></author><author><style face="normal" font="Arial"> Semenov,M.A.</style></author><author><style face="normal" font="Arial"> Solomon,F.</style></author><author><style face="normal" font="Arial"> Storkey,J.</style></author><author><style face="normal" font="Arial"> Vautard,R.</style></author><author><style face="normal" font="Arial"> Epstein,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Environmental Sciences, University of East Anglia, Norwich, United Kingdom</style></auth-address><titles><title><style face="normal" font="Arial">Climate Change and Future Pollen Allergy in Europe</style></title><secondary-title><style face="normal" font="Arial">Environ Health Perspect</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Health Perspect</style></full-title></periodical><pages end="391" start="385">385-391</pages><volume><style face="normal" font="Arial">125</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Common ragweed</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health burden</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hungary</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Invasion</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant invasion</style></keyword><keyword><style face="normal" font="Arial"> Plant species</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis,Allergic,Seasonal</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Globally, pollen allergy is a major public health problem, but a fundamental unknown is the likely impact of climate change. To our knowledge, this is the first study to quantify the consequences of climate change upon pollen allergy in humans. OBJECTIVES: We produced quantitative estimates of the potential impact of climate change upon pollen allergy in humans, focusing upon common ragweed (Ambrosia artemisiifolia) in Europe. METHODS: A process-based model estimated the change in ragweed's range under climate change. A second model simulated current and future ragweed pollen levels. These findings were translated into health burdens using a dose-response curve generated from a systematic review and from current and future population data. Models considered two different suites of regional climate/pollen models, two greenhouse gas emissions scenarios [Representative Concentration Pathways (RCPs) 4.5 and 8.5], and three different plant invasion scenarios. RESULTS: Our primary estimates indicated that sensitization to ragweed will more than double in Europe, from 33 to 77 million people, by 2041-2060. According to our projections, sensitization will increase in countries with an existing ragweed problem (e.g., Hungary, the Balkans), but the greatest proportional increases will occur where sensitization is uncommon (e.g., Germany, Poland, France). Higher pollen concentrations and a longer pollen season may also increase the severity of symptoms. Our model projections were driven predominantly by changes in climate (66%) but were also influenced by current trends in the spread of this invasive plant species. Assumptions about the rate at which ragweed spreads throughout Europe had a large influence upon the results. CONCLUSIONS: Our quantitative estimates indicate that ragweed pollen allergy will become a common health problem across Europe, expanding into areas where it is currently uncommon. Control of ragweed spread may be an important adaptation strategy in response to climate change. Citation: Lake IR, Jones NR, Agnew M, Goodess CM, Giorgi F, Hamaoui-Laguel L, Semenov MA, Solomon F, Storkey J, Vautard R, Epstein MM. 2017. Climate change and future pollen allergy in Europe. Environ Health Perspect 125:385-391; http://dx.doi.org/10.1289/EHP173</style></abstract><notes><style face="normal" font="Arial">DA - 20160824IS - 1552-9924 (Electronic)IS - 0091-6765 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)SB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1289/EHP173</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27557093">PM:27557093</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Health Perspect\2017-125-385-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Health Perspect\2017-125-385-91.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20160824, Lake IR</style></custom2><misc3><style face="normal" font="Arial">10.1289/EHP173</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">D'Amato,M.</style></author><author><style face="normal" font="Arial"> Annesi-Maesano,I.</style></author><author><style face="normal" font="Arial"> Molino,A.</style></author><author><style face="normal" font="Arial"> Mormile,M.</style></author><author><style face="normal" font="Arial"> Vitale,C.</style></author><author><style face="normal" font="Arial"> Vatrella,A.</style></author><author><style face="normal" font="Arial"> Sanduzzi,A.</style></author><author><style face="normal" font="Arial"> D'Amato,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Divisione di pneumologia, Azienda ospedaliera dei colli, Universita Federico II, Napoli</style></auth-address><titles><title><style face="normal" font="Arial">Thunderstorm and asthma outbreaks during pollen season</style></title><secondary-title><style face="normal" font="Arial">Epidemiol Prev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Epidemiol Prev</style></full-title></periodical><pages end="211" start="208">208-211</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">3-4</style></number><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> asthmatic reactions</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial obstruction</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Epidemics</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> thunderstorm</style></keyword><keyword><style face="normal" font="Arial"> Thunderstorms</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="Arial">An increasing body of evidence shows the occurrence of asthma epidemics, sometimes also severe, during thunderstorms in the pollen season in various geographical zones. The main hypothesis explaining association between thunderstorms and asthma claims that thunderstorms can concentrate pollen grains at ground level; these grains may then release allergenic particles of respirable size in the atmosphere after their rupture by osmotic shock. During the first 20-30 minutes of a thunderstorm, patients suffering from pollen allergy may inhale a high concentration of the allergenic material dispersed into the atmosphere, which can, in turn, induce asthmatic reactions, often severe. Subjects without asthma symptoms but affected by seasonal rhinitis can also experience an asthma attack. All subjects affected by pollen allergy should be alerted to the danger of being outdoors during a thunderstorm in the pollen season, as such events may be an important cause of severe bronchial obstruction. Considering this background, it is useful to predict thunderstorms during pollen season and, thus, to prevent thunderstorm-related clinical event. However, it is also important to focus on therapy, and it is not sufficient that subjects at risk of asthma follow a correct therapy with bronchodilators, but they also need to inhale corticosteroids, using both in case of emergency</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1120-9763 (Print)IS - 1120-9763 (Linking)LA - itaPT - English AbstractPT - Journal ArticleCO - Italy -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.19191/EP17.3-4.P208.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28929717">PM:28929717</url></web-urls><pdf-urls><url ppv-ref="no">gdamatomail@gmail.com</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20170920, DAmato M</style></custom2><misc3><style face="normal" font="Arial">10.19191/EP17.3-4.P208.054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yoshihara,S.</style></author><author><style face="normal" font="Arial"> Kikuchi,Y.</style></author><author><style face="normal" font="Arial"> Saitou,M.</style></author><author><style face="normal" font="Arial"> Yanagawa,S.</style></author><author><style face="normal" font="Arial"> Kanno,N.</style></author><author><style face="normal" font="Arial"> Igarashi,H.</style></author><author><style face="normal" font="Arial"> Fukuda,H.</style></author><author><style face="normal" font="Arial"> Iimura,A.</style></author><author><style face="normal" font="Arial"> Abe,T.</style></author><author><style face="normal" font="Arial"> Yamada,Y.</style></author><author><style face="normal" font="Arial"> Andou,T.</style></author><author><style face="normal" font="Arial"> Arisaka,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Dokkyo Medical University, Mibu, Tochigi 321-0293, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of a leukotriene receptor antagonist for pediatric cedar pollen allergy complicated by asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="3238" start="3233">3233-3238</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> antagonists</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> cedar pollen</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonists</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> Ocular symptoms</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">Leukotriene receptor antagonists (LTRAs) are identified as a monotherapy for asthma and allergic rhinitis; however, their use in children for treatment of these diseases has not been examined. Accordingly, the present study investigated the efficacy of pranlukast dry syrup for children with both pollinosis and asthma. The subjects were children receiving treatment for asthma who were also diagnosed with cedar pollen allergy. Patients were divided into a group that received continuous treatment with pranlukast (group A; n=20) and a group that commenced add-on treatment for pollinosis following the onset of symptoms (group B; n=20). Patients in group B were randomly allocated to subgroup B1 (add-on treatment with pranlukast dry syrup) or subgroup B2 (add-on treatment with a second-generation antihistamine). In both groups, nasal and ocular symptoms were evaluated every day and recorded in a diary. Exacerbation of nasal obstruction was demonstrated in group B; however, not in group A. There was a significant difference in symptoms observed between the two groups during the late peak pollen period (P&lt;0.05). The incidence of nasal obstruction (defined as a nasal obstruction score >/=3 or use of a nasal steroid spray) was significantly lower in group A compared with group B (P&lt;0.05). The maximum scores for sneezing and nasal obstruction during the late peak of the pollen season were lowest in group A, followed by subgroup B1 and subgroup B2. The present study demonstrated that long-term administration of LTRA for the management of asthma may improve nasal symptoms of pollinosis during the pollen season in children with pollinosis and asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4893</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28928804">PM:28928804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-14-3233-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-14-3233-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Yoshihara S</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4893</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,X.</style></author><author><style face="normal" font="Arial"> Zhu,J.</style></author><author><style face="normal" font="Arial"> Bian,T.</style></author><author><style face="normal" font="Arial"> Wang,R.</style></author><author><style face="normal" font="Arial"> Gao,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu 215300, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Mislocalization of Runt-related transcription factor 3 results in airway inflammation and airway hyper-responsiveness in a murine asthma model</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="2701" start="2695">2695-2701</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Lineage</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene family</style></keyword><keyword><style face="normal" font="Arial"> Genistein</style></keyword><keyword><style face="normal" font="Arial"> Hematopoiesis</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">The Runt-related transcription factor (RUNX) gene family consists of three members, RUNX1, -2 and -3, which heterodimerize with a common protein, core-binding factor beta, and contain the highly conserved Runt-homology domain. RUNX1 and -2 have essential roles in hematopoiesis and osteogenesis. Runx3 protein regulates cell lineage decisions in neurogenesis and thymopoiesis. The aim of the present study was to determine the expression features of the Runx3 protein in a murine asthma model. In vivo, Runx3 protein and mRNA were found to be almost equivalently expressed in the murine lung tissue of the control, ovalbumin (OVA) and genistein groups; however, the nuclear Runx3 protein was abated in lung tissue in OVA-immunized and challenged mice. Following treatment with genistein, which is a flavonoid previously demonstrated to decrease airway inflammation in asthma, the allergic airway inflammation and airway hyper-responsiveness were attenuated and the Runx3 protein tended to augment in the nucleus. These results were further determined in vitro. These results indicated that the mislocalization of Runx3 protein is a molecular mechanism of allergic inflammation and airway hyper-responsiveness in a murine asthma model</style></abstract><notes><style face="normal" font="Arial">DA - 20170930IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4812</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28962214">PM:28962214</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-14-2695-701.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-14-2695-701.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170930, Zhou X</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4812</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jia,A.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Sun,W.</style></author><author><style face="normal" font="Arial"> Xiao,B.</style></author><author><style face="normal" font="Arial"> Mu,L.</style></author><author><style face="normal" font="Arial"> Wei,Y.</style></author><author><style face="normal" font="Arial"> Xu,L.</style></author><author><style face="normal" font="Arial"> Peng,C.</style></author><author><style face="normal" font="Arial"> Zhang,D.</style></author><author><style face="normal" font="Arial"> Shen,H.</style></author><author><style face="normal" font="Arial"> Xiang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of the roles of house dust mite allergens, ovalbumin and lipopolysaccharides in the sensitization of mice to establish a model of severe neutrophilic asthma</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="2134" start="2126">2126-2134</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Lipopolysaccharides</style></keyword><keyword><style face="normal" font="Arial"> LPS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Neutrophilic asthma (NA) is associated with a severe disease course and poor response to corticosteroids. The present study aimed to compare the effects of various concentrations of house dust mite (HDM) allergens, ovalbumin (OVA), the major egg allergen, and lipopolysaccharide (LPS) in combination on the onset of severe NA. Female C57BL/6 mice were grouped according to a random number table and intranasally sensitized with HDM/LPS/OVA extracts on days 0, 1 and 2 of the study. In group 1, mice received 50 microg HDM + 50 microg OVA + 15 microg LPS, mice in group 2 received 50 microg HDM + 100 microg OVA + 15 microg LPS, mice in group 3 received 100 microg HDM + 50 microg OVA + 15 microg LPS and those in group 4 received 100 microg HDM + 100 microg OVA + 15 microg LPS, while mice in the control group received saline only. The mice were then challenged by OVA solution with atomized excitation on days 14, 15, 18, 19 and 20 for 30 min each. Ethology, airway hyperresponsiveness (AHR), immune cell distributions in bronchoalveolar lavage fluid (BALF), and specific cytokines interleukin 17A (IL-17A) and IL-4 in serum were assessed. Histological examination of inflammation by hematoxylin and eosin staining and immunohistochemical assessment of neutrophils (NEU), eosinophils (EOS), IL-17A and IL-4 were also performed. Compared with the control group, the HDM/OVA/LPS-sensitized groups 1-4 had markedly increased BALF cells, serum interleukin IL-17A and IL-4, inflammatory cell infiltration, EOS as well as IL-17A and IL-4 by immunohistochemical staining (all P&lt;0.05). Among the four HDM/OVA/LPS-sensitized groups, mice of group 4 had higher AHR, a significantly higher total cell number, NEU and EOS in BALF as well as significantly higher NEU and NEU/EOS ratios according to immunohistochemical staining when compared to groups 1-3 (P&lt;0.05 for all). In conclusion, sensitization with 100 microg HDM + 100 microg OVA + 15 microg LPS successfully established a severe asthma model with a predominantly neutrophilic inflammatory phenotype</style></abstract><notes><style face="normal" font="Arial">DA - 20170930IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4776</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28962133">PM:28962133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-14-2126-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-14-2126-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170930, Jia A</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4776</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Y.</style></author><author><style face="normal" font="Arial"> Chen,Y.</style></author><author><style face="normal" font="Arial"> Zhao,L.</style></author><author><style face="normal" font="Arial"> Kong,X.</style></author><author><style face="normal" font="Arial"> Yang,Z.</style></author><author><style face="normal" font="Arial"> Hua,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Food Science and Technology, Jiangnan University, China; School of Food Science and Technology, Jiangnan University, China.</style></auth-address><titles><title><style face="normal" font="Arial">A two-chain aspartic protease present in seeds with high affinity for peanut oil bodies</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="451" start="443">443-451</pages><volume><style face="normal" font="Arial">241</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Arachin</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> oil</style></keyword><keyword><style face="normal" font="Arial"> oxidative stability</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut oil</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein composition</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="2" Year="2018">2018/2/15</year></dates><abstract><style face="normal" font="Arial">Peanut seeds are rich in oil, which exists as oil bodies (OBs). By extraction, peanut crude OBs are obtained and can be used as a food ingredient. In a previous study, it was found that the crude OBs contained an unknown protease, which hydrolyzed the oleosins. This would disrupt the integrity of OBs, and therefore, affect their physical and oxidative stability. In this study, the protein composition of crude OBs and some properties of the unknown protease were examined. The results showed that the protease was a two-chain (32 and 9kDa) aspartic protease, which showed high affinity for OBs. The optimal pH and temperature for oleosin hydrolysis by the protease were pH 4.0 and 60 degrees C. Interestingly, the aspartic protease not only hydrolyzed OB intrinsic proteins (oleosin, caleosin, and steroleosin), but also extrinsic proteins (especially Ara h 1 allergen and 26-30kDa arachin)</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 0308-8146 (Print)IS - 0308-8146 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958552">PM:28958552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2018-241-443-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2018-241-443-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Chen Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.09.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Skuljec,J.</style></author><author><style face="normal" font="Arial"> Chmielewski,M.</style></author><author><style face="normal" font="Arial"> Happle,C.</style></author><author><style face="normal" font="Arial"> Habener,A.</style></author><author><style face="normal" font="Arial"> Busse,M.</style></author><author><style face="normal" font="Arial"> Abken,H.</style></author><author><style face="normal" font="Arial"> Hansen,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="1125">1125-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> experimental allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper-2</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1664-3224</style></isbn><abstract><style face="normal" font="Arial">Cellular therapy with chimeric antigen receptor (CAR)-redirected cytotoxic T cells has shown impressive efficacy in the treatment of hematologic malignancies. We explored a regulatory T (Treg) cell-based therapy in the treatment of allergic airway inflammation, a model for asthma, which is characterized by an airway hyper-reactivity (AHR) and a chronic, T helper-2 (Th2) cell dominated immune response to allergen. To restore the immune balance in the lung, we redirected Tregs by a CAR towards lung epithelia in mice upon experimentally induced allergic asthma, closely mimicking the clinical situation. Adoptively transferred CAR Tregs accumulated in the lung and in trachea-bronchial lymph nodes, reduced AHR and diminished eosinophilic airway inflammation, indicated by lower cell numbers in the broncho-alveolar lavage fluid and decreased cell infiltrates in the lung. CAR Treg cells furthermore prevented excessive pulmonary mucus production as well as increase in allergen-specific IgE and Th2 cytokine levels in exposed animals. CAR Tregs were more efficient in controlling asthma than non-modified Tregs, indicating the pivotal role of specific Treg cell activation in the affected organ. Data demonstrate that lung targeting CAR Treg cells ameliorate key features of experimental airway inflammation, paving the way for cell therapy of severe allergic asthma</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.01125</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28955341">PM:28955341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1125.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-1125.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Skuljec J</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.01125</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Triana,S.</style></author><author><style face="normal" font="Arial"> de Cock,H.</style></author><author><style face="normal" font="Arial"> Ohm,R.A.</style></author><author><style face="normal" font="Arial"> Danies,G.</style></author><author><style face="normal" font="Arial"> Wosten,H.A.B.</style></author><author><style face="normal" font="Arial"> Restrepo,S.</style></author><author><style face="normal" font="Arial"> Gonzalez Barrios,A.F.</style></author><author><style face="normal" font="Arial"> Celis,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biological Sciences, Universidad de los AndesBogota, Colombia</style></auth-address><titles><title><style face="normal" font="Arial">Lipid Metabolic Versatility in Malassezia spp. Yeasts Studied through Metabolic Modeling</style></title><secondary-title><style face="normal" font="Arial">Front Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Microbiol</style></full-title></periodical><pages end="" start="1772">1772-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Folliculitis</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Genome Size</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Malassezia</style></keyword><keyword><style face="normal" font="Arial"> Malassezia globosa</style></keyword><keyword><style face="normal" font="Arial"> Malassezia pachydermatis</style></keyword><keyword><style face="normal" font="Arial"> Malassezia species</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Palmitic Acid</style></keyword><keyword><style face="normal" font="Arial"> Pityriasis</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sebaceous Glands</style></keyword><keyword><style face="normal" font="Arial"> seborrheic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword><keyword><style face="normal" font="Arial"> Yeasts</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Malassezia species are lipophilic and lipid-dependent yeasts belonging to the human and animal microbiota. Typically, they are isolated from regions rich in sebaceous glands. They have been associated with dermatological diseases such as seborrheic dermatitis, pityriasis versicolor, atopic dermatitis, and folliculitis. The genomes of Malassezia globosa, Malassezia sympodialis, and Malassezia pachydermatis lack the genes related to fatty acid synthesis. Here, the lipid-synthesis pathways of these species, as well as of Malassezia furfur, and of an atypical M. furfur variant were reconstructed using genome data and Constraints Based Reconstruction and Analysis. To this end, the genomes of M. furfur CBS 1878 and the atypical M. furfur 4DS were sequenced and annotated. The resulting Enzyme Commission numbers and predicted reactions were similar to the other Malassezia strains despite the differences in their genome size. Proteomic profiling was utilized to validate flux distributions. Flux differences were observed in the production of steroids in M. furfur and in the metabolism of butanoate in M. pachydermatis. The predictions obtained via these metabolic reconstructions also suggested defects in the assimilation of palmitic acid in M. globosa, M. sympodialis, M. pachydermatis, and the atypical variant of M. furfur, but not in M. furfur. These predictions were validated via physiological characterization, showing the predictive power of metabolic network reconstructions to provide new clues about the metabolic versatility of Malassezia</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1664-302X (Print)IS - 1664-302X (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - Germany -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.3389/fmicb.2017.01772</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959251">PM:28959251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772AtypicalMalasseziaFurfur.xlsxC:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772MalasseziaFurfur.xlsxC:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772MalasseziaGlobosa.xlsxC:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772MalasseziaPachidermatysC:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772MalasseziaSympodialis.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772AtypicalMalasseziaFurfur.xlsxF:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772MalasseziaFurfur.xlsxF:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772MalasseziaGlobosa.xlsxF:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772MalasseziaPachidermatys.xlsxF:\A&amp;H HMW Papers\Front Microbiol\2017-8-1772MalasseziaSympodialis.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170929, Triana S</style></custom2><misc3><style face="normal" font="Arial">10.3389/fmicb.2017.01772</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mendes,E.</style></author><author><style face="normal" font="Arial"> Acetturi,B.G.</style></author><author><style face="normal" font="Arial"> Thomas,A.M.</style></author><author><style face="normal" font="Arial"> Martins,F.D.S.</style></author><author><style face="normal" font="Arial"> Crisma,A.R.</style></author><author><style face="normal" font="Arial"> Murata,G.</style></author><author><style face="normal" font="Arial"> Braga,T.T.</style></author><author><style face="normal" font="Arial"> Camara,N.O.S.</style></author><author><style face="normal" font="Arial"> Franco,A.L.D.S.</style></author><author><style face="normal" font="Arial"> Setubal,J.C.</style></author><author><style face="normal" font="Arial"> Ribeiro,W.R.</style></author><author><style face="normal" font="Arial"> Valduga,C.J.</style></author><author><style face="normal" font="Arial"> Curi,R.</style></author><author><style face="normal" font="Arial"> Dias-Neto,E.</style></author><author><style face="normal" font="Arial"> Tavares-de-Lima,W.</style></author><author><style face="normal" font="Arial"> Ferreira,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmaceutics Sciences, Institute of Environmental, Chemistry and Pharmaceutical Sciences, Universidade Federal de Sao PauloDiadema, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Prophylactic Supplementation of Bifidobacterium longum 51A Protects Mice from Ovariectomy-Induced Exacerbated Allergic Airway Inflammation and Airway Hyperresponsiveness</style></title><secondary-title><style face="normal" font="Arial">Front Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Microbiol</style></full-title></periodical><pages end="" start="1732">1732-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Hormones</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Menopause</style></keyword><keyword><style face="normal" font="Arial"> Menstruation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovariectomy</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> puberty</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> sex hormones</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory disease that affects more females than males after puberty, and its symptoms and severity in women change during menstruation and menopause. Recently, evidence has demonstrated that interactions among the microbiota, female sex hormones, and immunity are associated with the development of autoimmune diseases. However, no studies have investigated if therapeutic gut microbiota modulation strategies could affect asthma exacerbation during menstruation and menopause. Here we aimed to examine the preventive effects of a probiotic, Bifidobacterium longum 51A, on airway inflammation exacerbation in allergic ovariectomized mice. We first evaluated the gut microbiota composition and diversity in mice 10 days after ovariectomy. Next, we examined whether re-exposure of ovariectomized allergic mice to antigen (ovalbumin) would lead to exacerbation of lung inflammation. Finally, we evaluated the preventive and treatment effect of B. longum 51A on lung inflammation and airway hyperresponsiveness. Our results showed that whereas ovariectomy caused no alterations in the gut microbiota composition and diversity in this animal model, 10 days after ovariectomy, preventive use administration of B. longum 51A, rather than its use after surgery was capable of attenuate the exacerbated lung inflammation and hyperresponsiveness in ovariectomized allergic mice. This prophylactic effect of B. longum 51A involves acetate production, which led to increased fecal acetate levels and, consequently, increased Treg cells in ovariectomized allergic mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1664-302X (Print)IS - 1664-302X (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.3389/fmicb.2017.01732</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959241">PM:28959241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Microbiol\2017-8-1732.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Microbiol\2017-8-1732.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Mendes E</style></custom2><misc3><style face="normal" font="Arial">10.3389/fmicb.2017.01732</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,T.</style></author><author><style face="normal" font="Arial"> Tanida,M.</style></author><author><style face="normal" font="Arial"> Uchida,K.</style></author><author><style face="normal" font="Arial"> Suzuki,Y.</style></author><author><style face="normal" font="Arial"> Yang,W.</style></author><author><style face="normal" font="Arial"> Kuda,Y.</style></author><author><style face="normal" font="Arial"> Kurata,Y.</style></author><author><style face="normal" font="Arial"> Tominaga,M.</style></author><author><style face="normal" font="Arial"> Shibamoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physiology II, Kanazawa Medical UniversityUchinada, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Mouse Anaphylactic Hypotension Is Characterized by Initial Baroreflex Independent Renal Sympathoinhibition Followed by Sustained Renal Sympathoexcitation</style></title><secondary-title><style face="normal" font="Arial">Front Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Physiol</style></full-title></periodical><pages end="" start="669">669-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Heart Rate</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pentobarbital</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sympathetic Nervous System</style></keyword><keyword><style face="normal" font="Arial"> Tachycardia</style></keyword><keyword><style face="normal" font="Arial"> vagal</style></keyword><keyword><style face="normal" font="Arial"> Vagotomy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Aim: The hemodynamic response to mouse systemic anaphylaxis is characterized by an initial hypertension followed by sustained hypotension. However, the defense mechanisms of the sympathetic nervous system against this circulatory disturbance is not known. Here, we investigated the renal sympathetic nerve activity (RSNA) response to mouse systemic anaphylaxis, along with the roles of carotid sinus baroreceptor, vagal nerves and the transient receptor potential vanilloid type 1 channel (TRPV1). Methods: Male ovalbumin-sensitized C57BL/6N mice were used under pentobarbital anesthesia. RSNA, systemic arterial pressure (SAP) and heart rate (HR) were continuously measured for 60 min after the antigen injection. Results: Within 3 min after antigen injection, RSNA decreased along with a transient increase in SAP. Thereafter, RSNA showed a progressive increase during sustained hypotension. In contrast, HR continuously increased. Sinoaortic denervation, but not vagotomy, significantly attenuated the renal sympathoexcitation and tachycardia from 30 and 46 min, respectively, after antigen. The responses of RSNA, SAP and HR to anaphylaxis were not affected by pretreatment with a TRPV1 inhibitor, capsazepine, or by genetic knockout of TRPV1. Conclusion: The mouse systemic anaphylaxis causes a biphasic RSNA response with an initial baroreflex-independent decrease and secondary increase. The antigen-induced sympathoexcitation and tachycardia at the late stage are partly mediated by carotid sinus baroreceptors. Either vagal nerve or TRPV1 does not play any significant roles in the RSNA and HR responses in anesthetized mice</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 1664-042X (Print)IS - 1664-042X (Linking)LA - engPT - Journal ArticleCO - Japan -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.3389/fphys.2017.00669</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28936180">PM:28936180</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Physiol\2017-8-669.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Physiol\2017-8-669.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170922, Zhang T</style></custom2><misc3><style face="normal" font="Arial">10.3389/fphys.2017.00669</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Novakova,S.M.</style></author><author><style face="normal" font="Arial"> Staevska,M.T.</style></author><author><style face="normal" font="Arial"> Novakova,P.I.</style></author><author><style face="normal" font="Arial"> Yoncheva,M.D.</style></author><author><style face="normal" font="Arial"> Bratoycheva,M.S.</style></author><author><style face="normal" font="Arial"> Musurlieva,N.M.</style></author><author><style face="normal" font="Arial"> Tzekov,V.D.</style></author><author><style face="normal" font="Arial"> Nicolov,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Unit of Internal Consulting Department, University hospital St. George, "Peshtersko shosse" 66, Plovdiv, Bulgaria.</style></auth-address><titles><title><style face="normal" font="Arial">Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life</style></title><secondary-title><style face="normal" font="Arial">Health Qual Life Outcomes</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Health Qual Life Outcomes</style></full-title></periodical><pages end="" start="189">189-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> emotional problems</style></keyword><keyword><style face="normal" font="Arial"> Emotions</style></keyword><keyword><style face="normal" font="Arial"> Eye</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Sleep Disorders</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Along with its high prevalence, the burden of allergic rhinitis rests upon the serious impact on quality of life of patients. Allergic rhinitis is associated with impairments in daily activities, work and school performance, and practical problems. Patients suffer from sleep disorders and emotional problems. capital TE, Cyrilliche advantages of sublingual immunotherapy on quality of life have only recently begun to emerge. The objective of this prospective real-life study was to evaluate the effect of a three-year course of sublingual immunotherapy with house dust mite (HDM) and grass pollen extracts on quality of life in adults with allergic rhinitis. METHODS: A total number of 191 adult patients [105 (54,979%) men; mean age 27.3 years (SD-6.14)] with moderate to severe allergic rhinitis and clinically relevant sensitization to house dust mites or grass pollen were prospectively evaluated in the course of management of their disease. Health-related quality of life was assessed by Rhinoconjunctivitis Quality of Life Questionnaire at baseline and after three-year course of sublingual immunotherapy. RESULTS: The mean overall Qol score assessed at baseline and at the end of the third year of treatment decreased significantly in patients treated with HDM extract (from 2.95 to 0.76) as well as with Grass pollen extract (from 2.83 to 1.22) (small er, Cyrillic &lt; 0.001). The improvements in treated with HDM extract were as followed: activities - 3.52 to 0.68; sleep- 2.48 to 0.31; general problems - 1.79 to 0.49; practical problems - 3.57 to 0.68; nasal symptoms - 3.91 to 0.74; eye symptoms - 2.92 to 0.39; emotions - 3.03 to 0.39. The improvements in grass pollen group were: activities - 3.68 to 1.69; sleep- 1.85 to 0.84; general problems - 1.74 to 0.97; practical problems - 3.52 to 1.37; nasal symptoms - 3.72 to 1.57; eye symptoms - 3.58 to 1.3; emotions - 2.48 to 1.19. CONCLUSION: Our study conducted in real life provided evidence that a three-year course of SLIT with HDM extract as well as with grass pollen extract significantly increased QoL in patients with allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20170930IS - 1477-7525 (Electronic)IS - 1477-7525 (Linking)LA - engPT - Journal ArticleCO - Bulgaria -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12955-017-0764-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28962623">PM:28962623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Health Qual Life Outcomes\2017-15-189.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Health Qual Life Outcomes\2017-15-189.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170930, Novakova SM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12955-017-0764-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomas,W.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Broad perspectives of allergen specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1374522</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28933669">PM:28933669</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170921-ThomasWR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170921-ThomasWR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Thomas WR</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1374522</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fanuel,S.</style></author><author><style face="normal" font="Arial"> Tabesh,S.</style></author><author><style face="normal" font="Arial"> Rajani,H.F.</style></author><author><style face="normal" font="Arial"> Heidari,S.</style></author><author><style face="normal" font="Arial"> Sadroddiny,E.</style></author><author><style face="normal" font="Arial"> Kardar,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Medical Biotechnology , School of Advanced Technologies in Medicine, Tehran University of Medical Sciences-International Campus (IC-TUMS) Tehran , Iran</style></auth-address><titles><title><style face="normal" font="Arial">Decorating and Loading Ghosts with allergens for Allergen Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">More than 25% of the global population suffers from IgE mediated allergic diseases. Allergen immunotherapy (AIT) is the only available form of treatment that alters the underlying mechanism of IgE-mediated allergic diseases. AIT is aimed at desensitizing allergic individuals by repeatedly administering disease-causing allergens over a long period of time. Despite its proven efficacy in numerous clinical trials, the effectiveness of AIT still suffers some drawbacks due to the quality of allergens used and in particular the unavailability of efficient allergen delivery systems. Several studies have demonstrated that bacterial ghosts (BG) systems can be used to display and deliver antigens to their targets for the management of diseases. However, there is no report documenting the use of BG systems for immunotherapy of IgE-mediated diseases so far. Thus, in this review, we intend to discuss the potentialities of BG systems for displaying and delivering allergens for future management of IgE-mediated diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1365208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28934008">PM:28934008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170921-FanuelS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20170921-FanuelS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Fanuel S</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1365208</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Emminger,W.</style></author><author><style face="normal" font="Arial"> Hernandez,M.D.</style></author><author><style face="normal" font="Arial"> Cardona,V.</style></author><author><style face="normal" font="Arial"> Smeenk,F.</style></author><author><style face="normal" font="Arial"> Fogh,B.S.</style></author><author><style face="normal" font="Arial"> Calderon,M.A.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Outpatient Clinic, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="44" start="35">35-44</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The SQ house dust mite (HDM) SLIT-tablet (ALK, Denmark) addresses the underlying cause of HDM respiratory allergic disease, and a clinical effect has been demonstrated for both HDM allergic rhinitis and allergic asthma. Here, we present pooled safety data from an adult population with HDM respiratory allergy, with particular focus on the impact of asthma on the SQ HDM SLIT-tablet tolerability profile. METHODS: Safety data from 2 randomised double-blind, placebo-controlled clinical trials were included: MT-04: 834 adults with HDM allergic asthma not well controlled by inhaled corticosteroids and with HDM allergic rhinitis, and MT-06: 992 adults with moderate-to-severe HDM allergic rhinitis despite the use of allergy pharmacotherapy and with or without asthma. RESULTS: The proportion of subjects experiencing adverse events (AEs) was greater in the active treatment group (12 SQ-HDM; 73% of subjects) compared to placebo (53%). The most common treatment-related AEs were local allergic reactions. No AEs were reported as systemic allergic reactions. Regardless of asthma status, most AEs were mild or moderate (>97% of AEs) and the frequency of serious AEs was low. Subgroup analysis revealed no statistically significant difference in the risk of experiencing moderate or severe treatment-related AEs for subjects with asthma compared to subjects without asthma (p = 0.88). In addition, subjects with partly controlled or uncontrolled asthma were no more likely to experience moderate or severe treatment-related AEs than subjects with controlled asthma (p = 0.42). CONCLUSION: The SQ HDM SLIT-tablet is well tolerated, and the safety profile was comparable for subjects with HDM respiratory allergic disease irrespective of asthma status</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Spain -CO - Netherlands -CO - Denmark -CO - United Kingdom -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1159/000478699</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28950268">PM:28950268</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-35-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-35-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Emminger W</style></custom2><misc3><style face="normal" font="Arial">10.1159/000478699</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ohashi-Doi,K.</style></author><author><style face="normal" font="Arial"> Kito,H.</style></author><author><style face="normal" font="Arial"> Du,W.</style></author><author><style face="normal" font="Arial"> Nakazawa,H.</style></author><author><style face="normal" font="Arial"> Ipsen,H.</style></author><author><style face="normal" font="Arial"> Gudmann,P.</style></author><author><style face="normal" font="Arial"> Lund,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Torii Pharmaceutical Co. Ltd., Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="34" start="26">26-34</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Bioavailability</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergens</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mite allergens</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral mucosa</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In sublingual immunotherapy (SLIT), the immune system is addressed by solubilized allergen that interacts with immunocompetent cells of the oral mucosa, the efficiency of which is governed by 2 main factors of SLIT allergen bioavailability: the allergen concentration and the mucosal contact time. Recently, 3 house dust mite (HDM) SLIT tablets were developed that differ with regard to allergen content, nominal strength (maintenance doses: 6 SQ-HDM/10,000 Japanese Allergen Units [JAU], 12 SQ-HDM/ 20,000 JAU, and 300 IR/57,000 JAU), and formulation (freeze-dried/compressed). Here, the importance of the SLIT tablet formulation for HDM major allergen bioavailability is examined. METHODS: The HDM major allergen content, tablet disintegration times, and allergen release kinetics were determined. Dissolution kinetics (allergen concentration vs. time) of Der f 1, Der p 1, and Der 2 were measured. Area under the curve (AUC) was used as a surrogate parameter for allergen bioavailability. RESULTS: The release of HDM major allergens from the freeze-dried tablets was complete after 30 s, while only partial release was achieved with the compressed tablets, even after prolonged dissolution. At 1 min, i.e., the recommended sublingual holding time for the freeze-dried tablets, the allergen bioavailability (AUC) of the compressed 300 IR/57,000 JAU tablet was 4.7-fold (Der f 1), 10.8-fold (Der p 1), and 23.6-fold (Der 2) lower than that of the freeze-dried 12 SQ-HDM/20,000 JAU tablet and similar to (Der f 1) and 5.3-fold (Der p 1) and 12.5-fold (Der 2) lower than that of the freeze-dried 6 SQ-HDM/10,000 JAU tablet. CONCLUSIONS: SLIT tablet allergen bioavailability depends highly on the tablet formulation. Only the fast-dissolving freeze-dried tablets provide maximal delivery of soluble allergens and achieve allergen concentrations that reflect the nominal tablet strengths within the recommended sublingual holding time</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1159/000479693</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28950271">PM:28950271</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-26-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-26-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Ohashi-Doi K</style></custom2><misc3><style face="normal" font="Arial">10.1159/000479693</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosman,Y.</style></author><author><style face="normal" font="Arial"> Confino-Cohen,R.</style></author><author><style face="normal" font="Arial"> Goldberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar Saba, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="51" start="45">45-51</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Angiotensin-converting enzyme inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bee venom</style></keyword><keyword><style face="normal" font="Arial"> Beta-blockers</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Maintenance dose</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> venom allergy</style></keyword><keyword><style face="normal" font="Arial"> venom immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Venom immunotherapy (VIT) is considered to be the gold standard treatment for patients with hymenoptera venom allergy. This treatment induces systemic reactions (SR) in a significant number of patients. OBJECTIVE: To evaluate the outcome of VIT in patients with known risk factors for VIT-induced SR and to compare rush VIT (RVIT) and conventional VIT (CVIT). METHODS: All of the patients who received VIT and had at least one of the following risk factors were included: current cardiovascular disease, uncontrolled asthma, high basal serum tryptase, current treatment with beta-blockers or angiotensin-converting enzyme inhibitors, and age >70 or &lt;5 years. RESULTS: Sixty-four patients were included, and most of them (52; 81.5%) were allergic exclusively to bee venom. Thirty-five (54.7%) patients underwent RVIT and 29 CVIT. The incidence of patients who developed SR during the build-up phase was similar for RVIT and CVIT (25.7 and 27.5%, respectively; p = 1). However, the incidence of SR per injection was significantly higher in CVIT than in RVIT (5.6 and 2.75%, respectively; p = 0.01). Most reactions (79.1%) were mild, limited to the skin. Most of the patients (92.1%) reached the full maintenance dose of 100 mug. This dose was reached by a significantly larger number of patients receiving RVIT compared to CVIT (100 and 82.7%, respectively; p = 0.01). None of the patients experienced exacerbation of their concurrent chronic disease during VIT. CONCLUSION: VIT can be performed safely and efficiently in patients with risk factors for immunotherapy. In these patients RVIT appears to be safer and more efficient than CVIT</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1159/000479692</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28950273">PM:28950273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-45-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-45-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Rosman Y</style></custom2><misc3><style face="normal" font="Arial">10.1159/000479692</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kiykim,A.</style></author><author><style face="normal" font="Arial"> Mumcu,G.</style></author><author><style face="normal" font="Arial"> Ogulur,I.</style></author><author><style face="normal" font="Arial"> Karakoc-Aydiner,E.</style></author><author><style face="normal" font="Arial"> Direskeneli,H.</style></author><author><style face="normal" font="Arial"> Baris,S.</style></author><author><style face="normal" font="Arial"> Cagan,H.</style></author><author><style face="normal" font="Arial"> Ozen,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Allergy and Immunology, School of Medicine, Marmara University, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Could Sublingual Immunotherapy Affect Oral Health in Children with Asthma and/or Allergic Rhinitis Sensitized to House Dust Mite</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="56" start="52">52-56</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health service</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Sublingual immunotherapy (SLIT) has been successfully employed in IgE-mediated respiratory allergies. However, it is not known whether the modulation of immune responses in the sublingual area during SLIT has any deleterious effect on oral health. We sought to determine the oral health prospectively in children receiving SLIT for house dust mite allergy. MATERIAL AND METHODS: Eighteen children with allergic asthma and/or rhinitis and 31 age-matched healthy controls (HC) were included in an open-labeled trial. Oral health was evaluated by scoring the decayed, missing, and filled teeth for primary (dmft) and permanent (DMFT) dentition, and the plaque and gingival indices. Moreover, cariogenic food intake and teeth-brushing habits were also noted at baseline and at 19 months. RESULTS: The mean age of the SLIT participants was 9.5 +/- 3.1 years and that of the HC was 9.2 +/- 3.7 years. The mean duration of SLIT was 19.13 +/- 3.81 months. At baseline, the total dmft and DMFT indices were similar in the SLIT and HC groups (p > 0.05), which demonstrated poor hygiene overall. In the within-group comparisons at the examination at 19 months, the SLIT group had a lower number of carious primary teeth and a higher number of filled primary teeth compared to the count at baseline (p = 0.027 and p = 0.058, respectively). CONCLUSION: Our study showed no detrimental effect of SLIT on oral health during a period of 19 months of follow-up. Parents should be motivated to use dental health services to prevent new caries formation since our cohort had overall poor oral hygiene at the baseline</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1159/000480082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28950285">PM:28950285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-52-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-52-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Kiykim A</style></custom2><misc3><style face="normal" font="Arial">10.1159/000480082</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jin,Y.</style></author><author><style face="normal" font="Arial"> Ebaugh,S.</style></author><author><style face="normal" font="Arial"> Martens,A.</style></author><author><style face="normal" font="Arial"> Gao,H.</style></author><author><style face="normal" font="Arial"> Olson,E.</style></author><author><style face="normal" font="Arial"> Ng,P.K.W.</style></author><author><style face="normal" font="Arial"> Gangur,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy and Immunology Laboratory, Michigan State University, East Lansing, MI, USA</style></auth-address><titles><title><style face="normal" font="Arial">A Mouse Model of Anaphylaxis and Atopic Dermatitis to Salt-Soluble Wheat Protein Extract</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="16" start="7">7-16</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Balb/cJ</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Durum wheat</style></keyword><keyword><style face="normal" font="Arial"> E-Selectin</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Michigan</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein microarray</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> sIgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat allergy</style></keyword><keyword><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Wheat allergy and other immune-mediated disorders triggered by wheat proteins are growing at an alarming rate for reasons not well understood. A mouse model to study hypersensitivity responses to salt-soluble wheat protein (SSWP) extract is currently unavailable. Here we tested the hypothesis that SSWP extract from wheat will induce sensitization as well as allergic disease in mice. METHODS: Female BALB/cJ mice were weaned onto a plant protein-free diet. The mice were injected a total of 4 times with an SSWP (0.01 mg/mouse) fraction extracted from durum wheat along with alum as an adjuvant. Blood was collected biweekly and SSWP-specific IgE (SIgE) and total IgE (TIgE) levels were measured using ELISA. Systemic anaphylaxis upon intraperitoneal injection with SSWP was quantified by hypothermia shock response (HSR). Mucosal mast cell degranulation was measured by the elevation of mMCP-1 in the blood. The mice were monitored for dermatitis. Skin tissues were used in histopathology and for measuring cytokine/chemokine/adhesion molecule levels using a protein microarray system. RESULTS: Injection with SSWP resulted in time-dependent SIgE antibody responses associated with the elevation of TIgE concentration. Challenge with SSWP elicited severe HSR that correlated with a significant elevation of plasma mMCP-1 levels. Sensitized mice developed facial dermatitis associated with mast cell degranulation. Lesions expressed significant elevation of Th2/Th17/Th1 cytokines and chemokines and E-selectin adhesion molecule. CONCLUSION: Here we report a mouse model of anaphylaxis and atopic dermatitis to SSWP extract that may be used for further basic and applied research on wheat allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1159/000479386</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28950276">PM:28950276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-7-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-7-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Jin Y</style></custom2><misc3><style face="normal" font="Arial">10.1159/000479386</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schocker,F.</style></author><author><style face="normal" font="Arial"> Scharf,A.</style></author><author><style face="normal" font="Arial"> Kull,S.</style></author><author><style face="normal" font="Arial"> Jappe,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical and Molecular Allergology, Research Center Borstel, Priority Research Area Asthma and Allergy, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Detection of the Peanut Allergens Ara h 2 and Ara h 6 in Human Breast Milk: Development of 2 Sensitive and Specific Sandwich ELISA Assays</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="25" start="17">17-25</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ara h 1</style></keyword><keyword><style face="normal" font="Arial"> Ara h 2</style></keyword><keyword><style face="normal" font="Arial"> Ara h 6</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> ELISA assay</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergology</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sandwich ELISA</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> tree nut</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Little is known about breast milk as a vehicle for tolerance development or sensitization to peanuts very early in life. Thus, well-characterized and highly sensitive detection systems for the reliable determination of peanut allergens in breast milk are mandatory. METHODS: For the quantification of the marker allergens Ara h 2 and Ara h 6 in the low nanogram per milliliter range in breast milk samples of a German cohort, sensitive and highly specific sandwich ELISAs were optimized and validated. RESULTS: The Ara h 2 ELISA revealed a limit of detection (LOD) of 1.3 ng Ara h 2/mL and a quantification range of 2.3-250 ng/mL, the Ara h 6 ELISA showed an LOD of 0.7 ng/mL and a working range of 1.1-14.4 ng/mL. The assays showed no relevant cross-reactivity against other potentially cross-reactive legume, seed, and tree nut extracts (&lt;0.01%, except for Ara h 1 in the Ara h 2 ELISA &lt;0.1%). Ara h 2 was detectable in breast milk samples from 14/40 (35%) of the participants in concentrations from 2.3 to 184 ng/mL, Ara h 6 appeared in 9/40 (22.5%) of the lactating mothers between 1.1 and 9.7 ng/mL, and 1 highly positive sample with 79 ng/mL. Both allergens appeared at the same time points, but Ara h 6 in lower concentrations than Ara h 2. CONCLUSIONS: Sensitive and specific diagnostic tools for the determination of Ara h 2 and Ara h 6 in human breast milk were established. The kinetics of secreted Ara h 2 and Ara h 6 seem to be similar but with a difference in concentration. Follow-up investigations on their tolerogenic or sensitizing properties in breast milk become now accessible</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1159/000479388</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28950267">PM:28950267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-17-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-17-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Schocker F</style></custom2><misc3><style face="normal" font="Arial">10.1159/000479388</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rava,M.</style></author><author><style face="normal" font="Arial"> Czachorowski,M.J.</style></author><author><style face="normal" font="Arial"> Silverman,D.</style></author><author><style face="normal" font="Arial"> Marquez,M.</style></author><author><style face="normal" font="Arial"> Kishore,S.</style></author><author><style face="normal" font="Arial"> Tardon,A.</style></author><author><style face="normal" font="Arial"> Serra,C.</style></author><author><style face="normal" font="Arial"> Garcia-Closas,M.</style></author><author><style face="normal" font="Arial"> Garcia-Closas,R.</style></author><author><style face="normal" font="Arial"> Carrato,A.</style></author><author><style face="normal" font="Arial"> Rothman,N.</style></author><author><style face="normal" font="Arial"> Real,F.X.</style></author><author><style face="normal" font="Arial"> Kogevinas,M.</style></author><author><style face="normal" font="Arial"> Malats,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, and CIBERONC, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Asthma status is associated with decreased risk of aggressive urothelial bladder cancer</style></title><secondary-title><style face="normal" font="Arial">Int J Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Cancer</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic conditions</style></keyword><keyword><style face="normal" font="Arial"> Bladder</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">Previous studies suggested an association between atopic conditions and specific cancers. The results on the association with urothelial bladder cancer (UBC) are scarce and inconsistent. To evaluate the association between asthma and risk of UBC, we considered 936 cases and 1022 controls from the Spanish Bladder Cancer/EPICURO Study (86% males, mean age 65.4 years), a multicenter and hospital based case-control study conducted during 1998-2001. Participants were asked whether they had asthma and detailed information about occupational exposures, smoking habits, dietary factors, medical conditions, and history of medication was collected through face-to-face questionnaires performed by trained interviewers. Since asthma and UBC might share risk factors, association between patients' characteristics and asthma was studied in UBC controls. Association between UBC and asthma was assessed using logistic regression unadjusted and adjusted for potential confounders. The complex interrelationships, direct, and mediating effect of asthma on UBC, were appraised using counterfactual mediation models. Asthma was associated with a reduced risk of UBC (odds ratio (OR)=0.54, 95% confidence interval (CI) 0.37, 0.79) after adjusting for a wide range of confounders. No mediating effect was identified. The reduced risk associated with asthma was restricted to patients with high-risk non-muscle invasive (OR=0.25, 95%CI 0.10, 0.62) and muscle invasive UBC (OR=0.32, 95%CI 0.15, 0.69). Our results support that asthma is associated with a decreased risk of UBC, especially among aggressive tumors. Further work on the relationship between asthma and other atopic conditions and cancer risk should shed light on the relationship between immune response mechanisms and bladder carcinogenesis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1097-0215 (Electronic)IS - 0020-7136 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/ijc.31066</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940228">PM:28940228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Cancer\20170923-RavaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Cancer\20170923-RavaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Rava M</style></custom2><misc3><style face="normal" font="Arial">10.1002/ijc.31066</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sung,J.E.</style></author><author><style face="normal" font="Arial"> Lee,H.A.</style></author><author><style face="normal" font="Arial"> Kim,J.E.</style></author><author><style face="normal" font="Arial"> Yun,W.B.</style></author><author><style face="normal" font="Arial"> An,B.S.</style></author><author><style face="normal" font="Arial"> Yang,S.Y.</style></author><author><style face="normal" font="Arial"> Kim,D.S.</style></author><author><style face="normal" font="Arial"> Lee,C.Y.</style></author><author><style face="normal" font="Arial"> Lee,H.S.</style></author><author><style face="normal" font="Arial"> Bae,C.J.</style></author><author><style face="normal" font="Arial"> Hwang,D.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomaterials Science, College of Natural Resources and Life Science/Life and Industry Convergence Research Institute, Pusan National University, Miryang 50463, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Saponin-enriched extract of Asparagus cochinchinensis alleviates airway inflammation and remodeling in ovalbumin-induced asthma model</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asparagus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> biomaterials</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Convergence</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase-2</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory disease characterized by T-lymphocyte and eosinophil infiltration, mucus overproduction and airway hyper-responsiveness. The present study examined the therapeutic effects and action mechanism of a saponin-enriched extract of Asparagus cochinchinensis (SEAC) on airway inflammation and remodeling in an ovalbumin (OVA)-induced asthma model. To accomplish this, alterations of the nitric oxide (NO) level, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression levels, as well as variations in immune cell numbers, immunoglobulin E (IgE) concentration, histopathological structure and inflammatory cytokine levels were measured in lipopolysaccharide (LPS)-activated RAW264.7 cells or an OVA-induced mouse model of asthma treated with SEAC. The concentration of NO and mRNA levels of COX-2 and iNOS were significantly decreased in the SEAC + LPS-treated RAW264.7 cells compared with the vehicle + LPS-treated RAW264.7 cells. Additionally, in the OVA-induced asthma model, the number of immune cells in the bronchoalveolar lavage fluid, the concentration of OVA-specific IgE, the infiltration of inflammatory cells, the bronchial thickness and the levels of the inflammatory mediators interleukin-4 (IL-4), IL-13 and COX-2 were significantly lower in the OVA + SEACtreated group compared with the OVA + vehicletreated group. In addition, a significant reduction in goblet cell hyperplasia, peribronchiolar collagen layer thickness and VEGF expression for airway remodeling was detected in the OVA + SEACtreated group compared with the OVA + vehicletreated group. These findings indicate that SEAC is a suppressor of airway inflammation and remodeling, and may therefore be useful as an anti-inflammatory drug for the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1791-244X (Electronic)IS - 1107-3756 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3892/ijmm.2017.3147</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28949387">PM:28949387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Med\20170926-SungJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Med\20170926-SungJE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Sung JE</style></custom2><misc3><style face="normal" font="Arial">10.3892/ijmm.2017.3147</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lenberg,J.</style></author><author><style face="normal" font="Arial"> Qian,Q.</style></author><author><style face="normal" font="Arial"> Sun,Z.</style></author><author><style face="normal" font="Arial"> Alam,R.</style></author><author><style face="normal" font="Arial"> Gorska,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Jewish Health, Department of Medicine, Division of Allergy and Clinical Immunology, 1400 Jackson St, Denver, CO, 80206</style></auth-address><titles><title><style face="normal" font="Arial">Pre-Pregnancy Exposure to Diesel Exhaust Predisposes Offspring to Asthma through IL-1beta and IL-17A</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevention</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diesel</style></keyword><keyword><style face="normal" font="Arial"> Diesel exhaust</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">Using a mouse model we provided evidence that pre-pregnancy exposure to diesel exhaust predisposes offspring to asthma. We identified immunological mechanisms of this predisposition to facilitate future development of asthma prevention strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.09.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28943469">PM:28943469</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160925-LenbergJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160925-LenbergJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Lenberg J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.09.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Muniz,V.S.</style></author><author><style face="normal" font="Arial"> Silva,J.C.</style></author><author><style face="normal" font="Arial"> Braga,Y.A.V.</style></author><author><style face="normal" font="Arial"> Melo,R.C.N.</style></author><author><style face="normal" font="Arial"> Ueki,S.</style></author><author><style face="normal" font="Arial"> Takeda,M.</style></author><author><style face="normal" font="Arial"> Hebisawa,A.</style></author><author><style face="normal" font="Arial"> Asano,K.</style></author><author><style face="normal" font="Arial"> Figueiredo,R.T.</style></author><author><style face="normal" font="Arial"> Neves,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD11b</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal disease</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> molecular interactions</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> neutralizing</style></keyword><keyword><style face="normal" font="Arial"> neutralizing antibodies</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> tyrosine kinase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophils mediate the immune response in different infection conditions. The release of extracellular DNA traps (ETs) by leukocytes has been described as an innate immune response mechanism that is relevant in many disorders including fungal diseases. Different stimuli induce human eosinophil ETs (EETs) release. Aspergillus fumigatus (A. fumigatus) is an opportunistic fungus that may cause eosinophilic allergic bronchopulmonary aspergillosis (ABPA). It has been reported that eosinophils are important to the clearance of A. fumigatus in infected mice lungs. However, the immunological mechanisms that underlie the molecular interactions between A. fumigatus and eosinophils are poorly understood. OBJECTIVE: Here, we investigated the presence of EETs in the bronchial mucus plugs of ABPA patients. We also determined whether A. fumigatus-induced human eosinophils EETs release in vitro. METHODS: Mucus samples of ABPA patients were analyzed by light and confocal fluorescence microscopy. The release of EETs by human blood eosinophils was evaluated using different pharmacological tools and neutralizing antibodies by fluorescence microscopy and a fluorimetric method. RESULTS: We identified abundant nuclear histone-bearing EETs in the bronchial secretions obtained from ABPA patients. In vitro, we demonstrated that A. fumigatus induces EETs release through a mechanism independent of reactive oxygen species but associated to eosinophil death, histone citrullination, CD11b and the Syk tyrosine kinase pathway. EETs lack the killing or fungistatic activities against A. fumigatus. CONCLUSION: Our findings may contribute to the understanding of how eosinophils recognize and act as immune cells in response to A. fumigatus, which may lead to novel insights regarding ABPA patient treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28943470">PM:28943470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160925-MunizVS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160925-MunizVS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Muniz VS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Johnson-Weaver,B.T.</style></author><author><style face="normal" font="Arial"> McRitchie,S.</style></author><author><style face="normal" font="Arial"> Mercier,K.A.</style></author><author><style face="normal" font="Arial"> Pathmasiri,W.</style></author><author><style face="normal" font="Arial"> Sumner,S.J.</style></author><author><style face="normal" font="Arial"> Chan,C.</style></author><author><style face="normal" font="Arial"> Germolec,D.</style></author><author><style face="normal" font="Arial"> Kulis,M.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author><author><style face="normal" font="Arial"> Staats,H.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology, Duke University School of Medicine, Durham, NC 27710</style></auth-address><titles><title><style face="normal" font="Arial">Effect of endotoxin and alum adjuvant vaccine on peanut allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="16" Month="9" Year="2017">2017/9/16</year></dates><abstract><style face="normal" font="Arial">Environmental endotoxin and alum-adjuvanted vaccines did not influence peanut-allergy development in mice. Exposure to alum and CpG-adjuvanted vaccines indirectly reduced allergic disease severity. Fecal metabolites differentiated mice based on disease severity</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28927819">PM:28927819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160920-JohnsonWeaverBT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160920-JohnsonWeaverBT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Johnson-Weaver BT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.043</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berings,M.</style></author><author><style face="normal" font="Arial"> Karaaslan,C.</style></author><author><style face="normal" font="Arial"> Altunbulakli,C.</style></author><author><style face="normal" font="Arial"> Gevaert,P.</style></author><author><style face="normal" font="Arial"> Akdis,M.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Upper Airways Research Laboratory and ENT-Department, Ghent University Hospital, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Advances and Highlights in Allergen Immunotherapy: On the way to sustained clinical and immunologic tolerance</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biologicals</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> hypoallergenic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> new biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> Probiotics</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Statistical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy (AIT) is an effective treatment strategy for allergic diseases and has been used for more than 100 years. In recent years, however, the expectations on concepts, conduct, statistical evaluation and reporting have been significantly developed. Products have undergone dose-response and confirmative studies in adults and children to provide evidence for the optimal dosage, safety and efficacy of AIT vaccines using subcutaneous and sublingual delivery pathways in large patient cohorts, ensuring solid conclusions to be drawn from them for the advantage of patients and societies alike. Those standards should be followed today, and products answering to them should be preferred over others lacking optimization and proof of efficacy and safety. Molecular and cellular mechanisms of AIT include early mast cell and basophil desensitization effects, regulation of T and B cell responses, regulation of IgE and IgG4 production and inhibition of responses from eosinophils, mast cells and basophils in the affected tissues. There were many developments to improve vaccination strategies, demonstration of new molecules involved in molecular mechanisms and demonstration of new biomarkers for AIT during the last few years. The combination of probiotics, vitamins and biologicals with AIT are highlighting current advances. Development of allergoids, recombinant and hypoallergenic vaccines to skew the immune response from IgE to IgG4 and regulation of dendritic cell, mast cell, basophil, innate lymphoid cell, T and B cell responses to allergens are also discussed in detail</style></abstract><notes><style face="normal" font="Arial">DA - 20170924IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Switzerland -CO - Turkey -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941667">PM:28941667</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160924-BeringsM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160924-BeringsM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170924, Berings M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maridet,C.</style></author><author><style face="normal" font="Arial"> Perromat,M.</style></author><author><style face="normal" font="Arial"> Miquel,J.</style></author><author><style face="normal" font="Arial"> Chiaverini,C.</style></author><author><style face="normal" font="Arial"> Bessis,D.</style></author><author><style face="normal" font="Arial"> Lasek,A.</style></author><author><style face="normal" font="Arial"> Piram,M.</style></author><author><style face="normal" font="Arial"> Bursztejn,A.C.</style></author><author><style face="normal" font="Arial"> Abasq,C.</style></author><author><style face="normal" font="Arial"> Phan,A.</style></author><author><style face="normal" font="Arial"> Martin,L.</style></author><author><style face="normal" font="Arial"> Brechat,B.</style></author><author><style face="normal" font="Arial"> Ho,Chong J.</style></author><author><style face="normal" font="Arial"> Seneschal,J.</style></author><author><style face="normal" font="Arial"> Taieb,A.</style></author><author><style face="normal" font="Arial"> Boralevi,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Dermatology Unit, Hopital Pellegrin-enfants, Bordeaux University Hospital, Bordeaux, France.</style></auth-address><titles><title><style face="normal" font="Arial">Childhood Chronic Prurigo: interest of Patch tests and delayed reading Skin prick tests to environmental allergens</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic component</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Prurigo</style></keyword><keyword><style face="normal" font="Arial"> Reading</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">Childhood chronic prurigo is rarely studied in particular for allergic components. We propose a clinical classification according to seasonality of prurigo in three groups to help identifying causal agents and guide allergy testing with delayed readings tests</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28943471">PM:28943471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160925-MaridetC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160925-MaridetC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Maridet C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bachert,C.</style></author><author><style face="normal" font="Arial"> Akdis,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Upper Airways Research Laboratory and ENT-Department, Ghent University Hospital, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Specific Allergy &amp; Asthma Prevention Coming to an Age: A Milestone in Children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevention</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="9" Year="2017">2017/9/16</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Belgium -CO - Sweden -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28927818">PM:28927818</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160920-BachertC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160920-BachertC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Bachert C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wisniewski,J.A.</style></author><author><style face="normal" font="Arial"> Muehling,L.M.</style></author><author><style face="normal" font="Arial"> Eccles,J.D.</style></author><author><style face="normal" font="Arial"> Capaldo,B.J.</style></author><author><style face="normal" font="Arial"> Agrawal,R.</style></author><author><style face="normal" font="Arial"> Shirley,D.A.</style></author><author><style face="normal" font="Arial"> Patrie,J.T.</style></author><author><style face="normal" font="Arial"> Workman,L.J.</style></author><author><style face="normal" font="Arial"> Schuyler,A.J.</style></author><author><style face="normal" font="Arial"> Lawrence,M.G.</style></author><author><style face="normal" font="Arial"> Teague,W.G.</style></author><author><style face="normal" font="Arial"> Woodfolk,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Charlottesville, VA 22908, USA</style></auth-address><titles><title><style face="normal" font="Arial">Th1 Signatures Are Present in the Lower Airways of Children with Severe Asthma, Regardless of Allergic Status</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-23</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Modeling</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> myeloid dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathogenicity</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viruses</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The pathogenesis of severe asthma in childhood remains poorly understood. OBJECTIVE: To construct the immunological landscape in the airways of children with severe asthma. METHODS: Comprehensive analysis of multiple cell types and mediators was performed by flow cytometry and multiplex assay using bronchoalveolar lavage (BAL) specimens (n=68) from 52 highly characterized allergic and non-allergic children (0.5-17 years) with severe treatment-refractory asthma. Multiple relationships were tested by linear mixed-effects modeling. RESULTS: Memory CCR5+ Th1 cells were enriched in BAL fluid versus blood, and pathogenic respiratory viruses and bacteria were readily detected. IFN-gamma+IL-17+ and IFN-gamma-IL-17+ subsets constituted secondary Th types, and BAL CD8+ T cells were almost exclusively IFN-gamma+. The Th17-associated mediators, IL-23 and MIP-3alpha/CCL20 were highly expressed. Despite low Th2 numbers, Th2 cytokines were detected and Th2-skewing correlated with total IgE levels. ILC2s and basophils were scarce in BAL fluid. Levels of IL-5, IL-33 and IL-28A/IFN-lambda2, were increased in multi-sensitized children and correlated with IgE to dust mite, ryegrass and fungi, but not cat, ragweed or food sources. Additionally, levels of IL-5, but no other cytokine, increased with age and correlated with eosinophil numbers in BAL fluid and blood. Both plasmacytoid and IgE+FcepsilonRI+ myeloid dendritic cells were present in BAL fluid. CONCLUSIONS: The lower airways of children with severe asthma display a dominant Th1 signature, and atypical cytokine profiles that link to allergic status. Our findings deviate from established paradigms, and warrant further assessment of the pathogenicity of Th1 cells in severe asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939412">PM:28939412</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160923-WisniewskiJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20160923-WisniewskiJA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Wisniewski JA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Haroun-Diaz,E.</style></author><author><style face="normal" font="Arial"> Blanca-Lopez,N.</style></author><author><style face="normal" font="Arial"> Vazquez de la Torre,M.</style></author><author><style face="normal" font="Arial"> Ruano,F.J.</style></author><author><style face="normal" font="Arial"> Somoza Alvarez,M.L.</style></author><author><style face="normal" font="Arial"> Labrador Horrillo,M.</style></author><author><style face="normal" font="Arial"> Bartolome,B.</style></author><author><style face="normal" font="Arial"> Blanca,M.</style></author><author><style face="normal" font="Arial"> Canto Diez,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Service, Infanta Leonor University Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Severe anaphylaxis due to crocodile-meat allergy exhibiting wide cross-reactivity with fish allergens</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergens</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28923489">PM:28923489</url></web-urls><pdf-urls><url ppv-ref="no">elisaharoun@hotmail.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170919, Haroun-Diaz E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Motosue,M.S.</style></author><author><style face="normal" font="Arial"> Bellolio,M.F.</style></author><author><style face="normal" font="Arial"> Van Houten,H.K.</style></author><author><style face="normal" font="Arial"> Shah,N.D.</style></author><author><style face="normal" font="Arial"> Li,J.T.</style></author><author><style face="normal" font="Arial"> Campbell,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergic Diseases, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="Arial">Outcomes of Emergency Department Anaphylaxis Visits from 2005 to 2014</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">admissions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Claims data</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although the incidence of anaphylaxis appears to be increasing, trends in anaphylaxis-related health care utilization are not well understood. OBJECTIVE: To better understand the potential increasing health care burden, we analyzed the changes in anaphylaxis-related health care utilization, including emergency department (ED) discharges, observation stays, inpatient admissions, intensive care unit admissions, and endotracheal intubations. METHODS: We conducted an observational study examining outcomes of anaphylaxis-related ED visits between January 1, 2005, and December 31, 2014. We analyzed administrative claims data from OptumLabs Data Warehouse, which includes more than 100 million Medicare Advantage and privately insured enrollees in the United States. We studied trends in the proportions of ED-related anaphylaxis visits based on demographic characteristics, triggers, and ED disposition for our study population. RESULTS: Among 56,212 anaphylaxis-related ED visits during a 10-year period, the proportion of patient observation/inpatient admissions increased by 37.6% (P = .02), from 13.2% of anaphylaxis-related ED visits in 2005 to 18.2% in 2014. The proportion of patients admitted to the intensive care unit increased by 27.4% (P = .001), from 4.5% in 2005 to 5.8% in 2014. Proportions of endotracheal intubation increased by 145.2% (P &lt; .001). CONCLUSIONS: The increasing proportions of observation/inpatient admissions, intensive care unit admissions, and endotracheal intubations suggest an increase in anaphylaxis severity. Enhanced awareness of these trends among patients, practitioners, and the community is necessary to create effective strategies to prevent anaphylaxis and decrease associated adverse consequences</style></abstract><notes><style face="normal" font="Arial">DA - 20170924IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941671">PM:28941671</url></web-urls><pdf-urls><url ppv-ref="no">campbell.ronna@mayo.edu</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170924, Motosue MS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ledford,D.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Asthma Allergy Immunology Associates of Tampa Bay, Internal Medicine, Tampa, Fla.</style></auth-address><titles><title><style face="normal" font="Arial">Increased IgE in IgA Deficiency</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1795">1795-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgA Deficiency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170924IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941669">PM:28941669</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1795.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1795.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170924, Ledford DK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alvarez-Perea,A.</style></author><author><style face="normal" font="Arial"> Ojeda,P.</style></author><author><style face="normal" font="Arial"> Zubeldia,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy Service, Gregorio Maranon University General Hospital, Madrid, Spain; Gregorio Maranon Health Research Institute, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="Arial">Trends in Twitter use during the Annual Meeting of the Spanish Society of Allergology and Clinical Immunology (2013-2016)</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939139">PM:28939139</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170923-AlvarezPereaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170923-AlvarezPereaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Alvarez-Perea A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.031</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bakshi,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of ENT and Head &amp; Neck Surgery, Mahatma Gandhi Medical College and Research Institute, Pillaiyarkuppam, Pondicherry, India.</style></auth-address><titles><title><style face="normal" font="Arial">Erythematous Candidiasis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Candidiasis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170924IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941670">PM:28941670</url></web-urls><pdf-urls><url ppv-ref="no">saty.bakshi@gmail.com</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170924, Bakshi SS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jeffery,M.M.</style></author><author><style face="normal" font="Arial"> Shah,N.D.</style></author><author><style face="normal" font="Arial"> Karaca-Mandic,P.</style></author><author><style face="normal" font="Arial"> Ross,J.S.</style></author><author><style face="normal" font="Arial"> Rank,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minn; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="Arial">Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> medication adherence</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Utilization trends of omalizumab, a first-in-its-class asthma biologic approved in 2003 for individuals not controlled by inhaled corticosteroids (ICSs), may reveal lessons in patient selection. OBJECTIVE: To describe utilization patterns for omalizumab since its introduction in 2003, with a focus on patient-level characteristics of patients for whom omalizumab was initiated. METHODS: Using a large US database of administrative claims, we identified privately insured and Medicare Advantage beneficiaries with asthma between 2003 and 2015. Characteristics of incident (no omalizumab use in the previous 12 months) and prevalent users of omalizumab for asthma were described and omalizumab use trends graphed. A comparison cohort (1:5 matching proportion) of nonomalizumab users was compared with incident omalizumab users on demographic characteristics, medication adherence (medication possession ratio [MPR]) for ICSs and/or ICS/long-acting beta-agonist (ICS-LABA), exacerbation frequency, and asthma control in the 6 months before omalizumab initiation. RESULTS: We identified 7,658 prevalent and 3,399 incident omalizumab users. Omalizumab incidence peaked in the second quarter of 2004 at 0.65 per 1,000 individuals with asthma, whereas prevalence peaked in the fourth quarter of 2006 at 3.22; as of fourth quarter 2015, rates were 0.14 and 1.96, respectively. In the 12 months before omalizumab initiation, 72.5% had low adherence (MPR &lt;/= 0.75) and 48.6% had very low adherence (MPR &lt;/= 0.5) to ICSs and/or ICS-LABA. In the period 2003 to 2015, the mean number of exacerbations in the 12 months before incident use ranged from 1.50 to 2.11 and the proportion that had poor asthma control (>/=3 rescue inhalers dispensed) ranged from 54% to 67%. Incident omalizumab users were less likely to have good asthma control than the matched cohort of nonusers (adjusted odds ratio, 0.53 [0.48-0.59]). CONCLUSIONS: Omalizumab use for asthma has been gradually decreasing following a peak shortly after its market availability. Many omalizumab users have low or very low adherence rates for ICSs and/or ICS-LABA in the 12 months before omalizumab initiation</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958746">PM:28958746</url></web-urls><pdf-urls><url ppv-ref="no">rank.matthew@mayo.edu</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170929, Jeffery MM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wegienka,G.</style></author><author><style face="normal" font="Arial"> Sitarik,A.</style></author><author><style face="normal" font="Arial"> Bassirpour,G.</style></author><author><style face="normal" font="Arial"> Zoratti,E.M.</style></author><author><style face="normal" font="Arial"> Ownby,D.</style></author><author><style face="normal" font="Arial"> Johnson,C.C.</style></author><author><style face="normal" font="Arial"> Havstad,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Public Health Sciences, Henry Ford Health System, Detroit, Mich</style></auth-address><titles><title><style face="normal" font="Arial">The associations between eczema and food and inhalant allergen-specific IgE vary between black and white children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958743">PM:28958743</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170929-WegienkaG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170929-WegienkaG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Wegienka G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Crihalmeanu,T.</style></author><author><style face="normal" font="Arial"> Prabhu,A.V.</style></author><author><style face="normal" font="Arial"> Hansberry,D.R.</style></author><author><style face="normal" font="Arial"> Agarwal,N.</style></author><author><style face="normal" font="Arial"> Fine,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">West Virginia University School of Medicine, Morgantown, WVa</style></auth-address><titles><title><style face="normal" font="Arial">Readability of online allergy and immunology educational resources for patients: Implications for physicians</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Educational resources</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword><keyword><style face="normal" font="Arial"> West Virginia</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.07.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28923491">PM:28923491</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170919-CrihalmeanuT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170919-CrihalmeanuT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Crihalmeanu T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.07.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gernez,Y.</style></author><author><style face="normal" font="Arial"> Freeman,A.F.</style></author><author><style face="normal" font="Arial"> Holland,S.M.</style></author><author><style face="normal" font="Arial"> Garabedian,E.</style></author><author><style face="normal" font="Arial"> Patel,N.C.</style></author><author><style face="normal" font="Arial"> Puck,J.M.</style></author><author><style face="normal" font="Arial"> Sullivan,K.E.</style></author><author><style face="normal" font="Arial"> Akhter,J.</style></author><author><style face="normal" font="Arial"> Secord,E.</style></author><author><style face="normal" font="Arial"> Chen,K.</style></author><author><style face="normal" font="Arial"> Buckley,R.</style></author><author><style face="normal" font="Arial"> Haddad,E.</style></author><author><style face="normal" font="Arial"> Ochs,H.D.</style></author><author><style face="normal" font="Arial"> Fuleihan,R.</style></author><author><style face="normal" font="Arial"> Routes,J.</style></author><author><style face="normal" font="Arial"> Muskat,M.</style></author><author><style face="normal" font="Arial"> Lugar,P.</style></author><author><style face="normal" font="Arial"> Mancini,J.</style></author><author><style face="normal" font="Arial"> Cunningham-Rundles,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Icahn School of Medicine, Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Autosomal Dominant Hyper-IgE Syndrome in the USIDNET Registry</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Abscess</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Autosomal dominant hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Deficiency Diseases</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> HIES</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune deficiency</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin replacement therapy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas</style></keyword><keyword><style face="normal" font="Arial"> Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Registries</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Scoliosis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Autosomal dominant hyper-IgE syndrome (AD-HIES) is a rare condition. OBJECTIVE: Data from the USIDNET Registry provide a resource to examine the characteristics of patients with rare immune deficiency diseases. METHODS: A query was submitted to the USIDNET requesting deidentified data for patients with physician-diagnosed AD-HIES through July 2016. RESULTS: Data on 85 patients diagnosed with AD-HIES (50 males; 35 females) born between 1950 and 2013, collected by 14 physicians from 25 states and Quebec, were entered into the USIDNET Registry by July 2016. Cumulative follow-up was 2157 years. Of these patients, 45.9% had a family history of HIES. The complications reported included skin abscesses (74.4%), eczema (57.7%), retained primary teeth (41.4%), fractures (39%), scoliosis (34.1%), and cancer (7%). Reported allergic diseases included food (37.8%), environmental (18%), and drugs (42.7%). The mean serum IgE level was 8383.7 kU/mL and was inversely correlated to the patient's age. A total of 49.4% had eosinophilia; 56% were known to be on trimethoprim-sulfamethoxazole, 26.6% on antifungal coverage, and 30.6% on immunoglobulin replacement therapy. Pneumonias were more commonly attributed to Staphylococcus aureus (55.3%) or Aspergillus fumigatus (22.4%); 19.5% had a history of lung abscess; these were most often associated with Pseudomonas aeruginosa (P Fisher's exact test = .029) or A. fumigatus (P Fisher's exact test = .016). Lung abscesses were significantly associated with drug reactions (P chi2 = .01; odds ratio: 4.03 [1.2-12.97]), depression (P Fisher's exact test = .036), and lower Karnofsky index scores (P Mann-Whitney = .007). DISCUSSION: Data from the USIDNET Registry summarize the currently reported clinical characteristics of a large cohort of subjects with AD-HIES</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Canada -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939137">PM:28939137</url></web-urls><pdf-urls><url ppv-ref="no">charlotte.cunningham-rundles@mssm.edu</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20170923, Gernez Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.041</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ho,H.E.</style></author><author><style face="normal" font="Arial"> Chehade,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="Arial">Development of IgE-mediated immediate hypersensitivity to a previously tolerated food following its avoidance for eosinophilic gastrointestinal diseases</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disease</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic gastrointestinal diseases</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Diseases</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958748">PM:28958748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170929-HoHE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20170929-HoHE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Ho HE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.08.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamaguchi,K.</style></author><author><style face="normal" font="Arial"> Shindoh,C.</style></author><author><style face="normal" font="Arial"> Miura,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Diaphragm Muscle Contraction Decrease in a Mouse Model of Ovalbumin-Induced Allergic Airway Inflammation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="265">265-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Budesonide/formoterol</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Contraction</style></keyword><keyword><style face="normal" font="Arial"> Muscle Weakness</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> T lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> T-lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: We investigated diaphragm contractile and inflammatory properties of mice with OVA sensitization and challenge.Methods: BALB/c mice were sensitized to OVA by intraperitoneal (i.p.) injection at 0 and 7 days, and challenged with aerosolized OVA on 21, 22, and 23 days (O/O group). Budesonide/Formoterol combination was inhaled on days 21, 22, and 23 before OVA challenge on those same days (O/OC group). Control mice were sensitized and challenged with an aerosolized saline (O-group). The diaphragm contractile and inflammatory properties were measured on day 24. NOS activity in the diaphragm muscle was evaluated by NADPH diaphorase staining. IL-4 and IL-13 levels of BALF, as well as lung tissue and diaphragm muscle homogenates were measured by ELISA.Results: Force-frequency (F/f) curves of O/O and O/OC shifted downward in comparison with O- (p&lt;0.05). NADPH diaphorase staining results of O/O and O/OC showed a significantly higher density compared with O-. The IL-4 level of diaphragm muscle homogenates increased significantly in the O/O compared with the O- and O/OC.Conclusions: OVA sensitization and challenge decreased diaphragm muscle contraction, increased NOS activity, IL-4 levels of diaphragm in a mouse model. Budesonide/Formoterol combination could protect diaphragm muscle weakness and inflammation. According to the traditional concept of the contemporary Immunology, neither autoimmune diseases nor allergic diseases can be cured completely. Nevertheless, a fortunate coincidence led me to discovery of a novel concept that eliminations of the causes of these diseases are possible. In other words, combinations of pathogenic antibodies with responsible cells, namely, cytolytic T lymphocytes in cases of autoimmune diseases and mast cells in cases of allergic diseases, can be decomposed by replacing the pathogenic antibodies with non-specific antibodies. In more detail, intradermal injections with a non-specific antigen preparation induce production of non-specific antibodies in the body of the patient. Repetitions of the injections bring about an accumulation of them. Accumulated non-specific antibodies will occupy most of the receptors on the surface of responsible cells. When the accumulation reaches the sufficient level, virtually no pathogenic antibodies would remain on the receptors. That is, no causes of the diseases remain. Naturally, where there is no cause, there is no disease. Details are demonstrated elsewhere.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000256</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000256</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-265.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-265.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Yamaguchi K</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000256</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shrivastava,L.</style></author><author><style face="normal" font="Arial"> Schutte,H.</style></author><author><style face="normal" font="Arial"> Malik,P.</style></author><author><style face="normal" font="Arial"> Shrivastava,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A New Class of Polymeric Anti-Allergen Nasal Barrier Film Solution for the Treatment of Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="263">263-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cortisone</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> mucosal inflammation</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Polymers</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> RQLQ</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> total nasal symptom scores</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Arab Emirates</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: Allergic rhinitis (AR) is oversensitivity of nasal mucosa to allergen exposure leading to IgE-mediated nasal mucosal inflammation and cellular destruction. Applying any chemical drug over the nasal mucosa may provide symptomatic relief but at the same time the presence of chemicals, such as cortisones and antihistaminic, hampers mucosa repair and, in consequence, cellular defense functions. Therefore, cleaning, avoiding allergen exposure, and protecting nasal mucosa from contact with allergens with a cell-friendly mechanical device, could be an effective remedy to treat allergic rhinitis.Methods: A double blind, randomized, placebo controlled, multicenter clinical trial was conducted in patients suffering from severe AR. 15 patients were treated with saline as comparator product (CP) versus 31 treated with the test product (TP). The test product contained a natural gum-glycerol solution (VB-Gy) which was rendered filmogen using inert natural polymers (Allercyanidin-H) and termed as VB-Gy-Allercyanidin-H formula. The products (15 ml sprays) were applied topically over the nasal mucosa, 3-4 times a day over a period of 3 weeks. Total, reflective and instantaneous nasal symptom scores for rhinorrhea, nasal discharge, sneezing, and itching, as well as ocular scores (itching, tearing, redness) and rescue medicine use scores were evaluated daily during weeks -1 to +3 employing a 0 (no symptoms) to 3 (severe symptoms) scoring scale. Rhino-conjunctivitis quality of life (RQLQ) questionnaires were completed at the start and at the end of the study. Saline solution (CP) was used identically to the TP. Mean weekly results in CP and TP groups were compared with the scores at the start of treatment (baseline) and between the two groups.Results: CP was found to reduce only slightly the symptomatic manifestation of allergic rhinitis. The mean reduction compared to baseline at the end of weeks 1, 2, and 3 was respectively 11.7%, 13.6% and 15.1% for total nasal symptom scores (rTNSS); 9.9%, 14.5%, and 15.8% for total ocular symptom scores (rTOSS); and 4.97%, 8.45%, and 10.94% for pre-dose instantaneous total ocular symptom scores (am-iTOSS, p: Not Significant: NS). During the same period, compared to CP scores, the reduction in TP group was higher by 37.7%, 58.4%, and 73.5% for rTNSS; 38.3%, 54.6%, and 64.1% for rTOSS and 29.84%, 48.91%, and 59.77% for am-iTOSS (p&lt;0.05 for all parameters vs. CP at the same time points). The rhinoconjunctivitis quality of life questionnaire (RQLQ), measured using standard established questionnaire, was improved by 50.28% in TP group compared to 22.85% in CP group. During the study period, at least one rescue medicine was used by 80% patients in CP group compared to only 29% in TP group. Both products were well tolerated and induced no undesired effects.Conclusion: In the absence of any cell-friendly, safe, and multi-target treatment for allergic rhinitis, using a mechanically acting, filmogen barrier solution capable of blocking new allergen contact and minimizing the concentration of immune cells on the nasal surface represents a simple but highly effective approach for the treatment of common allergic rhinitis.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - France -CO - Germany -CO - United Arab Emirates -</style></notes><work-type><style face="normal" font="Arial">10.4172/2167-0412.1000246</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2167-0412.1000246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-263.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-263.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Shrivastava L</style></custom2><misc3><style face="normal" font="Arial">10.4172/2167-0412.1000246</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Okazaki,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Four Cases of Allergic and/or Autoimmune Diseases That Completely Recovered After Repetitions of Intradermal Injections with a Non-Specific Antigen Preparation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="264">264-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000264</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-264.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-264.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Okazaki K</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000264</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brooks,S.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Vocal Cord Dysfunction after an Inhalation Exposure</style></title><secondary-title><style face="normal" font="Arial">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Ther</style></full-title></periodical><pages end="" start="261">261-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> Glottis</style></keyword><keyword><style face="normal" font="Arial"> Hyperventilation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Inhalation Exposure</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Reflex</style></keyword><keyword><style face="normal" font="Arial"> Spasm</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vocal cord dysfunction</style></keyword><keyword><style face="normal" font="Arial"> Vocal Cords</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The manuscript embodies case material and the author's extensive personal experience to address a perceived or actual airborne exposure when incorrectly judged as due to intrathoracic/lung damage when in reality the outcome is the more innocuous extrathoracic/upper airway's vocal cord dysfunction (VCD). Because of the conviction of possible lung injury, the individual applies the fetal protective glottic closure reflex to counteract an odorant cue instigating acute VCD. Breathing against an obstructed glottis as well as hyperventilation from anxiety, panic and/or fear of personal harm worsens the laryngeal spasm. Spirometer shows flattening of the inspiratory loop of the flow-volume curve and endoscopy, while not done, would reveal adduction of the anterior two-thirds of the vocal cords with posterior chinking creating a diamond shape configuration. Successful therapy and management of VCD requires a speech therapy approach rather than physician prescribed medications.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.4172/2155-6121.1000261</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000261</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Ther\2017-8-261.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Ther\2017-8-261.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Brooks SM</style></custom2><misc3><style face="normal" font="Arial">10.4172/2155-6121.1000261</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,W.</style></author><author><style face="normal" font="Arial"> Huang,C.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Cai,J.</style></author><author><style face="normal" font="Arial"> Hu,Y.</style></author><author><style face="normal" font="Arial"> Zou,Z.</style></author><author><style face="normal" font="Arial"> Weschler,L.B.</style></author><author><style face="normal" font="Arial"> Shen,L.</style></author><author><style face="normal" font="Arial"> Sundell,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Building Environment and Energy Engineering , School of Environment and Architecture, University of Shanghai for Science and Technology , Shanghai , China</style></auth-address><titles><title><style face="normal" font="Arial">Multimorbidities of asthma, allergies, and airway illnesses in childhood: Chance or not chance?</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="698" start="687">687-698</pages><volume><style face="normal" font="Arial">54</style></volume><number><style face="normal" font="Arial">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Common Cold</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> ear infections</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> EPS</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Preschool children</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: We investigated patterns of multimorbidities among asthma, allergies, and respiratory illnesses in preschool children. We investigated multimorbidities of lifetime asthma, allergic rhinitis, eczema, food allergy, pneumonia, and ear infections; and multimorbidities of current (in the last year before the survey) wheeze, dry cough, rhinitis, eczema, and common cold during childhood. We further analyzed whether prevalences of these multimorbidities were due to chance. METHODS: A cross-sectional study was conducted in 72 kindergartens of Shanghai, China. Parents of preschool children were surveyed with a modified ISAAC questionnaire. Observed prevalences (OPs), expected prevalences (EPs), absolute excess comorbidities (AECs), and relative excess comorbidities (RECs) of various combinations of illnesses were calculated to indicate whether the combined illnesses were related. RESULTS: We analyzed questionnaires for children aged 4-6 years, whose 13,335 questionnaires were the majority of the total 15,266 returned questionnaires (response rate: 85.3%). The studied illnesses were common. For children who had more than three lifetime or current illnesses, OPs tended to be higher than EPs. Most OPs and EPs were higher in boys than in girls, and were higher in children with a family history of atopy (FHA) than in children without FHA. AECs and RECs between boys and girls as well as between children with and without FHA were substantially different. CONCLUSIONS: Our findings suggest that multimorbidities among childhood asthma, allergies, and respiratory illnesses are likely not random, but rather share etiology. Specific patterns of childhood asthma multimorbidities perhaps differ between boys and girls and between children with and without FHA</style></abstract><notes><style face="normal" font="Arial">DA - 20161123IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2016.1263648</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27880051">PM:27880051</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\2017-54-687-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\2017-54-687-98.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161123, Liu W</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2016.1263648</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hallit,S.</style></author><author><style face="normal" font="Arial"> Raherison,C.</style></author><author><style face="normal" font="Arial"> Abou,A.R.</style></author><author><style face="normal" font="Arial"> Hallit,R.</style></author><author><style face="normal" font="Arial"> Salameh,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Lebanese University, Faculty of Pharmacy , Beirut , Lebanon</style></auth-address><titles><title><style face="normal" font="Arial">Correlation of Types of Food and Asthma Diagnosis in Childhood: A Case-Control Study</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Studies concerning asthma in Lebanon investigated environmental and personal factors but none of them took into account the effect of nutritional habits. Our objective is to assess the effect of nutritional habits on asthma and allergies in Lebanese children aged between 3-16 years old. METHODS: This is a case-control study, conducted between December 2015 and April 2016. The Food Frequency Questionnaire was composed of 16 semi-quantitative questions covering different food categories. RESULTS: This study included 1276 children (976 healthy and 300 asthmatic children). Eating dairy products less than twice a week, 3-6 times per week and daily were significantly and inversely associated with asthma, as compared to never eating dairy product (p = 0.02, ORa = 0.285, CI 0.099-0.821; p&lt;0.001, ORa = 0.140, CI 0.052-0.378 and p&lt;0.001, ORa = 0.161, CI 0.061-0.422), whereas eating red meat daily compared to never, was associated with asthma significantly (p = 0.037, ORa = 2.051, CI 1.046-4.024). Eating nuts less than twice weekly as compared to never, was significantly and inversely associated with asthma (p = 0.035, ORa = 0.597, CI 0.369-0.965). The age category 7-10 and 11-13 years were significantly associated with asthma as compared to the 3-6 years category (p&lt;0.001, ORa = 3.359, CI 1.869-6.038 and p = 0.008, ORa = 2.191, CI 1.228-3.909 respectively), while male gender was significantly more prone to asthma (p = 0.014, ORa = 0.686, CI 0.507-0.926). CONCLUSION: Knowing the correlation between nutritional habits and asthma is important to promote healthy eating. Educational programs for parents about healthy food and breastfeeding encouragement is warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Lebanon -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2017.1379535</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28925766">PM:28925766</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20170919-HallitS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20170919-HallitS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Hallit S</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2017.1379535</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masieri,S.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Cavaliere,C.</style></author><author><style face="normal" font="Arial"> di Cara,G.</style></author><author><style face="normal" font="Arial"> Frati,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Sapienza University, Rome, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Is lingual tonsil a preferential target for processing sublingually administered materials?</style></title><secondary-title><style face="normal" font="Arial">J Biol Regul Homeost Agents</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Biol Regul Homeost Agents</style></full-title></periodical><pages end="762" start="761">761-762</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immune system</style></keyword><keyword><style face="normal" font="Arial"> Adenoids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> B lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> B lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> Tonsil</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">The oral cavity is a site of pivotal importance in the immune response to foreign antigens, ensuring tolerance induction to harmless agents but reactivity to potentially noxious antigens. Tolerance or reactivity are driven by a number of secondary lymphoid organs, all belonging to the Waldeyer ring, that include adenoids, tubal, palatine and lingual tonsils. Waldeyer's ring tissues were acknowledged as implicated not only in the adaptive immune system but also in the innate immune system modulation, involving the toll-like receptors. In particular, findings from animal studies suggested that the lingual tonsil can be considered as an inductive site sampling and processing antigens to stimulate naive T and B lymphocytes. According to a recent study showing that immunologically active or inactive materials placed under the tongue of allergic subjects rapidly reach the lingual tonsil, such a role seems likely also in humans, and warrants to be investigated in-depth for possible applications in medical treatments</style></abstract><notes><style face="normal" font="Arial">DA - 20170928IS - 0393-974X (Print)IS - 0393-974X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28956429">PM:28956429</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biol Regul Homeost Agents\2017-31-761-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biol Regul Homeost Agents\2017-31-761-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170928, Masieri S</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kawakami,Y.</style></author><author><style face="normal" font="Arial"> Taga,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Okayama City Hospital, Okayama, JapanDepartment of Clinical Laboratory, Tosei General Hospital, Aichi, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Anaphylaxis due to ingestion of jellyfish with possible evidence of epicutaneous sensitization</style></title><secondary-title><style face="normal" font="Arial">J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical laboratory</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> jellyfish</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword></keywords><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/1346-8138.14042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28944486">PM:28944486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol\20170925-KawakamiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol\20170925-KawakamiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Kawakami Y</style></custom2><misc3><style face="normal" font="Arial">10.1111/1346-8138.14042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nguyet,N.T.M.</style></author><author><style face="normal" font="Arial"> Lomunova,M.</style></author><author><style face="normal" font="Arial"> Duyen,V.T.P.</style></author><author><style face="normal" font="Arial"> Vinh,L.B.</style></author><author><style face="normal" font="Arial"> Ho,Kim Y.</style></author><author><style face="normal" font="Arial"> Kang,J.S.</style></author><author><style face="normal" font="Arial"> Hwang,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology and Immunopharmacology Laboratory, College of Pharmacy, Chungnam National University, 99 Daekak-ro Yuseong-gu, Daejeon, Republic of Korea, 34134.</style></auth-address><titles><title><style face="normal" font="Arial">Anti-allergic effects of the ethanol extract of Syzygium formosum (Wall.) Masam leaves and its immunoregulatory mechanisms</style></title><secondary-title><style face="normal" font="Arial">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effects</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Passive anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">ETHNOPHARMACOLOGICAL RELEVANCE: As documented in a Vietnamese traditional medical encyclopedia, Syzygium formosum (Wall.) Masam leaves have been routinely used among indigenous Vietnamese people for treatment of various allergy-like symptoms including dermatitis and rhinitis. AIM OF THE STUDY: Anti-allergic activity of S. formosum leaves was examined with a mouse model of chicken ovalbumin (cOVA)-induced food allergy, and mechanisms underlying the anti-allergic effect were explored. MATERIAL AND METHODS: BALB/c mice were administered i.p. cOVA (20 mug) plus alum (2mg) twice on day 0 and 14 for sensitization (immunization). Two weeks after the second immunization, the mice were administered cOVA (50mg) p.o. 5 times every 3 days to induce food allergy symptoms (i.e., anaphylaxis, diarrhea, and drop in the body temperature). Ethanol extract of dried leaves of S. formosum (80mg/ kg or 200mg/ kg body weight) was administered p.o. daily during the induction (challenge) period. RESULTS: Treatment with the S. formosum leaves ethanol extract ameliorated the allergic symptoms to a significant extent and in a dose-dependent manner. The treatment also resulted in a significant improvement in the inflammatory lesion in the small intestine and reduction in the numbers of mast cells and eosinophils recruited to the lesion. The treatment also brought about a significant reduction in the levels of Th2 cytokines produced by the mesenteric lymph node cells cultured ex vivo with cOVA. The passive anaphylaxis experiment also showed that the extract treatment impaired the mast cell function. CONCLUSION: Our study provides a scientific basis for the traditional (indigenous) use of the S. formosum leaves extract for the treatment of various allergy symptoms in Vietnam. In addition, the results show that the extract has activities to suppress antigen-specific Th2 T cell immune responses and the mast cell function, which are directly related with its anti-allergic effect</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jep.2017.09.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28943447">PM:28943447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20170925-NguyetNT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20170925-NguyetNT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Nguyet NT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jep.2017.09.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schmidt,T.</style></author><author><style face="normal" font="Arial"> Lorenz,N.</style></author><author><style face="normal" font="Arial"> Raker,V.K.</style></author><author><style face="normal" font="Arial"> Schmidgen,M.I.</style></author><author><style face="normal" font="Arial"> Mahnke,K.</style></author><author><style face="normal" font="Arial"> Enk,A.</style></author><author><style face="normal" font="Arial"> Roth,J.</style></author><author><style face="normal" font="Arial"> Steinbrink,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergen-specific low zone tolerance is independent of MRP8/14-, TLR4-, TLR7- and TLR9-mediated immune processes</style></title><secondary-title><style face="normal" font="Arial">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0022-202X</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jid.2017.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28947357">PM:28947357</url></web-urls><pdf-urls><url ppv-ref="no">kerstin.steinbrink@unimedizin-mainz.de</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Schmidt T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jid.2017.09.020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Franco,J.M.</style></author><author><style face="normal" font="Arial"> Pinheiro,A.P.S.G.</style></author><author><style face="normal" font="Arial"> Vieira,S.C.F.</style></author><author><style face="normal" font="Arial"> Barreto,I.D.C.</style></author><author><style face="normal" font="Arial"> Gurgel,R.Q.</style></author><author><style face="normal" font="Arial"> Cocco,R.R.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidade Federal de Sao Paulo (UNIFESP), Escola Paulista de Medicina (EPM), Sao Paulo, SP, Brazil;</style></auth-address><titles><title><style face="normal" font="Arial">Accuracy of serum IgE concentrations and papule diameter in the diagnosis of cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">J Pediatr (Rio J)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr (Rio J)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-lactalbumin</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> oral challenge test</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin reactivity</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To compare serum concentrations of specific IgE and mean papule diameters induced in the immediate skin reactivity test with cow's milk (CM) and its fractions with results of the oral challenge test (OCT), and to establish cutoff points capable of predicting clinical reactivity to CM in patients treated at a referral service. METHODS: One hundred and twenty-two children (median of 17 months) with a history of immediate reactions to CM and presence of specific IgE for CM and/or its fractions (positive skin and/or IgE serum tests) were submitted to open OCT with CM. RESULTS: The OCT was positive in 59.8% of the children, 49% of whom were males. Serum levels of specific IgE, as well as mean CM papule diameters, were significantly higher in allergic patients (medians: 3.39kUA/L vs. 1.16kUA/L, 2.5mm vs. 0mm). The optimal cutoff points (Youden's index) of serum IgE specific for CM and its fractions capable of predicting CM reactivity (positive OCT) were: 5.17kUA/L for CM, 0.95kUA/L for alpha-lactalbumin, 0.82kUA/L for beta-lactoglobulin, and 0.72kUA/L for casein, whereas for papule diameters the cutoff points were 3.5mm for CM and 6.5mm, 9.0mm, and 3.0mm for the alpha-lactalbumin, beta-lactoglobulin, and casein fractions, respectively. CONCLUSIONS: The cutoff points capable of predicting clinical reactivity to CM were: 5.17kUA/L for serum-specific IgE and 3.5mm for papule diameter measurement, values considered discriminatory for the diagnosis of CM allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170930IS - 1678-4782 (Electronic)IS - 0021-7557 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jped.2017.06.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28963879">PM:28963879</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr (Rio J)\20170930-FrancoJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr (Rio J)\20170930-FrancoJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170930, Franco JM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jped.2017.06.022</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sarinho,E.S.C.</style></author><author><style face="normal" font="Arial"> Lins,M.D.G.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidade Federal de Pernambuco (UFPE), Recife, PE, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Severe forms of food allergy</style></title><secondary-title><style face="normal" font="Arial">J Pediatr (Rio J)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr (Rio J)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic emergencies</style></keyword><keyword><style face="normal" font="Arial"> allergic emergency</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Exclusion diet</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> Food-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> Sesame</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Severe food allergy</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: To guide the diagnostic and therapeutic management of severe forms of food allergy. DATA SOURCES: Search in the Medline database using the terms "severe food allergy," "anaphylaxis and food allergy," "generalized urticaria and food allergy," and "food protein-induced enterocolitis syndrome" in the last ten years, searching in the title, abstract, or keyword fields. SUMMARY OF DATA: Food allergy can be serious and life-threatening. Milk, eggs, peanuts, nuts, walnuts, wheat, sesame seeds, shrimp, fish, and fruit can precipitate allergic emergencies. The severity of reactions will depend on associated cofactors such as age, drug use at the onset of the reaction, history and persistence of asthma and/or severe allergic rhinitis, history of previous anaphylaxis, exercise, and associated diseases. For generalized urticaria and anaphylaxis, intramuscular epinephrine is the first and fundamental treatment line. For the treatment in acute phase of food-induced enterocolitis syndrome in the emergency setting, prompt hydroelectrolytic replacement, administration of methylprednisolone and ondansetron IV are necessary. It is important to recommend to the patient with food allergy to maintain the exclusion diet, seek specialized follow-up and, in those who have anaphylaxis, to emphasize the need to carry epinephrine. CONCLUSION: Severe food allergy may occur in the form of anaphylaxis and food-protein-induced enterocolitis syndrome, which are increasingly observed in the pediatric emergency room; hence, pediatricians must be alert so they can provide the immediate diagnosis and treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1678-4782 (Electronic)IS - 0021-7557 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jped.2017.06.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941390">PM:28941390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr (Rio J)\20170923-SarinhoES.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr (Rio J)\20170923-SarinhoES.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Sarinho ES</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jped.2017.06.021</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Limone,B.A.</style></author><author><style face="normal" font="Arial"> Jacob,S.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Staphylococcal infections in atopic dermatitis and nickel allergy: Immunologic implications and elemental opportunities</style></title><secondary-title><style face="normal" font="Arial">J Trace Elem Med Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Trace Elem Med Biol</style></full-title></periodical><pages end="22" start="21">21-22</pages><volume><style face="normal" font="Arial">45</style></volume><number><style face="normal" font="Arial">Supplement C</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Nickel</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal Infections</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="Arial">0946-672X</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jtemb.2017.09.017</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jtemb.2017.09.017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Trace Elem Med Biol\2018-45SC-21-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Trace Elem Med Biol\2018-45SC-21-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Limone BA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jtemb.2017.09.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patadia,D.D.</style></author><author><style face="normal" font="Arial"> Stukus,D.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Are Expired EpiPens Still Viable?</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1470" start="1469">1469-1470</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">EpiPen</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">2213-2198</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.06.026</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jaip.2017.06.026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1469-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1469-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Patadia DD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.06.026</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yan,X.M.</style></author><author><style face="normal" font="Arial"> Yan,J.B.</style></author><author><style face="normal" font="Arial"> Huang,K.Y.</style></author><author><style face="normal" font="Arial"> Pan,T.T.</style></author><author><style face="normal" font="Arial"> Xu,Z.</style></author><author><style face="normal" font="Arial"> Lu,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Gastroenterology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325000, China</style></auth-address><titles><title><style face="normal" font="Arial">Protective effect of baicalin on the small intestine in rats with food allergy</style></title><secondary-title><style face="normal" font="Arial">Life Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Life Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Duodenum</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Organelles</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transmission</style></keyword><keyword><style face="normal" font="Arial"> ultrastructure</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="Arial">AIMS: The therapeutic effect of baicalin and its mechanism were explored. MATERIALS AND METHODS: A total of 30 Sprague Dawley (SD) rats were randomly divided into 3 groups of 10: ovalbumin group (OVA group), baicalin intervention group (HQ group), and saline-group (NC group). Serum OVA-IgE antibody levels were detected by enzyme-linked immunosorbent assay (ELISA); and diarrhea in rats was observed. Animals were sacrificed at week seven. Then, a 5-cm long duodenum beneath the Treitz ligament was collected from each rat, and was fixed, embedded, sliced and stained with toluidine blue to evaluate the integrity of mast cells. Next, pathological changes of the intestine were observed by hematoxylin and eosin (H&amp;E) staining, and the ultrastructure of the intestinal mucosa was observed under a transmission electron microscope. KEY FINDINGS: Serum OVA-sIgE level were significantly lower (at sixth week, OVA group: 12.86+/-1.35, HQ group: 3.47+/-0.51, F=117.05, P&lt;0.01), the number of eosinophils significantly decreased (HQ group: 2.73+/-1.02, OVA group: 16.48+/-2.32, P&lt;0.01), mast cell integrated rate was significantly increased (HQ group: 89.90+/-4.43, OVA group: 35.30+/-9.78, P&lt;0.01) uniform small intestinal villi were observed, the organelles were basically normal, and lesions were significantly fewer in the HQ group, compared with the OVA group. SIGNIFICANCE: Baicalin can effectively reduce serum OVA-sIgE in rats with food allergy, increase mast cell integrated rate and alleviate intestinal pathological changes. Hence, baicalin has a good therapeutic effect on food allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170930IS - 1879-0631 (Electronic)IS - 0024-3205 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.lfs.2017.09.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28962865">PM:28962865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Life Sci\20170930-YanXM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Life Sci\20170930-YanXM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170930, Yan XM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.lfs.2017.09.036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Z.</style></author><author><style face="normal" font="Arial"> Tan,X.</style></author><author><style face="normal" font="Arial"> Yu,B.</style></author><author><style face="normal" font="Arial"> Zhao,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aQingdao University Medical College, Qingdao bKey Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, Shandong cEmergency Department, The Affiliated Central Hospital of Qingdao University, Qingdao dDepartment of Neurology, The Affiliated Hospital of Qingdao University, Qingdao eLaboratory for Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergic shock caused by ingestion of cooked jellyfish: A case report</style></title><secondary-title><style face="normal" font="Arial">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicine (Baltimore)</style></full-title></periodical><pages end="" start="e7962">e7962-</pages><volume><style face="normal" font="Arial">96</style></volume><number><style face="normal" font="Arial">38</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cimetidine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Eating</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> jellyfish</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tachycardia</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">RATIONALE: Although anaphylaxis caused by jellyfish stings is common in coastal areas, an allergic shock caused by cooked jellyfish ingestion has never been reported in China. In this paper, we report a case of allergic shock being caused by ingestion of cooked salt-preserved jellyfish shortly after being stung by a live jellyfish. PATIENT CONCERNS: A 26-year-old Chinese man presented with dizziness, pruritus, dyspnea, hypotension, and tachycardia after eating cooked salted jellyfish. The patient had been stung twice by jellyfish half a year ago. DIAGNOSES: Allergic shock caused by ingestion of cooked jellyfish. INTERVENTIONS: The patient was treated with phenergan (25 mg, intramuscular injection), 250 mL normal saline (NS) and 10 mg dexamethasone (intravenous drip), 500 mL NS and 0.4 g cimetidine (intravenous drip), and 500 mL NS for rapid fluid infusion (intravenous drip). OUTCOMES: After the treatment, the main clinical symptoms of the patient improved quickly. Five days later, the patient's urticaria had dissipated. LESSONS: A history of jellyfish contact or sting might be an important allergic factor for individuals who consume any kind of jellyfish</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1097/MD.0000000000007962</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28930834">PM:28930834</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicine (Baltimore)\2017-96-e7962.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicine (Baltimore)\2017-96-e7962.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Li Z</style></custom2><misc3><style face="normal" font="Arial">10.1097/MD.0000000000007962</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Y.</style></author><author><style face="normal" font="Arial"> Yu,Q.</style></author><author><style face="normal" font="Arial"> Zhao,W.</style></author><author><style face="normal" font="Arial"> Zhang,J.</style></author><author><style face="normal" font="Arial"> Liu,W.</style></author><author><style face="normal" font="Arial"> Huang,M.</style></author><author><style face="normal" font="Arial"> Zeng,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory &amp; Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China</style></auth-address><titles><title><style face="normal" font="Arial">Oligomeric proanthocyanidins attenuate airway inflammation in asthma by inhibiting dendritic cells maturation</style></title><secondary-title><style face="normal" font="Arial">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Immunol</style></full-title></periodical><pages end="217" start="209">209-217</pages><volume><style face="normal" font="Arial">91</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma management</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> CAMP</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> shedding</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">To date, although a promising anti-inflammatory activity of oligomeric proanthocyanidins (OPCs) has been observed in asthma, the mechanism responsible for these immunomodulatory properties remains obscure. Dendritic cells (DCs) that reside in the airway have been widely perceived as an important contributor to asthma. Our study was to demonstrate OPCs' effects on maturation and immunoregulation of pulmonary CD11c+ dendritic cells (DCs). BALB/c mice were exposed to ovalbumin (OVA) to induce murine model of asthma. In addition, pulmonary DCs and bone marrow-derived DCs (BMDCs) cultures were used to evaluate impacts of OPCs on DCs function. The results obtained here indicated that OPCs treatment dramatically reduced airway inflammation, such as the infiltration of inflammatory cells and the levels of allergen-specific serum IgE and Th2 cytokines. The expression of co-stimulatory molecules especially CD86 distributed on pulmonary DCs and bone marrow-derived DCs (BMDCs) also markedly declined. The phosphorylation of cAMP responsive element-binding protein (CREB) was significantly inhibited while no changes were observed in the expression of cAMP responsive element modulator (CREM). By transferring BMDCs into the airways of naive mice, we found that OPCs-treated DCs (DC+OVA+OPC) were much less potent in promoting CD4+ T cells proliferation than OVA-pulsed DCs (DC+OVA), followed by the ameliorated eosinophilic inflammation in airway. Our findings tailor a novel profile of OPCs in the regulation of DCs function, shedding new light on the therapeutic potential of OPCs in asthma management</style></abstract><notes><style face="normal" font="Arial">DA - 20170930IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.molimm.2017.09.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28963930">PM:28963930</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\20170930-LiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\20170930-LiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170930, Li Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.molimm.2017.09.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Du,W.</style></author><author><style face="normal" font="Arial"> Chen,T.</style></author><author><style face="normal" font="Arial"> Ni,Y.</style></author><author><style face="normal" font="Arial"> Hou,X.</style></author><author><style face="normal" font="Arial"> Yu,Y.</style></author><author><style face="normal" font="Arial"> Zhou,Q.</style></author><author><style face="normal" font="Arial"> Wu,F.</style></author><author><style face="normal" font="Arial"> Tang,W.</style></author><author><style face="normal" font="Arial"> Shi,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Role of PIM2 in allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> forkhead box protein 3</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Leukocytes</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">T cellassociated inflammation, particularly type 2 inflammation, has an important role in asthma pathogenesis, which is suppressed by regulatory T cells (Tregs). Proviral integration site for Moloney murine leukemia virus 2 (PIM2), a member off the serine/threonine kinase family, promotes the growth and survival of T cells and influences the function of Treg cells. However, whether PIM2 affects asthma pathogenesis remains unclear. Peripheral blood mononuclear cells and Treg cells from asthmatic and healthy subjects were obtained, and the expression level of PIM2 was measured by reverse transcriptionquantitative polymerase chain reaction and immunocytochemistry. In addition, BALB/c female mice sensitized and challenged by ovalbumin were used as an asthma model, and PIM2 inhibitor was injected during the challenge period to observe the effect of PIM2 on asthma. The asthma symptoms were recorded, and airway hyperresponsiveness (AHR), expression levels of cytokines in the serum or bronchoalveolar lavage fluid (BALF), and the number of BALF leukocytes were evaluated. In addition, hematoxylin and eosin staining and immunohistochemistry of lung tissues was performed. The results demonstrated that PIM2 was overexpressed in patients with asthma in natural Treg cells. Inhibition of PIM2 attenuated asthma symptoms, and improved AHR and airway inflammation compared with asthmatic mice without inhibition of PIM2. In addition, expression levels of interleukin (IL)10 and forkhead box protein 3 (FOXP3) in BALF were increased following PIM2 inhibition (IL10, 470.3+/-21.78 vs. 533.7+/-25.55 pg/ml, P&lt;0.05; FOXP3, 259+/-4.68 vs. 279.3+/-3.68 pg/ml; asthma and PIM2 inhibition groups, respectively; P&lt;0.05). In conclusion, PIM2 may exhibit an important role in asthma pathogenesis and exacerbate AHR, airway inflammation and asthma symptoms. These effects of PIM2 may be dependent on Treg cells and the secretion of IL10 by Tregs. The results of the present study suggest that PIM2 may be a potential target molecule for asthma treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.7499</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28944837">PM:28944837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\20170925-DuW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\20170925-DuW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Du W</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.7499</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Y.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author><author><style face="normal" font="Arial"> Cao,Y.</style></author><author><style face="normal" font="Arial"> Wu,F.</style></author><author><style face="normal" font="Arial"> Ma,W.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Sun,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Nephrology, Rheumatism and Immunology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Placentaderived mesenchymal stem cells improve airway hyperresponsiveness and inflammation in asthmatic rats by modulating the Th17/Treg balance</style></title><secondary-title><style face="normal" font="Arial">Mol Med Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Med Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Control Groups</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-10</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> mesenchymal stem cells</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Placenta</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> transplantation</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="Arial">Mesenchymal stem cells (MSCs) possess reparative and immunoregulatory properties, representing a hope for stem cellbased treatments. However, the mechanisms by which transplanted MSCs affect T helper (Th)17/regulatory T cell (Treg) balance in asthma patients remain unclear. The aim of the present study was to assess the therapeutic effects of human placenta MSCs (hPMSCs) in asthma, and explore the underlying mechanisms; in addition, the impact of hPMSCs transplantation on Th17/Treg balance in lymph and serum samples from asthmatic animals was evaluated. SpragueDawley rats were sensitized and challenged with ovalbumin (OVA). Administration of hPMSCs from human placenta resulted in increased Th17 and Treg in lymph samples compared with peripheral blood specimens. Enhanced pause values in OVAtreated animals were significantly higher than those in the control and hPMSCs treatment groups. The numbers of total cells, macrophages, neutrophils, and eosinophils were markedly increased in the OVA group compared with those of control + hPMSCs and control groups. In addition, interleukin 10, forkhead box P3 (Foxp3) and Treg levels in lymph, peripheral blood and lung tissue samples from asthma rats were increased significantly following hPMSC transplantation. Furthermore, Foxp3 protein levels increased, while those of RARrelated orphan receptor gamma (RORgammat) decreased after hPMSCs transplantation compared with the asthma group. Reduced IL17, RORgammat and Th17 levels were accompanied by reduced inflammatory cell infiltration, subepithelial smooth layer attenuation and mucus production in lung tissues. These results suggest that hPMSCs may improve airway hyperresponsiveness and inflammation by regulating the Th17/Treg balance in rats with asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/mmr.2017.7605</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28944907">PM:28944907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Med Rep\20170925-LiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Med Rep\20170925-LiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Li Y</style></custom2><misc3><style face="normal" font="Arial">10.3892/mmr.2017.7605</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cabanillas,B.</style></author><author><style face="normal" font="Arial"> Jappe,U.</style></author><author><style face="normal" font="Arial"> Novak,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, University of Bonn Medical Center, Sigmund-Freud-Str., 25, 53127, Bonn, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergy to Peanut, Soybean, and Other Legumes: Recent Advances in Allergen Characterization, Stability to Processing and IgE Cross-Reactivity</style></title><secondary-title><style face="normal" font="Arial">Mol Nutr Food Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Nutr Food Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen characterization</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chickpea</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> Leguminosae</style></keyword><keyword><style face="normal" font="Arial"> lentil</style></keyword><keyword><style face="normal" font="Arial"> Lupine</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pea</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> thermal processing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="Arial">Peanut and soybean are members of the Leguminosae family. They are two of the eight foods that account for the most significant food allergies in the US and Europe. Allergic reactions to other legume species can be of importance in other regions of the world. The major allergens from peanut and soybean have been extensively analyzed and members of new protein families identified as potential marker allergens for symptom severity. Important recent advances concerning their molecular properties or clinical relevance have been made. Therefore, there is increasing interest in the characterization of allergens from other legume species such as lupine, lentil, chickpea, green bean or pea. As legumes are mainly consumed after thermal processing, knowledge about the effect of such processing on the allergenicity of legumes has increased during the last years. In the present review, we summarize and discuss recent advances in the identification of allergens from peanut, soybean, lupine and other legume species. We provide an overview of the most recently described effects of thermal processing on the allergenic properties of legumes and discuss the potential IgE cross-reactivity among members of the Leguminosae family. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170925IS - 1613-4133 (Electronic)IS - 1613-4125 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1002/mnfr.201700446</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28944625">PM:28944625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Nutr Food Res\20170925-CabanillasB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Nutr Food Res\20170925-CabanillasB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170925, Cabanillas B</style></custom2><misc3><style face="normal" font="Arial">10.1002/mnfr.201700446</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Celakovska,J.</style></author><author><style face="normal" font="Arial"> Bukac,J.</style></author><author><style face="normal" font="Arial"> Ettler,K.</style></author><author><style face="normal" font="Arial"> Vaneckova,J.</style></author><author><style face="normal" font="Arial"> Krcmova,I.</style></author><author><style face="normal" font="Arial"> Ettlerova,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Venereology Faculty Hospital and Medical Faculty of Charles University, Hradec Kralove, Czech Republic</style></auth-address><titles><title><style face="normal" font="Arial">Sensitisation to fungi in atopic dermatitis patients older 14 years of age and the relation to the occurrence of food hypersensitivity reactions</style></title><secondary-title><style face="normal" font="Arial">Mycoses</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycoses</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Capsicum</style></keyword><keyword><style face="normal" font="Arial"> Carrot</style></keyword><keyword><style face="normal" font="Arial"> Celery</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Kiwi</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> orange</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Spices</style></keyword><keyword><style face="normal" font="Arial"> Statistical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tomatoes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">The aim of this study is the evaluation, if there is some relation between the sensitisation to fungi and the occurrence of food hypersensitivity reactions in atopic dermatitis patients aged 14 years and older. The complete dermatological and allergological examinations were perfomed in all included patients; the occurrence of food hypersensitivity reactions was recorded and the sensitisation to mixture of fungi was examined (skin prick test, specific IgE). The statistical evaluation of the relation between the sensitisation to fungi and the occurrence of food hypersensitivity reactions was performed; 331 patients were included in the study, 110 men and 221 women, the average age 26.8 years. The sensitisation to fungi was recorded in 100 patients (30%), the occurrence of food hypersensitivity reactions was recorded in 261 patients (79%). We confirmed, that patients suffering from sensitisation to fungi suffer significantly more often from food hypersensitivity reactions to nuts (walnuts, peanust) and sea fish; no significant relation was confirmed between the sensitisation to fungi and the occurrence of food hypersensitivity reactions to tomatoes, kiwi, apples, spices, oranges, capsicum, celery, and carrot. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1439-0507 (Electronic)IS - 0933-7407 (Linking)LA - engPT - Journal ArticleCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1111/myc.12707</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940850">PM:28940850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycoses\20170923-CelakovskaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycoses\20170923-CelakovskaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Celakovska J</style></custom2><misc3><style face="normal" font="Arial">10.1111/myc.12707</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jones,S.M.</style></author><author><style face="normal" font="Arial"> Burks,A.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock (S.M.J.); and the Department of Pediatrics, University of North Carolina, Chapel Hill (A.W.B.)From the Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock (S.M.J.); and the Department of Pediatrics, University of North Carolina, Chapel Hill (A.W.B.)</style></auth-address><titles><title><style face="normal" font="Arial">Food Allergy</style></title><secondary-title><style face="normal" font="Arial">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">N Engl J Med</style></full-title></periodical><pages end="1176" start="1168">1168-1176</pages><volume><style face="normal" font="Arial">377</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Arkansas</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Desensitization,Immunologic</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Patient Education as Topic</style></keyword><keyword><style face="normal" font="Arial"> Peanut Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention &amp; control</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Support</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapeutic use</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - ReviewRN - YKH834O4BH (Epinephrine)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1056/NEJMcp1611971</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28930512">PM:28930512</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\N Engl J Med\2017-377-1168-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\N Engl J Med\2017-377-1168-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Jones SM</style></custom2><misc3><style face="normal" font="Arial">10.1056/NEJMcp1611971</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alessandrini,F.</style></author><author><style face="normal" font="Arial"> Vennemann,A.</style></author><author><style face="normal" font="Arial"> Gschwendtner,S.</style></author><author><style face="normal" font="Arial"> Neumann,A.U.</style></author><author><style face="normal" font="Arial"> Rothballer,M.</style></author><author><style face="normal" font="Arial"> Seher,T.</style></author><author><style face="normal" font="Arial"> Wimmer,M.</style></author><author><style face="normal" font="Arial"> Kublik,S.</style></author><author><style face="normal" font="Arial"> Traidl-Hoffmann,C.</style></author><author><style face="normal" font="Arial"> Schloter,M.</style></author><author><style face="normal" font="Arial"> Wiemann,M.</style></author><author><style face="normal" font="Arial"> Schmidt-Weber,C.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center of Allergy and Environment (ZAUM), Technical University and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Ingolstadter Landstr. 1, 85764 Neuherberg, Germany. franci@helmholtz-muenchen.deIBE R &amp; D Institute for Lung Health gGmbH, Mendelstr. 11, 48149 Munster, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Pro-Inflammatory versus Immunomodulatory Effects of Silver Nanoparticles in the Lung: The Critical Role of Dose, Size and Surface Modification</style></title><secondary-title><style face="normal" font="Arial">Nanomaterials (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nanomaterials (Basel)</style></abbr-1></periodical><pages end="" start="E300">E300-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and environment</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Bacteroidetes</style></keyword><keyword><style face="normal" font="Arial"> biphasic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Firmicutes</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Glucuronidase</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lactate Dehydrogenase</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Silver</style></keyword><keyword><style face="normal" font="Arial"> Silver nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Surface modification</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="Arial">The growing use of silver nanoparticles (Ag-NPs) in consumer products raises concerns about their toxicological potential. The purpose of the study was to investigate the size- and coating-dependent pulmonary toxicity of Ag-NPs in vitro and in vivo, using an ovalbumin (OVA)-mouse allergy model. Supernatants from (5.6-45 microg/mL) Ag50-PVP, Ag200-PVP or Ag50-citrate-treated NR8383 alveolar macrophages were tested for lactate dehydrogenase and glucuronidase activity, tumor necrosis factor (TNF)-alpha release and reactive oxygen species (ROS) production. For the in vivo study, NPs were intratracheally instilled in non-sensitized (NS) and OVA-sensitized (S) mice (1-50 microg/mouse) prior to OVA-challenge and bronchoalveolar lavage fluid (BALF) inflammatory infiltrate was evaluated five days after challenge. In vitro results showed a dose-dependent cytotoxicity of Ag-NPs, which was highest for Ag50-polyvinilpyrrolidone (PVP), followed by Ag50-citrate, and lowest for Ag200-PVP. In vivo 10-50 microg Ag50-PVP triggered a dose-dependent pulmonary inflammatory milieu in NS and S mice, which was significantly higher in S mice and was dampened upon instillation of Ag200-PVP. Surprisingly, instillation of 1 microg Ag50-PVP significantly reduced OVA-induced inflammatory infiltrate in S mice and had no adverse effect in NS mice. Ag50-citrate showed similar beneficial effects at low concentrations and attenuated pro-inflammatory effects at high concentrations. The lung microbiome was altered by NPs instillation dependent on coating and/or mouse batch, showing the most pronounced effects upon instillation of 50 microg Ag50-citrate, which caused an increased abundance of operational taxonomic units assigned to Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria. However, no correlation with the biphasic effect of low and high Ag-NPs dose was found. Altogether, both in vitro and in vivo data on the pulmonary effects of Ag-NPs suggest the critical role of the size, dose and surface functionalization of Ag-NPs, especially in susceptible allergic individuals. From the perspective of occupational health, care should be taken by the production of Ag-NPs-containing consumer products</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2079-4991 (Print)IS - 2079-4991 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.3390/nano7100300</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28961222">PM:28961222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nanomaterials (Basel)\2017-7-E300.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nanomaterials (Basel)\2017-7-E300.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Alessandrini F</style></custom2><misc3><style face="normal" font="Arial">10.3390/nano7100300</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,J.S.</style></author><author><style face="normal" font="Arial"> Subramaniam,S.</style></author><author><style face="normal" font="Arial"> Narang,V.</style></author><author><style face="normal" font="Arial"> Srinivasan,K.</style></author><author><style face="normal" font="Arial"> Saunders,S.P.</style></author><author><style face="normal" font="Arial"> Carbajo,D.</style></author><author><style face="normal" font="Arial"> Wen-Shan,T.</style></author><author><style face="normal" font="Arial"> Hidayah,H.N.</style></author><author><style face="normal" font="Arial"> Lum,J.</style></author><author><style face="normal" font="Arial"> Lee,A.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Poidinger,M.</style></author><author><style face="normal" font="Arial"> Zolezzi,F.</style></author><author><style face="normal" font="Arial"> Lafaille,J.J.</style></author><author><style face="normal" font="Arial"> Curotto de Lafaille,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Singapore Immunology Network (SIgN), 8A Biomedical Grove, Singapore, 138648, Singapore</style></auth-address><titles><title><style face="normal" font="Arial">IgG1 memory B cells keep the memory of IgE responses</style></title><secondary-title><style face="normal" font="Arial">Nat Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Commun</style></full-title></periodical><pages end="" start="641">641-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antibody production</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> class switch recombination</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Memory</style></keyword><keyword><style face="normal" font="Arial"> memory B cell</style></keyword><keyword><style face="normal" font="Arial"> memory B cells</style></keyword><keyword><style face="normal" font="Arial"> Mutagenesis</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> plasma cell</style></keyword><keyword><style face="normal" font="Arial"> Plasma Cells</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protective immunity</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Singapore</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">The unique differentiation of IgE cells suggests unconventional mechanisms of IgE memory. IgE germinal centre cells are transient, most IgE cells are plasma cells, and high affinity IgE is produced by the switching of IgG1 cells to IgE. Here we investigate the function of subsets of IgG1 memory B cells in IgE production and find that two subsets of IgG1 memory B cells, CD80+CD73+ and CD80-CD73-, contribute distinctively to the repertoires of high affinity pathogenic IgE and low affinity non-pathogenic IgE. Furthermore, repertoire analysis indicates that high affinity IgE and IgG1 plasma cells differentiate from rare CD80+CD73+ high affinity memory clones without undergoing further mutagenesis. By identifying the cellular origin of high affinity IgE and the clonal selection of high affinity memory B cells into the plasma cell fate, our findings provide fundamental insights into the pathogenesis of allergies, and on the mechanisms of antibody production in memory B cell responses.IgE is an important mediator of protective immunity as well as allergic reaction, but how high affinity IgE antibodies are produced in memory responses is not clear. Here the authors show that IgE can be generated via class-switch recombination in IgG1 memory B cells without additional somatic hypermutation</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 2041-1723 (Electronic)IS - 2041-1723 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41467-017-00723-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28935935">PM:28935935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Commun\2017-8-641.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Commun\2017-8-641.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Commun\2017-8-641_MOESM3_ESM.xlsxC:\A&amp;H HMW Papers\Nat Commun\2017-8-641_MOESM4_ESM.xlsxC:\A&amp;H HMW Papers\Nat Commun\2017-8-641_MOESM5_ESM.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Commun\2017-8-641_MOESM3_ESM.xlsxF:\A&amp;H HMW Papers\Nat Commun\2017-8-641_MOESM4_ESM.xlsxF:\A&amp;H HMW Papers\Nat Commun\2017-8-641_MOESM5_ESM.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170922, He JS</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41467-017-00723-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hohler,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Sharon E. Hohler is a team coordinator and CN IV at Saint Francis Medical Center in Cape Girardeau, Mo</style></auth-address><titles><title><style face="normal" font="Arial">Keeping children with latex allergies safe</style></title><secondary-title><style face="normal" font="Arial">Nursing</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nursing</style></full-title></periodical><pages end="5" start="1">1-5</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Allergy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170927IS - 1538-8689 (Electronic)IS - 0360-4039 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/01.NURSE.0000524760.51000.bd</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28953705">PM:28953705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nursing\2017-47-1-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nursing\2017-47-1-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170927, Hohler SE</style></custom2><misc3><style face="normal" font="Arial">10.1097/01.NURSE.0000524760.51000.bd</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yodoi,J.</style></author><author><style face="normal" font="Arial"> Matsuo,Y.</style></author><author><style face="normal" font="Arial"> Tian,H.</style></author><author><style face="normal" font="Arial"> Masutani,H.</style></author><author><style face="normal" font="Arial"> Inamoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Japan Biostress Research Promotion Alliance (JBPA), 1-6 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8397, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Anti-Inflammatory Thioredoxin Family Proteins for Medicare, Healthcare and Aging Care</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start=" E1081"> E1081-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aging</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> irradiation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lettuce</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung Injury</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Thioredoxin</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="Arial">Human thioredoxin (TRX) is a 12-kDa protein with redox-active dithiol in the active site -Cys-Gly-Pro-Cys-, which is induced by biological stress due to oxidative damage, metabolic dysfunction, chemicals, infection/inflammation, irradiation, or hypoxia/ischemia-reperfusion. Our research has demonstrated that exogenous TRX is effective in a wide variety of inflammatory diseases, including viral pneumonia, acute lung injury, gastric injury, and dermatitis, as well as in the prevention and amelioration of food allergies. Preclinical and clinical studies using recombinant TRX (rhTRX) are now underway. We have also identified substances that induce the expression of TRX in the body, in vegetables and other plant ingredients. Skincare products are being developed that take advantage of the anti-inflammatory and anti-allergic action of TRX. Furthermore, we are currently engaged in the highly efficient production of pure rhTRX in several plants, such as lettuce, grain and rice</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9101081</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28961169">PM:28961169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9- E1081.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9- E1081.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Yodoi J</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9101081</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barros,K.V.</style></author><author><style face="normal" font="Arial"> Flor Silveira,V.</style></author><author><style face="normal" font="Arial"> Laranjeira,M.S.</style></author><author><style face="normal" font="Arial"> Wandalsen,N.F.</style></author><author><style face="normal" font="Arial"> Passeti,S.</style></author><author><style face="normal" font="Arial"> de Oliveira,R.</style></author><author><style face="normal" font="Arial"> Munekata,R.V.</style></author><author><style face="normal" font="Arial"> Noakes,P.S.</style></author><author><style face="normal" font="Arial"> Miles,E.A.</style></author><author><style face="normal" font="Arial"> Calder,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Physiology, Federal University of Sao Paulo, Sao Paulo SP CEP 04023-900, Brazil.</style></auth-address><titles><title><style face="normal" font="Arial">Evidence for Involvement of IL-9 and IL-22 in Cows' Milk Allergy in Infants</style></title><secondary-title><style face="normal" font="Arial">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutrients</style></full-title></periodical><pages end="" start="1048">1048-</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino acid formula</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cows</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokine profiles</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">Although allergic inflammation is characterized by a T helper (Th) 2-dominant immune response, the discovery of a role for new T cell subsets in inflammatory diseases has added an additional layer of complexity to the understanding of the pathogeneses of allergic diseases. We evaluated plasma cytokine profiles in infants with cows' milk allergy (CMA), who were being treated with an elimination diet. In a prospective, randomized and controlled study, infants (aged 8.4 +/- 3.9 months) with CMA were treated with an elimination diet for 120 days, which replaced cows' milk with a hydrolysed soy protein formula (n = 26) or a free amino acid formula (n = 20). Blood samples were collected before treatment during active disease (T0) and after 120 days, when symptoms were absent (T1). Plasma cytokine concentrations were measured. Infants with CMA had higher plasma concentrations of interleukin (IL)-4 and IL-13 and lower concentrations of IL-9, IL-17A and interferon-gamma, compared with healthy breast-fed infants. At T0, there was a positive correlation between blood eosinophil numbers and plasma concentrations of IL-4, IL-9, IL-17A and IL-22. Treatment with a cows' milk elimination diet resulted in a decrease in plasma IL-4, IL-9, IL-13 and IL-22 and an increase in plasma IL-17A. We conclude that IL-4 and IL-13 are elevated in active CMA. The association of IL-9 and IL-22 with eosinophilia, and the decrease in these two cytokines with cows' milk elimination, suggests that they both play a role in the symptoms observed in CMA and may be important targets for future interventions</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.3390/nu9101048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28934137">PM:28934137</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutrients\2017-9- 1048.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutrients\2017-9- 1048.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Barros KV</style></custom2><misc3><style face="normal" font="Arial">10.3390/nu9101048</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mitsuboshi,A.</style></author><author><style face="normal" font="Arial"> Yamaguchi,H.</style></author><author><style face="normal" font="Arial"> Ito,Y.</style></author><author><style face="normal" font="Arial"> Mizuno,T.</style></author><author><style face="normal" font="Arial"> Tokoro,M.</style></author><author><style face="normal" font="Arial"> Kasai,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Infectious Disease Medicine, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Extra-gastrointestinal anisakidosis caused by Pseudoterranova azarasi manifesting as strangulated inguinal hernia</style></title><secondary-title><style face="normal" font="Arial">Parasitol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Pseudoterranova</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="9" Year="2017">2017/9/16</year></dates><abstract><style face="normal" font="Arial">The incidence of anisakidosis continues to increase worldwide due to increased consumption of undercooked fish. Although anisakidosis can be categorized into four clinical phenotypes (gastric, intestinal, ectopic, and allergic), ectopic forms of the condition are much less common than gastric or intestinal forms when caused by Pseudoterranova spp. We report the case of a 5-year-old patient who presented with a rapidly growing left inguinal mass and was subsequently diagnosed with extra-gastrointestinal anisakidosis caused by Pseudoterranova azarasi</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1873-0329 (Electronic)IS - 1383-5769 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.parint.2017.09.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28927907">PM:28927907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Int\20170920-MitsuboshiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Int\20170920-MitsuboshiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Mitsuboshi A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.parint.2017.09.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Calcagno,M.A.</style></author><author><style face="normal" font="Arial"> Forastiero,M.A.</style></author><author><style face="normal" font="Arial"> Saracino,M.P.</style></author><author><style face="normal" font="Arial"> Vila,C.C.</style></author><author><style face="normal" font="Arial"> Venturiello,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Microbiology, Immunology and Biotechnology Department, School of Pharmacy and Biochemistry, IDEHU-CONICET, Buenos Aires University, Junin 956, 1113, Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Serum IgE and IgG4 against muscle larva excretory-secretory products during the early and late phases of human trichinellosis</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">antigen</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Glycoprotein</style></keyword><keyword><style face="normal" font="Arial"> Glycoproteins</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human serum</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Larva</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> late phase</style></keyword><keyword><style face="normal" font="Arial"> late-phase</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trichinella</style></keyword><keyword><style face="normal" font="Arial"> Trichinella spiralis</style></keyword><keyword><style face="normal" font="Arial"> Trichinellosis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">In human trichinellosis, the relevance of the presence and persistence of specific serum IgE and IgG4 during the early and late phases of infection is still controversial.The aim of this work was to determine the percentage of human sera presenting IgE and IgG4 against Trichinella spiralis muscle larvae excretory-secretory products as well as their levels during the early and late phases of the infection. The antigen recognition pattern by serum total immunoglobulins (IgGAM), IgE, and IgG4 was assessed over time. Serum samples during early and late phases were analyzed by ELISA and immunoelectrotransfer blot (IETB).Results showed that (a)-IgE and IgG4 are present at constant levels in both phases; (b)-IgE recognized the glycoproteins of ~ 45 and ~ 55 kDa and IgG4 only the ~ 45 kDa;</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 1432-1955 (Electronic)IS - 0932-0113 (Linking)LA - engPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-017-5601-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28932905">PM:28932905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20170921-CalcagnoMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20170921-CalcagnoMA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Calcagno MA</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-017-5601-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ansari,A.M.</style></author><author><style face="normal" font="Arial"> Osmani,L.</style></author><author><style face="normal" font="Arial"> Matsangos,A.E.</style></author><author><style face="normal" font="Arial"> Li,Q.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MedStar Health Internal Medicine, Union Memorial Hospital, Baltimore, MD 21218 USA.</style></auth-address><titles><title><style face="normal" font="Arial">Current insight in the localized insulin-derived amyloidosis (LIDA): clinico-pathological characteristics and differential diagnosis</style></title><secondary-title><style face="normal" font="Arial">Pathol Res Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pathol Res Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> aggressive</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Amyloid</style></keyword><keyword><style face="normal" font="Arial"> Amyloidosis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal studies</style></keyword><keyword><style face="normal" font="Arial"> animal study</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> cardiomyopathy</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glycemic control</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunoreactivity</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Proteinuria</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: In diabetic patients, subcutaneous insulin injection may cause several types of injection site-related lesions, such as lipoatrophy, insulin-induced cutaneous lipohypertrophy (IICL), allergic reaction, and iatrogenic localized insulin-derived amyloidosis (LIDA). Among these complications, both IICL and LIDA present as tumor-like and slow growing lesions; and they may be confused with one another. The clinical implication and management of IICL and LIDA are different. LIDA causes poor blood glycemic controls due to inadequate absorption of the insulin. Thus, accurate diagnosis of the lesion is critical in diabetic patients. REVIEW OF LITERATURE: LIDA is an extremely rare complication and often overlooked, it is managed by a surgical intervention. Whereas, IICL is a common side effect and can be managed by a non-surgical approach. Furthermore, in long-standing diabetics, patients may develop hypertrophic cardiomyopathy, proteinuria, peripheral, and autonomic neuropathy; these symptoms can be mistaken for a systemic amyloidosis. It is also necessary to distinguish LIDA from the systemic amyloidosis, which requires a more aggressive systemic therapy. LIDA should also be distinguished from primary cutaneous amyloidosis, with high risk of progression to a systemic amyloidosis. In this effort we reviewed 25 published manuscripts, including case reports and case series studies. We also summarized the literature and discussed differential diagnosis, including the approach to diagnose LIDA. CONCLUSION: The identification of amyloid material and immunoreactivity with anti-insulin antibodies are key diagnostic features of LIDA. Although several clinical and animal studies were made in recent years, the lesion is still under-diagnosed and underreported. The clinical suspicion and knowledge of the lesion play a crucial role for the accurate diagnosis of LIDA. Surgical excision of the lesion can dramatically decrease insulin requirement and improve glycemic control</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 1618-0631 (Electronic)IS - 0344-0338 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.prp.2017.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28935176">PM:28935176</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pathol Res Pract\20170922-AnsariAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pathol Res Pract\20170922-AnsariAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170922, Ansari AM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.prp.2017.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hsu,S.</style></author><author><style face="normal" font="Arial"> Wood,C.</style></author><author><style face="normal" font="Arial"> Pan,Z.</style></author><author><style face="normal" font="Arial"> Rahat,H.</style></author><author><style face="normal" font="Arial"> Zeitler,P.</style></author><author><style face="normal" font="Arial"> Fleischer,D.</style></author><author><style face="normal" font="Arial"> Menard-Katcher,C.</style></author><author><style face="normal" font="Arial"> Furuta,G.T.</style></author><author><style face="normal" font="Arial"> Atkins,D.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Adrenal Insufficiency in Pediatric Eosinophilic Esophagitis Patients Treated with Swallowed Topical Steroids</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="140" start="135">135-140</pages><volume><style face="normal" font="Arial">30</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status date="10/07/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Adrenocorticotropic Hormone</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> Endocrinology</style></keyword><keyword><style face="normal" font="Arial"> EoE</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Fasting</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> Multicenter Studies</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> topical steroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year><pub-dates><date Day="5" Month="10" Year="2017">2017/10/5</date></pub-dates></dates><publisher><style face="normal" font="Arial">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="Arial">2151-321X</style></isbn><abstract><style face="normal" font="Arial">Swallowed topical steroids (STS) are the only effective pharmacological therapy for eosinophilic esophagitis (EoE). Thus far, studies of small populations of EoE patients have reported conflicting results in relation to adrenal insufficiency (AI). We sought to measure AI in a clinical setting in children taking STS for EoE. We performed a quality improvement study of pediatric EoE patients seen in a multidisciplinary clinic, who were treated with STS for at least 3 months. Two hundred twenty-five patients completed questionnaires to assess for signs of AI. All patients were requested to have fasting morning cortisol levels completed and if abnormal (&lt;5?µg/dL or 139?nmol/L) twice, endocrinology consultation, and low-dose adrenocorticotropic hormone stimulation test were performed. A peak stimulated cortisol level of &lt;18?µg/dL or 500?nmol/L was diagnostic of AI. Five of 106 STS-treated EoE patients who had morning cortisol levels drawn had AI. All 5 of these patients had asthma and were on additional topical steroid treatments. The number of steroid modalities and dose of steroid were not significant risk factors. Despite this low percentage, the life-threatening potential of AI warrants patient screening, as patients with iatrogenic AI are typically asymptomatic until an emergency triggers adrenal crisis. Further multicenter studies are needed to better define the risk attributable to STS alone, particularly in patients receiving combined steroid modalities.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1089/ped.2017.0779</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29062584">PM:29062584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-135-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-135-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Hsu S</style></custom2><misc3><style face="normal" font="Arial">10.1089/ped.2017.0779</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kruger,R.</style></author><author><style face="normal" font="Arial"> Hanitsch,L.G.</style></author><author><style face="normal" font="Arial"> Leistner,R.</style></author><author><style face="normal" font="Arial"> Schneider-Burrus,S.</style></author><author><style face="normal" font="Arial"> Hoppe,P.A.</style></author><author><style face="normal" font="Arial"> Steinberg,S.</style></author><author><style face="normal" font="Arial"> Hauck,F.</style></author><author><style face="normal" font="Arial"> von Bernuth,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Pediatric Pulmonology and Immunology, Charite Universitatsmedizin, Berlin, Germany 2 Sozialpadiatrisches Zentrum, Charite Universitatsmedizin Berlin, Germany 3 Department of Immunology, Charite Universitatsmedizin Berlin, Germany 4 Institute of Hygiene and Environmental Medicine, Charite Universitatsmedizin Berlin, Germany 5 Department of Dermatology, Charite Universitatsmedizin Berlin, Germany 6 Kinderarztpraxis Invalidenstr. Berlin, Germany 7 Department of Pediatric Immunology and Rheumatology, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universitat, Munich, Germany 8 Immunological Diagnostics Laboratory, Dr. von Hauner Childrens's Hospital, Ludwig-Maximilians-Universitat, Munich, Germany 9 Labor Berlin GmbH, Fachbereich Immunologie, Charite Universitatsmedizin -Vivantes, Berlin, Germany 10 Berlin Center for Regenerative Therapies (BCRT), Charite Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Scabies, Periorbital Cellulitis and Recurrent Skin Abscesses due to Panton-Valentine Leukocidin Positive S. aureus Mimic Hyper IgE Syndrome in an Infant</style></title><secondary-title><style face="normal" font="Arial">Pediatr Infect Dis J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Infect Dis J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abscess</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cellulitis</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE</style></keyword><keyword><style face="normal" font="Arial"> Hyper IgE syndrome</style></keyword><keyword><style face="normal" font="Arial"> hyper-IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunologie</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Labor</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Scabies</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">We describe the clinical course of a two-month-old infant that was evaluated for autosomal dominant Hyper IgE Syndrome based on eczema, periorbital cellulitis, skin abscesses, increased total IgE levels and blood eosinophilia. However, scabies and nasal colonization by Panton-Valentine Leucocidin positive S. aureus were eventually diagnosed. After specific treatment the child was asymptomatic</style></abstract><notes><style face="normal" font="Arial">DA - 20170922IS - 1532-0987 (Electronic)IS - 0891-3668 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1097/INF.0000000000001788</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28938255">PM:28938255</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Infect Dis J\20170922-KrugerR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Infect Dis J\20170922-KrugerR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170922, Kruger R</style></custom2><misc3><style face="normal" font="Arial">10.1097/INF.0000000000001788</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bermejo,I.</style></author><author><style face="normal" font="Arial"> Stevenson,M.</style></author><author><style face="normal" font="Arial"> Cooper,K.</style></author><author><style face="normal" font="Arial"> Harnan,S.</style></author><author><style face="normal" font="Arial"> Hamilton,J.</style></author><author><style face="normal" font="Arial"> Clowes,M.</style></author><author><style face="normal" font="Arial"> Carroll,C.</style></author><author><style face="normal" font="Arial"> Harrison,T.</style></author><author><style face="normal" font="Arial"> Saha,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Health and Related Research (ScHARR), University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK</style></auth-address><titles><title><style face="normal" font="Arial">Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal</style></title><secondary-title><style face="normal" font="Arial">Pharmacoeconomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharmacoeconomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma severity</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Maintenance</style></keyword><keyword><style face="normal" font="Arial"> Manufacture</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company (GlaxoSmithKline) that manufactures mepolizumab (Nucala(R)) to submit evidence on the clinical and cost effectiveness of mepolizumab for the treatment of severe eosinophilic asthma. The School of Health and Related Research Technology Appraisal Group (ScHARR-TAG) at the University of Sheffield was commissioned to act as the independent evidence review group (ERG). The ERG produced a review of the evidence for the clinical and cost effectiveness of mepolizumab as add-on to standard of care (SoC) compared with SoC and omalizumab, based upon the company's submission to NICE. The clinical-effectiveness evidence in the company's submission was based predominantly on three randomised controlled trials (DREAM, MENSA and SIRIUS) comparing add-on mepolizumab with placebo plus SoC. The relevant population was defined in terms of degree of asthma severity (four or more exacerbations in the previous year and/or dependency on maintenance oral corticosteroids [mOCS]) and degree of eosinophilia (a blood eosinophil count of >/= 300 cells/microl in the previous year) based on post hoc subgroup analyses of the pivotal trials. Other subpopulations were considered throughout the appraisal, defined by different eosinophil measurements, number of exacerbations and dependency (or lack thereof) on mOCS. Statistically significant reductions in clinically significant exacerbations were observed in patients receiving mepolizumab compared with SoC meta-analysed across MENSA and DREAM in the modified intention-to-treat (ITT) population (rate ratio [RR] 0.51; 95% confidence interval [CI] 0.42-0.62) as well as in the relevant population (RR 0.47; 95% CI 0.36-0.62). In terms of quality of life, differences on the St. George's Respiratory Questionnaire in MENSA for add-on subcutaneous mepolizumab 100 mg vs. placebo were 7 and 7.5 units in the modified ITT and relevant populations, respectively. A number of issues in the clinical evidence base warrant caution in its interpretation. The ERG noted that the definition of SoC used in the trials differed from that in clinical practice, where patients with severe uncontrolled asthma start treatment with a mOCS. The company's economic post-consultation analysis incorporating a confidential patient access scheme (PAS) estimated that the incremental cost-effectiveness ratio (ICER) for add-on mepolizumab compared with SoC was pound27,418 per quality-adjusted life-year (QALY) gained in the relevant population if patients stopped mepolizumab after 1 year unless (1) the number of exacerbations decreased at least 50% or (2) a reduction in corticosteroids dose was achieved whilst maintaining asthma control. The ERG applied an age adjustment to all utilities and corrected the post-continuation assessment utilities, which resulted in an ICER for add-on mepolizumab compared with SoC of pound29,163 per QALY gained. The ERG noted that this ICER was not robust for patients who continued treatment due to a corticosteroid dose reduction where exacerbations had decreased by less than 50%, because corticosteroid dose reduction was not allowed in the main trial in which the evidence was gathered (MENSA). The NICE appraisal committee (AC) concluded that add-on mepolizumab could be recommended as an option for treating severe refractory eosinophilic asthma in adults for the relevant population when the stopping rule suggested by the company was applied. The AC also concluded that the comparison between mepolizumab and omalizumab was not clinically relevant or methodologically robust</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 1179-2027 (Electronic)IS - 1170-7690 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s40273-017-0571-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28933002">PM:28933002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharmacoeconomics\20170921-BermejoI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharmacoeconomics\20170921-BermejoI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Bermejo I</style></custom2><misc3><style face="normal" font="Arial">10.1007/s40273-017-0571-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wiese,A.V.</style></author><author><style face="normal" font="Arial"> Ender,F.</style></author><author><style face="normal" font="Arial"> Quell,K.M.</style></author><author><style face="normal" font="Arial"> Antoniou,K.</style></author><author><style face="normal" font="Arial"> Vollbrandt,T.</style></author><author><style face="normal" font="Arial"> Konig,P.</style></author><author><style face="normal" font="Arial"> Kohl,J.</style></author><author><style face="normal" font="Arial"> Laumonnier,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Systemic Inflammation Research, University of Lubeck, Lubeck, Germany</style></auth-address><titles><title><style face="normal" font="Arial">The C5a/C5aR1 axis controls the development of experimental allergic asthma independent of LysM-expressing pulmonary immune cells</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0184956">e0184956-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> systemic inflammation</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">C5a regulates the development of maladaptive immune responses in allergic asthma mainly through the activation of C5a receptor 1 (C5aR1). Yet, the cell types and the mechanisms underlying this regulation are ill-defined. Recently, we described increased C5aR1 expression in lung tissue eosinophils but decreased expression in airway and pulmonary macrophages as well as in pulmonary CD11b+ conventional dendritic cells (cDCs) and monocyte-derived DCs (moDCs) during the allergic effector phase using a floxed green fluorescent protein (GFP)-C5aR1 knock-in mouse. Here, we determined the role of C5aR1 signaling in neutrophils, moDCs and macrophages for the pulmonary recruitment of such cells and the importance of C5aR1-mediated activation of LysM-expressing cells for the development of allergic asthma. We used LysM-C5aR1 KO mice with a specific deletion of C5aR1 in LysMCre-expressing cells and confirmed the specific deletion of C5aR1 in neutrophils, macrophages and moDCs in the airways and/or the lung tissue. We found that alveolar macrophage numbers were significantly increased in LysM-C5aR1 KO mice. Induction of ovalbumin (OVA)-driven experimental allergic asthma in GFP-C5aR1fl/fl and LysM-C5aR1 KO mice resulted in strong but similar airway resistance, mucus production and Th2/Th17 cytokine production. In contrast, the number of airway but not of pulmonary neutrophils was lower in LysM-C5aR1 KO as compared with GFP-C5aR1fl/fl mice. The recruitment of macrophages, cDCs, moDCs, T cells and type 2 innate lymphoid cells was not altered in LysM-C5aR1 KO mice. Our findings demonstrate that C5aR1 is critical for steady state control of alveolar macrophage numbers and the transition of neutrophils from the lung into the airways in OVA-driven allergic asthma. However, C5aR1 activation of LysM-expressing cells plays a surprisingly minor role in the recruitment and activation of such cells and the development of the allergic phenotype in OVA-driven experimental allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0184956</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28931049">PM:28931049</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0184956.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0184956.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Wiese AV</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0184956</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tjernberg,I.</style></author><author><style face="normal" font="Arial"> Hamsten,C.</style></author><author><style face="normal" font="Arial"> Apostolovic,D.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Chemistry and Transfusion Medicine, Kalmar County Hospital, Kalmar, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">IgE reactivity to alpha-Gal in relation to Lyme borreliosis</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0185723">e0185723-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood donor</style></keyword><keyword><style face="normal" font="Arial"> Blood Donors</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical chemistry</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Red meat allergy</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> tick</style></keyword><keyword><style face="normal" font="Arial"> Tick Bites</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An association between tick bites, the development of immunoglobulin E (IgE) antibodies to galactose-alpha-1, 3-galactose (alpha-Gal) and red meat allergy has recently been reported. Here we wanted to elucidate the relation between tick exposure, IgE antibodies to alpha-Gal and Lyme borreliosis (LB). METHODS: In the highly LB endemic area of Kalmar County, Sweden, serum samples and health inquiries from 518 blood donors were included. All sera were investigated for multiple IgG anti-Borrelia antibodies using a multiplex assay (recomBead, Mikrogen). In addition, three serially collected sera over a six month period from 148 patients with clinically defined erythema migrans (EM) were included. IgE antibodies against alpha-Gal were determined using ImmunoCAP (Thermo Fisher Scientific). RESULTS: In blood donors reporting previous LB (n = 124) IgE to alpha-Gal was found in 16%, while in donors denying previous LB but with multiple anti-Borrelia antibodies (n = 94; interpreted as asymptomatic LB) 10% were IgE alpha-Gal-positive. Finally, in donors without Borrelia antibodies denying previous LB (n = 300) 14% showed IgE to alpha-Gal. No significant difference in proportions among the groups were found. In EM patients, IgE to alpha-Gal was found in 32/148 (22%) at diagnosis, 31/148 (21%) after two-three months and 23/148 (16%) after six months. A significant reduction of proportion and level of IgE to alpha-Gal was found between the second and third sample (p&lt;0.01). A positive IgE anti alpha-Gal was more common among men compared with women both in blood donors and in EM patients (p&lt;/=0.01). CONCLUSIONS: IgE to alpha-Gal reactivity was common in a tick endemic area but showed no significant relation to previous LB. IgE anti-alpha-Gal reactivity in EM patients peaked within three months of diagnosis of EM, after which it waned indicating that recent tick exposure is of importance in alpha-Gal sensitization. Furthermore, IgE anti alpha-Gal was more common in men compared with women</style></abstract><notes><style face="normal" font="Arial">DA - 20170927IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0185723</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28953957">PM:28953957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0185723.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0185723.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0185723S1_Table.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0185723S2_Table.xlsxC:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0185723S3_Table.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0185723S1_Table.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0185723S2_Table.xlsxF:\A&amp;H HMW Papers\PLoS ONE\2017-12-e0185723S3_Table.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20170927, Tjernberg I</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0185723</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miranda-Machado,P.A.</style></author><author><style face="normal" font="Arial"> de la Cruz Hoyos-Sanchez,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Prevalence of urticaria in Cartagena, Colombia</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="170" start="163">163-170</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Acute urticaria</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: In Colombia, there have been studies on the prevalence of allergic diseases suchas asthma, allergic rhinitis and atopic dermatitis. Prevalence studies of urticaria in Colombia arescarce.Objective: Our objective of this study was to estimate the prevalence of urticaria in Cartagena(Colombia) in order to contribute to national epidemiological estimates of disease.Methods: A multicenter cross-sectional study in the city of Cartagena was conducted and 547patients aged 1-58 years treated at the Allergy specialist consultation in care centers selected forthis study between April and July 2015 were included, through non-probabilistic sampling.Results: The prevalence of urticaria in the care centers selected of city of Cartagena (Colombia)was 7.1 % (4 % children and adults 3.1 %). 3.4 % prevalence of acute urticaria and 3.6 % ofchronic urticaria was estimated.Conclusion: 46.1 % reported having a poor quality of life associated with urticaria</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-163-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-163-70.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Miranda-Machado PA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Azamar-Jacome,A.A.</style></author><author><style face="normal" font="Arial"> Azamar-Jacome,M.A.</style></author><author><style face="normal" font="Arial"> Borjas-Aguilar,K.L.</style></author><author><style face="normal" font="Arial"> Mendoza-Hernandez,D.A.</style></author><author><style face="normal" font="Arial"> Huerta-Lopez,J.G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical-epidemiological profile of oral allergy syndrome in the population aged 6 to 18 years</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="152" start="142">142-152</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Banana</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Nature</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peach</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: Oral allergy syndrome (OAS) or pollen-fruit syndrome is a type of food allergy. Itscharacteristics and associated allergens vary according to the studied population. There are fewstudies in Mexico about this topic, none in children.Objective: To describe clinical and epidemiological characteristics of OAS among children inMexico.Methods: A descriptive, observational, transversal and prospective study was conducted. Weincluded every patient from 6 to 18 years old with diagnostic suspicion of OAS, in which completeclinical history, skin test to food and pollens, and oral food challenge were performed.Results: We found a prevalence of 5.3% (29 patients): 55% were males. Average age was 10 ± 3years, and average number of food implicated were 6.8 ± 4.1. Apple, peach and banana, were themost frequent food associated, and sensitization to oak and European privet, the more prevalentpollens found in OAS.Conclusion: OAS is a common type of food allergy, transient and mild in nature. In more than90% of the cases is associated with allergic rhinitis and sensitization to pollens. In our population,profilins may be involved in its pathogenesis. However, more studies are required to prove this.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-142-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-142-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Azamar-Jacome AA</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sanchez,J.</style></author><author><style face="normal" font="Arial"> Calvo,V.</style></author><author><style face="normal" font="Arial"> Sanchez,A.</style></author><author><style face="normal" font="Arial"> Diez,S.</style></author><author><style face="normal" font="Arial"> Cardona,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sensitization to 10 mites in a tropic area. Der p and Der f are important risk factor for sensitization to other mites from Pyroglyphidae, Acaridae, Chortoglyphidae, and Glyciphagidae families</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="162" start="153">153-162</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Acaridae</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Blomia</style></keyword><keyword><style face="normal" font="Arial"> Blomia tropicalis</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> Explorations</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Pyroglyphidae</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: Much is known about the frequency of sensitization to Blomia tropicalis, Dermatophagoidespteronyssinus and Dermatophagoides farinae, although less is known about sensitization to otherspecies and their possible interactions.Objective: In patients with allergic manifestations, to evaluate the frequency of sensitization to 10species of mites in a tropical area and their possible interactions.Methods: Cross-sectional study. Sensitization was evaluated by skin tests. A generalized linearPoisson regression model with robust variance was used. Based on the sensitization probabilityreasons and social networking analysis, explorations of relationship for 10 mites were performed.Results: 147 patients were included. The highest sensitization was found to mites' family Pyroglyphidae(> 70 %) and less frequently was the Glycyphagidae family (&lt; 50 %). Sensitization to any mitessignificantly increased the likelihood of sensitization to others. Sensitization to Der f or Der p increased,more than 20 times the likelihood of sensitization to other mites of the Pyroglyphidae family and morethan 10 times to mites from other families. Sensitization to mites from Glycyphagidae, Chortoglyphidaeor Acaridae family also increased the risk of sensitization to other mites but less than 5 times.Conclusion: Sensitization to mites is frequent in tropical area. Pyroglyphidae sensitization is themain risk factor for polysensitization with other mites from Glycyphagidae, Chortoglyphidae orAcaridae. These results must be considered at diagnosis and treatment of allergy diseases.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-153-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-153-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Sanchez J</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cardona,V.</style></author><author><style face="normal" font="Arial"> Alvarez-Perea,A.</style></author><author><style face="normal" font="Arial"> Ansotegui,I.J.</style></author><author><style face="normal" font="Arial"> Arias-Cruz,A.</style></author><author><style face="normal" font="Arial"> Gonzalez-Diaz,S.N.</style></author><author><style face="normal" font="Arial"> Latour-Staffeld,P.</style></author><author><style face="normal" font="Arial"> Ivancevich,J.C.</style></author><author><style face="normal" font="Arial"> Sanchez-Borges,M.</style></author><author><style face="normal" font="Arial"> Serrano,C.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author><author><style face="normal" font="Arial"> Tanno,L.K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Management of anaphylaxis in Latin America: current situation</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="177" start="171">171-177</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adrenaline</style></keyword><keyword><style face="normal" font="Arial"> adrenaline autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> autoinjector</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Latin America</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Practice Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Self Administration</style></keyword><keyword><style face="normal" font="Arial"> self-administration</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Venezuela</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: Anaphylaxis is a systemic and severe allergic reaction, which can be fatal. The first-linetreatment of choice, according to international guidelines, is intramuscular adrenaline. However, differentstudies show that the performance of health professionals managing anaphylaxis is often inadequateObjective: To assess the current resources available in Latin American countries for the diagnosisand treatment of anaphylaxis.Methods: Online survey promoted by the Latin American Society of Allergy and Immunology torepresentatives of the national allergy societies of Latin American countries.Results: Responses were received from 10 countries out of the 14 countries invited to participate.Only five of the countries have clinical practice guidelines in anaphylaxis. Adrenaline autoinjectors areavailable only in two countries, Argentina and Brazil, but are not subsidized by public health systems.In all countries, adrenaline is available in ampoules, which is the presentation usually prescribed topatients for self-administration. The use of adrenaline was estimated to be less than 50 % of cases infive countries, while antihistamines and corticosteroids are almost always used. The determination ofserum tryptase is possible in some health centers, often private, in five of the countries surveyed.Conclusion: It is necessary to improve resources related to the diagnosis and management ofanaphylaxis in Latin American countries.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Spain -CO - Mexico -CO - Santo Domingo -CO - Argentina -CO - Venezuela -CO - Colombia -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-171-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-171-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Cardona V</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Morfin Maciel,B.M.</style></author><author><style face="normal" font="Arial"> Garcia-De la Puente,S.</style></author><author><style face="normal" font="Arial"> Bojorquez-Ochoa,A.</style></author><author><style face="normal" font="Arial"> Huante-Anaya,A.</style></author><author><style face="normal" font="Arial"> Orozco-Martinez,S.</style></author><author><style face="normal" font="Arial"> Zaltzman-Girshevich,S.</style></author><author><style face="normal" font="Arial"> Guzman-Vazquez,E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Prevalence of allergic diseases in children with secondary renal tubular acidosis attending a tertiary care pediatric center</style></title><secondary-title><style face="normal" font="Arial">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Alerg Mex</style></full-title></periodical><pages end="141" start="133">133-141</pages><volume><style face="normal" font="Arial">64</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Acidosis</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Age of Onset</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> ISAAC</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> open food challenge</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> patch testing</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background: It has been suggested a high prevalence of allergic disease in children with RTA.Objectives: To describe the prevalence of allergic diseases in children with secondary RTA (renaltubular acidosis) in the nephrology department of the National Institute of Pediatrics (NIP), México.Methods: An observational, prospective, cross-sectional, descriptive study. Children with secondaryRTA &lt; 18 years who attended the outpatient nephrology service in the NIP for 24 months, wereincluded. ISAAC questionnaire and the EAACI guidelines were applied. To prove a suspectedallergy, skin tests, total and specific IgE, patch testing and food challenge were performed. UsingSPSS 19, frequency of allergic diseases was described.Results: 113 patients were included. Age 8 to 168 months. Male: 53.9 %. RTA types: Distal(64.6 %), proximal (26.5 %), mixed (1.8 %) and undetermined (7 %). Age of onset between 1and 96 months. Serum bicarbonate 10.1 to 20 mEq/L. Allergic diseases were found in 24.8 %:allergic rhinitis (18.4 %), food allergy (9.7 %), atopic dermatitis (8 %), asthma (8 %) and allergicconjunctivitis (6.1 %). Total IgE was increased in 9 patients. Positive skin tests in 14.2 %. Positivechemiluminescence in 18 children; positive open food challenge in 11 children and patch tests in 4.Conclusions: Secondary RTA is common in children attending tertiary care hospitals. The prevalenceof allergic disease in children with secondary ATR, is similar to that described in the general population.</style></abstract><notes><style face="normal" font="Arial">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-133-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-133-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Morfin Maciel BM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sasaki,T.</style></author><author><style face="normal" font="Arial"> Akiyama,M.</style></author><author><style face="normal" font="Arial"> Kaneko,Y.</style></author><author><style face="normal" font="Arial"> Mori,T.</style></author><author><style face="normal" font="Arial"> Yasuoka,H.</style></author><author><style face="normal" font="Arial"> Suzuki,K.</style></author><author><style face="normal" font="Arial"> Yamaoka,K.</style></author><author><style face="normal" font="Arial"> Okamoto,S.</style></author><author><style face="normal" font="Arial"> Takeuchi,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease</style></title><secondary-title><style face="normal" font="Arial">RMD Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">RMD Open</style></abbr-1></periodical><pages end="" start="e000432">e000432-</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Orbit</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Pancreas</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Salivary Glands</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Differentiating IgG4-related disease (IgG4-RD) from multicentric Castleman's disease (MCD) is challenging because both diseases present high serum IgG4. The objective of this study is to clarify the differences in characteristics and identify a clinically useful approach to differentiate these two diseases. METHODS: Forty-five consecutive patients with untreated active IgG4-RD and 33 patients with MCD were included in this study, who visited our institution from January 2000 to August 2016. The clinical and laboratory findings for the patients of the two diseases were compared. Various combinations of the distinctive findings were evaluated to identify the most efficient differentiating features between IgG4-RD and MCD. RESULTS: The levels of serum IgG4 were not different between the two diseases. Orbits, lacrimal glands, salivary glands or pancreas were involved in 88.9% of IgG4-RD cases and only in 3.0% of MCD cases. All MCD cases involved lymph nodes. Atopic history was characteristic for IgG4-RD. The levels of C reactive protein (CRP) with a cut-off of 0.80 mg/dL and IgA with a cut-off of 330 mg/dL were the most distinctive. The combination of 'Orbits, lacrimal glands, salivary glands or pancreas involvement, atopic history, or non-involvement of lymph node' and 'CRP &lt;/= 0.8 mg/dL or IgA &lt;/= 330 mg/dL' yielded the probability of 97.8% in IgG4-RD, while that of 3.0 % in patients with MCD. CONCLUSIONS: Our study revealed distinct features between IgG4-RD and MCD. Differentiating between the diseases based on those distinct features, including distribution of organ involvement, atopic history, levels of IgA and CRP, was a useful approach</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 2056-5933 (Print)IS - 2056-5933 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1136/rmdopen-2017-000432</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959455">PM:28959455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\RMD Open\2017-3-e000432.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\RMD Open\2017-3-e000432.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Sasaki T</style></custom2><misc3><style face="normal" font="Arial">10.1136/rmdopen-2017-000432</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzalez,M.</style></author><author><style face="normal" font="Arial"> Dona,I.</style></author><author><style face="normal" font="Arial"> Palomares,F.</style></author><author><style face="normal" font="Arial"> Campo,P.</style></author><author><style face="normal" font="Arial"> Rodriguez,M.J.</style></author><author><style face="normal" font="Arial"> Rondon,C.</style></author><author><style face="normal" font="Arial"> Gomez,F.</style></author><author><style face="normal" font="Arial"> Fernandez,T.D.</style></author><author><style face="normal" font="Arial"> Perkins,J.R.</style></author><author><style face="normal" font="Arial"> Escribese,M.M.</style></author><author><style face="normal" font="Arial"> Torres,M.J.</style></author><author><style face="normal" font="Arial"> Mayorga,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Research Laboratory-Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Dermatophagoides pteronyssinus immunotherapy changes the T-regulatory cell activity</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11949">11949-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical improvement</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T regulatory cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">Subcutaneous specific immunotherapy (SCIT) has been shown to modify the Dermatophagoides pteronissinus (DP) allergic response, characterized by generation of Treg cells. However, studies have reported no changes in the proportion of Treg cells after immunotherapy, indicating that the effects may be due to modifications in their regulatory activities. We aimed to determine whether Tregs generated by DP-SCIT can switch the allergic response to tolerant and study the involvement of suppressive cytokines on it. Twenty-four DP-allergic rhinitis patients were recruited, 16 treated with DP-SCIT and 8 untreated. Treg and T effector cells were isolated before and after DP-SCIT, and cocultured in different combinations with alpha-IL-10, alpha-TGF-beta blocking antibodies and nDer p 1. Treg cells after DP-SCIT increased Th1 and decreased Th2 and Th9 proliferation. Similarly, they increased IL-10 and decreased IL-4 and IL-9-producing cells. alpha-IL-10 affected the activity of Treg cells obtained after DP-SCIT only. Finally, DP-specific IgG4 levels, Treg percentage and IL-10 production were correlated after DP-SCIT. These results demonstrate that DP-SCIT induces Treg cells with different suppressive activities. These changes could be mediated by IL-10 production and appear to play an important role in the induction of the tolerance response leading to a clinical improvement of symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-12261-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28931869">PM:28931869</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11949.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11949.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Gonzalez M</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-12261-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,J.</style></author><author><style face="normal" font="Arial"> Kang,J.</style></author><author><style face="normal" font="Arial"> Lin,B.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Zhu,Y.</style></author><author><style face="normal" font="Arial"> Du,J.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Xi,Z.</style></author><author><style face="normal" font="Arial"> Li,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Environmental Biomedicine, Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan, 430079, Hubei, China</style></auth-address><titles><title><style face="normal" font="Arial">Mediating Role of TRPV1 Ion Channels in the Co-exposure to PM2.5 and Formaldehyde of Balb/c Mice Asthma Model</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11926">11926-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Calcitonin</style></keyword><keyword><style face="normal" font="Arial"> Calcitonin Gene-Related Peptide</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Daily life</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Formaldehyde</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Ion Channels</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> neurogenic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Neuropeptides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> PM2.5</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Substance P</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="Arial">Asthma is a complex pulmonary inflammatory disease that can be promoted by air pollutants such as PM2.5 and formaldehyde (FA). However, existent experimental evidence principally focuses on the negative influence of a single air pollutant, neglecting the possible synergistic effect in biological responses to mixture of these pollutants, a more common situation in our daily life. In this study, allergic Balb/c mice were exposed to a mixture of PM2.5 and FA, and their toxicological effects and mechanisms were explored. It is demonstrated that the combined exposure to PM2.5 and FA can greatly aggravate allergic asthma in mice. When compared with exposure to PM2.5 or FA alone, the co-exposure showed a certain synergistic effect. Increased levels of ROS, inflammatory factors and total serum immunoglobulin E were concomitant with this deterioration. Furthermore, results suggested that co-exposure exacerbated the activation of TRPV1 signal pathways, with an enhancement in substance P and calcitonin gene-related peptide production, which contributed to inflammation in asthma by neurogenic inflammation. The study also proved that capsazepine treatment could reduce the levels of not only pro-inflammatory neuropeptides, but also oxidative stress. It is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation</style></abstract><notes><style face="normal" font="Arial">DA - 20170921IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-11833-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28931832">PM:28931832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11926.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11926.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170921, Song J</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-11833-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Curin,M.</style></author><author><style face="normal" font="Arial"> Weber,M.</style></author><author><style face="normal" font="Arial"> Hofer,G.</style></author><author><style face="normal" font="Arial"> Apostolovic,D.</style></author><author><style face="normal" font="Arial"> Keller,W.</style></author><author><style face="normal" font="Arial"> Reininger,R.</style></author><author><style face="normal" font="Arial"> Swoboda,I.</style></author><author><style face="normal" font="Arial"> Spitzauer,S.</style></author><author><style face="normal" font="Arial"> Focke-Tejkl,M.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Clustering of conformational IgE epitopes on the major dog allergen Can f 1</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="12135">12135-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Binding Sites</style></keyword><keyword><style face="normal" font="Arial"> Can f 1</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitope Mapping</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE epitopes</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-epitope</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Rabbits</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgG</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin E (IgE)-associated allergy affects more than 25% of the population. Can f 1 is the major dog allergen associated with respiratory symptoms but the epitopes recognized by allergic patients IgE on Can f 1 are unknown. To characterize IgE epitopes of Can f 1 recognized by dog allergic patients, six overlapping peptides spanning the Can f 1 sequence were synthesized. In direct IgE epitope mapping experiments peptides were analyzed for IgE reactivity by dot blot and Enzyme-linked immunosorbent assay (ELISA) with sera from dog allergic patients. For indirect epitope-mapping, rabbits were immunized with the peptides to generate specific IgG antibodies which were used to inhibit allergic patients' IgE binding to Can f 1. IgE binding sites were visualized on a model of the Can f 1 three-dimensional structure. We found that Can f 1 does not contain any relevant sequential IgE epitopes. However, IgE inhibition experiments with anti-peptide specific IgGs showed that Can f 1 N- and C-terminal portion assembled a major conformational binding site. In conclusion, our study is the first to identify the major IgE epitope-containing area of the dog allergen Can f 1. This finding is important for the development of allergen-specific treatment strategies</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-11672-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939849">PM:28939849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-12135.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-12135.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Curin M</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-11672-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Peng,S.</style></author><author><style face="normal" font="Arial"> Wang,S.</style></author><author><style face="normal" font="Arial"> Huang,C.Z.</style></author><author><style face="normal" font="Arial"> Huang,C.Z.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Li,D.</style></author><author><style face="normal" font="Arial"> Jiang,J.</style></author><author><style face="normal" font="Arial"> Ouyang,Q.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Li,S.</style></author><author><style face="normal" font="Arial"> Qiao,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Key Laboratory of TCM-information Engineer of State Administration of TCM, School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 6, Central Ring South Road, Wangjing, Beijing, 100102, Chinayjqiao@bucm.edu.cn</style></auth-address><titles><title><style face="normal" font="Arial">Identification of a specific agonist of human TAS2R14 from Radix Bupleuri through virtual screening, functional evaluation and binding studies</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="12174">12174-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Bioactivity</style></keyword><keyword><style face="normal" font="Arial"> Bioassay</style></keyword><keyword><style face="normal" font="Arial"> Bitter taste</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Hek293 Cells</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular docking</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> TCM</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">Bitter taste receptors (TAS2Rs) have attracted a great deal of interest because of their recently described bronchodilator and anti-inflammatory properties. The aim of this study was to identify natural direct TAS2R14 agonists from Radix Bupleuri that can inhibit mast cell degranulation. A ligand-based virtual screening was conducted on a library of chemicals contained in compositions of Radix Bupleuri, and these analyses were followed by cell-based functional validation through a HEK293-TAS2R14-G16gust44 cell line and IgE-induced mast cell degranulation assays, respectively. Saikosaponin b (SSb) was confirmed for the first time to be a specific agonist of TAS2R14 and had an EC50 value of 4.9 muM. A molecular docking study showed that SSb could directly bind to a TAS2R14 model through H-bond interactions with Arg160, Ser170 and Glu259. Moreover, SSb showed the ability to inhibit IgE-induced mast cell degranulation, as measured with a beta-hexosaminidase release model and real-time cell analysis (RTCA). In a cytotoxicity bioassay, SSb showed no significant cytotoxicity to HEK293 cells within 24 hours. This study demonstrated that SSb is a direct TAS2R14 agonist that inhibit IgE-induced mast cell degranulation. Although the target and in vitro bioactivity of SSb were revealed in this study, it still need in vivo study to further verify the anti-asthma activity of SSb</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-11720-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939897">PM:28939897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-12174.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-12174.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Zhang Y</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-11720-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hall,S.C.</style></author><author><style face="normal" font="Arial"> Agrawal,D.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, USA</style></auth-address><titles><title><style face="normal" font="Arial">Increased TREM-2 expression on the subsets of CD11c+ cells in the lungs and lymph nodes during allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11853">11853-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> CCR7</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disease models</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Myeloid Cells</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> traffic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">Dendritic cells (DCs) are professional APCs that traffic to the draining lymph nodes where they present processed antigens to naive T-cells. The recently discovered triggering receptor expressed on myeloid cells (TREM)-2 has been shown to be expressed on DCs in several disease models, however, its role in asthma is yet to be elucidated. In the present study, we examined the effect of allergen exposure on TREM-2 expression in the airways and on DC subsets in the lung and lymph nodes in murine model of allergic airway inflammation. Sensitization and challenge with ovalbumin reproduced hallmark features of asthma. TREM-2 mRNA expression in the whole lung was significantly higher in the OVA-sensitized and -challenged mice which was associated with increased protein expression in the lungs. Analysis of CD11c+MHC-IIhi DCs in the lung and draining lymph nodes revealed that allergen exposure increased TREM-2 expression on all DC subsets with significantly higher expression in the lymph nodes. This was associated with increased mRNA expression of Th2 and Th17 cytokines. Further analyses showed that these TREM-2+ cells expressed high levels of CCR-7 and CD86 suggesting a potential role of TREM-2 in mediating maturation and migration of DC subsets in allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-12330-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28928485">PM:28928485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11853.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11853.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Hall SC</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-12330-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ye,J.</style></author><author><style face="normal" font="Arial"> Piao,H.</style></author><author><style face="normal" font="Arial"> Jiang,J.</style></author><author><style face="normal" font="Arial"> Jin,G.</style></author><author><style face="normal" font="Arial"> Zheng,M.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author><author><style face="normal" font="Arial"> Jin,X.</style></author><author><style face="normal" font="Arial"> Sun,T.</style></author><author><style face="normal" font="Arial"> Choi,Y.H.</style></author><author><style face="normal" font="Arial"> Li,L.</style></author><author><style face="normal" font="Arial"> Yan,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anatomy and Histology and Embryology, Yanbian University Medical College, Yanji, 133002, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Polydatin inhibits mast cell-mediated allergic inflammation by targeting PI3K/Akt, MAPK, NF-kappaB and Nrf2/HO-1 pathways</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="11895">11895-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anatomy</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytotoxicity</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> embryology</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Evans Blue</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lyn</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> PCA</style></keyword><keyword><style face="normal" font="Arial"> Pigmentation</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Syk kinase</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">Polydatin(PD) shows anti-allergic inflammatory effect, and this study investigated its underlying mechanisms in in vitro and in vivo models. IgE-mediated passive cutaneous anaphylaxis (PCA) and passive systemic anaphylaxis (PSA) models were used to confirm PD effect in vivo. Various signaling pathway proteins in mast cell were examined. RT-PCR, ELISA and western blotting were applied when appropriate. Activity of Lyn and Fyn kinases in vitro was measured using the Kinase Enzyme System. PD dose-dependently reduced the pigmentation of Evans blue in the PCA model and decreased the concentration of serum histamine in PSA model, and attenuated the degranulation of mast cells without generating cytotoxicity. PD decreased pro-inflammatory cytokine expression (TNF-alpha, IL-4, IL-1beta, and IL-8). PD directly inhibited activity of Lyn and Syk kinases and down-regulated downstream signaling pathway including MAPK, PI3K/AKT and NF-kB. In addition, PD also targets Nrf2/HO-1 pathway to inhibit mast cell-derived allergic inflammatory reactions. In conclusion, the study demonstrates that PD is a possible therapeutic candidate for allergic inflammatory diseases. It directly inhibited activity of Lyn and Syk kinases and down-regulates the signaling pathway of MAPK, PI3K/AKT and NF-kappaB, and up-regulates the signaling pathway of Nrf2/HO-1 to inhibit the degranulation of mast cells</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-12252-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28928455">PM:28928455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-11895.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-11895.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170920, Ye J</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-12252-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fu,L.S.</style></author><author><style face="normal" font="Arial"> Wu,Y.R.</style></author><author><style face="normal" font="Arial"> Fang,S.L.</style></author><author><style face="normal" font="Arial"> Tsai,J.J.</style></author><author><style face="normal" font="Arial"> Lin,H.K.</style></author><author><style face="normal" font="Arial"> Chen,Y.J.</style></author><author><style face="normal" font="Arial"> Chen,T.Y.</style></author><author><style face="normal" font="Arial"> Chang,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Department, Taichung Veterans General Hospital, Taichung, Taiwan.</style></auth-address><titles><title><style face="normal" font="Arial">Cell Penetrating Peptide Derived from Human Eosinophil Cationic Protein Decreases Airway Allergic Inflammation</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="12352">12352-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> broncho-alveolar lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic</style></keyword><keyword><style face="normal" font="Arial"> cytotoxic effect</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Veterans</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">Cell penetrating peptide derived from human eosinophil cationic protein (CPPecp) is a 10-amino-acid peptide containing a core heparan sulfate (HS)-binding motif of human eosinophil cationic protein (ECP). It binds and penetrates bronchial epithelial cells without cytotoxic effects. Here we investigated airway-protective effects of CPPecp in BEAS-2B cell line and mite-induced airway allergic inflammation in BALB/c mice. In BEAS-2B cell, CPPecp decreases ECP-induced eotaxin mRNA expression. CPPecp also decreases eotaxin secretion and p-STAT6 activation induced by ECP, as well as by IL-4. In vivo studies showed CPPecp decreased mite-induced airway inflammation in terms of eosinophil and neutrophil count in broncho-alveolar lavage fluid, peri-bronchiolar and alveolar pathology scores, cytokine production in lung protein extract including interleukin (IL)-5, IL-13, IL-17A/F, eotaxin; and pause enhancement from methacholine stimulation. CPPecp treated groups also showed lower serum mite-specific IgE level. In this study, we have demonstrated the in vitro and in vivo anti-asthma effects of CPPecp</style></abstract><notes><style face="normal" font="Arial">DA - 20170928IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-12390-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28955044">PM:28955044</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-12352.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-12352.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170928, Fu LS</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-12390-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Campana,R.</style></author><author><style face="normal" font="Arial"> Huang,H.J.</style></author><author><style face="normal" font="Arial"> Freidl,R.</style></author><author><style face="normal" font="Arial"> Linhart,B.</style></author><author><style face="normal" font="Arial"> Vrtala,S.</style></author><author><style face="normal" font="Arial"> Wekerle,T.</style></author><author><style face="normal" font="Arial"> Karaulov,A.</style></author><author><style face="normal" font="Arial"> Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</style></title><secondary-title><style face="normal" font="Arial">Semin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen molecule</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical tolerance</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological tolerance</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intervention Studies</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy</style></keyword><keyword><style face="normal" font="Arial"> molecular allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> synthetic peptides</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20170923IS - 1096-3618 (Electronic)IS - 1044-5323 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Austria -CO - Russia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.smim.2017.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939389">PM:28939389</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunol\20170923-CampanaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunol\20170923-CampanaR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170923, Campana R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.smim.2017.08.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fujiwara,S.I.</style></author><author><style face="normal" font="Arial"> Kino,S.</style></author><author><style face="normal" font="Arial"> Tanaka,A.</style></author><author><style face="normal" font="Arial"> Hasegawa,Y.</style></author><author><style face="normal" font="Arial"> Yokohama,A.</style></author><author><style face="normal" font="Arial"> Fujino,K.</style></author><author><style face="normal" font="Arial"> Shigeyoshi,M.</style></author><author><style face="normal" font="Arial"> Matsumoto,M.</style></author><author><style face="normal" font="Arial"> Takeshita,A.</style></author><author><style face="normal" font="Arial"> Muroi,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Hematology, Jichi Medical University Hospital, Shimotsuke, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">A national survey of premedication for transfusion reactions in Japan</style></title><secondary-title><style face="normal" font="Arial">Transfus Apher Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfus Apher Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hematology</style></keyword><keyword><style face="normal" font="Arial"> Hydrocortisone</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> Inpatients</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Outpatients</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Platelet Transfusion</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Premedication before transfusion is commonly administered in clinical practice despite a lack of evidence for its efficacy. The aim of this study was to clarify the status of premedication and evaluate expert opinions regarding its use in Japanese medical institutions. METHOD: Between May and July 2016, we conducted a questionnaire survey on premedication before transfusion in 252 medical institutes that were certified by an academic society or employed transfusion experts. RESULTS: A total of 141 institutes (54.2%) responded, and hematologists (n=113) comprised the most frequent respondents. The purpose of premedication was to prevent urticaria, pruritus, and fever, and washed blood products were used for anaphylactic shock or refractory transfusion reactions before. Drugs for premedication were intravenously administered either just before or 30min before transfusion. Both inpatients and outpatients were premedicated in a similar manner, and institutional guidelines were not established. More than half of the experts recognized premedication as efficient and necessary, and premedication for previous transfusion reactions was frequently implemented, particularly for platelet transfusion or in patients with hematological diseases. Some institutions administered one or more drugs for premedication from the first transfusion. Antihistamines and hydrocortisone were the most frequently used as premedication. CONCLUSION: Our study reports the current status of premedication for transfusion in Japan. Antihistamines and hydrocortisone were most commonly used for premedication despite a lack of evidence of their use. These findings may help clarify the indications for premedication and the use of washed blood products</style></abstract><notes><style face="normal" font="Arial">DA - 20170924IS - 1473-0502 (Print)IS - 1473-0502 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.transci.2017.07.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941883">PM:28941883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfus Apher Sci\20170924-FujiwaraSI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfus Apher Sci\20170924-FujiwaraSI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170924, Fujiwara SI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.transci.2017.07.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hirayama,F.</style></author><author><style face="normal" font="Arial"> Yasui,K.</style></author><author><style face="normal" font="Arial"> Matsuyama,N.</style></author><author><style face="normal" font="Arial"> Okamura-Shiki,I.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Possible utility of the basophil activation test for the analysis of mechanisms involved in allergic transfusion reactions</style></title><secondary-title><style face="normal" font="Arial">Transfus Med Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfus Med Rev</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="Arial"> dasatinib</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> effector cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Pilot study</style></keyword><keyword><style face="normal" font="Arial"> Pitfalls</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Reference laboratories</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> transfusion</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0887-7963</style></isbn><abstract><style face="normal" font="Arial">Allergic transfusion reactions (ATRs) are the most common adverse reactions occurring during transfusion of blood components. Although most reactions are mild and involve cutaneous manifestations, severe ATRs including life-threatening anaphylaxis may also occur. The mechanisms of ATRs are largely unknown because they have not been well studied. One of the reasons for this may be the absence of a standard assay system for investigating these processes. Basophils and/or mast cells are key effector cells in immediate-type allergic reactions. They possess the unique ability to degranulate upon cross-linking of specific IgE bound on the membrane-bound, high-affinity IgE receptor or upon direct stimulation by exposure to allergens. Basophils are present in peripheral blood, unlike mast cells which are located in tissues. Therefore, basophils are valuable for the clinical testing of allergy. Consequently, the basophil activation test (BAT) was developed as a simple blood test for the diagnosis of allergic reactions to substances such as foods, inhalants, medicines and venom. In the last decade, the BAT has also been applied to transfusion medicine; 5 pilot studies revealed that the supernatants of the responsible blood products activated basophils in the BAT in 13 ATR cases, suggesting a causal relationship between ATRs and transfusion. In this review, we describe those cases and explore the potential utility of the BAT as a test performed in reference laboratories for the analysis of ATRs. We also describe the weaknesses, pitfalls, and unanswered issues of this assay</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tmrv.2017.09.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29017820">PM:29017820</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfus Med Rev\20171002-HirayamaF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfus Med Rev\20171002-HirayamaF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Hirayama F</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tmrv.2017.09.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vossoughi,S.</style></author><author><style face="normal" font="Arial"> Perez,G.</style></author><author><style face="normal" font="Arial"> Whitaker,B.I.</style></author><author><style face="normal" font="Arial"> Fung,M.K.</style></author><author><style face="normal" font="Arial"> Stotler,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of pediatric adverse reactions to transfusions</style></title><secondary-title><style face="normal" font="Arial">Transfusion</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transfusion</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Transfusion</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> transfusion</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Children are known to be physiologically and biochemically different from adults. However, there are no multi-institutional studies examining the differences in the frequency, type, and severity of transfusion reactions in pediatric versus adult patients. This study aims to characterize differences between pediatric and adult patients regarding adverse responses to transfusions. STUDY DESIGN AND METHODS: This is a retrospective data analysis of nine children's hospitals and 35 adult hospitals from January 2009 through December 2015. Included were pediatric and adult patients who had a reported reaction to transfusion of any blood component. Rates are reported as per 100,000 transfusions for comparison between pediatric and adult patients. RESULTS: Pediatric patients had an overall higher reaction rate compared to adults: 538 versus 252 per 100,000 transfusions, notably higher for red blood cell (577 vs. 278 per 100,000; p &lt; 0.001) and platelet (833 vs. 358 per 100,000; p &lt; 0.001) transfusions. Statistically higher rates of allergic reactions, febrile nonhemolytic reactions, and acute hemolytic reactions were observed in pediatric patients. Adults had a higher rate of delayed serologic transfusion reactions, delayed hemolytic transfusion reactions, and transfusion-associated circulatory overload. CONCLUSION: Pediatric patients had double the rate of transfusion reactions compared to adults. The nationally reported data on reaction rates are consistent with this study's findings in adults but much lower than the observed rates for pediatric patients. Future studies are needed to address the differences in reaction rates, particularly in allergic and febrile reactions, and to further address blood transfusion practices in the pediatric patient population</style></abstract><notes><style face="normal" font="Arial">DA - 20170926IS - 1537-2995 (Electronic)IS - 0041-1132 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/trf.14359</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28948619">PM:28948619</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transfusion\20170926-VossoughiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transfusion\20170926-VossoughiS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170926, Vossoughi S</style></custom2><misc3><style face="normal" font="Arial">10.1111/trf.14359</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cabral-Miranda,G.</style></author><author><style face="normal" font="Arial"> Heath,M.D.</style></author><author><style face="normal" font="Arial"> Gomes,A.C.</style></author><author><style face="normal" font="Arial"> Mohsen,M.O.</style></author><author><style face="normal" font="Arial"> Montoya-Diaz,E.</style></author><author><style face="normal" font="Arial"> Salman,A.M.</style></author><author><style face="normal" font="Arial"> Atcheson,E.</style></author><author><style face="normal" font="Arial"> Skinner,M.A.</style></author><author><style face="normal" font="Arial"> Kramer,M.F.</style></author><author><style face="normal" font="Arial"> Reyes-Sandoval,A.</style></author><author><style face="normal" font="Arial"> Bachmann,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford OX3 7BN, UK.</style></auth-address><titles><title><style face="normal" font="Arial">Microcrystalline Tyrosine (MCT(R)): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria</style></title><secondary-title><style face="normal" font="Arial">Vaccines (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vaccines (Basel)</style></full-title></periodical><pages end="" start="E32">E32-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Biodegradable</style></keyword><keyword><style face="normal" font="Arial"> C57BL/6</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Malaria</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microcrystalline Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Prophylactic vaccines</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">Microcrystalline Tyrosine (MCT(R)) is a widely used proprietary depot excipient in specific immunotherapy for allergy. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against malaria. To this end, we formulated the circumsporozoite protein (CSP) of P. vivax in MCT and compared the induced immune responses to CSP formulated in PBS or Alum. Both MCT and Alum strongly increased immunogenicity of CSP compared to PBS in both C57BL/6 and BALB/c mice. Challenge studies in mice using a chimeric P. bergei expressing CSP of P. vivax demonstrated clinically improved symptoms of malaria with CSP formulated in both MCT and Alum; protection was, however, more pronounced if CSP was formulated in MCT. Hence, MCT may be an attractive biodegradable adjuvant useful for the development of novel prophylactic vaccines</style></abstract><notes><style face="normal" font="Arial">DA - 20170927IS - 2076-393X (Print)IS - 2076-393X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.3390/vaccines5040032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28953265">PM:28953265</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vaccines (Basel)\2017-5-E32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vaccines (Basel)\2017-5-E32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170927, Cabral-Miranda G</style></custom2><misc3><style face="normal" font="Arial">10.3390/vaccines5040032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larenas-Linnemann,D.</style></author><author><style face="normal" font="Arial"> Luna-Pech,J.A.</style></author><author><style face="normal" font="Arial"> Mosges,R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Debates in Allergy Medicine: Allergy skin testing cannot be replaced by molecular diagnosis in the near future</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="32">32-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> molecular diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Selection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Purification</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Percutaneous skin prick tests (SPT) have been considered the preferred method for confirming IgE-mediated sensitization. This reliable and minimally invasive technique correlates with in vivo challenges, has good reproducibility, is easily quantified, and allows analyzing multiple allergens simultaneously. Potent extracts and a proficient tester improve its accuracy.Molecular-based allergy diagnostics (MA-Dx) quantifies allergenic components obtained either from purification of natural sources or recombinant technology to identify the patient's reactivity to those specific allergenic protein components. For a correct allergy diagnosis, the patient selection is crucial. MA-Dx has been shown to have a high specificity, however, as MA-Dx testing can be ordered by any physician, the pre-selection of patients might not always be optimal, reducing test specificity. Also, MA-Dx is less sensitive than in vitro testing with the whole allergen or SPT. Secondly, no allergen-specific immunotherapy (AIT) trial has yet shown efficacy with patients selected on the basis of their MA-Dx results. Thirdly, why would we need molecular diagnosis, as no molecular treatment can yet be offered? Then there are the practical arguments of costs (SPT highly cost-efficient), test availability for MA-Dx still lacking in wide areas of the world and scarce in others. As such, it is hard physicians can build confidence in the test and their interpretation of the MA-Dx results. In conclusion: as of now these techniques should be reserved for situations of complex allergies and polysensitization; in the future MA-Dx might help to reduce the number of allergens for AIT, but trials are needed to prove this concept.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0164-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29043011">PM:29043011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-32.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Larenas-Linnemann D</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0164-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jensen-Jarolim,E.</style></author><author><style face="normal" font="Arial"> Jensen,A.N.</style></author><author><style face="normal" font="Arial"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="Arial">Debates in allergy medicine: Molecular allergy diagnosis with ISAC will replace screenings by skin prick test in the future</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="33">33-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen extract</style></keyword><keyword><style face="normal" font="Arial"> Allergen extracts</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> false positive</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ISAC</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Molecular allergy</style></keyword><keyword><style face="normal" font="Arial"> molecular allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patient Care</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Screening</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Type I allergy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">In today's clinical practice patients' skin is used as screening organ for diagnosing type 1 allergy. According to European guidelines skin prick testing with a panel of 18 allergen extracts is recommended, in the US between 10 to 50 allergens are used. The specificity and sensitivity of skin testing is individually highly variable depending on age, body mass, and skin barrier status. In atopic inflammation skin testing gives more false positive results. Smaller skin area and strain limits prick testing in small children. Although the risk for systemic reactions in skin prick testing is very small, emergency medications must be available. Considering the fact that IgE is the only reliable biomarker for type I allergy, upfront IgE screening with ISAC, followed by fewer skin tests to approve positive sensitizations, is proposed. It is time to arrive in the age of molecular allergy diagnosis in daily patient care</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0162-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959378">PM:28959378</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World Allergy Organ J\2017-10-33.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Jensen-Jarolim E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0162-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martel,B.C.</style></author><author><style face="normal" font="Arial"> Lovato,P.</style></author><author><style face="normal" font="Arial"> Baumer,W.</style></author><author><style face="normal" font="Arial"> Olivry,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">LEO Pharma A/S, Ballerup, Denmark</style></auth-address><titles><title><style face="normal" font="Arial">Translational Animal Models of Atopic Dermatitis for Preclinical Studies</style></title><secondary-title><style face="normal" font="Arial">Yale J Biol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Yale J Biol Med</style></abbr-1></periodical><pages end="402" start="389">389-402</pages><volume><style face="normal" font="Arial">90</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH22</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">There is a medical need to develop new treatments for patients suffering from atopic dermatitis (AD). To improve the discovery and testing of novel treatments, relevant animal models for AD are needed. Generally, these animal models mimic different aspects of the pathophysiology of human AD, such as skin barrier defects and Th2 immune bias with additional Th1 and Th22, and in some populations Th17, activation. However, the pathomechanistic characterization and pharmacological validation of these animal models are generally incomplete. In this paper, we review animal models of AD in the context of preclinical use and their possible translation to the human disease. Most of these models use mice, but we will also critically evaluate dog models of AD, as increasing information on disease mechanism show their likely relevance for the human disease</style></abstract><notes><style face="normal" font="Arial">DA - 20170928IS - 1551-4056 (Electronic)IS - 0044-0086 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28955179">PM:28955179</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Yale J Biol Med\2017-90-389-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Yale J Biol Med\2017-90-389-402.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170928, Martel BC</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jiang,J.J.</style></author><author><style face="normal" font="Arial"> Xie,Y.M.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Yang,Z.X.</style></author><author><style face="normal" font="Arial"> Yi,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Basic Medical Sciences, Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China</style></auth-address><titles><title><style face="normal" font="Arial">[32 546 intensive hospital monitoring cases of Shuxuetong injection]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Zhong Yao Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Zhong Yao Za Zhi</style></full-title></periodical><pages end="3858" start="3852">3852-3858</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly patients</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Headache</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="Arial">This study adopted multi-center and large sample design to understand the incidence, characteristics and other information about adverse reaction of Shuxuetong injection. In 54 medical institutions, use of Shuxuetong injection of entire treatment period was monitored, including patients' general information, diagnostic information, medication, adverse reaction/event information, etc. Sixty four cases of adverse reactions in 32 546 patients was monitored, adverse rate was 0.197%, mainly characterized by skin itching, rash, flu-like, dyspnea, palpitations, headache, chest tightness and other allergic reactions. Adverse reaction occurred mainly in elderly patients and medication was consistent with the instruction. Based on these results, safety of Shuxuetong injection in clinical application is excellent</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1001-5302 (Print)IS - 1001-5302 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.4268/cjcmm20162023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28929666">PM:28929666</url></web-urls></urls><custom2><style face="normal" font="Arial">20170920, Jiang JJ</style></custom2><misc3><style face="normal" font="Arial">10.4268/cjcmm20162023</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gu,Y.Y.</style></author><author><style face="normal" font="Arial"> Zhang,D.D.</style></author><author><style face="normal" font="Arial"> Feng,C.</style></author><author><style face="normal" font="Arial"> Wang,Y.</style></author><author><style face="normal" font="Arial"> Chen,D.Z.</style></author><author><style face="normal" font="Arial"> Wang,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Traditional Chinese Medicine, Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, China</style></auth-address><titles><title><style face="normal" font="Arial">[Metabolomics of bovine serum albumin-induced allergic reactions based on UPLC-Q-TOF-MS]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Zhong Yao Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Zhong Yao Za Zhi</style></full-title></periodical><pages end="4035" start="4029">4029-4035</pages><volume><style face="normal" font="Arial">41</style></volume><number><style face="normal" font="Arial">21</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">albumin</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> folic acid</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> Metabolomics</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum Albumin</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Trachea</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Tryptophan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> urine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="Arial">The metabonomic techniques were used to study the changes in endogenous metabolites between urines of rats in normal physiological conditions and bovine serum albumin induced allergic reactions, identify potential biomarkers associated with allergic reactions, and then analyze the metabolic pathways and the metabolic mechanisms of allergic reactions. The bovine serum albumin-induced allergic reactions in rats were adopted as a model to detect histamine and tryptase in rat serum and observe the issue morphology of lungs and trachea in rats. UPLC-Q-TOF-MS was applied in metabonomic analysis on urines between control group and allergic reaction model group. Principal component analysis(PCA) and partial least squares discriminant analysis(PLS-DA) were applied to observe the differences in metabolic profiling between urines of the two groups and select differential metabolites. There were significant differences in metabolism spectrum between the model group and the control group. Totally 14 differential metabolites and 4 major metabolic pathways were screened out. The metabonomic research method for urines of rats with bovine serum albumin-induced allergic reactions based on UPLC-Q-TOF-MS was established in this study. It was speculated that the mechanism of bovine serum albumin-induced allergic reactions may involve biosynthesis of isoflavone and folic acid and metabolism of tryptophan, nicotinic acid and nicotinamide. It lays a foundation for further exploration of the application of metabolomics in drug allergy reaction studies</style></abstract><notes><style face="normal" font="Arial">DA - 20170920IS - 1001-5302 (Print)IS - 1001-5302 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.4268/cjcmm20162123</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28929692">PM:28929692</url></web-urls></urls><custom2><style face="normal" font="Arial">20170920, Gu YY</style></custom2><misc3><style face="normal" font="Arial">10.4268/cjcmm20162123</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ma,T.T.</style></author><author><style face="normal" font="Arial"> Feng,X.Z.</style></author><author><style face="normal" font="Arial"> Wang,X.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergic Consulting Department, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effects and mechanism of Angelicae Sinensis Radix on Th1/Th2 and Th17/Treg in mice with asthma and Yin deficiency syndrome]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Zhong Yao Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Zhong Yao Za Zhi</style></full-title></periodical><pages end="762" start="758">758-762</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Angelica</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Circulation</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Medicine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="Arial">Angelicae Sinensis Radix, with nourishing Yin, promoting blood circulation, and moisturizing dryness functions, is commonly used in clinical medicine. In order to investigate the effects and mechanism of Angelica sinensis(AS) on Th1/Th2 and Th17/Treg in mice with asthma and Yin deficiency syndrome, asthmatic and Yin deficiency syndrome Balb/c mice models were established by injecting and inhaling ovalbumin(OVA) and thyroxin. The models were treated with dexamethasone(DXM), AS extract and AS extract+DXM, respectively. Pathological examination of lung tissues was conducted by HE staining, and ELISA was used to detect the levels of IL-4, IL-17, IFN-gamma, TGF-beta as well as retinoic acid receptor-related orphan receptor (RORgammat). Results showed that AS could significantly improve the situation of inflammation infiltration, increase ratios of IFN-gamma/IL-4 and TGF-beta/IL-17, decrease the levels of RORgammat in lung tissues. The AS+DXM group showed a best treatment effect. The results indicated that AS played a therapeutic role for asthma with Yin deficiency syndrome and improved airway inflammation by inhibiting the expression of RORgammat in lung tissues and regulating the balance of Th1/Th2 and Th17/Treg</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1001-5302 (Print)IS - 1001-5302 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.19540/j.cnki.cjcmm.20170121.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959849">PM:28959849</url></web-urls></urls><custom2><style face="normal" font="Arial">20170929, Ma TT</style></custom2><misc3><style face="normal" font="Arial">10.19540/j.cnki.cjcmm.20170121.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,S.</style></author><author><style face="normal" font="Arial"> Jiang,Y.</style></author><author><style face="normal" font="Arial"> Jin,Y.M.</style></author><author><style face="normal" font="Arial"> Zhang,J.Y.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China</style></auth-address><titles><title><style face="normal" font="Arial">[Characteristics of allergic conjunctivitis with positive skin prick test]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Yan Ke Za Zhi</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Zhonghua Yan Ke Za Zhi</style></abbr-1></periodical><pages end="693" start="689">689-693</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Homogeneity</style></keyword><keyword><style face="normal" font="Arial"> Hyperemia</style></keyword><keyword><style face="normal" font="Arial"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> main allergens</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ophthalmology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> perennial allergic</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Spearman correlation</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Vernal keratoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">Objective: To observe the clinical characteristics of allergic conjunctivitis, and the correlations with skin prick test results. Methods: A retrospective study. Forty patients with positive skin prick test result were included. Patients underwent an ophthalmologic examination to identify their primary presenting signs and symptoms. The allergy types were divided into 5 groups. All dates were analyzed for the dependence, normality and homogeneity of variance. Chi-square test, Mann-Whitney U test, Kruskal-Wallis H test and Spearman correlation analysis were performed accordingly. Results: Among 40 patients, 18(45.0%) had a clinical diagnosis of seasonal allergic conjunctivitis, 14(35.0%) had perennial allergic conjunctivitis, 5(12.5%) had vernal keratoconjunctivitis, and 2(5.0%) had atopic keratoconjunctivits, and 1(2.5%) had giant papillary conjunctivitis. There was no significant difference in the number of symptoms and signs score among different types of allergic conjunctivitis, the score of itching and hyperemia had a positive relationship with the number of positive allergens (r=0.74, P&lt;0.05. r=0.96, P&lt;0.05). The primary symptoms and signs are itching and hyperemia; dust and pollens are the most common allergens. The more positive result of the test of the allergen, the more symptoms and signs encountered in terms of severity. Conclusion: Seasonal allergic conjunctivitis was the most prevalent disorder, the most important clinical characteristics of allergic conjunctivitis are itching and conjunctival congestion, the main allergens are dust and pollens, patients may be sensitive to multiple allergens. (Chin J Ophthalmol, 2017, 53: 689-693)</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 0412-4081 (Print)IS - 0412-4081 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.0412-4081.2017.09.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28926887">PM:28926887</url></web-urls></urls><custom2><style face="normal" font="Arial">20170919, Yang S</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.0412-4081.2017.09.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yamada,K.</style></author><author><style face="normal" font="Arial"> Matsushita,K.</style></author><author><style face="normal" font="Arial"> Jingshu,W.</style></author><author><style face="normal" font="Arial"> Kanekura,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, 890-8520 Kagoshima, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Topical Glucose Induces Claudin-1 and Filaggrin Expression in a Mouse Model of Atopic Dermatitis and in Keratinocyte Culture, Exerting Anti-inflammatory Effects by Repairing Skin Barrier Function</style></title><secondary-title><style face="normal" font="Arial">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Derm Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> barrier function</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Claudin-1</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> costimulation</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> Glucose</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> keratinocyte</style></keyword><keyword><style face="normal" font="Arial"> Keratinocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> skin barrier function</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> thymus and activation-regulated chemokine</style></keyword><keyword><style face="normal" font="Arial"> topical treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="10" Year="2017">2017/10/2</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic inflammatory skin disease. Corticosteroids, which are widely used for AD treatment, have adverse effects, and alternative treatments are urgently needed. This study examined the effect of topical application of high-dose glucose on inflamed skin in a murine model of AD. High-dose glucose treatment on the ear reduced dermatitis scores and ear thicknesses in mite antigen-treated NC/Nga mice. The levels of thymus and activation-regulated chemokine (TARC), Th cytokines (interleukin (IL)-4, IL-5, IL-12, IL-13, and (interferon) IFN-gamma), and IgE were decreased in the serum of high-dose glucose-treated mice. Expression of claudin-1 and filaggrin was reduced in the ear epithelium in the NC/Nga mice. However, the reduced expression was restored by topical treatment with high-dose glucose. High-dose glucose also induced the expression of claudin-1 and filaggrin in cultured human skin keratinocytes. Co-stimulation with IL-4, IL-13, and thymic stromal lymphoprotein (TSLP) downregulated the expression of filaggrin in culture. However, high-dose glucose treatment restored the reduced expression of filaggrin. These results suggest that high-dose glucose treatment suppresses inflammation in the skin lesions by improving the skin barrier function</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2340/00015555-2807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967978">PM:28967978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Derm Venereol\20171002-YamadaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Derm Venereol\20171002-YamadaK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Yamada K</style></custom2><misc3><style face="normal" font="Arial">10.2340/00015555-2807</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Balta,C.S.</style></author><author><style face="normal" font="Arial"> Moreno,R.N.</style></author><author><style face="normal" font="Arial"> Estrach Panella,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departamento de Dermatologia, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Espana.</style></auth-address><titles><title><style face="normal" font="Arial">Prospective Single-Center Observational Study of the Allergenic Potential of Mercromina Film and Other Common Antiseptics in Patients With Contact Dermatitis</style></title><secondary-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Actas Dermosifiliogr</style></full-title></periodical><pages end="22" start="21">21-22</pages><volume><style face="normal" font="Arial">45</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antiseptics</style></keyword><keyword><style face="normal" font="Arial"> Chlorhexidine</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch Tests</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patch-tests</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Povidone-Iodine</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin allergy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Although Mercromina Film and other topical antiseptics are widely used, they are not included in the standard series recommended by the Spanish Contact Dermatitis and Skin Allergy Research Group for testing suspected allergic contact dermatitis (ACD). Furthermore, no recent studies have investigated the allergenic potential of merbromin. OBJECTIVE: To determine the allergenic potential of merbromin and compare it with that of other topical antiseptics widely used in clinical practice, including povidone-iodine, chlorhexidine, and eosin. MATERIAL AND METHODS: Prospective single-center observational safety study of 105 patients with suspected ACD seen at the dermatology department of our hospital. RESULTS: Of the 105 patients studied, 1.9% had a positive patch test to merbromin and 12.4% were sensitized to povidone-iodine. The differences in the proportion of patients with ACD to Betadine Solucion Dermica (povidone-iodine) compared with the rest of the antiseptics was statistically significant (McNemar test, P&lt;.05). No adverse reactions were observed in any of the patients. CONCLUSIONS: Based on the patch tests conducted, Mercromina Film has very low allergenic potential. The highest allergenic potential was observed for povidone-iodine</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ad.2017.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28969846">PM:28969846</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20171003, Balta CS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ad.2017.06.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pusz,W.</style></author><author><style face="normal" font="Arial"> Krol,M.</style></author><author><style face="normal" font="Arial"> Zwijacz-Kozica,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Airborne fungi as indicators of ecosystem disturbance: an example from selected Tatra Mountains caves (Poland)</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agar</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne fungi</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus niger</style></keyword><keyword><style face="normal" font="Arial"> Cladosporium</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Culture Media</style></keyword><keyword><style face="normal" font="Arial"> Culture medium</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Ecosystem</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Potato</style></keyword><keyword><style face="normal" font="Arial"> Rhizoctonia</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spore concentration</style></keyword><keyword><style face="normal" font="Arial"> Stachybotrys</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">We report on the determination of the spore concentration and the species composition of the airborne fungi in selected caves of the Tatra Mountains, Poland. The following caves were surveyed: Mylna, Ob+éazkowa, Mro+¦na, Zimna and Naciekowa. The sampling was carried out in July 2015 and in January 2016. The aeromycological analyses were performed with the impact method, using the Air Ideal 3P apparatus and potato dextrose agar (PDA, Biocorp) culture medium. In the course of the July 2015 analysis, 17 species of fungi were isolated and 11 species were isolated in January 2016. In Mylna and Naciekowa caves, the dominant species were Cladosporium cladosporioides and Stachybotrys cylindrospora. In Ob+éazkowa cave, Rhizoctonia predominated and in Zimna cave</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çöthe colonies of the yeast-like fungi, along with S. cylindrospora. In Mro+¦na cave, Penicillium notatum was the most abundant taxon. In the winter time, in the majority of the caves Penicillium spp. predominated, with the exception of Mro+¦na and Naciekowa caves where Aspergillus niger was dominant. We propose that aeromycological monitoring be performed regularly in the following caves: Mro+¦na, Naciekowa and Zimna</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9498-y</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10453-017-9498-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20171015-PuszW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20171015-PuszW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Pusz W</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9498-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yanase,Y.</style></author><author><style face="normal" font="Arial"> Takahagi,S.</style></author><author><style face="normal" font="Arial"> Hide,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Institute of Biomedical &amp; Health Sciences, Hiroshima University, Hiroshima, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Chronic spontaneous urticaria and the extrinsic coagulation system</style></title><secondary-title><style face="normal" font="Arial">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Coagulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Coagulation pathway</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> endothelial cells</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Extrinsic</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> H1 receptor</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> histamine H1 receptor</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="Arial">Chronic spontaneous urticaria (CSU) is a common skin disorder characterized by daily or almost daily recurring skin edema and flare with itch. Recently, the activation of the blood coagulation cascade has been suggested to be involved in CSU, but the trigger of the coagulation cascade remains unclear. In this article, we review recent understanding of the relationship between the pathogenesis of CSU and extrinsic coagulation reactions. In CSU, vascular endothelial cells and eosinophils may play a role as TF-expressing cells for activating the extrinsic coagulation pathway. Moreover, the expression of TF on endothelial cells is synergistically enhanced by the activation of Toll-like receptors and histamine H1 receptors. The activated coagulation factors may induce plasma extravasation followed by degranulation of skin mast cells and edema formation recognized as wheal in CSU. Molecules involved in this cascade could be a target for new and more effective treatments of urticaria</style></abstract><notes><style face="normal" font="Arial">DA - 20171010IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.alit.2017.09.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28993062">PM:28993062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20171010-YanaseY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20171010-YanaseY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Yanase Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.alit.2017.09.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Eguiluz-Gracia,I.</style></author><author><style face="normal" font="Arial"> Gayraud,J.</style></author><author><style face="normal" font="Arial"> Gutermuth,J.</style></author><author><style face="normal" font="Arial"> Hamelmann,E.</style></author><author><style face="normal" font="Arial"> Heffler,E.</style></author><author><style face="normal" font="Arial"> Popov,T.A.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Tomazic,P.V.</style></author><author><style face="normal" font="Arial"> Tsilochistrou,O.</style></author><author><style face="normal" font="Arial"> Muelleneisen,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Section of Allergology, dept. of Internal Medicine, Erasmus MC, Rotterdam, the NetherlandsAllergy Unit and Research Laboratory, Regional University Hospital of Malaga and Biomedical Research Institute of Malaga (IBIMA). Malaga, Spain</style></auth-address><titles><title><style face="normal" font="Arial">The roadmap for Allergology in Europe: the subspecialty of Allergology as 'stop-over' on the way to a full specialty. An EAACI position statement</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Research</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">The vision of EAACI and the UEMS Section and Board (S&amp;B) on allergology is to promote and to establish a full specialty of allergology in all European countries. In many European countries a full specialty does not exist. In those countries organ-based (sub)specialists or paediatricians and internists with an expertise in allergology may deliver allergy care. There are no generally accepted requirements for the training of subspecialists available. To fill the gap between the need and availability of experienced and accredited physicians who can deliver optimal care to the allergic patients the EAACI Specialty Committee proposes the minimal requirements for training and certification of subspecialists in allergology. This paper describes the required theoretical knowledge, skills, competences and training facilities (staff and institution). The subspecialist as described in this paper should ideally show the necessary competence in providing good quality care to patients in an environment lacking those full specialists in allergology or tertiary care paediatric subspecialists in allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Spain -CO - France -CO - Belgium -CO - Germany -CO - Bulgaria -CO - Switzerland -CO - Austria -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13321</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960379">PM:28960379</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170929-GerthvanWijkR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170929-GerthvanWijkR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Gerth van Wijk R</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13321</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Datema,M.R.</style></author><author><style face="normal" font="Arial"> van Ree,R.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author><author><style face="normal" font="Arial"> Barreales,L.</style></author><author><style face="normal" font="Arial"> Belohlavkova,S.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Clausen,M.</style></author><author><style face="normal" font="Arial"> Dubakiene,R.</style></author><author><style face="normal" font="Arial"> Fernandez-Perez,C.</style></author><author><style face="normal" font="Arial"> Fritsche,P.</style></author><author><style face="normal" font="Arial"> Gislason,D.</style></author><author><style face="normal" font="Arial"> Hoffmann-Sommergruber,K.</style></author><author><style face="normal" font="Arial"> Jedrzejczak-Czechowicz,M.</style></author><author><style face="normal" font="Arial"> Jongejan,L.</style></author><author><style face="normal" font="Arial"> Knulst,A.C.</style></author><author><style face="normal" font="Arial"> Kowalski,M.</style></author><author><style face="normal" font="Arial"> Kralimarkova,T.Z.</style></author><author><style face="normal" font="Arial"> Le,T.M.</style></author><author><style face="normal" font="Arial"> Lidholm,J.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Popov,T.A.</style></author><author><style face="normal" font="Arial"> Del Prado,N.</style></author><author><style face="normal" font="Arial"> Purohit,A.</style></author><author><style face="normal" font="Arial"> Reig,I.</style></author><author><style face="normal" font="Arial"> Seneviratne,S.L.</style></author><author><style face="normal" font="Arial"> Sinaniotis,A.</style></author><author><style face="normal" font="Arial"> Versteeg,S.A.</style></author><author><style face="normal" font="Arial"> Vieths,S.</style></author><author><style face="normal" font="Arial"> Zwinderman,A.H.</style></author><author><style face="normal" font="Arial"> Clare Mills,E.N.</style></author><author><style face="normal" font="Arial"> Fernandez-Rivas,M.</style></author><author><style face="normal" font="Arial"> Ballmer-Weber,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Academic Medical Center, Department of Experimental Immunology, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">CRD and beyond: multivariable regression models to predict severity of hazelnut allergy</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bulgaria</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> Component resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Cor a 1</style></keyword><keyword><style face="normal" font="Arial"> Cor a 14</style></keyword><keyword><style face="normal" font="Arial"> Cor a 9</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> DBPCFC</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut allergy</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serology</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Walnut</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Component-resolved diagnosis (CRD) has revealed significant associations between IgE against individual allergens and severity of hazelnut allergy. Less attention has been given to combining them with clinical factors in predicting severity. AIM: To analyze associations between severity and sensitization patterns, patient characteristics and clinical history, and to develop models to improve predictive accuracy. METHODS: Patients reporting hazelnut allergy (n=423) from 12 European cities were tested for IgE against individual hazelnut allergens. Symptoms (reported and during DBPCFC) were categorized in mild, moderate and severe. Multiple regression models to predict severity were generated from clinical factors and sensitization patterns (CRD- and extract-based). Odds ratios (OR) and areas under receiver operating characteristic (ROC) curves (AUC) were used to evaluate their predictive value. RESULTS: Cor a 9 and 14 were positively (OR 10.5 and 10.1 respectively), and Cor a 1 negatively (OR 0.14) associated with severe symptoms during DBPCFC, with AUCs of 0.70-073. Combining Cor a 1 and 9 improved this to 0.76. A model using a combination of atopic dermatitis (risk), pollen allergy (protection), IgE against Cor a 14 (risk) and walnut (risk), increased the AUC to 0.91. At 92% sensitivity, the specificity was 76.3% and the positive and negative predictive values 62.2% and 95.7%, respectively. For reported symptoms, associations and generated models proved to be almost identical but weaker. CONCLUSION: A model combining CRD with clinical background and extract-based serology is superior to CRD alone in assessing the risk of severe reactions to hazelnut, particular in ruling out severe reactions. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171007IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Italy -CO - Spain -CO - Czech Republic -CO - France -CO - Iceland -CO - Lithuania -CO - Switzerland -CO - Austria -CO - Poland -CO - Bulgaria -CO - Sweden -CO - Greece -CO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13328</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28986984">PM:28986984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20171007-DatemaMR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20171007-DatemaMR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171007, Datema MR</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13328</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Suojalehto,H.</style></author><author><style face="normal" font="Arial"> Lindstrom,I.</style></author><author><style face="normal" font="Arial"> Wolff,H.</style></author><author><style face="normal" font="Arial"> Puustinen,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Nasal protein profiles in work-related asthma caused by different exposures</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Complement Activation</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> hierarchical clustering</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Isocyanates</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Health</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> S100A9</style></keyword><keyword><style face="normal" font="Arial"> Signalling</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> Two-Dimensional Difference Gel Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword><keyword><style face="normal" font="Arial"> work-related asthma</style></keyword></keywords><dates><year Day="28" Month="9" Year="2017">2017/9/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The mechanisms of work-related asthma are incompletely delineated. Nasal cell samples may be informative about processes in the lower airways. Our aim was to determine the nasal protein expression profiles of work-related asthma caused by different kind of exposures. METHODS: We collected nasal brush samples from 82 non-smoking participants, including healthy controls and work-related asthma patients exposed to 1) protein allergens, 2) isocyanates, and 3) welding fumes the day after relevant exposure. The proteome changes in samples were analysed by two-dimensional difference gel electrophoresis and the differentially regulated proteins found were identified by mass spectrometry. Immunological comparison was carried out using Western blot. RESULTS: We detected an average of 2500 spots per protein gel. Altogether 228 protein spots were chosen for identification, yielding 77 different proteins. Compared to the controls exposure to protein allergens had the largest effects on the proteome. Hierarchical clustering revealed that protein allergen and isocyanate related asthma had similar profiles, whereas asthma related to welding fumes differed. The highly overrepresented functional categories in the asthma groups were defence response, protease inhibitor activity, inflammatory and calcium signalling, complement activation, and cellular response to oxidative stress. Immunological analysis confirmed the found abundance differences in Galectin 10 and Protein S100-A9 between the groups. CONCLUSIONS: Work-related asthma patients exposed to protein allergens and isocyanates elicit similar nasal proteome responses and the profiles of welders and healthy controls were alike. Revealed biological activities of the protein expression changes are associated with allergic inflammation and asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13325</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960398">PM:28960398</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170929-SuojalehtoH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170929-SuojalehtoH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Suojalehto H</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13325</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Keller,T.</style></author><author><style face="normal" font="Arial"> Hohmann,C.</style></author><author><style face="normal" font="Arial"> Standl,M.</style></author><author><style face="normal" font="Arial"> Wijga,A.H.</style></author><author><style face="normal" font="Arial"> Gehring,U.</style></author><author><style face="normal" font="Arial"> Melen,E.</style></author><author><style face="normal" font="Arial"> Almqvist,C.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Eller,E.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Christiansen,E.S.</style></author><author><style face="normal" font="Arial"> Berg,V.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Lehmann,I.</style></author><author><style face="normal" font="Arial"> Maier,D.</style></author><author><style face="normal" font="Arial"> Postma,D.S.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Bousquet,J.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Roll,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Social Medicine, Epidemiology and Health Economics, Charite - Universitatsmedizin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">The sex-shift in single disease and multimorbid asthma and rhinitis during puberty</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> puberty</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum antibodies</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cross-sectional studies suggested that allergy prevalence in childhood is higher in boys compared to girls, but it remains unclear if this inequality changes after puberty. We examined the sex-specific prevalence of asthma and rhinitis as single and as multimorbid diseases before and after puberty-onset in longitudinal cohort data. METHODS: In six European population-based birth cohort studies we assessed the outcomes current rhinitis, current asthma, current allergic multimorbidity (i.e. concurrent asthma and rhinitis), puberty status, and allergic sensitization by specific serum antibodies (immunoglobulin E) against aero-allergens. With generalized estimating equations we analysed the effects of sex, age, puberty (yes/no), and possible confounders on the prevalence of asthma and rhinitis, and allergic multimorbidity in each cohort separately and performed individual participant data meta-analysis. FINDINGS: We included data from 19,013 participants from birth to age 14-20 years. Current rhinitis only affected girls less often than boys before and after puberty onset: adjusted odds ratio for females vs. males 0.79 (95%-confidence interval 0.73-0.86) and 0.86 (0.79-0.94) respectively (sex-puberty interaction p= 0.089). Similarly, for current asthma only, females were less often affected than boys both before and after puberty-onset: 0.71, 0.63-0.81 and 0.81, 0.64-1.02, respectively (sex-puberty interaction p=0.327). The prevalence of allergic multimorbidity showed the strongest sex-effect before puberty onset (female-male-OR 0.55, 0.46-0.64) and a considerable shift towards a sex-balanced prevalence after puberty onset (0.89, 0.74-1.04); sex-puberty interaction: p&lt;0.001. INTERPRETATION: The male predominance in prevalence before puberty and the 'sex-shift' towards females after puberty-onset was strongest in multimorbid patients who had asthma and rhinitis concurrently. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Sweden -CO - Netherlands -CO - Denmark -CO - Spain -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13312</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960325">PM:28960325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170929-KellerT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170929-KellerT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Keller T</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13312</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abuabara,K.</style></author><author><style face="normal" font="Arial"> Yu,A.M.</style></author><author><style face="normal" font="Arial"> Okhovat,J.P.</style></author><author><style face="normal" font="Arial"> Allen,E.</style></author><author><style face="normal" font="Arial"> Langan,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Program in Clinical Research, Department of Dermatology, University of California San Francisco (UCSF)</style></auth-address><titles><title><style face="normal" font="Arial">The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> San Francisco</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">There are sparse and conflicting data regarding the long-term clinical course of atopic dermatitis (AD). Although often described as a primarily childhood disease, newer population-based estimates suggest the prevalence of pediatric and adult disease may be similar. Our objective was to determine whether there is a decline in the prevalence of AD in population-based cohorts of patients followed longitudinally beyond childhood. We conducted a systematic review and meta-analysis including studies assessing AD prevalence across 3 or more points in time. The primary outcome was weighted overall risk difference (percentage decrease in AD prevalence). Of 2,080 references reviewed, 7 studies with 13,515 participants were included. Participants were assessed at 3-6 time points, ranging from age 3 months to 26 years. The percentage decrease in prevalence after age 12 was 1%, which was not significantly different from zero (95% confidence interval -2% to 5%). Similar results were found with other age cut-offs. In conclusion, the prevalence of AD in longitudinal birth cohort studies is similar in childhood and early adulthood. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13320</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960336">PM:28960336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20170929-AbuabaraK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20170929-AbuabaraK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Abuabara K</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13320</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zurzolo,G.A.</style></author><author><style face="normal" font="Arial"> Peters,R.L.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author><author><style face="normal" font="Arial"> de Court</style></author><author><style face="normal" font="Arial"> Mathai,M.L.</style></author><author><style face="normal" font="Arial"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Are food allergic consumers ready for informative precautionary allergen labelling?</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="42">42-</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic consumer</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> colour</style></keyword><keyword><style face="normal" font="Arial"> Confusion</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergic consumers</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mobile phone</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perception</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Precautionary allergen labelling (PAL) has resulted in consumer confusion. Previous research has shown that interpretive labels (using graphics, symbols, or colours) are better understood than the traditional forms of labels. In this study, we aimed to understand if consumers would use interpretive labels (symbol, mobile phone application and a toll-free number) with or without medical advice that was advocated by the food industry rather than the normal PAL. This is relevant information for industry and clinicians as it provides an insight into the food allergic perception regarding PAL</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0214-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033984">PM:29033984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\20171016-ZurzoloGA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\20171016-ZurzoloGA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Zurzolo GA</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0214-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,P.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Wu,Z.</style></author><author><style face="normal" font="Arial"> Wen,X.</style></author><author><style face="normal" font="Arial"> Li,L.</style></author><author><style face="normal" font="Arial"> Zhang,S.</style></author><author><style face="normal" font="Arial"> Xu,Y.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Adult reference intervals for IgG subclasses with Siemens immunonephelometric assays in Chinese population</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy Asthma Clin Immunol</style></abbr-1></periodical><pages end="" start="44">44-</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1710-1492</style></isbn><abstract><style face="normal" font="Arial">To determine the adult reference intervals for the Siemens IgG subclass reagents</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13223-017-0216-7</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s13223-017-0216-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\20171016-LiP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\20171016-LiP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Li P</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13223-017-0216-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yuan,X.</style></author><author><style face="normal" font="Arial"> Wang,E.</style></author><author><style face="normal" font="Arial"> Xiao,X.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Yang,P.</style></author><author><style face="normal" font="Arial"> Li,G.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inflammation &amp; Allergic Disease Lab, Affiliated Hospital of Southwest Medical CollegeLuzhou 646000, Sichuan, China</style></auth-address><titles><title><style face="normal" font="Arial">The role of IL-25 in the reduction of oxidative stress and the apoptosis of airway epithelial cells with specific immunotherapy in an asthma mouse model</style></title><secondary-title><style face="normal" font="Arial">Am J Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Transl Res</style></full-title></periodical><pages end="4148" start="4137">4137-4148</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-25</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> malondialdehyde</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oxidation</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Oxidative stress and cell apoptosis play important roles in the pathogenesis of asthma. Specific immunotherapy (SIT) is the only curative approach for asthma and is effective at decreasing asthmatic oxidation and cell apoptosis, but the mechanisms remain unclear. In this study, by using in vivo and in vitro models, we indirectly demonstrated that SIT alleviated the apoptosis and oxidative stress of bronchial epithelial cells in an asthma model through regulating interleukin (IL)-25. Female BALB/c mice were used for an asthma model induced by exposure to house dust mite (HDM) extracts as allergens. Prior to the challenge, the mice were either given the SIT vaccine or N-Acetyl-L-cysteine (NAC). RESULTS: Compared with that in asthma models, SIT administration decreased (1) airway hyper-responsiveness; (2) the production of cytokines, including IL-4, IL-5, IL-13, and IL-25, as well as serum HDM-specific IgE and IgG1, as shown by ELISA; and (3) lipid oxidative species, such as reactive oxidative species (ROS) and malondialdehyde (MDA), in the lung tissue. Moreover, TUNEL staining showed that SIT alleviated pulmonary cell apoptosis. In vitro, flow cytometry showed that human recombinant IL-25 (rIL-25) led to increased cell apoptosis and ROS in the human epithelial cell line 16HBE in a dose and time-dependent fashion. In conclusion, in vivo, SIT reduced asthmatic Th2 cytokine levels and the production of IL-25 and alleviated oxidative stress and cell apoptosis in the lung tissue. In vitro, IL-25 increased the number of apoptotic cells and the production of ROS in16HBE cells</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 1943-8141 (Print)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28979688">PM:28979688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Transl Res\2017-9-4137-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Transl Res\2017-9-4137-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171005, Yuan X</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">van der Valk,J.P.M.</style></author><author><style face="normal" font="Arial"> Berends,I.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.</style></author><author><style face="normal" font="Arial"> Arends,N.J.T.</style></author><author><style face="normal" font="Arial"> van Maaren,M.S.</style></author><author><style face="normal" font="Arial"> de Groot,H.</style></author><author><style face="normal" font="Arial"> Wichers,H.J.</style></author><author><style face="normal" font="Arial"> Emons,J.A.M.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.J.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Internal Medicine, Allergology, Erasmus Medical Center, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="Arial">Small percentage of anaphylactic reactions treated with epinephrine during food challenges in Dutch children</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Associated factors</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cashew</style></keyword><keyword><style face="normal" font="Arial"> cashew nut</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Hazelnut</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Severe allergic reactions, including anaphylaxis, occur during oral food challenges (OFCs) and the first-line treatment of anaphylaxis is epinephrine. OBJECTIVE: To evaluate the percentage of anaphylactic reactions treated with epinephrine during OFCs and to identify associated factors for the administration of epinephrine. METHODS: Children who underwent an OFC with peanut, hazelnut, cow's milk, hen's egg, or cashew nut from 2005 through 2015 in the Netherlands were evaluated. Children with reactions meeting the criteria for anaphylaxis according to the European Academy of Allergy and Clinical Immunology guidelines for food allergy and anaphylaxis were included. Children with an anaphylactic reaction treated with vs without epinephrine were compared. Possible factors associated with the administration of epinephrine, such as age, sex, symptoms consistent with asthma, history of an allergic reaction to the tested allergen, and symptom types during the anaphylactic reaction, were evaluated using logistic regression analysis. RESULTS: Eighty-three children in clinical and research settings (43% boys; median age, 7 years; range, 1-17) who met the criteria for anaphylaxis were included in this study. Thirty-two of 83 children (39%) with anaphylaxis were treated with epinephrine. Respiratory symptoms during the OFC were treated significantly more often with epinephrine than gastrointestinal symptoms (P = .01). CONCLUSION: Only 39% of children with anaphylaxis, according to the guideline criteria, were treated with epinephrine during the OFC and most of these children had respiratory symptoms. There is need for an easy-to-use international guideline for the treatment of allergic symptoms during OFCs</style></abstract><notes><style face="normal" font="Arial">DA - 20171011IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.08.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29017902">PM:29017902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20171011-vanderValkJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20171011-vanderValkJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171011, van der Valk JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.08.018</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,J.H.</style></author><author><style face="normal" font="Arial"> Jeon,Y.J.</style></author><author><style face="normal" font="Arial"> Choi,J.H.</style></author><author><style face="normal" font="Arial"> Kim,H.Y.</style></author><author><style face="normal" font="Arial"> Kim,T.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Effects of VitabridC12 on Skin Inflammation</style></title><secondary-title><style face="normal" font="Arial">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Dermatol</style></abbr-1></periodical><pages end="558" start="548">548-558</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> extracellular signal-regulated kinase</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin C</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: VitabridC12 is newly developed and composed of vitamin C and Vitabrid (lamellar, hydrated zinc oxide). OBJECTIVE: In this study, we aimed to investigate the effects of VitabridC12 on psoriasis and atopic dermatitis. METHODS: Mice with imiquimod-induced psoriasis or Dermatophagoides farinae-induced atopic dermatitis were applied with VitabridC12. The effects of VitabridC12 were evaluated by clinical features, histology, and immunologic features by examining cytokines and chemokines. RESULTS: In psoriasis model, VitabridC12 decreased epidermal thickness and reduced inflammatory cell infiltration. In atopic dermatitis model, VitabridC12 decreased dermal infiltration of inflammatory cells, epidermal hyperplasia, and hyperkeratosis. VitabridC12 reduced the expression levels of proinflammatory mediators such as interleukin (IL)-1beta, IL-6, IL-8, IL-17A, IL-22, tumor necrosis factor-alpha, CXCL1, CCL17, and CCL20 as well as COX-2 in imiquimod-induced psoriatic skin lesions. Likewise, VitabridC12 reduced the expression levels of IL-4, IL-5, IL-13, thymic stromal lymphopoietin, and CCL4 in D. farinae-induced skin lesions, and decreased the serum immunoglobulin E level in the atopic dermatitis mouse model. Particularly, the VitabridC12-treated mice showed downregulated expressions of mitogen-activated protein kinase (MAPK), including extracellular signal-regulated kinase (ERK), p38, and MAPK/ERK kinase, as well as inhibited phosphorylation of nuclear factor-kappaB p65. CONCLUSION: Taken together, these findings indicate that VitabridC12 exhibits anti-inflammatory activities and is a promising candidate as a treatment option for psoriasis or atopic dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.5021/ad.2017.29.5.548</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28966510">PM:28966510</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Dermatol\2017-29-548-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Dermatol\2017-29-548-58.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Lee JH</style></custom2><misc3><style face="normal" font="Arial">10.5021/ad.2017.29.5.548</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Newton,A.N.</style></author><author><style face="normal" font="Arial"> Davis,M.</style></author><author><style face="normal" font="Arial"> Koehler,K.</style></author><author><style face="normal" font="Arial"> Shreffler,W.</style></author><author><style face="normal" font="Arial"> Ahluwalia,S.</style></author><author><style face="normal" font="Arial"> Metwali,N.</style></author><author><style face="normal" font="Arial"> Thorne,P.S.</style></author><author><style face="normal" font="Arial"> Paigen,B.J.</style></author><author><style face="normal" font="Arial"> Matsui,E.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health</style></auth-address><titles><title><style face="normal" font="Arial">Atopy as a Modifier of the Relationships Between Endotoxin Exposure and Symptoms Among Laboratory Animal Workers</style></title><secondary-title><style face="normal" font="Arial">Ann Work Expo Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Work Expo Health</style></abbr-1></periodical><pages end="1028" start="1024">1024-1028</pages><volume><style face="normal" font="Arial">61</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotoxin</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="Arial">Background: Exposure to endotoxin is known to trigger airway inflammation and symptoms, and atopy may modify the relationship between endotoxin exposure and symptom development. Objective: To test the a priori hypothesis that atopic status modifies the relationship between endotoxin exposure and respiratory symptom development. Methods: A prospective study of laboratory workers at The Jackson Laboratories was conducted. Allergy skin testing was performed and population demographic and clinical information was obtained at baseline. Personal exposure assessments for airborne endotoxin and surveys of self-reported symptoms were performed every 6 months. Cox proportional hazards models were used to examine the relationship between endotoxin exposure and development of mouse-associated symptoms and multivariate regression was used to test for interaction. Results: Overall, 16 (9%) of 174 worker-participants developed mouse-associated rhinoconjunctivitis symptoms by 24 months and 8 (5%) developed mouse-associated lower respiratory symptoms by 24 months. Among workers with endotoxin exposure above the median (>/=2.4 EU m-3), 5 (6% of 80) atopics reported mouse-associated rhinoconjunctivitis symptoms at 24 months as compared to 3 (3% of 94) non-atopics. Among workers below the median endotoxin exposure (&lt;2.4 EU m-3), 1 (1% of 80) atopic reported mouse-associated rhinoconjunctivitis symptoms at 24 months as compared to 7 (7% of 94) non-atopics. For the combination of symptoms, the adjusted hazard ratio was 6.8 (95% confidence interval: 0.7-67.2) for atopics and 0.07 (95% confidence interval: 0.01-0.5) for non-atopics. Conclusion: In this occupational cohort, atopic workers may be more susceptible to, and non-atopic workers protected from, endotoxin-associated upper and lower respiratory symptoms</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 2398-7316 (Electronic)IS - 2398-7308 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/annweh/wxx061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29028247">PM:29028247</url></web-urls></urls><custom2><style face="normal" font="Arial">20171013, Newton AN</style></custom2><misc3><style face="normal" font="Arial">10.1093/annweh/wxx061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Olivier,C.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The use of Allergoids and Adjuvants in Allergen Immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Arch Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Asthma Allergy Immunol</style></full-title></periodical><pages end="060" start="040">040-060</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergoid</style></keyword><keyword><style face="normal" font="Arial"> Allergoids</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergen immunotherapy (AIT) is the unique curative treatment to help allergic patients to get over theirallergies. With a personalized approach, AIT is the best example of precision medicine. After a century ofintensive studies and innovative discoveries, allergists have in their hands many tools to orchestrate the beststrategy to re-educate the hypersensitive immune systems that decrease the quality of life of their patients. Thisreview describes both the historical and the promising acquisitions in this fi eld, focusing the biochemical andBioengineering tools that render an allergen more suitable for a secure, convenient and effective immunotherapy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.heighpubs.org/haard/articles.php?volume=1&amp;issue=1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Asthma Allergy Immunol\2017-1-040-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Asthma Allergy Immunol\2017-1-040-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Olivier CE</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santos,P.P.</style></author><author><style face="normal" font="Arial"> Games,P.D.</style></author><author><style face="normal" font="Arial"> Azevedo,D.O.</style></author><author><style face="normal" font="Arial"> Barros,E.</style></author><author><style face="normal" font="Arial"> de Oliveira,L.L.</style></author><author><style face="normal" font="Arial"> de Oliveira Ramos,H.J.</style></author><author><style face="normal" font="Arial"> Baracat-Pereira,M.C.</style></author><author><style face="normal" font="Arial"> Serrao,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Coordenacao de Ciencias Naturais, Universidade Federal do Maranhao, Bacabal, Maranhao, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Proteomic analysis of the venom of the predatory ant Pachycondyla striata (Hymenoptera: Formicidae)</style></title><secondary-title><style face="normal" font="Arial">Arch Insect Biochem Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Insect Biochem Physiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic potential</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="Arial"> aminopeptidase</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Ant Venoms</style></keyword><keyword><style face="normal" font="Arial"> Ants</style></keyword><keyword><style face="normal" font="Arial"> bioactive peptides</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Hyaluronidase</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Ion Exchange</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomic analysis</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Two dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Two-dimensional gel electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="Arial">The ants use their venom for predation, defense, and communication. The venom of these insects is rich in peptides and proteins, and compared with other animal venoms, ant venoms remain poorly explored. The objective of this study was to evaluate the protein content of the venom in the Ponerinae ant Pachycondyla striata. Venom samples were collected by manual gland reservoir dissection, and samples were submitted to two-dimensional gel electrophoresis and separation by ion-exchange and reverse-phase high-performance liquid chromatography followed by mass spectrometry using tanden matrix-assisted laser desorption/ionization with time-of-flight (MALDI-TOF/TOF) mass spectrometry and electrospray ionization-quadrupole with time-of-flight (ESI-Q/TOF) mass spectrometry for obtaining amino acid sequence. Spectra obtained were searched against the NCBInr and SwissProt database. Additional analysis was performed using PEAKS Studio 7.0 (Sequencing de novo). The venom of P. striata has a complex mixture of proteins from which 43 were identified. Within the identified proteins are classical venom proteins (phospholipase A, hyaluronidase, and aminopeptidase N), allergenic proteins (different venom allergens), and bioactive peptides (U10-ctenitoxin Pn1a). Venom allergens are among the most expressed proteins, suggesting that P. striata venom has high allergenic potential. This study discusses the possible functions of the proteins identified in the venom of P. striata</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 1520-6327 (Electronic)IS - 0739-4462 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1002/arch.21424</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29024043">PM:29024043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Insect Biochem Physiol\20171012-SantosPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Insect Biochem Physiol\20171012-SantosPP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Santos PP</style></custom2><misc3><style face="normal" font="Arial">10.1002/arch.21424</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bastola,R.</style></author><author><style face="normal" font="Arial"> Noh,G.</style></author><author><style face="normal" font="Arial"> Keum,T.</style></author><author><style face="normal" font="Arial"> Bashyal,S.</style></author><author><style face="normal" font="Arial"> Seo,J.E.</style></author><author><style face="normal" font="Arial"> Choi,J.</style></author><author><style face="normal" font="Arial"> Oh,Y.</style></author><author><style face="normal" font="Arial"> Cho,Y.</style></author><author><style face="normal" font="Arial"> Lee,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Vaccine adjuvants: smart components to boost the immune system</style></title><secondary-title><style face="normal" font="Arial">Arch Pharm Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Pharm Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1976-3786</style></isbn><abstract><style face="normal" font="Arial">Vaccination is an effective approach to prevent the consequences of infectious diseases. Vaccines strengthen immunity and make individuals resistant to infections with pathogens. Although conventional vaccines are highly immunogenic, they are associated with some safety issues. Subunit vaccines are safe, but they require adjuvants to stimulate the immune system because of their weaker immunogenicity. Adjuvants are entities incorporated into vaccines to increase the immunogenic responses of antigens. They play a crucial role in increasing the potency and efficacy of vaccines. Different adjuvants have different modes of action; therefore, a better understanding of their immunology could provide guidance for the development of novel adjuvants. Numerous studies have been conducted using different types of adjuvants to characterize their potency and safety; however, in practice, only few are used in human or animal vaccines. This review aims to introduce the different modes of action of adjuvants and give insight into the types of adjuvants that possess the greatest potential for adjuvanticity</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12272-017-0969-z</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s12272-017-0969-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Pharm Res\20171015-BastolaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Pharm Res\20171015-BastolaR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Bastola R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12272-017-0969-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Feng,S.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author><author><style face="normal" font="Arial"> Bian,X.H.</style></author><author><style face="normal" font="Arial"> Luo,Y.</style></author><author><style face="normal" font="Arial"> Qin,G.H.</style></author><author><style face="normal" font="Arial"> Shi,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">the First Affiliated Hospital of Xi'an Jiaotong University, Department of Pediatrics, Xi'an, China</style></auth-address><titles><title><style face="normal" font="Arial">Role of the TSLP/DC/OX40L pathway in asthma pathogenesis and airway inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">Biochem Cell Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochem Cell Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> OX40L</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> T-bet</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="Arial">This study aims to explore the effect of the TSLP/DC/OX40L pathway in asthma pathogenesis and airway inflammation in mice. Sixty-five male BALF/c mice were divided into the control, asthma, IgG + asthma (IgG, 500 g/500 l, intratracheal injection of 50 l each time), LY294002 (OX40L inhibitor) + asthma (intratracheal injection of 2 mg/kg LY294002), and anti-TSLP + asthma (intratracheal injection of 500 ug/500 l TSLP antibody, 50 l each time) groups. ELISA was applied to measure the serum levels of IgE, ovalbumin (OVA)-sIgE, interleukin-4 (IL-4), IL-5, IL-13 and interferon-gamma (IFN-gamma), flow cytometry was employed to detect Treg cells and dendritic cell (DC) and lymphopoiesis. RT-qPCR and Western blot assay were used to detect the levels of TSLP, OX40L, T-bet, GATA-3, NF-kappaB, p38 and ERK. Treatment of LY294002 and anti-TSLP resulted in increased numbers of total cells, eosinophils, neutrophils and lymphocytes in BALF, total serum levels of IgE, OVA-sIgE, IL-4, IL-5, and IL-13, level of DC cells, lymphopoiesis, and levels of TSLP, OX40L, GATA-3, NF-kappaB, p38, and ERK, while decreased levels of IFN-gamma and CD4+CD25+Treg cells, CD4+Foxp3+Treg cells and T-bet. TSLP/DC/OX40L pathway may contribute to asthma pathogenesis and airway inflammation by modulating level of CD4+CD25+Treg cells and content of inflammatory cytokines</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 1208-6002 (Electronic)IS - 0829-8211 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1139/bcb-2017-0126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29024606">PM:29024606</url></web-urls><pdf-urls><url ppv-ref="no">shiruiming56@163.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20171012, Feng S</style></custom2><misc3><style face="normal" font="Arial">10.1139/bcb-2017-0126</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,H.</style></author><author><style face="normal" font="Arial"> Song,X.</style></author><author><style face="normal" font="Arial"> Yan,L.</style></author><author><style face="normal" font="Arial"> Ren,M.</style></author><author><style face="normal" font="Arial"> Cui,X.X.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Gao,R.</style></author><author><style face="normal" font="Arial"> Zhang,W.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author><author><style face="normal" font="Arial"> Liu,B.</style></author><author><style face="normal" font="Arial"> Hu,Y.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing,China</style></auth-address><titles><title><style face="normal" font="Arial">IgE induces hypotension in asthma mice by down-regulating vascular NCX1 expression through activating MiR-212-5p</style></title><secondary-title><style face="normal" font="Arial">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biochim Biophys Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Pressure</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Down-Regulation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="Arial">Immunoglobulin E (IgE) has been suggested as a risk factor for allergy-induced low blood pressure, which has not been well explained in molecular details. Our current study shows a novel mechanism involving IgE, FcvarepsilonRI, miRNA-212-5p (miR-212-5p), and sodium/calcium exchanger protein 1(NCX1) for asthma to induce hypotension. In arterial smooth muscle cells, IgE up-regulated miR212-5p via its receptor FcvarepsilonRI, which resulted in down-regulation of NCX1 that is a regulating factor for blood pressure. In mice, asthma induced hypotension by interfering vasoconstrictive function; knockout of FcvarepsilonRI kept the asthmatic mice from developing hypotension; knock-down of miR-212-5p in asthmatic mice resulted in a significant restoration of blood pressure. In human, asthma and IgE were positively correlated with hypotension in cohort study on NIH epidemiological data. This study suggests a novel therapeutic target (miR-212-5p) for treatment of asthma-induced hypotension</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbadis.2017.10.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988887">PM:28988887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biochim Biophys Acta\20171009-ZhaoH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biochim Biophys Acta\20171009-ZhaoH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171009, Zhao H</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbadis.2017.10.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Oh,I.H.</style></author><author><style face="normal" font="Arial"> Rha,Y.H.</style></author><author><style face="normal" font="Arial"> Fujisawa,T.</style></author><author><style face="normal" font="Arial"> Lee,K.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Risk Factors of Allergic Disease: A Study with a Large Data Set</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="8969352">8969352-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/8969352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29130049">PM:29130049</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-8969352.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-8969352.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Oh IH</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/8969352</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dondi,A.</style></author><author><style face="normal" font="Arial"> Calamelli,E.</style></author><author><style face="normal" font="Arial"> Piccinno,V.</style></author><author><style face="normal" font="Arial"> Ricci,G.</style></author><author><style face="normal" font="Arial"> Corsini,I.</style></author><author><style face="normal" font="Arial"> Biagi,C.</style></author><author><style face="normal" font="Arial"> Lanari,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Acute Asthma in the Pediatric Emergency Department: Infections Are the Main Triggers of Exacerbations</style></title><secondary-title><style face="normal" font="Arial">Biomed Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomed Res Int</style></full-title></periodical><pages end="" start="9687061">9687061-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Action plan</style></keyword><keyword><style face="normal" font="Arial"> Acute asthma</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Vaccination</style></keyword><keyword><style face="normal" font="Arial"> Vaccinations</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Background. Asthma exacerbations are a common reason for Emergency Department (ED) visits in children. Aim. To analyze differences among age groups in terms of triggering factors and seasonality and to identify those with higher risk of severe exacerbations. Methods. We retrospectively revised the files of children admitted for acute asthma in 2016 in our Pediatric ED. Results. Visits for acute asthma were 603/23197 (2.6%). 76% of the patients were &lt;6 years old and 24% =6. Infections were the main trigger of exacerbations in both groups; 33% of the school-aged children had a triggering allergic condition (versus 3% in &lt;6 years;p &lt;.01). 191 patients had a previous history of asthma; among them, 95 were =6 years, 67% of whom were not using any controller medication, showing a higher risk of a moderate-to-severe exacerbation than those under long-term therapy (p &lt;.01). Exacerbations peaked in autumn and winter in preschoolers and in spring and early autumn in the school-aged children. Conclusions. Infections are the main trigger of acute asthma in children of any age, followed by allergy in the school-aged children. Efforts for an improved management of patients affected by chronic asthma might go through individualized action plans and possibly vaccinations and allergen-avoidance measures.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/9687061</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1155/2017/9687061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-9687061.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Res Int\2017-2017-9687061.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Dondi A</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/9687061</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Inoue,R.</style></author><author><style face="normal" font="Arial"> Sawai,T.</style></author><author><style face="normal" font="Arial"> Sawai,C.</style></author><author><style face="normal" font="Arial"> Nakatani,M.</style></author><author><style face="normal" font="Arial"> Romero-Perez,G.A.</style></author><author><style face="normal" font="Arial"> Ozeki,M.</style></author><author><style face="normal" font="Arial"> Nonomura,K.</style></author><author><style face="normal" font="Arial"> Tsukahara,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Laboratory of Animal Science, Department of Agricultural and Life Sciences , Kyoto Prefectural University , Kyoto , Japan</style></auth-address><titles><title><style face="normal" font="Arial">A preliminary study of gut dysbiosis in children with food allergy</style></title><secondary-title><style face="normal" font="Arial">Biosci Biotechnol Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biosci Biotechnol Biochem</style></full-title></periodical><pages end="2399" start="2396">2396-2399</pages><volume><style face="normal" font="Arial">81</style></volume><number><style face="normal" font="Arial">12</style></number><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">16S rRNA</style></keyword><keyword><style face="normal" font="Arial"> Abundance</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> High throughput</style></keyword><keyword><style face="normal" font="Arial"> high-throughput</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="Arial">Gut microbiota of food allergic children was analyzed by high throughput 16S rRNA gene sequencing. Signs of gut dysbiosis, which is likely associated with gut inflammation, was observed in children with food allergies. For example, decreased abundance of genus Akkermansia but increased abundance of Veillonella was found in children with food allergy in comparison with healthy control children</style></abstract><notes><style face="normal" font="Arial">DA - 20171011IS - 1347-6947 (Electronic)IS - 0916-8451 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1080/09168451.2017.1383849</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29017394">PM:29017394</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rhinology\2017-81-2396-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rhinology\2017-81-2396-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171011, Inoue R</style></custom2><misc3><style face="normal" font="Arial">10.1080/09168451.2017.1383849</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Landaeta,M.</style></author><author><style face="normal" font="Arial"> Vial,M.</style></author><author><style face="normal" font="Arial"> Jimenez,C.A.</style></author><author><style face="normal" font="Arial"> Debiane,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA</style></auth-address><titles><title><style face="normal" font="Arial">Allergic bronchopulmonary mycosis presenting as a new lung mass</style></title><secondary-title><style face="normal" font="Arial">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary mycosis</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United States -CO - Chile -</style></notes><work-type><style face="normal" font="Arial">10.1136/bcr-2017-221591</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29025778">PM:29025778</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ Case Rep\20171013-LandaetaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ Case Rep\20171013-LandaetaM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171013, Landaeta M</style></custom2><misc3><style face="normal" font="Arial">10.1136/bcr-2017-221591</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mafra Fonseca de Lima,C.</style></author><author><style face="normal" font="Arial"> Morais da Silva,A.</style></author><author><style face="normal" font="Arial"> Hernandes y Hernandes,G.</style></author><author><style face="normal" font="Arial"> Teixeira Rodrigues,A.</style></author><author><style face="normal" font="Arial"> Kalil,J.</style></author><author><style face="normal" font="Arial"> Clovis Galvao,E.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Local and systemic adverse reactions to allergen-specific immunotherapy for mites among patients seen at a university hospital's specialty outpatient clinic in São Paulo</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="292" start="287">287-292</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Beta-agonist</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: To report and classify adverse reactions tosubcutaneous immunotherapy (SCIT) to house dust mites inthe treatment of allergies. Method: We included 38 patientsundergoing treatment with SCIT using Dermatophagoidespteronyssinus (Der p) extracts isolated or combined with Blomiatropicalis (Blo t). Systemic adverse reactions to SCIT werereported and classified according to World Allergy Organization(WAO) criteria. Treatment details and reaction evolution were alsorecorded. Results: Mean age of patients was 36 years. A totalof 1,127 doses of SCIT with Der p extract were administered.Of these, 87.3% (984) caused reactions. The classification ofreactions according to WAO criteria was as follows: 35.49%Grade 1, 46.85% Grade 2, 17.6% Grade 3. Treatment consistedof antihistamine in 81.3% of the cases, corticosteroid in 81.3%,and inhaled beta-agonist in 70%. Epinephrine was used in 41% ofthe reactions. In the group that received Der p and Blo t extractscombined, 435 doses were administered, of which 155 (37.47%)resulted in reactions: 78% Grade 1 and 21.9% Grade 2. Treatmentconsisted of antihistamine in 77.2% of the reactions, corticosteroidsin 77.2%, and inhaled beta-agonist in 58%. Conclusion: In thestudied population, systemic reactions to Der p were mostly Grade2 according to the WAO classification. Conversely, reactionsto SCIT with Der p and Blo t extracts combined were mostlyGrade 1. Even though immunotherapy is considered a safetherapy, it may cause systemic adverse reactions, and shouldtherefore be performed by a specialist physician in an adequate,well-equipped setting for the treatment of systemic reactions.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170040</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170040</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-287-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-287-92.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Mafra Fonseca de Lima C</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gama da Silva,E.</style></author><author><style face="normal" font="Arial"> Lima Ribeiro,J.</style></author><author><style face="normal" font="Arial"> de Cassia Campos,M.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Sensitization profile to prevailing allergens in a specialty clinic in Catalão, state of Goiás</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="304" start="299">299-304</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> molds</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Objective: To investigate the profile of sensitization to allergensand the frequency of reactivity to skin prick tests with the mostcommon aeroallergens at a specialty clinic in the municipality ofCatalão, state of Goiás. Methods: In this retrospective study, 400charts of patients seen between 2008 and 2010 and who underwentskin prick testing for evaluation of sensitivity to aeroallergens wereanalyzed. Results: The prevalence of allergic sensitization was70.7%. Among the aeroallergens analyzed, there was a highfrequency of sensitization to house dust mites in all months,especially in July and December, followed by molds. Amonghouse dust mites, allergic sensitization to Dermatophagoidespteronyssinus was predominant (62%). In relation to the frequencyof patients with symptoms of atopic diseases, rhinitis was themain cause for seeking treatment (48.2%), followed by asthma(23.2%). There was an increase of 24% in the number of patientswho sought care, reflecting a possible increase in the prevalenceof allergic diseases over the years evaluated. Conclusions: Theresults obtained in the present study showed that house dust miteswere the most common causal agents of allergy and that rhinitiswas the most common atopic disease among patients seen at aspecialty clinic. There was an increase of 24% in the number ofconsults for allergic diseases over the years evaluated.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170042</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-299-304.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-299-304.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Gama da Silva E</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rosario,C.S.</style></author><author><style face="normal" font="Arial"> Rosario Filho,N.A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">House dust mite hypersensitivity and atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="320" start="319">319-320</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170046</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-319-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-319-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Rosario CS</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170046</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rufino Pereira,V.</style></author><author><style face="normal" font="Arial"> Tartuci,W.C.</style></author><author><style face="normal" font="Arial"> Ferreira de Mello,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mechanisms of allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="262" start="257">257-262</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergen specific IgG4</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgG4</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> migration</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy has been used for more than100 years as a desensitizing therapy for allergic diseases,representing a potentially curative and specific method. The aimof the present study was to review the mechanisms of allergen-specific immunotherapy based on papers published between 1998and 2016 and available in the PubMed database. The mechanismsof action of immunotherapy include modulation of T- and B-cellresponses, induction of allergen-specific IgG4 and suppressionof allergen-specific IgE production, migration of eosinophils,basophils, and mast cells to tissues, as well as release of theirmediators. Regulatory T cells (Treg) suppress dendritic cells thatsupport the generation of effector T cells, inhibiting TH1, TH2, andTH17 cells. Treg cells have been identified as key regulators of theinduction process of peripheral allergen tolerance.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170036</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-257-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-257-62.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Rufino Pereira V</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Figueredo Moreira,I.</style></author><author><style face="normal" font="Arial"> Duarte Auto,B.</style></author><author><style face="normal" font="Arial"> de Matos Braz,J.</style></author><author><style face="normal" font="Arial"> de Souza Rodrigues,H.V.</style></author><author><style face="normal" font="Arial"> Soares Rodrigues,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: the importance of family history for early diagnosis</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="315" start="311">311-315</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> IPEX</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> polyendocrinopathy</style></keyword><keyword><style face="normal" font="Arial"> premature</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein-Losing Enteropathies</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Immune dysregulation, polyendocrinopathy, enteropathy, X-linked(IPEX) syndrome is a rare recessive primary immunodeficiencysyndrome that affects male infants. The disease course ischaracterized by protein-losing enteropathy, eczematousdermatitis, and polyendocrinopathies, and may be fatal if notappropriately treated. The aim of this report was to describe a caseof IPEX, emphasizing the importance of family history for earlydiagnosis. The case describes an infant with a severe manifestationof the syndrome, with early clinical presentation and characteristicfamily history, with episodes of premature death affecting 12 menbelonging to the mother's lineage. Diagnosis was established bygenetic mapping after the patient's death due to septic shock; amutation in the FOXP3 gene was found. Hematopoietic stem celltransplantation is the best treatment available; in its absence, theIPEX syndrome can be fatal in the first 2 years of life. Therefore,ensuring early diagnosis is critical.</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170044</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170044</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-311-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-311-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Figueredo Moreira I</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Galvao,C.E.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergen-specific immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Braz J Allergy Immunol</style></full-title></periodical><pages end="" start="244">244-</pages><volume><style face="normal" font="Arial">1</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.5935/2526-5393.20170034</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170034</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-244.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Braz J Allergy Immunol\2017-1-244.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Galvao CE</style></custom2><misc3><style face="normal" font="Arial">10.5935/2526-5393.20170034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abrams,E.M.</style></author><author><style face="normal" font="Arial"> Watson,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chargee de cours au Departement de pediatrie dans la Section des allergies et de l'immunologie clinique de l'Universite du Manitoba a Winnipeg. Elissa.abrams@gmail.comDirecteur associe du perfectionnement professoral au Departement de pediatrie de l'Universite Dalhousie et directeur de la Division des allergies au Centre de sante IWKI a Halifax, en Nouvelle-Ecosse</style></auth-address><titles><title><style face="normal" font="Arial">Les arachides devraient-elles être permises dans les écoles? Oui</style></title><secondary-title><style face="normal" font="Arial">Can Fam Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Can Fam Physician</style></full-title></periodical><pages end="e405" start="e404">e404-e405</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arachide</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinique</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> Pediatrie</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 1715-5258 (Electronic)IS - 0008-350X (Linking)LA - frePT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29025815">PM:29025815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Can Fam Physician\2017-63-e404-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Can Fam Physician\2017-63-e404-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Abrams EM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Abrams,E.M.</style></author><author><style face="normal" font="Arial"> Watson,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Chargee de cours au Departement de pediatrie dans la Section des allergies et de l'immunologie clinique de l'Universite du Manitoba a Winnipeg. Elissa.abrams@gmail.comDirecteur associe du perfectionnement professoral au Departement de pediatrie de l'Universite Dalhousie et directeur de la Division des allergies au Centre de sante IWKI a Halifax, en Nouvelle-Ecosse</style></auth-address><titles><title><style face="normal" font="Arial">Les arachides devraient-elles être permises dans les écoles? Non</style></title><secondary-title><style face="normal" font="Arial">Can Fam Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Can Fam Physician</style></full-title></periodical><pages end="e407" start="e405">e405-e407</pages><volume><style face="normal" font="Arial">63</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arachide</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinique</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Manitoba</style></keyword><keyword><style face="normal" font="Arial"> Pediatrie</style></keyword><keyword><style face="normal" font="Arial"> Sante</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 1715-5258 (Electronic)IS - 0008-350X (Linking)LA - frePT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29025816">PM:29025816</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Can Fam Physician\2017-63-e405-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Can Fam Physician\2017-63-e405-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171013, Abrams EM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Seo,G.Y.</style></author><author><style face="normal" font="Arial"> Lee,J.M.</style></author><author><style face="normal" font="Arial"> Jang,Y.S.</style></author><author><style face="normal" font="Arial"> Kang,S.G.</style></author><author><style face="normal" font="Arial"> Yoon,S.</style></author><author><style face="normal" font="Arial"> Ko,Hyun J.</style></author><author><style face="normal" font="Arial"> Lee,G.S.</style></author><author><style face="normal" font="Arial"> Park,S.R.</style></author><author><style face="normal" font="Arial"> Nagler,C.R.</style></author><author><style face="normal" font="Arial"> Kim,P.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mechanism underlying the suppressor activity of retinoic acid on IL4-induced IgE synthesis and its physiological implication</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="55" start="49">49-55</pages><volume><style face="normal" font="Arial">322</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetylation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Class switching</style></keyword><keyword><style face="normal" font="Arial"> CSR</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE synthesis</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Promoter</style></keyword><keyword><style face="normal" font="Arial"> RAR+¦</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin A deficient mice</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0008-8749</style></isbn><abstract><style face="normal" font="Arial">The present study extends an earlier report that retinoic acid (RA) down-regulates IgE Ab synthesis in vitro. Here, we show the suppressive activity of RA on IgE production in vivo and its underlying mechanisms. We found that RA down-regulated IgE class switching recombination (CSR) mainly through RA receptor +¦ (RAR+¦). Additionally, RA inhibited histone acetylation of germ-line +Á (GL +Á) promoter, leading to suppression of IgE CSR. Consistently, serum IgE levels were substantially elevated in vitamin A-deficient (VAD) mice and this was more dramatic in VAD-lecithin:retinol acyltransferase deficient (LRAT</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ/</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ) mice. Further, serum mouse mast cell protease-1 (mMCP-1) level was elevated while frequency of intestinal regulatory T cells (Tregs) were diminished in VAD LRAT</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ/</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ mice, reflecting that deprivation of RA leads to allergic immune response. Taken together, our results reveal that RA has an IgE-repressive activity in vivo, which may ameliorate IgE-mediated allergic disease</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2017.10.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042055">PM:29042055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20171015-SeoGY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20171015-SeoGY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Seo GY</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2017.10.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McLeod,J.J.A.</style></author><author><style face="normal" font="Arial"> Caslin,H.L.</style></author><author><style face="normal" font="Arial"> Spence,A.J.</style></author><author><style face="normal" font="Arial"> Kolawole,E.M.</style></author><author><style face="normal" font="Arial"> Qayum,A.A.</style></author><author><style face="normal" font="Arial"> Paranjape,A.</style></author><author><style face="normal" font="Arial"> Taruselli,M.</style></author><author><style face="normal" font="Arial"> Haque,T.T.</style></author><author><style face="normal" font="Arial"> Kiwanuka,K.N.</style></author><author><style face="normal" font="Arial"> Elford,H.L.</style></author><author><style face="normal" font="Arial"> Ryan,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Virginia Commonwealth University, Richmond, VA, 23284, United States</style></auth-address><titles><title><style face="normal" font="Arial">Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IgE-mediated mast cell activation through attenuation of NFkappaB and AP-1 transcription</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="48" start="41">41-48</pages><volume><style face="normal" font="Arial">322</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> AP1</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow Derived Mast Cell</style></keyword><keyword><style face="normal" font="Arial"> bone marrow-derived mast cells</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell viability</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> high-affinity IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> Hydroxyurea</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE receptor</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> Virginia</style></keyword></keywords><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="Arial">Mast cell activation via the high-affinity IgE receptor (FcepsilonRI) elicits production of inflammatory mediators central to allergic disease. As a synthetic antioxidant and a potent ribonucleotide reductase (RNR) inhibitor, Didox (3,4-dihyroxybenzohydroxamic acid) has been tested in clinical trials for cancer and is an attractive therapeutic for inflammatory disease. We found that Didox treatment of mouse bone marrow-derived mast cells (BMMC) reduced IgE-stimulated degranulation and cytokine production, including IL-6, IL-13, TNF and MIP-1a (CCL3). These effects were consistent using BMMC of different genetic backgrounds and peritoneal mast cells. While the RNR inhibitor hydroxyurea had little or no effect on IgE-mediated function, high concentrations of the antioxidant N-acetylcysteine mimicked Didox-mediated suppression. Furthermore, Didox increased expression of the antioxidant genes superoxide dismutase and catalase, and suppressed DCFH-DA fluorescence, indicating reduced reactive oxygen species production. Didox effects were not due to changes in FcepsilonRI expression or cell viability, suggesting it inhibits signaling required for inflammatory cytokine production. In support of this, we found that Didox reduced FcepsilonRI-mediated AP-1 and NFkappaB transcriptional activity. Finally, Didox suppressed mast cell-dependent, IgE-mediated passive systemic anaphylaxis in vivo. These data demonstrate the potential use for Didox asa means of antagonizing mast cell responses in allergic disease</style></abstract><notes><style face="normal" font="Arial">DA - 20171001IS - 1090-2163 (Electronic)IS - 0008-8749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2017.09.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28964543">PM:28964543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20171001-McLeodJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20171001-McLeodJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171001, McLeod JJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2017.09.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mondoulet,L.</style></author><author><style face="normal" font="Arial"> Kalach,N.</style></author><author><style face="normal" font="Arial"> Dhelft,V.</style></author><author><style face="normal" font="Arial"> Larcher,T.</style></author><author><style face="normal" font="Arial"> Delayre-Orthez,C.</style></author><author><style face="normal" font="Arial"> Benhamou,P.H.</style></author><author><style face="normal" font="Arial"> Spergel,J.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author><author><style face="normal" font="Arial"> Dupont,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">DBV Technologies, Montrouge, France</style></auth-address><titles><title><style face="normal" font="Arial">Treatment of gastric eosinophilia by epicutaneous immunotherapy in piglets sensitized to peanuts</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Digestive tract</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic gastrointestinal disorders</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> EPIT</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gastric Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Gastritis</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity disorders</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Piglets</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="9" Year="2017">2017/9/28</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Eosinophilic Gastrointestinal Disorders (EGIDs) are hypersensitivity disorders frequently triggered by food allergy and manifested by mucosal eosinophilic infiltration at any level of the gastro-intestinal tract. This study established a model of gastric eosinophilia in peanut-sensitized piglets to evaluate the efficacy of epicutaneous immunotherapy (EPIT) for its treatment. METHODS: Experiments were carried out in piglets first sensitized by 3 intra-peritoneal injections of peanut protein extract (PPE) with adjuvant, and then given PPE orally for 10 days, a sequence leading to gastric eosinophilia assessed by endoscopy. For 3 months, 8 piglets received active EPIT, using Viaskin(R) loaded with PPE, applied daily on the ear, while 8 received placebo EPIT (Placebo). Piglets were exposed to a second 10-day period of PPE orally. Lesions were scored by endoscopy on the last day of PPE exposure. After sacrifice, all parts of the digestive tract were analysed by a pathologist unaware of the piglets' status. IgE response was measured and mechanistic parameters were analyzed in the spleen. RESULTS: After sensitization, a significant increase of total IgE was observed in sensitized compared to naive animals (61.1+/-13.3 vs 27.8+/-6 ng/mL, p&lt;0.01). Following oral intake of PPE, sensitized piglets developed moderate gastritis compared to naive piglets (1.5 vs 1.0, median score). After 3 months of immunotherapy, median IgE was significantly reduced in EPIT vs placebo piglets (61.4+/-16.3 vs 105.9+/-25.6 ng/mL, p&lt;0.01). Active EPIT significantly reduced gastric mucosal lesions induced by PPE oral intake (macroscopic score 0 [0-2] vs 2 [1-3], p&lt;0.01, respectively active vs placebo) and gastric mucosa eosinophils counts (239 eosinophils/mm2 [59-645] vs 2554 eosinophils/mm2 [462-8057], p&lt;0.01, respectively active vs placebo). GATA-3, IL-5 and eotaxin mRNA expression decreased significantly after EPIT (p&lt;0.05). CONCLUSIONS: This study describes a large animal model of gastric eosinophil in peanut-sensitized piglets. Utilizing this model, we demonstrated the efficacy of EPIT in treating peanut-induced EGIDs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - France -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960628">PM:28960628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20170929-MondouletL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20170929-MondouletL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Mondoulet L</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="Arial">Asthma comorbidities and making progress with food allergy</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1231" start="1230">1230-1231</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20170929IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960598">PM:28960598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-1230-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-1230-1.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170929, Roberts G</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13028</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guevara-Rattray,E.M.</style></author><author><style face="normal" font="Arial"> Garden,F.L.</style></author><author><style face="normal" font="Arial"> James,A.L.</style></author><author><style face="normal" font="Arial"> Wood-Baker,R.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Johns,D.P.</style></author><author><style face="normal" font="Arial"> Buist,A.S.</style></author><author><style face="normal" font="Arial"> Burney,P.G.J.</style></author><author><style face="normal" font="Arial"> Walters,E.H.</style></author><author><style face="normal" font="Arial"> Toelle,B.G.</style></author><author><style face="normal" font="Arial"> Marks,G.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Respiratory Sleep and Environmental Health, Ingham Institute of Applied Medical Research Sydney, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Atopy in people aged 40 and over: relation to airflow limitation</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> airflow limitation</style></keyword><keyword><style face="normal" font="Arial"> Airflow obstruction</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Race</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> socioeconomic status</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword></keywords><dates><year Day="3" Month="10" Year="2017">2017/10/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous studies have reached conflicting conclusions about the role of atopy as a risk factor for COPD. In part, this is attributable to variation in the definitions of airflow limitation and the treatment of people with asthma. OBJECTIVE: To establish whether there is any independent association between atopy and post-bronchodilator airflow limitation in the general population aged 40 years and over. METHODS: A cross-sectional survey was conducted in a general population sample of 2415 people aged 40 years and over in Australia. A history of ever being diagnosed with asthma was elicited by questionnaire. Atopy was defined as any skin prick test wheal to common aero-allergens >/=4mm. Airflow limitation was defined as post-bronchodilator spirometric (FEV1 /FVC) ratio &lt; lower limit of normal. Analyses were adjusted for potential confounding due to age, sex, smoking, race and socio-economic status. RESULTS: The prevalences of atopy, ever diagnosed asthma and post-bronchodilator airflow obstruction were 44.8%, 19.3% and 7.5%, respectively. In the population as a whole, atopy was associated with lower FEV(1) (adjusted difference -0.068L, 95% confidence interval(CI) -0.104 to -0.032), FVC (adj. difference -0.043L, 95%CI -0.086 to -0.0009) and post-bronchodilator FEV(1)/FVC ratio (adj. difference -0.011, 95%CI -0.017 to -0.0055). The effect of atopy on lung function was no longer apparent when participants who reported ever diagnosed asthma were excluded (FEV(1) -0.011L, [95% CI -0.05 to 0.028L], FVC -0.012L [95% CI -0.060 to 0.036] and FEV(1)/FVC ratio -0.0012 [95% CI -0.0072 to 0.0047L]). CONCLUSION AND CLINICAL RELEVANCE: The apparent association between atopy and post-bronchodilator airflow limitation in the general population appears to be explained by the association between atopy and having ever diagnosed asthma and the effect of asthma on lung function. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28972658">PM:28972658</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20171003-GuevaraRattrayEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20171003-GuevaraRattrayEM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Guevara-Rattray EM</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Castano,R.</style></author><author><style face="normal" font="Arial"> Yucesoy,B.</style></author><author><style face="normal" font="Arial"> Johnson,V.J.</style></author><author><style face="normal" font="Arial"> Castellanos,L.</style></author><author><style face="normal" font="Arial"> Cartier,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Hopital du Sacre-Coeur de Montreal, Montreal, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Inflammatory proteins in nasal lavage of workers exposed to occupational agents</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> Adhesion molecules</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion</style></keyword><keyword><style face="normal" font="Arial"> Cell Adhesion Molecules</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> fibrinogen</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> growth factors</style></keyword><keyword><style face="normal" font="Arial"> high molecular weight</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory Markers</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Vascular Cell Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> vascular endothelial growth factor</style></keyword><keyword><style face="normal" font="Arial"> VEGF</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Low-molecular-weight (LMW) and high-molecular-weight (HMW) agents have been recognized as causes of occupational rhinitis (OR). Immunological mechanisms underlying OR differ according to the type of exposure. While HMW agents act mainly through IgE-mediated mechanisms, LMW agents appear to act through both immunologic and non-immunologic mechanisms. OBJECTIVE: The objective of this study was to identify potential differences in the upper airways inflammatory response after exposure to LMW and HMW agents by specific inhalation challenge test (SIC). METHODS: Nasal lavage (NL) samples from 20 subjects who were exposed to HMW (n=10, Group I) and LMW (n=10, Group II) at their workplaces were collected after SIC with control and specific occupational agents. These samples were analyzed for 47 inflammatory markers using multiplex bead technology. RESULTS: After exposure to specific agent, Group I exhibited higher concentrations of the following proteins compared to Group II: fibrinogen (median (interquartile range) Group I: 0.09 (0.00) mug/ml, Group II: 0.04 (0.05) mug/ml, p=0.05); haptoglobin (Group I: 0.86 (0.01) mug/ml, Group II: 0.14 (0.20) mug /ml, p=0.02); vascular cell adhesion molecule-1 (VCAM-1) (Group I: 0.34 (0.67) ng/ml, Group II: 0.11(0.11) ng/ml, p=0.01); vascular endothelial growth factor (VEGF) (Group I: 157.0 (154.0) pg/ml, Group II: 98.0 (20.25) pg/ml, p=0.01) and vitamin D (VDBP) (Group I: 0.06 (0.13) mug /ml, Group II: 0.03 (0.03) mug /ml, p=0.04). No statistically significant differences in proteins profiles were observed between the groups after exposure to control agent. Also, subjects exposed to HMW agents showed a significant increase in NL levels of C-reactive protein compared to control day exposure. CONCLUSIONS AND CLINICAL RELEVANCE: Exposure to HMW and LMW agents by SIC induced a differential nasal airway response including acute-phase reactants proteins (fibrinogen, haptoblobin and CRP), cell adhesion molecules (VCAM-1), endothelial growth factors (VEGF) and VDBP. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28977704">PM:28977704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-CastanoR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-CastanoR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Castano R</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Malik,K.</style></author><author><style face="normal" font="Arial"> Ungar,B.</style></author><author><style face="normal" font="Arial"> Garcet,S.</style></author><author><style face="normal" font="Arial"> Dutt,R.</style></author><author><style face="normal" font="Arial"> Dickstein,D.</style></author><author><style face="normal" font="Arial"> Zheng,X.</style></author><author><style face="normal" font="Arial"> Xu,H.</style></author><author><style face="normal" font="Arial"> Estrada,Y.D.</style></author><author><style face="normal" font="Arial"> Suarez-Farinas,M.</style></author><author><style face="normal" font="Arial"> Shemer,A.</style></author><author><style face="normal" font="Arial"> Krueger,J.G.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, USA</style></auth-address><titles><title><style face="normal" font="Arial">Dust mite induces multiple polar T-cell axes in human skin</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> Animal models</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-9</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th9</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: House dust mite/HDM atopy patch test/APT elicits positive reactions in a high fraction of atopic dermatitis/AD and healthy individuals. Experimental systems for new-onset/chronic AD are needed to support rapid therapeutic development, particularly since animal models representing human AD are lacking. While HDM APT has been considered to simulate AD, its suitability to model AD's emerging Th2/Th22 phenotype with Th1 and Th17 components is unknown. OBJECTIVE: To assess whether HDM APT reproduces AD. METHODS: Positive HDM APTs (n=15) from patients with and without AD were evaluated, using genomic and immunohistochemistry studies, against intrapersonal control skin. RESULTS: APT lesions showed higher T-cell and dendritic cell infiltrates vs. CONTROLS: 743 up- and 326 downregulated genes were differentially expressed in HDM APT (fold-change>2 and false-discovery rate&lt;0.05), with increased expression of Th2, Th9, Th17/Th22 polar cytokines (i.e. IL-5, IL-13, IL-9, IL-17, IL-22). CONCLUSION: While HDM caused significant Th2 skewing, it also illustrated differences in Th2 induction and barrier defects, thus HDM APT does not fully simulate AD. Given its widespread availability and sensitization rates, HDM may potentially be a useful tool that represents select aspects of AD, psoriasis, or contact dermatitis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28977706">PM:28977706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS5..xlsxC:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS6..xlsxC:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS7..xlsxC:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS8..xlsxC:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS9..xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS5..xlsxF:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS6..xlsxF:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS7..xlsxF:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS8..xlsxF:\A&amp;H HMW Papers\Clin Exp Allergy\20171004-MalikK-0003-TableS9..xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20171004, Malik K</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ridolo,E.</style></author><author><style face="normal" font="Arial"> Rogkakou,A.</style></author><author><style face="normal" font="Arial"> Ventura,M.T.</style></author><author><style face="normal" font="Arial"> Martignago,I.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Di Lorenzo,G.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">How to fit allergen immunotherapy in the elderly</style></title><secondary-title><style face="normal" font="Arial">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Mol Allergy</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Aging</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Contraindication</style></keyword><keyword><style face="normal" font="Arial"> contraindications</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly people</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect sting</style></keyword><keyword><style face="normal" font="Arial"> insect sting allergy</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1476-7961</style></isbn><abstract><style face="normal" font="Arial">Asthma, allergic rhinitis (AR) and atopic dermatitis are very common in young people, but in the latest decades it was increasingly recognized that also individuals of higher ages, including the population over 65-áyears, are concerned. Actually, it is now acknowledged the aging does not considerably alter the immune response to allergens. Allergen immunotherapy (AIT) is the only treatment that works on the causes of allergy, but elderly people are commonly excluded from AIT, except the cases of insect sting allergy. A number of recent studies showed that aged individuals also successfully respond to AIT for respiratory allergy. Therefore, there is no reason to exclude elder patients from AIT. Anyhow, clinical conditions that are considered absolute or relative contraindications are quite frequent in this aged population, thus the risk/benefit ratio must be carefully evaluated for each patient, taking into account that the more frequent occurrence of co-morbidities and the consequent need of daily-based multidrug regimen can favor adverse effects. An important issue concern the ability of AIT, and particularly of sublingual immunotherapy, to significantly improve the quality of life, that often is particularly impaired in the elderly, reducing symptoms and drugs consumption</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s12948-017-0075-2</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s12948-017-0075-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Mol Allergy\2017-15-17.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Ridolo E</style></custom2><misc3><style face="normal" font="Arial">10.1186/s12948-017-0075-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Vanga,S.K.</style></author><author><style face="normal" font="Arial"> Raghavan,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Bioresource Engineering , Faculty of Agricultural and Environmental Sciences, McGill University, Sainte-Anne-de-Bellevue, Quebec H9 x 3V9 , Canada</style></auth-address><titles><title><style face="normal" font="Arial">Effect of pre-harvest and post-harvest conditions on the fruit allergenicity:A review</style></title><secondary-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Crit Rev Food Sci Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Aging</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen content</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> Apple</style></keyword><keyword><style face="normal" font="Arial"> Apples</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruit allergens</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Mal d 3</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> maturity</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> modified atmosphere packaging</style></keyword><keyword><style face="normal" font="Arial"> OAS</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Post-harvest</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Ripening</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tomatoes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword></keywords><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="Arial">Fruits are an important source of vitamins and antioxidants that can effectively delay aging and contribute to health and well-being of the human kind. However, they are growing to be one of the primary elicitors of food allergies around the world. Fruit allergens can induce an IgE-mediated (Immunoglobulin E) reaction, presenting with a symptom like localized oral allergy syndrome (OAS). Numerous studies showed that varying environmental and cultivation conditions can influence the fruit allergen content during flowering and ripening stages. Further, the variety, harvesting maturity, and storage conditions can also significantly influence the allergenicity potential. For example, unripe apples and tomatoes have lower levels of allergens compared to ripened fruits. Researchers have also reported that modified atmosphere packaging (MAP) can help reduce Mal d 3 content present in apples during storage. Post-harvest processing like peeling is also considered a good method to help reduce the overall allergenicity in few fruits whose peel might contain majority of the allergens. This review will discuss the overall influence of both pre-harvest and post-harvest factors on the fruit allergens. We will also discuss the progress regarding the cause, symptoms and diagnostic methods of fruit based allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20171011IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1080/10408398.2017.1389691</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29020459">PM:29020459</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\20171011-WangJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Crit Rev Food Sci Nutr\20171011-WangJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171011, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.1080/10408398.2017.1389691</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chenuet,P.</style></author><author><style face="normal" font="Arial"> Fauconnier,L.</style></author><author><style face="normal" font="Arial"> Madouri,F.</style></author><author><style face="normal" font="Arial"> Marchiol,T.</style></author><author><style face="normal" font="Arial"> Rouxel,N.</style></author><author><style face="normal" font="Arial"> Ledru,A.</style></author><author><style face="normal" font="Arial"> Mauny,P.</style></author><author><style face="normal" font="Arial"> Lory,R.</style></author><author><style face="normal" font="Arial"> Uttenhove,C.</style></author><author><style face="normal" font="Arial"> Van Snick,J.</style></author><author><style face="normal" font="Arial"> Iwakura,Y.</style></author><author><style face="normal" font="Arial"> di Padova,F.</style></author><author><style face="normal" font="Arial"> Quesniaux,V.</style></author><author><style face="normal" font="Arial"> Togbe,D.</style></author><author><style face="normal" font="Arial"> Ryffel,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, 3B, F-45071 Orleans-Cedex2, France</style></auth-address><titles><title><style face="normal" font="Arial">Neutralization of either IL-17A or IL-17F is sufficient to inhibit house dust mite induced allergic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Clin Sci (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Sci (Lond)</style></full-title></periodical><pages end="2548" start="2533">2533-2548</pages><volume><style face="normal" font="Arial">131</style></volume><number><style face="normal" font="Arial">20</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fibroblasts</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword></keywords><dates><year Day="15" Month="10" Year="2017">2017/10/15</year></dates><abstract><style face="normal" font="Arial">T helper (Th)17 immune response participates in allergic lung inflammation and asthma is reduced in the absence of interleukin (IL)-17 in mice. Since IL-17A and IL-17F are induced and bind the shared receptor IL-17RA, we asked whether both IL-17A and IL-17F contribute to house dust mite (HDM) induced asthma. We report that allergic lung inflammation is attenuated in absence of either IL-17A or IL-17F with reduced airway hyperreactivity, eosinophilic inflammation, goblet cell hyperplasia, cytokine and chemokine production as found in absence of IL-17RA. Furthermore, specific antibody neutralization of either IL-17A or IL-17F given during the sensitization phase attenuated allergic lung inflammation and airway hyperreactivity. In vitro activation by HDM of primary dendritic cells revealed a comparable induction of CXCL1 and IL-6 expression and the response to IL-17A and IL-17F relied on IL-17RA signaling via the adaptor protein act1 in fibroblasts. Therefore, HDM-induced allergic respiratory response depends on IL-17RA via act1 signaling and inactivation of either IL-17A or IL-17F is sufficient to attenuate allergic asthma in mice</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 1470-8736 (Electronic)IS - 0143-5221 (Linking)LA - engPT - Journal ArticleCO - France -CO - Belgium -CO - Japan -CO - Switzerland -CO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.1042/CS20171034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29026003">PM:29026003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Sci (Lond)\2017-131-2533-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Sci (Lond)\2017-131-2533-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171013, Chenuet P</style></custom2><misc3><style face="normal" font="Arial">10.1042/CS20171034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vonk,M.M.</style></author><author><style face="normal" font="Arial"> Wagenaar,L.</style></author><author><style face="normal" font="Arial"> Pieters,R.H.H.</style></author><author><style face="normal" font="Arial"> Knippels,L.M.J.</style></author><author><style face="normal" font="Arial"> Willemsen,L.E.M.</style></author><author><style face="normal" font="Arial"> Smit,J.J.</style></author><author><style face="normal" font="Arial"> van Esch,B.C.A.M.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsImmunology Platform, Nutricia Research, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow's milk- and peanut allergy models</style></title><secondary-title><style face="normal" font="Arial">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Transl Allergy</style></full-title></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="Arial">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acute allergic skin response</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgG1</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> PNA</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> Suspensions</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell subsets</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> Th1 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Antigen-specific immunotherapy (AIT) is a promising therapeutic approach for both cow's milk allergy (CMA) and peanut allergy (PNA), but needs optimization in terms of efficacy and safety. AIM: Compare oral immunotherapy (OIT) and subcutaneous immunotherapy (SCIT) in murine models for CMA and PNA and determine the dose of allergen needed to effectively modify parameters of allergy. METHODS: Female C3H/HeOuJ mice were sensitized intragastrically (i.g.) to whey or peanut extract with cholera toxin. Mice were treated orally (5 times/week) or subcutaneously (3 times/week) for three consecutive weeks. Hereafter, the acute allergic skin response, anaphylactic shock symptoms and body temperature were measured upon intradermal (i.d.) and intraperitoneal (i.p.) challenge, and mast cell degranulation was measured upon i.g. challenge. Allergen-specific IgE, IgG1 and IgG2a were measured in serum at different time points. Single cell suspensions derived from lymph organs were stimulated with allergen to induce cytokine production and T cell phenotypes were assessed using flow cytometry. RESULTS: Both OIT and SCIT decreased clinically related signs upon challenge in the CMA and PNA model. Interestingly, a rise in allergen-specific IgE was observed during immunotherapy, hereafter, treated mice were protected against the increase in IgE caused by allergen challenge. Allergen-specific IgG1 and IgG2a increased due to both types of AIT. In the CMA model, SCIT and OIT reduced the percentage of activated Th2 cells and increased the percentage of activated Th1 cells in the spleen. OIT increased the percentage of regulatory T cells (Tregs) and activated Th2 cells in the MLN. Th2 cytokines IL-5, IL-13 and IL-10 were reduced after OIT, but not after SCIT. In the PNA model, no differences were observed in percentages of T cell subsets. SCIT induced Th2 cytokines IL-5 and IL-10, whereas OIT had no effect. CONCLUSION: We have shown clinical protection against allergic manifestations after OIT and SCIT in a CMA and PNA model. Although similar allergen-specific antibody patterns were observed, differences in T cell and cytokine responses were shown. Whether these findings are related to a different mechanism of AIT in CMA and PNA needs to be elucidated</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13601-017-0170-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29021893">PM:29021893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Transl Allergy\2017-7-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Vonk MM</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13601-017-0170-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uguz,U.</style></author><author><style face="normal" font="Arial"> Guvensen,A.</style></author><author><style face="normal" font="Arial"> Tort,N.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Faculty of Science, Ege University, 35100, Izmir, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Annual and intradiurnal variation of dominant airborne pollen and the effects of meteorological factors in Cesme (Izmir, Turkey)</style></title><secondary-title><style face="normal" font="Arial">Environ Monit Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Monit Assess</style></full-title></periodical><pages end="" start="530">530-</pages><volume><style face="normal" font="Arial">189</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Atmosphere</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Meteorological factor</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Factors</style></keyword><keyword><style face="normal" font="Arial"> Olea</style></keyword><keyword><style face="normal" font="Arial"> Olea europaea</style></keyword><keyword><style face="normal" font="Arial"> Pinaceae</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Poaceae</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen count</style></keyword><keyword><style face="normal" font="Arial"> Pollen counts</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Quercus</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Spearman correlation</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Volumetric</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="30" Month="9" Year="2017">2017/9/30</year></dates><abstract><style face="normal" font="Arial">In this present study, airborne pollen in Cesme was investigated between February 17, 2012 and February 17, 2014 using the volumetric method. Cesme, one of Turkey's most important tourism centers, which attracts numerous local and foreign tourists each year, is a district of Izmir, a province in the western part of Turkey. During the 2-year study, 12,905 pollen grains belonging to 64 taxa (33 arboreal, 31 non-arboreal plants) were detected. However, the 2-year data results revealed that the taxa with the pollen concentration more than 4% in the atmosphere were Cupressaceae/Taxaceae (4268 pollen, 33.07%), Olea europaea (1614 pollen grains, 12.51%), Pinaceae (1085 pollen grains, 8.41%), Quercus spp. (1081 pollen grains, 8.38%), Pistacia spp. (743 pollen grains, 5.76%), and Poaceae (557 pollen grains, 4.32%), all of which comprised 72.44% of the total count. The relationship between the daily pollen counts belonging to these six taxa and the hourly average temperature ( degrees C), daily precipitation (mm), relative humidity (%), and wind speed (km/h) was assessed using the Spearman correlation test, and significant results were determined. During the study, the intradiurnal distribution of the aforementioned pollen varied. The highest pollen concentration was detected between 11:00 a.m. and 6:00 p.m. (first year 30.3%; second year 30.1%)</style></abstract><notes><style face="normal" font="Arial">DA - 20171001IS - 1573-2959 (Electronic)IS - 0167-6369 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10661-017-6238-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965257">PM:28965257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-530.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-530.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171001, Uguz U</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10661-017-6238-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pusz,W.</style></author><author><style face="normal" font="Arial"> Weber,R.</style></author><author><style face="normal" font="Arial"> Dancewicz,A.</style></author><author><style face="normal" font="Arial"> Kita,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Plant Protection, Wroclaw University of Environmental and Life Sciences, Plac Grunwaldzki 24A, 50-363, Wroclaw, Poland.</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of selected fungi variation and its dependence on season and mountain range in southern Poland-key factors in drawing up trial guidelines for aeromycological monitoring</style></title><secondary-title><style face="normal" font="Arial">Environ Monit Assess</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Monit Assess</style></full-title></periodical><pages end="" start="526">526-</pages><volume><style face="normal" font="Arial">189</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungal spore</style></keyword><keyword><style face="normal" font="Arial"> fungal spores</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> requirements</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Slovakia</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">The aim of the study was to identify fungal spores, in particular plant pathogenic fungi, occurring in the air in selected mountain ranges. The results revealed not only the array of fungal species migrating with air currents from the Czech Republic and Slovakia but also how the season of the year affects the distribution of spores. Such studies may lay a foundation for future aeromycological monitoring, in accordance with the requirements for integrated plant protection. Aeromycological research was carried out between 2013 and 2016 at 3-month intervals in mountainous areas along the southern borders of Poland: the Bieszczady, the Pieniny, the Giant Mountains (Karkonosze) and the Babia Gora Massif. The research relied on impact method employing Air Ideal 3P sampler, which, by drawing in atmospheric air, also collects fungal spores. Regardless of altitudinal zonation, the changing weather conditions appeared to be the main reason for the variations in the number of the fungal spores under study in those years</style></abstract><notes><style face="normal" font="Arial">DA - 20170927IS - 1573-2959 (Electronic)IS - 0167-6369 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10661-017-6243-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28952055">PM:28952055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-526.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Monit Assess\2017-189-526.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170927, Pusz W</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10661-017-6243-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghaffari,H.R.</style></author><author><style face="normal" font="Arial"> Aval,H.E.</style></author><author><style face="normal" font="Arial"> Alahabadi,A.</style></author><author><style face="normal" font="Arial"> Mokammel,A.</style></author><author><style face="normal" font="Arial"> Khamirchi,R.</style></author><author><style face="normal" font="Arial"> Yousefzadeh,S.</style></author><author><style face="normal" font="Arial"> Ahmadi,E.</style></author><author><style face="normal" font="Arial"> Rahmani-Sani,A.</style></author><author><style face="normal" font="Arial"> Estaji,M.</style></author><author><style face="normal" font="Arial"> Ghanbarnejad,A.</style></author><author><style face="normal" font="Arial"> Gholizadeh,A.</style></author><author><style face="normal" font="Arial"> Taghavi,M.</style></author><author><style face="normal" font="Arial"> Miri,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Health Engineering, Faculty of Health, Hormozgan University of Medical Sciences, Bandar Abbas, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Asthma disease as cause of admission to hospitals due to exposure to ambient oxidants in Mashhad, Iran</style></title><secondary-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Air Pollutants</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidants</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> Oxidants</style></keyword><keyword><style face="normal" font="Arial"> pollutants</style></keyword><keyword><style face="normal" font="Arial"> predictive model</style></keyword><keyword><style face="normal" font="Arial"> Predictive models</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">Nowadays, asthma is one of the most common chronic respiratory diseases, worldwide. Many reports have emphasized the correlation between the short-term exposure to the ambient air pollutants and acute respiratory diseases, especially among children with asthmatic symptoms. The aim of this study was to evaluate the relationship between the exposure to three atmospheric antioxidants (NO2, SO2, and O3) and hospital admission due to asthmatic disease (HAAD) in the city of Mashhad, Iran. The concentrations of atmospheric antioxidants were obtained from the real-time monitoring stations located in the city. The collected data were employed for developing predictive models in the AirQ software. In order to investigate the association between short-term exposure to air pollutants and HAAD, the study participants were categorized into two age groups: less than 15 and from 15 to 64 years old. The results indicated that in people less than 15 years increase in NO2 (attributable proportion (AP) = 3.775%, 95% CI 0.897-6.883%), SO2 (AP = 3.649%, 95% CI 1.295-5.937%), and O3 (AP = 0.554%,95% CI 0.00-3.321) results in increase in HAAD. While for those aged between 15 and 64 years, the AP was 4.192% (95% CI 0.450-7.662%) for NO2; 0.0% (95% CI 0.00-1.687%) for SO2; and 0.236% (95% CI 0.00-1.216%) for O3. The number of asthmatic cases who were less than 15 years admitted to the hospitals during the study period was higher than that of those within the age groups between 15 and 64 years as a consequence of exposure to NO2 (101 vs. 75), SO2 (98 vs. 0), and O3 (15 vs. 3), respectively. To the best of our knowledge, the AirQ model has not been applied before to estimate the effect of atmospheric antioxidant exposure on hospital admission because of asthma disease. Eventually, this model is proposed to be applicable for other cities around the world</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 1614-7499 (Electronic)IS - 0944-1344 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11356-017-0226-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28975536">PM:28975536</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20171004-GhaffariHR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20171004-GhaffariHR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Ghaffari HR</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11356-017-0226-5</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Han,M.</style></author><author><style face="normal" font="Arial"> Ji,X.</style></author><author><style face="normal" font="Arial"> Li,G.</style></author><author><style face="normal" font="Arial"> Sang,N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Environment and Resource, Research Center of Environment and Health, Shanxi University, Taiyuan, 030006, Shanxi, People's Republic of China.</style></auth-address><titles><title><style face="normal" font="Arial">NO2 inhalation enhances asthma susceptibility in a rat model</style></title><secondary-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adhesion</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> GATA-3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Intercellular Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Janus kinase</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucin</style></keyword><keyword><style face="normal" font="Arial"> mucin gene</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen</style></keyword><keyword><style face="normal" font="Arial"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="Arial"> NO2</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein-Tyrosine Kinase</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Respiratory diseases</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-box expressed in T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="Arial">Nitrogen dioxide (NO2) is a major air pollutant. Epidemiologic studies have found that NO2 exposure is associated with an increased risk of asthma. Nevertheless, the potential molecular mechanisms remain unclear. In this study, we investigated the effect of NO2 inhalation on the occurrence of allergic airway inflammation and its underlying mechanisms. Firstly, male Wistar rats were exposed to 2 and 5 mg/m3 NO2 (28 days, 5 h/day). The results showed that NO2 exposure could induce pulmonary inflammatory response, mucus formation, and Th1/Th2 imbalance in the lung of normal rats, resulting in allergic asthma-like features. Secondly, male Wistar rats were exposed to 5 mg/m3 NO2 (42 days, 5 h/day), sensitized with ovalbumin (OVA), challenged with aerosolized OVA, and characterized in asthma models. Results showed that NO2 exposure aggravated lung inflammation in the OVA-sensitized rats, accompanied by the increase in inflammatory cell infiltration, mucus hypersecretion, and collagen deposition. Furthermore, NO2 exposure promoted the increase in the expression of mucin gene (MUC5AC) and pro-inflammatory factors [interleukin (IL)-1beta, intercellular adhesion molecule-1 (ICAM-1), and IL-6] as well as serum OVA-specific immunoglobulin E (IgE) production. Taken together, we established that NO2 exposure promotes allergic airway inflammation and increases the asthma susceptibility. The underlying mechanisms involve the promotion of activation of interleukin-4/signal transducer and activator of transcription-6 (IL-4/STAT6) pathway [IL-4 receptor (IL-4R) alpha, janus kinase (JAK) 1, JAK 3, and STAT6] and related transcription factor [T cell-specific protein-tyrosine kinase (Lck), extracellular-regulated kinase (ERK)1/2, and nuclear factor-kappaB (NF-kappaB)]. In particular, the imbalance of Th1/Th2 cell differentiation [IL-4, interferon (IFN)-gamma, GATA-binding protein-3 (GATA-3), and T-box expressed in T cells (T-bet)] plays a pivotal role in NO2-induced inflammatory responses. These findings may provide a better understanding of mechanism of NO2-associated respiratory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20171007IS - 1614-7499 (Electronic)IS - 0944-1344 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11356-017-0402-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28986735">PM:28986735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20171007-HanM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20171007-HanM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171007, Han M</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11356-017-0402-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amsler,E.</style></author><author><style face="normal" font="Arial"> Autegarden,J.E.</style></author><author><style face="normal" font="Arial"> Gaouar,H.</style></author><author><style face="normal" font="Arial"> Frances,C.</style></author><author><style face="normal" font="Arial"> Soria,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service de Dermatologie et Allergologie, Hopital Tenon, 4 rue de la Chine, 75020 Paris</style></auth-address><titles><title><style face="normal" font="Arial">Management of immediate hypersensitivity reaction to glatiramer acetate</style></title><secondary-title><style face="normal" font="Arial">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur J Dermatol</style></full-title></periodical><pages end="95" start="92">92-95</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> allergologie</style></keyword><keyword><style face="normal" font="Arial"> chemically induced</style></keyword><keyword><style face="normal" font="Arial"> Dermatologie</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Drug Eruptions</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> glatiramer acetate</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity,Immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> immediate hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressive Agents</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Middle Aged</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Remission,Spontaneous</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20161101IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - LetterRN - 0 (Immunosuppressive Agents)RN - 5M691HL4BO (Glatiramer Acetate)SB - IMCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1684/ejd.2016.2907</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27799134">PM:27799134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Dermatol\2017-27-92-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Dermatol\2017-27-92-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20161101, Amsler E</style></custom2><misc3><style face="normal" font="Arial">10.1684/ejd.2016.2907</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pelaia,C.</style></author><author><style face="normal" font="Arial"> Vatrella,A.</style></author><author><style face="normal" font="Arial"> Gallelli,L.</style></author><author><style face="normal" font="Arial"> Terracciano,R.</style></author><author><style face="normal" font="Arial"> Navalesi,P.</style></author><author><style face="normal" font="Arial"> Maselli,R.</style></author><author><style face="normal" font="Arial"> Pelaia,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Medical and Surgical Sciences , University "Magna Graecia" of Catanzaro , Catanzaro , Italy</style></auth-address><titles><title><style face="normal" font="Arial">Dupilumab for the treatment of asthma</style></title><secondary-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Opin Biol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgG4</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> pharmacokinetics</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tolerability</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="8" Month="10" Year="2017">2017/10/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Dupilumab is a fully human IgG4 monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor (IL-4Ralpha). Since the activation of IL-4Ralpha is utilized by both IL-4 and IL-13 to mediate their pathophysiological effects, dupilumab behaves as a dual antagonist of these two sister cytokines, which blocks IL-4/IL-13-dependent signal transduction. Areas covered: Herein, the authors review the cellular and molecular pathways activated by IL-4 and IL-13, which are relevant to asthma pathobiology. They also review: the mechanism of action of dupilumab, the phase I, II and III studies evaluating the pharmacokinetics as well as the safety, tolerability and clinical efficacy of dupilumab in asthma therapy. Expert opinion: Supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma. It also may have benefits to comorbidities of asthma including atopic dermatitis, chronic sinusitis and nasal polyposis</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 1744-7682 (Electronic)IS - 1471-2598 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/14712598.2017.1387245</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28990423">PM:28990423</url></web-urls><pdf-urls><url ppv-ref="no">pelaia@unicz.it</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20171009, Pelaia C</style></custom2><misc3><style face="normal" font="Arial">10.1080/14712598.2017.1387245</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salas-Tovar,J.A.</style></author><author><style face="normal" font="Arial"> Flores-Gallegos,A.C.</style></author><author><style face="normal" font="Arial"> Contreras-Esquivel,J.C.</style></author><author><style face="normal" font="Arial"> Escobedo-Garcia,S.</style></author><author><style face="normal" font="Arial"> Morlett-Chavez,J.A.</style></author><author><style face="normal" font="Arial"> Rodriguez-Herrera,R.l</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Analytical Methods for Pectin Methylesterase Activity Determination: a Review</style></title><secondary-title><style face="normal" font="Arial">Food Anal Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Anal Methods</style></full-title></periodical><pages end="3646" start="3634">3634-3646</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Applications</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Beverages</style></keyword><keyword><style face="normal" font="Arial"> Cell Wall</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Food quality</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Methanol</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Pectin</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Texture</style></keyword><keyword><style face="normal" font="Arial"> Yeast</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1936-976X</style></isbn><abstract><style face="normal" font="Arial">Pectin methylesterase is an enzyme with an important in vivo role in plants as well as in food industry. This enzyme catalyzes the hydrolysis of methyl ester bounds in pectin which is one of the main components of cell wall in plants, producing methanol and free carboxylic groups. The effect of pectin methylesterase in food quality has been extensively studied, producing desirable effects in texture improvement as well as undesirable effects in some beverages. Likewise, the low methoxyl pectin produced by this enzyme has characteristics that contribute to formulate best quality food products. Pectin methylesterase is a ubiquitously enzyme that presents multiple isoforms, but is not only present in plants; it is also found in fungi, bacteria, and yeast, which have specific chemical and physical characteristics. The latter makes the task of analyzing the wide variety of these enzymes with its specific characteristics difficult. Based on this enzyme relevance and the aforementioned, multiple methods have been developed in order to evaluate pectin methylesterase activity with different research objectives. In this paper, the importance of the enzyme as well as advantages and drawbacks of the different methods will be discussed besides applications and evolution of these will be mentioned. Additionally, this paper will improve the understanding of the systems used in pectin methylesterase activity analysis</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12161-017-0934-y</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s12161-017-0934-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Anal Methods\20171015-SalasTovarJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Anal Methods\20171015-SalasTovarJA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Salas-Tovar</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12161-017-0934-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jimenez-Lopez,J.C.</style></author><author><style face="normal" font="Arial"> Foley,R.C.</style></author><author><style face="normal" font="Arial"> Brear,E.</style></author><author><style face="normal" font="Arial"> Clarke,V.C.</style></author><author><style face="normal" font="Arial"> Lima-Cabello,E.</style></author><author><style face="normal" font="Arial"> Florido,J.F.</style></author><author><style face="normal" font="Arial"> Singh,K.B.</style></author><author><style face="normal" font="Arial"> Alche,J.D.</style></author><author><style face="normal" font="Arial"> Smith,P.M.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Characterization of narrow-leaf lupin (Lupinus angustifolius L.) recombinant major allergen IgE-binding proteins and the natural +¦-conglutin counterparts in sweet lupin seed species</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="70" start="60">60-70</pages><volume><style face="normal" font="Arial">244</style></volume><number><style face="normal" font="Arial">Supplement C</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Conglutins</style></keyword><keyword><style face="normal" font="Arial"> Cross-allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Cultivar</style></keyword><keyword><style face="normal" font="Arial"> Cultivars</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding activity</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding protein</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> Isoforms</style></keyword><keyword><style face="normal" font="Arial"> Lupin</style></keyword><keyword><style face="normal" font="Arial"> Lupinus</style></keyword><keyword><style face="normal" font="Arial"> Lupinus angustifolius L</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein A</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Seed protein</style></keyword><keyword><style face="normal" font="Arial"> Seed proteins</style></keyword><keyword><style face="normal" font="Arial"> Seed storage proteins</style></keyword><keyword><style face="normal" font="Arial"> Seeds</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Sweet lupin</style></keyword><keyword><style face="normal" font="Arial"> Vicilin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">+¦-conglutin has been identified as a major allergen for Lupinus angustifolius seeds. The aim of this study was to evaluate the binding of IgE to five recombinant +¦-conglutin isoforms (r+¦) that we overexpressed and purified and to their natural counterparts in different lupin species and cultivars. Western blotting suggested +¦-conglutins were the main proteins responsible for the IgE reactivity of the lupin species and cultivars. Newly identified polypeptides from </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£sweet lupin</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ may constitute a potential new source of primary or cross-reactive sensitization to lupin, particularly to L. albus and L. angustifolius seed proteins. Several of them exhibited qualitative and quantitative differences in IgE-binding among these species and cultivars, mainly in sera from atopic patients that react to lupin rather than peanut. IgE-binding was more consistent to recombinant +¦2 than to any of the other isoforms, making this protein a potential candidate for diagnosis and immunotherapy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.10.015</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodchem.2017.10.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\20171015-JimenezLopezJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\20171015-JimenezLopezJC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Jimenez-Lopez JC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.10.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhao,D.</style></author><author><style face="normal" font="Arial"> Le,T.T.</style></author><author><style face="normal" font="Arial"> Larsen,L.B.</style></author><author><style face="normal" font="Arial"> Li,L.</style></author><author><style face="normal" font="Arial"> Qin,D.</style></author><author><style face="normal" font="Arial"> Su,G.</style></author><author><style face="normal" font="Arial"> Li,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of glycation derived from +¦-dicarbonyl compounds on the in vitro digestibility of +¦-casein and +¦-lactoglobulin: A model study with glyoxal, methylglyoxal and butanedione</style></title><secondary-title><style face="normal" font="Arial">Food Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Food Res Int</style></full-title></periodical><pages end="322" start="313">313-322</pages><volume><style face="normal" font="Arial">102</style></volume><number><style face="normal" font="Arial">Supplement C</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Advanced glycation end products</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> digestibility</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Digestive protease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal digestion</style></keyword><keyword><style face="normal" font="Arial"> Glycation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> In vitro digestibility</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0963-9969</style></isbn><abstract><style face="normal" font="Arial">+¦-Dicarbonyl compounds, which are widely found in common consumed food, are one of the precursors of advanced glycation end products (AGEs). In this study, the effect of glycation derived from glyoxal (GO), methylglyoxal (MGO) or butanedione (BU) on the in vitro digestibility of +¦-casein (+¦-CN) and +¦-lactoglobulin (+¦-Lg) was investigated. Glycation from +¦-dicarbonyl compounds reduced the in vitro digestibility of studied proteins in both gastric and intestinal stage. In addition, glycation substantially altered the peptides released through gastric and gastrointestinal digestion, as detected by liquid chromatography electrospray-ionization tandem mass spectrometry (LC-ESI-MS/MS). Crosslinked glycation structures derived from BU considerably reduced the sensitivity of glycated +¦-Lg towards digestive proteases, albeit to a lesser degree in glycated +¦-CN due to its intrinsic unordered structure. By contrast, non-crosslinked AGEs that formed adjacent to enzymatic cleavage sites did not block the enzymatic reaction in several cases, as evidenced by the corresponding digested peptides modified with glycation structures. These findings expand our understanding of the nutritional influence of +¦-dicarbonyl compounds and health impact of relevant dietary AGEs</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodres.2017.10.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodres.2017.10.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Res Int\2017-102SC-313-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Res Int\2017-102SC-313-22.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Zhao D</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodres.2017.10.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vonk Marlotte,M.</style></author><author><style face="normal" font="Arial"> Diks,M.A.P.</style></author><author><style face="normal" font="Arial"> Wagenaar,L.</style></author><author><style face="normal" font="Arial"> Smit,J.J.</style></author><author><style face="normal" font="Arial"> Pieters,R.H.H.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> van Esch,B.C.A.M.</style></author><author><style face="normal" font="Arial"> Knippels,L.M.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Improved Efficacy of Oral Immunotherapy Using Non-Digestible Oligosaccharides in a Murine Cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs Milk Allergy Model: A Potential Role for Foxp3+ Regulatory T Cells</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="1230">1230-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acute allergic skin response</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy protection</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD25</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk</style></keyword><keyword><style face="normal" font="Arial"> CowGÇÖs milk</style><style face="normal" font="Symbol"> </style><style face="normal" font="Arial">allergy</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> galectin-9</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Non-digestible oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> OIT</style></keyword><keyword><style face="normal" font="Arial"> oligosaccharide</style></keyword><keyword><style face="normal" font="Arial"> Oligosaccharides</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Oral sensitization</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> Suspensions</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"></style><style face="normal" font="Arial"></style><style face="normal" font="Arial"> whey</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29=received</year></dates><publisher><style face="normal" font="Arial">Frontiers Media S.A.</style></publisher><isbn><style face="normal" font="Arial">1664-3224</style></isbn><abstract><style face="normal" font="Arial">BACKGROUND: Oral immunotherapy (OIT) is a promising therapeutic approach to treat food allergic patients. However, there are some concerns regarding its safety and long-term efficacy. The use of non-digestible oligosaccharides might improve OIT efficacy since they are known to directly modulate intestinal epithelial and immune cells in addition to acting as prebiotics. AIM: To investigate whether a diet supplemented with plant-derived fructo-oligosaccharides (FOS) supports the efficacy of OIT in a murine cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk allergy model and to elucidate the potential mechanisms involved. METHODS: After oral sensitization to the cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk protein whey, female C3H/HeOuJ mice were fed either a control diet or a diet supplemented with FOS (1% w/w) and received OIT (10</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çëmg whey) 5</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çëdays a week for 3</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çëweeks by gavage. Intradermal (i.d.) and intragastric (i.g.) challenges were performed to measure acute allergic symptoms and mast cell degranulation. Blood and organs were collected to measure antibody levels and T cell and dendritic cell populations. Spleen-derived T cell fractions (whole spleen- and CD25-depleted) were transferred to na+»ve recipient mice to confirm the involvement of regulatory T cells (Tregs) in allergy protection induced by OIT</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çë+</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇëFOS. RESULTS: OIT</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çë+</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇëFOS decreased acute allergic symptoms and mast cell degranulation upon challenge and prevented the challenge-induced increase in whey-specific IgE as observed in sensitized mice. Early induction of Tregs in the mesenteric lymph nodes (MLN) of OIT</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çë+</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇëFOS mice coincided with reduced T cell responsiveness in splenocyte cultures. CD25 depletion in OIT</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çë+</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇëFOS-derived splenocyte suspensions prior to transfer abolished protection against signs of anaphylaxis in recipients. OIT</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çë+</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇëFOS increased serum galectin-9 levels. No differences in short-chain fatty acid (SCFA) levels in the cecum were observed between the treatment groups. Concisely, FOS supplementation significantly improved OIT in the acute allergic skin response, %Foxp3+ Tregs and %LAP+ Th3 cells in MLN, and serum galectin-9 levels. CONCLUSION: FOS supplementation improved the efficacy of OIT in cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk allergic mice. Increased levels of Tregs in the MLN and abolished protection against signs of anaphylaxis upon transfer of CD25-depleted cell fractions, suggest a role for Foxp3+ Tregs in the protective effect of OIT</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çë+</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇëFOS</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -CO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.01230</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033945">PM:29033945</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1230.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-1230.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Vonk Marlotte M</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.01230</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bender,L.</style></author><author><style face="normal" font="Arial"> Weidmann,H.</style></author><author><style face="normal" font="Arial"> Rose-John,S.</style></author><author><style face="normal" font="Arial"> Renne,T.</style></author><author><style face="normal" font="Arial"> Long,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="1115">1115-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Bradykinin</style></keyword><keyword><style face="normal" font="Arial"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical chemistry</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cross-link</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> factor XII</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> HAE</style></keyword><keyword><style face="normal" font="Arial"> Heparin</style></keyword><keyword><style face="normal" font="Arial"> hereditary angioedema</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> kallikrein</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Polysaccharide</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a life-threatening allergic reaction. It is triggered by the release of pro-inflammatory cytokines and mediators from mast cells and basophils in response to immunologic or non-immunologic mechanisms. Mediators that are released upon mast cell activation include the highly sulfated polysaccharide and inorganic polymer heparin and polyphosphate (polyP), respectively. Heparin and polyP supply a negative surface for factor XII (FXII) activation, a serine protease that drives contact system-mediated coagulation and inflammation. Activation of the FXII substrate plasma kallikrein leads to further activation of zymogen FXII and triggers the pro-inflammatory kallikrein-kinin system that results in the release of the mediator bradykinin (BK). The severity of anaphylaxis is correlated with the intensity of contact system activation, the magnitude of mast cell activation, and BK formation. The main inhibitor of the complement system, C1 esterase inhibitor, potently interferes with FXII activity, indicating a meaningful cross-link between complement and kallikrein-kinin systems. Deficiency in a functional C1 esterase inhibitor leads to a severe swelling disorder called hereditary angioedema (HAE). The significance of FXII in these disorders highlights the importance of studying how these processes are integrated and can be therapeutically targeted. In this review, we focus on how FXII integrates with inflammation and the complement system to cause anaphylaxis and HAE as well as highlight current diagnosis and treatments of BK-related diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -CO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.01115</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28966616">PM:28966616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1115.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-1115.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Bender L</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.01115</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Munoz-Cano,R.</style></author><author><style face="normal" font="Arial"> Pascal,M.</style></author><author><style face="normal" font="Arial"> Araujo,G.</style></author><author><style face="normal" font="Arial"> Goikoetxea,M.J.</style></author><author><style face="normal" font="Arial"> Valero,A.L.</style></author><author><style face="normal" font="Arial"> Picado,C.</style></author><author><style face="normal" font="Arial"> Bartra,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unitat d'Allergia, Servei de Pneumologia, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Mechanisms, Cofactors, and Augmenting Factors Involved in Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="1193">1193-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Alcohol</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Angiotensin-converting enzyme inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> Beta-blockers</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> cofactor</style></keyword><keyword><style face="normal" font="Arial"> cofactors</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> estrogen</style></keyword><keyword><style face="normal" font="Arial"> Estrogens</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is an acute and life-threatening systemic reaction. Many triggers have been described, including food, drug, and hymenoptera allergens, which are the most frequently involved. The mechanisms described in anaphylactic reactions are complex and implicate a diversity of pathways. Some of these mechanisms may be key to the development of the anaphylactic reaction, while others may only modify its severity. Although specific IgE, mast cells, and basophils are considered the principal players in anaphylaxis, alternative mechanisms have been proposed in non-IgE anaphylactic reactions. Neutrophils, macrophages, as well as basophils, have been involved, as have IgG-dependent, complement and contact system activation. A range of cationic substances can induce antibody-independent mast cells activation through MRGPRX2 receptor. Cofactors and augmenting factors may explain why, in some patients, food allergen exposure can cause anaphylaxis, while in other clinical scenario it can be tolerated or elicits a mild reaction. With the influence of these factors, food allergic reactions may be induced at lower doses of allergen and/or become more severe. Exercise, alcohol, estrogens, and some drugs such as Non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, beta-blockers, and lipid-lowering drugs are the main factors described, though their mechanisms and signaling pathways are poorly understood</style></abstract><notes><style face="normal" font="Arial">DA - 20171011IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.01193</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29018449">PM:29018449</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1193.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-1193.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171011, Munoz-Cano R</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.01193</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tefera,E.</style></author><author><style face="normal" font="Arial"> Knapp,J.</style></author><author><style face="normal" font="Arial"> Teodori,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics &amp; Child Health, Cardiology Division, School of Medicine, Addis Ababa University, Addis Ababa, EthiopiaInternational Heart Institute of Montana, Missoula, Montana, USADepartment of Surgery, Pediatric and Adult Congenital Heart Surgery division, University of Arizona Tucson, AZ, USA</style></auth-address><titles><title><style face="normal" font="Arial">Hydatid cyst of the interventricular septum</style></title><secondary-title><style face="normal" font="Arial">Glob Cardiol Sci Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Glob Cardiol Sci Pract</style></abbr-1></periodical><pages end="" start="e201709">e201709-</pages><volume><style face="normal" font="Arial">2017</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> congenital</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Echinococcosis</style></keyword><keyword><style face="normal" font="Arial"> Ethiopia</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medical treatment</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Rupture</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="Arial">While cardiac involvement is not a common presentation in human echinococcosis, it may lead to life-threatening complications including cyst rupture; anaphylactic shock; tamponade; pulmonary, cerebral or peripheral arterial embolism; acute coronary syndrome; dysrhythmias; infection; ventricular or valvular dysfunction, as well as sudden death. Here we report a 9-year old girl who was diagnosed to have hydatid cyst of the interventricular septum four years after diagnosis and medical treatment of pulmonary hydatidosis. Presentation, management and follow-up of the patient is discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2305-7823 (Print)IS - 2305-7823 (Linking)LA - engPT - Journal ArticleCO - Ethiopia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.21542/gcsp.2017.9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28971108">PM:28971108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Glob Cardiol Sci Pract\2017-2017-e201709.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Glob Cardiol Sci Pract\2017-2017-e201709.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Tefera E</style></custom2><misc3><style face="normal" font="Arial">10.21542/gcsp.2017.9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Klimek,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Surf the allergy Tsunami</style></title><secondary-title><style face="normal" font="Arial">HNO</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">HNO</style></full-title></periodical><pages end="800" start="797">797-800</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1433-0458</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - GERCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00106-017-0412-2</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s00106-017-0412-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\HNO\2017-65-797-800.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\HNO\2017-65-797-800.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Klimek L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00106-017-0412-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santos,R.B.</style></author><author><style face="normal" font="Arial"> Galvao,V.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Clinical Immunology and Allergy, University of Sao Paulo, School of Medicine, Av. Dr. Arnaldo, 455-Cerqueira Cesar, Sao Paulo, Sao Paulo 01246-903, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Monoclonal Antibodies Hypersensitivity: Prevalence and Management</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="711" start="695">695-711</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Biological agents</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">The use of monoclonal antibodies (mAbs) has become broader because of their recognized effectiveness in the treatment of autoimmune, neoplastic, and inflammatory diseases. Consequently, hypersensitivity reactions (HSR) secondary to mAbs are being reported more often, and each mAb-related HSR presents specific features. This article discusses the main biological agents and associated HSR, the clinical presentation of such reactions, and the role of tryptase and skin testing in the diagnosis. Rapid drug desensitization procedures to mAbs enable selected allergic patients to receive full therapeutic doses in a safe manner and are also discussed</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965635">PM:28965635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-695-711.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-695-711.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Santos RB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.07.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Foer,D.</style></author><author><style face="normal" font="Arial"> Buchheit,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Progestogen Hypersensitivity: An Evidence-Based Approach to Diagnosis and Management in Clinical Practice</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="784" start="773">773-784</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Contraception</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fertility</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Luteal Phase</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Menstrual Cycle</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pH</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Progesterone</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">Heterogeneous presentations of disease pose particular diagnostic and management challenges to the clinician. Progestogen hypersensitivity (PH) classically consists of hypersensitivity symptoms to endogenous progesterone during the luteal phase of the menstrual cycle. However, with the rise of assisted fertility and the exponential growth in the use of exogenous progestins for contraception, PH's prevalence and symptom heterogeneity have increased. In this article, we focus on the clinical approach to PH diagnosis with an emphasis on key elements of the history, physical, and testing modalities. We also review the current evidence for successful management and treatment across a broad range of patients</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/01652176.2017.1387828</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965640">PM:28965640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-773-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-773-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Foer D</style></custom2><misc3><style face="normal" font="Arial">10.1080/01652176.2017.1387828</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Norton,A.E.</style></author><author><style face="normal" font="Arial"> Broyles,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Pulmonary, Allergy and Immunology, Vanderbilt Children's Hospital, School of Medicine, 100 Oaks, 719 Thompson Lane, Nashville, TN 37204, USA. Electronic address: Allison.norton@vanderbilt.eduDivision of Allergy and Immunology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. Electronic address: ana.broyles@childrens.harvard.edu</style></auth-address><titles><title><style face="normal" font="Arial">Management of Children with Hypersensitivity to Antibiotics and Monoclonal Antibodies</style></title><secondary-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="725" start="713">713-725</pages><volume><style face="normal" font="Arial">37</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> betalactam</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug allergies</style></keyword><keyword><style face="normal" font="Arial"> drug allergy</style></keyword><keyword><style face="normal" font="Arial"> Drug reaction</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">Proper management of drug allergy in children is based on a thorough history, in vitro testing (if available), in vivo testing, and drug challenge. This approach has been well developed with beta-lactam drugs but not with non-beta-lactam drugs and monoclonal antibodies. Children commonly develop rashes during an antibiotic course, which can lead to misdiagnosis of drug allergy. Clinical reactions to monoclonal antibodies vary and are managed depending on the type. A better knowledge of drug reactions that can occur in antibiotic allergy and monoclonal allergy can aid a provider in better management of their drug-allergic pediatric patients</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.iac.2017.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965636">PM:28965636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-713-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunol Allergy Clin North Am\2017-37-713-25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Norton AE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.iac.2017.07.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mammen,M.J.</style></author><author><style face="normal" font="Arial"> Sands,M.F.</style></author><author><style face="normal" font="Arial"> Abou-Jaoude,E.</style></author><author><style face="normal" font="Arial"> Aalinkeel,R.</style></author><author><style face="normal" font="Arial"> Reynolds,J.L.</style></author><author><style face="normal" font="Arial"> Parikh,N.U.</style></author><author><style face="normal" font="Arial"> Sharma,U.</style></author><author><style face="normal" font="Arial"> Schwartz,S.A.</style></author><author><style face="normal" font="Arial"> Mahajan,S.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University at Buffalo, State University of New York, Buffalo, NY, 14214</style></auth-address><titles><title><style face="normal" font="Arial">Role of Galectin-3 in the pathophysiology underlying allergic lung inflammation in a TIMP-1 Knockout model of murine asthma</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> Buffalo</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Galectin 3</style></keyword><keyword><style face="normal" font="Arial"> Galectins</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> hyperreactivity</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Knockout mice</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> New York</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="10" Year="2017">2017/10/9</year></dates><abstract><style face="normal" font="Arial">Asthma is a chronic inflammatory respiratory disease characterized by airway inflammation, airway hyper-responsiveness and reversible airway obstruction. Understanding the mechanisms that underlie the various endotypes of asthma could lead to novel and more personalized therapies for individuals with asthma. Utilizing a Tissue inhibitors of metalloproteinase-1 (TIMP-1) knockout murine allergic asthma model, we previously showed that Tissue inhibitors of metalloproteinase-1 deficiency results in an asthma phenotype, exhibiting airway hyperreactivity, enhanced eosinophilic inflammation, and TH2 cytokine gene and protein expression following sensitization with ovalbumin. In the current study, we compared the expression of Galectins and other key cytokines in a murine allergic asthma model utilizing wild type and TIMP-1 knockout mice. We also examined the effects of Galectin-3 (Gal-3) inhibition on a non-TH2 cytokine IL-17 to evaluate the relationship between Gal-3 and IL-17 axis in allergic asthma. Our results showed a significant increase in Gal-3, IL-17 and TGFss1 gene expression in lung tissue isolated from an allergic asthma murine model utilizing Tissue inhibitors of metalloproteinase-1 knockout. Gal-3 gene and protein expression levels were also significantly higher in lung tissue from allergic asthma murine model utilizing TIMP-1 knockout. Our data shows that Gal-3 may regulate the IL-17 axis and play a pivotal role in the modulation of inflammation during experimental allergic asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12848</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28992358">PM:28992358</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20171009-MammenMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20171009-MammenMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171009, Mammen MJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12848</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kumar,R.</style></author><author><style face="normal" font="Arial"> Kumar,M.</style></author><author><style face="normal" font="Arial"> Bisht,I.</style></author><author><style face="normal" font="Arial"> Singh,K.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Prevalence of aeroallergens in patients of bronchial asthma and/or allergic rhinitis in India based on skin prick test reactivity</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="55" start="45">45-55</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> ARIA</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> Cotton</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mosquito</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Silk</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Tree pollens</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weed pollens</style></keyword><keyword><style face="normal" font="Arial"> Wool</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">&lt;b>Background:&lt;/b> Exposures to various aeroallergens play a crucial role in the pathogenesis of bronchial asthma (BA) and allergic rhinitis (AR). On the basis of climate change, the prevalence of aeroallergens may vary in different regions. &lt;b>AIMS:&lt;/b> The aim of the study was to determine the prevalence of the sensitivity to aeroallergens among patients with BA and/or AR based on skin prick test (SPT) reactivity in India. &lt;b>Settings And Design:&lt;/b> This study was conducted at National Centre of Respiratory Allergy, Asthma and Immunology and Department of Respiratory Allergy and Applied Immunology, (Department of Respiratory Medicine), Vallabhbhai Patel Chest Institute, University of Delhi, Delhi-110007 (India). &lt;b>Subjects And Methods:&lt;/b> A total of 4835 patients were screened from the Outpatient Department of institute during the period of August 2008 to July 2016. Out of 4835 patients, 4263 patients were performed SPT consisting of 2361 (55.38&amp;#37;) males and 1902 (44.62&amp;#37;) females, with a mean age of 30.06 years were included in the study. Diagnosis of BA and AR was made according to the GINA and ARIA guidelines, respectively. SPT was done with 58 different types of aeroallergens, which included grass pollens, weed pollens, tree pollens, dust, fungi, insects, kapok cotton, wool, and silk antigens. &lt;b>Statistical Analysis Used:&lt;/b> Data analysis was done using Excel 2007. &lt;b>Results:&lt;/b> Significant skin positive reaction (2 &amp;#43; and above) against aeroallergens were found in 1993 (46.77&amp;#37;) participants including 422 (9.9&amp;#37;) BA patients, 570 (13.37&amp;#37;) AR patients, and 1001 (23.48&amp;#37;) of both BA/AR. The younger adults aged 20&amp;#8211;29 years were the foremost commonly affected group with 626 (14.68&amp;#37;) significant skin-positive patients. Among individual allergens, most common aeroallergen was mosquito (30.89&amp;#37;) and least common was Ehretia (0.37&amp;#37;). &lt;b>Conclusions:&lt;/b> In different states of India, the mosquito was found the most common sensitizing allergen in BA and/or AR patients. Sensitization was the most common in the younger age group (20&amp;#8211;29 years) patients</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/ijaai.ijaai_23_17</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/ijaai.ijaai_23_17</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2017-31-45-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2017-31-45-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Kumar R</style></custom2><misc3><style face="normal" font="Arial">10.4103/ijaai.ijaai_23_17</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hoh,K.</style></author><author><style face="normal" font="Arial"> Swaminathan,V.</style></author></authors></contributors><titles><title><style face="italic" font="Arial">In silico</style><style face="normal" font="Arial"> identification and characterization of putative kuruma prawn (Marsupenaeus japonicus) allergens</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="93" start="87">87-93</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Arginine</style></keyword><keyword><style face="normal" font="Arial"> Arginine kinase</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cathepsin B</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Chymotrypsin</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> isoform</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> kuruma prawn</style></keyword><keyword><style face="normal" font="Arial"> leukocyte</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Malaysia</style></keyword><keyword><style face="normal" font="Arial"> myosin</style></keyword><keyword><style face="normal" font="Arial"> Myosin light chain</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> peptide immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Prawn</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> Proteinase</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sarcoplasmic</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Trypsin</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">&lt;b>Background:&lt;/b> Prawn is one of the major sources of shellfish allergens, which will induce mild to severe allergic reactions. &lt;b>Aim:&lt;/b> The objective of this study was to predict putative allergens and its characteristics present in &lt;i>Marsupenaeus japonicus&lt;/i> through an &lt;i>in silico&lt;/i> approach. &lt;b>Materials And Methods:&lt;/b> In this present study, &lt;i>in silico&lt;/i> tools, RaptorX, Bepipred Linear Epitope and Parker Hydrophilicity Prediction method, and MHC2Pred were used to predict the putative and cross-reactive allergens, tertiary and secondary structures, B-cell linear epitopes, and T-cell epitopes, respectively. &lt;b>Results:&lt;/b> As a result, eight putative and cross-reactive allergens including tropomyosin fast isoform, arginine kinase, sarcoplasmic calcium binding protein, myosin light chain, chymotrypsin like proteinase, superoxide dismutase, cathepsin B, and trypsin were predicted by analyzing the protein sequences of &lt;i>M. japonicus&lt;/i>. Furthermore, five amino acids (Ala, Ser, Asn, Gly, and Lys) play a vital role in immunoglobulin E binding allergenic epitope. At least one of them was found in the predicted B-cell epitope for each of the predicted putative allergens. Moreover, the predicted T-cell epitopes were highly associated with human leukocyte antigen (HLA) DRB1&amp;#42;0101 and HLA-DRB1&amp;#42;0901 alleles while mediating T-cell immune responses. &lt;b>Conclusion:&lt;/b> These results can be utilized to contribute in peptide immunotherapy and reduce the allergic diseases related to shellfish</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Malaysia -</style></notes><work-type><style face="normal" font="Arial">10.4103/0972-6691.215837</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/0972-6691.215837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2017-31-87-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2017-31-87-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Hoh K</style></custom2><misc3><style face="normal" font="Arial">10.4103/0972-6691.215837</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Singh,A.</style></author><author><style face="normal" font="Arial"> Upadhyay,R.</style></author><author><style face="normal" font="Arial"> Tayal,N.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Diagnostic and treatment challenges in management of allergic fungal rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="44" start="38">38-44</pages><volume><style face="normal" font="Arial">31</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal</style></keyword><keyword><style face="normal" font="Arial"> allergic fungal rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic parameters</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Terminology</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="Arial">Among infections pertaining to head and neck rhinosinusitis holds a significant position both with regard to the prevalence and morbidity. Allergic fungal rhinosinusitis (AFRS) was initially considered a counterpart of allergic bronchopulmonary aspergillosis when first diagnosed by Sa firstein in 1976 due to its clinical presentations and seemingly similar pathogenesis. Initially only &lt;i>Aspergillus&lt;/i> was known as the causative, but now various other fungal species are known to cause chronic rhinosinusitis; hence, the terminology allergic fungal sinusitis was preferred. Exposure to fungi results in similar as asthma in atopic individuals, but then, some nonatopic individuals may also present with similar symptoms. It has also been studied that the presence of serum immunoglobulin E does not ensure the presence of allergy. Till date, there are several controversies regarding pathogenesis, whether humoral or immune mediated, population at risk, variations in presentations, diagnostic parameters, and treatment protocols. In this review, we try to revisit and learn from past documented experiences to further our attempt toward better understanding of the disease process, its diagnosis, and management</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.4103/ijaai.ijaai_31_16</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/ijaai.ijaai_31_16</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2017-31-38-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Allergy Asthma Immunol\2017-31-38-44.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Singh A</style></custom2><misc3><style face="normal" font="Arial">10.4103/ijaai.ijaai_31_16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mueller,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Health and Human Services, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Contributions and Future Directions for Structural Biology in the Study of Allergens</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="66" start="57">57-66</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> hypoallergen</style></keyword><keyword><style face="normal" font="Arial"> Hypotheses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="Arial">Allergy is defined as an inappropriate immune response to something normally considered harmless. The symptomatic immune response is driven by IgE antibodies directed against allergens. The study of allergens has contributed significantly to our understanding of allergic disease in 3 main areas. First, identifying allergens as the cause of symptoms and developing allergen standards has led to many advances in exposure assessment and patient diagnostics. Second, a biochemical understanding of allergens has suggested a number of hypotheses related to the mechanisms of allergic sensitization. And finally, studies of allergen-antibody interactions have contributed to understanding the cross-reactivity of allergens, mapping patient epitopes, and the development of hypoallergens. In this review, a few select cases are highlighted where structural biology, in particular, has contributed significantly to allergen research and provided new avenues for investigation</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1159/000481078</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28992615">PM:28992615</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-57-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-57-66.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171009, Mueller GA</style></custom2><misc3><style face="normal" font="Arial">10.1159/000481078</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brotons-Canto,A.</style></author><author><style face="normal" font="Arial"> Gamazo,C.</style></author><author><style face="normal" font="Arial"> Martin-Arbella,N.</style></author><author><style face="normal" font="Arial"> Abdulkarim,M.</style></author><author><style face="normal" font="Arial"> Matias,J.</style></author><author><style face="normal" font="Arial"> Gumbleton,M.</style></author><author><style face="normal" font="Arial"> Irache,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008, Pamplona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy</style></title><secondary-title><style face="normal" font="Arial">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biol Macromol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Diffusion</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Hydrophobicity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intestinal epithelium</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Peyer's Patches</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> Survival Rate</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> vehicle</style></keyword><keyword><style face="normal" font="Arial"> Vehicles</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="28" Month="9" Year="2017">2017/9/28</year></dates><abstract><style face="normal" font="Arial">The aim of this work was to evaluate the potential application of an original oral immunotherapy, based on the use of nanoparticles, against an experimentally induced peanut allergy. In this context, a roasted peanut extract, containing the main allergenic proteins, were encapsulated into poly(anhydride) nanoparticles. The resulting devices (PE-NP) displayed a mean size of about 150nm and a significantly lower surface hydrophobicity than empty nanoparticles (NP). This low hydrophobicity correlated well with a higher in vitro diffusion in pig intestinal mucus than NP and an important in vivo capability to reach the intestinal epithelium and Peyer's patches. The immunotherapeutic capability of PE-NP was evaluated in a model of pre-sensitized CD1 mice to peanut. After completing therapy of three doses of peanut extract, either free or encapsulated into nanoparticles, mice underwent an intraperitoneal challenge. Anaphylaxis was evaluated by means of assessment of symptom scores and mouse mast cell protease-1 levels (mMCPT-1). PE-NP treatment was associated with significant lower levels of mMCPT-1, and a significant survival rate after challenge, confirming the protective effect of this formulation against the challenge. In summary, this nanoparticle-based formulation might be a valuable strategy for peanut-specific immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.09.109</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965967">PM:28965967</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biol Macromol\20171002-BrotonsCantoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biol Macromol\20171002-BrotonsCantoA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Brotons-Canto A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.09.109</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arriola,A.G.P.</style></author><author><style face="normal" font="Arial"> Martin,N.D.</style></author><author><style face="normal" font="Arial"> Tondon,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 University of Texas MD Anderson Cancer Center, Houston, TX, USA</style></auth-address><titles><title><style face="normal" font="Arial">Crystals in Perforated Bowel: Culprits or Innocent Bystanders</style></title><secondary-title><style face="normal" font="Arial">Int J Surg Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Surg Pathol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cancer</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171006IS - 1940-2465 (Electronic)IS - 1066-8969 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="Arial">10.1177/1066896917735172</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28982290">PM:28982290</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Surg Pathol\20171006-ArriolaAG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Surg Pathol\20171006-ArriolaAG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171006, Arriola AG</style></custom2><misc3><style face="normal" font="Arial">10.1177/1066896917735172</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Salzer,H.J.F.</style></author><author><style face="normal" font="Arial"> Lange,C.</style></author><author><style face="normal" font="Arial"> Honigl,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinische Infektiologie, Medizinische Klinik, Forschungszentrum Borstel, Leibniz-Zentrum fur Medizin und Biowissenschaften, Parkallee 35, 23845, Borstel, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Aspergillus in airway material : Ignore or treat?]</style></title><secondary-title><style face="normal" font="Arial">Internist (Berl)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Internist (Berl)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity pneumonitis</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological methods</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="Arial">Fungi of the genus Aspergillus are ubiquitously present. Even though humans inhale Aspergillus spores daily under natural conditions, Aspergillus-associated pulmonary diseases only occur under special circumstances. Whether an Aspergillus-associated disease develops and which type of Aspergillus-associated disease develops depends on the constitution of the host. The spectrum of Aspergillus-associated pulmonary diseases ranges from allergic diseases, such as hypersensitivity pneumonitis to allergic infectious diseases, such as allergic bronchopulmonary aspergillosis (ABPA) and bronchocentric granulomatosis (BG) to infectious diseases, such as invasive (IA) or semi-invasive aspergillosis (SIA) and chronic pulmonary aspergillosis (CPA). Identification of Aspergillus spp. from sputum or bronchopulmonary secretions is not sufficient for a definitive diagnosis of Aspergillus-associated infections. The gold standard is the identification of Aspergillus spp. from lung tissue by culture or by histopathological methods; however, in clinical practice the decision to initiate antifungal therapy is more often based on immunological methods, such as the detection of Aspergillus-specific IgG antibodies from peripheral blood or galactomannan antigens from bronchoalveolar lavages. Acute IA or SIA infections have a high mortality and require immediate antifungal therapy. With rare exceptions CPA cannot be cured by medicinal therapy alone; however, active CPA can be brought into remission with antifungal therapy. Eradication of Aspergillus in CPA can as a rule only be successful using a combined antimycotic and surgical intervention</style></abstract><notes><style face="normal" font="Arial">DA - 20171007IS - 1432-1289 (Electronic)IS - 0020-9554 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewCO - Germany -CO - Sweden -CO - Austria -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00108-017-0334-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28986661">PM:28986661</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Internist (Berl)\20171007-SalzerHJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Internist (Berl)\20171007-SalzerHJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171007, Salzer HJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00108-017-0334-9</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhong,C.</style></author><author><style face="normal" font="Arial"> Yang,W.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Zou,L.</style></author><author><style face="normal" font="Arial"> Deng,Z.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author><author><style face="normal" font="Arial"> Huang,X.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Clinical evaluation for sublingual immunotherapy with Dermatophagoides farinae drops in adult patients with allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Ir J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ir J Med Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical evaluation</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1863-4362</style></isbn><abstract><style face="normal" font="Arial">The efficacy and safety of sublingual immunotherapy (SLIT) in house dust mite-induced allergic asthma (AA) have yet to be firmly established, especially in adult patients. Our objective is to evaluate the efficacy of SLIT with Dermatophagoides farinae drops in adult patients with AA</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11845-017-1685-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29032417">PM:29032417</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ir J Med Sci\20171015-ZhongC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ir J Med Sci\20171015-ZhongC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Zhong C</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11845-017-1685-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cuomo,B.</style></author><author><style face="normal" font="Arial"> Indirli,G.C.</style></author><author><style face="normal" font="Arial"> Bianchi,A.</style></author><author><style face="normal" font="Arial"> Arasi,S.</style></author><author><style face="normal" font="Arial"> Caimmi,D.</style></author><author><style face="normal" font="Arial"> Dondi,A.</style></author><author><style face="normal" font="Arial"> La Grutta,S.</style></author><author><style face="normal" font="Arial"> Panetta,V.</style></author><author><style face="normal" font="Arial"> Verga,M.C.</style></author><author><style face="normal" font="Arial"> Calvani,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Operative Complex Unit of Pediatrics, Belcolle Hospital, Viterbo, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Specific IgE and skin prick tests to diagnose allergy to fresh and baked cow's milk according to age: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Ital J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ital J Pediatr</style></full-title></periodical><pages end="" start="93">93-</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> cooking</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Predictive values</style></keyword><keyword><style face="normal" font="Arial"> Prick by prick</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The diagnosis of IgE-mediated cow's milk allergy is often based on anamnesis, and on specific IgE (sIgE) levels and/or Skin Prick Tests (SPT), which have both a good sensitivity but a low specificity, often causing positive results in non-allergic subjects. Thus, oral food challenge is still the gold standard test for diagnosis, though being expensive, time-consuming and possibly at risk for severe allergic reactions. AIM: The aim of the present study was to perform a systematic review of the studies that have so far analyzed the positive predictive values for sIgE and SPT in the diagnosis of allergy to fresh and baked cow's milk according to age, and to identify possible cut-offs that may be useful in clinical practice. METHODS: A comprehensive search on Medline via PubMed and Scopus was performed August 2017. Studies were included if they investigated possible sIgE and/or SPT cut-off values for cow's milk allergy diagnosis in pediatric patients. The quality of the studies was evaluated according to QUADAS-2 criteria. RESULTS: The search produced 471 results on Scopus, and 2233 on PubMed. Thirty-one papers were included in the review and grouped according to patients' age, allergen type and cooking degree of the milk used for the oral food challenge. In children &lt; 2 years, CMA diagnosis seems to be highly likely when sIgE to CM extract are >/= 5 KUA/L or when SPT with commercial extract are above 6 mm or Prick by Prick (PbP) with fresh cow's milk are above 8 mm. Any cut-offs are proposed for single cow's milk proteins and for baked milk allergy in children younger than 2 years. In Children >/= 2 years of age it is hard to define practical cut-offs for allergy to fresh and baked cow's milk. Cut-offs identified are heterogeneous. CONCLUSIONS: None of the cut-offs proposed in the literature can be used to definitely confirm cow's milk allergy diagnosis, either to fresh pasteurized or to baked milk. However, in children &lt; 2 years, cut-offs for specific IgE or SPT seem to be more homogeneous and may be proposed</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 1824-7288 (Electronic)IS - 1720-8424 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1186/s13052-017-0410-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29025431">PM:29025431</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ital J Pediatr\2017-43-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ital J Pediatr\2017-43-93.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171013, Cuomo B</style></custom2><misc3><style face="normal" font="Arial">10.1186/s13052-017-0410-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kee,J.Y.</style></author><author><style face="normal" font="Arial"> Hong,S.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Inhibition of Mast cell-mediated Allergic Responses by Arctii Fructus Extracts and its Main Compound Arctigenin</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> anti-allergic activity</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory activity</style></keyword><keyword><style face="normal" font="Arial"> Antiallergic activity</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">The Arctium lappa (Arctii Fructus) seed and its major active compound, arctigenin (ARC), are known to have anti-cancer, anti-obesity, anti-osteoporosis, and anti-inflammatory activities. However, the effect of Arctii Fructus and ARC on mast cell-mediated allergic inflammation and the associated mechanism have not been elucidated. Therefore, we attempted to investigate the anti-allergic activity of Arctii Fructus and ARC on mast cells and experimental mouse models. Arctii Fructus water (AFW) or ethanol extract (AFE) and ARC reduced the production of histamine and pro-inflammatory cytokines such as interleukin (IL)-1beta, IL-6, IL-8, and TNF-alpha in mast cells. AFW, AFE, and ARC inhibited phosphorylation of MAPKs and NF-kappaB in activated mast cells. Moreover, IgE-mediated passive cutaneous anaphylaxis and compound 48/80-induced anaphylactic shock were suppressed by AFW, AFE, and ARC administration. These results suggest that Arctii Fructus and ARC are potential therapeutic agents against allergic inflammatory diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b02965</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28976750">PM:28976750</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20171004-KeeJY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20171004-KeeJY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Kee JY</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b02965</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vadasz,Z.</style></author><author><style face="normal" font="Arial"> Tal,Y.</style></author><author><style face="normal" font="Arial"> Rotem,M.</style></author><author><style face="normal" font="Arial"> Shichter-Confino,V.</style></author><author><style face="normal" font="Arial"> Mahlab-Guri,K.</style></author><author><style face="normal" font="Arial"> Graif,Y.</style></author><author><style face="normal" font="Arial"> Kessel,A.</style></author><author><style face="normal" font="Arial"> Agmon-Levin,N.</style></author><author><style face="normal" font="Arial"> Maoz-Segal,R.</style></author><author><style face="normal" font="Arial"> Kivity,S.</style></author><author><style face="normal" font="Arial"> Benor,S.</style></author><author><style face="normal" font="Arial"> Lachover-Roth,I.</style></author><author><style face="normal" font="Arial"> Zeldin,Y.</style></author><author><style face="normal" font="Arial"> Stein,M.</style></author><author><style face="normal" font="Arial"> Toker,O.</style></author><author><style face="normal" font="Arial"> Hassoun,G.</style></author><author><style face="normal" font="Arial"> Bezalel-Rosenberg,S.</style></author><author><style face="normal" font="Arial"> Toubi,E.</style></author><author><style face="normal" font="Arial"> Asher,I.</style></author><author><style face="normal" font="Arial"> Sthoeger,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Haifa, Israel.</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1745" start="1743">1743-1745</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.08.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988786">PM:28988786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1743-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1743-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171009, Vadasz Z</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.08.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jensen,E.T.</style></author><author><style face="normal" font="Arial"> Kuhl,J.T.</style></author><author><style face="normal" font="Arial"> Martin,L.J.</style></author><author><style face="normal" font="Arial"> Langefeld,C.D.</style></author><author><style face="normal" font="Arial"> Dellon,E.S.</style></author><author><style face="normal" font="Arial"> Rothenberg,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Epidemiology and Prevention, Wake Forest University Public Health Sciences, Winston-Salem, NC</style></auth-address><titles><title><style face="normal" font="Arial">Early-life environmental exposures interact with genetic susceptibility variants in pediatric patients with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analyses</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> CCL26</style></keyword><keyword><style face="normal" font="Arial"> cesarean</style></keyword><keyword><style face="normal" font="Arial"> Cesarean delivery</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> EoE</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> gene-environment</style></keyword><keyword><style face="normal" font="Arial"> gene-environment interaction</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> neonatal</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword></keywords><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Although eosinophilic esophagitis (EoE) is associated with certain gene variants, the rapidly increasing incidence of EoE suggests that environmental factors contribute to disease development. OBJECTIVE: We tested for gene-environment interaction between EoE-predisposing polymorphisms (within TSLP, LOC283710/KLF13, CAPN14, CCL26, and TGFB) and implicated early-life factors (antibiotic use in infancy, cesarean delivery, breast-feeding, neonatal intensive care unit [NICU] admission, and absence of pets in the home). METHODS: We conducted a case-control study using hospital-based cases (n = 127) and control subjects representative of the hospital catchment area (n = 121). We computed case-only interaction tests and in secondary analyses evaluated the combined and independent effects of genotype and environmental factors on the risk of EoE. RESULTS: Case-only analyses identified interactions between rs6736278 (CAPN14) and breast-feeding (P = .02) and rs17815905 (LOC283710/KLF13) and NICU admission (P = .02) but not with any of the factors examined. Case-control analyses suggested that disease risk might be modifiable in subjects with certain gene variants. In particular, breast-feeding in those with the susceptibility gene variant at rs6736278 (CAPN14) reduced the risk of EoE (adjusted odds ratio, 0.08; 95% CI, 0.01-0.59). Admission to the NICU in those without the susceptibility gene variant at rs17815905 (LOC283710/KLF13) significantly increased the risk of having disease (adjusted odds ratio, 4.83; 95% CI, 1.49-15.66). CONCLUSIONS: The interplay of gene (CAPN14 and LOC283710/KLF13) and early-life environment factors (breast-feeding and NICU admission) might contribute to EoE susceptibility</style></abstract><notes><style face="normal" font="Arial">DA - 20171014IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29029802">PM:29029802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171014-JensenET.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171014-JensenET.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171014, Jensen ET</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jartti,T.</style></author><author><style face="normal" font="Arial"> Gern,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Paediatrics, Turku University Hospital and University of Turku, Turku, Finland.</style></auth-address><titles><title><style face="normal" font="Arial">Role of viral infections in the development and exacerbation of asthma in children</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="906" start="895">895-906</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> Airway Obstruction</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Bronchiolitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> recurrent wheeze</style></keyword><keyword><style face="normal" font="Arial"> Recurrent wheezing</style></keyword><keyword><style face="normal" font="Arial"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> RSV</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> Virulence</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword><keyword><style face="normal" font="Arial"> young children</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">Viral infections are closely linked to wheezing illnesses in children of all ages. Respiratory syncytial virus (RSV) is the main causative agent of bronchiolitis, whereas rhinovirus (RV) is most commonly detected in wheezing children thereafter. Severe respiratory illness induced by either of these viruses is associated with subsequent development of asthma, and the risk is greatest for young children who wheeze with RV infections. Whether viral illnesses actually cause asthma is the subject of intense debate. RSV-induced wheezing illnesses during infancy influence respiratory health for years. There is definitive evidence that RSV-induced bronchiolitis can damage the airways to promote airway obstruction and recurrent wheezing. RV likely causes less structural damage and yet is a significant contributor to wheezing illnesses in young children and in the context of asthma. For both viruses, interactions between viral virulence factors, personal risk factors (eg, genetics), and environmental exposures (eg, airway microbiome) promote more severe wheezing illnesses and the risk for progression to asthma. In addition, allergy and asthma are major risk factors for more frequent and severe RV-related illnesses. Treatments that inhibit inflammation have efficacy for RV-induced wheezing, whereas the anti-RSV mAb palivizumab decreases the risk of severe RSV-induced illness and subsequent recurrent wheeze. Developing a greater understanding of personal and environmental factors that promote more severe viral illnesses might lead to new strategies for the prevention of viral wheezing illnesses and perhaps reduce the subsequent risk for asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20171008IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Finland -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987219">PM:28987219</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-895-906.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-895-906.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171008, Jartti T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Santos,N.</style></author><author><style face="normal" font="Arial"> Silva,P.M.</style></author><author><style face="normal" font="Arial"> Sao Braz,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergy and Clinical Immunology Department, Centro Hospitalar do Algarve, Portimao, Portugal.</style></auth-address><titles><title><style face="normal" font="Arial">A Case of Flagellate Dermatitis After Ingestion of Shiitake Mushrooms</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Mushrooms</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> Shiitake mushroom</style></keyword><keyword><style face="normal" font="Arial"> Shiitake Mushrooms</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.08.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28970086">PM:28970086</url></web-urls><pdf-urls><url ppv-ref="no">natachalsantos@gmail.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20171003, Santos N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.08.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al Enezi,M.</style></author><author><style face="normal" font="Arial"> Lack,G.</style></author><author><style face="normal" font="Arial"> Fox,A.T.</style></author><author><style face="normal" font="Arial"> Anagnostou,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Alberta, Stollery Hospital, Edmonton, Alberta, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Safety and allergic reaction profiles of children undergoing baked milk and egg challenges: a 6-year experience from a pediatric tertiary referral center</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Alberta</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> baked milk</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -CO - United KIngdom -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.08.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28970083">PM:28970083</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20171003-AlEneziM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20171003-AlEneziM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Al Enezi M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.08.033</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tang,M.L.K.</style></author><author><style face="normal" font="Arial"> Koplin,J.J.</style></author><author><style face="normal" font="Arial"> Sampson,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Murdoch Childrens Research Institute, Parkville, Victoria, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Parkville, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Skin Testing or sIgE Testing Is Necessary Before Early Introduction of Peanut for Prevention of Peanut Allergy: Pro-Con Debate</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Victoria</style></keyword></keywords><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - Austrialia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967547">PM:28967547</url></web-urls><pdf-urls><url ppv-ref="no">mimi.tang@rch.org.au</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20171002, Tang ML</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boguniewicz,M.</style></author><author><style face="normal" font="Arial"> Alexis,A.F.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author><author><style face="normal" font="Arial"> Block,J.</style></author><author><style face="normal" font="Arial"> Eichenfield,L.F.</style></author><author><style face="normal" font="Arial"> Fonacier,L.</style></author><author><style face="normal" font="Arial"> Guttman-Yassky,E.</style></author><author><style face="normal" font="Arial"> Paller,A.S.</style></author><author><style face="normal" font="Arial"> Pariser,D.</style></author><author><style face="normal" font="Arial"> Silverberg,J.I.</style></author><author><style face="normal" font="Arial"> Lebwohl,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colo.</style></auth-address><titles><title><style face="normal" font="Arial">Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Colorado</style></keyword><keyword><style face="normal" font="Arial"> Consensus</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressant</style></keyword><keyword><style face="normal" font="Arial"> Immunosuppressants</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory skin disease</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Opinion</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> systemic treatment</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> topical therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treatment Failure</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects children and adults. Until recently, the only Food and Drug Administration-approved systemic treatment option for patients with moderate-to-severe AD was systemic steroids, which are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants, which can have serious adverse effects. A significant number of these patients go untreated. Research on the immunopathogenesis of AD has paved the way for new, targeted, systemic therapies for moderate-to-severe AD. In early 2017, the Food and Drug Administration approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. Although the national guidelines can be very helpful to clinicians, the process for updating them does not allow for timely incorporation of novel therapies. A steering committee of AD experts, including dermatologists, allergists, and a patient advocacy group representative, developed recommendations on the basis of a literature review and expert opinion to help clinicians understand how new therapies fit into the current treatment paradigm and to provide practical recommendations for assessing AD severity, treatment response, and treatment failure</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28970084">PM:28970084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20171003-BoguniewiczM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\20171003-BoguniewiczM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Boguniewicz M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Edwards,M.R.</style></author><author><style face="normal" font="Arial"> Strong,K.</style></author><author><style face="normal" font="Arial"> Cameron,A.</style></author><author><style face="normal" font="Arial"> Walton,R.P.</style></author><author><style face="normal" font="Arial"> Jackson,D.J.</style></author><author><style face="normal" font="Arial"> Johnston,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">COPD &amp; Asthma Section, National Heart Lung Institute, Imperial College London, London, United Kingdom; MRC &amp; Asthma UK Centre for Allergic Mechanisms of Asthma, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="Arial">Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="920" start="909">909-920</pages><volume><style face="normal" font="Arial">140</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergen-sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic mechanism</style></keyword><keyword><style face="normal" font="Arial"> Allergic mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical study</style></keyword><keyword><style face="normal" font="Arial"> COPD</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferons</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="Arial"> Respiratory viruses</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> viral respiratory tract infections</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">Viral respiratory tract infections are associated with asthma inception in early life and asthma exacerbations in older children and adults. Although how viruses influence asthma inception is poorly understood, much research has focused on the host response to respiratory viruses and how viruses can promote; or how the host response is affected by subsequent allergen sensitization and exposure. This review focuses on the innate interferon-mediated host response to respiratory viruses and discusses and summarizes the available evidence that this response is impaired or suboptimal. In addition, the ability of respiratory viruses to act in a synergistic or additive manner with TH2 pathways will be discussed. In this review we argue that these 2 outcomes are likely linked and discuss the available evidence that shows reciprocal negative regulation between innate interferons and TH2 mediators. With the renewed interest in anti-TH2 biologics, we propose a rationale for why they are particularly successful in controlling asthma exacerbations and suggest ways in which future clinical studies could be used to find direct evidence for this hypothesis</style></abstract><notes><style face="normal" font="Arial">DA - 20171008IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.07.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987220">PM:28987220</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-909-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\2017-140-909-20.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171008, Edwards MR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.07.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asai,Y.</style></author><author><style face="normal" font="Arial"> Eslami,A.</style></author><author><style face="normal" font="Arial"> van Ginkel,C.D.</style></author><author><style face="normal" font="Arial"> Akhabir,L.</style></author><author><style face="normal" font="Arial"> Wan,M.</style></author><author><style face="normal" font="Arial"> Ellis,G.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author><author><style face="normal" font="Arial"> Martino,D.</style></author><author><style face="normal" font="Arial"> Ferreira,M.A.</style></author><author><style face="normal" font="Arial"> Allen,K.</style></author><author><style face="normal" font="Arial"> Mazer,B.</style></author><author><style face="normal" font="Arial"> de Groot,H.</style></author><author><style face="normal" font="Arial"> de Jong,N.W.</style></author><author><style face="normal" font="Arial"> Gerth van Wijk,R.N.</style></author><author><style face="normal" font="Arial"> Dubois,A.E.J.</style></author><author><style face="normal" font="Arial"> Chin,R.</style></author><author><style face="normal" font="Arial"> Cheuk,S.</style></author><author><style face="normal" font="Arial"> Hoffman,J.</style></author><author><style face="normal" font="Arial"> Jorgensen,E.</style></author><author><style face="normal" font="Arial"> Witte,J.S.</style></author><author><style face="normal" font="Arial"> Melles,R.B.</style></author><author><style face="normal" font="Arial"> Hong,X.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author><author><style face="normal" font="Arial"> Hui,J.</style></author><author><style face="normal" font="Arial"> Musk,A.W.B.</style></author><author><style face="normal" font="Arial"> Hunter,M.</style></author><author><style face="normal" font="Arial"> James,A.L.</style></author><author><style face="normal" font="Arial"> Koppelman,G.H.</style></author><author><style face="normal" font="Arial"> Sandford,A.J.</style></author><author><style face="normal" font="Arial"> Clarke,A.E.</style></author><author><style face="normal" font="Arial"> Daley,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, Department of Medicine, Queen's University, Kingston, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes c11orf30/EMSY as a genetic risk factor for food allergy</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epigenetic</style></keyword><keyword><style face="normal" font="Arial"> epigenetic regulation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Functional annotation</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association studies</style></keyword><keyword><style face="normal" font="Arial"> Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> peanut allergies</style></keyword><keyword><style face="normal" font="Arial"> peanut allergy</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> regulation</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="Arial"> single nucleotide polymorphisms</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Peanut allergy (PA) is a complex disease with both environmental and genetic risk factors. Previously PA loci were identified in FLG and HLA in candidate gene studies, and loci in HLA in a genome-wide association study and meta-analysis. OBJECTIVE: To investigate genetic susceptibility to PA. METHODS: Eight hundred and fifty cases and 926 hyper-controls and >7.8 million genotyped and imputed single nucleotide polymorphisms (SNPs) were analyzed in a genome-wide association study to identify susceptibility variants for PA in the Canadian population. Meta-analysis of two phenotypes (PA and food allergy) was conducted using 7 studies from the Canadian, American (2), Australian, German and Dutch (2) populations. RESULTS: A SNP near ITGA6 reached genome-wide significance with PA (p=1.80x10-8), while SNPs associated with SKAP1, MMP12/MMP13, CTNNA3, ARHGAP24, ANGPT4, c11orf30 (EMSY), and EXOC4 reached a threshold suggestive of association (p&lt;/=1.49x10-6). In the meta-analysis of PA, loci in or near ITGA6, ANGPT4, MMP12/MMP13, c11orf30 and EXOC4 were significant (p&lt;/=1.49x10-6). When a phenotype of any food allergy was used for meta-analysis, the c11orf30 locus reached genome-wide significance (p=7.50x10-11), while SNPs associated with ITGA6, ANGPT4, MMP12/MMP13, EXOC4 and additional c11orf30 SNPs were suggestive (p&lt;/=1.49x10-6). Functional annotation indicated SKAP1 regulates expression of CBX1, which co-localizes with the EMSY protein coded by c11orf30. CONCLUSION: This study identifies multiple novel loci as risk factors for PA and food allergy and establishes c11orf30 as a risk locus for both peanut and food allergy. Multiple genes (c11orf30/EMSY, SKAP1 and CTNNA3) identified by this study are involved in epigenetic regulation of gene expression</style></abstract><notes><style face="normal" font="Arial">DA - 20171014IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Netherlands -CO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.09.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29030101">PM:29030101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171014-AsaiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171014-AsaiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171014, Asai Y</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.09.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shamji,M.H.</style></author><author><style face="normal" font="Arial"> Ceuppens,J.</style></author><author><style face="normal" font="Arial"> Bachert,C.</style></author><author><style face="normal" font="Arial"> Hellings,P.</style></author><author><style face="normal" font="Arial"> Placier,G.</style></author><author><style face="normal" font="Arial"> Thirion,G.</style></author><author><style face="normal" font="Arial"> Bovy,N.</style></author><author><style face="normal" font="Arial"> Durham,S.R.</style></author><author><style face="normal" font="Arial"> Duchateau,J.</style></author><author><style face="normal" font="Arial"> Legon,T.</style></author><author><style face="normal" font="Arial"> Pirotton,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="Arial">Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grass pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Lolium</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword></keywords><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171014IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.09.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29030102">PM:29030102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171014-ShamjiMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171014-ShamjiMH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171014, Shamji MH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.09.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fania,L.</style></author><author><style face="normal" font="Arial"> Salemme,A.</style></author><author><style face="normal" font="Arial"> Provini,A.</style></author><author><style face="normal" font="Arial"> Pagnanelli,G.</style></author><author><style face="normal" font="Arial"> Collina,M.C.</style></author><author><style face="normal" font="Arial"> Abeni,D.</style></author><author><style face="normal" font="Arial"> Didona,B.</style></author><author><style face="normal" font="Arial"> Di Zenzo,G.</style></author><author><style face="normal" font="Arial"> Mazzanti,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, via dei Monti di Creta 104, 00167, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="Arial">Detection And Characterization Of Igg, Ige And Iga Autoantibodies In Patients With Bullous Pemphigoid Associated With Dipeptidyl Peptidase-Iv Inhibitors</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rome</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171008IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2017.09.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987492">PM:28987492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20171008-FaniaL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20171008-FaniaL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171008, Fania L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2017.09.051</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fleming,P.</style></author><author><style face="normal" font="Arial"> Drucker,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, University of Toronto, Toronto, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Risk of Infection in Patients with Atopic Dermatitis Treated with Dupilumab: A Meta-Analysis of Randomized Controlled Trials</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> eczema herpeticum</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is characterized by skin barrier defects, Th2 activation, and increased risk for cutaneous and extracutaneous infections. In clinical trials, dupilumab appeared to decrease rates of skin infections in AD. OBJECTIVE: We aimed to determine the impact of dupilumab on rates of skin and other infections in patients with moderate-to-severe AD. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of dupilumab for AD. We searched the PubMed database for relevant studies. Risk ratios (RR) and 95% confidence intervals (CI) for skin infections, herpesvirus infections and overall infections and infestations were calculated for dupilumab compared with placebo using binary random-effects meta-analysis. For the analysis of eczema herpeticum, Peto odds ratios (OR) were calculated. RESULTS: Eight RCTs in 4 publications with 2,706 participants were included with follow-up time ranging from 4-52 weeks. Meta-analysis including all dosing schedules and follow-up times showed a RR of skin infection of 0.54 (95% CI: 0.42-0.70) and an OR of eczema herpeticum of 0.34 (95% CI: 0.14-0.84) for dupilumab compared with placebo. No significant association was found for dupilumab with overall herpesvirus infections (RR=1.16, 95% CI: 0.78-1.74) and overall infections (RR=0.98, 95% CI: 0.83-1.16). LIMITATIONS: Our analysis is limited by short follow-up time in most trials and relatively low number of patients treated with dupilumab to date. CONCLUSION: Dupilumab is associated with a decreased incidence of skin infections and eczema herpeticum in adults with moderate-to-severe AD. The mechanism underlying this association is uncertain, but is likely related to improvement in AD severity</style></abstract><notes><style face="normal" font="Arial">DA - 20171008IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2017.09.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987493">PM:28987493</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20171008-FlemingP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20171008-FlemingP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171008, Fleming P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2017.09.052</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gardeux,V.</style></author><author><style face="normal" font="Arial"> Berghout,J.</style></author><author><style face="normal" font="Arial"> Achour,I.</style></author><author><style face="normal" font="Arial"> Schissler,A.G.</style></author><author><style face="normal" font="Arial"> Li,Q.</style></author><author><style face="normal" font="Arial"> Kenost,C.</style></author><author><style face="normal" font="Arial"> Li,J.</style></author><author><style face="normal" font="Arial"> Shang,Y.</style></author><author><style face="normal" font="Arial"> Bosco,A.</style></author><author><style face="normal" font="Arial"> Saner,D.</style></author><author><style face="normal" font="Arial"> Halonen,M.J.</style></author><author><style face="normal" font="Arial"> Jackson,D.J.</style></author><author><style face="normal" font="Arial"> Li,H.</style></author><author><style face="normal" font="Arial"> Martinez,F.D.</style></author><author><style face="normal" font="Arial"> Lussier,Y.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine, University of Arizona, Tucson, AZ, USA</style></auth-address><titles><title><style face="normal" font="Arial">A genome-by-environment interaction classifier for precision medicine: personal transcriptome response to rhinovirus identifies children prone to asthma exacerbations</style></title><secondary-title><style face="normal" font="Arial">J Am Med Inform Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Med Inform Assoc</style></full-title></periodical><pages end="1126" start="1116">1116-1126</pages><volume><style face="normal" font="Arial">24</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> Arizona</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Classifiers</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Disease Progression</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Precision medicine</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Prognosis</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinovirus</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="Arial">Objective: To introduce a disease prognosis framework enabled by a robust classification scheme derived from patient-specific transcriptomic response to stimulation. Materials and Methods: Within an illustrative case study to predict asthma exacerbation, we designed a stimulation assay that reveals individualized transcriptomic response to human rhinovirus. Gene expression from peripheral blood mononuclear cells was quantified from 23 pediatric asthmatic patients and stimulated in vitro with human rhinovirus. Responses were obtained via the single-subject gene set testing methodology "N-of-1-pathways." The classifier was trained on a related independent training dataset (n = 19). Novel visualizations of personal transcriptomic responses are provided. Results: Of the 23 pediatric asthmatic patients, 12 experienced recurrent exacerbations. Our classifier, using individualized responses and trained on an independent dataset, obtained 74% accuracy (area under the receiver operating curve of 71%; 2-sided P = .039). Conventional classifiers using messenger RNA (mRNA) expression within the viral-exposed samples were unsuccessful (all patients predicted to have recurrent exacerbations; accuracy of 52%). Discussion: Prognosis based on single time point, static mRNA expression alone neglects the importance of dynamic genome-by-environment interplay in phenotypic presentation. Individualized transcriptomic response quantified at the pathway (gene sets) level reveals interpretable signals related to clinical outcomes. Conclusion: The proposed framework provides an innovative approach to precision medicine. We show that quantifying personal pathway-level transcriptomic response to a disease-relevant environmental challenge predicts disease progression. This genome-by-environment interaction assay offers a noninvasive opportunity to translate omics data to clinical practice by improving the ability to predict disease exacerbation and increasing the potential to produce more effective treatment decisions</style></abstract><notes><style face="normal" font="Arial">DA - 20171010IS - 1527-974X (Electronic)IS - 1067-5027 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1093/jamia/ocx069</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29016970">PM:29016970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Med Inform Assoc\2017-24-1116-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Med Inform Assoc\2017-24-1116-26.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Gardeux V</style></custom2><misc3><style face="normal" font="Arial">10.1093/jamia/ocx069</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">ElRamlawy,K.G.</style></author><author><style face="normal" font="Arial"> Fujimura,T.</style></author><author><style face="normal" font="Arial"> Aki,T.</style></author><author><style face="normal" font="Arial"> Okada,A.</style></author><author><style face="normal" font="Arial"> Suzuki,T.</style></author><author><style face="normal" font="Arial"> Abe,T.</style></author><author><style face="normal" font="Arial"> Hayashi,T.</style></author><author><style face="normal" font="Arial"> Epton,M.J.</style></author><author><style face="normal" font="Arial"> Thomas,W.R.</style></author><author><style face="normal" font="Arial"> Rafeet,I.H.</style></author><author><style face="normal" font="Arial"> Al-Azhary,D.B.</style></author><author><style face="normal" font="Arial"> Ono,K.</style></author><author><style face="normal" font="Arial"> Kawamoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Hiroshima Research Center for Healthy Aging (HiHA), Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, Higashi-Hiroshima 739-8530, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Prominent IgE-binding and cytokine-inducing capacities of a newly cloned N-terminal region of Der f 14, an apolipophorin-like house dust mite allergen</style></title><secondary-title><style face="normal" font="Arial">J Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Biochem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aging</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> cDNA</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Der f 1</style></keyword><keyword><style face="normal" font="Arial"> Der f 14</style></keyword><keyword><style face="normal" font="Arial"> Der f 2</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Escherichia</style></keyword><keyword><style face="normal" font="Arial"> Escherichia coli</style></keyword><keyword><style face="normal" font="Arial"> Eur m 14</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Mag 3</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">We previously characterized a 177 kDa allergen, M-177, from Dermatophagoides farinae. Thereafter, a counterpart to M-177 for Euroglyphus maynei was cloned as Eur m 14, and its sequence revealed that two environmental allergens, Mag 1 and Mag 3, are digested fragments of M-177. The aims of this study were to clone the cDNA of Der f 14 corresponding to M-177 and to elucidate the allergenic capacities of the N-terminal fragment of Der f 14 (Der f 14-N). Recombinant allergens were produced as trigger-factor-fused proteins in Escherichia coli. Der f 14-N showed the highest IgE-binding frequency among Der f 14-derived fragments in patients allergic to house dust mite by enzyme-linked immunosorbent assay. Der f 14-N showed the highest capacity to induce cell proliferation in murine lymphocyte and human peripheral mononuclear cells among Der f 14-derived fragments. Der f 14-N induced IL-13, IFN-gamma, and IL-17 production more than Der f 1 and Der f 2 in mouse, and induced IL-5 and IFN-gamma production at levels comparable to those of Der f 1 and Der f 2 in some patients. The high prevalence of IgE binding to the Der f 14-N indicates that it could be an important mite allergen</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 1756-2651 (Electronic)IS - 0021-924X (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Egypt -CO - Australia -CO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1093/jb/mvx060</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28992042">PM:28992042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Biochem\20171009-ElRamlawyKG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Biochem\20171009-ElRamlawyKG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171009, ElRamlawy KG</style></custom2><misc3><style face="normal" font="Arial">10.1093/jb/mvx060</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Akutsu,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Kyoto University, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Selected Papers from the 16th International Conference on Bioinformatics (InCoB 2017)</style></title><secondary-title><style face="normal" font="Arial">J Bioinform Comput Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Bioinform Comput Biol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Bioinformatic</style></keyword><keyword><style face="normal" font="Arial"> bioinformatics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171006IS - 1757-6334 (Electronic)IS - 0219-7200 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1142/S0219720017020036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28982289">PM:28982289</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Bioinform Comput Biol\20171006-AkutsuT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Bioinform Comput Biol\20171006-AkutsuT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171006, Akutsu T</style></custom2><misc3><style face="normal" font="Arial">10.1142/S0219720017020036</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sun,D.</style></author><author><style face="normal" font="Arial"> Wang,M.</style></author><author><style face="normal" font="Arial"> Li,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 School of Information Science and Technology, University of Science and Technology of China, Hefei, Anhui 230027, P. R. China</style></auth-address><titles><title><style face="normal" font="Arial">MPTM: A tool for mining protein post-translational modifications from literature</style></title><secondary-title><style face="normal" font="Arial">J Bioinform Comput Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Bioinform Comput Biol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> Hydroxylation</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Information Science</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Mining</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> ontology</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> post-translational</style></keyword><keyword><style face="normal" font="Arial"> Pressing</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Text analysis</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="Arial">Due to the importance of post-translational modifications (PTMs) in human health and diseases, PTMs are regularly reported in the biomedical literature. However, the continuing and rapid pace of expansion of this literature brings a huge challenge for researchers and database curators. Therefore, there is a pressing need to aid them in identifying relevant PTM information more efficiently by using a text mining system. So far, only a few web servers are available for mining information of a very limited number of PTMs, which are based on simple pattern matching or pre-defined rules. In our work, in order to help researchers and database curators easily find and retrieve PTM information from available text, we have developed a text mining tool called MPTM, which extracts and organizes valuable knowledge about 11 common PTMs from abstracts in PubMed by using relations extracted from dependency parse trees and a heuristic algorithm. It is the first web server that provides literature mining service for hydroxylation, myristoylation and GPI-anchor. The tool is also used to find new publications on PTMs from PubMed and uncovers potential PTM information by large-scale text analysis. MPTM analyzes text sentences to identify protein names including substrates and protein-interacting enzymes, and automatically associates them with the UniProtKB protein entry. To facilitate further investigation, it also retrieves PTM-related information, such as human diseases, Gene Ontology terms and organisms from the input text and related databases. In addition, an online database (MPTMDB) with extracted PTM information and a local MPTM Lite package are provided on the MPTM website. MPTM is freely available online at http://bioinformatics.ustc.edu.cn/mptm/and the source codes are hosted on GitHub: https://github.com/USTC-HILAB/MPTM</style></abstract><notes><style face="normal" font="Arial">DA - 20171006IS - 1757-6334 (Electronic)IS - 0219-7200 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1142/S0219720017400054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28982288">PM:28982288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Bioinform Comput Biol\20171006-SunD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Bioinform Comput Biol\20171006-SunD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171006, Sun D</style></custom2><misc3><style face="normal" font="Arial">10.1142/S0219720017400054</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nelson,J.A.</style></author><author><style face="normal" font="Arial"> Maltais,S.</style></author><author><style face="normal" font="Arial"> Fox,J.J.</style></author><author><style face="normal" font="Arial"> Hagan,J.B.</style></author><author><style face="normal" font="Arial"> Rossow,K.L.</style></author><author><style face="normal" font="Arial"> Mauermann,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Anesthesiology, Mayo Clinic, Rochester, MN</style></auth-address><titles><title><style face="normal" font="Arial">Successful Minimally Invasive Mitral Valve Replacement Using Normothermic Fibrillatory Arrest in a Patient With Cold Urticaria</style></title><secondary-title><style face="normal" font="Arial">J Cardiothorac Vasc Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cardiothorac Vasc Anesth</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> cold urticaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Mitral Valve</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1532-8422 (Electronic)IS - 1053-0770 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1053/j.jvca.2017.05.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967621">PM:28967621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cardiothorac Vasc Anesth\20171002-NelsonJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cardiothorac Vasc Anesth\20171002-NelsonJA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Nelson JA</style></custom2><misc3><style face="normal" font="Arial">10.1053/j.jvca.2017.05.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khan,S.</style></author><author><style face="normal" font="Arial"> Hassan,M.J.</style></author><author><style face="normal" font="Arial"> Jairajpuri,Z.S.</style></author><author><style face="normal" font="Arial"> Jetley,S.</style></author><author><style face="normal" font="Arial"> Husain,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Associate Professor, Department of Pathology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi, India</style></auth-address><titles><title><style face="normal" font="Arial">Clinicopathological Study of Eosinophilic Cholecystitis: Five Year Single Institution Experience</style></title><secondary-title><style face="normal" font="Arial">J Clin Diagn Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Diagn Res</style></full-title></periodical><pages end="EC23" start="EC20">EC20-EC23</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Gallbladder Diseases</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Gallbladder diseases are very common in Northern India, most common of which is Chronic Cholecystitis. Rarely, histopathological diagnosis of Eosinophilic Cholecystitis (EC) is given when transmural cellular infiltrate consists of more than 90% eosinophils. AIM: To determine the prevalence and clinicopathological profile of eosinophilic cholecystitis at a tertiary care hospital of New Delhi. MATERIALS AND METHODS: This was a retrospective clinicopathological study done on twenty two cases of eosinophilic cholecystitis over a period of five years from January</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.7860/JCDR/2017/27886.10427</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28969136">PM:28969136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-EC20-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-EC20-3.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Khan S</style></custom2><misc3><style face="normal" font="Arial">10.7860/JCDR/2017/27886.10427</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sadagopan,K.</style></author><author><style face="normal" font="Arial"> Kalappan,D.</style></author><author><style face="normal" font="Arial"> Sivaprakasam,N.</style></author><author><style face="normal" font="Arial"> Vinoth</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Professor, Department of Dermatology, Madras Medical College, Chennai, Tamil Nadu, India</style></auth-address><titles><title><style face="normal" font="Arial">Patch Test Results from an Occupational and Contact Dermatitis Clinic in a Tertiary Care Hospital of Southern India: A Retrospective Study</style></title><secondary-title><style face="normal" font="Arial">J Clin Diagn Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Diagn Res</style></full-title></periodical><pages end="WC14" start="WC11">WC11-WC14</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cobalt</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> contact allergy</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Cosmetics</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> Detergents</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Foot</style></keyword><keyword><style face="normal" font="Arial"> Hair</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Kerosene</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nickel</style></keyword><keyword><style face="normal" font="Arial"> Occupation</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational dermatoses</style></keyword><keyword><style face="normal" font="Arial"> Occupations</style></keyword><keyword><style face="normal" font="Arial"> Paint</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Potassium</style></keyword><keyword><style face="normal" font="Arial"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: Occupational contact dermatitis, accounting for 95% of cases of occupational dermatoses, is the most common occupational skin disease. AIM: To find out the various allergens in different occupational and environmental settings causing contact allergy, from our patients presented with contact dermatitis. MATERIALS AND METHODS: It was a retrospective study from the data in hospital outpatient register over one year period, which includes patients with age ranging from 11 years to 73 years. Patch test was done with total of 24 allergens from Indian standard battery and Indian standard series and with materials suspected to cause contact allergy. Result was expressed in terms of percentage. RESULTS: Contact dermatitis constitutes about 0.75% of total dermatological cases in our Dermatology Outpatient Department. A total of 358 contact dermatitis were included in this study with M:F ratio 2.25:1 and majority of the cases in the age group of 26-55 years. Out of 358 cases, 157 cases were positive to at least one allergen. Building construction workers constitute about 35.75% (128 cases) of total contact dermatitis cases, among which potassium dichromate (39 out of 57) is the most common allergen, followed by nickel (31) and cobalt (28). In other occupations, contact allergy to parthenium, hair dye, foot wear, paint, kum-kum, turmeric, detergents and cosmetics were also present in significant number and none was positive for vegetables, dettol, kerosene and native medication. CONCLUSION: This study gives an idea about the common occupation and population who are prone to develop contact dermatitis in our environmental setting and also about the most common sensitizers involved in various occupation and environment</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.7860/JCDR/2017/26391.10349</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28969253">PM:28969253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-WC11-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-WC11-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Sadagopan K</style></custom2><misc3><style face="normal" font="Arial">10.7860/JCDR/2017/26391.10349</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chogtu,B.</style></author><author><style face="normal" font="Arial"> Magaji,N.</style></author><author><style face="normal" font="Arial"> Magazine,R.</style></author><author><style face="normal" font="Arial"> Acharya,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Associate Professor, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India</style></auth-address><titles><title><style face="normal" font="Arial">Pattern of Allergen Sensitivity among Patients with Bronchial Asthma and/or Allergic Rhinosinusitis in a Tertiary Care Centre of Southern India</style></title><secondary-title><style face="normal" font="Arial">J Clin Diagn Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Clin Diagn Res</style></full-title></periodical><pages end="OC04" start="OC01">OC01-OC04</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> Chicken</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> insect allergen</style></keyword><keyword><style face="normal" font="Arial"> Insect allergens</style></keyword><keyword><style face="normal" font="Arial"> Insects</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Prick testing</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Rice</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> skin prick testing</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword><keyword><style face="normal" font="Arial"> Wool</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="Arial">INTRODUCTION: The distribution of aeroallergens varies among various geographical areas of India and the knowledge of allergen sensitivity pattern in this part of Southern Indian (Karnataka) is limited. This data can provide clinically useful information and better understanding of common allergies prevalent in this area. AIM: To study the pattern of allergen sensitivity among patients with bronchial asthma and/or allergic rhinosinusitis. MATERIALS AND METHODS: In this retrospective study, patients diagnosed with bronchial asthma and/or allergic rhinitis who underwent skin prick testing, were included in the study. Patients who had taken drugs that could affect the test results, within one week prior to testing were excluded. Also, patients on long-acting oral antihistamines within four weeks of testing and pregnant women were excluded. A total of 64 antigens were used which included eight types of pollens, eight types of dusts, six types of fungi, eight types of insects, two types of danders, wool and 31 types of food items. Skin prick testing was done as per standard protocol. RESULTS: Out of 2219 patients, 1193 (53.8%) were males and 1026 (46.2%) were females. The mean age of the subjects was 41.47 (+/-14) years. There were 740 (33.3%) patients diagnosed with bronchial asthma, 357 (16.1%) allergic rhinitis and 1122 (50.6%) had both bronchial asthma and allergic rhinitis. Overall the highest percentage of skin-prick test positivity was found among insect allergens (24.45%) followed by dust (24.21%), grass and tree pollen (20.57%), fungus (13.92%) and food allergens (9.28%), in that order. Among the individual allergens, the highest percentage of skin-prick test positivity was present in rice grain dust allergen (33.30%) and the least common was chicken allergen (4.40%). CONCLUSION: Among the allergen groups, insects and dusts elicited the highest percentage of skin-prick test positive results. Whereas, among all the individual allergens rice grain dust elicited highest percentage of positives</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.7860/JCDR/2017/26973.10328</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28969175">PM:28969175</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-OC01-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Diagn Res\2017-11-OC01-4.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Chogtu B</style></custom2><misc3><style face="normal" font="Arial">10.7860/JCDR/2017/26973.10328</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soon,J.M.</style></author><author><style face="normal" font="Arial"> Manning,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">"May Contain" Allergen Statements: Facilitating or Frustrating Consumers?</style></title><secondary-title><style face="normal" font="Arial">J Consum Policy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Consum Policy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> case study</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> Food Industry</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Harmonization</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> language</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Mandatory labelling</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> packaging</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> policy</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-0700</style></isbn><abstract><style face="normal" font="Arial">As a result of mandatory labelling legislation, major food allergens that commonly cause allergic reactions are declared on packaging. The usage of precautionary allergen labelling (PAL) on packaging is not regulated in all countries, and the food industry uses various forms of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£may contain</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ labelling which firstly is often inconsistent and secondly over time may diminish the value of such advisory statements. Hence, the aims of this paper are to review the current industry usage of PAL and to provide recommendations on future use that are of value to academics, policy makers, food industry, and consumers. A case study example is used to illustrate the likely costs and benefits of improving the current PAL status by considering a </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£peanut-free</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ product and calculation using the Voluntary Incidental Trace Allergen Labelling (VITAL) calculator. Governance such as addressing the inconsistent usage of PALs, promoting the harmonization of language used in PALs, and improving PAL status to quantified PAL statements would be helpful in communicating risks to consumers, so they can make informed choices when purchasing food products</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10603-017-9358-8</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10603-017-9358-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Consum Policy\20171015-SoonJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Consum Policy\20171015-SoonJM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Soon JM</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10603-017-9358-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maronna,A.</style></author><author><style face="normal" font="Arial"> Psaier,S.</style></author><author><style face="normal" font="Arial"> Erfurt-Berge,C.</style></author><author><style face="normal" font="Arial"> Geier,J.</style></author><author><style face="normal" font="Arial"> Mahler,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Erlangen University Hospital, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Allergenic and microbiological hazards caused by skin markings during medical procedures?</style></title><secondary-title><style face="normal" font="Arial">J Dtsch Dermatol Ges</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dtsch Dermatol Ges</style></abbr-1></periodical><pages end="1036" start="1034">1034-1036</pages><volume><style face="normal" font="Arial">15</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 1610-0387 (Electronic)IS - 1610-0379 (Linking)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/ddg.13327</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28976102">PM:28976102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dtsch Dermatol Ges\2017-15-1034-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dtsch Dermatol Ges\2017-15-1034-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Maronna A</style></custom2><misc3><style face="normal" font="Arial">10.1111/ddg.13327</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gautam,P.B.</style></author><author><style face="normal" font="Arial"> Sharma,R.</style></author><author><style face="normal" font="Arial"> Lata,K.</style></author><author><style face="normal" font="Arial"> Rajput,Y.S.</style></author><author><style face="normal" font="Arial"> Mann,B.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Construction of a lateral flow strip for detection of soymilk in milk</style></title><secondary-title><style face="normal" font="Arial">J Food Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci Technol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Bovine milk</style></keyword><keyword><style face="normal" font="Arial"> Construction</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Rabbit</style></keyword><keyword><style face="normal" font="Arial"> Soymilk</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0975-8402</style></isbn><abstract><style face="normal" font="Arial">A lateral flow based detection method for ascertaining the presence of soymilk in whole bovine milk has been described. The method uses commercially available rabbit anti-soy protein antibodies conjugated to gold nanoparticles (AuNPs) wherein soymilk protein in adulterated milk and soymilk protein at test line competes for limited antibodies. At control line, anti-rabbit immunoglobulin was immobilized for ensuring flow properties of antibody</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çöconjugated AuNPs. Absence or diminished intensity of band at test line indicates presence of soymilk in milk. The soymilk detection limit was 1.75% (v/v) in whole bovine milk and results are available in 5-ámin. Constructed lateral flow device can be used for on-spot examination of soymilk in milk</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s13197-017-2890-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s13197-017-2890-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci Technol\20171014-GautamPB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci Technol\20171014-GautamPB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171014, Gautam PB</style></custom2><misc3><style face="normal" font="Arial">10.1007/s13197-017-2890-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cho,Y.</style></author><author><style face="normal" font="Arial"> Kwon,D.</style></author><author><style face="normal" font="Arial"> Kang,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">The Cooperative Role of CD326+ and CD11b+ Dendritic Cell Subsets for a Hapten-Induced Th2 Differentiation</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic contact</style></keyword><keyword><style face="normal" font="Arial"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Langerhans Cells</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Priming</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TH cell</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="10" Year="2017">2017/10/2</year></dates><abstract><style face="normal" font="Arial">Dendritic cells (DCs) play a critical role in directing immune responses. Previous studies have identified a variety of DC subsets and elucidated their context-dependent functions that parallel those of effector Th cell subsets. However, little is known about the DC subsets responsible for differentiation of Th2 cells governing allergic contact dermatitis. In this study, we sought to determine the DC subset(s) that mediate Th2 priming in hapten-sensitized mice. We induced hapten-specific Th2 differentiation by sensitizing the mice with a single application of FITC dissolved in acetone:dibutyl phthalate, and traced the immune cells responsible for inducing the Th2 differentiation process at the primary stimulation, enabling us to track Th2 priming in vivo and to delete basophils and specific DC subsets. Our analysis revealed that IL-4 was produced in vivo as early as day 3 from CD4+ T cells with a single application of FITC. Basophils, despite producing IL-4 1 d earlier than T cells, were found to be dispensable for Th2 differentiation. Instead, we demonstrated that CD326+ dermal DCs and Langerhans cells were redundantly required for FITC-induced Th2 differentiation in vivo. Moreover, the cooperation of CD326+ Langerhans cells and CD11b+ DCs differentiated naive T cells into Th2 cells in vitro. Collectively, our findings highlight at least two DC subsets that play a critical role in polarizing naive CD4+ T cells to Th2 cells and support a two-hit model for Th2 differentiation</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1601262</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28972093">PM:28972093</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20171002-ChoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20171002-ChoY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Cho Y</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1601262</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amoah,B.</style></author><author><style face="normal" font="Arial"> Schilling,M.W.</style></author><author><style face="normal" font="Arial"> Phillips,T.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Physical Factors Influencing Orientation of Tyrophagus putrescentiae (Schrank) (Sarcoptiformes: Acaridae) to Food-Baited Traps</style></title><secondary-title><style face="normal" font="Arial">J Insect Behav</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Insect Behav</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acaridae</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Darkness</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Post-harvest</style></keyword><keyword><style face="normal" font="Arial"> preference</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Stored product</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus</style></keyword><keyword><style face="normal" font="Arial"> Tyrophagus putrescentiae</style></keyword><keyword><style face="normal" font="Arial"> Ultraviolet</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1572-8889</style></isbn><abstract><style face="normal" font="Arial">Tyrophagus putrescentiae (Schrank) (Sarcoptiformes: Acaridae) is a serious pest of post-harvest durable stored food products for which traps are being developed as important tools for integrated pest management. This work addresses the effects of trap design, trap location, time of response, and light on the orientation of released groups of 7200 pedestrian T. putrescentiae to food-baited traps in experimental rooms maintained in full darkness at 28-á-¦C and 70% RH. A standard trap made from a disposable Petri dish and four commercially produced stored-product pest traps of different designs were compared and evaluated for efficacy in trapping mites. Subsequent experiments evaluated the effect of trap placement, trapping duration, and light on mite capture. More mites were captured in the standard Petri dish trap when compared singly or side by side with four different commercial trap designs, so the standard trap was used in all other studies. Further experiments found that mites could be trapped 1-áh after release at a distance of 2-ám from the release point and at six meters from a mite source within 24-áh. A greater number of mites were caught in traps placed along a wall than those away from a wall, demonstrating thigmotaxis to an edge. Traps at various heights on a shelf rack suggested that walking mites tended to be positively geotactic whether the source of mites was from the floor or from the top shelf at 1.8-ám from the floor. More mites were caught in black-painted traps than in unpainted clear plastic traps in fully lighted rooms, suggesting that mites seek refuge from brightly lighted conditions. Light emitting diodes deployed with traps or assayed alone determined mites oriented positively to traps with violet or ultraviolet, with least preference to green, yellow, red and white lights. This research provides new information on orientation by T. putrescentiae that may help optimize trap designs and trap deployment for pest management decisions</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10905-017-9639-8</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10905-017-9639-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Insect Behav\20171014-AmoahB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Insect Behav\20171014-AmoahB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171014, Amoah B</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10905-017-9639-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Berardi,L.</style></author><author><style face="normal" font="Arial"> Pivato,M.</style></author><author><style face="normal" font="Arial"> Arrigoni,G.</style></author><author><style face="normal" font="Arial"> Mitali,E.</style></author><author><style face="normal" font="Arial"> Trentin,A.R.</style></author><author><style face="normal" font="Arial"> Olivieri,M.</style></author><author><style face="normal" font="Arial"> Kerdelhue,C.</style></author><author><style face="normal" font="Arial"> Dorkeld,F.</style></author><author><style face="normal" font="Arial"> Nidelet,S.</style></author><author><style face="normal" font="Arial"> Dubois,E.</style></author><author><style face="normal" font="Arial"> Battisti,A.</style></author><author><style face="normal" font="Arial"> Masi,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Agronomy Food Natural Resources Animals and Environment (DAFNAE), University of Padova, Viale dell'Universita 16, 35020 Legnaro, Padova, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Proteome Analysis of Urticating Setae From Thaumetopoea pityocampa (Lepidoptera: Notodontidae)</style></title><secondary-title><style face="normal" font="Arial">J Med Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Entomol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> biosynthesis</style></keyword><keyword><style face="normal" font="Arial"> BLAST</style></keyword><keyword><style face="normal" font="Arial"> Chitin</style></keyword><keyword><style face="normal" font="Arial"> Chromatography</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> domestic animals</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lepidoptera</style></keyword><keyword><style face="normal" font="Arial"> Liquid chromatography</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> serine proteases</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Tha p 1</style></keyword><keyword><style face="normal" font="Arial"> Tha p 2</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="Arial">Thaumetopoea pityocampa (Denis &amp; Schiffermuller) (Lepidoptera: Notodontidae) is harmful to conifer trees because of defoliation and to public health because of the release of urticating setae from the caterpillars. Contact with setae by humans and domestic animals induces dermatitis, usually localized to the exposed areas. Recent studies demonstrated the presence of a complex urticating mechanism where proteins present in the setae may play a role as activators of immune responses. Yet, limited information is available at present about the proteins occurring in the setae of T. pityocampa. Using a refined method for protein extraction from the setae, and a combination of liquid chromatography tandem-mass spectrometry (LC-MS/MS), de novo assembly of transcriptomic data, and sequence similarity searches, an extensive data set of 353 proteins was obtained. These were further categorized by molecular function, biological process, and cellular location. All the 353 proteins identified were found to match through BLAST search with at least one Lepidoptera sequence available in databases. We found the previously known allergens Tha p 1 and Tha p 2 described from T. pityocampa, as well as enzymes involved in chitin biosynthesis, one of the principal components of the setae, and serine proteases that were responsible for inflammatory and allergic reactions in other urticating Lepidoptera. This new proteomic database may allow for a better understanding of the complexity of allergenic reactions due to T. pityocampa and to other Lepidoptera sharing similar defense systems</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 1938-2928 (Electronic)IS - 0022-2585 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - France -</style></notes><work-type><style face="normal" font="Arial">10.1093/jme/tjx144</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28981804">PM:28981804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Entomol\20171005-BerardiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Entomol\20171005-BerardiL.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Entomol\20171005-BerardiL.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Entomol\20171005-BerardiL.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20171005, Berardi L</style></custom2><misc3><style face="normal" font="Arial">10.1093/jme/tjx144</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Erwin,E.A.</style></author><author><style face="normal" font="Arial"> Rhoda,D.A.</style></author><author><style face="normal" font="Arial"> Redmond,M.</style></author><author><style face="normal" font="Arial"> Ly,J.B.</style></author><author><style face="normal" font="Arial"> Russo,J.M.</style></author><author><style face="normal" font="Arial"> Hill,I.D.</style></author><author><style face="normal" font="Arial"> Platts-Mills,T.A.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">*Center for Innovation in Pediatric Practice, Nationwide Children's Hospital, Columbus, OHdaggerBiostat Global Consulting, Worthington, OH</style></auth-address><titles><title><style face="normal" font="Arial">Using Serum IgE Antibodies to Predict Esophageal Eosinophilia in Children</style></title><secondary-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Pediatr Gastroenterol Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> EoE</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Esophageal biopsy</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagogastroduodenoscopy</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Food-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> food-specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric patients</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> ROC</style></keyword><keyword><style face="normal" font="Arial"> Roc Curve</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="Arial">OBJECTIVES: Symptoms of eosinophilic esophagitis (EoE) are variable and can be nonspecific. Food-specific serum IgE antibodies are frequently found in EoE patients and are obtained using a widely available blood test. Our objective was to evaluate the ability of food-specific IgE antibodies to predict the presence of esophageal eosinophilia. METHODS: We reviewed 144 medical records for pediatric patients having esophageal biopsy and serum analysis for IgE antibodies to food (exploratory group). We performed logistic regression using gender and number of positive food-specific IgE tests to develop a model that predicts >/=15 eosinophils/high power field (hpf) in the esophagus. We tested the model using 142 additional patients (validation group). RESULTS: The probability of having >/=15 eosinophils/hpf in the esophagus was higher in males and increased with the number of positive food-specific IgE tests from 12% (95% confidence interval [CI] 4.8-26) in females with 0 foods positive to 86% (95% CI 71-94) for males with 4 or 5 foods positive. The statistical model using gender and number of positive IgE tests to predict patients having >/=15 eosinophils/hpf showed acceptable discriminative ability (area under the receiver operating characteristic [ROC] curve 0.80). The performance metrics for the model to predict >/=15 eosinophils/hpf in the validation group were similar (area under the ROC curve 0.75). CONCLUSIONS: Requiring only a blood test and a simple algorithm, analysis for IgE antibodies to food may expedite an esophagogastroduodenoscopy and decrease delays in the diagnosis and treatment of patients with nonspecific gastrointestinal symptoms who have increased eosinophils in the esophagus</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1097/MPG.0000000000001553</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28981449">PM:28981449</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20171005-ErwinEA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr Gastroenterol Nutr\20171005-ErwinEA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171005, Erwin EA</style></custom2><misc3><style face="normal" font="Arial">10.1097/MPG.0000000000001553</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Amponsah,A.</style></author><author><style face="normal" font="Arial"> Nayak,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Science and Human Nutrition, School of Food and Agriculture. University of Maine, Orono, Maine, 04469, United StatesFood Science and Human Nutrition, School of Food and Agriculture. University of Maine, Orono, Maine, 04469, United States</style></auth-address><titles><title><style face="normal" font="Arial">Evaluation of the Efficiency of Three Extraction Conditions for the Immunochemical Detection of Allergenic Soy Proteins in Different Food Matrices</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Agriculture</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Soluble protein</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Soy protein</style></keyword><keyword><style face="normal" font="Arial"> Soy Proteins</style></keyword><keyword><style face="normal" font="Arial"> Ultrasound</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Recent studies have shown the need to improve soy allergen extraction using different extraction conditions to ensure more accurate results in allergen detection. This study investigated some of these extraction conditions to confirm that these methods, especially UAE and the use of Laemmli buffer instead of the conventional extraction with PBS buffer, could be helpful in improving the extraction step in allergen detection. RESULTS: Higher total soluble protein was obtained in all samples extracted with Laemmli buffer alone and in combination with ultrasound. For immunochemical detection of soy proteins using ELISA, comparable detection was observed in extract from all extraction conditions in all commercial samples with the exception of table cracker and veggie burger, where significantly higher detection was seen in extracts from Laemmli buffer only. For the dry mix and cookie samples, the degree of soy protein detection with ELISA varied among the different extraction conditions but overall, extraction with only Laemmli buffer showed higher detection. CONCLUSION: Laemmli buffer with conventional extraction and UAE may be better alternatives or additional extraction methods in soy allergen detection. Different food matrices performed differently (whether it was for the recovery of total proteins or detection by ELISA) under different extraction conditions</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8729</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29023789">PM:29023789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20171012-AmponsahA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20171012-AmponsahA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Amponsah A</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8729</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lamberti,C.</style></author><author><style face="normal" font="Arial"> Baro,C.</style></author><author><style face="normal" font="Arial"> Giribaldi,M.</style></author><author><style face="normal" font="Arial"> Napolitano,L.</style></author><author><style face="normal" font="Arial"> Cavallarin,L.</style></author><author><style face="normal" font="Arial"> Giuffrida,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Sciences of Food Production, National Research Council, Largo Braccini 2, 10095, Grugliasco, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Effects of Two Different Domestic Boiling Practices on The Allergenicity of Cow Milk Proteins</style></title><secondary-title><style face="normal" font="Arial">J Sci Food Agric</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Sci Food Agric</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregates</style></keyword><keyword><style face="normal" font="Arial"> aggregation</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> amino acid sequencing</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> boil</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Caseins</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Cow</style></keyword><keyword><style face="normal" font="Arial"> Cow milk</style></keyword><keyword><style face="normal" font="Arial"> Cow milk proteins</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Heating</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> milk protein allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Molecular Weight</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Raw milk</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: the sale of raw drinking milk through automatic dispensers is permitted in some European Member States, but consumers are usually advised to boil the milk before consumption. The present study has been conducted to evaluate the effects of two common domestic boiling techniques on the proteins of raw milk, and, in particular, on their potential allergenicity. RESULTS: Native 1-D electrophoresis, N-terminal amino acid sequencing and immunoblotting have been used to characterize the protein pattern, and to evaluate the possible changes in the allergenic properties of the processed milk. The main result of this investigation is that heating induces the aggregation of beta-lactoglobulin in higher molecular weight products, while caseins result to be more resistant to the treatments. beta-lactoglobulin aggregates have been found to be non-immunoreactive with the sera of subjects suffering from cow's milk protein allergy. CONCLUSION: domestic boiling modifies the milk protein profile causing minor reduction in milk allergenicity</style></abstract><notes><style face="normal" font="Arial">DA - 20171010IS - 1097-0010 (Electronic)IS - 0022-5142 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1002/jsfa.8728</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28994453">PM:28994453</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sci Food Agric\20171010-LambertiC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sci Food Agric\20171010-LambertiC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Lamberti C</style></custom2><misc3><style face="normal" font="Arial">10.1002/jsfa.8728</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nava Cruz,E.M.</style></author><author><style face="normal" font="Arial"> Castanedo-Cazares,J.P.</style></author><author><style face="normal" font="Arial"> Hernandez Blanco,D.V.</style></author><author><style face="normal" font="Arial"> Torres-Alvarez,B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Department, Hospital Central Dr. Ignacio Morones Prieto, Universidad Autonoma de San Luis Potosi, San Luis Potosi, Mexico</style></auth-address><titles><title><style face="normal" font="Arial">Yellow urticaria and biliary pancreatitis</style></title><secondary-title><style face="normal" font="Arial">JAAD Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAAD Case Rep</style></full-title></periodical><pages end="450" start="448">448-450</pages><volume><style face="normal" font="Arial">3</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Pancreatitis</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2352-5126 (Print)IS - 2352-5126 (Linking)LA - engPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jdcr.2017.06.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28971131">PM:28971131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAAD Case Rep\2017-3-448-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAAD Case Rep\2017-3-448-50.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Nava Cruz EM</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jdcr.2017.06.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Netchiporouk,E.</style></author><author><style face="normal" font="Arial"> Sasseville,D.</style></author><author><style face="normal" font="Arial"> Moreau,L.</style></author><author><style face="normal" font="Arial"> Habel,Y.</style></author><author><style face="normal" font="Arial"> Rahme,E.</style></author><author><style face="normal" font="Arial"> Ben-Shoshan,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Dermatology, McGill University Health Centre, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Evaluating Comorbidities, Natural History, and Predictors of Early Resolution in a Cohort of Children With Chronic Urticaria</style></title><secondary-title><style face="normal" font="Arial">JAMA Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> basophil</style></keyword><keyword><style face="normal" font="Arial"> basophil activation</style></keyword><keyword><style face="normal" font="Arial"> basophil activation test</style></keyword><keyword><style face="normal" font="Arial"> Basophils</style></keyword><keyword><style face="normal" font="Arial"> BAT</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Cell Count</style></keyword><keyword><style face="normal" font="Arial"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CD63</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hives</style></keyword><keyword><style face="normal" font="Arial"> Hormone</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> natural history</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quebec</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> type 1 diabetes</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">Importance: Chronic urticaria (CU) affects 0.1% to 0.3% of children. Most cases have no identifiable trigger and are classified as chronic spontaneous urticaria (CSU). At least half of patients with CSU may have an autoimmune etiology that can be determined in vitro using the basophil activation test (BAT). While 30% to 55% of CU cases resolve spontaneously within 5 years in adults, the natural history and predictors of resolution in children are not known. Objective: To assess the comorbidities, natural history of CU, and its subtypes in children and identify predictors of resolution. Design, Setting, and Participants: We followed a pediatric cohort with chronic urticaria that presented with hives lasting at least 6 weeks between 2013 and 2015 at a single tertiary care referral center. Exposures: Data were collected on disease activity, comorbidities, physical triggers, BAT results, complete blood cell count, C-reactive protein levels, thyroid-stimulating hormone levels, and thyroid peroxidase antibodies. Main Outcomes and Measures: We assessed the rate of resolution (defined as absence of hives for at least 1 year with no treatment) and the association with clinical and laboratory markers. Results: The cohort comprised 139 children younger than 18 years old. Thirty-one patients (20%) had inducible urticaria, most commonly cold induced. Six children had autoimmune comorbidity, such as thyroiditis and type 1 diabetes. Autoimmune disorders (24 patients [17%]) and CU (17 patients [12%]) were common in family members. Positive BAT results (CD63 levels > 1.8%) were found in 58% of patients. Patients with positive BAT results (CD63 level >1.8%) were twice as likely to resolve after 1 year compared with negative BAT results (hazard ratio [HR], 2.33; 95% CI, 1.08-5.05). In contrast, presence of basophils decreased the likelihood of resolution (HR, 0.40; 95% CI, 0.20-0.99). No correlation with age was found. Chronic urticaria resolved in 43 patients, with a rate of resolution of 10.3% per year. Levels of CD63 higher than 1.8% and absence of basophils were associated with earlier disease resolution. Conclusions and Relevance: Resolution rate in children with CU is low. The presence of certain biomarkers (positive BAT result and basophil count) may help to predict the likelihood of resolution</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamadermatol.2017.3182</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28973060">PM:28973060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Dermatol\20171003-NetchiporoukE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Dermatol\20171003-NetchiporoukE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Netchiporouk E</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamadermatol.2017.3182</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Maurer,M.</style></author><author><style face="normal" font="Arial"> Church,M.K.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Chronic Urticaria in Children: Still Itching for Insight</style></title><secondary-title><style face="normal" font="Arial">JAMA Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamadermatol.2017.3183</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28973428">PM:28973428</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Dermatol\20171003-MaurerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Dermatol\20171003-MaurerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Maurer M</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamadermatol.2017.3183</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sukumaran,S.</style></author><author><style face="normal" font="Arial"> Vijayan,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Rheumatology, Department of Pediatrics, Arkansas Children's Hospital, Little RockDivision of Pediatric Infectious Diseases, Department of Pediatrics, Arkansas Children's Hospital, Little Rock</style></auth-address><titles><title><style face="normal" font="Arial">Infantile-Onset Fever and Urticaria</style></title><secondary-title><style face="normal" font="Arial">JAMA Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">JAMA Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Arkansas</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 2168-6211 (Electronic)IS - 2168-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1001/jamapediatrics.2017.2531</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28975215">PM:28975215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAMA Pediatr\20171004-SukumaranS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAMA Pediatr\20171004-SukumaranS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Sukumaran S</style></custom2><misc3><style face="normal" font="Arial">10.1001/jamapediatrics.2017.2531</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hiller,A.M.</style></author><author><style face="normal" font="Arial"> Willers,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Skanes universitetssjukhus Malmo - Lung- och Allergisektionen Malmo, Sweden - Lung- och Allergi sektionen Skanes Universitetssjukhus Malmo, SwedenSkanes universitetssjukhus Lund - Lung- och Allergisektionen Lund, Sweden Skanes universitetssjukhus Lund - Lung- och Allergisektionen Lund, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Kanelbullar utlöste anafylaktisk reaktion - Genesen kan vara veteberoende ansträngningsutlöst anafylaxi.</style></title><secondary-title><style face="normal" font="Arial">Lakartidningen</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Lakartidningen</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Case reports</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Exercise</style></keyword><keyword><style face="normal" font="Arial"> Exercise-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Omega-5-gliadin</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Triticum</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Wheat Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Wheat proteins</style></keyword></keywords><dates><year Day="2" Month="10" Year="2017">2017/10/2</year></dates><abstract><style face="normal" font="Arial">Cinnamon rolls triggered anaphylactic reaction. The genesis could be wheat-dependent exercise-induced anaphylaxis Two case reports from our Department of Allergology illustrate the wheat-dependent exercise-induced anaphylaxis (WDEIA), which is a relatively rare, yet potentially fatal form of food allergy. Wheat (Triticum aestivum) is the most commonly grown crop world-wide, and some individuals cannot tolerate it due to wheat hypersensitivity. The most dangerous reaction is the anaphylaxis due to harmful immune responses to various parts of the wheat proteins. omega-5-gliadin is the major causative allergen in wheat hypersensitivity. WDEIA is a poorly recognized disorder. Therefore, any patient presenting anaphylactic reaction at the emergency department, typically after ingestion of wheat products followed by physical exercise within one to four hours, should be referred to an allergy clinic for the allergological evaluation. Further research should be carried out to better understand the mechanisms behind, and to increase the awareness on WDEIA</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 1652-7518 (Electronic)IS - 0023-7205 (Linking)LA - swePT - English AbstractPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28972639">PM:28972639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Lakartidningen\20171003-HillerAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Lakartidningen\20171003-HillerAM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Hiller AM</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boyd,B.</style></author><author><style face="normal" font="Arial"> Zamora,C.A.</style></author><author><style face="normal" font="Arial"> Castillo,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Neuroradiology, Department of Radiology, University of North Carolina School of Medicine, 2107 Old Clinic Building, Campus Box 7510, Chapel Hill, NC 27599-7510, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Managing Adverse Reactions to Contrast Agents</style></title><secondary-title><style face="normal" font="Arial">Magn Reson Imaging Clin N Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Magn Reson Imaging Clin N Am</style></abbr-1></periodical><pages end="742" start="737">737-742</pages><volume><style face="normal" font="Arial">25</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Premedication</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin testing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">Adverse reactions to iodinated and gadolinium-based contrast agents occur at an incidence of less than 1%. Although the exact pathophysiologic mechanisms are not completely understood, the treatment regimens are well accepted. Skin testing may be helpful in patients with a history of severe allergiclike reaction to aid in the selection of alternative contrast agents. Premedication should only be used for a history of allergiclike reaction. Imaging team members should be familiar with signs and symptoms of contrast reactions to allow for prompt assessment and treatment. A plan of action should be in place for contrast reactions and rehearsed regularly</style></abstract><notes><style face="normal" font="Arial">DA - 20171001IS - 1557-9786 (Electronic)IS - 1064-9689 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mric.2017.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28964463">PM:28964463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Magn Reson Imaging Clin N Am\2017-25-737-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Magn Reson Imaging Clin N Am\2017-25-737-42.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171001, Boyd B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mric.2017.06.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tong,X.</style></author><author><style face="normal" font="Arial"> Leung,M.H.Y.</style></author><author><style face="normal" font="Arial"> Wilkins,D.</style></author><author><style face="normal" font="Arial"> Lee,P.K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Energy and Environment, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong</style></auth-address><titles><title><style face="normal" font="Arial">City-scale distribution and dispersal routes of mycobiome in residences</style></title><secondary-title><style face="normal" font="Arial">Microbiome</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Microbiome</style></abbr-1></periodical><pages end="" start="131">131-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> airflow</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Distance</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Energy</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> geographic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health effects</style></keyword><keyword><style face="normal" font="Arial"> Hong Kong</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Residence</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> Ventilation</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Pathogenic and allergenic bacteria and fungi within the indoors can bring detrimental health effects on the occupants. We previously studied the bacterial communities found in households located throughout Hong Kong as well as the skin surfaces of the occupants. As a complementary study, here, we investigated the fungal communities (mycobiome) in the same residences and occupants and identified factors that are important in shaping their diversity, composition, distribution, and dispersal patterns. RESULTS: We observed that common skin and environmental fungal taxa dominated air, surface, and skin samples. Individual and touch frequency strongly and respectively shaped the fungal community structure on occupant skin and residential surfaces. Cross-domain analysis revealed positive correlations between bacterial and fungal community diversity and composition, especially for skin samples. SourceTracker prediction suggested that some fungi can be transferred bidirectionally between surfaces and skin sites, but bacteria showed a stronger dispersal potential. In addition, we detected a modest but significant association between indoor airborne bacterial composition and geographic distance on a city-wide scale, a pattern not observed for fungi. However, the distance-decay effects were more pronounced at shorter local scale for both communities, and airflow might play a prominent role in driving the spatial variation of the indoor airborne mycobiome. CONCLUSIONS: Our study suggests that occupants exert a weaker influence on surface fungal communities compared to bacterial communities, and local environmental factors, including air currents, appear to be stronger determinants of indoor airborne mycobiome than ventilation strategy, human occupancy, and room type</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 2049-2618 (Electronic)IS - 2049-2618 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40168-017-0346-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28978345">PM:28978345</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Microbiome\2017-5-131.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Microbiome\2017-5-131.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171005, Tong X</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40168-017-0346-7</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alves,M.F.</style></author><author><style face="normal" font="Arial"> da Fonsec,D.V.</style></author><author><style face="normal" font="Arial"> de Melo,S.A.L.</style></author><author><style face="normal" font="Arial"> Scotti,M.T.</style></author><author><style face="normal" font="Arial"> Scotti,L.</style></author><author><style face="normal" font="Arial"> Dos Santos,S.G.</style></author><author><style face="normal" font="Arial"> de Fatima Formiga Melo Diniz,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidade Federal da Paraiba - Chemistry Joao Pessoa, Paraiba. Brazil</style></auth-address><titles><title><style face="normal" font="Arial">New therapeutic targets and drugs for the treatment of asthma</style></title><secondary-title><style face="normal" font="Arial">Mini Rev Med Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mini Rev Med Chem</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukins</style></keyword><keyword><style face="normal" font="Arial"> investigational</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">Asthma is an inflammatory disease which affects millions of people worldwide. Therefore, it is necessary search for new sources of therapies for the treatment of these patients in order to improve their quality of life. From content analysis of new therapeutic targets literature, there are various targets and drugs reported as promising for treatment asthma. Interleukins involved in inflammatory processes are often presented as candidate targets for new drugs. The action of such therapeutics would not only affect interleukins, but also in their receptors. Ligustrazine and SP600125 are small molecules and compounds and lebrikizumab, benralizumab and dupilumab are large molecule antibodies investigational product, though are being considered as novel agents for the pharmacotherapy of asthma. Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor alpha monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. The lebrikizumab inhibit interleukins 13 and dupilumab is directed against IL-4Ra and hence inhibits activation of the receptor by IL-4 and IL-13. SP600125 and ligustrazine drugs act on the important inflammatory pathway, MAPK. Therefore, through this research, we can see advances in the search for new targets and promising drugs to treat asthma. It is expected that these new drug candidates will eventually be approved and marketed so that asthma patients can use them and enhance their quality of life</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 1875-5607 (Electronic)IS - 1389-5575 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.2174/1389557517666170927145011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28971769">PM:28971769</url></web-urls></urls><custom2><style face="normal" font="Arial">20171003, Alves MF</style></custom2><misc3><style face="normal" font="Arial">10.2174/1389557517666170927145011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pan,J.</style></author><author><style face="normal" font="Arial"> Song,G.</style></author><author><style face="normal" font="Arial"> Chen,D.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Liu,S.</style></author><author><style face="normal" font="Arial"> Hu,S.</style></author><author><style face="normal" font="Arial"> Rosa,C.</style></author><author><style face="normal" font="Arial"> Eichinger,D.J.</style></author><author><style face="normal" font="Arial"> Pino,I.</style></author><author><style face="normal" font="Arial"> Zhu,H.</style></author><author><style face="normal" font="Arial"> Qian,J.</style></author><author><style face="normal" font="Arial"> Huang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Johns Hopkins University School of Medicine, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach</style></title><secondary-title><style face="normal" font="Arial">Mol Cell Proteomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mol Cell Proteomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Arrays</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> early diagnosis</style></keyword><keyword><style face="normal" font="Arial"> early intervention</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung cancer</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> surveys</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> tumors</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="Arial">Lung cancer (LC) remains the leading cause of mortality from malignant tumors worldwide. Currently, a lack of serological biomarkers for early LC diagnosis is a major roadblock for early intervention and prevention of LC. To undertake this challenge, we employed a two-phase strategy to discover and validate a biomarker panel using a protein array-based approach. In Phase I, we obtained serological autoimmune profiles of 80 LC patients and 20 healthy subjects on HuProt arrays, and identified 170 candidate proteins significantly associated with LC. In Phase II, we constructed a LC focused array with the 170 proteins, and profiled a large cohort, comprised of 352 LC patients, 93 healthy individuals, and 101 patients with lung benign lesions (LBL). The comparison of autoimmune profiles between the early stage LC and the combined group of healthy and LBL allowed us to identify and validate a biomarker panel of p53, HRas, and ETHE1 for diagnosis of early stage LC with 50% sensitivity at >90% specificity. Finally, the performance of this biomarker panel was confirmed in ELISA tests. In summary, this study represents one of the most comprehensive proteome-wide surveys with one of the largest (i.e., 1,101 unique samples) and most diverse (i.e., nine disease groups) cohorts, resulting in a biomarker panel with good performance</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 1535-9484 (Electronic)IS - 1535-9476 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1074/mcp.RA117.000212</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29021294">PM:29021294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Cell Proteomics\20171012-PanJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Cell Proteomics\20171012-PanJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Pan J</style></custom2><misc3><style face="normal" font="Arial">10.1074/mcp.RA117.000212</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">VIB Center for Inflammation Research, Ghent University, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">The immunology of the allergy epidemic and the hygiene hypothesis</style></title><secondary-title><style face="normal" font="Arial">Nat Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Immunol</style></full-title></periodical><pages end="1083" start="1076">1076-1083</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Adoption</style></keyword><keyword><style face="normal" font="Arial"> Age Factors</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Danger signal</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Life Style</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="Arial">The immunology of the hygiene hypothesis of allergy is complex and involves the loss of cellular and humoral immunoregulatory pathways as a result of the adoption of a Western lifestyle and the disappearance of chronic infectious diseases. The influence of diet and reduced microbiome diversity now forms the foundation of scientific thinking on how the allergy epidemic occurred, although clear mechanistic insights into the process in humans are still lacking. Here we propose that barrier epithelial cells are heavily influenced by environmental factors and by microbiome-derived danger signals and metabolites, and thus act as important rheostats for immunoregulation, particularly during early postnatal development. Preventive strategies based on this new knowledge could exploit the diversity of the microbial world and the way humans react to it, and possibly restore old symbiotic relationships that have been lost in recent times, without causing disease or requiring a return to an unhygienic life style</style></abstract><notes><style face="normal" font="Arial">DA - 20170919IS - 1529-2916 (Electronic)IS - 1529-2908 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Allergens)SB - IMCO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1038/ni.3829</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28926539">PM:28926539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Immunol\2017-18-1076-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Immunol\2017-18-1076-83.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20170919, Lambrecht BN</style></custom2><misc3><style face="normal" font="Arial">10.1038/ni.3829</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Masi,M.</style></author><author><style face="normal" font="Arial"> Zonno,M.C.</style></author><author><style face="normal" font="Arial"> Cimmino,A.</style></author><author><style face="normal" font="Arial"> Reveglia,P.</style></author><author><style face="normal" font="Arial"> Berestetskiy,A.</style></author><author><style face="normal" font="Arial"> Boari,A.</style></author><author><style face="normal" font="Arial"> Vurro,M.</style></author><author><style face="normal" font="Arial"> Evidente,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Department of Chemical Sciences , University of Naples Federico II, Complesso Universitario Monte S. Angelo , Napoli , Italy</style></auth-address><titles><title><style face="normal" font="Arial">On the metabolites produced by Colletotrichum gloeosporioides a fungus proposed for the Ambrosia artemisiifolia biocontrol; spectroscopic data and absolute configuration assignment of colletochlorin A</style></title><secondary-title><style face="normal" font="Arial">Nat Prod Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Prod Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="12/24/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia artemisiifolia</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Chlorophyll</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal culture</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="Arial">Ambrosia artemisiifolia L. is responsible for serious allergies induced on humans. Different approaches for its control were proposed during the COST Action FA1203 "Sustainable management of Ambrosia artemisiifolia in Europe" (SMARTER). Fungal secondary metabolites often show potential herbicidal activity. Three phytotoxins were purified from the fungal culture filtrates of Colletotrichum gloeosporioides, isolated from infected leaves of A. artemisiifolia. They were identified by spectroscopic and chemical methods as colletochlorin A, orcinol and tyrosol (1, 2 and 3). The absolute configuration 6'R to colletochlorin A was assigned for the first time applying the advanced Mosher's method. When assayed by leaf-puncture on A. artemisiifolia only 1 caused the appearance of large necrosis. The same symptoms were also induced by 1 on ambrosia plantlets associated with plant wilting. On Lemna minor, colletochlorin A caused a clear fronds browning, with a total reduction in chlorophyll content</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 1478-6427 (Electronic)IS - 1478-6419 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1080/14786419.2017.1385020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29027474">PM:29027474</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Prod Res\20171013-MasiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Prod Res\20171013-MasiM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">201710013, Masi M</style></custom2><misc3><style face="normal" font="Arial">10.1080/14786419.2017.1385020</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tong,P.</style></author><author><style face="normal" font="Arial"> Gao,L.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Wu,Z.</style></author><author><style face="normal" font="Arial"> Yang,A.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Iron-induced Chelation Alleviates the Potential Allergenicity of Ovotransferrin in a BALB/c Mouse Model</style></title><secondary-title><style face="normal" font="Arial">Nutr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nutr Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mouse model</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> egg allergen</style></keyword><keyword><style face="normal" font="Arial"> egg allergens</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> interferon gamma</style></keyword><keyword><style face="normal" font="Arial"> Interferon-gamma</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> iron chelation</style></keyword><keyword><style face="normal" font="Arial"> Jejunum</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> milk allergen</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> ovotransferrin</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> specific antibodies</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0271-5317</style></isbn><abstract><style face="normal" font="Arial">Ovotransferrin (OVT) is one of the main egg allergens with two iron-binding sites. Several studies have demonstrated that iron-chelation decreased the allergenicity of milk allergen and birch pollen allergens. Therefore, we hypothesized that iron-chelation could also reduce the allergenicity of OVT. Apo-OVT (iron-free OVT, the natural state in egg white) and Holo-OVT (iron-chelated OVT) were prepared, and the allergenicity of them were assessed and compared using a BALB/c mouse model as well as dendritic cells (DCs) based on antigen uptake. Mice were orally sensitized with Apo-OVT or Holo-OVT using cholera toxin as adjuvant. Clinical signs of allergy, morphological structure of jejunum, specific antibody levels, mast cell protease-1 (mMCP-1) concentrations, cytokines and antigen uptake by DCs were determined after the mice were challenged with Apo-OVT or Holo-OVT. Results showed that both Apo-OVT and Holo-OVT induced intestinal allergy, but no systematic allergic symbols were observed. Serum levels of mouse mast cell protease-1 (mMCP-1) and specific IgE in Apo-OVT group were lower than in control group, and no significant difference between Apo-OVT group and Holo-OVT group (P>.05). The levels of OVT-specific IgG and IgG1, as well as the Th-1 cytokine interferon gamma and Th2-type cytokine interleukin-13 in Holo-OVT sensitized mice were significantly decreased compared to Apo-OVT group (P&lt;.05), while no significant difference with control group (P>.05). However, DCs took in less Apo-OVT than Holo-OVT. Overall, iron-induced chelation could alleviate the potential allergenicity of OVT in vivo</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.nutres.2017.09.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29241581">PM:29241581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nutr Res\20171015-TongP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nutr Res\20171015-TongP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Tong P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.nutres.2017.09.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Quirantes,S.B.</style></author><author><style face="normal" font="Arial"> Lara,J.A.</style></author><author><style face="normal" font="Arial"> Skodova,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Centro de Prevencion de Riesgos Laborales, Junta de Andalucia, Calle San Miguel 110, Granada 18100, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Sensitization to cow's milk protein in a dairy worker</style></title><secondary-title><style face="normal" font="Arial">Occup Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Occup Med (Lond)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> dairy</style></keyword><keyword><style face="normal" font="Arial"> Dairy product</style></keyword><keyword><style face="normal" font="Arial"> Dairy Products</style></keyword><keyword><style face="normal" font="Arial"> dried milk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><abstract><style face="normal" font="Arial">Background: Repeated skin exposure and inhalation of milk proteins may lead to IgE-mediated sensitization, normally manifested at the site of contact. Although this is a phenomenon predominantly found in children, it has also been observed in adults. Aims: To describe a case of a worker who, after being exposed to milk proteins for many years, eventually experienced episodes of anaphylaxis. Case report: A 62-year-old worker experienced severe episodes of anaphylaxis following the intake of dairy products. He had worked in the dairy industry for 17 years, where he was exposed to dried milk every day. Conclusions: This case report illustrates how continued exposure to milk proteins, either by skin contact or inhalation, may lead to sensitization which could result in severe manifestations of anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20171010IS - 1471-8405 (Electronic)IS - 0962-7480 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1093/occmed/kqx101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29016916">PM:29016916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Occup Med (Lond)\20171010-QuirantesSB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Occup Med (Lond)\20171010-QuirantesSB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Quirantes SB</style></custom2><misc3><style face="normal" font="Arial">10.1093/occmed/kqx101</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,J.</style></author><author><style face="normal" font="Arial"> Liu,X.</style></author><author><style face="normal" font="Arial"> Wang,H.</style></author><author><style face="normal" font="Arial"> Li,Y.</style></author><author><style face="normal" font="Arial"> Lan,N.</style></author><author><style face="normal" font="Arial"> Yuan,X.</style></author><author><style face="normal" font="Arial"> Wu,M.</style></author><author><style face="normal" font="Arial"> Liu,Z.</style></author><author><style face="normal" font="Arial"> Li,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inflammation &amp; Allergic Diseases Research Unit, Affiliated Hospital of Southwest Medical University, Luzhou 646000, China</style></auth-address><titles><title><style face="normal" font="Arial">Allergen specific immunotherapy enhanced defense against bacteria via TGF-beta1-induced CYP27B1 in asthma</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="68695" start="68681">68681-68695</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">40</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway responsiveness</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> bacterial infection</style></keyword><keyword><style face="normal" font="Arial"> Bacterial Infections</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> CYP27B1</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immunity</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> intranasal administration</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="Arial">Allergen specific immunotherapy (SIT) is the only specific treatment of allergic diseases at present. How SIT impacts pulmonary innate immunity against bacteria currently remains unclear. In this study, dust mite extracts (HDM)-sensitized mice were immunized with a subcutaneous injection of HDM. These mice were then challenged with an intranasal administration of HDM. After the last challenge, mice were infected with an intranasal instillation with P. aeruginosa (P.a). We measured the score of tissue inflammation, the expression of cathelicidin-related antimicrobial peptide (CRAMP) and 25-Hydroxyvitamin D-1Alpha-hydroxylase (CYP27B1) in lung. We analyzed the effect of TGF-beta1 on CRAMP and CYP27B1 in airway cells (16HBE), and investigate the role of TGF-beta1-induced CYP27B1 in defense against bacteria in16HBE cell. We found that SIT attenuates HDM-induced airway inflammation and airway responsiveness (AHR), which is involved in the increased levels of HDM-specific IgG2a, IL-10, TGF-beta1, IFN-gamma, CRAMP and CYP27B1. SIT ameliorates pulmonary infectious inflammation associated with an improving defense of HDM-challenged mice against P. aeruginosa. Meanwhile, TGF-beta1 significantly increased the expression of CYP27B1 in a dose-dependent manner. TGF-beta1 did not increase the levels of CRAMP in airway epithelial cells. Furthermore, 25-dihydroxyvitamin D3 (25VD3) is required for TGF-beta1-induced CRAMP in airway epithelial cells. CRAMP was significantly increased in TGF-beta1/25VD3-treated 16HBE cells. These findings illustrated that TGF-beta1 is a major player against bacterial infections in SIT models via induction of CYP27B1 rather than CRAMP. Collectively, these findings highlight a role for SIT enhancing host defense against bacteria depending on TGF-beta1-induced CYP27B1in asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.19826</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28978148">PM:28978148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\2017-8-68681-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\2017-8-68681-95.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171005, Wang J</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.19826</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Noh,K.</style></author><author><style face="normal" font="Arial"> Kim,M.</style></author><author><style face="normal" font="Arial"> Kim,Y.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Kim,H.</style></author><author><style face="normal" font="Arial"> Byun,J.</style></author><author><style face="normal" font="Arial"> Park,Y.</style></author><author><style face="normal" font="Arial"> Lee,H.</style></author><author><style face="normal" font="Arial"> Lee,Y.S.</style></author><author><style face="normal" font="Arial"> Choe,J.</style></author><author><style face="normal" font="Arial"> Kim,Y.M.</style></author><author><style face="normal" font="Arial"> Jeoung,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biochemistry, Kangwon National University, Chunchon 24341, Korea</style></auth-address><titles><title><style face="normal" font="Arial">miR-122-SOCS1-JAK2 axis regulates allergic inflammation and allergic inflammation-promoted cellular interactions</style></title><secondary-title><style face="normal" font="Arial">Oncotarget</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Oncotarget</style></full-title></periodical><pages end="63176" start="63155">63155-63176</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">38</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic</style></keyword><keyword><style face="normal" font="Arial"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="Arial"> Anticancer drugs</style></keyword><keyword><style face="normal" font="Arial"> Biochemistry</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Feedback</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Janus kinase</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Suppressor of cytokine signaling</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="Arial">The regulatory role of suppressor of cytokine signaling 1 (SOCS1) in inflammation has been reported. However, its role in allergic inflammation has not been previously reported. SOCS1 mediated in vitro and in vivo allergic inflammation. Histone deacetylase-3 (HDAC3), a mediator of allergic inflammation, interacted with SOCS1, and miR-384 inhibitor, a positive regulator of HDAC3, induced features of allergic inflammation in an SOCS1-dependent manner. miRNA array analysis showed that the expression of miR-122 was decreased by antigen-stimulation. TargetScan analysis predicted the binding of miR-122 to the 3'-UTR of SOCS1. miR-122 inhibitor induced in vitro and in vivo allergic features in SOCS1-dependent manner. SOCS1 was necessary for allergic inflammation-promoted enhanced tumorigenic and metastatic potential of cancer cells. SOCS1 and miR-122 regulated cellular interactions involving cancer cells, mast cells and macrophages during allergic inflammation. SOCS1 mimetic peptide, D-T-H-F-R-T-F-R-S-H-S-D-Y-R-R-I, inhibited in vitro and in vivo allergic inflammation, allergic inflammation-promoted enhanced tumorigenic and metastatic potential of cancer cells, and cellular interactions during allergic inflammation. Janus kinase 2 (JAK2) exhibited binding to SOCS1 mimetic peptide and mediated allergic inflammation. Transforming growth factor- Delta1 (TGF-Delta1) was decreased during allergic inflammation and showed an anti-allergic effect. SOCS1 and JAK2 regulated the production of anti-allergic TGF-Delta1. Taken together, our results show that miR-122-SOCS1 feedback loop can be employed as a target for the development of anti-allergic and anti-cancer drugs</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.18632/oncotarget.19149</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28968979">PM:28968979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\2017-8-63155-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\2017-8-63155-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Noh K</style></custom2><misc3><style face="normal" font="Arial">10.18632/oncotarget.19149</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schroder,K.</style></author><author><style face="normal" font="Arial"> Finis,D.</style></author><author><style face="normal" font="Arial"> Meller,S.</style></author><author><style face="normal" font="Arial"> Wagenmann,M.</style></author><author><style face="normal" font="Arial"> Geerling,G.</style></author><author><style face="normal" font="Arial"> Pleyer,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Klinik fur Augenheilkunde, Universitatsklinikum Dusseldorf, Medizinische Fakultat, Heinrich-Heine-Universitat Dusseldorf, Moorenstr. 5, 40225, Dusseldorf, Deutschland.</style></auth-address><titles><title><style face="normal" font="Arial">[Seasonal allergic conjunctivitis]</style></title><secondary-title><style face="normal" font="Arial">Ophthalmologe</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ophthalmologe</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword></keywords><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="Arial">Seasonal allergic conjunctivitis (SAC) is a frequent disease, which is often associated with allergic rhinitis and subsequently manifested as allergic rhinoconjunctivitis. In contrast to other types of chronic allergic conjunctivitis, the course of SAC is not sight-threatening. Pathogenetically, the underlying cause of SAC is an immunoglobulin E (IgE) mediated, Th2-driven type 1 hypersensitivity reaction. Clinically it presents with itching, light-red conjunctival injection as well as chemosis that exceeds the extent of conjunctival injection. The goals of treatment are relief of acute signs and symptoms, control of the underlying inflammatory process and utilization of preventive options. Dually effective local therapeutics combine the advantages of rapid action with a relatively long-lasting effect by a two-fold active approach. Specific immunotherapy is useful in selected patients</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 1433-0423 (Electronic)IS - 0941-293X (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00347-017-0580-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29022093">PM:29022093</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ophthalmologe\20171012-SchroderK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ophthalmologe\20171012-SchroderK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Schroder K</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00347-017-0580-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marino,M.J.</style></author><author><style face="normal" font="Arial"> Luong,A.U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, 6431 Fannin Street, MSB 5.036, Houston, TX 77030, USAamber.u.luong@uth.tmc.edu</style></auth-address><titles><title><style face="normal" font="Arial">Future Horizons in Allergy</style></title><secondary-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> extracellular vesicles</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> Leukotriene E4</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergen</style></keyword><keyword><style face="normal" font="Arial"> recombinant allergens</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="Arial">There are several advances in diagnosis and management for the otolaryngologist treating allergy. These include new technologies and the refinement of current techniques, and reflect overall trends in health care toward personalized medicine. Local immunoglobulin, urinary leukotriene E4, lipidomics, microRNA within extracellular vesicles, and optical rhinometry all offer to improve the diagnostic accuracy of allergy and related nonallergic conditions. New delivery systems for intranasal steroids and antihistamines, recombinant allergens, advances in allergen immunotherapy delivery, and biologics will improve current management options. These developments will aid the otolaryngologist in diagnosing and treating allergy and related diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20171010IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.otc.2017.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28992950">PM:28992950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171010-MarinoMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171010-MarinoMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Marino MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.otc.2017.08.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yang,B.</style></author><author><style face="normal" font="Arial"> Brook,C.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Boston University Medical Center, 820 Harrison Avenue, FGH Building 4th Floor, Boston, MA 02118, USADepartment of Otolaryngology-Head and Neck Surgery, Boston University Medical Center, 820 Harrison Avenue, FGH Building 4th Floor, Boston, MA 02118, USA. Electronic address: cdbrook@gmail.com</style></auth-address><titles><title><style face="normal" font="Arial">The Role of Allergy in Otologic Disease</style></title><secondary-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic otitis media</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Meniere's Disease</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Otitis</style></keyword><keyword><style face="normal" font="Arial"> Otitis Media</style></keyword><keyword><style face="normal" font="Arial"> Otitis Media with Effusion</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="Arial">Allergy is commonly associated with conditions such as rhinitis, sinusitis, and asthma, but the relationship between allergy and otologic diseases is less clear. This article examines the evidence for a relationship between allergic disease and several common otologic conditions, including otitis media with effusion, eosinophilic otitis media, and Meniere's disease</style></abstract><notes><style face="normal" font="Arial">DA - 20171010IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.otc.2017.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28992951">PM:28992951</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171010-YangB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171010-YangB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Yang B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.otc.2017.08.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shtraks,J.P.</style></author><author><style face="normal" font="Arial"> Toskala,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Lewis Katz School of Medicine at Temple University, 3440 North Broad Street, Kresge West 312, Philadelphia, PA 19140, USA</style></auth-address><titles><title><style face="normal" font="Arial">Manifestations of Inhalant Allergies Beyond the Nose</style></title><secondary-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergy</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="Arial">The upper and lower airways are linked epidemiologically and pathophysiologically. The upper and lower airways are considered a single, functional unit characterized by shared immunologic mechanisms, often referred to as the unified airway. Upper and lower airway inflammatory disease frequently coexist in the same patient. Allergic rhinitis and rhinosinusitis are associated with asthma. Treatment of both diseases impacts asthma outcomes. The otolaryngologist may be the first physician to suspect and diagnose asthma in patients with upper airway complaints. A thorough understanding of the relationship between allergic rhinitis, rhinosinusitis, and asthma will facilitate early identification of asthma and improve patient outcomes</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.otc.2017.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967389">PM:28967389</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171002-ShtraksJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171002-ShtraksJP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Shtraks JP</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.otc.2017.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Franzese,C.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, University of Missouri Medical Center-Columbia, One Hospital Drive, MA314, Columbia, MO 65212, USA. Electronic address: franzesec@health.missouri.edu</style></auth-address><titles><title><style face="normal" font="Arial">Advances in Food Allergy</style></title><secondary-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Care Costs</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Missouri</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">Food allergy has been increasing in prevalence for the last few decades, and numerous studies have evaluated ways of improving the allergy practitioner's ability to accurately diagnose patients who are truly food allergic, rather than sensitive but able to tolerate food. Once diagnosed, the current standard treatment is food elimination and avoidance, but other potential treatment options like oral immunotherapy, sublingual immunotherapy, and epicutaneous immunotherapy are becoming promising alternatives. Due the health care costs and potential for life-threatening adverse reactions, much attention has been given to the prevention of food allergies, resulting a shift in recent guideline recommendations</style></abstract><notes><style face="normal" font="Arial">DA - 20171001IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.otc.2017.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28964529">PM:28964529</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171001-FranzeseCB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171001-FranzeseCB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171001, Franzese CB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.otc.2017.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Damask,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Private Practice, Florida Hospital Altamonte Springs, 795 Primera Boulevard Suite 1031, Lake Mary, FL 32746, USA; University of Central Florida College of Medicine, 6850 Lake Nona Boulevard, Orlando, FL 32827, USA. Electronic address: cbaukus@yahoo.com</style></auth-address><titles><title><style face="normal" font="Arial">Immunotherapy: Treating with Fewer Allergens?</style></title><secondary-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Polyallergies</style></keyword><keyword><style face="normal" font="Arial"> Polyallergy</style></keyword><keyword><style face="normal" font="Arial"> polysensitization</style></keyword><keyword><style face="normal" font="Arial"> Polysensitized</style></keyword><keyword><style face="normal" font="Arial"> Private Practice</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">Polysensitization, sensitization to more than one allergen, is a common feature of patients with allergic rhinitis, and may be a risk factor for subsequent development of allergic diseases, especially allergic asthma. However, a polysensitized patient does not necessarily have polyallergy, a documented, causal relationship between exposure to 2 or more specific, sensitizing allergens and the subsequent occurrence of relevant clinical symptoms of allergy. Allergen immunotherapy treatment strategy for the polysensitized patient in Europe is to treat the single or 2 most clinically relevant allergen(s), whereas patients in the United States are usually treated for all potential clinically relevant allergens</style></abstract><notes><style face="normal" font="Arial">DA - 20171001IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - UnitedStates -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.otc.2017.08.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28964528">PM:28964528</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171001-DamaskC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171001-DamaskC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171001, Damask C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.otc.2017.08.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Roxbury,C.R.</style></author><author><style face="normal" font="Arial"> Lin,S.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, 601 North Caroline Street, 6th Floor, Baltimore, MD 21287, USA</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy and Safety of Subcutaneous and Sublingual Immunotherapy for Allergic Rhinoconjunctivitis and Asthma</style></title><secondary-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Otolaryngol Clin North Am</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen avoidance</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> Baltimore</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Care Costs</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> pharmacotherapy</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis is often associated with asthma and has significant impacts on health care costs and productivity in the United States. Although allergen avoidance and pharmacotherapy are effective, allergen-specific immunotherapy is the only treatment that may lead to improved allergy symptoms even after treatment is discontinued. Subcutaneous immunotherapy has been the mainstay of allergen-specific immunotherapy in the United States for decades, but sublingual immunotherapy has recently become available. This review discusses the use of subcutaneous immunotherapy and sublingual immunotherapy in the treatment of allergic rhinitis and asthma and reviews the current evidence regarding the safety and efficacy of both formulations</style></abstract><notes><style face="normal" font="Arial">DA - 20171001IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.otc.2017.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28964530">PM:28964530</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171001-RoxburyCR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Otolaryngol Clin North Am\20171001-RoxburyCR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171001, Roxbury CR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.otc.2017.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Martinez-Giron,R.</style></author><author><style face="normal" font="Arial"> Martinez-Torre,C.</style></author><author><style face="normal" font="Arial"> van Woerden,H.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The prevalence of protozoa in the gut of German cockroaches (Blattella germanica) with special reference to Lophomonas blattarum</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adjuvants</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Blattella germanica</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> German cockroach</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protozoa</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1432-1955</style></isbn><abstract><style face="normal" font="Arial">The German cockroach (Blattella germanica) is a common domestic pest, which produces allergens that have been associated with broncho-pulmonary disease. Various protozoan species have been identified in the intestine of this cockroach and it has been hypothesised that these protozoa, or their proteases, may contribute to the burden of cockroach-associated allergens and adjuvants present in domestic dust. The aim of this study was therefore to determine the prevalence of protozoan species in the intestine of Blattella germanica. German cockroaches were anesthetised and dissected and gut contents are used to produce wet slides for microscopy. Both, Giemsa and Papanicolaou stains were used to confirm correct identification of Lophomonas blattarum. Representatives of four genera of protozoa were identified in 110 cockroaches: Nyctoterus sp. was observed in 91.8% of cases, Gregarina sp. in 64.5%, Amoeba sp. in 25.4% and Lophomonas blattarum in 13.6%. Nyctoterus and Gregarina were statistically significantly more likely to be found in diseased cockroaches compared to Amoeba or Lophomonas. The prevalence of Lophomonas blattarum was similar to that in published studies of a different species of cockroach, Periplaneta americana. Further work is needed to assess the interplay between protozoa, cockroaches and broncho-pulmonary diseases</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-017-5640-6</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s00436-017-5640-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20171015-MartinezGironR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20171015-MartinezGironR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Martinez-Giron R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-017-5640-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schwarz,C.</style></author><author><style face="normal" font="Arial"> Muller,T.</style></author><author><style face="normal" font="Arial"> Lau,S.</style></author><author><style face="normal" font="Arial"> Parasher,K.</style></author><author><style face="normal" font="Arial"> Staab,D.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of pediatric Pneumology and Immunology, Charite-Universitaetsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Mepolizumab - a novel option for the treatment of hypereosinophilic syndrome in childhood</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Anti-IL-5</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug intolerance</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndrome</style></keyword><keyword><style face="normal" font="Arial"> hypereosinophilic syndromes</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mepolizumab</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Mepolizumab was originally intended as a therapeutic agent for atopic asthma in adults, and consequently little is known about its use in children. Up to now corticosteroids have formed the basis of the initial treatment of hypereosinophilic syndromes and are shown to be effective in most patients. To analyse the effect of mepolizumab in children is the aim of this study. METHODS: We are reporting the experience of the effect of mepolizumab in two paediatric patients of hypereosinophilic syndrome that was not sufficiently controlled by other drugs. In addition, the literature regarding the treatment with mepolizumab in paediatric and adult patients is reviewed for the most important studies regarding safety and efficacy. RESULTS: Mepolizumab therapy showed in two paediatric patients with severe hypereosinophilic syndrome a safe and efficient therapeutic approach. No significant intolerances appeared. Furthermore, treatment with systemic corticosteroids was terminated, and therefore severe side effects were avoided in our pediatric cases. CONCLUSIONS: Anti-IL-5 antibodies, which can be applied without substantial drug intolerances, are a new, safe and effective treatment option for paediatric patients with hypereosinophilic syndrome. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171007IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12809</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28986919">PM:28986919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171007-SchwarzC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171007-SchwarzC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171007, Schwarz C</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12809</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Grabenhenrich,L.B.</style></author><author><style face="normal" font="Arial"> Reich,A.</style></author><author><style face="normal" font="Arial"> McBride,D.</style></author><author><style face="normal" font="Arial"> Sprikkelman,A.</style></author><author><style face="normal" font="Arial"> Roberts,G.</style></author><author><style face="normal" font="Arial"> Grimshaw,K.E.C.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.G.</style></author><author><style face="normal" font="Arial"> Saxoni-Papageorgiou,P.</style></author><author><style face="normal" font="Arial"> Papadopoulos,N.G.</style></author><author><style face="normal" font="Arial"> Fiandor,A.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author><author><style face="normal" font="Arial"> Kowalski,M.L.</style></author><author><style face="normal" font="Arial"> Sigurdardottir,S.T.</style></author><author><style face="normal" font="Arial"> Dubakiene,R.</style></author><author><style face="normal" font="Arial"> Hourihane,J.O.B.</style></author><author><style face="normal" font="Arial"> Rosenfeld,L.</style></author><author><style face="normal" font="Arial"> Niggemann,B.</style></author><author><style face="normal" font="Arial"> Keil,T.</style></author><author><style face="normal" font="Arial"> Beyer,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Charite University Medical Centre Berlin, Institute for Social Medicine, Epidemiology and Health Economics</style></auth-address><titles><title><style face="normal" font="Arial">Physician's appraisal versus documented signs and symptoms in the interpretation of food challenge tests: the EuroPrevall birth cohort</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algorithms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Challenge tests</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> economics</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> EuroPrevall</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> food challenge outcome</style></keyword><keyword><style face="normal" font="Arial"> Food challenge test</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Gold</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> mandatory</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Symptom Assessment</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Blinded food challenges are considered the current gold standard for the diagnosis of food allergies. We used data from a pan-European multicentre project to assess differences between study centres, aiming to identify the impact of subjective aspects for the interpretation of oral food challenges. METHODS: Nine study centres of the EuroPrevall birth cohort study on food allergy recruited 12,049 newborns and followed them for up to 30 months in regular intervals. Intensive training was conducted and every centre visited to ensure similar handling of the protocols. Suspected food allergy was clinically evaluated by double-blind, placebo-controlled food challenges using a nine dose escalation protocol. The primary challenge outcomes based on physician's appraisal were compared to documented signs and symptoms. RESULTS: Of 839 challenges conducted, study centres confirmed food allergy in 15.6% to 53.6% of locally conducted challenges. Centres reported 0 to 16 positive placebo challenges. Worsening of eczema was the most common sign when challenged with placebo. Agreement between documented objective signs and the challenge outcome assigned by the physician was heterogeneous, with Cohen's kappa spanning from 0.42 to 0.84. CONCLUSIONS: These differences suggest that the comparison of food challenge outcomes between centres is difficult despite common protocols and training. We recommend detailed symptom assessment and documentation as well as objective sign-based challenge outcome algorithms to assure accuracy and comparability of blinded food challenges. Training and supervision of staff conducting food challenges is a mandatory component of reliable outcome data. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171007IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United Kingdom -CO - Italy -CO - Greece -CO - Bolivia -CO - Iceland -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12811</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28986924">PM:28986924</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171007-GrabenhenrichLB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171007-GrabenhenrichLB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171007, Grabenhenrich LB</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12811</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bourgoin-Heck,M.</style></author><author><style face="normal" font="Arial"> Amat,F.</style></author><author><style face="normal" font="Arial"> Trouve,C.</style></author><author><style face="normal" font="Arial"> Bernard,A.</style></author><author><style face="normal" font="Arial"> Magny,J.P.</style></author><author><style face="normal" font="Arial"> Lambert,N.</style></author><author><style face="normal" font="Arial"> Just,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergology-Centre de l'Asthme et des Allergies, Hopital d'Enfants Armand Trousseau, Assistance Publique-Hopitaux de Paris, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab could be effective in children with severe eosinophilic non-allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Aspirin</style></keyword><keyword><style face="normal" font="Arial"> Aspirin intolerance</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal polyposis</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Polyposis</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="Arial">Authors declare no relevant conflicts of interest related to the present work. Severe eosinophilic non-allergic asthma is a rare phenotype that could be effectively treated by omalizumab, especially when associated with elevated total serum IgE and nasal polyposis. Severe eosinophilic non-allergic asthma is a specific phenotype, rarely described in children, sometimes associated with nasal polyposis and aspirin intolerance (i.e., Widal's syndrome). This asthma phenotype is known to be particularly severe and steroid resistant (1). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12813</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28981968">PM:28981968</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171005-BourgoinHeckM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171005-BourgoinHeckM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171005, Bourgoin-Heck M</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12813</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kusunoki,T.</style></author><author><style face="normal" font="Arial"> Takeuchi,J.</style></author><author><style face="normal" font="Arial"> Morimoto,T.</style></author><author><style face="normal" font="Arial"> Sakuma,M.</style></author><author><style face="normal" font="Arial"> Yasumi,T.</style></author><author><style face="normal" font="Arial"> Nishikomori,R.</style></author><author><style face="normal" font="Arial"> Higashi,A.</style></author><author><style face="normal" font="Arial"> Heike,T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Shiga Medical Center for Children, Shiga, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Fruit intake reduces the onset of respiratory allergic symptoms in schoolchildren</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma symptoms</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Confidence Intervals</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food groups</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Primary schools</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> prospective cohort study</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Vegetable</style></keyword><keyword><style face="normal" font="Arial"> Vegetables</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Previous studies have shown that dietary pattern is associated with allergy prevention. METHODS: We conducted a prospective cohort study on all primary schools in Omihachiman City, Shiga Prefecture, Japan. Questionnaires regarding allergic symptoms and diet were distributed to the parents of all 759 7-year-old schoolchildren for 4 consecutive years, from 2011-2014. Specific immunoglobulin E to inhalant allergens were measured at 10 years of age. Participants were then categorized as low, medium, or high intake during the study period for four food groups (fruits, vegetables, fish and beans). Logistic regression analysis was performed to estimate odds ratios and 95% confidence intervals. RESULTS: A total of 520 children (68.5%) whose parents responded to the questionnaires all 4 years were included in the analysis. The prevalence of asthma, rhinitis, and any allergic symptoms at age 10 was significantly decreased with increases in fruit intake. In addition, the onset of any allergic symptoms during the study period was significantly decreased with increases in fruit intake (33.3%, 28.3%, and 14.3% in children with low, medium, and high fruit intake, respectively; P for trend = 0.01). The sensitization rate to ragweed at age 10 was significantly decreased with increases in fruit intake (P for trend = 0.046). No significant effect was observed for the other three food groups, except for the association between fish intake and new onset asthma symptoms. CONCLUSIONS: These findings suggest that higher intake of fruit can help prevent respiratory allergic symptoms in schoolchildren. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12817</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29024078">PM:29024078</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171012-KusunokiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171012-KusunokiT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Kusunoki T</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12817</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lazar,I.</style></author><author><style face="normal" font="Arial"> Cavari,Y.</style></author><author><style face="normal" font="Arial"> Levitas,A.</style></author><author><style face="normal" font="Arial"> Mandolla,A.B.</style></author><author><style face="normal" font="Arial"> Broides,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">From the *Pediatric Intensive Care Unit, Ben-Gurion University of the Negev</style></auth-address><titles><title><style face="normal" font="Arial">Gastric Drainage in the Treatment of Near-Fatal Food-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Absorption</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Adrenalin</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Drainage</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> food-induced anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="10" Year="2017">2017/10/9</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis should be treated with early administration of intramuscular Adrenalin; however, fatalities may still occur even with this therapy. We report a patient with near-fatal anaphylaxis due to milk whose symptoms persisted and were resistant to any therapeutic attempt; however, the patient had a prompt resolution of the anaphylaxis shortly after a nasogastric tube placement with gastric drainage, suggesting that this procedure ended the ongoing absorption of additional allergen from the gastrointestinal tract. We suggest that nasogastric drainage of gastric contents should be considered as part of the therapy in severe food-induced anaphylaxis</style></abstract><notes><style face="normal" font="Arial">DA - 20171010IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1097/PEC.0000000000001293</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29016518">PM:29016518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Emerg Care\20171010-LazarI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Emerg Care\20171010-LazarI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Lazar I</style></custom2><misc3><style face="normal" font="Arial">10.1097/PEC.0000000000001293</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pitrez,P.M.</style></author><author><style face="normal" font="Arial"> de Souza,R.G.</style></author><author><style face="normal" font="Arial"> Roncada,C.</style></author><author><style face="normal" font="Arial"> Heinzmann-Filho,J.P.</style></author><author><style face="normal" font="Arial"> Santos,G.</style></author><author><style face="normal" font="Arial"> Pinto,L.A.</style></author><author><style face="normal" font="Arial"> Jones,M.H.</style></author><author><style face="normal" font="Arial"> Stein,R.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Pediatric Respirology, Infant Center, Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Pulmonol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> anti-IgE</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma in children</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hospitalizations</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Severe asthma in children is a global health problem. Severe therapy-resistant asthma (STRA) in children is a major clinical challenge due to persistent symptoms despite high doses of corticosteroids and results in high public health costs. Omalizumab (anti-IgE monoclonal antibody) has been described as an effective add-on therapy in these patients. The characteristics of children with STRA from low- and middle-income countries have scarcely been reported, and no real-life study has been published on the effects of omalizumab in this group of patients. The aim of our study is to report the first clinical real-life experiences with omalizumab in Brazilian children with STRA. METHODS: Children (6-18 years old) from a referral center who were diagnosed with STRA were included in this retrospective study based on our clinical databases. The included children had undergone at least 6 months of omalizumab treatment and fulfilled the following initial criteria: 1) >6 years old; 2) a positive skin-prick test for at least one aeroallergen; and 3) a serum total IgE level between 30 and 1500 IU/mL. Clinical and lung function variables were analyzed before and after treatment. RESULTS: Fourteen children (mean age: 11.9 years; percentage female: 72%) were included in this study. Omalizumab treatment significantly increased control of the disease according to a standardized questionnaire administered at every visit (P &lt; 0.0001), ceased hospitalizations in 70% (P = 0.02) of patients, and allowed 8/9 (89%) patients to be weaned off oral steroids (P = 0.004). CONCLUSIONS: In this retrospective report, the use of omalizumab in Brazilian children with STRA significantly improved disease control, decreased hospitalizations, and allowed suspension of continuous oral corticosteroids</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1002/ppul.23845</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29027379">PM:29027379</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Pulmonol\20171013-PitrezPM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Pulmonol\20171013-PitrezPM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171013, Pitrez PM</style></custom2><misc3><style face="normal" font="Arial">10.1002/ppul.23845</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Guendouz,M.</style></author><author><style face="normal" font="Arial"> Haddi,A.</style></author><author><style face="normal" font="Arial"> Grar,H.</style></author><author><style face="normal" font="Arial"> Kheroua,O.</style></author><author><style face="normal" font="Arial"> Saidi,D.</style></author><author><style face="normal" font="Arial"> Kaddouri,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Laboratory of Physiology of the Nutrition and Food Safety, Department of Biology, Faculty of Natural and Life Sciences , University of Oran 1 Ahmed Ben Bella , Oran , Algeria</style></auth-address><titles><title><style face="normal" font="Arial">Preventive effects of royal jelly against anaphylactic response in a murine model of cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Pharm Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pharm Biol</style></full-title></periodical><pages end="2152" start="2145">2145-2152</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Algeria</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic response</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Body Temperature</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk protein</style></keyword><keyword><style face="normal" font="Arial"> cow's milk proteins</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food safety</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Human health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Jejunum</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Milk Proteins</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> physiology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> royal jelly</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Ussing chamber</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">CONTEXT: Royal jelly (RJ) has long been used to promote human health. OBJECTIVE: The current study investigated the preventive effects of RJ against the development of a systemic and intestinal immune response in mice allergic to cow's milk proteins. MATERIALS AND METHODS: Balb/c mice treated orally for seven days with RJ at doses of 0.5, 1 and 1.5 g/kg were sensitized intraperitoneally with beta-lactoglobulin (beta-Lg). Serum IgG and IgE anti-beta-Lg were determined by an enzyme-linked immunosorbent assay (ELISA). Plasma histamine levels, symptom scores and body temperature were determined after in vivo challenge to beta-Lg. Jejunums were used for assessment of local anaphylactic responses by an ex vivo study in Ussing chambers and morphologic changes by histological analysis. RESULTS: RJ significantly decreased serum IgG (31.15-43.78%) and IgE (64.28-66.6%) anti-beta-Lg and effectively reduced plasma histamine level (66.62-67.36%) (p &lt; 0.001) at all the doses tested. Additionally, no clinical symptoms or body temperature drops were observed in RJ-pretreated mice. Interestingly, RJ significantly reduced (p &lt; 0.001) intestinal dysfunction by abolishing the secretory response (70.73-72.23%) induced by sensitization and prevented length aberrations of jejunal villi by 44.32-59.01% (p &lt; 0.001). DISCUSSION AND CONCLUSIONS: We speculate that using RJ may help prevent systemic and anaphylactic response in allergic mice. These effects may be related to its inhibitory effects on the degranulation of mast cells</style></abstract><notes><style face="normal" font="Arial">DA - 20171006IS - 1744-5116 (Electronic)IS - 1388-0209 (Linking)LA - engPT - Journal ArticleCO - Algeria -</style></notes><work-type><style face="normal" font="Arial">10.1080/13880209.2017.1383487</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28982287">PM:28982287</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharm Biol\2017-55-2145-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharm Biol\2017-55-2145-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171006, Guendouz M</style></custom2><misc3><style face="normal" font="Arial">10.1080/13880209.2017.1383487</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Latocha,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Environmental Protection, Faculty of Horticulture, Biotechnology and Landscape Architecture, Warsaw University of Life Sciences - SGGW, Nowoursynowska 159, 02-776, Warsaw, Poland. piotr_latocha@sggw.pl</style></auth-address><titles><title><style face="normal" font="Arial">The Nutritional and Health Benefits of Kiwiberry (Actinidia arguta) - a Review</style></title><secondary-title><style face="normal" font="Arial">Plant Foods Hum Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Plant Foods Hum Nutr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptance</style></keyword><keyword><style face="normal" font="Arial"> Actinidia</style></keyword><keyword><style face="normal" font="Arial"> Actinidia arguta</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal System</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health benefit</style></keyword><keyword><style face="normal" font="Arial"> Health benefits</style></keyword><keyword><style face="normal" font="Arial"> Hypercholesterolemia</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> investigations</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Minerals</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Phenolics</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Potassium</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin C</style></keyword><keyword><style face="normal" font="Arial"> vitamins</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="Arial">The kiwiberry (Actinidia arguta) is a new product on the market that is enjoying growing consumer acceptance around the world. This widespread interest has created increased demand for identification of the kiwiberry's nutritional health benefits. Containing over 20 essential nutrients and a range of vitamins, the kiwiberry comes near the top of fruits classed as superfoods. It is one of the richest sources of vitamin C with up to 430 mg/100 g fresh weight (FW) and is considered the richest dietary source of myo-inositol (up to 982 mg/100 g FW). The kiwiberry is also one of the richest sources of lutein (up to 0.93 mg/100 g FW) in commonly consumed fruit. Furthermore, containing up to 1301.1 mg/100 g FW phenolics and significant amounts of the essential minerals of potassium, calcium and zinc, the kiwiberry rates very highly as a 'healthy food'. The type and number of this fruit's medicinally promising nutrients have motivated ongoing investigations into its antioxidant, anti-tumour and anti-inflammatory properties. Early research has pointed to the kiwiberry being a very promising treatment for some cancers and health issues involving the gastrointestinal system, hypercholesterolemia and certain cancers. A pharmaceutical composition of A. arguta, A. kolomikta, and A. polygama extracts has already been registered for the prevention and treatment of some immune (inflammatory) mediated diseases, as well as the treatment of some non-allergic inflammatory diseases. This paper reviews and highlights the limited nutritional and therapeutic information currently available on the kiwiberry, a minor fruit possessing such major properties</style></abstract><notes><style face="normal" font="Arial">DA - 20171008IS - 1573-9104 (Electronic)IS - 0921-9668 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11130-017-0637-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988409">PM:28988409</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Plant Foods Hum Nutr\20171008-LatochaP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Plant Foods Hum Nutr\20171008-LatochaP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171008, Latocha P</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11130-017-0637-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bordas-Le Floch,V.</style></author><author><style face="normal" font="Arial"> Le Mignon,M.</style></author><author><style face="normal" font="Arial"> Bussieres,L.</style></author><author><style face="normal" font="Arial"> Jain,K.</style></author><author><style face="normal" font="Arial"> Martelet,A.</style></author><author><style face="normal" font="Arial"> Baron-Bodo,V.</style></author><author><style face="normal" font="Arial"> Nony,E.</style></author><author><style face="normal" font="Arial"> Mascarell,L.</style></author><author><style face="normal" font="Arial"> Moingeon,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Stallergenes Greer, Antony cedex, France</style></auth-address><titles><title><style face="normal" font="Arial">A combined transcriptome and proteome analysis extends the allergome of house dust mite Dermatophagoides species</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0185830">e0185830-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Assembly</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Characterization</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> HDM allergens</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-reactivity</style></keyword><keyword><style face="normal" font="Arial"> IgEs</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> IUIS</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> New allergens</style></keyword><keyword><style face="normal" font="Arial"> Nomenclature</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein sequence</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteome</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Repertoire</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Transcriptome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: House dust mites (HDMs) such as Dermatophagoides farinae and D. pteronyssinus represent major causes of perennial allergy. HDM proteomes are currently poorly characterized, with information mostly restricted to allergens. As of today, 33 distinct allergen groups have been identified for these 2 mite species, with groups 1 and 2 established as major allergens. Given the multiplicity of IgE-reactive mite proteins, potential additional allergens have likely been overlooked. OBJECTIVE: To perform a comprehensive characterization of the transcriptomes, proteomes and allergomes of D. farinae and D. pteronyssinus in order to identify novel allergens. METHODS: Transcriptomes were analyzed by RNA sequencing and de novo assembly. Comprehensive mass spectrometry-based analyses proteomes were combined with two-dimensional IgE reactivity profiling. RESULTS: Transcripts from D. farinae and D. pteronyssinus were assembled, translated into protein sequences and used to populate derived sequence databases in order to inform immunoproteomic analyses. A total of 527 and 157 proteins were identified by bottom-up MS analyses in aqueous extracts from purified HDM bodies and fecal pellets, respectively. Based on high sequence similarities (>71% identity), we also identified 2 partial and 11 complete putative sequences of currently undisclosed D. pteronyssinus counterparts of D. farinae registered allergens. Immunoprofiling on 2D-gels revealed the presence of unknown 23 kDa IgE reactive proteins in both species. Following expression of non-glycosylated recombinant forms of these molecules, we confirm that these new allergens react with serum IgEs from 42% (8/19) of HDM-allergic individuals. CONCLUSIONS: Using combined transcriptome and immunoproteome approaches, we provide a comprehensive characterization of D. farinae and D. pteronyssinus allergomes. We expanded the known allergen repertoire for D. pteronyssinus and identified two novel HDM allergens, now officially referred by the International Union of Immunological Societies (IUIS) Nomenclature Subcommittee as Der f 36 and Der p 36</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0185830</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28982170">PM:28982170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0185830.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0185830.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171005, Bordas-Le Floch V</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0185830</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hugg,T.T.</style></author><author><style face="normal" font="Arial"> Hjort,J.</style></author><author><style face="normal" font="Arial"> Antikainen,H.</style></author><author><style face="normal" font="Arial"> Rusanen,J.</style></author><author><style face="normal" font="Arial"> Tuokila,M.</style></author><author><style face="normal" font="Arial"> Korkonen,S.</style></author><author><style face="normal" font="Arial"> Weckstrom,J.</style></author><author><style face="normal" font="Arial"> Jaakkola,M.S.</style></author><author><style face="normal" font="Arial"> Jaakkola,J.J.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center for Environmental and Respiratory Health Research, University of Oulu, Oulu, Finland</style></auth-address><titles><title><style face="normal" font="Arial">Urbanity as a determinant of exposure to grass pollen in Helsinki Metropolitan area, Finland</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0186348">e0186348-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Finland</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Peak pollen season</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> pollen exposure</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sampler</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban environment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Little is known about the levels of exposure to grass pollen in urban environments. We assessed the spatio-temporal variation of grass pollen concentrations and the role of urbanity as a determinant of grass pollen exposure in the Helsinki Metropolitan area. We monitored grass pollen concentrations in 2013 at 16 sites during the peak pollen season by using rotorod-type samplers at the breathing height. The sites were in the cities of Helsinki and Espoo, Finland, and formed city-specific lines that represented urban-rural gradient. The monitoring sites were both visually and based on land use data ranked as high to low (graded 1 to 8) pollen area. The lowest grass pollen concentrations were observed in the most urban sites compared to the least urban sites (mean 3.6 vs. 6.8 grains/m3 in Helsinki; P&lt;0.0001, and 5.2 vs. 87.5 grains/m3 in Espoo; P&lt;0.0001). Significant differences were observed between concentrations measured in morning periods compared to afternoon periods (4.9 vs. 5.4 in Helsinki, P = 0.0186, and 21.8 vs. 67.1 in Espoo, P = 0.0004). The mean pollen concentration increased with decreasing urbanity both in Helsinki (0.59 grains/m3 per urbanity rank, 95% CI 0.25-0.93) and Espoo (8.42, 6.23-10.61). Pollen concentrations were highest in the afternoons and they were related to the ambient temperature. Urbanity was a strong and significant determinant of pollen exposure in two Finnish cities. Pollen exposure can periodically reach such high levels even in the most urban environments that can cause allergic reactions among individuals with allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0186348</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29023565">PM:29023565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0186348.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0186348.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0186348.xls</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0186348.xls</url></image-urls></urls><custom2><style face="normal" font="Arial">20171012, Hugg TT</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0186348</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhou,W.</style></author><author><style face="normal" font="Arial"> Wan,Y.</style></author><author><style face="normal" font="Arial"> Guo,R.</style></author><author><style face="normal" font="Arial"> Deng,M.</style></author><author><style face="normal" font="Arial"> Deng,K.</style></author><author><style face="normal" font="Arial"> Wang,Z.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Wang,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Jiangsu Livestock Embryo Engineering Laboratory, Nanjing Agricultural University, Nanjing, Jiangsu, PR, China</style></auth-address><titles><title><style face="normal" font="Arial">Generation of beta-lactoglobulin knock-out goats using CRISPR/Cas9</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0186056">e0186056-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Embryo</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fibroblasts</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Goat milk</style></keyword><keyword><style face="normal" font="Arial"> Goat's milk</style></keyword><keyword><style face="normal" font="Arial"> Goats</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Livestock</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Nutritional value</style></keyword><keyword><style face="normal" font="Arial"> Optimization</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Goat's milk, considered a substitute for cow's milk, has a high nutritional value. However, goat's milk contains various allergens, predominantly beta-lactoglobulin (BLG). In this study, we employed the CRISPR/Cas9 system to target the BLG locus in goat fibroblasts for sgRNA optimization and generate BLG knock-out goats through co-injection of Cas9 mRNA and small guide RNAs (sgRNAs) into goat embryos at the one-cell stage. We firstly tested sgRNA editing efficiencies in goat fibroblast cells, and approximately 8.00%-9.09% of the cells were modified in single sgRNA-guided targeting experiment. Among the kids, the genome-targeting efficiencies of single sgRNA were 12.5% (10 ng/muL sg1) and 0% (10 ng/muL sg2) and efficiencies of dual sgRNAs were 25.0% (25 ng/muL sg2+sg3 group) and 28.6% (50 ng/muL sg2+sg3 group). Relative expression of BLG in BLG knock-out goat mammary glands significantly (p &lt; 0.01) decreased as well as other milk protein coding genes, such as CSN1S1, CSN1S2, CSN2, CSN3 and LALBA (p &lt; 0.05). As expected, BLG protein had been abolished in the milk of the BLG knock-out goat. In addition, most of the targeted kids were chimeric (3/4), and their various body tissues were edited simultaneously. Our study thus provides a basis for optimizing the quality of goat milk, which can be applied to biomedical and agricultural research</style></abstract><notes><style face="normal" font="Arial">DA - 20171010IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0186056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29016691">PM:29016691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0186056.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0186056.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171010, Zhou W</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0186056</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Giusti,A.</style></author><author><style face="normal" font="Arial"> Armani,A.</style></author><author><style face="normal" font="Arial"> Sotelo,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">FishLab, Department of Veterinary Sciences, University of Pisa, Pisa, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Advances in the analysis of complex food matrices: Species identification in surimi-based products using Next Generation Sequencing technologies</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0185586">e0185586-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic consumer</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Cephalopod</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Consumers</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Inspection</style></keyword><keyword><style face="normal" font="Arial"> Genome</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> inspection</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Libraries</style></keyword><keyword><style face="normal" font="Arial"> Library</style></keyword><keyword><style face="normal" font="Arial"> Mislabelling</style></keyword><keyword><style face="normal" font="Arial"> Mollusc</style></keyword><keyword><style face="normal" font="Arial"> Next generation sequencing</style></keyword><keyword><style face="normal" font="Arial"> NGS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Seafood</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Species identification</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Traceability</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> variability</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The Next Generation Sequencing (NGS) technologies represent a turning point in the food inspection field, particularly for species identification in matrices composed of a blend of two or more species. In this study NGS technologies were applied by testing the usefulness of the Ion Torrent Personal Genome Machine (PGM) in seafood traceability. Sixteen commercial surimi samples produced both in EU and non-EU countries were analysed. Libraries were prepared using a universal primer pair able to amplify a short 16SrRNA fragment from a wide range of fish and cephalopod species. The mislabelling rate of the samples was also evaluated. Overall, DNA from 13 families, 19 genera and 16 species of fish, and from 3 families, 3 genera and 3 species of cephalopods was found with the analysis. Samples produced in non-EU countries exhibited a higher variability in their composition. 37.5% of the surimi products were found to be mislabelled. Among them, 25% voluntary declared a species different from those identified and 25% (all produced in non-EU countries) did not report the presence of molluscs on the label, posing a potential health threat for allergic consumers. The use of vulnerable species was also proved. Although the protocol should be further optimized, PGM platform proved to be a useful tool for the analysis of complex, highly processed products</style></abstract><notes><style face="normal" font="Arial">DA - 20171002IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0185586</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28968423">PM:28968423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0185586.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0185586.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171002, Giusti A</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0185586</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aguiar,S.S.</style></author><author><style face="normal" font="Arial"> Damaceno,N.</style></author><author><style face="normal" font="Arial"> Forte,W.C.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Setor de Pneumologia do Departamento de Pediatria e Puericultura da Irmandade da Santa Casa de Misericordia de Sao Paulo, SP, BrasilEquipe Multidisciplinar do Servico de Referencia de Tratamento de Fibrose Cistica do Setor de Pneumologia do Departamento de Pediatria e Puericultura da Irmandade da Santa Casa de Misericordia de Sao Paulo, SP, BrasilDepartamento de Ciencias Patologicas da Faculdade de Ciencias Medicas da Santa Casa de Sao Paulo, SP, Brasil</style></auth-address><titles><title><style face="normal" font="Arial">Tests to assess sensitization to aspergillus fumigatus in cystic fibrosis.</style></title><secondary-title><style face="normal" font="Arial">Rev Paul Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Paul Pediatr</style></full-title></periodical><pages end="257" start="252">252-257</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Brasil</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immediate-type hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Swab</style></keyword><keyword><style face="normal" font="Arial"> Teaching</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To evaluate the results of the tests used to identify the IgE mediated sensitization to Aspergillus fumigatus in patients with cystic fibrosis. METHODS: This is a cross-sectional descriptive study with a convenience sample of 86 patients diagnosed with cystic fibrosis in the Reference Service in Cystic Fibrosis at a tertiary teaching hospital. The following tests were performed to assess the sensitization to A. fumigatus in patients with cystic fibrosis: Total serum IgE, eosinophil count, fungus detection through oropharyngeal swab or sputum culture, serum-specific IgE, and immediate-type hypersensitivity (IgE) skin tests. We compared the results of the different tests performed. RESULTS: In 33 (38.4%) patients with cystic fibrosis, with ages ranging from 1 to 33 years (median of 8 years), the IgE-mediated A. fumigatus sensitization test results were: in 16 patients, there was an increase in serum-specific IgE (>0.35 kU/L); in 23, skin tests were positive; and six had sensitization in both tests. We observed two patients with eosinophilia (>1,000 eosinophils/mm3) and seven with increasing total serum IgE (>1,000 IU/mL), all of whom obtained negative results in skin tests and had no IgE increase specific to A. fumigatus. A. fumigatus was not detected in oropharyngeal swabs and/or sputum culture of any patients. CONCLUSIONS: We conclude that, among the tests used to assess sensitization to A. fumigatus in cystic fibrosis patients, both serum-specific IgE and immediate-type hypersensitivity (IgE) skin tests are required. Serum eosinophilia and respiratory secretion culture were not essential in this study</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 1984-0462 (Electronic)IS - 0103-0582 (Linking)LA - porLA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1590/1984-0462/;2017;35;3;00003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28977288">PM:28977288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Paul Pediatr\2017-35-252-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Paul Pediatr\2017-35-252-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Aguiar SS</style></custom2><misc3><style face="normal" font="Arial">10.1590/1984-0462/;2017;35;3;00003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gray,C.L.</style></author><author><style face="normal" font="Arial"> Levin,M.E.</style></author><author><style face="normal" font="Arial"> Du Toit,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergology, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, Cape Town</style></auth-address><titles><title><style face="normal" font="Arial">Respiratory comorbidity in South African children with atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">S Afr Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">S Afr Med J</style></full-title></periodical><pages end="909" start="904">904-909</pages><volume><style face="normal" font="Arial">107</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Africa</style></keyword><keyword><style face="normal" font="Arial"> African children</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen chip</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic march</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Bermuda</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> ethnicity</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergen</style></keyword><keyword><style face="normal" font="Arial"> Indoor allergens</style></keyword><keyword><style face="normal" font="Arial"> International study of asthma and allergies in childhood</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Mould</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> paediatrics</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergies</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin barrier</style></keyword><keyword><style face="normal" font="Arial"> Solid phase</style></keyword><keyword><style face="normal" font="Arial"> South Africa</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> the allergic march</style></keyword><keyword><style face="normal" font="Arial"> Timothy grass</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> War</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopic dermatitis (AD) is an early and important step in the propagation of the allergic march, enhancing food and respiratory allergies via epicutaneous sensitisation to allergens. OBJECTIVES: To determine the prevalence and patterns of aeroallergen sensitisation, asthma and allergic rhinitis in South African (SA) children with AD. METHODS: This was a prospective, observational study in a paediatric university hospital in Cape Town, SA. Children with moderate to severe AD, aged 6 months - 10 years, were recruited randomly and investigated for food sensitisation and allergy. They were assessed for sensitisation to aeroallergens by the immuno solid-phase allergen chip test. House-dust mite DerP and DerF, dust mite Eur m, Timothy grass, Bermuda grass, tree pollen, mould (Alternaria), cat and dog sensitisation patterns were analysed. Symptoms of asthma and allergic rhinitis were elicited using a questionnaire modified from the International Study of Asthma and Allergies in Childhood study questions. RESULTS: One hundred participants (59 black Africans and 41 of mixed ethnicity) were enrolled (median age 42 months). Of the participants, 39% had symptoms of asthma and 53% symptoms of allergic rhinitis; 89% tested positive to at least one aeroallergen, most commonly house-dust mite DerP or DerF (81%), dust mite Eur m (51%), Timothy grass (36%) and cat (35%). Asthma, allergic rhinitis and aeroallergen sensitisation all increased with increasing age, while food allergy decreased with age. Food allergy was not an independent risk factor for respiratory allergies. Children were sensitised to indoor allergens (house-dust mite, pets) from an early age, while pollen allergies increased with age. CONCLUSIONS: In this cohort of SA children with moderate to severe AD, comorbidity with respiratory allergies was high. The prevalence of respiratory allergies increased with age while food allergy decreased with age, in keeping with the pattern of the allergic march. Seasonal allergies increased with age, while house-dust mite and pet allergy peaked in younger children, in keeping with early exposure via a defective skin barrier. Early and effective restoration of the skin barrier in AD may be a target for reducing aeroallergen-related diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 0256-9574 (Print)LA - engPT - Journal ArticleCO - South Africa -</style></notes><work-type><style face="normal" font="Arial">10.7196/SAMJ.2017.v107i10.12418</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29022537">PM:29022537</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\S Afr Med J\2017-107-904-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\S Afr Med J\2017-107-904-9.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Gray CL</style></custom2><misc3><style face="normal" font="Arial">10.7196/SAMJ.2017.v107i10.12418</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Seo,H.M.</style></author><author><style face="normal" font="Arial"> Kim,Y.H.</style></author><author><style face="normal" font="Arial"> Lee,J.H.</style></author><author><style face="normal" font="Arial"> Kim,J.S.</style></author><author><style face="normal" font="Arial"> Park,Y.M.</style></author><author><style face="normal" font="Arial"> Lee,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hanyang University Guri Hospital, Guri, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Serum Zinc Status and Its Association with Allergic Sensitization: The Fifth Korea National Health and Nutrition Examination Survey</style></title><secondary-title><style face="normal" font="Arial">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Rep</style></full-title></periodical><pages end="" start="12637">12637-</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> specific-IgE levels</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Trace Elements</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Zinc</style></keyword></keywords><dates><year Day="3" Month="10" Year="2017">2017/10/3</year></dates><abstract><style face="normal" font="Arial">Zinc (Zn) is an essential trace element that plays important roles in the immune system. There is little known about the role of trace elements in allergic diseases, and previous reports have shown conflicting results. The aim of this study was to investigate the relationship between serum Zn levels and total or allergen-specific immunoglobulin E (IgE) levels. The initial candidates for this study were those who participated in the 5th Korean National Health and Nutrition Examination Survey 2010 (n = 8,958), and 1,867 adults who had serum total and allergen specific-IgE levels measured were included. Upon adjusting for covariates, mean total IgE, Dermatophagoides farinae and dog-specific IgE levels increased significantly as the Zn levels decrease from the highest to the lowest quartile (p = 0.009, 0.004, and &lt; 0.001, respectively). The multiple logistic regression analyses showed significant negative linear correlations between serum Zn levels and total, D. farinae-, cockroach-, and dog-specific IgE levels (p-value for linear trend = 0.004, 0.006, 0.027, and &lt; 0.001, respectively). This study demonstrated that total/allergen specific IgE and Zn levels are significantly inversely related</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41598-017-13068-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28974756">PM:28974756</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-12637.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-12637.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Seo HM</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41598-017-13068-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,B.</style></author><author><style face="normal" font="Arial"> Liu,F.</style></author><author><style face="normal" font="Arial"> Dong,J.</style></author><author><style face="normal" font="Arial"> You,M.</style></author><author><style face="normal" font="Arial"> Fu,Y.</style></author><author><style face="normal" font="Arial"> Li,C.</style></author><author><style face="normal" font="Arial"> Lu,Y.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pneumoconiosis, School of Public Health, China Medical University, Shenyang, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Maternal exposure to environmental DEHP exacerbated OVA-induced asthmatic responses in rat offspring</style></title><secondary-title><style face="normal" font="Arial">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Sci Total Environ</style></full-title></periodical><pages end="261" start="253">253-261</pages><volume><style face="normal" font="Arial">615</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> Maternal Exposure</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> phthalates</style></keyword><keyword><style face="normal" font="Arial"> Pneumoconiosis</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> TSLP</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="9" Year="2017">2017/9/30</year></dates><abstract><style face="normal" font="Arial">Di (ethylhexyl) phthalate (DEHP) is a commonly used phthalates (PAEs) compound as plasticizer and becomes a severe environmental pollutant worldwide. Studies show that DEHP, as an environmental endocrine disruptor, has potential adverse effects on human. Epidemiologic studies indicate that DEHP is positively correlated to allergic diseases. Maternal exposure to DEHP may contribute to the increasing incidence of allergic diseases in offspring. However, the role of DEHP and its detailed mechanism in allergic disease of the offspring are still unclear. The aim of our study is to investigate whether DEHP maternal exposure could aggravate the allergic responses in offspring and its mechanism. Pregnant Wistar rats were randomly divided into three groups and exposed to different doses of DEHP. Half of the offspring were challenged with OVA after birth. All the pups of each group were sacrificed at postnatal day (PND)14, PND21 and PND28. The number of inflammatory cells in bronchoalveolar lavage was counted, lung pathological changes were observed, Th2 type cytokines expressions were checked, and the expression of TSLP signaling pathway were examined. Our results showed that maternal exposure to DEHP during pregnancy and lactation aggravated the eosinophils accumulation and the pathological inflammatory changes in pups' lung after OVA challenge. And maternal exposure to DEHP during pregnancy and lactation also elevated the levels of typical Th2 cytokines in OVA-challenged rats. What's more, maternal exposure to DEHP during pregnancy and lactation increased the levels of TSLP, TSLPR and IL-7R in the offspring after OVA challenge. Our study suggested that DEHP maternal exposure could aggravate the OVA-induced asthmatic responses in offspring. And this adjuvant effect of DEHP was related with the TSLP/TSLPR/IL-7R and its downstream signal pathways</style></abstract><notes><style face="normal" font="Arial">DA - 20171003IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.scitotenv.2017.09.276</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28972901">PM:28972901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Total Environ\2017-615-253-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Total Environ\2017-615-253-61.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171003, Wang B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.scitotenv.2017.09.276</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Barranco,P.</style></author><author><style face="normal" font="Arial"> Phillips-Angles,E.</style></author><author><style face="normal" font="Arial"> Dominguez-Ortega,J.</style></author><author><style face="normal" font="Arial"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Dupilumab in the management of moderate-to-severe asthma: the data so far</style></title><secondary-title><style face="normal" font="Arial">Ther Clin Risk Manag</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ther Clin Risk Manag</style></full-title></periodical><pages end="1149" start="1139">1139-1149</pages><volume><style face="normal" font="Arial">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> Biological Therapy</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukins</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> mAbs</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> Moderate to severe asthma</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> treatment guidelines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Severe asthma constitutes illness in a relatively small proportion of all patients with asthma, but it is a major public health problem - with considerable effect on morbidity, mortality, as well as a high burden on health care resources. Regardless of effective treatments being widely available and the existence of treatment guidelines, a large population of severe asthma cases remain uncontrolled. Achieving and maintaining asthma control in this group of patients is, therefore, of utmost importance. The recognition of distinct inflammatory phenotypes within this population has driven the development of targeted biological therapies - particularly, selective targeted monoclonal antibodies (mAbs). It is noteworthy that in approximately 50% of these patients, there is strong evidence of the pathogenic role of T helper type-2 (Th2) cytokines, such as interleukin (IL)-4 and IL-13, orchestrating the eosinophilic and allergic inflammatory processes. Among the recently developed antiasthma biologic drugs, the mAb dupilumab is very promising given its ability to inhibit the biological effects of both IL-4 and IL-13. In this review, we focused on IL-4 and IL-13, as these interleukins are considered to play a key role in the pathophysiology of asthma, and on dupilumab, an anti-IL-4 receptor human mAb, as a forthcoming treatment for uncontrolled severe asthma in the near future</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 1176-6336 (Print)IS - 1176-6336 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.2147/TCRM.S125964</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28979129">PM:28979129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ther Clin Risk Manag\2017-13-1139-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ther Clin Risk Manag\2017-13-1139-49.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171005, Barranco P</style></custom2><misc3><style face="normal" font="Arial">10.2147/TCRM.S125964</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Jarvis,D.</style></author><author><style face="normal" font="Arial"> Newson,R.</style></author><author><style face="normal" font="Arial"> Janson,C.</style></author><author><style face="normal" font="Arial"> Corsico,A.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author><author><style face="normal" font="Arial"> Anto,J.M.</style></author><author><style face="normal" font="Arial"> Abramson,M.J.</style></author><author><style face="normal" font="Arial"> Kirsten,A.M.</style></author><author><style face="normal" font="Arial"> Zock,J.P.</style></author><author><style face="normal" font="Arial"> Bono,R.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Leynaert,B.</style></author><author><style face="normal" font="Arial"> Raherison,C.</style></author><author><style face="normal" font="Arial"> Pin,I.</style></author><author><style face="normal" font="Arial"> Gislason,T.</style></author><author><style face="normal" font="Arial"> Jogi,R.</style></author><author><style face="normal" font="Arial"> Schlunssen,V.</style></author><author><style face="normal" font="Arial"> Svanes,C.</style></author><author><style face="normal" font="Arial"> Watkins,J.</style></author><author><style face="normal" font="Arial"> Weyler,J.</style></author><author><style face="normal" font="Arial"> Pereira-Vega,A.</style></author><author><style face="normal" font="Arial"> Urrutia,I.</style></author><author><style face="normal" font="Arial"> Gullon,J.A.</style></author><author><style face="normal" font="Arial"> Forsberg,B.</style></author><author><style face="normal" font="Arial"> Probst-Hensch,N.</style></author><author><style face="normal" font="Arial"> Boezen,H.M.</style></author><author><style face="normal" font="Arial"> Martinez-Moratalla,R.J.</style></author><author><style face="normal" font="Arial"> Accordini,S.</style></author><author><style face="normal" font="Arial"> De Marco,R.</style></author><author><style face="normal" font="Arial"> Burney,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Prevalence of asthma-like symptoms with ageing</style></title><secondary-title><style face="normal" font="Arial">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Thorax</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Estonia</style></keyword><keyword><style face="normal" font="Arial"> European Community Respiratory Health Survey</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> health survey</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Interpretation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Norway</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Probability</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> wheeze</style></keyword></keywords><dates><year Day="3" Month="10" Year="2017">2017/10/3</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Change in the prevalence of asthma-like symptoms in populations of ageing adults is likely to be influenced by smoking, asthma treatment and atopy. METHODS: The European Community Respiratory Health Survey collected information on prevalent asthma-like symptoms from representative samples of adults aged 20-44 years (29 centres in 13 European countries and Australia) at baseline and 10 and 20 years later (n=7844). Net changes in symptom prevalence were determined using generalised estimating equations (accounting for non-response through inverse probability weighting), followed by meta-analysis of centre level estimates. FINDINGS: Over 20 years the prevalence of 'wheeze' and 'wheeze in the absence of a cold' decreased (-2.4%, 95% CI -3.5 to -1.3%; -1.5%, 95% CI -2.4 to -0.6%, respectively) but the prevalence of asthma attacks, use of asthma medication and hay fever/nasal allergies increased (0.6%, 95% CI 0.1 to 1.11; 3.6%, 95% CI 3.0 to 4.2; 2.7%, 95% CI 1.7 to 3.7). Changes were similar in the first 10 years compared with the second 10 years, except for hay fever/nasal allergies (increase seen in the first 10 years only). Decreases in these wheeze-related symptoms were largely seen in the group who gave up smoking, and were seen in those who reported hay fever/nasal allergies at baseline. INTERPRETATION: European adults born between 1946 and 1970 have, over the last 20 years, experienced less wheeze, although they were more likely to report asthma attacks, use of asthma medication and hay fever. Decrease in wheeze is largely attributable to smoking cessation, rather than improved treatment of asthma. It may also be influenced by reductions in atopy with ageing</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Sweden -CO - Spain -CO - Italy -CO - Australia -CO - Germany -CO - France -CO - Iceland -CO - Estonia -CO - Denmark -CO - Norway -CO - Belgium -CO - Netherlands -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1136/thoraxjnl-2016-209596</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28974648">PM:28974648</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Thorax\20171004-JarvisD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Thorax\20171004-JarvisD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Jarvis D</style></custom2><misc3><style face="normal" font="Arial">10.1136/thoraxjnl-2016-209596</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zeller,K.S.</style></author><author><style face="normal" font="Arial"> Johansson,H.</style></author><author><style face="normal" font="Arial"> Lund,T.O.</style></author><author><style face="normal" font="Arial"> Kristensen,N.N.</style></author><author><style face="normal" font="Arial"> Roggen,E.L.</style></author><author><style face="normal" font="Arial"> Lindstedt,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunotechnology, Lund, Sweden</style></auth-address><titles><title><style face="normal" font="Arial">An alternative biomarker-based approach for the prediction of proteins known to sensitize the respiratory tract</style></title><secondary-title><style face="normal" font="Arial">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Toxicol In Vitro</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Rapid detection</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="Arial">Many natural and industrial proteins are known to have properties that can result in type I hypersensitivity, however, to date, no validated test system exists that can predict the sensitizing potential of these allergens. Thus, the objective of this study was to develop a protocol based on the myeloid cell-based Genomic Allergen Rapid Detection (GARD) assay that can be used to assess and predict the capacity of protein allergens known to induce sensitization in the respiratory tract. Cellular responses induced by eight selected proteins were assessed using transcriptional profiling, flow cytometry and multiplex cytokine analysis. 391 potential biomarkers were identified as a predictive signature and a series of cross-validations supported the validity of the model. These results together with biological pathway analysis of the transcriptomic data indicate that the investigated cell system is able to capture relevant events linked to type I hypersensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20171011IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.tiv.2017.09.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29017774">PM:29017774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol In Vitro\20171011-ZellerKS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol In Vitro\20171011-ZellerKS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171011, Zeller KS</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.tiv.2017.09.029</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saradna,A.</style></author><author><style face="normal" font="Arial"> Do,D.C.</style></author><author><style face="normal" font="Arial"> Kumar,S.</style></author><author><style face="normal" font="Arial"> Fu,Q.L.</style></author><author><style face="normal" font="Arial"> Gao,P.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Macrophage Polarization and Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Transl Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Transl Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophage polarization</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1931-5244</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -CO - India -CO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.trsl.2017.09.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.trsl.2017.09.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Transl Res\20171015-SaradnaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Transl Res\20171015-SaradnaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171015, Saradna A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.trsl.2017.09.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kar,K.O.</style></author><author><style face="normal" font="Arial"> Erkocoglu,M.</style></author><author><style face="normal" font="Arial"> Kurt,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Occupational Diseases, Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey. aghhozlem@yahoo.com</style></auth-address><titles><title><style face="normal" font="Arial">[Pollen food allergy syndrome]</style></title><secondary-title><style face="normal" font="Arial">Tuberk Toraks</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Tuberk Toraks</style></full-title></periodical><pages end="145" start="138">138-145</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cross reaction</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Lip</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mouth</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational disease</style></keyword><keyword><style face="normal" font="Arial"> Occupational Diseases</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Palate</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pharynx</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Swelling</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tongue</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Pollen food allergy syndrome, is a type I cross-reaction mediated by IgE antibodies between an aeroallergen and a plant-derived antigen. Main symptoms are typically consist of localized oral symptoms such as numbness of the lip or mouth, itching, tingling and swelling of lips, tongue, palate and pharynx without systemic symptoms. Patients with seasonal allergic rhinitis, asthma or both more frequently experience pollen food allergy syndrome. Because most patients have mild symptoms and the improvement by avoiding food, the true incidence is unknown. In this review, we aimed to discuss characteristics, diagnosis and treatment of pollen food allergy syndrome according to existing literature</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 0494-1373 (Print)IS - 0494-1373 (Linking)LA - turPT - English AbstractPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5578/tt.32167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28990893">PM:28990893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Tuberk Toraks\2017-65-138-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Tuberk Toraks\2017-65-138-45.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171009, Kar KO</style></custom2><misc3><style face="normal" font="Arial">10.5578/tt.32167</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Emiralioglu,N.</style></author><author><style face="normal" font="Arial"> Ozcan,H.N.</style></author><author><style face="normal" font="Arial"> Orhan,D.</style></author><author><style face="normal" font="Arial"> Haliloglu,M.</style></author><author><style face="normal" font="Arial"> Cengiz,A.B.</style></author><author><style face="normal" font="Arial"> Yalcin,E.E.</style></author><author><style face="normal" font="Arial"> Dogru,E.D.</style></author><author><style face="normal" font="Arial"> Kiper,N.</style></author><author><style face="normal" font="Arial"> Ozcelik,H.U.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pediatric Chest Diseases, Faculty of Medicine, Hacettepe University, Children Hospital, Ankara, Turkey. drnagehan@yahoo.com</style></auth-address><titles><title><style face="normal" font="Arial">Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient after the surgery of hydatid cyst</style></title><secondary-title><style face="normal" font="Arial">Tuberk Toraks</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Tuberk Toraks</style></full-title></periodical><pages end="160" start="157">157-160</pages><volume><style face="normal" font="Arial">65</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tuberculosis</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> voriconazole</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">Chronic necrotizing pulmonary aspergillosis (CNPA) is a condition caused by the ubiquitous fungus Aspergillus fumigatus in non-immunocompromised individuals. Numerous underlying conditions have been associated with CNPA. Tuberculosis, non-tuberculous mycobacterial infection and allergic bronchopulmonary aspergillosis (ABPA) remain the predominant risk factors for development of CNPA. Development of CNPA in echinococcal cyst cavities is very rare and the optimal therapeutic regimen and treatment duration have not been established. Here, we present a case of CNPA developed six years after the cystectomy operation of hydatid cyst and treated with voriconazole successfully</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 0494-1373 (Print)IS - 0494-1373 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.5578/tt.13957</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28990897">PM:28990897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Tuberk Toraks\2017-65-157-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Tuberk Toraks\2017-65-157-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171009, Emiralioglu N</style></custom2><misc3><style face="normal" font="Arial">10.5578/tt.13957</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lindemalm,C.</style></author><author><style face="normal" font="Arial"> Nordlund,B.</style></author><author><style face="normal" font="Arial"> Ortqvist,A.K.</style></author><author><style face="normal" font="Arial"> Lundholm,C.</style></author><author><style face="normal" font="Arial"> van Hage,M.</style></author><author><style face="normal" font="Arial"> Gong,T.</style></author><author><style face="normal" font="Arial"> Almqvist,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Epidemiology and Biostatistics,Karolinska Institutet,Stockholm,Sweden</style></auth-address><titles><title><style face="normal" font="Arial">Associations Between Asthma and Sensitization to Pet or Pollen Allergens in Young Swedish Twins - The STOPPA Study</style></title><secondary-title><style face="normal" font="Arial">Twin Res Hum Genet</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Twin Res Hum Genet</style></full-title></periodical><pages end="388" start="380">380-388</pages><volume><style face="normal" font="Arial">20</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> dose response</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> epidemiology</style></keyword><keyword><style face="normal" font="Arial"> familial</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic factors</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> pollen allergen</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> twin</style></keyword><keyword><style face="normal" font="Arial"> Twins</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: An association between childhood asthma and IgE sensitization has been established, but our understanding of the genetic and environmental contribution to it is incomplete. Our aim was to estimate the associations and dose-response relationship between asthma and sensitization to airborne allergens in Swedish 9- to 14-year-old twins. Additionally, we aimed to explore the importance of familial confounding from shared genes and environment using co-twin controls. METHODS: In the STOPPA cohort, 752 same-sex twin children were screened with Phadiatop(R) (Thermo Fisher Scientific; Pharmacia, Uppsala, Sweden); if positive further analysis of IgE antibodies to airborne allergens of pets (cat, horse, dog), pollens (birch, timothy, mugwort), mites, and mold were performed. The associations between asthma and airborne allergens were assessed with generalized estimating equations. The co-twin control analysis was performed by conditional logistic regression. RESULTS: Children with positive Phadiatop(R) had more than doubled odds of asthma (OR 2.53, 95% CI [1.74, 3.70]). Sensitization to pet allergens was associated with increased odds of asthma; for example, cat OR 4.15 (95% CI [2.67, 6.45]), with similar estimates for pollens; for example, birch OR 3.22 (95% CI [2.12, 4.91]). Associations persisted with sensitization as a categorical variable and for trend, indicating a dose-response relationship. Results remained in the co-twin analyses; for example, cat OR 4.75 (95% CI [1.62, 14.0]) and birch OR 5.00 (95% CI [1.45, 17.3]). CONCLUSION: The association between childhood asthma and sensitization to airborne allergens remains in co-twin analyses, indicating they are not due to confounding from shared environmental or genetic factors</style></abstract><notes><style face="normal" font="Arial">DA - 20171004IS - 1832-4274 (Print)IS - 1832-4274 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1017/thg.2017.48</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28975873">PM:28975873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Twin Res Hum Genet\2017-20-380-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Twin Res Hum Genet\2017-20-380-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171004, Lindemalm C</style></custom2><misc3><style face="normal" font="Arial">10.1017/thg.2017.48</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ziegler,A.</style></author><author><style face="normal" font="Arial"> Hamza,E.</style></author><author><style face="normal" font="Arial"> Jonsdottir,S.</style></author><author><style face="normal" font="Arial"> Rhyner,C.</style></author><author><style face="normal" font="Arial"> Wagner,B.</style></author><author><style face="normal" font="Arial"> Schupbach,G.</style></author><author><style face="normal" font="Arial"> Svansson,V.</style></author><author><style face="normal" font="Arial"> Torsteinsdottir,S.</style></author><author><style face="normal" font="Arial"> Marti,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Clinical Research and Veterinary Public Health, Vetsuisse Faculty, University of Berne, Langgass-Strasse 124, Berne, 3012, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Longitudinal analysis of allergen-specific IgE and IgG subclasses as potential predictors of insect bite hypersensitivity following first exposure to Culicoides in Icelandic horses</style></title><secondary-title><style face="normal" font="Arial">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgG1</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical research</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culicoides</style></keyword><keyword><style face="normal" font="Arial"> Culicoides obsoletus</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Horse</style></keyword><keyword><style face="normal" font="Arial"> Horses</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IBH</style></keyword><keyword><style face="normal" font="Arial"> Iceland</style></keyword><keyword><style face="normal" font="Arial"> Icelandic horses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE and IgG</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG subclass</style></keyword><keyword><style face="normal" font="Arial"> IgG subclasses</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> insect</style></keyword><keyword><style face="normal" font="Arial"> Insect bite hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="Arial"> Longitudinal study</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Insect bite hypersensitivity (IBH) is an allergic dermatitis of horses caused by bites of Culicoides spp. IBH does not occur in Iceland because of the absence of Culicoides, but the prevalence is high in horses imported from Iceland to environments where Culicoides are present. HYPOTHESIS/OBJECTIVE: Test, in a longitudinal study before and after Culicoides exposure, whether a primary sensitizing Culicoides allergen can be identified and if an increase of allergen-specific immunoglobulin (Ig)E or IgG subclasses precedes clinical signs of IBH. ANIMALS: Thirty two horses imported from Iceland to Europe; 16 developed IBH and 16 remained healthy. METHODS: Determination of IgE and IgG subclasses against recombinant (r)-Culicoides allergens and Culicoides extract in sera taken before first exposure to Culicoides and yearly over a period of 3-4 years. RESULTS: Before Culicoides exposure, there were no significant differences in Culicoides-specific serum IgE levels between horse that developed IBH or remained healthy. Culicoides exposure induced an individual IgE response pattern (to a median of 4.5 r-allergens) in the IBH but not in the healthy end-point group. The increase in serum IgE levels to Culicoides r-allergens was concurrent with the initial onset of clinical signs of IBH. IBH-affected horses displayed significantly higher allergen-specific IgG1 and IgG5 levels than healthy controls. Recombinant Culicoides obsoletus 1 (Cul o1) and Cul o3-specific IgG5 was significantly higher in the IBH compared to the healthy end-point group, before clinical signs of IBH. CONCLUSION/CLINICAL RELEVANCE: Allergen-specific serum IgE cannot be used as predictor for IBH, whereas allergen-specific IgG5 levels may have a predictive value</style></abstract><notes><style face="normal" font="Arial">DA - 20171005IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Egypt -CO - Iceland -CO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/vde.12493</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28980353">PM:28980353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Dermatol\20171005-ZieglerA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Dermatol\20171005-ZieglerA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171005, Ziegler A</style></custom2><misc3><style face="normal" font="Arial">10.1111/vde.12493</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Davies,O.</style></author><author><style face="normal" font="Arial"> Spencer,S.</style></author><author><style face="normal" font="Arial"> Necova,S.</style></author><author><style face="normal" font="Arial"> Holmes,E.</style></author><author><style face="normal" font="Arial"> Taylor,A.</style></author><author><style face="normal" font="Arial"> Blackwood,L.</style></author><author><style face="normal" font="Arial"> Lara-Garcia,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Queen Mother Hospital For Animals, Royal Veterinary College , University of London , North Mymms , UK</style></auth-address><titles><title><style face="normal" font="Arial">Intranasal melanoma treated with radiation therapy in three dogs</style></title><secondary-title><style face="normal" font="Arial">Vet Q</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Vet Q</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> CT scan</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Differential diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Melanoma</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Radiation</style></keyword><keyword><style face="normal" font="Arial"> radiotherapy</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Turbinate</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="Arial">Three dogs were investigated for chronic unilateral nasal discharge. In all cases CT imaging showed an intranasal mass causing turbinate lysis and no evidence of metastasis. Cytology in cases 1 (a 14-year-old neutered male crossbreed dog) and 2 (a five-year-old neutered male German Shepherd dog) demonstrated a pleomorphic cell population with variable intracellular pigment suspicious of melanocytic neoplasia. Histopathology with immunohistochemistry (Melan-A and vimentin, plus PNL-2 in one case) confirmed the diagnosis of melanoma in all dogs. All dogs were treated with megavoltage radiotherapy using linear accelerators. Cases 1 and 3 (a 9-year-old neutered female beagle dog) received a hypofractionated (4 x 8 Gy) protocol and case 2 received a definitive (12 x 4 Gy) protocol. Complete remission was demonstrated on repeat CT scan 5 months after diagnosis in case 1 and 7 months in case 2. Stable disease was documented on CT at four months for case 3, however, clinical signs in this dog remained controlled for 10 months in total. Case 1 died of unrelated causes 5 months after diagnosis, case 2 was euthanased due to the development of seizures 13 months after diagnosis, and case 3 was lost to follow-up 12 months after diagnosis. Melanoma should be considered as a rare differential diagnosis for primary nasal neoplasia in the dog and radiation therapy can be used as effective local therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20171006IS - 1875-5941 (Electronic)IS - 0165-2176 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1080/01652176.2017.1387828</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28982291">PM:28982291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Q\20171006-DaviesO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Q\20171006-DaviesO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171006, Davies O</style></custom2><misc3><style face="normal" font="Arial">10.1080/01652176.2017.1387828</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tan,L.</style></author><author><style face="normal" font="Arial"> Lu,J.</style></author><author><style face="normal" font="Arial"> Chen,M.</style></author><author><style face="normal" font="Arial"> Xiang,Y.</style></author><author><style face="normal" font="Arial"> Cheng,Q.</style></author><author><style face="normal" font="Arial"> Liang,Y.</style></author><author><style face="normal" font="Arial"> Huang,J.</style></author><author><style face="normal" font="Arial"> Huang,J.</style></author><author><style face="normal" font="Arial"> Chen,J.</style></author><author><style face="normal" font="Arial"> Gao,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha 410013, China</style></auth-address><titles><title><style face="normal" font="Arial">Epicutaneous sensitization with ovalbumin, staphylococcal enterotoxin B and vitamin D analogue induces atopic dermatitis in mice</style></title><secondary-title><style face="normal" font="Arial">Zhong Nan Da Xue Xue Bao Yi Xue Ban</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhong Nan Da Xue Xue Bao Yi Xue Ban</style></full-title></periodical><pages end="1029" start="1023">1023-1029</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">area</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Back</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> epicutaneous</style></keyword><keyword><style face="normal" font="Arial"> Epicutaneous sensitization</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-31</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> nerve growth factor</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> SEB</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> staphylococcal enterotoxin</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcal enterotoxin B</style></keyword><keyword><style face="normal" font="Arial"> superantigen</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> vitamin</style></keyword><keyword><style face="normal" font="Arial"> Vitamin D</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="9" Year="2017">2017/9/28</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To illuminate a method for establishment of a cost-efficient atopic dermatitis (AD) mouse model by topical application of ovalbumin (OVA), super-antigen staphylococcal enterotoxin B (SEB), and calcipotriene ointment (CO) on the back of BALB/c mice. Methods: Experimental mice were topically treated with OVA/SEB or OVA/SEB/CO every other day during 15 days of induction. Clinical alterations on the skin area were monitored every other day. Epidermal thickness were measured by reflectance confocal microscope (RCM) before harvest. Inflammatory cells in skin biopsies were marked by hematoxylin-eosin (HE) staining. Blood sample and skin biopsies were measured by ELISA and quantitative real-time PCR to detect the expression of IL-2, IL-4, IL-31, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha pruritus-associated nerve growth factor (NGF), and serum IgE. Results: Human AD-like cutaneous local inflammatory reaction was characterized by the accumulation of inflammatory cells, increased epidermal thickness and serum IgE levels as well as Th1 cell-associated cytokines (IFN-gamma, TNF-alpha), Th2 cell-associated cytokines (IL-4, IL-31), and NGF in the OVA/SEB/CO group compared with that in the normal control group or the OVA/SEB group. Conclusion: OVA/SEB/CO can induce an AD-like mouse model with lower economic and time consumption</style></abstract><notes><style face="normal" font="Arial">DA - 20171009IS - 1672-7347 (Print)IS - 1672-7347 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.11817/j.issn.1672-7347.2017.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28989146">PM:28989146</url></web-urls></urls><custom2><style face="normal" font="Arial">20171009, Tan L</style></custom2><misc3><style face="normal" font="Arial">10.11817/j.issn.1672-7347.2017.09.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Novak,J.</style></author><author><style face="normal" font="Arial"> Panska,L.</style></author><author><style face="normal" font="Arial"> Machacek,T.</style></author><author><style face="normal" font="Arial"> Kolarova,L.</style></author><author><style face="normal" font="Arial"> Horak,P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">.....</style></auth-address><titles><title><style face="normal" font="Arial">Humoral response of mice infected with Toxocara canis following different infection schemes</style></title><secondary-title><style face="normal" font="Arial">Acta Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Acta Parasitol</style></full-title></periodical><pages end="835" start="823">823-835</pages><volume><style face="normal" font="Arial">62</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Czech Republic</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Humoral response</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IgG3</style></keyword><keyword><style face="normal" font="Arial"> Igm</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Toxocara</style></keyword><keyword><style face="normal" font="Arial"> Toxocara canis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="Arial">The study was focused on the dynamics of humoral response to Toxocara canis excretory-secretory antigens (TES antigens) in mice experimentally infected by T. canis L3 larvae in different ways. In particular, we compared the effect of infection with two doses of 1000 larvae vs. repeated infections with a low number of larvae (daily infection with 10 larvae and weekly infection with 100 larvae in the course of 22 weeks). In ELISA, all infections, including both schemes with lower larval doses, elicited significant antibody response. Elevated levels of total IgE and TES-antigen-specific IgM were detected on day 12 after the first infection, followed by IgG and IgG1, and later by IgG3, IgG2a and IgG2b; specific IgE response was not detected. It seems that the high levels of IgM and IgG1 represent the best markers of infection. In addition, gradual increase of IgG2a and IgG2b could help in determination of the infection course. As a byproduct of our work, a new method of infection by repeated drinking of larvae was introduced; it minimizes the pain and discomfort for the experimental mice</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1896-1851 (Electronic)IS - 1230-2821 (Linking)LA - engPT - Journal ArticleCO - Czech Republic -</style></notes><work-type><style face="normal" font="Arial">10.1515/ap-2017-0099</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035857">PM:29035857</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Parasitol\2017-62-823-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Parasitol\2017-62-823-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Novak J</style></custom2><misc3><style face="normal" font="Arial">10.1515/ap-2017-0099</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Debinska,A.</style></author><author><style face="normal" font="Arial"> Danielewicz,H.</style></author><author><style face="normal" font="Arial"> Drabik-Chamerska,A.</style></author><author><style face="normal" font="Arial"> Kalita,D.</style></author><author><style face="normal" font="Arial"> Boznanski,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1st Department and Clinic of Pediatrics, Allergology and Cardiology, Wroclaw Medical University, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Filaggrin loss-of-function mutations as a predictor for atopic eczema, allergic sensitization and eczema-associated asthma in Polish children population</style></title><secondary-title><style face="normal" font="Arial">Adv Clin Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Adv Clin Exp Med</style></full-title></periodical><pages end="998" start="991">991-998</pages><volume><style face="normal" font="Arial">26</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> epidermal barrier</style></keyword><keyword><style face="normal" font="Arial"> filaggrin</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Loss-of-function mutations in the filaggrin (FLG) gene were identified as a major risk factor for atopic eczema. OBJECTIVES: The aim of the study was to investigate the importance of 4 common FLG null mutations in the susceptibility to atopic eczema and other allergic phenotypes in Polish children population. MATERIAL AND METHODS: The FLG mutations were determined in 158 children younger than 2 years of age. All subjects were selected using a detailed questionnaire and blood samples for total and specific IgE measurements were obtained. Cases of atopic eczema were diagnosed according to the criteria of Hanifin and Rajka and skin examination. All FLG mutations were genotyped by real-time PCR assays with a subsequent melting curve analysis using a SimpleProbe(R) probes. RESULTS: The combined genotype of all 4 mutations (carriage of >/= 1 FLG mutation) was significantly associated with atopic eczema (p = 0.016). The odds ratio (OR) for individuals carrying 1 of these 4 null mutations was 5.52 (95% CI; 1.11 / 37.12). The significant association between either the combined FLG genotype or 2282del14 deletion and eczema was seen only in the allergic group. The association with asthma was restricted to asthma occurring in the context of eczema (OR, 6.27; 95% CI, 0.89 / 53.56; p = 0.042). CONCLUSIONS: Our study confirms the previous findings that FLG mutations are strongly associated with atopic eczema and confer a significant risk of allergic sensitization and asthma in the context of eczema. These results underline the role of the epidermal barrier and filaggrin insufficiency in the pathogenesis of atopic eczema and eczema-associated asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20171025IS - 1899-5276 (Print)IS - 1899-5276 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.17219/acem/61430</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29068602">PM:29068602</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Adv Clin Exp Med\2017-26-991-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Adv Clin Exp Med\2017-26-991-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171025, Debinska A</style></custom2><misc3><style face="normal" font="Arial">10.17219/acem/61430</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pace,L.</style></author><author><style face="normal" font="Arial"> Boccacci,L.</style></author><author><style face="normal" font="Arial"> Casilli,M.</style></author><author><style face="normal" font="Arial"> Di Carlo,P.</style></author><author><style face="normal" font="Arial"> Fattorini,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Correlations between weather conditions and airborne pollen concentration and diversity in a Mediterranean high-altitude site disclose unexpected temporal patterns</style></title><secondary-title><style face="normal" font="Arial">Aerobiologia</style></secondary-title></titles><periodical><abbr-3><style face="normal" font="Arial">Aerobiologia</style></abbr-3></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abundance</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Altitude</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Anther</style></keyword><keyword><style face="normal" font="Arial"> Anthers</style></keyword><keyword><style face="normal" font="Arial"> Climate</style></keyword><keyword><style face="normal" font="Arial"> Climate change</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Juniperus</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Meteorological conditions</style></keyword><keyword><style face="normal" font="Arial"> Meteorological factor</style></keyword><keyword><style face="normal" font="Arial"> Meteorological Factors</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Portugal</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Short-term</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword><keyword><style face="normal" font="Arial"> Wind</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1573-3025</style></isbn><abstract><style face="normal" font="Arial">Relationships between meteorological factors and airborne pollen concentrations at high altitudes are virtually unknown. We used cross-correlation analyses to test the relationships between daily variation in meteorological factors (i.e. temperature, humidity and wind speed) and airborne pollen concentration, diversity (number of families and Shannon and Simpson diversity indices) and evenness (Pielou index) in an Apennine high-altitude site (Gran Sasso Massif, 2117-ám elevation). In contrast to patterns observed at low altitudes, the temperature had a negative correlation with pollen abundance and diversity, whereas humidity had a positive correlation. The unexpected negative correlations with temperature can be explained with the particular position of our sampling site. Wind speed was positively correlated with pollen diversity and abundance in the short term, which can be explained by the fact that higher wind speed promotes both primary emission of pollen from the anthers and subsequent re-suspension. Evenness and wind speed were negatively correlated in the short term because of the different response of different species to meteorological conditions. In the longer term, the average concentrations of the various taxa tend to reach similar values, leading to increased values of diversity. Our finding of a decrease in pollen emission with increasing temperature has important implications for the study of the impacts of global change on high-altitude plant communities. We also detected a high abundance of Cupressaceae/Taxaceae pollen, a reflection of the expansion of thermophilic species, such as Juniperus, due to climate change</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Italy -CO - Portugal -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10453-017-9499-x</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10453-017-9499-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Aerobiologia\20171030-PaceL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Aerobiologia\20171030-PaceL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Pace L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10453-017-9499-x</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Serra-Baldrich,E.</style></author><author><style face="normal" font="Arial"> de Frutos,J.O.</style></author><author><style face="normal" font="Arial"> Jauregui,I.</style></author><author><style face="normal" font="Arial"> Armario-Hita,J.C.</style></author><author><style face="normal" font="Arial"> Silvestre,J.F.</style></author><author><style face="normal" font="Arial"> Herraez,L.</style></author><author><style face="normal" font="Arial"> Martin-Santiago,A.</style></author><author><style face="normal" font="Arial"> Valero,A.</style></author><author><style face="normal" font="Arial"> Sastre,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Hospital Sant Pau, Universidad Autonoma de Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Changing perspectives in atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Habits</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> multifaceted</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a multifaceted disease that involves a complex interplay between the skin and the immune system. The course of the disease depends strongly on the genetic background of the patient and on yet poorly-defined environmental factors. Changes in lifestyle could be behind the dramatic rise in the prevalence of AD across continents; including hygienic conditions, food, social habits, skin microbiome or exposure to a number of allergens. Although AD typically develops in childhood and disappears after a few years, in a relatively large number of patients it continues into adulthood. Adult AD can also appear de novo but it is often underdiagnosed and its treatment can be challenging. New, highly effective drugs are being developed to manage moderate and severe forms of the disease in adults. In this review, we highlight the most recent developments in diagnostic tools, current insights into the mechanistic basis of this disease, and therapeutic innovations</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031890">PM:29031890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171016-SerraBaldrichE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171016-SerraBaldrichE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Serra-Baldrich E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.07.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bartoll,E.</style></author><author><style face="normal" font="Arial"> Nieto,M.</style></author><author><style face="normal" font="Arial"> Selva,B.</style></author><author><style face="normal" font="Arial"> Badillo,R.</style></author><author><style face="normal" font="Arial"> Pereira,G.</style></author><author><style face="normal" font="Arial"> Uixera,S.</style></author><author><style face="normal" font="Arial"> Nieto,A.</style></author><author><style face="normal" font="Arial"> Mazon,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unit of Pediatric Allergy and Pneumology, Instituto de Investigacion Sanitaria, Hospital Universitario y Politecnico La Fe, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Validation of a Spanish version of the EuroPrevall Food Allergy Quality of Life Questionnaire-Parental Form</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> EuroPrevall</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated food allergy</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mexico</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> pediatric allergy</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> validity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food allergy can have a major impact on quality of life of children and their parents. Questionnaires have been developed to measure the impact of this disorder. We aimed to validate the EuroPrevall questionnaire on Food Allergy-Quality of Life Questionnaire, Parent Form (FAQLQ-PF) and the Food Allergy Independent Measure (FAIM), translated into Spanish. METHODS: The internal consistency of the FAQLQ-PF and the FAIM, translated into Spanish (Spain) and completed by the parents of 74 children with IgE-mediated food allergy, were evaluated with Cronbach's alpha. To test construct validity of the FAQLQ-PF, its correlation with the FAIM was also calculated. To assess their discriminant validity, we compared the values of both depending on the number of offending foods and for children with and without anaphylaxis. RESULTS: The values of Cronbach's alpha for the three domains in the FAQLQ-PF were over 0.9. The value of alpha for FAIM questions was below 0.6, which was attributed to the wording of one question. When this question was removed, alpha increased to over 0.70. There was a significant correlation between the FAQLQ-PF score and the FAIM. There were significantly poorer FAQLQ-PF scores in children with more food allergies and worse FAIM in those who had had anaphylaxis. CONCLUSIONS: The Spanish version of the FAQLQ-PF had a good internal consistency, good construct validity and validity to discriminate patients with more food allergies and anaphylaxis. It can be used as a tool to evaluate and monitor the quality of life in families with food allergic children</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Mexico -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.06.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033200">PM:29033200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171016-BartoliE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171016-BartoliE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Bartoli E</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.06.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gonzaga,T.A.</style></author><author><style face="normal" font="Arial"> Alves,F.A.</style></author><author><style face="normal" font="Arial"> Cheik,M.F.A.</style></author><author><style face="normal" font="Arial"> de Barros,C.P.</style></author><author><style face="normal" font="Arial"> Rezende,E.R.</style></author><author><style face="normal" font="Arial"> Segundo,G.R.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Research Group, Pediatrics Department, Universidade Federal de Uberlandia, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Low efficacy of atopy patch test in predicting tolerance development in non-IgE-mediated cow's milk allergy</style></title><secondary-title><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergol Immunopathol (Madr)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Atopy patch test</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Patch test</style></keyword><keyword><style face="normal" font="Arial"> Patch-test</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The food atopy patch (APT) test has been used in previous studies to help the diagnosis of non-IgE mediated food allergies (FA). The aim of this study was to evaluate the efficacy of different cow's milk APT preparations to predict oral tolerance in children with previous non-IgE-mediated cow's milk allergy (CMA) diagnosis. METHODS: Thirty-two patients non-IgE-mediated CMA diagnosed by oral food challenge (OFC) were enrolled to perform APT with three different cow's milk preparations (fresh, 2% in saline solution, 2% in petrolatum) and comparing with a new OFC after at least three months of diet exclusion. RESULTS: Only six (18.7%) subjects presented positive OFC to cow's milk. No differences in gender, onset symptoms age, OFC age, Z-score, and exclusion period were found between positive and negative OFC patients. Preparations using fresh milk and powdered milk in petrolatum presented sensitivity equal to zero and specificity 92.3% and 96.1%. The preparation using powdered milk in saline solution showed sensitivity and specificity of 33.3% and 96.1%. Two patients presented typical IgE symptoms after OFC. CONCLUSION: Cow's milk APT presented a low efficacy to predict tolerance in patients with previous non-IgE-mediated CMA and should not be used in clinical routine. The presence of typical IgE reactions after OFC hallmark the necessity of previous IgE-mediated investigation for this patient group</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.aller.2017.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031891">PM:29031891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171016-GonzagaTA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171016-GonzagaTA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Gonzaga TA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.aller.2017.07.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Staubach,P.</style></author><author><style face="normal" font="Arial"> Metz,M.</style></author><author><style face="normal" font="Arial"> Chapman-Rothe,N.</style></author><author><style face="normal" font="Arial"> Sieder,C.</style></author><author><style face="normal" font="Arial"> Brautigam,M.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author><author><style face="normal" font="Arial"> Weller,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, University Medical Center Mainz, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab Rapidly Improves Angioedema-Related Quality of Life in Adult Patients with Chronic Spontaneous Urticaria: X-ACT Study Data</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fear</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The X-ACT study aims to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1 -antihistamines. METHODS: In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18-75 years) with >/=4 angioedema episodes during the 6 months before inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every 4 weeks for 28 weeks. Angioedema-related QoL, skin-related QoL impairment, and psychological well-being were assessed. RESULTS: Ninety-one patients were randomized and 68 (omalizumab, n=35; placebo, n=33) completed the 28-week treatment period. At baseline, the mean (SD) total Angioedema QoL (AE-QoL; 56.2 [18.7] and 59.9 [19.2]) and Dermatology Life Quality Index (DLQI; 14.6 [5.7] and 16.6 [7.3]) score was high in the omalizumab and placebo group, respectively. At Week 4 (after the first treatment), the least squares mean difference in the AE-QoL and DLQI score between groups was -17.6 (P&lt;0.001) and -7.2 (P&lt;0.001), respectively. Significant QoL improvements in the omalizumab versus placebo groups continued until Week 28, but returned to placebo levels at the follow-up visit. The mean (SD) baseline 5-item World Health Organization Well-being Index was 10.0 (5.5, omalizumab) and 7.7 (5.3, placebo), which increased above the depression threshold (&lt;13) from Week 4 and throughout with omalizumab but not placebo treatment. Compared to placebo, omalizumab was also associated with decreased fear of suffocation due to angioedema. CONCLUSIONS: Our findings support omalizumab treatment in patients with severe H1-antihistamine-refractory CSU with angioedema. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13339</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29058822">PM:29058822</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20171023-StaubachP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20171023-StaubachP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Staubach P</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13339</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Infante,S.</style></author><author><style face="normal" font="Arial"> Marco-Martin,G.</style></author><author><style face="normal" font="Arial"> Sanchez-Dominguez,M.</style></author><author><style face="normal" font="Arial"> Rodriguez-Fernandez,A.</style></author><author><style face="normal" font="Arial"> Fuentes-Aparicio,V.</style></author><author><style face="normal" font="Arial"> varez-Perea,A.</style></author><author><style face="normal" font="Arial"> Cabrera-Freitag,P.</style></author><author><style face="normal" font="Arial"> Morales-Cabeza,C.</style></author><author><style face="normal" font="Arial"> Zubeldia,J.M.</style></author><author><style face="normal" font="Arial"> Zapatero,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Paediatric Allergy Unit. Hospital Infantil Universitario Gregorio Maranon, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome by fish: Not necessarily a restricted diet</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Mediterranean</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="Arial">Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated gastrointestinal food hypersensitivity usually due to cow's milk or soy. Recent researches show that fish is one of the most important triggers of FPIES in the Mediterranean countries. Due to the risk of multiple-food-FPIES, avoiding foods in the same category or that often occur together may be reasonable. The aim of this study was to evaluate the evolution and follow-up of FPIES related to fish over a period of 20 years. We describe the clinical features of our population, discuss different approaches to oral food challenges and analyse the possibility of introducing the culprit fish or other non-related fish in order to avoid unnecessary restricted diets. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171020IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29052246">PM:29052246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20171020-InfanteS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20171020-InfanteS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171020, Infante S</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13336</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dunn Galvin,A.</style></author><author><style face="normal" font="Arial"> McMahon,S.</style></author><author><style face="normal" font="Arial"> Ponsonby,A.L.</style></author><author><style face="normal" font="Arial"> Hsiao,K.C.</style></author><author><style face="normal" font="Arial"> Tang,M.L.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Applied Psychology, University College Cork, Ireland</style></auth-address><titles><title><style face="normal" font="Arial">The longitudinal impact of Probiotic and Peanut Oral Immunotherapy (PPOIT) on health related quality of life (HRQL)</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analysis of Variance</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Ireland</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> Probiotic</style></keyword><keyword><style face="normal" font="Arial"> psychology</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> randomized trial</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Sustained unresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We previously reported that Probiotic and Peanut Oral Immunotherapy (PPOIT) was effective at inducing sustained unresponsiveness compared with placebo in a double-blind, placebo-controlled randomized trial. This study evaluated the impact of PPOIT on health related quality of life (HRQL). METHOD: Fifty-one participants (PPOIT 24; Placebo 27) from the PPOIT trial completed Food Allergy Quality of Life Questionnaire (FAQLQ-PF) and Food Allergy Independent Measure (FAIM) at pre-treatment, end-of-treatment and 3-months after end-of-treatment. 42 participants (20 PPOIT; 22 Placebo) completed measures at 12 months post-treatment. Changes over time in PPOIT and Placebo groups were examined by repeated measures analysis of variance and paired t-tests. RESULTS: PPOIT was associated with significant improvement in FAQLQ-PF (F=3.63, p=0.02), with Mean Difference 0.8 at 3 months post-treatment (p=0.05) and 1.3 at 12 months post-treatment (p=0.005), exceeding the 0.5 minimal clinically important difference for FAQLQ-PF. For FAIM, mean difference was 0.5 (p=0.03) at 3 months and 0.4 (p=0.04) at 12 months. In placebo group, post-treatment FAQLQ and FAIM remained unchanged from pre-treatment. Improvement in FAQLQ-PF and FAIM scores related specifically to acquisition of sustained unresponsiveness rather than to receiving PPOIT treatment or participation in the trial. CONCLUSIONS: PPOIT has a sustained beneficial effect on psychosocial impact of food allergy at 3 months and 12 months after end-of-treatment. Treatment was not associated with reduced HRQL relative to baseline in either PPOIT or placebo groups, indicating that PPOIT was well tolerated and psychological wellbeing was not negatively impacted. Improved HRQL was specifically associated with acquisition of sustained unresponsiveness. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171020IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Ireland -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13330</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29052245">PM:29052245</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20171020-DunnGalvinA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20171020-DunnGalvinA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171020, Dunn Galvin A</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13330</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cipriani,F.</style></author><author><style face="normal" font="Arial"> Mastrorilli,C.</style></author><author><style face="normal" font="Arial"> Tripodi,S.</style></author><author><style face="normal" font="Arial"> Ricci,G.</style></author><author><style face="normal" font="Arial"> Perna,S.</style></author><author><style face="normal" font="Arial"> Panetta,V.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author><author><style face="normal" font="Arial"> Dondi,A.</style></author><author><style face="normal" font="Arial"> Bianchi,A.</style></author><author><style face="normal" font="Arial"> Maiello,N.</style></author><author><style face="normal" font="Arial"> Miraglia Del Giudice,M.</style></author><author><style face="normal" font="Arial"> Frediani,T.</style></author><author><style face="normal" font="Arial"> Macri,F.</style></author><author><style face="normal" font="Arial"> Lucarelli,S.</style></author><author><style face="normal" font="Arial"> Dello Iacono,I.</style></author><author><style face="normal" font="Arial"> Patria,M.F.</style></author><author><style face="normal" font="Arial"> Varin,E.</style></author><author><style face="normal" font="Arial"> Peroni,D.</style></author><author><style face="normal" font="Arial"> Chini,L.</style></author><author><style face="normal" font="Arial"> Moschese,V.</style></author><author><style face="normal" font="Arial"> Bernardini,R.</style></author><author><style face="normal" font="Arial"> Pingitore,G.</style></author><author><style face="normal" font="Arial"> Pelosi,U.</style></author><author><style face="normal" font="Arial"> Tosca,M.</style></author><author><style face="normal" font="Arial"> Paravati,F.</style></author><author><style face="normal" font="Arial"> Sfika,I.</style></author><author><style face="normal" font="Arial"> Di Rienzo Businco,A.</style></author><author><style face="normal" font="Arial"> Dascola,C.P.</style></author><author><style face="normal" font="Arial"> Comberiati,P.</style></author><author><style face="normal" font="Arial"> Frediani,S.</style></author><author><style face="normal" font="Arial"> Lambiase,C.</style></author><author><style face="normal" font="Arial"> Verga,M.C.</style></author><author><style face="normal" font="Arial"> Faggian,D.</style></author><author><style face="normal" font="Arial"> Plebani,M.</style></author><author><style face="normal" font="Arial"> Calvani,M.</style></author><author><style face="normal" font="Arial"> Caffarelli,C.</style></author><author><style face="normal" font="Arial"> Matricardi,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dept. of Pediatric Pneumology and Immunology, Charite Medical University, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="Arial">Diagnostic relevance of IgE sensitization profiles to eight recombinant Phleum pratense molecules</style></title><secondary-title><style face="normal" font="Arial">Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergen</style></keyword><keyword><style face="normal" font="Arial"> Airborne allergens</style></keyword><keyword><style face="normal" font="Arial"> AIT</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> component-resolved diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral allergy syndrome</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Phl p 1</style></keyword><keyword><style face="normal" font="Arial"> Phl p 12</style></keyword><keyword><style face="normal" font="Arial"> Phl p 7</style></keyword><keyword><style face="normal" font="Arial"> Phleum</style></keyword><keyword><style face="normal" font="Arial"> Phleum pratense</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen extract</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> sensitization profiles</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Grass pollen-related seasonal allergic rhinoconjunctivitis (SARg) is clinically heterogeneous in severity, comorbidities and response to treatment. The component-resolved diagnostics disclosed also a high heterogeneity at molecular level. Our study aimed at analyzing the characteristics of the IgE sensitization to Phleum pratense molecules and investigating the diagnostic relevance of such molecules in childhood. METHODS: We examined 1120 children (age 4-18y) with SARg. Standardized questionnaires on atopy were acquired through informatics platform (AllergyCARD ). Skin prick tests were performed with pollen extracts. Serum IgE to airborne allergens and eight Phleum pratense molecules (rPhl p 1, rPhl p 2, rPhl p 4, rPhl p 5b, rPhl p 6, rPhl p 7, rPhl p 11, rPhl p 12) were tested by ImmunoCAP FEIA. RESULTS: The analysis of IgE responses against eight Phleum pratense molecules showed 87profiles. According to the number of molecules recognized by IgE, the more complex profiles were characterized by higher serum total IgE, higher grass-specific serum IgE and higher number and degree of sensitization to pollens. The most frequent IgE sensitization profile was the monomolecular Phl p 1. Sensitization to Phl p 7 was a reliable biomarker of asthma, whereas Phl p 12 of oral allergy syndrome. Sensitization to Phl p 7 was associated with a higher severity of SAR, and complex profiles were associated with longer disease duration. CONCLUSIONS: In a large pediatric population, the complexity of IgE sensitization profiles against Phleum pratense molecules is related to high atopic features although useless for predicting the clinical severity. The detection of serum IgE to Phl p 1, Phl p 7 and Phl p 12 can be used as clinical biomarkers of SARg and comorbidities. Further studies in different areas are required to test the impact of different IgE molecular profiles on AIT response. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171021IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1111/all.13338</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29055045">PM:29055045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20171021-CiprianiF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20171021-CiprianiF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171021, Cipriani F</style></custom2><misc3><style face="normal" font="Arial">10.1111/all.13338</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gelincik,A.</style></author><author><style face="normal" font="Arial"> Demir,S.</style></author><author><style face="normal" font="Arial"> Olgac,M.</style></author><author><style face="normal" font="Arial"> Issever,H.</style></author><author><style face="normal" font="Arial"> Khishigsuren,B.</style></author><author><style face="normal" font="Arial"> Ozseker,F.</style></author><author><style face="normal" font="Arial"> Colakoglu,B.</style></author><author><style face="normal" font="Arial"> Buyukozturk,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">High adherence to subcutaneous immunotherapy in a real-life study from a large tertiary medical center</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="84" start="78">78-84</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adherence</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergist</style></keyword><keyword><style face="normal" font="Arial"> Allergists</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> QOL</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> VAS</style></keyword><keyword><style face="normal" font="Arial"> Visual Analog Scale</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Studies on real-life adherence to subcutaneous allergen immunotherapy (SCIT) for respiratory allergy are scarce. The aim of this study was to evaluate adherence to SCIT. METHODS: The patients prescribed SCIT for allergic rhinitis and/or asthma in 2009-2011 were contacted in 2014 and asked whether they completed at least the 3 years of SCIT and/or whether they suspended the treatment for at least 2 months. The Total Symptom Score-6, visual analog scale (VAS), asthma control test (ACT), medication scores, quality of life (QoL) scores, and immunotherapy satisfaction scores with VAS obtained before the initiation of SCIT in the first year and at the end of SCIT were compared. RESULTS: A total of 204 patients (136 female [66.7%]; mean age, 38.83 +/- 12.02 years) were included; 73% (149/204) were both compliant and persistent; 14% (29/204) were only persistent; and, overall, 87.3% (178/204) were considered adherent. Adherence was more frequent in female patients (95% CI, 62.3-76.3%; p = 0.018). Medication, symptom, ACT, and QoL scores in the first year and at the end of the treatment were significantly lower than the initial scores, and the immunotherapy satisfaction scores at the end of treatment were higher than the scores in the first year in the patients who were adherent (p &lt; 0.001 for each score). CONCLUSION: The adherence rate to SCIT in our study was relatively high, in contrast to previous real-life data. Results of our study indicated that a close relationship between allergists and their patients during SCIT and the follow-up period in the same center improved the outcome of SCIT</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4091</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046189">PM:29046189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-78-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-78-84.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Gelincik A</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4091</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pena,L.E.</style></author><author><style face="normal" font="Arial"> Guffey,D.</style></author><author><style face="normal" font="Arial"> Minard,C.G.</style></author><author><style face="normal" font="Arial"> Anvari,S.</style></author><author><style face="normal" font="Arial"> Davis,C.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The role of intravenous access during oral food challenges in food protein-induced enterocolitis syndrome</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="473" start="467">467-473</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Age of Onset</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dehydration</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Food Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Food Protein Induced Enterocolitis Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Food protein-induced enterocolitis</style></keyword><keyword><style face="normal" font="Arial"> food protein-induced enterocolitis syndrome</style></keyword><keyword><style face="normal" font="Arial"> FPIES</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypotension</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> International Classification of Diseases</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lethargy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> revision</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Vomiting</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Food protein-induced enterocolitis syndrome (FPIES) is a non-immunoglobulin E mediated food hypersensitivity syndrome characterized by profuse vomiting and diarrhea, which leads to lethargy, dehydration, and hypotension. Given the potential severity of reactions, resolution of FPIES is confirmed via oral food challenge (OFC) during which intravenous (IV) access is recommended to facilitate IV fluids (IVF) and steroid therapy. Risk factors for IV treatment are not well characterized. OBJECTIVES: The objectives of this study were to analyze predictors for IV treatment during OFC in patients with FPIES. METHODS: A retrospective chart review was conducted of patients with The International Classification of Diseases, Ninth Revision codes 558.3 and 558.9, and with OFC who were seen in an allergy and immunology clinic from January 2000 to October 2015. OFC reaction severity was scored (1, mild; 2, moderate; 3, severe), and demographics, IV treatment frequency, and OFC outcomes were evaluated. The Fisher exact test and Wilcoxon rank sum test statistical analyses were performed. RESULTS: Of 184 patients, 28 met inclusion criteria, with 39 OFCs performed. The median age of onset of FPIES was 6 months. The median age at OFC was 2.6 years. This was 2.2 years (range, 0.3-8.5 years) from symptom onset. Of 39 OFCs, IV treatment, including IVF and/or steroids, was required in only 7.7%. Thirty-eight OFCs (97.4%) were of equal or lesser severity than historical reactions. The median severity of presenting reaction (3[IV+]:1[IV-]; p = 0.05) was greater in those who required IV treatment. OFCs with IV treatment were in younger patients (15 months [IV+]:32 months [IV-]; p = 0.039) who underwent OFCs earlier relative to the time of diagnosis (8 months [IV+]:28 months [IV-]); p = 0.018). CONCLUSION: Although FPIES can potentially elicit severe symptomatology, the patients most commonly experienced only vomiting and diarrhea, which often resolved with minimal treatment. Reactions generally did not worsen over time. Fewer than 10% of the patients challenged required IV treatment, all were young and with severe FPIES. It is reasonable to consider age and length of time from historical reactions when evaluating the necessity of IV placement in patients undergoing FPIES OFC</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38.4079</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046194">PM:29046194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-467-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-467-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Pena LE</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38.4079</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Isabwe,G.A.C.</style></author><author><style face="normal" font="Arial"> de Las Vecillas Sanchez,V.</style></author><author><style face="normal" font="Arial"> Castells,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Management of adverse reactions to biologic agents</style></title><secondary-title><style face="normal" font="Arial">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Allergy Asthma Proc</style></full-title></periodical><pages end="418" start="409">409-418</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> Biologic agents</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> Immediate type</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> immune complex</style></keyword><keyword><style face="normal" font="Arial"> Immune Complexes</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-6</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> mast cells/basophils</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Predictive value</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum tryptase</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword></keywords><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="Arial">Hypersensitivity reactions (HSR) to targeted biologic agents present as immediate reactions during infusion or as delayed reactions (after one or more exposures). The new classification includes phenotypes, endotypes, and biomarkers. Phenotypes include immediate type I (immunoglobulin E [IgE] or non-IgE mediated), cytokine release, mixed (type I/cytokine), and immune complexes type III (IgG mediated) reactions as well as delayed type IV reactions. Endotypes include IgE or non-IgE mediated mast cells/basophils activation with elevated serum tryptase and T cells values as well as macrophages, which lead to cytokine production, e.g., interleukin 6. A skin test is a valuable tool in evaluating HSRs to biologics; however, its predictive value depends on the type of reaction and the monoclonal antibody. Desensitization is a new approach to safely reintroduce biologics when they are first-line therapies, and it is available for immediate and delayed reactions. Research is needed to further understand the mechanisms of reactions to monoclonal antibodies and their management</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="Arial">10.2500/aap.2017.38</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046192">PM:29046192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-409-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2017-38-409-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Isabwe GA</style></custom2><misc3><style face="normal" font="Arial">10.2500/aap.2017.38</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Khoury,J.K.</style></author><author><style face="normal" font="Arial"> Khoury,N.C.</style></author><author><style face="normal" font="Arial"> Schaefer,D.</style></author><author><style face="normal" font="Arial"> Chitnis,A.</style></author><author><style face="normal" font="Arial"> Hassen,G.W.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A tick-acquired red meat allergy: A case series</style></title><secondary-title><style face="normal" font="Arial">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alpha-gal</style></keyword><keyword><style face="normal" font="Arial"> Alphagal</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lone star tick</style></keyword><keyword><style face="normal" font="Arial"> Meat</style></keyword><keyword><style face="normal" font="Arial"> Molecular Mimicry</style></keyword><keyword><style face="normal" font="Arial"> Morbidity</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Red meat</style></keyword><keyword><style face="normal" font="Arial"> Red meat allergy</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Tick bite</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> urgent care</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0735-6757</style></isbn><abstract><style face="normal" font="Arial">Allergic reaction is a common clinical picture in the Emergency Department (ED). Most allergic reactions are from food or drugs. A detailed history is an integral aspect of determining the causative agent of an allergy. Galactose-alpha-1,3-galactose (alpha-gal) allergy is a tick-acquired red meat allergy that causes delayed-onset allergic reaction or anaphylaxis due to molecular mimicry. Alpha-gal allergy may not be widely known as a cause of allergic reactions. Lack of universal awareness of this phenomenon in the ED and Urgent Care setting could lead to misdiagnosis, or delayed diagnosis. Subsequently, lack of proper instruction to avoid red meat could put patients at risk for future attacks with morbidity or mortality. We report three cases of allergic reaction presumed from red meat consumption secondary to alpha-gal allergy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -CO - Grenada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ajem.2017.10.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074067">PM:29074067</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Emerg Med\20171026-KhouryJK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Emerg Med\20171026-KhouryJK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Khoury JK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ajem.2017.10.044</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gottumukkala,R.V.</style></author><author><style face="normal" font="Arial"> McKinley,G.</style></author><author><style face="normal" font="Arial"> Yun,B.</style></author><author><style face="normal" font="Arial"> Sonis,J.D.</style></author><author><style face="normal" font="Arial"> Kalra,M.K.</style></author><author><style face="normal" font="Arial"> Otrakji,A.</style></author><author><style face="normal" font="Arial"> Raja,A.S.</style></author><author><style face="normal" font="Arial"> Prabhakar,A.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Allergic-like contrast reactions in the ED: Incidence, management, and impact on patient disposition</style></title><secondary-title><style face="normal" font="Arial">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> computed tomography</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Diphenhydramine</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Iodinated contrast</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0735-6757</style></isbn><abstract><style face="normal" font="Arial">Determine the incidence, management, and impact on patient disposition of allergic-like contrast reactions (ALCR) to intravenous iodinated contrast in the emergency department (ED). All ED patients who developed an ALCR following contrast-enhanced CT (CECT) from June 2011</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôDecember 2016 were retrospectively identified. Medical records were reviewed and reaction severity, management, and disposition were quantified using descriptive statistics. The total number of consecutive CECTs performed in the ED were available from June 2011</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôMarch 2016 and were used to derive ALCR incidence over that time period. A total of 90 patients developed an ALCR during the study period. An ALCR incidence of 0.2% was derived based on 74 ALCRs occurring out of 47,059 consecutive contrast injections in ED patients from June 2011</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇôApril 2016. Reaction severity was mild in 63/90 (70%) and moderate in 27/90 (30%) cases; no patient developed a severe reaction by American College of Radiology criteria. The most commonly administered treatments were diphenhydramine in 67/90 (74%), corticosteroid in 24/90 (27%), and epinephrine in 13/90 (14%); symptoms subsequently resolved in all cases. No patient required inpatient admission for contrast reaction alone, and 5 patients were sent to the ED observation unit for post-epinephrine monitoring and subsequently discharged. ALCR among ED patients undergoing CECT are rare, generally of mild severity, respond well to pharmacologic management, and do not alter patient disposition in most cases. Familiarity with symptoms, management, and prevention strategies is increasingly relevant to the emergency physician given the ubiquity of CECT</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ajem.2017.10.032</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ajem.2017.10.032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Emerg Med\20171026-GottumukkalaRV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Emerg Med\20171026-GottumukkalaRV.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Gottumukkala RV</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ajem.2017.10.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Watson,J.</style></author><author><style face="normal" font="Arial"> Schobitz,E.</style></author><author><style face="normal" font="Arial"> Davis,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Emergency Medicine, MedStar Georgetown University Hospital/Washington Hospital Center, 3800 Reservoir Road NW, Washington, DC 20007, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Gerbil bite anaphylaxis - A rare case report</style></title><secondary-title><style face="normal" font="Arial">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Case Report</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> emergency department</style></keyword><keyword><style face="normal" font="Arial"> emergency medicine</style></keyword><keyword><style face="normal" font="Arial"> Exotic pets</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Household pets</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> injuries</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Rodents</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Washington</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">Household pets are well known to cause allergic symptoms in susceptible individuals, most commonly conjunctivitis, rhinitis, bronchospasm or urticaria. The increasing prevalence of exotic pets, including rodents, may introduce novel allergens into the household setting. We describe the case of a 16-year-old female who presented to the emergency department (ED) with an immediate systemic reaction consistent with anaphylaxis following a bite injury from a pet Mongolian gerbil. Although rare, gerbil bite injury represents another possible allergen source for precipitating a severe allergic reaction</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1532-8171 (Electronic)IS - 0735-6757 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ajem.2017.10.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29070434">PM:29070434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Emerg Med\20171026-WatsonJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Emerg Med\20171026-WatsonJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Watson J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ajem.2017.10.040</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Beatty,N.L.</style></author><author><style face="normal" font="Arial"> Klotz,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of Arizona College of Medicine, Department of Medicine, Division of Infectious Diseases, Tucson, Arizona</style></auth-address><titles><title><style face="normal" font="Arial">The Midnight Bite! a Kissing Bug Nightmare</style></title><secondary-title><style face="normal" font="Arial">Am J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Arizona</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> kissing</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1555-7162 (Electronic)IS - 0002-9343 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.amjmed.2017.10.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074095">PM:29074095</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Med\20171027-BeattyNL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Med\20171027-BeattyNL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Beatty NL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.amjmed.2017.10.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Crowson,M.G.</style></author><author><style face="normal" font="Arial"> Schulz,K.</style></author><author><style face="normal" font="Arial"> Ulvila,A.</style></author><author><style face="normal" font="Arial"> Witsell,D.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Head &amp; Neck Surgery and Communication Sciences, Duke Voice Care Center, Duke University Medical Center, Durham, NC, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Payer database and geospatial analysis to evaluate practice patterns in treating allergy in North Carolina</style></title><secondary-title><style face="normal" font="Arial">Am J Otolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Am J Otolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy testing</style></keyword><keyword><style face="normal" font="Arial"> Allergy treatment</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Communication</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Family Practice</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Specialist</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The objective of this study was to characterize the delivery of allergy care in North Carolina using a large payer charge database and visualization techniques. STUDY DESIGN: Geospatial database analysis. SETTING: North Carolina State claims database. SUBJECTS &amp; METHODS: Medical data from the 2013 FAIR Health National Private Insurance Claims (FH NPIC) database for North Carolina was mined for CPT codes and charges for allergy testing, and for the preparation and provision of allergen immunotherapy. Provider and patient variables were analyzed. Analyses were performed to compare differences in allergy care delivery. A visualization strategy complemented the analytic approach. RESULTS: 162,037 CPT charge entries were analyzed. Allergy-immunology specialists were the most common provider specialty to perform allergy immunotherapy treatments (68.9%, p&lt;0.05). Among other specialties, there were no significant differences between specialists performing immunotherapy when comparing otolaryngology, family practice, and internal medicine (16.3%; 4.6%; 2.6%; p>0.05). Providers with an M.D. degree were the most common provider type. The three most commonly treated diagnoses were allergic rhinitis variants. Females were more likely to receive allergy treatments versus males (55.9% vs. 51.5%; p&lt;0.001), and were more likely to receive allergy testing (65.3% vs. 34.7%: p&lt;0.005). Internal medicine providers charged higher than any other specialist type (p&lt;0.05) for allergy immunotherapy. CONCLUSIONS: Using a large payer database coupled with visualization techniques was an efficient approach to characterizing the state-wide provision patterns of allergy diagnostic and therapy services in North Carolina. This first tier approach to efficiently exploring questions and describing populations is valuable</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1532-818X (Electronic)IS - 0196-0709 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.amjoto.2017.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031937">PM:29031937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Otolaryngol\20171016-CrowsonMG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Otolaryngol\20171016-CrowsonMG.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Otolaryngol\20171016-CrowsonMG.mp4</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Otolaryngol\20171016-CrowsonMG.mp4</url></image-urls></urls><custom2><style face="normal" font="Arial">20171016, Vrowson MG</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.amjoto.2017.10.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chipps,B.E.</style></author><author><style face="normal" font="Arial"> Zeiger,R.S.</style></author><author><style face="normal" font="Arial"> Luskin,A.T.</style></author><author><style face="normal" font="Arial"> Busse,W.W.</style></author><author><style face="normal" font="Arial"> Trzaskoma,B.L.</style></author><author><style face="normal" font="Arial"> Antonova,E.N.</style></author><author><style face="normal" font="Arial"> Pazwash,H.</style></author><author><style face="normal" font="Arial"> Limb,S.L.</style></author><author><style face="normal" font="Arial"> Solari,P.G.</style></author><author><style face="normal" font="Arial"> Griffin,N.M.</style></author><author><style face="normal" font="Arial"> Casale,T.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Capital Allergy &amp; Respiratory Disease Center, Sacramento, California</style></auth-address><titles><title><style face="normal" font="Arial">Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO</style></title><secondary-title><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Allergy Asthma Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Depression</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> Hospitalization</style></keyword><keyword><style face="normal" font="Arial"> Hypertension</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predictor</style></keyword><keyword><style face="normal" font="Arial"> predictors</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Respiratory disease</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Patients included in clinical trials do not necessarily reflect the real-world population. OBJECTIVE: To understand the characteristics, including disease and comorbidity burden, of patients with asthma receiving omalizumab in a real-world setting. METHODS: The Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) was a US-based, multicenter, single-arm, and prospective study. Patients (>/=12 years of age) with allergic asthma initiating omalizumab treatment based on physician-assessed need were included and followed for 12 months. Exacerbations, health care use, adverse events, and Asthma Control Test (ACT) scores were assessed monthly. Biomarkers (blood eosinophils, fractional exhaled nitric oxide, and periostin) were evaluated and patient-reported outcomes (Asthma Quality of Life Questionnaire for 12 Years and Older [AQLQ+12] and Work Productivity and Activity Impairment: Asthma questionnaire [WPAI:Asthma]) were completed at baseline and months 6 and 12. The Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) was completed at baseline and 12 months. RESULTS: Most of the 806 enrollees (91.4%) were adults (mean age 47.3 years, SD 17.4), white (70.3%), and female (63.5%). Allergic comorbidity was frequently reported (84.2%), as were hypertension (35.5%) and depression (22.1%). In the 12 months before study entry, 22.1% of patients reported at least 1 asthma-related hospitalization, 60.7% reported at least 2 exacerbations, and 83.3% reported ACT scores no higher than 19 (uncontrolled asthma). Most patients had low biomarker levels based on prespecified cut-points. Baseline mean patient-reported outcome scores were 4.0 (SD 1.4) for AQLQ+12, 2.7 (SD 1.4) for MiniRQLQ, and 47.7 (SD 28.9) for WPAI:Asthma percentage of activity impairment and 33.5 (SD 28.7) for percentage of overall work impairment. CONCLUSION: The population initiating omalizumab in PROSPERO reported poorly controlled asthma and a substantial disease burden. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01922037</style></abstract><notes><style face="normal" font="Arial">DA - 20171021IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.anai.2017.09.056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29054589">PM:29054589</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20171021-ChippsBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20171021-ChippsBE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171021, Chipps BE</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.anai.2017.09.056</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Albertini,R.</style></author><author><style face="normal" font="Arial"> Ugolotti,M.</style></author><author><style face="normal" font="Arial"> Ghillani,L.</style></author><author><style face="normal" font="Arial"> Adorni,M.</style></author><author><style face="normal" font="Arial"> Vitali,P.</style></author><author><style face="normal" font="Arial"> Signorelli,C.</style></author><author><style face="normal" font="Arial"> Pasquarella,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medicine and Surgery, University of Parma, Italy - Medical Immunology Unit, University Hospital of Parma, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Aerobiological monitoring and mapping of Ambrosia plants in the province of Parma (northern Italy, southern Po valley), a useful tool for targeted preventive measures</style></title><secondary-title><style face="normal" font="Arial">Ann Ig</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Ann Ig</style></abbr-1></periodical><pages end="528" start="515">515-528</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Air</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health expenditures</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> leaf</style></keyword><keyword><style face="normal" font="Arial"> Leaves</style></keyword><keyword><style face="normal" font="Arial"> Map</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Ophraella communa</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> pollination</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Sunflower</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Ambrosia is an annual anemophilous weed producing allergenic pollen affecting public health in European countries. In Italy, the most infested region is Lombardy where, in some areas, it is the major cause of hay fever. In the Parma district, until 2007, Ambrosia seemed to be very rare, despite an observed increase of Seasonal Pollen Index (SPI), of pollen peak value and of asthma among ragweed sensitized patients. The aims of this study were to calculate ragweed pollen season and trends from 1996 to 2015, to assess the relationships between pollen season characteristics and selected meteorological data, to map plants in the territory and to evaluate the presence of beetle Ophraella communa (Ophraella), known as an eater of Ambrosia leaves. METHODS: The following pollination parameters: start, end, duration, peak concentration date, peak values, SPI and the following climatic parameters: temperature, relative humidity, rainfall, were analyzed. The ragweed plants sites were mapped and the presence of Ophraella was assessed during naturalistic activities. RESULTS: Significant SPI and pollen peak value increase until 2011 were observed, but recently, 2012-2015 vs 2009-2011, a strong reduction (about 50%) of these parameters was observed. The spring average air temperature increased significantly. The results of the correlation analysis showed Ambrosia season characteristics significantly related. We identified the sites source of Ambrosia, even downtown at the confluence between Parma and Baganza rivers. Ophraella was observed for the first time in 2014. CONCLUSIONS: The results showed the spread of ragweed plants over the territory and the risk of allergy increase that ragweed could cause. It remains to evaluate the role of the Ophraella in the reduction of Ambrosia pollen concentration. It is important to consider the potential risk Ophraella may represent for sunflower and other taxonomically related crop plants and other native and exotic species. The lack of initiatives by the Health Authorities to prevent and to contrast the spread of Ambrosia in the Parma area could cause public health consequences and an increase in health expenditures</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1120-9135 (Print)IS - 1120-9135 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.7416/ai.2017.2182</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29048450">PM:29048450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Ig\2017-29-515-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Ig\2017-29-515-28.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Albertini R</style></custom2><misc3><style face="normal" font="Arial">10.7416/ai.2017.2182</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Park,K.H.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Sim,D.W.</style></author><author><style face="normal" font="Arial"> Lee,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="Arial">Comparison of Singleplex Specific IgE Detection Immunoassays: ImmunoCAP Phadia 250 and Immulite 2000 3gAllergy</style></title><secondary-title><style face="normal" font="Arial">Ann Lab Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Ann Lab Med</style></full-title></periodical><pages end="31" start="23">23-31</pages><volume><style face="normal" font="Arial">38</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Dander</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Detection methods</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> dog dander</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> German cockroach</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immulite</style></keyword><keyword><style face="normal" font="Arial"> Immulite 2000</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Korean</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> mugwort</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Rye</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> sIgE</style></keyword><keyword><style face="normal" font="Arial"> singleplex</style></keyword><keyword><style face="normal" font="Arial"> soybean</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The identification of clinically meaningful specific immunoglobulin E (sIgE) is important for the diagnosis and management of allergic diseases. Various in vitro sIgE detection methods are available worldwide. Depending on the number of antigens that can be tested simultaneously, there are two representative methods: singleplex and multiplex. Singleplex sIgE detection is mainly provided by Thermo Fisher (ImmunoCAP) and Siemens (Immulite). This study aimed to compare the diagnostic agreement of two singleplex sIgE detection assays. METHODS: Sera from 209 Korean patients with allergic disease were used to compare the ImmunoCAP and Immulite assays with respect to the following allergens: inhalant allergens (Dermatophagoides farinae, cat and dog dander, oak, rye grass, mugwort, Alternaria, German cockroach) and food allergens (hen's egg white, cow's milk, wheat, peanut, soybean, and shrimp). Data from 902 paired comparison tests were included for comparisons. Qualitative, semi-quantitative, and quantitative comparisons were performed using statistical analyses. RESULTS: In qualitative comparisons, the positivity and negativity agreements ranged from 75% (wheat, shrimp) to 96% (Alternaria). Class consistency (classes 0-6) was well matched. Spearman's rank correlation coefficients for all allergens except shrimp were over 0.7. In quantitative comparisons, all allergens excluding shrimp showed >0.7 intra-class correlation coefficients. CONCLUSIONS: The ImmunoCAP and Immulite systems showed similar performances. However, clinicians should consider fundamental methodological differences between the assays</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 2234-3814 (Electronic)IS - 2234-3806 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.3343/alm.2018.38.1.23</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29071815">PM:29071815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Lab Med\2018-38-23-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Lab Med\2018-38-23-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Park KH</style></custom2><misc3><style face="normal" font="Arial">10.3343/alm.2018.38.1.23</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saniklidou,A.H.</style></author><author><style face="normal" font="Arial"> Tighe,P.J.</style></author><author><style face="normal" font="Arial"> Fairclough,L.C.</style></author><author><style face="normal" font="Arial"> Todd,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">School of Life Sciences, University of Nottingham, Life Sciences Building, University Park, Nottingham, NG7 2RD, UK</style></auth-address><titles><title><style face="normal" font="Arial">IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review</style></title><secondary-title><style face="normal" font="Arial">Arch Dermatol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Arch Dermatol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adhesion</style></keyword><keyword><style face="normal" font="Arial"> adhesion molecule</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> autoantigen</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> bullous pemphigoid</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Clinical severity</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Epidermis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> serum IgE levels</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Type XVII collagen</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="Arial">Bullous pemphigoid (BP) is the most common autoimmune skin disease of blistering character. The underlying pathophysiological mechanism involves an immune attack, usually by IgG class autoantibodies, on the autoantigen BP 180/BPAg2, which is a type XVII collagen (COL17) protein acting as the adhesion molecule between the epidermis and the basement membrane of the dermis. About 40 years ago, following consistent findings of elevated total serum IgE levels in BP patients, it was hypothesized that IgE may be involved in the pathophysiology of BP. Our objective was to determine whether there is strong evidence for an association between IgE class autoantibodies and the clinical severity or phenotype of BP. Three databases were searched for relevant studies and appropriate exclusion and inclusion criteria were applied. Data was extracted and assessed in relation to the study questions concerning the clinical significance of IgE autoantibodies in BP. Nine studies found that anti-BP180 autoantibodies of IgE class are associated with increased severity of BP, whereas two studies did not find such an association. The number of studies which found an association between higher IgE autoantibody levels and the erythematous urticarial phenotype of BP (5) was equal in number to the studies which found no such association (5). In conclusion, higher serum IgE autoantibody levels are associated with more severe clinical manifestations of BP. There is insufficient evidence to support higher IgE autoantibody levels being associated with specific clinical phenotypes of BP</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1432-069X (Electronic)IS - 0340-3696 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00403-017-1789-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29071428">PM:29071428</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dermatol Res\20171026-SaniklidouAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dermatol Res\20171026-SaniklidouAH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Saniklidou AH</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00403-017-1789-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kolkhir,P.</style></author><author><style face="normal" font="Arial"> Borzova,E.</style></author><author><style face="normal" font="Arial"> Grattan,C.</style></author><author><style face="normal" font="Arial"> Asero,R.</style></author><author><style face="normal" font="Arial"> Pogorelov,D.</style></author><author><style face="normal" font="Arial"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">I.M. Sechenov First Moscow State Medical University, Department of Dermatology and Venereology, Division of Immune-mediated Skin Disorders, Trubetskaya st., 8/2, Moscow 119991, Russian Federation</style></auth-address><titles><title><style face="normal" font="Arial">Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review</style></title><secondary-title><style face="normal" font="Arial">Autoimmun Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Autoimmun Rev</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> AIDS</style></keyword><keyword><style face="normal" font="Arial"> Anemia</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antinuclear antibodies</style></keyword><keyword><style face="normal" font="Arial"> Arthritis</style></keyword><keyword><style face="normal" font="Arial"> Autoantibodies</style></keyword><keyword><style face="normal" font="Arial"> autoantibody</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Hashimoto's thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> rheumatoid arthritis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Systemic lupus Erythematosus</style></keyword><keyword><style face="normal" font="Arial"> Thyroid</style></keyword><keyword><style face="normal" font="Arial"> Thyroiditis</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Vitiligo</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="14" Month="10" Year="2017">2017/10/14</year></dates><abstract><style face="normal" font="Arial">BACKGROUND AND OBJECTIVE: Numerous autoimmune diseases (AIDs) have been linked to chronic spontaneous urticaria (CSU). Here, we provide the first extensive and comprehensive evaluation of the prevalence of AIDs in patients with CSU and vice versa. METHODS: A Pubmed and Google Scholar search was performed to identify studies reporting the prevalence of various AIDs in CSU and vice versa published before April 2017. RESULTS: The prevalence of individual AIDs in CSU is increased (>/=1% in most studies vs &lt;/=1% in the general population). AIDs with relatively high prevalence in the general population are also quite common in CSU patients, whereas those with low prevalence remain a rare finding in CSU. The rates of comorbidity in most studies were >/=1% for insulin-dependent diabetes mellitus, rheumatoid arthritis (RA), psoriasis and celiac disease (CD), >/=2% for Graves' disease, >/=3% for vitiligo, and >/=5% for pernicious anemia and Hashimoto's thyroiditis. Organ-specific AIDs are more prevalent in CSU than systemic (multiorgan or non organ-specific) AIDs. >2% of CSU patients have autoimmune polyglandular syndromes encompassing autoimmune thyroid disease (ATD) and vitiligo or pernicious anemia. Antithyroid and antinuclear antibodies are the most prevalent AID-associated autoantibodies in CSU. >15% of CSU patients have a positive family history for AIDs. The prevalence of urticarial rash in AID patients is >1% in most studies. This rash is more prevalent in eosinophilic granulomatosis with polyangiitis, ATD, systemic lupus erythematosus, RA and CD. CONCLUSIONS: CSU patients have an increased risk of AIDs, especially adult female patients and those with a positive family history and a genetic predisposition for AIDs, who should be screened for signs and symptoms of AIDs</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1873-0183 (Electronic)IS - 1568-9972 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Russia -CO - United Kingdom -CO - Italy -CO - Luxembourg -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.autrev.2017.10.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037900">PM:29037900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Autoimmun Rev\20171017-KolkhirP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Autoimmun Rev\20171017-KolkhirP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Kolkhir P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.autrev.2017.10.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kaveh,M.</style></author><author><style face="normal" font="Arial"> Eidi,A.</style></author><author><style face="normal" font="Arial"> Nemati,A.</style></author><author><style face="normal" font="Arial"> Boskabady,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Modulation of lung inflammation and immune markers in asthmatic rats treated by Portulaca oleracea</style></title><secondary-title><style face="normal" font="Arial">Avicenna J Phytomed</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Avicenna J Phytomed</style></full-title></periodical><pages end="416" start="409">409-416</pages><volume><style face="normal" font="Arial">7</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effect</style></keyword><keyword><style face="normal" font="Arial"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> PLA2</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Previous studies indicated anti-inflammatory effects for Portulaca oleracea in various inflammatory disorders. In this study, the effects of P. oleracea on bronchoalveolar lavage fluid (BALF) levels of total protein (TP), Phospholipase A2 (PLA2) and IgE in sensitized rats were examined. MATERIALS AND METHODS: Male rats were randomly divided into six groups namely, control (group C), sensitized rats (group S), sensitized animal treated with three concentrations of the extract of P. oleracea and dexamethasone (n = 8 for each group). The levels of TP, PLA2 and IgE in BALF were measured. RESULTS: The levels of TP, PLA2 and IgE were significantly increased in the BALF of group S compared to group C (p&lt;0.001 for all cases). However, treatment of S rats with all concentrations of the extract, resulted in a significant and concentration-dependent reduction in BALF levels of TP, PLA2 and IgE compared to group S (p&lt;0.001 for all cases except for the effect of the low extract concentration on TP). Dexamethasone treatment also led to significant reduction of TP, PLA2 and IgE (p&lt;0.001 for all cases). The effect of dexamethasone treatment on PLA2 was significantly higher than the effects of all extract concentrations (p&lt;0.001 for all cases). However, the effect of high extract concentration on TP and IgE was significantly higher than that of dexamethasone (p&lt;0.001 both cases). CONCLUSION: The results indicated anti-inflammatory and immunomodulatory effects of P. oleracea in sensitized rats (as an animal model of asthma) which was equal or more marked than dexamethasone at studied concentrations</style></abstract><notes><style face="normal" font="Arial">DA - 20171024IS - 2228-7930 (Print)IS - 2228-7930 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29062802">PM:29062802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Avicenna J Phytomed\2017-7-409-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Avicenna J Phytomed\2017-7-409-16.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171024, Kaveh M</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liao,Y.</style></author><author><style face="normal" font="Arial"> Zhang,Q.Y.</style></author><author><style face="normal" font="Arial"> Li,H.X.</style></author><author><style face="normal" font="Arial"> Wang,Y.L.</style></author><author><style face="normal" font="Arial"> Liu,P.</style></author><author><style face="normal" font="Arial"> Du,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Peking University First Hospital, Beijing 100034</style></auth-address><titles><title><style face="normal" font="Arial">[Co-morbidity of vasovagal syncope and postural tachycardia syndrome with allergic diseases in children]</style></title><secondary-title><style face="normal" font="Arial">Beijing Da Xue Xue Bao</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Beijing Da Xue Xue Bao</style></full-title></periodical><pages end="788" start="783">783-788</pages><volume><style face="normal" font="Arial">49</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic eczema</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Blood Pressure</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation analysis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Heart</style></keyword><keyword><style face="normal" font="Arial"> Heart Rate</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> hospitalized</style></keyword><keyword><style face="normal" font="Arial"> Intolerance</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syncope</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Tachycardia</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="18" Month="10" Year="2017">2017/10/18</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To explore the clinical characteristics of the co-morbidity of vasovagal syncope (VVS) and postural tachycardia syndrome (POTS) with allergic diseases in children. METHODS: A re-trospective analysis was launched to summarize the clinical data of children with VVS and POTS. They were divided into allergic group and non-allergic group according to the history of allergic diseases. The participants' clinical characteristics were compared between allergic group and non-allergic group using independent sample t test or rank sum test; composition comparisons were completed by Chi-square test. Bi-variate correlation analysis was used to explore the association between eosinophil percentage/count and symptom scores/frequency of syncope episodes. A P value &lt;0.05 was defined as statistically significant. RESULTS: Sixty-seven children complaining of orthostatic intolerance (43 patients diagnosed as VVS and 24 cases diagnosed as POTS) were enrolled. Totally 21 cases (31%) had allergic diseases, including allergic rhinitis, atopic eczema, asthma, as well as food allergy. And allergic rhinitis is the most common co-morbidity. There were no significant differences between the two groups in age, gender ratio, height, body weight and basement blood pressure. Compared with the non-allergic group, the allergic group showed later onset age (year) (11+/-2 vs. 9+/-3, P&lt;0.05) of orthostatic intolerance and shorter course of the diseases (month) [8.0 (0.1, 0.1) vs. 24.0 (0.1, 144.0), P&lt;0.05]. The frequency of syncope episodes in the allergic group among VVS children (times per month) [2.50 (0.08, 30.00) vs. 0.25 (0.03, 5.00), P&lt;0.05] was much higher than that in the non-allergic group. Additionally, the eosinophil percentage (%) [3.50 (0.70, 0.59) vs. 1.65 (0.30, 6.20), P&lt;0.001] and eosinophil count (x109) [0.18 (0.05, 0.71) vs. 0.10 (0.02, 0.38), P&lt;0.001] were increased in the allergic group. However, there were no remarkable differences in the results of head-up tilt test in children with VVS or in the maximum change of heart rate during standing test in children with POTS were involved. CONCLUSION: Allergic diseases are common co-morbidities in children with both VVS and POTS. Allergic rhinitis is the most common co-morbidity. Children with co-morbidity of VVS/POTS and allergic diseases had a later onset of symptoms of orthostatic intolerance, and were more likely to be hospitalized for intensive attacks of symptoms during a short period when compared with those without allergic diseases. Children diagnosed as VVS combined with allergic diseases had more frequent episodes of syncope</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1671-167X (Print)IS - 1671-167X (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29045956">PM:29045956</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Beijing Da Xue Xue Bao\2017-49-783-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Beijing Da Xue Xue Bao\2017-49-783-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Liao Y</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fanuel,S.</style></author><author><style face="normal" font="Arial"> Tabesh,S.</style></author><author><style face="normal" font="Arial"> Sadroddiny,E.</style></author><author><style face="normal" font="Arial"> Kardar,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences-International Campus (IC-TUMS) Tehran, Iran</style></auth-address><titles><title><style face="normal" font="Arial">Analysis of predicted B and T-cell epitopes in Der p 23, allergen from Dermatophagoides pteronyssinus</style></title><secondary-title><style face="normal" font="Arial">Bioinformation</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Bioinformation</style></full-title></periodical><pages end="312" start="307">307-312</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy diagnosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> B-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Biotechnology</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Der p 23</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Homology</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> IgE-mediated hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequence Analysis</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitope</style></keyword><keyword><style face="normal" font="Arial"> T-cell epitopes</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapeutic vaccines</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">House dust mite (HDM) allergy is the leading cause of IgE-mediated hypersensitivity. Therefore identifying potential epitopes in the Dermatophagoide pteronyssinus 23 (Der p 23), a major house dust mite allergen will aid in the development of therapeutic vaccines and diagnostic kits for HDM allergy. Experimental methods of epitope discovery have been widely exploited for the mapping of potential allergens. This study sought to use immunoinformatic methods to analyze the structure of Der p 23 for potential immunoreactive B and T-cell epitopes that could be useful for AIT and allergy diagnosis. We retrieved a Der p 23 allergen sequence from Genbank database and then analyzed it using a combination of web-based sequence analysis tools including the Immune Epitope Database (IEDB), Protparam, BCPREDS, ABCpred, BepiPred, Bcepred among others to predict the physiochemical properties and epitope spectra of the Der p 23 allergen. We then built 3D models of the predicted B-cell epitopes, T cell epitopes and Der p 23 for sequence structure homology analysis. Our results identified peptides 'TRWNEDE', 'TVHPTTTEQPDDK', and 'NDDDPTT' as immunogenic linear B-cell epitopes while 'CPSRFGYFADPKDPH' and 'CPGNTRWNEDEETCT' were found to be the most suitable T-cell epitopes that interacted well with a large number of MHC II alleles. Both epitopes had high population coverage as well as showing a 100% conservancy. These five Der p 23 epitopes are useful for AIT vaccines and HDM allergy diagnosis development</style></abstract><notes><style face="normal" font="Arial">DA - 20171030IS - 0973-2063 (Print)IS - 0973-2063 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">10.6026/97320630013307</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29081610">PM:29081610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Bioinformation\2017-13-307-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Bioinformation\2017-13-307-12.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Fanuel S</style></custom2><misc3><style face="normal" font="Arial">10.6026/97320630013307</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,J.H.</style></author><author><style face="normal" font="Arial"> Shin,J.U.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Noh,J.Y.</style></author><author><style face="normal" font="Arial"> Kim,H.R.</style></author><author><style face="normal" font="Arial"> Lee,J.</style></author><author><style face="normal" font="Arial"> Chu,H.</style></author><author><style face="normal" font="Arial"> Jeong,K.Y.</style></author><author><style face="normal" font="Arial"> Park,K.H.</style></author><author><style face="normal" font="Arial"> Kim,J.D.</style></author><author><style face="normal" font="Arial"> Kim,H.K.</style></author><author><style face="normal" font="Arial"> Jeong,D.H.</style></author><author><style face="normal" font="Arial"> Yong,T.S.</style></author><author><style face="normal" font="Arial"> Park,J.W.</style></author><author><style face="normal" font="Arial"> Lee,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology &amp; Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="Arial">Successful transdermal allergen delivery and allergen-specific immunotherapy using biodegradable microneedle patches</style></title><secondary-title><style face="normal" font="Arial">Biomaterials</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Biomaterials</style></full-title></periodical><pages end="48" start="38">38-48</pages><volume><style face="normal" font="Arial">150</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Biodegradable</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug delivery</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patient Compliance</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> SIT</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin lesion</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="Arial">Allergen-specific immunotherapy (SIT) is an effective treatment modality for allergic diseases such as atopic dermatitis (AD). However, frequent visits over a 3-year period as well as looming adverse events tend to discourage patient compliance. Therefore, a more convenient, effective, and safe method of SIT is needed. For several decades, use of microneedles has been promoted as an efficient and precise transdermal drug delivery method. In this study, we developed Dermatophagoides farinae (D. farinae) extract (DfE)-loaded microneedle patches, and evaluated their safety and efficacy as a novel SIT method. After 4 weeks of patch application, efficient allergen delivery and successful induction of immune response to DfE were demonstrated in mice, with no apparent adverse events. AD-induced NC/Nga mice received microneedle immunotherapy (MNIT) (10 mug), subcutaneous immunotherapy (SCIT) (10 mug), SCIT (100 mug), or placebo. Both MNIT (10 mug) and SCIT (100 mug) treatments improved clinical and histologic manifestations of AD skin lesions, altered immunoglobulin production, dampened Th2 cellular response, and boosted Treg infiltrates, without significant side effects; whereas SCIT (10 mug) or placebo subsets failed to show any effects. Based on the favorable safety and efficacy profiles demonstrated in mice by MNIT in the current study, we believe that MNIT may serve as a new SIT modality</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1878-5905 (Electronic)IS - 0142-9612 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.biomaterials.2017.10.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29032329">PM:29032329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomaterials\2018-150-38-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomaterials\2018-150-38-48.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Kim JH</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.biomaterials.2017.10.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Farah,I.O.</style></author><author><style face="normal" font="Arial"> Holt-Gray,C.</style></author><author><style face="normal" font="Arial"> Cameron,J.A.</style></author><author><style face="normal" font="Arial"> Tucci,M.</style></author><author><style face="normal" font="Arial"> Benghuzzi,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biology, Jackson State University, Jackson, MS 39217, and the University of Mississippi Medical Center</style></auth-address><titles><title><style face="normal" font="Arial">HISTOPATHOLOGICAL ANALYSIS OF THE F344 RAT LUNG UPON EXPOSURE TO RETENOIC ACID, OVALBUMIN, MOLD SPORES AND CITRAL</style></title><secondary-title><style face="normal" font="Arial">Biomed Sci Instrum</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Biomed Sci Instrum</style></abbr-1></periodical><pages end="127" start="120">120-127</pages><volume><style face="normal" font="Arial">53</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> complications</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lung disease</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mold</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retinoic acid</style></keyword><keyword><style face="normal" font="Arial"> Rodent</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Spore</style></keyword><keyword><style face="normal" font="Arial"> Spores</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="Arial">The paradoxical role of retinoic acid (All Trans Retinoic Acid; ATRA) in the development of allergic and/or inflammatory complications in contrast to a therapeutic modality for lung pathology is not well understood or established in the literature. As well, the role of Citral (inhibitor of retinoid function; a non-toxic chemical that exists in two forms (diethyl; C1 or cis-trans dimethyl; C2), in the reversal of retinoic acid, ovalbumin and allergic mold spore pathophysiology is also not well ascertained under an in vivo setting. Therefore, it is hypothesized that exposure of F344 lung tissues to supra-physiologic levels of retinoic acid, ovalbumin and mold spores individually or in combination with each other will lead to inflammatory tissue pathology and that Citral 1 and 2 will reverse or ameliorate the related pathological damage to lung tissues. Even though ovalbumin and retinoic acid have been previously applied through intra-tracheal route in cancer prevention and immunological research, the objective of this study was to evaluate the histopathological implications of such exposure in vivo. This IACUC approved in vivo study used Fischer 344 rats (n = 80 ; 229 to 273g), which were randomly assigned to controls as well as ovalbumin and mold-sensitized treatment groups (0.80 mg/kg and 1x109 mold spores combined from 4 strains/100 mul intra-tracheal; all others were dosed by intra-peritoneal injection at days 1 and 7 with 80 mg/kg each of ATRA as well as 20 and 50 mg/kg each of Citrals 1 or 2 individually or in combination to represent all four chemicals and mold spores treatments. Positive and negative controls for each treatment were also included in the study. Animals were housed in rat cages at the JSU Research Animal Core Facilities and were placed on a 12:12 light-dark cycle. A standard rodent diet and water access were provided ad libidum. All animals were sacrificed on day 21 and lung tissues were processed for histopathology. Slides were prepared and were digitized for comparison of tissues pathology. Results showed that exposure of the F344 rats to ovalbumin and ATRA showed various levels of lung tissue damage that was ameliorated by Citral 2 in combination. Mold and ATRA exposure caused various levels of lung tissue damage that was reversed by C1 in combination with each other. Taken together, the study showed that there are variable pathologic inflammatory responses from the interaction of ovalbumin, Citrals, mold spores and retinoic acid, and that the addition of Citrals have reversed lung tissue pathologies. These findings warrants further investigation as to the actual role of these interactions in relation to acute/chronic lung disease and the possibility of reversing retinoid-mediated pathologies in the Fisher rat model</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 0067-8856 (Print)IS - 0067-8856 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033472">PM:29033472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Biomed Sci Instrum\2017-53-120-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Biomed Sci Instrum\2017-53-120-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Farah IO</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Domingo,C.</style></author><author><style face="normal" font="Arial"> Pomares,X.</style></author><author><style face="normal" font="Arial"> Navarro,A.</style></author><author><style face="normal" font="Arial"> Amengual,M.J.</style></author><author><style face="normal" font="Arial"> Monton,C.</style></author><author><style face="normal" font="Arial"> Sogo,A.</style></author><author><style face="normal" font="Arial"> Mirapeix,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pulmonary Service, Corporacio Sanitaria Parc Tauli</style></auth-address><titles><title><style face="normal" font="Arial">A STEP-DOWN PROTOCOL FOR OMALIZUMAB TREATMENT IN ORAL CORTICOSTEROID-DEPENDENT ALLERGIC ASTHMA PATIENTS</style></title><secondary-title><style face="normal" font="Arial">Br J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Br J Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Emergencies</style></keyword><keyword><style face="normal" font="Arial"> emergency</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Viability</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="10" Year="2017">2017/10/18</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: there are no specific criteria for a step-down or withdrawal dose of omalizumab. Our purpose was to evaluate the viability of a protocol for OMAlizumab DOse REduction (the OMADORE study) in severe allergic asthma (SAA). METHODS: the study population included 35 SAA patients treated during a minimum period of one year with oral corticosteroids (OC) equivalent to a mean daily dose of 4 mg of methyl-prednisolone. To qualify for the protocol, the patients had to have received treatment with OMA >/= one year and a half, OC dose had to have reached the lowest tolerated dose and spirometry had to be >/= at entry. INTERVENTION: a) OMA dose was reduced by half; b) if patients were clinically stable after 6 months, the dose was halved again; c) if repeated OC boosters were needed and/or spirometry worsened >/= 10%, OMA dose was raised to the previous figure until stabilization. RESULTS: Mean age was 52.5 (17) years, median monthly OC dose was 120 (IQR: 225) mg. Pulmonary function: FVC: 79.7 (20.2)%; FEV1 : 64.8 (21.7)%; FEV1 / FVC: 61.7(13.8)%. OMA could be withdrawn in 34.3% of the patients; 22.9% tolerated a reduction, and in 42.9% the dose could not be modified. Follow-up time after reduction or withdrawal ranged from 12 to 30 months. There were no severe exacerbations requiring emergency assistance or admission. CONCLUSIONS: The OMADORE study found that in more than 50% of SAA patients on OC, OMA dose can be safely reduced or withdrawn based on a progressive dose reduction protocol</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1365-2125 (Electronic)IS - 0306-5251 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1111/bcp.13453</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29044640">PM:29044640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Br J Clin Pharmacol\20171018-DomingoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Br J Clin Pharmacol\20171018-DomingoC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Domingo C</style></custom2><misc3><style face="normal" font="Arial">10.1111/bcp.13453</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tamm,S.</style></author><author><style face="normal" font="Arial"> Cervenka,S.</style></author><author><style face="normal" font="Arial"> Forsberg,A.</style></author><author><style face="normal" font="Arial"> Estelius,J.</style></author><author><style face="normal" font="Arial"> Grunewald,J.</style></author><author><style face="normal" font="Arial"> Gyllfors,P..</style></author><author><style face="normal" font="Arial"> Karshikoff,B.</style></author><author><style face="normal" font="Arial"> Kosek,E.</style></author><author><style face="normal" font="Arial"> Lampa,J.</style></author><author><style face="normal" font="Arial"> Lensmar,C.</style></author><author><style face="normal" font="Arial"> Strand,V.</style></author><author><style face="normal" font="Arial"> Akerstedt,T.</style></author><author><style face="normal" font="Arial"> Halldin,C.</style></author><author><style face="normal" font="Arial"> Ingvar,M.</style></author><author><style face="normal" font="Arial"> Olgart Hoglund,C.</style></author><author><style face="normal" font="Arial"> Lekander,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy: A [11C]PBR28 PET study</style></title><secondary-title><style face="normal" font="Arial">Brain Behav Immun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Brain Behav Immun</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cognition</style></keyword><keyword><style face="normal" font="Arial"> Consequences</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fatigue</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL-8</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immune-to-brain signaling</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Positron emission tomography</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonal allergies</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Sickness behavior</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> TNF-+¦</style></keyword><keyword><style face="normal" font="Arial"> tomography</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0889-1591</style></isbn><abstract><style face="normal" font="Arial">Allergy is associated with non-specific symptoms such as fatigue, sleep problems and impaired cognition. One explanation could be that the allergic inflammatory state includes activation of immune cells in the brain, but this hypothesis has not been tested in humans. The aim of the present study was therefore to investigate seasonal changes in the glial cell marker translocator protein (TSPO), and to relate this to peripheral inflammation, fatigue and sleep, in allergy. We examined 18 patients with severe seasonal allergy, and 13 healthy subjects in and out-of pollen season using positron emission tomography (n</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç»=</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç»15/13) and the TSPO radioligand [11C]PBR28. In addition, TNF-+¦, IL-5, IL-6, IL-8 and IFN-+¦ were measured in peripheral blood, and subjective ratings of fatigue and sleepiness as well as objective and subjective sleep were investigated. No difference in levels of TSPO was seen between patients and healthy subjects, nor in relation to pollen season. However, allergic subjects displayed both increased fatigue, sleepiness and increased percentage of deep sleep, as well as increased levels of IL-5 and TNF-+¦ during pollen season, compared to healthy subjects. Allergic subjects also had shorter total sleep time, regardless of season. In conclusion, allergic subjects are indicated to respond to allergen exposure during pollen season with a clear pattern of behavioral disruption and peripheral inflammatory activation, but not with changes in brain TSPO levels. This underscores a need for development and use of more specific markers to understand brain consequences of peripheral inflammation that will be applicable in human subjects</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Sweden -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.bbi.2017.10.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29054675">PM:29054675</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Brain Behav Immun\20171030-TammS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Brain Behav Immun\20171030-TammS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Tamm S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.bbi.2017.10.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hashimoto,T.</style></author><author><style face="normal" font="Arial"> Muneta,K.</style></author><author><style face="normal" font="Arial"> Watanabe,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Facial Edema in an Elderly Man: An Unusual Presentation of Nonepisodic Angioedema with Eosinophilia</style></title><secondary-title><style face="normal" font="Arial">Case Rep Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Case Rep Dermatol</style></full-title></periodical><pages end="168" start="164">164-168</pages><volume><style face="normal" font="Arial">9</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> angioedema</style></keyword><keyword><style face="normal" font="Arial"> Asian</style></keyword><keyword><style face="normal" font="Arial"> Biopsy</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Dermis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> Elderly</style></keyword><keyword><style face="normal" font="Arial"> Elderly patients</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil count</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Extremities</style></keyword><keyword><style face="normal" font="Arial"> Face</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Organ</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> parasite infection</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> thymus</style></keyword><keyword><style face="normal" font="Arial"> Vasculitis</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="Arial">Nonepisodic angioedema with eosinophilia (NEAE) is a rare allergic disease with a young Japanese and East Asian female predominance. NEAE features transient, nonrecurrent angioedema and peripheral blood eosinophilia without visceral organ involvement. Angioedema in NEAE occurs on the extremities, while the trunk and face are rarely involved. Here, we report a case of NEAE affecting only the face in an 80-year-old Japanese man. He was otherwise healthy and took no medication until the sudden development of angioedema on the face. The extremities and trunk were not involved. Skin biopsy examination revealed eosinophilic infiltration and degranulation between collagen bundles through the entire dermis, and perivascular and perifollicular infiltration of eosinophils and lymphocytes, but no evidence of vasculitis. Peripheral hypereosinophilia and high serum thymus- and activation-regulated chemokine (TARC) level were noted. Visceral organ involvement, parasite infection, and an allergic response were not detected in the patient. Administration of oral corticosteroid improved his symptoms rapidly and dramatically with improvements in the blood eosinophil count and serum TARC level. After the corticosteroid was discontinued, no recurrence was observed for 3 years. Thus, he was diagnosed as having NEAE. It should be noted that angioedema with eosinophilia might occur with an unusual presentation and might develop in elderly patients</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1662-6567 (Print)IS - 1662-6567 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1159/000480398</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033822">PM:29033822</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Case Rep Dermatol\2017-9-164-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Case Rep Dermatol\2017-9-164-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Hashimoto T</style></custom2><misc3><style face="normal" font="Arial">10.1159/000480398</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vologzhannikova,A.A.</style></author><author><style face="normal" font="Arial"> Khorn,P.A.</style></author><author><style face="normal" font="Arial"> Kazakov,A.S.</style></author><author><style face="normal" font="Arial"> Ismailov,R.G.</style></author><author><style face="normal" font="Arial"> Sokolov,A.S.</style></author><author><style face="normal" font="Arial"> Uversky,V.N.</style></author><author><style face="normal" font="Arial"> Permyakov,E.A.</style></author><author><style face="normal" font="Arial"> Permyakov,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute for Biological Instrumentation of the Russian Academy of Sciences, Pushchino, Moscow region, 142290, Russia.</style></auth-address><titles><title><style face="normal" font="Arial">In search for globally disordered apo-parvalbumins: Case of parvalbumin beta-1 from coho salmon</style></title><secondary-title><style face="normal" font="Arial">Cell Calcium</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Calcium</style></full-title></periodical><pages end="64" start="53">53-64</pages><volume><style face="normal" font="Arial">67</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affinity</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Calcium</style></keyword><keyword><style face="normal" font="Arial"> Calorimetry</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> coho salmon</style></keyword><keyword><style face="normal" font="Arial"> Cold</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> discrimination</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish species</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> instrumentation</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Moscow</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parvalbumin</style></keyword><keyword><style face="normal" font="Arial"> PAS</style></keyword><keyword><style face="normal" font="Arial"> Prediction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Russia</style></keyword><keyword><style face="normal" font="Arial"> Salmon</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> secondary structure</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">Parvalbumin (PA) is a classical EF-hand calcium-binding protein of muscle, neuronal, and other tissues, and a major fish allergen. Although certain apo-PAs lack tertiary structure, functional implications of that feature and its structural prerequisites remain unclear. In a search for unstable PAs, we probed conformational stability of parvalbumin beta-1 from coho salmon (csPA), a cold water fish species, using circular dichroism, scanning calorimetry, hydrophobic probe fluorescence, limited proteolysis, chemical crosslinking and dynamic light scattering techniques. Apo-csPA is shown to be mainly monomeric protein with markedly disorganized secondary structure and lack of rigid tertiary structure. Examination of per-residue propensity for intrinsic disorder in the PA groups with either folded or unfolded apo-form using the average PONDR(R) VSL2P profiles revealed that the N-terminal region that includes alpha-helix A, AB-loop and N-terminal half of alpha-helix B is predicted to be less ordered in PAs with disordered apo-state. Application of the structural criteria developed for discrimination of disordered PAs indicate that the latter comprise about 16-19% of all PAs. We show that structural instability of apo-beta-PA serves as a hallmark of elevated calcium affinity of the protein. Therefore, the successful predictions of unstable apo-PAs might facilitate search for PAs with maximal calcium affinity and possibly serving as calcium sensors</style></abstract><notes><style face="normal" font="Arial">DA - 20171014IS - 1532-1991 (Electronic)IS - 0143-4160 (Linking)LA - engPT - Journal ArticleCO - Russia -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ceca.2017.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29029791">PM:29029791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Calcium\2017-67-53-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Calcium\2017-67-53-64.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171014, Vologzhannikova AA</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ceca.2017.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Y.C.</style></author><author><style face="normal" font="Arial"> Chang,Y.C.</style></author><author><style face="normal" font="Arial"> Chang,H.A.</style></author><author><style face="normal" font="Arial"> Lin,Y.S.</style></author><author><style face="normal" font="Arial"> Tsao,C.W.</style></author><author><style face="normal" font="Arial"> Shen,M.R.</style></author><author><style face="normal" font="Arial"> Chiu,W.T.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biomedical Engineering, National Cheng Kung University, Tainan 701, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Differential Ca2+ mobilization and mast cell degranulation by FcepsilonRI- and GPCR-mediated signaling</style></title><secondary-title><style face="normal" font="Arial">Cell Calcium</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Calcium</style></full-title></periodical><pages end="39" start="31">31-39</pages><volume><style face="normal" font="Arial">67</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Biomedical Engineering</style></keyword><keyword><style face="normal" font="Arial"> Ca2+</style></keyword><keyword><style face="normal" font="Arial"> Ca2+ influx</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cell Degranulation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3</style></keyword><keyword><style face="normal" font="Arial"> RBL-2H3 cells</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">Mast cells play a primary role in allergic diseases. During an allergic reaction, mast cell activation is initiated by cross-linking IgE-FcepsilonRI complex by multivalent antigen resulting in degranulation. Additionally, G protein-coupled receptors also induce degranulation upon activation. However, the spatio-temporal relationship between Ca2+ mobilization and mast cell degranulation is not well understood. We investigated the relationship between oscillations in Ca2+ level and mast cell degranulation upon stimulation in rat RBL-2H3 cells. Nile red and Fluo-4 were used as probes for monitoring histamine and intracellular Ca2+ levels, respectively. Histamine release and Ca2+ oscillations in real-time were monitored using total internal reflection fluorescence microscopy (TIRFM). Mast cell degranulation followed immediately after FcepsilonRI and GPCR-mediated Ca2+ increase. FcepsilonRI-induced Ca2+ increase was higher and more sustained than that induced by GPCRs. However, no significant difference in mast cell degranulation rates was observed. Although intracellular Ca2+ release was both necessary and sufficient for mast cell degranulation, extracellular Ca2+ influx enhanced the process. Furthermore, cytosolic Ca2+ levels and mast cell degranulation were significantly decreased by downregulation of store-operated Ca2+ entry (SOCE) via Orai1 knockdown, 2-aminoethyl diphenylborinate (2-APB) or tubastatin A (TSA) treatment. Collectively, this study has demonstrated the role of Ca2+ signaling in regulating histamine degranulation</style></abstract><notes><style face="normal" font="Arial">DA - 20171014IS - 1532-1991 (Electronic)IS - 0143-4160 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ceca.2017.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29029788">PM:29029788</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Calcium\2017-67-31-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Calcium\2017-67-31-9.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Calcium\2017-67-31-9-mmc2.mp4C:\A&amp;H HMW Papers\Cell Calcium\2017-67-31-9-mmc3.mp4</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Calcium\2017-67-31-9-mmc2.mp4F:\A&amp;H HMW Papers\Cell Calcium\2017-67-31-9-mmc3.mp4</url></image-urls></urls><custom2><style face="normal" font="Arial">20171014, Chen YC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ceca.2017.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bui,T.T.</style></author><author><style face="normal" font="Arial"> Piao,C.H.</style></author><author><style face="normal" font="Arial"> Song,C.H.</style></author><author><style face="normal" font="Arial"> Shin,H.S.</style></author><author><style face="normal" font="Arial"> Shon,D.H.</style></author><author><style face="normal" font="Arial"> Chai,O.H.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Piper nigrum extract ameliorated allergic inflammation through inhibiting Th2/Th17 responses and mast cells activation</style></title><secondary-title><style face="normal" font="Arial">Cell Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Immunol</style></full-title></periodical><pages end="73" start="64">64-73</pages><volume><style face="normal" font="Arial">322</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Anti-OVA specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Anti-oxidant</style></keyword><keyword><style face="normal" font="Arial"> Antibacterial</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> degranulation</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Ethanol</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> IL-1+¦</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Piper nigrum</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat peritoneal mast cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> Th1/Treg</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2/Th17</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> TNF-+¦</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Treg cells</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0008-8749</style></isbn><abstract><style face="normal" font="Arial">Piper nigrum (Piperaceae) is commonly used as a spice and traditional medicine in many countries. P. nigrum has been reported to have anti-oxidant, anti-bacterial, anti-tumor, anti-mutagenic, anti-diabetic, and anti-inflammatory properties. However, the effect of P. nigrum on allergic asthma has not been known. This study investigated the effect of P. nigrum ethanol extracts (PNE) on airway inflammation in asthmatic mice model. In the ovalbumin (OVA)-induced allergic asthma model, we analysed the number of inflammatory cells and cytokines production in bronchoalveolar lavage fluid (BALF) and lung tissue; histological structure; as well as the total immunoglobulin (Ig)E, anti-OVA IgE, anti-OVA IgG1 and histamine levels in serum. The oral administration (200</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç»mg/kg) of PNE reduced the accumulation of inflammatory cells (eosinophils, neutrophils in BALF and mast cells in lung tissue); regulated the balance of the cytokines production of Th1, Th2, Th17 and Treg cells, specifically, inhibited the expressions of GATA3, IL-4, IL-6, IL-1+¦, ROR+¦t, IL-17A, TNF-+¦ and increased the secretions of IL-10, INF-+¦ in BALF and lung homogenate. Moreover, PNE suppressed the levels of total IgE, anti-OVA IgE, anti-OVA IgG1 and histamine release in serum. The histological analysis showed that the fibrosis and infiltration of inflammatory cells were also ameliorated in PNE treated mice. On the other hand, PNE inhibited the allergic responses via inactivation of rat peritoneal mast cells degranulation. These results suggest that PNE has therapeutic potential for treating allergic asthma through inhibiting Th2/Th17 responses and mast cells activation</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.cellimm.2017.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29066080">PM:29066080</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Immunol\20171030-BuiTT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Immunol\20171030-BuiTT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Bui TT</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.cellimm.2017.10.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tang,L.</style></author><author><style face="normal" font="Arial"> Chen,Q.</style></author><author><style face="normal" font="Arial"> Meng,Z.</style></author><author><style face="normal" font="Arial"> Sun,L.</style></author><author><style face="normal" font="Arial"> Zhu,L.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Hu,J.</style></author><author><style face="normal" font="Arial"> Ni,Z.</style></author><author><style face="normal" font="Arial"> Wang,X.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="Arial">Suppression of Sirtuin-1 Increases IL-6 Expression by Activation of the Akt Pathway During Allergic Asthma</style></title><secondary-title><style face="normal" font="Arial">Cell Physiol Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Cell Physiol Biochem</style></full-title></periodical><pages end="1960" start="1950">1950-1960</pages><volume><style face="normal" font="Arial">43</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> AKT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immunochemistry</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modulation</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Real-Time Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> suppression</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Traditional Chinese medicine</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/AIMS: A growing number of studies have demonstrated that the activity and expression level of sirtuin-1 (SIRT1) are decreased in asthma patients; however, the mechanisms underlying decreased SIRT1 expression and function are still not completely understood. Interleukin (IL)-6 plays important roles in inflammation during allergic asthma. In this study, we examined whether loss of SIRT1 activity regulated the expression of IL-6 and further verified the underlying mechanisms. METHODS: The human airway epithelial cell line 16HBE was used to test the effects of the SIRT1 inhibitor (salermide) on expression of IL-6. IL-6 mRNA and protein expression were assessed with real-time polymerase chain reaction (PCR), immunochemistry, and ELISA. OVA-challenged mice were used as an asthma model to investigate the effect of SIRT1 activation on IL-6 and relative Akt phosphorylation level. RESULTS: We found that inhibition of SIRT1 increased IL-6 mRNA and protein levels in a time-dependent manner, which was accompanied by increased Akt pathway activation in 16HBE cells. Furthermore activation of Akt showed upregulated expression of the IL-6 protein whereas Akt inhibitor, LY294002 or Akt siRNA significantly inhibited SIRT1-regulated IL-6 expression. Conversely, activation of SIRT1 inhibited Akt activation and IL-6 expression in an asthmatic mice model and 16HBE cells. CONCLUSION: Our results indicate the potential role of SIRT1 in regulating inflammation by modulation of IL-6 expression in an Akt-dependent manner during allergic asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20171022IS - 1421-9778 (Electronic)IS - 1015-8987 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1159/000484119</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29055943">PM:29055943</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Cell Physiol Biochem\2017-43-1950-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Cell Physiol Biochem\2017-43-1950-60.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171022, Tang L</style></custom2><misc3><style face="normal" font="Arial">10.1159/000484119</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Aydin,E.</style></author><author><style face="normal" font="Arial"> Beser,O.F.</style></author><author><style face="normal" font="Arial"> Ozek,E.</style></author><author><style face="normal" font="Arial"> Sazak,S.</style></author><author><style face="normal" font="Arial"> Duras,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatric Surgery, Bahcelievler State Hospital, Kocasinan Karadeniz Mah. No. 48 Bahcelievler, Istanbul 34186, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Is There a Causal Relationship between Intussusception and Food Allergy?</style></title><secondary-title><style face="normal" font="Arial">Children (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Children (Basel)</style></abbr-1></periodical><pages end="" start="E89">E89-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> non-allergic</style></keyword><keyword><style face="normal" font="Arial"> Nutrition</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Recurrence</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Societies</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="Arial">Although intussusception and food allergy are common health problems in childhood, the relation between these two diseases remain obscure. The aim of this study is to investigate the relationship between food allergy and intussusception, and the factors associated with both. Patients diagnosed with intussusception by the Brighton Collaboration Intussusception Working Group criteria were prospectively investigated for food allergy per the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Guideline. They were analyzed per demographic features, clinical, physical and laboratory findings. There were eight (38.1%) patients diagnosed with food allergy, while 13 (61.9%) patients were non-allergic. The mean number of days of presenting symptoms was 1.13 days in the allergy group and 7.85 days in the non-allergy group. The mean number of intussusception attacks was 1.63 in the allergy group while 1 in the non-allergy group (p &lt; 0.05, relative risk (RR) = 2.6). In the allergy group, one (13%) patient was followed up, six (75%) patients were reduced with pneumatic and one (13%) patient reduced manually. In the non-allergy group, four (31%) patients were followed up, six (46%) patients were reduced with pneumotic, one (7%) patient was reduced manually, and resection anastomosis was performed in two (15%) patients. Food allergy is an unrecognized associated factor for intussusception patients, which increases the risk for recurrence. Due to the small patient population, these results should be interpreted with caution</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 2227-9067 (Print)IS - 2227-9067 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.3390/children4100089</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29048383">PM:29048383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Children (Basel)\2017-4-E89.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Children (Basel)\2017-4-E89.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Aydin E</style></custom2><misc3><style face="normal" font="Arial">10.3390/children4100089</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Topic,E.</style></author><author><style face="normal" font="Arial"> Nikolac,N.</style></author><author><style face="normal" font="Arial"> Panteghini,M.</style></author><author><style face="normal" font="Arial"> Theodorsson,E.</style></author><author><style face="normal" font="Arial"> Salvagno,G.L.</style></author><author><style face="normal" font="Arial"> Miler,M.</style></author><author><style face="normal" font="Arial"> Simundic,A.M.</style></author><author><style face="normal" font="Arial"> Infusino,I.</style></author><author><style face="normal" font="Arial"> Nordin,G.</style></author><author><style face="normal" font="Arial"> Westgard,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">How to assess the quality of your analytical method?</style></title><secondary-title><style face="normal" font="Arial">Clin Chem Lab Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Chem Lab Med</style></full-title></periodical><pages end="1718" start="1707">1707-1718</pages><volume><style face="normal" font="Arial">53</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">assessment</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Chemistry,Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical chemistry</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cost</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Croatia</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Laboratory assays</style></keyword><keyword><style face="normal" font="Arial"> Laboratory medicine</style></keyword><keyword><style face="normal" font="Arial"> Limit of Detection</style></keyword><keyword><style face="normal" font="Arial"> Medical Laboratory Science</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Paper</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality and safety</style></keyword><keyword><style face="normal" font="Arial"> Quality Assurance,Health Care</style></keyword><keyword><style face="normal" font="Arial"> Quality control</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> standards</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Uncertainty</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> utilization</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword></keywords><dates><year Day="0" Month="10" Year="2015">2015/10</year></dates><abstract><style face="normal" font="Arial">Laboratory medicine is amongst the fastest growing fields in medicine, crucial in diagnosis, support of prevention and in the monitoring of disease for individual patients and for the evaluation of treatment for populations of patients. Therefore, high quality and safety in laboratory testing has a prominent role in high-quality healthcare. Applied knowledge and competencies of professionals in laboratory medicine increases the clinical value of laboratory results by decreasing laboratory errors, increasing appropriate utilization of tests, and increasing cost effectiveness. This collective paper provides insights into how to validate the laboratory assays and assess the quality of methods. It is a synopsis of the lectures at the 15th European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Continuing Postgraduate Course in Clinical Chemistry and Laboratory Medicine entitled "How to assess the quality of your method?" (Zagreb, Croatia, 24-25 October 2015). The leading topics to be discussed include who, what and when to do in validation/verification of methods, verification of imprecision and bias, verification of reference intervals, verification of qualitative test procedures, verification of blood collection systems, comparability of results among methods and analytical systems, limit of detection, limit of quantification and limit of decision, how to assess the measurement uncertainty, the optimal use of Internal Quality Control and External Quality Assessment data, Six Sigma metrics, performance specifications, as well as biological variation. This article, which continues the annual tradition of collective papers from the EFLM continuing postgraduate courses in clinical chemistry and laboratory medicine, aims to provide further contributions by discussing the quality of laboratory methods and measurements and, at the same time, to offer continuing professional development to the attendees</style></abstract><notes><style face="normal" font="Arial">DA - 20151007IS - 1437-4331 (Electronic)IS - 1434-6621 (Linking)LA - engPT - Journal ArticleSB - IMCO - Croatia -CO - Sweden -CO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1515/cclm-2015-0869</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26408611">PM:26408611</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Chem Lab Med\2015-53-1707-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Chem Lab Med\2015-53-1707-18.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20151007, Topic E</style></custom2><misc3><style face="normal" font="Arial">10.1515/cclm-2015-0869</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cuello-Garcia,C.</style></author><author><style face="normal" font="Arial"> Fiocchi,A.</style></author><author><style face="normal" font="Arial"> Pawankar,R.</style></author><author><style face="normal" font="Arial"> Yepes-Nunez,J.J.</style></author><author><style face="normal" font="Arial"> Morgano,G.P.</style></author><author><style face="normal" font="Arial"> Zhang,Y.</style></author><author><style face="normal" font="Arial"> Agarwal,A.</style></author><author><style face="normal" font="Arial"> Gandhi,S.</style></author><author><style face="normal" font="Arial"> Terracciano,L.</style></author><author><style face="normal" font="Arial"> Schunemann,H.J.</style></author><author><style face="normal" font="Arial"> Brozek,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Prebiotics for the prevention of allergies: A systematic review and meta-analysis of randomized controlled trials</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="1477" start="1468">1468-1477</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Colombia</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food ingredients</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Growth rate</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> Meta-Analysis</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microflora</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prebiotic</style></keyword><keyword><style face="normal" font="Arial"> prebiotics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Prevalence of allergic diseases in infants is approximately 10% reaching 20 to 30% in those with an allergic first-degree relative. Prebiotics are selectively fermented food ingredients that allow specific changes in composition/activity of the gastrointestinal microflora. They modulate immune responses, and their supplementation has been proposed as an intervention to prevent allergies. OBJECTIVE: To assess in pregnant women, breastfeeding mothers, and infants (populations) the effect of supplementing prebiotics (intervention) versus no prebiotics (comparison) on the development of allergic diseases and to inform the World Allergy Organization guidelines. METHODS: We performed a systematic review of studies assessing the effects of prebiotic supplementation with an intention to prevent the development of allergies. RESULTS: Of 446 unique records published until November 2016 in Cochrane, MEDLINE, and EMBASE, 22 studies fulfilled a priori specified criteria. We did not find any studies of prebiotics given to pregnant women or breastfeeding mothers. Prebiotic supplementation in infants, compared to placebo, had the following effects: risk of developing eczema (RR: 0.68, 95% CI: 0.40 to 1.15), wheezing/asthma (RR, 0.37; 95% CI: 0.17 to 0.80), and food allergy (RR: 0.28, 95% CI: 0.08 to 1.00). There was no evidence of an increased risk of any adverse effects (RR: 1.01, 95% CI: 0.92 to 1.10). Prebiotic supplementation had little influence growth rate (MD: 0.92 g per day faster with prebiotics, 95% CI: 0 to 1.84) and the final infant weight (MD: 0.10 kg higher with prebiotics, 95% CI: -0.09 to 0.29). The certainty of these estimates is very low due to risk of bias and imprecision of the results. CONCLUSIONS: Currently available evidence on prebiotic supplementation to reduce the risk of developing allergies is very uncertain</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Italy -CO - Japan -CO - Colombia -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035013">PM:29035013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-1468-77.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\2017-47-1468-77.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Cuello-Garcia C</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fukuyama,T.</style></author><author><style face="normal" font="Arial"> Martel,B.C.</style></author><author><style face="normal" font="Arial"> Linder,K.</style></author><author><style face="normal" font="Arial"> Ehling,S.</style></author><author><style face="normal" font="Arial"> Ganchingco,J.R.</style></author><author><style face="normal" font="Arial"> Baumer,W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, NC, USA</style></auth-address><titles><title><style face="normal" font="Arial">Hypochlorous acid is anti-pruritic and anti-inflammatory in a mouse model of atopic dermatitis</style></title><secondary-title><style face="normal" font="Arial">Clin Exp Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Clin Exp Allergy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> anti-inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Antiinflammatory</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Betamethasone</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> dorsal root ganglia</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergen</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Itch</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mice model</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga</style></keyword><keyword><style face="normal" font="Arial"> NC/Nga mice</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pruritogens</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: It has been reported that topical hypochlorous acid (HOCl) formulations lead to relief of itch in human patients with atopic dermatitis, however the specific anti-pruritic mechanism of action remains unclear. OBJECTIVE: To confirm itch relief and reduction of lesions in a mouse model of atopic dermatitis and to elucidate possible HOCl's mode of action. METHODS: In this study, the effects of topical administration of HOCl hydrogel (0.05%) on atopic dermatitis-like lesions in NC/Nga mice model as well as in vitro effects of HOCl on dorsal root ganglia neurons and mouse bone marrow derived dendritic cells (mBMDC) were investigated. NC/Nga mice were sensitized with house dust mite allergen and treated topically with HOCl hydrogel both preventively as well as therapeutically against established lesions. Allergen challenge was continued during HOCl hydrogel application. RESULTS: Treatment with HOCl hydrogel prevented the development of lesions and scratching bouts during the whole observation period. When administered after full development of lesions, HOCl reduced lesions and scratching behaviour to a similar extent as a positive control 0.1% betamethasone dipropionate ointment. The reduced inflammatory response by HOCl treatment was demonstrated by reduced secretion of inflammatory cytokines in affected skin tissue from NC/Nga mice. In addition, HOCl significantly reduced IL-12 production in mBMDC. The diminished scratching behaviour was confirmed by impaired response to several pruritogens in dorsal root ganglia neurons excised from NC/Nga mice after termination of the studies. The response to the stimuli was also reduced by pre-incubation of sensory neurons from untreated BALB/c mice with 0.0001% HOCl. CONCLUSIONS AND CLINICAL RELEVANCE: These data indicate a direct reduction of sensory response by HOCl, leading to significantly reduced itch and inflammation in vivo. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171013IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/cea.13045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29028288">PM:29028288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20171013-FukuyamaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20171013-FukuyamaT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171013, Fukuyama T</style></custom2><misc3><style face="normal" font="Arial">10.1111/cea.13045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lee,C.C.</style></author><author><style face="normal" font="Arial"> Lin,C.L.</style></author><author><style face="normal" font="Arial"> Leu,S.J.</style></author><author><style face="normal" font="Arial"> Lee,Y.L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Overexpression of Notch ligand Delta-like-1 by dendritic cells enhances their immunoregulatory capacity and exerts antiallergic effects on Th2-mediated allergic asthma in mice</style></title><secondary-title><style face="normal" font="Arial">Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adenovirus</style></keyword><keyword><style face="normal" font="Arial"> Adoptive Transfer</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Antigen presenting cells</style></keyword><keyword><style face="normal" font="Arial"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="Arial"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Delta-like-1</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Notch</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH1 cell</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1521-6616</style></isbn><abstract><style face="normal" font="Arial">Dendritic cells (DCs) are professional antigen-presenting cells, and Notch ligand Delta-like-1 (DLL1) on DCs was implicated in type 1 T helper (Th1) differentiation. In this study, we produced genetically engineered bone marrow-derived DCs that expressed DLL1 (DLL1-DCs) by adenoviral transduction. DLL1-DCs exerted a fully mature phenotype, and had positive effects on expression levels of interleukin (IL)-12 and costimulatory molecules. Coculture of allogeneic T cells with ovalbumin (OVA)-pulsed DLL1-DCs enhanced T cell proliferative responses and promoted Th1 cell differentiation. Furthermore, adoptive transfer of OVA-stimulated DLL1-DCs into asthmatic mice alleviated the cardinal features of allergic asthma, including immunoglobulin E (IgE) production, airway hyperresponsiveness (AHR), airway inflammation, and production of Th2-type cytokines. Notably, enhanced levels of the Th1-biased IgG2a response and interferon (IFN)-+¦ production were observed in these mice. Taken together, these data indicate that DLL1-DCs promoted Th1 cell development to alter the Th1/Th2 ratio and ameliorate Th2-mediated allergic asthma in mice</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.clim.2017.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038036">PM:29038036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Immunol\20171030-LeeCC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Immunol\20171030-LeeCC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Lee CC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.clim.2017.10.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,L.</style></author><author><style face="normal" font="Arial"> Ke,X.</style></author><author><style face="normal" font="Arial"> Kavati,A.</style></author><author><style face="normal" font="Arial"> Wertz,D.</style></author><author><style face="normal" font="Arial"> Huang,Q.</style></author><author><style face="normal" font="Arial"> Willey,V.J.</style></author><author><style face="normal" font="Arial"> Stephenson,J.J.</style></author><author><style face="normal" font="Arial"> Ortiz,B.</style></author><author><style face="normal" font="Arial"> Paknis,B.</style></author><author><style face="normal" font="Arial"> Bernstein,J.A.</style></author><author><style face="normal" font="Arial"> Beck,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a HealthCore, Inc. , Wilmington , DE</style></auth-address><titles><title><style face="normal" font="Arial">Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria</style></title><secondary-title><style face="normal" font="Arial">Curr Med Res Opin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Res Opin</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> CIU</style></keyword><keyword><style face="normal" font="Arial"> Claims data</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Documentation</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Dosing</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eligibility</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To examine treatment patterns, treatment response, and demographic and clinical characteristics of patients with chronic idiopathic urticaria (CIU) newly initiated on omalizumab therapy in real-world practice in the United States. METHODS: This retrospective observational cohort study used US claims data from the HealthCore Integrated Research Database (HIRD(R)) augmented with medical record data to identify CIU patients newly treated with omalizumab (>/=4 omalizumab claims within 6 months of initial claim; index date = first omalizumab claim date) between March 21, 2014 and October 31, 2015 and with >/=6 months pre- and >/=12 months post-index health plan eligibility. Study outcomes were captured from medical records for up to 12 months pre-index and up to 24 months post-index. Descriptive statistics were reported. RESULTS: This study consisted of 88 patients with a mean (SD) age of 43.4 (+/-13.46) years, 68.2% were female, and 36 patients had >/=18 months post-index eligibility. Among 69 patients with documented index dose, 75.4% received omalizumab 300 mg and 69.6% remained on index dose throughout follow-up. For 52 patients with documented index dosing frequency, 96.2% had every 4-week dosing frequency. Among 86 patients with omalizumab documentation, 83.7% reported CIU improvement after omalizumab initiation and 24.4% discontinued omalizumab. For all patients, the proportion using oral corticosteroids (OCS) decreased pre- to post-index (52.3% vs. 39.8%). Similar results were observed for patients with >/=18 months post-index eligibility. CONCLUSIONS: In this real-world analysis, the majority of patients remained on omalizumab for >/=12 months, and had a positive response. OCS use decreased following omalizumab initiation</style></abstract><notes><style face="normal" font="Arial">DA - 20171024IS - 1473-4877 (Electronic)IS - 0300-7995 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/03007995.2017.1395732</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064325">PM:29064325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Med Res Opin\20171024-WangL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Med Res Opin\20171024-WangL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171024, Wang L</style></custom2><misc3><style face="normal" font="Arial">10.1080/03007995.2017.1395732</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Corren,J.</style></author><author><style face="normal" font="Arial"> Kavati,A.</style></author><author><style face="normal" font="Arial"> Ortiz,B.</style></author><author><style face="normal" font="Arial"> Vegesna,A.</style></author><author><style face="normal" font="Arial"> Colby,J.A.</style></author><author><style face="normal" font="Arial"> Ruiz,K.</style></author><author><style face="normal" font="Arial"> Panettieri,R.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a David Geffen School of Medicine at UCLA , Los Angeles , CA (10780 Santa Monica Blvd., Suite 280, Los Angeles, CA, USA 90025)</style></auth-address><titles><title><style face="normal" font="Arial">Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials</style></title><secondary-title><style face="normal" font="Arial">Curr Med Res Opin</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Med Res Opin</style></full-title></periodical><pages end="37" start="1">1-37</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> health-related quality of life</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> literature review</style></keyword><keyword><style face="normal" font="Arial"> Los Angeles</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> moderate-to-severe persistent allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcome assessment</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcome</style></keyword><keyword><style face="normal" font="Arial"> patient-reported outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Persistent asthma</style></keyword><keyword><style face="normal" font="Arial"> placebo</style></keyword><keyword><style face="normal" font="Arial"> productivity</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> work productivity</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Randomized controlled trials (RCTs) have established the safety and efficacy of omalizumab on clinical parameters, and have also evaluated its impact on patient-reported outcomes (PROs). The purpose of this systematic literature review was to review published data based on PRO endpoints in order to determine the benefit of omalizumab as add-on therapy to inhaled corticosteroids in patients with moderate-to-severe persistent allergic asthma. METHODS: A systematic literature review was conducted of reference databases and recent conferences. RCTs of add-on omalizumab therapy in adults, adolescents, and children with moderate-to-severe persistent asthma were included. Two researchers independently screened and reviewed articles with regards to inclusion and exclusion criteria for relevant studies. RESULTS: Twenty-six trials met the criteria for inclusion. Of these, PRO measures were included in 19 trials to capture the impact of omalizumab on symptoms, 11 assessed patients for health-related quality of life (HRQoL), and 4 evaluated asthma control. Other PROs related to global evaluation of treatment effectiveness and work productivity. Overall, results demonstrated a significant difference across most PROs in favor of omalizumab add-on therapy versus placebo or comparators. CONCLUSIONS: PROs are an integral part of outcome assessment in clinical trials related to asthma. The RCTs reviewed demonstrate that omalizumab treatment improves PROs in patients with moderate-to-severe persistent allergic asthma, particularly symptom control and HRQoL</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1473-4877 (Electronic)IS - 0300-7995 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1080/03007995.2017.1395734</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057669">PM:29057669</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Med Res Opin\20171023-CorrenJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Med Res Opin\20171023-CorrenJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Corren J</style></custom2><misc3><style face="normal" font="Arial">10.1080/03007995.2017.1395734</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wiesner,D.L.</style></author><author><style face="normal" font="Arial"> Klein,B.S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Lung epithelium: barrier immunity to inhaled fungi and driver of fungal-associated allergic asthma</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Microbiol</style></full-title></periodical><pages end="13" start="8">8-13</pages><volume><style face="normal" font="Arial">40</style></volume><number><style face="normal" font="Arial">Supplement C</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal infection</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Penetration</style></keyword><keyword><style face="normal" font="Arial"> Protective immunity</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1369-5274</style></isbn><abstract><style face="normal" font="Arial">Fungi are ubiquitous in the environment. The epithelium that lines our airways is the first point of contact with the frequent encounter of inhaled fungi. Consequently, the lung epithelium has evolved behaviors that instruct the earliest immune events to resist fungal penetration. Although the epithelium efficiently assists in immunity to invasive fungi, it also can be inappropriately triggered, to the detriment of the host, by normally innocuous fungi or fungal components. Thus, there is a tipping point of protective immunity against fungal pathogens versus inflammatory disease caused by an exuberant immune response to harmless fungal antigens. This review will discuss several aspects of barrier immunity to pulmonary fungal infection, as well as situations where fungal exposure leads to allergic asthma</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.mib.2017.10.007</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.mib.2017.10.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Microbiol\2017-40SC-8-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Microbiol\2017-40SC-8-13.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Wiesner DL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.mib.2017.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Parulekar,A.D.</style></author><author><style face="normal" font="Arial"> Kao,C.C.</style></author><author><style face="normal" font="Arial"> Diamant,Z.</style></author><author><style face="normal" font="Arial"> Hanania,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">aSection of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas, USA bDepartment of Respiratory Medicine and Allergology, Skane University Hospital, Lund, Sweden cDepartment of Clinical Pharmacy and Pharmacology dDepartment of General Practice and QPS-NL, Groningen, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs</style></title><secondary-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Curr Opin Pulm Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dupilumab</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> exacerbations</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> General practice</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-4 receptor</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Long-term efficacy</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> periostin</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> Sweden</style></keyword><keyword><style face="normal" font="Arial"> Targeted therapy</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="Arial">PURPOSE OF REVIEW: Severe asthma is a heterogeneous disease that can be classified into phenotypes and endotypes based upon clinical or biological characteristics. Interleukin (IL)-4 and IL-13 play a key role in type 2 (T2) asthma. This article reviews the signaling pathway of IL-4 and IL-13 and highlights its targeted therapy in severe asthma. RECENT FINDINGS: Several clinical trials of biologics targeting the IL-4/IL-13 pathway have recently been completed. In patients with severe, uncontrolled asthma, targeting IL-13 alone with biologics including lebrikizumab and tralokinumab has not shown consistent reduction in asthma exacerbations. Simultaneous targeting of both IL-4 and IL-13 by blocking IL-4 receptor alpha using dupilumab has yielded more consistent results in reducing asthma exacerbations and improving lung function, especially in patients with increased blood eosinophils. Other biomarkers of T2 inflammation such as exhaled nitric oxide and serum periostin may also predict response to biologics targeting the IL-4/IL-13 pathway. SUMMARY: No biologic targeting the IL-4/IL-13 pathway is currently available for treatment of asthma, but emerging data suggest that biologics targeting IL-4 and IL-13 together may benefit patients with T2 high asthma. Additional data are needed about long-term efficacy and safety prior to incorporating these drugs into routine clinical practice</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1097/MCP.0000000000000436</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29036019">PM:29036019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Pulm Med\20171016-ParulekarAD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Pulm Med\20171016-ParulekarAD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Parulekar AD</style></custom2><misc3><style face="normal" font="Arial">10.1097/MCP.0000000000000436</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Duba,A.</style></author><author><style face="normal" font="Arial"> Goriewa,K.</style></author><author><style face="normal" font="Arial"> Wachowska,U.</style></author><author><style face="normal" font="Arial"> Wiwart,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Entomology, Phytopathology and Molecular Diagnostics, University of Warmia and Mazury in Olsztyn, Prawochenskiego 17, 10-719, Olsztyn, Poland</style></auth-address><titles><title><style face="normal" font="Arial">Alternaria alternata (Fr.) Keissl with mutation G143A in the Cyt b gene is the source of a difficult-to-control allergen</style></title><secondary-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Environ Sci Pollut Res Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Alt a 1</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> Alternaria alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternaria-alternata</style></keyword><keyword><style face="normal" font="Arial"> Alternata</style></keyword><keyword><style face="normal" font="Arial"> Codon</style></keyword><keyword><style face="normal" font="Arial"> Cyt b</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Entomology</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Molecular diagnostic</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> winter</style></keyword></keywords><dates><year Day="18" Month="10" Year="2017">2017/10/18</year></dates><abstract><style face="normal" font="Arial">The saprotrophic fungus Alternaria alternata is widespread in the agro-environment and produces more than ten allergenic proteins, mostly protein Alt a 1. The frequency of the Alt a 1 gene was analyzed in a group of A. alternata isolates from winter wheat kernels obtained in Poland, and the effectiveness of various fungicides targeting the pathogen was evaluated. The Alt a 1 gene was identified in four of the seven tested isolates. A. alternata colonized 35.67% kernels on average, but its frequency increased in stored grain where the presence of epiphytes was noted on 23.09 to 51.38% kernels, and endophytes-in 26.21 to 42.01% of kernels. The efficacy of field-applied fungicides did not exceed 50%, despite the fact that A. alternata is highly sensitive to propiconazole, fenpropimorph, and tebuconazole under in vitro conditions. The analyzed isolates were characterized by limited sensitivity to azoxystrobin (EC50 ranged from 0.505 to 1.350 mug cm-3) due to a mutation at codon 143 of the CYT b gene, responsible for resistance to quinone outside inhibitor fungicides, which was noted in all isolates. The spread of A. alternata can be effectively controlled with suitable fungicides and by monitoring the prevalence of pathogenic isolates in the environment</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1614-7499 (Electronic)IS - 0944-1344 (Linking)LA - engPT - Journal ArticleCO - POland -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11356-017-0426-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29043591">PM:29043591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20171018-DubaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Environ Sci Pollut Res Int\20171018-DubaA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Duba A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11356-017-0426-z</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dogan,R.</style></author><author><style face="normal" font="Arial"> Aksoy,F.</style></author><author><style face="normal" font="Arial"> Goktas,S.S.</style></author><author><style face="normal" font="Arial"> Kocak,I.</style></author><author><style face="normal" font="Arial"> Yildirim,Y.S.</style></author><author><style face="normal" font="Arial"> Incir,S.</style></author><author><style face="normal" font="Arial"> Ozturan,O.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Bezmialem Vakif University, Fatih, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Effect of nasal antihistamine on secretory IgA in nasal lavage of rats</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> humoral</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Insulin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Irrigation</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Water</style></keyword></keywords><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="Arial">The humoral IgA is an immunoglobulin which plays a defensive role for organisms on mucosal surfaces. Today, intranasal antihistamines are effectively used in the treatment of allergic rhinitis. In our study, the effect of azelastine hydrochloride-a nasal antihistaminic-on humoral IgA of the nasal mucosa has been reviewed empirically. Twenty-four female Sprague-Dawley rats were included in our study. The rats were divided into three groups randomly. Group 1(azelastine hydrochloride): rats in this group had nasal azelastine hydrochloride (0.05%) applied for 30 days at 10 microl/nostril dosage. Group 2 (saline): saline (0.09%) was applied to the rats in this group for 30 days at 10 microl/nostril dosage. Group 3 (control): no application was made throughout the study. The chemicals applied in Groups 1 and 2 were applied to both nostrils by mounting a flexible micropipette to the end of an insulin injector. At the beginning of the study, nasal lavage was performed to both nostrils of the rats in every group on the 15th and 30th day to aspirate irrigation solution (distilled water). The aspirated liquids were kept at - 80 degrees temperature and reviewed together at the end of study. Within-group comparisons: in Group 1 (azelastine hydrochloride), the humoral IgA value on the 15th day was significantly higher than the basal value (p = 0.037). There is a significant difference between humoral IgA value on the 30th day and humoral IgA value on the 15th day (p = 0.045). In Group 2 (saline), no significant difference is available between basal, 15th day and 30th day humoral IgA values (p = 0.265). In Group 3 (control), no significant difference is available between basal, 15th day and 30th day humoral IgA values (p = 0.374). Between-group comparison: there is no significant difference in between-group humoral IgA basal values (p = 0.714). On days 15 and 30, Humoral IgA value of Group 1 was significantly higher than that of Groups 2 and 3 (p = 0.013, p = 0.024, respectively). According to the results we achieved in our study, nasal antihistaminic (azelastine hydrochloride) significantly increases the level of humoral IgA. Our study is the first one in the literature to reveal a relation between nasal antihistaminic and humoral IgA and there is a further need for clinical, randomized and prospective studies</style></abstract><notes><style face="normal" font="Arial">DA - 20171020IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4750-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29052012">PM:29052012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20171020-DoganR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20171020-DoganR.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171020, Dogan R</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4750-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Senturk,E.</style></author><author><style face="normal" font="Arial"> Yildirim,Y.S.</style></author><author><style face="normal" font="Arial"> Dogan,R.</style></author><author><style face="normal" font="Arial"> Ozturan,O.</style></author><author><style face="normal" font="Arial"> Guler,E.M.</style></author><author><style face="normal" font="Arial"> Aydin,M.S.</style></author><author><style face="normal" font="Arial"> Kocyigit,A.</style></author><author><style face="normal" font="Arial"> Esrefoglu,M.</style></author><author><style face="normal" font="Arial"> Kocak,I.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Alaca State Hospital, Alaca, Corum, Turkey.</style></auth-address><titles><title><style face="normal" font="Arial">Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Eur Arch Otorhinolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Cyclosporine</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Goblet Cells</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-17A</style></keyword><keyword><style face="normal" font="Arial"> IL-2</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Interferon</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> rat model</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> TNF</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tumor Necrosis Factor</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="Arial">The aim of this study is to show if cyclosporine has an antiallergic role in a rat model of ovalbumin-induced allergic rhinitis. The 54 rats were divided into six equal groups. The first group was a negative control group without induced allergic rhinitis; the second group a positive control with induced allergic rhinitis not receiving treatment. The remaining four groups, after induction of allergic rhinitis, received intranasal cyclosporine treatment in doses of 0.05, 0.1, or 0.2% or nasal steroid treatment. In the biochemical examination, on the surface of the tissue tumor necrosis factor (TNF) interferon (IFN), interleukin (IL)-5, IL-13, as well as IL-2, IL-4, IL-17A, and IgE were studied. Histologically, ciliary loss, increase of goblet cells, vascular congestion, and the degree of eosinophil infiltration were rated. In all treatment groups, on average, a significant reduction in all histological and biochemical values was found compared to the positive control group. Comparing each of the three cyclosporine-using groups with the group of nasal corticosteroid did not show any significant difference in the average scores. Cyclosporine nasal drops are effective to be used in an animal model of experimental allergic rhinitis without systemic effects</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00405-017-4786-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29071443">PM:29071443</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20171026-SenturkE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur Arch Otorhinolaryngol\20171026-SenturkE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Senturk E</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00405-017-4786-2</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kostadinova,A.I.</style></author><author><style face="normal" font="Arial"> Middelburg,J.</style></author><author><style face="normal" font="Arial"> Ciulla,M.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Hennink,W.E.</style></author><author><style face="normal" font="Arial"> Knippels,L.M.J.</style></author><author><style face="normal" font="Arial"> van Nostrum,C.F.</style></author><author><style face="normal" font="Arial"> Willemsen,L.E.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584CG Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">PLGA nanoparticles loaded with beta-lactoglobulin-derived peptides modulate mucosal immunity and may facilitate cow's milk allergy prevention</style></title><secondary-title><style face="normal" font="Arial">Eur J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Eur J Pharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acute allergic skin response</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy prevention</style></keyword><keyword><style face="normal" font="Arial"> Beta-Lactoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Bone Marrow</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD40</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IL-12</style></keyword><keyword><style face="normal" font="Arial"> IL-6</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucosal immunity</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticle</style></keyword><keyword><style face="normal" font="Arial"> Nanoparticles</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Oral sensitization</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> PLGA</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"> Whey protein</style></keyword></keywords><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="Arial">Beta-lactoglobulin (BLG)-derived peptides may facilitate oral tolerance to whey and prevent cow's milk allergy (CMA). Loading of BLG-peptides in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Pep-NP) may improve this. Here we studied the uptake of NP and the capacity of NP and Pep-NP to activate bone marrow dendritic cells (BMDC). Furthermore, CMA prevention was evaluated by orally exposing three-week-old female C3H/HeOuJ mice to Pep-NP, NP or free peptides (PepMix) for 6 days before oral sensitization with whole whey protein and effects on the spleen and small intestine lamina propria (SI-LP) were studied. In BMDC, NP and Pep-NP enhanced CD40 expression and IL-6 and TNF-alpha secretion, while tended to decrease CD80 expression and prevented PepMix-induced IL-12 secretion. In vivo, oral exposure to Pep-NP, but not NP or PepMix, prior to whey sensitization tended to partially prevent the acute allergic skin response to whole whey protein. Splenocytes of NP-pre-exposed mice secreted increased levels of whey specific IL-6, but this was silenced in Pep-NP-pre-exposed mice which also showed reduced TNF-alpha and IFN-gamma secretion. In the SI-LP, Pep-NP pre-exposure reduced the CD4+ T cell frequency in CMA mice compared to PBS pre-exposure. In addition, while NP increased whey-specific IL-6 secretion in the SI-LP, Pep-NP did not and maintained regulatory TGF-beta secretion. This study presents a proof-of-concept that PLGA nanoparticles facilitate the capacity of BLG peptides to suppress the allergic response to whole whey protein. Hence, PLGA nanoparticles may be further developed as an adjunct strategy for BLG-peptide-based oral tolerance induction and CMA prevention</style></abstract><notes><style face="normal" font="Arial">DA - 20171028IS - 1879-0712 (Electronic)IS - 0014-2999 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ejphar.2017.10.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29079360">PM:29079360</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Eur J Pharmacol\20171028-KostadinovaAI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Eur J Pharmacol\20171028-KostadinovaAI.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Kostadinova AI</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ejphar.2017.10.051</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wang,X.</style></author><author><style face="normal" font="Arial"> Zhu,Y.</style></author><author><style face="normal" font="Arial"> Ni,D.</style></author><author><style face="normal" font="Arial"> Lv,W.</style></author><author><style face="normal" font="Arial"> Gao,Z.</style></author><author><style face="normal" font="Arial"> Qi,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Intranasal application of glucocorticoid alleviates olfactory dysfunction in mice with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="3978" start="3971">3971-3978</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal model</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Betamethasone</style></keyword><keyword><style face="normal" font="Arial"> Budesonide</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> incidence rate</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Intranasal</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Olfactory Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">The aim of the present study was to investigate the effect of glucocorticoid intervention on olfactory dysfunction in mice with allergic rhinitis (AR). An AR animal model was established by intraperitoneal injection and intranasal application of ovalbumin to mice. The olfactory function of the mice was evaluated using a buried food test, and morphological changes in the nasal mucosa were determined using hematoxylin and eosin staining. The expression of olfactory marker protein (OMP) in the olfactory mucosa was tested by immunohistochemistry, and was observed on days 7 and 14 after the application of glucocorticoid. The incidence rate of olfactory dysfunction in AR mice was 75.34%, and the olfactory epithelium became thinner in mice with AR compared to the control group. In addition, the expression of OMP in the olfactory epithelium was downregulated in mice with AR compared with the control group. Expression of OMP in the olfactory epithelium was upregulated in the budesonide group A and betamethasone group A compared with the medicine-free group, whereas the expression of OMP in the olfactory epithelium of budesonide group A or betamethasone group A was not significantly different from the control group. Moreover, the expression of OMP in the budesonide group B was similar to budesonide group A, and expression of OMP in betamethasone group B was similar to betamethasone group A. The expression of OMP in olfactory mucosa is downregulated in AR mice with olfactory dysfunction. Following the application of glucocorticoid, the expression of OMP in the olfactory mucosa in mice is upregulated. Moreover, intranasal local glucocorticoid has a low incidence of systemic adverse reactions, and is recommended for the treatment of olfactory dysfunction in AR</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.5042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29075337">PM:29075337</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-14-3971-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-14-3971-8.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Wang X</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.5042</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,Z.Y.</style></author><author><style face="normal" font="Arial"> Zhou,S.H.</style></author><author><style face="normal" font="Arial"> Zhou,Q.F.</style></author><author><style face="normal" font="Arial"> Tang,H.B.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China</style></auth-address><titles><title><style face="normal" font="Arial">Inflammation and airway remodeling of the lung in guinea pigs with allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">Exp Ther Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Exp Ther Med</style></full-title></periodical><pages end="3490" start="3485">3485-3490</pages><volume><style face="normal" font="Arial">14</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> airways</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> guinea pig</style></keyword><keyword><style face="normal" font="Arial"> Guinea Pigs</style></keyword><keyword><style face="normal" font="Arial"> Hematoxylin</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> pig</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> total symptom score</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="Arial">Allergic rhinitis (AR) and asthma belong to the category of type I allergic diseases, whose pathological features are airway remodeling of the lung and allergic inflammation. The aim of the present study was to evaluate inflammation and remodeling of lung tissue in a guinea pig model of AR in order to confirm consistent pathological changes of upper and lower airways in AR. Male guinea pigs were randomly divided into an experimental and a control group (n=10 in each). The AR model was established by sensitization through intraperitoneal injection of ovalbumin for three weeks and bilateral nasal local excitation for twelve weeks. All tissues of nasal mucosa and lung were subjected to hematoxylin and eosin as well as toluidine blue staining, and characteristics of remodeling of lung tissue, including thickness of bronchial wall, epithelial mucosa and smooth muscle were histologically determined. Collagen deposition in lung tissue was observed by Masson's trichrome stain. Severe paroxysmal nose scratching action, frequent sneezing, visible outflow of secretion from the anterior naris and frequent nose friction were observed in the AR model group within 30 min after local excitation. The total symptom scores were significantly increased in the AR model group compared with those in the control group. Obvious inflammatory cell infiltration was observed in the AR model group. Compared with those in the control group, the numbers of eosinophils and mast cells in nasal mucosa and lung tissue were significantly increased. Obvious airway remodeling of the lung was observed in the AR model group. Compared with those in the control group, bronchial wall thickness, epithelial layer thickness and smooth muscle thickness in the airways were significantly increased in the AR model group. Increased collagen deposition was found in the AR model group compared with that in the control group. The results of the present study revealed that inflammation and airway remodeling of lungs arose in guinea pigs with AR, suggesting that pathological changes of upper and lower airways are consistent in this AR model</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3892/etm.2017.4937</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042937">PM:29042937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Ther Med\2017-14-3485-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Ther Med\2017-14-3485-90.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Chen ZY</style></custom2><misc3><style face="normal" font="Arial">10.3892/etm.2017.4937</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Devillier,P.</style></author><author><style face="normal" font="Arial"> Wahn,U.</style></author><author><style face="normal" font="Arial"> Zielen,S.</style></author><author><style face="normal" font="Arial"> Heinrich,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a UPRES EA 220, Hospital Foch , University Versailles Saint Quentin , Suresnes , France</style></auth-address><titles><title><style face="normal" font="Arial">Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis</style></title><secondary-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Expert Rev Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">AIT</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma progression</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> longitudinal</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prescription</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> progression</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research Design</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> SLIT</style></keyword><keyword><style face="normal" font="Arial"> SLIT-tablet</style></keyword><keyword><style face="normal" font="Arial"> sublingual</style></keyword><keyword><style face="normal" font="Arial"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> sublingual immunotherapy tablet</style></keyword><keyword><style face="normal" font="Arial"> tablet</style></keyword><keyword><style face="normal" font="Arial"> Tablets</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: We assessed real-world, long-term effectiveness of two marketed sublingual immunotherapy (SLIT) tablets for allergic rhinitis (AR), and their impact on allergic asthma (AA) onset/progression. RESEARCH DESIGN AND METHODS: Retrospective, longitudinal German prescription database subanalysis of AR patients receiving 5- or 1-grass pollen SLIT tablets (n=1,466/1,385), versus patients not using allergy immunotherapy (AIT) (n=71,275). MAIN OUTCOME MEASURES: Primary endpoint: change over time in AR symptomatic medication prescriptions after treatment cessation; secondary endpoints: new asthma onset, and change over time in asthma medication prescriptions during treatment/follow-up periods. RESULTS: Mean number of AR medication prescriptions was significantly decreased during follow-up (of up to 6 years) with both SLIT tablets versus the non-AIT group (p&lt;0.001). Over the full-analysis period, proportions of patients with new-onset asthma were 8.8% (odds ratio: 0.676, p=0.011), 10.3% (odds ratio: 0.720, p=0.060) and 11.6% in the 5- and 1-grass pollen SLIT tablet and non-AIT groups, respectively. For all treatment-analysis periods, both SLIT tablet groups were associated with fewer asthma medication prescriptions versus non-AIT controls. CONCLUSIONS: These findings confirm the real-world benefits of 5- and 1-grass-pollen SLIT tablets in slower AR progression, reduced risk of new asthma onset in the non-asthmatic population, and slower asthma progression in the asthmatic population</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - France -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1080/1744666X.2017.1398082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29072507">PM:29072507</url></web-urls><pdf-urls><url ppv-ref="no">p.devillier@hopital-foch.org</url></pdf-urls></urls><custom2><style face="normal" font="Arial">20171026, Devillier P</style></custom2><misc3><style face="normal" font="Arial">10.1080/1744666X.2017.1398082</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Durrani,S.</style></author><author><style face="normal" font="Arial"> Rothenberg,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati OH, 45529, USADivision of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati OH, 45529, USA</style></auth-address><titles><title><style face="normal" font="Arial">Recent advances in eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="Arial">F1000Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">F1000Res</style></full-title></periodical><pages end="" start="1775">1775-</pages><volume><style face="normal" font="Arial">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> association studies</style></keyword><keyword><style face="normal" font="Arial"> association study</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental risk factors</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="Arial"> epidemiologic study</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagus</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association</style></keyword><keyword><style face="normal" font="Arial"> genome-wide association studies</style></keyword><keyword><style face="normal" font="Arial"> Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Proton pump inhibitor</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> Scoring</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Topical corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> topical corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Eosinophilic esophagitis is a chronic, antigen-driven, eosinophil-predominant inflammatory disease of the esophagus and affects both children and adults. Cutting-edge technologies, such as genome-wide association studies, have advanced our understanding of the disease pathogenesis at a remarkable rate. Recent insights from genetic and mechanistic studies have concluded that a complex interplay between genetic and environmental risk factors, allergic sensitization, and esophageal-specific pathways leads to disease pathogenesis. Importantly, recent epidemiologic studies have found that the incidence and prevalence of eosinophilic esophagitis continue to rise. New guidelines have advocated the elimination of the term proton pump inhibitor (PPI)-responsive esophageal eosinophilia and have recommended using PPIs as a first-line treatment modality. Systemic reviews and meta-analyses confirm the efficacy of PPIs, topical corticosteroids, and empiric food elimination diets. Unmet needs include the development of birth cohort studies, validated diagnostic scoring systems, minimally invasive disease-monitoring methods, and the development of new therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 2046-1402 (Print)IS - 2046-1402 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.12688/f1000research.11798.1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29043074">PM:29043074</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\F1000Res\2017-6-1775.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\F1000Res\2017-6-1775.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Durrani S</style></custom2><misc3><style face="normal" font="Arial">10.12688/f1000research.11798.1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Eischeid,A.C.</style></author><author><style face="normal" font="Arial"> Stadig,S.R.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">A group-specific, quantitative real-time PCR assay for detection of crab, a crustacean shellfish allergen, in complex food matrices</style></title><secondary-title><style face="normal" font="Arial">Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Food Chem</style></abbr-1></periodical><pages end="231" start="224">224-231</pages><volume><style face="normal" font="Arial">244</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">12S rRNA gene</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> commercial food products</style></keyword><keyword><style face="normal" font="Arial"> crab</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustacean allergen</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Internal amplification control</style></keyword><keyword><style face="normal" font="Arial"> Method validation</style></keyword><keyword><style face="normal" font="Arial"> Mitochondria</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> qPCR</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real-Time PCR</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2018">2018/4/1</year></dates><isbn><style face="normal" font="Arial">0308-8146</style></isbn><abstract><style face="normal" font="Arial">A real-time PCR assay was developed for detection of crab, a crustacean allergen, in food products. Group-specific primers and probes were developed to detect numerous species of crab. Method validation included tests of detection in complex food matrices, evaluation of commercial food products, and cross-reactivity testing on a wide variety of crustaceans. The method was able to detect several species of crab spiked into complex food matrices at levels ranging from 0.1 to 105 parts per million (weight/weight), worked equally well on different platforms, exhibited high specificity for crab over other types of crustaceans, and yielded much higher signals from commercial food products listing crab as an ingredient than from those containing other crustaceans</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.foodchem.2017.10.045</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.foodchem.2017.10.045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem\2018-244-224-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem\2018-244-224-31.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Eischeid AC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.foodchem.2017.10.045</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arbeli,T.</style></author><author><style face="normal" font="Arial"> Liptz,Y.</style></author><author><style face="normal" font="Arial"> Bengiat,R.</style></author><author><style face="normal" font="Arial"> Levin-Elad,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Latent Fingerprint Laboratory, Division of Identification and Forensic Science (DIFS), Israel Police, National H.Q., Jerusalem, 9780204, Israel</style></auth-address><titles><title><style face="normal" font="Arial">Development of fingermarks on Latex gloves: The solution to a challenging surface</style></title><secondary-title><style face="normal" font="Arial">Forensic Sci Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Forensic Sci Int</style></full-title></periodical><pages end="152" start="147">147-152</pages><volume><style face="normal" font="Arial">280</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Amino acid</style></keyword><keyword><style face="normal" font="Arial"> Amino Acids</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Coating</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> crime</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Formulation</style></keyword><keyword><style face="normal" font="Arial"> Glove</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Intrinsic</style></keyword><keyword><style face="normal" font="Arial"> Israel</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Latent</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Latex Gloves</style></keyword><keyword><style face="normal" font="Arial"> Latex proteins</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Ninhydrin</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Petroleum</style></keyword><keyword><style face="normal" font="Arial"> Police</style></keyword><keyword><style face="normal" font="Arial"> Polymer coating</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> Protocols</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Techniques</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="28" Month="9" Year="2017">2017/9/28</year></dates><abstract><style face="normal" font="Arial">Used Latex gloves found at crime scenes can provide strong evidence against a suspect as they almost certainly contain both the fingermarks and DNA of the perpetrator who had worn them. However, over the years, Latex gloves have proved to be a rather difficult substrate for fingermarks development, with most of the standard techniques producing poor results. In this study, the two main protocols for development on either porous or non-porous surfaces: Ninhydrin-HFE and superglue fuming followed by crystal violet (CV) dyeing, respectively, had been examined on 100 disposable Latex gloves from twenty five donors. The results distinctly showed a high superiority of Ninhydrin-HFE over the superglue fuming indicating the porous rather than the non-porous properties of the interior of the gloves. Yet, not all the usual ninhydrin development formulations yielded the desirable results, leading to the conclusion that the success of development rests on the solvent-sensitive structure of the gloves. As natural latex contains contaminant proteins, that were found to cause allergic reactions in different people, the manufacturing of disposable gloves had been altered over the years to prevent contact with these proteins by adding an intrinsic polymer-coating. Thus, it was essential to use an inert solvent system that should keep the interior polymer-coating intact, allowing a reaction only with the amino acids on the surface rather than the latex proteins in the glove. The SEM analyses showed that HFE-7100 as opposed to petroleum ether, does not harm the inner coating, hence, providing the ideal solution to this challenging surface</style></abstract><notes><style face="normal" font="Arial">DA - 20171014IS - 1872-6283 (Electronic)IS - 0379-0738 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.forsciint.2017.09.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031159">PM:29031159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Forensic Sci Int\2017-280-147-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Forensic Sci Int\2017-280-147-52.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171014, Arbeli T</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.forsciint.2017.09.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kostadinova,A.I.</style></author><author><style face="normal" font="Arial"> Pablos-Tanarro,A.</style></author><author><style face="normal" font="Arial"> Diks,M.A.P.</style></author><author><style face="normal" font="Arial"> van Esch,B.C.A.M.</style></author><author><style face="normal" font="Arial"> Garssen,J.</style></author><author><style face="normal" font="Arial"> Knippels,L.M.J.</style></author><author><style face="normal" font="Arial"> Willemsen,L.E.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Dietary Intervention with +¦-Lactoglobulin-Derived Peptides and a Specific Mixture of Fructo-Oligosaccharides and Bifidobacterium breve M-16V Facilitates the Prevention of Whey-Induced Allergy in Mice by Supporting a Tolerance-Prone Immune Environment</style></title><secondary-title><style face="normal" font="Arial">Front Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Front Immunol</style></full-title></periodical><pages end="" start="1303">1303-</pages><volume><style face="normal" font="Arial">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acute allergic skin response</style></keyword><keyword><style face="normal" font="Arial"> adjuvant</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> bifidobacteria</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium</style></keyword><keyword><style face="normal" font="Arial"> Bifidobacterium breve</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Cholera Toxin</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> Cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk</style></keyword><keyword><style face="normal" font="Arial"> CowGÇÖs milk</style><style face="normal" font="Symbol"> </style><style face="normal" font="Arial">allergy</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> GATA3</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-22</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> oral challenge</style></keyword><keyword><style face="normal" font="Arial"> Oral sensitization</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Toxin</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Tregs</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> whey</style></keyword><keyword><style face="normal" font="Arial"></style><style face="normal" font="Arial"></style><style face="normal" font="Arial"> Whey protein</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1664-3224</style></isbn><abstract><style face="normal" font="Arial">Cow</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs milk allergy (CMA) prevails in infants and brings increased risk of developing other allergic diseases. Oral administration of specific +¦-lactoglobulin (BLG)-derived peptides (PepMix) and a specific blend of short- and long-chain fructo-oligosaccharides and Bifidobacterium breve M-16V (FF/Bb) was found to partially prevent CMA development in mice. In this study, we aimed to expand the knowledge on the preventive potential and the underlying mechanisms of this approach. Three-week-old female C3H/HeOuJ mice were orally exposed to PepMix -¦ FF/Bb prior to a 5-week oral sensitization with whole whey and cholera toxin as an adjuvant. The acute allergic skin response was determined after an intradermal challenge with whole whey protein. Following an oral challenge with whey, regulatory T cells (Tregs) in the small intestine lamina propria (SI-LP) and mRNA expression of immune markers in the Peyer</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇÖs patches (PP) were investigated. The early impact of PepMix and FF/Bb interventions on the immune system during the oral tolerance (OT) induction phase was investigated after the last OT administration. Pre-exposing mice to PepMix+FF/Bb partially prevented the acute allergic skin response compared to PBS and increased Tregs and activated T cells in the SI-LP compared to sham-sensitized mice. It also increased the mRNA expression of Tbet over GATA3 in the PP of whey-sensitized mice. Directly upon the 6-day OT phase, FF/Bb intervention enhanced caecal content levels of propionic and butyric acid in PepMix-fed mice and the former was positively correlated with Foxp3+ cell numbers in the colon. In the PP of PepMix+FF/Bb-exposed mice, IL-22 mRNA expression increased and IL-10 followed the same tendency, while the Foxp3 expression was increased over GATA3 and Ror+¦+ñ. In the colon, the Tbet mRNA expression increased over GATA3, while IL-22 decreased. In addition, the Foxp3+/GATA3+ and regulatory/effector T cell ratios in the MLN and the CD11b+/CD11b- conventional DC ratio in the SI-LP were increased. In conclusion, the FF/Bb diet facilitates the capacity of the specific BLG-peptides to partially prevent the allergic response after sensitization to whole whey protein, possibly by creating a tolerance-prone environment during the OT phase. Such a dietary intervention might contribute to tailoring successful strategies for CMA prevention</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Netherlands -CO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.3389/fimmu.2017.01303</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.3389/fimmu.2017.01303</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1303.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-1303.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Kostadinova AI</style></custom2><misc3><style face="normal" font="Arial">10.3389/fimmu.2017.01303</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Saintive,S.</style></author><author><style face="normal" font="Arial"> Abad,E.</style></author><author><style face="normal" font="Arial"> Ferreira,C.</style></author><author><style face="normal" font="Arial"> Stambovsky,M.</style></author><author><style face="normal" font="Arial"> Cavalcante,F.S.</style></author><author><style face="normal" font="Arial"> Goncalves,L.S.</style></author><author><style face="normal" font="Arial"> Vidal,F.</style></author><author><style face="normal" font="Arial"> Dos Santos,K.R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Pediatric Dermatology Service, IPPMG-Martagao Gesteira Pediatric Institute-Federal University of Rio de Janeiro-UFRJ, Rio de Janeiro, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">What is the role of Staphylococcus aureus and herpes virus infections in the pathogenesis of atopic dermatitis?</style></title><secondary-title><style face="normal" font="Arial">Future Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Future Microbiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> colonization</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Flare</style></keyword><keyword><style face="normal" font="Arial"> Flares</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> herpes</style></keyword><keyword><style face="normal" font="Arial"> Herpes Simplex</style></keyword><keyword><style face="normal" font="Arial"> herpes simplex virus</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus</style></keyword><keyword><style face="normal" font="Arial"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword><keyword><style face="normal" font="Arial"> virus</style></keyword><keyword><style face="normal" font="Arial"> virus infection</style></keyword></keywords><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis (AD) is a chronic, relapsing disease. Genetic, environmental and immunological factors are involved in its pathophysiology. Individuals with AD have an increased predisposition to colonization and/or infection of the skin by various pathogens, especially Staphylococcus aureus and herpes simplex virus. The composition of their skin microbiome is also different, and changes during flares. The disease severity can be related to the degree of colonization by S. aureus. In addition, the presence of this bacterial species can predispose the host to more severe and disseminated viral infections. This article reviews the role of S. aureus and herpes virus infections and the skin microbiome in the pathogenesis of AD and their importance in the treatment and prevention strategies of this dermatosis</style></abstract><notes><style face="normal" font="Arial">DA - 20171020IS - 1746-0921 (Electronic)IS - 1746-0913 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.2217/fmb-2017-0081</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29052452">PM:29052452</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Future Microbiol\20171020-SaintiveS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Future Microbiol\20171020-SaintiveS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171020, Saintive S</style></custom2><misc3><style face="normal" font="Arial">10.2217/fmb-2017-0081</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,Y.</style></author><author><style face="normal" font="Arial"> Chu,X.</style></author><author><style face="normal" font="Arial"> Liu,C.</style></author><author><style face="normal" font="Arial"> Huang,W.</style></author><author><style face="normal" font="Arial"> Yao,Y.</style></author><author><style face="normal" font="Arial"> Xia,Y.</style></author><author><style face="normal" font="Arial"> Sun,P.</style></author><author><style face="normal" font="Arial"> Long,Q.</style></author><author><style face="normal" font="Arial"> Feng,X.</style></author><author><style face="normal" font="Arial"> Li,K.</style></author><author><style face="normal" font="Arial"> Yang,X.</style></author><author><style face="normal" font="Arial"> Bai,H.</style></author><author><style face="normal" font="Arial"> Sun,W.</style></author><author><style face="normal" font="Arial"> Ma,Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Laboratory of Molecular Immunology , Institute of Medical Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College ; Kunming , China 650118</style></auth-address><titles><title><style face="normal" font="Arial">Exogenous murine antimicrobial peptide CRAMP significantly exacerbates Ovalbumin-induced airway inflammation but ameliorates oxazolone-induced intestinal colitis in BALB/c mice</style></title><secondary-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Hum Vaccin Immunother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> antimicrobial peptide</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Body Weight</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> cathelicidin</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> Colon</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> disease models</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> multifunctional</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Pro-inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> Real time PCR</style></keyword><keyword><style face="normal" font="Arial"> Real time-PCR</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TNF-alpha</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Ulcerative Colitis</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="Arial">Cathelicidin has been reported to be multifunctional. The current study aimed to investigate the influences of exogenous cathelicidin-related antimicrobial peptide (CRAMP) on inflammatory responses in different disease models. In OVA-induced allergic airway inflammation, CRAMP significantly enhanced the infiltration of inflammatory cells and accumulation of proinflammatory Th2 cytokine IL-13 and IL-33 in bronchial alveolar lavage fluid (BALF), exacerbated lung tissue inflammation and airway goblet cell hyperplasia, and elevated OVA-specific IgE level in serum. In oxazolone-induced intestinal colitis, the expression levels of CRAMP and its receptor FPR2 significantly increased in comparison with those of TNBS-induced mice, vesicle and normal controls. Exogenous CRAMP significantly prevented the development of ulcerative colitis, evidenced by improved body weight regain, decreased colons weight/length ratio, elevated epithelial integrity, and ameliorated colon tissue inflammation. In addition, pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-4 and IL-13, as well as chemokines CXCL2 and CXCL5 for neutrophils recruitment were significantly decreased in CRAMP-treated mice, and epithelial repair-related factors MUC2 and Claudin1 were increased, determined by real time-PCR and ELISAs. The results indicated that although CRAMP has pro-inflammatory effects in airway, local application of exogenous CRAMP might be a potential approach for the treatment of ulcerative colitis</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 2164-554X (Electronic)IS - 2164-5515 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1080/21645515.2017.1386823</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29049008">PM:29049008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Vaccin Immunother\20171019-LiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Vaccin Immunother\20171019-LiY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Li Y</style></custom2><misc3><style face="normal" font="Arial">10.1080/21645515.2017.1386823</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Osbourn,M.</style></author><author><style face="normal" font="Arial"> Soares,D.C.</style></author><author><style face="normal" font="Arial"> Vacca,F.</style></author><author><style face="normal" font="Arial"> Cohen,E.S.</style></author><author><style face="normal" font="Arial"> Scott,I.C.</style></author><author><style face="normal" font="Arial"> Gregory,W.F.</style></author><author><style face="normal" font="Arial"> Smyth,D.J.</style></author><author><style face="normal" font="Arial"> Toivakka,M.</style></author><author><style face="normal" font="Arial"> Kemter,A.M.</style></author><author><style face="normal" font="Arial"> le Bihan,T.</style></author><author><style face="normal" font="Arial"> Wear,M.</style></author><author><style face="normal" font="Arial"> Hoving,D.</style></author><author><style face="normal" font="Arial"> Filbey,K.J.</style></author><author><style face="normal" font="Arial"> Hewitson,J.P.</style></author><author><style face="normal" font="Arial"> Henderson,H.</style></author><author><style face="normal" font="Arial"> Gonzalez-Ciscar,A.</style></author><author><style face="normal" font="Arial"> Errington,C.</style></author><author><style face="normal" font="Arial"> Vermeren,S.</style></author><author><style face="normal" font="Arial"> Astier,A.L.</style></author><author><style face="normal" font="Arial"> Wallace,W.A.</style></author><author><style face="normal" font="Arial"> Schwarze,J.</style></author><author><style face="normal" font="Arial"> Ivens,A.C.</style></author><author><style face="normal" font="Arial"> Maizels,R.M.</style></author><author><style face="normal" font="Arial"> McSorley,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">MRC Centre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK</style></auth-address><titles><title><style face="normal" font="Arial">HpARI Protein Secreted by a Helminth Parasite Suppresses Interleukin-33</style></title><secondary-title><style face="normal" font="Arial">Immunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunity</style></full-title></periodical><pages end="751" start="739">739-751</pages><volume><style face="normal" font="Arial">47</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Alternaria</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-33</style></keyword><keyword><style face="normal" font="Arial"> ILC2</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Nippostrongylus</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> type 2 immunity</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">Infection by helminth parasites is associated with amelioration of allergic reactivity, but mechanistic insights into this association are lacking. Products secreted by the mouse parasite Heligmosomoides polygyrus suppress type 2 (allergic) immune responses through interference in the interleukin-33 (IL-33) pathway. Here, we identified H. polygyrus Alarmin Release Inhibitor (HpARI), an IL-33-suppressive 26-kDa protein, containing three predicted complement control protein (CCP) modules. In vivo, recombinant HpARI abrogated IL-33, group 2 innate lymphoid cell (ILC2) and eosinophilic responses to Alternaria allergen administration, and diminished eosinophilic responses to Nippostrongylus brasiliensis, increasing parasite burden. HpARI bound directly to both mouse and human IL-33 (in the cytokine's activated state) and also to nuclear DNA via its N-terminal CCP module pair (CCP1/2), tethering active IL-33 within necrotic cells, preventing its release, and forestalling initiation of type 2 allergic responses. Thus, HpARI employs a novel molecular strategy to suppress type 2 immunity in both infection and allergy</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1097-4180 (Electronic)IS - 1074-7613 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.immuni.2017.09.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29045903">PM:29045903</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunity\2017-47-739-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunity\2017-47-739-51.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Osbourn M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.immuni.2017.09.015</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Huang,F.L.</style></author><author><style face="normal" font="Arial"> Liao,E.C.</style></author><author><style face="normal" font="Arial"> Yu,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">House dust mite allergy: its innate immune response and immunotherapy</style></title><secondary-title><style face="normal" font="Arial">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunobiology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asia</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> DC-SIGN</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Innate immune response</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mite allergy</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physicians</style></keyword><keyword><style face="normal" font="Arial"> protease activated receptor</style></keyword><keyword><style face="normal" font="Arial"> Protease-activated receptor</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Signal Transduction</style></keyword><keyword><style face="normal" font="Arial"> specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> TLR</style></keyword><keyword><style face="normal" font="Arial"> TLRs</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0171-2985</style></isbn><abstract><style face="normal" font="Arial">Over the past few decades, allergic diseases have become increasingly prevalent worldwide. House dust mite (HDM) is the most important domestic source for allergic diseases such as allergic rhinitis, asthma and atopic dermatitis. Dermatophagoides pteronyssinus (Der p) is the major environmental allergen in southeast Asia because of the humid and warm environment is suitable for its growth. In the recent year, role of HDM allergen in allergic inflammation through innate immune system has been well studied. Toll-like receptors (TLRs), protease-activated receptors (PARs) and DC-SIGN could be activated by different HDM major allergens and proinflammatory cytokines also be upregulated. Treatment efficacy for HDM allergy is unsatisfied to the patients and the medication is limited. Immunotherapy provided an alternative option for treating HDM allergy through targeted to the mechanisms of allergic reaction and represented a long-term symptoms relief. Gene specific immunotherapy was currently being developed and it could decrease allergic inflammation and improve the efficacy of treatment. In this report, we reviewed recent studies about the role of HDM allergy in innate immune system and its immunotherapy. Understanding the HDM allergen induced signal transduction pathway and developed allergen specific immunotherapy could help physicians to create precise diagnosis and solve unmet need in HDM allergy</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imbio.2017.10.035</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.imbio.2017.10.035</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunobiology\20171030-HuangFL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunobiology\20171030-HuangFL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Huang FL</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imbio.2017.10.035</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Yin,S.C.</style></author><author><style face="normal" font="Arial"> Liao,E.C.</style></author><author><style face="normal" font="Arial"> Ye,C.X.</style></author><author><style face="normal" font="Arial"> Chang,C.Y.</style></author><author><style face="normal" font="Arial"> Tsai,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effect of Mite Allergenic Components on Innate Immune Response: Synergy of Protease (Group 1 &amp; 3) and Non-protease (Group 2&amp; 7) Allergens</style></title><secondary-title><style face="normal" font="Arial">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Immunobiology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Der p 1</style></keyword><keyword><style face="normal" font="Arial"> Der p 2</style></keyword><keyword><style face="normal" font="Arial"> Der p3</style></keyword><keyword><style face="normal" font="Arial"> Der p7</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> house dust mite (HDM)</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Innate immune response</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> serum specific IgE</style></keyword><keyword><style face="normal" font="Arial"> serum-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> transcription</style></keyword><keyword><style face="normal" font="Arial"> transcription factor</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0171-2985</style></isbn><abstract><style face="normal" font="Arial">The major mite allergenic components of protease allergens (group 1,3) and non-protease allergens (group 2,7) derived from Dermatophagoides peronyssinus (Dp) and D. farinae (Df) are reported to be capable of sensitizing 80-90% of mite</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çôallergic patients. Although protease and non-protease allergens have been demonstrated to trigger innate and adaptive immune responses through epithelium activation, the simultaneous or sequential effects of both groups of allergens has not been reported. Since all allergens are present in the mite crude extracts, it is important to determine whether these allergens can synergistically trigger the immune responses to cause airway inflammation. A total of 60 house dust mite (HDM)-allergic asthmatic patients were recruited to analyze their serum-specific IgE response to both groups of allergens. Recombinant protease allergen (Der p1 and Der p3) and non-protease allergens (Der p2 and Der p7) were used to activate the human airway epithelium cell (Beas-2B). The cells were analyzed for mRNA expression of IL-6/IL-8 and the culture supernatants were analyzed for neutrophil chemotactic activity (NCA). The results showed 48/60 (80%) HDM-allergic patients were sensitized to all allergenic components of Der p1, Der p2, Der f1, and Der f2. Most of the allergic patients were sensitized to both groups of allergens simultaneously. The associations of Der p1 with Der p2 were 83.3% (50/60) and Der f1 with Der f2 were 80% (48/60). When Beas</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2B cells were cultured with Der p2 in conjunction with Der p1 and Der p3, the results showed that there was increased expression of IL-6/IL-8 in comparison with culture with allergen alone. There was only a trivial effect on IL-6/IL-8 expression when Der p2 was co-cultured with Der p7. Similar findings were obtained in the NCA measurement. When Beas</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2B was cultured with Der p2 in conjunction with Der p1 and Der p3, there was increased NCA in comparison with culture with allergen alone. There were also trivial effects when Der p2 was co-cultured with Der p7. The allergens (Der p2 and Der p3)-induced IL-6/IL-8 expression and NCA released from Beas</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô2B could be downregulated by dexamethasone and transcription factor inhibitor SP600125. The allergenic components derived from Dp and Df can sensitize allergic patients simultaneously and activate epithelium through protease allergens (group 1, 3) and non-protease allergen (group 2) synergistically</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.imbio.2017.10.032</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.imbio.2017.10.032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunobiology\20171031-YinSC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunobiology\20171031-YinSC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171031, Yin SC</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.imbio.2017.10.032</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">McDermott,A.J.</style></author><author><style face="normal" font="Arial"> Tumey,T.A.</style></author><author><style face="normal" font="Arial"> Huang,M.</style></author><author><style face="normal" font="Arial"> Hull,C.M.</style></author><author><style face="normal" font="Arial"> Klein,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America</style></auth-address><titles><title><style face="normal" font="Arial">Inhaled Cryptococcus neoformans Elicits Allergic Airway Inflammation independent of NFkappaB signaling in lung epithelial cells</style></title><secondary-title><style face="normal" font="Arial">Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Immunology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> CD4</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4 T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcus</style></keyword><keyword><style face="normal" font="Arial"> Cryptococcus neoformans</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immunofluorescence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Kinetics</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> survival</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="Arial">Pulmonary challenge with the ubiquitous fungus Cryptococcus neoformans results in allergic airway inflammation (AAI) characterized by robust recruitment of eosinophils and T-cells producing type 2 cytokines to the lungs. Previous studies have demonstrated a critical role for NFkappaB activation within lung epithelial cells (LECs) in driving AAI in response to protein allergens, yet the role of LEC-intrinsic NFkappaB in promoting AAI following exposure to C. neoformans is poorly understood. To investigate the role of LEC-intrinsic NFkappaB in promoting AAI following C. neoformans challenge, we utilized IKKLEC mice, which lack canonical NFkappaB activation specifically within LECs. IKKLEC and littermate control mice were intranasally challenged with 106 CFU of C. neoformans strain 52D, and lung tissues collected at 7, 14, and 21 days post infection to assess the development of AAI. Notably, the absence of epithelial NFkappaB signaling did not affect the magnitude or kinetics of lung eosinophilia when compared to the response in wild-type control mice. The total numbers of lung T-cells producing the type 2 cytokines IL-5 and IL-13 also were unchanged in IKKLEC mice. Furthermore, IKKLEC mice showed no defect in the recruitment of protective IFNgamma-producing CD4 T-cells to the lungs, fungal clearance, or host survival as compared to controls. Immunofluorescence imaging surprisingly revealed no evidence of nuclear localization of NFkappaB in LECs in response to C. neoformans challenge, indicating that NFkappaB is not activated within these cells. Taken together, these data strongly suggest that NFkappaB signaling within LECs does not promote AAI observed in response to C. neoformans. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171021IS - 1365-2567 (Electronic)IS - 0019-2805 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/imm.12853</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29055116">PM:29055116</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immunology\20171021-McDermottAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immunology\20171021-McDermottAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171021, McDermott AJ</style></custom2><misc3><style face="normal" font="Arial">10.1111/imm.12853</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gupta,S.</style></author><author><style face="normal" font="Arial"> Bajpai,M.</style></author><author><style face="normal" font="Arial"> Pamecha,V.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Transfusion Medicine, Institute of Liver and Biliary Sciences, Sector D-1, Vasant Kunj, New Delhi, India</style></auth-address><titles><title><style face="normal" font="Arial">Dilemma-ABO Incompatible Liver Transplant in a Patient with an Anaphylactic Reaction to Fresh Frozen Plasma</style></title><secondary-title><style face="normal" font="Arial">Indian J Hematol Blood Transfus</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Indian J Hematol Blood Transfus</style></abbr-1></periodical><pages end="627" start="626">626-627</pages><volume><style face="normal" font="Arial">33</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Delhi</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Liver</style></keyword><keyword><style face="normal" font="Arial"> Liver transplant</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> transfusion</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 0971-4502 (Print)IS - 0971-4502 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12288-016-0774-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29075084">PM:29075084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Hematol Blood Transfus\2017-33-626-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Hematol Blood Transfus\2017-33-626-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Gupta S</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12288-016-0774-8</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Al-Sawalha,N.A.</style></author><author><style face="normal" font="Arial"> Al-Bo'ul,H.F.</style></author><author><style face="normal" font="Arial"> Alzoubi,K.H.</style></author><author><style face="normal" font="Arial"> Khabour,O.F.</style></author><author><style face="normal" font="Arial"> Thanawala,V.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a Faculty of Pharmacy , Jordan University of Science and Technology , Irbid , Jordand Vapogenix Inc , Houston , TX , USA</style></auth-address><titles><title><style face="normal" font="Arial">Effect of prenatal waterpipe tobacco smoke on airway inflammation in murine model of asthma of adult offspring mice</style></title><secondary-title><style face="normal" font="Arial">Inhal Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Inhal Toxicol</style></full-title></periodical><pages end="373" start="366">366-373</pages><volume><style face="normal" font="Arial">29</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Air</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Catalase</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Glutathione</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL-18</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Materials</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> oxidative stress</style></keyword><keyword><style face="normal" font="Arial"> Peroxidase</style></keyword><keyword><style face="normal" font="Arial"> Pharmacies</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> Prenatal</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Smoking</style></keyword><keyword><style face="normal" font="Arial"> SOD</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Stress</style></keyword><keyword><style face="normal" font="Arial"> superoxide</style></keyword><keyword><style face="normal" font="Arial"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="Arial"> TBARS</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> tobacco smoke</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: Worldwide popularity of waterpipe tobacco smoking has increased, including in pregnant women. This study investigates the effect of prenatal waterpipe tobacco smoke (WTS) exposure on airway inflammation in a murine model of asthma of adult offspring mice. MATERIALS AND METHODS: Pregnant BALB/c mice were exposed to fresh air or WTS, using a whole-body exposure system that mimics human use during WTS. Adult male offspring mice were divided into; (1) control (prenatal fresh air, postnatal ovalbumin sensitization and saline challenge), (2) postnatal Ova S/C (prenatal fresh air, postnatal ovalbumin sensitization and challenge (Ova S/C)), (3) prenatal WTS (prenatal WTS, postnatal ovalbumin sensitization and saline challenge) and (4) prenatal WTS + postnatal Ova S/C. Cells from the bronchoalveolar lavage fluid, cytokines, and oxidative stress markers (superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx) and thiobarbituric acid reactive substances (TBARS)) from lung homogenates were evaluated. RESULTS: Prenatal WTS increased recruitment of cells in lungs and levels of SOD and catalase when compared to unexposed offspring's. The levels of cytokines, GPx and TBARS were not affected by prenatal WTS. Prenatal WTS exposure and postnatal Ova S/C increased airway inflammation and activity of SOD compared to control and Ova S/C mice and reduced IL-18 levels compared to Ova S/C mice. DISCUSSION AND CONCLUSIONS: Prenatal exposure to WTS induced airway inflammation, further enhanced by a murine model of asthma in adult offspring. Prenatal exposure to WTS adversely affects the lung function of the offspring and careful strategies for increasing public awareness regarding the harmful effects of WTS during pregnancy is important</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1091-7691 (Electronic)IS - 0895-8378 (Linking)LA - engPT - Journal ArticleCO - Jordan -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="Arial">10.1080/08958378.2017.1385113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29039230">PM:29039230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inhal Toxicol\2017-29-366-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inhal Toxicol\2017-29-366-73.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Al-Sawalha NA</style></custom2><misc3><style face="normal" font="Arial">10.1080/08958378.2017.1385113</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rust,M.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Entomology, University of California Riverside, Riverside, CA 92521, USA.</style></auth-address><titles><title><style face="normal" font="Arial">The Biology and Ecology of Cat Fleas and Advancements in Their Pest Management: A Review</style></title><secondary-title><style face="normal" font="Arial">Insects</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Insects</style></abbr-1></periodical><pages end="" start="E118">E118-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> arthropod</style></keyword><keyword><style face="normal" font="Arial"> Awareness</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Bite</style></keyword><keyword><style face="normal" font="Arial"> California</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Ecology</style></keyword><keyword><style face="normal" font="Arial"> Entomology</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental controls</style></keyword><keyword><style face="normal" font="Arial"> Feces</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Flea Infestations</style></keyword><keyword><style face="normal" font="Arial"> Fleas</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> Insecticide Resistance</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> Spread</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="Arial">The cat flea Ctenocephalides felis felis (Bouche) is the most important ectoparasite of domestic cats and dogs worldwide. It has been two decades since the last comprehensive review concerning the biology and ecology of C. f. felis and its management. Since then there have been major advances in our understanding of the diseases associated with C. f. felis and their implications for humans and their pets. Two rickettsial diseases, flea-borne spotted fever and murine typhus, have been identified in domestic animal populations and cat fleas. Cat fleas are the primary vector of Bartonella henselae (cat scratch fever) with the spread of the bacteria when flea feces are scratched in to bites or wounds. Flea allergic dermatitis (FAD) common in dogs and cats has been successfully treated and tapeworm infestations prevented with a number of new products being used to control fleas. There has been a continuous development of new products with novel chemistries that have focused on increased convenience and the control of fleas and other arthropod ectoparasites. The possibility of feral animals serving as potential reservoirs for flea infestations has taken on additional importance because of the lack of effective environmental controls in recent years. Physiological insecticide resistance in C. f. felis continues to be of concern, especially because pyrethroid resistance now appears to be more widespread. In spite of their broad use since 1994, there is little evidence that resistance has developed to many of the on-animal or oral treatments such as fipronil, imidacloprid or lufenuron. Reports of the perceived lack of performance of some of the new on-animal therapies have been attributed to compliance issues and their misuse. Consequentially, there is a continuing need for consumer awareness of products registered for cats and dogs and their safety</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 2075-4450 (Print)IS - 2075-4450 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/insects8040118</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29077073">PM:29077073</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Insects\2017-8-E118.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Insects\2017-8-E118.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Rust MK</style></custom2><misc3><style face="normal" font="Arial">10.3390/insects8040118</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Malizia,V.</style></author><author><style face="normal" font="Arial"> Fasola,S.</style></author><author><style face="normal" font="Arial"> Ferrante,G.</style></author><author><style face="normal" font="Arial"> Cilluffo,G.</style></author><author><style face="normal" font="Arial"> Montalbano,L.</style></author><author><style face="normal" font="Arial"> Landi,M.</style></author><author><style face="normal" font="Arial"> Marchese,D.</style></author><author><style face="normal" font="Arial"> Passalacqua,G.</style></author><author><style face="normal" font="Arial"> La Grutta,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">National Research Council of Italy, Institute of Biomedicine and Molecular Immunology, University of Palermo, Palermo, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="103" start="97">97-103</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aged</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> Biomedicine</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytology</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Irrigation</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal cytology</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> Neutrophils</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> paediatric</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> randomized</style></keyword><keyword><style face="normal" font="Arial"> Randomized controlled trial</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinoconjunctivitis quality of life questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Sleep</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Saline nasal irrigation is labelled as an add-on treatment in patients with allergic rhinitis (AR). The primary aim of this study was to compare the efficacy of 21-day use of buffered hypertonic saline (BHS) versus normal saline solution (NSS) on reducing nasal symptoms in children with seasonal AR (SAR). Comparing their efficacy on nasal cytology counts (NCC), quality of life, and sleep quality was the secondary aim. METHODS: In this 21-day, open-label, randomized controlled study, 36 SAR children (aged 6-13 years) with a Total 5 Symptom Score (T5SS) >/=5 received twice-daily BHS or NSS delivered through a nasal douche. Efficacy measures were least square mean changes (LSmc) in T5SS, NCC, Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), and Pittsburgh Sleep Quality Index (PSQI) scores. RESULTS: BHS improved the T5SS total score to a greater extent than NSS (LSmc -6.45 vs. -5.45, p &lt; 0.001). Concerning NCC, BHS significantly reduced the scores of neutrophils (LSmc -0.76, p = 0.004) and eosinophils (LSmc -0.46, p = 0.018), while NSS did not. Similarly, only BHS yielded a significant improvement in the PRQLQ score (LSmc -0.57, p = 0.009), whereas the improvement in PSQI score was comparable between the BHS (LSmc -0.77, p = 0.025) and NSS (LSmc -1.39, p &lt; 0.001) groups. Overall, BHS was well tolerated. CONCLUSIONS: In children with SAR, BHS is effective in improving nasal symptoms and NCC, with an associated beneficial effect on quality of life</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1159/000481093</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29059673">PM:29059673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-97-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-97-103.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Malizia V</style></custom2><misc3><style face="normal" font="Arial">10.1159/000481093</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Manti,S.</style></author><author><style face="normal" font="Arial"> Cuppari,C.</style></author><author><style face="normal" font="Arial"> Marseglia,L.</style></author><author><style face="normal" font="Arial"> D'Angelo,G.</style></author><author><style face="normal" font="Arial"> Arrigo,T.</style></author><author><style face="normal" font="Arial"> Gitto,E.</style></author><author><style face="normal" font="Arial"> Leonardi,S.</style></author><author><style face="normal" font="Arial"> Salpietro,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Units of Pediatric Genetics and Immunology, University of Messina, Messina, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Association between Allergies and Hypercholesterolemia: A Systematic Review</style></title><secondary-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Arch Allergy Immunol</style></full-title></periodical><pages end="76" start="67">67-76</pages><volume><style face="normal" font="Arial">174</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bias</style></keyword><keyword><style face="normal" font="Arial"> BMI</style></keyword><keyword><style face="normal" font="Arial"> Cholesterol</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> confounding factors</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> familial</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> genetic predisposition</style></keyword><keyword><style face="normal" font="Arial"> genetics</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypercholesterolemia</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid Metabolism</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Predisposition</style></keyword><keyword><style face="normal" font="Arial"> Publications</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: There is controversy in the literature regarding the potential relationship between atopic predisposition (AP) and serum cholesterol levels. To this purpose, we reviewed human studies that investigated this possible link. METHODS: Following PRISMA guidelines, a literature search of PubMed and Science Direct for peer-reviewed journal articles in English from January 2003, with updates through to August 2016, was conducted. Relevant publications were reviewed that included pediatric and adult populations. Information on the study design, sample, intervention, comparators, outcome, time frame, and risk of bias were abstracted for each article. RESULTS: Of 601 reviewed reports, 18 were included in this systematic review. Fifteen studies assessed the relationship between AP and serum cholesterol levels. Due to the lack both of observational and cross-sectional studies from the literature search at this time (only 8 studies also analyzed confounding factors) there is a high possibility of confounding variables (familial and genetic predisposition, age, gender, BMI, comorbidity, and medication status) that could not be ruled out. CONCLUSION: Existing studies are heterogeneous, making it difficult to draw broad conclusions. Future studies and more detailed analyses, considering confounding variables and including a larger and homogeneous population, are needed to strengthen the argument for a link between lipid metabolism and atopy</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1159/000480081</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035883">PM:29035883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-67-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Arch Allergy Immunol\2017-174-67-76.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Manti S</style></custom2><misc3><style face="normal" font="Arial">10.1159/000480081</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ramsey,T.</style></author><author><style face="normal" font="Arial"> Lai,W.</style></author><author><style face="normal" font="Arial"> Svider,P.F.</style></author><author><style face="normal" font="Arial"> Hojjat,H.</style></author><author><style face="normal" font="Arial"> Eloy,J.A.</style></author><author><style face="normal" font="Arial"> Folbe,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI</style></auth-address><titles><title><style face="normal" font="Arial">Allergen immunotherapy: exploring areas for further inquiry</style></title><secondary-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Forum Allergy Rhinol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Impacts</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergy-related illness impacts millions of individuals worldwide. Our objectives were to characterize current trends of clinical trials research relating to allergen immunotherapy and to describe the landscape of allergen immunotherapy in National Institutes of Health (NIH)-supported research inquiry. METHODS: On ClinicalTrials.gov, the following terms were searched: allergen immunotherapy OR allergy immunotherapy. Variables, including completion status, dates, design, study population, funder, location, and allergen were recorded. The NIH Research Portfolio Online Reporting Tools (RePORTER) system was also used to gather relevant variables. RESULTS: A total of 372 clinical trials met inclusion criteria. The proportion of industry-funded clinical trials has declined over 15 years. There has been a slow decline in pollen allergy immunotherapy research, with an increase in both food and animal allergy immunotherapy research. Otolaryngologists comprised only 6.4% of clinical trials principal investigators (PIs). There was a total adjusted NIH funding of $74,986,125 for the 118 total funding years. CONCLUSION: Despite an immense interest in allergen immunotherapy, this analysis demonstrates that otolaryngologists represented a small proportion of PIs leading associated clinical trials and basic science inquiry. The proportion of trials with industry sponsorship has declined considerably in recent decades. These trends could help direct future resource allocation for allergen immunotherapy</style></abstract><notes><style face="normal" font="Arial">DA - 20171012IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1002/alr.22016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29024520">PM:29024520</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20171012-RamseyT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Forum Allergy Rhinol\20171012-RamseyT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171012, Ramsey T</style></custom2><misc3><style face="normal" font="Arial">10.1002/alr.22016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zuska-Prot,M.</style></author><author><style face="normal" font="Arial"> Maslanka,T.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Inhaled glucocorticoid treatment prevents the response of CD8+ T cells in a mouse model of allergic asthma and causes their depletion outside the respiratory system</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="72" start="63">63-72</pages><volume><style face="normal" font="Arial">53</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Apoptosis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD8+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoids</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Methylprednisolone</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><isbn><style face="normal" font="Arial">1567-5769</style></isbn><abstract><style face="normal" font="Arial">The principal objective of this research has been to determine the safety of inhaled glucocorticoids (GCs) in respect of their effect on CD8+ T cells within respiratory and extra-respiratory tissues, and to compare it with systemic GC treatment. Another purpose has been to identify whether inhaled and systemic GCs affect the CD8+ T cell response in the mediastinal lymph nodes (MLNs) and lungs in a mouse model of ovalbumin (OVA)-induced asthma. Ciclesonide and methylprednisolone were used as a model for inhaled and systemic GCs, respectively. The CD8+ T cell response was observed in untreated OVA-immunized mice, manifesting itself by the proliferation of these cells and their recruitment into the lower respiratory tract. Inhaled and systemic GC treatment fully prevented this response. This suggests that one of the elements contributing to the anti-asthmatic efficacy of inhaled and systemic GCs could be the inhibition of the effector CD8+ T cell response which accompanies the disease. The anti-asthmatic effect of GCs was rather not mediated through the generation or/and increased recruitment of Foxp3+ CD25+ CD8+ regulatory T cells into the MLNs and lungs. Inhaled and systemic GCs produced comparable depletions of normal CD8+ T cells in the MLNs, the head and neck lymph nodes and in peripheral blood, and this effect, at least to some extent, resulted from the proapoptotic action of GCs towards these cells. These results suggest that inhaled GC therapy might not be safer at all than treatment with systemic GCs in respect of the undesirable effects on CD8+ T cells residing within and outside the respiratory tract</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.10.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29040944">PM:29040944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-53-63-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-53-63-72.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Zuska-Prot M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.10.012</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ko,J.W.</style></author><author><style face="normal" font="Arial"> Shin,N.R.</style></author><author><style face="normal" font="Arial"> Park,S.H.</style></author><author><style face="normal" font="Arial"> Cho,Y.K.</style></author><author><style face="normal" font="Arial"> Kim,J.C.</style></author><author><style face="normal" font="Arial"> Seo,C.S.</style></author><author><style face="normal" font="Arial"> Shin,I.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">College of Veterinary Medicine (BK21 Plus Project Team), Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju 61186, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Genipin inhibits allergic responses in ovalbumin-induced asthmatic mice</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="55" start="49">49-55</pages><volume><style face="normal" font="Arial">53</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> Cell Count</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="Arial"> Cyclooxygenase-2</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory response</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-5</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Plethysmography</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="Arial">Genipin is a natural compound isolated from the fruit of Gardenia jasminoides with various pharmacological effects. In this study, we investigated whether genipin effectively alleviates allergic responses in a murine model of ovalbumin (OVA)-induced asthma. The mice were administered an intraperitoneal injection of OVA on day 0 and 14 to boost the immune response; genipin was then administered from day 18 to 23 by oral gavage. On days 21 to 23, mice were OVA-challenged using am ultrasonic nebulizer, and airway hyperresponsiveness (AHR) was determined on day 24 by plethysmography. Genipin significantly reduced the inflammatory cell count in bronchoalveolar lavage fluids (BALF) and AHR, which were accompanied by lower interleukin-5 (IL-5), IL-13 and OVA-specific immunoglobulin (Ig) E levels in the BALF or serum from OVA-induced asthmatic mice. In histology, genipin significantly decreased airway inflammation and mucus hypersecretion in OVA-induced asthmatic mice. Additionally, genipin inhibited OVA-induced increases in the expression of inducible nitric oxide synthase and cyclooxygenase-2 proteins. Further, genipin reduced the activity and protein levels of matrix metalloproteinase-9 in lung tissue from OVA induced asthmatic mice. Overall, genipin effectively alleviated the asthmatic inflammatory response in an OVA-induced asthmatic model. Therefore, our results suggest that genipin has therapeutic potential for treating asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035815">PM:29035815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-53-49-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-53-49-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Ko JW</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.10.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gu,X.</style></author><author><style face="normal" font="Arial"> Zhang,Q.</style></author><author><style face="normal" font="Arial"> Du,Q.</style></author><author><style face="normal" font="Arial"> Shen,H.</style></author><author><style face="normal" font="Arial"> Zhu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Rehabilitation, The Affiliated Jiangning Hospital of Nanjing Medical University, 168 drum Hill Road, Dongshan Street, Jiangning District, Nanjing 211100, PR China</style></auth-address><titles><title><style face="normal" font="Arial">Pinocembrin attenuates allergic airway inflammation via inhibition of NF-kappaB pathway in mice</style></title><secondary-title><style face="normal" font="Arial">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int Immunopharmacol</style></full-title></periodical><pages end="95" start="90">90-95</pages><volume><style face="normal" font="Arial">53</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> Flavonoids</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunoregulation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory disease</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phosphorylation</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Propolis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Subunit</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="18" Month="10" Year="2017">2017/10/18</year></dates><abstract><style face="normal" font="Arial">Pinocembrin, one of the primary flavonoids in propolis, possesses many biological activities, including anti-inflammation, anti-oxidation and immunoregulation. This study aimed to evaluate whether pinocembrin could attenuate ovalbumin (OVA)-induced allergic airway inflammation in mice and to explore the possible mechanism. BALB/c mice sensitized and challenged with OVA were administered intraperitoneally with pinocembrin. Airway inflammation and airway hyperresponsiveness were examined. T-helper type (Th) 2 cytokines in bronchoalveolar lavage fluid (BALF) and OVA-specific immunoglobulin E (IgE) in serum were determined. The activation of nuclear factor kappa B (NF-kappaB) p65 were also measured. Our results showed that pinocembrin resulted in significant inhibition of pathophysiological signs of allergic asthma, including increased pulmonary eosinophilia infiltration, mucus hypersecretion and airway hyperresponsiveness (AHR). Treatment with pinocembrin significantly reduced Th2 cytokines interleukin (IL)-4, IL-5 and IL-13 in BALF, and OVA-specific IgE in serum. Moreover, pinocembrin treatment suppressed phosphorylation of inhibitor-kappaBalpha (IkappaBalpha) and NF-kappaB subunit p65 activation in lung tissue of OVA-sensitized mice. These data suggest that pinocembrin may inhibit allergic airway inflammation, and providing potential benefits in the treatment of inflammatory disease</style></abstract><notes><style face="normal" font="Arial">DA - 20171021IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.intimp.2017.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29055190">PM:29055190</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int Immunopharmacol\2017-53-90-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int Immunopharmacol\2017-53-90-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171021, Gu X</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.intimp.2017.10.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,K.</style></author><author><style face="normal" font="Arial"> Chen,S.</style></author><author><style face="normal" font="Arial"> Chen,H.</style></author><author><style face="normal" font="Arial"> Tong,P.</style></author><author><style face="normal" font="Arial"> Gao,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China; School of Food Science and Technology, Nanchang University, Nanchang 330031, China</style></auth-address><titles><title><style face="normal" font="Arial">Cross-linked ovalbumin catalyzed by polyphenol oxidase: Preparation, structure and potential allergenicity</style></title><secondary-title><style face="normal" font="Arial">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biol Macromol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenicity</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> antigenicity</style></keyword><keyword><style face="normal" font="Arial"> Caffeic</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Circular Dichroism</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Cross-link</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Electrophoresis</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Fluorescence</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food protein</style></keyword><keyword><style face="normal" font="Arial"> food proteins</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE binding</style></keyword><keyword><style face="normal" font="Arial"> IgE Binding Ability</style></keyword><keyword><style face="normal" font="Arial"> IgE-binding</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Major allergens</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol</style></keyword><keyword><style face="normal" font="Arial"> Polyphenol oxidase</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sodium</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Tryptophan</style></keyword><keyword><style face="normal" font="Arial"> Tyrosine</style></keyword><keyword><style face="normal" font="Arial"> Ultraviolet</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="14" Month="10" Year="2017">2017/10/14</year></dates><abstract><style face="normal" font="Arial">Ovalbumin (OVA) is described as one of the major allergens in hen's egg, and it is the most abundant protein in egg white. Enzyme-mediated covalent cross-linking of food proteins, can influence their structure and allergenicity. The aim of this study was to investigate the potential of polyphenol oxidase from Agaricus bisporus to cross-link OVA (CL-OVA) in the presence or absence of caffeic acid, followed by characterizing the structure and allergenicity of CL-OVA. A single-factor experiment was designed to assess the optimum conditions for cross-linking of OVA by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Under the optimal conditions, structural changes in OVA were analyzed by circular dichroism, ultraviolet and fluorescence spectra. It was shown that CL-OVA became unordered and unfolded, and more tyrosine and tryptophan residues and hydrophobic groups were exposed onto the surface of molecules when compared to the native OVA. Enzyme-linked immunosorbent assay indicated that IgG and IgE binding abilities to OVA significantly reduced after cross-linking. All the findings demonstrated that enzymatic cross-linking in the presence of caffeic acid as a mediator may decrease the antigenicity and potential allergenicity, and the changes of the modified OVA were most likely a consequence of some changes or adjustment in the local conformation of OVA and the epitopes of OVA by cross-linking</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.10.072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037873">PM:29037873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biol Macromol\20171017-LiuK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biol Macromol\20171017-LiuK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Liu K</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.ijbiomac.2017.10.072</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bruffaerts,N.</style></author><author><style face="normal" font="Arial"> De Smedt,T.</style></author><author><style face="normal" font="Arial"> Delcloo,A.</style></author><author><style face="normal" font="Arial"> Simons,K.</style></author><author><style face="normal" font="Arial"> Hoebeke,L.</style></author><author><style face="normal" font="Arial"> Verstraeten,C.</style></author><author><style face="normal" font="Arial"> Van Nieuwenhuyse,A.</style></author><author><style face="normal" font="Arial"> Packeu,A.</style></author><author><style face="normal" font="Arial"> Hendrickx,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Service Mycology &amp; Aerobiology, Scientific Institute of Public Health, Rue Wytsmanstraat 14, 1050, Brussels, Belgium. nicolas.bruffaerts@wiv-isp.beService Health &amp; Environment, Scientific Institute of Public Health, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Comparative long-term trend analysis of daily weather conditions with daily pollen concentrations in Brussels, Belgium</style></title><secondary-title><style face="normal" font="Arial">Int J Biometeorol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Biometeorol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aerobiology</style></keyword><keyword><style face="normal" font="Arial"> Airborne</style></keyword><keyword><style face="normal" font="Arial"> Airborne pollen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic pollen</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Ash</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Beech</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Flowering</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Humidity</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Meteorological conditions</style></keyword><keyword><style face="normal" font="Arial"> Meteorological parameters</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> Mycology</style></keyword><keyword><style face="normal" font="Arial"> Oak</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plants</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentration</style></keyword><keyword><style face="normal" font="Arial"> Pollen concentrations</style></keyword><keyword><style face="normal" font="Arial"> Pollen season</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Radiation</style></keyword><keyword><style face="normal" font="Arial"> season</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> Seasons</style></keyword><keyword><style face="normal" font="Arial"> Temperature</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tree</style></keyword><keyword><style face="normal" font="Arial"> Tree pollen</style></keyword><keyword><style face="normal" font="Arial"> Trees</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Urticaceae</style></keyword><keyword><style face="normal" font="Arial"> Weather</style></keyword></keywords><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="Arial">A clear rise in seasonal and annual temperatures, a gradual increase of total radiation, and a relative trend of change in seasonal precipitation have been observed for the last four decades in Brussels (Belgium). These local modifications may have a direct and indirect public health impact by altering the timing and intensity of allergenic pollen seasons. In this study, we assessed the statistical correlations (Spearman's test) between pollen concentration and meteorological conditions by using long-term daily datasets of 11 pollen types (8 trees and 3 herbaceous plants) and 10 meteorological parameters observed in Brussels between 1982 and 2015. Furthermore, we analyzed the rate of change in the annual cycle of the same selected pollen types by the Mann-Kendall test. We revealed an overall trend of increase in daily airborne tree pollen (except for the European beech tree) and an overall trend of decrease in daily airborne pollen from herbaceous plants (except for Urticaceae). These results revealed an earlier onset of the flowering period for birch, oak, ash, plane, grasses, and Urticaceae. Finally, the rates of change in pollen annual cycles were shown to be associated with the rates of change in the annual cycles of several meteorological parameters such as temperature, radiation, humidity, and rainfall</style></abstract><notes><style face="normal" font="Arial">DA - 20171024IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00484-017-1457-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064036">PM:29064036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Biometeorol\20171024-BruffaertsN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Biometeorol\20171024-BruffaertsN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171024, Bruffaerts N</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00484-017-1457-3</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Koumaki,D.</style></author><author><style face="normal" font="Arial"> Seaton,E.D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Dermatology Department, Royal Free London NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="Arial">Successful treatment of refractory cholinergic urticaria with omalizumab</style></title><secondary-title><style face="normal" font="Arial">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Cholinergic</style></keyword><keyword><style face="normal" font="Arial"> Cholinergic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> London</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Refractory</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1111/ijd.13808</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057464">PM:29057464</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Dermatol\20171023-KoumakiD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Dermatol\20171023-KoumakiD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Koumaki D</style></custom2><misc3><style face="normal" font="Arial">10.1111/ijd.13808</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shin,H.H.</style></author><author><style face="normal" font="Arial"> Lynch,S.J.</style></author><author><style face="normal" font="Arial"> Gray,A.R.</style></author><author><style face="normal" font="Arial"> Sears,M.R.</style></author><author><style face="normal" font="Arial"> Hancox,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand</style></auth-address><titles><title><style face="normal" font="Arial">How much atopy is attributable to common childhood environmental exposures? A population-based birth cohort study followed to adulthood</style></title><secondary-title><style face="normal" font="Arial">Int J Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Epidemiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescence</style></keyword><keyword><style face="normal" font="Arial"> adulthood</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> atopic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> cat ownership</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> Crowding</style></keyword><keyword><style face="normal" font="Arial"> Day Care</style></keyword><keyword><style face="normal" font="Arial"> Day-care</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> early life</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Exposure</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Epidemiological studies</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Household</style></keyword><keyword><style face="normal" font="Arial"> Lifestyle</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> New Zealand</style></keyword><keyword><style face="normal" font="Arial"> ownership</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> preschool</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Preventive</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tobacco</style></keyword><keyword><style face="normal" font="Arial"> tobacco smoke</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="Arial">Background: The rising prevalence of atopic diseases implies a strong influence of environmental determinants. Epidemiological studies have identified several early life exposures that appear to influence the risk of developing atopic sensitization, but the combined influence of these exposures is unknown. We sought to estimate the proportion of atopy that could be attributed to common childhood exposures associated with atopic sensitization in adolescence and young adulthood. Methods: Atopic sensitization was measured by skin-prick tests for common aeroallergens in a population-based New Zealand birth cohort at ages 13 and 32 years. The independent effects of previously identified risk and protective factors for atopic sensitization were assessed using multiple logistic regression. Population attributable fractions were calculated for atopic sensitization in childhood and adulthood. Results: Tobacco smoke exposure, dog and cat ownership, nail-biting and thumb-sucking, attending pre-school day care, and household crowding were associated with a lower risk of atopic sensitization whereas breastfeeding was associated with a higher risk. Population attributable fractions for combined effects of these environmental factors suggest that they may account for 58% of atopic sensitization at age 13 and 49% at age 32 years. Conclusions: A substantial proportion of atopic sensitization appears to be attributable to common childhood environmental and lifestyle factors, and the influence of these exposures persists into adulthood. The absolute risks attributable to these exposures will be different in other cohorts and we cannot assume that these associations are necessarily causal. Nevertheless, the findings suggest that identifiable childhood environmental factors contribute substantially to atopic sensitization</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1464-3685 (Electronic)IS - 0300-5771 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="Arial">10.1093/ije/dyx098</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29040573">PM:29040573</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Epidemiol\20171017-ShinHH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Epidemiol\20171017-ShinHH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Shin HH</style></custom2><misc3><style face="normal" font="Arial">10.1093/ije/dyx098</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soh,W.T.</style></author><author><style face="normal" font="Arial"> Briza,P.</style></author><author><style face="normal" font="Arial"> Dall,E.</style></author><author><style face="normal" font="Arial"> Asam,C.</style></author><author><style face="normal" font="Arial"> Schubert,M.</style></author><author><style face="normal" font="Arial"> Huber,S.</style></author><author><style face="normal" font="Arial"> Aglas,L.</style></author><author><style face="normal" font="Arial"> Bohle,B.</style></author><author><style face="normal" font="Arial"> Ferreira,F.</style></author><author><style face="normal" font="Arial"> Brandstetter,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Molecular Biology, University of Salzburg, Salzburg 5020, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Two Distinct Conformations in Bet v 2 Determine Its Proteolytic Resistance to Cathepsin S</style></title><secondary-title><style face="normal" font="Arial">Int J Mol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Mol Sci</style></full-title></periodical><pages end="" start="E2156">E2156-</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Bet v 1</style></keyword><keyword><style face="normal" font="Arial"> Bet v 2</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Birch</style></keyword><keyword><style face="normal" font="Arial"> birch pollen</style></keyword><keyword><style face="normal" font="Arial"> Birch pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> Crystal structure</style></keyword><keyword><style face="normal" font="Arial"> Cysteine</style></keyword><keyword><style face="normal" font="Arial"> Disulfide bridge</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Leukemia</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Molecular Biology</style></keyword><keyword><style face="normal" font="Arial"> Motif</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen allergy</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Profilin</style></keyword><keyword><style face="normal" font="Arial"> Profilins</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> RBL</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Retention time</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">Birch pollen allergy affects more than 20% of the European allergic population. On a molecular level, birch pollen allergy can be linked to the two dominant allergens Bet v 1 and Bet v 2. Bet v 2 belongs to the profilin family, which is abundant in the plant kingdom. Importantly, the homologous plant profilins have a conserved cysteine motif with a currently unknown functional relevance. In particular, it is unknown whether the motif is relevant for disulfide formation and to what extent it would affect the profilins' structural, functional and immunological properties. Here we present crystal structures of Bet v 2 in the reduced and the oxidized state, i.e., without and with a disulfide bridge. Despite overall structural similarity, the two structures distinctly differ at their termini which are stabilized to each other in the oxidized, i.e., disulfide-linked state. These structural differences translate into differences in their proteolytic resistance. Whereas the oxidized Bet v 2 is rather resistant towards the endolysosomal protease cathepsin S, it is rapidly degraded in the reduced form. By contrast, both Bet v 2 forms exhibit similar immunological properties as evidenced by their binding to IgE antibodies from birch pollen allergic patients and by their ability to trigger histamine release in a humanized rat basophilic leukemia cells (RBL) assay, independent of the presence or absence of the disulfide bridge. Taken together our findings suggest that the oxidized Bet v 2 conformation should be the relevant species, with a much longer retention time to trigger immune responses</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.3390/ijms18102156</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035299">PM:29035299</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E2156.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Mol Sci\2017-18-E2156.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Soh WT</style></custom2><misc3><style face="normal" font="Arial">10.3390/ijms18102156</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wild,P.</style></author><author><style face="normal" font="Arial"> Mevel,H.</style></author><author><style face="normal" font="Arial"> Penven,E.</style></author><author><style face="normal" font="Arial"> Zmirou-Navier,D.</style></author><author><style face="normal" font="Arial"> Barbaud,A.</style></author><author><style face="normal" font="Arial"> Bohadana,A.</style></author><author><style face="normal" font="Arial"> Paris,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institut National de Recherche et de Securite, Vandoeuvre-les-Nancy</style></auth-address><titles><title><style face="normal" font="Arial">FeNO levels increase with degree of sensitisation in apprentices at risk of occupational asthma</style></title><secondary-title><style face="normal" font="Arial">Int J Tuberc Lung Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Int J Tuberc Lung Dis</style></full-title></periodical><pages end="1200" start="1194">1194-1200</pages><volume><style face="normal" font="Arial">21</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status date="12/24/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> Baking</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Challenge test</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Evolution</style></keyword><keyword><style face="normal" font="Arial"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> FeNO</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="Arial"> fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methacholine challenge</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal lavage</style></keyword><keyword><style face="normal" font="Arial"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Nitric Oxide</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> occupational asthma</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Securite</style></keyword><keyword><style face="normal" font="Arial"> Sensitisation</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> SPT</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Atopy has emerged as a major determinant of airway inflammation. OBJECTIVE: To examine whether early markers of occupational asthma increase with degree of sensitisation. METHOD: This study was a prospective follow-up study of apprentices in baking, pastry-cooking and hairdressing during their 2-year apprenticeship. Four visits were conducted to administer a standardised questionnaire, a methacholine challenge test to assess bronchial hyperresponsiveness (BHR) and to measure fractional exhaled nitric oxide (FeNO). Degree of sensitisation was estimated based on the number of positive skin prick tests (SPTs) for 12 common allergens. Mixed-effect models were applied to examine the association between the degree of sensitisation and FeNO levels, BHR and eosinophilic status (more than 3% of cells in nasal lavage fluid). RESULTS: Of the 441 apprentices who agreed to take part in the study, 417 had at least one SPT session providing usable results. Degree of sensitization was related to BHR and FeNO levels. Compared to non-sensitised subjects, FeNO levels were 83% higher (P &lt; 0.01) in highly sensitised subjects and 30% higher (P &lt; 0.01) in weakly sensitised subjects. However, the degree of sensitisation was not predictive of the evolution of these markers. CONCLUSION: Degree of sensitisation is related to early markers of airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1815-7920 (Electronic)IS - 1027-3719 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.5588/ijtld.16.0758</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037302">PM:29037302</url></web-urls><pdf-urls><url ppv-ref="no">researchgate</url></pdf-urls><related-urls><url ppv-ref="no">presto - 6 mesi</url></related-urls></urls><custom2><style face="normal" font="Arial">20171017, Wild P</style></custom2><misc3><style face="normal" font="Arial">10.5588/ijtld.16.0758</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nasu,S.</style></author><author><style face="normal" font="Arial"> Satoh,S.</style></author><author><style face="normal" font="Arial"> Shimizu,K.</style></author><author><style face="normal" font="Arial"> Matsuno,O.</style></author><author><style face="normal" font="Arial"> Morishita,H.</style></author><author><style face="normal" font="Arial"> Yaguchi,T.</style></author><author><style face="normal" font="Arial"> Kawahara,K.</style></author><author><style face="normal" font="Arial"> Matsuoka,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary and Critical Care Medicine, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, JapanDepartment of Pulmonary and Critical Care Medicine, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Spontaneous Regression of Allergic Bronchopulmonary Mycosis Due to Curvularia lunata</style></title><secondary-title><style face="normal" font="Arial">Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Intern Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary mycosis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus fumigatus</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Critical Care</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> Curvularia</style></keyword><keyword><style face="normal" font="Arial"> Curvularia lunata</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">Allergic bronchopulmonary mycosis (ABPM) is a pulmonary hypersensitivity disease mainly caused by Aspergillus fumigatus. The mainstay treatment for ABPM is systemic corticosteroid therapy. A 25-year-old man presented with pulmonary infiltrates. His peripheral eosinophil, total serum IgE, and serum Aspergillus-specific IgE levels were elevated. The patient tested positive in a skin test for Aspergillus. However, sputum cultures revealed a Curvularia lunata infection. We therefore diagnosed ABPM possibly caused by C. lunata, which is rare in Japan. The clinical state of the patient improved under observation. Identification of the causative fungus is an important aspect of the ABPM diagnosis</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1349-7235 (Electronic)IS - 0918-2918 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.2169/internalmedicine.8771-16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033414">PM:29033414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Med\20171016-NasuS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Med\20171016-NasuS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Nasu S</style></custom2><misc3><style face="normal" font="Arial">10.2169/internalmedicine.8771-16</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Boukid,F.</style></author><author><style face="normal" font="Arial"> Prandi,B.</style></author><author><style face="normal" font="Arial"> Buhler,S.</style></author><author><style face="normal" font="Arial"> Sforza,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Effectiveness of Germination on Protein Hydrolysis as a Way to Reduce Adverse Reactions to Wheat</style></title><secondary-title><style face="normal" font="Arial">J Agric Food Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Agric Food Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adaptive</style></keyword><keyword><style face="normal" font="Arial"> Adverse reaction</style></keyword><keyword><style face="normal" font="Arial"> adverse reactions</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Ash</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Baker's asthma</style></keyword><keyword><style face="normal" font="Arial"> Celiac Disease</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> components</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> Digestion</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal digestion</style></keyword><keyword><style face="normal" font="Arial"> Gel</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Germination</style></keyword><keyword><style face="normal" font="Arial"> Gluten</style></keyword><keyword><style face="normal" font="Arial"> Hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> Innate immune response</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein fraction</style></keyword><keyword><style face="normal" font="Arial"> Protein hydrolysis</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Raw</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Sequence</style></keyword><keyword><style face="normal" font="Arial"> Sequences</style></keyword><keyword><style face="normal" font="Arial"> Starch</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">In this work, the aim is to study the effectiveness of germination on wheat protein degradation, with a specific focus on proteins involved in adverse reactions to wheat. The effect of 8 days of germination at 25 degrees C on the chemical composition and the protein profile were determined. Germination did not have a significant effect on starch, protein, lipid and ash contents on dry basis. General protein profile, as indicated by gel analysis, revealed that germination induced a relevant degradation in protein fraction. After in vitro gastrointestinal digestion, gluten peptides with sequences involved in celiac disease (CD) were identified and quantified using UPLC/ESI-MS technique. Also, CM3 protein, involved in baker's asthma and intestinal inflammation, was quantified by measuring a marker peptide. Statistical analysis underlined that germination and genotype had significant impact on the amount of both components. Regarding gluten peptides related to CD, germination enabled an average reduction of 47% in peptides eliciting adaptive immune response and 46% in peptides eliciting innate immune response. CM3 protein showed also a high average reduction (56%). Thus, this study suggests that germination might be a good bio-alternative to provide a low "impact" raw ingredient for special wheat based foodstuffs</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1520-5118 (Electronic)IS - 0021-8561 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jafc.7b03175</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29059515">PM:29059515</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Agric Food Chem\20171023-BoukidF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Agric Food Chem\20171023-BoukidF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Boukid F</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jafc.7b03175</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Steelant,B.</style></author><author><style face="normal" font="Arial"> Seys,S.F.</style></author><author><style face="normal" font="Arial"> Van Gerven,L.</style></author><author><style face="normal" font="Arial"> Van Woensel,M.</style></author><author><style face="normal" font="Arial"> Farre,R.</style></author><author><style face="normal" font="Arial"> Wawrzyniak,P.</style></author><author><style face="normal" font="Arial"> Krohn,I.K.</style></author><author><style face="normal" font="Arial"> Bullens,D.M.</style></author><author><style face="normal" font="Arial"> Talavera,K.</style></author><author><style face="normal" font="Arial"> Raap,U.</style></author><author><style face="normal" font="Arial"> Boon,L.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Boeckxstaens,G.</style></author><author><style face="normal" font="Arial"> Ceuppens,J.L.</style></author><author><style face="normal" font="Arial"> Hellings,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Histamine and T helper cytokine driven epithelial barrier dysfunction in allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">air-liquid interface</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> barrier dysfunction</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial barrier</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory mediators</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> mucosal inflammation</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> nasal secretion</style></keyword><keyword><style face="normal" font="Arial"> Neurons</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Permeability</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> TH1</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cell</style></keyword><keyword><style face="normal" font="Arial"> Th2 Cells</style></keyword><keyword><style face="normal" font="Arial"> tight junction</style></keyword><keyword><style face="normal" font="Arial"> Tight Junctions</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis (AR) is characterized by mucosal inflammation, driven by activated immune cells. Mast cells and TH2 cells might decrease epithelial barrier integrity in AR maintaining a leaky epithelial barrier. OBJECTIVE: We sought to investigate the role of histamine and TH2 cells in driving epithelial barrier dysfunction in AR. METHODS: Air-liquid interface (ALI) cultures of primary nasal epithelial cells (pNECs) were used to measure trans-epithelial electrical resistance, paracellular flux of FITC-dextran 4kDa and mRNA expression of tight junctions. Nasal secretions were collected from healthy controls, AR patients and idiopathic rhinitis (IR) patients and were tested in vitro. In addition, the effect of activated TH1 and TH2 cells, mast cells and neurons was tested in vitro. The effect of IL-4, IL-13, IFN-gamma and TNFalpha on mucosal permeability was tested in vivo. RESULTS: Histamine as well as nasal secretions of AR but not IR patients rapidly decreased epithelial barrier integrity in vitro. Pretreatment with histamine receptor-1 antagonist, azelastine prevented the early effect of nasal secretions of AR patients on epithelial integrity. Supernatant of activated TH1 and TH2 cells impaired epithelial integrity, while treatment with anti-TNFalpha or anti-IL-4Ralpha monoclonal antibodies restored the TH1 and TH2 induced epithelial barrier dysfunction respectively. IL-4, IFN-gamma and TNFalpha enhanced mucosal permeability in mice. Antagonizing IL-4 prevented mucosal barrier disruption and tight junction downregulation in a mouse model of house dust mite allergic airway inflammation. CONCLUSION: Our data indicate a key role for allergic inflammatory mediators in modulating nasal epithelial barrier integrity in the pathophysiology in AR</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074456">PM:29074456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-SteelantB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-SteelantB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Steelant B</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.039</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ogasawara,N.</style></author><author><style face="normal" font="Arial"> Poposki,J.A.</style></author><author><style face="normal" font="Arial"> Klingler,A.I.</style></author><author><style face="normal" font="Arial"> Tan,B.K.</style></author><author><style face="normal" font="Arial"> Weibman,A.R.</style></author><author><style face="normal" font="Arial"> Hulse,K.E.</style></author><author><style face="normal" font="Arial"> Stevens,W.W.</style></author><author><style face="normal" font="Arial"> Peters,A.T.</style></author><author><style face="normal" font="Arial"> Grammer,L.C.</style></author><author><style face="normal" font="Arial"> Schleimer,R.P.</style></author><author><style face="normal" font="Arial"> Welch,K.C.</style></author><author><style face="normal" font="Arial"> Smith,S.S.</style></author><author><style face="normal" font="Arial"> Conley,D.B.</style></author><author><style face="normal" font="Arial"> Raviv,J.R.</style></author><author><style face="normal" font="Arial"> Soroosh,P.</style></author><author><style face="normal" font="Arial"> Akbari,O.</style></author><author><style face="normal" font="Arial"> Himi,T.</style></author><author><style face="normal" font="Arial"> Kern,R.C.</style></author><author><style face="normal" font="Arial"> Kato,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA</style></auth-address><titles><title><style face="normal" font="Arial">IL-10, TGF-beta and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Glucocorticoid</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate lymphoid cells</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.09.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074458">PM:29074458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-OgasawaraN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-OgasawaraN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Ogasawara N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.09.025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Molina-Infante,J.</style></author><author><style face="normal" font="Arial"> Arias,A.</style></author><author><style face="normal" font="Arial"> Alcedo,J.</style></author><author><style face="normal" font="Arial"> Garcia-Romero,R.</style></author><author><style face="normal" font="Arial"> Casabona-Frances,S.</style></author><author><style face="normal" font="Arial"> Prieto-Garcia,A.</style></author><author><style face="normal" font="Arial"> Modolell,I.</style></author><author><style face="normal" font="Arial"> Gonzalez-Cordero,P.L.</style></author><author><style face="normal" font="Arial"> Perez-Martinez,I.</style></author><author><style face="normal" font="Arial"> Martin-Lorente,J.L.</style></author><author><style face="normal" font="Arial"> Guarner-Argente,C.</style></author><author><style face="normal" font="Arial"> Masiques,M.L.</style></author><author><style face="normal" font="Arial"> Vila-Miravet,V.</style></author><author><style face="normal" font="Arial"> Garcia-Puig,R.</style></author><author><style face="normal" font="Arial"> Savarino,E.</style></author><author><style face="normal" font="Arial"> Sanchez-Vegazo,C.T.</style></author><author><style face="normal" font="Arial"> Santander,C.</style></author><author><style face="normal" font="Arial"> Lucendo,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Gastroenterology, Hospital Universitario San Pedro de Alcantara, Caceres, Spain; Centro de Investigacion Biomedica en Red Enfermedades Hepaticas y Digestivas (CIBEREHD), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 Study</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Cereal</style></keyword><keyword><style face="normal" font="Arial"> Cereals</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Elimination</style></keyword><keyword><style face="normal" font="Arial"> Elimination diet</style></keyword><keyword><style face="normal" font="Arial"> Elimination diets</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> EoE</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Esophagitis</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food groups</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Legume</style></keyword><keyword><style face="normal" font="Arial"> Legumes</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Nut</style></keyword><keyword><style face="normal" font="Arial"> Nuts</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Numerous dietary restrictions and endoscopies limit the implementation of empiric elimination diets in eosinophilic esophagitis (EoE). Milk and wheat/gluten are the most common food triggers. OBJECTIVE: To assess the effectiveness of a step-up dietary strategy for EoE. METHODS: Prospective study conducted in 14 centers. Patients underwent a 6-week two-food group elimination diet (TFGED) (milk and gluten-containing cereals). Remission was defined by symptom improvement and &lt;15 eos/HPF. Non-responders were gradually offered a four-food group elimination diet (FFGED: TFGED + egg and legumes) and a six-food group elimination diet (SFGED: FFGED + nuts and fish/seafood). In responders, eliminated food groups were individually reintroduced, followed by endoscopy. RESULTS: 130 patients (25 pediatric) were enrolled with 97 completing all phases of the study. A TFGED achieved EoE remission in 56 patients (43%), with no differences between ages. Food triggers in TFGED responders were milk (52%), gluten-containing grains (16%) and both (28%). EoE induced only by milk was present in 18% and 33% of adults and children, respectively. Remission rates with FFGED and SFGED were 60% and 79%, with increasing food triggers, especially after SFGED. Overall, 55/60 (91.6%) of responders to TFGED/FFGED had one or two food triggers. Compared to initial SFGED, a step-up strategy reduced endoscopic procedures and diagnostic process time by 20%. CONCLUSIONS: A TFGED diet achieves EoE remission in 43% of children and adults. A step-up approach identifies early a majority of responders to empiric diet with few food triggers, avoiding unnecessary dietary restrictions, saving endoscopies and shortening the diagnostic process</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074457">PM:29074457</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-MolinaInfanteJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-MolinaInfanteJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Molina-Infante J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Engeroff,P.</style></author><author><style face="normal" font="Arial"> Fellmann,M.</style></author><author><style face="normal" font="Arial"> Yerly,D.</style></author><author><style face="normal" font="Arial"> Bachmann,M.F.</style></author><author><style face="normal" font="Arial"> Vogel,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Rheumatology, Immunology, Allergology, Inselspital, University Hospital Bern, Freiburgstrasse, 3010, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentation</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">aggregation</style></keyword><keyword><style face="normal" font="Arial"> allergology</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigen Presentation</style></keyword><keyword><style face="normal" font="Arial"> APC</style></keyword><keyword><style face="normal" font="Arial"> B cell</style></keyword><keyword><style face="normal" font="Arial"> B cells</style></keyword><keyword><style face="normal" font="Arial"> B-cell</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> CD23</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> Coculture</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Degradation</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-dependent</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> maturation</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> MHC class II</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> monocyte-derived dendritic cells</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> surface</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cell responses</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: IgE-immune complexes have been shown to enhance antibody and T cell responses in mice by targeting CD23 (FcepsilonRII), the low-affinity receptor for IgE on B cells. In humans, the mechanism by which CD23-expressing cells take up IgE-immune complexes (IgE-IC) and process them is not well understood. OBJECTIVE: To investigate this question, we compared the fate of IgE-IC in human B cells and in CD23 expressing monocyte-derived dendritic cells (moDCs) that represent classical APCs and we aimed at studying IgE-dependent antigen presentation in both cell types. METHODS: B cells and monocytes were isolated from peripheral blood and monocytes were differentiated into moDCs. Both cell types were stimulated with IgE-immune complexes consisting of NIP-specific IgE JW8 and NIP-BSA to assess binding, uptake and degradation dynamics. To assess CD23-dependent T cell proliferation, B cells and moDCs were pulsed with IgE-NIP-Tetanus Toxoid (TT) complexes and cocultured with autologous T cells. RESULTS: IgE-IC binding was CD23-dependent in B cells and moDCs and CD23 aggregation, as well as IgE-IC internalization, occurred in both cell types. While IgE-IC was degraded in moDCs, B cells did not degrade the complexes but recycled them in native form to the cell surface enabling IgE-IC uptake by moDCs in cocultures. The resulting proliferation of specific T cells was dependent on cell-cell contact between B cells and moDC which was explained by increased upregulation of co-stimulatory molecules CD86 and MHC class II on moDCs induced by B cells. CONCLUSION: Our findings argue for a novel model in which human B cells promote specific T cell proliferation upon IgE-IC encounter. On one hand, B cells act as carriers transferring antigen to more efficient APCs such as dendritic cells, on the other hand, B cells can directly promote DC maturation and thereby enhance T cell stimulation</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.09.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074459">PM:29074459</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-EngeroffP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-EngeroffP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Engeroff P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.09.024</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,D.K.</style></author><author><style face="normal" font="Arial"> Beaven,M.A.</style></author><author><style face="normal" font="Arial"> Metcalfe,D.D.</style></author><author><style face="normal" font="Arial"> Olivera,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA</style></auth-address><titles><title><style face="normal" font="Arial">Interaction of DJ-1 with Lyn is essential for IgE-mediated stimulation of human mast cells</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> antioxidant</style></keyword><keyword><style face="normal" font="Arial"> Antioxidant activity</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Centrifugation</style></keyword><keyword><style face="normal" font="Arial"> density</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> GM-CSF</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human mast cells</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immunoprecipitation</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Initiation</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lyn</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> mediator release</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Oxygen</style></keyword><keyword><style face="normal" font="Arial"> Phosphatase</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> recombinant protein</style></keyword><keyword><style face="normal" font="Arial"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> ROS</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Src</style></keyword><keyword><style face="normal" font="Arial"> Sucrose</style></keyword><keyword><style face="normal" font="Arial"> Syk</style></keyword><keyword><style face="normal" font="Arial"> Syk kinase</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: DJ-1 is a redox-sensitive protein with multiple roles in cell homeostasis whose levels are altered in mast cell (MC)-related disorders. However, whether DJ-1 can regulate human MC function is unknown. OBJECTIVE: We sought to investigate the potential role of DJ-1 in the responses of human MCs to antigen stimulation. METHODS: DJ-1 was silenced in human CD34+-derived and LAD2 MCs using lentiviral sh-RNA constructs. Release of beta-hexosaminidase, PGD2 and GM-CSF and changes in reactive oxygen species (ROS) levels were measured after FcepsilonRI engagement. Enzymatic assays, sucrose density gradient centrifugation, immunoprecipitations, dot and Western blots, and confocal imaging were performed for signaling, cellular localization and co-association studies. RESULTS: DJ-1 knockdown substantially reduced mediator release as well as Lyn and Syk kinase activation and signaling by mechanisms which appeared largely unrelated to DJ-1 antioxidant activity. Upon FcepsilonRI activation, non-oxidized rather than oxidized DJ-1 translocated to lipid rafts where it associated with Lyn, an interaction that appeared critical for maximal Lyn activation and initiation of signaling. Using purified recombinant proteins, we demonstrated that DJ-1 bound to Lyn directly but no other Src kinases, and this interaction was specific for human but not mouse proteins. In addition, DJ-1 reduced SHP-2 phosphatase activity by scavenging ROS thus preventing Syk dephosphoryation and perpetuating MC signaling. CONCLUSION: We demonstrate a novel role for DJ-1 in the early activation of Lyn by FcepsilonRI that is essential for human MC responses and which provides the basis for an alternative target in allergic diseases therapy</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031599">PM:29031599</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171016-KimDK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171016-KimDK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Kim DK</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.030</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Christensen,M.J.</style></author><author><style face="normal" font="Arial"> Stahl,Skov P.</style></author><author><style face="normal" font="Arial"> Poulsen,L.K.</style></author><author><style face="normal" font="Arial"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="Arial"> Mortz,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Klovervaenget 15, 5000 Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="Arial">Clinical relevance of sensitization to hydrolyzed wheat protein in wheat-sensitized individuals</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical relevance</style></keyword><keyword><style face="normal" font="Arial"> Denmark</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hydrolyzed wheat protein</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.09.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031598">PM:29031598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171016-ChristensenMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171016-ChristensenMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Christensen MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.09.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lu,T.X.</style></author><author><style face="normal" font="Arial"> Rothenberg,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Gastroenterology, University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637</style></auth-address><titles><title><style face="normal" font="Arial">MicroRNA</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> Chicago</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Gastroenterology</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Isolation</style></keyword><keyword><style face="normal" font="Arial"> Maryland</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> microRNA</style></keyword><keyword><style face="normal" font="Arial"> MicroRNAs</style></keyword><keyword><style face="normal" font="Arial"> miRNA</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">MicroRNAs (miRNAs) are small endogenous RNAs that regulate gene-expression post-transcriptionally. MiRNA research in allergy is expanding because miRNAs are crucial regulators of gene expression and promising candidates for biomarker development. MiRNA mimics and miRNA inhibitors currently in preclinical development have shown promise as novel therapeutic agents. Multiple technological platforms have been developed for miRNA isolation, miRNA quantitation, miRNA profiling, miRNA target detection and for modulating miRNA levels in vitro and in vivo. Here we will review the major technological platforms with consideration given for the advantages and disadvantages of each platform</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074454">PM:29074454</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-LuTX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-LuTX.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Lu TX</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.034</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schawaller,M.</style></author><author><style face="normal" font="Arial"> Rhyner,C.</style></author><author><style face="normal" font="Arial"> Wiki,M.</style></author><author><style face="normal" font="Arial"> Quapil,G.</style></author><author><style face="normal" font="Arial"> Zuberbier,T.</style></author><author><style face="normal" font="Arial"> Akdis,C.A.</style></author><author><style face="normal" font="Arial"> Crameri,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Davos Diagnostics AG, Clavadelerstrasse 1, CH-7270 Davos, Switzerland; Swiss Institute for Allergy and Asthma Research (SIAF), University of Zurich, Obere Strasse 22, CH-7270 Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Evanescence Wave-Based Technology for the Rapid and Sensitive Quantification of Biological Analytes</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Allergy Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Analyte</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaci.2017.08.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074455">PM:29074455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-SchawallerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171027-SchawallerM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Schawaller M</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaci.2017.08.037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Patel,D.R.</style></author><author><style face="normal" font="Arial"> Upton,J.E.M.</style></author><author><style face="normal" font="Arial"> Wang,J.</style></author><author><style face="normal" font="Arial"> Harada,L.</style></author><author><style face="normal" font="Arial"> Guffey,D.</style></author><author><style face="normal" font="Arial"> Minard,C.G.</style></author><author><style face="normal" font="Arial"> Orange,J.</style></author><author><style face="normal" font="Arial"> Davis,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Section of Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston, Texas</style></auth-address><titles><title><style face="normal" font="Arial">Quality of life for parents of children with food allergy in peanut-restricted versus peanut-free schools in the United States and Canada</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> quality</style></keyword><keyword><style face="normal" font="Arial"> Quality of Life</style></keyword><keyword><style face="normal" font="Arial"> Quality-of-life</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171021IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29054706">PM:29054706</url></web-urls><pdf-urls><url ppv-ref="no">dipika.patel86@gmail.com</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20171021, Patel DR</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.08.013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Workman,A.D.</style></author><author><style face="normal" font="Arial"> Brooks,S.G.</style></author><author><style face="normal" font="Arial"> Kohanski,M.A.</style></author><author><style face="normal" font="Arial"> Blasetti,M.T.</style></author><author><style face="normal" font="Arial"> Cowart,B.J.</style></author><author><style face="normal" font="Arial"> Mansfield,C.</style></author><author><style face="normal" font="Arial"> Kennedy,D.W.</style></author><author><style face="normal" font="Arial"> Palmer,J.N.</style></author><author><style face="normal" font="Arial"> Adappa,N.D.</style></author><author><style face="normal" font="Arial"> Reed,D.R.</style></author><author><style face="normal" font="Arial"> Cohen,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pa</style></auth-address><titles><title><style face="normal" font="Arial">Bitter and sweet taste tests are reflective of disease status in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Pennsylvania</style></keyword><keyword><style face="normal" font="Arial"> Philadelphia</style></keyword><keyword><style face="normal" font="Arial"> rhinosinusitis</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Taste</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171021IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaip.2017.09.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29054707">PM:29054707</url></web-urls><pdf-urls><url ppv-ref="no">noam.cohen@uphs.upenn.edu</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20171021, Workman AD</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaip.2017.09.014</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Casale,T.B.</style></author><author><style face="normal" font="Arial"> Win,P.H.</style></author><author><style face="normal" font="Arial"> Bernstein,J.A.</style></author><author><style face="normal" font="Arial"> Rosen,K.</style></author><author><style face="normal" font="Arial"> Holden,M.</style></author><author><style face="normal" font="Arial"> Iqbal,A.</style></author><author><style face="normal" font="Arial"> Trzaskoma,B.L.</style></author><author><style face="normal" font="Arial"> Yang,M.</style></author><author><style face="normal" font="Arial"> Antonova,E.N.</style></author><author><style face="normal" font="Arial"> Murphy,T.</style></author><author><style face="normal" font="Arial"> Scarupa,M.D.</style></author><author><style face="normal" font="Arial"> Sofen,H.</style></author><author><style face="normal" font="Arial"> Kaplan,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">University of South Florida, Tampa, Florida</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab Response in Patients with Chronic Idiopathic Urticaria: Insights from the XTEND-CIU Study</style></title><secondary-title><style face="normal" font="Arial">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> Idiopathic</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jaad.2017.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037993">PM:29037993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Am Acad Dermatol\20171017-CasaleTB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Am Acad Dermatol\20171017-CasaleTB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Casale TB</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jaad.2017.10.010</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ziyaei,T.</style></author><author><style face="normal" font="Arial"> Berenji,F.</style></author><author><style face="normal" font="Arial"> Jabbari-Azad,F.</style></author><author><style face="normal" font="Arial"> Fata,A.</style></author><author><style face="normal" font="Arial"> Jarahi,L.</style></author><author><style face="normal" font="Arial"> Fereidouni,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Parasitology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="Arial">House Dust Mite Prevalence in the House of Patients with Atopic Dermatitis in Mashhad, Iran</style></title><secondary-title><style face="normal" font="Arial">J Arthropod Borne Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Arthropod Borne Dis</style></full-title></periodical><pages end="314" start="309">309-314</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> bedrooms</style></keyword><keyword><style face="normal" font="Arial"> carpet</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="Arial"> cross-sectional study</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> dust samples</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Iran</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> parasitology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vacuum</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Being exposed to house dust mites intensifies atopic dermatitis. This study has investigated the contamination rate with Dermatophagoides mites in patient's residential home with atopic dermatitis. METHODS: In this cross-sectional study, 40 patients took part with atopic dermatitis (positive or negative for mites by prick Dermal Test). Samples were collected from 3 locations (living room, bedroom and bed) by vacuum cleaner. Dust samples (transferred to freezer -20 degrees C) were examined by direct method and flotation. The data were analyzed using statistical SPSS vr.20 software. RESULTS: Twenty patients of positive prick test included 8 (40%) male and 12 (60%) female. The results of direct observation of mites: 7 cases (35%) in bedding sheets, 6 cases (30%) bedrooms' carpet, 3 cases (15%) living room's carpet. Twenty patients of negative prick test included 8 (40%) male and 12 (60%) female. Only mites were found (5%) in living room's carpets of negative prick test patients. Dermatophagoides pteronyssinus was more frequent than Dermatophagoides farinae. (98% vs 83%). CONCLUSION: Fifty-five percent of residential homes of prick test positive patients and only 5% of residential homes of prick test negative patients were positive for mite. Sunshine provided home had fewer mites than home where sunshine is not provided. Prick test positive patients used handmade carpets more than machine made ones. In positive prick test patients, mites were found in bed sheet and bedroom's carpet more than negative prick test patient's sheets and carpets</style></abstract><notes><style face="normal" font="Arial">DA - 20171024IS - 2322-1984 (Print)IS - 2322-1984 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29062855">PM:29062855</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Arthropod Borne Dis\2017-11-309-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Arthropod Borne Dis\2017-11-309-14.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171024, Ziyaei T</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Memona,H.</style></author><author><style face="normal" font="Arial"> Manzoor,F.</style></author><author><style face="normal" font="Arial"> Riaz,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Zoology, Lahore College for Women University, Lahore, Pakistan</style></auth-address><titles><title><style face="normal" font="Arial">Species Diversity and Distributional Pattern of Cockroaches in Lahore, Pakistan</style></title><secondary-title><style face="normal" font="Arial">J Arthropod Borne Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Arthropod Borne Dis</style></full-title></periodical><pages end="259" start="249">249-259</pages><volume><style face="normal" font="Arial">11</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Attention</style></keyword><keyword><style face="normal" font="Arial"> Behavior</style></keyword><keyword><style face="normal" font="Arial"> Biology</style></keyword><keyword><style face="normal" font="Arial"> Blattella germanica</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Habitat</style></keyword><keyword><style face="normal" font="Arial"> Hand</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Hospitals</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Humans</style></keyword><keyword><style face="normal" font="Arial"> indoor</style></keyword><keyword><style face="normal" font="Arial"> Insecticides</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbes</style></keyword><keyword><style face="normal" font="Arial"> Pakistan</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta</style></keyword><keyword><style face="normal" font="Arial"> Periplaneta americana</style></keyword><keyword><style face="normal" font="Arial"> pest</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Sanitation</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urban area</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Cockroaches are found as the most common urban pests of tropical countries, prompting economic and serious health risk problem for humans by carrying microbes and allergens, acting as vector for various pathogens of diseases. The present study was conducted from April 2013 to March 2014 in various human dwelling localities of urban area of district Lahore, Pakistan. METHODS: Cockroaches were collected randomly by hand, food baited and sticky traps throughout the year. Four species of cockroaches (Periplaneta Americana (P. amercana), Blattella germanica (B. germanica), Blatta orientalis (B. orientalis), and Blatta lateralis (B. lateralis) were collected and identified from the study site. RESULTS: B. germanica was the most dominant indoor species with highest diversity indices in study areas. Overall cockroach species diversity was highest in July-September, 2013 with highest Simpson index of diversity and Shannon index as well. P. americana was found second broadly distributed in the study area followed by B. orientalis and B. lateralis were intermediately distributed in residential areas and narrowly distributed in hospitals. Residential areas and hospitals were highly infested with B. germanica followed by P. americana. Population index of B. germanica for hospitals was double than residential areas. B. lateralis was observed as displacing B. orientalis in outdoor habitat through competing with its habitat and food sources. CONCLUSION: The infestation rate of different species depends on availability of food sources, sanitary conditions and climatic conditions. Cockroach infestation can be controlled with knowledge about their biology and behavior, attention to sanitation and effective use of commercial insecticides</style></abstract><notes><style face="normal" font="Arial">DA - 20171024IS - 2322-1984 (Print)IS - 2322-1984 (Linking)LA - engPT - Journal ArticleCO - Pakistan -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29062850">PM:29062850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Arthropod Borne Dis\2017-11-249-59.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Arthropod Borne Dis\2017-11-249-59.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171024, Memona H</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gamaletsou,M.N.</style></author><author><style face="normal" font="Arial"> Hayes,G.</style></author><author><style face="normal" font="Arial"> Harris,C.</style></author><author><style face="normal" font="Arial"> Brock,J.</style></author><author><style face="normal" font="Arial"> Muldoon,E.G.</style></author><author><style face="normal" font="Arial"> Denning,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a The National Aspergillosis Centre , University Hospital of South Manchester, The University of Manchester and Manchester Academic Health Science Centre , Manchester , UK</style></auth-address><titles><title><style face="normal" font="Arial">F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="Arial">J Asthma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Asthma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> bronchiectasis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Case-Control Studies</style></keyword><keyword><style face="normal" font="Arial"> case-control study</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic pulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> comorbidities</style></keyword><keyword><style face="normal" font="Arial"> Comorbidity</style></keyword><keyword><style face="normal" font="Arial"> Counseling</style></keyword><keyword><style face="normal" font="Arial"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> Delta</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Europe</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic Counseling</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Heterozygote</style></keyword><keyword><style face="normal" font="Arial"> Hypergammaglobulinemia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Igg</style></keyword><keyword><style face="normal" font="Arial"> IgG antibodies</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> multiplex</style></keyword><keyword><style face="normal" font="Arial"> Multiplex PCR</style></keyword><keyword><style face="normal" font="Arial"> Multiplex-PCR</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> mutation analysis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PCR</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> pulmonary function</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> UK</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: The F508del mutation occurs in approximately 3.5% of Caucasian population of Northern Europe. Heterozygotes have increased risk for asthma and reduced pulmonary function. Allergic bronchopulmonary aspergillosis (ABPA) is more common in patients with cystic fibrosis (CF). We aimed to establish the frequency of F508del mutation in adult patients with ABPA. METHODS: A retrospective matched case-control study of CF genotyped patients with ABPA seen at the National Aspergillosis Centre was undertaken. Key data were collected retrospectively from medical records, including respiratory comorbidities, total IgE, Aspergillus IgG and IgE, and immunoglobulins. Cystic fibrosis transmembrane regulator (CFTR) gene mutation analysis included multiplex PCR and sequencing. RESULTS: From a cohort of 189 ABPA patients, 156 were screened for common mutations and variants in the CFTR gene. Eighteen were heterozygous for at least one CFTR mutation; 12 (7.7%) were heterozygous for the F508del, notably; 3 were heterozygous for the intron 8 5T variant; and 1 for an intronic variant of uncertain significance, c.3139 + 18C>T. Eight (67%) had asthma, 7 (58%) had CT-defined bronchiectasis, 4 (33%) hypergammaglobulinemia (>16 g/L), 3 (25%) sinusitis and 1 (8%) chronic pulmonary aspergillosis. Eight (67%) had elevated Aspergillus IgG antibodies (42-98 mg/L), and 8 (67%) had total IgE above 1,000 KIU/L. Two individuals heterozygous for the F508del mutation and the TG12T5 variant were diagnosed with CF, leading to a de novo CF discovery rate of 1.3%. CONCLUSIONS: In our ABPA patient cohort, the presence of the delta F508 mutation was higher than that seen in general population. Genetic counseling for CFTR genotyping might be appropriate for these patients</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1080/02770903.2017.1373808</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035608">PM:29035608</url></web-urls><pdf-urls><url ppv-ref="no">magama@med.uoa.gr</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Gamaletsou MN</style></custom2><misc3><style face="normal" font="Arial">10.1080/02770903.2017.1373808</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Alroqi,F.J.</style></author><author><style face="normal" font="Arial"> Charbonnier,L.M.</style></author><author><style face="normal" font="Arial"> Keles,S.</style></author><author><style face="normal" font="Arial"> Ghandour,F.</style></author><author><style face="normal" font="Arial"> Mouawad,P.</style></author><author><style face="normal" font="Arial"> Sabouneh,R.</style></author><author><style face="normal" font="Arial"> Mohammed,R.</style></author><author><style face="normal" font="Arial"> Almutairi,A.</style></author><author><style face="normal" font="Arial"> Chou,J.</style></author><author><style face="normal" font="Arial"> Massaad,M.J.</style></author><author><style face="normal" font="Arial"> Geha,R.S.</style></author><author><style face="normal" font="Arial"> Baz,Z.</style></author><author><style face="normal" font="Arial"> Chatila,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunology, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Karp Family Building, Room 10-214. 1 Blackfan Street, Boston, MA, 02115, USA</style></auth-address><titles><title><style face="normal" font="Arial">DOCK8 Deficiency Presenting as an IPEX-Like Disorder</style></title><secondary-title><style face="normal" font="Arial">J Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anemia</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Boston</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> colitis</style></keyword><keyword><style face="normal" font="Arial"> deficiency</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> DOCK8</style></keyword><keyword><style face="normal" font="Arial"> dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Ear</style></keyword><keyword><style face="normal" font="Arial"> ear infections</style></keyword><keyword><style face="normal" font="Arial"> Eczema</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> enteropathy</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune dysregulation</style></keyword><keyword><style face="normal" font="Arial"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="Arial"> immunodeficiency</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Immunophenotyping</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> IPEX</style></keyword><keyword><style face="normal" font="Arial"> IPEX-like</style></keyword><keyword><style face="normal" font="Arial"> Lebanon</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> malignancy</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mutation</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> polyendocrinopathy</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein expression</style></keyword><keyword><style face="normal" font="Arial"> Recurrent infections</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> Saudi Arabia</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Treg</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="Arial">PURPOSE: The dedicator of cytokinesis 8 (DOCK8) deficiency is an autosomal recessive-combined immunodeficiency whose clinical spectra include recurrent infections, autoimmunity, malignancies, elevated serum IgE, eczema, and food allergies. Here, we report on patients with loss of function DOCK8 mutations with profound immune dysregulation suggestive of an immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)-like disorder. METHODS: Immunophenotyping of lymphocyte subpopulations and analysis of DOCK8 protein expression were evaluated by flow cytometry. T regulatory (Treg) cells were isolated by cell sorting, and their suppressive activity was analyzed by flow cytometry. Gene mutational analysis was performed by whole-exome and Sanger sequencing. RESULTS: Patient 1 (P1) presented at 10 months of age with chronic severe diarrhea and active colitis in the absence of an infectious trigger, severe eczema with elevated serum IgE, and autoimmune hemolytic anemia, suggestive of an IPEX-related disorder. Whole-exome sequencing revealed a homozygous nonsense mutation in DOCK8 at the DOCK-homology region (DHR)-1 (c.1498C>T; p. R500X). Patient P2, a cousin of P1 who carries the same DOCK8 nonsense mutation, presented with eczema and recurrent ear infections in early infancy, and she developed persistent diarrhea by 3 years of age. Patient P3 presented with lymphoproliferation, severe eczema with allergic dysregulation, and chronic diarrhea with colitis. She harbored a homozygous loss of function DOCK8 mutation (c.2402 -1G-->A). Treg cell function was severely compromised by both DOCK8 mutations. CONCLUSION: DOCK8 deficiency may present severe immune dysregulation with features that may overlap with those of IPEX and other IPEX-like disorders</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1573-2592 (Electronic)IS - 0271-9142 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Saudi Arabia -CO - Turkey -CO - Lebanon -</style></notes><work-type><style face="normal" font="Arial">10.1007/s10875-017-0451-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29058101">PM:29058101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Immunol\20171023-AlroqiFJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Immunol\20171023-AlroqiFJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Alroqi FJ</style></custom2><misc3><style face="normal" font="Arial">10.1007/s10875-017-0451-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Uddin,M.J.</style></author><author><style face="normal" font="Arial"> Gill,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA</style></auth-address><titles><title><style face="normal" font="Arial">Ragweed pollen as an oral vaccine delivery system: Mechanistic insights</style></title><secondary-title><style face="normal" font="Arial">J Control Release</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Control Release</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> activation marker</style></keyword><keyword><style face="normal" font="Arial"> adaptive</style></keyword><keyword><style face="normal" font="Arial"> adaptive immunity</style></keyword><keyword><style face="normal" font="Arial"> Affect</style></keyword><keyword><style face="normal" font="Arial"> Ambrosia</style></keyword><keyword><style face="normal" font="Arial"> antigen</style></keyword><keyword><style face="normal" font="Arial"> Antigens</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> CD40</style></keyword><keyword><style face="normal" font="Arial"> CD86</style></keyword><keyword><style face="normal" font="Arial"> Cell Membrane</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemical</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Class</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Delivery system</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> electron</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> grain</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> Immune System</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> Inflammatory cytokines</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune system</style></keyword><keyword><style face="normal" font="Arial"> intestine</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> MHC</style></keyword><keyword><style face="normal" font="Arial"> MHC class II</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Microscopy</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Pollen grain</style></keyword><keyword><style face="normal" font="Arial"> Pollen grains</style></keyword><keyword><style face="normal" font="Arial"> Pollens</style></keyword><keyword><style face="normal" font="Arial"> processing</style></keyword><keyword><style face="normal" font="Arial"> Ragweed</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> scanning electron microscopy</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> Vaccine</style></keyword><keyword><style face="normal" font="Arial"> Vaccines</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">We have recently developed pollen grains (PGs) as a unique method to deliver vaccines orally. Extensive chemical processing ensures allergen-free pollen microcapsules that can be loaded with vaccine antigens. Successful oral vaccine delivery has been previously demonstrated by us in a mouse model. However, the underlying mechanisms that help the processed PGs to achieve this goal were not fully understood. In this study, we wanted to understand the effects of chemically processed ragweed pollen (Ambrosia elatior) on the innate immune system. Intestinal epithelial cells, macrophages, and dendritic cells all bridge the innate and adaptive immunity. This study has shown that in response to ragweed pollen all these cells release inflammatory cytokines and chemokines. Scanning electron microscopy imaging revealed that macrophages can engulf ragweed pollen. In addition, in the presence of ragweed, mouse dendritic cells upregulated their activation markers, that is, CD40, CD80, CD86, and MHC class II molecules. Ragweed pollens did not cause significant cell membrane damage as compared to similarly sized poly (lactic-co-glycolic acid) particles. Moreover, ragweed did not affect the integrity of the intestinal epithelial cells. Ragweed pollens were also found in the subepithelial region of the small intestine 24h after pollens were gavaged to mice. Our current findings lead to the conclusion that besides transporting the vaccine cargo, ragweed pollen shells have additional immunomodulatory properties that help the orally delivered antigen to effectively induce an immune response</style></abstract><notes><style face="normal" font="Arial">DA - 20171021IS - 1873-4995 (Electronic)IS - 0168-3659 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.jconrel.2017.10.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29054371">PM:29054371</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Control Release\20171021-UddinMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Control Release\20171021-UddinMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171021, Uddin MJ</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.jconrel.2017.10.019</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dhadwal,G.</style></author><author><style face="normal" font="Arial"> Kirchhof,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">1 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada2 Division of Dermatology, Department of Medicine, Queen's University, Kingston, ON, Canada</style></auth-address><titles><title><style face="normal" font="Arial">The Risks and Benefits of Cannabis in the Dermatology Clinic</style></title><secondary-title><style face="normal" font="Arial">J Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Cutan Med Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Arteritis</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cannabis</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Indications</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Legislation</style></keyword><keyword><style face="normal" font="Arial"> lupus</style></keyword><keyword><style face="normal" font="Arial"> Marijuana</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Necrosis</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Presentation</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Pruritus</style></keyword><keyword><style face="normal" font="Arial"> Psoriasis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risks</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Smoke</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> Ulcer</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Wound Healing</style></keyword></keywords><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="Arial">Cannabis ( Cannabis sativa/indica), also known as marijuana, has been used for medicinal and recreational purposes for millennia. There has been a recent trend to legalize the use of cannabis, as illustrated by the recent legalization votes in numerous states in the United States and legislation in Canada to allow recreational cannabis use. With this increasing consumption of cannabis, dermatologists will see increased pressure to prescribe cannabis and will see the side effects of cannabis use with greater frequency. There are several approved medical indications for cannabis use, including psoriasis, lupus, nail-patella syndrome, and severe pain. In addition, very preliminary studies have suggested cannabis and its derivatives might have use in acne, dermatitis, pruritus, wound healing, and skin cancer. Further well-controlled studies are required to explore these potential uses. Conversely, the side effects of cannabis use are relatively well documented, and dermatologists should be aware of these presentations. Side effects of cannabis use include cannabis allergy manifesting as urticaria and pruritus, cannabis arteritis presenting with necrosis and ulcers, and oral cancers from cannabis smoke. In this review, we summarize some of the studies and reports regarding the medicinal uses of cannabis in the dermatology clinic and some of the side effects that might present more often to dermatologists as the use of cannabis increases</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1615-7109 (Electronic)IS - 1203-4754 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1177/1203475417738971</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29056081">PM:29056081</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cutan Med Surg\20171023-DhadwalG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cutan Med Surg\20171023-DhadwalG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Dhadwal G</style></custom2><misc3><style face="normal" font="Arial">10.1177/1203475417738971</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kulthanan,K.</style></author><author><style face="normal" font="Arial"> Tuchinda,P.</style></author><author><style face="normal" font="Arial"> Likitwattananurak,C.</style></author><author><style face="normal" font="Arial"> Weerasubpong,P.</style></author><author><style face="normal" font="Arial"> Chularojanamontri,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients</style></title><secondary-title><style face="normal" font="Arial">J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Asian</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic spontaneous</style></keyword><keyword><style face="normal" font="Arial"> chronic spontaneous urticaria</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cyclosporin A</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Injections</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical Records</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prednisolone</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> remission</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> urticaria activity score</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">Omalizumab has been approved for the treatment of recalcitrant chronic spontaneous urticaria (CSU). However, it remains unanswered whether omalizumab modifies a CSU course. We aimed to study a course of CSU after omalizumab treatment in an Asian population. Medical records of recalcitrant CSU patients who attended Siriraj Hospital between 2013 and 2017 were reviewed. All patients receiving omalizumab treatment were followed after the first injection for at least 1 year. Of 15 patients receiving omalizumab treatment, 11 patients (73.3%) responded well to 150 mg while the rest required 300 mg. The median follow-up period was 18 months (range, 13.5-25.3). Three patterns of response were proposed and measured: excellent (disease remission over than 6 months) was found in 20%; good (injection interval extended longer than 6 months) was found in 27%; and modest (frequently required injections) was found in 53%. The mean duration of complete remission was 33 weeks (range, 26-38). Two-thirds of patients had disease relapse and required omalizumab injections to control symptoms. The other third did not show relapses for at least 69 weeks of the follow-up period. After 1 year of treatment, Kaplan-Meier curves estimated that a higher percentage (86.7%) of recalcitrant CSU patients receiving omalizumab treatment would be free of symptoms (weekly Urticaria Activity Score = 0) without prednisolone and/or cyclosporin as compared with 42% of patients not receiving omalizumab treatment. In conclusion, patients seem to be easily and safely manageable with omalizumab. Prednisolone and cyclosporin could be discontinued in all patients. Further studies are needed to conclude whether omalizumab can exactly modify CSU</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1111/1346-8138.14081</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29044681">PM:29044681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatol\20171018-KulthananK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatol\20171018-KulthananK.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Kulthanan K</style></custom2><misc3><style face="normal" font="Arial">10.1111/1346-8138.14081</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ivens,K.O.</style></author><author><style face="normal" font="Arial"> Baumert,J.L.</style></author><author><style face="normal" font="Arial"> Hutkins,R.L.</style></author><author><style face="normal" font="Arial"> Taylor,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Food Allergy Research and Resource Program, Dept. of Food Science and Technology, Univ. of Nebraska-Lincoln, 281 Food Innovation Center, 1901 North 21st Street, P.O. Box 886207, Lincoln, NE, 68588, U.S.A</style></auth-address><titles><title><style face="normal" font="Arial">The Effect of Different Methods of Fermentation on the Detection of Milk Protein Residues in Retail Cheese by Enzyme-Linked Immunosorbent Assay (ELISA)</style></title><secondary-title><style face="normal" font="Arial">J Food Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Food Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen control</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic residues</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cheese</style></keyword><keyword><style face="normal" font="Arial"> Commercial</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Enzyme</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> Enzymes</style></keyword><keyword><style face="normal" font="Arial"> epitope</style></keyword><keyword><style face="normal" font="Arial"> Epitopes</style></keyword><keyword><style face="normal" font="Arial"> Fermentation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food ingredients</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Indication</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Innovation</style></keyword><keyword><style face="normal" font="Arial"> KIT</style></keyword><keyword><style face="normal" font="Arial"> Manufacture</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk protein</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteolysis</style></keyword><keyword><style face="normal" font="Arial"> Proteolytic enzyme</style></keyword><keyword><style face="normal" font="Arial"> Proteolytic enzymes</style></keyword><keyword><style face="normal" font="Arial"> Quantitative</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> reliability</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Residues</style></keyword><keyword><style face="normal" font="Arial"> Ripening</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> Validation</style></keyword></keywords><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="Arial">Milk and milk products are among the most important allergenic food ingredients, both in the United States and throughout the world; cheeses are among the most important of these milk products. Milk contains several major antigenic proteins, each with differing susceptibilities to proteolytic enzymes. The extent of proteolysis in cheese varies as a result of conditions during manufacture and ripening. Proteolysis has the potential to degrade antigenic and allergenic epitopes that are important for residue detection and elicitation of allergic reactions. Commercial enzyme-linked immunosorbent assays (ELISAs) are not currently validated for use in detecting residues in hydrolyzed or fermented food products. Eighteen retail cheeses produced using 5 different styles of fermentation were investigated for detectable milk protein residues with 4 commercial ELISA kits. Mozzarella, Swiss, Blue, Limburger, and Brie cheeses were assessed. The Neogen Veratox(R) Casein and Neogen Veratox(R) Total Milk kits were capable of detecting milk residues in most cheeses evaluated, including blue-veined cheeses that exhibit extensive proteolysis. The other 2 ELISA kits evaluated, r-Biopharm(R) Fast Casein and ELISA Systems Casein, can detect milk residues in cheeses other than blue-veined varieties. ELISA results cannot be quantitatively compared among kits. The quantitative reliability of ELISA results in detection of cheese residues is questionable, but some methods are sufficiently robust to use as a semi-quantitative indication of proper allergen control for the validation of cleaning programs in industry settings. PRACTICAL APPLICATION: Many commercially available enzyme-linked immunosorbent assays (ELISAs) are not validated for detection of allergenic residues in fermented or hydrolyzed products. This research seeks to determine if commercial milk ELISAs can detect milk residues in varieties of cheese that have undergone different styles of fermentation and different degrees of proteolysis. Only certain milk ELISA kits are capable of detecting residues in all varieties of cheese. However, commercial milk ELISA kits are capable of semiquantitative detection of cheese residues in foods, or in industry settings for the validation of allergen cleaning programs</style></abstract><notes><style face="normal" font="Arial">DA - 20171025IS - 1750-3841 (Electronic)IS - 0022-1147 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1111/1750-3841.13929</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29069538">PM:29069538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Food Sci\20171025-IvensKO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Food Sci\20171025-IvensKO.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171025, Ivens KO</style></custom2><misc3><style face="normal" font="Arial">10.1111/1750-3841.13929</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Kim,Y.W.</style></author><author><style face="normal" font="Arial"> Singh,A.</style></author><author><style face="normal" font="Arial"> Shannon,C.P.</style></author><author><style face="normal" font="Arial"> Thiele,J.</style></author><author><style face="normal" font="Arial"> Steacy,L.M.</style></author><author><style face="normal" font="Arial"> Ellis,A.K.</style></author><author><style face="normal" font="Arial"> Neighbour,H.</style></author><author><style face="normal" font="Arial"> Gliddon,D.R.</style></author><author><style face="normal" font="Arial"> Hickey,P.L.C.</style></author><author><style face="normal" font="Arial"> Larche,M.</style></author><author><style face="normal" font="Arial"> Tebbutt,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Experimental Medicine, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Investigating Immune Gene Signatures in Peripheral Blood from Subjects with Allergic Rhinitis Undergoing Nasal Allergen Challenge</style></title><secondary-title><style face="normal" font="Arial">J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> investigation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> nasal allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> Neutrophil</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="18" Month="10" Year="2017">2017/10/18</year></dates><abstract><style face="normal" font="Arial">Nasal allergen challenge (NAC) is a human model of allergic rhinitis (AR) that delivers standardized allergens locally to the nasal mucosa allowing clinical symptoms and biospecimens such as peripheral blood to be collected. Although many studies have focused on local inflammatory sites, peripheral blood, an important mediator and a component of the systemic immune response, has not been well studied in the setting of AR. We sought to investigate immune gene signatures in peripheral blood collected after NAC under the setting of AR. Clinical symptoms and peripheral blood samples from AR subjects were collected during NAC. Fuzzy c-means clustering method was used to identify immune gene expression patterns in blood over time points (before NAC and 1, 2, and 6 h after NAC). We identified and validated seven clusters of differentially expressed immune genes after NAC onset. Clusters 2, 3, and 4 were associated with neutrophil and lymphocyte frequencies and neutrophil/lymphocyte ratio after the allergen challenge. The patterns of the clusters and immune cell frequencies were associated with the clinical symptoms of the AR subjects and were significantly different from healthy nonallergic subjects who had also undergone NAC. Our approach identified dynamic signatures of immune gene expression in blood as a systemic immune response associated with clinical symptoms after NAC. The immune gene signatures may allow cross-sectional investigation of the pathophysiology of AR and may also be useful as a potential objective measurement for diagnosis and treatment of AR combined with the NAC model</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.4049/jimmunol.1700378</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046347">PM:29046347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Immunol\20171019-KimYW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Immunol\20171019-KimYW.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Kim YW</style></custom2><misc3><style face="normal" font="Arial">10.4049/jimmunol.1700378</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nahas,O.</style></author><author><style face="normal" font="Arial"> Colomb,S.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> Bourrain,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonology, Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France</style></auth-address><titles><title><style face="normal" font="Arial">Protein Contact Dermatitis to Chrysanthemum</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="319" start="318">318-319</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Contact</style></keyword><keyword><style face="normal" font="Arial"> Contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein contact dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0172</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057739">PM:29057739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Nahas O</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0172</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nunez-Orjales,R.</style></author><author><style face="normal" font="Arial"> Martin-Lazaro,J.</style></author><author><style face="normal" font="Arial"> Lopez-Freire,S.</style></author><author><style face="normal" font="Arial"> Galan-Nieto,A.</style></author><author><style face="normal" font="Arial"> Lombardero-Vega,M.</style></author><author><style face="normal" font="Arial"> Carballada-Gonzalez,F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Allergy, Lucus Augusti Hospital, Lugo, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Bovine Amniotic Fluid: A New and Occupational Source of Galactose-alpha-1,3-Galactose</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="314" start="313">313-314</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Amniotic Fluid</style></keyword><keyword><style face="normal" font="Arial"> Bovine</style></keyword><keyword><style face="normal" font="Arial"> Galactose-alpha-1,3-galactose</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0170</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057737">PM:29057737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Nunez-Orjales R</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0170</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Breynaert,C.</style></author><author><style face="normal" font="Arial"> Van Hoeyveld,E.</style></author><author><style face="normal" font="Arial"> Bullens,D.</style></author><author><style face="normal" font="Arial"> Schrijvers,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory Of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Initial False-Negative Specific IgE to Gelatin in Gelatin-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="335" start="333">333-335</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> false negative</style></keyword><keyword><style face="normal" font="Arial"> Gelatin</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0187</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057747">PM:29057747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Breynaert C</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0187</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Montagni,M.</style></author><author><style face="normal" font="Arial"> Peveri,S.</style></author><author><style face="normal" font="Arial"> Incorvaia,C.</style></author><author><style face="normal" font="Arial"> Savi,E.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departmental Unit of Allergology, Guglielmo da Saliceto Hospital, Piacenza, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Scoliid Wasp Sting: A New Cause of Anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="333" start="331">331-333</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> WASP</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0186</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057746">PM:29057746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Montagni M</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0186</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Carbonell,A.</style></author><author><style face="normal" font="Arial"> Miralles,J.C.</style></author><author><style face="normal" font="Arial"> Escudero,A.I.</style></author><author><style face="normal" font="Arial"> Cardona,P.</style></author><author><style face="normal" font="Arial"> Gonzalez,A.</style></author><author><style face="normal" font="Arial"> Navarro,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Allergology Section, Hospital General Universitario Reina Sofia, Murcia, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Fixed Eruption by Multiple Plant Foods</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="325" start="324">324-325</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergology</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Plant</style></keyword><keyword><style face="normal" font="Arial"> Plant food</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0176</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057742">PM:29057742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Carbonell A</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0176</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ensina,L.F.</style></author><author><style face="normal" font="Arial"> Cusato-Ensina,A.P.</style></author><author><style face="normal" font="Arial"> Camelo-Nunes,I.C.</style></author><author><style face="normal" font="Arial"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="Arial">Omalizumab as Third-Line Therapy for Urticaria During Pregnancy</style></title><secondary-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="327" start="326">326-327</pages><volume><style face="normal" font="Arial">27</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Brazil</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical immunology</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="Arial">10.18176/jiaci.0179</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057743">PM:29057743</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Investig Allergol Clin Immunol\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Ensina LF</style></custom2><misc3><style face="normal" font="Arial">10.18176/jiaci.0179</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sahin,E.</style></author><author><style face="normal" font="Arial"> Dizdar,D.</style></author><author><style face="normal" font="Arial"> Dinc,M.E.</style></author><author><style face="normal" font="Arial"> Cirik,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otolaryngology, Head and Neck Surgery,Bayindir Hospital Icerenkoy,Istanbul,Turkey</style></auth-address><titles><title><style face="normal" font="Arial">Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis</style></title><secondary-title><style face="normal" font="Arial">J Laryngol Otol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">J Laryngol Otol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Allergen-specific immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Otolaryngology</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptom scores</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Turkey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis. METHODS: The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients). RESULTS: The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p 0.0175). CONCLUSION: Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1748-5460 (Electronic)IS - 0022-2151 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="Arial">10.1017/S0022215117002110</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037263">PM:29037263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Laryngol Otol\20171017-SahinE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Laryngol Otol\20171017-SahinE.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Sahin E</style></custom2><misc3><style face="normal" font="Arial">10.1017/S0022215117002110</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ghosh,A.</style></author><author><style face="normal" font="Arial"> Dutta,S.</style></author><author><style face="normal" font="Arial"> Podder,S.</style></author><author><style face="normal" font="Arial"> Mondal,P.</style></author><author><style face="normal" font="Arial"> Laha,A.</style></author><author><style face="normal" font="Arial"> Saha,N.C.</style></author><author><style face="normal" font="Arial"> Moitra,S.</style></author><author><style face="normal" font="Arial"> Saha,G.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Life Sciences, Presidency University, Kolkata, West Bengal, India</style></auth-address><titles><title><style face="normal" font="Arial">Sensitivity to House Dust Mites Allergens with Atopic Asthma and Its Relationship with CD14 C(-159T) Polymorphism in Patients of West Bengal, India</style></title><secondary-title><style face="normal" font="Arial">J Med Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Entomol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acari</style></keyword><keyword><style face="normal" font="Arial"> Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> Alleles</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen specific IgE</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma prevalence</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic asthma</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial asthma</style></keyword><keyword><style face="normal" font="Arial"> candidate gene</style></keyword><keyword><style face="normal" font="Arial"> CD14</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genotype</style></keyword><keyword><style face="normal" font="Arial"> Genotypes</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Kolkata</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Pyroglyphidae</style></keyword><keyword><style face="normal" font="Arial"> Respiratory System</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> total serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">India is the home to around 15-20 million asthmatics, and asthma prevalence is increasing in Indian metropolitan area, including Kolkata, West Bengal. Complex interactions of genetic and environmental factors are involved in asthma. Genome-wide search for susceptible loci regulating IgE response (atopy) have identified a candidate gene CD14 which is most important in the context of allergic responses of respiratory system. This study was aimed to investigate the role of house dust and house dust mites in development of bronchial asthma and to explore the possible association of candidate gene CD14 with disease manifestation among Kolkata patient population. Skin-prick test was done among 950 asthmatic patients against 8 aeroallergens, including house dust and house dust mites and total serum IgE and allergen-specific IgE were measured. Polymerase chain reaction-restriction fragment length polymorphism was done in patients and nonasthmatic control (n = 255 in each) to characterize a functional polymorphism, C(-159)T, of CD14, a positional candidate gene for allergy. We identified house dust as the most common aeroallergen sensitizer among atopic patients in Kolkata followed by Dermatophagoides pteronyssinus and Dermatophagoides farinae Hughes (Acari: Pyroglyphidae) mites. Patient's sera contain significantly higher IgE level than that of control. Allergen-specific IgE antibody test revealed that 76.36% patients had specific IgE antibody against D. pteronyssinus mite. There was a significant difference in the distribution of alleles and genotypes for CD14 polymorphism with an increase in disease severity. So, in Kolkata, house dust mite is a common aeroallergen and D. pteronyssinus is predominant among mites. The present study revealed that bronchial asthma has a genetic background</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1938-2928 (Electronic)IS - 0022-2585 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1093/jme/tjx178</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29045689">PM:29045689</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Entomol\20171018-GhoshA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Entomol\20171018-GhoshA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Ghosh A</style></custom2><misc3><style face="normal" font="Arial">10.1093/jme/tjx178</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Brito-Casillas,Y.</style></author><author><style face="normal" font="Arial"> Diaz-Sarmiento,M.</style></author><author><style face="normal" font="Arial"> Garcia-Arencibia,M.</style></author><author><style face="normal" font="Arial"> Carranza,C.</style></author><author><style face="normal" font="Arial"> Castrillo,A.</style></author><author><style face="normal" font="Arial"> Fernandez-Perez,L.</style></author><author><style face="normal" font="Arial"> Zumbado-Pena,M.</style></author><author><style face="normal" font="Arial"> Gonzalez,J.F.</style></author><author><style face="normal" font="Arial"> Wagner,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Instituto Universitario de Investigaciones Biomedicas y Sanitarias de la Universidad de Las Palmas de Gran Canaria (IUIBS-ULPGC), Las Palmas De Gran Canaria, Canarias 35016, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Outbreak and Eradication of Tropical Rat Mite (Acari: Macronyssidae) in a European Animal Facility</style></title><secondary-title><style face="normal" font="Arial">J Med Entomol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Med Entomol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acari</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Status</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Ivermectin</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Origin</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> safety assessment</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> Strain</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> toxicity</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tropical</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="Arial">A zoonotic, opportunistic out-break of tropical rat mite Ornithonyssus bacoti [Acari: Macronyssidae; Ornithonyssus bacoti (Hirst)] in an animal facility, is described. Immunocompetent mice [Mus musculus (Linnaeus)] and rat [Rattus norvegicus (Berkenhout)] strains in a conventional health status facility suffered from scratching and allopecia and staff members suffered from pruritic, erythemato-papular lesions, presumed to be allergic in origin. O. bacoti was identified and treatment with a 0.1% ivermectin solution led to its complete erradication. Safety assessment revealed no signs of acute toxicity in any animal strain. Following this inexpensive strategy, 7 wk after the initial dose, samples were negative for the presence of acari. At the time of this report, 26 months after diagnosis, O. bacoti remains undetected</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1938-2928 (Electronic)IS - 0022-2585 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1093/jme/tjx184</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29045705">PM:29045705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Med Entomol\20171018-BritoCasillasY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Med Entomol\20171018-BritoCasillasY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Brito-Casillas Y</style></custom2><misc3><style face="normal" font="Arial">10.1093/jme/tjx184</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hsieh,M.H.</style></author><author><style face="normal" font="Arial"> Jan,R.L.</style></author><author><style face="normal" font="Arial"> Wu,L.S.</style></author><author><style face="normal" font="Arial"> Chen,P.C.</style></author><author><style face="normal" font="Arial"> Kao,H.F.</style></author><author><style face="normal" font="Arial"> Kuo,W.S.</style></author><author><style face="normal" font="Arial"> Wang,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Lactobacillus gasseri attenuates allergic airway inflammation through PPARgamma activation in dendritic cells</style></title><secondary-title><style face="normal" font="Arial">J Mol Med (Berl)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Mol Med (Berl)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> carbohydrate</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemokine</style></keyword><keyword><style face="normal" font="Arial"> Chemokines</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> cytokine secretion</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides</style></keyword><keyword><style face="normal" font="Arial"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulation</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> inflammatory cytokine</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lactobacilli</style></keyword><keyword><style face="normal" font="Arial"> Lactobacillus</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> Lipid Metabolism</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Lymph Nodes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microarray</style></keyword><keyword><style face="normal" font="Arial"> Microarray Analysis</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> mite allergen</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="14" Month="10" Year="2017">2017/10/14</year></dates><abstract><style face="normal" font="Arial">Lactobacilli prevent the early development of allergic diseases in children and experimental asthma in mice. However, the detailed mechanism underlying this action remains unknown. We aimed to explore the activation pathway in the host by Lactobacillus and identify its immunomodulation mechanism in allergic asthma. Continuous administration of 107 cfu, but not 109 cfu, of L. gasseri for 4 weeks prevented Dermatophagoides pteronyssinus (Der p)-induced airway hypersensitivity and inflammation in a mouse model of allergic asthma. DNA microarray analysis of the mesenteric and lung draining lymph nodes revealed a significant decrease in inflammatory chemokines and increase in gene expression in carbohydrate and lipid metabolism, particularly of PPARgamma, in 107 cfu L. gasseri-administered mice compared with untreated mice. Compared with WT mice, Der p-sensitized PPARgammaL/+ mice showed increased airway hyperresponsiveness to methacholine, inflammatory cell infiltration, and inflammatory cytokine secretion in bronchoalveolar fluid. Moreover, the protective effects of L. gasseri were lost in Der p-induced airway inflammation in PPARgammaL/+ mice, and L. gasseri-induced PPARgamma activation in BMDCs inhibited the development of allergic airway inflammation in both PPARgamma WT and PPARgammaL/+ mice. L. gasseri may act via a novel PPARgamma activation pathway in DCs to alleviate allergen-induced airway inflammation in allergic asthma. KEY MESSAGES: L. gasseri prevents mite allergen (Der p)-induced airway inflammation. Prevention of airway inflammation occurs via activation of PPARgamma in dendritic cells. L. gasseri administration does not reverse Der p-induced airway inflammation in PPARgamma(+/-) mice. L. gasseri-induced PPARgamma activation inhibits development of airway inflammation in WT and PPARgamma(+/-) mice</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1432-1440 (Electronic)IS - 0946-2716 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00109-017-1598-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29032406">PM:29032406</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Mol Med (Berl)\20171016-MsiehMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Mol Med (Berl)\20171016-MsiehMH.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Hsieh MH</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00109-017-1598-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sayers,R.L.</style></author><author><style face="normal" font="Arial"> Gethings,L.A.</style></author><author><style face="normal" font="Arial"> Lee,V.</style></author><author><style face="normal" font="Arial"> Balasundaram,A.</style></author><author><style face="normal" font="Arial"> Johnson,P.J.</style></author><author><style face="normal" font="Arial"> Marsh,J.A.</style></author><author><style face="normal" font="Arial"> Wallace,A.</style></author><author><style face="normal" font="Arial"> Brown,H.</style></author><author><style face="normal" font="Arial"> Rogers,A.</style></author><author><style face="normal" font="Arial"> Langridge,J.I.</style></author><author><style face="normal" font="Arial"> Mills,E.N.C.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Microfluidic separation coupled to mass spectrometry for quantification of peanut allergens in a complex food matrix</style></title><secondary-title><style face="normal" font="Arial">J Proteome Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">J Proteome Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen detection</style></keyword><keyword><style face="normal" font="Arial"> allergen labeling</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Chocolate</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Dilution</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Flour</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food matrix</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> matrix effect</style></keyword><keyword><style face="normal" font="Arial"> methodology</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergen</style></keyword><keyword><style face="normal" font="Arial"> Peanut allergens</style></keyword><keyword><style face="normal" font="Arial"> Peanut protein</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Processed food</style></keyword><keyword><style face="normal" font="Arial"> Processed foods</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Quantification</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Recovery</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="30" Month="10" Year="2017">2017/10/30</year></dates><abstract><style face="normal" font="Arial">Peanut is an important food allergen but cannot currently be reliably detected and quantified in processed foods at low levels. Three mg protein/Kg is increasingly being used as a reference dose above which precautionary allergen labeling (PAL) is applied to food products. Two exemplar matrices (chocolate dessert and chocolate bar) were prepared and incurred at 0, 3, 10 or 50 mg/Kg peanut protein using a commercially available lightly roasted peanut flour ingredient. After simple buffer extraction employing an acid labile detergent, multiple reaction monitoring (MRM) experiments were used to assess matrix effects on detection of a set of seven peptide targets derived from peanut allergens using either conventional or microfluidic chromatographic separation prior to mass spectrometry. Microfluidic separation provided greater sensitivity and increased ionisation efficiency at low levels. Individual monitored transitions were detected in consistent ratios across the dilution series performed, independent of matrix. The peanut protein content of each sample was then determined using ELISA and the optimised MRM method. Whilst other peptide targets were detected with three transitions at the 50 mg/Kg peanut protein level in both matrices, only Arah2(Q6PSU2)147-155 could quantify reliably, and only in the chocolate dessert at 10 mg/Kg peanut protein. Recoveries were consistent with ELISA analysis returning around 30-50% of the incurred dose. MS coupled with microfluidic separation shows great promise as a complementary analytical tool for allergen detection and quantification in complex foods using simple extraction methodology</style></abstract><notes><style face="normal" font="Arial">DA - 20171030IS - 1535-3907 (Electronic)IS - 1535-3893 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1021/acs.jproteome.7b00714</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29083186">PM:29083186</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Proteome Res\20171030-SayersRL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Proteome Res\20171030-SayersRL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Sayers RL</style></custom2><misc3><style face="normal" font="Arial">10.1021/acs.jproteome.7b00714</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dougherty,B.</style></author><author><style face="normal" font="Arial"> Badawy,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Northwestern University Weinberg College of Arts and Sciences, Evanston, IL, United States</style></auth-address><titles><title><style face="normal" font="Arial">Using Google Glass in Nonsurgical Medical Settings: Systematic Review</style></title><secondary-title><style face="normal" font="Arial">JMIR Mhealth Uhealth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">JMIR Mhealth Uhealth</style></abbr-1></periodical><pages end="" start="e159">e159-</pages><volume><style face="normal" font="Arial">5</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">acceptability</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Autopsy</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical outcomes</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> cost-effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Devices</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Egypt</style></keyword><keyword><style face="normal" font="Arial"> Feasibility Studies</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Glass</style></keyword><keyword><style face="normal" font="Arial"> google</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IL</style></keyword><keyword><style face="normal" font="Arial"> Industry</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Intervention</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> nursing</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Records</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Sample Size</style></keyword><keyword><style face="normal" font="Arial"> satisfaction</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> senior</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Student</style></keyword><keyword><style face="normal" font="Arial"> Systematic Review</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> Toxicology</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> web</style></keyword><keyword><style face="normal" font="Arial"> Web of Science</style></keyword><keyword><style face="normal" font="Arial"> weight</style></keyword></keywords><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Wearable technologies provide users hands-free access to computer functions and are becoming increasingly popular on both the consumer market and in various industries. The medical industry has pioneered research and implementation of head-mounted wearable devices, such as Google Glass. Most of this research has focused on surgical interventions; however, other medical fields have begun to explore the potential of this technology to support both patients and clinicians. OBJECTIVE: Our aim was to systematically evaluate the feasibility, usability, and acceptability of using Google Glass in nonsurgical medical settings and to determine the benefits, limitations, and future directions of its application. METHODS: This review covers literature published between January 2013 and May 2017. Searches included PubMed MEDLINE, Embase, INSPEC (Ebsco), Cochrane Central Register of Controlled Trials (CENTRAL), IEEE Explore, Web of Science, Scopus, and Compendex. The search strategy sought all articles on Google Glass. Two reviewers independently screened titles and abstracts, assessed full-text articles, and extracted data from articles that met all predefined criteria. Any disagreements were resolved by discussion or consultation by the senior author. Included studies were original research articles that evaluated the feasibility, usability, or acceptability of Google Glass in nonsurgical medical settings. The preferred reporting results of systematic reviews and meta-analyses (PRISMA) guidelines were followed for reporting of results. RESULTS: Of the 852 records examined, 51 met all predefined criteria, including patient-centered (n=21) and clinician-centered studies (n=30). Patient-centered studies explored the utility of Google Glass in supporting patients with motor impairments (n=8), visual impairments (n=5), developmental and psychiatric disorders (n=2), weight management concerns (n=3), allergies (n=1), or other health concerns (n=2). Clinician-centered studies explored the utility of Google Glass in student training (n=9), disaster relief (n=4), diagnostics (n=2), nursing (n=1), autopsy and postmortem examination (n=1), wound care (n=1), behavioral sciences (n=1), and various medical subspecialties, including, cardiology (n=3), radiology (n=3), neurology (n=1), anesthesiology (n=1), pulmonology (n=1), toxicology (n=1), and dermatology (n=1). Most of the studies were conducted in the United States (40/51, 78%), did not report specific age information for participants (38/51, 75%), had sample size &lt;30 participants (29/51, 57%), and were pilot or feasibility studies (31/51, 61%). Most patient-centered studies (19/21, 90%) demonstrated feasibility with high satisfaction and acceptability among participants, despite a few technical challenges with the device. A number of clinician-centered studies (11/30, 37%) reported low to moderate satisfaction among participants, with the most promising results being in the area of student training. Studies varied in sample size, approach for implementation of Google Glass, and outcomes assessment. CONCLUSIONS: The use of Google Glass in nonsurgical medical settings varied. More promising results regarding the feasibility, usability, and acceptability of using Google Glass were seen in patient-centered studies and student training settings. Further research evaluating the efficacy and cost-effectiveness of Google Glass as an intervention to improve important clinical outcomes is warranted</style></abstract><notes><style face="normal" font="Arial">DA - 20171020IS - 2291-5222 (Print)IS - 2291-5222 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Egypt -</style></notes><work-type><style face="normal" font="Arial">10.2196/mhealth.8671</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29051136">PM:29051136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JMIR Mhealth Uhealth\2017-5-E159.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JMIR Mhealth Uhealth\2017-5-E159.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171020, Dougherty B</style></custom2><misc3><style face="normal" font="Arial">10.2196/mhealth.8671</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Godar,M.</style></author><author><style face="normal" font="Arial"> Blanchetot,C.</style></author><author><style face="normal" font="Arial"> de Haard,H.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Brusselle,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">a argenx BVBA , Industriepark Zwijnaarde 7, Building C, 9052 Zwijnaarde , Belgium</style></auth-address><titles><title><style face="normal" font="Arial">Personalized medicine with biologics for severe type 2 asthma: current status and future prospects</style></title><secondary-title><style face="normal" font="Arial">MAbs</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">MAbs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status date="11/04/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Affect</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> biomarker</style></keyword><keyword><style face="normal" font="Arial"> biomarkers</style></keyword><keyword><style face="normal" font="Arial"> burden</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical Efficacy</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Clinical Trials</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Endotype</style></keyword><keyword><style face="normal" font="Arial"> endotypes</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> personalized medicine</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Therapeutics</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> type 2 inflammation</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe asthma forms, but the outcome has only been successful if the biologic, as add-on treatment, targeted specific patient subgroups. Indeed, we now realize that asthma is a heterogeneous disease with multiple phenotypes, based on distinct pathophysiological mechanisms, called endotypes. Thus, asthma therapy is gradually moving to a personalized medicine approach, tailored to individual's asthma endotypes identified through biomarkers. Here, we review the clinical efficacy of antibody-related therapeutics undergoing clinical trials, or those already approved, for the treatment of severe type 2 asthma. Biologics targeting type 2 cytokines have shown consistent efficacy, especially in patients with evidence of type 2 inflammation, suggesting that the future of asthma biologics is promising</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1942-0870 (Electronic)IS - 1942-0862 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1080/19420862.2017.1392425</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035619">PM:29035619</url></web-urls><pdf-urls><url ppv-ref="no">guy.brusselle@ugent.be</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="Arial">20171016, Godar M</style></custom2><misc3><style face="normal" font="Arial">10.1080/19420862.2017.1392425</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Gasperazzo,A.</style></author><author><style face="normal" font="Arial"> Toffanin,P.</style></author><author><style face="normal" font="Arial"> Larese,F.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Corso di Laurea Interateneo in Tecniche della Prevenzione nell'Ambiente e nei Luoghi di Lavoro.</style></auth-address><titles><title><style face="normal" font="Arial">Green coffee been exposure and symptoms in dock workers in Trieste (Italy)</style></title><secondary-title><style face="normal" font="Arial">Med Lav</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Lav</style></full-title></periodical><pages end="" start="6224">6224-</pages><volume><style face="normal" font="Arial">108</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="12/24/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic symptoms</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> Castor</style></keyword><keyword><style face="normal" font="Arial"> Castor Bean</style></keyword><keyword><style face="normal" font="Arial"> Coffee</style></keyword><keyword><style face="normal" font="Arial"> Dispersion</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath</style></keyword><keyword><style face="normal" font="Arial"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Particles</style></keyword><keyword><style face="normal" font="Arial"> Personal protective equipment</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptom</style></keyword><keyword><style face="normal" font="Arial"> respiratory symptoms</style></keyword><keyword><style face="normal" font="Arial"> Spirometry</style></keyword><keyword><style face="normal" font="Arial"> Storage</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tanzania</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold Limit Values</style></keyword><keyword><style face="normal" font="Arial"> Transportation</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword><keyword><style face="normal" font="Arial"> Workplace</style></keyword></keywords><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Green coffee workers can develop allergic symptoms due to green coffee beans (GCB) or to castor bean (CB) that can contaminate sacks used for the transportation. Data are limited in literature and a previous study performed in Trieste demonstrated allergic symptoms in 14.3% of dockworkers handling GCB. OBJECTIVES: To evaluate symptoms and exposure to GCB ultrafine particles in Trieste dockworkers. METHODS: Workers involved in GCB sacks transportation, storage and opening were asked to fill out a questionnaire on allergic respiratory symptoms. They performed a spirometry test and an evaluation of NO exhaled breath condensate. Inhalable and respirable dust exposures were evaluated by means of personal and environmental pumps. Ultrafine particles exposure was evaluated by means of portable particles counter DISCMini. RESULTS: Between the 40 dockworkers exposed to GCB, 28 participated in the study (70%). Five (17.9%) reported personal allergy symptoms and two workers (7.1%) reported allergic oculorhinitis during work. One subject had symptoms only with Tanzania sacks and he resulted sensitized to CB. Workplace dust evaluation demonstrated values below Threshold Limit Values, but some work tasks were associated with exposure to more than 40,000 ultrafine particles with a geometric mean size of 37.2+/-1.35 nm. CONCLUSIONS: Prevalence of allergic symptoms in GCB workers was low but the presence of peaks of ultrafine particles exposure suggests the need to protect workers from exposure, limiting powder dispersion, avoiding the unloading of sacks inside the container and suggesting personal protective equipment regular use (FFP3)</style></abstract><notes><style face="normal" font="Arial">DA - 20171030IS - 0025-7818 (Print)IS - 0025-7818 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="Arial">10.23749/mdl.v108i5.6224</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29084127">PM:29084127</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Lav\2017-108-6224.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Lav\2017-108-6224.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Gasperazzo A</style></custom2><misc3><style face="normal" font="Arial">10.23749/mdl.v108i5.6224</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Katotomichelakis,M.</style></author><author><style face="normal" font="Arial"> Iliou,T.</style></author><author><style face="normal" font="Arial"> Karvelis,I.</style></author><author><style face="normal" font="Arial"> Giotakis,E.</style></author><author><style face="normal" font="Arial"> Daniilides,G.</style></author><author><style face="normal" font="Arial"> Erkotidou,E.</style></author><author><style face="normal" font="Arial"> Lazaridis,C.</style></author><author><style face="normal" font="Arial"> Anastassopoulos,G.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Otorhinolaryngology, Medical School, Democritus University of Thrace, Alexandroupolis, Evros, Greece</style></auth-address><titles><title><style face="normal" font="Arial">Symptomatology Patterns in Children with Allergic Rhinitis</style></title><secondary-title><style face="normal" font="Arial">Med Sci Monit</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Med Sci Monit</style></full-title></periodical><pages end="4946" start="4939">4939-4946</pages><volume><style face="normal" font="Arial">23</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adolescent</style></keyword><keyword><style face="normal" font="Arial"> Adolescents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Children and adolescents</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Cross-sectional</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> global</style></keyword><keyword><style face="normal" font="Arial"> Global Health</style></keyword><keyword><style face="normal" font="Arial"> GRADE</style></keyword><keyword><style face="normal" font="Arial"> Grass</style></keyword><keyword><style face="normal" font="Arial"> grass pollen</style></keyword><keyword><style face="normal" font="Arial"> Grasses</style></keyword><keyword><style face="normal" font="Arial"> Greece</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> moderate to severe</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="Arial"> nasal symptom</style></keyword><keyword><style face="normal" font="Arial"> observational study</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> patterns</style></keyword><keyword><style face="normal" font="Arial"> Perennial</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> scale</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword><keyword><style face="normal" font="Arial"> seasonality</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Sneezing</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">BACKGROUND Although allergic rhinitis (AR) is recognized as a growing global health disease with considerable importance for patients' lives, especially among children and adolescents, there is a lack of population studies concerning symptomatology patterns of the disease. The present study aimed to explore symptoms prevalence among school-aged children, to detect any correlation between allergen sensitivities with symptomatology patterns, and, finally, to evaluate the association of the sensitivity grade score with symptoms severity or seasonality. MATERIAL AND METHODS This was a cross-sectional, observational study in a childhood population. The first stage included recruitment of children and parental-completed questionnaires. The second stage included skin-prick tests for the most common allergens. Severity of symptoms was self-evaluated using a scale that ranged from "0" (no symptoms), "1" (mild), and "2" (moderate-to-severe). AR was classified as seasonal (SAR) or perennial (PAR). RESULTS The most frequent symptoms were reported for nasal obstruction, sneezing, and rhinorrhea. All nasal symptoms were significantly more profound among children with HDM sensitivity. However, more symptoms, not only nasal, but also ocular and general ones, were detected among patients with grass pollen sensitivity. Patients with PAR reported more severe symptoms. SAR was associated with mild disease. Finally, the sensitivity grade score was significantly correlated with symptom severity. CONCLUSIONS Our results suggest that allergen sensitivity may be correlated with symptomatology patterns among children who have allergic rhinitis</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1643-3750 (Electronic)IS - 1234-1010 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.12659/MSM.903136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033449">PM:29033449</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Sci Monit\20171016-KatotomichelakisM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Sci Monit\20171016-KatotomichelakisM.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Katotomichelakis M</style></custom2><misc3><style face="normal" font="Arial">10.12659/MSM.903136</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Sung,Y.Y.</style></author><author><style face="normal" font="Arial"> Kim,S.H.</style></author><author><style face="normal" font="Arial"> Kim,D.S.</style></author><author><style face="normal" font="Arial"> Lee,J.E.</style></author><author><style face="normal" font="Arial"> Kim,H.K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mibyeong Research Center, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 305-811, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">Illicium verum Extract and Trans-Anethole Attenuate Ovalbumin-Induced Airway Inflammation via Enhancement of Foxp3+ Regulatory T Cells and Inhibition of Th2 Cytokines in Mice</style></title><secondary-title><style face="normal" font="Arial">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mediators Inflamm</style></full-title></periodical><pages end="" start="7506808">7506808-</pages><volume><style face="normal" font="Arial">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> allergen challenge</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> CCR3</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> forkhead box protein 3</style></keyword><keyword><style face="normal" font="Arial"> FOXP3</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cell</style></keyword><keyword><style face="normal" font="Arial"> regulatory T cells</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> splenocytes</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH1/TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Illicium verum is used in traditional medicine to treat inflammation. The study investigates the effects of IVE and its component, trans-anethole (AET), on airway inflammation in ovalbumin- (OVA-) induced asthmatic mice. Asthma was induced in BALB/c mice by systemic sensitization to OVA, followed by intratracheal, intraperitoneal, and aerosol allergen challenges. IVE and AET were orally administered for four weeks. We investigated the effects of treatment on airway hyperresponsiveness, IgE production, pulmonary eosinophilic infiltration, immune cell phenotypes, Th2 cytokine production in bronchoalveolar lavage, Th1/Th2 cytokine production in splenocytes, forkhead box protein 3 (Foxp3) expression, and lung histology. IVE and AET ameliorated OVA-driven airway hyperresponsiveness (p &lt; 0.01), pulmonary eosinophilic infiltration (p &lt; 0.05), mucus hypersecretion (p &lt; 0.01), and IL-4, IL-5, IL-13, and CCR3 production (p &lt; 0.05), as well as IgE levels (p &lt; 0.01). IVE and AET increased Foxp3 expression in lungs (p &lt; 0.05). IVE and AET reduced IL-4 and increased IFN-gamma production in the supernatant of splenocyte cultures (p &lt; 0.05). Histological studies showed that IVE and AET inhibited eosinophilia and lymphocyte infiltration in lungs (p &lt; 0.01). These results indicate that IVE and AET exert antiasthmatic effects through upregulation of Foxp3+ regulatory T cells and inhibition of Th2 cytokines, suggesting that IVE may be a potential therapeutic agent for allergic lung inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20171024IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1155/2017/7506808</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29062168">PM:29062168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mediators Inflamm\20171024-SungYY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mediators Inflamm\20171024-SungYY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171024, Sung YY</style></custom2><misc3><style face="normal" font="Arial">10.1155/2017/7506808</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Larrauri,B.J.</style></author><author><style face="normal" font="Arial"> Torre,M.G.</style></author><author><style face="normal" font="Arial"> Malbran,E.</style></author><author><style face="normal" font="Arial"> Juri,M.C.</style></author><author><style face="normal" font="Arial"> Fernandez Romero,D.S.</style></author><author><style face="normal" font="Arial"> Malbran,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Unidad de Alergia, Asma e Inmunologia Clinica, Buenos Aires, Argentina.</style></auth-address><titles><title><style face="normal" font="Arial">[Anaphylaxis and allergic reactions during surgery and medical procedures]</style></title><secondary-title><style face="normal" font="Arial">Medicina (B Aires)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Medicina (B Aires)</style></full-title></periodical><pages end="387" start="382">382-387</pages><volume><style face="normal" font="Arial">77</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Amoxicillin</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asma</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Detergents</style></keyword><keyword><style face="normal" font="Arial"> Disinfectants</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Endoscopy</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> Intensive Care</style></keyword><keyword><style face="normal" font="Arial"> intensive care unit</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> medication</style></keyword><keyword><style face="normal" font="Arial"> Medications</style></keyword><keyword><style face="normal" font="Arial"> Neuromuscular blocking agents</style></keyword><keyword><style face="normal" font="Arial"> OPA</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Ranitidine</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Rest</style></keyword><keyword><style face="normal" font="Arial"> retrospective</style></keyword><keyword><style face="normal" font="Arial"> Retrospective Studies</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Systemic allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> systemic reaction</style></keyword><keyword><style face="normal" font="Arial"> systemic reactions</style></keyword><keyword><style face="normal" font="Arial"> testing</style></keyword><keyword><style face="normal" font="Arial"> Ultrasound</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis during anesthesia is an unpredictable, severe, and rare reaction. It has an incidence of 1/10 000 to 1/20 000 surgeries. In most series, the responsible drugs include neuromuscular blocking agents, latex, or antibiotics. The frequency and etiology of systemic allergic reactions in other medical procedures are largely unknown. The identification of responsible drugs of anaphylaxis is a complex task, requiring testing of all medications and substances used during surgery. We describe our experience in a retrospective study of 15 patients. Ten subjects developed anaphylaxis during surgery, two in endoscopic studies and one in a trans-vaginal ultrasound. The remaining two subjects, one in a trans-vaginal ultrasound and another during a dental procedure had a systemic allergic reaction. We studied all patients with all medications administered during the procedures, including latex and detergents and disinfectants. Three surgeries had to be suspended at induction of anesthesia, five were stopped incomplete and two were completed. Both patients that presented a reaction during endoscopy required intensive care unit admission and the rest were observed in a Hospital. The responsible drugs during surgery anaphylaxis were neuromuscular blocking agents, latex, patent blue, and ranitidine. Ortho-phthalaldehyde (OPA) was identified during endoscopic studies; latex was responsible in transvaginal ultrasounds; and amoxicillin in the dental procedure. The aim of the present article is to review our experience studying allergic systemic reactions and anaphylaxis during general anesthesia and medical procedures, emphasizing the severity of these reactions and the need for causative drug identification</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 0025-7680 (Print)IS - 0025-7680 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29044014">PM:29044014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Medicina (B Aires)\2017-77-382-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Medicina (B Aires)\2017-77-382-7.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Larrauri BJ</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Thomas,S.Y.</style></author><author><style face="normal" font="Arial"> Whitehead,G.S.</style></author><author><style face="normal" font="Arial"> Takaku,M.</style></author><author><style face="normal" font="Arial"> Ward,J.M.</style></author><author><style face="normal" font="Arial"> Xu,X.</style></author><author><style face="normal" font="Arial"> Nakano,K.</style></author><author><style face="normal" font="Arial"> Lyons-Cohen,M.R.</style></author><author><style face="normal" font="Arial"> Nakano,H.</style></author><author><style face="normal" font="Arial"> Gowdy,K.M.</style></author><author><style face="normal" font="Arial"> Wade,P.A.</style></author><author><style face="normal" font="Arial"> Cook,D.N.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, USA</style></auth-address><titles><title><style face="normal" font="Arial">MyD88-dependent dendritic and epithelial cell crosstalk orchestrates immune responses to allergens</style></title><secondary-title><style face="normal" font="Arial">Mucosal Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mucosal Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Cell Differentiation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Chromatin</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> differentiation</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Environmental Health</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> Genes</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health Sciences</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> metabolism</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> mouse models</style></keyword><keyword><style face="normal" font="Arial"> MyD88</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> North Carolina</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Rna</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> TH17</style></keyword><keyword><style face="normal" font="Arial"> TH17 cell</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="Arial">Sensitization to inhaled allergens is dependent on activation of conventional dendritic cells (cDCs) and on the adaptor molecule, MyD88. However, many cell types in the lung express Myd88, and it is unclear how signaling in these different cell types reprograms cDCs and leads to allergic inflammation of the airway. By combining ATAC-seq with RNA profiling, we found that MyD88 signaling in cDCs maintained open chromatin at select loci even at steady state, allowing genes to be rapidly induced during allergic sensitization. A distinct set of genes related to metabolism was indirectly controlled in cDCs through MyD88 signaling in airway epithelial cells (ECs). In mouse models of asthma, Myd88 expression in ECs was critical for eosinophilic inflammation, whereas Myd88 expression in cDCs was required for Th17 cell differentiation and consequent airway neutrophilia. Thus, both cell-intrinsic and cell-extrinsic MyD88 signaling controls gene expression in cDCs and orchestrates immune responses to inhaled allergens.Mucosal Immunology advance online publication, 25 October 2017; doi:10.1038/mi.2017.84</style></abstract><notes><style face="normal" font="Arial">DA - 20171025IS - 1935-3456 (Electronic)IS - 1933-0219 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/mi.2017.84</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29067999">PM:29067999</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mucosal Immunol\20171025-ThomasSY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mucosal Immunol\20171025-ThomasSY.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mucosal Immunol\20171025-ThomasSYx6.xlsxC:\A&amp;H HMW Papers\Mucosal Immunol\20171025-ThomasSYx7.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mucosal Immunol\20171025-ThomasSYx6.xlsxF:\A&amp;H HMW Papers\Mucosal Immunol\20171025-ThomasSYx7.xlsx</url></image-urls></urls><custom2><style face="normal" font="Arial">20171025, Thomas SY</style></custom2><misc3><style face="normal" font="Arial">10.1038/mi.2017.84</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cait,A.</style></author><author><style face="normal" font="Arial"> Hughes,M.R.</style></author><author><style face="normal" font="Arial"> Antignano,F.</style></author><author><style face="normal" font="Arial"> Cait,J.</style></author><author><style face="normal" font="Arial"> Dimitriu,P.A.</style></author><author><style face="normal" font="Arial"> Maas,K.R.</style></author><author><style face="normal" font="Arial"> Reynolds,L.A.</style></author><author><style face="normal" font="Arial"> Hacker,L.</style></author><author><style face="normal" font="Arial"> Mohr,J.</style></author><author><style face="normal" font="Arial"> Finlay,B.B.</style></author><author><style face="normal" font="Arial"> Zaph,C.</style></author><author><style face="normal" font="Arial"> McNagny,K.M.</style></author><author><style face="normal" font="Arial"> Mohn,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="Arial">Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids</style></title><secondary-title><style face="normal" font="Arial">Mucosal Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mucosal Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acids</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma susceptibility</style></keyword><keyword><style face="normal" font="Arial"> British Columbia</style></keyword><keyword><style face="normal" font="Arial"> Canada</style></keyword><keyword><style face="normal" font="Arial"> CCL19</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cell</style></keyword><keyword><style face="normal" font="Arial"> CD4+ T cells</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Columbia</style></keyword><keyword><style face="normal" font="Arial"> community</style></keyword><keyword><style face="normal" font="Arial"> DC</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> Fatty Acids</style></keyword><keyword><style face="normal" font="Arial"> gastrointestinal</style></keyword><keyword><style face="normal" font="Arial"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> microbiology</style></keyword><keyword><style face="normal" font="Arial"> Microbiome</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Short-chain fatty acids</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Transport</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="Arial">The mammalian gastrointestinal tract harbors a microbial community with metabolic activity critical for host health, including metabolites that can modulate effector functions of immune cells. Mice treated with vancomycin have an altered microbiome and metabolite profile, exhibit exacerbated T helper type 2 cell (Th2) responses, and are more susceptible to allergic lung inflammation. Here we show that dietary supplementation with short-chain fatty acids (SCFAs) ameliorates this enhanced asthma susceptibility by modulating the activity of T cells and dendritic cells (DCs). Dysbiotic mice treated with SCFAs have fewer interleukin-4 (IL4)-producing CD4+ T cells and decreased levels of circulating immunoglobulin E (IgE). In addition, DCs exposed to SCFAs activate T cells less robustly, are less motile in response to CCL19 in vitro, and exhibit a dampened ability to transport inhaled allergens to lung draining nodes. Our data thus demonstrate that gut dysbiosis can exacerbate allergic lung inflammation through both T cell- and DC-dependent mechanisms that are inhibited by SCFAs.Mucosal Immunology advance online publication 25 October 2017; doi:10.1038/mi.2017.75</style></abstract><notes><style face="normal" font="Arial">DA - 20171025IS - 1935-3456 (Electronic)IS - 1933-0219 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="Arial">10.1038/mi.2017.75</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29067994">PM:29067994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mucosal Immunol\20171027-CaitA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mucosal Immunol\20171027-CaitA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171025, Cait A</style></custom2><misc3><style face="normal" font="Arial">10.1038/mi.2017.75</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Fleming,J.</style></author><author><style face="normal" font="Arial"> Hernandez,G.</style></author><author><style face="normal" font="Arial"> Hartman,L.</style></author><author><style face="normal" font="Arial"> Maksimovic,J.</style></author><author><style face="normal" font="Arial"> Nace,S.</style></author><author><style face="normal" font="Arial"> Lawler,B.</style></author><author><style face="normal" font="Arial"> Risa,T.</style></author><author><style face="normal" font="Arial"> Cook,T.</style></author><author><style face="normal" font="Arial"> Agni,R.</style></author><author><style face="normal" font="Arial"> Reichelderfer,M.</style></author><author><style face="normal" font="Arial"> Luzzio,C.</style></author><author><style face="normal" font="Arial"> Rolak,L.</style></author><author><style face="normal" font="Arial"> Field,A.</style></author><author><style face="normal" font="Arial"> Fabry,Z.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA</style></auth-address><titles><title><style face="normal" font="Arial">Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial</style></title><secondary-title><style face="normal" font="Arial">Mult Scler</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mult Scler</style></full-title></periodical><pages end="" start="1352458517736377">1352458517736377-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adverse event</style></keyword><keyword><style face="normal" font="Arial"> Adverse events</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Brain</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical trial</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> helminth</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> imaging</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> magnetic</style></keyword><keyword><style face="normal" font="Arial"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> microbial</style></keyword><keyword><style face="normal" font="Arial"> MRI</style></keyword><keyword><style face="normal" font="Arial"> MS</style></keyword><keyword><style face="normal" font="Arial"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral administration</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> Public Health</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> regulatory lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Safety</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Sclerosis</style></keyword><keyword><style face="normal" font="Arial"> Surveillance</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trial</style></keyword><keyword><style face="normal" font="Arial"> Trichuris</style></keyword><keyword><style face="normal" font="Arial"> Trichuris suis</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> variation</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Wisconsin</style></keyword></keywords><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The hygiene hypothesis suggests that microbial replacement may be therapeutic in allergic and autoimmune diseases. Nevertheless, the results of helminth treatment, including in multiple sclerosis (MS), have been inconclusive. OBJECTIVE: To assess safety and brain magnetic resonance imaging (MRI) activity in subjects with relapsing-remitting multiple sclerosis (RRMS) during oral administration of ova from the porcine whipworm, Trichuris suis (TSO). METHODS: A total of 16 disease-modifying treatment (DMT) naive RRMS subjects were studied in a baseline versus treatment (BVT) controlled prospective study. MRI scans were performed during 5 months of screening-observation, 10 months of treatment, and 4 months of post-treatment surveillance. RESULTS: No serious symptoms or adverse events occurred during treatment. For the cohort, there was a trend consistent with a 35% diminution in active lesions when observation MRIs were compared to treatment MRIs ( p = 0.08), and at the level of individuals, 12 of 16 subjects improved during TSO treatment. T regulatory lymphocytes were increased during TSO treatment. CONCLUSION: TSO is safe in RRMS subjects. Potentially favorable MRI outcomes and immunoregulatory changes were observed during TSO treatment; however, the magnitude of these effects was modest, and there was considerable variation among the responses of individual subjects</style></abstract><notes><style face="normal" font="Arial">DA - 20171024IS - 1477-0970 (Electronic)IS - 1352-4585 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1177/1352458517736377</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064315">PM:29064315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mult Scler\20171024-FlemingJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mult Scler\20171024-FlemingJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171024, Fleming J</style></custom2><misc3><style face="normal" font="Arial">10.1177/1352458517736377</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Li,L.</style></author><author><style face="normal" font="Arial"> Jiang,Z.</style></author><author><style face="normal" font="Arial"> Shao,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China</style></auth-address><titles><title><style face="normal" font="Arial">Pulmonary Aspergillus Overlap Syndromes</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">ABPA</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Antifungal</style></keyword><keyword><style face="normal" font="Arial"> Antifungal drug</style></keyword><keyword><style face="normal" font="Arial"> antifungal therapy</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillus</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Culture</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> discharge</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> Dyspnea</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> fungal culture</style></keyword><keyword><style face="normal" font="Arial"> Hemoptysis</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Pulmonary Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Research institute</style></keyword><keyword><style face="normal" font="Arial"> Sputum</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheezing</style></keyword></keywords><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Broadly, there are three main categories in pulmonary aspergillosis: chronic forms of aspergillosis; allergic bronchopulmonary aspergillosis; and invasive aspergillosis (IPA). IPA has been further subdivided into angioinvasive and airway-invasive aspergillosis. Aspergillus overlap syndromes is defined as the occurrence of more than one form aspergillus disease in a single individual. OBJECTIVES: To help clinicians correctly deal with AOS. METHODS: Retrospectively study the clinical findings of nine patients presenting with AOS. RESULTS: Four cases were diagnosed as angioinvasive aspergillosis complicated with ABPA, three cases as IPA overlap aspergilloma, and two cases as ABPA with AWIA. All the patients presented with cough and expectoration. In three patients with IPA overlap aspergilloma, two had hemoptysis, two had wheezing and fever. All of patients with IPA overlap ABPA had wheezing, dyspnea, and fever, three had sputum plugs, two had hemoptysis, and five patients had mucopurulent discharge and rhonchi in auscultation. Their total IgE ranged from 129 to 2124 IU/ml (676.5 +/- 557.33 IU/ml). Fungal culture in sputum showed A. Fumigatus in three patients. All the six patients with IPA overlap ABPA applied steroid therapy and antifungal therapy. Three of them received two or more antifungal drugs successively, and three received combinational therapy. All the patients improved except one diagnosed ABPA overlap IPA. CONCLUSIONS: Clinical manifestation of AOS is not typical. Poor first-line therapeutic effects and complicated diagnosis criteria require clinicians to be aware of AOS when facing patients with aspergillosis</style></abstract><notes><style face="normal" font="Arial">DA - 20171025IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-017-0212-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29067630">PM:29067630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20171025-LiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20171025-LiL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171025, Li L</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-017-0212-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Radulesco,T.</style></author><author><style face="normal" font="Arial"> Varoquaux,A.</style></author><author><style face="normal" font="Arial"> Ranque,S.</style></author><author><style face="normal" font="Arial"> Dessi,P.</style></author><author><style face="normal" font="Arial"> Michel,J.</style></author><author><style face="normal" font="Arial"> Cassagne,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique, Hopitaux de Marseille, La Conception University Hospital, 147 Bvd Baille, 13385, Marseille Cedex, France.</style></auth-address><titles><title><style face="normal" font="Arial">A Case of Fungus Ball-Type Maxillary Sinusitis Due to Penicillium Roqueforti</style></title><secondary-title><style face="normal" font="Arial">Mycopathologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Mycopathologia</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cheese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical laboratory</style></keyword><keyword><style face="normal" font="Arial"> Contaminants</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Fungal</style></keyword><keyword><style face="normal" font="Arial"> Fungi</style></keyword><keyword><style face="normal" font="Arial"> Fungus</style></keyword><keyword><style face="normal" font="Arial"> Head</style></keyword><keyword><style face="normal" font="Arial"> Hosts</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity pneumonitis</style></keyword><keyword><style face="normal" font="Arial"> Hyphae</style></keyword><keyword><style face="normal" font="Arial"> Immunocompromised Host</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> invasive</style></keyword><keyword><style face="normal" font="Arial"> Knowledge</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> maxillary</style></keyword><keyword><style face="normal" font="Arial"> Maxillary Sinus</style></keyword><keyword><style face="normal" font="Arial"> Maxillary Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> MRI</style></keyword><keyword><style face="normal" font="Arial"> Neck</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Penicillium</style></keyword><keyword><style face="normal" font="Arial"> Rhinorrhea</style></keyword><keyword><style face="normal" font="Arial"> Ripening</style></keyword><keyword><style face="normal" font="Arial"> Scanner</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> sinus</style></keyword><keyword><style face="normal" font="Arial"> Sinusitis</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="Arial">The Penicillium genera, encompassing about 225 different species of fungi, are naturally present in the environment. These genera are poorly linked to human disease, except for Penicillium marneffei causing septicemia in immunocompromised hosts. Thus, Penicillium species recovered from respiratory tract samples are often considered as inhaled contaminants in the clinical laboratory. However, we report here a case of fungal maxillary sinusitis due to Penicillium roqueforti diagnosed in a 40-year-old female, a teacher, complaining of moderate pain for months in the maxillary sinus and chronic posterior rhinorrhea. CT scanner and MRI enabled a preliminary diagnosis of left maxillary fungus ball-type sinusitis with calcified material seen on CT and marked very low signal in T2 weighted images seen on MRI. Anatomopathological and mycological examination of sinusal content showed septate hyphae. Direct sequencing of the sinusal content revealed P. roqueforti. P. roqueforti has been traditionally used in France for more than 200 years for cheese ripening. However, to our knowledge, this ascomycetous fungus has very rarely been associated in the literature with human disease. P. roqueforti is associated only with cheese worker's lung, a hypersensitivity pneumonitis affecting employees in blue cheese factories. Other species in the Penicillium genus are reported to cause various disorders such as invasive infection, superficial infection or allergic diseases. P. roqueforti has never previously been reported as a cause of human infection. Thus, we report the first case of fungus ball due to P. roqueforti in an immunocompetent patient</style></abstract><notes><style face="normal" font="Arial">DA - 20171027IS - 1573-0832 (Electronic)IS - 0301-486X (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1007/s11046-017-0217-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29075960">PM:29075960</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mycopathologia\20171027-RadulescoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mycopathologia\20171027-RadulescoT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171027, Radulesco T</style></custom2><misc3><style face="normal" font="Arial">10.1007/s11046-017-0217-6</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chassin,H.</style></author><author><style face="normal" font="Arial"> Geering,B.</style></author><author><style face="normal" font="Arial"> Schukur,L.</style></author><author><style face="normal" font="Arial"> Auslander,D.</style></author><author><style face="normal" font="Arial"> Lang,B.</style></author><author><style face="normal" font="Arial"> Fussenegger,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="Arial">Sensing and responding to allergic response cytokines through a genetically encoded circuit</style></title><secondary-title><style face="normal" font="Arial">Nat Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Commun</style></full-title></periodical><pages end="" start="1101">1101-</pages><volume><style face="normal" font="Arial">8</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergic inflammation</style></keyword><keyword><style face="normal" font="Arial"> allergic response</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anti-histamines</style></keyword><keyword><style face="normal" font="Arial"> Anti-immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Antihistamine</style></keyword><keyword><style face="normal" font="Arial"> Antihistamines</style></keyword><keyword><style face="normal" font="Arial"> Biologic</style></keyword><keyword><style face="normal" font="Arial"> biologics</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Chronic Disease</style></keyword><keyword><style face="normal" font="Arial"> Chronic diseases</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> Delivery</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Engineering</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Histamine Release</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> human IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> interleukin 4</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-13</style></keyword><keyword><style face="normal" font="Arial"> Interleukin-4</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> network</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein Binding</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secretion</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> steroid</style></keyword><keyword><style face="normal" font="Arial"> Steroids</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-helper-2</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="Arial">While constantly rising, the prevalence of allergies is globally one of the highest among chronic diseases. Current treatments of allergic diseases include the application of anti-histamines, immunotherapy, steroids, and anti-immunoglobulin E (IgE) antibodies. Here we report mammalian cells engineered with a synthetic signaling cascade able to monitor extracellular pathophysiological levels of interleukin 4 and interleukin 13, two main cytokines orchestrating allergic inflammation. Upon activation of transgenic cells by these cytokines, designed ankyrin repeat protein (DARPin) E2_79, a non-immunogenic protein binding human IgE, is secreted in a precisely controlled and reversible manner. Using human whole blood cell culturing, we demonstrate that the mammalian dual T helper 2 cytokine sensor produces sufficient levels of DARPin E2_79 to dampen histamine release in allergic subjects exposed to allergens. Hence, therapeutic gene networks monitoring disease-associated cytokines coupled with in situ production, secretion and systemic delivery of immunomodulatory biologics may foster advances in the treatment of allergies</style></abstract><notes><style face="normal" font="Arial">DA - 20171024IS - 2041-1723 (Electronic)IS - 2041-1723 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="Arial">10.1038/s41467-017-01211-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29062109">PM:29062109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Commun\2017-8-1101.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Commun\2017-8-1101.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171024, Chassin H</style></custom2><misc3><style face="normal" font="Arial">10.1038/s41467-017-01211-1</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Machiels,B.</style></author><author><style face="normal" font="Arial"> Dourcy,M.</style></author><author><style face="normal" font="Arial"> Xiao,X.</style></author><author><style face="normal" font="Arial"> Javaux,J.</style></author><author><style face="normal" font="Arial"> Mesnil,C.</style></author><author><style face="normal" font="Arial"> Sabatel,C.</style></author><author><style face="normal" font="Arial"> Desmecht,D.</style></author><author><style face="normal" font="Arial"> Lallemand,F.</style></author><author><style face="normal" font="Arial"> Martinive,P.</style></author><author><style face="normal" font="Arial"> Hammad,H.</style></author><author><style face="normal" font="Arial"> Guilliams,M.</style></author><author><style face="normal" font="Arial"> Dewals,B.</style></author><author><style face="normal" font="Arial"> Vanderplasschen,A.</style></author><author><style face="normal" font="Arial"> Lambrecht,B.N.</style></author><author><style face="normal" font="Arial"> Bureau,F.</style></author><author><style face="normal" font="Arial"> Gillet,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Immunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine - FARAH, University of Liege, Liege, Belgium</style></auth-address><titles><title><style face="normal" font="Arial">A gammaherpesvirus provides protection against allergic asthma by inducing the replacement of resident alveolar macrophages with regulatory monocytes</style></title><secondary-title><style face="normal" font="Arial">Nat Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> alveolar macrophage</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Belgium</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> dendritic cell</style></keyword><keyword><style face="normal" font="Arial"> Dendritic Cells</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay Fever</style></keyword><keyword><style face="normal" font="Arial"> Hay-fever</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune cells</style></keyword><keyword><style face="normal" font="Arial"> Immunity</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> linked</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> macrophage</style></keyword><keyword><style face="normal" font="Arial"> Macrophages</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> monocyte</style></keyword><keyword><style face="normal" font="Arial"> Monocytes</style></keyword><keyword><style face="normal" font="Arial"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="Arial"> Protection</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> subset</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Training</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">The hygiene hypothesis postulates that the recent increase in allergic diseases such as asthma and hay fever observed in Western countries is linked to reduced exposure to childhood infections. Here we investigated how infection with a gammaherpesvirus affected the subsequent development of allergic asthma. We found that murid herpesvirus 4 (MuHV-4) inhibited the development of house dust mite (HDM)-induced experimental asthma by modulating lung innate immune cells. Specifically, infection with MuHV-4 caused the replacement of resident alveolar macrophages (AMs) by monocytes with regulatory functions. Monocyte-derived AMs blocked the ability of dendritic cells to trigger a HDM-specific response by the TH2 subset of helper T cells. Our results indicate that replacement of embryonic AMs by regulatory monocytes is a major mechanism underlying the long-term training of lung immunity after infection</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1529-2916 (Electronic)IS - 1529-2908 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="Arial">10.1038/ni.3857</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035391">PM:29035391</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Immunol\20171016-MachielsB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Immunol\20171016-MachielsB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Machiels B</style></custom2><misc3><style face="normal" font="Arial">10.1038/ni.3857</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">De Rosa,V.</style></author><author><style face="normal" font="Arial"> La Cava,A.</style></author><author><style face="normal" font="Arial"> Matarese,G.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio di Immunologia, Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche, Napoli, Italy</style></auth-address><titles><title><style face="normal" font="Arial">Metabolic pressure and the breach of immunological self-tolerance</style></title><secondary-title><style face="normal" font="Arial">Nat Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Immunol</style></full-title></periodical><pages end="1196" start="1190">1190-1196</pages><volume><style face="normal" font="Arial">18</style></volume><number><style face="normal" font="Arial">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Art</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> epidemic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Homeostasis</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> immunological tolerance</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> Italy</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Self Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Workload</style></keyword></keywords><dates><year Day="18" Month="10" Year="2017">2017/10/18</year></dates><abstract><style face="normal" font="Arial">The prevalence of autoimmune disorders in affluent countries has reached epidemic proportions. Over the past 50 years, a reverse trend between the frequency of infectious diseases and the incidence of autoimmune and allergic diseases led to the so-called 'hygiene hypothesis'. Given the epidemiological evidence and recent experimental data, we propose that this concept should also include metabolic pressure secondary to exposure to excessive daily caloric intake and overnutrition. We discuss how metabolic workload can modulate immunological tolerance and review the molecular mechanisms and the state of the art of the field. We also critically evaluate possibilities for restoring immunological homeostasis under conditions of metabolic pressure</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1529-2916 (Electronic)IS - 1529-2908 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/ni.3851</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29044230">PM:29044230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Immunol\2017-18-1190-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Immunol\2017-18-1190-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, De Rosa V</style></custom2><misc3><style face="normal" font="Arial">10.1038/ni.3851</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Shimanaka,Y.</style></author><author><style face="normal" font="Arial"> Kono,N.</style></author><author><style face="normal" font="Arial"> Taketomi,Y.</style></author><author><style face="normal" font="Arial"> Arita,M.</style></author><author><style face="normal" font="Arial"> Okayama,Y.</style></author><author><style face="normal" font="Arial"> Tanaka,Y.</style></author><author><style face="normal" font="Arial"> Nishito,Y.</style></author><author><style face="normal" font="Arial"> Mochizuki,T.</style></author><author><style face="normal" font="Arial"> Kusuhara,H.</style></author><author><style face="normal" font="Arial"> Adibekian,A.</style></author><author><style face="normal" font="Arial"> Cravatt,B.F.</style></author><author><style face="normal" font="Arial"> Murakami,M.</style></author><author><style face="normal" font="Arial"> Arai,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Omega-3 fatty acid epoxides are autocrine mediators that control the magnitude of IgE-mediated mast cell activation</style></title><secondary-title><style face="normal" font="Arial">Nat Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Nat Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> cell activation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chemistry</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Cross-linking</style></keyword><keyword><style face="normal" font="Arial"> crosslinking</style></keyword><keyword><style face="normal" font="Arial"> deletion</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Eicosanoids</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Fatty acid</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Immune response</style></keyword><keyword><style face="normal" font="Arial"> immune responses</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lipid</style></keyword><keyword><style face="normal" font="Arial"> lipid mediators</style></keyword><keyword><style face="normal" font="Arial"> mast cell</style></keyword><keyword><style face="normal" font="Arial"> mast cell activation</style></keyword><keyword><style face="normal" font="Arial"> Mast Cells</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase</style></keyword><keyword><style face="normal" font="Arial"> Phospholipase A2</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="9" Month="10" Year="2017">2017/10/9</year></dates><abstract><style face="normal" font="Arial">Critical to the function of mast cells in immune responses including allergy is their production of lipid mediators, among which only omega-6 (omega-6) arachidonate-derived eicosanoids have been well characterized. Here, by employing comprehensive lipidomics, we identify omega-3 (omega-3) fatty acid epoxides as new mast cell-derived lipid mediators and show that they are produced by PAF-AH2, an oxidized-phospholipid-selective phospholipase A2. Genetic or pharmacological deletion of PAF-AH2 reduced the steady-state production of omega-3 epoxides, leading to attenuated mast cell activation and anaphylaxis following FcvarepsilonRI cross-linking. Mechanistically, the omega-3 epoxides promote IgE-mediated activation of mast cells by downregulating Srcin1, a Src-inhibitory protein that counteracts FcvarepsilonRI signaling, through a pathway involving PPARg. Thus, the PAF-AH2-omega-3 epoxide-Srcin1 axis presents new potential drug targets for allergic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1546-170X (Electronic)IS - 1078-8956 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="Arial">10.1038/nm.4417</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035365">PM:29035365</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Med\20171016-ShimanakaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Med\20171016-ShimanakaY.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Shimanaka Y</style></custom2><misc3><style face="normal" font="Arial">10.1038/nm.4417</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Bach,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universite Paris Descartes, Sorbonne Paris Cite, Paris, France</style></auth-address><titles><title><style face="normal" font="Arial">The hygiene hypothesis in autoimmunity: the role of pathogens and commensals</style></title><secondary-title><style face="normal" font="Arial">Nat Rev Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Nat Rev Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune</style></keyword><keyword><style face="normal" font="Arial"> autoimmune disease</style></keyword><keyword><style face="normal" font="Arial"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="Arial"> Autoimmunity</style></keyword><keyword><style face="normal" font="Arial"> Bacteria</style></keyword><keyword><style face="normal" font="Arial"> commensal bacteria</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Experimental models</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> Hygiene</style></keyword><keyword><style face="normal" font="Arial"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="Arial"> Immune</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> Infectious disease</style></keyword><keyword><style face="normal" font="Arial"> innate</style></keyword><keyword><style face="normal" font="Arial"> innate immune receptors</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Observation</style></keyword><keyword><style face="normal" font="Arial"> occurrence</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Parasites</style></keyword><keyword><style face="normal" font="Arial"> Paris</style></keyword><keyword><style face="normal" font="Arial"> Pathogen</style></keyword><keyword><style face="normal" font="Arial"> Pathogens</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> toll like receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like Receptor</style></keyword><keyword><style face="normal" font="Arial"> Toll-like receptors</style></keyword><keyword><style face="normal" font="Arial"> Viruses</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">The incidence of autoimmune diseases has been steadily rising. Concomitantly, the incidence of most infectious diseases has declined. This observation gave rise to the hygiene hypothesis, which postulates that a reduction in the frequency of infections contributes directly to the increase in the frequency of autoimmune and allergic diseases. This hypothesis is supported by robust epidemiological data, but the underlying mechanisms are unclear. Pathogens are known to be important, as autoimmune disease is prevented in various experimental models by infection with different bacteria, viruses and parasites. Gut commensal bacteria also play an important role: dysbiosis of the gut flora is observed in patients with autoimmune diseases, although the causal relationship with the occurrence of autoimmune diseases has not been established. Both pathogens and commensals act by stimulating immunoregulatory pathways. Here, I discuss the importance of innate immune receptors, in particular Toll-like receptors, in mediating the protective effect of pathogens and commensals on autoimmunity</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1474-1741 (Electronic)IS - 1474-1733 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1038/nri.2017.111</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29034905">PM:29034905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Nat Rev Immunol\20171016-BachJF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Nat Rev Immunol\20171016-BachJF.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Bach JF</style></custom2><misc3><style face="normal" font="Arial">10.1038/nri.2017.111</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Asnoussi,A.</style></author><author><style face="normal" font="Arial"> Aibinu,I.E.</style></author><author><style face="normal" font="Arial"> Gasser,R.B.</style></author><author><style face="normal" font="Arial"> Lopata,A.L.</style></author><author><style face="normal" font="Arial"> Smooker,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Biosciences &amp; Food Technology, School of Science, RMIT University, Bundoora West Campus, PO Box 71, Bundoora, VIC, 3083, Australia</style></auth-address><titles><title><style face="normal" font="Arial">Molecular and immunological characterisation of tropomyosin from Anisakis pegreffii</style></title><secondary-title><style face="normal" font="Arial">Parasitol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Parasitol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analyses</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis</style></keyword><keyword><style face="normal" font="Arial"> Anisakis pegreffii</style></keyword><keyword><style face="normal" font="Arial"> Antibodies</style></keyword><keyword><style face="normal" font="Arial"> Antibody</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Characterisation</style></keyword><keyword><style face="normal" font="Arial"> Cockroach</style></keyword><keyword><style face="normal" font="Arial"> Cockroaches</style></keyword><keyword><style face="normal" font="Arial"> Conformation</style></keyword><keyword><style face="normal" font="Arial"> cross reactivity</style></keyword><keyword><style face="normal" font="Arial"> Cross-reactivity</style></keyword><keyword><style face="normal" font="Arial"> crustacean</style></keyword><keyword><style face="normal" font="Arial"> Crustaceans</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dna</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Exploration</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food Technology</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE antibodies</style></keyword><keyword><style face="normal" font="Arial"> IgE antibody</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> ITS-1</style></keyword><keyword><style face="normal" font="Arial"> ITS2</style></keyword><keyword><style face="normal" font="Arial"> larvae</style></keyword><keyword><style face="normal" font="Arial"> mAb</style></keyword><keyword><style face="normal" font="Arial"> major allergen</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> nematode</style></keyword><keyword><style face="normal" font="Arial"> Nematodes</style></keyword><keyword><style face="normal" font="Arial"> parasite</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phylogenetic analysis</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibodies</style></keyword><keyword><style face="normal" font="Arial"> polyclonal antibody</style></keyword><keyword><style face="normal" font="Arial"> polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Recombinant</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Sequencing</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Single-strand conformation polymorphism</style></keyword><keyword><style face="normal" font="Arial"> Specific serum IgE</style></keyword><keyword><style face="normal" font="Arial"> Technology</style></keyword><keyword><style face="normal" font="Arial"> TIGER</style></keyword><keyword><style face="normal" font="Arial"> Tropomyosin</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> West</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="Arial">Tropomyosin (TM) is a major allergen in shellfish, known to cross-react with mite, cockroach and/or some roundworm (nematode) TM. In this study, we aimed to express and purify TM from the parasitic nematode Anisakis pegreffii and also to characterise its cross-reactivity with TM from shellfish. A. pegreffii was isolated from the flathead tiger fish (Neoplatycephalus richardsoni) and characterised using single-strand conformation polymorphism (SSCP)-based sequencing of the first and second internal transcribed spacers (ITS-1 and ITS-2) of nuclear ribosomal DNA. The recombinant tropomyosin (rTM) of A. pegreffii was expressed, purified and confirmed by immunohistochemistry, sequencing and LC-MS/MS analyses. Immunohistochemistry showed the muscle and the base layer of the third-stage larvae (L3) of A. pegreffii as the location of TM in A. pegreffii. The molecular relationship of TM of A. pegreffii with homologs from other nematodes and crustaceans was inferred from phylogenetic analysis. Immunogenicity of TM from A. pegreffii was tested by immunoblotting, which showed that rTM from A. pegreffii binds to IgE from sera of patients with allergy to crustaceans. Immunoblotting also showed that the anti-TM monoclonal antibody (MAb) did not recognise rTM from A. pegreffii. The rTM from A. pegreffii was, however, recognised by anti-TM polyclonal antibodies (PAbs) as well as anti-crustacean polyclonal antibodies (PAbs). The detection of specific serum IgE antibody against parasite TM has been proposed as a useful approach for the diagnosis of parasite-induced allergy. The findings of this study merit further exploration of the cross-reactive allergenic proteins of Anisakis for improved, future diagnosis of allergenic diseases</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1432-1955 (Electronic)IS - 0932-0113 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="Arial">10.1007/s00436-017-5642-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038898">PM:29038898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Parasitol Res\20171017-AsnoussiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Parasitol Res\20171017-AsnoussiA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Asnoussi A</style></custom2><misc3><style face="normal" font="Arial">10.1007/s00436-017-5642-4</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Tanno,L.K.</style></author><author><style face="normal" font="Arial"> Claverie,C.</style></author><author><style face="normal" font="Arial"> Lejeune,S.</style></author><author><style face="normal" font="Arial"> Labreuche,J.</style></author><author><style face="normal" font="Arial"> Dorkenoo,A.</style></author><author><style face="normal" font="Arial"> Renaudin,J.M.</style></author><author><style face="normal" font="Arial"> Eb,M.</style></author><author><style face="normal" font="Arial"> Leteurtre,S.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Children's Hospital, F-59056, Roubaix, France</style></auth-address><titles><title><style face="normal" font="Arial">Fatal anaphylaxis in children in France: analysis of national data</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cause of Death</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="Arial">Anaphylaxis is a recognized cause of death for all ages. A better understanding of mortality data could help identify patients at risk and implement prevention measures. However, accurate epidemiological mortality data can differ widely due to a number of variables. Currently, the anaphylaxis-related mortality rate (AMR) is less than 1 per million population per year in most countries. In France, it was 0.83 per million population per year (95%CI, 0.80-0.88) for the period 1979 to 2011 (1-6). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12828</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047172">PM:29047172</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171019-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171019-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Pouessel G</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12828</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Koet,L.B.M.</style></author><author><style face="normal" font="Arial"> Brand,P.L.P.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Princess Amalia Children's Center Isala Hospital, PO Box 10400, 8000, GK, Zwolle, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Increase in atopic sensitization rate among Dutch children with symptoms of allergic disease between 1994 and 2014</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aeroallergen</style></keyword><keyword><style face="normal" font="Arial"> aeroallergen sensitization</style></keyword><keyword><style face="normal" font="Arial"> aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> atopic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical laboratory</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> food and aeroallergens</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time trends</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: The prevalence of symptoms of allergic diseases has increased significantly during the last decades. However, studies into time trends of atopic sensitization among children are limited and have focused on aeroallergen sensitization. We aimed to investigate time trends in the prevalence and degree of atopic sensitization to inhalant and food allergens among children (0-17 years) with symptoms of allergic disease. METHODS: Sensitization data of all children tested in our clinical laboratory during 1994-2014 were analyzed. Sensitization was detected using the ImmunoCap system and defined as a specific IgE level of >/=0.35 kU/l. Trends in sensitization rates to five food and five aeroallergens for different age categories were investigated with logistic regression, adjusted for age and sex. RESULTS: Sensitization data of 18,199 children were analyzed. Between 1994-2014 a steady and statistically significant increase in overall sensitization rate was found (from 40.5% in 1994 to 48.9% in 2014, adjusted odds ratio [aOR] 1.01 per year, 95% confidence interval [CI] 1.00 to 1.01, p=0.003). This increase in sensitization rate was mainly explained by increasing aeroallergen sensitization among 4-11 year old children (aOR 1.02, 95% CI 1.01 to 1.02, p&lt;0.001). We found no increase in sensitization rates to food and aeroallergens in other age categories. The degree of sensitization did not change significantly during the study period (all tests p>0.15). CONCLUSION: We observed a statistically significant increase in sensitization rate between 1994 and 2014 among children with symptoms of allergic disease. This was mainly explained by increasing aeroallergen sensitization among 4-11 year olds. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12825</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047176">PM:29047176</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171019-KoetLB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171019-KoetLB.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Koet LB</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12825</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Arabkhazaeli,A.</style></author><author><style face="normal" font="Arial"> Ahmadizar,F.</style></author><author><style face="normal" font="Arial"> Leusink,M.</style></author><author><style face="normal" font="Arial"> Arets,H.G.M.</style></author><author><style face="normal" font="Arial"> Raaijmakers,J.A.M.</style></author><author><style face="normal" font="Arial"> Uiterwaal,C.S.</style></author><author><style face="normal" font="Arial"> van der Ent,C.K.</style></author><author><style face="normal" font="Arial"> Maitland-van der Zee,A.H.</style></author><author><style face="normal" font="Arial"> Vijverberg,S.J.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Faculty of Science, Utrecht University, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">The association between an genetic risk score for allergy and the risk of developing allergies in childhood - Results of the WHISTLER cohort</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Conjunctivitis</style></keyword><keyword><style face="normal" font="Arial"> COX</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Dust mites</style></keyword><keyword><style face="normal" font="Arial"> Dust-mites</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Genetic variants</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> House dust mites</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Logistic regression</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> Mites</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> newborn</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Pharmacoepidemiology</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Pollen</style></keyword><keyword><style face="normal" font="Arial"> predict</style></keyword><keyword><style face="normal" font="Arial"> Regression Analysis</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> Score</style></keyword><keyword><style face="normal" font="Arial"> SNP</style></keyword><keyword><style face="normal" font="Arial"> SNPs</style></keyword><keyword><style face="normal" font="Arial"> susceptibility</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> variants</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Several genetic variants have been associated with the susceptibility to allergic disease in adults, but it remains unclear whether these genetic variants are also associated with the onset of allergic disease early in life. The aim of this study was to develop a genetic risk score (GRS) for allergy based on findings in adults and study its predictive capacity for allergy in children. METHODS: A GRS was constructed based on 10 SNPs previously associated with allergies in adults. The GRS was tested in children who participated in a population-based newborn cohort (WHISTLER) and were followed from birth to school age. Logistic regression analysis was used to study the association between the GRS and the parental-reported allergies at age 5 (based on a reported allergy to >/=1 of the following allergens: pollen, house dust mites or pets). A Cox regression model was used to study the association between GRS and a physician-diagnosed allergy during follow-up (allergic conjunctivitis, allergic rhinitis and eczema/dermatitis). Cohen's kappa coefficient was calculated to study the agreement between physician-diagnosed allergy and parental-reported allergy at age 5. RESULTS: The GRS was significantly associated with parental-reported allergy (Odds Ratio: 15.9, 95% Confidence Interval (CI): 1.07-233.73) at age 5, as well as with a physician-diagnosed allergy during follow-up (Hazard Ratio: 1.89, 95% CI: 1.05 -3.41). The overall agreement between physician-diagnosed and parental-reported allergies was 70.5% (Kappa: 0.10, 95% CI: 0.03-0.18). CONCLUSIONS: An adult-derived GRS for allergy predicts the risk of developing allergies in childhood. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12824</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047167">PM:29047167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171019-ArabkhazaeliA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171019-ArabkhazaeliA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Arabkhazaeli A</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12824</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Miura,T.</style></author><author><style face="normal" font="Arial"> Yanagida,N.</style></author><author><style face="normal" font="Arial"> Sato,S.</style></author><author><style face="normal" font="Arial"> Ogura,K.</style></author><author><style face="normal" font="Arial"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Tokyo Medical University Hospital, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="Arial">Follow-up of patients with uncertain symptoms during an oral food challenge is useful for diagnosis</style></title><secondary-title><style face="normal" font="Arial">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatric Allergy and Immunology</style></full-title><abbr-1><style face="normal" font="Arial">Pediatr Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Abdominal Pain</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy symptom</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> associations</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cough</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> double-blind</style></keyword><keyword><style face="normal" font="Arial"> double-blind placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> food challenge</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Hen's egg</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral food challenge</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> placebo controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled</style></keyword><keyword><style face="normal" font="Arial"> placebo-controlled food challenge</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> Rash</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Tokyo</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Wheat</style></keyword></keywords><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Uncertain symptoms often emerge during an oral food challenge (OFC) and Open-OFCs with those uncertain mild symptoms are ordinarily regarded as positive. Double-blind placebo-controlled food challenges should be conducted in order to determine these associations. Nevertheless, studies regarding the diagnosis of uncertain food allergy symptoms are lacking. We examined the diagnostic decision for a food allergy based on uncertain symptoms during an Open-OFC. METHODS: We conducted an Open-OFC between August 2005 and April 2012 with 2271 cases who suspected as allergic to hen's eggs, cow's milk, or wheat. For the primary diagnosis, Open-OFC with obvious symptoms were classified as "positive," no symptoms as "negative," and uncertain, indeterminate symptoms as "uncertain." We encouraged the children in the uncertain group to consume the causative foods at home more than twice; if any definitive symptoms were induced, children were classified as "intolerant," and children without any symptoms were classified as "tolerant," for the final diagnosis. RESULTS: We analyzed 454 uncertain cases excluding 781 positive cases and 1036 negative cases. The symptoms that occurred for the uncertain cases included slight abdominal pain, localized skin rash, and an isolated cough. Of these cases, 362 (79.7%) were considered tolerant at the final diagnosis. Of the intolerant children at the final diagnosis, the induced symptoms at home were not serious. CONCLUSIONS: Monitoring of recurring symptoms following consumption of causative foods at home by patients with uncertain symptoms improve the diagnostic accuracy of an Open-OFC. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1111/pai.12823</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047183">PM:29047183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171019-MiuraT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20171019-MiuraT.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Miura T</style></custom2><misc3><style face="normal" font="Arial">10.1111/pai.12823</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hua,M.C.</style></author><author><style face="normal" font="Arial"> Yao,T.C.</style></author><author><style face="normal" font="Arial"> Chen,C.C.</style></author><author><style face="normal" font="Arial"> Tsai,M.H.</style></author><author><style face="normal" font="Arial"> Liao,S.L.</style></author><author><style face="normal" font="Arial"> Lai,S.H.</style></author><author><style face="normal" font="Arial"> Chiu,C.Y.</style></author><author><style face="normal" font="Arial"> Su,K.W.</style></author><author><style face="normal" font="Arial"> Yeh,K.W.</style></author><author><style face="normal" font="Arial"> Huang,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, and Chang Gung University College of Medicine, Taoyuan, Taiwan</style></auth-address><titles><title><style face="normal" font="Arial">Introduction of various allergenic foods during infancy reduces risk of IgE sensitization at 12 months of age: a birth cohort study</style></title><secondary-title><style face="normal" font="Arial">Pediatr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pediatr Res</style></full-title></periodical><pages end="740" start="733">733-740</pages><volume><style face="normal" font="Arial">82</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status date="12/24/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">age</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic food</style></keyword><keyword><style face="normal" font="Arial"> Allergenic foods</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> birth</style></keyword><keyword><style face="normal" font="Arial"> birth cohort</style></keyword><keyword><style face="normal" font="Arial"> birth cohort studies</style></keyword><keyword><style face="normal" font="Arial"> cationic protein</style></keyword><keyword><style face="normal" font="Arial"> Cohort</style></keyword><keyword><style face="normal" font="Arial"> Cohort Studies</style></keyword><keyword><style face="normal" font="Arial"> cohort study</style></keyword><keyword><style face="normal" font="Arial"> diversity</style></keyword><keyword><style face="normal" font="Arial"> ECP</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Egg Yolk</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="Arial"> Feeding</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> Fruit</style></keyword><keyword><style face="normal" font="Arial"> Fruits</style></keyword><keyword><style face="normal" font="Arial"> Iga</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE sensitization</style></keyword><keyword><style face="normal" font="Arial"> infancy</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> infants</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Inhalant</style></keyword><keyword><style face="normal" font="Arial"> inhalant allergen</style></keyword><keyword><style face="normal" font="Arial"> Inhalant allergens</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Odds Ratio</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Parents</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Pediatrics</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Questionnaire</style></keyword><keyword><style face="normal" font="Arial"> Questionnaires</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> Serum levels</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Taiwan</style></keyword><keyword><style face="normal" font="Arial"> total IgE</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">BackgroundIn this study, we aimed to determine whether introducing various allergenic foods during infancy is associated with IgE sensitization at 12 months of age.MethodsDetailed information on feeding practices regarding six possible allergenic foods (fruits, egg white, egg yolk, fish, shellfish, and peanuts) was obtained by administering age-specific questionnaires to parents of infants at ages 6 and 12 months. Fecal secretory IgA (sIgA), fecal eosinophil cationic protein (ECP), and serum levels of total IgE and IgE specific to 20 foods, and IgE specific to 20 inhalant allergens were also quantified at 12 months of age.ResultsAt 12 months of age, infants with IgE sensitization had been introduced to fewer allergenic food items during infancy (3.2+/-1.4 vs. 3.7+/-1.3 items). Compared with infants who were given 0-2 allergenic food items, infants introduced to 3-4 or >/=5 allergenic food items showed a significantly lower risk of IgE sensitization (odds ratios (ORs) 0.62 and 0.61, respectively) and lower total IgE levels. In addition, non-introduction of egg white or egg yolk was significantly related to IgE sensitization (ORs 1.41 and 1.26, respectively).ConclusionIncreasing the diversity of allergenic foods in infancy, including fruits, egg white, egg yolk, fish, shellfish, and peanuts, may protect infants from IgE sensitization at 12 months of age</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1530-0447 (Electronic)IS - 0031-3998 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="Arial">10.1038/pr.2017.174</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29040259">PM:29040259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Res\2017-82-733-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Res\2017-82-733-40.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Hua MC</style></custom2><misc3><style face="normal" font="Arial">10.1038/pr.2017.174</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Soto,A.S.</style></author><author><style face="normal" font="Arial"> Fenoy,I.M.</style></author><author><style face="normal" font="Arial"> Sanchez,V.R.</style></author><author><style face="normal" font="Arial"> March,F.</style></author><author><style face="normal" font="Arial"> Perrone Sibilia,M.D.</style></author><author><style face="normal" font="Arial"> Aldirico,M.L.A.</style></author><author><style face="normal" font="Arial"> Picchio,M.S.</style></author><author><style face="normal" font="Arial"> Arcon,N.</style></author><author><style face="normal" font="Arial"> Acosta,P.L.</style></author><author><style face="normal" font="Arial"> Polack,F.P.</style></author><author><style face="normal" font="Arial"> Martin,V.</style></author><author><style face="normal" font="Arial"> Goldman,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Laboratorio de Inmunologia, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin, Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="Arial">Toxoplasma gondii serine-protease inhibitor-1: A new adjuvant candidate for asthma therapy</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0187002">e0187002-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">adjuvant</style></keyword><keyword><style face="normal" font="Arial"> alergia</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Argentina</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma treatment</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Cell Proliferation</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophilia</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-10</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> IL-5</style></keyword><keyword><style face="normal" font="Arial"> IL10</style></keyword><keyword><style face="normal" font="Arial"> Immunomodulatory</style></keyword><keyword><style face="normal" font="Arial"> Increased prevalence</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inhibitory activity</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Lymph</style></keyword><keyword><style face="normal" font="Arial"> Lymph node</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> proliferation</style></keyword><keyword><style face="normal" font="Arial"> Protease</style></keyword><keyword><style face="normal" font="Arial"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="Arial"> proteases</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serine</style></keyword><keyword><style face="normal" font="Arial"> serine protease</style></keyword><keyword><style face="normal" font="Arial"> Serine protease inhibitor</style></keyword><keyword><style face="normal" font="Arial"> serine proteases</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> therapeutic</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> tissue remodeling</style></keyword><keyword><style face="normal" font="Arial"> Toxoplasma</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">Serine-proteases are important players in the pathogenesis of asthma, promoting inflammation and tissue remodeling. It's also known that many serine protease inhibitors display immunomodulatory properties. TgPI-1 is a Toxoplasma gondii protein that exhibits broad spectrum inhibitory activity against serine proteases. In view of the increased prevalence of atopic disorders and the need to develop new treatment strategies we sought to investigate the potential of TgPI-1 for treating respiratory allergies. For this purpose, we developed a therapeutic experimental model. BALB/c mice were rendered allergic by intraperitoneal ovalbumin-alum sensitization and airway-challenged. Once the asthmatic phenotype was achieved, mice were intranasally treated with rTgPI-1 alone or with a mixture of rTgPI-1 and ovalbumin (OVA). A week later mice were given a secondary aerosol challenge. Treatment with rTgPI-1 alone or co-administered with OVA diminished bronchoalveolar eosinophilia, mucus production and peribronchial lung infiltration. This effect was accompanied by a lung resistance reduction of 26.3% and 50.3% respectively. Both treatments resulted in the production of lower levels of IL-4, IL-5, IFN-gamma and regulatory IL-10 by thoracic lymph node cells stimulated with OVA. Interestingly, significant decreases in OVA specific IgE and T cell proliferation, and increases in FoxP3+ T cells at local and systemic levels were only detected when the inhibitor was administered along with OVA. These results show that both rTgPI-1 treatments reduced asthma hallmarks. However, co-administration of the inhibitor with the allergen was more effective. Hence, rTgPI-1 emerges as a novel adjuvant candidate for asthma treatment</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0187002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29073215">PM:29073215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0187002.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0187002.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Soto AS</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0187002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Stroo,I.</style></author><author><style face="normal" font="Arial"> Yang,J.</style></author><author><style face="normal" font="Arial"> Anas,A.A.</style></author><author><style face="normal" font="Arial"> de Boer,J.D.</style></author><author><style face="normal" font="Arial"> van Mierlo,G.</style></author><author><style face="normal" font="Arial"> Roem,D.</style></author><author><style face="normal" font="Arial"> Wouters,D.</style></author><author><style face="normal" font="Arial"> Engel,R.</style></author><author><style face="normal" font="Arial"> Roelofs,J.J.T.H.</style></author><author><style face="normal" font="Arial"> van't Veer,C.</style></author><author><style face="normal" font="Arial"> van der Poll,T.</style></author><author><style face="normal" font="Arial"> Zeerleder,S.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="Arial">Human plasma-derived C1 esterase inhibitor concentrate has limited effect on house dust mite-induced allergic lung inflammation in mice</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0186652">e0186652-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> administration</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="Arial"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="Arial"> C1-INH</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> coagulation</style></keyword><keyword><style face="normal" font="Arial"> Complement</style></keyword><keyword><style face="normal" font="Arial"> Dust</style></keyword><keyword><style face="normal" font="Arial"> Dust mite</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> Fibrinolysis</style></keyword><keyword><style face="normal" font="Arial"> HDM</style></keyword><keyword><style face="normal" font="Arial"> house dust</style></keyword><keyword><style face="normal" font="Arial"> house dust mite</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> IgG1</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung inflammation</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> Mite</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> NaCl</style></keyword><keyword><style face="normal" font="Arial"> Netherlands</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Plasma</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> Th2 response</style></keyword><keyword><style face="normal" font="Arial"> TH2 responses</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">C1 esterase inhibitor (C1-INH) can inhibit multiple pathways (complement, contact-kinin, coagulation, and fibrinolysis) that are all implicated in the pathophysiology of asthma. We explored the effect of human plasma-derived C1-INH on allergic lung inflammation in a house dust mite (HDM) induced asthma mouse model by daily administration of C1-INH (15 U) during the challenge phase. NaCl and HDM exposed mice had comparable plasma C1-INH levels, while bronchoalveolar lavage fluid (BALF) levels were increased in HDM exposed mice coinciding with slightly reduced activation of complement (C5a). C1-INH treatment reduced Th2 response and enhanced HDM-specific IgG1. Influx of eosinophils in BALF or lung, pulmonary damage, mucus production, procoagulant response or plasma leakage in BALF was similar in both groups. In conclusion, C1-INH dampens Th2 responses during HDM induced allergic lung inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="Arial">    10.1371/journal.pone.0186652</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29036225">PM:29036225</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0186652.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0186652.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Stroo I</style></custom2><misc3><style face="normal" font="Arial">    10.1371/journal.pone.0186652</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pluangnooch,P.</style></author><author><style face="normal" font="Arial"> Timalsena,S.</style></author><author><style face="normal" font="Arial"> Wongkajornsilp,A.</style></author><author><style face="normal" font="Arial"> Soontrapa,K.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="Arial">Cytokine-induced killer cells: A novel treatment for allergic airway inflammation</style></title><secondary-title><style face="normal" font="Arial">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">PLoS One</style></abbr-1></periodical><pages end="" start="e0186971">e0186971-</pages><volume><style face="normal" font="Arial">12</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> effectiveness</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Faculty</style></keyword><keyword><style face="normal" font="Arial"> Histology</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Killer Cells</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Modification</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> pharmacology</style></keyword><keyword><style face="normal" font="Arial"> Protocol</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T helper</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> Thailand</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">The effectiveness of cytokine-induced killer (CIK) cells for treatment of cancers has long been appreciated. Here, we report for the first time that CIK cells can be applied to treat allergic airway inflammation. Adopting from an established protocol with some modifications, we generated CIK cells ex vivo from mouse T cells, and examined their effectiveness in treatment of allergic airway inflammation using the ovalbumin-induced model of allergic airway inflammation. Based upon evaluation of bronchoalveolar lavage cellularity, T helper type2 cytokine levels and lung histology, all of which are important parameters for determining the severity of allergic airway inflammation, diseased mice treated with CIK cells showed significant reductions in all the parameters without any obvious adverse effects. Interestingly, the observed effects were comparable to those treated with dexamethasone. Thus, our study provides a novel application of CIK cells in treatment of allergic airway inflammation</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="Arial">10.1371/journal.pone.0186971</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29073213">PM:29073213</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0186971.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0186971.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Pluangnooch P</style></custom2><misc3><style face="normal" font="Arial">10.1371/journal.pone.0186971</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Piskorska-Jasiulewicz,M.M.</style></author><author><style face="normal" font="Arial"> Witkowska-Zimny,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Zaklad Biofizyki i Fizjologii Czlowieka, Warszawski Uniwersytet Medyczny</style></auth-address><titles><title><style face="normal" font="Arial">Non-nutritional use of breast milk</style></title><secondary-title><style face="normal" font="Arial">Postepy Hig Med Dosw (Online)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Postepy Hig Med Dosw (Online)</style></full-title></periodical><pages end="866" start="860">860-866</pages><volume><style face="normal" font="Arial">71</style></volume><number><style face="normal" font="Arial">0</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Breast</style></keyword><keyword><style face="normal" font="Arial"> breast milk</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> growth factors</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulins</style></keyword><keyword><style face="normal" font="Arial"> Infection</style></keyword><keyword><style face="normal" font="Arial"> Infections</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Poland</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Side effect</style></keyword><keyword><style face="normal" font="Arial"> side effects</style></keyword><keyword><style face="normal" font="Arial"> Stem Cells</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> viral</style></keyword><keyword><style face="normal" font="Arial"> viral infection</style></keyword><keyword><style face="normal" font="Arial"> Viral infections</style></keyword></keywords><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="Arial">Mammals milk, in addition to nutrients, contains many biologically active substances including immunoglobulins, growth factors, cytokines, acute phase proteins, and antimicrobial and antiviral proteins. Thanks to its unique composition, for hundreds of years it is used in post-natal care, treatment of wounds, as well as to fight bacterial and viral infections. The discovery of stem cells and HAMLET complex in breast milk resulted in increased interest in human breast milk as a natural medicine. Milk therapy is devoid of side effects, and breast milk banks may serve as a potential source of milk as a drug substance. In this study we collected information about the possible non-nutritional use of breast milk</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1732-2693 (Electronic)IS - 0032-5449 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="Arial">10.5604/01.3001.0010.5049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29039349">PM:29039349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Postepy Hig Med Dosw (Online)\2017-71-860-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Postepy Hig Med Dosw (Online)\2017-71-860-6.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Piskorska-Jasiulewicz MM</style></custom2><misc3><style face="normal" font="Arial">10.5604/01.3001.0010.5049</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Nguyen,L.P.</style></author><author><style face="normal" font="Arial"> Al-Sawalha,N.A.</style></author><author><style face="normal" font="Arial"> Parra,S.</style></author><author><style face="normal" font="Arial"> Pokkunuri,I.</style></author><author><style face="normal" font="Arial"> Omoluabi,O.</style></author><author><style face="normal" font="Arial"> Okulate,A.A.</style></author><author><style face="normal" font="Arial"> Windham,Li E.</style></author><author><style face="normal" font="Arial"> Hazen,M.</style></author><author><style face="normal" font="Arial"> Gonzalez-Granado,J.M.</style></author><author><style face="normal" font="Arial"> Daly,C.J.</style></author><author><style face="normal" font="Arial"> McGrath,J.C.</style></author><author><style face="normal" font="Arial"> Tuvim,M.J.</style></author><author><style face="normal" font="Arial"> Knoll,B.J.</style></author><author><style face="normal" font="Arial"> Dickey,B.F.</style></author><author><style face="normal" font="Arial"> Bond,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030</style></auth-address><titles><title><style face="normal" font="Arial">beta2-Adrenoceptor signaling in airway epithelial cells promotes eosinophilic inflammation, mucous metaplasia, and airway contractility</style></title><secondary-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Proc Natl Acad Sci U S A</style></full-title></periodical><pages end="E9171" start="E9163">E9163-E9171</pages><volume><style face="normal" font="Arial">114</style></volume><number><style face="normal" font="Arial">43</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">activation</style></keyword><keyword><style face="normal" font="Arial"> Adverse effect</style></keyword><keyword><style face="normal" font="Arial"> adverse effects</style></keyword><keyword><style face="normal" font="Arial"> agonists</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cell</style></keyword><keyword><style face="normal" font="Arial"> airway epithelial cells</style></keyword><keyword><style face="normal" font="Arial"> airway epithelium</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma phenotype</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> bronchodilator</style></keyword><keyword><style face="normal" font="Arial"> bronchodilators</style></keyword><keyword><style face="normal" font="Arial"> Cancer</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> epithelia</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Epithelial Cells</style></keyword><keyword><style face="normal" font="Arial"> Epithelium</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> IL-13</style></keyword><keyword><style face="normal" font="Arial"> IL13</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> Labeling</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Metaplasia</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> mucus production</style></keyword><keyword><style face="normal" font="Arial"> murine</style></keyword><keyword><style face="normal" font="Arial"> murine model</style></keyword><keyword><style face="normal" font="Arial"> murine models</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Muscle Cells</style></keyword><keyword><style face="normal" font="Arial"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> Receptors</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle cells</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> Transgenic</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United Kingdom</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="Arial">The mostly widely used bronchodilators in asthma therapy are beta2-adrenoreceptor (beta2AR) agonists, but their chronic use causes paradoxical adverse effects. We have previously determined that beta2AR activation is required for expression of the asthma phenotype in mice, but the cell types involved are unknown. We now demonstrate that beta2AR signaling in the airway epithelium is sufficient to mediate key features of the asthmatic responses to IL-13 in murine models. Our data show that inhibition of beta2AR signaling with an aerosolized antagonist attenuates airway hyperresponsiveness (AHR), eosinophilic inflammation, and mucus-production responses to IL-13, whereas treatment with an aerosolized agonist worsens these phenotypes, suggesting that beta2AR signaling on resident lung cells modulates the asthma phenotype. Labeling with a fluorescent beta2AR ligand shows the receptors are highly expressed in airway epithelium. In beta2AR-/- mice, transgenic expression of beta2ARs only in airway epithelium is sufficient to rescue IL-13-induced AHR, inflammation, and mucus production, and transgenic overexpression in WT mice exacerbates these phenotypes. Knockout of beta-arrestin-2 (betaarr-2-/-) attenuates the asthma phenotype as in beta2AR-/- mice. In contrast to eosinophilic inflammation, neutrophilic inflammation was not promoted by beta2AR signaling. Together, these results suggest beta2ARs on airway epithelial cells promote the asthma phenotype and that the proinflammatory pathway downstream of the beta2AR involves betaarr-2. These results identify beta2AR signaling in the airway epithelium as capable of controlling integrated responses to IL-13 and affecting the function of other cell types such as airway smooth muscle cells</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="Arial">10.1073/pnas.1710196114</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29073113">PM:29073113</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2017-114-E9163-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Proc Natl Acad Sci U S A\2017-114-E9163-71.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171026, Nguyen LP</style></custom2><misc3><style face="normal" font="Arial">10.1073/pnas.1710196114</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hur,J.</style></author><author><style face="normal" font="Arial"> Kang,J.Y.</style></author><author><style face="normal" font="Arial"> Rhee,C.K.</style></author><author><style face="normal" font="Arial"> Kim,Y.K.</style></author><author><style face="normal" font="Arial"> Lee,S.Y.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Allergy and Pulmonary Medicine, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="Arial">The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-beta signaling</style></title><secondary-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Pulm Pharmacol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">actin</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway disease</style></keyword><keyword><style face="normal" font="Arial"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic airway inflammation</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> antagonist</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Cell Line</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> cytokine</style></keyword><keyword><style face="normal" font="Arial"> Cytokines</style></keyword><keyword><style face="normal" font="Arial"> deposition</style></keyword><keyword><style face="normal" font="Arial"> Dimethyl Sulfoxide</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> Drug Discovery</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic</style></keyword><keyword><style face="normal" font="Arial"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Female</style></keyword><keyword><style face="normal" font="Arial"> fibroblast</style></keyword><keyword><style face="normal" font="Arial"> Fibrosis</style></keyword><keyword><style face="normal" font="Arial"> gene</style></keyword><keyword><style face="normal" font="Arial"> Gene Expression</style></keyword><keyword><style face="normal" font="Arial"> goblet cell</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> Hyperplasia</style></keyword><keyword><style face="normal" font="Arial"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> in vivo</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Internal Medicine</style></keyword><keyword><style face="normal" font="Arial"> Korea</style></keyword><keyword><style face="normal" font="Arial"> leukotriene</style></keyword><keyword><style face="normal" font="Arial"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> lung pathology</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> mouse model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> pathology</style></keyword><keyword><style face="normal" font="Arial"> Production</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> receptor</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> Republic of Korea</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Smad</style></keyword><keyword><style face="normal" font="Arial"> Smad signaling</style></keyword><keyword><style face="normal" font="Arial"> targets</style></keyword><keyword><style face="normal" font="Arial"> TH2</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokine</style></keyword><keyword><style face="normal" font="Arial"> TH2 cytokines</style></keyword><keyword><style face="normal" font="Arial"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND/OBJECTIVE: Asthma is a chronic airway disease characterized by airway eosinophilic inflammation and remodeling, which are associated with a loss in lung function. Although both contribute significantly to asthma pathogenesis, mechanistic studies and drug discovery have focused on inflammatory targets. In this study, we investigated the effect of the leukotriene receptor antagonist pranlukast on allergic airway inflammation and remodeling in vivo and in vitro. METHOD: Four groups of female BALB/c mice (control; ovalbumin [OVA]-sensitized and -challenged; dimethyl sulfoxide [DMSO]-treated OVA; and pranlukast-treated OVA) were examined. Lung pathology, cytokine production, and airway hyperresponsiveness (AHR) measurements were compared among these groups. A human fetal lung fibroblast HFL-1 cell line was used in the peribranchial fibrosis analysis. RESULTS: OVA-sensitized and -challenged mice exhibited allergic airway inflammation and significant increases in Th2 cytokines. Pranlukast-treated mice showed significant attenuation of allergic airway inflammation. The pranlukast treatment decreased AHR and attenuated airway remodeling to goblet cell hyperplasia, collagen deposition, alpha-smooth muscle actin expression, and pro-fibrotic gene expression. We further demonstrated that pranlukast not only inhibited transforming growth factor-beta 1 (TGF-beta1)-induced Smad signaling in human fetal lung fibroblast cells but also simultaneously reduced collagen synthesis and pro-fibrotic gene expression. CONCLUSIONS: The leukotriene receptor antagonist pranlukast can reduce airway inflammation and remodeling by inhibiting TGF-beta/Smad signaling in an OVA-sensitized and -challenged asthma mouse model, thus suppressing AHR</style></abstract><notes><style face="normal" font="Arial">DA - 20171016IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.pupt.2017.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031615">PM:29031615</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20171016-HurJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pulm Pharmacol Ther\20171016-HurJ.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171016, Hur J</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.pupt.2017.10.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agarwal,R.</style></author><author><style face="normal" font="Arial"> Sehgal,I.S.</style></author><author><style face="normal" font="Arial"> Dhooria,S.</style></author><author><style face="normal" font="Arial"> Garg,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Departments of Pulmonary Medicine Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India 160012</style></auth-address><titles><title><style face="normal" font="Arial">Inverted Mucoid Impaction Signal in Allergic Bronchopulmonary Aspergillosis: Are We Calling a Spade a Big Spoon?</style></title><secondary-title><style face="normal" font="Arial">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Radiology</style></full-title></periodical><pages end="692" start="691">691-692</pages><volume><style face="normal" font="Arial">285</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> Bronchopulmonary aspergillosis</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> India</style></keyword><keyword><style face="normal" font="Arial"> Indium</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medical education</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> pulmonary</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1527-1315 (Electronic)IS - 0033-8419 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="Arial">10.1148/radiol.2017171301</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29045221">PM:29045221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Radiology\2017-285-691-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Radiology\2017-285-691-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Agarwal R</style></custom2><misc3><style face="normal" font="Arial">10.1148/radiol.2017171301</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Garnier,L.</style></author><author><style face="normal" font="Arial"> Bienvenu,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Cow's milk allergy: Laboratory diagnostic tools</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy to cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Biological diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Boiling</style></keyword><keyword><style face="normal" font="Arial"> Casein</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> cellular mechanism</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic tool</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Future</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> immediate</style></keyword><keyword><style face="normal" font="Arial"> information</style></keyword><keyword><style face="normal" font="Arial"> Ingestion</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Milk allergy</style></keyword><keyword><style face="normal" font="Arial"> non-IgE</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Phenotype</style></keyword><keyword><style face="normal" font="Arial"> phenotypes</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Sensitization profile</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Tools</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Allergy to cow's milk (CM) is one of the three most frequent allergies in childhood (Alduraywish et al., 2016). Various mechanisms may be involved: either IgE-mediated or cellular mechanisms, with immediate or delayed symptoms. Furthermore, CM allergy has different phenotypes: although most CM allergic children become tolerant when they grow up and can tolerate milk after prolonged boiling, others develop a persistent allergy and react after ingestion of traces of milk, however much it is boiled. CM can cause very severe clinical symptoms and it is therefore important to have validated laboratory diagnostic tools available to confirm an allergy to CM, to identify the mechanisms involved, and to evaluate the patient's </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£allergic profile</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ. Numerous studies have shown that definition of the sensitization profile of CM allergic patients based on the study of specific IgE directed against CM and its different fractions can provide useful and non-invasive assistance with the IgE-mediated forms of CM allergy. In the future, new laboratory tools such as cellular tests will probably provide additional information, particularly regarding the non-IgE mediated forms</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.08.007</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-GarnierL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-GarnierL.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Garnier L</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.08.007</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Agodokpessi,G.</style></author><author><style face="normal" font="Arial"> Dossou-Yovo,S.</style></author><author><style face="normal" font="Arial"> Hountohotegbe,T.</style></author><author><style face="normal" font="Arial"> Panou,M.</style></author><author><style face="normal" font="Arial"> Djogbessi,D.</style></author><author><style face="normal" font="Arial"> Bigot,C.</style></author><author><style face="normal" font="Arial"> Bigot,A.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of the sensitization to 3 food allergens common in children followed for asthma and or allergic rhinitis in sub-Saharan Africa: A comparative study of prick-tests and IgE assay in Cotonou, Benin</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Africa</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Benin</style></keyword><keyword><style face="normal" font="Arial"> Blacks</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Comparative Study</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Egg White</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergen</style></keyword><keyword><style face="normal" font="Arial"> food allergens</style></keyword><keyword><style face="normal" font="Arial"> frequency</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> Peanut sensitization</style></keyword><keyword><style face="normal" font="Arial"> Peanuts</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Sex Ratio</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> skin prick-test</style></keyword><keyword><style face="normal" font="Arial"> skin prick-tests</style></keyword><keyword><style face="normal" font="Arial"> Sub-Saharan Africa</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Introduction The aim of this study was to assess sensitization to three food allergens in children followed for asthma and/or allergic rhinitis in African blacks in Benin. Methods Skin prick-tests and REAST tests for IgE using 3 common food allergens </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çö-áegg white, cow's milk and peanut-á</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çö were carried out in children aged 3 to 15 years followed for asthma and/or allergic rhinitis. Positive results for the two methods were compared. Results Of the 130 children initially included, 11 were excluded for ineligibility for the prick-test. The study was conducted in 119 (91.5%) children who underwent both tests. The mean age was 7 -¦ 1 years and the sex ratio (M/F) was 1.6. The most common association was rhinitis and asthma, seen in 66 (55.5%) children. The sensitization frequency with the prick-test and assay was 4.2% vs. 20% for egg white, 4.2% vs. 16.2% for milk and 3.4% vs. 0.0% for peanuts. Conclusion Sensitization to egg white was the most common, followed by milk and peanut sensitization. A divergence was noted between prick-tests and REAST assay in the evaluation of sensitization for these food allergens</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Benin -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.08.009</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-AgodokpessiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-AgodokpessiG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Agodokpessi G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.08.009</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tacquard,C.</style></author><author><style face="normal" font="Arial"> Stenger,R.</style></author><author><style face="normal" font="Arial"> Metz-Favre,C.</style></author><author><style face="normal" font="Arial"> Guenard,L.</style></author><author><style face="normal" font="Arial"> Chiriac,A.M.</style></author><author><style face="normal" font="Arial"> Malinovsky,J.M.</style></author><author><style face="normal" font="Arial"> Demoly,P.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author><author><style face="normal" font="Arial"> Mertes,P.M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Management of perioperative anaphylaxis</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">administration</style></keyword><keyword><style face="normal" font="Arial"> Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaesthesia</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Antibiotic</style></keyword><keyword><style face="normal" font="Arial"> Antibiotics</style></keyword><keyword><style face="normal" font="Arial"> blocking</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical symptom</style></keyword><keyword><style face="normal" font="Arial"> clinical symptoms</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> delayed</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> determination</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> dye</style></keyword><keyword><style face="normal" font="Arial"> Dyes</style></keyword><keyword><style face="normal" font="Arial"> Epinephrine</style></keyword><keyword><style face="normal" font="Arial"> Erythema</style></keyword><keyword><style face="normal" font="Arial"> expansion</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> Histamine</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> Immunoassay</style></keyword><keyword><style face="normal" font="Arial"> Immunoassays</style></keyword><keyword><style face="normal" font="Arial"> Incidence</style></keyword><keyword><style face="normal" font="Arial"> Intravenous</style></keyword><keyword><style face="normal" font="Arial"> Latex</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Neuromuscular blocking agents</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Perioperative Period</style></keyword><keyword><style face="normal" font="Arial"> Pressure</style></keyword><keyword><style face="normal" font="Arial"> Procedures</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> severity</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> Skin test</style></keyword><keyword><style face="normal" font="Arial"> Skin tests</style></keyword><keyword><style face="normal" font="Arial"> Skin-tests</style></keyword><keyword><style face="normal" font="Arial"> Specific IgE</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Anaphylactic reactions occurring during the perioperative period should be investigated and treated in compliance with the guidelines published by the SFAR and the SFA in 2011. In France, the estimated incidence of allergic reactions is 100.6 [76.2</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô125.3]/million procedures. In adults, the most frequently incriminated substances are neuromuscular blocking agents, followed by antibiotics and dyes. In most cases, clinical symptoms occur within minutes of intravenous administration of treatments. When symptoms are delayed and occur during the surgical procedure, a reaction involving latex, a vital dye, an antiseptic or a volume-expansion fluid should be suspected. Reaction severity may vary. The most frequently reported initial symptoms are pulselessness, erythema, increased airway pressure, desaturation and decreased end-tidal CO2. Clinical symptoms may occur as an isolated condition, making proper diagnosis difficult. Identification of the reaction mechanism relies on determination of mediators (tryptase, histamine) at the time of the reaction. In the event of an allergic reaction, the causative drug may be identified by the detection of specific IgE using immunoassays or by skin tests performed 6 weeks after the reaction. Treatment is based on suspension of allergen administration, on administration of epinephrine carefully titrated as a function of the severity of symptoms and on volume expansion</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.08.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-TacquardC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-TacquardC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Tacquard C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.08.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Rabehevitra,P.</style></author><author><style face="normal" font="Arial"> Solofoniary,V.H.</style></author><author><style face="normal" font="Arial"> Rasolofomanana,O.L.</style></author><author><style face="normal" font="Arial"> Nadison,T.C.</style></author><author><style face="normal" font="Arial"> Rabetaliana,L.</style></author><author><style face="normal" font="Arial"> Rakotonirina,J.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">The socio-temporo-spatial profile of allergic rhinitis patients in the Analamaga region of Madagascar</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Antananarivo</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal variation</style></keyword><keyword><style face="normal" font="Arial"> Student</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - Madagascar -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.08.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-RabehevitraP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-RabehevitraP.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Rabehevitra P</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.08.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hazebrouck,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Food allergy: The influence of breast-feeding and gut microbiota</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic children</style></keyword><keyword><style face="normal" font="Arial"> Allergic disease</style></keyword><keyword><style face="normal" font="Arial"> allergic diseases</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Breast Feeding</style></keyword><keyword><style face="normal" font="Arial"> Breast-feeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> composition</style></keyword><keyword><style face="normal" font="Arial"> Cow's milk</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diet</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Dysbiosis</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Gut</style></keyword><keyword><style face="normal" font="Arial"> gut microbiota</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> Introduction</style></keyword><keyword><style face="normal" font="Arial"> Maternal</style></keyword><keyword><style face="normal" font="Arial"> microbiota</style></keyword><keyword><style face="normal" font="Arial"> Milk</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Process</style></keyword><keyword><style face="normal" font="Arial"> recommendation</style></keyword><keyword><style face="normal" font="Arial"> Recommendations</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> World Health</style></keyword><keyword><style face="normal" font="Arial"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Numerous environmental factors have been incriminated in the increasing development of food allergies observed in recent decades. However, studies on the influence of certain of these factors such as infant diet and gut microbiota composition have generally yielded discrepant results that are insufficient to support firm recommendations for preventing the development of allergic diseases. The World Health Organization still recommends exclusive breast-feeding during the first six months of life but it has been reported that early introduction of some foods induces lasting oral tolerance that could protect children from allergy. Moreover, analysis of gut microbiota composition in allergic children has revealed no firm association between specific dysbiosis or specific bacterial taxa and increased risk of developing allergy. These studies are rendered even more complex due to the constant interaction between these environmental factors. Maternal milk can indeed modulate the composition of the gut microbiota via different processes. The establishment of new strategies for the prevention of food allergy thus requires consideration of the interaction between the different factors involved in the development of this disease</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.08.011</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-HazebrouckS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-HazebrouckS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Hazebrouck S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.08.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Lavigne,C.</style></author><author><style face="normal" font="Arial"> Lozac'h,P.</style></author><author><style face="normal" font="Arial"> Drouet,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Mastocytosis and anaphylactic reaction to hymenoptera venoms</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> allergic reactions</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> association</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical history</style></keyword><keyword><style face="normal" font="Arial"> desensitization</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> general population</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera sting</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venom</style></keyword><keyword><style face="normal" font="Arial"> Hymenoptera venoms</style></keyword><keyword><style face="normal" font="Arial"> Lead</style></keyword><keyword><style face="normal" font="Arial"> Mastocytosis</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Tryptase</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> Venoms</style></keyword><keyword><style face="normal" font="Arial"> Vigilance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Mastocytosis is a risk factor for frequent and severe allergic reactions, particularly following exposure to hymenoptera venoms. It is our intention to emphasize particular aspects of this association, which, if not known, can lead to misdiagnosis. These are as follows: allergic reactions following hymenoptera stings in patients with mastocytosis are often atypical, with allergological tests frequently showing low sensitivity to venom, thus occasionally casting doubt on the diagnosis of allergy. A rigorous diagnostic procedure is systematically required whenever mastocytosis is suggested by clinical history and an elevated intercritical tryptase rate. Moreover, implementation of venom desensitization treatments constitutes the cornerstone for prevention of shock relapses but this approach is complicated by syndromic reactions that are seen more frequently than in the general population. Great vigilance is called for when administering such treatments</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.08.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-LavigneC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-LavigneC.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Lavigne C</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.08.004</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Mejrhit,N.</style></author><author><style face="normal" font="Arial"> Azdad,O.</style></author><author><style face="normal" font="Arial"> Bousfiha,A.</style></author><author><style face="normal" font="Arial"> Chokri,A.</style></author><author><style face="normal" font="Arial"> Ouahidi,I.</style></author><author><style face="normal" font="Arial"> Aarab,L.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Evaluation of self-reported fish and shellfish allergy in schoolchildren in the Fez-Meknes Region and its relationship to breastfeeding</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding</style></keyword><keyword><style face="normal" font="Arial"> Breastfeeding status+®s</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> Cities</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="Arial"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="Arial"> Evaluation</style></keyword><keyword><style face="normal" font="Arial"> fish</style></keyword><keyword><style face="normal" font="Arial"> Fish allergy</style></keyword><keyword><style face="normal" font="Arial"> Fish/shellfish</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Mackerel</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Morocco</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> reactions</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> school</style></keyword><keyword><style face="normal" font="Arial"> school children</style></keyword><keyword><style face="normal" font="Arial"> Schoolchildren</style></keyword><keyword><style face="normal" font="Arial"> Schools</style></keyword><keyword><style face="normal" font="Arial"> Self-reported allergy</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Shellfish</style></keyword><keyword><style face="normal" font="Arial"> Shellfish allergy</style></keyword><keyword><style face="normal" font="Arial"> Shrimp</style></keyword><keyword><style face="normal" font="Arial"> Shrimps</style></keyword><keyword><style face="normal" font="Arial"> survey</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Objective The aim of the present study was to evaluate the prevalence of self-reported allergy to fish and shellfish among school children and its relation to breastfeeding. Patients and methods The study was based on a survey conducted between April 2014 and March 2015 in middle and high schools in Fez city and its surrounding areas. The total study population numbered 3010 people. Results The results show that 9.5% of children reported an allergy to fish and shellfish. Of these, 7% reported an allergy to sardines, 2.5% to mackerel and 2.1% to shrimps. The most common clinical manifestations observed in this population were cutaneous reactions (80.1%). The study of the effect of breastfeeding on self-reported fish allergy showed that such allergies were more frequent among children who have not been breastfed than in those who had, for all the types of fish studied (15.4% vs. 7.3%; P &amp;lt; 0.0001). Conclusion Self-reported allergy to fish and shellfish among schoolchildren, totalling 9.5%, indicates extensive sensitivity of school children to fish and shellfish. We showed that breastfed children were at lower risk of developing fish allergy than those who were not breastfed</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Morocco -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.06.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.06.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-MejrhitN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-MejrhitN.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Mejrhit N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.06.003</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Schaller,A.</style></author><author><style face="normal" font="Arial"> De Blay,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Precautionary labelling in food allergy: How to progress?</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Accidents</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen labelling</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic patients</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anxiety</style></keyword><keyword><style face="normal" font="Arial"> Australia</style></keyword><keyword><style face="normal" font="Arial"> Avoidance</style></keyword><keyword><style face="normal" font="Arial"> compliance</style></keyword><keyword><style face="normal" font="Arial"> Consumer</style></keyword><keyword><style face="normal" font="Arial"> contamination</style></keyword><keyword><style face="normal" font="Arial"> difficult</style></keyword><keyword><style face="normal" font="Arial"> eliciting dose</style></keyword><keyword><style face="normal" font="Arial"> Eviction regime</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> food allergies</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food labelling</style></keyword><keyword><style face="normal" font="Arial"> Foods</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> labelling</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Peanut</style></keyword><keyword><style face="normal" font="Arial"> precautionary labelling</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> products</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Threshold</style></keyword><keyword><style face="normal" font="Arial"> Threshold value</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">The prevalence of food allergies in France is continually increasing. Treatment is generally based on avoidance of the offending allergen. Due to the absence of standardized labelling of consumer foods indicating contaminant allergens, avoidance can be difficult. However, while such contamination may be predicted and thus displayed, it can also arise by chance. Based on the VITAL system in Australia, which uses threshold values called </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£public health thresholds</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ, we have attempted to define thresholds suitable for use in France. A system such as the VITAL system could perhaps improve the day-to-day life of allergic patients, giving them access to a wider variety of products. Compliance with the proposed food labelling would reduce anxiety and the risk of accidents due to food allergy</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.07.011</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-SchallerA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-SchallerA.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Schaller A</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.07.011</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Dutau,G.</style></author><author><style face="normal" font="Arial"> Lavaud,F.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Anaphylaxis: Classifications and history of the logical developments in definitions</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> classification</style></keyword><keyword><style face="normal" font="Arial"> Definition</style></keyword><keyword><style face="normal" font="Arial"> Definitions</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.09.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.09.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-DutauG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-DutauG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Dutau G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Pouessel,G.</style></author><author><style face="normal" font="Arial"> Claverie,C.</style></author><author><style face="normal" font="Arial"> Labreuche,J.</style></author><author><style face="normal" font="Arial"> Dorkenoo,A.</style></author><author><style face="normal" font="Arial"> Renaudin,J.M.</style></author><author><style face="normal" font="Arial"> Eb,M.</style></author><author><style face="normal" font="Arial"> Lejeune,S.</style></author><author><style face="normal" font="Arial"> Deschildre,A.</style></author><author><style face="normal" font="Arial"> Leteurtre,S.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Fatal anaphylaxis in France: Analysis of national anaphylaxis data, 1979-2011</style></title><secondary-title><style face="normal" font="Arial">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> adults</style></keyword><keyword><style face="normal" font="Arial"> age</style></keyword><keyword><style face="normal" font="Arial"> Aged</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic</style></keyword><keyword><style face="normal" font="Arial"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="Arial"> Anaphylaxis</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Databases</style></keyword><keyword><style face="normal" font="Arial"> Death</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> drug</style></keyword><keyword><style face="normal" font="Arial"> drugs</style></keyword><keyword><style face="normal" font="Arial"> fatalities</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Food allergy</style></keyword><keyword><style face="normal" font="Arial"> Food-induced</style></keyword><keyword><style face="normal" font="Arial"> France</style></keyword><keyword><style face="normal" font="Arial"> gender</style></keyword><keyword><style face="normal" font="Arial"> Iatrogenic</style></keyword><keyword><style face="normal" font="Arial"> insect venom</style></keyword><keyword><style face="normal" font="Arial"> Male</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> mortality</style></keyword><keyword><style face="normal" font="Arial"> Mortality rate</style></keyword><keyword><style face="normal" font="Arial"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="Arial"> national</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> pediatric</style></keyword><keyword><style face="normal" font="Arial"> Population</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> Risk factor</style></keyword><keyword><style face="normal" font="Arial"> Risk Factors</style></keyword><keyword><style face="normal" font="Arial"> sex</style></keyword><keyword><style face="normal" font="Arial"> Shock</style></keyword><keyword><style face="normal" font="Arial"> Specificity</style></keyword><keyword><style face="normal" font="Arial"> Statistics</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> time trends</style></keyword><keyword><style face="normal" font="Arial"> trend</style></keyword><keyword><style face="normal" font="Arial"> trends</style></keyword><keyword><style face="normal" font="Arial"> Trigger</style></keyword><keyword><style face="normal" font="Arial"> venom</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1877-0320</style></isbn><abstract><style face="normal" font="Arial">Data about anaphylaxis mortality are limited and conflicting. Objective To determine the anaphylaxis mortality rate (AMR), time trends and specificities according to trigger factor, age group, sex and geographical region in France from 1979 to 2011. Patients and methods Data were obtained from databases of: (1) the French Mortality Center (CepiDC) to collect cases of lethal anaphylaxis and; (2) the French Statistics Institute (INSEE) to define the reference populations. AMRs were expressed per million persons/year. Results Overall, 1603 cases of deaths from anaphylaxis were collected: 1564 in adults and 39 in children (age &amp;lt; 19 years). Overall and pediatric AMRs were respectively 0.83 (95%CI, 0.80</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.88) and 0.08 (95%CI: 0.05</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.10). AMR was higher in men (1.08 [95%CI, 1.00</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô1.16] than women (0.86 [95%CI, 0.80</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô0.92]) (P &amp;lt; 10</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ4). Annual percentage change for the case fatality rate was </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ2.1% (95%CI, </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ2.6; </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ1.7) indicating a decrease during the study period (P &amp;lt; 10</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ4). Causes of anaphylactic shock were iatrogenic (63%), mostly drugs, venom (14%) and food (0.6%). AMR was the highest in persons aged </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ëÑ 70 years (3.50 [95%IC: 3.25</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Çô3.76]). The venom-induced mortality rate was higher in the south of France (0.16) compared to the north (0.11) (P = 0.003). Only eight food-induced fatalities were recorded (age &amp;lt; 32 years in seven). Multivariate analysis showed that greater age, changes over time, and male gender were associated with a significant risk for death from anaphylaxis, irrespective of cause (P &amp;lt; 10</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">êÆ4). Conclusion Overall, AMR has decreased over the last three decades in France (2%/year). Iatrogenic causes are the most frequently involved trigger. Higher age and male gender are risk factors for fatal anaphylaxis of any cause other than food-related causes</style></abstract><notes><style face="normal" font="Arial">LA - FRECO - France -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.reval.2017.06.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.06.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171028-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Pouessel G</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.reval.2017.06.005</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Depreux,N.</style></author><author><style face="normal" font="Arial"> Basagana,M.</style></author><author><style face="normal" font="Arial"> Pascal,M.</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Negative allergy study in a case of postorgasmic illness syndrome (POIS)</style></title><secondary-title><style face="normal" font="Arial">Rev Int Androlog</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Rev Int Androlog</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status date="11/03/17" status="on-request"/><keywords><keyword><style face="normal" font="Arial">Alergia a semen</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Cause</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical criteria</style></keyword><keyword><style face="normal" font="Arial"> Cognition</style></keyword><keyword><style face="normal" font="Arial"> Cognition Disorders</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Disfunci+¦n sexual</style></keyword><keyword><style face="normal" font="Arial"> Dolor post-eyaculaci+¦n</style></keyword><keyword><style face="normal" font="Arial"> Ejaculation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IgE-Mediated</style></keyword><keyword><style face="normal" font="Arial"> Immunoblotting</style></keyword><keyword><style face="normal" font="Arial"> intracutaneous test</style></keyword><keyword><style face="normal" font="Arial"> Mediators</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Post-ejaculatory pain</style></keyword><keyword><style face="normal" font="Arial"> Postorgasmic illness syndrome</style></keyword><keyword><style face="normal" font="Arial"> Prick test</style></keyword><keyword><style face="normal" font="Arial"> prick tests</style></keyword><keyword><style face="normal" font="Arial"> Prick-test</style></keyword><keyword><style face="normal" font="Arial"> Prick-tests</style></keyword><keyword><style face="normal" font="Arial"> reactivity</style></keyword><keyword><style face="normal" font="Arial"> S+¡ndrome de enfermedad post-org+ísmica</style></keyword><keyword><style face="normal" font="Arial"> Semen</style></keyword><keyword><style face="normal" font="Arial"> Semen allergy</style></keyword><keyword><style face="normal" font="Arial"> Sexual dysfunction</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin prick test</style></keyword><keyword><style face="normal" font="Arial"> Skin prick tests</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Tests</style></keyword><keyword><style face="normal" font="Arial"> Western blot</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">1698-031X</style></isbn><abstract><style face="normal" font="Arial">Postorgasmic illness syndrome (POIS) is a rarely described syndrome characterized by transient flu-like symptoms and cognition disorders. Recent studies suggest that immunogenic reactivity to autologous semen is the underlying mechanism in POIS. Our study is regarding a 30-year-old that visited our unit for an allergy consultation because he experienced malaise after ejaculations. Skin prick tests and intracutaneous tests with autologous diluted semen with negative results were performed. Immunoblotting and western blot of the patient's autologous semen showed negative results. To complete the study, we intended to rule out other possible causes such as urological, hormonal, or neuropsychiatric disorders. We present a case of POIS based on the clinical criteria that did not show an IgE mediated cause. In the case of our patient, we could not identify the underlying cause; however, we believe that the possible involvement of neurobiochemical mediators should be studied.</style></abstract><notes><style face="normal" font="Arial">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.androl.2017.06.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.androl.2017.06.002</url></web-urls><pdf-urls><url ppv-ref="no">ndepreux.germanstrias@gencat.cat</url></pdf-urls><text-urls><url ppv-ref="no">researchgate</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Depreux N</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.androl.2017.06.002</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Ricke,C:</style></author></authors></contributors><titles><title><style face="normal" font="Arial">Some myths in anesthesia</style></title><secondary-title><style face="normal" font="Arial">Rev Med Clin Las Condes</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Med Clin Las Condes</style></full-title></periodical><pages end="755" start="747">747-755</pages><volume><style face="normal" font="Arial">28</style></volume><number><style face="normal" font="Arial">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">alergia</style></keyword><keyword><style face="normal" font="Arial"> alergia al yodo</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Anaesthesia</style></keyword><keyword><style face="normal" font="Arial"> anestesia general</style></keyword><keyword><style face="normal" font="Arial"> anestesia regional</style></keyword><keyword><style face="normal" font="Arial"> Anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Anesthesiology</style></keyword><keyword><style face="normal" font="Arial"> artroplast+¡a de cadera</style></keyword><keyword><style face="normal" font="Arial"> Chile</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic postoperative pain</style></keyword><keyword><style face="normal" font="Arial"> dolor cr+¦nico postoperatorio</style></keyword><keyword><style face="normal" font="Arial"> egg</style></keyword><keyword><style face="normal" font="Arial"> Eggs</style></keyword><keyword><style face="normal" font="Arial"> general anesthesia</style></keyword><keyword><style face="normal" font="Arial"> Hip</style></keyword><keyword><style face="normal" font="Arial"> hip arthroplasty</style></keyword><keyword><style face="normal" font="Arial"> hipertermia maligna</style></keyword><keyword><style face="normal" font="Arial"> huevo</style></keyword><keyword><style face="normal" font="Arial"> iodine allergy</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> Long term</style></keyword><keyword><style face="normal" font="Arial"> Long-term</style></keyword><keyword><style face="normal" font="Arial"> Malignant Hyperthermia</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mitos</style></keyword><keyword><style face="normal" font="Arial"> Myths</style></keyword><keyword><style face="normal" font="Arial"> Nervous System</style></keyword><keyword><style face="normal" font="Arial"> neurotoxicidad</style></keyword><keyword><style face="normal" font="Arial"> neurotoxicity</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> Pain</style></keyword><keyword><style face="normal" font="Arial"> propofol</style></keyword><keyword><style face="normal" font="Arial"> regional anesthesia</style></keyword><keyword><style face="normal" font="Arial"> resultado (outcome)</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> soy</style></keyword><keyword><style face="normal" font="Arial"> soy allergy</style></keyword><keyword><style face="normal" font="Arial"> surgery</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> use</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="Arial">0716-8640</style></isbn><abstract><style face="normal" font="Arial">In anesthesiology, as well as in other medical specialties, there are several concepts that we consider true without having previously analised any scientific evidence that supports or refutes them. The aim of this review is to asses the evidence behind some of these widespread </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£truths</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ, such as the relationship between egg or soy allergies and the use of propofol; the superiority of regional anaesthesia over general anaesthesia for hip surgery; the concept of </style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">Ç£iodine allergies</style><style face="normal" font="Symbol">G</style><style face="normal" font="Arial">ÇØ; post operatory chronic pain; long term effects of anaesthesia and negative effects of the anaesthesia on the nervous system. To achieve this aim, it was develop a nonsystematic review of the literature, showing some works that support or deny such beliefs</style></abstract><notes><style face="normal" font="Arial">LA - SPA CO - Chile -</style></notes><work-type><style face="normal" font="Arial">https://doi.org/10.1016/j.rmclc.2017.08.008</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.rmclc.2017.08.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Med Clin Las Condes\2017-28-747-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Med Clin Las Condes\2017-28-747-55.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171030, Ricke C</style></custom2><misc3><style face="normal" font="Arial">https://doi.org/10.1016/j.rmclc.2017.08.008</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Hamada,S.</style></author><author><style face="normal" font="Arial"> Yasuba,H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiratory Medicine, Hikone Municipal Hospital, Hikone, Japan; Department of Airway Medicine, Mitsubishi Kyoto Hospital, Kyoto, Japan.</style></auth-address><titles><title><style face="normal" font="Arial">Seasonal omalizumab reduces allergen-specific immunoglobulin E levels in patients with Japanese cedar pollinosis and asthma</style></title><secondary-title><style face="normal" font="Arial">Rev Port Pneumol (2006)</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Rev Port Pneumol (2006)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> allergen-specific</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunoglobulin</style></keyword><keyword><style face="normal" font="Arial"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="Arial"> Japan</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Pollinosis</style></keyword><keyword><style face="normal" font="Arial"> Seasonal</style></keyword></keywords><dates><year Day="14" Month="10" Year="2017">2017/10/14</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 2173-5115 (Electronic)IS - 0873-2159 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.rppnen.2017.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042155">PM:29042155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Pneumol (2006)\20171018-HamadaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Pneumol (2006)\20171018-HamadaS.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Hamada S</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.rppnen.2017.09.001</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Wu,C.</style></author><author><style face="normal" font="Arial"> Chen,X.</style></author><author><style face="normal" font="Arial"> Liu,J.</style></author><author><style face="normal" font="Arial"> Zhang,X.</style></author><author><style face="normal" font="Arial"> Xue,W.</style></author><author><style face="normal" font="Arial"> Liang,Z.</style></author><author><style face="normal" font="Arial"> Liu,M.</style></author><author><style face="normal" font="Arial"> Cui,Y.</style></author><author><style face="normal" font="Arial"> Huang,D.</style></author><author><style face="normal" font="Arial"> Zhang,L.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Inspection and Quarantine Technical Center of Dalian Entry-Exit Inspection and Quarantine Bureau, Dalian 116100, China</style></auth-address><titles><title><style face="normal" font="Arial">[High-sensitive detection of multiple allergenic proteins in infant food with high-resolution mass spectrometry]</style></title><secondary-title><style face="normal" font="Arial">Se Pu</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Se Pu</style></full-title></periodical><pages end="1041" start="1037">1037-1041</pages><volume><style face="normal" font="Arial">35</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acetone</style></keyword><keyword><style face="normal" font="Arial"> allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergenic</style></keyword><keyword><style face="normal" font="Arial"> Allergenic protein</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> correlation</style></keyword><keyword><style face="normal" font="Arial"> Correlation coefficient</style></keyword><keyword><style face="normal" font="Arial"> Detection</style></keyword><keyword><style face="normal" font="Arial"> Efficiency</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Extraction</style></keyword><keyword><style face="normal" font="Arial"> Food</style></keyword><keyword><style face="normal" font="Arial"> Infant</style></keyword><keyword><style face="normal" font="Arial"> Infant Food</style></keyword><keyword><style face="normal" font="Arial"> inspection</style></keyword><keyword><style face="normal" font="Arial"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Mass-spectrometry</style></keyword><keyword><style face="normal" font="Arial"> monitoring</style></keyword><keyword><style face="normal" font="Arial"> peptide</style></keyword><keyword><style face="normal" font="Arial"> Peptides</style></keyword><keyword><style face="normal" font="Arial"> Precipitation</style></keyword><keyword><style face="normal" font="Arial"> Preparation</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> Protein extraction</style></keyword><keyword><style face="normal" font="Arial"> Proteins</style></keyword><keyword><style face="normal" font="Arial"> Proteomic</style></keyword><keyword><style face="normal" font="Arial"> Proteomics</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> sensitivity</style></keyword><keyword><style face="normal" font="Arial"> Simultaneous detection</style></keyword><keyword><style face="normal" font="Arial"> Spectrometry</style></keyword><keyword><style face="normal" font="Arial"> Stability</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="8" Month="10" Year="2017">2017/10/8</year></dates><abstract><style face="normal" font="Arial">A novel method of the simultaneous detection of multiple kinds of allergenic proteins in infant food with parallel reaction monitoring (PRM) mode using liquid chromatography-tandem mass spectrometry (LC-MS/MS) was established. In this method, unique peptides with good stability and high sensibility were used to quantify the corresponding allergenic proteins. Furthermore, multiple kinds of allergenic proteins are inspected simultaneously with high sensitivity. In addition, such method was successfully used for the detection of multiple allergenic proteins in infant food. As for the sample preparation for infant food, compared with the traditional acetone precipitation strategy, the protein extraction efficiency and capacity of resisting disturbance are both higher with in-situ filter-aided sample pretreatment (i-FASP) method. All allergenic proteins gave a good linear response with the correlation coefficients (R2) >/= 0.99, and the largest concentration range of the allergenic proteins could be four orders of magnitude, and the lowest detection limit was 0.028 mg/L, which was better than that reported in references. Finally, the method was conveniently used to detect the allergens from four imported infant food real samples. All the results demonstrate that this novel strategy is of great significance for providing a rapid and reliable analytical technique for allergen proteomics</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 1000-8713 (Print)IS - 1000-8713 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3724/SP.J.1123.2017.06013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29048799">PM:29048799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Se Pu\2017-35-1037-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Se Pu\2017-35-1037-41.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171019, Wu C</style></custom2><misc3><style face="normal" font="Arial">10.3724/SP.J.1123.2017.06013</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Valenta,R.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="Arial">Oral tolerance induction in allergy: Kissing awake a sleeping beauty</style></title><secondary-title><style face="normal" font="Arial">Semin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Semin Immunol</style></full-title></periodical><pages end="2" start="1">1-2</pages><volume><style face="normal" font="Arial">30</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Austria</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> immunology</style></keyword><keyword><style face="normal" font="Arial"> immunopathology</style></keyword><keyword><style face="normal" font="Arial"> Induction</style></keyword><keyword><style face="normal" font="Arial"> kissing</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> oral</style></keyword><keyword><style face="normal" font="Arial"> oral tolerance</style></keyword><keyword><style face="normal" font="Arial"> Oral tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> pathophysiology</style></keyword><keyword><style face="normal" font="Arial"> Research</style></keyword><keyword><style face="normal" font="Arial"> Tolerance</style></keyword><keyword><style face="normal" font="Arial"> Tolerance induction</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">No Abstract Available</style></abstract><notes><style face="normal" font="Arial">DA - 20171017IS - 1096-3618 (Electronic)IS - 1044-5323 (Linking)LA - engPT - EditorialCO - Austria -</style></notes><work-type><style face="normal" font="Arial">10.1016/j.smim.2017.08.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037366">PM:29037366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Semin Immunol\2017-30-1-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Semin Immunol\2017-30-1-2.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171017, Valenta R</style></custom2><misc3><style face="normal" font="Arial">10.1016/j.smim.2017.08.016</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Vennera,M.D.C.</style></author><author><style face="normal" font="Arial"> Sabadell,C.</style></author><author><style face="normal" font="Arial"> Picado,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Pneumology and Respiratory Allergy, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="Arial">Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma</style></title><secondary-title><style face="normal" font="Arial">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Thorax</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> asthma exacerbation</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Efficacy</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> exacerbation</style></keyword><keyword><style face="normal" font="Arial"> follow up</style></keyword><keyword><style face="normal" font="Arial"> Follow-up</style></keyword><keyword><style face="normal" font="Arial"> Omalizumab</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> persistence</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Prospective Studies</style></keyword><keyword><style face="normal" font="Arial"> prospective study</style></keyword><keyword><style face="normal" font="Arial"> relapse</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergies</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergy</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> severe asthma</style></keyword><keyword><style face="normal" font="Arial"> Spain</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="Arial">Efficacy of omalizumab in severe asthma is well documented; however, the optimal duration of the treatment remains unclear. In an open prospective study, we sought to assess the persistence of response in subjects withdrawing from omalizumab treatment. We evaluated 49 patients who voluntarily accepted to discontinue omalizumab treatment after 6 years of therapy. Asthma relapse was defined as any severe asthma exacerbation associated with loss of asthma control. Twelve patients relapsed in the first year of follow-up, and 7 within 13 and 48 months. These results suggest that the effects of 6 years of omalizumab may persist after discontinuation of therapy in 60% of patients for at least 4 years</style></abstract><notes><style face="normal" font="Arial">DA - 20171028IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="Arial">10.1136/thoraxjnl-2017-210017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29079610">PM:29079610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Thorax\20171028-VenneraMD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Thorax\20171028-VenneraMD.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171028, Vennera MD</style></custom2><misc3><style face="normal" font="Arial">10.1136/thoraxjnl-2017-210017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zahradnik,E.</style></author><author><style face="normal" font="Arial"> Raulf,M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Center of Allergology/Immunology, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-Universitat Bochum (IPA), Burkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.</style></auth-address><titles><title><style face="normal" font="Arial">Respiratory Allergens from Furred Mammals: Environmental and Occupational Exposure</style></title><secondary-title><style face="normal" font="Arial">Vet Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Vet Sci</style></abbr-1></periodical><pages end="" start="E38">E38-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">allergen</style></keyword><keyword><style face="normal" font="Arial"> Allergen exposure</style></keyword><keyword><style face="normal" font="Arial"> Allergen sources</style></keyword><keyword><style face="normal" font="Arial"> Allergens</style></keyword><keyword><style face="normal" font="Arial"> Allergies</style></keyword><keyword><style face="normal" font="Arial"> Allergy</style></keyword><keyword><style face="normal" font="Arial"> allergy diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> animal allergen</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> assessment</style></keyword><keyword><style face="normal" font="Arial"> Diagnostic</style></keyword><keyword><style face="normal" font="Arial"> diagnostics</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environment</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> Family</style></keyword><keyword><style face="normal" font="Arial"> farm</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Human</style></keyword><keyword><style face="normal" font="Arial"> immunogenicity</style></keyword><keyword><style face="normal" font="Arial"> insurance</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> laboratory animal</style></keyword><keyword><style face="normal" font="Arial"> Laboratory animals</style></keyword><keyword><style face="normal" font="Arial"> mammal</style></keyword><keyword><style face="normal" font="Arial"> Mammalian</style></keyword><keyword><style face="normal" font="Arial"> mammalian allergen</style></keyword><keyword><style face="normal" font="Arial"> mammalian allergens</style></keyword><keyword><style face="normal" font="Arial"> Mammals</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Molecular Structure</style></keyword><keyword><style face="normal" font="Arial"> occupational</style></keyword><keyword><style face="normal" font="Arial"> Occupational Exposure</style></keyword><keyword><style face="normal" font="Arial"> Occupational Medicine</style></keyword><keyword><style face="normal" font="Arial"> Pet</style></keyword><keyword><style face="normal" font="Arial"> Pets</style></keyword><keyword><style face="normal" font="Arial"> Prevalence</style></keyword><keyword><style face="normal" font="Arial"> prevention</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> protein families</style></keyword><keyword><style face="normal" font="Arial"> Respiratory allergens</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="Arial">Furry mammals kept as pets, farm and laboratory animals are important allergen sources. The prevalence of sensitization to furred mammals appears to be increasing worldwide. Several mammalian allergens from diverse species are well characterized with regard to their molecular structure and immunogenicity, and some are already available for component-resolved allergy diagnostics. The distribution of various mammalian allergens has been extensively studied during the past few decades. Animal allergens were found to be ubiquitous in the human environment, even in places where no animals reside, with concentrations differing considerably between locations and geographical regions. This review presents an overview of identified mammalian respiratory allergens classified according to protein families, and compiles the results of allergen exposure assessment studies conducted in different public and occupational environments</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 2306-7381 (Electronic)IS - 2306-7381 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.3390/vetsci4030038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29056697">PM:29056697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Sci\2017-4-E38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Sci\2017-4-E38.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Zahradnik E</style></custom2><misc3><style face="normal" font="Arial">10.3390/vetsci4030038</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Marsella,R.</style></author><author><style face="normal" font="Arial"> De Benedetto,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Dermatology, College of Medicine, University of Florida, 4037 NW 86 Terrace, Gainesville, FL 32606, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Atopic Dermatitis in Animals and People: An Update and Comparative Review</style></title><secondary-title><style face="normal" font="Arial">Vet Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Vet Sci</style></abbr-1></periodical><pages end="" start="E37">E37-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic sensitization</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> Animals</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="Arial"> atopic disease</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical manifestations</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatology</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Domestic</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Environmental</style></keyword><keyword><style face="normal" font="Arial"> environmental factors</style></keyword><keyword><style face="normal" font="Arial"> Florida</style></keyword><keyword><style face="normal" font="Arial"> genetic</style></keyword><keyword><style face="normal" font="Arial"> Identification</style></keyword><keyword><style face="normal" font="Arial"> immunologic</style></keyword><keyword><style face="normal" font="Arial"> interaction</style></keyword><keyword><style face="normal" font="Arial"> interactions</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> natural course</style></keyword><keyword><style face="normal" font="Arial"> new treatments</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> response</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Species</style></keyword><keyword><style face="normal" font="Arial"> Syndrome</style></keyword><keyword><style face="normal" font="Arial"> Term</style></keyword><keyword><style face="normal" font="Arial"> therapy</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="Arial">Atopic dermatitis is an extremely common, pruritic, and frustrating disease to treat in both people and animals. Atopic dermatitis is multifactorial and results from complex interactions between genetic and environmental factors. Much progress has been done in recent years in terms of understanding the complex pathogenesis of this clinical syndrome and the identification of new treatments. As we learn more about it, we appreciate the striking similarities that exist in the clinical manifestations of this disease across species. Both in animals and people, atopic disease is becoming increasingly common and important similarities exist in terms of immunologic aberrations and the propensity for allergic sensitization. The purpose of this review is to highlight the most recent views on atopic dermatitis in both domestic species and in people emphasizing the similarities and the differences. A comparative approach can be beneficial in understanding the natural course of this disease and the variable response to existing therapies</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 2306-7381 (Electronic)IS - 2306-7381 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/vetsci4030037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29056696">PM:29056696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Sci\2017-4-E37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Sci\2017-4-E37.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Marsella R</style></custom2><misc3><style face="normal" font="Arial">10.3390/vetsci4030037</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Diesel,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&amp;M University, 4474 TAMU, College Station, TX 77843, USA.</style></auth-address><titles><title><style face="normal" font="Arial">Cutaneous Hypersensitivity Dermatoses in the Feline Patient: A Review of Allergic Skin Disease in Cats</style></title><secondary-title><style face="normal" font="Arial">Vet Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="Arial">Vet Sci</style></abbr-1></periodical><pages end="" start="E25">E25-</pages><volume><style face="normal" font="Arial">4</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic skin disease</style></keyword><keyword><style face="normal" font="Arial"> Animal</style></keyword><keyword><style face="normal" font="Arial"> atopic</style></keyword><keyword><style face="normal" font="Arial"> Biomedical</style></keyword><keyword><style face="normal" font="Arial"> Canine</style></keyword><keyword><style face="normal" font="Arial"> cat</style></keyword><keyword><style face="normal" font="Arial"> Cats</style></keyword><keyword><style face="normal" font="Arial"> Challenge</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Clinical signs</style></keyword><keyword><style face="normal" font="Arial"> cutaneous</style></keyword><keyword><style face="normal" font="Arial"> Dermatitis</style></keyword><keyword><style face="normal" font="Arial"> Dermatoses</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> dog</style></keyword><keyword><style face="normal" font="Arial"> Dogs</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> Hypersensitivity</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> outcome</style></keyword><keyword><style face="normal" font="Arial"> outcomes</style></keyword><keyword><style face="normal" font="Arial"> Pathogenesis</style></keyword><keyword><style face="normal" font="Arial"> Review</style></keyword><keyword><style face="normal" font="Arial"> Science</style></keyword><keyword><style face="normal" font="Arial"> secondary</style></keyword><keyword><style face="normal" font="Arial"> Skin</style></keyword><keyword><style face="normal" font="Arial"> skin disease</style></keyword><keyword><style face="normal" font="Arial"> Skin Diseases</style></keyword><keyword><style face="normal" font="Arial"> Texas</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> United States</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> USA</style></keyword><keyword><style face="normal" font="Arial"> veterinary</style></keyword><keyword><style face="normal" font="Arial"> Veterinary Medicine</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="Arial">Feline allergic skin disease presents a unique set of challenges to the veterinary practitioner. Although there is some similarity to what is seen in the allergic canine patient, cutaneous hypersensitivity dermatoses in cats can manifest with strikingly different clinical signs, treatment options and outcomes, and secondary complications/disease entities. Additionally, less is known about the pathogenesis of feline allergic skin diseases, particularly "feline atopic syndrome" when compared to dogs or people. This article aims to review what is currently known in regards to allergic skin disease in the feline patient, with focus on non-flea, non-food hypersensitivity dermatitis</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 2306-7381 (Electronic)IS - 2306-7381 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="Arial">10.3390/vetsci4020025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29056684">PM:29056684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Sci\2017-4-E25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Sci\2017-4-E25.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, Diesel A</style></custom2><misc3><style face="normal" font="Arial">10.3390/vetsci4020025</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Cherrez-Ojeda,I.</style></author><author><style face="normal" font="Arial"> Robles-Velasco,K.</style></author><author><style face="normal" font="Arial"> Bedoya-Riofrio,P.</style></author><author><style face="normal" font="Arial"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="Arial"> Cherrez,S.</style></author><author><style face="normal" font="Arial"> Colbatzky,F.</style></author><author><style face="normal" font="Arial"> Cardona,R.</style></author><author><style face="normal" font="Arial"> Barberan-Torres,P.</style></author><author><style face="normal" font="Arial"> Calero,E.</style></author><author><style face="normal" font="Arial"> Cherrez,A.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Universidad Espiritu Santo, Km. 2.5 via La Puntilla, Codigo postal: 0901-952 Samborondon, Ecuador</style></auth-address><titles><title><style face="normal" font="Arial">Checklist for a complete chronic urticaria medical history: an easy tool</style></title><secondary-title><style face="normal" font="Arial">World Allergy Organ J</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World Allergy Organ J</style></full-title></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="Arial">10</style></volume><number><style face="normal" font="Arial">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">angioedema</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Atopy</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> chronic urticaria</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> clinical features</style></keyword><keyword><style face="normal" font="Arial"> Color</style></keyword><keyword><style face="normal" font="Arial"> Consultation</style></keyword><keyword><style face="normal" font="Arial"> Consultations</style></keyword><keyword><style face="normal" font="Arial"> database</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> diagnosis</style></keyword><keyword><style face="normal" font="Arial"> Disease</style></keyword><keyword><style face="normal" font="Arial"> Distribution</style></keyword><keyword><style face="normal" font="Arial"> Duration</style></keyword><keyword><style face="normal" font="Arial"> Ecuador</style></keyword><keyword><style face="normal" font="Arial"> etiology</style></keyword><keyword><style face="normal" font="Arial"> Germany</style></keyword><keyword><style face="normal" font="Arial"> Guideline</style></keyword><keyword><style face="normal" font="Arial"> Guidelines</style></keyword><keyword><style face="normal" font="Arial"> history</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Literature</style></keyword><keyword><style face="normal" font="Arial"> management</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Medline</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Onset</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> Patients</style></keyword><keyword><style face="normal" font="Arial"> Physical Examination</style></keyword><keyword><style face="normal" font="Arial"> PubMed</style></keyword><keyword><style face="normal" font="Arial"> Switzerland</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Urticaria</style></keyword><keyword><style face="normal" font="Arial"> Wheal</style></keyword><keyword><style face="normal" font="Arial"> Wheals</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Existing guidelines do not offer a quick, efficient alternative to the patient's recollection of relevant clinical features during anamnesis and physical examination for chronic urticaria (CU). This study aimed to identify specific items reflecting the main characteristics of CU that should be included in a comprehensive medical history for patients with CU. We also aimed to clarify possible eliciting factors for CU to support accurate diagnosis of the disease. METHODS: A panel of postgraduate dermatologists conducted a literature search for relevant studies on CU using Medline, the Cochrane database, and PubMed. RESULTS: We identified82 articles from which we drew a collection of items to inform development of an easy-to-use checklist and collection of items that should be included in a correct medical history. The final version of the checklist included42 items across two areas: essential clues for anamnesis and diagnosis of CU; and typical symptoms/parameters or characteristics according to subtype, etiology, and laboratory findings. Items included time of disease onset; duration, shape, size, color, and distribution of wheals; associated angioedema; atopy; and triggering factors. CONCLUSIONS: Our guide provides an easy-to-use tool to support clinicians to focus, orient themselves, and save time in medical consultations for CU, allowing better diagnosis and management of this disease</style></abstract><notes><style face="normal" font="Arial">DA - 20171018IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Ecuador -CO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="Arial">10.1186/s40413-017-0165-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29043012">PM:29043012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Pediatr\2017-13-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Pediatr\2017-13-34.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171018, Cherrez-Ojeda I</style></custom2><misc3><style face="normal" font="Arial">10.1186/s40413-017-0165-0</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">He,C.H.</style></author><author><style face="normal" font="Arial"> Li,X.</style></author><author><style face="normal" font="Arial"> Lin,J.H.</style></author><author><style face="normal" font="Arial"> Xiao,Q.</style></author><author><style face="normal" font="Arial"> Yu,J.L.</style></author><author><style face="normal" font="Arial"> Liu,Y.F.</style></author><author><style face="normal" font="Arial"> Jiang,W.H.</style></author><author><style face="normal" font="Arial"> Chen,C.</style></author><author><style face="normal" font="Arial"> Deng,L.</style></author><author><style face="normal" font="Arial"> Zhou,J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Respiration, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9th Jinsui Road, Guangzhou, 510623, China</style></auth-address><titles><title><style face="normal" font="Arial">A 2-year step-down withdrawal from inhaled corticosteroids in asthmatic children receiving immunotherapy</style></title><secondary-title><style face="normal" font="Arial">World J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">World J Pediatr</style></full-title></periodical><pages end="565" start="560">560-565</pages><volume><style face="normal" font="Arial">13</style></volume><number><style face="normal" font="Arial">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> asthma control</style></keyword><keyword><style face="normal" font="Arial"> Asthma Control Test</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic children</style></keyword><keyword><style face="normal" font="Arial"> Attack</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> bronchial provocation</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> childhood</style></keyword><keyword><style face="normal" font="Arial"> Childhood asthma</style></keyword><keyword><style face="normal" font="Arial"> Children</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> Corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Criteria</style></keyword><keyword><style face="normal" font="Arial"> Decrease</style></keyword><keyword><style face="normal" font="Arial"> Dose</style></keyword><keyword><style face="normal" font="Arial"> Electronic</style></keyword><keyword><style face="normal" font="Arial"> FEV1</style></keyword><keyword><style face="normal" font="Arial"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> Immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="Arial"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methacholine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Pneumonia</style></keyword><keyword><style face="normal" font="Arial"> provocation</style></keyword><keyword><style face="normal" font="Arial"> Provocation test</style></keyword><keyword><style face="normal" font="Arial"> Respiration</style></keyword><keyword><style face="normal" font="Arial"> SCIT</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Strategies</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous</style></keyword><keyword><style face="normal" font="Arial"> subcutaneous immunotherapy</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> Vital Capacity</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Women</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="Arial">BACKGROUND: Inhaled corticosteroids (ICSs) for treating asthma are controversial because of their negative effects on the growth of asthmatic children and without clearly defined withdrawal strategy. A 2-year ICS step-down and withdrawal strategy has been developed for asthmatic children receiving 3-year subcutaneous immunotherapy (SCIT). METHODS: Eleven children were included into the SCIT group and 13 children into the ICS group. ICSs were discontinued when children met the following criteria: requiring only 1 puffper day, with good control, for at least 6 months; having a forced expiratory volume in 1 second (FEV1)/forced vital capacity >/=80%; and SCIT discontinued for >/=24 months. The main endpoints were the results of both the childhood asthma control test (C-CAT) and the methacholine bronchial provocation test. RESULTS: In the SCIT group, all the 11 children had ICS discontinued, with one child developed asthma attack after pneumonia and received ICS again after completion of SCIT. In the ICS group, five children discontinued ICS and developed asthma attacks later and received ICS again; the other eight children developed severe symptoms during ICS step-down. Thus, the discontinuation of ICS was only achieved in the SCIT group. The dose of methacholine that caused a decrease of 20% in FEV1 continued to improve after discontinuation of ICS for the SCIT group and presented better results than the ICS group (P=0.050). After completion of SCIT, the C-CAT had improved significantly after 30 months of treatment compared with the ICS group (P&lt;0.05). CONCLUSIONS: In the present study, we developed a 2-year step-down and withdrawal strategy from ICSs strategy for allergic asthma children receiving SCIT; the strategy was efficacious and safe</style></abstract><notes><style face="normal" font="Arial">DA - 20171023IS - 1867-0687 (Electronic)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.1007/s12519-017-0065-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29058249">PM:29058249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\World J Pediatr\2017-13-560-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\World J Pediatr\2017-13-560-5.pdf</url></text-urls></urls><custom2><style face="normal" font="Arial">20171023, He CH</style></custom2><misc3><style face="normal" font="Arial">10.1007/s12519-017-0065-y</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Chen,X.H.</style></author><author><style face="normal" font="Arial"> He,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical College of Acupuncture-moxibustion and Orthopedic, Anhui University of Chinese Medicine, Hefei 230038, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effects of Moxibustion at "Feishu"(BL 13) and "Shenshu"(BL 23) on Peripheral Blood T Cells and Serum Interleukin in Asthmatic Rats]</style></title><secondary-title><style face="normal" font="Arial">Zhen Ci Yan Jiu</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhen Ci Yan Jiu</style></full-title></periodical><pages end="162" start="159">159-162</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Aluminum</style></keyword><keyword><style face="normal" font="Arial"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> blood</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> Cells</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Edema</style></keyword><keyword><style face="normal" font="Arial"> ELISA</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="Arial"> epithelial</style></keyword><keyword><style face="normal" font="Arial"> Flow Cytometry</style></keyword><keyword><style face="normal" font="Arial"> Formation</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-1</style></keyword><keyword><style face="normal" font="Arial"> Immunological</style></keyword><keyword><style face="normal" font="Arial"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="Arial"> inflammatory</style></keyword><keyword><style face="normal" font="Arial"> Inhalation</style></keyword><keyword><style face="normal" font="Arial"> Interleukin</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Morphology</style></keyword><keyword><style face="normal" font="Arial"> mucosal</style></keyword><keyword><style face="normal" font="Arial"> Mucus</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> peripheral blood</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Role</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> serum IgE</style></keyword><keyword><style face="normal" font="Arial"> shedding</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> structure</style></keyword><keyword><style face="normal" font="Arial"> T cell</style></keyword><keyword><style face="normal" font="Arial"> T cells</style></keyword><keyword><style face="normal" font="Arial"> T-cell</style></keyword><keyword><style face="normal" font="Arial"> T-cells</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Whole blood</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To observe the effect of moxibustion at "Feishu" (BL 13) and "Shenshu"(BL 23) on peripheral blood T cells and serum interleukin in rats with asthma, so as to explore its immunological mechanisms in relieving asthma. METHODS: Thirty SD rats were randomly divided into normal, model and moxibustion groups(10 rats/group). Asthma model was established by intraperitoneal injection of ovalbumin and aluminum hydroxide, and ovalbumin inhalation. Moxibustion was applied to bilateral "Feishu" (BL 13) and "Shenshu"(BL 23) for 30 min, once daily for 14 d. The pathologic changes of the lung tissue were detected by H.E. staining. The levels of CD 3+, CD 4+, CD 8+ T cells in whole blood were detected by flow cytometry. Serum IgE, IL-1 beta, IL-1 Ra contents were assayed by ELISA (enzyme-linked immunosorbent assay). RESULTS: The thickened muscle of bronchial wall, mucosal edema, infiltration of inflammatory cells and partial destruction of the alveolar structure were found in the model group. While in the moxibustion group, the structure of the alveolar wall was complete, the morphology of the bronchioles was regular, and there were no mucus plug formation and epithelial cell shedding in the lumen. The contents of blood CD 8+ and CD 3+ T cells, and serum IgE and IL-1 beta in the model group were obviously higher than those in the normal group (P&lt;0.01). Compared with the model group, the levels of blood CD 8+ T cell, serum IgE and IL-1 beta in the moxibustion group were all decreased (P&lt;0.05,P&lt;0.01), meanwhile the levels of blood CD 4+ T cell and serum IL-1 Ra were increased (P&lt;0.01,P&lt;0.05). CONCLUSIONS: Moxibustion can reduce the levels of serum IgE and IL-1 beta, and increase the level of serum IL-1 Ra, which may play an important role in the treatment of asthma</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1000-0607 (Print)IS - 1000-0607 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29071966">PM:29071966</url></web-urls></urls><custom2><style face="normal" font="Arial">20171026, Chen XH</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Liu,C.Y.</style></author><author><style face="normal" font="Arial"> Qin,S.</style></author><author><style face="normal" font="Arial"> Liu,L.Y.</style></author><author><style face="normal" font="Arial"> He,Y.M.</style></author><author><style face="normal" font="Arial"> Wang,H.S.</style></author><author><style face="normal" font="Arial"> Wu,W.Z.</style></author><author><style face="normal" font="Arial"> Chen,D.</style></author><author><style face="normal" font="Arial"> Zhang,C.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Acupuncture and Rehabilitation Department, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China</style></auth-address><titles><title><style face="normal" font="Arial">[Inhibitory Effect of Acupoint Application on Airway Remodeling and Expression of TGF-beta 1/Smad 3 in the Lung Tissue of Chronic Asthma Mice]</style></title><secondary-title><style face="normal" font="Arial">Zhen Ci Yan Jiu</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhen Ci Yan Jiu</style></full-title></periodical><pages end="158" start="153">153-158</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Acupuncture</style></keyword><keyword><style face="normal" font="Arial"> Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Airway Resistance</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> area</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> Asthmatic</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> bronchial</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Chinese</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Growth</style></keyword><keyword><style face="normal" font="Arial"> image analysis</style></keyword><keyword><style face="normal" font="Arial"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> lung function</style></keyword><keyword><style face="normal" font="Arial"> Medicine</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mouse</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Mustard</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> rehabilitation</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> resistance</style></keyword><keyword><style face="normal" font="Arial"> Seed</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> signaling</style></keyword><keyword><style face="normal" font="Arial"> Smad</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Software</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> white</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To observe the effect of acupoint application on transforming growth factor (TGF)-beta 1/Smad 3 signaling pathway, so as to reveal its mechanism underlying improvement of airway remodeling in chronic asthma mice. METHODS: BALB/c mice were randomly divided into normal group,model group,sham acupoint application group (sham group),acupoint application group, and dexamethasone group (n=8 in each group). The chronic asthma model was established by intraperitoneal injection of ovalbumin sensitization. The acupoint application group was treated with plaster composed with White Mustard Seed, Rhizoma Corydalis, Unprocessed Radix Kansui, and Herba Asari, on bilateral "Feishu" (BL 13), "Xinshu" (BL 15) and "Geshu" (BL 17) points, 6 hours a day for 14 days. The sham group was treated with plaster containing vaseline on bilateral BL 13, BL 15 and BL 17, 6 hours a day for 14 days. The dexamethasone group was treated with dexamethasone 1 mg.kg-1.day-1 intraperi-toneally, once daily for 14 days. At the end of treatment, airway resistance was detected by mouse lung function instrument. Patho-logical changes of airway were observed under light microscope after hematoxylin-eosin staining, and the morphological parameters were measured by image analysis software. Immunohistochemistry method was used to detect the expression of TGF-beta 1 and Smad 3 in the lung tissue of mice. RESULTS: Compared with the normal group, the airway resistance, the total bronchial wall area (WAt)/lumen perimeter (Pi), the smooth muscle wall area (WAm)/Pi, and the expression of TGF-beta 1 and Smad 3 in the lung tissues were significantly higher in the model and sham groups (P&lt;0.01). Compared with the model group and the sham group, the airway resistance, WAt/Pi, WAm/Pi, the expression of TGF-beta 1 and Smad 3 in the lung tissues were decreased in the acupoint application group and the dexamethasone group (P&lt;0.05). There were no significant differences between the acupoint application group and the dexamethasone group in the above mentioned indexes (P>0.05). CONCLUSIONS: Acupoint application can improve airway remodeling by down-regulating the expression of TGF-beta 1/Smad 3 in the airway of chronic asthmatic mice</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1000-0607 (Print)IS - 1000-0607 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29071965">PM:29071965</url></web-urls></urls><custom2><style face="normal" font="Arial">20171026, Liu CY</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Zhang,Y.</style></author><author><style face="normal" font="Arial"> Hou,X.R.</style></author><author><style face="normal" font="Arial"> Li,L.H.</style></author><author><style face="normal" font="Arial"> Yang,M.</style></author><author><style face="normal" font="Arial"> Liang,F.H.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Clinical Medical College of Guizhou Medical University, Guiyang 550004, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effect of Acupoint Injection on Eosinophil Counts,Protein and mRNA Expressions of Eotaxin in Nasal Mucosa of Allergic Rhinitis Rats]</style></title><secondary-title><style face="normal" font="Arial">Zhen Ci Yan Jiu</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhen Ci Yan Jiu</style></full-title></periodical><pages end="144" start="141">141-144</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Allergic</style></keyword><keyword><style face="normal" font="Arial"> allergic rhinitis</style></keyword><keyword><style face="normal" font="Arial"> AR</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Clinical</style></keyword><keyword><style face="normal" font="Arial"> Dexamethasone</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Eosinophil</style></keyword><keyword><style face="normal" font="Arial"> Eosinophils</style></keyword><keyword><style face="normal" font="Arial"> eotaxin</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Inflammation</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lidocaine</style></keyword><keyword><style face="normal" font="Arial"> Light</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> methods</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> mRNA</style></keyword><keyword><style face="normal" font="Arial"> mucosa</style></keyword><keyword><style face="normal" font="Arial"> nasal</style></keyword><keyword><style face="normal" font="Arial"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Protein</style></keyword><keyword><style face="normal" font="Arial"> rat</style></keyword><keyword><style face="normal" font="Arial"> Rats</style></keyword><keyword><style face="normal" font="Arial"> Rhinitis</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Staining</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="Arial">OBJECTIVE: To observe the effect of acupoint injection on eosinophils (EOS) counts and expression of eotaxin in nasal mucosa of allergic rhinitis (AR) rats, so as to reveal its mechanism underlying improving AR. METHODS: Twenty-four Sprague-Dawley (SD) rats were randomly divided into normal, model and acupoint injection groups (n=8 in each group). The AR model was established by intraperitoneal injection of ovalbumin sensitization. Bilateral "Yingxiang"(LI 20) and "Yintang"(GV 29) were selected for acupoint injection of the mixture solution of lidocaine, dexamethasone, and transfer factor (0.1 mL/acupoint) on the 1st, 5th, 9th, and 13th day after AR model established, a total of four times. EOS in the nasal mucosa was counted under light microscope after HE staining. Protein and mRNA expressions of eotaxin in the nasal mucosa were detected by immunohistochemical and RT-PCR methods, respectively. RESULTS: Compared with the normal group, EOS counts, protein and mRNA expressions of eotaxin in the nasal mucosa were significantly higher in the model group (P&lt;0.05). Compared with the model group, EOS counts, protein and mRNA expressions of eotaxin in the nasal mucosa were significantly lower in the acupoint injection group (P&lt;0.05). CONCLUSIONS: Acupoint injection can reduce the nasal mucosa inflammation by suppressing the protein and mRNA expressions of eotaxin, decreasing the infiltration and gathering of EOS in the nasal mucosa</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1000-0607 (Print)IS - 1000-0607 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29071962">PM:29071962</url></web-urls></urls><custom2><style face="normal" font="Arial">20171026, Zhang Y</style></custom2><misc3><style face="normal" font="Arial">NO-DOI</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Tong,L.</style></author><author><style face="normal" font="Arial"> Sun,L.L.</style></author><author><style face="normal" font="Arial"> Liu,J.L.</style></author><author><style face="normal" font="Arial"> Gao,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Mudanjiang Medical University, Mudanjiang 157011, China</style></auth-address><titles><title><style face="normal" font="Arial">[Antiasthmatic effects of different tonifying kidney-Yin formulas and their effects on airway remodeling in chronic asthma]</style></title><secondary-title><style face="normal" font="Arial">Zhongguo Zhong Yao Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhongguo Zhong Yao Za Zhi</style></full-title></periodical><pages end="1590" start="1585">1585-1590</pages><volume><style face="normal" font="Arial">42</style></volume><number><style face="normal" font="Arial">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Airway</style></keyword><keyword><style face="normal" font="Arial"> airway remodeling</style></keyword><keyword><style face="normal" font="Arial"> Asthma</style></keyword><keyword><style face="normal" font="Arial"> BALB/c</style></keyword><keyword><style face="normal" font="Arial"> BALB/c mice</style></keyword><keyword><style face="normal" font="Arial"> Basement Membrane</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> chronic</style></keyword><keyword><style face="normal" font="Arial"> Collagen</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Induced</style></keyword><keyword><style face="normal" font="Arial"> ingredient</style></keyword><keyword><style face="normal" font="Arial"> Ingredients</style></keyword><keyword><style face="normal" font="Arial"> Inhibition</style></keyword><keyword><style face="normal" font="Arial"> ITS</style></keyword><keyword><style face="normal" font="Arial"> Lung</style></keyword><keyword><style face="normal" font="Arial"> mechanisms</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> MMP-9</style></keyword><keyword><style face="normal" font="Arial"> model</style></keyword><keyword><style face="normal" font="Arial"> Muscle</style></keyword><keyword><style face="normal" font="Arial"> Nose</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Regulatory</style></keyword><keyword><style face="normal" font="Arial"> remodeling</style></keyword><keyword><style face="normal" font="Arial"> scratching</style></keyword><keyword><style face="normal" font="Arial"> smooth muscle</style></keyword><keyword><style face="normal" font="Arial"> Time</style></keyword><keyword><style face="normal" font="Arial"> treatment</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword><keyword><style face="normal" font="Arial"> Western blotting</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="Arial">Both of Zuogui Wan(ZGW) and Liuwei Dihuang Wan(LWDHW) contain ingredients of Sanbufang(SBF), which have been proven to have antiasthmatic effects. In order to study the antiasthmatic effects of the three tonifying kidney-Yin formulas and their mechanisms, BALB/c mice were randomly divided into 5 groups. Chronic asthma was induced by ovalbumin. Mice in treated groups were respectively given 49.0 g*kg(-)(1)ZGW, 35.0 g*kg(-)(1)LWDHW and 22.4 g*kg(-)(1)SBF by gavage. Those in normal and model group were given normal saline. After treatment, sneeze and nose scratching times of mice were observed. Histological lung sections were prepared to determine the basement membrane thickness(BMT), smooth muscle thickness(SMT), collagen area(CA) and numbers of goblet cells(GCN). Western blotting and RT-PCR were used to determine the expression levels of MMP-9, TGF-beta1, Smad2, Smad3 and Smad7. The results showed that sneeze and nose scratching times of ZGW group were significantly lower than those of SBF group. Its inhibition degree on airway remodeling was significantly higher than SBF group. Sneeze and nose scratching times of LWDHW group were significantly lower than SBF group. Its CA and GCN were significantly lower than SBF group. Regarding the four airway remodeling related factors, MMP-9, TGF-beta1, Smad2 and Smad3 of ZGW group were significantly lower than those of SBF group, and its Smad7 was significantly higher than SBF. Smad7 of LWDHW group was significantly higher than SBF. There was no significant difference in MMP-9 between model group and SBF group. The results indicate that there are significant differences in the antiasthma effect of these tonifying kidney-Yin formulas. The regulatory effects of ZGW and LWDHW on MMP-9 and Smad7 may be correlated with the differences in the inhibitory effect of airway remodeling of the three formulas</style></abstract><notes><style face="normal" font="Arial">DA - 20171026IS - 1001-5302 (Print)IS - 1001-5302 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.19540/j.cnki.cjcmm.20170222.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29071866">PM:29071866</url></web-urls></urls><custom2><style face="normal" font="Arial">20171026, Tong L</style></custom2><misc3><style face="normal" font="Arial">10.19540/j.cnki.cjcmm.20170222.017</style></misc3></record><record><database name="HMW 2 Allergens" path="D:\Bibliografia Generale\HMW 2 Allergens">HMW 2 Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>86491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="Arial">Song,Z.</style></author><author><style face="normal" font="Arial"> Li,H.Q.</style></author></authors></contributors><auth-address><style face="normal" font="Arial">Department of Child Health Care, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China</style></auth-address><titles><title><style face="normal" font="Arial">[Effects of ovalbumin exposure during pregnancy of mice on the ovalbumin re-exposure in adult progeny]</style></title><secondary-title><style face="normal" font="Arial">Zhonghua Er Ke Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="Arial">Zhonghua Er Ke Za Zhi</style></full-title></periodical><pages end="770" start="766">766-770</pages><volume><style face="normal" font="Arial">55</style></volume><number><style face="normal" font="Arial">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="Arial">Adult</style></keyword><keyword><style face="normal" font="Arial"> Allergic</style></keyword><keyword><style face="normal" font="Arial"> Allergic reaction</style></keyword><keyword><style face="normal" font="Arial"> analysis</style></keyword><keyword><style face="normal" font="Arial"> Analysis of Variance</style></keyword><keyword><style face="normal" font="Arial"> Child</style></keyword><keyword><style face="normal" font="Arial"> Child Development</style></keyword><keyword><style face="normal" font="Arial"> China</style></keyword><keyword><style face="normal" font="Arial"> Control</style></keyword><keyword><style face="normal" font="Arial"> Development</style></keyword><keyword><style face="normal" font="Arial"> Diarrhea</style></keyword><keyword><style face="normal" font="Arial"> education</style></keyword><keyword><style face="normal" font="Arial"> English Abstract</style></keyword><keyword><style face="normal" font="Arial"> Exposure</style></keyword><keyword><style face="normal" font="Arial"> expression</style></keyword><keyword><style face="normal" font="Arial"> Health</style></keyword><keyword><style face="normal" font="Arial"> Health-care</style></keyword><keyword><style face="normal" font="Arial"> IgE</style></keyword><keyword><style face="normal" font="Arial"> IL-4</style></keyword><keyword><style face="normal" font="Arial"> In Vitro</style></keyword><keyword><style face="normal" font="Arial"> intrauterine</style></keyword><keyword><style face="normal" font="Arial"> Laboratories</style></keyword><keyword><style face="normal" font="Arial"> Lymphocyte</style></keyword><keyword><style face="normal" font="Arial"> Lymphocytes</style></keyword><keyword><style face="normal" font="Arial"> Medical</style></keyword><keyword><style face="normal" font="Arial"> Mice</style></keyword><keyword><style face="normal" font="Arial"> mother</style></keyword><keyword><style face="normal" font="Arial"> Mothers</style></keyword><keyword><style face="normal" font="Arial"> objective</style></keyword><keyword><style face="normal" font="Arial"> offspring</style></keyword><keyword><style face="normal" font="Arial"> Or</style></keyword><keyword><style face="normal" font="Arial"> OVA</style></keyword><keyword><style face="normal" font="Arial"> Ovalbumin</style></keyword><keyword><style face="normal" font="Arial"> Ovum</style></keyword><keyword><style face="normal" font="Arial"> Pregnancy</style></keyword><keyword><style face="normal" font="Arial"> primary</style></keyword><keyword><style face="normal" font="Arial"> prospective</style></keyword><keyword><style face="normal" font="Arial"> Reaction</style></keyword><keyword><style face="normal" font="Arial"> Risk</style></keyword><keyword><style face="normal" font="Arial"> sensitization</style></keyword><keyword><style face="normal" font="Arial"> Serum</style></keyword><keyword><style face="normal" font="Arial"> severe</style></keyword><keyword><style face="normal" font="Arial"> Spleen</style></keyword><keyword><style face="normal" font="Arial"> symptoms</style></keyword><keyword><style face="normal" font="Arial"> Test</style></keyword><keyword><style face="normal" font="Arial"> Universities</style></keyword><keyword><style face="normal" font="Arial"> WAS</style></keyword></keywords><dates><year Day="2" Month="10" Year="2017">2017/10/2</year></dates><abstract><style face="normal" font="Arial">Objective: To observe the immunoreaction of offspring mice by ovalbumin (OVA) re-exposure after their mothers exposed to OVA during pregnancy. Method: A prospective controlled study was conducted to observe mice after repeated OVA exposures at 6-8 weeks.Their mothers were exposed to OVA during different stages of pregnancy.The symptoms were recorded and scored.The levels of OVA-specific IgE in serum, interferon-gamma(IFN-gamma) and interleukin-4(IL-4) in supernatant of spleen primary lymphocytes in vitro were measured by ELISA.The results were analyzed by single factor analysis of variance or rank sum test. Result: All the mice in each group had acute diarrhea.The diarrhea happened earliest (2 days) and most severe in the late pregnancy group (early pregnancy group 7.0+/-1.0; middle pregnancy group: 7.1+/-1.1; late pregnancy group: 9.9+/-2.2, P&lt;0.01). The levels of absorbance of OVA-specific IgE in the pregnancy groups were higher than those of the control group.The absorbance of OVA-specific IgE in late pregnancy group was the highest (control: 0.27+/-0.06; early pregnancy group: 0.51+/-0.13; middle pregnancy group: 0.50+/-0.09; late pregnancy group: 0.63+/-0.13, P&lt;0.01). There was no significant change in IFN-gamma expression in cultured supernatant of spleen lymphocytes in each group (control: (133+/-7) pg/ml; early pregnancy group: (133+/-4) pg/ml; middle pregnancy group: (134+/-6) pg/ml; late pregnancy group: (132+/-4) pg/ml, all P value >0.05). The expression of IL-4 in the experimental groups was higher than that in the control group, especially in late pregnancy group(control: (25.3+/-2.4) pg/ml; early pregnancy group: (32.4+/-4.4) pg/ml; middle pregnancy group: (35.0+/-5.4) pg/ml; late pregnancy group: (47.1+/-5.8) pg/ml; P value all&lt;0.01). Conclusion: The allergic reaction of the OVA re-exposure progeny whose mothers were exposed to OVA in the late pregnancy period was most severe, suggesting that late pregnancy period might be the high risk stage of intrauterine sensitization, or"window period"</style></abstract><notes><style face="normal" font="Arial">DA - 20171019IS - 0578-1310 (Print)IS - 0578-1310 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="Arial">10.3760/cma.j.issn.0578-1310.2017.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29050115">PM:29050115</url></web-urls></urls><custom2><style face="normal" font="Arial">20171019, Song Z</style></custom2><misc3><style face="normal" font="Arial">10.3760/cma.j.issn.0578-1310.2017.10.010</style></misc3></record></records></xml>
